NCT000001023	NCT00000102_3_T0	COMPOUND	11	11	nifedipine
NCT000001023	NCT00000102_3_T1	COMPOUND	30	30	nifedipine
NCT000001023	NCT00000102_3_T2	GENE	18	18	ACTH
NCT000001023	NCT00000102_3_T3	GENE	16	17	adrenocorticotropic hormone
NCT000001040	NCT00000104_0_T0	BIOLOGICAL_PROCESS	5	5	Development
NCT000001043	NCT00000104_3_T0	PHENOTYPE	3	3	affects
NCT000001043	NCT00000104_3_T1	PHENOTYPE	4	5	cognitive functioning
NCT000001050	NCT00000105_0_T0	COMPOUND	4	4	KLH
NCT000001050	NCT00000105_0_T1	PHENOTYPE	2	2	Tetanus
NCT000001053	NCT00000105_3_T0	GENE	20	20	interleukin-2
NCT000001053	NCT00000105_3_T1	GENE	22	22	IL-2
NCT000001053	NCT00000105_3_T2	ORGAN	13	14	immune system
NCT000001054	NCT00000105_4_T0	ORGAN	21	22	immune system
NCT000001055	NCT00000105_5_T0	BIOLOGICAL_PROCESS	24	25	immune response
NCT000001056	NCT00000105_6_T0	ORGAN	13	14	immune systems
NCT000001057	NCT00000105_7_T0	CELL	7	7	cells
NCT000001058	NCT00000105_8_T0	CELL	5	5	cells
NCT000001058	NCT00000105_8_T1	CELL	10	10	T-cells
NCT000001059	NCT00000105_9_T0	CELL	12	12	cells
NCT000001059	NCT00000105_9_T1	CELL	1	1	T-cells
NCT0000010511	NCT00000105_11_T0	CELL	16	16	cells
NCT0000010511	NCT00000105_11_T1	CELL	10	10	T-cells
NCT0000010512	NCT00000105_12_T0	PHENOTYPE	12	12	recurrent
NCT0000010512	NCT00000105_12_T1	ORGAN	7	8	immune system
NCT0000010512	NCT00000105_12_T2	PHENOTYPE	13	14	virus infection
NCT0000010513	NCT00000105_13_T0	PHENOTYPE	9	9	mononucleosis
NCT0000010514	NCT00000105_14_T0	PHENOTYPE	12	12	remembers
NCT0000010514	NCT00000105_14_T1	ORGAN	10	11	immune system
NCT0000010515	NCT00000105_15_T0	PHENOTYPE	10	11	cancer relapse
NCT0000010515	NCT00000105_15_T1	ORGAN	6	7	immune system
NCT0000010522	NCT00000105_22_T0	PHENOTYPE	3	3	tetanus
NCT0000010522	NCT00000105_22_T1	COMPOUND	7	7	KLH
NCT0000010523	NCT00000105_23_T0	PHENOTYPE	9	9	tetanus
NCT0000010524	NCT00000105_24_T0	PHENOTYPE	5	5	tetanus
NCT0000010524	NCT00000105_24_T1	COMPOUND	32	32	KLH
NCT0000010524	NCT00000105_24_T2	GENE	12	12	has
NCT000001061	NCT00000106_1_T0	PHENOTYPE	15	15	diseases
NCT000001062	NCT00000106_2_T0	PHENOTYPE	25	25	remission
NCT000001062	NCT00000106_2_T1	GENE	18	18	TNF
NCT000001062	NCT00000106_2_T2	PHENOTYPE	30	31	rheumatoid arthritis
NCT000001063	NCT00000106_3_T0	GENE	12	12	TNF
NCT000001063	NCT00000106_3_T1	GENE	20	20	TNF
NCT000001071	NCT00000107_1_T0	GENE	22	22	fat-free
NCT000001071	NCT00000107_1_T1	PHENOTYPE	26	27	metabolic rates
NCT000001071	NCT00000107_1_T2	PHENOTYPE	11	13	congenital heart defects
NCT000001072	NCT00000107_2_T0	GENE	17	17	has
NCT000001073	NCT00000107_3_T0	PHENOTYPE	3	6	cyanotic congenital heart disease
NCT000001081	NCT00000108_1_T0	PHENOTYPE	0	1	Heart attacks
NCT000001083	NCT00000108_3_T0	TISSUE	14	15	body fat
NCT000001084	NCT00000108_4_T0	PHENOTYPE	15	15	understood
NCT000001085	NCT00000108_5_T0	PHENOTYPE	32	32	CVD
NCT000001085	NCT00000108_5_T1	PHENOTYPE	21	21	intensities
NCT000001085	NCT00000108_5_T2	TISSUE	24	25	body fat
NCT000001104	NCT00000110_4_T0	PHENOTYPE	11	11	obesity
NCT000001104	NCT00000110_4_T1	PHENOTYPE	26	26	obesity
NCT000001104	NCT00000110_4_T2	PHENOTYPE	23	24	insulin resistance
NCT000001114	NCT00000111_4_T0	GENE	14	14	had
NCT000001114	NCT00000111_4_T1	GENE	1	1	has
NCT000001114	NCT00000111_4_T2	PHENOTYPE	8	8	burns
NCT000001115	NCT00000111_5_T0	ORGAN	17	17	palate
NCT000001118	NCT00000111_8_T0	TISSUE	27	27	mucosa
NCT000001118	NCT00000111_8_T1	ORGAN	13	14	tissue graft
NCT000001121	NCT00000112_1_T0	PHENOTYPE	1	1	adiposity
NCT000001132	NCT00000113_2_T0	PHENOTYPE	7	7	myopia
NCT000001135	NCT00000113_5_T0	PHENOTYPE	9	9	blindness
NCT000001135	NCT00000113_5_T1	PHENOTYPE	0	1	High myopia
NCT000001135	NCT00000113_5_T2	PHENOTYPE	5	7	loss of vision
NCT000001136	NCT00000113_6_T0	PHENOTYPE	9	9	myopia
NCT000001137	NCT00000113_7_T0	PHENOTYPE	19	19	complications
NCT0000011310	NCT00000113_10_T0	PHENOTYPE	27	27	reasoning
NCT0000011310	NCT00000113_10_T1	PHENOTYPE	21	21	myopia
NCT0000011310	NCT00000113_10_T2	PHENOTYPE	19	19	progression
NCT0000011310	NCT00000113_10_T3	PHENOTYPE	10	10	progressive
NCT0000011312	NCT00000113_12_T0	PHENOTYPE	3	3	myopia
NCT0000011312	NCT00000113_12_T1	PHENOTYPE	24	24	myopia
NCT0000011312	NCT00000113_12_T2	PHENOTYPE	4	4	progression
NCT0000011312	NCT00000113_12_T3	PHENOTYPE	25	25	progression
NCT0000011313	NCT00000113_13_T0	PHENOTYPE	18	18	myopia
NCT0000011313	NCT00000113_13_T1	PHENOTYPE	15	15	progression
NCT0000011314	NCT00000113_14_T0	PHENOTYPE	20	20	centers
NCT0000011315	NCT00000113_15_T0	PHENOTYPE	7	7	myopia
NCT0000011315	NCT00000113_15_T1	ORGAN	10	10	eyes
NCT0000011315	NCT00000113_15_T2	GENE	12	12	met
NCT0000011317	NCT00000113_17_T0	PHENOTYPE	7	7	progressive
NCT0000011318	NCT00000113_18_T0	PHENOTYPE	19	20	refractive error
NCT0000011320	NCT00000113_20_T0	PHENOTYPE	8	8	centers
NCT0000011321	NCT00000113_21_T0	PHENOTYPE	9	9	myopia
NCT0000011321	NCT00000113_21_T1	PHENOTYPE	7	7	progression
NCT0000011322	NCT00000113_22_T0	PHENOTYPE	1	1	secondary
NCT000001145	NCT00000114_5_T0	GENE	47	47	ERG
NCT000001145	NCT00000114_5_T1	GENE	12	12	RP
NCT000001145	NCT00000114_5_T2	PHENOTYPE	5	6	retinal degeneration
NCT000001145	NCT00000114_5_T3	COMPOUND	34	35	vitamin A
NCT000001145	NCT00000114_5_T4	COMPOUND	37	38	vitamin E
NCT000001146	NCT00000114_6_T0	PHENOTYPE	40	40	progression
NCT000001146	NCT00000114_6_T1	GENE	46	46	RP
NCT0000011411	NCT00000114_11_T0	PHENOTYPE	9	9	adaptation
NCT0000011411	NCT00000114_11_T1	GENE	12	12	reduced
NCT0000011411	NCT00000114_11_T2	GENE	3	3	had
NCT0000011413	NCT00000114_13_T0	ORGAN	10	10	liver
NCT0000011413	NCT00000114_13_T1	GENE	3	3	had
NCT0000011413	NCT00000114_13_T2	ORGAN	6	6	serum
NCT0000011413	NCT00000114_13_T3	ORGAN	9	9	serum
NCT000001154	NCT00000115_4_T0	PHENOTYPE	9	10	active transport
NCT000001154	NCT00000115_4_T1	GENE	23	24	carbonic anhydrase
NCT000001154	NCT00000115_4_T2	ORGAN	16	18	retinal pigment epithelium
NCT000001155	NCT00000115_5_T0	PHENOTYPE	3	3	uveitis
NCT000001155	NCT00000115_5_T1	PHENOTYPE	4	6	cystoid macular edema
NCT000001156	NCT00000115_6_T0	PHENOTYPE	5	5	resistant
NCT000001157	NCT00000115_7_T0	PHENOTYPE	18	18	glaucoma
NCT000001157	NCT00000115_7_T1	COMPOUND	4	4	acetazolamide
NCT000001157	NCT00000115_7_T2	PHENOTYPE	27	27	uveitis
NCT000001157	NCT00000115_7_T3	PHENOTYPE	14	15	intraocular pressure
NCT000001157	NCT00000115_7_T4	GENE	6	7	carbonic anhydrase
NCT000001157	NCT00000115_7_T5	PHENOTYPE	28	30	cystoid macular edema
NCT000001159	NCT00000115_9_T0	COMPOUND	7	7	sodium
NCT000001159	NCT00000115_9_T1	COMPOUND	6	6	acetazolamide
NCT0000011512	NCT00000115_12_T0	COMPOUND	11	11	fluorescein
NCT0000011512	NCT00000115_12_T1	PHENOTYPE	23	24	Diabetic Retinopathy
NCT0000011512	NCT00000115_12_T2	PHENOTYPE	6	8	cystoid macular edema
NCT0000011513	NCT00000115_13_T0	PHENOTYPE	7	7	secondary
NCT0000011514	NCT00000115_14_T0	COMPOUND	4	4	acetazolamide
NCT0000011514	NCT00000115_14_T1	PHENOTYPE	0	1	Adverse effects
NCT0000011519	NCT00000115_19_T0	PHENOTYPE	9	9	uveitis
NCT000001162	NCT00000116_2_T0	PHENOTYPE	8	8	midperipheral
NCT000001162	NCT00000116_2_T1	PHENOTYPE	3	4	night blindness
NCT000001166	NCT00000116_6_T0	GENE	11	11	RP
NCT000001166	NCT00000116_6_T1	COMPOUND	8	9	vitamin A
NCT000001169	NCT00000116_9_T0	GENE	6	6	RP
NCT0000011610	NCT00000116_10_T0	COMPOUND	5	7	vitamin A palmitate
NCT0000011612	NCT00000116_12_T0	PHENOTYPE	14	14	HFA
NCT0000011613	NCT00000116_13_T0	GENE	5	5	ERG
NCT000001175	NCT00000117_5_T0	PHENOTYPE	0	1	Visual loss
NCT000001177	NCT00000117_7_T0	PHENOTYPE	17	17	symptoms
NCT000001178	NCT00000117_8_T0	GENE	22	22	MS
NCT000001178	NCT00000117_8_T1	CELL	55	55	oligodendrocyte
NCT000001178	NCT00000117_8_T2	CELL	43	43	macrophages
NCT000001178	NCT00000117_8_T3	PHENOTYPE	47	47	demyelination
NCT000001178	NCT00000117_8_T4	PHENOTYPE	60	60	gliosis
NCT000001178	NCT00000117_8_T5	PHENOTYPE	38	39	lymphocytic infiltration
NCT000001178	NCT00000117_8_T6	PHENOTYPE	30	31	primary demyelination
NCT000001178	NCT00000117_8_T7	PHENOTYPE	57	58	axonal loss
NCT000001179	NCT00000117_9_T0	GENE	7	7	MS
NCT000001179	NCT00000117_9_T1	CELL	2	2	oligodendrocytes
NCT000001179	NCT00000117_9_T2	CELL	20	20	axon
NCT000001179	NCT00000117_9_T3	CELL	12	13	myelin sheaths
NCT0000011710	NCT00000117_10_T0	PHENOTYPE	13	13	plaques
NCT0000011710	NCT00000117_10_T1	CELL	2	3	myelin sheaths
NCT0000011711	NCT00000117_11_T0	BIOLOGICAL_PROCESS	18	18	regeneration
NCT0000011711	NCT00000117_11_T1	CELL	17	17	oligodendrocyte
NCT0000011711	NCT00000117_11_T2	GENE	5	5	has
NCT0000011712	NCT00000117_12_T0	CELL	2	2	oligodendrocytes
NCT0000011713	NCT00000117_13_T0	PHENOTYPE	13	13	acute
NCT0000011713	NCT00000117_13_T1	PHENOTYPE	14	14	plaque
NCT0000011713	NCT00000117_13_T2	CELL	9	9	cells
NCT0000011713	NCT00000117_13_T3	CELL	26	26	oligodendrocytes
NCT0000011713	NCT00000117_13_T4	GENE	2	2	has
NCT0000011714	NCT00000117_14_T0	GENE	20	20	MS
NCT0000011715	NCT00000117_15_T0	GENE	11	11	IgG
NCT0000011715	NCT00000117_15_T1	GENE	21	21	IgG
NCT0000011715	NCT00000117_15_T2	GENE	5	5	has
NCT0000011715	NCT00000117_15_T3	ORGAN	14	15	spinal cord
NCT0000011716	NCT00000117_16_T0	PHENOTYPE	15	15	proliferation
NCT0000011716	NCT00000117_16_T1	GENE	7	7	IgG
NCT0000011717	NCT00000117_17_T0	PHENOTYPE	12	12	proliferation
NCT0000011717	NCT00000117_17_T1	CELL	16	16	oligodendrocytes
NCT0000011718	NCT00000117_18_T0	CELL	4	4	myelin
NCT0000011718	NCT00000117_18_T1	CELL	10	10	oligodendrocytes
NCT0000011719	NCT00000117_19_T0	CELL	13	13	cells
NCT0000011719	NCT00000117_19_T1	PHENOTYPE	8	8	proliferation
NCT0000011724	NCT00000117_24_T0	PHENOTYPE	35	36	Diabetic Retinopathy
NCT0000011725	NCT00000117_25_T0	GENE	5	5	0.4
NCT0000011725	NCT00000117_25_T1	COMPOUND	8	8	N
NCT0000011727	NCT00000117_27_T0	GENE	14	14	0.2
NCT0000011728	NCT00000117_28_T0	PHENOTYPE	1	1	secondary
NCT0000011728	NCT00000117_28_T1	GENE	52	52	AI
NCT0000011728	NCT00000117_28_T2	COMPOUND	50	50	EDSS
NCT0000011730	NCT00000117_30_T0	GENE	5	5	MS
NCT0000011734	NCT00000117_34_T0	GENE	15	15	separated
NCT0000011734	NCT00000117_34_T1	PHENOTYPE	5	5	dysfunction
NCT0000011735	NCT00000117_35_T0	PHENOTYPE	0	2	Optic disc pallor
NCT0000011736	NCT00000117_36_T0	PHENOTYPE	3	3	impairment
NCT0000011736	NCT00000117_36_T1	PHENOTYPE	14	14	dysfunction
NCT000001182	NCT00000118_2_T0	COMPOUND	2	2	ganciclovir
NCT000001182	NCT00000118_2_T1	COMPOUND	4	4	foscarnet
NCT000001187	NCT00000118_7_T0	GENE	2	2	half-life
NCT000001188	NCT00000118_8_T0	GENE	5	5	has
NCT000001189	NCT00000118_9_T0	GENE	14	14	has
NCT000001189	NCT00000118_9_T1	COMPOUND	9	9	ganciclovir
NCT000001189	NCT00000118_9_T2	PHENOTYPE	13	13	cavity
NCT0000011810	NCT00000118_10_T0	COMPOUND	8	8	ganciclovir
NCT0000011810	NCT00000118_10_T1	COMPOUND	21	21	ganciclovir
NCT0000011817	NCT00000118_17_T0	PHENOTYPE	1	2	adverse event
NCT000001199	NCT00000119_9_T0	COMPOUND	9	9	heparin
NCT000001199	NCT00000119_9_T1	GENE	22	22	has
NCT000001199	NCT00000119_9_T2	PHENOTYPE	16	16	uveitis
NCT000001204	NCT00000120_4_T0	ORGAN	8	8	genital
NCT000001204	NCT00000120_4_T1	PHENOTYPE	9	10	chlamydial infection
NCT000001204	NCT00000120_4_T2	PHENOTYPE	23	24	chlamydial infections
NCT000001205	NCT00000120_5_T0	PHENOTYPE	10	10	pneumonia
NCT000001205	NCT00000120_5_T1	PHENOTYPE	8	8	conjunctivitis
NCT0000012011	NCT00000120_11_T0	PHENOTYPE	6	6	gonorrhea
NCT0000012016	NCT00000120_16_T0	COMPOUND	4	4	tetracycline
NCT0000012023	NCT00000120_23_T0	PHENOTYPE	2	2	conjunctivitis
NCT0000012024	NCT00000120_24_T0	PHENOTYPE	3	3	conjunctivitis
NCT0000012025	NCT00000120_25_T0	PHENOTYPE	11	11	conjunctivitis
NCT0000012025	NCT00000120_25_T1	PHENOTYPE	15	17	nasolacrimal duct obstruction
NCT0000012027	NCT00000120_27_T0	GENE	10	10	had
NCT000001210	NCT00000121_0_T0	GENE	4	4	PAS
NCT000001210	NCT00000121_0_T1	PHENOTYPE	2	2	Adaptation
NCT000001212	NCT00000121_2_T0	PHENOTYPE	8	8	adaptation
NCT000001212	NCT00000121_2_T1	PHENOTYPE	31	31	adaptation
NCT000001213	NCT00000121_3_T0	PHENOTYPE	8	8	adaptation
NCT000001214	NCT00000121_4_T0	PHENOTYPE	36	36	adaptation
NCT000001214	NCT00000121_4_T1	PHENOTYPE	23	24	refractive error
NCT000001216	NCT00000121_6_T0	ORGAN	14	14	eyes
NCT000001216	NCT00000121_6_T1	PHENOTYPE	3	3	esotropia
NCT000001217	NCT00000121_7_T0	PHENOTYPE	7	7	secondary
NCT0000012110	NCT00000121_10_T0	GENE	4	4	pointed
NCT0000012111	NCT00000121_11_T0	PHENOTYPE	2	2	Adaptation
NCT0000012112	NCT00000121_12_T0	PHENOTYPE	9	9	adaptation
NCT0000012113	NCT00000121_13_T0	GENE	30	30	had
NCT0000012113	NCT00000121_13_T1	PHENOTYPE	37	37	esotropia
NCT0000012114	NCT00000121_14_T0	PHENOTYPE	30	30	adaptation
NCT0000012114	NCT00000121_14_T1	GENE	9	9	had
NCT0000012114	NCT00000121_14_T2	PHENOTYPE	16	16	esotropia
NCT0000012117	NCT00000121_17_T0	PHENOTYPE	16	16	adaptation
NCT0000012118	NCT00000121_18_T0	GENE	12	12	had
NCT000001223	NCT00000122_3_T0	PHENOTYPE	10	10	glaucoma
NCT000001223	NCT00000122_3_T1	PHENOTYPE	12	12	glaucoma
NCT000001223	NCT00000122_3_T2	ORGAN	15	15	eyes
NCT000001224	NCT00000122_4_T0	CELL	11	11	fibroblasts
NCT000001224	NCT00000122_4_T1	PHENOTYPE	9	9	proliferation
NCT000001225	NCT00000122_5_T0	CELL	14	14	fibroblasts
NCT000001225	NCT00000122_5_T1	PHENOTYPE	12	12	proliferation
NCT000001225	NCT00000122_5_T2	GENE	6	6	has
NCT000001225	NCT00000122_5_T3	GENE	23	23	has
NCT000001226	NCT00000122_6_T0	PHENOTYPE	18	18	glaucoma
NCT000001227	NCT00000122_7_T0	PHENOTYPE	11	11	severity
NCT000001227	NCT00000122_7_T1	PHENOTYPE	14	15	adverse effects
NCT000001229	NCT00000122_9_T0	PHENOTYPE	1	1	toxicity
NCT000001233	NCT00000123_3_T0	PHENOTYPE	6	7	refractive error
NCT000001234	NCT00000123_4_T0	PHENOTYPE	21	21	complications
NCT000001236	NCT00000123_6_T0	PHENOTYPE	10	10	fitted
NCT000001236	NCT00000123_6_T1	GENE	20	21	nearly normal
NCT0000012310	NCT00000123_10_T0	PHENOTYPE	25	25	fitted
NCT0000012311	NCT00000123_11_T0	GENE	7	7	1.5
NCT0000012312	NCT00000123_12_T0	PHENOTYPE	14	14	fitted
NCT0000012313	NCT00000123_13_T0	COMPOUND	12	12	methacrylate
NCT0000012314	NCT00000123_14_T0	PHENOTYPE	4	4	fitted
NCT0000012316	NCT00000123_16_T0	GENE	22	22	had
NCT000001240	NCT00000124_0_T0	PHENOTYPE	1	2	Ocular Melanoma
NCT000001243	NCT00000124_3_T0	ORGAN	10	10	eyes
NCT000001243	NCT00000124_3_T1	PHENOTYPE	13	14	choroidal melanoma
NCT000001247	NCT00000124_7_T0	ORGAN	25	25	eyes
NCT000001248	NCT00000124_8_T0	BIOLOGICAL_PROCESS	30	30	enucleation
NCT000001248	NCT00000124_8_T1	PHENOTYPE	42	43	choroidal melanoma
NCT0000012410	NCT00000124_10_T0	PHENOTYPE	17	17	plaque
NCT0000012410	NCT00000124_10_T1	PHENOTYPE	6	6	tumors
NCT0000012410	NCT00000124_10_T2	COMPOUND	15	15	iodine_125
NCT0000012410	NCT00000124_10_T3	BIOLOGICAL_PROCESS	10	10	enucleation
NCT0000012413	NCT00000124_13_T0	PHENOTYPE	4	4	plaque
NCT0000012413	NCT00000124_13_T1	PHENOTYPE	10	10	tumor
NCT0000012413	NCT00000124_13_T2	PHENOTYPE	18	18	tumor
NCT0000012415	NCT00000124_15_T0	GENE	18	18	Gy
NCT0000012415	NCT00000124_15_T1	PHENOTYPE	22	22	tumor
NCT0000012415	NCT00000124_15_T2	PHENOTYPE	15	15	localized
NCT0000012419	NCT00000124_19_T0	GENE	22	22	Gy
NCT0000012419	NCT00000124_19_T1	PHENOTYPE	10	10	tumors
NCT0000012419	NCT00000124_19_T2	BIOLOGICAL_PROCESS	14	14	enucleation
NCT0000012419	NCT00000124_19_T3	BIOLOGICAL_PROCESS	18	18	enucleation
NCT0000012423	NCT00000124_23_T0	GENE	18	18	halted
NCT0000012423	NCT00000124_23_T1	PHENOTYPE	16	16	tumors
NCT0000012425	NCT00000124_25_T0	PHENOTYPE	7	7	centers
NCT0000012426	NCT00000124_26_T0	PHENOTYPE	2	2	centers
NCT0000012427	NCT00000124_27_T0	PHENOTYPE	25	25	tumors
NCT0000012427	NCT00000124_27_T1	PHENOTYPE	26	26	complications
NCT0000012427	NCT00000124_27_T2	PHENOTYPE	18	19	choroidal melanoma
NCT0000012428	NCT00000124_28_T0	PHENOTYPE	15	15	plaque
NCT0000012428	NCT00000124_28_T1	PHENOTYPE	4	6	quality of life
NCT0000012429	NCT00000124_29_T0	PHENOTYPE	9	10	choroidal melanoma
NCT000001250	NCT00000125_0_T0	PHENOTYPE	0	1	Ocular Hypertension
NCT000001252	NCT00000125_2_T0	PHENOTYPE	15	16	open-angle glaucoma
NCT000001253	NCT00000125_3_T0	PHENOTYPE	6	7	open-angle glaucoma
NCT000001257	NCT00000125_7_T0	PHENOTYPE	5	5	POAG
NCT000001257	NCT00000125_7_T1	PHENOTYPE	19	19	POAG
NCT000001259	NCT00000125_9_T0	PHENOTYPE	21	21	POAG
NCT000001259	NCT00000125_9_T1	PHENOTYPE	6	7	ocular hypertension
NCT0000012511	NCT00000125_11_T0	PHENOTYPE	0	0	Glaucoma
NCT0000012511	NCT00000125_11_T1	PHENOTYPE	8	8	blindness
NCT0000012513	NCT00000125_13_T0	PHENOTYPE	12	12	blindness
NCT0000012513	NCT00000125_13_T1	PHENOTYPE	3	3	glaucoma
NCT0000012516	NCT00000125_16_T0	PHENOTYPE	30	30	hypotensive
NCT0000012516	NCT00000125_16_T1	PHENOTYPE	18	18	glaucoma
NCT0000012516	NCT00000125_16_T2	GENE	16	16	1.5
NCT0000012516	NCT00000125_16_T3	PHENOTYPE	13	14	ocular hypertension
NCT0000012519	NCT00000125_19_T0	PHENOTYPE	1	2	Ocular Hypertension
NCT0000012520	NCT00000125_20_T0	PHENOTYPE	11	13	primary open-angle glaucoma
NCT0000012522	NCT00000125_22_T0	GENE	30	30	30.2
NCT0000012522	NCT00000125_22_T1	GENE	8	8	disc
NCT0000012522	NCT00000125_22_T2	GENE	36	36	disc
NCT0000012522	NCT00000125_22_T3	PHENOTYPE	5	5	IOP
NCT0000012524	NCT00000125_24_T0	PHENOTYPE	15	15	Centers
NCT0000012524	NCT00000125_24_T1	GENE	5	5	disc
NCT0000012526	NCT00000125_26_T0	PHENOTYPE	5	5	glaucoma
NCT000001260	NCT00000126_0_T0	PHENOTYPE	0	2	Ischemic Optic Neuropathy
NCT000001265	NCT00000126_5_T0	GENE	30	30	SEK
NCT000001265	NCT00000126_5_T1	GENE	15	15	al
NCT000001265	NCT00000126_5_T2	ORGAN	3	3	eyes
NCT000001265	NCT00000126_5_T3	GENE	14	14	et
NCT000001269	NCT00000126_9_T0	PHENOTYPE	21	21	recruitment
NCT0000012614	NCT00000126_14_T0	PHENOTYPE	15	15	symptoms
NCT0000012616	NCT00000126_16_T0	ORGAN	23	23	eyes
NCT0000012617	NCT00000126_17_T0	GENE	10	10	lines
NCT0000012617	NCT00000126_17_T1	GENE	12	12	42/7
NCT0000012618	NCT00000126_18_T0	GENE	11	11	10.5
NCT0000012618	NCT00000126_18_T1	GENE	4	4	has
NCT0000012618	NCT00000126_18_T2	ORGAN	3	3	eyes
NCT0000012619	NCT00000126_19_T0	PHENOTYPE	4	4	bilateral
NCT0000012619	NCT00000126_19_T1	PHENOTYPE	22	22	bilateral
NCT0000012619	NCT00000126_19_T2	GENE	14	14	al
NCT0000012619	NCT00000126_19_T3	GENE	17	17	17.5
NCT0000012619	NCT00000126_19_T4	GENE	13	13	et
NCT0000012620	NCT00000126_20_T0	PHENOTYPE	22	22	bilateral
NCT0000012620	NCT00000126_20_T1	GENE	3	3	al
NCT0000012620	NCT00000126_20_T2	GENE	17	17	al
NCT0000012620	NCT00000126_20_T3	GENE	2	2	et
NCT0000012620	NCT00000126_20_T4	GENE	16	16	et
NCT0000012622	NCT00000126_22_T0	GENE	10	10	had
NCT0000012626	NCT00000126_26_T0	PHENOTYPE	13	13	symptoms
NCT0000012626	NCT00000126_26_T1	GENE	15	15	had
NCT000001273	NCT00000127_3_T0	ORGAN	3	3	eyes
NCT0000012711	NCT00000127_11_T0	GENE	26	26	disc
NCT0000012711	NCT00000127_11_T1	ORGAN	2	2	eyes
NCT0000012711	NCT00000127_11_T2	CELL	14	15	nerve fibers
NCT0000012712	NCT00000127_12_T0	PHENOTYPE	18	18	infarction
NCT0000012712	NCT00000127_12_T1	ORGAN	23	24	optic nerves
NCT0000012713	NCT00000127_13_T0	PHENOTYPE	9	9	edema
NCT0000012713	NCT00000127_13_T1	PHENOTYPE	14	14	ischemia
NCT0000012714	NCT00000127_14_T0	ORGAN	0	1	Optic nerve
NCT0000012719	NCT00000127_19_T0	GENE	7	7	had
NCT0000012721	NCT00000127_21_T0	GENE	8	8	lines
NCT0000012722	NCT00000127_22_T0	PHENOTYPE	13	13	peripheral
NCT0000012722	NCT00000127_22_T1	PHENOTYPE	0	0	Secondary
NCT0000012722	NCT00000127_22_T2	PHENOTYPE	31	33	quality of life
NCT000001283	NCT00000128_3_T0	PHENOTYPE	17	17	myopia
NCT000001283	NCT00000128_3_T1	PHENOTYPE	23	23	myopia
NCT000001283	NCT00000128_3_T2	PHENOTYPE	24	24	progression
NCT000001285	NCT00000128_5_T0	PHENOTYPE	5	5	myopia
NCT000001285	NCT00000128_5_T1	PHENOTYPE	8	8	myopia
NCT000001288	NCT00000128_8_T0	PHENOTYPE	14	14	myopia
NCT000001288	NCT00000128_8_T1	PHENOTYPE	15	15	progression
NCT000001289	NCT00000128_9_T0	PHENOTYPE	9	9	phoria
NCT0000012811	NCT00000128_11_T0	PHENOTYPE	25	25	esophoria
NCT0000012811	NCT00000128_11_T1	PHENOTYPE	19	19	myopia
NCT0000012811	NCT00000128_11_T2	PHENOTYPE	20	20	progression
NCT0000012812	NCT00000128_12_T0	PHENOTYPE	8	8	esophoria
NCT0000012812	NCT00000128_12_T1	PHENOTYPE	1	1	myopic
NCT0000012816	NCT00000128_16_T0	PHENOTYPE	5	5	myopia
NCT0000012816	NCT00000128_16_T1	PHENOTYPE	6	6	progression
NCT0000012817	NCT00000128_17_T0	PHENOTYPE	12	12	myopia
NCT0000012817	NCT00000128_17_T1	PHENOTYPE	13	13	progression
NCT0000012817	NCT00000128_17_T2	GENE	19	19	bifocal
NCT0000012818	NCT00000128_18_T0	PHENOTYPE	12	12	myopia
NCT0000012818	NCT00000128_18_T1	PHENOTYPE	13	13	progression
NCT0000012818	NCT00000128_18_T2	GENE	19	19	0.32
NCT0000012818	NCT00000128_18_T3	GENE	24	24	bifocal
NCT0000012821	NCT00000128_21_T0	GENE	24	24	lag
NCT0000012821	NCT00000128_21_T1	PHENOTYPE	9	9	esophoria
NCT0000012821	NCT00000128_21_T2	PHENOTYPE	30	30	esophoria
NCT0000012822	NCT00000128_22_T0	GENE	1	1	lag
NCT0000012822	NCT00000128_22_T1	GENE	11	11	bifocal
NCT0000012824	NCT00000128_24_T0	PHENOTYPE	8	8	esophoria
NCT0000012824	NCT00000128_24_T1	PHENOTYPE	3	3	myopic
NCT0000012824	NCT00000128_24_T2	PHENOTYPE	20	20	myopic
NCT0000012826	NCT00000128_26_T0	PHENOTYPE	10	10	cycloplegia
NCT0000012826	NCT00000128_26_T1	COMPOUND	14	14	tropicamide
NCT0000012827	NCT00000128_27_T0	PHENOTYPE	9	9	myopia
NCT000001290	NCT00000129_0_T0	GENE	5	5	PERK
NCT000001292	NCT00000129_2_T0	PHENOTYPE	2	2	complications
NCT000001296	NCT00000129_6_T0	PHENOTYPE	20	20	myopia
NCT0000012916	NCT00000129_16_T0	PHENOTYPE	8	9	refractive error
NCT0000012920	NCT00000129_20_T0	GENE	36	36	3.0
NCT0000012920	NCT00000129_20_T1	GENE	22	22	4.0
NCT0000012920	NCT00000129_20_T2	GENE	19	19	3/12
NCT0000012920	NCT00000129_20_T3	GENE	26	26	4.3
NCT0000012920	NCT00000129_20_T4	GENE	29	29	3.5
NCT0000012924	NCT00000129_24_T0	PHENOTYPE	32	32	fluctuation
NCT0000012925	NCT00000129_25_T0	PHENOTYPE	21	22	pupil dilated
NCT0000012925	NCT00000129_25_T1	PHENOTYPE	17	18	refractive error
NCT0000012928	NCT00000129_28_T0	PHENOTYPE	9	9	complications
NCT0000012929	NCT00000129_29_T0	PHENOTYPE	0	1	Contrast sensitivity
NCT0000012932	NCT00000129_32_T0	PHENOTYPE	7	7	myopia
NCT0000012932	NCT00000129_32_T1	GENE	2	2	had
NCT0000012933	NCT00000129_33_T0	PHENOTYPE	17	17	centers
NCT000001300	NCT00000130_0_T0	PHENOTYPE	0	0	Endophthalmitis
NCT000001302	NCT00000130_2_T0	PHENOTYPE	11	12	bacterial endophthalmitis
NCT000001303	NCT00000130_3_T0	PHENOTYPE	11	12	bacterial endophthalmitis
NCT000001305	NCT00000130_5_T0	PHENOTYPE	9	9	complication
NCT000001307	NCT00000130_7_T0	GENE	15	15	has
NCT000001307	NCT00000130_7_T1	PHENOTYPE	7	7	endophthalmitis
NCT000001307	NCT00000130_7_T2	PHENOTYPE	27	27	endophthalmitis
NCT000001309	NCT00000130_9_T0	ORGAN	7	7	eyes
NCT0000013010	NCT00000130_10_T0	PHENOTYPE	23	23	endophthalmitis
NCT0000013011	NCT00000130_11_T0	PHENOTYPE	26	26	endophthalmitis
NCT0000013013	NCT00000130_13_T0	PHENOTYPE	13	13	endophthalmitis
NCT0000013014	NCT00000130_14_T0	PHENOTYPE	13	13	strategies
NCT0000013014	NCT00000130_14_T1	PHENOTYPE	0	0	Endophthalmitis
NCT0000013014	NCT00000130_14_T2	PHENOTYPE	18	19	bacterial endophthalmitis
NCT0000013015	NCT00000130_15_T0	ORGAN	0	0	Eyes
NCT0000013015	NCT00000130_15_T1	ORGAN	20	20	eyes
NCT0000013015	NCT00000130_15_T2	ORGAN	51	51	eyes
NCT0000013015	NCT00000130_15_T3	ORGAN	32	33	anterior chamber
NCT0000013016	NCT00000130_16_T0	ORGAN	3	3	eyes
NCT0000013020	NCT00000130_20_T0	PHENOTYPE	10	10	recruitment
NCT0000013020	NCT00000130_20_T1	PHENOTYPE	1	1	centers
NCT0000013020	NCT00000130_20_T2	ORGAN	6	6	eyes
NCT0000013023	NCT00000130_23_T0	GENE	2	2	had
NCT0000013023	NCT00000130_23_T1	ORGAN	1	1	eyes
NCT000001312	NCT00000131_2_T0	PHENOTYPE	15	16	macular edema
NCT000001312	NCT00000131_2_T1	PHENOTYPE	16	17	edema secondary
NCT000001313	NCT00000131_3_T0	ORGAN	10	10	eyes
NCT000001317	NCT00000131_7_T0	GENE	7	7	grid
NCT000001317	NCT00000131_7_T1	PHENOTYPE	12	13	macular edema
NCT000001318	NCT00000131_8_T0	GENE	7	7	grid
NCT0000013110	NCT00000131_10_T0	ORGAN	2	2	Eyes
NCT0000013110	NCT00000131_10_T1	PHENOTYPE	8	9	macular edema
NCT0000013110	NCT00000131_10_T2	PHENOTYPE	4	5	visual loss
NCT0000013111	NCT00000131_11_T0	ORGAN	2	2	Eyes
NCT0000013111	NCT00000131_11_T1	ORGAN	6	6	retinas
NCT0000013113	NCT00000131_13_T0	GENE	5	5	slit
NCT0000013113	NCT00000131_13_T1	COMPOUND	1	1	argon
NCT0000013113	NCT00000131_13_T2	GENE	6	6	lamp
NCT0000013116	NCT00000131_16_T0	PHENOTYPE	10	11	macular edema
NCT0000013116	NCT00000131_16_T1	PHENOTYPE	20	21	Diabetic Retinopathy
NCT0000013118	NCT00000131_18_T0	GENE	5	5	has
NCT0000013119	NCT00000131_19_T0	PHENOTYPE	3	4	vascular disease
NCT0000013119	NCT00000131_19_T1	PHENOTYPE	2	3	retinal vascular
NCT0000013119	NCT00000131_19_T2	PHENOTYPE	14	15	diabetic retinopathy
NCT000001320	NCT00000132_0_T0	PHENOTYPE	2	2	Glaucoma
NCT000001322	NCT00000132_2_T0	PHENOTYPE	1	1	secondary
NCT000001322	NCT00000132_2_T1	PHENOTYPE	20	20	glaucoma
NCT000001322	NCT00000132_2_T2	PHENOTYPE	31	31	glaucoma
NCT000001322	NCT00000132_2_T3	PHENOTYPE	21	21	progression
NCT000001322	NCT00000132_2_T4	PHENOTYPE	9	9	IOP
NCT000001325	NCT00000132_5_T0	PHENOTYPE	12	12	glaucoma
NCT000001325	NCT00000132_5_T1	PHENOTYPE	5	6	intraocular pressure
NCT000001326	NCT00000132_6_T0	PHENOTYPE	19	19	glaucoma
NCT000001328	NCT00000132_8_T0	PHENOTYPE	6	6	progression
NCT000001329	NCT00000132_9_T0	PHENOTYPE	10	10	glaucoma
NCT000001329	NCT00000132_9_T1	PHENOTYPE	7	8	intraocular pressure
NCT0000013210	NCT00000132_10_T0	PHENOTYPE	3	3	Glaucoma
NCT0000013210	NCT00000132_10_T1	PHENOTYPE	25	25	progression
NCT0000013210	NCT00000132_10_T2	PHENOTYPE	21	22	intraocular pressure
NCT0000013210	NCT00000132_10_T3	PHENOTYPE	29	30	open-angle glaucoma
NCT0000013211	NCT00000132_11_T0	PHENOTYPE	4	4	glaucoma
NCT0000013211	NCT00000132_11_T1	PHENOTYPE	5	5	progression
NCT0000013211	NCT00000132_11_T2	PHENOTYPE	29	29	progression
NCT0000013211	NCT00000132_11_T3	PHENOTYPE	15	16	open-angle glaucoma
NCT0000013214	NCT00000132_14_T0	GENE	4	4	has
NCT0000013214	NCT00000132_14_T1	PHENOTYPE	0	0	Recruitment
NCT0000013216	NCT00000132_16_T0	PHENOTYPE	17	17	Center
NCT0000013217	NCT00000132_17_T0	GENE	6	6	had
NCT0000013218	NCT00000132_18_T0	GENE	8	8	blocker
NCT0000013218	NCT00000132_18_T1	COMPOUND	11	11	argon
NCT0000013218	NCT00000132_18_T2	GENE	7	7	beta
NCT0000013220	NCT00000132_20_T0	PHENOTYPE	10	10	IOP
NCT0000013222	NCT00000132_22_T0	GENE	2	2	disc
NCT0000013223	NCT00000132_23_T0	GENE	19	19	35
NCT0000013223	NCT00000132_23_T1	GENE	13	13	25
NCT0000013223	NCT00000132_23_T2	PHENOTYPE	9	9	progression
NCT0000013223	NCT00000132_23_T3	PHENOTYPE	11	11	IOP
NCT0000013223	NCT00000132_23_T4	GENE	15	15	Hg
NCT0000013223	NCT00000132_23_T5	GENE	21	21	Hg
NCT0000013224	NCT00000132_24_T0	PHENOTYPE	8	8	IOP
NCT0000013224	NCT00000132_24_T1	PHENOTYPE	27	27	IOP
NCT0000013224	NCT00000132_24_T2	GENE	12	12	Hg
NCT0000013224	NCT00000132_24_T3	GENE	31	31	Hg
NCT0000013225	NCT00000132_25_T0	PHENOTYPE	1	1	IOP
NCT0000013227	NCT00000132_27_T0	PHENOTYPE	4	4	glaucoma
NCT0000013227	NCT00000132_27_T1	PHENOTYPE	5	5	progression
NCT0000013227	NCT00000132_27_T2	GENE	23	23	disc
NCT000001330	NCT00000133_0_T0	PHENOTYPE	2	4	Retinopathy of Prematurity
NCT000001330	NCT00000133_0_T1	PHENOTYPE	12	14	Retinopathy of Prematurity
NCT000001337	NCT00000133_7_T0	PHENOTYPE	24	25	premature infants
NCT000001339	NCT00000133_9_T0	COMPOUND	12	12	oxygen
NCT000001339	NCT00000133_9_T1	COMPOUND	30	30	oxygen
NCT0000013321	NCT00000133_21_T0	ORGAN	1	1	eyes
NCT0000013326	NCT00000133_26_T0	ORGAN	31	31	eyes
NCT0000013328	NCT00000133_28_T0	ORGAN	20	20	eyes
NCT0000013329	NCT00000133_29_T0	GENE	21	21	had
NCT0000013329	NCT00000133_29_T1	ORGAN	11	11	eyes
NCT0000013329	NCT00000133_29_T2	ORGAN	20	20	eyes
NCT0000013333	NCT00000133_33_T0	GENE	1	1	had
NCT0000013333	NCT00000133_33_T1	PHENOTYPE	7	8	congenital anomalies
NCT000001340	NCT00000134_0_T0	PHENOTYPE	4	4	Complications
NCT000001340	NCT00000134_0_T1	PHENOTYPE	8	8	Retinitis
NCT000001342	NCT00000134_2_T0	COMPOUND	9	9	ganciclovir
NCT000001342	NCT00000134_2_T1	COMPOUND	15	15	ganciclovir
NCT000001342	NCT00000134_2_T2	COMPOUND	6	6	foscarnet
NCT000001342	NCT00000134_2_T3	COMPOUND	13	13	foscarnet
NCT000001347	NCT00000134_7_T0	PHENOTYPE	2	2	retinitis
NCT000001347	NCT00000134_7_T1	PHENOTYPE	24	24	retinitis
NCT000001347	NCT00000134_7_T2	PHENOTYPE	21	21	relapse
NCT0000013410	NCT00000134_10_T0	PHENOTYPE	16	16	retinitis
NCT000001356	NCT00000135_6_T0	COMPOUND	16	16	cidofovir
NCT000001356	NCT00000135_6_T1	COMPOUND	9	9	foscarnet
NCT0000013513	NCT00000135_13_T0	COMPOUND	3	3	ganciclovir
NCT0000013513	NCT00000135_13_T1	COMPOUND	4	4	foscarnet
NCT000001364	NCT00000136_4_T0	COMPOUND	7	7	ganciclovir
NCT000001364	NCT00000136_4_T1	COMPOUND	9	9	foscarnet
NCT000001365	NCT00000136_5_T0	PHENOTYPE	29	29	relapse
NCT000001369	NCT00000136_9_T0	PHENOTYPE	8	8	retinitis
NCT000001369	NCT00000136_9_T1	PHENOTYPE	9	9	progression
NCT000001374	NCT00000137_4_T0	ORGAN	14	14	graft
NCT000001375	NCT00000137_5_T0	GENE	14	14	HLA-A
NCT000001375	NCT00000137_5_T1	GENE	24	24	had
NCT0000013714	NCT00000137_14_T0	ORGAN	0	0	Transplant
NCT0000013715	NCT00000137_15_T0	GENE	6	6	tapered
NCT0000013716	NCT00000137_16_T0	ORGAN	5	5	allograft
NCT0000013717	NCT00000137_17_T0	PHENOTYPE	12	12	secondary
NCT0000013717	NCT00000137_17_T1	ORGAN	0	0	Allograft
NCT000001381	NCT00000138_1_T0	COMPOUND	20	20	trifluridine
NCT000001381	NCT00000138_1_T1	COMPOUND	6	6	acyclovir
NCT000001381	NCT00000138_1_T2	PHENOTYPE	11	12	stromal keratitis
NCT000001381	NCT00000138_1_T3	PHENOTYPE	9	10	herpes simplex
NCT000001382	NCT00000138_2_T0	COMPOUND	20	20	trifluridine
NCT000001382	NCT00000138_2_T1	COMPOUND	6	6	acyclovir
NCT000001382	NCT00000138_2_T2	PHENOTYPE	9	11	herpes simplex iridocyclitis
NCT000001387	NCT00000138_7_T0	PHENOTYPE	14	14	HSV
NCT000001387	NCT00000138_7_T1	PHENOTYPE	15	16	stromal keratitis
NCT000001389	NCT00000138_9_T0	PHENOTYPE	21	21	iridocyclitis
NCT000001389	NCT00000138_9_T1	COMPOUND	14	14	acyclovir
NCT000001389	NCT00000138_9_T2	PHENOTYPE	17	17	HSV
NCT000001389	NCT00000138_9_T3	PHENOTYPE	18	19	stromal keratitis
NCT0000013811	NCT00000138_11_T0	PHENOTYPE	12	12	centers
NCT0000013812	NCT00000138_12_T0	PHENOTYPE	10	10	recurrences
NCT0000013812	NCT00000138_12_T1	PHENOTYPE	14	14	ulceration
NCT0000013812	NCT00000138_12_T2	COMPOUND	6	6	trifluridine
NCT0000013812	NCT00000138_12_T3	PHENOTYPE	12	12	HSV
NCT0000013816	NCT00000138_16_T0	PHENOTYPE	0	0	Herpes
NCT0000013816	NCT00000138_16_T1	GENE	15	15	had
NCT0000013816	NCT00000138_16_T2	PHENOTYPE	11	11	HSV
NCT0000013816	NCT00000138_16_T3	PHENOTYPE	12	13	stromal keratitis
NCT0000013816	NCT00000138_16_T4	PHENOTYPE	1	2	Stromal Keratitis
NCT0000013816	NCT00000138_16_T5	COMPOUND	32	33	prednisolone phosphate
NCT0000013819	NCT00000138_19_T0	PHENOTYPE	0	0	Herpes
NCT0000013819	NCT00000138_19_T1	PHENOTYPE	10	10	HSV
NCT0000013819	NCT00000138_19_T2	COMPOUND	31	31	acyclovir
NCT0000013819	NCT00000138_19_T3	PHENOTYPE	11	12	stromal keratitis
NCT0000013819	NCT00000138_19_T4	PHENOTYPE	1	2	Stromal Keratitis
NCT0000013820	NCT00000138_20_T0	COMPOUND	4	5	prednisolone phosphate
NCT0000013821	NCT00000138_21_T0	PHENOTYPE	12	12	iridocyclitis
NCT0000013821	NCT00000138_21_T1	PHENOTYPE	3	3	Iridocyclitis
NCT0000013821	NCT00000138_21_T2	COMPOUND	22	22	acyclovir
NCT0000013821	NCT00000138_21_T3	PHENOTYPE	11	11	HSV
NCT0000013821	NCT00000138_21_T4	PHENOTYPE	0	1	Herpes Simplex
NCT0000013822	NCT00000138_22_T0	COMPOUND	4	5	prednisolone phosphate
NCT000001395	NCT00000139_5_T0	PHENOTYPE	26	26	recurrence
NCT000001395	NCT00000139_5_T1	PHENOTYPE	28	28	severity
NCT000001395	NCT00000139_5_T2	PHENOTYPE	13	13	keratitis
NCT000001395	NCT00000139_5_T3	PHENOTYPE	33	33	iridocyclitis
NCT000001395	NCT00000139_5_T4	PHENOTYPE	12	12	HSV
NCT000001395	NCT00000139_5_T5	PHENOTYPE	30	31	stromal keratitis
NCT000001396	NCT00000139_6_T0	ORGAN	21	21	corneas
NCT000001397	NCT00000139_7_T0	PHENOTYPE	18	18	recurrence
NCT000001397	NCT00000139_7_T1	PHENOTYPE	20	20	HSV
NCT000001397	NCT00000139_7_T2	COMPOUND	12	12	acyclovir
NCT0000013910	NCT00000139_10_T0	PHENOTYPE	13	13	centers
NCT0000013911	NCT00000139_11_T0	PHENOTYPE	14	14	practices
NCT0000013912	NCT00000139_12_T0	PHENOTYPE	20	20	keratitis
NCT0000013912	NCT00000139_12_T1	PHENOTYPE	24	24	keratitis
NCT0000013912	NCT00000139_12_T2	PHENOTYPE	18	18	acute
NCT0000013912	NCT00000139_12_T3	PHENOTYPE	4	4	Keratitis
NCT0000013912	NCT00000139_12_T4	PHENOTYPE	32	32	complications
NCT0000013912	NCT00000139_12_T5	COMPOUND	12	12	acyclovir
NCT0000013912	NCT00000139_12_T6	PHENOTYPE	19	19	HSV
NCT0000013912	NCT00000139_12_T7	PHENOTYPE	0	1	Herpes Simplex
NCT0000013914	NCT00000139_14_T0	COMPOUND	16	16	acyclovir
NCT0000013915	NCT00000139_15_T0	GENE	1	1	had
NCT0000013917	NCT00000139_17_T0	PHENOTYPE	2	2	recruitment
NCT0000013919	NCT00000139_19_T0	PHENOTYPE	19	19	iridocyclitis
NCT0000013919	NCT00000139_19_T1	PHENOTYPE	15	15	blepharitis
NCT0000013919	NCT00000139_19_T2	PHENOTYPE	16	16	conjunctivitis
NCT0000013919	NCT00000139_19_T3	PHENOTYPE	17	17	keratitis
NCT0000013919	NCT00000139_19_T4	PHENOTYPE	11	13	ocular herpes simplex
NCT0000013919	NCT00000139_19_T5	PHENOTYPE	12	14	herpes simplex infection
NCT0000013921	NCT00000139_21_T0	COMPOUND	7	7	acyclovir
NCT0000013925	NCT00000139_25_T0	PHENOTYPE	1	1	recruitment
NCT0000013929	NCT00000139_29_T0	PHENOTYPE	14	14	acute
NCT0000013929	NCT00000139_29_T1	PHENOTYPE	19	19	illnesses
NCT0000013929	NCT00000139_29_T2	PHENOTYPE	20	20	injuries
NCT0000013929	NCT00000139_29_T3	PHENOTYPE	16	16	chronic
NCT0000013930	NCT00000139_30_T0	PHENOTYPE	19	19	Center
NCT000001406	NCT00000140_6_T0	PHENOTYPE	1	1	complications
NCT000001409	NCT00000140_9_T0	GENE	11	11	had
NCT000001409	NCT00000140_9_T1	GENE	13	13	had
NCT000001409	NCT00000140_9_T2	GENE	22	22	had
NCT000001409	NCT00000140_9_T3	ORGAN	3	3	eyes
NCT000001409	NCT00000140_9_T4	ORGAN	9	9	eyes
NCT000001409	NCT00000140_9_T5	GENE	17	18	Group 1
NCT0000014017	NCT00000140_17_T0	PHENOTYPE	4	4	complication
NCT000001422	NCT00000142_2_T0	COMPOUND	1	1	cidofovir
NCT000001422	NCT00000142_2_T1	COMPOUND	17	17	cidofovir
NCT000001423	NCT00000142_3_T0	COMPOUND	1	1	cidofovir
NCT000001423	NCT00000142_3_T1	COMPOUND	13	13	cidofovir
NCT000001427	NCT00000142_7_T0	GENE	1	1	has
NCT0000014210	NCT00000142_10_T0	COMPOUND	8	8	cidofovir
NCT0000014213	NCT00000142_13_T0	COMPOUND	9	9	cidofovir
NCT0000014213	NCT00000142_13_T1	COMPOUND	32	32	cidofovir
NCT0000014214	NCT00000142_14_T0	PHENOTYPE	11	11	judgement
NCT0000014214	NCT00000142_14_T1	PHENOTYPE	2	2	retinitis
NCT0000014214	NCT00000142_14_T2	COMPOUND	21	21	cidofovir
NCT0000014215	NCT00000142_15_T0	PHENOTYPE	5	5	retinitis
NCT0000014215	NCT00000142_15_T1	PHENOTYPE	6	6	progression
NCT000001431	NCT00000143_1_T0	COMPOUND	11	11	ganciclovir
NCT000001437	NCT00000143_7_T0	PHENOTYPE	11	11	retinitis
NCT000001437	NCT00000143_7_T1	PHENOTYPE	8	8	relapse
NCT0000014312	NCT00000143_12_T0	COMPOUND	12	12	cidofovir
NCT0000014312	NCT00000143_12_T1	COMPOUND	5	5	ganciclovir
NCT0000014312	NCT00000143_12_T2	COMPOUND	7	7	ganciclovir
NCT0000014313	NCT00000143_13_T0	BIOLOGICAL_PROCESS	11	12	viral replication
NCT0000014314	NCT00000143_14_T0	PHENOTYPE	25	25	retinitis
NCT0000014314	NCT00000143_14_T1	PHENOTYPE	3	3	Retinitis
NCT0000014314	NCT00000143_14_T2	COMPOUND	10	10	ganciclovir
NCT0000014314	NCT00000143_14_T3	COMPOUND	12	12	foscarnet
NCT0000014315	NCT00000143_15_T0	COMPOUND	6	6	cidofovir
NCT0000014315	NCT00000143_15_T1	COMPOUND	10	10	ganciclovir
NCT0000014315	NCT00000143_15_T2	PHENOTYPE	17	18	relapsed disease
NCT0000014317	NCT00000143_17_T0	COMPOUND	20	20	cidofovir
NCT0000014317	NCT00000143_17_T1	COMPOUND	11	11	ganciclovir
NCT0000014317	NCT00000143_17_T2	COMPOUND	16	16	ganciclovir
NCT0000014319	NCT00000143_19_T0	COMPOUND	1	1	ganciclovir
NCT0000014322	NCT00000143_22_T0	COMPOUND	4	4	cidofovir
NCT0000014323	NCT00000143_23_T0	GENE	10	10	lines
NCT0000014323	NCT00000143_23_T1	PHENOTYPE	21	23	visual field loss
NCT0000014325	NCT00000143_25_T0	PHENOTYPE	24	24	progression
NCT000001443	NCT00000144_3_T0	PHENOTYPE	10	10	glaucoma
NCT000001443	NCT00000144_3_T1	GENE	2	2	has
NCT000001443	NCT00000144_3_T2	ORGAN	13	13	eyes
NCT000001447	NCT00000144_7_T0	PHENOTYPE	1	1	Glaucoma
NCT000001447	NCT00000144_7_T1	PHENOTYPE	20	20	Glaucoma
NCT000001448	NCT00000144_8_T0	PHENOTYPE	5	5	Glaucoma
NCT000001448	NCT00000144_8_T1	PHENOTYPE	18	19	open-angle glaucoma
NCT000001449	NCT00000144_9_T0	COMPOUND	1	1	argon
NCT000001449	NCT00000144_9_T1	PHENOTYPE	24	24	burns
NCT000001449	NCT00000144_9_T2	ORGAN	16	17	trabecular meshwork
NCT0000014411	NCT00000144_11_T0	ORGAN	6	6	eyes
NCT0000014411	NCT00000144_11_T1	PHENOTYPE	11	12	intraocular pressure
NCT0000014416	NCT00000144_16_T0	GENE	7	7	reduced
NCT0000014416	NCT00000144_16_T1	PHENOTYPE	1	2	intraocular pressure
NCT000001453	NCT00000145_3_T0	PHENOTYPE	13	13	diseases
NCT0000014516	NCT00000145_16_T0	COMPOUND	9	9	zinc
NCT0000014516	NCT00000145_16_T1	COMPOUND	13	13	zinc
NCT000001460	NCT00000146_0_T0	PHENOTYPE	0	1	Optic Neuritis
NCT000001462	NCT00000146_2_T0	PHENOTYPE	11	12	optic neuritis
NCT000001467	NCT00000146_7_T0	PHENOTYPE	6	7	multiple sclerosis
NCT0000014610	NCT00000146_10_T0	PHENOTYPE	16	17	contrast sensitivity
NCT0000014611	NCT00000146_11_T0	PHENOTYPE	3	4	Optic Neuritis
NCT0000014611	NCT00000146_11_T1	PHENOTYPE	12	13	optic neuritis
NCT0000014612	NCT00000146_12_T0	GENE	2	2	had
NCT0000014612	NCT00000146_12_T1	GENE	14	14	had
NCT0000014613	NCT00000146_13_T0	COMPOUND	6	6	prednisone
NCT0000014615	NCT00000146_15_T0	PHENOTYPE	6	7	multiple sclerosis
NCT0000014615	NCT00000146_15_T1	PHENOTYPE	3	4	optic neuritis
NCT0000014616	NCT00000146_16_T0	PHENOTYPE	0	1	Optic neuritis
NCT0000014616	NCT00000146_16_T1	PHENOTYPE	8	9	multiple sclerosis
NCT0000014618	NCT00000146_18_T0	PHENOTYPE	6	7	multiple sclerosis
NCT0000014618	NCT00000146_18_T1	PHENOTYPE	9	10	optic neuritis
NCT0000014620	NCT00000146_20_T0	GENE	10	10	MRI
NCT0000014620	NCT00000146_20_T1	PHENOTYPE	24	25	multiple sclerosis
NCT0000014620	NCT00000146_20_T2	PHENOTYPE	17	18	optic neuritis
NCT0000014621	NCT00000146_21_T0	PHENOTYPE	9	10	Optic Neuritis
NCT0000014621	NCT00000146_21_T1	PHENOTYPE	24	25	Optic Neuritis
NCT0000014622	NCT00000146_22_T0	PHENOTYPE	8	8	centers
NCT0000014623	NCT00000146_23_T0	PHENOTYPE	1	1	centers
NCT0000014625	NCT00000146_25_T0	COMPOUND	12	12	methylprednisolone
NCT0000014625	NCT00000146_25_T1	COMPOUND	2	2	prednisone
NCT0000014626	NCT00000146_26_T0	GENE	23	23	MRI
NCT0000014626	NCT00000146_26_T1	PHENOTYPE	8	8	syphilis
NCT0000014626	NCT00000146_26_T2	PHENOTYPE	19	19	sarcoidosis
NCT0000014626	NCT00000146_26_T3	PHENOTYPE	31	32	multiple sclerosis
NCT0000014626	NCT00000146_26_T4	PHENOTYPE	10	12	systemic lupus erythematosus
NCT0000014627	NCT00000146_27_T0	PHENOTYPE	18	19	contrast sensitivity
NCT0000014628	NCT00000146_28_T0	PHENOTYPE	8	9	multiple sclerosis
NCT000001470	NCT00000147_0_T0	PHENOTYPE	1	2	Optic Neuritis
NCT000001472	NCT00000147_2_T0	PHENOTYPE	11	12	optic neuritis
NCT000001477	NCT00000147_7_T0	PHENOTYPE	6	7	multiple sclerosis
NCT0000014710	NCT00000147_10_T0	PHENOTYPE	16	17	contrast sensitivity
NCT0000014711	NCT00000147_11_T0	PHENOTYPE	3	4	Optic Neuritis
NCT0000014711	NCT00000147_11_T1	PHENOTYPE	12	13	optic neuritis
NCT0000014712	NCT00000147_12_T0	GENE	2	2	had
NCT0000014712	NCT00000147_12_T1	GENE	14	14	had
NCT0000014713	NCT00000147_13_T0	COMPOUND	6	6	prednisone
NCT0000014715	NCT00000147_15_T0	PHENOTYPE	6	7	multiple sclerosis
NCT0000014715	NCT00000147_15_T1	PHENOTYPE	3	4	optic neuritis
NCT0000014716	NCT00000147_16_T0	PHENOTYPE	0	1	Optic neuritis
NCT0000014716	NCT00000147_16_T1	PHENOTYPE	8	9	multiple sclerosis
NCT0000014718	NCT00000147_18_T0	PHENOTYPE	6	7	multiple sclerosis
NCT0000014718	NCT00000147_18_T1	PHENOTYPE	9	10	optic neuritis
NCT0000014720	NCT00000147_20_T0	GENE	10	10	MRI
NCT0000014720	NCT00000147_20_T1	PHENOTYPE	24	25	multiple sclerosis
NCT0000014720	NCT00000147_20_T2	PHENOTYPE	17	18	optic neuritis
NCT0000014721	NCT00000147_21_T0	PHENOTYPE	9	10	Optic Neuritis
NCT0000014721	NCT00000147_21_T1	PHENOTYPE	24	25	Optic Neuritis
NCT0000014722	NCT00000147_22_T0	PHENOTYPE	8	8	centers
NCT0000014723	NCT00000147_23_T0	PHENOTYPE	1	1	centers
NCT0000014726	NCT00000147_26_T0	COMPOUND	12	12	methylprednisolone
NCT0000014726	NCT00000147_26_T1	COMPOUND	2	2	prednisone
NCT0000014727	NCT00000147_27_T0	GENE	23	23	MRI
NCT0000014727	NCT00000147_27_T1	PHENOTYPE	8	8	syphilis
NCT0000014727	NCT00000147_27_T2	PHENOTYPE	19	19	sarcoidosis
NCT0000014727	NCT00000147_27_T3	PHENOTYPE	31	32	multiple sclerosis
NCT0000014727	NCT00000147_27_T4	PHENOTYPE	10	12	systemic lupus erythematosus
NCT0000014728	NCT00000147_28_T0	PHENOTYPE	18	19	contrast sensitivity
NCT0000014729	NCT00000147_29_T0	PHENOTYPE	8	9	multiple sclerosis
NCT000001480	NCT00000148_0_T0	PHENOTYPE	1	1	Glaucoma
NCT000001484	NCT00000148_4_T0	GENE	4	4	has
NCT000001488	NCT00000148_8_T0	PHENOTYPE	2	2	Glaucoma
NCT000001488	NCT00000148_8_T1	PHENOTYPE	24	24	glaucoma
NCT0000014812	NCT00000148_12_T0	ORGAN	0	0	Eyes
NCT0000014814	NCT00000148_14_T0	PHENOTYPE	7	7	glaucoma
NCT0000014814	NCT00000148_14_T1	ORGAN	4	4	eyes
NCT0000014815	NCT00000148_15_T0	PHENOTYPE	28	28	complications
NCT0000014819	NCT00000148_19_T0	PHENOTYPE	30	30	attributable
NCT0000014819	NCT00000148_19_T1	PHENOTYPE	35	35	glaucoma
NCT0000014819	NCT00000148_19_T2	ORGAN	10	10	eyes
NCT0000014820	NCT00000148_20_T0	PHENOTYPE	0	0	Secondary
NCT0000014820	NCT00000148_20_T1	PHENOTYPE	14	14	glaucoma
NCT0000014820	NCT00000148_20_T2	PHENOTYPE	19	20	intraocular pressure
NCT0000014821	NCT00000148_21_T0	PHENOTYPE	5	6	filtering bleb
NCT000001492	NCT00000149_2_T0	GENE	14	14	has
NCT000001492	NCT00000149_2_T1	PHENOTYPE	11	13	quality of life
NCT000001493	NCT00000149_3_T0	PHENOTYPE	3	3	Glaucoma
NCT000001497	NCT00000149_7_T0	COMPOUND	15	15	argon
NCT0000014912	NCT00000149_12_T0	PHENOTYPE	17	18	intraocular pressure
NCT0000014914	NCT00000149_14_T0	PHENOTYPE	19	21	quality of life
NCT0000014915	NCT00000149_15_T0	PHENOTYPE	5	5	Sickness
NCT000001500	NCT00000150_0_T0	GENE	3	3	SST
NCT000001503	NCT00000150_3_T0	PHENOTYPE	17	18	macular degeneration
NCT000001508	NCT00000150_8_T0	PHENOTYPE	27	27	spots
NCT000001508	NCT00000150_8_T1	PHENOTYPE	21	21	histoplasmosis
NCT000001508	NCT00000150_8_T2	GENE	1	1	has
NCT000001508	NCT00000150_8_T3	ORGAN	40	40	eyes
NCT0000015013	NCT00000150_13_T0	PHENOTYPE	14	14	enlargement
NCT0000015013	NCT00000150_13_T1	PHENOTYPE	24	24	macula
NCT0000015013	NCT00000150_13_T2	PHENOTYPE	17	18	visual defect
NCT0000015025	NCT00000150_25_T0	PHENOTYPE	0	2	Quality of life
NCT000001511	NCT00000151_1_T0	PHENOTYPE	11	12	diabetic retinopathy
NCT000001516	NCT00000151_6_T0	PHENOTYPE	16	16	severity
NCT000001516	NCT00000151_6_T1	GENE	25	25	disc
NCT000001516	NCT00000151_6_T2	PHENOTYPE	14	15	macular edema
NCT000001519	NCT00000151_9_T0	PHENOTYPE	13	13	severity
NCT000001519	NCT00000151_9_T1	PHENOTYPE	4	5	macular edema
NCT0000015110	NCT00000151_10_T0	COMPOUND	4	4	aspirin
NCT0000015111	NCT00000151_11_T0	PHENOTYPE	20	20	retinopathy
NCT0000015111	NCT00000151_11_T1	COMPOUND	11	11	aspirin
NCT0000015111	NCT00000151_11_T2	PHENOTYPE	13	14	rheumatoid arthritis
NCT0000015113	NCT00000151_13_T0	COMPOUND	5	5	aspirin
NCT000001520	NCT00000152_0_T0	PHENOTYPE	5	6	Macular Degeneration
NCT000001527	NCT00000152_7_T0	PHENOTYPE	4	5	macular degeneration
NCT0000015213	NCT00000152_13_T0	BIOLOGICAL_PROCESS	17	17	beta-carotene
NCT0000015213	NCT00000152_13_T1	COMPOUND	8	8	aspirin
NCT0000015214	NCT00000152_14_T0	BIOLOGICAL_PROCESS	23	23	beta-carotene
NCT0000015214	NCT00000152_14_T1	COMPOUND	18	18	aspirin
NCT0000015219	NCT00000152_19_T0	COMPOUND	9	9	selenium
NCT0000015219	NCT00000152_19_T1	BIOLOGICAL_PROCESS	2	2	beta-carotene
NCT000001534	NCT00000153_4_T0	ORGAN	35	35	eyes
NCT000001534	NCT00000153_4_T1	COMPOUND	6	6	krypton
NCT000001534	NCT00000153_4_T2	TISSUE	33	33	epithelium
NCT000001534	NCT00000153_4_T3	PHENOTYPE	29	29	burns
NCT000001534	NCT00000153_4_T4	PHENOTYPE	37	38	vitreous hemorrhage
NCT000001534	NCT00000153_4_T5	PHENOTYPE	12	13	diabetic retinopathy
NCT000001537	NCT00000153_7_T0	COMPOUND	2	2	krypton
NCT000001537	NCT00000153_7_T1	PHENOTYPE	11	11	macula
NCT000001537	NCT00000153_7_T2	CELL	6	7	nerve fiber
NCT000001538	NCT00000153_8_T0	COMPOUND	10	10	argon
NCT000001538	NCT00000153_8_T1	PHENOTYPE	5	5	burns
NCT000001538	NCT00000153_8_T2	CELL	2	3	nerve fiber
NCT0000015311	NCT00000153_11_T0	COMPOUND	25	25	krypton
NCT0000015311	NCT00000153_11_T1	COMPOUND	23	23	argon
NCT0000015311	NCT00000153_11_T2	GENE	11	11	disc
NCT0000015311	NCT00000153_11_T3	GENE	8	8	NVD
NCT0000015311	NCT00000153_11_T4	PHENOTYPE	5	6	diabetic retinopathy
NCT0000015312	NCT00000153_12_T0	GENE	1	1	null
NCT0000015312	NCT00000153_12_T1	PHENOTYPE	16	16	regression
NCT0000015312	NCT00000153_12_T2	ORGAN	14	14	eyes
NCT0000015312	NCT00000153_12_T3	GENE	19	19	NVD
NCT0000015313	NCT00000153_13_T0	PHENOTYPE	15	15	proliferative
NCT0000015313	NCT00000153_13_T1	COMPOUND	8	8	argon
NCT0000015313	NCT00000153_13_T2	PHENOTYPE	16	17	diabetic retinopathy
NCT0000015313	NCT00000153_13_T3	PHENOTYPE	23	24	Diabetic Retinopathy
NCT0000015315	NCT00000153_15_T0	PHENOTYPE	3	3	centers
NCT0000015319	NCT00000153_19_T0	COMPOUND	11	11	krypton
NCT0000015319	NCT00000153_19_T1	COMPOUND	9	9	argon
NCT0000015320	NCT00000153_20_T0	GENE	10	10	0.5
NCT0000015320	NCT00000153_20_T1	PHENOTYPE	8	8	burns
NCT0000015322	NCT00000153_22_T0	GENE	12	12	disc
NCT0000015322	NCT00000153_22_T1	GENE	29	29	disc
NCT0000015322	NCT00000153_22_T2	PHENOTYPE	1	1	burns
NCT0000015323	NCT00000153_23_T0	PHENOTYPE	12	12	focal
NCT0000015323	NCT00000153_23_T1	PHENOTYPE	22	23	visual loss
NCT0000015323	NCT00000153_23_T2	PHENOTYPE	6	7	Diabetic Retinopathy
NCT0000015323	NCT00000153_23_T3	PHENOTYPE	29	31	diabetic macular edema
NCT0000015325	NCT00000153_25_T0	PHENOTYPE	6	6	regression
NCT0000015325	NCT00000153_25_T1	GENE	20	20	disc
NCT0000015325	NCT00000153_25_T2	GENE	25	25	disc
NCT0000015325	NCT00000153_25_T3	GENE	8	8	NVD
NCT000001540	NCT00000154_0_T0	PHENOTYPE	0	1	Diabetic Retinopathy
NCT000001542	NCT00000154_2_T0	PHENOTYPE	27	27	macula
NCT000001542	NCT00000154_2_T1	PHENOTYPE	5	5	hemorrhage
NCT000001542	NCT00000154_2_T2	PHENOTYPE	20	21	retinal detachment
NCT000001544	NCT00000154_4_T0	PHENOTYPE	7	7	proliferative
NCT000001544	NCT00000154_4_T1	PHENOTYPE	8	9	diabetic retinopathy
NCT000001546	NCT00000154_6_T0	PHENOTYPE	22	22	complications
NCT000001546	NCT00000154_6_T1	GENE	10	10	has
NCT000001549	NCT00000154_9_T0	ORGAN	1	1	eyes
NCT0000015410	NCT00000154_10_T0	PHENOTYPE	28	28	macula
NCT0000015410	NCT00000154_10_T1	PHENOTYPE	13	13	hemorrhage
NCT0000015410	NCT00000154_10_T2	PHENOTYPE	21	22	retinal detachment
NCT0000015412	NCT00000154_12_T0	ORGAN	1	1	eyes
NCT0000015413	NCT00000154_13_T0	PHENOTYPE	33	33	macula
NCT0000015413	NCT00000154_13_T1	PHENOTYPE	11	12	vitreous hemorrhage
NCT0000015413	NCT00000154_13_T2	PHENOTYPE	26	27	retinal detachment
NCT000001550	NCT00000155_0_T0	PHENOTYPE	5	5	Keratoconus
NCT000001552	NCT00000155_2_T0	PHENOTYPE	10	10	severity
NCT000001552	NCT00000155_2_T1	PHENOTYPE	14	14	keratoconus
NCT000001552	NCT00000155_2_T2	PHENOTYPE	12	12	progression
NCT000001554	NCT00000155_4_T0	PHENOTYPE	7	8	disease progression
NCT000001555	NCT00000155_5_T0	PHENOTYPE	14	14	rigid
NCT000001556	NCT00000155_6_T0	ORGAN	10	10	eyes
NCT000001557	NCT00000155_7_T0	PHENOTYPE	0	0	Keratoconus
NCT000001557	NCT00000155_7_T1	PHENOTYPE	1	1	affects
NCT000001557	NCT00000155_7_T2	PHENOTYPE	10	10	affects
NCT000001558	NCT00000155_8_T0	PHENOTYPE	4	4	keratoconus
NCT000001558	NCT00000155_8_T1	PHENOTYPE	17	17	keratoconus
NCT000001558	NCT00000155_8_T2	PHENOTYPE	6	6	focused
NCT000001559	NCT00000155_9_T0	PHENOTYPE	18	18	keratoconus
NCT000001559	NCT00000155_9_T1	PHENOTYPE	13	13	progression
NCT0000015511	NCT00000155_11_T0	PHENOTYPE	6	6	keratoconus
NCT0000015512	NCT00000155_12_T0	PHENOTYPE	8	8	keratoconus
NCT0000015514	NCT00000155_14_T0	PHENOTYPE	15	15	keratoconus
NCT0000015514	NCT00000155_14_T1	PHENOTYPE	5	5	Keratoconus
NCT0000015518	NCT00000155_18_T0	PHENOTYPE	6	6	centers
NCT0000015519	NCT00000155_19_T0	PHENOTYPE	2	2	centers
NCT000001560	NCT00000156_0_T0	PHENOTYPE	6	8	Retinopathy of Prematurity
NCT000001563	NCT00000156_3_T0	PHENOTYPE	9	11	low birth weight
NCT000001564	NCT00000156_4_T0	PHENOTYPE	24	24	blindness
NCT0000015614	NCT00000156_14_T0	COMPOUND	1	1	oxygen
NCT0000015617	NCT00000156_17_T0	PHENOTYPE	17	17	Center
NCT0000015622	NCT00000156_22_T0	GENE	2	2	has
NCT000001570	NCT00000157_0_T0	PHENOTYPE	5	5	Cataracts
NCT000001575	NCT00000157_5_T0	PHENOTYPE	0	0	Cataract
NCT000001578	NCT00000157_8_T0	GENE	6	6	has
NCT0000015719	NCT00000157_19_T0	BIOLOGICAL_PROCESS	25	25	beta-carotene
NCT0000015719	NCT00000157_19_T1	COMPOUND	16	16	aspirin
NCT0000015720	NCT00000157_20_T0	BIOLOGICAL_PROCESS	23	23	beta-carotene
NCT0000015720	NCT00000157_20_T1	COMPOUND	18	18	aspirin
NCT0000015722	NCT00000157_22_T0	GENE	27	27	reduced
NCT0000015722	NCT00000157_22_T1	COMPOUND	2	2	aspirin
NCT0000015722	NCT00000157_22_T2	COMPOUND	36	36	aspirin
NCT0000015722	NCT00000157_22_T3	PHENOTYPE	32	33	myocardial infarction
NCT0000015728	NCT00000157_28_T0	PHENOTYPE	14	14	cataracts
NCT000001580	NCT00000158_0_T0	GENE	3	3	MPS
NCT000001582	NCT00000158_2_T0	GENE	4	4	MPS
NCT000001583	NCT00000158_3_T0	GENE	13	13	MPS
NCT0000015810	NCT00000158_10_T0	PHENOTYPE	25	25	recurrent
NCT0000015810	NCT00000158_10_T1	PHENOTYPE	31	32	choroidal neovascularization
NCT0000015810	NCT00000158_10_T2	PHENOTYPE	15	17	visual acuity loss
NCT0000015816	NCT00000158_16_T0	COMPOUND	10	10	argon
NCT0000015816	NCT00000158_16_T1	PHENOTYPE	18	20	visual acuity loss
NCT0000015817	NCT00000158_17_T0	PHENOTYPE	2	2	initiation
NCT0000015817	NCT00000158_17_T1	COMPOUND	9	9	krypton
NCT0000015818	NCT00000158_18_T0	COMPOUND	8	8	argon
NCT0000015818	NCT00000158_18_T1	GENE	14	14	extended
NCT0000015818	NCT00000158_18_T2	PHENOTYPE	20	20	macula
NCT0000015821	NCT00000158_21_T0	COMPOUND	16	16	krypton
NCT0000015821	NCT00000158_21_T1	COMPOUND	10	10	argon
NCT0000015824	NCT00000158_24_T0	COMPOUND	14	14	fluorescein
NCT0000015824	NCT00000158_24_T1	GENE	4	4	had
NCT0000015824	NCT00000158_24_T2	PHENOTYPE	11	12	choroidal neovascularization
NCT0000015830	NCT00000158_30_T0	PHENOTYPE	16	16	neovascularization
NCT0000015830	NCT00000158_30_T1	GENE	10	10	had
NCT0000015830	NCT00000158_30_T2	GENE	23	23	extended
NCT0000015835	NCT00000158_35_T0	GENE	8	8	disc
NCT000001590	NCT00000159_0_T0	PHENOTYPE	1	1	Retinopathy
NCT0000015912	NCT00000159_12_T0	GENE	5	5	AR
NCT0000015912	NCT00000159_12_T1	COMPOUND	11	11	sorbinil
NCT0000015913	NCT00000159_13_T0	GENE	1	1	AR
NCT0000015913	NCT00000159_13_T1	PHENOTYPE	0	0	Other
NCT0000015915	NCT00000159_15_T0	PHENOTYPE	3	3	recruitment
NCT0000015922	NCT00000159_22_T0	PHENOTYPE	2	2	Retinopathy
NCT0000015923	NCT00000159_23_T0	PHENOTYPE	9	9	Centers
NCT0000015923	NCT00000159_23_T1	PHENOTYPE	23	23	Center
NCT0000015926	NCT00000159_26_T0	GENE	4	4	insulin
NCT0000015926	NCT00000159_26_T1	GENE	1	1	had
NCT0000015927	NCT00000159_27_T0	GENE	1	1	hemoglobin
NCT000001602	NCT00000160_2_T0	PHENOTYPE	17	17	proliferative
NCT000001602	NCT00000160_2_T1	COMPOUND	12	12	argon
NCT000001602	NCT00000160_2_T2	COMPOUND	14	14	xenon
NCT000001602	NCT00000160_2_T3	PHENOTYPE	18	19	diabetic retinopathy
NCT000001604	NCT00000160_4_T0	PHENOTYPE	6	7	proliferative retinopathy
NCT000001606	NCT00000160_6_T0	GENE	2	2	has
NCT000001608	NCT00000160_8_T0	PHENOTYPE	14	14	centers
NCT0000016013	NCT00000160_13_T0	COMPOUND	1	1	argon
NCT0000016013	NCT00000160_13_T1	GENE	26	26	disc
NCT0000016013	NCT00000160_13_T2	GENE	31	31	disc
NCT0000016013	NCT00000160_13_T3	GENE	32	32	NVD
NCT0000016013	NCT00000160_13_T4	PHENOTYPE	10	10	burns
NCT0000016014	NCT00000160_14_T0	PHENOTYPE	0	0	Focal
NCT0000016014	NCT00000160_14_T1	PHENOTYPE	6	6	microaneurysms
NCT0000016014	NCT00000160_14_T2	PHENOTYPE	14	15	macular edema
NCT0000016018	NCT00000160_18_T0	GENE	4	4	had
NCT0000016018	NCT00000160_18_T1	GENE	15	15	had
NCT0000016018	NCT00000160_18_T2	ORGAN	14	14	eyes
NCT000001618	NCT00000161_8_T0	PHENOTYPE	0	0	Cataract
NCT0000016128	NCT00000161_28_T0	COMPOUND	2	2	aspirin
NCT000001625	NCT00000162_5_T0	PHENOTYPE	10	11	visual loss
NCT000001627	NCT00000162_7_T0	COMPOUND	7	7	argon
NCT000001629	NCT00000162_9_T0	GENE	17	17	0.2
NCT000001629	NCT00000162_9_T1	PHENOTYPE	2	2	burns
NCT0000016210	NCT00000162_10_T0	PHENOTYPE	3	3	burns
NCT0000016210	NCT00000162_10_T1	PHENOTYPE	1	2	macular edema
NCT0000016211	NCT00000162_11_T0	COMPOUND	1	1	fluorescein
NCT0000016211	NCT00000162_11_T1	GENE	8	8	had
NCT0000016212	NCT00000162_12_T0	COMPOUND	23	23	fluorescein
NCT0000016212	NCT00000162_12_T1	ORGAN	19	19	capillary
NCT0000016212	NCT00000162_12_T2	GENE	13	13	grid
NCT0000016212	NCT00000162_12_T3	COMPOUND	8	8	argon
NCT0000016212	NCT00000162_12_T4	PHENOTYPE	5	5	anesthesia
NCT0000016212	NCT00000162_12_T5	PHENOTYPE	20	20	leakage
NCT0000016213	NCT00000162_13_T0	GENE	2	2	extended
NCT0000016217	NCT00000162_17_T0	PHENOTYPE	5	6	reduced vision
NCT0000016217	NCT00000162_17_T1	PHENOTYPE	2	3	macular edema
NCT0000016218	NCT00000162_18_T0	PHENOTYPE	9	9	symptoms
NCT0000016218	NCT00000162_18_T1	GENE	4	4	had
NCT000001630	NCT00000163_0_T0	PHENOTYPE	0	1	Congenital Esotropia
NCT000001633	NCT00000163_3_T0	PHENOTYPE	28	28	hyperopia
NCT000001633	NCT00000163_3_T1	PHENOTYPE	13	13	esotropia
NCT000001633	NCT00000163_3_T2	PHENOTYPE	21	21	esotropia
NCT000001634	NCT00000163_4_T0	PHENOTYPE	22	23	congenital esotropia
NCT000001638	NCT00000163_8_T0	PHENOTYPE	8	8	esotropia
NCT000001638	NCT00000163_8_T1	PHENOTYPE	17	17	esotropia
NCT000001638	NCT00000163_8_T2	PHENOTYPE	3	4	congenital esotropia
NCT000001639	NCT00000163_9_T0	PHENOTYPE	5	6	congenital esotropia
NCT0000016310	NCT00000163_10_T0	PHENOTYPE	7	8	congenital esotropia
NCT0000016311	NCT00000163_11_T0	PHENOTYPE	8	9	congenital esotropia
NCT0000016315	NCT00000163_15_T0	GENE	11	11	had
NCT0000016319	NCT00000163_19_T0	PHENOTYPE	5	5	amblyopia
NCT0000016319	NCT00000163_19_T1	PHENOTYPE	2	3	refractive error
NCT0000016320	NCT00000163_20_T0	GENE	5	5	has
NCT000001678	NCT00000167_8_T0	PHENOTYPE	15	15	drusen
NCT0000016712	NCT00000167_12_T0	PHENOTYPE	1	1	Complications
NCT0000016712	NCT00000167_12_T1	PHENOTYPE	13	13	drusen
NCT0000016712	NCT00000167_12_T2	PHENOTYPE	4	5	Macular Degeneration
NCT0000016712	NCT00000167_12_T3	PHENOTYPE	21	24	loss of visual acuity
NCT0000016713	NCT00000167_13_T0	PHENOTYPE	28	28	drusen
NCT0000016713	NCT00000167_13_T1	ORGAN	31	31	eyes
NCT0000016713	NCT00000167_13_T2	PHENOTYPE	22	23	vision loss
NCT0000016717	NCT00000167_17_T0	ORGAN	1	1	eyes
NCT0000016720	NCT00000167_20_T0	GENE	12	12	had
NCT0000016720	NCT00000167_20_T1	GENE	17	17	lines
NCT0000016720	NCT00000167_20_T2	ORGAN	6	6	eyes
NCT0000016720	NCT00000167_20_T3	ORGAN	11	11	eyes
NCT0000016721	NCT00000167_21_T0	ORGAN	9	9	eyes
NCT0000016722	NCT00000167_22_T0	ORGAN	8	8	eyes
NCT0000016722	NCT00000167_22_T1	ORGAN	14	14	eyes
NCT0000016723	NCT00000167_23_T0	ORGAN	9	9	eyes
NCT0000016723	NCT00000167_23_T1	ORGAN	15	15	eyes
NCT0000016725	NCT00000167_25_T0	PHENOTYPE	22	22	bilateral
NCT0000016725	NCT00000167_25_T1	PHENOTYPE	24	24	drusen
NCT0000016725	NCT00000167_25_T2	ORGAN	18	18	eyes
NCT000001680	NCT00000168_0_T0	PHENOTYPE	4	4	Complications
NCT000001683	NCT00000168_3_T0	ORGAN	12	12	wool
NCT000001683	NCT00000168_3_T1	PHENOTYPE	15	15	hemorrhages
NCT000001683	NCT00000168_3_T2	PHENOTYPE	7	7	HIV
NCT000001683	NCT00000168_3_T3	PHENOTYPE	8	8	retinopathy
NCT000001683	NCT00000168_3_T4	PHENOTYPE	13	13	spots
NCT000001683	NCT00000168_3_T5	PHENOTYPE	17	17	microaneurysms
NCT000001687	NCT00000168_7_T0	GENE	12	12	has
NCT000001687	NCT00000168_7_T1	PHENOTYPE	18	20	loss of vision
NCT0000016810	NCT00000168_10_T0	GENE	1	1	has
NCT0000016812	NCT00000168_12_T0	GENE	2	2	has
NCT0000016813	NCT00000168_13_T0	PHENOTYPE	27	27	complications
NCT0000016813	NCT00000168_13_T1	PHENOTYPE	9	9	HIV
NCT0000016813	NCT00000168_13_T2	PHENOTYPE	14	15	chronic disease
NCT0000016814	NCT00000168_14_T0	PHENOTYPE	22	22	complications
NCT0000016814	NCT00000168_14_T1	PHENOTYPE	15	16	immune status
NCT0000016815	NCT00000168_15_T0	PHENOTYPE	14	14	complications
NCT0000016815	NCT00000168_15_T1	PHENOTYPE	25	27	quality of life
NCT0000016816	NCT00000168_16_T0	PHENOTYPE	5	5	Complications
NCT0000016817	NCT00000168_17_T0	PHENOTYPE	11	11	Centers
NCT0000016817	NCT00000168_17_T1	PHENOTYPE	23	23	complications
NCT0000016820	NCT00000168_20_T0	PHENOTYPE	6	6	complications
NCT0000016821	NCT00000168_21_T0	PHENOTYPE	6	6	complications
NCT000001690	NCT00000169_0_T0	PHENOTYPE	7	8	Refractive Error
NCT000001693	NCT00000169_3_T0	PHENOTYPE	5	5	nearsighted
NCT000001696	NCT00000169_6_T0	PHENOTYPE	15	15	peripheral
NCT000001696	NCT00000169_6_T1	PHENOTYPE	12	12	myopia
NCT000001696	NCT00000169_6_T2	PHENOTYPE	18	19	intraocular pressure
NCT000001696	NCT00000169_6_T3	PHENOTYPE	16	17	refractive error
NCT000001697	NCT00000169_7_T0	PHENOTYPE	10	11	refractive error
NCT0000016911	NCT00000169_11_T0	PHENOTYPE	11	11	peripheral
NCT0000016911	NCT00000169_11_T1	GENE	6	6	lag
NCT0000016911	NCT00000169_11_T2	PHENOTYPE	7	7	phoria
NCT0000016911	NCT00000169_11_T3	PHENOTYPE	15	16	intraocular pressure
NCT0000016911	NCT00000169_11_T4	PHENOTYPE	12	13	refractive error
NCT0000016915	NCT00000169_15_T0	PHENOTYPE	3	3	myopia
NCT0000016915	NCT00000169_15_T1	PHENOTYPE	27	27	myopia
NCT0000016915	NCT00000169_15_T2	PHENOTYPE	7	7	myopic
NCT0000016916	NCT00000169_16_T0	PHENOTYPE	16	16	Myopia
NCT0000016916	NCT00000169_16_T1	PHENOTYPE	22	22	myopia
NCT0000016921	NCT00000169_21_T0	PHENOTYPE	34	34	peripheral
NCT0000016922	NCT00000169_22_T0	PHENOTYPE	6	6	centers
NCT0000016923	NCT00000169_23_T0	PHENOTYPE	2	2	centers
NCT000001702	NCT00000170_2_T0	PHENOTYPE	10	10	amblyopia
NCT000001702	NCT00000170_2_T1	PHENOTYPE	19	19	patching
NCT000001703	NCT00000170_3_T0	PHENOTYPE	5	5	amblyopia
NCT000001704	NCT00000170_4_T0	PHENOTYPE	6	6	learned
NCT000001704	NCT00000170_4_T1	PHENOTYPE	12	12	amblyopia
NCT000001706	NCT00000170_6_T0	PHENOTYPE	0	0	Occlusion
NCT000001706	NCT00000170_6_T1	PHENOTYPE	12	12	dislike
NCT000001707	NCT00000170_7_T0	PHENOTYPE	18	18	amblyopia
NCT000001709	NCT00000170_9_T0	PHENOTYPE	10	10	occlusion
NCT000001709	NCT00000170_9_T1	GENE	2	2	has
NCT0000017010	NCT00000170_10_T0	PHENOTYPE	11	11	amblyopia
NCT0000017010	NCT00000170_10_T1	GENE	2	2	has
NCT0000017011	NCT00000170_11_T0	GENE	2	2	has
NCT0000017011	NCT00000170_11_T1	GENE	6	6	has
NCT0000017012	NCT00000170_12_T0	PHENOTYPE	12	12	occlusion
NCT0000017012	NCT00000170_12_T1	GENE	7	7	has
NCT0000017012	NCT00000170_12_T2	ORGAN	21	21	eyes
NCT0000017013	NCT00000170_13_T0	ORGAN	21	21	eyes
NCT0000017014	NCT00000170_14_T0	PHENOTYPE	30	30	amblyopia
NCT0000017014	NCT00000170_14_T1	PHENOTYPE	22	22	occlusion
NCT0000017015	NCT00000170_15_T0	PHENOTYPE	8	8	amblyopia
NCT0000017016	NCT00000170_16_T0	PHENOTYPE	14	14	amblyopia
NCT0000017016	NCT00000170_16_T1	GENE	16	16	has
NCT0000017017	NCT00000170_17_T0	PHENOTYPE	25	25	amblyopia
NCT0000017017	NCT00000170_17_T1	PHENOTYPE	7	7	occlusion
NCT0000017018	NCT00000170_18_T0	PHENOTYPE	28	28	amblyopia
NCT0000017019	NCT00000170_19_T0	PHENOTYPE	22	22	amblyopia
NCT0000017019	NCT00000170_19_T1	PHENOTYPE	24	24	fixation
NCT0000017020	NCT00000170_20_T0	GENE	6	6	extended
NCT0000017021	NCT00000170_21_T0	PHENOTYPE	3	3	amblyopia
NCT0000017021	NCT00000170_21_T1	GENE	10	10	extended
NCT000001711	NCT00000171_1_T0	GENE	9	9	AD
NCT000001712	NCT00000171_2_T0	PHENOTYPE	8	8	injuries
NCT000001712	NCT00000171_2_T1	PHENOTYPE	3	4	agitated behavior
NCT000001714	NCT00000171_4_T0	GENE	6	6	secreted
NCT000001714	NCT00000171_4_T1	GENE	5	5	hormone
NCT000001714	NCT00000171_4_T2	ORGAN	9	10	pineal gland
NCT000001715	NCT00000171_5_T0	GENE	1	1	has
NCT000001717	NCT00000171_7_T0	GENE	8	8	AD
NCT000001717	NCT00000171_7_T1	PHENOTYPE	4	5	sleep disturbances
NCT000001719	NCT00000171_9_T0	PHENOTYPE	4	4	agitation
NCT0000017112	NCT00000171_12_T0	GENE	5	5	AD
NCT0000017113	NCT00000171_13_T0	GENE	8	8	AD
NCT0000017113	NCT00000171_13_T1	GENE	7	7	probable
NCT0000017114	NCT00000171_14_T0	ORGAN	21	21	wrist
NCT0000017116	NCT00000171_16_T0	ORGAN	6	6	wrist
NCT0000017119	NCT00000171_19_T0	COMPOUND	8	8	melatonin
NCT0000017120	NCT00000171_20_T0	PHENOTYPE	0	1	Adverse events
NCT0000017121	NCT00000171_21_T0	GENE	22	22	AD
NCT0000017121	NCT00000171_21_T1	COMPOUND	10	10	melatonin
NCT000001721	NCT00000172_1_T0	COMPOUND	7	7	galantamine
NCT000001721	NCT00000172_1_T1	PHENOTYPE	15	16	Alzheimer's disease
NCT000001722	NCT00000172_2_T0	PHENOTYPE	6	7	Alzheimer's disease
NCT000001724	NCT00000172_4_T0	CELL	6	6	cells
NCT000001724	NCT00000172_4_T1	PHENOTYPE	13	13	affects
NCT000001724	NCT00000172_4_T2	GENE	1	1	has
NCT000001724	NCT00000172_4_T3	COMPOUND	9	9	acetylcholine
NCT000001725	NCT00000172_5_T0	COMPOUND	13	13	acetylcholine
NCT000001726	NCT00000172_6_T0	COMPOUND	7	7	acetylcholine
NCT000001726	NCT00000172_6_T1	COMPOUND	21	21	acetylcholine
NCT0000017210	NCT00000172_10_T0	PHENOTYPE	6	7	adverse event
NCT0000017210	NCT00000172_10_T1	PHENOTYPE	20	21	adverse event
NCT0000017211	NCT00000172_11_T0	COMPOUND	7	7	galantamine
NCT0000017212	NCT00000172_12_T0	COMPOUND	7	7	galantamine
NCT0000017212	NCT00000172_12_T1	PHENOTYPE	3	5	dose response relationship
NCT000001735	NCT00000173_5_T0	COMPOUND	8	8	donepezil
NCT000001735	NCT00000173_5_T1	COMPOUND	5	6	vitamin E
NCT000001736	NCT00000173_6_T0	PHENOTYPE	19	19	dementia
NCT000001736	NCT00000173_6_T1	PHENOTYPE	29	29	dementia
NCT000001736	NCT00000173_6_T2	PHENOTYPE	26	26	progression
NCT000001739	NCT00000173_9_T0	COMPOUND	7	7	donepezil
NCT000001739	NCT00000173_9_T1	COMPOUND	17	18	vitamin E
NCT0000017311	NCT00000173_11_T0	COMPOUND	3	3	donepezil
NCT0000017313	NCT00000173_13_T0	COMPOUND	3	4	vitamin E
NCT0000017315	NCT00000173_15_T0	PHENOTYPE	5	5	recruitment
NCT0000017317	NCT00000173_17_T0	GENE	7	7	AD
NCT0000017317	NCT00000173_17_T1	GENE	14	14	ADCS
NCT0000017319	NCT00000173_19_T0	GENE	9	9	AD
NCT0000017321	NCT00000173_21_T0	PHENOTYPE	0	0	Secondary
NCT0000017321	NCT00000173_21_T1	GENE	31	31	ADCS
NCT0000017321	NCT00000173_21_T2	GENE	25	25	CDR
NCT0000017321	NCT00000173_21_T3	PHENOTYPE	15	15	Battery
NCT0000017321	NCT00000173_21_T4	GENE	30	30	GDS
NCT0000017321	NCT00000173_21_T5	PHENOTYPE	22	22	Dementia
NCT0000017321	NCT00000173_21_T6	PHENOTYPE	8	9	Alzheimer's Disease
NCT0000017321	NCT00000173_21_T7	PHENOTYPE	43	45	Quality of Life
NCT0000017325	NCT00000173_25_T0	PHENOTYPE	28	29	major depression
NCT000001742	NCT00000174_2_T0	PHENOTYPE	8	9	Alzheimer's disease
NCT000001743	NCT00000174_3_T0	GENE	2	2	has
NCT000001743	NCT00000174_3_T1	PHENOTYPE	13	14	Alzheimer's disease
NCT000001745	NCT00000174_5_T0	GENE	13	13	3.0
NCT000001745	NCT00000174_5_T1	GENE	8	8	6.0
NCT000001745	NCT00000174_5_T2	GENE	6	6	1.5
NCT000001745	NCT00000174_5_T3	GENE	10	10	bid
NCT000001747	NCT00000174_7_T0	PHENOTYPE	27	27	dementia
NCT000001747	NCT00000174_7_T1	PHENOTYPE	6	7	adverse events
NCT0000017412	NCT00000174_12_T0	PHENOTYPE	12	13	depressive episode
NCT000001755	NCT00000175_5_T0	COMPOUND	11	11	estrogen
NCT000001755	NCT00000175_5_T1	COMPOUND	26	26	estrogen
NCT000001755	NCT00000175_5_T2	COMPOUND	13	13	progesterone
NCT000001755	NCT00000175_5_T3	GENE	4	4	had
NCT000001771	NCT00000177_1_T0	COMPOUND	3	3	estrogen
NCT000001771	NCT00000177_1_T1	ORGAN	8	8	ovaries
NCT000001773	NCT00000177_3_T0	CELL	10	10	cells
NCT000001773	NCT00000177_3_T1	GENE	4	4	has
NCT000001773	NCT00000177_3_T2	GENE	2	2	hormone
NCT000001773	NCT00000177_3_T3	PHENOTYPE	20	21	Alzheimer's disease
NCT000001774	NCT00000177_4_T0	COMPOUND	13	13	estrogen
NCT000001774	NCT00000177_4_T1	COMPOUND	6	6	acetylcholine
NCT000001775	NCT00000177_5_T0	COMPOUND	21	21	estrogen
NCT000001775	NCT00000177_5_T1	PHENOTYPE	9	10	cognitive function
NCT000001775	NCT00000177_5_T2	PHENOTYPE	17	18	Alzheimer's disease
NCT000001784	NCT00000178_4_T0	COMPOUND	16	16	calcium
NCT000001791	NCT00000179_1_T0	PHENOTYPE	2	2	agitation
NCT000001791	NCT00000179_1_T1	PHENOTYPE	8	8	irritability
NCT000001791	NCT00000179_1_T2	PHENOTYPE	7	7	aggressiveness
NCT000001791	NCT00000179_1_T3	PHENOTYPE	11	11	restlessness
NCT000001793	NCT00000179_3_T0	PHENOTYPE	12	12	agitation
NCT000001793	NCT00000179_3_T1	GENE	14	14	AD
NCT000001794	NCT00000179_4_T0	PHENOTYPE	13	13	agitation
NCT000001794	NCT00000179_4_T1	GENE	6	6	has
NCT000001795	NCT00000179_5_T0	PHENOTYPE	15	15	agitation
NCT000001795	NCT00000179_5_T1	GENE	17	17	AD
NCT000001796	NCT00000179_6_T0	PHENOTYPE	16	16	agitation
NCT000001796	NCT00000179_6_T1	BIOLOGICAL_PROCESS	12	12	Aging
NCT000001796	NCT00000179_6_T2	PHENOTYPE	1	2	Alzheimer's Disease
NCT000001802	NCT00000180_2_T0	PHENOTYPE	17	18	age mental
NCT000002053	NCT00000205_3_T0	PHENOTYPE	0	1	Opiate dependence
NCT000002057	NCT00000205_7_T0	PHENOTYPE	2	2	seizures
NCT000002059	NCT00000205_9_T0	PHENOTYPE	0	1	Dependence on
NCT0000020510	NCT00000205_10_T0	PHENOTYPE	0	0	Acute
NCT0000020510	NCT00000205_10_T1	PHENOTYPE	1	1	hepatitis
NCT000002063	NCT00000206_3_T0	PHENOTYPE	0	1	Opiate dependence
NCT000002067	NCT00000206_7_T0	PHENOTYPE	2	2	seizures
NCT000002069	NCT00000206_9_T0	PHENOTYPE	0	1	Dependence on
NCT0000020610	NCT00000206_10_T0	PHENOTYPE	0	0	Acute
NCT0000020610	NCT00000206_10_T1	PHENOTYPE	1	1	hepatitis
NCT000002075	NCT00000207_5_T0	PHENOTYPE	2	2	seizures
NCT000002077	NCT00000207_7_T0	PHENOTYPE	0	1	Dependence on
NCT000002078	NCT00000207_8_T0	PHENOTYPE	0	0	Acute
NCT000002078	NCT00000207_8_T1	PHENOTYPE	1	1	hepatitis
NCT000002082	NCT00000208_2_T0	PHENOTYPE	0	1	Opiate dependence
NCT000002086	NCT00000208_6_T0	PHENOTYPE	2	2	seizures
NCT000002088	NCT00000208_8_T0	PHENOTYPE	0	1	Dependence on
NCT000002089	NCT00000208_9_T0	PHENOTYPE	0	0	Acute
NCT000002089	NCT00000208_9_T1	PHENOTYPE	1	1	hepatitis
NCT000002093	NCT00000209_3_T0	PHENOTYPE	0	1	Opiate dependence
NCT000002097	NCT00000209_7_T0	PHENOTYPE	2	2	seizures
NCT000002099	NCT00000209_9_T0	PHENOTYPE	0	1	Dependence on
NCT0000020910	NCT00000209_10_T0	PHENOTYPE	0	0	Acute
NCT0000020910	NCT00000209_10_T1	PHENOTYPE	1	1	hepatitis
NCT000002300	NCT00000230_0_T0	BIOLOGICAL_PROCESS	1	1	Detoxification
NCT000002310	NCT00000231_0_T0	BIOLOGICAL_PROCESS	1	1	Detoxification
NCT000002412	NCT00000241_2_T0	COMPOUND	9	9	methamphetamine
NCT000002412	NCT00000241_2_T1	COMPOUND	6	6	desipramine
NCT000002412	NCT00000241_2_T2	COMPOUND	4	4	flupenthixol
NCT000002431	NCT00000243_1_T0	COMPOUND	14	14	buprenorphine_naloxone
NCT000002431	NCT00000243_1_T1	COMPOUND	25	25	methadone
NCT000002433	NCT00000243_3_T0	COMPOUND	1	1	buprenorphine
NCT000002433	NCT00000243_3_T1	COMPOUND	15	15	buprenorphine
NCT000002433	NCT00000243_3_T2	GENE	5	5	mu
NCT000002433	NCT00000243_3_T3	PHENOTYPE	18	19	opioid withdrawal
NCT000002434	NCT00000243_4_T0	COMPOUND	11	11	buprenorphine
NCT000002434	NCT00000243_4_T1	PHENOTYPE	7	8	physical dependence
NCT000002435	NCT00000243_5_T0	PHENOTYPE	9	9	acute
NCT000002435	NCT00000243_5_T1	COMPOUND	15	15	buprenorphine_naloxone
NCT000002435	NCT00000243_5_T2	COMPOUND	22	22	methadone
NCT000002512	NCT00000251_2_T0	PHENOTYPE	3	3	acute
NCT000002512	NCT00000251_2_T1	PHENOTYPE	9	9	concentrations
NCT000002533	NCT00000253_3_T0	COMPOUND	9	10	nitrous oxide
NCT000002562	NCT00000256_2_T0	COMPOUND	6	6	benzodiazepine
NCT000002562	NCT00000256_2_T1	COMPOUND	2	3	nitrous oxide
NCT000002563	NCT00000256_3_T0	PHENOTYPE	6	6	exposures
NCT000002563	NCT00000256_3_T1	COMPOUND	8	9	nitrous oxide
NCT000002572	NCT00000257_2_T0	COMPOUND	6	6	benzodiazepine
NCT000002572	NCT00000257_2_T1	COMPOUND	2	3	nitrous oxide
NCT000002573	NCT00000257_3_T0	COMPOUND	14	15	nitrous oxide
NCT000002583	NCT00000258_3_T0	COMPOUND	6	6	benzodiazepine
NCT000002583	NCT00000258_3_T1	COMPOUND	2	3	nitrous oxide
NCT000002584	NCT00000258_4_T0	COMPOUND	7	8	nitrous oxide
NCT000002592	NCT00000259_2_T0	COMPOUND	6	6	benzodiazepine
NCT000002592	NCT00000259_2_T1	COMPOUND	2	3	nitrous oxide
NCT000002602	NCT00000260_2_T0	COMPOUND	6	6	benzodiazepine
NCT000002602	NCT00000260_2_T1	COMPOUND	2	3	nitrous oxide
NCT000002603	NCT00000260_3_T0	COMPOUND	14	15	nitrous oxide
NCT000002712	NCT00000271_2_T0	PHENOTYPE	6	6	relapse
NCT000002715	NCT00000271_5_T0	PHENOTYPE	6	6	relapse
NCT000002716	NCT00000271_6_T0	PHENOTYPE	10	11	cocaine use
NCT000002718	NCT00000271_8_T0	PHENOTYPE	5	6	cocaine dependence
NCT0000027110	NCT00000271_10_T0	COMPOUND	1	1	cocaine
NCT0000027112	NCT00000271_12_T0	PHENOTYPE	8	8	Dysthymia
NCT0000027112	NCT00000271_12_T1	PHENOTYPE	5	6	Major Depression
NCT0000027114	NCT00000271_14_T0	PHENOTYPE	58	58	schizophrenia
NCT0000027114	NCT00000271_14_T1	PHENOTYPE	66	66	psychosis
NCT0000027114	NCT00000271_14_T2	PHENOTYPE	54	54	mania
NCT0000027114	NCT00000271_14_T3	COMPOUND	4	4	1
NCT0000027114	NCT00000271_14_T4	COMPOUND	48	48	1
NCT0000027114	NCT00000271_14_T5	COMPOUND	12	12	2
NCT0000027114	NCT00000271_14_T6	COMPOUND	23	23	3
NCT0000027114	NCT00000271_14_T7	COMPOUND	26	26	3
NCT0000027114	NCT00000271_14_T8	PHENOTYPE	56	57	bipolar disorder
NCT0000027114	NCT00000271_14_T9	PHENOTYPE	69	70	drug abuse
NCT0000027114	NCT00000271_14_T10	PHENOTYPE	9	10	substance abuse
NCT0000027114	NCT00000271_14_T11	PHENOTYPE	61	62	psychotic disorder
NCT0000027114	NCT00000271_14_T12	PHENOTYPE	0	1	Depressive disorder
NCT0000027116	NCT00000271_16_T0	PHENOTYPE	2	2	seizures
NCT0000027118	NCT00000271_18_T0	COMPOUND	7	7	imipramine
NCT0000027118	NCT00000271_18_T1	COMPOUND	5	5	desipramine
NCT0000027118	NCT00000271_18_T2	PHENOTYPE	2	3	allergic reaction
NCT0000027120	NCT00000271_20_T0	PHENOTYPE	0	0	Chronic
NCT0000027120	NCT00000271_20_T1	PHENOTYPE	1	3	organic mental disorder
NCT0000027124	NCT00000271_24_T0	BIOLOGICAL_PROCESS	1	1	lactation
NCT0000027128	NCT00000271_28_T0	PHENOTYPE	1	2	vascular disease
NCT0000027128	NCT00000271_28_T1	PHENOTYPE	15	16	cardiac symptoms
NCT0000027130	NCT00000271_30_T0	GENE	7	7	QRS
NCT0000027130	NCT00000271_30_T1	BIOLOGICAL_PROCESS	0	1	Cardiac conduction
NCT0000027132	NCT00000271_32_T0	COMPOUND	11	11	desipramine
NCT000002733	NCT00000273_3_T0	COMPOUND	19	19	heroin
NCT000002733	NCT00000273_3_T1	COMPOUND	22	22	heroin
NCT000002733	NCT00000273_3_T2	COMPOUND	17	17	buprenorphine
NCT000002733	NCT00000273_3_T3	COMPOUND	13	13	fentanyl
NCT000002733	NCT00000273_3_T4	COMPOUND	15	15	oxycodone
NCT000002733	NCT00000273_3_T5	COMPOUND	16	16	morphine
NCT000002736	NCT00000273_6_T0	GENE	1	1	IV
NCT000002736	NCT00000273_6_T1	PHENOTYPE	4	5	opioid dependence
NCT000002737	NCT00000273_7_T0	PHENOTYPE	5	6	anxiety disorder
NCT0000027311	NCT00000273_11_T0	COMPOUND	4	4	heroin
NCT0000027312	NCT00000273_12_T0	PHENOTYPE	4	5	opioid dependence
NCT0000027313	NCT00000273_13_T0	GENE	1	1	IV
NCT0000027313	NCT00000273_13_T1	PHENOTYPE	4	5	dependence on
NCT0000027316	NCT00000273_16_T0	BIOLOGICAL_PROCESS	2	2	lactation
NCT0000027317	NCT00000273_17_T0	PHENOTYPE	1	1	miscarriage
NCT0000027318	NCT00000273_18_T0	PHENOTYPE	6	7	violent behavior
NCT0000027319	NCT00000273_19_T0	PHENOTYPE	19	19	schizophrenia
NCT0000027319	NCT00000273_19_T1	PHENOTYPE	15	15	impairment
NCT0000027319	NCT00000273_19_T2	PHENOTYPE	11	12	mood disorder
NCT0000027319	NCT00000273_19_T3	PHENOTYPE	7	8	heroin dependence
NCT0000027322	NCT00000273_22_T0	PHENOTYPE	4	4	chronic
NCT000002842	NCT00000284_2_T0	COMPOUND	18	18	nicotine
NCT000002842	NCT00000284_2_T1	COMPOUND	28	28	cotinine
NCT000002842	NCT00000284_2_T2	GENE	1	1	has
NCT000002842	NCT00000284_2_T3	GENE	22	22	has
NCT000002842	NCT00000284_2_T4	PHENOTYPE	31	32	nicotine addiction
NCT000002843	NCT00000284_3_T0	COMPOUND	9	9	nicotine
NCT000002843	NCT00000284_3_T1	COMPOUND	6	6	cotinine
NCT000002843	NCT00000284_3_T2	PHENOTYPE	17	18	withdrawal symptoms
NCT000002843	NCT00000284_3_T3	PHENOTYPE	16	17	tobacco withdrawal
NCT000002844	NCT00000284_4_T0	COMPOUND	11	11	nicotine
NCT000002844	NCT00000284_4_T1	COMPOUND	4	4	cotinine
NCT000002844	NCT00000284_4_T2	PHENOTYPE	15	16	withdrawal symptoms
NCT000002852	NCT00000285_2_T0	COMPOUND	8	8	phenytoin
NCT000002854	NCT00000285_4_T0	COMPOUND	5	5	cocaine
NCT000002855	NCT00000285_5_T0	COMPOUND	17	17	phenytoin
NCT000002856	NCT00000285_6_T0	COMPOUND	4	4	phenytoin
NCT000002856	NCT00000285_6_T1	COMPOUND	16	16	phenytoin
NCT000002856	NCT00000285_6_T2	ORGAN	15	15	plasma
NCT000002857	NCT00000285_7_T0	COMPOUND	9	9	cocaine
NCT000002857	NCT00000285_7_T1	GENE	4	4	had
NCT000002858	NCT00000285_8_T0	PHENOTYPE	24	24	concentrations
NCT000002858	NCT00000285_8_T1	COMPOUND	26	26	cocaine
NCT000002858	NCT00000285_8_T2	COMPOUND	2	2	phenytoin
NCT000002858	NCT00000285_8_T3	COMPOUND	22	22	phenytoin
NCT000002858	NCT00000285_8_T4	ORGAN	1	1	plasma
NCT000002858	NCT00000285_8_T5	ORGAN	23	23	plasma
NCT0000028510	NCT00000285_10_T0	PHENOTYPE	3	4	cocaine use
NCT0000028511	NCT00000285_11_T0	COMPOUND	8	8	cocaine
NCT0000028511	NCT00000285_11_T1	GENE	12	12	hr
NCT0000028513	NCT00000285_13_T0	PHENOTYPE	2	2	HIV
NCT0000028515	NCT00000285_15_T0	ORGAN	22	22	diaphragm
NCT0000028516	NCT00000285_16_T0	PHENOTYPE	8	8	schizophrenia
NCT0000028516	NCT00000285_16_T1	PHENOTYPE	6	7	bipolar disorder
NCT0000028516	NCT00000285_16_T2	PHENOTYPE	10	11	generalized anxiety
NCT0000028517	NCT00000285_17_T0	PHENOTYPE	3	5	major depressive disorder
NCT0000028519	NCT00000285_19_T0	PHENOTYPE	4	4	illnesses
NCT0000028521	NCT00000285_21_T0	PHENOTYPE	2	3	chemical dependency
NCT000002882	NCT00000288_2_T0	COMPOUND	4	4	nicotine
NCT000002882	NCT00000288_2_T1	COMPOUND	13	13	nicotine
NCT000002882	NCT00000288_2_T2	PHENOTYPE	17	18	withdrawal symptoms
NCT000002883	NCT00000288_3_T0	COMPOUND	11	11	cotinine
NCT000002884	NCT00000288_4_T0	COMPOUND	13	13	nicotine
NCT000002884	NCT00000288_4_T1	COMPOUND	22	22	cotinine
NCT000002884	NCT00000288_4_T2	COMPOUND	30	30	cotinine
NCT000002884	NCT00000288_4_T3	ORGAN	12	12	serum
NCT0000028812	NCT00000288_12_T0	PHENOTYPE	0	0	Chronic
NCT0000028815	NCT00000288_15_T0	COMPOUND	10	10	nicotine
NCT0000028816	NCT00000288_16_T0	COMPOUND	4	4	nicotine
NCT000002892	NCT00000289_2_T0	COMPOUND	5	5	cotinine
NCT000002893	NCT00000289_3_T0	COMPOUND	17	17	nicotine
NCT000002893	NCT00000289_3_T1	GENE	10	10	5HT3
NCT000002894	NCT00000289_4_T0	GENE	2	2	has
NCT000002894	NCT00000289_4_T1	PHENOTYPE	8	9	withdrawal symptoms
NCT000002894	NCT00000289_4_T2	PHENOTYPE	7	8	nicotine withdrawal
NCT000002895	NCT00000289_5_T0	COMPOUND	6	6	nicotine
NCT000002896	NCT00000289_6_T0	COMPOUND	26	26	nicotine
NCT000002896	NCT00000289_6_T1	COMPOUND	15	15	ondansetron
NCT000002896	NCT00000289_6_T2	PHENOTYPE	18	19	withdrawal symptoms
NCT000002896	NCT00000289_6_T3	PHENOTYPE	17	18	tobacco withdrawal
NCT000002899	NCT00000289_9_T0	GENE	1	1	has
NCT0000028910	NCT00000289_10_T0	GENE	1	1	has
NCT0000028910	NCT00000289_10_T1	PHENOTYPE	6	7	withdrawal symptoms
NCT0000028915	NCT00000289_15_T0	PHENOTYPE	0	0	Chronic
NCT0000028918	NCT00000289_18_T0	PHENOTYPE	2	2	schizophrenia
NCT0000028918	NCT00000289_18_T1	PHENOTYPE	4	6	manic depressive disorder
NCT000002903	NCT00000290_3_T0	COMPOUND	5	5	cocaine
NCT000002904	NCT00000290_4_T0	COMPOUND	12	12	norepinephrine
NCT000002904	NCT00000290_4_T1	COMPOUND	11	11	epinephrine
NCT000002904	NCT00000290_4_T2	ORGAN	10	10	serum
NCT000002904	NCT00000290_4_T3	ORGAN	17	17	heart
NCT000002904	NCT00000290_4_T4	PHENOTYPE	14	15	cortisol levels
NCT000002905	NCT00000290_5_T0	COMPOUND	15	15	cortisol
NCT000002905	NCT00000290_5_T1	COMPOUND	3	3	cocaine
NCT000002905	NCT00000290_5_T2	COMPOUND	17	17	cocaine
NCT000002905	NCT00000290_5_T3	COMPOUND	13	13	epinephrine
NCT000002907	NCT00000290_7_T0	PHENOTYPE	5	6	cocaine use
NCT000002909	NCT00000290_9_T0	PHENOTYPE	8	8	schizophrenia
NCT000002909	NCT00000290_9_T1	PHENOTYPE	6	7	bipolar disorder
NCT000002909	NCT00000290_9_T2	PHENOTYPE	10	11	generalized anxiety
NCT0000029010	NCT00000290_10_T0	PHENOTYPE	3	5	major depressive disorder
NCT0000029012	NCT00000290_12_T0	PHENOTYPE	4	4	illnesses
NCT0000029014	NCT00000290_14_T0	PHENOTYPE	2	3	chemical dependency
NCT000002914	NCT00000291_4_T0	COMPOUND	12	12	labetalol
NCT000002915	NCT00000291_5_T0	COMPOUND	1	1	labetalol
NCT000002919	NCT00000291_9_T0	PHENOTYPE	5	6	cocaine use
NCT0000029111	NCT00000291_11_T0	ORGAN	20	20	diaphragm
NCT0000029112	NCT00000291_12_T0	PHENOTYPE	7	7	illnesses
NCT0000029112	NCT00000291_12_T1	PHENOTYPE	11	11	schizophrenia
NCT0000029112	NCT00000291_12_T2	PHENOTYPE	9	10	bipolar disorder
NCT0000029112	NCT00000291_12_T3	PHENOTYPE	13	14	anxiety disorders
NCT0000029113	NCT00000291_13_T0	COMPOUND	9	9	cocaine
NCT0000029113	NCT00000291_13_T1	PHENOTYPE	1	2	dependence on
NCT0000029114	NCT00000291_14_T0	PHENOTYPE	4	4	illnesses
NCT0000029114	NCT00000291_14_T1	PHENOTYPE	6	6	asthma
NCT0000029114	NCT00000291_14_T2	PHENOTYPE	8	8	chronic
NCT0000029114	NCT00000291_14_T3	PHENOTYPE	10	11	pulmonary disease
NCT000002923	NCT00000292_3_T0	COMPOUND	8	8	cocaine
NCT000002923	NCT00000292_3_T1	COMPOUND	29	29	cocaine
NCT000002923	NCT00000292_3_T2	PHENOTYPE	26	27	withdrawal symptoms
NCT000002925	NCT00000292_5_T0	ORGAN	27	27	heart
NCT000002926	NCT00000292_6_T0	COMPOUND	11	11	cocaine
NCT000002926	NCT00000292_6_T1	GENE	17	17	0.4
NCT000002926	NCT00000292_6_T2	PHENOTYPE	4	6	signs and symptoms
NCT000002928	NCT00000292_8_T0	ORGAN	17	17	liver
NCT0000029210	NCT00000292_10_T0	COMPOUND	7	7	cocaine
NCT0000029211	NCT00000292_11_T0	COMPOUND	23	23	nicotine
NCT0000029211	NCT00000292_11_T1	COMPOUND	25	25	caffeine
NCT0000029211	NCT00000292_11_T2	PHENOTYPE	12	12	dependence
NCT0000029211	NCT00000292_11_T3	PHENOTYPE	14	14	dependence
NCT0000029211	NCT00000292_11_T4	PHENOTYPE	9	10	cocaine abuse
NCT0000029213	NCT00000292_13_T0	ORGAN	4	4	serum
NCT000002932	NCT00000293_2_T0	PHENOTYPE	1	1	relapse
NCT000002932	NCT00000293_2_T1	PHENOTYPE	17	17	relapse
NCT000002944	NCT00000294_4_T0	PHENOTYPE	2	2	adaptation
NCT000002944	NCT00000294_4_T1	GENE	9	9	2.9
NCT000002945	NCT00000294_5_T0	COMPOUND	17	17	carvedilol
NCT000002946	NCT00000294_6_T0	COMPOUND	14	14	cocaine
NCT000002946	NCT00000294_6_T1	COMPOUND	50	50	cocaine
NCT000002946	NCT00000294_6_T2	GENE	15	15	0.4
NCT000002946	NCT00000294_6_T3	COMPOUND	3	3	carvedilol
NCT000002946	NCT00000294_6_T4	GENE	25	25	had
NCT000002947	NCT00000294_7_T0	COMPOUND	18	18	cocaine
NCT000002947	NCT00000294_7_T1	COMPOUND	8	8	carvedilol
NCT000002949	NCT00000294_9_T0	PHENOTYPE	5	6	cocaine use
NCT0000029410	NCT00000294_10_T0	PHENOTYPE	30	30	illnesses
NCT0000029410	NCT00000294_10_T1	ORGAN	19	19	diaphragm
NCT0000029410	NCT00000294_10_T2	PHENOTYPE	34	34	schizophrenia
NCT0000029410	NCT00000294_10_T3	PHENOTYPE	36	37	anxiety disorders
NCT0000029410	NCT00000294_10_T4	PHENOTYPE	32	33	bipolar disorder
NCT0000029411	NCT00000294_11_T0	PHENOTYPE	4	4	illnesses
NCT0000029411	NCT00000294_11_T1	PHENOTYPE	6	6	asthma
NCT0000029411	NCT00000294_11_T2	PHENOTYPE	8	11	chronic obstructive pulmonary disease
NCT000002952	NCT00000295_2_T0	COMPOUND	19	19	nicotine
NCT000002952	NCT00000295_2_T1	COMPOUND	15	15	progesterone
NCT000002953	NCT00000295_3_T0	COMPOUND	13	13	progesterone
NCT000002953	NCT00000295_3_T1	ORGAN	2	2	plasma
NCT000002953	NCT00000295_3_T2	PHENOTYPE	3	4	progesterone levels
NCT000002954	NCT00000295_4_T0	BIOLOGICAL_PROCESS	20	21	follicular phase
NCT000002954	NCT00000295_4_T1	BIOLOGICAL_PROCESS	24	25	menstrual cycle
NCT000002955	NCT00000295_5_T0	COMPOUND	15	15	progesterone
NCT000002955	NCT00000295_5_T1	COMPOUND	31	31	progesterone
NCT000002955	NCT00000295_5_T2	ORGAN	28	28	plasma
NCT000002957	NCT00000295_7_T0	PHENOTYPE	13	13	concentrations
NCT000002957	NCT00000295_7_T1	COMPOUND	8	8	progesterone
NCT000002957	NCT00000295_7_T2	COMPOUND	12	12	progesterone
NCT000002957	NCT00000295_7_T3	ORGAN	11	11	plasma
NCT000002957	NCT00000295_7_T4	BIOLOGICAL_PROCESS	20	21	luteal phase
NCT000002957	NCT00000295_7_T5	BIOLOGICAL_PROCESS	24	25	menstrual cycle
NCT0000029516	NCT00000295_16_T0	COMPOUND	11	11	nicotine
NCT000002962	NCT00000296_2_T0	COMPOUND	4	4	nicotine
NCT000002962	NCT00000296_2_T1	COMPOUND	13	13	nicotine
NCT000002962	NCT00000296_2_T2	PHENOTYPE	17	18	withdrawal symptoms
NCT000002963	NCT00000296_3_T0	COMPOUND	38	38	nicotine
NCT000002963	NCT00000296_3_T1	COMPOUND	20	20	cotinine
NCT000002963	NCT00000296_3_T2	PHENOTYPE	25	26	withdrawal symptom
NCT000002964	NCT00000296_4_T0	COMPOUND	11	11	nicotine
NCT000002964	NCT00000296_4_T1	COMPOUND	3	3	cotinine
NCT000002964	NCT00000296_4_T2	COMPOUND	24	24	cotinine
NCT000002964	NCT00000296_4_T3	PHENOTYPE	15	16	withdrawal symptoms
NCT000002967	NCT00000296_7_T0	GENE	1	1	has
NCT000002968	NCT00000296_8_T0	PHENOTYPE	7	7	symptoms
NCT000002968	NCT00000296_8_T1	GENE	1	1	has
NCT0000029613	NCT00000296_13_T0	PHENOTYPE	0	0	Chronic
NCT0000029615	NCT00000296_15_T0	COMPOUND	4	4	nicotine
NCT0000029615	NCT00000296_15_T1	COMPOUND	11	11	nicotine
NCT0000029617	NCT00000296_17_T0	PHENOTYPE	2	2	schizophrenia
NCT0000029617	NCT00000296_17_T1	PHENOTYPE	4	6	manic depressive disorder
NCT000002975	NCT00000297_5_T0	COMPOUND	13	13	nicotine
NCT000002975	NCT00000297_5_T1	COMPOUND	3	3	labetalol
NCT000002977	NCT00000297_7_T0	COMPOUND	18	18	nicotine
NCT000002977	NCT00000297_7_T1	COMPOUND	8	8	labetalol
NCT0000029713	NCT00000297_13_T0	PHENOTYPE	0	0	Chronic
NCT000002992	NCT00000299_2_T0	PHENOTYPE	0	1	Opiate dependence
NCT000002995	NCT00000299_5_T0	PHENOTYPE	2	3	psychiatric disorder
NCT000002996	NCT00000299_6_T0	PHENOTYPE	2	2	seizures
NCT000002999	NCT00000299_9_T0	PHENOTYPE	0	0	Acute
NCT000002999	NCT00000299_9_T1	PHENOTYPE	1	1	hepatitis
NCT000003001	NCT00000300_1_T0	PHENOTYPE	39	40	drug use
NCT0000030014	NCT00000300_14_T0	PHENOTYPE	12	12	dependence
NCT0000030014	NCT00000300_14_T1	GENE	8	8	UA
NCT000003011	NCT00000301_1_T0	COMPOUND	3	3	amantadine
NCT000003013	NCT00000301_3_T0	COMPOUND	7	7	amantadine
NCT000003017	NCT00000301_7_T0	PHENOTYPE	10	10	seizures
NCT000003019	NCT00000301_9_T0	PHENOTYPE	0	1	Dependence on
NCT0000030110	NCT00000301_10_T0	PHENOTYPE	0	0	Acute
NCT0000030110	NCT00000301_10_T1	PHENOTYPE	1	1	hepatitis
NCT000003024	NCT00000302_4_T0	PHENOTYPE	0	1	Opiate dependence
NCT000003028	NCT00000302_8_T0	PHENOTYPE	2	2	seizures
NCT0000030210	NCT00000302_10_T0	PHENOTYPE	0	1	Dependence on
NCT0000030211	NCT00000302_11_T0	PHENOTYPE	0	0	Acute
NCT0000030211	NCT00000302_11_T1	PHENOTYPE	1	1	hepatitis
NCT000003031	NCT00000303_1_T0	COMPOUND	3	3	baclofen
NCT000003033	NCT00000303_3_T0	COMPOUND	7	7	baclofen
NCT000003038	NCT00000303_8_T0	PHENOTYPE	10	10	seizures
NCT000003038	NCT00000303_8_T1	COMPOUND	17	17	ethanol
NCT000003038	NCT00000303_8_T2	PHENOTYPE	15	16	dependence on
NCT000003039	NCT00000303_9_T0	PHENOTYPE	0	1	Acute hepatitis
NCT000003063	NCT00000306_3_T0	COMPOUND	4	4	methadone
NCT000003064	NCT00000306_4_T0	PHENOTYPE	4	5	cocaine dependence
NCT000003068	NCT00000306_8_T0	COMPOUND	9	9	methadone
NCT000003068	NCT00000306_8_T1	PHENOTYPE	15	16	opiate dependence
NCT000003104	NCT00000310_4_T0	PHENOTYPE	7	8	drug abuse
NCT000003152	NCT00000315_2_T0	PHENOTYPE	12	13	cocaine abuse
NCT000003162	NCT00000316_2_T0	PHENOTYPE	12	13	cocaine abuse
NCT000003171	NCT00000317_1_T0	COMPOUND	8	8	risperidone
NCT000003171	NCT00000317_1_T1	COMPOUND	13	13	methadone
NCT000003172	NCT00000317_2_T0	COMPOUND	8	8	cocaine
NCT000003172	NCT00000317_2_T1	COMPOUND	11	11	cocaine
NCT000003172	NCT00000317_2_T2	COMPOUND	21	21	cocaine
NCT000003172	NCT00000317_2_T3	COMPOUND	4	4	risperidone
NCT000003172	NCT00000317_2_T4	GENE	5	5	reduced
NCT000003172	NCT00000317_2_T5	GENE	25	25	had
NCT000003172	NCT00000317_2_T6	COMPOUND	17	17	methadone
NCT000003172	NCT00000317_2_T7	PHENOTYPE	28	29	side effect
NCT000003172	NCT00000317_2_T8	PHENOTYPE	6	7	cocaine use
NCT000003174	NCT00000317_4_T0	GENE	23	23	7.12
NCT000003174	NCT00000317_4_T1	COMPOUND	29	29	risperidone
NCT000003174	NCT00000317_4_T2	COMPOUND	36	36	risperidone
NCT000003174	NCT00000317_4_T3	GENE	21	21	1/6
NCT000003174	NCT00000317_4_T4	GENE	26	27	Group 1
NCT000003175	NCT00000317_5_T0	GENE	6	6	7.12
NCT000003176	NCT00000317_6_T0	COMPOUND	16	16	risperidone
NCT000003176	NCT00000317_6_T1	GENE	14	14	tapered
NCT000003176	NCT00000317_6_T2	GENE	3	4	Group 1
NCT0000031710	NCT00000317_10_T0	GENE	7	7	7.12
NCT0000031710	NCT00000317_10_T1	COMPOUND	4	4	risperidone
NCT0000031710	NCT00000317_10_T2	GENE	14	14	1/6
NCT0000031711	NCT00000317_11_T0	PHENOTYPE	11	11	relapse
NCT0000031711	NCT00000317_11_T1	PHENOTYPE	39	40	cocaine use
NCT000003203	NCT00000320_3_T0	PHENOTYPE	4	5	opiate dependence
NCT000003206	NCT00000320_6_T0	PHENOTYPE	0	0	Acute
NCT000003226	NCT00000322_6_T0	COMPOUND	3	3	methamphetamine
NCT000003228	NCT00000322_8_T0	COMPOUND	4	4	methamphetamine
NCT000003228	NCT00000322_8_T1	PHENOTYPE	5	5	dependence
NCT000003229	NCT00000322_9_T0	COMPOUND	13	13	nicotine
NCT000003229	NCT00000322_9_T1	PHENOTYPE	3	3	dependence
NCT000003264	NCT00000326_4_T0	PHENOTYPE	5	5	disorders
NCT000003264	NCT00000326_4_T1	PHENOTYPE	4	4	dependence
NCT000003264	NCT00000326_4_T2	PHENOTYPE	1	2	substance abuse
NCT000003265	NCT00000326_5_T0	PHENOTYPE	5	6	drug dependency
NCT000003274	NCT00000327_4_T0	PHENOTYPE	5	5	disorders
NCT000003274	NCT00000327_4_T1	PHENOTYPE	4	4	dependence
NCT000003274	NCT00000327_4_T2	PHENOTYPE	1	2	substance abuse
NCT000003275	NCT00000327_5_T0	PHENOTYPE	5	6	drug dependency
NCT000003282	NCT00000328_2_T0	PHENOTYPE	5	5	disorders
NCT000003282	NCT00000328_2_T1	PHENOTYPE	4	4	dependence
NCT000003282	NCT00000328_2_T2	PHENOTYPE	1	2	substance abuse
NCT000003283	NCT00000328_3_T0	PHENOTYPE	5	6	drug dependency
NCT000003291	NCT00000329_1_T0	PHENOTYPE	5	5	disorders
NCT000003291	NCT00000329_1_T1	PHENOTYPE	4	4	dependence
NCT000003291	NCT00000329_1_T2	PHENOTYPE	1	2	substance abuse
NCT000003292	NCT00000329_2_T0	GENE	12	12	IV
NCT000003292	NCT00000329_2_T1	PHENOTYPE	5	6	drug dependency
NCT000003292	NCT00000329_2_T2	PHENOTYPE	13	14	opioid use
NCT000003301	NCT00000330_1_T0	PHENOTYPE	5	5	disorders
NCT000003301	NCT00000330_1_T1	PHENOTYPE	4	4	dependence
NCT000003301	NCT00000330_1_T2	PHENOTYPE	1	2	substance abuse
NCT000003302	NCT00000330_2_T0	GENE	12	12	IV
NCT000003302	NCT00000330_2_T1	PHENOTYPE	5	6	drug dependency
NCT000003302	NCT00000330_2_T2	PHENOTYPE	13	14	opioid use
NCT000003362	NCT00000336_2_T0	COMPOUND	4	4	cocaine
NCT000003365	NCT00000336_5_T0	PHENOTYPE	2	2	seizures
NCT000003367	NCT00000336_7_T0	PHENOTYPE	0	1	Dependence on
NCT000003368	NCT00000336_8_T0	PHENOTYPE	0	0	Acute
NCT000003368	NCT00000336_8_T1	PHENOTYPE	1	1	hepatitis
NCT000003372	NCT00000337_2_T0	COMPOUND	3	3	cocaine
NCT000003372	NCT00000337_2_T1	COMPOUND	22	22	cocaine
NCT000003373	NCT00000337_3_T0	COMPOUND	13	13	cocaine
NCT000003373	NCT00000337_3_T1	PHENOTYPE	16	16	chronic
NCT000003374	NCT00000337_4_T0	COMPOUND	9	9	cocaine
NCT000003374	NCT00000337_4_T1	PHENOTYPE	15	15	chronic
NCT000003374	NCT00000337_4_T2	PHENOTYPE	3	4	safety issues
NCT000003376	NCT00000337_6_T0	PHENOTYPE	4	5	cocaine dependence
NCT000003379	NCT00000337_9_T0	PHENOTYPE	2	2	seizures
NCT0000033711	NCT00000337_11_T0	PHENOTYPE	0	1	Dependence on
NCT0000033712	NCT00000337_12_T0	PHENOTYPE	0	0	Acute
NCT0000033712	NCT00000337_12_T1	PHENOTYPE	1	1	hepatitis
NCT000003382	NCT00000338_2_T0	PHENOTYPE	4	5	cocaine dependence
NCT000003385	NCT00000338_5_T0	PHENOTYPE	2	2	seizures
NCT000003387	NCT00000338_7_T0	PHENOTYPE	0	1	Dependence on
NCT000003388	NCT00000338_8_T0	PHENOTYPE	0	0	Acute
NCT000003388	NCT00000338_8_T1	PHENOTYPE	1	1	hepatitis
NCT000003392	NCT00000339_2_T0	PHENOTYPE	4	5	cocaine dependence
NCT000003395	NCT00000339_5_T0	PHENOTYPE	2	2	seizures
NCT000003397	NCT00000339_7_T0	PHENOTYPE	0	1	Dependence on
NCT000003398	NCT00000339_8_T0	PHENOTYPE	0	0	Acute
NCT000003398	NCT00000339_8_T1	PHENOTYPE	1	1	hepatitis
NCT000003402	NCT00000340_2_T0	PHENOTYPE	4	5	cocaine dependence
NCT000003405	NCT00000340_5_T0	PHENOTYPE	2	2	seizures
NCT000003407	NCT00000340_7_T0	PHENOTYPE	0	1	Dependence on
NCT000003408	NCT00000340_8_T0	PHENOTYPE	0	0	Acute
NCT000003408	NCT00000340_8_T1	PHENOTYPE	1	1	hepatitis
NCT000003412	NCT00000341_2_T0	PHENOTYPE	4	5	opioid dependence
NCT000003415	NCT00000341_5_T0	PHENOTYPE	2	2	seizures
NCT000003417	NCT00000341_7_T0	PHENOTYPE	0	1	Dependence on
NCT000003418	NCT00000341_8_T0	PHENOTYPE	0	0	Acute
NCT000003418	NCT00000341_8_T1	PHENOTYPE	1	1	hepatitis
NCT000003422	NCT00000342_2_T0	PHENOTYPE	4	5	cocaine dependence
NCT000003425	NCT00000342_5_T0	PHENOTYPE	2	2	seizures
NCT000003427	NCT00000342_7_T0	PHENOTYPE	0	1	Dependence on
NCT000003428	NCT00000342_8_T0	PHENOTYPE	0	0	Acute
NCT000003428	NCT00000342_8_T1	PHENOTYPE	1	1	hepatitis
NCT000003434	NCT00000343_4_T0	PHENOTYPE	4	5	cocaine dependence
NCT000003437	NCT00000343_7_T0	PHENOTYPE	2	2	seizures
NCT000003439	NCT00000343_9_T0	PHENOTYPE	0	1	Dependence on
NCT0000034310	NCT00000343_10_T0	PHENOTYPE	0	0	Acute
NCT0000034310	NCT00000343_10_T1	PHENOTYPE	1	1	hepatitis
NCT000003442	NCT00000344_2_T0	PHENOTYPE	4	5	opiate dependence
NCT000003445	NCT00000344_5_T0	PHENOTYPE	2	2	seizures
NCT000003447	NCT00000344_7_T0	PHENOTYPE	0	1	Dependence on
NCT000003448	NCT00000344_8_T0	PHENOTYPE	0	0	Acute
NCT000003448	NCT00000344_8_T1	PHENOTYPE	1	1	hepatitis
NCT000003452	NCT00000345_2_T0	PHENOTYPE	4	5	opiate dependence
NCT000003455	NCT00000345_5_T0	PHENOTYPE	2	2	seizures
NCT000003457	NCT00000345_7_T0	PHENOTYPE	0	1	Dependence on
NCT000003458	NCT00000345_8_T0	PHENOTYPE	0	0	Acute
NCT000003458	NCT00000345_8_T1	PHENOTYPE	1	1	hepatitis
NCT000003462	NCT00000346_2_T0	COMPOUND	4	4	cocaine
NCT000003462	NCT00000346_2_T1	COMPOUND	6	6	methamphetamine
NCT000003462	NCT00000346_2_T2	PHENOTYPE	7	7	dependence
NCT000003472	NCT00000347_2_T0	PHENOTYPE	4	5	cocaine dependence
NCT000003475	NCT00000347_5_T0	PHENOTYPE	2	2	seizures
NCT000003477	NCT00000347_7_T0	PHENOTYPE	0	1	Dependence on
NCT000003478	NCT00000347_8_T0	PHENOTYPE	0	0	Acute
NCT000003478	NCT00000347_8_T1	PHENOTYPE	1	1	hepatitis
NCT000003482	NCT00000348_2_T0	PHENOTYPE	4	5	cocaine dependence
NCT000003485	NCT00000348_5_T0	PHENOTYPE	2	2	seizures
NCT000003487	NCT00000348_7_T0	PHENOTYPE	0	1	Dependence on
NCT000003488	NCT00000348_8_T0	PHENOTYPE	0	0	Acute
NCT000003488	NCT00000348_8_T1	PHENOTYPE	1	1	hepatitis
NCT000003493	NCT00000349_3_T0	PHENOTYPE	4	5	cocaine dependence
NCT000003496	NCT00000349_6_T0	PHENOTYPE	2	2	seizures
NCT000003498	NCT00000349_8_T0	PHENOTYPE	0	1	Dependence on
NCT000003499	NCT00000349_9_T0	PHENOTYPE	0	0	Acute
NCT000003499	NCT00000349_9_T1	PHENOTYPE	1	1	hepatitis
NCT000003504	NCT00000350_4_T0	GENE	11	11	3.5
NCT000003504	NCT00000350_4_T1	PHENOTYPE	15	16	drug use
NCT000003504	NCT00000350_4_T2	PHENOTYPE	24	25	drug use
NCT000003508	NCT00000350_8_T0	PHENOTYPE	14	15	drug use
NCT0000035011	NCT00000350_11_T0	COMPOUND	4	4	methamphetamine
NCT0000035011	NCT00000350_11_T1	PHENOTYPE	6	7	nicotine dependence
NCT0000035014	NCT00000350_14_T0	PHENOTYPE	2	2	seizures
NCT0000035016	NCT00000350_16_T0	PHENOTYPE	0	1	Dependence on
NCT0000035017	NCT00000350_17_T0	PHENOTYPE	0	0	Acute
NCT0000035017	NCT00000350_17_T1	PHENOTYPE	1	1	hepatitis
NCT000003514	NCT00000351_4_T0	PHENOTYPE	4	5	stimulant dependence
NCT000003541	NCT00000354_1_T0	COMPOUND	11	11	lofexidine
NCT000003541	NCT00000354_1_T1	PHENOTYPE	16	18	signs and symptoms
NCT000003581	NCT00000358_1_T0	COMPOUND	11	11	lofexidine
NCT000003581	NCT00000358_1_T1	PHENOTYPE	16	18	signs and symptoms
NCT000003614	NCT00000361_4_T0	GENE	4	4	III
NCT000003620	NCT00000362_0_T0	PHENOTYPE	7	7	Aspiration
NCT000003622	NCT00000362_2_T0	PHENOTYPE	14	14	suffering
NCT000003622	NCT00000362_2_T1	PHENOTYPE	17	17	dementia
NCT000003623	NCT00000362_3_T0	PHENOTYPE	0	0	Pneumonia
NCT000003625	NCT00000362_5_T0	GENE	36	36	swallow
NCT000003625	NCT00000362_5_T1	GENE	4	4	III
NCT000003625	NCT00000362_5_T2	COMPOUND	35	35	barium
NCT000003631	NCT00000363_1_T0	PHENOTYPE	15	15	recurrences
NCT000003631	NCT00000363_1_T1	PHENOTYPE	13	13	effusions
NCT000003631	NCT00000363_1_T2	PHENOTYPE	8	9	otitis media
NCT000003632	NCT00000363_2_T0	PHENOTYPE	23	23	acute
NCT000003632	NCT00000363_2_T1	GENE	2	2	III
NCT000003632	NCT00000363_2_T2	PHENOTYPE	30	32	acute otitis media
NCT000003673	NCT00000367_3_T0	PHENOTYPE	17	17	thoughts
NCT0000036710	NCT00000367_10_T0	PHENOTYPE	14	14	ideation
NCT0000036712	NCT00000367_12_T0	PHENOTYPE	11	12	moderate depression
NCT0000036713	NCT00000367_13_T0	PHENOTYPE	5	5	ideation
NCT0000036713	NCT00000367_13_T1	GENE	13	13	has
NCT0000036713	NCT00000367_13_T2	PHENOTYPE	21	22	depressive symptoms
NCT0000036713	NCT00000367_13_T3	PHENOTYPE	22	24	symptoms and signs
NCT0000036715	NCT00000367_15_T0	GENE	25	25	contrasted
NCT0000036715	NCT00000367_15_T1	PHENOTYPE	8	8	practices
NCT0000036715	NCT00000367_15_T2	PHENOTYPE	31	31	practices
NCT0000036717	NCT00000367_17_T0	PHENOTYPE	12	13	depressive symptoms
NCT0000036717	NCT00000367_17_T1	PHENOTYPE	13	15	symptoms and signs
NCT0000036718	NCT00000367_18_T0	GENE	2	2	DS
NCT0000036720	NCT00000367_20_T0	PHENOTYPE	32	32	Centers
NCT0000036720	NCT00000367_20_T1	PHENOTYPE	17	17	attitudes
NCT0000036812	NCT00000368_12_T0	PHENOTYPE	18	18	agoraphobia
NCT0000036812	NCT00000368_12_T1	GENE	10	10	has
NCT0000036812	NCT00000368_12_T2	PHENOTYPE	19	20	fear of
NCT0000036812	NCT00000368_12_T3	PHENOTYPE	11	12	panic disorder
NCT0000036821	NCT00000368_21_T0	PHENOTYPE	8	8	acute
NCT000003691	NCT00000369_1_T0	PHENOTYPE	3	3	manic
NCT000003694	NCT00000369_4_T0	PHENOTYPE	2	2	symptoms
NCT000003695	NCT00000369_5_T0	PHENOTYPE	17	17	manic
NCT000003697	NCT00000369_7_T0	PHENOTYPE	14	14	symptoms
NCT000003697	NCT00000369_7_T1	PHENOTYPE	1	1	adaptation
NCT000003697	NCT00000369_7_T2	PHENOTYPE	21	22	bipolar disorder
NCT000003698	NCT00000369_8_T0	COMPOUND	25	25	lithium
NCT000003698	NCT00000369_8_T1	PHENOTYPE	5	5	manic
NCT000003698	NCT00000369_8_T2	COMPOUND	26	26	carbonate
NCT0000036910	NCT00000369_10_T0	PHENOTYPE	11	11	strategies
NCT0000036911	NCT00000369_11_T0	PHENOTYPE	17	17	recurrence
NCT0000036911	NCT00000369_11_T1	PHENOTYPE	5	5	relapse
NCT0000036912	NCT00000369_12_T0	GENE	18	18	had
NCT000003705	NCT00000370_5_T0	GENE	0	1	Group 1
NCT000003708	NCT00000370_8_T0	PHENOTYPE	11	12	social phobia
NCT0000037010	NCT00000370_10_T0	PHENOTYPE	1	1	self-efficacy
NCT0000037010	NCT00000370_10_T1	PHENOTYPE	26	26	generalized
NCT0000037010	NCT00000370_10_T2	PHENOTYPE	12	12	perceived
NCT0000037010	NCT00000370_10_T3	PHENOTYPE	0	0	Perceived
NCT0000037010	NCT00000370_10_T4	PHENOTYPE	29	30	social phobia
NCT0000037010	NCT00000370_10_T5	BIOLOGICAL_PROCESS	3	4	social behavior
NCT0000037010	NCT00000370_10_T6	PHENOTYPE	21	23	avoidant personality disorder
NCT0000037011	NCT00000370_11_T0	PHENOTYPE	0	1	Social phobia
NCT0000037012	NCT00000370_12_T0	PHENOTYPE	10	11	social phobia
NCT0000037014	NCT00000370_14_T0	PHENOTYPE	11	12	social phobia
NCT0000037015	NCT00000370_15_T0	PHENOTYPE	22	23	social phobia
NCT0000037016	NCT00000370_16_T0	PHENOTYPE	5	5	perceived
NCT000003713	NCT00000371_3_T0	ORGAN	5	5	forebrain
NCT000003713	NCT00000371_3_T1	PHENOTYPE	2	2	dysfunction
NCT000003715	NCT00000371_5_T0	PHENOTYPE	7	7	symptoms
NCT000003715	NCT00000371_5_T1	COMPOUND	18	18	D-cycloserine
NCT000003716	NCT00000371_6_T0	GENE	16	16	SANS
NCT000003716	NCT00000371_6_T1	PHENOTYPE	15	15	Symptoms
NCT000003718	NCT00000371_8_T0	PHENOTYPE	17	17	concentrations
NCT000003718	NCT00000371_8_T1	GENE	8	8	CSF
NCT000003718	NCT00000371_8_T2	COMPOUND	19	19	D-cycloserine
NCT0000037112	NCT00000371_12_T0	ORGAN	5	5	forebrain
NCT0000037112	NCT00000371_12_T1	PHENOTYPE	2	2	dysfunction
NCT0000037114	NCT00000371_14_T0	PHENOTYPE	7	7	symptoms
NCT0000037114	NCT00000371_14_T1	COMPOUND	18	18	D-cycloserine
NCT0000037115	NCT00000371_15_T0	GENE	16	16	SANS
NCT0000037115	NCT00000371_15_T1	PHENOTYPE	15	15	Symptoms
NCT0000037117	NCT00000371_17_T0	PHENOTYPE	17	17	concentrations
NCT0000037117	NCT00000371_17_T1	GENE	8	8	CSF
NCT0000037117	NCT00000371_17_T2	COMPOUND	19	19	D-cycloserine
NCT000003721	NCT00000372_1_T0	PHENOTYPE	9	9	symptoms
NCT000003721	NCT00000372_1_T1	PHENOTYPE	11	11	schizophrenia
NCT000003722	NCT00000372_2_T0	COMPOUND	5	5	glycine
NCT000003722	NCT00000372_2_T1	COMPOUND	3	3	D-cycloserine
NCT000003724	NCT00000372_4_T0	PHENOTYPE	4	4	symptoms
NCT000003724	NCT00000372_4_T1	PHENOTYPE	13	13	symptoms
NCT000003724	NCT00000372_4_T2	COMPOUND	17	17	clozapine
NCT000003725	NCT00000372_5_T0	COMPOUND	6	6	glycine
NCT000003725	NCT00000372_5_T1	COMPOUND	4	4	D-cycloserine
NCT000003725	NCT00000372_5_T2	COMPOUND	12	12	clozapine
NCT000003727	NCT00000372_7_T0	COMPOUND	4	4	D-cycloserine
NCT000003727	NCT00000372_7_T1	COMPOUND	6	6	clozapine
NCT000003727	NCT00000372_7_T2	GENE	0	1	Group 1
NCT000003728	NCT00000372_8_T0	COMPOUND	4	4	glycine
NCT000003728	NCT00000372_8_T1	COMPOUND	6	6	clozapine
NCT000003729	NCT00000372_9_T0	COMPOUND	8	8	clozapine
NCT0000037211	NCT00000372_11_T0	PHENOTYPE	1	1	symptoms
NCT0000037211	NCT00000372_11_T1	PHENOTYPE	17	17	symptoms
NCT0000037211	NCT00000372_11_T2	PHENOTYPE	3	3	schizophrenia
NCT0000037211	NCT00000372_11_T3	PHENOTYPE	26	26	Syndrome
NCT0000037211	NCT00000372_11_T4	PHENOTYPE	15	15	Symptoms
NCT0000037212	NCT00000372_12_T0	PHENOTYPE	21	21	schizophrenia
NCT0000037212	NCT00000372_12_T1	GENE	17	17	has
NCT0000037215	NCT00000372_15_T0	COMPOUND	20	20	clozapine
NCT0000037215	NCT00000372_15_T1	PHENOTYPE	10	10	schizophrenia
NCT0000037217	NCT00000372_17_T0	PHENOTYPE	5	5	symptoms
NCT0000037217	NCT00000372_17_T1	PHENOTYPE	16	16	symptoms
NCT0000037217	NCT00000372_17_T2	COMPOUND	1	1	glycine
NCT0000037217	NCT00000372_17_T3	COMPOUND	13	13	glycine
NCT0000037217	NCT00000372_17_T4	COMPOUND	20	20	clozapine
NCT0000037217	NCT00000372_17_T5	GENE	7	7	has
NCT0000037218	NCT00000372_18_T0	PHENOTYPE	1	1	concentrations
NCT0000037218	NCT00000372_18_T1	COMPOUND	3	3	glycine
NCT0000037218	NCT00000372_18_T2	COMPOUND	9	9	glycine
NCT0000037218	NCT00000372_18_T3	COMPOUND	11	11	D-cycloserine
NCT0000037218	NCT00000372_18_T4	ORGAN	0	0	Serum
NCT0000037220	NCT00000372_20_T0	PHENOTYPE	33	33	symptoms
NCT0000037220	NCT00000372_20_T1	COMPOUND	14	14	glycine
NCT0000037220	NCT00000372_20_T2	COMPOUND	25	25	glycine
NCT0000037220	NCT00000372_20_T3	COMPOUND	1	1	D-cycloserine
NCT0000037220	NCT00000372_20_T4	COMPOUND	20	20	clozapine
NCT0000037220	NCT00000372_20_T5	COMPOUND	38	38	clozapine
NCT0000037221	NCT00000372_21_T0	COMPOUND	9	9	glycine
NCT0000037221	NCT00000372_21_T1	COMPOUND	8	8	D-cycloserine
NCT0000037221	NCT00000372_21_T2	COMPOUND	14	14	clozapine
NCT0000037221	NCT00000372_21_T3	PHENOTYPE	19	19	schizophrenia
NCT0000037223	NCT00000372_23_T0	PHENOTYPE	26	26	symptoms
NCT0000037223	NCT00000372_23_T1	COMPOUND	18	18	D-cycloserine
NCT000003731	NCT00000373_1_T0	PHENOTYPE	22	22	OCD
NCT000003732	NCT00000373_2_T0	COMPOUND	7	7	fluvoxamine
NCT000003733	NCT00000373_3_T0	COMPOUND	9	9	haloperidol
NCT000003736	NCT00000373_6_T0	PHENOTYPE	4	4	OCD
NCT000003736	NCT00000373_6_T1	PHENOTYPE	22	22	OCD
NCT000003737	NCT00000373_7_T0	PHENOTYPE	14	14	OCD
NCT000003737	NCT00000373_7_T1	GENE	9	9	putative
NCT000003738	NCT00000373_8_T0	GENE	2	2	II
NCT000003738	NCT00000373_8_T1	COMPOUND	17	17	fluoxetine
NCT000003738	NCT00000373_8_T2	GENE	14	14	5-HT
NCT000003739	NCT00000373_9_T0	COMPOUND	28	28	olanzapine
NCT000003739	NCT00000373_9_T1	COMPOUND	24	24	dopamine
NCT0000037311	NCT00000373_11_T0	PHENOTYPE	17	17	severity
NCT0000037311	NCT00000373_11_T1	PHENOTYPE	2	2	OCD
NCT0000037311	NCT00000373_11_T2	GENE	3	3	had
NCT0000037312	NCT00000373_12_T0	ORGAN	44	44	liver
NCT0000037312	NCT00000373_12_T1	PHENOTYPE	5	5	schizophrenia
NCT0000037312	NCT00000373_12_T2	ORGAN	43	43	heart
NCT0000037312	NCT00000373_12_T3	PHENOTYPE	9	9	disorders
NCT0000037312	NCT00000373_12_T4	PHENOTYPE	31	31	encephalitis
NCT0000037312	NCT00000373_12_T5	PHENOTYPE	26	26	seizures
NCT0000037312	NCT00000373_12_T6	PHENOTYPE	11	12	bipolar disorder
NCT0000037312	NCT00000373_12_T7	PHENOTYPE	34	35	head trauma
NCT000003744	NCT00000374_4_T0	PHENOTYPE	4	4	schizophrenia
NCT000003744	NCT00000374_4_T1	PHENOTYPE	14	15	psychotic symptoms
NCT000003748	NCT00000374_8_T0	PHENOTYPE	9	9	chronic
NCT000003749	NCT00000374_9_T0	COMPOUND	9	9	olanzapine
NCT000003749	NCT00000374_9_T1	COMPOUND	11	11	risperidone
NCT000003755	NCT00000375_5_T0	PHENOTYPE	12	12	relapse
NCT000003759	NCT00000375_9_T0	PHENOTYPE	5	5	symptoms
NCT0000037510	NCT00000375_10_T0	PHENOTYPE	9	10	drug abuse
NCT0000037513	NCT00000375_13_T0	PHENOTYPE	23	23	MDD
NCT0000037519	NCT00000375_19_T0	PHENOTYPE	5	5	symptoms
NCT0000037520	NCT00000375_20_T0	PHENOTYPE	16	16	symptoms
NCT0000037522	NCT00000375_22_T0	PHENOTYPE	9	9	relapse
NCT0000037522	NCT00000375_22_T1	PHENOTYPE	17	17	perceived
NCT0000037523	NCT00000375_23_T0	GENE	0	0	NOR
NCT0000037523	NCT00000375_23_T1	GENE	2	2	Li
NCT0000037525	NCT00000375_25_T0	PHENOTYPE	11	11	severity
NCT000003762	NCT00000376_2_T0	GENE	23	23	DMI
NCT000003762	NCT00000376_2_T1	COMPOUND	22	22	desipramine
NCT000003764	NCT00000376_4_T0	GENE	8	8	DMI
NCT000003764	NCT00000376_4_T1	GENE	13	13	DMI
NCT000003765	NCT00000376_5_T0	GENE	8	8	DMI
NCT0000037610	NCT00000376_10_T0	PHENOTYPE	23	23	symptoms
NCT0000037610	NCT00000376_10_T1	PHENOTYPE	21	21	remission
NCT0000037614	NCT00000376_14_T0	GENE	23	23	DMI
NCT0000037614	NCT00000376_14_T1	COMPOUND	22	22	desipramine
NCT0000037616	NCT00000376_16_T0	GENE	8	8	DMI
NCT0000037616	NCT00000376_16_T1	GENE	13	13	DMI
NCT0000037617	NCT00000376_17_T0	GENE	8	8	DMI
NCT0000037622	NCT00000376_22_T0	PHENOTYPE	23	23	symptoms
NCT0000037622	NCT00000376_22_T1	PHENOTYPE	21	21	remission
NCT000003772	NCT00000377_2_T0	GENE	17	17	has
NCT000003774	NCT00000377_4_T0	COMPOUND	16	16	nortriptyline
NCT000003774	NCT00000377_4_T1	COMPOUND	23	23	nortriptyline
NCT000003775	NCT00000377_5_T0	COMPOUND	3	3	nortriptyline
NCT000003775	NCT00000377_5_T1	PHENOTYPE	10	11	major depression
NCT000003776	NCT00000377_6_T0	PHENOTYPE	7	9	symptoms of depression
NCT000003778	NCT00000377_8_T0	COMPOUND	8	8	nortriptyline
NCT000003778	NCT00000377_8_T1	PHENOTYPE	12	12	recurrences
NCT000003778	NCT00000377_8_T2	PHENOTYPE	14	15	major depression
NCT0000037710	NCT00000377_10_T0	GENE	15	15	II
NCT0000037711	NCT00000377_11_T0	PHENOTYPE	4	4	recurrence
NCT0000037711	NCT00000377_11_T1	CELL	21	21	cells
NCT0000037712	NCT00000377_12_T0	PHENOTYPE	6	6	recurrence
NCT0000037712	NCT00000377_12_T1	PHENOTYPE	8	9	major depression
NCT0000037713	NCT00000377_13_T0	PHENOTYPE	6	6	recurrence
NCT0000037713	NCT00000377_13_T1	PHENOTYPE	11	11	recurrence
NCT0000037713	NCT00000377_13_T2	PHENOTYPE	24	24	ideation
NCT000003781	NCT00000378_1_T0	PHENOTYPE	7	8	major depression
NCT000003782	NCT00000378_2_T0	PHENOTYPE	21	21	melancholia
NCT000003782	NCT00000378_2_T1	PHENOTYPE	18	19	major depression
NCT000003785	NCT00000378_5_T0	PHENOTYPE	5	5	symptoms
NCT000003785	NCT00000378_5_T1	PHENOTYPE	9	11	quality of life
NCT000003787	NCT00000378_7_T0	PHENOTYPE	12	13	major depression
NCT0000037810	NCT00000378_10_T0	PHENOTYPE	6	6	severity
NCT0000037811	NCT00000378_11_T0	PHENOTYPE	7	8	major depression
NCT0000037812	NCT00000378_12_T0	PHENOTYPE	18	18	melancholia
NCT0000037813	NCT00000378_13_T0	PHENOTYPE	8	9	major depression
NCT0000037814	NCT00000378_14_T0	PHENOTYPE	8	8	overdose
NCT0000037816	NCT00000378_16_T0	PHENOTYPE	17	18	major depression
NCT0000037817	NCT00000378_17_T0	PHENOTYPE	17	17	melancholia
NCT0000037819	NCT00000378_19_T0	PHENOTYPE	13	13	symptoms
NCT0000037819	NCT00000378_19_T1	PHENOTYPE	5	5	acute
NCT0000037819	NCT00000378_19_T2	PHENOTYPE	22	24	quality of life
NCT0000037820	NCT00000378_20_T0	PHENOTYPE	5	5	acute
NCT000003793	NCT00000379_3_T0	COMPOUND	4	4	fluoxetine
NCT000003793	NCT00000379_3_T1	GENE	0	1	Group 1
NCT000003795	NCT00000379_5_T0	PHENOTYPE	11	11	PTSD
NCT000003797	NCT00000379_7_T0	PHENOTYPE	21	21	pathophysiology
NCT000003798	NCT00000379_8_T0	PHENOTYPE	18	18	PTSD
NCT000003799	NCT00000379_9_T0	GENE	5	5	PE
NCT000003799	NCT00000379_9_T1	GENE	9	9	SIT
NCT0000037910	NCT00000379_10_T0	GENE	1	1	PE
NCT0000037910	NCT00000379_10_T1	GENE	2	2	has
NCT0000037910	NCT00000379_10_T2	GENE	23	23	has
NCT0000037910	NCT00000379_10_T3	GENE	6	6	SIT
NCT0000037911	NCT00000379_11_T0	PHENOTYPE	12	12	PTSD
NCT0000037911	NCT00000379_11_T1	GENE	31	31	SIT
NCT0000037912	NCT00000379_12_T0	PHENOTYPE	6	6	PTSD
NCT0000037913	NCT00000379_13_T0	COMPOUND	14	14	fluoxetine
NCT0000037914	NCT00000379_14_T0	GENE	9	9	cease
NCT000003800	NCT00000380_0_T0	GENE	4	4	GHRH
NCT000003800	NCT00000380_0_T1	PHENOTYPE	8	9	Sleep Disturbances
NCT000003800	NCT00000380_0_T2	MOLECULAR_FUNCTION	0	1	Growth Hormone
NCT000003805	NCT00000380_5_T0	COMPOUND	23	23	estrogen
NCT000003805	NCT00000380_5_T1	PHENOTYPE	18	19	sleep disturbances
NCT000003808	NCT00000380_8_T0	GENE	13	13	GH
NCT000003808	NCT00000380_8_T1	PHENOTYPE	16	16	concentrations
NCT000003808	NCT00000380_8_T2	GENE	15	15	IGF-1
NCT000003809	NCT00000380_9_T0	PHENOTYPE	8	9	poor sleep
NCT0000038011	NCT00000380_11_T0	PHENOTYPE	28	28	falls
NCT0000038011	NCT00000380_11_T1	GENE	36	36	has
NCT0000038011	NCT00000380_11_T2	PHENOTYPE	29	29	fractures
NCT0000038011	NCT00000380_11_T3	PHENOTYPE	33	34	anterograde amnesia
NCT0000038011	NCT00000380_11_T4	PHENOTYPE	0	1	Poor sleep
NCT0000038011	NCT00000380_11_T5	PHENOTYPE	30	31	cognitive impairment
NCT0000038011	NCT00000380_11_T6	PHENOTYPE	18	19	sleep apnea
NCT0000038013	NCT00000380_13_T0	GENE	11	11	GHRH
NCT0000038013	NCT00000380_13_T1	GENE	9	9	axis
NCT000003812	NCT00000381_2_T0	PHENOTYPE	12	13	drug abuse
NCT000003812	NCT00000381_2_T1	PHENOTYPE	2	3	anxiety disorder
NCT000003814	NCT00000381_4_T0	COMPOUND	12	12	fluoxetine
NCT000003815	NCT00000381_5_T0	PHENOTYPE	6	6	symptoms
NCT000003816	NCT00000381_6_T0	PHENOTYPE	13	14	drug levels
NCT000003818	NCT00000381_8_T0	GENE	9	9	Is
NCT000003818	NCT00000381_8_T1	GENE	16	16	has
NCT000003818	NCT00000381_8_T2	PHENOTYPE	17	18	anxiety disorder
NCT000003819	NCT00000381_9_T0	PHENOTYPE	18	19	obsessive-compulsive disorder
NCT000003819	NCT00000381_9_T1	PHENOTYPE	13	14	major depression
NCT000003819	NCT00000381_9_T2	PHENOTYPE	15	16	panic disorder
NCT0000038111	NCT00000381_11_T0	PHENOTYPE	0	1	Anxiety disorders
NCT0000038111	NCT00000381_11_T1	PHENOTYPE	10	11	psychiatric disorders
NCT0000038112	NCT00000381_12_T0	PHENOTYPE	1	1	disorders
NCT0000038112	NCT00000381_12_T1	PHENOTYPE	13	14	substance abuse
NCT0000038112	NCT00000381_12_T2	PHENOTYPE	8	10	other psychiatric disorders
NCT0000038113	NCT00000381_13_T0	PHENOTYPE	2	3	Obsessive-Compulsive Disorder
NCT0000038113	NCT00000381_13_T1	PHENOTYPE	13	14	anxiety disorders
NCT0000038114	NCT00000381_14_T0	PHENOTYPE	29	29	disorders
NCT0000038115	NCT00000381_15_T0	COMPOUND	7	7	fluoxetine
NCT0000038117	NCT00000381_17_T0	COMPOUND	15	15	fluoxetine
NCT0000038117	NCT00000381_17_T1	ORGAN	12	12	plasma
NCT0000038117	NCT00000381_17_T2	COMPOUND	17	17	norfluoxetine
NCT0000038118	NCT00000381_18_T0	COMPOUND	11	11	fluoxetine
NCT0000038119	NCT00000381_19_T0	PHENOTYPE	11	11	severity
NCT0000038119	NCT00000381_19_T1	PHENOTYPE	24	25	mood disorders
NCT0000038119	NCT00000381_19_T2	PHENOTYPE	17	18	depressive symptoms
NCT000003827	NCT00000382_7_T0	GENE	9	9	has
NCT000003832	NCT00000383_2_T0	GENE	15	15	NST
NCT000003836	NCT00000383_6_T0	PHENOTYPE	17	17	PTSD
NCT000003836	NCT00000383_6_T1	PHENOTYPE	15	15	suffering
NCT0000038313	NCT00000383_13_T0	PHENOTYPE	19	19	perceptions
NCT0000038313	NCT00000383_13_T1	PHENOTYPE	23	23	adaptability
NCT0000038313	NCT00000383_13_T2	PHENOTYPE	21	21	practices
NCT0000038313	NCT00000383_13_T3	PHENOTYPE	17	17	attributions
NCT0000038315	NCT00000383_15_T0	PHENOTYPE	4	4	symptoms
NCT0000038315	NCT00000383_15_T1	PHENOTYPE	3	3	PTSD
NCT0000038315	NCT00000383_15_T2	PHENOTYPE	17	17	PTSD
NCT0000038315	NCT00000383_15_T3	PHENOTYPE	21	22	sexual abuse
NCT0000038315	NCT00000383_15_T4	PHENOTYPE	0	2	Post-Traumatic Stress Disorder
NCT0000038316	NCT00000383_16_T0	PHENOTYPE	1	3	child sexual abuse
NCT000003846	NCT00000384_6_T0	GENE	12	12	II
NCT000003846	NCT00000384_6_T1	GENE	20	20	reduced
NCT000003847	NCT00000384_7_T0	GENE	22	22	II
NCT000003847	NCT00000384_7_T1	PHENOTYPE	37	37	OCD
NCT0000038410	NCT00000384_10_T0	PHENOTYPE	6	6	OCD
NCT0000038410	NCT00000384_10_T1	PHENOTYPE	4	4	suffers
NCT0000038412	NCT00000384_12_T0	PHENOTYPE	13	13	OCD
NCT0000038415	NCT00000384_15_T0	GENE	2	2	II
NCT0000038418	NCT00000384_18_T0	PHENOTYPE	22	22	OCD
NCT0000038418	NCT00000384_18_T1	PHENOTYPE	25	25	impairment
NCT000003854	NCT00000385_4_T0	COMPOUND	7	7	lithium
NCT000003854	NCT00000385_4_T1	GENE	2	2	has
NCT000003858	NCT00000385_8_T0	COMPOUND	15	15	lithium
NCT000003858	NCT00000385_8_T1	COMPOUND	23	23	lithium
NCT000003859	NCT00000385_9_T0	COMPOUND	3	3	lithium
NCT0000038510	NCT00000385_10_T0	COMPOUND	8	8	lithium
NCT0000038518	NCT00000385_18_T0	PHENOTYPE	0	1	Mental Retardation
NCT0000038522	NCT00000385_22_T0	PHENOTYPE	4	5	Dysthymic Disorder
NCT0000038522	NCT00000385_22_T1	PHENOTYPE	0	2	Major Depressive Disorder
NCT0000038524	NCT00000385_24_T0	PHENOTYPE	0	1	Bipolar Disorder
NCT0000038526	NCT00000385_26_T0	PHENOTYPE	6	6	Schizophrenia
NCT0000038526	NCT00000385_26_T1	PHENOTYPE	3	4	Schizophreniform Disorder
NCT0000038526	NCT00000385_26_T2	PHENOTYPE	0	1	Psychotic Disorder
NCT0000038528	NCT00000385_28_T0	PHENOTYPE	8	9	thyroid diseases
NCT0000038528	NCT00000385_28_T1	PHENOTYPE	11	12	seizure disorder
NCT0000038534	NCT00000385_34_T0	PHENOTYPE	2	3	Substance Dependence
NCT000003861	NCT00000386_1_T0	GENE	4	4	ERP
NCT000003862	NCT00000386_2_T0	GENE	8	8	RT
NCT000003864	NCT00000386_4_T0	PHENOTYPE	8	8	OCD
NCT000003864	NCT00000386_4_T1	GENE	0	0	ERP
NCT000003865	NCT00000386_5_T0	GENE	0	0	RT
NCT000003866	NCT00000386_6_T0	GENE	16	16	RT
NCT000003869	NCT00000386_9_T0	PHENOTYPE	13	13	OCD
NCT000003869	NCT00000386_9_T1	PHENOTYPE	11	12	obsessive-compulsive disorder
NCT0000038611	NCT00000386_11_T0	PHENOTYPE	13	13	OCD
NCT0000038611	NCT00000386_11_T1	PHENOTYPE	23	23	OCD
NCT0000038611	NCT00000386_11_T2	PHENOTYPE	33	33	OCD
NCT0000038611	NCT00000386_11_T3	GENE	10	10	ERP
NCT0000038612	NCT00000386_12_T0	GENE	9	9	RT
NCT0000038613	NCT00000386_13_T0	PHENOTYPE	0	0	OCD
NCT0000038613	NCT00000386_13_T1	GENE	10	10	has
NCT0000038613	NCT00000386_13_T2	PHENOTYPE	3	3	chronic
NCT0000038614	NCT00000386_14_T0	PHENOTYPE	12	12	OCD
NCT0000038614	NCT00000386_14_T1	GENE	4	4	ERP
NCT0000038615	NCT00000386_15_T0	GENE	0	0	RT
NCT0000038615	NCT00000386_15_T1	PHENOTYPE	16	16	familiarity
NCT0000038616	NCT00000386_16_T0	PHENOTYPE	18	18	OCD
NCT0000038616	NCT00000386_16_T1	GENE	0	0	RT
NCT0000038616	NCT00000386_16_T2	GENE	14	14	ERP
NCT0000038616	NCT00000386_16_T3	GENE	1	1	has
NCT0000038617	NCT00000386_17_T0	GENE	2	2	has
NCT0000038618	NCT00000386_18_T0	GENE	14	14	RT
NCT000003873	NCT00000387_3_T0	PHENOTYPE	6	6	symptoms
NCT000003873	NCT00000387_3_T1	PHENOTYPE	8	8	schizophrenia
NCT000003877	NCT00000387_7_T0	GENE	10	10	Is
NCT000003877	NCT00000387_7_T1	PHENOTYPE	21	21	schizophrenia
NCT000003877	NCT00000387_7_T2	GENE	17	17	has
NCT0000038712	NCT00000387_12_T0	PHENOTYPE	30	31	cognitive processing
NCT0000038716	NCT00000387_16_T0	GENE	17	17	II
NCT0000038718	NCT00000387_18_T0	PHENOTYPE	8	9	mental health
NCT0000038720	NCT00000387_20_T0	PHENOTYPE	17	17	reinforcement
NCT000003881	NCT00000388_1_T0	GENE	43	43	mo
NCT000003881	NCT00000388_1_T1	PHENOTYPE	7	7	persistence
NCT000003881	NCT00000388_1_T2	GENE	13	13	MTA
NCT000003881	NCT00000388_1_T3	GENE	30	30	MTA
NCT000003882	NCT00000388_2_T0	PHENOTYPE	18	18	ADHD
NCT000003885	NCT00000388_5_T0	GENE	3	3	MTA
NCT000003887	NCT00000388_7_T0	GENE	2	2	MTA
NCT0000038811	NCT00000388_11_T0	GENE	43	43	mo
NCT0000038811	NCT00000388_11_T1	PHENOTYPE	7	7	persistence
NCT0000038811	NCT00000388_11_T2	GENE	13	13	MTA
NCT0000038811	NCT00000388_11_T3	GENE	30	30	MTA
NCT0000038812	NCT00000388_12_T0	PHENOTYPE	18	18	ADHD
NCT0000038815	NCT00000388_15_T0	GENE	3	3	MTA
NCT0000038817	NCT00000388_17_T0	GENE	2	2	MTA
NCT000003891	NCT00000389_1_T0	PHENOTYPE	9	9	OCD
NCT000003891	NCT00000389_1_T1	GENE	1	1	has
NCT000003891	NCT00000389_1_T2	PHENOTYPE	7	8	obsessive-compulsive disorder
NCT000003892	NCT00000389_2_T0	PHENOTYPE	4	4	OCD
NCT000003892	NCT00000389_2_T1	PHENOTYPE	10	11	social phobia
NCT000003892	NCT00000389_2_T2	PHENOTYPE	0	1	Anxiety disorders
NCT000003892	NCT00000389_2_T3	PHENOTYPE	13	14	separation anxiety
NCT000003892	NCT00000389_2_T4	PHENOTYPE	7	9	generalized anxiety disorder
NCT000003893	NCT00000389_3_T0	PHENOTYPE	1	1	disorders
NCT000003893	NCT00000389_3_T1	COMPOUND	5	5	fluvoxamine
NCT000003894	NCT00000389_4_T0	COMPOUND	20	20	fluvoxamine
NCT000003896	NCT00000389_6_T0	GENE	10	10	Is
NCT000003896	NCT00000389_6_T1	GENE	17	17	has
NCT000003896	NCT00000389_6_T2	PHENOTYPE	28	29	social phobia
NCT000003896	NCT00000389_6_T3	PHENOTYPE	31	32	separation anxiety
NCT000003896	NCT00000389_6_T4	PHENOTYPE	22	23	anxiety disorder
NCT000003896	NCT00000389_6_T5	PHENOTYPE	25	27	generalized anxiety disorder
NCT000003898	NCT00000389_8_T0	PHENOTYPE	15	15	OCD
NCT000003898	NCT00000389_8_T1	PHENOTYPE	13	14	obsessive-compulsive disorder
NCT000003899	NCT00000389_9_T0	PHENOTYPE	4	4	OCD
NCT000003899	NCT00000389_9_T1	PHENOTYPE	0	1	Anxiety disorders
NCT0000038911	NCT00000389_11_T0	COMPOUND	16	16	fluvoxamine
NCT000003900	NCT00000390_0_T0	PHENOTYPE	5	5	Depression
NCT000003903	NCT00000390_3_T0	PHENOTYPE	10	10	diseases
NCT000003903	NCT00000390_3_T1	PHENOTYPE	1	1	syndromes
NCT000003903	NCT00000390_3_T2	PHENOTYPE	6	6	chronic
NCT000003904	NCT00000390_4_T0	PHENOTYPE	12	12	reluctance
NCT000003904	NCT00000390_4_T1	PHENOTYPE	6	7	HIV infection
NCT000003905	NCT00000390_5_T0	GENE	4	4	has
NCT000003907	NCT00000390_7_T0	COMPOUND	7	7	hydrochloride
NCT000003907	NCT00000390_7_T1	COMPOUND	6	6	imipramine
NCT0000039010	NCT00000390_10_T0	COMPOUND	20	20	hydrochloride
NCT0000039010	NCT00000390_10_T1	COMPOUND	19	19	imipramine
NCT0000039012	NCT00000390_12_T0	PHENOTYPE	10	10	diseases
NCT0000039012	NCT00000390_12_T1	PHENOTYPE	1	1	syndromes
NCT0000039012	NCT00000390_12_T2	PHENOTYPE	6	6	chronic
NCT0000039013	NCT00000390_13_T0	PHENOTYPE	12	12	reluctance
NCT0000039013	NCT00000390_13_T1	PHENOTYPE	6	7	HIV infection
NCT0000039014	NCT00000390_14_T0	GENE	4	4	has
NCT0000039016	NCT00000390_16_T0	COMPOUND	7	7	hydrochloride
NCT0000039016	NCT00000390_16_T1	COMPOUND	6	6	imipramine
NCT0000039019	NCT00000390_19_T0	COMPOUND	20	20	hydrochloride
NCT0000039019	NCT00000390_19_T1	COMPOUND	19	19	imipramine
NCT000003910	NCT00000391_0_T0	PHENOTYPE	9	9	Toxicity
NCT000003910	NCT00000391_0_T1	PHENOTYPE	14	14	Immunodeficiency
NCT000003910	NCT00000391_0_T2	PHENOTYPE	11	11	Pharmacokinetics
NCT000003910	NCT00000391_0_T3	GENE	19	19	ed
NCT000003912	NCT00000391_2_T0	COMPOUND	8	9	peptide T
NCT000003912	NCT00000391_2_T1	ORGAN	21	23	central nervous system
NCT000003914	NCT00000391_4_T0	GENE	8	8	CD4
NCT000003914	NCT00000391_4_T1	CELL	9	9	cells
NCT000003914	NCT00000391_4_T2	ORGAN	16	17	immune system
NCT000003915	NCT00000391_5_T0	PHENOTYPE	11	11	illnesses
NCT000003915	NCT00000391_5_T1	PHENOTYPE	13	14	HIV encephalopathy
NCT000003917	NCT00000391_7_T0	GENE	5	5	CD4
NCT000003917	NCT00000391_7_T1	GENE	4	4	receptor
NCT000003917	NCT00000391_7_T2	PHENOTYPE	0	0	HIV
NCT000003919	NCT00000391_9_T0	COMPOUND	7	8	peptide T
NCT0000039111	NCT00000391_11_T0	COMPOUND	9	10	peptide T
NCT0000039116	NCT00000391_16_T0	PHENOTYPE	8	8	secondary
NCT0000039116	NCT00000391_16_T1	PHENOTYPE	10	11	immune dysregulation
NCT0000039116	NCT00000391_16_T2	PHENOTYPE	14	15	HIV infection
NCT0000039116	NCT00000391_16_T3	PHENOTYPE	4	7	central nervous system disease
NCT0000039117	NCT00000391_17_T0	PHENOTYPE	16	16	HIV
NCT0000039117	NCT00000391_17_T1	PHENOTYPE	4	5	psychiatric illness
NCT000003920	NCT00000392_0_T0	GENE	1	1	II
NCT000003920	NCT00000392_0_T1	PHENOTYPE	13	14	Cognitive Impairment
NCT000003924	NCT00000392_4_T0	COMPOUND	6	7	peptide T
NCT000003925	NCT00000392_5_T0	COMPOUND	5	6	peptide T
NCT000003928	NCT00000392_8_T0	PHENOTYPE	0	1	Cognitive dysfunction
NCT0000039210	NCT00000392_10_T0	PHENOTYPE	0	0	HIV
NCT0000039214	NCT00000392_14_T0	GENE	11	11	OR
NCT0000039219	NCT00000392_19_T0	COMPOUND	8	8	dapsone
NCT0000039219	NCT00000392_19_T1	COMPOUND	13	13	nystatin
NCT0000039219	NCT00000392_19_T2	COMPOUND	2	2	pentamidine
NCT0000039219	NCT00000392_19_T3	COMPOUND	15	15	ketoconazole
NCT0000039219	NCT00000392_19_T4	COMPOUND	16	16	acyclovir
NCT0000039219	NCT00000392_19_T5	PHENOTYPE	4	6	Pneumocystis carinii pneumonia
NCT0000039225	NCT00000392_25_T0	PHENOTYPE	22	22	mania
NCT0000039225	NCT00000392_25_T1	PHENOTYPE	18	19	psychotic disorder
NCT0000039228	NCT00000392_28_T0	PHENOTYPE	4	4	malignancy
NCT0000039228	NCT00000392_28_T1	PHENOTYPE	0	1	Kaposi's sarcoma
NCT000003930	NCT00000393_0_T0	PHENOTYPE	11	11	Complications
NCT000003930	NCT00000393_0_T1	PHENOTYPE	13	15	Acquired Immunodeficiency Syndrome
NCT000003932	NCT00000393_2_T0	PHENOTYPE	13	13	HIV
NCT000003932	NCT00000393_2_T1	ORGAN	5	7	central nervous system
NCT000003933	NCT00000393_3_T0	PHENOTYPE	1	1	dysfunction
NCT000003933	NCT00000393_3_T1	PHENOTYPE	15	16	HIV infection
NCT000003934	NCT00000393_4_T0	CELL	15	15	cells
NCT000003934	NCT00000393_4_T1	PHENOTYPE	4	5	HIV infection
NCT000003935	NCT00000393_5_T0	CELL	12	12	cells
NCT000003935	NCT00000393_5_T1	PHENOTYPE	10	10	HIV
NCT000003935	NCT00000393_5_T2	PHENOTYPE	15	15	susceptible
NCT000003935	NCT00000393_5_T3	PHENOTYPE	17	18	HIV infection
NCT000003936	NCT00000393_6_T0	COMPOUND	7	8	peptide T
NCT000003937	NCT00000393_7_T0	COMPOUND	23	24	peptide T
NCT000003937	NCT00000393_7_T1	GENE	8	9	group 2
NCT000003937	NCT00000393_7_T2	PHENOTYPE	12	13	mental impairment
NCT000003937	NCT00000393_7_T3	PHENOTYPE	10	11	cognitive dysfunction
NCT000003938	NCT00000393_8_T0	GENE	5	5	IV
NCT000003938	NCT00000393_8_T1	COMPOUND	8	9	peptide T
NCT000003939	NCT00000393_9_T0	GENE	5	5	IV
NCT000003939	NCT00000393_9_T1	GENE	24	24	IV
NCT000003939	NCT00000393_9_T2	COMPOUND	26	27	peptide T
NCT0000039315	NCT00000393_15_T0	PHENOTYPE	1	2	opportunistic infection
NCT0000039317	NCT00000393_17_T0	PHENOTYPE	1	2	opportunistic infection
NCT0000039420	NCT00000394_20_T0	PHENOTYPE	5	5	symptoms
NCT0000039420	NCT00000394_20_T1	ORGAN	16	17	median nerve
NCT000003951	NCT00000395_1_T0	PHENOTYPE	13	13	blocks
NCT000003951	NCT00000395_1_T1	COMPOUND	3	3	methotrexate
NCT000003951	NCT00000395_1_T2	COMPOUND	21	22	folic acid
NCT000003952	NCT00000395_2_T0	COMPOUND	23	23	methotrexate
NCT000003952	NCT00000395_2_T1	PHENOTYPE	28	29	rheumatoid arthritis
NCT000003953	NCT00000395_3_T0	PHENOTYPE	21	21	arthritis
NCT000003956	NCT00000395_6_T0	GENE	8	9	adenosine deaminase
NCT000003956	NCT00000395_6_T1	BIOLOGICAL_PROCESS	14	15	adenosine metabolism
NCT000003958	NCT00000395_8_T0	COMPOUND	20	20	methotrexate
NCT000003958	NCT00000395_8_T1	PHENOTYPE	23	24	rheumatoid arthritis
NCT000003958	NCT00000395_8_T2	MOLECULAR_FUNCTION	3	5	adenosine deaminase activity
NCT0000039510	NCT00000395_10_T0	GENE	8	8	lessen
NCT0000039510	NCT00000395_10_T1	COMPOUND	2	3	folic acid
NCT0000039511	NCT00000395_11_T0	COMPOUND	26	26	adenosine
NCT0000039511	NCT00000395_11_T1	COMPOUND	28	28	deoxyadenosine
NCT0000039511	NCT00000395_11_T2	COMPOUND	5	5	methotrexate
NCT0000039511	NCT00000395_11_T3	PHENOTYPE	14	14	inhibition
NCT0000039511	NCT00000395_11_T4	COMPOUND	30	31	folinic acid
NCT0000039511	NCT00000395_11_T5	COMPOUND	15	16	folic acid
NCT0000039512	NCT00000395_12_T0	PHENOTYPE	16	16	arthritis
NCT0000039512	NCT00000395_12_T1	PHENOTYPE	9	10	rheumatoid arthritis
NCT0000039513	NCT00000395_13_T0	COMPOUND	10	10	methotrexate
NCT0000039513	NCT00000395_13_T1	COMPOUND	50	50	methotrexate
NCT0000039513	NCT00000395_13_T2	COMPOUND	67	67	methotrexate
NCT0000039513	NCT00000395_13_T3	PHENOTYPE	22	22	arthritis
NCT0000039513	NCT00000395_13_T4	PHENOTYPE	55	55	arthritis
NCT0000039513	NCT00000395_13_T5	PHENOTYPE	75	76	rheumatoid arthritis
NCT0000039513	NCT00000395_13_T6	COMPOUND	64	65	folinic acid
NCT0000039513	NCT00000395_13_T7	BIOLOGICAL_PROCESS	26	27	adenosine metabolism
NCT0000039513	NCT00000395_13_T8	BIOLOGICAL_PROCESS	37	38	adenosine metabolism
NCT0000039513	NCT00000395_13_T9	BIOLOGICAL_PROCESS	70	71	adenosine metabolism
NCT0000039513	NCT00000395_13_T10	COMPOUND	61	62	folic acid
NCT0000039514	NCT00000395_14_T0	PHENOTYPE	24	24	arthritis
NCT000003961	NCT00000396_1_T0	PHENOTYPE	10	10	arthritis
NCT000003963	NCT00000396_3_T0	PHENOTYPE	22	22	arthritis
NCT000003963	NCT00000396_3_T1	PHENOTYPE	29	29	arthritis
NCT000003964	NCT00000396_4_T0	PHENOTYPE	11	11	arthritis
NCT000003968	NCT00000396_8_T0	GENE	6	6	longevity
NCT000003968	NCT00000396_8_T1	PHENOTYPE	16	16	reinforcement
NCT0000039612	NCT00000396_12_T0	PHENOTYPE	4	4	focused
NCT0000039612	NCT00000396_12_T1	PHENOTYPE	11	11	Arthritis
NCT0000039612	NCT00000396_12_T2	PHENOTYPE	5	5	reinforcement
NCT0000039614	NCT00000396_14_T0	PHENOTYPE	36	36	adaptation
NCT0000039616	NCT00000396_16_T0	PHENOTYPE	12	12	arthritis
NCT0000039616	NCT00000396_16_T1	PHENOTYPE	20	20	arthritis
NCT0000039617	NCT00000396_17_T0	PHENOTYPE	16	16	arthritis
NCT0000039617	NCT00000396_17_T1	PHENOTYPE	23	23	arthritis
NCT0000039618	NCT00000396_18_T0	GENE	6	6	longevity
NCT0000039618	NCT00000396_18_T1	PHENOTYPE	18	18	reinforcement
NCT0000039619	NCT00000396_19_T0	PHENOTYPE	9	9	arthritis
NCT000003970	NCT00000397_0_T0	PHENOTYPE	1	1	Insomnia
NCT000003970	NCT00000397_0_T1	PHENOTYPE	4	4	Fibromyalgia
NCT000003977	NCT00000397_7_T0	GENE	20	20	erratic
NCT000003977	NCT00000397_7_T1	PHENOTYPE	19	19	arousal
NCT000003977	NCT00000397_7_T2	PHENOTYPE	13	13	insomnia
NCT0000039717	NCT00000397_17_T0	GENE	20	20	NC
NCT000003980	NCT00000398_0_T0	PHENOTYPE	3	3	Fibromyalgia
NCT000003982	NCT00000398_2_T0	PHENOTYPE	1	1	affects
NCT000003982	NCT00000398_2_T1	PHENOTYPE	19	20	rheumatic diseases
NCT000003984	NCT00000398_4_T0	GENE	19	19	CST
NCT000003984	NCT00000398_4_T1	GENE	24	24	CST
NCT0000039811	NCT00000398_11_T0	GENE	13	13	CST
NCT0000039811	NCT00000398_11_T1	GENE	23	23	CST
NCT0000039812	NCT00000398_12_T0	GENE	19	19	CST
NCT0000039812	NCT00000398_12_T1	GENE	25	25	CST
NCT000003991	NCT00000399_1_T0	GENE	1	1	BEST
NCT000003992	NCT00000399_2_T0	GENE	6	6	hormone
NCT000003993	NCT00000399_3_T0	PHENOTYPE	3	3	affects
NCT000003993	NCT00000399_3_T1	TISSUE	0	0	Bone
NCT000003993	NCT00000399_3_T2	PHENOTYPE	10	10	osteoporosis
NCT000003993	NCT00000399_3_T3	PHENOTYPE	21	21	osteoporosis
NCT000003994	NCT00000399_4_T0	GENE	3	3	BEST
NCT000003997	NCT00000399_7_T0	PHENOTYPE	4	4	fractures
NCT000003998	NCT00000399_8_T0	PHENOTYPE	8	9	osteoporotic fractures
NCT0000039911	NCT00000399_11_T0	GENE	37	37	HRT
NCT0000039911	NCT00000399_11_T1	GENE	42	42	HRT
NCT0000039911	NCT00000399_11_T2	PHENOTYPE	23	23	osteoporosis
NCT0000039912	NCT00000399_12_T0	PHENOTYPE	4	4	progressive
NCT0000039921	NCT00000399_21_T0	PHENOTYPE	52	52	progressive
NCT0000039921	NCT00000399_21_T1	GENE	67	67	HRT
NCT0000039921	NCT00000399_21_T2	GENE	70	70	HRT
NCT0000039921	NCT00000399_21_T3	PHENOTYPE	30	30	osteoporosis
NCT0000039921	NCT00000399_21_T4	PHENOTYPE	63	63	osteoporosis
NCT000004000	NCT00000400_0_T0	PHENOTYPE	5	5	Osteoporosis
NCT000004000	NCT00000400_0_T1	PHENOTYPE	2	2	Parathyroid
NCT000004007	NCT00000400_7_T0	COMPOUND	9	9	alendronate
NCT000004008	NCT00000400_8_T0	COMPOUND	20	20	alendronate
NCT000004009	NCT00000400_9_T0	COMPOUND	21	21	alendronate
NCT000004011	NCT00000401_1_T0	CELL	9	9	cells
NCT000004011	NCT00000401_1_T1	ORGAN	11	11	joints
NCT000004011	NCT00000401_1_T2	GENE	1	1	RA
NCT000004011	NCT00000401_1_T3	ORGAN	3	4	immune system
NCT000004012	NCT00000401_2_T0	GENE	8	8	II
NCT000004012	NCT00000401_2_T1	GENE	11	11	CII
NCT000004012	NCT00000401_2_T2	GENE	9	9	collagen
NCT000004012	NCT00000401_2_T3	GENE	19	19	RA
NCT000004012	NCT00000401_2_T4	PHENOTYPE	16	17	joint inflammation
NCT000004017	NCT00000401_7_T0	COMPOUND	16	16	prednisone
NCT0000040111	NCT00000401_11_T0	PHENOTYPE	7	7	inflammation
NCT0000040113	NCT00000401_13_T0	GENE	1	1	has
NCT000004021	NCT00000402_1_T0	COMPOUND	6	6	calcium
NCT000004023	NCT00000402_3_T0	COMPOUND	10	10	calcium
NCT000004023	NCT00000402_3_T1	TISSUE	14	15	body fat
NCT000004024	NCT00000402_4_T0	COMPOUND	4	4	calcium
NCT000004025	NCT00000402_5_T0	PHENOTYPE	10	10	osteoporosis
NCT000004025	NCT00000402_5_T1	PHENOTYPE	26	26	osteoporosis
NCT0000040212	NCT00000402_12_T0	COMPOUND	10	10	calcium
NCT0000040212	NCT00000402_12_T1	PHENOTYPE	15	15	hypertension
NCT0000040212	NCT00000402_12_T2	PHENOTYPE	18	18	obesity
NCT0000040213	NCT00000402_13_T0	PHENOTYPE	10	10	osteoporosis
NCT000004030	NCT00000403_0_T0	PHENOTYPE	3	3	Progression
NCT000004033	NCT00000403_3_T0	PHENOTYPE	3	3	overweight
NCT000004034	NCT00000403_4_T0	COMPOUND	10	10	doxycycline
NCT000004035	NCT00000403_5_T0	COMPOUND	2	2	doxycycline
NCT000004035	NCT00000403_5_T1	COMPOUND	19	19	doxycycline
NCT000004036	NCT00000403_6_T0	PHENOTYPE	4	4	narrowing
NCT000004037	NCT00000403_7_T0	PHENOTYPE	2	2	narrowing
NCT000004038	NCT00000403_8_T0	PHENOTYPE	8	8	symptoms
NCT0000040312	NCT00000403_12_T0	PHENOTYPE	7	7	severity
NCT0000040312	NCT00000403_12_T1	PHENOTYPE	11	11	progression
NCT0000040312	NCT00000403_12_T2	COMPOUND	3	3	doxycycline
NCT0000040313	NCT00000403_13_T0	PHENOTYPE	9	9	centers
NCT0000040314	NCT00000403_14_T0	COMPOUND	4	4	doxycycline
NCT0000040317	NCT00000403_17_T0	PHENOTYPE	12	12	narrowing
NCT0000040318	NCT00000403_18_T0	PHENOTYPE	12	12	arthritis
NCT0000040410	NCT00000404_10_T0	GENE	39	39	reduced
NCT000004051	NCT00000405_1_T0	ORGAN	19	19	skeleton
NCT000004052	NCT00000405_2_T0	ORGAN	12	12	skeleton
NCT000004053	NCT00000405_3_T0	PHENOTYPE	4	5	broken bones
NCT000004054	NCT00000405_4_T0	PHENOTYPE	6	6	5-10
NCT0000040510	NCT00000405_10_T0	PHENOTYPE	21	21	fracture
NCT0000040511	NCT00000405_11_T0	PHENOTYPE	12	12	osteopenia
NCT0000040511	NCT00000405_11_T1	PHENOTYPE	14	14	osteoporosis
NCT0000040512	NCT00000405_12_T0	GENE	9	9	3.5
NCT0000040512	NCT00000405_12_T1	PHENOTYPE	13	13	fracture
NCT0000040516	NCT00000405_16_T0	ORGAN	15	15	femur
NCT0000040516	NCT00000405_16_T1	ORGAN	12	12	spine
NCT0000040516	NCT00000405_16_T2	PHENOTYPE	14	14	proximal
NCT0000040518	NCT00000405_18_T0	GENE	4	4	pubescent
NCT000004069	NCT00000406_9_T0	PHENOTYPE	12	14	quality of life
NCT000004069	NCT00000406_9_T1	PHENOTYPE	16	18	symptoms of depression
NCT000004072	NCT00000407_2_T0	PHENOTYPE	12	12	ARMD
NCT000004072	NCT00000407_2_T1	PHENOTYPE	38	38	ARMD
NCT000004074	NCT00000407_4_T0	PHENOTYPE	10	10	ARMD
NCT000004075	NCT00000407_5_T0	PHENOTYPE	10	10	ARMD
NCT000004078	NCT00000407_8_T0	PHENOTYPE	12	12	ARMD
NCT000004078	NCT00000407_8_T1	PHENOTYPE	38	38	ARMD
NCT000004087	NCT00000408_7_T0	PHENOTYPE	25	25	closed
NCT0000040914	NCT00000409_14_T0	PHENOTYPE	11	13	quality of life
NCT0000040915	NCT00000409_15_T0	PHENOTYPE	0	0	Secondary
NCT0000040919	NCT00000409_19_T0	GENE	5	5	has
NCT0000040920	NCT00000409_20_T0	GENE	22	22	SpS
NCT0000040920	NCT00000409_20_T1	GENE	21	21	IDH
NCT0000040920	NCT00000409_20_T2	GENE	24	24	DS
NCT0000040921	NCT00000409_21_T0	ORGAN	30	30	spine
NCT000004103	NCT00000410_3_T0	ORGAN	22	22	spine
NCT000004103	NCT00000410_3_T1	TISSUE	18	18	bones
NCT000004103	NCT00000410_3_T2	PHENOTYPE	32	33	herniated disc
NCT000004103	NCT00000410_3_T3	PHENOTYPE	9	11	intervertebral disc herniation
NCT000004107	NCT00000410_7_T0	TISSUE	11	11	muscles
NCT000004107	NCT00000410_7_T1	PHENOTYPE	8	8	reflecting
NCT000004107	NCT00000410_7_T2	GENE	5	5	midline
NCT000004107	NCT00000410_7_T3	PHENOTYPE	1	2	surgical incision
NCT000004109	NCT00000410_9_T0	GENE	8	8	facet
NCT0000041010	NCT00000410_10_T0	GENE	24	24	fragment
NCT0000041010	NCT00000410_10_T1	GENE	26	26	disc
NCT0000041010	NCT00000410_10_T2	GENE	33	33	disc
NCT0000041010	NCT00000410_10_T3	GENE	11	11	IDH
NCT0000041011	NCT00000410_11_T0	GENE	10	10	fragment
NCT0000041011	NCT00000410_11_T1	PHENOTYPE	22	22	pathology
NCT0000041011	NCT00000410_11_T2	GENE	19	19	disc
NCT0000041022	NCT00000410_22_T0	PHENOTYPE	11	13	quality of life
NCT0000041023	NCT00000410_23_T0	PHENOTYPE	0	0	Secondary
NCT0000041027	NCT00000410_27_T0	GENE	5	5	has
NCT0000041028	NCT00000410_28_T0	GENE	22	22	SpS
NCT0000041028	NCT00000410_28_T1	GENE	21	21	IDH
NCT0000041028	NCT00000410_28_T2	GENE	24	24	DS
NCT0000041029	NCT00000410_29_T0	ORGAN	35	35	spine
NCT0000041117	NCT00000411_17_T0	PHENOTYPE	11	13	quality of life
NCT0000041118	NCT00000411_18_T0	PHENOTYPE	0	0	Secondary
NCT0000041122	NCT00000411_22_T0	GENE	5	5	has
NCT0000041123	NCT00000411_23_T0	GENE	22	22	SpS
NCT0000041123	NCT00000411_23_T1	GENE	21	21	IDH
NCT0000041123	NCT00000411_23_T2	GENE	24	24	DS
NCT0000041124	NCT00000411_24_T0	ORGAN	30	30	spine
NCT000004121	NCT00000412_1_T0	ORGAN	7	7	heart
NCT000004121	NCT00000412_1_T1	ORGAN	8	8	transplants
NCT000004121	NCT00000412_1_T2	PHENOTYPE	11	12	broken bones
NCT000004123	NCT00000412_3_T0	COMPOUND	22	22	calcitriol
NCT000004123	NCT00000412_3_T1	COMPOUND	25	25	calcitriol
NCT000004123	NCT00000412_3_T2	ORGAN	10	10	transplant
NCT000004123	NCT00000412_3_T3	ORGAN	39	39	transplant
NCT000004123	NCT00000412_3_T4	ORGAN	45	45	transplant
NCT000004123	NCT00000412_3_T5	GENE	6	6	had
NCT000004123	NCT00000412_3_T6	COMPOUND	15	15	alendronate
NCT000004123	NCT00000412_3_T7	COMPOUND	32	32	alendronate
NCT000004123	NCT00000412_3_T8	ORGAN	9	9	heart
NCT000004125	NCT00000412_5_T0	PHENOTYPE	12	12	osteoporosis
NCT000004129	NCT00000412_9_T0	COMPOUND	11	11	calcitriol
NCT000004129	NCT00000412_9_T1	COMPOUND	6	6	alendronate
NCT0000041210	NCT00000412_10_T0	COMPOUND	9	9	calcitriol
NCT0000041210	NCT00000412_10_T1	COMPOUND	6	6	alendronate
NCT0000041210	NCT00000412_10_T2	GENE	12	12	BID
NCT0000041210	NCT00000412_10_T3	PHENOTYPE	3	4	Group B
NCT0000041213	NCT00000412_13_T0	PHENOTYPE	7	8	vertebral fracture
NCT0000041216	NCT00000412_16_T0	PHENOTYPE	3	3	recruitment
NCT0000041216	NCT00000412_16_T1	ORGAN	13	13	transplant
NCT0000041218	NCT00000412_18_T0	PHENOTYPE	17	18	vertebral fractures
NCT000004131	NCT00000413_1_T0	ORGAN	14	14	skeletons
NCT000004133	NCT00000413_3_T0	COMPOUND	13	13	calcium
NCT000004133	NCT00000413_3_T1	PHENOTYPE	9	9	affects
NCT000004133	NCT00000413_3_T2	PHENOTYPE	6	6	osteoporosis
NCT000004138	NCT00000413_8_T0	COMPOUND	22	22	calcium
NCT000004138	NCT00000413_8_T1	PHENOTYPE	5	5	osteoporosis
NCT000004138	NCT00000413_8_T2	PHENOTYPE	15	15	osteoporosis
NCT000004138	NCT00000413_8_T3	PHENOTYPE	29	29	osteoporosis
NCT0000041312	NCT00000413_12_T0	BIOLOGICAL_PROCESS	10	10	eating
NCT0000041313	NCT00000413_13_T0	COMPOUND	7	7	calcium
NCT0000041314	NCT00000413_14_T0	PHENOTYPE	1	1	secondary
NCT0000041314	NCT00000413_14_T1	GENE	12	12	os
NCT000004141	NCT00000414_1_T0	PHENOTYPE	3	3	Arthritis
NCT000004142	NCT00000414_2_T0	PHENOTYPE	4	4	Arthritis
NCT000004143	NCT00000414_3_T0	PHENOTYPE	10	10	osteoarthritis
NCT000004143	NCT00000414_3_T1	BIOLOGICAL_PROCESS	28	28	Aging
NCT000004143	NCT00000414_3_T2	PHENOTYPE	26	26	Rheumatism
NCT000004143	NCT00000414_3_T3	PHENOTYPE	25	25	Arthritis
NCT000004143	NCT00000414_3_T4	PHENOTYPE	7	8	rheumatoid arthritis
NCT000004147	NCT00000414_7_T0	PHENOTYPE	7	7	arthritis
NCT000004148	NCT00000414_8_T0	PHENOTYPE	14	14	arthritis
NCT000004149	NCT00000414_9_T0	PHENOTYPE	1	1	Arthritis
NCT0000041410	NCT00000414_10_T0	GENE	8	8	has
NCT0000041411	NCT00000414_11_T0	PHENOTYPE	2	2	Arthritis
NCT0000041413	NCT00000414_13_T0	GENE	21	21	RA
NCT0000041416	NCT00000414_16_T0	PHENOTYPE	20	20	arthritis
NCT0000041416	NCT00000414_16_T1	PHENOTYPE	29	29	arthritis
NCT0000041416	NCT00000414_16_T2	GENE	10	10	RA
NCT000004151	NCT00000415_1_T0	COMPOUND	10	10	calcium
NCT000004152	NCT00000415_2_T0	COMPOUND	10	10	calcium
NCT000004153	NCT00000415_3_T0	PHENOTYPE	11	11	centers
NCT000004154	NCT00000415_4_T0	TISSUE	8	8	muscles
NCT000004154	NCT00000415_4_T1	MOLECULAR_FUNCTION	10	11	motor activity
NCT000004155	NCT00000415_5_T0	TISSUE	7	7	muscles
NCT000004155	NCT00000415_5_T1	MOLECULAR_FUNCTION	9	10	motor activity
NCT000004158	NCT00000415_8_T0	COMPOUND	16	16	calcium
NCT0000041510	NCT00000415_10_T0	COMPOUND	14	14	calcium
NCT0000041512	NCT00000415_12_T0	BIOLOGICAL_PROCESS	15	17	response to activity
NCT0000041513	NCT00000415_13_T0	MOLECULAR_FUNCTION	59	60	motor activity
NCT0000041513	NCT00000415_13_T1	MOLECULAR_FUNCTION	67	68	motor activity
NCT0000041513	NCT00000415_13_T2	MOLECULAR_FUNCTION	84	85	motor activity
NCT0000041514	NCT00000415_14_T0	COMPOUND	14	14	3
NCT0000041515	NCT00000415_15_T0	PHENOTYPE	20	20	centers
NCT0000041515	NCT00000415_15_T1	MOLECULAR_FUNCTION	11	12	motor activity
NCT0000041518	NCT00000415_18_T0	MOLECULAR_FUNCTION	16	17	motor activity
NCT0000041521	NCT00000415_21_T0	PHENOTYPE	26	26	strategies
NCT000004161	NCT00000416_1_T0	PHENOTYPE	17	17	arthritis
NCT000004163	NCT00000416_3_T0	PHENOTYPE	14	14	symptoms
NCT000004164	NCT00000416_4_T0	PHENOTYPE	9	9	disorders
NCT000004169	NCT00000416_9_T0	PHENOTYPE	14	14	disorders
NCT0000041613	NCT00000416_13_T0	PHENOTYPE	14	14	symptoms
NCT0000041614	NCT00000416_14_T0	PHENOTYPE	12	12	disorders
NCT0000041614	NCT00000416_14_T1	PHENOTYPE	16	16	practices
NCT0000041616	NCT00000416_16_T0	PHENOTYPE	6	6	self-efficacy
NCT000004171	NCT00000417_1_T0	PHENOTYPE	17	17	self-efficacy
NCT000004171	NCT00000417_1_T1	PHENOTYPE	6	6	lupus
NCT000004171	NCT00000417_1_T2	PHENOTYPE	31	31	lupus
NCT000004171	NCT00000417_1_T3	PHENOTYPE	22	23	problem solving
NCT000004174	NCT00000417_4_T0	PHENOTYPE	12	12	self-efficacy
NCT000004175	NCT00000417_5_T0	PHENOTYPE	19	19	self-efficacy
NCT000004175	NCT00000417_5_T1	PHENOTYPE	4	4	lupus
NCT000004175	NCT00000417_5_T2	PHENOTYPE	26	26	lupus
NCT000004175	NCT00000417_5_T3	PHENOTYPE	35	35	lupus
NCT000004177	NCT00000417_7_T0	PHENOTYPE	15	15	self-efficacy
NCT000004177	NCT00000417_7_T1	PHENOTYPE	11	12	mental health
NCT000004183	NCT00000418_3_T0	GENE	20	20	ALBP
NCT000004184	NCT00000418_4_T0	PHENOTYPE	9	9	self-efficacy
NCT000004184	NCT00000418_4_T1	GENE	16	16	ALBP
NCT000004185	NCT00000418_5_T0	GENE	11	11	ALBP
NCT000004186	NCT00000418_6_T0	PHENOTYPE	47	47	strategies
NCT000004186	NCT00000418_6_T1	GENE	9	9	ALBP
NCT000004186	NCT00000418_6_T2	GENE	23	23	ALBP
NCT000004186	NCT00000418_6_T3	PHENOTYPE	36	36	hostility
NCT000004189	NCT00000418_9_T0	PHENOTYPE	0	0	Secondary
NCT000004189	NCT00000418_9_T1	PHENOTYPE	10	10	self-efficacy
NCT0000041811	NCT00000418_11_T0	ORGAN	14	14	shoulders
NCT0000041811	NCT00000418_11_T1	GENE	10	10	ALBP
NCT000004199	NCT00000419_9_T0	GENE	3	3	has
NCT000004207	NCT00000420_7_T0	PHENOTYPE	21	21	affects
NCT000004208	NCT00000420_8_T0	COMPOUND	11	11	cyclophosphamide
NCT000004208	NCT00000420_8_T1	PHENOTYPE	26	26	osteoporosis
NCT000004208	NCT00000420_8_T2	PHENOTYPE	19	21	coronary artery disease
NCT0000042012	NCT00000420_12_T0	ORGAN	10	10	diaphragm
NCT000004211	NCT00000421_1_T0	PHENOTYPE	25	25	lupus
NCT000004211	NCT00000421_1_T1	PHENOTYPE	43	43	lupus
NCT000004211	NCT00000421_1_T2	GENE	11	11	C3a
NCT000004211	NCT00000421_1_T3	GENE	22	22	C3a
NCT000004212	NCT00000421_2_T0	GENE	23	23	C3a
NCT000004212	NCT00000421_2_T1	COMPOUND	12	12	prednisone
NCT000004213	NCT00000421_3_T0	GENE	6	6	C3a
NCT000004213	NCT00000421_3_T1	PHENOTYPE	20	20	lupus
NCT000004215	NCT00000421_5_T0	GENE	1	1	C3a
NCT000004215	NCT00000421_5_T1	COMPOUND	24	24	prednisone
NCT000004216	NCT00000421_6_T0	PHENOTYPE	10	10	lupus
NCT000004219	NCT00000421_9_T0	GENE	3	3	C3a
NCT000004219	NCT00000421_9_T1	GENE	8	8	C3
NCT000004219	NCT00000421_9_T2	PHENOTYPE	15	15	lupus
NCT0000042112	NCT00000421_12_T0	GENE	2	2	has
NCT0000042113	NCT00000421_13_T0	PHENOTYPE	25	25	Lupus
NCT0000042114	NCT00000421_14_T0	GENE	30	30	C3a
NCT0000042114	NCT00000421_14_T1	GENE	26	26	C3
NCT0000042114	NCT00000421_14_T2	GENE	27	27	C4
NCT0000042114	NCT00000421_14_T3	GENE	28	28	CH50
NCT0000042115	NCT00000421_15_T0	COMPOUND	22	22	estrogen
NCT0000042115	NCT00000421_15_T1	GENE	28	28	CH50
NCT0000042116	NCT00000421_16_T0	GENE	20	20	C3a
NCT0000042116	NCT00000421_16_T1	ORGAN	19	19	plasma
NCT000004220	NCT00000422_0_T0	PHENOTYPE	3	3	Fibromyalgia
NCT000004222	NCT00000422_2_T0	PHENOTYPE	18	18	fibromyalgia
NCT000004230	NCT00000423_0_T0	PHENOTYPE	3	3	Fibromyalgia
NCT000004241	NCT00000424_1_T0	PHENOTYPE	5	5	flushes
NCT000004241	NCT00000424_1_T1	PHENOTYPE	21	21	anesthesia
NCT000004241	NCT00000424_1_T2	ORGAN	8	9	knee joint
NCT000004247	NCT00000424_7_T0	COMPOUND	11	11	bupivacaine
NCT000004247	NCT00000424_7_T1	COMPOUND	8	8	lidocaine
NCT000004247	NCT00000424_7_T2	PHENOTYPE	6	6	anesthesia
NCT000004247	NCT00000424_7_T3	GENE	23	23	ml
NCT000004247	NCT00000424_7_T4	GENE	36	36	ml
NCT000004247	NCT00000424_7_T5	ORGAN	25	26	synovial fluid
NCT0000042410	NCT00000424_10_T0	PHENOTYPE	13	13	pouch
NCT0000042410	NCT00000424_10_T1	PHENOTYPE	26	26	aspirated
NCT0000042410	NCT00000424_10_T2	PHENOTYPE	39	39	flush
NCT0000042410	NCT00000424_10_T3	PHENOTYPE	23	23	sterile
NCT0000042410	NCT00000424_10_T4	GENE	21	21	ml
NCT0000042411	NCT00000424_11_T0	GENE	18	18	retained
NCT0000042415	NCT00000424_15_T0	PHENOTYPE	3	3	arthritis
NCT000004251	NCT00000425_1_T0	GENE	17	17	3.5
NCT000004251	NCT00000425_1_T1	PHENOTYPE	9	10	disease progression
NCT000004257	NCT00000425_7_T0	PHENOTYPE	36	36	osteoarthritis
NCT000004257	NCT00000425_7_T1	PHENOTYPE	9	10	disease progression
NCT000004258	NCT00000425_8_T0	PHENOTYPE	14	14	toxicity
NCT0000042510	NCT00000425_10_T0	PHENOTYPE	10	10	toxicities
NCT0000042511	NCT00000425_11_T0	PHENOTYPE	17	17	degeneration
NCT0000042514	NCT00000425_14_T0	PHENOTYPE	0	0	Secondary
NCT0000042514	NCT00000425_14_T1	PHENOTYPE	13	14	medication side-effect
NCT0000042515	NCT00000425_15_T0	PHENOTYPE	15	15	progression
NCT000004260	NCT00000426_0_T0	PHENOTYPE	2	3	Calcium Deficiency
NCT000004262	NCT00000426_2_T0	COMPOUND	11	11	calcium
NCT000004274	NCT00000427_4_T0	PHENOTYPE	7	7	osteoporosis
NCT000004278	NCT00000427_8_T0	GENE	7	7	PTH
NCT000004278	NCT00000427_8_T1	GENE	22	22	PTH
NCT000004278	NCT00000427_8_T2	COMPOUND	15	15	alendronate
NCT000004278	NCT00000427_8_T3	COMPOUND	24	24	alendronate
NCT0000042710	NCT00000427_10_T0	PHENOTYPE	9	9	osteoporosis
NCT0000042711	NCT00000427_11_T0	ORGAN	0	0	Blood
NCT0000042714	NCT00000427_14_T0	COMPOUND	4	4	alendronate
NCT0000042714	NCT00000427_14_T1	COMPOUND	8	8	alendronate
NCT0000042715	NCT00000427_15_T0	GENE	16	16	PTH
NCT0000042715	NCT00000427_15_T1	GENE	28	28	PTH
NCT0000042715	NCT00000427_15_T2	COMPOUND	21	21	alendronate
NCT0000042716	NCT00000427_16_T0	GENE	26	26	PTH
NCT0000042717	NCT00000427_17_T0	COMPOUND	5	5	alendronate
NCT0000042717	NCT00000427_17_T1	COMPOUND	8	8	alendronate
NCT0000042718	NCT00000427_18_T0	GENE	12	12	PTH
NCT0000042718	NCT00000427_18_T1	GENE	21	21	PTH
NCT000004282	NCT00000428_2_T0	PHENOTYPE	28	28	decisions
NCT000004283	NCT00000428_3_T0	PHENOTYPE	21	21	centers
NCT000004289	NCT00000428_9_T0	GENE	6	6	paired
NCT0000042814	NCT00000428_14_T0	PHENOTYPE	8	8	Fibromyalgia
NCT0000042816	NCT00000428_16_T0	PHENOTYPE	20	20	one-sided
NCT0000042818	NCT00000428_18_T0	PHENOTYPE	15	15	decisions
NCT0000042821	NCT00000428_21_T0	PHENOTYPE	9	9	withdrawn
NCT0000042821	NCT00000428_21_T1	PHENOTYPE	4	6	adverse drug reactions
NCT000004292	NCT00000429_2_T0	COMPOUND	14	14	calcium
NCT000004293	NCT00000429_3_T0	COMPOUND	6	6	calcium
NCT000004295	NCT00000429_5_T0	COMPOUND	25	25	calcium
NCT000004295	NCT00000429_5_T1	COMPOUND	26	26	carbonate
NCT000004295	NCT00000429_5_T2	COMPOUND	18	19	vitamin D
NCT000004298	NCT00000429_8_T0	COMPOUND	5	5	calcium
NCT0000042910	NCT00000429_10_T0	PHENOTYPE	19	19	persistence
NCT0000042910	NCT00000429_10_T1	BIOLOGICAL_PROCESS	24	25	bone mineralization
NCT0000042911	NCT00000429_11_T0	PHENOTYPE	12	13	radiation exposure
NCT0000042913	NCT00000429_13_T0	COMPOUND	20	20	calcium
NCT0000042913	NCT00000429_13_T1	COMPOUND	21	21	carbonate
NCT0000042913	NCT00000429_13_T2	COMPOUND	29	30	vitamin D
NCT0000042914	NCT00000429_14_T0	COMPOUND	32	33	vitamin D
NCT0000042915	NCT00000429_15_T0	PHENOTYPE	14	14	Center
NCT0000042916	NCT00000429_16_T0	ORGAN	35	35	spine
NCT0000042916	NCT00000429_16_T1	COMPOUND	28	28	DXA
NCT0000042916	NCT00000429_16_T2	COMPOUND	22	22	BMI
NCT0000042918	NCT00000429_18_T0	GENE	9	9	VDR
NCT0000042918	NCT00000429_18_T1	GENE	6	8	vitamin D receptor
NCT0000042919	NCT00000429_19_T0	PHENOTYPE	15	15	hypercalciuria
NCT0000042924	NCT00000429_24_T0	COMPOUND	3	3	DXA
NCT0000042927	NCT00000429_27_T0	BIOLOGICAL_PROCESS	30	31	bone mineralization
NCT000004300	NCT00000430_0_T0	PHENOTYPE	7	7	Osteoporosis
NCT000004302	NCT00000430_2_T0	COMPOUND	15	15	alendronate
NCT000004302	NCT00000430_2_T1	GENE	13	13	HRT
NCT000004302	NCT00000430_2_T2	PHENOTYPE	22	22	osteoporosis
NCT000004302	NCT00000430_2_T3	GENE	9	9	hormone
NCT000004303	NCT00000430_3_T0	PHENOTYPE	19	19	osteoporosis
NCT000004304	NCT00000430_4_T0	GENE	13	13	3.5
NCT000004304	NCT00000430_4_T1	COMPOUND	9	9	alendronate
NCT000004304	NCT00000430_4_T2	COMPOUND	33	33	alendronate
NCT000004304	NCT00000430_4_T3	GENE	7	7	HRT
NCT000004304	NCT00000430_4_T4	GENE	31	31	HRT
NCT000004305	NCT00000430_5_T0	COMPOUND	9	9	calcium
NCT000004305	NCT00000430_5_T1	COMPOUND	11	12	vitamin D
NCT000004307	NCT00000430_7_T0	GENE	2	2	has
NCT000004307	NCT00000430_7_T1	PHENOTYPE	12	12	fractures
NCT000004309	NCT00000430_9_T0	PHENOTYPE	11	11	osteoporosis
NCT0000043010	NCT00000430_10_T0	GENE	4	4	ALN
NCT0000043010	NCT00000430_10_T1	GENE	6	6	HRT
NCT0000043011	NCT00000430_11_T0	GENE	16	16	CEE
NCT0000043011	NCT00000430_11_T1	GENE	24	24	ALN
NCT0000043011	NCT00000430_11_T2	GENE	10	10	HRT
NCT0000043013	NCT00000430_13_T0	GENE	15	15	reduced
NCT0000043013	NCT00000430_13_T1	GENE	3	3	HRT
NCT0000043013	NCT00000430_13_T2	PHENOTYPE	13	13	tolerance
NCT0000043013	NCT00000430_13_T3	PHENOTYPE	18	19	breast cancer
NCT0000043017	NCT00000430_17_T0	GENE	9	9	ALN
NCT0000043017	NCT00000430_17_T1	GENE	17	17	ALN
NCT0000043017	NCT00000430_17_T2	GENE	6	6	HRT
NCT0000043017	NCT00000430_17_T3	GENE	15	15	HRT
NCT0000043017	NCT00000430_17_T4	GENE	3	4	Group 1
NCT0000043018	NCT00000430_18_T0	COMPOUND	3	3	calcium
NCT0000043018	NCT00000430_18_T1	COMPOUND	5	6	vitamin D
NCT0000043020	NCT00000430_20_T0	PHENOTYPE	0	0	Secondary
NCT0000043020	NCT00000430_20_T1	ORGAN	11	11	forearm
NCT0000043023	NCT00000430_23_T0	PHENOTYPE	10	11	anabolic effect
NCT0000043023	NCT00000430_23_T1	BIOLOGICAL_PROCESS	37	38	bone remodeling
NCT0000043024	NCT00000430_24_T0	GENE	7	7	ALN
NCT0000043024	NCT00000430_24_T1	GENE	5	5	HRT
NCT0000043024	NCT00000430_24_T2	GENE	2	2	has
NCT0000043028	NCT00000430_28_T0	GENE	3	3	1.0
NCT000004310	NCT00000431_0_T0	PHENOTYPE	6	6	Chronic
NCT000004310	NCT00000431_0_T1	PHENOTYPE	8	8	Wounds
NCT000004312	NCT00000431_2_T0	PHENOTYPE	12	12	wounds
NCT000004313	NCT00000431_3_T0	PHENOTYPE	24	24	wounds
NCT000004313	NCT00000431_3_T1	GENE	16	16	reduced
NCT000004313	NCT00000431_3_T2	PHENOTYPE	23	23	chronic
NCT000004314	NCT00000431_4_T0	PHENOTYPE	15	15	chronic
NCT000004315	NCT00000431_5_T0	PHENOTYPE	14	14	chronic
NCT000004315	NCT00000431_5_T1	BIOLOGICAL_PROCESS	10	11	wound healing
NCT000004319	NCT00000431_9_T0	GENE	12	12	had
NCT000004319	NCT00000431_9_T1	PHENOTYPE	25	25	chronic
NCT0000043110	NCT00000431_10_T0	PHENOTYPE	15	15	chronic
NCT0000043111	NCT00000431_11_T0	PHENOTYPE	12	12	wounds
NCT0000043111	NCT00000431_11_T1	PHENOTYPE	11	11	chronic
NCT0000043114	NCT00000431_14_T0	PHENOTYPE	31	31	toxicity
NCT0000043114	NCT00000431_14_T1	GENE	24	24	PDGF-B
NCT0000043114	NCT00000431_14_T2	GENE	15	15	MTD
NCT0000043115	NCT00000431_15_T0	PHENOTYPE	7	7	acute
NCT0000043119	NCT00000431_19_T0	GENE	1	1	MTD
NCT0000043119	NCT00000431_19_T1	PHENOTYPE	19	20	adverse reaction
NCT0000043120	NCT00000431_20_T0	PHENOTYPE	8	9	adverse reactions
NCT0000043121	NCT00000431_21_T0	PHENOTYPE	0	0	Toxicity
NCT0000043121	NCT00000431_21_T1	PHENOTYPE	11	11	Toxicity
NCT0000043123	NCT00000431_23_T0	GENE	11	11	MTD
NCT000004322	NCT00000432_2_T0	PHENOTYPE	12	13	Lyme disease
NCT000004324	NCT00000432_4_T0	PHENOTYPE	8	9	Lyme disease
NCT000004326	NCT00000432_6_T0	PHENOTYPE	11	11	self-efficacy
NCT0000043210	NCT00000432_10_T0	PHENOTYPE	9	10	Lyme disease
NCT0000043213	NCT00000432_13_T0	PHENOTYPE	9	9	severity
NCT0000043213	NCT00000432_13_T1	PHENOTYPE	21	21	avoidance
NCT0000043213	NCT00000432_13_T2	PHENOTYPE	14	15	Lyme disease
NCT0000043216	NCT00000432_16_T0	PHENOTYPE	17	17	accidents
NCT0000043218	NCT00000432_18_T0	PHENOTYPE	20	20	self-efficacy
NCT0000043222	NCT00000432_22_T0	PHENOTYPE	4	5	Lyme disease
NCT0000043223	NCT00000432_23_T0	PHENOTYPE	0	0	Intermediate
NCT0000043223	NCT00000432_23_T1	PHENOTYPE	5	5	self-efficacy
NCT000004330	NCT00000433_0_T0	PHENOTYPE	0	0	Blocking
NCT000004330	NCT00000433_0_T1	PHENOTYPE	5	6	Ankylosing Spondylitis
NCT000004330	NCT00000433_0_T2	MOLECULAR_FUNCTION	1	3	Tumor Necrosis Factor
NCT000004333	NCT00000433_3_T0	GENE	8	8	TNF-alpha
NCT000004333	NCT00000433_3_T1	PHENOTYPE	1	1	blocks
NCT000004333	NCT00000433_3_T2	GENE	16	16	AS
NCT000004333	NCT00000433_3_T3	PHENOTYPE	17	18	rheumatoid arthritis
NCT000004333	NCT00000433_3_T4	GENE	5	7	tumor necrosis factor-alpha
NCT000004335	NCT00000433_5_T0	PHENOTYPE	7	7	stiffness
NCT000004338	NCT00000433_8_T0	GENE	12	12	receptor
NCT000004338	NCT00000433_8_T1	GENE	11	11	p75
NCT000004339	NCT00000433_9_T0	GENE	4	4	fused
NCT000004339	NCT00000433_9_T1	GENE	11	11	IgG1
NCT0000043311	NCT00000433_11_T0	GENE	12	12	TNF-alpha
NCT0000043311	NCT00000433_11_T1	PHENOTYPE	24	24	seronegative
NCT0000043311	NCT00000433_11_T2	GENE	21	21	AS
NCT0000043311	NCT00000433_11_T3	PHENOTYPE	25	25	spondyloarthropathies
NCT0000043311	NCT00000433_11_T4	GENE	9	11	tumor necrosis factor-alpha
NCT0000043312	NCT00000433_12_T0	GENE	19	19	AS
NCT000004341	NCT00000434_1_T0	PHENOTYPE	16	16	osteoarthritis
NCT000004343	NCT00000434_3_T0	PHENOTYPE	12	12	osteoarthritis
NCT0000043414	NCT00000434_14_T0	ORGAN	8	9	lower extremity
NCT0000043415	NCT00000434_15_T0	PHENOTYPE	6	6	arthritis
NCT0000043415	NCT00000434_15_T1	PHENOTYPE	9	9	perceived
NCT0000043415	NCT00000434_15_T2	PHENOTYPE	7	7	self-efficacy
NCT000004353	NCT00000435_3_T0	CELL	5	5	cells
NCT000004353	NCT00000435_3_T1	ORGAN	8	8	joints
NCT000004353	NCT00000435_3_T2	GENE	20	20	dnaJ
NCT000004353	NCT00000435_3_T3	GENE	16	16	RA
NCT000004354	NCT00000435_4_T0	CELL	2	2	cells
NCT000004354	NCT00000435_4_T1	PHENOTYPE	15	15	inflammation
NCT000004354	NCT00000435_4_T2	ORGAN	12	12	joints
NCT000004354	NCT00000435_4_T3	GENE	8	8	dnaJ
NCT000004355	NCT00000435_5_T0	GENE	0	0	dnaJ
NCT000004355	NCT00000435_5_T1	GENE	3	3	RA
NCT000004355	NCT00000435_5_T2	GENE	17	17	RA
NCT000004355	NCT00000435_5_T3	BIOLOGICAL_PROCESS	14	15	immune response
NCT000004355	NCT00000435_5_T4	ORGAN	7	8	immune system
NCT000004357	NCT00000435_7_T0	GENE	8	8	dnaJ
NCT0000043611	NCT00000436_11_T0	PHENOTYPE	0	0	Secondary
NCT0000043611	NCT00000436_11_T1	PHENOTYPE	19	19	falls
NCT0000043611	NCT00000436_11_T2	PHENOTYPE	18	18	recurrent
NCT000004370	NCT00000437_0_T0	PHENOTYPE	3	3	Alcoholism
NCT000004370	NCT00000437_0_T1	PHENOTYPE	0	1	Tobacco Dependence
NCT000004374	NCT00000437_4_T0	PHENOTYPE	22	22	symptoms
NCT000004374	NCT00000437_4_T1	BIOLOGICAL_PROCESS	15	15	drinking
NCT000004374	NCT00000437_4_T2	PHENOTYPE	21	21	dependence
NCT000004374	NCT00000437_4_T3	PHENOTYPE	18	18	persistence
NCT000004381	NCT00000438_1_T0	PHENOTYPE	15	16	withdrawal symptoms
NCT000004381	NCT00000438_1_T1	PHENOTYPE	14	15	alcohol withdrawal
NCT000004382	NCT00000438_2_T0	COMPOUND	10	10	naltrexone
NCT000004382	NCT00000438_2_T1	COMPOUND	12	12	naltrexone
NCT000004383	NCT00000438_3_T0	BIOLOGICAL_PROCESS	13	13	drinking
NCT000004392	NCT00000439_2_T0	COMPOUND	1	1	sodium
NCT000004392	NCT00000439_2_T1	COMPOUND	2	2	valproate
NCT000004392	NCT00000439_2_T2	ORGAN	0	0	Serum
NCT000004394	NCT00000439_4_T0	COMPOUND	10	10	lithium
NCT000004394	NCT00000439_4_T1	COMPOUND	22	22	sodium
NCT000004394	NCT00000439_4_T2	COMPOUND	23	23	valproate
NCT000004394	NCT00000439_4_T3	COMPOUND	11	11	carbonate
NCT000004421	NCT00000442_1_T0	COMPOUND	4	4	naltrexone
NCT000004431	NCT00000443_1_T0	PHENOTYPE	10	10	alcoholism
NCT000004431	NCT00000443_1_T1	PHENOTYPE	8	9	late onset
NCT000004441	NCT00000444_1_T0	PHENOTYPE	28	29	alcohol dependence
NCT000004442	NCT00000444_2_T0	PHENOTYPE	19	20	alcohol dependence
NCT000004452	NCT00000445_2_T0	COMPOUND	12	12	naltrexone
NCT000004452	NCT00000445_2_T1	PHENOTYPE	17	18	alcohol dependence
NCT000004453	NCT00000445_3_T0	COMPOUND	10	10	naltrexone
NCT000004462	NCT00000446_2_T0	COMPOUND	13	13	sertraline
NCT000004471	NCT00000447_1_T0	COMPOUND	9	9	nicotine
NCT000004471	NCT00000447_1_T1	COMPOUND	13	13	naltrexone
NCT000004471	NCT00000447_1_T2	BIOLOGICAL_PROCESS	28	28	drinking
NCT000004481	NCT00000448_1_T0	COMPOUND	17	17	naltrexone
NCT000004481	NCT00000448_1_T1	PHENOTYPE	6	7	eating disorders
NCT000004485	NCT00000448_5_T0	COMPOUND	8	8	naltrexone
NCT000004485	NCT00000448_5_T1	PHENOTYPE	28	28	pathology
NCT000004485	NCT00000448_5_T2	BIOLOGICAL_PROCESS	27	27	eating
NCT000004486	NCT00000448_6_T0	COMPOUND	21	21	naltrexone
NCT000004486	NCT00000448_6_T1	BIOLOGICAL_PROCESS	14	14	eating
NCT000004486	NCT00000448_6_T2	PHENOTYPE	9	10	alcohol dependence
NCT000004491	NCT00000449_1_T0	COMPOUND	21	21	naltrexone
NCT000004510	NCT00000451_0_T0	PHENOTYPE	3	4	Alcohol Dependence
NCT000004512	NCT00000451_2_T0	COMPOUND	9	9	naltrexone
NCT000004512	NCT00000451_2_T1	COMPOUND	18	18	naltrexone
NCT000004512	NCT00000451_2_T2	COMPOUND	11	11	sertraline
NCT000004541	NCT00000454_1_T0	GENE	21	21	cue
NCT000004541	NCT00000454_1_T1	BIOLOGICAL_PROCESS	28	30	response to alcohol
NCT000004542	NCT00000454_2_T0	PHENOTYPE	7	8	Substance Abuse
NCT000004544	NCT00000454_4_T0	COMPOUND	19	19	nicotine
NCT000004544	NCT00000454_4_T1	COMPOUND	22	22	nicotine
NCT000004552	NCT00000455_2_T0	COMPOUND	1	1	naltrexone
NCT000004552	NCT00000455_2_T1	GENE	3	3	has
NCT000004552	NCT00000455_2_T2	PHENOTYPE	10	11	alcohol dependence
NCT000004553	NCT00000455_3_T0	COMPOUND	7	7	naltrexone
NCT000004561	NCT00000456_1_T0	COMPOUND	23	23	naltrexone
NCT000004562	NCT00000456_2_T0	BIOLOGICAL_PROCESS	27	27	drinking
NCT000004562	NCT00000456_2_T1	PHENOTYPE	8	8	relapse
NCT000004562	NCT00000456_2_T2	PHENOTYPE	31	31	self-confidence
NCT000004571	NCT00000457_1_T0	COMPOUND	19	19	nicotine
NCT000004576	NCT00000457_6_T0	COMPOUND	2	2	nicotine
NCT000004576	NCT00000457_6_T1	COMPOUND	9	9	nicotine
NCT000004579	NCT00000457_9_T0	PHENOTYPE	14	14	relapse
NCT0000045710	NCT00000457_10_T0	COMPOUND	11	11	bupropion
NCT0000045711	NCT00000457_11_T0	PHENOTYPE	5	5	relapse
NCT000004592	NCT00000459_2_T0	PHENOTYPE	12	12	atherosclerosis
NCT000004592	NCT00000459_2_T1	GENE	8	8	had
NCT000004592	NCT00000459_2_T2	PHENOTYPE	14	15	fatty streaks
NCT000004593	NCT00000459_3_T0	PHENOTYPE	1	2	cholesterol levels
NCT000004595	NCT00000459_5_T0	GENE	5	5	had
NCT000004596	NCT00000459_6_T0	GENE	25	25	2.2
NCT000004596	NCT00000459_6_T1	GENE	2	2	2.3
NCT000004596	NCT00000459_6_T2	GENE	35	35	had
NCT000004596	NCT00000459_6_T3	PHENOTYPE	57	58	heart disease
NCT000004596	NCT00000459_6_T4	PHENOTYPE	7	9	coronary heart disease
NCT000004596	NCT00000459_6_T5	PHENOTYPE	42	44	coronary heart disease
NCT000004597	NCT00000459_7_T0	GENE	14	14	had
NCT000004597	NCT00000459_7_T1	PHENOTYPE	9	11	coronary heart disease
NCT000004598	NCT00000459_8_T0	PHENOTYPE	8	9	cholesterol levels
NCT000004599	NCT00000459_9_T0	GENE	3	3	had
NCT000004599	NCT00000459_9_T1	GENE	19	19	had
NCT000004599	NCT00000459_9_T2	PHENOTYPE	11	12	cholesterol levels
NCT000004599	NCT00000459_9_T3	PHENOTYPE	9	11	lower blood cholesterol
NCT0000045923	NCT00000459_23_T0	ORGAN	8	8	serum
NCT0000045923	NCT00000459_23_T1	PHENOTYPE	9	10	ferritin levels
NCT0000045925	NCT00000459_25_T0	PHENOTYPE	0	0	Recruitment
NCT0000045926	NCT00000459_26_T0	GENE	4	4	extended
NCT000004608	NCT00000460_8_T0	PHENOTYPE	0	0	Secondary
NCT000004608	NCT00000460_8_T1	PHENOTYPE	23	23	progression
NCT000004608	NCT00000460_8_T2	ORGAN	12	12	heart
NCT000004608	NCT00000460_8_T3	PHENOTYPE	15	16	glucose tolerance
NCT000004608	NCT00000460_8_T4	PHENOTYPE	17	19	quality of life
NCT000004609	NCT00000460_9_T0	PHENOTYPE	14	15	myocardial infarction
NCT000004609	NCT00000460_9_T1	PHENOTYPE	19	21	ventricular ejection fraction
NCT0000046016	NCT00000460_16_T0	PHENOTYPE	0	0	Recruitment
NCT000004611	NCT00000461_1_T0	PHENOTYPE	10	11	coronary atherosclerosis
NCT000004612	NCT00000461_2_T0	PHENOTYPE	19	20	cholesterol levels
NCT000004612	NCT00000461_2_T1	PHENOTYPE	14	16	coronary heart disease
NCT000004615	NCT00000461_5_T0	PHENOTYPE	6	6	severity
NCT000004615	NCT00000461_5_T1	GENE	18	18	lipoprotein
NCT000004615	NCT00000461_5_T2	ORGAN	17	17	plasma
NCT000004615	NCT00000461_5_T3	PHENOTYPE	8	9	coronary atherosclerosis
NCT000004616	NCT00000461_6_T0	PHENOTYPE	10	10	concentrations
NCT000004616	NCT00000461_6_T1	GENE	14	14	lipoprotein
NCT000004616	NCT00000461_6_T2	GENE	3	3	had
NCT000004616	NCT00000461_6_T3	ORGAN	9	9	plasma
NCT000004616	NCT00000461_6_T4	PHENOTYPE	21	23	coronary heart disease
NCT000004617	NCT00000461_7_T0	GENE	3	3	had
NCT000004617	NCT00000461_7_T1	PHENOTYPE	17	19	coronary heart disease
NCT000004619	NCT00000461_9_T0	GENE	17	17	HDL
NCT000004619	NCT00000461_9_T1	PHENOTYPE	9	10	coronary disease
NCT0000046110	NCT00000461_10_T0	COMPOUND	18	18	cholestyramine
NCT0000046110	NCT00000461_10_T1	GENE	47	47	2.0
NCT0000046110	NCT00000461_10_T2	COMPOUND	15	15	pravastatin
NCT0000046110	NCT00000461_10_T3	COMPOUND	20	20	gemfibrozil
NCT0000046110	NCT00000461_10_T4	COMPOUND	16	17	nicotinic acid
NCT0000046111	NCT00000461_11_T0	PHENOTYPE	1	1	concentrations
NCT0000046114	NCT00000461_14_T0	COMPOUND	17	18	eicosapentaenoic acid
NCT0000046114	NCT00000461_14_T1	COMPOUND	22	23	docosahexaenoic acid
NCT0000046115	NCT00000461_15_T0	GENE	17	17	HDL
NCT0000046115	NCT00000461_15_T1	PHENOTYPE	9	10	coronary disease
NCT0000046116	NCT00000461_16_T0	ORGAN	10	11	coronary artery
NCT0000046121	NCT00000461_21_T0	GENE	11	11	12
NCT0000046122	NCT00000461_22_T0	COMPOUND	30	30	cholestyramine
NCT0000046122	NCT00000461_22_T1	PHENOTYPE	3	4	cholesterol level
NCT0000046122	NCT00000461_22_T2	COMPOUND	32	33	nicotinic acid
NCT0000046124	NCT00000461_24_T0	GENE	52	52	2.0
NCT0000046124	NCT00000461_24_T1	GENE	42	42	lipoprotein
NCT0000046124	NCT00000461_24_T2	GENE	47	47	lipoprotein
NCT0000046124	NCT00000461_24_T3	COMPOUND	20	20	pravastatin
NCT0000046124	NCT00000461_24_T4	COMPOUND	25	25	gemfibrozil
NCT0000046124	NCT00000461_24_T5	COMPOUND	23	23	cholestyramine
NCT0000046124	NCT00000461_24_T6	PHENOTYPE	29	30	cholesterol levels
NCT0000046124	NCT00000461_24_T7	COMPOUND	21	22	nicotinic acid
NCT0000046125	NCT00000461_25_T0	GENE	4	4	lipoprotein
NCT0000046125	NCT00000461_25_T1	ORGAN	3	3	serum
NCT0000046125	NCT00000461_25_T2	PHENOTYPE	12	13	adverse effects
NCT000004622	NCT00000462_2_T0	PHENOTYPE	19	20	myocardial ischemia
NCT000004623	NCT00000462_3_T0	PHENOTYPE	15	17	coronary artery disease
NCT000004629	NCT00000462_9_T0	GENE	14	14	bypass
NCT0000046212	NCT00000462_12_T0	GENE	8	8	had
NCT0000046215	NCT00000462_15_T0	PHENOTYPE	9	9	strategies
NCT0000046215	NCT00000462_15_T1	ORGAN	34	34	heart
NCT0000046215	NCT00000462_15_T2	PHENOTYPE	19	19	circulation
NCT0000046215	NCT00000462_15_T3	PHENOTYPE	6	6	severely
NCT0000046215	NCT00000462_15_T4	PHENOTYPE	12	13	disease progression
NCT0000046215	NCT00000462_15_T5	ORGAN	28	30	internal mammary artery
NCT0000046216	NCT00000462_16_T0	PHENOTYPE	6	7	coronary disease
NCT0000046217	NCT00000462_17_T0	GENE	8	8	balloon
NCT0000046222	NCT00000462_22_T0	PHENOTYPE	11	13	coronary artery disease
NCT0000046223	NCT00000462_23_T0	PHENOTYPE	4	4	weaknesses
NCT0000046223	NCT00000462_23_T1	GENE	1	1	has
NCT0000046224	NCT00000462_24_T0	ORGAN	15	15	veins
NCT0000046224	NCT00000462_24_T1	ORGAN	17	17	mediastinum
NCT0000046229	NCT00000462_29_T0	PHENOTYPE	19	19	symptoms
NCT0000046230	NCT00000462_30_T0	PHENOTYPE	11	12	coronary disease
NCT0000046231	NCT00000462_31_T0	ORGAN	9	9	Graft
NCT0000046231	NCT00000462_31_T1	ORGAN	6	7	Coronary Artery
NCT0000046232	NCT00000462_32_T0	PHENOTYPE	15	17	coronary artery disease
NCT0000046240	NCT00000462_40_T0	GENE	3	3	sub
NCT0000046246	NCT00000462_46_T0	GENE	2	2	has
NCT0000046246	NCT00000462_46_T1	GENE	4	4	extended
NCT0000046250	NCT00000462_50_T0	PHENOTYPE	0	0	Angina
NCT0000046253	NCT00000462_53_T0	PHENOTYPE	2	2	centers
NCT0000046255	NCT00000462_55_T0	PHENOTYPE	8	10	Quality of Life
NCT0000046255	NCT00000462_55_T1	PHENOTYPE	30	32	quality of life
NCT000004630	NCT00000463_0_T0	ORGAN	4	4	Graft
NCT000004630	NCT00000463_0_T1	ORGAN	1	2	Coronary Artery
NCT000004634	NCT00000463_4_T0	ORGAN	12	12	graft
NCT000004634	NCT00000463_4_T1	PHENOTYPE	13	13	occlusions
NCT000004634	NCT00000463_4_T2	COMPOUND	4	4	aspirin
NCT000004639	NCT00000463_9_T0	ORGAN	7	7	grafts
NCT000004639	NCT00000463_9_T1	GENE	8	8	has
NCT000004639	NCT00000463_9_T2	PHENOTYPE	3	4	cholesterol deposition
NCT0000046311	NCT00000463_11_T0	PHENOTYPE	19	19	atherosclerosis
NCT0000046311	NCT00000463_11_T1	PHENOTYPE	10	10	distal
NCT0000046311	NCT00000463_11_T2	PHENOTYPE	18	18	progressive
NCT0000046311	NCT00000463_11_T3	PHENOTYPE	12	12	proximal
NCT0000046312	NCT00000463_12_T0	PHENOTYPE	16	16	acute
NCT0000046312	NCT00000463_12_T1	ORGAN	4	4	grafts
NCT0000046312	NCT00000463_12_T2	PHENOTYPE	12	12	thrombus
NCT0000046317	NCT00000463_17_T0	PHENOTYPE	5	5	obstruction
NCT0000046317	NCT00000463_17_T1	ORGAN	4	4	graft
NCT0000046317	NCT00000463_17_T2	PHENOTYPE	7	7	progression
NCT0000046317	NCT00000463_17_T3	PHENOTYPE	10	11	coronary atherosclerosis
NCT0000046319	NCT00000463_19_T0	GENE	1	1	had
NCT0000046320	NCT00000463_20_T0	PHENOTYPE	9	9	atherosclerosis
NCT0000046320	NCT00000463_20_T1	ORGAN	4	4	graft
NCT0000046320	NCT00000463_20_T2	PHENOTYPE	5	5	occlusion
NCT0000046320	NCT00000463_20_T3	PHENOTYPE	7	7	progression
NCT0000046321	NCT00000463_21_T0	COMPOUND	6	6	dipyridamole
NCT0000046321	NCT00000463_21_T1	ORGAN	16	16	graft
NCT0000046321	NCT00000463_21_T2	COMPOUND	4	4	aspirin
NCT0000046323	NCT00000463_23_T0	GENE	3	3	LDL
NCT0000046323	NCT00000463_23_T1	COMPOUND	13	13	warfarin
NCT0000046330	NCT00000463_30_T0	COMPOUND	5	5	warfarin
NCT0000046331	NCT00000463_31_T0	COMPOUND	7	7	warfarin
NCT0000046332	NCT00000463_32_T0	ORGAN	4	4	serum
NCT0000046334	NCT00000463_34_T0	ORGAN	15	15	graft
NCT0000046338	NCT00000463_38_T0	PHENOTYPE	1	1	recruitment
NCT0000046338	NCT00000463_38_T1	GENE	2	2	has
NCT0000046342	NCT00000463_42_T0	PHENOTYPE	1	3	quality of life
NCT000004642	NCT00000464_2_T0	PHENOTYPE	16	16	sequelae
NCT000004642	NCT00000464_2_T1	PHENOTYPE	7	9	sudden cardiac death
NCT000004643	NCT00000464_3_T0	PHENOTYPE	26	26	infarction
NCT000004643	NCT00000464_3_T1	PHENOTYPE	0	0	Recurrent
NCT000004643	NCT00000464_3_T2	GENE	32	32	ventricular
NCT000004643	NCT00000464_3_T3	PHENOTYPE	15	16	ventricular fibrillation
NCT000004643	NCT00000464_3_T4	PHENOTYPE	38	39	ventricular arrhythmias
NCT000004643	NCT00000464_3_T5	PHENOTYPE	53	54	ventricular arrhythmias
NCT000004643	NCT00000464_3_T6	PHENOTYPE	45	47	coronary artery disease
NCT000004643	NCT00000464_3_T7	PHENOTYPE	1	3	sudden cardiac death
NCT000004644	NCT00000464_4_T0	PHENOTYPE	9	10	ventricular fibrillation
NCT000004645	NCT00000464_5_T0	PHENOTYPE	5	6	myocardial ischemia
NCT000004647	NCT00000464_7_T0	GENE	13	13	has
NCT000004647	NCT00000464_7_T1	GENE	7	7	ventricular
NCT000004648	NCT00000464_8_T0	PHENOTYPE	11	11	toxicity
NCT000004648	NCT00000464_8_T1	PHENOTYPE	7	7	pharmacokinetics
NCT000004648	NCT00000464_8_T2	GENE	12	12	has
NCT000004649	NCT00000464_9_T0	PHENOTYPE	12	13	ventricular fibrillation
NCT0000046410	NCT00000464_10_T0	COMPOUND	4	4	amiodarone
NCT0000046410	NCT00000464_10_T1	GENE	17	17	had
NCT0000046410	NCT00000464_10_T2	PHENOTYPE	11	12	ventricular fibrillation
NCT0000046411	NCT00000464_11_T0	GENE	14	14	ventricular
NCT0000046411	NCT00000464_11_T1	PHENOTYPE	10	12	coronary artery disease
NCT0000046412	NCT00000464_12_T0	PHENOTYPE	7	9	ventricular ejection fraction
NCT0000046413	NCT00000464_13_T0	COMPOUND	24	24	tocainide
NCT0000046413	NCT00000464_13_T1	COMPOUND	22	22	quinidine
NCT0000046413	NCT00000464_13_T2	COMPOUND	27	27	flecainide
NCT0000046413	NCT00000464_13_T3	COMPOUND	21	21	procainamide
NCT0000046413	NCT00000464_13_T4	COMPOUND	23	23	disopyramide
NCT0000046413	NCT00000464_13_T5	COMPOUND	29	29	moricizine
NCT0000046413	NCT00000464_13_T6	COMPOUND	8	8	amiodarone
NCT0000046413	NCT00000464_13_T7	COMPOUND	28	28	propafenone
NCT0000046413	NCT00000464_13_T8	COMPOUND	26	26	encainide
NCT0000046413	NCT00000464_13_T9	COMPOUND	25	25	mexiletine
NCT0000046417	NCT00000464_17_T0	PHENOTYPE	9	10	ventricular fibrillation
NCT0000046417	NCT00000464_17_T1	PHENOTYPE	5	6	cardiac death
NCT0000046417	NCT00000464_17_T2	PHENOTYPE	13	14	cardiac death
NCT0000046418	NCT00000464_18_T0	COMPOUND	5	5	amiodarone
NCT0000046418	NCT00000464_18_T1	PHENOTYPE	6	7	pulmonary toxicity
NCT000004650	NCT00000465_0_T0	GENE	5	5	EAST
NCT000004653	NCT00000465_3_T0	GENE	2	2	has
NCT000004654	NCT00000465_4_T0	PHENOTYPE	26	28	coronary artery disease
NCT000004655	NCT00000465_5_T0	PHENOTYPE	6	6	CASS
NCT000004655	NCT00000465_5_T1	PHENOTYPE	19	19	tolerance
NCT000004655	NCT00000465_5_T2	PHENOTYPE	0	2	Quality of life
NCT000004657	NCT00000465_7_T0	PHENOTYPE	4	4	CASS
NCT000004657	NCT00000465_7_T1	GENE	7	7	has
NCT000004657	NCT00000465_7_T2	GENE	25	25	ventricular
NCT000004658	NCT00000465_8_T0	PHENOTYPE	11	11	separation
NCT000004658	NCT00000465_8_T1	GENE	28	28	has
NCT000004659	NCT00000465_9_T0	ORGAN	4	4	Heart
NCT000004659	NCT00000465_9_T1	ORGAN	12	12	grafts
NCT0000046510	NCT00000465_10_T0	ORGAN	4	4	grafts
NCT0000046512	NCT00000465_12_T0	ORGAN	16	16	graft
NCT0000046513	NCT00000465_13_T0	PHENOTYPE	5	7	coronary artery disease
NCT0000046514	NCT00000465_14_T0	PHENOTYPE	24	24	ischemia
NCT0000046515	NCT00000465_15_T0	PHENOTYPE	1	1	centers
NCT0000046516	NCT00000465_16_T0	GENE	6	6	has
NCT0000046517	NCT00000465_17_T0	PHENOTYPE	28	28	stenoses
NCT0000046517	NCT00000465_17_T1	GENE	27	27	had
NCT0000046524	NCT00000465_24_T0	COMPOUND	3	3	thallium
NCT0000046527	NCT00000465_27_T0	COMPOUND	0	0	Thallium
NCT0000046528	NCT00000465_28_T0	COMPOUND	24	24	thallium
NCT0000046528	NCT00000465_28_T1	PHENOTYPE	9	10	myocardial infarction
NCT0000046529	NCT00000465_29_T0	PHENOTYPE	0	0	Secondary
NCT0000046529	NCT00000465_29_T1	GENE	12	12	ventricular
NCT0000046529	NCT00000465_29_T2	PHENOTYPE	23	25	quality of life
NCT0000046531	NCT00000465_31_T0	PHENOTYPE	0	0	Recruitment
NCT000004662	NCT00000466_2_T0	ORGAN	9	9	endometrium
NCT000004662	NCT00000466_2_T1	GENE	1	1	extended
NCT000004664	NCT00000466_4_T0	PHENOTYPE	14	16	coronary heart disease
NCT000004665	NCT00000466_5_T0	PHENOTYPE	27	29	coronary heart disease
NCT000004666	NCT00000466_6_T0	ORGAN	0	0	Heart
NCT000004667	NCT00000466_7_T0	PHENOTYPE	16	17	heart disease
NCT0000046610	NCT00000466_10_T0	PHENOTYPE	26	26	atherosclerosis
NCT0000046610	NCT00000466_10_T1	GENE	15	15	pointed
NCT0000046610	NCT00000466_10_T2	PHENOTYPE	3	3	focused
NCT0000046611	NCT00000466_11_T0	COMPOUND	8	8	estrogen
NCT0000046612	NCT00000466_12_T0	GENE	17	17	lipoprotein
NCT0000046612	NCT00000466_12_T1	GENE	24	24	lipoprotein
NCT0000046612	NCT00000466_12_T2	ORGAN	14	14	plasma
NCT0000046612	NCT00000466_12_T3	ORGAN	21	21	plasma
NCT0000046613	NCT00000466_13_T0	GENE	8	8	lipoprotein
NCT0000046614	NCT00000466_14_T0	GENE	7	7	lipoprotein
NCT0000046614	NCT00000466_14_T1	ORGAN	20	20	plasma
NCT0000046614	NCT00000466_14_T2	PHENOTYPE	10	12	coronary heart disease
NCT0000046614	NCT00000466_14_T3	PHENOTYPE	28	30	coronary heart disease
NCT0000046615	NCT00000466_15_T0	PHENOTYPE	22	24	coronary heart disease
NCT0000046616	NCT00000466_16_T0	PHENOTYPE	12	12	profound
NCT0000046616	NCT00000466_16_T1	COMPOUND	17	17	estrogen
NCT0000046617	NCT00000466_17_T0	COMPOUND	8	8	estrogen
NCT0000046619	NCT00000466_19_T0	COMPOUND	16	16	estrogen
NCT0000046619	NCT00000466_19_T1	GENE	11	11	lipoprotein
NCT0000046620	NCT00000466_20_T0	COMPOUND	12	12	estrogen
NCT0000046620	NCT00000466_20_T1	PHENOTYPE	22	23	cardiovascular disease
NCT0000046620	NCT00000466_20_T2	PHENOTYPE	15	16	cardiovascular morbidity
NCT0000046621	NCT00000466_21_T0	COMPOUND	25	25	estrogen
NCT0000046621	NCT00000466_21_T1	PHENOTYPE	28	29	cardiovascular disease
NCT0000046622	NCT00000466_22_T0	COMPOUND	21	21	estrogen
NCT0000046622	NCT00000466_22_T1	PHENOTYPE	30	30	osteoporosis
NCT0000046622	NCT00000466_22_T2	PHENOTYPE	27	28	cardiovascular disease
NCT0000046624	NCT00000466_24_T0	PHENOTYPE	6	6	centers
NCT0000046626	NCT00000466_26_T0	GENE	31	31	fibrinogen
NCT0000046626	NCT00000466_26_T1	GENE	22	22	lipoprotein
NCT0000046626	NCT00000466_26_T2	PHENOTYPE	28	29	serum insulin
NCT0000046626	NCT00000466_26_T3	PHENOTYPE	16	17	cardiovascular disease
NCT0000046627	NCT00000466_27_T0	PHENOTYPE	0	0	Recruitment
NCT0000046628	NCT00000466_28_T0	ORGAN	7	7	heart
NCT0000046629	NCT00000466_29_T0	COMPOUND	11	11	glucose
NCT0000046629	NCT00000466_29_T1	GENE	9	9	insulin
NCT0000046629	NCT00000466_29_T2	GENE	14	14	fibrinogen
NCT0000046629	NCT00000466_29_T3	GENE	7	7	lipoprotein
NCT0000046629	NCT00000466_29_T4	COMPOUND	27	27	aldosterone
NCT0000046629	NCT00000466_29_T5	BIOLOGICAL_PROCESS	20	20	hemostasis
NCT0000046629	NCT00000466_29_T6	COMPOUND	30	30	heparin
NCT0000046629	NCT00000466_29_T7	ORGAN	24	24	plasma
NCT0000046629	NCT00000466_29_T8	MOLECULAR_FUNCTION	25	26	renin activity
NCT0000046629	NCT00000466_29_T9	COMPOUND	22	23	renin substrate
NCT0000046629	NCT00000466_29_T10	MOLECULAR_FUNCTION	31	32	lipase activity
NCT0000046631	NCT00000466_31_T0	PHENOTYPE	10	10	bleeding
NCT0000046632	NCT00000466_32_T0	GENE	3	3	had
NCT0000046633	NCT00000466_33_T0	PHENOTYPE	5	7	quality of life
NCT000004672	NCT00000467_2_T0	PHENOTYPE	9	10	fatty streak
NCT000004674	NCT00000467_4_T0	PHENOTYPE	2	3	fatty streaks
NCT000004679	NCT00000467_9_T0	PHENOTYPE	5	5	hypertension
NCT000004679	NCT00000467_9_T1	PHENOTYPE	4	4	hypercholesterolemia
NCT0000046710	NCT00000467_10_T0	GENE	16	16	has
NCT0000046710	NCT00000467_10_T1	ORGAN	4	4	serum
NCT0000046710	NCT00000467_10_T2	PHENOTYPE	5	6	cholesterol levels
NCT0000046710	NCT00000467_10_T3	PHENOTYPE	21	23	coronary heart disease
NCT0000046712	NCT00000467_12_T0	PHENOTYPE	6	6	avoidance
NCT0000046712	NCT00000467_12_T1	PHENOTYPE	11	11	overweight
NCT0000046715	NCT00000467_15_T0	GENE	5	5	had
NCT0000046715	NCT00000467_15_T1	TISSUE	8	9	body fat
NCT0000046716	NCT00000467_16_T0	PHENOTYPE	17	17	experiences
NCT0000046716	NCT00000467_16_T1	PHENOTYPE	7	8	drug use
NCT0000046718	NCT00000467_18_T0	PHENOTYPE	40	41	coronary disease
NCT0000046718	NCT00000467_18_T1	PHENOTYPE	17	19	coronary heart disease
NCT0000046727	NCT00000467_27_T0	PHENOTYPE	15	15	intentions
NCT0000046727	NCT00000467_27_T1	PHENOTYPE	34	34	intentions
NCT0000046727	NCT00000467_27_T2	PHENOTYPE	19	20	behavioral changes
NCT0000046728	NCT00000467_28_T0	GENE	11	11	has
NCT0000046729	NCT00000467_29_T0	PHENOTYPE	2	2	focused
NCT0000046730	NCT00000467_30_T0	PHENOTYPE	18	18	emphysema
NCT0000046730	NCT00000467_30_T1	PHENOTYPE	10	11	chronic diseases
NCT0000046730	NCT00000467_30_T2	PHENOTYPE	13	15	coronary heart disease
NCT0000046731	NCT00000467_31_T0	PHENOTYPE	9	10	drug dependence
NCT0000046732	NCT00000467_32_T0	PHENOTYPE	11	11	progression
NCT0000046732	NCT00000467_32_T1	PHENOTYPE	13	14	substance abuse
NCT0000046733	NCT00000467_33_T0	PHENOTYPE	19	19	initiation
NCT0000046734	NCT00000467_34_T0	PHENOTYPE	18	19	substance use
NCT0000046735	NCT00000467_35_T0	GENE	22	22	had
NCT0000046737	NCT00000467_37_T0	GENE	11	11	sparse
NCT0000046738	NCT00000467_38_T0	GENE	18	18	reduced
NCT0000046738	NCT00000467_38_T1	TISSUE	19	20	body fat
NCT0000046739	NCT00000467_39_T0	TISSUE	19	20	body fat
NCT0000046740	NCT00000467_40_T0	GENE	21	21	5.7
NCT0000046741	NCT00000467_41_T0	BIOLOGICAL_PROCESS	19	19	eating
NCT0000046743	NCT00000467_43_T0	GENE	5	5	has
NCT0000046747	NCT00000467_47_T0	PHENOTYPE	48	48	centered
NCT0000046752	NCT00000467_52_T0	GENE	5	5	II
NCT0000046757	NCT00000467_57_T0	GENE	24	24	PE
NCT0000046758	NCT00000467_58_T0	ORGAN	8	8	serum
NCT0000046759	NCT00000467_59_T0	COMPOUND	24	24	sodium
NCT0000046759	NCT00000467_59_T1	PHENOTYPE	0	0	Secondary
NCT0000046759	NCT00000467_59_T2	PHENOTYPE	5	5	self-efficacy
NCT0000046762	NCT00000467_62_T0	PHENOTYPE	11	11	centers
NCT0000046769	NCT00000467_69_T0	GENE	7	7	JAMA
NCT0000046771	NCT00000467_71_T0	GENE	5	5	III
NCT0000046776	NCT00000467_76_T0	GENE	1	1	III
NCT0000046778	NCT00000467_78_T0	COMPOUND	5	5	homocysteine
NCT0000046779	NCT00000467_79_T0	COMPOUND	17	17	homocysteine
NCT0000046779	NCT00000467_79_T1	ORGAN	3	3	serum
NCT0000046779	NCT00000467_79_T2	COMPOUND	18	19	folic acid
NCT0000046780	NCT00000467_80_T0	PHENOTYPE	14	15	cardiovascular disease
NCT0000046781	NCT00000467_81_T0	GENE	6	6	JAMA
NCT0000046784	NCT00000467_84_T0	GENE	3	3	IV
NCT000004681	NCT00000468_1_T0	PHENOTYPE	11	12	myocardial infarction
NCT000004682	NCT00000468_2_T0	GENE	2	2	II
NCT000004684	NCT00000468_4_T0	GENE	14	14	had
NCT000004684	NCT00000468_4_T1	ORGAN	23	23	heart
NCT000004684	NCT00000468_4_T2	ORGAN	38	38	heart
NCT000004684	NCT00000468_4_T3	PHENOTYPE	6	6	symptoms
NCT000004684	NCT00000468_4_T4	PHENOTYPE	11	13	acute myocardial infarction
NCT000004686	NCT00000468_6_T0	PHENOTYPE	0	0	Acute
NCT000004686	NCT00000468_6_T1	PHENOTYPE	11	11	infarction
NCT000004686	NCT00000468_6_T2	TISSUE	9	9	myocardium
NCT000004686	NCT00000468_6_T3	GENE	12	12	has
NCT000004687	NCT00000468_7_T0	PHENOTYPE	16	16	secondary
NCT000004687	NCT00000468_7_T1	PHENOTYPE	22	22	infarction
NCT000004687	NCT00000468_7_T2	TISSUE	20	20	myocardium
NCT000004687	NCT00000468_7_T3	PHENOTYPE	13	15	congestive heart failure
NCT000004688	NCT00000468_8_T0	TISSUE	3	3	myocardium
NCT000004689	NCT00000468_9_T0	PHENOTYPE	6	6	infarction
NCT000004689	NCT00000468_9_T1	PHENOTYPE	35	35	infarction
NCT000004689	NCT00000468_9_T2	ORGAN	43	43	artery
NCT000004689	NCT00000468_9_T3	PHENOTYPE	39	39	thrombus
NCT000004689	NCT00000468_9_T4	PHENOTYPE	42	42	infarct
NCT0000046810	NCT00000468_10_T0	PHENOTYPE	24	24	acute
NCT0000046810	NCT00000468_10_T1	PHENOTYPE	29	29	acute
NCT0000046810	NCT00000468_10_T2	TISSUE	5	5	myocardium
NCT0000046810	NCT00000468_10_T3	TISSUE	19	19	myocardium
NCT0000046810	NCT00000468_10_T4	PHENOTYPE	1	1	reperfusion
NCT0000046810	NCT00000468_10_T5	PHENOTYPE	31	31	chronic
NCT0000046810	NCT00000468_10_T6	PHENOTYPE	36	37	myocardial failure
NCT0000046812	NCT00000468_12_T0	PHENOTYPE	6	6	reflected
NCT0000046812	NCT00000468_12_T1	GENE	3	3	ventricular
NCT0000046813	NCT00000468_13_T0	GENE	11	11	clot
NCT0000046813	NCT00000468_13_T1	GENE	7	7	TPA
NCT0000046813	NCT00000468_13_T2	GENE	14	14	has
NCT0000046813	NCT00000468_13_T3	GENE	4	6	tissue plasminogen activator
NCT0000046814	NCT00000468_14_T0	PHENOTYPE	27	27	acute
NCT0000046814	NCT00000468_14_T1	GENE	6	6	TPA
NCT0000046814	NCT00000468_14_T2	TISSUE	33	33	myocardium
NCT0000046814	NCT00000468_14_T3	PHENOTYPE	15	15	symptoms
NCT0000046814	NCT00000468_14_T4	PHENOTYPE	1	1	initiation
NCT0000046815	NCT00000468_15_T0	GENE	23	23	has
NCT0000046815	NCT00000468_15_T1	GENE	27	27	has
NCT0000046815	NCT00000468_15_T2	BIOLOGICAL_PROCESS	18	18	transport
NCT0000046816	NCT00000468_16_T0	TISSUE	10	10	myocardium
NCT0000046818	NCT00000468_18_T0	TISSUE	40	40	myocardium
NCT0000046819	NCT00000468_19_T0	GENE	12	12	met
NCT0000046820	NCT00000468_20_T0	PHENOTYPE	11	13	acute myocardial infarction
NCT0000046822	NCT00000468_22_T0	GENE	7	7	II
NCT0000046823	NCT00000468_23_T0	GENE	5	5	II
NCT0000046823	NCT00000468_23_T1	PHENOTYPE	7	7	initiation
NCT0000046823	NCT00000468_23_T2	PHENOTYPE	19	19	initiation
NCT0000046823	NCT00000468_23_T3	GENE	14	14	TPA
NCT0000046823	NCT00000468_23_T4	GENE	11	13	tissue plasminogen activator
NCT0000046825	NCT00000468_25_T0	PHENOTYPE	4	4	symptoms
NCT0000046825	NCT00000468_25_T1	PHENOTYPE	15	15	bleeding
NCT0000046826	NCT00000468_26_T0	COMPOUND	4	4	aspirin
NCT0000046826	NCT00000468_26_T1	GENE	6	6	alteplase
NCT0000046827	NCT00000468_27_T0	COMPOUND	1	2	sodium heparin
NCT0000046829	NCT00000468_29_T0	PHENOTYPE	12	12	bleeding
NCT0000046829	NCT00000468_29_T1	PHENOTYPE	14	14	infarct
NCT0000046830	NCT00000468_30_T0	PHENOTYPE	10	10	infarct
NCT0000046831	NCT00000468_31_T0	GENE	2	2	II
NCT0000046831	NCT00000468_31_T1	PHENOTYPE	4	5	myocardial infarction
NCT0000046831	NCT00000468_31_T2	PHENOTYPE	22	24	acute myocardial infarction
NCT0000046834	NCT00000468_34_T0	PHENOTYPE	16	16	complications
NCT0000046834	NCT00000468_34_T1	BIOLOGICAL_PROCESS	10	10	transport
NCT0000046835	NCT00000468_35_T0	PHENOTYPE	44	44	severity
NCT0000046835	NCT00000468_35_T1	PHENOTYPE	32	32	infarction
NCT0000046835	NCT00000468_35_T2	BIOLOGICAL_PROCESS	17	17	transport
NCT0000046835	NCT00000468_35_T3	PHENOTYPE	48	48	symptoms
NCT000004693	NCT00000469_3_T0	COMPOUND	11	11	heparin
NCT000004695	NCT00000469_5_T0	COMPOUND	4	4	aspirin
NCT000004695	NCT00000469_5_T1	CELL	8	8	platelet
NCT000004695	NCT00000469_5_T2	PHENOTYPE	22	24	transient ischemic attacks
NCT000004696	NCT00000469_6_T0	COMPOUND	8	8	aspirin
NCT000004697	NCT00000469_7_T0	COMPOUND	4	4	aspirin
NCT000004698	NCT00000469_8_T0	COMPOUND	6	6	aspirin
NCT0000046910	NCT00000469_10_T0	PHENOTYPE	9	9	bleeding
NCT0000046910	NCT00000469_10_T1	PHENOTYPE	29	29	anticoagulation
NCT0000046910	NCT00000469_10_T2	GENE	3	3	pointed
NCT0000046910	NCT00000469_10_T3	PHENOTYPE	17	18	cerebrovascular disease
NCT0000046910	NCT00000469_10_T4	PHENOTYPE	20	21	venous thromboembolism
NCT0000046913	NCT00000469_13_T0	GENE	12	12	lipoprotein
NCT0000046913	NCT00000469_13_T1	GENE	24	24	lipoprotein
NCT0000046913	NCT00000469_13_T2	CELL	6	6	cells
NCT0000046913	NCT00000469_13_T3	GENE	13	13	receptor
NCT0000046913	NCT00000469_13_T4	PHENOTYPE	0	0	Inhibition
NCT0000046913	NCT00000469_13_T5	ORGAN	32	32	plasma
NCT0000046913	NCT00000469_13_T6	PHENOTYPE	33	34	cholesterol levels
NCT0000046914	NCT00000469_14_T0	GENE	6	6	lipoprotein
NCT0000046915	NCT00000469_15_T0	PHENOTYPE	18	18	atherosclerosis
NCT0000046915	NCT00000469_15_T1	PHENOTYPE	21	21	complications
NCT0000046917	NCT00000469_17_T0	COMPOUND	20	20	lovastatin
NCT0000046917	NCT00000469_17_T1	COMPOUND	24	24	lovastatin
NCT0000046917	NCT00000469_17_T2	COMPOUND	16	16	warfarin
NCT0000046917	NCT00000469_17_T3	COMPOUND	22	22	warfarin
NCT0000046918	NCT00000469_18_T0	COMPOUND	1	1	aspirin
NCT0000046920	NCT00000469_20_T0	GENE	21	21	beta
NCT0000046921	NCT00000469_21_T0	PHENOTYPE	0	0	Recruitment
NCT0000046923	NCT00000469_23_T0	GENE	4	4	2.7
NCT000004702	NCT00000470_2_T0	PHENOTYPE	19	19	trauma
NCT000004702	NCT00000470_2_T1	PHENOTYPE	16	16	hypoxemia
NCT000004702	NCT00000470_2_T2	PHENOTYPE	18	18	acidosis
NCT000004702	NCT00000470_2_T3	GENE	1	1	has
NCT000004702	NCT00000470_2_T4	PHENOTYPE	29	31	arterial oxygen saturation
NCT000004706	NCT00000470_6_T0	PHENOTYPE	11	12	brain injury
NCT000004709	NCT00000470_9_T0	PHENOTYPE	8	9	septal defect
NCT0000047010	NCT00000470_10_T0	PHENOTYPE	3	3	blocked
NCT0000047017	NCT00000470_17_T0	PHENOTYPE	1	1	recruitment
NCT0000047017	NCT00000470_17_T1	GENE	3	3	extended
NCT0000047018	NCT00000470_18_T0	GENE	3	3	extended
NCT0000047020	NCT00000470_20_T0	PHENOTYPE	24	24	apraxia
NCT0000047020	NCT00000470_20_T1	PHENOTYPE	21	21	dysfunction
NCT0000047020	NCT00000470_20_T2	PHENOTYPE	26	27	cerebral palsy
NCT0000047023	NCT00000470_23_T0	PHENOTYPE	0	0	Secondary
NCT0000047023	NCT00000470_23_T1	PHENOTYPE	23	23	temperament
NCT0000047023	NCT00000470_23_T2	PHENOTYPE	20	21	motor function
NCT0000047024	NCT00000470_24_T0	GENE	7	7	extended
NCT0000047026	NCT00000470_26_T0	PHENOTYPE	14	14	dysfunction
NCT000004710	NCT00000471_0_T0	ORGAN	1	1	Heart
NCT000004718	NCT00000471_8_T0	PHENOTYPE	14	14	regression
NCT000004718	NCT00000471_8_T1	PHENOTYPE	12	12	progression
NCT0000047112	NCT00000471_12_T0	GENE	13	13	QVR
NCT000004721	NCT00000472_1_T0	PHENOTYPE	13	13	thrombi
NCT000004721	NCT00000472_1_T1	PHENOTYPE	22	22	thrombi
NCT000004721	NCT00000472_1_T2	GENE	27	27	t-PA
NCT000004721	NCT00000472_1_T3	GENE	24	26	tissue-type plasminogen activator
NCT000004724	NCT00000472_4_T0	PHENOTYPE	23	24	myocardial infarction
NCT000004726	NCT00000472_6_T0	PHENOTYPE	2	2	syndromes
NCT000004728	NCT00000472_8_T0	PHENOTYPE	17	17	thrombosis
NCT0000047210	NCT00000472_10_T0	GENE	19	19	has
NCT0000047210	NCT00000472_10_T1	PHENOTYPE	8	10	coronary artery occlusion
NCT0000047210	NCT00000472_10_T2	PHENOTYPE	29	31	left ventricular dysfunction
NCT0000047216	NCT00000472_16_T0	PHENOTYPE	18	19	myocardial infarction
NCT0000047216	NCT00000472_16_T1	GENE	4	5	creatine kinase
NCT0000047220	NCT00000472_20_T0	PHENOTYPE	24	24	infarction
NCT0000047220	NCT00000472_20_T1	PHENOTYPE	1	1	ischemia
NCT0000047225	NCT00000472_25_T0	GENE	4	4	III
NCT0000047225	NCT00000472_25_T1	PHENOTYPE	9	10	myocardial infarction
NCT0000047225	NCT00000472_25_T2	PHENOTYPE	21	22	myocardial infarction
NCT0000047226	NCT00000472_26_T0	COMPOUND	1	1	heparin
NCT0000047226	NCT00000472_26_T1	PHENOTYPE	15	15	thrombosis
NCT0000047226	NCT00000472_26_T2	GENE	22	22	had
NCT0000047227	NCT00000472_27_T0	GENE	20	20	had
NCT0000047227	NCT00000472_27_T1	PHENOTYPE	18	19	myocardial infarction
NCT0000047228	NCT00000472_28_T0	GENE	9	9	had
NCT0000047232	NCT00000472_32_T0	PHENOTYPE	16	16	centers
NCT0000047232	NCT00000472_32_T1	GENE	14	14	III
NCT0000047233	NCT00000472_33_T0	COMPOUND	16	16	oxygen
NCT0000047234	NCT00000472_34_T0	GENE	15	15	t-PA
NCT0000047235	NCT00000472_35_T0	COMPOUND	5	5	heparin
NCT0000047241	NCT00000472_41_T0	COMPOUND	11	11	heparin
NCT0000047241	NCT00000472_41_T1	COMPOUND	9	9	aspirin
NCT0000047242	NCT00000472_42_T0	GENE	5	5	t-PA
NCT0000047242	NCT00000472_42_T1	PHENOTYPE	10	11	myocardial infarction
NCT000004730	NCT00000473_0_T0	PHENOTYPE	4	4	Restenosis
NCT000004734	NCT00000473_4_T0	GENE	8	8	has
NCT000004737	NCT00000473_7_T0	PHENOTYPE	15	15	restenosis
NCT000004739	NCT00000473_9_T0	PHENOTYPE	2	2	restenosis
NCT000004739	NCT00000473_9_T1	COMPOUND	35	35	calcium
NCT000004739	NCT00000473_9_T2	CELL	18	18	platelets
NCT000004739	NCT00000473_9_T3	COMPOUND	33	33	warfarin
NCT000004739	NCT00000473_9_T4	COMPOUND	34	34	heparin
NCT000004739	NCT00000473_9_T5	PHENOTYPE	8	8	thrombosis
NCT000004739	NCT00000473_9_T6	PHENOTYPE	9	9	spasm
NCT000004739	NCT00000473_9_T7	COMPOUND	32	32	aspirin
NCT000004739	NCT00000473_9_T8	PHENOTYPE	3	3	reflects
NCT000004739	NCT00000473_9_T9	BIOLOGICAL_PROCESS	22	24	arachidonic acid metabolism
NCT000004739	NCT00000473_9_T10	CELL	15	17	smooth muscle cells
NCT0000047310	NCT00000473_10_T0	PHENOTYPE	17	17	restenosis
NCT0000047312	NCT00000473_12_T0	GENE	10	10	pigs
NCT0000047312	NCT00000473_12_T1	GENE	17	17	balloon
NCT0000047312	NCT00000473_12_T2	GENE	11	11	reduced
NCT0000047312	NCT00000473_12_T3	CELL	12	12	platelet
NCT0000047312	NCT00000473_12_T4	BIOLOGICAL_PROCESS	15	15	vasoconstriction
NCT0000047312	NCT00000473_12_T5	GENE	2	2	has
NCT0000047312	NCT00000473_12_T6	ORGAN	20	21	carotid artery
NCT0000047315	NCT00000473_15_T0	PHENOTYPE	15	15	rigor
NCT0000047317	NCT00000473_17_T0	PHENOTYPE	21	21	restenosis
NCT0000047317	NCT00000473_17_T1	COMPOUND	14	14	aspirin
NCT0000047317	NCT00000473_17_T2	COMPOUND	26	26	aspirin
NCT0000047317	NCT00000473_17_T3	COMPOUND	11	12	n-3 PUFAs
NCT0000047321	NCT00000473_21_T0	GENE	32	32	EPA
NCT0000047321	NCT00000473_21_T1	COMPOUND	37	38	arachidonic acid
NCT0000047326	NCT00000473_26_T0	ORGAN	12	12	Heart
NCT0000047328	NCT00000473_28_T0	PHENOTYPE	0	0	Recruitment
NCT0000047330	NCT00000473_30_T0	PHENOTYPE	8	8	restenosis
NCT0000047331	NCT00000473_31_T0	GENE	3	3	extended
NCT000004743	NCT00000474_3_T0	PHENOTYPE	18	18	Alcoholism
NCT000004743	NCT00000474_3_T1	PHENOTYPE	15	16	Alcohol Abuse
NCT0000047412	NCT00000474_12_T0	PHENOTYPE	0	0	Recruitment
NCT0000047414	NCT00000474_14_T0	GENE	21	21	QVR
NCT000004756	NCT00000475_6_T0	PHENOTYPE	20	20	hypocholesterolemia
NCT000004756	NCT00000475_6_T1	PHENOTYPE	22	24	right bundle-branch block
NCT000004756	NCT00000475_6_T2	PHENOTYPE	17	19	congestive heart failure
NCT000004759	NCT00000475_9_T0	PHENOTYPE	1	1	secondary
NCT000004759	NCT00000475_9_T1	COMPOUND	18	18	sodium
NCT000004759	NCT00000475_9_T2	PHENOTYPE	22	24	adverse drug reactions
NCT000004759	NCT00000475_9_T3	PHENOTYPE	30	32	congestive heart failure
NCT000004759	NCT00000475_9_T4	PHENOTYPE	34	36	quality of life
NCT0000047511	NCT00000475_11_T0	PHENOTYPE	40	41	heart failure
NCT0000047511	NCT00000475_11_T1	PHENOTYPE	16	18	congestive heart failure
NCT0000047513	NCT00000475_13_T0	PHENOTYPE	19	19	symptoms
NCT0000047513	NCT00000475_13_T1	PHENOTYPE	18	18	recurrent
NCT0000047515	NCT00000475_15_T0	PHENOTYPE	0	0	Secondary
NCT0000047515	NCT00000475_15_T1	PHENOTYPE	27	27	quality-of-life
NCT0000047515	NCT00000475_15_T2	PHENOTYPE	15	17	congestive heart failure
NCT000004760	NCT00000476_0_T0	PHENOTYPE	3	3	DIG
NCT000004760	NCT00000476_0_T1	COMPOUND	0	0	Digitalis
NCT000004764	NCT00000476_4_T0	PHENOTYPE	10	10	centers
NCT000004765	NCT00000476_5_T0	GENE	30	30	ACE
NCT000004765	NCT00000476_5_T1	GENE	11	11	0.45
NCT000004765	NCT00000476_5_T2	COMPOUND	18	18	digoxin
NCT000004765	NCT00000476_5_T3	PHENOTYPE	7	9	ventricular ejection fractions
NCT000004766	NCT00000476_6_T0	GENE	11	11	0.45
NCT000004766	NCT00000476_6_T1	COMPOUND	18	18	digoxin
NCT000004767	NCT00000476_7_T0	PHENOTYPE	10	10	centers
NCT0000047613	NCT00000476_13_T0	PHENOTYPE	7	7	pathophysiology
NCT0000047613	NCT00000476_13_T1	PHENOTYPE	9	11	sudden cardiac death
NCT0000047614	NCT00000476_14_T0	COMPOUND	8	8	digoxin
NCT0000047614	NCT00000476_14_T1	PHENOTYPE	16	17	heart failure
NCT0000047615	NCT00000476_15_T0	GENE	21	21	QVR
NCT000004772	NCT00000477_2_T0	GENE	25	25	2.1
NCT000004772	NCT00000477_2_T1	PHENOTYPE	16	17	cholesterol levels
NCT000004772	NCT00000477_2_T2	PHENOTYPE	7	9	coronary heart disease
NCT000004777	NCT00000477_7_T0	PHENOTYPE	8	9	cholesterol levels
NCT0000047710	NCT00000477_10_T0	PHENOTYPE	22	22	attributable
NCT0000047710	NCT00000477_10_T1	ORGAN	25	25	plasma
NCT0000047710	NCT00000477_10_T2	PHENOTYPE	26	27	cholesterol levels
NCT0000047710	NCT00000477_10_T3	PHENOTYPE	20	21	myocardial infarctions
NCT0000047710	NCT00000477_10_T4	PHENOTYPE	7	9	coronary heart disease
NCT0000047713	NCT00000477_13_T0	GENE	11	11	reductase
NCT0000047713	NCT00000477_13_T1	GENE	9	9	HMG
NCT0000047713	NCT00000477_13_T2	COMPOUND	13	13	lovastatin
NCT0000047713	NCT00000477_13_T3	GENE	19	19	has
NCT0000047713	NCT00000477_13_T4	GENE	30	30	has
NCT0000047716	NCT00000477_16_T0	PHENOTYPE	24	24	centers
NCT0000047718	NCT00000477_18_T0	PHENOTYPE	6	6	centers
NCT0000047720	NCT00000477_20_T0	ORGAN	20	20	Heart
NCT0000047720	NCT00000477_20_T1	GENE	7	7	LDL
NCT0000047720	NCT00000477_20_T2	PHENOTYPE	8	9	cholesterol levels
NCT0000047721	NCT00000477_21_T0	COMPOUND	10	10	lovastatin
NCT0000047721	NCT00000477_21_T1	COMPOUND	19	19	lovastatin
NCT0000047723	NCT00000477_23_T0	PHENOTYPE	9	9	quality-of-life
NCT0000047723	NCT00000477_23_T1	PHENOTYPE	12	14	coronary heart disease
NCT0000047724	NCT00000477_24_T0	GENE	0	0	LDL
NCT0000047724	NCT00000477_24_T1	PHENOTYPE	1	2	cholesterol levels
NCT0000047725	NCT00000477_25_T0	PHENOTYPE	28	28	opacities
NCT0000047725	NCT00000477_25_T1	GENE	15	15	slit
NCT0000047725	NCT00000477_25_T2	ORGAN	12	12	liver
NCT0000047725	NCT00000477_25_T3	ORGAN	0	0	Serum
NCT0000047725	NCT00000477_25_T4	GENE	16	16	lamp
NCT0000047725	NCT00000477_25_T5	GENE	1	2	alanine aminotransferase
NCT000004780	NCT00000478_0_T0	COMPOUND	4	4	ACIP
NCT000004780	NCT00000478_0_T1	PHENOTYPE	1	2	Cardiac Ischemia
NCT000004783	NCT00000478_3_T0	PHENOTYPE	7	9	acute myocardial infarction
NCT000004785	NCT00000478_5_T0	GENE	2	2	has
NCT000004785	NCT00000478_5_T1	PHENOTYPE	1	1	ischemia
NCT000004785	NCT00000478_5_T2	PHENOTYPE	6	7	sudden death
NCT000004785	NCT00000478_5_T3	PHENOTYPE	9	10	myocardial infarction
NCT000004786	NCT00000478_6_T0	PHENOTYPE	13	13	chronic
NCT000004786	NCT00000478_6_T1	PHENOTYPE	29	30	myocardial ischemia
NCT000004786	NCT00000478_6_T2	PHENOTYPE	15	17	coronary heart disease
NCT000004789	NCT00000478_9_T0	PHENOTYPE	19	19	ischemia
NCT000004789	NCT00000478_9_T1	PHENOTYPE	8	9	cardiac ischemia
NCT0000047810	NCT00000478_10_T0	PHENOTYPE	4	4	suppression
NCT0000047810	NCT00000478_10_T1	PHENOTYPE	7	7	ischemia
NCT0000047810	NCT00000478_10_T2	PHENOTYPE	11	13	coronary heart disease
NCT0000047812	NCT00000478_12_T0	PHENOTYPE	16	16	strategies
NCT0000047812	NCT00000478_12_T1	PHENOTYPE	20	21	cardiac ischemia
NCT0000047813	NCT00000478_13_T0	PHENOTYPE	42	42	ischemia
NCT0000047813	NCT00000478_13_T1	PHENOTYPE	7	8	cardiac ischemia
NCT0000047813	NCT00000478_13_T2	PHENOTYPE	12	14	coronary heart disease
NCT0000047814	NCT00000478_14_T0	PHENOTYPE	23	23	ischemia
NCT0000047814	NCT00000478_14_T1	PHENOTYPE	27	28	cardiovascular morbidity
NCT0000047814	NCT00000478_14_T2	PHENOTYPE	32	34	coronary heart disease
NCT0000047815	NCT00000478_15_T0	GENE	14	14	had
NCT0000047815	NCT00000478_15_T1	PHENOTYPE	16	16	ischemia
NCT0000047817	NCT00000478_17_T0	COMPOUND	24	24	nifedipine
NCT0000047817	NCT00000478_17_T1	COMPOUND	26	26	diltiazem
NCT0000047817	NCT00000478_17_T2	COMPOUND	9	9	calcium
NCT0000047817	NCT00000478_17_T3	COMPOUND	22	22	atenolol
NCT0000047817	NCT00000478_17_T4	COMPOUND	28	29	isosorbide dinitrate
NCT0000047819	NCT00000478_19_T0	PHENOTYPE	7	7	ischemia
NCT0000047820	NCT00000478_20_T0	PHENOTYPE	0	0	Recruitment
NCT000004793	NCT00000479_3_T0	PHENOTYPE	7	7	secondary
NCT000004793	NCT00000479_3_T1	COMPOUND	1	1	aspirin
NCT000004793	NCT00000479_3_T2	GENE	2	2	has
NCT000004793	NCT00000479_3_T3	PHENOTYPE	10	11	myocardial infarction
NCT000004793	NCT00000479_3_T4	PHENOTYPE	16	18	coronary artery disease
NCT000004794	NCT00000479_4_T0	COMPOUND	13	13	aspirin
NCT000004794	NCT00000479_4_T1	PHENOTYPE	22	23	myocardial infarction
NCT000004794	NCT00000479_4_T2	PHENOTYPE	28	30	cerebral vascular events
NCT000004795	NCT00000479_5_T0	COMPOUND	8	8	aspirin
NCT000004795	NCT00000479_5_T1	PHENOTYPE	10	11	vascular diseases
NCT0000047912	NCT00000479_12_T0	COMPOUND	21	21	aspirin
NCT0000047913	NCT00000479_13_T0	COMPOUND	11	11	aspirin
NCT0000047913	NCT00000479_13_T1	COMPOUND	18	18	aspirin
NCT0000047913	NCT00000479_13_T2	COMPOUND	25	25	aspirin
NCT0000047913	NCT00000479_13_T3	COMPOUND	33	33	aspirin
NCT0000047913	NCT00000479_13_T4	COMPOUND	14	15	vitamin E
NCT0000047913	NCT00000479_13_T5	COMPOUND	21	22	vitamin E
NCT0000047913	NCT00000479_13_T6	COMPOUND	28	29	vitamin E
NCT0000047913	NCT00000479_13_T7	COMPOUND	36	37	vitamin E
NCT0000047914	NCT00000479_14_T0	GENE	19	19	Med
NCT0000047915	NCT00000479_15_T0	COMPOUND	8	8	aspirin
NCT0000047915	NCT00000479_15_T1	COMPOUND	16	16	aspirin
NCT0000047915	NCT00000479_15_T2	COMPOUND	32	32	aspirin
NCT0000047915	NCT00000479_15_T3	COMPOUND	23	24	vitamin E
NCT0000047916	NCT00000479_16_T0	GENE	20	20	has
NCT0000047918	NCT00000479_18_T0	PHENOTYPE	0	0	Secondary
NCT0000047920	NCT00000479_20_T0	GENE	17	17	JAMA
NCT0000047920	NCT00000479_20_T1	GENE	19	19	JAMA
NCT0000047920	NCT00000479_20_T2	GENE	15	15	Med
NCT0000047920	NCT00000479_20_T3	COMPOUND	12	12	N
NCT0000047920	NCT00000479_20_T4	GENE	13	13	Engl
NCT000004804	NCT00000480_4_T0	PHENOTYPE	4	5	sudden death
NCT000004804	NCT00000480_4_T1	PHENOTYPE	17	18	coronary disease
NCT000004804	NCT00000480_4_T2	PHENOTYPE	11	12	myocardial infarction
NCT000004807	NCT00000480_7_T0	PHENOTYPE	6	6	arrhythmia
NCT000004807	NCT00000480_7_T1	PHENOTYPE	12	12	palpitations
NCT0000048016	NCT00000480_16_T0	PHENOTYPE	3	5	sustained ventricular tachycardia
NCT0000048017	NCT00000480_17_T0	PHENOTYPE	0	0	Recruitment
NCT000004812	NCT00000481_2_T0	PHENOTYPE	17	19	coronary heart disease
NCT000004816	NCT00000481_6_T0	PHENOTYPE	0	0	Recruitment
NCT000004819	NCT00000481_9_T0	PHENOTYPE	12	12	centers
NCT000004819	NCT00000481_9_T1	PHENOTYPE	0	0	Recruitment
NCT0000048113	NCT00000481_13_T0	COMPOUND	0	0	NCI
NCT0000048113	NCT00000481_13_T1	GENE	1	1	extended
NCT000004822	NCT00000482_2_T0	PHENOTYPE	74	74	recurrences
NCT000004822	NCT00000482_2_T1	COMPOUND	68	68	aspirin
NCT000004822	NCT00000482_2_T2	CELL	70	70	platelet
NCT000004822	NCT00000482_2_T3	ORGAN	11	11	serum
NCT000004822	NCT00000482_2_T4	PHENOTYPE	32	33	myocardial infarction
NCT000004822	NCT00000482_2_T5	PHENOTYPE	76	77	myocardial infarction
NCT000004824	NCT00000482_4_T0	ORGAN	11	11	serum
NCT000004824	NCT00000482_4_T1	GENE	19	19	CHD
NCT000004825	NCT00000482_5_T0	PHENOTYPE	11	11	secondary
NCT000004826	NCT00000482_6_T0	GENE	13	13	hoc
NCT000004826	NCT00000482_6_T1	GENE	2	2	Dr
NCT000004827	NCT00000482_7_T0	ORGAN	2	2	Heart
NCT0000048214	NCT00000482_14_T0	GENE	13	13	QVR
NCT000004834	NCT00000483_4_T0	COMPOUND	4	4	clofibrate
NCT000004834	NCT00000483_4_T1	GENE	18	18	had
NCT000004836	NCT00000483_6_T0	COMPOUND	11	11	clofibrate
NCT000004836	NCT00000483_6_T1	GENE	8	8	CDP
NCT000004839	NCT00000483_9_T0	GENE	17	17	CDP
NCT0000048310	NCT00000483_10_T0	PHENOTYPE	4	4	questioning
NCT0000048311	NCT00000483_11_T0	GENE	13	13	QVR
NCT000004840	NCT00000484_0_T0	PHENOTYPE	2	2	Hypertension
NCT000004843	NCT00000484_3_T0	PHENOTYPE	1	1	centers
NCT000004846	NCT00000484_6_T0	PHENOTYPE	9	9	inferred
NCT000004851	NCT00000485_1_T0	PHENOTYPE	13	13	severity
NCT000004851	NCT00000485_1_T1	PHENOTYPE	42	42	complications
NCT000004851	NCT00000485_1_T2	PHENOTYPE	24	26	high blood pressure
NCT000004851	NCT00000485_1_T3	PHENOTYPE	44	46	high blood pressure
NCT000004853	NCT00000485_3_T0	GENE	15	15	Hg
NCT000004855	NCT00000485_5_T0	PHENOTYPE	6	6	Hypertension
NCT000004855	NCT00000485_5_T1	PHENOTYPE	44	44	hypertension
NCT000004858	NCT00000485_8_T0	PHENOTYPE	11	13	high blood pressure
NCT0000048513	NCT00000485_13_T0	PHENOTYPE	7	7	centers
NCT0000048515	NCT00000485_15_T0	GENE	3	3	extended
NCT0000048520	NCT00000485_20_T0	PHENOTYPE	12	12	secondary
NCT0000048520	NCT00000485_20_T1	PHENOTYPE	23	24	myocardial infarction
NCT0000048520	NCT00000485_20_T2	PHENOTYPE	30	31	EKG abnormalities
NCT0000048520	NCT00000485_20_T3	PHENOTYPE	26	28	hypertensive heart disease
NCT000004862	NCT00000486_2_T0	ORGAN	11	11	heart
NCT000004862	NCT00000486_2_T1	PHENOTYPE	19	21	coronary artery disease
NCT000004864	NCT00000486_4_T0	COMPOUND	13	13	nitroglycerin
NCT000004864	NCT00000486_4_T1	PHENOTYPE	8	8	discomfort
NCT000004864	NCT00000486_4_T2	PHENOTYPE	2	2	avoidance
NCT000004864	NCT00000486_4_T3	GENE	15	15	beta
NCT000004868	NCT00000486_8_T0	GENE	16	16	bypass
NCT000004868	NCT00000486_8_T1	ORGAN	14	15	coronary artery
NCT0000048610	NCT00000486_10_T0	PHENOTYPE	16	16	tolerance
NCT0000048612	NCT00000486_12_T0	GENE	10	10	bypass
NCT000004874	NCT00000487_4_T0	PHENOTYPE	11	11	Arteriosclerosis
NCT000004878	NCT00000487_8_T0	BIOLOGICAL_PROCESS	9	9	eating
NCT000004879	NCT00000487_9_T0	GENE	6	6	cease
NCT000004879	NCT00000487_9_T1	PHENOTYPE	18	18	aids
NCT0000048710	NCT00000487_10_T0	PHENOTYPE	0	0	Hypertension
NCT0000048710	NCT00000487_10_T1	PHENOTYPE	19	19	Hypertension
NCT0000048710	NCT00000487_10_T2	PHENOTYPE	9	10	weight reduction
NCT0000048712	NCT00000487_12_T0	PHENOTYPE	7	9	coronary heart disease
NCT0000048715	NCT00000487_15_T0	PHENOTYPE	11	12	myocardial infarction
NCT0000048716	NCT00000487_16_T0	PHENOTYPE	7	7	centers
NCT0000048716	NCT00000487_16_T1	PHENOTYPE	20	20	centers
NCT0000048717	NCT00000487_17_T0	GENE	2	2	has
NCT0000048724	NCT00000487_24_T0	COMPOUND	11	11	sodium
NCT0000048727	NCT00000487_27_T0	PHENOTYPE	7	7	hypercholesterolemia
NCT000004885	NCT00000488_5_T0	PHENOTYPE	13	13	atherosclerosis
NCT000004885	NCT00000488_5_T1	GENE	14	14	had
NCT000004885	NCT00000488_5_T2	ORGAN	8	8	serum
NCT000004886	NCT00000488_6_T0	GENE	16	16	had
NCT000004886	NCT00000488_6_T1	ORGAN	11	11	serum
NCT000004886	NCT00000488_6_T2	PHENOTYPE	21	23	coronary heart disease
NCT000004886	NCT00000488_6_T3	PHENOTYPE	30	32	coronary heart disease
NCT000004887	NCT00000488_7_T0	PHENOTYPE	0	2	Coronary heart disease
NCT000004889	NCT00000488_9_T0	GENE	10	10	has
NCT0000048810	NCT00000488_10_T0	BIOLOGICAL_PROCESS	13	14	Lipid Metabolism
NCT0000048811	NCT00000488_11_T0	PHENOTYPE	40	40	recruitment
NCT0000048817	NCT00000488_17_T0	COMPOUND	20	20	cholestyramine
NCT0000048817	NCT00000488_17_T1	GENE	2	2	met
NCT0000048818	NCT00000488_18_T0	PHENOTYPE	0	0	Recruitment
NCT0000048820	NCT00000488_20_T0	PHENOTYPE	19	19	toxic
NCT0000048824	NCT00000488_24_T0	PHENOTYPE	11	11	toxicity
NCT0000048824	NCT00000488_24_T1	COMPOUND	19	19	cholestyramine
NCT0000048824	NCT00000488_24_T2	PHENOTYPE	17	17	ingestion
NCT0000048829	NCT00000488_29_T0	GENE	1	1	II
NCT0000048829	NCT00000488_29_T1	PHENOTYPE	2	2	hyperlipoproteinemia
NCT000004890	NCT00000489_0_T0	PHENOTYPE	4	4	CASS
NCT000004890	NCT00000489_0_T1	ORGAN	0	1	Coronary Artery
NCT000004895	NCT00000489_5_T0	ORGAN	14	15	coronary artery
NCT000004895	NCT00000489_5_T1	PHENOTYPE	20	22	ischemic heart disease
NCT000004897	NCT00000489_7_T0	PHENOTYPE	31	33	quality of life
NCT000004898	NCT00000489_8_T0	ORGAN	12	13	coronary artery
NCT0000048910	NCT00000489_10_T0	ORGAN	19	20	coronary artery
NCT0000048912	NCT00000489_12_T0	PHENOTYPE	13	13	centers
NCT0000048913	NCT00000489_13_T0	PHENOTYPE	1	1	projections
NCT0000048913	NCT00000489_13_T1	PHENOTYPE	11	11	centers
NCT0000048915	NCT00000489_15_T0	GENE	7	7	met
NCT0000048920	NCT00000489_20_T0	PHENOTYPE	0	0	Recruitment
NCT0000048922	NCT00000489_22_T0	GENE	2	2	extended
NCT0000048926	NCT00000489_26_T0	PHENOTYPE	5	6	myocardial infarction
NCT000004902	NCT00000490_2_T0	GENE	18	18	reduced
NCT000004903	NCT00000490_3_T0	GENE	10	10	bypass
NCT000004903	NCT00000490_3_T1	PHENOTYPE	13	13	hyperlipidemia
NCT000004903	NCT00000490_3_T2	GENE	6	6	had
NCT000004904	NCT00000490_4_T0	GENE	8	8	had
NCT000004905	NCT00000490_5_T0	PHENOTYPE	4	4	concentrations
NCT000004905	NCT00000490_5_T1	ORGAN	2	2	serum
NCT000004906	NCT00000490_6_T0	GENE	22	22	had
NCT000004906	NCT00000490_6_T1	GENE	34	34	had
NCT000004906	NCT00000490_6_T2	GENE	18	18	bypass
NCT000004906	NCT00000490_6_T3	PHENOTYPE	23	23	suffered
NCT000004906	NCT00000490_6_T4	GENE	44	44	LDL
NCT000004906	NCT00000490_6_T5	ORGAN	35	35	serum
NCT000004906	NCT00000490_6_T6	PHENOTYPE	25	26	myocardial infarction
NCT000004906	NCT00000490_6_T7	PHENOTYPE	10	11	cardiovascular morbidity
NCT000004908	NCT00000490_8_T0	GENE	7	7	bypass
NCT000004908	NCT00000490_8_T1	ORGAN	13	13	serum
NCT0000049012	NCT00000490_12_T0	PHENOTYPE	1	1	secondary
NCT0000049012	NCT00000490_12_T1	GENE	6	6	bypass
NCT0000049012	NCT00000490_12_T2	PHENOTYPE	15	15	peripheral
NCT0000049012	NCT00000490_12_T3	ORGAN	4	5	coronary artery
NCT0000049016	NCT00000490_16_T0	GENE	11	11	II
NCT0000049016	NCT00000490_16_T1	GENE	25	25	bypass
NCT000004910	NCT00000491_0_T0	PHENOTYPE	1	1	Infarction
NCT000004914	NCT00000491_4_T0	CELL	8	8	platelets
NCT000004914	NCT00000491_4_T1	PHENOTYPE	16	18	coronary artery disease
NCT000004916	NCT00000491_6_T0	PHENOTYPE	3	3	reflected
NCT000004916	NCT00000491_6_T1	PHENOTYPE	11	12	myocardial infarction
NCT000004916	NCT00000491_6_T2	PHENOTYPE	20	22	coronary artery disease
NCT000004917	NCT00000491_7_T0	COMPOUND	10	10	aspirin
NCT000004917	NCT00000491_7_T1	GENE	2	2	had
NCT000004917	NCT00000491_7_T2	PHENOTYPE	19	21	coronary artery disease
NCT000004919	NCT00000491_9_T0	PHENOTYPE	25	25	secondary
NCT000004919	NCT00000491_9_T1	COMPOUND	22	22	aspirin
NCT000004919	NCT00000491_9_T2	PHENOTYPE	28	30	coronary heart disease
NCT0000049110	NCT00000491_10_T0	GENE	4	4	met
NCT0000049111	NCT00000491_11_T0	PHENOTYPE	0	0	Recruitment
NCT0000049112	NCT00000491_12_T0	COMPOUND	42	42	aspirin
NCT0000049112	NCT00000491_12_T1	GENE	4	4	had
NCT0000049112	NCT00000491_12_T2	PHENOTYPE	39	40	adverse reactions
NCT0000049113	NCT00000491_13_T0	COMPOUND	10	10	aspirin
NCT0000049114	NCT00000491_14_T0	PHENOTYPE	25	26	cardiovascular problems
NCT0000049117	NCT00000491_17_T0	PHENOTYPE	5	5	centers
NCT0000049118	NCT00000491_18_T0	PHENOTYPE	4	4	recruitment
NCT0000049119	NCT00000491_19_T0	PHENOTYPE	12	12	centers
NCT0000049122	NCT00000491_22_T0	GENE	10	10	gm
NCT0000049122	NCT00000491_22_T1	COMPOUND	12	12	aspirin
NCT0000049122	NCT00000491_22_T2	COMPOUND	19	19	aspirin
NCT000004920	NCT00000492_0_T0	PHENOTYPE	1	2	Heart Attack
NCT000004922	NCT00000492_2_T0	PHENOTYPE	20	20	acute
NCT000004923	NCT00000492_3_T0	COMPOUND	11	11	propranolol
NCT000004924	NCT00000492_4_T0	COMPOUND	7	7	propranolol
NCT000004924	NCT00000492_4_T1	PHENOTYPE	20	21	myocardial infarction
NCT000004924	NCT00000492_4_T2	PHENOTYPE	32	33	myocardial infarction
NCT000004924	NCT00000492_4_T3	PHENOTYPE	15	17	sudden cardiac death
NCT000004924	NCT00000492_4_T4	PHENOTYPE	11	13	coronary heart disease
NCT000004924	NCT00000492_4_T5	PHENOTYPE	23	25	coronary heart disease
NCT000004926	NCT00000492_6_T0	PHENOTYPE	1	1	arrhythmias
NCT000004926	NCT00000492_6_T1	PHENOTYPE	9	9	infarction
NCT000004928	NCT00000492_8_T0	PHENOTYPE	22	22	complications
NCT000004928	NCT00000492_8_T1	PHENOTYPE	30	30	arrhythmias
NCT000004928	NCT00000492_8_T2	GENE	6	6	has
NCT000004928	NCT00000492_8_T3	GENE	3	3	beta
NCT000004928	NCT00000492_8_T4	PHENOTYPE	24	26	coronary heart disease
NCT000004929	NCT00000492_9_T0	PHENOTYPE	3	3	reflected
NCT000004929	NCT00000492_9_T1	PHENOTYPE	11	13	coronary heart disease
NCT0000049210	NCT00000492_10_T0	PHENOTYPE	3	3	chronic
NCT0000049212	NCT00000492_12_T0	GENE	19	19	hoc
NCT0000049214	NCT00000492_14_T0	PHENOTYPE	0	0	Recruitment
NCT0000049216	NCT00000492_16_T0	PHENOTYPE	9	9	centers
NCT0000049218	NCT00000492_18_T0	PHENOTYPE	9	11	acute myocardial infarction
NCT0000049219	NCT00000492_19_T0	PHENOTYPE	8	10	acute myocardial infarction
NCT0000049220	NCT00000492_20_T0	GENE	10	10	QRS
NCT0000049221	NCT00000492_21_T0	COMPOUND	12	12	propranolol
NCT0000049223	NCT00000492_23_T0	COMPOUND	5	5	propranolol
NCT0000049223	NCT00000492_23_T1	ORGAN	14	14	serum
NCT0000049223	NCT00000492_23_T2	PHENOTYPE	15	16	drug levels
NCT0000049225	NCT00000492_25_T0	GENE	21	21	QVR
NCT000004930	NCT00000493_0_T0	PHENOTYPE	5	5	Infarct
NCT000004932	NCT00000493_2_T0	PHENOTYPE	1	1	secondary
NCT000004932	NCT00000493_2_T1	GENE	12	12	ventricular
NCT000004932	NCT00000493_2_T2	PHENOTYPE	17	18	myocardial infarction
NCT000004935	NCT00000493_5_T0	PHENOTYPE	3	3	enthusiastic
NCT000004936	NCT00000493_6_T0	TISSUE	9	9	myocardium
NCT000004938	NCT00000493_8_T0	PHENOTYPE	6	6	centers
NCT0000049310	NCT00000493_10_T0	GENE	8	8	hyaluronidase
NCT0000049310	NCT00000493_10_T1	GENE	23	23	hyaluronidase
NCT0000049310	NCT00000493_10_T2	COMPOUND	6	6	propranolol
NCT0000049310	NCT00000493_10_T3	COMPOUND	18	18	propranolol
NCT0000049310	NCT00000493_10_T4	PHENOTYPE	16	17	Group B
NCT0000049311	NCT00000493_11_T0	GENE	6	6	hyaluronidase
NCT0000049311	NCT00000493_11_T1	COMPOUND	2	2	propranolol
NCT0000049313	NCT00000493_13_T0	GENE	20	20	QVR
NCT000004943	NCT00000494_3_T0	PHENOTYPE	13	14	left-to-right shunt
NCT000004946	NCT00000494_6_T0	PHENOTYPE	10	10	progressive
NCT000004946	NCT00000494_6_T1	PHENOTYPE	11	12	pulmonary disease
NCT000004946	NCT00000494_6_T2	PHENOTYPE	6	7	respiratory distress
NCT000004947	NCT00000494_7_T0	PHENOTYPE	6	6	elimination
NCT000004949	NCT00000494_9_T0	COMPOUND	11	11	indomethacin
NCT0000049410	NCT00000494_10_T0	COMPOUND	13	13	indomethacin
NCT0000049411	NCT00000494_11_T0	GENE	2	2	had
NCT0000049411	NCT00000494_11_T1	COMPOUND	16	16	indomethacin
NCT0000049412	NCT00000494_12_T0	COMPOUND	9	9	indomethacin
NCT0000049413	NCT00000494_13_T0	COMPOUND	3	3	indomethacin
NCT0000049414	NCT00000494_14_T0	PHENOTYPE	1	1	Recruitment
NCT0000049417	NCT00000494_17_T0	GENE	0	1	Birth weight
NCT000004953	NCT00000495_3_T0	COMPOUND	8	8	sodium
NCT000004953	NCT00000495_3_T1	PHENOTYPE	3	3	overweight
NCT000004954	NCT00000495_4_T0	ORGAN	0	0	Heart
NCT000004954	NCT00000495_4_T1	PHENOTYPE	10	10	hypertension
NCT000004955	NCT00000495_5_T0	PHENOTYPE	20	20	hypertension
NCT0000049510	NCT00000495_10_T0	PHENOTYPE	15	15	hypertension
NCT0000049510	NCT00000495_10_T1	PHENOTYPE	11	13	high blood pressure
NCT000004960	NCT00000496_0_T0	CELL	0	0	Platelet
NCT000004960	NCT00000496_0_T1	PHENOTYPE	4	5	Coronary Disease
NCT000004960	NCT00000496_0_T2	PHENOTYPE	5	6	Disease Progression
NCT000004963	NCT00000496_3_T0	PHENOTYPE	38	39	coronary disease
NCT000004963	NCT00000496_3_T1	PHENOTYPE	14	16	acute myocardial infarction
NCT000004964	NCT00000496_4_T0	PHENOTYPE	18	18	complications
NCT000004964	NCT00000496_4_T1	PHENOTYPE	34	34	complications
NCT000004964	NCT00000496_4_T2	PHENOTYPE	29	29	progression
NCT000004964	NCT00000496_4_T3	PHENOTYPE	14	15	coronary disease
NCT000004965	NCT00000496_5_T0	GENE	17	17	bypass
NCT000004965	NCT00000496_5_T1	ORGAN	18	18	graft
NCT000004965	NCT00000496_5_T2	GENE	28	28	reduced
NCT000004965	NCT00000496_5_T3	PHENOTYPE	24	25	myocardial infarction
NCT000004966	NCT00000496_6_T0	PHENOTYPE	9	10	coronary disease
NCT000004966	NCT00000496_6_T1	ORGAN	16	17	coronary artery
NCT000004968	NCT00000496_8_T0	COMPOUND	9	9	dipyridamole
NCT000004968	NCT00000496_8_T1	COMPOUND	11	11	aspirin
NCT000004969	NCT00000496_9_T0	COMPOUND	7	7	lactose
NCT0000049611	NCT00000496_11_T0	PHENOTYPE	0	0	Secondary
NCT0000049611	NCT00000496_11_T1	PHENOTYPE	10	11	myocardial infarction
NCT0000049611	NCT00000496_11_T2	PHENOTYPE	16	17	myocardial infarction
NCT0000049612	NCT00000496_12_T0	PHENOTYPE	0	0	Recruitment
NCT0000049613	NCT00000496_13_T0	GENE	26	26	QVR
NCT0000049613	NCT00000496_13_T1	PHENOTYPE	15	15	Recruitment
NCT000004971	NCT00000497_1_T0	GENE	10	10	had
NCT000004971	NCT00000497_1_T1	PHENOTYPE	17	17	hypertension
NCT000004973	NCT00000497_3_T0	ORGAN	15	15	plasma
NCT000004973	NCT00000497_3_T1	MOLECULAR_FUNCTION	16	17	renin activity
NCT000004975	NCT00000497_5_T0	COMPOUND	11	11	sodium
NCT000004975	NCT00000497_5_T1	PHENOTYPE	25	27	elevated blood pressure
NCT000004977	NCT00000497_7_T0	COMPOUND	23	23	potassium
NCT000004977	NCT00000497_7_T1	COMPOUND	10	10	sodium
NCT000004977	NCT00000497_7_T2	COMPOUND	34	34	sodium
NCT000004977	NCT00000497_7_T3	PHENOTYPE	17	17	hypertension
NCT000004978	NCT00000497_8_T0	COMPOUND	5	5	sodium
NCT000004978	NCT00000497_8_T1	COMPOUND	8	8	potassium
NCT000004978	NCT00000497_8_T2	PHENOTYPE	9	9	ingestion
NCT000004978	NCT00000497_8_T3	PHENOTYPE	19	19	hypertension
NCT000004979	NCT00000497_9_T0	PHENOTYPE	23	23	Hypertension
NCT000004979	NCT00000497_9_T1	PHENOTYPE	17	17	centers
NCT0000049710	NCT00000497_10_T0	GENE	8	8	had
NCT000004984	NCT00000498_4_T0	COMPOUND	12	12	sodium
NCT000004984	NCT00000498_4_T1	GENE	4	5	Group I
NCT000004985	NCT00000498_5_T0	GENE	5	5	II
NCT000004986	NCT00000498_6_T0	GENE	5	5	III
NCT000004987	NCT00000498_7_T0	GENE	10	10	II
NCT000004987	NCT00000498_7_T1	GENE	22	22	Hg
NCT000004988	NCT00000498_8_T0	PHENOTYPE	0	0	Secondary
NCT000004990	NCT00000499_0_T0	GENE	7	7	Pilot
NCT000004990	NCT00000499_0_T1	GENE	6	6	SHEP
NCT000004990	NCT00000499_0_T2	PHENOTYPE	0	1	Systolic Hypertension
NCT000004992	NCT00000499_2_T0	PHENOTYPE	20	20	recruitment
NCT0000049914	NCT00000499_14_T0	PHENOTYPE	7	8	systolic hypertension
NCT0000049915	NCT00000499_15_T0	PHENOTYPE	15	16	systolic hypertension
NCT0000049917	NCT00000499_17_T0	GENE	2	2	had
NCT0000049917	NCT00000499_17_T1	PHENOTYPE	10	11	systolic hypertension
NCT0000049918	NCT00000499_18_T0	PHENOTYPE	13	13	Hypertension
NCT0000049918	NCT00000499_18_T1	PHENOTYPE	58	58	Stroke
NCT0000049918	NCT00000499_18_T2	BIOLOGICAL_PROCESS	8	8	Aging
NCT0000049918	NCT00000499_18_T3	BIOLOGICAL_PROCESS	41	41	Aging
NCT0000049918	NCT00000499_18_T4	PHENOTYPE	46	47	Mental Health
NCT0000049918	NCT00000499_18_T5	PHENOTYPE	55	56	Communicative Disorders
NCT0000049918	NCT00000499_18_T6	PHENOTYPE	22	24	High Blood Pressure
NCT0000049918	NCT00000499_18_T7	PHENOTYPE	32	34	High Blood Pressure
NCT0000049924	NCT00000499_24_T0	COMPOUND	12	12	chlorthalidone
NCT0000049925	NCT00000499_25_T0	COMPOUND	24	24	hydralazine
NCT0000049925	NCT00000499_25_T1	COMPOUND	26	26	metoprolol
NCT0000049925	NCT00000499_25_T2	COMPOUND	22	22	chlorthalidone
NCT0000049925	NCT00000499_25_T3	COMPOUND	23	23	reserpine
NCT0000049926	NCT00000499_26_T0	GENE	15	15	II
NCT0000049926	NCT00000499_26_T1	GENE	11	11	had
NCT0000049928	NCT00000499_28_T0	PHENOTYPE	1	2	systolic hypertension
NCT000005006	NCT00000500_6_T0	PHENOTYPE	10	10	inhibition
NCT000005006	NCT00000500_6_T1	CELL	12	12	platelet
NCT000005006	NCT00000500_6_T2	PHENOTYPE	15	17	prolonged bleeding time
NCT000005007	NCT00000500_7_T0	GENE	16	16	had
NCT0000050010	NCT00000500_10_T0	BIOLOGICAL_PROCESS	24	24	beta-carotene
NCT0000050010	NCT00000500_10_T1	BIOLOGICAL_PROCESS	35	35	beta-carotene
NCT0000050010	NCT00000500_10_T2	BIOLOGICAL_PROCESS	49	49	beta-carotene
NCT0000050010	NCT00000500_10_T3	BIOLOGICAL_PROCESS	63	63	beta-carotene
NCT0000050010	NCT00000500_10_T4	COMPOUND	12	12	aspirin
NCT0000050010	NCT00000500_10_T5	COMPOUND	26	26	aspirin
NCT0000050010	NCT00000500_10_T6	COMPOUND	38	38	aspirin
NCT0000050010	NCT00000500_10_T7	COMPOUND	52	52	aspirin
NCT0000050013	NCT00000500_13_T0	PHENOTYPE	4	5	myocardial infarction
NCT0000050013	NCT00000500_13_T1	PHENOTYPE	8	9	renal disease
NCT0000050014	NCT00000500_14_T0	BIOLOGICAL_PROCESS	5	5	beta-carotene
NCT0000050014	NCT00000500_14_T1	COMPOUND	3	3	aspirin
NCT000005012	NCT00000501_2_T0	GENE	3	3	l5
NCT000005013	NCT00000501_3_T0	PHENOTYPE	5	5	Hypertension
NCT000005014	NCT00000501_4_T0	PHENOTYPE	18	18	hypertension
NCT000005014	NCT00000501_4_T1	PHENOTYPE	33	33	tolerance
NCT000005014	NCT00000501_4_T2	PHENOTYPE	11	13	High Blood Pressure
NCT000005017	NCT00000501_7_T0	PHENOTYPE	13	13	hypertension
NCT000005018	NCT00000501_8_T0	PHENOTYPE	13	13	hypertension
NCT0000050110	NCT00000501_10_T0	PHENOTYPE	3	3	obesity
NCT0000050110	NCT00000501_10_T1	PHENOTYPE	5	7	elevated blood pressure
NCT0000050111	NCT00000501_11_T0	GENE	5	5	had
NCT0000050111	NCT00000501_11_T1	PHENOTYPE	10	11	weight reduction
NCT0000050112	NCT00000501_12_T0	GENE	25	25	HPT
NCT0000050112	NCT00000501_12_T1	PHENOTYPE	8	9	weight reduction
NCT0000050113	NCT00000501_13_T0	GENE	4	4	had
NCT0000050114	NCT00000501_14_T0	COMPOUND	6	6	sodium
NCT0000050114	NCT00000501_14_T1	PHENOTYPE	9	9	hypertension
NCT0000050115	NCT00000501_15_T0	COMPOUND	16	16	sodium
NCT0000050116	NCT00000501_16_T0	PHENOTYPE	4	4	hypertension
NCT0000050117	NCT00000501_17_T0	COMPOUND	8	8	sodium
NCT0000050117	NCT00000501_17_T1	GENE	16	16	had
NCT0000050118	NCT00000501_18_T0	GENE	5	5	fell
NCT0000050118	NCT00000501_18_T1	COMPOUND	12	12	sodium
NCT0000050118	NCT00000501_18_T2	GENE	15	15	reduced
NCT0000050119	NCT00000501_19_T0	COMPOUND	2	2	sodium
NCT0000050119	NCT00000501_19_T1	GENE	26	26	had
NCT0000050122	NCT00000501_22_T0	COMPOUND	8	8	sodium
NCT0000050122	NCT00000501_22_T1	COMPOUND	10	10	potassium
NCT0000050122	NCT00000501_22_T2	GENE	1	1	has
NCT0000050123	NCT00000501_23_T0	COMPOUND	4	4	potassium
NCT0000050123	NCT00000501_23_T1	GENE	19	19	HPT
NCT0000050126	NCT00000501_26_T0	PHENOTYPE	21	21	Center
NCT0000050126	NCT00000501_26_T1	PHENOTYPE	11	11	centers
NCT0000050128	NCT00000501_28_T0	COMPOUND	21	21	sodium
NCT0000050128	NCT00000501_28_T1	COMPOUND	23	23	potassium
NCT0000050128	NCT00000501_28_T2	PHENOTYPE	18	18	recruitment
NCT0000050129	NCT00000501_29_T0	PHENOTYPE	5	5	centers
NCT0000050130	NCT00000501_30_T0	PHENOTYPE	25	25	Center
NCT0000050132	NCT00000501_32_T0	PHENOTYPE	0	0	Recruitment
NCT0000050137	NCT00000501_37_T0	PHENOTYPE	10	10	recruitment
NCT0000050139	NCT00000501_39_T0	GENE	8	8	Hg
NCT000005024	NCT00000502_4_T0	GENE	23	23	EMS
NCT000005024	NCT00000502_4_T1	GENE	25	25	has
NCT000005024	NCT00000502_4_T2	PHENOTYPE	4	5	ventricular fibrillation
NCT000005026	NCT00000502_6_T0	GENE	6	6	CPR
NCT000005026	NCT00000502_6_T1	GENE	33	33	CPR
NCT0000050210	NCT00000502_10_T0	GENE	13	13	CPR
NCT0000050210	NCT00000502_10_T1	GENE	28	28	CPR
NCT0000050210	NCT00000502_10_T2	PHENOTYPE	7	7	ventilation
NCT0000050210	NCT00000502_10_T3	ORGAN	20	21	radial artery
NCT0000050212	NCT00000502_12_T0	PHENOTYPE	10	10	ventilation
NCT0000050213	NCT00000502_13_T0	GENE	7	7	CPR
NCT0000050213	NCT00000502_13_T1	GENE	8	8	had
NCT0000050216	NCT00000502_16_T0	GENE	19	19	CPR
NCT0000050216	NCT00000502_16_T1	GENE	12	12	had
NCT0000050217	NCT00000502_17_T0	GENE	10	10	CPR
NCT0000050218	NCT00000502_18_T0	GENE	7	7	CPR
NCT0000050218	NCT00000502_18_T1	GENE	14	14	CPR
NCT0000050219	NCT00000502_19_T0	GENE	10	10	CPR
NCT0000050220	NCT00000502_20_T0	GENE	9	9	CPR
NCT0000050220	NCT00000502_20_T1	GENE	17	17	CPR
NCT0000050221	NCT00000502_21_T0	GENE	2	2	CPR
NCT0000050221	NCT00000502_21_T1	GENE	10	10	CPR
NCT0000050223	NCT00000502_23_T0	GENE	13	13	QVR
NCT000005032	NCT00000503_2_T0	PHENOTYPE	2	2	spasm
NCT000005032	NCT00000503_2_T1	ORGAN	6	6	arteries
NCT000005032	NCT00000503_2_T2	PHENOTYPE	5	5	occluded
NCT000005032	NCT00000503_2_T3	GENE	7	7	has
NCT000005033	NCT00000503_3_T0	PHENOTYPE	19	19	obstruction
NCT000005034	NCT00000503_4_T0	PHENOTYPE	19	19	obstruction
NCT000005034	NCT00000503_4_T1	PHENOTYPE	15	15	infarct
NCT000005035	NCT00000503_5_T0	PHENOTYPE	6	6	spasm
NCT000005035	NCT00000503_5_T1	PHENOTYPE	10	11	coronary thrombosis
NCT000005036	NCT00000503_6_T0	PHENOTYPE	13	13	concentrations
NCT000005036	NCT00000503_6_T1	PHENOTYPE	8	8	occluded
NCT000005038	NCT00000503_8_T0	PHENOTYPE	12	12	acute
NCT000005038	NCT00000503_8_T1	PHENOTYPE	0	0	Reperfusion
NCT000005038	NCT00000503_8_T2	PHENOTYPE	15	15	infarction
NCT000005038	NCT00000503_8_T3	GENE	3	3	has
NCT000005039	NCT00000503_9_T0	GENE	7	7	ventricular
NCT0000050310	NCT00000503_10_T0	PHENOTYPE	7	7	acute
NCT0000050310	NCT00000503_10_T1	PHENOTYPE	8	9	coronary occlusion
NCT0000050311	NCT00000503_11_T0	PHENOTYPE	0	0	Reperfusion
NCT0000050311	NCT00000503_11_T1	GENE	5	5	has
NCT0000050311	NCT00000503_11_T2	GENE	18	18	ventricular
NCT0000050312	NCT00000503_12_T0	PHENOTYPE	10	10	symptoms
NCT0000050312	NCT00000503_12_T1	PHENOTYPE	13	13	reperfusion
NCT0000050312	NCT00000503_12_T2	GENE	3	3	ventricular
NCT0000050313	NCT00000503_13_T0	GENE	15	15	3.4
NCT0000050313	NCT00000503_13_T1	PHENOTYPE	11	11	reperfusion
NCT0000050315	NCT00000503_15_T0	COMPOUND	20	20	nitroglycerin
NCT0000050315	NCT00000503_15_T1	PHENOTYPE	10	10	reperfusion
NCT0000050315	NCT00000503_15_T2	PHENOTYPE	12	14	acute myocardial infarction
NCT0000050319	NCT00000503_19_T0	COMPOUND	7	7	heparin
NCT0000050319	NCT00000503_19_T1	COMPOUND	10	10	warfarin
NCT0000050321	NCT00000503_21_T0	GENE	13	13	QVR
NCT000005043	NCT00000504_3_T0	PHENOTYPE	16	17	ventricular arrhythmias
NCT000005044	NCT00000504_4_T0	PHENOTYPE	10	11	ventricular arrhythmias
NCT000005046	NCT00000504_6_T0	GENE	10	10	had
NCT000005046	NCT00000504_6_T1	PHENOTYPE	15	16	ventricular arrhythmias
NCT000005047	NCT00000504_7_T0	GENE	1	1	had
NCT000005047	NCT00000504_7_T1	PHENOTYPE	14	15	ventricular fibrillation
NCT000005048	NCT00000504_8_T0	GENE	1	1	had
NCT000005049	NCT00000504_9_T0	GENE	3	3	had
NCT0000050410	NCT00000504_10_T0	PHENOTYPE	22	22	arrhythmia
NCT0000050414	NCT00000504_14_T0	PHENOTYPE	1	1	recruitment
NCT0000050417	NCT00000504_17_T0	COMPOUND	14	14	encainide
NCT0000050417	NCT00000504_17_T1	COMPOUND	17	17	imipramine
NCT0000050417	NCT00000504_17_T2	COMPOUND	16	16	flecainide
NCT000005051	NCT00000505_1_T0	GENE	2	2	II
NCT000005051	NCT00000505_1_T1	GENE	7	7	rt-PA
NCT000005051	NCT00000505_1_T2	PHENOTYPE	14	16	acute myocardial infarction
NCT000005053	NCT00000505_3_T0	PHENOTYPE	12	12	thrombus
NCT000005053	NCT00000505_3_T1	PHENOTYPE	4	5	myocardial infarction
NCT000005054	NCT00000505_4_T0	GENE	8	8	rt-PA
NCT000005054	NCT00000505_4_T1	PHENOTYPE	21	21	occluded
NCT000005054	NCT00000505_4_T2	GENE	20	20	has
NCT000005054	NCT00000505_4_T3	PHENOTYPE	19	19	thrombus
NCT000005054	NCT00000505_4_T4	PHENOTYPE	23	23	infarct
NCT000005054	NCT00000505_4_T5	ORGAN	24	25	coronary artery
NCT000005055	NCT00000505_5_T0	PHENOTYPE	23	23	restenosis
NCT000005055	NCT00000505_5_T1	PHENOTYPE	39	39	complications
NCT000005055	NCT00000505_5_T2	PHENOTYPE	22	22	reocclusion
NCT000005055	NCT00000505_5_T3	PHENOTYPE	25	26	myocardial infarction
NCT000005057	NCT00000505_7_T0	GENE	10	10	24
NCT000005057	NCT00000505_7_T1	PHENOTYPE	22	22	Center
NCT000005057	NCT00000505_7_T2	PHENOTYPE	6	6	centers
NCT000005059	NCT00000505_9_T0	GENE	20	20	rt-PA
NCT000005059	NCT00000505_9_T1	GENE	22	22	1.5
NCT000005059	NCT00000505_9_T2	GENE	17	19	tissue-type plasminogen activator
NCT0000050512	NCT00000505_12_T0	GENE	20	20	rt-PA
NCT0000050512	NCT00000505_12_T1	PHENOTYPE	14	14	reperfusion
NCT0000050513	NCT00000505_13_T0	GENE	7	7	rt-PA
NCT0000050513	NCT00000505_13_T1	GENE	15	15	rt-PA
NCT0000050514	NCT00000505_14_T0	GENE	17	17	II
NCT0000050514	NCT00000505_14_T1	PHENOTYPE	13	13	initiation
NCT0000050515	NCT00000505_15_T0	GENE	23	23	rt-PA
NCT0000050517	NCT00000505_17_T0	PHENOTYPE	8	8	reocclusion
NCT0000050517	NCT00000505_17_T1	ORGAN	12	12	arteries
NCT0000050517	NCT00000505_17_T2	ORGAN	30	30	arteries
NCT0000050517	NCT00000505_17_T3	PHENOTYPE	11	11	infarct
NCT0000050517	NCT00000505_17_T4	PHENOTYPE	29	29	infarct
NCT0000050517	NCT00000505_17_T5	PHENOTYPE	34	34	recurrent
NCT0000050517	NCT00000505_17_T6	PHENOTYPE	35	36	myocardial infarction
NCT0000050518	NCT00000505_18_T0	GENE	21	21	rt-PA
NCT0000050518	NCT00000505_18_T1	PHENOTYPE	14	14	reperfusion
NCT0000050519	NCT00000505_19_T0	GENE	8	8	rt-PA
NCT0000050519	NCT00000505_19_T1	GENE	16	16	rt-PA
NCT0000050519	NCT00000505_19_T2	PHENOTYPE	3	3	complications
NCT0000050520	NCT00000505_20_T0	GENE	2	2	II
NCT0000050522	NCT00000505_22_T0	PHENOTYPE	7	7	recurrent
NCT0000050522	NCT00000505_22_T1	PHENOTYPE	8	9	myocardial infarction
NCT0000050523	NCT00000505_23_T0	GENE	21	21	rt-PA
NCT0000050527	NCT00000505_27_T0	PHENOTYPE	30	30	infarction
NCT0000050527	NCT00000505_27_T1	GENE	20	20	had
NCT0000050527	NCT00000505_27_T2	PHENOTYPE	24	25	myocardial ischemia
NCT0000050530	NCT00000505_30_T0	GENE	6	6	rt-PA
NCT0000050530	NCT00000505_30_T1	PHENOTYPE	14	16	acute myocardial infarction
NCT000005062	NCT00000506_2_T0	PHENOTYPE	14	14	hypertension
NCT000005062	NCT00000506_2_T1	PHENOTYPE	10	11	cardiovascular disease
NCT000005064	NCT00000506_4_T0	PHENOTYPE	16	16	overweight
NCT000005064	NCT00000506_4_T1	PHENOTYPE	9	9	hypertension
NCT000005068	NCT00000506_8_T0	PHENOTYPE	10	10	chronic
NCT0000050612	NCT00000506_12_T0	GENE	6	6	has
NCT0000050614	NCT00000506_14_T0	GENE	2	2	has
NCT0000050614	NCT00000506_14_T1	PHENOTYPE	9	10	adverse effects
NCT0000050615	NCT00000506_15_T0	PHENOTYPE	22	22	chronic
NCT0000050616	NCT00000506_16_T0	COMPOUND	22	22	phentermine
NCT0000050616	NCT00000506_16_T1	GENE	11	11	has
NCT0000050616	NCT00000506_16_T2	COMPOUND	20	20	fenfluramine
NCT0000050616	NCT00000506_16_T3	PHENOTYPE	30	31	weight loss
NCT0000050617	NCT00000506_17_T0	PHENOTYPE	12	12	anorectic
NCT0000050617	NCT00000506_17_T1	GENE	1	1	has
NCT0000050620	NCT00000506_20_T0	PHENOTYPE	5	5	tolerance
NCT0000050621	NCT00000506_21_T0	PHENOTYPE	23	24	weight loss
NCT0000050621	NCT00000506_21_T1	PHENOTYPE	28	29	weight loss
NCT0000050622	NCT00000506_22_T0	PHENOTYPE	15	15	obesity
NCT0000050623	NCT00000506_23_T0	COMPOUND	12	12	catecholamine
NCT0000050623	NCT00000506_23_T1	COMPOUND	5	5	phentermine
NCT0000050624	NCT00000506_24_T0	PHENOTYPE	12	12	tachycardia
NCT0000050624	NCT00000506_24_T1	PHENOTYPE	2	2	nervousness
NCT0000050624	NCT00000506_24_T2	PHENOTYPE	3	3	insomnia
NCT0000050624	NCT00000506_24_T3	MOLECULAR_FUNCTION	5	6	motor activity
NCT0000050627	NCT00000506_27_T0	PHENOTYPE	5	5	diarrhea
NCT0000050629	NCT00000506_29_T0	COMPOUND	19	19	phentermine
NCT0000050629	NCT00000506_29_T1	COMPOUND	17	17	fenfluramine
NCT0000050632	NCT00000506_32_T0	GENE	13	13	QVR
NCT000005072	NCT00000507_2_T0	GENE	2	2	1.4
NCT000005072	NCT00000507_2_T1	PHENOTYPE	4	5	heart attacks
NCT000005073	NCT00000507_3_T0	PHENOTYPE	9	9	infarct
NCT000005074	NCT00000507_4_T0	TISSUE	13	13	myocardium
NCT000005074	NCT00000507_4_T1	PHENOTYPE	3	3	reperfusion
NCT0000050712	NCT00000507_12_T0	COMPOUND	5	5	heparin
NCT0000050712	NCT00000507_12_T1	COMPOUND	7	7	warfarin
NCT0000050714	NCT00000507_14_T0	PHENOTYPE	0	0	Secondary
NCT0000050714	NCT00000507_14_T1	GENE	16	16	ventricular
NCT0000050714	NCT00000507_14_T2	PHENOTYPE	23	24	myocardial infarction
NCT0000050714	NCT00000507_14_T3	ORGAN	8	9	coronary artery
NCT000005082	NCT00000508_2_T0	PHENOTYPE	14	14	atherosclerosis
NCT000005084	NCT00000508_4_T0	ORGAN	10	10	arteries
NCT000005084	NCT00000508_4_T1	GENE	3	3	had
NCT000005087	NCT00000508_7_T0	GENE	4	4	had
NCT000005087	NCT00000508_7_T1	ORGAN	21	22	coronary artery
NCT000005089	NCT00000508_9_T0	GENE	20	20	SI
NCT000005089	NCT00000508_9_T1	GENE	11	11	UC
NCT0000050810	NCT00000508_10_T0	GENE	1	1	SI
NCT0000050810	NCT00000508_10_T1	PHENOTYPE	26	26	obesity
NCT0000050811	NCT00000508_11_T0	PHENOTYPE	9	10	disease progression
NCT0000050811	NCT00000508_11_T1	PHENOTYPE	7	9	coronary artery disease
NCT000005092	NCT00000509_2_T0	PHENOTYPE	12	12	hypertension
NCT000005094	NCT00000509_4_T0	COMPOUND	20	20	thiazide
NCT000005095	NCT00000509_5_T0	COMPOUND	12	12	sodium
NCT000005095	NCT00000509_5_T1	COMPOUND	30	30	potassium
NCT000005095	NCT00000509_5_T2	COMPOUND	27	27	calcium
NCT000005095	NCT00000509_5_T3	COMPOUND	28	28	magnesium
NCT000005095	NCT00000509_5_T4	PHENOTYPE	9	10	weight reduction
NCT000005097	NCT00000509_7_T0	COMPOUND	9	9	sodium
NCT000005097	NCT00000509_7_T1	COMPOUND	14	14	sodium
NCT000005097	NCT00000509_7_T2	COMPOUND	34	34	sodium
NCT000005097	NCT00000509_7_T3	COMPOUND	28	28	potassium
NCT000005098	NCT00000509_8_T0	PHENOTYPE	8	8	withdrawn
NCT000005104	NCT00000510_4_T0	GENE	32	32	bypass
NCT000005104	NCT00000510_4_T1	PHENOTYPE	1	1	restenosis
NCT000005104	NCT00000510_4_T2	PHENOTYPE	8	8	stenoses
NCT000005104	NCT00000510_4_T3	ORGAN	30	31	coronary artery
NCT000005105	NCT00000510_5_T0	TISSUE	8	8	endothelium
NCT000005105	NCT00000510_5_T1	PHENOTYPE	6	6	damages
NCT000005105	NCT00000510_5_T2	ORGAN	14	14	artery
NCT000005107	NCT00000510_7_T0	GENE	31	31	reduced
NCT000005107	NCT00000510_7_T1	GENE	1	1	had
NCT000005107	NCT00000510_7_T2	COMPOUND	5	5	dipyridamole
NCT000005107	NCT00000510_7_T3	PHENOTYPE	14	14	occlusion
NCT000005107	NCT00000510_7_T4	PHENOTYPE	33	33	occlusions
NCT000005107	NCT00000510_7_T5	COMPOUND	7	7	aspirin
NCT000005107	NCT00000510_7_T6	CELL	22	22	platelet
NCT000005107	NCT00000510_7_T7	PHENOTYPE	27	29	coronary artery disease
NCT000005108	NCT00000510_8_T0	PHENOTYPE	32	32	restenosis
NCT0000051010	NCT00000510_10_T0	COMPOUND	6	6	dipyridamole
NCT0000051010	NCT00000510_10_T1	COMPOUND	8	8	aspirin
NCT0000051011	NCT00000510_11_T0	GENE	13	13	QVR
NCT000005110	NCT00000511_0_T0	PHENOTYPE	5	5	Mild
NCT000005110	NCT00000511_0_T1	PHENOTYPE	6	6	Hypertension
NCT000005114	NCT00000511_4_T0	PHENOTYPE	10	10	hypotensive
NCT000005114	NCT00000511_4_T1	COMPOUND	17	18	linoleic acid
NCT000005115	NCT00000511_5_T0	PHENOTYPE	39	39	hypotensive
NCT000005115	NCT00000511_5_T1	PHENOTYPE	20	20	fed
NCT000005115	NCT00000511_5_T2	COMPOUND	32	33	linoleic acid
NCT000005116	NCT00000511_6_T0	COMPOUND	13	13	potassium
NCT000005116	NCT00000511_6_T1	COMPOUND	11	11	magnesium
NCT000005117	NCT00000511_7_T0	GENE	5	5	had
NCT000005119	NCT00000511_9_T0	COMPOUND	3	3	potassium
NCT000005119	NCT00000511_9_T1	COMPOUND	23	23	potassium
NCT000005119	NCT00000511_9_T2	PHENOTYPE	28	28	hypertension
NCT000005119	NCT00000511_9_T3	BIOLOGICAL_PROCESS	6	9	control of blood pressure
NCT0000051113	NCT00000511_13_T0	COMPOUND	3	3	1
NCT0000051116	NCT00000511_16_T0	COMPOUND	1	1	2
NCT0000051116	NCT00000511_16_T1	COMPOUND	15	15	potassium
NCT0000051116	NCT00000511_16_T2	COMPOUND	17	17	calcium
NCT0000051116	NCT00000511_16_T3	COMPOUND	13	13	magnesium
NCT0000051119	NCT00000511_19_T0	GENE	7	7	BP
NCT0000051120	NCT00000511_20_T0	GENE	13	13	QVR
NCT000005124	NCT00000512_4_T0	GENE	17	17	lipoprotein
NCT000005124	NCT00000512_4_T1	GENE	30	30	lipoprotein
NCT000005124	NCT00000512_4_T2	PHENOTYPE	18	19	cholesterol level
NCT000005124	NCT00000512_4_T3	PHENOTYPE	31	32	cholesterol level
NCT000005126	NCT00000512_6_T0	PHENOTYPE	21	21	atherogenesis
NCT000005126	NCT00000512_6_T1	PHENOTYPE	16	16	atherosclerosis
NCT000005126	NCT00000512_6_T2	PHENOTYPE	31	31	atherosclerosis
NCT000005126	NCT00000512_6_T3	PHENOTYPE	10	10	hyperlipidemia
NCT000005126	NCT00000512_6_T4	PHENOTYPE	19	19	insights
NCT000005126	NCT00000512_6_T5	PHENOTYPE	29	29	progression
NCT0000051210	NCT00000512_10_T0	PHENOTYPE	18	19	familial hypercholesterolemia
NCT0000051211	NCT00000512_11_T0	COMPOUND	27	27	niacin
NCT0000051211	NCT00000512_11_T1	COMPOUND	20	20	colestipol
NCT0000051211	NCT00000512_11_T2	COMPOUND	35	35	colestipol
NCT0000051211	NCT00000512_11_T3	COMPOUND	48	48	colestipol
NCT0000051211	NCT00000512_11_T4	GENE	51	51	LDL
NCT0000051211	NCT00000512_11_T5	COMPOUND	13	13	lovastatin
NCT0000051211	NCT00000512_11_T6	PHENOTYPE	52	53	cholesterol level
NCT0000051212	NCT00000512_12_T0	PHENOTYPE	10	10	severity
NCT0000051212	NCT00000512_12_T1	PHENOTYPE	15	15	proximal
NCT0000051212	NCT00000512_12_T2	ORGAN	16	17	coronary arteries
NCT000005133	NCT00000513_3_T0	PHENOTYPE	13	13	centers
NCT000005133	NCT00000513_3_T1	PHENOTYPE	17	17	DISH
NCT000005137	NCT00000513_7_T0	COMPOUND	9	9	sodium
NCT000005137	NCT00000513_7_T1	COMPOUND	13	13	potassium
NCT000005137	NCT00000513_7_T2	PHENOTYPE	6	7	weight loss
NCT000005138	NCT00000513_8_T0	COMPOUND	9	9	thiazide
NCT000005138	NCT00000513_8_T1	COMPOUND	7	7	atenolol
NCT000005138	NCT00000513_8_T2	COMPOUND	11	11	chlorthalidone
NCT0000051311	NCT00000513_11_T0	PHENOTYPE	8	9	psychological function
NCT0000051313	NCT00000513_13_T0	PHENOTYPE	5	6	weight loss
NCT0000051314	NCT00000513_14_T0	BIOLOGICAL_PROCESS	10	13	control of blood pressure
NCT0000051315	NCT00000513_15_T0	GENE	1	1	II
NCT0000051315	NCT00000513_15_T1	COMPOUND	10	10	sodium
NCT0000051315	NCT00000513_15_T2	PHENOTYPE	4	5	weight loss
NCT0000051316	NCT00000513_16_T0	BIOLOGICAL_PROCESS	4	7	control of blood pressure
NCT000005141	NCT00000514_1_T0	PHENOTYPE	1	1	secondary
NCT000005141	NCT00000514_1_T1	PHENOTYPE	28	28	chronic
NCT000005141	NCT00000514_1_T2	PHENOTYPE	44	44	quality-of-life
NCT000005141	NCT00000514_1_T3	PHENOTYPE	22	23	systolic hypertension
NCT000005141	NCT00000514_1_T4	PHENOTYPE	50	51	systolic hypertension
NCT000005141	NCT00000514_1_T5	PHENOTYPE	25	26	adverse effects
NCT000005145	NCT00000514_5_T0	GENE	9	9	2.0
NCT000005145	NCT00000514_5_T1	GENE	11	11	has
NCT000005147	NCT00000514_7_T0	PHENOTYPE	0	0	Recruitment
NCT0000051411	NCT00000514_11_T0	COMPOUND	22	22	atenolol
NCT0000051411	NCT00000514_11_T1	COMPOUND	12	12	chlorthalidone
NCT0000051411	NCT00000514_11_T2	COMPOUND	28	28	reserpine
NCT0000051412	NCT00000514_12_T0	GENE	13	13	Hg
NCT0000051412	NCT00000514_12_T1	GENE	21	21	Hg
NCT0000051414	NCT00000514_14_T0	PHENOTYPE	0	0	Secondary
NCT0000051414	NCT00000514_14_T1	PHENOTYPE	12	12	quality-of-life
NCT000005151	NCT00000515_1_T0	PHENOTYPE	0	0	Secondary
NCT000005151	NCT00000515_1_T1	PHENOTYPE	13	14	weight loss
NCT000005155	NCT00000515_5_T0	GENE	33	33	reduced
NCT000005155	NCT00000515_5_T1	PHENOTYPE	23	23	hypertension
NCT000005155	NCT00000515_5_T2	PHENOTYPE	13	14	weight reduction
NCT0000051511	NCT00000515_11_T0	PHENOTYPE	11	12	weight loss
NCT0000051513	NCT00000515_13_T0	GENE	10	10	Hg
NCT0000051514	NCT00000515_14_T0	GENE	13	13	QVR
NCT000005163	NCT00000516_3_T0	PHENOTYPE	4	6	congestive heart failure
NCT000005164	NCT00000516_4_T0	PHENOTYPE	6	6	hypertension
NCT000005164	NCT00000516_4_T1	PHENOTYPE	28	29	heart failure
NCT000005164	NCT00000516_4_T2	PHENOTYPE	7	9	coronary artery disease
NCT000005164	NCT00000516_4_T3	PHENOTYPE	16	18	valvular heart disease
NCT000005165	NCT00000516_5_T0	GENE	6	6	has
NCT000005165	NCT00000516_5_T1	PHENOTYPE	3	5	congestive heart failure
NCT000005166	NCT00000516_6_T0	PHENOTYPE	12	12	acute
NCT000005166	NCT00000516_6_T1	PHENOTYPE	14	17	chronic congestive heart failure
NCT000005167	NCT00000516_7_T0	PHENOTYPE	9	9	secondary
NCT000005167	NCT00000516_7_T1	PHENOTYPE	7	8	heart failure
NCT000005167	NCT00000516_7_T2	PHENOTYPE	11	13	ischemic heart disease
NCT000005167	NCT00000516_7_T3	PHENOTYPE	19	21	left ventricular failure
NCT000005168	NCT00000516_8_T0	PHENOTYPE	3	3	acute
NCT000005168	NCT00000516_8_T1	PHENOTYPE	26	27	heart failure
NCT000005169	NCT00000516_9_T0	GENE	2	2	mid
NCT0000051611	NCT00000516_11_T0	GENE	5	5	had
NCT0000051611	NCT00000516_11_T1	PHENOTYPE	19	21	chronic heart failure
NCT0000051612	NCT00000516_12_T0	PHENOTYPE	5	7	congestive heart failure
NCT0000051612	NCT00000516_12_T1	PHENOTYPE	11	13	peripheral vascular resistance
NCT0000051613	NCT00000516_13_T0	PHENOTYPE	31	31	symptoms
NCT0000051613	NCT00000516_13_T1	GENE	6	6	ACE
NCT0000051613	NCT00000516_13_T2	GENE	16	16	had
NCT0000051613	NCT00000516_13_T3	GENE	4	5	angiotensin-converting enzyme
NCT0000051613	NCT00000516_13_T4	PHENOTYPE	33	34	cardiac dilatation
NCT0000051613	NCT00000516_13_T5	PHENOTYPE	36	37	myocardial infarction
NCT0000051614	NCT00000516_14_T0	GENE	15	15	ACE
NCT0000051614	NCT00000516_14_T1	COMPOUND	11	11	enalapril
NCT0000051614	NCT00000516_14_T2	GENE	13	14	angiotensin-converting enzyme
NCT0000051615	NCT00000516_15_T0	GENE	18	18	had
NCT0000051615	NCT00000516_15_T1	GENE	58	58	axis
NCT0000051615	NCT00000516_15_T2	PHENOTYPE	33	35	left ventricular dysfunction
NCT0000051615	NCT00000516_15_T3	PHENOTYPE	20	22	congestive heart failure
NCT0000051617	NCT00000516_17_T0	PHENOTYPE	8	8	centers
NCT0000051619	NCT00000516_19_T0	COMPOUND	6	6	enalapril
NCT0000051620	NCT00000516_20_T0	COMPOUND	10	10	enalapril
NCT0000051620	NCT00000516_20_T1	PHENOTYPE	23	23	centers
NCT0000051625	NCT00000516_25_T0	PHENOTYPE	0	0	Secondary
NCT0000051625	NCT00000516_25_T1	PHENOTYPE	5	6	sudden death
NCT0000051625	NCT00000516_25_T2	PHENOTYPE	18	19	myocardial infarction
NCT0000051625	NCT00000516_25_T3	PHENOTYPE	10	12	congestive heart failure
NCT0000051625	NCT00000516_25_T4	PHENOTYPE	15	17	congestive heart failure
NCT0000051625	NCT00000516_25_T5	PHENOTYPE	26	28	quality of life
NCT0000051626	NCT00000516_26_T0	PHENOTYPE	0	0	Onset
NCT0000051626	NCT00000516_26_T1	PHENOTYPE	2	4	congestive heart failure
NCT0000051627	NCT00000516_27_T0	PHENOTYPE	19	20	sudden death
NCT0000051627	NCT00000516_27_T1	PHENOTYPE	15	17	quality of life
NCT0000051628	NCT00000516_28_T0	PHENOTYPE	1	1	recruitment
NCT0000051629	NCT00000516_29_T0	PHENOTYPE	0	0	Recruitment
NCT0000051630	NCT00000516_30_T0	PHENOTYPE	4	4	recruitment
NCT0000051633	NCT00000516_33_T0	PHENOTYPE	4	4	centers
NCT0000051634	NCT00000516_34_T0	GENE	11	11	45
NCT0000051634	NCT00000516_34_T1	PHENOTYPE	17	19	congestive heart failure
NCT000005172	NCT00000517_2_T0	GENE	14	14	had
NCT000005172	NCT00000517_2_T1	PHENOTYPE	8	9	atrial fibrillation
NCT000005172	NCT00000517_2_T2	PHENOTYPE	11	13	rheumatic heart disease
NCT000005173	NCT00000517_3_T0	PHENOTYPE	46	46	arrhythmia
NCT000005173	NCT00000517_3_T1	PHENOTYPE	13	14	atrial fibrillation
NCT000005173	NCT00000517_3_T2	PHENOTYPE	40	41	atrial fibrillation
NCT000005173	NCT00000517_3_T3	PHENOTYPE	21	22	valvular disease
NCT000005173	NCT00000517_3_T4	PHENOTYPE	31	32	valvular disease
NCT000005174	NCT00000517_4_T0	PHENOTYPE	17	17	anticoagulation
NCT000005174	NCT00000517_4_T1	PHENOTYPE	19	19	fibrillating
NCT000005174	NCT00000517_4_T2	PHENOTYPE	22	23	valvular disease
NCT000005175	NCT00000517_5_T0	PHENOTYPE	15	15	anticoagulation
NCT000005175	NCT00000517_5_T1	PHENOTYPE	29	30	atrial fibrillation
NCT000005176	NCT00000517_6_T0	PHENOTYPE	17	17	bleeding
NCT000005176	NCT00000517_6_T1	PHENOTYPE	6	6	hemorrhages
NCT000005176	NCT00000517_6_T2	PHENOTYPE	11	11	complications
NCT000005176	NCT00000517_6_T3	ORGAN	1	2	urinary tract
NCT000005176	NCT00000517_6_T4	PHENOTYPE	22	23	cerebral infarction
NCT000005176	NCT00000517_6_T5	PHENOTYPE	14	15	cerebral hemorrhage
NCT000005177	NCT00000517_7_T0	PHENOTYPE	21	21	infarcts
NCT000005177	NCT00000517_7_T1	PHENOTYPE	6	6	complications
NCT000005177	NCT00000517_7_T2	PHENOTYPE	3	3	focused
NCT000005177	NCT00000517_7_T3	GENE	1	1	had
NCT000005177	NCT00000517_7_T4	PHENOTYPE	17	17	hemorrhage
NCT000005178	NCT00000517_8_T0	PHENOTYPE	4	4	anticoagulation
NCT000005178	NCT00000517_8_T1	PHENOTYPE	33	34	intracerebral hemorrhage
NCT000005178	NCT00000517_8_T2	PHENOTYPE	19	20	hemorrhagic infarction
NCT0000051710	NCT00000517_10_T0	PHENOTYPE	0	0	Recruitment
NCT0000051711	NCT00000517_11_T0	COMPOUND	9	9	warfarin
NCT0000051713	NCT00000517_13_T0	GENE	3	3	2.2
NCT0000051714	NCT00000517_14_T0	PHENOTYPE	4	4	hemorrhage
NCT0000051716	NCT00000517_16_T0	PHENOTYPE	14	14	bleeding
NCT0000051716	NCT00000517_16_T1	PHENOTYPE	12	13	neurologic symptoms
NCT0000051720	NCT00000517_20_T0	GENE	1	2	Group I
NCT0000051721	NCT00000517_21_T0	GENE	2	2	II
NCT0000051722	NCT00000517_22_T0	GENE	1	1	III
NCT000005182	NCT00000518_2_T0	GENE	1	1	had
NCT000005183	NCT00000518_3_T0	GENE	19	19	had
NCT000005183	NCT00000518_3_T1	PHENOTYPE	17	18	sudden death
NCT000005185	NCT00000518_5_T0	PHENOTYPE	15	15	recurrent
NCT000005185	NCT00000518_5_T1	PHENOTYPE	16	17	ventricular tachycardia
NCT000005185	NCT00000518_5_T2	PHENOTYPE	34	35	ventricular tachycardia
NCT000005186	NCT00000518_6_T0	PHENOTYPE	2	3	ventricular tachycardia
NCT000005187	NCT00000518_7_T0	PHENOTYPE	13	13	EPS
NCT000005187	NCT00000518_7_T1	GENE	3	3	had
NCT000005187	NCT00000518_7_T2	PHENOTYPE	22	23	ventricular fibrillation
NCT000005187	NCT00000518_7_T3	PHENOTYPE	20	21	ventricular tachycardia
NCT000005188	NCT00000518_8_T0	PHENOTYPE	15	15	EPS
NCT000005188	NCT00000518_8_T1	GENE	7	7	ventricular
NCT000005188	NCT00000518_8_T2	PHENOTYPE	30	30	suppression
NCT000005188	NCT00000518_8_T3	PHENOTYPE	21	21	elimination
NCT000005188	NCT00000518_8_T4	PHENOTYPE	9	9	fibrillation
NCT000005188	NCT00000518_8_T5	PHENOTYPE	23	24	ventricular tachycardia
NCT000005188	NCT00000518_8_T6	PHENOTYPE	32	33	ventricular tachycardia
NCT000005189	NCT00000518_9_T0	PHENOTYPE	7	7	EPS
NCT0000051811	NCT00000518_11_T0	PHENOTYPE	4	4	EPS
NCT0000051811	NCT00000518_11_T1	BIOLOGICAL_PROCESS	18	20	response to drug
NCT0000051812	NCT00000518_12_T0	PHENOTYPE	19	19	elimination
NCT0000051812	NCT00000518_12_T1	PHENOTYPE	21	22	ventricular tachycardia
NCT0000051813	NCT00000518_13_T0	PHENOTYPE	19	19	EPS
NCT0000051813	NCT00000518_13_T1	PHENOTYPE	12	13	ventricular tachycardia
NCT0000051814	NCT00000518_14_T0	GENE	14	14	had
NCT0000051814	NCT00000518_14_T1	PHENOTYPE	6	7	ventricular tachycardia
NCT0000051814	NCT00000518_14_T2	PHENOTYPE	20	22	premature ventricular contractions
NCT0000051815	NCT00000518_15_T0	GENE	2	2	had
NCT0000051815	NCT00000518_15_T1	PHENOTYPE	14	15	ventricular ectopy
NCT0000051816	NCT00000518_16_T0	PHENOTYPE	4	4	EPS
NCT0000051817	NCT00000518_17_T0	GENE	20	20	ventricular
NCT0000051817	NCT00000518_17_T1	PHENOTYPE	22	22	fibrillation
NCT0000051826	NCT00000518_26_T0	GENE	9	9	had
NCT0000051827	NCT00000518_27_T0	PHENOTYPE	10	10	recurrence
NCT0000051827	NCT00000518_27_T1	PHENOTYPE	9	9	arrhythmia
NCT0000051827	NCT00000518_27_T2	PHENOTYPE	22	22	EPS
NCT000005193	NCT00000519_3_T0	PHENOTYPE	14	15	cardiovascular disease
NCT000005193	NCT00000519_3_T1	PHENOTYPE	11	12	weight loss
NCT000005195	NCT00000519_5_T0	PHENOTYPE	4	5	weight loss
NCT000005195	NCT00000519_5_T1	PHENOTYPE	10	11	weight loss
NCT000005203	NCT00000520_3_T0	PHENOTYPE	4	4	acute
NCT000005206	NCT00000520_6_T0	PHENOTYPE	0	2	Coronary artery aneurysms
NCT000005207	NCT00000520_7_T0	PHENOTYPE	14	14	complication
NCT000005207	NCT00000520_7_T1	GENE	5	5	had
NCT000005209	NCT00000520_9_T0	COMPOUND	30	30	aspirin
NCT0000052010	NCT00000520_10_T0	GENE	19	19	had
NCT0000052010	NCT00000520_10_T1	ORGAN	16	17	coronary artery
NCT0000052012	NCT00000520_12_T0	COMPOUND	11	11	aspirin
NCT0000052012	NCT00000520_12_T1	COMPOUND	42	42	aspirin
NCT0000052012	NCT00000520_12_T2	GENE	18	18	reduced
NCT0000052012	NCT00000520_12_T3	GENE	36	36	globulin
NCT0000052012	NCT00000520_12_T4	GENE	35	35	gamma
NCT0000052015	NCT00000520_15_T0	GENE	1	1	II
NCT0000052016	NCT00000520_16_T0	GENE	15	15	globulin
NCT0000052016	NCT00000520_16_T1	GENE	14	14	gamma
NCT0000052019	NCT00000520_19_T0	ORGAN	10	11	coronary artery
NCT000005212	NCT00000521_2_T0	PHENOTYPE	9	10	essential hypertension
NCT000005213	NCT00000521_3_T0	PHENOTYPE	32	32	hypertension
NCT000005214	NCT00000521_4_T0	GENE	3	3	had
NCT000005222	NCT00000522_2_T0	PHENOTYPE	17	17	hypertension
NCT000005222	NCT00000522_2_T1	PHENOTYPE	0	1	Weight loss
NCT000005225	NCT00000522_5_T0	GENE	14	14	has
NCT000005225	NCT00000522_5_T1	ORGAN	28	28	serum
NCT000005225	NCT00000522_5_T2	PHENOTYPE	10	10	hypertension
NCT000005229	NCT00000522_9_T0	GENE	11	11	II
NCT0000052211	NCT00000522_11_T0	COMPOUND	11	11	sodium
NCT0000052211	NCT00000522_11_T1	COMPOUND	12	12	chloride
NCT0000052211	NCT00000522_11_T2	PHENOTYPE	19	20	weight reduction
NCT0000052214	NCT00000522_14_T0	GENE	14	14	ventricular
NCT0000052214	NCT00000522_14_T1	PHENOTYPE	23	23	ischemia
NCT0000052214	NCT00000522_14_T2	PHENOTYPE	16	18	ventricular ectopic activity
NCT0000052214	NCT00000522_14_T3	PHENOTYPE	33	35	quality of life
NCT000005231	NCT00000523_1_T0	PHENOTYPE	3	3	strategies
NCT000005234	NCT00000523_4_T0	PHENOTYPE	5	5	strategies
NCT000005238	NCT00000523_8_T0	PHENOTYPE	12	13	heart disease
NCT000005239	NCT00000523_9_T0	COMPOUND	12	12	glucose
NCT000005239	NCT00000523_9_T1	GENE	14	14	insulin
NCT000005239	NCT00000523_9_T2	ORGAN	6	6	plasma
NCT000005239	NCT00000523_9_T3	MOLECULAR_FUNCTION	10	11	lipase activity
NCT000005239	NCT00000523_9_T4	PHENOTYPE	20	21	psychological stress
NCT0000052311	NCT00000523_11_T0	GENE	6	6	hormone
NCT000005243	NCT00000524_3_T0	PHENOTYPE	20	21	critically ill
NCT000005244	NCT00000524_4_T0	PHENOTYPE	16	16	myocarditis
NCT000005247	NCT00000524_7_T0	COMPOUND	7	7	cyclosporine
NCT000005247	NCT00000524_7_T1	COMPOUND	9	9	azathioprine
NCT000005247	NCT00000524_7_T2	COMPOUND	4	4	prednisone
NCT000005248	NCT00000524_8_T0	PHENOTYPE	10	12	ventricular ejection fraction
NCT000005249	NCT00000524_9_T0	PHENOTYPE	13	13	symptoms
NCT000005249	NCT00000524_9_T1	PHENOTYPE	0	0	Secondary
NCT000005249	NCT00000524_9_T2	PHENOTYPE	17	17	arrhythmias
NCT0000052410	NCT00000524_10_T0	GENE	13	13	QVR
NCT000005252	NCT00000525_2_T0	PHENOTYPE	2	2	Hypertension
NCT000005252	NCT00000525_2_T1	PHENOTYPE	21	21	toxic
NCT000005252	NCT00000525_2_T2	COMPOUND	24	24	hydrochlorothiazide
NCT000005252	NCT00000525_2_T3	PHENOTYPE	4	4	Arrhythmias
NCT000005254	NCT00000525_4_T0	COMPOUND	12	12	potassium
NCT000005254	NCT00000525_4_T1	COMPOUND	35	35	potassium
NCT000005254	NCT00000525_4_T2	COMPOUND	39	39	potassium
NCT000005254	NCT00000525_4_T3	COMPOUND	31	31	hydrochlorothiazide
NCT000005254	NCT00000525_4_T4	COMPOUND	32	32	hydrochlorothiazide
NCT000005254	NCT00000525_4_T5	COMPOUND	36	36	hydrochlorothiazide
NCT000005254	NCT00000525_4_T6	COMPOUND	45	45	chlorthalidone
NCT000005254	NCT00000525_4_T7	COMPOUND	14	14	magnesium
NCT000005254	NCT00000525_4_T8	COMPOUND	41	41	magnesium
NCT000005254	NCT00000525_4_T9	COMPOUND	42	44	hydrochlorothiazide and triamterene
NCT000005255	NCT00000525_5_T0	COMPOUND	15	15	potassium
NCT000005255	NCT00000525_5_T1	COMPOUND	17	17	magnesium
NCT000005255	NCT00000525_5_T2	ORGAN	12	12	serum
NCT000005255	NCT00000525_5_T3	PHENOTYPE	5	6	ventricular arrhythmias
NCT000005260	NCT00000526_0_T0	GENE	4	4	CAST
NCT000005260	NCT00000526_0_T1	PHENOTYPE	2	2	Suppression
NCT000005260	NCT00000526_0_T2	PHENOTYPE	0	1	Cardiac Arrhythmia
NCT000005263	NCT00000526_3_T0	PHENOTYPE	4	6	coronary heart disease
NCT000005264	NCT00000526_4_T0	PHENOTYPE	3	4	myocardial infarction
NCT000005265	NCT00000526_5_T0	PHENOTYPE	11	13	acute myocardial infarction
NCT000005266	NCT00000526_6_T0	PHENOTYPE	10	10	arrhythmia
NCT000005269	NCT00000526_9_T0	PHENOTYPE	6	6	acute
NCT000005269	NCT00000526_9_T1	GENE	15	15	had
NCT0000052611	NCT00000526_11_T0	GENE	9	9	had
NCT0000052611	NCT00000526_11_T1	GENE	18	18	had
NCT0000052612	NCT00000526_12_T0	GENE	7	7	ventricular
NCT0000052612	NCT00000526_12_T1	PHENOTYPE	22	23	sudden death
NCT0000052613	NCT00000526_13_T0	GENE	3	3	had
NCT0000052613	NCT00000526_13_T1	GENE	7	7	had
NCT0000052614	NCT00000526_14_T0	PHENOTYPE	16	17	ectopic beats
NCT0000052615	NCT00000526_15_T0	PHENOTYPE	12	13	adverse effects
NCT0000052616	NCT00000526_16_T0	PHENOTYPE	5	6	adverse effects
NCT0000052618	NCT00000526_18_T0	GENE	35	35	ventricular
NCT0000052618	NCT00000526_18_T1	PHENOTYPE	10	11	ventricular arrhythmia
NCT0000052619	NCT00000526_19_T0	COMPOUND	13	13	encainide
NCT0000052619	NCT00000526_19_T1	COMPOUND	16	16	imipramine
NCT0000052619	NCT00000526_19_T2	COMPOUND	15	15	flecainide
NCT0000052619	NCT00000526_19_T3	PHENOTYPE	1	2	Cardiac Arrhythmia
NCT0000052620	NCT00000526_20_T0	GENE	12	12	had
NCT0000052622	NCT00000526_22_T0	PHENOTYPE	6	6	recruitment
NCT0000052625	NCT00000526_25_T0	COMPOUND	24	24	moricizine
NCT0000052625	NCT00000526_25_T1	COMPOUND	21	21	encainide
NCT0000052625	NCT00000526_25_T2	PHENOTYPE	8	8	centers
NCT0000052625	NCT00000526_25_T3	COMPOUND	22	22	flecainide
NCT0000052625	NCT00000526_25_T4	PHENOTYPE	13	14	myocardial infarction
NCT0000052627	NCT00000526_27_T0	COMPOUND	18	18	moricizine
NCT0000052627	NCT00000526_27_T1	COMPOUND	11	11	encainide
NCT0000052627	NCT00000526_27_T2	COMPOUND	12	12	flecainide
NCT0000052628	NCT00000526_28_T0	COMPOUND	3	3	encainide
NCT0000052628	NCT00000526_28_T1	COMPOUND	5	5	flecainide
NCT0000052629	NCT00000526_29_T0	GENE	0	0	CAST
NCT0000052629	NCT00000526_29_T1	COMPOUND	4	4	moricizine
NCT0000052629	NCT00000526_29_T2	COMPOUND	18	18	moricizine
NCT0000052630	NCT00000526_30_T0	PHENOTYPE	16	16	secondary
NCT0000052630	NCT00000526_30_T1	PHENOTYPE	9	11	sudden cardiac death
NCT000005275	NCT00000527_5_T0	COMPOUND	18	18	dipyridamole
NCT000005275	NCT00000527_5_T1	COMPOUND	13	13	aspirin
NCT000005277	NCT00000527_7_T0	PHENOTYPE	12	12	restenosis
NCT000005282	NCT00000528_2_T0	PHENOTYPE	26	26	progressive
NCT000005282	NCT00000528_2_T1	PHENOTYPE	24	24	chronic
NCT000005282	NCT00000528_2_T2	PHENOTYPE	27	30	increase in blood pressure
NCT000005283	NCT00000528_3_T0	PHENOTYPE	17	17	hypertension
NCT000005285	NCT00000528_5_T0	PHENOTYPE	8	8	Hypertension
NCT000005287	NCT00000528_7_T0	PHENOTYPE	28	28	complications
NCT000005287	NCT00000528_7_T1	PHENOTYPE	30	30	hypertension
NCT000005287	NCT00000528_7_T2	PHENOTYPE	23	25	congestive heart failure
NCT000005289	NCT00000528_9_T0	PHENOTYPE	8	8	symptoms
NCT0000052810	NCT00000528_10_T0	PHENOTYPE	13	13	hypertension
NCT0000052811	NCT00000528_11_T0	PHENOTYPE	1	1	Hypertension
NCT0000052811	NCT00000528_11_T1	GENE	4	4	HPT
NCT0000052813	NCT00000528_13_T0	PHENOTYPE	16	16	hypertension
NCT0000052816	NCT00000528_16_T0	COMPOUND	11	11	potassium
NCT0000052816	NCT00000528_16_T1	GENE	2	2	has
NCT0000052817	NCT00000528_17_T0	GENE	8	8	has
NCT0000052825	NCT00000528_25_T0	PHENOTYPE	0	0	Recruitment
NCT0000052828	NCT00000528_28_T0	GENE	1	1	II
NCT0000052828	NCT00000528_28_T1	COMPOUND	15	15	sodium
NCT0000052828	NCT00000528_28_T2	GENE	2	2	had
NCT0000052828	NCT00000528_28_T3	PHENOTYPE	31	31	hypertension
NCT0000052828	NCT00000528_28_T4	PHENOTYPE	12	13	weight loss
NCT0000052830	NCT00000528_30_T0	GENE	7	7	fold
NCT0000052831	NCT00000528_31_T0	PHENOTYPE	0	0	Recruitment
NCT0000052834	NCT00000528_34_T0	ORGAN	9	9	Heart
NCT0000052835	NCT00000528_35_T0	GENE	2	2	II
NCT000005294	NCT00000529_4_T0	ORGAN	7	7	plasma
NCT000005294	NCT00000529_4_T1	COMPOUND	20	20	tamoxifen
NCT000005294	NCT00000529_4_T2	COMPOUND	37	37	tamoxifen
NCT000005294	NCT00000529_4_T3	PHENOTYPE	25	26	breast cancer
NCT000005295	NCT00000529_5_T0	COMPOUND	10	10	tamoxifen
NCT000005296	NCT00000529_6_T0	PHENOTYPE	6	8	invasive breast cancer
NCT000005297	NCT00000529_7_T0	PHENOTYPE	1	1	secondary
NCT000005297	NCT00000529_7_T1	PHENOTYPE	20	20	fractures
NCT000005297	NCT00000529_7_T2	PHENOTYPE	17	18	thromboembolic disease
NCT000005297	NCT00000529_7_T3	PHENOTYPE	12	14	coronary heart disease
NCT0000052911	NCT00000529_11_T0	COMPOUND	7	7	tamoxifen
NCT0000052914	NCT00000529_14_T0	PHENOTYPE	5	6	myocardial infarction
NCT0000052914	NCT00000529_14_T1	PHENOTYPE	8	9	myocardial infarction
NCT0000052914	NCT00000529_14_T2	PHENOTYPE	12	13	myocardial infarction
NCT000005302	NCT00000530_2_T0	PHENOTYPE	6	6	severity
NCT000005302	NCT00000530_2_T1	PHENOTYPE	26	28	quality of life
NCT000005306	NCT00000530_6_T0	GENE	15	15	blocker
NCT000005306	NCT00000530_6_T1	GENE	13	14	calcium channel
NCT000005312	NCT00000531_2_T0	PHENOTYPE	24	25	sudden death
NCT000005312	NCT00000531_2_T1	PHENOTYPE	4	5	cardiac deaths
NCT000005313	NCT00000531_3_T0	PHENOTYPE	7	8	cardiac deaths
NCT000005314	NCT00000531_4_T0	PHENOTYPE	16	16	tachycardia
NCT000005314	NCT00000531_4_T1	GENE	17	17	VT
NCT000005314	NCT00000531_4_T2	PHENOTYPE	12	13	ventricular fibrillation
NCT000005314	NCT00000531_4_T3	PHENOTYPE	4	5	cardiac deaths
NCT000005315	NCT00000531_5_T0	GENE	8	8	has
NCT000005315	NCT00000531_5_T1	PHENOTYPE	17	18	ventricular ectopy
NCT000005315	NCT00000531_5_T2	PHENOTYPE	5	7	sudden cardiac death
NCT000005316	NCT00000531_6_T0	PHENOTYPE	16	17	ventricular arrhythmia
NCT000005317	NCT00000531_7_T0	PHENOTYPE	21	21	arrhythmia
NCT000005317	NCT00000531_7_T1	PHENOTYPE	22	22	suppression
NCT000005319	NCT00000531_9_T0	GENE	33	33	VT
NCT000005319	NCT00000531_9_T1	PHENOTYPE	10	11	sudden death
NCT0000053110	NCT00000531_10_T0	GENE	3	3	has
NCT0000053113	NCT00000531_13_T0	PHENOTYPE	12	13	ventricular fibrillation
NCT0000053113	NCT00000531_13_T1	PHENOTYPE	9	10	ventricular tachycardia
NCT0000053114	NCT00000531_14_T0	PHENOTYPE	2	3	ventricular fibrillation
NCT0000053114	NCT00000531_14_T1	PHENOTYPE	6	7	ventricular tachycardia
NCT0000053117	NCT00000531_17_T0	PHENOTYPE	8	8	arrhythmia
NCT0000053117	NCT00000531_17_T1	PHENOTYPE	10	11	ventricular fibrillation
NCT0000053117	NCT00000531_17_T2	PHENOTYPE	13	14	ventricular tachycardia
NCT0000053118	NCT00000531_18_T0	COMPOUND	17	17	amiodarone
NCT0000053118	NCT00000531_18_T1	COMPOUND	11	11	sotalol
NCT0000053118	NCT00000531_18_T2	COMPOUND	19	19	sotalol
NCT0000053121	NCT00000531_21_T0	COMPOUND	5	5	amiodarone
NCT0000053122	NCT00000531_22_T0	COMPOUND	13	13	aspirin
NCT0000053122	NCT00000531_22_T1	GENE	10	11	angiotensin-converting enzyme
NCT0000053124	NCT00000531_24_T0	PHENOTYPE	0	0	Secondary
NCT0000053124	NCT00000531_24_T1	PHENOTYPE	8	10	quality of life
NCT0000053127	NCT00000531_27_T0	COMPOUND	24	24	amiodarone
NCT0000053130	NCT00000531_30_T0	COMPOUND	11	11	amiodarone
NCT0000053130	NCT00000531_30_T1	COMPOUND	9	9	sotalol
NCT0000053132	NCT00000531_32_T0	GENE	3	3	had
NCT000005321	NCT00000532_1_T0	COMPOUND	13	13	glucose
NCT000005321	NCT00000532_1_T1	GENE	12	12	insulin
NCT000005321	NCT00000532_1_T2	GENE	20	20	lipoprotein
NCT000005321	NCT00000532_1_T3	GENE	24	24	peri
NCT000005325	NCT00000532_5_T0	PHENOTYPE	5	6	weight loss
NCT000005327	NCT00000532_7_T0	GENE	12	12	LDL
NCT000005329	NCT00000532_9_T0	GENE	15	15	fibrinogen
NCT000005329	NCT00000532_9_T1	GENE	17	17	VIIc
NCT000005329	NCT00000532_9_T2	GENE	23	23	PAI-1
NCT000005329	NCT00000532_9_T3	ORGAN	25	25	plasma
NCT000005329	NCT00000532_9_T4	GENE	20	21	antithrombin III
NCT0000053211	NCT00000532_11_T0	GENE	26	26	4.5
NCT0000053211	NCT00000532_11_T1	GENE	7	7	extended
NCT000005335	NCT00000533_5_T0	PHENOTYPE	11	12	myocardial infarction
NCT0000053310	NCT00000533_10_T0	PHENOTYPE	11	12	myocardial infarction
NCT0000053312	NCT00000533_12_T0	PHENOTYPE	17	18	psychological symptoms
NCT0000053312	NCT00000533_12_T1	PHENOTYPE	18	20	symptoms of stress
NCT0000053316	NCT00000533_16_T0	COMPOUND	1	1	cortisol
NCT0000053317	NCT00000533_17_T0	PHENOTYPE	7	7	arrhythmias
NCT0000053317	NCT00000533_17_T1	PHENOTYPE	5	5	ischemia
NCT0000053317	NCT00000533_17_T2	PHENOTYPE	3	4	myocardial infarction
NCT000005343	NCT00000534_3_T0	PHENOTYPE	15	15	disorders
NCT000005343	NCT00000534_3_T1	COMPOUND	22	22	calcium
NCT000005344	NCT00000534_4_T0	COMPOUND	8	8	calcium
NCT000005344	NCT00000534_4_T1	PHENOTYPE	18	18	eclampsia
NCT000005345	NCT00000534_5_T0	PHENOTYPE	5	5	suffered
NCT000005345	NCT00000534_5_T1	PHENOTYPE	12	12	eclampsia
NCT000005346	NCT00000534_6_T0	COMPOUND	20	20	calcium
NCT000005346	NCT00000534_6_T1	COMPOUND	25	25	calcium
NCT000005347	NCT00000534_7_T0	GENE	3	3	has
NCT000005347	NCT00000534_7_T1	PHENOTYPE	10	11	kidney stones
NCT000005348	NCT00000534_8_T0	COMPOUND	7	7	calcium
NCT000005348	NCT00000534_8_T1	GENE	8	8	has
NCT000005349	NCT00000534_9_T0	COMPOUND	11	11	calcium
NCT000005349	NCT00000534_9_T1	PHENOTYPE	17	17	eclampsia
NCT0000053410	NCT00000534_10_T0	COMPOUND	20	20	calcium
NCT0000053410	NCT00000534_10_T1	PHENOTYPE	25	25	urolithiasis
NCT0000053413	NCT00000534_13_T0	COMPOUND	13	13	calcium
NCT0000053414	NCT00000534_14_T0	BIOLOGICAL_PROCESS	12	12	gestation
NCT0000053416	NCT00000534_16_T0	COMPOUND	22	22	creatinine
NCT0000053416	NCT00000534_16_T1	GENE	9	9	had
NCT0000053416	NCT00000534_16_T2	PHENOTYPE	19	20	serum calcium
NCT0000053417	NCT00000534_17_T0	BIOLOGICAL_PROCESS	12	12	gestation
NCT0000053419	NCT00000534_19_T0	PHENOTYPE	7	7	eclampsia
NCT0000053419	NCT00000534_19_T1	PHENOTYPE	8	8	eclampsia
NCT0000053419	NCT00000534_19_T2	PHENOTYPE	10	10	hypertension
NCT0000053419	NCT00000534_19_T3	PHENOTYPE	3	4	pregnancy hypertension
NCT0000053419	NCT00000534_19_T4	PHENOTYPE	5	6	pregnancy proteinuria
NCT0000053421	NCT00000534_21_T0	PHENOTYPE	4	5	renal calculi
NCT0000053422	NCT00000534_22_T0	PHENOTYPE	0	0	Recruitment
NCT000005351	NCT00000535_1_T0	BIOLOGICAL_PROCESS	8	8	Aging
NCT000005357	NCT00000535_7_T0	COMPOUND	18	18	sodium
NCT000005357	NCT00000535_7_T1	COMPOUND	24	24	sodium
NCT000005357	NCT00000535_7_T2	PHENOTYPE	4	4	overweight
NCT000005357	NCT00000535_7_T3	PHENOTYPE	16	17	weight loss
NCT000005357	NCT00000535_7_T4	PHENOTYPE	21	22	weight loss
NCT000005358	NCT00000535_8_T0	COMPOUND	15	15	sodium
NCT0000053510	NCT00000535_10_T0	PHENOTYPE	0	0	Withdrawal
NCT0000053511	NCT00000535_11_T0	PHENOTYPE	26	26	complication
NCT0000053511	NCT00000535_11_T1	GENE	10	10	Hg
NCT0000053512	NCT00000535_12_T0	PHENOTYPE	0	0	Recruitment
NCT0000053515	NCT00000535_15_T0	GENE	1	1	NIA
NCT0000053515	NCT00000535_15_T1	PHENOTYPE	9	9	centers
NCT000005362	NCT00000536_2_T0	COMPOUND	18	18	sodium
NCT000005362	NCT00000536_2_T1	GENE	2	2	had
NCT000005364	NCT00000536_4_T0	PHENOTYPE	13	14	urine sodium
NCT000005365	NCT00000536_5_T0	COMPOUND	17	17	sodium
NCT000005365	NCT00000536_5_T1	GENE	9	9	24
NCT000005365	NCT00000536_5_T2	GENE	20	20	had
NCT000005368	NCT00000536_8_T0	COMPOUND	24	24	norepinephrine
NCT000005368	NCT00000536_8_T1	COMPOUND	13	13	glucose
NCT000005368	NCT00000536_8_T2	GENE	15	15	insulin
NCT000005368	NCT00000536_8_T3	GENE	21	21	renin
NCT000005368	NCT00000536_8_T4	GENE	19	19	kallikrein
NCT000005368	NCT00000536_8_T5	ORGAN	20	20	serum
NCT000005368	NCT00000536_8_T6	ORGAN	23	23	plasma
NCT000005368	NCT00000536_8_T7	PHENOTYPE	11	12	glucose tolerance
NCT000005368	NCT00000536_8_T8	PHENOTYPE	16	17	insulin resistance
NCT000005369	NCT00000536_9_T0	COMPOUND	13	13	sodium
NCT000005369	NCT00000536_9_T1	COMPOUND	18	18	sodium
NCT000005369	NCT00000536_9_T2	COMPOUND	25	25	sodium
NCT0000053611	NCT00000536_11_T0	GENE	8	8	FY
NCT0000053611	NCT00000536_11_T1	GENE	3	3	extended
NCT000005372	NCT00000537_2_T0	PHENOTYPE	22	22	hypertension
NCT000005372	NCT00000537_2_T1	PHENOTYPE	10	11	cardiovascular disease
NCT000005373	NCT00000537_3_T0	PHENOTYPE	11	11	quality-of-life
NCT000005373	NCT00000537_3_T1	PHENOTYPE	8	9	adverse effects
NCT000005375	NCT00000537_5_T0	GENE	16	16	TM
NCT000005375	NCT00000537_5_T1	GENE	29	29	TM
NCT000005375	NCT00000537_5_T2	PHENOTYPE	40	40	quality-of-life
NCT000005376	NCT00000537_6_T0	GENE	9	9	TM
NCT000005376	NCT00000537_6_T1	PHENOTYPE	23	23	hypertension
NCT000005376	NCT00000537_6_T2	PHENOTYPE	40	40	quality-of-life
NCT000005376	NCT00000537_6_T3	GENE	0	0	Dr
NCT000005379	NCT00000537_9_T0	GENE	13	13	Hg
NCT000005379	NCT00000537_9_T1	GENE	20	20	Hg
NCT000005379	NCT00000537_9_T2	GENE	33	33	Hg
NCT0000053712	NCT00000537_12_T0	PHENOTYPE	22	22	quality-of-life
NCT0000053713	NCT00000537_13_T0	GENE	7	7	TM
NCT0000053715	NCT00000537_15_T0	PHENOTYPE	1	1	secondary
NCT0000053716	NCT00000537_16_T0	GENE	3	3	extended
NCT000005382	NCT00000538_2_T0	GENE	16	16	has
NCT000005382	NCT00000538_2_T1	PHENOTYPE	2	3	cholesterol levels
NCT000005384	NCT00000538_4_T0	PHENOTYPE	22	24	coronary heart disease
NCT000005385	NCT00000538_5_T0	GENE	16	16	has
NCT000005389	NCT00000538_9_T0	PHENOTYPE	19	19	atherosclerosis
NCT0000053813	NCT00000538_13_T0	GENE	1	1	bran
NCT0000053813	NCT00000538_13_T1	GENE	0	0	Oat
NCT0000053814	NCT00000538_14_T0	ORGAN	25	25	serum
NCT0000053814	NCT00000538_14_T1	PHENOTYPE	26	27	cholesterol levels
NCT0000053819	NCT00000538_19_T0	PHENOTYPE	2	2	complication
NCT0000053821	NCT00000538_21_T0	GENE	8	8	has
NCT0000053824	NCT00000538_24_T0	ORGAN	50	50	plasma
NCT0000053824	NCT00000538_24_T1	PHENOTYPE	51	52	cholesterol levels
NCT0000053825	NCT00000538_25_T0	GENE	21	21	lipoprotein
NCT0000053825	NCT00000538_25_T1	PHENOTYPE	20	20	obesity
NCT0000053826	NCT00000538_26_T0	ORGAN	21	21	plasma
NCT0000053829	NCT00000538_29_T0	GENE	37	37	lipoprotein
NCT0000053829	NCT00000538_29_T1	ORGAN	36	36	plasma
NCT0000053832	NCT00000538_32_T0	GENE	7	7	lipoprotein
NCT0000053832	NCT00000538_32_T1	GENE	19	19	lipoprotein
NCT0000053832	NCT00000538_32_T2	PHENOTYPE	26	27	high insulin
NCT0000053832	NCT00000538_32_T3	PHENOTYPE	27	28	insulin levels
NCT0000053833	NCT00000538_33_T0	GENE	0	0	DELTA
NCT0000053834	NCT00000538_34_T0	PHENOTYPE	21	21	centers
NCT000005392	NCT00000539_2_T0	PHENOTYPE	9	9	plaque
NCT000005392	NCT00000539_2_T1	PHENOTYPE	24	24	ulcerating
NCT000005392	NCT00000539_2_T2	GENE	11	11	has
NCT000005394	NCT00000539_4_T0	PHENOTYPE	11	13	peripheral arterial disease
NCT000005397	NCT00000539_7_T0	GENE	6	6	has
NCT000005397	NCT00000539_7_T1	PHENOTYPE	4	5	intermittent claudication
NCT000005398	NCT00000539_8_T0	PHENOTYPE	14	14	CVD
NCT000005398	NCT00000539_8_T1	PHENOTYPE	12	13	cardiovascular disease
NCT0000053911	NCT00000539_11_T0	GENE	6	6	has
NCT0000053911	NCT00000539_11_T1	PHENOTYPE	8	10	peripheral vascular disease
NCT0000053912	NCT00000539_12_T0	PHENOTYPE	24	24	hypertension
NCT0000053914	NCT00000539_14_T0	BIOLOGICAL_PROCESS	25	26	lipid modification
NCT0000053916	NCT00000539_16_T0	PHENOTYPE	19	19	atherosclerosis
NCT0000053916	NCT00000539_16_T1	PHENOTYPE	17	17	progression
NCT0000053918	NCT00000539_18_T0	PHENOTYPE	11	11	atherosclerosis
NCT0000053918	NCT00000539_18_T1	GENE	19	19	lipoprotein
NCT0000053918	NCT00000539_18_T2	COMPOUND	13	13	aspirin
NCT0000053918	NCT00000539_18_T3	CELL	2	2	platelet
NCT0000053918	NCT00000539_18_T4	PHENOTYPE	0	0	Inhibition
NCT0000053918	NCT00000539_18_T5	GENE	4	4	has
NCT0000053918	NCT00000539_18_T6	GENE	14	14	has
NCT0000053918	NCT00000539_18_T7	PHENOTYPE	8	9	slow progression
NCT0000053919	NCT00000539_19_T0	GENE	5	5	reduced
NCT0000053931	NCT00000539_31_T0	GENE	21	21	QVR
NCT000005400	NCT00000540_0_T0	ORGAN	3	3	Graft
NCT000005400	NCT00000540_0_T1	ORGAN	0	1	Coronary Artery
NCT000005403	NCT00000540_3_T0	GENE	9	9	has
NCT000005403	NCT00000540_3_T1	PHENOTYPE	6	8	sudden cardiac death
NCT000005404	NCT00000540_4_T0	GENE	16	16	structural
NCT000005404	NCT00000540_4_T1	PHENOTYPE	28	29	ventricular arrhythmia
NCT000005404	NCT00000540_4_T2	PHENOTYPE	17	18	heart disease
NCT000005404	NCT00000540_4_T3	PHENOTYPE	21	23	left ventricular dysfunction
NCT000005404	NCT00000540_4_T4	PHENOTYPE	4	6	sudden cardiac death
NCT000005409	NCT00000540_9_T0	PHENOTYPE	17	18	sudden death
NCT0000054010	NCT00000540_10_T0	PHENOTYPE	9	9	closed
NCT0000054010	NCT00000540_10_T1	GENE	7	7	has
NCT0000054016	NCT00000540_16_T0	PHENOTYPE	4	4	arrhythmia
NCT0000054016	NCT00000540_16_T1	COMPOUND	15	15	aspirin
NCT0000054016	NCT00000540_16_T2	PHENOTYPE	8	9	drug use
NCT0000054017	NCT00000540_17_T0	GENE	2	2	extended
NCT0000054017	NCT00000540_17_T1	PHENOTYPE	0	0	Recruitment
NCT0000054018	NCT00000540_18_T0	GENE	6	6	had
NCT0000054020	NCT00000540_20_T0	GENE	2	2	extended
NCT000005413	NCT00000541_3_T0	PHENOTYPE	10	11	cardiovascular disease
NCT000005421	NCT00000542_1_T0	GENE	17	17	reductase
NCT000005421	NCT00000542_1_T1	GENE	15	15	HMG
NCT000005421	NCT00000542_1_T2	ORGAN	11	11	serum
NCT000005424	NCT00000542_4_T0	PHENOTYPE	8	8	hypertension
NCT000005425	NCT00000542_5_T0	COMPOUND	32	32	thiazide
NCT000005425	NCT00000542_5_T1	PHENOTYPE	6	6	hypertension
NCT000005425	NCT00000542_5_T2	PHENOTYPE	19	19	hypertension
NCT000005425	NCT00000542_5_T3	PHENOTYPE	44	45	myocardial infarction
NCT000005425	NCT00000542_5_T4	PHENOTYPE	8	10	coronary heart disease
NCT000005425	NCT00000542_5_T5	PHENOTYPE	38	40	coronary heart disease
NCT000005426	NCT00000542_6_T0	COMPOUND	9	9	thiazide
NCT000005427	NCT00000542_7_T0	PHENOTYPE	11	13	coronary heart disease
NCT000005429	NCT00000542_9_T0	PHENOTYPE	13	13	hypertension
NCT0000054210	NCT00000542_10_T0	GENE	25	25	SHEP
NCT0000054210	NCT00000542_10_T1	GENE	30	30	reduced
NCT0000054210	NCT00000542_10_T2	PHENOTYPE	19	20	Systolic Hypertension
NCT0000054210	NCT00000542_10_T3	PHENOTYPE	38	40	coronary heart disease
NCT0000054211	NCT00000542_11_T0	GENE	14	14	ACE
NCT0000054211	NCT00000542_11_T1	COMPOUND	11	11	calcium
NCT0000054211	NCT00000542_11_T2	PHENOTYPE	23	23	chronic
NCT0000054213	NCT00000542_13_T0	COMPOUND	16	16	calcium
NCT0000054213	NCT00000542_13_T1	PHENOTYPE	11	13	High Blood Pressure
NCT0000054214	NCT00000542_14_T0	PHENOTYPE	25	25	hypertension
NCT0000054215	NCT00000542_15_T0	PHENOTYPE	18	18	hypertension
NCT0000054217	NCT00000542_17_T0	PHENOTYPE	10	12	coronary heart disease
NCT0000054218	NCT00000542_18_T0	GENE	24	24	had
NCT0000054218	NCT00000542_18_T1	COMPOUND	22	22	thiazide
NCT0000054218	NCT00000542_18_T2	GENE	11	11	MRC
NCT0000054218	NCT00000542_18_T3	PHENOTYPE	29	31	coronary heart disease
NCT0000054219	NCT00000542_19_T0	GENE	10	10	lipoprotein
NCT0000054219	NCT00000542_19_T1	GENE	11	11	LDL
NCT0000054219	NCT00000542_19_T2	PHENOTYPE	22	24	coronary heart disease
NCT0000054222	NCT00000542_22_T0	PHENOTYPE	34	34	judgement
NCT0000054223	NCT00000542_23_T0	PHENOTYPE	9	9	hypertension
NCT0000054223	NCT00000542_23_T1	PHENOTYPE	7	7	practices
NCT0000054226	NCT00000542_26_T0	PHENOTYPE	0	0	Secondary
NCT0000054226	NCT00000542_26_T1	PHENOTYPE	12	14	quality of life
NCT0000054227	NCT00000542_27_T0	GENE	50	50	HMG
NCT0000054227	NCT00000542_27_T1	COMPOUND	48	48	pravastatin
NCT0000054227	NCT00000542_27_T2	GENE	52	52	reductase
NCT0000054227	NCT00000542_27_T3	GENE	23	23	LDL
NCT0000054227	NCT00000542_27_T4	PHENOTYPE	24	25	cholesterol levels
NCT0000054227	NCT00000542_27_T5	PHENOTYPE	40	42	coronary heart disease
NCT0000054228	NCT00000542_28_T0	PHENOTYPE	0	0	Secondary
NCT0000054228	NCT00000542_28_T1	PHENOTYPE	17	18	heart disease
NCT0000054228	NCT00000542_28_T2	PHENOTYPE	8	9	myocardial infarction
NCT0000054228	NCT00000542_28_T3	PHENOTYPE	11	13	coronary heart disease
NCT0000054228	NCT00000542_28_T4	PHENOTYPE	24	26	quality of life
NCT0000054229	NCT00000542_29_T0	PHENOTYPE	0	0	Recruitment
NCT0000054231	NCT00000542_31_T0	PHENOTYPE	0	0	Recruitment
NCT000005430	NCT00000543_0_T0	PHENOTYPE	6	6	Hypertension
NCT000005433	NCT00000543_3_T0	COMPOUND	2	2	calcium
NCT000005433	NCT00000543_3_T1	COMPOUND	11	11	calcium
NCT000005433	NCT00000543_3_T2	GENE	5	5	renin
NCT000005433	NCT00000543_3_T3	COMPOUND	6	6	angiotensin
NCT000005433	NCT00000543_3_T4	BIOLOGICAL_PROCESS	3	3	metabolism
NCT000005434	NCT00000543_4_T0	COMPOUND	4	4	calcium
NCT000005434	NCT00000543_4_T1	PHENOTYPE	14	14	eclampsia
NCT000005434	NCT00000543_4_T2	BIOLOGICAL_PROCESS	27	27	vasoconstriction
NCT000005438	NCT00000543_8_T0	COMPOUND	13	13	calcium
NCT000005438	NCT00000543_8_T1	BIOLOGICAL_PROCESS	22	22	gestation
NCT000005442	NCT00000544_2_T0	COMPOUND	37	37	sodium
NCT000005442	NCT00000544_2_T1	GENE	31	31	reduced
NCT000005442	NCT00000544_2_T2	PHENOTYPE	25	25	hypertension
NCT000005442	NCT00000544_2_T3	PHENOTYPE	29	30	weight reduction
NCT000005442	NCT00000544_2_T4	PHENOTYPE	14	16	High Blood Pressure
NCT000005443	NCT00000544_3_T0	PHENOTYPE	7	7	associations
NCT000005443	NCT00000544_3_T1	COMPOUND	19	19	potassium
NCT000005443	NCT00000544_3_T2	COMPOUND	20	20	calcium
NCT000005443	NCT00000544_3_T3	COMPOUND	22	22	magnesium
NCT000005447	NCT00000544_7_T0	COMPOUND	21	21	calcium
NCT000005447	NCT00000544_7_T1	COMPOUND	20	20	potassium
NCT000005447	NCT00000544_7_T2	COMPOUND	23	23	magnesium
NCT000005447	NCT00000544_7_T3	PHENOTYPE	31	33	lower blood pressure
NCT000005448	NCT00000544_8_T0	COMPOUND	10	10	potassium
NCT000005448	NCT00000544_8_T1	COMPOUND	12	12	calcium
NCT000005448	NCT00000544_8_T2	PHENOTYPE	14	16	lower blood pressure
NCT000005449	NCT00000544_9_T0	COMPOUND	3	3	magnesium
NCT0000054414	NCT00000544_14_T0	PHENOTYPE	7	7	associations
NCT0000054414	NCT00000544_14_T1	PHENOTYPE	16	16	associations
NCT0000054417	NCT00000544_17_T0	PHENOTYPE	13	15	lower blood pressure
NCT0000054422	NCT00000544_22_T0	COMPOUND	38	38	calcium
NCT0000054422	NCT00000544_22_T1	COMPOUND	39	39	potassium
NCT0000054422	NCT00000544_22_T2	COMPOUND	55	55	potassium
NCT0000054422	NCT00000544_22_T3	PHENOTYPE	28	28	reflected
NCT0000054422	NCT00000544_22_T4	COMPOUND	41	41	magnesium
NCT0000054422	NCT00000544_22_T5	COMPOUND	56	56	magnesium
NCT0000054423	NCT00000544_23_T0	COMPOUND	3	3	calcium
NCT0000054424	NCT00000544_24_T0	GENE	17	17	had
NCT0000054425	NCT00000544_25_T0	COMPOUND	23	23	potassium
NCT0000054425	NCT00000544_25_T1	COMPOUND	22	22	calcium
NCT0000054425	NCT00000544_25_T2	COMPOUND	24	24	magnesium
NCT0000054425	NCT00000544_25_T3	GENE	17	17	had
NCT0000054426	NCT00000544_26_T0	COMPOUND	8	8	sodium
NCT0000054426	NCT00000544_26_T1	GENE	3	3	had
NCT0000054435	NCT00000544_35_T0	PHENOTYPE	11	11	Response
NCT0000054436	NCT00000544_36_T0	COMPOUND	20	20	homocysteine
NCT0000054436	NCT00000544_36_T1	COMPOUND	18	18	folate
NCT0000054436	NCT00000544_36_T2	ORGAN	17	17	plasma
NCT0000054436	NCT00000544_36_T3	PHENOTYPE	9	10	dose-response relationship
NCT0000054436	NCT00000544_36_T4	COMPOUND	13	14	folic acid
NCT0000054438	NCT00000544_38_T0	COMPOUND	13	14	folic acid
NCT000005457	NCT00000545_7_T0	GENE	9	9	has
NCT000005457	NCT00000545_7_T1	PHENOTYPE	5	5	obesity
NCT0000054510	NCT00000545_10_T0	PHENOTYPE	21	21	Obesity
NCT0000054510	NCT00000545_10_T1	GENE	13	13	Hoc
NCT0000054510	NCT00000545_10_T2	PHENOTYPE	23	24	Cardiovascular Disease
NCT0000054511	NCT00000545_11_T0	ORGAN	14	14	Heart
NCT0000054511	NCT00000545_11_T1	PHENOTYPE	21	21	obesity
NCT0000054514	NCT00000545_14_T0	GENE	3	3	has
NCT0000054515	NCT00000545_15_T0	PHENOTYPE	22	22	attitudes
NCT0000054515	NCT00000545_15_T1	PHENOTYPE	16	16	obesity
NCT0000054517	NCT00000545_17_T0	BIOLOGICAL_PROCESS	21	21	eating
NCT0000054517	NCT00000545_17_T1	PHENOTYPE	25	25	obesity
NCT0000054518	NCT00000545_18_T0	TISSUE	5	6	body fat
NCT0000054519	NCT00000545_19_T0	TISSUE	15	16	body fat
NCT0000054525	NCT00000545_25_T0	GENE	16	16	PBF
NCT0000054525	NCT00000545_25_T1	PHENOTYPE	4	4	centers
NCT0000054525	NCT00000545_25_T2	TISSUE	14	15	body fat
NCT0000054526	NCT00000545_26_T0	GENE	10	10	PBF
NCT000005460	NCT00000546_0_T0	PHENOTYPE	4	4	CVD
NCT000005463	NCT00000546_3_T0	PHENOTYPE	25	25	hypertension
NCT000005463	NCT00000546_3_T1	PHENOTYPE	7	9	hypertensive heart disease
NCT000005463	NCT00000546_3_T2	PHENOTYPE	0	2	Left ventricular hypertrophy
NCT000005464	NCT00000546_4_T0	GENE	1	1	has
NCT000005464	NCT00000546_4_T1	PHENOTYPE	3	3	chronic
NCT000005464	NCT00000546_4_T2	PHENOTYPE	12	12	hypertension
NCT000005464	NCT00000546_4_T3	PHENOTYPE	6	7	psychological stress
NCT000005464	NCT00000546_4_T4	PHENOTYPE	14	16	left ventricular hypertrophy
NCT000005465	NCT00000546_5_T0	PHENOTYPE	14	16	hypertensive heart disease
NCT000005466	NCT00000546_6_T0	PHENOTYPE	9	11	quality of life
NCT000005467	NCT00000546_7_T0	PHENOTYPE	11	12	transcendental meditation
NCT000005467	NCT00000546_7_T1	PHENOTYPE	17	19	hypertensive heart disease
NCT000005469	NCT00000546_9_T0	GENE	5	5	TM
NCT0000054611	NCT00000546_11_T0	PHENOTYPE	21	21	focused
NCT0000054611	NCT00000546_11_T1	PHENOTYPE	36	37	blood diseases
NCT0000054612	NCT00000546_12_T0	PHENOTYPE	13	13	Hypertension
NCT0000054617	NCT00000546_17_T0	GENE	6	6	FY
NCT0000054617	NCT00000546_17_T1	GENE	0	0	Dr
NCT0000054617	NCT00000546_17_T2	PHENOTYPE	23	25	coronary heart disease
NCT0000054619	NCT00000546_19_T0	GENE	12	12	TM
NCT0000054621	NCT00000546_21_T0	PHENOTYPE	4	4	CVD
NCT0000054621	NCT00000546_21_T1	PHENOTYPE	0	0	Secondary
NCT0000054621	NCT00000546_21_T2	PHENOTYPE	14	16	quality of life
NCT000005473	NCT00000547_3_T0	COMPOUND	22	22	enalapril
NCT000005473	NCT00000547_3_T1	PHENOTYPE	25	26	ventricular dysfunction
NCT000005476	NCT00000547_6_T0	COMPOUND	5	5	enalapril
NCT0000054710	NCT00000547_10_T0	PHENOTYPE	0	0	Secondary
NCT0000054710	NCT00000547_10_T1	PHENOTYPE	14	14	arrhythmias
NCT0000054710	NCT00000547_10_T2	PHENOTYPE	7	9	ventricular ejection fraction
NCT0000054711	NCT00000547_11_T0	COMPOUND	15	15	enalapril
NCT0000054713	NCT00000547_13_T0	GENE	21	21	QVR
NCT000005486	NCT00000548_6_T0	COMPOUND	16	17	nitric oxide
NCT000005486	NCT00000548_6_T1	PHENOTYPE	10	12	chronic lung disease
NCT000005488	NCT00000548_8_T0	PHENOTYPE	0	0	Secondary
NCT000005488	NCT00000548_8_T1	PHENOTYPE	5	5	ventilation
NCT000005488	NCT00000548_8_T2	COMPOUND	6	6	oxygen
NCT000005489	NCT00000548_9_T0	COMPOUND	21	22	nitric oxide
NCT0000054810	NCT00000548_10_T0	PHENOTYPE	2	2	inflammation
NCT0000054810	NCT00000548_10_T1	ORGAN	21	21	plasma
NCT0000054811	NCT00000548_11_T0	PHENOTYPE	10	10	toxicity
NCT0000054811	NCT00000548_11_T1	PHENOTYPE	15	15	bleeding
NCT0000054811	NCT00000548_11_T2	PHENOTYPE	31	32	necrotizing enterocolitis
NCT0000054811	NCT00000548_11_T3	PHENOTYPE	17	18	intraventricular hemorrhage
NCT0000054811	NCT00000548_11_T4	PHENOTYPE	33	35	retinopathy of prematurity
NCT0000054813	NCT00000548_13_T0	COMPOUND	13	14	nitric oxide
NCT0000054813	NCT00000548_13_T1	PHENOTYPE	20	23	disease of premature infants
NCT000005493	NCT00000549_3_T0	COMPOUND	1	1	estrogen
NCT000005493	NCT00000549_3_T1	PHENOTYPE	10	11	cardiovascular disease
NCT000005493	NCT00000549_3_T2	PHENOTYPE	19	21	coronary artery disease
NCT000005494	NCT00000549_4_T0	COMPOUND	7	7	estrogen
NCT000005494	NCT00000549_4_T1	COMPOUND	13	13	estrogen
NCT000005495	NCT00000549_5_T0	COMPOUND	23	23	estrogen
NCT000005495	NCT00000549_5_T1	COMPOUND	12	12	progesterone
NCT000005495	NCT00000549_5_T2	ORGAN	25	26	coronary arteries
NCT000005495	NCT00000549_5_T3	PHENOTYPE	15	16	endometrial hyperplasia
NCT000005496	NCT00000549_6_T0	COMPOUND	8	8	estrogen
NCT000005496	NCT00000549_6_T1	COMPOUND	44	44	estrogen
NCT000005496	NCT00000549_6_T2	PHENOTYPE	27	28	coronary atherosclerosis
NCT000005496	NCT00000549_6_T3	PHENOTYPE	13	15	coronary artery disease
NCT000005497	NCT00000549_7_T0	PHENOTYPE	14	14	recruitment
NCT000005499	NCT00000549_9_T0	COMPOUND	21	21	estrogen
NCT000005499	NCT00000549_9_T1	COMPOUND	27	27	estrogen
NCT000005499	NCT00000549_9_T2	PHENOTYPE	5	5	stenotic
NCT0000054911	NCT00000549_11_T0	PHENOTYPE	12	12	acute
NCT0000054911	NCT00000549_11_T1	TISSUE	16	16	endothelium
NCT0000054911	NCT00000549_11_T2	COMPOUND	13	13	estrogen
NCT0000054911	NCT00000549_11_T3	PHENOTYPE	0	0	Secondary
NCT0000054911	NCT00000549_11_T4	ORGAN	20	20	plasma
NCT0000054911	NCT00000549_11_T5	ORGAN	31	31	plasma
NCT0000054911	NCT00000549_11_T6	PHENOTYPE	10	10	chronic
NCT0000054911	NCT00000549_11_T7	MOLECULAR_FUNCTION	24	25	antioxidant activity
NCT0000054911	NCT00000549_11_T8	BIOLOGICAL_PROCESS	28	29	glucose metabolism
NCT000005501	NCT00000550_1_T0	GENE	15	15	EMS
NCT000005501	NCT00000550_1_T1	PHENOTYPE	23	23	AMI
NCT000005505	NCT00000550_5_T0	PHENOTYPE	8	8	symptoms
NCT000005506	NCT00000550_6_T0	PHENOTYPE	7	7	symptoms
NCT000005506	NCT00000550_6_T1	GENE	24	24	6.4
NCT000005506	NCT00000550_6_T2	PHENOTYPE	6	6	AMI
NCT000005507	NCT00000550_7_T0	PHENOTYPE	19	19	attributable
NCT000005507	NCT00000550_7_T1	GENE	0	0	EMS
NCT000005507	NCT00000550_7_T2	BIOLOGICAL_PROCESS	1	1	transport
NCT0000055010	NCT00000550_10_T0	PHENOTYPE	27	27	AMI
NCT0000055011	NCT00000550_11_T0	PHENOTYPE	8	8	symptoms
NCT0000055011	NCT00000550_11_T1	PHENOTYPE	7	7	AMI
NCT0000055013	NCT00000550_13_T0	GENE	11	11	had
NCT0000055015	NCT00000550_15_T0	GENE	25	25	EMS
NCT0000055018	NCT00000550_18_T0	PHENOTYPE	17	17	AMI
NCT0000055018	NCT00000550_18_T1	PHENOTYPE	13	15	symptoms and signs
NCT000005510	NCT00000551_0_T0	GENE	3	3	ACT
NCT000005513	NCT00000551_3_T0	PHENOTYPE	10	10	Hypertension
NCT000005513	NCT00000551_3_T1	PHENOTYPE	19	19	hypertension
NCT000005515	NCT00000551_5_T0	ORGAN	8	8	Heart
NCT000005515	NCT00000551_5_T1	PHENOTYPE	9	9	Association
NCT0000055111	NCT00000551_11_T0	GENE	5	5	has
NCT0000055111	NCT00000551_11_T1	PHENOTYPE	0	0	Recruitment
NCT0000055112	NCT00000551_12_T0	GENE	8	8	ACT
NCT0000055112	NCT00000551_12_T1	BIOLOGICAL_PROCESS	4	4	Aging
NCT0000055112	NCT00000551_12_T2	PHENOTYPE	16	17	arterial stiffness
NCT0000055113	NCT00000551_13_T0	GENE	1	1	NIA
NCT0000055113	NCT00000551_13_T1	PHENOTYPE	16	17	arterial stiffness
NCT000005520	NCT00000552_0_T0	PHENOTYPE	12	12	Shock
NCT000005520	NCT00000552_0_T1	PHENOTYPE	6	6	Occluded
NCT000005520	NCT00000552_0_T2	PHENOTYPE	9	10	Cardiogenic Shock
NCT000005523	NCT00000552_3_T0	GENE	4	4	has
NCT000005524	NCT00000552_4_T0	PHENOTYPE	11	12	cardiogenic shock
NCT000005524	NCT00000552_4_T1	PHENOTYPE	14	16	acute myocardial infarction
NCT000005526	NCT00000552_6_T0	GENE	5	5	III
NCT000005527	NCT00000552_7_T0	PHENOTYPE	9	10	myocardial infarction
NCT000005527	NCT00000552_7_T1	PHENOTYPE	5	7	left ventricular failure
NCT000005528	NCT00000552_8_T0	GENE	6	6	bypass
NCT0000055210	NCT00000552_10_T0	GENE	1	1	balloon
NCT0000055212	NCT00000552_12_T0	PHENOTYPE	0	0	Secondary
NCT0000055212	NCT00000552_12_T1	PHENOTYPE	12	14	quality of life
NCT0000055213	NCT00000552_13_T0	PHENOTYPE	11	12	myocardial infarction
NCT0000055213	NCT00000552_13_T1	PHENOTYPE	8	9	cardiogenic shock
NCT0000055214	NCT00000552_14_T0	GENE	2	2	has
NCT0000055214	NCT00000552_14_T1	GENE	4	4	extended
NCT0000055215	NCT00000552_15_T0	PHENOTYPE	19	19	acute
NCT0000055215	NCT00000552_15_T1	PHENOTYPE	23	24	cardiogenic shock
NCT0000055215	NCT00000552_15_T2	PHENOTYPE	13	15	quality of life
NCT0000055216	NCT00000552_16_T0	PHENOTYPE	70	70	complications
NCT0000055216	NCT00000552_16_T1	PHENOTYPE	41	42	disease course
NCT0000055216	NCT00000552_16_T2	PHENOTYPE	22	23	cardiogenic shock
NCT0000055216	NCT00000552_16_T3	PHENOTYPE	72	73	cardiogenic shock
NCT000005534	NCT00000553_4_T0	PHENOTYPE	11	11	imbalance
NCT000005534	NCT00000553_4_T1	GENE	26	26	HDL
NCT000005534	NCT00000553_4_T2	GENE	21	21	LDL
NCT000005534	NCT00000553_4_T3	ORGAN	18	19	arterial intima
NCT000005534	NCT00000553_4_T4	PHENOTYPE	2	4	coronary artery disease
NCT000005536	NCT00000553_6_T0	PHENOTYPE	44	44	atherogenesis
NCT000005536	NCT00000553_6_T1	GENE	14	14	HDL
NCT000005536	NCT00000553_6_T2	BIOLOGICAL_PROCESS	36	36	beta-carotene
NCT000005536	NCT00000553_6_T3	PHENOTYPE	18	20	coronary artery disease
NCT000005536	NCT00000553_6_T4	PHENOTYPE	39	41	coronary artery disease
NCT000005537	NCT00000553_7_T0	PHENOTYPE	11	13	coronary artery disease
NCT000005538	NCT00000553_8_T0	GENE	1	1	has
NCT000005538	NCT00000553_8_T1	PHENOTYPE	14	15	weight reduction
NCT000005538	NCT00000553_8_T2	BIOLOGICAL_PROCESS	9	11	response to exercise
NCT000005539	NCT00000553_9_T0	GENE	4	4	III
NCT0000055311	NCT00000553_11_T0	PHENOTYPE	24	24	strategies
NCT0000055314	NCT00000553_14_T0	GENE	20	20	bypass
NCT0000055314	NCT00000553_14_T1	PHENOTYPE	0	0	Secondary
NCT0000055314	NCT00000553_14_T2	PHENOTYPE	27	27	ischemia
NCT0000055314	NCT00000553_14_T3	PHENOTYPE	6	7	cardiac events
NCT0000055314	NCT00000553_14_T4	PHENOTYPE	9	10	cardiac death
NCT0000055314	NCT00000553_14_T5	PHENOTYPE	13	14	myocardial infarction
NCT0000055314	NCT00000553_14_T6	PHENOTYPE	15	16	cerebrovascular accident
NCT000005541	NCT00000554_1_T0	BIOLOGICAL_PROCESS	11	11	metabolism
NCT000005541	NCT00000554_1_T1	ORGAN	22	23	coronary arteries
NCT000005543	NCT00000554_3_T0	GENE	5	5	WISE
NCT000005543	NCT00000554_3_T1	PHENOTYPE	21	22	coronary disease
NCT000005543	NCT00000554_3_T2	PHENOTYPE	13	14	myocardial ischemia
NCT000005545	NCT00000554_5_T0	PHENOTYPE	0	2	Ischemic heart disease
NCT000005546	NCT00000554_6_T0	PHENOTYPE	2	4	ischemic heart disease
NCT000005546	NCT00000554_6_T1	PHENOTYPE	3	6	heart disease in women
NCT000005548	NCT00000554_8_T0	PHENOTYPE	14	15	myocardial ischemia
NCT0000055411	NCT00000554_11_T0	PHENOTYPE	12	12	acute
NCT0000055411	NCT00000554_11_T1	PHENOTYPE	10	10	chronic
NCT0000055411	NCT00000554_11_T2	PHENOTYPE	13	14	myocardial ischemia
NCT0000055413	NCT00000554_13_T0	PHENOTYPE	4	5	coronary atherosclerosis
NCT0000055416	NCT00000554_16_T0	PHENOTYPE	22	22	obstructions
NCT0000055416	NCT00000554_16_T1	PHENOTYPE	5	5	pathophysiology
NCT0000055416	NCT00000554_16_T2	PHENOTYPE	7	8	myocardial ischemia
NCT0000055418	NCT00000554_18_T0	TISSUE	1	1	endothelium
NCT0000055418	NCT00000554_18_T1	PHENOTYPE	12	12	thrombosis
NCT0000055423	NCT00000554_23_T0	GENE	7	7	WISE
NCT0000055423	NCT00000554_23_T1	PHENOTYPE	5	5	Syndrome
NCT0000055423	NCT00000554_23_T2	PHENOTYPE	4	4	Ischemia
NCT0000055423	NCT00000554_23_T3	PHENOTYPE	21	21	pathophysiology
NCT0000055423	NCT00000554_23_T4	PHENOTYPE	16	18	ischemic heart disease
NCT0000055424	NCT00000554_24_T0	GENE	0	0	WISE
NCT0000055424	NCT00000554_24_T1	PHENOTYPE	21	21	symptoms
NCT0000055424	NCT00000554_24_T2	PHENOTYPE	43	43	symptoms
NCT0000055424	NCT00000554_24_T3	PHENOTYPE	2	2	focused
NCT0000055424	NCT00000554_24_T4	PHENOTYPE	25	26	myocardial ischemia
NCT0000055424	NCT00000554_24_T5	PHENOTYPE	32	34	coronary artery disease
NCT0000055424	NCT00000554_24_T6	PHENOTYPE	14	16	ischemic heart disease
NCT0000055425	NCT00000554_25_T0	GENE	1	1	WISE
NCT0000055425	NCT00000554_25_T1	ORGAN	24	25	brachial artery
NCT0000055426	NCT00000554_26_T0	BIOLOGICAL_PROCESS	14	14	metabolism
NCT0000055429	NCT00000554_29_T0	GENE	1	1	II
NCT0000055429	NCT00000554_29_T1	GENE	2	2	has
NCT0000055430	NCT00000554_30_T0	PHENOTYPE	25	25	pathophysiology
NCT0000055430	NCT00000554_30_T1	GENE	1	1	WISE
NCT0000055430	NCT00000554_30_T2	PHENOTYPE	15	17	ischemic heart disease
NCT0000055430	NCT00000554_30_T3	PHENOTYPE	22	24	ischemic heart disease
NCT0000055431	NCT00000554_31_T0	GENE	2	2	has
NCT0000055432	NCT00000554_32_T0	GENE	36	36	WISE
NCT0000055432	NCT00000554_32_T1	GENE	0	0	Dr
NCT0000055433	NCT00000554_33_T0	PHENOTYPE	18	18	inflammation
NCT0000055433	NCT00000554_33_T1	GENE	0	0	Dr
NCT0000055433	NCT00000554_33_T2	PHENOTYPE	9	10	coronary disease
NCT0000055433	NCT00000554_33_T3	BIOLOGICAL_PROCESS	20	21	cytokine production
NCT0000055434	NCT00000554_34_T0	GENE	16	16	WISE
NCT0000055435	NCT00000554_35_T0	GENE	6	6	renin
NCT0000055435	NCT00000554_35_T1	COMPOUND	7	7	angiotensin
NCT0000055435	NCT00000554_35_T2	GENE	0	0	Dr
NCT0000055435	NCT00000554_35_T3	PHENOTYPE	12	12	dysfunction
NCT000005550	NCT00000555_0_T0	GENE	6	6	WAVE
NCT000005552	NCT00000555_2_T0	PHENOTYPE	7	7	atherosclerosis
NCT000005554	NCT00000555_4_T0	GENE	26	26	span
NCT000005554	NCT00000555_4_T1	PHENOTYPE	4	6	coronary artery disease
NCT000005557	NCT00000555_7_T0	PHENOTYPE	10	12	coronary artery disease
NCT000005557	NCT00000555_7_T1	PHENOTYPE	30	32	coronary artery disease
NCT000005558	NCT00000555_8_T0	PHENOTYPE	11	11	Atherosclerosis
NCT000005558	NCT00000555_8_T1	PHENOTYPE	21	23	coronary artery disease
NCT0000055510	NCT00000555_10_T0	GENE	50	50	hormone
NCT0000055511	NCT00000555_11_T0	GENE	13	13	hormone
NCT0000055512	NCT00000555_12_T0	GENE	9	9	hormone
NCT0000055512	NCT00000555_12_T1	GENE	14	14	hormone
NCT0000055512	NCT00000555_12_T2	GENE	24	24	hormone
NCT0000055513	NCT00000555_13_T0	COMPOUND	5	5	estrogen
NCT0000055513	NCT00000555_13_T1	COMPOUND	17	17	estrogen
NCT0000055514	NCT00000555_14_T0	COMPOUND	6	7	vitamin E
NCT0000055517	NCT00000555_17_T0	PHENOTYPE	0	0	Recruitment
NCT0000055519	NCT00000555_19_T0	GENE	12	12	WAVE
NCT0000055520	NCT00000555_20_T0	GENE	7	7	WAVE
NCT0000055520	NCT00000555_20_T1	GENE	8	8	has
NCT000005562	NCT00000556_2_T0	PHENOTYPE	2	3	atrial fibrillation
NCT000005566	NCT00000556_6_T0	GENE	20	20	met
NCT000005566	NCT00000556_6_T1	PHENOTYPE	17	18	Atrial Fibrillation
NCT0000055611	NCT00000556_11_T0	COMPOUND	8	8	warfarin
NCT0000055615	NCT00000556_15_T0	GENE	3	3	had
NCT0000055617	NCT00000556_17_T0	GENE	1	1	nodal
NCT0000055618	NCT00000556_18_T0	COMPOUND	10	10	amiodarone
NCT0000055618	NCT00000556_18_T1	COMPOUND	11	11	sotalol
NCT0000055618	NCT00000556_18_T2	PHENOTYPE	13	14	class I
NCT0000055622	NCT00000556_22_T0	GENE	21	21	II
NCT0000055623	NCT00000556_23_T0	GENE	2	2	II
NCT0000055623	NCT00000556_23_T1	COMPOUND	7	7	amiodarone
NCT0000055624	NCT00000556_24_T0	COMPOUND	3	3	amiodarone
NCT0000055624	NCT00000556_24_T1	COMPOUND	19	19	amiodarone
NCT0000055624	NCT00000556_24_T2	GENE	28	28	had
NCT0000055625	NCT00000556_25_T0	GENE	6	6	II
NCT0000055626	NCT00000556_26_T0	GENE	4	4	II
NCT0000055626	NCT00000556_26_T1	PHENOTYPE	73	73	centers
NCT0000055626	NCT00000556_26_T2	PHENOTYPE	47	47	bradycardia
NCT0000055626	NCT00000556_26_T3	PHENOTYPE	24	25	atrial flutter
NCT0000055626	NCT00000556_26_T4	PHENOTYPE	33	34	atrial flutter
NCT0000055626	NCT00000556_26_T5	PHENOTYPE	37	38	atrial fibrillation
NCT0000055632	NCT00000556_32_T0	ORGAN	7	7	heart
NCT0000055633	NCT00000556_33_T0	ORGAN	3	3	heart
NCT0000055633	NCT00000556_33_T1	PHENOTYPE	1	2	atrial fibrillation
NCT0000055635	NCT00000556_35_T0	GENE	20	20	II
NCT0000055637	NCT00000556_37_T0	PHENOTYPE	7	7	strategies
NCT000005570	NCT00000557_0_T0	PHENOTYPE	3	5	Coronary Heart Disease
NCT000005573	NCT00000557_3_T0	GENE	26	26	has
NCT000005573	NCT00000557_3_T1	PHENOTYPE	10	11	myocardial infarction
NCT000005573	NCT00000557_3_T2	PHENOTYPE	13	15	quality of life
NCT000005574	NCT00000557_4_T0	PHENOTYPE	24	26	coronary heart disease
NCT000005575	NCT00000557_5_T0	PHENOTYPE	10	11	myocardial infarction
NCT000005577	NCT00000557_7_T0	GENE	11	11	met
NCT0000055711	NCT00000557_11_T0	GENE	11	11	4.5
NCT0000055712	NCT00000557_12_T0	PHENOTYPE	0	0	Secondary
NCT0000055712	NCT00000557_12_T1	PHENOTYPE	6	8	quality of life
NCT0000055714	NCT00000557_14_T0	PHENOTYPE	0	0	Recruitment
NCT000005582	NCT00000558_2_T0	PHENOTYPE	11	13	coronary artery disease
NCT000005583	NCT00000558_3_T0	GENE	8	8	ventricular
NCT000005584	NCT00000558_4_T0	GENE	6	6	CEI
NCT000005584	NCT00000558_4_T1	GENE	25	25	reduced
NCT000005584	NCT00000558_4_T2	PHENOTYPE	28	29	myocardial infarction
NCT000005585	NCT00000558_5_T0	GENE	26	26	ventricular
NCT000005585	NCT00000558_5_T1	PHENOTYPE	20	22	coronary artery disease
NCT000005586	NCT00000558_6_T0	GENE	10	10	CEI
NCT000005586	NCT00000558_6_T1	GENE	30	30	ventricular
NCT000005586	NCT00000558_6_T2	PHENOTYPE	25	26	coronary disease
NCT000005586	NCT00000558_6_T3	PHENOTYPE	20	21	myocardial infarction
NCT0000055810	NCT00000558_10_T0	PHENOTYPE	4	4	centers
NCT0000055811	NCT00000558_11_T0	COMPOUND	17	17	trandolapril
NCT0000055811	NCT00000558_11_T1	GENE	15	15	ACE
NCT0000055811	NCT00000558_11_T2	GENE	13	14	angiotensin-converting enzyme
NCT0000055812	NCT00000558_12_T0	PHENOTYPE	13	14	myocardial infarction
NCT0000055812	NCT00000558_12_T1	PHENOTYPE	25	27	coronary artery disease
NCT0000055812	NCT00000558_12_T2	PHENOTYPE	31	33	ventricular ejection fraction
NCT0000055814	NCT00000558_14_T0	PHENOTYPE	0	0	Recruitment
NCT000005590	NCT00000559_0_T0	PHENOTYPE	5	5	Atherosclerosis
NCT000005590	NCT00000559_0_T1	PHENOTYPE	6	6	Regression
NCT000005593	NCT00000559_3_T0	COMPOUND	16	16	estrogen
NCT000005593	NCT00000559_3_T1	PHENOTYPE	11	13	coronary heart disease
NCT000005594	NCT00000559_4_T0	GENE	8	8	had
NCT000005595	NCT00000559_5_T0	COMPOUND	11	11	estrogen
NCT000005595	NCT00000559_5_T1	COMPOUND	19	19	estrogen
NCT000005595	NCT00000559_5_T2	GENE	6	6	had
NCT000005596	NCT00000559_6_T0	COMPOUND	14	14	estrogen
NCT000005596	NCT00000559_6_T1	GENE	18	18	reduced
NCT000005596	NCT00000559_6_T2	PHENOTYPE	19	21	coronary heart disease
NCT000005597	NCT00000559_7_T0	GENE	5	5	had
NCT000005597	NCT00000559_7_T1	PHENOTYPE	16	17	uterine cancer
NCT000005597	NCT00000559_7_T2	PHENOTYPE	20	21	breast cancer
NCT000005597	NCT00000559_7_T3	PHENOTYPE	44	46	coronary heart disease
NCT0000055911	NCT00000559_11_T0	PHENOTYPE	7	8	obstructive disease
NCT0000055912	NCT00000559_12_T0	PHENOTYPE	1	1	secondary
NCT0000055913	NCT00000559_13_T0	BIOLOGICAL_PROCESS	15	15	metabolism
NCT0000055913	NCT00000559_13_T1	COMPOUND	6	8	estradiol and medroxyprogesterone
NCT0000055914	NCT00000559_14_T0	PHENOTYPE	5	5	centers
NCT0000055915	NCT00000559_15_T0	PHENOTYPE	19	19	Center
NCT0000055915	NCT00000559_15_T1	PHENOTYPE	12	12	Endocrine
NCT0000055915	NCT00000559_15_T2	GENE	9	9	Lab
NCT0000055915	NCT00000559_15_T3	GENE	13	13	Lab
NCT0000055916	NCT00000559_16_T0	GENE	21	21	QVR
NCT000005600	NCT00000560_0_T0	GENE	5	5	BEST
NCT000005604	NCT00000560_4_T0	GENE	13	13	had
NCT000005604	NCT00000560_4_T1	PHENOTYPE	11	12	heart failure
NCT000005604	NCT00000560_4_T2	PHENOTYPE	3	4	Heart Attack
NCT000005605	NCT00000560_5_T0	PHENOTYPE	10	10	Suppression
NCT000005605	NCT00000560_5_T1	GENE	18	18	had
NCT000005605	NCT00000560_5_T2	PHENOTYPE	8	9	Cardiac Arrhythmia
NCT000005606	NCT00000560_6_T0	COMPOUND	14	14	metoprolol
NCT000005606	NCT00000560_6_T1	PHENOTYPE	9	10	dilated cardiomyopathies
NCT000005606	NCT00000560_6_T2	PHENOTYPE	3	4	Dilated Cardiomyopathy
NCT000005608	NCT00000560_8_T0	GENE	14	14	reduced
NCT000005608	NCT00000560_8_T1	PHENOTYPE	17	19	congestive heart failure
NCT0000056010	NCT00000560_10_T0	COMPOUND	12	12	bucindolol
NCT0000056013	NCT00000560_13_T0	COMPOUND	11	11	norepinephrine
NCT0000056013	NCT00000560_13_T1	ORGAN	10	10	plasma
NCT0000056014	NCT00000560_14_T0	PHENOTYPE	5	7	congestive heart failure
NCT0000056015	NCT00000560_15_T0	PHENOTYPE	8	10	congestive heart failure
NCT0000056015	NCT00000560_15_T1	PHENOTYPE	18	20	congestive heart failure
NCT0000056016	NCT00000560_16_T0	PHENOTYPE	4	4	recruitment
NCT0000056017	NCT00000560_17_T0	PHENOTYPE	5	5	recruitment
NCT0000056018	NCT00000560_18_T0	PHENOTYPE	0	0	Recruitment
NCT0000056020	NCT00000560_20_T0	ORGAN	28	28	Heart
NCT0000056020	NCT00000560_20_T1	GENE	22	22	0.35
NCT0000056020	NCT00000560_20_T2	GENE	1	1	had
NCT0000056020	NCT00000560_20_T3	GENE	34	34	IV
NCT0000056020	NCT00000560_20_T4	PHENOTYPE	12	13	coronary disease
NCT0000056020	NCT00000560_20_T5	PHENOTYPE	31	32	class III
NCT0000056020	NCT00000560_20_T6	GENE	39	40	angiotensin-converting enzyme
NCT0000056020	NCT00000560_20_T7	PHENOTYPE	8	10	idiopathic dilated cardiomyopathy
NCT0000056020	NCT00000560_20_T8	PHENOTYPE	3	5	congestive heart failure
NCT000005612	NCT00000561_2_T0	GENE	6	6	ventricular
NCT000005616	NCT00000561_6_T0	PHENOTYPE	11	13	paroxysmal atrial fibrillation
NCT000005617	NCT00000561_7_T0	PHENOTYPE	3	3	bradycardia
NCT0000056110	NCT00000561_10_T0	GENE	18	18	ventricular
NCT0000056113	NCT00000561_13_T0	PHENOTYPE	37	37	accidents
NCT0000056113	NCT00000561_13_T1	PHENOTYPE	30	31	atrial fibrillation
NCT0000056113	NCT00000561_13_T2	PHENOTYPE	32	34	congestive heart failure
NCT0000056116	NCT00000561_16_T0	GENE	8	8	probable
NCT0000056117	NCT00000561_17_T0	PHENOTYPE	9	11	quality of life
NCT0000056117	NCT00000561_17_T1	PHENOTYPE	24	26	quality of life
NCT0000056123	NCT00000561_23_T0	GENE	8	8	1.5
NCT0000056123	NCT00000561_23_T1	GENE	10	10	4.5
NCT0000056127	NCT00000561_27_T0	PHENOTYPE	0	2	Quality of life
NCT0000056128	NCT00000561_28_T0	PHENOTYPE	6	8	quality of life
NCT0000056130	NCT00000561_30_T0	PHENOTYPE	0	0	Recruitment
NCT000005622	NCT00000562_2_T0	GENE	0	0	ARI
NCT000005622	NCT00000562_2_T1	GENE	15	15	ARI
NCT000005623	NCT00000562_3_T0	GENE	3	3	pointed
NCT000005623	NCT00000562_3_T1	GENE	13	13	ARI
NCT000005625	NCT00000562_5_T0	PHENOTYPE	9	9	Centers
NCT000005625	NCT00000562_5_T1	GENE	19	19	ARI
NCT0000056210	NCT00000562_10_T0	PHENOTYPE	9	9	centers
NCT0000056212	NCT00000562_12_T0	GENE	13	13	QVR
NCT000005635	NCT00000563_5_T0	PHENOTYPE	19	20	adverse effects
NCT0000056310	NCT00000563_10_T0	COMPOUND	12	12	dexamethasone
NCT000005645	NCT00000564_5_T0	GENE	13	13	Vol
NCT000005645	NCT00000564_5_T1	COMPOUND	36	36	oxygen
NCT000005645	NCT00000564_5_T2	PHENOTYPE	11	12	Respiratory Disease
NCT000005645	NCT00000564_5_T3	PHENOTYPE	44	47	chronic obstructive pulmonary disease
NCT000005646	NCT00000564_6_T0	PHENOTYPE	12	12	hypoxic
NCT000005646	NCT00000564_6_T1	COMPOUND	1	1	oxygen
NCT000005646	NCT00000564_6_T2	PHENOTYPE	11	11	chronic
NCT000005646	NCT00000564_6_T3	PHENOTYPE	13	14	lung disease
NCT000005647	NCT00000564_7_T0	COMPOUND	2	2	oxygen
NCT000005648	NCT00000564_8_T0	COMPOUND	2	2	oxygen
NCT0000056410	NCT00000564_10_T0	PHENOTYPE	1	1	recruitment
NCT0000056411	NCT00000564_11_T0	PHENOTYPE	1	1	Recruitment
NCT0000056412	NCT00000564_12_T0	COMPOUND	11	11	oxygen
NCT0000056412	NCT00000564_12_T1	COMPOUND	17	17	oxygen
NCT0000056414	NCT00000564_14_T0	COMPOUND	13	13	oxygen
NCT0000056414	NCT00000564_14_T1	COMPOUND	17	17	oxygen
NCT0000056415	NCT00000564_15_T0	PHENOTYPE	9	10	respiratory function
NCT0000056415	NCT00000564_15_T1	PHENOTYPE	3	5	quality of life
NCT0000056416	NCT00000564_16_T0	GENE	13	13	19.3
NCT000005653	NCT00000565_3_T0	GENE	11	11	had
NCT000005654	NCT00000565_4_T0	GENE	5	5	had
NCT000005654	NCT00000565_4_T1	GENE	24	24	had
NCT000005654	NCT00000565_4_T2	GENE	26	27	too few
NCT000005656	NCT00000565_6_T0	PHENOTYPE	6	6	centers
NCT000005658	NCT00000565_8_T0	PHENOTYPE	0	0	Recruitment
NCT0000056514	NCT00000565_14_T0	PHENOTYPE	7	8	respiratory function
NCT0000056514	NCT00000565_14_T1	PHENOTYPE	3	5	quality of life
NCT000005662	NCT00000566_2_T0	PHENOTYPE	10	11	pulmonary embolism
NCT000005663	NCT00000566_3_T0	PHENOTYPE	1	1	attributable
NCT000005663	NCT00000566_3_T1	PHENOTYPE	3	4	pulmonary embolism
NCT000005664	NCT00000566_4_T0	PHENOTYPE	4	5	pulmonary embolism
NCT000005664	NCT00000566_4_T1	PHENOTYPE	16	17	false negatives
NCT000005664	NCT00000566_4_T2	PHENOTYPE	13	14	false positives
NCT000005667	NCT00000566_7_T0	PHENOTYPE	13	13	centers
NCT000005667	NCT00000566_7_T1	PHENOTYPE	6	7	pulmonary embolism
NCT000005668	NCT00000566_8_T0	PHENOTYPE	16	16	ventilation
NCT000005668	NCT00000566_8_T1	PHENOTYPE	8	9	pulmonary embolism
NCT000005669	NCT00000566_9_T0	PHENOTYPE	18	19	pulmonary embolism
NCT0000056610	NCT00000566_10_T0	PHENOTYPE	10	10	ventilation
NCT0000056611	NCT00000566_11_T0	GENE	2	2	had
NCT0000056611	NCT00000566_11_T1	GENE	22	22	had
NCT0000056611	NCT00000566_11_T2	PHENOTYPE	17	18	pulmonary embolism
NCT0000056611	NCT00000566_11_T3	PHENOTYPE	26	27	pulmonary embolism
NCT0000056613	NCT00000566_13_T0	GENE	2	2	had
NCT0000056618	NCT00000566_18_T0	PHENOTYPE	0	0	Recruitment
NCT0000056620	NCT00000566_20_T0	PHENOTYPE	5	6	pulmonary embolism
NCT000005676	NCT00000567_6_T0	PHENOTYPE	4	4	ventilation
NCT000005676	NCT00000567_6_T1	GENE	11	11	reduced
NCT000005676	NCT00000567_6_T2	PHENOTYPE	16	16	fluctuation
NCT000005676	NCT00000567_6_T3	COMPOUND	28	28	oxygen
NCT0000056710	NCT00000567_10_T0	PHENOTYPE	16	17	premature infants
NCT0000056712	NCT00000567_12_T0	PHENOTYPE	0	0	Recruitment
NCT0000056714	NCT00000567_14_T0	PHENOTYPE	9	9	ventilation
NCT0000056714	NCT00000567_14_T1	PHENOTYPE	13	13	ventilation
NCT0000056715	NCT00000567_15_T0	COMPOUND	15	15	oxygen
NCT0000056715	NCT00000567_15_T1	PHENOTYPE	7	8	bronchopulmonary dysplasia
NCT0000056717	NCT00000567_17_T0	PHENOTYPE	11	12	periventricular leukomalacia
NCT0000056717	NCT00000567_17_T1	PHENOTYPE	8	9	intracranial hemorrhage
NCT0000056717	NCT00000567_17_T2	PHENOTYPE	0	1	Adverse effects
NCT0000056813	NCT00000568_13_T0	COMPOUND	15	15	isoproterenol
NCT0000056813	NCT00000568_13_T1	COMPOUND	17	17	methacholine
NCT0000056813	NCT00000568_13_T2	PHENOTYPE	5	6	airways obstruction
NCT0000056815	NCT00000568_15_T0	COMPOUND	17	17	nicotine
NCT0000056815	NCT00000568_15_T1	PHENOTYPE	27	27	relapse
NCT0000056815	NCT00000568_15_T2	ORGAN	18	18	gum
NCT0000056819	NCT00000568_19_T0	PHENOTYPE	4	4	secondary
NCT0000056820	NCT00000568_20_T0	PHENOTYPE	0	0	Recruitment
NCT0000056824	NCT00000568_24_T0	GENE	27	27	12
NCT0000056824	NCT00000568_24_T1	GENE	10	10	LHS
NCT0000056824	NCT00000568_24_T2	PHENOTYPE	23	24	cardiovascular disease
NCT0000056825	NCT00000568_25_T0	PHENOTYPE	13	13	FVC
NCT0000056826	NCT00000568_26_T0	PHENOTYPE	15	16	weight gain
NCT0000056827	NCT00000568_27_T0	GENE	36	36	extended
NCT0000056827	NCT00000568_27_T1	PHENOTYPE	17	18	respiratory symptoms
NCT0000056827	NCT00000568_27_T2	PHENOTYPE	12	13	lung function
NCT0000056827	NCT00000568_27_T3	PHENOTYPE	27	29	quality of life
NCT000005699	NCT00000569_9_T0	PHENOTYPE	14	14	inflammation
NCT000005699	NCT00000569_9_T1	PHENOTYPE	21	22	lung function
NCT000005699	NCT00000569_9_T2	PHENOTYPE	32	33	lung function
NCT000005699	NCT00000569_9_T3	PHENOTYPE	18	19	bronchial hyperreactivity
NCT0000056912	NCT00000569_12_T0	PHENOTYPE	3	3	intent
NCT0000056915	NCT00000569_15_T0	COMPOUND	15	15	methacholine
NCT0000056918	NCT00000569_18_T0	PHENOTYPE	12	12	toxicity
NCT0000056918	NCT00000569_18_T1	PHENOTYPE	16	16	atopic
NCT0000056918	NCT00000569_18_T2	PHENOTYPE	5	6	respiratory symptoms
NCT0000056918	NCT00000569_18_T3	PHENOTYPE	14	15	bronchial hyperreactivity
NCT0000056918	NCT00000569_18_T4	PHENOTYPE	7	9	quality of life
NCT0000056919	NCT00000569_19_T0	GENE	13	13	3.5
NCT0000056919	NCT00000569_19_T1	GENE	15	15	4.5
NCT0000056919	NCT00000569_19_T2	PHENOTYPE	0	0	Recruitment
NCT0000056922	NCT00000569_22_T0	PHENOTYPE	6	7	adrenal suppression
NCT0000056930	NCT00000569_30_T0	PHENOTYPE	1	2	myocardial infarction
NCT0000056931	NCT00000569_31_T0	PHENOTYPE	0	0	Alcoholism
NCT0000056932	NCT00000569_32_T0	PHENOTYPE	0	1	Heart Failure
NCT0000056934	NCT00000569_34_T0	PHENOTYPE	1	1	disorders
NCT000005705	NCT00000570_5_T0	GENE	1	1	has
NCT000005709	NCT00000570_9_T0	PHENOTYPE	18	18	ventilation
NCT000005709	NCT00000570_9_T1	GENE	4	4	has
NCT000005709	NCT00000570_9_T2	GENE	20	20	has
NCT000005709	NCT00000570_9_T3	BIOLOGICAL_PROCESS	53	53	gestation
NCT0000057020	NCT00000570_20_T0	GENE	13	13	QVR
NCT000005714	NCT00000571_4_T0	PHENOTYPE	22	22	acute
NCT000005714	NCT00000571_4_T1	PHENOTYPE	29	29	chronic
NCT000005714	NCT00000571_4_T2	PHENOTYPE	10	13	chronic obstructive pulmonary disease
NCT000005715	NCT00000571_5_T0	TISSUE	16	16	muscles
NCT000005715	NCT00000571_5_T1	TISSUE	24	24	muscles
NCT000005715	NCT00000571_5_T2	PHENOTYPE	23	23	fatigued
NCT000005715	NCT00000571_5_T3	PHENOTYPE	4	4	strategies
NCT000005715	NCT00000571_5_T4	PHENOTYPE	12	13	muscle fatigue
NCT000005716	NCT00000571_6_T0	PHENOTYPE	5	6	chronic fatigue
NCT000005716	NCT00000571_6_T1	PHENOTYPE	17	18	chronic fatigue
NCT0000057110	NCT00000571_10_T0	GENE	12	12	grid
NCT0000057110	NCT00000571_10_T1	ORGAN	18	18	abdomen
NCT0000057110	NCT00000571_10_T2	ORGAN	32	32	lungs
NCT0000057110	NCT00000571_10_T3	PHENOTYPE	19	19	transmitted
NCT0000057110	NCT00000571_10_T4	ORGAN	24	25	chest wall
NCT0000057111	NCT00000571_11_T0	PHENOTYPE	23	23	ventilation
NCT0000057111	NCT00000571_11_T1	TISSUE	29	29	muscles
NCT0000057111	NCT00000571_11_T2	PHENOTYPE	10	10	COLD
NCT0000057111	NCT00000571_11_T3	PHENOTYPE	3	3	chronic
NCT0000057111	NCT00000571_11_T4	PHENOTYPE	5	6	muscle fatigue
NCT0000057112	NCT00000571_12_T0	PHENOTYPE	16	16	COLD
NCT0000057112	NCT00000571_12_T1	PHENOTYPE	13	14	muscle fatigue
NCT0000057115	NCT00000571_15_T0	PHENOTYPE	24	24	ventilation
NCT0000057116	NCT00000571_16_T0	PHENOTYPE	22	23	respiratory symptoms
NCT0000057116	NCT00000571_16_T1	PHENOTYPE	20	21	lung function
NCT0000057116	NCT00000571_16_T2	PHENOTYPE	25	27	quality of life
NCT0000057117	NCT00000571_17_T0	GENE	12	12	had
NCT0000057117	NCT00000571_17_T1	COMPOUND	15	15	oxygen
NCT0000057118	NCT00000571_18_T0	PHENOTYPE	1	1	ventilation
NCT000005726	NCT00000572_6_T0	PHENOTYPE	19	19	elimination
NCT000005728	NCT00000572_8_T0	ORGAN	3	3	lungs
NCT000005728	NCT00000572_8_T1	GENE	7	7	reduced
NCT000005728	NCT00000572_8_T2	PHENOTYPE	0	0	Ventilation
NCT000005728	NCT00000572_8_T3	COMPOUND	11	11	oxygen
NCT0000057210	NCT00000572_10_T0	GENE	12	12	Dr
NCT0000057210	NCT00000572_10_T1	GENE	23	23	Dr
NCT0000057212	NCT00000572_12_T0	PHENOTYPE	16	16	ventilation
NCT0000057216	NCT00000572_16_T0	GENE	12	12	bypass
NCT0000057216	NCT00000572_16_T1	PHENOTYPE	5	5	ventilation
NCT0000057216	NCT00000572_16_T2	GENE	8	8	CO2
NCT0000057216	NCT00000572_16_T3	PHENOTYPE	20	20	bilateral
NCT0000057216	NCT00000572_16_T4	ORGAN	21	22	saphenous veins
NCT0000057218	NCT00000572_18_T0	PHENOTYPE	17	17	trauma
NCT0000057219	NCT00000572_19_T0	PHENOTYPE	7	7	ventilation
NCT0000057219	NCT00000572_19_T1	GENE	26	26	CO2
NCT0000057221	NCT00000572_21_T0	PHENOTYPE	0	0	Secondary
NCT0000057229	NCT00000572_29_T0	PHENOTYPE	1	1	ventilation
NCT0000057229	NCT00000572_29_T1	GENE	2	2	21
NCT0000057231	NCT00000572_31_T0	PHENOTYPE	1	1	chronic
NCT0000057231	NCT00000572_31_T1	PHENOTYPE	2	3	systemic disease
NCT0000057232	NCT00000572_32_T0	PHENOTYPE	1	4	central nervous system disease
NCT0000057233	NCT00000572_33_T0	GENE	20	20	45
NCT0000057233	NCT00000572_33_T1	GENE	15	15	0.3
NCT0000057233	NCT00000572_33_T2	PHENOTYPE	30	30	infiltration
NCT0000057233	NCT00000572_33_T3	PHENOTYPE	1	1	chronic
NCT0000057233	NCT00000572_33_T4	PHENOTYPE	18	18	chronic
NCT0000057233	NCT00000572_33_T5	PHENOTYPE	35	35	chronic
NCT0000057233	NCT00000572_33_T6	GENE	22	22	Hg
NCT0000057233	NCT00000572_33_T7	PHENOTYPE	2	3	pulmonary disease
NCT0000057233	NCT00000572_33_T8	PHENOTYPE	36	37	respiratory insufficiency
NCT0000057234	NCT00000572_34_T0	PHENOTYPE	2	2	burns
NCT0000057235	NCT00000572_35_T0	PHENOTYPE	2	2	malignancy
NCT0000057236	NCT00000572_36_T0	PHENOTYPE	0	0	Chronic
NCT0000057236	NCT00000572_36_T1	PHENOTYPE	1	3	left ventricular failure
NCT0000057238	NCT00000572_38_T0	COMPOUND	7	7	bilirubin
NCT0000057238	NCT00000572_38_T1	ORGAN	6	6	serum
NCT0000057238	NCT00000572_38_T2	PHENOTYPE	0	2	Chronic liver failure
NCT000005732	NCT00000573_2_T0	PHENOTYPE	20	20	cachexia
NCT000005732	NCT00000573_2_T1	PHENOTYPE	12	13	weight loss
NCT000005732	NCT00000573_2_T2	PHENOTYPE	4	7	chronic obstructive pulmonary disease
NCT000005733	NCT00000573_3_T0	PHENOTYPE	5	5	associations
NCT000005733	NCT00000573_3_T1	PHENOTYPE	13	14	weight loss
NCT000005733	NCT00000573_3_T2	PHENOTYPE	7	10	chronic obstructive pulmonary disease
NCT000005736	NCT00000573_6_T0	PHENOTYPE	11	11	underweight
NCT000005737	NCT00000573_7_T0	PHENOTYPE	16	16	malnourished
NCT000005737	NCT00000573_7_T1	PHENOTYPE	17	20	chronic obstructive pulmonary disease
NCT000005739	NCT00000573_9_T0	PHENOTYPE	4	5	weight gain
NCT0000057310	NCT00000573_10_T0	GENE	6	6	ENS
NCT0000057311	NCT00000573_11_T0	GENE	3	3	ENS
NCT0000057312	NCT00000573_12_T0	GENE	16	16	1.7
NCT0000057315	NCT00000573_15_T0	PHENOTYPE	13	13	dyspnea
NCT0000057315	NCT00000573_15_T1	PHENOTYPE	15	17	quality of life
NCT0000057316	NCT00000573_16_T0	PHENOTYPE	0	0	Secondary
NCT0000057317	NCT00000573_17_T0	GENE	3	3	extended
NCT000005740	NCT00000574_0_T0	PHENOTYPE	2	2	Sepsis
NCT000005744	NCT00000574_4_T0	COMPOUND	23	23	ibuprofen
NCT000005744	NCT00000574_4_T1	GENE	19	19	cyclooxygenase
NCT000005744	NCT00000574_4_T2	PHENOTYPE	8	8	ARDS
NCT000005744	NCT00000574_4_T3	PHENOTYPE	40	40	sepsis
NCT000005748	NCT00000574_8_T0	GENE	55	55	PGI2
NCT000005748	NCT00000574_8_T1	COMPOUND	7	7	ibuprofen
NCT000005748	NCT00000574_8_T2	COMPOUND	27	27	ibuprofen
NCT000005748	NCT00000574_8_T3	GENE	50	50	reduced
NCT000005748	NCT00000574_8_T4	ORGAN	32	32	heart
NCT000005748	NCT00000574_8_T5	PHENOTYPE	17	17	centers
NCT000005748	NCT00000574_8_T6	PHENOTYPE	12	12	sepsis
NCT000005748	NCT00000574_8_T7	PHENOTYPE	24	25	antipyretic effect
NCT000005749	NCT00000574_9_T0	GENE	3	3	PGI2
NCT000005749	NCT00000574_9_T1	PHENOTYPE	8	10	systemic vascular resistance
NCT0000057410	NCT00000574_10_T0	COMPOUND	9	9	ibuprofen
NCT0000057411	NCT00000574_11_T0	COMPOUND	17	17	prostaglandin
NCT0000057411	NCT00000574_11_T1	PHENOTYPE	9	9	centers
NCT0000057413	NCT00000574_13_T0	GENE	2	2	extended
NCT0000057416	NCT00000574_16_T0	PHENOTYPE	0	0	Recruitment
NCT0000057417	NCT00000574_17_T0	COMPOUND	12	12	ibuprofen
NCT0000057421	NCT00000574_21_T0	TISSUE	8	8	peritoneum
NCT0000057421	NCT00000574_21_T1	ORGAN	7	7	lungs
NCT0000057421	NCT00000574_21_T2	ORGAN	10	11	urinary tract
NCT0000057422	NCT00000574_22_T0	PHENOTYPE	17	17	severity
NCT0000057422	NCT00000574_22_T1	PHENOTYPE	19	20	pulmonary edema
NCT0000057423	NCT00000574_23_T0	COMPOUND	4	4	ibuprofen
NCT0000057426	NCT00000574_26_T0	PHENOTYPE	3	3	infections
NCT0000057427	NCT00000574_27_T0	PHENOTYPE	3	3	dysfunction
NCT0000057427	NCT00000574_27_T1	PHENOTYPE	20	20	dysfunction
NCT0000057427	NCT00000574_27_T2	PHENOTYPE	4	5	organ failure
NCT000005750	NCT00000575_0_T0	GENE	8	8	II
NCT000005750	NCT00000575_0_T1	GENE	10	10	III
NCT000005750	NCT00000575_0_T2	GENE	13	13	IV
NCT000005750	NCT00000575_0_T3	GENE	4	4	CAMP
NCT000005750	NCT00000575_0_T4	PHENOTYPE	0	1	Childhood Asthma
NCT000005754	NCT00000575_4_T0	PHENOTYPE	2	2	asthma
NCT000005754	NCT00000575_4_T1	PHENOTYPE	16	16	asthma
NCT000005755	NCT00000575_5_T0	PHENOTYPE	0	0	Asthma
NCT000005756	NCT00000575_6_T0	PHENOTYPE	2	2	asthma
NCT000005758	NCT00000575_8_T0	PHENOTYPE	3	3	asthma
NCT000005759	NCT00000575_9_T0	PHENOTYPE	14	14	asthma
NCT0000057510	NCT00000575_10_T0	PHENOTYPE	12	12	asthma
NCT0000057510	NCT00000575_10_T1	GENE	6	6	has
NCT0000057513	NCT00000575_13_T0	PHENOTYPE	7	7	symptoms
NCT0000057513	NCT00000575_13_T1	PHENOTYPE	6	6	asthma
NCT0000057513	NCT00000575_13_T2	PHENOTYPE	12	13	lung function
NCT0000057516	NCT00000575_16_T0	PHENOTYPE	12	12	asthma
NCT0000057516	NCT00000575_16_T1	PHENOTYPE	7	8	lung function
NCT0000057516	NCT00000575_16_T2	PHENOTYPE	22	23	lung function
NCT0000057518	NCT00000575_18_T0	COMPOUND	13	13	sodium
NCT0000057521	NCT00000575_21_T0	PHENOTYPE	10	11	lung function
NCT0000057522	NCT00000575_22_T0	GENE	2	2	has
NCT0000057524	NCT00000575_24_T0	GENE	1	1	CAMP
NCT0000057525	NCT00000575_25_T0	COMPOUND	9	9	theophylline
NCT0000057525	NCT00000575_25_T1	PHENOTYPE	15	15	asthma
NCT0000057526	NCT00000575_26_T0	PHENOTYPE	25	25	asthma
NCT0000057530	NCT00000575_30_T0	COMPOUND	20	20	budesonide
NCT0000057533	NCT00000575_33_T0	PHENOTYPE	10	11	asthma attacks
NCT0000057535	NCT00000575_35_T0	PHENOTYPE	0	0	Recruitment
NCT000005764	NCT00000576_4_T0	PHENOTYPE	0	0	BPD
NCT000005765	NCT00000576_5_T0	PHENOTYPE	6	6	BPD
NCT000005768	NCT00000576_8_T0	PHENOTYPE	38	38	BPD
NCT0000057610	NCT00000576_10_T0	COMPOUND	6	6	beclomethasone
NCT0000057610	NCT00000576_10_T1	PHENOTYPE	1	2	premature infants
NCT0000057612	NCT00000576_12_T0	PHENOTYPE	5	6	bronchopulmonary dysplasia
NCT0000057613	NCT00000576_13_T0	PHENOTYPE	0	0	Secondary
NCT0000057613	NCT00000576_13_T1	PHENOTYPE	3	4	bronchopulmonary dysplasia
NCT000005772	NCT00000577_2_T0	PHENOTYPE	5	5	asthmatics
NCT000005772	NCT00000577_2_T1	PHENOTYPE	9	9	affects
NCT000005774	NCT00000577_4_T0	PHENOTYPE	8	8	symptoms
NCT000005774	NCT00000577_4_T1	COMPOUND	32	32	sodium
NCT000005774	NCT00000577_4_T2	COMPOUND	15	15	theophylline
NCT000005774	NCT00000577_4_T3	PHENOTYPE	25	25	inflammation
NCT000005777	NCT00000577_7_T0	PHENOTYPE	2	2	asthma
NCT000005778	NCT00000577_8_T0	PHENOTYPE	0	0	Asthma
NCT0000057710	NCT00000577_10_T0	PHENOTYPE	21	21	asthma
NCT0000057710	NCT00000577_10_T1	PHENOTYPE	29	30	clinical findings
NCT0000057717	NCT00000577_17_T0	PHENOTYPE	35	35	severity
NCT0000057717	NCT00000577_17_T1	PHENOTYPE	32	32	asthma
NCT0000057722	NCT00000577_22_T0	PHENOTYPE	6	6	symptoms
NCT0000057722	NCT00000577_22_T1	PHENOTYPE	5	5	asthma
NCT0000057722	NCT00000577_22_T2	PHENOTYPE	26	26	asthma
NCT0000057722	NCT00000577_22_T3	PHENOTYPE	2	3	lung function
NCT0000057723	NCT00000577_23_T0	PHENOTYPE	19	19	symptoms
NCT0000057723	NCT00000577_23_T1	PHENOTYPE	18	18	asthma
NCT0000057723	NCT00000577_23_T2	PHENOTYPE	32	32	asthma
NCT0000057723	NCT00000577_23_T3	PHENOTYPE	20	22	quality of life
NCT0000057724	NCT00000577_24_T0	PHENOTYPE	0	0	Recruitment
NCT0000057725	NCT00000577_25_T0	GENE	2	2	has
NCT0000057726	NCT00000577_26_T0	COMPOUND	9	9	colchicine
NCT0000057726	NCT00000577_26_T1	PHENOTYPE	21	21	asthma
NCT0000057726	NCT00000577_26_T2	PHENOTYPE	4	4	Asthma
NCT0000057730	NCT00000577_30_T0	PHENOTYPE	21	21	symptoms
NCT0000057730	NCT00000577_30_T1	PHENOTYPE	20	20	asthma
NCT0000057730	NCT00000577_30_T2	PHENOTYPE	34	34	asthma
NCT0000057730	NCT00000577_30_T3	PHENOTYPE	22	24	quality of life
NCT0000057732	NCT00000577_32_T0	GENE	1	1	ran
NCT0000057732	NCT00000577_32_T1	PHENOTYPE	0	0	Recruitment
NCT0000057737	NCT00000577_37_T0	PHENOTYPE	15	15	asthma
NCT0000057740	NCT00000577_40_T0	PHENOTYPE	7	7	severity
NCT0000057740	NCT00000577_40_T1	PHENOTYPE	0	0	Secondary
NCT0000057740	NCT00000577_40_T2	PHENOTYPE	6	6	asthma
NCT0000057740	NCT00000577_40_T3	PHENOTYPE	19	19	asthma
NCT0000057740	NCT00000577_40_T4	COMPOUND	16	16	methacholine
NCT0000057740	NCT00000577_40_T5	PHENOTYPE	14	14	quality-of-life
NCT0000057741	NCT00000577_41_T0	PHENOTYPE	4	4	inflammation
NCT0000057744	NCT00000577_44_T0	PHENOTYPE	24	24	symptoms
NCT0000057744	NCT00000577_44_T1	COMPOUND	13	13	salmeterol
NCT0000057744	NCT00000577_44_T2	PHENOTYPE	22	22	asthma
NCT0000057746	NCT00000577_46_T0	PHENOTYPE	6	6	asthma
NCT0000057746	NCT00000577_46_T1	PHENOTYPE	0	0	Recruitment
NCT0000057747	NCT00000577_47_T0	PHENOTYPE	7	7	Center
NCT0000057750	NCT00000577_50_T0	PHENOTYPE	16	17	adrenal suppression
NCT0000057751	NCT00000577_51_T0	GENE	36	36	MICE
NCT0000057752	NCT00000577_52_T0	PHENOTYPE	16	16	asthma
NCT0000057752	NCT00000577_52_T1	GENE	17	17	had
NCT0000057757	NCT00000577_57_T0	GENE	5	5	MICE
NCT0000057758	NCT00000577_58_T0	COMPOUND	18	18	cortisol
NCT0000057758	NCT00000577_58_T1	COMPOUND	28	28	cortisol
NCT0000057758	NCT00000577_58_T2	COMPOUND	33	33	cortisol
NCT0000057758	NCT00000577_58_T3	COMPOUND	39	39	cortisol
NCT0000057758	NCT00000577_58_T4	PHENOTYPE	19	19	suppression
NCT0000057758	NCT00000577_58_T5	PHENOTYPE	29	29	suppression
NCT0000057758	NCT00000577_58_T6	PHENOTYPE	34	34	suppression
NCT0000057758	NCT00000577_58_T7	PHENOTYPE	40	40	suppression
NCT0000057758	NCT00000577_58_T8	GENE	0	0	MICE
NCT0000057758	NCT00000577_58_T9	GENE	9	9	MICE
NCT0000057759	NCT00000577_59_T0	GENE	10	10	had
NCT0000057759	NCT00000577_59_T1	GENE	13	13	had
NCT0000057759	NCT00000577_59_T2	PHENOTYPE	1	1	intent
NCT0000057759	NCT00000577_59_T3	PHENOTYPE	19	20	chronic asthma
NCT0000057760	NCT00000577_60_T0	GENE	20	20	FP
NCT0000057760	NCT00000577_60_T1	GENE	0	0	MICE
NCT0000057760	NCT00000577_60_T2	GENE	16	16	BDP
NCT0000057760	NCT00000577_60_T3	COMPOUND	18	19	fluticasone propionate
NCT0000057760	NCT00000577_60_T4	COMPOUND	14	15	beclomethasone dipropionate
NCT0000057761	NCT00000577_61_T0	PHENOTYPE	30	30	inflammation
NCT0000057761	NCT00000577_61_T1	PHENOTYPE	24	24	asthma
NCT0000057761	NCT00000577_61_T2	PHENOTYPE	34	35	persistent asthma
NCT0000057762	NCT00000577_62_T0	COMPOUND	42	42	3
NCT0000057762	NCT00000577_62_T1	GENE	13	13	FP
NCT0000057762	NCT00000577_62_T2	GENE	24	24	FP
NCT0000057762	NCT00000577_62_T3	GENE	37	37	FP
NCT0000057762	NCT00000577_62_T4	PHENOTYPE	1	1	intent
NCT0000057762	NCT00000577_62_T5	GENE	11	11	BDP
NCT0000057762	NCT00000577_62_T6	GENE	22	22	BDP
NCT0000057762	NCT00000577_62_T7	GENE	35	35	BDP
NCT0000057763	NCT00000577_63_T0	GENE	23	23	FP
NCT0000057763	NCT00000577_63_T1	GENE	0	0	MICE
NCT0000057763	NCT00000577_63_T2	GENE	21	21	BDP
NCT0000057764	NCT00000577_64_T0	PHENOTYPE	0	0	Recruitment
NCT0000057766	NCT00000577_66_T0	GENE	1	1	Beta
NCT0000057767	NCT00000577_67_T0	PHENOTYPE	0	0	Recruitment
NCT0000057769	NCT00000577_69_T0	GENE	31	31	receptor
NCT0000057769	NCT00000577_69_T1	PHENOTYPE	13	13	asthma
NCT0000057769	NCT00000577_69_T2	GENE	9	9	had
NCT0000057770	NCT00000577_70_T0	GENE	20	20	receptor
NCT0000057771	NCT00000577_71_T0	COMPOUND	26	27	ipratropium bromide
NCT0000057772	NCT00000577_72_T0	PHENOTYPE	14	14	symptoms
NCT0000057772	NCT00000577_72_T1	PHENOTYPE	13	13	asthma
NCT0000057772	NCT00000577_72_T2	PHENOTYPE	28	28	asthma
NCT0000057772	NCT00000577_72_T3	PHENOTYPE	0	0	Asthma
NCT0000057772	NCT00000577_72_T4	PHENOTYPE	15	17	quality of life
NCT0000057773	NCT00000577_73_T0	COMPOUND	13	13	methacholine
NCT0000057773	NCT00000577_73_T1	COMPOUND	23	24	nitric oxide
NCT0000057773	NCT00000577_73_T2	PHENOTYPE	17	18	bronchodilator effect
NCT0000057775	NCT00000577_75_T0	PHENOTYPE	0	0	Asthma
NCT0000057778	NCT00000577_78_T0	PHENOTYPE	0	0	Asthma
NCT0000057780	NCT00000577_80_T0	COMPOUND	7	8	ipratropium bromide
NCT0000057781	NCT00000577_81_T0	PHENOTYPE	8	8	asthma
NCT0000057782	NCT00000577_82_T0	PHENOTYPE	2	2	asthma
NCT0000057784	NCT00000577_84_T0	PHENOTYPE	29	29	symptoms
NCT0000057784	NCT00000577_84_T1	GENE	5	5	IMPACT
NCT0000057784	NCT00000577_84_T2	PHENOTYPE	26	26	asthma
NCT0000057784	NCT00000577_84_T3	PHENOTYPE	2	2	Asthma
NCT0000057786	NCT00000577_86_T0	PHENOTYPE	14	14	symptoms
NCT0000057786	NCT00000577_86_T1	GENE	2	2	IMPACT
NCT0000057786	NCT00000577_86_T2	PHENOTYPE	21	21	centers
NCT0000057786	NCT00000577_86_T3	PHENOTYPE	8	8	asthma
NCT0000057786	NCT00000577_86_T4	GENE	10	10	had
NCT0000057788	NCT00000577_88_T0	PHENOTYPE	5	5	symptoms
NCT0000057790	NCT00000577_90_T0	PHENOTYPE	16	16	asthma
NCT0000057790	NCT00000577_90_T1	PHENOTYPE	25	27	quality of life
NCT0000057791	NCT00000577_91_T0	PHENOTYPE	0	0	Recruitment
NCT0000057793	NCT00000577_93_T0	GENE	9	9	IMPACT
NCT0000057794	NCT00000577_94_T0	GENE	3	3	has
NCT0000057795	NCT00000577_95_T0	PHENOTYPE	8	8	Asthma
NCT0000057795	NCT00000577_95_T1	PHENOTYPE	39	40	persistent asthma
NCT00000577100	NCT00000577_100_T0	PHENOTYPE	0	0	Secondary
NCT00000577100	NCT00000577_100_T1	PHENOTYPE	12	12	inflammation
NCT00000577100	NCT00000577_100_T2	COMPOUND	8	8	methacholine
NCT00000577101	NCT00000577_101_T0	PHENOTYPE	1	1	secondary
NCT00000577101	NCT00000577_101_T1	PHENOTYPE	17	17	asthmatics
NCT00000577101	NCT00000577_101_T2	GENE	14	14	receptor
NCT00000577102	NCT00000577_102_T0	GENE	14	14	receptor
NCT00000577107	NCT00000577_107_T0	PHENOTYPE	16	16	HFA
NCT00000577107	NCT00000577_107_T1	GENE	20	20	receptor
NCT00000577107	NCT00000577_107_T2	COMPOUND	15	15	beclomethasone
NCT00000577107	NCT00000577_107_T3	COMPOUND	23	23	montelukast
NCT00000577109	NCT00000577_109_T0	PHENOTYPE	10	10	Asthma
NCT00000577109	NCT00000577_109_T1	PHENOTYPE	27	27	symptoms
NCT00000577109	NCT00000577_109_T2	GENE	8	8	met
NCT00000577109	NCT00000577_109_T3	PHENOTYPE	16	17	persistent asthma
NCT00000577115	NCT00000577_115_T0	PHENOTYPE	14	14	symptoms
NCT00000577115	NCT00000577_115_T1	PHENOTYPE	13	13	asthma
NCT00000577116	NCT00000577_116_T0	PHENOTYPE	16	16	HFA
NCT00000577116	NCT00000577_116_T1	COMPOUND	15	15	beclomethasone
NCT00000577116	NCT00000577_116_T2	COMPOUND	19	19	montelukast
NCT00000577118	NCT00000577_118_T0	PHENOTYPE	15	15	symptoms
NCT00000577118	NCT00000577_118_T1	PHENOTYPE	14	14	asthma
NCT00000577119	NCT00000577_119_T0	GENE	17	17	had
NCT00000577120	NCT00000577_120_T0	PHENOTYPE	9	9	Thoracic
NCT00000577123	NCT00000577_123_T0	PHENOTYPE	11	11	asthma
NCT00000577132	NCT00000577_132_T0	GENE	16	16	II
NCT00000577132	NCT00000577_132_T1	GENE	8	8	LARGE
NCT00000577132	NCT00000577_132_T2	GENE	3	3	Beta
NCT00000577133	NCT00000577_133_T0	GENE	33	33	receptor
NCT00000577133	NCT00000577_133_T1	PHENOTYPE	18	18	asthma
NCT00000577134	NCT00000577_134_T0	GENE	8	8	B16
NCT00000577134	NCT00000577_134_T1	GENE	26	26	B16
NCT00000577134	NCT00000577_134_T2	COMPOUND	9	9	Arg-Arg
NCT00000577134	NCT00000577_134_T3	PHENOTYPE	14	14	asthma
NCT00000577135	NCT00000577_135_T0	PHENOTYPE	0	0	Recruitment
NCT000005781	NCT00000578_1_T0	PHENOTYPE	17	17	centers
NCT000005781	NCT00000578_1_T1	PHENOTYPE	27	28	Human Development
NCT000005784	NCT00000578_4_T0	PHENOTYPE	0	0	Asthma
NCT000005786	NCT00000578_6_T0	PHENOTYPE	17	17	toxemia
NCT000005786	NCT00000578_6_T1	PHENOTYPE	10	10	eclampsia
NCT000005786	NCT00000578_6_T2	PHENOTYPE	11	12	gestational hypertension
NCT000005786	NCT00000578_6_T3	PHENOTYPE	15	16	vaginal hemorrhage
NCT000005786	NCT00000578_6_T4	PHENOTYPE	13	14	hyperemesis gravidarum
NCT000005787	NCT00000578_7_T0	PHENOTYPE	8	8	prematurity
NCT000005787	NCT00000578_7_T1	PHENOTYPE	1	1	complications
NCT000005787	NCT00000578_7_T2	PHENOTYPE	13	14	neonatal hypoxia
NCT000005787	NCT00000578_7_T3	PHENOTYPE	9	11	low birth weight
NCT000005789	NCT00000578_9_T0	PHENOTYPE	10	10	complications
NCT000005789	NCT00000578_9_T1	PHENOTYPE	3	3	asthma
NCT000005789	NCT00000578_9_T2	PHENOTYPE	23	23	asthma
NCT0000057812	NCT00000578_12_T0	PHENOTYPE	4	4	asthma
NCT0000057813	NCT00000578_13_T0	PHENOTYPE	3	3	asthma
NCT0000057813	NCT00000578_13_T1	PHENOTYPE	6	6	chronic
NCT0000057813	NCT00000578_13_T2	PHENOTYPE	9	10	fetal hypoxia
NCT0000057814	NCT00000578_14_T0	PHENOTYPE	3	3	asthma
NCT0000057815	NCT00000578_15_T0	PHENOTYPE	26	26	asthma
NCT0000057815	NCT00000578_15_T1	TISSUE	13	14	uterine muscle
NCT0000057815	NCT00000578_15_T2	PHENOTYPE	22	23	gestational hypertension
NCT0000057815	NCT00000578_15_T3	ORGAN	7	9	autonomic nervous system
NCT0000057815	NCT00000578_15_T4	PHENOTYPE	8	10	nervous system abnormalities
NCT0000057818	NCT00000578_18_T0	PHENOTYPE	13	13	asthma
NCT0000057818	NCT00000578_18_T1	PHENOTYPE	30	30	asthma
NCT0000057818	NCT00000578_18_T2	PHENOTYPE	39	39	asthma
NCT0000057819	NCT00000578_19_T0	PHENOTYPE	24	24	asthma
NCT0000057819	NCT00000578_19_T1	PHENOTYPE	6	6	Asthma
NCT0000057819	NCT00000578_19_T2	PHENOTYPE	14	14	Asthma
NCT0000057820	NCT00000578_20_T0	PHENOTYPE	22	22	asthma
NCT0000057820	NCT00000578_20_T1	PHENOTYPE	41	41	asthma
NCT0000057821	NCT00000578_21_T0	PHENOTYPE	13	13	severity
NCT0000057821	NCT00000578_21_T1	PHENOTYPE	12	12	asthma
NCT0000057821	NCT00000578_21_T2	PHENOTYPE	3	3	Asthma
NCT0000057823	NCT00000578_23_T0	PHENOTYPE	14	14	secondary
NCT0000057823	NCT00000578_23_T1	PHENOTYPE	11	11	asthma
NCT0000057824	NCT00000578_24_T0	PHENOTYPE	16	18	other substance abuse
NCT0000057825	NCT00000578_25_T0	PHENOTYPE	0	0	Secondary
NCT0000057825	NCT00000578_25_T1	PHENOTYPE	6	6	prematurity
NCT0000057825	NCT00000578_25_T2	PHENOTYPE	12	12	asthma
NCT0000057825	NCT00000578_25_T3	PHENOTYPE	8	8	eclampsia
NCT0000057825	NCT00000578_25_T4	PHENOTYPE	9	10	gestational hypertension
NCT0000057826	NCT00000578_26_T0	PHENOTYPE	7	7	recruitment
NCT0000057827	NCT00000578_27_T0	PHENOTYPE	15	15	recruitment
NCT0000057827	NCT00000578_27_T1	PHENOTYPE	1	1	Asthma
NCT0000057828	NCT00000578_28_T0	COMPOUND	8	8	theophylline
NCT0000057828	NCT00000578_28_T1	COMPOUND	22	22	theophylline
NCT0000057828	NCT00000578_28_T2	COMPOUND	12	12	beclomethasone
NCT0000057828	NCT00000578_28_T3	COMPOUND	17	17	beclomethasone
NCT0000057829	NCT00000578_29_T0	PHENOTYPE	6	6	symptoms
NCT0000057831	NCT00000578_31_T0	PHENOTYPE	0	0	Secondary
NCT0000057831	NCT00000578_31_T1	PHENOTYPE	12	12	eclampsia
NCT0000057831	NCT00000578_31_T2	PHENOTYPE	10	11	gestational hypertension
NCT0000057831	NCT00000578_31_T3	PHENOTYPE	13	14	lung function
NCT0000057831	NCT00000578_31_T4	PHENOTYPE	19	21	quality of life
NCT0000057834	NCT00000578_34_T0	GENE	21	21	QVR
NCT000005794	NCT00000579_4_T0	PHENOTYPE	25	25	outlook
NCT000005794	NCT00000579_4_T1	PHENOTYPE	7	8	lung injury
NCT000005796	NCT00000579_6_T0	PHENOTYPE	10	11	lung injury
NCT000005798	NCT00000579_8_T0	PHENOTYPE	14	14	ARDS
NCT000005799	NCT00000579_9_T0	PHENOTYPE	25	25	ARDS
NCT0000057910	NCT00000579_10_T0	PHENOTYPE	5	5	ARDS
NCT0000057912	NCT00000579_12_T0	PHENOTYPE	11	12	critically ill
NCT0000057913	NCT00000579_13_T0	PHENOTYPE	17	17	acute
NCT0000057914	NCT00000579_14_T0	PHENOTYPE	6	6	ARDS
NCT0000057921	NCT00000579_21_T0	GENE	2	2	IIa
NCT0000057923	NCT00000579_23_T0	GENE	2	2	IIb
NCT0000057923	NCT00000579_23_T1	PHENOTYPE	26	26	closed
NCT0000057925	NCT00000579_25_T0	GENE	2	2	III
NCT0000057927	NCT00000579_27_T0	PHENOTYPE	12	12	ventilation
NCT0000057927	NCT00000579_27_T1	PHENOTYPE	25	25	ARDS
NCT0000057927	NCT00000579_27_T2	GENE	0	0	KARMA
NCT0000057927	NCT00000579_27_T3	PHENOTYPE	21	23	acute lung injury
NCT0000057928	NCT00000579_28_T0	COMPOUND	8	8	thromboxane
NCT0000057928	NCT00000579_28_T1	COMPOUND	6	6	ketoconazole
NCT0000057928	NCT00000579_28_T2	PHENOTYPE	23	23	ARDS
NCT0000057928	NCT00000579_28_T3	PHENOTYPE	19	21	acute lung injury
NCT0000057930	NCT00000579_30_T0	PHENOTYPE	10	10	ventilation
NCT0000057930	NCT00000579_30_T1	PHENOTYPE	15	16	lung function
NCT0000057933	NCT00000579_33_T0	COMPOUND	3	3	lisofylline
NCT0000057933	NCT00000579_33_T1	PHENOTYPE	13	13	ventilation
NCT0000057933	NCT00000579_33_T2	COMPOUND	8	8	ketoconazole
NCT0000057934	NCT00000579_34_T0	COMPOUND	1	1	lisofylline
NCT0000057935	NCT00000579_35_T0	COMPOUND	6	6	lisofylline
NCT0000057935	NCT00000579_35_T1	COMPOUND	10	10	pentoxifylline
NCT0000057935	NCT00000579_35_T2	GENE	12	12	has
NCT0000057936	NCT00000579_36_T0	COMPOUND	16	16	lisofylline
NCT0000057936	NCT00000579_36_T1	PHENOTYPE	11	11	ventilation
NCT0000057936	NCT00000579_36_T2	PHENOTYPE	9	10	tidal volume
NCT0000057937	NCT00000579_37_T0	COMPOUND	4	4	lisofylline
NCT0000057937	NCT00000579_37_T1	COMPOUND	13	13	lisofylline
NCT0000057937	NCT00000579_37_T2	PHENOTYPE	23	23	ARDS
NCT0000057937	NCT00000579_37_T3	PHENOTYPE	19	21	acute lung injury
NCT0000057940	NCT00000579_40_T0	PHENOTYPE	8	8	ventilation
NCT0000057940	NCT00000579_40_T1	PHENOTYPE	10	11	organ failure
NCT0000057941	NCT00000579_41_T0	PHENOTYPE	42	42	ARDS
NCT0000057941	NCT00000579_41_T1	PHENOTYPE	18	21	Acute Respiratory Distress Syndrome
NCT0000057942	NCT00000579_42_T0	COMPOUND	11	11	succinate
NCT0000057942	NCT00000579_42_T1	COMPOUND	10	10	sodium
NCT0000057942	NCT00000579_42_T2	COMPOUND	9	9	methylprednisolone
NCT0000057942	NCT00000579_42_T3	PHENOTYPE	14	14	ARDS
NCT0000057944	NCT00000579_44_T0	PHENOTYPE	0	0	Secondary
NCT0000057946	NCT00000579_46_T0	PHENOTYPE	7	7	recruitment
NCT0000057946	NCT00000579_46_T1	GENE	5	5	reduced
NCT0000057951	NCT00000579_51_T0	PHENOTYPE	0	0	Secondary
NCT0000057952	NCT00000579_52_T0	GENE	2	2	has
NCT0000057955	NCT00000579_55_T0	PHENOTYPE	35	35	PACs
NCT0000057955	NCT00000579_55_T1	ORGAN	10	11	Pulmonary Artery
NCT0000057959	NCT00000579_59_T0	PHENOTYPE	0	0	Secondary
NCT0000057962	NCT00000579_62_T0	GENE	2	2	II
NCT0000057964	NCT00000579_64_T0	GENE	30	30	II
NCT0000057964	NCT00000579_64_T1	GENE	3	3	III
NCT0000057966	NCT00000579_66_T0	PHENOTYPE	26	26	ARDS
NCT0000057967	NCT00000579_67_T0	GENE	2	2	has
NCT0000057967	NCT00000579_67_T1	GENE	4	4	extended
NCT000005802	NCT00000580_2_T0	PHENOTYPE	7	7	hepatoma
NCT000005802	NCT00000580_2_T1	GENE	17	17	had
NCT000005802	NCT00000580_2_T2	PHENOTYPE	16	16	disorders
NCT000005802	NCT00000580_2_T3	PHENOTYPE	5	5	cirrhosis
NCT000005802	NCT00000580_2_T4	PHENOTYPE	25	26	hepatitis B
NCT000005802	NCT00000580_2_T5	PHENOTYPE	3	4	acute hepatitis
NCT000005803	NCT00000580_3_T0	GENE	31	31	globulin
NCT000005803	NCT00000580_3_T1	PHENOTYPE	28	29	hepatitis B
NCT000005805	NCT00000580_5_T0	PHENOTYPE	10	10	fixation
NCT000005805	NCT00000580_5_T1	GENE	7	7	had
NCT000005805	NCT00000580_5_T2	GENE	13	13	1.8
NCT000005806	NCT00000580_6_T0	ORGAN	9	10	cord blood
NCT0000058010	NCT00000580_10_T0	GENE	19	19	albumin
NCT0000058010	NCT00000580_10_T1	GENE	14	14	globulin
NCT0000058010	NCT00000580_10_T2	GENE	17	17	globulin
NCT0000058010	NCT00000580_10_T3	PHENOTYPE	11	12	hepatitis B
NCT0000058011	NCT00000580_11_T0	GENE	13	13	QVR
NCT000005813	NCT00000581_3_T0	CELL	18	18	granulocyte
NCT000005813	NCT00000581_3_T1	PHENOTYPE	6	6	septicemia
NCT000005814	NCT00000581_4_T0	CELL	12	12	granulocytes
NCT000005814	NCT00000581_4_T1	PHENOTYPE	29	29	infections
NCT000005815	NCT00000581_5_T0	CELL	6	6	granulocyte
NCT000005815	NCT00000581_5_T1	PHENOTYPE	15	15	septicemia
NCT000005815	NCT00000581_5_T2	GENE	1	1	had
NCT000005815	NCT00000581_5_T3	PHENOTYPE	23	23	granulocytopenia
NCT000005816	NCT00000581_6_T0	CELL	18	18	granulocytes
NCT000005816	NCT00000581_6_T1	CELL	32	32	granulocytes
NCT000005816	NCT00000581_6_T2	PHENOTYPE	10	10	infections
NCT000005817	NCT00000581_7_T0	CELL	7	7	granulocytes
NCT000005819	NCT00000581_9_T0	CELL	9	9	granulocyte
NCT0000058112	NCT00000581_12_T0	PHENOTYPE	1	1	Recruitment
NCT0000058113	NCT00000581_13_T0	GENE	2	2	has
NCT0000058115	NCT00000581_15_T0	CELL	6	6	granulocyte
NCT0000058115	NCT00000581_15_T1	CELL	10	10	granulocyte
NCT0000058116	NCT00000581_16_T0	PHENOTYPE	9	9	inferred
NCT000005820	NCT00000582_0_T0	GENE	3	4	Factor VIII
NCT000005823	NCT00000582_3_T0	GENE	12	13	Factor VIII
NCT000005824	NCT00000582_4_T0	PHENOTYPE	18	18	hemophilia
NCT000005824	NCT00000582_4_T1	PHENOTYPE	40	40	hemophilia
NCT000005824	NCT00000582_4_T2	PHENOTYPE	3	4	Blood Diseases
NCT000005824	NCT00000582_4_T3	GENE	21	22	Factor VIII
NCT000005825	NCT00000582_5_T0	PHENOTYPE	10	10	bleeding
NCT000005826	NCT00000582_6_T0	GENE	12	12	prothrombin
NCT000005826	NCT00000582_6_T1	GENE	16	16	IX
NCT000005826	NCT00000582_6_T2	GENE	5	6	Factor VIII
NCT000005827	NCT00000582_7_T0	GENE	4	4	IX
NCT000005827	NCT00000582_7_T1	GENE	12	13	Factor VIII
NCT0000058210	NCT00000582_10_T0	GENE	13	13	DBDR
NCT0000058210	NCT00000582_10_T1	GENE	5	5	IX
NCT0000058211	NCT00000582_11_T0	GENE	16	17	Factor VIII
NCT0000058214	NCT00000582_14_T0	GENE	16	16	albumin
NCT000005832	NCT00000583_2_T0	PHENOTYPE	7	8	hepatitis B
NCT000005832	NCT00000583_2_T1	PHENOTYPE	18	19	hepatocellular carcinoma
NCT000005834	NCT00000583_4_T0	PHENOTYPE	11	12	hepatitis B
NCT000005836	NCT00000583_6_T0	ORGAN	26	26	plasma
NCT000005836	NCT00000583_6_T1	PHENOTYPE	28	28	chronic
NCT000005838	NCT00000583_8_T0	PHENOTYPE	12	12	recruitment
NCT000005838	NCT00000583_8_T1	GENE	13	13	had
NCT0000058312	NCT00000583_12_T0	ORGAN	25	25	plasma
NCT0000058312	NCT00000583_12_T1	PHENOTYPE	27	27	chronic
NCT0000058312	NCT00000583_12_T2	PHENOTYPE	30	31	hepatitis B
NCT000005842	NCT00000584_2_T0	PHENOTYPE	3	3	infections
NCT000005845	NCT00000584_5_T0	GENE	1	1	had
NCT000005846	NCT00000584_6_T0	GENE	12	12	globin
NCT000005846	NCT00000584_6_T1	PHENOTYPE	14	15	premature infants
NCT0000058412	NCT00000584_12_T0	PHENOTYPE	9	9	inferred
NCT000005852	NCT00000585_2_T0	PHENOTYPE	3	3	septicemia
NCT000005852	NCT00000585_2_T1	PHENOTYPE	1	1	pneumonia
NCT000005852	NCT00000585_2_T2	PHENOTYPE	0	0	Meningitis
NCT000005856	NCT00000585_6_T0	COMPOUND	21	21	penicillin
NCT000005856	NCT00000585_6_T1	GENE	15	15	reduced
NCT000005856	NCT00000585_6_T2	GENE	2	2	had
NCT000005856	NCT00000585_6_T3	PHENOTYPE	8	9	pneumococcal infection
NCT000005858	NCT00000585_8_T0	COMPOUND	9	9	penicillin
NCT000005859	NCT00000585_9_T0	PHENOTYPE	11	11	pneumoniae
NCT0000058510	NCT00000585_10_T0	PHENOTYPE	1	1	secondary
NCT0000058510	NCT00000585_10_T1	PHENOTYPE	14	14	pneumoniae
NCT0000058511	NCT00000585_11_T0	GENE	21	21	II
NCT0000058511	NCT00000585_11_T1	COMPOUND	12	12	penicillin
NCT0000058512	NCT00000585_12_T0	PHENOTYPE	0	0	Recruitment
NCT0000058513	NCT00000585_13_T0	GENE	5	5	II
NCT0000058514	NCT00000585_14_T0	GENE	1	1	II
NCT0000058514	NCT00000585_14_T1	COMPOUND	15	15	penicillin
NCT0000058515	NCT00000585_15_T0	COMPOUND	14	14	penicillin
NCT0000058517	NCT00000585_17_T0	COMPOUND	13	13	penicillin
NCT0000058517	NCT00000585_17_T1	PHENOTYPE	8	9	pneumococcal infection
NCT0000058517	NCT00000585_17_T2	PHENOTYPE	9	11	infection in children
NCT000005860	NCT00000586_0_T0	GENE	10	10	MSH
NCT000005860	NCT00000586_0_T1	PHENOTYPE	7	9	Sickle Cell Anemia
NCT000005864	NCT00000586_4_T0	PHENOTYPE	20	21	narcotics addiction
NCT0000058610	NCT00000586_10_T0	PHENOTYPE	12	12	toxicity
NCT0000058611	NCT00000586_11_T0	PHENOTYPE	0	0	Chronic
NCT0000058611	NCT00000586_11_T1	PHENOTYPE	14	14	isoimmunization
NCT0000058611	NCT00000586_11_T2	PHENOTYPE	22	22	hepatitis
NCT0000058611	NCT00000586_11_T3	PHENOTYPE	15	16	iron overload
NCT0000058611	NCT00000586_11_T4	PHENOTYPE	24	25	retroviral disease
NCT0000058612	NCT00000586_12_T0	GENE	20	20	Hb
NCT0000058612	NCT00000586_12_T1	GENE	33	33	Hb
NCT0000058612	NCT00000586_12_T2	GENE	19	19	hemoglobin
NCT0000058613	NCT00000586_13_T0	COMPOUND	7	7	hydroxyurea
NCT0000058613	NCT00000586_13_T1	COMPOUND	5	5	5_azacytidine
NCT0000058613	NCT00000586_13_T2	GENE	13	13	Hb
NCT0000058614	NCT00000586_14_T0	PHENOTYPE	15	15	malignancy
NCT0000058614	NCT00000586_14_T1	COMPOUND	3	3	5_azacytidine
NCT0000058614	NCT00000586_14_T2	GENE	5	5	had
NCT0000058614	NCT00000586_14_T3	GENE	4	4	has
NCT0000058617	NCT00000586_17_T0	GENE	8	8	had
NCT0000058617	NCT00000586_17_T1	GENE	2	2	has
NCT0000058620	NCT00000586_20_T0	GENE	4	4	has
NCT0000058621	NCT00000586_21_T0	GENE	1	1	II
NCT0000058622	NCT00000586_22_T0	GENE	4	4	II
NCT0000058622	NCT00000586_22_T1	COMPOUND	15	15	hydroxyurea
NCT0000058624	NCT00000586_24_T0	GENE	2	2	Hb
NCT0000058629	NCT00000586_29_T0	COMPOUND	6	6	hydroxyurea
NCT0000058631	NCT00000586_31_T0	COMPOUND	11	11	hydroxyurea
NCT0000058631	NCT00000586_31_T1	GENE	12	12	reduced
NCT0000058632	NCT00000586_32_T0	GENE	12	12	MSH
NCT0000058633	NCT00000586_33_T0	COMPOUND	9	9	hydroxyurea
NCT0000058634	NCT00000586_34_T0	PHENOTYPE	13	13	malignancies
NCT0000058634	NCT00000586_34_T1	PHENOTYPE	15	16	birth defects
NCT0000058634	NCT00000586_34_T2	PHENOTYPE	8	10	quality of life
NCT0000058635	NCT00000586_35_T0	PHENOTYPE	25	27	Sickle Cell Disease
NCT0000058638	NCT00000586_38_T0	GENE	1	1	II
NCT0000058638	NCT00000586_38_T1	GENE	13	13	extended
NCT0000058639	NCT00000586_39_T0	GENE	1	1	III
NCT0000058640	NCT00000586_40_T0	GENE	3	3	MSH
NCT0000058640	NCT00000586_40_T1	COMPOUND	12	12	hydroxyurea
NCT0000058640	NCT00000586_40_T2	GENE	5	5	III
NCT0000058640	NCT00000586_40_T3	GENE	14	14	reduced
NCT000005873	NCT00000587_3_T0	COMPOUND	3	3	zidovudine
NCT000005873	NCT00000587_3_T1	PHENOTYPE	4	4	anemia
NCT000005873	NCT00000587_3_T2	PHENOTYPE	25	26	blood supply
NCT000005874	NCT00000587_4_T0	PHENOTYPE	18	19	AIDS-Related Complex
NCT000005874	NCT00000587_4_T1	PHENOTYPE	12	14	Bone Marrow Suppression
NCT000005879	NCT00000587_9_T0	GENE	6	6	had
NCT0000058710	NCT00000587_10_T0	GENE	6	6	had
NCT0000058710	NCT00000587_10_T1	PHENOTYPE	4	5	Group B
NCT0000058711	NCT00000587_11_T0	GENE	17	17	hemoglobin
NCT0000058712	NCT00000587_12_T0	GENE	13	13	erythropoietin
NCT0000058713	NCT00000587_13_T0	PHENOTYPE	3	3	recruitment
NCT000005883	NCT00000588_3_T0	ORGAN	7	7	liver
NCT000005883	NCT00000588_3_T1	ORGAN	8	8	heart
NCT000005883	NCT00000588_3_T2	ORGAN	9	9	pancreas
NCT000005883	NCT00000588_3_T3	PHENOTYPE	24	25	cardiac failure
NCT000005888	NCT00000588_8_T0	PHENOTYPE	22	22	complications
NCT000005888	NCT00000588_8_T1	PHENOTYPE	11	12	thalassemia major
NCT000005888	NCT00000588_8_T2	PHENOTYPE	24	25	iron overload
NCT000005889	NCT00000588_9_T0	PHENOTYPE	15	15	anemias
NCT0000058811	NCT00000588_11_T0	PHENOTYPE	15	16	iron overload
NCT0000058812	NCT00000588_12_T0	GENE	0	0	PIH
NCT0000058813	NCT00000588_13_T0	COMPOUND	22	22	isoniazid
NCT0000058813	NCT00000588_13_T1	PHENOTYPE	8	8	condensation
NCT0000058813	NCT00000588_13_T2	COMPOUND	17	17	pyridoxal
NCT0000058816	NCT00000588_16_T0	PHENOTYPE	15	15	Disorders
NCT0000058816	NCT00000588_16_T1	PHENOTYPE	11	12	Cooley's Anemia
NCT0000058816	NCT00000588_16_T2	PHENOTYPE	9	10	Iron Overload
NCT0000058817	NCT00000588_17_T0	GENE	9	9	II
NCT0000058818	NCT00000588_18_T0	PHENOTYPE	24	24	anemias
NCT0000058818	NCT00000588_18_T1	GENE	9	9	PIH
NCT0000058819	NCT00000588_19_T0	GENE	20	20	had
NCT0000058819	NCT00000588_19_T1	PHENOTYPE	25	25	chronic
NCT0000058819	NCT00000588_19_T2	GENE	9	9	PIH
NCT0000058819	NCT00000588_19_T3	PHENOTYPE	14	15	iron stores
NCT0000058820	NCT00000588_20_T0	GENE	8	8	PIH
NCT0000058824	NCT00000588_24_T0	GENE	0	0	PIH
NCT0000058825	NCT00000588_25_T0	COMPOUND	10	10	deferiprone
NCT0000058825	NCT00000588_25_T1	PHENOTYPE	18	18	concentrations
NCT0000058825	NCT00000588_25_T2	PHENOTYPE	24	24	complications
NCT0000058825	NCT00000588_25_T3	PHENOTYPE	22	22	avoidance
NCT0000058825	NCT00000588_25_T4	PHENOTYPE	26	27	iron overload
NCT000005894	NCT00000589_4_T0	CELL	9	9	platelet
NCT000005895	NCT00000589_5_T0	CELL	14	14	platelet
NCT000005895	NCT00000589_5_T1	ORGAN	3	3	heart
NCT000005896	NCT00000589_6_T0	CELL	11	11	platelet
NCT000005896	NCT00000589_6_T1	PHENOTYPE	12	12	alloimmunization
NCT000005896	NCT00000589_6_T2	CELL	24	24	platelets
NCT000005897	NCT00000589_7_T0	CELL	23	23	platelet
NCT000005897	NCT00000589_7_T1	GENE	15	15	had
NCT000005899	NCT00000589_9_T0	CELL	1	1	platelet
NCT000005899	NCT00000589_9_T1	CELL	11	11	platelet
NCT000005899	NCT00000589_9_T2	PHENOTYPE	12	12	alloimmunization
NCT0000058910	NCT00000589_10_T0	CELL	11	11	platelet
NCT0000058910	NCT00000589_10_T1	CELL	29	29	platelet
NCT0000058910	NCT00000589_10_T2	CELL	50	50	platelet
NCT0000058910	NCT00000589_10_T3	CELL	57	57	platelet
NCT0000058910	NCT00000589_10_T4	PHENOTYPE	12	12	alloimmunization
NCT0000058910	NCT00000589_10_T5	CELL	45	45	lymphocyte
NCT0000058910	NCT00000589_10_T6	CELL	38	40	antigen presenting cells
NCT0000058916	NCT00000589_16_T0	CELL	9	9	platelets
NCT0000058918	NCT00000589_18_T0	CELL	16	16	granulocyte
NCT0000058918	NCT00000589_18_T1	ORGAN	20	20	transplant
NCT0000058918	NCT00000589_18_T2	CELL	14	14	platelet
NCT0000058918	NCT00000589_18_T3	PHENOTYPE	10	11	adverse reaction
NCT0000058918	NCT00000589_18_T4	ORGAN	18	19	bone marrow
NCT0000058919	NCT00000589_19_T0	CELL	9	9	platelet
NCT0000058921	NCT00000589_21_T0	PHENOTYPE	0	0	Recruitment
NCT000005901	NCT00000590_1_T0	PHENOTYPE	18	18	Allergy
NCT000005901	NCT00000590_1_T1	PHENOTYPE	11	12	Human Development
NCT000005901	NCT00000590_1_T2	PHENOTYPE	20	21	Infectious Diseases
NCT000005902	NCT00000590_2_T0	GENE	4	4	ACTG
NCT000005904	NCT00000590_4_T0	PHENOTYPE	14	14	infections
NCT000005904	NCT00000590_4_T1	GENE	10	10	reduced
NCT000005904	NCT00000590_4_T2	GENE	9	9	has
NCT000005905	NCT00000590_5_T0	PHENOTYPE	19	19	HIV
NCT000005908	NCT00000590_8_T0	PHENOTYPE	1	1	Centers
NCT000005909	NCT00000590_9_T0	PHENOTYPE	15	15	HIV
NCT0000059011	NCT00000590_11_T0	PHENOTYPE	5	5	understood
NCT0000059014	NCT00000590_14_T0	COMPOUND	9	9	zidovudine
NCT0000059014	NCT00000590_14_T1	PHENOTYPE	28	28	HIV
NCT0000059014	NCT00000590_14_T2	GENE	20	20	ACTG
NCT0000059017	NCT00000590_17_T0	PHENOTYPE	16	17	neonatal infection
NCT0000059018	NCT00000590_18_T0	PHENOTYPE	13	13	HIV
NCT0000059018	NCT00000590_18_T1	ORGAN	19	19	genital
NCT0000059018	NCT00000590_18_T2	BIOLOGICAL_PROCESS	24	24	parturition
NCT0000059019	NCT00000590_19_T0	GENE	9	9	ACTG
NCT0000059020	NCT00000590_20_T0	PHENOTYPE	9	9	HIV
NCT0000059020	NCT00000590_20_T1	PHENOTYPE	57	57	HIV
NCT0000059020	NCT00000590_20_T2	GENE	1	1	ACTG
NCT0000059020	NCT00000590_20_T3	BIOLOGICAL_PROCESS	25	25	gestation
NCT0000059023	NCT00000590_23_T0	PHENOTYPE	9	9	HIV
NCT0000059027	NCT00000590_27_T0	GENE	25	25	p24
NCT0000059027	NCT00000590_27_T1	PHENOTYPE	22	22	HIV
NCT0000059027	NCT00000590_27_T2	PHENOTYPE	31	31	HIV
NCT0000059027	NCT00000590_27_T3	ORGAN	28	28	plasma
NCT0000059027	NCT00000590_27_T4	PHENOTYPE	29	29	viremia
NCT000005912	NCT00000591_2_T0	CELL	23	23	Leukocyte
NCT000005912	NCT00000591_2_T1	ORGAN	9	9	transplant
NCT000005914	NCT00000591_4_T0	ORGAN	9	9	transplant
NCT000005915	NCT00000591_5_T0	ORGAN	2	2	transplant
NCT000005916	NCT00000591_6_T0	ORGAN	11	11	marrow
NCT000005916	NCT00000591_6_T1	PHENOTYPE	9	9	complication
NCT000005916	NCT00000591_6_T2	PHENOTYPE	0	3	Graft versus host disease
NCT000005918	NCT00000591_8_T0	PHENOTYPE	2	2	pathophysiology
NCT000005918	NCT00000591_8_T1	CELL	24	25	T cells
NCT000005919	NCT00000591_9_T0	ORGAN	10	10	marrow
NCT000005919	NCT00000591_9_T1	ORGAN	17	17	marrow
NCT0000059112	NCT00000591_12_T0	CELL	3	4	stem cells
NCT0000059113	NCT00000591_13_T0	PHENOTYPE	28	28	complications
NCT0000059113	NCT00000591_13_T1	ORGAN	11	11	transplants
NCT0000059113	NCT00000591_13_T2	PHENOTYPE	30	31	graft failure
NCT0000059113	NCT00000591_13_T3	PHENOTYPE	33	34	leukemia relapse
NCT0000059114	NCT00000591_14_T0	PHENOTYPE	25	25	acute
NCT0000059114	NCT00000591_14_T1	PHENOTYPE	15	15	leukemias
NCT0000059114	NCT00000591_14_T2	PHENOTYPE	22	22	relapse
NCT0000059114	NCT00000591_14_T3	PHENOTYPE	27	27	chronic
NCT0000059115	NCT00000591_15_T0	ORGAN	26	26	marrow
NCT0000059115	NCT00000591_15_T1	ORGAN	17	17	transplants
NCT0000059116	NCT00000591_16_T0	CELL	3	3	T-cell
NCT0000059116	NCT00000591_16_T1	ORGAN	7	7	transplants
NCT0000059117	NCT00000591_17_T0	PHENOTYPE	33	33	complication
NCT0000059117	NCT00000591_17_T1	GENE	40	40	has
NCT0000059117	NCT00000591_17_T2	ORGAN	37	37	transplants
NCT0000059117	NCT00000591_17_T3	ORGAN	14	15	bone marrow
NCT0000059117	NCT00000591_17_T4	PHENOTYPE	23	26	graft versus host disease
NCT0000059119	NCT00000591_19_T0	ORGAN	16	16	transplant
NCT0000059120	NCT00000591_20_T0	PHENOTYPE	0	0	Secondary
NCT0000059120	NCT00000591_20_T1	PHENOTYPE	13	13	complications
NCT0000059120	NCT00000591_20_T2	PHENOTYPE	10	10	infections
NCT0000059120	NCT00000591_20_T3	PHENOTYPE	8	9	graft failure
NCT0000059120	NCT00000591_20_T4	PHENOTYPE	17	18	disease relapse
NCT0000059121	NCT00000591_21_T0	ORGAN	14	14	transplant
NCT0000059121	NCT00000591_21_T1	ORGAN	22	22	transplant
NCT0000059121	NCT00000591_21_T2	ORGAN	24	24	transplant
NCT0000059123	NCT00000591_23_T0	ORGAN	13	13	transplant
NCT0000059123	NCT00000591_23_T1	CELL	8	8	T-cell
NCT0000059124	NCT00000591_24_T0	GENE	9	9	CD3
NCT0000059124	NCT00000591_24_T1	CELL	3	3	T-cell
NCT0000059125	NCT00000591_25_T0	PHENOTYPE	14	14	conditioning
NCT0000059125	NCT00000591_25_T1	ORGAN	13	13	transplant
NCT0000059129	NCT00000591_29_T0	PHENOTYPE	5	5	centers
NCT0000059129	NCT00000591_29_T1	ORGAN	4	4	transplant
NCT000005922	NCT00000592_2_T0	PHENOTYPE	8	8	recurrence
NCT000005922	NCT00000592_2_T1	PHENOTYPE	17	18	hemoglobin S
NCT000005923	NCT00000592_3_T0	PHENOTYPE	13	13	complications
NCT000005923	NCT00000592_3_T1	PHENOTYPE	9	10	iron overload
NCT000005924	NCT00000592_4_T0	GENE	14	14	SS
NCT000005924	NCT00000592_4_T1	GENE	2	2	has
NCT000005924	NCT00000592_4_T2	PHENOTYPE	11	11	recurrent
NCT000005925	NCT00000592_5_T0	PHENOTYPE	8	8	secondary
NCT000005926	NCT00000592_6_T0	PHENOTYPE	5	5	recurrence
NCT000005926	NCT00000592_6_T1	GENE	8	8	reduced
NCT000005928	NCT00000592_8_T0	PHENOTYPE	3	3	complications
NCT000005929	NCT00000592_9_T0	GENE	4	4	had
NCT0000059213	NCT00000592_13_T0	GENE	4	4	III
NCT0000059216	NCT00000592_16_T0	PHENOTYPE	5	5	symptoms
NCT0000059216	NCT00000592_16_T1	GENE	16	16	MRI
NCT0000059216	NCT00000592_16_T2	PHENOTYPE	19	20	intracranial hemorrhage
NCT0000059216	NCT00000592_16_T3	PHENOTYPE	7	8	cerebral infarction
NCT0000059217	NCT00000592_17_T0	PHENOTYPE	0	0	Secondary
NCT0000059217	NCT00000592_17_T1	GENE	8	8	MRI
NCT0000059217	NCT00000592_17_T2	PHENOTYPE	4	5	brain lesions
NCT0000059218	NCT00000592_18_T0	ORGAN	10	10	serum
NCT0000059219	NCT00000592_19_T0	PHENOTYPE	0	0	Recruitment
NCT000005930	NCT00000593_0_T0	PHENOTYPE	0	1	Viral Activation
NCT000005935	NCT00000593_5_T0	CELL	22	22	cells
NCT000005937	NCT00000593_7_T0	GENE	10	10	MM3
NCT000005937	NCT00000593_7_T1	GENE	6	6	CD4
NCT000005937	NCT00000593_7_T2	GENE	16	16	CD4
NCT000005938	NCT00000593_8_T0	COMPOUND	13	13	1st
NCT000005938	NCT00000593_8_T1	PHENOTYPE	9	9	HIV
NCT000005938	NCT00000593_8_T2	PHENOTYPE	10	10	viremia
NCT000005939	NCT00000593_9_T0	PHENOTYPE	1	1	secondary
NCT000005939	NCT00000593_9_T1	PHENOTYPE	10	10	complication
NCT0000059310	NCT00000593_10_T0	CELL	5	5	lymphocytes
NCT0000059310	NCT00000593_10_T1	PHENOTYPE	21	22	graft-vs-host disease
NCT0000059311	NCT00000593_11_T0	PHENOTYPE	2	2	recruitment
NCT0000059311	NCT00000593_11_T1	GENE	5	5	extended
NCT0000059312	NCT00000593_12_T0	GENE	4	4	protease
NCT0000059312	NCT00000593_12_T1	GENE	12	12	has
NCT0000059313	NCT00000593_13_T0	PHENOTYPE	4	4	severely
NCT0000059313	NCT00000593_13_T1	PHENOTYPE	11	11	anemia
NCT0000059314	NCT00000593_14_T0	PHENOTYPE	6	6	anemia
NCT0000059314	NCT00000593_14_T1	PHENOTYPE	9	10	side effect
NCT0000059316	NCT00000593_16_T0	GENE	21	21	QVR
NCT000005942	NCT00000594_2_T0	GENE	13	13	had
NCT000005942	NCT00000594_2_T1	PHENOTYPE	23	23	regression
NCT000005942	NCT00000594_2_T2	PHENOTYPE	38	39	myocardial infarction
NCT000005942	NCT00000594_2_T3	PHENOTYPE	14	16	coronary artery disease
NCT000005943	NCT00000594_3_T0	GENE	4	4	contrasted
NCT000005944	NCT00000594_4_T0	PHENOTYPE	14	16	coronary heart disease
NCT000005946	NCT00000594_6_T0	COMPOUND	6	6	cholestyramine
NCT000005948	NCT00000594_8_T0	PHENOTYPE	8	8	progression
NCT000005948	NCT00000594_8_T1	PHENOTYPE	10	11	coronary disease
NCT000005948	NCT00000594_8_T2	PHENOTYPE	22	23	myocardial infarction
NCT000005952	NCT00000595_2_T0	PHENOTYPE	18	18	arrhythmia
NCT000005952	NCT00000595_2_T1	PHENOTYPE	9	10	iron deposition
NCT000005952	NCT00000595_2_T2	PHENOTYPE	15	16	cardiac failure
NCT000005953	NCT00000595_3_T0	PHENOTYPE	1	1	complications
NCT000005953	NCT00000595_3_T1	PHENOTYPE	0	0	Endocrine
NCT000005953	NCT00000595_3_T2	PHENOTYPE	3	4	hepatic enlargement
NCT000005955	NCT00000595_5_T0	COMPOUND	3	3	deferoxamine
NCT000005955	NCT00000595_5_T1	GENE	16	16	10
NCT000005955	NCT00000595_5_T2	PHENOTYPE	27	28	cardiac complications
NCT000005957	NCT00000595_7_T0	COMPOUND	7	7	deferoxamine
NCT000005957	NCT00000595_7_T1	COMPOUND	9	10	ascorbic acid
NCT000005958	NCT00000595_8_T0	COMPOUND	1	2	ascorbic acid
NCT000005959	NCT00000595_9_T0	COMPOUND	6	6	deferoxamine
NCT000005959	NCT00000595_9_T1	PHENOTYPE	27	28	iron overload
NCT000005959	NCT00000595_9_T2	COMPOUND	12	13	ascorbic acid
NCT0000059510	NCT00000595_10_T0	PHENOTYPE	4	4	beta-thalassemia
NCT0000059511	NCT00000595_11_T0	COMPOUND	7	8	ascorbic acid
NCT0000059515	NCT00000595_15_T0	PHENOTYPE	9	10	iron stores
NCT0000059516	NCT00000595_16_T0	PHENOTYPE	0	1	Endocrine function
NCT0000059517	NCT00000595_17_T0	COMPOUND	6	6	deferoxamine
NCT0000059517	NCT00000595_17_T1	GENE	16	16	ferritin
NCT0000059517	NCT00000595_17_T2	ORGAN	22	22	liver
NCT0000059517	NCT00000595_17_T3	ORGAN	15	15	serum
NCT0000059518	NCT00000595_18_T0	PHENOTYPE	10	11	endocrine function
NCT0000059519	NCT00000595_19_T0	PHENOTYPE	9	9	inferred
NCT000005962	NCT00000596_2_T0	PHENOTYPE	14	14	sarcoidosis
NCT000005965	NCT00000596_5_T0	PHENOTYPE	34	34	symptoms
NCT000005965	NCT00000596_5_T1	PHENOTYPE	15	15	chronic
NCT000005965	NCT00000596_5_T2	PHENOTYPE	11	12	lung disorders
NCT000005965	NCT00000596_5_T3	PHENOTYPE	0	2	Idiopathic pulmonary fibrosis
NCT000005968	NCT00000596_8_T0	PHENOTYPE	4	4	pneumonitis
NCT000005968	NCT00000596_8_T1	PHENOTYPE	14	15	lung function
NCT000005969	NCT00000596_9_T0	GENE	18	18	has
NCT000005969	NCT00000596_9_T1	PHENOTYPE	20	20	resolved
NCT000005969	NCT00000596_9_T2	PHENOTYPE	15	16	pulmonary sarcoidosis
NCT0000059612	NCT00000596_12_T0	COMPOUND	3	3	dapsone
NCT0000059612	NCT00000596_12_T1	COMPOUND	11	11	dapsone
NCT0000059612	NCT00000596_12_T2	COMPOUND	13	13	prednisone
NCT0000059613	NCT00000596_13_T0	COMPOUND	4	4	methylprednisolone
NCT0000059613	NCT00000596_13_T1	COMPOUND	13	13	methylprednisolone
NCT0000059613	NCT00000596_13_T2	COMPOUND	24	24	methylprednisolone
NCT0000059614	NCT00000596_14_T0	COMPOUND	22	22	methylprednisolone
NCT0000059614	NCT00000596_14_T1	PHENOTYPE	12	13	pulmonary sarcoidosis
NCT0000059615	NCT00000596_15_T0	PHENOTYPE	9	9	inferred
NCT000005972	NCT00000597_2_T0	GENE	6	6	has
NCT000005972	NCT00000597_2_T1	GENE	20	20	has
NCT000005972	NCT00000597_2_T2	PHENOTYPE	4	5	aplastic anemia
NCT000005972	NCT00000597_2_T3	PHENOTYPE	15	17	mechanism of action
NCT000005973	NCT00000597_3_T0	CELL	9	9	thymocytes
NCT000005973	NCT00000597_3_T1	ORGAN	1	1	serum
NCT000005973	NCT00000597_3_T2	PHENOTYPE	16	17	human cells
NCT000005976	NCT00000597_6_T0	GENE	3	3	III
NCT000005976	NCT00000597_6_T1	PHENOTYPE	8	10	bone marrow diseases
NCT000005977	NCT00000597_7_T0	PHENOTYPE	9	9	inferred
NCT0000059810	NCT00000598_10_T0	PHENOTYPE	7	7	secondary
NCT000005990	NCT00000599_0_T0	PHENOTYPE	1	1	Atherosclerosis
NCT000005992	NCT00000599_2_T0	PHENOTYPE	20	20	atherosclerosis
NCT000005992	NCT00000599_2_T1	GENE	12	12	lipoprotein
NCT000005992	NCT00000599_2_T2	ORGAN	9	9	plasma
NCT000005992	NCT00000599_2_T3	ORGAN	26	27	carotid arteries
NCT000005992	NCT00000599_2_T4	PHENOTYPE	13	14	cholesterol levels
NCT000005994	NCT00000599_4_T0	PHENOTYPE	6	6	atherosclerosis
NCT000005994	NCT00000599_4_T1	GENE	25	25	II
NCT000005994	NCT00000599_4_T2	GENE	36	36	had
NCT000005994	NCT00000599_4_T3	GENE	35	35	al
NCT000005994	NCT00000599_4_T4	GENE	34	34	et
NCT000005999	NCT00000599_9_T0	COMPOUND	13	13	hydrochloride
NCT000005999	NCT00000599_9_T1	COMPOUND	12	12	colestipol
NCT000005999	NCT00000599_9_T2	COMPOUND	20	20	niacin
NCT0000059917	NCT00000599_17_T0	PHENOTYPE	10	10	atherosclerosis
NCT0000059917	NCT00000599_17_T1	GENE	21	21	bypass
NCT0000059917	NCT00000599_17_T2	ORGAN	22	22	grafts
NCT0000059917	NCT00000599_17_T3	ORGAN	19	19	aorta
NCT0000059917	NCT00000599_17_T4	ORGAN	16	17	coronary arteries
NCT0000059922	NCT00000599_22_T0	GENE	8	8	bypass
NCT0000059927	NCT00000599_27_T0	GENE	13	13	QVR
NCT000006004	NCT00000600_4_T0	PHENOTYPE	30	30	atherosclerosis
NCT000006004	NCT00000600_4_T1	ORGAN	13	15	common carotid artery
NCT000006006	NCT00000600_6_T0	PHENOTYPE	4	4	progression
NCT000006008	NCT00000600_8_T0	GENE	19	19	II
NCT000006008	NCT00000600_8_T1	PHENOTYPE	25	25	progression
NCT000006008	NCT00000600_8_T2	COMPOUND	40	41	vitamin E
NCT000006009	NCT00000600_9_T0	COMPOUND	10	11	vitamin E
NCT0000060010	NCT00000600_10_T0	GENE	11	11	12
NCT0000060010	NCT00000600_10_T1	ORGAN	0	2	Common carotid artery
NCT0000060011	NCT00000600_11_T0	ORGAN	10	12	common carotid artery
NCT0000060012	NCT00000600_12_T0	GENE	13	13	QVR
NCT000006013	NCT00000601_3_T0	PHENOTYPE	6	6	atherosclerosis
NCT000006013	NCT00000601_3_T1	BIOLOGICAL_PROCESS	27	27	vasoconstriction
NCT000006013	NCT00000601_3_T2	COMPOUND	34	34	acetylcholine
NCT000006013	NCT00000601_3_T3	PHENOTYPE	20	21	endothelial dysfunction
NCT000006013	NCT00000601_3_T4	PHENOTYPE	40	41	myocardial ischemia
NCT000006015	NCT00000601_5_T0	COMPOUND	1	1	estrogen
NCT000006015	NCT00000601_5_T1	ORGAN	12	13	coronary arteries
NCT000006015	NCT00000601_5_T2	TISSUE	7	8	smooth muscle
NCT000006016	NCT00000601_6_T0	COMPOUND	12	12	estrogen
NCT000006016	NCT00000601_6_T1	PHENOTYPE	7	7	menopausal
NCT000006016	NCT00000601_6_T2	PHENOTYPE	16	17	vascular resistance
NCT000006016	NCT00000601_6_T3	PHENOTYPE	32	33	endothelial dysfunction
NCT000006016	NCT00000601_6_T4	BIOLOGICAL_PROCESS	26	28	response to acetylcholine
NCT000006023	NCT00000602_3_T0	PHENOTYPE	5	5	impairment
NCT000006026	NCT00000602_6_T0	PHENOTYPE	12	12	susceptible
NCT000006026	NCT00000602_6_T1	PHENOTYPE	8	9	viral infections
NCT000006026	NCT00000602_6_T2	PHENOTYPE	14	15	pneumococcal septicemia
NCT000006027	NCT00000602_7_T0	GENE	10	10	MSH
NCT000006027	NCT00000602_7_T1	PHENOTYPE	18	18	focused
NCT000006027	NCT00000602_7_T2	GENE	15	15	has
NCT000006029	NCT00000602_9_T0	GENE	6	6	hemoglobin
NCT0000060210	NCT00000602_10_T0	COMPOUND	5	5	hydroxyurea
NCT0000060210	NCT00000602_10_T1	PHENOTYPE	14	15	hemoglobin levels
NCT0000060212	NCT00000602_12_T0	GENE	5	5	II
NCT0000060212	NCT00000602_12_T1	COMPOUND	12	12	hydroxyurea
NCT0000060214	NCT00000602_14_T0	PHENOTYPE	16	16	toxicity
NCT0000060217	NCT00000602_17_T0	GENE	6	6	MTD
NCT0000060217	NCT00000602_17_T1	GENE	12	12	MTD
NCT0000060218	NCT00000602_18_T0	PHENOTYPE	9	9	Centers
NCT0000060219	NCT00000602_19_T0	PHENOTYPE	5	5	Center
NCT000006037	NCT00000603_7_T0	CELL	10	11	progenitor cells
NCT000006037	NCT00000603_7_T1	ORGAN	1	2	bone marrow
NCT000006037	NCT00000603_7_T2	ORGAN	13	14	bone marrow
NCT000006038	NCT00000603_8_T0	ORGAN	19	20	bone marrow
NCT000006039	NCT00000603_9_T0	ORGAN	12	12	Marrow
NCT000006039	NCT00000603_9_T1	ORGAN	4	5	bone marrow
NCT000006039	NCT00000603_9_T2	ORGAN	32	33	bone marrow
NCT0000060310	NCT00000603_10_T0	ORGAN	5	5	marrow
NCT0000060311	NCT00000603_11_T0	PHENOTYPE	25	26	infectious diseases
NCT0000060312	NCT00000603_12_T0	PHENOTYPE	9	9	minds
NCT0000060313	NCT00000603_13_T0	ORGAN	4	4	marrow
NCT0000060313	NCT00000603_13_T1	PHENOTYPE	18	18	anesthesia
NCT0000060316	NCT00000603_16_T0	PHENOTYPE	26	26	diseases
NCT0000060316	NCT00000603_16_T1	CELL	12	13	progenitor cells
NCT0000060316	NCT00000603_16_T2	ORGAN	18	19	bone marrow
NCT0000060316	NCT00000603_16_T3	ORGAN	1	3	umbilical cord blood
NCT0000060317	NCT00000603_17_T0	ORGAN	0	1	Cord blood
NCT0000060317	NCT00000603_17_T1	CELL	4	5	progenitor cells
NCT0000060317	NCT00000603_17_T2	PHENOTYPE	19	20	hematologic diseases
NCT0000060319	NCT00000603_19_T0	GENE	26	26	reduced
NCT0000060319	NCT00000603_19_T1	PHENOTYPE	10	10	recruitment
NCT0000060319	NCT00000603_19_T2	ORGAN	5	6	bone marrow
NCT0000060319	NCT00000603_19_T3	ORGAN	11	12	bone marrow
NCT0000060319	NCT00000603_19_T4	ORGAN	32	34	umbilical cord blood
NCT0000060320	NCT00000603_20_T0	GENE	12	12	has
NCT0000060322	NCT00000603_22_T0	ORGAN	19	19	transplants
NCT0000060323	NCT00000603_23_T0	ORGAN	24	24	graft
NCT0000060323	NCT00000603_23_T1	ORGAN	11	11	transplants
NCT0000060323	NCT00000603_23_T2	ORGAN	9	10	cord blood
NCT0000060323	NCT00000603_23_T3	ORGAN	27	28	bone marrow
NCT0000060324	NCT00000603_24_T0	PHENOTYPE	1	1	severity
NCT0000060325	NCT00000603_25_T0	ORGAN	10	10	transplants
NCT0000060326	NCT00000603_26_T0	ORGAN	18	18	grafts
NCT0000060326	NCT00000603_26_T1	ORGAN	16	17	cord blood
NCT0000060328	NCT00000603_28_T0	CELL	13	14	stem cells
NCT0000060328	NCT00000603_28_T1	ORGAN	16	17	cord blood
NCT0000060334	NCT00000603_34_T0	PHENOTYPE	32	32	complications
NCT0000060334	NCT00000603_34_T1	PHENOTYPE	18	19	graft-versus-host disease
NCT0000060337	NCT00000603_37_T0	PHENOTYPE	7	7	severity
NCT0000060337	NCT00000603_37_T1	PHENOTYPE	3	3	engraftment
NCT0000060337	NCT00000603_37_T2	PHENOTYPE	9	9	acute
NCT0000060337	NCT00000603_37_T3	PHENOTYPE	0	0	Secondary
NCT0000060337	NCT00000603_37_T4	PHENOTYPE	11	11	chronic
NCT0000060339	NCT00000603_39_T0	PHENOTYPE	0	0	Recruitment
NCT000006040	NCT00000604_0_T0	GENE	2	2	CPB
NCT000006043	NCT00000604_3_T0	GENE	11	11	had
NCT000006045	NCT00000604_5_T0	GENE	5	5	had
NCT000006045	NCT00000604_5_T1	PHENOTYPE	20	20	dysfunction
NCT000006047	NCT00000604_7_T0	PHENOTYPE	11	11	anesthesia
NCT000006048	NCT00000604_8_T0	GENE	5	5	had
NCT000006052	NCT00000605_2_T0	GENE	3	3	bypass
NCT000006052	NCT00000605_2_T1	PHENOTYPE	11	11	ischemia
NCT000006052	NCT00000605_2_T2	ORGAN	1	2	coronary artery
NCT000006055	NCT00000605_5_T0	COMPOUND	5	5	estrogen
NCT000006057	NCT00000605_7_T0	GENE	15	15	bypass
NCT000006057	NCT00000605_7_T1	COMPOUND	4	5	conjugated estrogen
NCT0000060510	NCT00000605_10_T0	GENE	6	6	hormone
NCT000006060	NCT00000606_0_T0	PHENOTYPE	1	1	Emphysema
NCT000006062	NCT00000606_2_T0	PHENOTYPE	15	15	Centers
NCT000006062	NCT00000606_2_T1	GENE	21	21	CMS
NCT000006064	NCT00000606_4_T0	PHENOTYPE	11	11	distal
NCT000006064	NCT00000606_4_T1	PHENOTYPE	7	7	enlargement
NCT000006064	NCT00000606_4_T2	PHENOTYPE	27	27	fibrosis
NCT000006064	NCT00000606_4_T3	PHENOTYPE	0	0	Emphysema
NCT000006064	NCT00000606_4_T4	ORGAN	14	15	terminal bronchioles
NCT000006065	NCT00000606_5_T0	PHENOTYPE	9	9	peripheral
NCT000006066	NCT00000606_6_T0	PHENOTYPE	12	12	hyperinflation
NCT000006066	NCT00000606_6_T1	ORGAN	25	25	diaphragm
NCT000006066	NCT00000606_6_T2	ORGAN	20	21	chest wall
NCT000006067	NCT00000606_7_T0	GENE	5	5	Dr
NCT000006067	NCT00000606_7_T1	PHENOTYPE	33	34	airway obstruction
NCT0000060610	NCT00000606_10_T0	GENE	19	19	Dr
NCT0000060610	NCT00000606_10_T1	PHENOTYPE	12	12	emphysema
NCT0000060610	NCT00000606_10_T2	ORGAN	5	6	chest wall
NCT0000060612	NCT00000606_12_T0	PHENOTYPE	9	9	FVC
NCT0000060612	NCT00000606_12_T1	GENE	11	11	RV
NCT0000060612	NCT00000606_12_T2	GENE	10	10	TLC
NCT0000060612	NCT00000606_12_T3	PHENOTYPE	13	13	dyspnea
NCT0000060612	NCT00000606_12_T4	PHENOTYPE	15	17	quality of life
NCT0000060613	NCT00000606_13_T0	PHENOTYPE	4	4	excitement
NCT0000060614	NCT00000606_14_T0	PHENOTYPE	1	1	centers
NCT0000060614	NCT00000606_14_T1	GENE	15	15	had
NCT0000060615	NCT00000606_15_T0	PHENOTYPE	36	38	quality of life
NCT0000060622	NCT00000606_22_T0	PHENOTYPE	0	0	Centers
NCT0000060622	NCT00000606_22_T1	PHENOTYPE	48	48	bilateral
NCT0000060624	NCT00000606_24_T0	PHENOTYPE	12	12	centers
NCT0000060627	NCT00000606_27_T0	PHENOTYPE	0	0	Secondary
NCT0000060627	NCT00000606_27_T1	PHENOTYPE	8	10	quality of life
NCT0000060628	NCT00000606_28_T0	PHENOTYPE	12	14	quality of life
NCT0000060629	NCT00000606_29_T0	PHENOTYPE	0	0	Recruitment
NCT000006072	NCT00000607_2_T0	GENE	7	7	has
NCT000006072	NCT00000607_2_T1	PHENOTYPE	3	4	class IV
NCT000006072	NCT00000607_2_T2	PHENOTYPE	5	6	heart failure
NCT000006073	NCT00000607_3_T0	GENE	11	11	ACE
NCT000006076	NCT00000607_6_T0	ORGAN	5	5	hearts
NCT000006076	NCT00000607_6_T1	GENE	13	13	has
NCT000006077	NCT00000607_7_T0	GENE	12	12	ventricular
NCT000006079	NCT00000607_9_T0	GENE	3	3	TCI
NCT0000060710	NCT00000607_10_T0	ORGAN	11	11	transplant
NCT0000060711	NCT00000607_11_T0	PHENOTYPE	11	11	circulatory
NCT0000060712	NCT00000607_12_T0	ORGAN	15	15	Heart
NCT0000060712	NCT00000607_12_T1	GENE	6	6	TCI
NCT0000060712	NCT00000607_12_T2	PHENOTYPE	19	20	class I
NCT0000060712	NCT00000607_12_T3	PHENOTYPE	26	27	class II
NCT0000060713	NCT00000607_13_T0	PHENOTYPE	13	13	bleeding
NCT0000060713	NCT00000607_13_T1	PHENOTYPE	18	18	thromboembolism
NCT0000060713	NCT00000607_13_T2	PHENOTYPE	17	17	dysfunction
NCT0000060713	NCT00000607_13_T3	PHENOTYPE	6	7	adverse effects
NCT0000060713	NCT00000607_13_T4	PHENOTYPE	20	22	right heart failure
NCT0000060714	NCT00000607_14_T0	PHENOTYPE	1	1	complications
NCT0000060714	NCT00000607_14_T1	PHENOTYPE	13	13	anticoagulation
NCT0000060714	NCT00000607_14_T2	GENE	6	6	TCI
NCT0000060716	NCT00000607_16_T0	PHENOTYPE	18	19	adverse event
NCT0000060718	NCT00000607_18_T0	PHENOTYPE	19	21	quality of life
NCT0000060720	NCT00000607_20_T0	GENE	9	9	TCI
NCT0000060720	NCT00000607_20_T1	COMPOUND	18	18	OMM
NCT0000060722	NCT00000607_22_T0	GENE	17	17	ACE
NCT0000060722	NCT00000607_22_T1	COMPOUND	14	14	digoxin
NCT0000060722	NCT00000607_22_T2	MOLECULAR_FUNCTION	18	20	Angiotensin Converting Enzyme
NCT0000060724	NCT00000607_24_T0	PHENOTYPE	0	0	Secondary
NCT0000060724	NCT00000607_24_T1	PHENOTYPE	15	16	adverse effects
NCT0000060724	NCT00000607_24_T2	PHENOTYPE	12	14	quality of life
NCT0000060725	NCT00000607_25_T0	PHENOTYPE	0	0	Recruitment
NCT000006084	NCT00000608_4_T0	PHENOTYPE	4	5	cardiovascular disease
NCT000006089	NCT00000608_9_T0	GENE	23	23	160
NCT000006089	NCT00000608_9_T1	GENE	18	18	Hg
NCT000006089	NCT00000608_9_T2	GENE	25	25	Hg
NCT0000060810	NCT00000608_10_T0	COMPOUND	11	11	sodium
NCT0000060811	NCT00000608_11_T0	COMPOUND	4	4	sodium
NCT0000060811	NCT00000608_11_T1	PHENOTYPE	23	23	hypertension
NCT0000060812	NCT00000608_12_T0	GENE	34	34	reduced
NCT0000060813	NCT00000608_13_T0	COMPOUND	4	4	sodium
NCT0000060814	NCT00000608_14_T0	PHENOTYPE	17	17	fed
NCT0000060814	NCT00000608_14_T1	PHENOTYPE	20	21	sodium level
NCT0000060815	NCT00000608_15_T0	COMPOUND	22	22	sodium
NCT0000060820	NCT00000608_20_T0	COMPOUND	19	19	sodium
NCT0000060820	NCT00000608_20_T1	COMPOUND	21	21	creatinine
NCT0000060820	NCT00000608_20_T2	COMPOUND	17	17	potassium
NCT0000060820	NCT00000608_20_T3	COMPOUND	18	18	calcium
NCT0000060820	NCT00000608_20_T4	COMPOUND	16	16	magnesium
NCT0000060822	NCT00000608_22_T0	COMPOUND	16	16	sodium
NCT0000060823	NCT00000608_23_T0	COMPOUND	12	12	sodium
NCT0000060823	NCT00000608_23_T1	COMPOUND	29	29	sodium
NCT0000060823	NCT00000608_23_T2	COMPOUND	46	46	sodium
NCT0000060823	NCT00000608_23_T3	COMPOUND	50	50	sodium
NCT0000060824	NCT00000608_24_T0	PHENOTYPE	0	0	Recruitment
NCT0000060827	NCT00000608_27_T0	PHENOTYPE	11	11	Hypertension
NCT000006093	NCT00000609_3_T0	PHENOTYPE	11	13	congestive heart failure
NCT000006097	NCT00000609_7_T0	COMPOUND	7	7	amiodarone
NCT000006097	NCT00000609_7_T1	PHENOTYPE	11	13	congestive heart failure
NCT000006097	NCT00000609_7_T2	PHENOTYPE	31	33	congestive heart failure
NCT0000060915	NCT00000609_15_T0	PHENOTYPE	0	0	Secondary
NCT0000060915	NCT00000609_15_T1	PHENOTYPE	10	12	quality of life
NCT000006102	NCT00000610_2_T0	PHENOTYPE	26	26	acute
NCT000006102	NCT00000610_2_T1	PHENOTYPE	16	16	reperfusion
NCT000006102	NCT00000610_2_T2	GENE	10	10	beta
NCT000006104	NCT00000610_4_T0	GENE	18	18	11.5
NCT000006104	NCT00000610_4_T1	GENE	31	31	13.5
NCT000006106	NCT00000610_6_T0	COMPOUND	2	2	magnesium
NCT000006107	NCT00000610_7_T0	ORGAN	6	6	hands
NCT000006109	NCT00000610_9_T0	COMPOUND	3	3	magnesium
NCT000006109	NCT00000610_9_T1	COMPOUND	23	23	magnesium
NCT000006109	NCT00000610_9_T2	PHENOTYPE	10	12	acute myocardial infarction
NCT0000061010	NCT00000610_10_T0	GENE	8	8	blocker
NCT0000061010	NCT00000610_10_T1	COMPOUND	7	7	calcium
NCT0000061011	NCT00000610_11_T0	COMPOUND	7	7	calcium
NCT0000061011	NCT00000610_11_T1	COMPOUND	11	11	calcium
NCT0000061011	NCT00000610_11_T2	PHENOTYPE	21	21	reperfusion
NCT0000061011	NCT00000610_11_T3	CELL	5	5	myocytes
NCT0000061012	NCT00000610_12_T0	COMPOUND	9	9	calcium
NCT0000061012	NCT00000610_12_T1	PHENOTYPE	6	6	reperfusion
NCT0000061012	NCT00000610_12_T2	PHENOTYPE	26	26	reperfusion
NCT0000061012	NCT00000610_12_T3	PHENOTYPE	4	4	ischemia
NCT0000061014	NCT00000610_14_T0	COMPOUND	2	2	magnesium
NCT0000061014	NCT00000610_14_T1	ORGAN	1	1	serum
NCT0000061015	NCT00000610_15_T0	COMPOUND	10	10	magnesium
NCT0000061015	NCT00000610_15_T1	COMPOUND	21	21	magnesium
NCT0000061015	NCT00000610_15_T2	ORGAN	9	9	serum
NCT0000061015	NCT00000610_15_T3	PHENOTYPE	4	6	acute myocardial infarction
NCT0000061017	NCT00000610_17_T0	COMPOUND	4	4	magnesium
NCT0000061017	NCT00000610_17_T1	COMPOUND	8	8	magnesium
NCT0000061018	NCT00000610_18_T0	COMPOUND	9	9	magnesium
NCT0000061019	NCT00000610_19_T0	PHENOTYPE	13	13	acute
NCT0000061019	NCT00000610_19_T1	COMPOUND	11	11	magnesium
NCT0000061020	NCT00000610_20_T0	COMPOUND	20	20	magnesium
NCT0000061024	NCT00000610_24_T0	PHENOTYPE	8	8	heterogeneous
NCT0000061025	NCT00000610_25_T0	PHENOTYPE	30	30	estimation
NCT0000061026	NCT00000610_26_T0	GENE	13	13	OR
NCT0000061026	NCT00000610_26_T1	GENE	29	29	0.45
NCT0000061026	NCT00000610_26_T2	COMPOUND	17	17	magnesium
NCT0000061027	NCT00000610_27_T0	COMPOUND	18	18	magnesium
NCT0000061027	NCT00000610_27_T1	COMPOUND	25	25	magnesium
NCT0000061027	NCT00000610_27_T2	COMPOUND	37	37	magnesium
NCT0000061028	NCT00000610_28_T0	COMPOUND	1	1	magnesium
NCT0000061028	NCT00000610_28_T1	COMPOUND	23	23	magnesium
NCT0000061028	NCT00000610_28_T2	TISSUE	39	39	myocardium
NCT0000061028	NCT00000610_28_T3	PHENOTYPE	13	15	congestive heart failure
NCT0000061029	NCT00000610_29_T0	GENE	7	7	ventricular
NCT0000061030	NCT00000610_30_T0	COMPOUND	29	29	magnesium
NCT0000061030	NCT00000610_30_T1	GENE	37	37	2.7
NCT0000061030	NCT00000610_30_T2	PHENOTYPE	22	24	ischemic heart disease
NCT0000061031	NCT00000610_31_T0	PHENOTYPE	29	29	acute
NCT0000061031	NCT00000610_31_T1	PHENOTYPE	32	32	infarction
NCT0000061031	NCT00000610_31_T2	COMPOUND	25	25	magnesium
NCT0000061032	NCT00000610_32_T0	COMPOUND	10	10	magnesium
NCT0000061032	NCT00000610_32_T1	PHENOTYPE	30	30	reperfusion
NCT0000061034	NCT00000610_34_T0	COMPOUND	12	12	magnesium
NCT0000061035	NCT00000610_35_T0	GENE	22	22	OR
NCT0000061035	NCT00000610_35_T1	COMPOUND	11	11	magnesium
NCT0000061035	NCT00000610_35_T2	COMPOUND	29	29	magnesium
NCT0000061035	NCT00000610_35_T3	GENE	16	16	7.2
NCT0000061036	NCT00000610_36_T0	PHENOTYPE	24	24	acute
NCT0000061036	NCT00000610_36_T1	GENE	15	15	null
NCT0000061036	NCT00000610_36_T2	COMPOUND	18	18	magnesium
NCT0000061037	NCT00000610_37_T0	COMPOUND	27	27	magnesium
NCT0000061037	NCT00000610_37_T1	COMPOUND	47	47	magnesium
NCT0000061039	NCT00000610_39_T0	GENE	16	16	null
NCT0000061039	NCT00000610_39_T1	COMPOUND	19	19	magnesium
NCT0000061041	NCT00000610_41_T0	GENE	8	8	7.2
NCT0000061042	NCT00000610_42_T0	PHENOTYPE	57	57	CHF
NCT0000061042	NCT00000610_42_T1	GENE	65	65	SBP
NCT0000061042	NCT00000610_42_T2	GENE	43	43	had
NCT0000061042	NCT00000610_42_T3	GENE	52	52	had
NCT0000061042	NCT00000610_42_T4	GENE	61	61	had
NCT0000061042	NCT00000610_42_T5	GENE	66	66	100
NCT0000061042	NCT00000610_42_T6	GENE	68	68	Hg
NCT0000061042	NCT00000610_42_T7	PHENOTYPE	54	56	congestive heart failure
NCT0000061043	NCT00000610_43_T0	COMPOUND	5	5	magnesium
NCT0000061044	NCT00000610_44_T0	COMPOUND	11	11	magnesium
NCT0000061045	NCT00000610_45_T0	GENE	2	2	had
NCT0000061046	NCT00000610_46_T0	COMPOUND	16	16	magnesium
NCT0000061046	NCT00000610_46_T1	COMPOUND	31	31	magnesium
NCT0000061047	NCT00000610_47_T0	COMPOUND	23	23	magnesium
NCT0000061048	NCT00000610_48_T0	GENE	15	15	reduced
NCT0000061048	NCT00000610_48_T1	COMPOUND	20	20	magnesium
NCT0000061049	NCT00000610_49_T0	COMPOUND	11	11	magnesium
NCT0000061051	NCT00000610_51_T0	PHENOTYPE	5	5	acute
NCT0000061051	NCT00000610_51_T1	COMPOUND	16	16	magnesium
NCT0000061052	NCT00000610_52_T0	PHENOTYPE	7	7	lytic
NCT0000061053	NCT00000610_53_T0	GENE	24	24	OR
NCT0000061053	NCT00000610_53_T1	GENE	15	15	4.2
NCT0000061053	NCT00000610_53_T2	COMPOUND	19	19	magnesium
NCT0000061053	NCT00000610_53_T3	GENE	26	26	0.21
NCT0000061053	NCT00000610_53_T4	GENE	2	2	al
NCT0000061053	NCT00000610_53_T5	GENE	1	1	et
NCT0000061054	NCT00000610_54_T0	COMPOUND	5	5	magnesium
NCT0000061056	NCT00000610_56_T0	COMPOUND	4	4	magnesium
NCT0000061056	NCT00000610_56_T1	PHENOTYPE	14	15	myocardial rupture
NCT0000061056	NCT00000610_56_T2	PHENOTYPE	10	11	cardiogenic shock
NCT0000061056	NCT00000610_56_T3	PHENOTYPE	19	20	electromechanical dissociation
NCT0000061057	NCT00000610_57_T0	PHENOTYPE	26	26	acute
NCT0000061058	NCT00000610_58_T0	COMPOUND	23	23	magnesium
NCT0000061059	NCT00000610_59_T0	GENE	14	14	reduced
NCT0000061059	NCT00000610_59_T1	COMPOUND	27	27	magnesium
NCT0000061059	NCT00000610_59_T2	PHENOTYPE	10	12	congestive heart failure
NCT0000061062	NCT00000610_62_T0	PHENOTYPE	5	5	acute
NCT0000061062	NCT00000610_62_T1	PHENOTYPE	19	19	initiation
NCT0000061062	NCT00000610_62_T2	COMPOUND	25	25	magnesium
NCT0000061062	NCT00000610_62_T3	PHENOTYPE	11	11	lytic
NCT0000061063	NCT00000610_63_T0	COMPOUND	3	3	magnesium
NCT0000061063	NCT00000610_63_T1	PHENOTYPE	11	11	lytic
NCT0000061064	NCT00000610_64_T0	PHENOTYPE	6	6	symptoms
NCT0000061064	NCT00000610_64_T1	GENE	22	22	NOT
NCT0000061064	NCT00000610_64_T2	COMPOUND	20	20	magnesium
NCT0000061068	NCT00000610_68_T0	COMPOUND	12	12	magnesium
NCT0000061071	NCT00000610_71_T0	COMPOUND	6	6	calcium
NCT0000061071	NCT00000610_71_T1	COMPOUND	11	11	calcium
NCT0000061071	NCT00000610_71_T2	PHENOTYPE	17	17	reperfusion
NCT0000061071	NCT00000610_71_T3	PHENOTYPE	29	29	reperfusion
NCT0000061071	NCT00000610_71_T4	PHENOTYPE	34	34	contractile
NCT0000061071	NCT00000610_71_T5	PHENOTYPE	35	35	dysfunction
NCT0000061072	NCT00000610_72_T0	COMPOUND	5	5	magnesium
NCT0000061072	NCT00000610_72_T1	PHENOTYPE	10	10	reperfusion
NCT0000061073	NCT00000610_73_T0	PHENOTYPE	22	22	symptoms
NCT0000061073	NCT00000610_73_T1	GENE	25	25	had
NCT0000061074	NCT00000610_74_T0	COMPOUND	11	11	magnesium
NCT0000061074	NCT00000610_74_T1	COMPOUND	44	44	magnesium
NCT0000061074	NCT00000610_74_T2	PHENOTYPE	47	47	reperfusion
NCT0000061074	NCT00000610_74_T3	PHENOTYPE	57	59	acute myocardial infarction
NCT0000061075	NCT00000610_75_T0	COMPOUND	9	9	calcium
NCT0000061075	NCT00000610_75_T1	COMPOUND	18	18	magnesium
NCT0000061075	NCT00000610_75_T2	PHENOTYPE	31	31	reperfusion
NCT0000061075	NCT00000610_75_T3	CELL	13	13	myocytes
NCT0000061076	NCT00000610_76_T0	GENE	11	11	met
NCT0000061078	NCT00000610_78_T0	COMPOUND	25	25	magnesium
NCT0000061078	NCT00000610_78_T1	GENE	10	10	al
NCT0000061078	NCT00000610_78_T2	GENE	9	9	et
NCT0000061080	NCT00000610_80_T0	PHENOTYPE	13	13	acute
NCT0000061080	NCT00000610_80_T1	COMPOUND	27	27	magnesium
NCT0000061080	NCT00000610_80_T2	COMPOUND	40	40	magnesium
NCT0000061080	NCT00000610_80_T3	COMPOUND	28	28	sulphate
NCT0000061080	NCT00000610_80_T4	COMPOUND	41	41	sulphate
NCT0000061080	NCT00000610_80_T5	PHENOTYPE	17	17	STEMI
NCT0000061080	NCT00000610_80_T6	PHENOTYPE	15	16	myocardial infarction
NCT0000061082	NCT00000610_82_T0	PHENOTYPE	9	9	reperfusion
NCT0000061083	NCT00000610_83_T0	PHENOTYPE	15	15	reperfusion
NCT0000061083	NCT00000610_83_T1	PHENOTYPE	31	31	reperfusion
NCT0000061085	NCT00000610_85_T0	COMPOUND	8	8	magnesium
NCT0000061085	NCT00000610_85_T1	GENE	17	17	had
NCT0000061086	NCT00000610_86_T0	COMPOUND	5	5	magnesium
NCT0000061087	NCT00000610_87_T0	PHENOTYPE	12	12	regression
NCT0000061087	NCT00000610_87_T1	COMPOUND	17	17	magnesium
NCT000006114	NCT00000611_4_T0	PHENOTYPE	8	9	chronic diseases
NCT000006115	NCT00000611_5_T0	PHENOTYPE	22	22	menopausal
NCT000006115	NCT00000611_5_T1	PHENOTYPE	13	13	impairment
NCT000006115	NCT00000611_5_T2	PHENOTYPE	7	7	osteoporosis
NCT000006115	NCT00000611_5_T3	PHENOTYPE	2	4	coronary heart disease
NCT000006115	NCT00000611_5_T4	PHENOTYPE	15	17	quality of life
NCT000006117	NCT00000611_7_T0	PHENOTYPE	19	19	Centers
NCT000006119	NCT00000611_9_T0	PHENOTYPE	2	2	centers
NCT0000061111	NCT00000611_11_T0	GENE	3	3	has
NCT0000061111	NCT00000611_11_T1	GENE	11	11	has
NCT0000061112	NCT00000611_12_T0	PHENOTYPE	0	0	Recruitment
NCT0000061113	NCT00000611_13_T0	PHENOTYPE	4	4	recruitment
NCT0000061113	NCT00000611_13_T1	PHENOTYPE	2	2	centers
NCT0000061114	NCT00000611_14_T0	PHENOTYPE	5	5	recruitment
NCT0000061114	NCT00000611_14_T1	PHENOTYPE	3	3	centers
NCT0000061115	NCT00000611_15_T0	COMPOUND	21	21	calcium
NCT0000061115	NCT00000611_15_T1	GENE	12	12	hormone
NCT0000061115	NCT00000611_15_T2	COMPOUND	22	23	vitamin D
NCT0000061116	NCT00000611_16_T0	GENE	11	11	HRT
NCT0000061116	NCT00000611_16_T1	GENE	16	16	HRT
NCT0000061116	NCT00000611_16_T2	PHENOTYPE	22	22	fractures
NCT0000061116	NCT00000611_16_T3	PHENOTYPE	25	26	breast cancer
NCT0000061116	NCT00000611_16_T4	PHENOTYPE	18	20	coronary heart disease
NCT0000061119	NCT00000611_19_T0	COMPOUND	11	11	estrogen
NCT0000061119	NCT00000611_19_T1	GENE	3	3	had
NCT0000061120	NCT00000611_20_T0	COMPOUND	1	1	estrogen
NCT0000061120	NCT00000611_20_T1	GENE	17	17	5.2
NCT0000061122	NCT00000611_22_T0	COMPOUND	3	3	estrogen
NCT0000061123	NCT00000611_23_T0	PHENOTYPE	20	21	colorectal cancer
NCT0000061123	NCT00000611_23_T1	PHENOTYPE	18	19	breast cancer
NCT0000061123	NCT00000611_23_T2	PHENOTYPE	23	24	heart disease
NCT0000061129	NCT00000611_29_T0	GENE	3	3	hormone
NCT0000061131	NCT00000611_31_T0	COMPOUND	11	11	calcium
NCT0000061131	NCT00000611_31_T1	COMPOUND	13	13	calcium
NCT0000061131	NCT00000611_31_T2	COMPOUND	14	14	carbonate
NCT0000061136	NCT00000611_36_T0	PHENOTYPE	35	35	diseases
NCT0000061136	NCT00000611_36_T1	PHENOTYPE	23	23	cancers
NCT0000061136	NCT00000611_36_T2	PHENOTYPE	25	25	fractures
NCT0000061136	NCT00000611_36_T3	PHENOTYPE	21	22	heart disease
NCT0000061142	NCT00000611_42_T0	PHENOTYPE	33	33	practices
NCT0000061143	NCT00000611_43_T0	BIOLOGICAL_PROCESS	6	6	translation
NCT000006120	NCT00000612_0_T0	GENE	4	4	SEA
NCT000006123	NCT00000612_3_T0	GENE	11	11	ERT
NCT000006123	NCT00000612_3_T1	GENE	26	26	ERT
NCT000006125	NCT00000612_5_T0	COMPOUND	7	7	genistein
NCT000006125	NCT00000612_5_T1	COMPOUND	1	1	isoflavonoids
NCT000006125	NCT00000612_5_T2	GENE	4	4	soy
NCT000006125	NCT00000612_5_T3	PHENOTYPE	17	19	coronary heart disease
NCT000006126	NCT00000612_6_T0	BIOLOGICAL_PROCESS	10	10	vasomotion
NCT000006126	NCT00000612_6_T1	ORGAN	5	5	plasma
NCT000006126	NCT00000612_6_T2	ORGAN	8	9	coronary artery
NCT000006129	NCT00000612_9_T0	GENE	14	14	soy
NCT0000061210	NCT00000612_10_T0	PHENOTYPE	32	32	proliferation
NCT0000061210	NCT00000612_10_T1	GENE	24	24	lipoprotein
NCT0000061210	NCT00000612_10_T2	PHENOTYPE	6	6	menopausal
NCT0000061210	NCT00000612_10_T3	ORGAN	19	19	plasma
NCT0000061210	NCT00000612_10_T4	PHENOTYPE	10	11	hot flushes
NCT0000061210	NCT00000612_10_T5	PHENOTYPE	12	13	mood lability
NCT0000061210	NCT00000612_10_T6	PHENOTYPE	15	16	sleep disturbances
NCT0000061210	NCT00000612_10_T7	PHENOTYPE	28	29	vaginal bleeding
NCT0000061210	NCT00000612_10_T8	PHENOTYPE	36	38	quality of life
NCT0000061211	NCT00000612_11_T0	PHENOTYPE	0	0	Secondary
NCT0000061211	NCT00000612_11_T1	PHENOTYPE	12	12	progression
NCT0000061211	NCT00000612_11_T2	GENE	50	50	hormone
NCT0000061211	NCT00000612_11_T3	PHENOTYPE	66	66	symptoms
NCT0000061211	NCT00000612_11_T4	COMPOUND	56	56	genistein
NCT0000061211	NCT00000612_11_T5	ORGAN	14	15	carotid artery
NCT0000061213	NCT00000612_13_T0	PHENOTYPE	10	11	coronary atherosclerosis
NCT0000061214	NCT00000612_14_T0	GENE	0	0	Dr
NCT000006133	NCT00000613_3_T0	GENE	9	9	soy
NCT000006133	NCT00000613_3_T1	PHENOTYPE	28	28	osteoporosis
NCT000006133	NCT00000613_3_T2	PHENOTYPE	25	26	heart disease
NCT000006134	NCT00000613_4_T0	PHENOTYPE	15	16	heart disease
NCT000006134	NCT00000613_4_T1	PHENOTYPE	22	24	quality of life
NCT0000061311	NCT00000613_11_T0	COMPOUND	17	17	homocysteine
NCT0000061311	NCT00000613_11_T1	GENE	15	15	had
NCT0000061311	NCT00000613_11_T2	COMPOUND	14	14	phytoestrogens
NCT0000061311	NCT00000613_11_T3	GENE	21	21	E-selectin
NCT0000061311	NCT00000613_11_T4	GENE	18	18	interleukin-6
NCT0000061311	NCT00000613_11_T5	PHENOTYPE	24	24	obesity
NCT0000061311	NCT00000613_11_T6	GENE	19	20	C-reactive protein
NCT000006142	NCT00000614_2_T0	COMPOUND	5	5	heparin
NCT000006143	NCT00000614_3_T0	GENE	7	7	has
NCT000006143	NCT00000614_3_T1	COMPOUND	6	6	warfarin
NCT000006145	NCT00000614_5_T0	PHENOTYPE	4	5	recurrent disease
NCT000006149	NCT00000614_9_T0	PHENOTYPE	0	0	Recurrence
NCT0000061410	NCT00000614_10_T0	GENE	20	20	9.5
NCT0000061410	NCT00000614_10_T1	PHENOTYPE	4	5	recurrent thrombosis
NCT0000061411	NCT00000614_11_T0	PHENOTYPE	6	6	recurrence
NCT0000061413	NCT00000614_13_T0	PHENOTYPE	11	11	recurrence
NCT0000061413	NCT00000614_13_T1	PHENOTYPE	6	7	venous thrombosis
NCT0000061414	NCT00000614_14_T0	PHENOTYPE	15	15	recurrence
NCT0000061415	NCT00000614_15_T0	PHENOTYPE	7	7	bleeding
NCT0000061415	NCT00000614_15_T1	COMPOUND	13	13	warfarin
NCT0000061416	NCT00000614_16_T0	PHENOTYPE	6	6	recurrence
NCT0000061416	NCT00000614_16_T1	PHENOTYPE	22	22	recurrences
NCT0000061416	NCT00000614_16_T2	PHENOTYPE	19	19	mutation
NCT0000061416	NCT00000614_16_T3	PHENOTYPE	37	37	mutation
NCT0000061416	NCT00000614_16_T4	GENE	29	29	2.4
NCT0000061416	NCT00000614_16_T5	GENE	16	18	factor V Leiden
NCT0000061417	NCT00000614_17_T0	PHENOTYPE	4	4	mutation
NCT0000061417	NCT00000614_17_T1	PHENOTYPE	22	22	thromboembolism
NCT0000061417	NCT00000614_17_T2	GENE	1	3	factor V Leiden
NCT0000061418	NCT00000614_18_T0	PHENOTYPE	4	4	mutation
NCT0000061419	NCT00000614_19_T0	PHENOTYPE	9	9	mutation
NCT0000061423	NCT00000614_23_T0	GENE	1	1	INR
NCT0000061425	NCT00000614_25_T0	GENE	33	33	2.0
NCT0000061425	NCT00000614_25_T1	GENE	31	31	1.5
NCT0000061425	NCT00000614_25_T2	GENE	30	30	INR
NCT0000061425	NCT00000614_25_T3	COMPOUND	28	28	warfarin
NCT0000061426	NCT00000614_26_T0	GENE	1	1	INR
NCT0000061427	NCT00000614_27_T0	PHENOTYPE	7	7	bleeding
NCT0000061427	NCT00000614_27_T1	PHENOTYPE	3	3	recurrent
NCT0000061427	NCT00000614_27_T2	PHENOTYPE	4	5	venous thromboembolism
NCT0000061428	NCT00000614_28_T0	GENE	16	18	factor V Leiden
NCT0000061429	NCT00000614_29_T0	PHENOTYPE	6	6	centers
NCT000006153	NCT00000615_3_T0	PHENOTYPE	4	4	obesity
NCT000006153	NCT00000615_3_T1	PHENOTYPE	16	16	obesity
NCT000006154	NCT00000615_4_T0	GENE	20	20	30.7
NCT000006154	NCT00000615_4_T1	GENE	12	12	III
NCT000006154	NCT00000615_4_T2	PHENOTYPE	33	33	overweight
NCT000006155	NCT00000615_5_T0	GENE	15	15	has
NCT000006155	NCT00000615_5_T1	PHENOTYPE	9	9	obesity
NCT000006156	NCT00000615_6_T0	PHENOTYPE	3	3	obesity
NCT000006158	NCT00000615_8_T0	GENE	4	4	SEP
NCT000006158	NCT00000615_8_T1	PHENOTYPE	14	15	Cardiovascular Disease
NCT000006158	NCT00000615_8_T2	PHENOTYPE	34	35	cardiovascular disease
NCT000006159	NCT00000615_9_T0	GENE	10	10	SEP
NCT0000061517	NCT00000615_17_T0	PHENOTYPE	4	4	centers
NCT0000061519	NCT00000615_19_T0	GENE	2	2	II
NCT0000061520	NCT00000615_20_T0	PHENOTYPE	12	12	centers
NCT0000061521	NCT00000615_21_T0	PHENOTYPE	15	16	weight gain
NCT0000061523	NCT00000615_23_T0	PHENOTYPE	0	0	Secondary
NCT0000061524	NCT00000615_24_T0	PHENOTYPE	37	38	weight gain
NCT000006167	NCT00000616_7_T0	PHENOTYPE	13	13	hypertension
NCT000006173	NCT00000617_3_T0	PHENOTYPE	14	14	pneumonia
NCT000006173	NCT00000617_3_T1	GENE	27	27	CHD
NCT000006175	NCT00000617_5_T0	COMPOUND	8	8	azithromycin
NCT000006175	NCT00000617_5_T1	PHENOTYPE	16	18	coronary artery disease
NCT000006176	NCT00000617_6_T0	PHENOTYPE	12	12	centers
NCT000006178	NCT00000617_8_T0	COMPOUND	10	10	azithromycin
NCT000006179	NCT00000617_9_T0	PHENOTYPE	12	12	pneumoniae
NCT0000061715	NCT00000617_15_T0	PHENOTYPE	16	16	secondary
NCT0000061715	NCT00000617_15_T1	COMPOUND	11	11	azithromycin
NCT0000061715	NCT00000617_15_T2	PHENOTYPE	3	4	antibody titer
NCT0000061719	NCT00000617_19_T0	PHENOTYPE	17	17	pneumoniae
NCT0000061719	NCT00000617_19_T1	COMPOUND	11	11	azithromycin
NCT0000061719	NCT00000617_19_T2	PHENOTYPE	35	36	antibody titer
NCT0000061719	NCT00000617_19_T3	PHENOTYPE	25	27	coronary heart disease
NCT0000061721	NCT00000617_21_T0	PHENOTYPE	8	8	recruitment
NCT0000061722	NCT00000617_22_T0	GENE	21	21	QVR
NCT000006191	NCT00000619_1_T0	PHENOTYPE	1	1	secondary
NCT000006193	NCT00000619_3_T0	PHENOTYPE	9	9	CHF
NCT000006193	NCT00000619_3_T1	GENE	2	2	4.7
NCT000006194	NCT00000619_4_T0	PHENOTYPE	10	10	CHF
NCT000006194	NCT00000619_4_T1	PHENOTYPE	16	16	symptoms
NCT000006194	NCT00000619_4_T2	GENE	8	8	1.2
NCT000006199	NCT00000619_9_T0	PHENOTYPE	32	33	class IV
NCT000006199	NCT00000619_9_T1	PHENOTYPE	28	30	congestive heart failure
NCT0000061912	NCT00000619_12_T0	ORGAN	20	21	pulmonary artery
NCT0000061915	NCT00000619_15_T0	PHENOTYPE	24	24	symptoms
NCT0000061915	NCT00000619_15_T1	PHENOTYPE	23	23	CHF
NCT0000061918	NCT00000619_18_T0	BIOLOGICAL_PROCESS	6	6	diuresis
NCT0000061919	NCT00000619_19_T0	COMPOUND	10	10	dobutamine
NCT0000061919	NCT00000619_19_T1	BIOLOGICAL_PROCESS	13	13	diuresis
NCT0000061919	NCT00000619_19_T2	COMPOUND	8	8	dopamine
NCT0000061920	NCT00000619_20_T0	COMPOUND	1	1	nitroprusside
NCT0000061921	NCT00000619_21_T0	PHENOTYPE	54	54	peripheral
NCT0000061921	NCT00000619_21_T1	GENE	45	45	cm
NCT0000061921	NCT00000619_21_T2	ORGAN	57	57	extremities
NCT0000061921	NCT00000619_21_T3	PHENOTYPE	35	35	ascites
NCT0000061921	NCT00000619_21_T4	PHENOTYPE	64	64	pulse
NCT0000061921	NCT00000619_21_T5	PHENOTYPE	30	30	congestion
NCT0000061921	NCT00000619_21_T6	PHENOTYPE	22	22	orthopnea
NCT0000061921	NCT00000619_21_T7	PHENOTYPE	37	37	rales
NCT0000061921	NCT00000619_21_T8	PHENOTYPE	25	26	abdominal discomfort
NCT0000061921	NCT00000619_21_T9	PHENOTYPE	33	34	peripheral edema
NCT0000061924	NCT00000619_24_T0	PHENOTYPE	17	17	hypotension
NCT0000061924	NCT00000619_24_T1	PHENOTYPE	26	27	renal insufficiency
NCT0000061926	NCT00000619_26_T0	ORGAN	5	5	capillary
NCT0000061926	NCT00000619_26_T1	GENE	11	11	Hg
NCT0000061926	NCT00000619_26_T2	GENE	18	18	Hg
NCT0000061926	NCT00000619_26_T3	GENE	26	26	Hg
NCT0000061926	NCT00000619_26_T4	PHENOTYPE	6	7	wedge pressure
NCT0000061927	NCT00000619_27_T0	PHENOTYPE	32	32	anticoagulation
NCT0000061927	NCT00000619_27_T1	GENE	16	16	met
NCT0000061929	NCT00000619_29_T0	PHENOTYPE	6	6	CHF
NCT0000061929	NCT00000619_29_T1	PHENOTYPE	10	11	heart failure
NCT0000061931	NCT00000619_31_T0	ORGAN	18	18	serum
NCT0000061931	NCT00000619_31_T1	GENE	42	42	hormone
NCT0000061931	NCT00000619_31_T2	PHENOTYPE	58	60	quality of life
NCT0000061933	NCT00000619_33_T0	PHENOTYPE	8	8	recruitment
NCT0000061933	NCT00000619_33_T1	GENE	3	3	extended
NCT0000061933	NCT00000619_33_T2	GENE	9	9	extended
NCT0000061934	NCT00000619_34_T0	GENE	2	2	has
NCT0000061935	NCT00000619_35_T0	GENE	6	6	has
NCT0000061938	NCT00000619_38_T0	PHENOTYPE	49	49	peripheral
NCT0000061938	NCT00000619_38_T1	GENE	40	40	cm
NCT0000061938	NCT00000619_38_T2	GENE	1	1	had
NCT0000061938	NCT00000619_38_T3	ORGAN	54	54	extremities
NCT0000061938	NCT00000619_38_T4	PHENOTYPE	32	32	ascites
NCT0000061938	NCT00000619_38_T5	PHENOTYPE	29	29	congestion
NCT0000061938	NCT00000619_38_T6	PHENOTYPE	23	23	orthopnea
NCT0000061938	NCT00000619_38_T7	PHENOTYPE	33	33	rales
NCT0000061938	NCT00000619_38_T8	PHENOTYPE	24	25	abdominal discomfort
NCT0000061938	NCT00000619_38_T9	PHENOTYPE	3	4	class IV
NCT0000061938	NCT00000619_38_T10	PHENOTYPE	30	31	peripheral edema
NCT000006206	NCT00000620_6_T0	PHENOTYPE	8	8	strokes
NCT000006206	NCT00000620_6_T1	PHENOTYPE	5	6	heart attacks
NCT0000062011	NCT00000620_11_T0	PHENOTYPE	5	5	CVD
NCT0000062013	NCT00000620_13_T0	PHENOTYPE	45	45	CVD
NCT0000062013	NCT00000620_13_T1	PHENOTYPE	62	62	hypertension
NCT0000062013	NCT00000620_13_T2	GENE	41	41	Hg
NCT0000062013	NCT00000620_13_T3	GENE	69	69	Hg
NCT0000062016	NCT00000620_16_T0	GENE	18	18	HDL
NCT0000062016	NCT00000620_16_T1	GENE	11	11	LDL
NCT0000062016	NCT00000620_16_T2	GENE	27	27	LDL
NCT0000062017	NCT00000620_17_T0	COMPOUND	8	8	fibrates
NCT0000062017	NCT00000620_17_T1	GENE	16	16	HDL
NCT0000062017	NCT00000620_17_T2	GENE	32	32	LDL
NCT0000062019	NCT00000620_19_T0	ORGAN	5	5	Blood
NCT0000062019	NCT00000620_19_T1	PHENOTYPE	17	19	high blood pressure
NCT0000062022	NCT00000620_22_T0	COMPOUND	34	34	simvastatin
NCT0000062022	NCT00000620_22_T1	COMPOUND	28	28	fenofibrate
NCT0000062023	NCT00000620_23_T0	GENE	15	15	met
NCT0000062023	NCT00000620_23_T1	GENE	40	40	met
NCT000006211	NCT00000621_1_T0	PHENOTYPE	36	36	emphysema
NCT000006214	NCT00000621_4_T0	PHENOTYPE	19	19	distal
NCT000006214	NCT00000621_4_T1	PHENOTYPE	15	15	enlargement
NCT000006214	NCT00000621_4_T2	PHENOTYPE	27	27	fibrosis
NCT000006214	NCT00000621_4_T3	PHENOTYPE	0	0	Emphysema
NCT000006214	NCT00000621_4_T4	ORGAN	22	23	terminal bronchioles
NCT000006215	NCT00000621_5_T0	PHENOTYPE	22	22	hypoxia
NCT000006215	NCT00000621_5_T1	PHENOTYPE	8	8	hyperinflation
NCT000006215	NCT00000621_5_T2	PHENOTYPE	5	5	dyspnea
NCT000006215	NCT00000621_5_T3	ORGAN	16	17	chest wall
NCT000006215	NCT00000621_5_T4	ORGAN	19	20	respiratory muscles
NCT000006216	NCT00000621_6_T0	PHENOTYPE	14	14	dyspnea
NCT000006216	NCT00000621_6_T1	PHENOTYPE	3	3	emphysema
NCT000006217	NCT00000621_7_T0	COMPOUND	11	11	oxygen
NCT0000062111	NCT00000621_11_T0	PHENOTYPE	27	27	obstruction
NCT0000062111	NCT00000621_11_T1	PHENOTYPE	26	26	airflow
NCT0000062111	NCT00000621_11_T2	PHENOTYPE	15	16	Alpha-1-Antitrypsin Deficiency
NCT0000062111	NCT00000621_11_T3	PHENOTYPE	6	7	alpha-1-antitrypsin deficiency
NCT0000062114	NCT00000621_14_T0	GENE	3	3	elastase
NCT0000062114	NCT00000621_14_T1	PHENOTYPE	25	25	emphysema
NCT0000062115	NCT00000621_15_T0	GENE	4	4	all-trans
NCT0000062115	NCT00000621_15_T1	GENE	17	17	reduced
NCT0000062115	NCT00000621_15_T2	COMPOUND	5	6	retinoic acid
NCT0000062117	NCT00000621_17_T0	PHENOTYPE	11	11	emphysema
NCT0000062118	NCT00000621_18_T0	PHENOTYPE	18	18	Emphysema
NCT0000062118	NCT00000621_18_T1	PHENOTYPE	38	38	emphysema
NCT0000062118	NCT00000621_18_T2	COMPOUND	32	33	retinoic acid
NCT0000062120	NCT00000621_20_T0	PHENOTYPE	10	10	toxicity
NCT0000062120	NCT00000621_20_T1	PHENOTYPE	22	22	emphysema
NCT0000062120	NCT00000621_20_T2	PHENOTYPE	45	45	emphysema
NCT0000062123	NCT00000621_23_T0	PHENOTYPE	26	26	centers
NCT0000062123	NCT00000621_23_T1	PHENOTYPE	21	21	emphysema
NCT0000062139	NCT00000621_39_T0	GENE	13	13	hemoglobin
NCT000006234	NCT00000623_4_T0	PHENOTYPE	5	6	severe anemia
NCT000006238	NCT00000623_8_T0	PHENOTYPE	9	9	infections
NCT000006238	NCT00000623_8_T1	PHENOTYPE	4	4	alloimmunization
NCT000006238	NCT00000623_8_T2	PHENOTYPE	5	6	iron overload
NCT0000062310	NCT00000623_10_T0	PHENOTYPE	8	9	heart disease
NCT0000062311	NCT00000623_11_T0	COMPOUND	6	6	deferoxamine
NCT0000062311	NCT00000623_11_T1	GENE	14	14	has
NCT0000062311	NCT00000623_11_T2	GENE	7	7	DFO
NCT0000062311	NCT00000623_11_T3	PHENOTYPE	13	13	anemia
NCT0000062320	NCT00000623_20_T0	PHENOTYPE	15	15	thalassemia
NCT0000062321	NCT00000623_21_T0	PHENOTYPE	6	6	thalassemia
NCT0000062322	NCT00000623_22_T0	PHENOTYPE	9	9	thalassemia
NCT0000062326	NCT00000623_26_T0	PHENOTYPE	25	25	thalassemia
NCT0000062326	NCT00000623_26_T1	GENE	10	10	has
NCT0000062326	NCT00000623_26_T2	GENE	12	12	extended
NCT0000062327	NCT00000623_27_T0	GENE	15	15	DFO
NCT0000062327	NCT00000623_27_T1	GENE	18	18	DFO
NCT0000062327	NCT00000623_27_T2	COMPOUND	36	36	sildenafil
NCT0000062327	NCT00000623_27_T3	COMPOUND	20	20	deferiprone
NCT0000062327	NCT00000623_27_T4	COMPOUND	34	34	arginine
NCT0000062327	NCT00000623_27_T5	PHENOTYPE	48	48	hemolytic
NCT0000062327	NCT00000623_27_T6	PHENOTYPE	27	28	iron overload
NCT0000062327	NCT00000623_27_T7	PHENOTYPE	38	39	pulmonary hypertension
NCT0000062327	NCT00000623_27_T8	PHENOTYPE	22	23	cardiac disease
NCT0000062327	NCT00000623_27_T9	PHENOTYPE	44	45	thalassemia intermedia
NCT0000062329	NCT00000623_29_T0	ORGAN	35	35	liver
NCT0000062329	NCT00000623_29_T1	PHENOTYPE	8	8	Thalassemia
NCT0000062329	NCT00000623_29_T2	GENE	11	11	TLC
NCT0000062329	NCT00000623_29_T3	ORGAN	34	34	heart
NCT0000062329	NCT00000623_29_T4	PHENOTYPE	43	43	dysfunction
NCT0000062329	NCT00000623_29_T5	ORGAN	37	37	pancreas
NCT0000062330	NCT00000623_30_T0	PHENOTYPE	26	26	thalassemia
NCT000006250	NCT00000625_0_T0	GENE	18	18	CD4
NCT000006250	NCT00000625_0_T1	CELL	19	19	Cells
NCT000006258	NCT00000625_8_T0	GENE	2	2	ACTG
NCT000006261	NCT00000626_1_T0	PHENOTYPE	0	0	Secondary
NCT000006261	NCT00000626_1_T1	GENE	11	11	G-CSF
NCT000006261	NCT00000626_1_T2	PHENOTYPE	27	27	HIV
NCT000006261	NCT00000626_1_T3	PHENOTYPE	6	6	tumor
NCT000006261	NCT00000626_1_T4	PHENOTYPE	24	25	opportunistic infections
NCT000006261	NCT00000626_1_T5	PHENOTYPE	30	31	Hodgkin's disease
NCT000006261	NCT00000626_1_T6	PHENOTYPE	37	39	quality of life
NCT000006262	NCT00000626_2_T0	CELL	2	2	granulocyte
NCT000006262	NCT00000626_2_T1	PHENOTYPE	7	7	neutropenia
NCT000006264	NCT00000626_4_T0	PHENOTYPE	9	9	HIV
NCT000006264	NCT00000626_4_T1	PHENOTYPE	12	13	Hodgkin's disease
NCT000006269	NCT00000626_9_T0	PHENOTYPE	2	3	disease progression
NCT000006271	NCT00000627_1_T0	PHENOTYPE	0	0	Histoplasmosis
NCT000006271	NCT00000627_1_T1	PHENOTYPE	4	5	opportunistic infection
NCT000006273	NCT00000627_3_T0	GENE	1	1	has
NCT000006273	NCT00000627_3_T1	PHENOTYPE	13	14	fungal infections
NCT000006274	NCT00000627_4_T0	PHENOTYPE	9	9	histoplasmosis
NCT000006275	NCT00000627_5_T0	COMPOUND	10	10	fluconazole
NCT000006275	NCT00000627_5_T1	PHENOTYPE	13	13	histoplasmosis
NCT000006278	NCT00000627_8_T0	GENE	1	1	has
NCT000006278	NCT00000627_8_T1	PHENOTYPE	13	14	fungal infections
NCT000006279	NCT00000627_9_T0	PHENOTYPE	9	9	histoplasmosis
NCT0000062710	NCT00000627_10_T0	COMPOUND	10	10	fluconazole
NCT0000062710	NCT00000627_10_T1	PHENOTYPE	13	13	histoplasmosis
NCT0000062711	NCT00000627_11_T0	PHENOTYPE	11	12	disseminated histoplasmosis
NCT0000062712	NCT00000627_12_T0	COMPOUND	2	2	fluconazole
NCT0000062715	NCT00000627_15_T0	PHENOTYPE	12	12	toxicity
NCT0000062715	NCT00000627_15_T1	PHENOTYPE	21	21	relapse
NCT0000062715	NCT00000627_15_T2	PHENOTYPE	33	33	relapse
NCT0000062715	NCT00000627_15_T3	GENE	24	24	reduced
NCT0000062715	NCT00000627_15_T4	GENE	36	36	reduced
NCT0000062720	NCT00000627_20_T0	PHENOTYPE	4	4	severely
NCT000006281	NCT00000628_1_T0	COMPOUND	1	1	2
NCT000006281	NCT00000628_1_T1	COMPOUND	11	11	L-697,661
NCT000006283	NCT00000628_3_T0	PHENOTYPE	6	6	HIV
NCT000006285	NCT00000628_5_T0	PHENOTYPE	6	6	HIV
NCT000006286	NCT00000628_6_T0	COMPOUND	1	1	1
NCT000006287	NCT00000628_7_T0	COMPOUND	12	12	L-697,661
NCT000006287	NCT00000628_7_T1	GENE	0	1	Group 1
NCT000006288	NCT00000628_8_T0	COMPOUND	11	11	L-697,661
NCT0000062810	NCT00000628_10_T0	COMPOUND	1	1	2
NCT0000062810	NCT00000628_10_T1	COMPOUND	5	5	L-697,661
NCT0000062811	NCT00000628_11_T0	COMPOUND	2	2	L-697,661
NCT0000062811	NCT00000628_11_T1	GENE	5	5	extended
NCT000006290	NCT00000629_0_T0	PHENOTYPE	9	9	Pharmacokinetics
NCT000006290	NCT00000629_0_T1	GENE	13	13	ed
NCT000006292	NCT00000629_2_T0	PHENOTYPE	0	0	Secondary
NCT000006292	NCT00000629_2_T1	ORGAN	22	22	liver
NCT000006292	NCT00000629_2_T2	PHENOTYPE	25	26	asymptomatic HIV
NCT000006293	NCT00000629_3_T0	COMPOUND	16	16	zidovudine
NCT000006293	NCT00000629_3_T1	GENE	23	23	half-life
NCT000006293	NCT00000629_3_T2	ORGAN	4	4	liver
NCT000006293	NCT00000629_3_T3	ORGAN	22	22	plasma
NCT000006295	NCT00000629_5_T0	PHENOTYPE	1	2	asymptomatic HIV
NCT000006300	NCT00000630_0_T0	GENE	19	19	gp160
NCT000006302	NCT00000630_2_T0	PHENOTYPE	14	14	HIV
NCT000006302	NCT00000630_2_T1	GENE	18	18	gp160
NCT000006303	NCT00000630_3_T0	PHENOTYPE	43	43	vaccinia
NCT000006305	NCT00000630_5_T0	PHENOTYPE	43	43	vaccinia
NCT000006307	NCT00000630_7_T0	GENE	6	6	gp160
NCT000006308	NCT00000630_8_T0	PHENOTYPE	0	1	Group B
NCT000006311	NCT00000631_1_T0	GENE	15	15	envelope
NCT000006311	NCT00000631_1_T1	PHENOTYPE	0	0	Secondary
NCT000006311	NCT00000631_1_T2	PHENOTYPE	14	14	HIV
NCT000006312	NCT00000631_2_T0	GENE	40	41	soluble protein
NCT000006313	NCT00000631_3_T0	GENE	16	16	gp160
NCT000006315	NCT00000631_5_T0	GENE	16	16	gp160
NCT000006316	NCT00000631_6_T0	GENE	16	16	gp160
NCT000006316	NCT00000631_6_T1	GENE	22	22	gp160
NCT000006316	NCT00000631_6_T2	GENE	43	43	gp160
NCT000006320	NCT00000632_0_T0	GENE	16	16	2.3
NCT000006320	NCT00000632_0_T1	GENE	15	15	Env
NCT000006326	NCT00000632_6_T0	GENE	9	9	2.3
NCT000006326	NCT00000632_6_T1	GENE	8	8	Env
NCT000006330	NCT00000633_0_T0	PHENOTYPE	15	15	HIV
NCT000006330	NCT00000633_0_T1	GENE	16	16	gp160
NCT000006330	NCT00000633_0_T2	PHENOTYPE	19	20	HIV Seropositive
NCT000006332	NCT00000633_2_T0	GENE	10	10	gp160
NCT000006333	NCT00000633_3_T0	COMPOUND	10	10	Engerix-B
NCT000006333	NCT00000633_3_T1	GENE	5	5	gp160
NCT000006333	NCT00000633_3_T2	PHENOTYPE	7	8	hepatitis B
NCT000006334	NCT00000633_4_T0	PHENOTYPE	7	7	HIV
NCT000006334	NCT00000633_4_T1	BIOLOGICAL_PROCESS	4	5	immune response
NCT000006335	NCT00000633_5_T0	PHENOTYPE	16	16	HIV
NCT000006335	NCT00000633_5_T1	GENE	8	8	gp160
NCT000006336	NCT00000633_6_T0	PHENOTYPE	17	17	vaccinia
NCT000006336	NCT00000633_6_T1	PHENOTYPE	9	9	HIV
NCT000006336	NCT00000633_6_T2	PHENOTYPE	49	49	HIV
NCT000006336	NCT00000633_6_T3	PHENOTYPE	35	36	hepatitis B
NCT000006336	NCT00000633_6_T4	BIOLOGICAL_PROCESS	45	47	nonspecific immune response
NCT000006338	NCT00000633_8_T0	PHENOTYPE	16	16	HIV
NCT000006338	NCT00000633_8_T1	GENE	8	8	gp160
NCT000006339	NCT00000633_9_T0	PHENOTYPE	17	17	vaccinia
NCT000006339	NCT00000633_9_T1	PHENOTYPE	9	9	HIV
NCT000006339	NCT00000633_9_T2	PHENOTYPE	49	49	HIV
NCT000006339	NCT00000633_9_T3	PHENOTYPE	35	36	hepatitis B
NCT000006339	NCT00000633_9_T4	BIOLOGICAL_PROCESS	45	47	nonspecific immune response
NCT000006341	NCT00000634_1_T0	COMPOUND	6	6	nevirapine
NCT000006341	NCT00000634_1_T1	PHENOTYPE	12	12	HIV
NCT000006341	NCT00000634_1_T2	BIOLOGICAL_PROCESS	10	10	reproduction
NCT000006342	NCT00000634_2_T0	COMPOUND	3	3	zidovudine
NCT000006342	NCT00000634_2_T1	PHENOTYPE	15	15	resistant
NCT000006342	NCT00000634_2_T2	PHENOTYPE	9	9	strains
NCT000006343	NCT00000634_3_T0	PHENOTYPE	5	5	HIV
NCT000006343	NCT00000634_3_T1	PHENOTYPE	10	11	adverse effects
NCT000006345	NCT00000634_5_T0	COMPOUND	3	3	zidovudine
NCT000006345	NCT00000634_5_T1	PHENOTYPE	15	15	resistant
NCT000006345	NCT00000634_5_T2	PHENOTYPE	9	9	strains
NCT000006346	NCT00000634_6_T0	PHENOTYPE	5	5	HIV
NCT000006346	NCT00000634_6_T1	PHENOTYPE	10	11	adverse effects
NCT0000063410	NCT00000634_10_T0	PHENOTYPE	0	0	Pneumocystis
NCT0000063419	NCT00000634_19_T0	GENE	4	4	interferon
NCT000006350	NCT00000635_0_T0	PHENOTYPE	4	6	Herpes Simplex Disease
NCT000006352	NCT00000635_2_T0	PHENOTYPE	14	14	recurrences
NCT000006352	NCT00000635_2_T1	PHENOTYPE	0	0	HSV
NCT000006352	NCT00000635_2_T2	PHENOTYPE	10	11	skin sores
NCT000006356	NCT00000635_6_T0	COMPOUND	6	6	trifluridine
NCT000006356	NCT00000635_6_T1	PHENOTYPE	11	11	HSV
NCT000006356	NCT00000635_6_T2	COMPOUND	20	20	acyclovir
NCT0000063511	NCT00000635_11_T0	COMPOUND	6	6	trifluridine
NCT0000063511	NCT00000635_11_T1	PHENOTYPE	11	11	HSV
NCT0000063511	NCT00000635_11_T2	COMPOUND	20	20	acyclovir
NCT0000063512	NCT00000635_12_T0	COMPOUND	15	15	trifluridine
NCT0000063514	NCT00000635_14_T0	COMPOUND	10	10	trifluridine
NCT0000063514	NCT00000635_14_T1	COMPOUND	3	3	zinc
NCT000006362	NCT00000636_2_T0	PHENOTYPE	6	7	adverse reaction
NCT000006363	NCT00000636_3_T0	COMPOUND	10	10	pyrazinamide
NCT000006367	NCT00000636_7_T0	PHENOTYPE	6	7	adverse reaction
NCT000006368	NCT00000636_8_T0	COMPOUND	10	10	pyrazinamide
NCT0000063613	NCT00000636_13_T0	GENE	8	8	B6
NCT0000063614	NCT00000636_14_T0	COMPOUND	17	17	pyrazinamide
NCT0000063614	NCT00000636_14_T1	GENE	19	19	3.4
NCT000006371	NCT00000637_1_T0	PHENOTYPE	17	17	HIV
NCT000006371	NCT00000637_1_T1	PHENOTYPE	6	6	tolerance
NCT000006372	NCT00000637_2_T0	PHENOTYPE	11	11	HIV
NCT000006372	NCT00000637_2_T1	PHENOTYPE	7	7	progression
NCT000006372	NCT00000637_2_T2	GENE	1	1	has
NCT000006373	NCT00000637_3_T0	PHENOTYPE	7	8	adverse effect
NCT000006373	NCT00000637_3_T1	PHENOTYPE	1	3	bone marrow toxicity
NCT000006377	NCT00000637_7_T0	GENE	10	10	has
NCT0000063710	NCT00000637_10_T0	PHENOTYPE	7	8	adverse effect
NCT0000063710	NCT00000637_10_T1	PHENOTYPE	1	3	bone marrow toxicity
NCT0000063714	NCT00000637_14_T0	GENE	10	10	has
NCT0000063718	NCT00000637_18_T0	PHENOTYPE	12	13	drug toxicity
NCT0000063718	NCT00000637_18_T1	PHENOTYPE	19	20	HIV disease
NCT0000063719	NCT00000637_19_T0	PHENOTYPE	6	7	drug toxicity
NCT0000063719	NCT00000637_19_T1	PHENOTYPE	13	14	HIV disease
NCT0000063726	NCT00000637_26_T0	GENE	3	3	ACTG
NCT000006382	NCT00000638_2_T0	PHENOTYPE	10	10	HIV
NCT000006382	NCT00000638_2_T1	PHENOTYPE	18	18	tuberculosis
NCT000006383	NCT00000638_3_T0	PHENOTYPE	17	17	tuberculosis
NCT000006383	NCT00000638_3_T1	PHENOTYPE	20	20	resistant
NCT000006383	NCT00000638_3_T2	PHENOTYPE	6	7	adverse reaction
NCT000006388	NCT00000638_8_T0	PHENOTYPE	10	10	HIV
NCT000006388	NCT00000638_8_T1	PHENOTYPE	18	18	tuberculosis
NCT000006389	NCT00000638_9_T0	PHENOTYPE	17	17	tuberculosis
NCT000006389	NCT00000638_9_T1	PHENOTYPE	20	20	resistant
NCT000006389	NCT00000638_9_T2	PHENOTYPE	6	7	adverse reaction
NCT0000063816	NCT00000638_16_T0	COMPOUND	4	4	pyrazinamide
NCT000006391	NCT00000639_1_T0	GENE	9	9	CD4
NCT000006391	NCT00000639_1_T1	PHENOTYPE	16	16	meningitis
NCT000006391	NCT00000639_1_T2	PHENOTYPE	12	13	HIV infection
NCT000006396	NCT00000639_6_T0	COMPOUND	13	13	fluconazole
NCT000006396	NCT00000639_6_T1	COMPOUND	33	33	fluconazole
NCT000006396	NCT00000639_6_T2	COMPOUND	21	21	itraconazole
NCT000006396	NCT00000639_6_T3	COMPOUND	25	25	itraconazole
NCT000006402	NCT00000640_2_T0	GENE	6	6	has
NCT000006408	NCT00000640_8_T0	COMPOUND	23	23	primaquine
NCT000006408	NCT00000640_8_T1	COMPOUND	5	5	dapsone
NCT000006408	NCT00000640_8_T2	COMPOUND	14	14	trimethoprim
NCT000006408	NCT00000640_8_T3	COMPOUND	20	20	clindamycin
NCT000006409	NCT00000640_9_T0	COMPOUND	4	4	dapsone
NCT000006409	NCT00000640_9_T1	COMPOUND	6	6	trimethoprim
NCT000006409	NCT00000640_9_T2	PHENOTYPE	0	1	Group B
NCT0000064010	NCT00000640_10_T0	COMPOUND	14	14	primaquine
NCT0000064010	NCT00000640_10_T1	COMPOUND	11	11	clindamycin
NCT0000064011	NCT00000640_11_T0	COMPOUND	6	6	primaquine
NCT0000064011	NCT00000640_11_T1	COMPOUND	4	4	clindamycin
NCT0000064012	NCT00000640_12_T0	COMPOUND	11	11	dapsone
NCT0000064012	NCT00000640_12_T1	COMPOUND	14	14	trimethoprim
NCT0000064012	NCT00000640_12_T2	GENE	2	3	group C
NCT0000064026	NCT00000640_26_T0	PHENOTYPE	4	5	pulmonary pathology
NCT000006410	NCT00000641_0_T0	PHENOTYPE	16	18	Mycobacterium Avium Infection
NCT000006414	NCT00000641_4_T0	PHENOTYPE	22	22	anemia
NCT000006414	NCT00000641_4_T1	PHENOTYPE	16	17	opportunistic infections
NCT000006415	NCT00000641_5_T0	COMPOUND	14	14	clofazimine
NCT000006415	NCT00000641_5_T1	COMPOUND	17	17	rifamycin
NCT000006415	NCT00000641_5_T2	COMPOUND	15	15	ethambutol
NCT000006415	NCT00000641_5_T3	COMPOUND	20	20	ciprofloxacin
NCT000006416	NCT00000641_6_T0	COMPOUND	7	7	amikacin
NCT000006416	NCT00000641_6_T1	COMPOUND	20	20	ciprofloxacin
NCT000006417	NCT00000641_7_T0	PHENOTYPE	11	11	toxicity
NCT000006419	NCT00000641_9_T0	PHENOTYPE	22	22	anemia
NCT000006419	NCT00000641_9_T1	PHENOTYPE	16	17	opportunistic infections
NCT0000064110	NCT00000641_10_T0	COMPOUND	14	14	clofazimine
NCT0000064110	NCT00000641_10_T1	COMPOUND	17	17	rifamycin
NCT0000064110	NCT00000641_10_T2	COMPOUND	15	15	ethambutol
NCT0000064110	NCT00000641_10_T3	COMPOUND	20	20	ciprofloxacin
NCT0000064111	NCT00000641_11_T0	COMPOUND	7	7	amikacin
NCT0000064111	NCT00000641_11_T1	COMPOUND	20	20	ciprofloxacin
NCT0000064112	NCT00000641_12_T0	PHENOTYPE	11	11	toxicity
NCT0000064114	NCT00000641_14_T0	COMPOUND	29	29	amikacin
NCT0000064114	NCT00000641_14_T1	COMPOUND	15	15	clofazimine
NCT0000064114	NCT00000641_14_T2	COMPOUND	16	16	ethambutol
NCT0000064114	NCT00000641_14_T3	COMPOUND	14	14	ciprofloxacin
NCT0000064120	NCT00000641_20_T0	GENE	29	29	26
NCT0000064130	NCT00000641_30_T0	COMPOUND	4	4	clofazimine
NCT0000064130	NCT00000641_30_T1	COMPOUND	2	2	ethambutol
NCT000006422	NCT00000642_2_T0	PHENOTYPE	14	15	HIV seropositive
NCT000006423	NCT00000642_3_T0	COMPOUND	2	2	2
NCT000006425	NCT00000642_5_T0	PHENOTYPE	3	3	pharmacokinetics
NCT000006428	NCT00000642_8_T0	PHENOTYPE	19	19	infections
NCT000006428	NCT00000642_8_T1	PHENOTYPE	7	7	progression
NCT000006429	NCT00000642_9_T0	GENE	3	3	has
NCT0000064211	NCT00000642_11_T0	PHENOTYPE	19	19	infections
NCT0000064211	NCT00000642_11_T1	PHENOTYPE	7	7	progression
NCT0000064212	NCT00000642_12_T0	GENE	3	3	has
NCT0000064217	NCT00000642_17_T0	GENE	3	3	has
NCT0000064234	NCT00000642_34_T0	PHENOTYPE	2	3	drug use
NCT000006431	NCT00000643_1_T0	PHENOTYPE	9	10	opportunistic infections
NCT000006431	NCT00000643_1_T1	PHENOTYPE	0	1	Cerebral toxoplasmosis
NCT000006433	NCT00000643_3_T0	PHENOTYPE	15	15	HIV
NCT000006433	NCT00000643_3_T1	PHENOTYPE	12	13	cerebral toxoplasmosis
NCT000006436	NCT00000643_6_T0	PHENOTYPE	15	15	HIV
NCT000006436	NCT00000643_6_T1	PHENOTYPE	12	13	cerebral toxoplasmosis
NCT000006438	NCT00000643_8_T0	COMPOUND	6	6	pyrimethamine
NCT000006439	NCT00000643_9_T0	COMPOUND	4	4	calcium
NCT000006439	NCT00000643_9_T1	COMPOUND	3	3	leucovorin
NCT0000064313	NCT00000643_13_T0	COMPOUND	20	20	calcium
NCT0000064313	NCT00000643_13_T1	COMPOUND	14	14	pyrimethamine
NCT0000064313	NCT00000643_13_T2	COMPOUND	19	19	leucovorin
NCT0000064314	NCT00000643_14_T0	COMPOUND	6	6	pyrimethamine
NCT0000064315	NCT00000643_15_T0	COMPOUND	3	4	folinic acid
NCT000006440	NCT00000644_0_T0	GENE	2	2	II
NCT000006442	NCT00000644_2_T0	GENE	3	3	MAC
NCT000006442	NCT00000644_2_T1	PHENOTYPE	13	14	opportunistic infection
NCT000006442	NCT00000644_2_T2	PHENOTYPE	0	2	Mycobacterium avium complex
NCT000006443	NCT00000644_3_T0	GENE	6	6	has
NCT000006443	NCT00000644_3_T1	GENE	10	10	MAC
NCT000006444	NCT00000644_4_T0	COMPOUND	6	6	clarithromycin
NCT000006444	NCT00000644_4_T1	GENE	9	9	MAC
NCT000006445	NCT00000644_5_T0	PHENOTYPE	13	13	symptoms
NCT000006445	NCT00000644_5_T1	PHENOTYPE	6	7	adverse effects
NCT000006447	NCT00000644_7_T0	GENE	6	6	has
NCT000006447	NCT00000644_7_T1	GENE	10	10	MAC
NCT000006448	NCT00000644_8_T0	COMPOUND	6	6	clarithromycin
NCT000006448	NCT00000644_8_T1	GENE	9	9	MAC
NCT000006449	NCT00000644_9_T0	PHENOTYPE	13	13	symptoms
NCT000006449	NCT00000644_9_T1	PHENOTYPE	6	7	adverse effects
NCT0000064410	NCT00000644_10_T0	COMPOUND	11	11	clarithromycin
NCT0000064411	NCT00000644_11_T0	COMPOUND	9	9	clarithromycin
NCT0000064411	NCT00000644_11_T1	COMPOUND	27	27	clarithromycin
NCT0000064414	NCT00000644_14_T0	GENE	19	19	MAC
NCT0000064418	NCT00000644_18_T0	PHENOTYPE	4	5	opportunistic infections
NCT000006450	NCT00000645_0_T0	GENE	16	16	CD4
NCT000006450	NCT00000645_0_T1	CELL	17	17	Lymphocytes
NCT000006452	NCT00000645_2_T0	COMPOUND	6	6	hypericin
NCT000006452	NCT00000645_2_T1	COMPOUND	11	12	benzyl alcohol
NCT000006454	NCT00000645_4_T0	PHENOTYPE	2	2	HIV
NCT000006456	NCT00000645_6_T0	PHENOTYPE	2	2	HIV
NCT000006457	NCT00000645_7_T0	COMPOUND	10	10	hypericin
NCT000006459	NCT00000645_9_T0	PHENOTYPE	27	27	toxicity
NCT0000064511	NCT00000645_11_T0	PHENOTYPE	6	6	secondary
NCT0000064511	NCT00000645_11_T1	GENE	9	9	MTD
NCT0000064520	NCT00000645_20_T0	PHENOTYPE	1	2	substance abuse
NCT000006463	NCT00000646_3_T0	GENE	10	10	CD4
NCT000006463	NCT00000646_3_T1	CELL	11	11	cells
NCT000006463	NCT00000646_3_T2	COMPOUND	14	14	pentoxifylline
NCT000006463	NCT00000646_3_T3	GENE	5	5	TNF
NCT000006464	NCT00000646_4_T0	COMPOUND	21	21	pentoxifylline
NCT000006469	NCT00000646_9_T0	COMPOUND	6	6	caffeine
NCT000006469	NCT00000646_9_T1	COMPOUND	4	4	theophylline
NCT000006469	NCT00000646_9_T2	COMPOUND	3	3	pentoxifylline
NCT000006470	NCT00000647_0_T0	PHENOTYPE	16	16	Peripheral
NCT000006470	NCT00000647_0_T1	CELL	18	18	Lymphocytes
NCT000006470	NCT00000647_0_T2	ORGAN	13	14	Bone Marrow
NCT000006470	NCT00000647_0_T3	PHENOTYPE	29	30	HIV Infection
NCT000006472	NCT00000647_2_T0	PHENOTYPE	14	14	peripheral
NCT000006472	NCT00000647_2_T1	PHENOTYPE	67	67	peripheral
NCT000006472	NCT00000647_2_T2	CELL	68	68	lymphocytes
NCT000006472	NCT00000647_2_T3	COMPOUND	30	30	zidovudine
NCT000006472	NCT00000647_2_T4	CELL	15	15	lymphocyte
NCT000006472	NCT00000647_2_T5	PHENOTYPE	11	11	HIV
NCT000006472	NCT00000647_2_T6	PHENOTYPE	46	46	HIV
NCT000006472	NCT00000647_2_T7	PHENOTYPE	55	55	HIV
NCT000006472	NCT00000647_2_T8	ORGAN	18	19	bone marrow
NCT000006472	NCT00000647_2_T9	ORGAN	64	65	bone marrow
NCT000006474	NCT00000647_4_T0	GENE	30	30	twins
NCT000006474	NCT00000647_4_T1	PHENOTYPE	18	18	peripheral
NCT000006474	NCT00000647_4_T2	CELL	19	19	lymphocyte
NCT000006474	NCT00000647_4_T3	ORGAN	24	25	bone marrow
NCT000006475	NCT00000647_5_T0	ORGAN	1	2	bone marrow
NCT000006476	NCT00000647_6_T0	CELL	3	3	lymphocyte
NCT000006480	NCT00000648_0_T0	PHENOTYPE	12	12	Neurosyphilis
NCT000006480	NCT00000648_0_T1	PHENOTYPE	14	15	HIV Seropositive
NCT000006482	NCT00000648_2_T0	PHENOTYPE	3	3	syphilis
NCT000006482	NCT00000648_2_T1	PHENOTYPE	11	11	HIV
NCT000006482	NCT00000648_2_T2	PHENOTYPE	18	19	HIV infection
NCT000006482	NCT00000648_2_T3	ORGAN	31	33	central nervous system
NCT000006483	NCT00000648_3_T0	PHENOTYPE	18	18	HIV
NCT000006483	NCT00000648_3_T1	PHENOTYPE	10	10	neurosyphilis
NCT000006485	NCT00000648_5_T0	PHENOTYPE	18	18	HIV
NCT000006485	NCT00000648_5_T1	PHENOTYPE	10	10	neurosyphilis
NCT000006486	NCT00000648_6_T0	COMPOUND	23	23	ceftriaxone
NCT000006486	NCT00000648_6_T1	PHENOTYPE	0	0	HIV
NCT000006486	NCT00000648_6_T2	PHENOTYPE	8	8	neurosyphilis
NCT000006486	NCT00000648_6_T3	PHENOTYPE	12	12	neurosyphilis
NCT000006486	NCT00000648_6_T4	PHENOTYPE	17	17	neurosyphilis
NCT000006486	NCT00000648_6_T5	COMPOUND	20	21	penicillin G
NCT000006488	NCT00000648_8_T0	COMPOUND	9	9	penicillin
NCT000006488	NCT00000648_8_T1	COMPOUND	2	3	penicillin G
NCT000006489	NCT00000648_9_T0	COMPOUND	2	2	ceftriaxone
NCT0000064810	NCT00000648_10_T0	PHENOTYPE	13	14	opportunistic infections
NCT0000064811	NCT00000648_11_T0	PHENOTYPE	1	1	punctures
NCT000006491	NCT00000649_1_T0	PHENOTYPE	11	11	toxicity
NCT000006493	NCT00000649_3_T0	PHENOTYPE	7	7	toxic
NCT000006494	NCT00000649_4_T0	PHENOTYPE	11	11	HIV
NCT000006494	NCT00000649_4_T1	GENE	1	1	has
NCT000006494	NCT00000649_4_T2	BIOLOGICAL_PROCESS	13	13	reproduction
NCT000006495	NCT00000649_5_T0	COMPOUND	6	6	nevirapine
NCT000006495	NCT00000649_5_T1	PHENOTYPE	13	13	HIV
NCT000006498	NCT00000649_8_T0	PHENOTYPE	7	7	toxic
NCT000006499	NCT00000649_9_T0	PHENOTYPE	11	11	HIV
NCT000006499	NCT00000649_9_T1	GENE	1	1	has
NCT000006499	NCT00000649_9_T2	BIOLOGICAL_PROCESS	13	13	reproduction
NCT0000064910	NCT00000649_10_T0	COMPOUND	6	6	nevirapine
NCT0000064910	NCT00000649_10_T1	PHENOTYPE	13	13	HIV
NCT0000064916	NCT00000649_16_T0	COMPOUND	7	7	nevirapine
NCT0000064917	NCT00000649_17_T0	COMPOUND	13	13	nevirapine
NCT000006501	NCT00000650_1_T0	GENE	24	24	CD4
NCT000006501	NCT00000650_1_T1	PHENOTYPE	9	9	HIV
NCT000006501	NCT00000650_1_T2	GENE	1	1	has
NCT000006501	NCT00000650_1_T3	PHENOTYPE	17	18	disease progression
NCT000006510	NCT00000651_0_T0	PHENOTYPE	3	3	Blind
NCT000006510	NCT00000651_0_T1	PHENOTYPE	20	21	HIV Infection
NCT000006513	NCT00000651_3_T0	GENE	1	1	has
NCT000006515	NCT00000651_5_T0	PHENOTYPE	16	17	opportunistic infections
NCT000006516	NCT00000651_6_T0	PHENOTYPE	9	9	toxicity
NCT000006516	NCT00000651_6_T1	PHENOTYPE	13	14	cross tolerance
NCT000006516	NCT00000651_6_T2	PHENOTYPE	32	33	HIV infection
NCT000006519	NCT00000651_9_T0	PHENOTYPE	16	17	opportunistic infections
NCT0000065110	NCT00000651_10_T0	PHENOTYPE	9	9	toxicity
NCT0000065110	NCT00000651_10_T1	PHENOTYPE	13	14	cross tolerance
NCT0000065110	NCT00000651_10_T2	PHENOTYPE	32	33	HIV infection
NCT000006520	NCT00000652_0_T0	PHENOTYPE	9	9	Toxicity
NCT000006520	NCT00000652_0_T1	PHENOTYPE	21	22	HIV Infection
NCT000006523	NCT00000652_3_T0	PHENOTYPE	17	17	HIV
NCT000006523	NCT00000652_3_T1	PHENOTYPE	13	15	quality of life
NCT000006526	NCT00000652_6_T0	PHENOTYPE	17	17	HIV
NCT000006526	NCT00000652_6_T1	PHENOTYPE	13	15	quality of life
NCT0000065212	NCT00000652_12_T0	PHENOTYPE	10	10	toxicity
NCT000006530	NCT00000653_0_T0	PHENOTYPE	25	26	Progressive Disease
NCT000006530	NCT00000653_0_T1	PHENOTYPE	15	16	HIV Infection
NCT000006532	NCT00000653_2_T0	PHENOTYPE	20	20	toxicity
NCT000006532	NCT00000653_2_T1	PHENOTYPE	14	14	HIV
NCT000006532	NCT00000653_2_T2	PHENOTYPE	30	30	progression
NCT000006541	NCT00000654_1_T0	COMPOUND	9	9	FIAU
NCT000006541	NCT00000654_1_T1	COMPOUND	20	20	FIAU
NCT000006543	NCT00000654_3_T0	COMPOUND	7	7	FIAC
NCT000006543	NCT00000654_3_T1	COMPOUND	17	17	FIAC
NCT000006543	NCT00000654_3_T2	COMPOUND	25	25	FIAC
NCT000006543	NCT00000654_3_T3	COMPOUND	36	36	FIAC
NCT000006543	NCT00000654_3_T4	COMPOUND	1	1	FIAU
NCT000006543	NCT00000654_3_T5	COMPOUND	12	12	FIAU
NCT000006543	NCT00000654_3_T6	COMPOUND	27	27	FIAU
NCT000006543	NCT00000654_3_T7	BIOLOGICAL_PROCESS	15	15	metabolism
NCT000006544	NCT00000654_4_T0	PHENOTYPE	17	17	bloodstream
NCT000006544	NCT00000654_4_T1	COMPOUND	8	8	FIAC
NCT000006544	NCT00000654_4_T2	COMPOUND	25	25	FIAU
NCT000006545	NCT00000654_5_T0	PHENOTYPE	7	7	concentrations
NCT000006545	NCT00000654_5_T1	PHENOTYPE	21	21	herpes
NCT000006545	NCT00000654_5_T2	COMPOUND	9	9	FIAU
NCT000006545	NCT00000654_5_T3	PHENOTYPE	14	16	minimum inhibitory concentration
NCT000006547	NCT00000654_7_T0	COMPOUND	7	7	FIAC
NCT000006547	NCT00000654_7_T1	COMPOUND	17	17	FIAC
NCT000006547	NCT00000654_7_T2	COMPOUND	25	25	FIAC
NCT000006547	NCT00000654_7_T3	COMPOUND	36	36	FIAC
NCT000006547	NCT00000654_7_T4	COMPOUND	1	1	FIAU
NCT000006547	NCT00000654_7_T5	COMPOUND	12	12	FIAU
NCT000006547	NCT00000654_7_T6	COMPOUND	27	27	FIAU
NCT000006547	NCT00000654_7_T7	BIOLOGICAL_PROCESS	15	15	metabolism
NCT000006548	NCT00000654_8_T0	PHENOTYPE	17	17	bloodstream
NCT000006548	NCT00000654_8_T1	COMPOUND	8	8	FIAC
NCT000006548	NCT00000654_8_T2	COMPOUND	25	25	FIAU
NCT000006549	NCT00000654_9_T0	PHENOTYPE	7	7	concentrations
NCT000006549	NCT00000654_9_T1	PHENOTYPE	21	21	herpes
NCT000006549	NCT00000654_9_T2	COMPOUND	9	9	FIAU
NCT000006549	NCT00000654_9_T3	PHENOTYPE	14	16	minimum inhibitory concentration
NCT0000065410	NCT00000654_10_T0	PHENOTYPE	0	0	HIV
NCT0000065410	NCT00000654_10_T1	PHENOTYPE	13	13	herpes
NCT0000065410	NCT00000654_10_T2	PHENOTYPE	15	15	infections
NCT0000065410	NCT00000654_10_T3	PHENOTYPE	12	12	recurrent
NCT0000065411	NCT00000654_11_T0	COMPOUND	9	9	FIAU
NCT0000065411	NCT00000654_11_T1	COMPOUND	18	18	FIAU
NCT0000065412	NCT00000654_12_T0	GENE	35	35	met
NCT0000065412	NCT00000654_12_T1	PHENOTYPE	14	14	tolerance
NCT0000065412	NCT00000654_12_T2	PHENOTYPE	39	39	tolerance
NCT0000065415	NCT00000654_15_T0	PHENOTYPE	18	18	chronic
NCT0000065415	NCT00000654_15_T1	PHENOTYPE	19	19	HBV
NCT0000065415	NCT00000654_15_T2	PHENOTYPE	5	5	tolerance
NCT0000065416	NCT00000654_16_T0	ORGAN	0	0	Plasma
NCT0000065416	NCT00000654_16_T1	COMPOUND	11	11	FIAU
NCT0000065418	NCT00000654_18_T0	PHENOTYPE	17	17	tolerance
NCT000006550	NCT00000655_0_T0	PHENOTYPE	13	15	Pneumocystis Carinii Pneumonia
NCT0000065510	NCT00000655_10_T0	GENE	10	10	Hg
NCT0000065510	NCT00000655_10_T1	PHENOTYPE	0	1	Group B
NCT0000065512	NCT00000655_12_T0	PHENOTYPE	11	12	adverse effects
NCT0000065516	NCT00000655_16_T0	PHENOTYPE	4	4	toxicities
NCT000006560	NCT00000656_0_T0	COMPOUND	15	15	2
NCT000006560	NCT00000656_0_T1	PHENOTYPE	22	23	HIV Disease
NCT000006564	NCT00000656_4_T0	PHENOTYPE	19	20	asymptomatic HIV
NCT000006564	NCT00000656_4_T1	PHENOTYPE	20	21	HIV disease
NCT0000065613	NCT00000656_13_T0	PHENOTYPE	0	0	Hemophilia
NCT0000065613	NCT00000656_13_T1	GENE	2	2	has
NCT0000065622	NCT00000656_22_T0	PHENOTYPE	3	4	alcohol abuse
NCT000006571	NCT00000657_1_T0	GENE	6	6	ADC
NCT000006571	NCT00000657_1_T1	PHENOTYPE	0	0	HIV
NCT000006571	NCT00000657_1_T2	ORGAN	12	13	nervous system
NCT000006573	NCT00000657_3_T0	PHENOTYPE	6	6	symptoms
NCT000006573	NCT00000657_3_T1	GENE	10	10	ADC
NCT000006574	NCT00000657_4_T0	GENE	10	10	ADC
NCT000006574	NCT00000657_4_T1	GENE	1	1	has
NCT000006574	NCT00000657_4_T2	GENE	14	14	has
NCT000006575	NCT00000657_5_T0	GENE	20	20	ADC
NCT000006575	NCT00000657_5_T1	PHENOTYPE	18	18	symptoms
NCT000006578	NCT00000657_8_T0	PHENOTYPE	6	6	symptoms
NCT000006578	NCT00000657_8_T1	GENE	10	10	ADC
NCT000006579	NCT00000657_9_T0	GENE	10	10	ADC
NCT000006579	NCT00000657_9_T1	GENE	1	1	has
NCT000006579	NCT00000657_9_T2	GENE	14	14	has
NCT0000065710	NCT00000657_10_T0	GENE	20	20	ADC
NCT0000065710	NCT00000657_10_T1	PHENOTYPE	18	18	symptoms
NCT0000065723	NCT00000657_23_T0	COMPOUND	6	6	methadone
NCT0000065723	NCT00000657_23_T1	PHENOTYPE	1	4	alcohol or drug abuse
NCT000006583	NCT00000658_3_T0	PHENOTYPE	9	10	opportunistic infections
NCT000006583	NCT00000658_3_T1	ORGAN	18	19	bone marrow
NCT000006584	NCT00000658_4_T0	COMPOUND	17	17	dexamethasone
NCT000006584	NCT00000658_4_T1	COMPOUND	16	16	bleomycin
NCT000006584	NCT00000658_4_T2	COMPOUND	15	15	vincristine
NCT000006584	NCT00000658_4_T3	COMPOUND	13	13	cyclophosphamide
NCT000006584	NCT00000658_4_T4	COMPOUND	18	18	methotrexate
NCT000006584	NCT00000658_4_T5	COMPOUND	14	14	doxorubicin
NCT000006585	NCT00000658_5_T0	PHENOTYPE	24	24	toxicity
NCT000006585	NCT00000658_5_T1	GENE	23	23	reduced
NCT000006585	NCT00000658_5_T2	PHENOTYPE	21	21	remissions
NCT000006586	NCT00000658_6_T0	COMPOUND	11	11	methotrexate
NCT000006587	NCT00000658_7_T0	GENE	11	11	GM-CSF
NCT000006587	NCT00000658_7_T1	GENE	7	7	sargramostim
NCT000006587	NCT00000658_7_T2	ORGAN	14	15	bone marrow
NCT0000065810	NCT00000658_10_T0	PHENOTYPE	9	10	opportunistic infections
NCT0000065810	NCT00000658_10_T1	ORGAN	18	19	bone marrow
NCT0000065811	NCT00000658_11_T0	COMPOUND	17	17	dexamethasone
NCT0000065811	NCT00000658_11_T1	COMPOUND	16	16	bleomycin
NCT0000065811	NCT00000658_11_T2	COMPOUND	15	15	vincristine
NCT0000065811	NCT00000658_11_T3	COMPOUND	13	13	cyclophosphamide
NCT0000065811	NCT00000658_11_T4	COMPOUND	18	18	methotrexate
NCT0000065811	NCT00000658_11_T5	COMPOUND	14	14	doxorubicin
NCT0000065812	NCT00000658_12_T0	PHENOTYPE	24	24	toxicity
NCT0000065812	NCT00000658_12_T1	GENE	23	23	reduced
NCT0000065812	NCT00000658_12_T2	PHENOTYPE	21	21	remissions
NCT0000065813	NCT00000658_13_T0	COMPOUND	11	11	methotrexate
NCT0000065814	NCT00000658_14_T0	GENE	11	11	GM-CSF
NCT0000065814	NCT00000658_14_T1	GENE	7	7	sargramostim
NCT0000065814	NCT00000658_14_T2	ORGAN	14	15	bone marrow
NCT0000065817	NCT00000658_17_T0	PHENOTYPE	4	5	meningeal lymphoma
NCT0000065817	NCT00000658_17_T1	PHENOTYPE	7	9	Pneumocystis carinii pneumonia
NCT0000065818	NCT00000658_18_T0	PHENOTYPE	6	6	neutropenia
NCT0000065818	NCT00000658_18_T1	CELL	14	14	neutrophil
NCT0000065819	NCT00000658_19_T0	PHENOTYPE	14	14	remission
NCT0000065822	NCT00000658_22_T0	COMPOUND	8	8	allopurinol
NCT0000065826	NCT00000658_26_T0	COMPOUND	7	7	allopurinol
NCT000006593	NCT00000659_3_T0	PHENOTYPE	4	4	toxicity
NCT000006593	NCT00000659_3_T1	PHENOTYPE	8	8	inhibition
NCT000006593	NCT00000659_3_T2	ORGAN	10	11	bone marrow
NCT000006594	NCT00000659_4_T0	GENE	21	21	reduced
NCT000006598	NCT00000659_8_T0	PHENOTYPE	4	4	toxicity
NCT000006598	NCT00000659_8_T1	PHENOTYPE	8	8	inhibition
NCT000006598	NCT00000659_8_T2	ORGAN	10	11	bone marrow
NCT000006599	NCT00000659_9_T0	GENE	21	21	reduced
NCT0000065913	NCT00000659_13_T0	GENE	17	17	MED
NCT0000065918	NCT00000659_18_T0	GENE	15	15	p24
NCT0000065918	NCT00000659_18_T1	GENE	31	31	MED
NCT0000065918	NCT00000659_18_T2	GENE	41	41	MED
NCT0000065919	NCT00000659_19_T0	GENE	2	2	MED
NCT0000065920	NCT00000659_20_T0	GENE	27	27	16
NCT0000065920	NCT00000659_20_T1	GENE	44	44	16
NCT0000065920	NCT00000659_20_T2	GENE	14	14	MED
NCT0000065920	NCT00000659_20_T3	GENE	21	21	MED
NCT0000065920	NCT00000659_20_T4	GENE	31	31	MED
NCT0000065920	NCT00000659_20_T5	GENE	40	40	MED
NCT0000065921	NCT00000659_21_T0	COMPOUND	1	1	2
NCT0000065921	NCT00000659_21_T1	COMPOUND	3	3	2
NCT0000065922	NCT00000659_22_T0	GENE	16	16	p24
NCT0000065925	NCT00000659_25_T0	GENE	10	10	MED
NCT0000065925	NCT00000659_25_T1	GENE	23	23	MED
NCT000006601	NCT00000660_1_T0	PHENOTYPE	1	1	secondary
NCT000006601	NCT00000660_1_T1	PHENOTYPE	16	17	Kaposi's sarcoma
NCT000006603	NCT00000660_3_T0	PHENOTYPE	11	11	toxicities
NCT000006604	NCT00000660_4_T0	GENE	1	1	has
NCT000006604	NCT00000660_4_T1	PHENOTYPE	14	15	lung cancer
NCT000006604	NCT00000660_4_T2	PHENOTYPE	17	18	testicular cancer
NCT000006605	NCT00000660_5_T0	PHENOTYPE	6	6	lymphoma
NCT000006605	NCT00000660_5_T1	GENE	1	1	has
NCT0000066010	NCT00000660_10_T0	PHENOTYPE	11	11	toxicities
NCT0000066011	NCT00000660_11_T0	GENE	1	1	has
NCT0000066011	NCT00000660_11_T1	PHENOTYPE	14	15	lung cancer
NCT0000066011	NCT00000660_11_T2	PHENOTYPE	17	18	testicular cancer
NCT0000066012	NCT00000660_12_T0	PHENOTYPE	6	6	lymphoma
NCT0000066012	NCT00000660_12_T1	GENE	1	1	has
NCT0000066017	NCT00000660_17_T0	PHENOTYPE	36	36	toxicities
NCT0000066018	NCT00000660_18_T0	PHENOTYPE	14	14	toxicity
NCT0000066018	NCT00000660_18_T1	PHENOTYPE	25	26	progressive disease
NCT0000066020	NCT00000660_20_T0	PHENOTYPE	5	5	withdrawn
NCT0000066020	NCT00000660_20_T1	PHENOTYPE	2	3	progressive disease
NCT0000066021	NCT00000660_21_T0	PHENOTYPE	11	11	toxicity
NCT0000066021	NCT00000660_21_T1	PHENOTYPE	18	18	progression
NCT0000066023	NCT00000660_23_T0	GENE	2	2	reduced
NCT0000066023	NCT00000660_23_T1	GENE	16	16	reduced
NCT000006611	NCT00000661_1_T0	COMPOUND	3	3	oxazepam
NCT000006611	NCT00000661_1_T1	PHENOTYPE	21	22	chronic disease
NCT000006612	NCT00000661_2_T0	PHENOTYPE	9	9	toxicity
NCT000006612	NCT00000661_2_T1	PHENOTYPE	33	34	HIV infection
NCT000006614	NCT00000661_4_T0	PHENOTYPE	9	9	toxicity
NCT000006614	NCT00000661_4_T1	PHENOTYPE	33	34	HIV infection
NCT000006615	NCT00000661_5_T0	COMPOUND	13	13	oxazepam
NCT000006615	NCT00000661_5_T1	PHENOTYPE	14	14	pharmacokinetics
NCT000006616	NCT00000661_6_T0	COMPOUND	5	5	oxazepam
NCT000006620	NCT00000662_0_T0	GENE	2	2	IND
NCT000006620	NCT00000662_0_T1	PHENOTYPE	13	14	HIV Disease
NCT000006624	NCT00000662_4_T0	GENE	2	2	IND
NCT000006631	NCT00000663_1_T0	PHENOTYPE	6	6	HIV
NCT000006631	NCT00000663_1_T1	GENE	13	13	has
NCT000006633	NCT00000663_3_T0	PHENOTYPE	4	5	drug toxicities
NCT000006636	NCT00000663_6_T0	PHENOTYPE	4	5	drug toxicities
NCT000006639	NCT00000663_9_T0	GENE	16	16	0.3
NCT000006640	NCT00000664_0_T0	GENE	7	7	PEG
NCT000006640	NCT00000664_0_T1	GENE	6	6	IL-2
NCT000006640	NCT00000664_0_T2	GENE	8	8	IL-2
NCT000006640	NCT00000664_0_T3	PHENOTYPE	12	13	HIV Positive
NCT000006642	NCT00000664_2_T0	GENE	5	5	PEG
NCT000006642	NCT00000664_2_T1	PHENOTYPE	20	20	HIV
NCT000006642	NCT00000664_2_T2	GENE	6	6	IL2
NCT000006642	NCT00000664_2_T3	PHENOTYPE	23	24	antibody titers
NCT000006642	NCT00000664_2_T4	ORGAN	15	16	immune system
NCT000006643	NCT00000664_3_T0	PHENOTYPE	3	3	chronic
NCT000006649	NCT00000664_9_T0	GENE	12	12	PEG
NCT000006649	NCT00000664_9_T1	GENE	13	13	IL2
NCT0000066412	NCT00000664_12_T0	GENE	12	12	PEG
NCT0000066412	NCT00000664_12_T1	GENE	13	13	IL-2
NCT0000066413	NCT00000664_13_T0	GENE	7	7	PEG
NCT0000066413	NCT00000664_13_T1	GENE	8	8	IL-2
NCT0000066415	NCT00000664_15_T0	GENE	40	40	T4
NCT0000066415	NCT00000664_15_T1	GENE	9	9	IV
NCT0000066415	NCT00000664_15_T2	GENE	8	8	IL2
NCT0000066415	NCT00000664_15_T3	GENE	7	7	PEG
NCT0000066415	NCT00000664_15_T4	PHENOTYPE	47	47	suffered
NCT0000066415	NCT00000664_15_T5	PHENOTYPE	52	53	adverse events
NCT0000066420	NCT00000664_20_T0	COMPOUND	4	4	zidovudine
NCT0000066425	NCT00000664_25_T0	PHENOTYPE	1	1	focal
NCT0000066433	NCT00000664_33_T0	PHENOTYPE	1	2	substance abuse
NCT000006654	NCT00000665_4_T0	COMPOUND	13	13	zidovudine
NCT000006654	NCT00000665_4_T1	PHENOTYPE	6	6	toxicities
NCT000006654	NCT00000665_4_T2	COMPOUND	11	11	ganciclovir
NCT000006655	NCT00000665_5_T0	GENE	5	5	has
NCT000006655	NCT00000665_5_T1	COMPOUND	4	4	foscarnet
NCT0000066513	NCT00000665_13_T0	COMPOUND	13	13	zidovudine
NCT0000066513	NCT00000665_13_T1	PHENOTYPE	6	6	toxicities
NCT0000066513	NCT00000665_13_T2	COMPOUND	11	11	ganciclovir
NCT0000066514	NCT00000665_14_T0	GENE	5	5	has
NCT0000066514	NCT00000665_14_T1	COMPOUND	4	4	foscarnet
NCT0000066520	NCT00000665_20_T0	COMPOUND	10	10	ganciclovir
NCT0000066520	NCT00000665_20_T1	COMPOUND	18	18	foscarnet
NCT0000066521	NCT00000665_21_T0	COMPOUND	9	9	ganciclovir
NCT0000066521	NCT00000665_21_T1	COMPOUND	7	7	foscarnet
NCT0000066521	NCT00000665_21_T2	GENE	2	3	group 2
NCT0000066522	NCT00000665_22_T0	GENE	3	4	group 2
NCT0000066526	NCT00000665_26_T0	PHENOTYPE	19	19	toxicity
NCT0000066526	NCT00000665_26_T1	GENE	13	13	reduced
NCT0000066526	NCT00000665_26_T2	COMPOUND	7	7	ganciclovir
NCT0000066533	NCT00000665_33_T0	PHENOTYPE	4	5	alcohol abuse
NCT000006660	NCT00000666_0_T0	PHENOTYPE	11	11	Encephalitis
NCT000006660	NCT00000666_0_T1	PHENOTYPE	20	22	Toxoplasma Gondii Infection
NCT000006662	NCT00000666_2_T0	PHENOTYPE	1	1	encephalitis
NCT000006663	NCT00000666_3_T0	PHENOTYPE	4	4	encephalitis
NCT000006663	NCT00000666_3_T1	COMPOUND	8	8	pyrimethamine
NCT000006663	NCT00000666_3_T2	COMPOUND	10	10	sulfadiazine
NCT000006665	NCT00000666_5_T0	PHENOTYPE	11	11	encephalitis
NCT000006665	NCT00000666_5_T1	GENE	1	1	has
NCT000006668	NCT00000666_8_T0	PHENOTYPE	4	4	encephalitis
NCT000006668	NCT00000666_8_T1	COMPOUND	8	8	pyrimethamine
NCT000006668	NCT00000666_8_T2	COMPOUND	10	10	sulfadiazine
NCT0000066610	NCT00000666_10_T0	PHENOTYPE	11	11	encephalitis
NCT0000066610	NCT00000666_10_T1	GENE	1	1	has
NCT0000066612	NCT00000666_12_T0	COMPOUND	5	5	pyrimethamine
NCT000006673	NCT00000667_3_T0	PHENOTYPE	3	3	HIV
NCT000006673	NCT00000667_3_T1	PHENOTYPE	1	1	immunity
NCT000006673	NCT00000667_3_T2	PHENOTYPE	14	15	virus infection
NCT000006674	NCT00000667_4_T0	PHENOTYPE	6	6	HIV
NCT000006675	NCT00000667_5_T0	PHENOTYPE	16	16	HIV
NCT000006675	NCT00000667_5_T1	PHENOTYPE	24	24	progression
NCT000006675	NCT00000667_5_T2	GENE	5	5	has
NCT000006675	NCT00000667_5_T3	PHENOTYPE	26	27	HIV infection
NCT000006678	NCT00000667_8_T0	GENE	6	6	gp160
NCT000006678	NCT00000667_8_T1	PHENOTYPE	18	19	HIV seropositive
NCT0000066710	NCT00000667_10_T0	PHENOTYPE	6	6	HIV
NCT0000066711	NCT00000667_11_T0	PHENOTYPE	16	16	HIV
NCT0000066711	NCT00000667_11_T1	PHENOTYPE	24	24	progression
NCT0000066711	NCT00000667_11_T2	GENE	5	5	has
NCT0000066711	NCT00000667_11_T3	PHENOTYPE	26	27	HIV infection
NCT0000066714	NCT00000667_14_T0	GENE	6	6	gp160
NCT0000066714	NCT00000667_14_T1	PHENOTYPE	18	19	HIV seropositive
NCT000006680	NCT00000668_0_T0	PHENOTYPE	5	5	Tolerance
NCT000006684	NCT00000668_4_T0	PHENOTYPE	18	18	retinitis
NCT000006684	NCT00000668_4_T1	PHENOTYPE	19	19	progression
NCT000006684	NCT00000668_4_T2	COMPOUND	8	8	ganciclovir
NCT000006684	NCT00000668_4_T3	GENE	3	3	has
NCT000006687	NCT00000668_7_T0	PHENOTYPE	18	18	retinitis
NCT000006687	NCT00000668_7_T1	PHENOTYPE	19	19	progression
NCT000006687	NCT00000668_7_T2	COMPOUND	8	8	ganciclovir
NCT000006687	NCT00000668_7_T3	GENE	3	3	has
NCT000006690	NCT00000669_0_T0	PHENOTYPE	5	5	Pharmacokinetics
NCT000006690	NCT00000669_0_T1	PHENOTYPE	21	22	HIV Infection
NCT000006692	NCT00000669_2_T0	PHENOTYPE	4	4	bloodstream
NCT000006692	NCT00000669_2_T1	PHENOTYPE	25	25	HIV
NCT000006692	NCT00000669_2_T2	GENE	8	8	CSF
NCT000006693	NCT00000669_3_T0	GENE	25	25	extended
NCT000006694	NCT00000669_4_T0	PHENOTYPE	15	15	toxicity
NCT000006694	NCT00000669_4_T1	COMPOUND	17	17	zidovudine
NCT000006694	NCT00000669_4_T2	GENE	8	8	has
NCT000006696	NCT00000669_6_T0	PHENOTYPE	15	15	toxicity
NCT000006696	NCT00000669_6_T1	COMPOUND	17	17	zidovudine
NCT000006696	NCT00000669_6_T2	GENE	8	8	has
NCT0000066910	NCT00000669_10_T0	GENE	20	20	II
NCT0000066910	NCT00000669_10_T1	GENE	17	17	TC
NCT0000066911	NCT00000669_11_T0	PHENOTYPE	30	30	toxicities
NCT0000066911	NCT00000669_11_T1	GENE	5	5	MTD
NCT0000066915	NCT00000669_15_T0	PHENOTYPE	5	5	toxicities
NCT000006703	NCT00000670_3_T0	COMPOUND	17	17	probenecid
NCT000006706	NCT00000670_6_T0	COMPOUND	17	17	probenecid
NCT000006709	NCT00000670_9_T0	PHENOTYPE	21	21	bloodstream
NCT000006709	NCT00000670_9_T1	PHENOTYPE	22	22	pharmacokinetics
NCT0000067010	NCT00000670_10_T0	COMPOUND	15	15	probenecid
NCT0000067016	NCT00000670_16_T0	COMPOUND	6	6	zidovudine
NCT0000067016	NCT00000670_16_T1	PHENOTYPE	3	4	HIV infection
NCT000006713	NCT00000671_3_T0	PHENOTYPE	8	8	toxicities
NCT000006713	NCT00000671_3_T1	GENE	3	3	has
NCT000006716	NCT00000671_6_T0	PHENOTYPE	15	15	toxicity
NCT000006716	NCT00000671_6_T1	PHENOTYPE	11	11	HIV
NCT000006719	NCT00000671_9_T0	PHENOTYPE	8	8	toxicities
NCT000006719	NCT00000671_9_T1	GENE	3	3	has
NCT0000067112	NCT00000671_12_T0	PHENOTYPE	15	15	toxicity
NCT0000067112	NCT00000671_12_T1	PHENOTYPE	11	11	HIV
NCT0000067135	NCT00000671_35_T0	PHENOTYPE	1	4	alcohol or drug abuse
NCT000006724	NCT00000672_4_T0	PHENOTYPE	2	2	toxicity
NCT000006724	NCT00000672_4_T1	GENE	7	7	amylase
NCT000006729	NCT00000672_9_T0	PHENOTYPE	8	8	toxicities
NCT000006729	NCT00000672_9_T1	GENE	3	3	has
NCT0000067212	NCT00000672_12_T0	PHENOTYPE	16	16	toxicity
NCT0000067212	NCT00000672_12_T1	PHENOTYPE	12	12	HIV
NCT0000067212	NCT00000672_12_T2	BIOLOGICAL_PROCESS	10	10	reproduction
NCT0000067213	NCT00000672_13_T0	PHENOTYPE	36	36	symptoms
NCT0000067213	NCT00000672_13_T1	ORGAN	15	15	feet
NCT0000067213	NCT00000672_13_T2	ORGAN	17	17	legs
NCT0000067213	NCT00000672_13_T3	PHENOTYPE	3	3	toxicities
NCT0000067213	NCT00000672_13_T4	PHENOTYPE	12	12	pains
NCT0000067214	NCT00000672_14_T0	PHENOTYPE	2	2	symptoms
NCT0000067214	NCT00000672_14_T1	PHENOTYPE	22	22	symptoms
NCT0000067214	NCT00000672_14_T2	PHENOTYPE	1	1	neuropathy
NCT0000067215	NCT00000672_15_T0	PHENOTYPE	14	14	symptoms
NCT0000067215	NCT00000672_15_T1	GENE	8	8	reduced
NCT0000067219	NCT00000672_19_T0	PHENOTYPE	8	8	toxicities
NCT0000067219	NCT00000672_19_T1	GENE	3	3	has
NCT0000067222	NCT00000672_22_T0	PHENOTYPE	16	16	toxicity
NCT0000067222	NCT00000672_22_T1	PHENOTYPE	12	12	HIV
NCT0000067222	NCT00000672_22_T2	BIOLOGICAL_PROCESS	10	10	reproduction
NCT0000067223	NCT00000672_23_T0	PHENOTYPE	36	36	symptoms
NCT0000067223	NCT00000672_23_T1	ORGAN	15	15	feet
NCT0000067223	NCT00000672_23_T2	ORGAN	17	17	legs
NCT0000067223	NCT00000672_23_T3	PHENOTYPE	3	3	toxicities
NCT0000067223	NCT00000672_23_T4	PHENOTYPE	12	12	pains
NCT0000067224	NCT00000672_24_T0	PHENOTYPE	2	2	symptoms
NCT0000067224	NCT00000672_24_T1	PHENOTYPE	22	22	symptoms
NCT0000067224	NCT00000672_24_T2	PHENOTYPE	1	1	neuropathy
NCT0000067225	NCT00000672_25_T0	PHENOTYPE	14	14	symptoms
NCT0000067225	NCT00000672_25_T1	GENE	8	8	reduced
NCT0000067235	NCT00000672_35_T0	PHENOTYPE	24	24	initiation
NCT0000067236	NCT00000672_36_T0	GENE	7	7	IND
NCT0000067237	NCT00000672_37_T0	COMPOUND	1	1	acyclovir
NCT0000067250	NCT00000672_50_T0	PHENOTYPE	1	4	alcohol or drug abuse
NCT000006733	NCT00000673_3_T0	ORGAN	1	1	eyes
NCT000006737	NCT00000673_7_T0	PHENOTYPE	18	18	retinitis
NCT000006737	NCT00000673_7_T1	PHENOTYPE	8	8	granulocytopenia
NCT0000067311	NCT00000673_11_T0	PHENOTYPE	18	18	retinitis
NCT0000067311	NCT00000673_11_T1	PHENOTYPE	8	8	granulocytopenia
NCT0000067314	NCT00000673_14_T0	PHENOTYPE	23	23	retinitis
NCT0000067315	NCT00000673_15_T0	ORGAN	0	0	Eyes
NCT0000067315	NCT00000673_15_T1	ORGAN	5	5	eyes
NCT0000067315	NCT00000673_15_T2	ORGAN	13	13	eyes
NCT000006741	NCT00000674_1_T0	PHENOTYPE	13	13	focal
NCT000006741	NCT00000674_1_T1	PHENOTYPE	1	1	encephalitis
NCT000006741	NCT00000674_1_T2	PHENOTYPE	2	2	encephalitis
NCT000006741	NCT00000674_1_T3	PHENOTYPE	14	17	central nervous system infection
NCT000006742	NCT00000674_2_T0	PHENOTYPE	3	3	encephalitis
NCT000006743	NCT00000674_3_T0	PHENOTYPE	17	17	encephalitis
NCT000006743	NCT00000674_3_T1	COMPOUND	11	11	pyrimethamine
NCT000006743	NCT00000674_3_T2	COMPOUND	13	13	sulfadiazine
NCT000006744	NCT00000674_4_T0	PHENOTYPE	5	5	toxicity
NCT000006744	NCT00000674_4_T1	COMPOUND	4	4	sulfonamide
NCT000006745	NCT00000674_5_T0	PHENOTYPE	30	30	acute
NCT000006745	NCT00000674_5_T1	PHENOTYPE	34	34	encephalitis
NCT000006745	NCT00000674_5_T2	COMPOUND	16	16	pyrimethamine
NCT000006745	NCT00000674_5_T3	COMPOUND	22	22	pyrimethamine
NCT000006745	NCT00000674_5_T4	COMPOUND	13	13	clindamycin
NCT000006745	NCT00000674_5_T5	COMPOUND	24	24	sulfadiazine
NCT000006746	NCT00000674_6_T0	COMPOUND	3	3	clindamycin
NCT000006747	NCT00000674_7_T0	PHENOTYPE	10	10	acute
NCT000006747	NCT00000674_7_T1	PHENOTYPE	12	12	encephalitis
NCT000006747	NCT00000674_7_T2	COMPOUND	15	15	clindamycin
NCT000006748	NCT00000674_8_T0	COMPOUND	1	1	calcium
NCT000006748	NCT00000674_8_T1	COMPOUND	6	6	pyrimethamine
NCT000006748	NCT00000674_8_T2	PHENOTYPE	7	9	bone marrow toxicity
NCT0000067410	NCT00000674_10_T0	PHENOTYPE	3	3	encephalitis
NCT0000067411	NCT00000674_11_T0	PHENOTYPE	17	17	encephalitis
NCT0000067411	NCT00000674_11_T1	COMPOUND	11	11	pyrimethamine
NCT0000067411	NCT00000674_11_T2	COMPOUND	13	13	sulfadiazine
NCT0000067412	NCT00000674_12_T0	PHENOTYPE	5	5	toxicity
NCT0000067412	NCT00000674_12_T1	COMPOUND	4	4	sulfonamide
NCT0000067413	NCT00000674_13_T0	PHENOTYPE	30	30	acute
NCT0000067413	NCT00000674_13_T1	PHENOTYPE	34	34	encephalitis
NCT0000067413	NCT00000674_13_T2	COMPOUND	16	16	pyrimethamine
NCT0000067413	NCT00000674_13_T3	COMPOUND	22	22	pyrimethamine
NCT0000067413	NCT00000674_13_T4	COMPOUND	13	13	clindamycin
NCT0000067413	NCT00000674_13_T5	COMPOUND	24	24	sulfadiazine
NCT0000067414	NCT00000674_14_T0	COMPOUND	3	3	clindamycin
NCT0000067415	NCT00000674_15_T0	PHENOTYPE	10	10	acute
NCT0000067415	NCT00000674_15_T1	PHENOTYPE	12	12	encephalitis
NCT0000067415	NCT00000674_15_T2	COMPOUND	15	15	clindamycin
NCT0000067416	NCT00000674_16_T0	COMPOUND	1	1	calcium
NCT0000067416	NCT00000674_16_T1	COMPOUND	6	6	pyrimethamine
NCT0000067416	NCT00000674_16_T2	PHENOTYPE	7	9	bone marrow toxicity
NCT0000067423	NCT00000674_23_T0	COMPOUND	16	16	dexamethasone
NCT0000067423	NCT00000674_23_T1	GENE	30	30	tapered
NCT0000067423	NCT00000674_23_T2	PHENOTYPE	8	9	intracranial hypertension
NCT0000067425	NCT00000674_25_T0	COMPOUND	7	7	designee
NCT0000067428	NCT00000674_28_T0	PHENOTYPE	7	7	encephalitis
NCT0000067428	NCT00000674_28_T1	PHENOTYPE	28	28	encephalitis
NCT0000067428	NCT00000674_28_T2	COMPOUND	16	16	pyrimethamine
NCT0000067428	NCT00000674_28_T3	COMPOUND	20	20	pyrimethamine
NCT0000067428	NCT00000674_28_T4	COMPOUND	22	22	clindamycin
NCT0000067429	NCT00000674_29_T0	PHENOTYPE	0	0	Relapse
NCT0000067429	NCT00000674_29_T1	PHENOTYPE	17	17	encephalitis
NCT0000067429	NCT00000674_29_T2	PHENOTYPE	6	6	progression
NCT000006752	NCT00000675_2_T0	PHENOTYPE	8	9	HIV infection
NCT000006754	NCT00000675_4_T0	GENE	10	10	receptor
NCT000006754	NCT00000675_4_T1	PHENOTYPE	4	4	attachment
NCT000006754	NCT00000675_4_T2	PHENOTYPE	6	6	HIV
NCT000006756	NCT00000675_6_T0	PHENOTYPE	5	5	attachment
NCT000006756	NCT00000675_6_T1	GENE	7	7	gp120
NCT000006756	NCT00000675_6_T2	GENE	10	11	CD4 receptor
NCT000006757	NCT00000675_7_T0	GENE	11	11	CD4
NCT000006759	NCT00000675_9_T0	PHENOTYPE	6	7	HIV infection
NCT0000067510	NCT00000675_10_T0	GENE	30	30	IgG
NCT0000067510	NCT00000675_10_T1	GENE	28	28	IgG1
NCT0000067510	NCT00000675_10_T2	GENE	16	16	has
NCT0000067513	NCT00000675_13_T0	GENE	10	10	receptor
NCT0000067513	NCT00000675_13_T1	PHENOTYPE	4	4	attachment
NCT0000067513	NCT00000675_13_T2	PHENOTYPE	6	6	HIV
NCT0000067515	NCT00000675_15_T0	PHENOTYPE	5	5	attachment
NCT0000067515	NCT00000675_15_T1	GENE	7	7	gp120
NCT0000067515	NCT00000675_15_T2	GENE	10	11	CD4 receptor
NCT0000067516	NCT00000675_16_T0	GENE	11	11	CD4
NCT0000067518	NCT00000675_18_T0	PHENOTYPE	6	7	HIV infection
NCT0000067519	NCT00000675_19_T0	GENE	30	30	IgG
NCT0000067519	NCT00000675_19_T1	GENE	28	28	IgG1
NCT0000067519	NCT00000675_19_T2	GENE	16	16	has
NCT0000067522	NCT00000675_22_T0	GENE	8	8	MTD
NCT0000067523	NCT00000675_23_T0	PHENOTYPE	33	34	AIDS-Related Complex
NCT0000067527	NCT00000675_27_T0	GENE	2	2	extended
NCT0000067529	NCT00000675_29_T0	PHENOTYPE	18	19	HIV infection
NCT0000067532	NCT00000675_32_T0	PHENOTYPE	0	0	Pharmacokinetics
NCT000006760	NCT00000676_0_T0	PHENOTYPE	13	14	Fungal Infection
NCT000006760	NCT00000676_0_T1	PHENOTYPE	21	22	AIDS-Related Complex
NCT000006762	NCT00000676_2_T0	PHENOTYPE	12	12	mycoses
NCT000006762	NCT00000676_2_T1	PHENOTYPE	7	7	infections
NCT000006763	NCT00000676_3_T0	PHENOTYPE	7	8	fungal infections
NCT000006764	NCT00000676_4_T0	PHENOTYPE	17	17	infections
NCT000006764	NCT00000676_4_T1	PHENOTYPE	19	20	esophageal candidiasis
NCT000006764	NCT00000676_4_T2	PHENOTYPE	12	13	fungal infections
NCT000006765	NCT00000676_5_T0	PHENOTYPE	13	14	HIV infection
NCT000006765	NCT00000676_5_T1	PHENOTYPE	1	2	fungal infections
NCT000006767	NCT00000676_7_T0	PHENOTYPE	1	2	esophageal candidiasis
NCT000006768	NCT00000676_8_T0	PHENOTYPE	2	2	mycoses
NCT000006768	NCT00000676_8_T1	PHENOTYPE	0	0	Cryptococcosis
NCT000006768	NCT00000676_8_T2	PHENOTYPE	4	4	coccidioidomycosis
NCT000006769	NCT00000676_9_T0	PHENOTYPE	17	17	infections
NCT000006769	NCT00000676_9_T1	PHENOTYPE	2	3	fungal infections
NCT0000067610	NCT00000676_10_T0	GENE	1	1	has
NCT0000067610	NCT00000676_10_T1	PHENOTYPE	23	24	HIV infection
NCT0000067611	NCT00000676_11_T0	PHENOTYPE	15	15	coccidioidomycosis
NCT0000067611	NCT00000676_11_T1	PHENOTYPE	13	13	histoplasmosis
NCT0000067611	NCT00000676_11_T2	PHENOTYPE	11	11	candidiasis
NCT0000067611	NCT00000676_11_T3	PHENOTYPE	12	12	cryptococcosis
NCT0000067612	NCT00000676_12_T0	PHENOTYPE	6	7	cryptococcal meningitis
NCT0000067612	NCT00000676_12_T1	PHENOTYPE	13	14	oropharyngeal candidiasis
NCT0000067615	NCT00000676_15_T0	PHENOTYPE	1	2	esophageal candidiasis
NCT0000067616	NCT00000676_16_T0	PHENOTYPE	2	2	mycoses
NCT0000067616	NCT00000676_16_T1	PHENOTYPE	0	0	Cryptococcosis
NCT0000067616	NCT00000676_16_T2	PHENOTYPE	4	4	coccidioidomycosis
NCT0000067617	NCT00000676_17_T0	PHENOTYPE	17	17	infections
NCT0000067617	NCT00000676_17_T1	PHENOTYPE	2	3	fungal infections
NCT0000067618	NCT00000676_18_T0	GENE	1	1	has
NCT0000067618	NCT00000676_18_T1	PHENOTYPE	23	24	HIV infection
NCT0000067619	NCT00000676_19_T0	PHENOTYPE	15	15	coccidioidomycosis
NCT0000067619	NCT00000676_19_T1	PHENOTYPE	13	13	histoplasmosis
NCT0000067619	NCT00000676_19_T2	PHENOTYPE	11	11	candidiasis
NCT0000067619	NCT00000676_19_T3	PHENOTYPE	12	12	cryptococcosis
NCT0000067620	NCT00000676_20_T0	PHENOTYPE	6	7	cryptococcal meningitis
NCT0000067620	NCT00000676_20_T1	PHENOTYPE	13	14	oropharyngeal candidiasis
NCT0000067621	NCT00000676_21_T0	PHENOTYPE	11	11	centers
NCT0000067621	NCT00000676_21_T1	GENE	35	35	nested
NCT0000067623	NCT00000676_23_T0	GENE	11	11	nested
NCT0000067623	NCT00000676_23_T1	GENE	29	29	nested
NCT0000067624	NCT00000676_24_T0	GENE	9	9	ACTG
NCT0000067625	NCT00000676_25_T0	PHENOTYPE	5	5	centers
NCT0000067626	NCT00000676_26_T0	COMPOUND	7	7	fluconazole
NCT0000067626	NCT00000676_26_T1	COMPOUND	9	9	clotrimazole
NCT0000067627	NCT00000676_27_T0	GENE	29	29	nested
NCT0000067627	NCT00000676_27_T1	PHENOTYPE	5	6	fungal infection
NCT0000067634	NCT00000676_34_T0	ORGAN	8	8	feet
NCT000006771	NCT00000677_1_T0	PHENOTYPE	10	11	acute disease
NCT000006772	NCT00000677_2_T0	PHENOTYPE	11	11	HIV
NCT000006772	NCT00000677_2_T1	PHENOTYPE	0	1	Cryptococcal meningitis
NCT000006775	NCT00000677_5_T0	PHENOTYPE	9	9	toxic
NCT0000067711	NCT00000677_11_T0	PHENOTYPE	9	9	toxic
NCT0000067714	NCT00000677_14_T0	PHENOTYPE	6	6	acute
NCT0000067714	NCT00000677_14_T1	PHENOTYPE	17	17	acute
NCT0000067714	NCT00000677_14_T2	PHENOTYPE	0	0	HIV
NCT0000067714	NCT00000677_14_T3	PHENOTYPE	7	8	cryptococcal meningitis
NCT000006784	NCT00000678_4_T0	PHENOTYPE	16	17	opportunistic infections
NCT000006785	NCT00000678_5_T0	PHENOTYPE	9	9	resistant
NCT000006789	NCT00000678_9_T0	PHENOTYPE	16	17	opportunistic infections
NCT0000067810	NCT00000678_10_T0	PHENOTYPE	9	9	resistant
NCT0000067924	NCT00000679_24_T0	PHENOTYPE	3	4	alcohol abuse
NCT000006801	NCT00000680_1_T0	CELL	1	1	cells
NCT000006801	NCT00000680_1_T1	CELL	5	5	cells
NCT000006801	NCT00000680_1_T2	GENE	0	0	CD8
NCT000006801	NCT00000680_1_T3	CELL	4	4	lymphocyte
NCT000006802	NCT00000680_2_T0	PHENOTYPE	32	32	sickness
NCT000006802	NCT00000680_2_T1	CELL	10	10	cells
NCT000006802	NCT00000680_2_T2	PHENOTYPE	25	25	toxoplasmosis
NCT000006802	NCT00000680_2_T3	GENE	9	9	CD8
NCT000006802	NCT00000680_2_T4	PHENOTYPE	19	20	opportunistic infections
NCT000006803	NCT00000680_3_T0	PHENOTYPE	6	6	HIV
NCT000006804	NCT00000680_4_T0	CELL	4	4	cells
NCT000006805	NCT00000680_5_T0	CELL	20	20	cells
NCT000006805	NCT00000680_5_T1	GENE	4	4	IL-2
NCT000006805	NCT00000680_5_T2	GENE	19	19	CD8
NCT000006805	NCT00000680_5_T3	ORGAN	9	10	immune system
NCT000006806	NCT00000680_6_T0	GENE	1	1	IL-2
NCT000006808	NCT00000680_8_T0	PHENOTYPE	32	32	sickness
NCT000006808	NCT00000680_8_T1	CELL	10	10	cells
NCT000006808	NCT00000680_8_T2	PHENOTYPE	25	25	toxoplasmosis
NCT000006808	NCT00000680_8_T3	GENE	9	9	CD8
NCT000006808	NCT00000680_8_T4	PHENOTYPE	19	20	opportunistic infections
NCT000006809	NCT00000680_9_T0	PHENOTYPE	6	6	HIV
NCT0000068010	NCT00000680_10_T0	CELL	4	4	cells
NCT0000068011	NCT00000680_11_T0	CELL	20	20	cells
NCT0000068011	NCT00000680_11_T1	GENE	4	4	IL-2
NCT0000068011	NCT00000680_11_T2	GENE	19	19	CD8
NCT0000068011	NCT00000680_11_T3	ORGAN	9	10	immune system
NCT0000068012	NCT00000680_12_T0	GENE	1	1	IL-2
NCT0000068013	NCT00000680_13_T0	CELL	4	4	lymphocytes
NCT0000068013	NCT00000680_13_T1	GENE	3	3	CD8
NCT0000068015	NCT00000680_15_T0	CELL	9	9	cells
NCT0000068015	NCT00000680_15_T1	CELL	23	23	cells
NCT0000068015	NCT00000680_15_T2	PHENOTYPE	19	19	pharmacokinetics
NCT0000068015	NCT00000680_15_T3	COMPOUND	5	5	indium
NCT0000068021	NCT00000680_21_T0	CELL	6	6	lymphocytes
NCT0000068022	NCT00000680_22_T0	CELL	2	2	cells
NCT0000068022	NCT00000680_22_T1	GENE	1	1	CD8
NCT0000068022	NCT00000680_22_T2	GENE	15	15	10
NCT0000068023	NCT00000680_23_T0	CELL	1	1	cells
NCT0000068026	NCT00000680_26_T0	GENE	10	10	IL-2
NCT000006811	NCT00000681_1_T0	GENE	6	6	KS
NCT000006813	NCT00000681_3_T0	PHENOTYPE	32	32	complications
NCT000006813	NCT00000681_3_T1	CELL	38	38	granulocyte
NCT000006813	NCT00000681_3_T2	PHENOTYPE	35	35	granulocytopenia
NCT000006813	NCT00000681_3_T3	CELL	18	19	blood cells
NCT000006813	NCT00000681_3_T4	ORGAN	14	15	bone marrow
NCT000006813	NCT00000681_3_T5	PHENOTYPE	4	5	toxic effect
NCT000006816	NCT00000681_6_T0	PHENOTYPE	5	5	HIV
NCT000006816	NCT00000681_6_T1	PHENOTYPE	11	11	granulocytopenia
NCT000006816	NCT00000681_6_T2	GENE	3	3	GM-CSF
NCT000006816	NCT00000681_6_T3	GENE	24	24	GM-CSF
NCT000006816	NCT00000681_6_T4	CELL	19	20	blood cells
NCT000006816	NCT00000681_6_T5	CELL	16	17	progenitor cells
NCT000006819	NCT00000681_9_T0	PHENOTYPE	32	32	complications
NCT000006819	NCT00000681_9_T1	CELL	38	38	granulocyte
NCT000006819	NCT00000681_9_T2	PHENOTYPE	35	35	granulocytopenia
NCT000006819	NCT00000681_9_T3	CELL	18	19	blood cells
NCT000006819	NCT00000681_9_T4	ORGAN	14	15	bone marrow
NCT000006819	NCT00000681_9_T5	PHENOTYPE	4	5	toxic effect
NCT0000068112	NCT00000681_12_T0	PHENOTYPE	5	5	HIV
NCT0000068112	NCT00000681_12_T1	PHENOTYPE	11	11	granulocytopenia
NCT0000068112	NCT00000681_12_T2	GENE	3	3	GM-CSF
NCT0000068112	NCT00000681_12_T3	GENE	24	24	GM-CSF
NCT0000068112	NCT00000681_12_T4	CELL	19	20	blood cells
NCT0000068112	NCT00000681_12_T5	CELL	16	17	progenitor cells
NCT0000068113	NCT00000681_13_T0	PHENOTYPE	8	8	toxicities
NCT0000068113	NCT00000681_13_T1	GENE	28	28	reduced
NCT0000068113	NCT00000681_13_T2	GENE	26	26	has
NCT0000068113	NCT00000681_13_T3	GENE	7	7	GM-CSF
NCT0000068113	NCT00000681_13_T4	GENE	14	14	GM-CSF
NCT0000068113	NCT00000681_13_T5	GENE	21	21	GM-CSF
NCT0000068114	NCT00000681_14_T0	GENE	6	6	GM-CSF
NCT0000068115	NCT00000681_15_T0	GENE	11	11	GM-CSF
NCT0000068116	NCT00000681_16_T0	COMPOUND	33	33	bleomycin
NCT0000068116	NCT00000681_16_T1	COMPOUND	34	34	vincristine
NCT0000068116	NCT00000681_16_T2	COMPOUND	29	29	doxorubicin
NCT0000068122	NCT00000681_22_T0	GENE	10	10	GM-CSF
NCT0000068122	NCT00000681_22_T1	GENE	5	5	MTD
NCT0000068126	NCT00000681_26_T0	GENE	5	5	GM-CSF
NCT0000068128	NCT00000681_28_T0	PHENOTYPE	8	9	Kaposi's sarcoma
NCT000006822	NCT00000682_2_T0	PHENOTYPE	8	8	strain
NCT000006822	NCT00000682_2_T1	PHENOTYPE	10	10	HIV
NCT000006822	NCT00000682_2_T2	PHENOTYPE	28	28	HIV
NCT000006826	NCT00000682_6_T0	PHENOTYPE	8	8	strain
NCT000006826	NCT00000682_6_T1	PHENOTYPE	10	10	HIV
NCT000006826	NCT00000682_6_T2	PHENOTYPE	28	28	HIV
NCT0000068217	NCT00000682_17_T0	COMPOUND	14	14	zidovudine
NCT0000068217	NCT00000682_17_T1	PHENOTYPE	5	5	HIV
NCT0000068218	NCT00000682_18_T0	GENE	28	28	6.4
NCT0000068218	NCT00000682_18_T1	GENE	23	23	hemoglobin
NCT000006832	NCT00000683_2_T0	GENE	17	17	gp160
NCT000006832	NCT00000683_2_T1	PHENOTYPE	14	15	adverse reactions
NCT000006833	NCT00000683_3_T0	GENE	1	1	gp160
NCT000006835	NCT00000683_5_T0	PHENOTYPE	16	16	vaccinia
NCT000006835	NCT00000683_5_T1	GENE	0	0	Is
NCT000006835	NCT00000683_5_T2	GENE	7	7	gp160
NCT000006835	NCT00000683_5_T3	GENE	27	27	gp160
NCT000006835	NCT00000683_5_T4	GENE	8	8	booster
NCT000006835	NCT00000683_5_T5	GENE	14	14	GP160
NCT000006835	NCT00000683_5_T6	BIOLOGICAL_PROCESS	4	5	immune response
NCT000006836	NCT00000683_6_T0	GENE	7	7	has
NCT000006836	NCT00000683_6_T1	GENE	16	16	has
NCT000006836	NCT00000683_6_T2	GENE	6	6	gp160
NCT000006836	NCT00000683_6_T3	GENE	53	53	gp160
NCT000006836	NCT00000683_6_T4	GENE	12	12	booster
NCT000006837	NCT00000683_7_T0	PHENOTYPE	12	12	HIV
NCT000006837	NCT00000683_7_T1	GENE	9	10	envelope protein
NCT000006838	NCT00000683_8_T0	PHENOTYPE	8	8	vaccinia
NCT000006839	NCT00000683_9_T0	PHENOTYPE	11	11	immunity
NCT0000068312	NCT00000683_12_T0	PHENOTYPE	12	12	HIV
NCT0000068312	NCT00000683_12_T1	GENE	9	10	envelope protein
NCT0000068313	NCT00000683_13_T0	PHENOTYPE	8	8	vaccinia
NCT0000068314	NCT00000683_14_T0	PHENOTYPE	11	11	immunity
NCT0000068316	NCT00000683_16_T0	GENE	16	16	gp160
NCT0000068316	NCT00000683_16_T1	ORGAN	13	14	deltoid muscle
NCT0000068317	NCT00000683_17_T0	GENE	3	3	gp160
NCT0000068319	NCT00000683_19_T0	PHENOTYPE	23	23	symptoms
NCT0000068320	NCT00000683_20_T0	GENE	26	26	gp160
NCT0000068320	NCT00000683_20_T1	GENE	42	42	gp160
NCT0000068320	NCT00000683_20_T2	GENE	23	23	booster
NCT0000068320	NCT00000683_20_T3	GENE	39	39	booster
NCT0000068324	NCT00000683_24_T0	PHENOTYPE	8	8	smallpox
NCT0000068328	NCT00000683_28_T0	GENE	26	26	has
NCT0000068328	NCT00000683_28_T1	GENE	6	6	booster
NCT0000068331	NCT00000683_31_T0	PHENOTYPE	12	12	practices
NCT000006840	NCT00000684_0_T0	PHENOTYPE	7	7	Immunodeficiency
NCT000006842	NCT00000684_2_T0	COMPOUND	4	4	sulfate
NCT000006842	NCT00000684_2_T1	COMPOUND	31	31	sulfate
NCT000006842	NCT00000684_2_T2	PHENOTYPE	21	21	thrombocytopenia
NCT000006842	NCT00000684_2_T3	COMPOUND	3	3	dextran
NCT000006842	NCT00000684_2_T4	COMPOUND	30	30	dextran
NCT000006842	NCT00000684_2_T5	CELL	6	6	platelet
NCT000006842	NCT00000684_2_T6	PHENOTYPE	22	23	low platelets
NCT000006845	NCT00000684_5_T0	COMPOUND	10	10	sulfate
NCT000006845	NCT00000684_5_T1	PHENOTYPE	23	23	HIV
NCT000006845	NCT00000684_5_T2	COMPOUND	9	9	dextran
NCT000006847	NCT00000684_7_T0	COMPOUND	20	20	sulfate
NCT000006847	NCT00000684_7_T1	COMPOUND	19	19	dextran
NCT000006848	NCT00000684_8_T0	GENE	9	9	thromboplastin
NCT000006849	NCT00000684_9_T0	COMPOUND	13	13	sulfate
NCT000006849	NCT00000684_9_T1	PHENOTYPE	2	2	withdrawn
NCT000006849	NCT00000684_9_T2	COMPOUND	12	12	dextran
NCT000006852	NCT00000685_2_T0	PHENOTYPE	13	14	HIV infection
NCT000006853	NCT00000685_3_T0	ORGAN	15	15	kidney
NCT000006853	NCT00000685_3_T1	ORGAN	21	21	kidney
NCT000006853	NCT00000685_3_T2	PHENOTYPE	2	3	HIV infection
NCT000006854	NCT00000685_4_T0	ORGAN	10	10	kidneys
NCT000006857	NCT00000685_7_T0	ORGAN	15	15	kidney
NCT000006857	NCT00000685_7_T1	ORGAN	21	21	kidney
NCT000006857	NCT00000685_7_T2	PHENOTYPE	2	3	HIV infection
NCT000006858	NCT00000685_8_T0	ORGAN	10	10	kidneys
NCT0000068510	NCT00000685_10_T0	PHENOTYPE	1	1	pharmacokinetics
NCT0000068510	NCT00000685_10_T1	PHENOTYPE	12	13	renal disorders
NCT0000068520	NCT00000685_20_T0	PHENOTYPE	0	0	Chronic
NCT0000068522	NCT00000685_22_T0	GENE	5	5	1.2
NCT0000068526	NCT00000685_26_T0	PHENOTYPE	6	7	renal insufficiency
NCT0000068526	NCT00000685_26_T1	PHENOTYPE	3	4	HIV infection
NCT000006861	NCT00000686_1_T0	GENE	19	19	p24
NCT000006861	NCT00000686_1_T1	PHENOTYPE	13	13	HIV
NCT000006861	NCT00000686_1_T2	ORGAN	16	16	plasma
NCT000006862	NCT00000686_2_T0	PHENOTYPE	9	9	HIV
NCT000006862	NCT00000686_2_T1	GENE	12	12	has
NCT000006864	NCT00000686_4_T0	PHENOTYPE	18	18	secondary
NCT000006864	NCT00000686_4_T1	PHENOTYPE	7	7	progression
NCT000006864	NCT00000686_4_T2	PHENOTYPE	11	12	HIV infection
NCT000006865	NCT00000686_5_T0	PHENOTYPE	19	20	HIV infection
NCT000006867	NCT00000686_7_T0	PHENOTYPE	11	11	bloodstream
NCT000006869	NCT00000686_9_T0	BIOLOGICAL_PROCESS	14	15	thymidine metabolism
NCT0000068612	NCT00000686_12_T0	PHENOTYPE	18	18	secondary
NCT0000068612	NCT00000686_12_T1	PHENOTYPE	7	7	progression
NCT0000068612	NCT00000686_12_T2	PHENOTYPE	11	12	HIV infection
NCT0000068613	NCT00000686_13_T0	PHENOTYPE	19	20	HIV infection
NCT0000068615	NCT00000686_15_T0	PHENOTYPE	11	11	bloodstream
NCT0000068617	NCT00000686_17_T0	BIOLOGICAL_PROCESS	14	15	thymidine metabolism
NCT0000068628	NCT00000686_28_T0	PHENOTYPE	1	4	alcohol or drug abuse
NCT000006871	NCT00000687_1_T0	PHENOTYPE	23	23	toxic
NCT000006871	NCT00000687_1_T1	PHENOTYPE	17	17	tumors
NCT000006871	NCT00000687_1_T2	PHENOTYPE	15	15	affects
NCT000006872	NCT00000687_2_T0	GENE	17	17	KS
NCT000006873	NCT00000687_3_T0	GENE	11	11	KS
NCT000006874	NCT00000687_4_T0	PHENOTYPE	19	19	severity
NCT000006874	NCT00000687_4_T1	GENE	25	25	CD4
NCT000006874	NCT00000687_4_T2	GENE	32	32	p24
NCT000006874	NCT00000687_4_T3	CELL	26	26	cells
NCT000006874	NCT00000687_4_T4	GENE	9	9	KS
NCT000006874	NCT00000687_4_T5	ORGAN	31	31	serum
NCT000006874	NCT00000687_4_T6	PHENOTYPE	21	22	opportunistic infections
NCT000006876	NCT00000687_6_T0	GENE	11	11	KS
NCT000006877	NCT00000687_7_T0	PHENOTYPE	19	19	severity
NCT000006877	NCT00000687_7_T1	GENE	25	25	CD4
NCT000006877	NCT00000687_7_T2	GENE	32	32	p24
NCT000006877	NCT00000687_7_T3	CELL	26	26	cells
NCT000006877	NCT00000687_7_T4	GENE	9	9	KS
NCT000006877	NCT00000687_7_T5	ORGAN	31	31	serum
NCT000006877	NCT00000687_7_T6	PHENOTYPE	21	22	opportunistic infections
NCT0000068712	NCT00000687_12_T0	PHENOTYPE	18	18	toxicity
NCT0000068712	NCT00000687_12_T1	GENE	20	20	skip
NCT0000068712	NCT00000687_12_T2	GENE	3	3	had
NCT0000068712	NCT00000687_12_T3	GENE	7	7	interferon
NCT0000068720	NCT00000687_20_T0	PHENOTYPE	7	7	HIV
NCT0000068720	NCT00000687_20_T1	PHENOTYPE	4	5	positive antibody
NCT0000068724	NCT00000687_24_T0	PHENOTYPE	7	7	toxicity
NCT0000068724	NCT00000687_24_T1	COMPOUND	9	9	zidovudine
NCT0000068728	NCT00000687_28_T0	PHENOTYPE	3	4	alcohol abuse
NCT0000068812	NCT00000688_12_T0	PHENOTYPE	3	3	Condition
NCT0000068813	NCT00000688_13_T0	COMPOUND	8	8	ganciclovir
NCT000006891	NCT00000689_1_T0	PHENOTYPE	5	5	lymphoma
NCT000006894	NCT00000689_4_T0	GENE	1	1	has
NCT000006894	NCT00000689_4_T1	GENE	0	0	GM-CSF
NCT000006894	NCT00000689_4_T2	CELL	6	8	white blood cells
NCT000006895	NCT00000689_5_T0	PHENOTYPE	11	11	lymphoma
NCT000006895	NCT00000689_5_T1	GENE	5	5	GM-CSF
NCT000006895	NCT00000689_5_T2	GENE	16	16	lessen
NCT000006895	NCT00000689_5_T3	CELL	20	22	white blood cells
NCT000006899	NCT00000689_9_T0	GENE	1	1	has
NCT000006899	NCT00000689_9_T1	GENE	0	0	GM-CSF
NCT000006899	NCT00000689_9_T2	CELL	6	8	white blood cells
NCT0000068910	NCT00000689_10_T0	PHENOTYPE	11	11	lymphoma
NCT0000068910	NCT00000689_10_T1	GENE	5	5	GM-CSF
NCT0000068910	NCT00000689_10_T2	GENE	16	16	lessen
NCT0000068910	NCT00000689_10_T3	CELL	20	22	white blood cells
NCT0000068914	NCT00000689_14_T0	PHENOTYPE	13	13	toxicity
NCT0000068914	NCT00000689_14_T1	COMPOUND	4	4	cyclophosphamide
NCT0000068914	NCT00000689_14_T2	COMPOUND	2	2	doxorubicin
NCT0000068916	NCT00000689_16_T0	COMPOUND	4	4	methotrexate
NCT0000068916	NCT00000689_16_T1	COMPOUND	7	7	methotrexate
NCT0000068917	NCT00000689_17_T0	GENE	0	0	GM-CSF
NCT0000068918	NCT00000689_18_T0	COMPOUND	17	17	cytosine
NCT0000068918	NCT00000689_18_T1	PHENOTYPE	6	6	tumor
NCT0000068918	NCT00000689_18_T2	COMPOUND	18	18	arabinoside
NCT0000068919	NCT00000689_19_T0	CELL	2	2	cells
NCT0000068919	NCT00000689_19_T1	CELL	23	23	cells
NCT0000068919	NCT00000689_19_T2	COMPOUND	13	13	cytosine
NCT0000068919	NCT00000689_19_T3	PHENOTYPE	1	1	tumor
NCT0000068919	NCT00000689_19_T4	PHENOTYPE	22	22	tumor
NCT0000068919	NCT00000689_19_T5	COMPOUND	14	14	arabinoside
NCT0000068920	NCT00000689_20_T0	CELL	3	3	cells
NCT0000068920	NCT00000689_20_T1	PHENOTYPE	2	2	tumor
NCT0000068922	NCT00000689_22_T0	ORGAN	0	1	Bone marrow
NCT0000068925	NCT00000689_25_T0	TISSUE	19	19	tissues
NCT0000068925	NCT00000689_25_T1	PHENOTYPE	16	16	tolerance
NCT000006902	NCT00000690_2_T0	PHENOTYPE	6	6	HIV
NCT000006902	NCT00000690_2_T1	GENE	1	1	has
NCT000006902	NCT00000690_2_T2	GENE	0	0	DS
NCT000006906	NCT00000690_6_T0	GENE	12	12	DS
NCT000006907	NCT00000690_7_T0	PHENOTYPE	13	14	needle sticks
NCT0000069010	NCT00000690_10_T0	PHENOTYPE	2	2	withdrawn
NCT000006912	NCT00000691_2_T0	GENE	1	1	ACTG
NCT000006912	NCT00000691_2_T1	COMPOUND	12	12	foscarnet
NCT000006915	NCT00000691_5_T0	COMPOUND	11	11	foscarnet
NCT000006917	NCT00000691_7_T0	GENE	1	1	ACTG
NCT000006917	NCT00000691_7_T1	COMPOUND	12	12	foscarnet
NCT0000069110	NCT00000691_10_T0	COMPOUND	11	11	foscarnet
NCT0000069111	NCT00000691_11_T0	GENE	2	2	ACTG
NCT0000069111	NCT00000691_11_T1	GENE	5	5	extended
NCT0000069112	NCT00000691_12_T0	COMPOUND	6	6	foscarnet
NCT0000069115	NCT00000691_15_T0	COMPOUND	16	16	foscarnet
NCT0000069117	NCT00000691_17_T0	PHENOTYPE	1	1	retinitis
NCT0000069117	NCT00000691_17_T1	COMPOUND	5	5	foscarnet
NCT0000069117	NCT00000691_17_T2	GENE	11	11	extended
NCT0000069119	NCT00000691_19_T0	GENE	14	14	has
NCT0000069119	NCT00000691_19_T1	COMPOUND	8	8	foscarnet
NCT0000069119	NCT00000691_19_T2	COMPOUND	10	10	ciprofloxacin
NCT0000069119	NCT00000691_19_T3	PHENOTYPE	18	19	renal failure
NCT0000069128	NCT00000691_28_T0	PHENOTYPE	6	7	seizure disorder
NCT0000069128	NCT00000691_28_T1	PHENOTYPE	12	13	mass lesion
NCT0000069128	NCT00000691_28_T2	ORGAN	9	11	central nervous system
NCT000006921	NCT00000692_1_T0	GENE	5	5	MTD
NCT000006922	NCT00000692_2_T0	PHENOTYPE	2	2	HIV
NCT000006924	NCT00000692_4_T0	PHENOTYPE	28	28	HIV
NCT000006928	NCT00000692_8_T0	COMPOUND	31	31	1
NCT0000069214	NCT00000692_14_T0	GENE	21	21	has
NCT0000069221	NCT00000692_21_T0	PHENOTYPE	4	4	dysfunction
NCT000006934	NCT00000693_4_T0	PHENOTYPE	5	5	relapse
NCT000006937	NCT00000693_7_T0	PHENOTYPE	14	16	bone marrow toxicity
NCT000006938	NCT00000693_8_T0	GENE	1	1	has
NCT0000069315	NCT00000693_15_T0	PHENOTYPE	5	5	relapse
NCT0000069318	NCT00000693_18_T0	PHENOTYPE	14	16	bone marrow toxicity
NCT0000069319	NCT00000693_19_T0	GENE	1	1	has
NCT0000069327	NCT00000693_27_T0	GENE	12	12	met
NCT0000069327	NCT00000693_27_T1	PHENOTYPE	6	7	progressive disease
NCT0000069334	NCT00000693_34_T0	COMPOUND	8	8	ganciclovir
NCT000006947	NCT00000694_7_T0	GENE	2	2	GM-CSF
NCT000006948	NCT00000694_8_T0	GENE	10	10	WBC
NCT000006948	NCT00000694_8_T1	GENE	1	1	has
NCT0000069415	NCT00000694_15_T0	GENE	2	2	GM-CSF
NCT0000069416	NCT00000694_16_T0	GENE	10	10	WBC
NCT0000069416	NCT00000694_16_T1	GENE	1	1	has
NCT0000069418	NCT00000694_18_T0	GENE	2	2	GM-CSF
NCT0000069420	NCT00000694_20_T0	GENE	2	2	GM-CSF
NCT0000069426	NCT00000694_26_T0	PHENOTYPE	9	9	analgesia
NCT0000069426	NCT00000694_26_T1	PHENOTYPE	7	7	fever
NCT0000069427	NCT00000694_27_T0	TISSUE	7	8	lymph nodes
NCT0000069427	NCT00000694_27_T1	ORGAN	14	15	hard palate
NCT0000069427	NCT00000694_27_T2	PHENOTYPE	1	2	Kaposi's sarcoma
NCT0000069428	NCT00000694_28_T0	PHENOTYPE	3	3	HIV
NCT0000069428	NCT00000694_28_T1	GENE	11	11	kit
NCT0000069428	NCT00000694_28_T2	PHENOTYPE	0	1	Positive antibody
NCT0000069436	NCT00000694_36_T0	PHENOTYPE	3	4	alcohol abuse
NCT000006952	NCT00000695_2_T0	GENE	0	0	IFN_B
NCT000006952	NCT00000695_2_T1	PHENOTYPE	11	11	HIV
NCT000006952	NCT00000695_2_T2	GENE	1	1	has
NCT000006953	NCT00000695_3_T0	GENE	19	19	II
NCT000006953	NCT00000695_3_T1	PHENOTYPE	13	13	HIV
NCT000006953	NCT00000695_3_T2	PHENOTYPE	37	38	opportunistic infections
NCT000006953	NCT00000695_3_T3	GENE	14	15	reverse transcriptase
NCT000006954	NCT00000695_4_T0	PHENOTYPE	7	7	secondary
NCT000006955	NCT00000695_5_T0	GENE	13	13	IFN_B
NCT000006955	NCT00000695_5_T1	PHENOTYPE	28	31	AIDS related Kaposi's sarcoma
NCT000006956	NCT00000695_6_T0	PHENOTYPE	24	24	recurrences
NCT000006956	NCT00000695_6_T1	PHENOTYPE	19	19	toxicity
NCT000006956	NCT00000695_6_T2	PHENOTYPE	29	29	mutants
NCT000006958	NCT00000695_8_T0	GENE	19	19	II
NCT000006958	NCT00000695_8_T1	PHENOTYPE	13	13	HIV
NCT000006958	NCT00000695_8_T2	PHENOTYPE	37	38	opportunistic infections
NCT000006958	NCT00000695_8_T3	GENE	14	15	reverse transcriptase
NCT000006959	NCT00000695_9_T0	PHENOTYPE	7	7	secondary
NCT0000069510	NCT00000695_10_T0	GENE	13	13	IFN_B
NCT0000069510	NCT00000695_10_T1	PHENOTYPE	28	31	AIDS related Kaposi's sarcoma
NCT0000069511	NCT00000695_11_T0	PHENOTYPE	24	24	recurrences
NCT0000069511	NCT00000695_11_T1	PHENOTYPE	19	19	toxicity
NCT0000069511	NCT00000695_11_T2	PHENOTYPE	29	29	mutants
NCT0000069512	NCT00000695_12_T0	ORGAN	15	16	immune system
NCT0000069513	NCT00000695_13_T0	GENE	3	3	IFN_B
NCT0000069516	NCT00000695_16_T0	GENE	10	10	IFN_B
NCT0000069517	NCT00000695_17_T0	PHENOTYPE	3	3	toxicity
NCT0000069517	NCT00000695_17_T1	GENE	24	24	IFN_B
NCT0000069519	NCT00000695_19_T0	BIOLOGICAL_PROCESS	28	29	immune response
NCT0000069519	NCT00000695_19_T1	BIOLOGICAL_PROCESS	26	27	antiviral response
NCT0000069520	NCT00000695_20_T0	GENE	5	5	IFN_B
NCT0000069520	NCT00000695_20_T1	GENE	25	25	IFN_B
NCT000006960	NCT00000696_0_T0	PHENOTYPE	24	25	HIV Disease
NCT000006962	NCT00000696_2_T0	CELL	19	19	neutrophil
NCT000006964	NCT00000696_4_T0	PHENOTYPE	9	10	HIV infection
NCT0000069614	NCT00000696_14_T0	GENE	3	3	extended
NCT0000069615	NCT00000696_15_T0	COMPOUND	19	19	2
NCT0000069615	NCT00000696_15_T1	PHENOTYPE	13	13	initiation
NCT0000069634	NCT00000696_34_T0	PHENOTYPE	9	9	attributable
NCT0000069634	NCT00000696_34_T1	PHENOTYPE	7	8	adverse reaction
NCT0000069641	NCT00000696_41_T0	PHENOTYPE	1	2	substance abuse
NCT0000069711	NCT00000697_11_T0	PHENOTYPE	18	18	retinitis
NCT0000069711	NCT00000697_11_T1	GENE	19	19	has
NCT0000069711	NCT00000697_11_T2	COMPOUND	9	9	foscarnet
NCT0000069714	NCT00000697_14_T0	PHENOTYPE	12	12	toxic
NCT0000069714	NCT00000697_14_T1	ORGAN	19	19	kidneys
NCT0000069714	NCT00000697_14_T2	COMPOUND	16	16	foscarnet
NCT0000069714	NCT00000697_14_T3	GENE	7	7	IV
NCT0000069714	NCT00000697_14_T4	PHENOTYPE	13	14	side effect
NCT0000069715	NCT00000697_15_T0	PHENOTYPE	7	7	retinitis
NCT0000069716	NCT00000697_16_T0	COMPOUND	2	2	zidovudine
NCT0000069719	NCT00000697_19_T0	PHENOTYPE	18	18	retinitis
NCT0000069719	NCT00000697_19_T1	COMPOUND	6	6	foscarnet
NCT0000069719	NCT00000697_19_T2	COMPOUND	11	11	foscarnet
NCT0000069721	NCT00000697_21_T0	COMPOUND	4	4	foscarnet
NCT0000069723	NCT00000697_23_T0	COMPOUND	11	11	foscarnet
NCT0000069725	NCT00000697_25_T0	GENE	15	15	has
NCT0000069725	NCT00000697_25_T1	COMPOUND	9	9	foscarnet
NCT0000069725	NCT00000697_25_T2	COMPOUND	11	11	ciprofloxacin
NCT0000069725	NCT00000697_25_T3	PHENOTYPE	19	20	renal failure
NCT000006983	NCT00000698_3_T0	PHENOTYPE	17	17	blindness
NCT000006983	NCT00000698_3_T1	GENE	7	7	has
NCT000006987	NCT00000698_7_T0	PHENOTYPE	17	17	blindness
NCT000006987	NCT00000698_7_T1	GENE	7	7	has
NCT0000069812	NCT00000698_12_T0	PHENOTYPE	2	2	retinitis
NCT000006994	NCT00000699_4_T0	PHENOTYPE	11	11	HIV
NCT000006994	NCT00000699_4_T1	PHENOTYPE	4	4	infections
NCT000006994	NCT00000699_4_T2	ORGAN	1	2	immune system
NCT000006994	NCT00000699_4_T3	ORGAN	22	23	immune system
NCT000006994	NCT00000699_4_T4	CELL	13	14	T cells
NCT000006997	NCT00000699_7_T0	PHENOTYPE	11	11	HIV
NCT000006997	NCT00000699_7_T1	PHENOTYPE	4	4	infections
NCT000006997	NCT00000699_7_T2	ORGAN	1	2	immune system
NCT000006997	NCT00000699_7_T3	ORGAN	22	23	immune system
NCT000006997	NCT00000699_7_T4	CELL	13	14	T cells
NCT0000069910	NCT00000699_10_T0	PHENOTYPE	25	25	toxic
NCT0000069919	NCT00000699_19_T0	PHENOTYPE	17	17	secondary
NCT0000069919	NCT00000699_19_T1	PHENOTYPE	0	1	Constitutional symptoms
NCT0000069919	NCT00000699_19_T2	PHENOTYPE	5	6	neurologic symptoms
NCT0000069919	NCT00000699_19_T3	PHENOTYPE	18	19	infectious disease
NCT0000069920	NCT00000699_20_T0	PHENOTYPE	2	2	impairment
NCT0000069920	NCT00000699_20_T1	GENE	10	10	ACTG
NCT0000069920	NCT00000699_20_T2	PHENOTYPE	0	1	Grade 1
NCT0000069921	NCT00000699_21_T0	PHENOTYPE	3	4	alcohol abuse
NCT000007003	NCT00000700_3_T0	GENE	1	1	has
NCT000007006	NCT00000700_6_T0	GENE	1	1	has
NCT0000070012	NCT00000700_12_T0	PHENOTYPE	3	3	Condition
NCT0000070012	NCT00000700_12_T1	PHENOTYPE	7	8	opportunistic infections
NCT000007011	NCT00000701_1_T0	PHENOTYPE	11	11	bloodstream
NCT0000070111	NCT00000701_11_T0	GENE	12	12	IV
NCT000007020	NCT00000702_0_T0	PHENOTYPE	21	21	Immunodeficiency
NCT000007020	NCT00000702_0_T1	PHENOTYPE	24	24	Infection
NCT000007020	NCT00000702_0_T2	PHENOTYPE	23	23	HIV
NCT000007020	NCT00000702_0_T3	PHENOTYPE	12	14	AIDS Dementia Complex
NCT000007020	NCT00000702_0_T4	ORGAN	16	18	Central Nervous System
NCT000007022	NCT00000702_2_T0	GENE	11	11	CSF
NCT000007024	NCT00000702_4_T0	PHENOTYPE	18	18	HIV
NCT000007024	NCT00000702_4_T1	GENE	3	3	has
NCT000007024	NCT00000702_4_T2	ORGAN	21	22	nervous system
NCT000007024	NCT00000702_4_T3	PHENOTYPE	7	9	AIDS dementia complex
NCT000007026	NCT00000702_6_T0	PHENOTYPE	10	10	symptoms
NCT000007026	NCT00000702_6_T1	PHENOTYPE	13	15	AIDS dementia complex
NCT000007028	NCT00000702_8_T0	PHENOTYPE	18	18	HIV
NCT000007028	NCT00000702_8_T1	GENE	3	3	has
NCT000007028	NCT00000702_8_T2	ORGAN	21	22	nervous system
NCT000007028	NCT00000702_8_T3	PHENOTYPE	7	9	AIDS dementia complex
NCT0000070210	NCT00000702_10_T0	PHENOTYPE	10	10	symptoms
NCT0000070210	NCT00000702_10_T1	PHENOTYPE	13	15	AIDS dementia complex
NCT0000070217	NCT00000702_17_T0	COMPOUND	14	14	1
NCT0000070217	NCT00000702_17_T1	COMPOUND	26	26	1
NCT0000070218	NCT00000702_18_T0	PHENOTYPE	5	6	stage 1
NCT000007032	NCT00000703_2_T0	PHENOTYPE	17	17	toxic
NCT000007034	NCT00000703_4_T0	PHENOTYPE	17	17	toxic
NCT000007037	NCT00000703_7_T0	COMPOUND	13	13	dexamethasone
NCT000007037	NCT00000703_7_T1	COMPOUND	6	6	bleomycin
NCT000007037	NCT00000703_7_T2	COMPOUND	9	9	vincristine
NCT000007037	NCT00000703_7_T3	GENE	16	16	1.5
NCT000007037	NCT00000703_7_T4	COMPOUND	7	7	cyclophosphamide
NCT000007037	NCT00000703_7_T5	COMPOUND	18	18	methotrexate
NCT000007037	NCT00000703_7_T6	COMPOUND	5	5	doxorubicin
NCT000007038	NCT00000703_8_T0	COMPOUND	12	12	cytarabine
NCT000007038	NCT00000703_8_T1	PHENOTYPE	4	6	bone marrow disease
NCT000007039	NCT00000703_9_T0	PHENOTYPE	3	3	lymphomas
NCT000007039	NCT00000703_9_T1	ORGAN	42	43	bone marrow
NCT000007039	NCT00000703_9_T2	ORGAN	6	8	central nervous system
NCT0000070310	NCT00000703_10_T0	PHENOTYPE	1	1	punctures
NCT0000070311	NCT00000703_11_T0	PHENOTYPE	28	28	lymphoma
NCT0000070311	NCT00000703_11_T1	PHENOTYPE	25	25	remission
NCT0000070311	NCT00000703_11_T2	GENE	21	21	has
NCT000007042	NCT00000704_2_T0	PHENOTYPE	16	17	HIV infection
NCT000007044	NCT00000704_4_T0	GENE	1	1	has
NCT000007047	NCT00000704_7_T0	GENE	1	1	has
NCT0000070410	NCT00000704_10_T0	PHENOTYPE	17	17	HIV
NCT0000070410	NCT00000704_10_T1	ORGAN	21	21	serum
NCT0000070410	NCT00000704_10_T2	CELL	10	11	T4 cells
NCT0000070411	NCT00000704_11_T0	GENE	13	13	T4
NCT0000070411	NCT00000704_11_T1	PHENOTYPE	18	18	HIV
NCT0000070411	NCT00000704_11_T2	ORGAN	17	17	serum
NCT0000070418	NCT00000704_18_T0	PHENOTYPE	4	6	idiopathic thrombocytopenia purpura
NCT000007051	NCT00000705_1_T0	PHENOTYPE	0	0	HIV
NCT000007051	NCT00000705_1_T1	ORGAN	13	14	immune system
NCT000007051	NCT00000705_1_T2	CELL	5	6	blood cells
NCT000007056	NCT00000705_6_T0	PHENOTYPE	7	7	HIV
NCT000007056	NCT00000705_6_T1	GENE	2	2	has
NCT000007057	NCT00000705_7_T0	PHENOTYPE	13	13	immunity
NCT000007057	NCT00000705_7_T1	PHENOTYPE	6	7	opportunistic infections
NCT000007058	NCT00000705_8_T0	PHENOTYPE	3	4	laboratory abnormalities
NCT000007059	NCT00000705_9_T0	PHENOTYPE	5	5	toxicity
NCT000007059	NCT00000705_9_T1	PHENOTYPE	10	10	understood
NCT0000070510	NCT00000705_10_T0	PHENOTYPE	0	0	Hepatitis
NCT0000070510	NCT00000705_10_T1	PHENOTYPE	2	3	liver dysfunction
NCT0000070510	NCT00000705_10_T2	PHENOTYPE	17	18	HIV infection
NCT0000070511	NCT00000705_11_T0	ORGAN	7	7	liver
NCT0000070511	NCT00000705_11_T1	PHENOTYPE	9	9	pharmacokinetics
NCT0000070516	NCT00000705_16_T0	PHENOTYPE	2	2	HIV
NCT0000070516	NCT00000705_16_T1	CELL	7	7	leukocyte
NCT0000070516	NCT00000705_16_T2	CELL	9	9	lymphocyte
NCT0000070516	NCT00000705_16_T3	CELL	12	13	lymphocyte subsets
NCT0000070519	NCT00000705_19_T0	GENE	5	5	0.5
NCT000007061	NCT00000706_1_T0	COMPOUND	6	6	probenecid
NCT000007061	NCT00000706_1_T1	GENE	1	1	II
NCT000007061	NCT00000706_1_T2	COMPOUND	8	8	quinine
NCT000007062	NCT00000706_2_T0	PHENOTYPE	4	4	bloodstream
NCT000007063	NCT00000706_3_T0	COMPOUND	2	2	quinine
NCT000007066	NCT00000706_6_T0	COMPOUND	2	2	quinine
NCT000007068	NCT00000706_8_T0	COMPOUND	68	68	sulfate
NCT000007068	NCT00000706_8_T1	COMPOUND	67	67	quinine
NCT000007068	NCT00000706_8_T2	GENE	60	60	has
NCT000007069	NCT00000706_9_T0	COMPOUND	26	26	probenecid
NCT000007069	NCT00000706_9_T1	GENE	1	1	II
NCT000007069	NCT00000706_9_T2	COMPOUND	30	30	quinine
NCT000007069	NCT00000706_9_T3	PHENOTYPE	4	4	pharmacokinetics
NCT000007073	NCT00000707_3_T0	GENE	3	3	PEN
NCT000007073	NCT00000707_3_T1	PHENOTYPE	27	28	respiratory symptoms
NCT000007074	NCT00000707_4_T0	PHENOTYPE	29	29	toxicity
NCT000007074	NCT00000707_4_T1	PHENOTYPE	3	3	HIV
NCT000007076	NCT00000707_6_T0	GENE	3	3	PEN
NCT000007076	NCT00000707_6_T1	PHENOTYPE	27	28	respiratory symptoms
NCT000007077	NCT00000707_7_T0	PHENOTYPE	29	29	toxicity
NCT000007077	NCT00000707_7_T1	PHENOTYPE	3	3	HIV
NCT000007078	NCT00000707_8_T0	GENE	5	5	PEN
NCT0000070711	NCT00000707_11_T0	ORGAN	5	5	lungs
NCT0000070713	NCT00000707_13_T0	GENE	7	7	PEN
NCT0000070713	NCT00000707_13_T1	GENE	1	1	mist
NCT0000070714	NCT00000707_14_T0	ORGAN	10	10	lungs
NCT0000070714	NCT00000707_14_T1	GENE	1	1	gamma
NCT0000070715	NCT00000707_15_T0	ORGAN	11	11	ribs
NCT0000070717	NCT00000707_17_T0	GENE	9	9	PEN
NCT0000070722	NCT00000707_22_T0	PHENOTYPE	10	10	symptoms
NCT000007081	NCT00000708_1_T0	PHENOTYPE	0	1	Cryptococcal meningitis
NCT0000070812	NCT00000708_12_T0	PHENOTYPE	13	13	relapse
NCT0000070814	NCT00000708_14_T0	PHENOTYPE	13	13	relapse
NCT0000070815	NCT00000708_15_T0	PHENOTYPE	28	28	toxic
NCT0000070820	NCT00000708_20_T0	GENE	11	11	CSF
NCT0000070825	NCT00000708_25_T0	CELL	3	3	Lymphocyte
NCT000007092	NCT00000709_2_T0	ORGAN	5	7	central nervous system
NCT000007092	NCT00000709_2_T1	PHENOTYPE	24	26	AIDS dementia complex
NCT000007093	NCT00000709_3_T0	PHENOTYPE	12	12	symptoms
NCT000007093	NCT00000709_3_T1	PHENOTYPE	17	17	dementia
NCT000007093	NCT00000709_3_T2	PHENOTYPE	8	8	progressive
NCT000007094	NCT00000709_4_T0	PHENOTYPE	10	10	HIV
NCT000007094	NCT00000709_4_T1	PHENOTYPE	18	20	AIDS dementia complex
NCT000007095	NCT00000709_5_T0	PHENOTYPE	17	17	HIV
NCT000007095	NCT00000709_5_T1	GENE	8	8	has
NCT000007095	NCT00000709_5_T2	PHENOTYPE	24	26	AIDS dementia complex
NCT000007096	NCT00000709_6_T0	PHENOTYPE	10	12	AIDS dementia complex
NCT000007098	NCT00000709_8_T0	PHENOTYPE	12	12	symptoms
NCT000007098	NCT00000709_8_T1	PHENOTYPE	17	17	dementia
NCT000007098	NCT00000709_8_T2	PHENOTYPE	8	8	progressive
NCT000007099	NCT00000709_9_T0	PHENOTYPE	10	10	HIV
NCT000007099	NCT00000709_9_T1	PHENOTYPE	18	20	AIDS dementia complex
NCT0000070910	NCT00000709_10_T0	PHENOTYPE	17	17	HIV
NCT0000070910	NCT00000709_10_T1	GENE	8	8	has
NCT0000070910	NCT00000709_10_T2	PHENOTYPE	24	26	AIDS dementia complex
NCT0000070911	NCT00000709_11_T0	PHENOTYPE	10	12	AIDS dementia complex
NCT0000070917	NCT00000709_17_T0	GENE	2	2	p24
NCT0000070919	NCT00000709_19_T0	PHENOTYPE	1	2	substance abuse
NCT000007101	NCT00000710_1_T0	GENE	18	18	II
NCT000007101	NCT00000710_1_T1	GENE	21	21	III
NCT000007101	NCT00000710_1_T2	GENE	5	5	MTD
NCT000007103	NCT00000710_3_T0	PHENOTYPE	11	11	toxicity
NCT000007103	NCT00000710_3_T1	PHENOTYPE	5	5	possesses
NCT000007104	NCT00000710_4_T0	GENE	8	8	has
NCT000007106	NCT00000710_6_T0	PHENOTYPE	11	11	toxicity
NCT000007106	NCT00000710_6_T1	PHENOTYPE	5	5	possesses
NCT000007107	NCT00000710_7_T0	GENE	8	8	has
NCT0000071010	NCT00000710_10_T0	PHENOTYPE	18	18	toxic
NCT0000071019	NCT00000710_19_T0	BIOLOGICAL_PROCESS	1	1	Behavior
NCT0000071019	NCT00000710_19_T1	PHENOTYPE	4	7	alcohol or drug abuse
NCT000007111	NCT00000711_1_T0	PHENOTYPE	3	3	HIV
NCT000007113	NCT00000711_3_T0	GENE	9	9	has
NCT000007113	NCT00000711_3_T1	PHENOTYPE	18	19	HIV infection
NCT000007114	NCT00000711_4_T0	GENE	0	0	GM-CSF
NCT000007114	NCT00000711_4_T1	PHENOTYPE	27	27	HIV
NCT000007114	NCT00000711_4_T2	GENE	16	16	has
NCT000007114	NCT00000711_4_T3	CELL	13	14	blood cells
NCT000007114	NCT00000711_4_T4	ORGAN	5	6	bone marrow
NCT000007115	NCT00000711_5_T0	PHENOTYPE	8	8	complications
NCT000007115	NCT00000711_5_T1	GENE	3	3	GM-CSF
NCT000007115	NCT00000711_5_T2	PHENOTYPE	18	19	HIV infection
NCT000007118	NCT00000711_8_T0	GENE	9	9	has
NCT000007118	NCT00000711_8_T1	PHENOTYPE	18	19	HIV infection
NCT000007119	NCT00000711_9_T0	GENE	0	0	GM-CSF
NCT000007119	NCT00000711_9_T1	PHENOTYPE	27	27	HIV
NCT000007119	NCT00000711_9_T2	GENE	16	16	has
NCT000007119	NCT00000711_9_T3	CELL	13	14	blood cells
NCT000007119	NCT00000711_9_T4	ORGAN	5	6	bone marrow
NCT0000071110	NCT00000711_10_T0	PHENOTYPE	8	8	complications
NCT0000071110	NCT00000711_10_T1	GENE	3	3	GM-CSF
NCT0000071110	NCT00000711_10_T2	PHENOTYPE	18	19	HIV infection
NCT0000071115	NCT00000711_15_T0	PHENOTYPE	8	9	positive HIV
NCT000007120	NCT00000712_0_T0	PHENOTYPE	3	3	Blind
NCT000007120	NCT00000712_0_T1	GENE	19	19	CD4
NCT000007124	NCT00000712_4_T0	GENE	1	1	has
NCT000007124	NCT00000712_4_T1	GENE	8	8	span
NCT000007124	NCT00000712_4_T2	PHENOTYPE	23	25	Pneumocystis carinii pneumonia
NCT000007124	NCT00000712_4_T3	PHENOTYPE	15	17	AIDS related complex
NCT000007125	NCT00000712_5_T0	PHENOTYPE	8	8	HIV
NCT000007128	NCT00000712_8_T0	PHENOTYPE	8	8	HIV
NCT0000071212	NCT00000712_12_T0	COMPOUND	2	2	1
NCT0000071231	NCT00000712_31_T0	PHENOTYPE	12	12	HIV
NCT0000071231	NCT00000712_31_T1	PHENOTYPE	22	22	HIV
NCT0000071231	NCT00000712_31_T2	PHENOTYPE	32	32	HIV
NCT0000071231	NCT00000712_31_T3	PHENOTYPE	27	27	malignancies
NCT0000071238	NCT00000712_38_T0	PHENOTYPE	1	2	substance abuse
NCT000007132	NCT00000713_2_T0	PHENOTYPE	8	8	symptoms
NCT000007132	NCT00000713_2_T1	PHENOTYPE	12	12	HIV
NCT000007133	NCT00000713_3_T0	ORGAN	24	25	immune system
NCT000007134	NCT00000713_4_T0	PHENOTYPE	12	12	infections
NCT000007134	NCT00000713_4_T1	GENE	9	9	has
NCT000007134	NCT00000713_4_T2	ORGAN	1	2	immune system
NCT000007137	NCT00000713_7_T0	ORGAN	24	25	immune system
NCT000007138	NCT00000713_8_T0	PHENOTYPE	12	12	infections
NCT000007138	NCT00000713_8_T1	GENE	9	9	has
NCT000007138	NCT00000713_8_T2	ORGAN	1	2	immune system
NCT0000071313	NCT00000713_13_T0	PHENOTYPE	8	8	symptoms
NCT0000071313	NCT00000713_13_T1	PHENOTYPE	15	15	headache
NCT0000071313	NCT00000713_13_T2	PHENOTYPE	16	16	nausea
NCT0000071314	NCT00000713_14_T0	PHENOTYPE	1	1	HIV
NCT0000071314	NCT00000713_14_T1	COMPOUND	10	10	aspirin
NCT0000071315	NCT00000713_15_T0	PHENOTYPE	31	31	toxicity
NCT0000071315	NCT00000713_15_T1	PHENOTYPE	20	20	HIV
NCT0000071315	NCT00000713_15_T2	ORGAN	23	24	immune system
NCT000007141	NCT00000714_1_T0	GENE	32	32	NS
NCT000007141	NCT00000714_1_T1	COMPOUND	15	15	trimetrexate
NCT000007141	NCT00000714_1_T2	COMPOUND	22	22	trimetrexate
NCT000007141	NCT00000714_1_T3	COMPOUND	34	34	trimetrexate
NCT000007142	NCT00000714_2_T0	GENE	37	37	had
NCT000007142	NCT00000714_2_T1	COMPOUND	16	16	trimetrexate
NCT000007143	NCT00000714_3_T0	COMPOUND	13	13	trimetrexate
NCT000007147	NCT00000714_7_T0	PHENOTYPE	0	0	Toxicity
NCT0000071411	NCT00000714_11_T0	PHENOTYPE	16	16	toxicity
NCT0000071411	NCT00000714_11_T1	GENE	6	6	had
NCT0000071413	NCT00000714_13_T0	GENE	37	37	had
NCT0000071413	NCT00000714_13_T1	COMPOUND	16	16	trimetrexate
NCT0000071414	NCT00000714_14_T0	COMPOUND	13	13	trimetrexate
NCT0000071418	NCT00000714_18_T0	PHENOTYPE	0	0	Toxicity
NCT0000071422	NCT00000714_22_T0	PHENOTYPE	16	16	toxicity
NCT0000071422	NCT00000714_22_T1	GENE	6	6	had
NCT0000071426	NCT00000714_26_T0	GENE	28	28	has
NCT0000071428	NCT00000714_28_T0	COMPOUND	4	4	zidovudine
NCT0000071428	NCT00000714_28_T1	PHENOTYPE	14	16	bone marrow toxicity
NCT0000071429	NCT00000714_29_T0	GENE	13	13	has
NCT0000071431	NCT00000714_31_T0	COMPOUND	3	3	methylprednisolone
NCT000007152	NCT00000715_2_T0	PHENOTYPE	5	5	relapse
NCT000007155	NCT00000715_5_T0	PHENOTYPE	5	5	relapse
NCT000007157	NCT00000715_7_T0	GENE	10	10	PEN
NCT000007158	NCT00000715_8_T0	GENE	9	9	PEN
NCT0000071510	NCT00000715_10_T0	GENE	4	4	PEN
NCT0000071513	NCT00000715_13_T0	GENE	13	13	PEN
NCT0000071514	NCT00000715_14_T0	GENE	15	15	PEN
NCT0000071514	NCT00000715_14_T1	PHENOTYPE	9	10	adverse effects
NCT0000071515	NCT00000715_15_T0	COMPOUND	4	4	zidovudine
NCT0000071518	NCT00000715_18_T0	PHENOTYPE	15	15	Pneumocystis
NCT0000071518	NCT00000715_18_T1	PHENOTYPE	3	5	Pneumocystis carinii pneumonia
NCT0000071520	NCT00000715_20_T0	PHENOTYPE	15	15	withdrawn
NCT0000071521	NCT00000715_21_T0	GENE	15	15	San
NCT0000071521	NCT00000715_21_T1	GENE	12	12	ACTG
NCT000007160	NCT00000716_0_T0	PHENOTYPE	14	15	HIV Infection
NCT000007162	NCT00000716_2_T0	PHENOTYPE	6	7	HIV infection
NCT000007163	NCT00000716_3_T0	PHENOTYPE	0	1	HIV infection
NCT000007163	NCT00000716_3_T1	PHENOTYPE	1	3	infection in children
NCT000007165	NCT00000716_5_T0	GENE	1	1	has
NCT000007165	NCT00000716_5_T1	PHENOTYPE	13	14	HIV infection
NCT000007169	NCT00000716_9_T0	GENE	1	1	has
NCT000007169	NCT00000716_9_T1	PHENOTYPE	13	14	HIV infection
NCT0000071613	NCT00000716_13_T0	GENE	8	8	CSF
NCT0000071712	NCT00000717_12_T0	GENE	9	9	ACTG
NCT0000071713	NCT00000717_13_T0	PHENOTYPE	4	4	secondary
NCT0000071713	NCT00000717_13_T1	PHENOTYPE	6	6	toxic
NCT0000071715	NCT00000717_15_T0	GENE	2	2	has
NCT0000071717	NCT00000717_17_T0	COMPOUND	6	6	primaquine
NCT0000071717	NCT00000717_17_T1	COMPOUND	4	4	clindamycin
NCT0000071814	NCT00000718_14_T0	PHENOTYPE	15	15	toxic
NCT0000071814	NCT00000718_14_T1	PHENOTYPE	24	24	HIV
NCT0000071814	NCT00000718_14_T2	PHENOTYPE	4	4	withdrawn
NCT0000071814	NCT00000718_14_T3	ORGAN	13	14	immune system
NCT0000071815	NCT00000718_15_T0	PHENOTYPE	1	1	punctures
NCT0000071817	NCT00000718_17_T0	PHENOTYPE	24	24	symptoms
NCT0000071817	NCT00000718_17_T1	PHENOTYPE	23	23	HIV
NCT0000071817	NCT00000718_17_T2	PHENOTYPE	21	21	progression
NCT0000071817	NCT00000718_17_T3	GENE	8	8	ACTG
NCT0000071821	NCT00000718_21_T0	GENE	10	10	separated
NCT0000071830	NCT00000718_30_T0	GENE	3	3	p24
NCT0000071830	NCT00000718_30_T1	PHENOTYPE	2	2	HIV
NCT0000071831	NCT00000718_31_T0	PHENOTYPE	3	4	alcohol abuse
NCT000007190	NCT00000719_0_T0	PHENOTYPE	14	15	HIV Disease
NCT000007192	NCT00000719_2_T0	PHENOTYPE	4	5	infectious disease
NCT000007193	NCT00000719_3_T0	PHENOTYPE	5	5	HIV
NCT000007194	NCT00000719_4_T0	PHENOTYPE	22	22	toxicity
NCT000007195	NCT00000719_5_T0	PHENOTYPE	19	19	toxicity
NCT000007196	NCT00000719_6_T0	PHENOTYPE	9	9	toxicity
NCT000007196	NCT00000719_6_T1	PHENOTYPE	17	17	toxicity
NCT000007198	NCT00000719_8_T0	PHENOTYPE	5	5	HIV
NCT000007199	NCT00000719_9_T0	PHENOTYPE	22	22	toxicity
NCT0000071910	NCT00000719_10_T0	PHENOTYPE	19	19	toxicity
NCT0000071911	NCT00000719_11_T0	PHENOTYPE	9	9	toxicity
NCT0000071911	NCT00000719_11_T1	PHENOTYPE	17	17	toxicity
NCT0000071917	NCT00000719_17_T0	PHENOTYPE	11	11	inferred
NCT0000071918	NCT00000719_18_T0	PHENOTYPE	21	21	toxicity
NCT0000071918	NCT00000719_18_T1	PHENOTYPE	19	19	acute
NCT0000071918	NCT00000719_18_T2	GENE	11	11	p24
NCT0000071922	NCT00000719_22_T0	PHENOTYPE	10	10	toxicity
NCT0000071924	NCT00000719_24_T0	PHENOTYPE	6	6	toxicity
NCT0000071924	NCT00000719_24_T1	PHENOTYPE	14	14	toxicity
NCT0000071930	NCT00000719_30_T0	PHENOTYPE	7	7	symptoms
NCT0000071930	NCT00000719_30_T1	PHENOTYPE	6	6	bilateral
NCT0000071930	NCT00000719_30_T2	PHENOTYPE	20	20	unilateral
NCT0000071930	NCT00000719_30_T3	PHENOTYPE	9	10	peripheral neuropathy
NCT0000071931	NCT00000719_31_T0	PHENOTYPE	8	8	bilateral
NCT0000071931	NCT00000719_31_T1	PHENOTYPE	11	12	peripheral neuropathy
NCT0000071937	NCT00000719_37_T0	PHENOTYPE	7	7	symptoms
NCT0000071937	NCT00000719_37_T1	PHENOTYPE	6	6	bilateral
NCT0000071937	NCT00000719_37_T2	PHENOTYPE	20	20	unilateral
NCT0000071937	NCT00000719_37_T3	PHENOTYPE	9	10	peripheral neuropathy
NCT0000071938	NCT00000719_38_T0	PHENOTYPE	8	8	bilateral
NCT0000071938	NCT00000719_38_T1	PHENOTYPE	11	12	peripheral neuropathy
NCT0000071941	NCT00000719_41_T0	PHENOTYPE	3	4	alcohol abuse
NCT000007201	NCT00000720_1_T0	PHENOTYPE	12	12	HIV
NCT000007202	NCT00000720_2_T0	PHENOTYPE	0	1	HIV infection
NCT000007202	NCT00000720_2_T1	PHENOTYPE	1	3	infection in children
NCT000007204	NCT00000720_4_T0	GENE	2	2	has
NCT000007204	NCT00000720_4_T1	PHENOTYPE	12	13	opportunistic infections
NCT000007205	NCT00000720_5_T0	PHENOTYPE	8	8	HIV
NCT000007205	NCT00000720_5_T1	PHENOTYPE	2	3	bacterial infections
NCT000007206	NCT00000720_6_T0	PHENOTYPE	30	30	HIV
NCT000007206	NCT00000720_6_T1	PHENOTYPE	20	20	immunity
NCT000007206	NCT00000720_6_T2	ORGAN	3	3	serum
NCT000007206	NCT00000720_6_T3	PHENOTYPE	13	14	bacterial infection
NCT000007206	NCT00000720_6_T4	PHENOTYPE	27	28	bacterial infection
NCT000007207	NCT00000720_7_T0	PHENOTYPE	13	13	tolerance
NCT000007209	NCT00000720_9_T0	PHENOTYPE	0	1	HIV infection
NCT000007209	NCT00000720_9_T1	PHENOTYPE	1	3	infection in children
NCT0000072011	NCT00000720_11_T0	GENE	2	2	has
NCT0000072011	NCT00000720_11_T1	PHENOTYPE	12	13	opportunistic infections
NCT0000072012	NCT00000720_12_T0	PHENOTYPE	8	8	HIV
NCT0000072012	NCT00000720_12_T1	PHENOTYPE	2	3	bacterial infections
NCT0000072013	NCT00000720_13_T0	PHENOTYPE	30	30	HIV
NCT0000072013	NCT00000720_13_T1	PHENOTYPE	20	20	immunity
NCT0000072013	NCT00000720_13_T2	ORGAN	3	3	serum
NCT0000072013	NCT00000720_13_T3	PHENOTYPE	13	14	bacterial infection
NCT0000072013	NCT00000720_13_T4	PHENOTYPE	27	28	bacterial infection
NCT0000072014	NCT00000720_14_T0	PHENOTYPE	13	13	tolerance
NCT000007214	NCT00000721_4_T0	GENE	8	8	CD4
NCT000007214	NCT00000721_4_T1	GENE	15	15	CD4
NCT000007214	NCT00000721_4_T2	GENE	24	24	CD4
NCT000007215	NCT00000721_5_T0	GENE	12	12	has
NCT000007216	NCT00000721_6_T0	GENE	17	17	T4
NCT000007216	NCT00000721_6_T1	GENE	7	8	CD4 molecule
NCT0000072112	NCT00000721_12_T0	GENE	8	8	CD4
NCT0000072112	NCT00000721_12_T1	GENE	15	15	CD4
NCT0000072112	NCT00000721_12_T2	GENE	24	24	CD4
NCT0000072113	NCT00000721_13_T0	GENE	12	12	has
NCT0000072114	NCT00000721_14_T0	GENE	17	17	T4
NCT0000072114	NCT00000721_14_T1	GENE	7	8	CD4 molecule
NCT0000072117	NCT00000721_17_T0	GENE	22	22	IM
NCT0000072119	NCT00000721_19_T0	GENE	3	3	IM
NCT0000072119	NCT00000721_19_T1	GENE	9	9	CSCI
NCT0000072122	NCT00000721_22_T0	GENE	6	6	IM
NCT0000072125	NCT00000721_25_T0	GENE	11	11	CSCI
NCT0000072126	NCT00000721_26_T0	GENE	9	9	CSCI
NCT0000072127	NCT00000721_27_T0	CELL	21	21	T-cells
NCT0000072127	NCT00000721_27_T1	CELL	23	23	T-cell
NCT0000072134	NCT00000721_34_T0	PHENOTYPE	5	6	alcohol abuse
NCT0000072134	NCT00000721_34_T1	PHENOTYPE	2	3	drug use
NCT000007223	NCT00000722_3_T0	ORGAN	15	15	kidney
NCT000007223	NCT00000722_3_T1	ORGAN	13	13	liver
NCT000007223	NCT00000722_3_T2	COMPOUND	3	3	pentamidine
NCT000007223	NCT00000722_3_T3	COMPOUND	17	17	pentamidine
NCT000007223	NCT00000722_3_T4	ORGAN	6	6	lungs
NCT000007224	NCT00000722_4_T0	PHENOTYPE	4	4	toxicity
NCT000007224	NCT00000722_4_T1	COMPOUND	6	6	pentamidine
NCT000007226	NCT00000722_6_T0	ORGAN	15	15	kidney
NCT000007226	NCT00000722_6_T1	ORGAN	13	13	liver
NCT000007226	NCT00000722_6_T2	COMPOUND	3	3	pentamidine
NCT000007226	NCT00000722_6_T3	COMPOUND	17	17	pentamidine
NCT000007226	NCT00000722_6_T4	ORGAN	6	6	lungs
NCT000007227	NCT00000722_7_T0	PHENOTYPE	4	4	toxicity
NCT000007227	NCT00000722_7_T1	COMPOUND	6	6	pentamidine
NCT000007228	NCT00000722_8_T0	COMPOUND	9	9	pentamidine
NCT000007228	NCT00000722_8_T1	COMPOUND	30	30	pentamidine
NCT0000072211	NCT00000722_11_T0	COMPOUND	2	2	pentamidine
NCT000007230	NCT00000723_0_T0	PHENOTYPE	12	14	Lymph Node Cancer
NCT000007232	NCT00000723_2_T0	PHENOTYPE	50	50	complications
NCT000007232	NCT00000723_2_T1	PHENOTYPE	7	7	HIV
NCT000007232	NCT00000723_2_T2	PHENOTYPE	13	13	HIV
NCT000007232	NCT00000723_2_T3	PHENOTYPE	39	39	lymphoma
NCT000007232	NCT00000723_2_T4	PHENOTYPE	24	25	opportunistic infection
NCT000007233	NCT00000723_3_T0	GENE	3	3	has
NCT000007234	NCT00000723_4_T0	GENE	1	1	MTX
NCT000007238	NCT00000723_8_T0	GENE	3	3	has
NCT000007239	NCT00000723_9_T0	GENE	1	1	MTX
NCT0000072313	NCT00000723_13_T0	COMPOUND	2	2	dexamethasone
NCT0000072313	NCT00000723_13_T1	COMPOUND	12	12	1_10
NCT0000072313	NCT00000723_13_T2	GENE	9	9	IV
NCT0000072314	NCT00000723_14_T0	GENE	0	0	MTX
NCT0000072314	NCT00000723_14_T1	GENE	1	1	IV
NCT0000072315	NCT00000723_15_T0	GENE	9	9	MTX
NCT0000072315	NCT00000723_15_T1	GENE	10	10	has
NCT0000072315	NCT00000723_15_T2	GENE	2	2	IV
NCT0000072317	NCT00000723_17_T0	GENE	11	11	MRI
NCT0000072318	NCT00000723_18_T0	GENE	10	10	PR
NCT0000072318	NCT00000723_18_T1	GENE	8	8	CR
NCT0000072320	NCT00000723_20_T0	GENE	3	3	PR
NCT0000072320	NCT00000723_20_T1	GENE	1	1	CR
NCT0000072321	NCT00000723_21_T0	PHENOTYPE	6	6	progression
NCT0000072321	NCT00000723_21_T1	PHENOTYPE	17	17	lymphomatous
NCT0000072325	NCT00000723_25_T0	PHENOTYPE	32	32	toxoplasmosis
NCT0000072325	NCT00000723_25_T1	PHENOTYPE	41	41	toxoplasmosis
NCT0000072328	NCT00000723_28_T0	PHENOTYPE	0	0	Acute
NCT0000072329	NCT00000723_29_T0	PHENOTYPE	3	3	tumor
NCT0000072329	NCT00000723_29_T1	PHENOTYPE	7	8	skin cancer
NCT0000072329	NCT00000723_29_T2	PHENOTYPE	10	11	Kaposi's sarcoma
NCT0000072330	NCT00000723_30_T0	PHENOTYPE	5	6	mass lesion
NCT0000072330	NCT00000723_30_T1	PHENOTYPE	0	1	Lymphomatous meningitis
NCT000007240	NCT00000724_0_T0	PHENOTYPE	17	19	Pneumocystis Carinii Pneumonia
NCT000007248	NCT00000724_8_T0	GENE	37	37	had
NCT000007248	NCT00000724_8_T1	COMPOUND	16	16	trimetrexate
NCT000007249	NCT00000724_9_T0	COMPOUND	13	13	trimetrexate
NCT0000072413	NCT00000724_13_T0	PHENOTYPE	0	0	Toxicity
NCT0000072418	NCT00000724_18_T0	COMPOUND	4	4	zidovudine
NCT0000072418	NCT00000724_18_T1	PHENOTYPE	14	16	bone marrow toxicity
NCT0000072419	NCT00000724_19_T0	GENE	13	13	has
NCT000007252	NCT00000725_2_T0	GENE	35	35	II
NCT000007252	NCT00000725_2_T1	PHENOTYPE	3	3	pharmacokinetics
NCT0000072510	NCT00000725_10_T0	GENE	1	1	stops
NCT0000072510	NCT00000725_10_T1	GENE	6	6	MTD
NCT0000072514	NCT00000725_14_T0	PHENOTYPE	15	15	toxicity
NCT0000072514	NCT00000725_14_T1	GENE	1	1	MTD
NCT0000072514	NCT00000725_14_T2	CELL	20	20	neutrophil
NCT0000072514	NCT00000725_14_T3	GENE	19	19	hemoglobin
NCT000007262	NCT00000726_2_T0	COMPOUND	4	4	foscarnet
NCT000007266	NCT00000726_6_T0	PHENOTYPE	19	19	HIV
NCT000007266	NCT00000726_6_T1	CELL	10	10	leukocytes
NCT000007266	NCT00000726_6_T2	GENE	13	13	has
NCT000007266	NCT00000726_6_T3	CELL	7	7	neutrophils
NCT0000072610	NCT00000726_10_T0	PHENOTYPE	19	19	HIV
NCT0000072610	NCT00000726_10_T1	CELL	10	10	leukocytes
NCT0000072610	NCT00000726_10_T2	GENE	13	13	has
NCT0000072610	NCT00000726_10_T3	CELL	7	7	neutrophils
NCT0000072611	NCT00000726_11_T0	COMPOUND	20	20	foscarnet
NCT0000072612	NCT00000726_12_T0	PHENOTYPE	7	7	toxicity
NCT0000072612	NCT00000726_12_T1	COMPOUND	13	13	foscarnet
NCT0000072614	NCT00000726_14_T0	COMPOUND	20	20	zidovudine
NCT0000072614	NCT00000726_14_T1	COMPOUND	15	15	foscarnet
NCT0000072617	NCT00000726_17_T0	PHENOTYPE	1	1	allergy
NCT0000072617	NCT00000726_17_T1	COMPOUND	3	3	foscarnet
NCT0000072710	NCT00000727_10_T0	PHENOTYPE	0	2	Low body weight
NCT0000072713	NCT00000727_13_T0	GENE	3	3	PEN
NCT0000072714	NCT00000727_14_T0	PHENOTYPE	19	20	adverse effects
NCT000007281	NCT00000728_1_T0	PHENOTYPE	8	8	toxicity
NCT000007281	NCT00000728_1_T1	PHENOTYPE	26	26	concentrations
NCT000007281	NCT00000728_1_T2	ORGAN	39	39	kidneys
NCT000007281	NCT00000728_1_T3	PHENOTYPE	25	25	HIV
NCT000007281	NCT00000728_1_T4	ORGAN	21	22	immune system
NCT000007282	NCT00000728_2_T0	GENE	22	22	has
NCT000007282	NCT00000728_2_T1	GENE	9	9	MTD
NCT000007282	NCT00000728_2_T2	ORGAN	28	29	immune system
NCT000007283	NCT00000728_3_T0	GENE	1	1	has
NCT000007283	NCT00000728_3_T1	PHENOTYPE	8	9	HIV disease
NCT000007284	NCT00000728_4_T0	GENE	0	0	IL-2
NCT000007284	NCT00000728_4_T1	PHENOTYPE	14	14	HIV
NCT000007284	NCT00000728_4_T2	GENE	1	1	has
NCT000007285	NCT00000728_5_T0	GENE	0	0	IL-2
NCT000007285	NCT00000728_5_T1	GENE	1	1	has
NCT000007285	NCT00000728_5_T2	PHENOTYPE	7	8	Kaposi's sarcoma
NCT000007286	NCT00000728_6_T0	PHENOTYPE	12	12	toxicities
NCT000007288	NCT00000728_8_T0	GENE	0	0	IL-2
NCT000007288	NCT00000728_8_T1	PHENOTYPE	14	14	HIV
NCT000007288	NCT00000728_8_T2	GENE	1	1	has
NCT000007289	NCT00000728_9_T0	GENE	0	0	IL-2
NCT000007289	NCT00000728_9_T1	GENE	1	1	has
NCT000007289	NCT00000728_9_T2	PHENOTYPE	7	8	Kaposi's sarcoma
NCT0000072810	NCT00000728_10_T0	PHENOTYPE	12	12	toxicities
NCT0000072811	NCT00000728_11_T0	PHENOTYPE	5	5	staggered
NCT0000072813	NCT00000728_13_T0	GENE	17	17	IL-2
NCT0000072814	NCT00000728_14_T0	PHENOTYPE	0	0	Toxicity
NCT0000072815	NCT00000728_15_T0	GENE	11	11	IL-2
NCT0000072815	NCT00000728_15_T1	GENE	17	17	MTD
NCT0000072816	NCT00000728_16_T0	PHENOTYPE	6	6	toxicity
NCT0000072816	NCT00000728_16_T1	GENE	23	23	IL-2
NCT0000072819	NCT00000728_19_T0	PHENOTYPE	6	6	chills
NCT0000072819	NCT00000728_19_T1	COMPOUND	2	2	ibuprofen
NCT0000072819	NCT00000728_19_T2	PHENOTYPE	4	4	fever
NCT0000072819	NCT00000728_19_T3	GENE	12	12	MTD
NCT0000072820	NCT00000728_20_T0	PHENOTYPE	2	2	toxicity
NCT0000072820	NCT00000728_20_T1	GENE	9	9	IL-2
NCT0000072822	NCT00000728_22_T0	PHENOTYPE	4	4	HIV
NCT0000072822	NCT00000728_22_T1	GENE	12	12	kit
NCT0000072822	NCT00000728_22_T2	PHENOTYPE	1	2	positive antibody
NCT0000072830	NCT00000728_30_T0	PHENOTYPE	0	1	Weight loss
NCT0000072830	NCT00000728_30_T1	GENE	2	3	in excess
NCT0000072832	NCT00000728_32_T0	PHENOTYPE	9	10	night sweats
NCT0000072836	NCT00000728_36_T0	PHENOTYPE	0	1	Herpes zoster
NCT0000072838	NCT00000728_38_T0	PHENOTYPE	4	5	hairy leukoplakia
NCT0000072838	NCT00000728_38_T1	PHENOTYPE	0	1	Oral candidiasis
NCT0000072840	NCT00000728_40_T0	PHENOTYPE	1	2	substance abuse
NCT000007292	NCT00000729_2_T0	PHENOTYPE	13	13	toxic
NCT000007292	NCT00000729_2_T1	COMPOUND	1	1	zidovudine
NCT000007292	NCT00000729_2_T2	PHENOTYPE	23	23	HIV
NCT000007292	NCT00000729_2_T3	GENE	3	3	has
NCT000007292	NCT00000729_2_T4	GENE	12	12	has
NCT000007293	NCT00000729_3_T0	PHENOTYPE	23	23	HIV
NCT000007293	NCT00000729_3_T1	PHENOTYPE	10	10	herpes
NCT000007293	NCT00000729_3_T2	COMPOUND	15	15	foscarnet
NCT000007294	NCT00000729_4_T0	PHENOTYPE	6	6	HIV
NCT000007294	NCT00000729_4_T1	COMPOUND	9	9	foscarnet
NCT000007294	NCT00000729_4_T2	PHENOTYPE	15	16	HIV infections
NCT000007296	NCT00000729_6_T0	PHENOTYPE	23	23	HIV
NCT000007296	NCT00000729_6_T1	PHENOTYPE	10	10	herpes
NCT000007296	NCT00000729_6_T2	COMPOUND	15	15	foscarnet
NCT000007297	NCT00000729_7_T0	PHENOTYPE	6	6	HIV
NCT000007297	NCT00000729_7_T1	COMPOUND	9	9	foscarnet
NCT000007297	NCT00000729_7_T2	PHENOTYPE	15	16	HIV infections
NCT000007299	NCT00000729_9_T0	COMPOUND	11	11	foscarnet
NCT0000072914	NCT00000729_14_T0	COMPOUND	11	11	foscarnet
NCT0000072916	NCT00000729_16_T0	PHENOTYPE	7	7	toxicity
NCT0000072916	NCT00000729_16_T1	COMPOUND	18	18	foscarnet
NCT0000072927	NCT00000729_27_T0	PHENOTYPE	1	2	substance abuse
NCT000007300	NCT00000730_0_T0	PHENOTYPE	5	6	Pneumocystis Pneumonia
NCT000007302	NCT00000730_2_T0	COMPOUND	27	27	pentamidine
NCT000007302	NCT00000730_2_T1	GENE	28	28	PEN
NCT000007302	NCT00000730_2_T2	GENE	5	5	has
NCT000007303	NCT00000730_3_T0	COMPOUND	19	19	methylprednisolone
NCT000007303	NCT00000730_3_T1	COMPOUND	8	8	leucovorin
NCT000007303	NCT00000730_3_T2	COMPOUND	5	5	trimetrexate
NCT0000073012	NCT00000730_12_T0	GENE	9	9	PEN
NCT0000073013	NCT00000730_13_T0	COMPOUND	34	34	prednisolone
NCT0000073013	NCT00000730_13_T1	GENE	17	17	PEN
NCT0000073014	NCT00000730_14_T0	COMPOUND	8	8	methylprednisolone
NCT0000073015	NCT00000730_15_T0	PHENOTYPE	21	21	toxicity
NCT000007313	NCT00000731_3_T0	COMPOUND	10	10	APAP
NCT000007313	NCT00000731_3_T1	COMPOUND	37	37	APAP
NCT000007313	NCT00000731_3_T2	PHENOTYPE	44	45	adverse effects
NCT000007316	NCT00000731_6_T0	COMPOUND	10	10	APAP
NCT000007316	NCT00000731_6_T1	COMPOUND	37	37	APAP
NCT000007316	NCT00000731_6_T2	PHENOTYPE	44	45	adverse effects
NCT000007317	NCT00000731_7_T0	PHENOTYPE	8	8	symptoms
NCT000007317	NCT00000731_7_T1	PHENOTYPE	10	10	fatigue
NCT000007317	NCT00000731_7_T2	PHENOTYPE	5	5	HIV
NCT000007317	NCT00000731_7_T3	PHENOTYPE	9	9	fever
NCT000007317	NCT00000731_7_T4	PHENOTYPE	11	12	weight loss
NCT000007318	NCT00000731_8_T0	COMPOUND	10	10	APAP
NCT0000073110	NCT00000731_10_T0	COMPOUND	20	20	APAP
NCT0000073110	NCT00000731_10_T1	GENE	7	7	am
NCT0000073112	NCT00000731_12_T0	COMPOUND	18	18	APAP
NCT0000073112	NCT00000731_12_T1	COMPOUND	26	26	APAP
NCT0000073119	NCT00000731_19_T0	PHENOTYPE	1	2	positive HIV
NCT0000073120	NCT00000731_20_T0	GENE	21	21	has
NCT0000073120	NCT00000731_20_T1	PHENOTYPE	14	15	progressive disease
NCT0000073120	NCT00000731_20_T2	PHENOTYPE	9	10	positive HIV
NCT000007321	NCT00000732_1_T0	PHENOTYPE	5	5	pharmacokinetics
NCT000007321	NCT00000732_1_T1	PHENOTYPE	21	21	pharmacokinetics
NCT000007323	NCT00000732_3_T0	PHENOTYPE	32	32	toxic
NCT000007325	NCT00000732_5_T0	PHENOTYPE	32	32	toxic
NCT000007329	NCT00000732_9_T0	PHENOTYPE	0	0	Concentrations
NCT000007331	NCT00000733_1_T0	COMPOUND	8	8	ribavirin
NCT000007331	NCT00000733_1_T1	GENE	6	6	MTD
NCT000007337	NCT00000733_7_T0	PHENOTYPE	4	4	HIV
NCT000007338	NCT00000733_8_T0	COMPOUND	11	11	ribavirin
NCT000007339	NCT00000733_9_T0	PHENOTYPE	4	4	tolerance
NCT0000073310	NCT00000733_10_T0	GENE	16	16	MTD
NCT0000073311	NCT00000733_11_T0	COMPOUND	23	23	ribavirin
NCT0000073311	NCT00000733_11_T1	COMPOUND	30	30	ribavirin
NCT0000073311	NCT00000733_11_T2	PHENOTYPE	33	33	HIV
NCT0000073311	NCT00000733_11_T3	ORGAN	35	36	immune system
NCT0000073313	NCT00000733_13_T0	GENE	7	7	had
NCT0000073313	NCT00000733_13_T1	PHENOTYPE	11	13	AIDS related illness
NCT0000073315	NCT00000733_15_T0	GENE	3	3	had
NCT0000073315	NCT00000733_15_T1	PHENOTYPE	5	6	candida infection
NCT0000073315	NCT00000733_15_T2	PHENOTYPE	17	19	oral hairy leukoplakia
NCT0000073315	NCT00000733_15_T3	PHENOTYPE	21	23	herpes zoster infection
NCT0000073318	NCT00000733_18_T0	PHENOTYPE	1	4	alcohol or drug abuse
NCT000007341	NCT00000734_1_T0	PHENOTYPE	5	5	pharmacokinetics
NCT000007341	NCT00000734_1_T1	PHENOTYPE	22	22	pharmacokinetics
NCT000007341	NCT00000734_1_T2	COMPOUND	11	11	trimethoprim_sulfamethoxazole
NCT000007343	NCT00000734_3_T0	PHENOTYPE	32	32	toxic
NCT000007345	NCT00000734_5_T0	PHENOTYPE	32	32	toxic
NCT000007346	NCT00000734_6_T0	PHENOTYPE	2	3	HIV infection
NCT000007349	NCT00000734_9_T0	PHENOTYPE	0	0	Concentrations
NCT000007354	NCT00000735_4_T0	PHENOTYPE	12	12	hemophilia
NCT000007354	NCT00000735_4_T1	PHENOTYPE	14	14	centers
NCT000007356	NCT00000735_6_T0	PHENOTYPE	5	6	HIV infection
NCT000007357	NCT00000735_7_T0	PHENOTYPE	8	8	symptoms
NCT000007357	NCT00000735_7_T1	PHENOTYPE	15	15	headache
NCT000007357	NCT00000735_7_T2	PHENOTYPE	16	16	nausea
NCT000007358	NCT00000735_8_T0	PHENOTYPE	1	1	HIV
NCT000007358	NCT00000735_8_T1	COMPOUND	10	10	aspirin
NCT000007359	NCT00000735_9_T0	PHENOTYPE	32	32	toxicity
NCT000007359	NCT00000735_9_T1	PHENOTYPE	22	22	HIV
NCT000007359	NCT00000735_9_T2	ORGAN	25	26	immune system
NCT0000073514	NCT00000735_14_T0	PHENOTYPE	3	3	Condition
NCT0000073514	NCT00000735_14_T1	PHENOTYPE	6	7	AIDS encephalopathy
NCT0000073515	NCT00000735_15_T0	PHENOTYPE	2	3	AIDS encephalopathy
NCT000007368	NCT00000736_8_T0	GENE	13	13	am
NCT0000073617	NCT00000736_17_T0	PHENOTYPE	1	1	toxicity
NCT000007371	NCT00000737_1_T0	COMPOUND	14	15	megestrol acetate
NCT000007371	NCT00000737_1_T1	PHENOTYPE	23	24	appetite increase
NCT000007371	NCT00000737_1_T2	PHENOTYPE	21	22	weight gain
NCT000007371	NCT00000737_1_T3	PHENOTYPE	26	28	quality of life
NCT000007372	NCT00000737_2_T0	PHENOTYPE	3	3	pharmacokinetics
NCT000007372	NCT00000737_2_T1	COMPOUND	6	7	megestrol acetate
NCT000007374	NCT00000737_4_T0	PHENOTYPE	14	14	cachectic
NCT000007374	NCT00000737_4_T1	COMPOUND	9	10	megestrol acetate
NCT000007376	NCT00000737_6_T0	PHENOTYPE	14	14	cachectic
NCT000007376	NCT00000737_6_T1	COMPOUND	9	10	megestrol acetate
NCT000007379	NCT00000737_9_T0	PHENOTYPE	4	4	toxicity
NCT000007379	NCT00000737_9_T1	PHENOTYPE	14	14	pharmacokinetics
NCT000007379	NCT00000737_9_T2	PHENOTYPE	10	11	weight gain
NCT0000073718	NCT00000737_18_T0	PHENOTYPE	3	4	alcohol abuse
NCT000007384	NCT00000738_4_T0	PHENOTYPE	12	12	HIV
NCT000007384	NCT00000738_4_T1	COMPOUND	3	3	nimodipine
NCT000007384	NCT00000738_4_T2	CELL	5	6	nerve cells
NCT000007387	NCT00000738_7_T0	PHENOTYPE	12	12	HIV
NCT000007387	NCT00000738_7_T1	COMPOUND	3	3	nimodipine
NCT000007387	NCT00000738_7_T2	CELL	5	6	nerve cells
NCT0000073810	NCT00000738_10_T0	COMPOUND	18	18	nimodipine
NCT0000073813	NCT00000738_13_T0	COMPOUND	13	13	nimodipine
NCT0000073822	NCT00000738_22_T0	PHENOTYPE	9	10	neurological disorders
NCT000007390	NCT00000739_0_T0	PHENOTYPE	16	17	HIV Infection
NCT000007390	NCT00000739_0_T1	PHENOTYPE	11	13	Pneumocystis Carinii Pneumonia
NCT000007396	NCT00000739_6_T0	COMPOUND	6	6	dapsone
NCT000007396	NCT00000739_6_T1	GENE	7	7	has
NCT0000073910	NCT00000739_10_T0	COMPOUND	6	6	dapsone
NCT0000073910	NCT00000739_10_T1	GENE	7	7	has
NCT0000073912	NCT00000739_12_T0	GENE	7	7	has
NCT0000073913	NCT00000739_13_T0	COMPOUND	20	20	dapsone
NCT0000073918	NCT00000739_18_T0	GENE	9	9	ACTG
NCT000007401	NCT00000740_1_T0	PHENOTYPE	12	12	HIV
NCT000007401	NCT00000740_1_T1	PHENOTYPE	5	5	toxicities
NCT000007402	NCT00000740_2_T0	PHENOTYPE	6	6	toxicity
NCT000007403	NCT00000740_3_T0	PHENOTYPE	6	6	pharmacodynamics
NCT000007403	NCT00000740_3_T1	PHENOTYPE	25	25	methemoglobinemia
NCT000007403	NCT00000740_3_T2	PHENOTYPE	4	4	pharmacokinetics
NCT000007403	NCT00000740_3_T3	PHENOTYPE	28	28	toxicities
NCT000007409	NCT00000740_9_T0	PHENOTYPE	20	20	toxicity
NCT000007409	NCT00000740_9_T1	GENE	12	12	3-1
NCT0000074010	NCT00000740_10_T0	PHENOTYPE	14	14	toxicity
NCT0000074010	NCT00000740_10_T1	PHENOTYPE	8	8	experiences
NCT0000074011	NCT00000740_11_T0	PHENOTYPE	14	14	toxicity
NCT0000074011	NCT00000740_11_T1	GENE	23	23	3-1
NCT0000074012	NCT00000740_12_T0	PHENOTYPE	21	21	toxicity
NCT0000074012	NCT00000740_12_T1	PHENOTYPE	35	35	toxicity
NCT0000074013	NCT00000740_13_T0	GENE	1	1	MTD
NCT0000074014	NCT00000740_14_T0	GENE	9	9	MTD
NCT0000074014	NCT00000740_14_T1	PHENOTYPE	12	12	tolerance
NCT000007413	NCT00000741_3_T0	COMPOUND	7	7	pentamidine
NCT000007414	NCT00000741_4_T0	PHENOTYPE	14	15	respiratory failure
NCT000007422	NCT00000742_2_T0	GENE	1	1	II
NCT000007423	NCT00000742_3_T0	GENE	1	1	III
NCT0000074210	NCT00000742_10_T0	COMPOUND	13	13	zidovudine
NCT0000074211	NCT00000742_11_T0	ORGAN	2	2	plasma
NCT0000074212	NCT00000742_12_T0	GENE	12	12	has
NCT0000074213	NCT00000742_13_T0	GENE	10	10	II
NCT0000074214	NCT00000742_14_T0	GENE	1	1	II
NCT0000074218	NCT00000742_18_T0	GENE	1	1	III
NCT000007431	NCT00000743_1_T0	PHENOTYPE	8	8	toxicity
NCT000007432	NCT00000743_2_T0	PHENOTYPE	11	11	HIV
NCT000007432	NCT00000743_2_T1	GENE	8	8	has
NCT000007433	NCT00000743_3_T0	PHENOTYPE	7	7	toxicity
NCT000007433	NCT00000743_3_T1	COMPOUND	14	14	zidovudine
NCT000007434	NCT00000743_4_T0	PHENOTYPE	12	12	HIV
NCT000007434	NCT00000743_4_T1	PHENOTYPE	27	27	HIV
NCT000007436	NCT00000743_6_T0	GENE	13	13	IV
NCT000007437	NCT00000743_7_T0	PHENOTYPE	15	15	toxicity
NCT000007438	NCT00000743_8_T0	PHENOTYPE	25	25	toxicity
NCT000007438	NCT00000743_8_T1	PHENOTYPE	36	36	toxicity
NCT000007438	NCT00000743_8_T2	GENE	1	1	MTD
NCT000007439	NCT00000743_9_T0	GENE	2	2	MTD
NCT000007439	NCT00000743_9_T1	GENE	31	31	MTD
NCT0000074310	NCT00000743_10_T0	GENE	3	3	has
NCT0000074310	NCT00000743_10_T1	GENE	2	2	MTD
NCT000007441	NCT00000744_1_T0	GENE	1	1	has
NCT000007441	NCT00000744_1_T1	PHENOTYPE	11	11	candidiasis
NCT000007442	NCT00000744_2_T0	PHENOTYPE	12	12	immunosuppression
NCT000007442	NCT00000744_2_T1	PHENOTYPE	11	11	progressive
NCT000007442	NCT00000744_2_T2	PHENOTYPE	6	7	esophageal candidiasis
NCT000007444	NCT00000744_4_T0	PHENOTYPE	12	12	immunosuppression
NCT000007444	NCT00000744_4_T1	PHENOTYPE	11	11	progressive
NCT000007444	NCT00000744_4_T2	PHENOTYPE	6	7	esophageal candidiasis
NCT000007445	NCT00000744_5_T0	COMPOUND	8	8	fluconazole
NCT000007445	NCT00000744_5_T1	PHENOTYPE	2	2	HIV
NCT000007446	NCT00000744_6_T0	PHENOTYPE	15	15	candidiasis
NCT000007446	NCT00000744_6_T1	PHENOTYPE	10	12	signs and symptoms
NCT000007451	NCT00000745_1_T0	GENE	5	5	gp160
NCT000007456	NCT00000745_6_T0	GENE	15	15	gp160
NCT000007456	NCT00000745_6_T1	GENE	19	19	gp160
NCT000007456	NCT00000745_6_T2	PHENOTYPE	23	24	hepatitis B
NCT000007457	NCT00000745_7_T0	PHENOTYPE	1	2	hepatitis B
NCT000007463	NCT00000746_3_T0	PHENOTYPE	0	0	Secondary
NCT000007463	NCT00000746_3_T1	GENE	21	21	gp120
NCT000007464	NCT00000746_4_T0	PHENOTYPE	6	6	HIV
NCT000007464	NCT00000746_4_T1	GENE	15	15	booster
NCT000007464	NCT00000746_4_T2	BIOLOGICAL_PROCESS	26	27	immune response
NCT000007467	NCT00000746_7_T0	GENE	19	19	2.3
NCT000007467	NCT00000746_7_T1	GENE	16	16	gp120
NCT000007467	NCT00000746_7_T2	GENE	18	18	Env
NCT000007468	NCT00000746_8_T0	GENE	19	19	gp120
NCT000007468	NCT00000746_8_T1	PHENOTYPE	0	1	Group B
NCT000007469	NCT00000746_9_T0	GENE	7	7	gp120
NCT0000074613	NCT00000746_13_T0	PHENOTYPE	4	5	HIV infection
NCT000007471	NCT00000747_1_T0	COMPOUND	4	4	nevirapine
NCT000007471	NCT00000747_1_T1	GENE	10	10	CD4
NCT000007472	NCT00000747_2_T0	COMPOUND	6	6	nevirapine
NCT000007472	NCT00000747_2_T1	PHENOTYPE	0	0	Secondary
NCT000007473	NCT00000747_3_T0	COMPOUND	3	3	nevirapine
NCT000007473	NCT00000747_3_T1	GENE	23	23	CD4
NCT000007473	NCT00000747_3_T2	COMPOUND	18	18	zidovudine
NCT000007473	NCT00000747_3_T3	PHENOTYPE	1	1	HIV
NCT000007473	NCT00000747_3_T4	PHENOTYPE	20	20	HIV
NCT000007474	NCT00000747_4_T0	PHENOTYPE	5	6	HIV disease
NCT000007476	NCT00000747_6_T0	PHENOTYPE	5	6	HIV disease
NCT000007478	NCT00000747_8_T0	COMPOUND	24	24	nevirapine
NCT000007487	NCT00000748_7_T0	PHENOTYPE	7	8	drug toxicity
NCT000007491	NCT00000749_1_T0	GENE	7	7	gp120
NCT000007491	NCT00000749_1_T1	GENE	18	18	gp120
NCT000007500	NCT00000750_0_T0	GENE	2	2	III
NCT000007500	NCT00000750_0_T1	PHENOTYPE	8	8	Tolerance
NCT000007500	NCT00000750_0_T2	PHENOTYPE	21	22	HIV Infection
NCT000007502	NCT00000750_2_T0	PHENOTYPE	5	5	tolerance
NCT000007503	NCT00000750_3_T0	PHENOTYPE	0	0	Secondary
NCT000007511	NCT00000751_1_T0	PHENOTYPE	3	3	HIV
NCT000007511	NCT00000751_1_T1	BIOLOGICAL_PROCESS	14	14	parturition
NCT000007511	NCT00000751_1_T2	PHENOTYPE	0	1	Vertical transmission
NCT000007512	NCT00000751_2_T0	PHENOTYPE	14	15	vertical transmission
NCT000007515	NCT00000751_5_T0	PHENOTYPE	14	15	vertical transmission
NCT000007517	NCT00000751_7_T0	BIOLOGICAL_PROCESS	13	13	gestation
NCT000007519	NCT00000751_9_T0	PHENOTYPE	26	26	cord
NCT000007522	NCT00000752_2_T0	PHENOTYPE	10	11	maxillary sinusitis
NCT000007523	NCT00000752_3_T0	PHENOTYPE	4	4	HIV
NCT000007523	NCT00000752_3_T1	PHENOTYPE	22	22	immunosuppression
NCT000007523	NCT00000752_3_T2	PHENOTYPE	11	11	recurrent
NCT000007523	NCT00000752_3_T3	PHENOTYPE	0	0	Sinusitis
NCT000007524	NCT00000752_4_T0	PHENOTYPE	10	10	HIV
NCT000007524	NCT00000752_4_T1	PHENOTYPE	6	8	recurrent sinus disease
NCT000007526	NCT00000752_6_T0	PHENOTYPE	10	10	HIV
NCT000007526	NCT00000752_6_T1	PHENOTYPE	6	8	recurrent sinus disease
NCT000007527	NCT00000752_7_T0	PHENOTYPE	12	12	sinusitis
NCT0000075211	NCT00000752_11_T0	COMPOUND	27	28	cefuroxime axetil
NCT0000075211	NCT00000752_11_T1	COMPOUND	23	24	beclomethasone dipropionate
NCT000007538	NCT00000753_8_T0	PHENOTYPE	15	15	toxicity
NCT000007538	NCT00000753_8_T1	GENE	1	1	MTD
NCT0000075310	NCT00000753_10_T0	COMPOUND	29	29	zidovudine
NCT000007540	NCT00000754_0_T0	GENE	3	3	II
NCT000007540	NCT00000754_0_T1	GENE	11	11	IFN
NCT000007540	NCT00000754_0_T2	GENE	35	35	CD4
NCT000007540	NCT00000754_0_T3	GENE	9	9	Interferon
NCT000007540	NCT00000754_0_T4	PHENOTYPE	29	30	HIV Infection
NCT000007542	NCT00000754_2_T0	GENE	13	13	IFN
NCT000007542	NCT00000754_2_T1	PHENOTYPE	4	4	HIV
NCT000007542	NCT00000754_2_T2	BIOLOGICAL_PROCESS	16	16	translation
NCT000007542	NCT00000754_2_T3	GENE	8	9	reverse transcriptase
NCT000007543	NCT00000754_3_T0	PHENOTYPE	12	12	HIV
NCT000007543	NCT00000754_3_T1	PHENOTYPE	20	20	HIV
NCT000007543	NCT00000754_3_T2	PHENOTYPE	13	13	inhibition
NCT000007543	NCT00000754_3_T3	BIOLOGICAL_PROCESS	8	9	viral replication
NCT000007545	NCT00000754_5_T0	PHENOTYPE	12	12	HIV
NCT000007545	NCT00000754_5_T1	PHENOTYPE	20	20	HIV
NCT000007545	NCT00000754_5_T2	PHENOTYPE	13	13	inhibition
NCT000007545	NCT00000754_5_T3	BIOLOGICAL_PROCESS	8	9	viral replication
NCT0000075418	NCT00000754_18_T0	PHENOTYPE	1	2	substance abuse
NCT000007550	NCT00000755_0_T0	GENE	13	13	CD4
NCT000007554	NCT00000755_4_T0	PHENOTYPE	5	5	HIV
NCT000007554	NCT00000755_4_T1	BIOLOGICAL_PROCESS	15	15	quiescence
NCT000007554	NCT00000755_4_T2	GENE	1	1	has
NCT000007554	NCT00000755_4_T3	BIOLOGICAL_PROCESS	17	18	viral replication
NCT000007557	NCT00000755_7_T0	PHENOTYPE	5	5	HIV
NCT000007557	NCT00000755_7_T1	BIOLOGICAL_PROCESS	15	15	quiescence
NCT000007557	NCT00000755_7_T2	GENE	1	1	has
NCT000007557	NCT00000755_7_T3	BIOLOGICAL_PROCESS	17	18	viral replication
NCT000007559	NCT00000755_9_T0	COMPOUND	28	28	zidovudine
NCT0000075510	NCT00000755_10_T0	GENE	20	20	booster
NCT0000075511	NCT00000755_11_T0	GENE	5	5	CD4
NCT0000075519	NCT00000755_19_T0	PHENOTYPE	1	2	drug abuse
NCT000007560	NCT00000756_0_T0	CELL	14	14	T-Cells
NCT000007560	NCT00000756_0_T1	GENE	19	19	CD4
NCT000007560	NCT00000756_0_T2	PHENOTYPE	5	5	Tolerance
NCT000007560	NCT00000756_0_T3	GENE	11	11	Expanded
NCT000007562	NCT00000756_2_T0	PHENOTYPE	2	2	peripheral
NCT000007562	NCT00000756_2_T1	CELL	4	4	lymphocytes
NCT000007562	NCT00000756_2_T2	PHENOTYPE	18	18	vaccinia
NCT000007562	NCT00000756_2_T3	CELL	12	12	cells
NCT000007562	NCT00000756_2_T4	CELL	15	15	cells
NCT000007562	NCT00000756_2_T5	PHENOTYPE	20	20	encoding
NCT000007562	NCT00000756_2_T6	PHENOTYPE	9	9	lyse
NCT000007563	NCT00000756_3_T0	CELL	4	5	T lymphocytes
NCT000007563	NCT00000756_3_T1	PHENOTYPE	10	11	HIV disease
NCT000007563	NCT00000756_3_T2	PHENOTYPE	11	12	disease progression
NCT000007565	NCT00000756_5_T0	CELL	4	5	T lymphocytes
NCT000007565	NCT00000756_5_T1	PHENOTYPE	10	11	HIV disease
NCT000007565	NCT00000756_5_T2	PHENOTYPE	11	12	disease progression
NCT000007566	NCT00000756_6_T0	GENE	10	10	CTL
NCT000007567	NCT00000756_7_T0	GENE	10	10	CTL
NCT000007568	NCT00000756_8_T0	GENE	9	9	CTL
NCT000007568	NCT00000756_8_T1	GENE	16	16	CTL
NCT0000075610	NCT00000756_10_T0	PHENOTYPE	11	11	toxicity
NCT0000075610	NCT00000756_10_T1	PHENOTYPE	10	10	acute
NCT0000075611	NCT00000756_11_T0	PHENOTYPE	9	9	toxicity
NCT0000075611	NCT00000756_11_T1	PHENOTYPE	25	25	toxicity
NCT0000075611	NCT00000756_11_T2	PHENOTYPE	8	8	acute
NCT0000075611	NCT00000756_11_T3	PHENOTYPE	24	24	acute
NCT0000075611	NCT00000756_11_T4	GENE	19	19	MTD
NCT0000075619	NCT00000756_19_T0	PHENOTYPE	1	2	substance abuse
NCT000007571	NCT00000757_1_T0	PHENOTYPE	5	6	antibody response
NCT000007572	NCT00000757_2_T0	ORGAN	17	17	serum
NCT000007572	NCT00000757_2_T1	GENE	12	12	gp160
NCT000007572	NCT00000757_2_T2	GENE	18	18	gp160
NCT000007572	NCT00000757_2_T3	PHENOTYPE	19	20	antibody responses
NCT000007573	NCT00000757_3_T0	GENE	25	25	gp160
NCT000007573	NCT00000757_3_T1	GENE	15	15	booster
NCT000007573	NCT00000757_3_T2	PHENOTYPE	7	8	antibody responses
NCT000007575	NCT00000757_5_T0	GENE	25	25	gp160
NCT000007575	NCT00000757_5_T1	GENE	15	15	booster
NCT000007575	NCT00000757_5_T2	PHENOTYPE	7	8	antibody responses
NCT000007576	NCT00000757_6_T0	GENE	15	15	gp160
NCT000007581	NCT00000758_1_T0	PHENOTYPE	4	4	recurrence
NCT000007581	NCT00000758_1_T1	CELL	9	9	T-cell
NCT000007581	NCT00000758_1_T2	PHENOTYPE	6	7	cervical dysplasia
NCT000007582	NCT00000758_2_T0	PHENOTYPE	9	10	cervical dysplasia
NCT000007582	NCT00000758_2_T1	PHENOTYPE	2	3	HIV infection
NCT000007583	NCT00000758_3_T0	PHENOTYPE	7	7	recurrent
NCT000007583	NCT00000758_3_T1	PHENOTYPE	13	14	invasive cancer
NCT000007583	NCT00000758_3_T2	PHENOTYPE	8	9	cervical dysplasia
NCT000007585	NCT00000758_5_T0	PHENOTYPE	7	7	recurrent
NCT000007585	NCT00000758_5_T1	PHENOTYPE	13	14	invasive cancer
NCT000007585	NCT00000758_5_T2	PHENOTYPE	8	9	cervical dysplasia
NCT000007588	NCT00000758_8_T0	PHENOTYPE	4	4	recurrent
NCT000007588	NCT00000758_8_T1	PHENOTYPE	5	6	cervical dysplasia
NCT000007591	NCT00000759_1_T0	PHENOTYPE	26	26	Battery
NCT000007591	NCT00000759_1_T1	PHENOTYPE	0	0	Scaling
NCT000007594	NCT00000759_4_T0	PHENOTYPE	26	27	language skills
NCT000007597	NCT00000759_7_T0	ORGAN	6	8	central nervous system
NCT0000075911	NCT00000759_11_T0	GENE	10	10	ACTG
NCT0000075911	NCT00000759_11_T1	GENE	7	7	nested
NCT0000075913	NCT00000759_13_T0	GENE	7	7	ACTG
NCT0000075913	NCT00000759_13_T1	PHENOTYPE	25	25	seronegative
NCT0000075913	NCT00000759_13_T2	PHENOTYPE	4	4	HIV
NCT0000075913	NCT00000759_13_T3	PHENOTYPE	33	33	HIV
NCT0000075913	NCT00000759_13_T4	PHENOTYPE	42	42	HIV
NCT000007600	NCT00000760_0_T0	GENE	12	12	Tat
NCT000007600	NCT00000760_0_T1	PHENOTYPE	7	7	Tolerance
NCT000007600	NCT00000760_0_T2	PHENOTYPE	17	18	HIV Infection
NCT000007602	NCT00000760_2_T0	PHENOTYPE	5	5	tolerance
NCT000007603	NCT00000760_3_T0	PHENOTYPE	15	16	drug toxicity
NCT000007605	NCT00000760_5_T0	PHENOTYPE	1	1	HIV
NCT000007605	NCT00000760_5_T1	BIOLOGICAL_PROCESS	10	11	viral replication
NCT000007607	NCT00000760_7_T0	BIOLOGICAL_PROCESS	4	4	transcription
NCT000007607	NCT00000760_7_T1	PHENOTYPE	6	6	HIV
NCT000007607	NCT00000760_7_T2	GENE	1	1	tat
NCT000007607	NCT00000760_7_T3	PHENOTYPE	24	25	HIV infection
NCT0000076010	NCT00000760_10_T0	BIOLOGICAL_PROCESS	4	4	transcription
NCT0000076010	NCT00000760_10_T1	PHENOTYPE	6	6	HIV
NCT0000076010	NCT00000760_10_T2	GENE	1	1	tat
NCT0000076010	NCT00000760_10_T3	PHENOTYPE	24	25	HIV infection
NCT0000076022	NCT00000760_22_T0	PHENOTYPE	3	4	alcohol abuse
NCT000007611	NCT00000761_1_T0	PHENOTYPE	2	2	HIV
NCT000007611	NCT00000761_1_T1	CELL	7	7	monocyte
NCT000007611	NCT00000761_1_T2	CELL	5	5	neutrophil
NCT000007613	NCT00000761_3_T0	PHENOTYPE	7	7	severely
NCT000007613	NCT00000761_3_T1	PHENOTYPE	10	11	HIV infection
NCT000007614	NCT00000761_4_T0	PHENOTYPE	11	11	immunity
NCT000007614	NCT00000761_4_T1	GENE	1	1	has
NCT000007614	NCT00000761_4_T2	PHENOTYPE	8	8	severely
NCT000007614	NCT00000761_4_T3	PHENOTYPE	21	22	HIV infection
NCT000007616	NCT00000761_6_T0	PHENOTYPE	11	11	immunity
NCT000007616	NCT00000761_6_T1	GENE	1	1	has
NCT000007616	NCT00000761_6_T2	PHENOTYPE	8	8	severely
NCT000007616	NCT00000761_6_T3	PHENOTYPE	21	22	HIV infection
NCT000007620	NCT00000762_0_T0	GENE	20	20	gp120
NCT000007620	NCT00000762_0_T1	GENE	18	18	gp160
NCT000007620	NCT00000762_0_T2	PHENOTYPE	28	30	Asymptomatic HIV Infection
NCT000007622	NCT00000762_2_T0	PHENOTYPE	34	34	immunosuppression
NCT000007622	NCT00000762_2_T1	PHENOTYPE	31	31	progression
NCT000007622	NCT00000762_2_T2	PHENOTYPE	1	1	initiation
NCT000007622	NCT00000762_2_T3	PHENOTYPE	33	33	HIV
NCT000007622	NCT00000762_2_T4	PHENOTYPE	13	14	asymptomatic HIV
NCT000007631	NCT00000763_1_T0	PHENOTYPE	4	4	tumor
NCT000007631	NCT00000763_1_T1	PHENOTYPE	2	2	pharmacokinetics
NCT000007636	NCT00000763_6_T0	PHENOTYPE	12	12	toxicity
NCT000007636	NCT00000763_6_T1	GENE	20	20	MTD
NCT000007636	NCT00000763_6_T2	GENE	30	30	MTD
NCT0000076321	NCT00000763_21_T0	PHENOTYPE	14	14	HIV
NCT000007640	NCT00000764_0_T0	PHENOTYPE	5	5	Secondary
NCT000007640	NCT00000764_0_T1	PHENOTYPE	3	3	Neoplasia
NCT000007640	NCT00000764_0_T2	PHENOTYPE	14	15	HIV Infection
NCT000007640	NCT00000764_0_T3	PHENOTYPE	7	10	Anogenital Human Papillomavirus Infection
NCT000007641	NCT00000764_1_T0	PHENOTYPE	1	1	Infection
NCT000007644	NCT00000764_4_T0	GENE	12	12	IFN
NCT000007644	NCT00000764_4_T1	COMPOUND	6	6	isotretinoin
NCT000007645	NCT00000764_5_T0	PHENOTYPE	9	9	recurrence
NCT000007645	NCT00000764_5_T1	PHENOTYPE	32	32	HIV
NCT000007645	NCT00000764_5_T2	PHENOTYPE	14	15	intraepithelial neoplasia
NCT000007645	NCT00000764_5_T3	PHENOTYPE	2	3	HIV infection
NCT000007646	NCT00000764_6_T0	PHENOTYPE	3	3	HIV
NCT000007646	NCT00000764_6_T1	PHENOTYPE	12	12	progression
NCT000007646	NCT00000764_6_T2	PHENOTYPE	15	16	preneoplastic conditions
NCT000007648	NCT00000764_8_T0	PHENOTYPE	3	3	HIV
NCT000007648	NCT00000764_8_T1	PHENOTYPE	12	12	progression
NCT000007648	NCT00000764_8_T2	PHENOTYPE	15	16	preneoplastic conditions
NCT0000076410	NCT00000764_10_T0	PHENOTYPE	8	8	toxicity
NCT0000076410	NCT00000764_10_T1	PHENOTYPE	14	14	hypertriglyceridemia
NCT0000076410	NCT00000764_10_T2	GENE	17	17	reduced
NCT0000076410	NCT00000764_10_T3	PHENOTYPE	3	3	experiences
NCT0000076411	NCT00000764_11_T0	PHENOTYPE	17	17	toxicity
NCT0000076411	NCT00000764_11_T1	COMPOUND	24	24	isotretinoin
NCT0000076411	NCT00000764_11_T2	PHENOTYPE	10	10	progression
NCT0000076411	NCT00000764_11_T3	GENE	28	28	interferon
NCT0000076411	NCT00000764_11_T4	PHENOTYPE	6	6	neoplasia
NCT0000076423	NCT00000764_23_T0	PHENOTYPE	10	11	ventricular arrhythmias
NCT0000076423	NCT00000764_23_T1	PHENOTYPE	13	14	myocardial infarction
NCT0000076427	NCT00000764_27_T0	PHENOTYPE	5	6	drug use
NCT0000076427	NCT00000764_27_T1	PHENOTYPE	1	2	substance abuse
NCT000007650	NCT00000765_0_T0	GENE	10	10	CD4
NCT000007650	NCT00000765_0_T1	CELL	11	11	Lymphocyte
NCT000007650	NCT00000765_0_T2	PHENOTYPE	16	18	Primary HIV Infection
NCT000007652	NCT00000765_2_T0	PHENOTYPE	11	13	primary HIV infection
NCT000007655	NCT00000765_5_T0	COMPOUND	6	6	zidovudine
NCT000007657	NCT00000765_7_T0	PHENOTYPE	11	11	HIV
NCT0000076511	NCT00000765_11_T0	GENE	23	23	blot
NCT0000076511	NCT00000765_11_T1	GENE	0	0	p24
NCT0000076511	NCT00000765_11_T2	PHENOTYPE	12	12	HIV
NCT0000076511	NCT00000765_11_T3	PHENOTYPE	18	18	HIV
NCT000007662	NCT00000766_2_T0	PHENOTYPE	1	1	strategies
NCT000007664	NCT00000766_4_T0	PHENOTYPE	1	1	strategies
NCT000007665	NCT00000766_5_T0	COMPOUND	6	6	ganciclovir
NCT000007665	NCT00000766_5_T1	COMPOUND	5	5	foscarnet
NCT000007667	NCT00000766_7_T0	PHENOTYPE	4	4	retinitis
NCT000007672	NCT00000767_2_T0	GENE	10	10	envelope
NCT000007672	NCT00000767_2_T1	GENE	34	34	envelope
NCT000007672	NCT00000767_2_T2	PHENOTYPE	26	26	immunity
NCT000007672	NCT00000767_2_T3	BIOLOGICAL_PROCESS	15	16	antigenic variation
NCT000007673	NCT00000767_3_T0	GENE	5	5	polymerase
NCT000007673	NCT00000767_3_T1	GENE	9	10	envelope protein
NCT000007674	NCT00000767_4_T0	PHENOTYPE	19	19	strain
NCT000007674	NCT00000767_4_T1	GENE	13	13	pol
NCT000007674	NCT00000767_4_T2	GENE	11	11	gag
NCT000007674	NCT00000767_4_T3	GENE	10	10	env
NCT000007676	NCT00000767_6_T0	GENE	5	5	polymerase
NCT000007676	NCT00000767_6_T1	GENE	9	10	envelope protein
NCT000007677	NCT00000767_7_T0	PHENOTYPE	19	19	strain
NCT000007677	NCT00000767_7_T1	GENE	13	13	pol
NCT000007677	NCT00000767_7_T2	GENE	11	11	gag
NCT000007677	NCT00000767_7_T3	GENE	10	10	env
NCT0000076710	NCT00000767_10_T0	PHENOTYPE	0	1	Group B
NCT0000076711	NCT00000767_11_T0	GENE	25	25	II
NCT0000076714	NCT00000767_14_T0	GENE	2	2	II
NCT0000076720	NCT00000767_20_T0	PHENOTYPE	9	9	closed
NCT0000076720	NCT00000767_20_T1	GENE	8	8	has
NCT000007680	NCT00000768_0_T0	PHENOTYPE	15	16	Gastrointestinal Disease
NCT000007684	NCT00000768_4_T0	COMPOUND	21	21	hydrochloride
NCT000007684	NCT00000768_4_T1	GENE	14	14	pH
NCT000007684	NCT00000768_4_T2	COMPOUND	2	2	ganciclovir
NCT000007684	NCT00000768_4_T3	GENE	3	3	has
NCT000007684	NCT00000768_4_T4	COMPOUND	19	20	glutamic acid
NCT000007687	NCT00000768_7_T0	COMPOUND	21	21	hydrochloride
NCT000007687	NCT00000768_7_T1	GENE	14	14	pH
NCT000007687	NCT00000768_7_T2	COMPOUND	2	2	ganciclovir
NCT000007687	NCT00000768_7_T3	GENE	3	3	has
NCT000007687	NCT00000768_7_T4	COMPOUND	19	20	glutamic acid
NCT0000076810	NCT00000768_10_T0	COMPOUND	27	27	hydrochloride
NCT0000076810	NCT00000768_10_T1	COMPOUND	17	17	ganciclovir
NCT0000076810	NCT00000768_10_T2	COMPOUND	25	26	glutamic acid
NCT0000076814	NCT00000768_14_T0	PHENOTYPE	4	4	symptoms
NCT0000076814	NCT00000768_14_T1	PHENOTYPE	6	6	relapse
NCT0000076814	NCT00000768_14_T2	PHENOTYPE	16	16	relapse
NCT000007692	NCT00000769_2_T0	CELL	19	19	cells
NCT000007692	NCT00000769_2_T1	GENE	0	0	IL-4
NCT000007692	NCT00000769_2_T2	ORGAN	9	10	immune system
NCT000007692	NCT00000769_2_T3	PHENOTYPE	17	18	Kaposi's sarcoma
NCT000007695	NCT00000769_5_T0	PHENOTYPE	30	31	drug toxicity
NCT000007696	NCT00000769_6_T0	PHENOTYPE	18	18	toxicity
NCT000007696	NCT00000769_6_T1	GENE	1	1	MTD
NCT000007701	NCT00000770_1_T0	COMPOUND	23	23	nevirapine
NCT000007701	NCT00000770_1_T1	PHENOTYPE	6	6	HIV
NCT000007701	NCT00000770_1_T2	GENE	8	8	has
NCT000007701	NCT00000770_1_T3	GENE	26	27	reverse transcriptase
NCT000007702	NCT00000770_2_T0	PHENOTYPE	9	9	HIV
NCT000007704	NCT00000770_4_T0	PHENOTYPE	9	9	HIV
NCT000007705	NCT00000770_5_T0	COMPOUND	8	8	nevirapine
NCT000007706	NCT00000770_6_T0	GENE	4	4	ACTG
NCT0000077014	NCT00000770_14_T0	COMPOUND	13	13	TIBO
NCT0000077014	NCT00000770_14_T1	GENE	8	9	reverse transcriptase
NCT000007710	NCT00000771_0_T0	PHENOTYPE	9	9	Cryptosporidiosis
NCT000007710	NCT00000771_0_T1	GENE	17	17	CD4
NCT000007710	NCT00000771_0_T2	PHENOTYPE	14	15	HIV Disease
NCT000007712	NCT00000771_2_T0	COMPOUND	6	6	paromomycin
NCT000007713	NCT00000771_3_T0	COMPOUND	3	3	paromomycin
NCT000007714	NCT00000771_4_T0	COMPOUND	10	10	paromomycin
NCT000007714	NCT00000771_4_T1	PHENOTYPE	5	5	cryptosporidiosis
NCT000007716	NCT00000771_6_T0	COMPOUND	8	8	paromomycin
NCT000007717	NCT00000771_7_T0	COMPOUND	9	9	paromomycin
NCT000007718	NCT00000771_8_T0	COMPOUND	18	18	paromomycin
NCT0000077111	NCT00000771_11_T0	GENE	15	15	2.4
NCT000007720	NCT00000772_0_T0	PHENOTYPE	8	8	Tolerance
NCT000007722	NCT00000772_2_T0	PHENOTYPE	17	17	toxicity
NCT000007722	NCT00000772_2_T1	COMPOUND	11	11	ribavirin
NCT000007724	NCT00000772_4_T0	COMPOUND	20	20	zidovudine
NCT000007727	NCT00000772_7_T0	PHENOTYPE	9	9	toxicity
NCT000007732	NCT00000773_2_T0	COMPOUND	5	5	atovaquone
NCT000007732	NCT00000773_2_T1	GENE	9	9	has
NCT000007735	NCT00000773_5_T0	COMPOUND	5	5	atovaquone
NCT000007735	NCT00000773_5_T1	GENE	9	9	has
NCT000007737	NCT00000773_7_T0	COMPOUND	25	25	atovaquone
NCT000007737	NCT00000773_7_T1	GENE	7	7	2.12
NCT0000077310	NCT00000773_10_T0	PHENOTYPE	11	11	toxicity
NCT000007741	NCT00000774_1_T0	GENE	14	14	CD4
NCT000007742	NCT00000774_2_T0	GENE	7	7	envelope
NCT000007742	NCT00000774_2_T1	PHENOTYPE	14	14	HIV
NCT000007742	NCT00000774_2_T2	PHENOTYPE	18	18	HIV
NCT000007743	NCT00000774_3_T0	PHENOTYPE	4	4	HIV
NCT000007744	NCT00000774_4_T0	GENE	5	5	envelope
NCT000007744	NCT00000774_4_T1	PHENOTYPE	4	4	HIV
NCT000007744	NCT00000774_4_T2	PHENOTYPE	15	15	HIV
NCT000007744	NCT00000774_4_T3	PHENOTYPE	20	20	HIV
NCT000007744	NCT00000774_4_T4	BIOLOGICAL_PROCESS	2	2	sensitization
NCT000007744	NCT00000774_4_T5	PHENOTYPE	23	24	disease progression
NCT000007747	NCT00000774_7_T0	GENE	5	5	envelope
NCT000007747	NCT00000774_7_T1	PHENOTYPE	4	4	HIV
NCT000007747	NCT00000774_7_T2	PHENOTYPE	15	15	HIV
NCT000007747	NCT00000774_7_T3	PHENOTYPE	20	20	HIV
NCT000007747	NCT00000774_7_T4	BIOLOGICAL_PROCESS	2	2	sensitization
NCT000007747	NCT00000774_7_T5	PHENOTYPE	23	24	disease progression
NCT0000077411	NCT00000774_11_T0	PHENOTYPE	25	25	toxicity
NCT000007761	NCT00000776_1_T0	PHENOTYPE	9	10	cryptococcal meningitis
NCT000007761	NCT00000776_1_T1	PHENOTYPE	12	13	intracranial hypertension
NCT000007762	NCT00000776_2_T0	GENE	8	8	has
NCT000007762	NCT00000776_2_T1	PHENOTYPE	4	5	cryptococcal meningitis
NCT000007762	NCT00000776_2_T2	PHENOTYPE	15	17	elevated intracranial pressure
NCT000007763	NCT00000776_3_T0	COMPOUND	1	1	dexamethasone
NCT000007763	NCT00000776_3_T1	PHENOTYPE	14	14	meningitis
NCT000007763	NCT00000776_3_T2	PHENOTYPE	24	25	cryptococcal meningitis
NCT000007765	NCT00000776_5_T0	COMPOUND	1	1	dexamethasone
NCT000007765	NCT00000776_5_T1	PHENOTYPE	14	14	meningitis
NCT000007765	NCT00000776_5_T2	PHENOTYPE	24	25	cryptococcal meningitis
NCT000007766	NCT00000776_6_T0	COMPOUND	5	5	dexamethasone
NCT000007767	NCT00000776_7_T0	COMPOUND	8	8	flucytosine
NCT000007767	NCT00000776_7_T1	COMPOUND	16	16	fluconazole
NCT000007767	NCT00000776_7_T2	COMPOUND	5	6	amphotericin B
NCT000007768	NCT00000776_8_T0	PHENOTYPE	1	1	punctures
NCT000007772	NCT00000777_2_T0	ORGAN	10	10	plasma
NCT000007772	NCT00000777_2_T1	PHENOTYPE	11	11	viremia
NCT000007773	NCT00000777_3_T0	PHENOTYPE	2	2	progression
NCT000007773	NCT00000777_3_T1	ORGAN	11	11	plasma
NCT000007775	NCT00000777_5_T0	PHENOTYPE	2	2	progression
NCT000007775	NCT00000777_5_T1	ORGAN	11	11	plasma
NCT000007776	NCT00000777_6_T0	BIOLOGICAL_PROCESS	21	21	gestation
NCT000007776	NCT00000777_6_T1	GENE	25	25	booster
NCT000007777	NCT00000777_7_T0	GENE	4	4	booster
NCT000007780	NCT00000778_0_T0	PHENOTYPE	12	12	Tolerance
NCT000007780	NCT00000778_0_T1	PHENOTYPE	14	14	Pharmacokinetics
NCT000007780	NCT00000778_0_T2	PHENOTYPE	10	11	Bactericidal Activity
NCT000007780	NCT00000778_0_T3	PHENOTYPE	19	20	Pulmonary Tuberculosis
NCT000007785	NCT00000778_5_T0	ORGAN	16	16	lungs
NCT000007789	NCT00000778_9_T0	ORGAN	16	16	lungs
NCT0000077810	NCT00000778_10_T0	COMPOUND	6	6	isoniazid
NCT0000077810	NCT00000778_10_T1	COMPOUND	8	8	pyridoxine
NCT0000077811	NCT00000778_11_T0	PHENOTYPE	9	9	EBA
NCT0000077812	NCT00000778_12_T0	PHENOTYPE	24	24	EBA
NCT0000077812	NCT00000778_12_T1	COMPOUND	16	16	levofloxacin
NCT000007790	NCT00000779_0_T0	GENE	17	17	CD4
NCT000007793	NCT00000779_3_T0	PHENOTYPE	5	5	HIV
NCT000007796	NCT00000779_6_T0	GENE	11	11	2.3
NCT000007796	NCT00000779_6_T1	GENE	3	3	rgp
NCT000007796	NCT00000779_6_T2	GENE	5	5	rgp
NCT000007796	NCT00000779_6_T3	GENE	7	7	rgp
NCT000007796	NCT00000779_6_T4	GENE	10	10	env
NCT000007797	NCT00000779_7_T0	COMPOUND	17	17	citrate
NCT000007797	NCT00000779_7_T1	COMPOUND	5	6	aluminum hydroxide
NCT000007799	NCT00000779_9_T0	BIOLOGICAL_PROCESS	21	22	immune response
NCT000007802	NCT00000780_2_T0	PHENOTYPE	17	17	HIV
NCT000007802	NCT00000780_2_T1	GENE	8	8	ACTG
NCT000007802	NCT00000780_2_T2	GENE	13	13	ACTG
NCT000007803	NCT00000780_3_T0	PHENOTYPE	7	7	progression
NCT000007803	NCT00000780_3_T1	PHENOTYPE	9	10	HIV infection
NCT000007804	NCT00000780_4_T0	PHENOTYPE	4	4	HIV
NCT000007804	NCT00000780_4_T1	GENE	21	21	ACTG
NCT000007805	NCT00000780_5_T0	PHENOTYPE	8	8	HIV
NCT000007805	NCT00000780_5_T1	GENE	13	13	has
NCT000007807	NCT00000780_7_T0	PHENOTYPE	8	8	HIV
NCT000007807	NCT00000780_7_T1	GENE	13	13	has
NCT000007808	NCT00000780_8_T0	PHENOTYPE	21	21	HIV
NCT000007808	NCT00000780_8_T1	GENE	17	17	ACTG
NCT000007808	NCT00000780_8_T2	GENE	38	38	ACTG
NCT000007809	NCT00000780_9_T0	PHENOTYPE	4	4	attitudes
NCT000007810	NCT00000781_0_T0	GENE	20	20	CD4
NCT000007810	NCT00000781_0_T1	PHENOTYPE	18	19	HIV Disease
NCT000007812	NCT00000781_2_T0	PHENOTYPE	5	5	HIV
NCT000007812	NCT00000781_2_T1	PHENOTYPE	4	4	resistant
NCT000007812	NCT00000781_2_T2	GENE	7	7	has
NCT000007812	NCT00000781_2_T3	PHENOTYPE	6	6	strains
NCT000007812	NCT00000781_2_T4	GENE	20	21	reverse transcriptase
NCT000007813	NCT00000781_3_T0	GENE	18	18	RT
NCT000007813	NCT00000781_3_T1	PHENOTYPE	27	27	HIV
NCT000007813	NCT00000781_3_T2	PHENOTYPE	26	26	resistant
NCT000007813	NCT00000781_3_T3	PHENOTYPE	28	28	strains
NCT000007814	NCT00000781_4_T0	PHENOTYPE	1	1	toxicity
NCT000007814	NCT00000781_4_T1	PHENOTYPE	36	36	toxicity
NCT000007816	NCT00000781_6_T0	GENE	18	18	RT
NCT000007816	NCT00000781_6_T1	PHENOTYPE	27	27	HIV
NCT000007816	NCT00000781_6_T2	PHENOTYPE	26	26	resistant
NCT000007816	NCT00000781_6_T3	PHENOTYPE	28	28	strains
NCT000007817	NCT00000781_7_T0	PHENOTYPE	1	1	toxicity
NCT000007817	NCT00000781_7_T1	PHENOTYPE	36	36	toxicity
NCT000007818	NCT00000781_8_T0	COMPOUND	6	6	AZT-ddC
NCT0000078123	NCT00000781_23_T0	PHENOTYPE	1	4	alcohol or drug abuse
NCT000007830	NCT00000783_0_T0	PHENOTYPE	1	1	HIV
NCT000007830	NCT00000783_0_T1	PHENOTYPE	2	2	Transmission
NCT000007832	NCT00000783_2_T0	PHENOTYPE	25	25	HIV
NCT000007833	NCT00000783_3_T0	PHENOTYPE	6	6	peripheral
NCT000007833	NCT00000783_3_T1	CELL	9	9	cells
NCT000007833	NCT00000783_3_T2	PHENOTYPE	22	22	HIV
NCT000007833	NCT00000783_3_T3	PHENOTYPE	28	28	HIV
NCT000007833	NCT00000783_3_T4	ORGAN	5	5	serum
NCT000007833	NCT00000783_3_T5	PHENOTYPE	33	34	HIV infection
NCT000007835	NCT00000783_5_T0	PHENOTYPE	4	4	HIV
NCT000007835	NCT00000783_5_T1	PHENOTYPE	28	28	HIV
NCT000007835	NCT00000783_5_T2	PHENOTYPE	6	6	transmitted
NCT000007837	NCT00000783_7_T0	PHENOTYPE	4	4	HIV
NCT000007837	NCT00000783_7_T1	PHENOTYPE	28	28	HIV
NCT000007837	NCT00000783_7_T2	PHENOTYPE	6	6	transmitted
NCT000007839	NCT00000783_9_T0	PHENOTYPE	25	25	HIV
NCT000007839	NCT00000783_9_T1	PHENOTYPE	38	38	HIV
NCT000007839	NCT00000783_9_T2	GENE	27	27	has
NCT000007839	NCT00000783_9_T3	PHENOTYPE	14	15	HIV infection
NCT0000078310	NCT00000783_10_T0	PHENOTYPE	18	19	HIV infection
NCT0000078311	NCT00000783_11_T0	PHENOTYPE	4	4	secondary
NCT0000078311	NCT00000783_11_T1	PHENOTYPE	14	14	secondary
NCT0000078311	NCT00000783_11_T2	PHENOTYPE	3	3	HIV
NCT0000078314	NCT00000783_14_T0	PHENOTYPE	4	5	drug use
NCT000007843	NCT00000784_3_T0	PHENOTYPE	11	11	HIV
NCT000007845	NCT00000784_5_T0	PHENOTYPE	11	11	HIV
NCT000007847	NCT00000784_7_T0	PHENOTYPE	18	19	substance use
NCT000007848	NCT00000784_8_T0	PHENOTYPE	16	16	perceptions
NCT000007852	NCT00000785_2_T0	PHENOTYPE	11	11	HIV
NCT000007853	NCT00000785_3_T0	PHENOTYPE	19	19	HIV
NCT000007859	NCT00000785_9_T0	PHENOTYPE	11	11	HIV
NCT0000078511	NCT00000785_11_T0	PHENOTYPE	10	10	tuberculosis
NCT0000078512	NCT00000785_12_T0	PHENOTYPE	10	10	tuberculosis
NCT0000078514	NCT00000785_14_T0	PHENOTYPE	9	9	tuberculosis
NCT000007870	NCT00000787_0_T0	PHENOTYPE	1	1	HIV
NCT000007870	NCT00000787_0_T1	PHENOTYPE	2	2	Transmission
NCT000007879	NCT00000787_9_T0	PHENOTYPE	3	3	recruitment
NCT000007879	NCT00000787_9_T1	PHENOTYPE	12	13	drug use
NCT000007881	NCT00000788_1_T0	PHENOTYPE	15	16	HIV infection
NCT000007882	NCT00000788_2_T0	COMPOUND	8	8	methadone
NCT000007882	NCT00000788_2_T1	PHENOTYPE	0	1	Narcotic addiction
NCT000007885	NCT00000788_5_T0	COMPOUND	8	8	methadone
NCT000007885	NCT00000788_5_T1	PHENOTYPE	0	1	Narcotic addiction
NCT000007887	NCT00000788_7_T0	COMPOUND	8	8	fluconazole
NCT000007887	NCT00000788_7_T1	COMPOUND	5	5	methadone
NCT000007889	NCT00000788_9_T0	GENE	14	14	16
NCT000007890	NCT00000789_0_T0	PHENOTYPE	14	15	HIV Infection
NCT000007893	NCT00000789_3_T0	PHENOTYPE	22	23	drug intolerance
NCT000007893	NCT00000789_3_T1	PHENOTYPE	19	20	disease progression
NCT000007893	NCT00000789_3_T2	PHENOTYPE	16	17	HIV infection
NCT000007894	NCT00000789_4_T0	GENE	9	9	has
NCT000007894	NCT00000789_4_T1	GENE	17	17	has
NCT000007894	NCT00000789_4_T2	COMPOUND	7	8	HIV inhibitor
NCT000007896	NCT00000789_6_T0	GENE	9	9	has
NCT000007896	NCT00000789_6_T1	GENE	17	17	has
NCT000007896	NCT00000789_6_T2	COMPOUND	7	8	HIV inhibitor
NCT000007898	NCT00000789_8_T0	GENE	7	7	has
NCT000007900	NCT00000790_0_T0	PHENOTYPE	10	10	HIV
NCT000007900	NCT00000790_0_T1	PHENOTYPE	11	11	Viremia
NCT000007900	NCT00000790_0_T2	PHENOTYPE	7	8	Aphthous Ulcers
NCT000007900	NCT00000790_0_T3	PHENOTYPE	15	16	HIV Infection
NCT000007902	NCT00000790_2_T0	COMPOUND	5	5	thalidomide
NCT000007902	NCT00000790_2_T1	PHENOTYPE	7	7	HIV
NCT000007908	NCT00000790_8_T0	GENE	1	1	has
NCT000007908	NCT00000790_8_T1	PHENOTYPE	12	13	aphthous ulceration
NCT0000079010	NCT00000790_10_T0	GENE	1	1	has
NCT0000079010	NCT00000790_10_T1	PHENOTYPE	12	13	aphthous ulceration
NCT0000079011	NCT00000790_11_T0	COMPOUND	9	9	thalidomide
NCT0000079013	NCT00000790_13_T0	PHENOTYPE	6	6	acute
NCT000007911	NCT00000791_1_T0	PHENOTYPE	9	9	HIV
NCT000007913	NCT00000791_3_T0	PHENOTYPE	6	6	toxicity
NCT000007913	NCT00000791_3_T1	PHENOTYPE	25	26	HIV infection
NCT000007915	NCT00000791_5_T0	PHENOTYPE	6	6	toxicity
NCT000007915	NCT00000791_5_T1	PHENOTYPE	25	26	HIV infection
NCT000007921	NCT00000792_1_T0	COMPOUND	13	13	hypericin
NCT000007921	NCT00000792_1_T1	PHENOTYPE	8	9	HIV infection
NCT000007922	NCT00000792_2_T0	COMPOUND	18	18	hypericin
NCT000007926	NCT00000792_6_T0	COMPOUND	10	10	hypericin
NCT000007929	NCT00000792_9_T0	PHENOTYPE	19	19	toxicity
NCT0000079210	NCT00000792_10_T0	PHENOTYPE	17	17	toxicity
NCT0000079210	NCT00000792_10_T1	GENE	1	1	MTD
NCT000007930	NCT00000793_0_T0	PHENOTYPE	11	11	Neuropathy
NCT000007930	NCT00000793_0_T1	PHENOTYPE	13	14	HIV Infection
NCT000007932	NCT00000793_2_T0	PHENOTYPE	10	11	HIV neuropathy
NCT000007933	NCT00000793_3_T0	COMPOUND	1	1	amitriptyline
NCT000007933	NCT00000793_3_T1	PHENOTYPE	12	12	neuropathies
NCT000007933	NCT00000793_3_T2	PHENOTYPE	19	19	toxicities
NCT000007933	NCT00000793_3_T3	COMPOUND	3	3	mexiletine
NCT000007934	NCT00000793_4_T0	COMPOUND	5	5	amitriptyline
NCT000007934	NCT00000793_4_T1	COMPOUND	7	7	mexiletine
NCT000007934	NCT00000793_4_T2	COMPOUND	8	9	benztropine mesylate
NCT000007936	NCT00000793_6_T0	COMPOUND	1	1	amitriptyline
NCT000007936	NCT00000793_6_T1	PHENOTYPE	12	12	neuropathies
NCT000007936	NCT00000793_6_T2	PHENOTYPE	19	19	toxicities
NCT000007936	NCT00000793_6_T3	COMPOUND	3	3	mexiletine
NCT000007937	NCT00000793_7_T0	COMPOUND	5	5	amitriptyline
NCT000007937	NCT00000793_7_T1	COMPOUND	7	7	mexiletine
NCT000007937	NCT00000793_7_T2	COMPOUND	8	9	benztropine mesylate
NCT000007938	NCT00000793_8_T0	COMPOUND	5	5	amitriptyline
NCT000007938	NCT00000793_8_T1	COMPOUND	23	23	amitriptyline
NCT000007938	NCT00000793_8_T2	COMPOUND	6	6	mexiletine
NCT000007938	NCT00000793_8_T3	COMPOUND	25	25	mexiletine
NCT000007938	NCT00000793_8_T4	COMPOUND	8	9	benztropine mesylate
NCT000007939	NCT00000793_9_T0	GENE	13	13	MTD
NCT000007940	NCT00000794_0_T0	GENE	1	1	II
NCT000007940	NCT00000794_0_T1	PHENOTYPE	19	19	Encephalitis
NCT000007940	NCT00000794_0_T2	PHENOTYPE	17	17	Acute
NCT000007942	NCT00000794_2_T0	PHENOTYPE	21	21	toxicity
NCT000007942	NCT00000794_2_T1	PHENOTYPE	4	4	encephalitis
NCT000007942	NCT00000794_2_T2	COMPOUND	14	14	pyrimethamine
NCT000007942	NCT00000794_2_T3	COMPOUND	12	12	sulfadiazine
NCT000007943	NCT00000794_3_T0	PHENOTYPE	8	8	toxoplasmosis
NCT000007943	NCT00000794_3_T1	GENE	4	4	has
NCT000007943	NCT00000794_3_T2	GENE	16	16	has
NCT000007944	NCT00000794_4_T0	COMPOUND	5	5	atovaquone
NCT000007944	NCT00000794_4_T1	COMPOUND	11	11	pyrimethamine
NCT000007944	NCT00000794_4_T2	COMPOUND	9	9	sulfadiazine
NCT000007946	NCT00000794_6_T0	PHENOTYPE	8	8	toxoplasmosis
NCT000007946	NCT00000794_6_T1	GENE	4	4	has
NCT000007946	NCT00000794_6_T2	GENE	16	16	has
NCT000007947	NCT00000794_7_T0	COMPOUND	5	5	atovaquone
NCT000007947	NCT00000794_7_T1	COMPOUND	11	11	pyrimethamine
NCT000007947	NCT00000794_7_T2	COMPOUND	9	9	sulfadiazine
NCT000007948	NCT00000794_8_T0	COMPOUND	6	6	atovaquone
NCT000007948	NCT00000794_8_T1	COMPOUND	9	9	pyrimethamine
NCT000007949	NCT00000794_9_T0	PHENOTYPE	13	13	toxicity
NCT000007949	NCT00000794_9_T1	COMPOUND	21	21	atovaquone
NCT000007949	NCT00000794_9_T2	COMPOUND	27	27	atovaquone
NCT000007949	NCT00000794_9_T3	COMPOUND	15	15	pyrimethamine
NCT000007949	NCT00000794_9_T4	COMPOUND	29	29	clarithromycin
NCT000007949	NCT00000794_9_T5	COMPOUND	16	16	sulfadiazine
NCT0000079410	NCT00000794_10_T0	COMPOUND	3	3	pyrimethamine
NCT0000079410	NCT00000794_10_T1	COMPOUND	6	6	leucovorin
NCT0000079417	NCT00000794_17_T0	PHENOTYPE	7	7	toxicity
NCT0000079417	NCT00000794_17_T1	COMPOUND	18	18	atovaquone
NCT0000079417	NCT00000794_17_T2	COMPOUND	10	10	pyrimethamine
NCT0000079417	NCT00000794_17_T3	COMPOUND	20	20	clarithromycin
NCT000007951	NCT00000795_1_T0	GENE	18	18	has
NCT000007951	NCT00000795_1_T1	PHENOTYPE	8	8	strains
NCT000007960	NCT00000796_0_T0	GENE	37	37	ed
NCT000007960	NCT00000796_0_T1	PHENOTYPE	31	32	Pulmonary Tuberculosis
NCT000007964	NCT00000796_4_T0	PHENOTYPE	21	21	tuberculosis
NCT000007964	NCT00000796_4_T1	GENE	4	4	has
NCT000007964	NCT00000796_4_T2	PHENOTYPE	18	18	strains
NCT000007964	NCT00000796_4_T3	PHENOTYPE	9	10	progressive disease
NCT0000079611	NCT00000796_11_T0	GENE	20	20	222
NCT0000079611	NCT00000796_11_T1	GENE	19	19	ACTG
NCT0000079613	NCT00000796_13_T0	COMPOUND	13	13	capreomycin
NCT0000079613	NCT00000796_13_T1	COMPOUND	11	11	ethionamide
NCT0000079613	NCT00000796_13_T2	COMPOUND	12	12	cycloserine
NCT0000079613	NCT00000796_13_T3	COMPOUND	6	6	isoniazid
NCT0000079613	NCT00000796_13_T4	COMPOUND	17	17	clofazimine
NCT0000079613	NCT00000796_13_T5	COMPOUND	10	10	levofloxacin
NCT0000079613	NCT00000796_13_T6	COMPOUND	8	8	ethambutol
NCT0000079613	NCT00000796_13_T7	COMPOUND	9	9	streptomycin
NCT0000079615	NCT00000796_15_T0	COMPOUND	11	11	isoniazid
NCT000007970	NCT00000797_0_T0	PHENOTYPE	2	2	HIV
NCT000007972	NCT00000797_2_T0	PHENOTYPE	13	13	HIV
NCT000007972	NCT00000797_2_T1	PHENOTYPE	29	29	HIV
NCT000007972	NCT00000797_2_T2	PHENOTYPE	37	38	HIV infection
NCT000007975	NCT00000797_5_T0	PHENOTYPE	18	19	cardiovascular disease
NCT000007978	NCT00000797_8_T0	PHENOTYPE	7	7	HIV
NCT000007978	NCT00000797_8_T1	PHENOTYPE	15	15	HIV
NCT000007978	NCT00000797_8_T2	PHENOTYPE	8	8	malignancies
NCT000007978	NCT00000797_8_T3	PHENOTYPE	13	13	malignancies
NCT0000079711	NCT00000797_11_T0	PHENOTYPE	3	3	lipodystrophy
NCT000007981	NCT00000798_1_T0	PHENOTYPE	17	17	HIV
NCT000007981	NCT00000798_1_T1	PHENOTYPE	24	24	immunity
NCT000007981	NCT00000798_1_T2	CELL	28	29	T cells
NCT000007982	NCT00000798_2_T0	GENE	9	9	has
NCT000007985	NCT00000798_5_T0	GENE	9	9	has
NCT000007994	NCT00000799_4_T0	COMPOUND	4	4	probenecid
NCT000008002	NCT00000800_2_T0	COMPOUND	7	7	methadone
NCT000008002	NCT00000800_2_T1	COMPOUND	23	23	methadone
NCT000008003	NCT00000800_3_T0	PHENOTYPE	8	8	HIV
NCT000008004	NCT00000800_4_T0	PHENOTYPE	27	27	elimination
NCT000008004	NCT00000800_4_T1	COMPOUND	2	2	methadone
NCT000008004	NCT00000800_4_T2	COMPOUND	21	21	methadone
NCT000008004	NCT00000800_4_T3	PHENOTYPE	11	12	drug abuse
NCT000008006	NCT00000800_6_T0	PHENOTYPE	27	27	elimination
NCT000008006	NCT00000800_6_T1	COMPOUND	2	2	methadone
NCT000008006	NCT00000800_6_T2	COMPOUND	21	21	methadone
NCT000008006	NCT00000800_6_T3	PHENOTYPE	11	12	drug abuse
NCT000008007	NCT00000800_7_T0	COMPOUND	7	7	clonidine
NCT000008007	NCT00000800_7_T1	PHENOTYPE	32	32	pharmacokinetics
NCT000008007	NCT00000800_7_T2	ORGAN	29	29	plasma
NCT000008007	NCT00000800_7_T3	BIOLOGICAL_PROCESS	5	5	detoxification
NCT0000080010	NCT00000800_10_T0	COMPOUND	3	3	methadone
NCT0000080012	NCT00000800_12_T0	COMPOUND	38	38	methadone
NCT000008012	NCT00000801_2_T0	PHENOTYPE	11	13	primary CNS lymphoma
NCT000008014	NCT00000801_4_T0	COMPOUND	21	21	dexamethasone
NCT000008014	NCT00000801_4_T1	COMPOUND	20	20	vincristine
NCT000008014	NCT00000801_4_T2	COMPOUND	18	18	cyclophosphamide
NCT000008014	NCT00000801_4_T3	GENE	23	23	G-CSF
NCT000008014	NCT00000801_4_T4	COMPOUND	19	19	doxorubicin
NCT000008015	NCT00000801_5_T0	COMPOUND	3	3	vincristine
NCT000008015	NCT00000801_5_T1	COMPOUND	1	1	doxorubicin
NCT000008017	NCT00000801_7_T0	GENE	0	0	G-CSF
NCT000008018	NCT00000801_8_T0	COMPOUND	16	16	cytarabine
NCT000008018	NCT00000801_8_T1	CELL	5	5	cells
NCT000008018	NCT00000801_8_T2	CELL	25	25	cells
NCT000008018	NCT00000801_8_T3	GENE	10	10	CSF
NCT000008018	NCT00000801_8_T4	GENE	30	30	CSF
NCT0000080111	NCT00000801_11_T0	GENE	12	12	3/12
NCT0000080112	NCT00000801_12_T0	GENE	2	2	CSF
NCT000008028	NCT00000802_8_T0	COMPOUND	6	6	dapsone
NCT000008028	NCT00000802_8_T1	COMPOUND	8	8	atovaquone
NCT000008031	NCT00000803_1_T0	PHENOTYPE	3	3	HIV
NCT000008031	NCT00000803_1_T1	GENE	1	1	has
NCT000008032	NCT00000803_2_T0	GENE	11	11	has
NCT000008032	NCT00000803_2_T1	PHENOTYPE	55	56	HIV disease
NCT000008034	NCT00000803_4_T0	GENE	11	11	has
NCT000008034	NCT00000803_4_T1	PHENOTYPE	55	56	HIV disease
NCT000008040	NCT00000804_0_T0	PHENOTYPE	9	9	HIV
NCT000008040	NCT00000804_0_T1	PHENOTYPE	18	18	HIV
NCT000008040	NCT00000804_0_T2	GENE	10	10	Protease
NCT000008040	NCT00000804_0_T3	GENE	13	13	Interleukin-2
NCT000008042	NCT00000804_2_T0	GENE	5	5	interleukin-2
NCT000008042	NCT00000804_2_T1	PHENOTYPE	10	10	HIV
NCT000008053	NCT00000805_3_T0	COMPOUND	4	4	ganciclovir
NCT000008053	NCT00000805_3_T1	GENE	5	5	has
NCT000008055	NCT00000805_5_T0	COMPOUND	4	4	ganciclovir
NCT000008055	NCT00000805_5_T1	GENE	5	5	has
NCT000008061	NCT00000806_1_T0	PHENOTYPE	27	27	toxicity
NCT000008061	NCT00000806_1_T1	PHENOTYPE	18	18	concentrations
NCT000008061	NCT00000806_1_T2	PHENOTYPE	5	5	HIV
NCT000008061	NCT00000806_1_T3	ORGAN	17	17	plasma
NCT000008062	NCT00000806_2_T0	GENE	49	49	II
NCT000008062	NCT00000806_2_T1	GENE	8	9	protease inhibitor
NCT000008070	NCT00000807_0_T0	GENE	1	1	II
NCT000008070	NCT00000807_0_T1	PHENOTYPE	14	16	AIDS-Related Kaposi's Sarcoma
NCT000008074	NCT00000807_4_T0	COMPOUND	4	4	etoposide
NCT000008075	NCT00000807_5_T0	PHENOTYPE	14	14	toxicity
NCT000008077	NCT00000807_7_T0	PHENOTYPE	5	5	tumor
NCT000008077	NCT00000807_7_T1	PHENOTYPE	16	17	disease progression
NCT0000080715	NCT00000807_15_T0	PHENOTYPE	6	7	drug use
NCT000008081	NCT00000808_1_T0	COMPOUND	13	13	nevirapine
NCT000008081	NCT00000808_1_T1	COMPOUND	31	31	nevirapine
NCT000008081	NCT00000808_1_T2	COMPOUND	9	9	zidovudine
NCT000008082	NCT00000808_2_T0	COMPOUND	15	15	nevirapine
NCT000008082	NCT00000808_2_T1	BIOLOGICAL_PROCESS	27	27	parturition
NCT000008084	NCT00000808_4_T0	COMPOUND	10	10	nevirapine
NCT000008102	NCT00000810_2_T0	PHENOTYPE	17	17	toxicity
NCT000008103	NCT00000810_3_T0	PHENOTYPE	2	2	HIV
NCT000008104	NCT00000810_4_T0	GENE	26	26	RT
NCT000008104	NCT00000810_4_T1	COMPOUND	7	7	delavirdine
NCT000008104	NCT00000810_4_T2	PHENOTYPE	13	13	HIV
NCT000008104	NCT00000810_4_T3	COMPOUND	8	8	mesylate
NCT0000081019	NCT00000810_19_T0	PHENOTYPE	1	2	substance abuse
NCT000008111	NCT00000811_1_T0	COMPOUND	6	6	atovaquone
NCT000008111	NCT00000811_1_T1	COMPOUND	4	4	azithromycin
NCT000008112	NCT00000811_2_T0	PHENOTYPE	8	8	tolerance
NCT000008113	NCT00000811_3_T0	PHENOTYPE	10	11	bacterial infections
NCT000008114	NCT00000811_4_T0	COMPOUND	6	6	atovaquone
NCT000008114	NCT00000811_4_T1	COMPOUND	4	4	azithromycin
NCT000008118	NCT00000811_8_T0	GENE	9	9	atypical
NCT000008118	NCT00000811_8_T1	PHENOTYPE	7	7	mycoplasma
NCT000008118	NCT00000811_8_T2	PHENOTYPE	10	10	mycoplasma
NCT000008118	NCT00000811_8_T3	PHENOTYPE	21	22	HIV infection
NCT000008119	NCT00000811_9_T0	COMPOUND	4	4	atovaquone
NCT000008119	NCT00000811_9_T1	COMPOUND	6	6	azithromycin
NCT0000081111	NCT00000811_11_T0	PHENOTYPE	9	9	toxicity
NCT000008121	NCT00000812_1_T0	GENE	14	14	TNF-alpha
NCT000008121	NCT00000812_1_T1	GENE	20	20	TNF-alpha
NCT000008121	NCT00000812_1_T2	COMPOUND	6	6	thalidomide
NCT000008121	NCT00000812_1_T3	PHENOTYPE	21	21	inhibition
NCT000008121	NCT00000812_1_T4	GENE	11	13	tumor necrosis factor-alpha
NCT000008123	NCT00000812_3_T0	GENE	8	8	TNF-alpha
NCT000008123	NCT00000812_3_T1	COMPOUND	6	6	thalidomide
NCT000008123	NCT00000812_3_T2	PHENOTYPE	14	14	HIV
NCT000008124	NCT00000812_4_T0	COMPOUND	10	10	thalidomide
NCT000008126	NCT00000812_6_T0	GENE	8	8	TNF-alpha
NCT000008126	NCT00000812_6_T1	COMPOUND	6	6	thalidomide
NCT000008126	NCT00000812_6_T2	PHENOTYPE	14	14	HIV
NCT000008127	NCT00000812_7_T0	COMPOUND	10	10	thalidomide
NCT000008128	NCT00000812_8_T0	COMPOUND	6	6	thalidomide
NCT000008128	NCT00000812_8_T1	GENE	10	10	3-1
NCT0000081210	NCT00000812_10_T0	PHENOTYPE	23	23	toxicity
NCT0000081210	NCT00000812_10_T1	COMPOUND	20	20	thalidomide
NCT0000081210	NCT00000812_10_T2	GENE	1	1	MTD
NCT000008131	NCT00000813_1_T0	GENE	11	11	gp160
NCT000008132	NCT00000813_2_T0	GENE	11	11	SF-2
NCT000008132	NCT00000813_2_T1	GENE	6	6	gp160
NCT000008133	NCT00000813_3_T0	PHENOTYPE	13	13	strain
NCT000008133	NCT00000813_3_T1	PHENOTYPE	21	21	HIV
NCT000008133	NCT00000813_3_T2	GENE	7	7	gp160
NCT000008137	NCT00000813_7_T0	PHENOTYPE	30	30	rabies
NCT000008137	NCT00000813_7_T1	GENE	31	31	glycoprotein
NCT000008137	NCT00000813_7_T2	GENE	19	19	gp160
NCT000008138	NCT00000813_8_T0	PHENOTYPE	7	7	vaccinia
NCT000008138	NCT00000813_8_T1	PHENOTYPE	11	11	vaccinia
NCT000008138	NCT00000813_8_T2	PHENOTYPE	29	29	rabies
NCT000008138	NCT00000813_8_T3	GENE	30	30	glycoprotein
NCT000008138	NCT00000813_8_T4	GENE	18	18	gp160
NCT000008139	NCT00000813_9_T0	GENE	26	26	SF-2
NCT000008139	NCT00000813_9_T1	GENE	36	36	12
NCT000008139	NCT00000813_9_T2	GENE	23	23	booster
NCT000008139	NCT00000813_9_T3	GENE	42	42	booster
NCT000008139	NCT00000813_9_T4	GENE	9	9	gp160
NCT0000081310	NCT00000813_10_T0	GENE	13	13	SF-2
NCT0000081311	NCT00000813_11_T0	GENE	11	11	SF-2
NCT0000081312	NCT00000813_12_T0	PHENOTYPE	19	19	initiation
NCT0000081312	NCT00000813_12_T1	GENE	10	10	gp160
NCT000008140	NCT00000814_0_T0	PHENOTYPE	13	14	HIV Disease
NCT000008150	NCT00000815_0_T0	GENE	2	2	II
NCT000008150	NCT00000815_0_T1	PHENOTYPE	11	11	Measles
NCT000008150	NCT00000815_0_T2	PHENOTYPE	23	24	Pediatric AIDS
NCT000008153	NCT00000815_3_T0	PHENOTYPE	20	20	measles
NCT000008153	NCT00000815_3_T1	ORGAN	4	5	immune system
NCT000008153	NCT00000815_3_T2	PHENOTYPE	11	12	HIV infection
NCT000008154	NCT00000815_4_T0	PHENOTYPE	28	28	HIV
NCT000008154	NCT00000815_4_T1	PHENOTYPE	8	8	measles
NCT000008154	NCT00000815_4_T2	ORGAN	31	32	immune system
NCT000008154	NCT00000815_4_T3	PHENOTYPE	15	16	HIV infection
NCT000008156	NCT00000815_6_T0	PHENOTYPE	20	20	measles
NCT000008156	NCT00000815_6_T1	ORGAN	4	5	immune system
NCT000008156	NCT00000815_6_T2	PHENOTYPE	11	12	HIV infection
NCT000008157	NCT00000815_7_T0	PHENOTYPE	28	28	HIV
NCT000008157	NCT00000815_7_T1	PHENOTYPE	8	8	measles
NCT000008157	NCT00000815_7_T2	ORGAN	31	32	immune system
NCT000008157	NCT00000815_7_T3	PHENOTYPE	15	16	HIV infection
NCT000008158	NCT00000815_8_T0	PHENOTYPE	1	1	HIV
NCT000008158	NCT00000815_8_T1	PHENOTYPE	12	12	measles
NCT000008159	NCT00000815_9_T0	GENE	10	10	II
NCT000008160	NCT00000816_0_T0	PHENOTYPE	1	1	Initiation
NCT000008160	NCT00000816_0_T1	PHENOTYPE	6	8	Pneumocystis Carinii Pneumonia
NCT000008163	NCT00000816_3_T0	PHENOTYPE	22	23	adverse reactions
NCT000008165	NCT00000816_5_T0	PHENOTYPE	22	23	adverse reactions
NCT000008166	NCT00000816_6_T0	PHENOTYPE	15	15	initiation
NCT000008166	NCT00000816_6_T1	GENE	20	20	DS
NCT000008167	NCT00000816_7_T0	GENE	11	11	DS
NCT000008175	NCT00000817_5_T0	COMPOUND	32	32	amitriptyline
NCT000008180	NCT00000818_0_T0	GENE	23	23	CD4
NCT000008180	NCT00000818_0_T1	PHENOTYPE	8	8	Peripheral
NCT000008180	NCT00000818_0_T2	CELL	24	24	Cells
NCT000008180	NCT00000818_0_T3	TISSUE	11	12	Lymphoid Tissue
NCT000008184	NCT00000818_4_T0	PHENOTYPE	24	24	peripheral
NCT000008184	NCT00000818_4_T1	CELL	27	27	cells
NCT000008184	NCT00000818_4_T2	PHENOTYPE	7	7	HIV
NCT000008184	NCT00000818_4_T3	GENE	12	12	has
NCT000008184	NCT00000818_4_T4	ORGAN	22	22	plasma
NCT000008185	NCT00000818_5_T0	PHENOTYPE	20	20	HIV
NCT000008185	NCT00000818_5_T1	TISSUE	2	3	lymphoid tissues
NCT000008186	NCT00000818_6_T0	TISSUE	17	18	lymphoid tissue
NCT000008188	NCT00000818_8_T0	PHENOTYPE	20	20	HIV
NCT000008188	NCT00000818_8_T1	TISSUE	2	3	lymphoid tissues
NCT000008189	NCT00000818_9_T0	TISSUE	17	18	lymphoid tissue
NCT0000081811	NCT00000818_11_T0	TISSUE	3	4	lymph node
NCT000008191	NCT00000819_1_T0	COMPOUND	8	8	creatinine
NCT000008191	NCT00000819_1_T1	COMPOUND	12	12	creatinine
NCT000008191	NCT00000819_1_T2	COMPOUND	5	5	prednisone
NCT000008191	NCT00000819_1_T3	ORGAN	7	7	serum
NCT000008191	NCT00000819_1_T4	MOLECULAR_FUNCTION	9	10	urinary protein
NCT000008192	NCT00000819_2_T0	PHENOTYPE	5	6	heavy proteinuria
NCT000008192	NCT00000819_2_T1	PHENOTYPE	7	8	rapidly progressive
NCT000008192	NCT00000819_2_T2	PHENOTYPE	0	1	HIV nephropathy
NCT000008192	NCT00000819_2_T3	PHENOTYPE	8	10	progressive renal insufficiency
NCT000008194	NCT00000819_4_T0	PHENOTYPE	10	10	progression
NCT000008194	NCT00000819_4_T1	PHENOTYPE	12	13	HIV disease
NCT000008195	NCT00000819_5_T0	COMPOUND	16	16	prednisone
NCT000008195	NCT00000819_5_T1	PHENOTYPE	10	11	HIV nephropathy
NCT000008198	NCT00000819_8_T0	PHENOTYPE	10	10	progression
NCT000008198	NCT00000819_8_T1	PHENOTYPE	12	13	HIV disease
NCT000008199	NCT00000819_9_T0	COMPOUND	16	16	prednisone
NCT000008199	NCT00000819_9_T1	PHENOTYPE	10	11	HIV nephropathy
NCT0000081910	NCT00000819_10_T0	COMPOUND	5	5	prednisone
NCT000008201	NCT00000820_1_T0	GENE	6	6	IL-2
NCT000008203	NCT00000820_3_T0	PHENOTYPE	1	1	profound
NCT000008203	NCT00000820_3_T1	GENE	19	19	CD4
NCT000008203	NCT00000820_3_T2	CELL	26	26	cells
NCT000008203	NCT00000820_3_T3	GENE	29	29	IL-2
NCT000008203	NCT00000820_3_T4	PHENOTYPE	3	3	impairment
NCT000008203	NCT00000820_3_T5	CELL	20	21	T cells
NCT000008204	NCT00000820_4_T0	PHENOTYPE	10	10	impairment
NCT000008205	NCT00000820_5_T0	GENE	2	2	IL-2
NCT000008205	NCT00000820_5_T1	PHENOTYPE	11	11	immunosuppression
NCT000008205	NCT00000820_5_T2	PHENOTYPE	15	16	opportunistic infections
NCT000008206	NCT00000820_6_T0	GENE	14	14	IL-2
NCT000008208	NCT00000820_8_T0	PHENOTYPE	10	10	impairment
NCT000008209	NCT00000820_9_T0	GENE	2	2	IL-2
NCT000008209	NCT00000820_9_T1	PHENOTYPE	11	11	immunosuppression
NCT000008209	NCT00000820_9_T2	PHENOTYPE	15	16	opportunistic infections
NCT0000082010	NCT00000820_10_T0	GENE	14	14	IL-2
NCT0000082011	NCT00000820_11_T0	GENE	15	15	IL-2
NCT0000082011	NCT00000820_11_T1	GENE	32	32	IL-2
NCT0000082012	NCT00000820_12_T0	PHENOTYPE	6	6	influenza
NCT0000082012	NCT00000820_12_T1	PHENOTYPE	7	7	tetanus
NCT0000082012	NCT00000820_12_T2	PHENOTYPE	9	9	diphtheria
NCT0000082023	NCT00000820_23_T0	PHENOTYPE	3	4	substance abuse
NCT000008211	NCT00000821_1_T0	GENE	10	10	SC
NCT000008211	NCT00000821_1_T1	GENE	11	11	IL-2
NCT000008212	NCT00000821_2_T0	CELL	9	9	lymphocytes
NCT000008212	NCT00000821_2_T1	GENE	0	0	Interleukin-2
NCT000008213	NCT00000821_3_T0	GENE	15	15	SC
NCT000008213	NCT00000821_3_T1	GENE	29	29	CD4
NCT000008213	NCT00000821_3_T2	GENE	16	16	IL-2
NCT000008213	NCT00000821_3_T3	PHENOTYPE	23	23	infections
NCT000008215	NCT00000821_5_T0	GENE	15	15	SC
NCT000008215	NCT00000821_5_T1	GENE	29	29	CD4
NCT000008215	NCT00000821_5_T2	GENE	16	16	IL-2
NCT000008215	NCT00000821_5_T3	PHENOTYPE	23	23	infections
NCT000008220	NCT00000822_0_T0	GENE	30	30	CD4
NCT000008220	NCT00000822_0_T1	GENE	35	35	CD4
NCT000008220	NCT00000822_0_T2	GENE	17	17	AG
NCT000008220	NCT00000822_0_T3	CELL	31	32	T Cells
NCT000008220	NCT00000822_0_T4	CELL	36	37	T Cells
NCT000008225	NCT00000822_5_T0	PHENOTYPE	0	0	HIV
NCT000008225	NCT00000822_5_T1	PHENOTYPE	22	22	HIV
NCT000008225	NCT00000822_5_T2	PHENOTYPE	11	12	HIV disease
NCT000008225	NCT00000822_5_T3	PHENOTYPE	12	13	disease progression
NCT000008225	NCT00000822_5_T4	PHENOTYPE	25	26	disease progression
NCT000008227	NCT00000822_7_T0	GENE	2	2	CD4
NCT000008228	NCT00000822_8_T0	GENE	2	2	CD4
NCT000008228	NCT00000822_8_T1	COMPOUND	7	7	didanosine
NCT0000082212	NCT00000822_12_T0	COMPOUND	15	15	1
NCT0000082212	NCT00000822_12_T1	COMPOUND	32	32	1
NCT0000082212	NCT00000822_12_T2	GENE	27	27	has
NCT0000082214	NCT00000822_14_T0	GENE	8	8	CD4
NCT0000082214	NCT00000822_14_T1	PHENOTYPE	25	25	closed
NCT0000082214	NCT00000822_14_T2	CELL	9	10	T cells
NCT0000082215	NCT00000822_15_T0	COMPOUND	10	10	ritonavir
NCT000008241	NCT00000824_1_T0	PHENOTYPE	14	14	HIV
NCT000008241	NCT00000824_1_T1	ORGAN	10	11	immune system
NCT000008242	NCT00000824_2_T0	GENE	2	2	CD4
NCT000008242	NCT00000824_2_T1	CELL	15	15	lymphocytes
NCT000008242	NCT00000824_2_T2	CELL	20	20	cells
NCT000008242	NCT00000824_2_T3	PHENOTYPE	4	4	HIV
NCT000008242	NCT00000824_2_T4	PHENOTYPE	23	23	HIV
NCT000008242	NCT00000824_2_T5	CELL	12	13	dendritic cells
NCT000008243	NCT00000824_3_T0	CELL	9	9	lymphocytes
NCT000008243	NCT00000824_3_T1	PHENOTYPE	20	20	HIV
NCT000008243	NCT00000824_3_T2	CELL	6	7	dendritic cells
NCT000008243	NCT00000824_3_T3	BIOLOGICAL_PROCESS	25	26	immune response
NCT000008245	NCT00000824_5_T0	CELL	9	9	lymphocytes
NCT000008245	NCT00000824_5_T1	PHENOTYPE	20	20	HIV
NCT000008245	NCT00000824_5_T2	CELL	6	7	dendritic cells
NCT000008245	NCT00000824_5_T3	BIOLOGICAL_PROCESS	25	26	immune response
NCT000008246	NCT00000824_6_T0	CELL	3	3	lymphocytes
NCT000008246	NCT00000824_6_T1	CELL	0	1	Dendritic cells
NCT000008247	NCT00000824_7_T0	CELL	6	6	cells
NCT000008247	NCT00000824_7_T1	PHENOTYPE	0	0	HIV
NCT000008247	NCT00000824_7_T2	PHENOTYPE	12	12	HIV
NCT000008248	NCT00000824_8_T0	GENE	14	14	2.4
NCT000008250	NCT00000825_0_T0	GENE	13	13	CD4
NCT000008250	NCT00000825_0_T1	GENE	5	5	IL-2
NCT000008250	NCT00000825_0_T2	GENE	4	4	Interleukin-2
NCT000008252	NCT00000825_2_T0	GENE	12	12	IL-2
NCT000008252	NCT00000825_2_T1	ORGAN	16	17	immune system
NCT000008254	NCT00000825_4_T0	GENE	6	6	IL-2
NCT000008257	NCT00000825_7_T0	GENE	18	18	OR
NCT000008257	NCT00000825_7_T1	GENE	23	23	interleukin-2
NCT000008257	NCT00000825_7_T2	GENE	24	24	IL-2
NCT000008257	NCT00000825_7_T3	PHENOTYPE	1	1	HIV
NCT000008258	NCT00000825_8_T0	PHENOTYPE	5	5	toxicity
NCT000008258	NCT00000825_8_T1	GENE	6	6	DLT
NCT000008258	NCT00000825_8_T2	GENE	15	16	Group 1
NCT000008259	NCT00000825_9_T0	GENE	4	4	DLT
NCT0000082511	NCT00000825_11_T0	GENE	10	10	IL-2
NCT000008260	NCT00000826_0_T0	PHENOTYPE	8	8	Pharmacokinetics
NCT000008262	NCT00000826_2_T0	PHENOTYPE	19	20	HIV disease
NCT000008262	NCT00000826_2_T1	PHENOTYPE	6	7	opportunistic infection
NCT000008263	NCT00000826_3_T0	PHENOTYPE	5	5	pharmacokinetics
NCT000008263	NCT00000826_3_T1	PHENOTYPE	7	7	pharmacodynamic
NCT000008265	NCT00000826_5_T0	PHENOTYPE	5	5	pharmacokinetics
NCT000008265	NCT00000826_5_T1	PHENOTYPE	7	7	pharmacodynamic
NCT000008266	NCT00000826_6_T0	COMPOUND	15	15	fluconazole
NCT000008266	NCT00000826_6_T1	COMPOUND	16	16	rifabutin
NCT000008267	NCT00000826_7_T0	COMPOUND	13	13	rifabutin
NCT000008267	NCT00000826_7_T1	COMPOUND	10	10	clarithromycin
NCT000008268	NCT00000826_8_T0	COMPOUND	14	14	fluconazole
NCT000008268	NCT00000826_8_T1	COMPOUND	5	5	dapsone
NCT000008268	NCT00000826_8_T2	COMPOUND	15	15	rifabutin
NCT000008269	NCT00000826_9_T0	COMPOUND	17	17	rifabutin
NCT000008269	NCT00000826_9_T1	COMPOUND	14	14	clarithromycin
NCT000008271	NCT00000827_1_T0	GENE	3	3	has
NCT000008271	NCT00000827_1_T1	PHENOTYPE	12	13	HIV disease
NCT000008272	NCT00000827_2_T0	PHENOTYPE	4	4	HIV
NCT000008272	NCT00000827_2_T1	ORGAN	6	6	plasma
NCT000008275	NCT00000827_5_T0	PHENOTYPE	4	4	HIV
NCT000008275	NCT00000827_5_T1	ORGAN	6	6	plasma
NCT000008281	NCT00000828_1_T0	PHENOTYPE	1	1	HIV
NCT000008282	NCT00000828_2_T0	PHENOTYPE	40	40	strategies
NCT000008282	NCT00000828_2_T1	PHENOTYPE	4	4	strains
NCT000008284	NCT00000828_4_T0	PHENOTYPE	40	40	strategies
NCT000008284	NCT00000828_4_T1	PHENOTYPE	4	4	strains
NCT000008285	NCT00000828_5_T0	PHENOTYPE	0	0	HIV
NCT000008285	NCT00000828_5_T1	BIOLOGICAL_PROCESS	8	8	gestation
NCT000008286	NCT00000828_6_T0	PHENOTYPE	5	5	HIV
NCT000008287	NCT00000828_7_T0	PHENOTYPE	5	5	HIV
NCT000008292	NCT00000829_2_T0	PHENOTYPE	13	13	bacteremia
NCT000008292	NCT00000829_2_T1	PHENOTYPE	10	11	pneumococcal infection
NCT000008292	NCT00000829_2_T2	PHENOTYPE	2	3	HIV infection
NCT0000082917	NCT00000829_17_T0	PHENOTYPE	8	8	Acute
NCT0000082917	NCT00000829_17_T1	PHENOTYPE	15	15	fever
NCT000008300	NCT00000830_0_T0	PHENOTYPE	1	1	Pharmacokinetics
NCT000008300	NCT00000830_0_T1	CELL	12	12	Cells
NCT000008300	NCT00000830_0_T2	CELL	14	14	Cells
NCT000008300	NCT00000830_0_T3	ORGAN	9	10	Cord Blood
NCT000008302	NCT00000830_2_T0	CELL	15	15	cells
NCT000008302	NCT00000830_2_T1	COMPOUND	9	9	triphosphate
NCT000008312	NCT00000831_2_T0	COMPOUND	9	9	zidovudine
NCT000008312	NCT00000831_2_T1	COMPOUND	42	42	didanosine
NCT000008312	NCT00000831_2_T2	COMPOUND	22	22	lamivudine
NCT000008313	NCT00000831_3_T0	GENE	20	21	reverse transcriptase
NCT000008330	NCT00000833_0_T0	GENE	15	15	ed
NCT000008332	NCT00000833_2_T0	PHENOTYPE	3	3	toxicity
NCT000008332	NCT00000833_2_T1	PHENOTYPE	12	12	toxicity
NCT000008333	NCT00000833_3_T0	COMPOUND	6	6	ribavirin
NCT000008333	NCT00000833_3_T1	PHENOTYPE	9	9	pharmacokinetics
NCT000008334	NCT00000833_4_T0	COMPOUND	5	5	ribavirin
NCT000008335	NCT00000833_5_T0	PHENOTYPE	21	21	toxicity
NCT000008335	NCT00000833_5_T1	COMPOUND	12	12	didanosine
NCT000008336	NCT00000833_6_T0	BIOLOGICAL_PROCESS	4	4	metabolism
NCT000008338	NCT00000833_8_T0	BIOLOGICAL_PROCESS	4	4	metabolism
NCT000008340	NCT00000834_0_T0	PHENOTYPE	7	8	HIV Infection
NCT000008343	NCT00000834_3_T0	GENE	7	7	II
NCT000008343	NCT00000834_3_T1	PHENOTYPE	12	12	HIV
NCT000008343	NCT00000834_3_T2	GENE	9	9	III
NCT000008344	NCT00000834_4_T0	PHENOTYPE	15	15	chronic
NCT000008344	NCT00000834_4_T1	PHENOTYPE	1	2	HIV infection
NCT000008346	NCT00000834_6_T0	COMPOUND	4	4	methotrexate
NCT000008346	NCT00000834_6_T1	PHENOTYPE	19	19	chronic
NCT000008349	NCT00000834_9_T0	COMPOUND	4	4	methotrexate
NCT000008349	NCT00000834_9_T1	PHENOTYPE	19	19	chronic
NCT0000083410	NCT00000834_10_T0	COMPOUND	5	5	methotrexate
NCT0000083411	NCT00000834_11_T0	COMPOUND	20	20	methotrexate
NCT000008352	NCT00000835_2_T0	GENE	3	3	gag
NCT000008352	NCT00000835_2_T1	GENE	9	10	envelope glycoprotein
NCT000008353	NCT00000835_3_T0	GENE	12	12	pigs
NCT000008353	NCT00000835_3_T1	GENE	3	3	has
NCT000008355	NCT00000835_5_T0	GENE	3	3	gag
NCT000008355	NCT00000835_5_T1	GENE	9	10	envelope glycoprotein
NCT000008356	NCT00000835_6_T0	GENE	12	12	pigs
NCT000008356	NCT00000835_6_T1	GENE	3	3	has
NCT000008359	NCT00000835_9_T0	GENE	0	1	Group I
NCT0000083510	NCT00000835_10_T0	GENE	1	1	II
NCT0000083511	NCT00000835_11_T0	GENE	1	1	III
NCT0000083512	NCT00000835_12_T0	GENE	1	2	Group I
NCT0000083520	NCT00000835_20_T0	PHENOTYPE	4	5	HIV infection
NCT000008363	NCT00000836_3_T0	PHENOTYPE	7	7	relapse
NCT000008366	NCT00000836_6_T0	PHENOTYPE	7	7	relapse
NCT000008371	NCT00000837_1_T0	PHENOTYPE	17	17	zoster
NCT000008371	NCT00000837_1_T1	COMPOUND	8	8	VZV
NCT000008371	NCT00000837_1_T2	PHENOTYPE	13	13	chickenpox
NCT000008371	NCT00000837_1_T3	PHENOTYPE	16	16	shingles
NCT000008371	NCT00000837_1_T4	PHENOTYPE	14	14	varicella
NCT000008371	NCT00000837_1_T5	PHENOTYPE	5	6	varicella zoster
NCT000008373	NCT00000837_3_T0	COMPOUND	3	3	VZV
NCT000008373	NCT00000837_3_T1	GENE	6	6	has
NCT000008374	NCT00000837_4_T0	PHENOTYPE	12	12	HIV
NCT000008376	NCT00000837_6_T0	GENE	7	7	globulin
NCT000008378	NCT00000837_8_T0	PHENOTYPE	29	29	seronegative
NCT000008378	NCT00000837_8_T1	COMPOUND	31	31	VZV
NCT000008378	NCT00000837_8_T2	PHENOTYPE	4	5	varicella zoster
NCT000008378	NCT00000837_8_T3	PHENOTYPE	33	34	cytomegalovirus infection
NCT000008379	NCT00000837_9_T0	PHENOTYPE	8	8	varicella
NCT0000083710	NCT00000837_10_T0	PHENOTYPE	9	10	HIV infection
NCT0000083713	NCT00000837_13_T0	GENE	6	6	CD4
NCT0000083713	NCT00000837_13_T1	PHENOTYPE	18	18	HIV
NCT0000083713	NCT00000837_13_T2	GENE	3	3	had
NCT000008382	NCT00000838_2_T0	PHENOTYPE	6	6	mutation
NCT000008385	NCT00000838_5_T0	PHENOTYPE	6	6	mutation
NCT000008391	NCT00000839_1_T0	PHENOTYPE	5	5	toxicity
NCT000008392	NCT00000839_2_T0	PHENOTYPE	15	16	HIV infection
NCT000008393	NCT00000839_3_T0	PHENOTYPE	8	8	HIV
NCT000008393	NCT00000839_3_T1	PHENOTYPE	16	16	pharmacokinetics
NCT000008393	NCT00000839_3_T2	GENE	2	2	has
NCT000008393	NCT00000839_3_T3	GENE	22	22	has
NCT000008395	NCT00000839_5_T0	PHENOTYPE	8	8	HIV
NCT000008395	NCT00000839_5_T1	PHENOTYPE	16	16	pharmacokinetics
NCT000008395	NCT00000839_5_T2	GENE	2	2	has
NCT000008395	NCT00000839_5_T3	GENE	22	22	has
NCT000008396	NCT00000839_6_T0	PHENOTYPE	12	12	pharmacokinetics
NCT000008396	NCT00000839_6_T1	GENE	4	4	IV
NCT0000083910	NCT00000839_10_T0	PHENOTYPE	0	0	Pharmacokinetics
NCT0000083912	NCT00000839_12_T0	PHENOTYPE	2	2	cord
NCT0000083912	NCT00000839_12_T1	GENE	11	11	has
NCT0000083912	NCT00000839_12_T2	GENE	14	14	IV
NCT000008401	NCT00000840_1_T0	PHENOTYPE	53	53	initiation
NCT000008401	NCT00000840_1_T1	PHENOTYPE	5	5	HIV
NCT000008401	NCT00000840_1_T2	ORGAN	9	9	plasma
NCT000008402	NCT00000840_2_T0	GENE	10	10	has
NCT000008402	NCT00000840_2_T1	PHENOTYPE	8	9	drug withdrawal
NCT000008404	NCT00000840_4_T0	GENE	10	10	has
NCT000008404	NCT00000840_4_T1	PHENOTYPE	8	9	drug withdrawal
NCT000008405	NCT00000840_5_T0	GENE	6	6	cease
NCT000008412	NCT00000841_2_T0	COMPOUND	5	5	sulfate
NCT000008412	NCT00000841_2_T1	GENE	0	0	Protease
NCT000008412	NCT00000841_2_T2	COMPOUND	4	4	indinavir
NCT000008412	NCT00000841_2_T3	PHENOTYPE	13	14	HIV disease
NCT000008413	NCT00000841_3_T0	COMPOUND	22	22	sulfate
NCT000008413	NCT00000841_3_T1	COMPOUND	21	21	indinavir
NCT000008415	NCT00000841_5_T0	COMPOUND	22	22	sulfate
NCT000008415	NCT00000841_5_T1	COMPOUND	21	21	indinavir
NCT000008416	NCT00000841_6_T0	COMPOUND	13	13	sulfate
NCT000008416	NCT00000841_6_T1	COMPOUND	12	12	indinavir
NCT000008417	NCT00000841_7_T0	COMPOUND	17	17	stavudine
NCT000008417	NCT00000841_7_T1	PHENOTYPE	8	9	progressive disease
NCT000008423	NCT00000842_3_T0	PHENOTYPE	5	5	HIV
NCT000008423	NCT00000842_3_T1	PHENOTYPE	6	7	sensory neuropathy
NCT000008428	NCT00000842_8_T0	COMPOUND	15	15	stavudine
NCT000008428	NCT00000842_8_T1	COMPOUND	12	12	didanosine
NCT000008428	NCT00000842_8_T2	COMPOUND	13	13	zalcitabine
NCT0000084218	NCT00000842_18_T0	PHENOTYPE	3	4	alcohol abuse
NCT000008432	NCT00000843_2_T0	COMPOUND	7	7	adefovir
NCT000008432	NCT00000843_2_T1	GENE	15	15	has
NCT000008439	NCT00000843_9_T0	PHENOTYPE	14	14	toxicity
NCT0000084311	NCT00000843_11_T0	PHENOTYPE	2	2	concentrations
NCT0000084311	NCT00000843_11_T1	ORGAN	0	0	Serum
NCT000008440	NCT00000844_0_T0	GENE	19	19	CD4
NCT000008440	NCT00000844_0_T1	GENE	13	13	Alpha
NCT000008440	NCT00000844_0_T2	GENE	14	14	Interferon
NCT000008452	NCT00000845_2_T0	GENE	5	5	A33
NCT000008452	NCT00000845_2_T1	GENE	6	6	B8
NCT000008452	NCT00000845_2_T2	GENE	7	7	B27
NCT000008452	NCT00000845_2_T3	GENE	10	10	Bw62
NCT000008454	NCT00000845_4_T0	GENE	13	13	II
NCT000008454	NCT00000845_4_T1	GENE	0	1	Group 1
NCT000008455	NCT00000845_5_T0	GENE	4	4	II
NCT000008455	NCT00000845_5_T1	GENE	5	5	wil
NCT000008455	NCT00000845_5_T2	PHENOTYPE	21	22	adverse events
NCT000008455	NCT00000845_5_T3	GENE	12	13	Group I
NCT000008467	NCT00000846_7_T0	GENE	11	11	II
NCT000008467	NCT00000846_7_T1	GENE	8	8	deltoid
NCT000008467	NCT00000846_7_T2	ORGAN	18	18	thigh
NCT000008467	NCT00000846_7_T3	GENE	0	1	Group I
NCT000008472	NCT00000847_2_T0	PHENOTYPE	7	7	HIV
NCT000008472	NCT00000847_2_T1	PHENOTYPE	5	5	strains
NCT000008473	NCT00000847_3_T0	PHENOTYPE	6	6	strain
NCT000008473	NCT00000847_3_T1	PHENOTYPE	8	8	HIV
NCT000008474	NCT00000847_4_T0	PHENOTYPE	17	17	strain
NCT000008474	NCT00000847_4_T1	ORGAN	8	9	immune system
NCT000008476	NCT00000847_6_T0	PHENOTYPE	7	7	HIV
NCT000008476	NCT00000847_6_T1	PHENOTYPE	5	5	strains
NCT000008477	NCT00000847_7_T0	PHENOTYPE	6	6	strain
NCT000008477	NCT00000847_7_T1	PHENOTYPE	8	8	HIV
NCT000008478	NCT00000847_8_T0	PHENOTYPE	17	17	strain
NCT000008478	NCT00000847_8_T1	ORGAN	8	9	immune system
NCT000008479	NCT00000847_9_T0	PHENOTYPE	24	24	rabies
NCT000008479	NCT00000847_9_T1	GENE	25	25	glycoprotein
NCT000008479	NCT00000847_9_T2	GENE	18	18	SF2
NCT000008481	NCT00000848_1_T0	PHENOTYPE	2	2	HIV
NCT000008485	NCT00000848_5_T0	COMPOUND	7	7	saquinavir
NCT000008485	NCT00000848_5_T1	COMPOUND	15	15	saquinavir
NCT000008485	NCT00000848_5_T2	COMPOUND	23	23	saquinavir
NCT000008485	NCT00000848_5_T3	COMPOUND	25	25	indinavir
NCT000008486	NCT00000848_6_T0	COMPOUND	13	13	indinavir
NCT000008489	NCT00000848_9_T0	BIOLOGICAL_PROCESS	4	5	antiviral response
NCT0000084812	NCT00000848_12_T0	COMPOUND	4	4	saquinavir
NCT0000084812	NCT00000848_12_T1	COMPOUND	13	13	indinavir
NCT0000084814	NCT00000848_14_T0	COMPOUND	2	2	indinavir
NCT000008491	NCT00000849_1_T0	ORGAN	10	11	immune system
NCT000008492	NCT00000849_2_T0	GENE	0	0	IL-2
NCT000008492	NCT00000849_2_T1	CELL	9	11	white blood cells
NCT000008493	NCT00000849_3_T0	GENE	6	6	IL-2
NCT000008493	NCT00000849_3_T1	PHENOTYPE	0	0	HIV
NCT000008493	NCT00000849_3_T2	ORGAN	18	19	immune system
NCT000008494	NCT00000849_4_T0	PHENOTYPE	14	14	HIV
NCT000008496	NCT00000849_6_T0	GENE	2	2	IL-2
NCT000008499	NCT00000849_9_T0	GENE	11	11	IL-2
NCT0000084913	NCT00000849_13_T0	PHENOTYPE	21	21	toxicity
NCT0000084914	NCT00000849_14_T0	PHENOTYPE	14	14	toxicity
NCT0000084914	NCT00000849_14_T1	PHENOTYPE	9	9	experiences
NCT0000084915	NCT00000849_15_T0	PHENOTYPE	12	12	toxicity
NCT0000084915	NCT00000849_15_T1	PHENOTYPE	7	7	experiences
NCT000008502	NCT00000850_2_T0	PHENOTYPE	7	7	leukemia
NCT000008502	NCT00000850_2_T1	GENE	0	0	GM-CSF
NCT000008502	NCT00000850_2_T2	ORGAN	15	15	transplants
NCT000008502	NCT00000850_2_T3	ORGAN	13	14	bone marrow
NCT000008502	NCT00000850_2_T4	ORGAN	26	27	immune systems
NCT000008502	NCT00000850_2_T5	CELL	19	21	white blood cells
NCT000008505	NCT00000850_5_T0	PHENOTYPE	6	6	maturation
NCT000008505	NCT00000850_5_T1	CELL	22	22	cells
NCT000008505	NCT00000850_5_T2	GENE	11	11	GM-CSF
NCT000008507	NCT00000850_7_T0	GENE	12	12	GM-CSF
NCT000008509	NCT00000850_9_T0	GENE	9	9	CD4
NCT0000085011	NCT00000850_11_T0	GENE	8	8	ART
NCT0000085013	NCT00000850_13_T0	GENE	2	2	CD4
NCT0000085014	NCT00000850_14_T0	GENE	12	12	log
NCT0000085014	NCT00000850_14_T1	GENE	27	27	CD4
NCT0000085014	NCT00000850_14_T2	CELL	37	37	cells
NCT0000085016	NCT00000850_16_T0	GENE	12	12	ACTG
NCT0000085016	NCT00000850_16_T1	GENE	22	22	GM-CSF
NCT000008511	NCT00000851_1_T0	PHENOTYPE	21	21	concentrations
NCT000008511	NCT00000851_1_T1	PHENOTYPE	19	19	HIV
NCT000008511	NCT00000851_1_T2	ORGAN	18	18	plasma
NCT000008513	NCT00000851_3_T0	GENE	35	35	CD4
NCT000008513	NCT00000851_3_T1	PHENOTYPE	14	14	HIV
NCT000008513	NCT00000851_3_T2	CELL	36	36	lymphocyte
NCT000008514	NCT00000851_4_T0	PHENOTYPE	15	16	HIV disease
NCT000008516	NCT00000851_6_T0	PHENOTYPE	15	16	HIV disease
NCT000008520	NCT00000852_0_T0	CELL	5	5	Lymphocyte
NCT000008520	NCT00000852_0_T1	PHENOTYPE	8	9	HIV Infection
NCT000008522	NCT00000852_2_T0	CELL	8	8	lymphocytes
NCT000008522	NCT00000852_2_T1	PHENOTYPE	13	13	HIV
NCT000008522	NCT00000852_2_T2	PHENOTYPE	11	11	circulation
NCT000008522	NCT00000852_2_T3	PHENOTYPE	24	24	immunity
NCT000008523	NCT00000852_3_T0	PHENOTYPE	4	4	immunity
NCT000008528	NCT00000852_8_T0	PHENOTYPE	15	15	HIV
NCT000008528	NCT00000852_8_T1	CELL	0	0	Lymphocytes
NCT000008529	NCT00000852_9_T0	CELL	5	5	lymphocytes
NCT000008534	NCT00000853_4_T0	PHENOTYPE	10	11	antibody response
NCT000008536	NCT00000853_6_T0	GENE	33	33	interleukin-5
NCT000008536	NCT00000853_6_T1	GENE	32	32	interleukin-4
NCT000008536	NCT00000853_6_T2	GENE	31	31	interleukin-2
NCT000008536	NCT00000853_6_T3	GENE	22	22	lymphoproliferation
NCT000008536	NCT00000853_6_T4	GENE	3	3	has
NCT000008536	NCT00000853_6_T5	GENE	26	26	TH1
NCT000008536	NCT00000853_6_T6	GENE	35	35	interleukin-10
NCT000008536	NCT00000853_6_T7	BIOLOGICAL_PROCESS	16	17	immune response
NCT000008539	NCT00000853_9_T0	PHENOTYPE	10	11	antibody response
NCT0000085311	NCT00000853_11_T0	GENE	33	33	interleukin-5
NCT0000085311	NCT00000853_11_T1	GENE	32	32	interleukin-4
NCT0000085311	NCT00000853_11_T2	GENE	31	31	interleukin-2
NCT0000085311	NCT00000853_11_T3	GENE	22	22	lymphoproliferation
NCT0000085311	NCT00000853_11_T4	GENE	3	3	has
NCT0000085311	NCT00000853_11_T5	GENE	26	26	TH1
NCT0000085311	NCT00000853_11_T6	GENE	35	35	interleukin-10
NCT0000085311	NCT00000853_11_T7	BIOLOGICAL_PROCESS	16	17	immune response
NCT0000085316	NCT00000853_16_T0	GENE	3	3	has
NCT000008540	NCT00000854_0_T0	PHENOTYPE	13	14	Weight Loss
NCT000008542	NCT00000854_2_T0	PHENOTYPE	0	0	Wasting
NCT000008542	NCT00000854_2_T1	GENE	1	1	has
NCT000008545	NCT00000854_5_T0	PHENOTYPE	13	13	wasting
NCT000008545	NCT00000854_5_T1	GENE	2	2	has
NCT000008548	NCT00000854_8_T0	PHENOTYPE	2	2	hopes
NCT000008549	NCT00000854_9_T0	COMPOUND	7	8	nandrolone decanoate
NCT0000085410	NCT00000854_10_T0	COMPOUND	17	17	nandrolone
NCT000008550	NCT00000855_0_T0	PHENOTYPE	12	13	Premature Infants
NCT000008552	NCT00000855_2_T0	PHENOTYPE	10	10	HIV
NCT000008552	NCT00000855_2_T1	GENE	1	1	has
NCT000008553	NCT00000855_3_T0	GENE	2	2	has
NCT000008553	NCT00000855_3_T1	GENE	16	16	has
NCT000008553	NCT00000855_3_T2	PHENOTYPE	8	9	premature babies
NCT000008555	NCT00000855_5_T0	PHENOTYPE	17	17	toxicity
NCT000008555	NCT00000855_5_T1	PHENOTYPE	2	3	premature infants
NCT000008556	NCT00000855_6_T0	PHENOTYPE	10	10	toxicity
NCT000008556	NCT00000855_6_T1	PHENOTYPE	7	7	pharmacokinetics
NCT000008556	NCT00000855_6_T2	PHENOTYPE	18	18	pharmacokinetics
NCT000008556	NCT00000855_6_T3	PHENOTYPE	20	21	premature infants
NCT000008557	NCT00000855_7_T0	PHENOTYPE	0	1	Premature infants
NCT000008559	NCT00000855_9_T0	ORGAN	5	5	serum
NCT000008562	NCT00000856_2_T0	COMPOUND	9	9	ganciclovir
NCT000008562	NCT00000856_2_T1	COMPOUND	11	11	foscarnet
NCT000008563	NCT00000856_3_T0	COMPOUND	7	7	ganciclovir
NCT000008563	NCT00000856_3_T1	COMPOUND	9	9	foscarnet
NCT000008564	NCT00000856_4_T0	GENE	9	9	CSF
NCT000008564	NCT00000856_4_T1	PHENOTYPE	20	20	diseases
NCT000008568	NCT00000856_8_T0	COMPOUND	7	7	ganciclovir
NCT000008568	NCT00000856_8_T1	COMPOUND	9	9	foscarnet
NCT000008569	NCT00000856_9_T0	GENE	9	9	CSF
NCT000008569	NCT00000856_9_T1	PHENOTYPE	20	20	diseases
NCT0000085613	NCT00000856_13_T0	PHENOTYPE	4	4	encephalitis
NCT0000085613	NCT00000856_13_T1	PHENOTYPE	14	14	encephalitis
NCT0000085613	NCT00000856_13_T2	GENE	2	2	has
NCT0000085615	NCT00000856_15_T0	COMPOUND	11	11	ganciclovir
NCT0000085615	NCT00000856_15_T1	COMPOUND	9	9	foscarnet
NCT0000085616	NCT00000856_16_T0	COMPOUND	12	12	ganciclovir
NCT0000085616	NCT00000856_16_T1	COMPOUND	14	14	ganciclovir
NCT0000085616	NCT00000856_16_T2	COMPOUND	10	10	foscarnet
NCT0000085617	NCT00000856_17_T0	COMPOUND	16	16	ganciclovir
NCT0000085617	NCT00000856_17_T1	COMPOUND	14	14	foscarnet
NCT0000085629	NCT00000856_29_T0	ORGAN	0	1	Bone marrow
NCT000008570	NCT00000857_0_T0	GENE	13	13	CD4
NCT000008572	NCT00000857_2_T0	PHENOTYPE	15	15	HIV
NCT000008572	NCT00000857_2_T1	PHENOTYPE	17	17	HIV
NCT000008572	NCT00000857_2_T2	ORGAN	12	13	immune system
NCT000008572	NCT00000857_2_T3	PHENOTYPE	18	19	bacterial infections
NCT000008573	NCT00000857_3_T0	GENE	0	0	IL-12
NCT000008574	NCT00000857_4_T0	CELL	12	12	cells
NCT000008574	NCT00000857_4_T1	PHENOTYPE	3	3	HIV
NCT000008574	NCT00000857_4_T2	GENE	0	0	IL-12
NCT000008574	NCT00000857_4_T3	ORGAN	4	5	immune system
NCT000008575	NCT00000857_5_T0	GENE	0	0	IL-12
NCT000008575	NCT00000857_5_T1	GENE	16	16	MAC
NCT000008575	NCT00000857_5_T2	PHENOTYPE	9	10	bacterial infections
NCT000008575	NCT00000857_5_T3	PHENOTYPE	13	15	Mycobacterium avium complex
NCT000008577	NCT00000857_7_T0	GENE	8	8	CD4
NCT0000085713	NCT00000857_13_T0	GENE	6	6	CD4
NCT000008581	NCT00000858_1_T0	PHENOTYPE	6	6	HIV
NCT000008581	NCT00000858_1_T1	GENE	18	18	VCS
NCT000008584	NCT00000858_4_T0	PHENOTYPE	10	11	HIV infection
NCT000008585	NCT00000858_5_T0	PHENOTYPE	9	10	HIV disease
NCT000008585	NCT00000858_5_T1	PHENOTYPE	24	25	disease progression
NCT000008587	NCT00000858_7_T0	PHENOTYPE	10	11	HIV infection
NCT000008588	NCT00000858_8_T0	PHENOTYPE	9	10	HIV disease
NCT000008588	NCT00000858_8_T1	PHENOTYPE	24	25	disease progression
NCT0000085810	NCT00000858_10_T0	PHENOTYPE	19	19	HIV
NCT0000085812	NCT00000858_12_T0	PHENOTYPE	25	25	peripheral
NCT0000085812	NCT00000858_12_T1	GENE	19	19	VCS
NCT0000085813	NCT00000858_13_T0	GENE	4	4	CPT
NCT0000085813	NCT00000858_13_T1	GENE	3	3	ml
NCT0000085813	NCT00000858_13_T2	GENE	19	19	ml
NCT000008593	NCT00000859_3_T0	PHENOTYPE	11	11	toxicity
NCT000008593	NCT00000859_3_T1	GENE	0	0	AR
NCT000008593	NCT00000859_3_T2	PHENOTYPE	9	9	suppression
NCT000008593	NCT00000859_3_T3	PHENOTYPE	17	17	resistant
NCT000008593	NCT00000859_3_T4	PHENOTYPE	18	18	strains
NCT000008594	NCT00000859_4_T0	GENE	8	8	protease
NCT000008594	NCT00000859_4_T1	GENE	4	4	AR
NCT000008594	NCT00000859_4_T2	PHENOTYPE	7	7	HIV
NCT000008594	NCT00000859_4_T3	PHENOTYPE	14	14	HIV
NCT000008595	NCT00000859_5_T0	GENE	5	5	protease
NCT000008595	NCT00000859_5_T1	PHENOTYPE	19	20	HIV disease
NCT000008597	NCT00000859_7_T0	PHENOTYPE	11	11	toxicity
NCT000008597	NCT00000859_7_T1	GENE	0	0	AR
NCT000008597	NCT00000859_7_T2	PHENOTYPE	9	9	suppression
NCT000008597	NCT00000859_7_T3	PHENOTYPE	17	17	resistant
NCT000008597	NCT00000859_7_T4	PHENOTYPE	18	18	strains
NCT000008598	NCT00000859_8_T0	GENE	8	8	protease
NCT000008598	NCT00000859_8_T1	GENE	4	4	AR
NCT000008598	NCT00000859_8_T2	PHENOTYPE	7	7	HIV
NCT000008598	NCT00000859_8_T3	PHENOTYPE	14	14	HIV
NCT000008599	NCT00000859_9_T0	GENE	5	5	protease
NCT000008599	NCT00000859_9_T1	PHENOTYPE	19	20	HIV disease
NCT0000085910	NCT00000859_10_T0	GENE	10	10	AR
NCT0000085910	NCT00000859_10_T1	GENE	18	18	AR
NCT0000085911	NCT00000859_11_T0	GENE	12	12	protease
NCT0000085911	NCT00000859_11_T1	GENE	1	1	AR
NCT0000085912	NCT00000859_12_T0	GENE	10	11	protease inhibitor
NCT0000085915	NCT00000859_15_T0	GENE	4	4	protease
NCT0000085916	NCT00000859_16_T0	GENE	6	6	AR
NCT000008601	NCT00000860_1_T0	GENE	2	2	MAC
NCT000008603	NCT00000860_3_T0	GENE	5	5	MAC
NCT000008603	NCT00000860_3_T1	GENE	11	11	MAC
NCT000008604	NCT00000860_4_T0	GENE	5	5	MAC
NCT000008604	NCT00000860_4_T1	GENE	10	10	MAC
NCT000008604	NCT00000860_4_T2	GENE	21	21	MAC
NCT000008605	NCT00000860_5_T0	PHENOTYPE	11	11	symptoms
NCT000008605	NCT00000860_5_T1	COMPOUND	4	4	clarithromycin
NCT000008605	NCT00000860_5_T2	GENE	2	2	MAC
NCT000008607	NCT00000860_7_T0	GENE	19	19	MAC
NCT0000086010	NCT00000860_10_T0	GENE	5	5	MAC
NCT0000086010	NCT00000860_10_T1	GENE	11	11	MAC
NCT0000086011	NCT00000860_11_T0	GENE	5	5	MAC
NCT0000086011	NCT00000860_11_T1	GENE	10	10	MAC
NCT0000086011	NCT00000860_11_T2	GENE	21	21	MAC
NCT0000086012	NCT00000860_12_T0	PHENOTYPE	11	11	symptoms
NCT0000086012	NCT00000860_12_T1	COMPOUND	4	4	clarithromycin
NCT0000086012	NCT00000860_12_T2	GENE	2	2	MAC
NCT0000086014	NCT00000860_14_T0	GENE	19	19	MAC
NCT0000086015	NCT00000860_15_T0	COMPOUND	14	14	clarithromycin
NCT0000086015	NCT00000860_15_T1	GENE	4	4	MAC
NCT0000086015	NCT00000860_15_T2	GENE	16	16	MAC
NCT0000086019	NCT00000860_19_T0	COMPOUND	20	20	clarithromycin
NCT0000086019	NCT00000860_19_T1	GENE	25	25	MAC
NCT000008611	NCT00000861_1_T0	GENE	23	23	AR
NCT000008611	NCT00000861_1_T1	PHENOTYPE	7	7	strategies
NCT000008613	NCT00000861_3_T0	PHENOTYPE	22	22	initiation
NCT000008613	NCT00000861_3_T1	GENE	24	25	protease inhibitor
NCT000008613	NCT00000861_3_T2	PHENOTYPE	29	30	disease progression
NCT000008613	NCT00000861_3_T3	PHENOTYPE	48	49	decision making
NCT000008616	NCT00000861_6_T0	PHENOTYPE	22	22	initiation
NCT000008616	NCT00000861_6_T1	GENE	24	25	protease inhibitor
NCT000008616	NCT00000861_6_T2	PHENOTYPE	29	30	disease progression
NCT000008616	NCT00000861_6_T3	PHENOTYPE	48	49	decision making
NCT000008617	NCT00000861_7_T0	COMPOUND	15	15	zidovudine
NCT000008617	NCT00000861_7_T1	COMPOUND	18	18	lamivudine
NCT000008621	NCT00000862_1_T0	PHENOTYPE	3	3	tolerance
NCT000008621	NCT00000862_1_T1	PHENOTYPE	21	21	vomiting
NCT000008623	NCT00000862_3_T0	GENE	7	7	ACTG
NCT000008623	NCT00000862_3_T1	GENE	18	18	ACTG
NCT000008623	NCT00000862_3_T2	GENE	12	12	IV
NCT000008624	NCT00000862_4_T0	GENE	30	30	ACTG
NCT000008625	NCT00000862_5_T0	PHENOTYPE	14	15	early labor
NCT000008627	NCT00000862_7_T0	GENE	7	7	ACTG
NCT000008627	NCT00000862_7_T1	GENE	18	18	ACTG
NCT000008627	NCT00000862_7_T2	GENE	12	12	IV
NCT000008628	NCT00000862_8_T0	GENE	30	30	ACTG
NCT000008629	NCT00000862_9_T0	PHENOTYPE	14	15	early labor
NCT0000086210	NCT00000862_10_T0	COMPOUND	1	1	1
NCT0000086210	NCT00000862_10_T1	GENE	17	17	PK
NCT0000086211	NCT00000862_11_T0	PHENOTYPE	11	11	dilation
NCT0000086211	NCT00000862_11_T1	GENE	10	10	cm
NCT0000086211	NCT00000862_11_T2	GENE	1	1	PK
NCT0000086211	NCT00000862_11_T3	GENE	17	17	IV
NCT0000086212	NCT00000862_12_T0	GENE	9	9	PK
NCT0000086212	NCT00000862_12_T1	ORGAN	7	7	serum
NCT0000086212	NCT00000862_12_T2	ORGAN	1	2	cord blood
NCT0000086213	NCT00000862_13_T0	ORGAN	11	11	serum
NCT0000086213	NCT00000862_13_T1	PHENOTYPE	12	13	drug levels
NCT000008631	NCT00000863_1_T0	PHENOTYPE	5	5	tolerance
NCT000008632	NCT00000863_2_T0	PHENOTYPE	8	8	concentrations
NCT000008632	NCT00000863_2_T1	ORGAN	5	5	plasma
NCT000008642	NCT00000864_2_T0	PHENOTYPE	20	20	HIV
NCT000008642	NCT00000864_2_T1	PHENOTYPE	9	11	slow disease progression
NCT000008643	NCT00000864_3_T0	PHENOTYPE	1	1	HIV
NCT000008643	NCT00000864_3_T1	PHENOTYPE	2	2	suppression
NCT000008643	NCT00000864_3_T2	ORGAN	14	15	immune system
NCT000008643	NCT00000864_3_T3	PHENOTYPE	20	21	HIV infection
NCT000008646	NCT00000864_6_T0	PHENOTYPE	19	19	progression
NCT000008647	NCT00000864_7_T0	GENE	37	37	reduced
NCT000008647	NCT00000864_7_T1	PHENOTYPE	17	17	maturation
NCT000008647	NCT00000864_7_T2	PHENOTYPE	4	4	suppression
NCT000008647	NCT00000864_7_T3	PHENOTYPE	38	39	disease progression
NCT0000086411	NCT00000864_11_T0	PHENOTYPE	15	15	toxicity
NCT000008652	NCT00000865_2_T0	PHENOTYPE	19	20	HIV infection
NCT000008652	NCT00000865_2_T1	PHENOTYPE	20	22	infection in children
NCT000008658	NCT00000865_8_T0	PHENOTYPE	13	13	toxicity
NCT000008658	NCT00000865_8_T1	PHENOTYPE	19	19	attributable
NCT000008659	NCT00000865_9_T0	PHENOTYPE	10	10	attributable
NCT000008660	NCT00000866_0_T0	GENE	23	23	RGP
NCT000008661	NCT00000866_1_T0	GENE	0	0	V-1
NCT000008663	NCT00000866_3_T0	GENE	17	17	booster
NCT000008666	NCT00000866_6_T0	PHENOTYPE	9	9	concentrations
NCT000008667	NCT00000866_7_T0	PHENOTYPE	9	9	vaccinia
NCT000008667	NCT00000866_7_T1	GENE	23	23	ml
NCT000008668	NCT00000866_8_T0	GENE	46	46	pol
NCT000008668	NCT00000866_8_T1	GENE	44	44	gag
NCT0000086610	NCT00000866_10_T0	PHENOTYPE	9	9	concentrations
NCT0000086611	NCT00000866_11_T0	PHENOTYPE	9	9	vaccinia
NCT0000086611	NCT00000866_11_T1	GENE	23	23	ml
NCT0000086612	NCT00000866_12_T0	GENE	46	46	pol
NCT0000086612	NCT00000866_12_T1	GENE	44	44	gag
NCT0000086613	NCT00000866_13_T0	GENE	15	16	group C
NCT0000086615	NCT00000866_15_T0	PHENOTYPE	8	8	vaccinia
NCT0000086619	NCT00000866_19_T0	GENE	10	10	rgp
NCT0000086625	NCT00000866_25_T0	PHENOTYPE	0	0	Eczema
NCT0000086625	NCT00000866_25_T1	PHENOTYPE	2	3	Immunodeficiency disease
NCT000008672	NCT00000867_2_T0	PHENOTYPE	8	8	toxicities
NCT000008672	NCT00000867_2_T1	GENE	3	3	has
NCT000008673	NCT00000867_3_T0	GENE	9	9	ADC
NCT000008675	NCT00000867_5_T0	PHENOTYPE	8	8	toxicities
NCT000008675	NCT00000867_5_T1	GENE	3	3	has
NCT000008675	NCT00000867_5_T2	PHENOTYPE	10	12	bone marrow suppression
NCT000008677	NCT00000867_7_T0	PHENOTYPE	8	8	toxicity
NCT000008677	NCT00000867_7_T1	PHENOTYPE	6	6	reflects
NCT000008679	NCT00000867_9_T0	PHENOTYPE	7	7	symptoms
NCT0000086711	NCT00000867_11_T0	COMPOUND	4	4	memantine
NCT000008681	NCT00000868_1_T0	PHENOTYPE	15	15	HIV
NCT000008681	NCT00000868_1_T1	GENE	5	5	gp120
NCT000008688	NCT00000868_8_T0	GENE	16	16	IgA
NCT0000086810	NCT00000868_10_T0	PHENOTYPE	14	14	CVD
NCT0000086810	NCT00000868_10_T1	GENE	17	17	gp
NCT0000086811	NCT00000868_11_T0	PHENOTYPE	21	22	Group B
NCT0000086811	NCT00000868_11_T1	PHENOTYPE	2	3	typhoid fever
NCT0000086812	NCT00000868_12_T0	GENE	7	7	II
NCT0000086814	NCT00000868_14_T0	GENE	18	18	SF-2
NCT0000086814	NCT00000868_14_T1	GENE	23	23	SF
NCT0000086814	NCT00000868_14_T2	GENE	19	19	rgp
NCT0000086816	NCT00000868_16_T0	GENE	8	8	SF
NCT0000086818	NCT00000868_18_T0	GENE	3	3	SF
NCT000008690	NCT00000869_0_T0	PHENOTYPE	8	8	HIV
NCT000008690	NCT00000869_0_T1	PHENOTYPE	9	9	Transmission
NCT000008693	NCT00000869_3_T0	PHENOTYPE	11	11	HIV
NCT000008695	NCT00000869_5_T0	COMPOUND	5	5	nevirapine
NCT000008696	NCT00000869_6_T0	COMPOUND	2	2	nevirapine
NCT000008696	NCT00000869_6_T1	GENE	15	15	RT
NCT000008696	NCT00000869_6_T2	GENE	3	3	has
NCT000008696	NCT00000869_6_T3	GENE	13	14	reverse transcriptase
NCT000008697	NCT00000869_7_T0	ORGAN	12	12	genital
NCT000008698	NCT00000869_8_T0	COMPOUND	3	3	nevirapine
NCT000008698	NCT00000869_8_T1	COMPOUND	19	19	nevirapine
NCT000008698	NCT00000869_8_T2	COMPOUND	26	26	nevirapine
NCT000008698	NCT00000869_8_T3	PHENOTYPE	9	9	HIV
NCT000008699	NCT00000869_9_T0	COMPOUND	2	2	nevirapine
NCT000008699	NCT00000869_9_T1	GENE	7	7	RT
NCT000008699	NCT00000869_9_T2	ORGAN	14	14	genital
NCT0000086918	NCT00000869_18_T0	PHENOTYPE	12	12	HIV
NCT000008700	NCT00000870_0_T0	GENE	2	2	II
NCT000008700	NCT00000870_0_T1	GENE	8	8	Interleukin-2
NCT000008700	NCT00000870_0_T2	PHENOTYPE	18	19	HIV Infection
NCT000008702	NCT00000870_2_T0	GENE	16	16	CD4
NCT000008702	NCT00000870_2_T1	GENE	33	33	CD4
NCT000008703	NCT00000870_3_T0	PHENOTYPE	5	5	tolerance
NCT000008703	NCT00000870_3_T1	PHENOTYPE	13	15	quality of life
NCT000008707	NCT00000870_7_T0	GENE	3	3	protease
NCT000008708	NCT00000870_8_T0	GENE	16	16	CD4
NCT000008708	NCT00000870_8_T1	GENE	8	8	has
NCT0000087011	NCT00000870_11_T0	GENE	3	3	protease
NCT0000087012	NCT00000870_12_T0	GENE	16	16	CD4
NCT0000087012	NCT00000870_12_T1	GENE	8	8	has
NCT0000087013	NCT00000870_13_T0	COMPOUND	23	23	indinavir
NCT0000087013	NCT00000870_13_T1	GENE	21	22	protease inhibitor
NCT0000087014	NCT00000870_14_T0	PHENOTYPE	4	4	HIV
NCT0000087019	NCT00000870_19_T0	GENE	16	16	CD4
NCT000008712	NCT00000871_2_T0	GENE	2	2	II
NCT000008712	NCT00000871_2_T1	PHENOTYPE	17	18	HIV infection
NCT000008714	NCT00000871_4_T0	GENE	2	2	II
NCT000008714	NCT00000871_4_T1	PHENOTYPE	17	18	HIV infection
NCT000008717	NCT00000871_7_T0	PHENOTYPE	0	1	Group B
NCT0000087110	NCT00000871_10_T0	GENE	13	13	CTL
NCT000008720	NCT00000872_0_T0	PHENOTYPE	13	14	HIV Infection
NCT000008722	NCT00000872_2_T0	PHENOTYPE	1	1	HIV
NCT000008722	NCT00000872_2_T1	PHENOTYPE	25	25	HIV
NCT000008724	NCT00000872_4_T0	PHENOTYPE	11	11	maturation
NCT000008724	NCT00000872_4_T1	CELL	7	7	T-cell
NCT000008725	NCT00000872_5_T0	BIOLOGICAL_PROCESS	26	27	viral replication
NCT000008728	NCT00000872_8_T0	COMPOUND	11	11	1
NCT000008728	NCT00000872_8_T1	COMPOUND	22	22	2
NCT000008728	NCT00000872_8_T2	COMPOUND	29	29	2
NCT0000087210	NCT00000872_10_T0	COMPOUND	9	9	3
NCT0000087210	NCT00000872_10_T1	COMPOUND	17	17	3
NCT0000087210	NCT00000872_10_T2	COMPOUND	22	22	3
NCT000008732	NCT00000873_2_T0	PHENOTYPE	0	1	HIV disease
NCT000008732	NCT00000873_2_T1	PHENOTYPE	7	8	nutritional deficiencies
NCT000008733	NCT00000873_3_T0	PHENOTYPE	17	17	HIV
NCT000008733	NCT00000873_3_T1	PHENOTYPE	10	12	quality of life
NCT000008735	NCT00000873_5_T0	PHENOTYPE	10	10	severity
NCT000008735	NCT00000873_5_T1	PHENOTYPE	13	13	HIV
NCT000008735	NCT00000873_5_T2	PHENOTYPE	29	29	HIV
NCT000008735	NCT00000873_5_T3	PHENOTYPE	15	16	opportunistic infections
NCT000008735	NCT00000873_5_T4	PHENOTYPE	21	23	quality of life
NCT000008738	NCT00000873_8_T0	PHENOTYPE	10	10	HIV
NCT000008739	NCT00000873_9_T0	PHENOTYPE	3	4	positive HIV
NCT0000087310	NCT00000873_10_T0	GENE	34	34	28
NCT0000087310	NCT00000873_10_T1	GENE	63	63	28
NCT0000087312	NCT00000873_12_T0	ORGAN	20	20	thigh
NCT0000087312	NCT00000873_12_T1	ORGAN	26	26	thigh
NCT000008740	NCT00000874_0_T0	ORGAN	12	12	Plasma
NCT000008740	NCT00000874_0_T1	ORGAN	23	23	Plasma
NCT000008740	NCT00000874_0_T2	GENE	17	17	GART
NCT000008740	NCT00000874_0_T3	GENE	24	24	GART
NCT000008746	NCT00000874_6_T0	PHENOTYPE	6	6	HIV
NCT000008747	NCT00000874_7_T0	PHENOTYPE	18	18	decisions
NCT000008747	NCT00000874_7_T1	GENE	5	5	GART
NCT0000087410	NCT00000874_10_T0	PHENOTYPE	6	6	HIV
NCT0000087411	NCT00000874_11_T0	PHENOTYPE	18	18	decisions
NCT0000087411	NCT00000874_11_T1	GENE	5	5	GART
NCT0000087412	NCT00000874_12_T0	GENE	5	5	GART
NCT0000087412	NCT00000874_12_T1	GENE	8	8	GART
NCT000008753	NCT00000875_3_T0	PHENOTYPE	2	2	HIV
NCT000008753	NCT00000875_3_T1	PHENOTYPE	10	10	HIV
NCT000008754	NCT00000875_4_T0	PHENOTYPE	6	6	strategies
NCT000008755	NCT00000875_5_T0	PHENOTYPE	7	7	mutation
NCT000008755	NCT00000875_5_T1	PHENOTYPE	4	4	frustrated
NCT000008755	NCT00000875_5_T2	GENE	2	2	has
NCT0000087510	NCT00000875_10_T0	PHENOTYPE	6	6	strategies
NCT0000087511	NCT00000875_11_T0	PHENOTYPE	7	7	mutation
NCT0000087511	NCT00000875_11_T1	PHENOTYPE	4	4	frustrated
NCT0000087511	NCT00000875_11_T2	GENE	2	2	has
NCT0000087515	NCT00000875_15_T0	GENE	2	2	has
NCT0000087516	NCT00000875_16_T0	GENE	5	5	CTL
NCT0000087524	NCT00000875_24_T0	COMPOUND	6	6	cyclosporine
NCT000008761	NCT00000876_1_T0	PHENOTYPE	12	12	HIV
NCT000008762	NCT00000876_2_T0	GENE	3	3	CD4
NCT000008762	NCT00000876_2_T1	CELL	4	4	cells
NCT000008762	NCT00000876_2_T2	PHENOTYPE	0	0	HIV
NCT000008763	NCT00000876_3_T0	PHENOTYPE	1	1	HIV
NCT000008764	NCT00000876_4_T0	GENE	0	0	CD4
NCT000008764	NCT00000876_4_T1	CELL	1	1	cells
NCT000008764	NCT00000876_4_T2	PHENOTYPE	10	10	HIV
NCT000008764	NCT00000876_4_T3	GENE	5	5	disabled
NCT000008765	NCT00000876_5_T0	GENE	2	2	CD4
NCT000008765	NCT00000876_5_T1	CELL	3	3	cells
NCT000008765	NCT00000876_5_T2	ORGAN	8	9	immune system
NCT000008767	NCT00000876_7_T0	GENE	22	22	CD4
NCT000008767	NCT00000876_7_T1	CELL	23	23	cells
NCT000008767	NCT00000876_7_T2	PHENOTYPE	13	13	HIV
NCT000008768	NCT00000876_8_T0	PHENOTYPE	13	13	HIV
NCT0000087613	NCT00000876_13_T0	PHENOTYPE	11	11	toxicity
NCT0000087614	NCT00000876_14_T0	PHENOTYPE	8	8	toxicities
NCT0000087614	NCT00000876_14_T1	PHENOTYPE	24	24	toxicities
NCT0000087614	NCT00000876_14_T2	GENE	26	26	stops
NCT0000087614	NCT00000876_14_T3	GENE	39	39	MTD
NCT0000087615	NCT00000876_15_T0	PHENOTYPE	12	12	toxicities
NCT0000087615	NCT00000876_15_T1	PHENOTYPE	6	6	experiences
NCT0000087616	NCT00000876_16_T0	PHENOTYPE	14	14	toxicity
NCT0000087616	NCT00000876_16_T1	GENE	9	9	has
NCT0000087616	NCT00000876_16_T2	GENE	16	16	stops
NCT0000087617	NCT00000876_17_T0	PHENOTYPE	12	12	toxicity
NCT0000087617	NCT00000876_17_T1	GENE	7	7	has
NCT0000087618	NCT00000876_18_T0	PHENOTYPE	8	8	toxicity
NCT0000087618	NCT00000876_18_T1	PHENOTYPE	10	10	pharmacokinetics
NCT0000087619	NCT00000876_19_T0	GENE	6	6	MTD
NCT0000087623	NCT00000876_23_T0	PHENOTYPE	3	3	experiences
NCT000008772	NCT00000877_2_T0	COMPOUND	2	2	rifabutin
NCT000008773	NCT00000877_3_T0	PHENOTYPE	6	6	staggering
NCT000008774	NCT00000877_4_T0	COMPOUND	12	12	rifabutin
NCT000008774	NCT00000877_4_T1	COMPOUND	20	20	rifabutin
NCT000008774	NCT00000877_4_T2	COMPOUND	14	14	indinavir
NCT000008774	NCT00000877_4_T3	PHENOTYPE	19	19	staggered
NCT000008775	NCT00000877_5_T0	COMPOUND	3	3	rifabutin
NCT000008775	NCT00000877_5_T1	COMPOUND	9	9	indinavir
NCT000008777	NCT00000877_7_T0	PHENOTYPE	9	9	pharmacokinetics
NCT000008777	NCT00000877_7_T1	GENE	0	0	ACTG
NCT000008777	NCT00000877_7_T2	PHENOTYPE	16	17	HIV seropositive
NCT000008778	NCT00000877_8_T0	COMPOUND	7	7	rifabutin
NCT000008778	NCT00000877_8_T1	COMPOUND	9	9	indinavir
NCT000008778	NCT00000877_8_T2	PHENOTYPE	4	4	staggered
NCT000008779	NCT00000877_9_T0	PHENOTYPE	26	26	concentrations
NCT000008779	NCT00000877_9_T1	PHENOTYPE	30	30	concentrations
NCT000008779	NCT00000877_9_T2	COMPOUND	13	13	rifabutin
NCT000008779	NCT00000877_9_T3	COMPOUND	20	20	rifabutin
NCT000008779	NCT00000877_9_T4	COMPOUND	18	18	indinavir
NCT000008779	NCT00000877_9_T5	COMPOUND	28	28	indinavir
NCT000008779	NCT00000877_9_T6	COMPOUND	32	32	indinavir
NCT0000087710	NCT00000877_10_T0	PHENOTYPE	2	2	concentrations
NCT0000087710	NCT00000877_10_T1	PHENOTYPE	25	25	staggered
NCT0000087711	NCT00000877_11_T0	GENE	5	5	half-life
NCT0000087711	NCT00000877_11_T1	COMPOUND	35	35	rifabutin
NCT0000087711	NCT00000877_11_T2	COMPOUND	2	2	indinavir
NCT0000087711	NCT00000877_11_T3	GENE	7	7	1.8
NCT0000087711	NCT00000877_11_T4	GENE	3	3	has
NCT0000087711	NCT00000877_11_T5	PHENOTYPE	25	25	staggered
NCT0000087712	NCT00000877_12_T0	COMPOUND	4	4	rifabutin
NCT0000087712	NCT00000877_12_T1	COMPOUND	9	9	rifabutin
NCT0000087712	NCT00000877_12_T2	PHENOTYPE	17	17	tuberculosis
NCT0000087713	NCT00000877_13_T0	PHENOTYPE	26	26	HIV
NCT0000087713	NCT00000877_13_T1	PHENOTYPE	29	29	tuberculosis
NCT0000087713	NCT00000877_13_T2	PHENOTYPE	12	12	staggered
NCT0000087713	NCT00000877_13_T3	GENE	33	34	protease inhibitor
NCT0000087715	NCT00000877_15_T0	COMPOUND	11	11	rifabutin
NCT0000087715	NCT00000877_15_T1	COMPOUND	17	17	rifabutin
NCT0000087715	NCT00000877_15_T2	COMPOUND	23	23	rifabutin
NCT0000087715	NCT00000877_15_T3	COMPOUND	15	15	indinavir
NCT0000087715	NCT00000877_15_T4	COMPOUND	21	21	indinavir
NCT0000087715	NCT00000877_15_T5	GENE	13	13	Period
NCT0000087715	NCT00000877_15_T6	GENE	18	18	Period
NCT0000087715	NCT00000877_15_T7	GENE	24	24	Period
NCT0000087717	NCT00000877_17_T0	COMPOUND	19	19	rifabutin
NCT0000087717	NCT00000877_17_T1	COMPOUND	12	12	indinavir
NCT0000087717	NCT00000877_17_T2	COMPOUND	17	17	indinavir
NCT0000087717	NCT00000877_17_T3	GENE	14	14	Period
NCT0000087717	NCT00000877_17_T4	GENE	20	20	Period
NCT000008781	NCT00000878_1_T0	COMPOUND	9	9	zidovudine
NCT000008781	NCT00000878_1_T1	PHENOTYPE	7	7	HIV
NCT000008781	NCT00000878_1_T2	PHENOTYPE	13	13	HIV
NCT000008781	NCT00000878_1_T3	PHENOTYPE	20	20	HIV
NCT000008782	NCT00000878_2_T0	GENE	2	2	has
NCT000008786	NCT00000878_6_T0	PHENOTYPE	12	12	concentrations
NCT000008786	NCT00000878_6_T1	PHENOTYPE	10	10	HIV
NCT000008786	NCT00000878_6_T2	PHENOTYPE	20	20	HIV
NCT000008786	NCT00000878_6_T3	COMPOUND	3	3	thymidine
NCT000008789	NCT00000878_9_T0	GENE	7	8	Group I
NCT0000087811	NCT00000878_11_T0	GENE	8	8	II
NCT0000087811	NCT00000878_11_T1	GENE	10	10	II
NCT0000087812	NCT00000878_12_T0	BIOLOGICAL_PROCESS	10	10	gestation
NCT0000087812	NCT00000878_12_T1	GENE	0	1	Group I
NCT0000087816	NCT00000878_16_T0	PHENOTYPE	14	14	dilation
NCT0000087816	NCT00000878_16_T1	GENE	15	15	3.4
NCT0000087816	NCT00000878_16_T2	GENE	16	16	cm
NCT0000087816	NCT00000878_16_T3	PHENOTYPE	10	10	contractions
NCT0000087817	NCT00000878_17_T0	PHENOTYPE	15	15	cord
NCT0000087817	NCT00000878_17_T1	GENE	2	2	IV
NCT0000087823	NCT00000878_23_T0	GENE	3	3	IV
NCT0000087826	NCT00000878_26_T0	GENE	1	1	II
NCT0000087826	NCT00000878_26_T1	BIOLOGICAL_PROCESS	10	10	gestation
NCT0000087827	NCT00000878_27_T0	PHENOTYPE	5	5	cord
NCT0000087831	NCT00000878_31_T0	GENE	12	12	0.5
NCT0000087835	NCT00000878_35_T0	GENE	3	3	IV
NCT000008791	NCT00000879_1_T0	ORGAN	12	13	immune system
NCT000008792	NCT00000879_2_T0	PHENOTYPE	4	4	HIV
NCT000008794	NCT00000879_4_T0	PHENOTYPE	5	6	HIV infection
NCT000008796	NCT00000879_6_T0	PHENOTYPE	6	7	HIV infection
NCT000008799	NCT00000879_9_T0	PHENOTYPE	4	4	HIV
NCT000008799	NCT00000879_9_T1	BIOLOGICAL_PROCESS	2	2	sensitization
NCT000008799	NCT00000879_9_T2	PHENOTYPE	10	11	HIV infection
NCT0000087910	NCT00000879_10_T0	PHENOTYPE	4	4	HIV
NCT0000087910	NCT00000879_10_T1	PHENOTYPE	12	12	HIV
NCT0000087910	NCT00000879_10_T2	PHENOTYPE	16	17	disease progression
NCT000008800	NCT00000880_0_T0	ORGAN	10	11	Immune System
NCT000008800	NCT00000880_0_T1	PHENOTYPE	16	17	HIV Disease
NCT000008802	NCT00000880_2_T0	CELL	4	4	cells
NCT000008802	NCT00000880_2_T1	PHENOTYPE	11	11	HIV
NCT000008802	NCT00000880_2_T2	ORGAN	7	8	immune system
NCT000008802	NCT00000880_2_T3	CELL	2	3	T cells
NCT000008803	NCT00000880_3_T0	PHENOTYPE	0	0	Inhibition
NCT000008803	NCT00000880_3_T1	PHENOTYPE	16	17	HIV infection
NCT0000088016	NCT00000880_16_T0	COMPOUND	3	3	lamivudine
NCT0000088017	NCT00000880_17_T0	COMPOUND	2	2	didanosine
NCT0000088112	NCT00000881_12_T0	PHENOTYPE	10	10	toxicity
NCT0000088112	NCT00000881_12_T1	GENE	9	9	3.4
NCT0000088112	NCT00000881_12_T2	PHENOTYPE	6	6	experiences
NCT0000088113	NCT00000881_13_T0	PHENOTYPE	10	10	toxicity
NCT0000088113	NCT00000881_13_T1	GENE	9	9	3.4
NCT0000088113	NCT00000881_13_T2	PHENOTYPE	6	6	experiences
NCT0000088114	NCT00000881_14_T0	COMPOUND	4	4	cidofovir
NCT0000088115	NCT00000881_15_T0	PHENOTYPE	10	10	toxicity
NCT0000088116	NCT00000881_16_T0	COMPOUND	20	20	cidofovir
NCT0000088118	NCT00000881_18_T0	COMPOUND	8	8	cidofovir
NCT0000088122	NCT00000881_22_T0	PHENOTYPE	0	0	HIV
NCT0000088123	NCT00000881_23_T0	GENE	18	18	blot
NCT0000088123	NCT00000881_23_T1	GENE	20	20	IFA
NCT0000088123	NCT00000881_23_T2	PHENOTYPE	4	5	positive HIV
NCT000008823	NCT00000882_3_T0	COMPOUND	12	12	delavirdine
NCT000008823	NCT00000882_3_T1	COMPOUND	10	10	stavudine
NCT000008823	NCT00000882_3_T2	COMPOUND	15	15	indinavir
NCT000008823	NCT00000882_3_T3	COMPOUND	8	8	lamivudine
NCT000008828	NCT00000882_8_T0	ORGAN	41	41	plasma
NCT000008828	NCT00000882_8_T1	GENE	14	15	reverse transcriptase
NCT000008829	NCT00000882_9_T0	GENE	43	43	RT
NCT000008829	NCT00000882_9_T1	GENE	47	48	protease inhibitor
NCT000008829	NCT00000882_9_T2	GENE	12	13	reverse transcriptase
NCT0000088211	NCT00000882_11_T0	ORGAN	41	41	plasma
NCT0000088211	NCT00000882_11_T1	GENE	14	15	reverse transcriptase
NCT0000088212	NCT00000882_12_T0	GENE	43	43	RT
NCT0000088212	NCT00000882_12_T1	GENE	47	48	protease inhibitor
NCT0000088212	NCT00000882_12_T2	GENE	12	13	reverse transcriptase
NCT0000088225	NCT00000882_25_T0	PHENOTYPE	17	17	edema
NCT0000088225	NCT00000882_25_T1	PHENOTYPE	16	16	tumor
NCT0000088225	NCT00000882_25_T2	GENE	5	5	KS
NCT0000088225	NCT00000882_25_T3	PHENOTYPE	3	4	Kaposi's sarcoma
NCT000008833	NCT00000883_3_T0	GENE	0	0	CD4
NCT000008833	NCT00000883_3_T1	CELL	1	1	cells
NCT000008833	NCT00000883_3_T2	CELL	3	3	cells
NCT000008833	NCT00000883_3_T3	ORGAN	6	7	immune system
NCT000008834	NCT00000883_4_T0	GENE	4	4	CD4
NCT000008834	NCT00000883_4_T1	PHENOTYPE	14	14	infections
NCT000008835	NCT00000883_5_T0	PHENOTYPE	2	2	HIV
NCT000008835	NCT00000883_5_T1	PHENOTYPE	13	14	opportunistic infections
NCT000008835	NCT00000883_5_T2	PHENOTYPE	8	9	metabolic problems
NCT000008836	NCT00000883_6_T0	PHENOTYPE	8	8	HIV
NCT000008836	NCT00000883_6_T1	GENE	2	2	ACTG
NCT000008836	NCT00000883_6_T2	GENE	18	18	ACTG
NCT000008838	NCT00000883_8_T0	PHENOTYPE	10	10	HIV
NCT0000088310	NCT00000883_10_T0	PHENOTYPE	12	12	initiation
NCT0000088311	NCT00000883_11_T0	PHENOTYPE	16	16	decisions
NCT0000088314	NCT00000883_14_T0	GENE	6	6	CD4
NCT0000088314	NCT00000883_14_T1	COMPOUND	22	22	azithromycin
NCT000008843	NCT00000884_3_T0	CELL	11	11	cells
NCT000008843	NCT00000884_3_T1	PHENOTYPE	24	24	HIV
NCT000008844	NCT00000884_4_T0	PHENOTYPE	13	13	immunity
NCT000008845	NCT00000884_5_T0	PHENOTYPE	10	10	canarypox
NCT000008845	NCT00000884_5_T1	PHENOTYPE	26	26	immunity
NCT000008845	NCT00000884_5_T2	GENE	13	13	has
NCT000008847	NCT00000884_7_T0	CELL	11	11	cells
NCT000008847	NCT00000884_7_T1	PHENOTYPE	24	24	HIV
NCT000008848	NCT00000884_8_T0	PHENOTYPE	13	13	immunity
NCT000008849	NCT00000884_9_T0	PHENOTYPE	10	10	canarypox
NCT000008849	NCT00000884_9_T1	PHENOTYPE	26	26	immunity
NCT000008849	NCT00000884_9_T2	GENE	13	13	has
NCT0000088410	NCT00000884_10_T0	BIOLOGICAL_PROCESS	9	10	immune response
NCT0000088411	NCT00000884_11_T0	PHENOTYPE	60	60	rabies
NCT0000088411	NCT00000884_11_T1	GENE	28	29	Group F
NCT0000088411	NCT00000884_11_T2	PHENOTYPE	16	17	Group B
NCT000008854	NCT00000885_4_T0	COMPOUND	34	34	stavudine
NCT000008854	NCT00000885_4_T1	ORGAN	4	4	plasma
NCT000008854	NCT00000885_4_T2	ORGAN	17	17	plasma
NCT000008855	NCT00000885_5_T0	ORGAN	4	4	plasma
NCT000008857	NCT00000885_7_T0	GENE	7	7	ACTG
NCT000008857	NCT00000885_7_T1	GENE	17	17	ACTG
NCT0000088519	NCT00000885_19_T0	GENE	1	1	B3
NCT0000088519	NCT00000885_19_T1	COMPOUND	20	20	didanosine
NCT0000088519	NCT00000885_19_T2	GENE	0	0	ARM
NCT0000088519	NCT00000885_19_T3	COMPOUND	25	26	adefovir dipivoxil
NCT0000088519	NCT00000885_19_T4	GENE	4	5	reverse transcriptase
NCT0000088522	NCT00000885_22_T0	PHENOTYPE	15	15	concentrations
NCT0000088522	NCT00000885_22_T1	ORGAN	12	12	plasma
NCT0000088522	NCT00000885_22_T2	PHENOTYPE	8	9	Group B
NCT0000088526	NCT00000885_26_T0	PHENOTYPE	0	0	Chronic
NCT000008860	NCT00000886_0_T0	GENE	22	22	IFA
NCT000008860	NCT00000886_0_T1	GENE	9	9	gp120
NCT000008864	NCT00000886_4_T0	PHENOTYPE	11	11	HIV
NCT000008866	NCT00000886_6_T0	PHENOTYPE	11	11	HIV
NCT000008867	NCT00000886_7_T0	GENE	14	14	IFA
NCT000008867	NCT00000886_7_T1	GENE	17	17	IFA
NCT000008867	NCT00000886_7_T2	GENE	7	7	0.5
NCT000008867	NCT00000886_7_T3	GENE	8	8	ml
NCT000008872	NCT00000887_2_T0	PHENOTYPE	15	15	HIV
NCT000008872	NCT00000887_2_T1	GENE	1	1	has
NCT000008874	NCT00000887_4_T0	PHENOTYPE	4	4	HIV
NCT000008876	NCT00000887_6_T0	PHENOTYPE	0	0	Initiation
NCT000008876	NCT00000887_6_T1	BIOLOGICAL_PROCESS	6	6	gestation
NCT000008877	NCT00000887_7_T0	PHENOTYPE	19	19	cord
NCT000008877	NCT00000887_7_T1	COMPOUND	2	2	nelfinavir
NCT000008879	NCT00000887_9_T0	PHENOTYPE	16	16	concentrations
NCT000008879	NCT00000887_9_T1	COMPOUND	15	15	nelfinavir
NCT000008879	NCT00000887_9_T2	ORGAN	5	6	cord blood
NCT0000088710	NCT00000887_10_T0	PHENOTYPE	1	1	HIV
NCT0000088710	NCT00000887_10_T1	ORGAN	4	4	plasma
NCT0000088711	NCT00000887_11_T0	PHENOTYPE	15	15	HIV
NCT0000088711	NCT00000887_11_T1	BIOLOGICAL_PROCESS	7	7	gestation
NCT0000088713	NCT00000887_13_T0	BIOLOGICAL_PROCESS	9	9	gestation
NCT0000088714	NCT00000887_14_T0	COMPOUND	2	2	nelfinavir
NCT0000088715	NCT00000887_15_T0	COMPOUND	16	16	nelfinavir
NCT0000088716	NCT00000887_16_T0	PHENOTYPE	1	1	pharmacokinetics
NCT0000088718	NCT00000887_18_T0	COMPOUND	5	5	nelfinavir
NCT0000088718	NCT00000887_18_T1	GENE	1	1	has
NCT000008882	NCT00000888_2_T0	PHENOTYPE	10	10	HIV
NCT000008883	NCT00000888_3_T0	PHENOTYPE	13	13	HIV
NCT000008884	NCT00000888_4_T0	PHENOTYPE	12	12	HIV
NCT000008887	NCT00000888_7_T0	PHENOTYPE	24	24	HIV
NCT000008887	NCT00000888_7_T1	GENE	15	15	has
NCT000008888	NCT00000888_8_T0	BIOLOGICAL_PROCESS	5	5	metabolism
NCT000008888	NCT00000888_8_T1	PHENOTYPE	7	7	tolerance
NCT000008888	NCT00000888_8_T2	PHENOTYPE	24	24	tolerance
NCT000008889	NCT00000888_9_T0	GENE	0	0	Protease
NCT0000088811	NCT00000888_11_T0	PHENOTYPE	11	11	cord
NCT0000088815	NCT00000888_15_T0	GENE	10	10	2.3
NCT0000088816	NCT00000888_16_T0	PHENOTYPE	9	9	pharmacokinetics
NCT0000088819	NCT00000888_19_T0	PHENOTYPE	15	16	preterm delivery
NCT000008890	NCT00000889_0_T0	GENE	17	17	CD4
NCT000008890	NCT00000889_0_T1	GENE	9	9	IL-2
NCT000008890	NCT00000889_0_T2	GENE	8	8	Interleukin-2
NCT000008892	NCT00000889_2_T0	GENE	7	7	IL-2
NCT000008894	NCT00000889_4_T0	GENE	6	6	IL-2
NCT000008897	NCT00000889_7_T0	GENE	10	10	II
NCT000008897	NCT00000889_7_T1	GENE	16	16	IL-2
NCT000008897	NCT00000889_7_T2	GENE	33	33	III
NCT000008898	NCT00000889_8_T0	GENE	14	14	IL-2
NCT000008899	NCT00000889_9_T0	GENE	3	3	IL-2
NCT0000088910	NCT00000889_10_T0	PHENOTYPE	16	16	toxicities
NCT0000088911	NCT00000889_11_T0	GENE	8	8	IL-2
NCT000008906	NCT00000890_6_T0	GENE	3	3	has
NCT000008906	NCT00000890_6_T1	PHENOTYPE	1	2	weight gain
NCT000008908	NCT00000890_8_T0	GENE	3	3	has
NCT000008909	NCT00000890_9_T0	PHENOTYPE	32	32	complications
NCT000008909	NCT00000890_9_T1	GENE	1	1	has
NCT0000089010	NCT00000890_10_T0	PHENOTYPE	17	17	inflammation
NCT0000089010	NCT00000890_10_T1	GENE	28	28	ACTG
NCT0000089011	NCT00000890_11_T0	COMPOUND	7	7	BMI
NCT0000089012	NCT00000890_12_T0	PHENOTYPE	40	40	inflammation
NCT000008912	NCT00000891_2_T0	PHENOTYPE	26	26	suppression
NCT000008912	NCT00000891_2_T1	GENE	9	9	ACTG
NCT000008912	NCT00000891_2_T2	BIOLOGICAL_PROCESS	28	29	viral replication
NCT000008914	NCT00000891_4_T0	COMPOUND	8	8	zidovudine
NCT000008914	NCT00000891_4_T1	COMPOUND	12	12	ritonavir
NCT000008914	NCT00000891_4_T2	GENE	4	4	ACTG
NCT000008914	NCT00000891_4_T3	COMPOUND	10	10	lamivudine
NCT000008915	NCT00000891_5_T0	PHENOTYPE	1	1	decisions
NCT000008916	NCT00000891_6_T0	GENE	10	10	ACTG
NCT000008917	NCT00000891_7_T0	GENE	9	9	ACTG
NCT0000089119	NCT00000891_19_T0	COMPOUND	15	15	ritonavir
NCT0000089119	NCT00000891_19_T1	GENE	29	29	ACTG
NCT0000089119	NCT00000891_19_T2	GENE	8	8	bid
NCT0000089119	NCT00000891_19_T3	GENE	13	13	bid
NCT0000089119	NCT00000891_19_T4	GENE	20	20	bid
NCT0000089119	NCT00000891_19_T5	GENE	4	4	tid
NCT0000089119	NCT00000891_19_T6	GENE	24	24	tid
NCT0000089119	NCT00000891_19_T7	COMPOUND	10	10	lamivudine
NCT000008923	NCT00000892_3_T0	GENE	32	32	had
NCT000008923	NCT00000892_3_T1	GENE	15	15	protease
NCT000008923	NCT00000892_3_T2	GENE	31	31	has
NCT000008924	NCT00000892_4_T0	GENE	9	10	reverse transcriptase
NCT000008924	NCT00000892_4_T1	GENE	15	16	reverse transcriptase
NCT000008927	NCT00000892_7_T0	GENE	32	32	had
NCT000008927	NCT00000892_7_T1	GENE	15	15	protease
NCT000008927	NCT00000892_7_T2	GENE	31	31	has
NCT000008928	NCT00000892_8_T0	GENE	9	10	reverse transcriptase
NCT000008928	NCT00000892_8_T1	GENE	15	16	reverse transcriptase
NCT0000089216	NCT00000892_16_T0	COMPOUND	9	9	L-carnitine
NCT0000089218	NCT00000892_18_T0	PHENOTYPE	5	5	HIV
NCT0000089218	NCT00000892_18_T1	GENE	23	23	log
NCT000008931	NCT00000893_1_T0	GENE	1	1	II
NCT000008936	NCT00000893_6_T0	BIOLOGICAL_PROCESS	4	4	DMP
NCT000008937	NCT00000893_7_T0	BIOLOGICAL_PROCESS	10	10	DMP
NCT0000089310	NCT00000893_10_T0	COMPOUND	33	33	nelfinavir
NCT0000089310	NCT00000893_10_T1	BIOLOGICAL_PROCESS	30	30	DMP
NCT0000089310	NCT00000893_10_T2	ORGAN	27	27	plasma
NCT0000089311	NCT00000893_11_T0	GENE	11	11	II
NCT0000089311	NCT00000893_11_T1	GENE	0	0	APA
NCT0000089312	NCT00000893_12_T0	GENE	13	13	II
NCT0000089312	NCT00000893_12_T1	GENE	39	39	II
NCT0000089312	NCT00000893_12_T2	GENE	57	57	II
NCT0000089312	NCT00000893_12_T3	GENE	0	0	APA
NCT0000089312	NCT00000893_12_T4	GENE	26	26	APA
NCT0000089312	NCT00000893_12_T5	BIOLOGICAL_PROCESS	7	7	DMP
NCT0000089312	NCT00000893_12_T6	BIOLOGICAL_PROCESS	63	63	DMP
NCT0000089313	NCT00000893_13_T0	PHENOTYPE	30	30	concentrations
NCT0000089313	NCT00000893_13_T1	BIOLOGICAL_PROCESS	32	32	DMP
NCT0000089313	NCT00000893_13_T2	ORGAN	29	29	plasma
NCT0000089314	NCT00000893_14_T0	PHENOTYPE	28	28	toxicity
NCT0000089315	NCT00000893_15_T0	PHENOTYPE	10	10	toxicity
NCT0000089316	NCT00000893_16_T0	GENE	21	21	II
NCT0000089316	NCT00000893_16_T1	GENE	0	0	APA
NCT0000089316	NCT00000893_16_T2	PHENOTYPE	9	9	concentrations
NCT0000089316	NCT00000893_16_T3	BIOLOGICAL_PROCESS	37	37	DMP
NCT0000089316	NCT00000893_16_T4	ORGAN	8	8	plasma
NCT0000089320	NCT00000893_20_T0	BIOLOGICAL_PROCESS	5	5	DMP
NCT0000089321	NCT00000893_21_T0	PHENOTYPE	19	19	toxicity
NCT0000089321	NCT00000893_21_T1	PHENOTYPE	14	14	experiences
NCT0000089322	NCT00000893_22_T0	GENE	19	19	II
NCT0000089322	NCT00000893_22_T1	GENE	29	29	II
NCT0000089322	NCT00000893_22_T2	GENE	0	0	APA
NCT0000089323	NCT00000893_23_T0	PHENOTYPE	9	9	falls
NCT0000089324	NCT00000893_24_T0	GENE	23	23	IV
NCT0000089325	NCT00000893_25_T0	PHENOTYPE	157	157	toxicity
NCT0000089325	NCT00000893_25_T1	GENE	0	0	APA
NCT0000089325	NCT00000893_25_T2	GENE	164	164	APA
NCT0000089325	NCT00000893_25_T3	GENE	166	166	APA
NCT0000089325	NCT00000893_25_T4	PHENOTYPE	20	20	falls
NCT0000089325	NCT00000893_25_T5	PHENOTYPE	72	72	falls
NCT0000089325	NCT00000893_25_T6	PHENOTYPE	94	94	falls
NCT0000089325	NCT00000893_25_T7	PHENOTYPE	117	117	falls
NCT0000089325	NCT00000893_25_T8	GENE	168	168	208
NCT000008945	NCT00000894_5_T0	COMPOUND	7	7	cidofovir
NCT000008947	NCT00000894_7_T0	GENE	5	5	IV
NCT000008947	NCT00000894_7_T1	GENE	0	1	Group I
NCT000008948	NCT00000894_8_T0	PHENOTYPE	1	1	progression
NCT000008948	NCT00000894_8_T1	COMPOUND	4	4	ganciclovir
NCT000008949	NCT00000894_9_T0	COMPOUND	2	2	probenecid
NCT000008949	NCT00000894_9_T1	COMPOUND	10	10	cidofovir
NCT0000089410	NCT00000894_10_T0	GENE	1	1	II
NCT0000089410	NCT00000894_10_T1	COMPOUND	4	4	ganciclovir
NCT0000089410	NCT00000894_10_T2	COMPOUND	19	19	ganciclovir
NCT0000089411	NCT00000894_11_T0	PHENOTYPE	7	7	toxicity
NCT0000089411	NCT00000894_11_T1	PHENOTYPE	4	4	progression
NCT000008950	NCT00000895_0_T0	GENE	6	6	MAC
NCT000008950	NCT00000895_0_T1	PHENOTYPE	18	19	HIV Infection
NCT000008952	NCT00000895_2_T0	PHENOTYPE	10	10	HIV
NCT000008952	NCT00000895_2_T1	GENE	21	21	MAC
NCT000008952	NCT00000895_2_T2	ORGAN	14	15	immune system
NCT000008953	NCT00000895_3_T0	PHENOTYPE	16	16	HIV
NCT000008953	NCT00000895_3_T1	GENE	6	6	MAC
NCT000008953	NCT00000895_3_T2	ORGAN	10	11	immune systems
NCT000008954	NCT00000895_4_T0	PHENOTYPE	7	7	HIV
NCT000008954	NCT00000895_4_T1	GENE	18	18	MAC
NCT000008954	NCT00000895_4_T2	ORGAN	12	13	immune systems
NCT000008957	NCT00000895_7_T0	PHENOTYPE	6	6	HIV
NCT000008957	NCT00000895_7_T1	PHENOTYPE	11	11	DMAC
NCT000008957	NCT00000895_7_T2	PHENOTYPE	29	29	DMAC
NCT0000089512	NCT00000895_12_T0	GENE	13	13	II
NCT0000089512	NCT00000895_12_T1	GENE	3	3	III
NCT0000089513	NCT00000895_13_T0	GENE	20	20	II
NCT0000089513	NCT00000895_13_T1	GENE	6	6	III
NCT0000089513	NCT00000895_13_T2	COMPOUND	11	11	azithromycin
NCT0000089513	NCT00000895_13_T3	GENE	8	8	MAC
NCT0000089514	NCT00000895_14_T0	GENE	35	35	II
NCT0000089514	NCT00000895_14_T1	GENE	3	3	III
NCT0000089514	NCT00000895_14_T2	GENE	8	8	MAC
NCT0000089514	NCT00000895_14_T3	ORGAN	11	12	bone marrow
NCT000008961	NCT00000896_1_T0	PHENOTYPE	12	12	HIV
NCT000008961	NCT00000896_1_T1	PHENOTYPE	20	20	HIV
NCT000008961	NCT00000896_1_T2	GENE	9	9	IL-12
NCT000008961	NCT00000896_1_T3	GENE	22	22	reduced
NCT000008961	NCT00000896_1_T4	GENE	7	7	GM-CSF
NCT000008962	NCT00000896_2_T0	COMPOUND	15	15	nevirapine
NCT000008962	NCT00000896_2_T1	COMPOUND	11	11	zidovudine
NCT000008962	NCT00000896_2_T2	PHENOTYPE	1	1	HIV
NCT000008962	NCT00000896_2_T3	COMPOUND	18	18	stavudine
NCT000008962	NCT00000896_2_T4	COMPOUND	13	13	indinavir
NCT000008962	NCT00000896_2_T5	COMPOUND	9	9	lamivudine
NCT000008963	NCT00000896_3_T0	PHENOTYPE	7	7	HIV
NCT000008964	NCT00000896_4_T0	GENE	1	1	has
NCT000008964	NCT00000896_4_T1	GENE	0	0	GM-CSF
NCT000008964	NCT00000896_4_T2	PHENOTYPE	7	8	blood disorders
NCT000008965	NCT00000896_5_T0	GENE	1	1	interleukin-12
NCT000008965	NCT00000896_5_T1	GENE	0	0	IL-12
NCT000008965	NCT00000896_5_T2	ORGAN	16	17	immune system
NCT000008966	NCT00000896_6_T0	PHENOTYPE	9	9	HIV
NCT000008966	NCT00000896_6_T1	GENE	3	3	IL-12
NCT000008966	NCT00000896_6_T2	GENE	1	1	GM-CSF
NCT000008966	NCT00000896_6_T3	ORGAN	18	19	immune system
NCT000008968	NCT00000896_8_T0	GENE	1	1	de
NCT000008968	NCT00000896_8_T1	GENE	18	18	lag
NCT000008968	NCT00000896_8_T2	PHENOTYPE	5	5	blocked
NCT0000089610	NCT00000896_10_T0	COMPOUND	13	13	nevirapine
NCT0000089610	NCT00000896_10_T1	COMPOUND	11	11	zidovudine
NCT0000089610	NCT00000896_10_T2	COMPOUND	14	14	indinavir
NCT0000089610	NCT00000896_10_T3	PHENOTYPE	1	1	intent
NCT0000089610	NCT00000896_10_T4	COMPOUND	12	12	lamivudine
NCT0000089610	NCT00000896_10_T5	PHENOTYPE	25	26	drug kinetics
NCT0000089613	NCT00000896_13_T0	PHENOTYPE	10	11	Group B
NCT0000089615	NCT00000896_15_T0	GENE	0	0	ARM
NCT0000089616	NCT00000896_16_T0	GENE	0	0	ARM
NCT0000089621	NCT00000896_21_T0	GENE	27	27	GM-CSF
NCT0000089621	NCT00000896_21_T1	GENE	25	25	ARM
NCT0000089622	NCT00000896_22_T0	GENE	2	2	IL-12
NCT0000089622	NCT00000896_22_T1	GENE	0	0	ARM
NCT0000089623	NCT00000896_23_T0	GENE	0	0	ARM
NCT000008972	NCT00000897_2_T0	PHENOTYPE	11	11	HIV
NCT000008972	NCT00000897_2_T1	GENE	2	2	has
NCT000008975	NCT00000897_5_T0	COMPOUND	6	6	oxazepam
NCT000008975	NCT00000897_5_T1	BIOLOGICAL_PROCESS	25	25	metabolism
NCT000008975	NCT00000897_5_T2	GENE	16	16	transferase
NCT000008976	NCT00000897_6_T0	BIOLOGICAL_PROCESS	5	5	metabolism
NCT000008976	NCT00000897_6_T1	ORGAN	15	15	plasma
NCT000008977	NCT00000897_7_T0	COMPOUND	7	7	estrogen
NCT000008977	NCT00000897_7_T1	COMPOUND	5	5	progesterone
NCT0000089710	NCT00000897_10_T0	COMPOUND	29	29	acetate
NCT0000089710	NCT00000897_10_T1	COMPOUND	23	23	estradiol
NCT0000089711	NCT00000897_11_T0	GENE	20	20	IV
NCT0000089712	NCT00000897_12_T0	GENE	20	20	Cycle
NCT0000089712	NCT00000897_12_T1	GENE	19	19	LMP
NCT000008997	NCT00000899_7_T0	CELL	12	12	cells
NCT000008997	NCT00000899_7_T1	PHENOTYPE	11	11	HIV
NCT000008998	NCT00000899_8_T0	PHENOTYPE	0	0	Strategies
NCT000008998	NCT00000899_8_T1	PHENOTYPE	5	6	HIV infection
NCT0000089911	NCT00000899_11_T0	COMPOUND	17	17	stavudine
NCT0000089911	NCT00000899_11_T1	COMPOUND	14	14	nelfinavir
NCT0000089911	NCT00000899_11_T2	COMPOUND	20	20	lamivudine
NCT0000089917	NCT00000899_17_T0	TISSUE	8	8	thymus
NCT0000089918	NCT00000899_18_T0	PHENOTYPE	13	13	HIV
NCT000009002	NCT00000900_2_T0	GENE	10	10	CD4
NCT000009002	NCT00000900_2_T1	GENE	12	12	CD8
NCT000009002	NCT00000900_2_T2	CELL	13	14	lymphocyte subsets
NCT000009003	NCT00000900_3_T0	ORGAN	4	4	plasma
NCT000009003	NCT00000900_3_T1	ORGAN	14	14	plasma
NCT000009003	NCT00000900_3_T2	PHENOTYPE	16	16	viremia
NCT000009004	NCT00000900_4_T0	PHENOTYPE	20	20	acute
NCT000009004	NCT00000900_4_T1	PHENOTYPE	21	22	febrile illness
NCT000009005	NCT00000900_5_T0	PHENOTYPE	15	15	acute
NCT000009005	NCT00000900_5_T1	PHENOTYPE	32	32	progression
NCT000009005	NCT00000900_5_T2	PHENOTYPE	22	22	infections
NCT000009005	NCT00000900_5_T3	PHENOTYPE	16	17	febrile illness
NCT000009005	NCT00000900_5_T4	PHENOTYPE	34	35	HIV infection
NCT0000090011	NCT00000900_11_T0	BIOLOGICAL_PROCESS	13	14	viral replication
NCT0000090011	NCT00000900_11_T1	PHENOTYPE	22	23	febrile illness
NCT0000090012	NCT00000900_12_T0	GENE	18	18	ACTG
NCT0000090013	NCT00000900_13_T0	ORGAN	0	0	Plasma
NCT000009024	NCT00000902_4_T0	ORGAN	22	22	plasma
NCT000009026	NCT00000902_6_T0	COMPOUND	21	21	nevirapine
NCT000009026	NCT00000902_6_T1	COMPOUND	17	17	zidovudine
NCT000009026	NCT00000902_6_T2	COMPOUND	15	15	stavudine
NCT000009026	NCT00000902_6_T3	COMPOUND	23	23	nelfinavir
NCT000009026	NCT00000902_6_T4	COMPOUND	26	26	ritonavir
NCT000009026	NCT00000902_6_T5	COMPOUND	18	18	didanosine
NCT000009026	NCT00000902_6_T6	COMPOUND	16	16	lamivudine
NCT000009026	NCT00000902_6_T7	COMPOUND	19	19	zalcitabine
NCT000009026	NCT00000902_6_T8	GENE	12	13	reverse transcriptase
NCT000009028	NCT00000902_8_T0	PHENOTYPE	13	13	HIV
NCT000009031	NCT00000903_1_T0	COMPOUND	10	10	nelfinavir
NCT000009031	NCT00000903_1_T1	COMPOUND	13	13	efavirenz
NCT000009031	NCT00000903_1_T2	PHENOTYPE	4	4	tolerance
NCT000009031	NCT00000903_1_T3	PHENOTYPE	28	29	HIV disease
NCT000009032	NCT00000903_2_T0	GENE	1	1	ACTG
NCT000009033	NCT00000903_3_T0	PHENOTYPE	13	13	suppression
NCT000009033	NCT00000903_3_T1	BIOLOGICAL_PROCESS	15	16	RNA replication
NCT000009034	NCT00000903_4_T0	PHENOTYPE	19	19	suppression
NCT000009034	NCT00000903_4_T1	PHENOTYPE	3	3	progressive
NCT000009035	NCT00000903_5_T0	PHENOTYPE	7	7	HIV
NCT000009035	NCT00000903_5_T1	COMPOUND	16	16	nelfinavir
NCT000009035	NCT00000903_5_T2	PHENOTYPE	5	5	suppression
NCT000009036	NCT00000903_6_T0	COMPOUND	22	22	efavirenz
NCT000009036	NCT00000903_6_T1	BIOLOGICAL_PROCESS	12	13	viral replication
NCT000009036	NCT00000903_6_T2	GENE	6	7	reverse transcriptase
NCT000009038	NCT00000903_8_T0	PHENOTYPE	13	13	suppression
NCT000009038	NCT00000903_8_T1	BIOLOGICAL_PROCESS	15	16	RNA replication
NCT000009039	NCT00000903_9_T0	PHENOTYPE	19	19	suppression
NCT000009039	NCT00000903_9_T1	PHENOTYPE	3	3	progressive
NCT0000090310	NCT00000903_10_T0	PHENOTYPE	7	7	HIV
NCT0000090310	NCT00000903_10_T1	COMPOUND	16	16	nelfinavir
NCT0000090310	NCT00000903_10_T2	PHENOTYPE	5	5	suppression
NCT0000090311	NCT00000903_11_T0	COMPOUND	22	22	efavirenz
NCT0000090311	NCT00000903_11_T1	BIOLOGICAL_PROCESS	12	13	viral replication
NCT0000090311	NCT00000903_11_T2	GENE	6	7	reverse transcriptase
NCT0000090317	NCT00000903_17_T0	PHENOTYPE	4	4	relapse
NCT0000090317	NCT00000903_17_T1	GENE	22	22	ACTG
NCT0000090318	NCT00000903_18_T0	COMPOUND	12	12	amprenavir
NCT0000090318	NCT00000903_18_T1	COMPOUND	5	5	abacavir
NCT0000090318	NCT00000903_18_T2	COMPOUND	10	10	efavirenz
NCT0000090318	NCT00000903_18_T3	GENE	15	16	protease inhibitor
NCT000009042	NCT00000904_2_T0	PHENOTYPE	5	5	HIV
NCT000009042	NCT00000904_2_T1	GENE	7	7	gp160
NCT000009043	NCT00000904_3_T0	PHENOTYPE	9	9	HIV
NCT000009043	NCT00000904_3_T1	PHENOTYPE	19	19	HIV
NCT000009044	NCT00000904_4_T0	PHENOTYPE	3	3	HIV
NCT000009046	NCT00000904_6_T0	ORGAN	6	7	immune system
NCT000009047	NCT00000904_7_T0	CELL	9	9	cells
NCT000009047	NCT00000904_7_T1	CELL	13	13	cells
NCT000009048	NCT00000904_8_T0	PHENOTYPE	9	9	HIV
NCT000009049	NCT00000904_9_T0	CELL	24	24	cells
NCT000009049	NCT00000904_9_T1	GENE	11	11	gp160
NCT0000090413	NCT00000904_13_T0	GENE	0	1	Group I
NCT0000090414	NCT00000904_14_T0	GENE	1	1	II
NCT0000090415	NCT00000904_15_T0	GENE	1	1	III
NCT0000090416	NCT00000904_16_T0	PHENOTYPE	5	5	rabies
NCT0000090416	NCT00000904_16_T1	GENE	1	1	IV
NCT0000090418	NCT00000904_18_T0	GENE	9	9	II
NCT0000090418	NCT00000904_18_T1	GENE	11	11	III
NCT0000090418	NCT00000904_18_T2	GENE	14	14	gp160
NCT0000090419	NCT00000904_19_T0	GENE	1	1	IV
NCT000009056	NCT00000905_6_T0	GENE	6	6	CD4
NCT000009056	NCT00000905_6_T1	GENE	3	4	Group 1
NCT000009061	NCT00000906_1_T0	COMPOUND	7	7	methadone
NCT000009063	NCT00000906_3_T0	COMPOUND	9	9	methadone
NCT000009065	NCT00000906_5_T0	GENE	7	7	protease
NCT000009065	NCT00000906_5_T1	GENE	20	20	protease
NCT000009065	NCT00000906_5_T2	PHENOTYPE	6	6	HIV
NCT000009065	NCT00000906_5_T3	COMPOUND	4	4	methadone
NCT000009065	NCT00000906_5_T4	COMPOUND	23	23	methadone
NCT000009066	NCT00000906_6_T0	COMPOUND	10	10	ritonavir
NCT000009066	NCT00000906_6_T1	COMPOUND	12	12	saquinavir
NCT000009066	NCT00000906_6_T2	COMPOUND	7	7	methadone
NCT000009067	NCT00000906_7_T0	COMPOUND	12	12	ritonavir
NCT000009067	NCT00000906_7_T1	PHENOTYPE	9	9	tolerance
NCT000009068	NCT00000906_8_T0	COMPOUND	11	11	methadone
NCT000009069	NCT00000906_9_T0	COMPOUND	11	11	methadone
NCT000009069	NCT00000906_9_T1	GENE	5	6	protease inhibitor
NCT0000090610	NCT00000906_10_T0	GENE	1	1	protease
NCT0000090610	NCT00000906_10_T1	COMPOUND	4	4	methadone
NCT0000090611	NCT00000906_11_T0	PHENOTYPE	9	9	tolerance
NCT000009072	NCT00000907_2_T0	PHENOTYPE	10	10	DMAC
NCT000009074	NCT00000907_4_T0	GENE	1	1	CD4
NCT000009074	NCT00000907_4_T1	PHENOTYPE	7	7	DMAC
NCT000009075	NCT00000907_5_T0	GENE	14	14	CD4
NCT000009075	NCT00000907_5_T1	PHENOTYPE	12	12	DMAC
NCT000009075	NCT00000907_5_T2	PHENOTYPE	25	25	DMAC
NCT000009077	NCT00000907_7_T0	GENE	12	12	MAC
NCT000009079	NCT00000907_9_T0	PHENOTYPE	0	0	Peripheral
NCT000009079	NCT00000907_9_T1	PHENOTYPE	19	19	DMAC
NCT000009079	NCT00000907_9_T2	GENE	26	26	MAC
NCT000009079	NCT00000907_9_T3	ORGAN	4	5	bone marrow
NCT000009079	NCT00000907_9_T4	PHENOTYPE	16	18	Mycobacterium avium complex
NCT0000090710	NCT00000907_10_T0	GENE	10	10	MAC
NCT0000090710	NCT00000907_10_T1	ORGAN	2	3	bone marrow
NCT0000090711	NCT00000907_11_T0	PHENOTYPE	3	3	sterile
NCT0000090711	NCT00000907_11_T1	GENE	13	13	MAC
NCT0000090712	NCT00000907_12_T0	PHENOTYPE	11	11	recurrence
NCT0000090712	NCT00000907_12_T1	GENE	10	10	MAC
NCT0000090712	NCT00000907_12_T2	PHENOTYPE	6	8	signs and symptoms
NCT000009080	NCT00000908_0_T0	PHENOTYPE	13	13	Pneumonia
NCT000009080	NCT00000908_0_T1	GENE	23	23	CD4
NCT000009088	NCT00000908_8_T0	PHENOTYPE	5	5	symptoms
NCT000009088	NCT00000908_8_T1	GENE	7	7	CD4
NCT000009088	NCT00000908_8_T2	ORGAN	15	15	plasma
NCT000009089	NCT00000908_9_T0	GENE	2	2	CD4
NCT000009089	NCT00000908_9_T1	GENE	19	19	CD4
NCT000009089	NCT00000908_9_T2	PHENOTYPE	4	4	falls
NCT000009093	NCT00000909_3_T0	GENE	0	0	IL-2
NCT000009093	NCT00000909_3_T1	PHENOTYPE	15	15	HIV
NCT000009093	NCT00000909_3_T2	PHENOTYPE	11	12	HIV infection
NCT000009094	NCT00000909_4_T0	GENE	11	11	IL-2
NCT000009094	NCT00000909_4_T1	PHENOTYPE	15	16	HIV infection
NCT000009097	NCT00000909_7_T0	GENE	9	9	IL-2
NCT000009097	NCT00000909_7_T1	GENE	21	21	IL-2
NCT000009097	NCT00000909_7_T2	GENE	3	3	has
NCT000009099	NCT00000909_9_T0	GENE	20	20	IL-2
NCT000009099	NCT00000909_9_T1	GENE	18	19	Group I
NCT0000090910	NCT00000909_10_T0	GENE	1	1	II
NCT0000090910	NCT00000909_10_T1	GENE	2	2	IL-2
NCT0000090910	NCT00000909_10_T2	GENE	13	13	IL-2
NCT0000090911	NCT00000909_11_T0	GENE	1	1	III
NCT0000090914	NCT00000909_14_T0	GENE	6	6	II
NCT0000090914	NCT00000909_14_T1	GENE	13	13	IL-2
NCT0000090914	NCT00000909_14_T2	GENE	3	4	Group I
NCT000009103	NCT00000910_3_T0	GENE	15	15	has
NCT000009106	NCT00000910_6_T0	PHENOTYPE	9	9	HIV
NCT000009106	NCT00000910_6_T1	GENE	3	3	has
NCT000009108	NCT00000910_8_T0	PHENOTYPE	12	12	HIV
NCT000009109	NCT00000910_9_T0	PHENOTYPE	4	4	HIV
NCT000009109	NCT00000910_9_T1	GENE	16	16	had
NCT000009110	NCT00000911_0_T0	PHENOTYPE	9	10	HIV Infection
NCT000009112	NCT00000911_2_T0	PHENOTYPE	13	13	HIV
NCT000009112	NCT00000911_2_T1	PHENOTYPE	1	2	HIV infection
NCT000009113	NCT00000911_3_T0	PHENOTYPE	9	9	tiredness
NCT000009113	NCT00000911_3_T1	PHENOTYPE	8	8	fever
NCT000009113	NCT00000911_3_T2	PHENOTYPE	1	1	symptoms
NCT000009113	NCT00000911_3_T3	PHENOTYPE	10	10	headache
NCT000009113	NCT00000911_3_T4	PHENOTYPE	12	13	muscle aches
NCT000009113	NCT00000911_3_T5	PHENOTYPE	3	5	primary HIV infection
NCT000009114	NCT00000911_4_T0	PHENOTYPE	1	1	symptoms
NCT000009114	NCT00000911_4_T1	PHENOTYPE	15	15	symptoms
NCT000009118	NCT00000911_8_T0	PHENOTYPE	1	1	symptoms
NCT000009119	NCT00000911_9_T0	GENE	38	38	has
NCT000009119	NCT00000911_9_T1	PHENOTYPE	8	10	acute HIV infection
NCT0000091110	NCT00000911_10_T0	PHENOTYPE	10	10	acute
NCT0000091110	NCT00000911_10_T1	PHENOTYPE	13	14	HIV infection
NCT000009121	NCT00000912_1_T0	COMPOUND	16	16	amprenavir
NCT000009121	NCT00000912_1_T1	GENE	15	15	PI
NCT000009121	NCT00000912_1_T2	GENE	13	14	protease inhibitor
NCT000009122	NCT00000912_2_T0	PHENOTYPE	26	26	HIV
NCT000009122	NCT00000912_2_T1	GENE	9	9	PI
NCT000009122	NCT00000912_2_T2	GENE	7	7	had
NCT000009124	NCT00000912_4_T0	COMPOUND	3	3	amprenavir
NCT000009124	NCT00000912_4_T1	PHENOTYPE	11	11	HIV
NCT000009124	NCT00000912_4_T2	GENE	20	20	PI
NCT000009126	NCT00000912_6_T0	PHENOTYPE	45	45	mutation
NCT000009126	NCT00000912_6_T1	GENE	16	16	has
NCT0000091212	NCT00000912_12_T0	COMPOUND	3	3	L-carnitine
NCT0000091214	NCT00000912_14_T0	GENE	9	9	has
NCT0000091217	NCT00000912_17_T0	PHENOTYPE	11	12	congenital anomalies
NCT000009132	NCT00000913_2_T0	GENE	16	16	protease
NCT000009137	NCT00000913_7_T0	PHENOTYPE	22	23	fetal abnormality
NCT000009142	NCT00000914_2_T0	GENE	16	16	protease
NCT000009142	NCT00000914_2_T1	PHENOTYPE	4	4	HIV
NCT000009142	NCT00000914_2_T2	COMPOUND	6	6	efavirenz
NCT000009142	NCT00000914_2_T3	PHENOTYPE	27	28	HIV infection
NCT000009143	NCT00000914_3_T0	CELL	14	14	cells
NCT000009143	NCT00000914_3_T1	PHENOTYPE	9	9	HIV
NCT000009143	NCT00000914_3_T2	GENE	1	1	has
NCT000009145	NCT00000914_5_T0	GENE	16	16	PI
NCT000009145	NCT00000914_5_T1	GENE	1	1	has
NCT000009145	NCT00000914_5_T2	GENE	10	11	reverse transcriptase
NCT000009145	NCT00000914_5_T3	PHENOTYPE	23	24	disease progression
NCT000009147	NCT00000914_7_T0	GENE	10	10	has
NCT000009147	NCT00000914_7_T1	BIOLOGICAL_PROCESS	14	15	viral replication
NCT000009148	NCT00000914_8_T0	GENE	11	12	reverse transcriptase
NCT0000091410	NCT00000914_10_T0	COMPOUND	6	6	saquinavir
NCT0000091410	NCT00000914_10_T1	COMPOUND	9	9	efavirenz
NCT0000091413	NCT00000914_13_T0	GENE	8	8	PI
NCT0000091413	NCT00000914_13_T1	GENE	11	11	PI
NCT000009151	NCT00000915_1_T0	PHENOTYPE	18	18	HIV
NCT000009151	NCT00000915_1_T1	PHENOTYPE	22	22	HIV
NCT000009152	NCT00000915_2_T0	PHENOTYPE	26	26	HIV
NCT000009152	NCT00000915_2_T1	PHENOTYPE	29	29	HIV
NCT000009153	NCT00000915_3_T0	PHENOTYPE	7	7	HIV
NCT000009153	NCT00000915_3_T1	PHENOTYPE	18	18	HIV
NCT000009154	NCT00000915_4_T0	PHENOTYPE	3	4	HIV infection
NCT000009155	NCT00000915_5_T0	PHENOTYPE	14	14	HIV
NCT000009155	NCT00000915_5_T1	PHENOTYPE	32	33	HIV infection
NCT000009157	NCT00000915_7_T0	PHENOTYPE	20	20	HIV
NCT000009157	NCT00000915_7_T1	PHENOTYPE	10	11	HIV infection
NCT000009157	NCT00000915_7_T2	PHENOTYPE	30	31	HIV infection
NCT000009158	NCT00000915_8_T0	PHENOTYPE	15	15	HIV
NCT000009158	NCT00000915_8_T1	PHENOTYPE	33	34	HIV infection
NCT0000091510	NCT00000915_10_T0	PHENOTYPE	9	9	HIV
NCT0000091510	NCT00000915_10_T1	PHENOTYPE	13	13	HIV
NCT0000091510	NCT00000915_10_T2	PHENOTYPE	7	7	attitudes
NCT0000091511	NCT00000915_11_T0	GENE	11	11	blot
NCT0000091511	NCT00000915_11_T1	PHENOTYPE	7	7	HIV
NCT0000091511	NCT00000915_11_T2	PHENOTYPE	0	1	HIV infection
NCT0000091512	NCT00000915_12_T0	PHENOTYPE	13	13	symptoms
NCT0000091512	NCT00000915_12_T1	PHENOTYPE	16	16	exposures
NCT0000091512	NCT00000915_12_T2	PHENOTYPE	8	10	primary HIV infection
NCT0000091513	NCT00000915_13_T0	PHENOTYPE	0	0	HIV
NCT0000091514	NCT00000915_14_T0	PHENOTYPE	5	5	HIV
NCT000009160	NCT00000916_0_T0	PHENOTYPE	23	23	HIV
NCT000009160	NCT00000916_0_T1	ORGAN	27	27	Blood
NCT000009162	NCT00000916_2_T0	COMPOUND	13	13	hydroxyurea
NCT000009162	NCT00000916_2_T1	PHENOTYPE	18	18	suppression
NCT000009162	NCT00000916_2_T2	GENE	14	14	HU
NCT000009163	NCT00000916_3_T0	COMPOUND	10	10	stavudine
NCT000009163	NCT00000916_3_T1	COMPOUND	7	7	didanosine
NCT000009164	NCT00000916_4_T0	COMPOUND	8	8	zidovudine
NCT000009164	NCT00000916_4_T1	PHENOTYPE	16	16	suppression
NCT000009164	NCT00000916_4_T2	COMPOUND	6	6	indinavir
NCT000009164	NCT00000916_4_T3	COMPOUND	12	12	lamivudine
NCT000009165	NCT00000916_5_T0	PHENOTYPE	15	15	suppression
NCT000009166	NCT00000916_6_T0	GENE	6	6	HU
NCT000009166	NCT00000916_6_T1	GENE	9	10	reverse transcriptase
NCT000009167	NCT00000916_7_T0	PHENOTYPE	21	21	suppression
NCT000009167	NCT00000916_7_T1	GENE	11	11	HU
NCT000009169	NCT00000916_9_T0	COMPOUND	9	9	hydroxyurea
NCT000009169	NCT00000916_9_T1	PHENOTYPE	19	19	suppression
NCT000009169	NCT00000916_9_T2	GENE	10	10	HU
NCT0000091610	NCT00000916_10_T0	PHENOTYPE	17	17	suppression
NCT0000091610	NCT00000916_10_T1	GENE	7	7	HU
NCT0000091610	NCT00000916_10_T2	PHENOTYPE	5	5	tolerance
NCT000009173	NCT00000917_3_T0	CELL	0	1	Stem cells
NCT000009173	NCT00000917_3_T1	CELL	11	12	blood cells
NCT000009177	NCT00000917_7_T0	CELL	13	13	cells
NCT000009177	NCT00000917_7_T1	CELL	24	24	cells
NCT000009177	NCT00000917_7_T2	CELL	8	9	stem cells
NCT000009177	NCT00000917_7_T3	PHENOTYPE	27	28	HIV infection
NCT000009177	NCT00000917_7_T4	ORGAN	5	7	umbilical cord blood
NCT000009179	NCT00000917_9_T0	GENE	10	10	has
NCT000009179	NCT00000917_9_T1	ORGAN	3	5	umbilical cord blood
NCT0000091710	NCT00000917_10_T0	PHENOTYPE	25	25	HIV
NCT0000091710	NCT00000917_10_T1	ORGAN	7	9	umbilical cord blood
NCT0000091711	NCT00000917_11_T0	PHENOTYPE	0	0	HIV
NCT0000091711	NCT00000917_11_T1	PHENOTYPE	15	15	hepatitis
NCT0000091711	NCT00000917_11_T2	GENE	5	5	ml
NCT0000091711	NCT00000917_11_T3	PHENOTYPE	12	13	infectious diseases
NCT0000091712	NCT00000917_12_T0	PHENOTYPE	5	5	HIV
NCT0000091713	NCT00000917_13_T0	PHENOTYPE	12	12	cord
NCT0000091713	NCT00000917_13_T1	GENE	4	4	ml
NCT0000091713	NCT00000917_13_T2	ORGAN	21	23	umbilical cord blood
NCT0000091714	NCT00000917_14_T0	PHENOTYPE	3	3	HIV
NCT0000091715	NCT00000917_15_T0	PHENOTYPE	7	7	HIV
NCT0000091716	NCT00000917_16_T0	PHENOTYPE	5	5	HIV
NCT0000091716	NCT00000917_16_T1	ORGAN	7	8	cord blood
NCT000009181	NCT00000918_1_T0	GENE	17	17	has
NCT000009182	NCT00000918_2_T0	GENE	26	26	protease
NCT000009182	NCT00000918_2_T1	COMPOUND	14	14	efavirenz
NCT000009182	NCT00000918_2_T2	GENE	10	11	reverse transcriptase
NCT000009182	NCT00000918_2_T3	GENE	18	19	reverse transcriptase
NCT000009185	NCT00000918_5_T0	COMPOUND	15	15	efavirenz
NCT000009185	NCT00000918_5_T1	GENE	9	10	reverse transcriptase
NCT000009186	NCT00000918_6_T0	GENE	23	23	protease
NCT000009186	NCT00000918_6_T1	COMPOUND	33	33	nelfinavir
NCT000009186	NCT00000918_6_T2	COMPOUND	17	17	efavirenz
NCT000009186	NCT00000918_6_T3	GENE	11	12	reverse transcriptase
NCT000009190	NCT00000919_0_T0	PHENOTYPE	12	13	HIV Infection
NCT000009192	NCT00000919_2_T0	COMPOUND	24	24	zidovudine
NCT000009192	NCT00000919_2_T1	COMPOUND	15	15	stavudine
NCT000009192	NCT00000919_2_T2	COMPOUND	19	19	nelfinavir
NCT000009192	NCT00000919_2_T3	COMPOUND	13	13	didanosine
NCT000009192	NCT00000919_2_T4	COMPOUND	17	17	efavirenz
NCT000009192	NCT00000919_2_T5	COMPOUND	21	21	lamivudine
NCT000009193	NCT00000919_3_T0	PHENOTYPE	9	9	HIV
NCT000009195	NCT00000919_5_T0	PHENOTYPE	6	6	HIV
NCT000009198	NCT00000919_8_T0	PHENOTYPE	22	22	HIV
NCT000009199	NCT00000919_9_T0	PHENOTYPE	11	11	complications
NCT0000091916	NCT00000919_16_T0	PHENOTYPE	2	3	virologic failure
NCT000009203	NCT00000920_3_T0	PHENOTYPE	12	12	HIV
NCT000009203	NCT00000920_3_T1	PHENOTYPE	30	30	HIV
NCT000009203	NCT00000920_3_T2	GENE	2	2	has
NCT000009204	NCT00000920_4_T0	GENE	7	7	PI
NCT000009204	NCT00000920_4_T1	GENE	11	11	PI
NCT000009204	NCT00000920_4_T2	GENE	5	6	protease inhibitor
NCT000009204	NCT00000920_4_T3	GENE	15	16	reverse transcriptase
NCT000009206	NCT00000920_6_T0	PHENOTYPE	32	32	HIV
NCT000009206	NCT00000920_6_T1	PHENOTYPE	53	53	HIV
NCT000009206	NCT00000920_6_T2	PHENOTYPE	6	6	strategies
NCT000009206	NCT00000920_6_T3	PHENOTYPE	38	38	resistant
NCT000009206	NCT00000920_6_T4	GENE	36	36	has
NCT000009206	NCT00000920_6_T5	PHENOTYPE	52	52	transmitted
NCT000009221	NCT00000922_1_T0	PHENOTYPE	15	16	HIV infection
NCT000009223	NCT00000922_3_T0	PHENOTYPE	29	29	HIV
NCT000009223	NCT00000922_3_T1	GENE	9	9	PI
NCT000009223	NCT00000922_3_T2	GENE	15	15	PI
NCT000009224	NCT00000922_4_T0	PHENOTYPE	3	4	virologic failure
NCT000009225	NCT00000922_5_T0	PHENOTYPE	23	23	HIV
NCT000009228	NCT00000922_8_T0	COMPOUND	7	7	nelfinavir
NCT000009228	NCT00000922_8_T1	COMPOUND	5	5	indinavir
NCT000009229	NCT00000922_9_T0	COMPOUND	5	5	nevirapine
NCT000009229	NCT00000922_9_T1	COMPOUND	8	8	efavirenz
NCT0000092212	NCT00000922_12_T0	PHENOTYPE	2	2	HIV
NCT000009233	NCT00000923_3_T0	CELL	10	10	cells
NCT000009233	NCT00000923_3_T1	GENE	0	0	IL-2
NCT000009239	NCT00000923_9_T0	GENE	10	10	IL-2
NCT000009239	NCT00000923_9_T1	PHENOTYPE	21	21	HIV
NCT000009239	NCT00000923_9_T2	GENE	25	25	18
NCT000009239	NCT00000923_9_T3	GENE	0	0	ACTG
NCT0000092310	NCT00000923_10_T0	GENE	19	19	IL-2
NCT0000092310	NCT00000923_10_T1	GENE	25	25	IL-2
NCT0000092311	NCT00000923_11_T0	GENE	7	7	ACTG
NCT0000092313	NCT00000923_13_T0	GENE	3	3	II
NCT0000092313	NCT00000923_13_T1	GENE	6	6	SC
NCT0000092313	NCT00000923_13_T2	GENE	7	7	IL-2
NCT0000092314	NCT00000923_14_T0	GENE	0	0	IL-2
NCT0000092315	NCT00000923_15_T0	GENE	23	23	CD4
NCT0000092315	NCT00000923_15_T1	GENE	9	9	extended
NCT0000092317	NCT00000923_17_T0	GENE	15	15	IL-2
NCT0000092321	NCT00000923_21_T0	GENE	16	16	IL-2
NCT0000092322	NCT00000923_22_T0	GENE	8	9	protease inhibitor
NCT0000092324	NCT00000923_24_T0	COMPOUND	11	11	zidovudine
NCT0000092324	NCT00000923_24_T1	COMPOUND	20	20	stavudine
NCT0000092324	NCT00000923_24_T2	COMPOUND	14	14	didanosine
NCT0000092324	NCT00000923_24_T3	COMPOUND	18	18	lamivudine
NCT0000092326	NCT00000923_26_T0	GENE	4	4	CD4
NCT0000092326	NCT00000923_26_T1	GENE	12	12	IL-2
NCT0000092327	NCT00000923_27_T0	GENE	0	0	CD4
NCT0000092327	NCT00000923_27_T1	GENE	18	18	IL-2
NCT0000092327	NCT00000923_27_T2	PHENOTYPE	6	6	HIV
NCT0000092327	NCT00000923_27_T3	ORGAN	3	3	plasma
NCT0000092328	NCT00000923_28_T0	GENE	13	13	IL-2
NCT000009241	NCT00000924_1_T0	GENE	9	9	protease
NCT000009241	NCT00000924_1_T1	COMPOUND	28	28	nevirapine
NCT000009241	NCT00000924_1_T2	PHENOTYPE	1	1	HIV
NCT000009241	NCT00000924_1_T3	COMPOUND	19	19	stavudine
NCT000009241	NCT00000924_1_T4	COMPOUND	11	11	nelfinavir
NCT000009241	NCT00000924_1_T5	COMPOUND	13	13	ritonavir
NCT000009241	NCT00000924_1_T6	COMPOUND	21	21	didanosine
NCT000009241	NCT00000924_1_T7	GENE	16	17	reverse transcriptase
NCT000009241	NCT00000924_1_T8	GENE	25	26	reverse transcriptase
NCT000009243	NCT00000924_3_T0	PHENOTYPE	13	13	HIV
NCT000009246	NCT00000924_6_T0	PHENOTYPE	4	4	suppression
NCT000009248	NCT00000924_8_T0	COMPOUND	7	7	zidovudine
NCT000009250	NCT00000925_0_T0	PHENOTYPE	12	13	Weight Loss
NCT000009252	NCT00000925_2_T0	PHENOTYPE	3	4	lose weight
NCT000009253	NCT00000925_3_T0	BIOLOGICAL_PROCESS	7	7	eating
NCT000009253	NCT00000925_3_T1	BIOLOGICAL_PROCESS	13	13	eating
NCT000009254	NCT00000925_4_T0	PHENOTYPE	26	27	HIV infection
NCT000009255	NCT00000925_5_T0	PHENOTYPE	13	14	gain weight
NCT000009257	NCT00000925_7_T0	PHENOTYPE	15	16	HIV infection
NCT000009258	NCT00000925_8_T0	GENE	11	11	2.0
NCT000009258	NCT00000925_8_T1	GENE	9	9	1.5
NCT000009258	NCT00000925_8_T2	PHENOTYPE	17	17	diseases
NCT000009258	NCT00000925_8_T3	PHENOTYPE	28	29	anabolic effects
NCT0000092511	NCT00000925_11_T0	ORGAN	0	0	Plasma
NCT0000092511	NCT00000925_11_T1	GENE	6	6	prealbumin
NCT0000092511	NCT00000925_11_T2	GENE	10	10	IL-6
NCT0000092511	NCT00000925_11_T3	GENE	13	13	IL-1ra
NCT0000092511	NCT00000925_11_T4	GENE	3	4	C-reactive protein
NCT000009260	NCT00000926_0_T0	PHENOTYPE	6	7	HIV Infection
NCT000009262	NCT00000926_2_T0	PHENOTYPE	5	5	HIV
NCT000009268	NCT00000926_8_T0	GENE	2	2	III
NCT000009268	NCT00000926_8_T1	ORGAN	19	19	genital
NCT000009269	NCT00000926_9_T0	GENE	13	13	III
NCT0000092611	NCT00000926_11_T0	GENE	5	5	gel
NCT000009272	NCT00000927_2_T0	PHENOTYPE	4	4	HIV
NCT000009273	NCT00000927_3_T0	PHENOTYPE	13	13	HIV
NCT000009273	NCT00000927_3_T1	PHENOTYPE	19	19	STDs
NCT000009273	NCT00000927_3_T2	PHENOTYPE	16	18	sexually transmitted diseases
NCT000009274	NCT00000927_4_T0	PHENOTYPE	9	9	HIV
NCT000009276	NCT00000927_6_T0	PHENOTYPE	11	11	HIV
NCT000009276	NCT00000927_6_T1	PHENOTYPE	9	9	STDs
NCT000009277	NCT00000927_7_T0	ORGAN	6	6	genital
NCT0000092710	NCT00000927_10_T0	PHENOTYPE	16	16	HIV
NCT0000092710	NCT00000927_10_T1	PHENOTYPE	22	22	STDs
NCT0000092710	NCT00000927_10_T2	GENE	9	9	has
NCT0000092710	NCT00000927_10_T3	PHENOTYPE	19	21	sexually transmitted diseases
NCT0000092711	NCT00000927_11_T0	PHENOTYPE	10	10	HIV
NCT0000092714	NCT00000927_14_T0	ORGAN	13	13	genital
NCT000009281	NCT00000928_1_T0	PHENOTYPE	30	30	HIV
NCT000009281	NCT00000928_1_T1	PHENOTYPE	6	6	experiences
NCT000009283	NCT00000928_3_T0	PHENOTYPE	6	6	HIV
NCT000009284	NCT00000928_4_T0	GENE	3	3	has
NCT000009284	NCT00000928_4_T1	GENE	17	17	has
NCT000009287	NCT00000928_7_T0	GENE	3	3	has
NCT000009287	NCT00000928_7_T1	GENE	17	17	has
NCT0000092813	NCT00000928_13_T0	COMPOUND	11	11	2
NCT000009291	NCT00000929_1_T0	CELL	9	9	sperm
NCT000009296	NCT00000929_6_T0	COMPOUND	7	7	nonoxynol_9
NCT000009296	NCT00000929_6_T1	GENE	5	5	gel
NCT000009297	NCT00000929_7_T0	GENE	12	12	gel
NCT0000092911	NCT00000929_11_T0	ORGAN	5	5	genital
NCT0000092919	NCT00000929_19_T0	PHENOTYPE	11	11	burning
NCT000009300	NCT00000930_0_T0	PHENOTYPE	3	3	HIV
NCT000009302	NCT00000930_2_T0	PHENOTYPE	7	7	HIV
NCT000009303	NCT00000930_3_T0	PHENOTYPE	8	8	HIV
NCT000009307	NCT00000930_7_T0	PHENOTYPE	25	25	HIV
NCT000009307	NCT00000930_7_T1	PHENOTYPE	10	10	progression
NCT000009307	NCT00000930_7_T2	PHENOTYPE	5	6	HIV phenotype
NCT000009309	NCT00000930_9_T0	GENE	14	14	D01
NCT000009309	NCT00000930_9_T1	PHENOTYPE	3	3	HIV
NCT000009309	NCT00000930_9_T2	GENE	19	19	has
NCT000009309	NCT00000930_9_T3	PHENOTYPE	17	18	HIV disease
NCT0000093011	NCT00000930_11_T0	PHENOTYPE	4	4	HIV
NCT000009312	NCT00000931_2_T0	PHENOTYPE	20	20	HIV
NCT000009313	NCT00000931_3_T0	PHENOTYPE	15	15	HIV
NCT000009314	NCT00000931_4_T0	PHENOTYPE	14	14	HIV
NCT000009316	NCT00000931_6_T0	PHENOTYPE	10	10	HIV
NCT000009317	NCT00000931_7_T0	PHENOTYPE	13	14	HIV seroconversion
NCT0000093111	NCT00000931_11_T0	PHENOTYPE	18	18	HIV
NCT0000093111	NCT00000931_11_T1	PHENOTYPE	15	15	practices
NCT0000093111	NCT00000931_11_T2	PHENOTYPE	24	24	practices
NCT0000093111	NCT00000931_11_T3	PHENOTYPE	31	32	drug use
NCT0000093114	NCT00000931_14_T0	PHENOTYPE	11	11	HIV
NCT0000093114	NCT00000931_14_T1	BIOLOGICAL_PROCESS	6	6	phlebotomy
NCT000009321	NCT00000932_1_T0	GENE	2	2	has
NCT000009321	NCT00000932_1_T1	PHENOTYPE	7	8	disease progression
NCT000009322	NCT00000932_2_T0	PHENOTYPE	11	11	HIV
NCT000009323	NCT00000932_3_T0	PHENOTYPE	14	14	HIV
NCT000009325	NCT00000932_5_T0	PHENOTYPE	7	8	HIV disease
NCT000009326	NCT00000932_6_T0	PHENOTYPE	32	33	virologic failure
NCT000009331	NCT00000933_1_T0	COMPOUND	12	12	azithromycin
NCT000009331	NCT00000933_1_T1	GENE	24	24	MAC
NCT000009334	NCT00000933_4_T0	GENE	1	1	MAC
NCT000009335	NCT00000933_5_T0	PHENOTYPE	19	19	resistant
NCT000009335	NCT00000933_5_T1	PHENOTYPE	7	8	Streptococcus infection
NCT000009337	NCT00000933_7_T0	COMPOUND	9	9	penicillin
NCT000009337	NCT00000933_7_T1	COMPOUND	19	19	penicillin
NCT000009337	NCT00000933_7_T2	PHENOTYPE	17	17	resistant
NCT000009337	NCT00000933_7_T3	PHENOTYPE	7	7	susceptible
NCT000009338	NCT00000933_8_T0	PHENOTYPE	36	36	pneumoniae
NCT000009338	NCT00000933_8_T1	PHENOTYPE	16	16	resistant
NCT000009338	NCT00000933_8_T2	PHENOTYPE	33	33	strains
NCT000009338	NCT00000933_8_T3	PHENOTYPE	19	19	HIV
NCT000009338	NCT00000933_8_T4	GENE	4	4	has
NCT000009339	NCT00000933_9_T0	PHENOTYPE	14	14	initiation
NCT000009339	NCT00000933_9_T1	GENE	20	20	MAC
NCT0000093311	NCT00000933_11_T0	PHENOTYPE	17	17	pneumoniae
NCT0000093312	NCT00000933_12_T0	COMPOUND	8	8	penicillin
NCT0000093312	NCT00000933_12_T1	COMPOUND	7	7	macrolides
NCT0000093312	NCT00000933_12_T2	COMPOUND	10	10	quinolones
NCT0000093313	NCT00000933_13_T0	PHENOTYPE	29	29	pneumoniae
NCT0000093313	NCT00000933_13_T1	GENE	22	22	MAC
NCT000009351	NCT00000935_1_T0	PHENOTYPE	1	1	ESRD
NCT000009351	NCT00000935_1_T1	ORGAN	27	27	kidney
NCT000009351	NCT00000935_1_T2	ORGAN	8	8	transplant
NCT000009351	NCT00000935_1_T3	ORGAN	15	16	immune system
NCT000009352	NCT00000935_2_T0	ORGAN	0	0	Transplant
NCT000009353	NCT00000935_3_T0	ORGAN	17	17	kidney
NCT000009355	NCT00000935_5_T0	BIOLOGICAL_PROCESS	11	11	sensitization
NCT000009356	NCT00000935_6_T0	GENE	1	1	has
NCT000009357	NCT00000935_7_T0	ORGAN	12	12	graft
NCT000009357	NCT00000935_7_T1	ORGAN	15	15	transplant
NCT000009357	NCT00000935_7_T2	ORGAN	7	7	transplants
NCT000009358	NCT00000935_8_T0	GENE	27	27	albumin
NCT000009358	NCT00000935_8_T1	GENE	5	5	IV
NCT000009359	NCT00000935_9_T0	ORGAN	6	6	transplant
NCT000009359	NCT00000935_9_T1	ORGAN	27	27	transplant
NCT000009359	NCT00000935_9_T2	GENE	29	29	has
NCT000009359	NCT00000935_9_T3	GENE	13	13	booster
NCT000009359	NCT00000935_9_T4	GENE	22	22	booster
NCT0000093510	NCT00000935_10_T0	ORGAN	1	1	transplant
NCT0000093510	NCT00000935_10_T1	ORGAN	22	22	transplant
NCT0000093511	NCT00000935_11_T0	GENE	17	17	MLR
NCT0000093511	NCT00000935_11_T1	GENE	21	21	MLR
NCT0000093511	NCT00000935_11_T2	GENE	28	28	MLR
NCT0000093511	NCT00000935_11_T3	PHENOTYPE	3	3	initiation
NCT0000093511	NCT00000935_11_T4	BIOLOGICAL_PROCESS	25	25	transcription
NCT0000093511	NCT00000935_11_T5	PHENOTYPE	19	19	inhibition
NCT0000093511	NCT00000935_11_T6	ORGAN	18	18	serum
NCT0000093511	NCT00000935_11_T7	GENE	15	15	PRA
NCT0000093512	NCT00000935_12_T0	ORGAN	7	7	graft
NCT000009361	NCT00000936_1_T0	ORGAN	12	12	kidney
NCT000009365	NCT00000936_5_T0	ORGAN	8	8	transplant
NCT000009369	NCT00000936_9_T0	ORGAN	3	3	graft
NCT0000093610	NCT00000936_10_T0	ORGAN	22	22	graft
NCT0000093610	NCT00000936_10_T1	ORGAN	11	11	transplant
NCT0000093610	NCT00000936_10_T2	PHENOTYPE	18	18	immunosuppression
NCT0000093610	NCT00000936_10_T3	GENE	12	12	has
NCT0000093611	NCT00000936_11_T0	ORGAN	16	16	kidney
NCT0000093611	NCT00000936_11_T1	ORGAN	12	12	graft
NCT0000093611	NCT00000936_11_T2	ORGAN	17	17	transplant
NCT0000093612	NCT00000936_12_T0	GENE	11	11	1.1
NCT0000093613	NCT00000936_13_T0	COMPOUND	3	3	cyclosporine
NCT0000093613	NCT00000936_13_T1	GENE	14	14	1.1
NCT0000093614	NCT00000936_14_T0	GENE	0	1	Group 1
NCT0000093617	NCT00000936_17_T0	COMPOUND	4	4	cyclosporine
NCT0000093617	NCT00000936_17_T1	GENE	3	3	IV
NCT0000093618	NCT00000936_18_T0	COMPOUND	4	4	cyclosporine
NCT0000093618	NCT00000936_18_T1	GENE	3	3	IV
NCT0000093619	NCT00000936_19_T0	COMPOUND	1	1	cyclosporine
NCT0000093623	NCT00000936_23_T0	COMPOUND	6	6	1
NCT0000093623	NCT00000936_23_T1	COMPOUND	7	7	2
NCT0000093623	NCT00000936_23_T2	ORGAN	0	0	Graft
NCT000009371	NCT00000937_1_T0	PHENOTYPE	0	0	Fatigue
NCT000009371	NCT00000937_1_T1	PHENOTYPE	6	7	Lyme Disease
NCT000009373	NCT00000937_3_T0	PHENOTYPE	1	2	chronic fatigue
NCT000009373	NCT00000937_3_T1	PHENOTYPE	17	18	Lyme Disease
NCT000009379	NCT00000937_9_T0	PHENOTYPE	15	16	chronic fatigue
NCT000009379	NCT00000937_9_T1	PHENOTYPE	16	17	fatigue symptoms
NCT0000093710	NCT00000937_10_T0	PHENOTYPE	4	4	fatigue
NCT0000093710	NCT00000937_10_T1	PHENOTYPE	10	11	mental processing
NCT000009380	NCT00000938_0_T0	PHENOTYPE	21	21	Seronegative
NCT000009380	NCT00000938_0_T1	PHENOTYPE	22	24	Chronic Lyme Disease
NCT000009382	NCT00000938_2_T0	PHENOTYPE	6	6	Borrelia
NCT000009383	NCT00000938_3_T0	PHENOTYPE	35	35	transmitted
NCT000009383	NCT00000938_3_T1	PHENOTYPE	31	31	coinfection
NCT000009383	NCT00000938_3_T2	PHENOTYPE	5	5	chronic
NCT000009383	NCT00000938_3_T3	PHENOTYPE	24	25	infectious process
NCT000009383	NCT00000938_3_T4	PHENOTYPE	13	14	persistent infection
NCT000009387	NCT00000938_7_T0	GENE	7	7	IV
NCT000009391	NCT00000939_1_T0	COMPOUND	10	10	1
NCT000009391	NCT00000939_1_T1	COMPOUND	20	20	hydroxyurea
NCT000009391	NCT00000939_1_T2	COMPOUND	18	18	stavudine
NCT000009391	NCT00000939_1_T3	GENE	14	15	Group 1
NCT000009392	NCT00000939_2_T0	COMPOUND	1	1	2
NCT000009392	NCT00000939_2_T1	COMPOUND	4	4	stavudine
NCT000009392	NCT00000939_2_T2	COMPOUND	6	6	efavirenz
NCT000009393	NCT00000939_3_T0	COMPOUND	1	1	3
NCT000009395	NCT00000939_5_T0	GENE	5	5	protease
NCT000009396	NCT00000939_6_T0	PHENOTYPE	7	7	HIV
NCT000009396	NCT00000939_6_T1	GENE	11	11	PI
NCT000009397	NCT00000939_7_T0	PHENOTYPE	6	6	HIV
NCT000009398	NCT00000939_8_T0	PHENOTYPE	27	27	HIV
NCT000009398	NCT00000939_8_T1	GENE	21	21	PI
NCT0000093910	NCT00000939_10_T0	PHENOTYPE	16	16	HIV
NCT0000093911	NCT00000939_11_T0	PHENOTYPE	24	24	toxic
NCT0000093911	NCT00000939_11_T1	PHENOTYPE	1	1	HIV
NCT0000093911	NCT00000939_11_T2	GENE	29	29	PI
NCT0000093911	NCT00000939_11_T3	GENE	3	3	has
NCT0000093913	NCT00000939_13_T0	PHENOTYPE	3	3	HIV
NCT0000093913	NCT00000939_13_T1	GENE	6	6	PI
NCT0000093913	NCT00000939_13_T2	GENE	24	24	PI
NCT0000093913	NCT00000939_13_T3	PHENOTYPE	4	4	viremia
NCT000009401	NCT00000940_1_T0	PHENOTYPE	11	11	HIV
NCT000009403	NCT00000940_3_T0	ORGAN	1	1	plasma
NCT000009404	NCT00000940_4_T0	ORGAN	7	7	plasma
NCT000009405	NCT00000940_5_T0	PHENOTYPE	11	13	primary HIV infection
NCT000009407	NCT00000940_7_T0	GENE	17	17	reduced
NCT0000094011	NCT00000940_11_T0	GENE	6	6	CD4
NCT0000094013	NCT00000940_13_T0	GENE	14	14	CD4
NCT0000094016	NCT00000940_16_T0	GENE	5	5	CD4
NCT000009411	NCT00000941_1_T0	GENE	2	2	protease
NCT000009411	NCT00000941_1_T1	COMPOUND	12	12	nelfinavir
NCT000009411	NCT00000941_1_T2	COMPOUND	9	9	ritonavir
NCT000009411	NCT00000941_1_T3	COMPOUND	10	10	saquinavir
NCT000009412	NCT00000941_2_T0	COMPOUND	5	5	pravastatin
NCT000009412	NCT00000941_2_T1	COMPOUND	6	6	simvastatin
NCT000009412	NCT00000941_2_T2	COMPOUND	8	8	atorvastatin
NCT000009413	NCT00000941_3_T0	GENE	4	4	protease
NCT000009413	NCT00000941_3_T1	GENE	6	6	has
NCT000009414	NCT00000941_4_T0	GENE	17	17	protease
NCT000009418	NCT00000941_8_T0	GENE	10	10	protease
NCT0000094111	NCT00000941_11_T0	GENE	8	8	has
NCT0000094111	NCT00000941_11_T1	PHENOTYPE	6	7	myocardial infarction
NCT0000094111	NCT00000941_11_T2	PHENOTYPE	19	21	lipid metabolism disorders
NCT0000094112	NCT00000941_12_T0	PHENOTYPE	14	15	cardiovascular complications
NCT0000094113	NCT00000941_13_T0	COMPOUND	4	4	pravastatin
NCT0000094113	NCT00000941_13_T1	COMPOUND	5	5	simvastatin
NCT0000094113	NCT00000941_13_T2	COMPOUND	7	7	atorvastatin
NCT0000094116	NCT00000941_16_T0	GENE	3	3	PK
NCT0000094117	NCT00000941_17_T0	COMPOUND	2	2	simvastatin
NCT0000094117	NCT00000941_17_T1	GENE	6	6	stops
NCT0000094117	NCT00000941_17_T2	GENE	13	13	PK
NCT0000094117	NCT00000941_17_T3	COMPOUND	4	4	atorvastatin
NCT0000094118	NCT00000941_18_T0	COMPOUND	4	4	ritonavir
NCT0000094118	NCT00000941_18_T1	COMPOUND	6	6	saquinavir
NCT0000094119	NCT00000941_19_T0	COMPOUND	2	2	simvastatin
NCT0000094119	NCT00000941_19_T1	COMPOUND	4	4	atorvastatin
NCT0000094120	NCT00000941_20_T0	COMPOUND	5	5	pravastatin
NCT0000094120	NCT00000941_20_T1	COMPOUND	7	7	simvastatin
NCT0000094120	NCT00000941_20_T2	GENE	2	2	PK
NCT0000094120	NCT00000941_20_T3	COMPOUND	9	9	atorvastatin
NCT0000094122	NCT00000941_22_T0	COMPOUND	8	8	nelfinavir
NCT0000094122	NCT00000941_22_T1	GENE	5	5	PK
NCT0000094124	NCT00000941_24_T0	COMPOUND	8	8	nelfinavir
NCT0000094124	NCT00000941_24_T1	GENE	5	5	PK
NCT000009420	NCT00000942_0_T0	PHENOTYPE	6	6	HIV
NCT000009420	NCT00000942_0_T1	PHENOTYPE	7	7	Transmission
NCT000009422	NCT00000942_2_T0	PHENOTYPE	11	11	HIV
NCT000009425	NCT00000942_5_T0	ORGAN	10	10	plasma
NCT000009426	NCT00000942_6_T0	GENE	13	13	RT
NCT000009426	NCT00000942_6_T1	GENE	3	3	has
NCT000009427	NCT00000942_7_T0	ORGAN	12	12	genital
NCT000009428	NCT00000942_8_T0	PHENOTYPE	9	9	HIV
NCT000009429	NCT00000942_9_T0	GENE	7	7	RT
NCT000009429	NCT00000942_9_T1	ORGAN	14	14	genital
NCT0000094211	NCT00000942_11_T0	BIOLOGICAL_PROCESS	10	10	gestation
NCT0000094214	NCT00000942_14_T0	COMPOUND	23	23	zidovudine
NCT0000094214	NCT00000942_14_T1	GENE	5	5	ACTG
NCT0000094214	NCT00000942_14_T2	GENE	14	14	ACTG
NCT0000094218	NCT00000942_18_T0	PHENOTYPE	12	12	HIV
NCT000009431	NCT00000943_1_T0	GENE	20	20	IL-2
NCT000009431	NCT00000943_1_T1	PHENOTYPE	12	12	HIV
NCT000009431	NCT00000943_1_T2	GENE	24	24	ACTG
NCT000009432	NCT00000943_2_T0	PHENOTYPE	4	4	HIV
NCT000009433	NCT00000943_3_T0	ORGAN	5	6	immune system
NCT000009435	NCT00000943_5_T0	PHENOTYPE	10	10	HIV
NCT000009437	NCT00000943_7_T0	PHENOTYPE	8	8	HIV
NCT000009437	NCT00000943_7_T1	CELL	2	2	T-cell
NCT000009437	NCT00000943_7_T2	PHENOTYPE	15	16	hepatitis A
NCT000009439	NCT00000943_9_T0	PHENOTYPE	1	2	antibody response
NCT000009439	NCT00000943_9_T1	PHENOTYPE	4	5	hepatitis A
NCT000009439	NCT00000943_9_T2	PHENOTYPE	7	8	hepatitis B
NCT0000094312	NCT00000943_12_T0	PHENOTYPE	3	4	hepatitis A
NCT0000094312	NCT00000943_12_T1	PHENOTYPE	10	11	hepatitis A
NCT0000094312	NCT00000943_12_T2	PHENOTYPE	6	7	antibody negative
NCT0000094313	NCT00000943_13_T0	PHENOTYPE	4	5	hepatitis B
NCT0000094313	NCT00000943_13_T1	PHENOTYPE	9	10	hepatitis B
NCT0000094313	NCT00000943_13_T2	PHENOTYPE	19	20	hepatitis B
NCT0000094313	NCT00000943_13_T3	PHENOTYPE	15	16	antibody negative
NCT0000094314	NCT00000943_14_T0	PHENOTYPE	6	6	hepatitis
NCT0000094314	NCT00000943_14_T1	PHENOTYPE	9	10	hepatitis A
NCT0000094317	NCT00000943_17_T0	PHENOTYPE	0	1	Hepatitis A
NCT0000094318	NCT00000943_18_T0	PHENOTYPE	19	19	proliferative
NCT0000094318	NCT00000943_18_T1	CELL	18	18	lymphocyte
NCT0000094318	NCT00000943_18_T2	BIOLOGICAL_PROCESS	15	16	immune response
NCT000009443	NCT00000944_3_T0	PHENOTYPE	9	9	HIV
NCT000009443	NCT00000944_3_T1	PHENOTYPE	17	17	HIV
NCT000009446	NCT00000944_6_T0	PHENOTYPE	31	31	HIV
NCT000009446	NCT00000944_6_T1	PHENOTYPE	18	18	resistant
NCT000009446	NCT00000944_6_T2	PHENOTYPE	30	30	transmitted
NCT000009447	NCT00000944_7_T0	PHENOTYPE	1	1	initiation
NCT000009447	NCT00000944_7_T1	COMPOUND	10	10	indinavir
NCT000009447	NCT00000944_7_T2	BIOLOGICAL_PROCESS	12	12	gestation
NCT000009447	NCT00000944_7_T3	GENE	8	9	protease inhibitor
NCT000009449	NCT00000944_9_T0	PHENOTYPE	4	4	cord
NCT0000094410	NCT00000944_10_T0	PHENOTYPE	2	2	cord
NCT000009458	NCT00000945_8_T0	GENE	20	20	wk
NCT000009458	NCT00000945_8_T1	COMPOUND	8	8	cidofovir
NCT000009458	NCT00000945_8_T2	GENE	12	12	hr
NCT000009459	NCT00000945_9_T0	COMPOUND	1	1	probenecid
NCT000009459	NCT00000945_9_T1	COMPOUND	12	12	cidofovir
NCT0000094510	NCT00000945_10_T0	COMPOUND	10	10	probenecid
NCT0000094511	NCT00000945_11_T0	COMPOUND	5	5	probenecid
NCT0000094511	NCT00000945_11_T1	GENE	0	0	Protease
NCT000009460	NCT00000946_0_T0	PHENOTYPE	9	9	HIV
NCT000009462	NCT00000946_2_T0	ORGAN	17	18	immune system
NCT000009463	NCT00000946_3_T0	PHENOTYPE	10	10	HIV
NCT000009464	NCT00000946_4_T0	PHENOTYPE	10	10	canarypox
NCT000009465	NCT00000946_5_T0	GENE	14	14	SF-2
NCT000009465	NCT00000946_5_T1	GENE	18	18	SF-2
NCT000009465	NCT00000946_5_T2	GENE	15	15	p24
NCT000009465	NCT00000946_5_T3	PHENOTYPE	3	3	HIV
NCT000009466	NCT00000946_6_T0	GENE	2	2	SF-2
NCT000009466	NCT00000946_6_T1	GENE	6	6	SF-2
NCT000009466	NCT00000946_6_T2	GENE	3	3	p24
NCT000009466	NCT00000946_6_T3	BIOLOGICAL_PROCESS	20	21	immune response
NCT0000094610	NCT00000946_10_T0	GENE	20	20	SF-2
NCT0000094610	NCT00000946_10_T1	GENE	16	16	has
NCT0000094614	NCT00000946_14_T0	GENE	16	16	SF-2
NCT0000094614	NCT00000946_14_T1	GENE	17	17	p24
NCT0000094614	NCT00000946_14_T2	GENE	10	11	Group 1
NCT0000094615	NCT00000946_15_T0	GENE	13	13	SF-2
NCT0000094615	NCT00000946_15_T1	GENE	17	17	SF-2
NCT0000094615	NCT00000946_15_T2	GENE	29	29	SF-2
NCT0000094615	NCT00000946_15_T3	COMPOUND	23	23	1
NCT0000094615	NCT00000946_15_T4	COMPOUND	1	1	2
NCT0000094615	NCT00000946_15_T5	COMPOUND	8	8	citrate
NCT0000094615	NCT00000946_15_T6	GENE	14	14	p24
NCT0000094615	NCT00000946_15_T7	GENE	30	30	p24
NCT0000094616	NCT00000946_16_T0	GENE	16	16	SF-2
NCT0000094616	NCT00000946_16_T1	GENE	21	21	SF-2
NCT0000094616	NCT00000946_16_T2	COMPOUND	10	10	1
NCT0000094616	NCT00000946_16_T3	COMPOUND	1	1	3
NCT0000094616	NCT00000946_16_T4	COMPOUND	25	25	3
NCT0000094616	NCT00000946_16_T5	GENE	17	17	p24
NCT0000094617	NCT00000946_17_T0	GENE	16	16	SF-2
NCT0000094617	NCT00000946_17_T1	COMPOUND	10	10	1
NCT0000094617	NCT00000946_17_T2	GENE	17	17	rgp
NCT000009471	NCT00000947_1_T0	PHENOTYPE	18	18	HIV
NCT000009471	NCT00000947_1_T1	GENE	9	9	MAC
NCT000009474	NCT00000947_4_T0	COMPOUND	10	10	azithromycin
NCT000009474	NCT00000947_4_T1	GENE	16	16	MAC
NCT000009478	NCT00000947_8_T0	COMPOUND	10	10	azithromycin
NCT000009480	NCT00000948_0_T0	GENE	12	12	CD4
NCT000009480	NCT00000948_0_T1	GENE	4	4	IL-2
NCT000009480	NCT00000948_0_T2	GENE	3	3	Interleukin-2
NCT000009482	NCT00000948_2_T0	GENE	12	12	IL-2
NCT000009482	NCT00000948_2_T1	ORGAN	16	17	immune system
NCT000009484	NCT00000948_4_T0	GENE	6	6	IL-2
NCT000009487	NCT00000948_7_T0	GENE	10	10	II
NCT000009487	NCT00000948_7_T1	GENE	16	16	IL-2
NCT000009487	NCT00000948_7_T2	GENE	33	33	III
NCT000009488	NCT00000948_8_T0	GENE	7	7	IL-2
NCT000009489	NCT00000948_9_T0	GENE	3	3	IL-2
NCT0000094810	NCT00000948_10_T0	PHENOTYPE	16	16	toxicity
NCT0000094811	NCT00000948_11_T0	GENE	8	8	IL-2
NCT000009490	NCT00000949_0_T0	GENE	14	14	CD4
NCT000009498	NCT00000949_8_T0	GENE	9	9	sc
NCT0000094910	NCT00000949_10_T0	GENE	16	16	sc
NCT0000094911	NCT00000949_11_T0	GENE	16	16	CD4
NCT000009500	NCT00000950_0_T0	PHENOTYPE	8	8	Tuberculosis
NCT000009500	NCT00000950_0_T1	BIOLOGICAL_PROCESS	0	0	Metabolism
NCT000009511	NCT00000951_1_T0	PHENOTYPE	11	11	thrush
NCT000009511	NCT00000951_1_T1	PHENOTYPE	14	15	yeast infections
NCT000009512	NCT00000951_2_T0	COMPOUND	21	21	fluconazole
NCT000009512	NCT00000951_2_T1	PHENOTYPE	7	7	thrush
NCT000009517	NCT00000951_7_T0	GENE	22	22	CD4
NCT000009517	NCT00000951_7_T1	COMPOUND	9	9	fluconazole
NCT0000095110	NCT00000951_10_T0	PHENOTYPE	24	24	thrush
NCT0000095110	NCT00000951_10_T1	COMPOUND	13	13	fluconazole
NCT0000095110	NCT00000951_10_T2	PHENOTYPE	3	4	oropharyngeal candidiasis
NCT0000095111	NCT00000951_11_T0	PHENOTYPE	9	9	acute
NCT0000095112	NCT00000951_12_T0	PHENOTYPE	12	13	vulvovaginal candidiasis
NCT000009521	NCT00000952_1_T0	PHENOTYPE	14	14	HIV
NCT000009521	NCT00000952_1_T1	COMPOUND	10	10	ritonavir
NCT000009522	NCT00000952_2_T0	PHENOTYPE	3	3	HIV
NCT000009522	NCT00000952_2_T1	PHENOTYPE	9	10	disease progression
NCT000009523	NCT00000952_3_T0	PHENOTYPE	2	2	HIV
NCT000009523	NCT00000952_3_T1	PHENOTYPE	10	12	slow disease progression
NCT000009529	NCT00000952_9_T0	GENE	3	3	II
NCT000009529	NCT00000952_9_T1	PHENOTYPE	0	0	Progression
NCT000009529	NCT00000952_9_T2	PHENOTYPE	17	17	tolerance
NCT0000095210	NCT00000952_10_T0	GENE	10	10	II
NCT0000095210	NCT00000952_10_T1	COMPOUND	19	19	ritonavir
NCT0000095210	NCT00000952_10_T2	COMPOUND	23	23	ritonavir
NCT0000095212	NCT00000952_12_T0	PHENOTYPE	1	1	Progression
NCT0000095212	NCT00000952_12_T1	COMPOUND	17	17	ritonavir
NCT0000095212	NCT00000952_12_T2	PHENOTYPE	18	18	pharmacokinetics
NCT0000095212	NCT00000952_12_T3	GENE	19	19	PK
NCT0000095213	NCT00000952_13_T0	PHENOTYPE	11	11	HIV
NCT0000095214	NCT00000952_14_T0	PHENOTYPE	24	24	HIV
NCT0000095214	NCT00000952_14_T1	PHENOTYPE	33	33	HIV
NCT0000095214	NCT00000952_14_T2	COMPOUND	10	10	ritonavir
NCT000009531	NCT00000953_1_T0	COMPOUND	13	13	VZV
NCT000009531	NCT00000953_1_T1	PHENOTYPE	0	0	HIV
NCT000009531	NCT00000953_1_T2	PHENOTYPE	18	18	shingles
NCT000009531	NCT00000953_1_T3	PHENOTYPE	15	15	infections
NCT000009531	NCT00000953_1_T4	PHENOTYPE	7	8	herpesvirus infections
NCT000009532	NCT00000953_2_T0	COMPOUND	9	9	VZV
NCT000009532	NCT00000953_2_T1	PHENOTYPE	13	13	HIV
NCT000009532	NCT00000953_2_T2	PHENOTYPE	10	10	infections
NCT000009533	NCT00000953_3_T0	COMPOUND	16	16	VZV
NCT000009533	NCT00000953_3_T1	PHENOTYPE	19	19	HIV
NCT000009533	NCT00000953_3_T2	PHENOTYPE	17	17	infections
NCT000009533	NCT00000953_3_T3	COMPOUND	39	39	acyclovir
NCT000009535	NCT00000953_5_T0	COMPOUND	9	9	VZV
NCT000009535	NCT00000953_5_T1	PHENOTYPE	13	13	HIV
NCT000009535	NCT00000953_5_T2	PHENOTYPE	10	10	infections
NCT000009536	NCT00000953_6_T0	COMPOUND	16	16	VZV
NCT000009536	NCT00000953_6_T1	PHENOTYPE	19	19	HIV
NCT000009536	NCT00000953_6_T2	PHENOTYPE	17	17	infections
NCT000009536	NCT00000953_6_T3	COMPOUND	39	39	acyclovir
NCT000009537	NCT00000953_7_T0	COMPOUND	10	10	acyclovir
NCT000009537	NCT00000953_7_T1	COMPOUND	21	21	acyclovir
NCT0000095321	NCT00000953_21_T0	PHENOTYPE	0	3	Alcohol or drug abuse
NCT000009543	NCT00000954_3_T0	PHENOTYPE	7	8	Kaposi's sarcoma
NCT000009545	NCT00000954_5_T0	GENE	30	30	II
NCT000009545	NCT00000954_5_T1	COMPOUND	1	1	vincristine
NCT000009545	NCT00000954_5_T2	PHENOTYPE	10	10	neurotoxicity
NCT000009546	NCT00000954_6_T0	GENE	2	2	II
NCT000009546	NCT00000954_6_T1	GENE	35	35	has
NCT000009546	NCT00000954_6_T2	PHENOTYPE	29	29	tolerance
NCT000009547	NCT00000954_7_T0	COMPOUND	13	13	vincristine
NCT000009547	NCT00000954_7_T1	PHENOTYPE	11	11	deletion
NCT000009554	NCT00000955_4_T0	GENE	6	6	booster
NCT000009557	NCT00000955_7_T0	GENE	6	6	booster
NCT0000095510	NCT00000955_10_T0	PHENOTYPE	9	9	induration
NCT0000095510	NCT00000955_10_T1	GENE	13	13	knot
NCT0000095510	NCT00000955_10_T2	PHENOTYPE	3	5	positive skin test
NCT000009561	NCT00000956_1_T0	PHENOTYPE	5	6	antibody response
NCT000009562	NCT00000956_2_T0	ORGAN	17	17	serum
NCT000009562	NCT00000956_2_T1	GENE	12	12	gp160
NCT000009562	NCT00000956_2_T2	GENE	18	18	gp160
NCT000009562	NCT00000956_2_T3	PHENOTYPE	19	20	antibody responses
NCT000009563	NCT00000956_3_T0	GENE	25	25	gp160
NCT000009563	NCT00000956_3_T1	GENE	15	15	booster
NCT000009563	NCT00000956_3_T2	PHENOTYPE	7	8	antibody responses
NCT000009565	NCT00000956_5_T0	GENE	25	25	gp160
NCT000009565	NCT00000956_5_T1	GENE	15	15	booster
NCT000009565	NCT00000956_5_T2	PHENOTYPE	7	8	antibody responses
NCT000009566	NCT00000956_6_T0	GENE	13	13	gp160
NCT000009567	NCT00000956_7_T0	GENE	11	11	gp160
NCT000009575	NCT00000957_5_T0	GENE	44	44	112
NCT000009575	NCT00000957_5_T1	GENE	56	56	112
NCT000009575	NCT00000957_5_T2	GENE	17	17	gp160
NCT000009575	NCT00000957_5_T3	GENE	27	28	Group 1
NCT000009582	NCT00000958_2_T0	GENE	11	11	CD4
NCT000009582	NCT00000958_2_T1	CELL	26	26	cells
NCT000009582	NCT00000958_2_T2	PHENOTYPE	9	9	HIV
NCT000009582	NCT00000958_2_T3	PHENOTYPE	24	24	HIV
NCT000009582	NCT00000958_2_T4	GENE	21	21	CD8
NCT000009584	NCT00000958_4_T0	GENE	11	11	CD4
NCT000009584	NCT00000958_4_T1	CELL	26	26	cells
NCT000009584	NCT00000958_4_T2	PHENOTYPE	9	9	HIV
NCT000009584	NCT00000958_4_T3	PHENOTYPE	24	24	HIV
NCT000009584	NCT00000958_4_T4	GENE	21	21	CD8
NCT000009587	NCT00000958_7_T0	GENE	19	19	2.3
NCT000009587	NCT00000958_7_T1	GENE	28	28	2.3
NCT000009587	NCT00000958_7_T2	GENE	18	18	Env
NCT000009587	NCT00000958_7_T3	GENE	27	27	Env
NCT000009588	NCT00000958_8_T0	GENE	14	14	2.3
NCT000009588	NCT00000958_8_T1	GENE	13	13	Env
NCT000009592	NCT00000959_2_T0	PHENOTYPE	10	10	tuberculosis
NCT000009592	NCT00000959_2_T1	PHENOTYPE	14	15	reactivation tuberculosis
NCT000009593	NCT00000959_3_T0	PHENOTYPE	15	15	HIV
NCT000009593	NCT00000959_3_T1	PHENOTYPE	21	21	tuberculosis
NCT000009593	NCT00000959_3_T2	PHENOTYPE	34	34	tuberculosis
NCT000009593	NCT00000959_3_T3	PHENOTYPE	37	38	HIV infection
NCT000009597	NCT00000959_7_T0	PHENOTYPE	10	10	tuberculosis
NCT000009597	NCT00000959_7_T1	PHENOTYPE	14	15	reactivation tuberculosis
NCT000009598	NCT00000959_8_T0	PHENOTYPE	15	15	HIV
NCT000009598	NCT00000959_8_T1	PHENOTYPE	21	21	tuberculosis
NCT000009598	NCT00000959_8_T2	PHENOTYPE	34	34	tuberculosis
NCT000009598	NCT00000959_8_T3	PHENOTYPE	37	38	HIV infection
NCT0000095912	NCT00000959_12_T0	COMPOUND	6	6	hydrochloride
NCT0000095912	NCT00000959_12_T1	GENE	9	9	B6
NCT0000095912	NCT00000959_12_T2	COMPOUND	5	5	pyridoxine
NCT0000095913	NCT00000959_13_T0	GENE	9	9	B6
NCT000009602	NCT00000960_2_T0	PHENOTYPE	7	7	HIV
NCT000009606	NCT00000960_6_T0	BIOLOGICAL_PROCESS	12	12	gestation
NCT000009609	NCT00000960_9_T0	PHENOTYPE	8	8	cord
NCT0000096018	NCT00000960_18_T0	PHENOTYPE	9	9	anemia
NCT0000096018	NCT00000960_18_T1	GENE	10	10	hemoglobin
NCT000009611	NCT00000961_1_T0	PHENOTYPE	16	16	progression
NCT000009616	NCT00000961_6_T0	PHENOTYPE	24	25	disease progression
NCT000009621	NCT00000962_1_T0	PHENOTYPE	5	5	pharmacokinetics
NCT000009626	NCT00000962_6_T0	PHENOTYPE	5	5	toxic
NCT000009626	NCT00000962_6_T1	COMPOUND	13	13	zidovudine
NCT000009626	NCT00000962_6_T2	PHENOTYPE	24	25	HIV infection
NCT000009627	NCT00000962_7_T0	GENE	3	3	has
NCT000009628	NCT00000962_8_T0	GENE	12	12	RT
NCT000009628	NCT00000962_8_T1	GENE	2	2	has
NCT000009628	NCT00000962_8_T2	GENE	10	11	reverse transcriptase
NCT0000096211	NCT00000962_11_T0	GENE	3	3	has
NCT0000096212	NCT00000962_12_T0	GENE	12	12	RT
NCT0000096212	NCT00000962_12_T1	GENE	2	2	has
NCT0000096212	NCT00000962_12_T2	GENE	10	11	reverse transcriptase
NCT0000096214	NCT00000962_14_T0	PHENOTYPE	13	13	pharmacokinetics
NCT0000096214	NCT00000962_14_T1	PHENOTYPE	3	3	staggered
NCT0000096214	NCT00000962_14_T2	PHENOTYPE	12	12	tolerance
NCT0000096214	NCT00000962_14_T3	PHENOTYPE	22	23	HIV infection
NCT0000096221	NCT00000962_21_T0	GENE	1	1	II
NCT0000096222	NCT00000962_22_T0	GENE	12	12	III
NCT0000096223	NCT00000962_23_T0	PHENOTYPE	20	20	chronic
NCT0000096224	NCT00000962_24_T0	GENE	5	5	IV
NCT0000096225	NCT00000962_25_T0	PHENOTYPE	13	13	chronic
NCT000009633	NCT00000963_3_T0	PHENOTYPE	9	9	HIV
NCT000009633	NCT00000963_3_T1	GENE	6	6	reduced
NCT000009633	NCT00000963_3_T2	GENE	3	3	has
NCT000009637	NCT00000963_7_T0	PHENOTYPE	9	9	HIV
NCT000009637	NCT00000963_7_T1	GENE	6	6	reduced
NCT000009637	NCT00000963_7_T2	GENE	3	3	has
NCT000009639	NCT00000963_9_T0	PHENOTYPE	6	7	progressive disease
NCT000009642	NCT00000964_2_T0	PHENOTYPE	9	9	HIV
NCT000009644	NCT00000964_4_T0	GENE	7	7	pH
NCT000009645	NCT00000964_5_T0	PHENOTYPE	7	7	acidity
NCT000009645	NCT00000964_5_T1	GENE	4	4	pH
NCT000009645	NCT00000964_5_T2	COMPOUND	9	9	foscarnet
NCT000009646	NCT00000964_6_T0	COMPOUND	2	2	foscarnet
NCT000009648	NCT00000964_8_T0	PHENOTYPE	9	9	HIV
NCT0000096410	NCT00000964_10_T0	GENE	7	7	pH
NCT0000096411	NCT00000964_11_T0	PHENOTYPE	7	7	acidity
NCT0000096411	NCT00000964_11_T1	GENE	4	4	pH
NCT0000096411	NCT00000964_11_T2	COMPOUND	9	9	foscarnet
NCT0000096412	NCT00000964_12_T0	COMPOUND	2	2	foscarnet
NCT0000096414	NCT00000964_14_T0	COMPOUND	3	3	ranitidine
NCT0000096414	NCT00000964_14_T1	GENE	14	14	separated
NCT0000096414	NCT00000964_14_T2	COMPOUND	11	11	foscarnet
NCT0000096415	NCT00000964_15_T0	GENE	2	2	pH
NCT0000096415	NCT00000964_15_T1	GENE	15	15	pH
NCT000009651	NCT00000965_1_T0	PHENOTYPE	8	8	pharmacokinetics
NCT000009651	NCT00000965_1_T1	ORGAN	5	5	serum
NCT000009651	NCT00000965_1_T2	ORGAN	7	7	plasma
NCT000009661	NCT00000966_1_T0	PHENOTYPE	3	3	toxicity
NCT000009661	NCT00000966_1_T1	COMPOUND	7	7	azithromycin
NCT000009662	NCT00000966_2_T0	PHENOTYPE	0	0	Encephalitis
NCT000009662	NCT00000966_2_T1	PHENOTYPE	11	11	focal
NCT000009662	NCT00000966_2_T2	PHENOTYPE	12	15	central nervous system infection
NCT000009663	NCT00000966_3_T0	PHENOTYPE	2	2	encephalitis
NCT000009664	NCT00000966_4_T0	PHENOTYPE	4	4	encephalitis
NCT000009664	NCT00000966_4_T1	PHENOTYPE	9	10	adverse effects
NCT000009667	NCT00000966_7_T0	PHENOTYPE	2	2	encephalitis
NCT000009668	NCT00000966_8_T0	PHENOTYPE	4	4	encephalitis
NCT000009668	NCT00000966_8_T1	PHENOTYPE	9	10	adverse effects
NCT0000096610	NCT00000966_10_T0	PHENOTYPE	2	2	toxoplasmosis
NCT0000096610	NCT00000966_10_T1	COMPOUND	5	5	azithromycin
NCT0000096611	NCT00000966_11_T0	COMPOUND	4	4	azithromycin
NCT0000096611	NCT00000966_11_T1	GENE	13	13	MTD
NCT0000096612	NCT00000966_12_T0	COMPOUND	4	4	pyrimethamine
NCT0000096613	NCT00000966_13_T0	COMPOUND	11	11	pyrimethamine
NCT0000096615	NCT00000966_15_T0	COMPOUND	3	3	azithromycin
NCT0000096616	NCT00000966_16_T0	PHENOTYPE	10	10	toxicity
NCT0000096616	NCT00000966_16_T1	PHENOTYPE	7	7	relapse
NCT0000096616	NCT00000966_16_T2	PHENOTYPE	25	25	relapse
NCT0000096617	NCT00000966_17_T0	GENE	2	2	MTD
NCT000009673	NCT00000967_3_T0	PHENOTYPE	9	9	toxicity
NCT000009675	NCT00000967_5_T0	GENE	5	5	has
NCT000009677	NCT00000967_7_T0	PHENOTYPE	9	9	toxicity
NCT000009679	NCT00000967_9_T0	GENE	5	5	has
NCT0000096712	NCT00000967_12_T0	PHENOTYPE	16	16	toxicity
NCT0000096713	NCT00000967_13_T0	PHENOTYPE	5	5	toxicity
NCT0000096715	NCT00000967_15_T0	PHENOTYPE	24	24	toxicity
NCT0000096715	NCT00000967_15_T1	GENE	1	1	MTD
NCT0000096720	NCT00000967_20_T0	PHENOTYPE	19	19	toxicity
NCT0000096723	NCT00000967_23_T0	PHENOTYPE	7	7	acute
NCT0000096723	NCT00000967_23_T1	COMPOUND	5	5	nystatin
NCT0000096723	NCT00000967_23_T2	COMPOUND	1	1	ketoconazole
NCT0000096723	NCT00000967_23_T3	COMPOUND	2	2	acyclovir
NCT0000096728	NCT00000967_28_T0	PHENOTYPE	10	10	symptoms
NCT0000096728	NCT00000967_28_T1	PHENOTYPE	3	3	Condition
NCT0000096730	NCT00000967_30_T0	COMPOUND	1	1	fluconazole
NCT0000096730	NCT00000967_30_T1	COMPOUND	3	3	acyclovir
NCT000009686	NCT00000968_6_T0	GENE	13	13	gp160
NCT000009688	NCT00000968_8_T0	GENE	6	6	gp160
NCT000009689	NCT00000968_9_T0	GENE	4	4	booster
NCT0000096813	NCT00000968_13_T0	GENE	11	11	gp160
NCT0000096813	NCT00000968_13_T1	GENE	19	19	gp160
NCT000009692	NCT00000969_2_T0	PHENOTYPE	3	3	toxic
NCT000009692	NCT00000969_2_T1	PHENOTYPE	13	14	HIV infection
NCT000009693	NCT00000969_3_T0	PHENOTYPE	18	18	HIV
NCT000009694	NCT00000969_4_T0	PHENOTYPE	29	29	malignancy
NCT000009694	NCT00000969_4_T1	PHENOTYPE	16	16	tolerance
NCT000009694	NCT00000969_4_T2	PHENOTYPE	25	26	opportunistic infection
NCT000009695	NCT00000969_5_T0	PHENOTYPE	13	13	toxicities
NCT000009695	NCT00000969_5_T1	PHENOTYPE	31	31	progression
NCT000009695	NCT00000969_5_T2	GENE	30	30	had
NCT000009697	NCT00000969_7_T0	PHENOTYPE	18	18	HIV
NCT000009698	NCT00000969_8_T0	PHENOTYPE	29	29	malignancy
NCT000009698	NCT00000969_8_T1	PHENOTYPE	16	16	tolerance
NCT000009698	NCT00000969_8_T2	PHENOTYPE	25	26	opportunistic infection
NCT000009699	NCT00000969_9_T0	PHENOTYPE	13	13	toxicities
NCT000009699	NCT00000969_9_T1	PHENOTYPE	31	31	progression
NCT000009699	NCT00000969_9_T2	GENE	30	30	had
NCT0000096913	NCT00000969_13_T0	PHENOTYPE	17	18	drug intolerance
NCT0000096927	NCT00000969_27_T0	PHENOTYPE	13	14	pancreatic disease
NCT000009706	NCT00000970_6_T0	PHENOTYPE	12	12	toxicity
NCT000009706	NCT00000970_6_T1	COMPOUND	2	2	ganciclovir
NCT000009706	NCT00000970_6_T2	COMPOUND	4	4	foscarnet
NCT000009707	NCT00000970_7_T0	PHENOTYPE	12	12	toxicity
NCT000009707	NCT00000970_7_T1	PHENOTYPE	22	22	toxicities
NCT0000097011	NCT00000970_11_T0	PHENOTYPE	12	12	toxicity
NCT0000097011	NCT00000970_11_T1	COMPOUND	2	2	ganciclovir
NCT0000097011	NCT00000970_11_T2	COMPOUND	4	4	foscarnet
NCT0000097012	NCT00000970_12_T0	PHENOTYPE	12	12	toxicity
NCT0000097012	NCT00000970_12_T1	PHENOTYPE	22	22	toxicities
NCT0000097015	NCT00000970_15_T0	COMPOUND	13	13	ganciclovir
NCT0000097015	NCT00000970_15_T1	COMPOUND	19	19	ganciclovir
NCT0000097015	NCT00000970_15_T2	COMPOUND	11	11	foscarnet
NCT0000097015	NCT00000970_15_T3	COMPOUND	23	23	foscarnet
NCT0000097019	NCT00000970_19_T0	COMPOUND	10	10	ganciclovir
NCT0000097019	NCT00000970_19_T1	COMPOUND	17	17	ganciclovir
NCT0000097019	NCT00000970_19_T2	COMPOUND	30	30	foscarnet
NCT000009713	NCT00000971_3_T0	COMPOUND	10	10	zidovudine
NCT000009713	NCT00000971_3_T1	PHENOTYPE	5	5	HIV
NCT000009713	NCT00000971_3_T2	COMPOUND	13	13	didanosine
NCT000009715	NCT00000971_5_T0	COMPOUND	5	5	clarithromycin
NCT000009716	NCT00000971_6_T0	COMPOUND	8	8	clarithromycin
NCT000009723	NCT00000972_3_T0	GENE	6	6	2.3
NCT000009723	NCT00000972_3_T1	PHENOTYPE	15	15	Immunodeficiency
NCT000009723	NCT00000972_3_T2	GENE	5	5	Env
NCT000009726	NCT00000972_6_T0	GENE	8	8	2.3
NCT000009726	NCT00000972_6_T1	GENE	7	7	Env
NCT000009727	NCT00000972_7_T0	PHENOTYPE	15	15	HIV
NCT000009727	NCT00000972_7_T1	GENE	3	3	2.3
NCT000009727	NCT00000972_7_T2	GENE	19	19	gp120
NCT000009727	NCT00000972_7_T3	GENE	2	2	Env
NCT000009727	NCT00000972_7_T4	GENE	17	18	envelope glycoprotein
NCT000009728	NCT00000972_8_T0	PHENOTYPE	7	7	HIV
NCT0000097210	NCT00000972_10_T0	PHENOTYPE	18	18	HIV
NCT0000097212	NCT00000972_12_T0	PHENOTYPE	7	7	HIV
NCT0000097214	NCT00000972_14_T0	PHENOTYPE	18	18	HIV
NCT0000097215	NCT00000972_15_T0	GENE	27	27	2.3
NCT0000097215	NCT00000972_15_T1	GENE	26	26	Env
NCT0000097217	NCT00000972_17_T0	GENE	6	6	separated
NCT0000097217	NCT00000972_17_T1	PHENOTYPE	0	0	Initiation
NCT0000097220	NCT00000972_20_T0	COMPOUND	6	6	MTP-PE
NCT0000097221	NCT00000972_21_T0	GENE	3	3	Env
NCT000009732	NCT00000973_2_T0	PHENOTYPE	0	0	Encephalitis
NCT000009732	NCT00000973_2_T1	PHENOTYPE	13	13	focal
NCT000009732	NCT00000973_2_T2	GENE	5	5	has
NCT000009732	NCT00000973_2_T3	PHENOTYPE	14	17	central nervous system infection
NCT000009733	NCT00000973_3_T0	PHENOTYPE	2	2	encephalitis
NCT000009734	NCT00000973_4_T0	GENE	6	6	has
NCT000009735	NCT00000973_5_T0	COMPOUND	10	10	pyrimethamine
NCT000009735	NCT00000973_5_T1	COMPOUND	12	12	sulfadiazine
NCT000009736	NCT00000973_6_T0	COMPOUND	7	7	pyrimethamine
NCT000009736	NCT00000973_6_T1	PHENOTYPE	5	5	pharmacokinetics
NCT000009737	NCT00000973_7_T0	PHENOTYPE	9	9	toxoplasmosis
NCT000009737	NCT00000973_7_T1	COMPOUND	16	16	pyrimethamine
NCT000009739	NCT00000973_9_T0	PHENOTYPE	2	2	encephalitis
NCT0000097310	NCT00000973_10_T0	GENE	6	6	has
NCT0000097311	NCT00000973_11_T0	COMPOUND	10	10	pyrimethamine
NCT0000097311	NCT00000973_11_T1	COMPOUND	12	12	sulfadiazine
NCT0000097312	NCT00000973_12_T0	COMPOUND	7	7	pyrimethamine
NCT0000097312	NCT00000973_12_T1	PHENOTYPE	5	5	pharmacokinetics
NCT0000097313	NCT00000973_13_T0	PHENOTYPE	9	9	toxoplasmosis
NCT0000097313	NCT00000973_13_T1	COMPOUND	16	16	pyrimethamine
NCT0000097315	NCT00000973_15_T0	COMPOUND	7	7	pyrimethamine
NCT0000097317	NCT00000973_17_T0	COMPOUND	3	3	calcium
NCT0000097317	NCT00000973_17_T1	COMPOUND	2	2	leucovorin
NCT0000097318	NCT00000973_18_T0	COMPOUND	3	3	calcium
NCT0000097318	NCT00000973_18_T1	COMPOUND	2	2	leucovorin
NCT000009740	NCT00000974_0_T0	PHENOTYPE	13	15	Pneumocystis Carinii Pneumonia
NCT000009744	NCT00000974_4_T0	PHENOTYPE	11	12	adverse reactions
NCT000009745	NCT00000974_5_T0	PHENOTYPE	3	3	toxicities
NCT000009745	NCT00000974_5_T1	GENE	7	7	had
NCT000009745	NCT00000974_5_T2	GENE	6	6	has
NCT000009746	NCT00000974_6_T0	COMPOUND	5	5	pentamidine
NCT000009746	NCT00000974_6_T1	COMPOUND	6	6	pentamidine
NCT000009746	NCT00000974_6_T2	COMPOUND	15	15	pentamidine
NCT000009747	NCT00000974_7_T0	PHENOTYPE	10	10	toxic
NCT000009747	NCT00000974_7_T1	COMPOUND	13	13	pentamidine
NCT000009748	NCT00000974_8_T0	COMPOUND	12	12	pentamidine
NCT0000097411	NCT00000974_11_T0	PHENOTYPE	11	12	adverse reactions
NCT0000097412	NCT00000974_12_T0	PHENOTYPE	3	3	toxicities
NCT0000097412	NCT00000974_12_T1	GENE	7	7	had
NCT0000097412	NCT00000974_12_T2	GENE	6	6	has
NCT0000097413	NCT00000974_13_T0	COMPOUND	5	5	pentamidine
NCT0000097413	NCT00000974_13_T1	COMPOUND	6	6	pentamidine
NCT0000097413	NCT00000974_13_T2	COMPOUND	15	15	pentamidine
NCT0000097414	NCT00000974_14_T0	PHENOTYPE	10	10	toxic
NCT0000097414	NCT00000974_14_T1	COMPOUND	13	13	pentamidine
NCT0000097415	NCT00000974_15_T0	COMPOUND	12	12	pentamidine
NCT0000097417	NCT00000974_17_T0	COMPOUND	6	6	pentamidine
NCT0000097417	NCT00000974_17_T1	GENE	0	1	Group 1
NCT0000097419	NCT00000974_19_T0	GENE	1	1	2b
NCT0000097419	NCT00000974_19_T1	COMPOUND	6	6	pentamidine
NCT0000097420	NCT00000974_20_T0	GENE	1	1	2b
NCT000009751	NCT00000975_1_T0	PHENOTYPE	8	8	histoplasmosis
NCT000009753	NCT00000975_3_T0	PHENOTYPE	0	0	Histoplasmosis
NCT000009753	NCT00000975_3_T1	PHENOTYPE	4	5	opportunistic infection
NCT000009754	NCT00000975_4_T0	PHENOTYPE	18	18	toxicity
NCT000009754	NCT00000975_4_T1	COMPOUND	5	6	amphotericin B
NCT000009756	NCT00000975_6_T0	PHENOTYPE	13	13	Histoplasmosis
NCT000009757	NCT00000975_7_T0	COMPOUND	6	6	itraconazole
NCT000009757	NCT00000975_7_T1	PHENOTYPE	13	13	histoplasmosis
NCT000009758	NCT00000975_8_T0	COMPOUND	6	6	itraconazole
NCT000009758	NCT00000975_8_T1	GENE	7	7	has
NCT000009758	NCT00000975_8_T2	PHENOTYPE	3	4	adverse reactions
NCT000009759	NCT00000975_9_T0	PHENOTYPE	14	14	histoplasmosis
NCT000009759	NCT00000975_9_T1	COMPOUND	23	24	amphotericin B
NCT000009759	NCT00000975_9_T2	ORGAN	0	2	Central nervous system
NCT0000097510	NCT00000975_10_T0	PHENOTYPE	22	22	histoplasmosis
NCT0000097510	NCT00000975_10_T1	GENE	1	1	has
NCT0000097510	NCT00000975_10_T2	PHENOTYPE	12	13	cryptococcal meningitis
NCT0000097512	NCT00000975_12_T0	PHENOTYPE	18	18	toxicity
NCT0000097512	NCT00000975_12_T1	COMPOUND	5	6	amphotericin B
NCT0000097514	NCT00000975_14_T0	PHENOTYPE	13	13	Histoplasmosis
NCT0000097515	NCT00000975_15_T0	COMPOUND	6	6	itraconazole
NCT0000097515	NCT00000975_15_T1	PHENOTYPE	13	13	histoplasmosis
NCT0000097516	NCT00000975_16_T0	COMPOUND	6	6	itraconazole
NCT0000097516	NCT00000975_16_T1	GENE	7	7	has
NCT0000097516	NCT00000975_16_T2	PHENOTYPE	3	4	adverse reactions
NCT0000097517	NCT00000975_17_T0	PHENOTYPE	14	14	histoplasmosis
NCT0000097517	NCT00000975_17_T1	COMPOUND	23	24	amphotericin B
NCT0000097517	NCT00000975_17_T2	ORGAN	0	2	Central nervous system
NCT0000097518	NCT00000975_18_T0	PHENOTYPE	22	22	histoplasmosis
NCT0000097518	NCT00000975_18_T1	GENE	1	1	has
NCT0000097518	NCT00000975_18_T2	PHENOTYPE	12	13	cryptococcal meningitis
NCT0000097519	NCT00000975_19_T0	PHENOTYPE	11	12	disseminated histoplasmosis
NCT0000097520	NCT00000975_20_T0	PHENOTYPE	10	10	histoplasmosis
NCT0000097521	NCT00000975_21_T0	GENE	9	9	halted
NCT0000097522	NCT00000975_22_T0	COMPOUND	2	2	itraconazole
NCT0000097523	NCT00000975_23_T0	PHENOTYPE	13	13	toxicity
NCT0000097523	NCT00000975_23_T1	PHENOTYPE	22	22	relapse
NCT0000097523	NCT00000975_23_T2	GENE	25	25	reduced
NCT0000097524	NCT00000975_24_T0	COMPOUND	12	12	itraconazole
NCT0000097524	NCT00000975_24_T1	PHENOTYPE	7	7	histoplasmosis
NCT0000097534	NCT00000975_34_T0	PHENOTYPE	4	4	feels
NCT000009762	NCT00000976_2_T0	COMPOUND	17	17	didanosine
NCT000009762	NCT00000976_2_T1	GENE	6	7	reverse transcriptase
NCT000009763	NCT00000976_3_T0	GENE	5	5	has
NCT000009764	NCT00000976_4_T0	PHENOTYPE	8	9	opportunistic infection
NCT000009765	NCT00000976_5_T0	PHENOTYPE	7	7	toxicities
NCT000009766	NCT00000976_6_T0	GENE	6	6	has
NCT000009768	NCT00000976_8_T0	PHENOTYPE	6	7	HIV infection
NCT0000097610	NCT00000976_10_T0	COMPOUND	17	17	didanosine
NCT0000097610	NCT00000976_10_T1	GENE	6	7	reverse transcriptase
NCT0000097611	NCT00000976_11_T0	GENE	5	5	has
NCT0000097612	NCT00000976_12_T0	PHENOTYPE	8	9	opportunistic infection
NCT0000097613	NCT00000976_13_T0	PHENOTYPE	7	7	toxicities
NCT0000097614	NCT00000976_14_T0	GENE	6	6	has
NCT0000097616	NCT00000976_16_T0	PHENOTYPE	6	7	HIV infection
NCT0000097617	NCT00000976_17_T0	GENE	3	3	had
NCT0000097624	NCT00000976_24_T0	GENE	13	13	pg-m
NCT0000097624	NCT00000976_24_T1	GENE	8	8	p24
NCT0000097625	NCT00000976_25_T0	PHENOTYPE	14	14	toxicity
NCT0000097626	NCT00000976_26_T0	PHENOTYPE	0	0	Pharmacokinetics
NCT0000097627	NCT00000976_27_T0	GENE	3	3	IV
NCT0000097630	NCT00000976_30_T0	GENE	4	4	IV
NCT000009771	NCT00000977_1_T0	GENE	7	7	fold
NCT000009774	NCT00000977_4_T0	GENE	7	7	gp160
NCT000009776	NCT00000977_6_T0	PHENOTYPE	17	17	HIV
NCT000009778	NCT00000977_8_T0	GENE	18	18	gp160
NCT000009778	NCT00000977_8_T1	PHENOTYPE	20	21	hepatitis B
NCT0000097712	NCT00000977_12_T0	GENE	12	12	gp160
NCT0000097712	NCT00000977_12_T1	GENE	16	16	C1
NCT0000097712	NCT00000977_12_T2	GENE	17	17	C2
NCT0000097712	NCT00000977_12_T3	PHENOTYPE	29	30	hepatitis B
NCT000009781	NCT00000978_1_T0	PHENOTYPE	18	18	toxicity
NCT000009784	NCT00000978_4_T0	PHENOTYPE	14	14	mutants
NCT000009784	NCT00000978_4_T1	PHENOTYPE	13	13	resistant
NCT000009785	NCT00000978_5_T0	PHENOTYPE	7	7	HIV
NCT000009785	NCT00000978_5_T1	GENE	4	4	reduced
NCT000009787	NCT00000978_7_T0	PHENOTYPE	0	0	HIV
NCT000009787	NCT00000978_7_T1	PHENOTYPE	1	1	strains
NCT000009787	NCT00000978_7_T2	PHENOTYPE	3	4	decreased sensitivity
NCT0000097811	NCT00000978_11_T0	PHENOTYPE	14	14	mutants
NCT0000097811	NCT00000978_11_T1	PHENOTYPE	13	13	resistant
NCT0000097812	NCT00000978_12_T0	PHENOTYPE	7	7	HIV
NCT0000097812	NCT00000978_12_T1	GENE	4	4	reduced
NCT0000097814	NCT00000978_14_T0	PHENOTYPE	0	0	HIV
NCT0000097814	NCT00000978_14_T1	PHENOTYPE	1	1	strains
NCT0000097814	NCT00000978_14_T2	PHENOTYPE	3	4	decreased sensitivity
NCT0000097824	NCT00000978_24_T0	PHENOTYPE	3	3	HIV
NCT0000097824	NCT00000978_24_T1	GENE	10	10	kit
NCT0000097824	NCT00000978_24_T2	PHENOTYPE	0	1	Positive antibody
NCT0000097826	NCT00000978_26_T0	PHENOTYPE	3	4	alcohol abuse
NCT000009792	NCT00000979_2_T0	PHENOTYPE	8	8	toxicities
NCT000009792	NCT00000979_2_T1	GENE	3	3	has
NCT000009795	NCT00000979_5_T0	PHENOTYPE	16	16	toxicity
NCT000009795	NCT00000979_5_T1	PHENOTYPE	12	12	HIV
NCT000009795	NCT00000979_5_T2	BIOLOGICAL_PROCESS	10	10	reproduction
NCT000009797	NCT00000979_7_T0	PHENOTYPE	8	8	toxicities
NCT000009797	NCT00000979_7_T1	GENE	3	3	has
NCT0000097910	NCT00000979_10_T0	PHENOTYPE	16	16	toxicity
NCT0000097910	NCT00000979_10_T1	PHENOTYPE	12	12	HIV
NCT0000097910	NCT00000979_10_T2	BIOLOGICAL_PROCESS	10	10	reproduction
NCT0000097919	NCT00000979_19_T0	COMPOUND	18	18	zidovudine
NCT0000097919	NCT00000979_19_T1	PHENOTYPE	7	8	opportunistic infections
NCT0000097921	NCT00000979_21_T0	COMPOUND	1	1	acyclovir
NCT0000097922	NCT00000979_22_T0	GENE	7	7	IND
NCT0000097923	NCT00000979_23_T0	PHENOTYPE	9	9	toxicities
NCT0000097931	NCT00000979_31_T0	PHENOTYPE	11	11	toxicity
NCT0000097931	NCT00000979_31_T1	PHENOTYPE	6	6	recurrent
NCT0000097944	NCT00000979_44_T0	PHENOTYPE	1	4	alcohol or drug abuse
NCT000009801	NCT00000980_1_T0	GENE	4	4	has
NCT000009801	NCT00000980_1_T1	PHENOTYPE	16	16	diarrhea
NCT000009802	NCT00000980_2_T0	PHENOTYPE	10	10	symptoms
NCT000009802	NCT00000980_2_T1	PHENOTYPE	13	13	diarrhea
NCT000009802	NCT00000980_2_T2	COMPOUND	4	4	spiramycin
NCT000009803	NCT00000980_3_T0	COMPOUND	10	10	spiramycin
NCT000009804	NCT00000980_4_T0	COMPOUND	8	8	spiramycin
NCT000009805	NCT00000980_5_T0	COMPOUND	14	14	spiramycin
NCT000009807	NCT00000980_7_T0	PHENOTYPE	10	10	symptoms
NCT000009807	NCT00000980_7_T1	PHENOTYPE	13	13	diarrhea
NCT000009807	NCT00000980_7_T2	COMPOUND	4	4	spiramycin
NCT000009808	NCT00000980_8_T0	COMPOUND	10	10	spiramycin
NCT000009809	NCT00000980_9_T0	COMPOUND	8	8	spiramycin
NCT0000098010	NCT00000980_10_T0	COMPOUND	14	14	spiramycin
NCT0000098012	NCT00000980_12_T0	COMPOUND	17	17	spiramycin
NCT0000098013	NCT00000980_13_T0	COMPOUND	6	6	spiramycin
NCT0000098014	NCT00000980_14_T0	COMPOUND	15	15	spiramycin
NCT0000098016	NCT00000980_16_T0	PHENOTYPE	2	2	relapse
NCT0000098016	NCT00000980_16_T1	COMPOUND	16	16	spiramycin
NCT0000098019	NCT00000980_19_T0	GENE	12	12	has
NCT0000098019	NCT00000980_19_T1	COMPOUND	3	3	spiramycin
NCT0000098020	NCT00000980_20_T0	PHENOTYPE	7	7	toxicity
NCT0000098026	NCT00000980_26_T0	COMPOUND	3	3	lactose
NCT000009816	NCT00000981_6_T0	PHENOTYPE	17	17	bloodstream
NCT000009816	NCT00000981_6_T1	COMPOUND	8	8	FIAC
NCT000009816	NCT00000981_6_T2	COMPOUND	25	25	FIAU
NCT0000098112	NCT00000981_12_T0	PHENOTYPE	17	17	bloodstream
NCT0000098112	NCT00000981_12_T1	COMPOUND	8	8	FIAC
NCT0000098112	NCT00000981_12_T2	COMPOUND	25	25	FIAU
NCT0000098114	NCT00000981_14_T0	PHENOTYPE	17	17	toxicity
NCT0000098114	NCT00000981_14_T1	PHENOTYPE	15	15	tolerance
NCT0000098116	NCT00000981_16_T0	PHENOTYPE	15	15	tolerance
NCT0000098117	NCT00000981_17_T0	PHENOTYPE	15	15	severity
NCT0000098117	NCT00000981_17_T1	PHENOTYPE	18	18	tolerance
NCT000009823	NCT00000982_3_T0	PHENOTYPE	8	8	bloodstream
NCT000009823	NCT00000982_3_T1	COMPOUND	11	11	zidovudine
NCT000009823	NCT00000982_3_T2	PHENOTYPE	17	18	HIV infection
NCT000009823	NCT00000982_3_T3	PHENOTYPE	18	20	infection in children
NCT000009825	NCT00000982_5_T0	ORGAN	47	47	plasma
NCT000009825	NCT00000982_5_T1	PHENOTYPE	13	13	tolerance
NCT000009825	NCT00000982_5_T2	PHENOTYPE	75	76	HIV infection
NCT000009825	NCT00000982_5_T3	PHENOTYPE	92	93	HIV infection
NCT000009826	NCT00000982_6_T0	ORGAN	18	19	nervous system
NCT000009826	NCT00000982_6_T1	PHENOTYPE	7	8	HIV disease
NCT000009827	NCT00000982_7_T0	PHENOTYPE	1	1	complication
NCT000009827	NCT00000982_7_T1	PHENOTYPE	7	7	HIV
NCT000009827	NCT00000982_7_T2	PHENOTYPE	2	2	affects
NCT000009828	NCT00000982_8_T0	PHENOTYPE	21	21	symptoms
NCT000009828	NCT00000982_8_T1	GENE	26	26	had
NCT000009828	NCT00000982_8_T2	PHENOTYPE	13	14	HIV infection
NCT0000098210	NCT00000982_10_T0	PHENOTYPE	20	20	HIV
NCT0000098211	NCT00000982_11_T0	PHENOTYPE	25	25	encephalopathy
NCT0000098212	NCT00000982_12_T0	PHENOTYPE	3	4	cognitive function
NCT0000098212	NCT00000982_12_T1	PHENOTYPE	12	13	AIDS encephalopathy
NCT0000098212	NCT00000982_12_T2	ORGAN	25	27	central nervous system
NCT0000098214	NCT00000982_14_T0	PHENOTYPE	28	28	bloodstream
NCT0000098216	NCT00000982_16_T0	PHENOTYPE	1	1	complication
NCT0000098216	NCT00000982_16_T1	PHENOTYPE	7	7	HIV
NCT0000098216	NCT00000982_16_T2	PHENOTYPE	2	2	affects
NCT0000098217	NCT00000982_17_T0	PHENOTYPE	21	21	symptoms
NCT0000098217	NCT00000982_17_T1	GENE	26	26	had
NCT0000098217	NCT00000982_17_T2	PHENOTYPE	13	14	HIV infection
NCT0000098219	NCT00000982_19_T0	PHENOTYPE	20	20	HIV
NCT0000098220	NCT00000982_20_T0	PHENOTYPE	25	25	encephalopathy
NCT0000098221	NCT00000982_21_T0	PHENOTYPE	3	4	cognitive function
NCT0000098221	NCT00000982_21_T1	PHENOTYPE	12	13	AIDS encephalopathy
NCT0000098221	NCT00000982_21_T2	ORGAN	25	27	central nervous system
NCT0000098223	NCT00000982_23_T0	PHENOTYPE	28	28	bloodstream
NCT0000098224	NCT00000982_24_T0	PHENOTYPE	4	5	progressive encephalopathy
NCT0000098225	NCT00000982_25_T0	GENE	5	5	has
NCT0000098226	NCT00000982_26_T0	GENE	1	1	has
NCT0000098227	NCT00000982_27_T0	PHENOTYPE	8	8	toxicities
NCT0000098229	NCT00000982_29_T0	GENE	22	22	P2
NCT0000098229	NCT00000982_29_T1	PHENOTYPE	11	11	encephalopathy
NCT0000098238	NCT00000982_38_T0	PHENOTYPE	10	10	progressive
NCT0000098238	NCT00000982_38_T1	PHENOTYPE	11	11	encephalopathy
NCT0000098238	NCT00000982_38_T2	PHENOTYPE	3	4	HIV encephalopathy
NCT0000098239	NCT00000982_39_T0	PHENOTYPE	26	27	HIV Infection
NCT000009831	NCT00000983_1_T0	PHENOTYPE	26	26	toxicities
NCT000009832	NCT00000983_2_T0	GENE	1	1	has
NCT000009832	NCT00000983_2_T1	PHENOTYPE	12	13	opportunistic infections
NCT000009832	NCT00000983_2_T2	PHENOTYPE	20	21	HIV infection
NCT000009833	NCT00000983_3_T0	PHENOTYPE	6	6	HIV
NCT000009836	NCT00000983_6_T0	PHENOTYPE	5	5	learned
NCT000009838	NCT00000983_8_T0	PHENOTYPE	6	6	HIV
NCT0000098311	NCT00000983_11_T0	PHENOTYPE	5	5	learned
NCT000009843	NCT00000984_3_T0	PHENOTYPE	20	20	HIV
NCT000009843	NCT00000984_3_T1	PHENOTYPE	17	18	human cells
NCT000009843	NCT00000984_3_T2	PHENOTYPE	7	8	HIV infection
NCT000009845	NCT00000984_5_T0	PHENOTYPE	30	30	HIV
NCT000009848	NCT00000984_8_T0	PHENOTYPE	30	30	HIV
NCT0000098412	NCT00000984_12_T0	PHENOTYPE	3	3	withdrawn
NCT0000098413	NCT00000984_13_T0	PHENOTYPE	8	8	tetanus
NCT0000098413	NCT00000984_13_T1	GENE	5	5	DPT
NCT0000098413	NCT00000984_13_T2	PHENOTYPE	13	13	polio
NCT0000098413	NCT00000984_13_T3	PHENOTYPE	7	7	pertussis
NCT0000098413	NCT00000984_13_T4	PHENOTYPE	6	6	diphtheria
NCT0000098413	NCT00000984_13_T5	PHENOTYPE	18	19	antibody response
NCT0000098419	NCT00000984_19_T0	PHENOTYPE	7	7	HIV
NCT0000098419	NCT00000984_19_T1	PHENOTYPE	12	13	HIV infection
NCT0000098422	NCT00000984_22_T0	PHENOTYPE	10	11	HIV infection
NCT000009851	NCT00000985_1_T0	GENE	8	8	has
NCT000009851	NCT00000985_1_T1	PHENOTYPE	24	25	Herpes simplex
NCT000009853	NCT00000985_3_T0	PHENOTYPE	37	37	progression
NCT000009853	NCT00000985_3_T1	COMPOUND	5	5	vidarabine
NCT000009853	NCT00000985_3_T2	COMPOUND	22	22	acyclovir
NCT000009853	NCT00000985_3_T3	GENE	16	16	has
NCT000009853	NCT00000985_3_T4	COMPOUND	3	3	foscarnet
NCT000009853	NCT00000985_3_T5	PHENOTYPE	12	14	herpes simplex infection
NCT000009853	NCT00000985_3_T6	PHENOTYPE	40	42	herpes simplex infection
NCT000009856	NCT00000985_6_T0	PHENOTYPE	37	37	progression
NCT000009856	NCT00000985_6_T1	COMPOUND	5	5	vidarabine
NCT000009856	NCT00000985_6_T2	COMPOUND	22	22	acyclovir
NCT000009856	NCT00000985_6_T3	GENE	16	16	has
NCT000009856	NCT00000985_6_T4	COMPOUND	3	3	foscarnet
NCT000009856	NCT00000985_6_T5	PHENOTYPE	12	14	herpes simplex infection
NCT000009856	NCT00000985_6_T6	PHENOTYPE	40	42	herpes simplex infection
NCT000009857	NCT00000985_7_T0	COMPOUND	14	14	acyclovir
NCT000009857	NCT00000985_7_T1	GENE	11	11	IV
NCT000009858	NCT00000985_8_T0	COMPOUND	10	10	acyclovir
NCT000009858	NCT00000985_8_T1	ORGAN	6	6	serum
NCT000009859	NCT00000985_9_T0	COMPOUND	35	35	vidarabine
NCT000009859	NCT00000985_9_T1	COMPOUND	15	15	acyclovir
NCT000009859	NCT00000985_9_T2	COMPOUND	32	32	acyclovir
NCT000009859	NCT00000985_9_T3	COMPOUND	33	33	foscarnet
NCT0000098510	NCT00000985_10_T0	PHENOTYPE	9	9	resistant
NCT0000098510	NCT00000985_10_T1	COMPOUND	11	11	acyclovir
NCT0000098510	NCT00000985_10_T2	PHENOTYPE	6	7	herpes lesions
NCT0000098511	NCT00000985_11_T0	COMPOUND	30	30	vidarabine
NCT0000098511	NCT00000985_11_T1	COMPOUND	28	28	foscarnet
NCT0000098511	NCT00000985_11_T2	GENE	19	19	IV
NCT0000098512	NCT00000985_12_T0	GENE	4	4	IV
NCT0000098513	NCT00000985_13_T0	GENE	4	4	IV
NCT0000098514	NCT00000985_14_T0	COMPOUND	7	7	vidarabine
NCT0000098514	NCT00000985_14_T1	COMPOUND	27	27	vidarabine
NCT0000098514	NCT00000985_14_T2	COMPOUND	5	5	foscarnet
NCT0000098514	NCT00000985_14_T3	COMPOUND	25	25	foscarnet
NCT000009861	NCT00000986_1_T0	GENE	6	6	has
NCT000009862	NCT00000986_2_T0	CELL	20	20	cells
NCT000009862	NCT00000986_2_T1	GENE	0	0	IL-2
NCT000009862	NCT00000986_2_T2	PHENOTYPE	19	19	tumor
NCT000009862	NCT00000986_2_T3	BIOLOGICAL_PROCESS	13	14	immune response
NCT000009866	NCT00000986_6_T0	CELL	20	20	cells
NCT000009866	NCT00000986_6_T1	GENE	0	0	IL-2
NCT000009866	NCT00000986_6_T2	PHENOTYPE	19	19	tumor
NCT000009866	NCT00000986_6_T3	BIOLOGICAL_PROCESS	13	14	immune response
NCT0000098610	NCT00000986_10_T0	GENE	8	8	IL-2
NCT0000098611	NCT00000986_11_T0	GENE	11	11	IL-2
NCT0000098612	NCT00000986_12_T0	GENE	27	27	IL-2
NCT0000098626	NCT00000986_26_T0	PHENOTYPE	3	4	alcohol abuse
NCT000009871	NCT00000987_1_T0	PHENOTYPE	12	12	tumor
NCT000009871	NCT00000987_1_T1	PHENOTYPE	19	19	infections
NCT000009871	NCT00000987_1_T2	PHENOTYPE	27	28	Kaposi's sarcoma
NCT000009872	NCT00000987_2_T0	PHENOTYPE	30	30	learned
NCT000009872	NCT00000987_2_T1	GENE	28	28	has
NCT000009872	NCT00000987_2_T2	GENE	1	1	MTD
NCT000009874	NCT00000987_4_T0	PHENOTYPE	30	30	learned
NCT000009874	NCT00000987_4_T1	GENE	28	28	has
NCT000009874	NCT00000987_4_T2	GENE	1	1	MTD
NCT000009876	NCT00000987_6_T0	COMPOUND	23	23	bleomycin
NCT000009876	NCT00000987_6_T1	COMPOUND	25	25	vincristine
NCT000009876	NCT00000987_6_T2	COMPOUND	16	16	doxorubicin
NCT000009877	NCT00000987_7_T0	COMPOUND	28	28	bleomycin
NCT000009877	NCT00000987_7_T1	COMPOUND	30	30	vincristine
NCT000009877	NCT00000987_7_T2	GENE	4	4	MTD
NCT000009878	NCT00000987_8_T0	COMPOUND	22	22	bleomycin
NCT000009878	NCT00000987_8_T1	COMPOUND	23	23	vincristine
NCT000009878	NCT00000987_8_T2	COMPOUND	16	16	doxorubicin
NCT000009879	NCT00000987_9_T0	GENE	1	1	MTD
NCT0000098710	NCT00000987_10_T0	PHENOTYPE	6	6	tumor
NCT0000098712	NCT00000987_12_T0	COMPOUND	21	21	bleomycin
NCT0000098712	NCT00000987_12_T1	COMPOUND	23	23	vincristine
NCT0000098712	NCT00000987_12_T2	COMPOUND	28	28	doxorubicin
NCT0000098716	NCT00000987_16_T0	PHENOTYPE	6	6	toxicity
NCT0000098717	NCT00000987_17_T0	PHENOTYPE	0	0	Toxicity
NCT0000098717	NCT00000987_17_T1	PHENOTYPE	9	9	Acute
NCT0000098717	NCT00000987_17_T2	PHENOTYPE	11	11	Subacute
NCT0000098721	NCT00000987_21_T0	PHENOTYPE	1	4	alcohol or drug abuse
NCT000009881	NCT00000988_1_T0	GENE	13	13	II
NCT000009881	NCT00000988_1_T1	GENE	15	15	III
NCT000009882	NCT00000988_2_T0	PHENOTYPE	13	14	HIV infection
NCT000009885	NCT00000988_5_T0	PHENOTYPE	9	9	toxic
NCT000009885	NCT00000988_5_T1	CELL	11	12	blood cells
NCT000009888	NCT00000988_8_T0	PHENOTYPE	9	9	toxic
NCT000009888	NCT00000988_8_T1	CELL	11	12	blood cells
NCT000009889	NCT00000988_9_T0	GENE	5	5	has
NCT000009889	NCT00000988_9_T1	GENE	4	4	MTD
NCT0000098810	NCT00000988_10_T0	GENE	1	1	MED
NCT0000098816	NCT00000988_16_T0	PHENOTYPE	10	10	toxic
NCT0000098817	NCT00000988_17_T0	GENE	10	10	p24
NCT0000098819	NCT00000988_19_T0	PHENOTYPE	3	3	fever
NCT0000098819	NCT00000988_19_T1	COMPOUND	4	4	aspirin
NCT0000098831	NCT00000988_31_T0	PHENOTYPE	1	4	alcohol or drug abuse
NCT000009893	NCT00000989_3_T0	GENE	3	3	ANC
NCT000009897	NCT00000989_7_T0	PHENOTYPE	9	9	toxicity
NCT000009897	NCT00000989_7_T1	PHENOTYPE	26	26	OIs
NCT000009897	NCT00000989_7_T2	PHENOTYPE	15	15	granulocytopenia
NCT000009897	NCT00000989_7_T3	PHENOTYPE	28	29	staphylococcal septicemia
NCT0000098912	NCT00000989_12_T0	GENE	0	0	GM-CSF
NCT0000098912	NCT00000989_12_T1	GENE	5	5	hormone
NCT0000098912	NCT00000989_12_T2	ORGAN	9	10	bone marrow
NCT0000098912	NCT00000989_12_T3	CELL	14	16	white blood cells
NCT0000098915	NCT00000989_15_T0	GENE	3	3	ANC
NCT0000098919	NCT00000989_19_T0	PHENOTYPE	9	9	toxicity
NCT0000098919	NCT00000989_19_T1	PHENOTYPE	26	26	OIs
NCT0000098919	NCT00000989_19_T2	PHENOTYPE	15	15	granulocytopenia
NCT0000098919	NCT00000989_19_T3	PHENOTYPE	28	29	staphylococcal septicemia
NCT0000098924	NCT00000989_24_T0	GENE	0	0	GM-CSF
NCT0000098924	NCT00000989_24_T1	GENE	5	5	hormone
NCT0000098924	NCT00000989_24_T2	ORGAN	9	10	bone marrow
NCT0000098924	NCT00000989_24_T3	CELL	14	16	white blood cells
NCT0000098927	NCT00000989_27_T0	GENE	11	11	ANC
NCT0000098927	NCT00000989_27_T1	GENE	0	0	GM-CSF
NCT0000098928	NCT00000989_28_T0	GENE	7	7	ANC
NCT0000098928	NCT00000989_28_T1	GENE	21	21	ANC
NCT0000098928	NCT00000989_28_T2	PHENOTYPE	6	6	neutropenia
NCT0000098928	NCT00000989_28_T3	GENE	16	16	GM-CSF
NCT0000098929	NCT00000989_29_T0	GENE	21	21	extended
NCT0000098934	NCT00000989_34_T0	GENE	16	16	GM-CSF
NCT0000098937	NCT00000989_37_T0	GENE	6	6	GM-CSF
NCT0000098937	NCT00000989_37_T1	GENE	9	9	GM-CSF
NCT000009902	NCT00000990_2_T0	PHENOTYPE	12	12	symptoms
NCT000009902	NCT00000990_2_T1	PHENOTYPE	21	21	symptoms
NCT000009902	NCT00000990_2_T2	PHENOTYPE	14	14	infections
NCT000009903	NCT00000990_3_T0	CELL	12	12	cells
NCT000009903	NCT00000990_3_T1	PHENOTYPE	14	14	HIV
NCT000009903	NCT00000990_3_T2	GENE	1	1	has
NCT000009904	NCT00000990_4_T0	GENE	1	1	has
NCT000009904	NCT00000990_4_T1	PHENOTYPE	12	13	opportunistic infections
NCT000009904	NCT00000990_4_T2	PHENOTYPE	20	21	HIV infection
NCT000009905	NCT00000990_5_T0	PHENOTYPE	6	6	HIV
NCT000009907	NCT00000990_7_T0	GENE	1	1	has
NCT000009907	NCT00000990_7_T1	PHENOTYPE	12	13	opportunistic infections
NCT000009907	NCT00000990_7_T2	PHENOTYPE	20	21	HIV infection
NCT000009908	NCT00000990_8_T0	PHENOTYPE	6	6	HIV
NCT0000099015	NCT00000990_15_T0	GENE	5	5	CSF
NCT0000099015	NCT00000990_15_T1	ORGAN	21	22	nervous system
NCT0000099017	NCT00000990_17_T0	GENE	7	7	reduced
NCT0000099024	NCT00000990_24_T0	PHENOTYPE	16	16	malignancy
NCT0000099024	NCT00000990_24_T1	PHENOTYPE	9	9	diseases
NCT0000099024	NCT00000990_24_T2	PHENOTYPE	21	21	encephalopathy
NCT0000099024	NCT00000990_24_T3	PHENOTYPE	14	15	opportunistic infections
NCT0000099024	NCT00000990_24_T4	PHENOTYPE	17	19	recurrent bacterial infections
NCT000009911	NCT00000991_1_T0	COMPOUND	28	28	fluconazole
NCT000009911	NCT00000991_1_T1	GENE	22	22	ACTG
NCT000009911	NCT00000991_1_T2	GENE	20	20	nested
NCT000009911	NCT00000991_1_T3	PHENOTYPE	38	39	fungal disease
NCT0000099111	NCT00000991_11_T0	COMPOUND	14	14	dapsone
NCT0000099111	NCT00000991_11_T1	GENE	16	16	PEN
NCT0000099114	NCT00000991_14_T0	GENE	4	4	ACTG
NCT0000099115	NCT00000991_15_T0	GENE	0	0	ACTG
NCT000009921	NCT00000992_1_T0	PHENOTYPE	0	0	Histoplasmosis
NCT000009921	NCT00000992_1_T1	PHENOTYPE	4	5	opportunistic infection
NCT000009922	NCT00000992_2_T0	GENE	2	2	has
NCT000009923	NCT00000992_3_T0	PHENOTYPE	29	29	relapse
NCT000009923	NCT00000992_3_T1	PHENOTYPE	24	24	histoplasmosis
NCT000009923	NCT00000992_3_T2	COMPOUND	19	20	amphotericin B
NCT000009925	NCT00000992_5_T0	PHENOTYPE	6	6	recurrence
NCT000009926	NCT00000992_6_T0	PHENOTYPE	25	25	relapse
NCT000009926	NCT00000992_6_T1	PHENOTYPE	24	24	histoplasmosis
NCT000009926	NCT00000992_6_T2	GENE	1	1	has
NCT000009926	NCT00000992_6_T3	PHENOTYPE	7	8	disseminated histoplasmosis
NCT000009928	NCT00000992_8_T0	GENE	2	2	has
NCT000009929	NCT00000992_9_T0	PHENOTYPE	29	29	relapse
NCT000009929	NCT00000992_9_T1	PHENOTYPE	24	24	histoplasmosis
NCT000009929	NCT00000992_9_T2	COMPOUND	19	20	amphotericin B
NCT0000099211	NCT00000992_11_T0	PHENOTYPE	6	6	recurrence
NCT0000099212	NCT00000992_12_T0	PHENOTYPE	25	25	relapse
NCT0000099212	NCT00000992_12_T1	PHENOTYPE	24	24	histoplasmosis
NCT0000099212	NCT00000992_12_T2	GENE	1	1	has
NCT0000099212	NCT00000992_12_T3	PHENOTYPE	7	8	disseminated histoplasmosis
NCT0000099213	NCT00000992_13_T0	PHENOTYPE	12	12	acute
NCT0000099213	NCT00000992_13_T1	PHENOTYPE	16	17	disseminated histoplasmosis
NCT0000099213	NCT00000992_13_T2	COMPOUND	8	9	amphotericin B
NCT0000099214	NCT00000992_14_T0	COMPOUND	6	6	itraconazole
NCT0000099215	NCT00000992_15_T0	PHENOTYPE	6	6	toxicity
NCT0000099215	NCT00000992_15_T1	COMPOUND	15	15	itraconazole
NCT0000099215	NCT00000992_15_T2	COMPOUND	24	24	itraconazole
NCT0000099215	NCT00000992_15_T3	GENE	27	27	has
NCT0000099218	NCT00000992_18_T0	COMPOUND	1	1	itraconazole
NCT0000099218	NCT00000992_18_T1	PHENOTYPE	5	5	histoplasmosis
NCT000009931	NCT00000993_1_T0	PHENOTYPE	17	17	HIV
NCT000009933	NCT00000993_3_T0	PHENOTYPE	11	11	progression
NCT000009933	NCT00000993_3_T1	GENE	5	5	has
NCT000009937	NCT00000993_7_T0	PHENOTYPE	11	11	progression
NCT000009937	NCT00000993_7_T1	GENE	5	5	has
NCT0000099311	NCT00000993_11_T0	PHENOTYPE	43	43	HIV
NCT0000099311	NCT00000993_11_T1	PHENOTYPE	41	42	HIV infection
NCT0000099319	NCT00000993_19_T0	PHENOTYPE	3	4	alcohol abuse
NCT000009942	NCT00000994_2_T0	PHENOTYPE	12	13	HIV infection
NCT000009945	NCT00000994_5_T0	PHENOTYPE	12	13	HIV infection
NCT000009949	NCT00000994_9_T0	PHENOTYPE	16	17	oral lesions
NCT000009949	NCT00000994_9_T1	PHENOTYPE	25	26	oral lesions
NCT0000099413	NCT00000994_13_T0	PHENOTYPE	0	0	Toxicity
NCT0000099413	NCT00000994_13_T1	PHENOTYPE	8	8	Acute
NCT0000099413	NCT00000994_13_T2	PHENOTYPE	10	10	Subacute
NCT0000099510	NCT00000995_10_T0	GENE	0	0	IV
NCT000009962	NCT00000996_2_T0	PHENOTYPE	10	10	toxicity
NCT000009962	NCT00000996_2_T1	GENE	17	17	reduced
NCT000009964	NCT00000996_4_T0	PHENOTYPE	10	10	toxicity
NCT000009964	NCT00000996_4_T1	GENE	17	17	reduced
NCT000009965	NCT00000996_5_T0	COMPOUND	9	9	doxorubicin
NCT000009965	NCT00000996_5_T1	GENE	13	13	IV
NCT000009967	NCT00000996_7_T0	PHENOTYPE	4	4	toxicity
NCT000009977	NCT00000997_7_T0	GENE	13	13	IV
NCT000009979	NCT00000997_9_T0	PHENOTYPE	3	3	toxicity
NCT0000099710	NCT00000997_10_T0	PHENOTYPE	18	18	bloodstream
NCT0000099715	NCT00000997_15_T0	COMPOUND	3	3	aspirin
NCT0000099716	NCT00000997_16_T0	COMPOUND	3	3	aspirin
NCT000009992	NCT00000999_2_T0	PHENOTYPE	14	14	toxicity
NCT000009993	NCT00000999_3_T0	GENE	23	23	II
NCT000009993	NCT00000999_3_T1	PHENOTYPE	6	6	toxicity
NCT000009993	NCT00000999_3_T2	PHENOTYPE	37	37	toxicity
NCT000009995	NCT00000999_5_T0	PHENOTYPE	30	30	labeling
NCT000009995	NCT00000999_5_T1	GENE	18	18	IND
NCT000009996	NCT00000999_6_T0	PHENOTYPE	11	11	toxicity
NCT000010001	NCT00001000_1_T0	CELL	8	8	cells
NCT000010003	NCT00001000_3_T0	PHENOTYPE	10	11	HIV infection
NCT000010004	NCT00001000_4_T0	PHENOTYPE	5	5	toxicity
NCT000010004	NCT00001000_4_T1	COMPOUND	0	0	Ampligen
NCT000010004	NCT00001000_4_T2	PHENOTYPE	29	30	neurologic symptoms
NCT000010004	NCT00001000_4_T3	PHENOTYPE	32	33	HIV infection
NCT000010005	NCT00001000_5_T0	PHENOTYPE	26	27	HIV infection
NCT000010007	NCT00001000_7_T0	PHENOTYPE	10	11	HIV infection
NCT000010008	NCT00001000_8_T0	PHENOTYPE	5	5	toxicity
NCT000010008	NCT00001000_8_T1	COMPOUND	0	0	Ampligen
NCT000010008	NCT00001000_8_T2	PHENOTYPE	29	30	neurologic symptoms
NCT000010008	NCT00001000_8_T3	PHENOTYPE	32	33	HIV infection
NCT000010009	NCT00001000_9_T0	PHENOTYPE	26	27	HIV infection
NCT0000100019	NCT00001000_19_T0	PHENOTYPE	5	6	alcohol abuse
NCT000010012	NCT00001001_2_T0	GENE	7	7	has
NCT000010012	NCT00001001_2_T1	PHENOTYPE	17	18	HIV infection
NCT000010013	NCT00001001_3_T0	ORGAN	17	17	liver
NCT000010013	NCT00001001_3_T1	PHENOTYPE	44	44	susceptible
NCT000010013	NCT00001001_3_T2	PHENOTYPE	32	32	pharmacokinetics
NCT000010013	NCT00001001_3_T3	PHENOTYPE	26	27	liver disease
NCT000010013	NCT00001001_3_T4	PHENOTYPE	51	52	drug toxicity
NCT000010014	NCT00001001_4_T0	PHENOTYPE	5	5	pharmacokinetics
NCT000010014	NCT00001001_4_T1	BIOLOGICAL_PROCESS	8	8	metabolism
NCT000010014	NCT00001001_4_T2	PHENOTYPE	6	6	elimination
NCT000010014	NCT00001001_4_T3	PHENOTYPE	14	15	liver disease
NCT000010015	NCT00001001_5_T0	PHENOTYPE	14	14	HIV
NCT000010015	NCT00001001_5_T1	PHENOTYPE	37	37	pharmacokinetics
NCT000010017	NCT00001001_7_T0	ORGAN	17	17	liver
NCT000010017	NCT00001001_7_T1	PHENOTYPE	44	44	susceptible
NCT000010017	NCT00001001_7_T2	PHENOTYPE	32	32	pharmacokinetics
NCT000010017	NCT00001001_7_T3	PHENOTYPE	26	27	liver disease
NCT000010017	NCT00001001_7_T4	PHENOTYPE	51	52	drug toxicity
NCT000010018	NCT00001001_8_T0	PHENOTYPE	5	5	pharmacokinetics
NCT000010018	NCT00001001_8_T1	BIOLOGICAL_PROCESS	8	8	metabolism
NCT000010018	NCT00001001_8_T2	PHENOTYPE	6	6	elimination
NCT000010018	NCT00001001_8_T3	PHENOTYPE	14	15	liver disease
NCT000010019	NCT00001001_9_T0	PHENOTYPE	14	14	HIV
NCT000010019	NCT00001001_9_T1	PHENOTYPE	37	37	pharmacokinetics
NCT0000100110	NCT00001001_10_T0	PHENOTYPE	10	10	severity
NCT0000100110	NCT00001001_10_T1	ORGAN	7	7	liver
NCT0000100110	NCT00001001_10_T2	PHENOTYPE	12	13	liver disease
NCT0000100111	NCT00001001_11_T0	GENE	4	4	IV
NCT0000100114	NCT00001001_14_T0	COMPOUND	14	14	GAZT
NCT0000100114	NCT00001001_14_T1	ORGAN	6	6	serum
NCT0000100117	NCT00001001_17_T0	PHENOTYPE	17	18	liver disease
NCT0000100118	NCT00001001_18_T0	PHENOTYPE	0	0	Severity
NCT0000100119	NCT00001001_19_T0	ORGAN	4	4	kidney
NCT0000100123	NCT00001001_23_T0	PHENOTYPE	13	13	toxicity
NCT0000100123	NCT00001001_23_T1	PHENOTYPE	3	3	Condition
NCT0000100133	NCT00001001_33_T0	PHENOTYPE	3	4	alcohol abuse
NCT000010021	NCT00001002_1_T0	COMPOUND	23	23	foscarnet
NCT000010022	NCT00001002_2_T0	GENE	7	7	p24
NCT000010022	NCT00001002_2_T1	COMPOUND	25	25	foscarnet
NCT000010022	NCT00001002_2_T2	ORGAN	6	6	serum
NCT000010024	NCT00001002_4_T0	GENE	7	7	p24
NCT000010024	NCT00001002_4_T1	COMPOUND	25	25	foscarnet
NCT000010024	NCT00001002_4_T2	ORGAN	6	6	serum
NCT000010025	NCT00001002_5_T0	COMPOUND	27	27	foscarnet
NCT000010030	NCT00001003_0_T0	PHENOTYPE	8	10	Pneumocystis Carinii Pneumonia
NCT000010032	NCT00001003_2_T0	COMPOUND	5	5	pentamidine
NCT000010032	NCT00001003_2_T1	GENE	6	6	PEN
NCT000010032	NCT00001003_2_T2	GENE	13	13	ACTG
NCT000010032	NCT00001003_2_T3	GENE	16	16	ACTG
NCT000010034	NCT00001003_4_T0	GENE	8	8	PEN
NCT000010034	NCT00001003_4_T1	ORGAN	11	11	lungs
NCT000010034	NCT00001003_4_T2	ORGAN	23	23	lungs
NCT000010035	NCT00001003_5_T0	GENE	36	36	II
NCT000010035	NCT00001003_5_T1	GENE	8	8	PEN
NCT000010035	NCT00001003_5_T2	GENE	30	30	PEN
NCT000010035	NCT00001003_5_T3	ORGAN	14	14	lungs
NCT000010035	NCT00001003_5_T4	GENE	20	20	ACTG
NCT000010035	NCT00001003_5_T5	GENE	23	23	ACTG
NCT000010037	NCT00001003_7_T0	GENE	36	36	II
NCT000010037	NCT00001003_7_T1	GENE	8	8	PEN
NCT000010037	NCT00001003_7_T2	GENE	30	30	PEN
NCT000010037	NCT00001003_7_T3	ORGAN	14	14	lungs
NCT000010037	NCT00001003_7_T4	GENE	20	20	ACTG
NCT000010037	NCT00001003_7_T5	GENE	23	23	ACTG
NCT000010039	NCT00001003_9_T0	GENE	4	4	mist
NCT000010039	NCT00001003_9_T1	GENE	12	12	gamma
NCT0000100310	NCT00001003_10_T0	ORGAN	5	5	lungs
NCT0000100311	NCT00001003_11_T0	GENE	7	7	PEN
NCT0000100311	NCT00001003_11_T1	GENE	1	1	mist
NCT0000100312	NCT00001003_12_T0	ORGAN	10	10	lungs
NCT0000100312	NCT00001003_12_T1	GENE	1	1	gamma
NCT0000100313	NCT00001003_13_T0	ORGAN	11	11	ribs
NCT0000100314	NCT00001003_14_T0	GENE	11	11	gamma
NCT0000100315	NCT00001003_15_T0	PHENOTYPE	2	2	withdrawn
NCT0000100315	NCT00001003_15_T1	GENE	9	9	PEN
NCT0000100315	NCT00001003_15_T2	GENE	13	13	ACTG
NCT0000100315	NCT00001003_15_T3	GENE	16	16	ACTG
NCT0000100316	NCT00001003_16_T0	GENE	20	20	PEN
NCT0000100322	NCT00001003_22_T0	PHENOTYPE	1	2	substance abuse
NCT000010045	NCT00001004_5_T0	GENE	7	7	IFN-G
NCT000010045	NCT00001004_5_T1	GENE	5	5	TNF
NCT000010046	NCT00001004_6_T0	PHENOTYPE	11	11	HIV
NCT000010046	NCT00001004_6_T1	GENE	6	6	IFN-G
NCT000010046	NCT00001004_6_T2	GENE	4	4	TNF
NCT0000100410	NCT00001004_10_T0	GENE	7	7	IFN-G
NCT0000100410	NCT00001004_10_T1	GENE	5	5	TNF
NCT0000100411	NCT00001004_11_T0	PHENOTYPE	11	11	HIV
NCT0000100411	NCT00001004_11_T1	GENE	6	6	IFN-G
NCT0000100411	NCT00001004_11_T2	GENE	4	4	TNF
NCT0000100414	NCT00001004_14_T0	GENE	2	2	IM
NCT000010050	NCT00001005_0_T0	GENE	5	5	Interleukin-2
NCT000010050	NCT00001005_0_T1	PHENOTYPE	12	12	Symptoms
NCT000010050	NCT00001005_0_T2	TISSUE	19	20	Lymph Nodes
NCT000010053	NCT00001005_3_T0	GENE	13	13	MTD
NCT000010054	NCT00001005_4_T0	PHENOTYPE	28	28	HIV
NCT000010054	NCT00001005_4_T1	PHENOTYPE	14	14	pharmacokinetics
NCT000010059	NCT00001005_9_T0	GENE	25	25	IL-2
NCT0000100510	NCT00001005_10_T0	GENE	1	1	IL-2
NCT0000100510	NCT00001005_10_T1	GENE	7	7	IV
NCT0000100511	NCT00001005_11_T0	GENE	4	4	IL-2
NCT0000100512	NCT00001005_12_T0	PHENOTYPE	0	0	Toxicity
NCT0000100513	NCT00001005_13_T0	PHENOTYPE	22	22	toxicity
NCT0000100513	NCT00001005_13_T1	GENE	27	27	IL-2
NCT0000100513	NCT00001005_13_T2	GENE	3	3	MTD
NCT0000100514	NCT00001005_14_T0	GENE	9	9	IL-2
NCT0000100514	NCT00001005_14_T1	GENE	8	8	IV
NCT0000100515	NCT00001005_15_T0	GENE	12	12	IL-2
NCT0000100515	NCT00001005_15_T1	GENE	2	2	MTD
NCT0000100515	NCT00001005_15_T2	GENE	11	11	IV
NCT0000100516	NCT00001005_16_T0	GENE	14	14	IL-2
NCT0000100517	NCT00001005_17_T0	GENE	14	14	SC
NCT0000100517	NCT00001005_17_T1	GENE	15	15	IL-2
NCT0000100517	NCT00001005_17_T2	GENE	1	1	IV
NCT0000100520	NCT00001005_20_T0	PHENOTYPE	6	6	chills
NCT0000100520	NCT00001005_20_T1	PHENOTYPE	4	4	fever
NCT0000100520	NCT00001005_20_T2	COMPOUND	2	2	ibuprofen
NCT0000100522	NCT00001005_22_T0	PHENOTYPE	13	13	seizures
NCT0000100522	NCT00001005_22_T1	PHENOTYPE	17	17	embarrassment
NCT000010061	NCT00001006_1_T0	PHENOTYPE	17	17	infections
NCT000010063	NCT00001006_3_T0	PHENOTYPE	14	14	toxic
NCT000010063	NCT00001006_3_T1	PHENOTYPE	25	25	toxic
NCT000010063	NCT00001006_3_T2	COMPOUND	1	1	zidovudine
NCT000010063	NCT00001006_3_T3	GENE	3	3	has
NCT000010064	NCT00001006_4_T0	COMPOUND	9	9	tellurium
NCT000010066	NCT00001006_6_T0	PHENOTYPE	14	14	toxic
NCT000010066	NCT00001006_6_T1	PHENOTYPE	25	25	toxic
NCT000010066	NCT00001006_6_T2	COMPOUND	1	1	zidovudine
NCT000010066	NCT00001006_6_T3	GENE	3	3	has
NCT000010067	NCT00001006_7_T0	COMPOUND	9	9	tellurium
NCT000010069	NCT00001006_9_T0	PHENOTYPE	13	13	toxic
NCT0000100610	NCT00001006_10_T0	GENE	21	21	has
NCT0000100610	NCT00001006_10_T1	PHENOTYPE	2	3	adverse effects
NCT0000100611	NCT00001006_11_T0	PHENOTYPE	12	12	severity
NCT0000100611	NCT00001006_11_T1	PHENOTYPE	14	15	adverse effects
NCT0000100611	NCT00001006_11_T2	PHENOTYPE	42	43	HIV infection
NCT0000100613	NCT00001006_13_T0	PHENOTYPE	6	6	infections
NCT0000100623	NCT00001006_23_T0	PHENOTYPE	3	4	alcohol abuse
NCT000010070	NCT00001007_0_T0	PHENOTYPE	9	9	HIV
NCT000010073	NCT00001007_3_T0	PHENOTYPE	27	27	HIV
NCT000010073	NCT00001007_3_T1	PHENOTYPE	12	13	HIV infection
NCT000010073	NCT00001007_3_T2	PHENOTYPE	18	19	HIV infection
NCT000010073	NCT00001007_3_T3	PHENOTYPE	5	6	pediatric AIDS
NCT000010075	NCT00001007_5_T0	PHENOTYPE	14	14	HIV
NCT000010078	NCT00001007_8_T0	PHENOTYPE	14	14	HIV
NCT000010079	NCT00001007_9_T0	GENE	9	9	IV
NCT0000100712	NCT00001007_12_T0	GENE	12	12	has
NCT0000100712	NCT00001007_12_T1	PHENOTYPE	37	38	toxic effect
NCT0000100714	NCT00001007_14_T0	PHENOTYPE	23	23	toxic
NCT0000100716	NCT00001007_16_T0	GENE	19	19	P24
NCT0000100716	NCT00001007_16_T1	PHENOTYPE	16	16	HIV
NCT0000100716	NCT00001007_16_T2	ORGAN	20	20	serum
NCT0000100724	NCT00001007_24_T0	COMPOUND	19	19	methadone
NCT000010081	NCT00001008_1_T0	COMPOUND	6	6	methadone
NCT000010081	NCT00001008_1_T1	COMPOUND	21	21	methadone
NCT000010081	NCT00001008_1_T2	PHENOTYPE	29	30	narcotic withdrawal
NCT000010083	NCT00001008_3_T0	GENE	30	30	had
NCT000010083	NCT00001008_3_T1	GENE	9	9	IV
NCT000010083	NCT00001008_3_T2	GENE	34	34	IV
NCT000010083	NCT00001008_3_T3	PHENOTYPE	35	36	drug abuse
NCT000010084	NCT00001008_4_T0	GENE	5	5	IV
NCT000010084	NCT00001008_4_T1	GENE	14	14	IV
NCT000010084	NCT00001008_4_T2	COMPOUND	10	10	methadone
NCT000010084	NCT00001008_4_T3	COMPOUND	34	34	methadone
NCT000010084	NCT00001008_4_T4	PHENOTYPE	6	7	drug abuse
NCT000010084	NCT00001008_4_T5	PHENOTYPE	19	20	HIV positive
NCT000010087	NCT00001008_7_T0	GENE	30	30	had
NCT000010087	NCT00001008_7_T1	GENE	9	9	IV
NCT000010087	NCT00001008_7_T2	GENE	34	34	IV
NCT000010087	NCT00001008_7_T3	PHENOTYPE	35	36	drug abuse
NCT000010088	NCT00001008_8_T0	GENE	5	5	IV
NCT000010088	NCT00001008_8_T1	GENE	14	14	IV
NCT000010088	NCT00001008_8_T2	COMPOUND	10	10	methadone
NCT000010088	NCT00001008_8_T3	COMPOUND	34	34	methadone
NCT000010088	NCT00001008_8_T4	PHENOTYPE	6	7	drug abuse
NCT000010088	NCT00001008_8_T5	PHENOTYPE	19	20	HIV positive
NCT0000100811	NCT00001008_11_T0	COMPOUND	8	8	methadone
NCT0000100811	NCT00001008_11_T1	GENE	12	12	IV
NCT0000100812	NCT00001008_12_T0	GENE	3	3	IV
NCT0000100812	NCT00001008_12_T1	COMPOUND	11	11	methadone
NCT0000100812	NCT00001008_12_T2	COMPOUND	27	27	methadone
NCT0000100813	NCT00001008_13_T0	ORGAN	0	0	Plasma
NCT0000100813	NCT00001008_13_T1	COMPOUND	5	5	methadone
NCT0000100813	NCT00001008_13_T2	PHENOTYPE	2	3	urine levels
NCT0000100814	NCT00001008_14_T0	ORGAN	10	10	plasma
NCT0000100814	NCT00001008_14_T1	COMPOUND	31	31	methadone
NCT0000100816	NCT00001008_16_T0	PHENOTYPE	9	9	HIV
NCT0000100816	NCT00001008_16_T1	GENE	21	21	c2
NCT0000100817	NCT00001008_17_T0	COMPOUND	3	3	methadone
NCT0000100817	NCT00001008_17_T1	COMPOUND	10	10	methadone
NCT0000100817	NCT00001008_17_T2	COMPOUND	28	28	methadone
NCT000010092	NCT00001009_2_T0	PHENOTYPE	17	17	toxicity
NCT000010093	NCT00001009_3_T0	PHENOTYPE	25	25	toxicity
NCT000010093	NCT00001009_3_T1	PHENOTYPE	13	13	HIV
NCT000010093	NCT00001009_3_T2	GENE	8	8	has
NCT000010093	NCT00001009_3_T3	GENE	22	22	has
NCT000010093	NCT00001009_3_T4	GENE	0	0	DS
NCT000010094	NCT00001009_4_T0	GENE	7	7	has
NCT000010094	NCT00001009_4_T1	GENE	4	4	DS
NCT000010096	NCT00001009_6_T0	PHENOTYPE	17	17	toxicity
NCT000010097	NCT00001009_7_T0	PHENOTYPE	25	25	toxicity
NCT000010097	NCT00001009_7_T1	PHENOTYPE	13	13	HIV
NCT000010097	NCT00001009_7_T2	GENE	8	8	has
NCT000010097	NCT00001009_7_T3	GENE	22	22	has
NCT000010097	NCT00001009_7_T4	GENE	0	0	DS
NCT000010098	NCT00001009_8_T0	GENE	7	7	has
NCT000010098	NCT00001009_8_T1	GENE	4	4	DS
NCT0000100910	NCT00001009_10_T0	GENE	5	5	DS
NCT0000100913	NCT00001009_13_T0	GENE	7	7	DS
NCT0000100915	NCT00001009_15_T0	PHENOTYPE	4	4	HIV
NCT0000100918	NCT00001009_18_T0	PHENOTYPE	3	3	HIV
NCT0000100918	NCT00001009_18_T1	GENE	10	10	kit
NCT0000100919	NCT00001009_19_T0	GENE	7	7	p24
NCT0000100919	NCT00001009_19_T1	PHENOTYPE	6	6	HIV
NCT0000100926	NCT00001009_26_T0	PHENOTYPE	1	2	opportunistic infection
NCT0000100927	NCT00001009_27_T0	GENE	4	4	KS
NCT0000100927	NCT00001009_27_T1	GENE	7	7	KS
NCT0000100927	NCT00001009_27_T2	GENE	18	18	KS
NCT0000100927	NCT00001009_27_T3	PHENOTYPE	5	5	progression
NCT0000100927	NCT00001009_27_T4	PHENOTYPE	15	15	neoplasms
NCT0000100927	NCT00001009_27_T5	PHENOTYPE	2	3	Kaposi's sarcoma
NCT0000100929	NCT00001009_29_T0	PHENOTYPE	4	5	hemophilia A
NCT0000100929	NCT00001009_29_T1	PHENOTYPE	0	1	Hemorrhagic diseases
NCT0000100929	NCT00001009_29_T2	PHENOTYPE	9	10	von Willebrand
NCT0000100930	NCT00001009_30_T0	PHENOTYPE	3	4	alcohol abuse
NCT000010102	NCT00001010_2_T0	PHENOTYPE	12	12	HIV
NCT000010104	NCT00001010_4_T0	PHENOTYPE	12	12	HIV
NCT000010106	NCT00001010_6_T0	PHENOTYPE	18	19	adverse effect
NCT000010113	NCT00001011_3_T0	PHENOTYPE	20	20	toxicity
NCT000010113	NCT00001011_3_T1	PHENOTYPE	5	5	toxic
NCT000010116	NCT00001011_6_T0	PHENOTYPE	20	20	toxicity
NCT000010116	NCT00001011_6_T1	PHENOTYPE	5	5	toxic
NCT0000101110	NCT00001011_10_T0	PHENOTYPE	5	5	toxic
NCT0000101110	NCT00001011_10_T1	PHENOTYPE	17	17	toxic
NCT000010120	NCT00001012_0_T0	PHENOTYPE	8	10	Swollen Lymph Nodes
NCT000010122	NCT00001012_2_T0	PHENOTYPE	20	20	toxic
NCT000010122	NCT00001012_2_T1	COMPOUND	1	1	zidovudine
NCT000010122	NCT00001012_2_T2	GENE	19	19	has
NCT000010123	NCT00001012_3_T0	PHENOTYPE	9	9	HIV
NCT000010125	NCT00001012_5_T0	PHENOTYPE	11	11	HIV
NCT000010128	NCT00001012_8_T0	PHENOTYPE	9	9	HIV
NCT0000101210	NCT00001012_10_T0	PHENOTYPE	11	11	HIV
NCT0000101213	NCT00001012_13_T0	GENE	13	13	fat-free
NCT0000101217	NCT00001012_17_T0	PHENOTYPE	15	15	toxic
NCT0000101217	NCT00001012_17_T1	PHENOTYPE	32	32	HIV
NCT0000101217	NCT00001012_17_T2	ORGAN	12	13	immune system
NCT000010133	NCT00001013_3_T0	PHENOTYPE	11	11	toxicity
NCT000010133	NCT00001013_3_T1	COMPOUND	5	5	leucovorin
NCT0000101311	NCT00001013_11_T0	GENE	9	9	PEN
NCT0000101312	NCT00001013_12_T0	COMPOUND	4	4	zidovudine
NCT0000101312	NCT00001013_12_T1	PHENOTYPE	14	16	bone marrow toxicity
NCT0000101315	NCT00001013_15_T0	GENE	0	0	PEN
NCT0000101320	NCT00001013_20_T0	PHENOTYPE	15	15	withdrawn
NCT000010143	NCT00001014_3_T0	PHENOTYPE	11	11	toxicity
NCT000010143	NCT00001014_3_T1	COMPOUND	5	5	leucovorin
NCT000010147	NCT00001014_7_T0	PHENOTYPE	11	11	toxicity
NCT000010147	NCT00001014_7_T1	COMPOUND	5	5	leucovorin
NCT0000101414	NCT00001014_14_T0	COMPOUND	9	9	pentamidine
NCT0000101415	NCT00001014_15_T0	COMPOUND	4	4	zidovudine
NCT0000101415	NCT00001014_15_T1	PHENOTYPE	14	16	bone marrow toxicity
NCT000010151	NCT00001015_1_T0	PHENOTYPE	22	22	HIV
NCT000010151	NCT00001015_1_T1	CELL	26	27	T cells
NCT0000101510	NCT00001015_10_T0	GENE	8	8	MTD
NCT0000101511	NCT00001015_11_T0	PHENOTYPE	23	23	toxicity
NCT0000101511	NCT00001015_11_T1	GENE	1	1	MTD
NCT0000101512	NCT00001015_12_T0	PHENOTYPE	4	4	toxicity
NCT0000101512	NCT00001015_12_T1	PHENOTYPE	17	17	tolerance
NCT0000101525	NCT00001015_25_T0	PHENOTYPE	3	4	alcohol abuse
NCT0000101610	NCT00001016_10_T0	GENE	30	30	NS
NCT0000101610	NCT00001016_10_T1	COMPOUND	13	13	trimetrexate
NCT0000101610	NCT00001016_10_T2	COMPOUND	20	20	trimetrexate
NCT0000101610	NCT00001016_10_T3	COMPOUND	32	32	trimetrexate
NCT0000101611	NCT00001016_11_T0	GENE	37	37	had
NCT0000101611	NCT00001016_11_T1	COMPOUND	16	16	trimetrexate
NCT0000101612	NCT00001016_12_T0	COMPOUND	13	13	trimetrexate
NCT0000101615	NCT00001016_15_T0	PHENOTYPE	43	43	thrombocytopenia
NCT0000101615	NCT00001016_15_T1	PHENOTYPE	27	27	neutropenia
NCT0000101615	NCT00001016_15_T2	PHENOTYPE	8	8	toxicities
NCT0000101615	NCT00001016_15_T3	PHENOTYPE	34	34	fever
NCT0000101615	NCT00001016_15_T4	PHENOTYPE	20	20	anemia
NCT0000101616	NCT00001016_16_T0	PHENOTYPE	0	0	Toxicity
NCT0000101621	NCT00001016_21_T0	COMPOUND	4	4	zidovudine
NCT0000101621	NCT00001016_21_T1	PHENOTYPE	14	16	bone marrow toxicity
NCT0000101622	NCT00001016_22_T0	GENE	13	13	has
NCT0000101628	NCT00001016_28_T0	PHENOTYPE	3	3	Condition
NCT000010171	NCT00001017_1_T0	PHENOTYPE	6	6	complication
NCT000010171	NCT00001017_1_T1	PHENOTYPE	0	1	Cryptococcal meningitis
NCT000010172	NCT00001017_2_T0	PHENOTYPE	1	1	relapse
NCT000010172	NCT00001017_2_T1	GENE	16	16	IV
NCT000010172	NCT00001017_2_T2	PHENOTYPE	11	11	chronic
NCT000010172	NCT00001017_2_T3	COMPOUND	17	18	amphotericin B
NCT000010173	NCT00001017_3_T0	PHENOTYPE	8	8	toxic
NCT000010173	NCT00001017_3_T1	GENE	7	7	has
NCT000010173	NCT00001017_3_T2	COMPOUND	1	2	amphotericin B
NCT000010175	NCT00001017_5_T0	COMPOUND	12	12	fluconazole
NCT000010177	NCT00001017_7_T0	PHENOTYPE	1	1	relapse
NCT000010177	NCT00001017_7_T1	GENE	16	16	IV
NCT000010177	NCT00001017_7_T2	PHENOTYPE	11	11	chronic
NCT000010177	NCT00001017_7_T3	COMPOUND	17	18	amphotericin B
NCT000010178	NCT00001017_8_T0	PHENOTYPE	8	8	toxic
NCT000010178	NCT00001017_8_T1	GENE	7	7	has
NCT000010178	NCT00001017_8_T2	COMPOUND	1	2	amphotericin B
NCT0000101710	NCT00001017_10_T0	COMPOUND	12	12	fluconazole
NCT0000101711	NCT00001017_11_T0	COMPOUND	9	9	fluconazole
NCT0000101711	NCT00001017_11_T1	COMPOUND	11	12	amphotericin B
NCT0000101712	NCT00001017_12_T0	COMPOUND	8	9	amphotericin B
NCT0000101714	NCT00001017_14_T0	PHENOTYPE	11	11	discomfort
NCT0000101714	NCT00001017_14_T1	COMPOUND	5	6	amphotericin B
NCT000010181	NCT00001018_1_T0	PHENOTYPE	15	15	infections
NCT000010181	NCT00001018_1_T1	GENE	6	6	has
NCT000010181	NCT00001018_1_T2	COMPOUND	5	5	diclazuril
NCT000010182	NCT00001018_2_T0	PHENOTYPE	14	14	diarrhea
NCT000010182	NCT00001018_2_T1	COMPOUND	9	9	letrazuril
NCT000010184	NCT00001018_4_T0	PHENOTYPE	14	14	diarrhea
NCT000010184	NCT00001018_4_T1	COMPOUND	9	9	letrazuril
NCT000010185	NCT00001018_5_T0	COMPOUND	10	10	letrazuril
NCT000010186	NCT00001018_6_T0	COMPOUND	9	9	letrazuril
NCT000010187	NCT00001018_7_T0	PHENOTYPE	2	2	pharmacokinetics
NCT000010187	NCT00001018_7_T1	COMPOUND	14	14	letrazuril
NCT000010188	NCT00001018_8_T0	COMPOUND	16	16	letrazuril
NCT000010189	NCT00001018_9_T0	CELL	4	4	oocysts
NCT000010189	NCT00001018_9_T1	CELL	43	43	oocysts
NCT000010189	NCT00001018_9_T2	COMPOUND	22	22	letrazuril
NCT0000101810	NCT00001018_10_T0	CELL	4	4	oocysts
NCT000010190	NCT00001019_0_T0	GENE	9	9	SF-2
NCT000010190	NCT00001019_0_T1	PHENOTYPE	7	7	HIV
NCT000010190	NCT00001019_0_T2	GENE	10	10	gp120
NCT000010190	NCT00001019_0_T3	BIOLOGICAL_PROCESS	3	4	Immune Response
NCT000010192	NCT00001019_2_T0	GENE	9	9	gp120
NCT000010193	NCT00001019_3_T0	GENE	6	6	gp120
NCT000010194	NCT00001019_4_T0	PHENOTYPE	1	1	HIV
NCT000010194	NCT00001019_4_T1	GENE	2	3	envelope glycoprotein
NCT000010196	NCT00001019_6_T0	PHENOTYPE	5	5	HIV
NCT000010197	NCT00001019_7_T0	COMPOUND	5	5	MTP-PE
NCT000010197	NCT00001019_7_T1	GENE	24	24	gp120
NCT000010197	NCT00001019_7_T2	GENE	17	17	has
NCT000010199	NCT00001019_9_T0	PHENOTYPE	1	1	HIV
NCT000010199	NCT00001019_9_T1	GENE	2	3	envelope glycoprotein
NCT0000101911	NCT00001019_11_T0	PHENOTYPE	5	5	HIV
NCT0000101912	NCT00001019_12_T0	COMPOUND	5	5	MTP-PE
NCT0000101912	NCT00001019_12_T1	GENE	24	24	gp120
NCT0000101912	NCT00001019_12_T2	GENE	17	17	has
NCT0000101914	NCT00001019_14_T0	GENE	4	4	IM
NCT0000101916	NCT00001019_16_T0	GENE	3	3	IM
NCT000010201	NCT00001020_1_T0	GENE	12	12	gp120
NCT000010201	NCT00001020_1_T1	PHENOTYPE	18	18	seronegative
NCT000010202	NCT00001020_2_T0	GENE	8	8	gp120
NCT000010202	NCT00001020_2_T1	GENE	13	13	gp120
NCT000010202	NCT00001020_2_T2	BIOLOGICAL_PROCESS	3	4	immune response
NCT000010203	NCT00001020_3_T0	PHENOTYPE	30	30	proliferation
NCT000010203	NCT00001020_3_T1	GENE	3	3	gp120
NCT000010203	NCT00001020_3_T2	GENE	27	27	gp120
NCT000010203	NCT00001020_3_T3	BIOLOGICAL_PROCESS	9	10	immune response
NCT000010204	NCT00001020_4_T0	GENE	4	4	gp120
NCT000010205	NCT00001020_5_T0	GENE	1	1	gp120
NCT000010205	NCT00001020_5_T1	GENE	2	3	envelope protein
NCT000010207	NCT00001020_7_T0	GENE	1	1	gp120
NCT000010207	NCT00001020_7_T1	GENE	2	3	envelope protein
NCT0000102011	NCT00001020_11_T0	GENE	15	15	gp120
NCT0000102014	NCT00001020_14_T0	PHENOTYPE	14	14	toxicity
NCT000010211	NCT00001021_1_T0	PHENOTYPE	31	31	seronegative
NCT000010212	NCT00001021_2_T0	BIOLOGICAL_PROCESS	3	4	immune response
NCT000010213	NCT00001021_3_T0	BIOLOGICAL_PROCESS	3	4	immune response
NCT000010214	NCT00001021_4_T0	PHENOTYPE	4	4	immunity
NCT000010214	NCT00001021_4_T1	PHENOTYPE	12	13	primary infection
NCT000010216	NCT00001021_6_T0	PHENOTYPE	9	9	strains
NCT000010217	NCT00001021_7_T0	GENE	8	8	has
NCT0000102110	NCT00001021_10_T0	PHENOTYPE	9	9	strains
NCT0000102111	NCT00001021_11_T0	GENE	8	8	has
NCT000010221	NCT00001022_1_T0	PHENOTYPE	6	6	severity
NCT000010221	NCT00001022_1_T1	PHENOTYPE	0	0	Secondary
NCT000010221	NCT00001022_1_T2	PHENOTYPE	9	9	experiences
NCT000010224	NCT00001022_4_T0	PHENOTYPE	16	16	toxicity
NCT000010224	NCT00001022_4_T1	PHENOTYPE	25	25	HIV
NCT000010224	NCT00001022_4_T2	PHENOTYPE	26	26	strains
NCT000010224	NCT00001022_4_T3	GENE	9	9	extended
NCT000010231	NCT00001023_1_T0	COMPOUND	14	14	rifabutin
NCT000010231	NCT00001023_1_T1	COMPOUND	12	12	azithromycin
NCT000010231	NCT00001023_1_T2	ORGAN	8	8	plasma
NCT000010231	NCT00001023_1_T3	ORGAN	21	21	plasma
NCT000010231	NCT00001023_1_T4	PHENOTYPE	9	10	drug levels
NCT000010233	NCT00001023_3_T0	COMPOUND	17	17	rifabutin
NCT000010233	NCT00001023_3_T1	PHENOTYPE	11	11	pharmacokinetics
NCT000010235	NCT00001023_5_T0	ORGAN	12	12	serum
NCT000010236	NCT00001023_6_T0	COMPOUND	10	10	rifamycin
NCT000010236	NCT00001023_6_T1	COMPOUND	8	8	rifabutin
NCT000010236	NCT00001023_6_T2	COMPOUND	6	6	azithromycin
NCT000010236	NCT00001023_6_T3	COMPOUND	4	4	clarithromycin
NCT000010236	NCT00001023_6_T4	PHENOTYPE	27	28	bacterial infection
NCT0000102310	NCT00001023_10_T0	PHENOTYPE	6	6	HIV
NCT0000102310	NCT00001023_10_T1	COMPOUND	16	16	rifabutin
NCT0000102310	NCT00001023_10_T2	COMPOUND	14	14	azithromycin
NCT0000102314	NCT00001023_14_T0	COMPOUND	9	9	rifabutin
NCT0000102314	NCT00001023_14_T1	COMPOUND	5	5	azithromycin
NCT0000102314	NCT00001023_14_T2	COMPOUND	3	3	clarithromycin
NCT000010241	NCT00001024_1_T0	PHENOTYPE	9	9	HIV
NCT000010241	NCT00001024_1_T1	GENE	12	12	LT
NCT000010242	NCT00001024_2_T0	GENE	31	31	LT
NCT000010242	NCT00001024_2_T1	GENE	18	18	CD4
NCT000010242	NCT00001024_2_T2	GENE	29	29	PB
NCT000010242	NCT00001024_2_T3	PHENOTYPE	26	26	HIV
NCT000010242	NCT00001024_2_T4	GENE	19	20	beta-2 microglobulin
NCT000010242	NCT00001024_2_T5	PHENOTYPE	15	16	HIV disease
NCT000010243	NCT00001024_3_T0	GENE	4	4	PB
NCT000010243	NCT00001024_3_T1	GENE	6	6	LT
NCT000010243	NCT00001024_3_T2	BIOLOGICAL_PROCESS	20	21	antiviral response
NCT000010244	NCT00001024_4_T0	PHENOTYPE	35	35	peripheral
NCT000010244	NCT00001024_4_T1	GENE	31	31	CD4
NCT000010244	NCT00001024_4_T2	CELL	32	32	cells
NCT000010244	NCT00001024_4_T3	PHENOTYPE	30	30	HIV
NCT000010244	NCT00001024_4_T4	GENE	13	13	has
NCT000010244	NCT00001024_4_T5	PHENOTYPE	11	12	HIV infections
NCT000010245	NCT00001024_5_T0	PHENOTYPE	11	11	HIV
NCT000010245	NCT00001024_5_T1	TISSUE	8	9	lymph nodes
NCT000010246	NCT00001024_6_T0	ORGAN	19	19	lymph
NCT000010246	NCT00001024_6_T1	PHENOTYPE	9	9	HIV
NCT000010246	NCT00001024_6_T2	PHENOTYPE	26	27	disease progression
NCT000010248	NCT00001024_8_T0	PHENOTYPE	11	11	HIV
NCT000010248	NCT00001024_8_T1	TISSUE	8	9	lymph nodes
NCT000010249	NCT00001024_9_T0	ORGAN	19	19	lymph
NCT000010249	NCT00001024_9_T1	PHENOTYPE	9	9	HIV
NCT000010249	NCT00001024_9_T2	PHENOTYPE	26	27	disease progression
NCT0000102410	NCT00001024_10_T0	COMPOUND	13	13	zidovudine
NCT0000102411	NCT00001024_11_T0	COMPOUND	10	10	zidovudine
NCT0000102411	NCT00001024_11_T1	COMPOUND	25	25	didanosine
NCT0000102413	NCT00001024_13_T0	TISSUE	1	2	lymph node
NCT0000102426	NCT00001024_26_T0	PHENOTYPE	2	3	alcohol abuse
NCT000010251	NCT00001025_1_T0	PHENOTYPE	13	13	strategies
NCT000010253	NCT00001025_3_T0	PHENOTYPE	8	8	HIV
NCT000010253	NCT00001025_3_T1	GENE	4	4	has
NCT000010257	NCT00001025_7_T0	COMPOUND	25	25	didanosine
NCT0000102510	NCT00001025_10_T0	PHENOTYPE	13	13	HIV
NCT000010260	NCT00001026_0_T0	PHENOTYPE	27	27	HIV
NCT000010262	NCT00001026_2_T0	GENE	10	10	envelope
NCT000010262	NCT00001026_2_T1	PHENOTYPE	9	9	HIV
NCT000010264	NCT00001026_4_T0	GENE	16	16	envelope
NCT000010264	NCT00001026_4_T1	PHENOTYPE	0	0	Secondary
NCT000010264	NCT00001026_4_T2	PHENOTYPE	17	17	vaccinia
NCT000010264	NCT00001026_4_T3	PHENOTYPE	15	15	HIV
NCT000010265	NCT00001026_5_T0	GENE	14	14	envelope
NCT0000102610	NCT00001026_10_T0	GENE	24	24	gp160
NCT000010271	NCT00001027_1_T0	PHENOTYPE	5	5	tolerance
NCT000010273	NCT00001027_3_T0	PHENOTYPE	9	9	HIV
NCT000010273	NCT00001027_3_T1	PHENOTYPE	2	4	Pneumocystis carinii pneumonia
NCT000010278	NCT00001027_8_T0	COMPOUND	2	2	pentamidine
NCT000010279	NCT00001027_9_T0	COMPOUND	14	14	pentamidine
NCT000010279	NCT00001027_9_T1	GENE	7	7	has
NCT0000102711	NCT00001027_11_T0	PHENOTYPE	1	1	pharmacokinetics
NCT000010291	NCT00001029_1_T0	PHENOTYPE	18	18	HIV
NCT000010291	NCT00001029_1_T1	PHENOTYPE	15	15	resistant
NCT000010291	NCT00001029_1_T2	GENE	4	4	has
NCT000010291	NCT00001029_1_T3	PHENOTYPE	16	16	strains
NCT000010292	NCT00001029_2_T0	PHENOTYPE	16	16	toxicity
NCT000010293	NCT00001029_3_T0	PHENOTYPE	4	4	toxicity
NCT000010295	NCT00001029_5_T0	PHENOTYPE	16	16	toxicity
NCT000010296	NCT00001029_6_T0	PHENOTYPE	4	4	toxicity
NCT0000102917	NCT00001029_17_T0	PHENOTYPE	1	4	alcohol or drug abuse
NCT000010303	NCT00001030_3_T0	PHENOTYPE	5	5	HIV
NCT000010303	NCT00001030_3_T1	GENE	16	16	MAC
NCT000010307	NCT00001030_7_T0	COMPOUND	7	7	rifabutin
NCT000010307	NCT00001030_7_T1	COMPOUND	5	5	clarithromycin
NCT000010314	NCT00001031_4_T0	GENE	9	9	SF-2
NCT000010314	NCT00001031_4_T1	GENE	4	4	envelope
NCT000010314	NCT00001031_4_T2	PHENOTYPE	20	20	tolerance
NCT000010315	NCT00001031_5_T0	PHENOTYPE	17	18	HIV infection
NCT000010318	NCT00001031_8_T0	GENE	9	9	SF-2
NCT000010318	NCT00001031_8_T1	GENE	4	4	envelope
NCT000010318	NCT00001031_8_T2	PHENOTYPE	20	20	tolerance
NCT000010319	NCT00001031_9_T0	PHENOTYPE	17	18	HIV infection
NCT0000103110	NCT00001031_10_T0	PHENOTYPE	9	10	HIV infection
NCT0000103111	NCT00001031_11_T0	GENE	6	6	SF-2
NCT0000103111	NCT00001031_11_T1	GENE	7	7	rgp
NCT0000103119	NCT00001031_19_T0	GENE	2	2	extended
NCT000010321	NCT00001032_1_T0	PHENOTYPE	16	17	disease progression
NCT000010322	NCT00001032_2_T0	PHENOTYPE	8	9	disease progression
NCT000010323	NCT00001032_3_T0	PHENOTYPE	25	25	tolerance
NCT000010324	NCT00001032_4_T0	COMPOUND	9	9	AZT-ddC
NCT000010326	NCT00001032_6_T0	COMPOUND	9	9	AZT-ddC
NCT000010329	NCT00001032_9_T0	GENE	4	4	extended
NCT000010332	NCT00001033_2_T0	PHENOTYPE	19	19	HIV
NCT000010332	NCT00001033_2_T1	PHENOTYPE	47	47	susceptible
NCT000010334	NCT00001033_4_T0	GENE	20	20	has
NCT000010336	NCT00001033_6_T0	PHENOTYPE	8	8	HIV
NCT000010338	NCT00001033_8_T0	GENE	20	20	has
NCT0000103310	NCT00001033_10_T0	PHENOTYPE	8	8	HIV
NCT0000103313	NCT00001033_13_T0	GENE	3	3	1.5
NCT0000103314	NCT00001033_14_T0	COMPOUND	19	19	isoniazid
NCT0000103314	NCT00001033_14_T1	COMPOUND	29	29	isoniazid
NCT0000103314	NCT00001033_14_T2	COMPOUND	31	31	pyridoxine
NCT0000103314	NCT00001033_14_T3	COMPOUND	33	33	pyrazinamide
NCT0000103314	NCT00001033_14_T4	COMPOUND	35	35	ethambutol
NCT0000103315	NCT00001033_15_T0	COMPOUND	8	8	isoniazid
NCT0000103315	NCT00001033_15_T1	COMPOUND	24	24	levofloxacin
NCT0000103322	NCT00001033_22_T0	PHENOTYPE	2	2	resistant
NCT000010347	NCT00001034_7_T0	GENE	5	5	2.1
NCT000010347	NCT00001034_7_T1	COMPOUND	11	11	ganciclovir
NCT000010350	NCT00001035_0_T0	PHENOTYPE	18	19	HIV Infections
NCT000010350	NCT00001035_0_T1	PHENOTYPE	14	15	Hepatitis C
NCT000010352	NCT00001035_2_T0	GENE	7	7	IFN
NCT000010352	NCT00001035_2_T1	PHENOTYPE	17	18	HIV infections
NCT000010352	NCT00001035_2_T2	PHENOTYPE	10	11	chronic hepatitis
NCT000010352	NCT00001035_2_T3	PHENOTYPE	11	12	hepatitis C
NCT000010353	NCT00001035_3_T0	GENE	0	0	IFN
NCT000010353	NCT00001035_3_T1	PHENOTYPE	3	3	HIV
NCT000010353	NCT00001035_3_T2	GENE	2	2	has
NCT000010353	NCT00001035_3_T3	GENE	7	7	has
NCT000010353	NCT00001035_3_T4	PHENOTYPE	14	15	chronic hepatitis
NCT000010353	NCT00001035_3_T5	PHENOTYPE	15	16	hepatitis C
NCT000010357	NCT00001035_7_T0	GENE	2	2	interferon
NCT000010358	NCT00001035_8_T0	PHENOTYPE	18	18	relapse
NCT000010359	NCT00001035_9_T0	GENE	9	9	IFN
NCT0000103510	NCT00001035_10_T0	COMPOUND	10	10	zidovudine
NCT0000103510	NCT00001035_10_T1	COMPOUND	11	11	didanosine
NCT0000103510	NCT00001035_10_T2	COMPOUND	12	12	zalcitabine
NCT000010366	NCT00001036_6_T0	GENE	17	17	PEG
NCT000010366	NCT00001036_6_T1	GENE	18	18	IL-2
NCT0000103616	NCT00001036_16_T0	PHENOTYPE	1	2	substance abuse
NCT000010372	NCT00001037_2_T0	PHENOTYPE	7	7	strain
NCT000010372	NCT00001037_2_T1	GENE	10	10	has
NCT000010372	NCT00001037_2_T2	GENE	1	1	gp160
NCT000010373	NCT00001037_3_T0	PHENOTYPE	3	3	strain
NCT000010373	NCT00001037_3_T1	PHENOTYPE	23	23	strain
NCT000010373	NCT00001037_3_T2	PHENOTYPE	33	33	strain
NCT000010373	NCT00001037_3_T3	GENE	27	27	gp160
NCT000010375	NCT00001037_5_T0	PHENOTYPE	3	3	strain
NCT000010375	NCT00001037_5_T1	PHENOTYPE	23	23	strain
NCT000010375	NCT00001037_5_T2	PHENOTYPE	33	33	strain
NCT000010375	NCT00001037_5_T3	GENE	27	27	gp160
NCT000010381	NCT00001038_1_T0	GENE	5	5	BW
NCT000010381	NCT00001038_1_T1	COMPOUND	9	9	acyclovir
NCT000010381	NCT00001038_1_T2	COMPOUND	13	13	acyclovir
NCT000010382	NCT00001038_2_T0	GENE	6	6	BW
NCT000010382	NCT00001038_2_T1	GENE	39	39	BW
NCT000010382	NCT00001038_2_T2	PHENOTYPE	34	34	diseases
NCT000010382	NCT00001038_2_T3	PHENOTYPE	9	11	quality of life
NCT000010388	NCT00001038_8_T0	GENE	5	5	BW
NCT000010388	NCT00001038_8_T1	COMPOUND	9	9	acyclovir
NCT000010389	NCT00001038_9_T0	COMPOUND	1	1	acyclovir
NCT000010389	NCT00001038_9_T1	PHENOTYPE	8	10	herpes simplex infections
NCT0000103812	NCT00001038_12_T0	COMPOUND	4	4	acyclovir
NCT0000103812	NCT00001038_12_T1	PHENOTYPE	1	1	recurrent
NCT000010391	NCT00001039_1_T0	GENE	6	6	MAC
NCT000010391	NCT00001039_1_T1	GENE	12	12	MAC
NCT000010391	NCT00001039_1_T2	ORGAN	7	8	bone marrow
NCT000010392	NCT00001039_2_T0	GENE	0	0	MAC
NCT000010392	NCT00001039_2_T1	GENE	13	13	MAC
NCT000010393	NCT00001039_3_T0	GENE	6	6	MAC
NCT000010393	NCT00001039_3_T1	GENE	10	10	MAC
NCT000010394	NCT00001039_4_T0	GENE	3	3	MAC
NCT000010394	NCT00001039_4_T1	GENE	17	17	MAC
NCT000010394	NCT00001039_4_T2	ORGAN	10	11	bone marrow
NCT000010396	NCT00001039_6_T0	GENE	6	6	MAC
NCT000010396	NCT00001039_6_T1	GENE	10	10	MAC
NCT000010397	NCT00001039_7_T0	GENE	3	3	MAC
NCT000010397	NCT00001039_7_T1	GENE	17	17	MAC
NCT000010397	NCT00001039_7_T2	ORGAN	10	11	bone marrow
NCT000010398	NCT00001039_8_T0	COMPOUND	24	24	rifabutin
NCT000010398	NCT00001039_8_T1	COMPOUND	5	5	ethambutol
NCT000010398	NCT00001039_8_T2	COMPOUND	22	22	azithromycin
NCT000010398	NCT00001039_8_T3	COMPOUND	3	3	clarithromycin
NCT000010399	NCT00001039_9_T0	ORGAN	3	4	bone marrow
NCT000010402	NCT00001040_2_T0	PHENOTYPE	4	4	pharmacokinetics
NCT000010412	NCT00001041_2_T0	BIOLOGICAL_PROCESS	10	12	mucosal immune response
NCT000010413	NCT00001041_3_T0	PHENOTYPE	23	23	peripheral
NCT000010413	NCT00001041_3_T1	CELL	26	26	cells
NCT000010414	NCT00001041_4_T0	ORGAN	10	10	plasma
NCT000010414	NCT00001041_4_T1	PHENOTYPE	11	11	viremia
NCT000010415	NCT00001041_5_T0	PHENOTYPE	2	2	progression
NCT000010415	NCT00001041_5_T1	ORGAN	11	11	plasma
NCT000010417	NCT00001041_7_T0	PHENOTYPE	2	2	progression
NCT000010417	NCT00001041_7_T1	ORGAN	11	11	plasma
NCT000010418	NCT00001041_8_T0	BIOLOGICAL_PROCESS	23	23	gestation
NCT000010418	NCT00001041_8_T1	GENE	27	27	booster
NCT000010419	NCT00001041_9_T0	GENE	4	4	booster
NCT000010424	NCT00001042_4_T0	PHENOTYPE	3	4	vaccine immunogenicity
NCT000010424	NCT00001042_4_T1	PHENOTYPE	16	17	antibody response
NCT000010426	NCT00001042_6_T0	PHENOTYPE	3	4	vaccine immunogenicity
NCT000010426	NCT00001042_6_T1	PHENOTYPE	16	17	antibody response
NCT000010427	NCT00001042_7_T0	COMPOUND	38	38	threonyl
NCT000010427	NCT00001042_7_T1	GENE	39	39	MDP
NCT000010427	NCT00001042_7_T2	GENE	31	31	SAF-2
NCT000010427	NCT00001042_7_T3	GENE	33	33	SAF-2
NCT000010427	NCT00001042_7_T4	COMPOUND	36	37	muramyl dipeptide
NCT000010427	NCT00001042_7_T5	COMPOUND	16	17	aluminum hydroxide
NCT000010427	NCT00001042_7_T6	COMPOUND	35	36	threonyl muramyl
NCT000010427	NCT00001042_7_T7	COMPOUND	19	21	monophosphoryl lipid A
NCT000010427	NCT00001042_7_T8	COMPOUND	23	25	monophosphoryl lipid A
NCT0000104214	NCT00001042_14_T0	GENE	4	4	extended
NCT000010431	NCT00001043_1_T0	ORGAN	2	2	plasma
NCT000010433	NCT00001043_3_T0	PHENOTYPE	25	25	vaccinia
NCT000010433	NCT00001043_3_T1	PHENOTYPE	36	36	smallpox
NCT000010433	NCT00001043_3_T2	GENE	29	29	gp160
NCT000010434	NCT00001043_4_T0	PHENOTYPE	9	9	strain
NCT000010434	NCT00001043_4_T1	PHENOTYPE	13	13	strain
NCT000010434	NCT00001043_4_T2	GENE	20	20	has
NCT000010434	NCT00001043_4_T3	GENE	3	3	gp160
NCT000010435	NCT00001043_5_T0	GENE	19	19	gp160
NCT000010438	NCT00001043_8_T0	GENE	19	19	gp160
NCT0000104413	NCT00001044_13_T0	GENE	2	2	extended
NCT000010451	NCT00001045_1_T0	PHENOTYPE	18	18	peripheral
NCT000010451	NCT00001045_1_T1	GENE	21	21	CD4
NCT000010451	NCT00001045_1_T2	PHENOTYPE	26	27	HIV infection
NCT000010453	NCT00001045_3_T0	PHENOTYPE	12	12	mutation
NCT000010453	NCT00001045_3_T1	COMPOUND	9	9	zidovudine
NCT000010453	NCT00001045_3_T2	GENE	27	27	has
NCT000010453	NCT00001045_3_T3	GENE	18	19	reverse transcriptase
NCT000010454	NCT00001045_4_T0	PHENOTYPE	2	2	mutation
NCT000010456	NCT00001045_6_T0	PHENOTYPE	2	2	mutation
NCT000010461	NCT00001046_1_T0	PHENOTYPE	11	11	HIV
NCT000010463	NCT00001046_3_T0	PHENOTYPE	3	3	HIV
NCT000010463	NCT00001046_3_T1	PHENOTYPE	10	10	progression
NCT000010463	NCT00001046_3_T2	ORGAN	21	21	plasma
NCT000010464	NCT00001046_4_T0	PHENOTYPE	23	23	HIV
NCT000010464	NCT00001046_4_T1	PHENOTYPE	9	9	immunity
NCT000010464	NCT00001046_4_T2	GENE	3	3	has
NCT000010464	NCT00001046_4_T3	CELL	17	17	T-cell
NCT000010466	NCT00001046_6_T0	PHENOTYPE	23	23	HIV
NCT000010466	NCT00001046_6_T1	PHENOTYPE	9	9	immunity
NCT000010466	NCT00001046_6_T2	GENE	3	3	has
NCT000010466	NCT00001046_6_T3	CELL	17	17	T-cell
NCT000010468	NCT00001046_8_T0	BIOLOGICAL_PROCESS	10	10	gestation
NCT0000104622	NCT00001046_22_T0	PHENOTYPE	6	6	chronic
NCT000010470	NCT00001047_0_T0	GENE	14	14	MAC
NCT000010470	NCT00001047_0_T1	PHENOTYPE	10	12	Mycobacterium Avium Complex
NCT000010472	NCT00001047_2_T0	COMPOUND	29	29	azithromycin
NCT000010472	NCT00001047_2_T1	COMPOUND	27	27	clarithromycin
NCT000010472	NCT00001047_2_T2	GENE	9	9	MAC
NCT000010473	NCT00001047_3_T0	GENE	6	6	MAC
NCT000010475	NCT00001047_5_T0	GENE	6	6	MAC
NCT000010476	NCT00001047_6_T0	COMPOUND	17	17	clofazimine
NCT000010476	NCT00001047_6_T1	COMPOUND	15	15	rifabutin
NCT000010476	NCT00001047_6_T2	COMPOUND	12	12	ethambutol
NCT000010476	NCT00001047_6_T3	COMPOUND	5	5	clarithromycin
NCT000010477	NCT00001047_7_T0	GENE	18	18	1.5
NCT000010481	NCT00001048_1_T0	GENE	13	13	MRI
NCT0000104817	NCT00001048_17_T0	PHENOTYPE	10	10	allergy
NCT0000104817	NCT00001048_17_T1	GENE	14	14	G-CSF
NCT000010493	NCT00001049_3_T0	GENE	16	16	CD4
NCT000010493	NCT00001049_3_T1	PHENOTYPE	3	3	HIV
NCT000010499	NCT00001049_9_T0	PHENOTYPE	28	28	initiation
NCT0000104912	NCT00001049_12_T0	GENE	6	6	has
NCT0000104916	NCT00001049_16_T0	PHENOTYPE	13	13	toxicity
NCT0000104916	NCT00001049_16_T1	PHENOTYPE	19	19	HIV
NCT000010501	NCT00001050_1_T0	PHENOTYPE	13	14	intraepithelial neoplasia
NCT000010501	NCT00001050_1_T1	PHENOTYPE	9	10	HIV infection
NCT000010502	NCT00001050_2_T0	PHENOTYPE	11	11	infections
NCT000010502	NCT00001050_2_T1	PHENOTYPE	5	6	HIV disease
NCT000010502	NCT00001050_2_T2	PHENOTYPE	13	14	reproductive function
NCT000010531	NCT00001053_1_T0	GENE	12	12	CD8
NCT000010531	NCT00001053_1_T1	CELL	14	15	T lymphocytes
NCT000010532	NCT00001053_2_T0	PHENOTYPE	15	16	antibody responses
NCT000010533	NCT00001053_3_T0	GENE	2	2	CD8
NCT000010533	NCT00001053_3_T1	GENE	3	3	CTL
NCT000010534	NCT00001053_4_T0	PHENOTYPE	6	6	infections
NCT000010534	NCT00001053_4_T1	PHENOTYPE	20	20	immunity
NCT000010534	NCT00001053_4_T2	PHENOTYPE	25	25	immunity
NCT000010535	NCT00001053_5_T0	PHENOTYPE	1	1	HIV
NCT000010535	NCT00001053_5_T1	GENE	8	8	CTL
NCT000010535	NCT00001053_5_T2	PHENOTYPE	11	12	antibody responses
NCT000010537	NCT00001053_7_T0	PHENOTYPE	6	6	infections
NCT000010537	NCT00001053_7_T1	PHENOTYPE	20	20	immunity
NCT000010537	NCT00001053_7_T2	PHENOTYPE	25	25	immunity
NCT000010538	NCT00001053_8_T0	PHENOTYPE	1	1	HIV
NCT000010538	NCT00001053_8_T1	GENE	8	8	CTL
NCT000010538	NCT00001053_8_T2	PHENOTYPE	11	12	antibody responses
NCT000010539	NCT00001053_9_T0	GENE	8	8	IM
NCT000010539	NCT00001053_9_T1	PHENOTYPE	2	2	HIV
NCT0000105310	NCT00001053_10_T0	COMPOUND	9	9	omeprazole
NCT000010541	NCT00001054_1_T0	PHENOTYPE	2	2	zoster
NCT000010541	NCT00001054_1_T1	PHENOTYPE	7	7	HIV
NCT000010541	NCT00001054_1_T2	PHENOTYPE	0	0	Varicella
NCT000010542	NCT00001054_2_T0	PHENOTYPE	13	13	concentrations
NCT000010542	NCT00001054_2_T1	COMPOUND	8	8	acyclovir
NCT000010542	NCT00001054_2_T2	COMPOUND	15	15	acyclovir
NCT000010542	NCT00001054_2_T3	PHENOTYPE	4	4	chronic
NCT000010543	NCT00001054_3_T0	COMPOUND	1	1	hydrochloride
NCT000010543	NCT00001054_3_T1	GENE	14	14	fold
NCT000010543	NCT00001054_3_T2	GENE	13	13	3.5
NCT000010543	NCT00001054_3_T3	COMPOUND	5	5	acyclovir
NCT000010543	NCT00001054_3_T4	COMPOUND	10	10	acyclovir
NCT000010545	NCT00001054_5_T0	PHENOTYPE	13	13	concentrations
NCT000010545	NCT00001054_5_T1	COMPOUND	8	8	acyclovir
NCT000010545	NCT00001054_5_T2	COMPOUND	15	15	acyclovir
NCT000010545	NCT00001054_5_T3	PHENOTYPE	4	4	chronic
NCT000010546	NCT00001054_6_T0	COMPOUND	1	1	hydrochloride
NCT000010546	NCT00001054_6_T1	GENE	14	14	fold
NCT000010546	NCT00001054_6_T2	GENE	13	13	3.5
NCT000010546	NCT00001054_6_T3	COMPOUND	5	5	acyclovir
NCT000010546	NCT00001054_6_T4	COMPOUND	10	10	acyclovir
NCT000010547	NCT00001054_7_T0	COMPOUND	12	12	hydrochloride
NCT000010547	NCT00001054_7_T1	PHENOTYPE	7	8	herpes simplex
NCT000010548	NCT00001054_8_T0	PHENOTYPE	16	17	herpes simplex
NCT000010549	NCT00001054_9_T0	PHENOTYPE	8	8	zoster
NCT000010549	NCT00001054_9_T1	PHENOTYPE	6	6	varicella
NCT000010552	NCT00001055_2_T0	PHENOTYPE	18	18	strain
NCT000010552	NCT00001055_2_T1	PHENOTYPE	26	26	strain
NCT000010552	NCT00001055_2_T2	GENE	32	32	protease
NCT000010552	NCT00001055_2_T3	PHENOTYPE	16	16	HIV
NCT000010552	NCT00001055_2_T4	GENE	13	13	gp120
NCT000010552	NCT00001055_2_T5	PHENOTYPE	7	7	canarypox
NCT000010552	NCT00001055_2_T6	GENE	30	30	gag
NCT000010554	NCT00001055_4_T0	PHENOTYPE	18	18	strain
NCT000010554	NCT00001055_4_T1	PHENOTYPE	26	26	strain
NCT000010554	NCT00001055_4_T2	GENE	32	32	protease
NCT000010554	NCT00001055_4_T3	PHENOTYPE	16	16	HIV
NCT000010554	NCT00001055_4_T4	GENE	13	13	gp120
NCT000010554	NCT00001055_4_T5	PHENOTYPE	7	7	canarypox
NCT000010554	NCT00001055_4_T6	GENE	30	30	gag
NCT000010560	NCT00001056_0_T0	GENE	18	18	Glycoprotein
NCT000010560	NCT00001056_0_T1	PHENOTYPE	22	22	Immunodeficiency
NCT000010560	NCT00001056_0_T2	PHENOTYPE	13	13	Vaccinia
NCT000010560	NCT00001056_0_T3	GENE	19	19	gp160
NCT000010566	NCT00001056_6_T0	GENE	21	21	gp160
NCT000010568	NCT00001056_8_T0	GENE	4	4	booster
NCT0000105610	NCT00001056_10_T0	GENE	6	6	booster
NCT000010571	NCT00001057_1_T0	GENE	22	22	CD4
NCT000010571	NCT00001057_1_T1	CELL	25	25	macrophages
NCT000010571	NCT00001057_1_T2	CELL	23	23	lymphocytes
NCT000010571	NCT00001057_1_T3	PHENOTYPE	12	13	HIV infection
NCT000010572	NCT00001057_2_T0	GENE	10	11	reverse transcriptase
NCT000010574	NCT00001057_4_T0	GENE	10	11	reverse transcriptase
NCT000010582	NCT00001058_2_T0	COMPOUND	15	15	clofazimine
NCT000010582	NCT00001058_2_T1	COMPOUND	16	16	rifamycin
NCT000010582	NCT00001058_2_T2	COMPOUND	18	18	ethambutol
NCT000010582	NCT00001058_2_T3	COMPOUND	3	3	clarithromycin
NCT000010584	NCT00001058_4_T0	COMPOUND	15	15	clofazimine
NCT000010584	NCT00001058_4_T1	COMPOUND	16	16	rifamycin
NCT000010584	NCT00001058_4_T2	COMPOUND	18	18	ethambutol
NCT000010584	NCT00001058_4_T3	COMPOUND	3	3	clarithromycin
NCT000010586	NCT00001058_6_T0	COMPOUND	13	13	rifabutin
NCT000010586	NCT00001058_6_T1	COMPOUND	15	15	ethambutol
NCT000010586	NCT00001058_6_T2	PHENOTYPE	11	11	tolerance
NCT000010589	NCT00001058_9_T0	PHENOTYPE	6	6	toxicity
NCT0000105810	NCT00001058_10_T0	COMPOUND	18	18	clarithromycin
NCT0000105810	NCT00001058_10_T1	GENE	9	9	MAC
NCT000010591	NCT00001059_1_T0	PHENOTYPE	10	12	quality of life
NCT000010592	NCT00001059_2_T0	PHENOTYPE	25	25	toxicity
NCT000010592	NCT00001059_2_T1	PHENOTYPE	9	9	tumors
NCT000010592	NCT00001059_2_T2	PHENOTYPE	6	7	drug accumulation
NCT000010593	NCT00001059_3_T0	COMPOUND	17	17	bleomycin
NCT000010593	NCT00001059_3_T1	COMPOUND	19	19	vincristine
NCT000010595	NCT00001059_5_T0	COMPOUND	17	17	bleomycin
NCT000010595	NCT00001059_5_T1	COMPOUND	19	19	vincristine
NCT000010597	NCT00001059_7_T0	CELL	2	2	granulocyte
NCT000010597	NCT00001059_7_T1	PHENOTYPE	13	13	neutropenia
NCT000010597	NCT00001059_7_T2	GENE	5	5	G-CSF
NCT000010601	NCT00001060_1_T0	PHENOTYPE	22	22	proliferative
NCT000010601	NCT00001060_1_T1	GENE	31	31	CTL
NCT000010601	NCT00001060_1_T2	CELL	21	21	T-cell
NCT000010601	NCT00001060_1_T3	PHENOTYPE	19	20	antibody responses
NCT000010602	NCT00001060_2_T0	PHENOTYPE	18	18	HIV
NCT000010602	NCT00001060_2_T1	PHENOTYPE	34	34	HIV
NCT000010606	NCT00001060_6_T0	GENE	17	17	IFA
NCT000010606	NCT00001060_6_T1	GENE	19	19	IFA
NCT0000106010	NCT00001060_10_T0	GENE	8	8	IFA
NCT0000106010	NCT00001060_10_T1	GENE	13	13	IFA
NCT0000106011	NCT00001060_11_T0	GENE	5	5	52
NCT000010611	NCT00001061_1_T0	GENE	8	8	MS
NCT000010617	NCT00001061_7_T0	PHENOTYPE	31	31	progression
NCT000010617	NCT00001061_7_T1	COMPOUND	6	6	ganciclovir
NCT000010617	NCT00001061_7_T2	COMPOUND	8	8	foscarnet
NCT0000106112	NCT00001061_12_T0	GENE	10	10	has
NCT0000106112	NCT00001061_12_T1	PHENOTYPE	6	6	immunity
NCT0000106116	NCT00001061_16_T0	GENE	16	16	has
NCT000010622	NCT00001062_2_T0	COMPOUND	2	2	ganciclovir
NCT000010622	NCT00001062_2_T1	COMPOUND	12	12	ganciclovir
NCT000010622	NCT00001062_2_T2	GENE	3	3	has
NCT000010622	NCT00001062_2_T3	GENE	11	11	IV
NCT000010622	NCT00001062_2_T4	GENE	21	21	IV
NCT000010623	NCT00001062_3_T0	PHENOTYPE	15	15	progression
NCT000010623	NCT00001062_3_T1	COMPOUND	8	8	ganciclovir
NCT000010623	NCT00001062_3_T2	GENE	7	7	IV
NCT000010624	NCT00001062_4_T0	GENE	5	5	IV
NCT000010626	NCT00001062_6_T0	COMPOUND	2	2	ganciclovir
NCT000010626	NCT00001062_6_T1	COMPOUND	12	12	ganciclovir
NCT000010626	NCT00001062_6_T2	GENE	3	3	has
NCT000010626	NCT00001062_6_T3	GENE	11	11	IV
NCT000010626	NCT00001062_6_T4	GENE	21	21	IV
NCT000010627	NCT00001062_7_T0	PHENOTYPE	15	15	progression
NCT000010627	NCT00001062_7_T1	COMPOUND	8	8	ganciclovir
NCT000010627	NCT00001062_7_T2	GENE	7	7	IV
NCT000010628	NCT00001062_8_T0	GENE	5	5	IV
NCT000010629	NCT00001062_9_T0	COMPOUND	5	5	ganciclovir
NCT000010629	NCT00001062_9_T1	COMPOUND	19	19	ganciclovir
NCT000010629	NCT00001062_9_T2	GENE	2	2	IV
NCT000010629	NCT00001062_9_T3	GENE	24	24	IV
NCT000010634	NCT00001063_4_T0	PHENOTYPE	8	8	toxicity
NCT000010634	NCT00001063_4_T1	PHENOTYPE	14	14	HIV
NCT000010635	NCT00001063_5_T0	GENE	39	39	CD4
NCT000010635	NCT00001063_5_T1	PHENOTYPE	29	29	suppression
NCT000010635	NCT00001063_5_T2	PHENOTYPE	16	17	disease progression
NCT000010637	NCT00001063_7_T0	PHENOTYPE	8	8	toxicity
NCT000010637	NCT00001063_7_T1	PHENOTYPE	14	14	HIV
NCT000010638	NCT00001063_8_T0	GENE	39	39	CD4
NCT000010638	NCT00001063_8_T1	PHENOTYPE	29	29	suppression
NCT000010638	NCT00001063_8_T2	PHENOTYPE	16	17	disease progression
NCT000010643	NCT00001064_3_T0	PHENOTYPE	8	8	HIV
NCT000010643	NCT00001064_3_T1	ORGAN	13	14	immune system
NCT000010644	NCT00001064_4_T0	PHENOTYPE	8	8	HIV
NCT000010644	NCT00001064_4_T1	CELL	1	2	dendritic cells
NCT000010644	NCT00001064_4_T2	CELL	12	13	dendritic cells
NCT000010644	NCT00001064_4_T3	BIOLOGICAL_PROCESS	33	34	immune response
NCT000010644	NCT00001064_4_T4	ORGAN	23	24	immune system
NCT000010646	NCT00001064_6_T0	PHENOTYPE	8	8	HIV
NCT000010646	NCT00001064_6_T1	ORGAN	13	14	immune system
NCT000010647	NCT00001064_7_T0	PHENOTYPE	8	8	HIV
NCT000010647	NCT00001064_7_T1	CELL	1	2	dendritic cells
NCT000010647	NCT00001064_7_T2	CELL	12	13	dendritic cells
NCT000010647	NCT00001064_7_T3	BIOLOGICAL_PROCESS	33	34	immune response
NCT000010647	NCT00001064_7_T4	ORGAN	23	24	immune system
NCT000010648	NCT00001064_8_T0	PHENOTYPE	14	14	HIV
NCT000010648	NCT00001064_8_T1	CELL	0	1	Dendritic cells
NCT000010649	NCT00001064_9_T0	PHENOTYPE	8	8	HIV
NCT000010649	NCT00001064_9_T1	CELL	2	3	dendritic cells
NCT0000106410	NCT00001064_10_T0	GENE	14	14	2.4
NCT000010650	NCT00001065_0_T0	GENE	20	20	Had
NCT000010650	NCT00001065_0_T1	PHENOTYPE	9	10	Fungal Infections
NCT000010654	NCT00001065_4_T0	GENE	3	3	swallow
NCT000010654	NCT00001065_4_T1	COMPOUND	4	5	amphotericin B
NCT000010661	NCT00001066_1_T0	PHENOTYPE	5	5	tolerance
NCT000010662	NCT00001066_2_T0	PHENOTYPE	5	5	diseases
NCT000010663	NCT00001066_3_T0	GENE	9	9	has
NCT000010664	NCT00001066_4_T0	PHENOTYPE	16	16	HIV
NCT000010664	NCT00001066_4_T1	GENE	15	15	reduced
NCT000010664	NCT00001066_4_T2	CELL	22	24	white blood cells
NCT000010665	NCT00001066_5_T0	GENE	2	2	has
NCT000010667	NCT00001066_7_T0	PHENOTYPE	16	16	HIV
NCT000010667	NCT00001066_7_T1	GENE	15	15	reduced
NCT000010667	NCT00001066_7_T2	CELL	22	24	white blood cells
NCT000010668	NCT00001066_8_T0	GENE	2	2	has
NCT000010672	NCT00001067_2_T0	PHENOTYPE	10	10	HIV
NCT000010673	NCT00001067_3_T0	GENE	3	3	CD4
NCT000010674	NCT00001067_4_T0	PHENOTYPE	4	4	toxicity
NCT000010674	NCT00001067_4_T1	PHENOTYPE	8	8	HIV
NCT000010676	NCT00001067_6_T0	PHENOTYPE	4	4	toxicity
NCT000010676	NCT00001067_6_T1	PHENOTYPE	8	8	HIV
NCT000010680	NCT00001068_0_T0	PHENOTYPE	3	4	Disease Progression
NCT000010693	NCT00001069_3_T0	PHENOTYPE	11	12	HIV disease
NCT000010694	NCT00001069_4_T0	PHENOTYPE	4	4	HIV
NCT000010694	NCT00001069_4_T1	GENE	8	8	has
NCT000010694	NCT00001069_4_T2	ORGAN	7	7	plasma
NCT000010695	NCT00001069_5_T0	PHENOTYPE	36	36	symptoms
NCT000010695	NCT00001069_5_T1	GENE	32	32	CD4
NCT000010695	NCT00001069_5_T2	PHENOTYPE	10	10	HIV
NCT000010695	NCT00001069_5_T3	PHENOTYPE	35	35	HIV
NCT000010697	NCT00001069_7_T0	PHENOTYPE	4	4	HIV
NCT000010697	NCT00001069_7_T1	GENE	8	8	has
NCT000010697	NCT00001069_7_T2	ORGAN	7	7	plasma
NCT000010698	NCT00001069_8_T0	PHENOTYPE	36	36	symptoms
NCT000010698	NCT00001069_8_T1	GENE	32	32	CD4
NCT000010698	NCT00001069_8_T2	PHENOTYPE	10	10	HIV
NCT000010698	NCT00001069_8_T3	PHENOTYPE	35	35	HIV
NCT000010699	NCT00001069_9_T0	GENE	39	39	CD4
NCT000010699	NCT00001069_9_T1	PHENOTYPE	25	25	HIV
NCT000010699	NCT00001069_9_T2	ORGAN	24	24	plasma
NCT000010699	NCT00001069_9_T3	PHENOTYPE	5	6	decision making
NCT000010699	NCT00001069_9_T4	PHENOTYPE	20	21	decision making
NCT000010711	NCT00001071_1_T0	CELL	16	17	stem cells
NCT000010713	NCT00001071_3_T0	PHENOTYPE	10	10	peripheral
NCT000010713	NCT00001071_3_T1	CELL	13	13	cells
NCT000010714	NCT00001071_4_T0	PHENOTYPE	14	14	symptoms
NCT000010714	NCT00001071_4_T1	GENE	9	9	CD4
NCT000010721	NCT00001072_1_T0	PHENOTYPE	6	6	rabies
NCT000010721	NCT00001072_1_T1	GENE	7	7	glycoprotein
NCT000010731	NCT00001073_1_T0	PHENOTYPE	1	1	tumors
NCT000010731	NCT00001073_1_T1	PHENOTYPE	6	6	HIV
NCT000010732	NCT00001073_2_T0	PHENOTYPE	11	11	tumors
NCT000010732	NCT00001073_2_T1	PHENOTYPE	1	1	HIV
NCT000010734	NCT00001073_4_T0	COMPOUND	17	17	isotretinoin
NCT000010734	NCT00001073_4_T1	PHENOTYPE	3	3	tumors
NCT000010734	NCT00001073_4_T2	GENE	12	12	hesitant
NCT000010734	NCT00001073_4_T3	PHENOTYPE	22	23	birth defects
NCT000010735	NCT00001073_5_T0	PHENOTYPE	11	11	tumors
NCT000010735	NCT00001073_5_T1	PHENOTYPE	13	13	HIV
NCT000010737	NCT00001073_7_T0	PHENOTYPE	4	4	progression
NCT000010737	NCT00001073_7_T1	PHENOTYPE	2	2	seronegative
NCT000010737	NCT00001073_7_T2	PHENOTYPE	7	7	neoplasia
NCT000010737	NCT00001073_7_T3	PHENOTYPE	1	1	HIV
NCT000010737	NCT00001073_7_T4	PHENOTYPE	17	21	low grade squamous intraepithelial lesions
NCT000010741	NCT00001074_1_T0	COMPOUND	11	11	hydroxyurea
NCT000010741	NCT00001074_1_T1	ORGAN	17	17	plasma
NCT000010744	NCT00001074_4_T0	GENE	3	3	RT
NCT000010744	NCT00001074_4_T1	PHENOTYPE	16	16	HIV
NCT000010744	NCT00001074_4_T2	BIOLOGICAL_PROCESS	17	18	reverse transcription
NCT000010745	NCT00001074_5_T0	COMPOUND	13	13	hydroxyurea
NCT000010745	NCT00001074_5_T1	GENE	20	21	ribonucleotide reductase
NCT000010748	NCT00001074_8_T0	GENE	3	3	RT
NCT000010748	NCT00001074_8_T1	PHENOTYPE	16	16	HIV
NCT000010748	NCT00001074_8_T2	BIOLOGICAL_PROCESS	17	18	reverse transcription
NCT000010749	NCT00001074_9_T0	COMPOUND	13	13	hydroxyurea
NCT000010749	NCT00001074_9_T1	GENE	20	21	ribonucleotide reductase
NCT0000107413	NCT00001074_13_T0	COMPOUND	2	2	hydroxyurea
NCT0000107414	NCT00001074_14_T0	COMPOUND	0	0	2
NCT0000107414	NCT00001074_14_T1	COMPOUND	1	1	hydroxyurea
NCT0000107414	NCT00001074_14_T2	COMPOUND	11	11	hydroxyurea
NCT0000107415	NCT00001074_15_T0	COMPOUND	0	0	3
NCT0000107415	NCT00001074_15_T1	COMPOUND	1	1	hydroxyurea
NCT0000107415	NCT00001074_15_T2	COMPOUND	11	11	hydroxyurea
NCT0000107416	NCT00001074_16_T0	COMPOUND	1	1	hydroxyurea
NCT0000107417	NCT00001074_17_T0	COMPOUND	1	1	hydroxyurea
NCT0000107418	NCT00001074_18_T0	GENE	32	32	1.1
NCT0000107418	NCT00001074_18_T1	COMPOUND	22	22	hydroxyurea
NCT0000107422	NCT00001074_22_T0	COMPOUND	0	0	2
NCT0000107422	NCT00001074_22_T1	COMPOUND	1	1	hydroxyurea
NCT0000107423	NCT00001074_23_T0	COMPOUND	1	1	hydroxyurea
NCT0000107423	NCT00001074_23_T1	COMPOUND	0	0	3
NCT000010751	NCT00001075_1_T0	PHENOTYPE	27	27	initiation
NCT000010751	NCT00001075_1_T1	CELL	11	12	lymphocyte subpopulations
NCT000010752	NCT00001075_2_T0	PHENOTYPE	7	7	initiation
NCT000010752	NCT00001075_2_T1	ORGAN	1	1	plasma
NCT000010753	NCT00001075_3_T0	CELL	17	17	cells
NCT000010753	NCT00001075_3_T1	CELL	19	19	cells
NCT000010755	NCT00001075_5_T0	CELL	17	17	cells
NCT000010755	NCT00001075_5_T1	CELL	19	19	cells
NCT000010756	NCT00001075_6_T0	COMPOUND	22	22	zidovudine
NCT000010756	NCT00001075_6_T1	COMPOUND	11	11	ritonavir
NCT000010756	NCT00001075_6_T2	COMPOUND	21	21	ritonavir
NCT000010756	NCT00001075_6_T3	COMPOUND	24	24	lamivudine
NCT000010765	NCT00001076_5_T0	PHENOTYPE	12	12	rabies
NCT000010765	NCT00001076_5_T1	GENE	13	13	glycoprotein
NCT000010765	NCT00001076_5_T2	GENE	27	27	SF2
NCT000010770	NCT00001077_0_T0	PHENOTYPE	10	11	Weight Loss
NCT000010780	NCT00001078_0_T0	PHENOTYPE	8	8	Infections
NCT000010782	NCT00001078_2_T0	PHENOTYPE	17	17	infections
NCT000010784	NCT00001078_4_T0	GENE	8	8	CD4
NCT000010786	NCT00001078_6_T0	GENE	27	27	CD4
NCT000010786	NCT00001078_6_T1	PHENOTYPE	21	21	HIV
NCT000010786	NCT00001078_6_T2	GENE	18	18	has
NCT000010786	NCT00001078_6_T3	GENE	25	25	has
NCT000010787	NCT00001078_7_T0	PHENOTYPE	14	15	opportunistic infections
NCT000010789	NCT00001078_9_T0	ORGAN	19	20	immune systems
NCT0000107813	NCT00001078_13_T0	PHENOTYPE	0	1	Hepatitis A
NCT0000107815	NCT00001078_15_T0	PHENOTYPE	18	19	bacterial infections
NCT000010790	NCT00001079_0_T0	PHENOTYPE	18	19	Weight Loss
NCT000010792	NCT00001079_2_T0	PHENOTYPE	1	1	wasting
NCT000010792	NCT00001079_2_T1	PHENOTYPE	12	12	HIV
NCT000010793	NCT00001079_3_T0	PHENOTYPE	11	11	HIV
NCT000010793	NCT00001079_3_T1	PHENOTYPE	13	14	weight loss
NCT000010794	NCT00001079_4_T0	COMPOUND	1	1	acetate
NCT000010794	NCT00001079_4_T1	PHENOTYPE	19	19	HIV
NCT000010794	NCT00001079_4_T2	GENE	2	2	has
NCT000010794	NCT00001079_4_T3	PHENOTYPE	9	10	weight gain
NCT000010794	NCT00001079_4_T4	PHENOTYPE	21	22	weight loss
NCT000010794	NCT00001079_4_T5	PHENOTYPE	6	7	stimulate appetite
NCT000010795	NCT00001079_5_T0	COMPOUND	7	8	megestrol acetate
NCT000010796	NCT00001079_6_T0	PHENOTYPE	21	21	hypogonadism
NCT000010796	NCT00001079_6_T1	COMPOUND	30	31	megestrol acetate
NCT000010796	NCT00001079_6_T2	TISSUE	8	9	body fat
NCT000010797	NCT00001079_7_T0	GENE	13	13	LBM
NCT000010797	NCT00001079_7_T1	PHENOTYPE	0	0	Hypogonadism
NCT000010797	NCT00001079_7_T2	TISSUE	7	8	body fat
NCT000010798	NCT00001079_8_T0	COMPOUND	1	1	testosterone
NCT000010798	NCT00001079_8_T1	GENE	9	9	LBM
NCT000010798	NCT00001079_8_T2	COMPOUND	12	13	megestrol acetate
NCT0000107911	NCT00001079_11_T0	PHENOTYPE	11	11	HIV
NCT0000107911	NCT00001079_11_T1	PHENOTYPE	13	14	weight loss
NCT0000107912	NCT00001079_12_T0	COMPOUND	1	1	acetate
NCT0000107912	NCT00001079_12_T1	PHENOTYPE	19	19	HIV
NCT0000107912	NCT00001079_12_T2	GENE	2	2	has
NCT0000107912	NCT00001079_12_T3	PHENOTYPE	9	10	weight gain
NCT0000107912	NCT00001079_12_T4	PHENOTYPE	21	22	weight loss
NCT0000107912	NCT00001079_12_T5	PHENOTYPE	6	7	stimulate appetite
NCT0000107913	NCT00001079_13_T0	COMPOUND	7	8	megestrol acetate
NCT0000107914	NCT00001079_14_T0	PHENOTYPE	21	21	hypogonadism
NCT0000107914	NCT00001079_14_T1	COMPOUND	30	31	megestrol acetate
NCT0000107914	NCT00001079_14_T2	TISSUE	8	9	body fat
NCT0000107915	NCT00001079_15_T0	GENE	13	13	LBM
NCT0000107915	NCT00001079_15_T1	PHENOTYPE	0	0	Hypogonadism
NCT0000107915	NCT00001079_15_T2	TISSUE	7	8	body fat
NCT0000107916	NCT00001079_16_T0	COMPOUND	1	1	testosterone
NCT0000107916	NCT00001079_16_T1	GENE	9	9	LBM
NCT0000107916	NCT00001079_16_T2	COMPOUND	12	13	megestrol acetate
NCT000010800	NCT00001080_0_T0	PHENOTYPE	10	10	Resistant
NCT000010802	NCT00001080_2_T0	PHENOTYPE	4	5	immune stimulation
NCT000010803	NCT00001080_3_T0	GENE	37	37	CD4
NCT000010803	NCT00001080_3_T1	CELL	38	38	cells
NCT000010803	NCT00001080_3_T2	ORGAN	10	10	plasma
NCT000010805	NCT00001080_5_T0	PHENOTYPE	5	5	mutants
NCT000010805	NCT00001080_5_T1	PHENOTYPE	4	4	resistant
NCT000010807	NCT00001080_7_T0	GENE	37	37	CD4
NCT000010807	NCT00001080_7_T1	CELL	38	38	cells
NCT000010807	NCT00001080_7_T2	ORGAN	10	10	plasma
NCT000010809	NCT00001080_9_T0	PHENOTYPE	5	5	mutants
NCT000010809	NCT00001080_9_T1	PHENOTYPE	4	4	resistant
NCT0000108011	NCT00001080_11_T0	PHENOTYPE	13	13	influenza
NCT000010811	NCT00001081_1_T0	PHENOTYPE	9	9	cryptosporidiosis
NCT000010812	NCT00001081_2_T0	PHENOTYPE	6	6	cryptosporidiosis
NCT0000108110	NCT00001081_10_T0	GENE	12	12	2.1
NCT0000108113	NCT00001081_13_T0	PHENOTYPE	29	29	cryptosporidiosis
NCT0000108113	NCT00001081_13_T1	PHENOTYPE	26	26	diarrhea
NCT0000108113	NCT00001081_13_T2	PHENOTYPE	33	34	weight loss
NCT000010826	NCT00001082_6_T0	PHENOTYPE	8	8	HIV
NCT000010828	NCT00001082_8_T0	PHENOTYPE	3	3	HIV
NCT000010828	NCT00001082_8_T1	COMPOUND	7	8	adefovir dipivoxil
NCT000010828	NCT00001082_8_T2	PHENOTYPE	27	28	HIV infection
NCT000010828	NCT00001082_8_T3	PHENOTYPE	18	19	herpesvirus infections
NCT0000108213	NCT00001082_13_T0	PHENOTYPE	8	8	HIV
NCT0000108215	NCT00001082_15_T0	PHENOTYPE	3	3	HIV
NCT0000108215	NCT00001082_15_T1	COMPOUND	7	8	adefovir dipivoxil
NCT0000108215	NCT00001082_15_T2	PHENOTYPE	27	28	HIV infection
NCT0000108215	NCT00001082_15_T3	PHENOTYPE	18	19	herpesvirus infections
NCT0000108218	NCT00001082_18_T0	COMPOUND	14	14	L-carnitine
NCT0000108218	NCT00001082_18_T1	COMPOUND	30	30	L-carnitine
NCT0000108218	NCT00001082_18_T2	COMPOUND	11	12	adefovir dipivoxil
NCT0000108218	NCT00001082_18_T3	GENE	0	1	Group 1
NCT0000108218	NCT00001082_18_T4	GENE	16	17	group 2
NCT0000108315	NCT00001083_15_T0	GENE	6	6	II
NCT0000108315	NCT00001083_15_T1	GENE	2	2	PRAM
NCT0000108318	NCT00001083_18_T0	GENE	3	3	PRAM-1
NCT0000108320	NCT00001083_20_T0	GENE	7	7	PRAM-1
NCT0000108327	NCT00001083_27_T0	GENE	12	12	PRAM-1
NCT000010842	NCT00001084_2_T0	PHENOTYPE	6	6	HIV
NCT000010842	NCT00001084_2_T1	GENE	10	10	reduced
NCT000010842	NCT00001084_2_T2	ORGAN	15	15	plasma
NCT000010846	NCT00001084_6_T0	PHENOTYPE	6	6	HIV
NCT000010846	NCT00001084_6_T1	GENE	10	10	reduced
NCT000010846	NCT00001084_6_T2	ORGAN	15	15	plasma
NCT000010849	NCT00001084_9_T0	COMPOUND	9	9	zidovudine
NCT000010849	NCT00001084_9_T1	COMPOUND	14	14	indinavir
NCT000010849	NCT00001084_9_T2	COMPOUND	11	11	lamivudine
NCT0000108411	NCT00001084_11_T0	PHENOTYPE	9	9	HIV
NCT0000108416	NCT00001084_16_T0	GENE	7	7	has
NCT000010851	NCT00001085_1_T0	PHENOTYPE	19	20	HIV infection
NCT000010852	NCT00001085_2_T0	GENE	25	25	RT
NCT000010852	NCT00001085_2_T1	COMPOUND	9	9	ritonavir
NCT000010852	NCT00001085_2_T2	PHENOTYPE	17	17	suppression
NCT000010852	NCT00001085_2_T3	COMPOUND	11	11	indinavir
NCT000010852	NCT00001085_2_T4	PHENOTYPE	2	2	inhibition
NCT000010856	NCT00001085_6_T0	PHENOTYPE	6	6	HIV
NCT0000108519	NCT00001085_19_T0	PHENOTYPE	8	8	toxicity
NCT000010865	NCT00001086_5_T0	PHENOTYPE	38	38	HIV
NCT000010865	NCT00001086_5_T1	ORGAN	37	37	plasma
NCT000010865	NCT00001086_5_T2	GENE	10	11	protease inhibitor
NCT000010869	NCT00001086_9_T0	PHENOTYPE	38	38	HIV
NCT000010869	NCT00001086_9_T1	ORGAN	37	37	plasma
NCT000010869	NCT00001086_9_T2	GENE	10	11	protease inhibitor
NCT0000108625	NCT00001086_25_T0	PHENOTYPE	10	10	symptoms
NCT0000108625	NCT00001086_25_T1	PHENOTYPE	3	3	Condition
NCT0000108625	NCT00001086_25_T2	PHENOTYPE	15	15	Malignancy
NCT0000108625	NCT00001086_25_T3	PHENOTYPE	23	24	Kaposi's sarcoma
NCT000010872	NCT00001087_2_T0	PHENOTYPE	7	7	HIV
NCT000010873	NCT00001087_3_T0	COMPOUND	8	8	nelfinavir
NCT000010873	NCT00001087_3_T1	COMPOUND	11	11	efavirenz
NCT000010873	NCT00001087_3_T2	GENE	22	23	reverse transcriptase
NCT000010874	NCT00001087_4_T0	GENE	8	8	144
NCT000010876	NCT00001087_6_T0	PHENOTYPE	10	10	HIV
NCT000010876	NCT00001087_6_T1	GENE	1	1	III
NCT000010877	NCT00001087_7_T0	PHENOTYPE	3	3	toxicity
NCT000010877	NCT00001087_7_T1	PHENOTYPE	5	5	tolerance
NCT000010878	NCT00001087_8_T0	PHENOTYPE	21	21	HIV
NCT000010878	NCT00001087_8_T1	PHENOTYPE	11	11	suppression
NCT000010878	NCT00001087_8_T2	GENE	2	2	has
NCT000010878	NCT00001087_8_T3	GENE	12	12	has
NCT000010879	NCT00001087_9_T0	PHENOTYPE	27	27	toxicity
NCT000010879	NCT00001087_9_T1	PHENOTYPE	22	22	suppression
NCT0000108710	NCT00001087_10_T0	PHENOTYPE	4	4	HIV
NCT0000108710	NCT00001087_10_T1	PHENOTYPE	34	34	HIV
NCT0000108710	NCT00001087_10_T2	GENE	10	10	PI
NCT0000108710	NCT00001087_10_T3	GENE	8	9	protease inhibitor
NCT0000108710	NCT00001087_10_T4	GENE	15	16	reverse transcriptase
NCT0000108711	NCT00001087_11_T0	COMPOUND	26	26	L-carnitine
NCT0000108711	NCT00001087_11_T1	COMPOUND	19	19	saquinavir
NCT0000108711	NCT00001087_11_T2	PHENOTYPE	38	38	HIV
NCT0000108711	NCT00001087_11_T3	COMPOUND	21	21	ritonavir
NCT0000108711	NCT00001087_11_T4	GENE	17	17	PI
NCT0000108711	NCT00001087_11_T5	COMPOUND	23	24	adefovir dipivoxil
NCT0000108712	NCT00001087_12_T0	PHENOTYPE	14	14	suppression
NCT0000108712	NCT00001087_12_T1	GENE	10	10	PI
NCT0000108712	NCT00001087_12_T2	BIOLOGICAL_PROCESS	16	17	viral replication
NCT0000108712	NCT00001087_12_T3	COMPOUND	3	4	adefovir dipivoxil
NCT0000108712	NCT00001087_12_T4	PHENOTYPE	21	22	disease progression
NCT0000108714	NCT00001087_14_T0	PHENOTYPE	37	37	HIV
NCT0000108714	NCT00001087_14_T1	GENE	10	10	PI
NCT0000108714	NCT00001087_14_T2	GENE	8	9	protease inhibitor
NCT0000108714	NCT00001087_14_T3	GENE	15	16	reverse transcriptase
NCT0000108714	NCT00001087_14_T4	GENE	27	28	reverse transcriptase
NCT0000108717	NCT00001087_17_T0	COMPOUND	28	28	stavudine
NCT0000108717	NCT00001087_17_T1	COMPOUND	25	25	didanosine
NCT0000108717	NCT00001087_17_T2	COMPOUND	30	30	lamivudine
NCT0000108720	NCT00001087_20_T0	GENE	15	15	II
NCT0000108720	NCT00001087_20_T1	PHENOTYPE	4	4	HIV
NCT0000108720	NCT00001087_20_T2	ORGAN	3	3	plasma
NCT0000108720	NCT00001087_20_T3	PHENOTYPE	8	9	Group B
NCT000010882	NCT00001088_2_T0	GENE	36	36	II
NCT000010882	NCT00001088_2_T1	PHENOTYPE	6	6	strategies
NCT000010882	NCT00001088_2_T2	GENE	43	43	III
NCT000010882	NCT00001088_2_T3	GENE	38	38	has
NCT000010885	NCT00001088_5_T0	GENE	36	36	II
NCT000010885	NCT00001088_5_T1	PHENOTYPE	6	6	strategies
NCT000010885	NCT00001088_5_T2	GENE	43	43	III
NCT000010885	NCT00001088_5_T3	GENE	38	38	has
NCT000010887	NCT00001088_7_T0	GENE	29	29	IM
NCT000010889	NCT00001088_9_T0	GENE	20	20	IM
NCT0000108810	NCT00001088_10_T0	COMPOUND	14	14	bupivacaine
NCT000010902	NCT00001090_2_T0	GENE	28	28	CTL
NCT000010902	NCT00001090_2_T1	GENE	26	26	Nef
NCT000010904	NCT00001090_4_T0	PHENOTYPE	11	11	HIV
NCT000010904	NCT00001090_4_T1	PHENOTYPE	34	34	HIV
NCT000010904	NCT00001090_4_T2	GENE	35	35	CTL
NCT000010904	NCT00001090_4_T3	GENE	15	15	GM-CSF
NCT000010904	NCT00001090_4_T4	PHENOTYPE	12	13	antibody titers
NCT000010906	NCT00001090_6_T0	GENE	28	28	CTL
NCT000010906	NCT00001090_6_T1	GENE	26	26	Nef
NCT000010908	NCT00001090_8_T0	PHENOTYPE	11	11	HIV
NCT000010908	NCT00001090_8_T1	PHENOTYPE	34	34	HIV
NCT000010908	NCT00001090_8_T2	GENE	35	35	CTL
NCT000010908	NCT00001090_8_T3	GENE	15	15	GM-CSF
NCT000010908	NCT00001090_8_T4	PHENOTYPE	12	13	antibody titers
NCT000010909	NCT00001090_9_T0	GENE	16	16	GM-CSF
NCT000010909	NCT00001090_9_T1	GENE	35	35	GM-CSF
NCT000010909	NCT00001090_9_T2	GENE	45	45	GM-CSF
NCT000010909	NCT00001090_9_T3	GENE	54	54	GM-CSF
NCT000010909	NCT00001090_9_T4	GENE	62	62	GM-CSF
NCT000010909	NCT00001090_9_T5	PHENOTYPE	39	40	Group B
NCT000010914	NCT00001091_4_T0	ORGAN	19	19	plasma
NCT000010915	NCT00001091_5_T0	PHENOTYPE	23	23	pharmacokinetics
NCT000010915	NCT00001091_5_T1	PHENOTYPE	1	1	intent
NCT000010917	NCT00001091_7_T0	GENE	10	10	PRAM
NCT000010919	NCT00001091_9_T0	GENE	4	4	PRAM
NCT000010920	NCT00001092_0_T0	PHENOTYPE	3	3	HIV
NCT000010920	NCT00001092_0_T1	PHENOTYPE	4	4	Transmission
NCT000010922	NCT00001092_2_T0	ORGAN	10	11	immune systems
NCT000010922	NCT00001092_2_T1	PHENOTYPE	16	17	HIV infection
NCT000010923	NCT00001092_3_T0	PHENOTYPE	1	1	HIV
NCT000010923	NCT00001092_3_T1	PHENOTYPE	22	22	HIV
NCT000010923	NCT00001092_3_T2	PHENOTYPE	14	15	HIV infection
NCT000010924	NCT00001092_4_T0	GENE	9	9	saliva
NCT000010924	NCT00001092_4_T1	PHENOTYPE	3	3	HIV
NCT000010924	NCT00001092_4_T2	ORGAN	6	6	genital
NCT000010926	NCT00001092_6_T0	PHENOTYPE	14	15	rapid course
NCT000010926	NCT00001092_6_T1	PHENOTYPE	17	18	disease progression
NCT000010927	NCT00001092_7_T0	ORGAN	15	15	genital
NCT000010927	NCT00001092_7_T1	ORGAN	18	19	oral cavity
NCT000010928	NCT00001092_8_T0	PHENOTYPE	8	8	transmitted
NCT000010929	NCT00001092_9_T0	PHENOTYPE	3	4	HIV infection
NCT0000109210	NCT00001092_10_T0	PHENOTYPE	9	9	recruitment
NCT0000109213	NCT00001092_13_T0	GENE	13	13	CD4
NCT0000109213	NCT00001092_13_T1	CELL	14	14	cells
NCT0000109213	NCT00001092_13_T2	PHENOTYPE	4	4	HIV
NCT0000109213	NCT00001092_13_T3	ORGAN	7	7	plasma
NCT0000109214	NCT00001092_14_T0	GENE	15	15	CAF
NCT0000109214	NCT00001092_14_T1	ORGAN	5	5	plasma
NCT0000109214	NCT00001092_14_T2	ORGAN	10	10	plasma
NCT0000109215	NCT00001092_15_T0	PHENOTYPE	12	14	primary HIV infection
NCT0000109215	NCT00001092_15_T1	BIOLOGICAL_PROCESS	6	8	humoral immune response
NCT0000109216	NCT00001092_16_T0	GENE	3	3	saliva
NCT0000109216	NCT00001092_16_T1	ORGAN	0	0	Genital
NCT0000109217	NCT00001092_17_T0	PHENOTYPE	18	20	blood test results
NCT0000109219	NCT00001092_19_T0	PHENOTYPE	0	0	Compensation
NCT000010930	NCT00001093_0_T0	PHENOTYPE	6	7	HIV Infection
NCT000010932	NCT00001093_2_T0	PHENOTYPE	11	11	HIV
NCT000010932	NCT00001093_2_T1	PHENOTYPE	13	13	HIV
NCT000010933	NCT00001093_3_T0	PHENOTYPE	8	8	understood
NCT000010933	NCT00001093_3_T1	PHENOTYPE	2	3	HIV infection
NCT000010934	NCT00001093_4_T0	PHENOTYPE	9	9	HIV
NCT000010934	NCT00001093_4_T1	PHENOTYPE	13	14	HIV infection
NCT000010938	NCT00001093_8_T0	PHENOTYPE	15	17	primary HIV infection
NCT000010939	NCT00001093_9_T0	GENE	8	8	ACTG
NCT0000109310	NCT00001093_10_T0	PHENOTYPE	5	5	toxicity
NCT0000109312	NCT00001093_12_T0	PHENOTYPE	10	10	acute
NCT0000109312	NCT00001093_12_T1	PHENOTYPE	13	14	HIV infection
NCT0000109315	NCT00001093_15_T0	PHENOTYPE	23	23	exposures
NCT0000109318	NCT00001093_18_T0	PHENOTYPE	3	4	HIV infection
NCT000010941	NCT00001094_1_T0	GENE	8	8	protease
NCT000010941	NCT00001094_1_T1	PHENOTYPE	5	5	tolerance
NCT000010944	NCT00001094_4_T0	CELL	4	4	syncytium
NCT000010944	NCT00001094_4_T1	CELL	7	7	syncytium
NCT000010946	NCT00001094_6_T0	PHENOTYPE	17	17	HIV
NCT000010946	NCT00001094_6_T1	ORGAN	16	16	plasma
NCT000010947	NCT00001094_7_T0	GENE	13	13	bid
NCT000010947	NCT00001094_7_T1	GENE	15	15	tid
NCT0000109410	NCT00001094_10_T0	PHENOTYPE	15	15	HIV
NCT0000109410	NCT00001094_10_T1	PHENOTYPE	13	13	suppression
NCT0000109412	NCT00001094_12_T0	PHENOTYPE	13	14	HIV infection
NCT0000109414	NCT00001094_14_T0	PHENOTYPE	15	15	HIV
NCT0000109414	NCT00001094_14_T1	PHENOTYPE	13	13	suppression
NCT0000109416	NCT00001094_16_T0	PHENOTYPE	13	14	HIV infection
NCT0000109418	NCT00001094_18_T0	PHENOTYPE	7	7	HIV
NCT0000109426	NCT00001094_26_T0	PHENOTYPE	4	4	HIV
NCT0000109426	NCT00001094_26_T1	PHENOTYPE	15	15	HIV
NCT0000109426	NCT00001094_26_T2	GENE	17	17	has
NCT0000109426	NCT00001094_26_T3	ORGAN	3	3	plasma
NCT0000109426	NCT00001094_26_T4	ORGAN	14	14	plasma
NCT0000109427	NCT00001094_27_T0	PHENOTYPE	8	8	HIV
NCT0000109427	NCT00001094_27_T1	GENE	44	44	ACTG
NCT0000109427	NCT00001094_27_T2	ORGAN	7	7	plasma
NCT000010951	NCT00001095_1_T0	COMPOUND	10	10	nevirapine
NCT000010951	NCT00001095_1_T1	COMPOUND	8	8	indinavir
NCT000010952	NCT00001095_2_T0	COMPOUND	10	10	amprenavir
NCT000010952	NCT00001095_2_T1	COMPOUND	14	14	zidovudine
NCT000010952	NCT00001095_2_T2	COMPOUND	15	15	stavudine
NCT000010952	NCT00001095_2_T3	PHENOTYPE	8	8	pharmacokinetics
NCT000010952	NCT00001095_2_T4	COMPOUND	17	17	lamivudine
NCT000010954	NCT00001095_4_T0	COMPOUND	41	41	stavudine
NCT000010954	NCT00001095_4_T1	COMPOUND	37	37	indinavir
NCT000010954	NCT00001095_4_T2	GENE	10	10	reduced
NCT000010954	NCT00001095_4_T3	GENE	16	16	had
NCT000010954	NCT00001095_4_T4	COMPOUND	38	38	nevirapine
NCT000010954	NCT00001095_4_T5	ORGAN	21	21	plasma
NCT000010954	NCT00001095_4_T6	COMPOUND	39	39	lamivudine
NCT000010956	NCT00001095_6_T0	COMPOUND	41	41	stavudine
NCT000010956	NCT00001095_6_T1	COMPOUND	37	37	indinavir
NCT000010956	NCT00001095_6_T2	GENE	10	10	reduced
NCT000010956	NCT00001095_6_T3	GENE	16	16	had
NCT000010956	NCT00001095_6_T4	COMPOUND	38	38	nevirapine
NCT000010956	NCT00001095_6_T5	ORGAN	21	21	plasma
NCT000010956	NCT00001095_6_T6	COMPOUND	39	39	lamivudine
NCT000010961	NCT00001096_1_T0	COMPOUND	9	10	polysorbate 80
NCT000010962	NCT00001096_2_T0	GENE	11	11	16B
NCT000010963	NCT00001096_3_T0	GENE	14	14	CTL
NCT000010964	NCT00001096_4_T0	GENE	13	13	0.5
NCT000010968	NCT00001096_8_T0	PHENOTYPE	24	24	immunity
NCT000010968	NCT00001096_8_T1	PHENOTYPE	10	10	cytotoxicity
NCT0000109612	NCT00001096_12_T0	PHENOTYPE	24	24	immunity
NCT0000109612	NCT00001096_12_T1	PHENOTYPE	10	10	cytotoxicity
NCT0000109615	NCT00001096_15_T0	GENE	21	22	Group 1
NCT0000109616	NCT00001096_16_T0	COMPOUND	1	1	2
NCT0000109617	NCT00001096_17_T0	COMPOUND	1	1	3
NCT000010971	NCT00001097_1_T0	PHENOTYPE	10	10	infections
NCT000010971	NCT00001097_1_T1	PHENOTYPE	12	12	diseases
NCT000010971	NCT00001097_1_T2	PHENOTYPE	0	1	HIV infection
NCT000010972	NCT00001097_2_T0	PHENOTYPE	5	5	HIV
NCT000010972	NCT00001097_2_T1	ORGAN	11	12	immune system
NCT000010974	NCT00001097_4_T0	ORGAN	11	12	immune system
NCT000010978	NCT00001097_8_T0	GENE	13	13	thymic
NCT000010979	NCT00001097_9_T0	GENE	9	9	has
NCT0000109712	NCT00001097_12_T0	PHENOTYPE	5	5	initiation
NCT0000109715	NCT00001097_15_T0	PHENOTYPE	12	12	suppression
NCT0000109715	NCT00001097_15_T1	PHENOTYPE	18	19	virologic failure
NCT0000109717	NCT00001097_17_T0	PHENOTYPE	2	3	virologic failure
NCT000011010	NCT00001101_0_T0	PHENOTYPE	22	24	Chronic Lyme Disease
NCT000011012	NCT00001101_2_T0	PHENOTYPE	6	6	Borrelia
NCT000011013	NCT00001101_3_T0	PHENOTYPE	35	35	transmitted
NCT000011013	NCT00001101_3_T1	PHENOTYPE	31	31	co-infection
NCT000011013	NCT00001101_3_T2	PHENOTYPE	5	5	chronic
NCT000011013	NCT00001101_3_T3	PHENOTYPE	24	25	infectious process
NCT000011017	NCT00001101_7_T0	GENE	7	7	IV
NCT000011021	NCT00001102_1_T0	PHENOTYPE	24	25	cholesterol levels
NCT000011021	NCT00001102_1_T1	TISSUE	33	34	body fat
NCT000011022	NCT00001102_2_T0	PHENOTYPE	7	7	HIV
NCT000011022	NCT00001102_2_T1	GENE	15	15	PI
NCT000011022	NCT00001102_2_T2	GENE	13	14	protease inhibitor
NCT000011022	NCT00001102_2_T3	GENE	18	19	reverse transcriptase
NCT000011023	NCT00001102_3_T0	GENE	5	5	has
NCT000011027	NCT00001102_7_T0	GENE	15	15	PI
NCT000011028	NCT00001102_8_T0	GENE	13	13	PI
NCT0000110211	NCT00001102_11_T0	PHENOTYPE	7	7	complications
NCT0000110211	NCT00001102_11_T1	GENE	9	9	PI
NCT0000110211	NCT00001102_11_T2	GENE	18	18	PI
NCT0000110211	NCT00001102_11_T3	GENE	20	20	has
NCT0000110212	NCT00001102_12_T0	PHENOTYPE	8	8	peripheral
NCT0000110212	NCT00001102_12_T1	PHENOTYPE	3	3	complications
NCT0000110212	NCT00001102_12_T2	PHENOTYPE	23	23	HIV
NCT0000110212	NCT00001102_12_T3	PHENOTYPE	17	18	buffalo hump
NCT0000110212	NCT00001102_12_T4	TISSUE	14	15	visceral fat
NCT0000110213	NCT00001102_13_T0	GENE	13	13	058
NCT0000110213	NCT00001102_13_T1	GENE	21	21	PI
NCT0000110215	NCT00001102_15_T0	GENE	21	21	HDL
NCT0000110215	NCT00001102_15_T1	COMPOUND	17	17	glucose
NCT0000110215	NCT00001102_15_T2	GENE	18	18	insulin
NCT0000110215	NCT00001102_15_T3	GENE	23	23	LDL
NCT0000110215	NCT00001102_15_T4	ORGAN	16	16	serum
NCT0000110218	NCT00001102_18_T0	GENE	12	12	has
NCT000011032	NCT00001103_2_T0	GENE	0	0	CSF
NCT000011032	NCT00001103_2_T1	ORGAN	9	10	spinal cord
NCT000011035	NCT00001103_5_T0	PHENOTYPE	4	4	HIV
NCT000011035	NCT00001103_5_T1	GENE	7	7	CSF
NCT000011036	NCT00001103_6_T0	PHENOTYPE	11	11	HIV
NCT000011036	NCT00001103_6_T1	GENE	10	10	CSF
NCT000011038	NCT00001103_8_T0	PHENOTYPE	14	14	severity
NCT000011038	NCT00001103_8_T1	GENE	10	10	CSF
NCT000011038	NCT00001103_8_T2	PHENOTYPE	16	16	dementia
NCT000011039	NCT00001103_9_T0	GENE	22	22	CSF
NCT000011039	NCT00001103_9_T1	ORGAN	11	11	plasma
NCT000011039	NCT00001103_9_T2	BIOLOGICAL_PROCESS	19	20	viral replication
NCT0000110311	NCT00001103_11_T0	PHENOTYPE	6	6	peripheral
NCT0000110311	NCT00001103_11_T1	PHENOTYPE	10	10	HIV
NCT0000110311	NCT00001103_11_T2	GENE	2	2	CSF
NCT0000110311	NCT00001103_11_T3	BIOLOGICAL_PROCESS	35	36	viral replication
NCT0000110312	NCT00001103_12_T0	PHENOTYPE	8	9	cognitive function
NCT0000110312	NCT00001103_12_T1	PHENOTYPE	1	2	virologic failure
NCT0000110313	NCT00001103_13_T0	GENE	17	17	CSF
NCT0000110313	NCT00001103_13_T1	PHENOTYPE	24	24	suppression
NCT0000110322	NCT00001103_22_T0	GENE	4	4	ACTG
NCT000011042	NCT00001104_2_T0	PHENOTYPE	1	1	pharmacokinetics
NCT000011043	NCT00001104_3_T0	PHENOTYPE	14	14	HIV
NCT000011044	NCT00001104_4_T0	PHENOTYPE	20	21	HIV infection
NCT000011045	NCT00001104_5_T0	PHENOTYPE	5	5	HIV
NCT000011047	NCT00001104_7_T0	PHENOTYPE	6	6	HIV
NCT000011049	NCT00001104_9_T0	BIOLOGICAL_PROCESS	19	19	metabolism
NCT000011049	NCT00001104_9_T1	PHENOTYPE	11	12	hepatic disease
NCT0000110410	NCT00001104_10_T0	PHENOTYPE	2	2	HIV
NCT0000110410	NCT00001104_10_T1	PHENOTYPE	4	4	transmitted
NCT0000110411	NCT00001104_11_T0	PHENOTYPE	0	0	Transmission
NCT0000110412	NCT00001104_12_T0	PHENOTYPE	12	12	HIV
NCT0000110412	NCT00001104_12_T1	PHENOTYPE	23	24	HIV infection
NCT0000110414	NCT00001104_14_T0	PHENOTYPE	6	6	HIV
NCT0000110416	NCT00001104_16_T0	BIOLOGICAL_PROCESS	19	19	metabolism
NCT0000110416	NCT00001104_16_T1	PHENOTYPE	11	12	hepatic disease
NCT0000110417	NCT00001104_17_T0	PHENOTYPE	2	2	HIV
NCT0000110417	NCT00001104_17_T1	PHENOTYPE	4	4	transmitted
NCT0000110418	NCT00001104_18_T0	PHENOTYPE	0	0	Transmission
NCT0000110419	NCT00001104_19_T0	PHENOTYPE	12	12	HIV
NCT0000110419	NCT00001104_19_T1	PHENOTYPE	23	24	HIV infection
NCT0000110423	NCT00001104_23_T0	PHENOTYPE	11	11	closed
NCT0000110423	NCT00001104_23_T1	GENE	5	5	ACTG
NCT0000110423	NCT00001104_23_T2	GENE	9	9	has
NCT0000110425	NCT00001104_25_T0	GENE	7	7	ACTG
NCT0000110427	NCT00001104_27_T0	PHENOTYPE	15	15	toxicity
NCT0000110427	NCT00001104_27_T1	PHENOTYPE	27	27	toxicity
NCT0000110427	NCT00001104_27_T2	PHENOTYPE	37	37	toxicities
NCT0000110427	NCT00001104_27_T3	CELL	26	26	neutrophil
NCT0000110427	NCT00001104_27_T4	GENE	24	24	hemoglobin
NCT0000110427	NCT00001104_27_T5	PHENOTYPE	33	34	Grade 1
NCT0000110429	NCT00001104_29_T0	GENE	21	21	ACTG
NCT0000110433	NCT00001104_33_T0	PHENOTYPE	23	23	HIV
NCT0000110434	NCT00001104_34_T0	PHENOTYPE	10	10	HIV
NCT0000110437	NCT00001104_37_T0	PHENOTYPE	5	5	HIV
NCT000011051	NCT00001105_1_T0	PHENOTYPE	11	11	toxicity
NCT000011051	NCT00001105_1_T1	PHENOTYPE	4	4	concentrations
NCT000011053	NCT00001105_3_T0	PHENOTYPE	16	16	strain
NCT000011053	NCT00001105_3_T1	GENE	29	29	gp120
NCT000011053	NCT00001105_3_T2	PHENOTYPE	5	6	HIV infection
NCT000011053	NCT00001105_3_T3	BIOLOGICAL_PROCESS	9	11	humoral immune response
NCT000011057	NCT00001105_7_T0	GENE	13	13	IV
NCT000011059	NCT00001105_9_T0	PHENOTYPE	17	17	pharmacokinetics
NCT0000110512	NCT00001105_12_T0	PHENOTYPE	2	2	toxicity
NCT0000110526	NCT00001105_26_T0	PHENOTYPE	1	4	alcohol or drug abuse
NCT000011061	NCT00001106_1_T0	COMPOUND	9	9	zidovudine
NCT000011061	NCT00001106_1_T1	PHENOTYPE	7	7	elimination
NCT000011064	NCT00001106_4_T0	GENE	36	36	CD4
NCT000011064	NCT00001106_4_T1	CELL	37	37	cells
NCT000011064	NCT00001106_4_T2	PHENOTYPE	12	12	HIV
NCT000011064	NCT00001106_4_T3	GENE	2	2	has
NCT000011064	NCT00001106_4_T4	PHENOTYPE	30	31	opportunistic infections
NCT000011066	NCT00001106_6_T0	PHENOTYPE	9	9	pharmacokinetics
NCT000011066	NCT00001106_6_T1	GENE	12	12	IV
NCT000011069	NCT00001106_9_T0	GENE	36	36	CD4
NCT000011069	NCT00001106_9_T1	CELL	37	37	cells
NCT000011069	NCT00001106_9_T2	PHENOTYPE	12	12	HIV
NCT000011069	NCT00001106_9_T3	GENE	2	2	has
NCT000011069	NCT00001106_9_T4	PHENOTYPE	30	31	opportunistic infections
NCT0000110611	NCT00001106_11_T0	PHENOTYPE	9	9	pharmacokinetics
NCT0000110611	NCT00001106_11_T1	GENE	12	12	IV
NCT0000110614	NCT00001106_14_T0	PHENOTYPE	7	9	intravenous drug abuse
NCT0000110617	NCT00001106_17_T0	COMPOUND	13	13	methadone
NCT0000110617	NCT00001106_17_T1	COMPOUND	25	25	methadone
NCT0000110623	NCT00001106_23_T0	GENE	6	6	has
NCT0000110624	NCT00001106_24_T0	COMPOUND	28	28	methadone
NCT0000110624	NCT00001106_24_T1	PHENOTYPE	22	23	drug use
NCT0000110624	NCT00001106_24_T2	PHENOTYPE	10	12	intravenous drug abuse
NCT0000110629	NCT00001106_29_T0	COMPOUND	6	6	methadone
NCT0000110629	NCT00001106_29_T1	PHENOTYPE	11	12	drug use
NCT000011072	NCT00001107_2_T0	COMPOUND	8	8	fluconazole
NCT000011072	NCT00001107_2_T1	COMPOUND	0	0	AmBisome
NCT000011072	NCT00001107_2_T2	PHENOTYPE	13	14	fungal infections
NCT000011073	NCT00001107_3_T0	ORGAN	6	6	liver
NCT000011073	NCT00001107_3_T1	ORGAN	7	7	transplant
NCT000011073	NCT00001107_3_T2	GENE	18	18	IFI
NCT000011075	NCT00001107_5_T0	ORGAN	10	10	liver
NCT000011075	NCT00001107_5_T1	ORGAN	11	11	transplant
NCT000011076	NCT00001107_6_T0	PHENOTYPE	5	5	focused
NCT000011076	NCT00001107_6_T1	PHENOTYPE	20	20	resistant
NCT000011076	NCT00001107_6_T2	GENE	1	1	IFI
NCT0000110711	NCT00001107_11_T0	ORGAN	9	9	liver
NCT0000110711	NCT00001107_11_T1	ORGAN	10	10	transplant
NCT000011082	NCT00001108_2_T0	PHENOTYPE	9	9	HIV
NCT000011082	NCT00001108_2_T1	GENE	15	15	has
NCT000011082	NCT00001108_2_T2	PHENOTYPE	22	23	HIV infection
NCT000011083	NCT00001108_3_T0	COMPOUND	11	11	stavudine
NCT000011083	NCT00001108_3_T1	COMPOUND	17	17	nelfinavir
NCT000011083	NCT00001108_3_T2	COMPOUND	21	21	saquinavir
NCT000011083	NCT00001108_3_T3	COMPOUND	13	13	didanosine
NCT000011083	NCT00001108_3_T4	COMPOUND	24	24	nevirapine
NCT000011083	NCT00001108_3_T5	COMPOUND	19	19	ritonavir
NCT000011083	NCT00001108_3_T6	COMPOUND	15	15	lamivudine
NCT000011084	NCT00001108_4_T0	COMPOUND	19	19	hydroxyurea
NCT000011084	NCT00001108_4_T1	PHENOTYPE	37	37	HIV
NCT000011084	NCT00001108_4_T2	GENE	2	2	has
NCT000011084	NCT00001108_4_T3	GENE	20	20	HU
NCT000011085	NCT00001108_5_T0	PHENOTYPE	3	3	HIV
NCT000011085	NCT00001108_5_T1	PHENOTYPE	7	8	drug levels
NCT0000110810	NCT00001108_10_T0	PHENOTYPE	0	1	Virologic failure
NCT0000110817	NCT00001108_17_T0	GENE	23	23	halted
NCT0000110817	NCT00001108_17_T1	PHENOTYPE	18	18	toxicities
NCT0000110820	NCT00001108_20_T0	ORGAN	9	9	plasma
NCT0000110821	NCT00001108_21_T0	ORGAN	2	2	plasma
NCT000011091	NCT00001109_1_T0	CELL	7	7	cells
NCT000011091	NCT00001109_1_T1	PHENOTYPE	23	23	HIV
NCT000011091	NCT00001109_1_T2	PHENOTYPE	20	20	infections
NCT000011095	NCT00001109_5_T0	PHENOTYPE	20	20	peripheral
NCT000011095	NCT00001109_5_T1	GENE	22	22	CD4
NCT000011095	NCT00001109_5_T2	CELL	27	27	cells
NCT000011095	NCT00001109_5_T3	PHENOTYPE	13	13	HIV/AIDS
NCT000011095	NCT00001109_5_T4	GENE	6	6	has
NCT000011095	NCT00001109_5_T5	PHENOTYPE	33	34	disease progression
NCT000011095	NCT00001109_5_T6	CELL	23	24	T cells
NCT000011095	NCT00001109_5_T7	PHENOTYPE	32	33	HIV disease
NCT0000110913	NCT00001109_13_T0	GENE	11	11	CD4
NCT0000110913	NCT00001109_13_T1	GENE	13	13	CD8
NCT000011101	NCT00001110_1_T0	CELL	13	13	cells
NCT000011101	NCT00001110_1_T1	PHENOTYPE	3	3	HIV
NCT000011101	NCT00001110_1_T2	PHENOTYPE	1	1	inflammation
NCT000011101	NCT00001110_1_T3	PHENOTYPE	9	10	HIV infection
NCT000011102	NCT00001110_2_T0	PHENOTYPE	10	10	HIV
NCT000011102	NCT00001110_2_T1	PHENOTYPE	24	24	HIV
NCT000011102	NCT00001110_2_T2	PHENOTYPE	32	32	HIV
NCT000011102	NCT00001110_2_T3	PHENOTYPE	3	3	inflammation
NCT000011102	NCT00001110_2_T4	PHENOTYPE	18	18	inflammation
NCT000011102	NCT00001110_2_T5	PHENOTYPE	26	26	inflammation
NCT000011102	NCT00001110_2_T6	ORGAN	15	15	lungs
NCT000011103	NCT00001110_3_T0	PHENOTYPE	8	8	HIV
NCT000011104	NCT00001110_4_T0	PHENOTYPE	19	19	inflammation
NCT000011104	NCT00001110_4_T1	ORGAN	10	10	lungs
NCT000011106	NCT00001110_6_T0	PHENOTYPE	3	4	lymphocytic alveolitis
NCT000011107	NCT00001110_7_T0	CELL	19	20	T lymphocytes
NCT0000111012	NCT00001110_12_T0	PHENOTYPE	15	15	peripheral
NCT000011111	NCT00001111_1_T0	COMPOUND	15	15	nevirapine
NCT000011111	NCT00001111_1_T1	COMPOUND	20	20	zidovudine
NCT000011111	NCT00001111_1_T2	PHENOTYPE	27	27	HIV
NCT000011111	NCT00001111_1_T3	PHENOTYPE	10	10	pharmacokinetics
NCT000011111	NCT00001111_1_T4	PHENOTYPE	9	9	tolerance
NCT000011112	NCT00001111_2_T0	PHENOTYPE	12	12	toxic
NCT000011112	NCT00001111_2_T1	GENE	2	3	reverse transcriptase
NCT000011113	NCT00001111_3_T0	PHENOTYPE	27	27	plaque
NCT000011113	NCT00001111_3_T1	COMPOUND	23	23	zidovudine
NCT000011113	NCT00001111_3_T2	PHENOTYPE	16	16	inhibition
NCT000011113	NCT00001111_3_T3	GENE	2	2	has
NCT000011113	NCT00001111_3_T4	GENE	12	12	has
NCT000011115	NCT00001111_5_T0	PHENOTYPE	28	28	plaque
NCT000011115	NCT00001111_5_T1	COMPOUND	24	24	zidovudine
NCT000011115	NCT00001111_5_T2	PHENOTYPE	17	17	inhibition
NCT000011115	NCT00001111_5_T3	GENE	2	2	has
NCT000011115	NCT00001111_5_T4	GENE	13	13	has
NCT000011115	NCT00001111_5_T5	GENE	10	11	reverse transcriptase
NCT000011116	NCT00001111_6_T0	COMPOUND	18	18	nevirapine
NCT000011116	NCT00001111_6_T1	PHENOTYPE	5	5	HIV
NCT000011118	NCT00001111_8_T0	COMPOUND	17	17	nevirapine
NCT000011118	NCT00001111_8_T1	COMPOUND	13	13	zidovudine
NCT000011119	NCT00001111_9_T0	COMPOUND	18	18	nevirapine
NCT000011119	NCT00001111_9_T1	COMPOUND	11	11	zidovudine
NCT0000111110	NCT00001111_10_T0	COMPOUND	10	10	nevirapine
NCT0000111113	NCT00001111_13_T0	GENE	5	5	PCR
NCT0000111113	NCT00001111_13_T1	PHENOTYPE	14	15	HIV infection
NCT000011121	NCT00001112_1_T0	GENE	12	12	IFN-G
NCT000011121	NCT00001112_1_T1	CELL	13	15	white blood cells
NCT000011122	NCT00001112_2_T0	ORGAN	15	16	immune system
NCT000011123	NCT00001112_3_T0	CELL	8	8	cells
NCT000011124	NCT00001112_4_T0	PHENOTYPE	5	5	malignancies
NCT000011124	NCT00001112_4_T1	PHENOTYPE	27	27	toxicities
NCT000011124	NCT00001112_4_T2	PHENOTYPE	2	3	opportunistic infections
NCT000011125	NCT00001112_5_T0	CELL	27	27	lymphocyte
NCT000011125	NCT00001112_5_T1	ORGAN	28	28	transplants
NCT000011125	NCT00001112_5_T2	PHENOTYPE	14	15	retroviral infection
NCT000011126	NCT00001112_6_T0	COMPOUND	3	3	zidovudine
NCT000011126	NCT00001112_6_T1	GENE	17	17	lymphokine
NCT000011126	NCT00001112_6_T2	GENE	6	6	has
NCT000011126	NCT00001112_6_T3	GENE	15	15	IFN-G
NCT000011126	NCT00001112_6_T4	PHENOTYPE	12	13	HIV infection
NCT000011127	NCT00001112_7_T0	GENE	9	9	IFN-G
NCT000011129	NCT00001112_9_T0	CELL	8	8	cells
NCT0000111210	NCT00001112_10_T0	PHENOTYPE	5	5	malignancies
NCT0000111210	NCT00001112_10_T1	PHENOTYPE	27	27	toxicities
NCT0000111210	NCT00001112_10_T2	PHENOTYPE	2	3	opportunistic infections
NCT0000111211	NCT00001112_11_T0	CELL	27	27	lymphocyte
NCT0000111211	NCT00001112_11_T1	ORGAN	28	28	transplants
NCT0000111211	NCT00001112_11_T2	PHENOTYPE	14	15	retroviral infection
NCT0000111212	NCT00001112_12_T0	COMPOUND	3	3	zidovudine
NCT0000111212	NCT00001112_12_T1	GENE	17	17	lymphokine
NCT0000111212	NCT00001112_12_T2	GENE	6	6	has
NCT0000111212	NCT00001112_12_T3	GENE	15	15	IFN-G
NCT0000111212	NCT00001112_12_T4	PHENOTYPE	12	13	HIV infection
NCT0000111213	NCT00001112_13_T0	GENE	9	9	IFN-G
NCT0000111215	NCT00001112_15_T0	GENE	10	10	had
NCT0000111215	NCT00001112_15_T1	GENE	22	22	IFN-G
NCT0000111215	NCT00001112_15_T2	PHENOTYPE	14	15	opportunistic infection
NCT0000111216	NCT00001112_16_T0	CELL	0	0	Monocyte
NCT0000111216	NCT00001112_16_T1	GENE	15	15	IFN-G
NCT0000111216	NCT00001112_16_T2	PHENOTYPE	1	2	antimicrobial activity
NCT0000111217	NCT00001112_17_T0	GENE	10	10	IFN-G
NCT0000111219	NCT00001112_19_T0	GENE	18	18	IFN-G
NCT0000111219	NCT00001112_19_T1	PHENOTYPE	0	1	Antimicrobial activity
NCT0000111220	NCT00001112_20_T0	GENE	10	10	IFN-G
NCT0000111220	NCT00001112_20_T1	GENE	17	17	IFN-G
NCT0000111220	NCT00001112_20_T2	PHENOTYPE	5	5	tolerance
NCT0000111222	NCT00001112_22_T0	GENE	10	10	C-1
NCT0000111222	NCT00001112_22_T1	GENE	15	15	had
NCT0000111222	NCT00001112_22_T2	GENE	9	9	IV
NCT0000111222	NCT00001112_22_T3	PHENOTYPE	20	21	opportunistic infections
NCT0000111223	NCT00001112_23_T0	PHENOTYPE	18	18	secondary
NCT0000111223	NCT00001112_23_T1	GENE	24	24	C-1
NCT0000111223	NCT00001112_23_T2	GENE	14	14	had
NCT0000111223	NCT00001112_23_T3	PHENOTYPE	19	20	infectious diseases
NCT0000111223	NCT00001112_23_T4	PHENOTYPE	5	6	Kaposi's sarcoma
NCT000011132	NCT00001113_2_T0	PHENOTYPE	3	3	pharmacokinetics
NCT000011133	NCT00001113_3_T0	GENE	21	21	II
NCT000011133	NCT00001113_3_T1	GENE	6	6	MTD
NCT000011134	NCT00001113_4_T0	PHENOTYPE	11	11	HIV
NCT000011134	NCT00001113_4_T1	GENE	1	1	has
NCT000011134	NCT00001113_4_T2	PHENOTYPE	26	27	Kaposi's sarcoma
NCT0000111314	NCT00001113_14_T0	PHENOTYPE	15	15	toxicity
NCT0000111314	NCT00001113_14_T1	PHENOTYPE	21	21	toxicity
NCT0000111314	NCT00001113_14_T2	GENE	1	1	MTD
NCT0000111314	NCT00001113_14_T3	GENE	17	17	hemoglobin
NCT0000111315	NCT00001113_15_T0	GENE	2	2	MTD
NCT000011141	NCT00001114_1_T0	GENE	7	7	IFN-alpha
NCT000011141	NCT00001114_1_T1	PHENOTYPE	0	0	Secondary
NCT000011141	NCT00001114_1_T2	PHENOTYPE	12	12	HIV
NCT000011143	NCT00001114_3_T0	PHENOTYPE	27	27	toxicity
NCT000011143	NCT00001114_3_T1	GENE	4	4	IFN-alpha
NCT000011143	NCT00001114_3_T2	COMPOUND	11	11	zidovudine
NCT000011143	NCT00001114_3_T3	PHENOTYPE	23	23	HIV
NCT000011143	NCT00001114_3_T4	PHENOTYPE	24	24	suppression
NCT000011143	NCT00001114_3_T5	PHENOTYPE	29	29	neutropenia
NCT000011143	NCT00001114_3_T6	GENE	34	34	has
NCT000011144	NCT00001114_4_T0	PHENOTYPE	1	1	toxicity
NCT000011144	NCT00001114_4_T1	GENE	18	18	IFN-alpha
NCT000011144	NCT00001114_4_T2	COMPOUND	14	14	zidovudine
NCT000011146	NCT00001114_6_T0	PHENOTYPE	27	27	toxicity
NCT000011146	NCT00001114_6_T1	GENE	4	4	IFN-alpha
NCT000011146	NCT00001114_6_T2	COMPOUND	11	11	zidovudine
NCT000011146	NCT00001114_6_T3	PHENOTYPE	23	23	HIV
NCT000011146	NCT00001114_6_T4	PHENOTYPE	24	24	suppression
NCT000011146	NCT00001114_6_T5	PHENOTYPE	29	29	neutropenia
NCT000011146	NCT00001114_6_T6	GENE	34	34	has
NCT000011147	NCT00001114_7_T0	PHENOTYPE	1	1	toxicity
NCT000011147	NCT00001114_7_T1	GENE	18	18	IFN-alpha
NCT000011147	NCT00001114_7_T2	COMPOUND	14	14	zidovudine
NCT000011148	NCT00001114_8_T0	GENE	14	14	IFN-alpha
NCT0000111412	NCT00001114_12_T0	PHENOTYPE	15	15	tumor
NCT0000111413	NCT00001114_13_T0	PHENOTYPE	8	8	toxicity
NCT0000111413	NCT00001114_13_T1	PHENOTYPE	4	5	tumor progression
NCT000011152	NCT00001115_2_T0	PHENOTYPE	6	6	HIV
NCT000011152	NCT00001115_2_T1	PHENOTYPE	11	11	HSV
NCT000011153	NCT00001115_3_T0	PHENOTYPE	7	7	HSV
NCT000011153	NCT00001115_3_T1	PHENOTYPE	14	15	HIV disease
NCT000011153	NCT00001115_3_T2	PHENOTYPE	15	16	disease progression
NCT000011154	NCT00001115_4_T0	PHENOTYPE	10	10	HIV
NCT000011154	NCT00001115_4_T1	PHENOTYPE	35	35	HIV
NCT000011154	NCT00001115_4_T2	PHENOTYPE	26	26	suppression
NCT000011154	NCT00001115_4_T3	PHENOTYPE	16	16	HSV
NCT000011154	NCT00001115_4_T4	PHENOTYPE	22	22	HSV
NCT000011154	NCT00001115_4_T5	PHENOTYPE	28	28	HSV
NCT000011155	NCT00001115_5_T0	PHENOTYPE	13	13	HIV
NCT000011155	NCT00001115_5_T1	PHENOTYPE	11	11	HSV
NCT000011157	NCT00001115_7_T0	PHENOTYPE	7	7	HSV
NCT000011157	NCT00001115_7_T1	PHENOTYPE	14	15	HIV disease
NCT000011157	NCT00001115_7_T2	PHENOTYPE	15	16	disease progression
NCT000011158	NCT00001115_8_T0	PHENOTYPE	10	10	HIV
NCT000011158	NCT00001115_8_T1	PHENOTYPE	35	35	HIV
NCT000011158	NCT00001115_8_T2	PHENOTYPE	26	26	suppression
NCT000011158	NCT00001115_8_T3	PHENOTYPE	16	16	HSV
NCT000011158	NCT00001115_8_T4	PHENOTYPE	22	22	HSV
NCT000011158	NCT00001115_8_T5	PHENOTYPE	28	28	HSV
NCT000011159	NCT00001115_9_T0	PHENOTYPE	13	13	HIV
NCT000011159	NCT00001115_9_T1	PHENOTYPE	11	11	HSV
NCT0000111511	NCT00001115_11_T0	PHENOTYPE	2	2	HSV
NCT0000111511	NCT00001115_11_T1	ORGAN	3	3	serum
NCT000011161	NCT00001116_1_T0	GENE	10	10	TNF-alpha
NCT000011162	NCT00001116_2_T0	GENE	2	2	TNF-alpha
NCT000011162	NCT00001116_2_T1	PHENOTYPE	17	17	HIV
NCT000011162	NCT00001116_2_T2	GENE	0	0	IL-6
NCT000011162	NCT00001116_2_T3	ORGAN	9	10	immune system
NCT000011163	NCT00001116_3_T0	GENE	2	2	TNF-alpha
NCT000011163	NCT00001116_3_T1	GENE	0	0	IL-6
NCT000011164	NCT00001116_4_T0	GENE	3	3	TNF-alpha
NCT000011164	NCT00001116_4_T1	PHENOTYPE	11	11	HIV
NCT000011164	NCT00001116_4_T2	BIOLOGICAL_PROCESS	7	8	IL-6 production
NCT000011165	NCT00001116_5_T0	GENE	23	23	TNF-alpha
NCT000011165	NCT00001116_5_T1	GENE	5	5	interleukin-2
NCT000011165	NCT00001116_5_T2	GENE	4	4	IL-2
NCT000011165	NCT00001116_5_T3	GENE	28	28	IL-2
NCT000011165	NCT00001116_5_T4	GENE	21	21	IL-6
NCT000011165	NCT00001116_5_T5	ORGAN	11	12	immune system
NCT000011168	NCT00001116_8_T0	PHENOTYPE	18	18	symptoms
NCT000011168	NCT00001116_8_T1	GENE	21	21	IL-2
NCT000011168	NCT00001116_8_T2	PHENOTYPE	10	11	HIV disease
NCT0000111610	NCT00001116_10_T0	PHENOTYPE	11	11	HIV
NCT0000111610	NCT00001116_10_T1	BIOLOGICAL_PROCESS	3	4	TNF-alpha production
NCT0000111612	NCT00001116_12_T0	GENE	11	11	TNF-alpha
NCT0000111613	NCT00001116_13_T0	GENE	11	11	TNF-alpha
NCT0000111613	NCT00001116_13_T1	GENE	14	14	IL-6
NCT0000111613	NCT00001116_13_T2	PHENOTYPE	8	9	decreased activity
NCT0000111614	NCT00001116_14_T0	GENE	12	12	TNF-alpha
NCT0000111614	NCT00001116_14_T1	GENE	5	5	IL-2
NCT0000111614	NCT00001116_14_T2	GENE	22	22	IL-2
NCT0000111614	NCT00001116_14_T3	PHENOTYPE	0	0	HIV
NCT0000111614	NCT00001116_14_T4	GENE	4	4	Interleukin-2
NCT0000111614	NCT00001116_14_T5	GENE	14	14	IL-6
NCT0000111616	NCT00001116_16_T0	PHENOTYPE	36	36	symptoms
NCT0000111616	NCT00001116_16_T1	GENE	15	15	TNF-alpha
NCT0000111616	NCT00001116_16_T2	GENE	39	39	IL-2
NCT0000111616	NCT00001116_16_T3	GENE	5	5	IL-6
NCT0000111616	NCT00001116_16_T4	PHENOTYPE	28	29	HIV disease
NCT000011170	NCT00001117_0_T0	PHENOTYPE	15	17	Hepatitis C Infection
NCT000011172	NCT00001117_2_T0	PHENOTYPE	15	15	HIV
NCT000011172	NCT00001117_2_T1	COMPOUND	10	10	HCV
NCT000011174	NCT00001117_4_T0	PHENOTYPE	16	16	suppression
NCT000011175	NCT00001117_5_T0	ORGAN	13	13	plasma
NCT000011176	NCT00001117_6_T0	ORGAN	0	0	Plasma
NCT000011176	NCT00001117_6_T1	COMPOUND	15	15	HCV
NCT000011176	NCT00001117_6_T2	COMPOUND	17	17	HCV
NCT000011176	NCT00001117_6_T3	GENE	19	19	PCR
NCT000011176	NCT00001117_6_T4	PHENOTYPE	12	13	Hepatitis C
NCT000011181	NCT00001118_1_T0	CELL	13	13	cells
NCT000011181	NCT00001118_1_T1	PHENOTYPE	3	3	HIV
NCT000011181	NCT00001118_1_T2	PHENOTYPE	9	9	HIV
NCT000011181	NCT00001118_1_T3	CELL	14	15	T cells
NCT000011182	NCT00001118_2_T0	PHENOTYPE	5	5	HIV
NCT000011182	NCT00001118_2_T1	PHENOTYPE	10	10	HIV
NCT000011182	NCT00001118_2_T2	GENE	34	34	PI
NCT000011182	NCT00001118_2_T3	GENE	32	33	protease inhibitor
NCT000011182	NCT00001118_2_T4	GENE	19	20	reverse transcriptase
NCT000011182	NCT00001118_2_T5	GENE	26	27	reverse transcriptase
NCT000011186	NCT00001118_6_T0	PHENOTYPE	27	28	HIV infection
NCT000011189	NCT00001118_9_T0	GENE	23	23	SC
NCT000011189	NCT00001118_9_T1	GENE	28	28	deltoid
NCT000011189	NCT00001118_9_T2	ORGAN	35	35	thigh
NCT000011189	NCT00001118_9_T3	ORGAN	27	27	abdomen
NCT000011189	NCT00001118_9_T4	GENE	42	42	IV
NCT0000111810	NCT00001118_10_T0	GENE	4	4	met
NCT0000111813	NCT00001118_13_T0	ORGAN	25	25	plasma
NCT0000111822	NCT00001118_22_T0	GENE	29	29	PI
NCT000011191	NCT00001119_1_T0	PHENOTYPE	14	14	HIV
NCT000011191	NCT00001119_1_T1	PHENOTYPE	22	22	HIV
NCT000011191	NCT00001119_1_T2	GENE	21	21	had
NCT000011191	NCT00001119_1_T3	PHENOTYPE	9	10	HIV infection
NCT000011192	NCT00001119_2_T0	PHENOTYPE	6	6	HIV
NCT000011193	NCT00001119_3_T0	PHENOTYPE	9	9	HIV
NCT000011193	NCT00001119_3_T1	PHENOTYPE	25	25	diseases
NCT000011193	NCT00001119_3_T2	PHENOTYPE	16	17	HIV infection
NCT000011195	NCT00001119_5_T0	PHENOTYPE	11	11	HIV
NCT000011195	NCT00001119_5_T1	ORGAN	16	17	immune system
NCT000011196	NCT00001119_6_T0	PHENOTYPE	19	19	tetanus
NCT000011196	NCT00001119_6_T1	PHENOTYPE	14	15	hepatitis B
NCT000011197	NCT00001119_7_T0	PHENOTYPE	7	7	HIV
NCT000011197	NCT00001119_7_T1	PHENOTYPE	12	12	infections
NCT000011199	NCT00001119_9_T0	GENE	6	6	ART
NCT000011199	NCT00001119_9_T1	PHENOTYPE	12	12	progression
NCT000011199	NCT00001119_9_T2	PHENOTYPE	9	10	acute infection
NCT0000111911	NCT00001119_11_T0	GENE	7	7	has
NCT0000111912	NCT00001119_12_T0	PHENOTYPE	10	11	HIV infection
NCT0000111913	NCT00001119_13_T0	PHENOTYPE	12	12	tetanus
NCT0000111913	NCT00001119_13_T1	PHENOTYPE	9	10	hepatitis B
NCT0000111913	NCT00001119_13_T2	PHENOTYPE	4	5	antibody responses
NCT0000111919	NCT00001119_19_T0	GENE	15	15	ART
NCT0000111920	NCT00001119_20_T0	GENE	18	18	CD4
NCT0000111920	NCT00001119_20_T1	CELL	19	20	T cells
NCT0000111921	NCT00001119_21_T0	PHENOTYPE	25	26	antibody responses
NCT0000111925	NCT00001119_25_T0	PHENOTYPE	4	4	hepatitis
NCT0000111925	NCT00001119_25_T1	PHENOTYPE	18	19	hepatitis B
NCT0000111926	NCT00001119_26_T0	PHENOTYPE	28	28	tetanus
NCT0000111926	NCT00001119_26_T1	PHENOTYPE	21	22	hepatitis B
NCT0000111927	NCT00001119_27_T0	PHENOTYPE	8	8	HIV
NCT000011200	NCT00001120_0_T0	PHENOTYPE	6	6	Syndrome
NCT000011204	NCT00001120_4_T0	PHENOTYPE	9	9	HIV
NCT000011207	NCT00001120_7_T0	PHENOTYPE	16	17	HIV infection
NCT000011208	NCT00001120_8_T0	PHENOTYPE	7	7	HIV
NCT000011208	NCT00001120_8_T1	PHENOTYPE	16	16	tumor
NCT0000112011	NCT00001120_11_T0	PHENOTYPE	21	21	practices
NCT0000112011	NCT00001120_11_T1	PHENOTYPE	17	18	substance abuse
NCT0000112015	NCT00001120_15_T0	PHENOTYPE	14	14	malignancy
NCT0000112016	NCT00001120_16_T0	PHENOTYPE	1	1	malignancies
NCT0000112016	NCT00001120_16_T1	GENE	7	7	oncogene
NCT000011211	NCT00001121_1_T0	PHENOTYPE	17	17	HIV
NCT000011211	NCT00001121_1_T1	PHENOTYPE	23	23	HIV
NCT000011211	NCT00001121_1_T2	PHENOTYPE	10	11	HIV infection
NCT000011212	NCT00001121_2_T0	PHENOTYPE	3	3	HIV
NCT000011212	NCT00001121_2_T1	PHENOTYPE	9	10	HIV infection
NCT000011214	NCT00001121_4_T0	PHENOTYPE	17	17	HIV
NCT000011214	NCT00001121_4_T1	PHENOTYPE	23	23	HIV
NCT000011214	NCT00001121_4_T2	PHENOTYPE	10	11	HIV infection
NCT000011216	NCT00001121_6_T0	PHENOTYPE	10	10	immunity
NCT000011218	NCT00001121_8_T0	PHENOTYPE	33	33	symptoms
NCT000011218	NCT00001121_8_T1	PHENOTYPE	20	20	reflected
NCT000011218	NCT00001121_8_T2	BIOLOGICAL_PROCESS	13	14	immune response
NCT000011218	NCT00001121_8_T3	PHENOTYPE	17	18	disease course
NCT000011219	NCT00001121_9_T0	BIOLOGICAL_PROCESS	5	6	immune response
NCT000011219	NCT00001121_9_T1	PHENOTYPE	13	14	HIV infection
NCT0000112113	NCT00001121_13_T0	PHENOTYPE	1	1	HIV
NCT0000112114	NCT00001121_14_T0	BIOLOGICAL_PROCESS	13	15	cellular immune response
NCT000011222	NCT00001122_2_T0	PHENOTYPE	9	9	HIV
NCT000011223	NCT00001122_3_T0	PHENOTYPE	8	8	HIV
NCT000011225	NCT00001122_5_T0	PHENOTYPE	1	1	HIV
NCT000011225	NCT00001122_5_T1	PHENOTYPE	12	12	remembering
NCT0000112210	NCT00001122_10_T0	PHENOTYPE	19	20	drug intolerance
NCT0000112210	NCT00001122_10_T1	PHENOTYPE	9	10	HIV infection
NCT0000112211	NCT00001122_11_T0	PHENOTYPE	20	20	HIV
NCT0000112211	NCT00001122_11_T1	GENE	3	3	has
NCT0000112212	NCT00001122_12_T0	COMPOUND	9	9	stavudine
NCT0000112212	NCT00001122_12_T1	COMPOUND	14	14	nelfinavir
NCT0000112212	NCT00001122_12_T2	COMPOUND	7	7	didanosine
NCT0000112212	NCT00001122_12_T3	COMPOUND	11	11	efavirenz
NCT0000112213	NCT00001122_13_T0	GENE	8	8	MAT
NCT0000112213	NCT00001122_13_T1	GENE	5	5	SAT
NCT0000112215	NCT00001122_15_T0	GENE	10	10	MAT
NCT0000112217	NCT00001122_17_T0	GENE	3	3	SAT
NCT0000112219	NCT00001122_19_T0	GENE	9	9	SAT
NCT000011231	NCT00001123_1_T0	ORGAN	9	9	lungs
NCT000011232	NCT00001123_2_T0	PHENOTYPE	6	6	bleeding
NCT000011232	NCT00001123_2_T1	PHENOTYPE	4	4	fever
NCT000011251	NCT00001125_1_T0	COMPOUND	0	0	VZV
NCT000011251	NCT00001125_1_T1	PHENOTYPE	6	6	chickenpox
NCT000011253	NCT00001125_3_T0	PHENOTYPE	6	6	HIV
NCT000011253	NCT00001125_3_T1	PHENOTYPE	10	10	chickenpox
NCT000011253	NCT00001125_3_T2	PHENOTYPE	0	0	Shingles
NCT000011253	NCT00001125_3_T3	GENE	9	9	had
NCT000011254	NCT00001125_4_T0	COMPOUND	1	1	VZV
NCT000011254	NCT00001125_4_T1	PHENOTYPE	17	17	chickenpox
NCT000011254	NCT00001125_4_T2	PHENOTYPE	20	20	shingles
NCT000011254	NCT00001125_4_T3	GENE	16	16	had
NCT000011256	NCT00001125_6_T0	PHENOTYPE	14	14	HIV
NCT000011256	NCT00001125_6_T1	PHENOTYPE	25	25	shingles
NCT000011256	NCT00001125_6_T2	PHENOTYPE	0	0	Varicella
NCT000011257	NCT00001125_7_T0	COMPOUND	7	7	VZV
NCT000011257	NCT00001125_7_T1	PHENOTYPE	15	15	HIV
NCT000011257	NCT00001125_7_T2	GENE	19	19	had
NCT000011257	NCT00001125_7_T3	PHENOTYPE	10	10	varicella
NCT000011257	NCT00001125_7_T4	PHENOTYPE	21	21	varicella
NCT000011258	NCT00001125_8_T0	PHENOTYPE	19	21	quality of life
NCT000011259	NCT00001125_9_T0	COMPOUND	4	4	VZV
NCT000011259	NCT00001125_9_T1	PHENOTYPE	11	11	immunity
NCT0000112515	NCT00001125_15_T0	PHENOTYPE	9	9	toxicity
NCT0000112515	NCT00001125_15_T1	GENE	18	18	has
NCT0000112520	NCT00001125_20_T0	COMPOUND	4	4	VZV
NCT0000112520	NCT00001125_20_T1	PHENOTYPE	1	1	HIV
NCT0000112520	NCT00001125_20_T2	PHENOTYPE	2	2	progression
NCT0000112520	NCT00001125_20_T3	PHENOTYPE	0	0	Symptoms
NCT000011261	NCT00001126_1_T0	PHENOTYPE	0	1	Laryngeal papillomatosis
NCT000011263	NCT00001126_3_T0	COMPOUND	1	1	cidofovir
NCT0000112613	NCT00001126_13_T0	PHENOTYPE	6	6	anesthesia
NCT0000112615	NCT00001126_15_T0	COMPOUND	24	24	cidofovir
NCT000011280	NCT00001128_0_T0	PHENOTYPE	3	3	Cryptosporidiosis
NCT000011280	NCT00001128_0_T1	PHENOTYPE	2	2	Chronic
NCT000011282	NCT00001128_2_T0	GENE	10	10	IL-12
NCT000011282	NCT00001128_2_T1	COMPOUND	13	13	azithromycin
NCT000011282	NCT00001128_2_T2	COMPOUND	20	20	azithromycin
NCT000011282	NCT00001128_2_T3	COMPOUND	11	11	paromomycin
NCT000011282	NCT00001128_2_T4	COMPOUND	18	18	paromomycin
NCT000011283	NCT00001128_3_T0	PHENOTYPE	0	0	Cryptosporidiosis
NCT000011283	NCT00001128_3_T1	ORGAN	14	15	immune systems
NCT000011285	NCT00001128_5_T0	COMPOUND	3	3	azithromycin
NCT000011285	NCT00001128_5_T1	COMPOUND	1	1	paromomycin
NCT000011285	NCT00001128_5_T2	PHENOTYPE	9	9	cryptosporidiosis
NCT000011286	NCT00001128_6_T0	GENE	11	11	IL-12
NCT000011287	NCT00001128_7_T0	CELL	12	12	cells
NCT000011287	NCT00001128_7_T1	GENE	0	0	IL-12
NCT000011287	NCT00001128_7_T2	ORGAN	15	16	immune system
NCT0000112811	NCT00001128_11_T0	COMPOUND	2	2	azithromycin
NCT0000112813	NCT00001128_13_T0	GENE	11	11	IL-12
NCT0000112813	NCT00001128_13_T1	GENE	0	0	Interferon
NCT0000112813	NCT00001128_13_T2	PHENOTYPE	9	9	cryptosporidiosis
NCT0000112813	NCT00001128_13_T3	GENE	1	1	gamma
NCT0000112813	NCT00001128_13_T4	GENE	20	21	interferon gamma
NCT0000112815	NCT00001128_15_T0	GENE	13	13	IL-12
NCT0000112815	NCT00001128_15_T1	COMPOUND	3	3	azithromycin
NCT0000112815	NCT00001128_15_T2	COMPOUND	5	5	paromomycin
NCT0000112816	NCT00001128_16_T0	GENE	0	0	IL-12
NCT0000112818	NCT00001128_18_T0	PHENOTYPE	13	13	symptoms
NCT0000112818	NCT00001128_18_T1	GENE	9	9	bowel
NCT0000112819	NCT00001128_19_T0	GENE	12	12	IL-12
NCT0000112821	NCT00001128_21_T0	GENE	9	9	CD4
NCT000011291	NCT00001129_1_T0	PHENOTYPE	9	9	HIV
NCT000011292	NCT00001129_2_T0	PHENOTYPE	8	8	HIV
NCT000011293	NCT00001129_3_T0	PHENOTYPE	1	1	HIV
NCT000011293	NCT00001129_3_T1	PHENOTYPE	12	12	remembering
NCT000011297	NCT00001129_7_T0	GENE	1	1	AR
NCT000011298	NCT00001129_8_T0	PHENOTYPE	12	13	substance abuse
NCT0000112910	NCT00001129_10_T0	PHENOTYPE	19	19	HIV
NCT0000112915	NCT00001129_15_T0	GENE	6	6	ALR
NCT0000112916	NCT00001129_16_T0	GENE	20	20	AR
NCT0000112916	NCT00001129_16_T1	GENE	12	12	flash
NCT0000112917	NCT00001129_17_T0	GENE	33	33	has
NCT0000112919	NCT00001129_19_T0	ORGAN	11	11	plasma
NCT000011302	NCT00001130_2_T0	PHENOTYPE	10	10	symptoms
NCT000011302	NCT00001130_2_T1	PHENOTYPE	18	18	HIV
NCT000011302	NCT00001130_2_T2	PHENOTYPE	32	32	HIV
NCT000011305	NCT00001130_5_T0	PHENOTYPE	21	22	HIV infection
NCT000011306	NCT00001130_6_T0	PHENOTYPE	4	4	HIV
NCT000011306	NCT00001130_6_T1	PHENOTYPE	21	21	HIV
NCT000011306	NCT00001130_6_T2	PHENOTYPE	13	14	HIV infection
NCT000011308	NCT00001130_8_T0	PHENOTYPE	15	15	HIV
NCT000011308	NCT00001130_8_T1	PHENOTYPE	9	10	HIV positive
NCT0000113010	NCT00001130_10_T0	PHENOTYPE	8	8	HIV
NCT0000113010	NCT00001130_10_T1	PHENOTYPE	20	20	HIV
NCT0000113011	NCT00001130_11_T0	GENE	6	6	PHI
NCT0000113011	NCT00001130_11_T1	PHENOTYPE	2	2	HIV
NCT0000113017	NCT00001130_17_T0	PHENOTYPE	22	22	HIV
NCT0000113017	NCT00001130_17_T1	PHENOTYPE	8	8	syndromes
NCT0000113018	NCT00001130_18_T0	PHENOTYPE	5	6	HIV infection
NCT0000113020	NCT00001130_20_T0	GENE	13	13	p24
NCT0000113020	NCT00001130_20_T1	PHENOTYPE	6	6	HIV
NCT0000113020	NCT00001130_20_T2	PHENOTYPE	12	12	HIV
NCT000011312	NCT00001131_2_T0	GENE	7	7	CD4
NCT000011312	NCT00001131_2_T1	CELL	8	8	cells
NCT000011312	NCT00001131_2_T2	CELL	11	11	cells
NCT000011312	NCT00001131_2_T3	PHENOTYPE	0	0	HIV
NCT000011312	NCT00001131_2_T4	ORGAN	14	15	immune system
NCT000011314	NCT00001131_4_T0	PHENOTYPE	7	7	HIV
NCT000011314	NCT00001131_4_T1	PHENOTYPE	23	23	HIV
NCT000011314	NCT00001131_4_T2	PHENOTYPE	30	30	HIV
NCT000011314	NCT00001131_4_T3	GENE	32	32	has
NCT000011314	NCT00001131_4_T4	ORGAN	19	20	immune system
NCT000011314	NCT00001131_4_T5	PHENOTYPE	15	16	HIV infection
NCT000011314	NCT00001131_4_T6	PHENOTYPE	37	38	HIV infection
NCT000011316	NCT00001131_6_T0	CELL	4	4	cells
NCT000011317	NCT00001131_7_T0	GENE	16	16	CD4
NCT000011317	NCT00001131_7_T1	CELL	17	17	cells
NCT000011317	NCT00001131_7_T2	CELL	32	32	cells
NCT000011317	NCT00001131_7_T3	GENE	5	5	IL-2
NCT000011317	NCT00001131_7_T4	PHENOTYPE	25	25	HIV
NCT000011317	NCT00001131_7_T5	GENE	24	24	CD8
NCT000011317	NCT00001131_7_T6	GENE	26	26	CTL
NCT000011318	NCT00001131_8_T0	GENE	6	6	IL-2
NCT000011318	NCT00001131_8_T1	GENE	16	16	IL-2
NCT000011318	NCT00001131_8_T2	GENE	27	27	IL-2
NCT000011319	NCT00001131_9_T0	GENE	5	5	IL-2
NCT0000113110	NCT00001131_10_T0	GENE	0	0	IL-2
NCT0000113111	NCT00001131_11_T0	GENE	0	0	IL-2
NCT0000113113	NCT00001131_13_T0	GENE	13	13	CD4
NCT0000113113	NCT00001131_13_T1	GENE	11	11	IL-2
NCT0000113113	NCT00001131_13_T2	GENE	31	31	IL-2
NCT0000113113	NCT00001131_13_T3	PHENOTYPE	24	25	opportunistic infections
NCT0000113114	NCT00001131_14_T0	GENE	5	5	IL-2
NCT0000113114	NCT00001131_14_T1	GENE	11	11	IL-2
NCT000011323	NCT00001132_3_T0	PHENOTYPE	5	5	HIV
NCT000011328	NCT00001132_8_T0	ORGAN	17	17	plasma
NCT0000113210	NCT00001132_10_T0	PHENOTYPE	23	23	suppression
NCT0000113216	NCT00001132_16_T0	PHENOTYPE	4	5	virologic failure
NCT0000113220	NCT00001132_20_T0	ORGAN	0	0	Plasma
NCT0000113220	NCT00001132_20_T1	GENE	7	7	PR
NCT0000113220	NCT00001132_20_T2	GENE	9	9	RT
NCT0000113220	NCT00001132_20_T3	PHENOTYPE	24	25	virologic failure
NCT0000113221	NCT00001132_21_T0	GENE	6	6	PR
NCT0000113221	NCT00001132_21_T1	GENE	8	8	RT
NCT000011334	NCT00001133_4_T0	PHENOTYPE	5	5	HIV
NCT000011339	NCT00001133_9_T0	PHENOTYPE	3	3	pharmacokinetics
NCT0000113310	NCT00001133_10_T0	GENE	5	5	half-life
NCT0000113310	NCT00001133_10_T1	GENE	2	2	has
NCT0000113312	NCT00001133_12_T0	GENE	1	1	half-life
NCT0000113312	NCT00001133_12_T1	COMPOUND	6	6	3
NCT0000113315	NCT00001133_15_T0	GENE	6	7	reverse transcriptase
NCT0000113320	NCT00001133_20_T0	GENE	12	12	has
NCT000011351	NCT00001135_1_T0	PHENOTYPE	7	7	HIV
NCT000011353	NCT00001135_3_T0	PHENOTYPE	26	26	HIV
NCT000011356	NCT00001135_6_T0	ORGAN	10	10	plasma
NCT000011357	NCT00001135_7_T0	GENE	15	15	RT
NCT000011357	NCT00001135_7_T1	GENE	3	3	has
NCT000011357	NCT00001135_7_T2	GENE	13	14	reverse transcriptase
NCT000011358	NCT00001135_8_T0	ORGAN	12	12	genital
NCT000011359	NCT00001135_9_T0	PHENOTYPE	9	9	HIV
NCT0000113510	NCT00001135_10_T0	GENE	7	7	RT
NCT0000113510	NCT00001135_10_T1	ORGAN	14	14	genital
NCT0000113512	NCT00001135_12_T0	BIOLOGICAL_PROCESS	10	10	gestation
NCT0000113515	NCT00001135_15_T0	COMPOUND	6	6	zidovudine
NCT0000113520	NCT00001135_20_T0	PHENOTYPE	12	12	HIV
NCT000011360	NCT00001136_0_T0	PHENOTYPE	7	7	HIV
NCT000011360	NCT00001136_0_T1	PHENOTYPE	23	23	HIV
NCT000011363	NCT00001136_3_T0	PHENOTYPE	6	6	HIV
NCT000011364	NCT00001136_4_T0	PHENOTYPE	10	10	canarypox
NCT000011365	NCT00001136_5_T0	ORGAN	13	14	immune system
NCT000011367	NCT00001136_7_T0	PHENOTYPE	7	7	vaccinia
NCT000011367	NCT00001136_7_T1	GENE	12	12	has
NCT0000113610	NCT00001136_10_T0	PHENOTYPE	3	3	vaccinia
NCT0000113613	NCT00001136_13_T0	PHENOTYPE	2	2	symptoms
NCT0000113615	NCT00001136_15_T0	PHENOTYPE	3	3	HIV
NCT0000113617	NCT00001136_17_T0	PHENOTYPE	2	2	avoidance
NCT0000113617	NCT00001136_17_T1	PHENOTYPE	4	5	HIV infection
NCT000011371	NCT00001137_1_T0	PHENOTYPE	11	12	opportunistic infections
NCT000011373	NCT00001137_3_T0	PHENOTYPE	25	25	suppression
NCT000011373	NCT00001137_3_T1	PHENOTYPE	19	20	HIV infection
NCT000011420	NCT00001142_0_T0	BIOLOGICAL_PROCESS	0	0	Metabolism
NCT000011420	NCT00001142_0_T1	PHENOTYPE	10	11	Chronic Infections
NCT000011422	NCT00001142_2_T0	PHENOTYPE	7	7	disorders
NCT000011422	NCT00001142_2_T1	GENE	17	17	insulin
NCT000011422	NCT00001142_2_T2	BIOLOGICAL_PROCESS	9	9	metabolism
NCT000011422	NCT00001142_2_T3	PHENOTYPE	1	1	lipodystrophy
NCT000011423	NCT00001142_3_T0	GENE	14	14	protease
NCT000011424	NCT00001142_4_T0	PHENOTYPE	9	9	HIV
NCT000011425	NCT00001142_5_T0	PHENOTYPE	10	10	HIV
NCT000011425	NCT00001142_5_T1	PHENOTYPE	17	17	HIV
NCT000011425	NCT00001142_5_T2	PHENOTYPE	4	4	lipodystrophy
NCT000011427	NCT00001142_7_T0	GENE	13	13	protease
NCT000011427	NCT00001142_7_T1	PHENOTYPE	6	6	HIV
NCT000011427	NCT00001142_7_T2	PHENOTYPE	10	10	lipodystrophy
NCT000011428	NCT00001142_8_T0	PHENOTYPE	7	8	metabolic disorders
NCT000011428	NCT00001142_8_T1	GENE	18	19	protease inhibitor
NCT000011428	NCT00001142_8_T2	TISSUE	12	13	body fat
NCT000011429	NCT00001142_9_T0	PHENOTYPE	11	11	suffering
NCT000011429	NCT00001142_9_T1	GENE	22	22	protease
NCT000011429	NCT00001142_9_T2	PHENOTYPE	14	14	HIV
NCT000011429	NCT00001142_9_T3	PHENOTYPE	18	18	HIV
NCT000011429	NCT00001142_9_T4	PHENOTYPE	15	16	chronic infections
NCT0000114210	NCT00001142_10_T0	GENE	12	12	protease
NCT0000114210	NCT00001142_10_T1	PHENOTYPE	5	5	HIV
NCT0000114211	NCT00001142_11_T0	PHENOTYPE	6	6	disorders
NCT0000114211	NCT00001142_11_T1	BIOLOGICAL_PROCESS	8	8	metabolism
NCT0000114211	NCT00001142_11_T2	TISSUE	12	13	body fat
NCT0000114212	NCT00001142_12_T0	GENE	12	12	protease
NCT0000114212	NCT00001142_12_T1	PHENOTYPE	6	6	HIV
NCT0000114215	NCT00001142_15_T0	PHENOTYPE	9	9	hyperinsulinemia
NCT0000114215	NCT00001142_15_T1	PHENOTYPE	6	6	hypertriglyceridemia
NCT0000114215	NCT00001142_15_T2	PHENOTYPE	7	7	hypercholesterolemia
NCT0000114215	NCT00001142_15_T3	PHENOTYPE	1	1	lipodystrophy
NCT0000114217	NCT00001142_17_T0	GENE	10	10	protease
NCT0000114217	NCT00001142_17_T1	GENE	40	40	protease
NCT0000114217	NCT00001142_17_T2	GENE	34	34	longevity
NCT0000114217	NCT00001142_17_T3	PHENOTYPE	2	2	lipodystrophy
NCT0000114217	NCT00001142_17_T4	PHENOTYPE	17	18	HIV infection
NCT0000114217	NCT00001142_17_T5	PHENOTYPE	27	28	HIV infection
NCT0000114218	NCT00001142_18_T0	GENE	1	1	has
NCT0000114218	NCT00001142_18_T1	GENE	16	17	protease inhibitor
NCT0000114218	NCT00001142_18_T2	PHENOTYPE	13	14	adverse effect
NCT0000114219	NCT00001142_19_T0	GENE	13	13	protease
NCT0000114219	NCT00001142_19_T1	PHENOTYPE	5	5	HIV
NCT0000114219	NCT00001142_19_T2	PHENOTYPE	9	9	lipodystrophy
NCT0000114220	NCT00001142_20_T0	PHENOTYPE	16	16	affects
NCT0000114220	NCT00001142_20_T1	GENE	7	7	protease
NCT0000114220	NCT00001142_20_T2	PHENOTYPE	5	5	initiation
NCT0000114220	NCT00001142_20_T3	PHENOTYPE	33	33	pathophysiology
NCT0000114220	NCT00001142_20_T4	PHENOTYPE	20	20	dyslipidemia
NCT0000114220	NCT00001142_20_T5	PHENOTYPE	21	22	insulin resistance
NCT0000114220	NCT00001142_20_T6	PHENOTYPE	14	15	HIV infection
NCT0000114220	NCT00001142_20_T7	TISSUE	26	27	body fat
NCT0000114221	NCT00001142_21_T0	PHENOTYPE	11	11	HIV
NCT0000114221	NCT00001142_21_T1	PHENOTYPE	15	15	HIV
NCT0000114221	NCT00001142_21_T2	GENE	21	22	protease inhibitor
NCT0000114221	NCT00001142_21_T3	PHENOTYPE	12	13	chronic infections
NCT0000114222	NCT00001142_22_T0	GENE	2	2	has
NCT0000114223	NCT00001142_23_T0	GENE	9	9	protease
NCT0000114223	NCT00001142_23_T1	GENE	16	16	protease
NCT0000114223	NCT00001142_23_T2	BIOLOGICAL_PROCESS	41	42	glucose metabolism
NCT0000114223	NCT00001142_23_T3	PHENOTYPE	2	3	HIV infection
NCT0000114223	NCT00001142_23_T4	PHENOTYPE	24	25	HIV infection
NCT0000114225	NCT00001142_25_T0	GENE	24	24	protease
NCT0000114225	NCT00001142_25_T1	PHENOTYPE	11	11	lipodystrophy
NCT0000114226	NCT00001142_26_T0	PHENOTYPE	4	5	insulin levels
NCT0000114226	NCT00001142_26_T1	TISSUE	8	9	body fat
NCT0000114227	NCT00001142_27_T0	PHENOTYPE	20	20	HIV
NCT0000114227	NCT00001142_27_T1	PHENOTYPE	16	16	pathophysiology
NCT0000114227	NCT00001142_27_T2	PHENOTYPE	18	18	dyslipidemia
NCT0000114227	NCT00001142_27_T3	GENE	31	32	lipoprotein lipase
NCT0000114229	NCT00001142_29_T0	PHENOTYPE	6	6	HIV
NCT0000114231	NCT00001142_31_T0	GENE	5	5	protease
NCT0000114232	NCT00001142_32_T0	GENE	7	8	protease inhibitor
NCT0000114234	NCT00001142_34_T0	PHENOTYPE	7	8	pulmonary disorders
NCT0000114235	NCT00001142_35_T0	PHENOTYPE	7	7	HIV
NCT0000114235	NCT00001142_35_T1	PHENOTYPE	3	4	HIV infection
NCT0000114240	NCT00001142_40_T0	PHENOTYPE	7	7	HIV
NCT0000114240	NCT00001142_40_T1	PHENOTYPE	3	4	HIV infection
NCT0000114245	NCT00001142_45_T0	GENE	4	4	MRI
NCT0000114245	NCT00001142_45_T1	GENE	16	16	MRI
NCT0000114246	NCT00001142_46_T0	PHENOTYPE	10	11	foreign bodies
NCT0000114247	NCT00001142_47_T0	COMPOUND	4	4	heparin
NCT0000114247	NCT00001142_47_T1	PHENOTYPE	1	2	allergic reaction
NCT000011438	NCT00001143_8_T0	ORGAN	17	17	eyes
NCT0000114325	NCT00001143_25_T0	PHENOTYPE	14	14	malformations
NCT0000114325	NCT00001143_25_T1	PHENOTYPE	11	11	syndromes
NCT0000114325	NCT00001143_25_T2	PHENOTYPE	16	16	syndromes
NCT0000114325	NCT00001143_25_T3	PHENOTYPE	18	19	metabolic diseases
NCT0000114325	NCT00001143_25_T4	PHENOTYPE	7	8	developmental delay
NCT000011444	NCT00001144_4_T0	CELL	20	20	cells
NCT000011444	NCT00001144_4_T1	PHENOTYPE	1	1	complications
NCT000011444	NCT00001144_4_T2	ORGAN	13	13	transplant
NCT000011447	NCT00001144_7_T0	CELL	7	7	lymphocytes
NCT000011447	NCT00001144_7_T1	ORGAN	14	15	immune system
NCT000011447	NCT00001144_7_T2	CELL	8	10	white blood cells
NCT0000114410	NCT00001144_10_T0	ORGAN	7	7	transplant
NCT0000114410	NCT00001144_10_T1	GENE	16	16	G-CSF
NCT0000114410	NCT00001144_10_T2	CELL	21	22	stem cells
NCT0000114410	NCT00001144_10_T3	ORGAN	25	26	bone marrow
NCT0000114411	NCT00001144_11_T0	CELL	1	1	cells
NCT0000114412	NCT00001144_12_T0	CELL	18	18	cells
NCT0000114412	NCT00001144_12_T1	CELL	10	10	thymocyte
NCT0000114412	NCT00001144_12_T2	COMPOUND	7	7	fludarabine
NCT0000114412	NCT00001144_12_T3	COMPOUND	5	5	cyclophosphamide
NCT0000114412	NCT00001144_12_T4	GENE	11	11	globulin
NCT0000114413	NCT00001144_13_T0	CELL	20	20	cells
NCT0000114413	NCT00001144_13_T1	CELL	25	25	cells
NCT0000114413	NCT00001144_13_T2	COMPOUND	10	10	cyclosporin
NCT0000114413	NCT00001144_13_T3	ORGAN	5	5	transplant
NCT0000114413	NCT00001144_13_T4	PHENOTYPE	13	13	graft-versus-host-disease
NCT0000114414	NCT00001144_14_T0	PHENOTYPE	16	16	leukemia
NCT0000114414	NCT00001144_14_T1	CELL	5	5	lymphocytes
NCT0000114414	NCT00001144_14_T2	CELL	17	17	cells
NCT0000114414	NCT00001144_14_T3	ORGAN	8	8	transplant
NCT0000114414	NCT00001144_14_T4	ORGAN	12	13	immune system
NCT0000114416	NCT00001144_16_T0	CELL	10	10	lymphocytes
NCT0000114419	NCT00001144_19_T0	GENE	2	2	has
NCT0000114421	NCT00001144_21_T0	PHENOTYPE	10	10	complications
NCT0000114427	NCT00001144_27_T0	PHENOTYPE	26	26	toxicity
NCT0000114427	NCT00001144_27_T1	PHENOTYPE	22	22	engraftment
NCT0000114427	NCT00001144_27_T2	GENE	14	14	has
NCT0000114428	NCT00001144_28_T0	PHENOTYPE	17	17	complications
NCT0000114428	NCT00001144_28_T1	ORGAN	16	16	transplant
NCT0000114433	NCT00001144_33_T0	CELL	0	0	T-cell
NCT0000114433	NCT00001144_33_T1	GENE	3	6	granulocyte colony stimulating factor
NCT0000114433	NCT00001144_33_T2	CELL	8	11	peripheral blood stem cells
NCT0000114434	NCT00001144_34_T0	CELL	4	4	lymphocytes
NCT0000114434	NCT00001144_34_T1	ORGAN	19	19	graft
NCT0000114434	NCT00001144_34_T2	CELL	12	12	T-cell
NCT0000114435	NCT00001144_35_T0	ORGAN	7	7	transplant
NCT0000114436	NCT00001144_36_T0	PHENOTYPE	4	4	engraftment
NCT0000114436	NCT00001144_36_T1	PHENOTYPE	11	11	acute
NCT0000114436	NCT00001144_36_T2	PHENOTYPE	18	18	GVHD
NCT0000114436	NCT00001144_36_T3	ORGAN	19	19	transplant
NCT0000114436	NCT00001144_36_T4	PHENOTYPE	13	17	chronic graft versus host disease
NCT0000114443	NCT00001144_43_T0	PHENOTYPE	4	5	psychiatric disorder
NCT0000114443	NCT00001144_43_T1	PHENOTYPE	7	8	mental deficiency
NCT0000114444	NCT00001144_44_T0	ORGAN	14	14	transplant
NCT0000114444	NCT00001144_44_T1	PHENOTYPE	7	8	organ failure
NCT0000114445	NCT00001144_45_T0	COMPOUND	6	7	carbon monoxide
NCT0000114446	NCT00001144_46_T0	PHENOTYPE	4	6	ventricular ejection fraction
NCT0000114447	NCT00001144_47_T0	COMPOUND	4	4	creatinine
NCT0000114447	NCT00001144_47_T1	ORGAN	3	3	serum
NCT0000114448	NCT00001144_48_T0	COMPOUND	4	4	bilirubin
NCT0000114448	NCT00001144_48_T1	ORGAN	3	3	serum
NCT0000114450	NCT00001144_50_T0	PHENOTYPE	8	8	relapse
NCT0000114450	NCT00001144_50_T1	PHENOTYPE	5	5	diseases
NCT0000114456	NCT00001144_56_T0	PHENOTYPE	2	2	HIV
NCT000011450	NCT00001145_0_T0	GENE	9	9	CD40
NCT000011450	NCT00001145_0_T1	PHENOTYPE	15	16	Hyper-IgM Syndrome
NCT000011452	NCT00001145_2_T0	PHENOTYPE	12	12	encoding
NCT000011452	NCT00001145_2_T1	PHENOTYPE	0	0	XHIM
NCT000011452	NCT00001145_2_T2	GENE	13	14	CD40 ligand
NCT000011452	NCT00001145_2_T3	PHENOTYPE	4	5	genetic disease
NCT000011454	NCT00001145_4_T0	GENE	4	4	globulin
NCT000011454	NCT00001145_4_T1	PHENOTYPE	13	13	XHIM
NCT000011454	NCT00001145_4_T2	GENE	3	3	gamma
NCT0000114510	NCT00001145_10_T0	COMPOUND	28	28	KLH
NCT0000114510	NCT00001145_10_T1	GENE	26	26	limpet
NCT0000114510	NCT00001145_10_T2	GENE	19	19	globulin
NCT0000114510	NCT00001145_10_T3	GENE	18	18	gamma
NCT0000114510	NCT00001145_10_T4	BIOLOGICAL_PROCESS	1	2	immune response
NCT0000114511	NCT00001145_11_T0	PHENOTYPE	18	18	XHIM
NCT0000114513	NCT00001145_13_T0	GENE	15	15	CD154
NCT0000114513	NCT00001145_13_T1	PHENOTYPE	20	20	hypogammaglobulinemia
NCT0000114513	NCT00001145_13_T2	PHENOTYPE	12	12	encoding
NCT0000114513	NCT00001145_13_T3	PHENOTYPE	0	0	XHIM
NCT0000114513	NCT00001145_13_T4	PHENOTYPE	21	22	opportunistic infections
NCT0000114513	NCT00001145_13_T5	GENE	13	14	CD40 ligand
NCT0000114513	NCT00001145_13_T6	PHENOTYPE	28	29	neoplastic disease
NCT0000114513	NCT00001145_13_T7	PHENOTYPE	4	5	genetic disease
NCT0000114514	NCT00001145_14_T0	GENE	5	5	globulin
NCT0000114514	NCT00001145_14_T1	PHENOTYPE	12	12	XHIM
NCT0000114514	NCT00001145_14_T2	GENE	4	4	gamma
NCT0000114518	NCT00001145_18_T0	PHENOTYPE	18	18	XHIM
NCT0000114522	NCT00001145_22_T0	GENE	1	1	ANC
NCT0000114523	NCT00001145_23_T0	PHENOTYPE	4	5	opportunistic infection
NCT0000114524	NCT00001145_24_T0	GENE	15	15	0.4
NCT0000114524	NCT00001145_24_T1	COMPOUND	12	12	prednisone
NCT0000114524	NCT00001145_24_T2	COMPOUND	47	47	prednisone
NCT0000114526	NCT00001145_26_T0	PHENOTYPE	25	25	allergies
NCT0000114526	NCT00001145_26_T1	PHENOTYPE	11	11	judgement
NCT0000114526	NCT00001145_26_T2	PHENOTYPE	26	26	chronic
NCT0000114526	NCT00001145_26_T3	PHENOTYPE	29	30	pulmonary disease
NCT0000114526	NCT00001145_26_T4	PHENOTYPE	0	2	Chronic liver disease
NCT000011461	NCT00001146_1_T0	PHENOTYPE	13	14	mood disorders
NCT000011463	NCT00001146_3_T0	GENE	6	6	EPA
NCT000011463	NCT00001146_3_T1	PHENOTYPE	24	25	major depression
NCT000011463	NCT00001146_3_T2	CELL	18	20	red blood cells
NCT000011464	NCT00001146_4_T0	PHENOTYPE	8	9	bipolar illness
NCT000011465	NCT00001146_5_T0	PHENOTYPE	2	3	bipolar disorder
NCT000011467	NCT00001146_7_T0	COMPOUND	17	19	omega_3 fatty acid
NCT000011469	NCT00001146_9_T0	PHENOTYPE	18	19	mood changes
NCT0000114610	NCT00001146_10_T0	COMPOUND	28	30	omega_3 fatty acid
NCT0000114614	NCT00001146_14_T0	PHENOTYPE	17	18	mood disorders
NCT0000114618	NCT00001146_18_T0	COMPOUND	15	17	omega_3 fatty acid
NCT0000114623	NCT00001146_23_T0	PHENOTYPE	16	16	severity
NCT0000114623	NCT00001146_23_T1	PHENOTYPE	4	5	bipolar depression
NCT0000114624	NCT00001146_24_T0	PHENOTYPE	16	16	severity
NCT0000114624	NCT00001146_24_T1	PHENOTYPE	28	28	Mania
NCT0000114625	NCT00001146_25_T0	PHENOTYPE	22	22	acute
NCT0000114625	NCT00001146_25_T1	PHENOTYPE	14	14	fluctuations
NCT000011471	NCT00001147_1_T0	COMPOUND	48	48	catecholamine
NCT000011471	NCT00001147_1_T1	ORGAN	10	10	plasma
NCT000011477	NCT00001147_7_T0	COMPOUND	47	47	catecholamine
NCT000011477	NCT00001147_7_T1	ORGAN	9	9	plasma
NCT000011481	NCT00001148_1_T0	PHENOTYPE	12	12	tumors
NCT000011481	NCT00001148_1_T1	PHENOTYPE	2	2	tumor
NCT000011482	NCT00001148_2_T0	PHENOTYPE	6	6	glioblastoma
NCT000011482	NCT00001148_2_T1	PHENOTYPE	8	9	metastatic disease
NCT000011485	NCT00001148_5_T0	PHENOTYPE	13	13	tumors
NCT000011485	NCT00001148_5_T1	CELL	1	1	cells
NCT000011486	NCT00001148_6_T0	CELL	12	12	cells
NCT000011486	NCT00001148_6_T1	PHENOTYPE	11	11	tumor
NCT000011486	NCT00001148_6_T2	PHENOTYPE	15	15	circulation
NCT000011486	NCT00001148_6_T3	PHENOTYPE	10	10	glioma
NCT000011486	NCT00001148_6_T4	GENE	16	16	has
NCT000011486	NCT00001148_6_T5	PHENOTYPE	5	6	brain tumors
NCT000011488	NCT00001148_8_T0	CELL	2	2	cells
NCT000011488	NCT00001148_8_T1	PHENOTYPE	1	1	glioma
NCT000011488	NCT00001148_8_T2	ORGAN	14	15	blood-brain barrier
NCT0000114810	NCT00001148_10_T0	PHENOTYPE	16	17	malignant tumors
NCT0000114820	NCT00001148_20_T0	GENE	1	1	MRI
NCT0000114824	NCT00001148_24_T0	PHENOTYPE	5	5	glioblastoma
NCT0000114824	NCT00001148_24_T1	PHENOTYPE	3	3	metastasis
NCT0000114825	NCT00001148_25_T0	PHENOTYPE	5	5	glioblastoma
NCT0000114825	NCT00001148_25_T1	PHENOTYPE	7	8	metastatic disease
NCT0000114826	NCT00001148_26_T0	PHENOTYPE	5	6	metastatic disease
NCT0000114828	NCT00001148_28_T0	CELL	4	4	cells
NCT0000114828	NCT00001148_28_T1	PHENOTYPE	3	3	glioma
NCT0000114828	NCT00001148_28_T2	ORGAN	12	14	blood brain barrier
NCT0000114830	NCT00001148_30_T0	PHENOTYPE	14	15	malignant tumors
NCT0000114835	NCT00001148_35_T0	PHENOTYPE	8	8	gliomas
NCT0000114836	NCT00001148_36_T0	PHENOTYPE	6	6	glioma
NCT0000114837	NCT00001148_37_T0	PHENOTYPE	1	1	tumor
NCT0000114837	NCT00001148_37_T1	PHENOTYPE	15	15	tumor
NCT0000114841	NCT00001148_41_T0	PHENOTYPE	0	0	Thrombocytopenia
NCT0000114841	NCT00001148_41_T1	PHENOTYPE	1	2	platelet count
NCT0000114842	NCT00001148_42_T0	CELL	2	2	neutrophil
NCT0000114842	NCT00001148_42_T1	PHENOTYPE	0	0	Granulocytopenia
NCT0000114843	NCT00001148_43_T0	PHENOTYPE	0	1	Acute infection
NCT0000114844	NCT00001148_44_T0	PHENOTYPE	0	0	Acute
NCT0000114845	NCT00001148_45_T0	PHENOTYPE	0	1	Positive HIV
NCT0000114847	NCT00001148_47_T0	PHENOTYPE	0	0	Allergy
NCT0000114848	NCT00001148_48_T0	PHENOTYPE	4	4	mutation
NCT0000114848	NCT00001148_48_T1	PHENOTYPE	2	2	tumor
NCT0000114850	NCT00001148_50_T0	ORGAN	9	9	serum
NCT000011492	NCT00001149_2_T0	PHENOTYPE	15	15	seizures
NCT000011494	NCT00001149_4_T0	PHENOTYPE	16	16	seizures
NCT000011497	NCT00001149_7_T0	PHENOTYPE	20	20	epilepsy
NCT000011499	NCT00001149_9_T0	PHENOTYPE	29	29	epilepsy
NCT000011499	NCT00001149_9_T1	PHENOTYPE	18	19	seizure disorders
NCT0000114912	NCT00001149_12_T0	PHENOTYPE	0	0	Seizure
NCT000011502	NCT00001150_2_T0	PHENOTYPE	3	3	blister
NCT000011502	NCT00001150_2_T1	CELL	12	13	Langerhans cells
NCT000011504	NCT00001150_4_T0	PHENOTYPE	6	6	blister
NCT000011505	NCT00001150_5_T0	CELL	14	15	Langerhans cells
NCT000011509	NCT00001150_9_T0	PHENOTYPE	3	3	blister
NCT000011509	NCT00001150_9_T1	CELL	12	13	Langerhans cells
NCT0000115011	NCT00001150_11_T0	PHENOTYPE	6	6	blister
NCT0000115012	NCT00001150_12_T0	CELL	14	15	Langerhans cells
NCT000011511	NCT00001151_1_T0	PHENOTYPE	3	3	disorders
NCT000011511	NCT00001151_1_T1	COMPOUND	12	12	calcium
NCT000011511	NCT00001151_1_T2	PHENOTYPE	1	1	suffering
NCT000011512	NCT00001151_2_T0	PHENOTYPE	4	4	disorders
NCT000011512	NCT00001151_2_T1	COMPOUND	19	20	1,25-dihydroxyvitamin D3
NCT000011517	NCT00001151_7_T0	PHENOTYPE	0	0	Plan
NCT000011519	NCT00001151_9_T0	COMPOUND	0	0	1
NCT0000115110	NCT00001151_10_T0	COMPOUND	5	6	vitamin D
NCT0000115111	NCT00001151_11_T0	COMPOUND	7	8	vitamin D
NCT0000115111	NCT00001151_11_T1	PHENOTYPE	15	16	serum calcium
NCT0000115115	NCT00001151_15_T0	COMPOUND	1	1	calcium
NCT0000115115	NCT00001151_15_T1	ORGAN	0	0	Serum
NCT0000115116	NCT00001151_16_T0	GENE	4	4	has
NCT0000115118	NCT00001151_18_T0	COMPOUND	1	1	calcium
NCT0000115121	NCT00001151_21_T0	PHENOTYPE	1	1	hypercalcemia
NCT000011523	NCT00001152_3_T0	PHENOTYPE	8	8	glaucoma
NCT000011523	NCT00001152_3_T1	PHENOTYPE	5	6	ocular hypertension
NCT000011524	NCT00001152_4_T0	PHENOTYPE	10	11	intraocular pressure
NCT000011524	NCT00001152_4_T1	PHENOTYPE	0	1	Ocular hypertension
NCT000011524	NCT00001152_4_T2	PHENOTYPE	20	22	visual field loss
NCT000011525	NCT00001152_5_T0	PHENOTYPE	12	12	scotoma
NCT000011525	NCT00001152_5_T1	PHENOTYPE	0	0	Glaucoma
NCT000011525	NCT00001152_5_T2	PHENOTYPE	16	17	arcuate scotomas
NCT0000115211	NCT00001152_11_T0	PHENOTYPE	8	9	intraocular pressure
NCT0000115213	NCT00001152_13_T0	PHENOTYPE	20	20	POAG
NCT0000115213	NCT00001152_13_T1	PHENOTYPE	32	32	POAG
NCT0000115213	NCT00001152_13_T2	GENE	6	6	PG
NCT0000115213	NCT00001152_13_T3	GENE	24	24	PG
NCT0000115213	NCT00001152_13_T4	PHENOTYPE	4	5	pigmentary glaucoma
NCT0000115213	NCT00001152_13_T5	PHENOTYPE	17	19	primary open-angle glaucoma
NCT000011531	NCT00001153_1_T0	PHENOTYPE	10	11	ocular albinism
NCT000011534	NCT00001153_4_T0	ORGAN	21	22	visual pathways
NCT000011535	NCT00001153_5_T0	BIOLOGICAL_PROCESS	39	39	pigmentation
NCT000011535	NCT00001153_5_T1	PHENOTYPE	18	18	albinism
NCT000011535	NCT00001153_5_T2	ORGAN	31	32	visual pathways
NCT000011535	NCT00001153_5_T3	PHENOTYPE	13	14	pigmentary changes
NCT000011537	NCT00001153_7_T0	BIOLOGICAL_PROCESS	13	13	pigmentation
NCT000011537	NCT00001153_7_T1	ORGAN	18	18	eyes
NCT000011538	NCT00001153_8_T0	PHENOTYPE	14	15	clinical heterogeneity
NCT000011540	NCT00001154_0_T0	BIOLOGICAL_PROCESS	0	1	Lipoprotein Metabolism
NCT000011549	NCT00001154_9_T0	PHENOTYPE	21	21	dyslipidemia
NCT0000115410	NCT00001154_10_T0	PHENOTYPE	25	25	insights
NCT0000115410	NCT00001154_10_T1	PHENOTYPE	11	12	genetic disorders
NCT0000115410	NCT00001154_10_T2	PHENOTYPE	12	15	disorders of lipid metabolism
NCT0000115415	NCT00001154_15_T0	PHENOTYPE	12	12	hyperlipidemia
NCT0000115415	NCT00001154_15_T1	GENE	39	39	bowel
NCT0000115415	NCT00001154_15_T2	PHENOTYPE	49	49	asthma
NCT0000115415	NCT00001154_15_T3	PHENOTYPE	40	40	hepatitis
NCT0000115415	NCT00001154_15_T4	PHENOTYPE	9	9	secondary
NCT0000115415	NCT00001154_15_T5	PHENOTYPE	41	41	HIV
NCT0000115415	NCT00001154_15_T6	PHENOTYPE	48	48	acne
NCT0000115415	NCT00001154_15_T7	PHENOTYPE	37	37	migraines
NCT0000115415	NCT00001154_15_T8	PHENOTYPE	36	36	hypertension
NCT0000115415	NCT00001154_15_T9	PHENOTYPE	32	32	chronic
NCT0000115415	NCT00001154_15_T10	PHENOTYPE	45	45	chronic
NCT0000115415	NCT00001154_15_T11	PHENOTYPE	30	31	endocrine disease
NCT0000115415	NCT00001154_15_T12	PHENOTYPE	25	26	liver disease
NCT0000115415	NCT00001154_15_T13	PHENOTYPE	28	29	kidney disease
NCT0000115415	NCT00001154_15_T14	PHENOTYPE	22	23	laboratory abnormality
NCT0000115419	NCT00001154_19_T0	COMPOUND	2	2	iodine
NCT000011557	NCT00001155_7_T0	PHENOTYPE	12	12	peripheral
NCT000011557	NCT00001155_7_T1	PHENOTYPE	20	20	glomerulonephritis
NCT000011557	NCT00001155_7_T2	ORGAN	14	16	central nervous system
NCT000011559	NCT00001155_9_T0	PHENOTYPE	5	5	malignancies
NCT000011562	NCT00001156_2_T0	CELL	16	16	cells
NCT000011562	NCT00001156_2_T1	PHENOTYPE	3	3	diseases
NCT000011562	NCT00001156_2_T2	PHENOTYPE	0	0	Autoimmune
NCT000011562	NCT00001156_2_T3	ORGAN	8	9	immune system
NCT000011563	NCT00001156_3_T0	CELL	10	10	myelin
NCT000011563	NCT00001156_3_T1	CELL	12	12	cells
NCT000011563	NCT00001156_3_T2	GENE	4	4	MS
NCT000011563	NCT00001156_3_T3	ORGAN	6	7	immune system
NCT000011564	NCT00001156_4_T0	PHENOTYPE	10	10	symptoms
NCT000011564	NCT00001156_4_T1	CELL	1	1	myelin
NCT000011565	NCT00001156_5_T0	GENE	14	14	MS
NCT000011565	NCT00001156_5_T1	PHENOTYPE	12	13	Multiple Sclerosis
NCT000011566	NCT00001156_6_T0	GENE	9	9	MS
NCT000011566	NCT00001156_6_T1	PHENOTYPE	13	13	diseases
NCT000011569	NCT00001156_9_T0	GENE	13	13	MS
NCT0000115612	NCT00001156_12_T0	GENE	16	16	MS
NCT0000115614	NCT00001156_14_T0	GENE	7	7	MRI
NCT0000115614	NCT00001156_14_T1	GENE	14	14	MRI
NCT0000115614	NCT00001156_14_T2	GENE	18	18	MS
NCT0000115616	NCT00001156_16_T0	GENE	5	5	MRI
NCT0000115620	NCT00001156_20_T0	GENE	8	8	MS
NCT0000115620	NCT00001156_20_T1	PHENOTYPE	13	13	dysfunction
NCT0000115622	NCT00001156_22_T0	GENE	3	3	MRI
NCT0000115623	NCT00001156_23_T0	GENE	3	3	MRI
NCT000011591	NCT00001159_1_T0	PHENOTYPE	10	10	Dermopathy
NCT000011591	NCT00001159_1_T1	PHENOTYPE	5	5	hyperthyroidism
NCT000011591	NCT00001159_1_T2	ORGAN	12	12	thyroid
NCT000011591	NCT00001159_1_T3	PHENOTYPE	4	4	hypothyroidism
NCT000011591	NCT00001159_1_T4	GENE	14	14	TSH
NCT000011591	NCT00001159_1_T5	GENE	13	13	hormone
NCT000011591	NCT00001159_1_T6	PHENOTYPE	16	17	pituitary adenomas
NCT000011591	NCT00001159_1_T7	PHENOTYPE	6	8	thyroid hormone resistance
NCT000011592	NCT00001159_2_T0	PHENOTYPE	20	20	disorders
NCT000011592	NCT00001159_2_T1	PHENOTYPE	18	19	thyroid function
NCT000011593	NCT00001159_3_T0	PHENOTYPE	22	22	disorders
NCT000011593	NCT00001159_3_T1	PHENOTYPE	20	21	thyroid function
NCT000011596	NCT00001159_6_T0	PHENOTYPE	11	11	symptoms
NCT000011596	NCT00001159_6_T1	ORGAN	25	25	thyroid
NCT000011596	NCT00001159_6_T2	PHENOTYPE	17	18	thyroid dysfunction
NCT000011601	NCT00001160_1_T0	PHENOTYPE	21	22	thyroid cancer
NCT000011601	NCT00001160_1_T1	PHENOTYPE	18	19	thyroid nodules
NCT000011602	NCT00001160_2_T0	PHENOTYPE	23	24	thyroid cancer
NCT000011602	NCT00001160_2_T1	PHENOTYPE	20	21	thyroid nodules
NCT000011606	NCT00001160_6_T0	PHENOTYPE	8	9	thyroid nodules
NCT000011606	NCT00001160_6_T1	PHENOTYPE	26	27	recurrent disease
NCT000011609	NCT00001160_9_T0	GENE	7	7	Tg
NCT000011609	NCT00001160_9_T1	GENE	6	6	thyroglobulin
NCT000011609	NCT00001160_9_T2	ORGAN	5	5	serum
NCT000011609	NCT00001160_9_T3	PHENOTYPE	11	12	tumor recurrence
NCT0000116010	NCT00001160_10_T0	COMPOUND	29	29	lithium
NCT0000116010	NCT00001160_10_T1	PHENOTYPE	46	47	thyroid cancer
NCT0000116011	NCT00001160_11_T0	PHENOTYPE	32	32	tumors
NCT0000116011	NCT00001160_11_T1	PHENOTYPE	7	7	nodules
NCT0000116012	NCT00001160_12_T0	PHENOTYPE	16	16	hypothyroid
NCT0000116016	NCT00001160_16_T0	PHENOTYPE	2	3	thyroid nodules
NCT0000116017	NCT00001160_17_T0	PHENOTYPE	5	6	thyroid cancer
NCT0000116018	NCT00001160_18_T0	PHENOTYPE	3	4	thyroid cancer
NCT0000116019	NCT00001160_19_T0	COMPOUND	4	4	iodine
NCT0000116019	NCT00001160_19_T1	PHENOTYPE	7	8	thyroid cancer
NCT0000116019	NCT00001160_19_T2	PHENOTYPE	19	20	thyroid cancer
NCT000011619	NCT00001161_9_T0	PHENOTYPE	9	10	genetic disorder
NCT0000116114	NCT00001161_14_T0	PHENOTYPE	9	9	diseases
NCT000011621	NCT00001162_1_T0	ORGAN	16	16	intestines
NCT000011621	NCT00001162_1_T1	PHENOTYPE	0	1	Gastrointestinal parasites
NCT000011622	NCT00001162_2_T0	PHENOTYPE	1	2	parasitic infections
NCT000011625	NCT00001162_5_T0	PHENOTYPE	13	13	giardiasis
NCT000011625	NCT00001162_5_T1	PHENOTYPE	16	16	trichuriasis
NCT000011625	NCT00001162_5_T2	PHENOTYPE	12	12	amebiasis
NCT000011625	NCT00001162_5_T3	PHENOTYPE	19	19	trichinosis
NCT000011625	NCT00001162_5_T4	PHENOTYPE	22	22	coccidiosis
NCT000011625	NCT00001162_5_T5	PHENOTYPE	23	23	paragonimiasis
NCT000011625	NCT00001162_5_T6	PHENOTYPE	15	15	strongyloidiasis
NCT000011625	NCT00001162_5_T7	PHENOTYPE	18	18	tapeworm
NCT000011625	NCT00001162_5_T8	ORGAN	9	10	gastrointestinal tract
NCT000011625	NCT00001162_5_T9	PHENOTYPE	5	6	parasitic diseases
NCT000011626	NCT00001162_6_T0	ORGAN	23	23	duodenum
NCT000011626	NCT00001162_6_T1	ORGAN	28	29	small intestine
NCT000011628	NCT00001162_8_T0	TISSUE	4	4	tissues
NCT000011628	NCT00001162_8_T1	PHENOTYPE	15	15	infections
NCT000011628	NCT00001162_8_T2	ORGAN	7	7	intestines
NCT000011629	NCT00001162_9_T0	GENE	13	13	has
NCT0000116210	NCT00001162_10_T0	PHENOTYPE	18	18	allergies
NCT0000116210	NCT00001162_10_T1	PHENOTYPE	16	16	tuberculosis
NCT0000116210	NCT00001162_10_T2	PHENOTYPE	2	2	strongyloidiasis
NCT0000116219	NCT00001162_19_T0	PHENOTYPE	11	12	intestinal parasite
NCT0000116222	NCT00001162_22_T0	ORGAN	16	16	serum
NCT0000116222	NCT00001162_22_T1	CELL	12	14	white blood cells
NCT0000116223	NCT00001162_23_T0	PHENOTYPE	12	12	giardiasis
NCT0000116228	NCT00001162_28_T0	PHENOTYPE	2	2	Aspiration
NCT0000116228	NCT00001162_28_T1	PHENOTYPE	5	5	Amebiasis
NCT0000116228	NCT00001162_28_T2	PHENOTYPE	3	3	Coccidiosis
NCT0000116228	NCT00001162_28_T3	PHENOTYPE	13	13	Paragonimiasis
NCT0000116228	NCT00001162_28_T4	PHENOTYPE	9	9	Trichinosis
NCT0000116228	NCT00001162_28_T5	PHENOTYPE	6	7	Parasitic Disease
NCT000011631	NCT00001163_1_T0	PHENOTYPE	14	14	tumors
NCT000011631	NCT00001163_1_T1	PHENOTYPE	12	12	cancers
NCT000011632	NCT00001163_2_T0	PHENOTYPE	10	10	tumor
NCT000011632	NCT00001163_2_T1	PHENOTYPE	20	20	affection
NCT000011633	NCT00001163_3_T0	PHENOTYPE	9	9	tumor
NCT000011635	NCT00001163_5_T0	PHENOTYPE	10	10	pathology
NCT000011636	NCT00001163_6_T0	PHENOTYPE	18	18	tumor
NCT000011637	NCT00001163_7_T0	PHENOTYPE	20	20	carcinogenesis
NCT000011639	NCT00001163_9_T0	PHENOTYPE	20	20	mutation
NCT000011639	NCT00001163_9_T1	PHENOTYPE	3	3	tumor
NCT000011639	NCT00001163_9_T2	GENE	24	24	has
NCT0000116316	NCT00001163_16_T0	PHENOTYPE	25	25	tumor
NCT0000116319	NCT00001163_19_T0	PHENOTYPE	21	21	sporadic
NCT0000116319	NCT00001163_19_T1	PHENOTYPE	25	25	cancers
NCT0000116321	NCT00001163_21_T0	PHENOTYPE	14	14	syndromes
NCT0000116323	NCT00001163_23_T0	PHENOTYPE	4	4	tumors
NCT0000116327	NCT00001163_27_T0	PHENOTYPE	8	8	tumor
NCT0000116329	NCT00001163_29_T0	PHENOTYPE	23	23	neoplasia
NCT0000116329	NCT00001163_29_T1	PHENOTYPE	38	38	neoplasia
NCT0000116329	NCT00001163_29_T2	PHENOTYPE	44	45	environmental exposure
NCT0000116333	NCT00001163_33_T0	PHENOTYPE	13	13	neoplasm
NCT0000116336	NCT00001163_36_T0	PHENOTYPE	14	14	pathology
NCT0000116337	NCT00001163_37_T0	PHENOTYPE	2	2	neoplasms
NCT0000116339	NCT00001163_39_T0	PHENOTYPE	16	16	tumors
NCT000011641	NCT00001164_1_T0	PHENOTYPE	6	6	peripheral
NCT000011641	NCT00001164_1_T1	CELL	8	8	cells
NCT000011641	NCT00001164_1_T2	ORGAN	10	10	serum
NCT000011644	NCT00001164_4_T0	PHENOTYPE	6	6	peripheral
NCT000011644	NCT00001164_4_T1	CELL	8	8	cells
NCT000011644	NCT00001164_4_T2	ORGAN	10	10	serum
NCT000011647	NCT00001164_7_T0	PHENOTYPE	22	22	diseases
NCT000011647	NCT00001164_7_T1	PHENOTYPE	3	3	degenerations
NCT000011647	NCT00001164_7_T2	PHENOTYPE	12	14	viral skin diseases
NCT000011651	NCT00001165_1_T0	PHENOTYPE	9	9	ulcers
NCT000011651	NCT00001165_1_T1	PHENOTYPE	16	16	ulcers
NCT000011652	NCT00001165_2_T0	PHENOTYPE	8	8	ulcers
NCT000011652	NCT00001165_2_T1	PHENOTYPE	20	21	pancreatic tumors
NCT0000116510	NCT00001165_10_T0	PHENOTYPE	22	22	Progression
NCT0000116510	NCT00001165_10_T1	GENE	17	17	MRI
NCT0000116510	NCT00001165_10_T2	PHENOTYPE	10	10	tumor
NCT0000116510	NCT00001165_10_T3	PHENOTYPE	25	25	tumor
NCT0000116510	NCT00001165_10_T4	PHENOTYPE	2	2	gastrinoma
NCT0000116510	NCT00001165_10_T5	PHENOTYPE	5	6	metastatic disease
NCT000011661	NCT00001166_1_T0	PHENOTYPE	5	5	near-sightedness
NCT000011661	NCT00001166_1_T1	PHENOTYPE	0	0	Degeneration
NCT000011661	NCT00001166_1_T2	PHENOTYPE	6	6	cataracts
NCT000011661	NCT00001166_1_T3	PHENOTYPE	8	11	progressive loss of vision
NCT0000116613	NCT00001166_13_T0	GENE	7	7	B6
NCT0000116614	NCT00001166_14_T0	COMPOUND	7	7	ornithine
NCT0000116615	NCT00001166_15_T0	COMPOUND	14	14	ornithine
NCT0000116615	NCT00001166_15_T1	GENE	3	3	B6
NCT0000116618	NCT00001166_18_T0	COMPOUND	11	11	ornithine
NCT0000116618	NCT00001166_18_T1	PHENOTYPE	15	16	disease progression
NCT0000116620	NCT00001166_20_T0	COMPOUND	3	3	ornithine
NCT0000116626	NCT00001166_26_T0	PHENOTYPE	11	12	genetic heterogeneity
NCT0000116628	NCT00001166_28_T0	COMPOUND	12	12	arginine
NCT0000116629	NCT00001166_29_T0	COMPOUND	8	8	ornithine
NCT0000116629	NCT00001166_29_T1	ORGAN	7	7	plasma
NCT0000116629	NCT00001166_29_T2	GENE	12	12	ornithine-delta-aminotransferase
NCT0000116630	NCT00001166_30_T0	GENE	8	8	nested
NCT000011679	NCT00001167_9_T0	PHENOTYPE	12	12	visualization
NCT000011679	NCT00001167_9_T1	BIOLOGICAL_PROCESS	19	19	transport
NCT000011679	NCT00001167_9_T2	ORGAN	4	5	oral cavity
NCT0000116712	NCT00001167_12_T0	PHENOTYPE	11	11	tumors
NCT0000116712	NCT00001167_12_T1	GENE	3	3	has
NCT0000116712	NCT00001167_12_T2	GENE	22	22	has
NCT0000116713	NCT00001167_13_T0	ORGAN	20	20	larynx
NCT0000116713	NCT00001167_13_T1	PHENOTYPE	17	17	tumors
NCT0000116713	NCT00001167_13_T2	PHENOTYPE	7	7	tumor
NCT0000116713	NCT00001167_13_T3	PHENOTYPE	9	9	tumor
NCT0000116713	NCT00001167_13_T4	ORGAN	24	24	hypopharynx
NCT0000116713	NCT00001167_13_T5	PHENOTYPE	12	13	tumor recurrence
NCT0000116713	NCT00001167_13_T6	ORGAN	21	22	oral cavity
NCT0000116714	NCT00001167_14_T0	GENE	7	7	MRI
NCT0000116718	NCT00001167_18_T0	PHENOTYPE	13	13	affects
NCT0000116719	NCT00001167_19_T0	GENE	26	26	swallow
NCT0000116719	NCT00001167_19_T1	GENE	14	14	structural
NCT0000116719	NCT00001167_19_T2	PHENOTYPE	27	27	dysphagia
NCT0000116719	NCT00001167_19_T3	PHENOTYPE	18	18	dysfunction
NCT0000116719	NCT00001167_19_T4	PHENOTYPE	24	24	dysarthria
NCT0000116720	NCT00001167_20_T0	BIOLOGICAL_PROCESS	0	0	Aging
NCT0000116720	NCT00001167_20_T1	PHENOTYPE	5	5	dementia
NCT0000116722	NCT00001167_22_T0	PHENOTYPE	4	5	oral dryness
NCT0000116723	NCT00001167_23_T0	COMPOUND	10	10	NCI
NCT0000116723	NCT00001167_23_T1	PHENOTYPE	1	1	Tumors
NCT0000116723	NCT00001167_23_T2	PHENOTYPE	17	18	neck tumors
NCT000011684	NCT00001168_4_T0	GENE	10	10	lipoprotein
NCT000011686	NCT00001168_6_T0	GENE	9	9	hormone
NCT000011687	NCT00001168_7_T0	BIOLOGICAL_PROCESS	22	23	lipoprotein metabolism
NCT000011689	NCT00001168_9_T0	PHENOTYPE	20	20	diseases
NCT000011689	NCT00001168_9_T1	BIOLOGICAL_PROCESS	22	23	lipoprotein metabolism
NCT0000116811	NCT00001168_11_T0	GENE	1	1	lipoprotein
NCT0000116812	NCT00001168_12_T0	PHENOTYPE	15	15	concentrations
NCT0000116812	NCT00001168_12_T1	BIOLOGICAL_PROCESS	23	23	metabolism
NCT0000116812	NCT00001168_12_T2	BIOLOGICAL_PROCESS	4	5	lipoprotein transport
NCT0000116813	NCT00001168_13_T0	PHENOTYPE	8	8	hypolipoproteinemia
NCT0000116813	NCT00001168_13_T1	PHENOTYPE	6	6	hyperlipoproteinemia
NCT0000116814	NCT00001168_14_T0	PHENOTYPE	6	6	concentrations
NCT0000116814	NCT00001168_14_T1	GENE	5	5	lipoprotein
NCT0000116814	NCT00001168_14_T2	PHENOTYPE	0	0	Profound
NCT0000116816	NCT00001168_16_T0	PHENOTYPE	26	26	dyslipidemias
NCT0000116817	NCT00001168_17_T0	PHENOTYPE	58	58	hyperlipidemia
NCT0000116817	NCT00001168_17_T1	PHENOTYPE	51	51	concentrations
NCT0000116817	NCT00001168_17_T2	PHENOTYPE	67	67	xanthomas
NCT0000116817	NCT00001168_17_T3	ORGAN	40	40	plasma
NCT0000116817	NCT00001168_17_T4	ORGAN	50	50	plasma
NCT0000116817	NCT00001168_17_T5	PHENOTYPE	37	37	dyslipoproteinemias
NCT0000116817	NCT00001168_17_T6	PHENOTYPE	63	63	xanthelasma
NCT0000116817	NCT00001168_17_T7	PHENOTYPE	61	62	eruptive xanthomas
NCT0000116817	NCT00001168_17_T8	PHENOTYPE	69	70	corneal opacities
NCT000011697	NCT00001169_7_T0	COMPOUND	15	15	antimony
NCT000011705	NCT00001170_5_T0	PHENOTYPE	19	19	RDC
NCT000011705	NCT00001170_5_T1	PHENOTYPE	21	21	SCID
NCT000011705	NCT00001170_5_T2	PHENOTYPE	8	9	bipolar illness
NCT000011705	NCT00001170_5_T3	PHENOTYPE	5	6	major depression
NCT000011709	NCT00001170_9_T0	GENE	10	10	MRI
NCT0000117010	NCT00001170_10_T0	GENE	2	2	has
NCT000011713	NCT00001171_3_T0	PHENOTYPE	18	21	primary malignant brain tumors
NCT000011716	NCT00001171_6_T0	PHENOTYPE	1	3	primary brain tumor
NCT0000117110	NCT00001171_10_T0	PHENOTYPE	13	13	strategies
NCT0000117110	NCT00001171_10_T1	GENE	2	2	has
NCT0000117110	NCT00001171_10_T2	PHENOTYPE	18	19	brain tumors
NCT0000117112	NCT00001171_12_T0	PHENOTYPE	7	7	tumors
NCT0000117112	NCT00001171_12_T1	PHENOTYPE	21	22	brain tumors
NCT000011730	NCT00001173_0_T0	PHENOTYPE	10	10	Tetanus
NCT000011730	NCT00001173_0_T1	CELL	5	5	Lymphocyte
NCT000011732	NCT00001173_2_T0	PHENOTYPE	36	36	tetanus
NCT000011732	NCT00001173_2_T1	COMPOUND	19	19	KLH
NCT000011732	NCT00001173_2_T2	GENE	17	17	limpet
NCT000011733	NCT00001173_3_T0	BIOLOGICAL_PROCESS	20	21	immune response
NCT000011735	NCT00001173_5_T0	PHENOTYPE	18	18	tetanus
NCT000011735	NCT00001173_5_T1	GENE	11	11	IgG
NCT000011735	NCT00001173_5_T2	GENE	9	9	IgM
NCT000011735	NCT00001173_5_T3	PHENOTYPE	15	16	antibody responses
NCT000011737	NCT00001173_7_T0	PHENOTYPE	17	17	diseases
NCT000011739	NCT00001173_9_T0	PHENOTYPE	36	36	tetanus
NCT000011739	NCT00001173_9_T1	COMPOUND	19	19	KLH
NCT000011739	NCT00001173_9_T2	GENE	17	17	limpet
NCT0000117310	NCT00001173_10_T0	BIOLOGICAL_PROCESS	20	21	immune response
NCT0000117312	NCT00001173_12_T0	PHENOTYPE	18	18	tetanus
NCT0000117312	NCT00001173_12_T1	GENE	11	11	IgG
NCT0000117312	NCT00001173_12_T2	GENE	9	9	IgM
NCT0000117312	NCT00001173_12_T3	PHENOTYPE	15	16	antibody responses
NCT0000117314	NCT00001173_14_T0	PHENOTYPE	17	17	diseases
NCT0000117316	NCT00001173_16_T0	PHENOTYPE	26	26	tetanus
NCT0000117316	NCT00001173_16_T1	PHENOTYPE	18	18	diseases
NCT000011742	NCT00001174_2_T0	PHENOTYPE	6	6	understood
NCT000011742	NCT00001174_2_T1	PHENOTYPE	1	3	mode of inheritance
NCT000011743	NCT00001174_3_T0	PHENOTYPE	22	23	bipolar disorder
NCT000011744	NCT00001174_4_T0	PHENOTYPE	3	4	bipolar disorder
NCT000011748	NCT00001174_8_T0	PHENOTYPE	14	15	bipolar disorder
NCT000011748	NCT00001174_8_T1	PHENOTYPE	26	27	bipolar disorder
NCT000011749	NCT00001174_9_T0	PHENOTYPE	4	4	schizophrenia
NCT000011749	NCT00001174_9_T1	PHENOTYPE	2	3	major depression
NCT000011749	NCT00001174_9_T2	PHENOTYPE	5	6	panic disorder
NCT000011749	NCT00001174_9_T3	PHENOTYPE	8	11	attention deficit hyperactivity disorder
NCT0000117410	NCT00001174_10_T0	GENE	7	7	saliva
NCT0000117410	NCT00001174_10_T1	PHENOTYPE	14	15	substance abuse
NCT000011761	NCT00001176_1_T0	GENE	8	8	SS
NCT000011761	NCT00001176_1_T1	PHENOTYPE	9	9	hypertension
NCT000011762	NCT00001176_2_T0	PHENOTYPE	8	8	hypertension
NCT000011762	NCT00001176_2_T1	PHENOTYPE	37	37	hypertension
NCT000011762	NCT00001176_2_T2	ORGAN	15	16	nervous system
NCT000011762	NCT00001176_2_T3	ORGAN	23	25	autonomic nervous system
NCT000011763	NCT00001176_3_T0	PHENOTYPE	21	21	hypertension
NCT000011763	NCT00001176_3_T1	PHENOTYPE	27	27	hypertension
NCT000011763	NCT00001176_3_T2	ORGAN	10	11	nervous system
NCT000011765	NCT00001176_5_T0	GENE	14	14	SS
NCT000011766	NCT00001176_6_T0	GENE	18	18	SS
NCT000011766	NCT00001176_6_T1	PHENOTYPE	23	24	idiopathic hypertension
NCT000011773	NCT00001177_3_T0	PHENOTYPE	2	2	recurrent
NCT000011775	NCT00001177_5_T0	PHENOTYPE	17	18	endocrine function
NCT000011776	NCT00001177_6_T0	PHENOTYPE	13	14	mood disorder
NCT000011777	NCT00001177_7_T0	PHENOTYPE	10	10	recurrent
NCT000011777	NCT00001177_7_T1	PHENOTYPE	27	28	mood disorders
NCT000011777	NCT00001177_7_T2	BIOLOGICAL_PROCESS	25	26	menstrual cycle
NCT0000117710	NCT00001177_10_T0	PHENOTYPE	5	6	behavioral disorders
NCT000011781	NCT00001178_1_T0	PHENOTYPE	21	22	brain disorders
NCT000011784	NCT00001178_4_T0	PHENOTYPE	18	18	disorders
NCT000011785	NCT00001178_5_T0	GENE	2	2	MRI
NCT000011785	NCT00001178_5_T1	PHENOTYPE	10	10	neuropathology
NCT000011803	NCT00001180_3_T0	GENE	16	16	ACTH
NCT000011803	NCT00001180_3_T1	GENE	1	1	CRH
NCT000011803	NCT00001180_3_T2	ORGAN	6	6	hypothalamus
NCT000011803	NCT00001180_3_T3	GENE	15	15	hormone
NCT000011803	NCT00001180_3_T4	ORGAN	10	11	pituitary gland
NCT000011804	NCT00001180_4_T0	COMPOUND	11	11	cortisol
NCT000011804	NCT00001180_4_T1	GENE	0	0	ACTH
NCT000011804	NCT00001180_4_T2	GENE	10	10	hormone
NCT000011804	NCT00001180_4_T3	ORGAN	4	5	adrenal glands
NCT000011805	NCT00001180_5_T0	GENE	7	7	axis
NCT000011808	NCT00001180_8_T0	PHENOTYPE	17	17	disorders
NCT000011808	NCT00001180_8_T1	GENE	20	20	HPA
NCT000011808	NCT00001180_8_T2	GENE	21	21	axis
NCT0000118010	NCT00001180_10_T0	PHENOTYPE	9	10	hormone levels
NCT0000118013	NCT00001180_13_T0	GENE	7	7	CRH
NCT0000118013	NCT00001180_13_T1	GENE	8	8	has
NCT0000118014	NCT00001180_14_T0	PHENOTYPE	27	27	disorders
NCT0000118014	NCT00001180_14_T1	GENE	18	18	CRH
NCT0000118014	NCT00001180_14_T2	GENE	31	31	axis
NCT0000118014	NCT00001180_14_T3	PHENOTYPE	11	12	dose-response relationship
NCT0000118015	NCT00001180_15_T0	GENE	0	0	CRH
NCT0000118016	NCT00001180_16_T0	COMPOUND	4	4	cortisol
NCT0000118016	NCT00001180_16_T1	ORGAN	0	0	Plasma
NCT0000118016	NCT00001180_16_T2	GENE	3	3	ACTH
NCT0000118016	NCT00001180_16_T3	GENE	6	6	CRH
NCT0000118016	NCT00001180_16_T4	GENE	13	13	CRH
NCT0000118018	NCT00001180_18_T0	PHENOTYPE	10	10	chronic
NCT000011814	NCT00001181_4_T0	ORGAN	9	9	ovaries
NCT000011814	NCT00001181_4_T1	BIOLOGICAL_PROCESS	25	25	menstruation
NCT000011814	NCT00001181_4_T2	ORGAN	17	17	breasts
NCT000011814	NCT00001181_4_T3	ORGAN	4	5	pituitary gland
NCT000011816	NCT00001181_6_T0	GENE	16	16	LHRH
NCT000011816	NCT00001181_6_T1	GENE	15	15	hormone
NCT000011816	NCT00001181_6_T2	ORGAN	22	23	pituitary gland
NCT000011817	NCT00001181_7_T0	ORGAN	25	25	ovaries
NCT000011817	NCT00001181_7_T1	ORGAN	4	5	pituitary gland
NCT000011818	NCT00001181_8_T0	ORGAN	13	13	ovaries
NCT000011819	NCT00001181_9_T0	GENE	5	5	LHRH
NCT0000118110	NCT00001181_10_T0	ORGAN	9	9	ovary
NCT0000118111	NCT00001181_11_T0	COMPOUND	8	8	estrogen
NCT0000118111	NCT00001181_11_T1	ORGAN	12	12	ovary
NCT0000118115	NCT00001181_15_T0	PHENOTYPE	14	15	hormone levels
NCT0000118119	NCT00001181_19_T0	PHENOTYPE	1	1	intent
NCT0000118119	NCT00001181_19_T1	PHENOTYPE	9	10	short stature
NCT000011827	NCT00001182_7_T0	PHENOTYPE	31	31	experiences
NCT000011832	NCT00001183_2_T0	ORGAN	6	6	lungs
NCT000011832	NCT00001183_2_T1	ORGAN	13	13	lungs
NCT000011832	NCT00001183_2_T2	ORGAN	19	19	lungs
NCT000011832	NCT00001183_2_T3	TISSUE	20	20	pleura
NCT000011832	NCT00001183_2_T4	ORGAN	7	8	blood vessels
NCT000011834	NCT00001183_4_T0	PHENOTYPE	12	12	disorders
NCT000011834	NCT00001183_4_T1	ORGAN	15	15	lungs
NCT000011839	NCT00001183_9_T0	PHENOTYPE	5	6	lung disease
NCT0000118310	NCT00001183_10_T0	PHENOTYPE	2	2	diseases
NCT0000118310	NCT00001183_10_T1	PHENOTYPE	9	10	lung disease
NCT000011842	NCT00001184_2_T0	PHENOTYPE	19	19	symptoms
NCT000011842	NCT00001184_2_T1	PHENOTYPE	16	17	ulcerative colitis
NCT000011842	NCT00001184_2_T2	PHENOTYPE	21	23	inflammatory bowel disease
NCT000011842	NCT00001184_2_T3	PHENOTYPE	12	14	Crohn s disease
NCT000011843	NCT00001184_3_T0	GENE	25	25	GI
NCT000011843	NCT00001184_3_T1	GENE	32	32	bowel
NCT000011843	NCT00001184_3_T2	COMPOUND	21	21	barium
NCT000011844	NCT00001184_4_T0	PHENOTYPE	18	19	ulcerative colitis
NCT000011844	NCT00001184_4_T1	PHENOTYPE	14	16	Crohn s disease
NCT000011845	NCT00001184_5_T0	PHENOTYPE	11	11	infections
NCT0000118411	NCT00001184_11_T0	CELL	16	16	cells
NCT0000118414	NCT00001184_14_T0	ORGAN	7	7	rectum
NCT0000118414	NCT00001184_14_T1	TISSUE	17	18	intestinal mucosa
NCT0000118414	NCT00001184_14_T2	ORGAN	9	10	large intestine
NCT0000118417	NCT00001184_17_T0	PHENOTYPE	28	28	peripheral
NCT0000118417	NCT00001184_17_T1	TISSUE	31	31	tissues
NCT0000118417	NCT00001184_17_T2	PHENOTYPE	44	44	diseases
NCT0000118417	NCT00001184_17_T3	CELL	22	22	lymphocyte
NCT0000118417	NCT00001184_17_T4	CELL	24	25	antigen-presenting cells
NCT0000118419	NCT00001184_19_T0	PHENOTYPE	22	22	IBD
NCT0000118419	NCT00001184_19_T1	PHENOTYPE	46	46	IBD
NCT0000118421	NCT00001184_21_T0	PHENOTYPE	23	23	diseases
NCT0000118424	NCT00001184_24_T0	GENE	37	37	OR
NCT0000118424	NCT00001184_24_T1	PHENOTYPE	11	11	IBD
NCT0000118424	NCT00001184_24_T2	PHENOTYPE	6	7	Crohn's disease
NCT0000118424	NCT00001184_24_T3	PHENOTYPE	8	9	ulcerative colitis
NCT0000118425	NCT00001184_25_T0	ORGAN	18	18	intestine
NCT0000118425	NCT00001184_25_T1	GENE	19	19	OR
NCT0000118425	NCT00001184_25_T2	PHENOTYPE	15	15	inflammation
NCT0000118425	NCT00001184_25_T3	PHENOTYPE	9	10	bowel disease
NCT0000118431	NCT00001184_31_T0	GENE	40	40	1.3
NCT0000118431	NCT00001184_31_T1	GENE	34	34	INR
NCT0000118431	NCT00001184_31_T2	PHENOTYPE	42	43	PTT prolonged
NCT0000118431	NCT00001184_31_T3	PHENOTYPE	28	29	Platelet count
NCT0000118439	NCT00001184_39_T0	GENE	2	2	FOR
NCT0000118445	NCT00001184_45_T0	GENE	2	2	FOR
NCT0000118446	NCT00001184_46_T0	PHENOTYPE	2	4	inflammatory bowel disease
NCT0000118448	NCT00001184_48_T0	PHENOTYPE	0	0	Acute
NCT0000118448	NCT00001184_48_T1	PHENOTYPE	3	4	intestinal infection
NCT000011851	NCT00001185_1_T0	PHENOTYPE	12	12	fever
NCT000011851	NCT00001185_1_T1	PHENOTYPE	18	18	stiffness
NCT000011851	NCT00001185_1_T2	PHENOTYPE	10	10	symptoms
NCT000011851	NCT00001185_1_T3	CELL	3	3	cells
NCT000011851	NCT00001185_1_T4	PHENOTYPE	15	15	headache
NCT000011851	NCT00001185_1_T5	PHENOTYPE	16	16	vomiting
NCT000011851	NCT00001185_1_T6	PHENOTYPE	13	14	sore throat
NCT000011851	NCT00001185_1_T7	ORGAN	6	7	spinal cord
NCT000011856	NCT00001185_6_T0	ORGAN	6	7	spinal cord
NCT000011856	NCT00001185_6_T1	CELL	2	3	nerve cells
NCT000011857	NCT00001185_7_T0	CELL	13	13	cells
NCT000011857	NCT00001185_7_T1	CELL	1	2	nerve cells
NCT000011859	NCT00001185_9_T0	CELL	5	6	nerve cells
NCT0000118514	NCT00001185_14_T0	PHENOTYPE	2	2	weakness
NCT0000118514	NCT00001185_14_T1	PHENOTYPE	11	11	distal
NCT0000118514	NCT00001185_14_T2	PHENOTYPE	33	33	distal
NCT0000118514	NCT00001185_14_T3	GENE	21	21	has
NCT0000118514	NCT00001185_14_T4	PHENOTYPE	8	8	disintegration
NCT0000118514	NCT00001185_14_T5	CELL	17	18	motor neurons
NCT0000118515	NCT00001185_15_T0	PHENOTYPE	14	14	weakness
NCT0000118515	NCT00001185_15_T1	PHENOTYPE	16	16	fatigue
NCT0000118515	NCT00001185_15_T2	PHENOTYPE	5	5	disintegration
NCT0000118518	NCT00001185_18_T0	GENE	8	8	neuromuscular
NCT0000118518	NCT00001185_18_T1	ORGAN	25	25	serum
NCT0000118519	NCT00001185_19_T0	PHENOTYPE	20	20	weakness
NCT000011860	NCT00001186_0_T0	PHENOTYPE	10	10	Cancer
NCT000011862	NCT00001186_2_T0	PHENOTYPE	2	2	connotations
NCT000011866	NCT00001186_6_T0	PHENOTYPE	17	17	attitudes
NCT000011866	NCT00001186_6_T1	PHENOTYPE	20	20	experiences
NCT000011867	NCT00001186_7_T0	PHENOTYPE	18	19	pediatric cancer
NCT000011867	NCT00001186_7_T1	PHENOTYPE	13	15	quality of life
NCT000011868	NCT00001186_8_T0	PHENOTYPE	21	21	self-esteem
NCT0000118614	NCT00001186_14_T0	PHENOTYPE	2	2	connotations
NCT0000118618	NCT00001186_18_T0	PHENOTYPE	17	17	attitudes
NCT0000118618	NCT00001186_18_T1	PHENOTYPE	20	20	experiences
NCT0000118619	NCT00001186_19_T0	PHENOTYPE	18	19	pediatric cancer
NCT0000118619	NCT00001186_19_T1	PHENOTYPE	13	15	quality of life
NCT0000118620	NCT00001186_20_T0	PHENOTYPE	21	21	self-esteem
NCT0000118629	NCT00001186_29_T0	GENE	20	20	has
NCT000011880	NCT00001188_0_T0	ORGAN	15	15	Extremities
NCT000011880	NCT00001188_0_T1	PHENOTYPE	10	12	Soft Tissue Sarcomas
NCT000011887	NCT00001188_7_T0	PHENOTYPE	0	2	Malignant fibrous histiocytoma
NCT000011888	NCT00001188_8_T0	PHENOTYPE	0	3	Inflammatory malignant fibrous histiocytoma
NCT000011889	NCT00001188_9_T0	PHENOTYPE	0	3	Myxoid malignant fibrous histiocytoma
NCT0000118811	NCT00001188_11_T0	PHENOTYPE	0	3	Angiomatoid malignant fibrous histiocytoma
NCT0000118813	NCT00001188_13_T0	PHENOTYPE	1	1	hemangiopericytoma
NCT0000118814	NCT00001188_14_T0	PHENOTYPE	0	0	Rhabdomyosarcoma
NCT0000118815	NCT00001188_15_T0	PHENOTYPE	4	5	Ewing's sarcoma
NCT0000118815	NCT00001188_15_T1	PHENOTYPE	0	2	Soft tissue sarcoma
NCT0000118817	NCT00001188_17_T0	PHENOTYPE	1	1	sarcoma
NCT0000118820	NCT00001188_20_T0	PHENOTYPE	1	1	schwannoma
NCT0000118821	NCT00001188_21_T0	PHENOTYPE	0	2	Malignant triton tumor
NCT0000118823	NCT00001188_23_T0	PHENOTYPE	1	2	malignant mesenchymoma
NCT0000118824	NCT00001188_24_T0	PHENOTYPE	3	3	sarcoma
NCT0000118826	NCT00001188_26_T0	GENE	5	5	II
NCT0000118826	NCT00001188_26_T1	GENE	7	7	III
NCT0000118828	NCT00001188_28_T0	PHENOTYPE	11	11	tumor
NCT0000118828	NCT00001188_28_T1	GENE	12	12	has
NCT0000118829	NCT00001188_29_T0	ORGAN	12	12	lymph
NCT0000118829	NCT00001188_29_T1	PHENOTYPE	7	8	metastatic disease
NCT0000118831	NCT00001188_31_T0	PHENOTYPE	11	11	recurrence
NCT0000118831	NCT00001188_31_T1	PHENOTYPE	6	7	primary lesion
NCT0000118832	NCT00001188_32_T0	PHENOTYPE	12	12	sarcoma
NCT0000118834	NCT00001188_34_T0	GENE	4	4	had
NCT0000118834	NCT00001188_34_T1	PHENOTYPE	25	25	impairment
NCT0000118834	NCT00001188_34_T2	PHENOTYPE	17	17	cirrhosis
NCT0000118834	NCT00001188_34_T3	PHENOTYPE	9	10	bleeding disorders
NCT0000118834	NCT00001188_34_T4	PHENOTYPE	18	20	ischemic heart disease
NCT0000118835	NCT00001188_35_T0	PHENOTYPE	16	16	rhabdomyosarcoma
NCT000011897	NCT00001189_7_T0	PHENOTYPE	4	4	metastases
NCT000011898	NCT00001189_8_T0	PHENOTYPE	5	5	tumors
NCT000011899	NCT00001189_9_T0	PHENOTYPE	4	4	tumor
NCT0000118910	NCT00001189_10_T0	PHENOTYPE	1	3	von Recklinghausen's disease
NCT0000118912	NCT00001189_12_T0	PHENOTYPE	5	5	sarcoma
NCT0000118913	NCT00001189_13_T0	PHENOTYPE	0	0	Endocrine
NCT0000118914	NCT00001189_14_T0	PHENOTYPE	5	5	sarcoma
NCT0000118915	NCT00001189_15_T0	PHENOTYPE	13	13	recurrence
NCT0000118915	NCT00001189_15_T1	PHENOTYPE	10	11	primary lesion
NCT0000118917	NCT00001189_17_T0	GENE	2	2	Age
NCT0000118920	NCT00001189_20_T0	PHENOTYPE	2	2	cirrhosis
NCT0000118921	NCT00001189_21_T0	PHENOTYPE	5	6	renal impairment
NCT0000118922	NCT00001189_22_T0	PHENOTYPE	2	4	ischemic heart disease
NCT0000118925	NCT00001189_25_T0	PHENOTYPE	2	3	bleeding disorder
NCT0000118926	NCT00001189_26_T0	PHENOTYPE	2	3	concomitant disease
NCT000011901	NCT00001190_1_T0	PHENOTYPE	2	3	short stature
NCT000011908	NCT00001190_8_T0	GENE	11	11	LHRH
NCT000011908	NCT00001190_8_T1	COMPOUND	1	1	deslorelin
NCT000011908	NCT00001190_8_T2	COMPOUND	0	0	LHRHa
NCT000011908	NCT00001190_8_T3	GENE	4	4	hormone
NCT0000119012	NCT00001190_12_T0	PHENOTYPE	2	3	short stature
NCT0000119017	NCT00001190_17_T0	PHENOTYPE	8	9	short stature
NCT0000119017	NCT00001190_17_T1	GENE	15	17	luteinizing hormone-releasing hormone
NCT0000119020	NCT00001190_20_T0	COMPOUND	15	15	LHRHa
NCT000011913	NCT00001191_3_T0	PHENOTYPE	18	18	complications
NCT000011913	NCT00001191_3_T1	PHENOTYPE	15	15	ulcers
NCT000011914	NCT00001191_4_T0	PHENOTYPE	17	18	Zollinger-Ellison Syndrome
NCT000011915	NCT00001191_5_T0	GENE	13	13	secreted
NCT000011919	NCT00001191_9_T0	COMPOUND	11	11	omeprazole
NCT0000119111	NCT00001191_11_T0	PHENOTYPE	5	5	symptoms
NCT0000119111	NCT00001191_11_T1	PHENOTYPE	8	9	Zollinger-Ellison Syndrome
NCT0000119122	NCT00001191_22_T0	TISSUE	6	7	gastric mucosa
NCT0000119125	NCT00001191_25_T0	PHENOTYPE	22	22	Syndrome
NCT000011931	NCT00001193_1_T0	COMPOUND	12	12	5_fluorouracil
NCT000011931	NCT00001193_1_T1	COMPOUND	8	8	cyclophosphamide
NCT000011931	NCT00001193_1_T2	COMPOUND	10	10	methotrexate
NCT000011931	NCT00001193_1_T3	COMPOUND	17	17	tamoxifen
NCT000011932	NCT00001193_2_T0	ORGAN	53	53	axilla
NCT000011932	NCT00001193_2_T1	PHENOTYPE	29	30	residual disease
NCT000011932	NCT00001193_2_T2	ORGAN	45	46	chest wall
NCT000011932	NCT00001193_2_T3	TISSUE	19	20	lymph nodes
NCT000011932	NCT00001193_2_T4	TISSUE	49	50	lymph nodes
NCT000011932	NCT00001193_2_T5	PHENOTYPE	3	7	inflammatory carcinoma of the breast
NCT000011933	NCT00001193_3_T0	COMPOUND	16	16	melphalan
NCT000011933	NCT00001193_3_T1	ORGAN	26	27	bone marrow
NCT000011935	NCT00001193_5_T0	PHENOTYPE	2	4	metastatic breast cancer
NCT000011938	NCT00001193_8_T0	COMPOUND	12	12	5_fluorouracil
NCT000011938	NCT00001193_8_T1	COMPOUND	8	8	cyclophosphamide
NCT000011938	NCT00001193_8_T2	COMPOUND	10	10	methotrexate
NCT000011938	NCT00001193_8_T3	COMPOUND	17	17	tamoxifen
NCT000011939	NCT00001193_9_T0	ORGAN	53	53	axilla
NCT000011939	NCT00001193_9_T1	PHENOTYPE	29	30	residual disease
NCT000011939	NCT00001193_9_T2	ORGAN	45	46	chest wall
NCT000011939	NCT00001193_9_T3	TISSUE	19	20	lymph nodes
NCT000011939	NCT00001193_9_T4	TISSUE	49	50	lymph nodes
NCT000011939	NCT00001193_9_T5	PHENOTYPE	3	7	inflammatory carcinoma of the breast
NCT0000119310	NCT00001193_10_T0	COMPOUND	16	16	melphalan
NCT0000119310	NCT00001193_10_T1	ORGAN	26	27	bone marrow
NCT0000119312	NCT00001193_12_T0	PHENOTYPE	2	4	metastatic breast cancer
NCT0000119317	NCT00001193_17_T0	PHENOTYPE	7	8	evaluable disease
NCT0000119317	NCT00001193_17_T1	PHENOTYPE	2	4	metastatic breast cancer
NCT0000119319	NCT00001193_19_T0	PHENOTYPE	7	7	malignancy
NCT0000119319	NCT00001193_19_T1	PHENOTYPE	11	13	nonmelanoma skin cancer
NCT0000119319	NCT00001193_19_T2	PHENOTYPE	15	18	cervical carcinoma in situ
NCT0000119320	NCT00001193_20_T0	PHENOTYPE	13	14	breast cancer
NCT0000119321	NCT00001193_21_T0	PHENOTYPE	7	7	metastases
NCT0000119321	NCT00001193_21_T1	GENE	10	10	III
NCT0000119323	NCT00001193_23_T0	PHENOTYPE	8	8	tumor
NCT0000119325	NCT00001193_25_T0	PHENOTYPE	3	5	other malignant neoplasms
NCT0000119325	NCT00001193_25_T1	PHENOTYPE	16	19	carcinoma of the cervix
NCT000011941	NCT00001194_1_T0	GENE	13	13	coil
NCT000011941	NCT00001194_1_T1	PHENOTYPE	10	10	pulse
NCT000011941	NCT00001194_1_T2	PHENOTYPE	3	3	enables
NCT000011942	NCT00001194_2_T0	GENE	4	4	MRI
NCT000011942	NCT00001194_2_T1	GENE	18	18	MRI
NCT000011944	NCT00001194_4_T0	PHENOTYPE	15	15	diseases
NCT000011951	NCT00001195_1_T0	GENE	7	7	saliva
NCT000011952	NCT00001195_2_T0	PHENOTYPE	12	12	illnesses
NCT000011952	NCT00001195_2_T1	PHENOTYPE	5	6	hormone levels
NCT000011955	NCT00001195_5_T0	PHENOTYPE	2	3	hormone levels
NCT000011957	NCT00001195_7_T0	GENE	1	1	hormone
NCT000011957	NCT00001195_7_T1	PHENOTYPE	12	13	hormone levels
NCT000011960	NCT00001196_0_T0	PHENOTYPE	4	4	Dysfunction
NCT000011960	NCT00001196_0_T1	TISSUE	2	3	Salivary Gland
NCT000011962	NCT00001196_2_T0	TISSUE	0	1	Salivary gland
NCT000011964	NCT00001196_4_T0	PHENOTYPE	9	9	dysfunction
NCT000011964	NCT00001196_4_T1	PHENOTYPE	2	3	dry mouth
NCT000011964	NCT00001196_4_T2	TISSUE	7	8	salivary gland
NCT000011965	NCT00001196_5_T0	PHENOTYPE	7	7	arthritis
NCT000011968	NCT00001196_8_T0	ORGAN	19	19	jaw
NCT000011968	NCT00001196_8_T1	ORGAN	15	15	cheeks
NCT000011968	NCT00001196_8_T2	TISSUE	8	9	salivary glands
NCT0000119615	NCT00001196_15_T0	PHENOTYPE	9	9	dysfunction
NCT0000119615	NCT00001196_15_T1	PHENOTYPE	2	3	dry mouth
NCT0000119615	NCT00001196_15_T2	TISSUE	7	8	salivary gland
NCT0000119617	NCT00001196_17_T0	ORGAN	15	15	cheeks
NCT0000119617	NCT00001196_17_T1	TISSUE	8	9	salivary glands
NCT000011970	NCT00001197_0_T0	PHENOTYPE	7	9	Sickle Cell Anemia
NCT000011972	NCT00001197_2_T0	ORGAN	29	29	liver
NCT000011972	NCT00001197_2_T1	GENE	25	25	1.5
NCT000011972	NCT00001197_2_T2	COMPOUND	22	22	creatinine
NCT000011979	NCT00001197_9_T0	PHENOTYPE	23	23	severity
NCT000011979	NCT00001197_9_T1	CELL	18	18	cells
NCT0000119710	NCT00001197_10_T0	COMPOUND	9	9	hydroxyurea
NCT0000119714	NCT00001197_14_T0	ORGAN	29	29	liver
NCT0000119714	NCT00001197_14_T1	GENE	25	25	1.5
NCT0000119714	NCT00001197_14_T2	COMPOUND	22	22	creatinine
NCT000011981	NCT00001198_1_T0	PHENOTYPE	9	10	adult onset
NCT000011983	NCT00001198_3_T0	GENE	13	13	pre
NCT000011983	NCT00001198_3_T1	GENE	29	29	al
NCT000011983	NCT00001198_3_T2	GENE	28	28	et
NCT000011985	NCT00001198_5_T0	PHENOTYPE	37	37	translocation
NCT000011985	NCT00001198_5_T1	GENE	36	36	1.7
NCT000011985	NCT00001198_5_T2	GENE	24	24	al
NCT000011985	NCT00001198_5_T3	GENE	32	32	al
NCT000011985	NCT00001198_5_T4	GENE	40	40	al
NCT000011985	NCT00001198_5_T5	GENE	26	26	Mosaic
NCT000011985	NCT00001198_5_T6	GENE	23	23	et
NCT000011985	NCT00001198_5_T7	GENE	31	31	et
NCT000011985	NCT00001198_5_T8	GENE	39	39	et
NCT000011985	NCT00001198_5_T9	PHENOTYPE	15	16	cytogenetic abnormalities
NCT0000119811	NCT00001198_11_T0	PHENOTYPE	9	9	adult-onset
NCT0000119813	NCT00001198_13_T0	GENE	13	13	pre
NCT0000119817	NCT00001198_17_T0	PHENOTYPE	18	19	adult onset
NCT0000119820	NCT00001198_20_T0	GENE	6	6	has
NCT000012011	NCT00001201_1_T0	ORGAN	6	7	cranial nerves
NCT000012011	NCT00001201_1_T1	ORGAN	11	12	spinal nerves
NCT000012012	NCT00001201_2_T0	ORGAN	24	25	nervous system
NCT000012012	NCT00001201_2_T1	ORGAN	13	15	peripheral nervous system
NCT000012013	NCT00001201_3_T0	ORGAN	11	13	peripheral nervous system
NCT000012015	NCT00001201_5_T0	GENE	21	21	II
NCT000012015	NCT00001201_5_T1	GENE	32	32	III
NCT000012015	NCT00001201_5_T2	PHENOTYPE	15	15	diseases
NCT000012015	NCT00001201_5_T3	PHENOTYPE	26	26	diseases
NCT000012015	NCT00001201_5_T4	PHENOTYPE	40	40	diseases
NCT000012015	NCT00001201_5_T5	PHENOTYPE	58	58	diseases
NCT000012015	NCT00001201_5_T6	GENE	46	46	IV
NCT000012015	NCT00001201_5_T7	ORGAN	18	20	peripheral nervous system
NCT000012015	NCT00001201_5_T8	ORGAN	29	31	peripheral nervous system
NCT000012015	NCT00001201_5_T9	ORGAN	43	45	peripheral nervous system
NCT000012015	NCT00001201_5_T10	ORGAN	61	63	peripheral nervous system
NCT000012017	NCT00001201_7_T0	PHENOTYPE	17	17	disorders
NCT000012017	NCT00001201_7_T1	PHENOTYPE	12	12	centers
NCT000012017	NCT00001201_7_T2	PHENOTYPE	7	8	peripheral neuropathies
NCT000012019	NCT00001201_9_T0	ORGAN	8	10	peripheral nervous system
NCT000012019	NCT00001201_9_T1	PHENOTYPE	5	9	disorders of the peripheral nervous
NCT0000120112	NCT00001201_12_T0	PHENOTYPE	12	13	primary disorders
NCT0000120112	NCT00001201_12_T1	ORGAN	16	18	peripheral nervous system
NCT0000120112	NCT00001201_12_T2	PHENOTYPE	13	17	disorders of the peripheral nervous
NCT0000120113	NCT00001201_13_T0	PHENOTYPE	9	9	diseases
NCT0000120113	NCT00001201_13_T1	PHENOTYPE	16	16	diseases
NCT000012026	NCT00001202_6_T0	COMPOUND	18	18	estrogen
NCT000012026	NCT00001202_6_T1	GENE	17	17	hormone
NCT000012027	NCT00001202_7_T0	COMPOUND	16	16	estrogen
NCT000012027	NCT00001202_7_T1	COMPOUND	4	4	testolactone
NCT000012028	NCT00001202_8_T0	COMPOUND	13	13	androgen
NCT000012028	NCT00001202_8_T1	COMPOUND	23	23	estrogen
NCT000012028	NCT00001202_8_T2	COMPOUND	4	4	spironolactone
NCT000012028	NCT00001202_8_T3	COMPOUND	15	15	testolactone
NCT0000120217	NCT00001202_17_T0	PHENOTYPE	10	10	peripheral
NCT0000120217	NCT00001202_17_T1	TISSUE	16	16	tissues
NCT0000120217	NCT00001202_17_T2	COMPOUND	13	13	testosterone
NCT0000120217	NCT00001202_17_T3	ORGAN	4	4	plasma
NCT0000120217	NCT00001202_17_T4	PHENOTYPE	5	6	testosterone level
NCT0000120218	NCT00001202_18_T0	PHENOTYPE	7	7	acne
NCT0000120219	NCT00001202_19_T0	PHENOTYPE	10	10	gynecomastia
NCT0000120219	NCT00001202_19_T1	GENE	11	11	had
NCT0000120219	NCT00001202_19_T2	COMPOUND	8	8	spironolactone
NCT0000120220	NCT00001202_20_T0	COMPOUND	11	11	estradiol
NCT0000120224	NCT00001202_24_T0	PHENOTYPE	9	9	maturation
NCT0000120224	NCT00001202_24_T1	ORGAN	17	17	epiphyses
NCT0000120224	NCT00001202_24_T2	PHENOTYPE	20	21	short stature
NCT0000120229	NCT00001202_29_T0	GENE	13	13	met
NCT0000120231	NCT00001202_31_T0	ORGAN	1	1	epiphyses
NCT0000120233	NCT00001202_33_T0	COMPOUND	9	9	androgen
NCT0000120233	NCT00001202_33_T1	COMPOUND	21	21	11_deoxycortisol
NCT0000120233	NCT00001202_33_T2	GENE	14	14	ACTH
NCT0000120233	NCT00001202_33_T3	PHENOTYPE	3	5	congenital adrenal hyperplasia
NCT0000120235	NCT00001202_35_T0	PHENOTYPE	3	3	tumor
NCT0000120235	NCT00001202_35_T1	ORGAN	7	7	testes
NCT0000120235	NCT00001202_35_T2	BIOLOGICAL_PROCESS	19	19	androstenedione
NCT000012035	NCT00001203_5_T0	PHENOTYPE	3	3	diseases
NCT000012035	NCT00001203_5_T1	PHENOTYPE	12	13	heart problems
NCT0000120311	NCT00001203_11_T0	COMPOUND	7	7	deferoxamine
NCT0000120311	NCT00001203_11_T1	PHENOTYPE	15	15	complications
NCT0000120311	NCT00001203_11_T2	ORGAN	14	14	heart
NCT0000120317	NCT00001203_17_T0	PHENOTYPE	3	3	anemias
NCT0000120317	NCT00001203_17_T1	PHENOTYPE	10	11	cardiac disease
NCT0000120318	NCT00001203_18_T0	CELL	18	18	cells
NCT0000120318	NCT00001203_18_T1	PHENOTYPE	3	3	anemias
NCT0000120318	NCT00001203_18_T2	PHENOTYPE	10	11	iron deposition
NCT0000120319	NCT00001203_19_T0	GENE	7	7	has
NCT0000120320	NCT00001203_20_T0	PHENOTYPE	4	5	cardiac complications
NCT0000120322	NCT00001203_22_T0	PHENOTYPE	8	9	cardiac disease
NCT0000120322	NCT00001203_22_T1	PHENOTYPE	26	27	cardiac complications
NCT0000120324	NCT00001203_24_T0	PHENOTYPE	8	8	secondary
NCT0000120324	NCT00001203_24_T1	PHENOTYPE	14	14	anemia
NCT0000120325	NCT00001203_25_T0	PHENOTYPE	5	7	homozygous beta thalassemia
NCT000012042	NCT00001204_2_T0	PHENOTYPE	12	13	heart disease
NCT000012043	NCT00001204_3_T0	PHENOTYPE	10	10	suffered
NCT000012043	NCT00001204_3_T1	PHENOTYPE	11	12	heart attacks
NCT000012045	NCT00001204_5_T0	PHENOTYPE	15	15	atherosclerosis
NCT000012045	NCT00001204_5_T1	ORGAN	7	7	arteries
NCT000012045	NCT00001204_5_T2	ORGAN	14	14	arteries
NCT000012046	NCT00001204_6_T0	PHENOTYPE	10	10	atherosclerosis
NCT000012048	NCT00001204_8_T0	PHENOTYPE	16	16	atherosclerosis
NCT000012048	NCT00001204_8_T1	PHENOTYPE	7	8	familial hypercholesterolemia
NCT000012049	NCT00001204_9_T0	ORGAN	16	16	liver
NCT0000120414	NCT00001204_14_T0	PHENOTYPE	13	13	atherosclerosis
NCT0000120414	NCT00001204_14_T1	ORGAN	34	34	liver
NCT0000120414	NCT00001204_14_T2	PHENOTYPE	11	11	progression
NCT0000120414	NCT00001204_14_T3	PHENOTYPE	14	15	heart disease
NCT0000120416	NCT00001204_16_T0	PHENOTYPE	3	3	hypercholesterolemia
NCT0000120416	NCT00001204_16_T1	PHENOTYPE	5	6	cardiovascular disease
NCT0000120417	NCT00001204_17_T0	PHENOTYPE	2	3	tuberous xanthomas
NCT000012050	NCT00001205_0_T0	PHENOTYPE	4	4	Cysticercosis
NCT000012052	NCT00001205_2_T0	TISSUE	12	12	muscles
NCT000012052	NCT00001205_2_T1	PHENOTYPE	3	3	cysts
NCT000012052	NCT00001205_2_T2	PHENOTYPE	8	8	cysts
NCT000012052	NCT00001205_2_T3	COMPOUND	6	6	solium
NCT000012052	NCT00001205_2_T4	PHENOTYPE	2	2	ingest
NCT000012053	NCT00001205_3_T0	PHENOTYPE	5	5	inflammation
NCT000012053	NCT00001205_3_T1	PHENOTYPE	1	1	cysts
NCT000012054	NCT00001205_4_T0	PHENOTYPE	14	14	enlargement
NCT000012054	NCT00001205_4_T1	PHENOTYPE	3	3	seizures
NCT000012054	NCT00001205_4_T2	PHENOTYPE	4	4	headache
NCT000012054	NCT00001205_4_T3	PHENOTYPE	6	6	vomiting
NCT000012054	NCT00001205_4_T4	PHENOTYPE	5	5	nausea
NCT000012054	NCT00001205_4_T5	PHENOTYPE	10	11	poor vision
NCT000012054	NCT00001205_4_T6	PHENOTYPE	7	9	inability to walk
NCT000012055	NCT00001205_5_T0	PHENOTYPE	11	11	cysts
NCT000012057	NCT00001205_7_T0	PHENOTYPE	5	5	cysticercosis
NCT000012058	NCT00001205_8_T0	COMPOUND	13	13	praziquantel
NCT000012058	NCT00001205_8_T1	COMPOUND	15	15	albendazole
NCT000012059	NCT00001205_9_T0	GENE	6	6	lessen
NCT0000120511	NCT00001205_11_T0	TISSUE	18	18	bones
NCT0000120511	NCT00001205_11_T1	ORGAN	19	19	vertebrae
NCT0000120513	NCT00001205_13_T0	GENE	0	0	MRI
NCT0000120513	NCT00001205_13_T1	GENE	14	14	structural
NCT0000120520	NCT00001205_20_T0	PHENOTYPE	0	0	Cysticercosis
NCT0000120520	NCT00001205_20_T1	PHENOTYPE	31	31	complications
NCT0000120520	NCT00001205_20_T2	GENE	20	20	NCC
NCT0000120520	NCT00001205_20_T3	PHENOTYPE	19	19	neurocysticercosis
NCT0000120520	NCT00001205_20_T4	COMPOUND	12	12	solium
NCT0000120521	NCT00001205_21_T0	PHENOTYPE	9	9	learned
NCT0000120522	NCT00001205_22_T0	COMPOUND	2	2	praziquantel
NCT0000120522	NCT00001205_22_T1	PHENOTYPE	13	13	cysticercosis
NCT0000120522	NCT00001205_22_T2	COMPOUND	4	4	albendazole
NCT0000120524	NCT00001205_24_T0	PHENOTYPE	4	4	inflammation
NCT0000120530	NCT00001205_30_T0	GENE	5	5	NCC
NCT0000120531	NCT00001205_31_T0	GENE	11	11	MRI
NCT0000120531	NCT00001205_31_T1	PHENOTYPE	9	9	cysts
NCT0000120531	NCT00001205_31_T2	GENE	3	3	NCC
NCT0000120535	NCT00001205_35_T0	COMPOUND	15	15	albendazole
NCT0000120535	NCT00001205_35_T1	COMPOUND	18	18	methotrexate
NCT0000120535	NCT00001205_35_T2	COMPOUND	16	16	praziquantel
NCT0000120535	NCT00001205_35_T3	GENE	38	38	PI
NCT0000120544	NCT00001205_44_T0	COMPOUND	4	4	praziquantel
NCT0000120544	NCT00001205_44_T1	COMPOUND	2	2	albendazole
NCT000012061	NCT00001206_1_T0	PHENOTYPE	11	11	ADHD
NCT000012062	NCT00001206_2_T0	GENE	12	12	MRI
NCT000012063	NCT00001206_3_T0	GENE	16	16	MRI
NCT000012064	NCT00001206_4_T0	PHENOTYPE	18	18	ADHD
NCT000012065	NCT00001206_5_T0	PHENOTYPE	7	7	ADHD
NCT000012068	NCT00001206_8_T0	GENE	1	1	MRI
NCT000012069	NCT00001206_9_T0	PHENOTYPE	15	15	ADHD
NCT0000120610	NCT00001206_10_T0	PHENOTYPE	3	3	ADHD
NCT0000120612	NCT00001206_12_T0	PHENOTYPE	10	10	Weaknesses
NCT0000120612	NCT00001206_12_T1	PHENOTYPE	12	12	ADHD
NCT0000120612	NCT00001206_12_T2	GENE	16	16	SWAN
NCT0000120614	NCT00001206_14_T0	PHENOTYPE	3	3	ADHD
NCT0000120617	NCT00001206_17_T0	PHENOTYPE	9	9	ADHD
NCT0000120617	NCT00001206_17_T1	PHENOTYPE	32	32	pathology
NCT0000120617	NCT00001206_17_T2	GENE	29	29	gm
NCT0000120617	NCT00001206_17_T3	PHENOTYPE	30	30	meningitis
NCT0000120617	NCT00001206_17_T4	PHENOTYPE	0	0	Onset
NCT0000120617	NCT00001206_17_T5	PHENOTYPE	7	7	symptoms
NCT0000120617	NCT00001206_17_T6	PHENOTYPE	16	17	seizure disorders
NCT0000120617	NCT00001206_17_T7	PHENOTYPE	14	15	thyroid disorders
NCT0000120617	NCT00001206_17_T8	PHENOTYPE	23	25	low birth weight
NCT0000120617	NCT00001206_17_T9	PHENOTYPE	18	21	inborn errors of metabolism
NCT0000120627	NCT00001206_27_T0	PHENOTYPE	3	5	other psychiatric disorders
NCT0000120629	NCT00001206_29_T0	PHENOTYPE	12	12	ADHD
NCT0000120629	NCT00001206_29_T1	PHENOTYPE	35	35	pathology
NCT0000120629	NCT00001206_29_T2	GENE	32	32	gm
NCT0000120629	NCT00001206_29_T3	PHENOTYPE	33	33	meningitis
NCT0000120629	NCT00001206_29_T4	PHENOTYPE	0	0	Onset
NCT0000120629	NCT00001206_29_T5	PHENOTYPE	10	10	symptoms
NCT0000120629	NCT00001206_29_T6	BIOLOGICAL_PROCESS	24	24	metabolism
NCT0000120629	NCT00001206_29_T7	PHENOTYPE	19	20	seizure disorders
NCT0000120629	NCT00001206_29_T8	PHENOTYPE	17	18	thyroid disorders
NCT0000120629	NCT00001206_29_T9	PHENOTYPE	26	28	low birth weight
NCT000012081	NCT00001208_1_T0	GENE	10	10	toxin
NCT000012082	NCT00001208_2_T0	PHENOTYPE	4	4	symptoms
NCT000012082	NCT00001208_2_T1	GENE	1	1	toxin
NCT000012082	NCT00001208_2_T2	PHENOTYPE	6	7	food poisoning
NCT000012083	NCT00001208_3_T0	PHENOTYPE	15	15	stuttering
NCT000012083	NCT00001208_3_T1	TISSUE	20	20	muscles
NCT000012083	NCT00001208_3_T2	GENE	4	4	toxin
NCT000012083	NCT00001208_3_T3	ORGAN	23	23	eyes
NCT000012083	NCT00001208_3_T4	PHENOTYPE	11	12	speech disorders
NCT000012084	NCT00001208_4_T0	GENE	7	7	toxin
NCT000012084	NCT00001208_4_T1	PHENOTYPE	14	15	movement disorders
NCT000012085	NCT00001208_5_T0	GENE	24	24	toxin
NCT000012085	NCT00001208_5_T1	GENE	39	39	toxin
NCT000012085	NCT00001208_5_T2	PHENOTYPE	27	28	movement disorders
NCT000012087	NCT00001208_7_T0	GENE	4	4	toxin
NCT000012087	NCT00001208_7_T1	PHENOTYPE	7	8	movement disorders
NCT000012088	NCT00001208_8_T0	GENE	32	32	toxin
NCT000012088	NCT00001208_8_T1	GENE	53	53	toxin
NCT000012088	NCT00001208_8_T2	PHENOTYPE	42	42	physiology
NCT000012088	NCT00001208_8_T3	PHENOTYPE	13	14	movement disorders
NCT000012088	NCT00001208_8_T4	PHENOTYPE	23	24	movement disorders
NCT0000120810	NCT00001208_10_T0	GENE	29	29	BTX
NCT000012098	NCT00001209_8_T0	GENE	9	9	4.0
NCT000012098	NCT00001209_8_T1	COMPOUND	5	5	bilirubin
NCT000012112	NCT00001211_2_T0	PHENOTYPE	5	5	perceived
NCT000012112	NCT00001211_2_T1	BIOLOGICAL_PROCESS	8	8	chewing
NCT000012112	NCT00001211_2_T2	PHENOTYPE	1	2	Body image
NCT000012113	NCT00001211_3_T0	PHENOTYPE	20	21	Ectodermal Dysplasia
NCT000012113	NCT00001211_3_T1	PHENOTYPE	16	17	missing teeth
NCT000012114	NCT00001211_4_T0	ORGAN	4	4	teeth
NCT000012118	NCT00001211_8_T0	PHENOTYPE	5	5	perceived
NCT000012118	NCT00001211_8_T1	BIOLOGICAL_PROCESS	8	8	chewing
NCT000012118	NCT00001211_8_T2	PHENOTYPE	1	2	Body image
NCT000012119	NCT00001211_9_T0	PHENOTYPE	20	21	Ectodermal Dysplasia
NCT000012119	NCT00001211_9_T1	PHENOTYPE	16	17	missing teeth
NCT0000121110	NCT00001211_10_T0	ORGAN	4	4	teeth
NCT000012120	NCT00001212_0_T0	PHENOTYPE	3	3	Lupus
NCT000012120	NCT00001212_0_T1	PHENOTYPE	4	4	Nephropathy
NCT000012122	NCT00001212_2_T0	PHENOTYPE	17	18	kidney failure
NCT000012123	NCT00001212_3_T0	PHENOTYPE	7	7	toxic
NCT000012123	NCT00001212_3_T1	PHENOTYPE	18	18	nephropathy
NCT000012123	NCT00001212_3_T2	PHENOTYPE	17	17	lupus
NCT000012124	NCT00001212_4_T0	PHENOTYPE	14	15	kidney failure
NCT000012127	NCT00001212_7_T0	PHENOTYPE	9	9	severity
NCT000012127	NCT00001212_7_T1	ORGAN	16	16	kidney
NCT000012129	NCT00001212_9_T0	COMPOUND	11	11	cyclophosphamide
NCT000012129	NCT00001212_9_T1	COMPOUND	12	12	cyclosporin
NCT000012129	NCT00001212_9_T2	COMPOUND	10	10	prednisone
NCT0000121215	NCT00001212_15_T0	COMPOUND	18	18	cyclophosphamide
NCT0000121215	NCT00001212_15_T1	COMPOUND	12	12	prednisone
NCT0000121215	NCT00001212_15_T2	COMPOUND	16	16	prednisone
NCT0000121215	NCT00001212_15_T3	BIOLOGICAL_PROCESS	2	3	glomerular filtration
NCT0000121216	NCT00001212_16_T0	GENE	16	16	GFR
NCT0000121217	NCT00001212_17_T0	PHENOTYPE	18	18	toxicities
NCT0000121222	NCT00001212_22_T0	PHENOTYPE	8	8	nephropathy
NCT0000121222	NCT00001212_22_T1	PHENOTYPE	7	7	lupus
NCT0000121225	NCT00001212_25_T0	PHENOTYPE	1	1	acute
NCT0000121225	NCT00001212_25_T1	GENE	12	12	eg
NCT0000121225	NCT00001212_25_T2	PHENOTYPE	13	13	hepatitis
NCT0000121225	NCT00001212_25_T3	PHENOTYPE	14	15	herpes zoster
NCT0000121225	NCT00001212_25_T4	PHENOTYPE	3	4	chronic infection
NCT0000121227	NCT00001212_27_T0	ORGAN	5	5	kidney
NCT0000121228	NCT00001212_28_T0	PHENOTYPE	1	1	malignancy
NCT0000121230	NCT00001212_30_T0	GENE	0	0	GFR
NCT0000121231	NCT00001212_31_T0	PHENOTYPE	1	1	toxicity
NCT0000121231	NCT00001212_31_T1	COMPOUND	3	3	cyclophosphamide
NCT0000121232	NCT00001212_32_T0	PHENOTYPE	3	4	HIV infection
NCT000012131	NCT00001213_1_T0	CELL	19	19	cells
NCT000012131	NCT00001213_1_T1	TISSUE	23	23	tissues
NCT000012131	NCT00001213_1_T2	ORGAN	4	4	kidneys
NCT000012133	NCT00001213_3_T0	ORGAN	6	6	corneas
NCT0000121314	NCT00001213_14_T0	COMPOUND	10	10	cysteamine
NCT0000121314	NCT00001213_14_T1	ORGAN	16	16	eyes
NCT0000121315	NCT00001213_15_T0	PHENOTYPE	15	15	cystinosis
NCT0000121318	NCT00001213_18_T0	PHENOTYPE	23	23	cystinosis
NCT0000121318	NCT00001213_18_T1	CELL	10	10	cells
NCT0000121318	NCT00001213_18_T2	CELL	7	7	leukocytes
NCT0000121318	NCT00001213_18_T3	COMPOUND	4	4	cysteamine
NCT0000121319	NCT00001213_19_T0	TISSUE	5	5	tissues
NCT0000121321	NCT00001213_21_T0	COMPOUND	7	7	cysteamine
NCT0000121321	NCT00001213_21_T1	PHENOTYPE	21	22	corneal crystals
NCT0000121321	NCT00001213_21_T2	COMPOUND	12	13	benzalkonium chloride
NCT0000121322	NCT00001213_22_T0	COMPOUND	10	10	cysteamine
NCT0000121322	NCT00001213_22_T1	PHENOTYPE	15	16	nephropathic cystinosis
NCT0000121324	NCT00001213_24_T0	PHENOTYPE	18	18	cystinosis
NCT0000121326	NCT00001213_26_T0	COMPOUND	6	6	cysteamine
NCT0000121326	NCT00001213_26_T1	ORGAN	18	18	eyes
NCT0000121326	NCT00001213_26_T2	COMPOUND	11	12	benzalkonium chloride
NCT0000121330	NCT00001213_30_T0	PHENOTYPE	13	14	corneal crystals
NCT0000121331	NCT00001213_31_T0	GENE	1	1	hoc
NCT000012140	NCT00001214_0_T0	PHENOTYPE	6	6	Pancytopenia
NCT000012142	NCT00001214_2_T0	CELL	11	11	platelets
NCT000012142	NCT00001214_2_T1	PHENOTYPE	18	19	aplastic anemia
NCT000012142	NCT00001214_2_T2	CELL	7	9	red blood cells
NCT000012142	NCT00001214_2_T3	CELL	4	6	white blood cells
NCT000012143	NCT00001214_3_T0	ORGAN	16	17	immune system
NCT000012143	NCT00001214_3_T1	CELL	6	7	blood cells
NCT000012143	NCT00001214_3_T2	PHENOTYPE	10	11	aplastic anemia
NCT000012144	NCT00001214_4_T0	CELL	16	16	cells
NCT000012144	NCT00001214_4_T1	CELL	4	5	blood cells
NCT000012144	NCT00001214_4_T2	CELL	12	14	white blood cells
NCT000012145	NCT00001214_5_T0	CELL	6	6	lymphocytes
NCT000012145	NCT00001214_5_T1	PHENOTYPE	16	16	pancytopenia
NCT000012145	NCT00001214_5_T2	CELL	14	15	blood cells
NCT000012148	NCT00001214_8_T0	CELL	17	17	platelets
NCT000012148	NCT00001214_8_T1	CELL	13	15	red blood cells
NCT000012148	NCT00001214_8_T2	CELL	1	3	white blood cells
NCT0000121410	NCT00001214_10_T0	CELL	1	1	cells
NCT0000121410	NCT00001214_10_T1	PHENOTYPE	16	16	diseases
NCT0000121410	NCT00001214_10_T2	PHENOTYPE	18	19	aplastic anemia
NCT0000121412	NCT00001214_12_T0	PHENOTYPE	13	13	peripheral
NCT0000121412	NCT00001214_12_T1	CELL	16	16	cells
NCT0000121412	NCT00001214_12_T2	GENE	7	7	has
NCT0000121413	NCT00001214_13_T0	CELL	16	16	cells
NCT0000121413	NCT00001214_13_T1	CELL	21	21	cells
NCT0000121413	NCT00001214_13_T2	GENE	18	18	1.2
NCT000012151	NCT00001215_1_T0	PHENOTYPE	11	12	Gaucher disease
NCT000012151	NCT00001215_1_T1	PHENOTYPE	17	19	lysosomal storage disorders
NCT000012152	NCT00001215_2_T0	PHENOTYPE	7	7	disorders
NCT000012152	NCT00001215_2_T1	PHENOTYPE	27	27	disorders
NCT000012156	NCT00001215_6_T0	CELL	26	26	cells
NCT000012156	NCT00001215_6_T1	CELL	24	24	lysosomes
NCT000012156	NCT00001215_6_T2	PHENOTYPE	0	2	Lysosomal storage disorders
NCT000012157	NCT00001215_7_T0	PHENOTYPE	15	15	disorders
NCT000012157	NCT00001215_7_T1	PHENOTYPE	10	11	Gaucher disease
NCT000012158	NCT00001215_8_T0	GENE	16	16	glucocerebrosidase
NCT000012158	NCT00001215_8_T1	PHENOTYPE	0	1	Gaucher disease
NCT000012158	NCT00001215_8_T2	PHENOTYPE	5	7	lysosomal storage disorder
NCT000012159	NCT00001215_9_T0	PHENOTYPE	18	18	complications
NCT000012159	NCT00001215_9_T1	PHENOTYPE	20	21	Gaucher disease
NCT0000121510	NCT00001215_10_T0	PHENOTYPE	8	8	thrombocytopenia
NCT0000121510	NCT00001215_10_T1	PHENOTYPE	6	6	hepatosplenomegaly
NCT0000121510	NCT00001215_10_T2	PHENOTYPE	7	7	anemia
NCT0000121510	NCT00001215_10_T3	PHENOTYPE	3	4	Gaucher disease
NCT0000121511	NCT00001215_11_T0	PHENOTYPE	29	29	Acute
NCT0000121511	NCT00001215_11_T1	PHENOTYPE	21	21	progression
NCT0000121511	NCT00001215_11_T2	PHENOTYPE	79	79	disorders
NCT0000121511	NCT00001215_11_T3	PHENOTYPE	35	35	Chronic
NCT0000121511	NCT00001215_11_T4	GENE	26	26	TAB
NCT0000121511	NCT00001215_11_T5	GENE	32	32	TAB
NCT0000121511	NCT00001215_11_T6	GENE	2	2	has
NCT0000121511	NCT00001215_11_T7	PHENOTYPE	75	76	Parkinson disease
NCT0000121511	NCT00001215_11_T8	PHENOTYPE	0	1	Gaucher disease
NCT0000121511	NCT00001215_11_T9	PHENOTYPE	55	56	Gaucher disease
NCT0000121511	NCT00001215_11_T10	PHENOTYPE	67	68	Gaucher disease
NCT0000121512	NCT00001215_12_T0	PHENOTYPE	18	18	severity
NCT0000121512	NCT00001215_12_T1	PHENOTYPE	22	24	lysosomal storage disorders
NCT0000121513	NCT00001215_13_T0	PHENOTYPE	14	14	parkinsonism
NCT0000121513	NCT00001215_13_T1	PHENOTYPE	5	6	motor manifestations
NCT0000121515	NCT00001215_15_T0	GENE	27	27	atypical
NCT0000121516	NCT00001215_16_T0	PHENOTYPE	11	11	parkinsonism
NCT0000121516	NCT00001215_16_T1	PHENOTYPE	20	20	disorders
NCT0000121516	NCT00001215_16_T2	PHENOTYPE	8	9	Gaucher disease
NCT000012163	NCT00001216_3_T0	ORGAN	7	7	scalp
NCT000012164	NCT00001216_4_T0	TISSUE	17	17	muscles
NCT000012167	NCT00001216_7_T0	PHENOTYPE	24	25	neurological disorders
NCT000012167	NCT00001216_7_T1	ORGAN	14	16	peripheral nervous system
NCT0000121611	NCT00001216_11_T0	PHENOTYPE	17	17	syndromes
NCT0000121612	NCT00001216_12_T0	GENE	15	15	TES
NCT0000121613	NCT00001216_13_T0	GENE	4	4	lines
NCT0000121614	NCT00001216_14_T0	PHENOTYPE	39	39	trauma
NCT0000121614	NCT00001216_14_T1	PHENOTYPE	29	29	peripheral
NCT0000121614	NCT00001216_14_T2	PHENOTYPE	36	36	hemiplegia
NCT0000121614	NCT00001216_14_T3	PHENOTYPE	49	49	hemiplegia
NCT0000121614	NCT00001216_14_T4	PHENOTYPE	42	42	focal
NCT0000121614	NCT00001216_14_T5	PHENOTYPE	40	40	tumor
NCT0000121614	NCT00001216_14_T6	PHENOTYPE	43	43	demyelination
NCT0000121614	NCT00001216_14_T7	PHENOTYPE	25	25	syndromes
NCT0000121614	NCT00001216_14_T8	ORGAN	52	53	peripheral nerve
NCT0000121614	NCT00001216_14_T9	PHENOTYPE	56	58	spinal cord injury
NCT0000121614	NCT00001216_14_T10	ORGAN	31	33	central nervous system
NCT000012170	NCT00001217_0_T0	PHENOTYPE	0	0	Osteosarcoma
NCT000012170	NCT00001217_0_T1	PHENOTYPE	20	20	Osteosarcoma
NCT000012172	NCT00001217_2_T0	ORGAN	29	29	limb
NCT000012174	NCT00001217_4_T0	ORGAN	29	29	limb
NCT0000121710	NCT00001217_10_T0	PHENOTYPE	5	5	osteosarcoma
NCT0000121710	NCT00001217_10_T1	PHENOTYPE	3	4	high grade
NCT0000121711	NCT00001217_11_T0	PHENOTYPE	5	5	osteosarcoma
NCT0000121711	NCT00001217_11_T1	PHENOTYPE	9	9	osteosarcoma
NCT0000121711	NCT00001217_11_T2	PHENOTYPE	14	14	osteosarcoma
NCT0000121713	NCT00001217_13_T0	PHENOTYPE	3	3	metastases
NCT0000121713	NCT00001217_13_T1	GENE	5	5	PE
NCT0000121713	NCT00001217_13_T2	GENE	6	6	CXR
NCT0000121714	NCT00001217_14_T0	ORGAN	0	0	Chest
NCT0000121715	NCT00001217_15_T0	PHENOTYPE	0	0	Abnormalities
NCT000012193	NCT00001219_3_T0	GENE	5	5	MRI
NCT000012194	NCT00001219_4_T0	GENE	0	0	MRI
NCT000012194	NCT00001219_4_T1	GENE	1	1	has
NCT000012194	NCT00001219_4_T2	PHENOTYPE	12	13	multiple sclerosis
NCT000012195	NCT00001219_5_T0	PHENOTYPE	16	16	diseases
NCT000012198	NCT00001219_8_T0	PHENOTYPE	0	0	Pulse
NCT0000121911	NCT00001219_11_T0	GENE	23	23	MRI
NCT0000121912	NCT00001219_12_T0	PHENOTYPE	13	13	pulse
NCT000012204	NCT00001220_4_T0	BIOLOGICAL_PROCESS	9	9	chewing
NCT000012209	NCT00001220_9_T0	ORGAN	28	28	pharynx
NCT000012209	NCT00001220_9_T1	GENE	9	9	1.2
NCT000012209	NCT00001220_9_T2	COMPOUND	1	1	barium
NCT000012209	NCT00001220_9_T3	COMPOUND	13	13	barium
NCT000012209	NCT00001220_9_T4	ORGAN	36	36	esophagus
NCT0000122010	NCT00001220_10_T0	COMPOUND	1	1	barium
NCT0000122018	NCT00001220_18_T0	GENE	25	25	neuromuscular
NCT0000122018	NCT00001220_18_T1	GENE	11	11	swallow
NCT0000122021	NCT00001220_21_T0	GENE	9	9	swallow
NCT0000122021	NCT00001220_21_T1	PHENOTYPE	3	3	physiology
NCT0000122021	NCT00001220_21_T2	GENE	10	10	has
NCT0000122021	NCT00001220_21_T3	BIOLOGICAL_PROCESS	39	39	eating
NCT0000122022	NCT00001220_22_T0	ORGAN	20	20	larynx
NCT0000122022	NCT00001220_22_T1	BIOLOGICAL_PROCESS	25	25	drinking
NCT0000122022	NCT00001220_22_T2	ORGAN	22	22	pharynx
NCT0000122023	NCT00001220_23_T0	PHENOTYPE	19	19	dysphagia
NCT0000122023	NCT00001220_23_T1	GENE	5	5	paired
NCT0000122024	NCT00001220_24_T0	GENE	24	24	swallow
NCT0000122026	NCT00001220_26_T0	PHENOTYPE	14	14	self-assessment
NCT0000122026	NCT00001220_26_T1	PHENOTYPE	6	6	dysfunction
NCT0000122027	NCT00001220_27_T0	PHENOTYPE	12	12	impairment
NCT0000122027	NCT00001220_27_T1	PHENOTYPE	8	8	dysphagia
NCT0000122027	NCT00001220_27_T2	PHENOTYPE	23	24	Difficulty swallowing
NCT0000122027	NCT00001220_27_T3	PHENOTYPE	4	6	signs and symptoms
NCT0000122029	NCT00001220_29_T0	BIOLOGICAL_PROCESS	4	4	eating
NCT0000122029	NCT00001220_29_T1	PHENOTYPE	0	0	Coughing
NCT0000122029	NCT00001220_29_T2	PHENOTYPE	2	2	choking
NCT0000122030	NCT00001220_30_T0	PHENOTYPE	0	2	Shortness of breath
NCT0000122032	NCT00001220_32_T0	PHENOTYPE	0	0	Fever
NCT0000122034	NCT00001220_34_T0	PHENOTYPE	1	3	loss of weight
NCT0000122035	NCT00001220_35_T0	PHENOTYPE	6	6	demented
NCT0000122035	NCT00001220_35_T1	PHENOTYPE	5	5	severely
NCT0000122035	NCT00001220_35_T2	PHENOTYPE	8	8	severely
NCT0000122035	NCT00001220_35_T3	PHENOTYPE	19	20	cognitive ability
NCT0000122037	NCT00001220_37_T0	PHENOTYPE	1	1	agitated
NCT000012215	NCT00001221_5_T0	COMPOUND	7	7	estrogen
NCT000012216	NCT00001221_6_T0	PHENOTYPE	10	10	feminization
NCT0000122111	NCT00001221_11_T0	COMPOUND	6	6	estrogen
NCT0000122117	NCT00001221_17_T0	ORGAN	14	14	spine
NCT0000122117	NCT00001221_17_T1	ORGAN	16	16	forearm
NCT0000122121	NCT00001221_21_T0	GENE	11	11	has
NCT0000122121	NCT00001221_21_T1	GENE	5	5	hormone
NCT0000122126	NCT00001221_26_T0	PHENOTYPE	31	31	secondary
NCT0000122126	NCT00001221_26_T1	COMPOUND	5	5	estrogen
NCT0000122126	NCT00001221_26_T2	COMPOUND	20	20	estrogen
NCT0000122140	NCT00001221_40_T0	COMPOUND	8	8	androgen
NCT0000122140	NCT00001221_40_T1	COMPOUND	6	6	estrogen
NCT0000122141	NCT00001221_41_T0	CELL	8	8	chromosome
NCT0000122144	NCT00001221_44_T0	PHENOTYPE	17	17	malignancy
NCT0000122144	NCT00001221_44_T1	GENE	15	15	had
NCT0000122144	NCT00001221_44_T2	PHENOTYPE	10	11	renal disease
NCT0000122145	NCT00001221_45_T0	PHENOTYPE	4	4	hematuria
NCT0000122145	NCT00001221_45_T1	PHENOTYPE	6	6	proteinuria
NCT0000122147	NCT00001221_47_T0	PHENOTYPE	7	7	tuberculosis
NCT0000122147	NCT00001221_47_T1	PHENOTYPE	5	6	chronic infection
NCT000012231	NCT00001223_1_T0	PHENOTYPE	18	19	cystic fibrosis
NCT000012232	NCT00001223_2_T0	PHENOTYPE	2	3	cystic fibrosis
NCT000012233	NCT00001223_3_T0	ORGAN	27	27	pancreas
NCT000012233	NCT00001223_3_T1	PHENOTYPE	18	18	sweat
NCT000012233	NCT00001223_3_T2	PHENOTYPE	35	35	sweat
NCT000012233	NCT00001223_3_T3	PHENOTYPE	23	24	cystic fibrosis
NCT000012238	NCT00001223_8_T0	PHENOTYPE	20	21	cystic fibrosis
NCT000012239	NCT00001223_9_T0	PHENOTYPE	17	18	cystic fibrosis
NCT0000122311	NCT00001223_11_T0	PHENOTYPE	23	24	cystic fibrosis
NCT0000122312	NCT00001223_12_T0	PHENOTYPE	6	7	cystic fibrosis
NCT0000122312	NCT00001223_12_T1	PHENOTYPE	28	29	cystic fibrosis
NCT0000122412	NCT00001224_12_T0	PHENOTYPE	5	5	peripheral
NCT0000122412	NCT00001224_12_T1	CELL	1	2	lymphocyte subsets
NCT0000122417	NCT00001224_17_T0	PHENOTYPE	8	8	uveitis
NCT0000122418	NCT00001224_18_T0	PHENOTYPE	7	7	opacities
NCT0000122418	NCT00001224_18_T1	GENE	22	22	has
NCT0000122418	NCT00001224_18_T2	PHENOTYPE	21	21	opacity
NCT000012251	NCT00001225_1_T0	ORGAN	16	16	heart
NCT000012251	NCT00001225_1_T1	TISSUE	4	5	heart muscle
NCT000012251	NCT00001225_1_T2	ORGAN	18	19	left ventricle
NCT000012252	NCT00001225_2_T0	PHENOTYPE	9	10	sudden death
NCT000012252	NCT00001225_2_T1	PHENOTYPE	0	1	Hypertrophic cardiomyopathy
NCT000012253	NCT00001225_3_T0	PHENOTYPE	13	13	diseases
NCT000012256	NCT00001225_6_T0	ORGAN	21	21	heart
NCT000012258	NCT00001225_8_T0	GENE	21	21	beta-MHC
NCT000012258	NCT00001225_8_T1	PHENOTYPE	10	11	heart disease
NCT000012259	NCT00001225_9_T0	GENE	14	14	beta-MHC
NCT0000122511	NCT00001225_11_T0	PHENOTYPE	5	5	localize
NCT0000122511	NCT00001225_11_T1	PHENOTYPE	11	12	autosomal dominant
NCT0000122515	NCT00001225_15_T0	PHENOTYPE	3	3	localizing
NCT0000122516	NCT00001225_16_T0	GENE	5	5	beta-MHC
NCT0000122516	NCT00001225_16_T1	GENE	7	7	has
NCT0000122516	NCT00001225_16_T2	GENE	1	4	beta myosin heavy chain
NCT0000122518	NCT00001225_18_T0	GENE	8	8	beta-MHC
NCT0000122519	NCT00001225_19_T0	PHENOTYPE	12	12	physiology
NCT0000122519	NCT00001225_19_T1	GENE	1	1	has
NCT0000122519	NCT00001225_19_T2	TISSUE	6	7	skeletal muscle
NCT0000122520	NCT00001225_20_T0	GENE	34	34	beta-MHC
NCT000012260	NCT00001226_0_T0	BIOLOGICAL_PROCESS	0	1	Lipoprotein Metabolism
NCT0000122611	NCT00001226_11_T0	BIOLOGICAL_PROCESS	19	19	metabolism
NCT000012280	NCT00001228_0_T0	GENE	0	0	Interferon
NCT000012280	NCT00001228_0_T1	PHENOTYPE	5	6	Zollinger-Ellison Syndrome
NCT000012280	NCT00001228_0_T2	PHENOTYPE	10	12	Islet Cell Cancer
NCT000012282	NCT00001228_2_T0	ORGAN	7	7	pancreas
NCT000012282	NCT00001228_2_T1	PHENOTYPE	3	3	tumor
NCT000012282	NCT00001228_2_T2	PHENOTYPE	0	0	Gastrinoma
NCT000012282	NCT00001228_2_T3	PHENOTYPE	23	23	ulcers
NCT000012282	NCT00001228_2_T4	GENE	12	12	gastrin
NCT000012282	NCT00001228_2_T5	GENE	11	11	hormone
NCT000012283	NCT00001228_3_T0	PHENOTYPE	3	3	tumors
NCT000012284	NCT00001228_4_T0	PHENOTYPE	0	0	Gastrinomas
NCT0000122810	NCT00001228_10_T0	COMPOUND	6	6	octreotide
NCT0000122812	NCT00001228_12_T0	PHENOTYPE	2	2	tumors
NCT0000122819	NCT00001228_19_T0	GENE	28	28	interferon-alpha
NCT0000122819	NCT00001228_19_T1	GENE	11	11	has
NCT0000122819	NCT00001228_19_T2	PHENOTYPE	3	3	gastrinoma
NCT0000122821	NCT00001228_21_T0	PHENOTYPE	0	0	Tumor
NCT0000122822	NCT00001228_22_T0	PHENOTYPE	15	15	tumor
NCT0000122824	NCT00001228_24_T0	PHENOTYPE	38	38	progression
NCT0000122824	NCT00001228_24_T1	COMPOUND	14	14	1
NCT0000122824	NCT00001228_24_T2	COMPOUND	18	18	2
NCT0000122824	NCT00001228_24_T3	COMPOUND	12	12	3
NCT0000122824	NCT00001228_24_T4	COMPOUND	37	37	3
NCT0000122824	NCT00001228_24_T5	PHENOTYPE	40	40	tumor
NCT0000122824	NCT00001228_24_T6	PHENOTYPE	17	17	gastrinoma
NCT0000122824	NCT00001228_24_T7	PHENOTYPE	21	22	metastatic tumor
NCT0000122826	NCT00001228_26_T0	PHENOTYPE	0	2	Congestive heart failure
NCT0000122829	NCT00001228_29_T0	PHENOTYPE	0	1	Platelet count
NCT0000122832	NCT00001228_32_T0	PHENOTYPE	3	3	HIV
NCT0000122833	NCT00001228_33_T0	COMPOUND	4	4	octreotide
NCT000012292	NCT00001229_2_T0	COMPOUND	8	8	norepinephrine
NCT000012292	NCT00001229_2_T1	COMPOUND	6	6	epinephrine
NCT000012292	NCT00001229_2_T2	PHENOTYPE	1	1	pheochromocytomas
NCT000012294	NCT00001229_4_T0	PHENOTYPE	1	1	tumors
NCT000012295	NCT00001229_5_T0	PHENOTYPE	2	2	pheochromocytoma
NCT000012295	NCT00001229_5_T1	PHENOTYPE	14	15	heart attack
NCT000012296	NCT00001229_6_T0	PHENOTYPE	10	10	pheochromocytoma
NCT000012297	NCT00001229_7_T0	PHENOTYPE	13	13	suppression
NCT000012297	NCT00001229_7_T1	COMPOUND	12	12	clonidine
NCT000012297	NCT00001229_7_T2	GENE	16	16	glucagon
NCT000012299	NCT00001229_9_T0	PHENOTYPE	21	21	tumor
NCT0000122911	NCT00001229_11_T0	PHENOTYPE	7	7	suppression
NCT0000122911	NCT00001229_11_T1	COMPOUND	6	6	clonidine
NCT0000122911	NCT00001229_11_T2	GENE	12	12	glucagon
NCT0000122913	NCT00001229_13_T0	PHENOTYPE	19	19	pheochromocytoma
NCT0000122913	NCT00001229_13_T1	ORGAN	2	2	plasma
NCT000012301	NCT00001230_1_T0	PHENOTYPE	1	1	infections
NCT000012302	NCT00001230_2_T0	PHENOTYPE	5	5	transmitted
NCT000012302	NCT00001230_2_T1	PHENOTYPE	11	12	mosquito bite
NCT000012305	NCT00001230_5_T0	PHENOTYPE	20	20	volvulus
NCT000012305	NCT00001230_5_T1	GENE	21	21	Loa
NCT000012307	NCT00001230_7_T0	ORGAN	7	7	lungs
NCT000012307	NCT00001230_7_T1	ORGAN	10	10	heart
NCT000012308	NCT00001230_8_T0	GENE	7	7	punch
NCT0000123011	NCT00001230_11_T0	COMPOUND	10	10	lidocaine
NCT0000123015	NCT00001230_15_T0	CELL	13	13	cells
NCT0000123015	NCT00001230_15_T1	PHENOTYPE	7	7	withdrawn
NCT0000123016	NCT00001230_16_T0	COMPOUND	30	30	ivermectin
NCT0000123016	NCT00001230_16_T1	COMPOUND	28	28	diethylcarbamazine
NCT0000123020	NCT00001230_20_T0	CELL	15	15	cells
NCT0000123023	NCT00001230_23_T0	GENE	23	23	eg
NCT0000123023	NCT00001230_23_T1	CELL	27	27	clones
NCT0000123023	NCT00001230_23_T2	PHENOTYPE	44	44	pathology
NCT0000123023	NCT00001230_23_T3	CELL	26	26	T-cell
NCT0000123023	NCT00001230_23_T4	ORGAN	16	16	serum
NCT0000123023	NCT00001230_23_T5	CELL	13	14	blood cells
NCT0000123025	NCT00001230_25_T0	PHENOTYPE	14	14	infections
NCT0000123025	NCT00001230_25_T1	PHENOTYPE	42	43	helminth infections
NCT000012312	NCT00001231_2_T0	COMPOUND	6	6	estrogen
NCT000012312	NCT00001231_2_T1	COMPOUND	8	8	progesterone
NCT000012313	NCT00001231_3_T0	PHENOTYPE	13	14	behavioral disorders
NCT000012314	NCT00001231_4_T0	PHENOTYPE	3	4	depression symptoms
NCT000012315	NCT00001231_5_T0	COMPOUND	17	17	phytoestrogens
NCT000012315	NCT00001231_5_T1	GENE	20	21	estrogen receptor
NCT000012315	NCT00001231_5_T2	PHENOTYPE	2	3	depressive symptoms
NCT000012318	NCT00001231_8_T0	PHENOTYPE	30	30	depressions
NCT000012318	NCT00001231_8_T1	PHENOTYPE	34	34	perimenopause
NCT0000123110	NCT00001231_10_T0	PHENOTYPE	29	29	pathophysiology
NCT0000123110	NCT00001231_10_T1	PHENOTYPE	39	39	perimenopause
NCT000012321	NCT00001232_1_T0	ORGAN	1	1	hypothalamus
NCT000012322	NCT00001232_2_T0	GENE	17	17	FSH
NCT000012322	NCT00001232_2_T1	GENE	0	0	GnRH
NCT000012322	NCT00001232_2_T2	GENE	16	16	hormone
NCT000012322	NCT00001232_2_T3	GENE	20	20	hormone
NCT000012322	NCT00001232_2_T4	ORGAN	5	6	pituitary gland
NCT000012323	NCT00001232_3_T0	COMPOUND	18	18	estrogen
NCT000012323	NCT00001232_3_T1	ORGAN	6	6	ovary
NCT000012323	NCT00001232_3_T2	BIOLOGICAL_PROCESS	17	17	menstruation
NCT000012323	NCT00001232_3_T3	COMPOUND	20	20	progesterone
NCT000012323	NCT00001232_3_T4	GENE	2	2	FSH
NCT000012324	NCT00001232_4_T0	GENE	11	11	axis
NCT000012324	NCT00001232_4_T1	GENE	29	29	hormone
NCT000012324	NCT00001232_4_T2	GENE	18	18	FSH
NCT000012324	NCT00001232_4_T3	GENE	30	30	GnRH
NCT000012324	NCT00001232_4_T4	BIOLOGICAL_PROCESS	32	33	menstrual cycle
NCT000012339	NCT00001233_9_T0	PHENOTYPE	15	17	disruptive behavior disorders
NCT0000123313	NCT00001233_13_T0	PHENOTYPE	15	16	behavior problems
NCT0000123319	NCT00001233_19_T0	PHENOTYPE	8	8	emotions
NCT0000123319	NCT00001233_19_T1	PHENOTYPE	14	15	mood disorders
NCT0000123321	NCT00001233_21_T0	GENE	2	2	4.5
NCT0000123322	NCT00001233_22_T0	GENE	16	16	yrs
NCT0000123322	NCT00001233_22_T1	GENE	21	21	yrs
NCT0000123322	NCT00001233_22_T2	GENE	26	26	yrs
NCT0000123322	NCT00001233_22_T3	GENE	31	31	yrs
NCT0000123322	NCT00001233_22_T4	GENE	15	15	6/7
NCT0000123324	NCT00001233_24_T0	PHENOTYPE	1	1	experiences
NCT0000123326	NCT00001233_26_T0	PHENOTYPE	0	1	Behavior problems
NCT000012342	NCT00001234_2_T0	PHENOTYPE	20	21	rapidly progressive
NCT000012342	NCT00001234_2_T1	PHENOTYPE	6	7	Gaucher's Disease
NCT000012342	NCT00001234_2_T2	PHENOTYPE	21	23	progressive neurologic deterioration
NCT000012343	NCT00001234_3_T0	PHENOTYPE	9	11	autosomal recessive inheritance
NCT000012344	NCT00001234_4_T0	GENE	2	2	isa
NCT000012344	NCT00001234_4_T1	PHENOTYPE	3	4	genetic disorder
NCT000012344	NCT00001234_4_T2	PHENOTYPE	0	1	Fabry's disease
NCT000012344	NCT00001234_4_T3	PHENOTYPE	5	6	X-linked recessive
NCT000012345	NCT00001234_5_T0	ORGAN	19	19	thighs
NCT000012345	NCT00001234_5_T1	PHENOTYPE	25	25	tingling
NCT000012345	NCT00001234_5_T2	ORGAN	29	29	extremities
NCT000012345	NCT00001234_5_T3	PHENOTYPE	16	16	tumors
NCT000012345	NCT00001234_5_T4	CELL	10	10	cells
NCT000012345	NCT00001234_5_T5	CELL	11	11	histiocytes
NCT000012345	NCT00001234_5_T6	ORGAN	20	20	buttocks
NCT000012345	NCT00001234_5_T7	PHENOTYPE	31	31	cataracts
NCT000012345	NCT00001234_5_T8	ORGAN	13	14	blood vessel
NCT000012345	NCT00001234_5_T9	PHENOTYPE	23	24	decreased sweating
NCT000012346	NCT00001234_6_T0	ORGAN	9	9	kidney
NCT000012346	NCT00001234_6_T1	PHENOTYPE	6	6	complications
NCT000012346	NCT00001234_6_T2	ORGAN	10	10	heart
NCT000012346	NCT00001234_6_T3	PHENOTYPE	2	3	Fabry's disease
NCT000012348	NCT00001234_8_T0	GENE	9	9	defective
NCT000012349	NCT00001234_9_T0	CELL	4	4	cells
NCT000012349	NCT00001234_9_T1	CELL	27	27	cells
NCT000012349	NCT00001234_9_T2	ORGAN	6	7	bone marrow
NCT0000123410	NCT00001234_10_T0	CELL	23	23	cells
NCT0000123410	NCT00001234_10_T1	PHENOTYPE	29	30	Fabry disease
NCT0000123413	NCT00001234_13_T0	PHENOTYPE	31	32	Gaucher's disease
NCT0000123413	NCT00001234_13_T1	ORGAN	3	4	bone marrow
NCT0000123413	NCT00001234_13_T2	CELL	5	7	hematopoietic progenitor cells
NCT0000123414	NCT00001234_14_T0	GENE	12	12	cDNA
NCT0000123414	NCT00001234_14_T1	GENE	11	11	glucocerebrosidase
NCT0000123415	NCT00001234_15_T0	PHENOTYPE	19	20	Gaucher's Disease
NCT0000123417	NCT00001234_17_T0	CELL	2	2	platelet
NCT0000123417	NCT00001234_17_T1	ORGAN	21	22	bone marrow
NCT0000123418	NCT00001234_18_T0	ORGAN	17	18	bone marrow
NCT0000123418	NCT00001234_18_T1	PHENOTYPE	8	9	Fabry Disease
NCT0000123418	NCT00001234_18_T2	PHENOTYPE	12	13	iron deficiency
NCT0000123418	NCT00001234_18_T3	PHENOTYPE	6	7	Gaucher Disease
NCT0000123418	NCT00001234_18_T4	PHENOTYPE	2	3	hematologic disorders
NCT000012353	NCT00001235_3_T0	GENE	2	2	has
NCT000012354	NCT00001235_4_T0	PHENOTYPE	4	5	Alzheimer's disease
NCT000012355	NCT00001235_5_T0	PHENOTYPE	3	4	Alzheimer's disease
NCT000012356	NCT00001235_6_T0	PHENOTYPE	15	16	Alzheimer's disease
NCT000012356	NCT00001235_6_T1	PHENOTYPE	19	20	neurological disorders
NCT000012359	NCT00001235_9_T0	PHENOTYPE	20	20	diseases
NCT0000123510	NCT00001235_10_T0	PHENOTYPE	10	10	diseases
NCT0000123515	NCT00001235_15_T0	PHENOTYPE	17	17	diseases
NCT000012372	NCT00001237_2_T0	PHENOTYPE	17	17	resistant
NCT000012373	NCT00001237_3_T0	GENE	10	10	GM-CSF
NCT000012373	NCT00001237_3_T1	GENE	6	9	granulocyte-macrophage colony stimulating factor
NCT000012377	NCT00001237_7_T0	PHENOTYPE	17	17	resistant
NCT000012378	NCT00001237_8_T0	GENE	10	10	GM-CSF
NCT000012378	NCT00001237_8_T1	GENE	6	9	granulocyte-macrophage colony stimulating factor
NCT0000123714	NCT00001237_14_T0	PHENOTYPE	4	4	lymphomas
NCT0000123714	NCT00001237_14_T1	PHENOTYPE	8	9	follicular lymphomas
NCT0000123716	NCT00001237_16_T0	PHENOTYPE	6	6	lymphoma
NCT0000123716	NCT00001237_16_T1	PHENOTYPE	12	12	lymphoma
NCT0000123718	NCT00001237_18_T0	PHENOTYPE	3	4	HIV infection
NCT000012381	NCT00001238_1_T0	PHENOTYPE	3	3	malignancy
NCT000012383	NCT00001238_3_T0	GENE	16	16	has
NCT000012389	NCT00001238_9_T0	PHENOTYPE	2	2	Center
NCT000012392	NCT00001239_2_T0	GENE	15	15	MTD
NCT000012393	NCT00001239_3_T0	GENE	4	4	II
NCT000012393	NCT00001239_3_T1	PHENOTYPE	15	16	breast cancer
NCT000012396	NCT00001239_6_T0	GENE	15	15	MTD
NCT000012397	NCT00001239_7_T0	GENE	4	4	II
NCT000012397	NCT00001239_7_T1	PHENOTYPE	15	16	breast cancer
NCT000012399	NCT00001239_9_T0	PHENOTYPE	2	3	stage III
NCT0000123910	NCT00001239_10_T0	GENE	3	3	IV
NCT0000123910	NCT00001239_10_T1	PHENOTYPE	5	6	breast cancer
NCT0000123911	NCT00001239_11_T0	GENE	11	11	Dr
NCT0000123912	NCT00001239_12_T0	GENE	2	2	III
NCT0000123913	NCT00001239_13_T0	GENE	9	9	had
NCT0000123913	NCT00001239_13_T1	GENE	1	1	IV
NCT0000123914	NCT00001239_14_T0	GENE	16	16	II
NCT0000123915	NCT00001239_15_T0	GENE	3	3	had
NCT0000123918	NCT00001239_18_T0	PHENOTYPE	18	18	tumor
NCT0000123918	NCT00001239_18_T1	GENE	0	0	WBC
NCT0000123918	NCT00001239_18_T2	PHENOTYPE	6	7	platelet count
NCT0000123918	NCT00001239_18_T3	ORGAN	14	15	bone marrow
NCT000012411	NCT00001241_1_T0	PHENOTYPE	10	10	symptoms
NCT000012416	NCT00001241_6_T0	PHENOTYPE	33	34	pancreatic tumors
NCT000012418	NCT00001241_8_T0	COMPOUND	28	28	histamine
NCT000012419	NCT00001241_9_T0	COMPOUND	21	21	ranitidine
NCT000012419	NCT00001241_9_T1	COMPOUND	24	24	famotidine
NCT000012419	NCT00001241_9_T2	COMPOUND	22	22	nizatidine
NCT000012419	NCT00001241_9_T3	COMPOUND	20	20	cimetidine
NCT0000124110	NCT00001241_10_T0	COMPOUND	14	14	histamine
NCT0000124110	NCT00001241_10_T1	GENE	15	15	H2
NCT000012421	NCT00001242_1_T0	COMPOUND	9	9	calcium
NCT000012421	NCT00001242_1_T1	TISSUE	15	15	bones
NCT000012425	NCT00001242_5_T0	PHENOTYPE	5	5	osteomalacia
NCT000012425	NCT00001242_5_T1	PHENOTYPE	6	6	pseudohypoparathyroidism
NCT000012425	NCT00001242_5_T2	PHENOTYPE	3	3	hypocalcemia
NCT000012425	NCT00001242_5_T3	PHENOTYPE	4	4	rickets
NCT000012427	NCT00001242_7_T0	BIOLOGICAL_PROCESS	9	9	metabolism
NCT000012428	NCT00001242_8_T0	COMPOUND	7	7	calcium
NCT000012428	NCT00001242_8_T1	COMPOUND	8	8	phosphate
NCT000012428	NCT00001242_8_T2	COMPOUND	11	12	vitamin D
NCT000012430	NCT00001243_0_T0	PHENOTYPE	2	2	HIV
NCT000012430	NCT00001243_0_T1	CELL	9	11	Bone Marrow Cells
NCT000012433	NCT00001243_3_T0	PHENOTYPE	0	0	HIV
NCT000012438	NCT00001243_8_T0	ORGAN	20	20	marrow
NCT000012438	NCT00001243_8_T1	PHENOTYPE	25	25	cavity
NCT000012439	NCT00001243_9_T0	ORGAN	3	3	marrow
NCT000012439	NCT00001243_9_T1	CELL	1	1	cells
NCT000012439	NCT00001243_9_T2	PHENOTYPE	11	11	HIV
NCT0000124310	NCT00001243_10_T0	CELL	2	2	cells
NCT0000124310	NCT00001243_10_T1	CELL	11	11	cells
NCT0000124310	NCT00001243_10_T2	PHENOTYPE	13	13	HIV
NCT0000124311	NCT00001243_11_T0	ORGAN	3	3	marrow
NCT0000124311	NCT00001243_11_T1	CELL	1	1	cells
NCT0000124311	NCT00001243_11_T2	CELL	18	18	cells
NCT0000124311	NCT00001243_11_T3	PHENOTYPE	5	5	HIV
NCT0000124312	NCT00001243_12_T0	GENE	0	0	Or
NCT0000124312	NCT00001243_12_T1	PHENOTYPE	18	19	HIV infection
NCT0000124312	NCT00001243_12_T2	CELL	1	3	bone marrow cells
NCT0000124313	NCT00001243_13_T0	ORGAN	14	15	immune system
NCT0000124313	NCT00001243_13_T1	PHENOTYPE	18	19	HIV infection
NCT0000124313	NCT00001243_13_T2	CELL	0	2	White blood cells
NCT0000124317	NCT00001243_17_T0	BIOLOGICAL_PROCESS	33	33	hematopoiesis
NCT0000124317	NCT00001243_17_T1	CELL	8	8	cells
NCT0000124317	NCT00001243_17_T2	CELL	30	30	cells
NCT0000124317	NCT00001243_17_T3	PHENOTYPE	16	16	understood
NCT0000124317	NCT00001243_17_T4	PHENOTYPE	4	5	HIV infection
NCT0000124318	NCT00001243_18_T0	ORGAN	13	14	bone marrow
NCT0000124319	NCT00001243_19_T0	PHENOTYPE	27	27	pathology
NCT0000124319	NCT00001243_19_T1	PHENOTYPE	30	30	HIV
NCT0000124319	NCT00001243_19_T2	ORGAN	22	23	bone marrow
NCT0000124319	NCT00001243_19_T3	PHENOTYPE	13	14	direct infection
NCT0000124319	NCT00001243_19_T4	CELL	16	18	myeloid progenitor cells
NCT0000124321	NCT00001243_21_T0	PHENOTYPE	13	13	HIV
NCT0000124321	NCT00001243_21_T1	CELL	9	11	bone marrow cells
NCT0000124322	NCT00001243_22_T0	PHENOTYPE	11	11	HIV
NCT0000124322	NCT00001243_22_T1	PHENOTYPE	21	21	HIV
NCT0000124323	NCT00001243_23_T0	PHENOTYPE	6	6	HIV
NCT0000124323	NCT00001243_23_T1	GENE	7	7	has
NCT0000124324	NCT00001243_24_T0	ORGAN	8	9	bone marrow
NCT0000124325	NCT00001243_25_T0	BIOLOGICAL_PROCESS	32	32	hematopoiesis
NCT0000124325	NCT00001243_25_T1	PHENOTYPE	19	19	HIV
NCT0000124325	NCT00001243_25_T2	ORGAN	3	4	hematopoietic system
NCT000012444	NCT00001244_4_T0	PHENOTYPE	17	18	lung function
NCT000012445	NCT00001244_5_T0	PHENOTYPE	10	10	infections
NCT000012445	NCT00001244_5_T1	PHENOTYPE	6	7	serum globulin
NCT0000124411	NCT00001244_11_T0	TISSUE	3	4	lymph nodes
NCT0000124413	NCT00001244_13_T0	PHENOTYPE	3	3	closed
NCT0000124418	NCT00001244_18_T0	ORGAN	9	10	small intestine
NCT0000124419	NCT00001244_19_T0	TISSUE	8	9	intestinal mucosa
NCT0000124424	NCT00001244_24_T0	PHENOTYPE	10	10	pulse
NCT0000124430	NCT00001244_30_T0	PHENOTYPE	7	7	immunodeficiencies
NCT0000124433	NCT00001244_33_T0	PHENOTYPE	15	15	complications
NCT000012452	NCT00001245_2_T0	PHENOTYPE	22	22	filariasis
NCT000012453	NCT00001245_3_T0	COMPOUND	15	15	albendazole
NCT000012453	NCT00001245_3_T1	COMPOUND	13	13	thiabendazole
NCT000012453	NCT00001245_3_T2	COMPOUND	12	12	ivermectin
NCT000012458	NCT00001245_8_T0	GENE	15	15	has
NCT0000124513	NCT00001245_13_T0	CELL	2	2	cells
NCT0000124513	NCT00001245_13_T1	ORGAN	0	0	Serum
NCT0000124517	NCT00001245_17_T0	ORGAN	11	11	serum
NCT000012461	NCT00001246_1_T0	GENE	0	0	MRI
NCT000012464	NCT00001246_4_T0	GENE	6	6	MRI
NCT000012464	NCT00001246_4_T1	CELL	16	17	Y chromosome
NCT000012464	NCT00001246_4_T2	PHENOTYPE	27	28	childhood onset
NCT000012464	NCT00001246_4_T3	PHENOTYPE	29	30	psychiatric disorders
NCT0000124612	NCT00001246_12_T0	PHENOTYPE	33	33	Aneuploidy
NCT0000124612	NCT00001246_12_T1	PHENOTYPE	21	22	Childhood-Onset Schizophrenia
NCT0000124612	NCT00001246_12_T2	CELL	31	32	Sex Chromosome
NCT0000124612	NCT00001246_12_T3	PHENOTYPE	23	25	Autism Spectrum Disorder
NCT0000124613	NCT00001246_13_T0	GENE	1	1	span
NCT0000124617	NCT00001246_17_T0	GENE	12	12	structural
NCT0000124618	NCT00001246_18_T0	BIOLOGICAL_PROCESS	13	14	gene expression
NCT0000124622	NCT00001246_22_T0	GENE	2	2	DPA
NCT0000124624	NCT00001246_24_T0	PHENOTYPE	4	4	ADHD
NCT0000124624	NCT00001246_24_T1	PHENOTYPE	17	17	ADHD
NCT0000124624	NCT00001246_24_T2	GENE	3	3	FOR
NCT0000124624	NCT00001246_24_T3	PHENOTYPE	11	12	Mental Disorders
NCT0000124625	NCT00001246_25_T0	PHENOTYPE	4	4	ADHD
NCT0000124625	NCT00001246_25_T1	PHENOTYPE	19	19	Hyperactivity
NCT0000124628	NCT00001246_28_T0	PHENOTYPE	13	13	focused
NCT000012471	NCT00001247_1_T0	PHENOTYPE	15	15	pathophysiology
NCT000012471	NCT00001247_1_T1	PHENOTYPE	0	0	Schizophrenia
NCT000012471	NCT00001247_1_T2	PHENOTYPE	3	3	psychoses
NCT000012471	NCT00001247_1_T3	PHENOTYPE	5	5	chronic
NCT000012471	NCT00001247_1_T4	PHENOTYPE	6	7	brain disorders
NCT000012475	NCT00001247_5_T0	PHENOTYPE	9	9	symptoms
NCT0000124711	NCT00001247_11_T0	GENE	3	3	MRI
NCT0000124711	NCT00001247_11_T1	PHENOTYPE	17	17	affects
NCT0000124714	NCT00001247_14_T0	PHENOTYPE	28	28	pathophysiology
NCT0000124715	NCT00001247_15_T0	PHENOTYPE	10	10	severely
NCT0000124715	NCT00001247_15_T1	PHENOTYPE	7	8	psychotic disorders
NCT0000124717	NCT00001247_17_T0	PHENOTYPE	11	11	schizophrenia
NCT0000124724	NCT00001247_24_T0	PHENOTYPE	25	25	disorders
NCT0000124725	NCT00001247_25_T0	GENE	6	6	MEG
NCT0000124728	NCT00001247_28_T0	PHENOTYPE	28	28	schizophrenia
NCT0000124729	NCT00001247_29_T0	COMPOUND	14	14	dopamine
NCT0000124733	NCT00001247_33_T0	GENE	4	4	half-life
NCT0000124733	NCT00001247_33_T1	COMPOUND	10	11	paliperidone palmitate
NCT0000124736	NCT00001247_36_T0	GENE	13	13	half-life
NCT0000124736	NCT00001247_36_T1	PHENOTYPE	12	12	elimination
NCT000012481	NCT00001248_1_T0	GENE	20	20	MS
NCT000012482	NCT00001248_2_T0	GENE	10	10	MRI
NCT000012483	NCT00001248_3_T0	GENE	13	13	MRI
NCT000012483	NCT00001248_3_T1	GENE	31	31	MRI
NCT000012483	NCT00001248_3_T2	GENE	4	4	MS
NCT000012483	NCT00001248_3_T3	GENE	25	25	MS
NCT000012483	NCT00001248_3_T4	PHENOTYPE	22	22	dysfunction
NCT000012484	NCT00001248_4_T0	GENE	3	3	MRI
NCT000012484	NCT00001248_4_T1	GENE	9	9	MRI
NCT000012484	NCT00001248_4_T2	PHENOTYPE	26	27	brain atrophy
NCT000012485	NCT00001248_5_T0	GENE	20	20	MRI
NCT0000124812	NCT00001248_12_T0	GENE	22	22	MS
NCT0000124812	NCT00001248_12_T1	GENE	36	36	MS
NCT0000124812	NCT00001248_12_T2	GENE	27	27	MT
NCT0000124812	NCT00001248_12_T3	GENE	41	41	MT
NCT0000124812	NCT00001248_12_T4	ORGAN	19	20	white matter
NCT0000124812	NCT00001248_12_T5	ORGAN	33	34	white matter
NCT0000124814	NCT00001248_14_T0	GENE	4	4	MRI
NCT0000124822	NCT00001248_22_T0	GENE	17	17	MS
NCT0000124822	NCT00001248_22_T1	PHENOTYPE	10	10	diseases
NCT0000124822	NCT00001248_22_T2	PHENOTYPE	30	30	leukodystrophies
NCT0000124822	NCT00001248_22_T3	PHENOTYPE	31	32	neurodegenerative diseases
NCT0000124822	NCT00001248_22_T4	PHENOTYPE	28	29	mitochondrial disorders
NCT0000124822	NCT00001248_22_T5	PHENOTYPE	36	37	axonal loss
NCT0000124822	NCT00001248_22_T6	PHENOTYPE	39	40	oxidative stress
NCT0000124822	NCT00001248_22_T7	ORGAN	25	27	central nervous system
NCT0000124823	NCT00001248_23_T0	GENE	16	16	MRI
NCT0000124823	NCT00001248_23_T1	GENE	22	22	MS
NCT000012492	NCT00001249_2_T0	GENE	30	30	ATL
NCT000012492	NCT00001249_2_T1	GENE	13	13	IND
NCT000012493	NCT00001249_3_T0	GENE	12	12	ATL
NCT000012495	NCT00001249_5_T0	PHENOTYPE	6	6	peripheral
NCT000012495	NCT00001249_5_T1	CELL	13	13	cells
NCT000012495	NCT00001249_5_T2	GENE	24	24	receptor
NCT000012495	NCT00001249_5_T3	GENE	23	23	IL-2
NCT000012495	NCT00001249_5_T4	TISSUE	8	9	lymph node
NCT000012497	NCT00001249_7_T0	GENE	3	3	ATL
NCT000012499	NCT00001249_9_T0	CELL	6	6	cells
NCT000012499	NCT00001249_9_T1	GENE	9	9	CSF
NCT000012499	NCT00001249_9_T2	COMPOUND	18	18	methotrexate
NCT0000124912	NCT00001249_12_T0	GENE	0	0	ATL
NCT0000124912	NCT00001249_12_T1	GENE	6	6	had
NCT0000124914	NCT00001249_14_T0	PHENOTYPE	0	0	Endocrine
NCT0000124917	NCT00001249_17_T0	GENE	2	2	Age
NCT0000124920	NCT00001249_20_T0	GENE	1	1	WBC
NCT0000124920	NCT00001249_20_T1	CELL	5	5	Platelets
NCT0000124923	NCT00001249_23_T0	PHENOTYPE	0	0	Other
NCT000012502	NCT00001250_2_T0	PHENOTYPE	3	4	invasive carcinoma
NCT000012503	NCT00001250_3_T0	COMPOUND	11	11	5_fluorouracil
NCT000012503	NCT00001250_3_T1	COMPOUND	13	13	leucovorin
NCT000012505	NCT00001250_5_T0	GENE	21	21	3.4
NCT000012506	NCT00001250_6_T0	GENE	8	8	2.3
NCT000012508	NCT00001250_8_T0	COMPOUND	17	17	tamoxifen
NCT000012508	NCT00001250_8_T1	PHENOTYPE	12	14	estrogen receptor positive
NCT0000125012	NCT00001250_12_T0	GENE	15	15	G-CSF
NCT0000125012	NCT00001250_12_T1	COMPOUND	13	13	leucovorin
NCT0000125012	NCT00001250_12_T2	TISSUE	31	32	lymph node
NCT0000125014	NCT00001250_14_T0	PHENOTYPE	9	10	axillary metastases
NCT0000125016	NCT00001250_16_T0	GENE	9	9	TMM
NCT0000125017	NCT00001250_17_T0	GENE	21	21	II
NCT0000125017	NCT00001250_17_T1	PHENOTYPE	12	12	tumor
NCT0000125017	NCT00001250_17_T2	PHENOTYPE	26	27	stage III
NCT0000125017	NCT00001250_17_T3	PHENOTYPE	2	4	bilateral breast cancer
NCT0000125018	NCT00001250_18_T0	PHENOTYPE	14	14	neoplasm
NCT0000125018	NCT00001250_18_T1	PHENOTYPE	4	5	breast tumor
NCT0000125019	NCT00001250_19_T0	COMPOUND	16	16	NCI
NCT0000125022	NCT00001250_22_T0	PHENOTYPE	21	21	recurrence
NCT0000125022	NCT00001250_22_T1	PHENOTYPE	3	3	cancers
NCT0000125022	NCT00001250_22_T2	GENE	17	17	had
NCT0000125023	NCT00001250_23_T0	PHENOTYPE	18	18	metastases
NCT0000125023	NCT00001250_23_T1	GENE	22	22	IV
NCT0000125023	NCT00001250_23_T2	PHENOTYPE	14	15	local disease
NCT0000125023	NCT00001250_23_T3	PHENOTYPE	19	20	stage III
NCT0000125027	NCT00001250_27_T0	ORGAN	6	6	liver
NCT0000125027	NCT00001250_27_T1	ORGAN	4	4	heart
NCT0000125027	NCT00001250_27_T2	ORGAN	7	7	kidney
NCT0000125027	NCT00001250_27_T3	PHENOTYPE	10	11	metabolic disorders
NCT0000125027	NCT00001250_27_T4	PHENOTYPE	0	1	Chronic disease
NCT000012512	NCT00001251_2_T0	COMPOUND	6	6	mafosfamide
NCT000012513	NCT00001251_3_T0	COMPOUND	5	5	mafosfamide
NCT000012513	NCT00001251_3_T1	GENE	1	1	CSF
NCT000012513	NCT00001251_3_T2	PHENOTYPE	2	2	pharmacokinetics
NCT000012514	NCT00001251_4_T0	GENE	23	23	IT
NCT000012515	NCT00001251_5_T0	PHENOTYPE	12	12	leukemias
NCT000012515	NCT00001251_5_T1	PHENOTYPE	16	16	malignancies
NCT000012515	NCT00001251_5_T2	PHENOTYPE	13	13	lymphomas
NCT000012517	NCT00001251_7_T0	COMPOUND	6	6	mafosfamide
NCT000012518	NCT00001251_8_T0	COMPOUND	5	5	mafosfamide
NCT000012518	NCT00001251_8_T1	GENE	1	1	CSF
NCT000012518	NCT00001251_8_T2	PHENOTYPE	2	2	pharmacokinetics
NCT000012519	NCT00001251_9_T0	GENE	23	23	IT
NCT0000125110	NCT00001251_10_T0	PHENOTYPE	12	12	leukemias
NCT0000125110	NCT00001251_10_T1	PHENOTYPE	16	16	malignancies
NCT0000125110	NCT00001251_10_T2	PHENOTYPE	13	13	lymphomas
NCT0000125112	NCT00001251_12_T0	PHENOTYPE	4	4	secondary
NCT0000125112	NCT00001251_12_T1	PHENOTYPE	3	3	malignancies
NCT0000125112	NCT00001251_12_T2	PHENOTYPE	8	9	solid tumor
NCT0000125113	NCT00001251_13_T0	PHENOTYPE	3	3	leukemia
NCT0000125113	NCT00001251_13_T1	PHENOTYPE	17	17	tumor
NCT0000125113	NCT00001251_13_T2	PHENOTYPE	4	4	lymphoma
NCT0000125113	NCT00001251_13_T3	PHENOTYPE	7	8	solid tumor
NCT0000125119	NCT00001251_19_T0	PHENOTYPE	7	7	toxic
NCT0000125119	NCT00001251_19_T1	PHENOTYPE	6	6	acute
NCT0000125119	NCT00001251_19_T2	PHENOTYPE	27	28	systemic illness
NCT0000125122	NCT00001251_22_T0	COMPOUND	18	18	calcium
NCT0000125122	NCT00001251_22_T1	ORGAN	10	10	liver
NCT0000125122	NCT00001251_22_T2	COMPOUND	20	20	phosphorus
NCT0000125123	NCT00001251_23_T0	GENE	5	5	DPA
NCT0000125124	NCT00001251_24_T0	PHENOTYPE	16	16	malignancy
NCT0000125128	NCT00001251_28_T0	PHENOTYPE	9	9	focal
NCT0000125128	NCT00001251_28_T1	BIOLOGICAL_PROCESS	2	3	CSF flow
NCT0000125128	NCT00001251_28_T2	BIOLOGICAL_PROCESS	23	24	CSF flow
NCT0000125129	NCT00001251_29_T0	PHENOTYPE	3	3	leukemia
NCT0000125129	NCT00001251_29_T1	PHENOTYPE	11	11	relapse
NCT0000125129	NCT00001251_29_T2	PHENOTYPE	5	5	lymphoma
NCT0000125129	NCT00001251_29_T3	ORGAN	9	10	bone marrow
NCT0000125132	NCT00001251_32_T0	PHENOTYPE	20	20	toxicities
NCT0000125132	NCT00001251_32_T1	GENE	6	6	extended
NCT000012521	NCT00001252_1_T0	PHENOTYPE	19	19	diseases
NCT000012524	NCT00001252_4_T0	ORGAN	18	18	joints
NCT0000125210	NCT00001252_10_T0	TISSUE	4	4	muscles
NCT0000125212	NCT00001252_12_T0	ORGAN	49	49	limb
NCT0000125212	NCT00001252_12_T1	ORGAN	47	48	lower extremity
NCT0000125214	NCT00001252_14_T0	PHENOTYPE	7	7	rigid
NCT0000125218	NCT00001252_18_T0	PHENOTYPE	11	11	spasticity
NCT0000125218	NCT00001252_18_T1	PHENOTYPE	9	10	muscle weakness
NCT0000125223	NCT00001252_23_T0	ORGAN	7	7	limb
NCT0000125223	NCT00001252_23_T1	PHENOTYPE	26	26	dysfunction
NCT0000125223	NCT00001252_23_T2	ORGAN	29	30	lower extremities
NCT0000125224	NCT00001252_24_T0	PHENOTYPE	4	6	nervous system injuries
NCT0000125224	NCT00001252_24_T1	PHENOTYPE	10	12	foot drop gait
NCT0000125224	NCT00001252_24_T2	ORGAN	3	5	central nervous system
NCT0000125225	NCT00001252_25_T0	ORGAN	19	19	ankle
NCT0000125229	NCT00001252_29_T0	ORGAN	57	57	legs
NCT0000125229	NCT00001252_29_T1	GENE	31	31	unbalanced
NCT000012536	NCT00001253_6_T0	PHENOTYPE	23	24	cognitive ability
NCT0000125314	NCT00001253_14_T0	COMPOUND	8	8	estrogen
NCT0000125322	NCT00001253_22_T0	PHENOTYPE	8	8	impairment
NCT000012543	NCT00001254_3_T0	PHENOTYPE	10	10	localize
NCT000012543	NCT00001254_3_T1	PHENOTYPE	12	12	tumor
NCT000012543	NCT00001254_3_T2	PHENOTYPE	19	19	tumor
NCT000012553	NCT00001255_3_T0	PHENOTYPE	12	13	frequent infections
NCT000012553	NCT00001255_3_T1	GENE	7	8	immune deficient
NCT000012555	NCT00001255_5_T0	PHENOTYPE	5	5	resistant
NCT000012556	NCT00001255_6_T0	CELL	13	13	cells
NCT000012556	NCT00001255_6_T1	GENE	6	6	ADA
NCT000012557	NCT00001255_7_T0	PHENOTYPE	2	2	SCID
NCT000012557	NCT00001255_7_T1	GENE	5	5	ADA
NCT0000125521	NCT00001255_21_T0	CELL	8	8	lymphocytes
NCT0000125523	NCT00001255_23_T0	PHENOTYPE	18	19	adverse effects
NCT000012560	NCT00001256_0_T0	PHENOTYPE	6	6	Vasculitis
NCT000012562	NCT00001256_2_T0	PHENOTYPE	7	7	vasculitis
NCT000012562	NCT00001256_2_T1	ORGAN	21	21	joints
NCT000012562	NCT00001256_2_T2	PHENOTYPE	1	1	diseases
NCT000012562	NCT00001256_2_T3	ORGAN	17	17	kidneys
NCT000012562	NCT00001256_2_T4	ORGAN	14	14	eyes
NCT000012562	NCT00001256_2_T5	ORGAN	22	22	heart
NCT000012562	NCT00001256_2_T6	PHENOTYPE	3	3	inflammation
NCT000012562	NCT00001256_2_T7	ORGAN	16	16	lungs
NCT000012562	NCT00001256_2_T8	PHENOTYPE	15	15	sinuses
NCT000012562	NCT00001256_2_T9	ORGAN	5	6	blood vessels
NCT000012564	NCT00001256_4_T0	PHENOTYPE	7	7	vasculitis
NCT000012564	NCT00001256_4_T1	COMPOUND	27	27	cyclophosphamide
NCT000012564	NCT00001256_4_T2	COMPOUND	10	10	methotrexate
NCT000012564	NCT00001256_4_T3	COMPOUND	8	8	prednisone
NCT000012566	NCT00001256_6_T0	GENE	25	25	1.2
NCT000012566	NCT00001256_6_T1	PHENOTYPE	14	14	vasculitis
NCT000012566	NCT00001256_6_T2	PHENOTYPE	16	17	microscopic polyangiitis
NCT000012566	NCT00001256_6_T3	PHENOTYPE	9	10	Wegener's granulomatosis
NCT000012566	NCT00001256_6_T4	PHENOTYPE	11	12	polyarteritis nodosa
NCT000012567	NCT00001256_7_T0	PHENOTYPE	31	31	infiltrates
NCT000012567	NCT00001256_7_T1	GENE	16	16	C-ANCA
NCT000012567	NCT00001256_7_T2	PHENOTYPE	29	29	nodule
NCT000012567	NCT00001256_7_T3	PHENOTYPE	26	26	sinusitis
NCT000012567	NCT00001256_7_T4	PHENOTYPE	4	4	glomerulonephritis
NCT000012567	NCT00001256_7_T5	PHENOTYPE	8	9	kidney disease
NCT000012567	NCT00001256_7_T6	PHENOTYPE	22	23	kidney diseases
NCT000012569	NCT00001256_9_T0	COMPOUND	13	13	prednisone
NCT0000125610	NCT00001256_10_T0	GENE	13	13	1.2
NCT0000125610	NCT00001256_10_T1	PHENOTYPE	2	2	remission
NCT0000125610	NCT00001256_10_T2	GENE	8	8	reduced
NCT0000125610	NCT00001256_10_T3	COMPOUND	4	4	methotrexate
NCT0000125613	NCT00001256_13_T0	PHENOTYPE	21	21	severity
NCT0000125615	NCT00001256_15_T0	PHENOTYPE	13	13	drowsiness
NCT0000125616	NCT00001256_16_T0	ORGAN	4	4	liver
NCT0000125616	NCT00001256_16_T1	ORGAN	25	25	liver
NCT0000125616	NCT00001256_16_T2	ORGAN	7	7	abdomen
NCT0000125618	NCT00001256_18_T0	PHENOTYPE	17	17	toxicity
NCT0000125618	NCT00001256_18_T1	GENE	3	3	has
NCT0000125619	NCT00001256_19_T0	PHENOTYPE	16	16	toxic
NCT0000125619	NCT00001256_19_T1	GENE	19	19	CP
NCT0000125619	NCT00001256_19_T2	PHENOTYPE	11	11	vasculitides
NCT0000125622	NCT00001256_22_T0	PHENOTYPE	13	13	remission
NCT0000125622	NCT00001256_22_T1	GENE	8	8	GC
NCT0000125622	NCT00001256_22_T2	GENE	16	16	GC
NCT0000125623	NCT00001256_23_T0	GENE	21	21	MTX
NCT0000125623	NCT00001256_23_T1	GENE	7	7	GC
NCT0000125623	NCT00001256_23_T2	GENE	17	17	GC
NCT0000125623	NCT00001256_23_T3	PHENOTYPE	9	10	in remission
NCT0000125624	NCT00001256_24_T0	GENE	3	3	had
NCT0000125624	NCT00001256_24_T1	PHENOTYPE	4	5	progressive disease
NCT0000125627	NCT00001256_27_T0	PHENOTYPE	10	10	remission
NCT0000125627	NCT00001256_27_T1	GENE	4	4	had
NCT0000125628	NCT00001256_28_T0	GENE	9	9	GC
NCT0000125628	NCT00001256_28_T1	PHENOTYPE	4	5	in remission
NCT0000125629	NCT00001256_29_T0	GENE	6	6	MTX
NCT0000125629	NCT00001256_29_T1	PHENOTYPE	19	19	vasculitis
NCT0000125629	NCT00001256_29_T2	GENE	13	13	CP
NCT0000125630	NCT00001256_30_T0	PHENOTYPE	0	0	Judgement
NCT0000125632	NCT00001256_32_T0	GENE	0	0	Age
NCT0000125633	NCT00001256_33_T0	PHENOTYPE	6	6	vasculitis
NCT0000125633	NCT00001256_33_T1	PHENOTYPE	17	17	vasculitis
NCT0000125635	NCT00001256_35_T0	PHENOTYPE	11	11	toxicity
NCT0000125636	NCT00001256_36_T0	PHENOTYPE	9	9	vasculitis
NCT0000125639	NCT00001256_39_T0	PHENOTYPE	21	21	fungi
NCT0000125639	NCT00001256_39_T1	PHENOTYPE	7	7	sinusitis
NCT0000125639	NCT00001256_39_T2	PHENOTYPE	12	13	granulomatous inflammation
NCT0000125640	NCT00001256_40_T0	PHENOTYPE	27	27	influenza
NCT0000125640	NCT00001256_40_T1	PHENOTYPE	39	39	infiltrates
NCT0000125640	NCT00001256_40_T2	PHENOTYPE	37	37	nodule
NCT0000125640	NCT00001256_40_T3	PHENOTYPE	0	0	Sinusitis
NCT0000125640	NCT00001256_40_T4	PHENOTYPE	29	29	pneumonia
NCT0000125640	NCT00001256_40_T5	ORGAN	32	33	respiratory tract
NCT0000125641	NCT00001256_41_T0	ORGAN	19	19	Appendix
NCT0000125641	NCT00001256_41_T1	PHENOTYPE	8	8	Vasculitis
NCT0000125641	NCT00001256_41_T2	PHENOTYPE	35	35	Vasculitis
NCT0000125644	NCT00001256_44_T0	GENE	6	6	GC
NCT0000125646	NCT00001256_46_T0	PHENOTYPE	5	7	negative pregnancy test
NCT000012573	NCT00001257_3_T0	PHENOTYPE	11	11	inflammation
NCT000012573	NCT00001257_3_T1	PHENOTYPE	14	14	vasculitis
NCT000012573	NCT00001257_3_T2	PHENOTYPE	15	15	syndromes
NCT000012575	NCT00001257_5_T0	ORGAN	9	9	forearm
NCT000012575	NCT00001257_5_T1	PHENOTYPE	5	5	blisters
NCT000012576	NCT00001257_6_T0	PHENOTYPE	4	4	blisters
NCT000012576	NCT00001257_6_T1	PHENOTYPE	19	19	blisters
NCT000012577	NCT00001257_7_T0	CELL	26	26	cells
NCT000012577	NCT00001257_7_T1	ORGAN	19	19	serum
NCT000012579	NCT00001257_9_T0	PHENOTYPE	0	0	Blister
NCT0000125710	NCT00001257_10_T0	PHENOTYPE	1	1	scab
NCT0000125710	NCT00001257_10_T1	PHENOTYPE	6	6	blisters
NCT0000125711	NCT00001257_11_T0	PHENOTYPE	23	23	blister
NCT0000125715	NCT00001257_15_T0	PHENOTYPE	8	8	inflammation
NCT0000125715	NCT00001257_15_T1	PHENOTYPE	21	21	inflammation
NCT0000125715	NCT00001257_15_T2	PHENOTYPE	25	25	vasculitis
NCT0000125715	NCT00001257_15_T3	PHENOTYPE	26	26	syndromes
NCT0000125717	NCT00001257_17_T0	BIOLOGICAL_PROCESS	11	11	phagocytosis
NCT0000125717	NCT00001257_17_T1	CELL	15	15	cells
NCT0000125717	NCT00001257_17_T2	PHENOTYPE	19	19	blisters
NCT0000125717	NCT00001257_17_T3	BIOLOGICAL_PROCESS	10	10	chemotaxis
NCT0000125717	NCT00001257_17_T4	BIOLOGICAL_PROCESS	8	9	respiratory burst
NCT0000125720	NCT00001257_20_T0	PHENOTYPE	34	34	strategies
NCT0000125721	NCT00001257_21_T0	PHENOTYPE	3	3	blister
NCT0000125721	NCT00001257_21_T1	GENE	15	15	IRAK4
NCT0000125725	NCT00001257_25_T0	ORGAN	3	3	heart
NCT0000125725	NCT00001257_25_T1	PHENOTYPE	9	10	bleeding disorders
NCT0000125725	NCT00001257_25_T2	PHENOTYPE	6	7	kidney disease
NCT0000125726	NCT00001257_26_T0	PHENOTYPE	5	6	viral hepatitis
NCT0000125727	NCT00001257_27_T0	PHENOTYPE	7	8	drug use
NCT0000125732	NCT00001257_32_T0	PHENOTYPE	1	2	viral hepatitis
NCT0000125733	NCT00001257_33_T0	PHENOTYPE	0	1	HIV positive
NCT0000125734	NCT00001257_34_T0	PHENOTYPE	6	6	malignancy
NCT000012584	NCT00001258_4_T0	COMPOUND	9	9	oxygen_15
NCT000012586	NCT00001258_6_T0	PHENOTYPE	24	24	physiology
NCT000012586	NCT00001258_6_T1	ORGAN	22	23	frontal lobe
NCT0000125811	NCT00001258_11_T0	PHENOTYPE	7	8	radiation exposure
NCT0000125813	NCT00001258_13_T0	PHENOTYPE	29	29	Disorders
NCT0000125813	NCT00001258_13_T1	PHENOTYPE	27	27	Schizophrenia
NCT0000125813	NCT00001258_13_T2	PHENOTYPE	10	10	schizophrenia
NCT0000125815	NCT00001258_15_T0	PHENOTYPE	11	11	illnesses
NCT0000125815	NCT00001258_15_T1	PHENOTYPE	23	23	physiology
NCT0000125815	NCT00001258_15_T2	PHENOTYPE	7	8	neurologic disorders
NCT0000125816	NCT00001258_16_T0	BIOLOGICAL_PROCESS	11	11	metabolism
NCT0000125819	NCT00001258_19_T0	PHENOTYPE	29	29	physiology
NCT0000125820	NCT00001258_20_T0	PHENOTYPE	23	23	withdrawn
NCT0000125820	NCT00001258_20_T1	PHENOTYPE	4	4	Schizophrenia
NCT0000125821	NCT00001258_21_T0	PHENOTYPE	14	14	decisions
NCT0000125824	NCT00001258_24_T0	PHENOTYPE	9	11	symptoms and signs
NCT0000125826	NCT00001258_26_T0	PHENOTYPE	22	22	illnesses
NCT0000125826	NCT00001258_26_T1	PHENOTYPE	34	34	physiology
NCT0000125826	NCT00001258_26_T2	PHENOTYPE	14	14	disorders
NCT0000125826	NCT00001258_26_T3	BIOLOGICAL_PROCESS	52	52	metabolism
NCT000012597	NCT00001259_7_T0	ORGAN	0	0	Blood
NCT000012598	NCT00001259_8_T0	PHENOTYPE	3	4	stress response
NCT000012598	NCT00001259_8_T1	PHENOTYPE	0	1	Cognitive functioning
NCT0000125911	NCT00001259_11_T0	PHENOTYPE	7	7	suppression
NCT0000125911	NCT00001259_11_T1	GENE	3	3	GnRH
NCT0000125913	NCT00001259_13_T0	COMPOUND	34	34	progesterone
NCT0000125913	NCT00001259_13_T1	GENE	19	19	TAB
NCT0000125913	NCT00001259_13_T2	BIOLOGICAL_PROCESS	30	32	response to estrogen
NCT0000125916	NCT00001259_16_T0	PHENOTYPE	40	40	severity
NCT0000125916	NCT00001259_16_T1	PHENOTYPE	25	26	mood disorder
NCT0000125916	NCT00001259_16_T2	BIOLOGICAL_PROCESS	33	34	menstrual cycle
NCT0000125917	NCT00001259_17_T0	PHENOTYPE	6	6	Schizophrenia
NCT0000125917	NCT00001259_17_T1	PHENOTYPE	3	4	Affective Disorders
NCT0000125918	NCT00001259_18_T0	GENE	5	5	axis
NCT0000125918	NCT00001259_18_T1	PHENOTYPE	7	8	psychiatric diagnosis
NCT0000125920	NCT00001259_20_T0	COMPOUND	7	7	cortisol
NCT0000125920	NCT00001259_20_T1	COMPOUND	17	17	glucose
NCT0000125920	NCT00001259_20_T2	COMPOUND	15	15	creatinine
NCT0000125920	NCT00001259_20_T3	ORGAN	18	18	liver
NCT0000125920	NCT00001259_20_T4	PHENOTYPE	4	5	thyroid function
NCT0000125923	NCT00001259_23_T0	GENE	0	0	GnRH
NCT0000125923	NCT00001259_23_T1	PHENOTYPE	13	14	laboratory abnormalities
NCT0000125924	NCT00001259_24_T0	PHENOTYPE	25	25	toxicity
NCT0000125924	NCT00001259_24_T1	PHENOTYPE	20	20	acute
NCT0000125924	NCT00001259_24_T2	GENE	11	11	GnRH
NCT000012601	NCT00001260_1_T0	ORGAN	14	15	nervous system
NCT000012601	NCT00001260_1_T1	PHENOTYPE	17	18	mental disorders
NCT000012602	NCT00001260_2_T0	ORGAN	11	11	brains
NCT000012602	NCT00001260_2_T1	PHENOTYPE	23	24	psychiatric disorders
NCT000012608	NCT00001260_8_T0	GENE	10	10	mRNA
NCT000012609	NCT00001260_9_T0	GENE	19	19	ANOVA
NCT0000126011	NCT00001260_11_T0	ORGAN	2	2	brains
NCT0000126013	NCT00001260_13_T0	GENE	11	11	kin
NCT0000126013	NCT00001260_13_T1	GENE	21	21	MTA
NCT000012611	NCT00001261_1_T0	GENE	15	15	II
NCT000012611	NCT00001261_1_T1	PHENOTYPE	29	29	autoimmune
NCT000012611	NCT00001261_1_T2	PHENOTYPE	16	16	Dermatomyositis
NCT000012611	NCT00001261_1_T3	GENE	18	18	III
NCT000012611	NCT00001261_1_T4	PHENOTYPE	1	1	diseases
NCT000012611	NCT00001261_1_T5	PHENOTYPE	13	13	Polymyositis
NCT000012611	NCT00001261_1_T6	PHENOTYPE	22	22	IBM
NCT000012611	NCT00001261_1_T7	PHENOTYPE	23	24	Inflammatory myopathies
NCT000012611	NCT00001261_1_T8	PHENOTYPE	5	6	inflammatory myopathies
NCT000012611	NCT00001261_1_T9	PHENOTYPE	19	21	Inclusion Body Myositis
NCT000012613	NCT00001261_3_T0	PHENOTYPE	13	13	IBM
NCT000012613	NCT00001261_3_T1	PHENOTYPE	25	25	diseases
NCT000012614	NCT00001261_4_T0	GENE	5	5	has
NCT000012614	NCT00001261_4_T1	PHENOTYPE	12	13	immune diseases
NCT000012614	NCT00001261_4_T2	PHENOTYPE	13	17	diseases of the nervous system
NCT000012617	NCT00001261_7_T0	PHENOTYPE	11	11	sterile
NCT0000126111	NCT00001261_11_T0	PHENOTYPE	14	14	IBM
NCT0000126111	NCT00001261_11_T1	PHENOTYPE	6	6	polymyositis
NCT0000126111	NCT00001261_11_T2	PHENOTYPE	8	8	dermatomyositis
NCT0000126111	NCT00001261_11_T3	PHENOTYPE	11	13	Inclusion Body Myositis
NCT0000126113	NCT00001261_13_T0	PHENOTYPE	15	15	resistant
NCT0000126114	NCT00001261_14_T0	PHENOTYPE	15	15	IBM
NCT0000126115	NCT00001261_15_T0	GENE	6	6	has
NCT0000126115	NCT00001261_15_T1	PHENOTYPE	24	25	neuromuscular diseases
NCT0000126124	NCT00001261_24_T0	PHENOTYPE	17	17	cardiomyopathy
NCT0000126124	NCT00001261_24_T1	PHENOTYPE	0	1	Critically ill
NCT0000126124	NCT00001261_24_T2	PHENOTYPE	26	27	muscle weakness
NCT0000126124	NCT00001261_24_T3	PHENOTYPE	20	21	respiratory insufficiency
NCT0000126127	NCT00001261_27_T0	PHENOTYPE	3	4	allergic reaction
NCT000012622	NCT00001262_2_T0	GENE	9	9	2.3
NCT000012622	NCT00001262_2_T1	PHENOTYPE	0	1	Menkes disease
NCT000012626	NCT00001262_6_T0	PHENOTYPE	3	4	Menkes Disease
NCT000012626	NCT00001262_6_T1	PHENOTYPE	17	18	brain damage
NCT000012627	NCT00001262_7_T0	GENE	6	6	bypass
NCT000012627	NCT00001262_7_T1	COMPOUND	13	13	copper
NCT000012627	NCT00001262_7_T2	ORGAN	16	17	gastrointestinal tract
NCT000012628	NCT00001262_8_T0	CELL	7	7	cells
NCT000012628	NCT00001262_8_T1	COMPOUND	0	0	Copper
NCT0000126210	NCT00001262_10_T0	COMPOUND	15	15	copper
NCT0000126210	NCT00001262_10_T1	PHENOTYPE	8	9	Menkes disease
NCT0000126212	NCT00001262_12_T0	COMPOUND	17	17	copper
NCT0000126212	NCT00001262_12_T1	COMPOUND	25	25	copper
NCT0000126213	NCT00001262_13_T0	COMPOUND	10	10	copper
NCT0000126213	NCT00001262_13_T1	COMPOUND	17	17	copper
NCT0000126213	NCT00001262_13_T2	BIOLOGICAL_PROCESS	11	11	metabolism
NCT0000126214	NCT00001262_14_T0	COMPOUND	14	14	copper
NCT0000126214	NCT00001262_14_T1	COMPOUND	15	15	histidine
NCT0000126214	NCT00001262_14_T2	PHENOTYPE	17	18	Menkes disease
NCT0000126216	NCT00001262_16_T0	PHENOTYPE	8	8	strategies
NCT0000126216	NCT00001262_16_T1	PHENOTYPE	27	27	neurodegeneration
NCT0000126216	NCT00001262_16_T2	CELL	58	58	cells
NCT0000126216	NCT00001262_16_T3	COMPOUND	36	36	copper
NCT0000126216	NCT00001262_16_T4	COMPOUND	42	42	copper
NCT0000126216	NCT00001262_16_T5	COMPOUND	51	51	copper
NCT0000126216	NCT00001262_16_T6	BIOLOGICAL_PROCESS	33	34	intestinal absorption
NCT0000126218	NCT00001262_18_T0	COMPOUND	11	11	copper
NCT0000126218	NCT00001262_18_T1	PHENOTYPE	20	21	Menkes disease
NCT000012652	NCT00001265_2_T0	ORGAN	2	2	lungs
NCT000012653	NCT00001265_3_T0	PHENOTYPE	8	8	polymyositis
NCT000012653	NCT00001265_3_T1	PHENOTYPE	9	9	dermatomyositis
NCT0000126514	NCT00001265_14_T0	TISSUE	6	6	tissues
NCT0000126515	NCT00001265_15_T0	GENE	11	11	MRI
NCT0000126519	NCT00001265_19_T0	GENE	11	11	swallow
NCT0000126519	NCT00001265_19_T1	COMPOUND	10	10	barium
NCT0000126522	NCT00001265_22_T0	ORGAN	12	12	lungs
NCT0000126523	NCT00001265_23_T0	PHENOTYPE	8	9	lung function
NCT0000126525	NCT00001265_25_T0	PHENOTYPE	4	5	lung function
NCT0000126527	NCT00001265_27_T0	ORGAN	13	13	heart
NCT0000126527	NCT00001265_27_T1	ORGAN	20	20	heart
NCT0000126527	NCT00001265_27_T2	ORGAN	23	23	heart
NCT0000126529	NCT00001265_29_T0	CELL	2	4	white blood cells
NCT0000126534	NCT00001265_34_T0	COMPOUND	5	5	glycogen
NCT0000126534	NCT00001265_34_T1	TISSUE	7	8	muscle tissue
NCT0000126535	NCT00001265_35_T0	GENE	9	9	MRI
NCT0000126536	NCT00001265_36_T0	TISSUE	2	2	muscles
NCT0000126536	NCT00001265_36_T1	GENE	6	6	MRI
NCT0000126537	NCT00001265_37_T0	GENE	0	0	MRI
NCT0000126543	NCT00001265_43_T0	PHENOTYPE	3	3	IIM
NCT0000126544	NCT00001265_44_T0	PHENOTYPE	15	15	edema
NCT0000126544	NCT00001265_44_T1	GENE	0	0	MRI
NCT0000126544	NCT00001265_44_T2	GENE	18	18	MRI
NCT0000126545	NCT00001265_45_T0	PHENOTYPE	17	18	muscle disease
NCT0000126547	NCT00001265_47_T0	PHENOTYPE	12	13	muscle disease
NCT000012662	NCT00001266_2_T0	COMPOUND	11	11	androgen
NCT000012663	NCT00001266_3_T0	COMPOUND	13	13	androgen
NCT000012663	NCT00001266_3_T1	CELL	10	10	cells
NCT000012663	NCT00001266_3_T2	COMPOUND	1	1	suramin
NCT000012663	NCT00001266_3_T3	COMPOUND	20	20	suramin
NCT000012663	NCT00001266_3_T4	GENE	7	7	hormone
NCT000012663	NCT00001266_3_T5	PHENOTYPE	8	9	refractory tumor
NCT000012666	NCT00001266_6_T0	COMPOUND	1	1	androgen
NCT000012667	NCT00001266_7_T0	COMPOUND	8	8	androgen
NCT000012667	NCT00001266_7_T1	GENE	1	1	has
NCT0000126613	NCT00001266_13_T0	GENE	4	4	0.3
NCT0000126615	NCT00001266_15_T0	PHENOTYPE	3	4	bleeding diathesis
NCT0000126616	NCT00001266_16_T0	COMPOUND	21	21	barium
NCT0000126616	NCT00001266_16_T1	PHENOTYPE	13	13	ulcer
NCT0000126616	NCT00001266_16_T2	PHENOTYPE	18	18	resolved
NCT0000126616	NCT00001266_16_T3	PHENOTYPE	5	7	peptic ulcer disease
NCT0000126619	NCT00001266_19_T0	GENE	4	5	calcium channel
NCT0000126620	NCT00001266_20_T0	PHENOTYPE	6	7	brain metastases
NCT0000126621	NCT00001266_21_T0	ORGAN	3	3	liver
NCT0000126621	NCT00001266_21_T1	PHENOTYPE	9	9	tumor
NCT0000126623	NCT00001266_23_T0	COMPOUND	6	6	bilirubin
NCT0000126624	NCT00001266_24_T0	PHENOTYPE	24	24	initiation
NCT0000126624	NCT00001266_24_T1	PHENOTYPE	28	28	initiation
NCT0000126624	NCT00001266_24_T2	CELL	5	5	cells
NCT0000126624	NCT00001266_24_T3	GENE	3	3	has
NCT0000126624	NCT00001266_24_T4	ORGAN	14	15	urinary tract
NCT0000126626	NCT00001266_26_T0	CELL	2	2	granulocyte
NCT0000126626	NCT00001266_26_T1	PHENOTYPE	17	17	Hgb
NCT0000126626	NCT00001266_26_T2	GENE	12	12	Fibrinogen
NCT0000126626	NCT00001266_26_T3	PHENOTYPE	7	8	platelet count
NCT0000126712	NCT00001267_12_T0	PHENOTYPE	0	0	Lymphadenopathy
NCT0000126712	NCT00001267_12_T1	PHENOTYPE	15	16	HIV infection
NCT0000126713	NCT00001267_13_T0	PHENOTYPE	7	7	HIV
NCT0000126713	NCT00001267_13_T1	ORGAN	4	4	serum
NCT0000126717	NCT00001267_17_T0	PHENOTYPE	8	10	negative pregnancy test
NCT0000126718	NCT00001267_18_T0	GENE	8	8	CRC1
NCT0000126718	NCT00001267_18_T1	PHENOTYPE	6	7	renal disease
NCT0000126724	NCT00001267_24_T0	PHENOTYPE	12	12	infections
NCT0000126725	NCT00001267_25_T0	PHENOTYPE	7	7	fever
NCT0000126725	NCT00001267_25_T1	GENE	5	5	had
NCT0000126725	NCT00001267_25_T2	PHENOTYPE	35	36	underlying infection
NCT0000126728	NCT00001267_28_T0	COMPOUND	7	7	heroin
NCT0000126728	NCT00001267_28_T1	COMPOUND	9	9	cocaine
NCT0000126728	NCT00001267_28_T2	PHENOTYPE	21	21	pancreatitis
NCT0000126728	NCT00001267_28_T3	PHENOTYPE	11	11	ingestion
NCT0000126729	NCT00001267_29_T0	PHENOTYPE	10	10	peripheral
NCT0000126729	NCT00001267_29_T1	PHENOTYPE	11	11	neuropathy
NCT0000126729	NCT00001267_29_T2	PHENOTYPE	8	8	pancreatitis
NCT0000126729	NCT00001267_29_T3	PHENOTYPE	4	5	cardiac disease
NCT0000126730	NCT00001267_30_T0	COMPOUND	16	16	ribavirin
NCT0000126730	NCT00001267_30_T1	COMPOUND	8	8	suramin
NCT0000126730	NCT00001267_30_T2	GENE	32	32	interferon
NCT000012693	NCT00001269_3_T0	PHENOTYPE	0	1	Measurable disease
NCT000012694	NCT00001269_4_T0	GENE	7	7	ll
NCT000012694	NCT00001269_4_T1	GENE	3	3	III
NCT000012695	NCT00001269_5_T0	GENE	3	3	had
NCT000012696	NCT00001269_6_T0	GENE	3	3	had
NCT000012696	NCT00001269_6_T1	ORGAN	27	28	bone marrow
NCT000012698	NCT00001269_8_T0	PHENOTYPE	8	9	metastatic disease
NCT0000126910	NCT00001269_10_T0	GENE	10	10	0.2
NCT0000126910	NCT00001269_10_T1	GENE	8	8	70
NCT0000126911	NCT00001269_11_T0	CELL	1	1	granulocyte
NCT0000126911	NCT00001269_11_T1	PHENOTYPE	7	8	platelet count
NCT0000126913	NCT00001269_13_T0	COMPOUND	1	1	creatinine
NCT0000126913	NCT00001269_13_T1	COMPOUND	8	8	creatinine
NCT0000126913	NCT00001269_13_T2	PHENOTYPE	22	22	tumor
NCT0000126913	NCT00001269_13_T3	ORGAN	0	0	Serum
NCT0000126913	NCT00001269_13_T4	GENE	6	6	1.7
NCT0000126914	NCT00001269_14_T0	COMPOUND	14	14	NCI
NCT0000126920	NCT00001269_20_T0	PHENOTYPE	3	4	CNS metastasis
NCT0000126920	NCT00001269_20_T1	PHENOTYPE	7	8	seizure disorder
NCT0000126921	NCT00001269_21_T0	PHENOTYPE	1	1	allergy
NCT0000126923	NCT00001269_23_T0	PHENOTYPE	6	6	asthma
NCT000012701	NCT00001270_1_T0	PHENOTYPE	10	10	toxicity
NCT000012701	NCT00001270_1_T1	GENE	19	19	ICE
NCT000012702	NCT00001270_2_T0	PHENOTYPE	18	18	engraftment
NCT000012702	NCT00001270_2_T1	GENE	9	9	IL-1
NCT000012702	NCT00001270_2_T2	GENE	22	22	IL-1
NCT000012702	NCT00001270_2_T3	GENE	11	11	ICE
NCT000012702	NCT00001270_2_T4	GENE	19	19	4.5
NCT000012703	NCT00001270_3_T0	PHENOTYPE	10	10	engraftment
NCT000012703	NCT00001270_3_T1	GENE	8	8	G-CSF
NCT000012704	NCT00001270_4_T0	PHENOTYPE	5	5	engraftment
NCT000012704	NCT00001270_4_T1	GENE	11	11	IL-1
NCT000012704	NCT00001270_4_T2	GENE	13	13	G-CSF
NCT000012705	NCT00001270_5_T0	PHENOTYPE	7	7	toxicity
NCT000012707	NCT00001270_7_T0	PHENOTYPE	10	10	toxicity
NCT000012707	NCT00001270_7_T1	GENE	19	19	ICE
NCT000012708	NCT00001270_8_T0	PHENOTYPE	18	18	engraftment
NCT000012708	NCT00001270_8_T1	GENE	9	9	IL-1
NCT000012708	NCT00001270_8_T2	GENE	22	22	IL-1
NCT000012708	NCT00001270_8_T3	GENE	11	11	ICE
NCT000012708	NCT00001270_8_T4	GENE	19	19	4.5
NCT000012709	NCT00001270_9_T0	PHENOTYPE	10	10	engraftment
NCT000012709	NCT00001270_9_T1	GENE	8	8	G-CSF
NCT0000127010	NCT00001270_10_T0	PHENOTYPE	5	5	engraftment
NCT0000127010	NCT00001270_10_T1	GENE	11	11	IL-1
NCT0000127010	NCT00001270_10_T2	GENE	13	13	G-CSF
NCT0000127011	NCT00001270_11_T0	PHENOTYPE	7	7	toxicity
NCT0000127013	NCT00001270_13_T0	GENE	12	12	DSC
NCT0000127013	NCT00001270_13_T1	GENE	9	9	FSC
NCT0000127013	NCT00001270_13_T2	PHENOTYPE	1	1	lymphomas
NCT0000127013	NCT00001270_13_T3	GENE	13	13	DL
NCT0000127014	NCT00001270_14_T0	PHENOTYPE	9	9	relapse
NCT0000127014	NCT00001270_14_T1	PHENOTYPE	22	22	relapse
NCT0000127014	NCT00001270_14_T2	PHENOTYPE	37	37	relapse
NCT0000127014	NCT00001270_14_T3	PHENOTYPE	55	55	relapse
NCT0000127014	NCT00001270_14_T4	PHENOTYPE	20	20	remission
NCT0000127014	NCT00001270_14_T5	PHENOTYPE	30	30	remission
NCT0000127014	NCT00001270_14_T6	GENE	66	66	IV
NCT0000127014	NCT00001270_14_T7	PHENOTYPE	0	1	Hodgkin's lymphomas
NCT0000127015	NCT00001270_15_T0	PHENOTYPE	0	1	Testicular cancer
NCT0000127016	NCT00001270_16_T0	PHENOTYPE	3	6	central nervous system cancer
NCT0000127019	NCT00001270_19_T0	COMPOUND	29	29	calcium
NCT0000127019	NCT00001270_19_T1	GENE	15	15	1.5
NCT0000127019	NCT00001270_19_T2	COMPOUND	9	9	bilirubin
NCT0000127020	NCT00001270_20_T0	PHENOTYPE	1	1	HIV
NCT0000127020	NCT00001270_20_T1	PHENOTYPE	4	5	hepatitis B
NCT0000127022	NCT00001270_22_T0	PHENOTYPE	1	1	bilateral
NCT0000127022	NCT00001270_22_T1	ORGAN	2	3	bone marrow
NCT0000127022	NCT00001270_22_T2	ORGAN	7	8	bone marrow
NCT0000127023	NCT00001270_23_T0	ORGAN	7	7	pelvis
NCT0000127023	NCT00001270_23_T1	PHENOTYPE	3	4	metastatic disease
NCT000012713	NCT00001271_3_T0	CELL	11	11	cells
NCT000012713	NCT00001271_3_T1	PHENOTYPE	10	10	tumor
NCT000012713	NCT00001271_3_T2	GENE	2	3	CD22 antigen
NCT000012718	NCT00001271_8_T0	GENE	12	12	has
NCT000012718	NCT00001271_8_T1	PHENOTYPE	3	4	measurable disease
NCT000012719	NCT00001271_9_T0	PHENOTYPE	0	0	HIV
NCT0000127112	NCT00001271_12_T0	PHENOTYPE	3	3	ascites
NCT0000127112	NCT00001271_12_T1	PHENOTYPE	0	1	Pleural effusions
NCT0000127113	NCT00001271_13_T0	PHENOTYPE	2	2	progression
NCT0000127115	NCT00001271_15_T0	ORGAN	13	14	bone marrow
NCT0000127117	NCT00001271_17_T0	GENE	4	4	1.5
NCT0000127117	NCT00001271_17_T1	GENE	0	1	Total bilirubin
NCT0000127120	NCT00001271_20_T0	COMPOUND	4	4	doxorubicin
NCT0000127121	NCT00001271_21_T0	GENE	2	2	0.2
NCT000012721	NCT00001272_1_T0	GENE	14	14	G-CSF
NCT000012722	NCT00001272_2_T0	PHENOTYPE	4	5	ovarian cancer
NCT000012723	NCT00001272_3_T0	PHENOTYPE	1	1	pharmacokinetics
NCT000012723	NCT00001272_3_T1	COMPOUND	3	3	taxol
NCT000012723	NCT00001272_3_T2	COMPOUND	5	5	cisplatin
NCT000012725	NCT00001272_5_T0	GENE	14	14	G-CSF
NCT000012726	NCT00001272_6_T0	PHENOTYPE	4	5	ovarian cancer
NCT000012727	NCT00001272_7_T0	PHENOTYPE	1	1	pharmacokinetics
NCT000012727	NCT00001272_7_T1	COMPOUND	3	3	taxol
NCT000012727	NCT00001272_7_T2	COMPOUND	5	5	cisplatin
NCT0000127210	NCT00001272_10_T0	PHENOTYPE	27	27	initiation
NCT0000127210	NCT00001272_10_T1	GENE	7	7	IV
NCT0000127210	NCT00001272_10_T2	PHENOTYPE	4	5	stage III
NCT0000127214	NCT00001272_14_T0	PHENOTYPE	3	4	myocardial infarction
NCT0000127214	NCT00001272_14_T1	PHENOTYPE	5	6	cardiac arrhythmias
NCT0000127214	NCT00001272_14_T2	PHENOTYPE	14	16	left anterior hemiblock
NCT0000127214	NCT00001272_14_T3	PHENOTYPE	19	21	bundle branch block
NCT0000127214	NCT00001272_14_T4	PHENOTYPE	9	12	right bundle branch block
NCT0000127215	NCT00001272_15_T0	COMPOUND	2	2	creatinine
NCT0000127215	NCT00001272_15_T1	PHENOTYPE	13	14	ureteral obstruction
NCT0000127217	NCT00001272_17_T0	PHENOTYPE	4	4	dysfunction
NCT0000127217	NCT00001272_17_T1	PHENOTYPE	7	8	grade 1
NCT0000127218	NCT00001272_18_T0	PHENOTYPE	5	6	GI bleeding
NCT0000127219	NCT00001272_19_T0	CELL	10	10	granulocyte
NCT0000127219	NCT00001272_19_T1	PHENOTYPE	16	17	platelet count
NCT0000127220	NCT00001272_20_T0	PHENOTYPE	9	9	malignancy
NCT0000127220	NCT00001272_20_T1	GENE	4	4	had
NCT0000127220	NCT00001272_20_T2	PHENOTYPE	14	16	nonmelanoma skin cancer
NCT000012752	NCT00001275_2_T0	PHENOTYPE	15	16	ovarian failure
NCT000012753	NCT00001275_3_T0	PHENOTYPE	8	8	focused
NCT000012756	NCT00001275_6_T0	PHENOTYPE	9	11	primary ovarian insufficiency
NCT000012758	NCT00001275_8_T0	PHENOTYPE	23	25	primary ovarian insufficiency
NCT000012760	NCT00001276_0_T0	PHENOTYPE	4	6	Blood Sugar Levels
NCT000012760	NCT00001276_0_T1	PHENOTYPE	3	5	Low Blood Sugar
NCT000012762	NCT00001276_2_T0	PHENOTYPE	9	9	hypoglycemia
NCT000012771	NCT00001277_1_T0	PHENOTYPE	10	10	hyperthyroidism
NCT000012772	NCT00001277_2_T0	PHENOTYPE	10	10	hyperparathyroidism
NCT000012773	NCT00001277_3_T0	PHENOTYPE	8	9	parathyroid tumors
NCT000012776	NCT00001277_6_T0	PHENOTYPE	16	16	tumor
NCT000012776	NCT00001277_6_T1	PHENOTYPE	2	3	parathyroid tumors
NCT000012777	NCT00001277_7_T0	GENE	9	9	MRI
NCT000012778	NCT00001277_8_T0	PHENOTYPE	4	4	hypoparathyroidism
NCT0000127715	NCT00001277_15_T0	PHENOTYPE	15	15	mutation
NCT0000127715	NCT00001277_15_T1	COMPOUND	5	5	calcium
NCT0000127715	NCT00001277_15_T2	PHENOTYPE	20	20	tumor
NCT0000127715	NCT00001277_15_T3	ORGAN	7	7	serum
NCT0000127715	NCT00001277_15_T4	ORGAN	13	13	serum
NCT0000127715	NCT00001277_15_T5	GENE	10	11	parathyroid hormone
NCT0000127716	NCT00001277_16_T0	PHENOTYPE	5	6	primary hyperparathyroidism
NCT0000127718	NCT00001277_18_T0	PHENOTYPE	3	3	localize
NCT0000127718	NCT00001277_18_T1	GENE	13	13	extended
NCT0000127722	NCT00001277_22_T0	ORGAN	12	12	autografts
NCT0000127722	NCT00001277_22_T1	COMPOUND	7	7	calcium
NCT0000127722	NCT00001277_22_T2	PHENOTYPE	5	5	hypocalcemia
NCT0000127722	NCT00001277_22_T3	GENE	15	16	parathyroid hormone
NCT0000127722	NCT00001277_22_T4	COMPOUND	8	9	vitamin D
NCT0000127723	NCT00001277_23_T0	PHENOTYPE	7	7	tumors
NCT000012782	NCT00001278_2_T0	PHENOTYPE	0	0	Sarcoidosis
NCT000012782	NCT00001278_2_T1	ORGAN	19	19	liver
NCT000012782	NCT00001278_2_T2	PHENOTYPE	7	7	nodules
NCT000012782	NCT00001278_2_T3	ORGAN	18	18	lungs
NCT000012782	NCT00001278_2_T4	ORGAN	22	22	eyes
NCT000012782	NCT00001278_2_T5	PHENOTYPE	6	6	granulomas
NCT000012783	NCT00001278_3_T0	PHENOTYPE	1	1	symptoms
NCT000012783	NCT00001278_3_T1	TISSUE	6	6	tissues
NCT000012785	NCT00001278_5_T0	PHENOTYPE	15	15	sarcoidosis
NCT000012787	NCT00001278_7_T0	PHENOTYPE	11	11	sarcoidosis
NCT000012787	NCT00001278_7_T1	PHENOTYPE	18	18	sarcoidosis
NCT000012787	NCT00001278_7_T2	PHENOTYPE	32	32	sarcoidosis
NCT000012787	NCT00001278_7_T3	PHENOTYPE	2	2	uveitis
NCT0000127811	NCT00001278_11_T0	PHENOTYPE	9	9	sarcoidosis
NCT0000127813	NCT00001278_13_T0	PHENOTYPE	20	20	sarcoidosis
NCT0000127813	NCT00001278_13_T1	PHENOTYPE	24	24	sarcoidosis
NCT0000127813	NCT00001278_13_T2	PHENOTYPE	34	34	sarcoidosis
NCT0000127813	NCT00001278_13_T3	PHENOTYPE	28	28	uveitis
NCT0000127813	NCT00001278_13_T4	TISSUE	6	7	lacrimal gland
NCT0000127815	NCT00001278_15_T0	PHENOTYPE	26	26	nodules
NCT0000127815	NCT00001278_15_T1	GENE	1	1	has
NCT0000127815	NCT00001278_15_T2	PHENOTYPE	19	20	caseating granuloma
NCT0000127815	NCT00001278_15_T3	TISSUE	11	12	lacrimal gland
NCT000012802	NCT00001280_2_T0	PHENOTYPE	10	10	infections
NCT000012802	NCT00001280_2_T1	PHENOTYPE	8	8	recurrent
NCT000012804	NCT00001280_4_T0	COMPOUND	6	6	itraconazole
NCT000012805	NCT00001280_5_T0	GENE	18	18	gamma-interferon
NCT000012805	NCT00001280_5_T1	COMPOUND	3	3	itraconazole
NCT000012805	NCT00001280_5_T2	PHENOTYPE	11	12	bacterial infection
NCT000012806	NCT00001280_6_T0	GENE	12	13	gamma interferon
NCT000012808	NCT00001280_8_T0	PHENOTYPE	10	11	drug toxicity
NCT0000128012	NCT00001280_12_T0	PHENOTYPE	10	10	infections
NCT0000128012	NCT00001280_12_T1	PHENOTYPE	8	8	recurrent
NCT0000128014	NCT00001280_14_T0	COMPOUND	6	6	itraconazole
NCT0000128015	NCT00001280_15_T0	GENE	18	18	gamma-interferon
NCT0000128015	NCT00001280_15_T1	COMPOUND	3	3	itraconazole
NCT0000128015	NCT00001280_15_T2	PHENOTYPE	11	12	bacterial infection
NCT0000128016	NCT00001280_16_T0	GENE	12	13	gamma interferon
NCT0000128021	NCT00001280_21_T0	PHENOTYPE	1	2	fungal infection
NCT0000128023	NCT00001280_23_T0	COMPOUND	3	3	phenytoin
NCT000012811	NCT00001281_1_T0	PHENOTYPE	0	0	HIV
NCT000012816	NCT00001281_6_T0	GENE	4	4	cc
NCT000012819	NCT00001281_9_T0	CELL	19	19	cells
NCT000012819	NCT00001281_9_T1	CELL	22	22	cells
NCT0000128110	NCT00001281_10_T0	TISSUE	1	1	tissues
NCT0000128110	NCT00001281_10_T1	PHENOTYPE	14	15	HIV infection
NCT0000128110	NCT00001281_10_T2	PHENOTYPE	22	23	HIV infection
NCT0000128112	NCT00001281_12_T0	BIOLOGICAL_PROCESS	8	9	immune response
NCT0000128113	NCT00001281_13_T0	PHENOTYPE	10	11	HIV infection
NCT0000128117	NCT00001281_17_T0	PHENOTYPE	15	15	progression
NCT0000128117	NCT00001281_17_T1	PHENOTYPE	17	18	HIV disease
NCT0000128119	NCT00001281_19_T0	PHENOTYPE	14	14	arthritis
NCT0000128119	NCT00001281_19_T1	PHENOTYPE	12	12	diseases
NCT0000128121	NCT00001281_21_T0	PHENOTYPE	16	16	peripheral
NCT0000128121	NCT00001281_21_T1	CELL	17	18	blood cells
NCT0000128121	NCT00001281_21_T2	PHENOTYPE	29	30	HIV infection
NCT0000128122	NCT00001281_22_T0	PHENOTYPE	17	17	peripheral
NCT0000128122	NCT00001281_22_T1	CELL	20	20	cells
NCT0000128122	NCT00001281_22_T2	PHENOTYPE	13	14	HIV infection
NCT000012821	NCT00001282_1_T0	GENE	8	8	IL-2
NCT000012822	NCT00001282_2_T0	GENE	3	3	IL-2
NCT000012823	NCT00001282_3_T0	PHENOTYPE	16	16	toxicity
NCT000012825	NCT00001282_5_T0	GENE	8	8	IL-2
NCT000012826	NCT00001282_6_T0	GENE	3	3	IL-2
NCT000012827	NCT00001282_7_T0	PHENOTYPE	16	16	toxicity
NCT000012829	NCT00001282_9_T0	GENE	15	15	CD4
NCT000012829	NCT00001282_9_T1	CELL	5	5	neutrophil
NCT0000128210	NCT00001282_10_T0	GENE	10	10	IL-2
NCT0000128214	NCT00001282_14_T0	GENE	4	4	tid
NCT0000128215	NCT00001282_15_T0	PHENOTYPE	5	5	malignancy
NCT0000128215	NCT00001282_15_T1	PHENOTYPE	8	9	Kaposi sarcoma
NCT0000128216	NCT00001282_16_T0	PHENOTYPE	12	12	HSV
NCT0000128216	NCT00001282_16_T1	PHENOTYPE	10	10	candidiasis
NCT0000128216	NCT00001282_16_T2	PHENOTYPE	5	6	opportunistic infection
NCT0000128219	NCT00001282_19_T0	PHENOTYPE	8	8	autoimmune
NCT0000128221	NCT00001282_21_T0	GENE	17	17	IL-2
NCT0000128221	NCT00001282_21_T1	GENE	19	19	has
NCT0000128225	NCT00001282_25_T0	GENE	1	1	The
NCT0000128225	NCT00001282_25_T1	GENE	18	18	has
NCT0000128232	NCT00001282_32_T0	GENE	1	1	The
NCT000012841	NCT00001284_1_T0	PHENOTYPE	0	0	Schizophrenia
NCT000012841	NCT00001284_1_T1	CELL	13	13	neurons
NCT000012841	NCT00001284_1_T2	PHENOTYPE	3	4	brain disorder
NCT000012842	NCT00001284_2_T0	PHENOTYPE	5	5	localized
NCT000012846	NCT00001284_6_T0	PHENOTYPE	7	7	physiology
NCT000012847	NCT00001284_7_T0	PHENOTYPE	13	13	schizophrenia
NCT000012847	NCT00001284_7_T1	PHENOTYPE	16	17	brain disorder
NCT0000128413	NCT00001284_13_T0	BIOLOGICAL_PROCESS	40	40	digestion
NCT0000128414	NCT00001284_14_T0	PHENOTYPE	15	15	schizophrenia
NCT0000128415	NCT00001284_15_T0	GENE	4	4	endo
NCT0000128422	NCT00001284_22_T0	PHENOTYPE	1	1	Schizophrenia
NCT0000128422	NCT00001284_22_T1	GENE	10	10	IV
NCT0000128422	NCT00001284_22_T2	PHENOTYPE	5	6	schizoaffective disorder
NCT0000128423	NCT00001284_23_T0	GENE	8	8	IV
NCT0000128423	NCT00001284_23_T1	PHENOTYPE	0	1	Bipolar Disorder
NCT0000128424	NCT00001284_24_T0	PHENOTYPE	1	2	Mood Disorder
NCT0000128425	NCT00001284_25_T0	PHENOTYPE	0	0	Mild
NCT0000128425	NCT00001284_25_T1	GENE	9	9	1.3
NCT0000128428	NCT00001284_28_T0	PHENOTYPE	15	15	impairment
NCT0000128428	NCT00001284_28_T1	PHENOTYPE	21	22	head trauma
NCT0000128428	NCT00001284_28_T2	PHENOTYPE	0	1	Head trauma
NCT0000128428	NCT00001284_28_T3	PHENOTYPE	3	5	loss of consciousness
NCT0000128429	NCT00001284_29_T0	GENE	37	37	MRI
NCT0000128430	NCT00001284_30_T0	PHENOTYPE	5	6	mental illness
NCT0000128431	NCT00001284_31_T0	PHENOTYPE	6	6	illnesses
NCT0000128431	NCT00001284_31_T1	PHENOTYPE	11	12	major depression
NCT0000128432	NCT00001284_32_T0	GENE	4	4	met
NCT0000128432	NCT00001284_32_T1	PHENOTYPE	2	3	substance abuse
NCT0000128433	NCT00001284_33_T0	PHENOTYPE	2	3	substance dependence
NCT0000128434	NCT00001284_34_T0	PHENOTYPE	3	3	dependence
NCT0000128434	NCT00001284_34_T1	GENE	5	5	met
NCT000012853	NCT00001285_3_T0	GENE	2	2	has
NCT000012855	NCT00001285_5_T0	COMPOUND	28	28	estrogen
NCT000012855	NCT00001285_5_T1	COMPOUND	30	30	progesterone
NCT000012855	NCT00001285_5_T2	PHENOTYPE	23	24	hypogonadotropic hypogonadism
NCT000012855	NCT00001285_5_T3	ORGAN	16	18	central nervous system
NCT000012856	NCT00001285_6_T0	COMPOUND	23	23	testosterone
NCT000012856	NCT00001285_6_T1	PHENOTYPE	18	19	hypogonadotropic hypogonadism
NCT000012856	NCT00001285_6_T2	ORGAN	11	13	central nervous system
NCT000012857	NCT00001285_7_T0	COMPOUND	9	9	estrogen
NCT000012857	NCT00001285_7_T1	COMPOUND	12	12	testosterone
NCT000012857	NCT00001285_7_T2	COMPOUND	10	10	progesterone
NCT000012858	NCT00001285_8_T0	COMPOUND	26	26	melatonin
NCT000012858	NCT00001285_8_T1	ORGAN	15	15	wrist
NCT0000128511	NCT00001285_11_T0	COMPOUND	18	18	estrogen
NCT0000128511	NCT00001285_11_T1	COMPOUND	23	23	progesterone
NCT0000128511	NCT00001285_11_T2	COMPOUND	8	8	melatonin
NCT0000128511	NCT00001285_11_T3	PHENOTYPE	10	11	sleep onset
NCT0000128512	NCT00001285_12_T0	COMPOUND	20	20	estrogen
NCT0000128512	NCT00001285_12_T1	COMPOUND	15	15	progesterone
NCT0000128514	NCT00001285_14_T0	COMPOUND	24	24	estrogen
NCT0000128514	NCT00001285_14_T1	GENE	10	10	prolactin
NCT0000128514	NCT00001285_14_T2	COMPOUND	17	17	testosterone
NCT0000128514	NCT00001285_14_T3	COMPOUND	19	19	Lupron
NCT0000128514	NCT00001285_14_T4	COMPOUND	26	26	Lupron
NCT0000128517	NCT00001285_17_T0	PHENOTYPE	6	7	behavioral disturbances
NCT0000128518	NCT00001285_18_T0	PHENOTYPE	18	19	laboratory abnormalities
NCT000012871	NCT00001287_1_T0	CELL	12	12	myelin
NCT000012871	NCT00001287_1_T1	CELL	8	8	cells
NCT000012871	NCT00001287_1_T2	ORGAN	3	4	immune system
NCT000012872	NCT00001287_2_T0	CELL	3	3	myelin
NCT000012872	NCT00001287_2_T1	GENE	20	20	CSF
NCT000012872	NCT00001287_2_T2	ORGAN	25	26	nervous system
NCT000012872	NCT00001287_2_T3	PHENOTYPE	5	6	muscle weakness
NCT000012872	NCT00001287_2_T4	PHENOTYPE	7	9	loss of sensation
NCT000012873	NCT00001287_3_T0	PHENOTYPE	7	7	suffering
NCT000012877	NCT00001287_7_T0	GENE	5	5	has
NCT000012877	NCT00001287_7_T1	PHENOTYPE	12	13	immune diseases
NCT000012877	NCT00001287_7_T2	PHENOTYPE	13	17	diseases of the nervous system
NCT0000128711	NCT00001287_11_T0	PHENOTYPE	11	11	sterile
NCT0000128715	NCT00001287_15_T0	ORGAN	9	9	serum
NCT0000128715	NCT00001287_15_T1	PHENOTYPE	1	2	monoclonal gammopathy
NCT0000128717	NCT00001287_17_T0	PHENOTYPE	14	14	resistant
NCT0000128719	NCT00001287_19_T0	GENE	6	6	has
NCT0000128719	NCT00001287_19_T1	PHENOTYPE	25	26	neuromuscular diseases
NCT0000128726	NCT00001287_26_T0	PHENOTYPE	12	13	sensory deficit
NCT0000128726	NCT00001287_26_T1	PHENOTYPE	9	10	muscle weakness
NCT0000128726	NCT00001287_26_T2	PHENOTYPE	6	7	peripheral neuropathy
NCT0000128727	NCT00001287_27_T0	GENE	12	12	neuromuscular
NCT0000128728	NCT00001287_28_T0	GENE	5	5	CSF
NCT0000128729	NCT00001287_29_T0	PHENOTYPE	3	3	demyelination
NCT0000128732	NCT00001287_32_T0	PHENOTYPE	27	28	muscle weakness
NCT0000128732	NCT00001287_32_T1	PHENOTYPE	20	21	respiratory insufficiency
NCT0000128732	NCT00001287_32_T2	PHENOTYPE	4	5	critically ill
NCT000012882	NCT00001288_2_T0	COMPOUND	19	19	glucose
NCT000012882	NCT00001288_2_T1	COMPOUND	16	16	oxygen
NCT000012883	NCT00001288_3_T0	COMPOUND	11	12	carbon dioxide
NCT000012885	NCT00001288_5_T0	PHENOTYPE	1	2	brain activity
NCT000012888	NCT00001288_8_T0	PHENOTYPE	14	14	epilepsy
NCT000012888	NCT00001288_8_T1	PHENOTYPE	27	27	epileptic
NCT000012888	NCT00001288_8_T2	PHENOTYPE	28	28	focal
NCT0000128811	NCT00001288_11_T0	PHENOTYPE	10	11	neurological disease
NCT0000128811	NCT00001288_11_T1	PHENOTYPE	6	7	head injury
NCT0000128814	NCT00001288_14_T0	PHENOTYPE	12	12	Epilepsy
NCT000012892	NCT00001289_2_T0	PHENOTYPE	5	5	enlargement
NCT000012892	NCT00001289_2_T1	ORGAN	8	8	liver
NCT000012892	NCT00001289_2_T2	TISSUE	10	10	spleen
NCT000012892	NCT00001289_2_T3	PHENOTYPE	2	3	Gaucher's disease
NCT000012892	NCT00001289_2_T4	PHENOTYPE	12	13	bone destruction
NCT000012893	NCT00001289_3_T0	PHENOTYPE	9	11	autosomal recessive inheritance
NCT000012894	NCT00001289_4_T0	PHENOTYPE	6	7	Gaucher's disease
NCT000012896	NCT00001289_6_T0	PHENOTYPE	3	3	chronic
NCT000012896	NCT00001289_6_T1	CELL	12	13	nerve cells
NCT000012898	NCT00001289_8_T0	GENE	1	1	II
NCT0000128911	NCT00001289_11_T0	PHENOTYPE	8	8	subacute
NCT0000128911	NCT00001289_11_T1	GENE	1	1	III
NCT0000128912	NCT00001289_12_T0	PHENOTYPE	14	14	acute
NCT0000128912	NCT00001289_12_T1	PHENOTYPE	11	11	chronic
NCT0000128913	NCT00001289_13_T0	ORGAN	25	26	nervous system
NCT0000128913	NCT00001289_13_T1	PHENOTYPE	17	18	Gaucher's disease
NCT0000128914	NCT00001289_14_T0	GENE	5	5	II
NCT0000128914	NCT00001289_14_T1	GENE	7	7	III
NCT0000128914	NCT00001289_14_T2	PHENOTYPE	2	3	Gaucher's disease
NCT0000128915	NCT00001289_15_T0	ORGAN	14	14	liver
NCT0000128915	NCT00001289_15_T1	TISSUE	17	17	spleen
NCT0000128915	NCT00001289_15_T2	PHENOTYPE	12	13	hemoglobin concentration
NCT0000128916	NCT00001289_16_T0	ORGAN	15	16	nervous system
NCT0000128919	NCT00001289_19_T0	PHENOTYPE	15	16	hemoglobin concentration
NCT0000128920	NCT00001289_20_T0	PHENOTYPE	12	13	metabolic encephalopathy
NCT0000128922	NCT00001289_22_T0	PHENOTYPE	4	5	Gaucher's disease
NCT0000128922	NCT00001289_22_T1	PHENOTYPE	12	15	horizontal supranuclear gaze palsy
NCT0000128925	NCT00001289_25_T0	PHENOTYPE	0	1	HIV positive
NCT0000128927	NCT00001289_27_T0	PHENOTYPE	2	3	neoplastic disease
NCT0000128932	NCT00001289_32_T0	PHENOTYPE	13	14	Gaucher Disease
NCT000012911	NCT00001291_1_T0	ORGAN	7	7	joints
NCT000012911	NCT00001291_1_T1	ORGAN	0	1	Synovial fluid
NCT000012913	NCT00001291_3_T0	PHENOTYPE	11	11	arthritis
NCT000012913	NCT00001291_3_T1	PHENOTYPE	2	3	rheumatoid arthritis
NCT000012916	NCT00001291_6_T0	PHENOTYPE	12	12	inflammation
NCT000012916	NCT00001291_6_T1	PHENOTYPE	9	10	joint swelling
NCT000012916	NCT00001291_6_T2	ORGAN	0	1	Synovial fluid
NCT000012919	NCT00001291_9_T0	PHENOTYPE	18	19	rheumatoid arthritis
NCT0000129110	NCT00001291_10_T0	PHENOTYPE	13	13	withdrawn
NCT0000129110	NCT00001291_10_T1	ORGAN	10	11	synovial fluid
NCT0000129112	NCT00001291_12_T0	TISSUE	1	1	tissues
NCT0000129114	NCT00001291_14_T0	PHENOTYPE	7	7	aspirated
NCT0000129118	NCT00001291_18_T0	TISSUE	2	2	tissues
NCT0000129119	NCT00001291_19_T0	PHENOTYPE	16	16	autoimmune
NCT0000129119	NCT00001291_19_T1	PHENOTYPE	17	18	joint diseases
NCT0000129119	NCT00001291_19_T2	PHENOTYPE	12	13	rheumatoid arthritis
NCT0000129121	NCT00001291_21_T0	ORGAN	8	8	shoulders
NCT0000129121	NCT00001291_21_T1	ORGAN	17	17	joints
NCT0000129121	NCT00001291_21_T2	GENE	13	13	bursa
NCT0000129121	NCT00001291_21_T3	ORGAN	12	12	olecranon
NCT0000129121	NCT00001291_21_T4	ORGAN	11	11	ankles
NCT0000129121	NCT00001291_21_T5	ORGAN	10	10	wrists
NCT000012921	NCT00001292_1_T0	TISSUE	19	19	bones
NCT000012921	NCT00001292_1_T1	ORGAN	17	17	teeth
NCT000012921	NCT00001292_1_T2	ORGAN	16	16	eyes
NCT000012926	NCT00001292_6_T0	ORGAN	6	6	jaw
NCT0000129215	NCT00001292_15_T0	PHENOTYPE	8	9	clinical findings
NCT000012943	NCT00001294_3_T0	CELL	27	27	lymphocytes
NCT000012943	NCT00001294_3_T1	PHENOTYPE	15	15	HIV
NCT000012943	NCT00001294_3_T2	BIOLOGICAL_PROCESS	13	13	phlebotomy
NCT000012944	NCT00001294_4_T0	GENE	13	13	span
NCT000012948	NCT00001294_8_T0	CELL	27	27	lymphocytes
NCT000012948	NCT00001294_8_T1	PHENOTYPE	15	15	HIV
NCT000012948	NCT00001294_8_T2	BIOLOGICAL_PROCESS	13	13	phlebotomy
NCT000012949	NCT00001294_9_T0	GENE	13	13	span
NCT000012950	NCT00001295_0_T0	PHENOTYPE	8	8	Disease
NCT000012954	NCT00001295_4_T0	GENE	9	9	CCR
NCT000012956	NCT00001295_6_T0	GENE	9	9	CCR
NCT0000129512	NCT00001295_12_T0	GENE	11	11	CCR
NCT000012964	NCT00001296_4_T0	ORGAN	2	2	limb
NCT000012964	NCT00001296_4_T1	PHENOTYPE	0	0	Hyperthermic
NCT0000129610	NCT00001296_10_T0	PHENOTYPE	12	12	toxicity
NCT0000129612	NCT00001296_12_T0	PHENOTYPE	3	3	metastases
NCT0000129612	NCT00001296_12_T1	PHENOTYPE	6	6	distal
NCT0000129612	NCT00001296_12_T2	ORGAN	0	1	Lower limb
NCT0000129612	NCT00001296_12_T3	PHENOTYPE	16	18	lymph node metastases
NCT0000129613	NCT00001296_13_T0	GENE	9	9	deltoid
NCT0000129613	NCT00001296_13_T1	PHENOTYPE	3	3	metastases
NCT0000129613	NCT00001296_13_T2	PHENOTYPE	6	6	distal
NCT0000129613	NCT00001296_13_T3	ORGAN	0	1	Upper limb
NCT0000129613	NCT00001296_13_T4	PHENOTYPE	13	15	lymph node metastases
NCT0000129614	NCT00001296_14_T0	ORGAN	8	8	extremity
NCT0000129614	NCT00001296_14_T1	PHENOTYPE	3	4	systemic disease
NCT0000129615	NCT00001296_15_T0	ORGAN	6	6	limb
NCT0000129615	NCT00001296_15_T1	PHENOTYPE	0	1	Recurrent disease
NCT0000129617	NCT00001296_17_T0	ORGAN	5	5	limb
NCT0000129619	NCT00001296_19_T0	ORGAN	9	9	extremity
NCT0000129620	NCT00001296_20_T0	ORGAN	16	16	extremity
NCT0000129621	NCT00001296_21_T0	PHENOTYPE	0	0	Endocrine
NCT0000129624	NCT00001296_24_T0	GENE	2	2	Age
NCT0000129626	NCT00001296_26_T0	CELL	1	1	Platelets
NCT0000129628	NCT00001296_28_T0	GENE	4	4	2.0
NCT0000129629	NCT00001296_29_T0	PHENOTYPE	11	11	claudication
NCT0000129629	NCT00001296_29_T1	PHENOTYPE	4	6	peripheral vascular disease
NCT0000129630	NCT00001296_30_T0	PHENOTYPE	1	1	HIV
NCT000012980	NCT00001298_0_T0	PHENOTYPE	17	17	Dysfunction
NCT000012980	NCT00001298_0_T1	PHENOTYPE	13	14	Methotrexate Toxicity
NCT000012983	NCT00001298_3_T0	PHENOTYPE	9	9	secondary
NCT000012983	NCT00001298_3_T1	COMPOUND	8	8	methotrexate
NCT000012983	NCT00001298_3_T2	PHENOTYPE	12	12	dysfunction
NCT000012984	NCT00001298_4_T0	COMPOUND	2	2	methotrexate
NCT000012988	NCT00001298_8_T0	PHENOTYPE	9	9	secondary
NCT000012988	NCT00001298_8_T1	COMPOUND	8	8	methotrexate
NCT000012988	NCT00001298_8_T2	PHENOTYPE	12	12	dysfunction
NCT000012989	NCT00001298_9_T0	COMPOUND	2	2	methotrexate
NCT000013005	NCT00001300_5_T0	CELL	7	7	Granulocyte
NCT000013005	NCT00001300_5_T1	GENE	4	4	IFF
NCT000013005	NCT00001300_5_T2	GENE	12	12	G-CSF
NCT000013009	NCT00001300_9_T0	PHENOTYPE	1	1	recurrence
NCT0000130011	NCT00001300_11_T0	PHENOTYPE	3	3	tumor
NCT0000130011	NCT00001300_11_T1	PHENOTYPE	15	15	tumor
NCT0000130012	NCT00001300_12_T0	PHENOTYPE	1	1	tumor
NCT0000130013	NCT00001300_13_T0	PHENOTYPE	4	5	CNS metastases
NCT0000130015	NCT00001300_15_T0	GENE	1	1	RT
NCT0000130015	NCT00001300_15_T1	GENE	2	2	PCR
NCT0000130015	NCT00001300_15_T2	PHENOTYPE	8	9	tumor recurrence
NCT0000130016	NCT00001300_16_T0	PHENOTYPE	4	4	tumor
NCT0000130019	NCT00001300_19_T0	PHENOTYPE	12	12	toxic
NCT0000130019	NCT00001300_19_T1	PHENOTYPE	11	11	acute
NCT0000130020	NCT00001300_20_T0	COMPOUND	2	2	estrogen
NCT0000130021	NCT00001300_21_T0	GENE	2	2	Age
NCT0000130021	NCT00001300_21_T1	PHENOTYPE	10	11	alveolar rhabdomyosarcoma
NCT0000130023	NCT00001300_23_T0	GENE	3	3	0.2
NCT0000130025	NCT00001300_25_T0	GENE	1	1	ANC
NCT0000130026	NCT00001300_26_T0	GENE	3	3	9.0
NCT0000130027	NCT00001300_27_T0	PHENOTYPE	0	1	Platelet count
NCT0000130028	NCT00001300_28_T0	GENE	4	4	2.0
NCT0000130028	NCT00001300_28_T1	PHENOTYPE	11	11	tumor
NCT0000130029	NCT00001300_29_T0	PHENOTYPE	11	11	tumor
NCT0000130030	NCT00001300_30_T0	COMPOUND	7	7	creatinine
NCT0000130030	NCT00001300_30_T1	GENE	4	4	1.5
NCT0000130031	NCT00001300_31_T0	PHENOTYPE	3	6	disorder of cardiovascular system
NCT0000130034	NCT00001300_34_T0	PHENOTYPE	0	0	Other
NCT0000130035	NCT00001300_35_T0	PHENOTYPE	0	0	HIV
NCT0000130036	NCT00001300_36_T0	PHENOTYPE	0	1	Hepatitis B
NCT000013011	NCT00001301_1_T0	PHENOTYPE	9	9	lymphoma
NCT000013014	NCT00001301_4_T0	PHENOTYPE	20	21	late effects
NCT000013016	NCT00001301_6_T0	CELL	26	26	cells
NCT000013016	NCT00001301_6_T1	GENE	28	28	p53
NCT000013019	NCT00001301_9_T0	PHENOTYPE	9	9	lymphoma
NCT0000130112	NCT00001301_12_T0	PHENOTYPE	20	21	late effects
NCT0000130114	NCT00001301_14_T0	CELL	26	26	cells
NCT0000130114	NCT00001301_14_T1	GENE	28	28	p53
NCT0000130117	NCT00001301_17_T0	PHENOTYPE	23	23	acute
NCT0000130117	NCT00001301_17_T1	PHENOTYPE	24	25	lymphoblastic leukemia
NCT0000130117	NCT00001301_17_T2	PHENOTYPE	15	16	lymphoblastic lymphoma
NCT000013023	NCT00001302_3_T0	COMPOUND	15	15	vinblastine
NCT000013023	NCT00001302_3_T1	COMPOUND	26	26	vinblastine
NCT000013023	NCT00001302_3_T2	PHENOTYPE	24	24	pharmacokinetics
NCT000013023	NCT00001302_3_T3	PHENOTYPE	22	22	affects
NCT000013026	NCT00001302_6_T0	COMPOUND	6	6	vinblastine
NCT0000130214	NCT00001302_14_T0	COMPOUND	15	15	vinblastine
NCT0000130214	NCT00001302_14_T1	COMPOUND	26	26	vinblastine
NCT0000130214	NCT00001302_14_T2	PHENOTYPE	24	24	pharmacokinetics
NCT0000130214	NCT00001302_14_T3	PHENOTYPE	22	22	affects
NCT0000130217	NCT00001302_17_T0	COMPOUND	6	6	vinblastine
NCT0000130224	NCT00001302_24_T0	ORGAN	4	4	kidney
NCT0000130224	NCT00001302_24_T1	PHENOTYPE	9	9	lymphomas
NCT0000130224	NCT00001302_24_T2	PHENOTYPE	6	7	ovarian cancers
NCT0000130227	NCT00001302_27_T0	ORGAN	6	7	bone marrow
NCT0000130228	NCT00001302_28_T0	GENE	5	5	ACG
NCT0000130228	NCT00001302_28_T1	GENE	0	0	WBC
NCT0000130228	NCT00001302_28_T2	CELL	9	9	platelets
NCT0000130229	NCT00001302_29_T0	GENE	9	9	1.5
NCT0000130229	NCT00001302_29_T1	COMPOUND	6	6	bilirubin
NCT0000130231	NCT00001302_31_T0	PHENOTYPE	3	4	brain metastases
NCT0000130232	NCT00001302_32_T0	COMPOUND	17	17	cyclosporine
NCT0000130232	NCT00001302_32_T1	COMPOUND	34	34	diltiazem
NCT0000130232	NCT00001302_32_T2	COMPOUND	48	48	quinidine
NCT0000130232	NCT00001302_32_T3	COMPOUND	44	44	verapamil
NCT0000130232	NCT00001302_32_T4	COMPOUND	46	46	progesterone
NCT0000130232	NCT00001302_32_T5	COMPOUND	40	40	phenytoin
NCT0000130232	NCT00001302_32_T6	COMPOUND	36	36	fluconazole
NCT0000130232	NCT00001302_32_T7	COMPOUND	50	50	amiodarone
NCT0000130232	NCT00001302_32_T8	COMPOUND	43	43	trimethoprim
NCT0000130232	NCT00001302_32_T9	COMPOUND	47	47	quinine
NCT0000130232	NCT00001302_32_T10	COMPOUND	35	35	erythromycin
NCT0000130232	NCT00001302_32_T11	COMPOUND	31	31	acetazolamide
NCT0000130232	NCT00001302_32_T12	COMPOUND	37	37	ketoconazole
NCT0000130232	NCT00001302_32_T13	COMPOUND	38	38	nicardipine
NCT0000130232	NCT00001302_32_T14	COMPOUND	45	45	tamoxifen
NCT0000130233	NCT00001302_33_T0	PHENOTYPE	2	3	peripheral neuropathy
NCT0000130234	NCT00001302_34_T0	PHENOTYPE	4	4	HIV
NCT0000130234	NCT00001302_34_T1	PHENOTYPE	1	2	positive serology
NCT000013033	NCT00001303_3_T0	PHENOTYPE	14	14	bloodstream
NCT000013033	NCT00001303_3_T1	ORGAN	12	12	lungs
NCT000013033	NCT00001303_3_T2	BIOLOGICAL_PROCESS	7	9	response to endotoxin
NCT000013035	NCT00001303_5_T0	CELL	11	11	cells
NCT000013035	NCT00001303_5_T1	PHENOTYPE	17	18	bacterial infections
NCT000013036	NCT00001303_6_T0	PHENOTYPE	22	22	infections
NCT000013036	NCT00001303_6_T1	GENE	7	7	has
NCT000013039	NCT00001303_9_T0	PHENOTYPE	18	20	coronary artery disease
NCT0000130310	NCT00001303_10_T0	PHENOTYPE	23	24	lung function
NCT0000130313	NCT00001303_13_T0	CELL	30	30	cells
NCT0000130313	NCT00001303_13_T1	CELL	0	0	Cells
NCT0000130314	NCT00001303_14_T0	GENE	12	12	pen
NCT0000130316	NCT00001303_16_T0	BIOLOGICAL_PROCESS	28	29	immune response
NCT0000130316	NCT00001303_16_T1	PHENOTYPE	32	35	bacteria in the blood
NCT0000130317	NCT00001303_17_T0	GENE	20	20	lobe
NCT0000130317	NCT00001303_17_T1	ORGAN	4	4	Lungs
NCT0000130317	NCT00001303_17_T2	COMPOUND	1	1	Endotoxin
NCT0000130319	NCT00001303_19_T0	PHENOTYPE	4	4	withdrawn
NCT0000130321	NCT00001303_21_T0	COMPOUND	6	7	nitric oxide
NCT0000130321	NCT00001303_21_T1	COMPOUND	25	26	nitric oxide
NCT0000130321	NCT00001303_21_T2	PHENOTYPE	29	30	lung inflammation
NCT0000130322	NCT00001303_22_T0	ORGAN	16	16	artery
NCT0000130322	NCT00001303_22_T1	ORGAN	15	15	wrist
NCT0000130323	NCT00001303_23_T0	COMPOUND	8	8	lidocaine
NCT0000130324	NCT00001303_24_T0	ORGAN	7	7	artery
NCT0000130326	NCT00001303_26_T0	COMPOUND	0	0	Endotoxin
NCT0000130328	NCT00001303_28_T0	PHENOTYPE	10	10	sepsis
NCT0000130328	NCT00001303_28_T1	PHENOTYPE	12	13	septic shock
NCT0000130329	NCT00001303_29_T0	PHENOTYPE	15	15	acute
NCT0000130329	NCT00001303_29_T1	PHENOTYPE	16	17	inflammatory responses
NCT0000130331	NCT00001303_31_T0	ORGAN	12	12	heart
NCT0000130331	NCT00001303_31_T1	PHENOTYPE	14	15	lung function
NCT0000130337	NCT00001303_37_T0	GENE	8	8	IV
NCT0000130337	NCT00001303_37_T1	PHENOTYPE	5	6	inflammatory responses
NCT0000130339	NCT00001303_39_T0	PHENOTYPE	0	1	Pulmonary effects
NCT0000130340	NCT00001303_40_T0	GENE	11	11	lobe
NCT0000130340	NCT00001303_40_T1	CELL	27	27	neutrophil
NCT0000130340	NCT00001303_40_T2	PHENOTYPE	22	23	inflammatory responses
NCT0000130342	NCT00001303_42_T0	COMPOUND	3	4	nitric oxide
NCT0000130342	NCT00001303_42_T1	PHENOTYPE	7	8	inflammatory responses
NCT0000130343	NCT00001303_43_T0	PHENOTYPE	48	48	inflammation
NCT0000130343	NCT00001303_43_T1	COMPOUND	9	10	nitric oxide
NCT0000130343	NCT00001303_43_T2	PHENOTYPE	13	14	lung inflammation
NCT0000130347	NCT00001303_47_T0	GENE	49	49	thromboplastin
NCT0000130347	NCT00001303_47_T1	GENE	46	46	prothrombin
NCT0000130347	NCT00001303_47_T2	COMPOUND	37	37	urea
NCT0000130347	NCT00001303_47_T3	COMPOUND	35	35	creatinine
NCT0000130347	NCT00001303_47_T4	COMPOUND	13	13	aspirin
NCT0000130347	NCT00001303_47_T5	COMPOUND	39	39	glucose
NCT0000130347	NCT00001303_47_T6	ORGAN	40	40	liver
NCT0000130347	NCT00001303_47_T7	COMPOUND	3	3	1
NCT0000130347	NCT00001303_47_T8	COMPOUND	22	22	2
NCT0000130347	NCT00001303_47_T9	COMPOUND	31	31	3
NCT0000130347	NCT00001303_47_T10	CELL	29	29	platelet
NCT0000130347	NCT00001303_47_T11	ORGAN	32	32	serum
NCT0000130349	NCT00001303_49_T0	PHENOTYPE	15	17	coronary artery disease
NCT0000130352	NCT00001303_52_T0	PHENOTYPE	5	5	asthma
NCT000013040	NCT00001304_0_T0	PHENOTYPE	2	2	Hypoparathyroidism
NCT000013040	NCT00001304_0_T1	PHENOTYPE	6	6	Parathyroid
NCT000013042	NCT00001304_2_T0	GENE	6	6	PTH
NCT000013042	NCT00001304_2_T1	GENE	29	29	PTH
NCT000013042	NCT00001304_2_T2	PHENOTYPE	20	20	hypoparathyroidism
NCT000013042	NCT00001304_2_T3	GENE	15	15	has
NCT000013042	NCT00001304_2_T4	GENE	3	4	parathyroid hormone
NCT000013046	NCT00001304_6_T0	COMPOUND	19	19	calcium
NCT000013046	NCT00001304_6_T1	PHENOTYPE	24	24	nephrocalcinosis
NCT000013046	NCT00001304_6_T2	ORGAN	23	23	kidney
NCT000013046	NCT00001304_6_T3	PHENOTYPE	1	2	side effect
NCT000013046	NCT00001304_6_T4	PHENOTYPE	26	27	renal insufficiency
NCT000013046	NCT00001304_6_T5	PHENOTYPE	9	10	serum calcium
NCT000013047	NCT00001304_7_T0	COMPOUND	13	13	calcium
NCT000013047	NCT00001304_7_T1	GENE	10	10	PTH
NCT000013047	NCT00001304_7_T2	BIOLOGICAL_PROCESS	14	14	metabolism
NCT000013047	NCT00001304_7_T3	GENE	8	9	parathyroid hormone
NCT000013049	NCT00001304_9_T0	GENE	9	9	PTH
NCT0000130410	NCT00001304_10_T0	ORGAN	12	12	kidney
NCT0000130410	NCT00001304_10_T1	GENE	3	3	PTH
NCT000013051	NCT00001305_1_T0	PHENOTYPE	11	11	understood
NCT000013052	NCT00001305_2_T0	PHENOTYPE	11	11	suffered
NCT000013052	NCT00001305_2_T1	PHENOTYPE	10	10	fractures
NCT000013052	NCT00001305_2_T2	PHENOTYPE	22	23	short stature
NCT000013053	NCT00001305_3_T0	GENE	11	11	III
NCT000013053	NCT00001305_3_T1	GENE	13	13	IV
NCT000013056	NCT00001305_6_T0	GENE	8	8	III
NCT0000130513	NCT00001305_13_T0	GENE	9	9	IV
NCT0000130528	NCT00001305_28_T0	PHENOTYPE	4	5	short stature
NCT0000130530	NCT00001305_30_T0	GENE	19	19	IV
NCT0000130533	NCT00001305_33_T0	GENE	4	4	III
NCT0000130533	NCT00001305_33_T1	GENE	15	15	IV
NCT0000130533	NCT00001305_33_T2	PHENOTYPE	7	9	severe short stature
NCT0000130535	NCT00001305_35_T0	GENE	15	15	fused
NCT0000130535	NCT00001305_35_T1	ORGAN	11	11	epiphyses
NCT0000130536	NCT00001305_36_T0	ORGAN	9	9	femur
NCT0000130537	NCT00001305_37_T0	ORGAN	0	0	Spine
NCT0000130537	NCT00001305_37_T1	PHENOTYPE	7	7	scoliosis
NCT0000130538	NCT00001305_38_T0	PHENOTYPE	2	2	scoliosis
NCT0000130538	NCT00001305_38_T1	PHENOTYPE	16	16	scoliosis
NCT0000130538	NCT00001305_38_T2	GENE	17	17	has
NCT0000130539	NCT00001305_39_T0	ORGAN	6	6	spine
NCT0000130540	NCT00001305_40_T0	PHENOTYPE	14	15	Basilar Invagination
NCT0000130541	NCT00001305_41_T0	GENE	10	10	MRI
NCT0000130543	NCT00001305_43_T0	PHENOTYPE	25	25	severity
NCT0000130547	NCT00001305_47_T0	PHENOTYPE	5	5	scoliosis
NCT0000130547	NCT00001305_47_T1	PHENOTYPE	16	17	basilar invagination
NCT000013061	NCT00001306_1_T0	PHENOTYPE	18	18	autoimmune
NCT000013061	NCT00001306_1_T1	COMPOUND	10	10	prednisone
NCT000013061	NCT00001306_1_T2	PHENOTYPE	19	20	ovarian failure
NCT000013062	NCT00001306_2_T0	GENE	11	11	has
NCT000013062	NCT00001306_2_T1	COMPOUND	1	1	prednisone
NCT000013062	NCT00001306_2_T2	PHENOTYPE	16	19	aseptic necrosis of bone
NCT000013063	NCT00001306_3_T0	PHENOTYPE	0	3	Aseptic necrosis of bone
NCT000013064	NCT00001306_4_T0	PHENOTYPE	9	11	premature ovarian failure
NCT000013065	NCT00001306_5_T0	PHENOTYPE	21	21	autoimmune
NCT000013065	NCT00001306_5_T1	PHENOTYPE	19	19	remission
NCT000013065	NCT00001306_5_T2	COMPOUND	15	15	prednisone
NCT000013065	NCT00001306_5_T3	PHENOTYPE	22	23	ovarian failure
NCT000013066	NCT00001306_6_T0	PHENOTYPE	11	13	premature ovarian failure
NCT000013067	NCT00001306_7_T0	ORGAN	20	20	ovaries
NCT000013067	NCT00001306_7_T1	PHENOTYPE	21	22	autoimmune oophoritis
NCT000013068	NCT00001306_8_T0	ORGAN	11	11	abdomen
NCT000013069	NCT00001306_9_T0	PHENOTYPE	20	20	autoimmune
NCT000013069	NCT00001306_9_T1	GENE	2	2	has
NCT000013069	NCT00001306_9_T2	PHENOTYPE	14	16	premature ovarian failure
NCT0000130610	NCT00001306_10_T0	BIOLOGICAL_PROCESS	11	11	ovulation
NCT0000130610	NCT00001306_10_T1	PHENOTYPE	16	17	serum progesterone
NCT0000130610	NCT00001306_10_T2	PHENOTYPE	17	18	progesterone levels
NCT0000130613	NCT00001306_13_T0	PHENOTYPE	3	3	infertile
NCT0000130613	NCT00001306_13_T1	GENE	13	13	has
NCT0000130613	NCT00001306_13_T2	PHENOTYPE	11	12	autoimmune oophoritis
NCT0000130613	NCT00001306_13_T3	PHENOTYPE	6	8	premature ovarian failure
NCT0000130614	NCT00001306_14_T0	PHENOTYPE	14	14	autoimmune
NCT0000130614	NCT00001306_14_T1	COMPOUND	7	7	prednisone
NCT0000130614	NCT00001306_14_T2	PHENOTYPE	15	16	ovarian failure
NCT0000130615	NCT00001306_15_T0	GENE	9	9	has
NCT0000130615	NCT00001306_15_T1	COMPOUND	1	1	prednisone
NCT0000130615	NCT00001306_15_T2	PHENOTYPE	14	17	aseptic necrosis of bone
NCT0000130616	NCT00001306_16_T0	PHENOTYPE	5	7	premature ovarian failure
NCT0000130617	NCT00001306_17_T0	COMPOUND	19	19	prednisone
NCT0000130617	NCT00001306_17_T1	PHENOTYPE	7	9	premature ovarian failure
NCT0000130617	NCT00001306_17_T2	PHENOTYPE	12	15	aseptic necrosis of bone
NCT0000130618	NCT00001306_18_T0	PHENOTYPE	18	18	remission
NCT0000130618	NCT00001306_18_T1	COMPOUND	15	15	prednisone
NCT0000130618	NCT00001306_18_T2	PHENOTYPE	20	21	ovarian failure
NCT0000130618	NCT00001306_18_T3	PHENOTYPE	24	25	autoimmune oophoritis
NCT0000130621	NCT00001306_21_T0	BIOLOGICAL_PROCESS	9	9	ovulation
NCT0000130621	NCT00001306_21_T1	PHENOTYPE	14	15	serum progesterone
NCT0000130621	NCT00001306_21_T2	PHENOTYPE	15	16	progesterone levels
NCT0000130622	NCT00001306_22_T0	COMPOUND	5	5	prednisone
NCT0000130622	NCT00001306_22_T1	COMPOUND	35	35	prednisone
NCT0000130622	NCT00001306_22_T2	BIOLOGICAL_PROCESS	8	8	ovulation
NCT000013079	NCT00001307_9_T0	ORGAN	12	13	wisdom tooth
NCT0000130711	NCT00001307_11_T0	GENE	8	8	MRI
NCT0000130712	NCT00001307_12_T0	TISSUE	15	15	tissues
NCT0000130712	NCT00001307_12_T1	GENE	0	0	MRI
NCT0000130712	NCT00001307_12_T2	GENE	10	10	structural
NCT0000130717	NCT00001307_17_T0	ORGAN	14	14	artery
NCT0000130719	NCT00001307_19_T0	ORGAN	13	13	veins
NCT0000130719	NCT00001307_19_T1	ORGAN	12	12	arteries
NCT0000130720	NCT00001307_20_T0	GENE	1	1	gel
NCT0000130720	NCT00001307_20_T1	GENE	19	19	gel
NCT0000130720	NCT00001307_20_T2	ORGAN	9	10	blood vessel
NCT0000130721	NCT00001307_21_T0	ORGAN	18	18	artery
NCT0000130724	NCT00001307_24_T0	GENE	11	11	0.8
NCT000013082	NCT00001308_2_T0	PHENOTYPE	8	8	visualization
NCT000013086	NCT00001308_6_T0	COMPOUND	19	19	glucose
NCT000013086	NCT00001308_6_T1	COMPOUND	16	16	oxygen
NCT000013087	NCT00001308_7_T0	COMPOUND	11	12	carbon dioxide
NCT000013089	NCT00001308_9_T0	PHENOTYPE	1	2	brain activity
NCT0000130813	NCT00001308_13_T0	ORGAN	24	24	jaw
NCT0000130813	NCT00001308_13_T1	TISSUE	21	21	muscles
NCT0000130816	NCT00001308_16_T0	PHENOTYPE	1	1	secondary
NCT0000130817	NCT00001308_17_T0	PHENOTYPE	18	18	epilepsy
NCT0000130817	NCT00001308_17_T1	PHENOTYPE	14	14	aphasia
NCT0000130817	NCT00001308_17_T2	PHENOTYPE	20	21	developmental stuttering
NCT0000130817	NCT00001308_17_T3	PHENOTYPE	7	8	neurological disorders
NCT0000130817	NCT00001308_17_T4	PHENOTYPE	15	17	traumatic brain injury
NCT0000130821	NCT00001308_21_T0	GENE	5	5	MRI
NCT0000130821	NCT00001308_21_T1	GENE	9	9	MEG
NCT0000130823	NCT00001308_23_T0	PHENOTYPE	28	28	aphasia
NCT0000130823	NCT00001308_23_T1	PHENOTYPE	12	12	disorders
NCT0000130824	NCT00001308_24_T0	GENE	17	17	MRI
NCT0000130824	NCT00001308_24_T1	GENE	20	20	MEG
NCT0000130831	NCT00001308_31_T0	GENE	3	3	FOR
NCT0000130831	NCT00001308_31_T1	PHENOTYPE	4	4	EPILEPSY
NCT0000130832	NCT00001308_32_T0	PHENOTYPE	2	2	seizures
NCT0000130836	NCT00001308_36_T0	GENE	10	10	MRI
NCT0000130838	NCT00001308_38_T0	PHENOTYPE	9	10	visual agnosia
NCT000013091	NCT00001309_1_T0	COMPOUND	5	6	ascorbic acid
NCT000013093	NCT00001309_3_T0	PHENOTYPE	14	14	affects
NCT000013093	NCT00001309_3_T1	ORGAN	25	25	plasma
NCT000013095	NCT00001309_5_T0	ORGAN	26	26	plasma
NCT000013095	NCT00001309_5_T1	COMPOUND	27	28	ascorbic acid
NCT0000130911	NCT00001309_11_T0	PHENOTYPE	2	4	vitamin C deficiency
NCT0000130913	NCT00001309_13_T0	PHENOTYPE	9	9	5-10
NCT0000130913	NCT00001309_13_T1	COMPOUND	6	6	ascorbate
NCT0000130913	NCT00001309_13_T2	ORGAN	5	5	plasma
NCT0000130914	NCT00001309_14_T0	COMPOUND	6	6	ascorbate
NCT0000130914	NCT00001309_14_T1	CELL	3	3	leukocytes
NCT0000130914	NCT00001309_14_T2	CELL	1	1	platelets
NCT0000130915	NCT00001309_15_T0	COMPOUND	3	3	ascorbate
NCT0000130917	NCT00001309_17_T0	COMPOUND	2	2	ascorbate
NCT0000130918	NCT00001309_18_T0	COMPOUND	2	2	ascorbate
NCT0000130918	NCT00001309_18_T1	GENE	14	14	hr
NCT0000130918	NCT00001309_18_T2	GENE	21	21	hr
NCT0000130918	NCT00001309_18_T3	ORGAN	1	1	plasma
NCT0000130918	NCT00001309_18_T4	ORGAN	15	15	plasma
NCT0000130922	NCT00001309_22_T0	PHENOTYPE	17	18	metabolic profiles
NCT0000130922	NCT00001309_22_T1	BIOLOGICAL_PROCESS	14	15	gene expression
NCT0000130924	NCT00001309_24_T0	PHENOTYPE	2	4	vitamin C deficiency
NCT0000130926	NCT00001309_26_T0	PHENOTYPE	9	9	5-10
NCT0000130926	NCT00001309_26_T1	COMPOUND	6	6	ascorbate
NCT0000130926	NCT00001309_26_T2	ORGAN	5	5	plasma
NCT0000130927	NCT00001309_27_T0	COMPOUND	6	6	ascorbate
NCT0000130927	NCT00001309_27_T1	CELL	3	3	leukocytes
NCT0000130927	NCT00001309_27_T2	CELL	1	1	platelets
NCT0000130928	NCT00001309_28_T0	COMPOUND	3	3	ascorbate
NCT0000130930	NCT00001309_30_T0	COMPOUND	2	2	ascorbate
NCT0000130931	NCT00001309_31_T0	COMPOUND	2	2	ascorbate
NCT0000130931	NCT00001309_31_T1	GENE	14	14	hr
NCT0000130931	NCT00001309_31_T2	GENE	21	21	hr
NCT0000130931	NCT00001309_31_T3	ORGAN	1	1	plasma
NCT0000130931	NCT00001309_31_T4	ORGAN	15	15	plasma
NCT0000130932	NCT00001309_32_T0	GENE	22	22	lt
NCT0000130932	NCT00001309_32_T1	CELL	21	21	leukocytes
NCT0000130932	NCT00001309_32_T2	CELL	19	19	platelets
NCT0000130937	NCT00001309_37_T0	COMPOUND	6	6	ascorbate
NCT0000130941	NCT00001309_41_T0	PHENOTYPE	2	2	ingestion
NCT0000130941	NCT00001309_41_T1	COMPOUND	10	10	ethanol
NCT000013102	NCT00001310_2_T0	GENE	15	15	polymerase
NCT000013102	NCT00001310_2_T1	GENE	32	32	mitochondrial
NCT000013102	NCT00001310_2_T2	CELL	30	30	organelles
NCT000013103	NCT00001310_3_T0	PHENOTYPE	3	3	peripheral
NCT000013103	NCT00001310_3_T1	TISSUE	11	11	tissues
NCT000013103	NCT00001310_3_T2	CELL	0	0	Lymphocytes
NCT000013105	NCT00001310_5_T0	PHENOTYPE	5	5	infiltrating
NCT000013105	NCT00001310_5_T1	PHENOTYPE	29	29	disorders
NCT000013105	NCT00001310_5_T2	CELL	6	6	cells
NCT000013105	NCT00001310_5_T3	CELL	9	9	cells
NCT000013105	NCT00001310_5_T4	PHENOTYPE	15	15	diseases
NCT000013108	NCT00001310_8_T0	TISSUE	1	1	tissues
NCT000013109	NCT00001310_9_T0	CELL	1	1	cells
NCT0000131012	NCT00001310_12_T0	PHENOTYPE	13	13	pathology
NCT0000131012	NCT00001310_12_T1	GENE	17	17	polymerase
NCT0000131012	NCT00001310_12_T2	GENE	35	35	mitochondrial
NCT0000131012	NCT00001310_12_T3	CELL	33	33	organelles
NCT0000131013	NCT00001310_13_T0	PHENOTYPE	3	3	peripheral
NCT0000131013	NCT00001310_13_T1	TISSUE	12	12	tissues
NCT0000131013	NCT00001310_13_T2	CELL	0	0	Lymphocytes
NCT0000131013	NCT00001310_13_T3	ORGAN	5	5	serum
NCT0000131016	NCT00001310_16_T0	PHENOTYPE	5	5	infiltrating
NCT0000131016	NCT00001310_16_T1	PHENOTYPE	28	28	disorders
NCT0000131016	NCT00001310_16_T2	CELL	6	6	cells
NCT0000131016	NCT00001310_16_T3	CELL	9	9	cells
NCT0000131016	NCT00001310_16_T4	PHENOTYPE	15	15	diseases
NCT000013113	NCT00001311_3_T0	PHENOTYPE	13	13	IOL
NCT0000131110	NCT00001311_10_T0	COMPOUND	15	15	cyclosporine
NCT0000131110	NCT00001311_10_T1	PHENOTYPE	6	6	uveitis
NCT0000131110	NCT00001311_10_T2	PHENOTYPE	10	11	in remission
NCT0000131115	NCT00001311_15_T0	PHENOTYPE	21	21	centers
NCT000013132	NCT00001313_2_T0	ORGAN	14	14	heart
NCT000013135	NCT00001313_5_T0	PHENOTYPE	5	6	cardiovascular diseases
NCT0000131311	NCT00001313_11_T0	PHENOTYPE	0	0	Cardiomyopathies
NCT0000131313	NCT00001313_13_T0	PHENOTYPE	8	8	ischemia
NCT0000131313	NCT00001313_13_T1	PHENOTYPE	4	5	intermittent claudication
NCT0000131313	NCT00001313_13_T2	PHENOTYPE	0	2	Peripheral artery disease
NCT0000131315	NCT00001313_15_T0	PHENOTYPE	0	0	Renovascular
NCT0000131315	NCT00001313_15_T1	PHENOTYPE	4	4	hypertension
NCT0000131315	NCT00001313_15_T2	PHENOTYPE	6	7	pulmonary edema
NCT0000131315	NCT00001313_15_T3	PHENOTYPE	11	12	ischemic nephropathy
NCT0000131317	NCT00001313_17_T0	ORGAN	0	1	Upper extremity
NCT0000131317	NCT00001313_17_T1	PHENOTYPE	2	4	peripheral artery disease
NCT0000131319	NCT00001313_19_T0	PHENOTYPE	0	0	Diabetes
NCT0000131319	NCT00001313_19_T1	PHENOTYPE	2	3	heart failure
NCT0000131321	NCT00001313_21_T0	PHENOTYPE	0	1	Pulmonary hypertension
NCT000013142	NCT00001314_2_T0	ORGAN	15	15	esophagus
NCT000013142	NCT00001314_2_T1	ORGAN	4	4	heart
NCT000013143	NCT00001314_3_T0	TISSUE	25	25	muscles
NCT000013143	NCT00001314_3_T1	TISSUE	28	28	bones
NCT000013143	NCT00001314_3_T2	ORGAN	16	16	esophagus
NCT000013143	NCT00001314_3_T3	ORGAN	10	10	heart
NCT000013143	NCT00001314_3_T4	ORGAN	31	32	chest wall
NCT000013144	NCT00001314_4_T0	COMPOUND	20	20	dobutamine
NCT000013144	NCT00001314_4_T1	ORGAN	6	6	heart
NCT000013145	NCT00001314_5_T0	ORGAN	7	7	heart
NCT000013145	NCT00001314_5_T1	ORGAN	19	19	heart
NCT000013146	NCT00001314_6_T0	ORGAN	14	14	heart
NCT000013146	NCT00001314_6_T1	PHENOTYPE	16	17	aortic regurgitation
NCT000013146	NCT00001314_6_T2	PHENOTYPE	19	20	mitral regurgitation
NCT000013147	NCT00001314_7_T0	ORGAN	19	20	left ventricle
NCT000013147	NCT00001314_7_T1	ORGAN	6	7	heart valves
NCT000013148	NCT00001314_8_T0	PHENOTYPE	22	22	circulation
NCT000013148	NCT00001314_8_T1	ORGAN	11	11	heart
NCT000013148	NCT00001314_8_T2	ORGAN	19	19	heart
NCT000013148	NCT00001314_8_T3	ORGAN	1	2	left ventricle
NCT000013149	NCT00001314_9_T0	TISSUE	10	11	heart muscle
NCT000013149	NCT00001314_9_T1	PHENOTYPE	21	22	muscle damage
NCT0000131414	NCT00001314_14_T0	PHENOTYPE	3	4	aortic regurgitation
NCT0000131414	NCT00001314_14_T1	PHENOTYPE	9	10	mitral regurgitation
NCT0000131417	NCT00001314_17_T0	PHENOTYPE	13	13	regurgitation
NCT0000131417	NCT00001314_17_T1	PHENOTYPE	26	27	mitral regurgitation
NCT0000131417	NCT00001314_17_T2	PHENOTYPE	35	37	aortic valve disease
NCT0000131417	NCT00001314_17_T3	PHENOTYPE	6	8	valvular heart disease
NCT0000131417	NCT00001314_17_T4	PHENOTYPE	21	23	mitral valve disease
NCT0000131418	NCT00001314_18_T0	PHENOTYPE	7	7	cardiomyopathy
NCT0000131419	NCT00001314_19_T0	PHENOTYPE	4	6	coronary artery disease
NCT0000131422	NCT00001314_22_T0	PHENOTYPE	7	9	congestive heart failure
NCT0000131423	NCT00001314_23_T0	PHENOTYPE	4	4	hypotension
NCT0000131426	NCT00001314_26_T0	PHENOTYPE	4	5	atrial fibrillation
NCT0000131427	NCT00001314_27_T0	PHENOTYPE	4	5	sinus tachycardia
NCT0000131428	NCT00001314_28_T0	PHENOTYPE	4	5	esophageal disease
NCT000013160	NCT00001316_0_T0	TISSUE	6	6	Tissues
NCT000013160	NCT00001316_0_T1	ORGAN	5	5	Lymph
NCT000013163	NCT00001316_3_T0	GENE	14	14	A1
NCT000013163	NCT00001316_3_T1	GENE	16	16	A2
NCT000013163	NCT00001316_3_T2	PHENOTYPE	9	9	progressive
NCT000013163	NCT00001316_3_T3	PHENOTYPE	10	11	generalized lymphadenopathy
NCT000013164	NCT00001316_4_T0	PHENOTYPE	14	14	HIV
NCT000013167	NCT00001316_7_T0	PHENOTYPE	16	16	peripheral
NCT000013167	NCT00001316_7_T1	TISSUE	13	14	lymph nodes
NCT000013168	NCT00001316_8_T0	PHENOTYPE	34	34	peripheral
NCT000013168	NCT00001316_8_T1	TISSUE	11	12	lymph node
NCT000013169	NCT00001316_9_T0	COMPOUND	17	17	zidovudine
NCT000013169	NCT00001316_9_T1	COMPOUND	19	19	didanosine
NCT000013169	NCT00001316_9_T2	TISSUE	41	42	lymph nodes
NCT0000131610	NCT00001316_10_T0	PHENOTYPE	17	17	peripheral
NCT0000131610	NCT00001316_10_T1	CELL	20	20	cells
NCT0000131610	NCT00001316_10_T2	ORGAN	33	33	plasma
NCT0000131610	NCT00001316_10_T3	PHENOTYPE	34	34	viremia
NCT0000131610	NCT00001316_10_T4	TISSUE	14	15	lymph node
NCT0000131612	NCT00001316_12_T0	PHENOTYPE	16	16	peripheral
NCT0000131612	NCT00001316_12_T1	CELL	21	21	cells
NCT0000131612	NCT00001316_12_T2	PHENOTYPE	32	33	HIV infection
NCT0000131612	NCT00001316_12_T3	TISSUE	19	20	lymphoid tissues
NCT0000131614	NCT00001316_14_T0	PHENOTYPE	21	21	peripheral
NCT0000131614	NCT00001316_14_T1	CELL	24	24	cells
NCT0000131614	NCT00001316_14_T2	CELL	29	29	cells
NCT0000131614	NCT00001316_14_T3	ORGAN	39	40	bone marrow
NCT0000131614	NCT00001316_14_T4	TISSUE	36	37	lymph nodes
NCT0000131614	NCT00001316_14_T5	PHENOTYPE	13	14	HIV infection
NCT0000131616	NCT00001316_16_T0	GENE	14	14	blot
NCT0000131616	NCT00001316_16_T1	ORGAN	16	16	plasma
NCT0000131616	NCT00001316_16_T2	PHENOTYPE	17	17	viremia
NCT0000131616	NCT00001316_16_T3	PHENOTYPE	0	1	HIV infection
NCT0000131623	NCT00001316_23_T0	CELL	1	1	neutrophil
NCT0000131625	NCT00001316_25_T0	PHENOTYPE	24	24	bleeding
NCT0000131625	NCT00001316_25_T1	PHENOTYPE	13	13	lupus
NCT0000131627	NCT00001316_27_T0	PHENOTYPE	28	28	HIV
NCT0000131627	NCT00001316_27_T1	GENE	37	37	11-2
NCT0000131627	NCT00001316_27_T2	GENE	14	14	HCT
NCT0000131627	NCT00001316_27_T3	GENE	39	39	HCT
NCT0000131627	NCT00001316_27_T4	GENE	12	12	9.0
NCT0000131627	NCT00001316_27_T5	CELL	21	21	platelets
NCT0000131627	NCT00001316_27_T6	CELL	46	46	platelets
NCT0000131627	NCT00001316_27_T7	GENE	6	6	hemoglobin
NCT0000131627	NCT00001316_27_T8	GENE	31	31	hemoglobin
NCT0000131627	NCT00001316_27_T9	PHENOTYPE	3	4	HIV positive
NCT0000131629	NCT00001316_29_T0	PHENOTYPE	8	9	pulse rate
NCT0000131629	NCT00001316_29_T1	PHENOTYPE	14	15	pulse rate
NCT0000131631	NCT00001316_31_T0	PHENOTYPE	0	0	HIV
NCT0000131633	NCT00001316_33_T0	TISSUE	6	7	lymph node
NCT0000131635	NCT00001316_35_T0	PHENOTYPE	12	12	HIV
NCT0000131635	NCT00001316_35_T1	PHENOTYPE	22	22	hepatitis
NCT0000131638	NCT00001316_38_T0	COMPOUND	9	9	cocaine
NCT0000131640	NCT00001316_40_T0	PHENOTYPE	9	9	malignancy
NCT0000131640	NCT00001316_40_T1	PHENOTYPE	2	3	AIDS dementia
NCT0000131640	NCT00001316_40_T2	PHENOTYPE	13	14	Kaposi's sarcoma
NCT0000131645	NCT00001316_45_T0	PHENOTYPE	7	7	feels
NCT0000131645	NCT00001316_45_T1	GENE	8	8	LN
NCT0000131645	NCT00001316_45_T2	GENE	6	6	PI
NCT0000131648	NCT00001316_48_T0	COMPOUND	11	11	cocaine
NCT000013171	NCT00001317_1_T0	GENE	3	3	had
NCT000013172	NCT00001317_2_T0	GENE	12	12	had
NCT000013179	NCT00001317_9_T0	GENE	3	3	had
NCT0000131710	NCT00001317_10_T0	GENE	12	12	had
NCT0000131717	NCT00001317_17_T0	COMPOUND	17	17	2
NCT0000131717	NCT00001317_17_T1	COMPOUND	3	3	creatinine
NCT0000131717	NCT00001317_17_T2	GENE	9	9	2.0
NCT0000131717	NCT00001317_17_T3	PHENOTYPE	18	18	proteinuria
NCT0000131718	NCT00001317_18_T0	GENE	19	19	1.3
NCT0000131718	NCT00001317_18_T1	GENE	9	9	1.5
NCT0000131718	NCT00001317_18_T2	COMPOUND	3	3	bilirubin
NCT0000131718	NCT00001317_18_T3	GENE	12	12	prothrombin
NCT0000131719	NCT00001317_19_T0	CELL	10	10	granulocytes
NCT0000131719	NCT00001317_19_T1	GENE	3	3	WBC
NCT0000131719	NCT00001317_19_T2	CELL	14	14	platelets
NCT0000131724	NCT00001317_24_T0	PHENOTYPE	5	5	infections
NCT000013181	NCT00001318_1_T0	GENE	3	4	interferon gamma
NCT000013182	NCT00001318_2_T0	PHENOTYPE	26	26	disorders
NCT000013184	NCT00001318_4_T0	GENE	3	4	interferon gamma
NCT000013185	NCT00001318_5_T0	PHENOTYPE	26	26	disorders
NCT0000131814	NCT00001318_14_T0	PHENOTYPE	1	2	seizure disorders
NCT000013191	NCT00001319_1_T0	GENE	0	0	CD4
NCT000013191	NCT00001319_1_T1	PHENOTYPE	19	19	infections
NCT000013191	NCT00001319_1_T2	PHENOTYPE	16	16	susceptible
NCT000013191	NCT00001319_1_T3	CELL	1	2	T lymphocytes
NCT0000131918	NCT00001319_18_T0	GENE	0	0	CD4
NCT0000131921	NCT00001319_21_T0	ORGAN	17	18	bone marrow
NCT000013202	NCT00001320_2_T0	COMPOUND	4	4	dopamine
NCT000013203	NCT00001320_3_T0	PHENOTYPE	14	14	disorders
NCT000013203	NCT00001320_3_T1	PHENOTYPE	16	16	schizophrenia
NCT000013203	NCT00001320_3_T2	GENE	3	3	has
NCT000013203	NCT00001320_3_T3	COMPOUND	1	1	dopamine
NCT000013203	NCT00001320_3_T4	PHENOTYPE	9	10	substance abuse
NCT000013208	NCT00001320_8_T0	PHENOTYPE	19	19	Disorders
NCT000013208	NCT00001320_8_T1	PHENOTYPE	17	17	Schizophrenia
NCT000013208	NCT00001320_8_T2	PHENOTYPE	2	2	schizophrenia
NCT0000132010	NCT00001320_10_T0	COMPOUND	21	21	IBZM
NCT0000132012	NCT00001320_12_T0	PHENOTYPE	12	12	schizophrenia
NCT0000132014	NCT00001320_14_T0	PHENOTYPE	26	26	fluctuations
NCT0000132014	NCT00001320_14_T1	GENE	6	6	has
NCT0000132014	NCT00001320_14_T2	COMPOUND	14	14	dopamine
NCT0000132014	NCT00001320_14_T3	COMPOUND	31	31	dopamine
NCT0000132014	NCT00001320_14_T4	COMPOUND	1	1	IBZM
NCT0000132014	NCT00001320_14_T5	GENE	21	21	D2
NCT0000132014	NCT00001320_14_T6	GENE	23	23	D3
NCT0000132014	NCT00001320_14_T7	GENE	15	16	type 2
NCT0000132016	NCT00001320_16_T0	COMPOUND	3	3	IBZM
NCT0000132028	NCT00001320_28_T0	GENE	10	10	has
NCT0000132030	NCT00001320_30_T0	COMPOUND	8	8	iodine
NCT0000132030	NCT00001320_30_T1	COMPOUND	9	9	iodine
NCT0000132031	NCT00001320_31_T0	ORGAN	6	6	thyroid
NCT0000132031	NCT00001320_31_T1	PHENOTYPE	9	9	dysfunction
NCT0000132032	NCT00001320_32_T0	PHENOTYPE	0	1	Substance abuse
NCT0000132032	NCT00001320_32_T1	PHENOTYPE	8	9	substance abuse
NCT0000132033	NCT00001320_33_T0	GENE	15	15	MRI
NCT0000132035	NCT00001320_35_T0	PHENOTYPE	0	0	Schizophrenia
NCT0000132036	NCT00001320_36_T0	GENE	2	2	FOR
NCT0000132036	NCT00001320_36_T1	PHENOTYPE	5	5	SCHIZOPHRENIA
NCT0000132036	NCT00001320_36_T2	PHENOTYPE	9	10	mental illness
NCT0000132039	NCT00001320_39_T0	GENE	5	5	II
NCT0000132040	NCT00001320_40_T0	GENE	11	11	II
NCT0000132040	NCT00001320_40_T1	GENE	2	2	FOR
NCT000013222	NCT00001322_2_T0	COMPOUND	16	16	acetate
NCT000013222	NCT00001322_2_T1	COMPOUND	28	28	estrogen
NCT000013222	NCT00001322_2_T2	COMPOUND	26	26	progesterone
NCT000013222	NCT00001322_2_T3	COMPOUND	15	15	leuprolide
NCT000013222	NCT00001322_2_T4	BIOLOGICAL_PROCESS	12	13	menstrual cycle
NCT000013222	NCT00001322_2_T5	BIOLOGICAL_PROCESS	23	24	menstrual cycle
NCT000013223	NCT00001322_3_T0	COMPOUND	18	18	estrogen
NCT000013223	NCT00001322_3_T1	COMPOUND	23	23	estrogen
NCT000013223	NCT00001322_3_T2	COMPOUND	20	20	progesterone
NCT000013223	NCT00001322_3_T3	COMPOUND	21	21	progesterone
NCT000013226	NCT00001322_6_T0	ORGAN	0	0	Blood
NCT000013227	NCT00001322_7_T0	PHENOTYPE	3	4	stress response
NCT000013227	NCT00001322_7_T1	PHENOTYPE	0	1	Cognitive functioning
NCT0000132210	NCT00001322_10_T0	PHENOTYPE	10	10	seizures
NCT0000132210	NCT00001322_10_T1	PHENOTYPE	14	14	epileptics
NCT0000132210	NCT00001322_10_T2	BIOLOGICAL_PROCESS	3	4	menstrual cycle
NCT0000132211	NCT00001322_11_T0	PHENOTYPE	9	9	inferred
NCT0000132211	NCT00001322_11_T1	BIOLOGICAL_PROCESS	27	28	menstrual cycle
NCT0000132211	NCT00001322_11_T2	ORGAN	0	2	Central nervous system
NCT0000132213	NCT00001322_13_T0	COMPOUND	19	19	estrogen
NCT0000132213	NCT00001322_13_T1	PHENOTYPE	13	13	hypogonadism
NCT0000132213	NCT00001322_13_T2	COMPOUND	21	21	progesterone
NCT0000132213	NCT00001322_13_T3	COMPOUND	12	12	Lupron
NCT0000132217	NCT00001322_17_T0	PHENOTYPE	30	32	major depressive episode
NCT0000132218	NCT00001322_18_T0	COMPOUND	30	30	estrogen
NCT0000132218	NCT00001322_18_T1	GENE	31	31	gel
NCT0000132219	NCT00001322_19_T0	PHENOTYPE	81	81	Porphyria
NCT0000132219	NCT00001322_19_T1	PHENOTYPE	58	58	enlargement
NCT0000132219	NCT00001322_19_T2	PHENOTYPE	109	109	perimenopause
NCT0000132219	NCT00001322_19_T3	BIOLOGICAL_PROCESS	103	103	Aging
NCT0000132219	NCT00001322_19_T4	PHENOTYPE	48	48	endometriosis
NCT0000132219	NCT00001322_19_T5	PHENOTYPE	90	90	pancreatitis
NCT0000132219	NCT00001322_19_T6	PHENOTYPE	77	77	phlebothrombosis
NCT0000132219	NCT00001322_19_T7	PHENOTYPE	88	88	Cholecystitis
NCT0000132219	NCT00001322_19_T8	PHENOTYPE	59	60	Hepatic disease
NCT0000132219	NCT00001322_19_T9	PHENOTYPE	25	26	psychiatric diagnosis
NCT0000132219	NCT00001322_19_T10	PHENOTYPE	93	94	renal disease
NCT0000132219	NCT00001322_19_T11	PHENOTYPE	70	71	mammary carcinoma
NCT0000132219	NCT00001322_19_T12	PHENOTYPE	79	80	vaginal bleeding
NCT0000132219	NCT00001322_19_T13	PHENOTYPE	74	75	pulmonary embolism
NCT0000132219	NCT00001322_19_T14	PHENOTYPE	82	83	Diabetes mellitus
NCT0000132219	NCT00001322_19_T15	PHENOTYPE	86	87	malignant melanoma
NCT0000132219	NCT00001322_19_T16	PHENOTYPE	64	67	abnormal liver function tests
NCT0000132223	NCT00001322_23_T0	COMPOUND	25	25	lithium
NCT0000132223	NCT00001322_23_T1	COMPOUND	6	6	pyridoxine
NCT0000132223	NCT00001322_23_T2	COMPOUND	3	3	prostaglandin
NCT0000132223	NCT00001322_23_T3	GENE	7	7	putative
NCT0000132223	NCT00001322_23_T4	COMPOUND	26	26	carbonate
NCT0000132225	NCT00001322_25_T0	PHENOTYPE	14	14	osteoporosis
NCT000013233	NCT00001323_3_T0	PHENOTYPE	17	17	impairment
NCT000013233	NCT00001323_3_T1	PHENOTYPE	19	19	schizophrenia
NCT000013233	NCT00001323_3_T2	PHENOTYPE	21	22	neurological disorder
NCT000013235	NCT00001323_5_T0	PHENOTYPE	14	14	ADHD
NCT000013235	NCT00001323_5_T1	PHENOTYPE	25	25	vigilance
NCT000013235	NCT00001323_5_T2	PHENOTYPE	4	5	Alzheimers disease
NCT000013236	NCT00001323_6_T0	PHENOTYPE	7	7	schizophrenia
NCT000013237	NCT00001323_7_T0	PHENOTYPE	26	26	impairment
NCT0000132311	NCT00001323_11_T0	PHENOTYPE	30	30	infections
NCT0000132311	NCT00001323_11_T1	PHENOTYPE	25	25	seizures
NCT0000132311	NCT00001323_11_T2	PHENOTYPE	26	27	head injury
NCT0000132312	NCT00001323_12_T0	PHENOTYPE	18	19	mental health
NCT0000132312	NCT00001323_12_T1	PHENOTYPE	27	28	substance abuse
NCT0000132314	NCT00001323_14_T0	PHENOTYPE	13	13	disorders
NCT0000132314	NCT00001323_14_T1	PHENOTYPE	8	8	dementing
NCT0000132314	NCT00001323_14_T2	PHENOTYPE	10	11	movement disorder
NCT0000132314	NCT00001323_14_T3	PHENOTYPE	16	18	acquired brain injury
NCT0000132315	NCT00001323_15_T0	PHENOTYPE	22	22	SCID
NCT0000132316	NCT00001323_16_T0	PHENOTYPE	20	21	psychiatric disorder
NCT0000132316	NCT00001323_16_T1	PHENOTYPE	25	26	neurological disease
NCT0000132316	NCT00001323_16_T2	PHENOTYPE	22	23	substance abuse
NCT000013242	NCT00001324_2_T0	COMPOUND	19	19	glucose
NCT000013242	NCT00001324_2_T1	COMPOUND	16	16	oxygen
NCT000013243	NCT00001324_3_T0	COMPOUND	11	12	carbon dioxide
NCT000013245	NCT00001324_5_T0	PHENOTYPE	1	2	brain activity
NCT000013249	NCT00001324_9_T0	MOLECULAR_FUNCTION	14	15	motor activity
NCT0000132415	NCT00001324_15_T0	GENE	3	3	half-life
NCT0000132417	NCT00001324_17_T0	GENE	11	11	MRI
NCT000013253	NCT00001325_3_T0	COMPOUND	19	19	glucose
NCT000013253	NCT00001325_3_T1	COMPOUND	16	16	oxygen
NCT000013254	NCT00001325_4_T0	COMPOUND	11	12	carbon dioxide
NCT000013256	NCT00001325_6_T0	PHENOTYPE	1	2	brain activity
NCT000013258	NCT00001325_8_T0	GENE	14	14	FDG
NCT0000132510	NCT00001325_10_T0	PHENOTYPE	13	13	epilepsy
NCT0000132510	NCT00001325_10_T1	BIOLOGICAL_PROCESS	6	6	metabolism
NCT0000132511	NCT00001325_11_T0	PHENOTYPE	7	7	severity
NCT0000132511	NCT00001325_11_T1	PHENOTYPE	10	10	seizures
NCT0000132511	NCT00001325_11_T2	BIOLOGICAL_PROCESS	4	4	metabolism
NCT0000132513	NCT00001325_13_T0	PHENOTYPE	1	1	severity
NCT0000132513	NCT00001325_13_T1	PHENOTYPE	20	20	focal
NCT0000132513	NCT00001325_13_T2	PHENOTYPE	4	5	seizure disorder
NCT0000132513	NCT00001325_13_T3	PHENOTYPE	7	8	cognitive impairment
NCT0000132515	NCT00001325_15_T0	PHENOTYPE	10	10	epilepsy
NCT0000132515	NCT00001325_15_T1	GENE	5	5	structural
NCT0000132516	NCT00001325_16_T0	PHENOTYPE	2	3	metabolic disease
NCT000013271	NCT00001327_1_T0	GENE	1	1	CSF
NCT000013271	NCT00001327_1_T1	ORGAN	11	12	spinal cord
NCT000013272	NCT00001327_2_T0	PHENOTYPE	5	5	malformations
NCT000013273	NCT00001327_3_T0	PHENOTYPE	0	0	Syringomyelia
NCT000013273	NCT00001327_3_T1	GENE	6	6	CSF
NCT000013273	NCT00001327_3_T2	BIOLOGICAL_PROCESS	12	13	CSF flow
NCT000013274	NCT00001327_4_T0	PHENOTYPE	0	0	Syringomyelia
NCT000013274	NCT00001327_4_T1	ORGAN	7	8	nervous system
NCT000013278	NCT00001327_8_T0	GENE	6	6	CSF
NCT0000132710	NCT00001327_10_T0	PHENOTYPE	21	21	syringomyelia
NCT0000132710	NCT00001327_10_T1	GENE	12	12	CSF
NCT0000132710	NCT00001327_10_T2	PHENOTYPE	19	19	progression
NCT0000132711	NCT00001327_11_T0	GENE	5	5	MRI
NCT0000132715	NCT00001327_15_T0	PHENOTYPE	23	23	occluding
NCT0000132715	NCT00001327_15_T1	PHENOTYPE	7	7	progression
NCT0000132715	NCT00001327_15_T2	PHENOTYPE	71	71	progression
NCT0000132715	NCT00001327_15_T3	TISSUE	21	21	tonsils
NCT0000132715	NCT00001327_15_T4	PHENOTYPE	9	9	syringomyelia
NCT0000132715	NCT00001327_15_T5	PHENOTYPE	61	61	syrinx
NCT0000132715	NCT00001327_15_T6	PHENOTYPE	70	70	syrinx
NCT0000132715	NCT00001327_15_T7	ORGAN	25	26	subarachnoid space
NCT0000132715	NCT00001327_15_T8	ORGAN	41	42	subarachnoid space
NCT0000132715	NCT00001327_15_T9	ORGAN	29	30	foramen magnum
NCT0000132715	NCT00001327_15_T10	ORGAN	52	53	spinal cord
NCT0000132715	NCT00001327_15_T11	PHENOTYPE	13	15	Chiari I malformation
NCT0000132718	NCT00001327_18_T0	GENE	17	17	CSF
NCT0000132718	NCT00001327_18_T1	PHENOTYPE	7	7	syrinx
NCT0000132718	NCT00001327_18_T2	PHENOTYPE	20	20	syrinx
NCT0000132718	NCT00001327_18_T3	BIOLOGICAL_PROCESS	2	4	cerebrospinal fluid flow
NCT0000132720	NCT00001327_20_T0	PHENOTYPE	7	7	syringomyelia
NCT0000132720	NCT00001327_20_T1	GENE	8	8	has
NCT0000132725	NCT00001327_25_T0	PHENOTYPE	1	1	syringomyelia
NCT0000132726	NCT00001327_26_T0	ORGAN	15	15	skull
NCT0000132727	NCT00001327_27_T0	PHENOTYPE	3	3	syringomyelia
NCT0000132727	NCT00001327_27_T1	PHENOTYPE	19	19	syrinx
NCT0000132727	NCT00001327_27_T2	PHENOTYPE	30	30	syrinx
NCT0000132729	NCT00001327_29_T0	GENE	17	17	Is
NCT0000132730	NCT00001327_30_T0	GENE	3	3	MRI
NCT0000132731	NCT00001327_31_T0	PHENOTYPE	4	4	bleeding
NCT0000132732	NCT00001327_32_T0	GENE	0	0	Is
NCT000013282	NCT00001328_2_T0	PHENOTYPE	14	16	malignant brain tumor
NCT000013283	NCT00001328_3_T0	PHENOTYPE	17	18	brain tumor
NCT000013284	NCT00001328_4_T0	CELL	15	15	cells
NCT000013284	NCT00001328_4_T1	PHENOTYPE	18	18	tumor
NCT000013287	NCT00001328_7_T0	GENE	11	11	Kinase
NCT000013287	NCT00001328_7_T1	PHENOTYPE	5	5	herpes
NCT000013287	NCT00001328_7_T2	GENE	12	12	TK
NCT000013289	NCT00001328_9_T0	CELL	14	14	cells
NCT000013289	NCT00001328_9_T1	PHENOTYPE	13	13	tumor
NCT000013289	NCT00001328_9_T2	GENE	10	10	TK
NCT000013289	NCT00001328_9_T3	COMPOUND	19	19	ganciclovir
NCT0000132810	NCT00001328_10_T0	CELL	9	9	cells
NCT0000132810	NCT00001328_10_T1	PHENOTYPE	8	8	tumor
NCT0000132810	NCT00001328_10_T2	GENE	13	13	TK
NCT0000132810	NCT00001328_10_T3	COMPOUND	4	4	ganciclovir
NCT0000132812	NCT00001328_12_T0	PHENOTYPE	2	2	tumors
NCT0000132813	NCT00001328_13_T0	PHENOTYPE	13	13	recurrence
NCT0000132814	NCT00001328_14_T0	PHENOTYPE	25	25	melanoma
NCT0000132814	NCT00001328_14_T1	PHENOTYPE	18	18	secondary
NCT0000132814	NCT00001328_14_T2	PHENOTYPE	19	19	metastasis
NCT0000132814	NCT00001328_14_T3	GENE	6	6	grim
NCT0000132814	NCT00001328_14_T4	PHENOTYPE	28	29	breast cancer
NCT0000132814	NCT00001328_14_T5	PHENOTYPE	12	13	brain tumors
NCT0000132814	NCT00001328_14_T6	PHENOTYPE	39	40	brain tumors
NCT0000132814	NCT00001328_14_T7	PHENOTYPE	15	16	primary tumors
NCT0000132815	NCT00001328_15_T0	PHENOTYPE	15	16	brain tumor
NCT0000132818	NCT00001328_18_T0	CELL	7	7	cells
NCT0000132820	NCT00001328_20_T0	CELL	11	11	cells
NCT0000132820	NCT00001328_20_T1	PHENOTYPE	10	10	tumor
NCT0000132820	NCT00001328_20_T2	PHENOTYPE	18	18	encoded
NCT0000132821	NCT00001328_21_T0	COMPOUND	18	18	ganciclovir
NCT0000132821	NCT00001328_21_T1	CELL	13	13	cells
NCT0000132821	NCT00001328_21_T2	PHENOTYPE	12	12	tumor
NCT0000132821	NCT00001328_21_T3	GENE	7	8	thymidine kinase
NCT0000132821	NCT00001328_21_T4	PHENOTYPE	3	4	herpes simplex
NCT0000132824	NCT00001328_24_T0	PHENOTYPE	18	18	toxicity
NCT0000132824	NCT00001328_24_T1	CELL	10	10	cells
NCT0000132824	NCT00001328_24_T2	GENE	11	11	has
NCT0000132825	NCT00001328_25_T0	GENE	7	7	has
NCT0000132826	NCT00001328_26_T0	CELL	11	11	cells
NCT0000132828	NCT00001328_28_T0	CELL	6	6	cells
NCT0000132828	NCT00001328_28_T1	CELL	11	11	cells
NCT0000132828	NCT00001328_28_T2	CELL	33	33	cells
NCT0000132828	NCT00001328_28_T3	PHENOTYPE	5	5	tumor
NCT0000132828	NCT00001328_28_T4	BIOLOGICAL_PROCESS	28	28	mutagenesis
NCT0000132828	NCT00001328_28_T5	BIOLOGICAL_PROCESS	18	19	immune response
NCT0000132829	NCT00001328_29_T0	PHENOTYPE	8	9	malignant tumors
NCT000013291	NCT00001329_1_T0	ORGAN	9	10	nervous system
NCT000013291	NCT00001329_1_T1	ORGAN	16	18	sympathetic nervous system
NCT000013292	NCT00001329_2_T0	PHENOTYPE	11	12	pulse rate
NCT000013292	NCT00001329_2_T1	ORGAN	1	3	sympathetic nervous system
NCT000013297	NCT00001329_7_T0	COMPOUND	10	10	norepinephrine
NCT000013303	NCT00001330_3_T0	PHENOTYPE	16	17	lung function
NCT000013304	NCT00001330_4_T0	PHENOTYPE	26	26	complications
NCT000013304	NCT00001330_4_T1	PHENOTYPE	28	28	illnesses
NCT000013306	NCT00001330_6_T0	PHENOTYPE	48	48	diseases
NCT000013306	NCT00001330_6_T1	PHENOTYPE	37	37	symptoms
NCT000013306	NCT00001330_6_T2	PHENOTYPE	17	17	sclerosis
NCT000013306	NCT00001330_6_T3	PHENOTYPE	42	43	laboratory abnormalities
NCT000013307	NCT00001330_7_T0	PHENOTYPE	34	34	complications
NCT000013307	NCT00001330_7_T1	GENE	31	31	peri
NCT0000133012	NCT00001330_12_T0	PHENOTYPE	16	16	sclerosis
NCT0000133012	NCT00001330_12_T1	COMPOUND	7	7	silicon
NCT0000133012	NCT00001330_12_T2	PHENOTYPE	18	18	myositis
NCT0000133012	NCT00001330_12_T3	GENE	6	6	had
NCT0000133012	NCT00001330_12_T4	GENE	1	2	Group 1
NCT0000133013	NCT00001330_13_T0	PHENOTYPE	9	9	myositis
NCT0000133013	NCT00001330_13_T1	PHENOTYPE	7	7	sclerosis
NCT0000133013	NCT00001330_13_T2	COMPOUND	2	2	2
NCT0000133013	NCT00001330_13_T3	GENE	31	32	Group 1
NCT000013311	NCT00001331_1_T0	GENE	0	0	PFK
NCT000013313	NCT00001331_3_T0	PHENOTYPE	14	14	weakness
NCT000013313	NCT00001331_3_T1	PHENOTYPE	8	8	degeneration
NCT000013313	NCT00001331_3_T2	PHENOTYPE	16	17	muscle wasting
NCT000013313	NCT00001331_3_T3	TISSUE	10	11	skeletal muscles
NCT000013314	NCT00001331_4_T0	GENE	15	15	PFK
NCT000013314	NCT00001331_4_T1	PHENOTYPE	17	19	acid maltase deficiency
NCT000013316	NCT00001331_6_T0	PHENOTYPE	0	1	Group B
NCT0000133111	NCT00001331_11_T0	PHENOTYPE	13	13	identities
NCT0000133115	NCT00001331_15_T0	PHENOTYPE	8	8	diseases
NCT0000133115	NCT00001331_15_T1	PHENOTYPE	6	7	autosomal recessive
NCT0000133116	NCT00001331_16_T0	PHENOTYPE	25	25	diseases
NCT0000133116	NCT00001331_16_T1	PHENOTYPE	33	33	diseases
NCT0000133117	NCT00001331_17_T0	GENE	44	44	has
NCT0000133124	NCT00001331_24_T0	PHENOTYPE	26	26	mutation
NCT0000133124	NCT00001331_24_T1	GENE	6	6	has
NCT0000133125	NCT00001331_25_T0	PHENOTYPE	19	19	mutation
NCT000013320	NCT00001332_0_T0	PHENOTYPE	5	5	Hyperthermic
NCT000013322	NCT00001332_2_T0	GENE	2	2	has
NCT000013324	NCT00001332_4_T0	PHENOTYPE	36	36	hyperthermic
NCT000013324	NCT00001332_4_T1	ORGAN	38	38	limb
NCT000013324	NCT00001332_4_T2	CELL	9	9	cells
NCT000013324	NCT00001332_4_T3	PHENOTYPE	45	45	sarcoma
NCT000013324	NCT00001332_4_T4	PHENOTYPE	43	43	melanoma
NCT000013324	NCT00001332_4_T5	GENE	19	19	has
NCT000013324	NCT00001332_4_T6	GENE	27	27	has
NCT000013324	NCT00001332_4_T7	ORGAN	42	42	extremity
NCT000013325	NCT00001332_5_T0	PHENOTYPE	13	13	hyperthermic
NCT000013325	NCT00001332_5_T1	PHENOTYPE	32	32	adenocarcinoma
NCT000013327	NCT00001332_7_T0	GENE	2	2	has
NCT000013329	NCT00001332_9_T0	PHENOTYPE	36	36	hyperthermic
NCT000013329	NCT00001332_9_T1	ORGAN	38	38	limb
NCT000013329	NCT00001332_9_T2	CELL	9	9	cells
NCT000013329	NCT00001332_9_T3	PHENOTYPE	45	45	sarcoma
NCT000013329	NCT00001332_9_T4	PHENOTYPE	43	43	melanoma
NCT000013329	NCT00001332_9_T5	GENE	19	19	has
NCT000013329	NCT00001332_9_T6	GENE	27	27	has
NCT000013329	NCT00001332_9_T7	ORGAN	42	42	extremity
NCT0000133210	NCT00001332_10_T0	PHENOTYPE	13	13	hyperthermic
NCT0000133210	NCT00001332_10_T1	PHENOTYPE	32	32	adenocarcinoma
NCT0000133212	NCT00001332_12_T0	PHENOTYPE	8	8	sarcoma
NCT0000133212	NCT00001332_12_T1	PHENOTYPE	5	5	adenocarcinoma
NCT0000133212	NCT00001332_12_T2	PHENOTYPE	6	6	mesothelioma
NCT0000133214	NCT00001332_14_T0	PHENOTYPE	9	9	symptoms
NCT0000133214	NCT00001332_14_T1	PHENOTYPE	15	15	malignancy
NCT0000133214	NCT00001332_14_T2	PHENOTYPE	4	5	metastatic disease
NCT0000133215	NCT00001332_15_T0	GENE	7	7	N-2
NCT0000133215	NCT00001332_15_T1	ORGAN	8	8	lymph
NCT0000133215	NCT00001332_15_T2	PHENOTYPE	19	20	malignant ascites
NCT0000133215	NCT00001332_15_T3	PHENOTYPE	3	4	gastric cancer
NCT0000133216	NCT00001332_16_T0	PHENOTYPE	3	4	peritoneal disease
NCT0000133217	NCT00001332_17_T0	PHENOTYPE	6	6	toxicity
NCT0000133218	NCT00001332_18_T0	PHENOTYPE	6	7	systemic illness
NCT0000133220	NCT00001332_20_T0	COMPOUND	8	8	creatinine
NCT0000133220	NCT00001332_20_T1	COMPOUND	16	16	creatinine
NCT0000133220	NCT00001332_20_T2	GENE	14	14	2.0
NCT0000133220	NCT00001332_20_T3	ORGAN	7	7	serum
NCT0000133221	NCT00001332_21_T0	PHENOTYPE	3	3	HIV
NCT0000133223	NCT00001332_23_T0	PHENOTYPE	16	16	toxicity
NCT0000133224	NCT00001332_24_T0	PHENOTYPE	6	6	toxicity
NCT0000133224	NCT00001332_24_T1	PHENOTYPE	4	4	chronic
NCT0000133225	NCT00001332_25_T0	GENE	7	7	2.0
NCT0000133225	NCT00001332_25_T1	ORGAN	11	11	liver
NCT0000133226	NCT00001332_26_T0	GENE	4	4	sec
NCT0000133226	NCT00001332_26_T1	PHENOTYPE	13	13	thrombocytopenia
NCT0000133226	NCT00001332_26_T2	PHENOTYPE	0	0	Abnormalities
NCT0000133227	NCT00001332_27_T0	PHENOTYPE	3	3	secondary
NCT0000133227	NCT00001332_27_T1	PHENOTYPE	2	2	Hgb
NCT0000133227	NCT00001332_27_T2	PHENOTYPE	6	6	tumor
NCT0000133227	NCT00001332_27_T3	PHENOTYPE	5	5	chronic
NCT0000133227	NCT00001332_27_T4	PHENOTYPE	7	8	blood loss
NCT000013333	NCT00001333_3_T0	GENE	1	1	CSF
NCT000013333	NCT00001333_3_T1	PHENOTYPE	2	2	pharmacokinetics
NCT000013333	NCT00001333_3_T2	COMPOUND	5	5	topotecan
NCT000013334	NCT00001333_4_T0	GENE	30	30	IT
NCT000013337	NCT00001333_7_T0	CELL	1	1	cells
NCT000013337	NCT00001333_7_T1	GENE	13	13	MRI
NCT000013337	NCT00001333_7_T2	PHENOTYPE	0	0	Tumor
NCT000013337	NCT00001333_7_T3	PHENOTYPE	18	19	solid tumors
NCT000013338	NCT00001333_8_T0	COMPOUND	15	15	indium_111
NCT000013338	NCT00001333_8_T1	BIOLOGICAL_PROCESS	10	11	CSF flow
NCT000013338	NCT00001333_8_T2	PHENOTYPE	4	5	obstructive hydrocephalus
NCT0000133310	NCT00001333_10_T0	PHENOTYPE	4	4	toxic
NCT0000133311	NCT00001333_11_T0	PHENOTYPE	3	3	toxic
NCT0000133312	NCT00001333_12_T0	PHENOTYPE	6	6	malignancy
NCT0000133313	NCT00001333_13_T0	PHENOTYPE	4	5	systemic disease
NCT0000133314	NCT00001333_14_T0	COMPOUND	10	10	cytarabine
NCT0000133314	NCT00001333_14_T1	COMPOUND	8	8	thiotepa
NCT0000133314	NCT00001333_14_T2	COMPOUND	7	7	methotrexate
NCT0000133316	NCT00001333_16_T0	PHENOTYPE	0	0	Endocrine
NCT0000133317	NCT00001333_17_T0	PHENOTYPE	3	3	toxic
NCT0000133318	NCT00001333_18_T0	PHENOTYPE	6	6	focal
NCT0000133320	NCT00001333_20_T0	GENE	2	2	Age
NCT0000133321	NCT00001333_21_T0	GENE	3	3	0.2
NCT0000133324	NCT00001333_24_T0	GENE	4	4	2.0
NCT0000133325	NCT00001333_25_T0	GENE	4	4	1.5
NCT0000133326	NCT00001333_26_T0	COMPOUND	4	4	calcium
NCT0000133326	NCT00001333_26_T1	COMPOUND	6	6	phosphate
NCT0000133326	NCT00001333_26_T2	ORGAN	1	1	Serum
NCT0000133327	NCT00001333_27_T0	PHENOTYPE	0	0	Other
NCT0000133327	NCT00001333_27_T1	PHENOTYPE	3	4	systemic illness
NCT000013353	NCT00001335_3_T0	GENE	11	11	II
NCT000013354	NCT00001335_4_T0	COMPOUND	15	15	vincristine
NCT000013354	NCT00001335_4_T1	COMPOUND	17	17	cyclophosphamide
NCT000013354	NCT00001335_4_T2	COMPOUND	13	13	doxorubicin
NCT000013355	NCT00001335_5_T0	GENE	25	25	MIME
NCT000013355	NCT00001335_5_T1	PHENOTYPE	5	5	relapse
NCT0000133510	NCT00001335_10_T0	GENE	11	11	II
NCT0000133511	NCT00001335_11_T0	COMPOUND	15	15	vincristine
NCT0000133511	NCT00001335_11_T1	COMPOUND	17	17	cyclophosphamide
NCT0000133511	NCT00001335_11_T2	COMPOUND	13	13	doxorubicin
NCT0000133512	NCT00001335_12_T0	GENE	25	25	MIME
NCT0000133512	NCT00001335_12_T1	PHENOTYPE	5	5	relapse
NCT0000133516	NCT00001335_16_T0	GENE	63	63	1.1
NCT0000133516	NCT00001335_16_T1	GENE	8	8	POG
NCT0000133516	NCT00001335_16_T2	GENE	21	21	POG
NCT0000133516	NCT00001335_16_T3	PHENOTYPE	0	0	Neuroblastoma
NCT0000133516	NCT00001335_16_T4	GENE	14	14	IV
NCT0000133516	NCT00001335_16_T5	PHENOTYPE	26	26	infiltrating
NCT0000133516	NCT00001335_16_T6	PHENOTYPE	25	25	tumor
NCT0000133516	NCT00001335_16_T7	GENE	29	29	midline
NCT0000133516	NCT00001335_16_T8	GENE	33	33	IF
NCT0000133516	NCT00001335_16_T9	GENE	46	46	N-myc
NCT0000133516	NCT00001335_16_T10	PHENOTYPE	31	32	stage III
NCT0000133516	NCT00001335_16_T11	PHENOTYPE	4	5	metastatic disease
NCT0000133516	NCT00001335_16_T12	PHENOTYPE	19	20	metastatic disease
NCT0000133516	NCT00001335_16_T13	PHENOTYPE	37	39	elevated serum ferritin
NCT0000133521	NCT00001335_21_T0	ORGAN	11	11	serum
NCT0000133522	NCT00001335_22_T0	GENE	10	10	Blot
NCT0000133522	NCT00001335_22_T1	PHENOTYPE	6	6	HIV
NCT0000133523	NCT00001335_23_T0	COMPOUND	21	21	MUGA
NCT0000133523	NCT00001335_23_T1	PHENOTYPE	8	10	ventricular ejection fraction
NCT0000133524	NCT00001335_24_T0	COMPOUND	8	8	creatinine
NCT0000133524	NCT00001335_24_T1	ORGAN	7	7	serum
NCT0000133524	NCT00001335_24_T2	PHENOTYPE	4	6	impaired renal function
NCT0000133525	NCT00001335_25_T0	GENE	30	30	NOT
NCT0000133525	NCT00001335_25_T1	GENE	17	17	2.0
NCT0000133525	NCT00001335_25_T2	GENE	8	8	4.0
NCT0000133525	NCT00001335_25_T3	PHENOTYPE	38	38	tumor
NCT0000133525	NCT00001335_25_T4	COMPOUND	13	13	bilirubin
NCT0000133525	NCT00001335_25_T5	PHENOTYPE	3	4	total bilirubin
NCT0000133526	NCT00001335_26_T0	PHENOTYPE	3	4	second malignancy
NCT0000133528	NCT00001335_28_T0	PHENOTYPE	3	3	HIV
NCT000013366	NCT00001336_6_T0	GENE	22	22	thymic
NCT000013366	NCT00001336_6_T1	CELL	10	10	lymphocyte
NCT000013366	NCT00001336_6_T2	PHENOTYPE	24	24	secondary
NCT000013366	NCT00001336_6_T3	GENE	16	16	ex
NCT000013366	NCT00001336_6_T4	CELL	4	5	stem cells
NCT000013366	NCT00001336_6_T5	TISSUE	25	26	lymphoid tissues
NCT000013374	NCT00001337_4_T0	COMPOUND	16	16	EPOCH
NCT000013374	NCT00001337_4_T1	GENE	22	22	G-CSF
NCT000013375	NCT00001337_5_T0	GENE	15	15	G-CSF
NCT000013375	NCT00001337_5_T1	GENE	5	5	CR
NCT000013375	NCT00001337_5_T2	PHENOTYPE	18	19	B-cell lymphomas
NCT000013378	NCT00001337_8_T0	PHENOTYPE	3	3	PMBL
NCT0000133710	NCT00001337_10_T0	PHENOTYPE	0	0	HIV
NCT0000133712	NCT00001337_12_T0	COMPOUND	12	12	vincristine
NCT0000133712	NCT00001337_12_T1	COMPOUND	20	20	cyclophosphamide
NCT0000133712	NCT00001337_12_T2	COMPOUND	15	15	etoposide
NCT0000133712	NCT00001337_12_T3	COMPOUND	13	13	doxorubicin
NCT0000133712	NCT00001337_12_T4	COMPOUND	2	2	prednisone
NCT0000133714	NCT00001337_14_T0	GENE	2	2	CD20
NCT0000133714	NCT00001337_14_T1	PHENOTYPE	4	4	tumors
NCT0000133714	NCT00001337_14_T2	GENE	19	20	CD20 receptor
NCT0000133714	NCT00001337_14_T3	PHENOTYPE	7	8	B-cell lymphomas
NCT0000133717	NCT00001337_17_T0	COMPOUND	11	11	NCI
NCT0000133718	NCT00001337_18_T0	COMPOUND	13	13	NCI
NCT0000133718	NCT00001337_18_T1	PHENOTYPE	1	1	blocks
NCT0000133718	NCT00001337_18_T2	GENE	17	17	bcl-2
NCT0000133720	NCT00001337_20_T0	PHENOTYPE	10	10	PMBL
NCT0000133723	NCT00001337_23_T0	PHENOTYPE	0	0	HIV
NCT000013381	NCT00001338_1_T0	PHENOTYPE	11	11	thrombocytopenia
NCT000013381	NCT00001338_1_T1	CELL	18	18	platelets
NCT000013382	NCT00001338_2_T0	GENE	17	17	RBC
NCT000013382	NCT00001338_2_T1	PHENOTYPE	10	10	leukopenia
NCT000013382	NCT00001338_2_T2	PHENOTYPE	31	31	fever
NCT000013382	NCT00001338_2_T3	PHENOTYPE	11	11	neutropenia
NCT000013382	NCT00001338_2_T4	PHENOTYPE	33	33	neutropenia
NCT000013382	NCT00001338_2_T5	CELL	15	15	platelet
NCT000013382	NCT00001338_2_T6	PHENOTYPE	13	13	anemia
NCT000013382	NCT00001338_2_T7	PHENOTYPE	27	27	sepsis
NCT000013383	NCT00001338_3_T0	GENE	16	16	GM-CSF
NCT000013383	NCT00001338_3_T1	ORGAN	28	29	bone marrow
NCT000013383	NCT00001338_3_T2	CELL	12	14	hematopoietic progenitor cells
NCT000013384	NCT00001338_4_T0	COMPOUND	20	20	taxol
NCT000013384	NCT00001338_4_T1	GENE	6	6	GM-CSF
NCT000013385	NCT00001338_5_T0	PHENOTYPE	13	13	toxicity
NCT000013385	NCT00001338_5_T1	COMPOUND	19	19	taxol
NCT000013387	NCT00001338_7_T0	PHENOTYPE	11	11	thrombocytopenia
NCT000013387	NCT00001338_7_T1	CELL	18	18	platelets
NCT000013388	NCT00001338_8_T0	GENE	17	17	RBC
NCT000013388	NCT00001338_8_T1	PHENOTYPE	10	10	leukopenia
NCT000013388	NCT00001338_8_T2	PHENOTYPE	31	31	fever
NCT000013388	NCT00001338_8_T3	PHENOTYPE	11	11	neutropenia
NCT000013388	NCT00001338_8_T4	PHENOTYPE	33	33	neutropenia
NCT000013388	NCT00001338_8_T5	CELL	15	15	platelet
NCT000013388	NCT00001338_8_T6	PHENOTYPE	13	13	anemia
NCT000013388	NCT00001338_8_T7	PHENOTYPE	27	27	sepsis
NCT000013389	NCT00001338_9_T0	GENE	16	16	GM-CSF
NCT000013389	NCT00001338_9_T1	ORGAN	28	29	bone marrow
NCT000013389	NCT00001338_9_T2	CELL	12	14	hematopoietic progenitor cells
NCT0000133810	NCT00001338_10_T0	COMPOUND	20	20	taxol
NCT0000133810	NCT00001338_10_T1	GENE	6	6	GM-CSF
NCT0000133811	NCT00001338_11_T0	PHENOTYPE	13	13	toxicity
NCT0000133811	NCT00001338_11_T1	COMPOUND	19	19	taxol
NCT0000133813	NCT00001338_13_T0	GENE	6	6	II
NCT0000133813	NCT00001338_13_T1	GENE	3	3	III
NCT0000133813	NCT00001338_13_T2	GENE	16	16	IV
NCT0000133814	NCT00001338_14_T0	GENE	3	3	had
NCT0000133814	NCT00001338_14_T1	GENE	18	18	has
NCT0000133814	NCT00001338_14_T2	ORGAN	16	17	bone marrow
NCT0000133816	NCT00001338_16_T0	PHENOTYPE	8	9	metastatic disease
NCT0000133818	NCT00001338_18_T0	GENE	10	10	0.2
NCT0000133818	NCT00001338_18_T1	GENE	8	8	70
NCT0000133819	NCT00001338_19_T0	CELL	1	1	granulocyte
NCT0000133819	NCT00001338_19_T1	PHENOTYPE	8	9	platelet count
NCT0000133821	NCT00001338_21_T0	COMPOUND	1	1	creatinine
NCT0000133821	NCT00001338_21_T1	COMPOUND	8	8	creatinine
NCT0000133821	NCT00001338_21_T2	ORGAN	0	0	Serum
NCT0000133821	NCT00001338_21_T3	GENE	6	6	1.7
NCT0000133823	NCT00001338_23_T0	COMPOUND	13	13	NCI
NCT0000133825	NCT00001338_25_T0	ORGAN	10	10	heart
NCT0000133825	NCT00001338_25_T1	PHENOTYPE	7	8	cardiac arrhythmias
NCT0000133825	NCT00001338_25_T2	PHENOTYPE	13	15	coronary artery disease
NCT0000133826	NCT00001338_26_T0	COMPOUND	22	22	MUGA
NCT0000133826	NCT00001338_26_T1	PHENOTYPE	11	12	cardiac disease
NCT0000133827	NCT00001338_27_T0	PHENOTYPE	3	4	CNS metastasis
NCT0000133827	NCT00001338_27_T1	PHENOTYPE	7	8	seizure disorder
NCT0000133828	NCT00001338_28_T0	PHENOTYPE	1	1	allergy
NCT0000133830	NCT00001338_30_T0	PHENOTYPE	6	6	asthma
NCT0000133831	NCT00001338_31_T0	PHENOTYPE	13	13	anticoagulation
NCT0000133831	NCT00001338_31_T1	PHENOTYPE	12	12	chronic
NCT0000133831	NCT00001338_31_T2	PHENOTYPE	3	4	bleeding disorders
NCT000013396	NCT00001339_6_T0	COMPOUND	1	1	mitotane
NCT000013396	NCT00001339_6_T1	COMPOUND	24	24	mitotane
NCT000013396	NCT00001339_6_T2	GENE	2	2	has
NCT000013396	NCT00001339_6_T3	GENE	10	10	has
NCT000013396	NCT00001339_6_T4	PHENOTYPE	7	8	adrenocortical cancer
NCT000013397	NCT00001339_7_T0	COMPOUND	8	8	mitotane
NCT000013397	NCT00001339_7_T1	GENE	26	26	P-glycoprotein
NCT0000133911	NCT00001339_11_T0	COMPOUND	11	11	mitotane
NCT0000133913	NCT00001339_13_T0	PHENOTYPE	7	7	metastases
NCT0000133913	NCT00001339_13_T1	ORGAN	9	9	liver
NCT0000133913	NCT00001339_13_T2	GENE	6	6	nodal
NCT0000133913	NCT00001339_13_T3	PHENOTYPE	11	12	lung metastases
NCT0000133913	NCT00001339_13_T4	PHENOTYPE	4	5	primary lesion
NCT0000133915	NCT00001339_15_T0	PHENOTYPE	0	1	Measurable disease
NCT0000133918	NCT00001339_18_T0	COMPOUND	27	27	MUGA
NCT0000133918	NCT00001339_18_T1	COMPOUND	5	5	doxorubicin
NCT0000133919	NCT00001339_19_T0	COMPOUND	1	1	mitotane
NCT0000133921	NCT00001339_21_T0	COMPOUND	7	7	mitotane
NCT0000133922	NCT00001339_22_T0	GENE	17	17	1.5
NCT0000133922	NCT00001339_22_T1	COMPOUND	14	14	bilirubin
NCT0000133922	NCT00001339_22_T2	GENE	0	0	WBC
NCT0000133922	NCT00001339_22_T3	ORGAN	19	19	serum
NCT0000133922	NCT00001339_22_T4	PHENOTYPE	3	4	Platelet count
NCT0000133926	NCT00001339_26_T0	PHENOTYPE	2	3	systemic infection
NCT0000133927	NCT00001339_27_T0	COMPOUND	14	14	diltiazem
NCT0000133927	NCT00001339_27_T1	COMPOUND	18	18	terfenadine
NCT0000133927	NCT00001339_27_T2	COMPOUND	20	20	verapamil
NCT0000133927	NCT00001339_27_T3	COMPOUND	15	15	nicardipine
NCT0000133927	NCT00001339_27_T4	COMPOUND	17	17	phenytoin
NCT0000133928	NCT00001339_28_T0	PHENOTYPE	4	4	HIV
NCT0000133928	NCT00001339_28_T1	PHENOTYPE	1	2	positive serology
NCT000013411	NCT00001341_1_T0	COMPOUND	5	5	folate
NCT000013411	NCT00001341_1_T1	GENE	10	10	TS
NCT000013412	NCT00001341_2_T0	PHENOTYPE	20	20	pharmacokinetics
NCT000013412	NCT00001341_2_T1	PHENOTYPE	12	12	toxicities
NCT000013412	NCT00001341_2_T2	GENE	15	15	MTD
NCT000013412	NCT00001341_2_T3	ORGAN	19	19	plasma
NCT000013412	NCT00001341_2_T4	PHENOTYPE	27	28	refractory cancer
NCT000013413	NCT00001341_3_T0	GENE	8	8	2.0
NCT000013413	NCT00001341_3_T1	GENE	15	15	IV
NCT000013415	NCT00001341_5_T0	COMPOUND	5	5	folate
NCT000013415	NCT00001341_5_T1	GENE	10	10	TS
NCT000013416	NCT00001341_6_T0	PHENOTYPE	20	20	pharmacokinetics
NCT000013416	NCT00001341_6_T1	PHENOTYPE	12	12	toxicities
NCT000013416	NCT00001341_6_T2	GENE	15	15	MTD
NCT000013416	NCT00001341_6_T3	ORGAN	19	19	plasma
NCT000013416	NCT00001341_6_T4	PHENOTYPE	27	28	refractory cancer
NCT000013417	NCT00001341_7_T0	GENE	8	8	2.0
NCT000013417	NCT00001341_7_T1	GENE	15	15	IV
NCT000013419	NCT00001341_9_T0	PHENOTYPE	3	3	progression
NCT0000134110	NCT00001341_10_T0	PHENOTYPE	1	1	leukemia
NCT0000134111	NCT00001341_11_T0	PHENOTYPE	4	4	tumor
NCT0000134111	NCT00001341_11_T1	ORGAN	0	1	Bone marrow
NCT0000134112	NCT00001341_12_T0	PHENOTYPE	11	11	peripheral
NCT0000134112	NCT00001341_12_T1	ORGAN	0	0	Marrow
NCT0000134113	NCT00001341_13_T0	PHENOTYPE	6	6	toxic
NCT0000134116	NCT00001341_16_T0	PHENOTYPE	0	0	Endocrine
NCT0000134117	NCT00001341_17_T0	ORGAN	10	10	pelvis
NCT0000134117	NCT00001341_17_T1	ORGAN	8	8	spine
NCT0000134117	NCT00001341_17_T2	ORGAN	7	7	skull
NCT0000134117	NCT00001341_17_T3	GENE	4	4	axis
NCT0000134117	NCT00001341_17_T4	ORGAN	9	9	ribs
NCT0000134118	NCT00001341_18_T0	PHENOTYPE	2	2	toxic
NCT0000134120	NCT00001341_20_T0	PHENOTYPE	0	0	Other
NCT0000134120	NCT00001341_20_T1	ORGAN	3	4	bone marrow
NCT0000134121	NCT00001341_21_T0	GENE	2	2	Age
NCT0000134122	NCT00001341_22_T0	GENE	3	3	0.2
NCT0000134124	NCT00001341_24_T0	PHENOTYPE	9	9	tumor
NCT0000134124	NCT00001341_24_T1	ORGAN	5	6	bone marrow
NCT0000134125	NCT00001341_25_T0	GENE	0	0	AGC
NCT0000134126	NCT00001341_26_T0	PHENOTYPE	0	1	Platelet count
NCT0000134127	NCT00001341_27_T0	GENE	3	3	8.0
NCT0000134131	NCT00001341_31_T0	GENE	6	6	OR
NCT0000134131	NCT00001341_31_T1	GENE	4	4	1.5
NCT0000134135	NCT00001341_35_T0	PHENOTYPE	2	3	systemic illness
NCT000013421	NCT00001342_1_T0	ORGAN	10	10	liver
NCT000013422	NCT00001342_2_T0	COMPOUND	6	6	glucose
NCT000013422	NCT00001342_2_T1	COMPOUND	15	15	glucose
NCT000013422	NCT00001342_2_T2	TISSUE	1	1	tissues
NCT000013422	NCT00001342_2_T3	COMPOUND	11	11	glycogen
NCT000013423	NCT00001342_3_T0	PHENOTYPE	3	3	GSD
NCT000013423	NCT00001342_3_T1	COMPOUND	15	15	glycogen
NCT000013423	NCT00001342_3_T2	COMPOUND	31	31	glycogen
NCT000013423	NCT00001342_3_T3	PHENOTYPE	0	2	Glycogen storage disease
NCT000013424	NCT00001342_4_T0	PHENOTYPE	11	11	GSD
NCT000013424	NCT00001342_4_T1	PHENOTYPE	8	10	glycogen storage disease
NCT000013425	NCT00001342_5_T0	PHENOTYPE	3	3	disorders
NCT000013425	NCT00001342_5_T1	BIOLOGICAL_PROCESS	5	6	glycogen metabolism
NCT000013426	NCT00001342_6_T0	PHENOTYPE	8	8	disorders
NCT000013426	NCT00001342_6_T1	PHENOTYPE	4	4	suffering
NCT000013426	NCT00001342_6_T2	COMPOUND	6	6	glycogen
NCT000013426	NCT00001342_6_T3	PHENOTYPE	17	18	metabolic disorders
NCT000013427	NCT00001342_7_T0	PHENOTYPE	10	10	disorders
NCT000013427	NCT00001342_7_T1	PHENOTYPE	14	14	GSD
NCT0000134210	NCT00001342_10_T0	GENE	47	47	hindsight
NCT0000134210	NCT00001342_10_T1	PHENOTYPE	19	19	glycogenosis
NCT0000134210	NCT00001342_10_T2	PHENOTYPE	5	7	glycogen storage disease
NCT000013435	NCT00001343_5_T0	COMPOUND	11	11	estrogen
NCT000013435	NCT00001343_5_T1	COMPOUND	9	9	androgen
NCT000013437	NCT00001343_7_T0	COMPOUND	12	12	oxandrolone
NCT000013437	NCT00001343_7_T1	GENE	11	11	hormone
NCT0000134317	NCT00001343_17_T0	GENE	3	3	10.0
NCT000013441	NCT00001344_1_T0	COMPOUND	19	19	memantine
NCT000013441	NCT00001344_1_T1	PHENOTYPE	17	17	antitussive
NCT000013441	NCT00001344_1_T2	COMPOUND	8	8	dextromethorphan
NCT000013448	NCT00001344_8_T0	COMPOUND	19	19	memantine
NCT000013448	NCT00001344_8_T1	PHENOTYPE	17	17	antitussive
NCT000013448	NCT00001344_8_T2	COMPOUND	8	8	dextromethorphan
NCT0000134416	NCT00001344_16_T0	PHENOTYPE	2	2	symptoms
NCT0000134423	NCT00001344_23_T0	PHENOTYPE	10	10	alcoholism
NCT0000134423	NCT00001344_23_T1	GENE	3	3	IV
NCT0000134423	NCT00001344_23_T2	PHENOTYPE	4	5	drug abuse
NCT0000134423	NCT00001344_23_T3	PHENOTYPE	7	8	drug abuse
NCT0000134424	NCT00001344_24_T0	ORGAN	2	2	liver
NCT0000134424	NCT00001344_24_T1	PHENOTYPE	4	5	kidney disease
NCT0000134425	NCT00001344_25_T0	GENE	1	1	MAO
NCT000013452	NCT00001345_2_T0	COMPOUND	8	8	calcium
NCT000013453	NCT00001345_3_T0	PHENOTYPE	17	17	disorders
NCT000013455	NCT00001345_5_T0	GENE	11	11	had
NCT000013455	NCT00001345_5_T1	BIOLOGICAL_PROCESS	19	19	metabolism
NCT000013457	NCT00001345_7_T0	CELL	5	5	cells
NCT0000134516	NCT00001345_16_T0	PHENOTYPE	4	4	mutation
NCT0000134517	NCT00001345_17_T0	GENE	0	0	PHP
NCT0000134517	NCT00001345_17_T1	PHENOTYPE	17	17	encoding
NCT0000134517	NCT00001345_17_T2	GENE	4	5	parathyroid hormone
NCT0000134517	NCT00001345_17_T3	GENE	20	21	G protein
NCT0000134523	NCT00001345_23_T0	GENE	1	1	has
NCT0000134523	NCT00001345_23_T1	PHENOTYPE	5	6	familial hyperparathyroidism
NCT000013461	NCT00001346_1_T0	PHENOTYPE	12	13	macular edema
NCT000013461	NCT00001346_1_T1	PHENOTYPE	1	2	visual loss
NCT000013462	NCT00001346_2_T0	PHENOTYPE	12	13	contrast sensitivity
NCT000013463	NCT00001346_3_T0	PHENOTYPE	10	11	macular edema
NCT000013463	NCT00001346_3_T1	PHENOTYPE	6	7	visual loss
NCT000013464	NCT00001346_4_T0	PHENOTYPE	1	2	visual loss
NCT000013465	NCT00001346_5_T0	PHENOTYPE	0	1	Visual loss
NCT000013467	NCT00001346_7_T0	PHENOTYPE	12	13	macular edema
NCT000013467	NCT00001346_7_T1	PHENOTYPE	1	2	visual loss
NCT000013468	NCT00001346_8_T0	PHENOTYPE	12	13	contrast sensitivity
NCT000013469	NCT00001346_9_T0	PHENOTYPE	10	11	macular edema
NCT000013469	NCT00001346_9_T1	PHENOTYPE	6	7	visual loss
NCT0000134610	NCT00001346_10_T0	PHENOTYPE	1	2	visual loss
NCT0000134611	NCT00001346_11_T0	PHENOTYPE	0	1	Visual loss
NCT000013470	NCT00001347_0_T0	PHENOTYPE	2	3	Usher Syndromes
NCT000013476	NCT00001347_6_T0	PHENOTYPE	9	9	syndromes
NCT0000134712	NCT00001347_12_T0	GENE	19	20	eyes closed
NCT0000134717	NCT00001347_17_T0	GENE	3	3	USH
NCT0000134717	NCT00001347_17_T1	GENE	24	24	USH
NCT0000134717	NCT00001347_17_T2	GENE	31	31	USH
NCT0000134717	NCT00001347_17_T3	GENE	29	30	type 2
NCT0000134717	NCT00001347_17_T4	PHENOTYPE	20	21	Usher Syndrome
NCT0000134717	NCT00001347_17_T5	PHENOTYPE	27	28	Usher Syndrome
NCT0000134718	NCT00001347_18_T0	GENE	2	2	USH
NCT0000134718	NCT00001347_18_T1	PHENOTYPE	13	15	absent vestibular function
NCT0000134719	NCT00001347_19_T0	PHENOTYPE	16	16	profound
NCT0000134719	NCT00001347_19_T1	COMPOUND	5	5	1st
NCT0000134719	NCT00001347_19_T2	GENE	14	14	ERG
NCT0000134719	NCT00001347_19_T3	PHENOTYPE	12	13	extinguished electroretinogram
NCT0000134721	NCT00001347_21_T0	GENE	18	18	ERG
NCT0000134722	NCT00001347_22_T0	PHENOTYPE	0	0	Heterogeneity
NCT0000134722	NCT00001347_22_T1	GENE	23	23	al
NCT0000134722	NCT00001347_22_T2	GENE	27	27	al
NCT0000134722	NCT00001347_22_T3	GENE	31	31	al
NCT0000134722	NCT00001347_22_T4	GENE	35	35	al
NCT0000134722	NCT00001347_22_T5	GENE	1	1	has
NCT0000134722	NCT00001347_22_T6	GENE	11	11	USH
NCT0000134722	NCT00001347_22_T7	GENE	16	16	USH
NCT0000134722	NCT00001347_22_T8	GENE	53	53	USH
NCT0000134722	NCT00001347_22_T9	GENE	22	22	et
NCT0000134722	NCT00001347_22_T10	GENE	26	26	et
NCT0000134722	NCT00001347_22_T11	GENE	30	30	et
NCT0000134722	NCT00001347_22_T12	GENE	34	34	et
NCT000013499	NCT00001349_9_T0	GENE	5	5	separated
NCT000013499	NCT00001349_9_T1	CELL	1	3	red blood cells
NCT0000134910	NCT00001349_10_T0	PHENOTYPE	3	4	needle stick
NCT000013503	NCT00001350_3_T0	PHENOTYPE	9	9	ALPS
NCT000013506	NCT00001350_6_T0	PHENOTYPE	27	27	ALPS
NCT000013506	NCT00001350_6_T1	PHENOTYPE	12	12	autoimmunity
NCT000013506	NCT00001350_6_T2	PHENOTYPE	7	7	insights
NCT000013506	NCT00001350_6_T3	ORGAN	21	22	immune system
NCT000013506	NCT00001350_6_T4	TISSUE	14	15	thymus gland
NCT000013509	NCT00001350_9_T0	PHENOTYPE	5	5	ALPS
NCT000013509	NCT00001350_9_T1	PHENOTYPE	2	2	autoimmune
NCT000013509	NCT00001350_9_T2	ORGAN	11	12	immune system
NCT0000135010	NCT00001350_10_T0	CELL	10	10	cells
NCT0000135012	NCT00001350_12_T0	CELL	4	4	lymphocytes
NCT0000135013	NCT00001350_13_T0	PHENOTYPE	3	3	ALPS
NCT0000135013	NCT00001350_13_T1	CELL	16	16	cells
NCT0000135013	NCT00001350_13_T2	CELL	28	28	cells
NCT0000135015	NCT00001350_15_T0	PHENOTYPE	10	10	lymphoma
NCT0000135015	NCT00001350_15_T1	PHENOTYPE	9	9	cancers
NCT0000135017	NCT00001350_17_T0	PHENOTYPE	3	3	ALPS
NCT0000135023	NCT00001350_23_T0	PHENOTYPE	3	3	ALPS
NCT0000135029	NCT00001350_29_T0	PHENOTYPE	4	4	ALPS
NCT0000135029	NCT00001350_29_T1	PHENOTYPE	8	8	cytopenias
NCT0000135029	NCT00001350_29_T2	PHENOTYPE	5	6	autoimmune disease
NCT0000135031	NCT00001350_31_T0	PHENOTYPE	0	0	ALPS
NCT0000135032	NCT00001350_32_T0	PHENOTYPE	1	1	Distribution
NCT0000135036	NCT00001350_36_T0	PHENOTYPE	10	10	lymphadenopathy
NCT0000135036	NCT00001350_36_T1	PHENOTYPE	3	3	chronic
NCT0000135036	NCT00001350_36_T2	PHENOTYPE	12	12	splenomegaly
NCT0000135042	NCT00001350_42_T0	PHENOTYPE	8	8	lymphadenopathy
NCT0000135042	NCT00001350_42_T1	PHENOTYPE	3	3	chronic
NCT0000135042	NCT00001350_42_T2	PHENOTYPE	10	10	splenomegaly
NCT0000135046	NCT00001350_46_T0	PHENOTYPE	3	3	ALPS
NCT0000135047	NCT00001350_47_T0	PHENOTYPE	5	5	ALPS
NCT0000135047	NCT00001350_47_T1	PHENOTYPE	18	18	mutation
NCT0000135054	NCT00001350_54_T0	GENE	15	15	PI
NCT0000135057	NCT00001350_57_T0	PHENOTYPE	11	11	ALPS
NCT0000135057	NCT00001350_57_T1	PHENOTYPE	15	15	peripheral
NCT0000135112	NCT00001351_12_T0	GENE	4	4	cc
NCT0000135112	NCT00001351_12_T1	GENE	21	21	cc
NCT0000135112	NCT00001351_12_T2	GENE	22	22	1.2
NCT0000135115	NCT00001351_15_T0	PHENOTYPE	11	11	disorders
NCT0000135115	NCT00001351_15_T1	GENE	23	23	LCID
NCT0000135116	NCT00001351_16_T0	PHENOTYPE	19	19	allergy
NCT0000135116	NCT00001351_16_T1	PHENOTYPE	16	17	infectious diseases
NCT0000135116	NCT00001351_16_T2	PHENOTYPE	40	41	Infectious Diseases
NCT0000135123	NCT00001351_23_T0	PHENOTYPE	23	23	disorders
NCT000013521	NCT00001352_1_T0	PHENOTYPE	28	28	sarcoidosis
NCT000013521	NCT00001352_1_T1	PHENOTYPE	22	22	cryptococcosis
NCT000013521	NCT00001352_1_T2	PHENOTYPE	15	16	HIV infection
NCT000013521	NCT00001352_1_T3	PHENOTYPE	31	32	blood cancer
NCT000013522	NCT00001352_2_T0	PHENOTYPE	5	6	HIV infection
NCT000013524	NCT00001352_4_T0	PHENOTYPE	5	5	cryptococcosis
NCT0000135210	NCT00001352_10_T0	PHENOTYPE	7	7	cryptococcosis
NCT0000135210	NCT00001352_10_T1	BIOLOGICAL_PROCESS	10	11	immune response
NCT0000135211	NCT00001352_11_T0	PHENOTYPE	12	12	cryptococcosis
NCT0000135212	NCT00001352_12_T0	PHENOTYPE	10	10	cryptococcosis
NCT0000135213	NCT00001352_13_T0	GENE	4	4	saliva
NCT0000135219	NCT00001352_19_T0	PHENOTYPE	26	26	cryptococcosis
NCT0000135233	NCT00001352_33_T0	ORGAN	13	14	bone marrow
NCT0000135243	NCT00001352_43_T0	PHENOTYPE	19	19	immunity
NCT0000135243	NCT00001352_43_T1	PHENOTYPE	41	41	cryptococcosis
NCT0000135243	NCT00001352_43_T2	PHENOTYPE	32	33	cortisol levels
NCT0000135244	NCT00001352_44_T0	ORGAN	27	28	immune system
NCT0000135246	NCT00001352_46_T0	PHENOTYPE	0	0	HIV
NCT0000135246	NCT00001352_46_T1	PHENOTYPE	2	3	viral hepatitis
NCT0000135248	NCT00001352_48_T0	PHENOTYPE	5	5	infections
NCT0000135248	NCT00001352_48_T1	PHENOTYPE	2	2	recurrent
NCT0000135250	NCT00001352_50_T0	PHENOTYPE	3	4	drug use
NCT0000135252	NCT00001352_52_T0	PHENOTYPE	10	10	HIV
NCT0000135253	NCT00001352_53_T0	PHENOTYPE	7	7	malignancy
NCT0000135257	NCT00001352_57_T0	ORGAN	3	3	heart
NCT0000135257	NCT00001352_57_T1	PHENOTYPE	8	9	bleeding disorders
NCT0000135257	NCT00001352_57_T2	PHENOTYPE	5	6	kidney disease
NCT000013531	NCT00001353_1_T0	CELL	4	4	cells
NCT000013531	NCT00001353_1_T1	CELL	21	21	cells
NCT000013531	NCT00001353_1_T2	PHENOTYPE	23	23	HIV
NCT000013531	NCT00001353_1_T3	PHENOTYPE	30	30	strategies
NCT000013532	NCT00001353_2_T0	PHENOTYPE	11	11	HIV
NCT000013534	NCT00001353_4_T0	PHENOTYPE	5	5	tetanus
NCT000013534	NCT00001353_4_T1	GENE	6	6	booster
NCT000013535	NCT00001353_5_T0	GENE	1	1	twins
NCT000013535	NCT00001353_5_T1	CELL	10	12	white blood cells
NCT000013538	NCT00001353_8_T0	CELL	3	3	cells
NCT000013539	NCT00001353_9_T0	CELL	14	14	cells
NCT000013539	NCT00001353_9_T1	CELL	18	18	cells
NCT000013539	NCT00001353_9_T2	PHENOTYPE	24	24	HIV
NCT000013539	NCT00001353_9_T3	COMPOUND	3	3	NeoR
NCT0000135313	NCT00001353_13_T0	CELL	14	14	cells
NCT0000135323	NCT00001353_23_T0	PHENOTYPE	15	15	proliferation
NCT0000135323	NCT00001353_23_T1	GENE	24	24	neoR
NCT0000135323	NCT00001353_23_T2	PHENOTYPE	4	4	seronegative
NCT0000135323	NCT00001353_23_T3	GENE	30	30	fold
NCT0000135323	NCT00001353_23_T4	GENE	17	17	CD3
NCT0000135323	NCT00001353_23_T5	CELL	0	1	T cells
NCT0000135328	NCT00001353_28_T0	GENE	3	3	KS
NCT0000135332	NCT00001353_32_T0	GENE	12	12	CD4
NCT0000135334	NCT00001353_34_T0	PHENOTYPE	3	3	lymphoma
NCT0000135336	NCT00001353_36_T0	PHENOTYPE	4	5	substance abuse
NCT000013542	NCT00001354_2_T0	GENE	3	3	IL-2
NCT000013548	NCT00001354_8_T0	ORGAN	18	19	immune system
NCT000013549	NCT00001354_9_T0	PHENOTYPE	23	23	progression
NCT000013549	NCT00001354_9_T1	ORGAN	4	5	bone marrow
NCT000013549	NCT00001354_9_T2	PHENOTYPE	25	26	HIV disease
NCT000013549	NCT00001354_9_T3	ORGAN	7	8	organ transplants
NCT0000135411	NCT00001354_11_T0	GENE	4	4	IL-2
NCT0000135414	NCT00001354_14_T0	GENE	14	14	IL-2
NCT0000135415	NCT00001354_15_T0	GENE	15	15	IL-2
NCT0000135415	NCT00001354_15_T1	PHENOTYPE	2	3	Kaposi sarcoma
NCT0000135415	NCT00001354_15_T2	PHENOTYPE	19	20	Kaposi sarcoma
NCT0000135418	NCT00001354_18_T0	GENE	11	11	IL-2
NCT0000135422	NCT00001354_22_T0	GENE	3	3	CD4
NCT0000135426	NCT00001354_26_T0	GENE	3	3	IL-2
NCT0000135427	NCT00001354_27_T0	PHENOTYPE	2	2	malignancy
NCT0000135427	NCT00001354_27_T1	PHENOTYPE	5	6	Kaposi sarcoma
NCT0000135429	NCT00001354_29_T0	PHENOTYPE	6	7	opportunistic infection
NCT0000135430	NCT00001354_30_T0	PHENOTYPE	3	4	substance abuse
NCT0000135432	NCT00001354_32_T0	ORGAN	6	6	kidney
NCT0000135432	NCT00001354_32_T1	ORGAN	5	5	thyroid
NCT000013551	NCT00001355_1_T0	PHENOTYPE	54	54	diseases
NCT000013551	NCT00001355_1_T1	GENE	21	21	saliva
NCT000013554	NCT00001355_4_T0	CELL	11	11	phagocytes
NCT000013554	NCT00001355_4_T1	PHENOTYPE	8	9	immune diseases
NCT000013554	NCT00001355_4_T2	PHENOTYPE	20	21	fungal infections
NCT000013554	NCT00001355_4_T3	CELL	12	14	white blood cells
NCT0000135510	NCT00001355_10_T0	PHENOTYPE	57	57	diseases
NCT0000135510	NCT00001355_10_T1	GENE	22	22	saliva
NCT0000135517	NCT00001355_17_T0	PHENOTYPE	5	5	autoimmune
NCT0000135517	NCT00001355_17_T1	PHENOTYPE	9	9	infections
NCT0000135517	NCT00001355_17_T2	PHENOTYPE	15	15	encephalopathy
NCT0000135517	NCT00001355_17_T3	PHENOTYPE	17	17	coma
NCT0000135517	NCT00001355_17_T4	PHENOTYPE	14	14	delirium
NCT0000135517	NCT00001355_17_T5	PHENOTYPE	3	4	immune disorders
NCT0000135528	NCT00001355_28_T0	PHENOTYPE	19	19	malignancy
NCT0000135528	NCT00001355_28_T1	PHENOTYPE	15	15	HIV
NCT000013560	NCT00001356_0_T0	PHENOTYPE	5	5	Mastocytosis
NCT000013560	NCT00001356_0_T1	CELL	2	3	Mast Cells
NCT000013565	NCT00001356_5_T0	CELL	10	11	mast cells
NCT000013568	NCT00001356_8_T0	ORGAN	5	5	marrow
NCT000013568	NCT00001356_8_T1	PHENOTYPE	7	7	withdrawn
NCT0000135612	NCT00001356_12_T0	GENE	27	27	GI
NCT0000135612	NCT00001356_12_T1	PHENOTYPE	16	16	diarrhea
NCT0000135612	NCT00001356_12_T2	PHENOTYPE	7	7	itching
NCT0000135612	NCT00001356_12_T3	PHENOTYPE	15	15	cramping
NCT0000135612	NCT00001356_12_T4	PHENOTYPE	11	12	abdominal symptoms
NCT0000135612	NCT00001356_12_T5	CELL	21	22	mast cells
NCT0000135612	NCT00001356_12_T6	PHENOTYPE	32	33	anaphylactic shock
NCT0000135619	NCT00001356_19_T0	GENE	8	8	extended
NCT000013574	NCT00001357_4_T0	GENE	20	20	extended
NCT000013575	NCT00001357_5_T0	GENE	0	0	IL-2
NCT0000135710	NCT00001357_10_T0	GENE	20	20	extended
NCT0000135711	NCT00001357_11_T0	GENE	0	0	IL-2
NCT0000135714	NCT00001357_14_T0	GENE	2	2	IL-2
NCT0000135718	NCT00001357_18_T0	PHENOTYPE	8	8	Hgb
NCT0000135718	NCT00001357_18_T1	GENE	28	28	2.0
NCT0000135718	NCT00001357_18_T2	GENE	37	37	2.0
NCT0000135718	NCT00001357_18_T3	CELL	13	13	Granulocyte
NCT0000135718	NCT00001357_18_T4	COMPOUND	45	45	1
NCT0000135718	NCT00001357_18_T5	COMPOUND	31	31	creatinine
NCT0000135718	NCT00001357_18_T6	COMPOUND	22	22	bilirubin
NCT0000135718	NCT00001357_18_T7	ORGAN	30	30	Serum
NCT0000135718	NCT00001357_18_T8	CELL	46	46	platelet
NCT0000135718	NCT00001357_18_T9	PHENOTYPE	39	39	Proteinuria
NCT0000135719	NCT00001357_19_T0	PHENOTYPE	7	7	malignancy
NCT0000135719	NCT00001357_19_T1	PHENOTYPE	11	12	Kaposi sarcoma
NCT0000135719	NCT00001357_19_T2	PHENOTYPE	4	5	opportunistic infection
NCT0000135720	NCT00001357_20_T0	ORGAN	4	4	kidney
NCT0000135720	NCT00001357_20_T1	PHENOTYPE	9	10	neurological disease
NCT0000135722	NCT00001357_22_T0	PHENOTYPE	1	2	avascular necrosis
NCT0000135724	NCT00001357_24_T0	GENE	19	19	IL-2
NCT0000135725	NCT00001357_25_T0	GENE	17	17	IL-2
NCT0000135725	NCT00001357_25_T1	GENE	19	19	has
NCT0000135726	NCT00001357_26_T0	GENE	13	13	IL-2
NCT0000135726	NCT00001357_26_T1	GENE	25	25	IL-2
NCT0000135728	NCT00001357_28_T0	GENE	20	20	0.5
NCT0000135729	NCT00001357_29_T0	GENE	17	17	has
NCT0000135738	NCT00001357_38_T0	GENE	14	14	IL-2
NCT0000135738	NCT00001357_38_T1	PHENOTYPE	9	9	sterile
NCT000013592	NCT00001359_2_T0	PHENOTYPE	14	15	Streptococcal infections
NCT000013592	NCT00001359_2_T1	PHENOTYPE	8	12	Pediatric Autoimmune Neuropsychiatric Disorders Associated
NCT000013594	NCT00001359_4_T0	PHENOTYPE	11	11	infections
NCT000013594	NCT00001359_4_T1	PHENOTYPE	20	20	chorea
NCT000013594	NCT00001359_4_T2	PHENOTYPE	25	26	rheumatic fever
NCT000013595	NCT00001359_5_T0	PHENOTYPE	9	9	autoimmune
NCT000013595	NCT00001359_5_T1	PHENOTYPE	0	1	Rheumatic fever
NCT000013599	NCT00001359_9_T0	PHENOTYPE	9	9	symptoms
NCT000013599	NCT00001359_9_T1	PHENOTYPE	4	4	severity
NCT000013599	NCT00001359_9_T2	PHENOTYPE	6	6	tics
NCT0000135911	NCT00001359_11_T0	COMPOUND	3	3	penicillin
NCT0000135911	NCT00001359_11_T1	PHENOTYPE	16	16	severity
NCT0000135911	NCT00001359_11_T2	PHENOTYPE	11	11	infections
NCT0000135911	NCT00001359_11_T3	COMPOUND	1	1	azithromycin
NCT0000135913	NCT00001359_13_T0	PHENOTYPE	16	16	remission
NCT0000135913	NCT00001359_13_T1	PHENOTYPE	7	7	infections
NCT0000135915	NCT00001359_15_T0	PHENOTYPE	19	19	symptoms
NCT0000135915	NCT00001359_15_T1	PHENOTYPE	16	16	severity
NCT0000135915	NCT00001359_15_T2	PHENOTYPE	21	21	tics
NCT0000135915	NCT00001359_15_T3	PHENOTYPE	7	7	infections
NCT0000135916	NCT00001359_16_T0	COMPOUND	1	1	penicillin
NCT0000135916	NCT00001359_16_T1	COMPOUND	12	12	azithromycin
NCT0000135916	NCT00001359_16_T2	GENE	2	2	has
NCT0000135917	NCT00001359_17_T0	ORGAN	32	32	Heart
NCT0000135917	NCT00001359_17_T1	COMPOUND	1	1	penicillin
NCT0000135917	NCT00001359_17_T2	PHENOTYPE	33	33	Association
NCT0000135917	NCT00001359_17_T3	GENE	8	8	has
NCT0000135917	NCT00001359_17_T4	PHENOTYPE	19	20	rheumatic fever
NCT0000135918	NCT00001359_18_T0	COMPOUND	1	1	penicillin
NCT0000135918	NCT00001359_18_T1	GENE	2	2	has
NCT0000135919	NCT00001359_19_T0	PHENOTYPE	0	0	Blister
NCT0000135922	NCT00001359_22_T0	COMPOUND	15	15	penicillin
NCT0000135922	NCT00001359_22_T1	PHENOTYPE	1	1	infections
NCT0000135923	NCT00001359_23_T0	COMPOUND	7	7	penicillin
NCT0000135923	NCT00001359_23_T1	PHENOTYPE	13	13	OCD
NCT0000135923	NCT00001359_23_T2	PHENOTYPE	15	15	tics
NCT0000135925	NCT00001359_25_T0	COMPOUND	4	4	penicillin
NCT0000135925	NCT00001359_25_T1	COMPOUND	15	15	penicillin
NCT0000135927	NCT00001359_27_T0	COMPOUND	24	24	penicillin
NCT0000135927	NCT00001359_27_T1	PHENOTYPE	11	11	OCD
NCT0000135927	NCT00001359_27_T2	PHENOTYPE	13	13	tics
NCT0000135927	NCT00001359_27_T3	GENE	3	3	has
NCT0000135935	NCT00001359_35_T0	PHENOTYPE	6	6	infections
NCT0000135936	NCT00001359_36_T0	PHENOTYPE	2	3	choreiform movements
NCT0000135937	NCT00001359_37_T0	PHENOTYPE	20	20	symptoms
NCT0000135937	NCT00001359_37_T1	PHENOTYPE	3	3	relapse
NCT0000135937	NCT00001359_37_T2	PHENOTYPE	26	26	remission
NCT0000135938	NCT00001359_38_T0	PHENOTYPE	6	6	severity
NCT0000135940	NCT00001359_40_T0	PHENOTYPE	3	4	penicillin allergy
NCT0000135941	NCT00001359_41_T0	PHENOTYPE	6	6	chorea
NCT0000135941	NCT00001359_41_T1	PHENOTYPE	2	3	rheumatic fever
NCT0000135942	NCT00001359_42_T0	PHENOTYPE	3	3	schizophrenia
NCT0000135942	NCT00001359_42_T1	PHENOTYPE	2	2	autism
NCT0000135942	NCT00001359_42_T2	PHENOTYPE	6	7	psychotic disorder
NCT000013602	NCT00001360_2_T0	GENE	6	6	MEG
NCT000013602	NCT00001360_2_T1	PHENOTYPE	15	16	brain activity
NCT000013604	NCT00001360_4_T0	GENE	2	2	MEG
NCT000013606	NCT00001360_6_T0	GENE	13	13	MEG
NCT0000136011	NCT00001360_11_T0	GENE	15	15	MRI
NCT000013612	NCT00001361_2_T0	GENE	2	2	MRI
NCT000013612	NCT00001361_2_T1	PHENOTYPE	28	28	diseases
NCT000013612	NCT00001361_2_T2	ORGAN	18	18	skull
NCT000013613	NCT00001361_3_T0	GENE	6	6	MRI
NCT000013613	NCT00001361_3_T1	BIOLOGICAL_PROCESS	18	19	sensory processing
NCT000013614	NCT00001361_4_T0	PHENOTYPE	14	14	remembering
NCT000013615	NCT00001361_5_T0	PHENOTYPE	23	23	disorders
NCT000013615	NCT00001361_5_T1	PHENOTYPE	14	14	remembering
NCT000013615	NCT00001361_5_T2	ORGAN	28	29	nervous system
NCT000013619	NCT00001361_9_T0	BIOLOGICAL_PROCESS	14	15	sensory processing
NCT0000136110	NCT00001361_10_T0	GENE	13	13	1.5
NCT000013621	NCT00001362_1_T0	GENE	8	8	MRI
NCT000013621	NCT00001362_1_T1	PHENOTYPE	18	19	neurological disorders
NCT000013622	NCT00001362_2_T0	PHENOTYPE	19	19	amnesia
NCT000013622	NCT00001362_2_T1	ORGAN	15	15	brains
NCT000013622	NCT00001362_2_T2	PHENOTYPE	21	21	dementia
NCT000013624	NCT00001362_4_T0	GENE	11	11	MRI
NCT000013624	NCT00001362_4_T1	PHENOTYPE	20	21	neurological disorders
NCT000013625	NCT00001362_5_T0	GENE	0	0	MRI
NCT000013626	NCT00001362_6_T0	PHENOTYPE	13	14	neurological disorders
NCT0000136210	NCT00001362_10_T0	GENE	14	14	MRI
NCT0000136211	NCT00001362_11_T0	GENE	5	5	MRI
NCT0000136213	NCT00001362_13_T0	GENE	15	15	MRI
NCT000013632	NCT00001363_2_T0	COMPOUND	19	19	glucose
NCT000013632	NCT00001363_2_T1	COMPOUND	16	16	oxygen
NCT000013633	NCT00001363_3_T0	COMPOUND	11	12	carbon dioxide
NCT000013635	NCT00001363_5_T0	PHENOTYPE	1	2	brain activity
NCT000013637	NCT00001363_7_T0	PHENOTYPE	16	17	decision making
NCT000013638	NCT00001363_8_T0	PHENOTYPE	21	22	decision making
NCT0000136316	NCT00001363_16_T0	PHENOTYPE	7	8	psychiatric disorder
NCT0000136319	NCT00001363_19_T0	PHENOTYPE	4	4	bilateral
NCT0000136319	NCT00001363_19_T1	PHENOTYPE	2	2	unilateral
NCT000013643	NCT00001364_3_T0	PHENOTYPE	12	12	malformation
NCT000013643	NCT00001364_3_T1	ORGAN	17	17	spine
NCT000013645	NCT00001364_5_T0	PHENOTYPE	18	18	AVM
NCT000013647	NCT00001364_7_T0	GENE	3	3	has
NCT0000136411	NCT00001364_11_T0	PHENOTYPE	6	6	paraplegia
NCT0000136411	NCT00001364_11_T1	PHENOTYPE	8	8	quadriplegia
NCT0000136411	NCT00001364_11_T2	PHENOTYPE	2	2	progressive
NCT0000136411	NCT00001364_11_T3	PHENOTYPE	3	3	myelopathy
NCT0000136412	NCT00001364_12_T0	PHENOTYPE	20	20	pathophysiology
NCT0000136412	NCT00001364_12_T1	PHENOTYPE	39	39	centers
NCT0000136412	NCT00001364_12_T2	GENE	31	31	has
NCT0000136412	NCT00001364_12_T3	PHENOTYPE	22	22	myelopathy
NCT0000136420	NCT00001364_20_T0	PHENOTYPE	8	8	AVM
NCT0000136421	NCT00001364_21_T0	GENE	5	5	MRI
NCT000013651	NCT00001365_1_T0	COMPOUND	9	9	dopamine
NCT000013651	NCT00001365_1_T1	PHENOTYPE	2	3	Parkinson's disease
NCT000013652	NCT00001365_2_T0	COMPOUND	17	17	dopamine
NCT000013652	NCT00001365_2_T1	ORGAN	19	20	basal ganglia
NCT000013654	NCT00001365_4_T0	COMPOUND	3	3	dextromethorphan
NCT000013654	NCT00001365_4_T1	PHENOTYPE	15	16	Parkinson's Disease
NCT000013654	NCT00001365_4_T2	PHENOTYPE	10	11	psychomotor function
NCT000013659	NCT00001365_9_T0	PHENOTYPE	26	27	psychiatric disease
NCT000013661	NCT00001366_1_T0	COMPOUND	19	19	glucose
NCT000013661	NCT00001366_1_T1	COMPOUND	16	16	oxygen
NCT000013662	NCT00001366_2_T0	COMPOUND	11	12	carbon dioxide
NCT000013664	NCT00001366_4_T0	PHENOTYPE	1	2	brain activity
NCT000013665	NCT00001366_5_T0	GENE	19	19	MRI
NCT000013665	NCT00001366_5_T1	COMPOUND	27	27	oxygen
NCT000013665	NCT00001366_5_T2	PHENOTYPE	14	15	language skills
NCT000013667	NCT00001366_7_T0	GENE	5	5	MRI
NCT000013667	NCT00001366_7_T1	GENE	3	3	1.5
NCT000013669	NCT00001366_9_T0	PHENOTYPE	2	2	localized
NCT000013669	NCT00001366_9_T1	PHENOTYPE	0	1	Partial epilepsy
NCT0000136611	NCT00001366_11_T0	PHENOTYPE	10	10	claustrophobia
NCT000013682	NCT00001368_2_T0	PHENOTYPE	10	10	atherosclerosis
NCT000013682	NCT00001368_2_T1	BIOLOGICAL_PROCESS	23	24	leukocyte activation
NCT000013682	NCT00001368_2_T2	ORGAN	19	20	immune system
NCT000013684	NCT00001368_4_T0	ORGAN	4	5	immune system
NCT000013686	NCT00001368_6_T0	BIOLOGICAL_PROCESS	7	8	leukocyte activation
NCT000013686	NCT00001368_6_T1	PHENOTYPE	40	41	cerebral infarctions
NCT000013686	NCT00001368_6_T2	PHENOTYPE	36	37	carotid atherosclerosis
NCT0000136810	NCT00001368_10_T0	CELL	44	44	leukocyte
NCT0000136810	NCT00001368_10_T1	CELL	24	24	leukocytes
NCT0000136810	NCT00001368_10_T2	ORGAN	62	63	carotid arteries
NCT0000136810	NCT00001368_10_T3	PHENOTYPE	58	59	accelerated atherosclerosis
NCT0000136812	NCT00001368_12_T0	COMPOUND	51	51	glucose
NCT0000136812	NCT00001368_12_T1	GENE	23	23	OR
NCT0000136812	NCT00001368_12_T2	GENE	48	48	OR
NCT0000136812	NCT00001368_12_T3	GENE	67	67	OR
NCT0000136812	NCT00001368_12_T4	GENE	60	60	insulin
NCT0000136812	NCT00001368_12_T5	GENE	42	42	1/6
NCT0000136812	NCT00001368_12_T6	GENE	6	6	BP
NCT0000136812	NCT00001368_12_T7	GENE	13	13	BP
NCT0000136812	NCT00001368_12_T8	PHENOTYPE	24	24	hypercholesterolemia
NCT0000136812	NCT00001368_12_T9	GENE	25	25	LDL
NCT0000136812	NCT00001368_12_T10	PHENOTYPE	49	49	Diabetes
NCT0000136812	NCT00001368_12_T11	PHENOTYPE	4	4	hypertension
NCT0000136813	NCT00001368_13_T0	GENE	22	22	MRI
NCT0000136813	NCT00001368_13_T1	PHENOTYPE	26	26	infarction
NCT0000136813	NCT00001368_13_T2	PHENOTYPE	28	28	TIA
NCT0000136814	NCT00001368_14_T0	PHENOTYPE	15	15	infarction
NCT000013719	NCT00001371_9_T0	GENE	11	11	tar
NCT0000137112	NCT00001371_12_T0	GENE	3	3	2.0
NCT0000137113	NCT00001371_13_T0	GENE	15	15	1.3
NCT0000137113	NCT00001371_13_T1	GENE	6	6	1.5
NCT0000137113	NCT00001371_13_T2	GENE	8	8	prothrombin
NCT0000137114	NCT00001371_14_T0	CELL	4	4	granulocytes
NCT0000137114	NCT00001371_14_T1	GENE	0	0	WBC
NCT0000137114	NCT00001371_14_T2	CELL	8	8	platelets
NCT0000137115	NCT00001371_15_T0	PHENOTYPE	3	4	cardiac disease
NCT000013727	NCT00001372_7_T0	GENE	11	11	MRI
NCT000013729	NCT00001372_9_T0	PHENOTYPE	14	14	complications
NCT0000137211	NCT00001372_11_T0	ORGAN	3	3	plasma
NCT0000137211	NCT00001372_11_T1	CELL	9	10	blood cells
NCT0000137217	NCT00001372_17_T0	GENE	15	15	1.4
NCT0000137219	NCT00001372_19_T0	ORGAN	0	0	Kidney
NCT0000137219	NCT00001372_19_T1	ORGAN	1	2	bone marrow
NCT0000137228	NCT00001372_28_T0	PHENOTYPE	24	24	complications
NCT0000137228	NCT00001372_28_T1	PHENOTYPE	32	33	drug toxicities
NCT0000137229	NCT00001372_29_T0	ORGAN	0	0	Blood
NCT0000137230	NCT00001372_30_T0	ORGAN	18	19	blood vessels
NCT000013736	NCT00001373_6_T0	GENE	5	5	saliva
NCT0000137310	NCT00001373_10_T0	CELL	7	7	cells
NCT0000137314	NCT00001373_14_T0	PHENOTYPE	10	10	symptoms
NCT0000137318	NCT00001373_18_T0	GENE	5	5	saliva
NCT0000137321	NCT00001373_21_T0	PHENOTYPE	5	5	gout
NCT0000137321	NCT00001373_21_T1	PHENOTYPE	20	20	pulse
NCT0000137321	NCT00001373_21_T2	GENE	30	30	ml
NCT0000137328	NCT00001373_28_T0	PHENOTYPE	29	29	inflammation
NCT0000137328	NCT00001373_28_T1	PHENOTYPE	12	12	syndromes
NCT0000137328	NCT00001373_28_T2	CELL	22	22	T-cells
NCT0000137330	NCT00001373_30_T0	PHENOTYPE	9	9	inflammation
NCT0000137330	NCT00001373_30_T1	PHENOTYPE	7	7	fevers
NCT0000137331	NCT00001373_31_T0	PHENOTYPE	13	13	sporadic
NCT0000137341	NCT00001373_41_T0	GENE	19	19	saliva
NCT0000137345	NCT00001373_45_T0	PHENOTYPE	3	3	aspirations
NCT0000137345	NCT00001373_45_T1	ORGAN	1	2	bone marrow
NCT0000137347	NCT00001373_47_T0	GENE	26	26	saliva
NCT0000137347	NCT00001373_47_T1	COMPOUND	7	7	1
NCT0000137348	NCT00001373_48_T0	ORGAN	15	16	bone marrow
NCT0000137350	NCT00001373_50_T0	BIOLOGICAL_PROCESS	12	12	phlebotomy
NCT0000137351	NCT00001373_51_T0	BIOLOGICAL_PROCESS	9	9	phlebotomy
NCT000013751	NCT00001375_1_T0	GENE	18	18	RA
NCT000013751	NCT00001375_1_T1	PHENOTYPE	23	23	arthropathies
NCT000013751	NCT00001375_1_T2	PHENOTYPE	21	21	chronic
NCT000013751	NCT00001375_1_T3	PHENOTYPE	10	11	disease course
NCT000013751	NCT00001375_1_T4	PHENOTYPE	16	17	rheumatoid arthritis
NCT000013752	NCT00001375_2_T0	ORGAN	3	4	synovial fluid
NCT000013755	NCT00001375_5_T0	GENE	18	18	RA
NCT000013755	NCT00001375_5_T1	PHENOTYPE	23	23	arthropathies
NCT000013755	NCT00001375_5_T2	PHENOTYPE	21	21	chronic
NCT000013755	NCT00001375_5_T3	PHENOTYPE	10	11	disease course
NCT000013755	NCT00001375_5_T4	PHENOTYPE	16	17	rheumatoid arthritis
NCT000013756	NCT00001375_6_T0	ORGAN	3	4	synovial fluid
NCT0000137511	NCT00001375_11_T0	PHENOTYPE	10	10	arthritis
NCT0000137511	NCT00001375_11_T1	PHENOTYPE	9	9	degenerative
NCT0000137511	NCT00001375_11_T2	PHENOTYPE	5	6	septic arthritis
NCT0000137512	NCT00001375_12_T0	CELL	9	9	platelet
NCT0000137512	NCT00001375_12_T1	PHENOTYPE	24	24	sepsis
NCT0000137512	NCT00001375_12_T2	PHENOTYPE	15	16	bleeding diathesis
NCT0000137514	NCT00001375_14_T0	GENE	1	1	MRI
NCT0000137516	NCT00001375_16_T0	GENE	1	1	MRI
NCT0000137516	NCT00001375_16_T1	GENE	11	11	MRI
NCT0000137517	NCT00001375_17_T0	GENE	1	1	MRI
NCT0000137517	NCT00001375_17_T1	PHENOTYPE	6	6	claustrophobia
NCT0000137518	NCT00001375_18_T0	GENE	1	1	MRI
NCT0000137518	NCT00001375_18_T1	GENE	5	5	had
NCT0000137518	NCT00001375_18_T2	PHENOTYPE	8	9	anaphylactoid reaction
NCT0000137519	NCT00001375_19_T0	GENE	1	1	MRI
NCT000013761	NCT00001376_1_T0	PHENOTYPE	2	3	hormone levels
NCT000013762	NCT00001376_2_T0	BIOLOGICAL_PROCESS	7	7	gestation
NCT000013763	NCT00001376_3_T0	PHENOTYPE	15	16	rheumatoid arthritis
NCT000013769	NCT00001376_9_T0	PHENOTYPE	2	3	hormone levels
NCT0000137610	NCT00001376_10_T0	BIOLOGICAL_PROCESS	7	7	gestation
NCT0000137611	NCT00001376_11_T0	PHENOTYPE	15	16	rheumatoid arthritis
NCT000013781	NCT00001378_1_T0	COMPOUND	2	2	fenretinide
NCT000013781	NCT00001378_1_T1	COMPOUND	24	24	fenretinide
NCT000013781	NCT00001378_1_T2	COMPOUND	14	14	tamoxifen
NCT000013784	NCT00001378_4_T0	PHENOTYPE	12	12	toxicity
NCT000013784	NCT00001378_4_T1	PHENOTYPE	9	9	acute
NCT000013784	NCT00001378_4_T2	GENE	70	70	PCNA
NCT000013784	NCT00001378_4_T3	PHENOTYPE	38	38	malignancy
NCT000013784	NCT00001378_4_T4	ORGAN	40	40	nipple
NCT000013784	NCT00001378_4_T5	GENE	62	62	TGF-beta
NCT000013784	NCT00001378_4_T6	GENE	68	68	ki67
NCT000013784	NCT00001378_4_T7	PHENOTYPE	35	35	proliferative
NCT000013784	NCT00001378_4_T8	PHENOTYPE	66	66	proliferative
NCT000013784	NCT00001378_4_T9	COMPOUND	14	14	tamoxifen
NCT000013784	NCT00001378_4_T10	COMPOUND	58	58	tamoxifen
NCT000013786	NCT00001378_6_T0	PHENOTYPE	12	12	LCIS
NCT000013786	NCT00001378_6_T1	PHENOTYPE	6	6	hyperplasia
NCT000013786	NCT00001378_6_T2	PHENOTYPE	2	3	lobular neoplasia
NCT000013786	NCT00001378_6_T3	PHENOTYPE	9	11	carcinoma in situ
NCT000013787	NCT00001378_7_T0	PHENOTYPE	2	4	atypical ductal hyperplasia
NCT000013788	NCT00001378_8_T0	PHENOTYPE	17	18	breast cancer
NCT000013788	NCT00001378_8_T1	PHENOTYPE	2	4	atypical ductal hyperplasia
NCT000013789	NCT00001378_9_T0	PHENOTYPE	15	16	breast cancer
NCT000013789	NCT00001378_9_T1	PHENOTYPE	2	4	atypical ductal hyperplasia
NCT0000137810	NCT00001378_10_T0	PHENOTYPE	11	12	ovarian cancer
NCT0000137810	NCT00001378_10_T1	PHENOTYPE	19	20	breast cancer
NCT0000137811	NCT00001378_11_T0	PHENOTYPE	11	12	breast cancer
NCT0000137812	NCT00001378_12_T0	GENE	18	18	had
NCT0000137812	NCT00001378_12_T1	GENE	16	16	extended
NCT0000137812	NCT00001378_12_T2	PHENOTYPE	19	20	ovarian cancer
NCT0000137812	NCT00001378_12_T3	PHENOTYPE	7	8	breast cancer
NCT0000137813	NCT00001378_13_T0	PHENOTYPE	5	6	breast cancer
NCT0000137813	NCT00001378_13_T1	PHENOTYPE	15	17	premenopausal breast cancer
NCT0000137814	NCT00001378_14_T0	PHENOTYPE	4	5	breast cancer
NCT0000137816	NCT00001378_16_T0	PHENOTYPE	4	6	invasive breast cancer
NCT0000137817	NCT00001378_17_T0	PHENOTYPE	3	3	malignancy
NCT0000137818	NCT00001378_18_T0	COMPOUND	18	18	NCI
NCT0000137818	NCT00001378_18_T1	PHENOTYPE	6	7	breast cancer
NCT0000137819	NCT00001378_19_T0	PHENOTYPE	14	14	DCIS
NCT0000137820	NCT00001378_20_T0	PHENOTYPE	2	2	DCIS
NCT0000137821	NCT00001378_21_T0	PHENOTYPE	5	6	breast cancer
NCT0000137822	NCT00001378_22_T0	PHENOTYPE	7	9	invasive breast cancer
NCT0000137823	NCT00001378_23_T0	COMPOUND	5	5	estrogen
NCT0000137823	NCT00001378_23_T1	COMPOUND	7	7	progesterone
NCT0000137824	NCT00001378_24_T0	GENE	2	2	Age
NCT0000137829	NCT00001378_29_T0	COMPOUND	1	1	phosphate
NCT0000137830	NCT00001378_30_T0	GENE	0	0	AST
NCT0000137832	NCT00001378_32_T0	PHENOTYPE	3	4	bleeding disorder
NCT0000137833	NCT00001378_33_T0	PHENOTYPE	6	6	cirrhosis
NCT0000137833	NCT00001378_33_T1	PHENOTYPE	3	4	chronic hepatitis
NCT0000137834	NCT00001378_34_T0	GENE	3	3	1.5
NCT0000137835	NCT00001378_35_T0	PHENOTYPE	4	6	deep venous thrombosis
NCT0000137836	NCT00001378_36_T0	PHENOTYPE	3	4	pulmonary embolus
NCT0000137837	NCT00001378_37_T0	PHENOTYPE	2	2	allergy
NCT0000137837	NCT00001378_37_T1	PHENOTYPE	0	0	Other
NCT0000137839	NCT00001378_39_T0	PHENOTYPE	4	5	vaginal bleeding
NCT0000137840	NCT00001378_40_T0	PHENOTYPE	2	3	vaginal bleeding
NCT0000137841	NCT00001378_41_T0	PHENOTYPE	3	4	retinal disease
NCT0000137841	NCT00001378_41_T1	PHENOTYPE	8	9	night blindness
NCT0000137841	NCT00001378_41_T2	PHENOTYPE	5	6	macular degeneration
NCT0000137842	NCT00001378_42_T0	PHENOTYPE	8	9	systemic disease
NCT0000137843	NCT00001378_43_T0	PHENOTYPE	3	3	malignancy
NCT0000137843	NCT00001378_43_T1	PHENOTYPE	8	9	skin cancer
NCT0000137844	NCT00001378_44_T0	PHENOTYPE	4	5	cervical carcinoma
NCT0000137845	NCT00001378_45_T0	PHENOTYPE	0	1	Hodgkin's disease
NCT0000137847	NCT00001378_47_T0	COMPOUND	12	12	fenretinide
NCT0000137847	NCT00001378_47_T1	COMPOUND	18	18	tamoxifen
NCT000013791	NCT00001379_1_T0	CELL	6	6	cells
NCT000013791	NCT00001379_1_T1	PHENOTYPE	3	3	proliferation
NCT000013791	NCT00001379_1_T2	ORGAN	9	9	lungs
NCT000013791	NCT00001379_1_T3	ORGAN	11	11	kidneys
NCT000013791	NCT00001379_1_T4	ORGAN	13	15	central nervous system
NCT000013793	NCT00001379_3_T0	GENE	0	0	Alpha
NCT000013793	NCT00001379_3_T1	GENE	1	1	interferon
NCT000013794	NCT00001379_4_T0	GENE	0	0	Alpha
NCT000013794	NCT00001379_4_T1	GENE	1	1	interferon
NCT0000137917	NCT00001379_17_T0	COMPOUND	3	3	vincristine
NCT0000137917	NCT00001379_17_T1	COMPOUND	1	1	doxorubicin
NCT0000137920	NCT00001379_20_T0	GENE	12	12	G-CSF
NCT0000137920	NCT00001379_20_T1	ORGAN	4	5	bone marrow
NCT0000137920	NCT00001379_20_T2	GENE	8	11	granulocyte colony stimulating factor
NCT0000137928	NCT00001379_28_T0	PHENOTYPE	11	11	tumors
NCT0000137939	NCT00001379_39_T0	COMPOUND	15	15	designee
NCT000013811	NCT00001381_1_T0	PHENOTYPE	1	1	toxicity
NCT000013811	NCT00001381_1_T1	COMPOUND	3	3	suramin
NCT000013813	NCT00001381_3_T0	PHENOTYPE	1	1	toxicity
NCT000013813	NCT00001381_3_T1	COMPOUND	3	3	suramin
NCT000013815	NCT00001381_5_T0	PHENOTYPE	1	1	tumors
NCT000013816	NCT00001381_6_T0	PHENOTYPE	1	2	metastatic disease
NCT000013817	NCT00001381_7_T0	ORGAN	3	3	bladder
NCT000013818	NCT00001381_8_T0	PHENOTYPE	4	4	symptoms
NCT000013818	NCT00001381_8_T1	ORGAN	10	10	bladder
NCT000013819	NCT00001381_9_T0	PHENOTYPE	2	4	urinary tract infection
NCT0000138111	NCT00001381_11_T0	PHENOTYPE	14	14	toxicity
NCT0000138112	NCT00001381_12_T0	GENE	2	2	Age
NCT0000138114	NCT00001381_14_T0	GENE	1	1	WBC
NCT0000138116	NCT00001381_16_T0	GENE	5	5	1.5
NCT000013823	NCT00001382_3_T0	PHENOTYPE	12	12	adenocarcinomas
NCT000013823	NCT00001382_3_T1	ORGAN	15	16	GI tract
NCT000013824	NCT00001382_4_T0	PHENOTYPE	1	1	toxicities
NCT000013824	NCT00001382_4_T1	PHENOTYPE	4	5	local reactions
NCT000013825	NCT00001382_5_T0	PHENOTYPE	8	9	autoimmune reaction
NCT000013827	NCT00001382_7_T0	GENE	6	6	10.5
NCT0000138212	NCT00001382_12_T0	PHENOTYPE	0	0	Toxicity
NCT0000138212	NCT00001382_12_T1	PHENOTYPE	1	1	tumor
NCT0000138212	NCT00001382_12_T2	PHENOTYPE	7	7	immunity
NCT0000138213	NCT00001382_13_T0	GENE	10	10	A2
NCT0000138216	NCT00001382_16_T0	GENE	0	0	LHRH
NCT0000138219	NCT00001382_19_T0	PHENOTYPE	3	5	allergy to eggs
NCT0000138220	NCT00001382_20_T0	PHENOTYPE	5	6	CNS metastases
NCT0000138221	NCT00001382_21_T0	PHENOTYPE	4	5	bony metastasis
NCT0000138222	NCT00001382_22_T0	PHENOTYPE	1	2	measurable disease
NCT0000138228	NCT00001382_28_T0	PHENOTYPE	0	0	Endocrine
NCT0000138232	NCT00001382_32_T0	GENE	8	8	nodal
NCT0000138236	NCT00001382_36_T0	GENE	2	2	Age
NCT0000138237	NCT00001382_37_T0	GENE	4	4	0.2
NCT0000138238	NCT00001382_38_T0	CELL	2	2	granulocyte
NCT0000138238	NCT00001382_38_T1	GENE	15	15	8.0
NCT0000138238	NCT00001382_38_T2	PHENOTYPE	7	8	Platelet count
NCT0000138240	NCT00001382_40_T0	GENE	4	4	1/6
NCT0000138244	NCT00001382_44_T0	PHENOTYPE	6	6	chronic
NCT0000138246	NCT00001382_46_T0	PHENOTYPE	4	4	encephalitis
NCT0000138246	NCT00001382_46_T1	PHENOTYPE	3	3	seizures
NCT0000138246	NCT00001382_46_T2	PHENOTYPE	6	7	multiple sclerosis
NCT0000138248	NCT00001382_48_T0	PHENOTYPE	44	44	Leukemia
NCT0000138248	NCT00001382_48_T1	PHENOTYPE	46	46	lymphoma
NCT0000138248	NCT00001382_48_T2	PHENOTYPE	38	38	eczema
NCT0000138248	NCT00001382_48_T3	PHENOTYPE	40	41	skin conditions
NCT000013832	NCT00001383_2_T0	COMPOUND	10	10	paclitaxel
NCT000013832	NCT00001383_2_T1	CELL	17	17	neutrophil
NCT000013836	NCT00001383_6_T0	COMPOUND	15	15	paclitaxel
NCT000013836	NCT00001383_6_T1	COMPOUND	26	26	paclitaxel
NCT000013836	NCT00001383_6_T2	PHENOTYPE	24	24	pharmacokinetics
NCT000013836	NCT00001383_6_T3	PHENOTYPE	22	22	affects
NCT0000138319	NCT00001383_19_T0	GENE	0	0	WBC
NCT0000138319	NCT00001383_19_T1	GENE	5	5	AGC
NCT0000138319	NCT00001383_19_T2	CELL	9	9	platelets
NCT0000138320	NCT00001383_20_T0	GENE	9	9	1.5
NCT0000138320	NCT00001383_20_T1	COMPOUND	6	6	bilirubin
NCT0000138322	NCT00001383_22_T0	PHENOTYPE	3	4	brain metastases
NCT0000138323	NCT00001383_23_T0	COMPOUND	18	18	cyclosporine
NCT0000138323	NCT00001383_23_T1	COMPOUND	37	37	diltiazem
NCT0000138323	NCT00001383_23_T2	COMPOUND	51	51	quinidine
NCT0000138323	NCT00001383_23_T3	COMPOUND	47	47	verapamil
NCT0000138323	NCT00001383_23_T4	COMPOUND	49	49	progesterone
NCT0000138323	NCT00001383_23_T5	COMPOUND	43	43	phenytoin
NCT0000138323	NCT00001383_23_T6	COMPOUND	39	39	fluconazole
NCT0000138323	NCT00001383_23_T7	COMPOUND	53	53	amiodarone
NCT0000138323	NCT00001383_23_T8	COMPOUND	46	46	trimethoprim
NCT0000138323	NCT00001383_23_T9	COMPOUND	50	50	quinine
NCT0000138323	NCT00001383_23_T10	COMPOUND	38	38	erythromycin
NCT0000138323	NCT00001383_23_T11	COMPOUND	34	34	acetazolamide
NCT0000138323	NCT00001383_23_T12	COMPOUND	40	40	ketoconazole
NCT0000138323	NCT00001383_23_T13	COMPOUND	41	41	nicardipine
NCT0000138323	NCT00001383_23_T14	COMPOUND	48	48	tamoxifen
NCT0000138326	NCT00001383_26_T0	PHENOTYPE	4	5	peripheral neuropathy
NCT0000138327	NCT00001383_27_T0	PHENOTYPE	7	7	HIV
NCT0000138327	NCT00001383_27_T1	PHENOTYPE	4	5	positive serology
NCT000013842	NCT00001384_2_T0	COMPOUND	22	22	paclitaxel
NCT000013842	NCT00001384_2_T1	GENE	8	8	filgrastim
NCT000013843	NCT00001384_3_T0	PHENOTYPE	10	10	toxicity
NCT000013843	NCT00001384_3_T1	COMPOUND	21	21	paclitaxel
NCT000013846	NCT00001384_6_T0	COMPOUND	22	22	paclitaxel
NCT000013846	NCT00001384_6_T1	GENE	8	8	filgrastim
NCT000013847	NCT00001384_7_T0	PHENOTYPE	10	10	toxicity
NCT000013847	NCT00001384_7_T1	COMPOUND	21	21	paclitaxel
NCT0000138410	NCT00001384_10_T0	PHENOTYPE	2	3	stage III
NCT0000138414	NCT00001384_14_T0	GENE	8	8	70
NCT0000138418	NCT00001384_18_T0	COMPOUND	14	14	NCI
NCT0000138421	NCT00001384_21_T0	PHENOTYPE	11	12	systemic disease
NCT0000138423	NCT00001384_23_T0	PHENOTYPE	7	8	cardiac arrhythmias
NCT0000138423	NCT00001384_23_T1	PHENOTYPE	13	15	coronary artery disease
NCT0000138423	NCT00001384_23_T2	PHENOTYPE	9	11	congestive heart failure
NCT0000138425	NCT00001384_25_T0	PHENOTYPE	3	3	allergy
NCT000013851	NCT00001385_1_T0	PHENOTYPE	15	15	tumor
NCT000013851	NCT00001385_1_T1	BIOLOGICAL_PROCESS	16	16	metabolism
NCT000013851	NCT00001385_1_T2	COMPOUND	3	3	2_deoxyglucose
NCT000013851	NCT00001385_1_T3	PHENOTYPE	20	21	breast cancer
NCT000013852	NCT00001385_2_T0	GENE	3	3	II
NCT000013852	NCT00001385_2_T1	PHENOTYPE	14	15	evaluable disease
NCT000013852	NCT00001385_2_T2	PHENOTYPE	9	12	stage IV breast cancer
NCT000013854	NCT00001385_4_T0	GENE	19	19	II
NCT000013854	NCT00001385_4_T1	PHENOTYPE	21	22	stage III
NCT000013854	NCT00001385_4_T2	PHENOTYPE	12	13	breast cancer
NCT000013856	NCT00001385_6_T0	GENE	17	17	MRI
NCT000013856	NCT00001385_6_T1	PHENOTYPE	32	32	tumor
NCT000013857	NCT00001385_7_T0	PHENOTYPE	2	2	tumor
NCT000013857	NCT00001385_7_T1	BIOLOGICAL_PROCESS	3	4	glucose metabolism
NCT000013859	NCT00001385_9_T0	PHENOTYPE	15	15	tumor
NCT000013859	NCT00001385_9_T1	BIOLOGICAL_PROCESS	16	16	metabolism
NCT000013859	NCT00001385_9_T2	COMPOUND	3	3	2_deoxyglucose
NCT000013859	NCT00001385_9_T3	PHENOTYPE	20	21	breast cancer
NCT0000138510	NCT00001385_10_T0	GENE	3	3	II
NCT0000138510	NCT00001385_10_T1	PHENOTYPE	14	15	evaluable disease
NCT0000138510	NCT00001385_10_T2	PHENOTYPE	9	12	stage IV breast cancer
NCT0000138512	NCT00001385_12_T0	GENE	19	19	II
NCT0000138512	NCT00001385_12_T1	PHENOTYPE	21	22	stage III
NCT0000138512	NCT00001385_12_T2	PHENOTYPE	12	13	breast cancer
NCT0000138514	NCT00001385_14_T0	GENE	17	17	MRI
NCT0000138514	NCT00001385_14_T1	PHENOTYPE	32	32	tumor
NCT0000138515	NCT00001385_15_T0	PHENOTYPE	2	2	tumor
NCT0000138515	NCT00001385_15_T1	BIOLOGICAL_PROCESS	3	4	glucose metabolism
NCT0000138517	NCT00001385_17_T0	GENE	3	3	II
NCT0000138517	NCT00001385_17_T1	TISSUE	24	25	lymph nodes
NCT0000138517	NCT00001385_17_T2	PHENOTYPE	9	12	stage IV breast cancer
NCT0000138518	NCT00001385_18_T0	PHENOTYPE	0	0	Evaluable
NCT0000138518	NCT00001385_18_T1	PHENOTYPE	1	1	tumor
NCT0000138520	NCT00001385_20_T0	PHENOTYPE	3	3	malignancy
NCT0000138520	NCT00001385_20_T1	PHENOTYPE	7	8	breast cancer
NCT000013861	NCT00001386_1_T0	GENE	8	8	CD4
NCT000013861	NCT00001386_1_T1	GENE	7	7	500
NCT000013861	NCT00001386_1_T2	ORGAN	17	18	bone marrow
NCT000013862	NCT00001386_2_T0	PHENOTYPE	19	19	HIV
NCT000013864	NCT00001386_4_T0	PHENOTYPE	18	18	HIV
NCT000013867	NCT00001386_7_T0	GENE	12	12	Dr
NCT0000138613	NCT00001386_13_T0	GENE	0	0	ANC
NCT0000138614	NCT00001386_14_T0	COMPOUND	9	9	creatinine
NCT0000138614	NCT00001386_14_T1	GENE	6	6	1.5
NCT0000138616	NCT00001386_16_T0	GENE	1	1	phosphatase
NCT0000138617	NCT00001386_17_T0	GENE	14	15	protease inhibitor
NCT0000138617	NCT00001386_17_T1	PHENOTYPE	7	8	Gilbert's Syndrome
NCT0000138618	NCT00001386_18_T0	GENE	13	13	0.3
NCT0000138618	NCT00001386_18_T1	COMPOUND	7	7	bilirubin
NCT0000138618	NCT00001386_18_T2	COMPOUND	17	17	bilirubin
NCT0000138618	NCT00001386_18_T3	GENE	23	23	4.5
NCT0000138618	NCT00001386_18_T4	GENE	3	4	protease inhibitor
NCT0000138621	NCT00001386_21_T0	PHENOTYPE	5	5	allergies
NCT0000138622	NCT00001386_22_T0	PHENOTYPE	4	4	HIV
NCT0000138624	NCT00001386_24_T0	PHENOTYPE	2	2	Aids
NCT0000138626	NCT00001386_26_T0	PHENOTYPE	2	2	malabsorption
NCT0000138628	NCT00001386_28_T0	PHENOTYPE	2	2	acute
NCT0000138628	NCT00001386_28_T1	PHENOTYPE	5	5	infections
NCT000013872	NCT00001387_2_T0	GENE	5	5	has
NCT000013873	NCT00001387_3_T0	COMPOUND	16	16	paclitaxel
NCT000013873	NCT00001387_3_T1	PHENOTYPE	27	27	malignancy
NCT000013873	NCT00001387_3_T2	PHENOTYPE	14	14	toxicities
NCT000013874	NCT00001387_4_T0	COMPOUND	5	5	paclitaxel
NCT000013874	NCT00001387_4_T1	PHENOTYPE	3	3	pharmacokinetics
NCT000013876	NCT00001387_6_T0	PHENOTYPE	5	5	toxic
NCT000013879	NCT00001387_9_T0	COMPOUND	10	10	nitrosourea
NCT0000138710	NCT00001387_10_T0	PHENOTYPE	0	0	Endocrine
NCT0000138713	NCT00001387_13_T0	ORGAN	4	4	transplant
NCT0000138713	NCT00001387_13_T1	PHENOTYPE	0	0	Other
NCT0000138713	NCT00001387_13_T2	ORGAN	2	3	bone marrow
NCT0000138714	NCT00001387_14_T0	GENE	10	10	0.2
NCT0000138714	NCT00001387_14_T1	GENE	2	2	Age
NCT0000138714	NCT00001387_14_T2	GENE	6	6	21
NCT0000138715	NCT00001387_15_T0	PHENOTYPE	3	3	leukemia
NCT0000138715	NCT00001387_15_T1	ORGAN	4	5	bone marrow
NCT0000138715	NCT00001387_15_T2	ORGAN	9	10	bone marrow
NCT0000138716	NCT00001387_16_T0	CELL	1	1	granulocyte
NCT0000138716	NCT00001387_16_T1	GENE	14	14	8.0
NCT0000138716	NCT00001387_16_T2	PHENOTYPE	6	7	Platelet count
NCT0000138717	NCT00001387_17_T0	GENE	7	7	AST
NCT0000138717	NCT00001387_17_T1	GENE	5	5	1.5
NCT0000138720	NCT00001387_20_T0	PHENOTYPE	5	5	neuropathy
NCT000013901	NCT00001390_1_T0	PHENOTYPE	5	5	disorders
NCT000013901	NCT00001390_1_T1	GENE	2	2	has
NCT000013901	NCT00001390_1_T2	TISSUE	7	8	salivary glands
NCT000013902	NCT00001390_2_T0	PHENOTYPE	20	20	dysfunction
NCT000013907	NCT00001390_7_T0	GENE	12	12	MRI
NCT000013907	NCT00001390_7_T1	TISSUE	16	17	salivary glands
NCT000013909	NCT00001390_9_T0	PHENOTYPE	5	5	disorders
NCT000013909	NCT00001390_9_T1	GENE	2	2	has
NCT000013909	NCT00001390_9_T2	TISSUE	7	8	salivary glands
NCT0000139010	NCT00001390_10_T0	PHENOTYPE	20	20	dysfunction
NCT0000139015	NCT00001390_15_T0	GENE	12	12	MRI
NCT0000139015	NCT00001390_15_T1	TISSUE	16	17	salivary glands
NCT000013911	NCT00001391_1_T0	PHENOTYPE	20	20	trauma
NCT000013911	NCT00001391_1_T1	GENE	25	25	has
NCT000013911	NCT00001391_1_T2	PHENOTYPE	21	22	bone loss
NCT000013914	NCT00001391_4_T0	CELL	21	22	progenitor cells
NCT000013914	NCT00001391_4_T1	CELL	9	12	bone marrow stromal cells
NCT000013915	NCT00001391_5_T0	CELL	1	1	cells
NCT000013915	NCT00001391_5_T1	ORGAN	7	7	graft
NCT000013916	NCT00001391_6_T0	CELL	18	19	progenitor cells
NCT000013916	NCT00001391_6_T1	ORGAN	21	22	bone marrow
NCT000013916	NCT00001391_6_T2	CELL	32	35	bone marrow stromal cells
NCT000013916	NCT00001391_6_T3	CELL	54	57	bone marrow stromal cells
NCT000013919	NCT00001391_9_T0	PHENOTYPE	20	20	trauma
NCT000013919	NCT00001391_9_T1	GENE	25	25	has
NCT000013919	NCT00001391_9_T2	PHENOTYPE	21	22	bone loss
NCT0000139112	NCT00001391_12_T0	CELL	21	22	progenitor cells
NCT0000139112	NCT00001391_12_T1	CELL	9	12	bone marrow stromal cells
NCT0000139113	NCT00001391_13_T0	CELL	1	1	cells
NCT0000139113	NCT00001391_13_T1	ORGAN	7	7	graft
NCT0000139114	NCT00001391_14_T0	CELL	18	19	progenitor cells
NCT0000139114	NCT00001391_14_T1	ORGAN	21	22	bone marrow
NCT0000139114	NCT00001391_14_T2	CELL	32	35	bone marrow stromal cells
NCT0000139114	NCT00001391_14_T3	CELL	54	57	bone marrow stromal cells
NCT000013922	NCT00001392_2_T0	COMPOUND	75	75	cyclosporine
NCT000013922	NCT00001392_2_T1	ORGAN	31	31	kidney
NCT000013922	NCT00001392_2_T2	PHENOTYPE	9	9	opinions
NCT000013922	NCT00001392_2_T3	PHENOTYPE	21	22	kidney diseases
NCT000013923	NCT00001392_3_T0	GENE	23	23	Sri
NCT000013923	NCT00001392_3_T1	PHENOTYPE	3	3	chronic
NCT000013923	NCT00001392_3_T2	PHENOTYPE	4	5	kidney disease
NCT000013924	NCT00001392_4_T0	ORGAN	3	3	kidney
NCT000013924	NCT00001392_4_T1	ORGAN	17	17	plasma
NCT000013924	NCT00001392_4_T2	ORGAN	18	18	serum
NCT000013927	NCT00001392_7_T0	ORGAN	25	25	kidney
NCT000013927	NCT00001392_7_T1	PHENOTYPE	10	10	chronic
NCT000013927	NCT00001392_7_T2	PHENOTYPE	13	14	kidney diseases
NCT000013928	NCT00001392_8_T0	ORGAN	12	12	kidney
NCT0000139214	NCT00001392_14_T0	COMPOUND	75	75	cyclosporine
NCT0000139214	NCT00001392_14_T1	ORGAN	31	31	kidney
NCT0000139214	NCT00001392_14_T2	PHENOTYPE	9	9	opinions
NCT0000139214	NCT00001392_14_T3	PHENOTYPE	21	22	kidney diseases
NCT0000139215	NCT00001392_15_T0	GENE	23	23	Sri
NCT0000139215	NCT00001392_15_T1	PHENOTYPE	3	3	chronic
NCT0000139215	NCT00001392_15_T2	PHENOTYPE	4	5	kidney disease
NCT0000139216	NCT00001392_16_T0	ORGAN	3	3	kidney
NCT0000139216	NCT00001392_16_T1	ORGAN	17	17	plasma
NCT0000139216	NCT00001392_16_T2	ORGAN	18	18	serum
NCT0000139219	NCT00001392_19_T0	ORGAN	25	25	kidney
NCT0000139219	NCT00001392_19_T1	PHENOTYPE	10	10	chronic
NCT0000139219	NCT00001392_19_T2	PHENOTYPE	13	14	kidney diseases
NCT0000139220	NCT00001392_20_T0	ORGAN	12	12	kidney
NCT0000139236	NCT00001392_36_T0	COMPOUND	2	2	cyclosporine
NCT0000139239	NCT00001392_39_T0	PHENOTYPE	8	9	kidney disease
NCT0000139239	NCT00001392_39_T1	PHENOTYPE	12	13	kidney disease
NCT0000139247	NCT00001392_47_T0	PHENOTYPE	15	15	secondary
NCT0000139311	NCT00001393_11_T0	GENE	7	7	ml
NCT0000139312	NCT00001393_12_T0	CELL	9	11	white blood cells
NCT0000139322	NCT00001393_22_T0	PHENOTYPE	4	4	HIV
NCT0000139322	NCT00001393_22_T1	PHENOTYPE	5	6	collapsing glomerulopathy
NCT0000139326	NCT00001393_26_T0	PHENOTYPE	3	3	HIV
NCT0000139326	NCT00001393_26_T1	PHENOTYPE	6	7	kidney disease
NCT0000139330	NCT00001393_30_T0	ORGAN	0	0	Kidney
NCT0000139344	NCT00001393_44_T0	PHENOTYPE	3	3	HIV
NCT0000139344	NCT00001393_44_T1	PHENOTYPE	6	7	kidney disease
NCT0000139349	NCT00001393_49_T0	PHENOTYPE	5	6	cardiovascular disease
NCT0000139349	NCT00001393_49_T1	PHENOTYPE	8	9	renal disease
NCT0000139352	NCT00001393_52_T0	GENE	7	7	Dr
NCT0000139355	NCT00001393_55_T0	PHENOTYPE	7	8	renal disease
NCT0000139355	NCT00001393_55_T1	PHENOTYPE	12	13	renal disease
NCT0000139358	NCT00001393_58_T0	ORGAN	0	0	Kidney
NCT0000139361	NCT00001393_61_T0	PHENOTYPE	30	30	albuminuria
NCT0000139361	NCT00001393_61_T1	ORGAN	18	18	kidney
NCT0000139361	NCT00001393_61_T2	PHENOTYPE	21	21	hypertrophy
NCT0000139361	NCT00001393_61_T3	GENE	12	12	MYH9
NCT0000139362	NCT00001393_62_T0	ORGAN	21	21	kidney
NCT0000139362	NCT00001393_62_T1	GENE	13	13	MYH9
NCT0000139370	NCT00001393_70_T0	GENE	12	12	MYH9
NCT0000139371	NCT00001393_71_T0	PHENOTYPE	13	13	progression
NCT0000139371	NCT00001393_71_T1	PHENOTYPE	15	16	kidney disease
NCT000013941	NCT00001394_1_T0	PHENOTYPE	4	4	tumor
NCT000013941	NCT00001394_1_T1	PHENOTYPE	13	13	localized
NCT000013943	NCT00001394_3_T0	ORGAN	13	13	groin
NCT000013943	NCT00001394_3_T1	ORGAN	9	10	blood vessel
NCT000013944	NCT00001394_4_T0	ORGAN	6	7	blood vessels
NCT000013945	NCT00001394_5_T0	ORGAN	12	12	thyroid
NCT000013945	NCT00001394_5_T1	ORGAN	1	2	blood vessels
NCT000013946	NCT00001394_6_T0	GENE	2	2	dye
NCT000013946	NCT00001394_6_T1	ORGAN	11	11	arteries
NCT000013947	NCT00001394_7_T0	ORGAN	9	9	veins
NCT000013948	NCT00001394_8_T0	PHENOTYPE	8	8	discomfort
NCT0000139411	NCT00001394_11_T0	GENE	7	7	PTH
NCT0000139411	NCT00001394_11_T1	PHENOTYPE	0	0	Parathyroid
NCT0000139411	NCT00001394_11_T2	GENE	4	4	hormone
NCT0000139411	NCT00001394_11_T3	GENE	8	9	parathyroid hormone
NCT0000139412	NCT00001394_12_T0	COMPOUND	10	10	calcium
NCT0000139412	NCT00001394_12_T1	GENE	3	3	PTH
NCT0000139413	NCT00001394_13_T0	GENE	9	9	dye
NCT0000139413	NCT00001394_13_T1	GENE	22	22	PTH
NCT0000139414	NCT00001394_14_T0	GENE	12	12	PTH
NCT0000139415	NCT00001394_15_T0	PHENOTYPE	34	34	localizing
NCT0000139415	NCT00001394_15_T1	COMPOUND	22	22	calcium
NCT0000139415	NCT00001394_15_T2	ORGAN	17	17	arteries
NCT0000139415	NCT00001394_15_T3	GENE	14	14	dye
NCT0000139415	NCT00001394_15_T4	PHENOTYPE	35	36	parathyroid tumors
NCT0000139418	NCT00001394_18_T0	COMPOUND	4	4	calcium
NCT0000139418	NCT00001394_18_T1	GENE	16	16	PTH
NCT0000139418	NCT00001394_18_T2	PHENOTYPE	9	10	parathyroid adenoma
NCT0000139420	NCT00001394_20_T0	COMPOUND	25	25	calcium
NCT0000139420	NCT00001394_20_T1	GENE	32	32	insulin
NCT0000139420	NCT00001394_20_T2	GENE	23	23	secretin
NCT0000139420	NCT00001394_20_T3	GENE	2	2	portal
NCT0000139420	NCT00001394_20_T4	GENE	30	30	gastrin
NCT0000139421	NCT00001394_21_T0	PHENOTYPE	25	25	SVC
NCT0000139421	NCT00001394_21_T1	GENE	3	3	PTH
NCT0000139421	NCT00001394_21_T2	GENE	31	31	PTH
NCT0000139421	NCT00001394_21_T3	ORGAN	53	53	arteries
NCT0000139421	NCT00001394_21_T4	ORGAN	52	52	thyroid
NCT0000139421	NCT00001394_21_T5	PHENOTYPE	5	6	parathyroid adenomas
NCT0000139421	NCT00001394_21_T6	ORGAN	56	58	internal mammary arteries
NCT0000139422	NCT00001394_22_T0	PHENOTYPE	3	3	SVC
NCT0000139422	NCT00001394_22_T1	PHENOTYPE	21	21	peripheral
NCT0000139423	NCT00001394_23_T0	GENE	5	5	1.5
NCT0000139423	NCT00001394_23_T1	GENE	3	4	parathyroid hormone
NCT0000139424	NCT00001394_24_T0	PHENOTYPE	27	27	localizing
NCT0000139424	NCT00001394_24_T1	PHENOTYPE	20	20	adenoma
NCT0000139424	NCT00001394_24_T2	GENE	24	24	PTH
NCT0000139425	NCT00001394_25_T0	COMPOUND	22	22	sodium
NCT0000139425	NCT00001394_25_T1	PHENOTYPE	21	21	adenoma
NCT0000139425	NCT00001394_25_T2	COMPOUND	23	23	citrate
NCT0000139425	NCT00001394_25_T3	COMPOUND	25	25	calcium
NCT0000139425	NCT00001394_25_T4	ORGAN	33	33	artery
NCT0000139426	NCT00001394_26_T0	COMPOUND	20	20	sodium
NCT0000139426	NCT00001394_26_T1	COMPOUND	21	21	citrate
NCT0000139426	NCT00001394_26_T2	GENE	17	17	PTH
NCT000013950	NCT00001395_0_T0	PHENOTYPE	4	5	Diabetic Retinopathy
NCT000013953	NCT00001395_3_T0	PHENOTYPE	30	30	edema
NCT000013953	NCT00001395_3_T1	PHENOTYPE	23	23	focal
NCT000013953	NCT00001395_3_T2	GENE	7	7	extended
NCT000013953	NCT00001395_3_T3	PHENOTYPE	29	29	macula
NCT000013953	NCT00001395_3_T4	PHENOTYPE	3	4	Diabetic Retinopathy
NCT000013954	NCT00001395_4_T0	PHENOTYPE	3	3	Regression
NCT000013954	NCT00001395_4_T1	COMPOUND	12	12	krypton
NCT000013954	NCT00001395_4_T2	PHENOTYPE	30	30	proliferative
NCT000013954	NCT00001395_4_T3	COMPOUND	23	23	argon
NCT000013954	NCT00001395_4_T4	PHENOTYPE	4	4	Neovascularization
NCT000013954	NCT00001395_4_T5	PHENOTYPE	31	32	diabetic retinopathy
NCT000013956	NCT00001395_6_T0	PHENOTYPE	16	17	diabetic retinopathy
NCT000013958	NCT00001395_8_T0	PHENOTYPE	7	7	focal
NCT0000139513	NCT00001395_13_T0	PHENOTYPE	30	30	edema
NCT0000139513	NCT00001395_13_T1	PHENOTYPE	23	23	focal
NCT0000139513	NCT00001395_13_T2	GENE	7	7	extended
NCT0000139513	NCT00001395_13_T3	PHENOTYPE	29	29	macula
NCT0000139513	NCT00001395_13_T4	PHENOTYPE	3	4	Diabetic Retinopathy
NCT0000139514	NCT00001395_14_T0	PHENOTYPE	3	3	Regression
NCT0000139514	NCT00001395_14_T1	COMPOUND	12	12	krypton
NCT0000139514	NCT00001395_14_T2	PHENOTYPE	30	30	proliferative
NCT0000139514	NCT00001395_14_T3	COMPOUND	23	23	argon
NCT0000139514	NCT00001395_14_T4	PHENOTYPE	4	4	Neovascularization
NCT0000139514	NCT00001395_14_T5	PHENOTYPE	31	32	diabetic retinopathy
NCT0000139516	NCT00001395_16_T0	PHENOTYPE	16	17	diabetic retinopathy
NCT0000139518	NCT00001395_18_T0	PHENOTYPE	7	7	focal
NCT000013965	NCT00001396_5_T0	PHENOTYPE	34	34	overweight
NCT000013965	NCT00001396_5_T1	ORGAN	3	3	heart
NCT0000139612	NCT00001396_12_T0	PHENOTYPE	8	8	obstruction
NCT0000139612	NCT00001396_12_T1	PHENOTYPE	4	4	arrhythmias
NCT0000139612	NCT00001396_12_T2	COMPOUND	16	16	thallium
NCT0000139612	NCT00001396_12_T3	PHENOTYPE	2	3	myocardial ischemia
NCT0000139615	NCT00001396_15_T0	PHENOTYPE	7	7	obstruction
NCT0000139615	NCT00001396_15_T1	PHENOTYPE	3	3	hypertrophy
NCT0000139617	NCT00001396_17_T0	PHENOTYPE	0	2	Chronic atrial fibrillation
NCT0000139618	NCT00001396_18_T0	PHENOTYPE	0	2	Positive pregnancy test
NCT0000139620	NCT00001396_20_T0	PHENOTYPE	6	6	obstruction
NCT0000139620	NCT00001396_20_T1	PHENOTYPE	3	3	hypertrophy
NCT0000139621	NCT00001396_21_T0	PHENOTYPE	5	6	systemic disease
NCT0000139622	NCT00001396_22_T0	PHENOTYPE	0	2	Chronic atrial fibrillation
NCT000013971	NCT00001397_1_T0	PHENOTYPE	25	25	diseases
NCT000013971	NCT00001397_1_T1	PHENOTYPE	11	12	blood disorders
NCT000013972	NCT00001397_2_T0	PHENOTYPE	23	23	diseases
NCT000013976	NCT00001397_6_T0	PHENOTYPE	12	13	hematologic disease
NCT000013976	NCT00001397_6_T1	PHENOTYPE	58	59	hematologic disease
NCT000013981	NCT00001398_1_T0	PHENOTYPE	29	29	peripheral
NCT000013981	NCT00001398_1_T1	PHENOTYPE	19	20	aplastic anemia
NCT000013984	NCT00001398_4_T0	PHENOTYPE	29	29	peripheral
NCT000013984	NCT00001398_4_T1	PHENOTYPE	19	20	aplastic anemia
NCT000013987	NCT00001398_7_T0	COMPOUND	13	13	cyclosporin
NCT000013988	NCT00001398_8_T0	COMPOUND	14	14	cyclosporin
NCT0000139811	NCT00001398_11_T0	GENE	10	10	2.0
NCT0000139811	NCT00001398_11_T1	GENE	17	17	2.0
NCT0000139811	NCT00001398_11_T2	COMPOUND	7	7	creatine
NCT0000139811	NCT00001398_11_T3	COMPOUND	14	14	bilirubin
NCT0000139811	NCT00001398_11_T4	ORGAN	6	6	serum
NCT0000139813	NCT00001398_13_T0	PHENOTYPE	7	8	myelodysplastic syndromes
NCT0000139814	NCT00001398_14_T0	PHENOTYPE	5	6	dyskeratosis congenita
NCT0000139814	NCT00001398_14_T1	PHENOTYPE	12	13	aplastic anemia
NCT0000139814	NCT00001398_14_T2	PHENOTYPE	3	4	Fanconi's anemia
NCT0000139816	NCT00001398_16_T0	PHENOTYPE	3	4	eosinophilic fasciitis
NCT0000139817	NCT00001398_17_T0	COMPOUND	17	17	cyclosporine
NCT0000139817	NCT00001398_17_T1	GENE	20	20	IL-3
NCT0000139817	NCT00001398_17_T2	GENE	4	4	ALG
NCT0000139820	NCT00001398_20_T0	PHENOTYPE	2	2	allergy
NCT0000139822	NCT00001398_22_T0	PHENOTYPE	12	12	bronchospasm
NCT0000139822	NCT00001398_22_T1	PHENOTYPE	8	8	urticaria
NCT0000139822	NCT00001398_22_T2	PHENOTYPE	9	10	laryngeal edema
NCT0000139822	NCT00001398_22_T3	PHENOTYPE	17	18	insect bites
NCT0000139824	NCT00001398_24_T0	PHENOTYPE	4	4	urticaria
NCT0000139829	NCT00001398_29_T0	GENE	4	4	beta
NCT0000139830	NCT00001398_30_T0	GENE	14	14	MAO
NCT000013991	NCT00001399_1_T0	ORGAN	13	13	skeleton
NCT000013991	NCT00001399_1_T1	ORGAN	15	15	kidneys
NCT000013991	NCT00001399_1_T2	PHENOTYPE	5	6	Fanconi's anemia
NCT000013992	NCT00001399_2_T0	CELL	20	20	platelets
NCT000013992	NCT00001399_2_T1	CELL	31	31	cells
NCT000013992	NCT00001399_2_T2	ORGAN	25	26	bone marrow
NCT000013992	NCT00001399_2_T3	PHENOTYPE	7	8	aplastic anemia
NCT000013992	NCT00001399_2_T4	CELL	13	15	red blood cells
NCT000013992	NCT00001399_2_T5	CELL	16	18	white blood cells
NCT000013994	NCT00001399_4_T0	CELL	18	18	cells
NCT000013994	NCT00001399_4_T1	PHENOTYPE	6	7	Fanconi's anemia
NCT000013995	NCT00001399_5_T0	GENE	14	14	has
NCT000013995	NCT00001399_5_T1	PHENOTYPE	10	11	Fanconi's anemia
NCT000013996	NCT00001399_6_T0	GENE	7	7	defective
NCT000013996	NCT00001399_6_T1	PHENOTYPE	11	12	Fanconi's anemia
NCT000013997	NCT00001399_7_T0	PHENOTYPE	7	8	Fanconi's anemia
NCT000013998	NCT00001399_8_T0	CELL	10	10	cells
NCT000013998	NCT00001399_8_T1	PHENOTYPE	18	19	Fanconi's anemia
NCT0000139911	NCT00001399_11_T0	CELL	2	2	cells
NCT0000139913	NCT00001399_13_T0	CELL	7	7	cells
NCT0000139913	NCT00001399_13_T1	CELL	13	14	stem cells
NCT0000139913	NCT00001399_13_T2	ORGAN	10	11	bone marrow
NCT0000139914	NCT00001399_14_T0	CELL	15	15	platelets
NCT0000139914	NCT00001399_14_T1	CELL	1	2	stem cells
NCT0000139914	NCT00001399_14_T2	CELL	8	10	red blood cells
NCT0000139914	NCT00001399_14_T3	CELL	11	13	white blood cells
NCT0000139916	NCT00001399_16_T0	ORGAN	6	6	marrow
NCT0000139916	NCT00001399_16_T1	PHENOTYPE	16	16	aplasia
NCT0000139916	NCT00001399_16_T2	PHENOTYPE	18	19	acute leukemia
NCT0000139920	NCT00001399_20_T0	PHENOTYPE	22	22	mutation
NCT0000139920	NCT00001399_20_T1	CELL	12	14	hematopoietic progenitor cells
NCT0000139926	NCT00001399_26_T0	CELL	2	2	cells
NCT0000139927	NCT00001399_27_T0	PHENOTYPE	5	5	toxicities
NCT0000139928	NCT00001399_28_T0	GENE	15	15	2.4
NCT0000139933	NCT00001399_33_T0	GENE	12	12	30
NCT0000139933	NCT00001399_33_T1	GENE	19	19	30
NCT0000139934	NCT00001399_34_T0	COMPOUND	5	5	creatinine
NCT0000139935	NCT00001399_35_T0	COMPOUND	6	6	creatinine
NCT0000139935	NCT00001399_35_T1	COMPOUND	10	10	creatinine
NCT0000139935	NCT00001399_35_T2	ORGAN	5	5	serum
NCT0000139936	NCT00001399_36_T0	ORGAN	1	1	liver
NCT0000139936	NCT00001399_36_T1	PHENOTYPE	32	33	hepatitis B
NCT0000139936	NCT00001399_36_T2	PHENOTYPE	31	32	a hepatitis
NCT0000139936	NCT00001399_36_T3	GENE	7	8	alkaline phosphatase
NCT0000139938	NCT00001399_38_T0	GENE	6	6	1.5
NCT0000139939	NCT00001399_39_T0	GENE	7	7	1.5
NCT0000139939	NCT00001399_39_T1	ORGAN	0	0	Serum
NCT0000139940	NCT00001399_40_T0	GENE	6	6	3.0
NCT0000139944	NCT00001399_44_T0	COMPOUND	2	2	oxygen
NCT0000139946	NCT00001399_46_T0	PHENOTYPE	28	28	thrombocytopenia
NCT0000139946	NCT00001399_46_T1	PHENOTYPE	23	23	reflected
NCT0000139946	NCT00001399_46_T2	PHENOTYPE	26	26	neutropenia
NCT0000139946	NCT00001399_46_T3	PHENOTYPE	25	25	anemia
NCT0000139946	NCT00001399_46_T4	ORGAN	20	20	marrow
NCT0000139948	NCT00001399_48_T0	PHENOTYPE	20	21	acute leukemia
NCT0000139948	NCT00001399_48_T1	ORGAN	23	24	bone marrow
NCT0000139949	NCT00001399_49_T0	ORGAN	20	20	serum
NCT0000139950	NCT00001399_50_T0	PHENOTYPE	3	3	acute
NCT0000139950	NCT00001399_50_T1	PHENOTYPE	7	8	fungal infection
NCT0000139950	NCT00001399_50_T2	PHENOTYPE	0	1	Acute infection
NCT0000139951	NCT00001399_51_T0	PHENOTYPE	0	0	Acute
NCT0000139953	NCT00001399_53_T0	PHENOTYPE	0	0	HIV
NCT0000139954	NCT00001399_54_T0	PHENOTYPE	0	0	Acute
NCT0000139954	NCT00001399_54_T1	ORGAN	6	6	heart
NCT0000139954	NCT00001399_54_T2	PHENOTYPE	8	9	lung disease
NCT0000139955	NCT00001399_55_T0	PHENOTYPE	14	14	allergies
NCT000014002	NCT00001400_2_T0	ORGAN	14	14	heart
NCT000014020	NCT00001402_0_T0	ORGAN	12	12	Hearts
NCT000014020	NCT00001402_0_T1	PHENOTYPE	16	17	Heart Disease
NCT000014022	NCT00001402_2_T0	PHENOTYPE	22	22	circulation
NCT000014022	NCT00001402_2_T1	ORGAN	19	19	heart
NCT000014022	NCT00001402_2_T2	ORGAN	6	7	left ventricle
NCT000014024	NCT00001402_4_T0	ORGAN	10	11	left ventricle
NCT000014024	NCT00001402_4_T1	ORGAN	19	20	left ventricle
NCT000014024	NCT00001402_4_T2	PHENOTYPE	27	28	heart disease
NCT000014025	NCT00001402_5_T0	ORGAN	3	4	left ventricle
NCT000014026	NCT00001402_6_T0	TISSUE	18	19	heart muscle
NCT000014026	NCT00001402_6_T1	ORGAN	8	9	left ventricle
NCT000014027	NCT00001402_7_T0	COMPOUND	19	19	glucose
NCT000014027	NCT00001402_7_T1	COMPOUND	16	16	oxygen
NCT000014027	NCT00001402_7_T2	ORGAN	5	5	heart
NCT000014028	NCT00001402_8_T0	ORGAN	1	1	heart
NCT0000140210	NCT00001402_10_T0	PHENOTYPE	22	22	CHF
NCT0000140210	NCT00001402_10_T1	COMPOUND	7	7	glucose
NCT0000140210	NCT00001402_10_T2	TISSUE	10	11	heart muscle
NCT0000140210	NCT00001402_10_T3	TISSUE	17	18	heart muscle
NCT0000140212	NCT00001402_12_T0	PHENOTYPE	19	19	cardiomyopathies
NCT0000140212	NCT00001402_12_T1	GENE	10	10	ventricular
NCT0000140214	NCT00001402_14_T0	BIOLOGICAL_PROCESS	10	10	metabolism
NCT0000140214	NCT00001402_14_T1	PHENOTYPE	27	29	congestive heart failure
NCT0000140219	NCT00001402_19_T0	PHENOTYPE	3	4	coronary disease
NCT0000140222	NCT00001402_22_T0	PHENOTYPE	4	5	renal disease
NCT0000140224	NCT00001402_24_T0	PHENOTYPE	2	4	valvular heart disease
NCT0000140227	NCT00001402_27_T0	GENE	7	7	bpm
NCT0000140227	NCT00001402_27_T1	ORGAN	2	2	heart
NCT000014032	NCT00001403_2_T0	PHENOTYPE	17	17	symptoms
NCT000014035	NCT00001403_5_T0	GENE	25	25	MRI
NCT000014037	NCT00001403_7_T0	PHENOTYPE	19	19	affects
NCT000014039	NCT00001403_9_T0	PHENOTYPE	62	62	disorders
NCT000014039	NCT00001403_9_T1	PHENOTYPE	16	16	overgrowth
NCT000014039	NCT00001403_9_T2	PHENOTYPE	61	61	overgrowth
NCT000014039	NCT00001403_9_T3	PHENOTYPE	51	51	insights
NCT0000140310	NCT00001403_10_T0	PHENOTYPE	15	15	disorders
NCT0000140310	NCT00001403_10_T1	PHENOTYPE	14	14	overgrowth
NCT0000140311	NCT00001403_11_T0	GENE	14	14	AKT1
NCT0000140312	NCT00001403_12_T0	GENE	15	15	AKT1
NCT0000140313	NCT00001403_13_T0	PHENOTYPE	6	6	mutation
NCT0000140313	NCT00001403_13_T1	GENE	4	4	AKT1
NCT0000140314	NCT00001403_14_T0	PHENOTYPE	16	16	mutation
NCT0000140315	NCT00001403_15_T0	PHENOTYPE	4	4	disorders
NCT0000140318	NCT00001403_18_T0	PHENOTYPE	2	2	overgrowth
NCT0000140326	NCT00001403_26_T0	PHENOTYPE	6	6	overgrowth
NCT0000140326	NCT00001403_26_T1	GENE	10	10	disabled
NCT0000140326	NCT00001403_26_T2	PHENOTYPE	13	14	developmentally delayed
NCT0000140328	NCT00001403_28_T0	GENE	16	16	has
NCT000014045	NCT00001404_5_T0	PHENOTYPE	24	24	disorders
NCT000014045	NCT00001404_5_T1	PHENOTYPE	22	23	congenital anomaly
NCT0000140415	NCT00001404_15_T0	ORGAN	0	1	Cord blood
NCT0000140416	NCT00001404_16_T0	GENE	25	25	FWA
NCT0000140416	NCT00001404_16_T1	PHENOTYPE	23	23	MPA
NCT0000140419	NCT00001404_19_T0	PHENOTYPE	4	4	disorders
NCT0000140419	NCT00001404_19_T1	PHENOTYPE	17	17	disorders
NCT0000140511	NCT00001405_11_T0	PHENOTYPE	24	25	needle sticks
NCT0000140517	NCT00001405_17_T0	CELL	1	1	cells
NCT0000140517	NCT00001405_17_T1	CELL	26	26	cells
NCT0000140522	NCT00001405_22_T0	GENE	27	27	G-CSF
NCT0000140532	NCT00001405_32_T0	PHENOTYPE	9	9	peripheral
NCT0000140532	NCT00001405_32_T1	GENE	6	6	HSC
NCT0000140533	NCT00001405_33_T0	CELL	5	5	granulocyte
NCT0000140533	NCT00001405_33_T1	PHENOTYPE	24	24	peripheral
NCT0000140533	NCT00001405_33_T2	GENE	21	21	HSC
NCT0000140533	NCT00001405_33_T3	GENE	4	4	G-CSF
NCT0000140534	NCT00001405_34_T0	GENE	12	12	HSC
NCT0000140534	NCT00001405_34_T1	GENE	25	25	HSC
NCT0000140534	NCT00001405_34_T2	GENE	9	9	GCSF
NCT0000140535	NCT00001405_35_T0	GENE	18	18	HSC
NCT0000140535	NCT00001405_35_T1	ORGAN	14	15	bone marrow
NCT0000140536	NCT00001405_36_T0	ORGAN	11	12	bone marrow
NCT0000140537	NCT00001405_37_T0	PHENOTYPE	9	9	peripheral
NCT0000140537	NCT00001405_37_T1	GENE	4	4	gran
NCT0000140537	NCT00001405_37_T2	GENE	16	16	G-CSF
NCT0000140537	NCT00001405_37_T3	GENE	24	24	G-CSF
NCT0000140537	NCT00001405_37_T4	CELL	1	1	cells
NCT0000140537	NCT00001405_37_T5	CELL	3	3	Granulocytes
NCT0000140540	NCT00001405_40_T0	CELL	2	2	cells
NCT0000140540	NCT00001405_40_T1	GENE	4	4	gran
NCT0000140540	NCT00001405_40_T2	GENE	0	0	HSC
NCT0000140541	NCT00001405_41_T0	GENE	0	0	HSC
NCT0000140542	NCT00001405_42_T0	GENE	1	1	HSC
NCT0000140543	NCT00001405_43_T0	GENE	1	1	HSC
NCT0000140544	NCT00001405_44_T0	GENE	0	0	HSC
NCT0000140544	NCT00001405_44_T1	ORGAN	14	14	transplant
NCT0000140545	NCT00001405_45_T0	CELL	6	6	granulocytes
NCT0000140545	NCT00001405_45_T1	CELL	4	4	monocytes
NCT0000140545	NCT00001405_45_T2	CELL	2	2	lymphocytes
NCT0000140545	NCT00001405_45_T3	CELL	1	1	Cells
NCT0000140546	NCT00001405_46_T0	CELL	1	1	lymphocytes
NCT0000140547	NCT00001405_47_T0	CELL	4	4	granulocytes
NCT0000140547	NCT00001405_47_T1	CELL	2	2	monocytes
NCT0000140547	NCT00001405_47_T2	CELL	1	1	lymphocytes
NCT0000140547	NCT00001405_47_T3	CELL	5	5	neutrophils
NCT0000140551	NCT00001405_51_T0	GENE	0	0	Is
NCT0000140552	NCT00001405_52_T0	CELL	14	14	granulocytes
NCT0000140554	NCT00001405_54_T0	PHENOTYPE	7	8	fungal infection
NCT0000140558	NCT00001405_58_T0	PHENOTYPE	4	4	thrombocytopenia
NCT0000140558	NCT00001405_58_T1	PHENOTYPE	3	3	chronic
NCT0000140558	NCT00001405_58_T2	CELL	33	33	platelets
NCT0000140558	NCT00001405_58_T3	PHENOTYPE	21	22	platelet count
NCT0000140559	NCT00001405_59_T0	CELL	0	0	Platelets
NCT0000140561	NCT00001405_61_T0	GENE	25	25	G-CSF
NCT0000140561	NCT00001405_61_T1	ORGAN	15	15	serum
NCT0000140569	NCT00001405_69_T0	GENE	0	0	Is
NCT0000140571	NCT00001405_71_T0	CELL	39	39	granulocytes
NCT0000140571	NCT00001405_71_T1	PHENOTYPE	17	17	proteinuria
NCT0000140571	NCT00001405_71_T2	GENE	9	9	1.5
NCT0000140571	NCT00001405_71_T3	GENE	27	27	1.5
NCT0000140571	NCT00001405_71_T4	GENE	53	53	hematocrit
NCT0000140571	NCT00001405_71_T5	CELL	46	46	platelets
NCT0000140571	NCT00001405_71_T6	COMPOUND	16	16	1
NCT0000140571	NCT00001405_71_T7	COMPOUND	3	3	creatinine
NCT0000140571	NCT00001405_71_T8	COMPOUND	21	21	bilirubin
NCT0000140571	NCT00001405_71_T9	GENE	32	32	WBC
NCT0000140573	NCT00001405_73_T0	GENE	27	27	G-CSF
NCT0000140573	NCT00001405_73_T1	ORGAN	17	17	serum
NCT0000140576	NCT00001405_76_T0	CELL	13	13	cells
NCT0000140576	NCT00001405_76_T1	ORGAN	5	6	bone marrow
NCT0000140577	NCT00001405_77_T0	PHENOTYPE	11	12	recurrent infection
NCT0000140580	NCT00001405_80_T0	CELL	39	39	granulocytes
NCT0000140580	NCT00001405_80_T1	PHENOTYPE	17	17	proteinuria
NCT0000140580	NCT00001405_80_T2	GENE	9	9	1.5
NCT0000140580	NCT00001405_80_T3	GENE	27	27	1.5
NCT0000140580	NCT00001405_80_T4	GENE	53	53	hematocrit
NCT0000140580	NCT00001405_80_T5	CELL	46	46	platelets
NCT0000140580	NCT00001405_80_T6	COMPOUND	16	16	1
NCT0000140580	NCT00001405_80_T7	COMPOUND	3	3	creatinine
NCT0000140580	NCT00001405_80_T8	COMPOUND	21	21	bilirubin
NCT0000140580	NCT00001405_80_T9	GENE	32	32	WBC
NCT0000140582	NCT00001405_82_T0	ORGAN	17	17	serum
NCT0000140582	NCT00001405_82_T1	GENE	27	27	GCSF
NCT0000140585	NCT00001405_85_T0	CELL	13	13	cells
NCT0000140585	NCT00001405_85_T1	ORGAN	5	6	bone marrow
NCT0000140587	NCT00001405_87_T0	GENE	14	14	Hg
NCT0000140589	NCT00001405_89_T0	PHENOTYPE	12	14	positive pregnancy test
NCT0000140594	NCT00001405_94_T0	PHENOTYPE	0	0	XSCID
NCT0000140594	NCT00001405_94_T1	PHENOTYPE	7	8	false positives
NCT00001405108	NCT00001405_108_T0	ORGAN	9	10	bone marrow
NCT00001405109	NCT00001405_109_T0	ORGAN	8	9	bone marrow
NCT000014060	NCT00001406_0_T0	PHENOTYPE	11	11	Eosinophilia
NCT000014060	NCT00001406_0_T1	CELL	4	4	Eosinophils
NCT000014062	NCT00001406_2_T0	PHENOTYPE	7	7	allergies
NCT000014062	NCT00001406_2_T1	PHENOTYPE	12	12	infections
NCT000014062	NCT00001406_2_T2	PHENOTYPE	8	8	asthma
NCT000014062	NCT00001406_2_T3	CELL	0	0	Eosinophil
NCT000014064	NCT00001406_4_T0	CELL	4	4	cells
NCT000014064	NCT00001406_4_T1	PHENOTYPE	7	7	eosinophilia
NCT000014066	NCT00001406_6_T0	TISSUE	24	24	tissues
NCT000014066	NCT00001406_6_T1	CELL	18	18	eosinophils
NCT000014066	NCT00001406_6_T2	CELL	8	8	eosinophil
NCT0000140612	NCT00001406_12_T0	CELL	29	29	eosinophils
NCT0000140612	NCT00001406_12_T1	CELL	15	15	cells
NCT0000140614	NCT00001406_14_T0	ORGAN	31	32	bone marrow
NCT0000140622	NCT00001406_22_T0	PHENOTYPE	8	8	focused
NCT0000140622	NCT00001406_22_T1	PHENOTYPE	16	16	eosinophilia
NCT0000140624	NCT00001406_24_T0	PHENOTYPE	16	16	eosinophilia
NCT0000140625	NCT00001406_25_T0	PHENOTYPE	21	21	eosinophilia
NCT0000140625	NCT00001406_25_T1	CELL	31	31	eosinophils
NCT0000140626	NCT00001406_26_T0	PHENOTYPE	40	40	eosinophilia
NCT0000140626	NCT00001406_26_T1	BIOLOGICAL_PROCESS	41	42	eosinophil activation
NCT0000140627	NCT00001406_27_T0	PHENOTYPE	4	4	hypereosinophilia
NCT0000140628	NCT00001406_28_T0	PHENOTYPE	10	10	HES
NCT0000140629	NCT00001406_29_T0	PHENOTYPE	15	15	eosinophilia
NCT0000140629	NCT00001406_29_T1	PHENOTYPE	24	24	eosinophilia
NCT0000140631	NCT00001406_31_T0	CELL	22	22	eosinophil
NCT0000140631	NCT00001406_31_T1	PHENOTYPE	34	35	gastrointestinal disease
NCT0000140633	NCT00001406_33_T0	COMPOUND	12	13	vitamin D
NCT0000140636	NCT00001406_36_T0	PHENOTYPE	23	23	feels
NCT0000140636	NCT00001406_36_T1	COMPOUND	4	4	2
NCT0000140636	NCT00001406_36_T2	GENE	5	5	extended
NCT0000140639	NCT00001406_39_T0	PHENOTYPE	4	4	HES
NCT0000140639	NCT00001406_39_T1	PHENOTYPE	2	3	Hypereosinophilic Syndrome
NCT0000140640	NCT00001406_40_T0	PHENOTYPE	2	2	HES
NCT0000140641	NCT00001406_41_T0	PHENOTYPE	2	2	symptoms
NCT0000140642	NCT00001406_42_T0	PHENOTYPE	3	3	symptoms
NCT0000140646	NCT00001406_46_T0	PHENOTYPE	10	10	HES
NCT0000140646	NCT00001406_46_T1	PHENOTYPE	8	9	Hypereosinophilic Syndrome
NCT0000140647	NCT00001406_47_T0	PHENOTYPE	5	5	impairment
NCT0000140650	NCT00001406_50_T0	GENE	4	4	fusion
NCT0000140650	NCT00001406_50_T1	PHENOTYPE	8	8	translocation
NCT0000140650	NCT00001406_50_T2	GENE	5	6	tyrosine kinase
NCT0000140651	NCT00001406_51_T0	BIOLOGICAL_PROCESS	2	2	Development
NCT0000140651	NCT00001406_51_T1	PHENOTYPE	5	6	Hypereosinophilic Syndrome
NCT0000140652	NCT00001406_52_T0	PHENOTYPE	5	5	HES
NCT000014070	NCT00001407_0_T0	GENE	0	0	Interferon
NCT000014070	NCT00001407_0_T1	PHENOTYPE	3	5	Drug Resistant Tuberculosis
NCT000014073	NCT00001407_3_T0	PHENOTYPE	9	10	drug-resistant tuberculosis
NCT000014076	NCT00001407_6_T0	TISSUE	6	6	tissues
NCT000014078	NCT00001407_8_T0	PHENOTYPE	6	6	tuberculosis
NCT000014078	NCT00001407_8_T1	GENE	22	23	gamma interferon
NCT0000140711	NCT00001407_11_T0	PHENOTYPE	20	20	tuberculosis
NCT0000140712	NCT00001407_12_T0	COMPOUND	15	15	1
NCT0000140713	NCT00001407_13_T0	GENE	2	3	interferon gamma
NCT0000140713	NCT00001407_13_T1	PHENOTYPE	19	20	lung infection
NCT0000140714	NCT00001407_14_T0	GENE	17	18	interferon gamma
NCT0000140714	NCT00001407_14_T1	PHENOTYPE	2	3	lung infection
NCT0000140717	NCT00001407_17_T0	PHENOTYPE	29	29	tuberculous
NCT0000140717	NCT00001407_17_T1	GENE	3	4	interferon gamma
NCT0000140719	NCT00001407_19_T0	COMPOUND	9	9	2
NCT0000140719	NCT00001407_19_T1	COMPOUND	17	17	2
NCT0000140719	NCT00001407_19_T2	COMPOUND	3	3	creatinine
NCT0000140719	NCT00001407_19_T3	PHENOTYPE	18	18	proteinuria
NCT0000140719	NCT00001407_19_T4	GENE	11	11	ml
NCT0000140720	NCT00001407_20_T0	GENE	9	9	1.5
NCT0000140720	NCT00001407_20_T1	COMPOUND	3	3	bilirubin
NCT0000140720	NCT00001407_20_T2	GENE	12	12	prothrombin
NCT0000140720	NCT00001407_20_T3	GENE	11	11	ml
NCT0000140721	NCT00001407_21_T0	CELL	10	10	granulocytes
NCT0000140721	NCT00001407_21_T1	GENE	3	3	WBC
NCT0000140721	NCT00001407_21_T2	CELL	14	14	platelets
NCT0000140726	NCT00001407_26_T0	PHENOTYPE	4	5	seizure disorder
NCT0000140727	NCT00001407_27_T0	PHENOTYPE	8	8	arrhythmias
NCT0000140727	NCT00001407_27_T1	ORGAN	10	11	coronary artery
NCT0000140727	NCT00001407_27_T2	PHENOTYPE	4	5	cardiac disease
NCT000014082	NCT00001408_2_T0	CELL	0	1	T cells
NCT000014084	NCT00001408_4_T0	PHENOTYPE	10	11	allergic asthma
NCT0000140811	NCT00001408_11_T0	GENE	8	8	allergen
NCT0000140811	NCT00001408_11_T1	PHENOTYPE	11	12	lung function
NCT0000140813	NCT00001408_13_T0	GENE	6	6	3.5
NCT0000140813	NCT00001408_13_T1	GENE	4	4	ml
NCT0000140821	NCT00001408_21_T0	GENE	0	0	IL-5
NCT0000140821	NCT00001408_21_T1	CELL	10	10	eosinophil
NCT0000140822	NCT00001408_22_T0	CELL	8	8	cells
NCT0000140822	NCT00001408_22_T1	PHENOTYPE	10	10	asthma
NCT0000140822	NCT00001408_22_T2	CELL	0	0	Eosinophils
NCT0000140823	NCT00001408_23_T0	GENE	13	13	allergen
NCT0000140823	NCT00001408_23_T1	PHENOTYPE	8	8	airflow
NCT0000140823	NCT00001408_23_T2	GENE	10	10	4-8
NCT0000140823	NCT00001408_23_T3	PHENOTYPE	25	26	chronic asthma
NCT0000140824	NCT00001408_24_T0	PHENOTYPE	9	9	peripheral
NCT0000140824	NCT00001408_24_T1	ORGAN	16	16	lungs
NCT0000140824	NCT00001408_24_T2	GENE	21	21	IL-4
NCT0000140824	NCT00001408_24_T3	GENE	23	23	IL-5
NCT0000140824	NCT00001408_24_T4	CELL	11	12	T cells
NCT0000140825	NCT00001408_25_T0	PHENOTYPE	22	22	peripheral
NCT0000140825	NCT00001408_25_T1	CELL	13	13	cells
NCT0000140825	NCT00001408_25_T2	PHENOTYPE	28	29	allergic asthma
NCT0000140828	NCT00001408_28_T0	PHENOTYPE	0	0	Asthma
NCT0000140830	NCT00001408_30_T0	PHENOTYPE	1	1	HIV
NCT0000140832	NCT00001408_32_T0	GENE	20	20	10.0
NCT0000140832	NCT00001408_32_T1	GENE	16	16	hemoglobin
NCT0000140832	NCT00001408_32_T2	GENE	5	5	ml
NCT0000140834	NCT00001408_34_T0	PHENOTYPE	7	7	asthma
NCT0000140834	NCT00001408_34_T1	PHENOTYPE	3	4	lung diseases
NCT0000140838	NCT00001408_38_T0	PHENOTYPE	1	1	HIV
NCT0000140840	NCT00001408_40_T0	GENE	20	20	10.0
NCT0000140840	NCT00001408_40_T1	GENE	16	16	hemoglobin
NCT0000140840	NCT00001408_40_T2	GENE	5	5	ml
NCT0000140842	NCT00001408_42_T0	PHENOTYPE	0	2	Positive skin test
NCT0000140843	NCT00001408_43_T0	PHENOTYPE	6	6	diseases
NCT0000140843	NCT00001408_43_T1	PHENOTYPE	2	2	asthma
NCT0000140843	NCT00001408_43_T2	PHENOTYPE	9	10	hay fever
NCT0000140844	NCT00001408_44_T0	PHENOTYPE	7	7	asthma
NCT0000140844	NCT00001408_44_T1	PHENOTYPE	3	4	lung diseases
NCT0000140847	NCT00001408_47_T0	PHENOTYPE	15	15	asthma
NCT0000140847	NCT00001408_47_T1	PHENOTYPE	0	0	Asthma
NCT0000140850	NCT00001408_50_T0	PHENOTYPE	2	4	allergy to latex
NCT0000140853	NCT00001408_53_T0	PHENOTYPE	7	7	asthma
NCT0000140853	NCT00001408_53_T1	PHENOTYPE	3	4	lung diseases
NCT0000140854	NCT00001408_54_T0	PHENOTYPE	2	4	allergy to latex
NCT000014095	NCT00001409_5_T0	PHENOTYPE	16	16	HIV
NCT000014095	NCT00001409_5_T1	GENE	15	15	gp120
NCT000014095	NCT00001409_5_T2	GENE	17	18	envelope protein
NCT000014096	NCT00001409_6_T0	GENE	7	7	II
NCT000014098	NCT00001409_8_T0	GENE	2	2	CD4
NCT0000140910	NCT00001409_10_T0	GENE	3	3	KS
NCT0000140917	NCT00001409_17_T0	PHENOTYPE	3	4	substance abuse
NCT0000140920	NCT00001409_20_T0	GENE	4	4	Barr
NCT0000140920	NCT00001409_20_T1	PHENOTYPE	3	3	Epstein
NCT0000140920	NCT00001409_20_T2	PHENOTYPE	20	20	seronegative
NCT0000140920	NCT00001409_20_T3	PHENOTYPE	10	11	Hepatitis C
NCT0000140920	NCT00001409_20_T4	PHENOTYPE	7	8	Hepatitis B
NCT000014102	NCT00001410_2_T0	PHENOTYPE	5	5	enlargement
NCT000014102	NCT00001410_2_T1	ORGAN	8	8	liver
NCT000014102	NCT00001410_2_T2	TISSUE	10	10	spleen
NCT000014102	NCT00001410_2_T3	PHENOTYPE	11	11	hepatosplenomegaly
NCT000014102	NCT00001410_2_T4	CELL	15	15	platelet
NCT000014103	NCT00001410_3_T0	PHENOTYPE	10	12	autosomal recessive inheritance
NCT000014104	NCT00001410_4_T0	PHENOTYPE	6	7	Gaucher disease
NCT000014106	NCT00001410_6_T0	PHENOTYPE	3	3	chronic
NCT000014106	NCT00001410_6_T1	ORGAN	13	14	nervous system
NCT000014108	NCT00001410_8_T0	PHENOTYPE	2	3	Gaucher disease
NCT0000141011	NCT00001410_11_T0	PHENOTYPE	10	10	subacute
NCT0000141011	NCT00001410_11_T1	PHENOTYPE	2	3	Gaucher disease
NCT0000141012	NCT00001410_12_T0	PHENOTYPE	14	14	acute
NCT0000141012	NCT00001410_12_T1	PHENOTYPE	11	11	chronic
NCT0000141013	NCT00001410_13_T0	PHENOTYPE	7	8	Gaucher disease
NCT0000141014	NCT00001410_14_T0	GENE	4	4	has
NCT0000141016	NCT00001410_16_T0	GENE	8	8	has
NCT0000141018	NCT00001410_18_T0	GENE	13	13	PEG
NCT0000141018	NCT00001410_18_T1	COMPOUND	11	12	polyethylene glycol
NCT0000141019	NCT00001410_19_T0	GENE	4	4	PEG
NCT0000141020	NCT00001410_20_T0	GENE	4	4	PEG
NCT0000141020	NCT00001410_20_T1	GENE	2	2	glucocerebrosidase
NCT0000141021	NCT00001410_21_T0	GENE	17	17	PEG
NCT0000141021	NCT00001410_21_T1	GENE	18	18	glucocerebrosidase
NCT0000141021	NCT00001410_21_T2	PHENOTYPE	23	24	Gaucher disease
NCT0000141023	NCT00001410_23_T0	GENE	20	20	PEG
NCT0000141023	NCT00001410_23_T1	GENE	17	17	glucocerebrosidase
NCT0000141024	NCT00001410_24_T0	CELL	6	6	platelet
NCT0000141024	NCT00001410_24_T1	GENE	5	5	hemoglobin
NCT0000141025	NCT00001410_25_T0	PHENOTYPE	1	1	pharmacodynamic
NCT0000141027	NCT00001410_27_T0	PHENOTYPE	16	17	Gaucher disease
NCT0000141028	NCT00001410_28_T0	PHENOTYPE	26	26	hepatomegaly
NCT0000141028	NCT00001410_28_T1	PHENOTYPE	28	28	splenomegaly
NCT0000141028	NCT00001410_28_T2	CELL	22	22	platelets
NCT0000141028	NCT00001410_28_T3	GENE	17	17	hemoglobin
NCT0000141032	NCT00001410_32_T0	GENE	4	4	alglucerase
NCT0000141032	NCT00001410_32_T1	GENE	6	6	imiglucerase
NCT0000141033	NCT00001410_33_T0	GENE	6	7	type 2
NCT0000141033	NCT00001410_33_T1	PHENOTYPE	8	9	Gaucher disease
NCT0000141035	NCT00001410_35_T0	PHENOTYPE	10	10	malignancy
NCT0000141035	NCT00001410_35_T1	PHENOTYPE	5	5	progressing
NCT0000141036	NCT00001410_36_T0	PHENOTYPE	9	9	HIV
NCT0000141036	NCT00001410_36_T1	PHENOTYPE	5	5	chronic
NCT0000141036	NCT00001410_36_T2	PHENOTYPE	11	12	hepatitis B
NCT0000141036	NCT00001410_36_T3	PHENOTYPE	6	7	infectious disease
NCT0000141037	NCT00001410_37_T0	BIOLOGICAL_PROCESS	12	12	metabolism
NCT000014126	NCT00001412_6_T0	COMPOUND	9	9	testosterone
NCT000014126	NCT00001412_6_T1	COMPOUND	17	17	testosterone
NCT000014129	NCT00001412_9_T0	GENE	0	0	Is
NCT0000141211	NCT00001412_11_T0	GENE	7	7	hormone
NCT0000141212	NCT00001412_12_T0	GENE	9	9	HPA
NCT0000141212	NCT00001412_12_T1	GENE	10	10	axis
NCT0000141213	NCT00001412_13_T0	GENE	18	18	CSF
NCT0000141218	NCT00001412_18_T0	COMPOUND	7	7	androgen
NCT0000141218	NCT00001412_18_T1	ORGAN	6	6	plasma
NCT0000141223	NCT00001412_23_T0	COMPOUND	11	11	testosterone
NCT0000141223	NCT00001412_23_T1	COMPOUND	29	29	testosterone
NCT0000141224	NCT00001412_24_T0	PHENOTYPE	24	24	hypogonadism
NCT0000141224	NCT00001412_24_T1	PHENOTYPE	26	26	hypogonadism
NCT0000141224	NCT00001412_24_T2	COMPOUND	28	28	testosterone
NCT0000141224	NCT00001412_24_T3	PHENOTYPE	5	6	cognitive function
NCT0000141229	NCT00001412_29_T0	PHENOTYPE	3	3	symptoms
NCT000014133	NCT00001413_3_T0	PHENOTYPE	15	16	side effect
NCT000014134	NCT00001413_4_T0	COMPOUND	4	4	calcium
NCT000014135	NCT00001413_5_T0	COMPOUND	9	9	calcium
NCT000014137	NCT00001413_7_T0	COMPOUND	15	15	calcium
NCT000014137	NCT00001413_7_T1	GENE	17	17	TFCA
NCT000014138	NCT00001413_8_T0	PHENOTYPE	14	14	adiposity
NCT0000141310	NCT00001413_10_T0	PHENOTYPE	3	3	osteoporosis
NCT0000141310	NCT00001413_10_T1	PHENOTYPE	26	28	Major Depressive Disorder
NCT0000141312	NCT00001413_12_T0	ORGAN	24	24	trochanter
NCT0000141312	NCT00001413_12_T1	ORGAN	13	14	femoral neck
NCT0000141312	NCT00001413_12_T2	TISSUE	6	7	trabecular bone
NCT0000141313	NCT00001413_13_T0	PHENOTYPE	21	21	fracture
NCT0000141313	NCT00001413_13_T1	TISSUE	6	7	trabecular bone
NCT0000141317	NCT00001413_17_T0	PHENOTYPE	9	9	affects
NCT0000141317	NCT00001413_17_T1	PHENOTYPE	33	33	osteoporosis
NCT0000141317	NCT00001413_17_T2	PHENOTYPE	7	8	major depression
NCT0000141321	NCT00001413_21_T0	PHENOTYPE	2	3	Bipolar Disorder
NCT0000141321	NCT00001413_21_T1	PHENOTYPE	11	12	depressive episode
NCT0000141324	NCT00001413_24_T0	PHENOTYPE	4	4	osteoporosis
NCT0000141326	NCT00001413_26_T0	PHENOTYPE	0	0	Chronic
NCT0000141328	NCT00001413_28_T0	PHENOTYPE	4	4	osteoporosis
NCT0000141329	NCT00001413_29_T0	PHENOTYPE	12	13	drug abuse
NCT0000141329	NCT00001413_29_T1	PHENOTYPE	7	8	eating disorders
NCT000014142	NCT00001414_2_T0	CELL	13	13	cells
NCT000014144	NCT00001414_4_T0	BIOLOGICAL_PROCESS	18	18	neurotransmission
NCT000014145	NCT00001414_5_T0	GENE	2	2	has
NCT000014147	NCT00001414_7_T0	PHENOTYPE	4	4	associations
NCT000014149	NCT00001414_9_T0	BIOLOGICAL_PROCESS	18	18	neurotransmission
NCT0000141410	NCT00001414_10_T0	BIOLOGICAL_PROCESS	18	18	neurotransmission
NCT0000141412	NCT00001414_12_T0	GENE	2	2	has
NCT000014151	NCT00001415_1_T0	COMPOUND	7	7	cortisol
NCT000014151	NCT00001415_1_T1	GENE	6	6	hormone
NCT000014151	NCT00001415_1_T2	ORGAN	12	13	immune system
NCT000014152	NCT00001415_2_T0	GENE	3	3	hormone
NCT000014152	NCT00001415_2_T1	ORGAN	16	17	pituitary gland
NCT000014152	NCT00001415_2_T2	ORGAN	7	8	adrenal glands
NCT000014153	NCT00001415_3_T0	COMPOUND	3	3	cortisol
NCT000014153	NCT00001415_3_T1	PHENOTYPE	9	9	diseases
NCT000014153	NCT00001415_3_T2	PHENOTYPE	14	15	multiple sclerosis
NCT000014154	NCT00001415_4_T0	CELL	6	8	white blood cells
NCT000014155	NCT00001415_5_T0	CELL	5	5	cells
NCT000014155	NCT00001415_5_T1	CELL	13	13	cells
NCT000014155	NCT00001415_5_T2	CELL	20	20	cells
NCT000014155	NCT00001415_5_T3	PHENOTYPE	17	17	paracrine
NCT000014155	NCT00001415_5_T4	PHENOTYPE	24	25	endocrine effect
NCT000014156	NCT00001415_6_T0	PHENOTYPE	5	5	inflammation
NCT000014158	NCT00001415_8_T0	PHENOTYPE	16	16	diseases
NCT0000141510	NCT00001415_10_T0	GENE	9	11	corticotropin releasing hormone
NCT0000141511	NCT00001415_11_T0	PHENOTYPE	16	17	acute illness
NCT0000141515	NCT00001415_15_T0	PHENOTYPE	0	0	Fibromyalgia
NCT0000141516	NCT00001415_16_T0	PHENOTYPE	0	1	Chronic fatigue
NCT0000141518	NCT00001415_18_T0	PHENOTYPE	5	5	chronic
NCT0000141519	NCT00001415_19_T0	PHENOTYPE	20	20	infections
NCT000014161	NCT00001416_1_T0	CELL	12	12	macrophages
NCT000014161	NCT00001416_1_T1	GENE	21	21	glucocerebrosidase
NCT000014161	NCT00001416_1_T2	PHENOTYPE	0	1	Gaucher disease
NCT000014161	NCT00001416_1_T3	PHENOTYPE	4	6	lysosomal storage disease
NCT000014163	NCT00001416_3_T0	PHENOTYPE	5	5	enlargement
NCT000014163	NCT00001416_3_T1	ORGAN	8	8	liver
NCT000014163	NCT00001416_3_T2	TISSUE	10	10	spleen
NCT000014163	NCT00001416_3_T3	PHENOTYPE	2	3	Gaucher's disease
NCT000014163	NCT00001416_3_T4	PHENOTYPE	12	13	bone destruction
NCT000014164	NCT00001416_4_T0	PHENOTYPE	9	11	autosomal recessive inheritance
NCT000014166	NCT00001416_6_T0	PHENOTYPE	3	3	chronic
NCT000014166	NCT00001416_6_T1	CELL	12	13	nerve cells
NCT0000141610	NCT00001416_10_T0	COMPOUND	17	17	calcitriol
NCT0000141610	NCT00001416_10_T1	COMPOUND	15	16	vitamin D
NCT0000141611	NCT00001416_11_T0	COMPOUND	5	6	vitamin D
NCT0000141615	NCT00001416_15_T0	COMPOUND	18	18	calcium
NCT0000141615	NCT00001416_15_T1	GENE	15	15	D3
NCT0000141615	NCT00001416_15_T2	CELL	26	26	macrophages
NCT0000141615	NCT00001416_15_T3	COMPOUND	16	16	calcitriol
NCT0000141615	NCT00001416_15_T4	ORGAN	24	25	bone marrow
NCT0000141618	NCT00001416_18_T0	GENE	7	7	0.6
NCT0000141618	NCT00001416_18_T1	GENE	49	49	0.6
NCT0000141618	NCT00001416_18_T2	ORGAN	84	84	spine
NCT0000141618	NCT00001416_18_T3	COMPOUND	17	17	2
NCT0000141618	NCT00001416_18_T4	COMPOUND	38	38	3
NCT0000141618	NCT00001416_18_T5	GENE	28	28	7.12
NCT0000141618	NCT00001416_18_T6	GENE	0	1	Group 1
NCT0000141618	NCT00001416_18_T7	TISSUE	78	79	trabecular bone
NCT000014171	NCT00001417_1_T0	PHENOTYPE	6	7	primary tumors
NCT000014171	NCT00001417_1_T1	PHENOTYPE	0	1	Metastatic tumors
NCT000014174	NCT00001417_4_T0	PHENOTYPE	2	2	tumors
NCT000014174	NCT00001417_4_T1	ORGAN	5	5	spine
NCT000014175	NCT00001417_5_T0	PHENOTYPE	6	7	spinal tumors
NCT000014176	NCT00001417_6_T0	PHENOTYPE	2	2	tumors
NCT000014176	NCT00001417_6_T1	PHENOTYPE	7	7	resistant
NCT000014176	NCT00001417_6_T2	ORGAN	5	5	spine
NCT000014178	NCT00001417_8_T0	COMPOUND	2	2	ethanol
NCT0000141711	NCT00001417_11_T0	PHENOTYPE	17	18	spinal tumors
NCT0000141715	NCT00001417_15_T0	PHENOTYPE	3	3	debility
NCT0000141715	NCT00001417_15_T1	PHENOTYPE	16	17	blood loss
NCT0000141715	NCT00001417_15_T2	PHENOTYPE	11	12	spinal metastases
NCT0000141716	NCT00001417_16_T0	PHENOTYPE	29	29	metastases
NCT0000141716	NCT00001417_16_T1	PHENOTYPE	13	13	hemangiomas
NCT0000141716	NCT00001417_16_T2	COMPOUND	9	9	ethanol
NCT0000141716	NCT00001417_16_T3	COMPOUND	20	20	ethanol
NCT0000141716	NCT00001417_16_T4	PHENOTYPE	15	16	hepatic metastases
NCT0000141718	NCT00001417_18_T0	COMPOUND	1	1	ethanol
NCT0000141718	NCT00001417_18_T1	ORGAN	20	21	spinal cord
NCT0000141727	NCT00001417_27_T0	ORGAN	10	10	vertebrae
NCT0000141728	NCT00001417_28_T0	PHENOTYPE	6	7	spinal tumor
NCT0000141729	NCT00001417_29_T0	PHENOTYPE	15	15	symptoms
NCT0000141729	NCT00001417_29_T1	PHENOTYPE	10	10	tumors
NCT0000141730	NCT00001417_30_T0	PHENOTYPE	5	5	tumor
NCT0000141733	NCT00001417_33_T0	PHENOTYPE	7	8	radiation exposure
NCT0000141735	NCT00001417_35_T0	GENE	6	6	MRI
NCT0000141736	NCT00001417_36_T0	PHENOTYPE	23	23	analgesia
NCT0000141736	NCT00001417_36_T1	COMPOUND	2	2	ethanol
NCT0000141737	NCT00001417_37_T0	PHENOTYPE	2	2	tumors
NCT0000141737	NCT00001417_37_T1	COMPOUND	13	13	ethanol
NCT0000141738	NCT00001417_38_T0	PHENOTYPE	2	2	tumors
NCT0000141738	NCT00001417_38_T1	COMPOUND	19	19	ethanol
NCT0000141738	NCT00001417_38_T2	ORGAN	13	14	spinal cord
NCT0000141739	NCT00001417_39_T0	COMPOUND	12	12	ethanol
NCT0000141740	NCT00001417_40_T0	COMPOUND	17	17	ethanol
NCT0000141742	NCT00001417_42_T0	PHENOTYPE	16	16	neuroblastoma
NCT0000141742	NCT00001417_42_T1	ORGAN	8	8	kidney
NCT0000141742	NCT00001417_42_T2	PHENOTYPE	13	13	myeloma
NCT0000141742	NCT00001417_42_T3	PHENOTYPE	12	12	lymphoma
NCT0000141742	NCT00001417_42_T4	PHENOTYPE	27	27	tumors
NCT0000141742	NCT00001417_42_T5	PHENOTYPE	17	17	seminoma
NCT0000141742	NCT00001417_42_T6	PHENOTYPE	10	11	lung carcinoma
NCT0000141742	NCT00001417_42_T7	PHENOTYPE	3	4	spinal tumors
NCT0000141742	NCT00001417_42_T8	PHENOTYPE	14	15	Ewing's sarcoma
NCT0000141742	NCT00001417_42_T9	ORGAN	36	37	spinal cord
NCT0000141744	NCT00001417_44_T0	PHENOTYPE	4	4	metastases
NCT0000141745	NCT00001417_45_T0	PHENOTYPE	4	4	metastases
NCT000014181	NCT00001418_1_T0	ORGAN	9	10	nervous system
NCT000014181	NCT00001418_1_T1	ORGAN	1	3	sympathetic nervous system
NCT000014184	NCT00001418_4_T0	COMPOUND	13	13	fluorodopamine
NCT000014185	NCT00001418_5_T0	ORGAN	10	12	sympathetic nervous system
NCT000014187	NCT00001418_7_T0	ORGAN	12	12	heart
NCT000014187	NCT00001418_7_T1	ORGAN	8	9	nerve endings
NCT000014188	NCT00001418_8_T0	COMPOUND	5	5	fluorodopamine
NCT000014188	NCT00001418_8_T1	ORGAN	24	24	heart
NCT000014188	NCT00001418_8_T2	ORGAN	16	17	nerve endings
NCT000014189	NCT00001418_9_T0	ORGAN	16	16	hearts
NCT000014189	NCT00001418_9_T1	ORGAN	12	13	nervous system
NCT0000141811	NCT00001418_11_T0	ORGAN	13	14	body regions
NCT0000141813	NCT00001418_13_T0	PHENOTYPE	24	24	disorders
NCT0000141813	NCT00001418_13_T1	BIOLOGICAL_PROCESS	19	19	innervation
NCT0000141821	NCT00001418_21_T0	GENE	20	20	DIR
NCT0000141823	NCT00001418_23_T0	COMPOUND	16	16	aspirin
NCT000014202	NCT00001420_2_T0	PHENOTYPE	5	6	psoriatic arthritis
NCT000014205	NCT00001420_5_T0	CELL	2	4	white blood cells
NCT0000142013	NCT00001420_13_T0	ORGAN	7	8	synovial fluid
NCT0000142021	NCT00001420_21_T0	PHENOTYPE	14	14	spitting
NCT000014211	NCT00001421_1_T0	PHENOTYPE	9	9	diseases
NCT000014213	NCT00001421_3_T0	COMPOUND	7	7	methimazole
NCT000014213	NCT00001421_3_T1	PHENOTYPE	17	19	inflammatory muscle diseases
NCT000014213	NCT00001421_3_T2	PHENOTYPE	23	25	drug side effects
NCT000014214	NCT00001421_4_T0	PHENOTYPE	2	2	polymyositis
NCT000014214	NCT00001421_4_T1	PHENOTYPE	4	4	dermatomyositis
NCT000014214	NCT00001421_4_T2	PHENOTYPE	8	9	thyroid function
NCT000014215	NCT00001421_5_T0	TISSUE	30	30	muscles
NCT000014215	NCT00001421_5_T1	TISSUE	40	41	muscle tissue
NCT000014217	NCT00001421_7_T0	COMPOUND	6	6	methimazole
NCT000014218	NCT00001421_8_T0	ORGAN	27	27	liver
NCT000014218	NCT00001421_8_T1	PHENOTYPE	29	30	thyroid function
NCT0000142113	NCT00001421_13_T0	PHENOTYPE	4	4	weakness
NCT0000142113	NCT00001421_13_T1	PHENOTYPE	8	8	inflammation
NCT0000142113	NCT00001421_13_T2	PHENOTYPE	20	20	myopathy
NCT0000142115	NCT00001421_15_T0	PHENOTYPE	14	14	peripheral
NCT0000142115	NCT00001421_15_T1	CELL	16	16	lymphocytes
NCT0000142115	NCT00001421_15_T2	GENE	17	17	PBL
NCT0000142115	NCT00001421_15_T3	PHENOTYPE	19	20	drug toxicities
NCT0000142117	NCT00001421_17_T0	GENE	17	17	MMT
NCT0000142117	NCT00001421_17_T1	PHENOTYPE	1	2	muscle weakness
NCT0000142121	NCT00001421_21_T0	PHENOTYPE	6	6	polymyositis
NCT0000142121	NCT00001421_21_T1	PHENOTYPE	8	8	dermatomyositis
NCT0000142122	NCT00001421_22_T0	PHENOTYPE	1	3	proximal muscle weakness
NCT0000142123	NCT00001421_23_T0	BIOLOGICAL_PROCESS	19	19	phagocytosis
NCT0000142123	NCT00001421_23_T1	BIOLOGICAL_PROCESS	12	12	regeneration
NCT0000142123	NCT00001421_23_T2	BIOLOGICAL_PROCESS	17	17	necrosis
NCT0000142123	NCT00001421_23_T3	PHENOTYPE	10	10	degeneration
NCT0000142123	NCT00001421_23_T4	PHENOTYPE	23	23	infiltration
NCT0000142124	NCT00001421_24_T0	GENE	9	9	LDH
NCT0000142124	NCT00001421_24_T1	COMPOUND	3	3	creatinine
NCT0000142124	NCT00001421_24_T2	GENE	8	8	dehydrogenase
NCT0000142124	NCT00001421_24_T3	ORGAN	2	2	serum
NCT0000142124	NCT00001421_24_T4	GENE	5	5	CPK
NCT0000142124	NCT00001421_24_T5	MOLECULAR_FUNCTION	11	12	aldolase activity
NCT0000142125	NCT00001421_25_T0	PHENOTYPE	21	21	irritability
NCT0000142125	NCT00001421_25_T1	PHENOTYPE	15	15	fibrillations
NCT0000142128	NCT00001421_28_T0	PHENOTYPE	7	7	weakness
NCT0000142128	NCT00001421_28_T1	GENE	15	15	MRI
NCT0000142128	NCT00001421_28_T2	GENE	11	11	CK
NCT0000142129	NCT00001421_29_T0	COMPOUND	18	18	prednisone
NCT0000142129	NCT00001421_29_T1	GENE	2	2	tapered
NCT0000142130	NCT00001421_30_T0	PHENOTYPE	20	20	initiation
NCT0000142133	NCT00001421_33_T0	PHENOTYPE	3	3	hepatitis
NCT0000142133	NCT00001421_33_T1	PHENOTYPE	5	8	abnormal liver function tests
NCT0000142134	NCT00001421_34_T0	PHENOTYPE	4	5	thyroid disease
NCT0000142135	NCT00001421_35_T0	PHENOTYPE	2	2	acute
NCT0000142135	NCT00001421_35_T1	PHENOTYPE	4	5	chronic infections
NCT0000142135	NCT00001421_35_T2	PHENOTYPE	13	14	fungal infections
NCT0000142137	NCT00001421_37_T0	PHENOTYPE	10	10	myelitis
NCT0000142137	NCT00001421_37_T1	PHENOTYPE	3	4	cerebrovascular accidents
NCT0000142137	NCT00001421_37_T2	PHENOTYPE	5	6	seizure disorder
NCT0000142137	NCT00001421_37_T3	PHENOTYPE	7	8	aseptic meningitis
NCT0000142137	NCT00001421_37_T4	PHENOTYPE	12	15	central nervous system disease
NCT0000142138	NCT00001421_38_T0	PHENOTYPE	14	14	dysrhythmia
NCT0000142138	NCT00001421_38_T1	PHENOTYPE	7	7	cardiomyopathy
NCT0000142138	NCT00001421_38_T2	PHENOTYPE	11	12	heart block
NCT0000142138	NCT00001421_38_T3	PHENOTYPE	4	6	coronary artery disease
NCT0000142139	NCT00001421_39_T0	PHENOTYPE	7	7	judgement
NCT0000142140	NCT00001421_40_T0	PHENOTYPE	6	6	leukoplakia
NCT0000142140	NCT00001421_40_T1	GENE	8	8	WBC
NCT0000142140	NCT00001421_40_T2	CELL	15	15	neutrophil
NCT0000142140	NCT00001421_40_T3	PHENOTYPE	1	1	anemia
NCT0000142140	NCT00001421_40_T4	PHENOTYPE	22	23	platelet count
NCT000014223	NCT00001422_3_T0	GENE	18	18	2.3
NCT000014223	NCT00001422_3_T1	COMPOUND	14	14	fludarabine
NCT000014225	NCT00001422_5_T0	ORGAN	5	5	joints
NCT000014226	NCT00001422_6_T0	PHENOTYPE	16	17	drug toxicities
NCT000014229	NCT00001422_9_T0	ORGAN	30	30	nail
NCT000014229	NCT00001422_9_T1	PHENOTYPE	15	16	skin lesion
NCT000014229	NCT00001422_9_T2	PHENOTYPE	21	22	skin lesion
NCT000014229	NCT00001422_9_T3	PHENOTYPE	0	1	Psoriatic arthritis
NCT0000142210	NCT00001422_10_T0	PHENOTYPE	7	7	sacroiliitis
NCT0000142210	NCT00001422_10_T1	PHENOTYPE	0	0	Peripheral
NCT0000142210	NCT00001422_10_T2	PHENOTYPE	1	1	arthritis
NCT0000142212	NCT00001422_12_T0	ORGAN	2	2	serum
NCT0000142212	NCT00001422_12_T1	PHENOTYPE	10	11	subcutaneous nodules
NCT0000142216	NCT00001422_16_T0	PHENOTYPE	6	6	peripheral
NCT0000142216	NCT00001422_16_T1	ORGAN	7	7	joints
NCT0000142216	NCT00001422_16_T2	ORGAN	11	11	spine
NCT0000142216	NCT00001422_16_T3	PHENOTYPE	4	4	stiffness
NCT0000142219	NCT00001422_19_T0	PHENOTYPE	22	22	initiation
NCT0000142219	NCT00001422_19_T1	COMPOUND	24	24	fludarabine
NCT0000142222	NCT00001422_22_T0	PHENOTYPE	3	4	arthritis mutilans
NCT0000142223	NCT00001422_23_T0	COMPOUND	11	11	prednisone
NCT0000142224	NCT00001422_24_T0	PHENOTYPE	4	4	acute
NCT0000142224	NCT00001422_24_T1	PHENOTYPE	15	15	hepatitis
NCT0000142224	NCT00001422_24_T2	PHENOTYPE	16	17	herpes zoster
NCT0000142224	NCT00001422_24_T3	PHENOTYPE	6	7	chronic infections
NCT0000142224	NCT00001422_24_T4	PHENOTYPE	22	23	fungal infections
NCT0000142224	NCT00001422_24_T5	PHENOTYPE	19	20	HIV infections
NCT0000142230	NCT00001422_30_T0	PHENOTYPE	8	8	chronic
NCT0000142230	NCT00001422_30_T1	PHENOTYPE	3	4	cerebrovascular accidents
NCT0000142230	NCT00001422_30_T2	PHENOTYPE	5	6	seizure disorder
NCT0000142231	NCT00001422_31_T0	PHENOTYPE	9	9	dysrhythmia
NCT0000142231	NCT00001422_31_T1	PHENOTYPE	7	7	cardiomyopathy
NCT0000142231	NCT00001422_31_T2	PHENOTYPE	4	6	coronary artery disease
NCT0000142232	NCT00001422_32_T0	CELL	46	46	platelets
NCT0000142232	NCT00001422_32_T1	GENE	51	51	WBC
NCT0000142232	NCT00001422_32_T2	GENE	41	41	Hb
NCT0000142232	NCT00001422_32_T3	PHENOTYPE	23	24	pulmonary disease
NCT0000142232	NCT00001422_32_T4	PHENOTYPE	19	20	chronic hepatic
NCT0000142232	NCT00001422_32_T5	PHENOTYPE	38	40	bone marrow hypoplasia
NCT000014244	NCT00001424_4_T0	COMPOUND	23	23	NCI
NCT000014244	NCT00001424_4_T1	COMPOUND	44	44	NCI
NCT000014244	NCT00001424_4_T2	PHENOTYPE	20	20	experiences
NCT000014244	NCT00001424_4_T3	PHENOTYPE	14	15	clinical findings
NCT000014261	NCT00001426_1_T0	COMPOUND	11	11	paclitaxel
NCT000014261	NCT00001426_1_T1	COMPOUND	18	18	paclitaxel
NCT000014261	NCT00001426_1_T2	ORGAN	26	26	plasma
NCT000014263	NCT00001426_3_T0	COMPOUND	12	12	paclitaxel
NCT000014265	NCT00001426_5_T0	COMPOUND	11	11	paclitaxel
NCT000014265	NCT00001426_5_T1	COMPOUND	18	18	paclitaxel
NCT000014265	NCT00001426_5_T2	ORGAN	26	26	plasma
NCT000014267	NCT00001426_7_T0	COMPOUND	12	12	paclitaxel
NCT000014269	NCT00001426_9_T0	PHENOTYPE	7	7	pathology
NCT000014269	NCT00001426_9_T1	PHENOTYPE	15	15	initiation
NCT0000142612	NCT00001426_12_T0	PHENOTYPE	18	18	initiation
NCT0000142612	NCT00001426_12_T1	GENE	7	7	IV
NCT0000142612	NCT00001426_12_T2	PHENOTYPE	4	5	stage III
NCT0000142617	NCT00001426_17_T0	GENE	21	21	EST
NCT0000142618	NCT00001426_18_T0	GENE	18	18	MRI
NCT0000142619	NCT00001426_19_T0	PHENOTYPE	6	6	dysrhythmia
NCT0000142619	NCT00001426_19_T1	PHENOTYPE	2	3	myocardial infarction
NCT0000142620	NCT00001426_20_T0	GENE	7	7	ANC
NCT0000142620	NCT00001426_20_T1	PHENOTYPE	11	12	platelet count
NCT0000142621	NCT00001426_21_T0	PHENOTYPE	3	4	GI bleeding
NCT0000142622	NCT00001426_22_T0	PHENOTYPE	7	7	malignancy
NCT0000142623	NCT00001426_23_T0	COMPOUND	4	4	bilirubin
NCT0000142625	NCT00001426_25_T0	PHENOTYPE	4	4	malignancy
NCT0000142626	NCT00001426_26_T0	PHENOTYPE	2	3	ureteral obstruction
NCT000014272	NCT00001427_2_T0	COMPOUND	25	25	paclitaxel
NCT000014272	NCT00001427_2_T1	PHENOTYPE	18	19	ovarian cancer
NCT000014272	NCT00001427_2_T2	PHENOTYPE	22	23	recurrent disease
NCT000014275	NCT00001427_5_T0	COMPOUND	3	3	paclitaxel
NCT000014275	NCT00001427_5_T1	COMPOUND	6	6	cisplatin
NCT000014275	NCT00001427_5_T2	PHENOTYPE	0	1	Recurrent disease
NCT000014277	NCT00001427_7_T0	PHENOTYPE	1	2	measurable disease
NCT0000142710	NCT00001427_10_T0	PHENOTYPE	1	2	CNS metastasis
NCT0000142711	NCT00001427_11_T0	PHENOTYPE	1	1	borderline
NCT0000142714	NCT00001427_14_T0	COMPOUND	2	2	camptothecin
NCT0000142716	NCT00001427_16_T0	GENE	2	2	Age
NCT0000142717	NCT00001427_17_T0	GENE	3	3	0.2
NCT0000142718	NCT00001427_18_T0	GENE	1	1	WBC
NCT0000142719	NCT00001427_19_T0	GENE	0	0	AGC
NCT0000142720	NCT00001427_20_T0	CELL	0	0	Platelets
NCT0000142721	NCT00001427_21_T0	GENE	5	5	OR
NCT0000142722	NCT00001427_22_T0	GENE	5	5	1.5
NCT0000142723	NCT00001427_23_T0	ORGAN	0	0	Serum
NCT0000142724	NCT00001427_24_T0	COMPOUND	2	2	creatinine
NCT0000142724	NCT00001427_24_T1	COMPOUND	10	10	NCI
NCT0000142725	NCT00001427_25_T0	PHENOTYPE	2	3	myocardial infarction
NCT0000142726	NCT00001427_26_T0	PHENOTYPE	2	4	congestive heart failure
NCT0000142727	NCT00001427_27_T0	PHENOTYPE	1	2	heart block
NCT0000142728	NCT00001427_28_T0	PHENOTYPE	1	1	arrhythmia
NCT0000142730	NCT00001427_30_T0	PHENOTYPE	2	2	HIV
NCT000014282	NCT00001428_2_T0	GENE	9	9	SC
NCT000014282	NCT00001428_2_T1	GENE	0	0	IFN
NCT000014282	NCT00001428_2_T2	GENE	11	11	1/6
NCT000014282	NCT00001428_2_T3	GENE	33	33	IV
NCT000014284	NCT00001428_4_T0	PHENOTYPE	28	28	toxicity
NCT000014284	NCT00001428_4_T1	CELL	11	11	granulocyte
NCT000014284	NCT00001428_4_T2	GENE	29	29	has
NCT000014284	NCT00001428_4_T3	PHENOTYPE	30	30	resolved
NCT000014284	NCT00001428_4_T4	PHENOTYPE	14	15	platelet count
NCT000014285	NCT00001428_5_T0	PHENOTYPE	10	10	tolerance
NCT000014286	NCT00001428_6_T0	PHENOTYPE	15	15	toxic
NCT000014287	NCT00001428_7_T0	PHENOTYPE	12	12	toxic
NCT000014288	NCT00001428_8_T0	PHENOTYPE	38	38	toxicity
NCT000014288	NCT00001428_8_T1	PHENOTYPE	35	35	pharmacokinetics
NCT000014288	NCT00001428_8_T2	ORGAN	1	1	plasma
NCT000014288	NCT00001428_8_T3	ORGAN	27	27	plasma
NCT0000142811	NCT00001428_11_T0	GENE	31	31	cease
NCT0000142813	NCT00001428_13_T0	COMPOUND	27	27	sensitizer
NCT0000142814	NCT00001428_14_T0	GENE	10	10	cease
NCT0000142817	NCT00001428_17_T0	PHENOTYPE	1	2	measurable disease
NCT0000142818	NCT00001428_18_T0	PHENOTYPE	1	2	cerebral metastases
NCT0000142819	NCT00001428_19_T0	GENE	9	9	interferon
NCT0000142821	NCT00001428_21_T0	PHENOTYPE	7	8	recurrent disease
NCT0000142822	NCT00001428_22_T0	COMPOUND	13	13	levamisole
NCT0000142822	NCT00001428_22_T1	COMPOUND	14	14	leucovorin
NCT0000142823	NCT00001428_23_T0	PHENOTYPE	2	2	toxicity
NCT0000142824	NCT00001428_24_T0	PHENOTYPE	0	0	Endocrine
NCT0000142825	NCT00001428_25_T0	GENE	7	7	abdominal
NCT0000142825	NCT00001428_25_T1	PHENOTYPE	15	16	radiation enteritis
NCT0000142826	NCT00001428_26_T0	GENE	9	9	Age
NCT0000142828	NCT00001428_28_T0	GENE	1	1	AGC
NCT0000142829	NCT00001428_29_T0	CELL	0	0	Platelets
NCT0000142830	NCT00001428_30_T0	GENE	5	5	2.0
NCT0000142830	NCT00001428_30_T1	GENE	12	12	2.0
NCT0000142831	NCT00001428_31_T0	PHENOTYPE	2	4	ischemic heart disease
NCT0000142833	NCT00001428_33_T0	PHENOTYPE	2	2	arrhythmia
NCT0000142834	NCT00001428_34_T0	PHENOTYPE	10	11	autoimmune disorders
NCT0000142836	NCT00001428_36_T0	COMPOUND	2	2	cimetidine
NCT0000142836	NCT00001428_36_T1	COMPOUND	4	4	oxypurinol
NCT0000142837	NCT00001428_37_T0	PHENOTYPE	1	1	HIV
NCT0000142838	NCT00001428_38_T0	PHENOTYPE	3	4	seizure disorder
NCT000014301	NCT00001430_1_T0	COMPOUND	13	13	vincristine
NCT000014301	NCT00001430_1_T1	COMPOUND	17	17	3
NCT000014301	NCT00001430_1_T2	COMPOUND	24	24	3
NCT000014301	NCT00001430_1_T3	COMPOUND	23	23	cyclophosphamide
NCT000014301	NCT00001430_1_T4	COMPOUND	11	11	etoposide
NCT000014301	NCT00001430_1_T5	COMPOUND	10	10	doxorubicin
NCT000014302	NCT00001430_2_T0	GENE	23	23	IL-2
NCT000014302	NCT00001430_2_T1	GENE	6	6	2.1
NCT000014306	NCT00001430_6_T0	COMPOUND	13	13	vincristine
NCT000014306	NCT00001430_6_T1	COMPOUND	17	17	3
NCT000014306	NCT00001430_6_T2	COMPOUND	24	24	3
NCT000014306	NCT00001430_6_T3	COMPOUND	23	23	cyclophosphamide
NCT000014306	NCT00001430_6_T4	COMPOUND	11	11	etoposide
NCT000014306	NCT00001430_6_T5	COMPOUND	10	10	doxorubicin
NCT000014307	NCT00001430_7_T0	GENE	23	23	IL-2
NCT000014307	NCT00001430_7_T1	GENE	6	6	2.1
NCT0000143011	NCT00001430_11_T0	PHENOTYPE	12	13	Hodgkin's disease
NCT0000143011	NCT00001430_11_T1	PHENOTYPE	9	10	Hodgkin's lymphomas
NCT0000143012	NCT00001430_12_T0	PHENOTYPE	12	12	progression
NCT0000143012	NCT00001430_12_T1	PHENOTYPE	6	7	low-grade lymphoma
NCT0000143014	NCT00001430_14_T0	COMPOUND	18	18	NCI
NCT0000143014	NCT00001430_14_T1	PHENOTYPE	9	9	lymphoma
NCT0000143018	NCT00001430_18_T0	PHENOTYPE	3	3	HIV
NCT0000143021	NCT00001430_21_T0	PHENOTYPE	18	19	systemic disease
NCT000014311	NCT00001431_1_T0	GENE	3	3	4.15
NCT000014317	NCT00001431_7_T0	COMPOUND	3	3	NCI
NCT000014319	NCT00001431_9_T0	PHENOTYPE	0	1	Metastatic disease
NCT0000143110	NCT00001431_10_T0	PHENOTYPE	1	2	CNS metastasis
NCT0000143111	NCT00001431_11_T0	PHENOTYPE	1	1	lymphomas
NCT0000143111	NCT00001431_11_T1	PHENOTYPE	3	4	neuroendocrine tumors
NCT0000143112	NCT00001431_12_T0	PHENOTYPE	1	2	peritoneal carcinomatosis
NCT0000143115	NCT00001431_15_T0	COMPOUND	15	15	suramin
NCT0000143115	NCT00001431_15_T1	PHENOTYPE	7	8	recurrent disease
NCT0000143116	NCT00001431_16_T0	PHENOTYPE	0	0	Endocrine
NCT0000143118	NCT00001431_18_T0	GENE	2	2	abdominal
NCT0000143119	NCT00001431_19_T0	PHENOTYPE	7	8	recurrent disease
NCT0000143122	NCT00001431_22_T0	GENE	4	4	bypass
NCT0000143123	NCT00001431_23_T0	GENE	2	2	Age
NCT0000143124	NCT00001431_24_T0	GENE	3	3	0.2
NCT0000143125	NCT00001431_25_T0	GENE	1	1	ANC
NCT0000143126	NCT00001431_26_T0	CELL	0	0	Platelets
NCT0000143128	NCT00001431_28_T0	GENE	4	4	1.5
NCT0000143129	NCT00001431_29_T0	PHENOTYPE	8	9	myocardial infarction
NCT0000143131	NCT00001431_31_T0	PHENOTYPE	1	3	congestive heart failure
NCT0000143132	NCT00001431_32_T0	PHENOTYPE	1	1	HIV
NCT0000143132	NCT00001431_32_T1	PHENOTYPE	2	2	seronegative
NCT000014320	NCT00001432_0_T0	PHENOTYPE	3	3	Peripheral
NCT000014320	NCT00001432_0_T1	CELL	5	5	Lymphocytes
NCT000014320	NCT00001432_0_T2	ORGAN	7	7	Marrow
NCT000014320	NCT00001432_0_T3	PHENOTYPE	18	19	Hematologic Malignancies
NCT000014320	NCT00001432_0_T4	CELL	8	9	Progenitor Cells
NCT000014322	NCT00001432_2_T0	PHENOTYPE	25	25	malignancies
NCT000014327	NCT00001432_7_T0	GENE	22	22	genesis
NCT000014327	NCT00001432_7_T1	CELL	11	11	leukocyte
NCT000014327	NCT00001432_7_T2	CELL	29	29	leukocyte
NCT000014327	NCT00001432_7_T3	CELL	26	27	stem cells
NCT000014327	NCT00001432_7_T4	ORGAN	8	9	bone marrow
NCT000014328	NCT00001432_8_T0	COMPOUND	8	8	glucose
NCT000014328	NCT00001432_8_T1	COMPOUND	24	24	glucose
NCT000014328	NCT00001432_8_T2	COMPOUND	35	35	glucose
NCT000014328	NCT00001432_8_T3	CELL	13	13	cells
NCT0000143210	NCT00001432_10_T0	PHENOTYPE	25	25	malignancies
NCT0000143215	NCT00001432_15_T0	GENE	22	22	genesis
NCT0000143215	NCT00001432_15_T1	CELL	11	11	leukocyte
NCT0000143215	NCT00001432_15_T2	CELL	29	29	leukocyte
NCT0000143215	NCT00001432_15_T3	CELL	26	27	stem cells
NCT0000143215	NCT00001432_15_T4	ORGAN	8	9	bone marrow
NCT0000143216	NCT00001432_16_T0	COMPOUND	8	8	glucose
NCT0000143216	NCT00001432_16_T1	COMPOUND	24	24	glucose
NCT0000143216	NCT00001432_16_T2	COMPOUND	35	35	glucose
NCT0000143216	NCT00001432_16_T3	CELL	13	13	cells
NCT0000143219	NCT00001432_19_T0	PHENOTYPE	20	20	acute
NCT0000143219	NCT00001432_19_T1	PHENOTYPE	13	13	malignancy
NCT0000143219	NCT00001432_19_T2	PHENOTYPE	19	19	lymphoma
NCT0000143219	NCT00001432_19_T3	PHENOTYPE	17	18	multiple myeloma
NCT0000143219	NCT00001432_19_T4	PHENOTYPE	21	22	myelogenous leukemia
NCT0000143219	NCT00001432_19_T5	PHENOTYPE	14	16	chronic myelogenous leukemia
NCT0000143219	NCT00001432_19_T6	PHENOTYPE	23	25	chronic lymphocytic leukemia
NCT0000143219	NCT00001432_19_T7	PHENOTYPE	26	28	acute lymphocytic leukemia
NCT0000143220	NCT00001432_20_T0	PHENOTYPE	3	3	peripheral
NCT0000143220	NCT00001432_20_T1	PHENOTYPE	22	22	peripheral
NCT0000143220	NCT00001432_20_T2	GENE	12	12	hematocrit
NCT0000143220	NCT00001432_20_T3	PHENOTYPE	23	24	platelet count
NCT0000143221	NCT00001432_21_T0	PHENOTYPE	18	18	peripheral
NCT0000143221	NCT00001432_21_T1	PHENOTYPE	4	4	malignancy
NCT0000143221	NCT00001432_21_T2	GENE	8	8	hematocrit
NCT0000143221	NCT00001432_21_T3	PHENOTYPE	19	20	platelet count
NCT0000143224	NCT00001432_24_T0	PHENOTYPE	15	15	malignancies
NCT0000143224	NCT00001432_24_T1	ORGAN	6	7	bone marrow
NCT0000143224	NCT00001432_24_T2	PHENOTYPE	22	23	abnormal bleeding
NCT0000143225	NCT00001432_25_T0	PHENOTYPE	7	7	peripheral
NCT0000143225	NCT00001432_25_T1	PHENOTYPE	25	25	malignancy
NCT0000143225	NCT00001432_25_T2	ORGAN	3	4	bone marrow
NCT0000143225	NCT00001432_25_T3	PHENOTYPE	9	10	platelet count
NCT0000143225	NCT00001432_25_T4	PHENOTYPE	27	28	platelet count
NCT0000143225	NCT00001432_25_T5	CELL	8	9	blood platelet
NCT0000143229	NCT00001432_29_T0	PHENOTYPE	6	6	malignancies
NCT0000143229	NCT00001432_29_T1	ORGAN	14	15	bone marrow
NCT0000143230	NCT00001432_30_T0	GENE	17	17	has
NCT0000143231	NCT00001432_31_T0	ORGAN	7	7	marrow
NCT0000143231	NCT00001432_31_T1	PHENOTYPE	3	3	peripheral
NCT0000143231	NCT00001432_31_T2	GENE	21	21	has
NCT0000143234	NCT00001432_34_T0	PHENOTYPE	12	12	HIV
NCT0000143234	NCT00001432_34_T1	PHENOTYPE	6	6	malignancies
NCT0000143234	NCT00001432_34_T2	PHENOTYPE	14	14	hepatitis
NCT0000143235	NCT00001432_35_T0	GENE	11	11	ex
NCT0000143235	NCT00001432_35_T1	PHENOTYPE	25	25	HIV
NCT0000143235	NCT00001432_35_T2	PHENOTYPE	27	28	hepatitis B
NCT0000143236	NCT00001432_36_T0	PHENOTYPE	10	10	Hepatitis
NCT0000143236	NCT00001432_36_T1	PHENOTYPE	8	8	HIV
NCT0000143239	NCT00001432_39_T0	PHENOTYPE	10	10	malignancy
NCT0000143240	NCT00001432_40_T0	PHENOTYPE	8	8	malignancy
NCT0000143240	NCT00001432_40_T1	PHENOTYPE	14	14	HIV
NCT0000143240	NCT00001432_40_T2	PHENOTYPE	16	17	hepatitis B
NCT0000143241	NCT00001432_41_T0	PHENOTYPE	8	8	malignancy
NCT0000143241	NCT00001432_41_T1	PHENOTYPE	11	11	anticoagulation
NCT0000143241	NCT00001432_41_T2	PHENOTYPE	10	10	chronic
NCT0000143242	NCT00001432_42_T0	PHENOTYPE	8	8	peripheral
NCT0000143242	NCT00001432_42_T1	PHENOTYPE	5	5	malignancy
NCT0000143242	NCT00001432_42_T2	CELL	17	17	lymphocyte
NCT0000143243	NCT00001432_43_T0	PHENOTYPE	4	4	malignancy
NCT0000143243	NCT00001432_43_T1	COMPOUND	15	15	NCI
NCT0000143244	NCT00001432_44_T0	PHENOTYPE	8	8	malignancy
NCT0000143244	NCT00001432_44_T1	PHENOTYPE	13	14	hepatitis B
NCT000014351	NCT00001435_1_T0	PHENOTYPE	13	13	HIV/AIDS
NCT000014352	NCT00001435_2_T0	PHENOTYPE	16	16	HIV/AIDS
NCT000014352	NCT00001435_2_T1	PHENOTYPE	10	10	strategies
NCT000014353	NCT00001435_3_T0	PHENOTYPE	19	19	perceptions
NCT000014356	NCT00001435_6_T0	PHENOTYPE	13	13	HIV/AIDS
NCT000014357	NCT00001435_7_T0	PHENOTYPE	17	17	HIV/AIDS
NCT000014357	NCT00001435_7_T1	PHENOTYPE	11	11	strategies
NCT000014358	NCT00001435_8_T0	PHENOTYPE	16	16	perceptions
NCT0000143510	NCT00001435_10_T0	PHENOTYPE	10	10	strategies
NCT0000143510	NCT00001435_10_T1	PHENOTYPE	15	15	hopeful
NCT0000143510	NCT00001435_10_T2	PHENOTYPE	24	25	psychological adjustment
NCT0000143510	NCT00001435_10_T3	PHENOTYPE	4	5	chronic illnesses
NCT0000143510	NCT00001435_10_T4	PHENOTYPE	36	37	chronic illness
NCT0000143512	NCT00001435_12_T0	PHENOTYPE	6	7	HIV disease
NCT0000143514	NCT00001435_14_T0	PHENOTYPE	8	8	strategies
NCT0000143515	NCT00001435_15_T0	PHENOTYPE	10	10	HIV
NCT0000143515	NCT00001435_15_T1	PHENOTYPE	25	26	overanxious disorder
NCT0000143515	NCT00001435_15_T2	PHENOTYPE	21	22	separation anxiety
NCT0000143515	NCT00001435_15_T3	PHENOTYPE	7	8	psychiatric disturbances
NCT0000143516	NCT00001435_16_T0	PHENOTYPE	8	8	HIV
NCT0000143518	NCT00001435_18_T0	PHENOTYPE	1	1	HIV
NCT0000143518	NCT00001435_18_T1	PHENOTYPE	3	3	perceived
NCT0000143518	NCT00001435_18_T2	PHENOTYPE	6	6	self-esteem
NCT0000143518	NCT00001435_18_T3	PHENOTYPE	7	8	psychological adjustment
NCT0000143519	NCT00001435_19_T0	GENE	21	21	has
NCT0000143522	NCT00001435_22_T0	PHENOTYPE	5	6	disease progression
NCT0000143525	NCT00001435_25_T0	PHENOTYPE	23	23	perceptions
NCT0000143526	NCT00001435_26_T0	PHENOTYPE	14	15	cognitive deficits
NCT0000143527	NCT00001435_27_T0	PHENOTYPE	19	20	cognitive functioning
NCT000014360	NCT00001436_0_T0	PHENOTYPE	15	15	Osteosarcoma
NCT000014360	NCT00001436_0_T1	GENE	8	8	NSC
NCT000014363	NCT00001436_3_T0	GENE	12	12	IGF-I
NCT000014363	NCT00001436_3_T1	GENE	5	5	has
NCT000014363	NCT00001436_3_T2	COMPOUND	3	3	tamoxifen
NCT0000143613	NCT00001436_13_T0	COMPOUND	7	7	estrogen
NCT0000143613	NCT00001436_13_T1	GENE	10	10	reduced
NCT0000143613	NCT00001436_13_T2	GENE	12	12	IGF
NCT0000143613	NCT00001436_13_T3	COMPOUND	8	8	tamoxifen
NCT0000143614	NCT00001436_14_T0	GENE	7	7	somatostatin
NCT0000143614	NCT00001436_14_T1	COMPOUND	17	17	tamoxifen
NCT0000143614	NCT00001436_14_T2	PHENOTYPE	21	21	osteosarcoma
NCT0000143617	NCT00001436_17_T0	PHENOTYPE	46	46	recurrence
NCT0000143617	NCT00001436_17_T1	PHENOTYPE	11	11	tumor
NCT0000143617	NCT00001436_17_T2	GENE	23	23	has
NCT0000143617	NCT00001436_17_T3	GENE	27	27	has
NCT0000143617	NCT00001436_17_T4	PHENOTYPE	6	6	osteosarcoma
NCT0000143617	NCT00001436_17_T5	PHENOTYPE	19	20	metastatic osteosarcoma
NCT0000143617	NCT00001436_17_T6	PHENOTYPE	40	41	recurrent osteosarcoma
NCT0000143618	NCT00001436_18_T0	PHENOTYPE	0	1	Measurable disease
NCT0000143620	NCT00001436_20_T0	PHENOTYPE	3	4	thyroid function
NCT0000143622	NCT00001436_22_T0	COMPOUND	4	4	bilirubin
NCT0000143622	NCT00001436_22_T1	COMPOUND	9	9	bilirubin
NCT0000143623	NCT00001436_23_T0	PHENOTYPE	7	8	platelet count
NCT0000143623	NCT00001436_23_T1	ORGAN	2	3	bone marrow
NCT0000143625	NCT00001436_25_T0	COMPOUND	3	3	glucose
NCT0000143625	NCT00001436_25_T1	GENE	4	4	150
NCT0000143627	NCT00001436_27_T0	PHENOTYPE	16	16	acute
NCT0000143628	NCT00001436_28_T0	PHENOTYPE	4	4	HIV
NCT0000143629	NCT00001436_29_T0	ORGAN	8	8	serum
NCT0000143633	NCT00001436_33_T0	PHENOTYPE	4	4	hypothyroidism
NCT0000143635	NCT00001436_35_T0	PHENOTYPE	3	4	HIV infection
NCT0000143636	NCT00001436_36_T0	GENE	20	20	III
NCT0000143636	NCT00001436_36_T1	GENE	21	21	has
NCT0000143636	NCT00001436_36_T2	PHENOTYPE	6	7	thromboembolic events
NCT0000143636	NCT00001436_36_T3	PHENOTYPE	12	13	thromboembolic events
NCT000014376	NCT00001437_6_T0	COMPOUND	25	25	pentoxifylline
NCT000014376	NCT00001437_6_T1	GENE	30	30	TID
NCT000014376	NCT00001437_6_T2	GENE	29	29	po
NCT000014378	NCT00001437_8_T0	GENE	18	18	FGF
NCT000014378	NCT00001437_8_T1	GENE	16	16	TGF-beta
NCT000014378	NCT00001437_8_T2	GENE	15	15	TNF
NCT000014379	NCT00001437_9_T0	GENE	18	18	MRI
NCT000014379	NCT00001437_9_T1	GENE	4	4	collagen
NCT000014379	NCT00001437_9_T2	TISSUE	21	22	subcutaneous tissue
NCT0000143714	NCT00001437_14_T0	PHENOTYPE	9	10	degenerative disease
NCT0000143715	NCT00001437_15_T0	PHENOTYPE	1	1	recurrent
NCT0000143715	NCT00001437_15_T1	PHENOTYPE	3	4	metastatic cancer
NCT0000143716	NCT00001437_16_T0	PHENOTYPE	2	3	second cancer
NCT0000143717	NCT00001437_17_T0	COMPOUND	7	7	pentoxifylline
NCT0000143718	NCT00001437_18_T0	GENE	2	2	Age
NCT0000143719	NCT00001437_19_T0	PHENOTYPE	7	7	fibrosis
NCT0000143720	NCT00001437_20_T0	GENE	21	21	bypass
NCT0000143720	NCT00001437_20_T1	ORGAN	19	20	Coronary artery
NCT0000143720	NCT00001437_20_T2	PHENOTYPE	3	5	coronary artery disease
NCT0000143721	NCT00001437_21_T0	PHENOTYPE	1	3	chronic cardiac failure
NCT0000143723	NCT00001437_23_T0	COMPOUND	9	9	caffeine
NCT0000143723	NCT00001437_23_T1	COMPOUND	10	10	theophylline
NCT0000143723	NCT00001437_23_T2	COMPOUND	11	11	theobromine
NCT0000143723	NCT00001437_23_T3	COMPOUND	4	4	pentoxifylline
NCT0000143724	NCT00001437_24_T0	PHENOTYPE	1	2	seizure disorder
NCT0000143725	NCT00001437_25_T0	PHENOTYPE	1	3	peptic ulcer disease
NCT0000143726	NCT00001437_26_T0	COMPOUND	11	11	NCI
NCT0000143726	NCT00001437_26_T1	GENE	9	9	MRI
NCT000014382	NCT00001438_2_T0	CELL	8	8	B-cell
NCT000014382	NCT00001438_2_T1	CELL	10	10	T-cell
NCT000014382	NCT00001438_2_T2	PHENOTYPE	4	5	lymphoproliferative disorders
NCT000014385	NCT00001438_5_T0	ORGAN	19	19	transplant
NCT000014385	NCT00001438_5_T1	PHENOTYPE	17	17	immunosuppression
NCT000014385	NCT00001438_5_T2	COMPOUND	12	12	acyclovir
NCT000014388	NCT00001438_8_T0	PHENOTYPE	19	19	disorders
NCT0000143811	NCT00001438_11_T0	CELL	8	8	B-cell
NCT0000143811	NCT00001438_11_T1	CELL	10	10	T-cell
NCT0000143811	NCT00001438_11_T2	PHENOTYPE	4	5	lymphoproliferative disorders
NCT0000143814	NCT00001438_14_T0	PHENOTYPE	1	1	imbalance
NCT0000143814	NCT00001438_14_T1	PHENOTYPE	21	21	proliferation
NCT0000143816	NCT00001438_16_T0	ORGAN	19	19	transplant
NCT0000143816	NCT00001438_16_T1	PHENOTYPE	17	17	immunosuppression
NCT0000143816	NCT00001438_16_T2	COMPOUND	12	12	acyclovir
NCT0000143820	NCT00001438_20_T0	PHENOTYPE	19	19	disorders
NCT0000143823	NCT00001438_23_T0	PHENOTYPE	5	6	interstitial pneumonitis
NCT0000143824	NCT00001438_24_T0	GENE	2	2	LPD
NCT0000143824	NCT00001438_24_T1	CELL	1	1	B-cell
NCT0000143825	NCT00001438_25_T0	PHENOTYPE	3	4	malignant lymphoma
NCT0000143826	NCT00001438_26_T0	PHENOTYPE	5	5	acute
NCT0000143826	NCT00001438_26_T1	PHENOTYPE	2	3	opportunistic infection
NCT0000143828	NCT00001438_28_T0	PHENOTYPE	6	6	hypogammaglobulinemia
NCT0000143829	NCT00001438_29_T0	ORGAN	1	1	transplant
NCT0000143832	NCT00001438_32_T0	PHENOTYPE	0	0	Endocrine
NCT0000143832	NCT00001438_32_T1	PHENOTYPE	12	13	autoimmune process
NCT0000143832	NCT00001438_32_T2	PHENOTYPE	7	9	lymphocytic interstitial pneumonitis
NCT0000143836	NCT00001438_36_T0	PHENOTYPE	8	8	HIV
NCT0000143836	NCT00001438_36_T1	PHENOTYPE	5	6	HIV infection
NCT0000143839	NCT00001438_39_T0	PHENOTYPE	2	4	Pneumocystis carinii pneumonia
NCT0000143841	NCT00001438_41_T0	GENE	2	2	Age
NCT0000143844	NCT00001438_44_T0	GENE	23	23	interferon-alpha
NCT0000143844	NCT00001438_44_T1	COMPOUND	20	21	retinoic acid
NCT0000143844	NCT00001438_44_T2	PHENOTYPE	5	6	acute infection
NCT0000143845	NCT00001438_45_T0	GENE	3	3	swallow
NCT0000143846	NCT00001438_46_T0	COMPOUND	21	21	Lithium
NCT0000143846	NCT00001438_46_T1	PHENOTYPE	7	8	pseudotumor cerebri
NCT000014392	NCT00001439_2_T0	PHENOTYPE	7	7	toxicity
NCT000014392	NCT00001439_2_T1	GENE	18	18	gp100
NCT000014396	NCT00001439_6_T0	PHENOTYPE	7	7	toxicity
NCT000014396	NCT00001439_6_T1	GENE	18	18	gp100
NCT000014399	NCT00001439_9_T0	PHENOTYPE	2	2	melanoma
NCT0000143910	NCT00001439_10_T0	PHENOTYPE	3	4	metastatic disease
NCT0000143913	NCT00001439_13_T0	PHENOTYPE	0	0	ENDOCRINE
NCT0000143913	NCT00001439_13_T1	GENE	10	10	hormone
NCT0000143917	NCT00001439_17_T0	GENE	2	2	Age
NCT0000143921	NCT00001439_21_T0	GENE	5	5	2.0
NCT0000143922	NCT00001439_22_T0	PHENOTYPE	1	1	Hepatitis
NCT0000143923	NCT00001439_23_T0	GENE	5	5	2.0
NCT0000143926	NCT00001439_26_T0	PHENOTYPE	3	4	allergic reaction
NCT0000143927	NCT00001439_27_T0	PHENOTYPE	0	0	HIV
NCT0000143928	NCT00001439_28_T0	PHENOTYPE	2	3	systemic infection
NCT000014400	NCT00001440_0_T0	CELL	1	1	T-Cell
NCT000014400	NCT00001440_0_T1	CELL	16	16	T-Cell
NCT000014400	NCT00001440_0_T2	PHENOTYPE	7	8	Residual Disease
NCT000014400	NCT00001440_0_T3	PHENOTYPE	10	11	Breast Cancer
NCT000014402	NCT00001440_2_T0	CELL	8	8	cells
NCT000014402	NCT00001440_2_T1	PHENOTYPE	2	2	strategies
NCT000014402	NCT00001440_2_T2	PHENOTYPE	6	7	residual tumor
NCT000014403	NCT00001440_3_T0	CELL	27	27	cells
NCT000014403	NCT00001440_3_T1	PHENOTYPE	4	4	tumor
NCT000014403	NCT00001440_3_T2	CELL	12	12	T-cells
NCT000014403	NCT00001440_3_T3	PHENOTYPE	23	23	elimination
NCT000014403	NCT00001440_3_T4	PHENOTYPE	25	26	residual tumor
NCT000014404	NCT00001440_4_T0	PHENOTYPE	21	21	acute
NCT000014404	NCT00001440_4_T1	CELL	7	7	T-cell
NCT000014404	NCT00001440_4_T2	CELL	17	17	T-cell
NCT000014404	NCT00001440_4_T3	CELL	22	22	T-cell
NCT000014404	NCT00001440_4_T4	PHENOTYPE	8	9	mediated responses
NCT000014404	NCT00001440_4_T5	PHENOTYPE	30	31	residual tumor
NCT000014405	NCT00001440_5_T0	CELL	8	8	T-cell
NCT000014406	NCT00001440_6_T0	PHENOTYPE	23	23	immunity
NCT000014406	NCT00001440_6_T1	GENE	3	3	has
NCT000014406	NCT00001440_6_T2	CELL	22	22	T-cell
NCT000014408	NCT00001440_8_T0	CELL	10	10	T-cell
NCT000014408	NCT00001440_8_T1	CELL	12	12	T-cell
NCT000014408	NCT00001440_8_T2	CELL	15	15	T-cell
NCT000014408	NCT00001440_8_T3	CELL	21	21	T-cell
NCT000014409	NCT00001440_9_T0	PHENOTYPE	9	9	generalized
NCT000014409	NCT00001440_9_T1	PHENOTYPE	17	17	tumor
NCT000014409	NCT00001440_9_T2	PHENOTYPE	11	11	immunity
NCT000014409	NCT00001440_9_T3	CELL	10	10	T-cell
NCT000014409	NCT00001440_9_T4	CELL	18	18	T-cell
NCT0000144018	NCT00001440_18_T0	PHENOTYPE	7	7	relapse
NCT0000144020	NCT00001440_20_T0	COMPOUND	26	26	NCI
NCT0000144020	NCT00001440_20_T1	PHENOTYPE	27	28	breast cancer
NCT0000144026	NCT00001440_26_T0	GENE	2	2	II
NCT0000144026	NCT00001440_26_T1	GENE	4	4	III
NCT0000144030	NCT00001440_30_T0	PHENOTYPE	7	8	bleeding tendency
NCT0000144030	NCT00001440_30_T1	PHENOTYPE	6	7	abnormal bleeding
NCT0000144032	NCT00001440_32_T0	PHENOTYPE	20	20	impairment
NCT0000144032	NCT00001440_32_T1	PHENOTYPE	19	19	tumor
NCT0000144034	NCT00001440_34_T0	PHENOTYPE	20	20	impairment
NCT0000144034	NCT00001440_34_T1	PHENOTYPE	19	19	tumor
NCT0000144035	NCT00001440_35_T0	PHENOTYPE	8	8	symptoms
NCT0000144035	NCT00001440_35_T1	PHENOTYPE	20	20	FVC
NCT0000144035	NCT00001440_35_T2	PHENOTYPE	30	30	tumor
NCT0000144035	NCT00001440_35_T3	PHENOTYPE	5	6	pulmonary disease
NCT0000144036	NCT00001440_36_T0	COMPOUND	11	11	MUGA
NCT0000144037	NCT00001440_37_T0	PHENOTYPE	22	22	chronic
NCT0000144037	NCT00001440_37_T1	PHENOTYPE	24	25	pulmonary disease
NCT0000144037	NCT00001440_37_T2	PHENOTYPE	14	15	artery disease
NCT0000144037	NCT00001440_37_T3	PHENOTYPE	16	18	congestive heart failure
NCT0000144041	NCT00001440_41_T0	CELL	10	10	cells
NCT0000144041	NCT00001440_41_T1	GENE	13	13	IL-2
NCT0000144043	NCT00001440_43_T0	GENE	12	12	II
NCT0000144043	NCT00001440_43_T1	GENE	14	14	III
NCT0000144045	NCT00001440_45_T0	PHENOTYPE	19	20	measurable disease
NCT0000144049	NCT00001440_49_T0	PHENOTYPE	4	5	HIV positive
NCT0000144049	NCT00001440_49_T1	PHENOTYPE	8	9	Hepatitis B
NCT0000144050	NCT00001440_50_T0	PHENOTYPE	5	5	chronic
NCT0000144051	NCT00001440_51_T0	CELL	9	10	T cells
NCT000014420	NCT00001442_0_T0	PHENOTYPE	11	14	Head and Neck Cancer
NCT000014422	NCT00001442_2_T0	PHENOTYPE	24	24	adenopathy
NCT000014422	NCT00001442_2_T1	PHENOTYPE	2	2	tumor
NCT000014422	NCT00001442_2_T2	GENE	29	29	TAX
NCT000014422	NCT00001442_2_T3	PHENOTYPE	14	15	primary tumor
NCT000014427	NCT00001442_7_T0	GENE	8	8	IV
NCT000014428	NCT00001442_8_T0	PHENOTYPE	14	14	toxicity
NCT000014428	NCT00001442_8_T1	PHENOTYPE	0	0	Tolerance
NCT0000144214	NCT00001442_14_T0	PHENOTYPE	5	5	metastasis
NCT0000144216	NCT00001442_16_T0	PHENOTYPE	24	24	cancers
NCT0000144216	NCT00001442_16_T1	GENE	3	3	had
NCT0000144218	NCT00001442_18_T0	CELL	5	5	granulocyte
NCT0000144218	NCT00001442_18_T1	PHENOTYPE	16	17	platelet count
NCT0000144219	NCT00001442_19_T0	GENE	20	20	2.0
NCT0000144219	NCT00001442_19_T1	GENE	30	30	4.0
NCT0000144219	NCT00001442_19_T2	GENE	49	49	1.5
NCT0000144219	NCT00001442_19_T3	COMPOUND	42	42	creatinine
NCT0000144219	NCT00001442_19_T4	COMPOUND	13	13	bilirubin
NCT0000144219	NCT00001442_19_T5	ORGAN	12	12	serum
NCT0000144219	NCT00001442_19_T6	ORGAN	41	41	serum
NCT0000144220	NCT00001442_20_T0	PHENOTYPE	6	7	psychiatric illness
NCT0000144223	NCT00001442_23_T0	PHENOTYPE	40	40	discomforts
NCT000014430	NCT00001443_0_T0	GENE	3	3	II
NCT000014430	NCT00001443_0_T1	GENE	7	7	Protease
NCT000014430	NCT00001443_0_T2	PHENOTYPE	14	15	HIV Infection
NCT000014432	NCT00001443_2_T0	COMPOUND	1	1	sulfate
NCT000014432	NCT00001443_2_T1	GENE	5	5	has
NCT000014433	NCT00001443_3_T0	PHENOTYPE	22	22	toxicity
NCT000014433	NCT00001443_3_T1	PHENOTYPE	0	0	HIV
NCT000014437	NCT00001443_7_T0	COMPOUND	9	9	indinavir
NCT000014438	NCT00001443_8_T0	PHENOTYPE	12	12	initiation
NCT0000144310	NCT00001443_10_T0	COMPOUND	20	20	indinavir
NCT0000144310	NCT00001443_10_T1	PHENOTYPE	11	11	pharmacokinetics
NCT0000144310	NCT00001443_10_T2	PHENOTYPE	10	10	toxicities
NCT0000144312	NCT00001443_12_T0	COMPOUND	11	11	zidovudine
NCT0000144312	NCT00001443_12_T1	COMPOUND	42	42	indinavir
NCT0000144312	NCT00001443_12_T2	GENE	40	40	protease
NCT0000144312	NCT00001443_12_T3	COMPOUND	13	13	lamivudine
NCT0000144312	NCT00001443_12_T4	GENE	33	34	reverse transcriptase
NCT0000144313	NCT00001443_13_T0	COMPOUND	2	2	lamivudine
NCT0000144314	NCT00001443_14_T0	PHENOTYPE	0	0	Toxicity
NCT0000144314	NCT00001443_14_T1	COMPOUND	6	6	indinavir
NCT0000144314	NCT00001443_14_T2	PHENOTYPE	1	1	pharmacokinetics
NCT0000144315	NCT00001443_15_T0	COMPOUND	32	32	indinavir
NCT0000144315	NCT00001443_15_T1	GENE	27	27	extended
NCT0000144316	NCT00001443_16_T0	COMPOUND	17	17	zidovudine
NCT0000144316	NCT00001443_16_T1	COMPOUND	8	8	indinavir
NCT0000144316	NCT00001443_16_T2	COMPOUND	19	19	lamivudine
NCT0000144317	NCT00001443_17_T0	ORGAN	16	16	plasma
NCT0000144318	NCT00001443_18_T0	PHENOTYPE	24	25	drug levels
NCT0000144320	NCT00001443_20_T0	COMPOUND	1	1	sulfate
NCT0000144320	NCT00001443_20_T1	GENE	5	5	has
NCT0000144321	NCT00001443_21_T0	PHENOTYPE	22	22	toxicity
NCT0000144321	NCT00001443_21_T1	PHENOTYPE	0	0	HIV
NCT0000144325	NCT00001443_25_T0	COMPOUND	9	9	indinavir
NCT0000144326	NCT00001443_26_T0	PHENOTYPE	12	12	initiation
NCT0000144328	NCT00001443_28_T0	COMPOUND	20	20	indinavir
NCT0000144328	NCT00001443_28_T1	PHENOTYPE	11	11	pharmacokinetics
NCT0000144328	NCT00001443_28_T2	PHENOTYPE	10	10	toxicities
NCT0000144330	NCT00001443_30_T0	COMPOUND	11	11	zidovudine
NCT0000144330	NCT00001443_30_T1	COMPOUND	42	42	indinavir
NCT0000144330	NCT00001443_30_T2	GENE	40	40	protease
NCT0000144330	NCT00001443_30_T3	COMPOUND	13	13	lamivudine
NCT0000144330	NCT00001443_30_T4	GENE	33	34	reverse transcriptase
NCT0000144331	NCT00001443_31_T0	COMPOUND	2	2	lamivudine
NCT0000144332	NCT00001443_32_T0	PHENOTYPE	0	0	Toxicity
NCT0000144332	NCT00001443_32_T1	COMPOUND	6	6	indinavir
NCT0000144332	NCT00001443_32_T2	PHENOTYPE	1	1	pharmacokinetics
NCT0000144333	NCT00001443_33_T0	COMPOUND	32	32	indinavir
NCT0000144333	NCT00001443_33_T1	GENE	27	27	extended
NCT0000144334	NCT00001443_34_T0	COMPOUND	17	17	zidovudine
NCT0000144334	NCT00001443_34_T1	COMPOUND	8	8	indinavir
NCT0000144334	NCT00001443_34_T2	COMPOUND	19	19	lamivudine
NCT0000144335	NCT00001443_35_T0	ORGAN	16	16	plasma
NCT0000144336	NCT00001443_36_T0	PHENOTYPE	24	25	drug levels
NCT0000144338	NCT00001443_38_T0	GENE	2	2	OR
NCT0000144338	NCT00001443_38_T1	GENE	13	13	CD4
NCT0000144338	NCT00001443_38_T2	PHENOTYPE	7	7	HIV
NCT0000144338	NCT00001443_38_T3	PHENOTYPE	24	25	opportunistic infection
NCT0000144338	NCT00001443_38_T4	PHENOTYPE	33	34	HIV infection
NCT0000144339	NCT00001443_39_T0	PHENOTYPE	6	6	acute
NCT0000144339	NCT00001443_39_T1	PHENOTYPE	3	4	opportunistic infection
NCT0000144342	NCT00001443_42_T0	PHENOTYPE	43	43	toxicity
NCT0000144342	NCT00001443_42_T1	COMPOUND	23	23	zidovudine
NCT0000144342	NCT00001443_42_T2	GENE	6	6	OR
NCT0000144342	NCT00001443_42_T3	COMPOUND	26	26	stavudine
NCT0000144342	NCT00001443_42_T4	COMPOUND	24	24	didanosine
NCT0000144342	NCT00001443_42_T5	PHENOTYPE	11	11	HIV
NCT0000144342	NCT00001443_42_T6	PHENOTYPE	49	49	progressive
NCT0000144342	NCT00001443_42_T7	COMPOUND	27	27	zalcitabine
NCT0000144342	NCT00001443_42_T8	COMPOUND	25	25	lamivudine
NCT0000144342	NCT00001443_42_T9	GENE	30	31	protease inhibitor
NCT0000144345	NCT00001443_45_T0	PHENOTYPE	5	6	acute infection
NCT0000144346	NCT00001443_46_T0	COMPOUND	7	7	THE
NCT0000144346	NCT00001443_46_T1	GENE	1	1	NOT
NCT0000144346	NCT00001443_46_T2	GENE	17	17	NOT
NCT0000144346	NCT00001443_46_T3	GENE	4	4	OR
NCT0000144346	NCT00001443_46_T4	COMPOUND	18	18	YET
NCT0000144346	NCT00001443_46_T5	GENE	21	21	WBC
NCT0000144347	NCT00001443_47_T0	CELL	0	0	Neutrophil
NCT0000144348	NCT00001443_48_T0	GENE	3	3	8.0
NCT0000144349	NCT00001443_49_T0	PHENOTYPE	0	1	Platelet count
NCT0000144352	NCT00001443_52_T0	GENE	3	3	1.5
NCT0000144356	NCT00001443_56_T0	GENE	27	27	G-CSF
NCT0000144356	NCT00001443_56_T1	PHENOTYPE	21	22	autoimmune process
NCT0000144356	NCT00001443_56_T2	PHENOTYPE	16	18	lymphocytic interstitial pneumonitis
NCT0000144357	NCT00001443_57_T0	PHENOTYPE	8	8	acute
NCT0000144357	NCT00001443_57_T1	PHENOTYPE	5	6	opportunistic infection
NCT000014445	NCT00001444_5_T0	PHENOTYPE	5	5	toxicity
NCT000014447	NCT00001444_7_T0	PHENOTYPE	3	3	leukemia
NCT000014447	NCT00001444_7_T1	PHENOTYPE	4	5	brain metastasis
NCT000014447	NCT00001444_7_T2	PHENOTYPE	7	9	primary brain tumors
NCT0000144411	NCT00001444_11_T0	COMPOUND	13	13	creatinine
NCT0000144411	NCT00001444_11_T1	GENE	6	6	1.5
NCT0000144411	NCT00001444_11_T2	GENE	0	1	Total bilirubin
NCT0000144412	NCT00001444_12_T0	GENE	5	5	9.0
NCT0000144413	NCT00001444_13_T0	CELL	9	9	granulocyte
NCT0000144413	NCT00001444_13_T1	PHENOTYPE	0	1	Platelet count
NCT0000144415	NCT00001444_15_T0	GENE	7	7	0.2
NCT0000144418	NCT00001444_18_T0	PHENOTYPE	20	20	toxicities
NCT0000144419	NCT00001444_19_T0	COMPOUND	7	8	mitomycin C
NCT0000144421	NCT00001444_21_T0	COMPOUND	2	2	flutamide
NCT0000144421	NCT00001444_21_T1	COMPOUND	6	6	androgen
NCT0000144421	NCT00001444_21_T2	PHENOTYPE	23	23	progression
NCT0000144422	NCT00001444_22_T0	GENE	14	14	had
NCT0000144422	NCT00001444_22_T1	GENE	12	12	has
NCT0000144424	NCT00001444_24_T0	COMPOUND	2	2	suramin
NCT0000144424	NCT00001444_24_T1	COMPOUND	8	8	suramin
NCT0000144424	NCT00001444_24_T2	COMPOUND	26	26	suramin
NCT0000144425	NCT00001444_25_T0	PHENOTYPE	28	28	progression
NCT0000144425	NCT00001444_25_T1	PHENOTYPE	2	3	breast carcinoma
NCT0000144427	NCT00001444_27_T0	PHENOTYPE	2	2	secondary
NCT0000144427	NCT00001444_27_T1	PHENOTYPE	8	8	pouch
NCT0000144428	NCT00001444_28_T0	PHENOTYPE	3	3	HIV
NCT0000144428	NCT00001444_28_T1	PHENOTYPE	0	1	Positive serology
NCT0000144429	NCT00001444_29_T0	PHENOTYPE	4	5	peripheral neuropathy
NCT0000144430	NCT00001444_30_T0	ORGAN	12	13	bone marrow
NCT0000144434	NCT00001444_34_T0	PHENOTYPE	9	9	seizure
NCT0000144434	NCT00001444_34_T1	PHENOTYPE	6	6	seizures
NCT0000144435	NCT00001444_35_T0	PHENOTYPE	3	3	coagulopathy
NCT0000144435	NCT00001444_35_T1	PHENOTYPE	6	7	renal disease
NCT0000144438	NCT00001444_38_T0	PHENOTYPE	11	13	negative pregnancy test
NCT000014455	NCT00001445_5_T0	BIOLOGICAL_PROCESS	9	10	immune response
NCT000014457	NCT00001445_7_T0	PHENOTYPE	11	11	initiation
NCT000014458	NCT00001445_8_T0	PHENOTYPE	16	16	labeling
NCT000014459	NCT00001445_9_T0	GENE	3	3	has
NCT000014459	NCT00001445_9_T1	GENE	13	13	has
NCT0000144515	NCT00001445_15_T0	BIOLOGICAL_PROCESS	9	10	immune response
NCT0000144517	NCT00001445_17_T0	PHENOTYPE	11	11	initiation
NCT0000144518	NCT00001445_18_T0	PHENOTYPE	16	16	labeling
NCT0000144519	NCT00001445_19_T0	GENE	3	3	has
NCT0000144519	NCT00001445_19_T1	GENE	13	13	has
NCT0000144521	NCT00001445_21_T0	PHENOTYPE	8	8	Centers
NCT0000144524	NCT00001445_24_T0	GENE	0	0	ARM
NCT0000144525	NCT00001445_25_T0	PHENOTYPE	3	4	immune suppression
NCT0000144527	NCT00001445_27_T0	GENE	50	50	0.5
NCT0000144527	NCT00001445_27_T1	GENE	10	10	had
NCT0000144527	NCT00001445_27_T2	ORGAN	11	11	plasma
NCT0000144529	NCT00001445_29_T0	GENE	0	0	ARM
NCT0000144530	NCT00001445_30_T0	PHENOTYPE	3	4	immune suppression
NCT0000144531	NCT00001445_31_T0	GENE	53	53	0.5
NCT0000144531	NCT00001445_31_T1	ORGAN	18	18	plasma
NCT0000144535	NCT00001445_35_T0	PHENOTYPE	1	2	critically ill
NCT0000144536	NCT00001445_36_T0	PHENOTYPE	4	5	immune suppression
NCT0000144537	NCT00001445_37_T0	ORGAN	9	9	plasma
NCT0000144538	NCT00001445_38_T0	PHENOTYPE	7	7	hyperalimentation
NCT0000144540	NCT00001445_40_T0	COMPOUND	32	32	creatinine
NCT0000144540	NCT00001445_40_T1	GENE	44	44	ANC
NCT0000144540	NCT00001445_40_T2	GENE	39	39	WBC
NCT0000144540	NCT00001445_40_T3	GENE	51	51	8.0
NCT0000144540	NCT00001445_40_T4	PHENOTYPE	56	57	Platelet count
NCT0000144540	NCT00001445_40_T5	GENE	23	24	Total bilirubin
NCT0000144542	NCT00001445_42_T0	PHENOTYPE	2	3	substance abuse
NCT000014467	NCT00001446_7_T0	PHENOTYPE	6	6	toxicity
NCT000014467	NCT00001446_7_T1	COMPOUND	10	10	thalidomide
NCT000014467	NCT00001446_7_T2	PHENOTYPE	1	1	complications
NCT000014467	NCT00001446_7_T3	PHENOTYPE	9	9	chronic
NCT0000144613	NCT00001446_13_T0	PHENOTYPE	1	2	bone metastasis
NCT0000144614	NCT00001446_14_T0	PHENOTYPE	0	0	Progression
NCT0000144614	NCT00001446_14_T1	PHENOTYPE	6	6	metastases
NCT0000144617	NCT00001446_17_T0	COMPOUND	1	1	androgen
NCT0000144619	NCT00001446_19_T0	GENE	4	4	LHRH
NCT0000144619	NCT00001446_19_T1	GENE	1	3	luteinizing hormone-releasing hormone
NCT0000144622	NCT00001446_22_T0	PHENOTYPE	1	2	brain metastases
NCT0000144625	NCT00001446_25_T0	PHENOTYPE	13	13	toxic
NCT0000144626	NCT00001446_26_T0	COMPOUND	3	3	suramin
NCT0000144627	NCT00001446_27_T0	PHENOTYPE	10	10	toxic
NCT0000144628	NCT00001446_28_T0	PHENOTYPE	0	0	Endocrine
NCT0000144629	NCT00001446_29_T0	GENE	8	8	LHRH
NCT0000144631	NCT00001446_31_T0	COMPOUND	9	9	strontium
NCT0000144633	NCT00001446_33_T0	GENE	2	2	Age
NCT0000144634	NCT00001446_34_T0	GENE	3	3	0.2
NCT0000144636	NCT00001446_36_T0	CELL	2	2	granulocyte
NCT0000144637	NCT00001446_37_T0	PHENOTYPE	0	1	Platelet count
NCT0000144638	NCT00001446_38_T0	PHENOTYPE	16	16	bleeding
NCT0000144638	NCT00001446_38_T1	GENE	15	15	OR
NCT0000144638	NCT00001446_38_T2	GENE	3	3	8.0
NCT0000144639	NCT00001446_39_T0	GENE	5	5	1.5
NCT0000144641	NCT00001446_41_T0	GENE	7	7	OR
NCT0000144641	NCT00001446_41_T1	GENE	5	5	1.5
NCT0000144642	NCT00001446_42_T0	COMPOUND	4	4	2
NCT0000144642	NCT00001446_42_T1	GENE	5	5	OR
NCT0000144642	NCT00001446_42_T2	GENE	10	10	hr
NCT0000144642	NCT00001446_42_T3	PHENOTYPE	0	0	Proteinuria
NCT0000144647	NCT00001446_47_T0	PHENOTYPE	1	2	myocardial infarction
NCT0000144648	NCT00001446_48_T0	PHENOTYPE	4	6	congestive heart failure
NCT0000144649	NCT00001446_49_T0	COMPOUND	7	7	oxygen
NCT0000144649	NCT00001446_49_T1	PHENOTYPE	2	5	chronic obstructive lung disease
NCT0000144650	NCT00001446_50_T0	PHENOTYPE	8	9	grade 1
NCT0000144650	NCT00001446_50_T1	PHENOTYPE	4	5	peripheral neuropathy
NCT0000144651	NCT00001446_51_T0	PHENOTYPE	1	1	seizures
NCT0000144654	NCT00001446_54_T0	PHENOTYPE	2	3	thyroid function
NCT0000144659	NCT00001446_59_T0	PHENOTYPE	0	0	HIV
NCT0000144661	NCT00001446_61_T0	PHENOTYPE	2	2	malignancies
NCT000014480	NCT00001448_0_T0	PHENOTYPE	3	4	Oral Candidiasis
NCT000014480	NCT00001448_0_T1	PHENOTYPE	19	20	HIV Infection
NCT000014482	NCT00001448_2_T0	PHENOTYPE	2	3	HIV disease
NCT000014482	NCT00001448_2_T1	PHENOTYPE	9	10	oral thrush
NCT000014484	NCT00001448_4_T0	PHENOTYPE	8	8	severity
NCT000014484	NCT00001448_4_T1	PHENOTYPE	10	10	thrush
NCT000014485	NCT00001448_5_T0	PHENOTYPE	10	11	oral thrush
NCT000014486	NCT00001448_6_T0	PHENOTYPE	26	26	self-concept
NCT000014486	NCT00001448_6_T1	PHENOTYPE	21	21	affects
NCT000014486	NCT00001448_6_T2	PHENOTYPE	20	20	thrush
NCT000014487	NCT00001448_7_T0	PHENOTYPE	21	22	HIV infection
NCT000014488	NCT00001448_8_T0	PHENOTYPE	12	12	HIV
NCT000014488	NCT00001448_8_T1	PHENOTYPE	9	10	feeding problems
NCT000014488	NCT00001448_8_T2	PHENOTYPE	17	18	oral thrush
NCT0000144811	NCT00001448_11_T0	PHENOTYPE	10	10	HIV
NCT0000144811	NCT00001448_11_T1	GENE	17	17	al
NCT0000144811	NCT00001448_11_T2	GENE	16	16	et
NCT0000144812	NCT00001448_12_T0	PHENOTYPE	17	17	HIV
NCT0000144813	NCT00001448_13_T0	PHENOTYPE	29	29	severity
NCT0000144813	NCT00001448_13_T1	PHENOTYPE	2	2	thrush
NCT0000144813	NCT00001448_13_T2	PHENOTYPE	32	32	thrush
NCT0000144813	NCT00001448_13_T3	PHENOTYPE	14	14	HIV
NCT0000144813	NCT00001448_13_T4	PHENOTYPE	0	1	Oral candidiasis
NCT0000144813	NCT00001448_13_T5	PHENOTYPE	4	5	fungal infection
NCT0000144813	NCT00001448_13_T6	ORGAN	8	9	oral cavity
NCT0000144814	NCT00001448_14_T0	PHENOTYPE	3	3	self-concept
NCT0000144814	NCT00001448_14_T1	PHENOTYPE	9	10	oral thrush
NCT0000144815	NCT00001448_15_T0	PHENOTYPE	12	12	self-concept
NCT0000144815	NCT00001448_15_T1	PHENOTYPE	3	4	oral candidiasis
NCT0000144815	NCT00001448_15_T2	PHENOTYPE	18	19	HIV infection
NCT0000144816	NCT00001448_16_T0	PHENOTYPE	14	14	severity
NCT0000144816	NCT00001448_16_T1	PHENOTYPE	16	17	oral candidiasis
NCT0000144816	NCT00001448_16_T2	PHENOTYPE	6	7	Infectious Disease
NCT0000144817	NCT00001448_17_T0	PHENOTYPE	26	26	HIV
NCT0000144817	NCT00001448_17_T1	PHENOTYPE	6	7	oral thrush
NCT0000144818	NCT00001448_18_T0	PHENOTYPE	23	23	severity
NCT0000144818	NCT00001448_18_T1	PHENOTYPE	25	26	oral thrush
NCT0000144819	NCT00001448_19_T0	PHENOTYPE	15	15	dysfunction
NCT0000144819	NCT00001448_19_T1	PHENOTYPE	9	10	oral thrush
NCT0000144820	NCT00001448_20_T0	PHENOTYPE	11	11	self-concept
NCT0000144820	NCT00001448_20_T1	PHENOTYPE	6	7	oral candidiasis
NCT0000144820	NCT00001448_20_T2	PHENOTYPE	17	18	HIV infection
NCT0000144822	NCT00001448_22_T0	PHENOTYPE	6	6	diseases
NCT0000144822	NCT00001448_22_T1	PHENOTYPE	4	4	infections
NCT0000144822	NCT00001448_22_T2	PHENOTYPE	9	9	candidiasis
NCT0000144822	NCT00001448_22_T3	ORGAN	12	13	oral cavity
NCT0000144823	NCT00001448_23_T0	GENE	12	12	structural
NCT000014493	NCT00001449_3_T0	PHENOTYPE	1	2	measurable disease
NCT000014494	NCT00001449_4_T0	PHENOTYPE	3	3	leukemia
NCT000014494	NCT00001449_4_T1	PHENOTYPE	9	9	malignancies
NCT000014495	NCT00001449_5_T0	PHENOTYPE	15	15	toxic
NCT000014496	NCT00001449_6_T0	PHENOTYPE	12	12	toxic
NCT000014496	NCT00001449_6_T1	COMPOUND	26	26	nitrosourea
NCT000014496	NCT00001449_6_T2	COMPOUND	23	24	mitomycin C
NCT000014497	NCT00001449_7_T0	COMPOUND	6	6	suramin
NCT000014498	NCT00001449_8_T0	ORGAN	19	19	marrow
NCT000014498	NCT00001449_8_T1	PHENOTYPE	25	25	toxic
NCT000014498	NCT00001449_8_T2	PHENOTYPE	0	0	Endocrine
NCT0000144910	NCT00001449_10_T0	GENE	2	2	Age
NCT0000144911	NCT00001449_11_T0	GENE	3	3	0.2
NCT0000144911	NCT00001449_11_T1	GENE	5	5	AGC
NCT0000144912	NCT00001449_12_T0	PHENOTYPE	0	1	Platelet count
NCT0000144913	NCT00001449_13_T0	GENE	5	5	2.0
NCT0000144914	NCT00001449_14_T0	GENE	5	5	2.0
NCT0000144915	NCT00001449_15_T0	COMPOUND	5	5	gemcitabine
NCT0000144916	NCT00001449_16_T0	COMPOUND	3	3	ranitidine
NCT0000144916	NCT00001449_16_T1	COMPOUND	2	2	cimetidine
NCT0000144916	NCT00001449_16_T2	PHENOTYPE	6	6	ulcer
NCT0000144918	NCT00001449_18_T0	PHENOTYPE	0	0	HIV
NCT000014501	NCT00001450_1_T0	GENE	5	5	II
NCT000014501	NCT00001450_1_T1	COMPOUND	16	16	paclitaxel
NCT000014501	NCT00001450_1_T2	PHENOTYPE	25	25	NSCLC
NCT000014501	NCT00001450_1_T3	COMPOUND	19	19	cisplatin
NCT000014503	NCT00001450_3_T0	GENE	5	5	II
NCT000014503	NCT00001450_3_T1	COMPOUND	16	16	paclitaxel
NCT000014503	NCT00001450_3_T2	PHENOTYPE	25	25	NSCLC
NCT000014503	NCT00001450_3_T3	COMPOUND	19	19	cisplatin
NCT000014504	NCT00001450_4_T0	COMPOUND	6	6	paclitaxel
NCT000014504	NCT00001450_4_T1	COMPOUND	14	14	paclitaxel
NCT000014504	NCT00001450_4_T2	CELL	19	19	cells
NCT000014504	NCT00001450_4_T3	PHENOTYPE	18	18	tumor
NCT000014504	NCT00001450_4_T4	ORGAN	3	3	plasma
NCT000014505	NCT00001450_5_T0	COMPOUND	17	17	paclitaxel
NCT000014505	NCT00001450_5_T1	PHENOTYPE	15	15	concentrations
NCT000014505	NCT00001450_5_T2	ORGAN	14	14	plasma
NCT000014507	NCT00001450_7_T0	PHENOTYPE	13	13	recurrence
NCT000014507	NCT00001450_7_T1	GENE	4	4	IV
NCT000014508	NCT00001450_8_T0	PHENOTYPE	0	1	CNS Metastases
NCT0000145010	NCT00001450_10_T0	PHENOTYPE	1	2	carcinomatous meningitis
NCT0000145011	NCT00001450_11_T0	PHENOTYPE	2	2	metastases
NCT0000145012	NCT00001450_12_T0	PHENOTYPE	0	1	Measurable disease
NCT0000145014	NCT00001450_14_T0	PHENOTYPE	5	6	lung cancer
NCT0000145015	NCT00001450_15_T0	PHENOTYPE	0	0	Endocrine
NCT0000145016	NCT00001450_16_T0	PHENOTYPE	6	7	lung cancer
NCT0000145018	NCT00001450_18_T0	GENE	2	2	Age
NCT0000145019	NCT00001450_19_T0	GENE	3	3	0.2
NCT0000145020	NCT00001450_20_T0	CELL	2	2	granulocyte
NCT0000145021	NCT00001450_21_T0	PHENOTYPE	0	1	Platelet count
NCT0000145022	NCT00001450_22_T0	GENE	5	5	1.5
NCT0000145023	NCT00001450_23_T0	GENE	5	5	1.5
NCT0000145024	NCT00001450_24_T0	PHENOTYPE	2	2	CHF
NCT0000145025	NCT00001450_25_T0	PHENOTYPE	3	5	third-degree heart block
NCT0000145026	NCT00001450_26_T0	PHENOTYPE	4	4	dysrhythmia
NCT0000145026	NCT00001450_26_T1	PHENOTYPE	6	7	sinus bradycardia
NCT0000145027	NCT00001450_27_T0	PHENOTYPE	1	3	sustained ventricular tachycardia
NCT0000145029	NCT00001450_29_T0	ORGAN	9	9	bronchus
NCT0000145030	NCT00001450_30_T0	PHENOTYPE	2	3	psychiatric problems
NCT0000145033	NCT00001450_33_T0	PHENOTYPE	1	2	second malignancy
NCT0000145033	NCT00001450_33_T1	PHENOTYPE	8	9	skin cancer
NCT0000145034	NCT00001450_34_T0	PHENOTYPE	2	3	cervical cancer
NCT000014512	NCT00001451_2_T0	ORGAN	35	35	marrow
NCT000014512	NCT00001451_2_T1	ORGAN	26	26	transplant
NCT000014512	NCT00001451_2_T2	ORGAN	24	25	bone marrow
NCT000014519	NCT00001451_9_T0	ORGAN	20	20	transplant
NCT0000145114	NCT00001451_14_T0	PHENOTYPE	4	4	hepatitis
NCT0000145116	NCT00001451_16_T0	PHENOTYPE	10	10	HIV
NCT0000145116	NCT00001451_16_T1	PHENOTYPE	12	12	hepatitis
NCT0000145117	NCT00001451_17_T0	PHENOTYPE	4	4	HIV
NCT0000145117	NCT00001451_17_T1	PHENOTYPE	9	9	anesthesia
NCT000014521	NCT00001452_1_T0	GENE	12	12	hormone
NCT000014521	NCT00001452_1_T1	PHENOTYPE	7	8	multiple tumors
NCT000014523	NCT00001452_3_T0	PHENOTYPE	7	7	diseases
NCT000014524	NCT00001452_4_T0	PHENOTYPE	13	13	hypercortisolism
NCT000014525	NCT00001452_5_T0	COMPOUND	6	6	dexamethasone
NCT000014525	NCT00001452_5_T1	PHENOTYPE	2	2	suppression
NCT000014528	NCT00001452_8_T0	PHENOTYPE	5	5	associations
NCT000014528	NCT00001452_8_T1	PHENOTYPE	13	14	Carney Complex
NCT000014529	NCT00001452_9_T0	PHENOTYPE	11	12	Carney Complex
NCT0000145211	NCT00001452_11_T0	PHENOTYPE	14	14	diseases
NCT0000145212	NCT00001452_12_T0	PHENOTYPE	8	9	Carney Complex
NCT0000145224	NCT00001452_24_T0	PHENOTYPE	4	4	tumors
NCT0000145225	NCT00001452_25_T0	PHENOTYPE	15	16	Carney complex
NCT0000145227	NCT00001452_27_T0	PHENOTYPE	5	6	Carney Complex
NCT0000145238	NCT00001452_38_T0	PHENOTYPE	3	3	illnesses
NCT0000145238	NCT00001452_38_T1	PHENOTYPE	16	16	anemia
NCT0000145238	NCT00001452_38_T2	PHENOTYPE	14	15	cardiac disease
NCT0000145238	NCT00001452_38_T3	PHENOTYPE	18	19	terminal cancer
NCT0000145238	NCT00001452_38_T4	PHENOTYPE	7	8	renal failure
NCT0000145238	NCT00001452_38_T5	PHENOTYPE	11	13	obstructive lung disease
NCT0000145239	NCT00001452_39_T0	PHENOTYPE	30	30	tumor
NCT0000145239	NCT00001452_39_T1	PHENOTYPE	11	11	myxoma
NCT0000145239	NCT00001452_39_T2	ORGAN	10	10	heart
NCT0000145239	NCT00001452_39_T3	PHENOTYPE	8	9	heart tumor
NCT0000145239	NCT00001452_39_T4	PHENOTYPE	3	4	Carney complex
NCT000014531	NCT00001453_1_T0	PHENOTYPE	2	2	tumors
NCT000014531	NCT00001453_1_T1	GENE	14	14	MRI
NCT000014532	NCT00001453_2_T0	ORGAN	6	6	veins
NCT000014532	NCT00001453_2_T1	PHENOTYPE	3	3	sinuses
NCT000014532	NCT00001453_2_T2	ORGAN	13	14	pituitary gland
NCT000014534	NCT00001453_4_T0	GENE	10	10	ACTH
NCT000014534	NCT00001453_4_T1	PHENOTYPE	14	14	sinuses
NCT000014534	NCT00001453_4_T2	GENE	9	9	hormone
NCT000014534	NCT00001453_4_T3	PHENOTYPE	2	3	Cushing disease
NCT0000145310	NCT00001453_10_T0	GENE	0	0	ACTH
NCT0000145310	NCT00001453_10_T1	GENE	16	16	CRH
NCT0000145310	NCT00001453_10_T2	ORGAN	20	20	hypothalamus
NCT0000145310	NCT00001453_10_T3	ORGAN	5	6	pituitary gland
NCT0000145312	NCT00001453_12_T0	ORGAN	4	5	jugular veins
NCT0000145313	NCT00001453_13_T0	PHENOTYPE	10	10	tumors
NCT0000145313	NCT00001453_13_T1	GENE	7	7	ACTH
NCT0000145313	NCT00001453_13_T2	GENE	3	3	CRH
NCT0000145313	NCT00001453_13_T3	PHENOTYPE	15	16	corticotroph adenomas
NCT0000145313	NCT00001453_13_T4	ORGAN	13	14	pituitary gland
NCT0000145316	NCT00001453_16_T0	PHENOTYPE	13	13	adenoma
NCT0000145316	NCT00001453_16_T1	PHENOTYPE	0	0	Bilateral
NCT0000145317	NCT00001453_17_T0	ORGAN	22	22	hands
NCT0000145317	NCT00001453_17_T1	PHENOTYPE	15	15	complications
NCT0000145317	NCT00001453_17_T2	GENE	8	8	has
NCT0000145319	NCT00001453_19_T0	ORGAN	4	5	jugular veins
NCT0000145320	NCT00001453_20_T0	GENE	9	9	ACTH
NCT0000145320	NCT00001453_20_T1	GENE	5	5	CRH
NCT0000145320	NCT00001453_20_T2	PHENOTYPE	34	34	sinuses
NCT0000145320	NCT00001453_20_T3	GENE	4	4	hormone
NCT0000145320	NCT00001453_20_T4	PHENOTYPE	12	13	corticotroph adenomas
NCT0000145324	NCT00001453_24_T0	GENE	27	27	CRH
NCT0000145324	NCT00001453_24_T1	PHENOTYPE	6	7	Cushing disease
NCT0000145330	NCT00001453_30_T0	PHENOTYPE	14	15	pituitary tumor
NCT0000145332	NCT00001453_32_T0	PHENOTYPE	22	24	contrast media reaction
NCT0000145334	NCT00001453_34_T0	GENE	15	15	hematocrit
NCT0000145334	NCT00001453_34_T1	GENE	12	12	ml
NCT0000145335	NCT00001453_35_T0	COMPOUND	20	20	creatinine
NCT0000145335	NCT00001453_35_T1	GENE	23	23	1.3
NCT0000145335	NCT00001453_35_T2	PHENOTYPE	16	16	dysfunction
NCT0000145336	NCT00001453_36_T0	GENE	11	11	Hg
NCT0000145337	NCT00001453_37_T0	GENE	2	2	had
NCT0000145337	NCT00001453_37_T1	PHENOTYPE	3	4	radiation exposure
NCT0000145338	NCT00001453_38_T0	PHENOTYPE	9	11	exposure to radiation
NCT000014540	NCT00001454_0_T0	ORGAN	4	4	Uterus
NCT000014540	NCT00001454_0_T1	ORGAN	6	6	Endometrium
NCT000014545	NCT00001454_5_T0	ORGAN	28	28	endometrium
NCT000014545	NCT00001454_5_T1	PHENOTYPE	11	13	female sex hormones
NCT000014546	NCT00001454_6_T0	COMPOUND	16	16	1
NCT000014546	NCT00001454_6_T1	COMPOUND	32	32	progesterone
NCT000014546	NCT00001454_6_T2	GENE	21	21	CYCLE
NCT000014546	NCT00001454_6_T3	BIOLOGICAL_PROCESS	39	40	luteal phase
NCT000014546	NCT00001454_6_T4	BIOLOGICAL_PROCESS	43	44	menstrual cycle
NCT000014547	NCT00001454_7_T0	COMPOUND	0	0	2
NCT000014547	NCT00001454_7_T1	GENE	1	1	TAB
NCT000014547	NCT00001454_7_T2	GENE	6	6	CYCLE
NCT000014547	NCT00001454_7_T3	GENE	13	13	hormone
NCT0000145412	NCT00001454_12_T0	COMPOUND	4	4	estrogen
NCT0000145412	NCT00001454_12_T1	COMPOUND	6	6	progesterone
NCT0000145412	NCT00001454_12_T2	ORGAN	12	12	endometrium
NCT0000145413	NCT00001454_13_T0	PHENOTYPE	18	18	endometriosis
NCT0000145413	NCT00001454_13_T1	ORGAN	8	8	endometrium
NCT0000145413	NCT00001454_13_T2	PHENOTYPE	22	22	infertility
NCT0000145414	NCT00001454_14_T0	COMPOUND	27	27	estrogen
NCT0000145414	NCT00001454_14_T1	COMPOUND	29	29	progesterone
NCT0000145414	NCT00001454_14_T2	ORGAN	16	16	endometrium
NCT0000145414	NCT00001454_14_T3	ORGAN	41	41	endometrium
NCT0000145416	NCT00001454_16_T0	COMPOUND	17	17	progesterone
NCT0000145416	NCT00001454_16_T1	BIOLOGICAL_PROCESS	15	16	luteal phase
NCT0000145416	NCT00001454_16_T2	CELL	9	10	basal body
NCT0000145421	NCT00001454_21_T0	PHENOTYPE	12	12	endometriosis
NCT0000145422	NCT00001454_22_T0	PHENOTYPE	3	3	infertility
NCT0000145422	NCT00001454_22_T1	PHENOTYPE	8	8	dysfunction
NCT0000145422	NCT00001454_22_T2	BIOLOGICAL_PROCESS	14	15	luteal phase
NCT0000145424	NCT00001454_24_T0	ORGAN	12	12	diaphragm
NCT0000145425	NCT00001454_25_T0	COMPOUND	17	17	progesterone
NCT0000145425	NCT00001454_25_T1	BIOLOGICAL_PROCESS	15	16	luteal phase
NCT0000145425	NCT00001454_25_T2	PHENOTYPE	4	6	negative pregnancy test
NCT0000145426	NCT00001454_26_T0	PHENOTYPE	2	2	endometriosis
NCT0000145426	NCT00001454_26_T1	PHENOTYPE	10	10	endometriosis
NCT000014554	NCT00001455_4_T0	PHENOTYPE	10	10	affects
NCT000014555	NCT00001455_5_T0	PHENOTYPE	14	15	iron overload
NCT000014556	NCT00001455_6_T0	PHENOTYPE	14	15	iron overload
NCT000014557	NCT00001455_7_T0	GENE	23	23	polymerase
NCT000014557	NCT00001455_7_T1	ORGAN	13	13	serum
NCT000014557	NCT00001455_7_T2	GENE	26	26	PCR
NCT000014557	NCT00001455_7_T3	PHENOTYPE	14	15	ferritin levels
NCT000014558	NCT00001455_8_T0	PHENOTYPE	29	30	iron overload
NCT000014558	NCT00001455_8_T1	PHENOTYPE	6	7	iron levels
NCT0000145510	NCT00001455_10_T0	PHENOTYPE	10	11	iron overload
NCT0000145512	NCT00001455_12_T0	GENE	18	18	ferritin
NCT0000145512	NCT00001455_12_T1	GENE	14	14	transferrin
NCT0000145512	NCT00001455_12_T2	ORGAN	17	17	serum
NCT0000145514	NCT00001455_14_T0	BIOLOGICAL_PROCESS	6	6	metabolism
NCT000014568	NCT00001456_8_T0	CELL	3	3	cells
NCT000014568	NCT00001456_8_T1	ORGAN	6	6	plasma
NCT0000145610	NCT00001456_10_T0	PHENOTYPE	21	21	cardiomyopathy
NCT0000145610	NCT00001456_10_T1	PHENOTYPE	13	13	chronic
NCT0000145610	NCT00001456_10_T2	PHENOTYPE	14	15	granulomatous colitis
NCT0000145610	NCT00001456_10_T3	PHENOTYPE	3	4	pulmonary fibrosis
NCT0000145613	NCT00001456_13_T0	PHENOTYPE	4	4	severity
NCT0000145613	NCT00001456_13_T1	PHENOTYPE	11	11	severity
NCT0000145622	NCT00001456_22_T0	PHENOTYPE	32	32	Center
NCT000014570	NCT00001457_0_T0	PHENOTYPE	2	4	Chronic Hepatitis B
NCT000014572	NCT00001457_2_T0	PHENOTYPE	1	1	affects
NCT000014573	NCT00001457_3_T0	PHENOTYPE	6	7	hepatitis B
NCT000014573	NCT00001457_3_T1	PHENOTYPE	10	11	liver cirrhosis
NCT000014573	NCT00001457_3_T2	PHENOTYPE	5	6	chronic hepatitis
NCT000014573	NCT00001457_3_T3	PHENOTYPE	18	19	liver cancer
NCT000014575	NCT00001457_5_T0	GENE	0	0	Alpha
NCT000014575	NCT00001457_5_T1	GENE	1	1	interferon
NCT000014575	NCT00001457_5_T2	ORGAN	9	10	immune system
NCT000014576	NCT00001457_6_T0	COMPOUND	4	4	3_thiacytidine
NCT000014579	NCT00001457_9_T0	COMPOUND	2	2	lamivudine
NCT0000145710	NCT00001457_10_T0	COMPOUND	3	3	lamivudine
NCT0000145711	NCT00001457_11_T0	COMPOUND	12	12	lamivudine
NCT0000145712	NCT00001457_12_T0	PHENOTYPE	8	9	hepatitis B
NCT0000145713	NCT00001457_13_T0	ORGAN	6	6	liver
NCT0000145713	NCT00001457_13_T1	COMPOUND	12	12	lamivudine
NCT0000145715	NCT00001457_15_T0	ORGAN	22	22	liver
NCT0000145717	NCT00001457_17_T0	ORGAN	2	2	liver
NCT0000145720	NCT00001457_20_T0	PHENOTYPE	22	23	chronic hepatitis
NCT0000145720	NCT00001457_20_T1	PHENOTYPE	23	24	hepatitis B
NCT0000145720	NCT00001457_20_T2	PHENOTYPE	12	13	HIV infection
NCT0000145721	NCT00001457_21_T0	COMPOUND	6	6	lamivudine
NCT0000145721	NCT00001457_21_T1	PHENOTYPE	15	16	hepatitis B
NCT0000145721	NCT00001457_21_T2	PHENOTYPE	34	35	hepatitis B
NCT0000145721	NCT00001457_21_T3	PHENOTYPE	14	15	chronic hepatitis
NCT0000145721	NCT00001457_21_T4	PHENOTYPE	33	34	chronic hepatitis
NCT0000145721	NCT00001457_21_T5	PHENOTYPE	26	28	chronic delta hepatitis
NCT0000145722	NCT00001457_22_T0	ORGAN	3	3	liver
NCT0000145722	NCT00001457_22_T1	PHENOTYPE	23	23	symptoms
NCT0000145722	NCT00001457_22_T2	ORGAN	31	31	serum
NCT0000145722	NCT00001457_22_T3	COMPOUND	8	8	lamivudine
NCT0000145722	NCT00001457_22_T4	COMPOUND	30	30	lamivudine
NCT0000145722	NCT00001457_22_T5	PHENOTYPE	25	26	liver disease
NCT0000145722	NCT00001457_22_T6	PHENOTYPE	40	41	hepatitis B
NCT0000145723	NCT00001457_23_T0	ORGAN	11	11	liver
NCT0000145726	NCT00001457_26_T0	ORGAN	32	32	liver
NCT0000145726	NCT00001457_26_T1	PHENOTYPE	12	12	HBV
NCT0000145726	NCT00001457_26_T2	COMPOUND	3	3	lamivudine
NCT0000145728	NCT00001457_28_T0	ORGAN	5	5	serum
NCT0000145732	NCT00001457_32_T0	GENE	33	33	1.3
NCT0000145732	NCT00001457_32_T1	GENE	9	9	atypical
NCT0000145732	NCT00001457_32_T2	ORGAN	15	15	serum
NCT0000145732	NCT00001457_32_T3	ORGAN	19	19	serum
NCT0000145732	NCT00001457_32_T4	PHENOTYPE	6	7	hepatitis B
NCT0000145732	NCT00001457_32_T5	PHENOTYPE	5	6	chronic hepatitis
NCT0000145734	NCT00001457_34_T0	ORGAN	19	19	liver
NCT0000145734	NCT00001457_34_T1	PHENOTYPE	3	3	polyarteritis
NCT0000145734	NCT00001457_34_T2	PHENOTYPE	7	7	arteritis
NCT0000145735	NCT00001457_35_T0	ORGAN	15	15	liver
NCT0000145735	NCT00001457_35_T1	ORGAN	10	10	serum
NCT0000145735	NCT00001457_35_T2	ORGAN	21	21	serum
NCT0000145735	NCT00001457_35_T3	ORGAN	25	25	serum
NCT0000145735	NCT00001457_35_T4	PHENOTYPE	5	7	chronic delta hepatitis
NCT0000145741	NCT00001457_41_T0	ORGAN	29	29	pancreas
NCT0000145741	NCT00001457_41_T1	ORGAN	39	39	abdomen
NCT0000145741	NCT00001457_41_T2	PHENOTYPE	5	5	pancreatitis
NCT0000145741	NCT00001457_41_T3	PHENOTYPE	10	10	pancreatitis
NCT0000145741	NCT00001457_41_T4	ORGAN	14	14	serum
NCT0000145741	NCT00001457_41_T5	GENE	15	15	amylase
NCT0000145742	NCT00001457_42_T0	PHENOTYPE	2	2	cirrhosis
NCT0000145743	NCT00001457_43_T0	PHENOTYPE	2	2	HIV
NCT0000145743	NCT00001457_43_T1	COMPOUND	4	4	HCV
NCT0000145743	NCT00001457_43_T2	COMPOUND	6	6	HCV
NCT0000145743	NCT00001457_43_T3	ORGAN	9	9	serum
NCT0000145745	NCT00001457_45_T0	PHENOTYPE	4	5	chronic hepatitis
NCT0000145745	NCT00001457_45_T1	PHENOTYPE	5	6	hepatitis B
NCT0000145746	NCT00001457_46_T0	PHENOTYPE	2	3	motor neuropathy
NCT000014581	NCT00001458_1_T0	PHENOTYPE	6	6	focused
NCT000014581	NCT00001458_1_T1	PHENOTYPE	9	9	diseases
NCT000014581	NCT00001458_1_T2	PHENOTYPE	16	16	diseases
NCT000014581	NCT00001458_1_T3	PHENOTYPE	12	14	signs and symptoms
NCT000014585	NCT00001458_5_T0	PHENOTYPE	11	11	diseases
NCT000014585	NCT00001458_5_T1	GENE	2	2	has
NCT000014586	NCT00001458_6_T0	PHENOTYPE	52	52	ideas
NCT0000145810	NCT00001458_10_T0	PHENOTYPE	0	2	Valvular heart disease
NCT0000145811	NCT00001458_11_T0	PHENOTYPE	5	5	hypertrophic
NCT0000145811	NCT00001458_11_T1	PHENOTYPE	0	0	Cardiomyopathies
NCT0000145813	NCT00001458_13_T0	PHENOTYPE	0	0	Renovascular
NCT0000145813	NCT00001458_13_T1	PHENOTYPE	4	4	hypertension
NCT0000145813	NCT00001458_13_T2	PHENOTYPE	6	7	pulmonary edema
NCT0000145813	NCT00001458_13_T3	PHENOTYPE	11	12	ischemic nephropathy
NCT0000145814	NCT00001458_14_T0	ORGAN	10	10	Heart
NCT0000145814	NCT00001458_14_T1	ORGAN	23	23	Heart
NCT0000145814	NCT00001458_14_T2	COMPOUND	40	40	dobutamine
NCT0000145814	NCT00001458_14_T3	COMPOUND	41	41	gadolinium
NCT0000145814	NCT00001458_14_T4	PHENOTYPE	46	47	radiation exposure
NCT0000145814	NCT00001458_14_T5	PHENOTYPE	0	2	Congenital heart disease
NCT000014596	NCT00001459_6_T0	ORGAN	11	11	heart
NCT000014596	NCT00001459_6_T1	PHENOTYPE	18	18	ischemia
NCT000014599	NCT00001459_9_T0	BIOLOGICAL_PROCESS	3	5	response to exercise
NCT0000145911	NCT00001459_11_T0	PHENOTYPE	18	18	separation
NCT0000145912	NCT00001459_12_T0	GENE	2	2	has
NCT0000145912	NCT00001459_12_T1	ORGAN	12	12	heart
NCT0000145914	NCT00001459_14_T0	PHENOTYPE	16	17	myocardial infarction
NCT0000145915	NCT00001459_15_T0	PHENOTYPE	16	17	myocardial ischemia
NCT0000145917	NCT00001459_17_T0	PHENOTYPE	2	3	hypertrophic cardiomyopathy
NCT0000145920	NCT00001459_20_T0	PHENOTYPE	3	4	renal failure
NCT0000145921	NCT00001459_21_T0	PHENOTYPE	0	1	Infective endocarditis
NCT0000145921	NCT00001459_21_T1	PHENOTYPE	4	5	valvular disease
NCT0000145922	NCT00001459_22_T0	PHENOTYPE	1	3	congenital heart disease
NCT000014603	NCT00001460_3_T0	PHENOTYPE	10	11	heart disease
NCT000014607	NCT00001460_7_T0	ORGAN	6	6	Heart
NCT000014607	NCT00001460_7_T1	PHENOTYPE	9	10	class IV
NCT000014607	NCT00001460_7_T2	PHENOTYPE	11	12	heart failure
NCT000014611	NCT00001461_1_T0	TISSUE	7	7	endothelium
NCT000014611	NCT00001461_1_T1	CELL	1	1	cells
NCT000014611	NCT00001461_1_T2	ORGAN	10	11	blood vessel
NCT000014612	NCT00001461_2_T0	TISSUE	7	7	endothelium
NCT000014612	NCT00001461_2_T1	COMPOUND	10	11	nitric oxide
NCT000014615	NCT00001461_5_T0	TISSUE	8	8	endothelium
NCT000014615	NCT00001461_5_T1	CELL	5	5	cells
NCT000014615	NCT00001461_5_T2	GENE	11	11	bradykinin
NCT000014616	NCT00001461_6_T0	COMPOUND	7	8	nitric oxide
NCT000014617	NCT00001461_7_T0	GENE	1	1	bradykinin
NCT000014617	NCT00001461_7_T1	ORGAN	11	12	blood vessels
NCT000014618	NCT00001461_8_T0	GENE	9	9	ACE
NCT000014618	NCT00001461_8_T1	COMPOUND	18	19	nitric oxide
NCT000014618	NCT00001461_8_T2	GENE	7	8	angiotensin-converting enzyme
NCT000014619	NCT00001461_9_T0	GENE	3	3	ACE
NCT0000146110	NCT00001461_10_T0	GENE	3	3	ACE
NCT0000146110	NCT00001461_10_T1	MOLECULAR_FUNCTION	14	15	ACE activity
NCT0000146112	NCT00001461_12_T0	COMPOUND	9	10	nitric oxide
NCT0000146113	NCT00001461_13_T0	GENE	8	8	bradykinin
NCT0000146113	NCT00001461_13_T1	ORGAN	3	4	blood vessel
NCT0000146114	NCT00001461_14_T0	ORGAN	4	5	blood vessel
NCT0000146117	NCT00001461_17_T0	PHENOTYPE	22	22	atherosclerosis
NCT0000146117	NCT00001461_17_T1	PHENOTYPE	30	30	atherosclerosis
NCT0000146117	NCT00001461_17_T2	PHENOTYPE	17	17	peripheral
NCT0000146117	NCT00001461_17_T3	GENE	12	12	reduced
NCT0000146117	NCT00001461_17_T4	COMPOUND	8	9	nitric oxide
NCT0000146118	NCT00001461_18_T0	TISSUE	2	2	endothelium
NCT0000146118	NCT00001461_18_T1	TISSUE	21	21	endothelium
NCT0000146120	NCT00001461_20_T0	GENE	4	4	ACE
NCT0000146120	NCT00001461_20_T1	ORGAN	3	3	plasma
NCT0000146121	NCT00001461_21_T0	TISSUE	19	19	endothelium
NCT0000146121	NCT00001461_21_T1	GENE	12	12	ACE
NCT0000146121	NCT00001461_21_T2	GENE	9	9	bradykinin
NCT0000146121	NCT00001461_21_T3	MOLECULAR_FUNCTION	0	1	ACE activity
NCT0000146121	NCT00001461_21_T4	MOLECULAR_FUNCTION	26	27	ACE activity
NCT0000146212	NCT00001462_12_T0	PHENOTYPE	19	21	reactive airways disease
NCT0000146213	NCT00001462_13_T0	PHENOTYPE	3	3	influenza
NCT0000146216	NCT00001462_16_T0	PHENOTYPE	1	1	allergy
NCT0000146216	NCT00001462_16_T1	COMPOUND	8	8	lidocaine
NCT0000146218	NCT00001462_18_T0	PHENOTYPE	1	2	HIV positive
NCT0000146219	NCT00001462_19_T0	PHENOTYPE	1	1	Hepatitis
NCT0000146221	NCT00001462_21_T0	PHENOTYPE	6	7	cardiac diseases
NCT0000146222	NCT00001462_22_T0	PHENOTYPE	7	7	disorders
NCT0000146223	NCT00001462_23_T0	COMPOUND	4	4	oxygen
NCT000014641	NCT00001464_1_T0	COMPOUND	6	6	oxygen
NCT000014643	NCT00001464_3_T0	COMPOUND	3	3	oxygen
NCT000014647	NCT00001464_7_T0	ORGAN	21	21	lungs
NCT000014647	NCT00001464_7_T1	COMPOUND	9	9	oxygen
NCT000014648	NCT00001464_8_T0	ORGAN	24	24	lungs
NCT000014648	NCT00001464_8_T1	COMPOUND	11	11	oxygen
NCT0000146412	NCT00001464_12_T0	PHENOTYPE	18	18	peripheral
NCT0000146412	NCT00001464_12_T1	COMPOUND	24	24	oxygen
NCT0000146412	NCT00001464_12_T2	CELL	15	16	epithelial cells
NCT0000146413	NCT00001464_13_T0	PHENOTYPE	9	9	hyperoxia
NCT0000146413	NCT00001464_13_T1	PHENOTYPE	11	11	inflammation
NCT000014652	NCT00001465_2_T0	CELL	14	14	cells
NCT000014655	NCT00001465_5_T0	GENE	38	38	0.5
NCT000014655	NCT00001465_5_T1	GENE	47	47	cm
NCT0000146516	NCT00001465_16_T0	PHENOTYPE	27	28	pulmonary disease
NCT0000146519	NCT00001465_19_T0	GENE	38	38	MRI
NCT0000146519	NCT00001465_19_T1	PHENOTYPE	30	31	radiation exposure
NCT0000146520	NCT00001465_20_T0	PHENOTYPE	16	17	pulmonary disease
NCT0000146522	NCT00001465_22_T0	PHENOTYPE	7	8	systemic illness
NCT0000146523	NCT00001465_23_T0	COMPOUND	17	17	oxygen
NCT000014665	NCT00001466_5_T0	GENE	21	21	MRI
NCT000014668	NCT00001466_8_T0	PHENOTYPE	16	16	disorders
NCT0000146611	NCT00001466_11_T0	PHENOTYPE	7	7	disorders
NCT0000146611	NCT00001466_11_T1	PHENOTYPE	26	26	disorders
NCT0000146612	NCT00001466_12_T0	PHENOTYPE	12	13	genetic disorders
NCT000014671	NCT00001467_1_T0	ORGAN	1	2	immune system
NCT000014672	NCT00001467_2_T0	PHENOTYPE	17	17	allergies
NCT000014672	NCT00001467_2_T1	TISSUE	42	42	tissues
NCT000014672	NCT00001467_2_T2	PHENOTYPE	24	24	lupus
NCT000014672	NCT00001467_2_T3	PHENOTYPE	15	15	susceptible
NCT000014672	NCT00001467_2_T4	CELL	31	31	cells
NCT000014672	NCT00001467_2_T5	PHENOTYPE	26	26	arthritis
NCT000014672	NCT00001467_2_T6	PHENOTYPE	10	10	infections
NCT000014672	NCT00001467_2_T7	PHENOTYPE	20	21	autoimmune diseases
NCT000014672	NCT00001467_2_T8	CELL	32	34	white blood cells
NCT000014673	NCT00001467_3_T0	PHENOTYPE	2	3	immune disorders
NCT000014677	NCT00001467_7_T0	CELL	22	22	cells
NCT000014677	NCT00001467_7_T1	ORGAN	14	14	cheeks
NCT000014678	NCT00001467_8_T0	GENE	10	10	1.8
NCT000014679	NCT00001467_9_T0	CELL	12	12	cells
NCT000014679	NCT00001467_9_T1	TISSUE	14	15	chorionic villus
NCT0000146710	NCT00001467_10_T0	PHENOTYPE	14	15	immune disorder
NCT0000146711	NCT00001467_11_T0	PHENOTYPE	13	14	immune disorder
NCT0000146713	NCT00001467_13_T0	PHENOTYPE	9	9	disorders
NCT0000146714	NCT00001467_14_T0	ORGAN	9	10	immune system
NCT0000146715	NCT00001467_15_T0	PHENOTYPE	12	12	affects
NCT0000146715	NCT00001467_15_T1	PHENOTYPE	29	29	decisions
NCT0000146715	NCT00001467_15_T2	PHENOTYPE	9	10	immune disorder
NCT0000146719	NCT00001467_19_T0	PHENOTYPE	2	2	mutation
NCT0000146719	NCT00001467_19_T1	ORGAN	23	24	immune system
NCT0000146720	NCT00001467_20_T0	PHENOTYPE	23	23	allergies
NCT0000146720	NCT00001467_20_T1	PHENOTYPE	3	3	disorders
NCT0000146720	NCT00001467_20_T2	PHENOTYPE	28	28	arthritis
NCT0000146720	NCT00001467_20_T3	PHENOTYPE	30	30	lupus
NCT0000146720	NCT00001467_20_T4	PHENOTYPE	25	26	autoimmune diseases
NCT0000146721	NCT00001467_21_T0	PHENOTYPE	4	5	immune disorders
NCT0000146725	NCT00001467_25_T0	GENE	27	27	PI
NCT000014680	NCT00001468_0_T0	GENE	6	6	BRCA1
NCT000014683	NCT00001468_3_T0	PHENOTYPE	7	8	familial cancer
NCT000014688	NCT00001468_8_T0	PHENOTYPE	20	20	self-esteem
NCT000014688	NCT00001468_8_T1	PHENOTYPE	25	25	practices
NCT000014689	NCT00001468_9_T0	PHENOTYPE	19	19	feelings
NCT0000146811	NCT00001468_11_T0	PHENOTYPE	16	16	attitudes
NCT0000146811	NCT00001468_11_T1	PHENOTYPE	14	14	feelings
NCT0000146815	NCT00001468_15_T0	PHENOTYPE	11	11	decision-making
NCT0000146820	NCT00001468_20_T0	PHENOTYPE	36	37	colon cancer
NCT0000146822	NCT00001468_22_T0	COMPOUND	9	9	NCI
NCT000014692	NCT00001469_2_T0	PHENOTYPE	16	16	sporadic
NCT000014692	NCT00001469_2_T1	PHENOTYPE	17	17	cancers
NCT000014692	NCT00001469_2_T2	GENE	8	8	has
NCT000014692	NCT00001469_2_T3	PHENOTYPE	6	7	neoplastic transformation
NCT000014694	NCT00001469_4_T0	PHENOTYPE	25	25	sporadic
NCT000014694	NCT00001469_4_T1	PHENOTYPE	26	26	cancers
NCT000014694	NCT00001469_4_T2	PHENOTYPE	9	11	hereditary cancer syndromes
NCT000014698	NCT00001469_8_T0	PHENOTYPE	4	4	diseases
NCT0000146913	NCT00001469_13_T0	PHENOTYPE	16	16	sporadic
NCT0000146913	NCT00001469_13_T1	PHENOTYPE	17	17	cancers
NCT0000146913	NCT00001469_13_T2	GENE	8	8	has
NCT0000146913	NCT00001469_13_T3	PHENOTYPE	6	7	neoplastic transformation
NCT0000146915	NCT00001469_15_T0	PHENOTYPE	25	25	sporadic
NCT0000146915	NCT00001469_15_T1	PHENOTYPE	26	26	cancers
NCT0000146915	NCT00001469_15_T2	PHENOTYPE	9	11	hereditary cancer syndromes
NCT0000146919	NCT00001469_19_T0	PHENOTYPE	4	4	diseases
NCT000014711	NCT00001471_1_T0	PHENOTYPE	3	3	HIV
NCT000014713	NCT00001471_3_T0	ORGAN	10	11	immune system
NCT000014716	NCT00001471_6_T0	TISSUE	7	7	tonsil
NCT000014719	NCT00001471_9_T0	COMPOUND	11	11	2
NCT0000147110	NCT00001471_10_T0	TISSUE	4	5	lymph nodes
NCT0000147112	NCT00001471_12_T0	GENE	10	10	separated
NCT0000147121	NCT00001471_21_T0	TISSUE	9	10	lymph node
NCT0000147127	NCT00001471_27_T0	ORGAN	9	9	serum
NCT0000147128	NCT00001471_28_T0	PHENOTYPE	15	15	HIV/AIDS
NCT0000147128	NCT00001471_28_T1	PHENOTYPE	17	17	diseases
NCT0000147128	NCT00001471_28_T2	ORGAN	20	21	immune system
NCT0000147129	NCT00001471_29_T0	GENE	0	0	FOR
NCT0000147129	NCT00001471_29_T1	TISSUE	9	10	lymph node
NCT0000147130	NCT00001471_30_T0	TISSUE	13	14	lymph nodes
NCT0000147130	NCT00001471_30_T1	TISSUE	9	10	lymph node
NCT0000147131	NCT00001471_31_T0	COMPOUND	3	3	piroxicam
NCT0000147131	NCT00001471_31_T1	COMPOUND	18	18	ibuprofen
NCT0000147131	NCT00001471_31_T2	COMPOUND	1	1	aspirin
NCT0000147136	NCT00001471_36_T0	GENE	18	18	blot
NCT0000147136	NCT00001471_36_T1	GENE	21	21	blot
NCT0000147136	NCT00001471_36_T2	GENE	5	5	FOR
NCT0000147136	NCT00001471_36_T3	GENE	20	20	dot
NCT0000147136	NCT00001471_36_T4	PHENOTYPE	6	7	HIV POSITIVE
NCT0000147136	NCT00001471_36_T5	PHENOTYPE	9	10	HIV infection
NCT0000147137	NCT00001471_37_T0	PHENOTYPE	8	8	HIV
NCT0000147137	NCT00001471_37_T1	PHENOTYPE	11	11	HIV
NCT0000147137	NCT00001471_37_T2	ORGAN	10	10	plasma
NCT0000147137	NCT00001471_37_T3	PHENOTYPE	3	5	acute HIV infection
NCT0000147139	NCT00001471_39_T0	GENE	13	13	blot
NCT0000147139	NCT00001471_39_T1	GENE	16	16	blot
NCT0000147139	NCT00001471_39_T2	GENE	15	15	dot
NCT0000147139	NCT00001471_39_T3	PHENOTYPE	2	3	HIV infection
NCT0000147141	NCT00001471_41_T0	GENE	13	13	blot
NCT0000147141	NCT00001471_41_T1	GENE	16	16	blot
NCT0000147141	NCT00001471_41_T2	GENE	15	15	dot
NCT0000147141	NCT00001471_41_T3	PHENOTYPE	2	3	HIV infection
NCT0000147147	NCT00001471_47_T0	ORGAN	1	2	heart valve
NCT0000147148	NCT00001471_48_T0	ORGAN	8	8	graft
NCT0000147152	NCT00001471_52_T0	PHENOTYPE	0	0	Allergy
NCT0000147152	NCT00001471_52_T1	COMPOUND	2	2	lidocaine
NCT000014730	NCT00001473_0_T0	PHENOTYPE	8	8	Vasculitides
NCT000014732	NCT00001473_2_T0	PHENOTYPE	6	6	vasculitis
NCT000014732	NCT00001473_2_T1	ORGAN	20	20	joints
NCT000014732	NCT00001473_2_T2	ORGAN	16	16	kidneys
NCT000014732	NCT00001473_2_T3	ORGAN	13	13	eyes
NCT000014732	NCT00001473_2_T4	ORGAN	21	21	heart
NCT000014732	NCT00001473_2_T5	PHENOTYPE	0	0	Vasculitides
NCT000014732	NCT00001473_2_T6	PHENOTYPE	2	2	inflammation
NCT000014732	NCT00001473_2_T7	ORGAN	15	15	lungs
NCT000014732	NCT00001473_2_T8	PHENOTYPE	14	14	sinuses
NCT000014732	NCT00001473_2_T9	ORGAN	4	5	blood vessels
NCT000014735	NCT00001473_5_T0	COMPOUND	3	3	cyclophosphamide
NCT000014735	NCT00001473_5_T1	COMPOUND	7	7	methotrexate
NCT000014736	NCT00001473_6_T0	PHENOTYPE	17	17	vasculitis
NCT000014736	NCT00001473_6_T1	PHENOTYPE	9	10	Wegener's granulomatosis
NCT000014736	NCT00001473_6_T2	PHENOTYPE	11	12	polyarteritis nodosa
NCT000014739	NCT00001473_9_T0	COMPOUND	20	20	cyclophosphamide
NCT000014739	NCT00001473_9_T1	COMPOUND	11	11	prednisone
NCT0000147310	NCT00001473_10_T0	PHENOTYPE	14	14	remission
NCT0000147310	NCT00001473_10_T1	COMPOUND	17	17	cyclophosphamide
NCT0000147310	NCT00001473_10_T2	GENE	9	9	reduced
NCT0000147310	NCT00001473_10_T3	COMPOUND	5	5	prednisone
NCT0000147311	NCT00001473_11_T0	GENE	6	6	0.3
NCT0000147311	NCT00001473_11_T1	GENE	17	17	0.5
NCT0000147313	NCT00001473_13_T0	GENE	17	17	reduced
NCT0000147313	NCT00001473_13_T1	COMPOUND	13	13	methotrexate
NCT0000147313	NCT00001473_13_T2	PHENOTYPE	10	11	in remission
NCT0000147315	NCT00001473_15_T0	PHENOTYPE	11	11	recurrence
NCT0000147315	NCT00001473_15_T1	PHENOTYPE	9	9	severity
NCT0000147315	NCT00001473_15_T2	COMPOUND	21	21	cyclophosphamide
NCT0000147315	NCT00001473_15_T3	COMPOUND	23	23	methotrexate
NCT0000147315	NCT00001473_15_T4	COMPOUND	20	20	prednisone
NCT0000147315	NCT00001473_15_T5	PHENOTYPE	17	18	adverse reactions
NCT0000147316	NCT00001473_16_T0	PHENOTYPE	20	22	drug side effects
NCT0000147318	NCT00001473_18_T0	COMPOUND	13	13	methotrexate
NCT0000147318	NCT00001473_18_T1	GENE	10	10	has
NCT0000147319	NCT00001473_19_T0	PHENOTYPE	4	5	in remission
NCT0000147321	NCT00001473_21_T0	PHENOTYPE	17	17	disorders
NCT0000147321	NCT00001473_21_T1	COMPOUND	4	4	cyclophosphamide
NCT0000147322	NCT00001473_22_T0	PHENOTYPE	18	18	toxicity
NCT0000147322	NCT00001473_22_T1	GENE	3	3	has
NCT0000147322	NCT00001473_22_T2	GENE	13	13	has
NCT0000147323	NCT00001473_23_T0	PHENOTYPE	21	21	toxicity
NCT0000147323	NCT00001473_23_T1	PHENOTYPE	34	35	disease relapse
NCT0000147324	NCT00001473_24_T0	PHENOTYPE	25	25	toxicity
NCT0000147324	NCT00001473_24_T1	PHENOTYPE	12	12	remission
NCT0000147324	NCT00001473_24_T2	COMPOUND	4	4	cyclophosphamide
NCT0000147324	NCT00001473_24_T3	COMPOUND	20	20	cyclophosphamide
NCT0000147324	NCT00001473_24_T4	COMPOUND	10	10	methotrexate
NCT0000147324	NCT00001473_24_T5	COMPOUND	28	28	methotrexate
NCT0000147325	NCT00001473_25_T0	PHENOTYPE	22	22	severity
NCT0000147326	NCT00001473_26_T0	COMPOUND	9	9	cyclophosphamide
NCT0000147326	NCT00001473_26_T1	COMPOUND	16	16	cyclophosphamide
NCT0000147326	NCT00001473_26_T2	BIOLOGICAL_PROCESS	20	20	quiescence
NCT0000147326	NCT00001473_26_T3	COMPOUND	18	18	methotrexate
NCT0000147327	NCT00001473_27_T0	PHENOTYPE	17	17	remission
NCT0000147327	NCT00001473_27_T1	COMPOUND	9	9	methotrexate
NCT0000147327	NCT00001473_27_T2	GENE	22	22	tapered
NCT0000147328	NCT00001473_28_T0	PHENOTYPE	11	12	drug toxicity
NCT0000147329	NCT00001473_29_T0	PHENOTYPE	11	11	remission
NCT0000147329	NCT00001473_29_T1	PHENOTYPE	25	26	adverse effects
NCT0000147329	NCT00001473_29_T2	PHENOTYPE	17	18	disease relapse
NCT0000147330	NCT00001473_30_T0	PHENOTYPE	21	21	severity
NCT0000147330	NCT00001473_30_T1	PHENOTYPE	14	14	vasculitis
NCT0000147330	NCT00001473_30_T2	PHENOTYPE	10	11	Wegener's granulomatosis
NCT0000147335	NCT00001473_35_T0	PHENOTYPE	10	10	judgement
NCT0000147335	NCT00001473_35_T1	PHENOTYPE	24	24	vasculitis
NCT0000147335	NCT00001473_35_T2	PHENOTYPE	5	6	systemic infection
NCT0000147338	NCT00001473_38_T0	PHENOTYPE	5	7	negative pregnancy test
NCT000014743	NCT00001474_3_T0	GENE	3	3	interleukin-2
NCT000014745	NCT00001474_5_T0	GENE	20	20	CD4
NCT000014745	NCT00001474_5_T1	GENE	39	39	p24
NCT000014745	NCT00001474_5_T2	GENE	29	29	receptor
NCT000014745	NCT00001474_5_T3	GENE	28	28	IL-2
NCT0000147410	NCT00001474_10_T0	GENE	3	3	interleukin-2
NCT0000147412	NCT00001474_12_T0	GENE	20	20	CD4
NCT0000147412	NCT00001474_12_T1	GENE	39	39	p24
NCT0000147412	NCT00001474_12_T2	GENE	29	29	receptor
NCT0000147412	NCT00001474_12_T3	GENE	28	28	IL-2
NCT0000147414	NCT00001474_14_T0	COMPOUND	10	10	1
NCT0000147414	NCT00001474_14_T1	COMPOUND	28	28	2
NCT0000147414	NCT00001474_14_T2	GENE	54	54	CD4
NCT0000147414	NCT00001474_14_T3	COMPOUND	37	37	3
NCT0000147414	NCT00001474_14_T4	GENE	42	42	IL-2
NCT0000147414	NCT00001474_14_T5	GENE	66	66	IL-2
NCT0000147414	NCT00001474_14_T6	GENE	95	95	IL-2
NCT0000147414	NCT00001474_14_T7	GENE	104	104	IL-2
NCT0000147414	NCT00001474_14_T8	GENE	119	119	IL-2
NCT0000147414	NCT00001474_14_T9	GENE	133	133	IL-2
NCT0000147414	NCT00001474_14_T10	ORGAN	83	83	plasma
NCT0000147414	NCT00001474_14_T11	ORGAN	85	85	serum
NCT0000147414	NCT00001474_14_T12	PHENOTYPE	16	17	Group B
NCT0000147414	NCT00001474_14_T13	PHENOTYPE	30	31	Group B
NCT0000147415	NCT00001474_15_T0	GENE	13	13	IL-2
NCT0000147415	NCT00001474_15_T1	GENE	24	24	IL-2
NCT0000147421	NCT00001474_21_T0	ORGAN	3	3	serum
NCT0000147424	NCT00001474_24_T0	GENE	7	7	2.0
NCT0000147424	NCT00001474_24_T1	GENE	0	1	Total bilirubin
NCT0000147425	NCT00001474_25_T0	COMPOUND	1	1	creatinine
NCT0000147425	NCT00001474_25_T1	GENE	7	7	2.0
NCT0000147425	NCT00001474_25_T2	ORGAN	0	0	Serum
NCT0000147426	NCT00001474_26_T0	COMPOUND	6	6	1
NCT0000147426	NCT00001474_26_T1	PHENOTYPE	0	0	Proteinuria
NCT0000147427	NCT00001474_27_T0	CELL	0	0	Granulocyte
NCT0000147428	NCT00001474_28_T0	PHENOTYPE	9	10	platelet count
NCT0000147429	NCT00001474_29_T0	GENE	14	14	IL-2
NCT0000147431	NCT00001474_31_T0	GENE	2	2	IL-2
NCT0000147432	NCT00001474_32_T0	PHENOTYPE	1	1	malignancy
NCT0000147432	NCT00001474_32_T1	PHENOTYPE	5	6	Kaposi sarcoma
NCT0000147433	NCT00001474_33_T0	PHENOTYPE	5	6	opportunistic infection
NCT0000147434	NCT00001474_34_T0	PHENOTYPE	9	9	dependence
NCT0000147434	NCT00001474_34_T1	PHENOTYPE	6	7	substance abuse
NCT0000147435	NCT00001474_35_T0	PHENOTYPE	5	6	cognitive disturbance
NCT0000147436	NCT00001474_36_T0	ORGAN	6	6	kidney
NCT0000147436	NCT00001474_36_T1	ORGAN	4	4	thyroid
NCT0000147436	NCT00001474_36_T2	PHENOTYPE	9	9	impairment
NCT0000147440	NCT00001474_40_T0	GENE	9	9	G-CSF
NCT0000147440	NCT00001474_40_T1	GENE	10	10	GM-CSF
NCT0000147441	NCT00001474_41_T0	PHENOTYPE	14	14	complications
NCT0000147441	NCT00001474_41_T1	PHENOTYPE	9	10	autoimmune diseases
NCT0000147442	NCT00001474_42_T0	PHENOTYPE	3	4	avascular necrosis
NCT0000147444	NCT00001474_44_T0	GENE	17	17	IL-2
NCT0000147444	NCT00001474_44_T1	GENE	19	19	has
NCT0000147448	NCT00001474_48_T0	GENE	1	1	The
NCT0000147448	NCT00001474_48_T1	GENE	18	18	has
NCT0000147455	NCT00001474_55_T0	GENE	1	1	The
NCT000014751	NCT00001475_1_T0	GENE	9	9	has
NCT000014751	NCT00001475_1_T1	PHENOTYPE	4	5	avascular necrosis
NCT000014752	NCT00001475_2_T0	GENE	9	9	interleukin-2
NCT000014753	NCT00001475_3_T0	GENE	3	3	IL-2
NCT000014755	NCT00001475_5_T0	GENE	3	3	IL-2
NCT000014759	NCT00001475_9_T0	PHENOTYPE	12	12	complications
NCT0000147512	NCT00001475_12_T0	PHENOTYPE	10	10	severity
NCT0000147512	NCT00001475_12_T1	PHENOTYPE	0	0	Secondary
NCT0000147512	NCT00001475_12_T2	GENE	6	6	CD4
NCT0000147512	NCT00001475_12_T3	GENE	12	12	IL-2
NCT0000147512	NCT00001475_12_T4	ORGAN	18	18	serum
NCT0000147512	NCT00001475_12_T5	ORGAN	22	22	plasma
NCT0000147512	NCT00001475_12_T6	GENE	19	19	TNF
NCT0000147515	NCT00001475_15_T0	PHENOTYPE	36	36	toxicity
NCT0000147515	NCT00001475_15_T1	GENE	15	15	CD4
NCT0000147515	NCT00001475_15_T2	GENE	34	34	IL-2
NCT0000147515	NCT00001475_15_T3	COMPOUND	31	31	prednisone
NCT0000147515	NCT00001475_15_T4	PHENOTYPE	12	13	HIV infection
NCT0000147516	NCT00001475_16_T0	GENE	9	9	IL-2
NCT0000147516	NCT00001475_16_T1	GENE	11	11	IL-2
NCT0000147516	NCT00001475_16_T2	COMPOUND	13	13	prednisone
NCT0000147516	NCT00001475_16_T3	COMPOUND	14	14	prednisone
NCT0000147517	NCT00001475_17_T0	GENE	17	18	protease inhibitor
NCT0000147518	NCT00001475_18_T0	GENE	0	0	IL-2
NCT0000147518	NCT00001475_18_T1	GENE	30	30	IL-2
NCT0000147518	NCT00001475_18_T2	GENE	27	27	0.5
NCT0000147518	NCT00001475_18_T3	COMPOUND	20	20	prednisone
NCT0000147518	NCT00001475_18_T4	GENE	12	12	bid
NCT0000147519	NCT00001475_19_T0	PHENOTYPE	7	7	fatigue
NCT0000147519	NCT00001475_19_T1	GENE	10	10	CD4
NCT0000147519	NCT00001475_19_T2	GENE	5	5	IL-2
NCT0000147519	NCT00001475_19_T3	PHENOTYPE	9	9	fever
NCT0000147525	NCT00001475_25_T0	COMPOUND	6	6	thalidomide
NCT0000147525	NCT00001475_25_T1	COMPOUND	5	5	pentoxifylline
NCT0000147528	NCT00001475_28_T0	ORGAN	5	6	upper extremities
NCT0000147529	NCT00001475_29_T0	GENE	2	2	IL-2
NCT0000147530	NCT00001475_30_T0	PHENOTYPE	1	1	malignancy
NCT0000147530	NCT00001475_30_T1	PHENOTYPE	4	5	Kaposi's sarcoma
NCT0000147532	NCT00001475_32_T0	PHENOTYPE	12	13	recurrent pneumonia
NCT0000147532	NCT00001475_32_T1	PHENOTYPE	5	6	opportunistic infection
NCT0000147533	NCT00001475_33_T0	PHENOTYPE	2	3	substance abuse
NCT0000147535	NCT00001475_35_T0	ORGAN	8	8	kidney
NCT0000147535	NCT00001475_35_T1	GENE	34	34	IL-2
NCT0000147535	NCT00001475_35_T2	GENE	51	51	IL-2
NCT0000147535	NCT00001475_35_T3	ORGAN	7	7	thyroid
NCT0000147535	NCT00001475_35_T4	PHENOTYPE	11	12	neurological disease
NCT0000147535	NCT00001475_35_T5	PHENOTYPE	27	28	fluid shifts
NCT0000147536	NCT00001475_36_T0	PHENOTYPE	3	3	hypertension
NCT0000147542	NCT00001475_42_T0	GENE	1	1	IL-2
NCT000014762	NCT00001476_2_T0	CELL	19	19	cells
NCT000014762	NCT00001476_2_T1	GENE	23	23	had
NCT000014768	NCT00001476_8_T0	PHENOTYPE	13	15	chronic granulomatous diseases
NCT0000147614	NCT00001476_14_T0	PHENOTYPE	15	15	relapse
NCT0000147617	NCT00001476_17_T0	GENE	36	36	G-CSF
NCT0000147617	NCT00001476_17_T1	CELL	11	11	cells
NCT0000147617	NCT00001476_17_T2	GENE	10	10	CD34
NCT0000147617	NCT00001476_17_T3	GENE	32	35	granulocyte colony stimulating factor
NCT0000147619	NCT00001476_19_T0	GENE	0	0	CD34
NCT0000147619	NCT00001476_19_T1	GENE	14	14	CD34
NCT0000147621	NCT00001476_21_T0	BIOLOGICAL_PROCESS	43	43	transduction
NCT0000147621	NCT00001476_21_T1	GENE	15	15	CD34
NCT0000147621	NCT00001476_21_T2	CELL	11	12	stem cells
NCT0000147621	NCT00001476_21_T3	CELL	16	17	stem cells
NCT0000147624	NCT00001476_24_T0	GENE	1	1	CD34
NCT0000147625	NCT00001476_25_T0	GENE	9	9	envelope
NCT0000147625	NCT00001476_25_T1	GENE	5	5	defective
NCT0000147625	NCT00001476_25_T2	GENE	14	14	CRIP
NCT0000147625	NCT00001476_25_T3	GENE	10	10	lines
NCT0000147627	NCT00001476_27_T0	ORGAN	10	10	serum
NCT0000147628	NCT00001476_28_T0	PHENOTYPE	4	4	sterility
NCT0000147628	NCT00001476_28_T1	CELL	24	24	cells
NCT0000147628	NCT00001476_28_T2	GENE	18	18	lines
NCT0000147631	NCT00001476_31_T0	PHENOTYPE	9	9	persistence
NCT0000147631	NCT00001476_31_T1	CELL	11	11	neutrophils
NCT0000147634	NCT00001476_34_T0	PHENOTYPE	12	12	toxicity
NCT0000147637	NCT00001476_37_T0	PHENOTYPE	3	3	infections
NCT0000147637	NCT00001476_37_T1	PHENOTYPE	5	5	infections
NCT0000147638	NCT00001476_38_T0	CELL	20	20	neutrophils
NCT0000147638	NCT00001476_38_T1	PHENOTYPE	3	5	Chronic Granulomatous Disease
NCT0000147643	NCT00001476_43_T0	GENE	30	30	G-CSF
NCT0000147643	NCT00001476_43_T1	GENE	26	26	GM-CSF
NCT0000147643	NCT00001476_43_T2	ORGAN	13	13	serum
NCT0000147647	NCT00001476_47_T0	PHENOTYPE	26	26	hypotension
NCT0000147647	NCT00001476_47_T1	PHENOTYPE	38	38	hypoxia
NCT0000147647	NCT00001476_47_T2	PHENOTYPE	41	41	ventilation
NCT0000147648	NCT00001476_48_T0	PHENOTYPE	0	0	HIV
NCT0000147648	NCT00001476_48_T1	PHENOTYPE	4	5	hepatitis B
NCT0000147649	NCT00001476_49_T0	PHENOTYPE	24	25	fungal infection
NCT0000147652	NCT00001476_52_T0	GENE	3	3	RBC
NCT000014772	NCT00001477_2_T0	GENE	11	11	PCR
NCT000014777	NCT00001477_7_T0	GENE	11	11	PCR
NCT0000147712	NCT00001477_12_T0	BIOLOGICAL_PROCESS	4	4	phlebotomy
NCT0000147713	NCT00001477_13_T0	PHENOTYPE	4	4	tuberculosis
NCT0000147713	NCT00001477_13_T1	PHENOTYPE	8	9	opportunistic infection
NCT000014782	NCT00001478_2_T0	COMPOUND	19	19	glucose
NCT000014782	NCT00001478_2_T1	COMPOUND	16	16	oxygen
NCT000014783	NCT00001478_3_T0	COMPOUND	11	12	carbon dioxide
NCT000014785	NCT00001478_5_T0	PHENOTYPE	1	2	brain activity
NCT000014787	NCT00001478_7_T0	PHENOTYPE	3	4	mood disorders
NCT0000147812	NCT00001478_12_T0	PHENOTYPE	12	13	mood disorders
NCT0000147814	NCT00001478_14_T0	PHENOTYPE	14	14	disorders
NCT0000147816	NCT00001478_16_T0	PHENOTYPE	19	19	symptoms
NCT0000147816	NCT00001478_16_T1	PHENOTYPE	12	13	mood disorders
NCT0000147817	NCT00001478_17_T0	PHENOTYPE	12	13	mood disorders
NCT0000147822	NCT00001478_22_T0	PHENOTYPE	21	23	course of illness
NCT0000147824	NCT00001478_24_T0	PHENOTYPE	29	29	HIV
NCT0000147824	NCT00001478_24_T1	ORGAN	23	23	liver
NCT0000147824	NCT00001478_24_T2	PHENOTYPE	32	32	syphilis
NCT0000147824	NCT00001478_24_T3	ORGAN	26	26	serum
NCT0000147824	NCT00001478_24_T4	PHENOTYPE	30	31	hepatitis B
NCT0000147825	NCT00001478_25_T0	PHENOTYPE	0	2	Negative pregnancy test
NCT0000147827	NCT00001478_27_T0	PHENOTYPE	15	15	secondary
NCT0000147827	NCT00001478_27_T1	PHENOTYPE	14	14	disorders
NCT0000147827	NCT00001478_27_T2	PHENOTYPE	1	1	HIV
NCT0000147827	NCT00001478_27_T3	PHENOTYPE	10	11	anxiety disorders
NCT0000147827	NCT00001478_27_T4	PHENOTYPE	17	18	HIV infection
NCT000014791	NCT00001479_1_T0	GENE	6	6	has
NCT000014792	NCT00001479_2_T0	GENE	15	15	5.2
NCT000014793	NCT00001479_3_T0	PHENOTYPE	13	14	major depression
NCT000014798	NCT00001479_8_T0	ORGAN	4	4	hippocampus
NCT000014798	NCT00001479_8_T1	PHENOTYPE	15	15	osteoporosis
NCT000014798	NCT00001479_8_T2	PHENOTYPE	8	9	heart disease
NCT000014798	NCT00001479_8_T3	PHENOTYPE	20	21	major depression
NCT000014798	NCT00001479_8_T4	PHENOTYPE	11	14	decreased bone mineral density
NCT000014799	NCT00001479_9_T0	PHENOTYPE	32	32	illnesses
NCT000014799	NCT00001479_9_T1	GENE	22	22	axis
NCT000014799	NCT00001479_9_T2	GENE	21	21	HPA
NCT000014799	NCT00001479_9_T3	ORGAN	11	12	pituitary gland
NCT000014799	NCT00001479_9_T4	ORGAN	14	15	adrenal gland
NCT0000147910	NCT00001479_10_T0	GENE	12	12	HPA
NCT0000147910	NCT00001479_10_T1	GENE	13	13	axis
NCT0000147911	NCT00001479_11_T0	PHENOTYPE	24	24	guilt
NCT0000147911	NCT00001479_11_T1	PHENOTYPE	0	0	Melancholia
NCT0000147911	NCT00001479_11_T2	PHENOTYPE	6	6	anhedonia
NCT0000147911	NCT00001479_11_T3	PHENOTYPE	4	4	feelings
NCT0000147911	NCT00001479_11_T4	PHENOTYPE	20	20	insomnia
NCT0000147913	NCT00001479_13_T0	GENE	15	15	HPA
NCT0000147913	NCT00001479_13_T1	GENE	2	2	has
NCT0000147913	NCT00001479_13_T2	GENE	16	16	axis
NCT0000147914	NCT00001479_14_T0	GENE	20	20	HPA
NCT0000147914	NCT00001479_14_T1	GENE	21	21	axis
NCT0000147914	NCT00001479_14_T2	PHENOTYPE	12	13	depressive disorders
NCT0000147916	NCT00001479_16_T0	GENE	22	22	5.2
NCT0000147916	NCT00001479_16_T1	GENE	6	6	has
NCT0000147917	NCT00001479_17_T0	PHENOTYPE	12	13	major depression
NCT0000147920	NCT00001479_20_T0	PHENOTYPE	7	8	major depression
NCT0000147920	NCT00001479_20_T1	PHENOTYPE	22	25	decreased bone mineral density
NCT0000147921	NCT00001479_21_T0	PHENOTYPE	2	3	myocardial infarction
NCT0000147923	NCT00001479_23_T0	GENE	23	23	atypical
NCT0000147923	NCT00001479_23_T1	GENE	18	18	HPA
NCT0000147923	NCT00001479_23_T2	GENE	28	28	HPA
NCT0000147925	NCT00001479_25_T0	GENE	28	28	atypical
NCT0000147925	NCT00001479_25_T1	GENE	23	23	HPA
NCT0000147925	NCT00001479_25_T2	GENE	2	2	has
NCT0000147925	NCT00001479_25_T3	PHENOTYPE	13	14	major depression
NCT0000147927	NCT00001479_27_T0	GENE	17	17	atypical
NCT0000147927	NCT00001479_27_T1	PHENOTYPE	7	7	strategies
NCT0000147928	NCT00001479_28_T0	GENE	8	8	has
NCT0000147928	NCT00001479_28_T1	PHENOTYPE	6	7	major depression
NCT0000147928	NCT00001479_28_T2	PHENOTYPE	31	32	major depression
NCT0000147929	NCT00001479_29_T0	GENE	16	16	HPA
NCT0000147929	NCT00001479_29_T1	PHENOTYPE	8	9	major depression
NCT0000147931	NCT00001479_31_T0	PHENOTYPE	14	14	SCID
NCT0000147931	NCT00001479_31_T1	PHENOTYPE	0	1	Psychiatric diagnosis
NCT0000147933	NCT00001479_33_T0	PHENOTYPE	5	5	illnesses
NCT0000147936	NCT00001479_36_T0	COMPOUND	3	3	lithium
NCT0000147936	NCT00001479_36_T1	PHENOTYPE	2	2	chronic
NCT000014801	NCT00001480_1_T0	GENE	9	9	AD
NCT000014801	NCT00001480_1_T1	PHENOTYPE	5	5	progression
NCT000014801	NCT00001480_1_T2	PHENOTYPE	7	8	Alzheimer's disease
NCT000014802	NCT00001480_2_T0	GENE	8	8	AD
NCT000014802	NCT00001480_2_T1	PHENOTYPE	17	19	progressive cognitive decline
NCT000014803	NCT00001480_3_T0	GENE	20	20	AD
NCT000014804	NCT00001480_4_T0	GENE	27	27	AD
NCT000014804	NCT00001480_4_T1	PHENOTYPE	23	24	emotional disturbances
NCT000014804	NCT00001480_4_T2	PHENOTYPE	12	13	progressive dementia
NCT000014805	NCT00001480_5_T0	GENE	6	6	AD
NCT000014808	NCT00001480_8_T0	GENE	11	11	AD
NCT000014808	NCT00001480_8_T1	PHENOTYPE	21	21	progressive
NCT000014808	NCT00001480_8_T2	PHENOTYPE	22	23	cognitive deterioration
NCT0000148011	NCT00001480_11_T0	PHENOTYPE	15	16	motor function
NCT0000148012	NCT00001480_12_T0	GENE	20	20	APO
NCT0000148012	NCT00001480_12_T1	GENE	6	6	AD
NCT0000148012	NCT00001480_12_T2	GENE	36	36	AD
NCT0000148013	NCT00001480_13_T0	GENE	21	21	AD
NCT0000148014	NCT00001480_14_T0	GENE	6	6	AD
NCT0000148014	NCT00001480_14_T1	GENE	28	28	CSF
NCT0000148015	NCT00001480_15_T0	GENE	29	29	APP
NCT0000148015	NCT00001480_15_T1	GENE	24	24	presenilin
NCT0000148015	NCT00001480_15_T2	GENE	26	26	presenilin
NCT0000148016	NCT00001480_16_T0	GENE	17	17	AD
NCT0000148016	NCT00001480_16_T1	PHENOTYPE	8	8	dementia
NCT0000148016	NCT00001480_16_T2	PHENOTYPE	22	22	dementia
NCT0000148017	NCT00001480_17_T0	GENE	38	38	AD
NCT0000148017	NCT00001480_17_T1	PHENOTYPE	21	21	progressive
NCT0000148017	NCT00001480_17_T2	PHENOTYPE	34	35	emotional disturbances
NCT0000148018	NCT00001480_18_T0	GENE	13	13	AD
NCT0000148018	NCT00001480_18_T1	GENE	21	21	AD
NCT0000148018	NCT00001480_18_T2	GENE	38	38	AD
NCT0000148018	NCT00001480_18_T3	PHENOTYPE	29	29	dementia
NCT0000148018	NCT00001480_18_T4	PHENOTYPE	24	26	mild cognitive impairments
NCT0000148021	NCT00001480_21_T0	GENE	20	20	AD
NCT0000148021	NCT00001480_21_T1	GENE	27	27	AD
NCT0000148021	NCT00001480_21_T2	PHENOTYPE	24	25	cognitive changes
NCT0000148022	NCT00001480_22_T0	GENE	27	27	AD
NCT0000148027	NCT00001480_27_T0	GENE	18	18	DPA
NCT0000148030	NCT00001480_30_T0	GENE	21	21	AD
NCT0000148030	NCT00001480_30_T1	GENE	44	44	AD
NCT0000148030	NCT00001480_30_T2	PHENOTYPE	42	42	mutation
NCT0000148030	NCT00001480_30_T3	GENE	0	0	AT
NCT0000148031	NCT00001480_31_T0	PHENOTYPE	11	11	dementia
NCT000014811	NCT00001481_1_T0	GENE	13	13	has
NCT000014811	NCT00001481_1_T1	PHENOTYPE	5	6	behavioral symptoms
NCT000014814	NCT00001481_4_T0	GENE	24	24	had
NCT000014814	NCT00001481_4_T1	PHENOTYPE	67	67	symptoms
NCT000014814	NCT00001481_4_T2	PHENOTYPE	15	15	puerperium
NCT000014815	NCT00001481_5_T0	GENE	13	13	reduced
NCT000014815	NCT00001481_5_T1	ORGAN	1	1	plasma
NCT000014815	NCT00001481_5_T2	BIOLOGICAL_PROCESS	23	23	parturition
NCT000014816	NCT00001481_6_T0	COMPOUND	8	8	progesterone
NCT000014816	NCT00001481_6_T1	GENE	18	18	hormone
NCT000014816	NCT00001481_6_T2	GENE	19	19	GnRH
NCT000014816	NCT00001481_6_T3	COMPOUND	6	6	estradiol
NCT000014816	NCT00001481_6_T4	COMPOUND	21	21	Lupron
NCT000014817	NCT00001481_7_T0	ORGAN	23	23	plasma
NCT000014817	NCT00001481_7_T1	PHENOTYPE	24	25	hormone levels
NCT000014818	NCT00001481_8_T0	COMPOUND	9	9	estrogen
NCT000014818	NCT00001481_8_T1	COMPOUND	11	11	progesterone
NCT0000148113	NCT00001481_13_T0	GENE	24	24	had
NCT0000148113	NCT00001481_13_T1	PHENOTYPE	67	67	symptoms
NCT0000148113	NCT00001481_13_T2	PHENOTYPE	15	15	puerperium
NCT0000148114	NCT00001481_14_T0	GENE	13	13	reduced
NCT0000148114	NCT00001481_14_T1	ORGAN	1	1	plasma
NCT0000148114	NCT00001481_14_T2	BIOLOGICAL_PROCESS	23	23	parturition
NCT0000148115	NCT00001481_15_T0	COMPOUND	8	8	progesterone
NCT0000148115	NCT00001481_15_T1	GENE	18	18	hormone
NCT0000148115	NCT00001481_15_T2	GENE	19	19	GnRH
NCT0000148115	NCT00001481_15_T3	COMPOUND	6	6	estradiol
NCT0000148115	NCT00001481_15_T4	COMPOUND	21	21	Lupron
NCT0000148116	NCT00001481_16_T0	ORGAN	23	23	plasma
NCT0000148116	NCT00001481_16_T1	PHENOTYPE	24	25	hormone levels
NCT0000148117	NCT00001481_17_T0	COMPOUND	11	11	progesterone
NCT0000148117	NCT00001481_17_T1	COMPOUND	9	9	estradiol
NCT0000148120	NCT00001481_20_T0	COMPOUND	9	9	1
NCT0000148120	NCT00001481_20_T1	GENE	0	1	Group 1
NCT0000148120	NCT00001481_20_T2	PHENOTYPE	7	8	postpartum depression
NCT0000148121	NCT00001481_21_T0	PHENOTYPE	20	20	SCID
NCT0000148121	NCT00001481_21_T1	GENE	23	23	has
NCT0000148121	NCT00001481_21_T2	COMPOUND	22	22	2
NCT0000148121	NCT00001481_21_T3	COMPOUND	32	32	3
NCT0000148121	NCT00001481_21_T4	PHENOTYPE	4	5	major depression
NCT0000148121	NCT00001481_21_T5	PHENOTYPE	70	71	psychotic episodes
NCT0000148121	NCT00001481_21_T6	BIOLOGICAL_PROCESS	35	36	menstrual cycle
NCT0000148122	NCT00001481_22_T0	COMPOUND	1	1	2
NCT0000148122	NCT00001481_22_T1	PHENOTYPE	7	10	Major Depressive Disorder 1
NCT0000148123	NCT00001481_23_T0	COMPOUND	17	17	2
NCT0000148123	NCT00001481_23_T1	COMPOUND	27	27	3
NCT0000148123	NCT00001481_23_T2	GENE	18	18	has
NCT0000148123	NCT00001481_23_T3	PHENOTYPE	64	65	psychotic episodes
NCT0000148123	NCT00001481_23_T4	BIOLOGICAL_PROCESS	30	31	menstrual cycle
NCT0000148123	NCT00001481_23_T5	PHENOTYPE	4	5	major depression
NCT0000148124	NCT00001481_24_T0	COMPOUND	1	1	3
NCT0000148125	NCT00001481_25_T0	PHENOTYPE	23	24	mood disorders
NCT000014821	NCT00001482_1_T0	COMPOUND	9	9	lamotrigine
NCT000014821	NCT00001482_1_T1	COMPOUND	14	14	gabapentin
NCT000014824	NCT00001482_4_T0	GENE	4	4	2.4
NCT000014828	NCT00001482_8_T0	COMPOUND	1	1	lamotrigine
NCT000014828	NCT00001482_8_T1	COMPOUND	3	3	gabapentin
NCT0000148213	NCT00001482_13_T0	PHENOTYPE	13	13	symptoms
NCT0000148213	NCT00001482_13_T1	COMPOUND	21	21	lithium
NCT0000148213	NCT00001482_13_T2	COMPOUND	24	24	valproate
NCT0000148213	NCT00001482_13_T3	PHENOTYPE	9	9	recurrent
NCT0000148213	NCT00001482_13_T4	COMPOUND	22	22	carbamazepine
NCT0000148213	NCT00001482_13_T5	PHENOTYPE	10	11	affective disorder
NCT0000148215	NCT00001482_15_T0	PHENOTYPE	28	28	pathophysiology
NCT0000148215	NCT00001482_15_T1	GENE	9	9	has
NCT0000148215	NCT00001482_15_T2	PHENOTYPE	31	32	mood disorders
NCT0000148216	NCT00001482_16_T0	GENE	6	6	blocker
NCT0000148216	NCT00001482_16_T1	COMPOUND	2	2	phenyltriazine
NCT0000148216	NCT00001482_16_T2	COMPOUND	4	4	sodium
NCT0000148216	NCT00001482_16_T3	PHENOTYPE	39	40	partial seizures
NCT0000148217	NCT00001482_17_T0	COMPOUND	8	8	lamotrigine
NCT0000148218	NCT00001482_18_T0	GENE	9	9	GABA
NCT0000148218	NCT00001482_18_T1	GENE	14	14	GABA
NCT0000148218	NCT00001482_18_T2	GENE	17	17	has
NCT0000148219	NCT00001482_19_T0	COMPOUND	10	10	gabapentin
NCT0000148219	NCT00001482_19_T1	GENE	7	7	had
NCT0000148219	NCT00001482_19_T2	PHENOTYPE	16	17	antianxiety effects
NCT0000148220	NCT00001482_20_T0	COMPOUND	7	7	lamotrigine
NCT0000148220	NCT00001482_20_T1	COMPOUND	9	9	gabapentin
NCT0000148220	NCT00001482_20_T2	PHENOTYPE	13	14	mood disorders
NCT0000148221	NCT00001482_21_T0	COMPOUND	10	10	lamotrigine
NCT0000148221	NCT00001482_21_T1	COMPOUND	12	12	gabapentin
NCT0000148222	NCT00001482_22_T0	PHENOTYPE	31	31	insights
NCT0000148222	NCT00001482_22_T1	PHENOTYPE	34	34	pathophysiology
NCT0000148222	NCT00001482_22_T2	PHENOTYPE	12	13	mood disorders
NCT0000148222	NCT00001482_22_T3	PHENOTYPE	36	37	mood disorders
NCT000014831	NCT00001483_1_T0	COMPOUND	4	4	dopamine
NCT000014833	NCT00001483_3_T0	COMPOUND	7	7	norepinephrine
NCT000014833	NCT00001483_3_T1	COMPOUND	9	9	dopamine
NCT000014835	NCT00001483_5_T0	PHENOTYPE	35	36	bipolar disorder
NCT000014836	NCT00001483_6_T0	PHENOTYPE	15	17	major depressive disorder
NCT0000148315	NCT00001483_15_T0	COMPOUND	19	19	norepinephrine
NCT0000148315	NCT00001483_15_T1	COMPOUND	14	14	venlafaxine
NCT0000148315	NCT00001483_15_T2	COMPOUND	25	25	dopamine
NCT0000148315	NCT00001483_15_T3	COMPOUND	5	5	sertraline
NCT0000148316	NCT00001483_16_T0	PHENOTYPE	16	18	major depressive episode
NCT0000148317	NCT00001483_17_T0	PHENOTYPE	26	26	acute
NCT0000148317	NCT00001483_17_T1	COMPOUND	22	22	venlafaxine
NCT0000148317	NCT00001483_17_T2	COMPOUND	19	19	bupropion
NCT0000148317	NCT00001483_17_T3	COMPOUND	20	20	sertraline
NCT0000148319	NCT00001483_19_T0	PHENOTYPE	14	16	major depressive disorder
NCT0000148322	NCT00001483_22_T0	PHENOTYPE	51	51	acute
NCT0000148322	NCT00001483_22_T1	COMPOUND	46	46	venlafaxine
NCT0000148322	NCT00001483_22_T2	COMPOUND	40	40	bupropion
NCT0000148322	NCT00001483_22_T3	COMPOUND	44	44	sertraline
NCT0000148323	NCT00001483_23_T0	PHENOTYPE	3	3	acute
NCT0000148323	NCT00001483_23_T1	PHENOTYPE	26	26	mania
NCT0000148324	NCT00001483_24_T0	PHENOTYPE	11	11	acute
NCT0000148324	NCT00001483_24_T1	PHENOTYPE	27	28	bipolar illness
NCT0000148325	NCT00001483_25_T0	PHENOTYPE	8	8	acute
NCT0000148326	NCT00001483_26_T0	COMPOUND	11	11	venlafaxine
NCT0000148326	NCT00001483_26_T1	COMPOUND	22	22	bupropion
NCT0000148326	NCT00001483_26_T2	COMPOUND	24	24	sertraline
NCT0000148326	NCT00001483_26_T3	PHENOTYPE	19	19	mania
NCT0000148329	NCT00001483_29_T0	PHENOTYPE	23	23	HIV
NCT0000148329	NCT00001483_29_T1	ORGAN	17	17	liver
NCT0000148329	NCT00001483_29_T2	ORGAN	20	20	serum
NCT0000148329	NCT00001483_29_T3	PHENOTYPE	24	25	hepatitis B
NCT0000148329	NCT00001483_29_T4	PHENOTYPE	39	41	drugs of abuse
NCT0000148331	NCT00001483_31_T0	PHENOTYPE	7	7	severity
NCT0000148333	NCT00001483_33_T0	PHENOTYPE	11	12	mood disorder
NCT0000148334	NCT00001483_34_T0	ORGAN	4	4	liver
NCT0000148334	NCT00001483_34_T1	PHENOTYPE	8	9	neurological disease
NCT0000148336	NCT00001483_36_T0	PHENOTYPE	9	9	dependence
NCT0000148336	NCT00001483_36_T1	PHENOTYPE	6	7	substance use
NCT000014851	NCT00001485_1_T0	COMPOUND	22	22	melatonin
NCT000014851	NCT00001485_1_T1	GENE	21	21	hormone
NCT000014851	NCT00001485_1_T2	ORGAN	17	18	pineal gland
NCT000014853	NCT00001485_3_T0	COMPOUND	4	4	melatonin
NCT000014853	NCT00001485_3_T1	PHENOTYPE	18	20	seasonal affective disorder
NCT000014855	NCT00001485_5_T0	PHENOTYPE	8	9	depressive symptoms
NCT000014856	NCT00001485_6_T0	PHENOTYPE	9	9	overeating
NCT0000148521	NCT00001485_21_T0	PHENOTYPE	8	8	illnesses
NCT000014862	NCT00001486_2_T0	GENE	7	7	has
NCT000014862	NCT00001486_2_T1	PHENOTYPE	5	6	genetic disorders
NCT000014863	NCT00001486_3_T0	PHENOTYPE	1	1	strategies
NCT000014865	NCT00001486_5_T0	PHENOTYPE	16	16	schizophrenia
NCT000014867	NCT00001486_7_T0	PHENOTYPE	16	16	schizophrenia
NCT000014867	NCT00001486_7_T1	GENE	0	0	Traits
NCT000014871	NCT00001487_1_T0	COMPOUND	7	7	DHEA
NCT000014872	NCT00001487_2_T0	COMPOUND	3	3	DHEA
NCT000014872	NCT00001487_2_T1	PHENOTYPE	24	24	osteoporosis
NCT000014872	NCT00001487_2_T2	PHENOTYPE	15	16	heart disease
NCT000014872	NCT00001487_2_T3	ORGAN	18	19	immune system
NCT000014873	NCT00001487_3_T0	COMPOUND	3	3	DHEA
NCT000014873	NCT00001487_3_T1	COMPOUND	6	6	sulfate
NCT000014874	NCT00001487_4_T0	COMPOUND	12	12	DHEA
NCT000014875	NCT00001487_5_T0	PHENOTYPE	16	16	enjoyment
NCT000014875	NCT00001487_5_T1	PHENOTYPE	12	12	feelings
NCT000014877	NCT00001487_7_T0	COMPOUND	11	11	DHEA
NCT000014877	NCT00001487_7_T1	PHENOTYPE	15	15	symptoms
NCT000014877	NCT00001487_7_T2	PHENOTYPE	19	19	disorders
NCT000014877	NCT00001487_7_T3	GENE	13	13	lessen
NCT000014879	NCT00001487_9_T0	COMPOUND	3	3	DHEA
NCT000014879	NCT00001487_9_T1	PHENOTYPE	17	18	cardiovascular disease
NCT000014879	NCT00001487_9_T2	PHENOTYPE	19	21	decreased immune function
NCT0000148711	NCT00001487_11_T0	COMPOUND	5	5	DHEA
NCT0000148711	NCT00001487_11_T1	PHENOTYPE	15	15	symptoms
NCT0000148711	NCT00001487_11_T2	PHENOTYPE	19	19	disorders
NCT0000148711	NCT00001487_11_T3	PHENOTYPE	14	14	neurasthenia
NCT0000148714	NCT00001487_14_T0	PHENOTYPE	18	18	severity
NCT0000148714	NCT00001487_14_T1	PHENOTYPE	32	32	impairment
NCT0000148714	NCT00001487_14_T2	PHENOTYPE	60	61	physical symptoms
NCT0000148714	NCT00001487_14_T3	PHENOTYPE	12	13	major depression
NCT000014891	NCT00001489_1_T0	COMPOUND	24	24	glucose
NCT000014892	NCT00001489_2_T0	COMPOUND	5	5	glucose
NCT000014892	NCT00001489_2_T1	PHENOTYPE	11	12	brain activity
NCT000014893	NCT00001489_3_T0	COMPOUND	14	14	glucose
NCT000014895	NCT00001489_5_T0	GENE	9	9	CBF
NCT000014897	NCT00001489_7_T0	PHENOTYPE	1	1	seizures
NCT000014899	NCT00001489_9_T0	PHENOTYPE	1	2	systemic illness
NCT000014911	NCT00001491_1_T0	ORGAN	19	19	thighs
NCT000014911	NCT00001491_1_T1	PHENOTYPE	25	25	tingling
NCT000014911	NCT00001491_1_T2	ORGAN	29	29	extremities
NCT000014911	NCT00001491_1_T3	PHENOTYPE	16	16	tumors
NCT000014911	NCT00001491_1_T4	CELL	10	10	cells
NCT000014911	NCT00001491_1_T5	ORGAN	22	22	genitalia
NCT000014911	NCT00001491_1_T6	CELL	11	11	histiocytes
NCT000014911	NCT00001491_1_T7	ORGAN	20	20	buttocks
NCT000014911	NCT00001491_1_T8	PHENOTYPE	31	31	cataracts
NCT000014911	NCT00001491_1_T9	ORGAN	13	14	blood vessel
NCT000014911	NCT00001491_1_T10	PHENOTYPE	23	24	decreased sweating
NCT000014912	NCT00001491_2_T0	ORGAN	10	10	kidney
NCT000014912	NCT00001491_2_T1	PHENOTYPE	7	7	complications
NCT000014912	NCT00001491_2_T2	ORGAN	11	11	heart
NCT000014913	NCT00001491_3_T0	GENE	27	27	CSF
NCT000014913	NCT00001491_3_T1	PHENOTYPE	31	32	Fabry's disease
NCT000014913	NCT00001491_3_T2	GENE	13	14	PGP 9.5
NCT000014913	NCT00001491_3_T3	ORGAN	25	26	spinal cord
NCT000014914	NCT00001491_4_T0	PHENOTYPE	18	18	severity
NCT000014914	NCT00001491_4_T1	ORGAN	23	24	nervous system
NCT000014915	NCT00001491_5_T0	PHENOTYPE	28	29	Fabry's disease
NCT000014915	NCT00001491_5_T1	GENE	0	1	PGP 9.5
NCT000014915	NCT00001491_5_T2	PHENOTYPE	14	18	diseases of the nervous system
NCT000014916	NCT00001491_6_T0	PHENOTYPE	10	11	Fabry's disease
NCT0000149110	NCT00001491_10_T0	PHENOTYPE	17	18	Fabry's disease
NCT0000149111	NCT00001491_11_T0	PHENOTYPE	4	5	Fabry disease
NCT0000149115	NCT00001491_15_T0	PHENOTYPE	18	19	Fabry disease
NCT0000149116	NCT00001491_16_T0	PHENOTYPE	23	24	Fabry disease
NCT0000149116	NCT00001491_16_T1	PHENOTYPE	20	21	peripheral neuropathy
NCT0000149119	NCT00001491_19_T0	ORGAN	16	17	nervous system
NCT0000149119	NCT00001491_19_T1	PHENOTYPE	0	1	HIV positive
NCT000014933	NCT00001493_3_T0	PHENOTYPE	27	27	bloodstream
NCT000014933	NCT00001493_3_T1	CELL	11	12	blood cells
NCT000014935	NCT00001493_5_T0	GENE	24	24	MDR1
NCT000014935	NCT00001493_5_T1	GENE	10	10	disabled
NCT000014936	NCT00001493_6_T0	GENE	5	5	MDR1
NCT000014937	NCT00001493_7_T0	PHENOTYPE	25	25	toxic
NCT000014937	NCT00001493_7_T1	PHENOTYPE	22	22	resistant
NCT000014937	NCT00001493_7_T2	GENE	5	5	MDR1
NCT000014937	NCT00001493_7_T3	CELL	17	18	blood cells
NCT000014937	NCT00001493_7_T4	PHENOTYPE	31	32	breast cancer
NCT000014939	NCT00001493_9_T0	GENE	12	12	disabled
NCT000014939	NCT00001493_9_T1	COMPOUND	20	20	NeoR
NCT0000149310	NCT00001493_10_T0	CELL	13	13	cells
NCT0000149310	NCT00001493_10_T1	COMPOUND	1	1	NeoR
NCT0000149310	NCT00001493_10_T2	PHENOTYPE	7	9	effects of chemotherapy
NCT0000149312	NCT00001493_12_T0	PHENOTYPE	18	18	toxic
NCT0000149312	NCT00001493_12_T1	PHENOTYPE	11	12	breast cancer
NCT0000149312	NCT00001493_12_T2	CELL	20	22	bone marrow cells
NCT0000149313	NCT00001493_13_T0	COMPOUND	11	11	paclitaxel
NCT0000149313	NCT00001493_13_T1	COMPOUND	14	14	doxorubicin
NCT0000149314	NCT00001493_14_T0	GENE	12	12	MDR1
NCT0000149314	NCT00001493_14_T1	PHENOTYPE	8	9	breast cancer
NCT0000149314	NCT00001493_14_T2	CELL	17	19	bone marrow cells
NCT0000149315	NCT00001493_15_T0	PHENOTYPE	2	2	peripheral
NCT0000149315	NCT00001493_15_T1	GENE	26	26	MDR1
NCT0000149315	NCT00001493_15_T2	GENE	38	38	has
NCT0000149315	NCT00001493_15_T3	COMPOUND	36	36	NeoR
NCT0000149315	NCT00001493_15_T4	CELL	3	4	blood cells
NCT0000149315	NCT00001493_15_T5	CELL	21	22	blood cells
NCT0000149317	NCT00001493_17_T0	COMPOUND	41	41	paclitaxel
NCT0000149317	NCT00001493_17_T1	COMPOUND	44	44	doxorubicin
NCT0000149317	NCT00001493_17_T2	PHENOTYPE	37	38	breast cancer
NCT0000149318	NCT00001493_18_T0	COMPOUND	11	11	5_fluorouracil
NCT0000149318	NCT00001493_18_T1	COMPOUND	8	8	methotrexate
NCT0000149318	NCT00001493_18_T2	COMPOUND	9	9	leucovorin
NCT0000149321	NCT00001493_21_T0	COMPOUND	10	10	cyclophosphamide
NCT0000149322	NCT00001493_22_T0	CELL	3	3	cells
NCT0000149322	NCT00001493_22_T1	COMPOUND	38	38	neomycin
NCT0000149322	NCT00001493_22_T2	COMPOUND	41	41	NeoR
NCT0000149322	NCT00001493_22_T3	GENE	19	21	multidrug resistance protein
NCT0000149323	NCT00001493_23_T0	BIOLOGICAL_PROCESS	16	16	transduction
NCT0000149324	NCT00001493_24_T0	COMPOUND	9	9	thiotepa
NCT0000149325	NCT00001493_25_T0	COMPOUND	23	23	thiotepa
NCT0000149325	NCT00001493_25_T1	COMPOUND	9	9	cyclophosphamide
NCT0000149325	NCT00001493_25_T2	ORGAN	28	29	bone marrow
NCT0000149325	NCT00001493_25_T3	CELL	0	2	Hematopoietic stem cells
NCT0000149326	NCT00001493_26_T0	COMPOUND	15	15	paclitaxel
NCT0000149326	NCT00001493_26_T1	COMPOUND	28	28	doxorubicin
NCT0000149327	NCT00001493_27_T0	COMPOUND	11	11	paclitaxel
NCT0000149327	NCT00001493_27_T1	PHENOTYPE	0	0	Peripheral
NCT0000149327	NCT00001493_27_T2	CELL	3	3	cells
NCT0000149327	NCT00001493_27_T3	COMPOUND	13	13	doxorubicin
NCT0000149327	NCT00001493_27_T4	COMPOUND	21	21	NeoR
NCT0000149328	NCT00001493_28_T0	PHENOTYPE	11	11	peripheral
NCT0000149328	NCT00001493_28_T1	GENE	27	27	has
NCT0000149328	NCT00001493_28_T2	COMPOUND	8	8	NeoR
NCT0000149332	NCT00001493_32_T0	PHENOTYPE	2	5	stage IV breast cancer
NCT0000149333	NCT00001493_33_T0	COMPOUND	5	5	doxorubicin
NCT0000149334	NCT00001493_34_T0	COMPOUND	29	29	vinblastine
NCT0000149334	NCT00001493_34_T1	COMPOUND	17	17	MUGA
NCT0000149334	NCT00001493_34_T2	COMPOUND	6	6	doxorubicin
NCT0000149334	NCT00001493_34_T3	COMPOUND	32	32	doxorubicin
NCT0000149336	NCT00001493_36_T0	GENE	4	4	0.2
NCT0000149337	NCT00001493_37_T0	COMPOUND	15	15	MUGA
NCT0000149338	NCT00001493_38_T0	CELL	4	4	neutrophils
NCT0000149338	NCT00001493_38_T1	CELL	9	9	platelets
NCT0000149338	NCT00001493_38_T2	ORGAN	17	18	bone marrow
NCT0000149339	NCT00001493_39_T0	COMPOUND	6	6	creatinine
NCT0000149339	NCT00001493_39_T1	GENE	9	9	2.0
NCT0000149339	NCT00001493_39_T2	COMPOUND	11	11	bilirubin
NCT0000149339	NCT00001493_39_T3	GENE	14	14	1.8
NCT0000149339	NCT00001493_39_T4	PHENOTYPE	31	32	metastatic cancer
NCT0000149340	NCT00001493_40_T0	COMPOUND	3	3	creatinine
NCT000014950	NCT00001495_0_T0	PHENOTYPE	16	17	Solid Tumors
NCT000014953	NCT00001495_3_T0	PHENOTYPE	18	18	diarrhea
NCT000014953	NCT00001495_3_T1	PHENOTYPE	11	12	drug toxicities
NCT000014954	NCT00001495_4_T0	PHENOTYPE	20	21	drug toxicity
NCT000014955	NCT00001495_5_T0	COMPOUND	11	11	irinotecan
NCT000014955	NCT00001495_5_T1	PHENOTYPE	21	22	solid tumors
NCT000014957	NCT00001495_7_T0	COMPOUND	16	16	irinotecan
NCT000014957	NCT00001495_7_T1	PHENOTYPE	6	6	tumor
NCT000014957	NCT00001495_7_T2	PHENOTYPE	14	14	pharmacokinetics
NCT000014957	NCT00001495_7_T3	PHENOTYPE	3	4	drug toxicity
NCT000014958	NCT00001495_8_T0	PHENOTYPE	20	20	tumor
NCT000014958	NCT00001495_8_T1	ORGAN	15	16	bone marrow
NCT0000149510	NCT00001495_10_T0	PHENOTYPE	1	1	leukemia
NCT0000149512	NCT00001495_12_T0	GENE	5	5	OR
NCT0000149513	NCT00001495_13_T0	PHENOTYPE	0	1	Measurable disease
NCT0000149516	NCT00001495_16_T0	COMPOUND	3	3	irinotecan
NCT0000149517	NCT00001495_17_T0	PHENOTYPE	0	0	Endocrine
NCT0000149520	NCT00001495_20_T0	GENE	2	2	Age
NCT0000149521	NCT00001495_21_T0	GENE	3	3	0.2
NCT0000149522	NCT00001495_22_T0	GENE	1	1	AGC
NCT0000149523	NCT00001495_23_T0	CELL	0	0	Platelets
NCT0000149524	NCT00001495_24_T0	GENE	5	5	1.5
NCT0000149525	NCT00001495_25_T0	GENE	0	0	AST
NCT0000149526	NCT00001495_26_T0	GENE	5	5	1.5
NCT0000149527	NCT00001495_27_T0	PHENOTYPE	1	1	HIV
NCT000014964	NCT00001496_4_T0	CELL	7	8	epithelial cells
NCT0000149610	NCT00001496_10_T0	CELL	7	8	epithelial cells
NCT000014973	NCT00001497_3_T0	GENE	28	28	al
NCT000014973	NCT00001497_3_T1	PHENOTYPE	7	7	susceptible
NCT000014973	NCT00001497_3_T2	GENE	27	27	et
NCT000014973	NCT00001497_3_T3	PHENOTYPE	12	13	HIV infection
NCT000014973	NCT00001497_3_T4	ORGAN	16	18	central nervous system
NCT000014974	NCT00001497_4_T0	PHENOTYPE	8	8	weakness
NCT000014974	NCT00001497_4_T1	GENE	20	20	al
NCT000014974	NCT00001497_4_T2	GENE	28	28	al
NCT000014974	NCT00001497_4_T3	GENE	19	19	et
NCT000014974	NCT00001497_4_T4	GENE	27	27	et
NCT000014974	NCT00001497_4_T5	PHENOTYPE	0	1	Attention deficits
NCT000014975	NCT00001497_5_T0	PHENOTYPE	11	11	vigilance
NCT000014975	NCT00001497_5_T1	PHENOTYPE	0	0	Attention
NCT000014975	NCT00001497_5_T2	GENE	2	2	has
NCT000014975	NCT00001497_5_T3	GENE	21	21	has
NCT000014975	NCT00001497_5_T4	PHENOTYPE	9	10	divided attention
NCT000014975	NCT00001497_5_T5	PHENOTYPE	7	8	focused attention
NCT0000149713	NCT00001497_13_T0	GENE	28	28	al
NCT0000149713	NCT00001497_13_T1	PHENOTYPE	7	7	susceptible
NCT0000149713	NCT00001497_13_T2	GENE	27	27	et
NCT0000149713	NCT00001497_13_T3	PHENOTYPE	12	13	HIV infection
NCT0000149713	NCT00001497_13_T4	ORGAN	16	18	central nervous system
NCT0000149714	NCT00001497_14_T0	PHENOTYPE	8	8	weakness
NCT0000149714	NCT00001497_14_T1	GENE	20	20	al
NCT0000149714	NCT00001497_14_T2	GENE	28	28	al
NCT0000149714	NCT00001497_14_T3	GENE	19	19	et
NCT0000149714	NCT00001497_14_T4	GENE	27	27	et
NCT0000149714	NCT00001497_14_T5	PHENOTYPE	0	1	Attention deficits
NCT0000149715	NCT00001497_15_T0	PHENOTYPE	11	11	vigilance
NCT0000149715	NCT00001497_15_T1	PHENOTYPE	0	0	Attention
NCT0000149715	NCT00001497_15_T2	GENE	2	2	has
NCT0000149715	NCT00001497_15_T3	GENE	21	21	has
NCT0000149715	NCT00001497_15_T4	PHENOTYPE	9	10	divided attention
NCT0000149715	NCT00001497_15_T5	PHENOTYPE	7	8	focused attention
NCT0000149721	NCT00001497_21_T0	COMPOUND	13	13	NCI
NCT0000149722	NCT00001497_22_T0	PHENOTYPE	14	14	trauma
NCT0000149722	NCT00001497_22_T1	PHENOTYPE	3	3	HIV
NCT000014981	NCT00001498_1_T0	PHENOTYPE	16	16	Consolidation
NCT000014981	NCT00001498_1_T1	PHENOTYPE	11	11	ascites
NCT000014981	NCT00001498_1_T2	PHENOTYPE	9	10	pleural effusions
NCT000014982	NCT00001498_2_T0	COMPOUND	5	5	methotrexate
NCT000014983	NCT00001498_3_T0	CELL	14	14	granulocyte
NCT000014983	NCT00001498_3_T1	COMPOUND	10	10	cyclophosphamide
NCT000014985	NCT00001498_5_T0	COMPOUND	8	8	paclitaxel
NCT000014985	NCT00001498_5_T1	COMPOUND	19	19	vinblastine
NCT000014985	NCT00001498_5_T2	COMPOUND	17	17	doxorubicin
NCT000014989	NCT00001498_9_T0	COMPOUND	11	11	5_fluorouracil
NCT000014989	NCT00001498_9_T1	COMPOUND	8	8	methotrexate
NCT000014989	NCT00001498_9_T2	COMPOUND	9	9	leucovorin
NCT0000149812	NCT00001498_12_T0	COMPOUND	10	10	cyclophosphamide
NCT0000149813	NCT00001498_13_T0	COMPOUND	9	9	thiotepa
NCT0000149814	NCT00001498_14_T0	COMPOUND	17	17	thiotepa
NCT0000149814	NCT00001498_14_T1	COMPOUND	9	9	cyclophosphamide
NCT0000149814	NCT00001498_14_T2	ORGAN	22	23	bone marrow
NCT0000149814	NCT00001498_14_T3	CELL	0	2	Hematopoietic stem cells
NCT0000149815	NCT00001498_15_T0	COMPOUND	15	15	paclitaxel
NCT0000149815	NCT00001498_15_T1	COMPOUND	28	28	doxorubicin
NCT0000149817	NCT00001498_17_T0	GENE	3	3	II
NCT0000149817	NCT00001498_17_T1	GENE	5	5	III
NCT0000149818	NCT00001498_18_T0	GENE	22	22	MDR1
NCT0000149818	NCT00001498_18_T1	BIOLOGICAL_PROCESS	19	19	transduction
NCT0000149818	NCT00001498_18_T2	COMPOUND	24	24	NeoR
NCT0000149820	NCT00001498_20_T0	PHENOTYPE	3	3	tumor
NCT0000149820	NCT00001498_20_T1	PHENOTYPE	15	15	tumor
NCT0000149821	NCT00001498_21_T0	PHENOTYPE	1	1	tumor
NCT0000149822	NCT00001498_22_T0	PHENOTYPE	4	5	CNS metastases
NCT0000149823	NCT00001498_23_T0	GENE	19	19	RT
NCT0000149823	NCT00001498_23_T1	PHENOTYPE	24	24	tumor
NCT0000149823	NCT00001498_23_T2	PHENOTYPE	33	33	tumor
NCT0000149823	NCT00001498_23_T3	GENE	2	2	ARM
NCT0000149823	NCT00001498_23_T4	GENE	20	20	PCR
NCT0000149823	NCT00001498_23_T5	GENE	25	26	fusion protein
NCT0000149824	NCT00001498_24_T0	GENE	1	1	RT
NCT0000149824	NCT00001498_24_T1	GENE	2	2	PCR
NCT0000149824	NCT00001498_24_T2	PHENOTYPE	8	9	tumor recurrence
NCT0000149825	NCT00001498_25_T0	PHENOTYPE	4	4	tumor
NCT0000149826	NCT00001498_26_T0	GENE	19	19	AR
NCT0000149826	NCT00001498_26_T1	GENE	0	0	ARM
NCT0000149826	NCT00001498_26_T2	PHENOTYPE	3	4	Tumor recurrence
NCT0000149828	NCT00001498_28_T0	PHENOTYPE	12	12	toxic
NCT0000149828	NCT00001498_28_T1	PHENOTYPE	11	11	acute
NCT0000149829	NCT00001498_29_T0	COMPOUND	2	2	estrogen
NCT0000149830	NCT00001498_30_T0	GENE	2	2	Age
NCT0000149830	NCT00001498_30_T1	PHENOTYPE	10	11	alveolar rhabdomyosarcoma
NCT0000149832	NCT00001498_32_T0	GENE	3	3	0.2
NCT0000149834	NCT00001498_34_T0	GENE	1	1	ANC
NCT0000149835	NCT00001498_35_T0	GENE	3	3	9.0
NCT0000149836	NCT00001498_36_T0	PHENOTYPE	0	1	Platelet count
NCT0000149837	NCT00001498_37_T0	GENE	4	4	2.0
NCT0000149837	NCT00001498_37_T1	PHENOTYPE	11	11	tumor
NCT0000149838	NCT00001498_38_T0	PHENOTYPE	11	11	tumor
NCT0000149839	NCT00001498_39_T0	COMPOUND	7	7	creatinine
NCT0000149839	NCT00001498_39_T1	GENE	4	4	1.5
NCT0000149840	NCT00001498_40_T0	PHENOTYPE	3	6	disorder of cardiovascular system
NCT0000149844	NCT00001498_44_T0	PHENOTYPE	0	0	HIV
NCT0000149845	NCT00001498_45_T0	PHENOTYPE	0	1	Hepatitis B
NCT000014992	NCT00001499_2_T0	GENE	11	11	4.15
NCT000014992	NCT00001499_2_T1	GENE	1	1	TAX
NCT000014995	NCT00001499_5_T0	GENE	5	5	II
NCT000014995	NCT00001499_5_T1	COMPOUND	18	18	paclitaxel
NCT000014995	NCT00001499_5_T2	COMPOUND	21	21	cisplatin
NCT000014995	NCT00001499_5_T3	PHENOTYPE	25	27	stage III NSCLC
NCT000014997	NCT00001499_7_T0	COMPOUND	19	19	paclitaxel
NCT000014997	NCT00001499_7_T1	PHENOTYPE	17	17	tumors
NCT000014997	NCT00001499_7_T2	COMPOUND	21	21	cisplatin
NCT000014997	NCT00001499_7_T3	PHENOTYPE	9	10	p53 mutation
NCT000014998	NCT00001499_8_T0	COMPOUND	6	6	paclitaxel
NCT000014998	NCT00001499_8_T1	COMPOUND	14	14	paclitaxel
NCT000014998	NCT00001499_8_T2	CELL	19	19	cells
NCT000014998	NCT00001499_8_T3	PHENOTYPE	18	18	tumor
NCT000014998	NCT00001499_8_T4	ORGAN	3	3	plasma
NCT000014999	NCT00001499_9_T0	COMPOUND	19	19	paclitaxel
NCT000014999	NCT00001499_9_T1	PHENOTYPE	17	17	concentrations
NCT000014999	NCT00001499_9_T2	ORGAN	16	16	plasma
NCT000014999	NCT00001499_9_T3	GENE	9	9	p53
NCT0000149911	NCT00001499_11_T0	ORGAN	6	6	thorax
NCT0000149911	NCT00001499_11_T1	PHENOTYPE	21	22	stage III
NCT0000149912	NCT00001499_12_T0	PHENOTYPE	11	11	relapse
NCT0000149912	NCT00001499_12_T1	PHENOTYPE	19	20	stage III
NCT0000149913	NCT00001499_13_T0	PHENOTYPE	2	2	tumor
NCT0000149913	NCT00001499_13_T1	GENE	0	0	T3
NCT0000149913	NCT00001499_13_T2	ORGAN	7	8	chest wall
NCT0000149914	NCT00001499_14_T0	PHENOTYPE	5	6	pleural effusion
NCT0000149915	NCT00001499_15_T0	PHENOTYPE	2	2	carcinoid
NCT0000149915	NCT00001499_15_T1	PHENOTYPE	4	4	mesothelioma
NCT0000149918	NCT00001499_18_T0	GENE	2	2	Age
NCT0000149919	NCT00001499_19_T0	GENE	3	3	0.2
NCT0000149920	NCT00001499_20_T0	GENE	1	1	AGC
NCT0000149921	NCT00001499_21_T0	CELL	0	0	Platelets
NCT0000149922	NCT00001499_22_T0	GENE	5	5	1.5
NCT0000149923	NCT00001499_23_T0	GENE	5	5	1.5
NCT0000149924	NCT00001499_24_T0	PHENOTYPE	25	25	dysrhythmia
NCT0000149924	NCT00001499_24_T1	GENE	31	31	ventricular
NCT0000149924	NCT00001499_24_T2	PHENOTYPE	14	14	arrhythmias
NCT0000149924	NCT00001499_24_T3	PHENOTYPE	32	32	tachycardia
NCT0000149924	NCT00001499_24_T4	PHENOTYPE	28	28	bradycardia
NCT0000149924	NCT00001499_24_T5	PHENOTYPE	33	34	Myocardial infarction
NCT0000149924	NCT00001499_24_T6	PHENOTYPE	19	20	heart block
NCT0000149924	NCT00001499_24_T7	PHENOTYPE	3	4	heart disease
NCT0000149925	NCT00001499_25_T0	ORGAN	10	10	bronchus
NCT0000149926	NCT00001499_26_T0	PHENOTYPE	4	5	psychiatric problem
NCT0000149927	NCT00001499_27_T0	PHENOTYPE	2	3	second malignancy
NCT0000149927	NCT00001499_27_T1	PHENOTYPE	9	10	skin cancer
NCT0000149927	NCT00001499_27_T2	PHENOTYPE	13	16	carcinoma of the cervix
NCT000015001	NCT00001500_1_T0	PHENOTYPE	14	14	HIV/AIDS
NCT000015001	NCT00001500_1_T1	PHENOTYPE	17	17	progression
NCT000015003	NCT00001500_3_T0	PHENOTYPE	12	12	HIV
NCT000015003	NCT00001500_3_T1	PHENOTYPE	15	15	progression
NCT000015007	NCT00001500_7_T0	PHENOTYPE	14	14	HIV/AIDS
NCT000015007	NCT00001500_7_T1	PHENOTYPE	17	17	progression
NCT000015009	NCT00001500_9_T0	PHENOTYPE	12	12	HIV
NCT000015009	NCT00001500_9_T1	PHENOTYPE	15	15	progression
NCT0000150014	NCT00001500_14_T0	PHENOTYPE	13	13	Center
NCT000015022	NCT00001502_2_T0	GENE	10	10	B2
NCT000015022	NCT00001502_2_T1	PHENOTYPE	26	26	tumors
NCT000015022	NCT00001502_2_T2	ORGAN	22	22	capillary
NCT000015022	NCT00001502_2_T3	COMPOUND	3	4	synthetic bradykinin
NCT000015022	NCT00001502_2_T4	CELL	16	18	capillary endothelial cells
NCT000015023	NCT00001502_3_T0	PHENOTYPE	15	16	brain tumors
NCT000015024	NCT00001502_4_T0	PHENOTYPE	27	28	brain tumors
NCT000015026	NCT00001502_6_T0	GENE	10	10	B2
NCT000015026	NCT00001502_6_T1	PHENOTYPE	26	26	tumors
NCT000015026	NCT00001502_6_T2	ORGAN	22	22	capillary
NCT000015026	NCT00001502_6_T3	COMPOUND	3	4	synthetic bradykinin
NCT000015026	NCT00001502_6_T4	CELL	16	18	capillary endothelial cells
NCT000015027	NCT00001502_7_T0	PHENOTYPE	15	16	brain tumors
NCT000015028	NCT00001502_8_T0	PHENOTYPE	27	28	brain tumors
NCT0000150211	NCT00001502_11_T0	PHENOTYPE	10	10	progression
NCT0000150211	NCT00001502_11_T1	PHENOTYPE	2	3	evaluable disease
NCT0000150216	NCT00001502_16_T0	PHENOTYPE	2	2	toxic
NCT0000150217	NCT00001502_17_T0	GENE	2	2	Age
NCT0000150218	NCT00001502_18_T0	GENE	3	3	0.2
NCT0000150220	NCT00001502_20_T0	CELL	2	2	granulocyte
NCT0000150221	NCT00001502_21_T0	PHENOTYPE	0	1	Platelet count
NCT0000150221	NCT00001502_21_T1	ORGAN	12	13	bone marrow
NCT0000150222	NCT00001502_22_T0	GENE	3	3	8.0
NCT0000150226	NCT00001502_26_T0	PHENOTYPE	3	4	systemic illness
NCT0000150228	NCT00001502_28_T0	PHENOTYPE	0	2	Negative pregnancy test
NCT000015030	NCT00001503_0_T0	PHENOTYPE	6	6	Disease
NCT000015035	NCT00001503_5_T0	GENE	8	8	CCR
NCT000015035	NCT00001503_5_T1	COMPOUND	18	18	NCI
NCT000015039	NCT00001503_9_T0	COMPOUND	10	10	NCI
NCT000015041	NCT00001504_1_T0	COMPOUND	18	18	tamoxifen
NCT000015042	NCT00001504_2_T0	COMPOUND	9	9	tamoxifen
NCT000015044	NCT00001504_4_T0	PHENOTYPE	29	29	toxicities
NCT000015045	NCT00001504_5_T0	PHENOTYPE	45	45	carcinogenesis
NCT000015045	NCT00001504_5_T1	PHENOTYPE	20	20	tumor
NCT000015045	NCT00001504_5_T2	PHENOTYPE	12	12	pharmacokinetics
NCT000015047	NCT00001504_7_T0	GENE	14	14	PR
NCT000015047	NCT00001504_7_T1	GENE	9	9	receptor
NCT000015047	NCT00001504_7_T2	PHENOTYPE	16	16	tumor
NCT000015047	NCT00001504_7_T3	GENE	5	5	has
NCT000015047	NCT00001504_7_T4	GENE	10	10	ER
NCT000015047	NCT00001504_7_T5	PHENOTYPE	2	3	stage III
NCT000015047	NCT00001504_7_T6	GENE	12	13	progesterone receptor
NCT000015048	NCT00001504_8_T0	PHENOTYPE	4	4	tumor
NCT000015049	NCT00001504_9_T0	PHENOTYPE	9	9	tumor
NCT000015049	NCT00001504_9_T1	GENE	4	4	IV
NCT0000150410	NCT00001504_10_T0	PHENOTYPE	3	3	pseudotumor
NCT0000150410	NCT00001504_10_T1	PHENOTYPE	6	6	seizures
NCT0000150410	NCT00001504_10_T2	PHENOTYPE	1	2	CNS metastases
NCT0000150411	NCT00001504_11_T0	PHENOTYPE	8	8	toxic
NCT0000150412	NCT00001504_12_T0	COMPOUND	3	3	tamoxifen
NCT0000150414	NCT00001504_14_T0	GENE	2	2	Age
NCT0000150416	NCT00001504_16_T0	PHENOTYPE	0	0	Menopausal
NCT0000150417	NCT00001504_17_T0	GENE	8	8	0.2
NCT0000150418	NCT00001504_18_T0	GENE	6	6	ANC
NCT0000150419	NCT00001504_19_T0	PHENOTYPE	0	1	Platelet count
NCT0000150420	NCT00001504_20_T0	PHENOTYPE	10	10	tumor
NCT0000150420	NCT00001504_20_T1	COMPOUND	25	25	phosphate
NCT0000150421	NCT00001504_21_T0	COMPOUND	7	7	creatinine
NCT0000150421	NCT00001504_21_T1	GENE	13	13	OR
NCT0000150421	NCT00001504_21_T2	GENE	11	11	1.5
NCT0000150421	NCT00001504_21_T3	ORGAN	6	6	Serum
NCT0000150422	NCT00001504_22_T0	PHENOTYPE	2	2	allergy
NCT0000150422	NCT00001504_22_T1	PHENOTYPE	0	0	Other
NCT0000150423	NCT00001504_23_T0	PHENOTYPE	2	3	systemic disease
NCT0000150425	NCT00001504_25_T0	PHENOTYPE	0	3	Cervical carcinoma in situ
NCT0000150427	NCT00001504_27_T0	PHENOTYPE	0	2	Negative pregnancy test
NCT000015051	NCT00001505_1_T0	PHENOTYPE	21	21	diseases
NCT000015055	NCT00001505_5_T0	PHENOTYPE	21	21	diseases
NCT000015062	NCT00001506_2_T0	PHENOTYPE	23	24	disease progression
NCT000015064	NCT00001506_4_T0	PHENOTYPE	16	16	opinions
NCT000015065	NCT00001506_5_T0	GENE	9	9	CCR
NCT000015065	NCT00001506_5_T1	COMPOUND	8	8	NCI
NCT000015067	NCT00001506_7_T0	PHENOTYPE	11	12	dermatologic disease
NCT000015067	NCT00001506_7_T1	PHENOTYPE	14	15	systemic disease
NCT000015069	NCT00001506_9_T0	PHENOTYPE	23	24	disease progression
NCT000015072	NCT00001507_2_T0	PHENOTYPE	16	16	metastasized
NCT000015072	NCT00001507_2_T1	GENE	14	14	has
NCT000015072	NCT00001507_2_T2	PHENOTYPE	10	12	inflammatory breast cancer
NCT000015074	NCT00001507_4_T0	COMPOUND	30	30	MUGA
NCT000015074	NCT00001507_4_T1	ORGAN	9	9	abdomen
NCT000015074	NCT00001507_4_T2	ORGAN	11	11	pelvis
NCT0000150712	NCT00001507_12_T0	ORGAN	12	12	bladder
NCT0000150712	NCT00001507_12_T1	COMPOUND	16	16	cyclophosphamide
NCT0000150721	NCT00001507_21_T0	GENE	10	10	has
NCT0000150723	NCT00001507_23_T0	PHENOTYPE	13	15	Inflammatory Breast Cancer
NCT0000150724	NCT00001507_24_T0	PHENOTYPE	20	22	Inflammatory Breast Cancer
NCT0000150725	NCT00001507_25_T0	BIOLOGICAL_PROCESS	22	22	regeneration
NCT0000150725	NCT00001507_25_T1	CELL	9	9	T-cells
NCT0000150725	NCT00001507_25_T2	CELL	10	10	T-cell
NCT0000150725	NCT00001507_25_T3	CELL	21	21	T-cell
NCT0000150726	NCT00001507_26_T0	PHENOTYPE	10	11	stage III
NCT0000150726	NCT00001507_26_T1	PHENOTYPE	7	9	Inflammatory Breast Cancer
NCT0000150728	NCT00001507_28_T0	PHENOTYPE	20	20	peripheral
NCT0000150728	NCT00001507_28_T1	PHENOTYPE	27	27	intent
NCT0000150728	NCT00001507_28_T2	CELL	22	23	progenitor cells
NCT0000150730	NCT00001507_30_T0	CELL	18	18	granulocytes
NCT0000150730	NCT00001507_30_T1	PHENOTYPE	13	13	peripheral
NCT0000150730	NCT00001507_30_T2	GENE	20	20	G-CSF
NCT0000150730	NCT00001507_30_T3	CELL	15	16	progenitor cells
NCT0000150732	NCT00001507_32_T0	PHENOTYPE	11	11	Carcinoma
NCT0000150732	NCT00001507_32_T1	PHENOTYPE	12	13	stage III
NCT0000150734	NCT00001507_34_T0	PHENOTYPE	2	3	metastatic disease
NCT0000150734	NCT00001507_34_T1	PHENOTYPE	5	7	Inflammatory Breast Carcinoma
NCT0000150735	NCT00001507_35_T0	PHENOTYPE	25	25	pathology
NCT0000150736	NCT00001507_36_T0	COMPOUND	13	13	NCI
NCT0000150740	NCT00001507_40_T0	COMPOUND	3	3	MUGA
NCT0000150743	NCT00001507_43_T0	GENE	3	3	1.5
NCT0000150743	NCT00001507_43_T1	PHENOTYPE	8	9	Gilbert's disease
NCT0000150744	NCT00001507_44_T0	GENE	0	0	ANC
NCT0000150745	NCT00001507_45_T0	PHENOTYPE	0	1	Platelet count
NCT0000150747	NCT00001507_47_T0	PHENOTYPE	5	6	psychiatric disease
NCT0000150748	NCT00001507_48_T0	PHENOTYPE	10	10	infections
NCT0000150748	NCT00001507_48_T1	PHENOTYPE	4	5	bleeding tendency
NCT0000150748	NCT00001507_48_T2	PHENOTYPE	3	4	abnormal bleeding
NCT0000150752	NCT00001507_52_T0	PHENOTYPE	9	9	anticoagulation
NCT0000150752	NCT00001507_52_T1	PHENOTYPE	6	6	chronic
NCT0000150753	NCT00001507_53_T0	PHENOTYPE	5	5	HIV
NCT0000150753	NCT00001507_53_T1	PHENOTYPE	8	9	hepatitis B
NCT0000150756	NCT00001507_56_T0	PHENOTYPE	12	12	carcinoma
NCT0000150756	NCT00001507_56_T1	PHENOTYPE	5	6	second malignancy
NCT0000150756	NCT00001507_56_T2	PHENOTYPE	9	10	skin cancers
NCT000015090	NCT00001509_0_T0	GENE	2	2	II
NCT000015090	NCT00001509_0_T1	PHENOTYPE	19	19	Tumor
NCT000015090	NCT00001509_0_T2	GENE	11	11	2a
NCT000015090	NCT00001509_0_T3	PHENOTYPE	15	16	Recurrent Neuroblastoma
NCT000015093	NCT00001509_3_T0	GENE	20	20	IFN-alpha
NCT000015093	NCT00001509_3_T1	PHENOTYPE	33	33	malignancies
NCT000015097	NCT00001509_7_T0	PHENOTYPE	13	13	concentrations
NCT000015097	NCT00001509_7_T1	ORGAN	12	12	plasma
NCT000015098	NCT00001509_8_T0	PHENOTYPE	19	19	tumor
NCT000015098	NCT00001509_8_T1	PHENOTYPE	16	16	neuroblastoma
NCT000015098	NCT00001509_8_T2	GENE	5	5	has
NCT000015098	NCT00001509_8_T3	GENE	4	4	2a
NCT000015099	NCT00001509_9_T0	GENE	20	20	IFN-alpha
NCT000015099	NCT00001509_9_T1	PHENOTYPE	33	33	malignancies
NCT0000150912	NCT00001509_12_T0	PHENOTYPE	21	21	tumor
NCT0000150912	NCT00001509_12_T1	PHENOTYPE	18	18	neuroblastoma
NCT0000150913	NCT00001509_13_T0	PHENOTYPE	5	6	measurable disease
NCT0000150914	NCT00001509_14_T0	GENE	27	27	MRI
NCT0000150914	NCT00001509_14_T1	PHENOTYPE	2	3	evaluable disease
NCT0000150914	NCT00001509_14_T2	ORGAN	12	13	bone marrow
NCT0000150915	NCT00001509_15_T0	PHENOTYPE	7	8	progressive disease
NCT0000150916	NCT00001509_16_T0	PHENOTYPE	11	11	toxicity
NCT0000150917	NCT00001509_17_T0	PHENOTYPE	26	26	toxicity
NCT0000150917	NCT00001509_17_T1	PHENOTYPE	6	6	tumor
NCT0000150917	NCT00001509_17_T2	ORGAN	2	3	bone marrow
NCT0000150918	NCT00001509_18_T0	PHENOTYPE	4	4	toxicity
NCT0000150918	NCT00001509_18_T1	PHENOTYPE	13	13	peripheral
NCT0000150918	NCT00001509_18_T2	GENE	24	24	8.0
NCT0000150918	NCT00001509_18_T3	GENE	21	21	hemoglobin
NCT0000150918	NCT00001509_18_T4	CELL	15	15	granulocyte
NCT0000150918	NCT00001509_18_T5	ORGAN	8	9	bone marrow
NCT0000150918	NCT00001509_18_T6	PHENOTYPE	27	28	platelet count
NCT0000150919	NCT00001509_19_T0	GENE	11	11	2.0
NCT0000150919	NCT00001509_19_T1	ORGAN	6	6	liver
NCT0000150919	NCT00001509_19_T2	COMPOUND	8	8	bilirubin
NCT0000150921	NCT00001509_21_T0	PHENOTYPE	10	10	toxic
NCT0000150923	NCT00001509_23_T0	PHENOTYPE	4	5	malignant disease
NCT0000150923	NCT00001509_23_T1	PHENOTYPE	8	9	pseudotumor cerebri
NCT0000150924	NCT00001509_24_T0	COMPOUND	6	7	retinoic acid
NCT000015123	NCT00001512_3_T0	GENE	47	47	polymerase
NCT000015123	NCT00001512_3_T1	PHENOTYPE	21	21	lymphoma
NCT000015123	NCT00001512_3_T2	GENE	55	55	oncogene
NCT000015123	NCT00001512_3_T3	GENE	54	54	bcl-2
NCT000015123	NCT00001512_3_T4	CELL	39	39	cells
NCT000015123	NCT00001512_3_T5	ORGAN	35	36	bone marrow
NCT000015124	NCT00001512_4_T0	PHENOTYPE	16	16	remission
NCT000015124	NCT00001512_4_T1	PHENOTYPE	12	13	follicular lymphomas
NCT000015124	NCT00001512_4_T2	PHENOTYPE	18	20	minimal residual disease
NCT000015125	NCT00001512_5_T0	PHENOTYPE	14	14	relapse
NCT000015125	NCT00001512_5_T1	PHENOTYPE	20	20	resistant
NCT000015125	NCT00001512_5_T2	GENE	34	34	GM-CSF
NCT000015126	NCT00001512_6_T0	GENE	1	1	0.5
NCT000015127	NCT00001512_7_T0	GENE	0	0	GM-CSF
NCT0000151215	NCT00001512_15_T0	GENE	47	47	polymerase
NCT0000151215	NCT00001512_15_T1	PHENOTYPE	21	21	lymphoma
NCT0000151215	NCT00001512_15_T2	GENE	55	55	oncogene
NCT0000151215	NCT00001512_15_T3	GENE	54	54	bcl-2
NCT0000151215	NCT00001512_15_T4	CELL	39	39	cells
NCT0000151215	NCT00001512_15_T5	ORGAN	35	36	bone marrow
NCT0000151216	NCT00001512_16_T0	PHENOTYPE	16	16	remission
NCT0000151216	NCT00001512_16_T1	PHENOTYPE	12	13	follicular lymphomas
NCT0000151216	NCT00001512_16_T2	PHENOTYPE	18	20	minimal residual disease
NCT0000151217	NCT00001512_17_T0	PHENOTYPE	14	14	relapse
NCT0000151217	NCT00001512_17_T1	PHENOTYPE	20	20	resistant
NCT0000151217	NCT00001512_17_T2	GENE	34	34	GM-CSF
NCT0000151218	NCT00001512_18_T0	GENE	1	1	0.5
NCT0000151219	NCT00001512_19_T0	GENE	0	0	GM-CSF
NCT0000151223	NCT00001512_23_T0	PHENOTYPE	4	4	lymphoma
NCT0000151223	NCT00001512_23_T1	GENE	1	1	III
NCT0000151223	NCT00001512_23_T2	GENE	3	3	IV
NCT0000151226	NCT00001512_26_T0	PHENOTYPE	2	2	peripheral
NCT0000151226	NCT00001512_26_T1	GENE	9	9	cm
NCT0000151226	NCT00001512_26_T2	TISSUE	3	4	lymph node
NCT0000151230	NCT00001512_30_T0	PHENOTYPE	12	12	secondary
NCT0000151230	NCT00001512_30_T1	GENE	6	6	1.5
NCT0000151230	NCT00001512_30_T2	PHENOTYPE	14	14	lymphoma
NCT0000151230	NCT00001512_30_T3	PHENOTYPE	16	17	Gilbert's disease
NCT0000151231	NCT00001512_31_T0	GENE	6	6	3.5
NCT0000151235	NCT00001512_35_T0	PHENOTYPE	4	4	HIV
NCT0000151235	NCT00001512_35_T1	PHENOTYPE	5	6	hepatitis B
NCT0000151236	NCT00001512_36_T0	BIOLOGICAL_PROCESS	2	2	lactation
NCT0000151243	NCT00001512_43_T0	PHENOTYPE	3	3	lymphoma
NCT000015152	NCT00001515_2_T0	ORGAN	20	20	trachea
NCT000015152	NCT00001515_2_T1	ORGAN	22	22	bronchi
NCT000015153	NCT00001515_3_T0	GENE	3	3	lets
NCT000015153	NCT00001515_3_T1	PHENOTYPE	11	11	narrowing
NCT000015158	NCT00001515_8_T0	COMPOUND	7	7	oxygen
NCT0000151514	NCT00001515_14_T0	PHENOTYPE	13	13	understood
NCT0000151515	NCT00001515_15_T0	PHENOTYPE	5	5	stenotic
NCT0000151517	NCT00001515_17_T0	GENE	22	22	had
NCT0000151519	NCT00001515_19_T0	ORGAN	8	8	thorax
NCT0000151525	NCT00001515_25_T0	PHENOTYPE	10	10	disorders
NCT0000151528	NCT00001515_28_T0	ORGAN	12	12	thorax
NCT0000151528	NCT00001515_28_T1	PHENOTYPE	6	6	malignancies
NCT0000151528	NCT00001515_28_T2	PHENOTYPE	8	9	metastatic disease
NCT0000151528	NCT00001515_28_T3	PHENOTYPE	2	3	bronchogenic carcinoma
NCT0000151529	NCT00001515_29_T0	PHENOTYPE	15	15	suspicion
NCT0000151529	NCT00001515_29_T1	PHENOTYPE	20	21	bronchial disease
NCT0000151611	NCT00001516_11_T0	PHENOTYPE	10	10	affects
NCT000015180	NCT00001518_0_T0	PHENOTYPE	10	10	Flush
NCT000015182	NCT00001518_2_T0	PHENOTYPE	15	15	occlusion
NCT000015182	NCT00001518_2_T1	PHENOTYPE	19	19	flushed
NCT000015185	NCT00001518_5_T0	PHENOTYPE	8	8	flushed
NCT000015186	NCT00001518_6_T0	PHENOTYPE	20	20	occlusion
NCT000015187	NCT00001518_7_T0	PHENOTYPE	4	4	flushes
NCT000015187	NCT00001518_7_T1	PHENOTYPE	14	14	flushes
NCT000015187	NCT00001518_7_T2	PHENOTYPE	21	21	flushes
NCT000015187	NCT00001518_7_T3	PHENOTYPE	32	32	flushes
NCT0000151810	NCT00001518_10_T0	PHENOTYPE	15	15	occlusion
NCT0000151810	NCT00001518_10_T1	PHENOTYPE	19	19	flushed
NCT0000151813	NCT00001518_13_T0	PHENOTYPE	8	8	flushed
NCT0000151814	NCT00001518_14_T0	PHENOTYPE	20	20	occlusion
NCT0000151815	NCT00001518_15_T0	PHENOTYPE	4	4	flushes
NCT0000151815	NCT00001518_15_T1	PHENOTYPE	14	14	flushes
NCT0000151815	NCT00001518_15_T2	PHENOTYPE	21	21	flushes
NCT0000151815	NCT00001518_15_T3	PHENOTYPE	32	32	flushes
NCT0000151818	NCT00001518_18_T0	COMPOUND	8	8	heparin
NCT0000151818	NCT00001518_18_T1	PHENOTYPE	6	6	allergy
NCT000015193	NCT00001519_3_T0	GENE	32	32	delta
NCT000015193	NCT00001519_3_T1	GENE	21	21	LT
NCT000015193	NCT00001519_3_T2	GENE	28	28	LT
NCT000015194	NCT00001519_4_T0	PHENOTYPE	19	19	repetitions
NCT000015194	NCT00001519_4_T1	GENE	6	6	span
NCT000015195	NCT00001519_5_T0	PHENOTYPE	17	17	regression
NCT000015196	NCT00001519_6_T0	GENE	30	30	delta
NCT000015196	NCT00001519_6_T1	GENE	27	27	LT
NCT0000151912	NCT00001519_12_T0	GENE	32	32	delta
NCT0000151912	NCT00001519_12_T1	GENE	21	21	LT
NCT0000151912	NCT00001519_12_T2	GENE	28	28	LT
NCT0000151913	NCT00001519_13_T0	PHENOTYPE	19	19	repetitions
NCT0000151913	NCT00001519_13_T1	GENE	6	6	span
NCT0000151914	NCT00001519_14_T0	PHENOTYPE	17	17	regression
NCT0000151915	NCT00001519_15_T0	GENE	30	30	delta
NCT0000151915	NCT00001519_15_T1	GENE	27	27	LT
NCT000015202	NCT00001520_2_T0	GENE	5	5	neuromuscular
NCT000015202	NCT00001520_2_T1	PHENOTYPE	15	15	paralysis
NCT000015202	NCT00001520_2_T2	PHENOTYPE	28	28	paralysis
NCT000015203	NCT00001520_3_T0	GENE	15	15	neuromuscular
NCT000015203	NCT00001520_3_T1	PHENOTYPE	20	20	pharmacodynamic
NCT000015205	NCT00001520_5_T0	PHENOTYPE	2	2	paralysis
NCT000015205	NCT00001520_5_T1	COMPOUND	1	1	rocuronium
NCT000015206	NCT00001520_6_T0	PHENOTYPE	16	16	attachment
NCT000015206	NCT00001520_6_T1	GENE	18	18	acetylcholinesterase
NCT000015206	NCT00001520_6_T2	COMPOUND	10	10	acetylcholine
NCT000015206	NCT00001520_6_T3	COMPOUND	14	14	acetylcholine
NCT000015208	NCT00001520_8_T0	PHENOTYPE	19	19	paralysis
NCT000015208	NCT00001520_8_T1	COMPOUND	18	18	rocuronium
NCT000015208	NCT00001520_8_T2	COMPOUND	11	11	neostigmine
NCT0000152010	NCT00001520_10_T0	GENE	5	5	neuromuscular
NCT0000152010	NCT00001520_10_T1	PHENOTYPE	15	15	paralysis
NCT0000152010	NCT00001520_10_T2	PHENOTYPE	28	28	paralysis
NCT0000152011	NCT00001520_11_T0	GENE	15	15	neuromuscular
NCT0000152011	NCT00001520_11_T1	PHENOTYPE	20	20	pharmacodynamic
NCT0000152013	NCT00001520_13_T0	PHENOTYPE	2	2	paralysis
NCT0000152013	NCT00001520_13_T1	COMPOUND	1	1	rocuronium
NCT0000152014	NCT00001520_14_T0	PHENOTYPE	16	16	attachment
NCT0000152014	NCT00001520_14_T1	GENE	18	18	acetylcholinesterase
NCT0000152014	NCT00001520_14_T2	COMPOUND	10	10	acetylcholine
NCT0000152014	NCT00001520_14_T3	COMPOUND	14	14	acetylcholine
NCT0000152016	NCT00001520_16_T0	PHENOTYPE	19	19	paralysis
NCT0000152016	NCT00001520_16_T1	COMPOUND	18	18	rocuronium
NCT0000152016	NCT00001520_16_T2	COMPOUND	11	11	neostigmine
NCT000015210	NCT00001521_0_T0	PHENOTYPE	10	12	Congenital Adrenal Hyperplasia
NCT000015214	NCT00001521_4_T0	COMPOUND	11	11	hydrocortisone
NCT000015214	NCT00001521_4_T1	COMPOUND	13	13	fludrocortisone
NCT000015214	NCT00001521_4_T2	PHENOTYPE	8	10	congenital adrenal hyperplasia
NCT000015215	NCT00001521_5_T0	PHENOTYPE	32	34	congenital adrenal hyperplasia
NCT000015216	NCT00001521_6_T0	COMPOUND	32	32	flutamide
NCT000015216	NCT00001521_6_T1	PHENOTYPE	28	30	congenital adrenal hyperplasia
NCT0000152111	NCT00001521_11_T0	COMPOUND	16	16	flutamide
NCT0000152112	NCT00001521_12_T0	COMPOUND	2	2	flutamide
NCT0000152112	NCT00001521_12_T1	BIOLOGICAL_PROCESS	10	10	menarche
NCT000015223	NCT00001522_3_T0	PHENOTYPE	9	9	diseases
NCT000015223	NCT00001522_3_T1	PHENOTYPE	16	16	obesity
NCT000015224	NCT00001522_4_T0	PHENOTYPE	7	7	obesity
NCT000015224	NCT00001522_4_T1	PHENOTYPE	13	13	obesity
NCT000015224	NCT00001522_4_T2	PHENOTYPE	10	11	associated conditions
NCT000015225	NCT00001522_5_T0	COMPOUND	24	24	glucose
NCT000015225	NCT00001522_5_T1	BIOLOGICAL_PROCESS	28	28	metabolism
NCT000015225	NCT00001522_5_T2	PHENOTYPE	17	17	obesity
NCT000015225	NCT00001522_5_T3	PHENOTYPE	22	23	insulin sensitivity
NCT000015228	NCT00001522_8_T0	PHENOTYPE	16	16	obesity
NCT0000152211	NCT00001522_11_T0	PHENOTYPE	21	21	obesity
NCT0000152211	NCT00001522_11_T1	PHENOTYPE	6	7	energy expenditure
NCT0000152211	NCT00001522_11_T2	BIOLOGICAL_PROCESS	8	9	glucose metabolism
NCT0000152222	NCT00001522_22_T0	PHENOTYPE	2	3	psychiatric illness
NCT0000152226	NCT00001522_26_T0	GENE	6	6	MRI
NCT0000152227	NCT00001522_27_T0	GENE	10	10	MRI
NCT0000152232	NCT00001522_32_T0	PHENOTYPE	24	26	negative pregnancy test
NCT000015230	NCT00001523_0_T0	TISSUE	5	6	Parotid Glands
NCT000015232	NCT00001523_2_T0	PHENOTYPE	6	6	hypofunction
NCT000015232	NCT00001523_2_T1	GENE	30	30	has
NCT000015232	NCT00001523_2_T2	TISSUE	28	29	parenchymal tissue
NCT000015234	NCT00001523_4_T0	GENE	12	12	structural
NCT000015234	NCT00001523_4_T1	TISSUE	18	19	parotid glands
NCT000015236	NCT00001523_6_T0	GENE	53	53	MRI
NCT000015236	NCT00001523_6_T1	COMPOUND	41	41	99mTcO4
NCT000015236	NCT00001523_6_T2	TISSUE	30	31	salivary gland
NCT000015236	NCT00001523_6_T3	TISSUE	45	46	salivary glands
NCT000015236	NCT00001523_6_T4	TISSUE	38	39	parotid gland
NCT000015236	NCT00001523_6_T5	TISSUE	57	58	parotid glands
NCT000015237	NCT00001523_7_T0	GENE	21	21	reduced
NCT000015237	NCT00001523_7_T1	TISSUE	22	23	parotid gland
NCT000015237	NCT00001523_7_T2	TISSUE	28	29	parenchymal tissue
NCT000015237	NCT00001523_7_T3	CELL	37	38	ductal cells
NCT000015238	NCT00001523_8_T0	PHENOTYPE	20	20	progressive
NCT000015238	NCT00001523_8_T1	PHENOTYPE	23	23	dysfunction
NCT000015238	NCT00001523_8_T2	TISSUE	15	16	connective tissue
NCT0000152310	NCT00001523_10_T0	PHENOTYPE	6	6	hypofunction
NCT0000152310	NCT00001523_10_T1	GENE	30	30	has
NCT0000152310	NCT00001523_10_T2	TISSUE	28	29	parenchymal tissue
NCT0000152312	NCT00001523_12_T0	GENE	12	12	structural
NCT0000152312	NCT00001523_12_T1	TISSUE	18	19	parotid glands
NCT0000152314	NCT00001523_14_T0	GENE	53	53	MRI
NCT0000152314	NCT00001523_14_T1	COMPOUND	41	41	99mTcO4
NCT0000152314	NCT00001523_14_T2	TISSUE	30	31	salivary gland
NCT0000152314	NCT00001523_14_T3	TISSUE	45	46	salivary glands
NCT0000152314	NCT00001523_14_T4	TISSUE	38	39	parotid gland
NCT0000152314	NCT00001523_14_T5	TISSUE	57	58	parotid glands
NCT0000152315	NCT00001523_15_T0	GENE	21	21	reduced
NCT0000152315	NCT00001523_15_T1	TISSUE	22	23	parotid gland
NCT0000152315	NCT00001523_15_T2	TISSUE	28	29	parenchymal tissue
NCT0000152315	NCT00001523_15_T3	CELL	37	38	ductal cells
NCT0000152316	NCT00001523_16_T0	PHENOTYPE	20	20	progressive
NCT0000152316	NCT00001523_16_T1	PHENOTYPE	23	23	dysfunction
NCT0000152316	NCT00001523_16_T2	TISSUE	15	16	connective tissue
NCT0000152318	NCT00001523_18_T0	PHENOTYPE	2	5	head and neck cancer
NCT0000152319	NCT00001523_19_T0	GENE	2	2	OR
NCT0000152319	NCT00001523_19_T1	TISSUE	5	6	parotid glands
NCT0000152320	NCT00001523_20_T0	GENE	8	8	Gy
NCT0000152322	NCT00001523_22_T0	GENE	1	1	OR
NCT0000152323	NCT00001523_23_T0	PHENOTYPE	1	1	Metastasis
NCT0000152324	NCT00001523_24_T0	PHENOTYPE	1	1	allergy
NCT0000152325	NCT00001523_25_T0	PHENOTYPE	1	1	allergy
NCT0000152327	NCT00001523_27_T0	PHENOTYPE	3	4	bleeding disorder
NCT0000152328	NCT00001523_28_T0	PHENOTYPE	6	6	xerostomia
NCT0000152328	NCT00001523_28_T1	PHENOTYPE	4	5	dry mouth
NCT0000152330	NCT00001523_30_T0	PHENOTYPE	1	1	HIV
NCT000015243	NCT00001524_3_T0	COMPOUND	11	11	thalidomide
NCT000015243	NCT00001524_3_T1	PHENOTYPE	19	19	sore
NCT000015245	NCT00001524_5_T0	PHENOTYPE	17	17	HIV/AIDS
NCT000015246	NCT00001524_6_T0	PHENOTYPE	1	1	HIV
NCT000015247	NCT00001524_7_T0	GENE	65	65	II
NCT000015247	NCT00001524_7_T1	PHENOTYPE	39	39	acute
NCT000015247	NCT00001524_7_T2	PHENOTYPE	57	57	allergy
NCT000015247	NCT00001524_7_T3	COMPOUND	19	19	lidocaine
NCT000015247	NCT00001524_7_T4	COMPOUND	28	28	thalidomide
NCT000015247	NCT00001524_7_T5	COMPOUND	59	59	thalidomide
NCT000015247	NCT00001524_7_T6	COMPOUND	82	82	thalidomide
NCT000015247	NCT00001524_7_T7	PHENOTYPE	36	36	neoplasms
NCT000015247	NCT00001524_7_T8	PHENOTYPE	61	62	peripheral neuropathy
NCT000015247	NCT00001524_7_T9	PHENOTYPE	42	43	opportunistic infections
NCT0000152411	NCT00001524_11_T0	COMPOUND	14	14	thalidomide
NCT0000152411	NCT00001524_11_T1	COMPOUND	18	18	thalidomide
NCT0000152412	NCT00001524_12_T0	COMPOUND	3	3	thalidomide
NCT0000152416	NCT00001524_16_T0	GENE	22	22	CD4
NCT0000152416	NCT00001524_16_T1	PHENOTYPE	17	17	HIV/AIDS
NCT0000152417	NCT00001524_17_T0	PHENOTYPE	1	1	HIV
NCT0000152418	NCT00001524_18_T0	GENE	69	69	II
NCT0000152418	NCT00001524_18_T1	PHENOTYPE	43	43	acute
NCT0000152418	NCT00001524_18_T2	GENE	2	2	FOR
NCT0000152418	NCT00001524_18_T3	PHENOTYPE	61	61	allergy
NCT0000152418	NCT00001524_18_T4	COMPOUND	24	24	lidocaine
NCT0000152418	NCT00001524_18_T5	COMPOUND	34	34	thalidomide
NCT0000152418	NCT00001524_18_T6	COMPOUND	63	63	thalidomide
NCT0000152418	NCT00001524_18_T7	PHENOTYPE	41	41	neoplasms
NCT0000152418	NCT00001524_18_T8	PHENOTYPE	46	47	opportunistic infection
NCT0000152418	NCT00001524_18_T9	PHENOTYPE	65	66	peripheral neuropathy
NCT0000152420	NCT00001524_20_T0	GENE	2	2	FOR
NCT0000152421	NCT00001524_21_T0	GENE	2	2	FOR
NCT0000152422	NCT00001524_22_T0	PHENOTYPE	2	2	acute
NCT0000152422	NCT00001524_22_T1	PHENOTYPE	6	6	infections
NCT0000152422	NCT00001524_22_T2	PHENOTYPE	4	4	chronic
NCT0000152425	NCT00001524_25_T0	PHENOTYPE	7	8	allergy medications
NCT000015260	NCT00001526_0_T0	GENE	2	2	FOR
NCT000015260	NCT00001526_0_T1	PHENOTYPE	3	3	UVEITIS
NCT000015263	NCT00001526_3_T0	PHENOTYPE	7	8	side effect
NCT000015264	NCT00001526_4_T0	GENE	3	3	has
NCT000015264	NCT00001526_4_T1	PHENOTYPE	15	16	posterior uveitis
NCT000015265	NCT00001526_5_T0	PHENOTYPE	19	19	uveitis
NCT000015265	NCT00001526_5_T1	GENE	15	15	IV
NCT000015265	NCT00001526_5_T2	GENE	1	1	extended
NCT000015266	NCT00001526_6_T0	GENE	2	2	SC
NCT000015266	NCT00001526_6_T1	GENE	18	18	SC
NCT000015266	NCT00001526_6_T2	GENE	28	28	IV
NCT000015267	NCT00001526_7_T0	GENE	8	8	SC
NCT000015268	NCT00001526_8_T0	GENE	5	5	SC
NCT000015268	NCT00001526_8_T1	GENE	14	14	IV
NCT000015269	NCT00001526_9_T0	GENE	0	0	SC
NCT000015269	NCT00001526_9_T1	GENE	6	6	SC
NCT0000152610	NCT00001526_10_T0	GENE	19	19	SC
NCT0000152611	NCT00001526_11_T0	GENE	7	7	HAT
NCT0000152611	NCT00001526_11_T1	GENE	19	21	interleukin 2 receptor
NCT0000152612	NCT00001526_12_T0	GENE	10	10	IV
NCT0000152613	NCT00001526_13_T0	GENE	1	1	SC
NCT0000152614	NCT00001526_14_T0	GENE	5	5	SC
NCT0000152614	NCT00001526_14_T1	PHENOTYPE	16	17	autoimmune disease
NCT0000152615	NCT00001526_15_T0	GENE	15	15	SC
NCT0000152615	NCT00001526_15_T1	GENE	12	12	IV
NCT0000152616	NCT00001526_16_T0	PHENOTYPE	11	12	reduced vision
NCT0000152616	NCT00001526_16_T1	PHENOTYPE	17	18	adverse events
NCT0000152617	NCT00001526_17_T0	PHENOTYPE	0	0	Secondary
NCT0000152617	NCT00001526_17_T1	CELL	16	16	cells
NCT0000152617	NCT00001526_17_T2	PHENOTYPE	18	19	vitreous haze
NCT0000152617	NCT00001526_17_T3	ORGAN	12	13	anterior chamber
NCT0000152620	NCT00001526_20_T0	PHENOTYPE	7	8	side effect
NCT0000152621	NCT00001526_21_T0	GENE	3	3	has
NCT0000152621	NCT00001526_21_T1	PHENOTYPE	15	16	posterior uveitis
NCT0000152622	NCT00001526_22_T0	PHENOTYPE	19	19	uveitis
NCT0000152622	NCT00001526_22_T1	GENE	15	15	IV
NCT0000152622	NCT00001526_22_T2	GENE	1	1	extended
NCT0000152623	NCT00001526_23_T0	GENE	2	2	SC
NCT0000152623	NCT00001526_23_T1	GENE	18	18	SC
NCT0000152623	NCT00001526_23_T2	GENE	28	28	IV
NCT0000152624	NCT00001526_24_T0	GENE	8	8	SC
NCT0000152625	NCT00001526_25_T0	GENE	5	5	SC
NCT0000152625	NCT00001526_25_T1	GENE	14	14	IV
NCT0000152626	NCT00001526_26_T0	GENE	0	0	SC
NCT0000152626	NCT00001526_26_T1	GENE	6	6	SC
NCT0000152627	NCT00001526_27_T0	GENE	19	19	SC
NCT0000152628	NCT00001526_28_T0	GENE	7	7	HAT
NCT0000152628	NCT00001526_28_T1	GENE	19	21	interleukin 2 receptor
NCT0000152629	NCT00001526_29_T0	GENE	10	10	IV
NCT0000152630	NCT00001526_30_T0	GENE	1	1	SC
NCT0000152631	NCT00001526_31_T0	GENE	5	5	SC
NCT0000152631	NCT00001526_31_T1	PHENOTYPE	16	17	autoimmune disease
NCT0000152632	NCT00001526_32_T0	GENE	15	15	SC
NCT0000152632	NCT00001526_32_T1	GENE	12	12	IV
NCT0000152633	NCT00001526_33_T0	PHENOTYPE	11	12	reduced vision
NCT0000152633	NCT00001526_33_T1	PHENOTYPE	17	18	adverse events
NCT0000152634	NCT00001526_34_T0	PHENOTYPE	0	0	Secondary
NCT0000152634	NCT00001526_34_T1	CELL	16	16	cells
NCT0000152634	NCT00001526_34_T2	PHENOTYPE	18	19	vitreous haze
NCT0000152634	NCT00001526_34_T3	ORGAN	12	13	anterior chamber
NCT0000152636	NCT00001526_36_T0	COMPOUND	53	53	cyclosporine
NCT0000152636	NCT00001526_36_T1	COMPOUND	54	54	azathioprine
NCT0000152636	NCT00001526_36_T2	COMPOUND	57	57	methotrexate
NCT0000152636	NCT00001526_36_T3	PHENOTYPE	47	47	uveitis
NCT0000152636	NCT00001526_36_T4	PHENOTYPE	70	70	uveitis
NCT0000152636	NCT00001526_36_T5	PHENOTYPE	74	74	uveitis
NCT0000152636	NCT00001526_36_T6	COMPOUND	52	52	cyclophosphamide
NCT0000152636	NCT00001526_36_T7	GENE	1	1	has
NCT0000152636	NCT00001526_36_T8	COMPOUND	34	34	prednisone
NCT0000152636	NCT00001526_36_T9	COMPOUND	51	51	prednisone
NCT0000152636	NCT00001526_36_T10	PHENOTYPE	26	27	inflammatory disease
NCT0000152636	NCT00001526_36_T11	COMPOUND	55	56	mycophenolate mofetil
NCT0000152636	NCT00001526_36_T12	PHENOTYPE	8	9	posterior uveitis
NCT0000152638	NCT00001526_38_T0	ORGAN	5	5	liver
NCT0000152638	NCT00001526_38_T1	GENE	1	1	has
NCT0000152642	NCT00001526_42_T0	GENE	8	8	IL-2
NCT0000152642	NCT00001526_42_T1	PHENOTYPE	29	29	pharmacokinetics
NCT0000152642	NCT00001526_42_T2	GENE	2	2	had
NCT0000152643	NCT00001526_43_T0	PHENOTYPE	7	8	Behcet's disease
NCT0000152644	NCT00001526_44_T0	GENE	1	1	has
NCT0000152645	NCT00001526_45_T0	GENE	1	1	has
NCT0000152645	NCT00001526_45_T1	PHENOTYPE	9	11	melanoma skin cancer
NCT000015273	NCT00001527_3_T0	GENE	2	2	ET-1
NCT000015274	NCT00001527_4_T0	GENE	18	18	ET-1
NCT000015274	NCT00001527_4_T1	GENE	31	31	ET-1
NCT000015274	NCT00001527_4_T2	GENE	19	19	receptor
NCT000015274	NCT00001527_4_T3	ORGAN	11	11	forearm
NCT000015274	NCT00001527_4_T4	PHENOTYPE	39	39	hypertension
NCT000015275	NCT00001527_5_T0	GENE	11	11	ET-1
NCT000015275	NCT00001527_5_T1	TISSUE	16	18	vascular smooth muscle
NCT000015277	NCT00001527_7_T0	PHENOTYPE	22	22	strain
NCT000015277	NCT00001527_7_T1	ORGAN	14	14	forearm
NCT000015277	NCT00001527_7_T2	ORGAN	7	8	brachial artery
NCT0000152711	NCT00001527_11_T0	GENE	2	2	ET-1
NCT0000152712	NCT00001527_12_T0	GENE	18	18	ET-1
NCT0000152712	NCT00001527_12_T1	GENE	31	31	ET-1
NCT0000152712	NCT00001527_12_T2	GENE	19	19	receptor
NCT0000152712	NCT00001527_12_T3	ORGAN	11	11	forearm
NCT0000152712	NCT00001527_12_T4	PHENOTYPE	39	39	hypertension
NCT0000152713	NCT00001527_13_T0	GENE	11	11	ET-1
NCT0000152713	NCT00001527_13_T1	TISSUE	16	18	vascular smooth muscle
NCT0000152715	NCT00001527_15_T0	PHENOTYPE	22	22	strain
NCT0000152715	NCT00001527_15_T1	ORGAN	14	14	forearm
NCT0000152715	NCT00001527_15_T2	ORGAN	7	8	brachial artery
NCT0000152723	NCT00001527_23_T0	ORGAN	0	0	Serum
NCT0000152725	NCT00001527_25_T0	PHENOTYPE	4	5	cholesterol level
NCT000015281	NCT00001528_1_T0	ORGAN	12	12	heart
NCT000015281	NCT00001528_1_T1	ORGAN	3	4	coronary arteries
NCT000015282	NCT00001528_2_T0	PHENOTYPE	11	11	symptoms
NCT000015282	NCT00001528_2_T1	TISSUE	6	7	heart muscle
NCT000015282	NCT00001528_2_T2	PHENOTYPE	2	3	blood supply
NCT000015283	NCT00001528_3_T0	ORGAN	3	3	heart
NCT000015283	NCT00001528_3_T1	PHENOTYPE	9	10	blood supply
NCT000015286	NCT00001528_6_T0	ORGAN	19	19	heart
NCT000015287	NCT00001528_7_T0	ORGAN	4	4	heart
NCT000015288	NCT00001528_8_T0	PHENOTYPE	17	17	bloodstream
NCT000015288	NCT00001528_8_T1	ORGAN	22	22	heart
NCT000015289	NCT00001528_9_T0	TISSUE	9	10	heart muscle
NCT0000152810	NCT00001528_10_T0	BIOLOGICAL_PROCESS	5	5	metabolism
NCT0000152810	NCT00001528_10_T1	TISSUE	8	9	heart muscle
NCT0000152811	NCT00001528_11_T0	PHENOTYPE	20	20	suffering
NCT0000152811	NCT00001528_11_T1	TISSUE	14	15	heart muscle
NCT0000152811	NCT00001528_11_T2	PHENOTYPE	22	24	coronary artery disease
NCT0000152814	NCT00001528_14_T0	GENE	7	7	has
NCT0000152814	NCT00001528_14_T1	PHENOTYPE	5	5	contractile
NCT0000152814	NCT00001528_14_T2	PHENOTYPE	6	6	dysfunction
NCT0000152818	NCT00001528_18_T0	PHENOTYPE	11	11	physiology
NCT0000152818	NCT00001528_18_T1	PHENOTYPE	15	17	coronary artery disease
NCT0000152820	NCT00001528_20_T0	GENE	5	5	ventricular
NCT0000152822	NCT00001528_22_T0	COMPOUND	22	22	fluorodeoxyglucose
NCT0000152823	NCT00001528_23_T0	COMPOUND	20	20	dobutamine
NCT0000152826	NCT00001528_26_T0	PHENOTYPE	2	4	valvular heart disease
NCT0000152827	NCT00001528_27_T0	PHENOTYPE	1	3	congenital heart disease
NCT0000152828	NCT00001528_28_T0	PHENOTYPE	1	2	myocardial disease
NCT0000152828	NCT00001528_28_T1	PHENOTYPE	6	8	coronary artery disease
NCT0000152832	NCT00001528_32_T0	PHENOTYPE	7	7	arrhythmias
NCT0000152832	NCT00001528_32_T1	PHENOTYPE	3	4	ventricular tachycardia
NCT000015290	NCT00001529_0_T0	ORGAN	8	8	Transplant
NCT000015290	NCT00001529_0_T1	ORGAN	6	7	Bone Marrow
NCT000015292	NCT00001529_2_T0	PHENOTYPE	19	19	illnesses
NCT000015293	NCT00001529_3_T0	PHENOTYPE	13	13	GVHD
NCT000015293	NCT00001529_3_T1	ORGAN	6	6	transplants
NCT000015293	NCT00001529_3_T2	PHENOTYPE	11	12	graft-versus-host disease
NCT000015293	NCT00001529_3_T3	ORGAN	4	5	bone marrow
NCT000015294	NCT00001529_4_T0	PHENOTYPE	0	0	GVHD
NCT000015295	NCT00001529_5_T0	CELL	9	9	cells
NCT000015295	NCT00001529_5_T1	CELL	19	19	cells
NCT000015296	NCT00001529_6_T0	CELL	9	9	lymphocytes
NCT000015296	NCT00001529_6_T1	CELL	6	8	white blood cells
NCT000015297	NCT00001529_7_T0	CELL	1	1	lymphocytes
NCT000015297	NCT00001529_7_T1	CELL	7	7	cells
NCT000015297	NCT00001529_7_T2	TISSUE	9	9	tissues
NCT000015298	NCT00001529_8_T0	PHENOTYPE	11	11	peripheral
NCT000015298	NCT00001529_8_T1	CELL	26	26	lymphocytes
NCT000015298	NCT00001529_8_T2	PHENOTYPE	4	4	GVHD
NCT000015298	NCT00001529_8_T3	CELL	21	22	stem cells
NCT000015298	NCT00001529_8_T4	ORGAN	15	16	bone marrow
NCT0000152916	NCT00001529_16_T0	GENE	9	9	G-CSF
NCT0000152916	NCT00001529_16_T1	GENE	10	10	has
NCT0000152916	NCT00001529_16_T2	CELL	14	14	lymphocyte
NCT0000152916	NCT00001529_16_T3	ORGAN	24	25	bone marrow
NCT0000152923	NCT00001529_23_T0	GENE	18	18	G-CSF
NCT0000152923	NCT00001529_23_T1	PHENOTYPE	3	3	intent
NCT0000152925	NCT00001529_25_T0	GENE	8	8	G-CSF
NCT0000152925	NCT00001529_25_T1	GENE	10	10	has
NCT0000152925	NCT00001529_25_T2	CELL	15	15	lymphocyte
NCT0000152925	NCT00001529_25_T3	ORGAN	26	27	bone marrow
NCT0000152928	NCT00001529_28_T0	PHENOTYPE	6	7	recurrent infection
NCT0000152929	NCT00001529_29_T0	COMPOUND	11	11	1
NCT0000152929	NCT00001529_29_T1	COMPOUND	3	3	creatinine
NCT0000152929	NCT00001529_29_T2	PHENOTYPE	8	8	proteinuria
NCT0000152929	NCT00001529_29_T3	GENE	6	6	1.5
NCT0000152930	NCT00001529_30_T0	CELL	24	24	granulocytes
NCT0000152930	NCT00001529_30_T1	GENE	37	37	MCV
NCT0000152930	NCT00001529_30_T2	ORGAN	1	1	liver
NCT0000152930	NCT00001529_30_T3	GENE	6	6	1.5
NCT0000152930	NCT00001529_30_T4	GENE	11	11	1.5
NCT0000152930	NCT00001529_30_T5	CELL	28	28	platelets
NCT0000152930	NCT00001529_30_T6	GENE	32	32	hemoglobin
NCT0000152930	NCT00001529_30_T7	GENE	12	12	fold
NCT0000152930	NCT00001529_30_T8	GENE	39	39	MCHC
NCT0000152930	NCT00001529_30_T9	COMPOUND	3	3	bilirubin
NCT0000152930	NCT00001529_30_T10	GENE	20	20	WBC
NCT0000152932	NCT00001529_32_T0	GENE	18	18	G-CSF
NCT0000152932	NCT00001529_32_T1	ORGAN	10	10	serum
NCT0000152935	NCT00001529_35_T0	PHENOTYPE	8	8	syphilis
NCT0000152935	NCT00001529_35_T1	PHENOTYPE	19	19	HIV
NCT0000152935	NCT00001529_35_T2	GENE	9	9	RPR
NCT0000152935	NCT00001529_35_T3	COMPOUND	18	18	HCV
NCT0000152935	NCT00001529_35_T4	PHENOTYPE	10	11	hepatitis B
NCT0000152937	NCT00001529_37_T0	PHENOTYPE	6	6	peripheral
NCT0000152937	NCT00001529_37_T1	ORGAN	1	1	veins
NCT0000152940	NCT00001529_40_T0	PHENOTYPE	2	4	positive pregnancy test
NCT0000152941	NCT00001529_41_T0	PHENOTYPE	2	3	autoimmune disease
NCT0000152941	NCT00001529_41_T1	PHENOTYPE	6	7	rheumatoid arthritis
NCT0000152941	NCT00001529_41_T2	PHENOTYPE	8	10	systemic lupus erythematosus
NCT0000152942	NCT00001529_42_T0	PHENOTYPE	4	5	squamous carcinoma
NCT0000152942	NCT00001529_42_T1	PHENOTYPE	5	8	carcinoma of the skin
NCT0000152943	NCT00001529_43_T0	PHENOTYPE	3	4	hematologic disorders
NCT0000152945	NCT00001529_45_T0	ORGAN	2	2	serum
NCT0000152946	NCT00001529_46_T0	PHENOTYPE	0	0	Allergy
NCT0000152946	NCT00001529_46_T1	GENE	2	2	G-CSF
NCT0000153011	NCT00001530_11_T0	PHENOTYPE	23	23	obstruction
NCT0000153011	NCT00001530_11_T1	PHENOTYPE	45	45	obstruction
NCT0000153011	NCT00001530_11_T2	COMPOUND	1	1	2
NCT0000153011	NCT00001530_11_T3	COMPOUND	38	38	2
NCT0000153011	NCT00001530_11_T4	GENE	6	7	Group 1
NCT0000153012	NCT00001530_12_T0	PHENOTYPE	5	6	heart block
NCT0000153012	NCT00001530_12_T1	GENE	11	12	group 2
NCT000015322	NCT00001532_2_T0	PHENOTYPE	18	18	diseases
NCT000015322	NCT00001532_2_T1	ORGAN	21	21	lungs
NCT000015325	NCT00001532_5_T0	PHENOTYPE	13	14	lung disease
NCT000015326	NCT00001532_6_T0	GENE	13	13	had
NCT000015329	NCT00001532_9_T0	GENE	38	38	0.5
NCT000015329	NCT00001532_9_T1	GENE	47	47	cm
NCT0000153216	NCT00001532_16_T0	GENE	24	24	delta
NCT0000153216	NCT00001532_16_T1	PHENOTYPE	11	11	mutation
NCT0000153216	NCT00001532_16_T2	GENE	20	20	CFTR
NCT0000153216	NCT00001532_16_T3	PHENOTYPE	5	6	cystic fibrosis
NCT0000153216	NCT00001532_16_T4	PHENOTYPE	29	30	cystic fibrosis
NCT0000153217	NCT00001532_17_T0	PHENOTYPE	3	3	fibrosis
NCT0000153217	NCT00001532_17_T1	GENE	2	2	cystic
NCT0000153220	NCT00001532_20_T0	PHENOTYPE	2	2	lymphangiomatosis
NCT0000153221	NCT00001532_21_T0	PHENOTYPE	2	2	asthma
NCT0000153222	NCT00001532_22_T0	PHENOTYPE	13	14	pulmonary disease
NCT0000153222	NCT00001532_22_T1	PHENOTYPE	21	22	pulmonary disease
NCT0000153222	NCT00001532_22_T2	PHENOTYPE	16	17	rheumatoid arthritis
NCT0000153226	NCT00001532_26_T0	GENE	38	38	MRI
NCT0000153226	NCT00001532_26_T1	PHENOTYPE	30	31	radiation exposure
NCT0000153227	NCT00001532_27_T0	PHENOTYPE	16	17	pulmonary disease
NCT000015330	NCT00001533_0_T0	CELL	4	4	Lymphocyte
NCT000015330	NCT00001533_0_T1	PHENOTYPE	6	7	Lymphoproliferative Disorders
NCT000015332	NCT00001533_2_T0	PHENOTYPE	10	10	thrombocytopenia
NCT000015332	NCT00001533_2_T1	PHENOTYPE	7	7	neutropenia
NCT000015332	NCT00001533_2_T2	PHENOTYPE	8	8	anemia
NCT000015333	NCT00001533_3_T0	BIOLOGICAL_PROCESS	16	16	hematopoiesis
NCT000015333	NCT00001533_3_T1	PHENOTYPE	13	13	cytopenias
NCT000015333	NCT00001533_3_T2	CELL	8	8	lymphocyte
NCT000015334	NCT00001533_4_T0	PHENOTYPE	13	13	cytopenia
NCT000015334	NCT00001533_4_T1	CELL	8	9	T cells
NCT000015335	NCT00001533_5_T0	COMPOUND	13	13	cyclosporine
NCT000015335	NCT00001533_5_T1	PHENOTYPE	25	25	cytopenia
NCT000015337	NCT00001533_7_T0	PHENOTYPE	10	10	thrombocytopenia
NCT000015337	NCT00001533_7_T1	PHENOTYPE	7	7	neutropenia
NCT000015337	NCT00001533_7_T2	PHENOTYPE	8	8	anemia
NCT000015338	NCT00001533_8_T0	BIOLOGICAL_PROCESS	16	16	hematopoiesis
NCT000015338	NCT00001533_8_T1	PHENOTYPE	13	13	cytopenias
NCT000015338	NCT00001533_8_T2	CELL	8	8	lymphocyte
NCT000015339	NCT00001533_9_T0	PHENOTYPE	13	13	cytopenia
NCT000015339	NCT00001533_9_T1	CELL	8	9	T cells
NCT0000153310	NCT00001533_10_T0	COMPOUND	13	13	cyclosporine
NCT0000153310	NCT00001533_10_T1	PHENOTYPE	25	25	cytopenia
NCT0000153313	NCT00001533_13_T0	PHENOTYPE	3	3	peripheral
NCT0000153313	NCT00001533_13_T1	GENE	13	13	CD3
NCT0000153313	NCT00001533_13_T2	GENE	14	14	CD8
NCT0000153313	NCT00001533_13_T3	GENE	17	17	CD16
NCT0000153313	NCT00001533_13_T4	GENE	19	19	CD57
NCT0000153313	NCT00001533_13_T5	GENE	20	20	CD56
NCT0000153315	NCT00001533_15_T0	GENE	4	4	had
NCT0000153315	NCT00001533_15_T1	GENE	10	10	FK506
NCT000015341	NCT00001534_1_T0	PHENOTYPE	21	21	circulation
NCT000015341	NCT00001534_1_T1	ORGAN	19	19	heart
NCT000015341	NCT00001534_1_T2	ORGAN	6	7	left ventricle
NCT000015342	NCT00001534_2_T0	TISSUE	14	15	heart muscle
NCT000015342	NCT00001534_2_T1	ORGAN	22	23	left ventricle
NCT000015342	NCT00001534_2_T2	PHENOTYPE	0	1	Hypertrophic cardiomyopathy
NCT000015342	NCT00001534_2_T3	PHENOTYPE	6	7	inherited disease
NCT000015343	NCT00001534_3_T0	PHENOTYPE	13	13	LVH
NCT000015343	NCT00001534_3_T1	ORGAN	2	3	left ventricle
NCT000015343	NCT00001534_3_T2	PHENOTYPE	10	12	left ventricular hypertrophy
NCT000015345	NCT00001534_5_T0	PHENOTYPE	16	16	symptoms
NCT000015345	NCT00001534_5_T1	COMPOUND	11	11	enalapril
NCT000015345	NCT00001534_5_T2	COMPOUND	13	13	losartan
NCT000015345	NCT00001534_5_T3	ORGAN	18	18	heart
NCT000015345	NCT00001534_5_T4	PHENOTYPE	24	25	hypertrophic cardiomyopathy
NCT000015346	NCT00001534_6_T0	PHENOTYPE	18	18	diseases
NCT000015346	NCT00001534_6_T1	GENE	10	10	has
NCT000015346	NCT00001534_6_T2	TISSUE	23	24	heart muscle
NCT000015347	NCT00001534_7_T0	PHENOTYPE	9	9	symptoms
NCT000015347	NCT00001534_7_T1	COMPOUND	4	4	enalapril
NCT000015347	NCT00001534_7_T2	COMPOUND	6	6	losartan
NCT000015347	NCT00001534_7_T3	TISSUE	14	15	heart muscle
NCT000015347	NCT00001534_7_T4	TISSUE	23	24	heart muscle
NCT000015347	NCT00001534_7_T5	TISSUE	32	33	heart muscle
NCT000015348	NCT00001534_8_T0	COMPOUND	9	9	enalapril
NCT000015348	NCT00001534_8_T1	COMPOUND	11	11	losartan
NCT000015348	NCT00001534_8_T2	PHENOTYPE	20	21	hypertrophic cardiomyopathy
NCT0000153410	NCT00001534_10_T0	PHENOTYPE	5	6	diastolic dysfunction
NCT0000153410	NCT00001534_10_T1	PHENOTYPE	8	9	myocardial ischemia
NCT0000153411	NCT00001534_11_T0	PHENOTYPE	1	1	severity
NCT0000153411	NCT00001534_11_T1	PHENOTYPE	5	5	hypertrophy
NCT0000153411	NCT00001534_11_T2	PHENOTYPE	6	7	diastolic dysfunction
NCT0000153411	NCT00001534_11_T3	PHENOTYPE	9	10	myocardial ischemia
NCT0000153416	NCT00001534_16_T0	GENE	11	11	bradykinin
NCT0000153421	NCT00001534_21_T0	ORGAN	2	2	Heart
NCT0000153422	NCT00001534_22_T0	PHENOTYPE	7	7	toxicity
NCT0000153423	NCT00001534_23_T0	COMPOUND	9	9	losartan
NCT0000153423	NCT00001534_23_T1	MOLECULAR_FUNCTION	6	7	ACE inhibitor
NCT0000153424	NCT00001534_24_T0	GENE	8	8	IV
NCT0000153424	NCT00001534_24_T1	PHENOTYPE	3	4	cardiac symptoms
NCT0000153426	NCT00001534_26_T0	COMPOUND	13	13	MUGA
NCT0000153426	NCT00001534_26_T1	PHENOTYPE	1	1	diseases
NCT0000153426	NCT00001534_26_T2	COMPOUND	14	14	thallium
NCT0000153428	NCT00001534_28_T0	PHENOTYPE	0	2	Chronic atrial fibrillation
NCT0000153429	NCT00001534_29_T0	GENE	6	6	sec
NCT0000153429	NCT00001534_29_T1	GENE	12	12	sec
NCT0000153429	NCT00001534_29_T2	GENE	7	7	pro
NCT0000153429	NCT00001534_29_T3	GENE	11	11	14/7
NCT0000153429	NCT00001534_29_T4	PHENOTYPE	13	14	platelet count
NCT0000153429	NCT00001534_29_T5	PHENOTYPE	0	1	Bleeding disorder
NCT0000153430	NCT00001534_30_T0	PHENOTYPE	0	0	Anemia
NCT0000153430	NCT00001534_30_T1	GENE	27	27	1.4
NCT0000153430	NCT00001534_30_T2	GENE	11	11	11.0
NCT0000153430	NCT00001534_30_T3	GENE	32	32	3.3
NCT0000153430	NCT00001534_30_T4	GENE	37	37	5-1
NCT0000153430	NCT00001534_30_T5	COMPOUND	24	24	creatinine
NCT0000153430	NCT00001534_30_T6	PHENOTYPE	16	16	impairment
NCT0000153430	NCT00001534_30_T7	GENE	1	1	Hb
NCT0000153430	NCT00001534_30_T8	ORGAN	23	23	serum
NCT0000153431	NCT00001534_31_T0	PHENOTYPE	0	0	Hypertension
NCT0000153431	NCT00001534_31_T1	GENE	22	22	separated
NCT0000153431	NCT00001534_31_T2	GENE	11	11	Hg
NCT0000153431	NCT00001534_31_T3	GENE	17	17	Hg
NCT0000153432	NCT00001534_32_T0	PHENOTYPE	0	0	Hypotension
NCT0000153432	NCT00001534_32_T1	GENE	10	10	Hg
NCT0000153434	NCT00001534_34_T0	PHENOTYPE	6	7	pulmonary edema
NCT0000153434	NCT00001534_34_T1	PHENOTYPE	4	5	cardiac failure
NCT0000153438	NCT00001534_38_T0	PHENOTYPE	15	15	symptoms
NCT0000153438	NCT00001534_38_T1	PHENOTYPE	17	17	arrhythmias
NCT0000153438	NCT00001534_38_T2	COMPOUND	8	8	verapamil
NCT0000153438	NCT00001534_38_T3	PHENOTYPE	0	1	Dependence on
NCT0000153439	NCT00001534_39_T0	PHENOTYPE	1	1	HIV
NCT0000153440	NCT00001534_40_T0	PHENOTYPE	5	5	angioedema
NCT0000153440	NCT00001534_40_T1	PHENOTYPE	0	0	Sensitivity
NCT0000153440	NCT00001534_40_T2	MOLECULAR_FUNCTION	2	3	ACE inhibitor
NCT000015350	NCT00001535_0_T0	PHENOTYPE	6	7	HIV Infection
NCT000015352	NCT00001535_2_T0	CELL	1	1	lymphocytes
NCT000015352	NCT00001535_2_T1	CELL	41	41	cells
NCT000015352	NCT00001535_2_T2	PHENOTYPE	11	11	HIV
NCT000015352	NCT00001535_2_T3	PHENOTYPE	16	16	HIV
NCT000015352	NCT00001535_2_T4	BIOLOGICAL_PROCESS	17	17	reproduction
NCT000015354	NCT00001535_4_T0	PHENOTYPE	15	15	tetanus
NCT000015354	NCT00001535_4_T1	GENE	16	16	booster
NCT000015355	NCT00001535_5_T0	CELL	10	10	lymphocytes
NCT000015355	NCT00001535_5_T1	PHENOTYPE	2	2	HIV
NCT000015359	NCT00001535_9_T0	CELL	2	2	cells
NCT0000153510	NCT00001535_10_T0	CELL	3	3	cells
NCT0000153513	NCT00001535_13_T0	CELL	1	1	lymphocyte
NCT0000153515	NCT00001535_15_T0	CELL	19	19	cells
NCT0000153515	NCT00001535_15_T1	PHENOTYPE	20	21	immune status
NCT0000153516	NCT00001535_16_T0	PHENOTYPE	14	14	learned
NCT0000153519	NCT00001535_19_T0	PHENOTYPE	23	23	strategies
NCT0000153519	NCT00001535_19_T1	PHENOTYPE	15	16	HIV infection
NCT0000153520	NCT00001535_20_T0	PHENOTYPE	5	5	HIV
NCT0000153520	NCT00001535_20_T1	PHENOTYPE	25	25	HIV
NCT0000153520	NCT00001535_20_T2	GENE	12	12	reduced
NCT000015361	NCT00001536_1_T0	PHENOTYPE	5	5	achondroplasia
NCT000015362	NCT00001536_2_T0	PHENOTYPE	13	13	achondroplasia
NCT000015363	NCT00001536_3_T0	PHENOTYPE	5	5	achondroplasia
NCT000015363	NCT00001536_3_T1	PHENOTYPE	33	33	achondroplasia
NCT000015365	NCT00001536_5_T0	PHENOTYPE	11	11	achondroplasia
NCT000015368	NCT00001536_8_T0	PHENOTYPE	13	13	achondroplasia
NCT0000153610	NCT00001536_10_T0	PHENOTYPE	5	5	achondroplasia
NCT0000153611	NCT00001536_11_T0	PHENOTYPE	13	13	achondroplasia
NCT0000153612	NCT00001536_12_T0	PHENOTYPE	5	5	achondroplasia
NCT0000153612	NCT00001536_12_T1	PHENOTYPE	33	33	achondroplasia
NCT0000153614	NCT00001536_14_T0	PHENOTYPE	11	11	achondroplasia
NCT0000153617	NCT00001536_17_T0	PHENOTYPE	13	13	achondroplasia
NCT0000153619	NCT00001536_19_T0	PHENOTYPE	7	7	achondroplasia
NCT0000153620	NCT00001536_20_T0	PHENOTYPE	12	12	achondroplasia
NCT000015383	NCT00001538_3_T0	GENE	14	14	booster
NCT0000153810	NCT00001538_10_T0	GENE	14	14	booster
NCT0000153816	NCT00001538_16_T0	CELL	12	12	granulocyte
NCT0000153816	NCT00001538_16_T1	GENE	25	25	hematocrit
NCT0000153816	NCT00001538_16_T2	PHENOTYPE	18	19	platelet count
NCT0000153817	NCT00001538_17_T0	COMPOUND	6	6	creatine
NCT0000153817	NCT00001538_17_T1	GENE	9	9	1/6
NCT0000153818	NCT00001538_18_T0	GENE	6	6	1.5
NCT0000153818	NCT00001538_18_T1	ORGAN	1	1	serum
NCT0000153818	NCT00001538_18_T2	PHENOTYPE	2	3	total bilirubin
NCT0000153821	NCT00001538_21_T0	GENE	16	16	IgA
NCT0000153821	NCT00001538_21_T1	GENE	1	1	CD4
NCT0000153821	NCT00001538_21_T2	GENE	14	14	IgG
NCT0000153821	NCT00001538_21_T3	ORGAN	11	11	serum
NCT0000153821	NCT00001538_21_T4	GENE	13	13	IgM
NCT0000153822	NCT00001538_22_T0	PHENOTYPE	4	5	laboratory abnormalities
NCT0000153823	NCT00001538_23_T0	PHENOTYPE	9	9	HIV
NCT0000153823	NCT00001538_23_T1	PHENOTYPE	17	17	infections
NCT0000153824	NCT00001538_24_T0	PHENOTYPE	9	11	negative pregnancy test
NCT0000153827	NCT00001538_27_T0	PHENOTYPE	11	11	HIV
NCT0000153829	NCT00001538_29_T0	PHENOTYPE	7	7	HIV
NCT0000153829	NCT00001538_29_T1	PHENOTYPE	18	18	HIV
NCT0000153832	NCT00001538_32_T0	COMPOUND	26	26	ibuprofen
NCT0000153832	NCT00001538_32_T1	COMPOUND	28	28	aspirin
NCT0000153834	NCT00001538_34_T0	PHENOTYPE	12	12	disorders
NCT0000153834	NCT00001538_34_T1	PHENOTYPE	6	7	alcohol abuse
NCT0000153835	NCT00001538_35_T0	PHENOTYPE	5	5	HIV
NCT0000153835	NCT00001538_35_T1	PHENOTYPE	18	19	drug use
NCT0000153836	NCT00001538_36_T0	COMPOUND	7	7	HCV
NCT0000153836	NCT00001538_36_T1	PHENOTYPE	5	5	HBV
NCT0000153837	NCT00001538_37_T0	GENE	20	20	ANA
NCT000015390	NCT00001539_0_T0	PHENOTYPE	15	15	Syndrome
NCT000015390	NCT00001539_0_T1	PHENOTYPE	13	14	Lyme Disease
NCT000015392	NCT00001539_2_T0	PHENOTYPE	16	17	Lyme disease
NCT000015394	NCT00001539_4_T0	PHENOTYPE	3	3	chronic
NCT000015394	NCT00001539_4_T1	PHENOTYPE	4	5	Lyme disease
NCT000015399	NCT00001539_9_T0	GENE	4	4	cc
NCT000015399	NCT00001539_9_T1	GENE	19	19	CSF
NCT000015399	NCT00001539_9_T2	ORGAN	26	27	spinal cord
NCT0000153910	NCT00001539_10_T0	TISSUE	15	15	bones
NCT0000153910	NCT00001539_10_T1	ORGAN	27	28	spinal cord
NCT0000153911	NCT00001539_11_T0	GENE	13	13	MRI
NCT0000153915	NCT00001539_15_T0	COMPOUND	11	11	ceftriaxone
NCT0000153918	NCT00001539_18_T0	GENE	2	2	MRI
NCT0000153918	NCT00001539_18_T1	GENE	11	11	MRI
NCT0000153919	NCT00001539_19_T0	PHENOTYPE	3	3	chronic
NCT0000153919	NCT00001539_19_T1	PHENOTYPE	6	6	chronic
NCT0000153919	NCT00001539_19_T2	PHENOTYPE	4	5	Lyme disease
NCT0000153919	NCT00001539_19_T3	PHENOTYPE	7	8	Lyme arthritis
NCT0000153921	NCT00001539_21_T0	PHENOTYPE	5	5	learned
NCT0000153921	NCT00001539_21_T1	GENE	3	3	has
NCT0000153921	NCT00001539_21_T2	PHENOTYPE	7	8	Lyme borreliosis
NCT0000153926	NCT00001539_26_T0	GENE	6	6	probable
NCT0000153927	NCT00001539_27_T0	PHENOTYPE	11	11	symptoms
NCT0000153928	NCT00001539_28_T0	PHENOTYPE	12	12	symptoms
NCT0000153929	NCT00001539_29_T0	GENE	53	53	blot
NCT0000153929	NCT00001539_29_T1	PHENOTYPE	31	31	arthritis
NCT0000153929	NCT00001539_29_T2	ORGAN	46	46	serum
NCT0000153929	NCT00001539_29_T3	PHENOTYPE	0	1	Lyme arthritis
NCT0000153929	NCT00001539_29_T4	PHENOTYPE	9	10	Lyme arthritis
NCT0000153930	NCT00001539_30_T0	GENE	26	26	had
NCT0000153930	NCT00001539_30_T1	GENE	40	40	had
NCT0000153930	NCT00001539_30_T2	GENE	25	25	has
NCT0000153930	NCT00001539_30_T3	PHENOTYPE	27	28	Lyme disease
NCT0000153930	NCT00001539_30_T4	PHENOTYPE	46	47	Lyme disease
NCT0000153930	NCT00001539_30_T5	PHENOTYPE	32	33	Lyme Disease
NCT0000153931	NCT00001539_31_T0	GENE	34	34	blot
NCT0000153931	NCT00001539_31_T1	GENE	28	28	IgG
NCT0000153931	NCT00001539_31_T2	GENE	25	25	has
NCT0000153931	NCT00001539_31_T3	ORGAN	27	27	serum
NCT0000153931	NCT00001539_31_T4	PHENOTYPE	61	62	Lyme disease
NCT0000153932	NCT00001539_32_T0	GENE	27	27	has
NCT0000153932	NCT00001539_32_T1	PHENOTYPE	38	39	Lyme disease
NCT0000153934	NCT00001539_34_T0	GENE	64	64	blot
NCT0000153934	NCT00001539_34_T1	ORGAN	69	69	serum
NCT0000153934	NCT00001539_34_T2	PHENOTYPE	59	60	Lyme disease
NCT0000153934	NCT00001539_34_T3	PHENOTYPE	0	1	Multiple sclerosis
NCT0000153934	NCT00001539_34_T4	PHENOTYPE	10	11	multiple sclerosis
NCT0000153934	NCT00001539_34_T5	PHENOTYPE	42	43	Multiple Sclerosis
NCT0000153934	NCT00001539_34_T6	PHENOTYPE	29	31	progressive multiple sclerosis
NCT0000153935	NCT00001539_35_T0	GENE	6	6	Expanded
NCT0000153935	NCT00001539_35_T1	COMPOUND	10	10	EDSS
NCT0000153936	NCT00001539_36_T0	PHENOTYPE	27	28	Lyme disease
NCT0000153938	NCT00001539_38_T0	PHENOTYPE	15	15	PTLDS
NCT0000153940	NCT00001539_40_T0	BIOLOGICAL_PROCESS	2	2	lactation
NCT0000153942	NCT00001539_42_T0	PHENOTYPE	12	12	HIV
NCT0000153942	NCT00001539_42_T1	GENE	9	9	RPR
NCT0000153942	NCT00001539_42_T2	PHENOTYPE	8	8	syphilis
NCT0000153942	NCT00001539_42_T3	COMPOUND	11	11	HCV
NCT0000153942	NCT00001539_42_T4	PHENOTYPE	2	3	laboratory abnormalities
NCT0000153943	NCT00001539_43_T0	PHENOTYPE	0	0	Chronic
NCT0000153945	NCT00001539_45_T0	GENE	2	2	FOR
NCT0000153945	NCT00001539_45_T1	PHENOTYPE	3	3	PTLDS
NCT0000153945	NCT00001539_45_T2	PHENOTYPE	6	7	LYME ARTHRITIS
NCT0000153948	NCT00001539_48_T0	PHENOTYPE	10	10	vasculitis
NCT0000153948	NCT00001539_48_T1	PHENOTYPE	13	13	lupus
NCT0000153948	NCT00001539_48_T2	PHENOTYPE	4	5	autoimmune disease
NCT0000153948	NCT00001539_48_T3	PHENOTYPE	8	9	rheumatoid arthritis
NCT0000153949	NCT00001539_49_T0	PHENOTYPE	8	8	illnesses
NCT0000153949	NCT00001539_49_T1	PHENOTYPE	4	4	chronic
NCT0000153949	NCT00001539_49_T2	PHENOTYPE	11	12	Lyme disease
NCT0000153951	NCT00001539_51_T0	PHENOTYPE	26	27	cerebrovascular disease
NCT0000153951	NCT00001539_51_T1	PHENOTYPE	4	5	head trauma
NCT0000153951	NCT00001539_51_T2	PHENOTYPE	8	9	substance abuse
NCT0000153957	NCT00001539_57_T0	PHENOTYPE	0	0	Chronic
NCT0000153959	NCT00001539_59_T0	PHENOTYPE	26	26	reasoning
NCT0000153959	NCT00001539_59_T1	PHENOTYPE	19	19	impairment
NCT0000153959	NCT00001539_59_T2	PHENOTYPE	33	33	decisions
NCT0000153960	NCT00001539_60_T0	GENE	2	2	FOR
NCT0000153960	NCT00001539_60_T1	PHENOTYPE	26	26	PTLDS
NCT0000153960	NCT00001539_60_T2	PHENOTYPE	29	30	Lyme arthritis
NCT0000153961	NCT00001539_61_T0	PHENOTYPE	4	4	chronic
NCT0000153961	NCT00001539_61_T1	PHENOTYPE	7	8	psychiatric illness
NCT0000153962	NCT00001539_62_T0	GENE	2	2	FOR
NCT0000153962	NCT00001539_62_T1	PHENOTYPE	3	4	MULTIPLE SCLEROSIS
NCT0000153963	NCT00001539_63_T0	PHENOTYPE	6	6	chronic
NCT0000153963	NCT00001539_63_T1	PHENOTYPE	10	11	Multiple Sclerosis
NCT0000153965	NCT00001539_65_T0	PHENOTYPE	29	30	cerebrovascular disease
NCT0000153965	NCT00001539_65_T1	PHENOTYPE	20	21	Multiple Sclerosis
NCT0000153965	NCT00001539_65_T2	PHENOTYPE	4	5	head trauma
NCT0000153965	NCT00001539_65_T3	PHENOTYPE	8	9	substance abuse
NCT0000153967	NCT00001539_67_T0	COMPOUND	7	7	cladribine
NCT000015401	NCT00001540_1_T0	PHENOTYPE	29	29	secondary
NCT000015401	NCT00001540_1_T1	GENE	1	1	phi
NCT000015401	NCT00001540_1_T2	PHENOTYPE	30	30	immunodeficiencies
NCT000015401	NCT00001540_1_T3	PHENOTYPE	33	33	HIV
NCT000015401	NCT00001540_1_T4	PHENOTYPE	20	20	immunity
NCT000015401	NCT00001540_1_T5	GENE	8	8	has
NCT000015402	NCT00001540_2_T0	PHENOTYPE	11	11	HIV
NCT000015404	NCT00001540_4_T0	PHENOTYPE	15	15	secondary
NCT000015404	NCT00001540_4_T1	GENE	26	26	phi
NCT000015404	NCT00001540_4_T2	GENE	22	22	10.9
NCT0000154010	NCT00001540_10_T0	PHENOTYPE	29	29	secondary
NCT0000154010	NCT00001540_10_T1	GENE	1	1	phi
NCT0000154010	NCT00001540_10_T2	PHENOTYPE	30	30	immunodeficiencies
NCT0000154010	NCT00001540_10_T3	PHENOTYPE	33	33	HIV
NCT0000154010	NCT00001540_10_T4	PHENOTYPE	20	20	immunity
NCT0000154010	NCT00001540_10_T5	GENE	8	8	has
NCT0000154011	NCT00001540_11_T0	PHENOTYPE	11	11	HIV
NCT0000154013	NCT00001540_13_T0	PHENOTYPE	15	15	secondary
NCT0000154013	NCT00001540_13_T1	GENE	26	26	phi
NCT0000154013	NCT00001540_13_T2	GENE	22	22	10.9
NCT0000154019	NCT00001540_19_T0	PHENOTYPE	8	10	negative pregnancy test
NCT0000154024	NCT00001540_24_T0	GENE	9	9	Blot
NCT0000154024	NCT00001540_24_T1	PHENOTYPE	2	3	HIV seropositivity
NCT0000154028	NCT00001540_28_T0	PHENOTYPE	0	0	HIV
NCT0000154030	NCT00001540_30_T0	PHENOTYPE	14	14	autoimmunity
NCT0000154030	NCT00001540_30_T1	PHENOTYPE	9	9	infections
NCT0000154030	NCT00001540_30_T2	PHENOTYPE	7	8	recurrent infections
NCT0000154031	NCT00001540_31_T0	GENE	5	5	phi
NCT0000154032	NCT00001540_32_T0	PHENOTYPE	3	4	opportunistic infection
NCT0000154033	NCT00001540_33_T0	COMPOUND	18	18	prednisone
NCT000015413	NCT00001541_3_T0	CELL	10	10	cells
NCT000015413	NCT00001541_3_T1	CELL	15	15	cells
NCT000015413	NCT00001541_3_T2	PHENOTYPE	24	24	inflammation
NCT000015413	NCT00001541_3_T3	TISSUE	6	6	mucosa
NCT000015413	NCT00001541_3_T4	ORGAN	4	4	bronchi
NCT000015414	NCT00001541_4_T0	PHENOTYPE	17	18	Wegener's granulomatosis
NCT000015415	NCT00001541_5_T0	PHENOTYPE	9	10	Wegener's granulomatosis
NCT000015417	NCT00001541_7_T0	COMPOUND	10	10	lidocaine
NCT0000154112	NCT00001541_12_T0	CELL	13	13	cells
NCT0000154112	NCT00001541_12_T1	PHENOTYPE	7	7	withdrawn
NCT0000154116	NCT00001541_16_T0	GENE	19	19	has
NCT0000154120	NCT00001541_20_T0	PHENOTYPE	16	17	Wegener's granulomatosis
NCT0000154121	NCT00001541_21_T0	PHENOTYPE	18	18	infiltrating
NCT0000154121	NCT00001541_21_T1	CELL	19	19	leukocytes
NCT0000154121	NCT00001541_21_T2	PHENOTYPE	24	24	adhesion
NCT0000154122	NCT00001541_22_T0	PHENOTYPE	10	10	pathophysiology
NCT0000154126	NCT00001541_26_T0	PHENOTYPE	7	7	FVC
NCT0000154128	NCT00001541_28_T0	PHENOTYPE	8	8	FVC
NCT0000154130	NCT00001541_30_T0	PHENOTYPE	4	5	platelet count
NCT0000154131	NCT00001541_31_T0	COMPOUND	5	5	lidocaine
NCT0000154131	NCT00001541_31_T1	PHENOTYPE	2	3	adverse reaction
NCT000015425	NCT00001542_5_T0	COMPOUND	6	6	fluconazole
NCT000015425	NCT00001542_5_T1	GENE	7	7	has
NCT000015426	NCT00001542_6_T0	COMPOUND	11	11	fluconazole
NCT000015426	NCT00001542_6_T1	PHENOTYPE	0	0	Recurrences
NCT000015427	NCT00001542_7_T0	COMPOUND	3	3	fluconazole
NCT000015427	NCT00001542_7_T1	GENE	6	6	has
NCT000015428	NCT00001542_8_T0	COMPOUND	7	7	fluconazole
NCT000015429	NCT00001542_9_T0	PHENOTYPE	8	8	immunosuppression
NCT0000154212	NCT00001542_12_T0	COMPOUND	10	10	fluconazole
NCT0000154212	NCT00001542_12_T1	PHENOTYPE	13	13	HIV
NCT0000154213	NCT00001542_13_T0	GENE	4	4	CD4
NCT0000154213	NCT00001542_13_T1	COMPOUND	17	17	fluconazole
NCT0000154213	NCT00001542_13_T2	PHENOTYPE	3	3	immunosuppression
NCT0000154214	NCT00001542_14_T0	COMPOUND	11	11	fluconazole
NCT0000154216	NCT00001542_16_T0	COMPOUND	11	11	fluconazole
NCT0000154216	NCT00001542_16_T1	PHENOTYPE	23	23	recurrent
NCT0000154218	NCT00001542_18_T0	COMPOUND	9	9	fluconazole
NCT0000154218	NCT00001542_18_T1	COMPOUND	19	19	fluconazole
NCT0000154218	NCT00001542_18_T2	GENE	22	22	has
NCT0000154223	NCT00001542_23_T0	GENE	0	0	CD4
NCT0000154224	NCT00001542_24_T0	PHENOTYPE	10	11	oropharyngeal candidiasis
NCT0000154225	NCT00001542_25_T0	COMPOUND	5	5	azoles
NCT0000154225	NCT00001542_25_T1	PHENOTYPE	1	1	allergy
NCT0000154226	NCT00001542_26_T0	PHENOTYPE	5	6	oropharyngeal candidiasis
NCT0000154227	NCT00001542_27_T0	PHENOTYPE	3	4	esophageal candidiasis
NCT0000154228	NCT00001542_28_T0	PHENOTYPE	3	5	systemic fungal infection
NCT0000154229	NCT00001542_29_T0	COMPOUND	14	14	fluconazole
NCT0000154229	NCT00001542_29_T1	PHENOTYPE	24	24	infections
NCT0000154229	NCT00001542_29_T2	COMPOUND	16	16	ketoconazole
NCT0000154229	NCT00001542_29_T3	COMPOUND	15	15	itraconazole
NCT0000154231	NCT00001542_31_T0	COMPOUND	14	14	fluconazole
NCT0000154231	NCT00001542_31_T1	PHENOTYPE	5	6	mucosal infection
NCT0000154233	NCT00001542_33_T0	PHENOTYPE	3	5	negative pregnancy test
NCT0000154236	NCT00001542_36_T0	PHENOTYPE	7	7	symptoms
NCT0000154236	NCT00001542_36_T1	PHENOTYPE	4	5	mucosal infection
NCT0000154238	NCT00001542_38_T0	PHENOTYPE	9	10	mucosal infection
NCT000015431	NCT00001543_1_T0	GENE	14	14	CRH
NCT000015431	NCT00001543_1_T1	GENE	1	1	hormone
NCT000015431	NCT00001543_1_T2	GENE	13	13	hormone
NCT000015431	NCT00001543_1_T3	PHENOTYPE	8	9	stress response
NCT000015432	NCT00001543_2_T0	GENE	19	19	ACTH
NCT000015432	NCT00001543_2_T1	GENE	0	0	CRH
NCT000015432	NCT00001543_2_T2	ORGAN	5	5	hypothalamus
NCT000015432	NCT00001543_2_T3	GENE	17	17	hormone
NCT000015432	NCT00001543_2_T4	ORGAN	12	13	pituitary gland
NCT000015433	NCT00001543_3_T0	COMPOUND	15	15	cortisol
NCT000015433	NCT00001543_3_T1	GENE	2	2	ACTH
NCT000015433	NCT00001543_3_T2	GENE	1	1	hormone
NCT000015433	NCT00001543_3_T3	GENE	14	14	hormone
NCT000015433	NCT00001543_3_T4	ORGAN	7	8	adrenal glands
NCT000015434	NCT00001543_4_T0	GENE	1	1	CRH
NCT000015438	NCT00001543_8_T0	GENE	3	3	has
NCT000015438	NCT00001543_8_T1	GENE	11	11	leptin
NCT000015438	NCT00001543_8_T2	PHENOTYPE	21	21	overweight
NCT000015438	NCT00001543_8_T3	PHENOTYPE	16	16	obesity
NCT0000154311	NCT00001543_11_T0	GENE	6	6	leptin
NCT0000154311	NCT00001543_11_T1	ORGAN	24	24	hypothalamus
NCT0000154311	NCT00001543_11_T2	GENE	5	5	hormone
NCT0000154311	NCT00001543_11_T3	CELL	14	15	fat cells
NCT0000154312	NCT00001543_12_T0	GENE	16	16	HPA
NCT0000154312	NCT00001543_12_T1	GENE	17	17	axis
NCT0000154312	NCT00001543_12_T2	GENE	3	3	leptin
NCT0000154313	NCT00001543_13_T0	GENE	18	18	HPA
NCT0000154313	NCT00001543_13_T1	GENE	19	19	axis
NCT0000154313	NCT00001543_13_T2	GENE	9	9	leptin
NCT0000154314	NCT00001543_14_T0	GENE	10	10	leptin
NCT0000154315	NCT00001543_15_T0	PHENOTYPE	17	18	major depression
NCT0000154321	NCT00001543_21_T0	PHENOTYPE	20	20	peripheral
NCT0000154321	NCT00001543_21_T1	BIOLOGICAL_PROCESS	7	7	transduction
NCT0000154321	NCT00001543_21_T2	GENE	18	18	leptin
NCT0000154322	NCT00001543_22_T0	GENE	19	19	axis
NCT0000154322	NCT00001543_22_T1	GENE	13	13	leptin
NCT0000154324	NCT00001543_24_T0	PHENOTYPE	3	4	insulin resistance
NCT0000154324	NCT00001543_24_T1	PHENOTYPE	11	13	coronary artery disease
NCT0000154325	NCT00001543_25_T0	PHENOTYPE	14	14	pathophysiology
NCT0000154325	NCT00001543_25_T1	PHENOTYPE	19	20	major depression
NCT0000154327	NCT00001543_27_T0	PHENOTYPE	2	2	overweight
NCT0000154329	NCT00001543_29_T0	PHENOTYPE	0	0	Overweight
NCT0000154330	NCT00001543_30_T0	PHENOTYPE	3	3	chronic
NCT0000154333	NCT00001543_33_T0	PHENOTYPE	3	4	HIV infection
NCT000015441	NCT00001544_1_T0	PHENOTYPE	16	16	ADHD
NCT000015441	NCT00001544_1_T1	PHENOTYPE	17	18	atypical psychosis
NCT000015441	NCT00001544_1_T2	PHENOTYPE	7	8	mental retardation
NCT000015441	NCT00001544_1_T3	PHENOTYPE	9	11	childhood onset schizophrenia
NCT000015441	NCT00001544_1_T4	PHENOTYPE	22	24	bipolar affective disorder
NCT000015441	NCT00001544_1_T5	PHENOTYPE	12	15	attention deficit hyperactivity disorder
NCT000015444	NCT00001544_4_T0	PHENOTYPE	23	23	severity
NCT000015444	NCT00001544_4_T1	PHENOTYPE	13	15	age of onset
NCT000015446	NCT00001544_6_T0	GENE	14	14	triplet
NCT000015446	NCT00001544_6_T1	PHENOTYPE	17	18	chromosome rearrangements
NCT000015449	NCT00001544_9_T0	PHENOTYPE	18	19	psychiatric disorders
NCT0000154410	NCT00001544_10_T0	PHENOTYPE	16	16	severity
NCT0000154410	NCT00001544_10_T1	PHENOTYPE	20	21	psychiatric symptoms
NCT0000154410	NCT00001544_10_T2	PHENOTYPE	12	14	age of onset
NCT0000154413	NCT00001544_13_T0	GENE	45	45	IV
NCT0000154413	NCT00001544_13_T1	PHENOTYPE	18	19	Affective Disorders
NCT000015451	NCT00001545_1_T0	ORGAN	10	10	scalp
NCT000015451	NCT00001545_1_T1	ORGAN	12	12	skull
NCT000015451	NCT00001545_1_T2	COMPOUND	1	1	rTMS
NCT000015455	NCT00001545_5_T0	COMPOUND	22	22	rTMS
NCT000015456	NCT00001545_6_T0	COMPOUND	10	10	rTMS
NCT000015457	NCT00001545_7_T0	COMPOUND	11	11	rTMS
NCT000015459	NCT00001545_9_T0	PHENOTYPE	6	6	localized
NCT000015459	NCT00001545_9_T1	GENE	1	1	has
NCT000015459	NCT00001545_9_T2	GENE	12	12	has
NCT0000154511	NCT00001545_11_T0	COMPOUND	10	10	rTMS
NCT0000154511	NCT00001545_11_T1	PHENOTYPE	32	33	endocrine effects
NCT0000154516	NCT00001545_16_T0	COMPOUND	15	15	lithium
NCT0000154516	NCT00001545_16_T1	COMPOUND	18	18	valproate
NCT0000154516	NCT00001545_16_T2	COMPOUND	16	16	carbamazepine
NCT0000154516	NCT00001545_16_T3	PHENOTYPE	2	3	bipolar disorder
NCT0000154518	NCT00001545_18_T0	ORGAN	23	23	eyes
NCT0000154519	NCT00001545_19_T0	COMPOUND	3	3	rTMS
NCT0000154519	NCT00001545_19_T1	PHENOTYPE	11	12	substance abuse
NCT000015463	NCT00001546_3_T0	GENE	2	2	secreted
NCT000015466	NCT00001546_6_T0	COMPOUND	7	7	cortisol
NCT000015466	NCT00001546_6_T1	PHENOTYPE	10	10	sleepiness
NCT000015466	NCT00001546_6_T2	COMPOUND	5	5	melatonin
NCT0000154614	NCT00001546_14_T0	COMPOUND	15	15	cortisol
NCT0000154614	NCT00001546_14_T1	PHENOTYPE	8	8	waking
NCT0000154614	NCT00001546_14_T2	PHENOTYPE	12	12	sleepiness
NCT0000154614	NCT00001546_14_T3	ORGAN	4	4	plasma
NCT0000154614	NCT00001546_14_T4	ORGAN	14	14	plasma
NCT0000154614	NCT00001546_14_T5	COMPOUND	5	5	melatonin
NCT0000154615	NCT00001546_15_T0	GENE	24	24	lib
NCT0000154615	NCT00001546_15_T1	GENE	4	4	extended
NCT0000154623	NCT00001546_23_T0	PHENOTYPE	4	5	psychiatric illness
NCT0000154623	NCT00001546_23_T1	PHENOTYPE	8	9	head injury
NCT000015472	NCT00001547_2_T0	GENE	10	10	Alpha
NCT000015472	NCT00001547_2_T1	GENE	11	11	Interferon
NCT000015472	NCT00001547_2_T2	PHENOTYPE	20	22	Chronic Hepatitis C
NCT000015473	NCT00001547_3_T0	COMPOUND	14	14	ribavirin
NCT000015473	NCT00001547_3_T1	GENE	6	6	interferon-alpha
NCT000015479	NCT00001547_9_T0	PHENOTYPE	11	12	Hepatitis C
NCT0000154712	NCT00001547_12_T0	COMPOUND	16	16	ribavirin
NCT0000154712	NCT00001547_12_T1	COMPOUND	24	24	proton
NCT0000154713	NCT00001547_13_T0	COMPOUND	19	19	ribavirin
NCT0000154713	NCT00001547_13_T1	COMPOUND	27	27	HCV
NCT0000154713	NCT00001547_13_T2	PHENOTYPE	24	25	hepatitis C
NCT0000154714	NCT00001547_14_T0	ORGAN	21	23	central nervous system
NCT0000154715	NCT00001547_15_T0	COMPOUND	16	16	proton
NCT0000154715	NCT00001547_15_T1	PHENOTYPE	33	34	behavioral symptoms
NCT0000154720	NCT00001547_20_T0	COMPOUND	23	23	ribavirin
NCT0000154720	NCT00001547_20_T1	COMPOUND	14	14	HCV
NCT000015482	NCT00001548_2_T0	PHENOTYPE	0	0	OCD
NCT000015482	NCT00001548_2_T1	PHENOTYPE	7	7	affects
NCT000015484	NCT00001548_4_T0	PHENOTYPE	13	13	OCD
NCT000015484	NCT00001548_4_T1	PHENOTYPE	5	5	localize
NCT000015488	NCT00001548_8_T0	PHENOTYPE	13	13	OCD
NCT000015488	NCT00001548_8_T1	GENE	4	4	has
NCT000015488	NCT00001548_8_T2	GENE	32	32	MH
NCT000015488	NCT00001548_8_T3	GENE	16	16	Dr
NCT0000154811	NCT00001548_11_T0	PHENOTYPE	10	10	OCD
NCT0000154813	NCT00001548_13_T0	PHENOTYPE	1	1	disorders
NCT0000154813	NCT00001548_13_T1	PHENOTYPE	8	8	disorders
NCT0000154813	NCT00001548_13_T2	PHENOTYPE	6	6	OCD
NCT0000154813	NCT00001548_13_T3	PHENOTYPE	15	15	OCD
NCT0000154814	NCT00001548_14_T0	PHENOTYPE	7	7	tics
NCT0000154814	NCT00001548_14_T1	PHENOTYPE	9	9	Trichotillomania
NCT0000154814	NCT00001548_14_T2	PHENOTYPE	3	3	Syndrome
NCT0000154814	NCT00001548_14_T3	PHENOTYPE	11	12	hair pulling
NCT000015501	NCT00001550_1_T0	ORGAN	13	13	limbs
NCT000015501	NCT00001550_1_T1	TISSUE	10	10	muscles
NCT000015501	NCT00001550_1_T2	PHENOTYPE	8	8	rigidity
NCT000015501	NCT00001550_1_T3	PHENOTYPE	5	6	muscle spasms
NCT000015503	NCT00001550_3_T0	ORGAN	17	18	nervous system
NCT000015503	NCT00001550_3_T1	PHENOTYPE	2	3	Stiff-man Syndrome
NCT000015504	NCT00001550_4_T0	PHENOTYPE	14	14	symptoms
NCT000015504	NCT00001550_4_T1	PHENOTYPE	16	17	Stiff-man Syndrome
NCT000015506	NCT00001550_6_T0	PHENOTYPE	17	17	Syndrome
NCT000015509	NCT00001550_9_T0	PHENOTYPE	9	9	sterile
NCT0000155011	NCT00001550_11_T0	PHENOTYPE	19	19	stiffness
NCT0000155014	NCT00001550_14_T0	PHENOTYPE	21	21	symptoms
NCT0000155016	NCT00001550_16_T0	PHENOTYPE	18	18	stiffness
NCT0000155024	NCT00001550_24_T0	PHENOTYPE	14	14	severely
NCT0000155024	NCT00001550_24_T1	PHENOTYPE	9	9	cardiomyopathy
NCT0000155024	NCT00001550_24_T2	PHENOTYPE	1	2	critically ill
NCT000015512	NCT00001551_2_T0	PHENOTYPE	0	0	Stuttering
NCT000015512	NCT00001551_2_T1	PHENOTYPE	7	7	repetitions
NCT000015514	NCT00001551_4_T0	PHENOTYPE	0	2	Speech articulation disorders
NCT000015517	NCT00001551_7_T0	GENE	9	9	extended
NCT000015517	NCT00001551_7_T1	PHENOTYPE	47	48	speech disorders
NCT000015517	NCT00001551_7_T2	PHENOTYPE	18	20	speech articulation disorders
NCT0000155110	NCT00001551_10_T0	PHENOTYPE	5	6	developmental stuttering
NCT0000155111	NCT00001551_11_T0	PHENOTYPE	12	12	stuttering
NCT0000155111	NCT00001551_11_T1	PHENOTYPE	7	8	developmental stuttering
NCT0000155112	NCT00001551_12_T0	PHENOTYPE	7	8	developmental stuttering
NCT0000155113	NCT00001551_13_T0	PHENOTYPE	8	8	disorders
NCT0000155125	NCT00001551_25_T0	PHENOTYPE	81	81	severity
NCT0000155125	NCT00001551_25_T1	PHENOTYPE	64	64	Stuttering
NCT0000155125	NCT00001551_25_T2	GENE	58	58	FOR
NCT0000155125	NCT00001551_25_T3	GENE	4	4	III
NCT0000155125	NCT00001551_25_T4	PHENOTYPE	65	65	Severity
NCT0000155125	NCT00001551_25_T5	PHENOTYPE	49	49	Comprehension
NCT0000155125	NCT00001551_25_T6	GENE	29	29	Span
NCT0000155125	NCT00001551_25_T7	PHENOTYPE	83	83	stuttering
NCT0000155125	NCT00001551_25_T8	COMPOUND	67	67	3
NCT0000155125	NCT00001551_25_T9	GENE	70	70	has
NCT0000155125	NCT00001551_25_T10	PHENOTYPE	62	62	STUTTERING
NCT0000155126	NCT00001551_26_T0	PHENOTYPE	5	5	stuttering
NCT0000155129	NCT00001551_29_T0	GENE	2	2	FOR
NCT0000155130	NCT00001551_30_T0	PHENOTYPE	18	18	persistence
NCT0000155130	NCT00001551_30_T1	PHENOTYPE	12	13	speech disorder
NCT0000155130	NCT00001551_30_T2	PHENOTYPE	5	6	autosomal dominant
NCT0000155131	NCT00001551_31_T0	PHENOTYPE	1	1	symptoms
NCT0000155131	NCT00001551_31_T1	PHENOTYPE	6	6	deletion
NCT0000155131	NCT00001551_31_T2	PHENOTYPE	14	14	deletion
NCT0000155131	NCT00001551_31_T3	PHENOTYPE	15	15	deletion
NCT0000155135	NCT00001551_35_T0	GENE	7	7	1.2
NCT0000155135	NCT00001551_35_T1	GENE	22	22	III
NCT0000155143	NCT00001551_43_T0	PHENOTYPE	2	3	delayed language
NCT0000155145	NCT00001551_45_T0	PHENOTYPE	0	1	Language impairment
NCT0000155147	NCT00001551_47_T0	PHENOTYPE	0	1	Cognitive impairment
NCT000015522	NCT00001552_2_T0	PHENOTYPE	0	1	Spasmodic dysphonia
NCT000015526	NCT00001552_6_T0	PHENOTYPE	12	12	paralysis
NCT000015526	NCT00001552_6_T1	ORGAN	10	11	vocal fold
NCT000015529	NCT00001552_9_T0	PHENOTYPE	23	23	tremor
NCT000015529	NCT00001552_9_T1	PHENOTYPE	17	18	voice disorders
NCT000015529	NCT00001552_9_T2	PHENOTYPE	20	21	spasmodic dysphonia
NCT0000155210	NCT00001552_10_T0	PHENOTYPE	20	20	symptoms
NCT0000155210	NCT00001552_10_T1	PHENOTYPE	14	14	paralysis
NCT0000155210	NCT00001552_10_T2	ORGAN	12	13	vocal fold
NCT0000155210	NCT00001552_10_T3	PHENOTYPE	22	23	spasmodic dysphonia
NCT0000155211	NCT00001552_11_T0	PHENOTYPE	13	13	paralysis
NCT0000155211	NCT00001552_11_T1	PHENOTYPE	6	6	focused
NCT0000155211	NCT00001552_11_T2	PHENOTYPE	30	30	neuropathies
NCT0000155211	NCT00001552_11_T3	GENE	5	5	has
NCT0000155211	NCT00001552_11_T4	ORGAN	11	12	vocal fold
NCT0000155212	NCT00001552_12_T0	PHENOTYPE	5	5	disorders
NCT0000155212	NCT00001552_12_T1	PHENOTYPE	10	11	peripheral neuropathies
NCT0000155213	NCT00001552_13_T0	GENE	3	3	shifted
NCT0000155213	NCT00001552_13_T1	PHENOTYPE	15	16	spasmodic dysphonia
NCT0000155214	NCT00001552_14_T0	PHENOTYPE	6	7	spasmodic dysphonia
NCT0000155215	NCT00001552_15_T0	PHENOTYPE	15	16	spasmodic dysphonia
NCT0000155216	NCT00001552_16_T0	PHENOTYPE	13	14	spasmodic dysphonia
NCT0000155217	NCT00001552_17_T0	PHENOTYPE	14	14	tremor
NCT0000155217	NCT00001552_17_T1	PHENOTYPE	12	12	paralysis
NCT0000155217	NCT00001552_17_T2	ORGAN	10	11	vocal fold
NCT0000155217	NCT00001552_17_T3	PHENOTYPE	8	9	spasmodic dysphonia
NCT0000155220	NCT00001552_20_T0	PHENOTYPE	19	19	pathology
NCT0000155222	NCT00001552_22_T0	PHENOTYPE	18	18	disorders
NCT0000155224	NCT00001552_24_T0	PHENOTYPE	0	0	Symptoms
NCT0000155225	NCT00001552_25_T0	PHENOTYPE	11	11	coughing
NCT0000155226	NCT00001552_26_T0	PHENOTYPE	8	9	airway obstruction
NCT0000155227	NCT00001552_27_T0	PHENOTYPE	10	10	polyps
NCT0000155227	NCT00001552_27_T1	PHENOTYPE	9	9	nodules
NCT0000155227	NCT00001552_27_T2	ORGAN	4	4	larynx
NCT0000155227	NCT00001552_27_T3	PHENOTYPE	16	16	inflammation
NCT0000155227	NCT00001552_27_T4	PHENOTYPE	11	11	carcinoma
NCT0000155227	NCT00001552_27_T5	PHENOTYPE	12	12	cysts
NCT0000155227	NCT00001552_27_T6	PHENOTYPE	17	17	laryngitis
NCT0000155227	NCT00001552_27_T7	PHENOTYPE	13	14	contact ulcers
NCT0000155227	NCT00001552_27_T8	ORGAN	7	8	vocal fold
NCT0000155228	NCT00001552_28_T0	PHENOTYPE	16	16	paralysis
NCT0000155228	NCT00001552_28_T1	PHENOTYPE	22	22	neoplasm
NCT0000155228	NCT00001552_28_T2	PHENOTYPE	18	18	paresis
NCT0000155228	NCT00001552_28_T3	PHENOTYPE	19	20	joint abnormality
NCT0000155228	NCT00001552_28_T4	ORGAN	2	3	vocal fold
NCT0000155230	NCT00001552_30_T0	PHENOTYPE	5	6	psychiatric disorder
NCT0000155230	NCT00001552_30_T1	PHENOTYPE	20	21	psychiatric disorder
NCT0000155231	NCT00001552_31_T0	PHENOTYPE	23	23	schizophrenia
NCT0000155231	NCT00001552_31_T1	PHENOTYPE	11	11	disorders
NCT0000155231	NCT00001552_31_T2	PHENOTYPE	8	9	somatoform disorders
NCT0000155231	NCT00001552_31_T3	PHENOTYPE	26	27	bipolar disorder
NCT0000155231	NCT00001552_31_T4	PHENOTYPE	17	18	major depression
NCT0000155231	NCT00001552_31_T5	PHENOTYPE	2	3	psychiatric disorders
NCT000015531	NCT00001553_1_T0	PHENOTYPE	15	15	understood
NCT000015531	NCT00001553_1_T1	PHENOTYPE	8	9	motor function
NCT000015532	NCT00001553_2_T0	ORGAN	16	16	limb
NCT000015535	NCT00001553_5_T0	PHENOTYPE	15	16	motor function
NCT000015536	NCT00001553_6_T0	ORGAN	7	7	limb
NCT000015536	NCT00001553_6_T1	ORGAN	14	14	limb
NCT000015537	NCT00001553_7_T0	ORGAN	12	12	limb
NCT000015538	NCT00001553_8_T0	PHENOTYPE	15	16	motor function
NCT000015539	NCT00001553_9_T0	ORGAN	17	17	limbs
NCT0000155311	NCT00001553_11_T0	PHENOTYPE	12	12	understood
NCT0000155311	NCT00001553_11_T1	PHENOTYPE	6	7	motor function
NCT0000155312	NCT00001553_12_T0	ORGAN	27	27	limb
NCT0000155312	NCT00001553_12_T1	PHENOTYPE	16	16	chronic
NCT0000155317	NCT00001553_17_T0	PHENOTYPE	12	13	motor function
NCT0000155319	NCT00001553_19_T0	PHENOTYPE	17	18	motor function
NCT0000155325	NCT00001553_25_T0	GENE	5	5	MRI
NCT000015542	NCT00001554_2_T0	GENE	14	14	MRI
NCT0000155410	NCT00001554_10_T0	BIOLOGICAL_PROCESS	9	9	diuresis
NCT0000155410	NCT00001554_10_T1	PHENOTYPE	5	7	cerebrospinal fluid drainage
NCT000015607	NCT00001560_7_T0	PHENOTYPE	0	0	Tumor
NCT0000156026	NCT00001560_26_T0	PHENOTYPE	0	0	Tumor
NCT000015612	NCT00001561_2_T0	GENE	17	17	PP
NCT000015612	NCT00001561_2_T1	PHENOTYPE	2	2	myeloma
NCT000015612	NCT00001561_2_T2	COMPOUND	15	15	KLH
NCT000015612	NCT00001561_2_T3	GENE	19	19	GM-CSF
NCT000015612	NCT00001561_2_T4	ORGAN	4	4	plasma
NCT000015612	NCT00001561_2_T5	ORGAN	10	10	plasma
NCT000015613	NCT00001561_3_T0	PHENOTYPE	23	23	GVHD
NCT000015616	NCT00001561_6_T0	ORGAN	14	14	marrow
NCT000015616	NCT00001561_6_T1	ORGAN	15	15	grafts
NCT000015616	NCT00001561_6_T2	ORGAN	1	2	bone marrow
NCT0000156110	NCT00001561_10_T0	GENE	43	43	PR
NCT0000156110	NCT00001561_10_T1	PHENOTYPE	26	28	minimal residual disease
NCT0000156111	NCT00001561_11_T0	ORGAN	17	18	bone marrow
NCT0000156112	NCT00001561_12_T0	GENE	9	9	booster
NCT0000156113	NCT00001561_13_T0	GENE	1	1	0.5
NCT0000156114	NCT00001561_14_T0	GENE	0	0	GM-CSF
NCT0000156115	NCT00001561_15_T0	ORGAN	13	13	marrow
NCT0000156115	NCT00001561_15_T1	PHENOTYPE	26	26	myeloma
NCT0000156115	NCT00001561_15_T2	ORGAN	14	14	transplant
NCT0000156115	NCT00001561_15_T3	PHENOTYPE	11	11	immunity
NCT0000156117	NCT00001561_17_T0	GENE	5	5	3.4
NCT0000156117	NCT00001561_17_T1	COMPOUND	11	11	cyclophosphamide
NCT0000156117	NCT00001561_17_T2	ORGAN	14	15	autologous transplant
NCT0000156119	NCT00001561_19_T0	PHENOTYPE	9	9	toxicity
NCT0000156125	NCT00001561_25_T0	COMPOUND	34	34	MUGA
NCT0000156125	NCT00001561_25_T1	GENE	36	36	ventricular
NCT0000156125	NCT00001561_25_T2	ORGAN	20	20	transplant
NCT0000156125	NCT00001561_25_T3	ORGAN	29	29	transplant
NCT0000156125	NCT00001561_25_T4	GENE	57	57	Hb
NCT0000156125	NCT00001561_25_T5	GENE	39	39	has
NCT0000156125	NCT00001561_25_T6	ORGAN	27	28	bone marrow
NCT0000156126	NCT00001561_26_T0	GENE	11	11	2.4
NCT0000156127	NCT00001561_27_T0	COMPOUND	1	1	creatinine
NCT0000156127	NCT00001561_27_T1	COMPOUND	5	5	creatinine
NCT0000156128	NCT00001561_28_T0	GENE	21	21	2.4
NCT0000156128	NCT00001561_28_T1	COMPOUND	1	1	bilirubin
NCT0000156129	NCT00001561_29_T0	PHENOTYPE	6	7	Hepatitis C
NCT0000156132	NCT00001561_32_T0	GENE	0	0	M-protein
NCT0000156132	NCT00001561_32_T1	ORGAN	5	5	plasma
NCT0000156134	NCT00001561_34_T0	ORGAN	16	16	marrow
NCT0000156137	NCT00001561_37_T0	PHENOTYPE	0	0	HIV
NCT0000156137	NCT00001561_37_T1	PHENOTYPE	1	2	hepatitis B
NCT000015632	NCT00001563_2_T0	PHENOTYPE	18	18	lymphoma
NCT000015632	NCT00001563_2_T1	COMPOUND	11	11	EPOCH
NCT000015633	NCT00001563_3_T0	PHENOTYPE	6	6	toxicity
NCT000015635	NCT00001563_5_T0	GENE	12	12	c-myc
NCT000015635	NCT00001563_5_T1	PHENOTYPE	11	11	proliferation
NCT000015635	NCT00001563_5_T2	PHENOTYPE	10	10	tumor
NCT000015635	NCT00001563_5_T3	GENE	8	8	bcl-2
NCT000015635	NCT00001563_5_T4	GENE	5	5	p53
NCT000015635	NCT00001563_5_T5	PHENOTYPE	0	0	Tumors
NCT000015638	NCT00001563_8_T0	PHENOTYPE	18	18	lymphoma
NCT000015638	NCT00001563_8_T1	COMPOUND	11	11	EPOCH
NCT000015639	NCT00001563_9_T0	PHENOTYPE	6	6	toxicity
NCT0000156311	NCT00001563_11_T0	GENE	12	12	c-myc
NCT0000156311	NCT00001563_11_T1	PHENOTYPE	11	11	proliferation
NCT0000156311	NCT00001563_11_T2	PHENOTYPE	10	10	tumor
NCT0000156311	NCT00001563_11_T3	GENE	8	8	bcl-2
NCT0000156311	NCT00001563_11_T4	GENE	5	5	p53
NCT0000156311	NCT00001563_11_T5	PHENOTYPE	0	0	Tumors
NCT0000156317	NCT00001563_17_T0	PHENOTYPE	2	2	Abnormalities
NCT0000156317	NCT00001563_17_T1	PHENOTYPE	11	11	lymphoma
NCT0000156318	NCT00001563_18_T0	GENE	6	6	1.7
NCT0000156319	NCT00001563_19_T0	GENE	5	5	2.0
NCT0000156319	NCT00001563_19_T1	GENE	25	25	0.2
NCT0000156319	NCT00001563_19_T2	GENE	35	35	3.5
NCT0000156319	NCT00001563_19_T3	GENE	15	15	3.7
NCT0000156319	NCT00001563_19_T4	GENE	49	49	protease
NCT0000156319	NCT00001563_19_T5	PHENOTYPE	8	9	total bilirubin
NCT0000156321	NCT00001563_21_T0	GENE	0	0	ANC
NCT0000156325	NCT00001563_25_T0	PHENOTYPE	3	4	heart failure
NCT0000156325	NCT00001563_25_T1	PHENOTYPE	7	9	ischemic heart disease
NCT0000156326	NCT00001563_26_T0	PHENOTYPE	8	8	HIV
NCT0000156326	NCT00001563_26_T1	COMPOUND	12	12	EPOCH
NCT0000156327	NCT00001563_27_T0	COMPOUND	4	4	EPOCH
NCT000015641	NCT00001564_1_T0	GENE	5	5	separated
NCT000015641	NCT00001564_1_T1	CELL	16	16	monocyte
NCT000015641	NCT00001564_1_T2	CELL	0	1	T cells
NCT000015646	NCT00001564_6_T0	GENE	13	13	IL-2
NCT000015646	NCT00001564_6_T1	PHENOTYPE	1	2	toxic effect
NCT000015647	NCT00001564_7_T0	PHENOTYPE	13	13	toxic
NCT000015647	NCT00001564_7_T1	GENE	17	17	IL-2
NCT0000156410	NCT00001564_10_T0	PHENOTYPE	7	8	recurrent disease
NCT0000156411	NCT00001564_11_T0	GENE	12	12	AR
NCT0000156411	NCT00001564_11_T1	PHENOTYPE	9	9	recurrent
NCT0000156413	NCT00001564_13_T0	GENE	13	13	fusion
NCT0000156413	NCT00001564_13_T1	GENE	3	3	AR
NCT0000156413	NCT00001564_13_T2	PHENOTYPE	23	23	tumors
NCT0000156413	NCT00001564_13_T3	PHENOTYPE	4	4	tumor
NCT0000156413	NCT00001564_13_T4	PHENOTYPE	5	6	chromosomal translocations
NCT0000156414	NCT00001564_14_T0	GENE	4	4	fusion
NCT0000156414	NCT00001564_14_T1	PHENOTYPE	12	12	tumor
NCT0000156414	NCT00001564_14_T2	CELL	16	17	T cells
NCT0000156417	NCT00001564_17_T0	GENE	24	24	fusion
NCT0000156417	NCT00001564_17_T1	PHENOTYPE	10	10	tumor
NCT0000156417	NCT00001564_17_T2	PHENOTYPE	23	23	tumor
NCT0000156417	NCT00001564_17_T3	GENE	11	12	fusion protein
NCT0000156418	NCT00001564_18_T0	PHENOTYPE	17	18	alveolar rhabdomyosarcoma
NCT0000156423	NCT00001564_23_T0	PHENOTYPE	11	12	tumor recurrence
NCT0000156427	NCT00001564_27_T0	PHENOTYPE	12	12	recurrence
NCT0000156428	NCT00001564_28_T0	PHENOTYPE	7	7	recurrence
NCT0000156428	NCT00001564_28_T1	PHENOTYPE	14	14	peripheral
NCT0000156431	NCT00001564_31_T0	PHENOTYPE	19	19	acute
NCT0000156431	NCT00001564_31_T1	PHENOTYPE	20	20	toxicities
NCT0000156433	NCT00001564_33_T0	GENE	31	31	2.0
NCT0000156433	NCT00001564_33_T1	ORGAN	21	21	liver
NCT0000156433	NCT00001564_33_T2	GENE	10	10	1.5
NCT0000156433	NCT00001564_33_T3	COMPOUND	28	28	bilirubin
NCT0000156433	NCT00001564_33_T4	ORGAN	6	6	serum
NCT0000156434	NCT00001564_34_T0	PHENOTYPE	17	17	tumor
NCT0000156435	NCT00001564_35_T0	COMPOUND	26	26	MUGA
NCT0000156435	NCT00001564_35_T1	ORGAN	10	11	cardiovascular system
NCT0000156436	NCT00001564_36_T0	PHENOTYPE	10	10	Hgb
NCT0000156436	NCT00001564_36_T1	PHENOTYPE	21	21	Hgb
NCT0000156436	NCT00001564_36_T2	GENE	39	39	1.0
NCT0000156436	NCT00001564_36_T3	GENE	24	24	8.0
NCT0000156436	NCT00001564_36_T4	GENE	13	13	9.0
NCT0000156436	NCT00001564_36_T5	GENE	36	36	ANC
NCT0000156436	NCT00001564_36_T6	ORGAN	4	5	bone marrow
NCT0000156439	NCT00001564_39_T0	PHENOTYPE	2	3	hepatitis B
NCT0000156439	NCT00001564_39_T1	PHENOTYPE	5	6	hepatitis C
NCT000015653	NCT00001565_3_T0	PHENOTYPE	13	13	toxicities
NCT000015653	NCT00001565_3_T1	GENE	14	14	DLT
NCT000015653	NCT00001565_3_T2	PHENOTYPE	8	9	tumor progression
NCT000015655	NCT00001565_5_T0	GENE	15	15	DLT
NCT0000156510	NCT00001565_10_T0	PHENOTYPE	14	14	toxicities
NCT0000156511	NCT00001565_11_T0	PHENOTYPE	3	3	pharmacokinetics
NCT0000156513	NCT00001565_13_T0	PHENOTYPE	4	4	progressive
NCT0000156513	NCT00001565_13_T1	PHENOTYPE	2	2	neurofibromatosis
NCT0000156513	NCT00001565_13_T2	PHENOTYPE	6	7	plexiform neurofibromas
NCT0000156514	NCT00001565_14_T0	ORGAN	2	2	brainstem
NCT0000156514	NCT00001565_14_T1	PHENOTYPE	3	3	gliomas
NCT0000156515	NCT00001565_15_T0	PHENOTYPE	9	9	diseases
NCT0000156517	NCT00001565_17_T0	PHENOTYPE	7	7	toxicity
NCT0000156522	NCT00001565_22_T0	COMPOUND	8	8	dexamethasone
NCT0000156523	NCT00001565_23_T0	PHENOTYPE	0	0	Endocrine
NCT0000156526	NCT00001565_26_T0	PHENOTYPE	6	6	toxic
NCT0000156526	NCT00001565_26_T1	PHENOTYPE	0	0	Other
NCT0000156528	NCT00001565_28_T0	GENE	2	2	Age
NCT0000156529	NCT00001565_29_T0	GENE	3	3	0.2
NCT0000156531	NCT00001565_31_T0	PHENOTYPE	31	31	toxicity
NCT0000156531	NCT00001565_31_T1	CELL	33	33	granulocyte
NCT0000156531	NCT00001565_31_T2	GENE	35	35	AGC
NCT0000156531	NCT00001565_31_T3	ORGAN	12	13	bone marrow
NCT0000156531	NCT00001565_31_T4	ORGAN	19	20	bone marrow
NCT0000156532	NCT00001565_32_T0	PHENOTYPE	0	1	Platelet count
NCT0000156536	NCT00001565_36_T0	GENE	7	7	OR
NCT0000156536	NCT00001565_36_T1	GENE	5	5	1.5
NCT0000156537	NCT00001565_37_T0	PHENOTYPE	0	0	Other
NCT0000156537	NCT00001565_37_T1	PHENOTYPE	2	3	systemic illness
NCT000015661	NCT00001566_1_T0	PHENOTYPE	1	1	tumor
NCT000015661	NCT00001566_1_T1	GENE	10	11	fusion protein
NCT000015666	NCT00001566_6_T0	PHENOTYPE	10	10	malignancy
NCT0000156612	NCT00001566_12_T0	GENE	10	10	AR
NCT0000156612	NCT00001566_12_T1	PHENOTYPE	5	5	tumors
NCT0000156612	NCT00001566_12_T2	PHENOTYPE	18	18	diseases
NCT0000156612	NCT00001566_12_T3	PHENOTYPE	8	9	alveolar rhabdomyosarcoma
NCT0000156612	NCT00001566_12_T4	PHENOTYPE	1	2	Ewing's sarcoma
NCT0000156614	NCT00001566_14_T0	GENE	10	10	fusion
NCT0000156614	NCT00001566_14_T1	PHENOTYPE	21	21	tumors
NCT0000156614	NCT00001566_14_T2	PHENOTYPE	1	1	tumor
NCT0000156614	NCT00001566_14_T3	PHENOTYPE	2	3	chromosomal translocations
NCT0000156615	NCT00001566_15_T0	GENE	4	4	fusion
NCT0000156615	NCT00001566_15_T1	PHENOTYPE	12	12	tumor
NCT0000156615	NCT00001566_15_T2	CELL	16	17	T cells
NCT0000156620	NCT00001566_20_T0	GENE	18	18	polymerase
NCT0000156620	NCT00001566_20_T1	PHENOTYPE	10	10	tumor
NCT0000156620	NCT00001566_20_T2	PHENOTYPE	28	28	tumor
NCT0000156620	NCT00001566_20_T3	BIOLOGICAL_PROCESS	16	17	reverse transcription
NCT0000156620	NCT00001566_20_T4	GENE	11	12	fusion protein
NCT0000156621	NCT00001566_21_T0	PHENOTYPE	21	21	tumor
NCT0000156621	NCT00001566_21_T1	GENE	3	3	IV
NCT0000156621	NCT00001566_21_T2	PHENOTYPE	5	6	metastatic disease
NCT0000156623	NCT00001566_23_T0	GENE	8	8	IV
NCT0000156623	NCT00001566_23_T1	PHENOTYPE	10	11	metastatic disease
NCT0000156625	NCT00001566_25_T0	PHENOTYPE	17	18	alveolar rhabdomyosarcoma
NCT0000156628	NCT00001566_28_T0	COMPOUND	7	7	creatinine
NCT0000156628	NCT00001566_28_T1	COMPOUND	14	14	creatinine
NCT0000156628	NCT00001566_28_T2	GENE	35	35	2.0
NCT0000156628	NCT00001566_28_T3	ORGAN	24	24	liver
NCT0000156628	NCT00001566_28_T4	GENE	11	11	1.5
NCT0000156628	NCT00001566_28_T5	COMPOUND	32	32	bilirubin
NCT0000156628	NCT00001566_28_T6	ORGAN	6	6	serum
NCT0000156629	NCT00001566_29_T0	PHENOTYPE	17	17	tumor
NCT0000156630	NCT00001566_30_T0	GENE	5	5	CD4
NCT0000156633	NCT00001566_33_T0	PHENOTYPE	2	3	hepatitis B
NCT0000156633	NCT00001566_33_T1	PHENOTYPE	5	6	hepatitis C
NCT000015672	NCT00001567_2_T0	PHENOTYPE	8	8	remission
NCT000015673	NCT00001567_3_T0	GENE	1	1	interferon
NCT000015673	NCT00001567_3_T1	PHENOTYPE	6	7	disease progression
NCT000015674	NCT00001567_4_T0	GENE	23	23	interferon
NCT000015676	NCT00001567_6_T0	PHENOTYPE	16	16	remission
NCT000015676	NCT00001567_6_T1	PHENOTYPE	19	19	remissions
NCT000015676	NCT00001567_6_T2	PHENOTYPE	33	34	disease progression
NCT000015677	NCT00001567_7_T0	GENE	17	17	9_2
NCT000015677	NCT00001567_7_T1	GENE	5	5	interferon
NCT000015677	NCT00001567_7_T2	GENE	14	14	interferon
NCT000015679	NCT00001567_9_T0	GENE	3	3	interferon
NCT0000156713	NCT00001567_13_T0	PHENOTYPE	25	25	relapse
NCT0000156714	NCT00001567_14_T0	GENE	13	13	has
NCT0000156714	NCT00001567_14_T1	GENE	12	12	interferon
NCT0000156715	NCT00001567_15_T0	PHENOTYPE	9	9	toxicity
NCT0000156715	NCT00001567_15_T1	PHENOTYPE	36	36	complication
NCT0000156715	NCT00001567_15_T2	GENE	12	12	interferon
NCT0000156715	NCT00001567_15_T3	GENE	30	30	interferon
NCT0000156715	NCT00001567_15_T4	PHENOTYPE	11	11	chronic
NCT0000156715	NCT00001567_15_T5	PHENOTYPE	33	34	second malignancies
NCT0000156721	NCT00001567_21_T0	PHENOTYPE	8	8	remission
NCT0000156722	NCT00001567_22_T0	GENE	1	1	interferon
NCT0000156722	NCT00001567_22_T1	PHENOTYPE	6	7	disease progression
NCT0000156723	NCT00001567_23_T0	GENE	23	23	interferon
NCT0000156725	NCT00001567_25_T0	PHENOTYPE	16	16	remission
NCT0000156725	NCT00001567_25_T1	PHENOTYPE	19	19	remissions
NCT0000156725	NCT00001567_25_T2	PHENOTYPE	33	34	disease progression
NCT0000156726	NCT00001567_26_T0	GENE	17	17	9_2
NCT0000156726	NCT00001567_26_T1	GENE	5	5	interferon
NCT0000156726	NCT00001567_26_T2	GENE	14	14	interferon
NCT0000156728	NCT00001567_28_T0	GENE	3	3	interferon
NCT0000156732	NCT00001567_32_T0	PHENOTYPE	25	25	relapse
NCT0000156733	NCT00001567_33_T0	GENE	13	13	has
NCT0000156733	NCT00001567_33_T1	GENE	12	12	interferon
NCT0000156734	NCT00001567_34_T0	PHENOTYPE	9	9	toxicity
NCT0000156734	NCT00001567_34_T1	PHENOTYPE	36	36	complication
NCT0000156734	NCT00001567_34_T2	GENE	12	12	interferon
NCT0000156734	NCT00001567_34_T3	GENE	30	30	interferon
NCT0000156734	NCT00001567_34_T4	PHENOTYPE	11	11	chronic
NCT0000156734	NCT00001567_34_T5	PHENOTYPE	33	34	second malignancies
NCT0000156739	NCT00001567_39_T0	PHENOTYPE	8	8	peripheral
NCT0000156739	NCT00001567_39_T1	ORGAN	12	12	marrow
NCT0000156739	NCT00001567_39_T2	GENE	5	5	hairy
NCT0000156739	NCT00001567_39_T3	GENE	36	36	hairy
NCT0000156739	NCT00001567_39_T4	CELL	6	6	cells
NCT0000156739	NCT00001567_39_T5	CELL	37	37	cells
NCT0000156739	NCT00001567_39_T6	GENE	28	30	tartrate-resistant acid phosphatase
NCT0000156741	NCT00001567_41_T0	PHENOTYPE	16	16	infiltrate
NCT0000156741	NCT00001567_41_T1	PHENOTYPE	18	18	Lymphadenopathy
NCT0000156741	NCT00001567_41_T2	PHENOTYPE	11	11	Pancytopenia
NCT0000156741	NCT00001567_41_T3	PHENOTYPE	21	21	hepatomegaly
NCT0000156741	NCT00001567_41_T4	PHENOTYPE	19	19	splenomegaly
NCT0000156741	NCT00001567_41_T5	ORGAN	13	14	Bone marrow
NCT0000156743	NCT00001567_43_T0	PHENOTYPE	5	6	Hepatitis B
NCT0000156747	NCT00001567_47_T0	GENE	3	3	III
NCT0000156747	NCT00001567_47_T1	GENE	5	5	IV
NCT0000156747	NCT00001567_47_T2	PHENOTYPE	6	7	cardiovascular disease
NCT0000156748	NCT00001567_48_T0	GENE	9	9	had
NCT0000156749	NCT00001567_49_T0	COMPOUND	7	7	creatinine
NCT0000156749	NCT00001567_49_T1	GENE	10	10	1.8
NCT0000156749	NCT00001567_49_T2	ORGAN	6	6	serum
NCT0000156749	NCT00001567_49_T3	PHENOTYPE	3	5	impaired renal function
NCT0000156750	NCT00001567_50_T0	GENE	10	10	1.4
NCT0000156750	NCT00001567_50_T1	PHENOTYPE	6	7	total bilirubin
NCT0000156751	NCT00001567_51_T0	PHENOTYPE	3	4	serum calcium
NCT0000156753	NCT00001567_53_T0	CELL	9	9	fibroblast
NCT0000156753	NCT00001567_53_T1	CELL	7	7	leukocyte
NCT0000156753	NCT00001567_53_T2	GENE	4	4	had
NCT0000156753	NCT00001567_53_T3	GENE	10	10	interferon
NCT000015681	NCT00001568_1_T0	GENE	3	3	FDG
NCT000015682	NCT00001568_2_T0	ORGAN	8	8	heart
NCT000015684	NCT00001568_4_T0	GENE	1	1	CEA
NCT0000156811	NCT00001568_11_T0	PHENOTYPE	5	5	recurrences
NCT0000156812	NCT00001568_12_T0	GENE	11	11	CEA
NCT0000156814	NCT00001568_14_T0	ORGAN	4	4	serum
NCT0000156814	NCT00001568_14_T1	GENE	5	5	CEA
NCT0000156815	NCT00001568_15_T0	PHENOTYPE	20	20	localizing
NCT0000156815	NCT00001568_15_T1	GENE	10	10	CEA
NCT0000156816	NCT00001568_16_T0	ORGAN	27	27	serum
NCT0000156816	NCT00001568_16_T1	GENE	15	15	CEA
NCT0000156816	NCT00001568_16_T2	GENE	28	28	CEA
NCT0000156816	NCT00001568_16_T3	PHENOTYPE	22	23	colorectal carcinoma
NCT0000156817	NCT00001568_17_T0	GENE	10	10	CEA
NCT0000156818	NCT00001568_18_T0	GENE	21	21	CEA
NCT0000156823	NCT00001568_23_T0	ORGAN	1	1	serum
NCT0000156823	NCT00001568_23_T1	GENE	2	2	CEA
NCT0000156824	NCT00001568_24_T0	PHENOTYPE	3	4	recurrent disease
NCT0000156826	NCT00001568_26_T0	GENE	25	25	MRI
NCT0000156826	NCT00001568_26_T1	ORGAN	21	21	abdomen
NCT0000156826	NCT00001568_26_T2	ORGAN	22	22	pelvis
NCT0000156826	NCT00001568_26_T3	PHENOTYPE	10	11	recurrent disease
NCT0000156831	NCT00001568_31_T0	GENE	8	8	abdominal
NCT0000156832	NCT00001568_32_T0	GENE	6	6	abdominal
NCT0000156833	NCT00001568_33_T0	PHENOTYPE	3	4	recurrent disease
NCT0000156834	NCT00001568_34_T0	PHENOTYPE	0	1	Metastatic disease
NCT0000156834	NCT00001568_34_T1	ORGAN	6	7	abdominal cavity
NCT0000156834	NCT00001568_34_T2	PHENOTYPE	1	2	disease localized
NCT000015691	NCT00001569_1_T0	PHENOTYPE	7	7	tumor
NCT000015692	NCT00001569_2_T0	ORGAN	17	17	liver
NCT000015692	NCT00001569_2_T1	GENE	22	22	bowel
NCT000015693	NCT00001569_3_T0	PHENOTYPE	4	4	hyperthermic
NCT000015693	NCT00001569_3_T1	COMPOUND	10	10	cisplatin
NCT000015693	NCT00001569_3_T2	ORGAN	21	22	abdominal wall
NCT000015694	NCT00001569_4_T0	GENE	5	5	1.5
NCT000015694	NCT00001569_4_T1	COMPOUND	3	3	cisplatin
NCT000015698	NCT00001569_8_T0	PHENOTYPE	23	23	toxicity
NCT000015698	NCT00001569_8_T1	GENE	0	0	MTD
NCT000015698	NCT00001569_8_T2	GENE	24	24	DLT
NCT000015698	NCT00001569_8_T3	GENE	33	33	DLT
NCT0000156910	NCT00001569_10_T0	PHENOTYPE	1	1	tumor
NCT0000156913	NCT00001569_13_T0	PHENOTYPE	27	27	hyperthermic
NCT0000156913	NCT00001569_13_T1	COMPOUND	9	9	paclitaxel
NCT0000156913	NCT00001569_13_T2	COMPOUND	11	11	5_fluorouracil
NCT0000156913	NCT00001569_13_T3	COMPOUND	31	31	cisplatin
NCT000015705	NCT00001570_5_T0	PHENOTYPE	18	18	toxicity
NCT000015705	NCT00001570_5_T1	GENE	1	1	MTD
NCT0000157010	NCT00001570_10_T0	PHENOTYPE	5	5	toxicity
NCT0000157010	NCT00001570_10_T1	PHENOTYPE	0	0	Ataxia
NCT0000157016	NCT00001570_16_T0	PHENOTYPE	5	5	tumor
NCT0000157020	NCT00001570_20_T0	PHENOTYPE	0	0	Endocrine
NCT0000157023	NCT00001570_23_T0	COMPOUND	7	7	cyclosporine
NCT0000157023	NCT00001570_23_T1	PHENOTYPE	0	0	Other
NCT0000157023	NCT00001570_23_T2	PHENOTYPE	8	9	blood concentrations
NCT0000157024	NCT00001570_24_T0	GENE	2	2	Age
NCT0000157025	NCT00001570_25_T0	GENE	3	3	0.2
NCT0000157027	NCT00001570_27_T0	GENE	1	1	ANC
NCT0000157027	NCT00001570_27_T1	PHENOTYPE	8	9	Platelet count
NCT0000157029	NCT00001570_29_T0	GENE	7	7	OR
NCT0000157029	NCT00001570_29_T1	GENE	5	5	2.0
NCT0000157031	NCT00001570_31_T0	PHENOTYPE	0	0	Other
NCT0000157034	NCT00001570_34_T0	PHENOTYPE	1	2	HIV seropositivity
NCT0000157035	NCT00001570_35_T0	PHENOTYPE	4	4	cirrhosis
NCT0000157035	NCT00001570_35_T1	PHENOTYPE	1	2	chronic hepatitis
NCT000015713	NCT00001571_3_T0	PHENOTYPE	4	5	environmental exposures
NCT000015718	NCT00001571_8_T0	ORGAN	15	15	serum
NCT0000157117	NCT00001571_17_T0	PHENOTYPE	4	5	environmental exposures
NCT0000157122	NCT00001571_22_T0	ORGAN	15	15	serum
NCT000015721	NCT00001572_1_T0	GENE	26	26	1.2
NCT000015721	NCT00001572_1_T1	PHENOTYPE	37	37	tumor
NCT000015721	NCT00001572_1_T2	COMPOUND	42	42	KLH
NCT000015721	NCT00001572_1_T3	GENE	34	34	0.5
NCT000015721	NCT00001572_1_T4	PHENOTYPE	14	14	remission
NCT000015723	NCT00001572_3_T0	PHENOTYPE	11	11	toxicity
NCT000015723	NCT00001572_3_T1	PHENOTYPE	32	32	lymphoma
NCT000015724	NCT00001572_4_T0	PHENOTYPE	14	14	remission
NCT000015724	NCT00001572_4_T1	PHENOTYPE	10	11	follicular lymphomas
NCT000015724	NCT00001572_4_T2	PHENOTYPE	16	18	minimal residual disease
NCT000015725	NCT00001572_5_T0	PHENOTYPE	14	14	relapse
NCT000015725	NCT00001572_5_T1	PHENOTYPE	20	20	resistant
NCT000015728	NCT00001572_8_T0	GENE	0	0	Age
NCT0000157211	NCT00001572_11_T0	PHENOTYPE	4	4	lymphoma
NCT0000157211	NCT00001572_11_T1	GENE	1	1	III
NCT0000157211	NCT00001572_11_T2	GENE	3	3	IV
NCT0000157212	NCT00001572_12_T0	PHENOTYPE	2	2	peripheral
NCT0000157212	NCT00001572_12_T1	GENE	11	11	cm
NCT0000157212	NCT00001572_12_T2	TISSUE	3	4	lymph node
NCT0000157215	NCT00001572_15_T0	PHENOTYPE	13	13	secondary
NCT0000157215	NCT00001572_15_T1	COMPOUND	1	1	creatinine
NCT0000157215	NCT00001572_15_T2	GENE	7	7	1.5
NCT0000157215	NCT00001572_15_T3	PHENOTYPE	15	15	lymphoma
NCT0000157215	NCT00001572_15_T4	ORGAN	0	0	Serum
NCT0000157216	NCT00001572_16_T0	PHENOTYPE	12	12	secondary
NCT0000157216	NCT00001572_16_T1	GENE	6	6	1.5
NCT0000157216	NCT00001572_16_T2	PHENOTYPE	14	14	lymphoma
NCT0000157216	NCT00001572_16_T3	PHENOTYPE	16	17	Gilbert's disease
NCT0000157217	NCT00001572_17_T0	GENE	6	6	3.5
NCT0000157223	NCT00001572_23_T0	PHENOTYPE	4	4	HIV
NCT0000157223	NCT00001572_23_T1	PHENOTYPE	6	7	hepatitis B
NCT0000157224	NCT00001572_24_T0	BIOLOGICAL_PROCESS	2	2	lactation
NCT0000157229	NCT00001572_29_T0	GENE	10	10	3-2
NCT0000157231	NCT00001572_31_T0	PHENOTYPE	3	3	lymphoma
NCT000015732	NCT00001573_2_T0	PHENOTYPE	19	19	toxicity
NCT000015732	NCT00001573_2_T1	GENE	0	0	MTD
NCT000015734	NCT00001573_4_T0	GENE	12	12	1.4
NCT000015734	NCT00001573_4_T1	GENE	6	6	IV
NCT000015736	NCT00001573_6_T0	PHENOTYPE	12	12	tumors
NCT000015736	NCT00001573_6_T1	PHENOTYPE	19	19	sarcomas
NCT000015737	NCT00001573_7_T0	PHENOTYPE	26	26	toxicity
NCT000015737	NCT00001573_7_T1	PHENOTYPE	11	11	malignancies
NCT000015738	NCT00001573_8_T0	PHENOTYPE	6	6	pharmacokinetics
NCT0000157310	NCT00001573_10_T0	PHENOTYPE	4	4	toxic
NCT0000157310	NCT00001573_10_T1	PHENOTYPE	5	5	affects
NCT0000157314	NCT00001573_14_T0	COMPOUND	1	1	nitrosourea
NCT0000157315	NCT00001573_15_T0	COMPOUND	4	4	dexamethasone
NCT0000157315	NCT00001573_15_T1	PHENOTYPE	0	0	ENDOCRINE
NCT0000157318	NCT00001573_18_T0	GENE	2	2	Age
NCT0000157319	NCT00001573_19_T0	GENE	3	3	0.2
NCT0000157321	NCT00001573_21_T0	GENE	1	1	AGC
NCT0000157322	NCT00001573_22_T0	GENE	6	6	8.0
NCT0000157323	NCT00001573_23_T0	PHENOTYPE	0	1	Platelet count
NCT0000157324	NCT00001573_24_T0	GENE	22	22	6.0
NCT0000157324	NCT00001573_24_T1	GENE	15	15	AGC
NCT0000157324	NCT00001573_24_T2	PHENOTYPE	24	25	Platelet count
NCT0000157324	NCT00001573_24_T3	ORGAN	3	4	bone marrow
NCT0000157324	NCT00001573_24_T4	ORGAN	9	10	bone marrow
NCT0000157325	NCT00001573_25_T0	GENE	4	5	alkaline phosphatase
NCT0000157326	NCT00001573_26_T0	GENE	7	7	1.5
NCT0000157327	NCT00001573_27_T0	GENE	2	2	3.5
NCT0000157327	NCT00001573_27_T1	GENE	7	7	0.8
NCT0000157328	NCT00001573_28_T0	PHENOTYPE	1	1	5-10
NCT0000157328	NCT00001573_28_T1	GENE	6	6	1.0
NCT0000157329	NCT00001573_29_T0	GENE	6	6	1.2
NCT0000157330	NCT00001573_30_T0	GENE	6	6	1.5
NCT0000157332	NCT00001573_32_T0	GENE	13	13	DPA
NCT0000157332	NCT00001573_32_T1	PHENOTYPE	3	4	brain tumors
NCT0000157334	NCT00001573_34_T0	COMPOUND	3	3	etoposide
NCT000015743	NCT00001574_3_T0	PHENOTYPE	14	14	resistant
NCT000015744	NCT00001574_4_T0	GENE	14	14	MRI
NCT000015744	NCT00001574_4_T1	PHENOTYPE	2	3	brain tumors
NCT000015745	NCT00001574_5_T0	PHENOTYPE	11	11	edema
NCT000015745	NCT00001574_5_T1	BIOLOGICAL_PROCESS	12	12	necrosis
NCT000015745	NCT00001574_5_T2	PHENOTYPE	6	6	tumor
NCT000015745	NCT00001574_5_T3	PHENOTYPE	14	15	radiation injury
NCT000015747	NCT00001574_7_T0	GENE	4	4	MRI
NCT000015747	NCT00001574_7_T1	GENE	16	16	MRI
NCT000015748	NCT00001574_8_T0	PHENOTYPE	43	43	edema
NCT000015748	NCT00001574_8_T1	BIOLOGICAL_PROCESS	45	45	necrosis
NCT000015748	NCT00001574_8_T2	PHENOTYPE	37	37	tumor
NCT000015748	NCT00001574_8_T3	PHENOTYPE	39	39	tumor
NCT000015748	NCT00001574_8_T4	PHENOTYPE	22	23	brain tumors
NCT0000157416	NCT00001574_16_T0	PHENOTYPE	14	14	Oncology
NCT0000157418	NCT00001574_18_T0	PHENOTYPE	4	6	metastatic brain tumor
NCT0000157419	NCT00001574_19_T0	PHENOTYPE	4	4	glioma
NCT0000157419	NCT00001574_19_T1	GENE	11	11	had
NCT0000157419	NCT00001574_19_T2	ORGAN	3	3	brainstem
NCT0000157420	NCT00001574_20_T0	PHENOTYPE	3	3	tumor
NCT0000157425	NCT00001574_25_T0	PHENOTYPE	21	21	anesthesia
NCT0000157425	NCT00001574_25_T1	PHENOTYPE	10	11	psychological factors
NCT0000157426	NCT00001574_26_T0	COMPOUND	15	15	ferrous
NCT0000157427	NCT00001574_27_T0	COMPOUND	10	10	Gadolinium
NCT000015752	NCT00001575_2_T0	CELL	10	10	cells
NCT000015752	NCT00001575_2_T1	PHENOTYPE	9	9	tumor
NCT000015754	NCT00001575_4_T0	CELL	21	21	cells
NCT000015754	NCT00001575_4_T1	PHENOTYPE	13	14	lymphoid leukemia
NCT000015754	NCT00001575_4_T2	PHENOTYPE	8	9	Hodgkin's disease
NCT000015754	NCT00001575_4_T3	PHENOTYPE	10	11	Hodgkin's lymphoma
NCT000015755	NCT00001575_5_T0	ORGAN	26	26	abdomen
NCT000015758	NCT00001575_8_T0	TISSUE	15	15	bones
NCT000015758	NCT00001575_8_T1	ORGAN	27	28	spinal cord
NCT0000157515	NCT00001575_15_T0	GENE	13	13	IV
NCT0000157520	NCT00001575_20_T0	TISSUE	2	3	lymph node
NCT0000157520	NCT00001575_20_T1	ORGAN	0	1	Bone marrow
NCT0000157524	NCT00001575_24_T0	GENE	9	9	CD25
NCT0000157526	NCT00001575_26_T0	COMPOUND	1	1	yttrium
NCT0000157526	NCT00001575_26_T1	PHENOTYPE	13	13	tumor
NCT0000157526	NCT00001575_26_T2	GENE	6	6	CD25
NCT0000157527	NCT00001575_27_T0	PHENOTYPE	4	4	toxicity
NCT0000157527	NCT00001575_27_T1	PHENOTYPE	16	17	hematologic malignancies
NCT0000157529	NCT00001575_29_T0	PHENOTYPE	10	10	malignancies
NCT0000157529	NCT00001575_29_T1	GENE	7	7	CD25
NCT0000157529	NCT00001575_29_T2	PHENOTYPE	3	4	Hodgkin's disease
NCT0000157530	NCT00001575_30_T0	CELL	5	5	granulocyte
NCT0000157530	NCT00001575_30_T1	PHENOTYPE	12	13	platelet count
NCT0000157531	NCT00001575_31_T0	COMPOUND	24	24	yttrium
NCT0000157531	NCT00001575_31_T1	ORGAN	12	12	transplant
NCT0000157531	NCT00001575_31_T2	ORGAN	10	11	bone marrow
NCT0000157534	NCT00001575_34_T0	PHENOTYPE	0	0	Tumor
NCT0000157538	NCT00001575_38_T0	ORGAN	18	18	transplant
NCT0000157538	NCT00001575_38_T1	GENE	3	3	had
NCT0000157538	NCT00001575_38_T2	ORGAN	7	8	autologous transplant
NCT0000157539	NCT00001575_39_T0	PHENOTYPE	9	9	peripheral
NCT0000157539	NCT00001575_39_T1	CELL	7	7	cells
NCT0000157539	NCT00001575_39_T2	TISSUE	11	12	lymph node
NCT0000157540	NCT00001575_40_T0	PHENOTYPE	9	9	infiltrating
NCT0000157540	NCT00001575_40_T1	PHENOTYPE	23	23	infiltrating
NCT0000157540	NCT00001575_40_T2	CELL	33	33	cells
NCT0000157540	NCT00001575_40_T3	GENE	21	21	CD25
NCT0000157540	NCT00001575_40_T4	CELL	10	11	T cells
NCT0000157540	NCT00001575_40_T5	CELL	24	25	T cells
NCT0000157540	NCT00001575_40_T6	PHENOTYPE	13	14	Hodgkin's disease
NCT0000157544	NCT00001575_44_T0	PHENOTYPE	1	2	Hodgkin's disease
NCT0000157545	NCT00001575_45_T0	PHENOTYPE	19	19	remission
NCT0000157545	NCT00001575_45_T1	ORGAN	35	36	bone marrow
NCT0000157545	NCT00001575_45_T2	PHENOTYPE	5	6	Hodgkin's disease
NCT0000157547	NCT00001575_47_T0	GENE	5	5	III
NCT0000157547	NCT00001575_47_T1	GENE	3	3	Ib
NCT0000157548	NCT00001575_48_T0	GENE	11	11	had
NCT0000157548	NCT00001575_48_T1	GENE	3	3	IV
NCT0000157550	NCT00001575_50_T0	PHENOTYPE	6	6	lymphomas
NCT0000157550	NCT00001575_50_T1	PHENOTYPE	0	0	Other
NCT0000157550	NCT00001575_50_T2	ORGAN	31	32	bone marrow
NCT0000157550	NCT00001575_50_T3	PHENOTYPE	3	4	lymphoid leukemias
NCT0000157552	NCT00001575_52_T0	COMPOUND	4	4	creatinine
NCT0000157552	NCT00001575_52_T1	GENE	8	8	2.0
NCT0000157553	NCT00001575_53_T0	COMPOUND	9	9	creatinine
NCT0000157553	NCT00001575_53_T1	GENE	3	3	has
NCT0000157553	NCT00001575_53_T2	PHENOTYPE	6	7	elevated creatinine
NCT0000157554	NCT00001575_54_T0	GENE	26	26	3.0
NCT0000157554	NCT00001575_54_T1	PHENOTYPE	36	36	malignancy
NCT0000157554	NCT00001575_54_T2	COMPOUND	23	23	bilirubin
NCT0000157554	NCT00001575_54_T3	ORGAN	3	3	serum
NCT0000157554	NCT00001575_54_T4	ORGAN	9	9	serum
NCT0000157555	NCT00001575_55_T0	PHENOTYPE	5	6	cardiac failure
NCT0000157556	NCT00001575_56_T0	PHENOTYPE	15	15	malignancy
NCT0000157556	NCT00001575_56_T1	PHENOTYPE	4	4	dysfunction
NCT0000157557	NCT00001575_57_T0	CELL	5	5	granulocyte
NCT0000157557	NCT00001575_57_T1	PHENOTYPE	13	14	platelet count
NCT0000157560	NCT00001575_60_T0	PHENOTYPE	10	10	malignancy
NCT0000157562	NCT00001575_62_T0	COMPOUND	16	16	yttrium
NCT0000157567	NCT00001575_67_T0	ORGAN	13	14	nervous system
NCT0000157568	NCT00001575_68_T0	PHENOTYPE	3	5	second primary cancer
NCT0000157569	NCT00001575_69_T0	PHENOTYPE	2	2	chronic
NCT0000157570	NCT00001575_70_T0	PHENOTYPE	11	11	malignancy
NCT000015761	NCT00001576_1_T0	GENE	12	12	0.2
NCT000015761	NCT00001576_1_T1	COMPOUND	15	15	leucovorin
NCT000015762	NCT00001576_2_T0	PHENOTYPE	3	3	toxicity
NCT000015764	NCT00001576_4_T0	GENE	12	12	0.2
NCT000015764	NCT00001576_4_T1	COMPOUND	15	15	leucovorin
NCT000015765	NCT00001576_5_T0	PHENOTYPE	3	3	toxicity
NCT000015768	NCT00001576_8_T0	ORGAN	9	9	artery
NCT000015769	NCT00001576_9_T0	PHENOTYPE	12	12	malignancy
NCT000015769	NCT00001576_9_T1	ORGAN	19	19	liver
NCT000015769	NCT00001576_9_T2	GENE	3	3	had
NCT0000157611	NCT00001576_11_T0	GENE	12	12	2.0
NCT0000157611	NCT00001576_11_T1	GENE	21	21	1.2
NCT0000157611	NCT00001576_11_T2	COMPOUND	9	9	bilirubin
NCT0000157612	NCT00001576_12_T0	GENE	11	11	portal
NCT0000157612	NCT00001576_12_T1	PHENOTYPE	12	12	hypertension
NCT0000157612	NCT00001576_12_T2	PHENOTYPE	6	6	cirrhosis
NCT0000157613	NCT00001576_13_T0	PHENOTYPE	7	9	congestive heart failure
NCT0000157616	NCT00001576_16_T0	COMPOUND	24	24	creatinine
NCT0000157616	NCT00001576_16_T1	COMPOUND	33	33	creatinine
NCT0000157616	NCT00001576_16_T2	GENE	30	30	1.5
NCT0000157616	NCT00001576_16_T3	GENE	10	10	Hct
NCT0000157616	NCT00001576_16_T4	PHENOTYPE	4	5	platelet count
NCT0000157618	NCT00001576_18_T0	PHENOTYPE	10	10	anticoagulation
NCT0000157618	NCT00001576_18_T1	PHENOTYPE	9	9	chronic
NCT0000157621	NCT00001576_21_T0	PHENOTYPE	4	5	HIV disease
NCT000015771	NCT00001577_1_T0	ORGAN	3	3	limb
NCT000015771	NCT00001577_1_T1	COMPOUND	6	6	melphalan
NCT000015772	NCT00001577_2_T0	GENE	5	5	leak
NCT000015772	NCT00001577_2_T1	COMPOUND	22	22	melphalan
NCT000015772	NCT00001577_2_T2	GENE	7	7	has
NCT000015773	NCT00001577_3_T0	COMPOUND	3	3	melphalan
NCT000015773	NCT00001577_3_T1	PHENOTYPE	15	15	flushed
NCT000015773	NCT00001577_3_T2	ORGAN	13	13	extremity
NCT000015774	NCT00001577_4_T0	COMPOUND	3	3	melphalan
NCT000015777	NCT00001577_7_T0	ORGAN	13	13	limb
NCT000015777	NCT00001577_7_T1	ORGAN	25	25	limb
NCT000015777	NCT00001577_7_T2	COMPOUND	8	8	melphalan
NCT000015778	NCT00001577_8_T0	ORGAN	14	14	limb
NCT000015778	NCT00001577_8_T1	PHENOTYPE	4	4	sarcoma
NCT000015778	NCT00001577_8_T2	PHENOTYPE	6	6	tumor
NCT000015778	NCT00001577_8_T3	ORGAN	3	3	extremity
NCT0000157710	NCT00001577_10_T0	PHENOTYPE	7	7	recurrence
NCT0000157712	NCT00001577_12_T0	PHENOTYPE	1	1	sarcoma
NCT0000157712	NCT00001577_12_T1	PHENOTYPE	18	18	tumor
NCT0000157712	NCT00001577_12_T2	ORGAN	0	0	Extremity
NCT0000157713	NCT00001577_13_T0	GENE	39	39	cm
NCT0000157713	NCT00001577_13_T1	PHENOTYPE	11	11	metastases
NCT0000157713	NCT00001577_13_T2	PHENOTYPE	0	0	MELANOMA
NCT0000157713	NCT00001577_13_T3	PHENOTYPE	32	32	tumor
NCT0000157713	NCT00001577_13_T4	PHENOTYPE	31	31	recurrent
NCT0000157713	NCT00001577_13_T5	PHENOTYPE	34	35	metastatic tumor
NCT0000157714	NCT00001577_14_T0	GENE	32	32	deltoid
NCT0000157714	NCT00001577_14_T1	PHENOTYPE	13	13	distal
NCT0000157714	NCT00001577_14_T2	PHENOTYPE	26	26	distal
NCT0000157714	NCT00001577_14_T3	PHENOTYPE	2	2	melanoma
NCT0000157714	NCT00001577_14_T4	GENE	1	1	IV
NCT0000157714	NCT00001577_14_T5	ORGAN	23	24	lower limb
NCT0000157714	NCT00001577_14_T6	ORGAN	35	36	upper limb
NCT0000157715	NCT00001577_15_T0	ORGAN	6	6	extremity
NCT0000157715	NCT00001577_15_T1	PHENOTYPE	2	3	evaluable disease
NCT0000157718	NCT00001577_18_T0	ORGAN	13	13	extremity
NCT0000157721	NCT00001577_21_T0	PHENOTYPE	0	0	ENDOCRINE
NCT0000157724	NCT00001577_24_T0	GENE	2	2	AGE
NCT0000157725	NCT00001577_25_T0	GENE	3	3	0.2
NCT0000157727	NCT00001577_27_T0	PHENOTYPE	1	2	Platelet count
NCT0000157728	NCT00001577_28_T0	GENE	4	4	2.0
NCT0000157729	NCT00001577_29_T0	GENE	4	4	2.0
NCT0000157730	NCT00001577_30_T0	PHENOTYPE	4	6	congestive heart failure
NCT0000157731	NCT00001577_31_T0	PHENOTYPE	2	5	chronic obstructive pulmonary disease
NCT0000157732	NCT00001577_32_T0	PHENOTYPE	1	4	other chronic pulmonary disease
NCT0000157735	NCT00001577_35_T0	PHENOTYPE	4	6	peripheral vascular disease
NCT0000157736	NCT00001577_36_T0	PHENOTYPE	3	3	claudication
NCT0000157736	NCT00001577_36_T1	PHENOTYPE	7	8	vascular disease
NCT000015790	NCT00001579_0_T0	PHENOTYPE	17	18	Solid Tumors
NCT000015792	NCT00001579_2_T0	COMPOUND	19	19	calcium
NCT000015792	NCT00001579_2_T1	COMPOUND	18	18	leucovorin
NCT000015793	NCT00001579_3_T0	COMPOUND	1	1	calcium
NCT000015793	NCT00001579_3_T1	GENE	8	8	1.3
NCT000015793	NCT00001579_3_T2	GENE	5	5	bid
NCT000015795	NCT00001579_5_T0	COMPOUND	33	33	ethynyluracil
NCT000015795	NCT00001579_5_T1	COMPOUND	31	31	calcium
NCT000015795	NCT00001579_5_T2	PHENOTYPE	10	10	toxicities
NCT000015795	NCT00001579_5_T3	COMPOUND	30	30	leucovorin
NCT000015796	NCT00001579_6_T0	COMPOUND	3	3	calcium
NCT000015796	NCT00001579_6_T1	GENE	10	10	1.3
NCT000015796	NCT00001579_6_T2	COMPOUND	2	2	leucovorin
NCT000015796	NCT00001579_6_T3	GENE	6	6	bid
NCT000015797	NCT00001579_7_T0	GENE	3	3	bid
NCT0000157910	NCT00001579_10_T0	GENE	8	8	MTD
NCT0000157911	NCT00001579_11_T0	PHENOTYPE	17	17	toxicity
NCT0000157911	NCT00001579_11_T1	GENE	0	0	MTD
NCT0000157915	NCT00001579_15_T0	PHENOTYPE	8	9	solid tumors
NCT0000157916	NCT00001579_16_T0	GENE	23	23	II
NCT0000157916	NCT00001579_16_T1	GENE	17	17	IV
NCT0000157920	NCT00001579_20_T0	PHENOTYPE	10	10	tolerance
NCT0000157921	NCT00001579_21_T0	PHENOTYPE	19	19	toxicity
NCT0000157922	NCT00001579_22_T0	PHENOTYPE	8	9	disease progression
NCT0000157923	NCT00001579_23_T0	PHENOTYPE	6	6	profound
NCT0000157923	NCT00001579_23_T1	GENE	22	22	1.3
NCT0000157923	NCT00001579_23_T2	GENE	11	11	DPD
NCT0000157923	NCT00001579_23_T3	PHENOTYPE	9	9	inhibition
NCT0000157924	NCT00001579_24_T0	GENE	3	3	has
NCT0000157924	NCT00001579_24_T1	COMPOUND	38	38	leucovorin
NCT0000157924	NCT00001579_24_T2	GENE	2	2	MTD
NCT0000157927	NCT00001579_27_T0	PHENOTYPE	0	0	Tumor
NCT0000157927	NCT00001579_27_T1	PHENOTYPE	7	7	recurrent
NCT0000157928	NCT00001579_28_T0	PHENOTYPE	0	0	Lymphomas
NCT0000157928	NCT00001579_28_T1	ORGAN	7	8	bone marrow
NCT0000157929	NCT00001579_29_T0	PHENOTYPE	2	2	malignancies
NCT0000157929	NCT00001579_29_T1	PHENOTYPE	4	5	metastatic disease
NCT0000157930	NCT00001579_30_T0	PHENOTYPE	3	4	peripheral neuropathy
NCT0000157932	NCT00001579_32_T0	PHENOTYPE	2	2	toxic
NCT0000157935	NCT00001579_35_T0	PHENOTYPE	2	2	toxic
NCT0000157936	NCT00001579_36_T0	PHENOTYPE	0	0	ENDOCRINE
NCT0000157937	NCT00001579_37_T0	COMPOUND	10	10	strontium
NCT0000157938	NCT00001579_38_T0	PHENOTYPE	2	2	toxic
NCT0000157940	NCT00001579_40_T0	COMPOUND	3	3	cimetidine
NCT0000157941	NCT00001579_41_T0	GENE	2	2	AGE
NCT0000157942	NCT00001579_42_T0	GENE	3	3	0.2
NCT0000157944	NCT00001579_44_T0	CELL	2	2	granulocyte
NCT0000157944	NCT00001579_44_T1	PHENOTYPE	7	8	Platelet count
NCT0000157946	NCT00001579_46_T0	GENE	5	5	1/6
NCT0000157949	NCT00001579_49_T0	PHENOTYPE	1	2	HIV positive
NCT0000157950	NCT00001579_50_T0	PHENOTYPE	2	2	infections
NCT000015803	NCT00001580_3_T0	PHENOTYPE	8	8	pathology
NCT000015804	NCT00001580_4_T0	PHENOTYPE	1	1	pathology
NCT000015807	NCT00001580_7_T0	PHENOTYPE	8	8	pathology
NCT000015808	NCT00001580_8_T0	PHENOTYPE	1	1	pathology
NCT000015825	NCT00001582_5_T0	BIOLOGICAL_PROCESS	14	14	phlebotomy
NCT000015825	NCT00001582_5_T1	PHENOTYPE	26	26	immunity
NCT000015828	NCT00001582_8_T0	ORGAN	15	16	immune system
NCT0000158212	NCT00001582_12_T0	GENE	7	7	hematocrit
NCT0000158212	NCT00001582_12_T1	CELL	12	12	platelet
NCT0000158215	NCT00001582_15_T0	PHENOTYPE	45	45	allergy
NCT0000158215	NCT00001582_15_T1	ORGAN	30	31	bone marrow
NCT0000158215	NCT00001582_15_T2	TISSUE	27	28	lymph node
NCT0000158217	NCT00001582_17_T0	PHENOTYPE	13	14	Candida skin
NCT0000158220	NCT00001582_20_T0	PHENOTYPE	0	2	Congestive Heart Failure
NCT0000158223	NCT00001582_23_T0	PHENOTYPE	2	2	hypertension
NCT000015841	NCT00001584_1_T0	PHENOTYPE	4	4	HIV
NCT000015844	NCT00001584_4_T0	PHENOTYPE	5	5	HIV
NCT000015844	NCT00001584_4_T1	PHENOTYPE	14	14	HIV
NCT000015844	NCT00001584_4_T2	PHENOTYPE	9	9	insights
NCT000015847	NCT00001584_7_T0	PHENOTYPE	4	4	HIV
NCT0000158410	NCT00001584_10_T0	PHENOTYPE	5	5	HIV
NCT0000158410	NCT00001584_10_T1	PHENOTYPE	14	14	HIV
NCT0000158410	NCT00001584_10_T2	PHENOTYPE	9	9	insights
NCT0000158419	NCT00001584_19_T0	PHENOTYPE	6	7	bacterial prostatitis
NCT0000158422	NCT00001584_22_T0	CELL	1	1	neutrophil
NCT0000158423	NCT00001584_23_T0	CELL	0	0	Platelets
NCT0000158424	NCT00001584_24_T0	GENE	4	4	had
NCT000015861	NCT00001586_1_T0	COMPOUND	13	13	fludarabine
NCT000015861	NCT00001586_1_T1	PHENOTYPE	6	6	CLL/SLL
NCT000015862	NCT00001586_2_T0	PHENOTYPE	13	13	CLL/SLL
NCT000015864	NCT00001586_4_T0	GENE	12	12	1.5
NCT000015864	NCT00001586_4_T1	COMPOUND	7	7	fludarabine
NCT000015866	NCT00001586_6_T0	ORGAN	2	3	bone marrow
NCT0000158613	NCT00001586_13_T0	CELL	12	12	lymphocytes
NCT0000158621	NCT00001586_21_T0	COMPOUND	7	7	fludarabine
NCT0000158623	NCT00001586_23_T0	PHENOTYPE	9	9	CLL/SLL
NCT0000158624	NCT00001586_24_T0	ORGAN	7	8	bone marrow
NCT0000158625	NCT00001586_25_T0	PHENOTYPE	21	22	disease progression
NCT0000158626	NCT00001586_26_T0	PHENOTYPE	7	7	CLL/SLL
NCT0000158629	NCT00001586_29_T0	PHENOTYPE	2	2	Oncology
NCT0000158632	NCT00001586_32_T0	GENE	8	8	2.0
NCT0000158632	NCT00001586_32_T1	PHENOTYPE	13	14	Gilbert's disease
NCT0000158638	NCT00001586_38_T0	PHENOTYPE	8	8	chronic
NCT000015871	NCT00001587_1_T0	PHENOTYPE	13	14	colorectal cancer
NCT000015872	NCT00001587_2_T0	PHENOTYPE	3	3	toxicity
NCT000015874	NCT00001587_4_T0	PHENOTYPE	13	14	colorectal cancer
NCT000015875	NCT00001587_5_T0	PHENOTYPE	3	3	toxicity
NCT000015878	NCT00001587_8_T0	PHENOTYPE	2	3	colorectal cancer
NCT000015879	NCT00001587_9_T0	PHENOTYPE	12	12	malignancy
NCT000015879	NCT00001587_9_T1	ORGAN	19	19	liver
NCT000015879	NCT00001587_9_T2	GENE	3	3	had
NCT0000158711	NCT00001587_11_T0	GENE	12	12	2.0
NCT0000158711	NCT00001587_11_T1	GENE	21	21	1.2
NCT0000158711	NCT00001587_11_T2	COMPOUND	9	9	bilirubin
NCT0000158712	NCT00001587_12_T0	PHENOTYPE	5	5	cirrhosis
NCT0000158712	NCT00001587_12_T1	PHENOTYPE	10	11	portal hypertension
NCT0000158713	NCT00001587_13_T0	PHENOTYPE	6	8	congestive heart failure
NCT0000158716	NCT00001587_16_T0	COMPOUND	24	24	creatinine
NCT0000158716	NCT00001587_16_T1	COMPOUND	33	33	creatinine
NCT0000158716	NCT00001587_16_T2	GENE	30	30	1.5
NCT0000158716	NCT00001587_16_T3	GENE	10	10	HCT
NCT0000158716	NCT00001587_16_T4	PHENOTYPE	4	5	platelet count
NCT0000158718	NCT00001587_18_T0	PHENOTYPE	10	10	anticoagulation
NCT0000158718	NCT00001587_18_T1	PHENOTYPE	9	9	chronic
NCT0000158721	NCT00001587_21_T0	PHENOTYPE	4	5	HIV disease
NCT000015890	NCT00001589_0_T0	PHENOTYPE	3	4	Carotid Atherosclerosis
NCT000015893	NCT00001589_3_T0	PHENOTYPE	13	14	carotid atherosclerosis
NCT000015895	NCT00001589_5_T0	BIOLOGICAL_PROCESS	12	12	phlebotomy
NCT000015898	NCT00001589_8_T0	PHENOTYPE	2	2	Center
NCT0000158910	NCT00001589_10_T0	PHENOTYPE	9	9	secondary
NCT0000158913	NCT00001589_13_T0	PHENOTYPE	13	14	carotid atherosclerosis
NCT0000158915	NCT00001589_15_T0	BIOLOGICAL_PROCESS	12	12	phlebotomy
NCT0000158918	NCT00001589_18_T0	PHENOTYPE	2	2	Center
NCT0000158920	NCT00001589_20_T0	PHENOTYPE	9	9	secondary
NCT0000158924	NCT00001589_24_T0	BIOLOGICAL_PROCESS	4	4	lactation
NCT0000158925	NCT00001589_25_T0	PHENOTYPE	4	4	dementia
NCT0000158925	NCT00001589_25_T1	PHENOTYPE	6	7	psychiatric disturbances
NCT0000158925	NCT00001589_25_T2	PHENOTYPE	11	12	substance abuse
NCT000015917	NCT00001591_7_T0	GENE	6	6	MRI
NCT000015918	NCT00001591_8_T0	GENE	1	1	coil
NCT0000159116	NCT00001591_16_T0	COMPOUND	13	13	gadopentetate
NCT000015941	NCT00001594_1_T0	PHENOTYPE	21	21	secondary
NCT000015941	NCT00001594_1_T1	PHENOTYPE	17	17	progression
NCT000015941	NCT00001594_1_T2	PHENOTYPE	24	25	osteogenesis imperfecta
NCT000015944	NCT00001594_4_T0	GENE	20	20	III
NCT000015944	NCT00001594_4_T1	GENE	22	22	IV
NCT000015945	NCT00001594_5_T0	GENE	6	6	has
NCT000015947	NCT00001594_7_T0	GENE	15	15	III
NCT000015947	NCT00001594_7_T1	GENE	17	17	IV
NCT000015949	NCT00001594_9_T0	PHENOTYPE	8	8	secondary
NCT000015949	NCT00001594_9_T1	PHENOTYPE	16	17	basilar invagination
NCT0000159412	NCT00001594_12_T0	GENE	6	6	collagen
NCT0000159413	NCT00001594_13_T0	PHENOTYPE	12	12	mutation
NCT0000159415	NCT00001594_15_T0	CELL	18	18	osteoblast
NCT0000159417	NCT00001594_17_T0	PHENOTYPE	21	21	secondary
NCT0000159417	NCT00001594_17_T1	PHENOTYPE	17	17	progression
NCT0000159417	NCT00001594_17_T2	PHENOTYPE	24	25	osteogenesis imperfecta
NCT0000159420	NCT00001594_20_T0	GENE	20	20	III
NCT0000159420	NCT00001594_20_T1	GENE	22	22	IV
NCT0000159421	NCT00001594_21_T0	GENE	6	6	has
NCT0000159423	NCT00001594_23_T0	GENE	15	15	III
NCT0000159423	NCT00001594_23_T1	GENE	17	17	IV
NCT0000159425	NCT00001594_25_T0	PHENOTYPE	8	8	secondary
NCT0000159425	NCT00001594_25_T1	PHENOTYPE	16	17	basilar invagination
NCT0000159428	NCT00001594_28_T0	GENE	6	6	collagen
NCT0000159429	NCT00001594_29_T0	PHENOTYPE	12	12	mutation
NCT0000159431	NCT00001594_31_T0	CELL	18	18	osteoblast
NCT0000159433	NCT00001594_33_T0	PHENOTYPE	1	1	recruitment
NCT0000159433	NCT00001594_33_T1	PHENOTYPE	10	11	Osteogenesis Imperfecta
NCT0000159435	NCT00001594_35_T0	GENE	13	13	III
NCT0000159435	NCT00001594_35_T1	GENE	15	15	IV
NCT0000159437	NCT00001594_37_T0	GENE	9	9	collagen
NCT0000159437	NCT00001594_37_T1	GENE	4	4	had
NCT0000159441	NCT00001594_41_T0	PHENOTYPE	16	16	falls
NCT0000159441	NCT00001594_41_T1	PHENOTYPE	32	32	falls
NCT0000159441	NCT00001594_41_T2	GENE	38	38	7.1
NCT0000159442	NCT00001594_42_T0	GENE	25	25	prop
NCT0000159442	NCT00001594_42_T1	ORGAN	28	29	upper extremities
NCT000015954	NCT00001595_4_T0	PHENOTYPE	19	20	pituitary tumors
NCT0000159510	NCT00001595_10_T0	PHENOTYPE	19	20	pituitary tumors
NCT000015966	NCT00001596_6_T0	COMPOUND	2	2	pirfenidone
NCT000015966	NCT00001596_6_T1	PHENOTYPE	8	8	inflammation
NCT000015966	NCT00001596_6_T2	PHENOTYPE	3	3	blocks
NCT000015966	NCT00001596_6_T3	GENE	10	10	has
NCT000015966	NCT00001596_6_T4	PHENOTYPE	17	18	pulmonary fibrosis
NCT000015969	NCT00001596_9_T0	COMPOUND	9	9	pirfenidone
NCT0000159611	NCT00001596_11_T0	COMPOUND	8	8	pirfenidone
NCT0000159613	NCT00001596_13_T0	PHENOTYPE	25	26	lung function
NCT0000159613	NCT00001596_13_T1	PHENOTYPE	27	29	forced vital capacity
NCT0000159617	NCT00001596_17_T0	PHENOTYPE	3	3	complication
NCT0000159617	NCT00001596_17_T1	PHENOTYPE	14	15	pulmonary fibrosis
NCT0000159619	NCT00001596_19_T0	COMPOUND	4	4	pirfenidone
NCT0000159619	NCT00001596_19_T1	GENE	5	5	has
NCT0000159619	NCT00001596_19_T2	PHENOTYPE	12	13	lung fibrosis
NCT0000159620	NCT00001596_20_T0	GENE	3	3	IND
NCT0000159621	NCT00001596_21_T0	PHENOTYPE	3	3	inflammation
NCT0000159623	NCT00001596_23_T0	COMPOUND	15	15	pirfenidone
NCT0000159624	NCT00001596_24_T0	PHENOTYPE	19	21	forced vital capacity
NCT0000159625	NCT00001596_25_T0	COMPOUND	25	25	pirfenidone
NCT0000159625	NCT00001596_25_T1	GENE	5	5	had
NCT0000159627	NCT00001596_27_T0	COMPOUND	12	12	pirfenidone
NCT0000159630	NCT00001596_30_T0	PHENOTYPE	7	9	forced vital capacity
NCT0000159631	NCT00001596_31_T0	PHENOTYPE	0	0	Secondary
NCT0000159633	NCT00001596_33_T0	GENE	15	15	SAP
NCT0000159634	NCT00001596_34_T0	GENE	6	6	SAP
NCT0000159636	NCT00001596_36_T0	COMPOUND	7	7	pirfenidone
NCT0000159636	NCT00001596_36_T1	COMPOUND	34	34	pirfenidone
NCT0000159636	NCT00001596_36_T2	CELL	40	41	alveolar macrophages
NCT0000159638	NCT00001596_38_T0	COMPOUND	13	13	pirfenidone
NCT0000159642	NCT00001596_42_T0	PHENOTYPE	20	21	Hermansky-Pudlak Syndrome
NCT000015971	NCT00001597_1_T0	ORGAN	7	8	third molar
NCT000015977	NCT00001597_7_T0	ORGAN	10	11	third molar
NCT0000159717	NCT00001597_17_T0	ORGAN	25	25	liver
NCT0000159717	NCT00001597_17_T1	ORGAN	22	22	heart
NCT0000159717	NCT00001597_17_T2	PHENOTYPE	19	20	emotional distress
NCT0000159717	NCT00001597_17_T3	PHENOTYPE	15	16	psychotic disorder
NCT000015981	NCT00001598_1_T0	PHENOTYPE	15	15	affects
NCT000015981	NCT00001598_1_T1	PHENOTYPE	1	2	autoimmune disorder
NCT000015981	NCT00001598_1_T2	ORGAN	6	7	immune system
NCT000015981	NCT00001598_1_T3	TISSUE	10	11	salivary glands
NCT000015983	NCT00001598_3_T0	PHENOTYPE	13	13	severity
NCT000015983	NCT00001598_3_T1	BIOLOGICAL_PROCESS	6	7	immune response
NCT000015984	NCT00001598_4_T0	COMPOUND	0	0	DHEA
NCT000015984	NCT00001598_4_T1	GENE	1	1	has
NCT000015984	NCT00001598_4_T2	PHENOTYPE	8	9	autoimmune diseases
NCT000015984	NCT00001598_4_T3	PHENOTYPE	10	11	rheumatoid arthritis
NCT000015984	NCT00001598_4_T4	PHENOTYPE	13	15	systemic lupus erythematosus
NCT000015987	NCT00001598_7_T0	COMPOUND	12	12	DHEA
NCT000015988	NCT00001598_8_T0	GENE	16	16	saliva
NCT000015988	NCT00001598_8_T1	ORGAN	27	27	eyes
NCT000015989	NCT00001598_9_T0	PHENOTYPE	18	18	symptoms
NCT000015989	NCT00001598_9_T1	GENE	1	1	hormone
NCT0000159813	NCT00001598_13_T0	GENE	7	7	SS
NCT0000159813	NCT00001598_13_T1	PHENOTYPE	12	12	dysfunction
NCT0000159813	NCT00001598_13_T2	TISSUE	10	11	salivary gland
NCT0000159814	NCT00001598_14_T0	GENE	16	16	SS
NCT0000159814	NCT00001598_14_T1	PHENOTYPE	8	8	autoimmune
NCT0000159814	NCT00001598_14_T2	PHENOTYPE	14	14	dysfunction
NCT0000159814	NCT00001598_14_T3	TISSUE	12	13	salivary gland
NCT0000159815	NCT00001598_15_T0	GENE	0	0	SS
NCT0000159815	NCT00001598_15_T1	PHENOTYPE	9	9	affects
NCT0000159815	NCT00001598_15_T2	PHENOTYPE	6	7	autoimmune diseases
NCT0000159816	NCT00001598_16_T0	GENE	6	6	SS
NCT0000159816	NCT00001598_16_T1	PHENOTYPE	20	20	severity
NCT0000159816	NCT00001598_16_T2	PHENOTYPE	9	10	autoimmune disease
NCT0000159817	NCT00001598_17_T0	COMPOUND	8	8	DHEA
NCT0000159817	NCT00001598_17_T1	GENE	21	21	SS
NCT0000159817	NCT00001598_17_T2	GENE	15	15	lacrimal
NCT0000159817	NCT00001598_17_T3	COMPOUND	7	7	dehydroepiandrosterone
NCT0000159817	NCT00001598_17_T4	GENE	13	13	hormone
NCT0000159817	NCT00001598_17_T5	TISSUE	17	18	salivary gland
NCT0000159818	NCT00001598_18_T0	COMPOUND	9	9	DHEA
NCT0000159819	NCT00001598_19_T0	PHENOTYPE	24	24	symptoms
NCT0000159819	NCT00001598_19_T1	GENE	10	10	lacrimal
NCT0000159819	NCT00001598_19_T2	PHENOTYPE	15	15	autoimmune
NCT0000159821	NCT00001598_21_T0	PHENOTYPE	3	4	breast cancer
NCT000015991	NCT00001599_1_T0	PHENOTYPE	16	17	dry mouth
NCT000015991	NCT00001599_1_T1	ORGAN	5	6	immune system
NCT000015991	NCT00001599_1_T2	TISSUE	13	14	salivary glands
NCT000015991	NCT00001599_1_T3	PHENOTYPE	2	3	autoimmune disease
NCT000015991	NCT00001599_1_T4	PHENOTYPE	19	20	dry eyes
NCT000015992	NCT00001599_2_T0	GENE	1	1	has
NCT000015992	NCT00001599_2_T1	PHENOTYPE	7	8	autoimmune disorders
NCT000015992	NCT00001599_2_T2	PHENOTYPE	11	12	rheumatoid arthritis
NCT000015992	NCT00001599_2_T3	PHENOTYPE	14	16	systemic lupus erythematosus
NCT000015994	NCT00001599_4_T0	COMPOUND	17	17	thalidomide
NCT000015994	NCT00001599_4_T1	PHENOTYPE	13	14	birth defects
NCT000015997	NCT00001599_7_T0	ORGAN	21	21	eyes
NCT000015998	NCT00001599_8_T0	COMPOUND	8	8	thalidomide
NCT000015999	NCT00001599_9_T0	COMPOUND	1	1	thalidomide
NCT0000159910	NCT00001599_10_T0	GENE	6	6	had
NCT0000159910	NCT00001599_10_T1	PHENOTYPE	12	12	infertility
NCT0000159912	NCT00001599_12_T0	GENE	0	0	SS
NCT0000159912	NCT00001599_12_T1	PHENOTYPE	18	18	symptoms
NCT0000159912	NCT00001599_12_T2	GENE	7	7	lacrimal
NCT0000159912	NCT00001599_12_T3	TISSUE	9	10	salivary glands
NCT0000159912	NCT00001599_12_T4	PHENOTYPE	23	24	dry mouth
NCT0000159912	NCT00001599_12_T5	PHENOTYPE	4	5	lymphocytic infiltration
NCT0000159912	NCT00001599_12_T6	PHENOTYPE	20	21	dry eyes
NCT0000159913	NCT00001599_13_T0	GENE	25	25	SS
NCT0000159913	NCT00001599_13_T1	PHENOTYPE	12	12	GVHD
NCT0000159913	NCT00001599_13_T2	PHENOTYPE	14	14	symptoms
NCT0000159913	NCT00001599_13_T3	ORGAN	1	2	bone marrow
NCT0000159913	NCT00001599_13_T4	TISSUE	19	20	salivary gland
NCT0000159913	NCT00001599_13_T5	PHENOTYPE	21	22	lymphocytic infiltrates
NCT0000159913	NCT00001599_13_T6	PHENOTYPE	16	17	oral dryness
NCT0000159913	NCT00001599_13_T7	PHENOTYPE	7	11	chronic graft versus host disease
NCT0000159915	NCT00001599_15_T0	COMPOUND	4	4	thalidomide
NCT0000159915	NCT00001599_15_T1	PHENOTYPE	7	7	neuropathy
NCT0000159915	NCT00001599_15_T2	PHENOTYPE	6	6	teratogenicity
NCT0000159915	NCT00001599_15_T3	PHENOTYPE	1	2	adverse effects
NCT000016003	NCT00001600_3_T0	PHENOTYPE	13	13	recruitment
NCT0000160014	NCT00001600_14_T0	GENE	17	17	III
NCT000016012	NCT00001601_2_T0	PHENOTYPE	22	24	soft tissue diseases
NCT000016013	NCT00001601_3_T0	PHENOTYPE	24	24	diseases
NCT000016013	NCT00001601_3_T1	PHENOTYPE	27	27	diseases
NCT000016018	NCT00001601_8_T0	COMPOUND	10	10	epinephrine
NCT000016018	NCT00001601_8_T1	COMPOUND	6	6	lidocaine
NCT000016019	NCT00001601_9_T0	COMPOUND	14	14	1_10
NCT000016019	NCT00001601_9_T1	GENE	1	1	punch
NCT0000160115	NCT00001601_15_T0	TISSUE	5	5	tissues
NCT0000160115	NCT00001601_15_T1	PHENOTYPE	23	24	disease progression
NCT0000160120	NCT00001601_20_T0	PHENOTYPE	4	5	cognitive impairment
NCT0000160121	NCT00001601_21_T0	BIOLOGICAL_PROCESS	3	3	lactation
NCT000016022	NCT00001602_2_T0	PHENOTYPE	15	15	stuttering
NCT000016023	NCT00001602_3_T0	CELL	12	12	cells
NCT000016028	NCT00001602_8_T0	PHENOTYPE	12	12	stuttering
NCT000016029	NCT00001602_9_T0	PHENOTYPE	13	13	stutter
NCT0000160210	NCT00001602_10_T0	PHENOTYPE	21	21	stuttered
NCT0000160210	NCT00001602_10_T1	PHENOTYPE	35	35	stuttered
NCT0000160210	NCT00001602_10_T2	PHENOTYPE	15	15	stutter
NCT0000160211	NCT00001602_11_T0	PHENOTYPE	12	12	stuttering
NCT0000160211	NCT00001602_11_T1	PHENOTYPE	26	26	stuttering
NCT0000160212	NCT00001602_12_T0	PHENOTYPE	13	13	stuttering
NCT0000160212	NCT00001602_12_T1	PHENOTYPE	20	20	stuttering
NCT0000160214	NCT00001602_14_T0	PHENOTYPE	11	11	stuttering
NCT0000160216	NCT00001602_16_T0	PHENOTYPE	11	11	stutter
NCT0000160217	NCT00001602_17_T0	PHENOTYPE	27	27	stuttering
NCT0000160217	NCT00001602_17_T1	PHENOTYPE	11	11	stutter
NCT0000160217	NCT00001602_17_T2	PHENOTYPE	19	20	language skills
NCT0000160219	NCT00001602_19_T0	PHENOTYPE	10	10	chronic
NCT0000160220	NCT00001602_20_T0	PHENOTYPE	23	23	trauma
NCT0000160220	NCT00001602_20_T1	PHENOTYPE	2	2	stuttering
NCT0000160220	NCT00001602_20_T2	PHENOTYPE	0	0	Onset
NCT0000160221	NCT00001602_21_T0	PHENOTYPE	9	9	HIV
NCT0000160222	NCT00001602_22_T0	PHENOTYPE	2	3	positive HIV
NCT0000160223	NCT00001602_23_T0	PHENOTYPE	14	15	obsessive-compulsive disorders
NCT0000160223	NCT00001602_23_T1	PHENOTYPE	7	8	psychiatric illness
NCT000016031	NCT00001603_1_T0	PHENOTYPE	5	5	tumors
NCT000016031	NCT00001603_1_T1	PHENOTYPE	16	17	tumor escape
NCT000016032	NCT00001603_2_T0	PHENOTYPE	2	2	hoping
NCT000016032	NCT00001603_2_T1	CELL	11	11	cells
NCT000016032	NCT00001603_2_T2	CELL	20	20	cells
NCT000016032	NCT00001603_2_T3	PHENOTYPE	10	10	tumor
NCT000016032	NCT00001603_2_T4	PHENOTYPE	19	19	tumor
NCT000016034	NCT00001603_4_T0	CELL	1	1	cells
NCT000016034	NCT00001603_4_T1	PHENOTYPE	0	0	Tumor
NCT000016036	NCT00001603_6_T0	BIOLOGICAL_PROCESS	23	23	metabolism
NCT000016036	NCT00001603_6_T1	ORGAN	20	21	immune systems
NCT0000160311	NCT00001603_11_T0	BIOLOGICAL_PROCESS	5	5	metabolism
NCT0000160311	NCT00001603_11_T1	PHENOTYPE	3	3	immunity
NCT0000160313	NCT00001603_13_T0	CELL	16	16	cells
NCT0000160313	NCT00001603_13_T1	CELL	25	25	cells
NCT0000160313	NCT00001603_13_T2	PHENOTYPE	19	19	tumor
NCT0000160313	NCT00001603_13_T3	PHENOTYPE	24	24	tumor
NCT0000160313	NCT00001603_13_T4	CELL	27	27	leukocytes
NCT0000160315	NCT00001603_15_T0	PHENOTYPE	31	31	tumor
NCT000016042	NCT00001604_2_T0	PHENOTYPE	0	0	Stuttering
NCT000016042	NCT00001604_2_T1	PHENOTYPE	17	17	blocks
NCT000016042	NCT00001604_2_T2	PHENOTYPE	4	4	repetitions
NCT000016043	NCT00001604_3_T0	PHENOTYPE	8	8	stuttering
NCT000016044	NCT00001604_4_T0	PHENOTYPE	13	13	stuttering
NCT000016044	NCT00001604_4_T1	PHENOTYPE	27	27	stuttering
NCT000016045	NCT00001604_5_T0	PHENOTYPE	17	17	stutter
NCT000016045	NCT00001604_5_T1	GENE	14	14	had
NCT000016046	NCT00001604_6_T0	GENE	2	2	has
NCT000016047	NCT00001604_7_T0	PHENOTYPE	15	15	stuttering
NCT000016047	NCT00001604_7_T1	PHENOTYPE	23	23	stutter
NCT000016047	NCT00001604_7_T2	PHENOTYPE	28	28	stutter
NCT0000160411	NCT00001604_11_T0	PHENOTYPE	25	25	stutter
NCT0000160412	NCT00001604_12_T0	PHENOTYPE	2	2	stutter
NCT0000160413	NCT00001604_13_T0	GENE	22	22	cc
NCT0000160413	NCT00001604_13_T1	GENE	28	28	cc
NCT0000160413	NCT00001604_13_T2	GENE	24	24	saliva
NCT0000160415	NCT00001604_15_T0	PHENOTYPE	13	13	stuttering
NCT0000160416	NCT00001604_16_T0	PHENOTYPE	16	16	stuttering
NCT0000160418	NCT00001604_18_T0	PHENOTYPE	1	1	secondary
NCT0000160418	NCT00001604_18_T1	PHENOTYPE	22	22	stuttering
NCT000016054	NCT00001605_4_T0	PHENOTYPE	2	2	influenzae
NCT000016054	NCT00001605_4_T1	PHENOTYPE	17	18	respiratory infections
NCT000016056	NCT00001605_6_T0	CELL	10	10	cells
NCT000016057	NCT00001605_7_T0	PHENOTYPE	5	5	symptoms
NCT000016057	NCT00001605_7_T1	PHENOTYPE	11	11	feels
NCT000016057	NCT00001605_7_T2	PHENOTYPE	7	7	sickness
NCT0000160511	NCT00001605_11_T0	ORGAN	2	3	immune system
NCT0000160516	NCT00001605_16_T0	PHENOTYPE	18	18	toxic
NCT0000160517	NCT00001605_17_T0	PHENOTYPE	12	12	toxic
NCT0000160520	NCT00001605_20_T0	PHENOTYPE	12	12	tetanus
NCT0000160520	NCT00001605_20_T1	ORGAN	21	22	immune system
NCT0000160521	NCT00001605_21_T0	PHENOTYPE	7	7	infections
NCT0000160521	NCT00001605_21_T1	PHENOTYPE	9	10	otitis media
NCT0000160523	NCT00001605_23_T0	PHENOTYPE	11	12	respiratory infections
NCT0000160525	NCT00001605_25_T0	PHENOTYPE	2	2	influenzae
NCT0000160525	NCT00001605_25_T1	PHENOTYPE	11	12	respiratory infections
NCT0000160527	NCT00001605_27_T0	ORGAN	3	3	serum
NCT0000160529	NCT00001605_29_T0	PHENOTYPE	5	5	toxic
NCT0000160530	NCT00001605_30_T0	PHENOTYPE	12	12	tetanus
NCT0000160531	NCT00001605_31_T0	PHENOTYPE	11	12	otitis media
NCT0000160533	NCT00001605_33_T0	PHENOTYPE	10	11	respiratory infections
NCT0000160536	NCT00001605_36_T0	PHENOTYPE	0	0	HIV
NCT0000160537	NCT00001605_37_T0	PHENOTYPE	0	1	Hepatitis B
NCT0000160538	NCT00001605_38_T0	PHENOTYPE	1	1	chronic
NCT0000160538	NCT00001605_38_T1	PHENOTYPE	2	4	Respiratory Tract Infections
NCT0000160539	NCT00001605_39_T0	ORGAN	4	5	immune system
NCT0000160611	NCT00001606_11_T0	PHENOTYPE	6	8	mode of inheritance
NCT0000160620	NCT00001606_20_T0	PHENOTYPE	1	1	mutated
NCT000016097	NCT00001609_7_T0	PHENOTYPE	7	7	cataracts
NCT000016099	NCT00001609_9_T0	PHENOTYPE	5	5	cataracts
NCT000016099	NCT00001609_9_T1	PHENOTYPE	8	9	genetic heterogeneity
NCT0000160912	NCT00001609_12_T0	PHENOTYPE	19	19	cataracts
NCT0000160912	NCT00001609_12_T1	PHENOTYPE	27	27	cataracts
NCT0000160913	NCT00001609_13_T0	PHENOTYPE	25	25	cataracts
NCT0000160914	NCT00001609_14_T0	PHENOTYPE	12	12	cataracts
NCT000016104	NCT00001610_4_T0	ORGAN	14	14	eyes
NCT000016104	NCT00001610_4_T1	PHENOTYPE	28	29	retinal diseases
NCT000016105	NCT00001610_5_T0	ORGAN	10	10	eyes
NCT0000161010	NCT00001610_10_T0	ORGAN	37	37	eyes
NCT0000161010	NCT00001610_10_T1	ORGAN	19	19	heart
NCT0000161023	NCT00001610_23_T0	PHENOTYPE	10	11	visual loss
NCT0000161024	NCT00001610_24_T0	PHENOTYPE	14	15	light sensitivity
NCT0000161027	NCT00001610_27_T0	PHENOTYPE	4	5	systemic disease
NCT000016110	NCT00001611_0_T0	PHENOTYPE	4	4	Retinitis
NCT000016115	NCT00001611_5_T0	GENE	8	8	CD4
NCT000016115	NCT00001611_5_T1	PHENOTYPE	1	1	HIV
NCT0000161111	NCT00001611_11_T0	GENE	2	2	CD4
NCT0000161111	NCT00001611_11_T1	GENE	4	4	has
NCT0000161126	NCT00001611_26_T0	CELL	0	0	Platelets
NCT0000161127	NCT00001611_27_T0	GENE	3	3	8.5
NCT0000161128	NCT00001611_28_T0	CELL	1	1	neutrophil
NCT0000161131	NCT00001611_31_T0	PHENOTYPE	1	1	HIV
NCT0000161132	NCT00001611_32_T0	GENE	5	5	IL-2
NCT0000161135	NCT00001611_35_T0	PHENOTYPE	23	23	fixation
NCT0000161135	NCT00001611_35_T1	GENE	10	10	disc
NCT0000161138	NCT00001611_38_T0	PHENOTYPE	4	4	disorders
NCT000016122	NCT00001612_2_T0	PHENOTYPE	3	3	retinopathy
NCT000016122	NCT00001612_2_T1	PHENOTYPE	1	1	progression
NCT000016124	NCT00001612_4_T0	PHENOTYPE	24	24	focal
NCT000016124	NCT00001612_4_T1	PHENOTYPE	20	20	strategies
NCT000016124	NCT00001612_4_T2	PHENOTYPE	14	15	diabetic retinopathy
NCT000016136	NCT00001613_6_T0	PHENOTYPE	21	21	cataracts
NCT000016139	NCT00001613_9_T0	GENE	6	6	lines
NCT0000161313	NCT00001613_13_T0	PHENOTYPE	14	14	toxic
NCT0000161315	NCT00001613_15_T0	PHENOTYPE	4	4	cataracts
NCT0000161316	NCT00001613_16_T0	PHENOTYPE	18	18	Cataract
NCT0000161316	NCT00001613_16_T1	PHENOTYPE	24	24	cataracts
NCT0000161319	NCT00001613_19_T0	PHENOTYPE	3	3	concentrations
NCT0000161320	NCT00001613_20_T0	PHENOTYPE	5	5	cataracts
NCT0000161320	NCT00001613_20_T1	PHENOTYPE	17	17	cataracts
NCT0000161320	NCT00001613_20_T2	PHENOTYPE	39	39	cataracts
NCT0000161320	NCT00001613_20_T3	GENE	19	19	crystallin
NCT0000161320	NCT00001613_20_T4	GENE	32	32	crystallin
NCT0000161320	NCT00001613_20_T5	GENE	8	9	too few
NCT000016141	NCT00001614_1_T0	PHENOTYPE	8	9	autoimmune disorders
NCT000016141	NCT00001614_1_T1	BIOLOGICAL_PROCESS	11	12	oral tolerance
NCT000016142	NCT00001614_2_T0	GENE	2	2	II
NCT000016142	NCT00001614_2_T1	GENE	3	3	collagen
NCT000016142	NCT00001614_2_T2	BIOLOGICAL_PROCESS	10	11	oral tolerance
NCT000016142	NCT00001614_2_T3	PHENOTYPE	17	18	rheumatoid arthritis
NCT000016143	NCT00001614_3_T0	GENE	12	12	II
NCT000016143	NCT00001614_3_T1	GENE	13	13	collagen
NCT000016143	NCT00001614_3_T2	PHENOTYPE	24	24	uveitis
NCT000016143	NCT00001614_3_T3	PHENOTYPE	27	29	juvenile rheumatoid arthritis
NCT000016144	NCT00001614_4_T0	CELL	19	19	cells
NCT000016144	NCT00001614_4_T1	ORGAN	17	18	anterior chamber
NCT000016148	NCT00001614_8_T0	PHENOTYPE	8	9	autoimmune disorders
NCT000016148	NCT00001614_8_T1	BIOLOGICAL_PROCESS	11	12	oral tolerance
NCT000016149	NCT00001614_9_T0	GENE	2	2	II
NCT000016149	NCT00001614_9_T1	GENE	3	3	collagen
NCT000016149	NCT00001614_9_T2	BIOLOGICAL_PROCESS	10	11	oral tolerance
NCT000016149	NCT00001614_9_T3	PHENOTYPE	17	18	rheumatoid arthritis
NCT0000161410	NCT00001614_10_T0	GENE	12	12	II
NCT0000161410	NCT00001614_10_T1	GENE	13	13	collagen
NCT0000161410	NCT00001614_10_T2	PHENOTYPE	24	24	uveitis
NCT0000161410	NCT00001614_10_T3	PHENOTYPE	27	29	juvenile rheumatoid arthritis
NCT0000161411	NCT00001614_11_T0	CELL	19	19	cells
NCT0000161411	NCT00001614_11_T1	ORGAN	17	18	anterior chamber
NCT0000161417	NCT00001614_17_T0	GENE	2	2	had
NCT0000161417	NCT00001614_17_T1	PHENOTYPE	6	6	uveitis
NCT0000161418	NCT00001614_18_T0	GENE	6	6	slit
NCT0000161418	NCT00001614_18_T1	CELL	14	14	cells
NCT0000161418	NCT00001614_18_T2	GENE	7	7	lamp
NCT0000161418	NCT00001614_18_T3	ORGAN	12	13	anterior chamber
NCT0000161419	NCT00001614_19_T0	PHENOTYPE	12	12	inflammation
NCT0000161419	NCT00001614_19_T1	PHENOTYPE	5	5	opacity
NCT0000161419	NCT00001614_19_T2	ORGAN	10	11	anterior chamber
NCT0000161421	NCT00001614_21_T0	COMPOUND	24	24	methotrexate
NCT0000161421	NCT00001614_21_T1	COMPOUND	14	14	prednisone
NCT0000161423	NCT00001614_23_T0	GENE	10	10	II
NCT0000161423	NCT00001614_23_T1	GENE	11	11	collagen
NCT0000161424	NCT00001614_24_T0	GENE	9	9	shark
NCT0000161424	NCT00001614_24_T1	GENE	12	12	collagen
NCT0000161425	NCT00001614_25_T0	GENE	15	15	II
NCT0000161425	NCT00001614_25_T1	GENE	16	16	collagen
NCT0000161425	NCT00001614_25_T2	PHENOTYPE	6	7	gastrointestinal disease
NCT000016150	NCT00001615_0_T0	PHENOTYPE	8	9	Choroidal Neovascularization
NCT000016150	NCT00001615_0_T1	PHENOTYPE	11	13	Age-Related Macular Degeneration
NCT000016154	NCT00001615_4_T0	COMPOUND	18	18	fluorescein
NCT000016154	NCT00001615_4_T1	ORGAN	5	5	eyes
NCT000016155	NCT00001615_5_T0	GENE	9	9	has
NCT000016155	NCT00001615_5_T1	PHENOTYPE	7	8	choroidal neovascularization
NCT0000161514	NCT00001615_14_T0	COMPOUND	18	18	fluorescein
NCT0000161514	NCT00001615_14_T1	ORGAN	5	5	eyes
NCT0000161515	NCT00001615_15_T0	GENE	9	9	has
NCT0000161515	NCT00001615_15_T1	PHENOTYPE	7	8	choroidal neovascularization
NCT0000161531	NCT00001615_31_T0	PHENOTYPE	14	14	glaucoma
NCT0000161531	NCT00001615_31_T1	PHENOTYPE	21	21	glaucoma
NCT0000161531	NCT00001615_31_T2	PHENOTYPE	39	39	glaucoma
NCT0000161531	NCT00001615_31_T3	PHENOTYPE	3	4	intraocular pressure
NCT0000161531	NCT00001615_31_T4	PHENOTYPE	30	31	intraocular pressure
NCT0000161531	NCT00001615_31_T5	PHENOTYPE	42	44	visual field defects
NCT0000161532	NCT00001615_32_T0	COMPOUND	15	15	fluorescein
NCT0000161533	NCT00001615_33_T0	PHENOTYPE	7	7	complications
NCT0000161533	NCT00001615_33_T1	PHENOTYPE	12	14	elevated intraocular pressure
NCT000016171	NCT00001617_1_T0	PHENOTYPE	7	7	cataracts
NCT0000161710	NCT00001617_10_T0	GENE	6	6	dim
NCT0000161719	NCT00001617_19_T0	PHENOTYPE	10	10	recruitment
NCT000016181	NCT00001618_1_T0	CELL	6	6	cells
NCT000016181	NCT00001618_1_T1	PHENOTYPE	1	1	sterile
NCT000016181	NCT00001618_1_T2	ORGAN	12	13	respiratory tract
NCT000016185	NCT00001618_5_T0	PHENOTYPE	16	16	progression
NCT000016185	NCT00001618_5_T1	PHENOTYPE	18	19	pulmonary disease
NCT000016187	NCT00001618_7_T0	PHENOTYPE	23	23	sarcoidosis
NCT000016187	NCT00001618_7_T1	PHENOTYPE	14	14	lymphangioleiomyomatosis
NCT000016187	NCT00001618_7_T2	PHENOTYPE	20	21	pulmonary fibrosis
NCT000016187	NCT00001618_7_T3	PHENOTYPE	11	13	alpha-1 antitrypsin deficiency
NCT000016187	NCT00001618_7_T4	PHENOTYPE	17	19	cystic lung disease
NCT0000161810	NCT00001618_10_T0	PHENOTYPE	9	9	HIV
NCT0000161810	NCT00001618_10_T1	PHENOTYPE	18	18	HIV
NCT0000161810	NCT00001618_10_T2	ORGAN	21	21	lungs
NCT000016191	NCT00001619_1_T0	GENE	0	0	MRI
NCT000016192	NCT00001619_2_T0	GENE	7	7	MRI
NCT000016192	NCT00001619_2_T1	COMPOUND	14	14	gadolinium
NCT000016193	NCT00001619_3_T0	COMPOUND	0	0	Gadolinium
NCT000016194	NCT00001619_4_T0	COMPOUND	13	13	gadolinium
NCT000016195	NCT00001619_5_T0	GENE	15	15	MRI
NCT000016199	NCT00001619_9_T0	PHENOTYPE	11	11	pulse
NCT0000161911	NCT00001619_11_T0	GENE	9	9	has
NCT0000161916	NCT00001619_16_T0	PHENOTYPE	1	2	foreign body
NCT0000161920	NCT00001619_20_T0	PHENOTYPE	0	0	Claustrophobia
NCT0000161921	NCT00001619_21_T0	PHENOTYPE	6	6	judgement
NCT0000161921	NCT00001619_21_T1	GENE	13	13	FOR
NCT0000162011	NCT00001620_11_T0	GENE	0	0	OR
NCT0000162011	NCT00001620_11_T1	GENE	11	11	has
NCT000016211	NCT00001621_1_T0	PHENOTYPE	13	14	lung disease
NCT000016213	NCT00001621_3_T0	GENE	8	8	CPB
NCT000016213	NCT00001621_3_T1	PHENOTYPE	16	17	pulmonary disease
NCT000016221	NCT00001622_1_T0	CELL	1	1	cells
NCT000016221	NCT00001622_1_T1	ORGAN	9	10	blood vessels
NCT000016222	NCT00001622_2_T0	COMPOUND	14	15	nitric oxide
NCT000016222	NCT00001622_2_T1	ORGAN	10	11	blood vessel
NCT000016223	NCT00001622_3_T0	ORGAN	10	11	blood vessels
NCT000016224	NCT00001622_4_T0	TISSUE	9	9	endothelium
NCT000016224	NCT00001622_4_T1	PHENOTYPE	23	23	hypercholesterolemia
NCT000016224	NCT00001622_4_T2	PHENOTYPE	16	17	essential hypertension
NCT000016224	NCT00001622_4_T3	PHENOTYPE	13	15	high blood pressure
NCT000016225	NCT00001622_5_T0	TISSUE	5	5	endothelium
NCT000016225	NCT00001622_5_T1	TISSUE	14	14	endothelium
NCT000016225	NCT00001622_5_T2	COMPOUND	7	8	nitric oxide
NCT000016225	NCT00001622_5_T3	PHENOTYPE	22	24	high blood pressure
NCT000016226	NCT00001622_6_T0	PHENOTYPE	7	7	dysfunction
NCT000016226	NCT00001622_6_T1	COMPOUND	15	16	nitric oxide
NCT000016227	NCT00001622_7_T0	ORGAN	10	11	blood vessel
NCT000016227	NCT00001622_7_T1	PHENOTYPE	24	26	high blood pressure
NCT000016229	NCT00001622_9_T0	PHENOTYPE	27	27	strain
NCT000016229	NCT00001622_9_T1	TISSUE	6	6	endothelium
NCT000016229	NCT00001622_9_T2	TISSUE	8	8	endothelium
NCT000016229	NCT00001622_9_T3	ORGAN	22	22	forearm
NCT000016229	NCT00001622_9_T4	ORGAN	12	13	brachial artery
NCT0000162210	NCT00001622_10_T0	TISSUE	30	30	endothelium
NCT0000162210	NCT00001622_10_T1	PHENOTYPE	22	22	hypercholesterolemia
NCT0000162210	NCT00001622_10_T2	COMPOUND	31	32	nitric oxide
NCT0000162210	NCT00001622_10_T3	PHENOTYPE	16	17	essential hypertension
NCT0000162210	NCT00001622_10_T4	PHENOTYPE	11	12	endothelial dysfunction
NCT0000162210	NCT00001622_10_T5	PHENOTYPE	38	39	endothelial dysfunction
NCT0000162212	NCT00001622_12_T0	TISSUE	24	24	endothelium
NCT0000162212	NCT00001622_12_T1	GENE	27	27	has
NCT0000162213	NCT00001622_13_T0	PHENOTYPE	20	20	hypercholesterolemia
NCT0000162213	NCT00001622_13_T1	PHENOTYPE	15	16	essential hypertension
NCT0000162216	NCT00001622_16_T0	PHENOTYPE	1	2	renovascular hypertension
NCT0000162216	NCT00001622_16_T1	PHENOTYPE	7	9	elevated blood pressure
NCT0000162217	NCT00001622_17_T0	PHENOTYPE	17	17	papilledema
NCT0000162217	NCT00001622_17_T1	PHENOTYPE	6	7	malignant hypertension
NCT0000162217	NCT00001622_17_T2	PHENOTYPE	22	24	congestive heart failure
NCT0000162217	NCT00001622_17_T3	PHENOTYPE	18	20	progressive renal failure
NCT0000162221	NCT00001622_21_T0	PHENOTYPE	3	3	hypertension
NCT0000162221	NCT00001622_21_T1	PHENOTYPE	5	5	hypercholesterolemia
NCT000016231	NCT00001623_1_T0	PHENOTYPE	5	5	complications
NCT000016232	NCT00001623_2_T0	PHENOTYPE	3	3	complication
NCT000016232	NCT00001623_2_T1	PHENOTYPE	9	9	GVHD
NCT000016232	NCT00001623_2_T2	PHENOTYPE	7	8	graft-versus-host disease
NCT000016233	NCT00001623_3_T0	CELL	11	11	cells
NCT000016233	NCT00001623_3_T1	CELL	14	14	cells
NCT000016233	NCT00001623_3_T2	PHENOTYPE	1	1	GVHD
NCT000016235	NCT00001623_5_T0	CELL	1	1	lymphocytes
NCT000016235	NCT00001623_5_T1	CELL	7	7	cells
NCT000016235	NCT00001623_5_T2	TISSUE	9	9	tissues
NCT000016236	NCT00001623_6_T0	ORGAN	18	18	marrow
NCT000016236	NCT00001623_6_T1	CELL	14	14	lymphocytes
NCT000016237	NCT00001623_7_T0	PHENOTYPE	18	18	leukemia
NCT000016237	NCT00001623_7_T1	CELL	2	2	lymphocytes
NCT000016237	NCT00001623_7_T2	PHENOTYPE	16	16	relapse
NCT000016237	NCT00001623_7_T3	ORGAN	6	7	immune system
NCT0000162310	NCT00001623_10_T0	PHENOTYPE	7	7	peripheral
NCT0000162310	NCT00001623_10_T1	CELL	10	10	lymphocytes
NCT0000162310	NCT00001623_10_T2	ORGAN	14	15	bone marrow
NCT0000162311	NCT00001623_11_T0	PHENOTYPE	15	15	leukemia
NCT0000162311	NCT00001623_11_T1	CELL	10	10	cells
NCT0000162311	NCT00001623_11_T2	ORGAN	25	25	transplant
NCT0000162311	NCT00001623_11_T3	GENE	21	21	G-CSF
NCT0000162311	NCT00001623_11_T4	CELL	7	8	progenitor cells
NCT0000162315	NCT00001623_15_T0	CELL	15	15	lymphocytes
NCT0000162315	NCT00001623_15_T1	PHENOTYPE	27	27	relapse
NCT0000162315	NCT00001623_15_T2	ORGAN	11	11	transplant
NCT0000162319	NCT00001623_19_T0	PHENOTYPE	8	8	leukemia
NCT0000162319	NCT00001623_19_T1	PHENOTYPE	25	25	GVHD
NCT0000162319	NCT00001623_19_T2	ORGAN	6	6	transplants
NCT0000162319	NCT00001623_19_T3	CELL	11	12	T cells
NCT0000162319	NCT00001623_19_T4	CELL	22	23	T cells
NCT0000162319	NCT00001623_19_T5	ORGAN	4	5	bone marrow
NCT0000162319	NCT00001623_19_T6	BIOLOGICAL_PROCESS	29	30	immune response
NCT0000162319	NCT00001623_19_T7	PHENOTYPE	33	34	hematologic malignancy
NCT0000162320	NCT00001623_20_T0	ORGAN	10	10	marrow
NCT0000162320	NCT00001623_20_T1	ORGAN	14	14	transplant
NCT0000162320	NCT00001623_20_T2	CELL	11	12	progenitor cells
NCT0000162322	NCT00001623_22_T0	ORGAN	13	13	transplant
NCT0000162322	NCT00001623_22_T1	PHENOTYPE	10	10	GVHD
NCT0000162323	NCT00001623_23_T0	CELL	23	23	lymphocytes
NCT0000162323	NCT00001623_23_T1	PHENOTYPE	13	13	GVHD
NCT0000162324	NCT00001623_24_T0	PHENOTYPE	25	25	leukemia
NCT0000162324	NCT00001623_24_T1	CELL	13	13	lymphocytes
NCT0000162324	NCT00001623_24_T2	PHENOTYPE	28	28	GVHD
NCT0000162324	NCT00001623_24_T3	PHENOTYPE	19	19	immunity
NCT0000162326	NCT00001623_26_T0	GENE	4	4	G-CSF
NCT0000162329	NCT00001623_29_T0	PHENOTYPE	15	16	graft failure
NCT0000162330	NCT00001623_30_T0	PHENOTYPE	11	11	acute
NCT0000162330	NCT00001623_30_T1	PHENOTYPE	3	3	withdrawn
NCT0000162330	NCT00001623_30_T2	PHENOTYPE	12	12	GVHD
NCT0000162331	NCT00001623_31_T0	CELL	10	10	lymphocytes
NCT0000162331	NCT00001623_31_T1	PHENOTYPE	21	21	relapse
NCT0000162331	NCT00001623_31_T2	ORGAN	18	18	transplant
NCT0000162332	NCT00001623_32_T0	PHENOTYPE	3	3	acute
NCT0000162332	NCT00001623_32_T1	PHENOTYPE	4	4	GVHD
NCT0000162334	NCT00001623_34_T0	PHENOTYPE	9	9	acute
NCT0000162334	NCT00001623_34_T1	ORGAN	7	7	graft
NCT0000162334	NCT00001623_34_T2	PHENOTYPE	14	14	relapse
NCT0000162334	NCT00001623_34_T3	ORGAN	15	15	transplant
NCT0000162334	NCT00001623_34_T4	PHENOTYPE	12	12	GVHD
NCT0000162334	NCT00001623_34_T5	PHENOTYPE	11	11	chronic
NCT000016242	NCT00001624_2_T0	PHENOTYPE	12	12	hyperinsulinemia
NCT000016242	NCT00001624_2_T1	PHENOTYPE	11	11	chronic
NCT000016243	NCT00001624_3_T0	PHENOTYPE	13	13	hyperinsulinemia
NCT000016243	NCT00001624_3_T1	PHENOTYPE	20	20	circulation
NCT000016243	NCT00001624_3_T2	ORGAN	19	19	forearm
NCT000016244	NCT00001624_4_T0	GENE	13	13	receptor
NCT000016244	NCT00001624_4_T1	GENE	23	23	insulin
NCT000016244	NCT00001624_4_T2	ORGAN	7	7	forearm
NCT000016245	NCT00001624_5_T0	GENE	7	7	ET-1
NCT000016245	NCT00001624_5_T1	ORGAN	6	6	plasma
NCT000016247	NCT00001624_7_T0	PHENOTYPE	12	12	hyperinsulinemia
NCT000016247	NCT00001624_7_T1	PHENOTYPE	11	11	chronic
NCT000016248	NCT00001624_8_T0	PHENOTYPE	13	13	hyperinsulinemia
NCT000016248	NCT00001624_8_T1	PHENOTYPE	20	20	circulation
NCT000016248	NCT00001624_8_T2	ORGAN	19	19	forearm
NCT000016249	NCT00001624_9_T0	GENE	13	13	receptor
NCT000016249	NCT00001624_9_T1	GENE	23	23	insulin
NCT000016249	NCT00001624_9_T2	ORGAN	7	7	forearm
NCT0000162410	NCT00001624_10_T0	GENE	7	7	ET-1
NCT0000162410	NCT00001624_10_T1	ORGAN	6	6	plasma
NCT0000162414	NCT00001624_14_T0	ORGAN	1	1	serum
NCT0000162414	NCT00001624_14_T1	PHENOTYPE	2	3	cholesterol levels
NCT000016252	NCT00001625_2_T0	COMPOUND	21	21	glucose
NCT000016252	NCT00001625_2_T1	GENE	18	18	insulin
NCT000016256	NCT00001625_6_T0	PHENOTYPE	6	8	high blood pressure
NCT000016257	NCT00001625_7_T0	PHENOTYPE	3	3	overweight
NCT000016259	NCT00001625_9_T0	COMPOUND	6	6	glucose
NCT0000162511	NCT00001625_11_T0	COMPOUND	20	20	glucose
NCT0000162511	NCT00001625_11_T1	GENE	22	22	insulin
NCT0000162512	NCT00001625_12_T0	PHENOTYPE	9	10	glucose tolerance
NCT0000162513	NCT00001625_13_T0	ORGAN	11	11	veins
NCT0000162513	NCT00001625_13_T1	COMPOUND	7	7	glucose
NCT0000162513	NCT00001625_13_T2	GENE	20	20	insulin
NCT0000162519	NCT00001625_19_T0	COMPOUND	14	14	glucose
NCT0000162519	NCT00001625_19_T1	COMPOUND	32	32	glucose
NCT0000162519	NCT00001625_19_T2	GENE	34	34	insulin
NCT0000162519	NCT00001625_19_T3	PHENOTYPE	10	11	insulin sensitivity
NCT0000162520	NCT00001625_20_T0	PHENOTYPE	9	10	insulin sensitivity
NCT0000162521	NCT00001625_21_T0	COMPOUND	19	19	glucose
NCT0000162523	NCT00001625_23_T0	PHENOTYPE	0	0	Obese
NCT0000162523	NCT00001625_23_T1	PHENOTYPE	18	18	illnesses
NCT0000162524	NCT00001625_24_T0	PHENOTYPE	19	19	hypertension
NCT0000162526	NCT00001625_26_T0	PHENOTYPE	22	22	withdrawn
NCT0000162529	NCT00001625_29_T0	PHENOTYPE	11	11	withdrawn
NCT0000162529	NCT00001625_29_T1	PHENOTYPE	1	3	fasting blood glucose
NCT000016261	NCT00001626_1_T0	PHENOTYPE	7	8	autoimmune reaction
NCT000016262	NCT00001626_2_T0	GENE	1	1	SAA
NCT000016262	NCT00001626_2_T1	ORGAN	3	4	immune system
NCT000016262	NCT00001626_2_T2	ORGAN	8	9	bone marrow
NCT0000162611	NCT00001626_11_T0	GENE	15	15	SAA
NCT0000162611	NCT00001626_11_T1	PHENOTYPE	13	13	relapse
NCT0000162613	NCT00001626_13_T0	GENE	17	17	SAA
NCT0000162613	NCT00001626_13_T1	COMPOUND	9	9	cyclophosphamide
NCT0000162613	NCT00001626_13_T2	GENE	10	10	has
NCT0000162614	NCT00001626_14_T0	PHENOTYPE	13	13	disorders
NCT0000162614	NCT00001626_14_T1	COMPOUND	5	5	cyclophosphamide
NCT0000162617	NCT00001626_17_T0	PHENOTYPE	3	3	strategies
NCT0000162617	NCT00001626_17_T1	PHENOTYPE	10	10	immunosuppression
NCT0000162617	NCT00001626_17_T2	ORGAN	5	6	bone marrow
NCT0000162618	NCT00001626_18_T0	CELL	6	6	leukocyte
NCT0000162618	NCT00001626_18_T1	ORGAN	11	12	bone marrow
NCT0000162619	NCT00001626_19_T0	PHENOTYPE	15	15	toxicity
NCT0000162622	NCT00001626_22_T0	GENE	5	5	SAA
NCT0000162622	NCT00001626_22_T1	PHENOTYPE	3	3	immunosuppression
NCT0000162622	NCT00001626_22_T2	COMPOUND	11	11	cyclophosphamide
NCT0000162625	NCT00001626_25_T0	PHENOTYPE	0	0	Secondary
NCT0000162627	NCT00001626_27_T0	CELL	8	8	lymphocytes
NCT0000162627	NCT00001626_27_T1	ORGAN	0	1	Bone marrow
NCT0000162629	NCT00001626_29_T0	CELL	17	17	Reticulocyte
NCT0000162629	NCT00001626_29_T1	CELL	7	7	neutrophil
NCT0000162629	NCT00001626_29_T2	PHENOTYPE	12	13	Platelet count
NCT0000162631	NCT00001626_31_T0	COMPOUND	7	7	MUGA
NCT0000162636	NCT00001626_36_T0	PHENOTYPE	0	0	HIV
NCT0000162638	NCT00001626_38_T0	PHENOTYPE	16	16	severity
NCT0000162638	NCT00001626_38_T1	PHENOTYPE	13	13	diseases
NCT0000162638	NCT00001626_38_T2	GENE	20	20	7-10
NCT000016271	NCT00001627_1_T0	PHENOTYPE	29	30	blood disease
NCT000016276	NCT00001627_6_T0	ORGAN	39	39	marrow
NCT000016276	NCT00001627_6_T1	BIOLOGICAL_PROCESS	24	24	hematopoiesis
NCT000016276	NCT00001627_6_T2	PHENOTYPE	29	30	blood diseases
NCT000016276	NCT00001627_6_T3	ORGAN	36	37	immune system
NCT000016276	NCT00001627_6_T4	ORGAN	4	5	bone marrow
NCT000016278	NCT00001627_8_T0	PHENOTYPE	2	3	hematologic disease
NCT000016278	NCT00001627_8_T1	ORGAN	18	19	bone marrow
NCT000016279	NCT00001627_9_T0	PHENOTYPE	6	7	bleeding disorder
NCT000016281	NCT00001628_1_T0	GENE	3	3	RAS
NCT000016281	NCT00001628_1_T1	PHENOTYPE	0	0	Inhibition
NCT000016281	NCT00001628_1_T2	PHENOTYPE	10	10	hypertension
NCT000016281	NCT00001628_1_T3	PHENOTYPE	18	19	myocardial infarction
NCT000016281	NCT00001628_1_T4	PHENOTYPE	11	12	cardiac failure
NCT000016284	NCT00001628_4_T0	PHENOTYPE	25	25	peripheral
NCT000016284	NCT00001628_4_T1	GENE	35	35	bradykinin
NCT000016284	NCT00001628_4_T2	TISSUE	19	20	vascular endothelium
NCT000016288	NCT00001628_8_T0	GENE	3	3	RAS
NCT000016288	NCT00001628_8_T1	PHENOTYPE	0	0	Inhibition
NCT000016288	NCT00001628_8_T2	PHENOTYPE	10	10	hypertension
NCT000016288	NCT00001628_8_T3	PHENOTYPE	18	19	myocardial infarction
NCT000016288	NCT00001628_8_T4	PHENOTYPE	11	12	cardiac failure
NCT0000162811	NCT00001628_11_T0	PHENOTYPE	25	25	peripheral
NCT0000162811	NCT00001628_11_T1	GENE	35	35	bradykinin
NCT0000162811	NCT00001628_11_T2	TISSUE	19	20	vascular endothelium
NCT0000162815	NCT00001628_15_T0	PHENOTYPE	15	15	atherosclerosis
NCT0000162815	NCT00001628_15_T1	ORGAN	9	10	coronary arteries
NCT0000162818	NCT00001628_18_T0	PHENOTYPE	2	3	myocardial infarction
NCT0000162819	NCT00001628_19_T0	BIOLOGICAL_PROCESS	2	2	lactation
NCT0000162820	NCT00001628_20_T0	PHENOTYPE	1	1	allergy
NCT0000162820	NCT00001628_20_T1	COMPOUND	3	3	losartan
NCT000016291	NCT00001629_1_T0	GENE	3	3	RAS
NCT000016291	NCT00001629_1_T1	PHENOTYPE	0	0	Inhibition
NCT000016291	NCT00001629_1_T2	PHENOTYPE	10	10	hypertension
NCT000016291	NCT00001629_1_T3	PHENOTYPE	18	19	myocardial infarction
NCT000016291	NCT00001629_1_T4	PHENOTYPE	11	12	cardiac failure
NCT000016298	NCT00001629_8_T0	GENE	3	3	RAS
NCT000016298	NCT00001629_8_T1	PHENOTYPE	0	0	Inhibition
NCT000016298	NCT00001629_8_T2	PHENOTYPE	10	10	hypertension
NCT000016298	NCT00001629_8_T3	PHENOTYPE	18	19	myocardial infarction
NCT000016298	NCT00001629_8_T4	PHENOTYPE	11	12	cardiac failure
NCT0000162915	NCT00001629_15_T0	COMPOUND	3	3	estrogen
NCT0000162915	NCT00001629_15_T1	PHENOTYPE	2	2	chronic
NCT000016302	NCT00001630_2_T0	PHENOTYPE	9	9	thrombocytopenia
NCT000016302	NCT00001630_2_T1	PHENOTYPE	3	4	low platelets
NCT000016304	NCT00001630_4_T0	PHENOTYPE	3	3	disorders
NCT000016304	NCT00001630_4_T1	ORGAN	8	9	immune system
NCT000016304	NCT00001630_4_T2	PHENOTYPE	0	1	Autoimmune reactions
NCT000016305	NCT00001630_5_T0	CELL	13	13	platelets
NCT000016305	NCT00001630_5_T1	PHENOTYPE	2	2	AITP
NCT000016305	NCT00001630_5_T2	PHENOTYPE	0	1	Autoimmune thrombocytopenia
NCT000016305	NCT00001630_5_T3	CELL	8	9	blood platelet
NCT000016305	NCT00001630_5_T4	ORGAN	21	22	immune system
NCT000016306	NCT00001630_6_T0	PHENOTYPE	12	12	thrombocytopenia
NCT000016306	NCT00001630_6_T1	PHENOTYPE	4	4	AITP
NCT000016307	NCT00001630_7_T0	ORGAN	12	13	immune system
NCT000016308	NCT00001630_8_T0	PHENOTYPE	17	17	AITP
NCT000016308	NCT00001630_8_T1	CELL	10	11	stem cells
NCT000016309	NCT00001630_9_T0	PHENOTYPE	19	19	AITP
NCT0000163010	NCT00001630_10_T0	CELL	14	14	platelet
NCT0000163013	NCT00001630_13_T0	PHENOTYPE	7	7	AITP
NCT0000163013	NCT00001630_13_T1	GENE	16	16	globulin
NCT0000163013	NCT00001630_13_T2	PHENOTYPE	6	6	chronic
NCT0000163014	NCT00001630_14_T0	PHENOTYPE	10	10	remissions
NCT0000163014	NCT00001630_14_T1	PHENOTYPE	13	14	autoimmune diseases
NCT0000163017	NCT00001630_17_T0	GENE	45	45	CD3
NCT0000163017	NCT00001630_17_T1	CELL	41	41	cells
NCT0000163017	NCT00001630_17_T2	CELL	46	46	cells
NCT0000163017	NCT00001630_17_T3	COMPOUND	27	27	cyclophosphamide
NCT0000163017	NCT00001630_17_T4	PHENOTYPE	54	54	AITP
NCT0000163017	NCT00001630_17_T5	GENE	40	40	CD34
NCT0000163019	NCT00001630_19_T0	PHENOTYPE	37	37	bleeding
NCT0000163019	NCT00001630_19_T1	PHENOTYPE	14	14	remission
NCT0000163019	NCT00001630_19_T2	PHENOTYPE	22	22	remission
NCT0000163019	NCT00001630_19_T3	PHENOTYPE	15	16	platelet count
NCT0000163019	NCT00001630_19_T4	PHENOTYPE	23	24	platelet count
NCT0000163019	NCT00001630_19_T5	PHENOTYPE	32	33	platelet count
NCT0000163020	NCT00001630_20_T0	CELL	14	14	platelet
NCT0000163020	NCT00001630_20_T1	GENE	16	16	glycoprotein
NCT0000163025	NCT00001630_25_T0	PHENOTYPE	0	1	Platelet count
NCT0000163027	NCT00001630_27_T0	CELL	3	3	megakaryocytes
NCT0000163027	NCT00001630_27_T1	ORGAN	5	6	bone marrow
NCT0000163031	NCT00001630_31_T0	COMPOUND	8	8	prednisone
NCT0000163034	NCT00001630_34_T0	PHENOTYPE	5	5	ecchymoses
NCT0000163034	NCT00001630_34_T1	PHENOTYPE	1	1	bleeding
NCT0000163036	NCT00001630_36_T0	PHENOTYPE	0	1	Cardiopulmonary disease
NCT0000163041	NCT00001630_41_T0	COMPOUND	14	14	UNL
NCT0000163041	NCT00001630_41_T1	COMPOUND	3	3	bilirubin
NCT0000163041	NCT00001630_41_T2	PHENOTYPE	1	2	hepatic dysfunction
NCT0000163042	NCT00001630_42_T0	PHENOTYPE	1	1	coagulopathy
NCT0000163044	NCT00001630_44_T0	PHENOTYPE	5	5	malignancy
NCT0000163044	NCT00001630_44_T1	PHENOTYPE	13	15	carcinoma in situ
NCT0000163044	NCT00001630_44_T2	PHENOTYPE	8	10	melanoma skin cancer
NCT0000163045	NCT00001630_45_T0	PHENOTYPE	0	1	HIV positive
NCT0000163046	NCT00001630_46_T0	BIOLOGICAL_PROCESS	2	2	lactation
NCT0000163047	NCT00001630_47_T0	PHENOTYPE	0	1	Psychiatric illness
NCT000016310	NCT00001631_0_T0	TISSUE	5	6	Heart Muscle
NCT000016313	NCT00001631_3_T0	PHENOTYPE	3	5	coronary artery disease
NCT000016315	NCT00001631_5_T0	TISSUE	22	23	heart muscle
NCT000016317	NCT00001631_7_T0	COMPOUND	12	12	dipyridamole
NCT000016317	NCT00001631_7_T1	GENE	11	11	ex
NCT000016317	NCT00001631_7_T2	GENE	1	1	MRI
NCT000016317	NCT00001631_7_T3	COMPOUND	13	13	thallium
NCT0000163112	NCT00001631_12_T0	GENE	0	1	Group 1
NCT0000163112	NCT00001631_12_T1	PHENOTYPE	7	9	coronary artery disease
NCT0000163113	NCT00001631_13_T0	COMPOUND	1	1	2
NCT0000163113	NCT00001631_13_T1	PHENOTYPE	5	6	hypertrophic cardiomyopathy
NCT0000163114	NCT00001631_14_T0	COMPOUND	1	1	3
NCT0000163118	NCT00001631_18_T0	GENE	2	2	SBP
NCT0000163118	NCT00001631_18_T1	GENE	6	6	DBP
NCT0000163118	NCT00001631_18_T2	PHENOTYPE	1	1	hypertension
NCT0000163119	NCT00001631_19_T0	PHENOTYPE	1	2	myocardial infarction
NCT0000163120	NCT00001631_20_T0	PHENOTYPE	4	5	heart block
NCT0000163121	NCT00001631_21_T0	PHENOTYPE	4	4	acute
NCT0000163121	NCT00001631_21_T1	PHENOTYPE	8	8	pneumonia
NCT0000163121	NCT00001631_21_T2	GENE	12	12	hct
NCT0000163121	NCT00001631_21_T3	PHENOTYPE	7	7	fever
NCT0000163121	NCT00001631_21_T4	PHENOTYPE	11	11	anemia
NCT0000163121	NCT00001631_21_T5	PHENOTYPE	0	0	Asthma
NCT0000163121	NCT00001631_21_T6	PHENOTYPE	1	1	emphysema
NCT0000163121	NCT00001631_21_T7	PHENOTYPE	2	3	renal failure
NCT000016321	NCT00001632_1_T0	PHENOTYPE	22	22	circulation
NCT000016321	NCT00001632_1_T1	ORGAN	19	19	heart
NCT000016321	NCT00001632_1_T2	ORGAN	6	7	left ventricle
NCT000016322	NCT00001632_2_T0	TISSUE	12	13	heart muscle
NCT000016322	NCT00001632_2_T1	ORGAN	20	21	left ventricle
NCT000016322	NCT00001632_2_T2	PHENOTYPE	0	1	Hypertrophic cardiomyopathy
NCT000016322	NCT00001632_2_T3	PHENOTYPE	5	6	inherited disease
NCT000016323	NCT00001632_3_T0	PHENOTYPE	13	13	LVH
NCT000016323	NCT00001632_3_T1	ORGAN	2	3	left ventricle
NCT000016323	NCT00001632_3_T2	PHENOTYPE	10	12	left ventricular hypertrophy
NCT000016325	NCT00001632_5_T0	PHENOTYPE	14	14	LVH
NCT000016326	NCT00001632_6_T0	PHENOTYPE	16	16	LVH
NCT000016327	NCT00001632_7_T0	PHENOTYPE	10	10	IBS
NCT000016327	NCT00001632_7_T1	PHENOTYPE	24	24	LVH
NCT000016328	NCT00001632_8_T0	PHENOTYPE	9	9	IBS
NCT000016329	NCT00001632_9_T0	PHENOTYPE	7	7	IBS
NCT000016329	NCT00001632_9_T1	TISSUE	25	26	heart muscle
NCT000016329	NCT00001632_9_T2	PHENOTYPE	24	25	enlarged heart
NCT0000163212	NCT00001632_12_T0	PHENOTYPE	17	17	LVH
NCT0000163214	NCT00001632_14_T0	GENE	11	11	has
NCT0000163214	NCT00001632_14_T1	PHENOTYPE	3	3	IBS
NCT0000163214	NCT00001632_14_T2	PHENOTYPE	18	19	cardiac diseases
NCT0000163215	NCT00001632_15_T0	GENE	3	3	has
NCT0000163221	NCT00001632_21_T0	PHENOTYPE	1	1	CARDIOMYOPATHY
NCT0000163221	NCT00001632_21_T1	PHENOTYPE	9	9	LVH
NCT000016332	NCT00001633_2_T0	GENE	0	0	MRI
NCT000016332	NCT00001633_2_T1	ORGAN	7	7	arteries
NCT000016332	NCT00001633_2_T2	ORGAN	10	10	heart
NCT000016335	NCT00001633_5_T0	ORGAN	15	15	arteries
NCT000016335	NCT00001633_5_T1	ORGAN	18	18	heart
NCT000016337	NCT00001633_7_T0	GENE	18	18	II
NCT0000163311	NCT00001633_11_T0	PHENOTYPE	11	11	menopausal
NCT0000163311	NCT00001633_11_T1	PHENOTYPE	4	4	sterile
NCT0000163318	NCT00001633_18_T0	GENE	3	3	bypass
NCT0000163318	NCT00001633_18_T1	ORGAN	4	4	graft
NCT0000163319	NCT00001633_19_T0	PHENOTYPE	1	1	acute
NCT0000163319	NCT00001633_19_T1	PHENOTYPE	3	3	chronic
NCT0000163320	NCT00001633_20_T0	PHENOTYPE	3	3	claustrophobia
NCT0000163331	NCT00001633_31_T0	GENE	9	9	FOV
NCT0000163333	NCT00001633_33_T0	GENE	12	12	8.0
NCT0000163333	NCT00001633_33_T1	PHENOTYPE	6	6	anemia
NCT0000163335	NCT00001633_35_T0	PHENOTYPE	2	2	suspicion
NCT0000163335	NCT00001633_35_T1	ORGAN	10	10	artery
NCT0000163336	NCT00001633_36_T0	COMPOUND	2	2	warfarin
NCT000016370	NCT00001637_0_T0	CELL	4	5	Blood Cell
NCT000016370	NCT00001637_0_T1	ORGAN	5	6	Cell Transplant
NCT000016370	NCT00001637_0_T2	PHENOTYPE	11	12	Blood Cancers
NCT000016373	NCT00001637_3_T0	ORGAN	27	27	transplant
NCT000016373	NCT00001637_3_T1	GENE	8	8	has
NCT000016377	NCT00001637_7_T0	PHENOTYPE	5	5	toxic
NCT000016377	NCT00001637_7_T1	ORGAN	11	11	transplant
NCT000016378	NCT00001637_8_T0	CELL	12	12	cells
NCT0000163710	NCT00001637_10_T0	ORGAN	19	19	graft
NCT0000163710	NCT00001637_10_T1	GENE	3	3	has
NCT0000163712	NCT00001637_12_T0	PHENOTYPE	0	0	Toxicity
NCT0000163712	NCT00001637_12_T1	PHENOTYPE	11	11	centers
NCT0000163712	NCT00001637_12_T2	ORGAN	10	10	transplant
NCT0000163712	NCT00001637_12_T3	ORGAN	37	38	bone marrow
NCT0000163713	NCT00001637_13_T0	PHENOTYPE	21	21	leukemia
NCT0000163713	NCT00001637_13_T1	PHENOTYPE	27	27	leukemia
NCT0000163713	NCT00001637_13_T2	GENE	10	10	CD4
NCT0000163713	NCT00001637_13_T3	ORGAN	25	25	graft
NCT0000163713	NCT00001637_13_T4	CELL	12	14	CD8 positive lymphocytes
NCT0000163717	NCT00001637_17_T0	GENE	7	7	G-CSF
NCT0000163717	NCT00001637_17_T1	CELL	0	0	T-cell
NCT0000163717	NCT00001637_17_T2	GENE	3	6	granulocyte colony stimulating factor
NCT0000163717	NCT00001637_17_T3	CELL	9	12	peripheral blood stem cells
NCT0000163718	NCT00001637_18_T0	ORGAN	12	12	marrow
NCT0000163718	NCT00001637_18_T1	CELL	4	4	lymphocytes
NCT0000163718	NCT00001637_18_T2	ORGAN	19	19	graft
NCT0000163719	NCT00001637_19_T0	PHENOTYPE	7	7	engraftment
NCT0000163719	NCT00001637_19_T1	PHENOTYPE	14	14	acute
NCT0000163719	NCT00001637_19_T2	ORGAN	18	18	transplant
NCT0000163719	NCT00001637_19_T3	PHENOTYPE	17	17	GVHD
NCT0000163719	NCT00001637_19_T4	PHENOTYPE	16	16	chronic
NCT0000163723	NCT00001637_23_T0	PHENOTYPE	3	3	AML
NCT0000163723	NCT00001637_23_T1	PHENOTYPE	4	4	AML
NCT0000163723	NCT00001637_23_T2	PHENOTYPE	10	10	remission
NCT0000163723	NCT00001637_23_T3	PHENOTYPE	0	2	Acute myelogenous leukemia
NCT0000163725	NCT00001637_25_T0	PHENOTYPE	1	1	AML
NCT0000163725	NCT00001637_25_T1	PHENOTYPE	7	7	remission
NCT0000163726	NCT00001637_26_T0	PHENOTYPE	1	1	syndromes
NCT0000163726	NCT00001637_26_T1	PHENOTYPE	15	16	acute leukemia
NCT0000163726	NCT00001637_26_T2	PHENOTYPE	18	20	Chronic myelomonocytic leukemia
NCT0000163726	NCT00001637_26_T3	PHENOTYPE	2	6	refractory anemia with excess of
NCT0000163727	NCT00001637_27_T0	PHENOTYPE	3	3	CLL
NCT0000163727	NCT00001637_27_T1	PHENOTYPE	7	8	progressive disease
NCT0000163727	NCT00001637_27_T2	PHENOTYPE	0	2	Chronic lymphocytic leukemia
NCT0000163730	NCT00001637_30_T0	PHENOTYPE	3	3	dysfunction
NCT0000163732	NCT00001637_32_T0	PHENOTYPE	1	3	ventricular ejection fraction
NCT0000163733	NCT00001637_33_T0	GENE	4	4	0.2
NCT0000163735	NCT00001637_35_T0	GENE	3	3	G-CSF
NCT0000163735	NCT00001637_35_T1	PHENOTYPE	22	23	heart disease
NCT0000163735	NCT00001637_35_T2	CELL	6	9	peripheral blood stem cells
NCT0000163740	NCT00001637_40_T0	PHENOTYPE	3	4	mental deficiency
NCT0000163741	NCT00001637_41_T0	PHENOTYPE	4	5	organ failure
NCT0000163743	NCT00001637_43_T0	PHENOTYPE	1	3	ventricular ejection fraction
NCT0000163745	NCT00001637_45_T0	COMPOUND	1	1	bilirubin
NCT0000163745	NCT00001637_45_T1	ORGAN	0	0	Serum
NCT0000163746	NCT00001637_46_T0	PHENOTYPE	0	1	HIV positive
NCT0000163747	NCT00001637_47_T0	COMPOUND	6	6	HCV
NCT0000163747	NCT00001637_47_T1	PHENOTYPE	5	5	HBV
NCT0000163748	NCT00001637_48_T0	PHENOTYPE	5	5	relapse
NCT0000163748	NCT00001637_48_T1	PHENOTYPE	2	2	diseases
NCT0000163749	NCT00001637_49_T0	GENE	4	4	G-CSF
NCT000016381	NCT00001638_1_T0	PHENOTYPE	21	23	coronary artery disease
NCT000016383	NCT00001638_3_T0	GENE	13	13	MRI
NCT000016384	NCT00001638_4_T0	GENE	14	14	MRI
NCT000016387	NCT00001638_7_T0	PHENOTYPE	3	4	cardiovascular disease
NCT0000163814	NCT00001638_14_T0	PHENOTYPE	3	3	aneurysm
NCT0000163814	NCT00001638_14_T1	ORGAN	0	2	Central nervous system
NCT0000163818	NCT00001638_18_T0	PHENOTYPE	1	2	foreign body
NCT0000163819	NCT00001638_19_T0	GENE	1	1	insulin
NCT0000163823	NCT00001638_23_T0	GENE	32	32	MRI
NCT0000163823	NCT00001638_23_T1	PHENOTYPE	2	2	symptoms
NCT0000163823	NCT00001638_23_T2	COMPOUND	35	35	1
NCT0000163823	NCT00001638_23_T3	COMPOUND	49	49	2
NCT0000163823	NCT00001638_23_T4	COMPOUND	17	17	nitroglycerin
NCT0000163823	NCT00001638_23_T5	BIOLOGICAL_PROCESS	53	54	glomerular filtration
NCT0000163823	NCT00001638_23_T6	PHENOTYPE	50	51	renal disease
NCT0000163823	NCT00001638_23_T7	PHENOTYPE	4	5	myocardial ischemia
NCT0000163825	NCT00001638_25_T0	GENE	39	39	MRI
NCT0000163825	NCT00001638_25_T1	ORGAN	16	16	serum
NCT0000163825	NCT00001638_25_T2	PHENOTYPE	8	10	acute renal insufficiency
NCT0000163826	NCT00001638_26_T0	PHENOTYPE	0	1	Myocardial infarction
NCT0000163828	NCT00001638_28_T0	PHENOTYPE	1	2	heart failure
NCT0000163829	NCT00001638_29_T0	GENE	2	2	SBP
NCT0000163829	NCT00001638_29_T1	GENE	6	6	DBP
NCT0000163829	NCT00001638_29_T2	PHENOTYPE	1	1	hypertension
NCT0000163830	NCT00001638_30_T0	PHENOTYPE	0	1	Atrial fibrillation
NCT0000163831	NCT00001638_31_T0	PHENOTYPE	0	1	Ventricular tachycardia
NCT0000163832	NCT00001638_32_T0	ORGAN	7	7	heart
NCT0000163832	NCT00001638_32_T1	PHENOTYPE	11	12	ventricular tachycardia
NCT0000163833	NCT00001638_33_T0	GENE	27	27	MRI
NCT0000163833	NCT00001638_33_T1	COMPOUND	20	20	atropine
NCT0000163833	NCT00001638_33_T2	PHENOTYPE	15	16	prostatic hypertrophy
NCT0000163833	NCT00001638_33_T3	PHENOTYPE	10	12	bladder outlet obstruction
NCT0000163833	NCT00001638_33_T4	PHENOTYPE	2	4	narrow angle glaucoma
NCT0000163834	NCT00001638_34_T0	PHENOTYPE	0	1	Myocardial infarction
NCT0000163836	NCT00001638_36_T0	ORGAN	28	28	heart
NCT0000163836	NCT00001638_36_T1	PHENOTYPE	13	14	heart failure
NCT000016392	NCT00001639_2_T0	GENE	11	11	dye
NCT000016392	NCT00001639_2_T1	CELL	8	8	chromosomes
NCT000016392	NCT00001639_2_T2	PHENOTYPE	0	1	Chromosome abnormalities
NCT000016395	NCT00001639_5_T0	PHENOTYPE	17	18	chromosome abnormalities
NCT000016397	NCT00001639_7_T0	PHENOTYPE	16	16	symptoms
NCT000016397	NCT00001639_7_T1	COMPOUND	9	9	1
NCT000016398	NCT00001639_8_T0	GENE	25	25	MRI
NCT000016399	NCT00001639_9_T0	CELL	5	5	chromosome
NCT0000163913	NCT00001639_13_T0	GENE	13	13	Mb
NCT0000163913	NCT00001639_13_T1	GENE	23	23	Mb
NCT0000163914	NCT00001639_14_T0	GENE	20	20	Mb
NCT0000163914	NCT00001639_14_T1	GENE	12	12	has
NCT0000163916	NCT00001639_16_T0	GENE	9	9	FISH
NCT0000163917	NCT00001639_17_T0	BIOLOGICAL_PROCESS	12	12	phlebotomy
NCT0000163918	NCT00001639_18_T0	GENE	9	9	FISH
NCT0000163920	NCT00001639_20_T0	PHENOTYPE	3	4	chromosome abnormality
NCT0000163920	NCT00001639_20_T1	PHENOTYPE	2	3	derivative chromosome
NCT0000163924	NCT00001639_24_T0	CELL	19	19	chromosomes
NCT0000163924	NCT00001639_24_T1	CELL	8	8	chromosome
NCT0000163925	NCT00001639_25_T0	CELL	6	6	chromosome
NCT0000163926	NCT00001639_26_T0	GENE	2	2	has
NCT0000163929	NCT00001639_29_T0	GENE	13	13	PI
NCT000016401	NCT00001640_1_T0	COMPOUND	10	10	dopamine
NCT000016401	NCT00001640_1_T1	PHENOTYPE	1	2	Parkinson's disease
NCT000016402	NCT00001640_2_T0	ORGAN	16	16	hands
NCT000016402	NCT00001640_2_T1	ORGAN	18	18	fingers
NCT000016403	NCT00001640_3_T0	PHENOTYPE	0	1	Parkinson's disease
NCT000016404	NCT00001640_4_T0	PHENOTYPE	14	14	mutation
NCT000016405	NCT00001640_5_T0	PHENOTYPE	10	10	mutated
NCT000016407	NCT00001640_7_T0	PHENOTYPE	11	12	Parkinson's disease
NCT0000164011	NCT00001640_11_T0	PHENOTYPE	7	7	sporadic
NCT0000164011	NCT00001640_11_T1	PHENOTYPE	8	9	Parkinson's disease
NCT0000164013	NCT00001640_13_T0	GENE	34	34	defective
NCT0000164013	NCT00001640_13_T1	PHENOTYPE	39	40	Parkinson's disease
NCT0000164016	NCT00001640_16_T0	PHENOTYPE	7	7	mutation
NCT0000164019	NCT00001640_19_T0	PHENOTYPE	9	9	tremor
NCT0000164019	NCT00001640_19_T1	PHENOTYPE	10	10	bradykinesia
NCT0000164022	NCT00001640_22_T0	PHENOTYPE	6	6	dementia
NCT0000164022	NCT00001640_22_T1	PHENOTYPE	0	1	Parkinson's disease
NCT000016411	NCT00001641_1_T0	PHENOTYPE	22	22	syndromes
NCT000016411	NCT00001641_1_T1	PHENOTYPE	16	18	signs and symptoms
NCT000016415	NCT00001641_5_T0	PHENOTYPE	15	17	connective tissue disorder
NCT000016418	NCT00001641_8_T0	PHENOTYPE	9	11	connective tissue disorder
NCT0000164111	NCT00001641_11_T0	GENE	5	5	has
NCT0000164111	NCT00001641_11_T1	GENE	29	29	has
NCT0000164112	NCT00001641_12_T0	PHENOTYPE	13	13	syndromes
NCT0000164113	NCT00001641_13_T0	PHENOTYPE	27	27	mutation
NCT0000164113	NCT00001641_13_T1	PHENOTYPE	19	19	disorders
NCT0000164116	NCT00001641_16_T0	PHENOTYPE	14	14	mutation
NCT000016424	NCT00001642_4_T0	GENE	11	11	receptor
NCT000016424	NCT00001642_4_T1	GENE	10	10	Notch1
NCT000016424	NCT00001642_4_T2	PHENOTYPE	15	16	Alagille Syndrome
NCT000016431	NCT00001643_1_T0	COMPOUND	10	10	dopamine
NCT000016431	NCT00001643_1_T1	PHENOTYPE	1	2	Parkinson's disease
NCT000016432	NCT00001643_2_T0	ORGAN	16	16	hands
NCT000016432	NCT00001643_2_T1	ORGAN	18	18	fingers
NCT000016433	NCT00001643_3_T0	PHENOTYPE	0	1	Parkinson's disease
NCT000016434	NCT00001643_4_T0	PHENOTYPE	14	14	mutation
NCT000016435	NCT00001643_5_T0	PHENOTYPE	10	10	mutated
NCT000016437	NCT00001643_7_T0	PHENOTYPE	11	12	Parkinson's disease
NCT0000164316	NCT00001643_16_T0	PHENOTYPE	5	5	dementia
NCT0000164317	NCT00001643_17_T0	PHENOTYPE	9	9	impairment
NCT0000164319	NCT00001643_19_T0	GENE	21	21	parkin
NCT000016440	NCT00001644_0_T0	PHENOTYPE	10	11	HIV Infection
NCT000016443	NCT00001644_3_T0	PHENOTYPE	0	0	HIV
NCT000016446	NCT00001644_6_T0	COMPOUND	16	16	nevirapine
NCT000016446	NCT00001644_6_T1	COMPOUND	13	13	zidovudine
NCT000016446	NCT00001644_6_T2	COMPOUND	12	12	indinavir
NCT000016446	NCT00001644_6_T3	COMPOUND	14	14	lamivudine
NCT000016449	NCT00001644_9_T0	PHENOTYPE	13	13	closed
NCT0000164412	NCT00001644_12_T0	TISSUE	0	1	Lymph node
NCT0000164416	NCT00001644_16_T0	CELL	3	3	cells
NCT0000164416	NCT00001644_16_T1	CELL	15	16	T cells
NCT0000164418	NCT00001644_18_T0	GENE	2	2	CD4
NCT0000164418	NCT00001644_18_T1	PHENOTYPE	23	23	initiation
NCT0000164420	NCT00001644_20_T0	GENE	34	34	de
NCT0000164420	NCT00001644_20_T1	PHENOTYPE	46	46	susceptible
NCT0000164420	NCT00001644_20_T2	GENE	74	74	retained
NCT0000164420	NCT00001644_20_T3	CELL	65	65	macrophages
NCT0000164420	NCT00001644_20_T4	CELL	7	7	cells
NCT0000164420	NCT00001644_20_T5	CELL	13	13	cells
NCT0000164420	NCT00001644_20_T6	CELL	48	48	cells
NCT0000164420	NCT00001644_20_T7	PHENOTYPE	12	12	infections
NCT0000164420	NCT00001644_20_T8	PHENOTYPE	9	9	chronic
NCT0000164420	NCT00001644_20_T9	PHENOTYPE	36	37	virus infection
NCT0000164420	NCT00001644_20_T10	PHENOTYPE	50	51	virus infection
NCT0000164420	NCT00001644_20_T11	ORGAN	40	42	central nervous system
NCT0000164420	NCT00001644_20_T12	CELL	79	81	follicular dendritic cells
NCT0000164427	NCT00001644_27_T0	TISSUE	4	5	lymph node
NCT0000164428	NCT00001644_28_T0	GENE	7	7	blot
NCT0000164428	NCT00001644_28_T1	PHENOTYPE	0	1	HIV infection
NCT0000164430	NCT00001644_30_T0	ORGAN	0	0	Plasma
NCT0000164433	NCT00001644_33_T0	GENE	9	9	CD4
NCT0000164433	NCT00001644_33_T1	CELL	10	10	cells
NCT0000164434	NCT00001644_34_T0	GENE	18	18	protease
NCT0000164434	NCT00001644_34_T1	COMPOUND	16	16	nevirapine
NCT0000164434	NCT00001644_34_T2	GENE	9	9	CD4
NCT0000164434	NCT00001644_34_T3	COMPOUND	15	15	lamivudine
NCT0000164435	NCT00001644_35_T0	TISSUE	4	5	lymph nodes
NCT0000164438	NCT00001644_38_T0	PHENOTYPE	2	3	Platelet count
NCT0000164439	NCT00001644_39_T0	COMPOUND	8	8	cardiolipin
NCT0000164440	NCT00001644_40_T0	PHENOTYPE	2	3	bleeding disorder
NCT0000164442	NCT00001644_42_T0	PHENOTYPE	0	1	Psychiatric illness
NCT0000164443	NCT00001644_43_T0	PHENOTYPE	1	2	substance abuse
NCT0000164443	NCT00001644_43_T1	PHENOTYPE	7	8	substance abuse
NCT000016451	NCT00001645_1_T0	PHENOTYPE	6	7	parasitic infection
NCT0000164511	NCT00001645_11_T0	PHENOTYPE	5	6	parasitic infection
NCT0000164511	NCT00001645_11_T1	PHENOTYPE	19	20	parasitic infection
NCT0000164512	NCT00001645_12_T0	PHENOTYPE	22	23	parasitic infections
NCT0000164518	NCT00001645_18_T0	PHENOTYPE	5	6	parasitic infection
NCT0000164520	NCT00001645_20_T0	PHENOTYPE	5	6	parasitic infection
NCT000016461	NCT00001646_1_T0	PHENOTYPE	4	4	secondary
NCT000016461	NCT00001646_1_T1	PHENOTYPE	14	14	acute
NCT000016461	NCT00001646_1_T2	PHENOTYPE	15	15	aspergillosis
NCT000016461	NCT00001646_1_T3	PHENOTYPE	3	3	neutropenia
NCT000016462	NCT00001646_2_T0	PHENOTYPE	15	16	HIV infection
NCT000016462	NCT00001646_2_T1	ORGAN	2	3	bone marrow
NCT000016463	NCT00001646_3_T0	PHENOTYPE	7	7	acute
NCT000016463	NCT00001646_3_T1	PHENOTYPE	4	4	aspergillosis
NCT000016463	NCT00001646_3_T2	GENE	10	10	has
NCT000016464	NCT00001646_4_T0	ORGAN	1	2	bone marrow
NCT000016466	NCT00001646_6_T0	COMPOUND	4	5	amphotericin B
NCT000016468	NCT00001646_8_T0	PHENOTYPE	3	3	nephrotoxicity
NCT000016468	NCT00001646_8_T1	PHENOTYPE	6	7	adverse effects
NCT000016468	NCT00001646_8_T2	COMPOUND	11	12	amphotericin B
NCT000016469	NCT00001646_9_T0	COMPOUND	9	9	itraconazole
NCT000016469	NCT00001646_9_T1	COMPOUND	6	7	amphotericin B
NCT0000164610	NCT00001646_10_T0	GENE	14	14	has
NCT0000164610	NCT00001646_10_T1	PHENOTYPE	7	8	adverse effects
NCT0000164610	NCT00001646_10_T2	COMPOUND	23	24	amphotericin B
NCT0000164611	NCT00001646_11_T0	GENE	11	11	III
NCT0000164612	NCT00001646_12_T0	GENE	8	8	spp
NCT0000164612	NCT00001646_12_T1	PHENOTYPE	23	23	aspergillosis
NCT0000164612	NCT00001646_12_T2	GENE	2	2	has
NCT0000164613	NCT00001646_13_T0	GENE	1	1	has
NCT0000164614	NCT00001646_14_T0	PHENOTYPE	22	22	acute
NCT0000164614	NCT00001646_14_T1	COMPOUND	10	10	voriconazole
NCT0000164614	NCT00001646_14_T2	PHENOTYPE	23	24	invasive aspergillosis
NCT0000164614	NCT00001646_14_T3	COMPOUND	16	17	amphotericin B
NCT0000164615	NCT00001646_15_T0	COMPOUND	8	8	voriconazole
NCT0000164615	NCT00001646_15_T1	COMPOUND	10	11	amphotericin B
NCT0000164617	NCT00001646_17_T0	PHENOTYPE	4	4	secondary
NCT0000164617	NCT00001646_17_T1	PHENOTYPE	14	14	acute
NCT0000164617	NCT00001646_17_T2	PHENOTYPE	15	15	aspergillosis
NCT0000164617	NCT00001646_17_T3	PHENOTYPE	3	3	neutropenia
NCT0000164618	NCT00001646_18_T0	PHENOTYPE	15	16	HIV infection
NCT0000164618	NCT00001646_18_T1	ORGAN	2	3	bone marrow
NCT0000164619	NCT00001646_19_T0	PHENOTYPE	7	7	acute
NCT0000164619	NCT00001646_19_T1	PHENOTYPE	4	4	aspergillosis
NCT0000164619	NCT00001646_19_T2	GENE	10	10	has
NCT0000164620	NCT00001646_20_T0	ORGAN	1	2	bone marrow
NCT0000164622	NCT00001646_22_T0	COMPOUND	4	5	amphotericin B
NCT0000164624	NCT00001646_24_T0	PHENOTYPE	3	3	nephrotoxicity
NCT0000164624	NCT00001646_24_T1	PHENOTYPE	6	7	adverse effects
NCT0000164624	NCT00001646_24_T2	COMPOUND	11	12	amphotericin B
NCT0000164625	NCT00001646_25_T0	COMPOUND	9	9	itraconazole
NCT0000164625	NCT00001646_25_T1	COMPOUND	6	7	amphotericin B
NCT0000164626	NCT00001646_26_T0	GENE	14	14	has
NCT0000164626	NCT00001646_26_T1	PHENOTYPE	7	8	adverse effects
NCT0000164626	NCT00001646_26_T2	COMPOUND	23	24	amphotericin B
NCT0000164627	NCT00001646_27_T0	GENE	11	11	III
NCT0000164628	NCT00001646_28_T0	PHENOTYPE	23	23	aspergillosis
NCT0000164628	NCT00001646_28_T1	GENE	2	2	has
NCT0000164628	NCT00001646_28_T2	GENE	8	8	sp
NCT0000164629	NCT00001646_29_T0	GENE	1	1	has
NCT0000164630	NCT00001646_30_T0	PHENOTYPE	22	22	acute
NCT0000164630	NCT00001646_30_T1	COMPOUND	10	10	voriconazole
NCT0000164630	NCT00001646_30_T2	PHENOTYPE	23	24	invasive aspergillosis
NCT0000164630	NCT00001646_30_T3	COMPOUND	16	17	amphotericin B
NCT0000164632	NCT00001646_32_T0	COMPOUND	8	8	voriconazole
NCT0000164632	NCT00001646_32_T1	COMPOUND	10	11	amphotericin B
NCT0000164634	NCT00001646_34_T0	PHENOTYPE	3	3	lymphoma
NCT0000164634	NCT00001646_34_T1	PHENOTYPE	0	1	Hematological malignancy
NCT0000164635	NCT00001646_35_T0	PHENOTYPE	0	1	Aplastic anemia
NCT0000164635	NCT00001646_35_T1	PHENOTYPE	3	4	myelodysplastic syndromes
NCT0000164637	NCT00001646_37_T0	PHENOTYPE	2	2	malignancy
NCT0000164638	NCT00001646_38_T0	PHENOTYPE	0	0	HIV
NCT0000164639	NCT00001646_39_T0	COMPOUND	30	30	azathioprine
NCT0000164639	NCT00001646_39_T1	COMPOUND	31	31	methotrexate
NCT0000164639	NCT00001646_39_T2	COMPOUND	14	14	prednisone
NCT0000164640	NCT00001646_40_T0	PHENOTYPE	7	7	acute
NCT0000164640	NCT00001646_40_T1	GENE	6	6	probable
NCT0000164640	NCT00001646_40_T2	PHENOTYPE	8	9	invasive aspergillosis
NCT0000164641	NCT00001646_41_T0	PHENOTYPE	11	11	acute
NCT0000164641	NCT00001646_41_T1	PHENOTYPE	13	13	aspergillosis
NCT0000164641	NCT00001646_41_T2	PHENOTYPE	1	2	fungal infection
NCT0000164642	NCT00001646_42_T0	COMPOUND	13	13	itraconazole
NCT0000164642	NCT00001646_42_T1	COMPOUND	6	7	amphotericin B
NCT0000164645	NCT00001646_45_T0	PHENOTYPE	8	10	negative pregnancy test
NCT0000164646	NCT00001646_46_T0	PHENOTYPE	4	4	aspergilloma
NCT0000164646	NCT00001646_46_T1	PHENOTYPE	3	3	sarcoidosis
NCT0000164646	NCT00001646_46_T2	PHENOTYPE	7	8	bronchopulmonary aspergillosis
NCT0000164647	NCT00001646_47_T0	PHENOTYPE	10	10	symptoms
NCT0000164647	NCT00001646_47_T1	PHENOTYPE	3	3	chronic
NCT0000164647	NCT00001646_47_T2	PHENOTYPE	4	5	invasive aspergillosis
NCT0000164648	NCT00001646_48_T0	GENE	12	12	0.5
NCT0000164648	NCT00001646_48_T1	COMPOUND	28	28	itraconazole
NCT0000164648	NCT00001646_48_T2	COMPOUND	20	21	amphotericin B
NCT0000164653	NCT00001646_53_T0	COMPOUND	19	19	cisapride
NCT0000164653	NCT00001646_53_T1	PHENOTYPE	47	47	hypoglycemia
NCT0000164653	NCT00001646_53_T2	ORGAN	42	42	plasma
NCT0000164653	NCT00001646_53_T3	COMPOUND	21	21	astemizole
NCT0000164654	NCT00001646_54_T0	COMPOUND	33	33	voriconazole
NCT0000164654	NCT00001646_54_T1	COMPOUND	15	15	carbamazepine
NCT0000164655	NCT00001646_55_T0	PHENOTYPE	32	32	HIV/AIDS
NCT0000164655	NCT00001646_55_T1	PHENOTYPE	34	34	infections
NCT0000164660	NCT00001646_60_T0	PHENOTYPE	4	4	ventilation
NCT000016470	NCT00001647_0_T0	PHENOTYPE	6	7	HIV Infection
NCT000016470	NCT00001647_0_T1	CELL	0	2	White Blood Cell
NCT000016475	NCT00001647_5_T0	PHENOTYPE	6	6	tetanus
NCT000016475	NCT00001647_5_T1	GENE	7	7	booster
NCT000016476	NCT00001647_6_T0	CELL	8	10	white blood cells
NCT0000164712	NCT00001647_12_T0	PHENOTYPE	31	32	immune status
NCT0000164714	NCT00001647_14_T0	CELL	21	21	cells
NCT0000164715	NCT00001647_15_T0	GENE	7	7	reduced
NCT0000164717	NCT00001647_17_T0	CELL	1	1	lymphocytes
NCT0000164717	NCT00001647_17_T1	PHENOTYPE	4	4	seronegative
NCT0000164719	NCT00001647_19_T0	GENE	15	15	CD4
NCT0000164719	NCT00001647_19_T1	CELL	16	16	T-cell
NCT0000164721	NCT00001647_21_T0	GENE	2	2	CD4
NCT0000164721	NCT00001647_21_T1	PHENOTYPE	5	5	HIV
NCT0000164723	NCT00001647_23_T0	GENE	1	1	KS
NCT0000164724	NCT00001647_24_T0	GENE	3	3	KS
NCT0000164730	NCT00001647_30_T0	PHENOTYPE	4	4	lymphoma
NCT0000164730	NCT00001647_30_T1	PHENOTYPE	8	9	opportunistic infection
NCT0000164731	NCT00001647_31_T0	PHENOTYPE	2	2	HIV
NCT0000164731	NCT00001647_31_T1	PHENOTYPE	3	3	infections
NCT0000164731	NCT00001647_31_T2	GENE	15	15	has
NCT0000164731	NCT00001647_31_T3	PHENOTYPE	5	5	chronic
NCT0000164733	NCT00001647_33_T0	PHENOTYPE	4	5	substance abuse
NCT0000164737	NCT00001647_37_T0	PHENOTYPE	12	13	acute infection
NCT0000164738	NCT00001647_38_T0	GENE	6	6	Barr
NCT0000164738	NCT00001647_38_T1	PHENOTYPE	5	5	Epstein
NCT0000164738	NCT00001647_38_T2	PHENOTYPE	15	15	seronegative
NCT0000164739	NCT00001647_39_T0	PHENOTYPE	10	11	Hepatitis C
NCT0000164739	NCT00001647_39_T1	PHENOTYPE	6	7	Hepatitis B
NCT0000164741	NCT00001647_41_T0	PHENOTYPE	5	5	HIV
NCT0000164742	NCT00001647_42_T0	GENE	1	1	CD4
NCT000016481	NCT00001648_1_T0	PHENOTYPE	5	5	herpes
NCT000016483	NCT00001648_3_T0	CELL	5	5	cells
NCT000016483	NCT00001648_3_T1	PHENOTYPE	1	1	herpes
NCT000016484	NCT00001648_4_T0	GENE	12	12	receptor
NCT000016484	NCT00001648_4_T1	PHENOTYPE	11	11	HSV
NCT000016486	NCT00001648_6_T0	PHENOTYPE	11	11	HSV
NCT000016487	NCT00001648_7_T0	PHENOTYPE	11	11	HSV
NCT0000164811	NCT00001648_11_T0	PHENOTYPE	23	25	sexually transmitted diseases
NCT0000164813	NCT00001648_13_T0	PHENOTYPE	4	4	HSV
NCT0000164814	NCT00001648_14_T0	PHENOTYPE	33	33	symptoms
NCT0000164814	NCT00001648_14_T1	GENE	14	14	receptor
NCT0000164814	NCT00001648_14_T2	PHENOTYPE	13	13	HSV
NCT0000164814	NCT00001648_14_T3	PHENOTYPE	30	30	HSV
NCT0000164814	NCT00001648_14_T4	PHENOTYPE	35	35	HSV
NCT0000164814	NCT00001648_14_T5	PHENOTYPE	26	28	susceptibility to infection
NCT0000164815	NCT00001648_15_T0	PHENOTYPE	12	12	symptoms
NCT0000164815	NCT00001648_15_T1	PHENOTYPE	26	26	HSV
NCT0000164815	NCT00001648_15_T2	PHENOTYPE	6	6	seronegative
NCT0000164816	NCT00001648_16_T0	PHENOTYPE	16	16	HSV
NCT0000164817	NCT00001648_17_T0	PHENOTYPE	8	8	insights
NCT0000164817	NCT00001648_17_T1	PHENOTYPE	14	14	HSV
NCT0000164821	NCT00001648_21_T0	GENE	13	13	blot
NCT0000164821	NCT00001648_21_T1	PHENOTYPE	3	3	seronegative
NCT0000164823	NCT00001648_23_T0	PHENOTYPE	6	6	symptoms
NCT0000164824	NCT00001648_24_T0	GENE	13	13	blot
NCT000016491	NCT00001649_1_T0	PHENOTYPE	0	1	Genital herpes
NCT000016491	NCT00001649_1_T1	PHENOTYPE	6	7	herpes simplex
NCT000016491	NCT00001649_1_T2	PHENOTYPE	13	14	herpes simplex
NCT000016492	NCT00001649_2_T0	PHENOTYPE	3	3	herpes
NCT000016493	NCT00001649_3_T0	PHENOTYPE	22	22	susceptible
NCT000016495	NCT00001649_5_T0	ORGAN	11	11	genital
NCT000016495	NCT00001649_5_T1	PHENOTYPE	19	19	practices
NCT000016495	NCT00001649_5_T2	PHENOTYPE	33	34	genital herpes
NCT000016495	NCT00001649_5_T3	PHENOTYPE	24	26	signs and symptoms
NCT000016496	NCT00001649_6_T0	PHENOTYPE	12	12	susceptible
NCT000016496	NCT00001649_6_T1	PHENOTYPE	22	22	practices
NCT000016496	NCT00001649_6_T2	PHENOTYPE	9	10	genital herpes
NCT000016498	NCT00001649_8_T0	PHENOTYPE	32	32	HSV
NCT000016498	NCT00001649_8_T1	PHENOTYPE	22	22	susceptible
NCT000016498	NCT00001649_8_T2	PHENOTYPE	29	29	symptoms
NCT000016498	NCT00001649_8_T3	PHENOTYPE	17	19	drug side effects
NCT0000164910	NCT00001649_10_T0	PHENOTYPE	69	69	recurrences
NCT0000164910	NCT00001649_10_T1	PHENOTYPE	47	47	practices
NCT0000164910	NCT00001649_10_T2	PHENOTYPE	67	67	symptoms
NCT0000164910	NCT00001649_10_T3	PHENOTYPE	50	51	genital herpes
NCT0000164910	NCT00001649_10_T4	PHENOTYPE	62	63	genital herpes
NCT0000164910	NCT00001649_10_T5	PHENOTYPE	71	72	genital herpes
NCT0000164910	NCT00001649_10_T6	PHENOTYPE	54	56	signs and symptoms
NCT0000164910	NCT00001649_10_T7	PHENOTYPE	20	22	drug side effects
NCT0000164912	NCT00001649_12_T0	PHENOTYPE	20	20	symptoms
NCT0000164912	NCT00001649_12_T1	PHENOTYPE	0	0	Susceptible
NCT0000164912	NCT00001649_12_T2	PHENOTYPE	10	10	HSV
NCT0000164912	NCT00001649_12_T3	PHENOTYPE	33	33	practices
NCT0000164913	NCT00001649_13_T0	PHENOTYPE	5	5	recurrence
NCT0000164913	NCT00001649_13_T1	PHENOTYPE	8	8	HSV
NCT0000164913	NCT00001649_13_T2	ORGAN	7	7	genital
NCT0000164914	NCT00001649_14_T0	PHENOTYPE	0	0	Susceptible
NCT0000164914	NCT00001649_14_T1	ORGAN	16	16	genital
NCT0000164914	NCT00001649_14_T2	PHENOTYPE	4	5	genital herpes
NCT0000164914	NCT00001649_14_T3	PHENOTYPE	24	25	genital herpes
NCT0000164915	NCT00001649_15_T0	ORGAN	8	8	genitals
NCT0000164915	NCT00001649_15_T1	PHENOTYPE	27	29	treatment side effects
NCT0000164917	NCT00001649_17_T0	PHENOTYPE	39	39	recurrences
NCT0000164917	NCT00001649_17_T1	PHENOTYPE	37	37	symptoms
NCT0000164917	NCT00001649_17_T2	PHENOTYPE	41	42	genital herpes
NCT0000164917	NCT00001649_17_T3	PHENOTYPE	25	27	drug side effects
NCT0000164918	NCT00001649_18_T0	PHENOTYPE	15	16	genital herpes
NCT0000164920	NCT00001649_20_T0	PHENOTYPE	34	34	HSV
NCT0000164920	NCT00001649_20_T1	PHENOTYPE	22	22	seronegative
NCT0000164920	NCT00001649_20_T2	PHENOTYPE	21	21	susceptible
NCT0000164923	NCT00001649_23_T0	PHENOTYPE	0	0	Susceptible
NCT0000164923	NCT00001649_23_T1	PHENOTYPE	5	5	seronegative
NCT0000164924	NCT00001649_24_T0	PHENOTYPE	9	9	HSV
NCT0000164924	NCT00001649_24_T1	PHENOTYPE	13	13	susceptible
NCT0000164925	NCT00001649_25_T0	GENE	14	14	1.1
NCT0000164926	NCT00001649_26_T0	PHENOTYPE	17	17	HSV
NCT0000164926	NCT00001649_26_T1	ORGAN	16	16	genital
NCT0000164926	NCT00001649_26_T2	PHENOTYPE	20	20	susceptible
NCT0000164927	NCT00001649_27_T0	PHENOTYPE	7	7	symptoms
NCT0000164927	NCT00001649_27_T1	PHENOTYPE	26	26	recurrence
NCT0000164927	NCT00001649_27_T2	PHENOTYPE	0	0	Secondary
NCT0000164927	NCT00001649_27_T3	PHENOTYPE	10	10	HSV
NCT0000164927	NCT00001649_27_T4	PHENOTYPE	28	28	HSV
NCT0000164927	NCT00001649_27_T5	ORGAN	9	9	genital
NCT0000164927	NCT00001649_27_T6	PHENOTYPE	13	13	susceptible
NCT0000164927	NCT00001649_27_T7	PHENOTYPE	20	20	susceptible
NCT0000164930	NCT00001649_30_T0	PHENOTYPE	3	3	tolerance
NCT0000164930	NCT00001649_30_T1	PHENOTYPE	18	19	adverse events
NCT0000164931	NCT00001649_31_T0	PHENOTYPE	9	9	centers
NCT0000164934	NCT00001649_34_T0	PHENOTYPE	4	4	susceptible
NCT0000164935	NCT00001649_35_T0	GENE	9	9	blot
NCT0000164935	NCT00001649_35_T1	ORGAN	3	3	serum
NCT0000164936	NCT00001649_36_T0	PHENOTYPE	3	5	recurrent genital herpes
NCT0000164937	NCT00001649_37_T0	PHENOTYPE	1	1	HSV
NCT0000164943	NCT00001649_43_T0	COMPOUND	7	7	creatinine
NCT0000164943	NCT00001649_43_T1	COMPOUND	14	14	creatinine
NCT0000164943	NCT00001649_43_T2	GENE	10	10	1.5
NCT0000164943	NCT00001649_43_T3	ORGAN	6	6	serum
NCT0000164943	NCT00001649_43_T4	PHENOTYPE	0	2	Impaired renal function
NCT0000164945	NCT00001649_45_T0	COMPOUND	6	6	ganciclovir
NCT0000164945	NCT00001649_45_T1	COMPOUND	4	4	famciclovir
NCT0000164948	NCT00001649_48_T0	PHENOTYPE	4	5	lactose intolerant
NCT0000164951	NCT00001649_51_T0	PHENOTYPE	0	2	Positive pregnancy test
NCT0000164955	NCT00001649_55_T0	GENE	9	9	blot
NCT0000164955	NCT00001649_55_T1	ORGAN	3	3	serum
NCT0000164959	NCT00001649_59_T0	PHENOTYPE	6	6	HSV
NCT0000164960	NCT00001649_60_T0	PHENOTYPE	3	4	genital herpes
NCT0000164964	NCT00001649_64_T0	PHENOTYPE	0	2	Positive pregnancy test
NCT000016501	NCT00001650_1_T0	PHENOTYPE	19	19	blocks
NCT000016501	NCT00001650_1_T1	COMPOUND	14	14	thymidine
NCT000016503	NCT00001650_3_T0	CELL	5	5	cells
NCT000016503	NCT00001650_3_T1	CELL	11	11	cells
NCT000016504	NCT00001650_4_T0	PHENOTYPE	0	0	HIV
NCT0000165012	NCT00001650_12_T0	PHENOTYPE	12	12	discomfort
NCT0000165014	NCT00001650_14_T0	GENE	4	4	blot
NCT0000165014	NCT00001650_14_T1	PHENOTYPE	8	8	acute
NCT0000165014	NCT00001650_14_T2	GENE	10	10	PCR
NCT0000165014	NCT00001650_14_T3	PHENOTYPE	1	2	HIV infection
NCT0000165016	NCT00001650_16_T0	ORGAN	3	3	serum
NCT0000165019	NCT00001650_19_T0	CELL	9	9	neutrophils
NCT0000165019	NCT00001650_19_T1	CELL	5	5	platelets
NCT0000165021	NCT00001650_21_T0	PHENOTYPE	5	5	toxicity
NCT0000165022	NCT00001650_22_T0	PHENOTYPE	3	4	substance abuse
NCT0000165022	NCT00001650_22_T1	PHENOTYPE	9	10	substance abuse
NCT0000165023	NCT00001650_23_T0	PHENOTYPE	0	1	Psychiatric illness
NCT0000165026	NCT00001650_26_T0	COMPOUND	6	6	5_fluorouracil
NCT0000165027	NCT00001650_27_T0	PHENOTYPE	12	13	HIV infections
NCT000016511	NCT00001651_1_T0	COMPOUND	8	8	glucose
NCT000016514	NCT00001651_4_T0	PHENOTYPE	10	10	HIV
NCT000016515	NCT00001651_5_T0	PHENOTYPE	0	0	HIV
NCT0000165114	NCT00001651_14_T0	COMPOUND	9	9	glucose
NCT0000165118	NCT00001651_18_T0	PHENOTYPE	9	9	HIV
NCT0000165118	NCT00001651_18_T1	PHENOTYPE	13	13	progressive
NCT0000165118	NCT00001651_18_T2	PHENOTYPE	23	23	immunity
NCT0000165118	NCT00001651_18_T3	ORGAN	17	18	immune system
NCT0000165121	NCT00001651_21_T0	COMPOUND	25	25	glucose
NCT0000165121	NCT00001651_21_T1	PHENOTYPE	7	7	HIV
NCT0000165122	NCT00001651_22_T0	COMPOUND	9	9	glucose
NCT0000165122	NCT00001651_22_T1	COMPOUND	1	1	deuterium
NCT0000165122	NCT00001651_22_T2	COMPOUND	11	11	ribose
NCT0000165122	NCT00001651_22_T3	BIOLOGICAL_PROCESS	7	7	metabolism
NCT0000165124	NCT00001651_24_T0	PHENOTYPE	34	34	diseases
NCT0000165124	NCT00001651_24_T1	CELL	15	15	lymphocyte
NCT0000165124	NCT00001651_24_T2	ORGAN	22	23	immune systems
NCT0000165124	NCT00001651_24_T3	ORGAN	25	26	immune systems
NCT0000165125	NCT00001651_25_T0	PHENOTYPE	12	12	discomfort
NCT0000165132	NCT00001651_32_T0	GENE	6	6	blot
NCT0000165132	NCT00001651_32_T1	PHENOTYPE	1	1	HIV
NCT0000165132	NCT00001651_32_T2	GENE	0	0	FOR
NCT0000165133	NCT00001651_33_T0	PHENOTYPE	2	3	Diabetes mellitus
NCT0000165134	NCT00001651_34_T0	PHENOTYPE	1	2	substance abuse
NCT0000165134	NCT00001651_34_T1	PHENOTYPE	7	8	substance abuse
NCT0000165135	NCT00001651_35_T0	PHENOTYPE	0	1	Psychiatric illness
NCT0000165137	NCT00001651_37_T0	PHENOTYPE	8	8	acute
NCT0000165137	NCT00001651_37_T1	GENE	6	6	had
NCT0000165137	NCT00001651_37_T2	PHENOTYPE	10	10	chronic
NCT000016521	NCT00001652_1_T0	COMPOUND	47	47	calcium
NCT000016521	NCT00001652_1_T1	ORGAN	43	43	thyroid
NCT000016521	NCT00001652_1_T2	PHENOTYPE	19	19	LCM
NCT000016522	NCT00001652_2_T0	PHENOTYPE	15	15	acute
NCT000016522	NCT00001652_2_T1	PHENOTYPE	6	6	stepping
NCT000016523	NCT00001652_3_T0	PHENOTYPE	19	19	focused
NCT000016526	NCT00001652_6_T0	COMPOUND	47	47	calcium
NCT000016526	NCT00001652_6_T1	ORGAN	43	43	thyroid
NCT000016526	NCT00001652_6_T2	PHENOTYPE	19	19	LCM
NCT000016527	NCT00001652_7_T0	PHENOTYPE	15	15	acute
NCT000016527	NCT00001652_7_T1	PHENOTYPE	6	6	stepping
NCT000016528	NCT00001652_8_T0	PHENOTYPE	19	19	focused
NCT0000165212	NCT00001652_12_T0	PHENOTYPE	26	26	HIV
NCT0000165212	NCT00001652_12_T1	ORGAN	20	20	liver
NCT0000165212	NCT00001652_12_T2	ORGAN	23	23	serum
NCT0000165212	NCT00001652_12_T3	PHENOTYPE	27	28	hepatitis B
NCT0000165212	NCT00001652_12_T4	PHENOTYPE	42	44	drugs of abuse
NCT0000165214	NCT00001652_14_T0	PHENOTYPE	16	17	mood disorder
NCT0000165215	NCT00001652_15_T0	ORGAN	21	21	diaphragm
NCT000016543	NCT00001654_3_T0	PHENOTYPE	5	5	experiences
NCT000016543	NCT00001654_3_T1	PHENOTYPE	7	8	biological processes
NCT000016546	NCT00001654_6_T0	PHENOTYPE	9	9	emotions
NCT0000165412	NCT00001654_12_T0	PHENOTYPE	5	5	experiences
NCT0000165412	NCT00001654_12_T1	PHENOTYPE	7	8	biological processes
NCT0000165415	NCT00001654_15_T0	PHENOTYPE	14	14	symptoms
NCT0000165422	NCT00001654_22_T0	PHENOTYPE	5	5	impairment
NCT0000165422	NCT00001654_22_T1	PHENOTYPE	11	12	head trauma
NCT0000165422	NCT00001654_22_T2	PHENOTYPE	9	10	cerebral palsy
NCT0000165422	NCT00001654_22_T3	PHENOTYPE	7	8	seizure disorder
NCT0000165423	NCT00001654_23_T0	PHENOTYPE	1	2	intellectual impairment
NCT0000165424	NCT00001654_24_T0	PHENOTYPE	2	2	psychosis
NCT000016561	NCT00001656_1_T0	PHENOTYPE	0	1	Childhood psychosis
NCT000016563	NCT00001656_3_T0	PHENOTYPE	11	12	childhood psychosis
NCT000016564	NCT00001656_4_T0	GENE	20	20	MRI
NCT000016564	NCT00001656_4_T1	PHENOTYPE	12	12	electroencephalogram
NCT000016565	NCT00001656_5_T0	GENE	4	4	tapered
NCT000016567	NCT00001656_7_T0	COMPOUND	15	15	olanzapine
NCT000016567	NCT00001656_7_T1	COMPOUND	13	13	clozapine
NCT0000165610	NCT00001656_10_T0	COMPOUND	9	9	olanzapine
NCT0000165610	NCT00001656_10_T1	COMPOUND	7	7	clozapine
NCT0000165613	NCT00001656_13_T0	COMPOUND	10	10	olanzapine
NCT0000165613	NCT00001656_13_T1	COMPOUND	5	5	clozapine
NCT0000165613	NCT00001656_13_T2	GENE	6	6	has
NCT0000165614	NCT00001656_14_T0	PHENOTYPE	12	12	schizophrenia
NCT0000165614	NCT00001656_14_T1	PHENOTYPE	24	24	psychosis
NCT0000165614	NCT00001656_14_T2	PHENOTYPE	16	17	psychotic disorder
NCT0000165614	NCT00001656_14_T3	PHENOTYPE	13	14	schizoaffective disorder
NCT0000165616	NCT00001656_16_T0	GENE	13	13	1.4
NCT0000165618	NCT00001656_18_T0	COMPOUND	10	10	olanzapine
NCT0000165618	NCT00001656_18_T1	COMPOUND	8	8	clozapine
NCT0000165619	NCT00001656_19_T0	COMPOUND	6	6	olanzapine
NCT0000165619	NCT00001656_19_T1	COMPOUND	4	4	clozapine
NCT0000165623	NCT00001656_23_T0	PHENOTYPE	2	2	impairment
NCT0000165623	NCT00001656_23_T1	PHENOTYPE	17	17	discomfort
NCT0000165623	NCT00001656_23_T2	PHENOTYPE	8	9	psychotic symptoms
NCT0000165623	NCT00001656_23_T3	PHENOTYPE	20	21	psychotic symptoms
NCT0000165624	NCT00001656_24_T0	COMPOUND	24	24	chlorpromazine
NCT0000165624	NCT00001656_24_T1	GENE	11	11	atypical
NCT0000165625	NCT00001656_25_T0	PHENOTYPE	10	10	symptoms
NCT0000165625	NCT00001656_25_T1	COMPOUND	36	36	olanzapine
NCT0000165625	NCT00001656_25_T2	PHENOTYPE	8	8	persistence
NCT0000165625	NCT00001656_25_T3	COMPOUND	34	34	clozapine
NCT0000165626	NCT00001656_26_T0	COMPOUND	9	9	olanzapine
NCT0000165626	NCT00001656_26_T1	GENE	16	16	20
NCT0000165627	NCT00001656_27_T0	GENE	16	16	200
NCT0000165627	NCT00001656_27_T1	COMPOUND	9	9	clozapine
NCT0000165628	NCT00001656_28_T0	PHENOTYPE	1	2	psychiatric disorders
NCT0000165632	NCT00001656_32_T0	PHENOTYPE	4	4	dependence
NCT0000165632	NCT00001656_32_T1	PHENOTYPE	1	2	substance abuse
NCT0000165633	NCT00001656_33_T0	COMPOUND	4	4	olanzapine
NCT0000165633	NCT00001656_33_T1	COMPOUND	6	6	clozapine
NCT0000165635	NCT00001656_35_T0	COMPOUND	17	17	olanzapine
NCT0000165635	NCT00001656_35_T1	COMPOUND	22	22	clozapine
NCT000016572	NCT00001657_2_T0	PHENOTYPE	2	2	PTSD
NCT000016572	NCT00001657_2_T1	PHENOTYPE	18	18	PTSD
NCT000016573	NCT00001657_3_T0	PHENOTYPE	43	43	symptoms
NCT000016573	NCT00001657_3_T1	PHENOTYPE	31	31	PTSD
NCT000016573	NCT00001657_3_T2	PHENOTYPE	36	36	recalling
NCT000016573	NCT00001657_3_T3	COMPOUND	14	14	glucose
NCT000016573	NCT00001657_3_T4	GENE	5	5	MRI
NCT000016574	NCT00001657_4_T0	COMPOUND	22	22	rTMS
NCT000016575	NCT00001657_5_T0	GENE	12	12	coil
NCT000016575	NCT00001657_5_T1	ORGAN	16	16	scalp
NCT000016578	NCT00001657_8_T0	COMPOUND	7	7	rTMS
NCT0000165711	NCT00001657_11_T0	PHENOTYPE	34	34	symptoms
NCT0000165711	NCT00001657_11_T1	PHENOTYPE	22	22	PTSD
NCT0000165711	NCT00001657_11_T2	PHENOTYPE	27	27	recalling
NCT0000165711	NCT00001657_11_T3	COMPOUND	9	9	glucose
NCT0000165712	NCT00001657_12_T0	PHENOTYPE	17	17	symptoms
NCT0000165712	NCT00001657_12_T1	PHENOTYPE	4	5	brain activity
NCT0000165713	NCT00001657_13_T0	PHENOTYPE	8	8	PTSD
NCT0000165713	NCT00001657_13_T1	GENE	3	3	ANS
NCT0000165713	NCT00001657_13_T2	ORGAN	0	2	Autonomic Nervous System
NCT0000165714	NCT00001657_14_T0	ORGAN	8	8	thyroid
NCT0000165714	NCT00001657_14_T1	GENE	13	13	axis
NCT0000165714	NCT00001657_14_T2	PHENOTYPE	4	5	hormone levels
NCT0000165715	NCT00001657_15_T0	PHENOTYPE	23	23	symptoms
NCT0000165715	NCT00001657_15_T1	PHENOTYPE	22	22	PTSD
NCT0000165715	NCT00001657_15_T2	GENE	28	28	ANS
NCT0000165715	NCT00001657_15_T3	BIOLOGICAL_PROCESS	16	16	metabolism
NCT0000165716	NCT00001657_16_T0	COMPOUND	13	13	rTMS
NCT0000165718	NCT00001657_18_T0	PHENOTYPE	22	22	physiology
NCT0000165718	NCT00001657_18_T1	PHENOTYPE	20	20	symptoms
NCT0000165718	NCT00001657_18_T2	PHENOTYPE	19	19	PTSD
NCT0000165718	NCT00001657_18_T3	COMPOUND	9	9	rTMS
NCT0000165718	NCT00001657_18_T4	PHENOTYPE	35	36	hormone levels
NCT0000165720	NCT00001657_20_T0	PHENOTYPE	6	6	PTSD
NCT0000165720	NCT00001657_20_T1	PHENOTYPE	5	5	chronic
NCT0000165721	NCT00001657_21_T0	ORGAN	30	30	eyes
NCT0000165721	NCT00001657_21_T1	PHENOTYPE	34	35	seizure disorder
NCT0000165722	NCT00001657_22_T0	PHENOTYPE	5	5	symptoms
NCT0000165722	NCT00001657_22_T1	PHENOTYPE	18	19	substance use
NCT0000165722	NCT00001657_22_T2	PHENOTYPE	10	11	eating disorder
NCT0000165722	NCT00001657_22_T3	PHENOTYPE	13	14	substance abuse
NCT0000165722	NCT00001657_22_T4	PHENOTYPE	7	8	self-injurious behavior
NCT000016581	NCT00001658_1_T0	CELL	10	10	cells
NCT000016582	NCT00001658_2_T0	PHENOTYPE	5	5	symptoms
NCT000016582	NCT00001658_2_T1	PHENOTYPE	11	11	feels
NCT000016582	NCT00001658_2_T2	PHENOTYPE	7	7	sickness
NCT000016585	NCT00001658_5_T0	ORGAN	2	3	immune system
NCT000016586	NCT00001658_6_T0	TISSUE	8	8	tissues
NCT000016587	NCT00001658_7_T0	PHENOTYPE	4	5	autoimmune reaction
NCT000016588	NCT00001658_8_T0	PHENOTYPE	5	6	autoimmune reactions
NCT000016589	NCT00001658_9_T0	PHENOTYPE	5	5	infections
NCT000016589	NCT00001658_9_T1	PHENOTYPE	9	10	strep throat
NCT0000165813	NCT00001658_13_T0	PHENOTYPE	22	23	Streptococcal infections
NCT0000165813	NCT00001658_13_T1	PHENOTYPE	16	20	Pediatric Autoimmune Neuropsychiatric Disorders Associated
NCT0000165815	NCT00001658_15_T0	PHENOTYPE	13	13	symptoms
NCT0000165819	NCT00001658_19_T0	PHENOTYPE	15	15	symptoms
NCT0000165819	NCT00001658_19_T1	PHENOTYPE	17	17	tics
NCT0000165820	NCT00001658_20_T0	COMPOUND	18	18	amoxicillin
NCT0000165821	NCT00001658_21_T0	COMPOUND	11	11	amoxicillin
NCT0000165821	NCT00001658_21_T1	GENE	12	12	has
NCT0000165821	NCT00001658_21_T2	ORGAN	28	29	immune system
NCT0000165821	NCT00001658_21_T3	ORGAN	15	17	central nervous system
NCT0000165822	NCT00001658_22_T0	COMPOUND	9	9	amoxicillin
NCT0000165823	NCT00001658_23_T0	COMPOUND	13	13	amoxicillin
NCT0000165827	NCT00001658_27_T0	PHENOTYPE	14	14	symptoms
NCT0000165827	NCT00001658_27_T1	PHENOTYPE	4	4	severity
NCT0000165828	NCT00001658_28_T0	PHENOTYPE	10	10	severity
NCT0000165828	NCT00001658_28_T1	PHENOTYPE	16	16	fluctuation
NCT0000165828	NCT00001658_28_T2	GENE	14	14	20
NCT0000165829	NCT00001658_29_T0	PHENOTYPE	28	29	antibody titers
NCT0000165829	NCT00001658_29_T1	PHENOTYPE	16	17	Streptococcal infections
NCT0000165830	NCT00001658_30_T0	PHENOTYPE	25	25	tics
NCT0000165830	NCT00001658_30_T1	PHENOTYPE	17	17	hyperactivity
NCT0000165830	NCT00001658_30_T2	PHENOTYPE	22	23	choreiform movements
NCT0000165831	NCT00001658_31_T0	COMPOUND	14	14	amoxicillin
NCT0000165831	NCT00001658_31_T1	PHENOTYPE	10	10	OCD
NCT0000165831	NCT00001658_31_T2	PHENOTYPE	8	8	tics
NCT0000165832	NCT00001658_32_T0	PHENOTYPE	6	6	Autism
NCT0000165833	NCT00001658_33_T0	PHENOTYPE	4	5	neurologic disorders
NCT0000165835	NCT00001658_35_T0	PHENOTYPE	8	8	chronic
NCT0000165836	NCT00001658_36_T0	COMPOUND	7	7	penicillin
NCT0000165836	NCT00001658_36_T1	PHENOTYPE	9	10	amoxicillin allergy
NCT000016591	NCT00001659_1_T0	GENE	1	1	has
NCT000016593	NCT00001659_3_T0	PHENOTYPE	4	4	symptoms
NCT000016593	NCT00001659_3_T1	PHENOTYPE	9	9	bereavement
NCT000016593	NCT00001659_3_T2	GENE	5	5	has
NCT000016593	NCT00001659_3_T3	PHENOTYPE	14	15	sleep disturbances
NCT000016595	NCT00001659_5_T0	PHENOTYPE	0	0	Bereavement
NCT000016595	NCT00001659_5_T1	GENE	1	1	has
NCT000016595	NCT00001659_5_T2	PHENOTYPE	6	6	dysfunction
NCT000016595	NCT00001659_5_T3	ORGAN	9	10	immune system
NCT000016597	NCT00001659_7_T0	PHENOTYPE	5	5	bereavement
NCT000016597	NCT00001659_7_T1	PHENOTYPE	7	7	immunity
NCT000016598	NCT00001659_8_T0	PHENOTYPE	12	12	bereavement
NCT000016598	NCT00001659_8_T1	PHENOTYPE	13	13	immunity
NCT000016599	NCT00001659_9_T0	PHENOTYPE	11	11	bereavement
NCT000016599	NCT00001659_9_T1	ORGAN	15	16	immune system
NCT0000165914	NCT00001659_14_T0	PHENOTYPE	6	6	bereavement
NCT0000165914	NCT00001659_14_T1	PHENOTYPE	21	21	bereavement
NCT0000165914	NCT00001659_14_T2	GENE	28	28	al
NCT0000165914	NCT00001659_14_T3	GENE	27	27	et
NCT0000165915	NCT00001659_15_T0	GENE	1	1	has
NCT0000165916	NCT00001659_16_T0	PHENOTYPE	8	8	loved
NCT0000165916	NCT00001659_16_T1	PHENOTYPE	13	13	sadness
NCT0000165918	NCT00001659_18_T0	PHENOTYPE	3	3	symptoms
NCT0000165918	NCT00001659_18_T1	PHENOTYPE	17	17	bereavement
NCT0000165918	NCT00001659_18_T2	PHENOTYPE	21	21	understood
NCT000016612	NCT00001661_2_T0	CELL	9	9	cells
NCT000016612	NCT00001661_2_T1	CELL	18	18	cells
NCT000016612	NCT00001661_2_T2	PHENOTYPE	7	7	neighboring
NCT0000166110	NCT00001661_10_T0	GENE	10	10	TMS
NCT0000166112	NCT00001661_12_T0	PHENOTYPE	16	16	secondary
NCT0000166112	NCT00001661_12_T1	GENE	12	12	MEP
NCT0000166112	NCT00001661_12_T2	GENE	38	38	MEP
NCT0000166112	NCT00001661_12_T3	PHENOTYPE	27	27	inhibition
NCT0000166112	NCT00001661_12_T4	GENE	14	14	TMS
NCT0000166112	NCT00001661_12_T5	PHENOTYPE	19	19	disinhibition
NCT0000166113	NCT00001661_13_T0	PHENOTYPE	6	6	disinhibition
NCT0000166117	NCT00001661_17_T0	PHENOTYPE	15	15	allergies
NCT0000166117	NCT00001661_17_T1	PHENOTYPE	6	6	seizures
NCT0000166117	NCT00001661_17_T2	PHENOTYPE	10	10	hypertension
NCT0000166117	NCT00001661_17_T3	PHENOTYPE	11	11	psychosis
NCT0000166117	NCT00001661_17_T4	ORGAN	12	12	heart
NCT0000166117	NCT00001661_17_T5	PHENOTYPE	7	9	loss of consciousness
NCT000016620	NCT00001662_0_T0	PHENOTYPE	2	3	Alzheimer's Disease
NCT000016622	NCT00001662_2_T0	GENE	8	8	AMPA
NCT000016622	NCT00001662_2_T1	CELL	6	6	cells
NCT000016623	NCT00001662_3_T0	CELL	2	2	cells
NCT000016623	NCT00001662_3_T1	PHENOTYPE	18	18	reasoning
NCT000016623	NCT00001662_3_T2	PHENOTYPE	10	11	Alzheimer's disease
NCT000016624	NCT00001662_4_T0	PHENOTYPE	17	17	symptoms
NCT000016624	NCT00001662_4_T1	GENE	13	13	AMPA
NCT000016624	NCT00001662_4_T2	PHENOTYPE	19	20	Alzheimer's disease
NCT000016625	NCT00001662_5_T0	GENE	9	9	AMPA
NCT000016625	NCT00001662_5_T1	PHENOTYPE	7	7	affects
NCT000016626	NCT00001662_6_T0	PHENOTYPE	13	14	Alzheimer's disease
NCT0000166211	NCT00001662_11_T0	PHENOTYPE	15	15	disorders
NCT0000166211	NCT00001662_11_T1	PHENOTYPE	14	14	dementing
NCT0000166211	NCT00001662_11_T2	PHENOTYPE	18	19	cognitive function
NCT0000166211	NCT00001662_11_T3	PHENOTYPE	11	12	Alzheimer's disease
NCT0000166216	NCT00001662_16_T0	PHENOTYPE	1	1	severity
NCT0000166216	NCT00001662_16_T1	PHENOTYPE	0	0	Dementia
NCT0000166217	NCT00001662_17_T0	PHENOTYPE	3	3	Ischemia
NCT0000166217	NCT00001662_17_T1	GENE	12	12	MRI
NCT0000166218	NCT00001662_18_T0	PHENOTYPE	0	0	Dementia
NCT0000166219	NCT00001662_19_T0	PHENOTYPE	1	1	electroencephalogram
NCT0000166221	NCT00001662_21_T0	PHENOTYPE	2	2	Ischemia
NCT0000166224	NCT00001662_24_T0	PHENOTYPE	1	1	electroencephalogram
NCT0000166227	NCT00001662_27_T0	PHENOTYPE	4	4	menopausal
NCT0000166227	NCT00001662_27_T1	PHENOTYPE	3	3	sterile
NCT0000166229	NCT00001662_29_T0	PHENOTYPE	10	10	suffering
NCT0000166229	NCT00001662_29_T1	PHENOTYPE	12	12	dementia
NCT0000166237	NCT00001662_37_T0	COMPOUND	8	8	rivastigmine
NCT0000166237	NCT00001662_37_T1	COMPOUND	6	6	tacrine
NCT0000166237	NCT00001662_37_T2	COMPOUND	7	7	donepezil
NCT0000166237	NCT00001662_37_T3	COMPOUND	9	9	galantamine
NCT000016630	NCT00001663_0_T0	PHENOTYPE	2	3	Cortical Myoclonus
NCT000016634	NCT00001663_4_T0	PHENOTYPE	7	7	myoclonus
NCT000016634	NCT00001663_4_T1	PHENOTYPE	17	18	involuntary movements
NCT000016637	NCT00001663_7_T0	GENE	9	9	coil
NCT000016637	NCT00001663_7_T1	ORGAN	16	16	scalp
NCT000016637	NCT00001663_7_T2	COMPOUND	4	4	rTMS
NCT000016638	NCT00001663_8_T0	GENE	13	13	coil
NCT0000166311	NCT00001663_11_T0	COMPOUND	4	4	rTMS
NCT0000166313	NCT00001663_13_T0	COMPOUND	13	13	rTMS
NCT0000166313	NCT00001663_13_T1	COMPOUND	25	25	rTMS
NCT0000166315	NCT00001663_15_T0	COMPOUND	6	6	rTMS
NCT0000166315	NCT00001663_15_T1	PHENOTYPE	10	11	cortical myoclonus
NCT0000166317	NCT00001663_17_T0	GENE	14	14	lines
NCT0000166317	NCT00001663_17_T1	PHENOTYPE	19	21	increased intracranial pressure
NCT000016641	NCT00001664_1_T0	PHENOTYPE	14	15	sleep disorders
NCT000016643	NCT00001664_3_T0	PHENOTYPE	10	10	diseases
NCT000016643	NCT00001664_3_T1	PHENOTYPE	12	13	sleep disorders
NCT000016649	NCT00001664_9_T0	PHENOTYPE	8	8	acute
NCT000016649	NCT00001664_9_T1	PHENOTYPE	10	10	progressive
NCT000016649	NCT00001664_9_T2	PHENOTYPE	11	12	neurological disorders
NCT000016651	NCT00001665_1_T0	PHENOTYPE	10	10	bradykinesia
NCT000016651	NCT00001665_1_T1	PHENOTYPE	2	3	Parkinson's disease
NCT000016651	NCT00001665_1_T2	PHENOTYPE	8	9	slow movements
NCT000016656	NCT00001665_6_T0	GENE	15	15	coil
NCT000016656	NCT00001665_6_T1	ORGAN	19	19	scalp
NCT000016656	NCT00001665_6_T2	COMPOUND	4	4	rTMS
NCT000016659	NCT00001665_9_T0	COMPOUND	12	12	rTMS
NCT000016659	NCT00001665_9_T1	BIOLOGICAL_PROCESS	15	16	motor behavior
NCT000016659	NCT00001665_9_T2	PHENOTYPE	20	21	Parkinson's disease
NCT0000166512	NCT00001665_12_T0	PHENOTYPE	12	12	bradykinesia
NCT0000166519	NCT00001665_19_T0	GENE	2	2	has
NCT0000166519	NCT00001665_19_T1	COMPOUND	1	1	rTMS
NCT0000166519	NCT00001665_19_T2	PHENOTYPE	10	11	psychiatric disorders
NCT0000166524	NCT00001665_24_T0	PHENOTYPE	1	1	epilepsy
NCT0000166525	NCT00001665_25_T0	PHENOTYPE	1	1	seizures
NCT000016663	NCT00001666_3_T0	PHENOTYPE	16	17	partial epilepsy
NCT000016665	NCT00001666_5_T0	PHENOTYPE	13	13	epilepsy
NCT000016665	NCT00001666_5_T1	GENE	9	9	TMS
NCT000016666	NCT00001666_6_T0	PHENOTYPE	8	8	excitability
NCT000016666	NCT00001666_6_T1	PHENOTYPE	17	17	seizures
NCT000016666	NCT00001666_6_T2	GENE	4	4	TMS
NCT0000166610	NCT00001666_10_T0	PHENOTYPE	4	6	Complex Partial Epilepsy
NCT0000166614	NCT00001666_14_T0	PHENOTYPE	5	5	seizure
NCT0000166614	NCT00001666_14_T1	PHENOTYPE	4	4	localized
NCT0000166615	NCT00001666_15_T0	PHENOTYPE	0	0	Epilepsy
NCT0000166617	NCT00001666_17_T0	PHENOTYPE	2	3	coronary disease
NCT0000166618	NCT00001666_18_T0	ORGAN	5	5	cranium
NCT0000166619	NCT00001666_19_T0	GENE	2	2	lines
NCT0000166620	NCT00001666_20_T0	PHENOTYPE	10	10	papilledema
NCT0000166620	NCT00001666_20_T1	PHENOTYPE	1	3	increased intracranial pressure
NCT0000166814	NCT00001668_14_T0	GENE	8	8	ANA
NCT0000166814	NCT00001668_14_T1	PHENOTYPE	16	16	Syphilis
NCT0000166814	NCT00001668_14_T2	PHENOTYPE	22	22	Granulomatosis
NCT0000166814	NCT00001668_14_T3	ORGAN	7	7	serum
NCT0000166814	NCT00001668_14_T4	PHENOTYPE	1	2	laboratory abnormalities
NCT0000166814	NCT00001668_14_T5	PHENOTYPE	17	19	Systemic Lupus Erythematosus
NCT0000166815	NCT00001668_15_T0	COMPOUND	10	10	cisplatin
NCT0000166816	NCT00001668_16_T0	PHENOTYPE	14	14	ototoxicity
NCT0000166818	NCT00001668_18_T0	PHENOTYPE	12	12	ELST
NCT0000166818	NCT00001668_18_T1	PHENOTYPE	3	3	unilateral
NCT0000166818	NCT00001668_18_T2	GENE	17	17	ENG
NCT000016690	NCT00001669_0_T0	GENE	10	10	II
NCT000016690	NCT00001669_0_T1	GENE	29	29	MS
NCT000016690	NCT00001669_0_T2	PHENOTYPE	27	28	Multiple Sclerosis
NCT000016692	NCT00001669_2_T0	CELL	7	7	myelin
NCT000016692	NCT00001669_2_T1	GENE	6	6	MS
NCT000016692	NCT00001669_2_T2	CELL	22	23	myelin sheaths
NCT000016693	NCT00001669_3_T0	PHENOTYPE	18	18	severity
NCT000016694	NCT00001669_4_T0	GENE	17	17	MRI
NCT000016694	NCT00001669_4_T1	GENE	22	22	MS
NCT000016696	NCT00001669_6_T0	CELL	7	7	myelin
NCT000016696	NCT00001669_6_T1	GENE	6	6	MS
NCT000016696	NCT00001669_6_T2	CELL	22	23	myelin sheaths
NCT000016697	NCT00001669_7_T0	PHENOTYPE	18	18	severity
NCT000016698	NCT00001669_8_T0	GENE	17	17	MRI
NCT000016698	NCT00001669_8_T1	GENE	22	22	MS
NCT0000166914	NCT00001669_14_T0	PHENOTYPE	4	4	tumors
NCT0000166914	NCT00001669_14_T1	PHENOTYPE	6	7	reactive hypoglycemia
NCT0000166917	NCT00001669_17_T0	PHENOTYPE	7	8	breast cancer
NCT0000166919	NCT00001669_19_T0	CELL	11	11	myelin
NCT0000166919	NCT00001669_19_T1	GENE	3	3	interferon-alpha
NCT0000166919	NCT00001669_19_T2	COMPOUND	7	7	cyclophosphamide
NCT0000166919	NCT00001669_19_T3	GENE	4	4	interferon-beta
NCT000016711	NCT00001671_1_T0	ORGAN	0	1	White matter
NCT000016712	NCT00001671_2_T0	CELL	3	3	myelin
NCT000016712	NCT00001671_2_T1	CELL	1	1	cells
NCT000016712	NCT00001671_2_T2	ORGAN	12	13	white matter
NCT000016712	NCT00001671_2_T3	CELL	8	9	nerve cells
NCT000016713	NCT00001671_3_T0	CELL	1	1	myelin
NCT000016715	NCT00001671_5_T0	PHENOTYPE	22	22	disorders
NCT000016715	NCT00001671_5_T1	PHENOTYPE	12	12	leukodystrophies
NCT000016716	NCT00001671_6_T0	PHENOTYPE	10	10	leukodystrophies
NCT000016718	NCT00001671_8_T0	CELL	20	20	myelin
NCT000016718	NCT00001671_8_T1	PHENOTYPE	9	9	disorders
NCT000016718	NCT00001671_8_T2	PHENOTYPE	30	30	disorders
NCT0000167110	NCT00001671_10_T0	PHENOTYPE	25	25	disorders
NCT0000167112	NCT00001671_12_T0	PHENOTYPE	12	12	centers
NCT0000167112	NCT00001671_12_T1	PHENOTYPE	9	9	leukodystrophies
NCT0000167113	NCT00001671_13_T0	PHENOTYPE	18	18	peripheral
NCT0000167113	NCT00001671_13_T1	PHENOTYPE	3	3	Center
NCT0000167116	NCT00001671_16_T0	CELL	11	11	myelin
NCT0000167116	NCT00001671_16_T1	GENE	10	10	structural
NCT0000167119	NCT00001671_19_T0	CELL	5	5	myelin
NCT0000167122	NCT00001671_22_T0	PHENOTYPE	18	18	leukodystrophy
NCT0000167123	NCT00001671_23_T0	PHENOTYPE	8	8	adrenoleukodystrophy
NCT0000167123	NCT00001671_23_T1	PHENOTYPE	9	9	adrenomyeloneuropathy
NCT0000167123	NCT00001671_23_T2	PHENOTYPE	10	11	metachromatic leukodystrophy
NCT0000167123	NCT00001671_23_T3	PHENOTYPE	14	15	Canavan disease
NCT0000167123	NCT00001671_23_T4	PHENOTYPE	12	13	Krabbe disease
NCT0000167123	NCT00001671_23_T5	PHENOTYPE	26	27	mitochondrial cytopathy
NCT0000167125	NCT00001671_25_T0	PHENOTYPE	6	6	leukodystrophies
NCT000016721	NCT00001672_1_T0	PHENOTYPE	14	14	naming
NCT000016721	NCT00001672_1_T1	COMPOUND	7	7	rTMS
NCT000016721	NCT00001672_1_T2	ORGAN	21	22	temporal lobe
NCT000016721	NCT00001672_1_T3	PHENOTYPE	26	28	temporal lobe epilepsy
NCT000016722	NCT00001672_2_T0	PHENOTYPE	18	18	unilateral
NCT000016722	NCT00001672_2_T1	ORGAN	19	20	temporal lobe
NCT000016722	NCT00001672_2_T2	ORGAN	14	15	temporal lobes
NCT000016725	NCT00001672_5_T0	PHENOTYPE	14	14	naming
NCT000016725	NCT00001672_5_T1	COMPOUND	7	7	rTMS
NCT000016725	NCT00001672_5_T2	ORGAN	21	22	temporal lobe
NCT000016725	NCT00001672_5_T3	PHENOTYPE	26	28	temporal lobe epilepsy
NCT000016726	NCT00001672_6_T0	PHENOTYPE	18	18	unilateral
NCT000016726	NCT00001672_6_T1	ORGAN	19	20	temporal lobe
NCT000016726	NCT00001672_6_T2	ORGAN	14	15	temporal lobes
NCT000016729	NCT00001672_9_T0	PHENOTYPE	6	6	progressive
NCT000016729	NCT00001672_9_T1	PHENOTYPE	7	8	neurological disorder
NCT0000167210	NCT00001672_10_T0	PHENOTYPE	8	8	cavity
NCT0000167210	NCT00001672_10_T1	GENE	17	17	lines
NCT0000167210	NCT00001672_10_T2	PHENOTYPE	24	26	increased intracranial pressure
NCT000016731	NCT00001673_1_T0	PHENOTYPE	34	34	alcoholism
NCT000016731	NCT00001673_1_T1	ORGAN	14	14	liver
NCT000016731	NCT00001673_1_T2	PHENOTYPE	28	29	substance use
NCT000016733	NCT00001673_3_T0	PHENOTYPE	13	13	HIV
NCT000016733	NCT00001673_3_T1	GENE	21	21	MRI
NCT000016734	NCT00001673_4_T0	PHENOTYPE	23	23	alcoholism
NCT000016734	NCT00001673_4_T1	PHENOTYPE	33	33	alcoholism
NCT000016735	NCT00001673_5_T0	PHENOTYPE	20	20	suffering
NCT000016735	NCT00001673_5_T1	GENE	4	4	has
NCT000016735	NCT00001673_5_T2	PHENOTYPE	22	24	acute alcohol withdrawal
NCT0000167310	NCT00001673_10_T0	PHENOTYPE	19	19	alcoholism
NCT0000167316	NCT00001673_16_T0	PHENOTYPE	4	8	alcohol or other drug use
NCT000016753	NCT00001675_3_T0	PHENOTYPE	11	11	emotions
NCT000016753	NCT00001675_3_T1	PHENOTYPE	22	22	pleasant
NCT000016754	NCT00001675_4_T0	PHENOTYPE	13	13	sweating
NCT000016754	NCT00001675_4_T1	ORGAN	11	11	heart
NCT000016755	NCT00001675_5_T0	GENE	7	7	MRI
NCT000016756	NCT00001675_6_T0	PHENOTYPE	14	14	reward
NCT000016756	NCT00001675_6_T1	GENE	21	21	MRI
NCT000016756	NCT00001675_6_T2	PHENOTYPE	24	25	brain activity
NCT000016758	NCT00001675_8_T0	PHENOTYPE	20	22	alcohol use disorder
NCT000016761	NCT00001676_1_T0	CELL	18	18	lymphocytes
NCT000016761	NCT00001676_1_T1	CELL	16	16	cells
NCT000016761	NCT00001676_1_T2	ORGAN	21	21	kidneys
NCT000016761	NCT00001676_1_T3	PHENOTYPE	6	8	systemic lupus erythematosus
NCT000016763	NCT00001676_3_T0	PHENOTYPE	17	17	infertility
NCT000016766	NCT00001676_6_T0	PHENOTYPE	12	12	proliferative
NCT000016766	NCT00001676_6_T1	PHENOTYPE	9	10	lupus nephritis
NCT000016766	NCT00001676_6_T2	PHENOTYPE	13	14	lupus nephritis
NCT000016768	NCT00001676_8_T0	COMPOUND	23	23	fludarabine
NCT000016768	NCT00001676_8_T1	COMPOUND	18	18	cyclophosphamide
NCT000016769	NCT00001676_9_T0	COMPOUND	11	11	fludarabine
NCT0000167613	NCT00001676_13_T0	GENE	11	11	0.5
NCT0000167613	NCT00001676_13_T1	GENE	13	13	1.5
NCT0000167616	NCT00001676_16_T0	CELL	15	15	lymphocytes
NCT0000167619	NCT00001676_19_T0	ORGAN	0	1	Bone marrow
NCT0000167622	NCT00001676_22_T0	TISSUE	2	2	tonsils
NCT0000167625	NCT00001676_25_T0	GENE	3	3	MRI
NCT0000167625	NCT00001676_25_T1	GENE	17	17	MRI
NCT0000167628	NCT00001676_28_T0	PHENOTYPE	5	5	autoimmune
NCT0000167628	NCT00001676_28_T1	COMPOUND	21	21	fludarabine
NCT0000167628	NCT00001676_28_T2	CELL	16	16	lymphocyte
NCT0000167628	NCT00001676_28_T3	PHENOTYPE	6	7	rheumatic diseases
NCT0000167630	NCT00001676_30_T0	PHENOTYPE	19	19	toxicity
NCT0000167630	NCT00001676_30_T1	COMPOUND	6	6	cyclophosphamide
NCT0000167630	NCT00001676_30_T2	COMPOUND	24	24	cyclophosphamide
NCT0000167630	NCT00001676_30_T3	GENE	25	25	has
NCT0000167631	NCT00001676_31_T0	PHENOTYPE	8	8	proliferative
NCT0000167631	NCT00001676_31_T1	COMPOUND	29	29	fludarabine
NCT0000167631	NCT00001676_31_T2	COMPOUND	21	21	cyclophosphamide
NCT0000167631	NCT00001676_31_T3	PHENOTYPE	9	10	lupus nephritis
NCT0000167633	NCT00001676_33_T0	PHENOTYPE	6	6	toxicity
NCT0000167633	NCT00001676_33_T1	PHENOTYPE	4	4	tolerance
NCT0000167634	NCT00001676_34_T0	BIOLOGICAL_PROCESS	0	0	Regeneration
NCT0000167634	NCT00001676_34_T1	CELL	4	5	B cells
NCT0000167635	NCT00001676_35_T0	PHENOTYPE	9	9	remission
NCT0000167636	NCT00001676_36_T0	COMPOUND	19	19	fludarabine
NCT0000167639	NCT00001676_39_T0	GENE	32	32	OR
NCT0000167639	NCT00001676_39_T1	GENE	43	43	OR
NCT0000167639	NCT00001676_39_T2	PHENOTYPE	38	38	proteinuria
NCT0000167639	NCT00001676_39_T3	GENE	47	47	3.5
NCT0000167639	NCT00001676_39_T4	GENE	27	27	RBC
NCT0000167639	NCT00001676_39_T5	GENE	28	28	WBC
NCT0000167639	NCT00001676_39_T6	PHENOTYPE	1	1	glomerulonephritis
NCT0000167639	NCT00001676_39_T7	PHENOTYPE	44	44	Proteinuria
NCT0000167639	NCT00001676_39_T8	PHENOTYPE	12	13	class IV
NCT0000167639	NCT00001676_39_T9	PHENOTYPE	9	10	class III
NCT0000167639	NCT00001676_39_T10	PHENOTYPE	15	16	lupus nephritis
NCT0000167641	NCT00001676_41_T0	COMPOUND	13	13	cyclosporine
NCT0000167641	NCT00001676_41_T1	COMPOUND	12	12	azathioprine
NCT0000167641	NCT00001676_41_T2	COMPOUND	14	14	methotrexate
NCT0000167641	NCT00001676_41_T3	GENE	3	3	had
NCT0000167641	NCT00001676_41_T4	GENE	1	1	has
NCT0000167642	NCT00001676_42_T0	GENE	52	52	OR
NCT0000167642	NCT00001676_42_T1	COMPOUND	31	31	cyclophosphamide
NCT0000167643	NCT00001676_43_T0	PHENOTYPE	5	5	pulse
NCT0000167643	NCT00001676_43_T1	GENE	4	4	had
NCT0000167644	NCT00001676_44_T0	GENE	12	12	0.5
NCT0000167645	NCT00001676_45_T0	PHENOTYPE	4	5	chronic infection
NCT0000167648	NCT00001676_48_T0	PHENOTYPE	5	5	seizures
NCT0000167648	NCT00001676_48_T1	PHENOTYPE	12	12	chronic
NCT0000167648	NCT00001676_48_T2	PHENOTYPE	3	4	cerebrovascular accident
NCT000016773	NCT00001677_3_T0	COMPOUND	1	1	fludarabine
NCT000016774	NCT00001677_4_T0	GENE	20	20	MRI
NCT000016779	NCT00001677_9_T0	COMPOUND	1	1	fludarabine
NCT0000167710	NCT00001677_10_T0	GENE	20	20	MRI
NCT0000167714	NCT00001677_14_T0	GENE	5	5	RA
NCT0000167714	NCT00001677_14_T1	PHENOTYPE	3	4	Rheumatoid Arthritis
NCT0000167716	NCT00001677_16_T0	GENE	77	77	1.3
NCT0000167716	NCT00001677_16_T1	GENE	31	31	17.5
NCT0000167716	NCT00001677_16_T2	GENE	39	39	17.5
NCT0000167716	NCT00001677_16_T3	GENE	56	56	17.5
NCT0000167716	NCT00001677_16_T4	GENE	73	73	17.5
NCT0000167716	NCT00001677_16_T5	GENE	85	85	17.5
NCT0000167716	NCT00001677_16_T6	GENE	24	24	MTX
NCT0000167716	NCT00001677_16_T7	GENE	33	33	MTX
NCT0000167716	NCT00001677_16_T8	GENE	50	50	MTX
NCT0000167716	NCT00001677_16_T9	GENE	67	67	MTX
NCT0000167716	NCT00001677_16_T10	GENE	79	79	MTX
NCT0000167716	NCT00001677_16_T11	COMPOUND	113	113	prednisone
NCT0000167717	NCT00001677_17_T0	PHENOTYPE	2	2	acute
NCT0000167717	NCT00001677_17_T1	PHENOTYPE	18	18	HIV
NCT0000167717	NCT00001677_17_T2	PHENOTYPE	11	11	infections
NCT0000167717	NCT00001677_17_T3	PHENOTYPE	14	14	hepatitis
NCT0000167717	NCT00001677_17_T4	PHENOTYPE	15	16	herpes zoster
NCT0000167717	NCT00001677_17_T5	PHENOTYPE	4	5	chronic infections
NCT0000167717	NCT00001677_17_T6	PHENOTYPE	21	22	fungal infections
NCT0000167721	NCT00001677_21_T0	PHENOTYPE	7	7	chronic
NCT0000167721	NCT00001677_21_T1	PHENOTYPE	4	5	seizure disorder
NCT0000167722	NCT00001677_22_T0	PHENOTYPE	15	15	dysrhythmia
NCT0000167722	NCT00001677_22_T1	PHENOTYPE	5	5	cardiomyopathy
NCT0000167722	NCT00001677_22_T2	PHENOTYPE	7	8	heart block
NCT0000167722	NCT00001677_22_T3	PHENOTYPE	2	4	coronary artery disease
NCT0000167723	NCT00001677_23_T0	PHENOTYPE	23	24	pulmonary disease
NCT0000167723	NCT00001677_23_T1	PHENOTYPE	19	20	chronic hepatic
NCT0000167723	NCT00001677_23_T2	PHENOTYPE	27	28	marrow hypoplasia
NCT0000167725	NCT00001677_25_T0	COMPOUND	2	2	creatinine
NCT0000167725	NCT00001677_25_T1	GENE	5	5	2.0
NCT0000167725	NCT00001677_25_T2	ORGAN	1	1	serum
NCT0000167726	NCT00001677_26_T0	GENE	1	1	hematocrit
NCT0000167726	NCT00001677_26_T1	GENE	9	9	9.0
NCT0000167726	NCT00001677_26_T2	GENE	6	6	hemoglobin
NCT0000167726	NCT00001677_26_T3	PHENOTYPE	12	13	platelet count
NCT0000167728	NCT00001677_28_T0	GENE	4	4	IgG
NCT0000167728	NCT00001677_28_T1	PHENOTYPE	3	3	hypogammaglobulinemia
NCT000016782	NCT00001678_2_T0	GENE	0	0	RA
NCT000016783	NCT00001678_3_T0	GENE	11	11	RA
NCT000016784	NCT00001678_4_T0	PHENOTYPE	2	3	rheumatoid arthritis
NCT000016786	NCT00001678_6_T0	CELL	1	1	cells
NCT000016787	NCT00001678_7_T0	CELL	18	20	white blood cells
NCT000016788	NCT00001678_8_T0	PHENOTYPE	11	11	severity
NCT000016788	NCT00001678_8_T1	GENE	13	13	RA
NCT0000167810	NCT00001678_10_T0	GENE	38	38	NARAC
NCT0000167810	NCT00001678_10_T1	PHENOTYPE	29	29	centers
NCT0000167810	NCT00001678_10_T2	GENE	24	24	has
NCT0000167810	NCT00001678_10_T3	PHENOTYPE	15	15	Diseases
NCT0000167810	NCT00001678_10_T4	PHENOTYPE	35	36	Rheumatoid Arthritis
NCT0000167811	NCT00001678_11_T0	PHENOTYPE	30	30	Center
NCT0000167811	NCT00001678_11_T1	PHENOTYPE	17	18	rheumatoid arthritis
NCT0000167814	NCT00001678_14_T0	PHENOTYPE	7	7	peripheral
NCT0000167817	NCT00001678_17_T0	PHENOTYPE	23	24	rheumatoid arthritis
NCT0000167819	NCT00001678_19_T0	PHENOTYPE	2	2	erosions
NCT0000167826	NCT00001678_26_T0	PHENOTYPE	44	44	transmitted
NCT0000167826	NCT00001678_26_T1	GENE	9	9	extended
NCT0000167827	NCT00001678_27_T0	PHENOTYPE	5	5	Psoriasis
NCT0000167827	NCT00001678_27_T1	GENE	2	2	FOR
NCT0000167827	NCT00001678_27_T2	PHENOTYPE	9	11	systemic lupus erythematosus
NCT0000167827	NCT00001678_27_T3	PHENOTYPE	6	8	inflammatory bowel disease
NCT000016791	NCT00001679_1_T0	PHENOTYPE	34	34	arthropathy
NCT000016792	NCT00001679_2_T0	PHENOTYPE	24	24	arthritis
NCT000016795	NCT00001679_5_T0	PHENOTYPE	10	10	synovitis
NCT000016796	NCT00001679_6_T0	ORGAN	14	14	synovium
NCT000016796	NCT00001679_6_T1	PHENOTYPE	8	8	persistence
NCT000016797	NCT00001679_7_T0	PHENOTYPE	19	19	strategies
NCT000016797	NCT00001679_7_T1	PHENOTYPE	23	24	disease course
NCT000016798	NCT00001679_8_T0	PHENOTYPE	14	14	synovitis
NCT0000167910	NCT00001679_10_T0	PHENOTYPE	34	34	arthropathy
NCT0000167911	NCT00001679_11_T0	PHENOTYPE	24	24	arthritis
NCT0000167914	NCT00001679_14_T0	PHENOTYPE	10	10	synovitis
NCT0000167915	NCT00001679_15_T0	ORGAN	14	14	synovium
NCT0000167915	NCT00001679_15_T1	PHENOTYPE	8	8	persistence
NCT0000167916	NCT00001679_16_T0	PHENOTYPE	19	19	strategies
NCT0000167916	NCT00001679_16_T1	PHENOTYPE	23	24	disease course
NCT0000167917	NCT00001679_17_T0	PHENOTYPE	14	14	synovitis
NCT0000167922	NCT00001679_22_T0	GENE	9	9	MRI
NCT0000167923	NCT00001679_23_T0	PHENOTYPE	5	5	claustrophobia
NCT0000167924	NCT00001679_24_T0	GENE	4	4	had
NCT0000167924	NCT00001679_24_T1	PHENOTYPE	7	8	anaphylactoid reaction
NCT000016809	NCT00001680_9_T0	COMPOUND	30	30	hydroxychloroquine
NCT0000168011	NCT00001680_11_T0	PHENOTYPE	7	9	negative pregnancy test
NCT0000168012	NCT00001680_12_T0	COMPOUND	29	29	thalidomide
NCT0000168012	NCT00001680_12_T1	COMPOUND	41	41	thalidomide
NCT0000168012	NCT00001680_12_T2	PHENOTYPE	6	6	sterile
NCT0000168013	NCT00001680_13_T0	COMPOUND	29	29	thalidomide
NCT0000168016	NCT00001680_16_T0	COMPOUND	7	7	creatinine
NCT0000168016	NCT00001680_16_T1	ORGAN	23	23	liver
NCT0000168016	NCT00001680_16_T2	ORGAN	6	6	serum
NCT0000168016	NCT00001680_16_T3	PHENOTYPE	4	5	renal disease
NCT0000168016	NCT00001680_16_T4	PHENOTYPE	21	22	hepatic dysfunction
NCT0000168017	NCT00001680_17_T0	PHENOTYPE	5	7	systemic lupus erythematosus
NCT0000168019	NCT00001680_19_T0	COMPOUND	7	7	thalidomide
NCT000016811	NCT00001681_1_T0	PHENOTYPE	25	26	disease progression
NCT000016812	NCT00001681_2_T0	PHENOTYPE	14	14	concentrations
NCT000016812	NCT00001681_2_T1	ORGAN	11	11	plasma
NCT000016813	NCT00001681_3_T0	PHENOTYPE	19	19	concentrations
NCT000016813	NCT00001681_3_T1	PHENOTYPE	17	17	HIV
NCT000016813	NCT00001681_3_T2	ORGAN	16	16	plasma
NCT000016816	NCT00001681_6_T0	PHENOTYPE	1	1	influenza
NCT000016816	NCT00001681_6_T1	PHENOTYPE	13	13	concentrations
NCT0000168112	NCT00001681_12_T0	PHENOTYPE	25	26	disease progression
NCT0000168113	NCT00001681_13_T0	PHENOTYPE	14	14	concentrations
NCT0000168113	NCT00001681_13_T1	ORGAN	11	11	plasma
NCT0000168114	NCT00001681_14_T0	PHENOTYPE	19	19	concentrations
NCT0000168114	NCT00001681_14_T1	PHENOTYPE	17	17	HIV
NCT0000168114	NCT00001681_14_T2	ORGAN	16	16	plasma
NCT0000168117	NCT00001681_17_T0	PHENOTYPE	1	1	influenza
NCT0000168117	NCT00001681_17_T1	PHENOTYPE	13	13	concentrations
NCT0000168117	NCT00001681_17_T2	PHENOTYPE	26	26	concentrations
NCT0000168123	NCT00001681_23_T0	GENE	0	0	CD4
NCT0000168123	NCT00001681_23_T1	CELL	1	1	cells
NCT0000168127	NCT00001681_27_T0	COMPOUND	5	5	thalidomide
NCT0000168127	NCT00001681_27_T1	GENE	3	3	G-CSF
NCT0000168128	NCT00001681_28_T0	PHENOTYPE	3	3	influenza
NCT0000168132	NCT00001681_32_T0	GENE	3	3	9.0
NCT0000168133	NCT00001681_33_T0	GENE	10	10	ml
NCT0000168134	NCT00001681_34_T0	PHENOTYPE	6	6	acute
NCT0000168134	NCT00001681_34_T1	PHENOTYPE	7	7	illnesses
NCT0000168134	NCT00001681_34_T2	PHENOTYPE	1	3	upper respiratory infections
NCT0000168139	NCT00001681_39_T0	PHENOTYPE	6	6	acute
NCT0000168139	NCT00001681_39_T1	PHENOTYPE	7	7	illnesses
NCT0000168139	NCT00001681_39_T2	PHENOTYPE	1	3	upper respiratory infections
NCT0000168140	NCT00001681_40_T0	GENE	9	9	ml
NCT000016831	NCT00001683_1_T0	GENE	0	0	MMP-2
NCT000016831	NCT00001683_1_T1	PHENOTYPE	8	8	progression
NCT000016831	NCT00001683_1_T2	GENE	2	2	MMP-9
NCT000016832	NCT00001683_2_T0	GENE	9	9	MMP
NCT000016832	NCT00001683_2_T1	PHENOTYPE	5	5	imbalance
NCT000016832	NCT00001683_2_T2	CELL	25	25	cells
NCT000016832	NCT00001683_2_T3	PHENOTYPE	29	29	metastasize
NCT000016832	NCT00001683_2_T4	PHENOTYPE	24	24	tumor
NCT000016832	NCT00001683_2_T5	CELL	16	17	extracellular matrix
NCT000016834	NCT00001683_4_T0	GENE	10	11	matrix metalloproteinase
NCT000016834	NCT00001683_4_T1	MOLECULAR_FUNCTION	11	12	metalloproteinase inhibitor
NCT000016834	NCT00001683_4_T2	PHENOTYPE	17	18	metastatic cancer
NCT000016835	NCT00001683_5_T0	COMPOUND	5	5	tetracycline
NCT000016836	NCT00001683_6_T0	PHENOTYPE	4	5	progressive disease
NCT000016839	NCT00001683_9_T0	PHENOTYPE	7	7	malignancies
NCT000016839	NCT00001683_9_T1	PHENOTYPE	2	3	brain metastases
NCT0000168311	NCT00001683_11_T0	PHENOTYPE	9	9	toxicity
NCT0000168311	NCT00001683_11_T1	PHENOTYPE	13	13	pharmacokinetics
NCT0000168313	NCT00001683_13_T0	GENE	0	0	MMP-2
NCT0000168313	NCT00001683_13_T1	PHENOTYPE	8	8	progression
NCT0000168313	NCT00001683_13_T2	GENE	2	2	MMP-9
NCT0000168314	NCT00001683_14_T0	GENE	9	9	MMP
NCT0000168314	NCT00001683_14_T1	PHENOTYPE	5	5	imbalance
NCT0000168314	NCT00001683_14_T2	CELL	25	25	cells
NCT0000168314	NCT00001683_14_T3	PHENOTYPE	29	29	metastasize
NCT0000168314	NCT00001683_14_T4	PHENOTYPE	24	24	tumor
NCT0000168314	NCT00001683_14_T5	CELL	16	17	extracellular matrix
NCT0000168316	NCT00001683_16_T0	GENE	10	11	matrix metalloproteinase
NCT0000168316	NCT00001683_16_T1	MOLECULAR_FUNCTION	11	12	metalloproteinase inhibitor
NCT0000168316	NCT00001683_16_T2	PHENOTYPE	17	18	metastatic cancer
NCT0000168317	NCT00001683_17_T0	COMPOUND	5	5	tetracycline
NCT0000168318	NCT00001683_18_T0	PHENOTYPE	4	5	progressive disease
NCT0000168321	NCT00001683_21_T0	PHENOTYPE	7	7	malignancies
NCT0000168321	NCT00001683_21_T1	PHENOTYPE	2	3	brain metastases
NCT0000168323	NCT00001683_23_T0	PHENOTYPE	9	9	toxicity
NCT0000168323	NCT00001683_23_T1	PHENOTYPE	13	13	pharmacokinetics
NCT0000168325	NCT00001683_25_T0	PHENOTYPE	2	2	tumor
NCT0000168326	NCT00001683_26_T0	PHENOTYPE	8	9	metastatic disease
NCT0000168328	NCT00001683_28_T0	PHENOTYPE	4	5	progressive disease
NCT0000168332	NCT00001683_32_T0	PHENOTYPE	6	6	malignancies
NCT0000168335	NCT00001683_35_T0	COMPOUND	58	58	creatinine
NCT0000168335	NCT00001683_35_T1	PHENOTYPE	42	42	bleeding
NCT0000168335	NCT00001683_35_T2	CELL	9	9	Granulocyte
NCT0000168335	NCT00001683_35_T3	GENE	62	62	1.5
NCT0000168335	NCT00001683_35_T4	GENE	22	22	9.0
NCT0000168335	NCT00001683_35_T5	GENE	30	30	hemoglobin
NCT0000168335	NCT00001683_35_T6	PHENOTYPE	47	48	Platelet count
NCT0000168337	NCT00001683_37_T0	PHENOTYPE	6	6	toxicity
NCT0000168338	NCT00001683_38_T0	PHENOTYPE	20	20	initiation
NCT0000168339	NCT00001683_39_T0	COMPOUND	4	5	mitomycin C
NCT0000168340	NCT00001683_40_T0	COMPOUND	4	4	suramin
NCT0000168343	NCT00001683_43_T0	GENE	5	5	LHRH
NCT0000168343	NCT00001683_43_T1	GENE	7	7	has
NCT0000168343	NCT00001683_43_T2	PHENOTYPE	22	23	disease progression
NCT0000168345	NCT00001683_45_T0	PHENOTYPE	5	5	acute
NCT0000168345	NCT00001683_45_T1	PHENOTYPE	6	7	critical illness
NCT0000168350	NCT00001683_50_T0	PHENOTYPE	9	11	negative pregnancy test
NCT0000168355	NCT00001683_55_T0	PHENOTYPE	8	8	HIV
NCT0000168355	NCT00001683_55_T1	PHENOTYPE	5	6	positive serology
NCT0000168356	NCT00001683_56_T0	ORGAN	1	2	urinary tract
NCT0000168357	NCT00001683_57_T0	PHENOTYPE	7	7	malignancies
NCT0000168357	NCT00001683_57_T1	PHENOTYPE	2	3	brain metastases
NCT0000168361	NCT00001683_61_T0	PHENOTYPE	2	2	toxicity
NCT0000168363	NCT00001683_63_T0	PHENOTYPE	6	7	HIV positive
NCT0000168364	NCT00001683_64_T0	PHENOTYPE	9	9	HIV
NCT0000168364	NCT00001683_64_T1	GENE	7	8	neutrophil gelatinase
NCT0000168365	NCT00001683_65_T0	PHENOTYPE	0	0	HIV
NCT0000168366	NCT00001683_66_T0	COMPOUND	6	6	phenobarbital
NCT0000168366	NCT00001683_66_T1	COMPOUND	7	7	phenytoin
NCT0000168366	NCT00001683_66_T2	COMPOUND	8	8	carbamazepine
NCT000016852	NCT00001685_2_T0	PHENOTYPE	13	13	toxicity
NCT000016856	NCT00001685_6_T0	PHENOTYPE	13	13	toxicity
NCT0000168510	NCT00001685_10_T0	COMPOUND	1	1	creatinine
NCT0000168510	NCT00001685_10_T1	GENE	3	3	2.0
NCT0000168510	NCT00001685_10_T2	ORGAN	0	0	Serum
NCT0000168511	NCT00001685_11_T0	GENE	1	1	1/6
NCT0000168512	NCT00001685_12_T0	GENE	0	0	WBC
NCT0000168513	NCT00001685_13_T0	PHENOTYPE	0	1	Platelet count
NCT0000168514	NCT00001685_14_T0	ORGAN	0	0	Serum
NCT0000168521	NCT00001685_21_T0	PHENOTYPE	8	8	HIV
NCT0000168521	NCT00001685_21_T1	PHENOTYPE	5	5	hepatitis
NCT0000168522	NCT00001685_22_T0	GENE	12	12	IFA
NCT0000168522	NCT00001685_22_T1	GENE	3	3	had
NCT0000168522	NCT00001685_22_T2	PHENOTYPE	6	7	allergic reaction
NCT000016865	NCT00001686_5_T0	GENE	33	33	POB
NCT000016866	NCT00001686_6_T0	PHENOTYPE	24	24	Oncology
NCT000016866	NCT00001686_6_T1	PHENOTYPE	15	15	syndromes
NCT000016866	NCT00001686_6_T2	PHENOTYPE	18	19	rare diseases
NCT000016881	NCT00001688_1_T0	COMPOUND	13	13	nevirapine
NCT000016881	NCT00001688_1_T1	COMPOUND	28	28	nevirapine
NCT000016881	NCT00001688_1_T2	PHENOTYPE	21	21	HIV
NCT000016881	NCT00001688_1_T3	COMPOUND	15	15	stavudine
NCT000016881	NCT00001688_1_T4	COMPOUND	30	30	stavudine
NCT000016881	NCT00001688_1_T5	COMPOUND	12	12	ritonavir
NCT000016881	NCT00001688_1_T6	COMPOUND	27	27	ritonavir
NCT000016882	NCT00001688_2_T0	PHENOTYPE	14	14	severely
NCT000016883	NCT00001688_3_T0	COMPOUND	7	7	nevirapine
NCT000016883	NCT00001688_3_T1	COMPOUND	9	9	stavudine
NCT000016883	NCT00001688_3_T2	COMPOUND	6	6	ritonavir
NCT000016887	NCT00001688_7_T0	COMPOUND	13	13	nevirapine
NCT000016887	NCT00001688_7_T1	COMPOUND	28	28	nevirapine
NCT000016887	NCT00001688_7_T2	PHENOTYPE	21	21	HIV
NCT000016887	NCT00001688_7_T3	COMPOUND	15	15	stavudine
NCT000016887	NCT00001688_7_T4	COMPOUND	30	30	stavudine
NCT000016887	NCT00001688_7_T5	COMPOUND	12	12	ritonavir
NCT000016887	NCT00001688_7_T6	COMPOUND	27	27	ritonavir
NCT000016888	NCT00001688_8_T0	PHENOTYPE	14	14	severely
NCT000016889	NCT00001688_9_T0	COMPOUND	7	7	nevirapine
NCT000016889	NCT00001688_9_T1	COMPOUND	9	9	stavudine
NCT000016889	NCT00001688_9_T2	COMPOUND	6	6	ritonavir
NCT0000168813	NCT00001688_13_T0	PHENOTYPE	8	8	Centers
NCT0000168815	NCT00001688_15_T0	PHENOTYPE	3	4	critically ill
NCT0000168816	NCT00001688_16_T0	GENE	5	5	A1
NCT0000168816	NCT00001688_16_T1	PHENOTYPE	25	25	HIV
NCT0000168816	NCT00001688_16_T2	PHENOTYPE	10	11	HIV infection
NCT0000168816	NCT00001688_16_T3	PHENOTYPE	11	13	infection in children
NCT0000168820	NCT00001688_20_T0	GENE	39	39	2.0
NCT0000168820	NCT00001688_20_T1	GENE	29	29	8.0
NCT0000168820	NCT00001688_20_T2	GENE	65	65	amylase
NCT0000168820	NCT00001688_20_T3	CELL	21	21	neutrophil
NCT0000168820	NCT00001688_20_T4	ORGAN	64	64	Serum
NCT0000168820	NCT00001688_20_T5	GENE	13	13	WBC
NCT0000168820	NCT00001688_20_T6	PHENOTYPE	4	5	laboratory abnormalities
NCT0000168820	NCT00001688_20_T7	PHENOTYPE	31	32	Platelet count
NCT0000168820	NCT00001688_20_T8	GENE	51	52	Total bilirubin
NCT0000168821	NCT00001688_21_T0	ORGAN	0	0	Serum
NCT0000168821	NCT00001688_21_T1	GENE	1	1	amylase
NCT0000168821	NCT00001688_21_T2	GENE	11	11	amylase
NCT0000168821	NCT00001688_21_T3	ORGAN	10	10	serum
NCT0000168822	NCT00001688_22_T0	PHENOTYPE	4	4	pancreatitis
NCT0000168822	NCT00001688_22_T1	GENE	9	9	amylase
NCT0000168822	NCT00001688_22_T2	ORGAN	8	8	serum
NCT0000168823	NCT00001688_23_T0	GENE	7	7	II
NCT0000168823	NCT00001688_23_T1	PHENOTYPE	10	10	severity
NCT0000168823	NCT00001688_23_T2	PHENOTYPE	3	4	peripheral neuropathy
NCT0000168824	NCT00001688_24_T0	COMPOUND	7	7	nevirapine
NCT0000168824	NCT00001688_24_T1	COMPOUND	6	6	nelfinavir
NCT0000168824	NCT00001688_24_T2	COMPOUND	9	9	stavudine
NCT0000168824	NCT00001688_24_T3	COMPOUND	4	4	ritonavir
NCT0000168824	NCT00001688_24_T4	COMPOUND	5	5	indinavir
NCT0000168825	NCT00001688_25_T0	COMPOUND	8	8	nelfinavir
NCT0000168825	NCT00001688_25_T1	COMPOUND	6	6	ritonavir
NCT0000168825	NCT00001688_25_T2	COMPOUND	7	7	indinavir
NCT0000168826	NCT00001688_26_T0	GENE	2	2	swallow
NCT000016892	NCT00001689_2_T0	COMPOUND	14	14	vincristine
NCT000016892	NCT00001689_2_T1	PHENOTYPE	15	15	pharmacokinetics
NCT000016893	NCT00001689_3_T0	PHENOTYPE	4	4	neurotoxicity
NCT000016893	NCT00001689_3_T1	COMPOUND	3	3	vincristine
NCT000016893	NCT00001689_3_T2	COMPOUND	6	6	vincristine
NCT000016893	NCT00001689_3_T3	PHENOTYPE	7	7	pharmacokinetics
NCT000016896	NCT00001689_6_T0	COMPOUND	14	14	vincristine
NCT000016896	NCT00001689_6_T1	PHENOTYPE	15	15	pharmacokinetics
NCT000016897	NCT00001689_7_T0	PHENOTYPE	4	4	neurotoxicity
NCT000016897	NCT00001689_7_T1	COMPOUND	3	3	vincristine
NCT000016897	NCT00001689_7_T2	COMPOUND	6	6	vincristine
NCT000016897	NCT00001689_7_T3	PHENOTYPE	7	7	pharmacokinetics
NCT000016899	NCT00001689_9_T0	PHENOTYPE	5	7	acute lymphoblastic leukemia
NCT0000168914	NCT00001689_14_T0	PHENOTYPE	4	5	peripheral neuropathy
NCT0000168915	NCT00001689_15_T0	PHENOTYPE	5	5	dysfunction
NCT0000168915	NCT00001689_15_T1	ORGAN	2	4	central nervous system
NCT000016932	NCT00001693_2_T0	GENE	0	0	BID
NCT000016933	NCT00001693_3_T0	GENE	0	0	BID
NCT000016934	NCT00001693_4_T0	GENE	0	0	BID
NCT000016936	NCT00001693_6_T0	PHENOTYPE	4	4	polyps
NCT000016937	NCT00001693_7_T0	ORGAN	0	0	Plasma
NCT0000169310	NCT00001693_10_T0	PHENOTYPE	6	7	side effect
NCT0000169310	NCT00001693_10_T1	PHENOTYPE	19	20	adverse events
NCT0000169313	NCT00001693_13_T0	GENE	0	0	BID
NCT0000169314	NCT00001693_14_T0	GENE	0	0	BID
NCT0000169315	NCT00001693_15_T0	GENE	0	0	BID
NCT0000169317	NCT00001693_17_T0	PHENOTYPE	4	4	polyps
NCT0000169318	NCT00001693_18_T0	ORGAN	0	0	Plasma
NCT0000169321	NCT00001693_21_T0	PHENOTYPE	6	7	side effect
NCT0000169321	NCT00001693_21_T1	PHENOTYPE	19	20	adverse events
NCT0000169327	NCT00001693_27_T0	COMPOUND	8	8	aspirin
NCT0000169327	NCT00001693_27_T1	GENE	14	14	OTC
NCT0000169328	NCT00001693_28_T0	PHENOTYPE	24	24	IUD
NCT0000169328	NCT00001693_28_T1	ORGAN	28	28	diaphragm
NCT0000169328	NCT00001693_28_T2	ORGAN	57	57	serum
NCT0000169328	NCT00001693_28_T3	GENE	31	31	gel
NCT0000169332	NCT00001693_32_T0	GENE	18	18	PI
NCT0000169339	NCT00001693_39_T0	PHENOTYPE	25	26	Helicobacter pylori
NCT0000169339	NCT00001693_39_T1	PHENOTYPE	41	42	Helicobacter pylori
NCT0000169339	NCT00001693_39_T2	PHENOTYPE	10	11	duodenal ulcer
NCT0000169339	NCT00001693_39_T3	PHENOTYPE	27	29	peptic ulcer disease
NCT0000169341	NCT00001693_41_T0	PHENOTYPE	4	5	psychiatric problems
NCT0000169342	NCT00001693_42_T0	PHENOTYPE	26	26	carcinoma
NCT0000169342	NCT00001693_42_T1	PHENOTYPE	27	27	suspicion
NCT0000169342	NCT00001693_42_T2	PHENOTYPE	20	21	bleeding diathesis
NCT000016952	NCT00001695_2_T0	PHENOTYPE	16	16	toxicities
NCT000016952	NCT00001695_2_T1	PHENOTYPE	7	8	adverse effects
NCT000016955	NCT00001695_5_T0	GENE	22	22	has
NCT000016957	NCT00001695_7_T0	PHENOTYPE	8	8	perceptions
NCT000016957	NCT00001695_7_T1	PHENOTYPE	5	6	patient attitudes
NCT0000169511	NCT00001695_11_T0	PHENOTYPE	16	16	toxicities
NCT0000169511	NCT00001695_11_T1	PHENOTYPE	7	8	adverse effects
NCT0000169514	NCT00001695_14_T0	GENE	22	22	has
NCT0000169516	NCT00001695_16_T0	PHENOTYPE	8	8	perceptions
NCT0000169516	NCT00001695_16_T1	PHENOTYPE	5	6	patient attitudes
NCT000016963	NCT00001696_3_T0	COMPOUND	8	8	genistein
NCT000016963	NCT00001696_3_T1	COMPOUND	17	17	genistein
NCT000016963	NCT00001696_3_T2	PHENOTYPE	6	6	pharmacokinetics
NCT000016964	NCT00001696_4_T0	COMPOUND	8	8	genistein
NCT000016964	NCT00001696_4_T1	COMPOUND	11	11	genistein
NCT0000169611	NCT00001696_11_T0	COMPOUND	8	8	genistein
NCT0000169611	NCT00001696_11_T1	COMPOUND	17	17	genistein
NCT0000169611	NCT00001696_11_T2	PHENOTYPE	6	6	pharmacokinetics
NCT0000169612	NCT00001696_12_T0	COMPOUND	8	8	genistein
NCT0000169612	NCT00001696_12_T1	COMPOUND	11	11	genistein
NCT0000169620	NCT00001696_20_T0	PHENOTYPE	16	16	pathology
NCT0000169620	NCT00001696_20_T1	COMPOUND	25	25	NCI
NCT0000169620	NCT00001696_20_T2	PHENOTYPE	8	9	skin cancer
NCT0000169623	NCT00001696_23_T0	PHENOTYPE	0	0	Hgb
NCT0000169623	NCT00001696_23_T1	CELL	7	7	platelets
NCT0000169623	NCT00001696_23_T2	COMPOUND	21	21	creatinine
NCT0000169623	NCT00001696_23_T3	GENE	14	14	ANC
NCT0000169623	NCT00001696_23_T4	COMPOUND	55	55	bilirubin
NCT0000169623	NCT00001696_23_T5	COMPOUND	62	62	bilirubin
NCT0000169623	NCT00001696_23_T6	BIOLOGICAL_PROCESS	63	63	metabolism
NCT0000169623	NCT00001696_23_T7	PHENOTYPE	40	41	total bilirubin
NCT0000169624	NCT00001696_24_T0	PHENOTYPE	3	4	breast cancer
NCT0000169626	NCT00001696_26_T0	PHENOTYPE	3	4	HIV positive
NCT0000169627	NCT00001696_27_T0	PHENOTYPE	3	4	venous thrombosis
NCT0000169629	NCT00001696_29_T0	PHENOTYPE	10	10	disorders
NCT0000169631	NCT00001696_31_T0	COMPOUND	5	5	estrogen
NCT000016981	NCT00001698_1_T0	PHENOTYPE	18	18	reflected
NCT000016981	NCT00001698_1_T1	GENE	35	35	IL-1beta
NCT000016981	NCT00001698_1_T2	PHENOTYPE	16	16	inflammation
NCT000016981	NCT00001698_1_T3	GENE	4	4	has
NCT000016981	NCT00001698_1_T4	GENE	34	34	beta
NCT000016981	NCT00001698_1_T5	PHENOTYPE	2	3	periodontal disease
NCT000016981	NCT00001698_1_T6	COMPOUND	28	29	prostaglandin E2
NCT000016983	NCT00001698_3_T0	COMPOUND	26	26	ketorolac
NCT000016983	NCT00001698_3_T1	PHENOTYPE	15	15	leukoplakia
NCT000016984	NCT00001698_4_T0	TISSUE	25	25	tissues
NCT000016984	NCT00001698_4_T1	GENE	7	7	cyclooxygenase-2
NCT000016984	NCT00001698_4_T2	GENE	10	10	has
NCT000016984	NCT00001698_4_T3	GENE	8	8	Cox-2
NCT000016985	NCT00001698_5_T0	PHENOTYPE	21	21	Center
NCT000016985	NCT00001698_5_T1	GENE	18	18	MD
NCT000016987	NCT00001698_7_T0	PHENOTYPE	16	16	leukoplakia
NCT000016988	NCT00001698_8_T0	PHENOTYPE	9	9	secondary
NCT000016988	NCT00001698_8_T1	GENE	22	22	punch
NCT000016988	NCT00001698_8_T2	ORGAN	26	27	oral cavity
NCT000016989	NCT00001698_9_T0	PHENOTYPE	5	5	carcinogenesis
NCT0000169811	NCT00001698_11_T0	COMPOUND	13	13	ketorolac
NCT0000169811	NCT00001698_11_T1	PHENOTYPE	20	21	oropharyngeal cancer
NCT0000169812	NCT00001698_12_T0	COMPOUND	1	1	ketorolac
NCT0000169812	NCT00001698_12_T1	PHENOTYPE	14	14	leukoplakia
NCT0000169812	NCT00001698_12_T2	GENE	19	19	III
NCT0000169814	NCT00001698_14_T0	PHENOTYPE	18	18	reflected
NCT0000169814	NCT00001698_14_T1	GENE	35	35	IL-1beta
NCT0000169814	NCT00001698_14_T2	PHENOTYPE	16	16	inflammation
NCT0000169814	NCT00001698_14_T3	GENE	4	4	has
NCT0000169814	NCT00001698_14_T4	GENE	34	34	beta
NCT0000169814	NCT00001698_14_T5	PHENOTYPE	2	3	periodontal disease
NCT0000169814	NCT00001698_14_T6	COMPOUND	28	29	prostaglandin E2
NCT0000169816	NCT00001698_16_T0	COMPOUND	26	26	ketorolac
NCT0000169816	NCT00001698_16_T1	PHENOTYPE	15	15	leukoplakia
NCT0000169817	NCT00001698_17_T0	TISSUE	25	25	tissues
NCT0000169817	NCT00001698_17_T1	GENE	7	7	cyclooxygenase-2
NCT0000169817	NCT00001698_17_T2	GENE	10	10	has
NCT0000169817	NCT00001698_17_T3	GENE	8	8	Cox-2
NCT0000169818	NCT00001698_18_T0	PHENOTYPE	21	21	Center
NCT0000169818	NCT00001698_18_T1	GENE	18	18	MD
NCT0000169820	NCT00001698_20_T0	PHENOTYPE	16	16	leukoplakia
NCT0000169821	NCT00001698_21_T0	PHENOTYPE	9	9	secondary
NCT0000169821	NCT00001698_21_T1	GENE	22	22	punch
NCT0000169821	NCT00001698_21_T2	ORGAN	26	27	oral cavity
NCT0000169822	NCT00001698_22_T0	PHENOTYPE	5	5	carcinogenesis
NCT0000169824	NCT00001698_24_T0	COMPOUND	13	13	ketorolac
NCT0000169824	NCT00001698_24_T1	PHENOTYPE	20	21	oropharyngeal cancer
NCT0000169825	NCT00001698_25_T0	COMPOUND	1	1	ketorolac
NCT0000169825	NCT00001698_25_T1	PHENOTYPE	14	14	leukoplakia
NCT0000169825	NCT00001698_25_T2	GENE	19	19	III
NCT0000169827	NCT00001698_27_T0	GENE	5	5	had
NCT0000169827	NCT00001698_27_T1	PHENOTYPE	14	15	oral cancer
NCT0000169834	NCT00001698_34_T0	COMPOUND	6	6	probenecid
NCT0000169834	NCT00001698_34_T1	COMPOUND	26	26	lithium
NCT0000169834	NCT00001698_34_T2	COMPOUND	5	5	aspirin
NCT0000169834	NCT00001698_34_T3	COMPOUND	27	27	methotrexate
NCT0000169834	NCT00001698_34_T4	GENE	11	11	extended
NCT0000169834	NCT00001698_34_T5	COMPOUND	38	39	test product
NCT0000169836	NCT00001698_36_T0	ORGAN	13	14	root canal
NCT0000169838	NCT00001698_38_T0	PHENOTYPE	14	14	dependency
NCT0000169838	NCT00001698_38_T1	COMPOUND	17	17	oxygen
NCT0000169838	NCT00001698_38_T2	PHENOTYPE	3	4	respiratory function
NCT0000169838	NCT00001698_38_T3	PHENOTYPE	7	9	shortness of breath
NCT0000169840	NCT00001698_40_T0	GENE	1	1	FOR
NCT000016992	NCT00001699_2_T0	PHENOTYPE	12	12	HIV
NCT000016997	NCT00001699_7_T0	PHENOTYPE	12	12	HIV
NCT0000169911	NCT00001699_11_T0	PHENOTYPE	12	12	HIV
NCT0000169916	NCT00001699_16_T0	PHENOTYPE	12	12	HIV
NCT0000169919	NCT00001699_19_T0	PHENOTYPE	5	5	HIV
NCT0000169919	NCT00001699_19_T1	PHENOTYPE	20	20	chronic
NCT000017011	NCT00001701_1_T0	BIOLOGICAL_PROCESS	9	10	innate immunity
NCT000017013	NCT00001701_3_T0	PHENOTYPE	19	19	severity
NCT000017013	NCT00001701_3_T1	BIOLOGICAL_PROCESS	12	13	innate immunity
NCT000017015	NCT00001701_5_T0	BIOLOGICAL_PROCESS	9	10	innate immunity
NCT000017017	NCT00001701_7_T0	PHENOTYPE	19	19	severity
NCT000017017	NCT00001701_7_T1	BIOLOGICAL_PROCESS	12	13	innate immunity
NCT0000170110	NCT00001701_10_T0	PHENOTYPE	7	7	HIV
NCT000017021	NCT00001702_1_T0	PHENOTYPE	23	23	Blastomycosis
NCT000017021	NCT00001702_1_T1	BIOLOGICAL_PROCESS	9	10	innate immunity
NCT000017023	NCT00001702_3_T0	PHENOTYPE	19	19	severity
NCT000017023	NCT00001702_3_T1	PHENOTYPE	22	22	Blastomycosis
NCT000017023	NCT00001702_3_T2	BIOLOGICAL_PROCESS	12	13	innate immunity
NCT000017025	NCT00001702_5_T0	PHENOTYPE	23	23	Blastomycosis
NCT000017025	NCT00001702_5_T1	BIOLOGICAL_PROCESS	9	10	innate immunity
NCT000017027	NCT00001702_7_T0	PHENOTYPE	19	19	severity
NCT000017027	NCT00001702_7_T1	PHENOTYPE	22	22	Blastomycosis
NCT000017027	NCT00001702_7_T2	BIOLOGICAL_PROCESS	12	13	innate immunity
NCT0000170210	NCT00001702_10_T0	PHENOTYPE	7	7	HIV
NCT0000170210	NCT00001702_10_T1	GENE	5	5	co
NCT000017032	NCT00001703_2_T0	PHENOTYPE	9	10	metastatic disease
NCT000017034	NCT00001703_4_T0	PHENOTYPE	0	0	Cancers
NCT000017035	NCT00001703_5_T0	PHENOTYPE	3	3	mutated
NCT000017035	NCT00001703_5_T1	CELL	10	10	cells
NCT0000170313	NCT00001703_13_T0	PHENOTYPE	9	9	peripheral
NCT0000170313	NCT00001703_13_T1	CELL	11	11	cells
NCT0000170317	NCT00001703_17_T0	PHENOTYPE	9	10	metastatic disease
NCT0000170319	NCT00001703_19_T0	PHENOTYPE	0	0	Cancers
NCT0000170320	NCT00001703_20_T0	PHENOTYPE	3	3	mutated
NCT0000170320	NCT00001703_20_T1	CELL	10	10	cells
NCT0000170322	NCT00001703_22_T0	PHENOTYPE	21	21	mutated
NCT0000170322	NCT00001703_22_T1	GENE	8	8	MHC
NCT0000170322	NCT00001703_22_T2	GENE	10	10	CTL
NCT000017051	NCT00001705_1_T0	GENE	18	18	IL-2
NCT000017054	NCT00001705_4_T0	GENE	18	18	IL-2
NCT000017057	NCT00001705_7_T0	COMPOUND	1	1	creatinine
NCT000017057	NCT00001705_7_T1	GENE	3	3	2.0
NCT000017057	NCT00001705_7_T2	ORGAN	0	0	Serum
NCT000017058	NCT00001705_8_T0	GENE	1	1	1/6
NCT000017059	NCT00001705_9_T0	GENE	0	0	WBC
NCT0000170510	NCT00001705_10_T0	PHENOTYPE	0	1	Platelet count
NCT0000170511	NCT00001705_11_T0	ORGAN	0	0	Serum
NCT0000170516	NCT00001705_16_T0	GENE	11	11	IFA
NCT0000170516	NCT00001705_16_T1	PHENOTYPE	2	3	cardiovascular disease
NCT0000170519	NCT00001705_19_T0	PHENOTYPE	12	12	HIV
NCT0000170519	NCT00001705_19_T1	PHENOTYPE	9	9	hepatitis
NCT000017112	NCT00001711_2_T0	GENE	5	5	MRI
NCT000017112	NCT00001711_2_T1	PHENOTYPE	26	26	diseases
NCT000017114	NCT00001711_4_T0	GENE	22	22	MRI
NCT000017119	NCT00001711_9_T0	PHENOTYPE	13	13	hyperoxia
NCT000017119	NCT00001711_9_T1	COMPOUND	7	7	oxygen
NCT000017119	NCT00001711_9_T2	COMPOUND	15	15	oxygen
NCT000017119	NCT00001711_9_T3	COMPOUND	5	5	carbogen
NCT000017119	NCT00001711_9_T4	COMPOUND	10	11	carbon dioxide
NCT0000171110	NCT00001711_10_T0	GENE	16	16	rf
NCT0000171110	NCT00001711_10_T1	PHENOTYPE	11	11	pulse
NCT0000171113	NCT00001711_13_T0	GENE	9	9	has
NCT0000171113	NCT00001711_13_T1	PHENOTYPE	33	33	twisting
NCT0000171115	NCT00001711_15_T0	PHENOTYPE	0	0	Aneurysm
NCT0000171115	NCT00001711_15_T1	GENE	1	1	clip
NCT0000171119	NCT00001711_19_T0	PHENOTYPE	1	2	foreign body
NCT0000171121	NCT00001711_21_T0	PHENOTYPE	1	1	injuries
NCT0000171125	NCT00001711_25_T0	PHENOTYPE	5	5	hemoglobinopathies
NCT0000171125	NCT00001711_25_T1	PHENOTYPE	6	6	asthma
NCT0000171125	NCT00001711_25_T2	PHENOTYPE	10	11	hepatic disease
NCT0000171126	NCT00001711_26_T0	GENE	29	29	MRI
NCT0000171127	NCT00001711_27_T0	PHENOTYPE	2	2	exposures
NCT0000171127	NCT00001711_27_T1	PHENOTYPE	38	38	Center
NCT0000171129	NCT00001711_29_T0	GENE	34	34	MRI
NCT0000171129	NCT00001711_29_T1	COMPOUND	19	19	Gadolinium
NCT0000171129	NCT00001711_29_T2	ORGAN	26	26	serum
NCT0000171129	NCT00001711_29_T3	PHENOTYPE	5	6	renal failure
NCT000017124	NCT00001712_4_T0	PHENOTYPE	4	4	infections
NCT0000171210	NCT00001712_10_T0	PHENOTYPE	4	4	infections
NCT000017132	NCT00001713_2_T0	PHENOTYPE	12	12	anticoagulation
NCT000017132	NCT00001713_2_T1	GENE	4	4	has
NCT000017133	NCT00001713_3_T0	PHENOTYPE	16	16	thrombus
NCT000017134	NCT00001713_4_T0	PHENOTYPE	16	16	bleeding
NCT000017134	NCT00001713_4_T1	PHENOTYPE	17	17	complications
NCT000017136	NCT00001713_6_T0	PHENOTYPE	16	16	pulse
NCT000017136	NCT00001713_6_T1	PHENOTYPE	25	26	venous thrombosis
NCT000017136	NCT00001713_6_T2	ORGAN	30	31	lower extremity
NCT000017139	NCT00001713_9_T0	PHENOTYPE	12	12	anticoagulation
NCT000017139	NCT00001713_9_T1	GENE	4	4	has
NCT0000171310	NCT00001713_10_T0	PHENOTYPE	16	16	thrombus
NCT0000171311	NCT00001713_11_T0	PHENOTYPE	16	16	bleeding
NCT0000171311	NCT00001713_11_T1	PHENOTYPE	17	17	complications
NCT0000171313	NCT00001713_13_T0	PHENOTYPE	16	16	pulse
NCT0000171313	NCT00001713_13_T1	PHENOTYPE	25	26	venous thrombosis
NCT0000171313	NCT00001713_13_T2	ORGAN	30	31	lower extremity
NCT0000171315	NCT00001713_15_T0	PHENOTYPE	1	3	negative pregnancy test
NCT0000171316	NCT00001713_16_T0	PHENOTYPE	5	5	acute
NCT0000171316	NCT00001713_16_T1	PHENOTYPE	6	6	DVT
NCT0000171319	NCT00001713_19_T0	GENE	24	24	fibrinogen
NCT0000171319	NCT00001713_19_T1	PHENOTYPE	9	9	attributable
NCT0000171319	NCT00001713_19_T2	PHENOTYPE	78	78	thrombocytopenia
NCT0000171319	NCT00001713_19_T3	GENE	12	12	prothrombin
NCT0000171319	NCT00001713_19_T4	COMPOUND	11	11	heparin
NCT0000171319	NCT00001713_19_T5	COMPOUND	77	77	heparin
NCT0000171319	NCT00001713_19_T6	COMPOUND	38	38	creatinine
NCT0000171319	NCT00001713_19_T7	CELL	29	29	platelet
NCT0000171319	NCT00001713_19_T8	CELL	36	36	platelet
NCT0000171319	NCT00001713_19_T9	PHENOTYPE	44	44	hypertension
NCT0000171319	NCT00001713_19_T10	GENE	50	50	Hg
NCT0000171319	NCT00001713_19_T11	GENE	57	57	Hg
NCT0000171319	NCT00001713_19_T12	PHENOTYPE	6	7	bleeding diathesis
NCT0000171319	NCT00001713_19_T13	PHENOTYPE	58	59	atrial fibrillation
NCT0000171319	NCT00001713_19_T14	PHENOTYPE	68	69	anaphylactic reactions
NCT0000171321	NCT00001713_21_T0	PHENOTYPE	24	24	trauma
NCT0000171321	NCT00001713_21_T1	PHENOTYPE	21	21	hematuria
NCT0000171321	NCT00001713_21_T2	PHENOTYPE	15	15	hemoptysis
NCT0000171321	NCT00001713_21_T3	PHENOTYPE	18	18	hemorrhage
NCT0000171321	NCT00001713_21_T4	PHENOTYPE	9	10	gastrointestinal hemorrhage
NCT0000171321	NCT00001713_21_T5	PHENOTYPE	12	14	peptic ulcer disease
NCT0000171322	NCT00001713_22_T0	PHENOTYPE	12	12	hemorrhage
NCT0000171322	NCT00001713_22_T1	PHENOTYPE	9	10	cerebrovascular accident
NCT000017141	NCT00001714_1_T0	GENE	7	7	MT
NCT000017142	NCT00001714_2_T0	GENE	6	6	MT
NCT000017142	NCT00001714_2_T1	GENE	13	13	MT
NCT000017143	NCT00001714_3_T0	ORGAN	7	7	kidney
NCT000017144	NCT00001714_4_T0	GENE	31	31	MT
NCT000017144	NCT00001714_4_T1	COMPOUND	26	26	proton
NCT000017145	NCT00001714_5_T0	TISSUE	20	20	tissues
NCT000017145	NCT00001714_5_T1	GENE	10	10	MT
NCT000017147	NCT00001714_7_T0	GENE	7	7	MT
NCT000017148	NCT00001714_8_T0	GENE	6	6	MT
NCT000017148	NCT00001714_8_T1	GENE	13	13	MT
NCT000017149	NCT00001714_9_T0	ORGAN	7	7	kidney
NCT0000171410	NCT00001714_10_T0	GENE	31	31	MT
NCT0000171410	NCT00001714_10_T1	COMPOUND	26	26	proton
NCT0000171411	NCT00001714_11_T0	GENE	10	10	MT
NCT0000171414	NCT00001714_14_T0	PHENOTYPE	17	17	symptoms
NCT0000171414	NCT00001714_14_T1	PHENOTYPE	21	21	insulinoma
NCT0000171415	NCT00001714_15_T0	PHENOTYPE	5	5	hemoglobinopathies
NCT0000171415	NCT00001714_15_T1	PHENOTYPE	6	6	asthma
NCT0000171415	NCT00001714_15_T2	PHENOTYPE	10	11	hepatic disease
NCT0000171416	NCT00001714_16_T0	PHENOTYPE	30	30	twisting
NCT000017151	NCT00001715_1_T0	PHENOTYPE	6	7	hematologic disorders
NCT000017153	NCT00001715_3_T0	PHENOTYPE	31	32	blood disorders
NCT000017155	NCT00001715_5_T0	PHENOTYPE	14	15	blood disorders
NCT000017159	NCT00001715_9_T0	PHENOTYPE	6	7	hematologic disorders
NCT000017160	NCT00001716_0_T0	PHENOTYPE	9	11	Sickle Cell Anemia
NCT000017162	NCT00001716_2_T0	GENE	6	6	has
NCT0000171615	NCT00001716_15_T0	GENE	13	13	ACS
NCT0000171615	NCT00001716_15_T1	GENE	4	4	has
NCT0000171615	NCT00001716_15_T2	COMPOUND	1	2	nitric oxide
NCT0000171616	NCT00001716_16_T0	PHENOTYPE	9	9	hypoxemia
NCT0000171616	NCT00001716_16_T1	GENE	16	16	ACS
NCT0000171616	NCT00001716_16_T2	GENE	2	2	has
NCT0000171619	NCT00001716_19_T0	BIOLOGICAL_PROCESS	8	8	metabolism
NCT0000171619	NCT00001716_19_T1	COMPOUND	30	30	oxygen
NCT0000171619	NCT00001716_19_T2	GENE	18	18	hemoglobin
NCT0000171619	NCT00001716_19_T3	GENE	29	29	hemoglobin
NCT0000171619	NCT00001716_19_T4	GENE	40	40	hemoglobin
NCT0000171619	NCT00001716_19_T5	CELL	37	37	erythrocyte
NCT0000171619	NCT00001716_19_T6	PHENOTYPE	46	47	sickle hemoglobin
NCT0000171621	NCT00001716_21_T0	COMPOUND	14	14	nitroglycerin
NCT0000171623	NCT00001716_23_T0	GENE	3	3	MRI
NCT0000171623	NCT00001716_23_T1	COMPOUND	16	16	gadolinium
NCT0000171623	NCT00001716_23_T2	TISSUE	7	8	skeletal muscle
NCT0000171623	NCT00001716_23_T3	TISSUE	24	25	skeletal muscle
NCT0000171623	NCT00001716_23_T4	ORGAN	5	6	lower extremity
NCT0000171624	NCT00001716_24_T0	COMPOUND	20	20	phosphate
NCT0000171624	NCT00001716_24_T1	GENE	4	4	paired
NCT0000171631	NCT00001716_31_T0	PHENOTYPE	7	8	reticulocyte count
NCT0000171632	NCT00001716_32_T0	GENE	12	12	ml
NCT0000171632	NCT00001716_32_T1	PHENOTYPE	5	6	reticulocyte count
NCT0000171636	NCT00001716_36_T0	BIOLOGICAL_PROCESS	3	3	lactation
NCT0000171642	NCT00001716_42_T0	COMPOUND	9	9	caffeine
NCT0000171642	NCT00001716_42_T1	COMPOUND	1	1	aspirin
NCT000017174	NCT00001717_4_T0	GENE	14	14	7-10
NCT000017175	NCT00001717_5_T0	PHENOTYPE	10	10	motivations
NCT0000171710	NCT00001717_10_T0	GENE	14	14	7-10
NCT0000171711	NCT00001717_11_T0	PHENOTYPE	10	10	motivations
NCT000017181	NCT00001718_1_T0	GENE	2	2	has
NCT000017181	NCT00001718_1_T1	GENE	23	23	has
NCT000017181	NCT00001718_1_T2	GENE	1	1	EPG
NCT000017183	NCT00001718_3_T0	PHENOTYPE	4	4	dysphagia
NCT000017184	NCT00001718_4_T0	ORGAN	22	22	palate
NCT000017185	NCT00001718_5_T0	GENE	7	7	swallow
NCT000017185	NCT00001718_5_T1	GENE	17	17	EPG
NCT000017186	NCT00001718_6_T0	GENE	8	8	swallow
NCT000017186	NCT00001718_6_T1	GENE	9	9	EPG
NCT000017189	NCT00001718_9_T0	GENE	2	2	has
NCT000017189	NCT00001718_9_T1	GENE	23	23	has
NCT000017189	NCT00001718_9_T2	GENE	1	1	EPG
NCT0000171812	NCT00001718_12_T0	ORGAN	22	22	palate
NCT0000171813	NCT00001718_13_T0	GENE	7	7	swallow
NCT0000171813	NCT00001718_13_T1	GENE	17	17	EPG
NCT0000171814	NCT00001718_14_T0	GENE	8	8	swallow
NCT0000171814	NCT00001718_14_T1	GENE	9	9	EPG
NCT000017192	NCT00001719_2_T0	ORGAN	3	3	liver
NCT000017192	NCT00001719_2_T1	PHENOTYPE	15	16	liver disease
NCT000017194	NCT00001719_4_T0	GENE	17	17	structural
NCT000017195	NCT00001719_5_T0	GENE	15	15	1.5
NCT0000171911	NCT00001719_11_T0	GENE	16	16	portal
NCT0000171911	NCT00001719_11_T1	PHENOTYPE	22	22	MRA
NCT0000171911	NCT00001719_11_T2	PHENOTYPE	37	38	hepatic disease
NCT0000171913	NCT00001719_13_T0	GENE	12	12	1.2
NCT0000171915	NCT00001719_15_T0	GENE	9	9	Hg
NCT0000171915	NCT00001719_15_T1	GENE	18	18	Hg
NCT000017201	NCT00001720_1_T0	COMPOUND	11	11	calcium
NCT000017201	NCT00001720_1_T1	TISSUE	17	17	bones
NCT000017202	NCT00001720_2_T0	TISSUE	15	15	bones
NCT000017203	NCT00001720_3_T0	PHENOTYPE	4	4	osteoporosis
NCT000017207	NCT00001720_7_T0	PHENOTYPE	3	3	osteoporosis
NCT000017207	NCT00001720_7_T1	PHENOTYPE	35	35	osteoporosis
NCT000017208	NCT00001720_8_T0	BIOLOGICAL_PROCESS	9	10	bone resorption
NCT000017209	NCT00001720_9_T0	PHENOTYPE	6	6	menopausal
NCT000017209	NCT00001720_9_T1	GENE	1	1	has
NCT000017209	NCT00001720_9_T2	PHENOTYPE	7	7	osteoporosis
NCT000017209	NCT00001720_9_T3	PHENOTYPE	9	9	osteoporosis
NCT000017209	NCT00001720_9_T4	PHENOTYPE	13	13	osteoporosis
NCT0000172010	NCT00001720_10_T0	COMPOUND	11	11	alendronate
NCT0000172010	NCT00001720_10_T1	PHENOTYPE	15	17	idiopathic juvenile osteoporosis
NCT0000172011	NCT00001720_11_T0	COMPOUND	6	6	alendronate
NCT0000172011	NCT00001720_11_T1	PHENOTYPE	19	19	osteoporosis
NCT0000172011	NCT00001720_11_T2	PHENOTYPE	16	16	fractures
NCT0000172013	NCT00001720_13_T0	PHENOTYPE	9	9	osteoporosis
NCT0000172013	NCT00001720_13_T1	PHENOTYPE	5	5	understood
NCT0000172013	NCT00001720_13_T2	PHENOTYPE	11	13	idiopathic juvenile osteoporosis
NCT0000172015	NCT00001720_15_T0	GENE	20	20	2.3
NCT0000172015	NCT00001720_15_T1	PHENOTYPE	3	3	osteoporosis
NCT0000172015	NCT00001720_15_T2	PHENOTYPE	30	30	osteoporosis
NCT0000172017	NCT00001720_17_T0	GENE	1	1	has
NCT0000172017	NCT00001720_17_T1	PHENOTYPE	10	10	osteoporosis
NCT0000172017	NCT00001720_17_T2	PHENOTYPE	14	14	osteoporosis
NCT0000172017	NCT00001720_17_T3	PHENOTYPE	6	7	postmenopausal osteoporosis
NCT0000172018	NCT00001720_18_T0	PHENOTYPE	18	20	idiopathic juvenile osteoporosis
NCT0000172019	NCT00001720_19_T0	PHENOTYPE	19	20	osteoporotic fractures
NCT0000172022	NCT00001720_22_T0	COMPOUND	11	11	2
NCT0000172022	NCT00001720_22_T1	ORGAN	2	2	spine
NCT0000172026	NCT00001720_26_T0	GENE	4	4	swallow
NCT0000172027	NCT00001720_27_T0	ORGAN	0	2	Upper gastrointestinal tract
NCT0000172029	NCT00001720_29_T0	COMPOUND	3	3	bisphosphonates
NCT0000172030	NCT00001720_30_T0	COMPOUND	6	6	salicylate
NCT0000172030	NCT00001720_30_T1	PHENOTYPE	16	16	distal
NCT0000172030	NCT00001720_30_T2	COMPOUND	4	4	aspirin
NCT0000172030	NCT00001720_30_T3	COMPOUND	22	22	sulfasalazine
NCT0000172030	NCT00001720_30_T4	ORGAN	17	18	gastrointestinal tract
NCT0000172032	NCT00001720_32_T0	GENE	4	4	calcitonin
NCT0000172034	NCT00001720_34_T0	PHENOTYPE	0	2	Positive pregnancy test
NCT0000172119	NCT00001721_19_T0	PHENOTYPE	14	14	mutation
NCT0000172119	NCT00001721_19_T1	GENE	20	20	DHCR7
NCT0000172119	NCT00001721_19_T2	COMPOUND	8	8	3beta_hydroxysterol
NCT0000172119	NCT00001721_19_T3	COMPOUND	17	17	3beta_hydroxysterol
NCT0000172121	NCT00001721_21_T0	PHENOTYPE	2	2	malformations
NCT0000172121	NCT00001721_21_T1	GENE	27	27	had
NCT0000172121	NCT00001721_21_T2	GENE	26	26	has
NCT0000172124	NCT00001721_24_T0	PHENOTYPE	8	8	disorders
NCT0000172124	NCT00001721_24_T1	PHENOTYPE	11	11	lathosterolosis
NCT0000172125	NCT00001721_25_T0	PHENOTYPE	0	0	Lathosterolosis
NCT0000172125	NCT00001721_25_T1	COMPOUND	9	9	sterol
NCT0000172125	NCT00001721_25_T2	COMPOUND	18	18	lathosterol
NCT0000172127	NCT00001721_27_T0	PHENOTYPE	0	0	Lathosterolosis
NCT0000172127	NCT00001721_27_T1	PHENOTYPE	6	7	autosomal recessive
NCT0000172134	NCT00001721_34_T0	PHENOTYPE	11	11	hypoplasia
NCT0000172134	NCT00001721_34_T1	ORGAN	10	10	genital
NCT0000172142	NCT00001721_42_T0	PHENOTYPE	10	10	recruitment
NCT000017221	NCT00001722_1_T0	CELL	4	5	fat cells
NCT000017226	NCT00001722_6_T0	CELL	6	6	cells
NCT000017226	NCT00001722_6_T1	ORGAN	8	9	blood vessels
NCT000017227	NCT00001722_7_T0	COMPOUND	10	10	glucose
NCT000017227	NCT00001722_7_T1	GENE	9	9	insulin
NCT000017227	NCT00001722_7_T2	COMPOUND	15	15	isoproterenol
NCT000017227	NCT00001722_7_T3	GENE	17	17	leptin
NCT000017228	NCT00001722_8_T0	GENE	14	14	HSL
NCT000017228	NCT00001722_8_T1	GENE	3	3	leptin
NCT000017228	NCT00001722_8_T2	GENE	11	13	hormone sensitive lipase
NCT000017229	NCT00001722_9_T0	BIOLOGICAL_PROCESS	14	14	lipolysis
NCT000017229	NCT00001722_9_T1	GENE	1	3	hormone sensitive lipase
NCT0000172210	NCT00001722_10_T0	GENE	5	5	HSL
NCT0000172210	NCT00001722_10_T1	GENE	11	11	leptin
NCT0000172213	NCT00001722_13_T0	GENE	17	17	leptin
NCT0000172213	NCT00001722_13_T1	TISSUE	9	10	adipose tissue
NCT0000172213	NCT00001722_13_T2	TISSUE	19	20	adipose tissue
NCT0000172213	NCT00001722_13_T3	CELL	21	22	interstitial fluid
NCT0000172215	NCT00001722_15_T0	GENE	4	4	HSL
NCT0000172215	NCT00001722_15_T1	TISSUE	15	16	adipose tissue
NCT0000172215	NCT00001722_15_T2	GENE	1	3	hormone sensitive lipase
NCT0000172216	NCT00001722_16_T0	BIOLOGICAL_PROCESS	12	12	lipolysis
NCT0000172217	NCT00001722_17_T0	GENE	1	1	HSL
NCT0000172217	NCT00001722_17_T1	GENE	15	15	leptin
NCT0000172219	NCT00001722_19_T0	GENE	11	11	leptin
NCT0000172219	NCT00001722_19_T1	COMPOUND	13	13	glycerol
NCT0000172219	NCT00001722_19_T2	TISSUE	15	16	adipose tissue
NCT0000172220	NCT00001722_20_T0	GENE	19	19	adiponectin
NCT0000172220	NCT00001722_20_T1	GENE	17	17	resistin
NCT0000172222	NCT00001722_22_T0	GENE	14	14	interleukin-6
NCT0000172222	NCT00001722_22_T1	GENE	12	12	TNF-alpha
NCT0000172222	NCT00001722_22_T2	GENE	25	25	insulin
NCT0000172222	NCT00001722_22_T3	GENE	11	11	leptin
NCT0000172222	NCT00001722_22_T4	TISSUE	16	17	adipose tissue
NCT0000172226	NCT00001722_26_T0	GENE	4	4	HPA
NCT0000172226	NCT00001722_26_T1	GENE	5	5	axis
NCT0000172226	NCT00001722_26_T2	PHENOTYPE	7	8	thyroid dysfunction
NCT0000172230	NCT00001722_30_T0	PHENOTYPE	2	2	allergies
NCT0000172231	NCT00001722_31_T0	PHENOTYPE	3	3	allergy
NCT0000172231	NCT00001722_31_T1	COMPOUND	5	5	isoproterenol
NCT000017231	NCT00001723_1_T0	PHENOTYPE	17	17	diseases
NCT000017231	NCT00001723_1_T1	PHENOTYPE	5	5	obesity
NCT000017231	NCT00001723_1_T2	PHENOTYPE	16	16	obesity
NCT000017232	NCT00001723_2_T0	PHENOTYPE	18	18	diseases
NCT000017232	NCT00001723_2_T1	PHENOTYPE	11	11	obesity
NCT000017232	NCT00001723_2_T2	PHENOTYPE	17	17	obesity
NCT000017233	NCT00001723_3_T0	PHENOTYPE	18	18	obesity
NCT000017234	NCT00001723_4_T0	PHENOTYPE	13	14	severe obesity
NCT000017234	NCT00001723_4_T1	PHENOTYPE	14	16	obesity in children
NCT000017236	NCT00001723_6_T0	GENE	18	18	1.3
NCT0000172312	NCT00001723_12_T0	PHENOTYPE	5	5	obesity
NCT0000172312	NCT00001723_12_T1	PHENOTYPE	15	15	obesity
NCT0000172313	NCT00001723_13_T0	PHENOTYPE	10	10	obesity
NCT0000172313	NCT00001723_13_T1	PHENOTYPE	16	16	obesity
NCT0000172314	NCT00001723_14_T0	PHENOTYPE	17	17	obesity
NCT0000172315	NCT00001723_15_T0	PHENOTYPE	13	14	severe obesity
NCT0000172315	NCT00001723_15_T1	PHENOTYPE	14	16	obesity in children
NCT0000172316	NCT00001723_16_T0	COMPOUND	13	13	orlistat
NCT0000172317	NCT00001723_17_T0	PHENOTYPE	14	14	ingested
NCT0000172317	NCT00001723_17_T1	GENE	12	12	1.3
NCT0000172320	NCT00001723_20_T0	COMPOUND	11	11	orlistat
NCT0000172320	NCT00001723_20_T1	COMPOUND	16	16	orlistat
NCT0000172320	NCT00001723_20_T2	GENE	17	17	has
NCT0000172320	NCT00001723_20_T3	PHENOTYPE	20	21	side effect
NCT0000172321	NCT00001723_21_T0	COMPOUND	9	9	orlistat
NCT0000172321	NCT00001723_21_T1	PHENOTYPE	12	12	obesity
NCT0000172322	NCT00001723_22_T0	PHENOTYPE	18	18	strategies
NCT0000172322	NCT00001723_22_T1	PHENOTYPE	9	10	weight loss
NCT0000172323	NCT00001723_23_T0	COMPOUND	7	7	orlistat
NCT0000172323	NCT00001723_23_T1	PHENOTYPE	22	23	weight loss
NCT0000172323	NCT00001723_23_T2	PHENOTYPE	19	20	energy expenditure
NCT0000172326	NCT00001723_26_T0	PHENOTYPE	4	4	obesity
NCT0000172327	NCT00001723_27_T0	PHENOTYPE	0	0	Obesity
NCT0000172329	NCT00001723_29_T0	PHENOTYPE	4	4	obesity
NCT0000172332	NCT00001723_32_T0	PHENOTYPE	6	8	negative pregnancy test
NCT0000172334	NCT00001723_34_T0	COMPOUND	20	20	acetate
NCT0000172334	NCT00001723_34_T1	PHENOTYPE	14	14	IUD
NCT0000172338	NCT00001723_38_T0	GENE	9	9	has
NCT0000172349	NCT00001723_49_T0	PHENOTYPE	6	8	negative pregnancy test
NCT0000172355	NCT00001723_55_T0	GENE	8	8	has
NCT0000172355	NCT00001723_55_T1	PHENOTYPE	14	15	psychiatric disorder
NCT0000172355	NCT00001723_55_T2	PHENOTYPE	10	11	substance abuse
NCT0000172357	NCT00001723_57_T0	PHENOTYPE	12	13	weight reduction
NCT000017242	NCT00001724_2_T0	ORGAN	10	11	wisdom tooth
NCT000017242	NCT00001724_2_T1	ORGAN	8	9	third molar
NCT000017243	NCT00001724_3_T0	ORGAN	11	11	teeth
NCT000017243	NCT00001724_3_T1	ORGAN	9	10	third molar
NCT000017245	NCT00001724_5_T0	COMPOUND	10	10	flurbiprofen
NCT000017245	NCT00001724_5_T1	COMPOUND	33	33	flurbiprofen
NCT000017249	NCT00001724_9_T0	COMPOUND	30	30	flurbiprofen
NCT0000172410	NCT00001724_10_T0	GENE	4	4	ml
NCT0000172414	NCT00001724_14_T0	COMPOUND	38	38	flurbiprofen
NCT0000172414	NCT00001724_14_T1	COMPOUND	42	42	bupivacaine
NCT0000172414	NCT00001724_14_T2	ORGAN	7	8	third molars
NCT0000172416	NCT00001724_16_T0	COMPOUND	17	17	flurbiprofen
NCT0000172418	NCT00001724_18_T0	COMPOUND	6	6	flurbiprofen
NCT0000172418	NCT00001724_18_T1	COMPOUND	31	31	flurbiprofen
NCT0000172418	NCT00001724_18_T2	COMPOUND	36	36	bupivacaine
NCT0000172418	NCT00001724_18_T3	PHENOTYPE	13	13	analgesia
NCT0000172421	NCT00001724_21_T0	COMPOUND	11	11	midazolam
NCT0000172421	NCT00001724_21_T1	PHENOTYPE	8	8	anesthesia
NCT0000172422	NCT00001724_22_T0	ORGAN	10	11	third molars
NCT0000172423	NCT00001724_23_T0	COMPOUND	7	7	flurbiprofen
NCT0000172423	NCT00001724_23_T1	PHENOTYPE	5	5	allergy
NCT0000172423	NCT00001724_23_T2	COMPOUND	8	8	aspirin
NCT0000172424	NCT00001724_24_T0	COMPOUND	5	5	aspirin
NCT0000172424	NCT00001724_24_T1	PHENOTYPE	8	8	asthma
NCT0000172427	NCT00001724_27_T0	PHENOTYPE	18	18	impairment
NCT0000172428	NCT00001724_28_T0	PHENOTYPE	2	3	psychiatric disorders
NCT000017256	NCT00001725_6_T0	COMPOUND	26	26	lorazepam
NCT000017256	NCT00001725_6_T1	COMPOUND	8	8	dextromethorphan
NCT000017256	NCT00001725_6_T2	COMPOUND	24	24	dextromethorphan
NCT000017256	NCT00001725_6_T3	COMPOUND	10	10	topiramate
NCT000017258	NCT00001725_8_T0	COMPOUND	7	7	lorazepam
NCT0000172516	NCT00001725_16_T0	COMPOUND	15	15	dextromethorphan
NCT0000172516	NCT00001725_16_T1	COMPOUND	4	4	topiramate
NCT0000172517	NCT00001725_17_T0	GENE	12	12	has
NCT0000172517	NCT00001725_17_T1	COMPOUND	3	3	topiramate
NCT0000172523	NCT00001725_23_T0	COMPOUND	7	7	topiramate
NCT0000172524	NCT00001725_24_T0	COMPOUND	8	8	topiramate
NCT0000172530	NCT00001725_30_T0	PHENOTYPE	21	21	pathology
NCT0000172530	NCT00001725_30_T1	PHENOTYPE	28	28	pathology
NCT0000172530	NCT00001725_30_T2	PHENOTYPE	43	43	pathology
NCT0000172530	NCT00001725_30_T3	COMPOUND	8	8	dextromethorphan
NCT0000172530	NCT00001725_30_T4	COMPOUND	30	30	topiramate
NCT0000172530	NCT00001725_30_T5	ORGAN	19	20	trigeminal nerve
NCT0000172530	NCT00001725_30_T6	ORGAN	26	27	trigeminal nerve
NCT0000172530	NCT00001725_30_T7	ORGAN	41	42	trigeminal nerve
NCT0000172531	NCT00001725_31_T0	GENE	18	18	OR
NCT0000172531	NCT00001725_31_T1	COMPOUND	12	12	lorazepam
NCT0000172531	NCT00001725_31_T2	GENE	13	13	LOR
NCT0000172531	NCT00001725_31_T3	COMPOUND	9	9	dextromethorphan
NCT0000172531	NCT00001725_31_T4	COMPOUND	19	19	topiramate
NCT0000172541	NCT00001725_41_T0	PHENOTYPE	1	2	cognitive function
NCT0000172541	NCT00001725_41_T1	PHENOTYPE	5	6	language skills
NCT0000172544	NCT00001725_44_T0	PHENOTYPE	7	8	hepatic disease
NCT0000172546	NCT00001725_46_T0	PHENOTYPE	3	3	symptoms
NCT0000172546	NCT00001725_46_T1	PHENOTYPE	10	10	seizures
NCT0000172546	NCT00001725_46_T2	PHENOTYPE	7	8	neurologic disorder
NCT0000172549	NCT00001725_49_T0	PHENOTYPE	5	5	alcoholism
NCT0000172549	NCT00001725_49_T1	PHENOTYPE	1	1	chronic
NCT0000172549	NCT00001725_49_T2	PHENOTYPE	2	3	substance abuse
NCT000017261	NCT00001726_1_T0	PHENOTYPE	5	5	plaque
NCT0000172611	NCT00001726_11_T0	ORGAN	15	15	teeth
NCT0000172614	NCT00001726_14_T0	GENE	21	21	saliva
NCT0000172614	NCT00001726_14_T1	PHENOTYPE	15	15	spit
NCT0000172616	NCT00001726_16_T0	ORGAN	7	7	teeth
NCT0000172616	NCT00001726_16_T1	ORGAN	21	21	teeth
NCT0000172620	NCT00001726_20_T0	GENE	22	22	saliva
NCT0000172620	NCT00001726_20_T1	PHENOTYPE	16	16	spit
NCT0000172622	NCT00001726_22_T0	ORGAN	16	16	enamel
NCT0000172622	NCT00001726_22_T1	ORGAN	21	22	oral cavity
NCT0000172626	NCT00001726_26_T0	GENE	1	1	spp
NCT0000172628	NCT00001726_28_T0	CELL	11	11	cells
NCT0000172629	NCT00001726_29_T0	ORGAN	30	30	enamel
NCT0000172629	NCT00001726_29_T1	PHENOTYPE	10	11	dental plaque
NCT0000172632	NCT00001726_32_T0	PHENOTYPE	12	12	adhesions
NCT0000172632	NCT00001726_32_T1	PHENOTYPE	3	3	strains
NCT0000172632	NCT00001726_32_T2	PHENOTYPE	17	17	strains
NCT0000172637	NCT00001726_37_T0	PHENOTYPE	9	10	dental plaque
NCT0000172643	NCT00001726_43_T0	ORGAN	7	7	molar
NCT0000172643	NCT00001726_43_T1	ORGAN	3	3	premolar
NCT000017275	NCT00001727_5_T0	PHENOTYPE	18	19	bone disease
NCT0000172712	NCT00001727_12_T0	PHENOTYPE	18	19	bone disease
NCT000017284	NCT00001728_4_T0	COMPOUND	4	4	bisphosphonates
NCT000017286	NCT00001728_6_T0	PHENOTYPE	20	21	McCune-Albright Syndrome
NCT000017286	NCT00001728_6_T1	PHENOTYPE	16	18	Polyostotic Fibrous Dysplasia
NCT000017287	NCT00001728_7_T0	COMPOUND	20	20	alendronate
NCT000017287	NCT00001728_7_T1	GENE	27	27	has
NCT0000172810	NCT00001728_10_T0	COMPOUND	9	9	calcium
NCT0000172810	NCT00001728_10_T1	COMPOUND	29	29	calcium
NCT0000172810	NCT00001728_10_T2	PHENOTYPE	15	15	secondary
NCT0000172810	NCT00001728_10_T3	COMPOUND	2	2	alendronate
NCT0000172810	NCT00001728_10_T4	COMPOUND	20	20	alendronate
NCT0000172810	NCT00001728_10_T5	PHENOTYPE	17	18	side effect
NCT0000172810	NCT00001728_10_T6	COMPOUND	11	12	vitamin D
NCT0000172812	NCT00001728_12_T0	GENE	21	21	duplicated
NCT0000172814	NCT00001728_14_T0	COMPOUND	7	7	alendronate
NCT0000172814	NCT00001728_14_T1	COMPOUND	24	24	alendronate
NCT0000172820	NCT00001728_20_T0	PHENOTYPE	9	10	bone disease
NCT0000172821	NCT00001728_21_T0	COMPOUND	8	8	pamidronate
NCT0000172821	NCT00001728_21_T1	COMPOUND	11	11	bisphosphonates
NCT0000172822	NCT00001728_22_T0	COMPOUND	16	16	alendronate
NCT0000172822	NCT00001728_22_T1	PHENOTYPE	21	22	fibrous dysplasia
NCT0000172825	NCT00001728_25_T0	PHENOTYPE	8	8	dysplastic
NCT0000172825	NCT00001728_25_T1	ORGAN	17	17	skeleton
NCT0000172836	NCT00001728_36_T0	BIOLOGICAL_PROCESS	8	8	lactation
NCT0000172837	NCT00001728_37_T0	PHENOTYPE	11	11	complications
NCT0000172837	NCT00001728_37_T1	PHENOTYPE	2	2	motility
NCT0000172837	NCT00001728_37_T2	COMPOUND	13	13	alendronate
NCT000017290	NCT00001729_0_T0	PHENOTYPE	6	7	Hepatitis C
NCT000017294	NCT00001729_4_T0	GENE	0	0	Interferon
NCT000017294	NCT00001729_4_T1	GENE	20	20	has
NCT0000172910	NCT00001729_10_T0	PHENOTYPE	6	7	hepatitis C
NCT0000172911	NCT00001729_11_T0	PHENOTYPE	28	28	strain
NCT0000172915	NCT00001729_15_T0	ORGAN	17	17	liver
NCT0000172916	NCT00001729_16_T0	PHENOTYPE	7	8	hepatitis C
NCT0000172916	NCT00001729_16_T1	PHENOTYPE	14	15	liver enzymes
NCT0000172917	NCT00001729_17_T0	COMPOUND	13	13	ribavirin
NCT0000172918	NCT00001729_18_T0	COMPOUND	12	12	ribavirin
NCT0000172920	NCT00001729_20_T0	COMPOUND	10	10	HCV
NCT0000172920	NCT00001729_20_T1	ORGAN	13	13	serum
NCT0000172920	NCT00001729_20_T2	ORGAN	17	17	serum
NCT0000172920	NCT00001729_20_T3	PHENOTYPE	7	8	chronic hepatitis
NCT0000172920	NCT00001729_20_T4	PHENOTYPE	8	9	hepatitis C
NCT0000172923	NCT00001729_23_T0	COMPOUND	8	8	ribavirin
NCT0000172925	NCT00001729_25_T0	COMPOUND	14	14	HCV
NCT0000172925	NCT00001729_25_T1	ORGAN	18	18	serum
NCT0000172927	NCT00001729_27_T0	COMPOUND	12	12	ribavirin
NCT0000172927	NCT00001729_27_T1	GENE	3	3	interferon
NCT0000172928	NCT00001729_28_T0	ORGAN	19	19	liver
NCT0000172929	NCT00001729_29_T0	COMPOUND	3	3	ribavirin
NCT0000172929	NCT00001729_29_T1	GENE	13	13	had
NCT0000172929	NCT00001729_29_T2	GENE	12	12	has
NCT0000172930	NCT00001729_30_T0	COMPOUND	20	20	ribavirin
NCT0000172930	NCT00001729_30_T1	GENE	24	24	reduced
NCT0000172930	NCT00001729_30_T2	BIOLOGICAL_PROCESS	7	9	response to ribavirin
NCT0000172932	NCT00001729_32_T0	ORGAN	21	21	liver
NCT0000172933	NCT00001729_33_T0	COMPOUND	3	3	ribavirin
NCT0000172933	NCT00001729_33_T1	COMPOUND	15	15	ribavirin
NCT0000172933	NCT00001729_33_T2	COMPOUND	21	21	ribavirin
NCT0000172933	NCT00001729_33_T3	GENE	22	22	has
NCT0000172933	NCT00001729_33_T4	PHENOTYPE	28	29	hepatitis C
NCT0000172934	NCT00001729_34_T0	COMPOUND	13	13	HCV
NCT0000172935	NCT00001729_35_T0	COMPOUND	12	12	ribavirin
NCT0000172935	NCT00001729_35_T1	ORGAN	22	22	liver
NCT0000172941	NCT00001729_41_T0	COMPOUND	2	2	HCV
NCT0000172941	NCT00001729_41_T1	COMPOUND	4	4	HCV
NCT0000172941	NCT00001729_41_T2	ORGAN	7	7	serum
NCT0000172942	NCT00001729_42_T0	ORGAN	5	5	liver
NCT0000172942	NCT00001729_42_T1	PHENOTYPE	2	3	chronic hepatitis
NCT0000172944	NCT00001729_44_T0	COMPOUND	8	8	ribavirin
NCT0000172944	NCT00001729_44_T1	COMPOUND	24	24	HCV
NCT0000172944	NCT00001729_44_T2	ORGAN	27	27	serum
NCT0000172944	NCT00001729_44_T3	GENE	6	6	interferon
NCT0000172946	NCT00001729_46_T0	GENE	14	14	3.0
NCT0000172946	NCT00001729_46_T1	GENE	16	16	prothrombin
NCT0000172946	NCT00001729_46_T2	GENE	21	21	sec
NCT0000172946	NCT00001729_46_T3	PHENOTYPE	28	28	varices
NCT0000172946	NCT00001729_46_T4	PHENOTYPE	29	29	ascites
NCT0000172946	NCT00001729_46_T5	GENE	11	11	albumin
NCT0000172946	NCT00001729_46_T6	COMPOUND	6	6	bilirubin
NCT0000172946	NCT00001729_46_T7	PHENOTYPE	1	2	liver disease
NCT0000172946	NCT00001729_46_T8	PHENOTYPE	31	32	hepatic encephalopathy
NCT0000172946	NCT00001729_46_T9	PHENOTYPE	26	27	bleeding esophageal
NCT0000172953	NCT00001729_53_T0	PHENOTYPE	8	9	vascular disease
NCT0000172953	NCT00001729_53_T1	PHENOTYPE	3	5	coronary artery disease
NCT0000172953	NCT00001729_53_T2	PHENOTYPE	30	32	coronary artery disease
NCT0000172954	NCT00001729_54_T0	PHENOTYPE	1	2	substance abuse
NCT0000172955	NCT00001729_55_T0	GENE	6	6	AFP
NCT0000172955	NCT00001729_55_T1	PHENOTYPE	30	31	liver cancer
NCT0000172955	NCT00001729_55_T2	PHENOTYPE	2	3	hepatocellular carcinoma
NCT000017303	NCT00001730_3_T0	ORGAN	4	4	thyroid
NCT000017303	NCT00001730_3_T1	ORGAN	8	8	thyroid
NCT000017303	NCT00001730_3_T2	GENE	9	9	hormone
NCT000017305	NCT00001730_5_T0	ORGAN	20	20	thyroid
NCT000017305	NCT00001730_5_T1	COMPOUND	12	12	iodine
NCT000017307	NCT00001730_7_T0	ORGAN	9	9	thyroid
NCT000017307	NCT00001730_7_T1	COMPOUND	15	15	iodine
NCT0000173010	NCT00001730_10_T0	ORGAN	1	1	thyroid
NCT0000173010	NCT00001730_10_T1	GENE	20	20	TSH
NCT0000173010	NCT00001730_10_T2	GENE	2	2	hormone
NCT0000173010	NCT00001730_10_T3	ORGAN	12	13	pituitary gland
NCT0000173011	NCT00001730_11_T0	ORGAN	6	6	thyroid
NCT0000173011	NCT00001730_11_T1	GENE	11	11	TSH
NCT0000173011	NCT00001730_11_T2	GENE	7	7	hormone
NCT0000173012	NCT00001730_12_T0	ORGAN	9	9	thyroid
NCT0000173012	NCT00001730_12_T1	PHENOTYPE	16	16	hypothyroidism
NCT0000173012	NCT00001730_12_T2	GENE	10	10	hormone
NCT0000173013	NCT00001730_13_T0	PHENOTYPE	9	9	symptoms
NCT0000173014	NCT00001730_14_T0	GENE	0	0	TSH
NCT0000173014	NCT00001730_14_T1	GENE	1	1	has
NCT0000173015	NCT00001730_15_T0	GENE	7	7	TSH
NCT0000173015	NCT00001730_15_T1	ORGAN	12	13	pituitary gland
NCT0000173016	NCT00001730_16_T0	ORGAN	14	14	thyroid
NCT0000173016	NCT00001730_16_T1	GENE	6	6	TSH
NCT0000173017	NCT00001730_17_T0	PHENOTYPE	5	5	hypothyroidism
NCT0000173017	NCT00001730_17_T1	COMPOUND	11	11	iodine
NCT0000173018	NCT00001730_18_T0	ORGAN	19	19	thyroid
NCT0000173018	NCT00001730_18_T1	ORGAN	27	27	thyroid
NCT0000173018	NCT00001730_18_T2	PHENOTYPE	24	24	hypothyroid
NCT0000173018	NCT00001730_18_T3	PHENOTYPE	31	31	withdrawn
NCT0000173019	NCT00001730_19_T0	COMPOUND	10	10	iodine
NCT0000173020	NCT00001730_20_T0	ORGAN	25	25	thyroid
NCT0000173021	NCT00001730_21_T0	PHENOTYPE	6	8	medullary thyroid cancer
NCT0000173025	NCT00001730_25_T0	ORGAN	14	14	thyroid
NCT0000173025	NCT00001730_25_T1	ORGAN	23	23	thyroid
NCT0000173025	NCT00001730_25_T2	GENE	15	15	hormone
NCT0000173025	NCT00001730_25_T3	GENE	24	24	hormone
NCT0000173026	NCT00001730_26_T0	PHENOTYPE	7	7	hypothyroid
NCT0000173029	NCT00001730_29_T0	PHENOTYPE	0	0	Secondary
NCT0000173029	NCT00001730_29_T1	PHENOTYPE	22	22	hypothyroid
NCT0000173030	NCT00001730_30_T0	PHENOTYPE	5	7	medullary thyroid cancer
NCT0000173032	NCT00001730_32_T0	ORGAN	15	15	thyroid
NCT0000173032	NCT00001730_32_T1	ORGAN	25	25	thyroid
NCT0000173032	NCT00001730_32_T2	GENE	16	16	hormone
NCT0000173032	NCT00001730_32_T3	GENE	26	26	hormone
NCT0000173033	NCT00001730_33_T0	PHENOTYPE	7	7	hypothyroid
NCT0000173036	NCT00001730_36_T0	GENE	22	22	99
NCT0000173036	NCT00001730_36_T1	COMPOUND	20	20	technetium
NCT0000173036	NCT00001730_36_T2	ORGAN	6	6	thyroid
NCT0000173036	NCT00001730_36_T3	ORGAN	9	9	thyroid
NCT0000173036	NCT00001730_36_T4	COMPOUND	23	23	pertechnetate
NCT0000173036	NCT00001730_36_T5	COMPOUND	25	25	thallium
NCT0000173037	NCT00001730_37_T0	ORGAN	7	7	thyroid
NCT0000173042	NCT00001730_42_T0	PHENOTYPE	19	20	pituitary dysfunction
NCT0000173043	NCT00001730_43_T0	ORGAN	20	20	liver
NCT0000173043	NCT00001730_43_T1	PHENOTYPE	14	15	cardiopulmonary disease
NCT0000173043	NCT00001730_43_T2	PHENOTYPE	24	25	pulmonary disease
NCT0000173043	NCT00001730_43_T3	PHENOTYPE	17	18	renal failure
NCT0000173047	NCT00001730_47_T0	COMPOUND	15	15	lithium
NCT0000173047	NCT00001730_47_T1	ORGAN	8	8	thyroid
NCT000017318	NCT00001731_8_T0	PHENOTYPE	14	15	dry eyes
NCT0000173116	NCT00001731_16_T0	GENE	1	1	SS
NCT0000173116	NCT00001731_16_T1	PHENOTYPE	2	3	lymphocytic infiltration
NCT0000173116	NCT00001731_16_T2	TISSUE	6	7	lacrimal gland
NCT0000173126	NCT00001731_26_T0	PHENOTYPE	1	3	negative pregnancy test
NCT0000173127	NCT00001731_27_T0	GENE	1	1	lid
NCT0000173128	NCT00001731_28_T0	COMPOUND	35	35	estrogen
NCT0000173128	NCT00001731_28_T1	GENE	17	17	has
NCT0000173133	NCT00001731_33_T0	COMPOUND	9	9	cyclosporine
NCT0000173134	NCT00001731_34_T0	ORGAN	15	15	eyes
NCT0000173134	NCT00001731_34_T1	PHENOTYPE	12	12	anesthesia
NCT0000173134	NCT00001731_34_T2	TISSUE	22	23	lacrimal gland
NCT0000173136	NCT00001731_36_T0	PHENOTYPE	7	7	recurrent
NCT0000173136	NCT00001731_36_T1	PHENOTYPE	8	9	herpes keratitis
NCT0000173137	NCT00001731_37_T0	GENE	20	20	SPK
NCT0000173137	NCT00001731_37_T1	PHENOTYPE	10	11	corneal sensitivity
NCT0000173137	NCT00001731_37_T2	PHENOTYPE	4	5	corneal disorder
NCT0000173138	NCT00001731_38_T0	PHENOTYPE	8	8	inflammation
NCT0000173138	NCT00001731_38_T1	GENE	11	11	lid
NCT0000173138	NCT00001731_38_T2	PHENOTYPE	5	5	blepharitis
NCT0000173139	NCT00001731_39_T0	GENE	7	7	collagen
NCT0000173140	NCT00001731_40_T0	PHENOTYPE	2	2	occlusion
NCT0000173217	NCT00001732_17_T0	GENE	17	17	III
NCT000017331	NCT00001733_1_T0	PHENOTYPE	23	24	retinal disease
NCT000017335	NCT00001733_5_T0	COMPOUND	4	4	fluorescein
NCT0000173317	NCT00001733_17_T0	GENE	17	17	III
NCT0000173414	NCT00001734_14_T0	GENE	17	17	III
NCT0000173420	NCT00001734_20_T0	GENE	10	10	OR
NCT0000173421	NCT00001734_21_T0	GENE	0	0	2.2
NCT0000173422	NCT00001734_22_T0	GENE	5	5	OR
NCT000017352	NCT00001735_2_T0	COMPOUND	25	25	ornithine
NCT000017352	NCT00001735_2_T1	GENE	17	17	OAT
NCT000017352	NCT00001735_2_T2	GENE	15	16	ornithine aminotransferase
NCT000017352	NCT00001735_2_T3	PHENOTYPE	0	1	Gyrate atrophy
NCT000017353	NCT00001735_3_T0	COMPOUND	4	4	ornithine
NCT000017353	NCT00001735_3_T1	PHENOTYPE	8	9	retinal thinning
NCT000017356	NCT00001735_6_T0	GENE	7	7	defective
NCT0000173511	NCT00001735_11_T0	CELL	2	2	cells
NCT0000173511	NCT00001735_11_T1	CELL	4	4	keratinocytes
NCT0000173512	NCT00001735_12_T0	GENE	5	5	OAT
NCT0000173512	NCT00001735_12_T1	CELL	10	10	cells
NCT0000173518	NCT00001735_18_T0	CELL	8	8	cells
NCT0000173518	NCT00001735_18_T1	GENE	4	4	1.4
NCT0000173519	NCT00001735_19_T0	GENE	13	13	OAT
NCT0000173519	NCT00001735_19_T1	CELL	8	8	cells
NCT0000173520	NCT00001735_20_T0	COMPOUND	12	12	ornithine
NCT0000173522	NCT00001735_22_T0	COMPOUND	15	15	fluorescein
NCT0000173522	NCT00001735_22_T1	GENE	5	5	ERG
NCT0000173524	NCT00001735_24_T0	PHENOTYPE	12	12	complications
NCT0000173524	NCT00001735_24_T1	CELL	26	26	keratinocytes
NCT0000173524	NCT00001735_24_T2	BIOLOGICAL_PROCESS	15	16	immune response
NCT0000173526	NCT00001735_26_T0	GENE	23	23	OAT
NCT0000173526	NCT00001735_26_T1	CELL	0	0	Keratinocytes
NCT0000173526	NCT00001735_26_T2	GENE	18	18	GMP
NCT0000173527	NCT00001735_27_T0	ORGAN	21	21	graft
NCT0000173527	NCT00001735_27_T1	ORGAN	13	13	thigh
NCT0000173527	NCT00001735_27_T2	CELL	3	3	keratinocytes
NCT0000173529	NCT00001735_29_T0	PHENOTYPE	10	10	secondary
NCT0000173529	NCT00001735_29_T1	COMPOUND	50	50	ornithine
NCT0000173529	NCT00001735_29_T2	GENE	21	21	OAT
NCT0000173529	NCT00001735_29_T3	CELL	17	17	keratinocytes
NCT0000173529	NCT00001735_29_T4	CELL	42	42	keratinocytes
NCT0000173529	NCT00001735_29_T5	ORGAN	47	47	serum
NCT0000173531	NCT00001735_31_T0	GENE	7	7	blot
NCT0000173531	NCT00001735_31_T1	GENE	2	2	OAT
NCT0000173531	NCT00001735_31_T2	MOLECULAR_FUNCTION	11	12	enzyme activity
NCT0000173534	NCT00001735_34_T0	PHENOTYPE	30	30	initiation
NCT0000173536	NCT00001735_36_T0	PHENOTYPE	9	9	atrophy
NCT0000173536	NCT00001735_36_T1	PHENOTYPE	2	2	progression
NCT0000173536	NCT00001735_36_T2	PHENOTYPE	20	20	progression
NCT0000173537	NCT00001735_37_T0	COMPOUND	12	12	ornithine
NCT0000173537	NCT00001735_37_T1	GENE	1	1	has
NCT0000173538	NCT00001735_38_T0	GENE	1	1	has
NCT0000173540	NCT00001735_40_T0	PHENOTYPE	5	5	malignancy
NCT0000173540	NCT00001735_40_T1	PHENOTYPE	7	8	chronic infection
NCT000017361	NCT00001736_1_T0	PHENOTYPE	0	0	Cystinosis
NCT000017361	NCT00001736_1_T1	GENE	8	8	defective
NCT000017361	NCT00001736_1_T2	PHENOTYPE	3	4	inherited disease
NCT000017368	NCT00001736_8_T0	PHENOTYPE	9	9	cystinosis
NCT0000173610	NCT00001736_10_T0	PHENOTYPE	8	8	waking
NCT0000173614	NCT00001736_14_T0	GENE	6	6	Ann
NCT0000173617	NCT00001736_17_T0	ORGAN	11	11	eyes
NCT0000173622	NCT00001736_22_T0	GENE	5	5	slit
NCT0000173622	NCT00001736_22_T1	PHENOTYPE	22	22	Center
NCT0000173622	NCT00001736_22_T2	GENE	6	6	lamp
NCT0000173630	NCT00001736_30_T0	PHENOTYPE	7	7	cystinosis
NCT0000173630	NCT00001736_30_T1	GENE	1	1	has
NCT0000173635	NCT00001736_35_T0	GENE	9	9	has
NCT0000173637	NCT00001736_37_T0	PHENOTYPE	3	3	cystinosis
NCT0000173638	NCT00001736_38_T0	PHENOTYPE	7	7	cystinosis
NCT0000173638	NCT00001736_38_T1	GENE	1	1	has
NCT0000173645	NCT00001736_45_T0	COMPOUND	4	4	cysteamine
NCT000017371	NCT00001737_1_T0	COMPOUND	12	12	cyclosporin
NCT000017371	NCT00001737_1_T1	PHENOTYPE	17	18	chronic uveitis
NCT000017372	NCT00001737_2_T0	PHENOTYPE	0	0	Uveitis
NCT000017372	NCT00001737_2_T1	COMPOUND	11	11	cyclosporin
NCT000017372	NCT00001737_2_T2	COMPOUND	12	12	cyclophosphamide
NCT000017372	NCT00001737_2_T3	COMPOUND	14	14	azathioprine
NCT000017372	NCT00001737_2_T4	COMPOUND	13	13	methotrexate
NCT000017376	NCT00001737_6_T0	COMPOUND	4	4	cyclosporin
NCT000017379	NCT00001737_9_T0	PHENOTYPE	6	6	inflammation
NCT000017379	NCT00001737_9_T1	PHENOTYPE	2	2	uveitis
NCT000017379	NCT00001737_9_T2	PHENOTYPE	8	9	poor vision
NCT0000173711	NCT00001737_11_T0	GENE	25	25	1.4
NCT0000173711	NCT00001737_11_T1	GENE	9	9	0.8
NCT0000173715	NCT00001737_15_T0	GENE	9	9	1.5
NCT0000173715	NCT00001737_15_T1	PHENOTYPE	20	20	anesthesia
NCT0000173719	NCT00001737_19_T0	COMPOUND	8	8	cyclosporin
NCT0000173719	NCT00001737_19_T1	ORGAN	18	18	kidneys
NCT0000173727	NCT00001737_27_T0	PHENOTYPE	0	0	Secondary
NCT0000173727	NCT00001737_27_T1	PHENOTYPE	10	11	ocular inflammation
NCT0000173729	NCT00001737_29_T0	PHENOTYPE	5	5	panuveitis
NCT0000173729	NCT00001737_29_T1	COMPOUND	23	23	prednisone
NCT0000173734	NCT00001737_34_T0	GENE	2	2	ERG
NCT0000173737	NCT00001737_37_T0	ORGAN	1	1	serum
NCT0000173739	NCT00001737_39_T0	PHENOTYPE	6	7	retinal detachment
NCT0000173740	NCT00001737_40_T0	PHENOTYPE	7	8	retinal detachment
NCT0000173743	NCT00001737_43_T0	BIOLOGICAL_PROCESS	35	35	spermatogenesis
NCT0000173745	NCT00001737_45_T0	PHENOTYPE	4	4	allergy
NCT000017384	NCT00001738_4_T0	GENE	12	12	cc
NCT000017384	NCT00001738_4_T1	GENE	22	22	VEGF
NCT000017384	NCT00001738_4_T2	PHENOTYPE	2	2	uveitis
NCT0000173810	NCT00001738_10_T0	GENE	8	8	VEGF
NCT0000173810	NCT00001738_10_T1	PHENOTYPE	26	26	neovascularization
NCT0000173810	NCT00001738_10_T2	PHENOTYPE	15	15	uveitis
NCT0000173810	NCT00001738_10_T3	ORGAN	19	19	eyes
NCT0000173811	NCT00001738_11_T0	GENE	8	8	VEGF
NCT0000173811	NCT00001738_11_T1	PHENOTYPE	18	19	macular edema
NCT0000173815	NCT00001738_15_T0	COMPOUND	12	12	fluorescein
NCT0000173815	NCT00001738_15_T1	PHENOTYPE	9	10	macular edema
NCT000017402	NCT00001740_2_T0	PHENOTYPE	8	8	estimation
NCT000017402	NCT00001740_2_T1	GENE	11	11	ventricular
NCT000017404	NCT00001740_4_T0	GENE	13	13	ventricular
NCT000017405	NCT00001740_5_T0	GENE	6	6	ventricular
NCT000017408	NCT00001740_8_T0	PHENOTYPE	8	8	estimation
NCT000017408	NCT00001740_8_T1	GENE	11	11	ventricular
NCT0000174010	NCT00001740_10_T0	GENE	13	13	ventricular
NCT0000174011	NCT00001740_11_T0	GENE	6	6	ventricular
NCT000017421	NCT00001742_1_T0	CELL	1	1	cells
NCT000017421	NCT00001742_1_T1	ORGAN	9	10	blood vessels
NCT000017422	NCT00001742_2_T0	TISSUE	5	5	endothelium
NCT000017422	NCT00001742_2_T1	ORGAN	15	16	blood vessels
NCT000017422	NCT00001742_2_T2	PHENOTYPE	18	20	high blood pressure
NCT000017422	NCT00001742_2_T3	PHENOTYPE	10	13	diseases of the heart
NCT000017423	NCT00001742_3_T0	GENE	3	3	pointed
NCT000017423	NCT00001742_3_T1	GENE	2	2	has
NCT000017423	NCT00001742_3_T2	COMPOUND	11	12	nitric oxide
NCT000017424	NCT00001742_4_T0	TISSUE	11	11	endothelium
NCT000017424	NCT00001742_4_T1	CELL	8	8	cells
NCT000017424	NCT00001742_4_T2	ORGAN	20	21	blood vessels
NCT000017425	NCT00001742_5_T0	ORGAN	15	15	forearms
NCT000017425	NCT00001742_5_T1	COMPOUND	24	24	L-NMMA
NCT000017425	NCT00001742_5_T2	COMPOUND	26	26	aspirin
NCT000017425	NCT00001742_5_T3	COMPOUND	23	23	acetylcholine
NCT000017425	NCT00001742_5_T4	ORGAN	11	12	blood vessels
NCT000017425	NCT00001742_5_T5	COMPOUND	21	22	sodium nitroprusside
NCT000017426	NCT00001742_6_T0	ORGAN	10	10	forearm
NCT000017426	NCT00001742_6_T1	ORGAN	6	7	blood vessels
NCT000017427	NCT00001742_7_T0	ORGAN	13	13	forearm
NCT000017427	NCT00001742_7_T1	COMPOUND	2	3	sodium nitroprusside
NCT000017427	NCT00001742_7_T2	ORGAN	9	10	blood vessels
NCT000017428	NCT00001742_8_T0	PHENOTYPE	5	5	blocks
NCT000017428	NCT00001742_8_T1	COMPOUND	0	0	L-NMMA
NCT000017428	NCT00001742_8_T2	COMPOUND	8	9	nitric oxide
NCT0000174211	NCT00001742_11_T0	PHENOTYPE	9	9	diseases
NCT0000174211	NCT00001742_11_T1	ORGAN	15	15	heart
NCT0000174211	NCT00001742_11_T2	ORGAN	12	13	blood vessels
NCT0000174213	NCT00001742_13_T0	TISSUE	5	5	endothelium
NCT0000174213	NCT00001742_13_T1	PHENOTYPE	18	18	hypercholesterolemia
NCT0000174213	NCT00001742_13_T2	PHENOTYPE	15	16	essential hypertension
NCT0000174214	NCT00001742_14_T0	TISSUE	11	11	endothelium
NCT0000174214	NCT00001742_14_T1	COMPOUND	12	13	nitric oxide
NCT0000174215	NCT00001742_15_T0	GENE	2	2	reduced
NCT0000174216	NCT00001742_16_T0	GENE	22	22	reduced
NCT0000174216	NCT00001742_16_T1	GENE	15	15	cyclooxygenase
NCT0000174216	NCT00001742_16_T2	GENE	16	16	COX
NCT0000174216	NCT00001742_16_T3	PHENOTYPE	30	30	hypercholesterolemia
NCT0000174216	NCT00001742_16_T4	PHENOTYPE	27	28	essential hypertension
NCT0000174219	NCT00001742_19_T0	GENE	9	9	FBF
NCT0000174219	NCT00001742_19_T1	ORGAN	6	6	forearm
NCT0000174219	NCT00001742_19_T2	GENE	15	15	ASA
NCT0000174220	NCT00001742_20_T0	PHENOTYPE	23	23	strain
NCT0000174220	NCT00001742_20_T1	ORGAN	18	18	forearm
NCT0000174220	NCT00001742_20_T2	ORGAN	8	9	brachial artery
NCT0000174222	NCT00001742_22_T0	PHENOTYPE	3	3	allergies
NCT0000174222	NCT00001742_22_T1	COMPOUND	2	2	aspirin
NCT0000174222	NCT00001742_22_T2	PHENOTYPE	8	9	platelet count
NCT000017461	NCT00001746_1_T0	PHENOTYPE	10	10	illnesses
NCT000017461	NCT00001746_1_T1	ORGAN	6	6	heart
NCT000017462	NCT00001746_2_T0	PHENOTYPE	18	18	symptoms
NCT000017462	NCT00001746_2_T1	PHENOTYPE	23	24	heart diseases
NCT000017463	NCT00001746_3_T0	PHENOTYPE	17	18	heart disease
NCT000017465	NCT00001746_5_T0	ORGAN	17	17	heart
NCT000017472	NCT00001747_2_T0	PHENOTYPE	22	23	heart disease
NCT000017472	NCT00001747_2_T1	ORGAN	9	10	blood vessels
NCT000017472	NCT00001747_2_T2	PHENOTYPE	6	7	biological processes
NCT000017473	NCT00001747_3_T0	ORGAN	3	4	blood vessels
NCT000017473	NCT00001747_3_T1	ORGAN	17	18	blood vessels
NCT000017473	NCT00001747_3_T2	PHENOTYPE	22	24	increased blood pressure
NCT000017474	NCT00001747_4_T0	PHENOTYPE	9	9	dilation
NCT000017474	NCT00001747_4_T1	CELL	15	15	cells
NCT000017474	NCT00001747_4_T2	ORGAN	7	7	artery
NCT000017474	NCT00001747_4_T3	ORGAN	17	18	blood vessels
NCT000017475	NCT00001747_5_T0	ORGAN	27	27	heart
NCT000017475	NCT00001747_5_T1	PHENOTYPE	24	25	heart disease
NCT000017478	NCT00001747_8_T0	PHENOTYPE	21	22	cardiovascular disease
NCT000017479	NCT00001747_9_T0	GENE	7	7	has
NCT000017479	NCT00001747_9_T1	PHENOTYPE	23	23	hypertension
NCT000017479	NCT00001747_9_T2	ORGAN	6	6	microvasculature
NCT0000174711	NCT00001747_11_T0	PHENOTYPE	21	21	atherosclerosis
NCT0000174711	NCT00001747_11_T1	ORGAN	12	12	arteries
NCT0000174711	NCT00001747_11_T2	PHENOTYPE	7	8	endothelial dysfunction
NCT0000174711	NCT00001747_11_T3	PHENOTYPE	37	39	coronary heart disease
NCT0000174712	NCT00001747_12_T0	TISSUE	14	14	endothelium
NCT0000174712	NCT00001747_12_T1	PHENOTYPE	10	10	dilation
NCT0000174712	NCT00001747_12_T2	ORGAN	8	9	brachial artery
NCT0000174712	NCT00001747_12_T3	PHENOTYPE	41	42	cardiovascular morbidity
NCT000017480	NCT00001748_0_T0	PHENOTYPE	1	1	Peripheral
NCT000017480	NCT00001748_0_T1	PHENOTYPE	9	10	Hematological Malignancies
NCT000017482	NCT00001748_2_T0	ORGAN	9	9	transplant
NCT000017484	NCT00001748_4_T0	ORGAN	7	7	graft
NCT000017484	NCT00001748_4_T1	ORGAN	5	5	transplants
NCT000017484	NCT00001748_4_T2	PHENOTYPE	9	10	graft-vs-host disease
NCT000017485	NCT00001748_5_T0	ORGAN	6	6	transplants
NCT000017485	NCT00001748_5_T1	PHENOTYPE	20	21	hematological malignancy
NCT000017488	NCT00001748_8_T0	PHENOTYPE	15	16	graft failure
NCT000017489	NCT00001748_9_T0	PHENOTYPE	9	9	acute
NCT000017489	NCT00001748_9_T1	ORGAN	7	7	graft
NCT000017489	NCT00001748_9_T2	PHENOTYPE	14	14	relapse
NCT000017489	NCT00001748_9_T3	ORGAN	15	15	transplant
NCT000017489	NCT00001748_9_T4	PHENOTYPE	12	12	GVHD
NCT000017489	NCT00001748_9_T5	PHENOTYPE	11	11	chronic
NCT0000174813	NCT00001748_13_T0	ORGAN	9	9	transplant
NCT0000174815	NCT00001748_15_T0	ORGAN	7	7	graft
NCT0000174815	NCT00001748_15_T1	ORGAN	5	5	transplants
NCT0000174815	NCT00001748_15_T2	PHENOTYPE	9	10	graft-vs-host disease
NCT0000174816	NCT00001748_16_T0	ORGAN	6	6	transplants
NCT0000174816	NCT00001748_16_T1	PHENOTYPE	20	21	hematological malignancy
NCT0000174819	NCT00001748_19_T0	PHENOTYPE	15	16	graft failure
NCT0000174820	NCT00001748_20_T0	PHENOTYPE	9	9	acute
NCT0000174820	NCT00001748_20_T1	ORGAN	7	7	graft
NCT0000174820	NCT00001748_20_T2	PHENOTYPE	14	14	relapse
NCT0000174820	NCT00001748_20_T3	ORGAN	15	15	transplant
NCT0000174820	NCT00001748_20_T4	PHENOTYPE	12	12	GVHD
NCT0000174820	NCT00001748_20_T5	PHENOTYPE	11	11	chronic
NCT0000174824	NCT00001748_24_T0	PHENOTYPE	0	2	Chronic myelogenous leukemia
NCT0000174825	NCT00001748_25_T0	PHENOTYPE	32	32	leukemia
NCT0000174825	NCT00001748_25_T1	CELL	19	19	leukocyte
NCT0000174825	NCT00001748_25_T2	PHENOTYPE	14	14	remission
NCT0000174825	NCT00001748_25_T3	PHENOTYPE	0	2	Acute lymphoblastic leukemia
NCT0000174826	NCT00001748_26_T0	PHENOTYPE	13	13	relapse
NCT0000174826	NCT00001748_26_T1	PHENOTYPE	8	8	remission
NCT0000174826	NCT00001748_26_T2	PHENOTYPE	2	2	remissions
NCT0000174827	NCT00001748_27_T0	PHENOTYPE	3	3	AML
NCT0000174827	NCT00001748_27_T1	PHENOTYPE	5	5	AML
NCT0000174827	NCT00001748_27_T2	PHENOTYPE	19	19	relapse
NCT0000174827	NCT00001748_27_T3	PHENOTYPE	10	10	remission
NCT0000174827	NCT00001748_27_T4	PHENOTYPE	16	16	remission
NCT0000174827	NCT00001748_27_T5	PHENOTYPE	18	18	resistant
NCT0000174827	NCT00001748_27_T6	PHENOTYPE	0	2	Acute myelogenous leukemia
NCT0000174828	NCT00001748_28_T0	PHENOTYPE	0	1	Myelodysplastic syndromes
NCT0000174828	NCT00001748_28_T1	PHENOTYPE	14	15	acute leukemia
NCT0000174828	NCT00001748_28_T2	PHENOTYPE	16	18	chronic myelomonocytic leukemia
NCT0000174828	NCT00001748_28_T3	PHENOTYPE	6	10	refractory anemia with excess of
NCT0000174829	NCT00001748_29_T0	PHENOTYPE	0	1	Myeloproliferative disorders
NCT0000174830	NCT00001748_30_T0	PHENOTYPE	3	3	CLL
NCT0000174830	NCT00001748_30_T1	PHENOTYPE	5	6	Richter transformation
NCT0000174830	NCT00001748_30_T2	PHENOTYPE	0	2	Chronic lymphocytic leukemia
NCT0000174832	NCT00001748_32_T0	PHENOTYPE	3	3	dysfunction
NCT0000174834	NCT00001748_34_T0	PHENOTYPE	1	3	ventricular ejection fraction
NCT0000174838	NCT00001748_38_T0	PHENOTYPE	6	8	negative pregnancy test
NCT0000174840	NCT00001748_40_T0	GENE	3	3	G-CSF
NCT0000174840	NCT00001748_40_T1	CELL	6	9	peripheral blood stem cells
NCT0000174844	NCT00001748_44_T0	PHENOTYPE	2	3	psychiatric illness
NCT0000174844	NCT00001748_44_T1	PHENOTYPE	8	9	Mental deficiency
NCT0000174845	NCT00001748_45_T0	PHENOTYPE	5	6	organ failure
NCT0000174847	NCT00001748_47_T0	PHENOTYPE	2	4	ventricular ejection fraction
NCT0000174848	NCT00001748_48_T0	COMPOUND	4	4	creatinine
NCT0000174848	NCT00001748_48_T1	ORGAN	3	3	serum
NCT0000174849	NCT00001748_49_T0	COMPOUND	4	4	bilirubin
NCT0000174849	NCT00001748_49_T1	ORGAN	3	3	serum
NCT0000174850	NCT00001748_50_T0	PHENOTYPE	6	7	HIV positive
NCT000017493	NCT00001749_3_T0	CELL	14	14	platelets
NCT000017493	NCT00001749_3_T1	ORGAN	6	7	bone marrow
NCT000017493	NCT00001749_3_T2	CELL	10	12	white blood cells
NCT000017494	NCT00001749_4_T0	PHENOTYPE	17	17	relapse
NCT000017494	NCT00001749_4_T1	ORGAN	12	12	transplants
NCT000017494	NCT00001749_4_T2	ORGAN	10	11	bone marrow
NCT0000174910	NCT00001749_10_T0	PHENOTYPE	2	2	relapse
NCT0000174915	NCT00001749_15_T0	ORGAN	3	3	marrow
NCT0000174915	NCT00001749_15_T1	PHENOTYPE	4	4	disorders
NCT0000174916	NCT00001749_16_T0	GENE	4	4	II
NCT0000174916	NCT00001749_16_T1	COMPOUND	14	14	cyclosporine
NCT0000174916	NCT00001749_16_T2	PHENOTYPE	25	25	anemia
NCT0000174919	NCT00001749_19_T0	ORGAN	6	6	transplant
NCT0000174921	NCT00001749_21_T0	COMPOUND	3	3	creatinine
NCT0000174921	NCT00001749_21_T1	COMPOUND	11	11	creatinine
NCT0000174921	NCT00001749_21_T2	ORGAN	2	2	Serum
NCT0000174923	NCT00001749_23_T0	PHENOTYPE	2	2	epilepsy
NCT0000174923	NCT00001749_23_T1	PHENOTYPE	4	4	seizures
NCT0000174923	NCT00001749_23_T2	PHENOTYPE	7	8	febrile seizures
NCT0000174926	NCT00001749_26_T0	PHENOTYPE	0	0	HIV
NCT0000174928	NCT00001749_28_T0	PHENOTYPE	1	2	organ failure
NCT000017501	NCT00001750_1_T0	PHENOTYPE	9	9	understood
NCT000017503	NCT00001750_3_T0	CELL	14	15	stem cells
NCT000017503	NCT00001750_3_T1	ORGAN	19	20	bone marrow
NCT000017504	NCT00001750_4_T0	PHENOTYPE	19	20	multiple myeloma
NCT000017504	NCT00001750_4_T1	CELL	14	15	blood cells
NCT000017507	NCT00001750_7_T0	PHENOTYPE	24	24	disorders
NCT000017508	NCT00001750_8_T0	CELL	22	22	cells
NCT000017508	NCT00001750_8_T1	PHENOTYPE	29	30	multiple myeloma
NCT000017509	NCT00001750_9_T0	CELL	1	1	cells
NCT0000175010	NCT00001750_10_T0	PHENOTYPE	13	13	remission
NCT0000175010	NCT00001750_10_T1	GENE	8	8	has
NCT0000175010	NCT00001750_10_T2	PHENOTYPE	6	7	multiple myeloma
NCT0000175011	NCT00001750_11_T0	PHENOTYPE	13	13	toxicity
NCT0000175011	NCT00001750_11_T1	CELL	8	9	stem cells
NCT0000175012	NCT00001750_12_T0	CELL	14	14	cells
NCT0000175012	NCT00001750_12_T1	ORGAN	20	21	bone marrow
NCT0000175015	NCT00001750_15_T0	PHENOTYPE	4	5	multiple myeloma
NCT0000175017	NCT00001750_17_T0	CELL	15	15	cells
NCT0000175017	NCT00001750_17_T1	ORGAN	14	14	plasma
NCT0000175017	NCT00001750_17_T2	ORGAN	0	0	Marrow
NCT0000175018	NCT00001750_18_T0	GENE	5	5	ANC
NCT0000175018	NCT00001750_18_T1	PHENOTYPE	0	1	Platelet count
NCT0000175019	NCT00001750_19_T0	ORGAN	22	22	serum
NCT0000175021	NCT00001750_21_T0	COMPOUND	13	13	creatinine
NCT0000175021	NCT00001750_21_T1	GENE	3	3	2.0
NCT0000175021	NCT00001750_21_T2	GENE	16	16	3.0
NCT0000175021	NCT00001750_21_T3	ORGAN	12	12	serum
NCT0000175023	NCT00001750_23_T0	ORGAN	7	7	transplant
NCT0000175023	NCT00001750_23_T1	ORGAN	3	4	bone marrow
NCT0000175024	NCT00001750_24_T0	PHENOTYPE	0	0	HIV
NCT0000175025	NCT00001750_25_T0	ORGAN	1	1	marrow
NCT0000175025	NCT00001750_25_T1	ORGAN	4	4	marrow
NCT0000175025	NCT00001750_25_T2	ORGAN	12	12	marrow
NCT0000175025	NCT00001750_25_T3	PHENOTYPE	2	2	fibrosis
NCT0000175025	NCT00001750_25_T4	CELL	13	14	plasma cells
NCT0000175026	NCT00001750_26_T0	COMPOUND	15	15	melphalan
NCT0000175026	NCT00001750_26_T1	COMPOUND	18	18	BCNU
NCT0000175026	NCT00001750_26_T2	COMPOUND	16	16	cyclophosphamide
NCT0000175030	NCT00001750_30_T0	PHENOTYPE	15	15	allergy
NCT0000175031	NCT00001750_31_T0	PHENOTYPE	6	6	asthma
NCT0000175031	NCT00001750_31_T1	PHENOTYPE	5	5	recurrent
NCT0000175034	NCT00001750_34_T0	PHENOTYPE	3	3	angioedema
NCT0000175034	NCT00001750_34_T1	PHENOTYPE	6	6	urticaria
NCT0000175034	NCT00001750_34_T2	PHENOTYPE	11	11	urticaria
NCT0000175034	NCT00001750_34_T3	PHENOTYPE	5	5	recurrent
NCT0000175035	NCT00001750_35_T0	PHENOTYPE	7	7	symptoms
NCT0000175035	NCT00001750_35_T1	PHENOTYPE	11	11	fever
NCT0000175036	NCT00001750_36_T0	PHENOTYPE	2	2	allergy
NCT0000175037	NCT00001750_37_T0	GENE	4	4	beta
NCT000017521	NCT00001752_1_T0	COMPOUND	4	4	estrogen
NCT000017521	NCT00001752_1_T1	GENE	6	6	lipoprotein
NCT000017521	NCT00001752_1_T2	PHENOTYPE	7	8	cholesterol levels
NCT000017521	NCT00001752_1_T3	GENE	22	25	regulated by nitric oxide
NCT000017522	NCT00001752_2_T0	TISSUE	23	23	endothelium
NCT000017522	NCT00001752_2_T1	COMPOUND	8	8	estrogen
NCT000017522	NCT00001752_2_T2	PHENOTYPE	12	12	circulation
NCT000017524	NCT00001752_4_T0	COMPOUND	19	19	estrogen
NCT000017524	NCT00001752_4_T1	GENE	9	10	NO synthase
NCT000017526	NCT00001752_6_T0	COMPOUND	4	4	estrogen
NCT000017526	NCT00001752_6_T1	GENE	6	6	lipoprotein
NCT000017526	NCT00001752_6_T2	PHENOTYPE	7	8	cholesterol levels
NCT000017526	NCT00001752_6_T3	GENE	22	25	regulated by nitric oxide
NCT000017527	NCT00001752_7_T0	TISSUE	23	23	endothelium
NCT000017527	NCT00001752_7_T1	COMPOUND	8	8	estrogen
NCT000017527	NCT00001752_7_T2	PHENOTYPE	12	12	circulation
NCT000017529	NCT00001752_9_T0	COMPOUND	19	19	estrogen
NCT000017529	NCT00001752_9_T1	GENE	9	10	NO synthase
NCT0000175211	NCT00001752_11_T0	ORGAN	8	8	thyroid
NCT0000175211	NCT00001752_11_T1	GENE	14	14	FSH
NCT0000175211	NCT00001752_11_T2	GENE	6	6	SMAC
NCT0000175211	NCT00001752_11_T3	COMPOUND	12	12	estradiol
NCT0000175214	NCT00001752_14_T0	GENE	2	2	LDL
NCT0000175214	NCT00001752_14_T1	GENE	14	14	hormone
NCT0000175215	NCT00001752_15_T0	GENE	11	11	FSH
NCT0000175215	NCT00001752_15_T1	ORGAN	3	3	plasma
NCT0000175215	NCT00001752_15_T2	COMPOUND	4	4	estradiol
NCT000017530	NCT00001753_0_T0	TISSUE	10	10	Muscle
NCT000017530	NCT00001753_0_T1	BIOLOGICAL_PROCESS	7	7	Metabolism
NCT000017532	NCT00001753_2_T0	GENE	11	11	MRI
NCT000017533	NCT00001753_3_T0	GENE	3	3	MRI
NCT000017534	NCT00001753_4_T0	TISSUE	16	16	muscles
NCT000017534	NCT00001753_4_T1	GENE	3	3	MRI
NCT000017535	NCT00001753_5_T0	TISSUE	3	3	muscles
NCT000017535	NCT00001753_5_T1	PHENOTYPE	16	16	affects
NCT000017537	NCT00001753_7_T0	GENE	15	15	TA
NCT000017539	NCT00001753_9_T0	GENE	21	21	mitochondrial
NCT0000175315	NCT00001753_15_T0	PHENOTYPE	1	1	aneurysm
NCT0000175315	NCT00001753_15_T1	GENE	2	2	clip
NCT0000175319	NCT00001753_19_T0	GENE	4	4	insulin
NCT000017541	NCT00001754_1_T0	PHENOTYPE	13	13	disorders
NCT000017541	NCT00001754_1_T1	PHENOTYPE	17	19	signs and symptoms
NCT000017542	NCT00001754_2_T0	PHENOTYPE	18	18	mutation
NCT000017542	NCT00001754_2_T1	PHENOTYPE	2	3	short stature
NCT000017542	NCT00001754_2_T2	PHENOTYPE	7	8	skeletal dysplasia
NCT0000175410	NCT00001754_10_T0	PHENOTYPE	28	28	feelings
NCT0000175416	NCT00001754_16_T0	PHENOTYPE	3	3	dysplasias
NCT0000175416	NCT00001754_16_T1	PHENOTYPE	5	6	short stature
NCT0000175417	NCT00001754_17_T0	PHENOTYPE	8	9	skeletal dysplasia
NCT0000175418	NCT00001754_18_T0	PHENOTYPE	7	7	disorders
NCT0000175420	NCT00001754_20_T0	GENE	19	19	II
NCT0000175420	NCT00001754_20_T1	PHENOTYPE	25	25	pyknodysostosis
NCT0000175420	NCT00001754_20_T2	PHENOTYPE	29	29	brachydactyly
NCT0000175420	NCT00001754_20_T3	GENE	16	16	FGFR3
NCT0000175420	NCT00001754_20_T4	PHENOTYPE	23	24	metaphyseal dysplasia
NCT0000175420	NCT00001754_20_T5	PHENOTYPE	26	27	proximal symphalangism
NCT0000175420	NCT00001754_20_T6	PHENOTYPE	20	21	collagen disorder
NCT0000175421	NCT00001754_21_T0	GENE	2	2	II
NCT0000175421	NCT00001754_21_T1	GENE	29	29	van
NCT0000175421	NCT00001754_21_T2	PHENOTYPE	17	17	dysplasia
NCT0000175421	NCT00001754_21_T3	PHENOTYPE	31	31	brachydactyly
NCT0000175421	NCT00001754_21_T4	PHENOTYPE	37	38	cartilage-hair hypoplasia
NCT0000175423	NCT00001754_23_T0	PHENOTYPE	6	6	generalized
NCT0000175423	NCT00001754_23_T1	PHENOTYPE	0	1	Short Stature
NCT0000175423	NCT00001754_23_T2	PHENOTYPE	7	8	short stature
NCT000017561	NCT00001756_1_T0	ORGAN	22	22	liver
NCT000017561	NCT00001756_1_T1	TISSUE	24	24	spleen
NCT000017561	NCT00001756_1_T2	PHENOTYPE	4	4	diseases
NCT000017561	NCT00001756_1_T3	PHENOTYPE	8	8	mastocytosis
NCT000017561	NCT00001756_1_T4	CELL	9	10	mast cells
NCT000017561	NCT00001756_1_T5	ORGAN	20	21	bone marrow
NCT000017561	NCT00001756_1_T6	TISSUE	18	19	lymphoid tissues
NCT000017562	NCT00001756_2_T0	PHENOTYPE	3	3	mastocytosis
NCT000017564	NCT00001756_4_T0	PHENOTYPE	15	15	insights
NCT000017564	NCT00001756_4_T1	PHENOTYPE	23	23	mastocytosis
NCT000017564	NCT00001756_4_T2	CELL	4	5	mast cells
NCT000017565	NCT00001756_5_T0	PHENOTYPE	2	3	systemic mastocytosis
NCT0000175612	NCT00001756_12_T0	CELL	0	0	Granulocyte
NCT0000175612	NCT00001756_12_T1	GENE	4	4	G-CSF
NCT0000175613	NCT00001756_13_T0	CELL	29	29	cells
NCT0000175613	NCT00001756_13_T1	GENE	28	28	CD34
NCT0000175616	NCT00001756_16_T0	CELL	14	14	cells
NCT0000175620	NCT00001756_20_T0	PHENOTYPE	2	2	peripheral
NCT0000175621	NCT00001756_21_T0	COMPOUND	4	4	creatinine
NCT0000175621	NCT00001756_21_T1	PHENOTYPE	18	18	proteinuria
NCT0000175622	NCT00001756_22_T0	GENE	10	10	1.5
NCT0000175622	NCT00001756_22_T1	COMPOUND	4	4	bilirubin
NCT0000175626	NCT00001756_26_T0	PHENOTYPE	2	2	peripheral
NCT0000175629	NCT00001756_29_T0	COMPOUND	4	4	creatinine
NCT0000175629	NCT00001756_29_T1	PHENOTYPE	19	19	proteinuria
NCT0000175630	NCT00001756_30_T0	GENE	10	10	1.5
NCT0000175630	NCT00001756_30_T1	COMPOUND	4	4	bilirubin
NCT0000175633	NCT00001756_33_T0	GENE	16	16	G-CSF
NCT0000175633	NCT00001756_33_T1	ORGAN	3	3	serum
NCT0000175634	NCT00001756_34_T0	PHENOTYPE	5	6	viral infections
NCT0000175635	NCT00001756_35_T0	PHENOTYPE	5	5	HIV
NCT0000175635	NCT00001756_35_T1	PHENOTYPE	7	8	hepatitis B
NCT0000175637	NCT00001756_37_T0	PHENOTYPE	10	10	vasculitis
NCT0000175637	NCT00001756_37_T1	PHENOTYPE	11	12	pyoderma gangrenosum
NCT0000175637	NCT00001756_37_T2	PHENOTYPE	4	5	autoimmune disease
NCT0000175637	NCT00001756_37_T3	PHENOTYPE	8	9	rheumatoid arthritis
NCT0000175639	NCT00001756_39_T0	PHENOTYPE	0	0	Splenomegaly
NCT0000175639	NCT00001756_39_T1	PHENOTYPE	1	2	pulmonary fibrosis
NCT000017571	NCT00001757_1_T0	PHENOTYPE	4	4	secondary
NCT000017571	NCT00001757_1_T1	PHENOTYPE	14	14	infections
NCT000017571	NCT00001757_1_T2	PHENOTYPE	3	3	neutropenia
NCT000017572	NCT00001757_2_T0	PHENOTYPE	15	16	HIV infection
NCT000017572	NCT00001757_2_T1	ORGAN	2	3	bone marrow
NCT000017573	NCT00001757_3_T0	PHENOTYPE	11	11	infections
NCT000017574	NCT00001757_4_T0	PHENOTYPE	14	15	fungal infections
NCT000017575	NCT00001757_5_T0	PHENOTYPE	3	3	nephrotoxicity
NCT000017575	NCT00001757_5_T1	PHENOTYPE	6	7	adverse effects
NCT000017575	NCT00001757_5_T2	COMPOUND	11	12	amphotericin B
NCT000017576	NCT00001757_6_T0	COMPOUND	9	9	fluconazole
NCT000017576	NCT00001757_6_T1	COMPOUND	10	10	itraconazole
NCT000017576	NCT00001757_6_T2	COMPOUND	7	8	amphotericin B
NCT000017577	NCT00001757_7_T0	GENE	20	20	has
NCT000017577	NCT00001757_7_T1	COMPOUND	29	30	amphotericin B
NCT000017577	NCT00001757_7_T2	PHENOTYPE	18	19	fungal infections
NCT000017577	NCT00001757_7_T3	PHENOTYPE	11	12	adverse effects
NCT000017578	NCT00001757_8_T0	GENE	11	11	III
NCT000017579	NCT00001757_9_T0	GENE	2	2	has
NCT0000175710	NCT00001757_10_T0	PHENOTYPE	17	17	aspergillosis
NCT0000175710	NCT00001757_10_T1	GENE	10	10	has
NCT0000175711	NCT00001757_11_T0	GENE	1	1	has
NCT0000175712	NCT00001757_12_T0	COMPOUND	15	15	voriconazole
NCT0000175712	NCT00001757_12_T1	PHENOTYPE	20	22	invasive fungal infections
NCT0000175713	NCT00001757_13_T0	PHENOTYPE	10	11	fungal infections
NCT0000175714	NCT00001757_14_T0	PHENOTYPE	7	7	secondary
NCT0000175714	NCT00001757_14_T1	PHENOTYPE	31	31	toxicity
NCT0000175716	NCT00001757_16_T0	PHENOTYPE	4	4	secondary
NCT0000175716	NCT00001757_16_T1	PHENOTYPE	14	14	infections
NCT0000175716	NCT00001757_16_T2	PHENOTYPE	3	3	neutropenia
NCT0000175717	NCT00001757_17_T0	PHENOTYPE	15	16	HIV infection
NCT0000175717	NCT00001757_17_T1	ORGAN	2	3	bone marrow
NCT0000175718	NCT00001757_18_T0	PHENOTYPE	11	11	infections
NCT0000175719	NCT00001757_19_T0	PHENOTYPE	14	15	fungal infections
NCT0000175720	NCT00001757_20_T0	PHENOTYPE	3	3	nephrotoxicity
NCT0000175720	NCT00001757_20_T1	PHENOTYPE	6	7	adverse effects
NCT0000175720	NCT00001757_20_T2	COMPOUND	11	12	amphotericin B
NCT0000175721	NCT00001757_21_T0	COMPOUND	9	9	fluconazole
NCT0000175721	NCT00001757_21_T1	COMPOUND	11	11	itraconazole
NCT0000175721	NCT00001757_21_T2	COMPOUND	7	8	amphotericin B
NCT0000175722	NCT00001757_22_T0	GENE	20	20	has
NCT0000175722	NCT00001757_22_T1	COMPOUND	29	30	amphotericin B
NCT0000175722	NCT00001757_22_T2	PHENOTYPE	18	19	fungal infections
NCT0000175722	NCT00001757_22_T3	PHENOTYPE	11	12	adverse effects
NCT0000175723	NCT00001757_23_T0	GENE	11	11	III
NCT0000175724	NCT00001757_24_T0	GENE	2	2	has
NCT0000175725	NCT00001757_25_T0	PHENOTYPE	17	17	aspergillosis
NCT0000175725	NCT00001757_25_T1	GENE	10	10	has
NCT0000175726	NCT00001757_26_T0	GENE	1	1	has
NCT0000175727	NCT00001757_27_T0	COMPOUND	15	15	voriconazole
NCT0000175727	NCT00001757_27_T1	PHENOTYPE	20	22	invasive fungal infections
NCT0000175728	NCT00001757_28_T0	PHENOTYPE	10	11	fungal infections
NCT0000175729	NCT00001757_29_T0	PHENOTYPE	7	7	secondary
NCT0000175729	NCT00001757_29_T1	PHENOTYPE	31	31	toxicity
NCT0000175731	NCT00001757_31_T0	PHENOTYPE	36	37	fungal infection
NCT0000175731	NCT00001757_31_T1	PHENOTYPE	9	11	invasive fungal infections
NCT0000175732	NCT00001757_32_T0	PHENOTYPE	39	39	esophagitis
NCT0000175732	NCT00001757_32_T1	COMPOUND	51	51	fluconazole
NCT0000175732	NCT00001757_32_T2	PHENOTYPE	12	13	invasive aspergillosis
NCT0000175732	NCT00001757_32_T3	PHENOTYPE	16	18	invasive fungal infections
NCT0000175733	NCT00001757_33_T0	GENE	65	65	2.0
NCT0000175733	NCT00001757_33_T1	GENE	40	40	1.5
NCT0000175733	NCT00001757_33_T2	PHENOTYPE	15	15	toxicities
NCT0000175733	NCT00001757_33_T3	GENE	32	32	had
NCT0000175733	NCT00001757_33_T4	COMPOUND	30	30	creatinine
NCT0000175733	NCT00001757_33_T5	COMPOUND	56	56	creatinine
NCT0000175733	NCT00001757_33_T6	PHENOTYPE	25	25	nephrotoxicity
NCT0000175733	NCT00001757_33_T7	ORGAN	29	29	serum
NCT0000175733	NCT00001757_33_T8	ORGAN	55	55	serum
NCT0000175733	NCT00001757_33_T9	COMPOUND	17	18	amphotericin B
NCT0000175733	NCT00001757_33_T10	COMPOUND	44	45	amphotericin B
NCT0000175733	NCT00001757_33_T11	COMPOUND	72	73	amphotericin B
NCT0000175733	NCT00001757_33_T12	PHENOTYPE	50	51	renal impairment
NCT0000175735	NCT00001757_35_T0	PHENOTYPE	10	10	menopausal
NCT0000175735	NCT00001757_35_T1	ORGAN	15	15	serum
NCT0000175739	NCT00001757_39_T0	COMPOUND	21	21	cisapride
NCT0000175739	NCT00001757_39_T1	COMPOUND	20	20	terfenadine
NCT0000175739	NCT00001757_39_T2	COMPOUND	22	22	astemizole
NCT0000175740	NCT00001757_40_T0	COMPOUND	35	35	voriconazole
NCT0000175740	NCT00001757_40_T1	COMPOUND	17	17	carbamazepine
NCT0000175742	NCT00001757_42_T0	COMPOUND	6	6	creatinine
NCT0000175742	NCT00001757_42_T1	GENE	9	9	3.5
NCT0000175742	NCT00001757_42_T2	ORGAN	5	5	serum
NCT0000175742	NCT00001757_42_T3	PHENOTYPE	16	16	chronic
NCT0000175742	NCT00001757_42_T4	PHENOTYPE	12	14	end-stage renal disease
NCT0000175743	NCT00001757_43_T0	PHENOTYPE	7	7	aspergilloma
NCT0000175743	NCT00001757_43_T1	PHENOTYPE	8	8	zygomycoses
NCT0000175743	NCT00001757_43_T2	PHENOTYPE	14	14	candidemia
NCT0000175743	NCT00001757_43_T3	PHENOTYPE	5	6	bronchopulmonary aspergillosis
NCT0000175744	NCT00001757_44_T0	PHENOTYPE	16	16	dermatophytosis
NCT0000175744	NCT00001757_44_T1	PHENOTYPE	18	19	oropharyngeal candidiasis
NCT0000175744	NCT00001757_44_T2	PHENOTYPE	4	5	fungal infections
NCT0000175745	NCT00001757_45_T0	PHENOTYPE	32	32	HIV/AIDS
NCT0000175745	NCT00001757_45_T1	PHENOTYPE	34	34	infections
NCT000017589	NCT00001758_9_T0	GENE	1	1	has
NCT000017591	NCT00001759_1_T0	PHENOTYPE	16	16	severity
NCT000017591	NCT00001759_1_T1	COMPOUND	25	25	2-deoxy-2-(18F)fluoro-D-glucose
NCT000017591	NCT00001759_1_T2	GENE	26	26	FDG
NCT000017591	NCT00001759_1_T3	ORGAN	8	8	lungs
NCT000017591	NCT00001759_1_T4	PHENOTYPE	12	13	atopic asthma
NCT000017594	NCT00001759_4_T0	PHENOTYPE	15	15	severity
NCT000017594	NCT00001759_4_T1	PHENOTYPE	11	11	inflammation
NCT000017594	NCT00001759_4_T2	PHENOTYPE	17	17	asthma
NCT000017594	NCT00001759_4_T3	PHENOTYPE	26	28	signs and symptoms
NCT000017597	NCT00001759_7_T0	PHENOTYPE	5	5	atopic
NCT000017597	NCT00001759_7_T1	PHENOTYPE	2	3	atopic asthma
NCT000017598	NCT00001759_8_T0	PHENOTYPE	2	3	Wegener's granulomatosis
NCT0000175910	NCT00001759_10_T0	PHENOTYPE	25	26	atopic asthma
NCT0000175910	NCT00001759_10_T1	PHENOTYPE	20	21	allergic inflammation
NCT0000175911	NCT00001759_11_T0	PHENOTYPE	16	17	allergic inflammation
NCT0000175914	NCT00001759_14_T0	PHENOTYPE	16	16	severity
NCT0000175914	NCT00001759_14_T1	COMPOUND	25	25	2-deoxy-2-(18F)fluoro-D-glucose
NCT0000175914	NCT00001759_14_T2	GENE	26	26	FDG
NCT0000175914	NCT00001759_14_T3	ORGAN	8	8	lungs
NCT0000175914	NCT00001759_14_T4	PHENOTYPE	12	13	atopic asthma
NCT0000175917	NCT00001759_17_T0	PHENOTYPE	15	15	severity
NCT0000175917	NCT00001759_17_T1	PHENOTYPE	11	11	inflammation
NCT0000175917	NCT00001759_17_T2	PHENOTYPE	17	17	asthma
NCT0000175917	NCT00001759_17_T3	PHENOTYPE	26	28	signs and symptoms
NCT0000175920	NCT00001759_20_T0	PHENOTYPE	5	5	atopic
NCT0000175920	NCT00001759_20_T1	PHENOTYPE	2	3	atopic asthma
NCT0000175921	NCT00001759_21_T0	PHENOTYPE	2	3	Wegener's granulomatosis
NCT0000175923	NCT00001759_23_T0	PHENOTYPE	25	26	atopic asthma
NCT0000175923	NCT00001759_23_T1	PHENOTYPE	20	21	allergic inflammation
NCT0000175924	NCT00001759_24_T0	PHENOTYPE	16	17	allergic inflammation
NCT0000175927	NCT00001759_27_T0	PHENOTYPE	0	2	Negative pregnancy test
NCT0000175929	NCT00001759_29_T0	PHENOTYPE	11	11	asthma
NCT0000175930	NCT00001759_30_T0	PHENOTYPE	5	6	prick skin
NCT0000175931	NCT00001759_31_T0	PHENOTYPE	4	4	asthma
NCT0000175932	NCT00001759_32_T0	PHENOTYPE	5	6	prick skin
NCT0000175938	NCT00001759_38_T0	PHENOTYPE	3	5	coronary artery disease
NCT0000175939	NCT00001759_39_T0	PHENOTYPE	11	11	autoimmune
NCT0000175939	NCT00001759_39_T1	PHENOTYPE	7	7	asthma
NCT0000175939	NCT00001759_39_T2	PHENOTYPE	22	23	lupus erythematosus
NCT0000175939	NCT00001759_39_T3	PHENOTYPE	3	4	lung disease
NCT0000175939	NCT00001759_39_T4	PHENOTYPE	18	19	lung function
NCT0000175939	NCT00001759_39_T5	PHENOTYPE	30	31	Wegener's granulomatosis
NCT0000175940	NCT00001759_40_T0	PHENOTYPE	4	4	acute
NCT0000175940	NCT00001759_40_T1	PHENOTYPE	11	11	chronic
NCT0000175940	NCT00001759_40_T2	PHENOTYPE	13	13	bronchiectasis
NCT0000175940	NCT00001759_40_T3	PHENOTYPE	14	15	lung infection
NCT0000175940	NCT00001759_40_T4	PHENOTYPE	8	9	viral pneumonia
NCT0000175942	NCT00001759_42_T0	PHENOTYPE	1	1	allergy
NCT0000175942	NCT00001759_42_T1	COMPOUND	3	3	methacholine
NCT0000175944	NCT00001759_44_T0	PHENOTYPE	8	8	asthma
NCT0000175944	NCT00001759_44_T1	PHENOTYPE	9	10	atopic rhinitis
NCT0000175944	NCT00001759_44_T2	PHENOTYPE	12	13	atopic dermatitis
NCT0000175945	NCT00001759_45_T0	COMPOUND	9	9	methacholine
NCT000017600	NCT00001760_0_T0	PHENOTYPE	10	11	Atopic Dermatitis
NCT000017600	NCT00001760_0_T1	PHENOTYPE	6	7	Systemic Mastocytosis
NCT000017600	NCT00001760_0_T2	BIOLOGICAL_PROCESS	0	1	Cytokine Production
NCT000017603	NCT00001760_3_T0	PHENOTYPE	10	10	mastocytosis
NCT000017603	NCT00001760_3_T1	CELL	17	18	mast cells
NCT000017605	NCT00001760_5_T0	PHENOTYPE	4	4	mastocytosis
NCT000017605	NCT00001760_5_T1	PHENOTYPE	8	9	atopic dermatitis
NCT000017607	NCT00001760_7_T0	PHENOTYPE	4	4	blisters
NCT000017609	NCT00001760_9_T0	GENE	17	17	blistered
NCT000017609	NCT00001760_9_T1	PHENOTYPE	11	11	blister
NCT0000176015	NCT00001760_15_T0	PHENOTYPE	9	9	proliferation
NCT0000176015	NCT00001760_15_T1	CELL	11	12	mast cells
NCT0000176016	NCT00001760_16_T0	PHENOTYPE	18	18	mastocytosis
NCT0000176016	NCT00001760_16_T1	PHENOTYPE	37	37	blister
NCT0000176016	NCT00001760_16_T2	BIOLOGICAL_PROCESS	9	10	chemokine production
NCT0000176016	NCT00001760_16_T3	PHENOTYPE	28	29	atopic dermatitis
NCT0000176018	NCT00001760_18_T0	PHENOTYPE	26	27	urticaria pigmentosa
NCT0000176018	NCT00001760_18_T1	CELL	12	13	mast cells
NCT0000176019	NCT00001760_19_T0	PHENOTYPE	13	13	blister
NCT0000176019	NCT00001760_19_T1	PHENOTYPE	1	1	blisters
NCT0000176029	NCT00001760_29_T0	PHENOTYPE	8	8	blistering
NCT0000176030	NCT00001760_30_T0	PHENOTYPE	4	5	acute infection
NCT0000176031	NCT00001760_31_T0	GENE	6	6	1.5
NCT0000176031	NCT00001760_31_T1	GENE	0	0	INR
NCT0000176031	NCT00001760_31_T2	PHENOTYPE	14	15	platelet count
NCT0000176033	NCT00001760_33_T0	COMPOUND	1	1	glucose
NCT0000176035	NCT00001760_35_T0	PHENOTYPE	1	1	allergy
NCT0000176035	NCT00001760_35_T1	COMPOUND	3	3	lidocaine
NCT0000176036	NCT00001760_36_T0	PHENOTYPE	10	10	mastocytosis
NCT0000176036	NCT00001760_36_T1	PHENOTYPE	13	13	urticaria
NCT0000176036	NCT00001760_36_T2	PHENOTYPE	12	12	chronic
NCT0000176036	NCT00001760_36_T3	PHENOTYPE	8	9	atopic dermatitis
NCT0000176038	NCT00001760_38_T0	PHENOTYPE	0	1	Atopic Dermatitis
NCT000017611	NCT00001761_1_T0	PHENOTYPE	1	1	secondary
NCT000017611	NCT00001761_1_T1	GENE	7	7	IL-10
NCT000017611	NCT00001761_1_T2	PHENOTYPE	16	17	Wegener's granulomatosis
NCT000017612	NCT00001761_2_T0	GENE	3	3	IL-10
NCT000017612	NCT00001761_2_T1	COMPOUND	19	19	cyclophosphamide
NCT000017612	NCT00001761_2_T2	COMPOUND	20	20	methotrexate
NCT000017612	NCT00001761_2_T3	COMPOUND	22	22	prednisone
NCT000017613	NCT00001761_3_T0	GENE	6	6	IL-10
NCT000017614	NCT00001761_4_T0	GENE	0	0	IL-10
NCT000017616	NCT00001761_6_T0	PHENOTYPE	1	1	secondary
NCT000017616	NCT00001761_6_T1	GENE	7	7	IL-10
NCT000017616	NCT00001761_6_T2	PHENOTYPE	16	17	Wegener's granulomatosis
NCT000017617	NCT00001761_7_T0	GENE	3	3	IL-10
NCT000017617	NCT00001761_7_T1	COMPOUND	19	19	cyclophosphamide
NCT000017617	NCT00001761_7_T2	COMPOUND	20	20	methotrexate
NCT000017617	NCT00001761_7_T3	COMPOUND	22	22	prednisone
NCT000017618	NCT00001761_8_T0	GENE	6	6	IL-10
NCT000017619	NCT00001761_9_T0	GENE	0	0	IL-10
NCT0000176115	NCT00001761_15_T0	COMPOUND	1	1	creatinine
NCT0000176115	NCT00001761_15_T1	ORGAN	0	0	Serum
NCT0000176115	NCT00001761_15_T2	GENE	5	5	3.5
NCT0000176116	NCT00001761_16_T0	CELL	7	7	leukocyte
NCT0000176116	NCT00001761_16_T1	GENE	13	13	hemoglobin
NCT0000176116	NCT00001761_16_T2	PHENOTYPE	1	2	platelet count
NCT0000176118	NCT00001761_18_T0	PHENOTYPE	3	3	HIV
NCT0000176118	NCT00001761_18_T1	COMPOUND	4	4	HCV
NCT0000176118	NCT00001761_18_T2	PHENOTYPE	6	7	Hepatitis B
NCT0000176121	NCT00001761_21_T0	PHENOTYPE	2	2	malignancy
NCT0000176122	NCT00001761_22_T0	GENE	8	8	IL-10
NCT0000176122	NCT00001761_22_T1	PHENOTYPE	2	2	allergy
NCT000017621	NCT00001762_1_T0	COMPOUND	6	6	AVN
NCT000017622	NCT00001762_2_T0	GENE	7	7	MRI
NCT000017622	NCT00001762_2_T1	COMPOUND	20	20	AVN
NCT000017623	NCT00001762_3_T0	PHENOTYPE	0	0	HIV
NCT000017627	NCT00001762_7_T0	PHENOTYPE	4	4	closed
NCT0000176210	NCT00001762_10_T0	COMPOUND	3	3	AVN
NCT0000176210	NCT00001762_10_T1	COMPOUND	16	16	AVN
NCT0000176211	NCT00001762_11_T0	GENE	2	2	MRI
NCT0000176214	NCT00001762_14_T0	COMPOUND	8	8	3
NCT0000176214	NCT00001762_14_T1	GENE	1	1	MRI
NCT0000176222	NCT00001762_22_T0	GENE	6	6	MRI
NCT0000176222	NCT00001762_22_T1	PHENOTYPE	8	8	claustrophobia
NCT0000176223	NCT00001762_23_T0	GENE	15	15	MRI
NCT0000176223	NCT00001762_23_T1	PHENOTYPE	6	8	negative pregnancy test
NCT0000176224	NCT00001762_24_T0	COMPOUND	6	6	1
NCT0000176224	NCT00001762_24_T1	PHENOTYPE	23	23	aneurysm
NCT0000176224	NCT00001762_24_T2	COMPOUND	16	16	2
NCT0000176224	NCT00001762_24_T3	GENE	5	5	MRI
NCT0000176224	NCT00001762_24_T4	GENE	24	24	clip
NCT0000176224	NCT00001762_24_T5	ORGAN	32	33	cardiac valve
NCT000017631	NCT00001763_1_T0	PHENOTYPE	7	7	HIV
NCT000017631	NCT00001763_1_T1	PHENOTYPE	18	18	toxicities
NCT000017631	NCT00001763_1_T2	GENE	4	4	MAC
NCT000017632	NCT00001763_2_T0	PHENOTYPE	10	10	resistant
NCT000017632	NCT00001763_2_T1	PHENOTYPE	11	11	strains
NCT000017633	NCT00001763_3_T0	PHENOTYPE	14	14	HIV
NCT000017633	NCT00001763_3_T1	GENE	12	12	MAC
NCT000017635	NCT00001763_5_T0	GENE	0	0	IL-12
NCT000017635	NCT00001763_5_T1	CELL	9	10	NK cells
NCT000017635	NCT00001763_5_T2	CELL	20	21	NK cells
NCT000017635	NCT00001763_5_T3	GENE	14	15	IFN gamma
NCT000017636	NCT00001763_6_T0	GENE	15	15	interleukin-12
NCT000017636	NCT00001763_6_T1	PHENOTYPE	18	18	HIV
NCT000017636	NCT00001763_6_T2	GENE	25	25	MAC
NCT000017637	NCT00001763_7_T0	GENE	17	17	IL-12
NCT000017637	NCT00001763_7_T1	GENE	5	5	MAC
NCT000017637	NCT00001763_7_T2	GENE	21	21	MAC
NCT000017638	NCT00001763_8_T0	GENE	0	0	IL-12
NCT000017639	NCT00001763_9_T0	GENE	10	10	MAC
NCT000017639	NCT00001763_9_T1	PHENOTYPE	6	8	blood cultures negative
NCT0000176310	NCT00001763_10_T0	GENE	18	18	IL-12
NCT0000176313	NCT00001763_13_T0	GENE	1	1	IL-12
NCT0000176315	NCT00001763_15_T0	PHENOTYPE	7	7	HIV
NCT0000176315	NCT00001763_15_T1	PHENOTYPE	18	18	toxicities
NCT0000176315	NCT00001763_15_T2	GENE	4	4	MAC
NCT0000176316	NCT00001763_16_T0	PHENOTYPE	10	10	resistant
NCT0000176316	NCT00001763_16_T1	PHENOTYPE	11	11	strains
NCT0000176317	NCT00001763_17_T0	PHENOTYPE	14	14	HIV
NCT0000176317	NCT00001763_17_T1	GENE	12	12	MAC
NCT0000176319	NCT00001763_19_T0	GENE	0	0	IL-12
NCT0000176319	NCT00001763_19_T1	CELL	9	10	NK cells
NCT0000176319	NCT00001763_19_T2	CELL	20	21	NK cells
NCT0000176319	NCT00001763_19_T3	GENE	14	15	IFN gamma
NCT0000176320	NCT00001763_20_T0	GENE	15	15	interleukin-12
NCT0000176320	NCT00001763_20_T1	PHENOTYPE	18	18	HIV
NCT0000176320	NCT00001763_20_T2	PHENOTYPE	28	28	localized
NCT0000176320	NCT00001763_20_T3	GENE	25	25	MAC
NCT0000176320	NCT00001763_20_T4	GENE	29	29	MAC
NCT0000176321	NCT00001763_21_T0	GENE	17	17	IL-12
NCT0000176321	NCT00001763_21_T1	GENE	5	5	MAC
NCT0000176321	NCT00001763_21_T2	GENE	21	21	MAC
NCT0000176322	NCT00001763_22_T0	GENE	0	0	IL-12
NCT0000176323	NCT00001763_23_T0	GENE	10	10	MAC
NCT0000176323	NCT00001763_23_T1	PHENOTYPE	6	8	blood cultures negative
NCT0000176324	NCT00001763_24_T0	PHENOTYPE	3	4	localized disease
NCT0000176324	NCT00001763_24_T1	PHENOTYPE	14	15	localized infection
NCT0000176325	NCT00001763_25_T0	GENE	18	18	IL-12
NCT0000176328	NCT00001763_28_T0	GENE	1	1	IL-12
NCT0000176332	NCT00001763_32_T0	ORGAN	3	3	serum
NCT0000176335	NCT00001763_35_T0	GENE	25	25	MAC
NCT0000176335	NCT00001763_35_T1	PHENOTYPE	16	16	sterile
NCT0000176335	NCT00001763_35_T2	ORGAN	21	22	bone marrow
NCT0000176335	NCT00001763_35_T3	TISSUE	19	20	lymph node
NCT0000176335	NCT00001763_35_T4	PHENOTYPE	6	8	positive blood culture
NCT0000176337	NCT00001763_37_T0	PHENOTYPE	13	14	total bilirubin
NCT0000176337	NCT00001763_37_T1	GENE	11	12	alkaline phosphatase
NCT0000176338	NCT00001763_38_T0	COMPOUND	1	1	creatinine
NCT0000176338	NCT00001763_38_T1	GENE	7	7	2.0
NCT0000176338	NCT00001763_38_T2	ORGAN	0	0	Serum
NCT0000176339	NCT00001763_39_T0	PHENOTYPE	0	0	Proteinuria
NCT0000176341	NCT00001763_41_T0	CELL	0	0	Granulocyte
NCT0000176342	NCT00001763_42_T0	PHENOTYPE	9	10	platelet count
NCT0000176343	NCT00001763_43_T0	COMPOUND	2	2	glucose
NCT0000176346	NCT00001763_46_T0	GENE	11	11	MAC
NCT0000176346	NCT00001763_46_T1	PHENOTYPE	6	7	opportunistic infection
NCT0000176347	NCT00001763_47_T0	PHENOTYPE	4	5	substance abuse
NCT0000176347	NCT00001763_47_T1	PHENOTYPE	13	14	substance abuse
NCT0000176349	NCT00001763_49_T0	PHENOTYPE	5	5	autoimmune
NCT0000176350	NCT00001763_50_T0	PHENOTYPE	1	1	hypertension
NCT000017641	NCT00001764_1_T0	ORGAN	24	24	joints
NCT000017641	NCT00001764_1_T1	ORGAN	20	20	kidneys
NCT000017641	NCT00001764_1_T2	ORGAN	17	17	eyes
NCT000017641	NCT00001764_1_T3	ORGAN	25	25	heart
NCT000017641	NCT00001764_1_T4	PHENOTYPE	2	2	inflammation
NCT000017641	NCT00001764_1_T5	ORGAN	19	19	lungs
NCT000017641	NCT00001764_1_T6	PHENOTYPE	18	18	sinuses
NCT000017641	NCT00001764_1_T7	ORGAN	0	1	Blood vessel
NCT000017643	NCT00001764_3_T0	COMPOUND	13	13	cyclophosphamide
NCT000017643	NCT00001764_3_T1	COMPOUND	15	15	methotrexate
NCT000017643	NCT00001764_3_T2	COMPOUND	8	8	prednisone
NCT000017644	NCT00001764_4_T0	PHENOTYPE	12	13	disease relapse
NCT000017645	NCT00001764_5_T0	PHENOTYPE	11	13	kidney transplant rejection
NCT000017646	NCT00001764_6_T0	PHENOTYPE	16	16	remission
NCT000017646	NCT00001764_6_T1	COMPOUND	28	28	cyclophosphamide
NCT000017646	NCT00001764_6_T2	COMPOUND	9	9	azathioprine
NCT000017646	NCT00001764_6_T3	GENE	11	11	has
NCT000017646	NCT00001764_6_T4	PHENOTYPE	20	21	Wegener's granulomatosis
NCT000017647	NCT00001764_7_T0	COMPOUND	6	6	azathioprine
NCT000017647	NCT00001764_7_T1	PHENOTYPE	9	10	organ rejection
NCT000017647	NCT00001764_7_T2	PHENOTYPE	21	22	Wegener's granulomatosis
NCT000017648	NCT00001764_8_T0	PHENOTYPE	13	13	relapse
NCT000017648	NCT00001764_8_T1	PHENOTYPE	8	8	diseases
NCT000017648	NCT00001764_8_T2	COMPOUND	19	19	methotrexate
NCT000017648	NCT00001764_8_T3	GENE	11	11	had
NCT000017648	NCT00001764_8_T4	COMPOUND	17	17	cyclophosphamide
NCT000017648	NCT00001764_8_T5	PHENOTYPE	2	3	Wegener's granulomatosis
NCT0000176412	NCT00001764_12_T0	COMPOUND	9	9	prednisone
NCT0000176413	NCT00001764_13_T0	COMPOUND	7	7	prednisone
NCT0000176414	NCT00001764_14_T0	GENE	7	7	reduced
NCT0000176414	NCT00001764_14_T1	COMPOUND	4	4	prednisone
NCT0000176416	NCT00001764_16_T0	GENE	15	15	reduced
NCT0000176416	NCT00001764_16_T1	PHENOTYPE	7	8	in remission
NCT0000176418	NCT00001764_18_T0	PHENOTYPE	8	8	severity
NCT0000176420	NCT00001764_20_T0	GENE	3	3	has
NCT0000176420	NCT00001764_20_T1	PHENOTYPE	5	6	in remission
NCT0000176424	NCT00001764_24_T0	GENE	8	8	has
NCT0000176425	NCT00001764_25_T0	PHENOTYPE	13	13	acute
NCT0000176425	NCT00001764_25_T1	PHENOTYPE	30	30	vasculitis
NCT0000176425	NCT00001764_25_T2	COMPOUND	17	17	azathioprine
NCT0000176425	NCT00001764_25_T3	ORGAN	14	14	transplant
NCT0000176425	NCT00001764_25_T4	GENE	6	6	has
NCT0000176425	NCT00001764_25_T5	GENE	21	21	has
NCT0000176426	NCT00001764_26_T0	COMPOUND	12	12	methotrexate
NCT0000176426	NCT00001764_26_T1	GENE	6	6	had
NCT0000176426	NCT00001764_26_T2	PHENOTYPE	29	29	remission
NCT0000176426	NCT00001764_26_T3	COMPOUND	16	16	cyclophosphamide
NCT0000176426	NCT00001764_26_T4	COMPOUND	23	23	cyclophosphamide
NCT0000176426	NCT00001764_26_T5	COMPOUND	25	26	mycophenolate mofetil
NCT0000176426	NCT00001764_26_T6	PHENOTYPE	7	8	disease relapse
NCT0000176427	NCT00001764_27_T0	PHENOTYPE	17	17	remission
NCT0000176427	NCT00001764_27_T1	GENE	22	22	tapered
NCT0000176427	NCT00001764_27_T2	COMPOUND	8	9	mycophenolate mofetil
NCT0000176428	NCT00001764_28_T0	COMPOUND	7	7	methotrexate
NCT0000176428	NCT00001764_28_T1	PHENOTYPE	28	28	remission
NCT0000176428	NCT00001764_28_T2	COMPOUND	5	5	cyclophosphamide
NCT0000176428	NCT00001764_28_T3	COMPOUND	13	13	prednisone
NCT0000176428	NCT00001764_28_T4	GENE	31	31	tapered
NCT0000176428	NCT00001764_28_T5	COMPOUND	15	16	mycophenolate mofetil
NCT0000176428	NCT00001764_28_T6	COMPOUND	18	19	mycophenolate mofetil
NCT0000176429	NCT00001764_29_T0	COMPOUND	6	6	methotrexate
NCT0000176429	NCT00001764_29_T1	COMPOUND	8	8	cyclophosphamide
NCT0000176429	NCT00001764_29_T2	GENE	31	31	tapered
NCT0000176429	NCT00001764_29_T3	PHENOTYPE	13	14	in remission
NCT0000176429	NCT00001764_29_T4	COMPOUND	15	16	mycophenolate mofetil
NCT0000176430	NCT00001764_30_T0	PHENOTYPE	11	12	drug toxicity
NCT0000176431	NCT00001764_31_T0	PHENOTYPE	11	11	remission
NCT0000176431	NCT00001764_31_T1	PHENOTYPE	25	26	adverse effects
NCT0000176431	NCT00001764_31_T2	PHENOTYPE	17	18	disease relapse
NCT0000176436	NCT00001764_36_T0	PHENOTYPE	0	0	Relapse
NCT0000176436	NCT00001764_36_T1	PHENOTYPE	5	5	Vasculitis
NCT0000176439	NCT00001764_39_T0	GENE	8	8	MTX
NCT0000176439	NCT00001764_39_T1	GENE	16	16	MTX
NCT0000176439	NCT00001764_39_T2	PHENOTYPE	4	4	relapse
NCT0000176439	NCT00001764_39_T3	GENE	9	9	has
NCT0000176440	NCT00001764_40_T0	GENE	9	9	MTX
NCT0000176441	NCT00001764_41_T0	PHENOTYPE	8	8	Vasculitis
NCT0000176443	NCT00001764_43_T0	PHENOTYPE	8	8	Vasculitis
NCT0000176449	NCT00001764_49_T0	PHENOTYPE	23	23	vasculitis
NCT0000176452	NCT00001764_52_T0	PHENOTYPE	5	7	negative pregnancy test
NCT0000176454	NCT00001764_54_T0	PHENOTYPE	0	2	Active peptic ulcer
NCT0000176454	NCT00001764_54_T1	PHENOTYPE	1	3	peptic ulcer disease
NCT000017653	NCT00001765_3_T0	ORGAN	21	22	immune system
NCT000017654	NCT00001765_4_T0	ORGAN	16	16	graft
NCT000017654	NCT00001765_4_T1	CELL	25	25	cells
NCT000017654	NCT00001765_4_T2	CELL	29	29	cells
NCT000017654	NCT00001765_4_T3	BIOLOGICAL_PROCESS	35	36	immune response
NCT000017655	NCT00001765_5_T0	PHENOTYPE	35	36	immune suppression
NCT000017656	NCT00001765_6_T0	CELL	3	3	lymphocytes
NCT000017656	NCT00001765_6_T1	CELL	12	13	stem cells
NCT000017659	NCT00001765_9_T0	ORGAN	1	2	bone marrow
NCT0000176510	NCT00001765_10_T0	ORGAN	13	14	bone marrow
NCT0000176511	NCT00001765_11_T0	CELL	0	1	Stem cells
NCT0000176513	NCT00001765_13_T0	CELL	2	3	stem cells
NCT0000176517	NCT00001765_17_T0	COMPOUND	14	14	fludarabine
NCT0000176517	NCT00001765_17_T1	COMPOUND	12	12	cyclophosphamide
NCT0000176517	NCT00001765_17_T2	ORGAN	4	4	transplant
NCT0000176518	NCT00001765_18_T0	CELL	13	13	cells
NCT0000176518	NCT00001765_18_T1	CELL	5	5	thymocyte
NCT0000176518	NCT00001765_18_T2	GENE	6	6	globulin
NCT0000176519	NCT00001765_19_T0	PHENOTYPE	2	2	conditioning
NCT0000176519	NCT00001765_19_T1	CELL	7	8	stem cells
NCT0000176525	NCT00001765_25_T0	ORGAN	17	17	transplant
NCT0000176527	NCT00001765_27_T0	PHENOTYPE	15	15	infections
NCT0000176527	NCT00001765_27_T1	PHENOTYPE	11	11	recurrent
NCT0000176531	NCT00001765_31_T0	PHENOTYPE	12	12	acute
NCT0000176531	NCT00001765_31_T1	ORGAN	1	1	graft
NCT0000176531	NCT00001765_31_T2	ORGAN	13	13	graft
NCT0000176531	NCT00001765_31_T3	CELL	4	4	T-cell
NCT0000176532	NCT00001765_32_T0	PHENOTYPE	7	7	engraftment
NCT0000176532	NCT00001765_32_T1	ORGAN	5	5	transplant
NCT0000176532	NCT00001765_32_T2	CELL	1	1	T-cells
NCT0000176532	NCT00001765_32_T3	CELL	10	11	stem cells
NCT0000176533	NCT00001765_33_T0	PHENOTYPE	9	9	myeloablation
NCT0000176533	NCT00001765_33_T1	PHENOTYPE	7	7	immunosuppression
NCT0000176535	NCT00001765_35_T0	PHENOTYPE	7	7	engraftment
NCT0000176535	NCT00001765_35_T1	PHENOTYPE	14	14	acute
NCT0000176535	NCT00001765_35_T2	ORGAN	18	18	transplant
NCT0000176535	NCT00001765_35_T3	PHENOTYPE	17	17	GVHD
NCT0000176535	NCT00001765_35_T4	PHENOTYPE	16	16	chronic
NCT0000176538	NCT00001765_38_T0	PHENOTYPE	7	7	infections
NCT0000176538	NCT00001765_38_T1	GENE	1	1	has
NCT0000176539	NCT00001765_39_T0	PHENOTYPE	0	0	HIV
NCT0000176540	NCT00001765_40_T0	PHENOTYPE	3	3	dysfunction
NCT0000176542	NCT00001765_42_T0	PHENOTYPE	1	3	ventricular ejection fraction
NCT0000176545	NCT00001765_45_T0	GENE	3	3	G-CSF
NCT0000176545	NCT00001765_45_T1	PHENOTYPE	22	23	heart disease
NCT0000176545	NCT00001765_45_T2	CELL	6	9	peripheral blood stem cells
NCT0000176550	NCT00001765_50_T0	PHENOTYPE	6	6	progressive
NCT0000176551	NCT00001765_51_T0	PHENOTYPE	1	3	ventricular ejection fraction
NCT0000176553	NCT00001765_53_T0	COMPOUND	1	1	bilirubin
NCT0000176553	NCT00001765_53_T1	ORGAN	0	0	Serum
NCT0000176554	NCT00001765_54_T0	PHENOTYPE	0	0	HIV
NCT0000176555	NCT00001765_55_T0	COMPOUND	6	6	HCV
NCT0000176555	NCT00001765_55_T1	PHENOTYPE	5	5	HBV
NCT0000176556	NCT00001765_56_T0	PHENOTYPE	4	4	relapse
NCT0000176556	NCT00001765_56_T1	PHENOTYPE	1	1	diseases
NCT0000176557	NCT00001765_57_T0	GENE	4	4	G-CSF
NCT000017662	NCT00001766_2_T0	GENE	30	30	protease
NCT000017662	NCT00001766_2_T1	COMPOUND	48	48	amprenavir
NCT000017662	NCT00001766_2_T2	PHENOTYPE	0	0	HIV
NCT000017662	NCT00001766_2_T3	COMPOUND	47	47	abacavir
NCT000017662	NCT00001766_2_T4	COMPOUND	50	50	efavirenz
NCT000017662	NCT00001766_2_T5	GENE	24	25	protease inhibitor
NCT000017663	NCT00001766_3_T0	COMPOUND	31	31	amprenavir
NCT000017663	NCT00001766_3_T1	COMPOUND	20	20	abacavir
NCT000017663	NCT00001766_3_T2	COMPOUND	9	9	efavirenz
NCT000017663	NCT00001766_3_T3	GENE	33	34	protease inhibitor
NCT000017663	NCT00001766_3_T4	GENE	12	13	reverse transcriptase
NCT000017664	NCT00001766_4_T0	COMPOUND	40	40	nelfinavir
NCT000017664	NCT00001766_4_T1	COMPOUND	15	15	ritonavir
NCT000017664	NCT00001766_4_T2	COMPOUND	29	29	ritonavir
NCT000017664	NCT00001766_4_T3	GENE	17	18	protease inhibitor
NCT000017664	NCT00001766_4_T4	GENE	42	43	protease inhibitor
NCT000017665	NCT00001766_5_T0	COMPOUND	14	14	amprenavir
NCT000017665	NCT00001766_5_T1	GENE	38	38	1.2
NCT000017665	NCT00001766_5_T2	COMPOUND	4	4	ritonavir
NCT000017665	NCT00001766_5_T3	COMPOUND	12	12	abacavir
NCT000017665	NCT00001766_5_T4	PHENOTYPE	29	30	drug levels
NCT000017666	NCT00001766_6_T0	COMPOUND	4	4	ritonavir
NCT000017668	NCT00001766_8_T0	GENE	9	9	had
NCT000017668	NCT00001766_8_T1	COMPOUND	4	4	efavirenz
NCT000017669	NCT00001766_9_T0	COMPOUND	7	7	amprenavir
NCT000017669	NCT00001766_9_T1	COMPOUND	3	3	nelfinavir
NCT000017669	NCT00001766_9_T2	COMPOUND	9	9	nelfinavir
NCT000017669	NCT00001766_9_T3	COMPOUND	23	23	ritonavir
NCT000017669	NCT00001766_9_T4	COMPOUND	6	6	abacavir
NCT0000176610	NCT00001766_10_T0	COMPOUND	4	4	efavirenz
NCT0000176613	NCT00001766_13_T0	COMPOUND	39	39	amprenavir
NCT0000176613	NCT00001766_13_T1	COMPOUND	62	62	amprenavir
NCT0000176613	NCT00001766_13_T2	COMPOUND	86	86	amprenavir
NCT0000176613	NCT00001766_13_T3	COMPOUND	91	91	nelfinavir
NCT0000176613	NCT00001766_13_T4	COMPOUND	44	44	ritonavir
NCT0000176613	NCT00001766_13_T5	COMPOUND	67	67	ritonavir
NCT0000176613	NCT00001766_13_T6	COMPOUND	34	34	abacavir
NCT0000176613	NCT00001766_13_T7	COMPOUND	57	57	abacavir
NCT0000176613	NCT00001766_13_T8	COMPOUND	81	81	abacavir
NCT0000176613	NCT00001766_13_T9	GENE	38	38	BID
NCT0000176613	NCT00001766_13_T10	GENE	43	43	BID
NCT0000176613	NCT00001766_13_T11	GENE	48	48	BID
NCT0000176613	NCT00001766_13_T12	GENE	61	61	BID
NCT0000176613	NCT00001766_13_T13	GENE	66	66	BID
NCT0000176613	NCT00001766_13_T14	GENE	71	71	BID
NCT0000176613	NCT00001766_13_T15	GENE	85	85	BID
NCT0000176613	NCT00001766_13_T16	GENE	90	90	BID
NCT0000176613	NCT00001766_13_T17	GENE	95	95	BID
NCT0000176613	NCT00001766_13_T18	COMPOUND	50	50	efavirenz
NCT0000176613	NCT00001766_13_T19	COMPOUND	73	73	efavirenz
NCT0000176613	NCT00001766_13_T20	COMPOUND	97	97	efavirenz
NCT0000176613	NCT00001766_13_T21	GENE	37	37	po
NCT0000176613	NCT00001766_13_T22	GENE	42	42	po
NCT0000176613	NCT00001766_13_T23	GENE	47	47	po
NCT0000176613	NCT00001766_13_T24	GENE	53	53	po
NCT0000176613	NCT00001766_13_T25	GENE	60	60	po
NCT0000176613	NCT00001766_13_T26	GENE	65	65	po
NCT0000176613	NCT00001766_13_T27	GENE	70	70	po
NCT0000176613	NCT00001766_13_T28	GENE	76	76	po
NCT0000176613	NCT00001766_13_T29	GENE	84	84	po
NCT0000176613	NCT00001766_13_T30	GENE	89	89	po
NCT0000176613	NCT00001766_13_T31	GENE	94	94	po
NCT0000176613	NCT00001766_13_T32	GENE	100	100	po
NCT0000176613	NCT00001766_13_T33	GENE	17	18	protease inhibitor
NCT0000176614	NCT00001766_14_T0	COMPOUND	18	18	nelfinavir
NCT0000176614	NCT00001766_14_T1	COMPOUND	5	5	ritonavir
NCT0000176614	NCT00001766_14_T2	COMPOUND	12	12	ritonavir
NCT0000176615	NCT00001766_15_T0	COMPOUND	7	7	1
NCT0000176615	NCT00001766_15_T1	COMPOUND	13	13	1
NCT0000176617	NCT00001766_17_T0	COMPOUND	14	14	amprenavir
NCT0000176617	NCT00001766_17_T1	COMPOUND	25	25	amprenavir
NCT0000176617	NCT00001766_17_T2	COMPOUND	6	6	ritonavir
NCT0000176617	NCT00001766_17_T3	COMPOUND	12	12	abacavir
NCT0000176617	NCT00001766_17_T4	ORGAN	19	19	plasma
NCT0000176618	NCT00001766_18_T0	COMPOUND	1	1	ritonavir
NCT0000176618	NCT00001766_18_T1	ORGAN	18	18	plasma
NCT0000176618	NCT00001766_18_T2	ORGAN	35	35	plasma
NCT0000176618	NCT00001766_18_T3	COMPOUND	26	26	efavirenz
NCT0000176619	NCT00001766_19_T0	COMPOUND	10	10	amprenavir
NCT0000176619	NCT00001766_19_T1	COMPOUND	2	2	nelfinavir
NCT0000176619	NCT00001766_19_T2	COMPOUND	9	9	nelfinavir
NCT0000176619	NCT00001766_19_T3	COMPOUND	12	12	abacavir
NCT0000176619	NCT00001766_19_T4	ORGAN	19	19	plasma
NCT0000176619	NCT00001766_19_T5	ORGAN	30	30	plasma
NCT0000176619	NCT00001766_19_T6	COMPOUND	23	23	efavirenz
NCT0000176620	NCT00001766_20_T0	GENE	10	10	log
NCT0000176621	NCT00001766_21_T0	PHENOTYPE	16	16	toxicity
NCT0000176624	NCT00001766_24_T0	ORGAN	0	0	Plasma
NCT0000176624	NCT00001766_24_T1	GENE	17	18	protease inhibitor
NCT0000176625	NCT00001766_25_T0	GENE	3	4	protease inhibitor
NCT0000176625	NCT00001766_25_T1	GENE	14	15	protease inhibitor
NCT0000176626	NCT00001766_26_T0	CELL	9	9	granulocyte
NCT0000176626	NCT00001766_26_T1	GENE	21	21	AST
NCT0000176626	NCT00001766_26_T2	GENE	4	4	hemoglobin
NCT0000176626	NCT00001766_26_T3	PHENOTYPE	15	16	platelet count
NCT0000176627	NCT00001766_27_T0	ORGAN	25	25	diaphragms
NCT0000176628	NCT00001766_28_T0	PHENOTYPE	20	20	concentrations
NCT0000176630	NCT00001766_30_T0	ORGAN	1	1	serum
NCT0000176631	NCT00001766_31_T0	COMPOUND	5	5	nelfinavir
NCT0000176631	NCT00001766_31_T1	COMPOUND	3	3	ritonavir
NCT0000176632	NCT00001766_32_T0	PHENOTYPE	48	48	sarcoma
NCT0000176634	NCT00001766_34_T0	COMPOUND	20	20	foscarnet
NCT0000176635	NCT00001766_35_T0	COMPOUND	4	4	amprenavir
NCT0000176635	NCT00001766_35_T1	COMPOUND	3	3	abacavir
NCT0000176635	NCT00001766_35_T2	COMPOUND	6	6	efavirenz
NCT0000176637	NCT00001766_37_T0	PHENOTYPE	20	21	adverse events
NCT0000176637	NCT00001766_37_T1	PHENOTYPE	2	3	opportunistic infection
NCT0000176638	NCT00001766_38_T0	PHENOTYPE	0	0	Lymphoma
NCT0000176639	NCT00001766_39_T0	PHENOTYPE	4	5	psychiatric illness
NCT0000176639	NCT00001766_39_T1	PHENOTYPE	1	2	substance abuse
NCT0000176640	NCT00001766_40_T0	COMPOUND	10	10	efavirenz
NCT0000176641	NCT00001766_41_T0	PHENOTYPE	0	0	Malabsorption
NCT0000176641	NCT00001766_41_T1	PHENOTYPE	3	4	gastrointestinal dysfunction
NCT0000176641	NCT00001766_41_T2	PHENOTYPE	15	16	drug absorption
NCT0000176643	NCT00001766_43_T0	COMPOUND	7	7	cisapride
NCT0000176643	NCT00001766_43_T1	COMPOUND	2	2	phenobarbital
NCT0000176643	NCT00001766_43_T2	COMPOUND	5	5	midazolam
NCT0000176643	NCT00001766_43_T3	COMPOUND	4	4	rifabutin
NCT0000176643	NCT00001766_43_T4	COMPOUND	9	9	triazolam
NCT0000176643	NCT00001766_43_T5	COMPOUND	6	6	astemizole
NCT0000176644	NCT00001766_44_T0	BIOLOGICAL_PROCESS	2	2	lactation
NCT000017681	NCT00001768_1_T0	PHENOTYPE	19	19	autoimmunity
NCT000017681	NCT00001768_1_T1	PHENOTYPE	25	25	schizophrenia
NCT000017681	NCT00001768_1_T2	GENE	4	4	has
NCT000017682	NCT00001768_2_T0	PHENOTYPE	0	0	Autoimmune
NCT000017682	NCT00001768_2_T1	ORGAN	6	7	immune system
NCT000017683	NCT00001768_3_T0	CELL	4	4	cells
NCT000017683	NCT00001768_3_T1	ORGAN	1	2	immune system
NCT000017684	NCT00001768_4_T0	PHENOTYPE	8	8	schizophrenia
NCT000017684	NCT00001768_4_T1	PHENOTYPE	5	6	autoimmune diseases
NCT000017686	NCT00001768_6_T0	PHENOTYPE	14	14	symptoms
NCT000017687	NCT00001768_7_T0	ORGAN	19	20	immune system
NCT000017687	NCT00001768_7_T1	PHENOTYPE	15	16	neurologic diseases
NCT000017689	NCT00001768_9_T0	PHENOTYPE	12	12	diseases
NCT000017689	NCT00001768_9_T1	GENE	7	7	has
NCT000017689	NCT00001768_9_T2	PHENOTYPE	14	15	Kawasaki disease
NCT000017689	NCT00001768_9_T3	PHENOTYPE	20	21	lupus nephritis
NCT000017689	NCT00001768_9_T4	PHENOTYPE	23	25	idiopathic thrombocytopenic purpura
NCT000017689	NCT00001768_9_T5	PHENOTYPE	16	19	systemic juvenile rheumatoid arthritis
NCT0000176811	NCT00001768_11_T0	PHENOTYPE	13	13	suffering
NCT0000176811	NCT00001768_11_T1	PHENOTYPE	15	16	childhood-onset schizophrenia
NCT0000176814	NCT00001768_14_T0	PHENOTYPE	18	18	schizophrenia
NCT0000176814	NCT00001768_14_T1	GENE	4	4	has
NCT0000176816	NCT00001768_16_T0	PHENOTYPE	16	16	suffering
NCT0000176816	NCT00001768_16_T1	PHENOTYPE	19	20	childhood-onset schizophrenia
NCT0000176819	NCT00001768_19_T0	PHENOTYPE	29	29	disorders
NCT0000176819	NCT00001768_19_T1	PHENOTYPE	13	13	schizophrenia
NCT0000176819	NCT00001768_19_T2	PHENOTYPE	17	18	psychotic symptoms
NCT0000176819	NCT00001768_19_T3	PHENOTYPE	27	28	substance abuse
NCT000017701	NCT00001770_1_T0	COMPOUND	5	5	estrogen
NCT000017701	NCT00001770_1_T1	COMPOUND	7	7	progesterone
NCT000017703	NCT00001770_3_T0	COMPOUND	1	1	progesterone
NCT000017703	NCT00001770_3_T1	GENE	5	5	HRT
NCT000017703	NCT00001770_3_T2	PHENOTYPE	14	15	uterine cancer
NCT000017705	NCT00001770_5_T0	PHENOTYPE	14	14	symptoms
NCT000017705	NCT00001770_5_T1	COMPOUND	9	9	progestins
NCT000017706	NCT00001770_6_T0	COMPOUND	11	11	acetate
NCT000017707	NCT00001770_7_T0	PHENOTYPE	1	1	moods
NCT000017709	NCT00001770_9_T0	COMPOUND	1	1	progestins
NCT000017709	NCT00001770_9_T1	GENE	8	8	hormone
NCT0000177011	NCT00001770_11_T0	COMPOUND	1	1	progestins
NCT0000177011	NCT00001770_11_T1	COMPOUND	17	17	estrogen
NCT0000177011	NCT00001770_11_T2	PHENOTYPE	5	6	mood disturbance
NCT0000177014	NCT00001770_14_T0	GENE	8	8	putative
NCT0000177015	NCT00001770_15_T0	COMPOUND	3	3	progestins
NCT0000177015	NCT00001770_15_T1	COMPOUND	10	10	progesterone
NCT0000177015	NCT00001770_15_T2	GENE	12	13	androgen receptor
NCT0000177015	NCT00001770_15_T3	PHENOTYPE	0	1	Adverse effects
NCT0000177016	NCT00001770_16_T0	COMPOUND	4	4	progestins
NCT0000177016	NCT00001770_16_T1	COMPOUND	13	13	progesterone
NCT0000177017	NCT00001770_17_T0	PHENOTYPE	29	29	acute
NCT0000177017	NCT00001770_17_T1	COMPOUND	30	30	estrogen
NCT0000177017	NCT00001770_17_T2	COMPOUND	18	18	estradiol
NCT0000177017	NCT00001770_17_T3	PHENOTYPE	26	27	mood disturbance
NCT0000177018	NCT00001770_18_T0	COMPOUND	6	6	progesterone
NCT0000177018	NCT00001770_18_T1	GENE	20	20	HRT
NCT0000177018	NCT00001770_18_T2	PHENOTYPE	8	9	mood disturbances
NCT0000177019	NCT00001770_19_T0	COMPOUND	9	9	progestins
NCT0000177019	NCT00001770_19_T1	COMPOUND	20	20	progestins
NCT0000177019	NCT00001770_19_T2	COMPOUND	36	36	estrogen
NCT0000177019	NCT00001770_19_T3	GENE	16	16	HRT
NCT0000177019	NCT00001770_19_T4	PHENOTYPE	24	25	mood disturbance
NCT0000177021	NCT00001770_21_T0	PHENOTYPE	10	11	laboratory abnormalities
NCT0000177022	NCT00001770_22_T0	COMPOUND	13	13	estrogen
NCT000017711	NCT00001771_1_T0	COMPOUND	11	11	dopamine
NCT000017713	NCT00001771_3_T0	PHENOTYPE	4	4	concentrations
NCT000017713	NCT00001771_3_T1	GENE	14	14	has
NCT000017714	NCT00001771_4_T0	PHENOTYPE	38	38	disorders
NCT000017714	NCT00001771_4_T1	COMPOUND	16	16	dopamine
NCT000017716	NCT00001771_6_T0	COMPOUND	11	11	dopamine
NCT000017718	NCT00001771_8_T0	PHENOTYPE	4	4	concentrations
NCT000017718	NCT00001771_8_T1	GENE	14	14	has
NCT000017719	NCT00001771_9_T0	PHENOTYPE	38	38	disorders
NCT000017719	NCT00001771_9_T1	COMPOUND	16	16	dopamine
NCT0000177113	NCT00001771_13_T0	COMPOUND	6	6	iodine
NCT0000177113	NCT00001771_13_T1	COMPOUND	7	7	iodine
NCT0000177114	NCT00001771_14_T0	PHENOTYPE	8	8	dysfunction
NCT0000177114	NCT00001771_14_T1	PHENOTYPE	5	6	thyroid disease
NCT0000177115	NCT00001771_15_T0	PHENOTYPE	6	7	substance abuse
NCT0000177116	NCT00001771_16_T0	GENE	11	11	MRI
NCT0000177117	NCT00001771_17_T0	GENE	10	10	MRI
NCT0000177117	NCT00001771_17_T1	GENE	2	2	structural
NCT0000177117	NCT00001771_17_T2	PHENOTYPE	3	6	abnormality of the brain
NCT0000177118	NCT00001771_18_T0	GENE	12	12	II
NCT0000177118	NCT00001771_18_T1	GENE	2	2	FOR
NCT000017722	NCT00001772_2_T0	PHENOTYPE	24	24	mania
NCT000017722	NCT00001772_2_T1	PHENOTYPE	25	25	mania
NCT000017722	NCT00001772_2_T2	PHENOTYPE	10	11	bipolar disorder
NCT0000177213	NCT00001772_13_T0	PHENOTYPE	9	10	cardiovascular disease
NCT000017741	NCT00001774_1_T0	ORGAN	19	19	thighs
NCT000017741	NCT00001774_1_T1	PHENOTYPE	25	25	tingling
NCT000017741	NCT00001774_1_T2	ORGAN	29	29	extremities
NCT000017741	NCT00001774_1_T3	PHENOTYPE	16	16	tumors
NCT000017741	NCT00001774_1_T4	CELL	10	10	cells
NCT000017741	NCT00001774_1_T5	ORGAN	22	22	genitalia
NCT000017741	NCT00001774_1_T6	CELL	11	11	histiocytes
NCT000017741	NCT00001774_1_T7	ORGAN	20	20	buttocks
NCT000017741	NCT00001774_1_T8	PHENOTYPE	31	31	cataracts
NCT000017741	NCT00001774_1_T9	ORGAN	13	14	blood vessel
NCT000017741	NCT00001774_1_T10	PHENOTYPE	23	24	decreased sweating
NCT000017742	NCT00001774_2_T0	ORGAN	10	10	kidney
NCT000017742	NCT00001774_2_T1	PHENOTYPE	7	7	complications
NCT000017742	NCT00001774_2_T2	ORGAN	11	11	heart
NCT000017743	NCT00001774_3_T0	PHENOTYPE	13	14	Fabry's disease
NCT000017743	NCT00001774_3_T1	ORGAN	19	20	blood vessels
NCT000017744	NCT00001774_4_T0	TISSUE	6	6	muscles
NCT000017744	NCT00001774_4_T1	ORGAN	3	4	blood vessels
NCT000017746	NCT00001774_6_T0	TISSUE	14	14	endothelium
NCT000017746	NCT00001774_6_T1	GENE	13	13	EDRF
NCT000017746	NCT00001774_6_T2	CELL	8	8	cells
NCT000017746	NCT00001774_6_T3	ORGAN	10	11	blood vessels
NCT000017748	NCT00001774_8_T0	GENE	11	11	EDRF
NCT000017749	NCT00001774_9_T0	PHENOTYPE	20	21	Fabry's disease
NCT000017749	NCT00001774_9_T1	ORGAN	12	13	blood vessels
NCT0000177413	NCT00001774_13_T0	TISSUE	1	1	endothelium
NCT0000177413	NCT00001774_13_T1	TISSUE	18	19	smooth muscle
NCT0000177414	NCT00001774_14_T0	TISSUE	18	18	endothelium
NCT0000177414	NCT00001774_14_T1	GENE	1	1	has
NCT0000177414	NCT00001774_14_T2	PHENOTYPE	8	9	essential hypertension
NCT0000177414	NCT00001774_14_T3	BIOLOGICAL_PROCESS	14	16	response to acetylcholine
NCT0000177416	NCT00001774_16_T0	PHENOTYPE	20	20	strain
NCT0000177416	NCT00001774_16_T1	ORGAN	15	15	forearm
NCT0000177416	NCT00001774_16_T2	ORGAN	6	7	brachial artery
NCT0000177417	NCT00001774_17_T0	ORGAN	0	0	Forearm
NCT0000177417	NCT00001774_17_T1	PHENOTYPE	4	5	vascular resistance
NCT0000177418	NCT00001774_18_T0	GENE	8	8	Dr
NCT0000177419	NCT00001774_19_T0	GENE	0	0	Panza
NCT000017763	NCT00001776_3_T0	GENE	15	15	coil
NCT000017763	NCT00001776_3_T1	ORGAN	19	19	scalp
NCT000017763	NCT00001776_3_T2	COMPOUND	4	4	rTMS
NCT0000177620	NCT00001776_20_T0	PHENOTYPE	1	1	reasoning
NCT0000177622	NCT00001776_22_T0	PHENOTYPE	22	22	reasoning
NCT0000177622	NCT00001776_22_T1	PHENOTYPE	33	33	focal
NCT0000177622	NCT00001776_22_T2	PHENOTYPE	29	31	frontal lobe dementia
NCT0000177623	NCT00001776_23_T0	PHENOTYPE	8	8	reasoning
NCT0000177623	NCT00001776_23_T1	PHENOTYPE	31	31	reasoning
NCT0000177623	NCT00001776_23_T2	COMPOUND	4	4	rTMS
NCT0000177624	NCT00001776_24_T0	PHENOTYPE	19	19	reasoning
NCT0000177626	NCT00001776_26_T0	PHENOTYPE	2	3	Parkinson's disease
NCT0000177628	NCT00001776_28_T0	ORGAN	2	3	frontal lobe
NCT0000177629	NCT00001776_29_T0	PHENOTYPE	2	4	frontal lobe dementia
NCT0000177630	NCT00001776_30_T0	PHENOTYPE	9	9	seizures
NCT0000177630	NCT00001776_30_T1	PHENOTYPE	12	13	neurological disorders
NCT0000177632	NCT00001776_32_T0	PHENOTYPE	5	7	coronary artery disease
NCT0000177633	NCT00001776_33_T0	ORGAN	3	3	cranium
NCT0000177634	NCT00001776_34_T0	GENE	1	1	lines
NCT0000177635	NCT00001776_35_T0	PHENOTYPE	0	2	Increased intracranial pressure
NCT000017771	NCT00001777_1_T0	PHENOTYPE	4	4	progressive
NCT000017772	NCT00001777_2_T0	CELL	13	13	cells
NCT000017772	NCT00001777_2_T1	GENE	5	5	FLD
NCT000017772	NCT00001777_2_T2	ORGAN	17	18	frontal lobe
NCT000017772	NCT00001777_2_T3	PHENOTYPE	2	4	frontal lobe dementia
NCT000017774	NCT00001777_4_T0	GENE	4	4	FLD
NCT000017775	NCT00001777_5_T0	CELL	4	4	cells
NCT000017775	NCT00001777_5_T1	ORGAN	8	9	frontal lobe
NCT000017776	NCT00001777_6_T0	CELL	10	10	neurons
NCT000017776	NCT00001777_6_T1	CELL	15	15	neurons
NCT000017777	NCT00001777_7_T0	PHENOTYPE	11	11	symptoms
NCT000017777	NCT00001777_7_T1	GENE	13	13	FLD
NCT0000177710	NCT00001777_10_T0	GENE	5	5	blocker
NCT0000177710	NCT00001777_10_T1	GENE	32	32	has
NCT0000177710	NCT00001777_10_T2	GENE	29	30	cytochrome P-450
NCT0000177711	NCT00001777_11_T0	PHENOTYPE	14	14	symptoms
NCT0000177711	NCT00001777_11_T1	GENE	17	17	FLD
NCT0000177715	NCT00001777_15_T0	PHENOTYPE	12	12	dysfunction
NCT0000177715	NCT00001777_15_T1	ORGAN	10	11	frontal lobe
NCT0000177717	NCT00001777_17_T0	PHENOTYPE	22	23	cognitive functions
NCT0000177718	NCT00001777_18_T0	GENE	21	21	CSF
NCT0000177720	NCT00001777_20_T0	GENE	0	0	FLD
NCT0000177726	NCT00001777_26_T0	PHENOTYPE	17	17	psychosis
NCT0000177726	NCT00001777_26_T1	PHENOTYPE	19	20	multiple sclerosis
NCT0000177726	NCT00001777_26_T2	PHENOTYPE	22	24	spinal cord injury
NCT0000177726	NCT00001777_26_T3	PHENOTYPE	5	7	traumatic brain injury
NCT000017782	NCT00001778_2_T0	PHENOTYPE	16	16	progression
NCT000017786	NCT00001778_6_T0	PHENOTYPE	12	12	progression
NCT000017789	NCT00001778_9_T0	CELL	6	6	lymphocytes
NCT000017789	NCT00001778_9_T1	ORGAN	3	3	serum
NCT000017789	NCT00001778_9_T2	ORGAN	4	4	plasma
NCT0000177810	NCT00001778_10_T0	PHENOTYPE	1	1	punctures
NCT0000177815	NCT00001778_15_T0	PHENOTYPE	20	20	associations
NCT0000177817	NCT00001778_17_T0	PHENOTYPE	14	14	myositis
NCT0000177818	NCT00001778_18_T0	GENE	14	14	IV
NCT0000177818	NCT00001778_18_T1	PHENOTYPE	15	16	drug abuse
NCT0000177818	NCT00001778_18_T2	PHENOTYPE	28	29	neurological disease
NCT0000177820	NCT00001778_20_T0	PHENOTYPE	12	13	viral infections
NCT0000177824	NCT00001778_24_T0	PHENOTYPE	12	12	progression
NCT0000177827	NCT00001778_27_T0	CELL	6	6	lymphocytes
NCT0000177827	NCT00001778_27_T1	ORGAN	3	3	serum
NCT0000177827	NCT00001778_27_T2	ORGAN	4	4	plasma
NCT0000177828	NCT00001778_28_T0	PHENOTYPE	1	1	punctures
NCT000017804	NCT00001780_4_T0	MOLECULAR_FUNCTION	23	24	motor activity
NCT000017805	NCT00001780_5_T0	TISSUE	11	11	muscles
NCT0000178010	NCT00001780_10_T0	GENE	3	3	has
NCT0000178010	NCT00001780_10_T1	PHENOTYPE	9	10	neurologic disorders
NCT0000178014	NCT00001780_14_T0	ORGAN	4	5	corticospinal tract
NCT0000178019	NCT00001780_19_T0	ORGAN	5	5	cranium
NCT0000178020	NCT00001780_20_T0	GENE	3	3	lines
NCT000017812	NCT00001781_2_T0	CELL	16	16	cells
NCT000017812	NCT00001781_2_T1	PHENOTYPE	3	3	diseases
NCT000017812	NCT00001781_2_T2	PHENOTYPE	0	0	Autoimmune
NCT000017812	NCT00001781_2_T3	ORGAN	8	9	immune system
NCT000017813	NCT00001781_3_T0	CELL	10	10	myelin
NCT000017813	NCT00001781_3_T1	CELL	12	12	cells
NCT000017813	NCT00001781_3_T2	GENE	4	4	MS
NCT000017813	NCT00001781_3_T3	ORGAN	6	7	immune system
NCT000017814	NCT00001781_4_T0	PHENOTYPE	10	10	symptoms
NCT000017814	NCT00001781_4_T1	CELL	1	1	myelin
NCT000017815	NCT00001781_5_T0	GENE	18	18	MS
NCT000017815	NCT00001781_5_T1	PHENOTYPE	16	17	Multiple Sclerosis
NCT000017816	NCT00001781_6_T0	CELL	10	10	myelin
NCT000017816	NCT00001781_6_T1	GENE	4	5	protein similar
NCT000017817	NCT00001781_7_T0	CELL	11	11	myelin
NCT000017818	NCT00001781_8_T0	GENE	7	7	has
NCT0000178111	NCT00001781_11_T0	GENE	28	28	MRI
NCT0000178111	NCT00001781_11_T1	PHENOTYPE	20	21	Multiple Sclerosis
NCT0000178113	NCT00001781_13_T0	GENE	16	16	MRI
NCT0000178113	NCT00001781_13_T1	GENE	12	12	MS
NCT0000178114	NCT00001781_14_T0	GENE	2	2	MS
NCT0000178115	NCT00001781_15_T0	GENE	0	0	II
NCT0000178115	NCT00001781_15_T1	GENE	12	12	MS
NCT0000178117	NCT00001781_17_T0	GENE	15	15	MRI
NCT0000178117	NCT00001781_17_T1	GENE	0	0	III
NCT0000178120	NCT00001781_20_T0	GENE	18	18	MRI
NCT0000178120	NCT00001781_20_T1	GENE	35	35	MS
NCT0000178120	NCT00001781_20_T2	PHENOTYPE	32	32	progressive
NCT0000178120	NCT00001781_20_T3	PHENOTYPE	12	13	inflammatory disease
NCT0000178124	NCT00001781_24_T0	GENE	0	0	MS
NCT0000178124	NCT00001781_24_T1	PHENOTYPE	22	22	demyelination
NCT0000178124	NCT00001781_24_T2	CELL	11	12	T cells
NCT0000178124	NCT00001781_24_T3	ORGAN	4	5	immune system
NCT0000178124	NCT00001781_24_T4	CELL	24	25	myelin sheaths
NCT0000178124	NCT00001781_24_T5	ORGAN	16	18	central nervous system
NCT0000178125	NCT00001781_25_T0	GENE	19	19	MS
NCT0000178125	NCT00001781_25_T1	GENE	2	2	MBP
NCT0000178125	NCT00001781_25_T2	GENE	11	11	MBP
NCT0000178125	NCT00001781_25_T3	BIOLOGICAL_PROCESS	12	13	immune response
NCT0000178125	NCT00001781_25_T4	CELL	4	5	T cells
NCT0000178127	NCT00001781_27_T0	GENE	9	9	MRI
NCT0000178127	NCT00001781_27_T1	GENE	18	18	MRI
NCT0000178127	NCT00001781_27_T2	GENE	24	24	MRI
NCT0000178127	NCT00001781_27_T3	GENE	33	33	0.5
NCT0000178127	NCT00001781_27_T4	GENE	3	3	had
NCT0000178128	NCT00001781_28_T0	PHENOTYPE	3	3	relapse
NCT0000178130	NCT00001781_30_T0	GENE	0	0	Expanded
NCT0000178130	NCT00001781_30_T1	COMPOUND	4	4	EDSS
NCT0000178132	NCT00001781_32_T0	PHENOTYPE	4	4	menopausal
NCT000017822	NCT00001782_2_T0	GENE	22	22	ASL
NCT000017822	NCT00001782_2_T1	PHENOTYPE	8	10	right and left
NCT000017824	NCT00001782_4_T0	GENE	15	15	ASL
NCT000017825	NCT00001782_5_T0	GENE	16	16	ASL
NCT0000178211	NCT00001782_11_T0	PHENOTYPE	8	8	seizures
NCT0000178211	NCT00001782_11_T1	PHENOTYPE	13	14	demyelinating disorders
NCT0000178213	NCT00001782_13_T0	PHENOTYPE	4	5	coronary disease
NCT0000178214	NCT00001782_14_T0	ORGAN	6	6	cranium
NCT0000178215	NCT00001782_15_T0	GENE	4	4	lines
NCT0000178216	NCT00001782_16_T0	PHENOTYPE	3	5	increased intracranial pressure
NCT000017832	NCT00001783_2_T0	GENE	9	9	MRI
NCT000017832	NCT00001783_2_T1	GENE	16	16	TMS
NCT000017832	NCT00001783_2_T2	PHENOTYPE	3	4	motor function
NCT000017838	NCT00001783_8_T0	GENE	27	27	TMS
NCT000017838	NCT00001783_8_T1	PHENOTYPE	7	8	motor function
NCT000017839	NCT00001783_9_T0	GENE	10	10	amph
NCT0000178313	NCT00001783_13_T0	GENE	4	4	II
NCT0000178316	NCT00001783_16_T0	ORGAN	5	6	brain stem
NCT0000178317	NCT00001783_17_T0	PHENOTYPE	1	2	cerebral lesions
NCT0000178320	NCT00001783_20_T0	PHENOTYPE	2	3	head injury
NCT0000178320	NCT00001783_20_T1	PHENOTYPE	5	7	loss of consciousness
NCT0000178321	NCT00001783_21_T0	PHENOTYPE	0	1	Terminal illness
NCT0000178322	NCT00001783_22_T0	PHENOTYPE	2	2	diseases
NCT0000178323	NCT00001783_23_T0	PHENOTYPE	3	6	alcohol or drug abuse
NCT0000178324	NCT00001783_24_T0	PHENOTYPE	2	3	psychiatric illness
NCT0000178325	NCT00001783_25_T0	PHENOTYPE	5	6	arterial hypertension
NCT0000178325	NCT00001783_25_T1	PHENOTYPE	1	2	cardiac dysrhythmia
NCT0000178326	NCT00001783_26_T0	PHENOTYPE	1	1	hyperthyroidism
NCT0000178328	NCT00001783_28_T0	COMPOUND	9	9	haloperidol
NCT0000178328	NCT00001783_28_T1	COMPOUND	3	3	clonidine
NCT0000178328	NCT00001783_28_T2	GENE	6	6	GABA
NCT0000178328	NCT00001783_28_T3	COMPOUND	5	5	phenytoin
NCT0000178328	NCT00001783_28_T4	COMPOUND	8	8	scopolamine
NCT0000178328	NCT00001783_28_T5	COMPOUND	4	4	prazosin
NCT0000178329	NCT00001783_29_T0	PHENOTYPE	2	2	aphasia
NCT0000178329	NCT00001783_29_T1	PHENOTYPE	4	5	cognitive deficit
NCT000017844	NCT00001784_4_T0	PHENOTYPE	12	12	dystonia
NCT000017844	NCT00001784_4_T1	COMPOUND	5	5	lidocaine
NCT000017846	NCT00001784_6_T0	PHENOTYPE	13	13	dystonia
NCT000017847	NCT00001784_7_T0	GENE	11	12	Group 1
NCT0000178412	NCT00001784_12_T0	COMPOUND	14	14	mexiletine
NCT0000178412	NCT00001784_12_T1	ORGAN	18	19	nervous system
NCT0000178414	NCT00001784_14_T0	PHENOTYPE	6	6	dystonia
NCT0000178415	NCT00001784_15_T0	COMPOUND	6	6	lidocaine
NCT0000178415	NCT00001784_15_T1	PHENOTYPE	11	12	dystonic movements
NCT0000178419	NCT00001784_19_T0	PHENOTYPE	7	7	dystonia
NCT0000178419	NCT00001784_19_T1	PHENOTYPE	16	16	dysfunction
NCT0000178419	NCT00001784_19_T2	ORGAN	19	20	nervous system
NCT0000178420	NCT00001784_20_T0	PHENOTYPE	18	18	dystonia
NCT0000178420	NCT00001784_20_T1	COMPOUND	8	8	mexiletine
NCT0000178422	NCT00001784_22_T0	PHENOTYPE	20	20	peripheral
NCT0000178422	NCT00001784_22_T1	PHENOTYPE	10	10	localize
NCT0000178422	NCT00001784_22_T2	PHENOTYPE	23	23	inhibition
NCT0000178422	NCT00001784_22_T3	COMPOUND	17	17	mexiletine
NCT0000178423	NCT00001784_23_T0	GENE	4	4	blink
NCT0000178423	NCT00001784_23_T1	BIOLOGICAL_PROCESS	5	5	reflex
NCT0000178423	NCT00001784_23_T2	BIOLOGICAL_PROCESS	10	10	reflex
NCT0000178426	NCT00001784_26_T0	PHENOTYPE	15	16	cardiac disease
NCT0000178427	NCT00001784_27_T0	PHENOTYPE	27	27	Disease
NCT0000178427	NCT00001784_27_T1	GENE	15	15	structural
NCT0000178427	NCT00001784_27_T2	PHENOTYPE	44	44	seizures
NCT0000178427	NCT00001784_27_T3	PHENOTYPE	37	37	deformities
NCT0000178427	NCT00001784_27_T4	PHENOTYPE	25	25	trauma
NCT0000178427	NCT00001784_27_T5	PHENOTYPE	33	33	contractures
NCT0000178427	NCT00001784_27_T6	PHENOTYPE	21	21	dystonia
NCT0000178427	NCT00001784_27_T7	PHENOTYPE	16	17	brain lesions
NCT0000178427	NCT00001784_27_T8	PHENOTYPE	31	32	peripheral neuropathy
NCT0000178427	NCT00001784_27_T9	PHENOTYPE	28	29	Wilson's Disease
NCT0000178427	NCT00001784_27_T10	PHENOTYPE	60	62	peptic ulcer disease
NCT0000178428	NCT00001784_28_T0	COMPOUND	7	7	mexiletine
NCT000017851	NCT00001785_1_T0	CELL	13	14	T cells
NCT000017851	NCT00001785_1_T1	CELL	9	11	white blood cells
NCT000017852	NCT00001785_2_T0	CELL	0	1	T cells
NCT000017853	NCT00001785_3_T0	PHENOTYPE	5	5	leukemia
NCT000017853	NCT00001785_3_T1	PHENOTYPE	7	7	lymphoma
NCT000017853	NCT00001785_3_T2	GENE	1	1	has
NCT000017857	NCT00001785_7_T0	CELL	11	11	cells
NCT000017857	NCT00001785_7_T1	GENE	1	1	interferon
NCT000017858	NCT00001785_8_T0	GENE	0	0	Interferon
NCT000017858	NCT00001785_8_T1	GENE	1	1	has
NCT000017858	NCT00001785_8_T2	GENE	11	11	has
NCT000017858	NCT00001785_8_T3	PHENOTYPE	16	16	hepatitis
NCT000017858	NCT00001785_8_T4	PHENOTYPE	18	19	multiple sclerosis
NCT000017859	NCT00001785_9_T0	CELL	7	7	fibroblasts
NCT000017859	NCT00001785_9_T1	CELL	5	5	cells
NCT000017859	NCT00001785_9_T2	GENE	0	0	Interferon
NCT000017859	NCT00001785_9_T3	GENE	1	1	Beta
NCT0000178510	NCT00001785_10_T0	CELL	1	1	cells
NCT0000178510	NCT00001785_10_T1	TISSUE	9	10	connective tissue
NCT0000178511	NCT00001785_11_T0	GENE	13	14	interferon beta
NCT0000178515	NCT00001785_15_T0	GENE	15	15	MRI
NCT0000178518	NCT00001785_18_T0	GENE	6	6	CD8
NCT0000178518	NCT00001785_18_T1	CELL	7	8	T cells
NCT0000178520	NCT00001785_20_T0	GENE	26	26	CD86
NCT0000178520	NCT00001785_20_T1	GENE	25	25	CD80
NCT0000178520	NCT00001785_20_T2	BIOLOGICAL_PROCESS	12	12	transactivation
NCT0000178520	NCT00001785_20_T3	GENE	30	30	receptor
NCT0000178520	NCT00001785_20_T4	GENE	27	27	IL-2
NCT0000178520	NCT00001785_20_T5	PHENOTYPE	16	16	encoded
NCT0000178521	NCT00001785_21_T0	GENE	6	6	has
NCT0000178526	NCT00001785_26_T0	PHENOTYPE	9	9	acute
NCT0000178526	NCT00001785_26_T1	GENE	4	4	has
NCT0000178526	NCT00001785_26_T2	GENE	3	3	interferon
NCT0000178526	NCT00001785_26_T3	PHENOTYPE	11	12	chronic hepatitis
NCT0000178528	NCT00001785_28_T0	GENE	13	13	interferon
NCT0000178528	NCT00001785_28_T1	ORGAN	19	21	blood brain barrier
NCT0000178529	NCT00001785_29_T0	PHENOTYPE	26	26	peripheral
NCT0000178529	NCT00001785_29_T1	CELL	28	28	lymphocytes
NCT0000178529	NCT00001785_29_T2	PHENOTYPE	24	24	proliferation
NCT0000178529	NCT00001785_29_T3	GENE	4	5	interferon beta
NCT0000178531	NCT00001785_31_T0	PHENOTYPE	11	12	immune dysregulation
NCT0000178533	NCT00001785_33_T0	PHENOTYPE	10	10	proliferation
NCT0000178534	NCT00001785_34_T0	PHENOTYPE	2	2	secondary
NCT0000178537	NCT00001785_37_T0	PHENOTYPE	1	1	proliferation
NCT000017887	NCT00001788_7_T0	PHENOTYPE	10	10	recurrent
NCT000017887	NCT00001788_7_T1	PHENOTYPE	8	9	opportunistic infection
NCT000017891	NCT00001789_1_T0	ORGAN	2	3	immune system
NCT000017892	NCT00001789_2_T0	TISSUE	14	14	tissues
NCT000017892	NCT00001789_2_T1	PHENOTYPE	16	16	inflammation
NCT000017892	NCT00001789_2_T2	PHENOTYPE	4	4	lupus
NCT000017892	NCT00001789_2_T3	PHENOTYPE	1	2	autoimmune diseases
NCT000017893	NCT00001789_3_T0	PHENOTYPE	0	0	Lupus
NCT000017893	NCT00001789_3_T1	ORGAN	5	5	kidney
NCT000017893	NCT00001789_3_T2	CELL	6	6	cells
NCT000017897	NCT00001789_7_T0	GENE	5	5	tapered
NCT000017898	NCT00001789_8_T0	PHENOTYPE	22	24	quality of life
NCT000017899	NCT00001789_9_T0	ORGAN	4	4	kidney
NCT000017899	NCT00001789_9_T1	GENE	9	9	ray
NCT0000178911	NCT00001789_11_T0	PHENOTYPE	10	11	lupus nephritis
NCT0000178913	NCT00001789_13_T0	PHENOTYPE	6	7	lupus nephritis
NCT0000178914	NCT00001789_14_T0	GENE	13	13	CD40L
NCT0000178914	NCT00001789_14_T1	PHENOTYPE	24	24	blocks
NCT0000178914	NCT00001789_14_T2	PHENOTYPE	38	38	initiation
NCT0000178914	NCT00001789_14_T3	CELL	20	21	T lymphocytes
NCT0000178914	NCT00001789_14_T4	CELL	31	32	B cells
NCT0000178914	NCT00001789_14_T5	GENE	11	12	CD40 ligand
NCT0000178914	NCT00001789_14_T6	PHENOTYPE	41	42	antibody responses
NCT0000178915	NCT00001789_15_T0	PHENOTYPE	29	29	circulation
NCT0000178915	NCT00001789_15_T1	BIOLOGICAL_PROCESS	14	15	immune response
NCT0000178916	NCT00001789_16_T0	PHENOTYPE	12	12	proliferative
NCT0000178916	NCT00001789_16_T1	GENE	21	21	IV
NCT0000178916	NCT00001789_16_T2	PHENOTYPE	13	14	lupus nephritis
NCT0000178918	NCT00001789_18_T0	PHENOTYPE	1	1	secondary
NCT0000178918	NCT00001789_18_T1	GENE	24	24	C-3
NCT0000178918	NCT00001789_18_T2	PHENOTYPE	9	9	pharmacokinetics
NCT0000178918	NCT00001789_18_T3	COMPOUND	31	31	prednisone
NCT0000178918	NCT00001789_18_T4	PHENOTYPE	33	33	lupus
NCT0000178918	NCT00001789_18_T5	PHENOTYPE	36	38	quality of life
NCT0000178922	NCT00001789_22_T0	GENE	9	9	1.0
NCT0000178922	NCT00001789_22_T1	PHENOTYPE	2	2	proteinuria
NCT0000178924	NCT00001789_24_T0	GENE	0	0	C3
NCT0000178925	NCT00001789_25_T0	PHENOTYPE	0	0	Hematuria
NCT0000178928	NCT00001789_28_T0	COMPOUND	20	20	cardiolipin
NCT0000178928	NCT00001789_28_T1	PHENOTYPE	11	12	recurrent abortion
NCT0000178928	NCT00001789_28_T2	PHENOTYPE	6	7	venous thrombosis
NCT0000178929	NCT00001789_29_T0	PHENOTYPE	12	12	neoplasm
NCT0000178930	NCT00001789_30_T0	COMPOUND	12	12	creatinine
NCT0000178930	NCT00001789_30_T1	ORGAN	11	11	serum
NCT0000178930	NCT00001789_30_T2	PHENOTYPE	3	5	rapidly progressive glomerulonephritis
NCT0000178931	NCT00001789_31_T0	PHENOTYPE	3	4	fibrinoid necrosis
NCT0000178933	NCT00001789_33_T0	PHENOTYPE	16	16	HIV
NCT0000178933	NCT00001789_33_T1	PHENOTYPE	5	6	hepatitis B
NCT0000178933	NCT00001789_33_T2	PHENOTYPE	10	11	hepatitis C
NCT0000178934	NCT00001789_34_T0	GENE	5	5	CD4
NCT0000178937	NCT00001789_37_T0	COMPOUND	8	8	cyclophosphamide
NCT0000178937	NCT00001789_37_T1	GENE	5	5	IV
NCT0000178938	NCT00001789_38_T0	COMPOUND	24	24	cyclosporine
NCT0000178938	NCT00001789_38_T1	GENE	39	39	0.5
NCT0000178938	NCT00001789_38_T2	COMPOUND	23	23	methylprednisolone
NCT0000178938	NCT00001789_38_T3	COMPOUND	30	30	prednisone
NCT0000178938	NCT00001789_38_T4	GENE	22	22	IV
NCT0000178939	NCT00001789_39_T0	PHENOTYPE	3	3	initiation
NCT0000178939	NCT00001789_39_T1	GENE	7	7	ACE
NCT0000178940	NCT00001789_40_T0	PHENOTYPE	3	3	initiation
NCT0000178940	NCT00001789_40_T1	COMPOUND	7	7	azathioprine
NCT0000178940	NCT00001789_40_T2	COMPOUND	8	8	methotrexate
NCT0000178941	NCT00001789_41_T0	GENE	10	10	IV
NCT0000178943	NCT00001789_43_T0	PHENOTYPE	3	3	menopausal
NCT0000178943	NCT00001789_43_T1	PHENOTYPE	6	6	sterile
NCT0000178945	NCT00001789_45_T0	PHENOTYPE	4	6	positive pregnancy test
NCT000017900	NCT00001790_0_T0	PHENOTYPE	6	6	Tolerance
NCT000017900	NCT00001790_0_T1	PHENOTYPE	8	8	Pharmacokinetics
NCT000017900	NCT00001790_0_T2	PHENOTYPE	15	15	Fever
NCT000017900	NCT00001790_0_T3	PHENOTYPE	17	17	Neutropenia
NCT000017903	NCT00001790_3_T0	PHENOTYPE	16	16	fever
NCT000017903	NCT00001790_3_T1	PHENOTYPE	18	18	neutropenia
NCT000017903	NCT00001790_3_T2	CELL	20	20	neutrophil
NCT000017904	NCT00001790_4_T0	GENE	19	19	2.12
NCT000017905	NCT00001790_5_T0	GENE	10	10	1.0
NCT000017905	NCT00001790_5_T1	GENE	17	17	1.5
NCT000017907	NCT00001790_7_T0	GENE	16	16	2.12
NCT000017908	NCT00001790_8_T0	GENE	9	9	0.5
NCT000017909	NCT00001790_9_T0	GENE	7	7	1.0
NCT0000179010	NCT00001790_10_T0	GENE	7	7	1.5
NCT0000179012	NCT00001790_12_T0	PHENOTYPE	7	7	neutropenia
NCT0000179012	NCT00001790_12_T1	PHENOTYPE	19	19	initiation
NCT0000179012	NCT00001790_12_T2	GENE	8	8	ANC
NCT0000179012	NCT00001790_12_T3	COMPOUND	30	31	amphotericin B
NCT0000179012	NCT00001790_12_T4	PHENOTYPE	39	40	fungal infection
NCT0000179012	NCT00001790_12_T5	COMPOUND	22	24	deoxycholate amphotericin B
NCT0000179014	NCT00001790_14_T0	GENE	34	34	has
NCT0000179014	NCT00001790_14_T1	COMPOUND	23	24	amphotericin B
NCT0000179014	NCT00001790_14_T2	COMPOUND	54	55	amphotericin B
NCT0000179014	NCT00001790_14_T3	PHENOTYPE	38	39	fungal infection
NCT0000179014	NCT00001790_14_T4	COMPOUND	15	17	deoxycholate amphotericin B
NCT0000179014	NCT00001790_14_T5	COMPOUND	46	48	deoxycholate amphotericin B
NCT0000179017	NCT00001790_17_T0	PHENOTYPE	17	17	fever
NCT0000179017	NCT00001790_17_T1	PHENOTYPE	19	19	neutropenia
NCT0000179017	NCT00001790_17_T2	CELL	21	21	neutrophil
NCT0000179018	NCT00001790_18_T0	GENE	19	19	2.12
NCT0000179019	NCT00001790_19_T0	GENE	11	11	1.0
NCT0000179019	NCT00001790_19_T1	GENE	4	4	0.5
NCT0000179019	NCT00001790_19_T2	GENE	18	18	1.5
NCT0000179020	NCT00001790_20_T0	GENE	0	0	2.0
NCT0000179020	NCT00001790_20_T1	GENE	7	7	3.0
NCT0000179020	NCT00001790_20_T2	GENE	15	15	4.0
NCT0000179022	NCT00001790_22_T0	GENE	16	16	2.12
NCT0000179023	NCT00001790_23_T0	GENE	9	9	0.5
NCT0000179024	NCT00001790_24_T0	GENE	7	7	1.0
NCT0000179025	NCT00001790_25_T0	GENE	7	7	1.5
NCT0000179026	NCT00001790_26_T0	GENE	7	7	2.0
NCT0000179027	NCT00001790_27_T0	GENE	7	7	3.0
NCT0000179028	NCT00001790_28_T0	GENE	7	7	4.0
NCT0000179029	NCT00001790_29_T0	PHENOTYPE	7	7	neutropenia
NCT0000179029	NCT00001790_29_T1	PHENOTYPE	19	19	initiation
NCT0000179029	NCT00001790_29_T2	GENE	8	8	ANC
NCT0000179029	NCT00001790_29_T3	COMPOUND	30	31	amphotericin B
NCT0000179029	NCT00001790_29_T4	PHENOTYPE	39	40	fungal infection
NCT0000179029	NCT00001790_29_T5	COMPOUND	22	24	deoxycholate amphotericin B
NCT0000179031	NCT00001790_31_T0	GENE	34	34	has
NCT0000179031	NCT00001790_31_T1	COMPOUND	23	24	amphotericin B
NCT0000179031	NCT00001790_31_T2	COMPOUND	54	55	amphotericin B
NCT0000179031	NCT00001790_31_T3	PHENOTYPE	38	39	fungal infection
NCT0000179031	NCT00001790_31_T4	COMPOUND	15	17	deoxycholate amphotericin B
NCT0000179031	NCT00001790_31_T5	COMPOUND	46	48	deoxycholate amphotericin B
NCT0000179033	NCT00001790_33_T0	PHENOTYPE	7	7	neutropenia
NCT0000179033	NCT00001790_33_T1	PHENOTYPE	5	5	fever
NCT0000179036	NCT00001790_36_T0	PHENOTYPE	7	9	negative pregnancy test
NCT0000179039	NCT00001790_39_T0	PHENOTYPE	7	8	fungal infection
NCT0000179041	NCT00001790_41_T0	COMPOUND	6	7	amphotericin B
NCT0000179041	NCT00001790_41_T1	COMPOUND	11	12	amphotericin B
NCT0000179042	NCT00001790_42_T0	COMPOUND	5	5	fluconazole
NCT000017973	NCT00001797_3_T0	GENE	14	14	SC
NCT000017973	NCT00001797_3_T1	GENE	21	21	SC
NCT000017974	NCT00001797_4_T0	PHENOTYPE	24	24	Psoriasis
NCT000017974	NCT00001797_4_T1	PHENOTYPE	26	26	Severity
NCT0000179715	NCT00001797_15_T0	GENE	14	14	SC
NCT0000179715	NCT00001797_15_T1	GENE	21	21	SC
NCT0000179716	NCT00001797_16_T0	PHENOTYPE	24	24	Psoriasis
NCT0000179716	NCT00001797_16_T1	PHENOTYPE	26	26	Severity
NCT0000179733	NCT00001797_33_T0	PHENOTYPE	3	3	acute
NCT0000179733	NCT00001797_33_T1	PHENOTYPE	14	14	hepatitis
NCT0000179733	NCT00001797_33_T2	GENE	26	26	IL-10
NCT0000179733	NCT00001797_33_T3	PHENOTYPE	18	18	HIV
NCT0000179733	NCT00001797_33_T4	PHENOTYPE	15	16	herpes zoster
NCT0000179733	NCT00001797_33_T5	PHENOTYPE	5	6	chronic infections
NCT0000179733	NCT00001797_33_T6	PHENOTYPE	20	21	fungal infections
NCT0000179733	NCT00001797_33_T7	ORGAN	29	30	immune system
NCT0000179735	NCT00001797_35_T0	COMPOUND	10	10	hydroxychloroquine
NCT0000179735	NCT00001797_35_T1	COMPOUND	8	8	sulfasalazine
NCT0000179735	NCT00001797_35_T2	COMPOUND	11	11	cyclosporin
NCT0000179735	NCT00001797_35_T3	COMPOUND	13	13	cyclophosphamide
NCT0000179735	NCT00001797_35_T4	COMPOUND	12	12	azathioprine
NCT0000179735	NCT00001797_35_T5	COMPOUND	7	7	methotrexate
NCT0000179735	NCT00001797_35_T6	COMPOUND	14	14	chlorambucil
NCT0000179735	NCT00001797_35_T7	COMPOUND	16	17	vitamin D
NCT0000179739	NCT00001797_39_T0	GENE	22	22	hematocrit
NCT0000179739	NCT00001797_39_T1	CELL	30	30	platelet
NCT0000179740	NCT00001797_40_T0	COMPOUND	4	4	creatinine
NCT0000179740	NCT00001797_40_T1	COMPOUND	9	9	creatinine
NCT0000179740	NCT00001797_40_T2	GENE	7	7	1.8
NCT0000179740	NCT00001797_40_T3	ORGAN	3	3	serum
NCT0000179741	NCT00001797_41_T0	COMPOUND	27	27	UNL
NCT0000179741	NCT00001797_41_T1	COMPOUND	32	32	UNL
NCT0000179741	NCT00001797_41_T2	ORGAN	8	8	serum
NCT0000179741	NCT00001797_41_T3	ORGAN	12	12	serum
NCT0000179741	NCT00001797_41_T4	PHENOTYPE	29	30	bilirubin levels
NCT0000179741	NCT00001797_41_T5	GENE	17	18	alkaline phosphatase
NCT0000179741	NCT00001797_41_T6	PHENOTYPE	3	6	abnormal liver function tests
NCT000018036	NCT00001803_6_T0	PHENOTYPE	3	3	discomfort
NCT0000180319	NCT00001803_19_T0	PHENOTYPE	3	3	discomfort
NCT000018051	NCT00001805_1_T0	GENE	29	29	B3
NCT000018051	NCT00001805_1_T1	PHENOTYPE	25	25	carcinoma
NCT000018052	NCT00001805_2_T0	PHENOTYPE	8	8	tumor
NCT000018052	NCT00001805_2_T1	PHENOTYPE	6	6	pharmacokinetics
NCT000018054	NCT00001805_4_T0	GENE	29	29	B3
NCT000018054	NCT00001805_4_T1	PHENOTYPE	25	25	carcinoma
NCT000018055	NCT00001805_5_T0	PHENOTYPE	8	8	tumor
NCT000018055	NCT00001805_5_T1	PHENOTYPE	6	6	pharmacokinetics
NCT000018057	NCT00001805_7_T0	GENE	5	5	B3
NCT000018057	NCT00001805_7_T1	CELL	17	17	cells
NCT000018057	NCT00001805_7_T2	PHENOTYPE	16	16	tumor
NCT0000180512	NCT00001805_12_T0	PHENOTYPE	5	5	toxic
NCT0000180514	NCT00001805_14_T0	COMPOUND	16	16	nitrosourea
NCT0000180515	NCT00001805_15_T0	ORGAN	3	3	serum
NCT0000180516	NCT00001805_16_T0	PHENOTYPE	12	12	HIV
NCT0000180516	NCT00001805_16_T1	PHENOTYPE	4	5	hepatitis B
NCT0000180516	NCT00001805_16_T2	PHENOTYPE	8	9	hepatitis C
NCT0000180517	NCT00001805_17_T0	PHENOTYPE	12	12	CHF
NCT0000180517	NCT00001805_17_T1	PHENOTYPE	13	13	arrhythmia
NCT0000180517	NCT00001805_17_T2	PHENOTYPE	6	8	coronary artery disease
NCT0000180518	NCT00001805_18_T0	PHENOTYPE	5	5	FVC
NCT0000180520	NCT00001805_20_T0	PHENOTYPE	14	14	malignancy
NCT0000180520	NCT00001805_20_T1	PHENOTYPE	6	7	CNS metastasis
NCT0000180520	NCT00001805_20_T2	PHENOTYPE	10	11	seizure disorders
NCT0000180521	NCT00001805_21_T0	PHENOTYPE	4	4	acute
NCT0000180521	NCT00001805_21_T1	PHENOTYPE	15	15	resolved
NCT0000180521	NCT00001805_21_T2	PHENOTYPE	5	6	bacterial infection
NCT0000180525	NCT00001805_25_T0	COMPOUND	9	9	penicillin
NCT0000180525	NCT00001805_25_T1	PHENOTYPE	6	7	allergic reaction
NCT000018061	NCT00001806_1_T0	GENE	7	7	BRCA1
NCT000018061	NCT00001806_1_T1	GENE	9	9	BRCA2
NCT000018061	NCT00001806_1_T2	PHENOTYPE	20	21	ovarian cancer
NCT000018063	NCT00001806_3_T0	PHENOTYPE	12	12	focused
NCT000018063	NCT00001806_3_T1	PHENOTYPE	19	19	decisions
NCT000018063	NCT00001806_3_T2	PHENOTYPE	6	6	oncology
NCT0000180611	NCT00001806_11_T0	GENE	8	8	BRCA1
NCT0000180611	NCT00001806_11_T1	GENE	10	10	BRCA2
NCT0000180613	NCT00001806_13_T0	PHENOTYPE	23	24	breast cancer
NCT0000180614	NCT00001806_14_T0	GENE	4	4	has
NCT0000180616	NCT00001806_16_T0	PHENOTYPE	2	2	centers
NCT0000180625	NCT00001806_25_T0	PHENOTYPE	14	15	psychological disorder
NCT000018072	NCT00001807_2_T0	GENE	3	3	MRI
NCT000018075	NCT00001807_5_T0	PHENOTYPE	9	9	disorders
NCT000018075	NCT00001807_5_T1	PHENOTYPE	12	12	disorders
NCT000018075	NCT00001807_5_T2	GENE	1	1	has
NCT000018076	NCT00001807_6_T0	PHENOTYPE	11	11	toxicities
NCT000018077	NCT00001807_7_T0	PHENOTYPE	27	27	toxicity
NCT000018077	NCT00001807_7_T1	PHENOTYPE	11	11	neurotoxicity
NCT0000180711	NCT00001807_11_T0	PHENOTYPE	9	9	disorders
NCT0000180711	NCT00001807_11_T1	PHENOTYPE	12	12	disorders
NCT0000180711	NCT00001807_11_T2	GENE	1	1	has
NCT0000180712	NCT00001807_12_T0	PHENOTYPE	13	13	neurotoxicity
NCT0000180713	NCT00001807_13_T0	PHENOTYPE	28	28	neurotoxicity
NCT0000180713	NCT00001807_13_T1	GENE	21	21	OR
NCT0000180713	NCT00001807_13_T2	PHENOTYPE	3	4	brain tumors
NCT0000180716	NCT00001807_16_T0	GENE	4	4	DPA
NCT0000180721	NCT00001807_21_T0	PHENOTYPE	10	10	tumor
NCT0000180722	NCT00001807_22_T0	PHENOTYPE	22	22	anesthesia
NCT0000180722	NCT00001807_22_T1	PHENOTYPE	9	10	psychological factors
NCT0000180723	NCT00001807_23_T0	BIOLOGICAL_PROCESS	6	6	reflex
NCT0000180723	NCT00001807_23_T1	GENE	5	5	gag
NCT0000180723	NCT00001807_23_T2	PHENOTYPE	8	9	swallowing difficulties
NCT0000180724	NCT00001807_24_T0	COMPOUND	11	11	ferrous
NCT000018101	NCT00001810_1_T0	GENE	5	5	II
NCT000018101	NCT00001810_1_T1	COMPOUND	14	14	voriconazole
NCT000018101	NCT00001810_1_T2	PHENOTYPE	21	23	invasive fungal infections
NCT000018102	NCT00001810_2_T0	PHENOTYPE	11	11	centers
NCT000018103	NCT00001810_3_T0	PHENOTYPE	11	12	fungal infection
NCT000018107	NCT00001810_7_T0	COMPOUND	14	14	voriconazole
NCT000018107	NCT00001810_7_T1	GENE	5	5	III
NCT000018107	NCT00001810_7_T2	PHENOTYPE	21	23	invasive fungal infections
NCT000018108	NCT00001810_8_T0	PHENOTYPE	11	11	centers
NCT000018109	NCT00001810_9_T0	PHENOTYPE	11	12	fungal infection
NCT0000181013	NCT00001810_13_T0	PHENOTYPE	35	36	fungal infection
NCT0000181013	NCT00001810_13_T1	PHENOTYPE	9	11	invasive fungal infections
NCT0000181015	NCT00001810_15_T0	GENE	23	23	OR
NCT0000181015	NCT00001810_15_T1	GENE	43	43	OR
NCT0000181015	NCT00001810_15_T2	GENE	57	57	2.0
NCT0000181015	NCT00001810_15_T3	GENE	36	36	1.5
NCT0000181015	NCT00001810_15_T4	PHENOTYPE	14	14	toxicities
NCT0000181015	NCT00001810_15_T5	GENE	31	31	had
NCT0000181015	NCT00001810_15_T6	COMPOUND	29	29	creatinine
NCT0000181015	NCT00001810_15_T7	COMPOUND	51	51	creatinine
NCT0000181015	NCT00001810_15_T8	ORGAN	28	28	serum
NCT0000181015	NCT00001810_15_T9	ORGAN	50	50	serum
NCT0000181015	NCT00001810_15_T10	PHENOTYPE	24	24	Nephrotoxicity
NCT0000181015	NCT00001810_15_T11	COMPOUND	16	17	amphotericin B
NCT0000181015	NCT00001810_15_T12	COMPOUND	40	41	amphotericin B
NCT0000181015	NCT00001810_15_T13	COMPOUND	64	65	amphotericin B
NCT0000181015	NCT00001810_15_T14	PHENOTYPE	45	46	renal impairment
NCT0000181017	NCT00001810_17_T0	PHENOTYPE	10	10	menopausal
NCT0000181017	NCT00001810_17_T1	ORGAN	15	15	serum
NCT0000181022	NCT00001810_22_T0	COMPOUND	21	21	cisapride
NCT0000181022	NCT00001810_22_T1	COMPOUND	20	20	terfenadine
NCT0000181022	NCT00001810_22_T2	COMPOUND	23	23	astemizole
NCT0000181023	NCT00001810_23_T0	PHENOTYPE	35	35	hypoglycemia
NCT0000181023	NCT00001810_23_T1	ORGAN	30	30	plasma
NCT0000181024	NCT00001810_24_T0	COMPOUND	33	33	voriconazole
NCT0000181024	NCT00001810_24_T1	COMPOUND	15	15	carbamazepine
NCT0000181027	NCT00001810_27_T0	COMPOUND	5	5	creatinine
NCT0000181027	NCT00001810_27_T1	GENE	8	8	3.5
NCT0000181027	NCT00001810_27_T2	ORGAN	4	4	serum
NCT0000181027	NCT00001810_27_T3	PHENOTYPE	16	16	chronic
NCT0000181027	NCT00001810_27_T4	PHENOTYPE	12	14	end-stage renal disease
NCT0000181028	NCT00001810_28_T0	PHENOTYPE	7	7	aspergilloma
NCT0000181028	NCT00001810_28_T1	PHENOTYPE	8	8	zygomycoses
NCT0000181028	NCT00001810_28_T2	PHENOTYPE	13	13	candidemia
NCT0000181028	NCT00001810_28_T3	PHENOTYPE	5	6	bronchopulmonary aspergillosis
NCT0000181029	NCT00001810_29_T0	PHENOTYPE	14	14	dermatophytosis
NCT0000181029	NCT00001810_29_T1	PHENOTYPE	16	17	oropharyngeal candidiasis
NCT0000181029	NCT00001810_29_T2	PHENOTYPE	4	5	fungal infections
NCT0000181030	NCT00001810_30_T0	PHENOTYPE	33	33	HIV/AIDS
NCT0000181030	NCT00001810_30_T1	PHENOTYPE	34	35	opportunistic infections
NCT000018120	NCT00001812_0_T0	GENE	23	23	Interleukin-2
NCT000018120	NCT00001812_0_T1	PHENOTYPE	16	16	Irritation
NCT000018123	NCT00001812_3_T0	GENE	17	17	IL-2
NCT000018126	NCT00001812_6_T0	GENE	17	17	IL-2
NCT000018128	NCT00001812_8_T0	COMPOUND	29	29	nystatin
NCT000018128	NCT00001812_8_T1	PHENOTYPE	40	40	infections
NCT000018131	NCT00001813_1_T0	GENE	15	15	TTD
NCT000018136	NCT00001813_6_T0	GENE	14	14	TTD
NCT000018136	NCT00001813_6_T1	PHENOTYPE	18	19	overlap syndromes
NCT000018143	NCT00001814_3_T0	PHENOTYPE	2	2	mutation
NCT000018144	NCT00001814_4_T0	PHENOTYPE	4	4	disorders
NCT000018149	NCT00001814_9_T0	PHENOTYPE	7	7	disorders
NCT000018149	NCT00001814_9_T1	PHENOTYPE	13	14	renal cancer
NCT0000181410	NCT00001814_10_T0	PHENOTYPE	26	27	rare diseases
NCT0000181416	NCT00001814_16_T0	PHENOTYPE	2	2	mutation
NCT0000181417	NCT00001814_17_T0	PHENOTYPE	4	4	disorders
NCT0000181422	NCT00001814_22_T0	PHENOTYPE	7	7	disorders
NCT0000181422	NCT00001814_22_T1	PHENOTYPE	13	14	renal cancer
NCT0000181423	NCT00001814_23_T0	PHENOTYPE	26	27	rare diseases
NCT0000181614	NCT00001816_14_T0	PHENOTYPE	3	4	mental illness
NCT000018180	NCT00001818_0_T0	PHENOTYPE	5	6	HIV Infection
NCT000018182	NCT00001818_2_T0	COMPOUND	5	5	hydroxyurea
NCT000018182	NCT00001818_2_T1	PHENOTYPE	9	9	HIV
NCT000018182	NCT00001818_2_T2	PHENOTYPE	21	21	resistant
NCT000018183	NCT00001818_3_T0	COMPOUND	6	6	hydroxyurea
NCT000018183	NCT00001818_3_T1	PHENOTYPE	7	7	affects
NCT000018183	NCT00001818_3_T2	ORGAN	10	11	immune system
NCT000018184	NCT00001818_4_T0	PHENOTYPE	7	8	HIV infection
NCT000018186	NCT00001818_6_T0	COMPOUND	11	11	stavudine
NCT000018186	NCT00001818_6_T1	COMPOUND	7	7	didanosine
NCT000018186	NCT00001818_6_T2	COMPOUND	16	16	efavirenz
NCT000018188	NCT00001818_8_T0	COMPOUND	15	15	hydroxyurea
NCT000018188	NCT00001818_8_T1	COMPOUND	28	28	hydroxyurea
NCT000018188	NCT00001818_8_T2	PHENOTYPE	22	22	HIV
NCT000018188	NCT00001818_8_T3	PHENOTYPE	35	35	HIV
NCT0000181811	NCT00001818_11_T0	COMPOUND	7	7	hydroxyurea
NCT0000181814	NCT00001818_14_T0	PHENOTYPE	3	3	HIV
NCT0000181816	NCT00001818_16_T0	COMPOUND	4	4	hydroxyurea
NCT0000181817	NCT00001818_17_T0	GENE	26	26	CD4
NCT0000181817	NCT00001818_17_T1	COMPOUND	23	23	hydroxyurea
NCT0000181818	NCT00001818_18_T0	COMPOUND	25	25	hydroxyurea
NCT0000181818	NCT00001818_18_T1	COMPOUND	11	11	stavudine
NCT0000181818	NCT00001818_18_T2	COMPOUND	10	10	didanosine
NCT0000181818	NCT00001818_18_T3	COMPOUND	13	13	efavirenz
NCT0000181821	NCT00001818_21_T0	COMPOUND	12	12	hydroxyurea
NCT0000181824	NCT00001818_24_T0	PHENOTYPE	16	16	initiation
NCT0000181827	NCT00001818_27_T0	GENE	16	16	4.0
NCT0000181827	NCT00001818_27_T1	ORGAN	4	4	plasma
NCT0000181828	NCT00001818_28_T0	GENE	16	16	swallow
NCT0000181829	NCT00001818_29_T0	COMPOUND	7	7	creatinine
NCT0000181829	NCT00001818_29_T1	COMPOUND	10	10	creatinine
NCT0000181829	NCT00001818_29_T2	ORGAN	6	6	serum
NCT0000181830	NCT00001818_30_T0	CELL	5	5	granulocyte
NCT0000181830	NCT00001818_30_T1	GENE	10	10	hemoglobin
NCT0000181830	NCT00001818_30_T2	PHENOTYPE	16	17	platelet count
NCT0000181832	NCT00001818_32_T0	GENE	8	8	1.5
NCT0000181832	NCT00001818_32_T1	GENE	5	5	amylase
NCT0000181832	NCT00001818_32_T2	ORGAN	4	4	serum
NCT0000181833	NCT00001818_33_T0	GENE	4	5	pancreatic amylase
NCT0000181835	NCT00001818_35_T0	PHENOTYPE	3	4	critically ill
NCT0000181836	NCT00001818_36_T0	PHENOTYPE	8	8	malignancy
NCT0000181837	NCT00001818_37_T0	COMPOUND	7	7	hydroxyurea
NCT0000181838	NCT00001818_38_T0	PHENOTYPE	10	10	acute
NCT0000181841	NCT00001818_41_T0	GENE	4	4	G-CSF
NCT0000181841	NCT00001818_41_T1	GENE	6	6	GM-CSF
NCT0000181841	NCT00001818_41_T2	CELL	11	11	neutrophil
NCT0000181842	NCT00001818_42_T0	PHENOTYPE	4	5	peripheral neuropathy
NCT0000181843	NCT00001818_43_T0	PHENOTYPE	10	10	severity
NCT0000181843	NCT00001818_43_T1	GENE	7	7	III
NCT0000181843	NCT00001818_43_T2	PHENOTYPE	3	4	peripheral neuropathy
NCT0000181844	NCT00001818_44_T0	PHENOTYPE	7	7	pancreatitis
NCT0000181845	NCT00001818_45_T0	PHENOTYPE	4	4	pancreatitis
NCT0000181846	NCT00001818_46_T0	COMPOUND	11	11	stavudine
NCT0000181846	NCT00001818_46_T1	COMPOUND	12	12	didanosine
NCT0000181846	NCT00001818_46_T2	COMPOUND	14	14	efavirenz
NCT0000181846	NCT00001818_46_T3	PHENOTYPE	17	18	allergic symptoms
NCT0000181847	NCT00001818_47_T0	PHENOTYPE	13	13	attributable
NCT0000181847	NCT00001818_47_T1	COMPOUND	16	16	didanosine
NCT0000181847	NCT00001818_47_T2	PHENOTYPE	7	8	erythema multiforme
NCT0000181847	NCT00001818_47_T3	PHENOTYPE	10	12	Stevens Johnson Syndrome
NCT0000181848	NCT00001818_48_T0	PHENOTYPE	18	18	toxicity
NCT0000181848	NCT00001818_48_T1	TISSUE	14	14	epithelium
NCT0000181848	NCT00001818_48_T2	COMPOUND	17	17	didanosine
NCT000018236	NCT00001823_6_T0	GENE	12	12	neo
NCT000018236	NCT00001823_6_T1	PHENOTYPE	15	16	malignant tumors
NCT000018239	NCT00001823_9_T0	PHENOTYPE	8	9	malignant disease
NCT0000182315	NCT00001823_15_T0	PHENOTYPE	8	9	malignant disease
NCT000018261	NCT00001826_1_T0	GENE	18	19	protease inhibitor
NCT000018261	NCT00001826_1_T1	GENE	22	23	reverse transcriptase
NCT000018263	NCT00001826_3_T0	CELL	16	16	cells
NCT000018264	NCT00001826_4_T0	PHENOTYPE	9	9	influenza
NCT000018264	NCT00001826_4_T1	PHENOTYPE	11	11	tetanus
NCT000018264	NCT00001826_4_T2	ORGAN	5	6	immune system
NCT000018265	NCT00001826_5_T0	PHENOTYPE	8	8	HIV
NCT000018265	NCT00001826_5_T1	GENE	25	26	protease inhibitor
NCT000018265	NCT00001826_5_T2	GENE	28	29	reverse transcriptase
NCT000018267	NCT00001826_7_T0	CELL	9	11	white blood cells
NCT000018268	NCT00001826_8_T0	CELL	13	13	cells
NCT000018268	NCT00001826_8_T1	CELL	23	23	cells
NCT000018268	NCT00001826_8_T2	GENE	15	15	separated
NCT0000182610	NCT00001826_10_T0	GENE	20	20	protease
NCT0000182610	NCT00001826_10_T1	PHENOTYPE	22	22	HIV
NCT0000182610	NCT00001826_10_T2	PHENOTYPE	26	26	HIV
NCT0000182610	NCT00001826_10_T3	PHENOTYPE	29	29	Malignancy
NCT0000182613	NCT00001826_13_T0	GENE	13	14	protease inhibitor
NCT0000182613	NCT00001826_13_T1	GENE	34	35	protease inhibitor
NCT0000182613	NCT00001826_13_T2	GENE	16	17	reverse transcriptase
NCT0000182613	NCT00001826_13_T3	GENE	37	38	reverse transcriptase
NCT0000182616	NCT00001826_16_T0	PHENOTYPE	4	4	attributable
NCT0000182616	NCT00001826_16_T1	PHENOTYPE	3	3	toxicities
NCT0000182617	NCT00001826_17_T0	PHENOTYPE	21	22	cardiovascular disease
NCT0000182617	NCT00001826_17_T1	BIOLOGICAL_PROCESS	8	9	glucose metabolism
NCT0000182617	NCT00001826_17_T2	TISSUE	15	16	body fat
NCT0000182619	NCT00001826_19_T0	PHENOTYPE	8	8	Centers
NCT0000182620	NCT00001826_20_T0	GENE	13	13	PI
NCT0000182620	NCT00001826_20_T1	GENE	11	12	protease inhibitor
NCT0000182620	NCT00001826_20_T2	GENE	15	16	reverse transcriptase
NCT0000182622	NCT00001826_22_T0	GENE	1	1	CD4
NCT0000182622	NCT00001826_22_T1	CELL	2	3	T lymphocytes
NCT0000182623	NCT00001826_23_T0	PHENOTYPE	15	15	initiation
NCT0000182623	NCT00001826_23_T1	CELL	5	6	T lymphocytes
NCT0000182625	NCT00001826_25_T0	PHENOTYPE	2	3	Critically ill
NCT0000182628	NCT00001826_28_T0	CELL	23	23	T-cell
NCT000018271	NCT00001827_1_T0	PHENOTYPE	8	8	mutated
NCT000018271	NCT00001827_1_T1	CELL	23	23	cells
NCT000018271	NCT00001827_1_T2	PHENOTYPE	22	22	tumor
NCT000018271	NCT00001827_1_T3	GENE	11	11	p53
NCT000018271	NCT00001827_1_T4	PHENOTYPE	3	4	ovarian cancer
NCT000018272	NCT00001827_2_T0	ORGAN	3	4	immune system
NCT000018273	NCT00001827_3_T0	GENE	8	8	p53
NCT000018273	NCT00001827_3_T1	GENE	15	15	p53
NCT000018273	NCT00001827_3_T2	PHENOTYPE	27	27	tumor
NCT000018273	NCT00001827_3_T3	PHENOTYPE	3	4	ovarian cancer
NCT000018273	NCT00001827_3_T4	BIOLOGICAL_PROCESS	35	36	immune response
NCT000018275	NCT00001827_5_T0	GENE	5	5	p53
NCT000018277	NCT00001827_7_T0	GENE	13	13	IL-2
NCT000018277	NCT00001827_7_T1	GENE	15	15	GM-CSF
NCT000018277	NCT00001827_7_T2	ORGAN	11	12	immune system
NCT000018278	NCT00001827_8_T0	GENE	5	5	p53
NCT000018278	NCT00001827_8_T1	PHENOTYPE	0	1	Group B
NCT0000182711	NCT00001827_11_T0	GENE	11	11	has
NCT0000182711	NCT00001827_11_T1	GENE	13	13	p53
NCT0000182711	NCT00001827_11_T2	ORGAN	18	19	immune system
NCT0000182712	NCT00001827_12_T0	CELL	29	29	lymphocytes
NCT0000182712	NCT00001827_12_T1	PHENOTYPE	46	46	tuberculosis
NCT0000182712	NCT00001827_12_T2	CELL	34	34	cells
NCT0000182712	NCT00001827_12_T3	PHENOTYPE	5	5	tumor
NCT0000182712	NCT00001827_12_T4	PHENOTYPE	14	14	tumor
NCT0000182712	NCT00001827_12_T5	BIOLOGICAL_PROCESS	37	38	immune response
NCT0000182712	NCT00001827_12_T6	CELL	25	27	white blood cells
NCT0000182715	NCT00001827_15_T0	PHENOTYPE	1	1	mutation
NCT0000182715	NCT00001827_15_T1	GENE	3	3	p53
NCT0000182716	NCT00001827_16_T0	PHENOTYPE	14	14	mutation
NCT0000182716	NCT00001827_16_T1	PHENOTYPE	11	11	tumors
NCT0000182716	NCT00001827_16_T2	GENE	5	5	p53
NCT0000182721	NCT00001827_21_T0	PHENOTYPE	13	13	tumors
NCT0000182721	NCT00001827_21_T1	GENE	16	16	p53
NCT0000182721	NCT00001827_21_T2	GENE	21	21	p53
NCT0000182721	NCT00001827_21_T3	PHENOTYPE	8	9	ovarian cancer
NCT0000182722	NCT00001827_22_T0	GENE	23	23	IL-2
NCT0000182722	NCT00001827_22_T1	GENE	10	10	GM-CSF
NCT0000182722	NCT00001827_22_T2	CELL	16	17	dendritic cells
NCT0000182725	NCT00001827_25_T0	PHENOTYPE	3	6	adenocarcinoma of the ovary
NCT0000182726	NCT00001827_26_T0	PHENOTYPE	11	11	mutation
NCT0000182726	NCT00001827_26_T1	PHENOTYPE	0	0	Tumor
NCT0000182726	NCT00001827_26_T2	GENE	6	6	p53
NCT0000182727	NCT00001827_27_T0	PHENOTYPE	4	4	tumor
NCT0000182727	NCT00001827_27_T1	GENE	8	8	p53
NCT0000182728	NCT00001827_28_T0	PHENOTYPE	16	16	recurrent
NCT0000182728	NCT00001827_28_T1	GENE	14	14	IV
NCT0000182728	NCT00001827_28_T2	PHENOTYPE	12	13	stage III
NCT0000182728	NCT00001827_28_T3	PHENOTYPE	3	4	ovarian cancer
NCT0000182732	NCT00001827_32_T0	PHENOTYPE	8	8	acute
NCT0000182732	NCT00001827_32_T1	PHENOTYPE	9	9	toxicities
NCT0000182733	NCT00001827_33_T0	ORGAN	3	4	bone marrow
NCT0000182734	NCT00001827_34_T0	PHENOTYPE	34	34	toxicities
NCT0000182737	NCT00001827_37_T0	GENE	11	11	2.0
NCT0000182737	NCT00001827_37_T1	GENE	17	17	2.0
NCT0000182737	NCT00001827_37_T2	PHENOTYPE	27	27	HIV
NCT0000182737	NCT00001827_37_T3	PHENOTYPE	35	35	HBS
NCT0000182737	NCT00001827_37_T4	ORGAN	13	13	Serum
NCT0000182737	NCT00001827_37_T5	CELL	4	4	Platelets
NCT0000182737	NCT00001827_37_T6	ORGAN	49	50	immune system
NCT0000182737	NCT00001827_37_T7	PHENOTYPE	29	30	Hepatitis B
NCT0000182739	NCT00001827_39_T0	PHENOTYPE	6	8	negative pregnancy test
NCT0000182740	NCT00001827_40_T0	ORGAN	14	14	Heart
NCT0000182740	NCT00001827_40_T1	GENE	8	8	III
NCT0000182740	NCT00001827_40_T2	GENE	10	10	IV
NCT0000182740	NCT00001827_40_T3	GENE	32	32	ventricular
NCT0000182740	NCT00001827_40_T4	PHENOTYPE	15	15	Association
NCT0000182740	NCT00001827_40_T5	PHENOTYPE	20	21	myocardial infarction
NCT0000182740	NCT00001827_40_T6	PHENOTYPE	3	5	ischemic heart disease
NCT0000182740	NCT00001827_40_T7	PHENOTYPE	29	31	congestive heart failure
NCT0000182742	NCT00001827_42_T0	PHENOTYPE	14	14	mutation
NCT0000182742	NCT00001827_42_T1	PHENOTYPE	19	19	malignancy
NCT0000182743	NCT00001827_43_T0	PHENOTYPE	2	3	CNS metastases
NCT0000182745	NCT00001827_45_T0	PHENOTYPE	3	3	infections
NCT0000182746	NCT00001827_46_T0	PHENOTYPE	2	2	chronic
NCT000018306	NCT00001830_6_T0	PHENOTYPE	11	11	toxicity
NCT000018306	NCT00001830_6_T1	PHENOTYPE	3	3	GVHD
NCT000018306	NCT00001830_6_T2	GENE	6	6	has
NCT0000183010	NCT00001830_10_T0	PHENOTYPE	6	6	toxicity
NCT0000183010	NCT00001830_10_T1	PHENOTYPE	20	20	acute
NCT0000183010	NCT00001830_10_T2	PHENOTYPE	21	21	GVHD
NCT0000183010	NCT00001830_10_T3	ORGAN	8	8	transplants
NCT0000183012	NCT00001830_12_T0	PHENOTYPE	2	2	leukemia
NCT0000183012	NCT00001830_12_T1	PHENOTYPE	11	11	malignancy
NCT0000183012	NCT00001830_12_T2	PHENOTYPE	5	5	remission
NCT0000183013	NCT00001830_13_T0	ORGAN	27	27	graft
NCT0000183013	NCT00001830_13_T1	COMPOUND	8	8	EPOCH
NCT0000183013	NCT00001830_13_T2	COMPOUND	6	6	fludarabine
NCT0000183013	NCT00001830_13_T3	COMPOUND	13	13	fludarabine
NCT0000183013	NCT00001830_13_T4	ORGAN	10	10	transplant
NCT0000183013	NCT00001830_13_T5	CELL	22	23	T cells
NCT0000183014	NCT00001830_14_T0	ORGAN	14	14	graft
NCT0000183014	NCT00001830_14_T1	GENE	11	11	G-CSF
NCT0000183015	NCT00001830_15_T0	ORGAN	12	12	graft
NCT0000183015	NCT00001830_15_T1	COMPOUND	11	11	NCI
NCT0000183015	NCT00001830_15_T2	ORGAN	7	7	transplant
NCT0000183015	NCT00001830_15_T3	ORGAN	24	24	transplant
NCT0000183015	NCT00001830_15_T4	GENE	14	14	has
NCT0000183016	NCT00001830_16_T0	GENE	19	19	III
NCT0000183016	NCT00001830_16_T1	PHENOTYPE	1	1	GVHD
NCT0000183016	NCT00001830_16_T2	PHENOTYPE	17	17	GVHD
NCT0000183016	NCT00001830_16_T3	GENE	2	2	has
NCT0000183027	NCT00001830_27_T0	PHENOTYPE	10	10	toxicity
NCT0000183027	NCT00001830_27_T1	PHENOTYPE	3	3	GVHD
NCT0000183027	NCT00001830_27_T2	GENE	6	6	has
NCT0000183028	NCT00001830_28_T0	PHENOTYPE	6	6	toxicity
NCT0000183028	NCT00001830_28_T1	PHENOTYPE	20	20	acute
NCT0000183028	NCT00001830_28_T2	PHENOTYPE	21	21	GVHD
NCT0000183028	NCT00001830_28_T3	ORGAN	8	8	transplants
NCT0000183030	NCT00001830_30_T0	ORGAN	28	28	graft
NCT0000183030	NCT00001830_30_T1	COMPOUND	14	14	EPOCH
NCT0000183030	NCT00001830_30_T2	COMPOUND	12	12	fludarabine
NCT0000183030	NCT00001830_30_T3	COMPOUND	18	18	fludarabine
NCT0000183030	NCT00001830_30_T4	ORGAN	16	16	transplant
NCT0000183030	NCT00001830_30_T5	CELL	24	25	T cells
NCT0000183030	NCT00001830_30_T6	PHENOTYPE	7	8	hematologic malignancy
NCT0000183032	NCT00001830_32_T0	GENE	15	15	II
NCT0000183032	NCT00001830_32_T1	PHENOTYPE	22	22	acute
NCT0000183032	NCT00001830_32_T2	PHENOTYPE	9	9	complication
NCT0000183032	NCT00001830_32_T3	GENE	21	21	III
NCT0000183032	NCT00001830_32_T4	GENE	2	2	reduced
NCT0000183032	NCT00001830_32_T5	PHENOTYPE	5	5	GVHD
NCT0000183032	NCT00001830_32_T6	PHENOTYPE	23	23	GVHD
NCT0000183041	NCT00001830_41_T0	PHENOTYPE	8	10	Chronic Lymphocytic Leukemia
NCT0000183042	NCT00001830_42_T0	PHENOTYPE	0	0	Relapse
NCT0000183043	NCT00001830_43_T0	PHENOTYPE	6	7	Non-Hodgkin's Lymphoma
NCT0000183043	NCT00001830_43_T1	PHENOTYPE	11	13	Mantle Cell Lymphoma
NCT0000183045	NCT00001830_45_T0	PHENOTYPE	0	0	Relapse
NCT0000183046	NCT00001830_46_T0	PHENOTYPE	4	5	Multiple Myeloma
NCT0000183048	NCT00001830_48_T0	PHENOTYPE	0	0	Relapse
NCT0000183049	NCT00001830_49_T0	PHENOTYPE	4	6	Acute Myelogenous Leukemia
NCT0000183050	NCT00001830_50_T0	GENE	1	1	CR
NCT0000183051	NCT00001830_51_T0	ORGAN	7	7	marrow
NCT0000183051	NCT00001830_51_T1	PHENOTYPE	1	1	Relapse
NCT0000183051	NCT00001830_51_T2	PHENOTYPE	10	12	Acute Lymphocytic Leukemia
NCT0000183054	NCT00001830_54_T0	ORGAN	7	7	marrow
NCT0000183054	NCT00001830_54_T1	PHENOTYPE	1	1	Relapse
NCT0000183055	NCT00001830_55_T0	PHENOTYPE	0	1	Myelodysplastic Syndrome
NCT0000183056	NCT00001830_56_T0	PHENOTYPE	0	0	RAEB
NCT0000183057	NCT00001830_57_T0	ORGAN	8	8	marrow
NCT0000183057	NCT00001830_57_T1	PHENOTYPE	0	0	RAEB-T
NCT0000183057	NCT00001830_57_T2	PHENOTYPE	14	16	Chronic Myelogenous Leukemia
NCT0000183064	NCT00001830_64_T0	PHENOTYPE	30	30	malignancy
NCT0000183064	NCT00001830_64_T1	PHENOTYPE	25	25	tumor
NCT0000183064	NCT00001830_64_T2	GENE	12	12	PI
NCT0000183065	NCT00001830_65_T0	ORGAN	18	18	transplant
NCT0000183066	NCT00001830_66_T0	COMPOUND	11	11	creatinine
NCT0000183066	NCT00001830_66_T1	GENE	18	18	1.5
NCT0000183066	NCT00001830_66_T2	ORGAN	10	10	serum
NCT0000183068	NCT00001830_68_T0	COMPOUND	12	12	MUGA
NCT0000183068	NCT00001830_68_T1	PHENOTYPE	1	3	ventricular ejection fraction
NCT0000183072	NCT00001830_72_T0	PHENOTYPE	4	4	peripheral
NCT0000183077	NCT00001830_77_T0	PHENOTYPE	4	4	tumor
NCT0000183078	NCT00001830_78_T0	PHENOTYPE	0	1	HIV positive
NCT0000183079	NCT00001830_79_T0	PHENOTYPE	0	1	Hepatitis B
NCT0000183081	NCT00001830_81_T0	ORGAN	9	9	transplant
NCT0000183081	NCT00001830_81_T1	PHENOTYPE	2	3	psychiatric disorder
NCT0000183083	NCT00001830_83_T0	PHENOTYPE	2	2	hypertension
NCT0000183083	NCT00001830_83_T1	PHENOTYPE	12	13	heart disease
NCT0000183087	NCT00001830_87_T0	PHENOTYPE	0	1	HIV positive
NCT0000183088	NCT00001830_88_T0	PHENOTYPE	0	1	Hepatitis B
NCT000018321	NCT00001832_1_T0	CELL	17	17	lymphocytes
NCT000018321	NCT00001832_1_T1	GENE	5	5	interleukin-2
NCT000018321	NCT00001832_1_T2	GENE	6	6	IL-2
NCT000018322	NCT00001832_2_T0	PHENOTYPE	6	6	tumor
NCT000018322	NCT00001832_2_T1	GENE	15	15	gp100
NCT000018322	NCT00001832_2_T2	PHENOTYPE	4	4	melanoma
NCT000018322	NCT00001832_2_T3	GENE	7	7	has
NCT000018322	NCT00001832_2_T4	PHENOTYPE	2	3	metastatic melanoma
NCT000018323	NCT00001832_3_T0	CELL	12	12	lymphocytes
NCT000018323	NCT00001832_3_T1	PHENOTYPE	6	6	tumor
NCT000018325	NCT00001832_5_T0	CELL	10	10	cells
NCT000018327	NCT00001832_7_T0	PHENOTYPE	12	12	tumor
NCT0000183210	NCT00001832_10_T0	CELL	1	1	lymphocytes
NCT0000183212	NCT00001832_12_T0	COMPOUND	4	4	fludarabine
NCT0000183212	NCT00001832_12_T1	COMPOUND	2	2	cyclophosphamide
NCT0000183213	NCT00001832_13_T0	CELL	18	18	lymphocytes
NCT0000183213	NCT00001832_13_T1	ORGAN	4	5	immune system
NCT0000183214	NCT00001832_14_T0	CELL	1	1	lymphocytes
NCT0000183215	NCT00001832_15_T0	GENE	6	6	IL-2
NCT0000183216	NCT00001832_16_T0	ORGAN	35	35	thigh
NCT0000183216	NCT00001832_16_T1	ORGAN	37	37	abdomen
NCT0000183216	NCT00001832_16_T2	ORGAN	13	13	heart
NCT0000183216	NCT00001832_16_T3	GENE	7	7	IL-2
NCT0000183218	NCT00001832_18_T0	PHENOTYPE	18	18	tumor
NCT0000183219	NCT00001832_19_T0	PHENOTYPE	9	9	tumor
NCT0000183219	NCT00001832_19_T1	GENE	1	1	3.5
NCT0000183219	NCT00001832_19_T2	GENE	10	10	has
NCT0000183223	NCT00001832_23_T0	PHENOTYPE	5	5	toxicity
NCT000018352	NCT00001835_2_T0	ORGAN	6	6	kidneys
NCT000018352	NCT00001835_2_T1	PHENOTYPE	2	3	advanced cancer
NCT000018353	NCT00001835_3_T0	ORGAN	30	30	kidney
NCT000018353	NCT00001835_3_T1	ORGAN	32	32	liver
NCT000018353	NCT00001835_3_T2	GENE	11	11	MRI
NCT000018355	NCT00001835_5_T0	GENE	9	9	reduced
NCT000018357	NCT00001835_7_T0	COMPOUND	20	20	oxaliplatin
NCT0000183511	NCT00001835_11_T0	PHENOTYPE	18	20	impaired renal function
NCT0000183512	NCT00001835_12_T0	COMPOUND	20	20	creatinine
NCT0000183512	NCT00001835_12_T1	PHENOTYPE	12	13	renal impairment
NCT0000183516	NCT00001835_16_T0	PHENOTYPE	11	11	pharmacokinetics
NCT0000183516	NCT00001835_16_T1	PHENOTYPE	9	9	toxicities
NCT0000183516	NCT00001835_16_T2	PHENOTYPE	34	34	dysfunction
NCT0000183518	NCT00001835_18_T0	COMPOUND	23	23	oxaliplatin
NCT0000183518	NCT00001835_18_T1	GENE	19	19	had
NCT0000183521	NCT00001835_21_T0	ORGAN	6	6	marrow
NCT0000183521	NCT00001835_21_T1	CELL	10	10	Leukocytes
NCT0000183522	NCT00001835_22_T0	CELL	1	1	neutrophil
NCT0000183523	NCT00001835_23_T0	PHENOTYPE	0	1	Platelet count
NCT0000183524	NCT00001835_24_T0	GENE	0	1	Total bilirubin
NCT0000183525	NCT00001835_25_T0	GENE	0	0	AST
NCT0000183525	NCT00001835_25_T1	GENE	7	7	1.5
NCT0000183526	NCT00001835_26_T0	PHENOTYPE	7	7	neuropathy
NCT0000183529	NCT00001835_29_T0	COMPOUND	21	21	platinum
NCT0000183529	NCT00001835_29_T1	GENE	3	3	had
NCT0000183532	NCT00001835_32_T0	COMPOUND	8	8	platinum
NCT0000183532	NCT00001835_32_T1	PHENOTYPE	6	6	allergy
NCT000018365	NCT00001836_5_T0	COMPOUND	29	29	calcium
NCT000018365	NCT00001836_5_T1	ORGAN	11	12	coronary arteries
NCT000018365	NCT00001836_5_T2	PHENOTYPE	22	24	coronary artery disease
NCT0000183612	NCT00001836_12_T0	COMPOUND	35	35	calcium
NCT0000183612	NCT00001836_12_T1	ORGAN	11	12	coronary arteries
NCT0000183612	NCT00001836_12_T2	PHENOTYPE	22	24	coronary artery calcification
NCT0000183618	NCT00001836_18_T0	ORGAN	11	12	heart valves
NCT000018371	NCT00001837_1_T0	COMPOUND	4	4	NCI
NCT000018371	NCT00001837_1_T1	COMPOUND	13	13	raloxifene
NCT000018371	NCT00001837_1_T2	PHENOTYPE	25	26	breast cancer
NCT000018373	NCT00001837_3_T0	COMPOUND	14	14	NCI
NCT000018377	NCT00001837_7_T0	GENE	2	2	II
NCT000018377	NCT00001837_7_T1	GENE	21	21	has
NCT000018377	NCT00001837_7_T2	COMPOUND	10	10	raloxifene
NCT000018377	NCT00001837_7_T3	PHENOTYPE	19	20	breast cancer
NCT000018378	NCT00001837_8_T0	ORGAN	14	14	ovaries
NCT000018378	NCT00001837_8_T1	ORGAN	12	12	endometrium
NCT000018378	NCT00001837_8_T2	COMPOUND	9	9	raloxifene
NCT000018378	NCT00001837_8_T3	BIOLOGICAL_PROCESS	29	30	menstrual cycle
NCT0000183710	NCT00001837_10_T0	COMPOUND	6	6	clomiphene
NCT0000183710	NCT00001837_10_T1	COMPOUND	13	13	raloxifene
NCT0000183710	NCT00001837_10_T2	COMPOUND	7	7	tamoxifen
NCT0000183710	NCT00001837_10_T3	COMPOUND	21	21	estradiol
NCT0000183711	NCT00001837_11_T0	ORGAN	17	17	ovaries
NCT0000183711	NCT00001837_11_T1	ORGAN	22	22	ovaries
NCT0000183711	NCT00001837_11_T2	ORGAN	24	24	endometrium
NCT0000183711	NCT00001837_11_T3	COMPOUND	10	10	raloxifene
NCT0000183711	NCT00001837_11_T4	PHENOTYPE	30	31	hormone levels
NCT000018392	NCT00001839_2_T0	PHENOTYPE	6	6	cytopenia
NCT0000183912	NCT00001839_12_T0	PHENOTYPE	6	6	cytopenia
NCT0000183924	NCT00001839_24_T0	ORGAN	13	13	marrow
NCT0000183924	NCT00001839_24_T1	GENE	5	5	FAB
NCT0000183924	NCT00001839_24_T2	PHENOTYPE	1	1	transforming
NCT0000183924	NCT00001839_24_T3	PHENOTYPE	3	4	acute leukemia
NCT0000183925	NCT00001839_25_T0	ORGAN	2	2	marrow
NCT0000183925	NCT00001839_25_T1	ORGAN	17	17	appendix
NCT0000183931	NCT00001839_31_T0	ORGAN	6	6	transplant
NCT0000183931	NCT00001839_31_T1	ORGAN	4	5	bone marrow
NCT0000183934	NCT00001839_34_T0	PHENOTYPE	1	2	HIV positive
NCT0000183936	NCT00001839_36_T0	COMPOUND	4	4	creatine
NCT0000183936	NCT00001839_36_T1	ORGAN	3	3	serum
NCT0000183937	NCT00001839_37_T0	PHENOTYPE	18	18	severity
NCT0000183937	NCT00001839_37_T1	GENE	22	22	7-10
NCT000018401	NCT00001840_1_T0	PHENOTYPE	13	13	acute
NCT000018401	NCT00001840_1_T1	PHENOTYPE	15	15	subacute
NCT000018402	NCT00001840_2_T0	PHENOTYPE	11	11	acute
NCT000018403	NCT00001840_3_T0	PHENOTYPE	22	22	infarction
NCT000018403	NCT00001840_3_T1	PHENOTYPE	18	18	ischemia
NCT000018405	NCT00001840_5_T0	PHENOTYPE	10	11	cerebral ischemia
NCT000018407	NCT00001840_7_T0	PHENOTYPE	13	13	acute
NCT000018407	NCT00001840_7_T1	PHENOTYPE	15	15	subacute
NCT000018408	NCT00001840_8_T0	PHENOTYPE	11	11	acute
NCT000018409	NCT00001840_9_T0	PHENOTYPE	22	22	infarction
NCT000018409	NCT00001840_9_T1	PHENOTYPE	18	18	ischemia
NCT0000184011	NCT00001840_11_T0	PHENOTYPE	10	11	cerebral ischemia
NCT0000184014	NCT00001840_14_T0	PHENOTYPE	34	34	symptoms
NCT0000184014	NCT00001840_14_T1	GENE	19	19	paralyzed
NCT0000184014	NCT00001840_14_T2	PHENOTYPE	38	38	insulinoma
NCT0000184014	NCT00001840_14_T3	PHENOTYPE	36	36	pheochromocytoma
NCT0000184014	NCT00001840_14_T4	PHENOTYPE	23	23	claustrophobia
NCT0000184014	NCT00001840_14_T5	PHENOTYPE	21	22	morbid obesity
NCT0000184016	NCT00001840_16_T0	PHENOTYPE	3	3	hemoglobinopathies
NCT0000184016	NCT00001840_16_T1	PHENOTYPE	5	5	asthma
NCT0000184017	NCT00001840_17_T0	PHENOTYPE	5	6	hepatic disease
NCT000018411	NCT00001841_1_T0	GENE	2	2	has
NCT000018411	NCT00001841_1_T1	GENE	7	7	has
NCT000018411	NCT00001841_1_T2	PHENOTYPE	15	15	narrowing
NCT000018411	NCT00001841_1_T3	PHENOTYPE	0	0	MRA
NCT000018411	NCT00001841_1_T4	ORGAN	17	18	blood vessels
NCT000018412	NCT00001841_2_T0	ORGAN	17	17	arteries
NCT000018412	NCT00001841_2_T1	GENE	2	2	has
NCT000018412	NCT00001841_2_T2	PHENOTYPE	7	7	narrowing
NCT000018412	NCT00001841_2_T3	PHENOTYPE	1	1	MRA
NCT000018412	NCT00001841_2_T4	ORGAN	10	11	blood vessels
NCT000018413	NCT00001841_3_T0	PHENOTYPE	15	15	atherosclerosis
NCT000018413	NCT00001841_3_T1	ORGAN	19	19	arteries
NCT000018413	NCT00001841_3_T2	PHENOTYPE	31	31	MRA
NCT000018417	NCT00001841_7_T0	PHENOTYPE	23	23	stenoses
NCT000018417	NCT00001841_7_T1	GENE	3	3	has
NCT000018417	NCT00001841_7_T2	PHENOTYPE	20	20	MRA
NCT000018418	NCT00001841_8_T0	PHENOTYPE	31	31	strategies
NCT000018418	NCT00001841_8_T1	PHENOTYPE	25	25	pulse
NCT000018418	NCT00001841_8_T2	PHENOTYPE	19	19	MRA
NCT0000184112	NCT00001841_12_T0	PHENOTYPE	23	23	MRA
NCT0000184112	NCT00001841_12_T1	PHENOTYPE	8	9	clinical findings
NCT0000184116	NCT00001841_16_T0	GENE	8	8	3.0
NCT0000184116	NCT00001841_16_T1	ORGAN	3	3	serum
NCT0000184118	NCT00001841_18_T0	PHENOTYPE	0	0	Allergy
NCT0000184118	NCT00001841_18_T1	COMPOUND	2	2	Gadolinium
NCT0000184119	NCT00001841_19_T0	GENE	17	17	MRI
NCT0000184121	NCT00001841_21_T0	PHENOTYPE	11	11	MRA
NCT0000184122	NCT00001841_22_T0	GENE	4	4	MRI
NCT000018423	NCT00001842_3_T0	CELL	12	12	cells
NCT000018423	NCT00001842_3_T1	GENE	4	4	G-CSF
NCT000018424	NCT00001842_4_T0	GENE	7	7	G-CSF
NCT0000184211	NCT00001842_11_T0	GENE	0	0	G-CSF
NCT0000184212	NCT00001842_12_T0	CELL	12	12	granulocytes
NCT0000184212	NCT00001842_12_T1	GENE	9	9	G-CSF
NCT0000184213	NCT00001842_13_T0	CELL	8	8	granulocyte
NCT0000184213	NCT00001842_13_T1	CELL	14	14	granulocyte
NCT0000184215	NCT00001842_15_T0	COMPOUND	29	29	dexamethasone
NCT0000184215	NCT00001842_15_T1	CELL	8	8	granulocyte
NCT0000184215	NCT00001842_15_T2	GENE	25	25	G-CSF
NCT0000184218	NCT00001842_18_T0	COMPOUND	22	22	dexamethasone
NCT0000184218	NCT00001842_18_T1	COMPOUND	32	32	dexamethasone
NCT0000184218	NCT00001842_18_T2	GENE	8	8	G-CSF
NCT0000184218	NCT00001842_18_T3	GENE	13	13	G-CSF
NCT0000184218	NCT00001842_18_T4	GENE	17	17	G-CSF
NCT0000184218	NCT00001842_18_T5	GENE	27	27	G-CSF
NCT0000184221	NCT00001842_21_T0	GENE	10	10	G-CSF
NCT0000184221	NCT00001842_21_T1	GENE	20	20	G-CSF
NCT0000184221	NCT00001842_21_T2	CELL	1	1	neutrophil
NCT0000184227	NCT00001842_27_T0	GENE	4	4	11.0
NCT0000184227	NCT00001842_27_T1	CELL	11	11	platelet
NCT0000184227	NCT00001842_27_T2	GENE	1	1	hemoglobin
NCT000018441	NCT00001844_1_T0	GENE	0	0	MRI
NCT000018443	NCT00001844_3_T0	PHENOTYPE	26	26	listening
NCT000018443	NCT00001844_3_T1	GENE	6	6	MRI
NCT000018443	NCT00001844_3_T2	PHENOTYPE	31	31	flashing
NCT000018443	NCT00001844_3_T3	BIOLOGICAL_PROCESS	15	15	metabolism
NCT000018444	NCT00001844_4_T0	GENE	5	5	MRI
NCT000018445	NCT00001844_5_T0	GENE	14	14	MRI
NCT000018446	NCT00001844_6_T0	GENE	3	3	coil
NCT0000184410	NCT00001844_10_T0	GENE	14	14	MRI
NCT0000184414	NCT00001844_14_T0	PHENOTYPE	15	15	pathology
NCT0000184417	NCT00001844_17_T0	COMPOUND	0	0	2
NCT000018451	NCT00001845_1_T0	GENE	0	0	MRI
NCT000018452	NCT00001845_2_T0	GENE	12	12	MRI
NCT000018453	NCT00001845_3_T0	GENE	18	18	MRI
NCT000018455	NCT00001845_5_T0	GENE	3	3	CO2
NCT000018455	NCT00001845_5_T1	COMPOUND	12	12	oxygen
NCT000018455	NCT00001845_5_T2	ORGAN	7	7	heart
NCT000018457	NCT00001845_7_T0	GENE	10	10	CO2
NCT000018457	NCT00001845_7_T1	COMPOUND	12	12	acetazolamide
NCT000018457	NCT00001845_7_T2	PHENOTYPE	3	3	experiences
NCT0000184510	NCT00001845_10_T0	PHENOTYPE	20	20	hypercapnic
NCT0000184511	NCT00001845_11_T0	GENE	15	15	CO2
NCT0000184511	NCT00001845_11_T1	COMPOUND	24	24	acetazolamide
NCT0000184511	NCT00001845_11_T2	GENE	17	17	IV
NCT0000184511	NCT00001845_11_T3	COMPOUND	9	9	carbogen
NCT0000184511	NCT00001845_11_T4	GENE	21	22	carbonic anhydrase
NCT0000184512	NCT00001845_12_T0	PHENOTYPE	26	26	hypercapnia
NCT0000184514	NCT00001845_14_T0	GENE	36	36	insulin
NCT0000184514	NCT00001845_14_T1	GENE	18	18	clip
NCT0000184514	NCT00001845_14_T2	PHENOTYPE	30	31	foreign body
NCT0000184515	NCT00001845_15_T0	PHENOTYPE	15	15	complications
NCT0000184515	NCT00001845_15_T1	GENE	17	17	CO2
NCT0000184515	NCT00001845_15_T2	PHENOTYPE	33	33	allergy
NCT0000184515	NCT00001845_15_T3	COMPOUND	35	35	acetazolamide
NCT0000184515	NCT00001845_15_T4	COMPOUND	28	28	aspirin
NCT0000184515	NCT00001845_15_T5	PHENOTYPE	23	23	cirrhosis
NCT0000184515	NCT00001845_15_T6	PHENOTYPE	8	9	panic disorder
NCT000018462	NCT00001846_2_T0	BIOLOGICAL_PROCESS	17	17	phlebotomy
NCT000018463	NCT00001846_3_T0	PHENOTYPE	17	17	discomforts
NCT000018464	NCT00001846_4_T0	PHENOTYPE	14	14	discomfort
NCT000018482	NCT00001848_2_T0	PHENOTYPE	3	3	endometriosis
NCT000018483	NCT00001848_3_T0	PHENOTYPE	3	3	endometriosis
NCT000018486	NCT00001848_6_T0	PHENOTYPE	4	4	symptoms
NCT000018487	NCT00001848_7_T0	COMPOUND	26	26	estrogen
NCT000018487	NCT00001848_7_T1	TISSUE	14	14	bones
NCT000018487	NCT00001848_7_T2	PHENOTYPE	5	5	endometriosis
NCT000018487	NCT00001848_7_T3	PHENOTYPE	15	15	osteoporosis
NCT000018487	NCT00001848_7_T4	PHENOTYPE	17	18	hot flashes
NCT000018488	NCT00001848_8_T0	PHENOTYPE	8	8	endometriosis
NCT0000184811	NCT00001848_11_T0	TISSUE	6	6	tissues
NCT0000184812	NCT00001848_12_T0	GENE	9	9	had
NCT0000184812	NCT00001848_12_T1	PHENOTYPE	8	8	osteoporosis
NCT0000184818	NCT00001848_18_T0	GENE	4	4	has
NCT0000184818	NCT00001848_18_T1	PHENOTYPE	17	18	bone loss
NCT0000184819	NCT00001848_19_T0	COMPOUND	16	16	estrogen
NCT0000184819	NCT00001848_19_T1	GENE	2	2	has
NCT0000184819	NCT00001848_19_T2	GENE	15	15	hormone
NCT0000184824	NCT00001848_24_T0	GENE	13	13	LN
NCT0000184824	NCT00001848_24_T1	PHENOTYPE	0	0	Chronic
NCT000018491	NCT00001849_1_T0	GENE	14	14	ACTH
NCT000018491	NCT00001849_1_T1	ORGAN	5	6	adrenal gland
NCT000018491	NCT00001849_1_T2	ORGAN	17	18	pituitary gland
NCT000018492	NCT00001849_2_T0	PHENOTYPE	7	7	hypercortisolism
NCT000018492	NCT00001849_2_T1	GENE	16	16	ACTH
NCT000018492	NCT00001849_2_T2	GENE	15	15	hormone
NCT000018492	NCT00001849_2_T3	PHENOTYPE	8	9	Cushing Syndrome
NCT000018493	NCT00001849_3_T0	GENE	2	2	hormone
NCT000018493	NCT00001849_3_T1	ORGAN	12	13	pituitary gland
NCT000018494	NCT00001849_4_T0	TISSUE	15	15	thymus
NCT000018494	NCT00001849_4_T1	ORGAN	17	17	pancreas
NCT000018494	NCT00001849_4_T2	GENE	5	5	ACTH
NCT000018494	NCT00001849_4_T3	PHENOTYPE	11	14	tumor of the lung
NCT000018495	NCT00001849_5_T0	COMPOUND	32	32	pentetreotide
NCT000018495	NCT00001849_5_T1	GENE	11	11	ACTH
NCT000018497	NCT00001849_7_T0	GENE	8	8	ACTH
NCT000018498	NCT00001849_8_T0	GENE	10	10	has
NCT0000184910	NCT00001849_10_T0	COMPOUND	41	41	pentetreotide
NCT0000184910	NCT00001849_10_T1	GENE	10	10	ACTH
NCT0000184910	NCT00001849_10_T2	COMPOUND	40	40	indium_111
NCT0000184910	NCT00001849_10_T3	COMPOUND	32	32	octreotide
NCT0000184912	NCT00001849_12_T0	GENE	6	6	has
NCT0000184926	NCT00001849_26_T0	GENE	17	17	P450
NCT0000184926	NCT00001849_26_T1	COMPOUND	13	13	mifepristone
NCT0000184926	NCT00001849_26_T2	COMPOUND	20	20	mifepristone
NCT0000184926	NCT00001849_26_T3	GENE	5	5	CYP3A4
NCT000018501	NCT00001850_1_T0	GENE	7	7	saliva
NCT000018505	NCT00001850_5_T0	BIOLOGICAL_PROCESS	19	19	reproduction
NCT000018507	NCT00001850_7_T0	GENE	11	11	saliva
NCT0000185014	NCT00001850_14_T0	GENE	21	21	PI
NCT000018512	NCT00001851_2_T0	PHENOTYPE	12	12	deformities
NCT000018512	NCT00001851_2_T1	PHENOTYPE	10	10	fracture
NCT000018514	NCT00001851_4_T0	PHENOTYPE	21	22	McCune-Albright Syndrome
NCT000018514	NCT00001851_4_T1	PHENOTYPE	39	40	McCune-Albright Syndrome
NCT000018514	NCT00001851_4_T2	PHENOTYPE	17	19	Polyostotic Fibrous Dysplasia
NCT000018514	NCT00001851_4_T3	PHENOTYPE	35	37	Polyostotic Fibrous Dysplasia
NCT000018515	NCT00001851_5_T0	PHENOTYPE	25	25	pulse
NCT000018515	NCT00001851_5_T1	PHENOTYPE	33	33	quality-of-life
NCT0000185110	NCT00001851_10_T0	GENE	13	13	collagen
NCT0000185110	NCT00001851_10_T1	ORGAN	10	11	bone marrow
NCT0000185110	NCT00001851_10_T2	TISSUE	14	15	connective tissue
NCT0000185121	NCT00001851_21_T0	PHENOTYPE	26	26	fracture
NCT0000185121	NCT00001851_21_T1	PHENOTYPE	11	12	bone disease
NCT0000185122	NCT00001851_22_T0	TISSUE	11	11	bones
NCT0000185122	NCT00001851_22_T1	PHENOTYPE	22	22	fracture
NCT0000185122	NCT00001851_22_T2	ORGAN	16	17	lower extremities
NCT0000185123	NCT00001851_23_T0	CELL	19	19	cells
NCT0000185128	NCT00001851_28_T0	ORGAN	16	16	femur
NCT0000185128	NCT00001851_28_T1	ORGAN	15	15	humerus
NCT0000185128	NCT00001851_28_T2	ORGAN	18	18	tibia
NCT0000185128	NCT00001851_28_T3	GENE	51	51	has
NCT0000185128	NCT00001851_28_T4	GENE	66	66	has
NCT0000185128	NCT00001851_28_T5	PHENOTYPE	11	12	lytic lesion
NCT0000185130	NCT00001851_30_T0	ORGAN	20	21	bone marrow
NCT0000185131	NCT00001851_31_T0	ORGAN	25	25	transplant
NCT0000185135	NCT00001851_35_T0	GENE	8	8	hormone
NCT0000185137	NCT00001851_37_T0	COMPOUND	9	9	phenobarbital
NCT0000185141	NCT00001851_41_T0	PHENOTYPE	10	11	anorexia nervosa
NCT000018522	NCT00001852_2_T0	TISSUE	24	24	tissues
NCT000018525	NCT00001852_5_T0	GENE	14	14	saliva
NCT0000185211	NCT00001852_11_T0	TISSUE	4	6	minor salivary glands
NCT0000185215	NCT00001852_15_T0	PHENOTYPE	2	2	dysfunction
NCT0000185215	NCT00001852_15_T1	PHENOTYPE	16	18	quality of life
NCT0000185218	NCT00001852_18_T0	PHENOTYPE	14	14	complications
NCT0000185218	NCT00001852_18_T1	PHENOTYPE	19	19	autoimmune
NCT0000185218	NCT00001852_18_T2	CELL	24	24	B-cell
NCT0000185218	NCT00001852_18_T3	PHENOTYPE	5	5	progression
NCT0000185218	NCT00001852_18_T4	PHENOTYPE	17	17	xerostomia
NCT0000185218	NCT00001852_18_T5	PHENOTYPE	8	8	dysfunction
NCT0000185218	NCT00001852_18_T6	PHENOTYPE	21	22	autoimmune diseases
NCT0000185221	NCT00001852_21_T0	PHENOTYPE	30	30	dysfunction
NCT0000185221	NCT00001852_21_T1	TISSUE	28	29	salivary gland
NCT0000185221	NCT00001852_21_T2	PHENOTYPE	24	26	signs and symptoms
NCT0000185226	NCT00001852_26_T0	GENE	14	14	SS
NCT0000185226	NCT00001852_26_T1	GENE	16	16	SS
NCT0000185226	NCT00001852_26_T2	PHENOTYPE	21	21	dysfunction
NCT0000185226	NCT00001852_26_T3	PHENOTYPE	13	13	secondary
NCT0000185226	NCT00001852_26_T4	PHENOTYPE	6	6	xerostomia
NCT0000185226	NCT00001852_26_T5	PHENOTYPE	4	5	mouth symptoms
NCT0000185226	NCT00001852_26_T6	PHENOTYPE	3	4	dry mouth
NCT0000185226	NCT00001852_26_T7	TISSUE	19	20	salivary gland
NCT0000185229	NCT00001852_29_T0	PHENOTYPE	1	1	symptoms
NCT0000185229	NCT00001852_29_T1	PHENOTYPE	7	8	dry eyes
NCT0000185230	NCT00001852_30_T0	PHENOTYPE	0	0	Recurrent
NCT0000185230	NCT00001852_30_T1	ORGAN	8	8	eyes
NCT0000185232	NCT00001852_32_T0	PHENOTYPE	1	1	symptoms
NCT0000185232	NCT00001852_32_T1	PHENOTYPE	14	14	Recurrent
NCT0000185232	NCT00001852_32_T2	TISSUE	18	19	salivary glands
NCT0000185235	NCT00001852_35_T0	PHENOTYPE	3	3	xerostomia
NCT0000185238	NCT00001852_38_T0	PHENOTYPE	2	2	dysfunction
NCT0000185238	NCT00001852_38_T1	TISSUE	0	1	Salivary gland
NCT0000185240	NCT00001852_40_T0	COMPOUND	6	6	THE
NCT0000185241	NCT00001852_41_T0	TISSUE	15	16	parotid gland
NCT0000185245	NCT00001852_45_T0	PHENOTYPE	4	5	bleeding diathesis
NCT000018532	NCT00001853_2_T0	PHENOTYPE	5	5	obesity
NCT000018532	NCT00001853_2_T1	PHENOTYPE	10	11	heart disease
NCT000018533	NCT00001853_3_T0	GENE	40	40	insulin
NCT000018533	NCT00001853_3_T1	GENE	28	28	HDL
NCT000018533	NCT00001853_3_T2	GENE	23	23	LDL
NCT000018533	NCT00001853_3_T3	TISSUE	8	9	body fat
NCT000018533	NCT00001853_3_T4	TISSUE	10	11	body fat
NCT000018534	NCT00001853_4_T0	PHENOTYPE	5	5	obesity
NCT000018534	NCT00001853_4_T1	PHENOTYPE	20	21	heart disease
NCT000018539	NCT00001853_9_T0	PHENOTYPE	13	14	heart disease
NCT0000185311	NCT00001853_11_T0	PHENOTYPE	0	0	Diabetes
NCT0000185311	NCT00001853_11_T1	PHENOTYPE	6	7	heart disease
NCT0000185314	NCT00001853_14_T0	PHENOTYPE	7	8	energy expenditure
NCT0000185314	NCT00001853_14_T1	TISSUE	3	4	body fat
NCT0000185315	NCT00001853_15_T0	PHENOTYPE	12	12	obesity
NCT0000185315	NCT00001853_15_T1	PHENOTYPE	14	15	heart disease
NCT0000185317	NCT00001853_17_T0	COMPOUND	8	8	glucose
NCT0000185317	NCT00001853_17_T1	PHENOTYPE	5	5	obesity
NCT0000185317	NCT00001853_17_T2	PHENOTYPE	17	19	coronary artery disease
NCT0000185318	NCT00001853_18_T0	ORGAN	14	14	Heart
NCT0000185318	NCT00001853_18_T1	GENE	4	4	had
NCT0000185318	NCT00001853_18_T2	PHENOTYPE	22	22	obesity
NCT0000185318	NCT00001853_18_T3	PHENOTYPE	26	28	coronary artery disease
NCT0000185319	NCT00001853_19_T0	PHENOTYPE	15	17	coronary artery disease
NCT0000185322	NCT00001853_22_T0	COMPOUND	17	17	glucose
NCT0000185322	NCT00001853_22_T1	PHENOTYPE	2	2	Diabetes
NCT0000185322	NCT00001853_22_T2	PHENOTYPE	16	16	obesity
NCT0000185322	NCT00001853_22_T3	PHENOTYPE	4	5	Heart Disease
NCT0000185322	NCT00001853_22_T4	PHENOTYPE	23	24	heart disease
NCT0000185329	NCT00001853_29_T0	PHENOTYPE	7	7	Center
NCT0000185329	NCT00001853_29_T1	PHENOTYPE	18	19	glucose tolerance
NCT0000185329	NCT00001853_29_T2	PHENOTYPE	29	30	glucose tolerance
NCT0000185329	NCT00001853_29_T3	TISSUE	11	12	body fat
NCT0000185333	NCT00001853_33_T0	GENE	0	0	Age
NCT0000185339	NCT00001853_39_T0	PHENOTYPE	8	8	hyperlipidemia
NCT0000185339	NCT00001853_39_T1	COMPOUND	12	12	niacin
NCT0000185339	NCT00001853_39_T2	GENE	13	14	bile acid
NCT0000185339	NCT00001853_39_T3	COMPOUND	17	18	fibric acid
NCT0000185340	NCT00001853_40_T0	ORGAN	2	2	thyroid
NCT0000185340	NCT00001853_40_T1	GENE	10	10	TSH
NCT0000185340	NCT00001853_40_T2	GENE	3	3	hormone
NCT0000185344	NCT00001853_44_T0	PHENOTYPE	7	9	irregular menstrual cycles
NCT0000185345	NCT00001853_45_T0	PHENOTYPE	23	23	bilateral
NCT000018540	NCT00001854_0_T0	PHENOTYPE	5	7	Chronic Hepatitis C
NCT000018543	NCT00001854_3_T0	PHENOTYPE	10	10	cirrhosis
NCT000018543	NCT00001854_3_T1	PHENOTYPE	6	7	hepatitis C
NCT000018543	NCT00001854_3_T2	PHENOTYPE	23	24	liver failure
NCT000018543	NCT00001854_3_T3	PHENOTYPE	5	6	chronic hepatitis
NCT000018543	NCT00001854_3_T4	PHENOTYPE	18	21	cancer of the liver
NCT000018545	NCT00001854_5_T0	GENE	0	0	Alpha
NCT000018545	NCT00001854_5_T1	GENE	1	1	interferon
NCT000018549	NCT00001854_9_T0	GENE	29	29	interferon
NCT000018549	NCT00001854_9_T1	PHENOTYPE	10	11	hepatitis C
NCT000018549	NCT00001854_9_T2	PHENOTYPE	9	10	chronic hepatitis
NCT0000185410	NCT00001854_10_T0	ORGAN	7	7	liver
NCT0000185410	NCT00001854_10_T1	ORGAN	13	13	liver
NCT0000185411	NCT00001854_11_T0	COMPOUND	13	13	ribavirin
NCT0000185415	NCT00001854_15_T0	PHENOTYPE	19	20	liver enzymes
NCT0000185417	NCT00001854_17_T0	PHENOTYPE	7	8	liver enzymes
NCT0000185420	NCT00001854_20_T0	ORGAN	15	15	liver
NCT0000185421	NCT00001854_21_T0	COMPOUND	8	8	ribavirin
NCT0000185424	NCT00001854_24_T0	COMPOUND	10	10	ribavirin
NCT0000185424	NCT00001854_24_T1	ORGAN	4	4	liver
NCT0000185430	NCT00001854_30_T0	ORGAN	16	16	liver
NCT0000185436	NCT00001854_36_T0	COMPOUND	2	2	HCV
NCT0000185436	NCT00001854_36_T1	COMPOUND	4	4	HCV
NCT0000185436	NCT00001854_36_T2	ORGAN	7	7	serum
NCT0000185437	NCT00001854_37_T0	ORGAN	5	5	liver
NCT0000185437	NCT00001854_37_T1	PHENOTYPE	2	3	chronic hepatitis
NCT0000185441	NCT00001854_41_T0	GENE	12	12	had
NCT0000185449	NCT00001854_49_T0	GENE	0	0	Interferon
NCT0000185450	NCT00001854_50_T0	PHENOTYPE	14	14	autoimmune
NCT0000185450	NCT00001854_50_T1	PHENOTYPE	10	11	viral hepatitis
NCT0000185450	NCT00001854_50_T2	PHENOTYPE	5	6	liver disease
NCT0000185450	NCT00001854_50_T3	PHENOTYPE	16	18	alcoholic liver disease
NCT000018560	NCT00001856_0_T0	ORGAN	4	4	Transplants
NCT000018560	NCT00001856_0_T1	ORGAN	3	3	Kidney
NCT000018562	NCT00001856_2_T0	ORGAN	8	8	transplant
NCT000018563	NCT00001856_3_T0	ORGAN	18	18	kidneys
NCT000018564	NCT00001856_4_T0	GENE	1	1	has
NCT000018564	NCT00001856_4_T1	ORGAN	4	4	kidneys
NCT000018564	NCT00001856_4_T2	ORGAN	13	13	kidneys
NCT000018565	NCT00001856_5_T0	ORGAN	0	0	Kidneys
NCT000018568	NCT00001856_8_T0	ORGAN	16	16	kidney
NCT0000185610	NCT00001856_10_T0	ORGAN	8	8	kidney
NCT0000185612	NCT00001856_12_T0	PHENOTYPE	11	11	Center
NCT0000185616	NCT00001856_16_T0	COMPOUND	18	18	creatinine
NCT0000185616	NCT00001856_16_T1	GENE	8	8	ABO
NCT0000185619	NCT00001856_19_T0	PHENOTYPE	4	5	organ failure
NCT0000185619	NCT00001856_19_T1	PHENOTYPE	13	15	coronary artery disease
NCT000018572	NCT00001857_2_T0	ORGAN	2	3	immune system
NCT000018573	NCT00001857_3_T0	ORGAN	12	12	graft
NCT000018573	NCT00001857_3_T1	ORGAN	10	10	allograft
NCT000018573	NCT00001857_3_T2	PHENOTYPE	4	5	organ rejection
NCT000018574	NCT00001857_4_T0	ORGAN	8	9	immune system
NCT000018575	NCT00001857_5_T0	PHENOTYPE	11	11	infections
NCT000018578	NCT00001857_8_T0	PHENOTYPE	8	8	acute
NCT000018578	NCT00001857_8_T1	ORGAN	14	14	graft
NCT000018578	NCT00001857_8_T2	PHENOTYPE	10	10	chronic
NCT0000185710	NCT00001857_10_T0	ORGAN	10	10	kidney
NCT0000185710	NCT00001857_10_T1	ORGAN	11	11	transplants
NCT0000185715	NCT00001857_15_T0	ORGAN	6	7	immune system
NCT0000185717	NCT00001857_17_T0	GENE	32	32	calcineurin
NCT0000185717	NCT00001857_17_T1	PHENOTYPE	36	36	chronic
NCT0000185717	NCT00001857_17_T2	ORGAN	26	26	allograft
NCT0000185718	NCT00001857_18_T0	PHENOTYPE	7	7	acute
NCT0000185718	NCT00001857_18_T1	PHENOTYPE	9	9	chronic
NCT0000185718	NCT00001857_18_T2	PHENOTYPE	14	15	graft loss
NCT0000185721	NCT00001857_21_T0	ORGAN	10	10	allografts
NCT0000185721	NCT00001857_21_T1	ORGAN	28	28	allograft
NCT0000185722	NCT00001857_22_T0	PHENOTYPE	1	1	recruitment
NCT0000185723	NCT00001857_23_T0	GENE	22	22	IV
NCT0000185723	NCT00001857_23_T1	GENE	39	39	IV
NCT0000185724	NCT00001857_24_T0	PHENOTYPE	4	4	staggered
NCT0000185725	NCT00001857_25_T0	GENE	8	8	extended
NCT0000185729	NCT00001857_29_T0	PHENOTYPE	10	12	ischemic reperfusion injury
NCT0000185734	NCT00001857_34_T0	PHENOTYPE	4	4	menopausal
NCT0000185734	NCT00001857_34_T1	PHENOTYPE	7	7	sterile
NCT0000185735	NCT00001857_35_T0	GENE	0	0	WBC
NCT0000185737	NCT00001857_37_T0	PHENOTYPE	10	10	zoster
NCT0000185737	NCT00001857_37_T1	PHENOTYPE	6	7	viral infections
NCT0000185738	NCT00001857_38_T0	PHENOTYPE	4	4	HIV
NCT0000185738	NCT00001857_38_T1	COMPOUND	5	5	HCV
NCT0000185739	NCT00001857_39_T0	PHENOTYPE	1	3	active peptic ulcer
NCT0000185739	NCT00001857_39_T1	PHENOTYPE	2	4	peptic ulcer disease
NCT0000185742	NCT00001857_42_T0	PHENOTYPE	4	5	Thromboembolic event
NCT0000185742	NCT00001857_42_T1	PHENOTYPE	8	9	pulmonary embolus
NCT0000185743	NCT00001857_43_T0	GENE	9	9	PRA
NCT0000185746	NCT00001857_46_T0	ORGAN	6	6	kidney
NCT0000185746	NCT00001857_46_T1	PHENOTYPE	2	2	Ischemia
NCT000018580	NCT00001858_0_T0	PHENOTYPE	2	2	Tolerance
NCT000018580	NCT00001858_0_T1	ORGAN	8	8	Transplants
NCT000018580	NCT00001858_0_T2	ORGAN	4	4	Kidney
NCT000018582	NCT00001858_2_T0	ORGAN	23	23	allografts
NCT000018582	NCT00001858_2_T1	ORGAN	19	19	kidney
NCT000018582	NCT00001858_2_T2	PHENOTYPE	7	7	peripheral
NCT000018583	NCT00001858_3_T0	PHENOTYPE	2	2	Center
NCT000018584	NCT00001858_4_T0	ORGAN	8	8	kidney
NCT000018584	NCT00001858_4_T1	PHENOTYPE	19	19	peripheral
NCT000018584	NCT00001858_4_T2	CELL	22	22	cells
NCT000018584	NCT00001858_4_T3	ORGAN	12	12	allograft
NCT000018588	NCT00001858_8_T0	ORGAN	23	23	allografts
NCT000018588	NCT00001858_8_T1	ORGAN	19	19	kidney
NCT000018588	NCT00001858_8_T2	PHENOTYPE	7	7	peripheral
NCT000018589	NCT00001858_9_T0	PHENOTYPE	2	2	Center
NCT0000185810	NCT00001858_10_T0	ORGAN	8	8	kidney
NCT0000185810	NCT00001858_10_T1	PHENOTYPE	19	19	peripheral
NCT0000185810	NCT00001858_10_T2	CELL	22	22	cells
NCT0000185810	NCT00001858_10_T3	ORGAN	12	12	allograft
NCT0000185814	NCT00001858_14_T0	ORGAN	3	3	kidney
NCT0000185814	NCT00001858_14_T1	ORGAN	7	7	transplants
NCT0000185815	NCT00001858_15_T0	ORGAN	2	2	kidney
NCT0000185815	NCT00001858_15_T1	ORGAN	14	14	Allograft
NCT0000185815	NCT00001858_15_T2	ORGAN	6	6	transplants
NCT0000185815	NCT00001858_15_T3	PHENOTYPE	12	13	Recurrent Disease
NCT0000185818	NCT00001858_18_T0	ORGAN	1	1	transplant
NCT0000185819	NCT00001858_19_T0	PHENOTYPE	5	5	peripheral
NCT0000185819	NCT00001858_19_T1	PHENOTYPE	31	31	peripheral
NCT0000185819	NCT00001858_19_T2	CELL	7	7	lymphocytes
NCT0000185819	NCT00001858_19_T3	BIOLOGICAL_PROCESS	29	29	phlebotomy
NCT0000185819	NCT00001858_19_T4	CELL	33	33	lymphocyte
NCT0000185821	NCT00001858_21_T0	PHENOTYPE	2	2	malignancy
NCT0000185823	NCT00001858_23_T0	PHENOTYPE	5	5	anticoagulation
NCT0000185823	NCT00001858_23_T1	PHENOTYPE	1	1	coagulopathy
NCT0000185823	NCT00001858_23_T2	ORGAN	11	11	allograft
NCT000018591	NCT00001859_1_T0	PHENOTYPE	17	18	organ rejection
NCT000018597	NCT00001859_7_T0	ORGAN	2	2	kidney
NCT000018599	NCT00001859_9_T0	PHENOTYPE	11	12	endocrine function
NCT000018607	NCT00001860_7_T0	PHENOTYPE	4	4	acromegaly
NCT000018608	NCT00001860_8_T0	PHENOTYPE	3	4	pituitary tumor
NCT000018609	NCT00001860_9_T0	GENE	4	4	GH
NCT000018609	NCT00001860_9_T1	GENE	13	13	GH
NCT000018609	NCT00001860_9_T2	GENE	26	26	GH
NCT000018609	NCT00001860_9_T3	COMPOUND	35	35	glucose
NCT000018609	NCT00001860_9_T4	GENE	8	8	2.0
NCT000018609	NCT00001860_9_T5	PHENOTYPE	2	2	suppression
NCT0000186010	NCT00001860_10_T0	GENE	0	0	IGF-1
NCT0000186011	NCT00001860_11_T0	PHENOTYPE	1	1	tolerance
NCT0000186014	NCT00001860_14_T0	GENE	11	11	GH
NCT0000186014	NCT00001860_14_T1	PHENOTYPE	7	7	suppression
NCT0000186017	NCT00001860_17_T0	COMPOUND	1	2	octreotide acetate
NCT0000186018	NCT00001860_18_T0	COMPOUND	13	13	bromocriptine
NCT0000186018	NCT00001860_18_T1	COMPOUND	14	14	lanreotide
NCT0000186018	NCT00001860_18_T2	PHENOTYPE	9	9	acromegaly
NCT0000186018	NCT00001860_18_T3	COMPOUND	12	12	octreotide
NCT0000186020	NCT00001860_20_T0	ORGAN	5	6	optic chiasm
NCT0000186021	NCT00001860_21_T0	PHENOTYPE	11	11	symptoms
NCT0000186021	NCT00001860_21_T1	PHENOTYPE	15	15	tumor
NCT0000186021	NCT00001860_21_T2	PHENOTYPE	8	9	neurologic signs
NCT0000186022	NCT00001860_22_T0	PHENOTYPE	3	3	cholelithiasis
NCT0000186027	NCT00001860_27_T0	PHENOTYPE	6	9	alcohol or drug abuse
NCT0000186029	NCT00001860_29_T0	PHENOTYPE	3	4	mental impairment
NCT000018623	NCT00001862_3_T0	PHENOTYPE	2	2	uveitis
NCT000018623	NCT00001862_3_T1	PHENOTYPE	27	27	uveitis
NCT000018628	NCT00001862_8_T0	COMPOUND	30	30	methotrexate
NCT000018628	NCT00001862_8_T1	COMPOUND	28	28	prednisone
NCT0000186211	NCT00001862_11_T0	PHENOTYPE	18	18	discomfort
NCT0000186220	NCT00001862_20_T0	CELL	26	26	cells
NCT0000186220	NCT00001862_20_T1	PHENOTYPE	34	34	sepsis
NCT0000186220	NCT00001862_20_T2	PHENOTYPE	9	10	adverse event
NCT0000186220	NCT00001862_20_T3	ORGAN	24	25	anterior chamber
NCT0000186221	NCT00001862_21_T0	CELL	8	8	cells
NCT0000186221	NCT00001862_21_T1	PHENOTYPE	21	21	uveitis
NCT0000186221	NCT00001862_21_T2	ORGAN	6	7	anterior chamber
NCT0000186227	NCT00001862_27_T0	GENE	4	4	slit
NCT0000186227	NCT00001862_27_T1	CELL	12	12	cells
NCT0000186227	NCT00001862_27_T2	GENE	5	5	lamp
NCT0000186227	NCT00001862_27_T3	ORGAN	10	11	anterior chamber
NCT0000186230	NCT00001862_30_T0	PHENOTYPE	4	4	arthritis
NCT0000186231	NCT00001862_31_T0	PHENOTYPE	12	12	inflammation
NCT0000186231	NCT00001862_31_T1	PHENOTYPE	5	5	opacity
NCT0000186231	NCT00001862_31_T2	ORGAN	10	11	anterior chamber
NCT0000186233	NCT00001862_33_T0	GENE	19	19	1.0
NCT0000186233	NCT00001862_33_T1	COMPOUND	22	22	methotrexate
NCT0000186233	NCT00001862_33_T2	COMPOUND	12	12	prednisone
NCT0000186239	NCT00001862_39_T0	PHENOTYPE	3	3	infections
NCT0000186239	NCT00001862_39_T1	PHENOTYPE	9	9	infections
NCT000018631	NCT00001863_1_T0	PHENOTYPE	15	15	arthritis
NCT000018631	NCT00001863_1_T1	GENE	6	6	has
NCT000018631	NCT00001863_1_T2	PHENOTYPE	11	12	autoimmune diseases
NCT000018631	NCT00001863_1_T3	PHENOTYPE	16	17	joint inflammation
NCT000018631	NCT00001863_1_T4	ORGAN	2	3	immune system
NCT000018632	NCT00001863_2_T0	PHENOTYPE	4	4	symptoms
NCT000018632	NCT00001863_2_T1	GENE	1	1	has
NCT000018632	NCT00001863_2_T2	GENE	16	16	has
NCT000018632	NCT00001863_2_T3	PHENOTYPE	8	9	rheumatoid arthritis
NCT000018635	NCT00001863_5_T0	COMPOUND	26	26	cyclosporine
NCT000018635	NCT00001863_5_T1	COMPOUND	30	30	azathioprine
NCT000018635	NCT00001863_5_T2	COMPOUND	28	28	methotrexate
NCT000018635	NCT00001863_5_T3	PHENOTYPE	2	2	uveitis
NCT000018635	NCT00001863_5_T4	PHENOTYPE	23	23	uveitis
NCT000018635	NCT00001863_5_T5	COMPOUND	27	27	cyclophosphamide
NCT0000186314	NCT00001863_14_T0	COMPOUND	8	8	prednisone
NCT0000186316	NCT00001863_16_T0	PHENOTYPE	18	18	discomfort
NCT0000186319	NCT00001863_19_T0	PHENOTYPE	13	13	uveitis
NCT0000186320	NCT00001863_20_T0	PHENOTYPE	23	24	side effect
NCT0000186321	NCT00001863_21_T0	PHENOTYPE	5	5	profound
NCT0000186321	NCT00001863_21_T1	GENE	4	4	has
NCT0000186321	NCT00001863_21_T2	COMPOUND	2	2	isoxazole
NCT0000186322	NCT00001863_22_T0	GENE	8	8	has
NCT0000186322	NCT00001863_22_T1	GENE	17	17	RA
NCT0000186322	NCT00001863_22_T2	PHENOTYPE	2	3	autoimmune disease
NCT0000186322	NCT00001863_22_T3	PHENOTYPE	15	16	rheumatoid arthritis
NCT0000186323	NCT00001863_23_T0	COMPOUND	8	8	leflunomide
NCT0000186323	NCT00001863_23_T1	PHENOTYPE	15	15	uveitis
NCT0000186324	NCT00001863_24_T0	COMPOUND	22	22	leflunomide
NCT0000186324	NCT00001863_24_T1	PHENOTYPE	13	13	panuveitis
NCT0000186324	NCT00001863_24_T2	COMPOUND	20	20	prednisone
NCT0000186324	NCT00001863_24_T3	COMPOUND	24	24	prednisone
NCT0000186325	NCT00001863_25_T0	COMPOUND	5	5	prednisone
NCT0000186325	NCT00001863_25_T1	GENE	6	6	tapered
NCT0000186326	NCT00001863_26_T0	COMPOUND	14	14	leflunomide
NCT0000186328	NCT00001863_28_T0	ORGAN	8	8	liver
NCT0000186328	NCT00001863_28_T1	PHENOTYPE	2	3	weight loss
NCT0000186329	NCT00001863_29_T0	COMPOUND	35	35	prednisone
NCT0000186329	NCT00001863_29_T1	COMPOUND	51	51	prednisone
NCT0000186329	NCT00001863_29_T2	PHENOTYPE	69	70	inflammatory disease
NCT0000186330	NCT00001863_30_T0	PHENOTYPE	0	0	Secondary
NCT0000186330	NCT00001863_30_T1	PHENOTYPE	6	7	vitreous haze
NCT0000186330	NCT00001863_30_T2	PHENOTYPE	13	15	cystoid macular edema
NCT0000186332	NCT00001863_32_T0	PHENOTYPE	5	5	inflammation
NCT0000186332	NCT00001863_32_T1	PHENOTYPE	11	12	vitreous haze
NCT0000186332	NCT00001863_32_T2	PHENOTYPE	16	17	retinal vasculitis
NCT0000186332	NCT00001863_32_T3	PHENOTYPE	19	21	cystoid macular edema
NCT0000186336	NCT00001863_36_T0	PHENOTYPE	32	32	infiltrates
NCT0000186336	NCT00001863_36_T1	PHENOTYPE	12	12	peripheral
NCT0000186336	NCT00001863_36_T2	PHENOTYPE	30	30	peripheral
NCT0000186336	NCT00001863_36_T3	PHENOTYPE	9	9	vitritis
NCT0000186336	NCT00001863_36_T4	GENE	23	23	snowballs
NCT0000186336	NCT00001863_36_T5	PHENOTYPE	13	14	retinal vascular
NCT0000186336	NCT00001863_36_T6	PHENOTYPE	14	15	vascular disease
NCT0000186336	NCT00001863_36_T7	PHENOTYPE	3	4	intermediate uveitis
NCT0000186338	NCT00001863_38_T0	PHENOTYPE	15	15	Angiogram
NCT0000186338	NCT00001863_38_T1	PHENOTYPE	3	5	cystoid macular edema
NCT0000186339	NCT00001863_39_T0	PHENOTYPE	12	12	vitritis
NCT0000186339	NCT00001863_39_T1	PHENOTYPE	11	11	inflammation
NCT0000186340	NCT00001863_40_T0	COMPOUND	12	12	prednisone
NCT0000186340	NCT00001863_40_T1	PHENOTYPE	4	5	systemic disease
NCT0000186344	NCT00001863_44_T0	COMPOUND	20	20	cholestyramine
NCT0000186345	NCT00001863_45_T0	PHENOTYPE	2	3	Behcet's disease
NCT0000186349	NCT00001863_49_T0	GENE	1	1	AST
NCT000018648	NCT00001864_8_T0	PHENOTYPE	8	8	patching
NCT0000186414	NCT00001864_14_T0	GENE	9	9	has
NCT0000186415	NCT00001864_15_T0	GENE	14	14	reduced
NCT0000186415	NCT00001864_15_T1	GENE	2	2	has
NCT0000186419	NCT00001864_19_T0	PHENOTYPE	10	10	amblyopia
NCT0000186420	NCT00001864_20_T0	PHENOTYPE	11	11	amblyopia
NCT0000186421	NCT00001864_21_T0	PHENOTYPE	9	9	amblyopia
NCT0000186425	NCT00001864_25_T0	PHENOTYPE	6	6	amblyopia
NCT0000186429	NCT00001864_29_T0	GENE	11	11	lines
NCT0000186429	NCT00001864_29_T1	PHENOTYPE	3	3	IAD
NCT0000186430	NCT00001864_30_T0	PHENOTYPE	4	6	reduced visual acuity
NCT0000186432	NCT00001864_32_T0	PHENOTYPE	1	1	myopia
NCT0000186433	NCT00001864_33_T0	PHENOTYPE	1	2	refractive error
NCT0000186435	NCT00001864_35_T0	PHENOTYPE	0	1	Downs Syndrome
NCT0000186437	NCT00001864_37_T0	PHENOTYPE	2	2	allergy
NCT0000186437	NCT00001864_37_T1	COMPOUND	4	4	atropine
NCT000018651	NCT00001865_1_T0	PHENOTYPE	9	9	inflammation
NCT000018651	NCT00001865_1_T1	PHENOTYPE	0	1	Behcet's disease
NCT000018652	NCT00001865_2_T0	COMPOUND	5	5	cyclophosphamide
NCT000018652	NCT00001865_2_T1	COMPOUND	7	7	azathioprine
NCT000018652	NCT00001865_2_T2	COMPOUND	4	4	methotrexate
NCT000018654	NCT00001865_4_T0	GENE	23	23	interleukin-2
NCT000018654	NCT00001865_4_T1	CELL	12	14	white blood cells
NCT000018655	NCT00001865_5_T0	PHENOTYPE	4	4	inflammation
NCT000018655	NCT00001865_5_T1	PHENOTYPE	0	0	Blocking
NCT000018656	NCT00001865_6_T0	GENE	7	7	had
NCT0000186515	NCT00001865_15_T0	PHENOTYPE	8	8	uveitis
NCT0000186518	NCT00001865_18_T0	PHENOTYPE	8	8	inflammation
NCT0000186518	NCT00001865_18_T1	PHENOTYPE	15	15	resistant
NCT0000186519	NCT00001865_19_T0	GENE	13	13	receptor
NCT0000186519	NCT00001865_19_T1	CELL	16	16	cells
NCT0000186519	NCT00001865_19_T2	GENE	12	12	interleukin-2
NCT0000186519	NCT00001865_19_T3	PHENOTYPE	4	5	Behcet's disease
NCT0000186520	NCT00001865_20_T0	GENE	3	3	TAC
NCT0000186520	NCT00001865_20_T1	GENE	9	9	HAT
NCT0000186520	NCT00001865_20_T2	GENE	10	10	has
NCT0000186520	NCT00001865_20_T3	PHENOTYPE	34	34	uveitis
NCT0000186520	NCT00001865_20_T4	CELL	4	4	T-cell
NCT0000186523	NCT00001865_23_T0	PHENOTYPE	11	12	Behcet's disease
NCT0000186525	NCT00001865_25_T0	PHENOTYPE	18	18	recurrent
NCT0000186525	NCT00001865_25_T1	PHENOTYPE	27	28	Behcet's disease
NCT0000186532	NCT00001865_32_T0	PHENOTYPE	3	3	complications
NCT0000186532	NCT00001865_32_T1	GENE	1	1	has
NCT0000186532	NCT00001865_32_T2	PHENOTYPE	5	6	Behcet's disease
NCT0000186533	NCT00001865_33_T0	COMPOUND	12	12	cyclosporine
NCT0000186533	NCT00001865_33_T1	COMPOUND	10	10	prednisone
NCT0000186533	NCT00001865_33_T2	PHENOTYPE	26	27	inflammatory disease
NCT0000186533	NCT00001865_33_T3	PHENOTYPE	29	30	retinal vasculitis
NCT0000186534	NCT00001865_34_T0	GENE	3	3	had
NCT0000186534	NCT00001865_34_T1	PHENOTYPE	13	14	Behcet's disease
NCT0000186535	NCT00001865_35_T0	ORGAN	5	5	liver
NCT0000186535	NCT00001865_35_T1	GENE	1	1	has
NCT0000186536	NCT00001865_36_T0	GENE	1	1	has
NCT0000186536	NCT00001865_36_T1	CELL	3	3	neutrophil
NCT0000186538	NCT00001865_38_T0	GENE	7	7	has
NCT0000186541	NCT00001865_41_T0	GENE	9	9	IL-2
NCT0000186541	NCT00001865_41_T1	PHENOTYPE	30	30	pharmacokinetics
NCT0000186541	NCT00001865_41_T2	GENE	3	3	has
NCT0000186542	NCT00001865_42_T0	GENE	1	1	has
NCT0000186543	NCT00001865_43_T0	GENE	1	1	has
NCT0000186543	NCT00001865_43_T1	PHENOTYPE	8	10	melanoma skin cancer
NCT0000186545	NCT00001865_45_T0	PHENOTYPE	11	11	sequelae
NCT0000186545	NCT00001865_45_T1	PHENOTYPE	13	14	Behcet's disease
NCT0000186545	NCT00001865_45_T2	PHENOTYPE	4	5	neurological disease
NCT0000186546	NCT00001865_46_T0	PHENOTYPE	8	9	neurodegenerative disease
NCT0000186546	NCT00001865_46_T1	PHENOTYPE	3	4	multiple sclerosis
NCT0000186549	NCT00001865_49_T0	GENE	1	1	has
NCT0000186549	NCT00001865_49_T1	GENE	11	11	has
NCT000018661	NCT00001866_1_T0	PHENOTYPE	0	0	Nystagmus
NCT000018662	NCT00001866_2_T0	GENE	18	18	had
NCT000018665	NCT00001866_5_T0	TISSUE	6	6	muscles
NCT000018667	NCT00001866_7_T0	GENE	2	2	has
NCT000018668	NCT00001866_8_T0	PHENOTYPE	10	11	congenital nystagmus
NCT0000186614	NCT00001866_14_T0	PHENOTYPE	7	8	congenital nystagmus
NCT0000186615	NCT00001866_15_T0	PHENOTYPE	15	15	nystagmus
NCT0000186616	NCT00001866_16_T0	GENE	13	13	NAF
NCT0000186616	NCT00001866_16_T1	PHENOTYPE	5	5	nystagmus
NCT0000186616	NCT00001866_16_T2	PHENOTYPE	10	10	Nystagmus
NCT0000186617	NCT00001866_17_T0	GENE	1	1	II
NCT0000186618	NCT00001866_18_T0	GENE	4	4	NAF
NCT0000186618	NCT00001866_18_T1	PHENOTYPE	13	13	nystagmus
NCT0000186618	NCT00001866_18_T2	PHENOTYPE	22	23	binocular vision
NCT0000186619	NCT00001866_19_T0	PHENOTYPE	0	0	Secondary
NCT0000186619	NCT00001866_19_T1	GENE	8	8	null
NCT0000186619	NCT00001866_19_T2	PHENOTYPE	16	16	nystagmus
NCT0000186623	NCT00001866_23_T0	GENE	28	28	II
NCT0000186624	NCT00001866_24_T0	GENE	28	28	II
NCT0000186624	NCT00001866_24_T1	PHENOTYPE	8	9	adverse events
NCT0000186625	NCT00001866_25_T0	GENE	4	4	II
NCT0000186625	NCT00001866_25_T1	PHENOTYPE	1	1	initiation
NCT0000186626	NCT00001866_26_T0	PHENOTYPE	31	31	nystagmus
NCT0000186626	NCT00001866_26_T1	GENE	22	22	had
NCT0000186626	NCT00001866_26_T2	GENE	36	36	null
NCT0000186626	NCT00001866_26_T3	PHENOTYPE	9	10	congenital nystagmus
NCT0000186626	NCT00001866_26_T4	ORGAN	24	25	extraocular muscle
NCT0000186630	NCT00001866_30_T0	GENE	2	2	II
NCT0000186631	NCT00001866_31_T0	ORGAN	5	6	extraocular muscle
NCT0000186637	NCT00001866_37_T0	GENE	23	23	II
NCT0000186640	NCT00001866_40_T0	ORGAN	7	8	extraocular muscle
NCT0000186644	NCT00001866_44_T0	ORGAN	2	3	extraocular muscle
NCT0000186646	NCT00001866_46_T0	GENE	7	7	null
NCT0000186650	NCT00001866_50_T0	PHENOTYPE	19	19	anesthesia
NCT0000186650	NCT00001866_50_T1	GENE	23	23	ASA
NCT0000186650	NCT00001866_50_T2	PHENOTYPE	14	15	adverse event
NCT0000186650	NCT00001866_50_T3	PHENOTYPE	32	33	malignant hyperthermia
NCT000018672	NCT00001867_2_T0	PHENOTYPE	15	15	suppression
NCT000018673	NCT00001867_3_T0	PHENOTYPE	3	3	uveitis
NCT000018674	NCT00001867_4_T0	PHENOTYPE	7	7	decisions
NCT000018678	NCT00001867_8_T0	PHENOTYPE	20	20	uveitis
NCT0000186712	NCT00001867_12_T0	PHENOTYPE	5	5	uveitis
NCT0000186713	NCT00001867_13_T0	PHENOTYPE	9	9	autoimmune
NCT0000186713	NCT00001867_13_T1	PHENOTYPE	10	10	uveitis
NCT0000186714	NCT00001867_14_T0	GENE	18	18	had
NCT0000186714	NCT00001867_14_T1	PHENOTYPE	21	21	uveitis
NCT0000186714	NCT00001867_14_T2	PHENOTYPE	8	9	ocular inflammation
NCT0000186714	NCT00001867_14_T3	PHENOTYPE	19	20	ocular inflammation
NCT0000186715	NCT00001867_15_T0	BIOLOGICAL_PROCESS	11	11	gestation
NCT0000186715	NCT00001867_15_T1	GENE	30	30	hormone
NCT0000186717	NCT00001867_17_T0	PHENOTYPE	2	2	uveitis
NCT0000186719	NCT00001867_19_T0	PHENOTYPE	7	7	decisions
NCT0000186719	NCT00001867_19_T1	PHENOTYPE	16	16	uveitis
NCT0000186723	NCT00001867_23_T0	PHENOTYPE	1	2	pregnancy complications
NCT0000186725	NCT00001867_25_T0	PHENOTYPE	4	5	systemic infection
NCT0000186726	NCT00001867_26_T0	PHENOTYPE	2	2	malignancy
NCT000018693	NCT00001869_3_T0	PHENOTYPE	10	10	centers
NCT000018701	NCT00001870_1_T0	COMPOUND	12	13	nitric oxide
NCT000018701	NCT00001870_1_T1	ORGAN	4	5	blood vessel
NCT000018702	NCT00001870_2_T0	TISSUE	13	13	endothelium
NCT000018702	NCT00001870_2_T1	CELL	8	8	cells
NCT000018702	NCT00001870_2_T2	ORGAN	10	11	blood vessel
NCT000018703	NCT00001870_3_T0	COMPOUND	10	10	glucose
NCT000018704	NCT00001870_4_T0	TISSUE	8	8	endothelium
NCT000018704	NCT00001870_4_T1	CELL	3	3	cells
NCT000018704	NCT00001870_4_T2	ORGAN	5	6	blood vessel
NCT000018704	NCT00001870_4_T3	PHENOTYPE	17	18	insulin resistance
NCT000018705	NCT00001870_5_T0	ORGAN	7	7	arteries
NCT000018705	NCT00001870_5_T1	COMPOUND	17	18	nitric oxide
NCT000018705	NCT00001870_5_T2	ORGAN	13	14	blood vessel
NCT000018706	NCT00001870_6_T0	COMPOUND	15	16	nitric oxide
NCT000018706	NCT00001870_6_T1	ORGAN	18	19	blood vessels
NCT000018708	NCT00001870_8_T0	PHENOTYPE	17	19	vitamin C deficiency
NCT000018709	NCT00001870_9_T0	ORGAN	10	10	testes
NCT000018709	NCT00001870_9_T1	PHENOTYPE	13	14	insulin sensitivity
NCT000018709	NCT00001870_9_T2	ORGAN	16	17	blood vessel
NCT0000187013	NCT00001870_13_T0	PHENOTYPE	14	15	insulin sensitivity
NCT0000187013	NCT00001870_13_T1	ORGAN	17	18	blood vessel
NCT0000187014	NCT00001870_14_T0	TISSUE	22	22	endothelium
NCT0000187014	NCT00001870_14_T1	PHENOTYPE	17	18	insulin sensitivity
NCT0000187014	NCT00001870_14_T2	PHENOTYPE	12	14	vitamin C deficiency
NCT0000187017	NCT00001870_17_T0	COMPOUND	9	10	nitric oxide
NCT0000187018	NCT00001870_18_T0	COMPOUND	13	13	glucose
NCT0000187018	NCT00001870_18_T1	GENE	17	17	insulin
NCT0000187018	NCT00001870_18_T2	TISSUE	11	12	skeletal muscle
NCT0000187019	NCT00001870_19_T0	PHENOTYPE	1	2	endothelial dysfunction
NCT0000187019	NCT00001870_19_T1	PHENOTYPE	6	7	insulin resistance
NCT0000187023	NCT00001870_23_T0	PHENOTYPE	1	1	secondary
NCT0000187023	NCT00001870_23_T1	PHENOTYPE	2	2	peripheral
NCT0000187024	NCT00001870_24_T0	COMPOUND	2	2	glucose
NCT0000187024	NCT00001870_24_T1	ORGAN	6	6	forearm
NCT0000187024	NCT00001870_24_T2	ORGAN	30	30	plasma
NCT0000187024	NCT00001870_24_T3	PHENOTYPE	16	17	insulin sensitivity
NCT0000187025	NCT00001870_25_T0	PHENOTYPE	21	22	insulin sensitivity
NCT0000187026	NCT00001870_26_T0	ORGAN	0	0	Plasma
NCT0000187027	NCT00001870_27_T0	PHENOTYPE	3	3	chronic
NCT0000187027	NCT00001870_27_T1	PHENOTYPE	23	24	insulin sensitivity
NCT0000187028	NCT00001870_28_T0	PHENOTYPE	21	22	endothelial dysfunction
NCT0000187028	NCT00001870_28_T1	PHENOTYPE	24	25	insulin resistance
NCT0000187030	NCT00001870_30_T0	ORGAN	4	4	plasma
NCT000018711	NCT00001871_1_T0	ORGAN	16	16	heart
NCT000018711	NCT00001871_1_T1	TISSUE	4	5	heart muscle
NCT000018711	NCT00001871_1_T2	ORGAN	18	19	left ventricle
NCT000018713	NCT00001871_3_T0	TISSUE	18	19	heart muscle
NCT000018718	NCT00001871_8_T0	TISSUE	9	9	muscles
NCT000018718	NCT00001871_8_T1	PHENOTYPE	29	29	diseases
NCT000018718	NCT00001871_8_T2	TISSUE	10	11	skeletal muscle
NCT0000187114	NCT00001871_14_T0	PHENOTYPE	13	13	mutation
NCT0000187114	NCT00001871_14_T1	GENE	12	12	alpha-tropomyosin
NCT0000187116	NCT00001871_16_T0	CELL	12	14	skeletal muscle fibers
NCT0000187117	NCT00001871_17_T0	PHENOTYPE	14	14	diseases
NCT0000187117	NCT00001871_17_T1	TISSUE	5	6	skeletal muscle
NCT0000187118	NCT00001871_18_T0	GENE	15	15	alpha-tropomyosin
NCT0000187118	NCT00001871_18_T1	PHENOTYPE	29	29	diseases
NCT0000187118	NCT00001871_18_T2	PHENOTYPE	21	21	mutation
NCT0000187118	NCT00001871_18_T3	GENE	19	19	PABP2
NCT0000187118	NCT00001871_18_T4	PHENOTYPE	10	11	skeletal myopathy
NCT0000187118	NCT00001871_18_T5	TISSUE	4	5	skeletal muscle
NCT0000187120	NCT00001871_20_T0	PHENOTYPE	1	2	bleeding diathesis
NCT000018720	NCT00001872_0_T0	PHENOTYPE	8	8	Graft-Versus-Host-Disease
NCT000018720	NCT00001872_0_T1	ORGAN	5	5	Transplants
NCT000018720	NCT00001872_0_T2	ORGAN	3	4	Bone Marrow
NCT000018723	NCT00001872_3_T0	PHENOTYPE	11	11	leukemia
NCT000018723	NCT00001872_3_T1	CELL	4	6	white blood cells
NCT000018727	NCT00001872_7_T0	GENE	6	6	OR
NCT000018729	NCT00001872_9_T0	BIOLOGICAL_PROCESS	4	4	lactation
NCT0000187213	NCT00001872_13_T0	PHENOTYPE	2	2	chronic
NCT000018732	NCT00001873_2_T0	PHENOTYPE	7	7	blocks
NCT000018732	NCT00001873_2_T1	PHENOTYPE	29	29	progression
NCT000018732	NCT00001873_2_T2	CELL	27	27	platelets
NCT000018732	NCT00001873_2_T3	PHENOTYPE	21	21	anemia
NCT000018732	NCT00001873_2_T4	ORGAN	13	13	marrow
NCT000018732	NCT00001873_2_T5	CELL	19	19	cells
NCT000018732	NCT00001873_2_T6	CELL	23	23	cells
NCT000018733	NCT00001873_3_T0	ORGAN	2	2	transplants
NCT000018733	NCT00001873_3_T1	PHENOTYPE	12	13	hematologic malignancies
NCT000018733	NCT00001873_3_T2	ORGAN	0	1	Bone marrow
NCT0000187318	NCT00001873_18_T0	GENE	5	5	II
NCT0000187318	NCT00001873_18_T1	PHENOTYPE	28	28	severity
NCT0000187318	NCT00001873_18_T2	PHENOTYPE	30	30	acute
NCT0000187318	NCT00001873_18_T3	ORGAN	15	15	transplant
NCT0000187318	NCT00001873_18_T4	PHENOTYPE	16	16	immunosuppression
NCT0000187318	NCT00001873_18_T5	PHENOTYPE	8	8	GVHD
NCT0000187318	NCT00001873_18_T6	PHENOTYPE	31	31	GVHD
NCT0000187319	NCT00001873_19_T0	PHENOTYPE	5	5	severity
NCT0000187319	NCT00001873_19_T1	PHENOTYPE	4	4	GVHD
NCT0000187321	NCT00001873_21_T0	ORGAN	25	25	transplant
NCT0000187321	NCT00001873_21_T1	CELL	15	15	lymphocyte
NCT0000187322	NCT00001873_22_T0	COMPOUND	3	3	cyclosporine
NCT0000187324	NCT00001873_24_T0	PHENOTYPE	7	7	acute
NCT0000187324	NCT00001873_24_T1	ORGAN	10	10	transplant
NCT0000187324	NCT00001873_24_T2	PHENOTYPE	8	8	GVHD
NCT0000187325	NCT00001873_25_T0	PHENOTYPE	4	4	engraftment
NCT0000187325	NCT00001873_25_T1	PHENOTYPE	5	5	acute
NCT0000187325	NCT00001873_25_T2	PHENOTYPE	10	10	relapse
NCT0000187325	NCT00001873_25_T3	ORGAN	11	11	transplant
NCT0000187325	NCT00001873_25_T4	PHENOTYPE	8	8	GVHD
NCT0000187325	NCT00001873_25_T5	PHENOTYPE	7	7	chronic
NCT0000187328	NCT00001873_28_T0	PHENOTYPE	7	7	chronic
NCT0000187328	NCT00001873_28_T1	PHENOTYPE	0	2	Chronic myelogenous leukemia
NCT0000187329	NCT00001873_29_T0	PHENOTYPE	31	31	leukemia
NCT0000187329	NCT00001873_29_T1	PHENOTYPE	44	44	relapse
NCT0000187329	NCT00001873_29_T2	CELL	19	19	leukocyte
NCT0000187329	NCT00001873_29_T3	PHENOTYPE	14	14	remission
NCT0000187329	NCT00001873_29_T4	PHENOTYPE	36	36	remissions
NCT0000187329	NCT00001873_29_T5	PHENOTYPE	0	2	Acute lymphoblastic leukemia
NCT0000187331	NCT00001873_31_T0	PHENOTYPE	1	1	AML
NCT0000187331	NCT00001873_31_T1	PHENOTYPE	12	12	relapse
NCT0000187331	NCT00001873_31_T2	PHENOTYPE	6	6	remission
NCT0000187331	NCT00001873_31_T3	PHENOTYPE	11	11	resistant
NCT0000187332	NCT00001873_32_T0	PHENOTYPE	10	10	dependence
NCT0000187332	NCT00001873_32_T1	PHENOTYPE	0	1	Myelodysplastic syndromes
NCT0000187332	NCT00001873_32_T2	PHENOTYPE	6	7	refractory anemia
NCT0000187332	NCT00001873_32_T3	PHENOTYPE	19	20	acute leukemia
NCT0000187332	NCT00001873_32_T4	PHENOTYPE	21	23	chronic myelomonocytic leukemia
NCT0000187332	NCT00001873_32_T5	PHENOTYPE	11	15	refractory anemia with excess of
NCT0000187333	NCT00001873_33_T0	PHENOTYPE	2	2	myelofibrosis
NCT0000187333	NCT00001873_33_T1	PHENOTYPE	0	1	Myeloproliferative disorders
NCT0000187333	NCT00001873_33_T2	PHENOTYPE	3	4	polycythemia vera
NCT0000187333	NCT00001873_33_T3	PHENOTYPE	10	11	acute leukemia
NCT0000187333	NCT00001873_33_T4	PHENOTYPE	5	6	essential thrombocythemia
NCT0000187335	NCT00001873_35_T0	PHENOTYPE	3	3	dysfunction
NCT0000187337	NCT00001873_37_T0	PHENOTYPE	1	3	ventricular ejection fraction
NCT0000187342	NCT00001873_42_T0	PHENOTYPE	6	8	negative pregnancy test
NCT0000187346	NCT00001873_46_T0	PHENOTYPE	1	2	psychiatric illness
NCT0000187347	NCT00001873_47_T0	PHENOTYPE	0	1	Mental deficiency
NCT0000187348	NCT00001873_48_T0	ORGAN	10	10	transplant
NCT0000187348	NCT00001873_48_T1	PHENOTYPE	4	5	organ failure
NCT0000187350	NCT00001873_50_T0	PHENOTYPE	1	3	ventricular ejection fraction
NCT0000187351	NCT00001873_51_T0	COMPOUND	1	1	creatinine
NCT0000187351	NCT00001873_51_T1	ORGAN	0	0	Serum
NCT0000187352	NCT00001873_52_T0	COMPOUND	1	1	bilirubin
NCT0000187352	NCT00001873_52_T1	ORGAN	0	0	Serum
NCT0000187354	NCT00001873_54_T0	PHENOTYPE	0	1	HIV positive
NCT0000187359	NCT00001873_59_T0	GENE	3	3	G-CSF
NCT0000187359	NCT00001873_59_T1	CELL	6	9	peripheral blood stem cells
NCT0000187364	NCT00001873_64_T0	PHENOTYPE	1	2	psychiatric illness
NCT0000187365	NCT00001873_65_T0	PHENOTYPE	0	1	Mental deficiency
NCT000018742	NCT00001874_2_T0	GENE	0	0	MRI
NCT000018743	NCT00001874_3_T0	GENE	7	7	MRI
NCT000018749	NCT00001874_9_T0	PHENOTYPE	11	11	pulse
NCT0000187411	NCT00001874_11_T0	GENE	9	9	has
NCT0000187417	NCT00001874_17_T0	PHENOTYPE	1	2	foreign body
NCT0000187421	NCT00001874_21_T0	ORGAN	0	0	Kidney
NCT0000187425	NCT00001874_25_T0	PHENOTYPE	5	5	judgement
NCT0000187425	NCT00001874_25_T1	GENE	12	12	FOR
NCT0000187427	NCT00001874_27_T0	PHENOTYPE	2	2	hemoglobinopathies
NCT0000187428	NCT00001874_28_T0	PHENOTYPE	0	0	Asthma
NCT0000187430	NCT00001874_30_T0	PHENOTYPE	5	5	hemoglobinopathies
NCT0000187430	NCT00001874_30_T1	PHENOTYPE	6	6	asthma
NCT0000187430	NCT00001874_30_T2	PHENOTYPE	10	11	hepatic disease
NCT000018761	NCT00001876_1_T0	GENE	1	1	has
NCT000018761	NCT00001876_1_T1	GENE	17	17	RA
NCT000018761	NCT00001876_1_T2	PHENOTYPE	15	16	rheumatoid arthritis
NCT000018762	NCT00001876_2_T0	GENE	9	9	RA
NCT000018762	NCT00001876_2_T1	PHENOTYPE	4	5	pulmonary fibrosis
NCT000018766	NCT00001876_6_T0	PHENOTYPE	3	4	pulmonary fibrosis
NCT000018766	NCT00001876_6_T1	PHENOTYPE	9	10	rheumatoid arthritis
NCT000018767	NCT00001876_7_T0	PHENOTYPE	5	6	pulmonary fibrosis
NCT000018767	NCT00001876_7_T1	PHENOTYPE	10	11	rheumatoid arthritis
NCT000018768	NCT00001876_8_T0	PHENOTYPE	7	8	pulmonary fibrosis
NCT000018768	NCT00001876_8_T1	PHENOTYPE	10	11	rheumatoid arthritis
NCT0000187613	NCT00001876_13_T0	GENE	11	11	1L
NCT0000187614	NCT00001876_14_T0	COMPOUND	9	9	silica
NCT0000187614	NCT00001876_14_T1	COMPOUND	11	11	beryllium
NCT0000187615	NCT00001876_15_T0	PHENOTYPE	2	2	disorders
NCT0000187615	NCT00001876_15_T1	PHENOTYPE	0	0	Chronic
NCT0000187615	NCT00001876_15_T2	PHENOTYPE	5	6	pulmonary fibrosis
NCT0000187616	NCT00001876_16_T0	PHENOTYPE	8	8	scleroderma
NCT0000187616	NCT00001876_16_T1	GENE	1	1	collagen
NCT0000187616	NCT00001876_16_T2	PHENOTYPE	9	9	polymyositis
NCT0000187616	NCT00001876_16_T3	PHENOTYPE	2	3	vascular disorders
NCT0000187616	NCT00001876_16_T4	PHENOTYPE	5	7	systemic lupus erythematosus
NCT0000187616	NCT00001876_16_T5	PHENOTYPE	10	13	mixed connective tissue disease
NCT0000187617	NCT00001876_17_T0	PHENOTYPE	1	1	arthritis
NCT0000187619	NCT00001876_19_T0	PHENOTYPE	1	2	bleeding diathesis
NCT000018774	NCT00001877_4_T0	PHENOTYPE	0	0	Granuloma
NCT000018774	NCT00001877_4_T1	CELL	7	7	cells
NCT000018777	NCT00001877_7_T0	PHENOTYPE	5	5	sarcoidosis
NCT0000187710	NCT00001877_10_T0	PHENOTYPE	14	14	sarcoidosis
NCT0000187712	NCT00001877_12_T0	COMPOUND	10	10	pentoxifylline
NCT0000187714	NCT00001877_14_T0	PHENOTYPE	4	4	sarcoidosis
NCT0000187720	NCT00001877_20_T0	GENE	3	3	TNF-alpha
NCT0000187720	NCT00001877_20_T1	CELL	9	10	alveolar macrophages
NCT0000187722	NCT00001877_22_T0	PHENOTYPE	35	35	sarcoidosis
NCT0000187722	NCT00001877_22_T1	PHENOTYPE	41	41	granuloma
NCT0000187722	NCT00001877_22_T2	PHENOTYPE	14	15	ocular sarcoidosis
NCT0000187722	NCT00001877_22_T3	PHENOTYPE	9	10	pulmonary sarcoidosis
NCT0000187722	NCT00001877_22_T4	TISSUE	28	29	lymph nodes
NCT0000187727	NCT00001877_27_T0	ORGAN	10	10	lungs
NCT0000187727	NCT00001877_27_T1	PHENOTYPE	3	3	sarcoidosis
NCT0000187727	NCT00001877_27_T2	ORGAN	12	12	eyes
NCT0000187727	NCT00001877_27_T3	ORGAN	14	16	central nervous system
NCT000018781	NCT00001878_1_T0	PHENOTYPE	22	22	circulation
NCT000018781	NCT00001878_1_T1	ORGAN	19	19	heart
NCT000018781	NCT00001878_1_T2	ORGAN	6	7	left ventricle
NCT000018782	NCT00001878_2_T0	ORGAN	7	7	heart
NCT000018782	NCT00001878_2_T1	PHENOTYPE	12	13	hypertrophic cardiomyopathy
NCT000018783	NCT00001878_3_T0	PHENOTYPE	12	12	LVH
NCT000018783	NCT00001878_3_T1	ORGAN	3	4	left ventricle
NCT000018783	NCT00001878_3_T2	PHENOTYPE	9	11	left ventricular hypertrophy
NCT000018784	NCT00001878_4_T0	PHENOTYPE	15	15	LVH
NCT0000187811	NCT00001878_11_T0	ORGAN	19	19	heart
NCT0000187811	NCT00001878_11_T1	ORGAN	28	28	heart
NCT0000187814	NCT00001878_14_T0	PHENOTYPE	20	20	mutation
NCT0000187814	NCT00001878_14_T1	PHENOTYPE	1	1	LVH
NCT0000187814	NCT00001878_14_T2	PHENOTYPE	24	24	LVH
NCT0000187819	NCT00001878_19_T0	GENE	0	0	Age
NCT0000187820	NCT00001878_20_T0	PHENOTYPE	29	29	hypertrophy
NCT0000187820	NCT00001878_20_T1	PHENOTYPE	4	4	hypertension
NCT0000187820	NCT00001878_20_T2	GENE	13	13	Hg
NCT0000187820	NCT00001878_20_T3	GENE	17	17	Hg
NCT0000187820	NCT00001878_20_T4	PHENOTYPE	23	24	cardiac disease
NCT0000187821	NCT00001878_21_T0	GENE	15	15	IGF-I
NCT0000187821	NCT00001878_21_T1	GENE	17	17	IGFBP3
NCT0000187821	NCT00001878_21_T2	ORGAN	12	12	plasma
NCT0000187821	NCT00001878_21_T3	PHENOTYPE	7	8	chronic illness
NCT0000187821	NCT00001878_21_T4	PHENOTYPE	3	4	acute illness
NCT000018792	NCT00001879_2_T0	PHENOTYPE	9	9	hepatitis
NCT000018792	NCT00001879_2_T1	PHENOTYPE	14	14	hepatitis
NCT000018792	NCT00001879_2_T2	PHENOTYPE	23	23	hepatitis
NCT000018793	NCT00001879_3_T0	PHENOTYPE	5	5	seronegative
NCT000018793	NCT00001879_3_T1	PHENOTYPE	6	6	hepatitis
NCT000018795	NCT00001879_5_T0	PHENOTYPE	11	11	disorders
NCT000018795	NCT00001879_5_T1	PHENOTYPE	1	1	hepatitis
NCT000018795	NCT00001879_5_T2	PHENOTYPE	18	18	hepatitis
NCT000018795	NCT00001879_5_T3	PHENOTYPE	0	0	Seronegative
NCT000018795	NCT00001879_5_T4	PHENOTYPE	6	7	autoimmune disorders
NCT000018795	NCT00001879_5_T5	PHENOTYPE	19	20	aplastic anemia
NCT000018795	NCT00001879_5_T6	PHENOTYPE	13	14	fulminant hepatitis
NCT000018797	NCT00001879_7_T0	PHENOTYPE	14	14	seronegative
NCT000018797	NCT00001879_7_T1	PHENOTYPE	15	15	hepatitis
NCT000018799	NCT00001879_9_T0	PHENOTYPE	7	7	autoimmune
NCT000018799	NCT00001879_9_T1	PHENOTYPE	19	19	hepatitis
NCT000018799	NCT00001879_9_T2	PHENOTYPE	0	0	Seronegative
NCT000018799	NCT00001879_9_T3	PHENOTYPE	1	2	acute hepatitis
NCT000018799	NCT00001879_9_T4	PHENOTYPE	20	21	aplastic anemia
NCT000018799	NCT00001879_9_T5	PHENOTYPE	14	15	fulminant hepatitis
NCT0000187910	NCT00001879_10_T0	PHENOTYPE	14	14	syndromes
NCT0000187911	NCT00001879_11_T0	PHENOTYPE	13	13	seronegative
NCT0000187911	NCT00001879_11_T1	PHENOTYPE	14	15	acute hepatitis
NCT000018800	NCT00001880_0_T0	CELL	0	1	Stem Cell
NCT000018800	NCT00001880_0_T1	PHENOTYPE	5	6	Solid Tumors
NCT000018804	NCT00001880_4_T0	ORGAN	4	4	transplants
NCT000018804	NCT00001880_4_T1	ORGAN	2	3	bone marrow
NCT000018808	NCT00001880_8_T0	ORGAN	18	18	transplant
NCT000018808	NCT00001880_8_T1	PHENOTYPE	5	5	progressive
NCT000018808	NCT00001880_8_T2	PHENOTYPE	7	8	solid tumors
NCT000018809	NCT00001880_9_T0	CELL	7	7	cells
NCT0000188012	NCT00001880_12_T0	CELL	1	1	T-cell
NCT0000188012	NCT00001880_12_T1	GENE	4	7	granulocyte colony stimulating factor
NCT0000188012	NCT00001880_12_T2	CELL	9	12	peripheral blood stem cells
NCT0000188013	NCT00001880_13_T0	CELL	3	3	lymphocytes
NCT0000188013	NCT00001880_13_T1	ORGAN	22	22	graft
NCT0000188013	NCT00001880_13_T2	CELL	9	9	T-cell
NCT0000188013	NCT00001880_13_T3	PHENOTYPE	15	16	tumor progression
NCT0000188015	NCT00001880_15_T0	PHENOTYPE	11	11	tumor
NCT0000188015	NCT00001880_15_T1	PHENOTYPE	19	19	tumor
NCT0000188016	NCT00001880_16_T0	PHENOTYPE	7	7	tumor
NCT0000188020	NCT00001880_20_T0	PHENOTYPE	0	1	HIV positive
NCT0000188021	NCT00001880_21_T0	COMPOUND	6	6	HCV
NCT0000188021	NCT00001880_21_T1	PHENOTYPE	5	5	HBV
NCT000018811	NCT00001881_1_T0	PHENOTYPE	10	10	illnesses
NCT000018811	NCT00001881_1_T1	ORGAN	6	6	heart
NCT000018812	NCT00001881_2_T0	PHENOTYPE	20	21	heart diseases
NCT000018812	NCT00001881_2_T1	PHENOTYPE	8	10	signs and symptoms
NCT000018813	NCT00001881_3_T0	PHENOTYPE	18	19	heart disease
NCT000018815	NCT00001881_5_T0	GENE	8	8	MRI
NCT000018815	NCT00001881_5_T1	ORGAN	11	11	heart
NCT000018835	NCT00001883_5_T0	PHENOTYPE	8	10	valvular heart disease
NCT000018836	NCT00001883_6_T0	PHENOTYPE	4	4	chronic
NCT000018836	NCT00001883_6_T1	PHENOTYPE	5	6	pulmonary disease
NCT000018841	NCT00001884_1_T0	GENE	1	1	has
NCT000018841	NCT00001884_1_T1	GENE	17	17	RA
NCT000018841	NCT00001884_1_T2	PHENOTYPE	15	16	rheumatoid arthritis
NCT000018842	NCT00001884_2_T0	GENE	9	9	RA
NCT000018842	NCT00001884_2_T1	PHENOTYPE	4	5	pulmonary fibrosis
NCT000018843	NCT00001884_3_T0	GENE	14	14	RA
NCT000018844	NCT00001884_4_T0	PHENOTYPE	27	27	diseases
NCT000018844	NCT00001884_4_T1	PHENOTYPE	16	17	pulmonary fibrosis
NCT000018844	NCT00001884_4_T2	PHENOTYPE	23	24	pulmonary fibrosis
NCT000018844	NCT00001884_4_T3	PHENOTYPE	10	11	rheumatoid arthritis
NCT000018844	NCT00001884_4_T4	PHENOTYPE	30	32	idiopathic pulmonary fibrosis
NCT000018846	NCT00001884_6_T0	PHENOTYPE	33	34	rheumatoid arthritis
NCT000018846	NCT00001884_6_T1	PHENOTYPE	30	31	pulmonary fibrosis
NCT000018847	NCT00001884_7_T0	PHENOTYPE	21	22	rheumatoid arthritis
NCT000018847	NCT00001884_7_T1	PHENOTYPE	27	28	pulmonary fibrosis
NCT000018847	NCT00001884_7_T2	PHENOTYPE	31	33	idiopathic pulmonary fibrosis
NCT000018849	NCT00001884_9_T0	GENE	17	17	1L
NCT0000188410	NCT00001884_10_T0	COMPOUND	9	9	silica
NCT0000188410	NCT00001884_10_T1	COMPOUND	11	11	beryllium
NCT0000188411	NCT00001884_11_T0	PHENOTYPE	2	2	disorders
NCT0000188411	NCT00001884_11_T1	PHENOTYPE	0	0	Chronic
NCT0000188411	NCT00001884_11_T2	PHENOTYPE	5	6	pulmonary fibrosis
NCT0000188412	NCT00001884_12_T0	PHENOTYPE	8	8	scleroderma
NCT0000188412	NCT00001884_12_T1	GENE	1	1	collagen
NCT0000188412	NCT00001884_12_T2	PHENOTYPE	9	9	polymyositis
NCT0000188412	NCT00001884_12_T3	PHENOTYPE	2	3	vascular disorders
NCT0000188412	NCT00001884_12_T4	PHENOTYPE	5	7	systemic lupus erythematosus
NCT0000188412	NCT00001884_12_T5	PHENOTYPE	10	13	mixed connective tissue disease
NCT0000188413	NCT00001884_13_T0	PHENOTYPE	1	1	arthritis
NCT0000188415	NCT00001884_15_T0	PHENOTYPE	1	2	bleeding diathesis
NCT000018851	NCT00001885_1_T0	GENE	1	1	has
NCT000018851	NCT00001885_1_T1	GENE	17	17	RA
NCT000018851	NCT00001885_1_T2	PHENOTYPE	15	16	rheumatoid arthritis
NCT000018852	NCT00001885_2_T0	GENE	9	9	RA
NCT000018852	NCT00001885_2_T1	PHENOTYPE	4	5	pulmonary fibrosis
NCT000018855	NCT00001885_5_T0	PHENOTYPE	14	15	pulmonary fibrosis
NCT000018855	NCT00001885_5_T1	PHENOTYPE	17	18	rheumatoid arthritis
NCT000018858	NCT00001885_8_T0	PHENOTYPE	3	3	intent
NCT000018858	NCT00001885_8_T1	PHENOTYPE	15	16	pulmonary fibrosis
NCT000018858	NCT00001885_8_T2	PHENOTYPE	18	19	rheumatoid arthritis
NCT0000188510	NCT00001885_10_T0	COMPOUND	17	17	silica
NCT0000188510	NCT00001885_10_T1	COMPOUND	19	19	beryllium
NCT0000188511	NCT00001885_11_T0	PHENOTYPE	0	0	Chronic
NCT0000188511	NCT00001885_11_T1	PHENOTYPE	1	2	pulmonary disorders
NCT0000188511	NCT00001885_11_T2	PHENOTYPE	5	6	pulmonary fibrosis
NCT0000188512	NCT00001885_12_T0	PHENOTYPE	8	8	scleroderma
NCT0000188512	NCT00001885_12_T1	GENE	1	1	collagen
NCT0000188512	NCT00001885_12_T2	PHENOTYPE	9	9	polymyositis
NCT0000188512	NCT00001885_12_T3	PHENOTYPE	2	3	vascular disorders
NCT0000188512	NCT00001885_12_T4	PHENOTYPE	5	7	systemic lupus erythematosus
NCT0000188512	NCT00001885_12_T5	PHENOTYPE	10	13	mixed connective tissue disease
NCT0000188513	NCT00001885_13_T0	PHENOTYPE	1	1	arthritis
NCT000018861	NCT00001886_1_T0	ORGAN	6	6	heart
NCT000018862	NCT00001886_2_T0	GENE	3	3	has
NCT000018862	NCT00001886_2_T1	ORGAN	13	13	heart
NCT000018863	NCT00001886_3_T0	TISSUE	18	19	heart muscle
NCT000018864	NCT00001886_4_T0	ORGAN	17	17	heart
NCT000018864	NCT00001886_4_T1	ORGAN	13	14	chest wall
NCT000018865	NCT00001886_5_T0	COMPOUND	7	7	dobutamine
NCT000018866	NCT00001886_6_T0	ORGAN	6	6	heart
NCT000018867	NCT00001886_7_T0	PHENOTYPE	9	9	suffering
NCT000018867	NCT00001886_7_T1	COMPOUND	14	14	oxygen
NCT000018867	NCT00001886_7_T2	ORGAN	7	7	heart
NCT000018868	NCT00001886_8_T0	PHENOTYPE	20	21	heart disease
NCT000018868	NCT00001886_8_T1	PHENOTYPE	22	24	coronary artery disease
NCT0000188611	NCT00001886_11_T0	GENE	2	2	has
NCT0000188614	NCT00001886_14_T0	GENE	16	16	ventricular
NCT0000188616	NCT00001886_16_T0	PHENOTYPE	14	16	coronary artery disease
NCT0000188617	NCT00001886_17_T0	PHENOTYPE	19	21	coronary artery disease
NCT0000188619	NCT00001886_19_T0	PHENOTYPE	1	1	menopausal
NCT0000188621	NCT00001886_21_T0	PHENOTYPE	2	3	myocardial infarction
NCT0000188623	NCT00001886_23_T0	PHENOTYPE	1	3	congestive heart failure
NCT0000188624	NCT00001886_24_T0	PHENOTYPE	11	11	hypotension
NCT0000188624	NCT00001886_24_T1	PHENOTYPE	2	2	hypertension
NCT0000188625	NCT00001886_25_T0	PHENOTYPE	1	2	sinus tachycardia
NCT0000188626	NCT00001886_26_T0	PHENOTYPE	2	2	acute
NCT000018872	NCT00001887_2_T0	PHENOTYPE	2	2	diseases
NCT000018872	NCT00001887_2_T1	PHENOTYPE	5	5	asthma
NCT000018873	NCT00001887_3_T0	PHENOTYPE	6	6	inflammation
NCT000018873	NCT00001887_3_T1	PHENOTYPE	0	0	Asthma
NCT000018874	NCT00001887_4_T0	PHENOTYPE	13	13	inflammation
NCT000018876	NCT00001887_6_T0	GENE	4	4	receptor
NCT000018876	NCT00001887_6_T1	GENE	8	8	aminopeptidase
NCT000018877	NCT00001887_7_T0	PHENOTYPE	12	12	inflammation
NCT000018877	NCT00001887_7_T1	GENE	8	8	TNF
NCT000018878	NCT00001887_8_T0	ORGAN	18	18	lungs
NCT000018878	NCT00001887_8_T1	PHENOTYPE	14	15	allergic reaction
NCT0000188710	NCT00001887_10_T0	PHENOTYPE	5	5	asthma
NCT0000188710	NCT00001887_10_T1	PHENOTYPE	14	14	asthma
NCT0000188712	NCT00001887_12_T0	PHENOTYPE	13	13	asthma
NCT0000188715	NCT00001887_15_T0	GENE	1	1	aminopeptidase
NCT0000188715	NCT00001887_15_T1	GENE	16	17	soluble form
NCT0000188715	NCT00001887_15_T2	GENE	12	13	TNF receptor
NCT0000188718	NCT00001887_18_T0	PHENOTYPE	3	3	asthma
NCT0000188719	NCT00001887_19_T0	PHENOTYPE	5	5	asthma
NCT0000188721	NCT00001887_21_T0	COMPOUND	3	3	methacholine
NCT0000188721	NCT00001887_21_T1	COMPOUND	27	27	methacholine
NCT0000188724	NCT00001887_24_T0	PHENOTYPE	28	28	acute
NCT0000188724	NCT00001887_24_T1	ORGAN	7	7	serum
NCT0000188724	NCT00001887_24_T2	GENE	16	16	ml
NCT0000188724	NCT00001887_24_T3	PHENOTYPE	29	30	pulmonary infiltrates
NCT0000188725	NCT00001887_25_T0	PHENOTYPE	7	9	negative pregnancy test
NCT0000188726	NCT00001887_26_T0	PHENOTYPE	14	14	bronchitis
NCT0000188726	NCT00001887_26_T1	PHENOTYPE	11	11	asthma
NCT0000188726	NCT00001887_26_T2	PHENOTYPE	17	17	bronchiectasis
NCT0000188726	NCT00001887_26_T3	PHENOTYPE	18	18	HIV
NCT0000188726	NCT00001887_26_T4	PHENOTYPE	21	21	inflammation
NCT0000188726	NCT00001887_26_T5	PHENOTYPE	13	13	chronic
NCT0000188726	NCT00001887_26_T6	PHENOTYPE	15	16	cystic fibrosis
NCT0000188726	NCT00001887_26_T7	PHENOTYPE	7	8	pulmonary disorder
NCT0000188728	NCT00001887_28_T0	PHENOTYPE	7	7	asthma
NCT0000188728	NCT00001887_28_T1	PHENOTYPE	3	5	respiratory tract infection
NCT0000188729	NCT00001887_29_T0	COMPOUND	11	11	sodium
NCT0000188729	NCT00001887_29_T1	GENE	14	14	receptor
NCT0000188729	NCT00001887_29_T2	COMPOUND	3	3	theophylline
NCT0000188729	NCT00001887_29_T3	COMPOUND	19	19	montelukast
NCT0000188729	NCT00001887_29_T4	COMPOUND	17	17	zafirlukast
NCT0000188729	NCT00001887_29_T5	COMPOUND	8	9	nedocromil sodium
NCT0000188730	NCT00001887_30_T0	COMPOUND	8	8	hydroxyzine
NCT0000188733	NCT00001887_33_T0	COMPOUND	6	6	lidocaine
NCT0000188733	NCT00001887_33_T1	PHENOTYPE	3	4	adverse reactions
NCT0000188734	NCT00001887_34_T0	PHENOTYPE	10	11	alcohol abuse
NCT0000188734	NCT00001887_34_T1	PHENOTYPE	6	8	intravenous drug abuse
NCT0000188735	NCT00001887_35_T0	PHENOTYPE	9	11	coronary artery disease
NCT0000188736	NCT00001887_36_T0	PHENOTYPE	3	3	chronic
NCT0000188737	NCT00001887_37_T0	COMPOUND	3	3	aspirin
NCT0000188739	NCT00001887_39_T0	PHENOTYPE	3	3	allergy
NCT0000188740	NCT00001887_40_T0	COMPOUND	3	3	methacholine
NCT0000188742	NCT00001887_42_T0	PHENOTYPE	0	1	Platelet count
NCT0000188744	NCT00001887_44_T0	ORGAN	20	20	feet
NCT0000188745	NCT00001887_45_T0	COMPOUND	3	3	methacholine
NCT0000188745	NCT00001887_45_T1	COMPOUND	26	26	methacholine
NCT0000188746	NCT00001887_46_T0	PHENOTYPE	1	3	negative skin test
NCT0000188747	NCT00001887_47_T0	ORGAN	7	7	serum
NCT0000188747	NCT00001887_47_T1	GENE	16	16	ml
NCT0000188748	NCT00001887_48_T0	PHENOTYPE	1	1	hepatitis
NCT0000188749	NCT00001887_49_T0	PHENOTYPE	6	6	acute
NCT0000188749	NCT00001887_49_T1	PHENOTYPE	7	8	pulmonary infiltrates
NCT0000188750	NCT00001887_50_T0	PHENOTYPE	7	9	negative pregnancy test
NCT0000188751	NCT00001887_51_T0	PHENOTYPE	3	3	asthma
NCT0000188751	NCT00001887_51_T1	PHENOTYPE	7	8	atopic dermatitis
NCT0000188751	NCT00001887_51_T2	PHENOTYPE	4	5	allergic rhinitis
NCT0000188752	NCT00001887_52_T0	PHENOTYPE	14	14	bronchitis
NCT0000188752	NCT00001887_52_T1	PHENOTYPE	11	11	asthma
NCT0000188752	NCT00001887_52_T2	PHENOTYPE	17	17	bronchiectasis
NCT0000188752	NCT00001887_52_T3	PHENOTYPE	18	18	HIV
NCT0000188752	NCT00001887_52_T4	PHENOTYPE	21	21	inflammation
NCT0000188752	NCT00001887_52_T5	PHENOTYPE	13	13	chronic
NCT0000188752	NCT00001887_52_T6	PHENOTYPE	15	16	cystic fibrosis
NCT0000188752	NCT00001887_52_T7	PHENOTYPE	7	8	pulmonary disorder
NCT0000188754	NCT00001887_54_T0	PHENOTYPE	7	7	asthma
NCT0000188754	NCT00001887_54_T1	PHENOTYPE	3	5	respiratory tract infection
NCT0000188755	NCT00001887_55_T0	COMPOUND	11	11	sodium
NCT0000188755	NCT00001887_55_T1	GENE	14	14	receptor
NCT0000188755	NCT00001887_55_T2	COMPOUND	3	3	theophylline
NCT0000188755	NCT00001887_55_T3	COMPOUND	19	19	montelukast
NCT0000188755	NCT00001887_55_T4	COMPOUND	17	17	zafirlukast
NCT0000188755	NCT00001887_55_T5	COMPOUND	8	9	nedocromil sodium
NCT0000188756	NCT00001887_56_T0	COMPOUND	8	8	hydroxyzine
NCT0000188759	NCT00001887_59_T0	COMPOUND	6	6	lidocaine
NCT0000188759	NCT00001887_59_T1	PHENOTYPE	3	4	adverse reactions
NCT0000188760	NCT00001887_60_T0	PHENOTYPE	10	11	alcohol abuse
NCT0000188760	NCT00001887_60_T1	PHENOTYPE	6	8	intravenous drug abuse
NCT0000188761	NCT00001887_61_T0	PHENOTYPE	9	11	coronary artery disease
NCT0000188762	NCT00001887_62_T0	PHENOTYPE	3	3	chronic
NCT0000188763	NCT00001887_63_T0	COMPOUND	3	3	aspirin
NCT0000188765	NCT00001887_65_T0	PHENOTYPE	3	3	allergy
NCT0000188766	NCT00001887_66_T0	COMPOUND	3	3	methacholine
NCT0000188768	NCT00001887_68_T0	PHENOTYPE	0	1	Platelet count
NCT000018882	NCT00001888_2_T0	CELL	23	23	cells
NCT000018882	NCT00001888_2_T1	PHENOTYPE	6	6	sterile
NCT000018883	NCT00001888_3_T0	PHENOTYPE	12	12	asthma
NCT000018884	NCT00001888_4_T0	PHENOTYPE	14	14	inflammation
NCT000018884	NCT00001888_4_T1	PHENOTYPE	16	16	asthma
NCT000018887	NCT00001888_7_T0	PHENOTYPE	3	3	asthma
NCT000018888	NCT00001888_8_T0	COMPOUND	11	11	methacholine
NCT000018888	NCT00001888_8_T1	PHENOTYPE	15	16	airway obstruction
NCT000018889	NCT00001888_9_T0	COMPOUND	2	2	methacholine
NCT0000188810	NCT00001888_10_T0	GENE	15	15	cc
NCT0000188810	NCT00001888_10_T1	PHENOTYPE	21	21	FVC
NCT0000188810	NCT00001888_10_T2	PHENOTYPE	1	2	airway obstruction
NCT0000188811	NCT00001888_11_T0	PHENOTYPE	14	14	allergy
NCT0000188811	NCT00001888_11_T1	GENE	10	10	has
NCT0000188812	NCT00001888_12_T0	PHENOTYPE	18	18	obstruction
NCT0000188812	NCT00001888_12_T1	PHENOTYPE	17	17	airflow
NCT0000188813	NCT00001888_13_T0	PHENOTYPE	5	7	negative pregnancy test
NCT0000188814	NCT00001888_14_T0	PHENOTYPE	32	32	asthma
NCT0000188815	NCT00001888_15_T0	PHENOTYPE	9	9	obstruction
NCT0000188815	NCT00001888_15_T1	PHENOTYPE	8	8	airflow
NCT0000188815	NCT00001888_15_T2	COMPOUND	4	4	methacholine
NCT0000188815	NCT00001888_15_T3	PHENOTYPE	12	14	negative pregnancy test
NCT0000188816	NCT00001888_16_T0	PHENOTYPE	16	16	HIV
NCT0000188816	NCT00001888_16_T1	PHENOTYPE	19	19	inflammation
NCT0000188816	NCT00001888_16_T2	PHENOTYPE	10	10	asthma
NCT0000188816	NCT00001888_16_T3	PHENOTYPE	15	15	fibrosis
NCT0000188816	NCT00001888_16_T4	GENE	14	14	cystic
NCT0000188816	NCT00001888_16_T5	PHENOTYPE	12	13	chronic bronchitis
NCT0000188816	NCT00001888_16_T6	PHENOTYPE	6	7	pulmonary disorder
NCT0000188817	NCT00001888_17_T0	PHENOTYPE	4	5	alcohol abuse
NCT0000188820	NCT00001888_20_T0	GENE	21	21	960
NCT0000188820	NCT00001888_20_T1	GENE	7	7	bv
NCT0000188820	NCT00001888_20_T2	COMPOUND	3	3	methacholine
NCT0000188820	NCT00001888_20_T3	PHENOTYPE	24	25	bronchial hyperresponsiveness
NCT0000188821	NCT00001888_21_T0	PHENOTYPE	14	14	allergy
NCT0000188821	NCT00001888_21_T1	GENE	10	10	has
NCT0000188821	NCT00001888_21_T2	COMPOUND	16	16	methacholine
NCT0000188822	NCT00001888_22_T0	COMPOUND	18	18	methacholine
NCT0000188823	NCT00001888_23_T0	PHENOTYPE	5	7	negative pregnancy test
NCT0000188824	NCT00001888_24_T0	PHENOTYPE	46	46	asthma
NCT0000188824	NCT00001888_24_T1	COMPOUND	29	29	methacholine
NCT0000188824	NCT00001888_24_T2	PHENOTYPE	33	35	negative pregnancy test
NCT000018895	NCT00001889_5_T0	COMPOUND	4	4	Optison
NCT000018895	NCT00001889_5_T1	CELL	12	14	red blood cells
NCT000018897	NCT00001889_7_T0	ORGAN	6	6	heart
NCT000018898	NCT00001889_8_T0	COMPOUND	13	13	adenosine
NCT000018898	NCT00001889_8_T1	ORGAN	17	17	heart
NCT0000188911	NCT00001889_11_T0	COMPOUND	10	10	dobutamine
NCT0000188911	NCT00001889_11_T1	ORGAN	14	14	heart
NCT0000188914	NCT00001889_14_T0	GENE	2	2	has
NCT0000188915	NCT00001889_15_T0	COMPOUND	15	15	oxygen
NCT0000188915	NCT00001889_15_T1	CELL	19	19	myocytes
NCT0000188921	NCT00001889_21_T0	PHENOTYPE	1	1	menopausal
NCT0000188923	NCT00001889_23_T0	PHENOTYPE	2	3	myocardial infarction
NCT0000188925	NCT00001889_25_T0	PHENOTYPE	3	3	asthma
NCT0000188925	NCT00001889_25_T1	PHENOTYPE	5	8	chronic obstructive pulmonary disease
NCT0000188926	NCT00001889_26_T0	COMPOUND	6	6	dipyridamole
NCT0000188926	NCT00001889_26_T1	COMPOUND	4	4	theophylline
NCT0000188926	NCT00001889_26_T2	COMPOUND	3	3	aminophylline
NCT0000188927	NCT00001889_27_T0	PHENOTYPE	5	8	third degree heart block
NCT0000188928	NCT00001889_28_T0	PHENOTYPE	12	12	hypotension
NCT0000188928	NCT00001889_28_T1	PHENOTYPE	2	2	hypertension
NCT0000188928	NCT00001889_28_T2	GENE	10	10	Hg
NCT0000188928	NCT00001889_28_T3	GENE	20	20	Hg
NCT0000188929	NCT00001889_29_T0	PHENOTYPE	1	1	hypotension
NCT0000188929	NCT00001889_29_T1	GENE	11	11	Hg
NCT0000188931	NCT00001889_31_T0	PHENOTYPE	1	2	atrial fibrillation
NCT000018900	NCT00001890_0_T0	ORGAN	6	7	Immune Systems
NCT000018900	NCT00001890_0_T1	PHENOTYPE	12	13	Chronic Infections
NCT000018903	NCT00001890_3_T0	COMPOUND	4	4	estrogen
NCT000018903	NCT00001890_3_T1	PHENOTYPE	12	13	heart disease
NCT000018904	NCT00001890_4_T0	COMPOUND	15	15	estrogen
NCT000018904	NCT00001890_4_T1	PHENOTYPE	5	5	menopausal
NCT000018904	NCT00001890_4_T2	GENE	9	9	hormone
NCT000018904	NCT00001890_4_T3	PHENOTYPE	20	21	heart disease
NCT000018905	NCT00001890_5_T0	ORGAN	17	18	blood vessels
NCT000018906	NCT00001890_6_T0	PHENOTYPE	19	19	atherosclerosis
NCT000018906	NCT00001890_6_T1	PHENOTYPE	11	11	infections
NCT0000189013	NCT00001890_13_T0	PHENOTYPE	8	8	seronegative
NCT0000189016	NCT00001890_16_T0	GENE	20	20	FSH
NCT0000189016	NCT00001890_16_T1	ORGAN	13	13	plasma
NCT0000189016	NCT00001890_16_T2	COMPOUND	14	14	estradiol
NCT0000189018	NCT00001890_18_T0	GENE	4	4	hormone
NCT0000189021	NCT00001890_21_T0	PHENOTYPE	6	6	alcoholism
NCT0000189024	NCT00001890_24_T0	PHENOTYPE	9	9	embolism
NCT0000189026	NCT00001890_26_T0	ORGAN	7	7	liver
NCT0000189026	NCT00001890_26_T1	PHENOTYPE	5	6	liver disease
NCT0000189027	NCT00001890_27_T0	COMPOUND	6	6	creatinine
NCT0000189027	NCT00001890_27_T1	GENE	9	9	1/6
NCT0000189027	NCT00001890_27_T2	PHENOTYPE	3	5	impaired renal function
NCT0000189028	NCT00001890_28_T0	PHENOTYPE	15	15	thyroiditis
NCT0000189028	NCT00001890_28_T1	PHENOTYPE	16	17	Raynaud's Disease
NCT0000189028	NCT00001890_28_T2	PHENOTYPE	13	14	rheumatoid arthritis
NCT0000189028	NCT00001890_28_T3	PHENOTYPE	7	8	autoimmune disease
NCT0000189028	NCT00001890_28_T4	PHENOTYPE	10	12	systemic lupus erythematosus
NCT0000189029	NCT00001890_29_T0	PHENOTYPE	7	8	vaginal bleeding
NCT0000189030	NCT00001890_30_T0	ORGAN	3	3	serum
NCT000018910	NCT00001891_0_T0	TISSUE	10	11	Heart Muscle
NCT000018913	NCT00001891_3_T0	ORGAN	14	14	heart
NCT000018913	NCT00001891_3_T1	PHENOTYPE	4	5	heart disease
NCT000018916	NCT00001891_6_T0	COMPOUND	16	16	dobutamine
NCT000018916	NCT00001891_6_T1	TISSUE	24	25	heart muscle
NCT000018916	NCT00001891_6_T2	PHENOTYPE	34	35	heart disease
NCT0000189110	NCT00001891_10_T0	COMPOUND	4	4	Optison
NCT0000189110	NCT00001891_10_T1	CELL	12	14	red blood cells
NCT0000189114	NCT00001891_14_T0	COMPOUND	10	10	dobutamine
NCT0000189114	NCT00001891_14_T1	ORGAN	14	14	heart
NCT0000189115	NCT00001891_15_T0	COMPOUND	8	8	dobutamine
NCT0000189115	NCT00001891_15_T1	PHENOTYPE	19	20	heart attack
NCT0000189115	NCT00001891_15_T2	TISSUE	0	1	Heart muscle
NCT0000189117	NCT00001891_17_T0	COMPOUND	15	15	oxygen
NCT0000189117	NCT00001891_17_T1	CELL	19	19	myocytes
NCT0000189122	NCT00001891_22_T0	PHENOTYPE	1	1	menopausal
NCT0000189124	NCT00001891_24_T0	PHENOTYPE	4	5	myocardial infarction
NCT0000189126	NCT00001891_26_T0	PHENOTYPE	4	4	hypertension
NCT0000189126	NCT00001891_26_T1	GENE	12	12	Hg
NCT0000189127	NCT00001891_27_T0	PHENOTYPE	1	1	hypotension
NCT0000189128	NCT00001891_28_T0	PHENOTYPE	3	4	sinus tachycardia
NCT0000189129	NCT00001891_29_T0	PHENOTYPE	1	2	atrial fibrillation
NCT000018934	NCT00001893_4_T0	PHENOTYPE	16	16	asthma
NCT000018934	NCT00001893_4_T1	GENE	11	11	TNF
NCT000018939	NCT00001893_9_T0	PHENOTYPE	16	16	asthma
NCT000018939	NCT00001893_9_T1	GENE	11	11	TNF
NCT0000189311	NCT00001893_11_T0	PHENOTYPE	3	3	asthma
NCT0000189312	NCT00001893_12_T0	PHENOTYPE	4	5	allergic asthma
NCT0000189313	NCT00001893_13_T0	PHENOTYPE	7	7	asthma
NCT0000189315	NCT00001893_15_T0	COMPOUND	3	3	methacholine
NCT0000189315	NCT00001893_15_T1	COMPOUND	27	27	methacholine
NCT0000189318	NCT00001893_18_T0	PHENOTYPE	28	28	acute
NCT0000189318	NCT00001893_18_T1	ORGAN	7	7	serum
NCT0000189318	NCT00001893_18_T2	GENE	16	16	ml
NCT0000189318	NCT00001893_18_T3	PHENOTYPE	29	30	pulmonary infiltrates
NCT0000189319	NCT00001893_19_T0	PHENOTYPE	5	7	negative pregnancy test
NCT0000189321	NCT00001893_21_T0	PHENOTYPE	7	7	asthma
NCT0000189321	NCT00001893_21_T1	PHENOTYPE	13	13	bronchiectasis
NCT0000189321	NCT00001893_21_T2	PHENOTYPE	14	14	HIV
NCT0000189321	NCT00001893_21_T3	PHENOTYPE	17	17	inflammation
NCT0000189321	NCT00001893_21_T4	PHENOTYPE	12	12	fibrosis
NCT0000189321	NCT00001893_21_T5	GENE	11	11	cystic
NCT0000189321	NCT00001893_21_T6	PHENOTYPE	9	10	chronic bronchitis
NCT0000189321	NCT00001893_21_T7	PHENOTYPE	3	4	pulmonary disorder
NCT0000189322	NCT00001893_22_T0	PHENOTYPE	4	4	asthma
NCT0000189322	NCT00001893_22_T1	PHENOTYPE	0	2	Respiratory tract infection
NCT0000189324	NCT00001893_24_T0	COMPOUND	10	10	sodium
NCT0000189324	NCT00001893_24_T1	GENE	13	13	receptor
NCT0000189324	NCT00001893_24_T2	COMPOUND	2	2	theophylline
NCT0000189324	NCT00001893_24_T3	COMPOUND	18	18	montelukast
NCT0000189324	NCT00001893_24_T4	COMPOUND	16	16	zafirlukast
NCT0000189324	NCT00001893_24_T5	COMPOUND	7	8	nedocromil sodium
NCT0000189325	NCT00001893_25_T0	COMPOUND	8	8	hydroxyzine
NCT0000189328	NCT00001893_28_T0	COMPOUND	5	5	lidocaine
NCT0000189328	NCT00001893_28_T1	PHENOTYPE	2	3	adverse reactions
NCT0000189329	NCT00001893_29_T0	COMPOUND	2	2	aspirin
NCT0000189331	NCT00001893_31_T0	PHENOTYPE	2	2	allergy
NCT0000189332	NCT00001893_32_T0	PHENOTYPE	0	0	Allergy
NCT0000189332	NCT00001893_32_T1	COMPOUND	2	2	methacholine
NCT0000189334	NCT00001893_34_T0	PHENOTYPE	3	3	hepatitis
NCT0000189334	NCT00001893_34_T1	PHENOTYPE	9	9	hepatitis
NCT0000189334	NCT00001893_34_T2	PHENOTYPE	19	19	fibrosis
NCT0000189334	NCT00001893_34_T3	PHENOTYPE	14	15	pleural effusions
NCT0000189334	NCT00001893_34_T4	PHENOTYPE	16	17	interstitial pneumonitis
NCT0000189335	NCT00001893_35_T0	PHENOTYPE	12	12	lymphocytosis
NCT0000189335	NCT00001893_35_T1	PHENOTYPE	2	3	Crohn's disease
NCT0000189335	NCT00001893_35_T2	PHENOTYPE	8	10	inflammatory bowel disease
NCT0000189337	NCT00001893_37_T0	CELL	18	18	neutrophil
NCT0000189337	NCT00001893_37_T1	CELL	19	19	lymphocyte
NCT0000189338	NCT00001893_38_T0	PHENOTYPE	8	8	chronic
NCT0000189339	NCT00001893_39_T0	PHENOTYPE	6	8	coronary artery disease
NCT0000189339	NCT00001893_39_T1	PHENOTYPE	2	4	chronic heart failure
NCT0000189340	NCT00001893_40_T0	PHENOTYPE	11	11	myelitis
NCT0000189340	NCT00001893_40_T1	PHENOTYPE	5	6	demyelinating disorders
NCT0000189340	NCT00001893_40_T2	PHENOTYPE	9	10	multiple sclerosis
NCT0000189340	NCT00001893_40_T3	PHENOTYPE	13	14	optic neuritis
NCT0000189340	NCT00001893_40_T4	ORGAN	2	4	central nervous system
NCT0000189341	NCT00001893_41_T0	PHENOTYPE	14	14	leukopenia
NCT0000189341	NCT00001893_41_T1	PHENOTYPE	12	12	thrombocytopenia
NCT0000189341	NCT00001893_41_T2	PHENOTYPE	6	6	anemia
NCT0000189341	NCT00001893_41_T3	PHENOTYPE	2	3	hematologic disorders
NCT0000189341	NCT00001893_41_T4	PHENOTYPE	9	11	iron deficiency anemia
NCT000018944	NCT00001894_4_T0	PHENOTYPE	27	27	symptoms
NCT000018944	NCT00001894_4_T1	PHENOTYPE	24	24	obstruction
NCT000018944	NCT00001894_4_T2	ORGAN	13	13	heart
NCT000018945	NCT00001894_5_T0	PHENOTYPE	6	6	anesthesia
NCT000018947	NCT00001894_7_T0	PHENOTYPE	21	21	obstruction
NCT000018947	NCT00001894_7_T1	TISSUE	15	16	heart muscle
NCT000018947	NCT00001894_7_T2	ORGAN	10	11	blood vessel
NCT000018948	NCT00001894_8_T0	PHENOTYPE	19	19	obstruction
NCT000018949	NCT00001894_9_T0	COMPOUND	17	17	thallium
NCT0000189412	NCT00001894_12_T0	PHENOTYPE	11	13	quality of life
NCT0000189415	NCT00001894_15_T0	PHENOTYPE	4	4	quality-of-life
NCT0000189419	NCT00001894_19_T0	PHENOTYPE	13	13	presyncope
NCT0000189419	NCT00001894_19_T1	COMPOUND	15	15	verapamil
NCT0000189419	NCT00001894_19_T2	PHENOTYPE	5	5	syncope
NCT0000189420	NCT00001894_20_T0	COMPOUND	24	24	isoproterenol
NCT0000189420	NCT00001894_20_T1	ORGAN	28	28	heart
NCT0000189420	NCT00001894_20_T2	GENE	34	34	bpm
NCT0000189420	NCT00001894_20_T3	GENE	11	11	Hg
NCT0000189420	NCT00001894_20_T4	GENE	22	22	Hg
NCT0000189423	NCT00001894_23_T0	PHENOTYPE	8	8	narrowing
NCT0000189423	NCT00001894_23_T1	ORGAN	12	13	coronary artery
NCT0000189424	NCT00001894_24_T0	PHENOTYPE	3	5	chronic atrial fibrillation
NCT000018950	NCT00001895_0_T0	TISSUE	4	5	Heart Muscle
NCT000018952	NCT00001895_2_T0	ORGAN	17	17	groin
NCT000018952	NCT00001895_2_T1	ORGAN	23	23	heart
NCT000018953	NCT00001895_3_T0	GENE	3	3	dye
NCT000018953	NCT00001895_3_T1	TISSUE	20	21	heart muscle
NCT000018955	NCT00001895_5_T0	ORGAN	33	34	left ventricle
NCT000018958	NCT00001895_8_T0	COMPOUND	13	13	dobutamine
NCT000018959	NCT00001895_9_T0	ORGAN	1	1	heart
NCT000018959	NCT00001895_9_T1	ORGAN	8	8	heart
NCT0000189511	NCT00001895_11_T0	GENE	10	10	MRI
NCT0000189511	NCT00001895_11_T1	BIOLOGICAL_PROCESS	30	30	metabolism
NCT0000189511	NCT00001895_11_T2	TISSUE	23	24	heart muscle
NCT0000189513	NCT00001895_13_T0	TISSUE	41	41	myocardium
NCT0000189513	NCT00001895_13_T1	PHENOTYPE	13	14	myocardial ischemia
NCT0000189514	NCT00001895_14_T0	GENE	11	11	viability
NCT0000189514	NCT00001895_14_T1	PHENOTYPE	13	13	ischemia
NCT0000189515	NCT00001895_15_T0	GENE	28	28	MRI
NCT0000189515	NCT00001895_15_T1	TISSUE	11	11	myocardium
NCT0000189515	NCT00001895_15_T2	COMPOUND	30	30	thallium
NCT0000189515	NCT00001895_15_T3	PHENOTYPE	36	38	coronary artery disease
NCT0000189519	NCT00001895_19_T0	PHENOTYPE	2	3	myocardial infarction
NCT0000189521	NCT00001895_21_T0	PHENOTYPE	1	3	chronic atrial fibrillation
NCT0000189522	NCT00001895_22_T0	ORGAN	2	3	heart valves
NCT0000189524	NCT00001895_24_T0	PHENOTYPE	2	3	ventricular thrombus
NCT0000189525	NCT00001895_25_T0	PHENOTYPE	2	3	heart failure
NCT0000189526	NCT00001895_26_T0	PHENOTYPE	10	11	ventricular tachycardia
NCT000018984	NCT00001898_4_T0	PHENOTYPE	20	20	disorders
NCT000018984	NCT00001898_4_T1	PHENOTYPE	17	17	cancers
NCT000018984	NCT00001898_4_T2	BIOLOGICAL_PROCESS	13	14	gene expression
NCT000018985	NCT00001898_5_T0	TISSUE	10	10	tissues
NCT000018985	NCT00001898_5_T1	PHENOTYPE	20	20	melanoma
NCT000018985	NCT00001898_5_T2	PHENOTYPE	18	18	sarcomas
NCT000018985	NCT00001898_5_T3	PHENOTYPE	0	0	Tumors
NCT000018985	NCT00001898_5_T4	PHENOTYPE	16	17	colon cancer
NCT000018986	NCT00001898_6_T0	GENE	29	29	Ann
NCT000018986	NCT00001898_6_T1	PHENOTYPE	50	50	sarcoma
NCT000018986	NCT00001898_6_T2	PHENOTYPE	41	41	melanoma
NCT000018986	NCT00001898_6_T3	PHENOTYPE	14	14	Oncology
NCT000018986	NCT00001898_6_T4	PHENOTYPE	45	46	colon cancer
NCT000018986	NCT00001898_6_T5	PHENOTYPE	21	22	breast cancer
NCT000018986	NCT00001898_6_T6	PHENOTYPE	32	33	breast cancer
NCT000018989	NCT00001898_9_T0	GENE	9	9	has
NCT000018989	NCT00001898_9_T1	PHENOTYPE	0	1	Breast cancer
NCT0000189812	NCT00001898_12_T0	TISSUE	12	12	tissues
NCT0000189813	NCT00001898_13_T0	BIOLOGICAL_PROCESS	6	7	gene expression
NCT000018993	NCT00001899_3_T0	ORGAN	13	14	immune system
NCT000018998	NCT00001899_8_T0	CELL	1	1	cells
NCT0000189914	NCT00001899_14_T0	GENE	3	3	CD4
NCT0000189915	NCT00001899_15_T0	GENE	5	5	CD4
NCT0000189915	NCT00001899_15_T1	ORGAN	40	41	immune system
NCT0000189918	NCT00001899_18_T0	PHENOTYPE	18	18	acute
NCT0000189922	NCT00001899_22_T0	PHENOTYPE	13	13	HIV
NCT0000189922	NCT00001899_22_T1	BIOLOGICAL_PROCESS	20	21	immune response
NCT0000189924	NCT00001899_24_T0	GENE	7	7	blot
NCT0000189924	NCT00001899_24_T1	PHENOTYPE	0	1	HIV infection
NCT0000189926	NCT00001899_26_T0	GENE	5	5	PI
NCT0000189926	NCT00001899_26_T1	GENE	7	7	has
NCT0000189928	NCT00001899_28_T0	GENE	43	43	OR
NCT0000189928	NCT00001899_28_T1	GENE	25	26	protease inhibitor
NCT0000189929	NCT00001899_29_T0	GENE	2	2	CD4
NCT0000189930	NCT00001899_30_T0	PHENOTYPE	3	3	HIV
NCT0000189930	NCT00001899_30_T1	PHENOTYPE	4	4	illnesses
NCT0000189930	NCT00001899_30_T2	PHENOTYPE	10	10	malignancies
NCT0000189930	NCT00001899_30_T3	PHENOTYPE	7	8	opportunistic infections
NCT0000189930	NCT00001899_30_T4	PHENOTYPE	14	15	Kaposi's sarcoma
NCT0000189931	NCT00001899_31_T0	GENE	3	3	IL-2
NCT0000189932	NCT00001899_32_T0	GENE	10	10	PI
NCT0000189932	NCT00001899_32_T1	PHENOTYPE	2	3	Psychiatric illness
NCT0000189933	NCT00001899_33_T0	PHENOTYPE	1	2	substance abuse
NCT0000189933	NCT00001899_33_T1	PHENOTYPE	7	8	substance abuse
NCT0000189937	NCT00001899_37_T0	CELL	10	10	neutrophils
NCT0000189937	NCT00001899_37_T1	GENE	5	5	hemoglobin
NCT0000189937	NCT00001899_37_T2	PHENOTYPE	0	1	Platelet count
NCT0000189938	NCT00001899_38_T0	COMPOUND	8	8	cardiolipin
NCT0000189939	NCT00001899_39_T0	PHENOTYPE	2	3	bleeding disorder
NCT0000189940	NCT00001899_40_T0	ORGAN	3	3	kidney
NCT0000189941	NCT00001899_41_T0	PHENOTYPE	7	7	malignancy
NCT0000189941	NCT00001899_41_T1	PHENOTYPE	6	6	HIV
NCT0000189941	NCT00001899_41_T2	PHENOTYPE	3	4	opportunistic infection
NCT0000189942	NCT00001899_42_T0	GENE	8	8	CD4
NCT0000189942	NCT00001899_42_T1	GENE	5	5	had
NCT0000189945	NCT00001899_45_T0	COMPOUND	13	13	tenofovir
NCT0000189945	NCT00001899_45_T1	COMPOUND	11	11	adefovir
NCT0000189945	NCT00001899_45_T2	COMPOUND	10	10	lamivudine
NCT0000189945	NCT00001899_45_T3	PHENOTYPE	3	4	hepatitis B
NCT0000189945	NCT00001899_45_T4	PHENOTYPE	2	3	chronic hepatitis
NCT000019011	NCT00001901_1_T0	ORGAN	20	20	joints
NCT000019011	NCT00001901_1_T1	ORGAN	16	16	kidneys
NCT000019011	NCT00001901_1_T2	ORGAN	13	13	eyes
NCT000019011	NCT00001901_1_T3	ORGAN	21	21	heart
NCT000019011	NCT00001901_1_T4	ORGAN	15	15	lungs
NCT000019011	NCT00001901_1_T5	PHENOTYPE	14	14	sinuses
NCT000019011	NCT00001901_1_T6	PHENOTYPE	0	1	Wegener's granulomatosis
NCT000019013	NCT00001901_3_T0	COMPOUND	11	11	cyclophosphamide
NCT000019013	NCT00001901_3_T1	COMPOUND	13	13	methotrexate
NCT000019013	NCT00001901_3_T2	COMPOUND	6	6	prednisone
NCT000019014	NCT00001901_4_T0	PHENOTYPE	9	10	disease relapse
NCT000019015	NCT00001901_5_T0	COMPOUND	17	17	prednisone
NCT000019015	NCT00001901_5_T1	PHENOTYPE	20	21	disease relapse
NCT000019016	NCT00001901_6_T0	GENE	5	5	has
NCT000019016	NCT00001901_6_T1	PHENOTYPE	13	14	inflammatory disease
NCT000019016	NCT00001901_6_T2	PHENOTYPE	10	11	rheumatoid arthritis
NCT000019017	NCT00001901_7_T0	GENE	8	8	TNF-a
NCT000019017	NCT00001901_7_T1	CELL	12	14	white blood cells
NCT000019018	NCT00001901_8_T0	PHENOTYPE	3	3	affects
NCT000019018	NCT00001901_8_T1	COMPOUND	1	1	prednisone
NCT000019018	NCT00001901_8_T2	COMPOUND	19	19	prednisone
NCT000019018	NCT00001901_8_T3	BIOLOGICAL_PROCESS	8	9	TNF production
NCT000019018	NCT00001901_8_T4	PHENOTYPE	23	24	Wegener's granulomatosis
NCT000019019	NCT00001901_9_T0	COMPOUND	18	18	cyclophosphamide
NCT000019019	NCT00001901_9_T1	COMPOUND	16	16	methotrexate
NCT000019019	NCT00001901_9_T2	COMPOUND	15	15	prednisone
NCT000019019	NCT00001901_9_T3	PHENOTYPE	9	10	Wegener's granulomatosis
NCT0000190112	NCT00001901_12_T0	COMPOUND	7	7	methotrexate
NCT0000190112	NCT00001901_12_T1	COMPOUND	6	6	prednisone
NCT0000190113	NCT00001901_13_T0	COMPOUND	8	8	prednisone
NCT0000190114	NCT00001901_14_T0	COMPOUND	22	22	methotrexate
NCT0000190114	NCT00001901_14_T1	COMPOUND	34	34	methotrexate
NCT0000190114	NCT00001901_14_T2	COMPOUND	42	42	methotrexate
NCT0000190114	NCT00001901_14_T3	PHENOTYPE	4	4	remission
NCT0000190115	NCT00001901_15_T0	PHENOTYPE	18	18	remission
NCT0000190115	NCT00001901_15_T1	PHENOTYPE	4	5	in remission
NCT0000190116	NCT00001901_16_T0	PHENOTYPE	5	5	remission
NCT0000190117	NCT00001901_17_T0	COMPOUND	20	20	methotrexate
NCT0000190117	NCT00001901_17_T1	COMPOUND	22	22	cyclophosphamide
NCT0000190117	NCT00001901_17_T2	COMPOUND	17	17	prednisone
NCT0000190117	NCT00001901_17_T3	PHENOTYPE	4	5	disease relapse
NCT0000190120	NCT00001901_20_T0	PHENOTYPE	4	5	in remission
NCT0000190124	NCT00001901_24_T0	PHENOTYPE	1	1	secondary
NCT0000190124	NCT00001901_24_T1	PHENOTYPE	15	16	Wegener's granulomatosis
NCT0000190125	NCT00001901_25_T0	PHENOTYPE	19	19	relapse
NCT0000190127	NCT00001901_27_T0	COMPOUND	13	13	methotrexate
NCT0000190127	NCT00001901_27_T1	COMPOUND	15	15	prednisone
NCT0000190128	NCT00001901_28_T0	COMPOUND	4	4	prednisone
NCT0000190128	NCT00001901_28_T1	GENE	7	7	tapered
NCT0000190129	NCT00001901_29_T0	PHENOTYPE	7	8	in remission
NCT0000190130	NCT00001901_30_T0	PHENOTYPE	11	11	remission
NCT0000190130	NCT00001901_30_T1	COMPOUND	4	4	methotrexate
NCT0000190130	NCT00001901_30_T2	GENE	18	18	tapered
NCT0000190136	NCT00001901_36_T0	PHENOTYPE	6	7	bacterial sepsis
NCT0000190137	NCT00001901_37_T0	PHENOTYPE	25	25	vasculitis
NCT0000190137	NCT00001901_37_T1	PHENOTYPE	6	7	systemic infection
NCT0000190139	NCT00001901_39_T0	PHENOTYPE	5	7	negative pregnancy test
NCT0000190147	NCT00001901_47_T0	PHENOTYPE	1	1	allergy
NCT0000190148	NCT00001901_48_T0	GENE	15	15	PI
NCT0000190148	NCT00001901_48_T1	PHENOTYPE	5	6	psychiatric illness
NCT0000190149	NCT00001901_49_T0	PHENOTYPE	6	7	demyelinating disease
NCT0000190149	NCT00001901_49_T1	PHENOTYPE	2	3	multiple sclerosis
NCT000019031	NCT00001903_1_T0	PHENOTYPE	13	13	strain
NCT000019031	NCT00001903_1_T1	GENE	5	5	has
NCT000019033	NCT00001903_3_T0	PHENOTYPE	14	14	pneumonia
NCT000019033	NCT00001903_3_T1	ORGAN	3	3	Transplant
NCT000019033	NCT00001903_3_T2	PHENOTYPE	12	13	progressing to
NCT000019033	NCT00001903_3_T3	ORGAN	1	2	Bone Marrow
NCT000019035	NCT00001903_5_T0	GENE	6	6	has
NCT000019035	NCT00001903_5_T1	PHENOTYPE	29	30	premature babies
NCT000019035	NCT00001903_5_T2	PHENOTYPE	35	36	bronchopulmonary dysplasia
NCT000019036	NCT00001903_6_T0	PHENOTYPE	21	21	complications
NCT000019036	NCT00001903_6_T1	GENE	2	2	has
NCT000019036	NCT00001903_6_T2	ORGAN	14	14	Transplant
NCT000019036	NCT00001903_6_T3	ORGAN	12	13	Bone Marrow
NCT000019036	NCT00001903_6_T4	PHENOTYPE	8	10	pneumonia in children
NCT000019037	NCT00001903_7_T0	PHENOTYPE	3	3	strategies
NCT000019037	NCT00001903_7_T1	ORGAN	13	13	transplant
NCT000019037	NCT00001903_7_T2	ORGAN	11	12	bone marrow
NCT000019038	NCT00001903_8_T0	PHENOTYPE	12	12	pneumonia
NCT000019038	NCT00001903_8_T1	ORGAN	7	7	transplant
NCT000019038	NCT00001903_8_T2	PHENOTYPE	20	21	premature babies
NCT000019038	NCT00001903_8_T3	ORGAN	5	6	bone marrow
NCT0000190312	NCT00001903_12_T0	PHENOTYPE	13	13	strain
NCT0000190312	NCT00001903_12_T1	GENE	5	5	has
NCT0000190314	NCT00001903_14_T0	PHENOTYPE	14	14	pneumonia
NCT0000190314	NCT00001903_14_T1	ORGAN	3	3	Transplant
NCT0000190314	NCT00001903_14_T2	PHENOTYPE	12	13	progressing to
NCT0000190314	NCT00001903_14_T3	ORGAN	1	2	Bone Marrow
NCT0000190316	NCT00001903_16_T0	GENE	6	6	has
NCT0000190316	NCT00001903_16_T1	PHENOTYPE	29	30	premature babies
NCT0000190316	NCT00001903_16_T2	PHENOTYPE	35	36	bronchopulmonary dysplasia
NCT0000190317	NCT00001903_17_T0	PHENOTYPE	21	21	complications
NCT0000190317	NCT00001903_17_T1	GENE	2	2	has
NCT0000190317	NCT00001903_17_T2	ORGAN	14	14	Transplant
NCT0000190317	NCT00001903_17_T3	ORGAN	12	13	Bone Marrow
NCT0000190317	NCT00001903_17_T4	PHENOTYPE	8	10	pneumonia in children
NCT0000190318	NCT00001903_18_T0	PHENOTYPE	3	3	strategies
NCT0000190318	NCT00001903_18_T1	ORGAN	13	13	transplant
NCT0000190318	NCT00001903_18_T2	ORGAN	11	12	bone marrow
NCT0000190319	NCT00001903_19_T0	PHENOTYPE	12	12	pneumonia
NCT0000190319	NCT00001903_19_T1	ORGAN	7	7	transplant
NCT0000190319	NCT00001903_19_T2	PHENOTYPE	20	21	premature babies
NCT0000190319	NCT00001903_19_T3	ORGAN	5	6	bone marrow
NCT0000190327	NCT00001903_27_T0	PHENOTYPE	4	4	symptoms
NCT0000190327	NCT00001903_27_T1	PHENOTYPE	11	11	pneumonia
NCT0000190327	NCT00001903_27_T2	ORGAN	7	8	Respiratory Tract
NCT000019051	NCT00001905_1_T0	PHENOTYPE	12	12	adhesion
NCT000019051	NCT00001905_1_T1	CELL	25	25	cells
NCT000019051	NCT00001905_1_T2	PHENOTYPE	4	5	immune disorder
NCT000019051	NCT00001905_1_T3	CELL	17	19	white blood cells
NCT000019052	NCT00001905_2_T0	TISSUE	9	9	tissues
NCT000019052	NCT00001905_2_T1	ORGAN	14	14	gums
NCT000019052	NCT00001905_2_T2	PHENOTYPE	5	6	recurrent infections
NCT000019052	NCT00001905_2_T3	ORGAN	16	17	gastrointestinal tract
NCT000019052	NCT00001905_2_T4	PHENOTYPE	19	21	poor wound healing
NCT000019054	NCT00001905_4_T0	GENE	0	0	Interferon
NCT000019054	NCT00001905_4_T1	PHENOTYPE	7	7	adhesion
NCT000019054	NCT00001905_4_T2	GENE	1	1	gamma
NCT000019054	NCT00001905_4_T3	CELL	10	12	white blood cells
NCT000019057	NCT00001905_7_T0	GENE	5	6	interferon gamma
NCT0000190510	NCT00001905_10_T0	GENE	27	28	interferon gamma
NCT0000190510	NCT00001905_10_T1	CELL	23	25	white blood cells
NCT0000190514	NCT00001905_14_T0	PHENOTYPE	13	13	impairment
NCT0000190514	NCT00001905_14_T1	CELL	7	7	leukocyte
NCT0000190514	NCT00001905_14_T2	CELL	15	15	leukocyte
NCT0000190514	NCT00001905_14_T3	GENE	10	10	CD18
NCT0000190514	NCT00001905_14_T4	GENE	1	1	reduced
NCT0000190514	NCT00001905_14_T5	GENE	8	8	integrin
NCT0000190515	NCT00001905_15_T0	TISSUE	10	10	tissues
NCT0000190515	NCT00001905_15_T1	ORGAN	18	18	gingiva
NCT0000190515	NCT00001905_15_T2	PHENOTYPE	4	4	leukocytosis
NCT0000190515	NCT00001905_15_T3	PHENOTYPE	6	7	recurrent infections
NCT0000190515	NCT00001905_15_T4	ORGAN	15	16	gastrointestinal tract
NCT0000190517	NCT00001905_17_T0	PHENOTYPE	8	8	infections
NCT0000190517	NCT00001905_17_T1	ORGAN	10	11	bone marrow
NCT0000190519	NCT00001905_19_T0	GENE	14	14	CD18
NCT0000190519	NCT00001905_19_T1	GENE	12	12	IFN-gamma
NCT0000190519	NCT00001905_19_T2	GENE	2	2	has
NCT0000190519	NCT00001905_19_T3	GENE	10	11	interferon gamma
NCT0000190519	NCT00001905_19_T4	BIOLOGICAL_PROCESS	20	21	leukocyte trafficking
NCT0000190523	NCT00001905_23_T0	PHENOTYPE	7	7	infections
NCT0000190527	NCT00001905_27_T0	PHENOTYPE	3	4	HIV infection
NCT0000190528	NCT00001905_28_T0	PHENOTYPE	1	1	malignancy
NCT0000190529	NCT00001905_29_T0	PHENOTYPE	1	2	cardiac disease
NCT0000190531	NCT00001905_31_T0	GENE	10	10	IFN-gamma
NCT0000190534	NCT00001905_34_T0	PHENOTYPE	8	8	judgement
NCT000019062	NCT00001906_2_T0	GENE	17	17	interleukin-12
NCT000019062	NCT00001906_2_T1	GENE	22	22	gel
NCT000019062	NCT00001906_2_T2	COMPOUND	20	21	aluminum hydroxide
NCT000019066	NCT00001906_6_T0	GENE	17	17	interleukin-12
NCT000019066	NCT00001906_6_T1	GENE	22	22	gel
NCT000019066	NCT00001906_6_T2	COMPOUND	20	21	aluminum hydroxide
NCT0000190612	NCT00001906_12_T0	GENE	14	14	interleukin-12
NCT0000190614	NCT00001906_14_T0	PHENOTYPE	3	3	chronic
NCT0000190615	NCT00001906_15_T0	GENE	10	10	0.5
NCT0000190615	NCT00001906_15_T1	GENE	0	0	For
NCT0000190615	NCT00001906_15_T2	COMPOUND	5	5	prednisone
NCT0000190615	NCT00001906_15_T3	PHENOTYPE	22	22	leishmaniasis
NCT0000190615	NCT00001906_15_T4	PHENOTYPE	31	31	leishmaniasis
NCT0000190615	NCT00001906_15_T5	GENE	47	47	East
NCT0000190619	NCT00001906_19_T0	PHENOTYPE	21	21	fever
NCT0000190619	NCT00001906_19_T1	PHENOTYPE	1	2	acute disease
NCT0000190620	NCT00001906_20_T0	PHENOTYPE	1	1	acute
NCT0000190620	NCT00001906_20_T1	PHENOTYPE	3	3	chronic
NCT0000190622	NCT00001906_22_T0	PHENOTYPE	6	9	alcohol or drug abuse
NCT000019081	NCT00001908_1_T0	PHENOTYPE	10	10	asthma
NCT000019081	NCT00001908_1_T1	PHENOTYPE	20	20	asthma
NCT000019083	NCT00001908_3_T0	GENE	8	8	IL-4R
NCT000019083	NCT00001908_3_T1	GENE	5	5	receptor
NCT000019083	NCT00001908_3_T2	GENE	7	7	IL-4
NCT000019083	NCT00001908_3_T3	GENE	10	10	has
NCT000019083	NCT00001908_3_T4	GENE	13	13	has
NCT000019083	NCT00001908_3_T5	GENE	1	2	soluble form
NCT0000190814	NCT00001908_14_T0	PHENOTYPE	10	10	asthma
NCT0000190814	NCT00001908_14_T1	PHENOTYPE	20	20	asthma
NCT0000190816	NCT00001908_16_T0	GENE	8	8	IL-4R
NCT0000190816	NCT00001908_16_T1	GENE	5	5	receptor
NCT0000190816	NCT00001908_16_T2	GENE	7	7	IL-4
NCT0000190816	NCT00001908_16_T3	GENE	10	10	has
NCT0000190816	NCT00001908_16_T4	GENE	13	13	has
NCT0000190816	NCT00001908_16_T5	GENE	1	2	soluble form
NCT0000190827	NCT00001908_27_T0	GENE	6	6	II
NCT0000190827	NCT00001908_27_T1	GENE	13	13	IL-4
NCT0000190827	NCT00001908_27_T2	PHENOTYPE	16	16	Asthma
NCT0000190829	NCT00001908_29_T0	PHENOTYPE	2	2	HIV
NCT000019091	NCT00001909_1_T0	PHENOTYPE	10	10	asthma
NCT000019091	NCT00001909_1_T1	PHENOTYPE	20	20	asthma
NCT000019094	NCT00001909_4_T0	COMPOUND	4	4	sIL-4R
NCT000019094	NCT00001909_4_T1	GENE	3	3	IL-4R
NCT000019094	NCT00001909_4_T2	GENE	12	12	IL-4
NCT000019094	NCT00001909_4_T3	GENE	5	5	has
NCT000019099	NCT00001909_9_T0	PHENOTYPE	14	14	symptoms
NCT000019099	NCT00001909_9_T1	PHENOTYPE	6	6	FVC
NCT000019099	NCT00001909_9_T2	PHENOTYPE	0	0	Secondary
NCT000019099	NCT00001909_9_T3	PHENOTYPE	23	23	pharmacokinetics
NCT000019099	NCT00001909_9_T4	PHENOTYPE	13	13	asthma
NCT000019099	NCT00001909_9_T5	PHENOTYPE	15	17	quality of life
NCT0000190910	NCT00001909_10_T0	PHENOTYPE	9	9	asthmatics
NCT0000190913	NCT00001909_13_T0	PHENOTYPE	10	10	asthma
NCT0000190913	NCT00001909_13_T1	PHENOTYPE	20	20	asthma
NCT0000190916	NCT00001909_16_T0	COMPOUND	4	4	sIL-4R
NCT0000190916	NCT00001909_16_T1	GENE	3	3	IL-4R
NCT0000190916	NCT00001909_16_T2	GENE	12	12	IL-4
NCT0000190916	NCT00001909_16_T3	GENE	5	5	has
NCT0000190921	NCT00001909_21_T0	PHENOTYPE	14	14	symptoms
NCT0000190921	NCT00001909_21_T1	PHENOTYPE	6	6	FVC
NCT0000190921	NCT00001909_21_T2	PHENOTYPE	0	0	Secondary
NCT0000190921	NCT00001909_21_T3	PHENOTYPE	23	23	pharmacokinetics
NCT0000190921	NCT00001909_21_T4	PHENOTYPE	13	13	asthma
NCT0000190921	NCT00001909_21_T5	PHENOTYPE	15	17	quality of life
NCT0000190922	NCT00001909_22_T0	PHENOTYPE	9	9	asthmatics
NCT0000190925	NCT00001909_25_T0	GENE	16	16	beta-2
NCT0000190925	NCT00001909_25_T1	PHENOTYPE	2	3	persistent asthma
NCT0000190929	NCT00001909_29_T0	PHENOTYPE	11	11	wheal
NCT0000190929	NCT00001909_29_T1	PHENOTYPE	18	18	erythema
NCT0000190929	NCT00001909_29_T2	PHENOTYPE	1	2	prick skin
NCT0000190930	NCT00001909_30_T0	PHENOTYPE	3	3	symptoms
NCT0000190930	NCT00001909_30_T1	PHENOTYPE	2	2	asthma
NCT0000190930	NCT00001909_30_T2	PHENOTYPE	4	4	wheezing
NCT0000190930	NCT00001909_30_T3	PHENOTYPE	8	8	cough
NCT0000190930	NCT00001909_30_T4	PHENOTYPE	9	10	chest tightness
NCT0000190930	NCT00001909_30_T5	PHENOTYPE	5	7	shortness of breath
NCT0000190931	NCT00001909_31_T0	PHENOTYPE	0	0	Fulfillment
NCT0000190931	NCT00001909_31_T1	COMPOUND	42	42	sodium
NCT0000190931	NCT00001909_31_T2	COMPOUND	55	55	montelukast
NCT0000190931	NCT00001909_31_T3	COMPOUND	68	68	fexofenadine
NCT0000190931	NCT00001909_31_T4	COMPOUND	50	50	zileuton
NCT0000190931	NCT00001909_31_T5	COMPOUND	52	52	zafirlukast
NCT0000190934	NCT00001909_34_T0	PHENOTYPE	11	11	asthma
NCT0000190934	NCT00001909_34_T1	GENE	5	5	CXR
NCT0000190942	NCT00001909_42_T0	PHENOTYPE	3	4	acute asthma
NCT0000190943	NCT00001909_43_T0	PHENOTYPE	3	4	acute asthma
NCT0000190944	NCT00001909_44_T0	PHENOTYPE	6	6	affects
NCT0000190944	NCT00001909_44_T1	PHENOTYPE	7	7	asthma
NCT0000190944	NCT00001909_44_T2	PHENOTYPE	3	4	respiratory infection
NCT0000190945	NCT00001909_45_T0	PHENOTYPE	6	6	asthma
NCT0000190947	NCT00001909_47_T0	GENE	9	9	receptor
NCT0000190947	NCT00001909_47_T1	GENE	8	8	IL-4
NCT0000190948	NCT00001909_48_T0	PHENOTYPE	8	9	psychiatric illness
NCT0000190948	NCT00001909_48_T1	PHENOTYPE	5	6	drug abuse
NCT0000190948	NCT00001909_48_T2	PHENOTYPE	3	4	alcohol abuse
NCT000019102	NCT00001910_2_T0	CELL	4	5	Th1 cells
NCT000019102	NCT00001910_2_T1	CELL	1	2	T cells
NCT000019104	NCT00001910_4_T0	PHENOTYPE	14	14	allergy
NCT000019105	NCT00001910_5_T0	GENE	10	10	had
NCT000019105	NCT00001910_5_T1	PHENOTYPE	11	12	allergic asthma
NCT000019106	NCT00001910_6_T0	PHENOTYPE	2	2	allergy
NCT000019106	NCT00001910_6_T1	PHENOTYPE	24	25	lung function
NCT0000191013	NCT00001910_13_T0	COMPOUND	15	15	ranitidine
NCT0000191013	NCT00001910_13_T1	COMPOUND	11	11	cetirizine
NCT0000191013	NCT00001910_13_T2	COMPOUND	20	20	montelukast
NCT0000191013	NCT00001910_13_T3	COMPOUND	10	10	prednisone
NCT0000191013	NCT00001910_13_T4	PHENOTYPE	6	7	allergic reaction
NCT0000191018	NCT00001910_18_T0	GENE	10	10	allergen
NCT0000191019	NCT00001910_19_T0	GENE	3	3	allergen
NCT0000191019	NCT00001910_19_T1	PHENOTYPE	6	6	asthma
NCT0000191019	NCT00001910_19_T2	PHENOTYPE	19	20	allergic asthma
NCT0000191023	NCT00001910_23_T0	GENE	18	18	allergen
NCT0000191023	NCT00001910_23_T1	GENE	48	48	allergen
NCT0000191027	NCT00001910_27_T0	PHENOTYPE	2	2	asthma
NCT0000191028	NCT00001910_28_T0	PHENOTYPE	1	1	symptoms
NCT0000191028	NCT00001910_28_T1	GENE	11	11	allergen
NCT0000191028	NCT00001910_28_T2	PHENOTYPE	2	2	wheezing
NCT0000191028	NCT00001910_28_T3	PHENOTYPE	0	0	Asthma
NCT0000191028	NCT00001910_28_T4	PHENOTYPE	3	4	chest tightness
NCT0000191028	NCT00001910_28_T5	PHENOTYPE	5	7	shortness of breath
NCT0000191029	NCT00001910_29_T0	PHENOTYPE	15	15	prick
NCT0000191029	NCT00001910_29_T1	PHENOTYPE	6	6	wheal
NCT0000191029	NCT00001910_29_T2	PHENOTYPE	2	2	erythema
NCT0000191031	NCT00001910_31_T0	GENE	4	4	allergen
NCT0000191031	NCT00001910_31_T1	GENE	6	6	CD4
NCT0000191031	NCT00001910_31_T2	GENE	2	2	IL-4
NCT0000191031	NCT00001910_31_T3	CELL	7	8	T cells
NCT0000191033	NCT00001910_33_T0	PHENOTYPE	21	21	IUD
NCT0000191033	NCT00001910_33_T1	ORGAN	13	13	diaphragm
NCT0000191034	NCT00001910_34_T0	PHENOTYPE	2	2	Asthma
NCT0000191037	NCT00001910_37_T0	PHENOTYPE	6	6	asthma
NCT0000191037	NCT00001910_37_T1	PHENOTYPE	0	2	Upper respiratory infection
NCT000019111	NCT00001911_1_T0	GENE	0	0	IL-12
NCT000019113	NCT00001911_3_T0	GENE	3	3	IL-12
NCT000019113	NCT00001911_3_T1	GENE	4	4	has
NCT000019114	NCT00001911_4_T0	PHENOTYPE	7	8	mycobacterial infections
NCT000019115	NCT00001911_5_T0	GENE	2	2	has
NCT000019115	NCT00001911_5_T1	PHENOTYPE	15	16	hepatitis C
NCT000019115	NCT00001911_5_T2	PHENOTYPE	12	13	HIV infection
NCT000019116	NCT00001911_6_T0	GENE	6	6	IL-12
NCT0000191112	NCT00001911_12_T0	ORGAN	29	29	kidney
NCT0000191112	NCT00001911_12_T1	ORGAN	30	30	liver
NCT0000191115	NCT00001911_15_T0	PHENOTYPE	17	17	infections
NCT0000191115	NCT00001911_15_T1	GENE	9	9	has
NCT0000191115	NCT00001911_15_T2	GENE	7	8	IFN gamma
NCT0000191116	NCT00001911_16_T0	GENE	1	1	interleukin-12
NCT0000191116	NCT00001911_16_T1	GENE	2	2	IL-12
NCT0000191116	NCT00001911_16_T2	GENE	3	3	has
NCT0000191116	NCT00001911_16_T3	GENE	12	13	IFN gamma
NCT0000191117	NCT00001911_17_T0	GENE	12	12	IL-12
NCT0000191118	NCT00001911_18_T0	GENE	4	4	IL-12
NCT0000191118	NCT00001911_18_T1	GENE	32	33	IFN gamma
NCT0000191118	NCT00001911_18_T2	PHENOTYPE	16	17	mycobacterial infections
NCT0000191119	NCT00001911_19_T0	GENE	13	13	IL-12
NCT0000191120	NCT00001911_20_T0	GENE	3	3	IL-12
NCT0000191122	NCT00001911_22_T0	PHENOTYPE	11	11	toxicity
NCT0000191122	NCT00001911_22_T1	PHENOTYPE	9	9	tolerance
NCT0000191128	NCT00001911_28_T0	GENE	33	33	IL-12
NCT0000191128	NCT00001911_28_T1	ORGAN	12	12	serum
NCT0000191128	NCT00001911_28_T2	PHENOTYPE	7	9	negative pregnancy test
NCT0000191129	NCT00001911_29_T0	GENE	8	8	IL-12
NCT0000191129	NCT00001911_29_T1	CELL	10	10	sperm
NCT0000191134	NCT00001911_34_T0	PHENOTYPE	1	2	HIV infection
NCT0000191135	NCT00001911_35_T0	PHENOTYPE	2	2	malignancy
NCT0000191136	NCT00001911_36_T0	PHENOTYPE	2	3	cardiac disease
NCT0000191137	NCT00001911_37_T0	PHENOTYPE	2	3	seizure disorder
NCT0000191138	NCT00001911_38_T0	BIOLOGICAL_PROCESS	3	3	lactation
NCT0000191139	NCT00001911_39_T0	GENE	11	11	IL-12
NCT0000191142	NCT00001911_42_T0	PHENOTYPE	1	2	gastrointestinal bleeding
NCT0000191142	NCT00001911_42_T1	PHENOTYPE	5	7	peptic ulcer disease
NCT0000191143	NCT00001911_43_T0	PHENOTYPE	7	8	autoimmune disease
NCT0000191143	NCT00001911_43_T1	PHENOTYPE	11	12	rheumatoid arthritis
NCT0000191143	NCT00001911_43_T2	PHENOTYPE	3	5	inflammatory bowel disease
NCT0000191143	NCT00001911_43_T3	PHENOTYPE	14	16	systemic lupus erythematosus
NCT0000191144	NCT00001911_44_T0	PHENOTYPE	8	8	judgement
NCT000019121	NCT00001912_1_T0	PHENOTYPE	14	14	seizures
NCT000019122	NCT00001912_2_T0	COMPOUND	6	6	solium
NCT000019122	NCT00001912_2_T1	PHENOTYPE	3	4	pork tapeworm
NCT000019122	NCT00001912_2_T2	ORGAN	10	11	small intestine
NCT000019123	NCT00001912_3_T0	PHENOTYPE	14	14	cysts
NCT000019124	NCT00001912_4_T0	PHENOTYPE	5	5	symptoms
NCT000019124	NCT00001912_4_T1	PHENOTYPE	2	2	cysts
NCT000019125	NCT00001912_5_T0	PHENOTYPE	11	11	seizures
NCT000019125	NCT00001912_5_T1	PHENOTYPE	13	14	other symptoms
NCT000019127	NCT00001912_7_T0	PHENOTYPE	6	6	cysts
NCT000019129	NCT00001912_9_T0	PHENOTYPE	14	14	seizures
NCT000019129	NCT00001912_9_T1	PHENOTYPE	9	10	calcified cysts
NCT0000191210	NCT00001912_10_T0	PHENOTYPE	36	36	seizure
NCT0000191210	NCT00001912_10_T1	PHENOTYPE	19	19	cysts
NCT0000191210	NCT00001912_10_T2	PHENOTYPE	30	30	cysts
NCT0000191211	NCT00001912_11_T0	PHENOTYPE	2	2	cysticercosis
NCT0000191211	NCT00001912_11_T1	GENE	27	27	MRI
NCT0000191211	NCT00001912_11_T2	GENE	5	5	had
NCT0000191211	NCT00001912_11_T3	PHENOTYPE	6	6	seizures
NCT0000191211	NCT00001912_11_T4	PHENOTYPE	15	16	calcified cysts
NCT0000191212	NCT00001912_12_T0	PHENOTYPE	8	8	seizures
NCT0000191215	NCT00001912_15_T0	PHENOTYPE	0	0	Edema
NCT0000191215	NCT00001912_15_T1	PHENOTYPE	3	3	foci
NCT0000191215	NCT00001912_15_T2	PHENOTYPE	5	6	idiopathic epilepsy
NCT0000191215	NCT00001912_15_T3	PHENOTYPE	20	21	calcified cysts
NCT0000191218	NCT00001912_18_T0	PHENOTYPE	6	6	edema
NCT0000191218	NCT00001912_18_T1	PHENOTYPE	20	20	edema
NCT0000191218	NCT00001912_18_T2	PHENOTYPE	18	18	inflammation
NCT0000191218	NCT00001912_18_T3	BIOLOGICAL_PROCESS	14	15	immune response
NCT0000191220	NCT00001912_20_T0	PHENOTYPE	18	18	seizure
NCT0000191220	NCT00001912_20_T1	PHENOTYPE	9	9	edema
NCT0000191220	NCT00001912_20_T2	PHENOTYPE	35	35	seizures
NCT0000191220	NCT00001912_20_T3	PHENOTYPE	33	33	foci
NCT0000191223	NCT00001912_23_T0	PHENOTYPE	29	29	seizure
NCT0000191224	NCT00001912_24_T0	PHENOTYPE	13	13	seizure
NCT0000191224	NCT00001912_24_T1	PHENOTYPE	5	5	edema
NCT0000191225	NCT00001912_25_T0	PHENOTYPE	10	10	seizure
NCT0000191228	NCT00001912_28_T0	PHENOTYPE	24	24	seizure
NCT0000191228	NCT00001912_28_T1	PHENOTYPE	27	27	edema
NCT0000191231	NCT00001912_31_T0	PHENOTYPE	4	4	cysticercosis
NCT0000191231	NCT00001912_31_T1	PHENOTYPE	9	9	seizure
NCT0000191233	NCT00001912_33_T0	PHENOTYPE	5	5	seizure
NCT0000191233	NCT00001912_33_T1	PHENOTYPE	2	2	seizures
NCT0000191234	NCT00001912_34_T0	GENE	3	3	has
NCT0000191235	NCT00001912_35_T0	PHENOTYPE	4	5	positive serology
NCT0000191238	NCT00001912_38_T0	GENE	2	2	cystic
NCT0000191244	NCT00001912_44_T0	GENE	3	3	MRI
NCT0000191246	NCT00001912_46_T0	GENE	1	1	MRI
NCT0000191246	NCT00001912_46_T1	PHENOTYPE	2	2	Seizures
NCT0000191246	NCT00001912_46_T2	PHENOTYPE	3	4	Calcified Cysts
NCT000019131	NCT00001913_1_T0	GENE	2	2	MRI
NCT000019132	NCT00001913_2_T0	GENE	15	15	MRI
NCT000019132	NCT00001913_2_T1	GENE	14	14	structural
NCT000019134	NCT00001913_4_T0	ORGAN	21	21	faces
NCT000019135	NCT00001913_5_T0	ORGAN	5	5	faces
NCT000019136	NCT00001913_6_T0	ORGAN	4	4	faces
NCT000019139	NCT00001913_9_T0	ORGAN	4	4	faces
NCT000019139	NCT00001913_9_T1	ORGAN	6	6	faces
NCT000019139	NCT00001913_9_T2	ORGAN	14	14	faces
NCT0000191311	NCT00001913_11_T0	PHENOTYPE	7	7	attachment
NCT0000191311	NCT00001913_11_T1	PHENOTYPE	8	8	affects
NCT0000191314	NCT00001913_14_T0	PHENOTYPE	8	8	attachment
NCT0000191317	NCT00001913_17_T0	ORGAN	16	16	faces
NCT0000191318	NCT00001913_18_T0	PHENOTYPE	18	18	attachment
NCT0000191318	NCT00001913_18_T1	ORGAN	5	5	faces
NCT0000191326	NCT00001913_26_T0	PHENOTYPE	31	31	bereavement
NCT0000191326	NCT00001913_26_T1	PHENOTYPE	25	26	adjustment disorder
NCT0000191326	NCT00001913_26_T2	PHENOTYPE	21	23	major depressive disorder
NCT000019150	NCT00001915_0_T0	PHENOTYPE	2	4	Attention Deficit-Hyperactivity Disorder
NCT000019153	NCT00001915_3_T0	PHENOTYPE	2	3	involuntary movements
NCT000019154	NCT00001915_4_T0	GENE	7	7	overflow
NCT000019154	NCT00001915_4_T1	PHENOTYPE	5	5	synkinesis
NCT000019156	NCT00001915_6_T0	PHENOTYPE	4	4	ADHD
NCT000019156	NCT00001915_6_T1	GENE	6	6	overflow
NCT000019158	NCT00001915_8_T0	GENE	3	3	TMS
NCT0000191510	NCT00001915_10_T0	TISSUE	25	25	muscles
NCT0000191510	NCT00001915_10_T1	TISSUE	29	29	muscles
NCT0000191512	NCT00001915_12_T0	TISSUE	6	6	muscles
NCT0000191512	NCT00001915_12_T1	TISSUE	21	21	muscles
NCT0000191516	NCT00001915_16_T0	PHENOTYPE	43	43	maturation
NCT0000191516	NCT00001915_16_T1	GENE	16	16	has
NCT0000191516	NCT00001915_16_T2	ORGAN	12	13	corticospinal tract
NCT0000191519	NCT00001915_19_T0	PHENOTYPE	21	21	ADHD
NCT0000191519	NCT00001915_19_T1	PHENOTYPE	34	34	inhibition
NCT0000191519	NCT00001915_19_T2	PHENOTYPE	26	27	executive function
NCT0000191520	NCT00001915_20_T0	GENE	3	3	TMS
NCT0000191523	NCT00001915_23_T0	PHENOTYPE	19	19	inhibition
NCT0000191523	NCT00001915_23_T1	GENE	0	0	TMS
NCT0000191526	NCT00001915_26_T0	PHENOTYPE	26	26	ADHD
NCT0000191534	NCT00001915_34_T0	GENE	31	31	bee
NCT0000191536	NCT00001915_36_T0	PHENOTYPE	4	5	neurological disorders
NCT0000191537	NCT00001915_37_T0	PHENOTYPE	12	12	epilepsy
NCT0000191537	NCT00001915_37_T1	PHENOTYPE	15	15	disorders
NCT0000191537	NCT00001915_37_T2	GENE	13	13	structural
NCT0000191537	NCT00001915_37_T3	PHENOTYPE	10	10	seizures
NCT0000191537	NCT00001915_37_T4	PHENOTYPE	17	17	hemiplegia
NCT0000191537	NCT00001915_37_T5	ORGAN	23	24	corticospinal tracts
NCT0000191539	NCT00001915_39_T0	BIOLOGICAL_PROCESS	4	4	pigmentation
NCT0000191539	NCT00001915_39_T1	PHENOTYPE	5	5	albinism
NCT0000191542	NCT00001915_42_T0	PHENOTYPE	10	10	dysmetria
NCT0000191542	NCT00001915_42_T1	ORGAN	7	7	tendon
NCT0000191542	NCT00001915_42_T2	PHENOTYPE	2	2	localizing
NCT0000191542	NCT00001915_42_T3	PHENOTYPE	11	11	hypotonia
NCT0000191543	NCT00001915_43_T0	GENE	9	9	ODD
NCT0000191543	NCT00001915_43_T1	PHENOTYPE	2	3	psychiatric disorders
NCT0000191543	NCT00001915_43_T2	PHENOTYPE	6	8	oppositional defiant disorder
NCT000019162	NCT00001916_2_T0	BIOLOGICAL_PROCESS	6	7	bone remodeling
NCT000019163	NCT00001916_3_T0	COMPOUND	11	11	calcium
NCT000019163	NCT00001916_3_T1	TISSUE	17	17	bones
NCT000019164	NCT00001916_4_T0	TISSUE	15	15	bones
NCT000019165	NCT00001916_5_T0	PHENOTYPE	4	4	osteoporosis
NCT0000191612	NCT00001916_12_T0	TISSUE	18	18	bones
NCT0000191612	NCT00001916_12_T1	ORGAN	8	9	bone marrow
NCT0000191616	NCT00001916_16_T0	PHENOTYPE	34	37	decreased bone mineral density
NCT0000191618	NCT00001916_18_T0	CELL	16	16	osteoblast
NCT0000191618	NCT00001916_18_T1	CELL	18	18	osteoclast
NCT0000191618	NCT00001916_18_T2	CELL	19	20	progenitor cells
NCT0000191618	NCT00001916_18_T3	ORGAN	2	3	bone marrow
NCT0000191618	NCT00001916_18_T4	PHENOTYPE	40	43	decreased bone mineral density
NCT0000191619	NCT00001916_19_T0	GENE	21	21	has
NCT0000191619	NCT00001916_19_T1	PHENOTYPE	10	13	decreased bone mineral density
NCT0000191621	NCT00001916_21_T0	PHENOTYPE	4	5	psychiatric disorders
NCT0000191625	NCT00001916_25_T0	PHENOTYPE	6	6	illnesses
NCT0000191629	NCT00001916_29_T0	COMPOUND	13	13	fentanyl
NCT0000191629	NCT00001916_29_T1	COMPOUND	15	15	lidocaine
NCT0000191629	NCT00001916_29_T2	PHENOTYPE	8	9	adverse reactions
NCT000019171	NCT00001917_1_T0	CELL	6	6	cells
NCT000019171	NCT00001917_1_T1	CELL	8	8	neurons
NCT000019172	NCT00001917_2_T0	CELL	1	1	neurons
NCT000019173	NCT00001917_3_T0	CELL	8	8	neurons
NCT000019175	NCT00001917_5_T0	GENE	4	4	AD
NCT000019175	NCT00001917_5_T1	BIOLOGICAL_PROCESS	2	2	aging
NCT000019175	NCT00001917_5_T2	CELL	8	8	neurons
NCT000019176	NCT00001917_6_T0	GENE	19	19	AD
NCT000019176	NCT00001917_6_T1	GENE	29	29	receptor
NCT000019176	NCT00001917_6_T2	GENE	24	24	M2
NCT000019176	NCT00001917_6_T3	GENE	22	23	type 2
NCT000019177	NCT00001917_7_T0	GENE	17	17	M2
NCT000019177	NCT00001917_7_T1	COMPOUND	13	13	FP-TZTP
NCT000019178	NCT00001917_8_T0	GENE	15	15	M2
NCT0000191711	NCT00001917_11_T0	PHENOTYPE	43	43	progression
NCT0000191713	NCT00001917_13_T0	PHENOTYPE	18	18	concentrations
NCT0000191713	NCT00001917_13_T1	CELL	21	21	synapse
NCT0000191713	NCT00001917_13_T2	COMPOUND	17	17	acetylcholine
NCT0000191714	NCT00001917_14_T0	PHENOTYPE	20	20	concentrations
NCT0000191714	NCT00001917_14_T1	COMPOUND	35	35	physostigmine
NCT0000191714	NCT00001917_14_T2	CELL	19	19	synapse
NCT0000191714	NCT00001917_14_T3	COMPOUND	18	18	acetylcholine
NCT0000191714	NCT00001917_14_T4	COMPOUND	11	11	FP-TZTP
NCT0000191715	NCT00001917_15_T0	COMPOUND	5	5	physostigmine
NCT0000191715	NCT00001917_15_T1	COMPOUND	22	22	acetylcholine
NCT0000191717	NCT00001917_17_T0	GENE	0	0	AD
NCT0000191717	NCT00001917_17_T1	GENE	12	12	AD
NCT0000191717	NCT00001917_17_T2	GENE	9	9	probable
NCT0000191721	NCT00001917_21_T0	PHENOTYPE	5	6	chronic disease
NCT000019181	NCT00001918_1_T0	PHENOTYPE	1	1	symptoms
NCT000019181	NCT00001918_1_T1	PHENOTYPE	7	7	inflammation
NCT000019181	NCT00001918_1_T2	PHENOTYPE	3	3	fever
NCT000019181	NCT00001918_1_T3	PHENOTYPE	4	5	muscle aches
NCT000019181	NCT00001918_1_T4	PHENOTYPE	9	10	skin rashes
NCT000019185	NCT00001918_5_T0	GENE	8	8	EMS
NCT000019186	NCT00001918_6_T0	PHENOTYPE	10	10	myalgia
NCT000019186	NCT00001918_6_T1	PHENOTYPE	9	9	eosinophilia
NCT000019188	NCT00001918_8_T0	GENE	11	11	MRI
NCT000019188	NCT00001918_8_T1	PHENOTYPE	17	17	tuberculosis
NCT0000191816	NCT00001918_16_T0	GENE	10	10	EMS
NCT0000191818	NCT00001918_18_T0	PHENOTYPE	9	9	ingested
NCT0000191818	NCT00001918_18_T1	PHENOTYPE	6	6	myalgia
NCT0000191818	NCT00001918_18_T2	PHENOTYPE	4	4	eosinophilia
NCT000019193	NCT00001919_3_T0	GENE	28	28	MRI
NCT000019195	NCT00001919_5_T0	PHENOTYPE	14	14	electroencephalogram
NCT0000191910	NCT00001919_10_T0	COMPOUND	20	20	dopamine
NCT0000191911	NCT00001919_11_T0	COMPOUND	9	10	potassium iodide
NCT0000191912	NCT00001919_12_T0	GENE	2	2	ml
NCT0000191915	NCT00001919_15_T0	GENE	10	10	ml
NCT0000191916	NCT00001919_16_T0	GENE	7	7	MRI
NCT0000191918	NCT00001919_18_T0	PHENOTYPE	13	14	moderate depression
NCT0000191920	NCT00001919_20_T0	PHENOTYPE	0	0	Inhibition
NCT0000191920	NCT00001919_20_T1	GENE	14	14	has
NCT0000191920	NCT00001919_20_T2	GENE	3	4	serotonin transporter
NCT0000191920	NCT00001919_20_T3	PHENOTYPE	20	22	mechanism of action
NCT0000191921	NCT00001919_21_T0	GENE	29	30	dopamine transporter
NCT0000191922	NCT00001919_22_T0	GENE	20	20	separated
NCT0000191923	NCT00001919_23_T0	GENE	16	17	serotonin transporter
NCT0000191925	NCT00001919_25_T0	GENE	9	9	II
NCT0000191926	NCT00001919_26_T0	PHENOTYPE	6	7	neurological disorders
NCT0000191926	NCT00001919_26_T1	ORGAN	17	19	central nervous system
NCT0000191929	NCT00001919_29_T0	COMPOUND	7	7	iodine
NCT0000191929	NCT00001919_29_T1	COMPOUND	8	8	iodine
NCT0000191930	NCT00001919_30_T0	PHENOTYPE	9	9	dysfunction
NCT0000191930	NCT00001919_30_T1	PHENOTYPE	6	7	thyroid disease
NCT0000191931	NCT00001919_31_T0	PHENOTYPE	7	8	substance abuse
NCT0000191933	NCT00001919_33_T0	PHENOTYPE	5	6	adverse reaction
NCT000019201	NCT00001920_1_T0	ORGAN	19	19	brains
NCT000019201	NCT00001920_1_T1	ORGAN	14	14	hippocampus
NCT000019201	NCT00001920_1_T2	GENE	8	8	structural
NCT000019201	NCT00001920_1_T3	PHENOTYPE	6	6	schizophrenia
NCT000019201	NCT00001920_1_T4	GENE	1	1	has
NCT000019201	NCT00001920_1_T5	ORGAN	16	16	cerebellum
NCT000019207	NCT00001920_7_T0	PHENOTYPE	4	4	electroencephalogram
NCT000019208	NCT00001920_8_T0	GENE	6	6	MRI
NCT0000192010	NCT00001920_10_T0	ORGAN	22	22	hippocampus
NCT0000192010	NCT00001920_10_T1	GENE	2	2	has
NCT0000192010	NCT00001920_10_T2	PHENOTYPE	19	19	understood
NCT0000192010	NCT00001920_10_T3	ORGAN	24	24	cerebellum
NCT0000192014	NCT00001920_14_T0	GENE	12	12	structural
NCT0000192014	NCT00001920_14_T1	PHENOTYPE	18	18	conditioning
NCT0000192014	NCT00001920_14_T2	PHENOTYPE	2	2	schizophrenia
NCT0000192014	NCT00001920_14_T3	GENE	19	19	has
NCT0000192016	NCT00001920_16_T0	PHENOTYPE	10	10	schizophrenia
NCT0000192017	NCT00001920_17_T0	PHENOTYPE	15	15	conditioning
NCT0000192017	NCT00001920_17_T1	PHENOTYPE	19	19	schizophrenia
NCT0000192017	NCT00001920_17_T2	ORGAN	6	6	heart
NCT0000192025	NCT00001920_25_T0	PHENOTYPE	4	4	schizophrenia
NCT0000192026	NCT00001920_26_T0	PHENOTYPE	1	1	Schizophrenia
NCT0000192026	NCT00001920_26_T1	GENE	11	11	IV
NCT0000192026	NCT00001920_26_T2	PHENOTYPE	5	6	schizoaffective disorder
NCT0000192028	NCT00001920_28_T0	GENE	9	9	atypical
NCT0000192028	NCT00001920_28_T1	PHENOTYPE	25	26	conditioned response
NCT0000192030	NCT00001920_30_T0	PHENOTYPE	3	3	withdrawn
NCT0000192033	NCT00001920_33_T0	COMPOUND	2	2	caffeine
NCT0000192034	NCT00001920_34_T0	PHENOTYPE	15	15	impairment
NCT0000192034	NCT00001920_34_T1	PHENOTYPE	21	22	head trauma
NCT0000192034	NCT00001920_34_T2	PHENOTYPE	0	1	Head trauma
NCT0000192034	NCT00001920_34_T3	PHENOTYPE	3	5	loss of consciousness
NCT0000192036	NCT00001920_36_T0	GENE	9	9	MRI
NCT0000192036	NCT00001920_36_T1	PHENOTYPE	13	13	claustrophobia
NCT0000192038	NCT00001920_38_T0	GENE	37	37	MRI
NCT0000192038	NCT00001920_38_T1	GENE	46	46	MRI
NCT0000192039	NCT00001920_39_T0	PHENOTYPE	5	6	mental illness
NCT0000192041	NCT00001920_41_T0	GENE	4	4	met
NCT0000192041	NCT00001920_41_T1	PHENOTYPE	2	3	substance abuse
NCT0000192042	NCT00001920_42_T0	GENE	4	4	met
NCT0000192042	NCT00001920_42_T1	PHENOTYPE	2	3	substance dependence
NCT0000192043	NCT00001920_43_T0	PHENOTYPE	3	3	dependence
NCT0000192043	NCT00001920_43_T1	GENE	5	5	met
NCT0000192047	NCT00001920_47_T0	GENE	16	16	MRI
NCT0000192048	NCT00001920_48_T0	PHENOTYPE	4	4	Schizophrenia
NCT000019211	NCT00001921_1_T0	PHENOTYPE	2	2	schizophrenia
NCT000019214	NCT00001921_4_T0	PHENOTYPE	4	4	schizophrenia
NCT000019216	NCT00001921_6_T0	ORGAN	14	14	scalp
NCT000019217	NCT00001921_7_T0	GENE	9	9	has
NCT0000192110	NCT00001921_10_T0	PHENOTYPE	18	19	information processing
NCT0000192110	NCT00001921_10_T1	PHENOTYPE	8	9	brain activity
NCT0000192115	NCT00001921_15_T0	PHENOTYPE	14	14	schizophrenics
NCT0000192117	NCT00001921_17_T0	PHENOTYPE	19	19	pathophysiology
NCT0000192117	NCT00001921_17_T1	PHENOTYPE	18	18	schizophrenia
NCT0000192119	NCT00001921_19_T0	PHENOTYPE	4	4	chronic
NCT0000192126	NCT00001921_26_T0	PHENOTYPE	2	2	Schizophrenia
NCT0000192126	NCT00001921_26_T1	GENE	11	11	IV
NCT0000192126	NCT00001921_26_T2	GENE	23	23	Dr
NCT0000192126	NCT00001921_26_T3	GENE	41	41	Dr
NCT0000192126	NCT00001921_26_T4	PHENOTYPE	6	7	schizoaffective disorder
NCT0000192130	NCT00001921_30_T0	GENE	5	5	MRI
NCT0000192131	NCT00001921_31_T0	PHENOTYPE	15	15	impairment
NCT0000192131	NCT00001921_31_T1	PHENOTYPE	21	22	head trauma
NCT0000192131	NCT00001921_31_T2	PHENOTYPE	0	1	Head trauma
NCT0000192131	NCT00001921_31_T3	PHENOTYPE	3	5	loss of consciousness
NCT0000192132	NCT00001921_32_T0	GENE	37	37	MRI
NCT0000192134	NCT00001921_34_T0	PHENOTYPE	4	5	mental illness
NCT0000192137	NCT00001921_37_T0	GENE	4	4	met
NCT0000192137	NCT00001921_37_T1	PHENOTYPE	2	3	substance abuse
NCT0000192139	NCT00001921_39_T0	GENE	4	4	met
NCT0000192139	NCT00001921_39_T1	PHENOTYPE	2	3	substance dependence
NCT0000192140	NCT00001921_40_T0	PHENOTYPE	3	3	dependence
NCT0000192140	NCT00001921_40_T1	GENE	5	5	met
NCT000019221	NCT00001922_1_T0	TISSUE	8	8	muscles
NCT000019221	NCT00001922_1_T1	PHENOTYPE	3	4	voice disorder
NCT000019222	NCT00001922_2_T0	PHENOTYPE	7	8	weak voice
NCT000019222	NCT00001922_2_T1	PHENOTYPE	1	2	spasmodic dysphonia
NCT000019223	NCT00001922_3_T0	PHENOTYPE	1	2	spasmodic dysphonia
NCT000019224	NCT00001922_4_T0	PHENOTYPE	7	7	strained
NCT000019224	NCT00001922_4_T1	PHENOTYPE	2	2	dysphonia
NCT000019226	NCT00001922_6_T0	ORGAN	11	12	brain stem
NCT000019226	NCT00001922_6_T1	ORGAN	23	25	superior laryngeal nerve
NCT000019227	NCT00001922_7_T0	PHENOTYPE	13	13	conditioning
NCT000019227	NCT00001922_7_T1	PHENOTYPE	9	10	voice disorders
NCT000019228	NCT00001922_8_T0	ORGAN	13	14	brain stem
NCT000019228	NCT00001922_8_T1	PHENOTYPE	9	10	voice disorders
NCT000019229	NCT00001922_9_T0	PHENOTYPE	18	18	disorders
NCT000019229	NCT00001922_9_T1	PHENOTYPE	20	20	bilateral
NCT000019229	NCT00001922_9_T2	PHENOTYPE	28	29	voice disorders
NCT0000192210	NCT00001922_10_T0	GENE	20	20	toxin
NCT0000192210	NCT00001922_10_T1	PHENOTYPE	8	8	pathophysiology
NCT0000192210	NCT00001922_10_T2	PHENOTYPE	25	26	spasmodic dysphonia
NCT0000192211	NCT00001922_11_T0	PHENOTYPE	18	19	voice disorders
NCT0000192212	NCT00001922_12_T0	PHENOTYPE	12	13	sensory disorders
NCT0000192212	NCT00001922_12_T1	PHENOTYPE	27	28	voice disorders
NCT0000192212	NCT00001922_12_T2	PHENOTYPE	20	21	sensory feedback
NCT0000192213	NCT00001922_13_T0	PHENOTYPE	25	25	disorders
NCT0000192213	NCT00001922_13_T1	PHENOTYPE	9	9	pathophysiology
NCT0000192213	NCT00001922_13_T2	PHENOTYPE	15	16	voice disorders
NCT0000192216	NCT00001922_16_T0	PHENOTYPE	23	23	schizophrenia
NCT0000192216	NCT00001922_16_T1	PHENOTYPE	8	9	somatoform disorders
NCT0000192216	NCT00001922_16_T2	PHENOTYPE	10	11	conversion disorders
NCT0000192216	NCT00001922_16_T3	PHENOTYPE	26	27	bipolar disorder
NCT0000192216	NCT00001922_16_T4	PHENOTYPE	17	18	major depression
NCT0000192216	NCT00001922_16_T5	PHENOTYPE	2	3	psychiatric disorders
NCT0000192217	NCT00001922_17_T0	PHENOTYPE	10	11	reactive depression
NCT0000192222	NCT00001922_22_T0	PHENOTYPE	23	23	schizophrenia
NCT0000192222	NCT00001922_22_T1	PHENOTYPE	8	9	somatoform disorders
NCT0000192222	NCT00001922_22_T2	PHENOTYPE	10	11	conversion disorders
NCT0000192222	NCT00001922_22_T3	PHENOTYPE	26	27	bipolar disorder
NCT0000192222	NCT00001922_22_T4	PHENOTYPE	17	18	major depression
NCT0000192222	NCT00001922_22_T5	PHENOTYPE	2	3	psychiatric disorders
NCT0000192227	NCT00001922_27_T0	PHENOTYPE	9	9	strained
NCT0000192229	NCT00001922_29_T0	ORGAN	21	22	vocal folds
NCT0000192230	NCT00001922_30_T0	GENE	2	2	has
NCT0000192230	NCT00001922_30_T1	PHENOTYPE	4	4	hoarseness
NCT0000192232	NCT00001922_32_T0	ORGAN	15	16	vocal folds
NCT0000192238	NCT00001922_38_T0	PHENOTYPE	11	11	initiation
NCT0000192239	NCT00001922_39_T0	PHENOTYPE	10	11	spasmodic dysphonia
NCT0000192243	NCT00001922_43_T0	TISSUE	9	9	muscles
NCT0000192245	NCT00001922_45_T0	ORGAN	4	4	larynx
NCT0000192247	NCT00001922_47_T0	GENE	25	25	ventricular
NCT0000192247	NCT00001922_47_T1	ORGAN	15	16	arytenoid cartilages
NCT0000192249	NCT00001922_49_T0	ORGAN	3	3	larynx
NCT0000192252	NCT00001922_52_T0	PHENOTYPE	6	7	airway obstruction
NCT0000192254	NCT00001922_54_T0	PHENOTYPE	16	16	paralysis
NCT0000192254	NCT00001922_54_T1	PHENOTYPE	22	22	neoplasm
NCT0000192254	NCT00001922_54_T2	PHENOTYPE	18	18	paresis
NCT0000192254	NCT00001922_54_T3	PHENOTYPE	19	20	joint abnormality
NCT0000192254	NCT00001922_54_T4	ORGAN	5	6	vocal fold
NCT0000192256	NCT00001922_56_T0	PHENOTYPE	1	1	symptoms
NCT0000192256	NCT00001922_56_T1	GENE	13	13	spasmodic
NCT0000192256	NCT00001922_56_T2	PHENOTYPE	11	11	remission
NCT0000192256	NCT00001922_56_T3	PHENOTYPE	23	24	spasmodic dysphonia
NCT0000192262	NCT00001922_62_T0	PHENOTYPE	8	8	polyps
NCT0000192262	NCT00001922_62_T1	PHENOTYPE	6	6	nodules
NCT0000192264	NCT00001922_64_T0	PHENOTYPE	6	7	psychiatric disorder
NCT0000192264	NCT00001922_64_T1	PHENOTYPE	21	22	psychiatric disorder
NCT0000192265	NCT00001922_65_T0	PHENOTYPE	23	23	schizophrenia
NCT0000192265	NCT00001922_65_T1	PHENOTYPE	8	9	somatoform disorders
NCT0000192265	NCT00001922_65_T2	PHENOTYPE	10	11	conversion disorders
NCT0000192265	NCT00001922_65_T3	PHENOTYPE	26	27	bipolar disorder
NCT0000192265	NCT00001922_65_T4	PHENOTYPE	17	18	major depression
NCT0000192265	NCT00001922_65_T5	PHENOTYPE	2	3	psychiatric disorders
NCT0000192266	NCT00001922_66_T0	PHENOTYPE	10	11	reactive depression
NCT0000192267	NCT00001922_67_T0	PHENOTYPE	13	14	rheumatic fever
NCT0000192267	NCT00001922_67_T1	PHENOTYPE	19	20	cardiac arrhythmias
NCT0000192267	NCT00001922_67_T2	PHENOTYPE	15	17	mitral valve prolapse
NCT0000192268	NCT00001922_68_T0	PHENOTYPE	7	7	endocarditis
NCT000019237	NCT00001923_7_T0	GENE	11	11	coil
NCT000019237	NCT00001923_7_T1	ORGAN	15	15	scalp
NCT000019237	NCT00001923_7_T2	GENE	0	0	TMS
NCT0000192316	NCT00001923_16_T0	PHENOTYPE	13	13	excitability
NCT0000192316	NCT00001923_16_T1	GENE	7	7	TMS
NCT0000192323	NCT00001923_23_T0	GENE	4	4	had
NCT0000192323	NCT00001923_23_T1	PHENOTYPE	9	10	brain lesions
NCT0000192324	NCT00001923_24_T0	PHENOTYPE	4	5	severe depression
NCT0000192325	NCT00001923_25_T0	PHENOTYPE	5	6	cognitive deficits
NCT0000192326	NCT00001923_26_T0	PHENOTYPE	20	20	epilepsy
NCT0000192326	NCT00001923_26_T1	PHENOTYPE	9	10	cardiovascular disease
NCT0000192326	NCT00001923_26_T2	PHENOTYPE	17	18	cardiovascular disease
NCT0000192327	NCT00001923_27_T0	PHENOTYPE	8	8	seizures
NCT0000192327	NCT00001923_27_T1	PHENOTYPE	11	12	neurological disorders
NCT0000192329	NCT00001923_29_T0	PHENOTYPE	5	6	coronary disease
NCT0000192330	NCT00001923_30_T0	ORGAN	7	7	cranium
NCT0000192331	NCT00001923_31_T0	GENE	5	5	lines
NCT0000192332	NCT00001923_32_T0	PHENOTYPE	4	6	increased intracranial pressure
NCT000019251	NCT00001925_1_T0	PHENOTYPE	4	4	tremors
NCT000019251	NCT00001925_1_T1	PHENOTYPE	7	7	understood
NCT000019252	NCT00001925_2_T0	PHENOTYPE	3	3	tremors
NCT000019252	NCT00001925_2_T1	ORGAN	18	19	olivary nucleus
NCT000019254	NCT00001925_4_T0	PHENOTYPE	8	8	tremors
NCT000019254	NCT00001925_4_T1	GENE	3	3	has
NCT000019255	NCT00001925_5_T0	CELL	10	10	cells
NCT000019255	NCT00001925_5_T1	ORGAN	13	14	olivary nucleus
NCT000019256	NCT00001925_6_T0	PHENOTYPE	17	17	tremors
NCT000019258	NCT00001925_8_T0	GENE	9	9	has
NCT000019258	NCT00001925_8_T1	PHENOTYPE	4	5	essential tremor
NCT0000192512	NCT00001925_12_T0	PHENOTYPE	16	16	tremor
NCT0000192512	NCT00001925_12_T1	PHENOTYPE	26	26	tremor
NCT0000192512	NCT00001925_12_T2	PHENOTYPE	30	30	tremor
NCT0000192512	NCT00001925_12_T3	PHENOTYPE	22	23	physiological tremor
NCT0000192513	NCT00001925_13_T0	PHENOTYPE	13	13	tremor
NCT0000192513	NCT00001925_13_T1	PHENOTYPE	31	31	tremor
NCT0000192513	NCT00001925_13_T2	PHENOTYPE	22	22	ingestion
NCT0000192513	NCT00001925_13_T3	PHENOTYPE	40	41	essential tremor
NCT0000192516	NCT00001925_16_T0	PHENOTYPE	9	9	tremor
NCT0000192518	NCT00001925_18_T0	PHENOTYPE	5	5	tremor
NCT0000192518	NCT00001925_18_T1	PHENOTYPE	12	12	tremor
NCT0000192521	NCT00001925_21_T0	PHENOTYPE	4	4	tremor
NCT0000192521	NCT00001925_21_T1	PHENOTYPE	13	13	tremor
NCT0000192521	NCT00001925_21_T2	PHENOTYPE	14	14	secondary
NCT0000192521	NCT00001925_21_T3	GENE	18	18	structural
NCT0000192521	NCT00001925_21_T4	PHENOTYPE	19	20	brain lesions
NCT0000192521	NCT00001925_21_T5	PHENOTYPE	8	9	rest tremor
NCT0000192521	NCT00001925_21_T6	PHENOTYPE	10	11	essential tremor
NCT0000192522	NCT00001925_22_T0	PHENOTYPE	3	4	laboratory abnormalities
NCT000019264	NCT00001926_4_T0	PHENOTYPE	3	3	blindness
NCT000019267	NCT00001926_7_T0	PHENOTYPE	15	15	disorders
NCT000019267	NCT00001926_7_T1	PHENOTYPE	9	9	seizures
NCT000019269	NCT00001926_9_T0	ORGAN	5	5	cranium
NCT0000192610	NCT00001926_10_T0	GENE	3	3	lines
NCT0000192611	NCT00001926_11_T0	PHENOTYPE	2	4	increased intracranial pressure
NCT000019273	NCT00001927_3_T0	GENE	6	6	prothrombin
NCT000019273	NCT00001927_3_T1	PHENOTYPE	20	20	thromboses
NCT000019273	NCT00001927_3_T2	GENE	12	13	antithrombin III
NCT000019273	NCT00001927_3_T3	GENE	7	8	protein C
NCT000019273	NCT00001927_3_T4	GENE	3	5	factor V Leiden
NCT000019279	NCT00001927_9_T0	GENE	6	6	prothrombin
NCT000019279	NCT00001927_9_T1	PHENOTYPE	20	20	thromboses
NCT000019279	NCT00001927_9_T2	GENE	12	13	antithrombin III
NCT000019279	NCT00001927_9_T3	GENE	7	8	protein C
NCT0000192713	NCT00001927_13_T0	PHENOTYPE	12	12	porencephaly
NCT0000192714	NCT00001927_14_T0	PHENOTYPE	15	15	Stroke
NCT0000192714	NCT00001927_14_T1	PHENOTYPE	12	13	Neurological Disorders
NCT0000192715	NCT00001927_15_T0	PHENOTYPE	5	5	porencephaly
NCT0000192720	NCT00001927_20_T0	PHENOTYPE	11	11	porencephaly
NCT0000192720	NCT00001927_20_T1	PHENOTYPE	13	14	cerebral infarction
NCT0000192724	NCT00001927_24_T0	PHENOTYPE	9	9	cavity
NCT0000192724	NCT00001927_24_T1	PHENOTYPE	3	3	porencephaly
NCT0000192724	NCT00001927_24_T2	GENE	21	21	CSF
NCT0000192724	NCT00001927_24_T3	ORGAN	12	13	cerebral hemispheres
NCT0000192726	NCT00001927_26_T0	PHENOTYPE	11	11	focal
NCT0000192726	NCT00001927_26_T1	PHENOTYPE	3	4	cerebral infarction
NCT0000192731	NCT00001927_31_T0	PHENOTYPE	7	7	STROKE
NCT0000192731	NCT00001927_31_T1	PHENOTYPE	5	5	PORENCEPHALY
NCT0000192732	NCT00001927_32_T0	PHENOTYPE	10	10	porencephaly
NCT0000192749	NCT00001927_49_T0	PHENOTYPE	9	9	STROKE
NCT0000192749	NCT00001927_49_T1	PHENOTYPE	7	7	PORENCEPHALY
NCT0000192752	NCT00001927_52_T0	PHENOTYPE	3	4	cocaine abuse
NCT0000192756	NCT00001927_56_T0	PHENOTYPE	5	6	metabolic disorder
NCT0000192758	NCT00001927_58_T0	PHENOTYPE	2	2	trauma
NCT0000192758	NCT00001927_58_T1	PHENOTYPE	5	6	child abuse
NCT0000192760	NCT00001927_60_T0	PHENOTYPE	1	2	subdural hematomas
NCT0000192762	NCT00001927_62_T0	PHENOTYPE	2	2	aneurysm
NCT0000192762	NCT00001927_62_T1	PHENOTYPE	4	5	vascular malformations
NCT0000192764	NCT00001927_64_T0	PHENOTYPE	0	2	Congenital heart disease
NCT0000192767	NCT00001927_67_T0	PHENOTYPE	2	3	CNS infection
NCT0000192771	NCT00001927_71_T0	PHENOTYPE	3	4	cocaine abuse
NCT0000192775	NCT00001927_75_T0	PHENOTYPE	5	6	metabolic disorder
NCT0000192777	NCT00001927_77_T0	PHENOTYPE	2	2	trauma
NCT0000192777	NCT00001927_77_T1	PHENOTYPE	5	6	child abuse
NCT0000192779	NCT00001927_79_T0	PHENOTYPE	1	2	subdural hematomas
NCT0000192781	NCT00001927_81_T0	PHENOTYPE	2	2	aneurysm
NCT0000192781	NCT00001927_81_T1	PHENOTYPE	4	5	vascular malformations
NCT0000192783	NCT00001927_83_T0	PHENOTYPE	0	2	Congenital heart disease
NCT0000192787	NCT00001927_87_T0	PHENOTYPE	4	4	porencephaly
NCT000019281	NCT00001928_1_T0	PHENOTYPE	4	5	motor function
NCT000019282	NCT00001928_2_T0	TISSUE	9	9	muscles
NCT000019282	NCT00001928_2_T1	PHENOTYPE	7	7	tremors
NCT000019282	NCT00001928_2_T2	PHENOTYPE	8	8	rigid
NCT000019282	NCT00001928_2_T3	PHENOTYPE	2	3	Parkinson's disease
NCT000019283	NCT00001928_3_T0	COMPOUND	2	2	levodopa
NCT000019283	NCT00001928_3_T1	GENE	10	10	has
NCT000019283	NCT00001928_3_T2	GENE	12	12	has
NCT000019283	NCT00001928_3_T3	COMPOUND	8	8	dopamine
NCT000019283	NCT00001928_3_T4	PHENOTYPE	23	24	Parkinsons disease
NCT000019284	NCT00001928_4_T0	COMPOUND	4	4	levodopa
NCT000019284	NCT00001928_4_T1	GENE	5	5	has
NCT000019284	NCT00001928_4_T2	PHENOTYPE	10	11	Parkinson's disease
NCT000019284	NCT00001928_4_T3	PHENOTYPE	18	19	Parkinson's disease
NCT000019285	NCT00001928_5_T0	COMPOUND	1	1	levodopa
NCT000019285	NCT00001928_5_T1	GENE	2	2	has
NCT000019287	NCT00001928_7_T0	COMPOUND	13	13	levodopa
NCT000019288	NCT00001928_8_T0	COMPOUND	6	6	levodopa
NCT000019288	NCT00001928_8_T1	PHENOTYPE	24	25	Parkinson's disease
NCT0000192811	NCT00001928_11_T0	PHENOTYPE	5	5	parkinsonism
NCT0000192811	NCT00001928_11_T1	COMPOUND	18	18	levodopa
NCT0000192811	NCT00001928_11_T2	PHENOTYPE	25	26	Parkinson's disease
NCT0000192812	NCT00001928_12_T0	PHENOTYPE	6	6	acute
NCT0000192812	NCT00001928_12_T1	COMPOUND	10	10	levodopa
NCT0000192812	NCT00001928_12_T2	PHENOTYPE	13	14	safety issues
NCT000019291	NCT00001929_1_T0	COMPOUND	17	17	dopamine
NCT000019291	NCT00001929_1_T1	ORGAN	19	20	basal ganglia
NCT000019292	NCT00001929_2_T0	TISSUE	6	6	muscles
NCT000019292	NCT00001929_2_T1	PHENOTYPE	5	5	rigid
NCT000019293	NCT00001929_3_T0	COMPOUND	12	12	eliprodil
NCT000019293	NCT00001929_3_T1	PHENOTYPE	17	18	Parkinson's Disease
NCT000019297	NCT00001929_7_T0	PHENOTYPE	10	10	complications
NCT000019303	NCT00001930_3_T0	PHENOTYPE	18	18	chorea
NCT000019303	NCT00001930_3_T1	COMPOUND	13	13	amantadine
NCT000019303	NCT00001930_3_T2	PHENOTYPE	21	22	Huntington's disease
NCT000019304	NCT00001930_4_T0	PHENOTYPE	14	14	illnesses
NCT000019304	NCT00001930_4_T1	GENE	6	6	has
NCT000019304	NCT00001930_4_T2	PHENOTYPE	16	17	Parkinson's disease
NCT000019306	NCT00001930_6_T0	PHENOTYPE	15	15	symptoms
NCT000019306	NCT00001930_6_T1	CELL	8	8	cells
NCT000019306	NCT00001930_6_T2	GENE	10	10	has
NCT000019306	NCT00001930_6_T3	PHENOTYPE	17	18	Parkinson's disease
NCT000019308	NCT00001930_8_T0	PHENOTYPE	12	12	chorea
NCT0000193010	NCT00001930_10_T0	PHENOTYPE	10	10	chorea
NCT0000193014	NCT00001930_14_T0	COMPOUND	6	6	creatinine
NCT0000193014	NCT00001930_14_T1	ORGAN	5	5	serum
NCT0000193014	NCT00001930_14_T2	PHENOTYPE	3	4	renal impairment
NCT0000193015	NCT00001930_15_T0	COMPOUND	11	11	amantadine
NCT0000193017	NCT00001930_17_T0	PHENOTYPE	4	4	chorea
NCT0000193018	NCT00001930_18_T0	PHENOTYPE	3	3	chorea
NCT000019311	NCT00001931_1_T0	COMPOUND	17	17	dopamine
NCT000019311	NCT00001931_1_T1	ORGAN	19	20	basal ganglia
NCT000019315	NCT00001931_5_T0	PHENOTYPE	20	21	Parkinson's disease
NCT000019315	NCT00001931_5_T1	PHENOTYPE	16	18	signs and symptoms
NCT000019317	NCT00001931_7_T0	GENE	1	2	dopamine receptor
NCT000019319	NCT00001931_9_T0	PHENOTYPE	1	2	adverse events
NCT0000193113	NCT00001931_13_T0	COMPOUND	15	15	levodopa
NCT0000193113	NCT00001931_13_T1	PHENOTYPE	18	19	Parkinson's disease
NCT0000193115	NCT00001931_15_T0	PHENOTYPE	16	16	dysrhythmia
NCT0000193115	NCT00001931_15_T1	PHENOTYPE	8	9	myocardial infarction
NCT0000193116	NCT00001931_16_T0	COMPOUND	20	20	creatinine
NCT0000193116	NCT00001931_16_T1	PHENOTYPE	8	9	renal disorders
NCT000019321	NCT00001932_1_T0	CELL	17	17	cells
NCT000019321	NCT00001932_1_T1	PHENOTYPE	31	31	seizures
NCT000019321	NCT00001932_1_T2	GENE	19	19	5HT1A
NCT000019323	NCT00001932_3_T0	GENE	8	8	5HT1A
NCT000019324	NCT00001932_4_T0	PHENOTYPE	12	12	seizures
NCT000019324	NCT00001932_4_T1	MOLECULAR_FUNCTION	2	3	receptor activity
NCT000019326	NCT00001932_6_T0	COMPOUND	13	13	glucose
NCT000019326	NCT00001932_6_T1	PHENOTYPE	18	18	seizures
NCT000019327	NCT00001932_7_T0	PHENOTYPE	28	28	seizures
NCT000019329	NCT00001932_9_T0	PHENOTYPE	16	16	seizure
NCT000019329	NCT00001932_9_T1	GENE	26	26	5-HT-1A
NCT0000193211	NCT00001932_11_T0	PHENOTYPE	16	16	generalized
NCT0000193211	NCT00001932_11_T1	GENE	8	8	5-HT-1A
NCT0000193211	NCT00001932_11_T2	PHENOTYPE	18	20	complex partial seizures
NCT0000193212	NCT00001932_12_T0	PHENOTYPE	10	10	epileptic
NCT0000193212	NCT00001932_12_T1	GENE	7	7	5-HT
NCT0000193214	NCT00001932_14_T0	PHENOTYPE	32	32	epilepsy
NCT0000193214	NCT00001932_14_T1	GENE	11	11	5-HT-1A
NCT0000193215	NCT00001932_15_T0	GENE	16	16	MRI
NCT0000193215	NCT00001932_15_T1	GENE	5	6	serotonin receptor
NCT0000193217	NCT00001932_17_T0	GENE	7	8	serotonin transporter
NCT0000193225	NCT00001932_25_T0	PHENOTYPE	14	14	epilepsy
NCT0000193225	NCT00001932_25_T1	PHENOTYPE	36	36	epilepsy
NCT0000193225	NCT00001932_25_T2	PHENOTYPE	56	56	Recurrent
NCT0000193225	NCT00001932_25_T3	PHENOTYPE	65	67	major depressive episode
NCT0000193225	NCT00001932_25_T4	PHENOTYPE	46	48	Major Depressive Disorder
NCT0000193225	NCT00001932_25_T5	PHENOTYPE	53	55	Major Depressive Disorder
NCT0000193226	NCT00001932_26_T0	PHENOTYPE	29	29	epilepsy
NCT0000193226	NCT00001932_26_T1	PHENOTYPE	18	18	Disorders
NCT0000193226	NCT00001932_26_T2	PHENOTYPE	31	32	depressive symptoms
NCT0000193228	NCT00001932_28_T0	PHENOTYPE	8	8	Epilepsy
NCT0000193229	NCT00001932_29_T0	PHENOTYPE	2	3	chronic illnesses
NCT0000193232	NCT00001932_32_T0	PHENOTYPE	5	5	seizure
NCT0000193232	NCT00001932_32_T1	PHENOTYPE	11	12	infectious disease
NCT0000193233	NCT00001932_33_T0	PHENOTYPE	8	8	trauma
NCT0000193233	NCT00001932_33_T1	GENE	2	2	MRI
NCT0000193233	NCT00001932_33_T2	PHENOTYPE	6	7	brain tumors
NCT0000193234	NCT00001932_34_T0	PHENOTYPE	2	2	progressive
NCT0000193234	NCT00001932_34_T1	PHENOTYPE	3	4	neurologic disorders
NCT000019331	NCT00001933_1_T0	COMPOUND	7	7	acetylcholine
NCT000019335	NCT00001933_5_T0	GENE	8	8	MRI
NCT000019335	NCT00001933_5_T1	GENE	18	18	had
NCT000019335	NCT00001933_5_T2	GENE	3	3	ray
NCT0000193312	NCT00001933_12_T0	GENE	19	19	had
NCT0000193316	NCT00001933_16_T0	PHENOTYPE	16	16	acute
NCT0000193316	NCT00001933_16_T1	COMPOUND	22	22	nefiracetam
NCT0000193317	NCT00001933_17_T0	GENE	6	6	cholinesterase
NCT0000193317	NCT00001933_17_T1	COMPOUND	8	8	nefiracetam
NCT0000193317	NCT00001933_17_T2	COMPOUND	14	14	acetylcholine
NCT0000193317	NCT00001933_17_T3	COMPOUND	26	26	acetylcholine
NCT0000193317	NCT00001933_17_T4	GENE	20	22	protein kinase C
NCT0000193318	NCT00001933_18_T0	GENE	28	28	AD
NCT0000193318	NCT00001933_18_T1	COMPOUND	26	26	nefiracetam
NCT0000193318	NCT00001933_18_T2	PHENOTYPE	7	7	dementia
NCT0000193322	NCT00001933_22_T0	PHENOTYPE	11	11	dementia
NCT0000193323	NCT00001933_23_T0	GENE	26	26	AD
NCT0000193323	NCT00001933_23_T1	PHENOTYPE	3	3	Ischemia
NCT0000193323	NCT00001933_23_T2	GENE	13	13	MRI
NCT0000193324	NCT00001933_24_T0	PHENOTYPE	12	12	symptoms
NCT0000193324	NCT00001933_24_T1	GENE	20	20	AD
NCT0000193324	NCT00001933_24_T2	GENE	6	6	MRI
NCT0000193324	NCT00001933_24_T3	PHENOTYPE	11	11	dementia
NCT0000193324	NCT00001933_24_T4	GENE	3	3	had
NCT0000193326	NCT00001933_26_T0	PHENOTYPE	4	4	sterile
NCT0000193327	NCT00001933_27_T0	PHENOTYPE	3	3	menopausal
NCT0000193328	NCT00001933_28_T0	PHENOTYPE	15	15	dementing
NCT0000193332	NCT00001933_32_T0	PHENOTYPE	1	1	acute
NCT0000193332	NCT00001933_32_T1	PHENOTYPE	2	3	systemic infection
NCT0000193333	NCT00001933_33_T0	PHENOTYPE	1	1	hypothyroidism
NCT0000193333	NCT00001933_33_T1	GENE	5	5	6.0
NCT0000193333	NCT00001933_33_T2	GENE	2	2	TSH
NCT0000193335	NCT00001933_35_T0	PHENOTYPE	3	3	acute
NCT0000193335	NCT00001933_35_T1	PHENOTYPE	4	4	HAV
NCT0000193335	NCT00001933_35_T2	PHENOTYPE	6	6	HBV
NCT0000193335	NCT00001933_35_T3	PHENOTYPE	10	10	HBV
NCT0000193335	NCT00001933_35_T4	PHENOTYPE	9	9	chronic
NCT0000193337	NCT00001933_37_T0	PHENOTYPE	3	3	leukopenia
NCT0000193337	NCT00001933_37_T1	PHENOTYPE	6	6	thrombocytopenia
NCT0000193337	NCT00001933_37_T2	PHENOTYPE	4	4	neutropenia
NCT0000193337	NCT00001933_37_T3	PHENOTYPE	10	12	recurrent skin cancer
NCT0000193339	NCT00001933_39_T0	PHENOTYPE	1	1	homocysteinemia
NCT0000193340	NCT00001933_40_T0	PHENOTYPE	4	4	schizophrenia
NCT0000193341	NCT00001933_41_T0	PHENOTYPE	8	8	dementia
NCT0000193341	NCT00001933_41_T1	PHENOTYPE	1	3	substance use disorder
NCT0000193343	NCT00001933_43_T0	COMPOUND	3	3	tacrine
NCT0000193344	NCT00001933_44_T0	COMPOUND	23	23	fluconazole
NCT0000193344	NCT00001933_44_T1	COMPOUND	20	20	erythromycin
NCT0000193344	NCT00001933_44_T2	COMPOUND	25	25	ketoconazole
NCT0000193344	NCT00001933_44_T3	COMPOUND	24	24	miconazole
NCT0000193344	NCT00001933_44_T4	COMPOUND	26	26	itraconazole
NCT0000193344	NCT00001933_44_T5	GENE	17	17	CYP
NCT0000193344	NCT00001933_44_T6	COMPOUND	22	22	troleandomycin
NCT0000193352	NCT00001933_52_T0	GENE	11	11	ADAS
NCT0000193353	NCT00001933_53_T0	BIOLOGICAL_PROCESS	13	13	spermatogenesis
NCT0000193353	NCT00001933_53_T1	PHENOTYPE	10	11	adverse effects
NCT000019341	NCT00001934_1_T0	CELL	16	17	T lymphocytes
NCT000019341	NCT00001934_1_T1	PHENOTYPE	0	1	Multiple sclerosis
NCT000019341	NCT00001934_1_T2	BIOLOGICAL_PROCESS	8	9	immune response
NCT000019341	NCT00001934_1_T3	CELL	20	21	myelin sheath
NCT000019341	NCT00001934_1_T4	ORGAN	29	30	spinal cord
NCT000019341	NCT00001934_1_T5	CELL	12	14	white blood cells
NCT000019343	NCT00001934_3_T0	PHENOTYPE	10	10	relapse
NCT000019343	NCT00001934_3_T1	GENE	6	6	had
NCT000019343	NCT00001934_3_T2	GENE	23	23	interferon-beta
NCT000019343	NCT00001934_3_T3	GENE	25	25	has
NCT000019343	NCT00001934_3_T4	PHENOTYPE	2	3	multiple sclerosis
NCT000019345	NCT00001934_5_T0	GENE	11	11	MRI
NCT000019348	NCT00001934_8_T0	GENE	3	3	MRI
NCT0000193410	NCT00001934_10_T0	COMPOUND	0	0	Gadolinium
NCT0000193410	NCT00001934_10_T1	PHENOTYPE	4	5	multiple sclerosis
NCT0000193412	NCT00001934_12_T0	PHENOTYPE	24	24	punctures
NCT0000193412	NCT00001934_12_T1	PHENOTYPE	14	15	immune status
NCT0000193413	NCT00001934_13_T0	CELL	0	0	Lymphocytes
NCT0000193416	NCT00001934_16_T0	GENE	9	9	CD4
NCT0000193416	NCT00001934_16_T1	CELL	19	20	myelin sheath
NCT0000193416	NCT00001934_16_T2	CELL	11	12	T cells
NCT0000193421	NCT00001934_21_T0	GENE	49	49	MRI
NCT0000193422	NCT00001934_22_T0	GENE	50	50	MS
NCT0000193422	NCT00001934_22_T1	CELL	47	48	T lymphocytes
NCT0000193424	NCT00001934_24_T0	PHENOTYPE	4	4	secondary
NCT0000193424	NCT00001934_24_T1	PHENOTYPE	14	14	relapse
NCT0000193424	NCT00001934_24_T2	PHENOTYPE	5	5	progressive
NCT0000193424	NCT00001934_24_T3	GENE	10	10	had
NCT0000193424	NCT00001934_24_T4	PHENOTYPE	6	7	Multiple Sclerosis
NCT0000193427	NCT00001934_27_T0	GENE	5	5	IFN-beta
NCT0000193429	NCT00001934_29_T0	PHENOTYPE	8	8	relapse
NCT0000193429	NCT00001934_29_T1	GENE	11	11	has
NCT0000193431	NCT00001934_31_T0	PHENOTYPE	15	15	toxicity
NCT0000193431	NCT00001934_31_T1	COMPOUND	8	8	mitoxantrone
NCT0000193431	NCT00001934_31_T2	COMPOUND	10	10	cyclophosphamide
NCT0000193432	NCT00001934_32_T0	GENE	6	6	MS
NCT0000193432	NCT00001934_32_T1	PHENOTYPE	10	10	progression
NCT0000193432	NCT00001934_32_T2	PHENOTYPE	5	5	progressive
NCT0000193436	NCT00001934_36_T0	PHENOTYPE	3	3	HIV
NCT0000193438	NCT00001934_38_T0	GENE	10	10	MS
NCT0000193439	NCT00001934_39_T0	PHENOTYPE	2	5	alcohol or drug abuse
NCT0000193441	NCT00001934_41_T0	PHENOTYPE	5	5	menopausal
NCT0000193441	NCT00001934_41_T1	PHENOTYPE	8	8	sterile
NCT0000193443	NCT00001934_43_T0	PHENOTYPE	6	6	menopausal
NCT0000193443	NCT00001934_43_T1	PHENOTYPE	9	9	sterile
NCT000019361	NCT00001936_1_T0	ORGAN	23	23	esophagus
NCT000019361	NCT00001936_1_T1	ORGAN	11	13	upper esophageal sphincter
NCT000019362	NCT00001936_2_T0	PHENOTYPE	10	11	swallowing disorders
NCT000019364	NCT00001936_4_T0	ORGAN	12	12	larynx
NCT000019364	NCT00001936_4_T1	ORGAN	7	8	laryngeal muscles
NCT000019366	NCT00001936_6_T0	PHENOTYPE	17	17	chronic
NCT000019366	NCT00001936_6_T1	PHENOTYPE	18	19	pharyngeal dysphagia
NCT000019368	NCT00001936_8_T0	ORGAN	12	14	upper esophageal sphincter
NCT0000193610	NCT00001936_10_T0	GENE	7	7	has
NCT0000193610	NCT00001936_10_T1	PHENOTYPE	15	16	chronic dysphagia
NCT0000193615	NCT00001936_15_T0	PHENOTYPE	9	9	chronic
NCT0000193615	NCT00001936_15_T1	PHENOTYPE	10	11	pharyngeal dysphagia
NCT0000193616	NCT00001936_16_T0	TISSUE	13	13	muscles
NCT0000193617	NCT00001936_17_T0	TISSUE	30	30	muscles
NCT0000193617	NCT00001936_17_T1	ORGAN	23	23	cricopharyngeus
NCT0000193617	NCT00001936_17_T2	ORGAN	34	36	upper esophageal sphincter
NCT0000193619	NCT00001936_19_T0	PHENOTYPE	21	22	cardiac arrhythmias
NCT0000193619	NCT00001936_19_T1	PHENOTYPE	15	16	Rheumatic fever
NCT0000193619	NCT00001936_19_T2	PHENOTYPE	17	19	mitral valve prolapse
NCT0000193620	NCT00001936_20_T0	PHENOTYPE	20	20	endocarditis
NCT0000193620	NCT00001936_20_T1	PHENOTYPE	5	6	cardiac murmurs
NCT0000193624	NCT00001936_24_T0	PHENOTYPE	6	7	psychiatric disorder
NCT0000193624	NCT00001936_24_T1	PHENOTYPE	21	22	psychiatric disorder
NCT0000193625	NCT00001936_25_T0	PHENOTYPE	19	19	schizophrenia
NCT0000193625	NCT00001936_25_T1	PHENOTYPE	10	11	conversion disorders
NCT0000193625	NCT00001936_25_T2	PHENOTYPE	8	9	somatoform disorders
NCT0000193625	NCT00001936_25_T3	PHENOTYPE	22	23	bipolar disorder
NCT0000193625	NCT00001936_25_T4	PHENOTYPE	13	14	major depression
NCT0000193625	NCT00001936_25_T5	PHENOTYPE	2	3	psychiatric disorders
NCT0000193626	NCT00001936_26_T0	PHENOTYPE	10	11	reactive depression
NCT0000193628	NCT00001936_28_T0	PHENOTYPE	15	15	allergies
NCT0000193628	NCT00001936_28_T1	COMPOUND	17	17	lidocaine
NCT0000193629	NCT00001936_29_T0	PHENOTYPE	3	3	HIV
NCT0000193632	NCT00001936_32_T0	GENE	15	15	1.2
NCT0000193633	NCT00001936_33_T0	PHENOTYPE	29	29	neoplasm
NCT0000193633	NCT00001936_33_T1	PHENOTYPE	25	25	paresis
NCT0000193633	NCT00001936_33_T2	ORGAN	13	14	vocal fold
NCT0000193633	NCT00001936_33_T3	PHENOTYPE	22	23	laryngeal paralysis
NCT0000193634	NCT00001936_34_T0	PHENOTYPE	17	17	epilepsy
NCT0000193634	NCT00001936_34_T1	PHENOTYPE	10	11	heart problems
NCT0000193635	NCT00001936_35_T0	PHENOTYPE	7	7	DYSPHAGIA
NCT0000193635	NCT00001936_35_T1	PHENOTYPE	5	5	CHRONIC
NCT0000193635	NCT00001936_35_T2	PHENOTYPE	9	9	peripheral
NCT0000193635	NCT00001936_35_T3	GENE	2	2	FOR
NCT0000193635	NCT00001936_35_T4	PHENOTYPE	10	12	laryngeal nerve injury
NCT0000193636	NCT00001936_36_T0	TISSUE	6	6	muscles
NCT0000193636	NCT00001936_36_T1	PHENOTYPE	1	3	peripheral nerve injury
NCT0000193637	NCT00001936_37_T0	PHENOTYPE	1	2	laryngeal trauma
NCT0000193639	NCT00001936_39_T0	GENE	9	9	PEG
NCT0000193639	NCT00001936_39_T1	PHENOTYPE	1	2	dependence on
NCT0000193641	NCT00001936_41_T0	GENE	5	5	has
NCT0000193641	NCT00001936_41_T1	GENE	15	15	has
NCT0000193646	NCT00001936_46_T0	PHENOTYPE	2	3	pharyngeal dysphagia
NCT0000193651	NCT00001936_51_T0	PHENOTYPE	4	4	progressive
NCT0000193651	NCT00001936_51_T1	PHENOTYPE	13	14	swallowing difficulties
NCT0000193651	NCT00001936_51_T2	PHENOTYPE	7	9	amyotrophic lateral sclerosis
NCT0000193652	NCT00001936_52_T0	PHENOTYPE	4	4	agitation
NCT0000193652	NCT00001936_52_T1	PHENOTYPE	2	2	somnolence
NCT0000193652	NCT00001936_52_T2	PHENOTYPE	1	1	obtundation
NCT0000193652	NCT00001936_52_T3	PHENOTYPE	0	0	Dementia
NCT0000193655	NCT00001936_55_T0	PHENOTYPE	6	6	dysfunction
NCT0000193656	NCT00001936_56_T0	PHENOTYPE	8	8	diverticulum
NCT0000193656	NCT00001936_56_T1	GENE	1	1	structural
NCT0000193657	NCT00001936_57_T0	PHENOTYPE	1	1	motility
NCT0000193660	NCT00001936_60_T0	PHENOTYPE	9	9	dementia
NCT0000193660	NCT00001936_60_T1	PHENOTYPE	14	14	reflux
NCT0000193660	NCT00001936_60_T2	PHENOTYPE	23	24	drug toxicity
NCT0000193661	NCT00001936_61_T0	PHENOTYPE	19	19	epilepsy
NCT0000193661	NCT00001936_61_T1	PHENOTYPE	12	13	heart problems
NCT000019371	NCT00001937_1_T0	PHENOTYPE	16	16	neutropenia
NCT000019371	NCT00001937_1_T1	GENE	12	12	has
NCT000019371	NCT00001937_1_T2	GENE	18	18	has
NCT000019371	NCT00001937_1_T3	CELL	4	6	white blood cells
NCT000019372	NCT00001937_2_T0	PHENOTYPE	5	5	fever
NCT000019373	NCT00001937_3_T0	PHENOTYPE	8	9	fungal infections
NCT000019374	NCT00001937_4_T0	PHENOTYPE	4	5	fungal infections
NCT000019376	NCT00001937_6_T0	COMPOUND	14	14	fluconazole
NCT000019376	NCT00001937_6_T1	PHENOTYPE	11	12	fungal infections
NCT000019377	NCT00001937_7_T0	COMPOUND	14	14	fluconazole
NCT000019377	NCT00001937_7_T1	PHENOTYPE	8	8	tolerance
NCT000019379	NCT00001937_9_T0	COMPOUND	8	8	fluconazole
NCT0000193714	NCT00001937_14_T0	PHENOTYPE	10	11	fungal infection
NCT0000193715	NCT00001937_15_T0	PHENOTYPE	10	10	fungi
NCT0000193715	NCT00001937_15_T1	PHENOTYPE	1	1	fever
NCT0000193716	NCT00001937_16_T0	COMPOUND	12	12	fluconazole
NCT0000193716	NCT00001937_16_T1	PHENOTYPE	1	1	fever
NCT0000193716	NCT00001937_16_T2	PHENOTYPE	3	3	neutropenia
NCT0000193716	NCT00001937_16_T3	COMPOUND	21	22	amphotericin B
NCT0000193720	NCT00001937_20_T0	GENE	4	4	III
NCT0000193721	NCT00001937_21_T0	GENE	7	7	1.0
NCT0000193721	NCT00001937_21_T1	COMPOUND	17	17	fluconazole
NCT0000193722	NCT00001937_22_T0	GENE	15	15	ANC
NCT0000193722	NCT00001937_22_T1	CELL	5	5	neutrophil
NCT0000193722	NCT00001937_22_T2	CELL	13	13	neutrophil
NCT0000193723	NCT00001937_23_T0	GENE	5	5	probable
NCT0000193723	NCT00001937_23_T1	PHENOTYPE	12	13	fungal infection
NCT0000193724	NCT00001937_24_T0	ORGAN	13	13	transplant
NCT0000193735	NCT00001937_35_T0	PHENOTYPE	10	11	fungal infection
NCT0000193737	NCT00001937_37_T0	PHENOTYPE	8	8	malignancies
NCT0000193737	NCT00001937_37_T1	ORGAN	4	5	autologous transplant
NCT0000193738	NCT00001937_38_T0	PHENOTYPE	7	7	HIV
NCT000019381	NCT00001938_1_T0	CELL	13	13	cells
NCT000019382	NCT00001938_2_T0	PHENOTYPE	20	21	in remission
NCT000019383	NCT00001938_3_T0	PHENOTYPE	7	8	in remission
NCT000019383	NCT00001938_3_T1	PHENOTYPE	3	5	epithelial ovarian cancer
NCT000019384	NCT00001938_4_T0	GENE	6	6	saliva
NCT000019389	NCT00001938_9_T0	CELL	15	15	cells
NCT000019389	NCT00001938_9_T1	PHENOTYPE	21	21	tumor
NCT0000193812	NCT00001938_12_T0	PHENOTYPE	22	22	relapse
NCT0000193816	NCT00001938_16_T0	PHENOTYPE	19	19	relapse
NCT0000193817	NCT00001938_17_T0	PHENOTYPE	43	43	relapse
NCT0000193817	NCT00001938_17_T1	PHENOTYPE	22	22	remission
NCT0000193817	NCT00001938_17_T2	PHENOTYPE	15	16	ovarian cancer
NCT0000193821	NCT00001938_21_T0	PHENOTYPE	6	7	primary tumor
NCT0000193822	NCT00001938_22_T0	PHENOTYPE	6	7	primary tumor
NCT0000193824	NCT00001938_24_T0	PHENOTYPE	5	6	ovarian cancer
NCT0000193824	NCT00001938_24_T1	PHENOTYPE	10	11	ovarian cancer
NCT000019401	NCT00001940_1_T0	GENE	6	6	had
NCT000019401	NCT00001940_1_T1	PHENOTYPE	18	19	fungal infections
NCT000019402	NCT00001940_2_T0	COMPOUND	7	7	voriconazole
NCT000019402	NCT00001940_2_T1	GENE	4	4	extended
NCT000019402	NCT00001940_2_T2	PHENOTYPE	12	13	fungal infections
NCT000019404	NCT00001940_4_T0	COMPOUND	9	9	voriconazole
NCT000019408	NCT00001940_8_T0	GENE	18	18	stops
NCT0000194011	NCT00001940_11_T0	PHENOTYPE	4	5	fungal infections
NCT0000194013	NCT00001940_13_T0	COMPOUND	17	17	voriconazole
NCT0000194013	NCT00001940_13_T1	GENE	8	8	III
NCT0000194013	NCT00001940_13_T2	PHENOTYPE	24	26	invasive fungal infections
NCT0000194014	NCT00001940_14_T0	PHENOTYPE	11	11	centers
NCT0000194015	NCT00001940_15_T0	COMPOUND	39	39	voriconazole
NCT0000194015	NCT00001940_15_T1	PHENOTYPE	11	12	fungal infection
NCT0000194016	NCT00001940_16_T0	GENE	6	6	3.4
NCT0000194016	NCT00001940_16_T1	GENE	16	16	BID
NCT0000194019	NCT00001940_19_T0	COMPOUND	6	6	voriconazole
NCT0000194019	NCT00001940_19_T1	COMPOUND	15	15	voriconazole
NCT0000194019	NCT00001940_19_T2	PHENOTYPE	21	22	fungal disease
NCT0000194019	NCT00001940_19_T3	PHENOTYPE	28	29	fungal infections
NCT0000194020	NCT00001940_20_T0	COMPOUND	6	6	voriconazole
NCT0000194021	NCT00001940_21_T0	COMPOUND	7	7	voriconazole
NCT0000194021	NCT00001940_21_T1	GENE	6	6	extended
NCT0000194022	NCT00001940_22_T0	PHENOTYPE	10	10	menopausal
NCT0000194022	NCT00001940_22_T1	ORGAN	15	15	serum
NCT0000194025	NCT00001940_25_T0	COMPOUND	12	12	voriconazole
NCT0000194025	NCT00001940_25_T1	COMPOUND	22	22	voriconazole
NCT0000194025	NCT00001940_25_T2	PHENOTYPE	7	8	adverse events
NCT0000194025	NCT00001940_25_T3	PHENOTYPE	17	18	adverse events
NCT0000194027	NCT00001940_27_T0	COMPOUND	18	18	cisapride
NCT0000194027	NCT00001940_27_T1	COMPOUND	17	17	terfenadine
NCT0000194027	NCT00001940_27_T2	COMPOUND	20	20	astemizole
NCT0000194029	NCT00001940_29_T0	COMPOUND	14	14	carbamazepine
NCT000019411	NCT00001941_1_T0	COMPOUND	11	11	NCI
NCT000019411	NCT00001941_1_T1	GENE	31	31	ATL
NCT000019411	NCT00001941_1_T2	BIOLOGICAL_PROCESS	6	6	Metabolism
NCT000019416	NCT00001941_6_T0	GENE	13	13	receptor
NCT000019416	NCT00001941_6_T1	GENE	12	12	IL-2
NCT000019418	NCT00001941_8_T0	PHENOTYPE	7	7	leukemia
NCT000019418	NCT00001941_8_T1	GENE	18	18	receptor
NCT000019418	NCT00001941_8_T2	CELL	17	17	T-cell
NCT000019418	NCT00001941_8_T3	PHENOTYPE	9	11	Southern blot analysis
NCT000019419	NCT00001941_9_T0	PHENOTYPE	7	7	pharmacokinetics
NCT000019419	NCT00001941_9_T1	GENE	12	12	had
NCT000019419	NCT00001941_9_T2	ORGAN	17	17	serum
NCT0000194111	NCT00001941_11_T0	PHENOTYPE	51	51	acute
NCT0000194111	NCT00001941_11_T1	PHENOTYPE	53	53	lymphoma
NCT0000194111	NCT00001941_11_T2	GENE	17	17	ATL
NCT0000194111	NCT00001941_11_T3	GENE	35	35	ATL
NCT0000194111	NCT00001941_11_T4	GENE	56	56	ATL
NCT0000194111	NCT00001941_11_T5	PHENOTYPE	34	34	chronic
NCT0000194111	NCT00001941_11_T6	PHENOTYPE	13	13	remissions
NCT0000194114	NCT00001941_14_T0	GENE	2	2	had
NCT0000194114	NCT00001941_14_T1	GENE	1	1	has
NCT0000194118	NCT00001941_18_T0	PHENOTYPE	4	4	toxicity
NCT0000194118	NCT00001941_18_T1	GENE	18	18	ATL
NCT0000194118	NCT00001941_18_T2	GENE	9	9	MTD
NCT0000194123	NCT00001941_23_T0	PHENOTYPE	9	9	peripheral
NCT0000194123	NCT00001941_23_T1	CELL	6	6	cells
NCT0000194123	NCT00001941_23_T2	GENE	19	19	CD25
NCT0000194123	NCT00001941_23_T3	TISSUE	12	13	lymph nodes
NCT0000194125	NCT00001941_25_T0	PHENOTYPE	3	4	measurable disease
NCT0000194127	NCT00001941_27_T0	CELL	4	4	granulocyte
NCT0000194127	NCT00001941_27_T1	COMPOUND	23	23	creatinine
NCT0000194127	NCT00001941_27_T2	GENE	26	26	3.0
NCT0000194127	NCT00001941_27_T3	CELL	14	14	platelets
NCT0000194128	NCT00001941_28_T0	COMPOUND	11	11	1
NCT0000194128	NCT00001941_28_T1	COMPOUND	20	20	1
NCT0000194128	NCT00001941_28_T2	COMPOUND	33	33	1
NCT0000194128	NCT00001941_28_T3	COMPOUND	46	46	1
NCT0000194128	NCT00001941_28_T4	COMPOUND	60	60	1
NCT0000194128	NCT00001941_28_T5	COMPOUND	12	12	2
NCT0000194128	NCT00001941_28_T6	COMPOUND	22	22	2
NCT0000194128	NCT00001941_28_T7	COMPOUND	24	24	2
NCT0000194128	NCT00001941_28_T8	COMPOUND	37	37	3
NCT0000194128	NCT00001941_28_T9	GENE	6	6	1.4
NCT0000194129	NCT00001941_29_T0	GENE	6	6	ATL
NCT0000194129	NCT00001941_29_T1	PHENOTYPE	4	4	chronic
NCT0000194131	NCT00001941_31_T0	GENE	5	5	CR
NCT0000194132	NCT00001941_32_T0	PHENOTYPE	28	28	toxicity
NCT0000194132	NCT00001941_32_T1	GENE	5	5	PR
NCT0000194132	NCT00001941_32_T2	GENE	19	19	PR
NCT0000194132	NCT00001941_32_T3	PHENOTYPE	25	26	adverse event
NCT000019440	NCT00001944_0_T0	PHENOTYPE	5	5	Cancer
NCT000019442	NCT00001944_2_T0	CELL	10	10	cells
NCT000019442	NCT00001944_2_T1	CELL	17	17	cells
NCT000019442	NCT00001944_2_T2	GENE	6	6	P-glycoprotein
NCT000019443	NCT00001944_3_T0	PHENOTYPE	9	9	blocked
NCT000019443	NCT00001944_3_T1	GENE	8	8	has
NCT000019444	NCT00001944_4_T0	COMPOUND	17	17	vinorelbine
NCT000019444	NCT00001944_4_T1	CELL	20	20	cells
NCT000019445	NCT00001944_5_T0	CELL	30	30	cells
NCT000019445	NCT00001944_5_T1	PHENOTYPE	29	29	tumor
NCT000019445	NCT00001944_5_T2	PHENOTYPE	14	14	cancers
NCT000019445	NCT00001944_5_T3	GENE	32	32	P-glycoprotein
NCT000019445	NCT00001944_5_T4	GENE	1	1	has
NCT000019448	NCT00001944_8_T0	PHENOTYPE	1	1	tumor
NCT000019449	NCT00001944_9_T0	PHENOTYPE	4	4	tumor
NCT0000194410	NCT00001944_10_T0	CELL	5	5	cells
NCT0000194410	NCT00001944_10_T1	CELL	23	23	cells
NCT0000194410	NCT00001944_10_T2	PHENOTYPE	4	4	tumor
NCT0000194413	NCT00001944_13_T0	CELL	15	15	cells
NCT0000194413	NCT00001944_13_T1	PHENOTYPE	14	14	tumor
NCT0000194413	NCT00001944_13_T2	PHENOTYPE	6	6	affects
NCT0000194413	NCT00001944_13_T3	PHENOTYPE	10	10	elimination
NCT0000194415	NCT00001944_15_T0	COMPOUND	22	22	vinorelbine
NCT0000194417	NCT00001944_17_T0	COMPOUND	13	13	vinorelbine
NCT0000194420	NCT00001944_20_T0	PHENOTYPE	27	27	toxicity
NCT0000194420	NCT00001944_20_T1	GENE	3	3	P-glycoprotein
NCT0000194421	NCT00001944_21_T0	GENE	4	4	P-glycoprotein
NCT0000194421	NCT00001944_21_T1	GENE	10	10	has
NCT0000194422	NCT00001944_22_T0	COMPOUND	15	15	vinorelbine
NCT0000194426	NCT00001944_26_T0	GENE	3	3	0.2
NCT0000194428	NCT00001944_28_T0	PHENOTYPE	0	1	Platelet count
NCT0000194429	NCT00001944_29_T0	CELL	1	1	granulocyte
NCT0000194429	NCT00001944_29_T1	GENE	3	3	AGC
NCT0000194430	NCT00001944_30_T0	COMPOUND	1	1	creatinine
NCT0000194430	NCT00001944_30_T1	COMPOUND	15	15	creatinine
NCT0000194430	NCT00001944_30_T2	GENE	7	7	1.5
NCT0000194430	NCT00001944_30_T3	GENE	13	13	1.5
NCT0000194430	NCT00001944_30_T4	ORGAN	0	0	Serum
NCT0000194432	NCT00001944_32_T0	PHENOTYPE	11	11	toxicities
NCT0000194438	NCT00001944_38_T0	PHENOTYPE	4	4	malignancy
NCT0000194438	NCT00001944_38_T1	PHENOTYPE	11	11	malignancy
NCT0000194438	NCT00001944_38_T2	PHENOTYPE	22	22	malignancy
NCT0000194438	NCT00001944_38_T3	PHENOTYPE	14	14	melanoma
NCT0000194438	NCT00001944_38_T4	GENE	24	24	has
NCT0000194439	NCT00001944_39_T0	PHENOTYPE	28	28	recurrence
NCT0000194439	NCT00001944_39_T1	PHENOTYPE	12	12	malignancy
NCT0000194440	NCT00001944_40_T0	PHENOTYPE	8	9	CNS metastases
NCT0000194441	NCT00001944_41_T0	PHENOTYPE	13	14	systemic disease
NCT0000194442	NCT00001944_42_T0	PHENOTYPE	1	2	HIV seropositive
NCT0000194443	NCT00001944_43_T0	COMPOUND	2	2	vinorelbine
NCT000019461	NCT00001946_1_T0	ORGAN	10	10	veins
NCT000019461	NCT00001946_1_T1	ORGAN	8	8	arteries
NCT000019461	NCT00001946_1_T2	PHENOTYPE	0	0	MRA
NCT000019461	NCT00001946_1_T3	ORGAN	21	22	blood vessel
NCT000019462	NCT00001946_2_T0	PHENOTYPE	9	9	cavity
NCT000019462	NCT00001946_2_T1	PHENOTYPE	22	22	narrowing
NCT000019462	NCT00001946_2_T2	PHENOTYPE	1	1	MRA
NCT000019464	NCT00001946_4_T0	PHENOTYPE	2	2	atherosclerosis
NCT000019464	NCT00001946_4_T1	GENE	13	13	MD
NCT000019464	NCT00001946_4_T2	GENE	5	5	had
NCT000019465	NCT00001946_5_T0	PHENOTYPE	17	17	MRA
NCT000019467	NCT00001946_7_T0	ORGAN	16	16	legs
NCT0000194612	NCT00001946_12_T0	PHENOTYPE	21	21	stenoses
NCT0000194612	NCT00001946_12_T1	GENE	5	5	has
NCT0000194612	NCT00001946_12_T2	PHENOTYPE	4	4	MRA
NCT0000194612	NCT00001946_12_T3	PHENOTYPE	18	18	MRA
NCT0000194613	NCT00001946_13_T0	GENE	28	28	MRI
NCT0000194613	NCT00001946_13_T1	PHENOTYPE	26	26	MRA
NCT0000194614	NCT00001946_14_T0	PHENOTYPE	8	8	pulse
NCT0000194614	NCT00001946_14_T1	PHENOTYPE	20	20	MRA
NCT0000194614	NCT00001946_14_T2	PHENOTYPE	30	30	MRA
NCT0000194617	NCT00001946_17_T0	PHENOTYPE	18	18	MRA
NCT0000194619	NCT00001946_19_T0	GENE	22	22	1.5
NCT0000194620	NCT00001946_20_T0	ORGAN	3	3	serum
NCT0000194622	NCT00001946_22_T0	COMPOUND	6	6	Gadolinium
NCT0000194622	NCT00001946_22_T1	PHENOTYPE	4	4	allergy
NCT0000194623	NCT00001946_23_T0	GENE	20	20	MRI
NCT0000194623	NCT00001946_23_T1	GENE	23	23	1.5
NCT0000194625	NCT00001946_25_T0	PHENOTYPE	14	14	MRA
NCT0000194626	NCT00001946_26_T0	GENE	6	6	MRI
NCT000019482	NCT00001948_2_T0	PHENOTYPE	7	7	Allergy
NCT000019482	NCT00001948_2_T1	PHENOTYPE	9	9	Infectious
NCT000019482	NCT00001948_2_T2	PHENOTYPE	29	30	HIV Disease
NCT000019487	NCT00001948_7_T0	PHENOTYPE	4	4	HIV
NCT000019487	NCT00001948_7_T1	PHENOTYPE	8	10	quality of life
NCT000019489	NCT00001948_9_T0	PHENOTYPE	15	15	symptoms
NCT000019489	NCT00001948_9_T1	PHENOTYPE	24	26	quality of life
NCT0000194810	NCT00001948_10_T0	PHENOTYPE	19	19	symptoms
NCT0000194810	NCT00001948_10_T1	PHENOTYPE	16	16	discomfort
NCT0000194810	NCT00001948_10_T2	PHENOTYPE	40	41	HIV disease
NCT000019503	NCT00001950_3_T0	GENE	6	6	has
NCT000019504	NCT00001950_4_T0	COMPOUND	0	0	1
NCT000019506	NCT00001950_6_T0	COMPOUND	0	0	2
NCT000019509	NCT00001950_9_T0	COMPOUND	0	0	3
NCT000019511	NCT00001951_1_T0	COMPOUND	1	1	androgen
NCT000019511	NCT00001951_1_T1	GENE	6	6	hormone
NCT000019511	NCT00001951_1_T2	PHENOTYPE	12	14	premature ovarian failure
NCT000019513	NCT00001951_3_T0	ORGAN	10	10	ovaries
NCT000019514	NCT00001951_4_T0	GENE	9	9	hormone
NCT000019515	NCT00001951_5_T0	PHENOTYPE	6	6	menopausal
NCT000019515	NCT00001951_5_T1	PHENOTYPE	23	23	osteoporosis
NCT000019515	NCT00001951_5_T2	GENE	7	7	hormone
NCT000019515	NCT00001951_5_T3	PHENOTYPE	18	20	premature ovarian failure
NCT000019516	NCT00001951_6_T0	PHENOTYPE	2	4	premature ovarian failure
NCT000019517	NCT00001951_7_T0	PHENOTYPE	8	8	osteoporosis
NCT000019518	NCT00001951_8_T0	PHENOTYPE	10	12	premature ovarian failure
NCT000019519	NCT00001951_9_T0	COMPOUND	6	6	estrogen
NCT000019519	NCT00001951_9_T1	GENE	7	7	hormone
NCT0000195110	NCT00001951_10_T0	COMPOUND	6	6	estrogen
NCT0000195110	NCT00001951_10_T1	COMPOUND	10	10	androgen
NCT0000195110	NCT00001951_10_T2	GENE	7	7	hormone
NCT0000195111	NCT00001951_11_T0	PHENOTYPE	16	16	osteoporosis
NCT0000195111	NCT00001951_11_T1	PHENOTYPE	18	19	heart disease
NCT0000195113	NCT00001951_13_T0	ORGAN	18	18	ovary
NCT0000195113	NCT00001951_13_T1	GENE	10	10	hormone
NCT0000195116	NCT00001951_16_T0	ORGAN	9	9	spine
NCT0000195116	NCT00001951_16_T1	PHENOTYPE	12	13	heart disease
NCT0000195119	NCT00001951_19_T0	PHENOTYPE	6	6	menopausal
NCT0000195119	NCT00001951_19_T1	PHENOTYPE	23	23	osteoporosis
NCT0000195119	NCT00001951_19_T2	GENE	7	7	hormone
NCT0000195119	NCT00001951_19_T3	PHENOTYPE	18	20	premature ovarian failure
NCT0000195120	NCT00001951_20_T0	COMPOUND	9	9	androgen
NCT0000195120	NCT00001951_20_T1	PHENOTYPE	18	18	osteoporosis
NCT0000195120	NCT00001951_20_T2	PHENOTYPE	2	4	premature ovarian failure
NCT0000195121	NCT00001951_21_T0	COMPOUND	11	11	androgen
NCT0000195121	NCT00001951_21_T1	COMPOUND	5	5	estrogen
NCT0000195121	NCT00001951_21_T2	COMPOUND	9	9	estrogen
NCT0000195121	NCT00001951_21_T3	PHENOTYPE	40	41	cardiovascular disease
NCT0000195121	NCT00001951_21_T4	PHENOTYPE	17	19	premature ovarian failure
NCT0000195122	NCT00001951_22_T0	ORGAN	22	22	ovary
NCT0000195122	NCT00001951_22_T1	COMPOUND	6	6	testosterone
NCT0000195122	NCT00001951_22_T2	COMPOUND	4	4	estradiol
NCT0000195123	NCT00001951_23_T0	COMPOUND	18	18	testosterone
NCT0000195123	NCT00001951_23_T1	COMPOUND	11	11	estradiol
NCT0000195123	NCT00001951_23_T2	COMPOUND	16	16	estradiol
NCT0000195123	NCT00001951_23_T3	PHENOTYPE	2	4	premature ovarian failure
NCT0000195126	NCT00001951_26_T0	ORGAN	5	6	femoral neck
NCT0000195127	NCT00001951_27_T0	ORGAN	5	5	spine
NCT0000195127	NCT00001951_27_T1	PHENOTYPE	18	19	cognitive function
NCT0000195127	NCT00001951_27_T2	PHENOTYPE	13	14	cardiovascular disease
NCT0000195131	NCT00001951_31_T0	COMPOUND	3	3	BMI
NCT0000195134	NCT00001951_34_T0	PHENOTYPE	1	2	dermatologic disorders
NCT0000195135	NCT00001951_35_T0	PHENOTYPE	0	0	Hirsutism
NCT0000195136	NCT00001951_36_T0	PHENOTYPE	0	0	Acne
NCT0000195137	NCT00001951_37_T0	COMPOUND	3	3	testosterone
NCT0000195137	NCT00001951_37_T1	GENE	12	12	6-3
NCT0000195137	NCT00001951_37_T2	GENE	19	19	SHBG
NCT0000195137	NCT00001951_37_T3	GENE	4	4	FT
NCT0000195138	NCT00001951_38_T0	COMPOUND	31	31	DHEA
NCT0000195138	NCT00001951_38_T1	COMPOUND	16	16	estrogen
NCT0000195138	NCT00001951_38_T2	COMPOUND	23	23	testosterone
NCT0000195138	NCT00001951_38_T3	GENE	18	18	calcitonin
NCT0000195138	NCT00001951_38_T4	COMPOUND	20	20	fluoride
NCT0000195138	NCT00001951_38_T5	BIOLOGICAL_PROCESS	29	29	androstenedione
NCT0000195139	NCT00001951_39_T0	COMPOUND	7	7	heparin
NCT0000195139	NCT00001951_39_T1	GENE	11	12	gonadotropin-releasing hormone
NCT000019520	NCT00001952_0_T0	ORGAN	16	16	Teeth
NCT000019520	NCT00001952_0_T1	ORGAN	15	15	Molar
NCT000019523	NCT00001952_3_T0	TISSUE	17	17	tissues
NCT000019523	NCT00001952_3_T1	ORGAN	25	25	teeth
NCT000019523	NCT00001952_3_T2	ORGAN	16	16	gum
NCT000019526	NCT00001952_6_T0	ORGAN	8	9	wisdom teeth
NCT000019527	NCT00001952_7_T0	ORGAN	14	14	gum
NCT000019529	NCT00001952_9_T0	TISSUE	17	17	tissues
NCT0000195210	NCT00001952_10_T0	COMPOUND	3	3	fentanyl
NCT0000195210	NCT00001952_10_T1	GENE	27	27	numb
NCT0000195211	NCT00001952_11_T0	COMPOUND	7	7	epinephrine
NCT0000195212	NCT00001952_12_T0	ORGAN	8	9	wisdom teeth
NCT0000195212	NCT00001952_12_T1	ORGAN	17	18	root canal
NCT0000195213	NCT00001952_13_T0	ORGAN	12	12	gum
NCT0000195214	NCT00001952_14_T0	TISSUE	17	17	tissues
NCT0000195215	NCT00001952_15_T0	COMPOUND	3	3	fentanyl
NCT0000195216	NCT00001952_16_T0	COMPOUND	7	7	epinephrine
NCT0000195219	NCT00001952_19_T0	ORGAN	10	11	wisdom teeth
NCT0000195222	NCT00001952_22_T0	PHENOTYPE	24	24	inflammation
NCT0000195222	NCT00001952_22_T1	TISSUE	15	16	mucosal tissues
NCT0000195222	NCT00001952_22_T2	ORGAN	11	12	dental pulp
NCT0000195223	NCT00001952_23_T0	COMPOUND	12	12	fentanyl
NCT0000195223	NCT00001952_23_T1	ORGAN	31	31	teeth
NCT0000195223	NCT00001952_23_T2	COMPOUND	24	24	epinephrine
NCT0000195223	NCT00001952_23_T3	COMPOUND	21	21	lidocaine
NCT0000195223	NCT00001952_23_T4	ORGAN	30	30	molar
NCT0000195224	NCT00001952_24_T0	TISSUE	26	26	tissues
NCT0000195224	NCT00001952_24_T1	ORGAN	29	29	molars
NCT0000195224	NCT00001952_24_T2	COMPOUND	10	10	fentanyl
NCT0000195224	NCT00001952_24_T3	COMPOUND	5	5	epinephrine
NCT0000195224	NCT00001952_24_T4	COMPOUND	1	1	lidocaine
NCT0000195224	NCT00001952_24_T5	PHENOTYPE	21	21	anesthesia
NCT0000195225	NCT00001952_25_T0	PHENOTYPE	2	2	strategies
NCT0000195225	NCT00001952_25_T1	COMPOUND	8	8	fentanyl
NCT0000195225	NCT00001952_25_T2	PHENOTYPE	14	14	anesthesia
NCT0000195226	NCT00001952_26_T0	TISSUE	21	21	tissues
NCT0000195226	NCT00001952_26_T1	ORGAN	17	17	molars
NCT0000195227	NCT00001952_27_T0	PHENOTYPE	1	1	anesthesia
NCT0000195228	NCT00001952_28_T0	TISSUE	24	24	tissues
NCT0000195228	NCT00001952_28_T1	ORGAN	20	20	molars
NCT0000195229	NCT00001952_29_T0	PHENOTYPE	11	11	anesthesia
NCT0000195229	NCT00001952_29_T1	ORGAN	0	1	Root canal
NCT0000195231	NCT00001952_31_T0	PHENOTYPE	18	18	inflammation
NCT0000195233	NCT00001952_33_T0	ORGAN	7	7	molar
NCT0000195235	NCT00001952_35_T0	COMPOUND	12	12	fentanyl
NCT0000195235	NCT00001952_35_T1	PHENOTYPE	9	9	allergy
NCT0000195235	NCT00001952_35_T2	PHENOTYPE	5	5	asthma
NCT0000195235	NCT00001952_35_T3	COMPOUND	11	11	lidocaine
NCT0000195235	NCT00001952_35_T4	PHENOTYPE	3	4	stomach ulcers
NCT0000195239	NCT00001952_39_T0	GENE	10	10	hr
NCT0000195241	NCT00001952_41_T0	ORGAN	3	4	root canal
NCT0000195243	NCT00001952_43_T0	ORGAN	12	12	heart
NCT0000195243	NCT00001952_43_T1	PHENOTYPE	16	17	liver dysfunction
NCT0000195244	NCT00001952_44_T0	PHENOTYPE	8	9	drug abuse
NCT0000195244	NCT00001952_44_T1	PHENOTYPE	3	4	personality disorder
NCT0000195244	NCT00001952_44_T2	PHENOTYPE	5	6	alcohol abuse
NCT0000195245	NCT00001952_45_T0	PHENOTYPE	1	1	chronic
NCT0000195245	NCT00001952_45_T1	GENE	14	14	beta
NCT0000195246	NCT00001952_46_T0	ORGAN	4	4	molars
NCT000019537	NCT00001953_7_T0	PHENOTYPE	9	10	glucose tolerance
NCT000019538	NCT00001953_8_T0	BIOLOGICAL_PROCESS	20	20	eating
NCT0000195310	NCT00001953_10_T0	GENE	8	8	cola
NCT0000195315	NCT00001953_15_T0	PHENOTYPE	5	5	soreness
NCT0000195315	NCT00001953_15_T1	PHENOTYPE	15	15	dizziness
NCT0000195315	NCT00001953_15_T2	PHENOTYPE	6	6	bruising
NCT0000195316	NCT00001953_16_T0	PHENOTYPE	9	9	bloating
NCT0000195316	NCT00001953_16_T1	PHENOTYPE	10	10	headache
NCT0000195316	NCT00001953_16_T2	PHENOTYPE	13	13	vomiting
NCT0000195316	NCT00001953_16_T3	PHENOTYPE	11	11	nausea
NCT0000195316	NCT00001953_16_T4	PHENOTYPE	2	3	glucose tolerance
NCT0000195332	NCT00001953_32_T0	COMPOUND	43	43	thyroxine
NCT0000195332	NCT00001953_32_T1	COMPOUND	38	38	niacin
NCT0000195332	NCT00001953_32_T2	COMPOUND	80	80	terbutaline
NCT0000195332	NCT00001953_32_T3	COMPOUND	41	41	phenytoin
NCT0000195332	NCT00001953_32_T4	GENE	77	77	Beta
NCT0000195332	NCT00001953_32_T5	COMPOUND	39	39	thiazide
NCT0000195332	NCT00001953_32_T6	PHENOTYPE	89	90	Glucose intolerance
NCT0000195332	NCT00001953_32_T7	PHENOTYPE	87	88	Diabetes mellitus
NCT0000195332	NCT00001953_32_T8	PHENOTYPE	5	6	acute illness
NCT0000195332	NCT00001953_32_T9	PHENOTYPE	35	36	glucose tolerance
NCT0000195336	NCT00001953_36_T0	GENE	1	1	H-2
NCT000019541	NCT00001954_1_T0	TISSUE	10	10	tissues
NCT000019541	NCT00001954_1_T1	GENE	12	12	lacrimal
NCT000019541	NCT00001954_1_T2	PHENOTYPE	1	2	autoimmune diseases
NCT000019541	NCT00001954_1_T3	ORGAN	4	5	immune system
NCT000019541	NCT00001954_1_T4	PHENOTYPE	17	18	dry eyes
NCT000019543	NCT00001954_3_T0	BIOLOGICAL_PROCESS	4	4	chewing
NCT000019543	NCT00001954_3_T1	PHENOTYPE	0	1	Dry mouth
NCT000019549	NCT00001954_9_T0	PHENOTYPE	13	13	symptoms
NCT000019549	NCT00001954_9_T1	GENE	6	6	saliva
NCT000019549	NCT00001954_9_T2	COMPOUND	1	1	1
NCT000019549	NCT00001954_9_T3	PHENOTYPE	15	17	treatment side effects
NCT0000195411	NCT00001954_11_T0	PHENOTYPE	14	14	symptoms
NCT0000195411	NCT00001954_11_T1	PHENOTYPE	16	18	treatment side effects
NCT0000195415	NCT00001954_15_T0	GENE	2	2	SS
NCT0000195415	NCT00001954_15_T1	PHENOTYPE	8	8	dysfunction
NCT0000195415	NCT00001954_15_T2	TISSUE	6	7	lacrimal gland
NCT0000195416	NCT00001954_16_T0	GENE	17	17	SS
NCT0000195416	NCT00001954_16_T1	PHENOTYPE	9	9	autoimmune
NCT0000195416	NCT00001954_16_T2	PHENOTYPE	15	15	dysfunction
NCT0000195416	NCT00001954_16_T3	TISSUE	13	14	exocrine gland
NCT0000195420	NCT00001954_20_T0	PHENOTYPE	24	24	symptoms
NCT0000195420	NCT00001954_20_T1	GENE	10	10	lacrimal
NCT0000195420	NCT00001954_20_T2	PHENOTYPE	15	15	autoimmune
NCT0000195425	NCT00001954_25_T0	GENE	0	0	SS
NCT0000195425	NCT00001954_25_T1	PHENOTYPE	8	8	lymphoma
NCT0000195425	NCT00001954_25_T2	PHENOTYPE	4	4	sarcoidosis
NCT0000195425	NCT00001954_25_T3	PHENOTYPE	5	6	HIV infection
NCT0000195426	NCT00001954_26_T0	GENE	12	12	SS
NCT0000195426	NCT00001954_26_T1	PHENOTYPE	8	8	autoimmune
NCT0000195426	NCT00001954_26_T2	GENE	18	18	SS-A
NCT0000195426	NCT00001954_26_T3	GENE	15	15	ANA
NCT0000195426	NCT00001954_26_T4	GENE	20	20	SS-B
NCT0000195427	NCT00001954_27_T0	COMPOUND	3	3	pilocarpine
NCT0000195427	NCT00001954_27_T1	GENE	14	14	saliva
NCT0000195428	NCT00001954_28_T0	COMPOUND	5	5	hydroxychloroquine
NCT0000195431	NCT00001954_31_T0	TISSUE	18	19	salivary gland
NCT000019550	NCT00001955_0_T0	PHENOTYPE	9	9	Painful
NCT000019550	NCT00001955_0_T1	PHENOTYPE	7	8	Temporomandibular Disorders
NCT000019552	NCT00001955_2_T0	COMPOUND	4	4	celecoxib
NCT000019553	NCT00001955_3_T0	PHENOTYPE	16	16	arthritis
NCT000019553	NCT00001955_3_T1	GENE	5	5	has
NCT000019554	NCT00001955_4_T0	ORGAN	11	11	jaw
NCT0000195511	NCT00001955_11_T0	ORGAN	18	18	jaw
NCT0000195516	NCT00001955_16_T0	PHENOTYPE	31	31	inhibition
NCT0000195516	NCT00001955_16_T1	GENE	15	15	COX-2
NCT0000195516	NCT00001955_16_T2	GENE	34	34	COX-1
NCT0000195516	NCT00001955_16_T3	CELL	26	26	platelet
NCT0000195516	NCT00001955_16_T4	GENE	13	14	cyclooxygenase 2
NCT0000195530	NCT00001955_30_T0	ORGAN	7	7	joints
NCT0000195530	NCT00001955_30_T1	PHENOTYPE	19	19	arthropathies
NCT0000195530	NCT00001955_30_T2	GENE	6	6	TM
NCT0000195530	NCT00001955_30_T3	PHENOTYPE	15	16	infectious arthritis
NCT0000195530	NCT00001955_30_T4	PHENOTYPE	21	22	musculoskeletal disorders
NCT0000195531	NCT00001955_31_T0	ORGAN	11	11	kidney
NCT0000195531	NCT00001955_31_T1	ORGAN	9	9	liver
NCT0000195533	NCT00001955_33_T0	PHENOTYPE	4	5	psychiatric disease
NCT000019564	NCT00001956_4_T0	COMPOUND	6	6	1
NCT000019564	NCT00001956_4_T1	ORGAN	14	15	third molars
NCT000019568	NCT00001956_8_T0	PHENOTYPE	0	1	Heat sensitivity
NCT0000195615	NCT00001956_15_T0	ORGAN	14	15	third molars
NCT0000195627	NCT00001956_27_T0	GENE	2	2	has
NCT0000195627	NCT00001956_27_T1	GENE	20	20	has
NCT000019571	NCT00001957_1_T0	PHENOTYPE	17	17	aphasia
NCT000019571	NCT00001957_1_T1	PHENOTYPE	15	15	autism
NCT000019571	NCT00001957_1_T2	PHENOTYPE	16	16	stuttering
NCT000019571	NCT00001957_1_T3	PHENOTYPE	18	19	multiple sclerosis
NCT000019571	NCT00001957_1_T4	PHENOTYPE	24	25	language disorders
NCT000019571	NCT00001957_1_T5	PHENOTYPE	13	14	voice disorder
NCT000019571	NCT00001957_1_T6	PHENOTYPE	27	28	psychiatric disorders
NCT000019571	NCT00001957_1_T7	PHENOTYPE	20	22	traumatic brain injury
NCT000019572	NCT00001957_2_T0	GENE	5	5	reduced
NCT000019572	NCT00001957_2_T1	PHENOTYPE	9	10	Group B
NCT000019575	NCT00001957_5_T0	BIOLOGICAL_PROCESS	16	18	response to sound
NCT0000195712	NCT00001957_12_T0	PHENOTYPE	9	9	listening
NCT0000195712	NCT00001957_12_T1	PHENOTYPE	7	7	tiredness
NCT0000195716	NCT00001957_16_T0	GENE	7	7	has
NCT0000195718	NCT00001957_18_T0	PHENOTYPE	6	6	peripheral
NCT0000195718	NCT00001957_18_T1	GENE	4	4	has
NCT0000195719	NCT00001957_19_T0	PHENOTYPE	7	9	auditory processing disorders
NCT0000195719	NCT00001957_19_T1	PHENOTYPE	17	19	auditory processing disorders
NCT0000195722	NCT00001957_22_T0	PHENOTYPE	3	3	suppression
NCT0000195722	NCT00001957_22_T1	GENE	19	19	reduced
NCT0000195723	NCT00001957_23_T0	PHENOTYPE	21	22	Group B
NCT0000195727	NCT00001957_27_T0	PHENOTYPE	18	18	suppression
NCT0000195727	NCT00001957_27_T1	PHENOTYPE	5	6	speech recognition
NCT0000195730	NCT00001957_30_T0	PHENOTYPE	6	6	suppression
NCT0000195730	NCT00001957_30_T1	PHENOTYPE	39	39	suppression
NCT0000195730	NCT00001957_30_T2	GENE	24	24	reduced
NCT0000195734	NCT00001957_34_T0	PHENOTYPE	0	1	Group B
NCT0000195736	NCT00001957_36_T0	PHENOTYPE	13	13	aphasia
NCT0000195736	NCT00001957_36_T1	PHENOTYPE	11	11	autism
NCT0000195736	NCT00001957_36_T2	PHENOTYPE	24	24	disorders
NCT0000195736	NCT00001957_36_T3	PHENOTYPE	12	12	stuttering
NCT0000195736	NCT00001957_36_T4	PHENOTYPE	14	15	multiple sclerosis
NCT0000195736	NCT00001957_36_T5	PHENOTYPE	9	10	voice disorders
NCT0000195736	NCT00001957_36_T6	PHENOTYPE	20	21	language disorders
NCT0000195736	NCT00001957_36_T7	PHENOTYPE	16	18	traumatic brain injury
NCT0000195737	NCT00001957_37_T0	PHENOTYPE	6	7	hyperactivity disorder
NCT0000195738	NCT00001957_38_T0	PHENOTYPE	7	7	hyperactivity
NCT000019581	NCT00001958_1_T0	GENE	7	7	globin
NCT000019581	NCT00001958_1_T1	PHENOTYPE	15	15	beta-thalassemia
NCT000019581	NCT00001958_1_T2	GENE	10	11	beta globin
NCT000019581	NCT00001958_1_T3	GENE	19	20	beta globin
NCT000019583	NCT00001958_3_T0	PHENOTYPE	3	4	iron overload
NCT000019585	NCT00001958_5_T0	GENE	12	13	beta globin
NCT000019586	NCT00001958_6_T0	GENE	16	17	beta globin
NCT000019586	NCT00001958_6_T1	GENE	12	13	gamma globin
NCT000019589	NCT00001958_9_T0	PHENOTYPE	8	8	beta-thalassemia
NCT0000195810	NCT00001958_10_T0	COMPOUND	3	3	hydroxyurea
NCT0000195813	NCT00001958_13_T0	COMPOUND	10	10	hydroxyurea
NCT0000195821	NCT00001958_21_T0	GENE	14	14	hematocrit
NCT0000195821	NCT00001958_21_T1	GENE	12	12	hemoglobin
NCT0000195822	NCT00001958_22_T0	GENE	9	9	beta-globin
NCT0000195823	NCT00001958_23_T0	COMPOUND	13	13	hydroxyurea
NCT0000195825	NCT00001958_25_T0	GENE	1	1	Hb
NCT0000195830	NCT00001958_30_T0	PHENOTYPE	1	1	beta-thalassemia
NCT0000195832	NCT00001958_32_T0	GENE	3	3	WBC
NCT0000195833	NCT00001958_33_T0	PHENOTYPE	4	5	platelet count
NCT0000195834	NCT00001958_34_T0	PHENOTYPE	7	8	viral hepatitis
NCT0000195836	NCT00001958_36_T0	COMPOUND	5	5	creatinine
NCT0000195836	NCT00001958_36_T1	GENE	7	7	1.5
NCT0000195836	NCT00001958_36_T2	PHENOTYPE	1	3	abnormal renal function
NCT000019594	NCT00001959_4_T0	PHENOTYPE	8	8	proteinuria
NCT000019594	NCT00001959_4_T1	COMPOUND	4	4	cyclosporin
NCT000019594	NCT00001959_4_T2	COMPOUND	6	6	cyclophosphamide
NCT000019596	NCT00001959_6_T0	COMPOUND	27	27	pirfenidone
NCT000019596	NCT00001959_6_T1	PHENOTYPE	19	19	proteinuria
NCT000019596	NCT00001959_6_T2	MOLECULAR_FUNCTION	9	10	ACE inhibitor
NCT000019597	NCT00001959_7_T0	GENE	19	19	ACE
NCT000019597	NCT00001959_7_T1	PHENOTYPE	29	30	elevated cholesterol
NCT000019597	NCT00001959_7_T2	MOLECULAR_FUNCTION	7	8	ACE inhibitor
NCT000019599	NCT00001959_9_T0	COMPOUND	3	3	pirfenidone
NCT0000195916	NCT00001959_16_T0	COMPOUND	17	17	pirfenidone
NCT0000195916	NCT00001959_16_T1	GENE	32	32	TID
NCT0000195922	NCT00001959_22_T0	ORGAN	16	16	kidney
NCT0000195922	NCT00001959_22_T1	COMPOUND	5	5	pirfenidone
NCT0000195923	NCT00001959_23_T0	PHENOTYPE	22	22	secondary
NCT0000195923	NCT00001959_23_T1	PHENOTYPE	18	18	proteinuria
NCT0000195923	NCT00001959_23_T2	BIOLOGICAL_PROCESS	8	9	glomerular filtration
NCT0000195932	NCT00001959_32_T0	GENE	25	25	GFR
NCT0000195932	NCT00001959_32_T1	BIOLOGICAL_PROCESS	0	1	Glomerular filtration
NCT0000195932	NCT00001959_32_T2	PHENOTYPE	23	24	renal disease
NCT0000195934	NCT00001959_34_T0	COMPOUND	16	16	pirfenidone
NCT0000195934	NCT00001959_34_T1	GENE	32	32	0.4
NCT0000195936	NCT00001959_36_T0	COMPOUND	6	6	cyclophosphamide
NCT0000195938	NCT00001959_38_T0	COMPOUND	5	5	cyclosporin
NCT0000195942	NCT00001959_42_T0	PHENOTYPE	3	4	HIV seropositive
NCT0000195942	NCT00001959_42_T1	PHENOTYPE	10	11	HIV disease
NCT0000195950	NCT00001959_50_T0	COMPOUND	3	3	pirfenidone
NCT0000195954	NCT00001959_54_T0	PHENOTYPE	6	7	myocardial infarction
NCT0000195956	NCT00001959_56_T0	PHENOTYPE	2	3	peptic ulcer
NCT0000195958	NCT00001959_58_T0	PHENOTYPE	2	3	cerebrovascular disease
NCT0000195958	NCT00001959_58_T1	PHENOTYPE	10	11	cerebrovascular accident
NCT0000195958	NCT00001959_58_T2	PHENOTYPE	6	8	transient ischemic attack
NCT0000195962	NCT00001959_62_T0	PHENOTYPE	2	3	photosensitivity dermatitis
NCT0000195964	NCT00001959_64_T0	COMPOUND	7	7	erythromycin
NCT0000195964	NCT00001959_64_T1	PHENOTYPE	16	16	hyperkalemia
NCT0000195964	NCT00001959_64_T2	COMPOUND	5	5	cyclosporin
NCT0000195964	NCT00001959_64_T3	COMPOUND	4	4	gemfibrozil
NCT0000195966	NCT00001959_66_T0	GENE	2	2	interleukin-2
NCT0000195969	NCT00001959_69_T0	ORGAN	8	8	serum
NCT0000195969	NCT00001959_69_T1	PHENOTYPE	3	4	hepatic disease
NCT000019600	NCT00001960_0_T0	TISSUE	11	12	Heart Muscle
NCT000019602	NCT00001960_2_T0	PHENOTYPE	5	5	obstruction
NCT000019602	NCT00001960_2_T1	PHENOTYPE	16	16	fainting
NCT000019602	NCT00001960_2_T2	PHENOTYPE	15	15	breathlessness
NCT000019602	NCT00001960_2_T3	PHENOTYPE	21	22	heart pounding
NCT000019602	NCT00001960_2_T4	PHENOTYPE	13	14	chest discomfort
NCT000019603	NCT00001960_3_T0	ORGAN	8	8	heart
NCT000019604	NCT00001960_4_T0	ORGAN	21	21	hearts
NCT000019604	NCT00001960_4_T1	TISSUE	11	12	heart muscle
NCT000019605	NCT00001960_5_T0	PHENOTYPE	9	9	obstruction
NCT000019605	NCT00001960_5_T1	ORGAN	12	12	heart
NCT000019607	NCT00001960_7_T0	GENE	9	9	blocker
NCT000019607	NCT00001960_7_T1	COMPOUND	11	11	verapamil
NCT000019607	NCT00001960_7_T2	GENE	23	23	reduced
NCT000019607	NCT00001960_7_T3	ORGAN	20	20	heart
NCT000019607	NCT00001960_7_T4	GENE	8	8	beta
NCT000019608	NCT00001960_8_T0	ORGAN	5	5	heart
NCT000019609	NCT00001960_9_T0	GENE	12	12	numb
NCT000019609	NCT00001960_9_T1	PHENOTYPE	7	7	anesthesia
NCT0000196013	NCT00001960_13_T0	COMPOUND	1	1	3
NCT0000196020	NCT00001960_20_T0	PHENOTYPE	11	11	bleeding
NCT0000196020	NCT00001960_20_T1	PHENOTYPE	5	6	lung collapse
NCT0000196020	NCT00001960_20_T2	ORGAN	8	9	blood vessel
NCT0000196020	NCT00001960_20_T3	PHENOTYPE	12	13	heart attack
NCT0000196021	NCT00001960_21_T0	PHENOTYPE	6	6	bleeding
NCT0000196021	NCT00001960_21_T1	ORGAN	15	15	heart
NCT0000196021	NCT00001960_21_T2	PHENOTYPE	7	8	blood clots
NCT0000196021	NCT00001960_21_T3	PHENOTYPE	9	11	abnormal heart rhythms
NCT0000196028	NCT00001960_28_T0	PHENOTYPE	16	16	symptoms
NCT0000196028	NCT00001960_28_T1	COMPOUND	11	11	verapamil
NCT0000196030	NCT00001960_30_T0	PHENOTYPE	7	7	severity
NCT0000196030	NCT00001960_30_T1	PHENOTYPE	11	11	obstruction
NCT0000196035	NCT00001960_35_T0	PHENOTYPE	4	4	diseases
NCT0000196036	NCT00001960_36_T0	PHENOTYPE	0	2	Chronic atrial fibrillation
NCT0000196037	NCT00001960_37_T0	COMPOUND	18	18	thallium
NCT0000196037	NCT00001960_37_T1	PHENOTYPE	0	2	Positive pregnancy test
NCT000019613	NCT00001961_3_T0	GENE	5	5	MRI
NCT000019614	NCT00001961_4_T0	GENE	13	13	MRI
NCT000019617	NCT00001961_7_T0	TISSUE	9	10	heart muscle
NCT000019618	NCT00001961_8_T0	ORGAN	12	13	coronary artery
NCT0000196112	NCT00001961_12_T0	PHENOTYPE	10	11	cardiovascular disease
NCT0000196114	NCT00001961_14_T0	GENE	4	4	has
NCT0000196115	NCT00001961_15_T0	GENE	8	8	MRI
NCT0000196115	NCT00001961_15_T1	GENE	9	9	has
NCT0000196122	NCT00001961_22_T0	PHENOTYPE	1	3	congestive heart failure
NCT0000196124	NCT00001961_24_T0	GENE	0	0	MRI
NCT0000196125	NCT00001961_25_T0	GENE	5	5	clip
NCT0000196125	NCT00001961_25_T1	PHENOTYPE	3	4	cerebral aneurysm
NCT000019621	NCT00001962_1_T0	CELL	11	11	platelets
NCT000019621	NCT00001962_1_T1	GENE	6	6	stops
NCT000019621	NCT00001962_1_T2	ORGAN	4	5	bone marrow
NCT000019621	NCT00001962_1_T3	PHENOTYPE	1	2	aplastic anemia
NCT000019621	NCT00001962_1_T4	CELL	8	10	red blood cells
NCT000019621	NCT00001962_1_T5	CELL	13	15	white blood cells
NCT000019623	NCT00001962_3_T0	PHENOTYPE	5	5	disorders
NCT000019623	NCT00001962_3_T1	PHENOTYPE	11	11	immunosuppression
NCT000019623	NCT00001962_3_T2	ORGAN	9	9	transplant
NCT000019623	NCT00001962_3_T3	ORGAN	7	8	bone marrow
NCT000019624	NCT00001962_4_T0	PHENOTYPE	9	9	immunosuppression
NCT000019624	NCT00001962_4_T1	ORGAN	3	3	transplant
NCT000019624	NCT00001962_4_T2	GENE	10	10	has
NCT000019624	NCT00001962_4_T3	ORGAN	1	2	bone marrow
NCT000019626	NCT00001962_6_T0	GENE	11	11	receptor
NCT000019626	NCT00001962_6_T1	CELL	14	14	cells
NCT000019626	NCT00001962_6_T2	GENE	10	10	interleukin-2
NCT000019626	NCT00001962_6_T3	PHENOTYPE	8	8	blocks
NCT000019627	NCT00001962_7_T0	ORGAN	7	7	transplant
NCT000019627	NCT00001962_7_T1	GENE	1	1	has
NCT000019627	NCT00001962_7_T2	PHENOTYPE	14	15	organ rejection
NCT000019629	NCT00001962_9_T0	ORGAN	1	2	bone marrow
NCT000019629	NCT00001962_9_T1	PHENOTYPE	14	16	bone marrow failure
NCT0000196217	NCT00001962_17_T0	PHENOTYPE	11	11	discomfort
NCT0000196217	NCT00001962_17_T1	ORGAN	2	3	bone marrow
NCT0000196218	NCT00001962_18_T0	PHENOTYPE	8	8	immunity
NCT0000196224	NCT00001962_24_T0	CELL	5	5	lymphocytes
NCT0000196224	NCT00001962_24_T1	PHENOTYPE	10	12	mechanism of action
NCT0000196225	NCT00001962_25_T0	PHENOTYPE	6	6	toxic
NCT0000196233	NCT00001962_33_T0	PHENOTYPE	9	9	toxicity
NCT0000196233	NCT00001962_33_T1	PHENOTYPE	0	0	Secondary
NCT0000196233	NCT00001962_33_T2	PHENOTYPE	4	4	dependence
NCT0000196240	NCT00001962_40_T0	PHENOTYPE	1	1	allergy
NCT0000196241	NCT00001962_41_T0	GENE	1	1	B19
NCT0000196241	NCT00001962_41_T1	PHENOTYPE	2	3	parvovirus infection
NCT0000196243	NCT00001962_43_T0	PHENOTYPE	0	0	Chronic
NCT0000196243	NCT00001962_43_T1	PHENOTYPE	7	7	HIV
NCT0000196243	NCT00001962_43_T2	PHENOTYPE	10	10	hepatitis
NCT0000196243	NCT00001962_43_T3	PHENOTYPE	14	15	virus infection
NCT0000196245	NCT00001962_45_T0	PHENOTYPE	32	32	severity
NCT0000196245	NCT00001962_45_T1	GENE	36	36	1.4
NCT0000196245	NCT00001962_45_T2	PHENOTYPE	39	39	initiation
NCT0000196245	NCT00001962_45_T3	PHENOTYPE	28	29	metabolic disease
NCT0000196249	NCT00001962_49_T0	BIOLOGICAL_PROCESS	2	2	lactation
NCT0000196310	NCT00001963_10_T0	COMPOUND	33	33	aspirin
NCT000019641	NCT00001964_1_T0	COMPOUND	8	8	cyclosporine
NCT000019641	NCT00001964_1_T1	PHENOTYPE	14	15	aplastic anemia
NCT000019642	NCT00001964_2_T0	COMPOUND	39	40	mycophenolate mofetil
NCT000019642	NCT00001964_2_T1	PHENOTYPE	30	31	kidney damage
NCT000019642	NCT00001964_2_T2	PHENOTYPE	45	46	disease relapse
NCT000019643	NCT00001964_3_T0	ORGAN	11	12	bone marrow
NCT000019643	NCT00001964_3_T1	ORGAN	17	18	bone marrow
NCT000019643	NCT00001964_3_T2	PHENOTYPE	2	4	severe aplastic anemia
NCT000019644	NCT00001964_4_T0	PHENOTYPE	8	8	allergy
NCT000019644	NCT00001964_4_T1	ORGAN	14	15	bone marrow
NCT000019647	NCT00001964_7_T0	COMPOUND	17	17	prednisone
NCT000019647	NCT00001964_7_T1	PHENOTYPE	27	28	side effect
NCT000019647	NCT00001964_7_T2	PHENOTYPE	20	21	serum sickness
NCT0000196411	NCT00001964_11_T0	GENE	22	22	has
NCT0000196411	NCT00001964_11_T1	ORGAN	12	13	bone marrow
NCT0000196414	NCT00001964_14_T0	COMPOUND	19	19	cyclosporine
NCT0000196414	NCT00001964_14_T1	ORGAN	10	10	kidney
NCT0000196414	NCT00001964_14_T2	ORGAN	12	12	liver
NCT0000196417	NCT00001964_17_T0	ORGAN	0	1	Bone marrow
NCT0000196419	NCT00001964_19_T0	BIOLOGICAL_PROCESS	8	8	hematopoiesis
NCT0000196419	NCT00001964_19_T1	PHENOTYPE	6	6	suppression
NCT0000196419	NCT00001964_19_T2	PHENOTYPE	12	12	proximal
NCT0000196421	NCT00001964_21_T0	PHENOTYPE	18	18	myelodysplasia
NCT0000196421	NCT00001964_21_T1	PHENOTYPE	16	16	complications
NCT0000196421	NCT00001964_21_T2	PHENOTYPE	6	6	relapse
NCT0000196421	NCT00001964_21_T3	PHENOTYPE	2	2	immunosuppression
NCT0000196422	NCT00001964_22_T0	COMPOUND	12	12	cyclosporine
NCT0000196422	NCT00001964_22_T1	CELL	35	35	lymphocytes
NCT0000196422	NCT00001964_22_T2	PHENOTYPE	43	43	relapse
NCT0000196422	NCT00001964_22_T3	COMPOUND	20	21	mycophenolate mofetil
NCT0000196424	NCT00001964_24_T0	CELL	10	10	granulocyte
NCT0000196424	NCT00001964_24_T1	PHENOTYPE	20	21	reticulocyte count
NCT0000196424	NCT00001964_24_T2	PHENOTYPE	15	16	platelet count
NCT0000196427	NCT00001964_27_T0	COMPOUND	3	3	creatinine
NCT0000196427	NCT00001964_27_T1	COMPOUND	10	10	creatinine
NCT0000196427	NCT00001964_27_T2	ORGAN	2	2	Serum
NCT0000196428	NCT00001964_28_T0	PHENOTYPE	1	1	carcinoma
NCT0000196431	NCT00001964_31_T0	PHENOTYPE	13	13	severity
NCT0000196431	NCT00001964_31_T1	PHENOTYPE	9	10	metabolic disease
NCT000019653	NCT00001965_3_T0	COMPOUND	3	3	cyclosporine
NCT000019653	NCT00001965_3_T1	ORGAN	18	18	hearts
NCT000019653	NCT00001965_3_T2	GENE	12	12	had
NCT000019653	NCT00001965_3_T3	TISSUE	5	6	heart muscle
NCT000019655	NCT00001965_5_T0	GENE	31	31	MRI
NCT000019655	NCT00001965_5_T1	ORGAN	8	8	heart
NCT000019655	NCT00001965_5_T2	ORGAN	37	37	heart
NCT000019655	NCT00001965_5_T3	COMPOUND	24	24	thallium
NCT000019655	NCT00001965_5_T4	PHENOTYPE	40	41	blood supply
NCT000019656	NCT00001965_6_T0	COMPOUND	12	12	cyclosporine
NCT000019657	NCT00001965_7_T0	COMPOUND	18	18	cyclosporine
NCT000019658	NCT00001965_8_T0	ORGAN	2	2	heart
NCT000019659	NCT00001965_9_T0	ORGAN	22	22	heart
NCT0000196510	NCT00001965_10_T0	GENE	6	6	MRI
NCT0000196510	NCT00001965_10_T1	COMPOUND	2	2	thallium
NCT0000196511	NCT00001965_11_T0	GENE	3	3	MRI
NCT0000196513	NCT00001965_13_T0	GENE	5	5	ventricular
NCT0000196513	NCT00001965_13_T1	PHENOTYPE	7	8	diastolic dysfunction
NCT0000196513	NCT00001965_13_T2	PHENOTYPE	10	11	myocardial ischemia
NCT0000196514	NCT00001965_14_T0	PHENOTYPE	1	1	severity
NCT0000196514	NCT00001965_14_T1	PHENOTYPE	5	5	hypertrophy
NCT0000196514	NCT00001965_14_T2	PHENOTYPE	6	7	diastolic dysfunction
NCT0000196514	NCT00001965_14_T3	PHENOTYPE	9	10	myocardial ischemia
NCT0000196519	NCT00001965_19_T0	GENE	17	17	MRI
NCT0000196520	NCT00001965_20_T0	ORGAN	8	8	Heart
NCT0000196520	NCT00001965_20_T1	PHENOTYPE	1	1	symptoms
NCT0000196520	NCT00001965_20_T2	GENE	14	14	IV
NCT0000196520	NCT00001965_20_T3	PHENOTYPE	11	12	class III
NCT0000196521	NCT00001965_21_T0	PHENOTYPE	4	4	obstruction
NCT0000196521	NCT00001965_21_T1	GENE	11	11	Hg
NCT0000196522	NCT00001965_22_T0	PHENOTYPE	9	9	narrowing
NCT0000196522	NCT00001965_22_T1	PHENOTYPE	1	3	coronary artery disease
NCT0000196523	NCT00001965_23_T0	PHENOTYPE	1	3	chronic atrial fibrillation
NCT0000196524	NCT00001965_24_T0	GENE	7	7	sec
NCT0000196524	NCT00001965_24_T1	GENE	13	13	sec
NCT0000196524	NCT00001965_24_T2	GENE	8	8	pro
NCT0000196524	NCT00001965_24_T3	PHENOTYPE	14	15	platelet count
NCT0000196524	NCT00001965_24_T4	PHENOTYPE	1	2	bleeding disorder
NCT0000196525	NCT00001965_25_T0	GENE	12	12	11.0
NCT0000196525	NCT00001965_25_T1	GENE	2	2	Hb
NCT0000196525	NCT00001965_25_T2	PHENOTYPE	1	1	anemia
NCT0000196526	NCT00001965_26_T0	COMPOUND	4	4	creatinine
NCT0000196526	NCT00001965_26_T1	GENE	7	7	1.3
NCT0000196526	NCT00001965_26_T2	ORGAN	3	3	serum
NCT0000196526	NCT00001965_26_T3	PHENOTYPE	1	2	renal impairment
NCT0000196527	NCT00001965_27_T0	PHENOTYPE	1	2	hepatitis B
NCT000019662	NCT00001966_2_T0	PHENOTYPE	11	11	meditation
NCT000019662	NCT00001966_2_T1	PHENOTYPE	13	13	imagery
NCT000019671	NCT00001967_1_T0	ORGAN	10	10	plasma
NCT000019671	NCT00001967_1_T1	PHENOTYPE	11	11	viremia
NCT000019672	NCT00001967_2_T0	PHENOTYPE	11	11	suppression
NCT000019672	NCT00001967_2_T1	ORGAN	20	20	plasma
NCT000019672	NCT00001967_2_T2	PHENOTYPE	21	21	viremia
NCT000019673	NCT00001967_3_T0	PHENOTYPE	14	14	toxicity
NCT000019674	NCT00001967_4_T0	PHENOTYPE	30	30	toxicity
NCT000019674	NCT00001967_4_T1	PHENOTYPE	17	17	suppression
NCT000019675	NCT00001967_5_T0	PHENOTYPE	16	16	HIV
NCT000019679	NCT00001967_9_T0	PHENOTYPE	10	10	toxicity
NCT000019679	NCT00001967_9_T1	GENE	3	3	CD4
NCT000019679	NCT00001967_9_T2	PHENOTYPE	14	14	HIV
NCT000019679	NCT00001967_9_T3	ORGAN	28	28	plasma
NCT000019679	NCT00001967_9_T4	PHENOTYPE	29	29	viremia
NCT000019679	NCT00001967_9_T5	CELL	4	4	T-cell
NCT0000196711	NCT00001967_11_T0	ORGAN	10	10	plasma
NCT0000196711	NCT00001967_11_T1	PHENOTYPE	11	11	viremia
NCT0000196712	NCT00001967_12_T0	PHENOTYPE	11	11	suppression
NCT0000196712	NCT00001967_12_T1	ORGAN	20	20	plasma
NCT0000196712	NCT00001967_12_T2	PHENOTYPE	21	21	viremia
NCT0000196713	NCT00001967_13_T0	PHENOTYPE	14	14	toxicity
NCT0000196714	NCT00001967_14_T0	PHENOTYPE	30	30	toxicity
NCT0000196714	NCT00001967_14_T1	PHENOTYPE	17	17	suppression
NCT0000196715	NCT00001967_15_T0	PHENOTYPE	16	16	HIV
NCT0000196722	NCT00001967_22_T0	PHENOTYPE	10	10	toxicity
NCT0000196722	NCT00001967_22_T1	GENE	3	3	CD4
NCT0000196722	NCT00001967_22_T2	PHENOTYPE	14	14	HIV
NCT0000196722	NCT00001967_22_T3	ORGAN	28	28	plasma
NCT0000196722	NCT00001967_22_T4	PHENOTYPE	29	29	viremia
NCT0000196722	NCT00001967_22_T5	CELL	4	4	T-cell
NCT0000196724	NCT00001967_24_T0	GENE	1	1	CD4
NCT0000196724	NCT00001967_24_T1	GENE	23	23	CD4
NCT0000196724	NCT00001967_24_T2	GENE	16	16	For
NCT0000196724	NCT00001967_24_T3	CELL	2	2	T-cell
NCT0000196724	NCT00001967_24_T4	CELL	24	24	T-cell
NCT0000196725	NCT00001967_25_T0	GENE	8	8	CD4
NCT0000196725	NCT00001967_25_T1	CELL	9	9	T-cell
NCT0000196726	NCT00001967_26_T0	GENE	11	11	PI
NCT0000196729	NCT00001967_29_T0	ORGAN	9	9	serum
NCT0000196729	NCT00001967_29_T1	PHENOTYPE	6	8	negative pregnancy test
NCT0000196731	NCT00001967_31_T0	PHENOTYPE	15	15	HIV
NCT0000196732	NCT00001967_32_T0	PHENOTYPE	3	3	malignancy
NCT0000196733	NCT00001967_33_T0	PHENOTYPE	3	3	HIV
NCT0000196733	NCT00001967_33_T1	PHENOTYPE	4	4	illnesses
NCT0000196733	NCT00001967_33_T2	PHENOTYPE	10	10	malignancies
NCT0000196733	NCT00001967_33_T3	PHENOTYPE	7	8	opportunistic infections
NCT0000196733	NCT00001967_33_T4	PHENOTYPE	14	15	Kaposi's sarcoma
NCT0000196735	NCT00001967_35_T0	COMPOUND	6	6	hydroxyurea
NCT0000196736	NCT00001967_36_T0	GENE	12	12	IL-2
NCT0000196736	NCT00001967_36_T1	GENE	18	18	IL-2
NCT0000196737	NCT00001967_37_T0	GENE	14	14	IL-2
NCT0000196740	NCT00001967_40_T0	ORGAN	3	3	kidney
NCT0000196742	NCT00001967_42_T0	GENE	8	8	PI
NCT0000196742	NCT00001967_42_T1	PHENOTYPE	0	1	Psychiatric illness
NCT0000196743	NCT00001967_43_T0	PHENOTYPE	1	2	substance abuse
NCT0000196743	NCT00001967_43_T1	PHENOTYPE	7	8	substance abuse
NCT0000196745	NCT00001967_45_T0	PHENOTYPE	6	7	chronic hepatitis
NCT0000196745	NCT00001967_45_T1	PHENOTYPE	7	8	hepatitis B
NCT0000196746	NCT00001967_46_T0	PHENOTYPE	9	10	clinical resistance
NCT0000196747	NCT00001967_47_T0	COMPOUND	7	7	nevirapine
NCT0000196748	NCT00001967_48_T0	COMPOUND	2	2	nevirapine
NCT0000196748	NCT00001967_48_T1	COMPOUND	4	4	abacavir
NCT0000196749	NCT00001967_49_T0	GENE	0	0	Expanded
NCT000019683	NCT00001968_3_T0	PHENOTYPE	0	0	HIV
NCT000019685	NCT00001968_5_T0	COMPOUND	12	12	amprenavir
NCT000019685	NCT00001968_5_T1	COMPOUND	18	18	ritonavir
NCT000019685	NCT00001968_5_T2	COMPOUND	24	24	abacavir
NCT000019685	NCT00001968_5_T3	COMPOUND	31	31	lamivudine
NCT000019686	NCT00001968_6_T0	GENE	33	33	48
NCT000019686	NCT00001968_6_T1	GENE	26	26	16
NCT000019687	NCT00001968_7_T0	PHENOTYPE	19	20	drug levels
NCT0000196814	NCT00001968_14_T0	COMPOUND	5	5	amprenavir
NCT0000196814	NCT00001968_14_T1	PHENOTYPE	29	29	HIV
NCT0000196814	NCT00001968_14_T2	COMPOUND	9	9	ritonavir
NCT0000196814	NCT00001968_14_T3	COMPOUND	18	18	abacavir
NCT0000196814	NCT00001968_14_T4	COMPOUND	13	13	lamivudine
NCT0000196815	NCT00001968_15_T0	PHENOTYPE	14	14	concentrations
NCT0000196815	NCT00001968_15_T1	COMPOUND	16	16	amprenavir
NCT0000196815	NCT00001968_15_T2	ORGAN	13	13	plasma
NCT0000196825	NCT00001968_25_T0	PHENOTYPE	4	4	malabsorption
NCT0000196826	NCT00001968_26_T0	PHENOTYPE	1	2	chronic diarrhea
NCT0000196827	NCT00001968_27_T0	GENE	3	3	had
NCT0000196827	NCT00001968_27_T1	PHENOTYPE	50	51	Kaposi's sarcoma
NCT0000196829	NCT00001968_29_T0	PHENOTYPE	23	24	adverse events
NCT0000196829	NCT00001968_29_T1	PHENOTYPE	5	6	opportunistic infection
NCT0000196830	NCT00001968_30_T0	PHENOTYPE	7	8	psychiatric illness
NCT0000196830	NCT00001968_30_T1	PHENOTYPE	4	5	substance abuse
NCT0000196831	NCT00001968_31_T0	COMPOUND	40	40	Rifater
NCT0000196832	NCT00001968_32_T0	COMPOUND	12	12	phenobarbital
NCT0000196832	NCT00001968_32_T1	COMPOUND	13	13	phenytoin
NCT0000196832	NCT00001968_32_T2	COMPOUND	14	14	carbamazepine
NCT000019691	NCT00001969_1_T0	PHENOTYPE	79	79	progression
NCT000019691	NCT00001969_1_T1	PHENOTYPE	32	32	hypertension
NCT000019691	NCT00001969_1_T2	PHENOTYPE	14	15	major depression
NCT000019691	NCT00001969_1_T3	PHENOTYPE	59	60	major depression
NCT000019691	NCT00001969_1_T4	PHENOTYPE	8	10	coronary artery disease
NCT000019691	NCT00001969_1_T5	PHENOTYPE	53	55	ischemic heart disease
NCT000019692	NCT00001969_2_T0	PHENOTYPE	19	20	major depression
NCT000019692	NCT00001969_2_T1	PHENOTYPE	27	29	ischemic heart disease
NCT000019694	NCT00001969_4_T0	PHENOTYPE	9	10	insulin resistance
NCT000019696	NCT00001969_6_T0	PHENOTYPE	14	14	inflammation
NCT000019696	NCT00001969_6_T1	PHENOTYPE	10	10	dyslipidemia
NCT000019696	NCT00001969_6_T2	PHENOTYPE	11	11	hypercoagulation
NCT000019696	NCT00001969_6_T3	PHENOTYPE	7	8	coronary disease
NCT000019697	NCT00001969_7_T0	PHENOTYPE	13	13	severity
NCT000019697	NCT00001969_7_T1	PHENOTYPE	15	16	insulin resistance
NCT000019697	NCT00001969_7_T2	PHENOTYPE	20	21	major depression
NCT000019698	NCT00001969_8_T0	COMPOUND	16	16	glucose
NCT000019698	NCT00001969_8_T1	PHENOTYPE	3	4	insulin resistance
NCT000019699	NCT00001969_9_T0	COMPOUND	18	18	glucose
NCT000019699	NCT00001969_9_T1	GENE	24	24	insulin
NCT000019699	NCT00001969_9_T2	PHENOTYPE	13	13	reflects
NCT000019699	NCT00001969_9_T3	PHENOTYPE	9	10	insulin sensitivity
NCT0000196910	NCT00001969_10_T0	PHENOTYPE	27	27	hypercortisolism
NCT0000196910	NCT00001969_10_T1	PHENOTYPE	11	12	major depression
NCT0000196912	NCT00001969_12_T0	PHENOTYPE	79	79	progression
NCT0000196912	NCT00001969_12_T1	PHENOTYPE	32	32	hypertension
NCT0000196912	NCT00001969_12_T2	PHENOTYPE	14	15	major depression
NCT0000196912	NCT00001969_12_T3	PHENOTYPE	59	60	major depression
NCT0000196912	NCT00001969_12_T4	PHENOTYPE	8	10	coronary artery disease
NCT0000196912	NCT00001969_12_T5	PHENOTYPE	53	55	ischemic heart disease
NCT0000196913	NCT00001969_13_T0	PHENOTYPE	19	20	major depression
NCT0000196913	NCT00001969_13_T1	PHENOTYPE	27	29	ischemic heart disease
NCT0000196915	NCT00001969_15_T0	PHENOTYPE	9	10	insulin resistance
NCT0000196917	NCT00001969_17_T0	PHENOTYPE	14	14	inflammation
NCT0000196917	NCT00001969_17_T1	PHENOTYPE	10	10	dyslipidemia
NCT0000196917	NCT00001969_17_T2	PHENOTYPE	11	11	hypercoagulation
NCT0000196917	NCT00001969_17_T3	PHENOTYPE	7	8	coronary disease
NCT0000196918	NCT00001969_18_T0	PHENOTYPE	13	13	severity
NCT0000196918	NCT00001969_18_T1	PHENOTYPE	15	16	insulin resistance
NCT0000196918	NCT00001969_18_T2	PHENOTYPE	20	21	major depression
NCT0000196919	NCT00001969_19_T0	COMPOUND	16	16	glucose
NCT0000196919	NCT00001969_19_T1	PHENOTYPE	3	4	insulin resistance
NCT0000196920	NCT00001969_20_T0	COMPOUND	18	18	glucose
NCT0000196920	NCT00001969_20_T1	GENE	24	24	insulin
NCT0000196920	NCT00001969_20_T2	PHENOTYPE	13	13	reflects
NCT0000196920	NCT00001969_20_T3	PHENOTYPE	9	10	insulin sensitivity
NCT0000196921	NCT00001969_21_T0	PHENOTYPE	27	27	hypercortisolism
NCT0000196921	NCT00001969_21_T1	PHENOTYPE	11	12	major depression
NCT0000196923	NCT00001969_23_T0	GENE	18	18	atypical
NCT0000196925	NCT00001969_25_T0	PHENOTYPE	19	20	major depression
NCT0000196927	NCT00001969_27_T0	COMPOUND	6	6	glucose
NCT0000196928	NCT00001969_28_T0	PHENOTYPE	6	6	illnesses
NCT0000196928	NCT00001969_28_T1	PHENOTYPE	10	11	insulin sensitivity
NCT0000196933	NCT00001969_33_T0	PHENOTYPE	7	7	diseases
NCT0000196933	NCT00001969_33_T1	PHENOTYPE	1	2	cardiovascular diseases
NCT0000196934	NCT00001969_34_T0	PHENOTYPE	1	3	peripheral vascular disease
NCT0000196935	NCT00001969_35_T0	PHENOTYPE	0	1	HIV infection
NCT000019711	NCT00001971_1_T0	ORGAN	9	9	liver
NCT000019711	NCT00001971_1_T1	PHENOTYPE	6	6	diseases
NCT000019713	NCT00001971_3_T0	ORGAN	20	20	liver
NCT000019714	NCT00001971_4_T0	ORGAN	13	13	liver
NCT0000197111	NCT00001971_11_T0	GENE	11	11	abdominal
NCT0000197115	NCT00001971_15_T0	PHENOTYPE	14	15	liver disease
NCT0000197118	NCT00001971_18_T0	PHENOTYPE	2	2	acute
NCT0000197118	NCT00001971_18_T1	PHENOTYPE	4	6	chronic liver disease
NCT0000197119	NCT00001971_19_T0	PHENOTYPE	5	5	illnesses
NCT0000197122	NCT00001971_22_T0	COMPOUND	29	29	HCV
NCT0000197122	NCT00001971_22_T1	PHENOTYPE	12	13	hepatitis B
NCT0000197122	NCT00001971_22_T2	PHENOTYPE	23	24	hepatitis C
NCT0000197122	NCT00001971_22_T3	PHENOTYPE	11	12	chronic hepatitis
NCT0000197122	NCT00001971_22_T4	PHENOTYPE	22	23	chronic hepatitis
NCT0000197122	NCT00001971_22_T5	PHENOTYPE	4	6	chronic liver disease
NCT0000197123	NCT00001971_23_T0	PHENOTYPE	8	8	hepatitis
NCT0000197123	NCT00001971_23_T1	PHENOTYPE	17	18	liver disease
NCT0000197123	NCT00001971_23_T2	PHENOTYPE	23	24	adverse effects
NCT0000197127	NCT00001971_27_T0	GENE	13	13	18
NCT0000197128	NCT00001971_28_T0	CELL	27	27	cells
NCT0000197128	NCT00001971_28_T1	BIOLOGICAL_PROCESS	15	15	phlebotomy
NCT0000197128	NCT00001971_28_T2	ORGAN	3	3	Serum
NCT0000197128	NCT00001971_28_T3	PHENOTYPE	10	10	anemia
NCT000019721	NCT00001972_1_T0	CELL	2	2	cells
NCT000019723	NCT00001972_3_T0	COMPOUND	5	5	glucose
NCT000019723	NCT00001972_3_T1	COMPOUND	3	3	oxygen
NCT000019727	NCT00001972_7_T0	PHENOTYPE	3	3	diseases
NCT000019727	NCT00001972_7_T1	BIOLOGICAL_PROCESS	12	12	aging
NCT000019728	NCT00001972_8_T0	BIOLOGICAL_PROCESS	17	18	phospholipid metabolism
NCT0000197214	NCT00001972_14_T0	PHENOTYPE	20	21	energy metabolism
NCT0000197215	NCT00001972_15_T0	GENE	14	14	reduced
NCT0000197215	NCT00001972_15_T1	PHENOTYPE	16	17	Alzheimer disease
NCT0000197215	NCT00001972_15_T2	PHENOTYPE	6	7	energy metabolism
NCT0000197216	NCT00001972_16_T0	GENE	43	43	reduced
NCT0000197216	NCT00001972_16_T1	GENE	55	55	reduced
NCT0000197216	NCT00001972_16_T2	PHENOTYPE	70	70	regression
NCT0000197216	NCT00001972_16_T3	PHENOTYPE	57	58	Alzheimer disease
NCT0000197216	NCT00001972_16_T4	PHENOTYPE	80	81	Alzheimer disease
NCT0000197217	NCT00001972_17_T0	GENE	32	32	Niemann-Pick
NCT0000197217	NCT00001972_17_T1	PHENOTYPE	30	31	Alzheimer disease
NCT0000197217	NCT00001972_17_T2	PHENOTYPE	37	38	brain tumors
NCT0000197218	NCT00001972_18_T0	PHENOTYPE	3	4	Alzheimer disease
NCT0000197219	NCT00001972_19_T0	PHENOTYPE	28	29	Alzheimer disease
NCT0000197220	NCT00001972_20_T0	GENE	22	22	has
NCT0000197224	NCT00001972_24_T0	PHENOTYPE	1	2	occupational exposure
NCT0000197226	NCT00001972_26_T0	PHENOTYPE	2	3	ALZHEIMER DISEASE
NCT0000197227	NCT00001972_27_T0	PHENOTYPE	5	6	Alzheimer Disease
NCT0000197228	NCT00001972_28_T0	PHENOTYPE	2	3	Alzheimer Disease
NCT000019732	NCT00001973_2_T0	PHENOTYPE	5	5	calcinosis
NCT000019732	NCT00001973_2_T1	PHENOTYPE	15	16	juvenile dermatomyositis
NCT000019733	NCT00001973_3_T0	PHENOTYPE	11	13	polyostotic fibrous dysplasia
NCT000019734	NCT00001973_4_T0	TISSUE	4	5	bone tissue
NCT000019735	NCT00001973_5_T0	PHENOTYPE	11	11	mutation
NCT000019736	NCT00001973_6_T0	CELL	5	5	cells
NCT000019736	NCT00001973_6_T1	CELL	26	26	cells
NCT000019738	NCT00001973_8_T0	PHENOTYPE	7	7	calcinosis
NCT000019738	NCT00001973_8_T1	PHENOTYPE	3	3	Dermatomyositis
NCT0000197315	NCT00001973_15_T0	PHENOTYPE	7	7	pathology
NCT0000197321	NCT00001973_21_T0	PHENOTYPE	11	11	calcinosis
NCT0000197321	NCT00001973_21_T1	PHENOTYPE	4	5	juvenile dermatomyositis
NCT000019752	NCT00001975_2_T0	PHENOTYPE	1	1	severity
NCT000019753	NCT00001975_3_T0	PHENOTYPE	6	7	skin tumors
NCT000019754	NCT00001975_4_T0	PHENOTYPE	2	3	tuberous sclerosis
NCT000019756	NCT00001975_6_T0	PHENOTYPE	2	3	skin tumors
NCT000019758	NCT00001975_8_T0	PHENOTYPE	27	28	tuberous sclerosis
NCT0000197510	NCT00001975_10_T0	PHENOTYPE	1	1	tumors
NCT0000197510	NCT00001975_10_T1	PHENOTYPE	6	6	plaques
NCT0000197510	NCT00001975_10_T2	PHENOTYPE	10	10	fibromas
NCT0000197510	NCT00001975_10_T3	PHENOTYPE	13	13	fibromas
NCT0000197510	NCT00001975_10_T4	ORGAN	5	5	forehead
NCT0000197510	NCT00001975_10_T5	PHENOTYPE	3	4	facial angiofibromas
NCT0000197511	NCT00001975_11_T0	PHENOTYPE	1	1	tumors
NCT0000197512	NCT00001975_12_T0	PHENOTYPE	13	13	tumors
NCT0000197514	NCT00001975_14_T0	PHENOTYPE	14	14	tumor
NCT0000197514	NCT00001975_14_T1	PHENOTYPE	10	11	cutaneous tumors
NCT0000197524	NCT00001975_24_T0	PHENOTYPE	0	0	Allergy
NCT000019761	NCT00001976_1_T0	GENE	10	10	pp65
NCT000019768	NCT00001976_8_T0	GENE	10	10	RT
NCT000019768	NCT00001976_8_T1	ORGAN	31	31	transplant
NCT000019768	NCT00001976_8_T2	GENE	11	11	PCR
NCT000019768	NCT00001976_8_T3	ORGAN	18	19	bone marrow
NCT0000197611	NCT00001976_11_T0	GENE	0	0	RT
NCT0000197611	NCT00001976_11_T1	GENE	1	1	PCR
NCT0000197621	NCT00001976_21_T0	ORGAN	15	15	transplant
NCT0000197621	NCT00001976_21_T1	GENE	22	22	pp65
NCT0000197628	NCT00001976_28_T0	PHENOTYPE	12	12	conditioning
NCT0000197628	NCT00001976_28_T1	ORGAN	7	7	transplant
NCT000019774	NCT00001977_4_T0	GENE	26	26	MRI
NCT000019774	NCT00001977_4_T1	PHENOTYPE	5	6	Alzheimer's disease
NCT000019779	NCT00001977_9_T0	GENE	10	10	MRI
NCT0000197711	NCT00001977_11_T0	PHENOTYPE	14	14	separation
NCT0000197712	NCT00001977_12_T0	ORGAN	6	6	faces
NCT0000197721	NCT00001977_21_T0	PHENOTYPE	4	6	positive pregnancy test
NCT0000197722	NCT00001977_22_T0	GENE	8	8	MRI
NCT0000197722	NCT00001977_22_T1	ORGAN	20	20	eyes
NCT0000197723	NCT00001977_23_T0	PHENOTYPE	10	11	chronic disease
NCT0000197724	NCT00001977_24_T0	GENE	30	30	AD
NCT0000197724	NCT00001977_24_T1	PHENOTYPE	17	17	dementia
NCT0000197724	NCT00001977_24_T2	PHENOTYPE	19	20	Alzheimer's disease
NCT0000197724	NCT00001977_24_T3	PHENOTYPE	6	7	chronic disease
NCT000019781	NCT00001978_1_T0	GENE	16	16	GFR
NCT000019781	NCT00001978_1_T1	ORGAN	23	23	Capillary
NCT000019781	NCT00001978_1_T2	ORGAN	6	6	kidneys
NCT000019781	NCT00001978_1_T3	BIOLOGICAL_PROCESS	13	14	glomerular filtration
NCT000019781	NCT00001978_1_T4	PHENOTYPE	17	19	Renal Plasma Flow
NCT000019782	NCT00001978_2_T0	PHENOTYPE	5	5	suffering
NCT000019782	NCT00001978_2_T1	PHENOTYPE	10	11	kidney diseases
NCT000019783	NCT00001978_3_T0	PHENOTYPE	17	17	proteinuria
NCT000019784	NCT00001978_4_T0	ORGAN	15	15	kidney
NCT000019785	NCT00001978_5_T0	ORGAN	11	11	kidney
NCT000019786	NCT00001978_6_T0	ORGAN	11	11	veins
NCT000019786	NCT00001978_6_T1	GENE	2	2	para
NCT000019786	NCT00001978_6_T2	ORGAN	21	21	kidneys
NCT000019788	NCT00001978_8_T0	ORGAN	13	13	capillary
NCT000019788	NCT00001978_8_T1	PHENOTYPE	3	3	proteinuria
NCT000019788	NCT00001978_8_T2	GENE	25	25	albumin
NCT000019788	NCT00001978_8_T3	GENE	27	27	IgG
NCT000019788	NCT00001978_8_T4	COMPOUND	36	36	dextran
NCT0000197814	NCT00001978_14_T0	GENE	24	24	insulin
NCT0000197814	NCT00001978_14_T1	ORGAN	5	5	plasma
NCT0000197815	NCT00001978_15_T0	ORGAN	7	7	plasma
NCT0000197819	NCT00001978_19_T0	PHENOTYPE	13	13	allergy
NCT000019791	NCT00001979_1_T0	ORGAN	16	16	kidney
NCT000019791	NCT00001979_1_T1	PHENOTYPE	10	10	suffering
NCT000019791	NCT00001979_1_T2	PHENOTYPE	12	13	autoimmune diseases
NCT000019792	NCT00001979_2_T0	PHENOTYPE	14	14	autoimmune
NCT000019792	NCT00001979_2_T1	PHENOTYPE	15	16	kidney disease
NCT000019793	NCT00001979_3_T0	PHENOTYPE	14	14	diseases
NCT000019793	NCT00001979_3_T1	ORGAN	9	10	immune system
NCT000019793	NCT00001979_3_T2	ORGAN	17	18	immune system
NCT000019793	NCT00001979_3_T3	PHENOTYPE	2	3	kidney disease
NCT000019793	NCT00001979_3_T4	PHENOTYPE	23	24	kidney disease
NCT000019794	NCT00001979_4_T0	PHENOTYPE	19	19	symptoms
NCT000019794	NCT00001979_4_T1	PHENOTYPE	26	26	diseases
NCT000019798	NCT00001979_8_T0	PHENOTYPE	4	4	diseases
NCT000019798	NCT00001979_8_T1	PHENOTYPE	8	9	kidney disease
NCT000019799	NCT00001979_9_T0	PHENOTYPE	12	12	disorders
NCT000019799	NCT00001979_9_T1	PHENOTYPE	18	18	complications
NCT0000197912	NCT00001979_12_T0	PHENOTYPE	1	1	diseases
NCT0000197912	NCT00001979_12_T1	PHENOTYPE	5	6	kidney disease
NCT0000197914	NCT00001979_14_T0	PHENOTYPE	15	16	kidney disorder
NCT000019811	NCT00001981_1_T0	PHENOTYPE	6	6	acromegaly
NCT000019811	NCT00001981_1_T1	GENE	12	12	has
NCT000019813	NCT00001981_3_T0	PHENOTYPE	18	18	acromegaly
NCT000019813	NCT00001981_3_T1	PHENOTYPE	2	3	pituitary tumor
NCT000019815	NCT00001981_5_T0	PHENOTYPE	6	6	acromegaly
NCT000019815	NCT00001981_5_T1	GENE	12	12	has
NCT000019820	NCT00001982_0_T0	PHENOTYPE	2	3	Hepatitis C
NCT000019822	NCT00001982_2_T0	PHENOTYPE	12	12	symptoms
NCT000019822	NCT00001982_2_T1	PHENOTYPE	2	3	hepatitis C
NCT000019824	NCT00001982_4_T0	ORGAN	14	14	liver
NCT000019824	NCT00001982_4_T1	ORGAN	25	25	liver
NCT000019824	NCT00001982_4_T2	COMPOUND	9	9	HCV
NCT000019824	NCT00001982_4_T3	PHENOTYPE	6	7	hepatitis C
NCT000019824	NCT00001982_4_T4	PHENOTYPE	5	6	chronic hepatitis
NCT000019824	NCT00001982_4_T5	MOLECULAR_FUNCTION	15	16	enzyme activity
NCT000019825	NCT00001982_5_T0	PHENOTYPE	16	17	liver disease
NCT000019826	NCT00001982_6_T0	PHENOTYPE	14	15	hepatitis C
NCT000019826	NCT00001982_6_T1	PHENOTYPE	20	21	liver damage
NCT000019828	NCT00001982_8_T0	COMPOUND	16	16	HCV
NCT000019828	NCT00001982_8_T1	PHENOTYPE	22	23	liver disease
NCT0000198211	NCT00001982_11_T0	GENE	14	14	RIBA
NCT0000198211	NCT00001982_11_T1	COMPOUND	0	0	HCV
NCT0000198211	NCT00001982_11_T2	COMPOUND	7	7	HCV
NCT0000198216	NCT00001982_16_T0	PHENOTYPE	4	5	HIV infection
NCT0000198314	NCT00001983_14_T0	GENE	3	3	has
NCT000019841	NCT00001984_1_T0	GENE	10	10	CD52
NCT000019841	NCT00001984_1_T1	CELL	8	8	monocyte
NCT000019841	NCT00001984_1_T2	CELL	6	6	lymphocyte
NCT000019842	NCT00001984_2_T0	CELL	8	8	monocytes
NCT000019842	NCT00001984_2_T1	CELL	5	5	lymphocytes
NCT000019842	NCT00001984_2_T2	CELL	11	11	neutrophils
NCT000019842	NCT00001984_2_T3	CELL	13	15	hematopoietic stem cells
NCT000019843	NCT00001984_3_T0	CELL	7	7	monocyte
NCT000019843	NCT00001984_3_T1	GENE	3	3	NFkB
NCT000019843	NCT00001984_3_T2	BIOLOGICAL_PROCESS	9	10	macrophage activation
NCT000019844	NCT00001984_4_T0	PHENOTYPE	21	21	peripheral
NCT000019844	NCT00001984_4_T1	ORGAN	29	29	graft
NCT000019844	NCT00001984_4_T2	ORGAN	6	6	kidneys
NCT000019844	NCT00001984_4_T3	PHENOTYPE	30	30	reperfusion
NCT000019845	NCT00001984_5_T0	CELL	26	26	cells
NCT000019845	NCT00001984_5_T1	ORGAN	17	17	transplant
NCT000019845	NCT00001984_5_T2	CELL	22	22	leukocytes
NCT000019845	NCT00001984_5_T3	ORGAN	33	33	allograft
NCT000019846	NCT00001984_6_T0	GENE	7	7	DSG
NCT000019848	NCT00001984_8_T0	PHENOTYPE	4	4	peripheral
NCT0000198410	NCT00001984_10_T0	PHENOTYPE	14	14	immunosuppression
NCT0000198410	NCT00001984_10_T1	GENE	7	7	DSG
NCT0000198411	NCT00001984_11_T0	ORGAN	8	8	transplant
NCT0000198412	NCT00001984_12_T0	COMPOUND	9	9	methylprednisolone
NCT0000198412	NCT00001984_12_T1	PHENOTYPE	12	12	immunosuppression
NCT0000198413	NCT00001984_13_T0	GENE	8	8	DSG
NCT0000198413	NCT00001984_13_T1	GENE	11	11	has
NCT0000198413	NCT00001984_13_T2	ORGAN	20	20	allograft
NCT0000198416	NCT00001984_16_T0	GENE	16	16	1.2
NCT0000198422	NCT00001984_22_T0	GENE	10	10	CD52
NCT0000198422	NCT00001984_22_T1	CELL	8	8	monocyte
NCT0000198422	NCT00001984_22_T2	CELL	6	6	lymphocyte
NCT0000198423	NCT00001984_23_T0	CELL	8	8	monocytes
NCT0000198423	NCT00001984_23_T1	CELL	5	5	lymphocytes
NCT0000198423	NCT00001984_23_T2	CELL	11	11	neutrophils
NCT0000198423	NCT00001984_23_T3	CELL	13	15	hematopoietic stem cells
NCT0000198424	NCT00001984_24_T0	CELL	8	8	monocyte
NCT0000198424	NCT00001984_24_T1	GENE	4	4	NFkB
NCT0000198424	NCT00001984_24_T2	BIOLOGICAL_PROCESS	10	11	macrophage activation
NCT0000198426	NCT00001984_26_T0	GENE	13	13	DSG
NCT0000198429	NCT00001984_29_T0	PHENOTYPE	21	21	peripheral
NCT0000198429	NCT00001984_29_T1	ORGAN	29	29	graft
NCT0000198429	NCT00001984_29_T2	ORGAN	6	6	kidneys
NCT0000198429	NCT00001984_29_T3	PHENOTYPE	30	30	reperfusion
NCT0000198430	NCT00001984_30_T0	CELL	26	26	cells
NCT0000198430	NCT00001984_30_T1	ORGAN	17	17	transplant
NCT0000198430	NCT00001984_30_T2	CELL	22	22	leukocytes
NCT0000198430	NCT00001984_30_T3	ORGAN	33	33	allograft
NCT0000198433	NCT00001984_33_T0	PHENOTYPE	4	4	peripheral
NCT0000198435	NCT00001984_35_T0	PHENOTYPE	13	13	immunosuppression
NCT0000198435	NCT00001984_35_T1	GENE	12	12	reduced
NCT0000198436	NCT00001984_36_T0	CELL	9	9	monocytes
NCT0000198436	NCT00001984_36_T1	PHENOTYPE	11	11	infiltrated
NCT0000198436	NCT00001984_36_T2	ORGAN	13	13	allograft
NCT0000198436	NCT00001984_36_T3	ORGAN	17	17	allograft
NCT0000198436	NCT00001984_36_T4	PHENOTYPE	18	18	dysfunction
NCT0000198437	NCT00001984_37_T0	CELL	40	40	monocytes
NCT0000198437	NCT00001984_37_T1	CELL	24	24	cells
NCT0000198437	NCT00001984_37_T2	GENE	5	5	DSG
NCT0000198437	NCT00001984_37_T3	PHENOTYPE	19	19	elimination
NCT0000198437	NCT00001984_37_T4	PHENOTYPE	30	30	reperfusion
NCT0000198438	NCT00001984_38_T0	PHENOTYPE	11	11	peripheral
NCT0000198438	NCT00001984_38_T1	CELL	14	14	monocytes
NCT0000198438	NCT00001984_38_T2	GENE	4	4	DSG
NCT0000198439	NCT00001984_39_T0	ORGAN	8	8	transplant
NCT0000198439	NCT00001984_39_T1	ORGAN	19	19	allograft
NCT0000198439	NCT00001984_39_T2	BIOLOGICAL_PROCESS	15	16	immune response
NCT0000198440	NCT00001984_40_T0	CELL	18	18	monocytes
NCT0000198440	NCT00001984_40_T1	PHENOTYPE	21	21	peripheral
NCT0000198440	NCT00001984_40_T2	BIOLOGICAL_PROCESS	25	25	transcription
NCT0000198440	NCT00001984_40_T3	ORGAN	5	5	graft
NCT0000198440	NCT00001984_40_T4	GENE	32	32	TNF-a
NCT0000198440	NCT00001984_40_T5	PHENOTYPE	7	7	immunity
NCT0000198440	NCT00001984_40_T6	ORGAN	35	35	allograft
NCT0000198440	NCT00001984_40_T7	PHENOTYPE	9	10	graft dysfunction
NCT0000198440	NCT00001984_40_T8	GENE	29	31	Tumor Necrosis Factor-alpha
NCT0000198442	NCT00001984_42_T0	COMPOUND	12	12	methylprednisolone
NCT0000198442	NCT00001984_42_T1	PHENOTYPE	15	15	immunosuppression
NCT0000198442	NCT00001984_42_T2	PHENOTYPE	4	5	graft dysfunction
NCT0000198443	NCT00001984_43_T0	GENE	2	2	has
NCT0000198443	NCT00001984_43_T1	ORGAN	11	11	allograft
NCT0000198448	NCT00001984_48_T0	PHENOTYPE	2	2	Center
NCT0000198452	NCT00001984_52_T0	PHENOTYPE	5	5	peripheral
NCT0000198452	NCT00001984_52_T1	PHENOTYPE	31	31	peripheral
NCT0000198452	NCT00001984_52_T2	CELL	7	7	lymphocytes
NCT0000198452	NCT00001984_52_T3	BIOLOGICAL_PROCESS	29	29	phlebotomy
NCT0000198452	NCT00001984_52_T4	CELL	33	33	lymphocyte
NCT0000198454	NCT00001984_54_T0	COMPOUND	7	7	cyclosporine
NCT0000198454	NCT00001984_54_T1	COMPOUND	8	8	tacrolimus
NCT0000198454	NCT00001984_54_T2	COMPOUND	14	14	cyclophosphamide
NCT0000198454	NCT00001984_54_T3	COMPOUND	9	9	azathioprine
NCT0000198454	NCT00001984_54_T4	COMPOUND	15	15	methotrexate
NCT0000198454	NCT00001984_54_T5	COMPOUND	6	6	prednisone
NCT0000198454	NCT00001984_54_T6	COMPOUND	10	11	mycophenolate mofetil
NCT0000198456	NCT00001984_56_T0	PHENOTYPE	2	2	malignancy
NCT0000198456	NCT00001984_56_T1	PHENOTYPE	9	9	malignancy
NCT0000198456	NCT00001984_56_T2	PHENOTYPE	11	11	lymphoma
NCT0000198458	NCT00001984_58_T0	PHENOTYPE	5	5	anticoagulation
NCT0000198458	NCT00001984_58_T1	PHENOTYPE	1	1	coagulopathy
NCT0000198458	NCT00001984_58_T2	ORGAN	11	11	allograft
NCT0000198459	NCT00001984_59_T0	PHENOTYPE	0	1	Platelet count
NCT0000198460	NCT00001984_60_T0	GENE	3	3	9.0
NCT0000198464	NCT00001984_64_T0	PHENOTYPE	7	8	vascular disease
NCT0000198464	NCT00001984_64_T1	PHENOTYPE	4	5	cardiac insufficiency
NCT0000198464	NCT00001984_64_T2	PHENOTYPE	11	13	coronary artery disease
NCT0000198465	NCT00001984_65_T0	PHENOTYPE	2	3	pulmonary edema
NCT0000198467	NCT00001984_67_T0	GENE	2	2	SBP
NCT0000198467	NCT00001984_67_T1	PHENOTYPE	0	1	Chronic hypotension
NCT000019851	NCT00001985_1_T0	GENE	18	18	CD152
NCT000019855	NCT00001985_5_T0	GENE	19	19	CD152
NCT000019856	NCT00001985_6_T0	GENE	2	2	CD152
NCT000019856	NCT00001985_6_T1	GENE	19	19	ml
NCT000019858	NCT00001985_8_T0	CELL	2	2	cells
NCT000019858	NCT00001985_8_T1	GENE	17	17	ml
NCT0000198518	NCT00001985_18_T0	PHENOTYPE	6	6	malignancy
NCT0000198519	NCT00001985_19_T0	GENE	8	8	9.0
NCT0000198519	NCT00001985_19_T1	GENE	3	3	hemoglobin
NCT000019861	NCT00001986_1_T0	ORGAN	10	10	hands
NCT000019861	NCT00001986_1_T1	GENE	11	11	has
NCT000019861	NCT00001986_1_T2	PHENOTYPE	6	6	shaking
NCT000019862	NCT00001986_2_T0	PHENOTYPE	1	1	affects
NCT000019863	NCT00001986_3_T0	COMPOUND	3	3	1_octanol
NCT000019863	NCT00001986_3_T1	PHENOTYPE	7	7	tremors
NCT000019863	NCT00001986_3_T2	GENE	4	4	reduced
NCT000019863	NCT00001986_3_T3	PHENOTYPE	5	6	chemically induced
NCT000019865	NCT00001986_5_T0	ORGAN	32	32	liver
NCT000019865	NCT00001986_5_T1	ORGAN	31	31	thyroid
NCT000019865	NCT00001986_5_T2	PHENOTYPE	34	35	kidney problems
NCT000019865	NCT00001986_5_T3	PHENOTYPE	2	3	essential tremor
NCT000019866	NCT00001986_6_T0	COMPOUND	8	8	1_octanol
NCT000019868	NCT00001986_8_T0	COMPOUND	3	3	1_octanol
NCT000019868	NCT00001986_8_T1	COMPOUND	9	9	1_octanol
NCT000019869	NCT00001986_9_T0	COMPOUND	12	12	1_octanol
NCT0000198610	NCT00001986_10_T0	PHENOTYPE	0	0	Tremors
NCT0000198611	NCT00001986_11_T0	PHENOTYPE	1	1	tremors
NCT0000198614	NCT00001986_14_T0	PHENOTYPE	4	4	pulse
NCT0000198618	NCT00001986_18_T0	COMPOUND	38	38	calcium
NCT0000198618	NCT00001986_18_T1	GENE	13	13	defective
NCT0000198618	NCT00001986_18_T2	CELL	25	25	neurons
NCT0000198619	NCT00001986_19_T0	PHENOTYPE	15	15	tremor
NCT0000198619	NCT00001986_19_T1	CELL	8	8	neurons
NCT0000198619	NCT00001986_19_T2	CELL	27	27	neurons
NCT0000198619	NCT00001986_19_T3	COMPOUND	20	20	harmaline
NCT0000198620	NCT00001986_20_T0	COMPOUND	11	11	1_octanol
NCT0000198622	NCT00001986_22_T0	COMPOUND	12	12	1_octanol
NCT0000198622	NCT00001986_22_T1	PHENOTYPE	8	8	tremor
NCT0000198623	NCT00001986_23_T0	COMPOUND	6	6	1_octanol
NCT0000198624	NCT00001986_24_T0	ORGAN	9	9	liver
NCT0000198624	NCT00001986_24_T1	PHENOTYPE	0	0	Toxicity
NCT0000198624	NCT00001986_24_T2	COMPOUND	2	2	octanol
NCT0000198626	NCT00001986_26_T0	PHENOTYPE	7	8	essential tremor
NCT0000198630	NCT00001986_30_T0	PHENOTYPE	9	9	tremor
NCT0000198630	NCT00001986_30_T1	PHENOTYPE	5	6	neurological disease
NCT0000198631	NCT00001986_31_T0	ORGAN	8	8	kidney
NCT0000198631	NCT00001986_31_T1	ORGAN	6	6	thyroid
NCT0000198631	NCT00001986_31_T2	ORGAN	7	7	liver
NCT0000198631	NCT00001986_31_T3	PHENOTYPE	10	12	chronic lung disease
NCT000019875	NCT00001987_5_T0	CELL	8	8	cells
NCT000019875	NCT00001987_5_T1	GENE	5	5	insulin
NCT000019876	NCT00001987_6_T0	GENE	8	8	ml
NCT0000198711	NCT00001987_11_T0	PHENOTYPE	16	16	disorders
NCT0000198711	NCT00001987_11_T1	GENE	7	7	has
NCT0000198711	NCT00001987_11_T2	PHENOTYPE	19	20	insulin resistance
NCT0000198712	NCT00001987_12_T0	PHENOTYPE	4	4	learned
NCT0000198712	NCT00001987_12_T1	PHENOTYPE	21	21	learned
NCT0000198712	NCT00001987_12_T2	PHENOTYPE	14	15	rare diseases
NCT0000198712	NCT00001987_12_T3	PHENOTYPE	28	29	insulin resistance
NCT0000198716	NCT00001987_16_T0	PHENOTYPE	8	8	disorders
NCT0000198716	NCT00001987_16_T1	PHENOTYPE	6	7	insulin resistance
NCT0000198720	NCT00001987_20_T0	PHENOTYPE	4	5	insulin resistance
NCT0000198722	NCT00001987_22_T0	PHENOTYPE	3	3	syndromes
NCT0000198722	NCT00001987_22_T1	PHENOTYPE	5	5	lipodystrophy
NCT0000198723	NCT00001987_23_T0	GENE	8	9	insulin receptor
NCT0000198724	NCT00001987_24_T0	GENE	8	9	insulin receptor
NCT0000198725	NCT00001987_25_T0	PHENOTYPE	22	23	clinical heterogeneity
NCT0000198725	NCT00001987_25_T1	PHENOTYPE	6	7	insulin resistance
NCT000019895	NCT00001989_5_T0	COMPOUND	1	1	fluconazole
NCT000019895	NCT00001989_5_T1	PHENOTYPE	0	0	Cryptococcosis
NCT000019896	NCT00001989_6_T0	PHENOTYPE	0	0	Candidiasis
NCT000019896	NCT00001989_6_T1	COMPOUND	1	1	ketoconazole
NCT000019897	NCT00001989_7_T0	COMPOUND	3	3	acyclovir
NCT000019897	NCT00001989_7_T1	PHENOTYPE	0	1	Herpes simplex
NCT000019898	NCT00001989_8_T0	COMPOUND	4	4	amikacin
NCT000019898	NCT00001989_8_T1	COMPOUND	2	2	isoniazid
NCT000019898	NCT00001989_8_T2	COMPOUND	3	3	clofazimine
NCT000019898	NCT00001989_8_T3	COMPOUND	6	6	rifabutin
NCT000019898	NCT00001989_8_T4	COMPOUND	7	7	ethambutol
NCT000019904	NCT00001990_4_T0	PHENOTYPE	21	21	attributable
NCT000019904	NCT00001990_4_T1	PHENOTYPE	12	13	adverse experience
NCT000019910	NCT00001991_0_T0	GENE	2	2	IND
NCT000019910	NCT00001991_0_T1	PHENOTYPE	7	9	Pneumocystis Carinii Pneumonia
NCT000019915	NCT00001991_5_T0	COMPOUND	3	3	pentamidine
NCT000019940	NCT00001994_0_T0	PHENOTYPE	11	11	Encephalitis
NCT000019940	NCT00001994_0_T1	PHENOTYPE	20	20	HIV
NCT000019940	NCT00001994_0_T2	PHENOTYPE	18	18	Immunodeficiency
NCT000019942	NCT00001994_2_T0	PHENOTYPE	8	8	acute
NCT000019942	NCT00001994_2_T1	PHENOTYPE	14	14	toxoplasmosis
NCT000019942	NCT00001994_2_T2	PHENOTYPE	11	11	suppression
NCT0000199410	NCT00001994_10_T0	PHENOTYPE	3	4	alcohol abuse
NCT000019970	NCT00001997_0_T0	GENE	7	7	PEG
NCT000019970	NCT00001997_0_T1	GENE	6	6	IL-2
NCT000019970	NCT00001997_0_T2	GENE	8	8	IL-2
NCT000019970	NCT00001997_0_T3	PHENOTYPE	14	15	HIV Positive
NCT000019973	NCT00001997_3_T0	GENE	4	4	CD4
NCT000019975	NCT00001997_5_T0	COMPOUND	18	18	zidovudine
NCT000019975	NCT00001997_5_T1	GENE	4	4	p24
NCT000019975	NCT00001997_5_T2	COMPOUND	21	21	didanosine
NCT000019976	NCT00001997_6_T0	GENE	3	3	PEG
NCT000019976	NCT00001997_6_T1	GENE	4	4	IL-2
NCT000019977	NCT00001997_7_T0	GENE	17	17	PEG
NCT000019977	NCT00001997_7_T1	GENE	18	18	IL-2
NCT0000199714	NCT00001997_14_T0	PHENOTYPE	1	2	substance abuse
NCT000019991	NCT00001999_1_T0	PHENOTYPE	11	11	remission
NCT000019991	NCT00001999_1_T1	GENE	4	4	globulin
NCT000019992	NCT00001999_2_T0	PHENOTYPE	3	3	toxicities
NCT000019992	NCT00001999_2_T1	GENE	11	11	globulin
NCT000020004	NCT00002000_4_T0	COMPOUND	17	17	creatinine
NCT000020004	NCT00002000_4_T1	ORGAN	16	16	serum
NCT000020011	NCT00002001_1_T0	COMPOUND	6	6	zidovudine
NCT000020012	NCT00002001_2_T0	COMPOUND	5	5	zidovudine
NCT000020013	NCT00002001_3_T0	COMPOUND	11	11	zidovudine
NCT000020013	NCT00002001_3_T1	PHENOTYPE	6	6	tolerance
NCT0000200112	NCT00002001_12_T0	PHENOTYPE	1	4	alcohol or drug abuse
NCT000020052	NCT00002005_2_T0	ORGAN	4	4	serum
NCT000020060	NCT00002006_0_T0	PHENOTYPE	26	26	Leukopenia
NCT000020060	NCT00002006_0_T1	GENE	9	9	GM-CSF
NCT000020060	NCT00002006_0_T2	PHENOTYPE	27	27	Pharmacokinetics
NCT000020060	NCT00002006_0_T3	PHENOTYPE	23	24	HIV Infection
NCT000020060	NCT00002006_0_T4	CELL	11	12	CHO Cell
NCT000020062	NCT00002006_2_T0	PHENOTYPE	18	18	HIV
NCT000020062	NCT00002006_2_T1	PHENOTYPE	22	22	neutropenia
NCT000020062	NCT00002006_2_T2	GENE	9	9	GM-CSF
NCT000020062	NCT00002006_2_T3	CELL	15	15	neutrophil
NCT000020063	NCT00002006_3_T0	PHENOTYPE	21	21	complications
NCT000020063	NCT00002006_3_T1	GENE	8	8	GM-CSF
NCT000020063	NCT00002006_3_T2	PHENOTYPE	16	17	HIV infection
NCT0000200610	NCT00002006_10_T0	PHENOTYPE	3	4	alcohol abuse
NCT0000200611	NCT00002006_11_T0	PHENOTYPE	13	13	HIV
NCT0000200612	NCT00002006_12_T0	PHENOTYPE	19	19	HIV
NCT000020071	NCT00002007_1_T0	PHENOTYPE	14	14	toxicity
NCT000020071	NCT00002007_1_T1	PHENOTYPE	26	26	leukopenia
NCT000020071	NCT00002007_1_T2	COMPOUND	17	17	zidovudine
NCT000020071	NCT00002007_1_T3	GENE	5	5	GM-CSF
NCT000020079	NCT00002007_9_T0	PHENOTYPE	19	19	HIV
NCT000020091	NCT00002009_1_T0	PHENOTYPE	7	7	pharmacokinetics
NCT000020101	NCT00002010_1_T0	PHENOTYPE	4	4	tolerance
NCT000020112	NCT00002011_2_T0	ORGAN	12	12	plasma
NCT000020112	NCT00002011_2_T1	CELL	7	9	white blood cells
NCT000020113	NCT00002011_3_T0	GENE	1	1	separated
NCT000020113	NCT00002011_3_T1	ORGAN	6	6	plasma
NCT000020113	NCT00002011_3_T2	CELL	2	4	white blood cells
NCT000020114	NCT00002011_4_T0	CELL	17	17	cells
NCT000020115	NCT00002011_5_T0	CELL	6	8	white blood cells
NCT0000201113	NCT00002011_13_T0	PHENOTYPE	3	4	drug abuse
NCT0000201210	NCT00002012_10_T0	GENE	1	1	IV
NCT0000201210	NCT00002012_10_T1	PHENOTYPE	2	3	drug abuse
NCT000020130	NCT00002013_0_T0	PHENOTYPE	3	3	Pharmacokinetics
NCT000020139	NCT00002013_9_T0	PHENOTYPE	1	2	substance abuse
NCT000020140	NCT00002014_0_T0	PHENOTYPE	27	27	HIV
NCT000020140	NCT00002014_0_T1	PHENOTYPE	25	25	Immunodeficiency
NCT000020140	NCT00002014_0_T2	PHENOTYPE	7	7	Pharmacokinetics
NCT000020142	NCT00002014_2_T0	PHENOTYPE	3	3	pharmacokinetics
NCT000020145	NCT00002014_5_T0	COMPOUND	4	4	acyclovir
NCT0000201412	NCT00002014_12_T0	PHENOTYPE	8	8	toxoplasmosis
NCT0000201412	NCT00002014_12_T1	PHENOTYPE	9	9	cryptococcosis
NCT0000201412	NCT00002014_12_T2	PHENOTYPE	5	6	opportunistic infections
NCT0000201412	NCT00002014_12_T3	ORGAN	2	4	Central Nervous System
NCT0000201413	NCT00002014_13_T0	PHENOTYPE	2	3	seizure disorders
NCT0000201414	NCT00002014_14_T0	PHENOTYPE	3	3	pancreatitis
NCT0000201415	NCT00002014_15_T0	PHENOTYPE	9	9	symptoms
NCT0000201415	NCT00002014_15_T1	PHENOTYPE	11	12	neurological disease
NCT0000201415	NCT00002014_15_T2	PHENOTYPE	2	3	peripheral neuropathy
NCT0000201416	NCT00002014_16_T0	ORGAN	8	8	extremities
NCT0000201416	NCT00002014_16_T1	PHENOTYPE	2	3	peripheral neuropathy
NCT0000201417	NCT00002014_17_T0	PHENOTYPE	2	2	hyperuricemia
NCT0000201417	NCT00002014_17_T1	PHENOTYPE	3	4	tophaceous gout
NCT0000201417	NCT00002014_17_T2	PHENOTYPE	5	6	urate nephropathy
NCT0000201418	NCT00002014_18_T0	PHENOTYPE	2	2	cardiomyopathy
NCT0000201424	NCT00002014_24_T0	PHENOTYPE	1	2	substance abuse
NCT000020151	NCT00002015_1_T0	COMPOUND	15	15	ganciclovir
NCT000020151	NCT00002015_1_T1	GENE	16	16	IV
NCT000020151	NCT00002015_1_T2	PHENOTYPE	5	5	tolerance
NCT000020151	NCT00002015_1_T3	PHENOTYPE	26	27	cytomegalovirus infections
NCT000020173	NCT00002017_3_T0	GENE	3	3	PEG
NCT000020173	NCT00002017_3_T1	GENE	1	1	IL-2
NCT000020173	NCT00002017_3_T2	PHENOTYPE	8	8	HIV
NCT000020175	NCT00002017_5_T0	GENE	18	18	half-life
NCT000020175	NCT00002017_5_T1	GENE	5	5	PEG
NCT000020175	NCT00002017_5_T2	GENE	22	22	PEG
NCT000020175	NCT00002017_5_T3	GENE	8	8	IL-2
NCT000020175	NCT00002017_5_T4	GENE	13	13	has
NCT000020178	NCT00002017_8_T0	GENE	18	18	half-life
NCT000020178	NCT00002017_8_T1	GENE	5	5	PEG
NCT000020178	NCT00002017_8_T2	GENE	22	22	PEG
NCT000020178	NCT00002017_8_T3	GENE	8	8	IL-2
NCT000020178	NCT00002017_8_T4	GENE	13	13	has
NCT0000201710	NCT00002017_10_T0	PHENOTYPE	11	11	toxicity
NCT0000201710	NCT00002017_10_T1	GENE	3	3	SC
NCT000020180	NCT00002018_0_T0	PHENOTYPE	17	17	HIV
NCT000020180	NCT00002018_0_T1	CELL	14	14	Leukocyte
NCT000020180	NCT00002018_0_T2	GENE	8	8	Low
NCT000020180	NCT00002018_0_T3	GENE	11	11	Interferon
NCT0000202011	NCT00002020_11_T0	PHENOTYPE	4	6	bone marrow suppression
NCT0000202013	NCT00002020_13_T0	PHENOTYPE	4	4	nephrotoxicity
NCT0000202013	NCT00002020_13_T1	PHENOTYPE	6	6	hepatotoxicity
NCT0000202025	NCT00002020_25_T0	PHENOTYPE	24	24	toxicity
NCT0000202026	NCT00002020_26_T0	BIOLOGICAL_PROCESS	8	8	metabolism
NCT000020211	NCT00002021_1_T0	COMPOUND	10	10	foscarnet
NCT000020211	NCT00002021_1_T1	GENE	8	8	IV
NCT000020211	NCT00002021_1_T2	PHENOTYPE	14	15	recurrent disease
NCT000020212	NCT00002021_2_T0	PHENOTYPE	3	3	pharmacokinetics
NCT000020212	NCT00002021_2_T1	GENE	9	9	IV
NCT000020215	NCT00002021_5_T0	PHENOTYPE	7	7	HSV
NCT000020215	NCT00002021_5_T1	COMPOUND	17	17	acyclovir
NCT000020215	NCT00002021_5_T2	COMPOUND	26	26	acyclovir
NCT000020215	NCT00002021_5_T3	COMPOUND	29	29	acyclovir
NCT000020215	NCT00002021_5_T4	COMPOUND	34	34	acyclovir
NCT000020215	NCT00002021_5_T5	PHENOTYPE	54	55	renal insufficiency
NCT000020215	NCT00002021_5_T6	PHENOTYPE	4	5	herpes simplex
NCT000020220	NCT00002022_0_T0	PHENOTYPE	3	3	Anemia
NCT000020230	NCT00002023_0_T0	GENE	14	14	III
NCT000020230	NCT00002023_0_T1	PHENOTYPE	8	9	HIV Disease
NCT000020233	NCT00002023_3_T0	PHENOTYPE	26	27	HIV disease
NCT000020234	NCT00002023_4_T0	PHENOTYPE	11	11	toxicity
NCT000020235	NCT00002023_5_T0	PHENOTYPE	17	17	toxicity
NCT000020235	NCT00002023_5_T1	GENE	3	3	has
NCT000020237	NCT00002023_7_T0	PHENOTYPE	9	9	toxicity
NCT000020237	NCT00002023_7_T1	PHENOTYPE	11	11	viremia
NCT000020237	NCT00002023_7_T2	PHENOTYPE	0	1	Drug levels
NCT000020262	NCT00002026_2_T0	GENE	9	9	HL
NCT000020262	NCT00002026_2_T1	PHENOTYPE	3	3	progression
NCT000020262	NCT00002026_2_T2	PHENOTYPE	5	6	HIV disease
NCT000020265	NCT00002026_5_T0	PHENOTYPE	3	3	Condition
NCT000020265	NCT00002026_5_T1	PHENOTYPE	13	13	allergy
NCT000020265	NCT00002026_5_T2	COMPOUND	15	15	acyclovir
NCT000020267	NCT00002026_7_T0	PHENOTYPE	9	9	allergy
NCT000020267	NCT00002026_7_T1	COMPOUND	11	11	acyclovir
NCT000020283	NCT00002028_3_T0	COMPOUND	3	3	zidovudine
NCT000020284	NCT00002028_4_T0	GENE	9	9	II
NCT000020284	NCT00002028_4_T1	COMPOUND	10	10	didanosine
NCT000020289	NCT00002028_9_T0	PHENOTYPE	9	10	intractable diarrhea
NCT0000202811	NCT00002028_11_T0	PHENOTYPE	25	25	peripheral
NCT0000202811	NCT00002028_11_T1	ORGAN	37	37	liver
NCT0000202811	NCT00002028_11_T2	PHENOTYPE	8	8	disorders
NCT0000202811	NCT00002028_11_T3	PHENOTYPE	32	32	gout
NCT0000202811	NCT00002028_11_T4	PHENOTYPE	26	26	neuropathy
NCT0000202811	NCT00002028_11_T5	PHENOTYPE	27	27	pancreatitis
NCT0000202811	NCT00002028_11_T6	PHENOTYPE	30	31	cardiac abnormalities
NCT0000202811	NCT00002028_11_T7	PHENOTYPE	28	29	seizure disorder
NCT000020290	NCT00002029_0_T0	GENE	18	18	II
NCT000020290	NCT00002029_0_T1	GENE	13	13	III
NCT000020290	NCT00002029_0_T2	PHENOTYPE	7	9	Acquired Immunodeficiency Syndrome
NCT000020293	NCT00002029_3_T0	GENE	7	7	p24
NCT000020293	NCT00002029_3_T1	PHENOTYPE	2	2	HIV
NCT000020294	NCT00002029_4_T0	PHENOTYPE	3	3	HIV
NCT0000202911	NCT00002029_11_T0	PHENOTYPE	2	3	drug abuse
NCT000020300	NCT00002030_0_T0	PHENOTYPE	18	20	Pneumocystis Carinii Pneumonia
NCT0000203012	NCT00002030_12_T0	PHENOTYPE	1	2	substance abuse
NCT000020321	NCT00002032_1_T0	GENE	5	5	MAC
NCT000020322	NCT00002032_2_T0	PHENOTYPE	1	1	secondary
NCT000020322	NCT00002032_2_T1	PHENOTYPE	8	10	quality of life
NCT000020342	NCT00002034_2_T0	COMPOUND	13	13	zidovudine
NCT000020342	NCT00002034_2_T1	PHENOTYPE	5	5	tolerance
NCT000020370	NCT00002037_0_T0	PHENOTYPE	16	16	Infection
NCT000020370	NCT00002037_0_T1	GENE	15	15	MAI
NCT000020372	NCT00002037_2_T0	GENE	11	11	SC
NCT000020372	NCT00002037_2_T1	GENE	5	6	gamma interferon
NCT000020382	NCT00002038_2_T0	COMPOUND	16	16	fluconazole
NCT000020382	NCT00002038_2_T1	GENE	9	9	had
NCT000020382	NCT00002038_2_T2	GENE	7	7	has
NCT000020382	NCT00002038_2_T3	PHENOTYPE	12	13	adverse effect
NCT000020392	NCT00002039_2_T0	COMPOUND	9	9	foscarnet
NCT000020393	NCT00002039_3_T0	COMPOUND	15	15	zidovudine
NCT000020393	NCT00002039_3_T1	PHENOTYPE	3	3	pharmacokinetics
NCT000020393	NCT00002039_3_T2	COMPOUND	8	8	foscarnet
NCT000020402	NCT00002040_2_T0	COMPOUND	4	4	fluconazole
NCT000020404	NCT00002040_4_T0	PHENOTYPE	2	4	Pneumocystis carinii pneumonia
NCT000020405	NCT00002040_5_T0	COMPOUND	1	1	pentamidine
NCT000020408	NCT00002040_8_T0	GENE	11	11	CSF
NCT000020409	NCT00002040_9_T0	COMPOUND	13	14	amphotericin B
NCT0000204011	NCT00002040_11_T0	PHENOTYPE	2	4	Pneumocystis carinii pneumonia
NCT0000204012	NCT00002040_12_T0	COMPOUND	1	1	pentamidine
NCT000020411	NCT00002041_1_T0	PHENOTYPE	15	16	Candida esophagitis
NCT000020411	NCT00002041_1_T1	COMPOUND	7	8	amphotericin B
NCT000020412	NCT00002041_2_T0	PHENOTYPE	8	8	toxic
NCT000020412	NCT00002041_2_T1	COMPOUND	4	5	amphotericin B
NCT000020413	NCT00002041_3_T0	PHENOTYPE	4	4	pharmacodynamic
NCT000020431	NCT00002043_1_T0	COMPOUND	9	9	dapsone
NCT000020431	NCT00002043_1_T1	PHENOTYPE	5	5	toxicities
NCT000020443	NCT00002044_3_T0	ORGAN	14	15	nervous system
NCT000020443	NCT00002044_3_T1	PHENOTYPE	5	6	HIV infection
NCT000020450	NCT00002045_0_T0	PHENOTYPE	8	9	HIV Infection
NCT000020452	NCT00002045_2_T0	PHENOTYPE	11	12	HIV disease
NCT000020454	NCT00002045_4_T0	GENE	7	7	ACTG
NCT0000204510	NCT00002045_10_T0	PHENOTYPE	9	9	malignancies
NCT0000204510	NCT00002045_10_T1	PHENOTYPE	7	7	lymphomas
NCT0000204510	NCT00002045_10_T2	PHENOTYPE	5	6	opportunistic infections
NCT000020461	NCT00002046_1_T0	PHENOTYPE	5	5	tolerance
NCT000020465	NCT00002046_5_T0	PHENOTYPE	2	2	HIV
NCT0000204610	NCT00002046_10_T0	ORGAN	8	8	Plasma
NCT0000204610	NCT00002046_10_T1	GENE	10	10	RPR
NCT0000204610	NCT00002046_10_T2	PHENOTYPE	27	27	syphilis
NCT0000204610	NCT00002046_10_T3	PHENOTYPE	1	2	Venereal Disease
NCT0000204617	NCT00002046_17_T0	PHENOTYPE	3	4	alcohol abuse
NCT000020472	NCT00002047_2_T0	PHENOTYPE	7	7	ESRD
NCT000020476	NCT00002047_6_T0	PHENOTYPE	4	6	bone marrow suppression
NCT000020479	NCT00002047_9_T0	PHENOTYPE	4	4	hepatotoxicity
NCT000020480	NCT00002048_0_T0	GENE	16	16	II
NCT000020480	NCT00002048_0_T1	PHENOTYPE	10	10	HIV
NCT000020480	NCT00002048_0_T2	GENE	24	24	III
NCT000020480	NCT00002048_0_T3	PHENOTYPE	20	21	Generalized Lymphadenopathy
NCT000020482	NCT00002048_2_T0	PHENOTYPE	11	12	HIV disease
NCT0000204811	NCT00002048_11_T0	PHENOTYPE	3	4	alcohol abuse
NCT000020491	NCT00002049_1_T0	PHENOTYPE	19	19	HIV
NCT000020491	NCT00002049_1_T1	PHENOTYPE	13	14	clinical findings
NCT000020491	NCT00002049_1_T2	ORGAN	8	9	immune system
NCT000020494	NCT00002049_4_T0	PHENOTYPE	13	13	peripheral
NCT000020494	NCT00002049_4_T1	CELL	15	15	monocytes
NCT000020494	NCT00002049_4_T2	GENE	1	1	p24
NCT000020501	NCT00002050_1_T0	PHENOTYPE	19	19	HIV
NCT000020501	NCT00002050_1_T1	PHENOTYPE	13	14	clinical findings
NCT000020501	NCT00002050_1_T2	ORGAN	8	9	immune system
NCT000020511	NCT00002051_1_T0	PHENOTYPE	13	13	HIV
NCT000020511	NCT00002051_1_T1	PHENOTYPE	7	8	clinical findings
NCT000020511	NCT00002051_1_T2	ORGAN	2	3	immune system
NCT0000205311	NCT00002053_11_T0	PHENOTYPE	3	3	tuberculosis
NCT0000205313	NCT00002053_13_T0	PHENOTYPE	1	2	substance abuse
NCT000020540	NCT00002054_0_T0	PHENOTYPE	23	25	Pneumocystis Carinii Pneumonia
NCT000020559	NCT00002055_9_T0	PHENOTYPE	1	2	substance abuse
NCT000020580	NCT00002058_0_T0	PHENOTYPE	14	15	HIV Disease
NCT000020580	NCT00002058_0_T1	PHENOTYPE	9	11	Mycobacterium Avium Complex
NCT000020584	NCT00002058_4_T0	PHENOTYPE	11	12	opportunistic infections
NCT000020585	NCT00002058_5_T0	COMPOUND	9	9	clofazimine
NCT000020585	NCT00002058_5_T1	PHENOTYPE	2	2	hopes
NCT000020585	NCT00002058_5_T2	PHENOTYPE	15	17	Mycobacterium avium complex
NCT000020616	NCT00002061_6_T0	GENE	0	0	IV
NCT000020616	NCT00002061_6_T1	PHENOTYPE	1	2	drug abuse
NCT000020623	NCT00002062_3_T0	COMPOUND	10	10	spiramycin
NCT000020627	NCT00002062_7_T0	COMPOUND	10	10	spiramycin
NCT000020630	NCT00002063_0_T0	PHENOTYPE	4	6	AIDS Related Complex
NCT000020634	NCT00002063_4_T0	GENE	17	17	CD4
NCT000020634	NCT00002063_4_T1	CELL	18	18	lymphocyte
NCT000020635	NCT00002063_5_T0	PHENOTYPE	14	14	HIV
NCT000020636	NCT00002063_6_T0	PHENOTYPE	0	0	Secondary
NCT000020636	NCT00002063_6_T1	PHENOTYPE	15	15	HIV
NCT000020636	NCT00002063_6_T2	CELL	19	19	lymphocyte
NCT000020636	NCT00002063_6_T3	PHENOTYPE	12	13	immune status
NCT000020637	NCT00002063_7_T0	PHENOTYPE	4	4	toxicities
NCT000020637	NCT00002063_7_T1	GENE	15	15	BL
NCT000020637	NCT00002063_7_T2	ORGAN	24	26	central nervous system
NCT000020640	NCT00002064_0_T0	PHENOTYPE	1	1	Encephalitis
NCT000020643	NCT00002064_3_T0	PHENOTYPE	3	4	opportunistic infections
NCT000020643	NCT00002064_3_T1	PHENOTYPE	6	7	brain diseases
NCT000020653	NCT00002065_3_T0	PHENOTYPE	7	8	organic disease
NCT000020654	NCT00002065_4_T0	PHENOTYPE	7	8	organic disease
NCT000020661	NCT00002066_1_T0	PHENOTYPE	13	13	HIV
NCT000020661	NCT00002066_1_T1	PHENOTYPE	7	8	clinical findings
NCT000020661	NCT00002066_1_T2	ORGAN	2	3	immune system
NCT000020664	NCT00002066_4_T0	PHENOTYPE	3	3	Condition
NCT000020671	NCT00002067_1_T0	PHENOTYPE	17	17	cachexia
NCT000020671	NCT00002067_1_T1	COMPOUND	3	4	megestrol acetate
NCT000020672	NCT00002067_2_T0	CELL	16	16	lymphocytes
NCT000020672	NCT00002067_2_T1	COMPOUND	2	2	megestrol
NCT000020684	NCT00002068_4_T0	COMPOUND	13	14	amphotericin B
NCT000020702	NCT00002070_2_T0	GENE	50	50	T4
NCT000020702	NCT00002070_2_T1	CELL	51	51	lymphocytes
NCT000020702	NCT00002070_2_T2	PHENOTYPE	20	20	progression
NCT000020702	NCT00002070_2_T3	COMPOUND	6	6	ganciclovir
NCT000020702	NCT00002070_2_T4	COMPOUND	30	30	ganciclovir
NCT000020702	NCT00002070_2_T5	COMPOUND	58	58	ganciclovir
NCT000020702	NCT00002070_2_T6	GENE	32	32	GM-CSF
NCT000020702	NCT00002070_2_T7	GENE	62	62	GM-CSF
NCT000020702	NCT00002070_2_T8	GENE	42	42	p24
NCT000020702	NCT00002070_2_T9	PHENOTYPE	22	22	retinitis
NCT000020702	NCT00002070_2_T10	PHENOTYPE	41	41	HIV
NCT000020702	NCT00002070_2_T11	ORGAN	46	46	serum
NCT000020702	NCT00002070_2_T12	PHENOTYPE	4	4	tolerance
NCT000020710	NCT00002071_0_T0	PHENOTYPE	19	19	Anemia
NCT000020720	NCT00002072_0_T0	PHENOTYPE	19	19	Anemia
NCT000020730	NCT00002073_0_T0	PHENOTYPE	22	22	Anemia
NCT000020732	NCT00002073_2_T0	PHENOTYPE	7	7	anemia
NCT000020744	NCT00002074_4_T0	COMPOUND	4	5	amphotericin B
NCT000020754	NCT00002075_4_T0	COMPOUND	13	14	amphotericin B
NCT000020765	NCT00002076_5_T0	COMPOUND	13	14	amphotericin B
NCT000020776	NCT00002077_6_T0	GENE	11	11	CSF
NCT000020777	NCT00002077_7_T0	COMPOUND	13	14	amphotericin B
NCT000020780	NCT00002078_0_T0	PHENOTYPE	15	15	Infection
NCT000020780	NCT00002078_0_T1	PHENOTYPE	14	14	HIV
NCT000020780	NCT00002078_0_T2	PHENOTYPE	12	12	Immunodeficiency
NCT000020780	NCT00002078_0_T3	COMPOUND	5	5	N
NCT000020805	NCT00002080_5_T0	COMPOUND	10	10	rifabutin
NCT000020807	NCT00002080_7_T0	GENE	13	13	MAC
NCT0000208013	NCT00002080_13_T0	PHENOTYPE	31	31	tuberculosis
NCT0000208013	NCT00002080_13_T1	GENE	22	22	MAC
NCT0000208013	NCT00002080_13_T2	PHENOTYPE	25	26	mycobacterial disease
NCT000020810	NCT00002081_0_T0	PHENOTYPE	21	22	HIV Disease
NCT000020812	NCT00002081_2_T0	PHENOTYPE	3	3	toxicities
NCT000020837	NCT00002083_7_T0	PHENOTYPE	0	2	Chronic alcohol abuse
NCT000020855	NCT00002085_5_T0	COMPOUND	11	11	azithromycin
NCT000020855	NCT00002085_5_T1	GENE	22	22	has
NCT000020856	NCT00002085_6_T0	COMPOUND	5	5	azithromycin
NCT000020860	NCT00002086_0_T0	GENE	28	28	Interferon
NCT000020860	NCT00002086_0_T1	PHENOTYPE	35	36	HIV Infection
NCT000020862	NCT00002086_2_T0	PHENOTYPE	21	21	centers
NCT000020864	NCT00002086_4_T0	PHENOTYPE	8	8	secondary
NCT000020864	NCT00002086_4_T1	GENE	30	30	p24
NCT000020864	NCT00002086_4_T2	ORGAN	29	29	serum
NCT000020864	NCT00002086_4_T3	PHENOTYPE	19	20	secondary infections
NCT000020865	NCT00002086_5_T0	PHENOTYPE	5	5	tolerance
NCT000020870	NCT00002087_0_T0	PHENOTYPE	1	1	Tolerance
NCT000020870	NCT00002087_0_T1	PHENOTYPE	4	4	Pharmacokinetics
NCT000020872	NCT00002087_2_T0	COMPOUND	32	32	neopterin
NCT000020872	NCT00002087_2_T1	GENE	24	24	CD4
NCT000020872	NCT00002087_2_T2	GENE	26	26	p24
NCT000020872	NCT00002087_2_T3	CELL	25	25	cells
NCT000020872	NCT00002087_2_T4	PHENOTYPE	14	14	HIV
NCT000020872	NCT00002087_2_T5	PHENOTYPE	18	18	HIV
NCT000020872	NCT00002087_2_T6	ORGAN	13	13	plasma
NCT000020872	NCT00002087_2_T7	ORGAN	28	28	serum
NCT000020872	NCT00002087_2_T8	GENE	29	30	beta-2 microglobulin
NCT000020872	NCT00002087_2_T9	CELL	10	12	T lymphocyte subsets
NCT000020877	NCT00002087_7_T0	PHENOTYPE	1	2	substance abuse
NCT000020880	NCT00002088_0_T0	PHENOTYPE	5	5	Immunodeficiency
NCT000020880	NCT00002088_0_T1	PHENOTYPE	8	9	Chronic Diarrhea
NCT000020884	NCT00002088_4_T0	PHENOTYPE	7	8	HIV infection
NCT000020912	NCT00002091_2_T0	GENE	7	7	CD4
NCT000020912	NCT00002091_2_T1	PHENOTYPE	22	22	HIV
NCT000020912	NCT00002091_2_T2	COMPOUND	20	20	pentoxifylline
NCT000020912	NCT00002091_2_T3	ORGAN	10	10	serum
NCT000020914	NCT00002091_4_T0	PHENOTYPE	3	3	HIV
NCT000020920	NCT00002092_0_T0	GENE	9	9	CD4
NCT000020920	NCT00002092_0_T1	CELL	10	10	Lymphocyte
NCT000020920	NCT00002092_0_T2	PHENOTYPE	13	14	HIV Infection
NCT000020922	NCT00002092_2_T0	GENE	15	15	CD4
NCT000020922	NCT00002092_2_T1	COMPOUND	20	20	cimetidine
NCT000020923	NCT00002092_3_T0	COMPOUND	6	6	cimetidine
NCT000020925	NCT00002092_5_T0	PHENOTYPE	3	3	HIV
NCT000020930	NCT00002093_0_T0	GENE	3	3	III
NCT000020930	NCT00002093_0_T1	PHENOTYPE	19	20	Kaposi's Sarcoma
NCT000020931	NCT00002093_1_T0	PHENOTYPE	1	1	Sarcoma
NCT000020941	NCT00002094_1_T0	PHENOTYPE	6	6	HIV
NCT000020941	NCT00002094_1_T1	GENE	7	8	reverse transcriptase
NCT000020943	NCT00002094_3_T0	PHENOTYPE	8	8	HIV
NCT000020943	NCT00002094_3_T1	PHENOTYPE	19	19	mutants
NCT000020943	NCT00002094_3_T2	PHENOTYPE	18	18	resistant
NCT000020947	NCT00002094_7_T0	PHENOTYPE	27	27	dysfunction
NCT000020947	NCT00002094_7_T1	PHENOTYPE	24	24	dementia
NCT000020947	NCT00002094_7_T2	PHENOTYPE	21	21	seizures
NCT000020947	NCT00002094_7_T3	PHENOTYPE	12	13	cardiovascular disease
NCT000020947	NCT00002094_7_T4	PHENOTYPE	22	23	peripheral neuropathy
NCT000020947	NCT00002094_7_T5	ORGAN	15	16	nervous system
NCT000020961	NCT00002096_1_T0	COMPOUND	6	6	probenecid
NCT000020961	NCT00002096_1_T1	PHENOTYPE	9	9	pharmacokinetics
NCT000020961	NCT00002096_1_T2	PHENOTYPE	7	7	affects
NCT000020961	NCT00002096_1_T3	COMPOUND	12	12	ganciclovir
NCT000020962	NCT00002096_2_T0	COMPOUND	16	16	probenecid
NCT000020962	NCT00002096_2_T1	COMPOUND	9	9	ganciclovir
NCT000020971	NCT00002097_1_T0	PHENOTYPE	4	5	HIV Infection
NCT000020972	NCT00002097_2_T0	PHENOTYPE	1	1	Infection
NCT000020974	NCT00002097_4_T0	PHENOTYPE	4	4	HIV
NCT000020974	NCT00002097_4_T1	COMPOUND	11	11	nystatin
NCT000020976	NCT00002097_6_T0	PHENOTYPE	5	5	toxicity
NCT0000209715	NCT00002097_15_T0	PHENOTYPE	3	4	alcohol abuse
NCT000020981	NCT00002098_1_T0	GENE	43	43	p24
NCT000020981	NCT00002098_1_T1	COMPOUND	6	6	lentinan
NCT000020981	NCT00002098_1_T2	CELL	37	37	T-cell
NCT000020981	NCT00002098_1_T3	CELL	33	33	neutrophil
NCT0000209810	NCT00002098_10_T0	PHENOTYPE	1	2	drug abuse
NCT000020991	NCT00002099_1_T0	GENE	43	43	p24
NCT000020991	NCT00002099_1_T1	COMPOUND	6	6	lentinan
NCT000020991	NCT00002099_1_T2	CELL	37	37	T-cell
NCT000020991	NCT00002099_1_T3	CELL	33	33	neutrophil
NCT0000209912	NCT00002099_12_T0	GENE	1	1	IV
NCT0000209912	NCT00002099_12_T1	PHENOTYPE	2	3	drug abuse
NCT000021002	NCT00002100_2_T0	GENE	2	2	II
NCT000021002	NCT00002100_2_T1	COMPOUND	4	4	sulfate
NCT000021006	NCT00002100_6_T0	COMPOUND	10	10	heparin
NCT000021009	NCT00002100_9_T0	GENE	1	1	IV
NCT000021009	NCT00002100_9_T1	PHENOTYPE	2	3	drug abuse
NCT000021020	NCT00002102_0_T0	PHENOTYPE	16	18	Pneumocystis Carinii Pneumonia
NCT000021021	NCT00002102_1_T0	PHENOTYPE	1	1	Pneumonia
NCT000021024	NCT00002102_4_T0	COMPOUND	10	11	trimetrexate glucuronate
NCT000021028	NCT00002102_8_T0	COMPOUND	4	4	trimetrexate
NCT000021030	NCT00002103_0_T0	PHENOTYPE	23	25	Pneumocystis Carinii Pneumonia
NCT000021033	NCT00002103_3_T0	COMPOUND	10	11	trimetrexate glucuronate
NCT000021041	NCT00002104_1_T0	PHENOTYPE	13	13	tuberculosis
NCT000021041	NCT00002104_1_T1	PHENOTYPE	11	11	fever
NCT000021044	NCT00002104_4_T0	PHENOTYPE	5	5	HIV
NCT000021044	NCT00002104_4_T1	PHENOTYPE	10	11	HIV infection
NCT000021051	NCT00002105_1_T0	GENE	21	21	KS
NCT000021051	NCT00002105_1_T1	PHENOTYPE	5	5	tolerance
NCT000021054	NCT00002105_4_T0	PHENOTYPE	0	1	Kaposi's sarcoma
NCT000021056	NCT00002105_6_T0	GENE	9	9	KS
NCT000021060	NCT00002106_0_T0	GENE	25	25	CD4
NCT000021071	NCT00002107_1_T0	GENE	18	18	IL-2
NCT000021071	NCT00002107_1_T1	GENE	23	23	IL-2
NCT000021086	NCT00002108_6_T0	ORGAN	4	4	serum
NCT000021100	NCT00002110_0_T0	PHENOTYPE	13	14	HIV Disease
NCT000021102	NCT00002110_2_T0	PHENOTYPE	3	3	pharmacokinetics
NCT000021104	NCT00002110_4_T0	COMPOUND	4	4	cysteamine
NCT0000211012	NCT00002110_12_T0	PHENOTYPE	25	25	toxicity
NCT0000211012	NCT00002110_12_T1	PHENOTYPE	31	31	toxicity
NCT0000211012	NCT00002110_12_T2	PHENOTYPE	22	22	recurrent
NCT000021110	NCT00002111_0_T0	PHENOTYPE	7	7	HIV
NCT000021110	NCT00002111_0_T1	GENE	8	8	Protease
NCT000021110	NCT00002111_0_T2	PHENOTYPE	14	15	HIV Disease
NCT000021111	NCT00002111_1_T0	PHENOTYPE	0	1	HIV Disease
NCT000021114	NCT00002111_4_T0	GENE	21	21	has
NCT000021122	NCT00002112_2_T0	COMPOUND	12	12	nystatin
NCT000021128	NCT00002112_8_T0	COMPOUND	23	23	nystatin
NCT000021128	NCT00002112_8_T1	PHENOTYPE	13	13	allergy
NCT000021130	NCT00002113_0_T0	PHENOTYPE	14	14	Acute
NCT000021130	NCT00002113_0_T1	PHENOTYPE	15	16	Cryptococcal Meningitis
NCT000021133	NCT00002113_3_T0	COMPOUND	2	2	flucytosine
NCT000021137	NCT00002113_7_T0	COMPOUND	15	15	flucytosine
NCT000021137	NCT00002113_7_T1	COMPOUND	9	9	fluconazole
NCT000021137	NCT00002113_7_T2	COMPOUND	21	21	fluconazole
NCT0000211310	NCT00002113_10_T0	GENE	7	7	CSF
NCT0000211310	NCT00002113_10_T1	PHENOTYPE	9	10	culture negative
NCT0000211317	NCT00002113_17_T0	COMPOUND	18	18	flucytosine
NCT0000211317	NCT00002113_17_T1	PHENOTYPE	10	10	allergy
NCT000021144	NCT00002114_4_T0	GENE	0	1	Group 1
NCT0000211414	NCT00002114_14_T0	BIOLOGICAL_PROCESS	1	1	Behavior
NCT0000211414	NCT00002114_14_T1	PHENOTYPE	4	7	alcohol or drug abuse
NCT000021150	NCT00002115_0_T0	PHENOTYPE	7	7	Tolerance
NCT000021150	NCT00002115_0_T1	PHENOTYPE	9	9	Pharmacokinetics
NCT000021150	NCT00002115_0_T2	PHENOTYPE	20	21	HIV Disease
NCT000021151	NCT00002115_1_T0	PHENOTYPE	0	1	HIV Disease
NCT0000211512	NCT00002115_12_T0	PHENOTYPE	0	1	Substance abuse
NCT000021162	NCT00002116_2_T0	PHENOTYPE	12	13	virus shedding
NCT000021162	NCT00002116_2_T1	PHENOTYPE	10	11	herpes simplex
NCT000021167	NCT00002116_7_T0	PHENOTYPE	8	8	symptoms
NCT000021167	NCT00002116_7_T1	PHENOTYPE	3	3	Condition
NCT000021170	NCT00002117_0_T0	PHENOTYPE	18	19	HIV Infection
NCT000021190	NCT00002119_0_T0	COMPOUND	11	11	TCDO
NCT000021190	NCT00002119_0_T1	GENE	8	8	IV
NCT000021190	NCT00002119_0_T2	PHENOTYPE	16	17	HIV Infection
NCT000021192	NCT00002119_2_T0	PHENOTYPE	4	4	HIV
NCT000021192	NCT00002119_2_T1	COMPOUND	7	7	TCDO
NCT000021197	NCT00002119_7_T0	PHENOTYPE	13	13	arrhythmias
NCT000021197	NCT00002119_7_T1	PHENOTYPE	10	11	myocardial infarction
NCT000021211	NCT00002121_1_T0	COMPOUND	1	1	DEHSPM
NCT000021211	NCT00002121_1_T1	PHENOTYPE	12	13	AIDS diarrhea
NCT000021221	NCT00002122_1_T0	COMPOUND	8	8	fluconazole
NCT000021221	NCT00002122_1_T1	PHENOTYPE	14	15	fungal infections
NCT000021222	NCT00002122_2_T0	PHENOTYPE	12	12	toxoplasmosis
NCT000021222	NCT00002122_2_T1	PHENOTYPE	9	9	infections
NCT000021222	NCT00002122_2_T2	COMPOUND	14	14	azithromycin
NCT000021222	NCT00002122_2_T3	COMPOUND	16	16	azithromycin
NCT000021222	NCT00002122_2_T4	PHENOTYPE	10	10	cryptosporidiosis
NCT000021223	NCT00002122_3_T0	COMPOUND	16	16	fluconazole
NCT000021223	NCT00002122_3_T1	PHENOTYPE	7	8	vaginal candidiasis
NCT000021226	NCT00002122_6_T0	COMPOUND	13	13	fluconazole
NCT000021226	NCT00002122_6_T1	COMPOUND	22	22	fluconazole
NCT0000212310	NCT00002123_10_T0	PHENOTYPE	1	2	substance abuse
NCT000021241	NCT00002124_1_T0	GENE	1	1	II
NCT000021241	NCT00002124_1_T1	PHENOTYPE	9	9	pharmacokinetics
NCT000021241	NCT00002124_1_T2	PHENOTYPE	6	6	tolerance
NCT0000212419	NCT00002124_19_T0	PHENOTYPE	1	2	substance abuse
NCT000021251	NCT00002125_1_T0	BIOLOGICAL_PROCESS	14	14	diuresis
NCT000021252	NCT00002125_2_T0	PHENOTYPE	4	4	tolerance
NCT000021252	NCT00002125_2_T1	PHENOTYPE	11	12	adverse event
NCT000021260	NCT00002126_0_T0	CELL	9	9	Granulocyte
NCT000021260	NCT00002126_0_T1	GENE	13	13	G-CSF
NCT000021260	NCT00002126_0_T2	PHENOTYPE	20	20	Neutropenia
NCT000021260	NCT00002126_0_T3	PHENOTYPE	24	25	HIV Infection
NCT000021261	NCT00002126_1_T0	PHENOTYPE	1	1	Infection
NCT000021265	NCT00002126_5_T0	GENE	6	6	G-CSF
NCT0000212612	NCT00002126_12_T0	PHENOTYPE	0	1	Substance abuse
NCT000021272	NCT00002127_2_T0	COMPOUND	17	17	thalidomide
NCT0000212713	NCT00002127_13_T0	PHENOTYPE	1	2	drug abuse
NCT000021307	NCT00002130_7_T0	COMPOUND	11	11	vesnarinone
NCT0000213114	NCT00002131_14_T0	COMPOUND	8	8	heroin
NCT0000213114	NCT00002131_14_T1	COMPOUND	5	5	cocaine
NCT0000213114	NCT00002131_14_T2	PHENOTYPE	2	3	drug abuse
NCT0000213114	NCT00002131_14_T3	COMPOUND	6	7	amyl nitrate
NCT000021320	NCT00002132_0_T0	PHENOTYPE	15	16	Esophageal Candidiasis
NCT000021330	NCT00002133_0_T0	PHENOTYPE	16	17	Oropharyngeal Candidiasis
NCT000021335	NCT00002133_5_T0	PHENOTYPE	2	2	relapse
NCT000021341	NCT00002134_1_T0	PHENOTYPE	7	7	progression
NCT000021341	NCT00002134_1_T1	COMPOUND	19	19	ganciclovir
NCT000021341	NCT00002134_1_T2	COMPOUND	25	25	ganciclovir
NCT000021341	NCT00002134_1_T3	COMPOUND	30	30	ganciclovir
NCT000021341	NCT00002134_1_T4	GENE	29	29	IV
NCT000021341	NCT00002134_1_T5	PHENOTYPE	4	4	tolerance
NCT000021341	NCT00002134_1_T6	PHENOTYPE	8	10	quality of life
NCT000021363	NCT00002136_3_T0	GENE	1	1	punch
NCT000021363	NCT00002136_3_T1	PHENOTYPE	9	10	Kaposi's sarcoma
NCT000021373	NCT00002137_3_T0	GENE	1	1	punch
NCT000021373	NCT00002137_3_T1	PHENOTYPE	9	10	Kaposi's sarcoma
NCT000021380	NCT00002138_0_T0	COMPOUND	6	6	Sodium
NCT000021384	NCT00002138_4_T0	GENE	1	1	punch
NCT000021384	NCT00002138_4_T1	PHENOTYPE	9	10	Kaposi's sarcoma
NCT000021390	NCT00002139_0_T0	GENE	10	10	Buffy
NCT000021390	NCT00002139_0_T1	GENE	15	15	ed
NCT000021400	NCT00002140_0_T0	GENE	21	21	MAC
NCT000021400	NCT00002140_0_T1	PHENOTYPE	18	20	Mycobacterium Avium Complex
NCT000021411	NCT00002141_1_T0	PHENOTYPE	3	3	pharmacokinetics
NCT000021417	NCT00002141_7_T0	PHENOTYPE	11	11	pharmacokinetics
NCT0000214111	NCT00002141_11_T0	PHENOTYPE	22	22	concentrations
NCT0000214111	NCT00002141_11_T1	ORGAN	19	19	plasma
NCT0000214111	NCT00002141_11_T2	PHENOTYPE	31	32	adverse events
NCT0000214116	NCT00002141_16_T0	PHENOTYPE	4	4	symptoms
NCT0000214116	NCT00002141_16_T1	PHENOTYPE	12	12	pancreatitis
NCT0000214116	NCT00002141_16_T2	PHENOTYPE	14	14	cardiomyopathy
NCT0000214116	NCT00002141_16_T3	PHENOTYPE	11	11	hepatitis
NCT0000214117	NCT00002141_17_T0	BIOLOGICAL_PROCESS	1	1	Behavior
NCT0000214117	NCT00002141_17_T1	PHENOTYPE	7	8	drug use
NCT000021421	NCT00002142_1_T0	PHENOTYPE	5	5	retinitis
NCT000021421	NCT00002142_1_T1	PHENOTYPE	6	6	progression
NCT000021422	NCT00002142_2_T0	COMPOUND	5	5	cidofovir
NCT000021425	NCT00002142_5_T0	COMPOUND	4	4	probenecid
NCT000021426	NCT00002142_6_T0	PHENOTYPE	12	12	toxicity
NCT000021426	NCT00002142_6_T1	PHENOTYPE	3	3	retinitis
NCT000021426	NCT00002142_6_T2	PHENOTYPE	4	4	progression
NCT000021432	NCT00002143_2_T0	GENE	9	9	half-life
NCT000021432	NCT00002143_2_T1	GENE	5	5	has
NCT000021432	NCT00002143_2_T2	COMPOUND	4	4	etretinate
NCT000021435	NCT00002143_5_T0	GENE	9	9	half-life
NCT000021435	NCT00002143_5_T1	GENE	5	5	has
NCT000021435	NCT00002143_5_T2	COMPOUND	4	4	etretinate
NCT000021437	NCT00002143_7_T0	COMPOUND	2	2	acitretin
NCT000021437	NCT00002143_7_T1	PHENOTYPE	19	19	Psoriasis
NCT000021437	NCT00002143_7_T2	PHENOTYPE	22	22	Severity
NCT000021441	NCT00002144_1_T0	COMPOUND	10	10	foscarnet
NCT000021442	NCT00002144_2_T0	COMPOUND	11	11	foscarnet
NCT000021442	NCT00002144_2_T1	PHENOTYPE	4	4	tolerance
NCT000021444	NCT00002144_4_T0	COMPOUND	8	8	foscarnet
NCT000021454	NCT00002145_4_T0	PHENOTYPE	9	9	relapse
NCT000021460	NCT00002146_0_T0	GENE	22	22	IV
NCT000021460	NCT00002146_0_T1	PHENOTYPE	11	11	Symptoms
NCT000021462	NCT00002146_2_T0	COMPOUND	22	22	sulfate
NCT000021462	NCT00002146_2_T1	COMPOUND	8	8	calcium
NCT000021462	NCT00002146_2_T2	COMPOUND	6	6	magnesium
NCT000021462	NCT00002146_2_T3	COMPOUND	21	21	magnesium
NCT000021462	NCT00002146_2_T4	COMPOUND	14	14	foscarnet
NCT000021462	NCT00002146_2_T5	GENE	10	11	parathyroid hormone
NCT000021462	NCT00002146_2_T6	PHENOTYPE	11	12	hormone levels
NCT000021466	NCT00002146_6_T0	COMPOUND	1	1	foscarnet
NCT000021467	NCT00002146_7_T0	COMPOUND	8	8	sulfate
NCT000021467	NCT00002146_7_T1	COMPOUND	7	7	magnesium
NCT000021470	NCT00002147_0_T0	COMPOUND	5	5	HCl
NCT000021470	NCT00002147_0_T1	PHENOTYPE	16	18	AIDS-Related Kaposi's Sarcoma
NCT000021471	NCT00002147_1_T0	PHENOTYPE	1	1	Sarcoma
NCT000021473	NCT00002147_3_T0	PHENOTYPE	12	13	Kaposi's sarcoma
NCT000021479	NCT00002147_9_T0	PHENOTYPE	12	13	allergic reaction
NCT000021480	NCT00002148_0_T0	PHENOTYPE	11	12	HIV Dementia
NCT000021482	NCT00002148_2_T0	PHENOTYPE	6	7	cognitive function
NCT000021482	NCT00002148_2_T1	PHENOTYPE	8	10	quality of life
NCT000021489	NCT00002148_9_T0	PHENOTYPE	0	0	Alcoholism
NCT000021490	NCT00002149_0_T0	PHENOTYPE	5	5	Chronic
NCT000021490	NCT00002149_0_T1	PHENOTYPE	6	6	HIV
NCT000021490	NCT00002149_0_T2	PHENOTYPE	7	7	Sinusitis
NCT000021501	NCT00002150_1_T0	PHENOTYPE	9	9	pharmacodynamics
NCT000021501	NCT00002150_1_T1	PHENOTYPE	7	7	pharmacokinetics
NCT000021504	NCT00002150_4_T0	PHENOTYPE	3	3	Condition
NCT000021511	NCT00002151_1_T0	PHENOTYPE	9	9	pharmacodynamics
NCT000021511	NCT00002151_1_T1	PHENOTYPE	7	7	pharmacokinetics
NCT000021514	NCT00002151_4_T0	PHENOTYPE	3	3	Condition
NCT000021520	NCT00002152_0_T0	GENE	5	5	IV
NCT000021520	NCT00002152_0_T1	PHENOTYPE	11	12	HIV Disease
NCT000021522	NCT00002152_2_T0	PHENOTYPE	10	10	HIV
NCT000021522	NCT00002152_2_T1	PHENOTYPE	6	6	affects
NCT000021522	NCT00002152_2_T2	COMPOUND	5	5	TCDO
NCT000021528	NCT00002152_8_T0	PHENOTYPE	13	13	arrhythmias
NCT000021528	NCT00002152_8_T1	PHENOTYPE	10	11	myocardial infarction
NCT000021550	NCT00002155_0_T0	GENE	12	12	CD4
NCT000021563	NCT00002156_3_T0	COMPOUND	35	35	ganciclovir
NCT000021563	NCT00002156_3_T1	COMPOUND	45	45	ganciclovir
NCT000021571	NCT00002157_1_T0	PHENOTYPE	14	14	wasting
NCT000021571	NCT00002157_1_T1	PHENOTYPE	13	13	HIV
NCT000021577	NCT00002157_7_T0	PHENOTYPE	4	4	wasting
NCT000021577	NCT00002157_7_T1	PHENOTYPE	3	3	HIV
NCT000021583	NCT00002158_3_T0	PHENOTYPE	17	17	relapse
NCT000021592	NCT00002159_2_T0	COMPOUND	8	8	itraconazole
NCT000021592	NCT00002159_2_T1	GENE	0	0	IV
NCT000021598	NCT00002159_8_T0	COMPOUND	13	13	fluconazole
NCT000021598	NCT00002159_8_T1	COMPOUND	15	15	ketoconazole
NCT000021598	NCT00002159_8_T2	COMPOUND	11	12	amphotericin B
NCT0000216111	NCT00002161_11_T0	PHENOTYPE	3	4	substance abuse
NCT000021623	NCT00002162_3_T0	COMPOUND	16	16	saquinavir
NCT0000216313	NCT00002163_13_T0	BIOLOGICAL_PROCESS	1	1	Behavior
NCT0000216313	NCT00002163_13_T1	PHENOTYPE	7	8	drug use
NCT000021648	NCT00002164_8_T0	COMPOUND	10	10	zidovudine
NCT000021648	NCT00002164_8_T1	COMPOUND	12	12	stavudine
NCT000021648	NCT00002164_8_T2	COMPOUND	13	13	didanosine
NCT000021648	NCT00002164_8_T3	COMPOUND	15	15	zalcitabine
NCT000021648	NCT00002164_8_T4	COMPOUND	11	11	lamivudine
NCT000021651	NCT00002165_1_T0	COMPOUND	9	9	nelfinavir
NCT000021651	NCT00002165_1_T1	COMPOUND	10	10	mesylate
NCT000021660	NCT00002166_0_T0	PHENOTYPE	19	19	Progressive
NCT000021660	NCT00002166_0_T1	PHENOTYPE	20	21	HIV Disease
NCT000021670	NCT00002167_0_T0	PHENOTYPE	6	8	AIDS-Related Kaposi's Sarcoma
NCT000021672	NCT00002167_2_T0	PHENOTYPE	6	6	toxicity
NCT000021681	NCT00002168_1_T0	COMPOUND	4	4	stavudine
NCT000021681	NCT00002168_1_T1	COMPOUND	7	7	didanosine
NCT000021686	NCT00002168_6_T0	PHENOTYPE	8	8	symptoms
NCT000021686	NCT00002168_6_T1	PHENOTYPE	3	3	Condition
NCT000021702	NCT00002170_2_T0	GENE	12	12	MAC
NCT000021720	NCT00002172_0_T0	GENE	13	13	CD4
NCT000021720	NCT00002172_0_T1	GENE	1	1	Expanded
NCT000021730	NCT00002173_0_T0	GENE	14	14	CD4
NCT000021730	NCT00002173_0_T1	CELL	17	17	Cells
NCT000021730	NCT00002173_0_T2	GENE	1	1	Expanded
NCT000021742	NCT00002174_2_T0	GENE	3	3	II
NCT000021743	NCT00002174_3_T0	GENE	1	1	III
NCT000021743	NCT00002174_3_T1	GENE	3	3	IV
NCT000021744	NCT00002174_4_T0	COMPOUND	8	8	thalidomide
NCT000021744	NCT00002174_4_T1	GENE	5	5	III
NCT000021744	NCT00002174_4_T2	GENE	15	15	IV
NCT000021744	NCT00002174_4_T3	GENE	12	13	group II
NCT000021745	NCT00002174_5_T0	COMPOUND	15	15	glucose
NCT000021745	NCT00002174_5_T1	COMPOUND	10	10	thalidomide
NCT000021746	NCT00002174_6_T0	COMPOUND	6	6	thalidomide
NCT000021746	NCT00002174_6_T1	PHENOTYPE	2	2	ingest
NCT000021749	NCT00002174_9_T0	PHENOTYPE	10	10	HIV
NCT000021749	NCT00002174_9_T1	PHENOTYPE	13	14	peripheral neuropathy
NCT0000217410	NCT00002174_10_T0	COMPOUND	18	18	thalidomide
NCT0000217410	NCT00002174_10_T1	COMPOUND	11	11	pentoxifylline
NCT000021750	NCT00002175_0_T0	COMPOUND	3	3	DNCB
NCT000021750	NCT00002175_0_T1	PHENOTYPE	6	7	HIV Infection
NCT000021751	NCT00002175_1_T0	PHENOTYPE	1	1	Infection
NCT000021753	NCT00002175_3_T0	PHENOTYPE	13	13	HIV
NCT000021756	NCT00002175_6_T0	PHENOTYPE	3	3	Condition
NCT000021756	NCT00002175_6_T1	PHENOTYPE	10	11	skin damage
NCT000021760	NCT00002176_0_T0	PHENOTYPE	6	6	HIV
NCT000021760	NCT00002176_0_T1	PHENOTYPE	20	22	Asymptomatic HIV Infection
NCT000021765	NCT00002176_5_T0	PHENOTYPE	10	10	acute
NCT000021765	NCT00002176_5_T1	PHENOTYPE	12	13	chronic pancreatitis
NCT000021770	NCT00002177_0_T0	PHENOTYPE	6	6	HIV
NCT000021770	NCT00002177_0_T1	PHENOTYPE	20	21	HIV Infection
NCT000021775	NCT00002177_5_T0	PHENOTYPE	10	10	acute
NCT000021775	NCT00002177_5_T1	PHENOTYPE	12	13	chronic pancreatitis
NCT000021783	NCT00002178_3_T0	GENE	9	9	gel
NCT000021791	NCT00002179_1_T0	COMPOUND	8	8	zidovudine
NCT000021791	NCT00002179_1_T1	COMPOUND	7	7	indinavir
NCT000021791	NCT00002179_1_T2	COMPOUND	10	10	lamivudine
NCT000021792	NCT00002179_2_T0	GENE	9	9	CSF
NCT000021792	NCT00002179_2_T1	TISSUE	6	7	lymph node
NCT000021794	NCT00002179_4_T0	PHENOTYPE	1	1	suppression
NCT000021794	NCT00002179_4_T1	ORGAN	11	11	serum
NCT000021796	NCT00002179_6_T0	PHENOTYPE	0	0	Suppression
NCT000021796	NCT00002179_6_T1	ORGAN	10	10	serum
NCT000021798	NCT00002179_8_T0	COMPOUND	36	36	zidovudine
NCT000021798	NCT00002179_8_T1	PHENOTYPE	0	0	Suppression
NCT000021798	NCT00002179_8_T2	COMPOUND	35	35	indinavir
NCT000021798	NCT00002179_8_T3	PHENOTYPE	47	47	suppression
NCT000021798	NCT00002179_8_T4	ORGAN	14	14	serum
NCT000021798	NCT00002179_8_T5	COMPOUND	38	38	lamivudine
NCT0000217910	NCT00002179_10_T0	GENE	9	9	CSF
NCT0000217910	NCT00002179_10_T1	TISSUE	6	7	lymph node
NCT0000217912	NCT00002179_12_T0	PHENOTYPE	1	1	suppression
NCT0000217912	NCT00002179_12_T1	ORGAN	11	11	serum
NCT0000217914	NCT00002179_14_T0	PHENOTYPE	0	0	Suppression
NCT0000217914	NCT00002179_14_T1	ORGAN	10	10	serum
NCT0000217916	NCT00002179_16_T0	COMPOUND	36	36	zidovudine
NCT0000217916	NCT00002179_16_T1	PHENOTYPE	0	0	Suppression
NCT0000217916	NCT00002179_16_T2	COMPOUND	35	35	indinavir
NCT0000217916	NCT00002179_16_T3	PHENOTYPE	47	47	suppression
NCT0000217916	NCT00002179_16_T4	ORGAN	14	14	serum
NCT0000217916	NCT00002179_16_T5	COMPOUND	38	38	lamivudine
NCT0000217917	NCT00002179_17_T0	COMPOUND	5	5	zidovudine
NCT0000217917	NCT00002179_17_T1	COMPOUND	3	3	indinavir
NCT0000217917	NCT00002179_17_T2	COMPOUND	7	7	lamivudine
NCT0000217918	NCT00002179_18_T0	ORGAN	13	13	serum
NCT0000217920	NCT00002179_20_T0	ORGAN	8	8	serum
NCT0000217922	NCT00002179_22_T0	COMPOUND	24	24	zidovudine
NCT0000217922	NCT00002179_22_T1	COMPOUND	23	23	indinavir
NCT0000217922	NCT00002179_22_T2	ORGAN	4	4	serum
NCT0000217922	NCT00002179_22_T3	COMPOUND	26	26	lamivudine
NCT000021808	NCT00002180_8_T0	PHENOTYPE	3	4	alcohol abuse
NCT000021808	NCT00002180_8_T1	PHENOTYPE	25	26	substance abuse
NCT000021814	NCT00002181_4_T0	PHENOTYPE	19	19	herpes
NCT000021814	NCT00002181_4_T1	COMPOUND	10	10	cidofovir
NCT000021814	NCT00002181_4_T2	COMPOUND	6	6	ganciclovir
NCT000021814	NCT00002181_4_T3	COMPOUND	7	7	foscarnet
NCT000021814	NCT00002181_4_T4	COMPOUND	5	5	famciclovir
NCT000021824	NCT00002182_4_T0	PHENOTYPE	9	9	symptoms
NCT000021824	NCT00002182_4_T1	PHENOTYPE	22	22	hypertension
NCT000021824	NCT00002182_4_T2	PHENOTYPE	27	28	heart failure
NCT000021824	NCT00002182_4_T3	COMPOUND	15	16	megestrol acetate
NCT000021824	NCT00002182_4_T4	PHENOTYPE	23	25	deep venous thrombosis
NCT000021830	NCT00002183_0_T0	PHENOTYPE	8	8	Pharmacokinetics
NCT000021830	NCT00002183_0_T1	PHENOTYPE	20	21	HIV Infection
NCT000021832	NCT00002183_2_T0	PHENOTYPE	4	4	pharmacokinetics
NCT000021835	NCT00002183_5_T0	GENE	3	3	has
NCT0000218319	NCT00002183_19_T0	PHENOTYPE	6	7	drug use
NCT000021841	NCT00002184_1_T0	PHENOTYPE	11	11	falls
NCT000021841	NCT00002184_1_T1	GENE	17	17	500
NCT000021841	NCT00002184_1_T2	ORGAN	7	7	plasma
NCT000021842	NCT00002184_2_T0	BIOLOGICAL_PROCESS	6	7	antiviral response
NCT000021844	NCT00002184_4_T0	COMPOUND	22	22	zidovudine
NCT000021844	NCT00002184_4_T1	COMPOUND	25	25	stavudine
NCT000021844	NCT00002184_4_T2	COMPOUND	8	8	nelfinavir
NCT000021844	NCT00002184_4_T3	COMPOUND	15	15	nelfinavir
NCT000021844	NCT00002184_4_T4	COMPOUND	10	10	saquinavir
NCT000021844	NCT00002184_4_T5	COMPOUND	17	17	saquinavir
NCT000021844	NCT00002184_4_T6	COMPOUND	23	23	lamivudine
NCT000021844	NCT00002184_4_T7	COMPOUND	5	6	adefovir dipivoxil
NCT000021844	NCT00002184_4_T8	COMPOUND	12	13	adefovir dipivoxil
NCT000021846	NCT00002184_6_T0	COMPOUND	14	14	zidovudine
NCT000021846	NCT00002184_6_T1	COMPOUND	17	17	stavudine
NCT000021846	NCT00002184_6_T2	COMPOUND	15	15	lamivudine
NCT000021847	NCT00002184_7_T0	COMPOUND	4	4	L-carnitine
NCT0000218418	NCT00002184_18_T0	PHENOTYPE	5	6	substance abuse
NCT000021850	NCT00002185_0_T0	GENE	1	1	Pilot
NCT000021850	NCT00002185_0_T1	GENE	4	4	II
NCT000021850	NCT00002185_0_T2	GENE	25	25	CD4
NCT000021850	NCT00002185_0_T3	GENE	20	20	KS
NCT000021854	NCT00002185_4_T0	GENE	8	8	2.1
NCT0000218515	NCT00002185_15_T0	GENE	2	2	KS
NCT000021862	NCT00002186_2_T0	COMPOUND	10	10	acyclovir
NCT000021862	NCT00002186_2_T1	COMPOUND	19	19	acyclovir
NCT000021862	NCT00002186_2_T2	GENE	7	7	gel
NCT000021862	NCT00002186_2_T3	GENE	16	16	gel
NCT000021882	NCT00002188_2_T0	PHENOTYPE	5	5	toxicity
NCT000021886	NCT00002188_6_T0	PHENOTYPE	10	10	symptoms
NCT000021886	NCT00002188_6_T1	PHENOTYPE	3	3	Condition
NCT000021893	NCT00002189_3_T0	PHENOTYPE	20	20	progression
NCT0000218912	NCT00002189_12_T0	PHENOTYPE	3	3	malignancy
NCT000021911	NCT00002191_1_T0	COMPOUND	5	5	albendazole
NCT000021911	NCT00002191_1_T1	GENE	15	15	bowel
NCT000021911	NCT00002191_1_T2	PHENOTYPE	9	10	weight gain
NCT000021912	NCT00002191_2_T0	PHENOTYPE	9	9	microsporidiosis
NCT000021917	NCT00002191_7_T0	PHENOTYPE	7	7	HIV
NCT000021920	NCT00002192_0_T0	PHENOTYPE	0	0	Tolerance
NCT000021920	NCT00002192_0_T1	PHENOTYPE	18	18	Bacteremia
NCT000021920	NCT00002192_0_T2	PHENOTYPE	15	17	Mycobacterium Avium Complex
NCT000021923	NCT00002192_3_T0	COMPOUND	5	5	rifapentine
NCT000021923	NCT00002192_3_T1	PHENOTYPE	3	3	pharmacokinetics
NCT000021924	NCT00002192_4_T0	PHENOTYPE	3	3	pharmacokinetics
NCT000021924	NCT00002192_4_T1	COMPOUND	5	5	azithromycin
NCT000021924	NCT00002192_4_T2	COMPOUND	7	7	clarithromycin
NCT000021926	NCT00002192_6_T0	COMPOUND	13	13	rifapentine
NCT0000219212	NCT00002192_12_T0	GENE	3	3	MAC
NCT000021933	NCT00002193_3_T0	GENE	5	5	swallow
NCT000021940	NCT00002194_0_T0	PHENOTYPE	4	4	HIV
NCT000021940	NCT00002194_0_T1	PHENOTYPE	15	15	Pharmacokinetics
NCT000021943	NCT00002194_3_T0	COMPOUND	11	11	nevirapine
NCT000021943	NCT00002194_3_T1	COMPOUND	5	5	clarithromycin
NCT000021943	NCT00002194_3_T2	GENE	2	3	Group I
NCT000021944	NCT00002194_4_T0	GENE	3	3	II
NCT000021944	NCT00002194_4_T1	COMPOUND	15	15	nevirapine
NCT000021944	NCT00002194_4_T2	COMPOUND	5	5	erythromycin
NCT000021947	NCT00002194_7_T0	COMPOUND	7	7	clarithromycin
NCT000021948	NCT00002194_8_T0	PHENOTYPE	3	3	Condition
NCT000021948	NCT00002194_8_T1	PHENOTYPE	11	11	Malabsorption
NCT000021948	NCT00002194_8_T2	PHENOTYPE	13	14	chronic diarrhea
NCT000021949	NCT00002194_9_T0	COMPOUND	14	14	rifabutin
NCT000021949	NCT00002194_9_T1	COMPOUND	7	7	dirithromycin
NCT000021949	NCT00002194_9_T2	COMPOUND	12	12	itraconazole
NCT000021949	NCT00002194_9_T3	COMPOUND	6	6	azithromycin
NCT000021949	NCT00002194_9_T4	COMPOUND	19	19	triazolam
NCT000021949	NCT00002194_9_T5	COMPOUND	15	15	phenytoin
NCT000021949	NCT00002194_9_T6	COMPOUND	18	18	cisapride
NCT000021949	NCT00002194_9_T7	COMPOUND	11	11	fluconazole
NCT000021949	NCT00002194_9_T8	COMPOUND	16	16	terfenadine
NCT000021949	NCT00002194_9_T9	COMPOUND	20	20	midazolam
NCT000021949	NCT00002194_9_T10	COMPOUND	5	5	erythromycin
NCT000021949	NCT00002194_9_T11	COMPOUND	10	10	ketoconazole
NCT000021949	NCT00002194_9_T12	COMPOUND	17	17	astemizole
NCT000021949	NCT00002194_9_T13	GENE	23	24	reverse transcriptase
NCT000021949	NCT00002194_9_T14	COMPOUND	28	29	clavulanic acid
NCT000021953	NCT00002195_3_T0	PHENOTYPE	8	8	symptoms
NCT000021953	NCT00002195_3_T1	PHENOTYPE	3	3	Condition
NCT000021954	NCT00002195_4_T0	COMPOUND	5	5	cisapride
NCT000021954	NCT00002195_4_T1	COMPOUND	6	6	triazolam
NCT000021954	NCT00002195_4_T2	COMPOUND	4	4	astemizole
NCT000021955	NCT00002195_5_T0	PHENOTYPE	10	10	hepatitis
NCT000021958	NCT00002195_8_T0	BIOLOGICAL_PROCESS	1	1	Behavior
NCT000021958	NCT00002195_8_T1	PHENOTYPE	7	8	drug use
NCT000021964	NCT00002196_4_T0	PHENOTYPE	3	3	Condition
NCT000021964	NCT00002196_4_T1	PHENOTYPE	14	15	bacterial infection
NCT000021971	NCT00002197_1_T0	PHENOTYPE	12	12	HIV
NCT000021971	NCT00002197_1_T1	GENE	7	7	has
NCT000021982	NCT00002198_2_T0	COMPOUND	1	1	2
NCT000021983	NCT00002198_3_T0	COMPOUND	1	1	3
NCT000021987	NCT00002198_7_T0	PHENOTYPE	6	7	Kaposi's sarcoma
NCT000021990	NCT00002199_0_T0	GENE	2	2	III
NCT000021996	NCT00002199_6_T0	PHENOTYPE	6	7	Kaposi's sarcoma
NCT0000219912	NCT00002199_12_T0	PHENOTYPE	11	11	pancreatitis
NCT0000219912	NCT00002199_12_T1	PHENOTYPE	13	13	hepatitis
NCT0000219915	NCT00002199_15_T0	PHENOTYPE	4	5	drug use
NCT000022001	NCT00002200_1_T0	PHENOTYPE	7	7	HIV
NCT000022001	NCT00002200_1_T1	GENE	9	9	has
NCT000022006	NCT00002200_6_T0	GENE	11	12	protease inhibitor
NCT000022006	NCT00002200_6_T1	GENE	17	18	protease inhibitor
NCT000022006	NCT00002200_6_T2	GENE	34	35	protease inhibitor
NCT000022006	NCT00002200_6_T3	GENE	5	6	reverse transcriptase
NCT000022007	NCT00002200_7_T0	PHENOTYPE	3	4	drug use
NCT000022011	NCT00002201_1_T0	PHENOTYPE	21	21	HIV
NCT000022011	NCT00002201_1_T1	COMPOUND	8	8	nelfinavir
NCT000022011	NCT00002201_1_T2	COMPOUND	6	6	ritonavir
NCT000022013	NCT00002201_3_T0	GENE	7	8	protease inhibitor
NCT000022025	NCT00002202_5_T0	PHENOTYPE	9	10	Kaposi's sarcoma
NCT000022026	NCT00002202_6_T0	PHENOTYPE	10	10	pancreatitis
NCT000022026	NCT00002202_6_T1	PHENOTYPE	12	12	hepatitis
NCT000022028	NCT00002202_8_T0	PHENOTYPE	17	18	Kaposi's sarcoma
NCT000022029	NCT00002202_9_T0	BIOLOGICAL_PROCESS	1	1	Behavior
NCT000022029	NCT00002202_9_T1	PHENOTYPE	7	8	drug use
NCT000022029	NCT00002202_9_T2	PHENOTYPE	13	14	drug absorption
NCT000022033	NCT00002203_3_T0	GENE	7	7	PI
NCT000022033	NCT00002203_3_T1	GENE	19	19	PI
NCT000022041	NCT00002204_1_T0	PHENOTYPE	6	6	HIV
NCT000022043	NCT00002204_3_T0	PHENOTYPE	11	11	HIV
NCT000022045	NCT00002204_5_T0	PHENOTYPE	3	4	adverse events
NCT000022046	NCT00002204_6_T0	PHENOTYPE	10	10	HIV
NCT000022052	NCT00002205_2_T0	PHENOTYPE	14	15	HIV disease
NCT000022052	NCT00002205_2_T1	PHENOTYPE	15	16	disease progression
NCT000022053	NCT00002205_3_T0	PHENOTYPE	10	10	HIV
NCT000022053	NCT00002205_3_T1	PHENOTYPE	11	11	progression
NCT000022055	NCT00002205_5_T0	PHENOTYPE	10	10	HIV
NCT000022055	NCT00002205_5_T1	PHENOTYPE	11	11	progression
NCT000022058	NCT00002205_8_T0	GENE	21	21	ACTG
NCT000022058	NCT00002205_8_T1	GENE	24	24	ACTG
NCT0000220511	NCT00002205_11_T0	BIOLOGICAL_PROCESS	1	1	Behavior
NCT0000220511	NCT00002205_11_T1	PHENOTYPE	9	10	drug use
NCT000022062	NCT00002206_2_T0	COMPOUND	8	9	adefovir dipivoxil
NCT000022064	NCT00002206_4_T0	COMPOUND	10	11	adefovir dipivoxil
NCT0000220613	NCT00002206_13_T0	PHENOTYPE	3	4	substance abuse
NCT000022081	NCT00002208_1_T0	COMPOUND	7	7	indinavir
NCT000022084	NCT00002208_4_T0	PHENOTYPE	8	8	toxicity
NCT000022084	NCT00002208_4_T1	COMPOUND	6	6	zidovudine
NCT000022090	NCT00002209_0_T0	COMPOUND	4	4	CPI-1189
NCT000022092	NCT00002209_2_T0	COMPOUND	7	7	CPI-1189
NCT000022092	NCT00002209_2_T1	COMPOUND	27	27	zidovudine
NCT000022092	NCT00002209_2_T2	COMPOUND	30	30	indinavir
NCT000022092	NCT00002209_2_T3	PHENOTYPE	8	8	affects
NCT000022092	NCT00002209_2_T4	CELL	15	15	cells
NCT000022092	NCT00002209_2_T5	PHENOTYPE	12	12	HIV
NCT000022092	NCT00002209_2_T6	PHENOTYPE	25	25	HIV
NCT000022092	NCT00002209_2_T7	COMPOUND	28	28	lamivudine
NCT000022092	NCT00002209_2_T8	CELL	13	14	T cells
NCT000022094	NCT00002209_4_T0	COMPOUND	0	0	CPI-1189
NCT000022094	NCT00002209_4_T1	PHENOTYPE	6	7	AIDS dementia
NCT000022096	NCT00002209_6_T0	COMPOUND	0	0	CPI-1189
NCT000022096	NCT00002209_6_T1	PHENOTYPE	6	7	AIDS dementia
NCT000022097	NCT00002209_7_T0	COMPOUND	14	14	CPI-1189
NCT000022097	NCT00002209_7_T1	PHENOTYPE	6	6	HIV
NCT0000220910	NCT00002209_10_T0	CELL	16	16	sperm
NCT000022111	NCT00002211_1_T0	COMPOUND	7	7	delavirdine
NCT000022111	NCT00002211_1_T1	COMPOUND	14	14	stavudine
NCT000022111	NCT00002211_1_T2	COMPOUND	9	9	nelfinavir
NCT000022111	NCT00002211_1_T3	COMPOUND	11	11	didanosine
NCT000022115	NCT00002211_5_T0	COMPOUND	3	3	delavirdine
NCT000022115	NCT00002211_5_T1	COMPOUND	6	6	nelfinavir
NCT000022115	NCT00002211_5_T2	COMPOUND	9	9	stavudine
NCT000022115	NCT00002211_5_T3	GENE	0	1	Group 1
NCT000022116	NCT00002211_6_T0	COMPOUND	7	7	didanosine
NCT0000221110	NCT00002211_10_T0	GENE	2	2	opt
NCT000022122	NCT00002212_2_T0	PHENOTYPE	10	10	toxicity
NCT000022122	NCT00002212_2_T1	GENE	6	6	reduced
NCT000022126	NCT00002212_6_T0	GENE	12	12	KS
NCT000022135	NCT00002213_5_T0	GENE	14	15	reverse transcriptase
NCT000022136	NCT00002213_6_T0	BIOLOGICAL_PROCESS	16	16	DMP
NCT0000221311	NCT00002213_11_T0	PHENOTYPE	16	16	sarcoma
NCT0000221316	NCT00002213_16_T0	PHENOTYPE	4	5	drug use
NCT000022140	NCT00002214_0_T0	PHENOTYPE	8	9	HIV Infection
NCT000022143	NCT00002214_3_T0	GENE	11	11	CD4
NCT000022143	NCT00002214_3_T1	PHENOTYPE	2	2	HIV
NCT000022146	NCT00002214_6_T0	COMPOUND	3	3	1
NCT000022146	NCT00002214_6_T1	GENE	7	7	po
NCT000022147	NCT00002214_7_T0	GENE	3	3	po
NCT000022148	NCT00002214_8_T0	COMPOUND	3	3	2
NCT000022148	NCT00002214_8_T1	PHENOTYPE	19	19	initiation
NCT000022148	NCT00002214_8_T2	GENE	29	29	po
NCT000022149	NCT00002214_9_T0	GENE	3	3	po
NCT0000221413	NCT00002214_13_T0	PHENOTYPE	5	5	toxicity
NCT0000221413	NCT00002214_13_T1	GENE	6	6	DLT
NCT0000221415	NCT00002214_15_T0	PHENOTYPE	25	25	toxicity
NCT0000221415	NCT00002214_15_T1	PHENOTYPE	7	7	experiences
NCT0000221415	NCT00002214_15_T2	GENE	8	8	DLT
NCT0000221416	NCT00002214_16_T0	GENE	20	20	MTD
NCT0000221416	NCT00002214_16_T1	GENE	10	10	DLT
NCT0000221422	NCT00002214_22_T0	PHENOTYPE	8	8	symptoms
NCT0000221422	NCT00002214_22_T1	PHENOTYPE	3	3	Condition
NCT0000221422	NCT00002214_22_T2	PHENOTYPE	14	15	opportunistic infection
NCT000022152	NCT00002215_2_T0	COMPOUND	10	10	nelfinavir
NCT000022155	NCT00002215_5_T0	GENE	9	10	reverse transcriptase
NCT000022174	NCT00002217_4_T0	GENE	6	7	reverse transcriptase
NCT000022177	NCT00002217_7_T0	PHENOTYPE	12	12	pancreatitis
NCT000022177	NCT00002217_7_T1	PHENOTYPE	14	14	hepatitis
NCT000022180	NCT00002218_0_T0	PHENOTYPE	11	11	HIV
NCT000022184	NCT00002218_4_T0	PHENOTYPE	8	8	pharmacokinetics
NCT000022192	NCT00002219_2_T0	COMPOUND	8	8	nelfinavir
NCT000022193	NCT00002219_3_T0	GENE	0	0	ADF
NCT000022193	NCT00002219_3_T1	PHENOTYPE	1	1	pharmacokinetics
NCT000022201	NCT00002220_1_T0	PHENOTYPE	15	15	HIV
NCT000022203	NCT00002220_3_T0	COMPOUND	11	11	L-carnitine
NCT000022203	NCT00002220_3_T1	COMPOUND	3	3	indinavir
NCT000022203	NCT00002220_3_T2	COMPOUND	5	5	efavirenz
NCT000022203	NCT00002220_3_T3	COMPOUND	7	8	adefovir dipivoxil
NCT000022204	NCT00002220_4_T0	ORGAN	0	0	Plasma
NCT000022204	NCT00002220_4_T1	GENE	1	1	vRNA
NCT000022212	NCT00002221_2_T0	CELL	5	5	cells
NCT000022212	NCT00002221_2_T1	CELL	0	1	Stem cells
NCT000022212	NCT00002221_2_T2	CELL	16	17	blood cells
NCT000022213	NCT00002221_3_T0	CELL	16	16	cells
NCT000022213	NCT00002221_3_T1	CELL	6	7	stem cells
NCT000022214	NCT00002221_4_T0	CELL	1	1	cells
NCT000022214	NCT00002221_4_T1	PHENOTYPE	14	14	HIV
NCT000022215	NCT00002221_5_T0	CELL	1	1	cells
NCT000022216	NCT00002221_6_T0	CELL	1	1	cells
NCT000022219	NCT00002221_9_T0	CELL	2	2	cells
NCT000022219	NCT00002221_9_T1	ORGAN	13	13	transplant
NCT000022219	NCT00002221_9_T2	ORGAN	11	12	bone marrow
NCT0000222110	NCT00002221_10_T0	ORGAN	3	4	bone marrow
NCT0000222111	NCT00002221_11_T0	GENE	4	4	LN
NCT0000222112	NCT00002221_12_T0	PHENOTYPE	15	15	HIV
NCT0000222112	NCT00002221_12_T1	GENE	3	3	has
NCT0000222113	NCT00002221_13_T0	GENE	1	1	LN
NCT0000222113	NCT00002221_13_T1	PHENOTYPE	6	7	internal control
NCT0000222114	NCT00002221_14_T0	ORGAN	3	4	bone marrow
NCT0000222115	NCT00002221_15_T0	GENE	15	15	G-CSF
NCT0000222115	NCT00002221_15_T1	CELL	22	23	stem cells
NCT0000222118	NCT00002221_18_T0	CELL	6	7	stem cells
NCT0000222119	NCT00002221_19_T0	PHENOTYPE	2	2	conditioning
NCT0000222119	NCT00002221_19_T1	CELL	7	8	stem cells
NCT0000222120	NCT00002221_20_T0	CELL	2	2	cells
NCT0000222122	NCT00002221_22_T0	GENE	1	1	LN
NCT0000222122	NCT00002221_22_T1	GENE	13	13	IV
NCT0000222123	NCT00002221_23_T0	CELL	2	2	cells
NCT0000222124	NCT00002221_24_T0	CELL	7	8	blood cells
NCT000022233	NCT00002223_3_T0	PHENOTYPE	10	10	symptoms
NCT000022233	NCT00002223_3_T1	PHENOTYPE	3	3	Condition
NCT000022237	NCT00002223_7_T0	COMPOUND	6	6	ritonavir
NCT000022238	NCT00002223_8_T0	BIOLOGICAL_PROCESS	1	1	Behavior
NCT000022238	NCT00002223_8_T1	PHENOTYPE	6	7	substance abuse
NCT000022241	NCT00002224_1_T0	COMPOUND	7	7	didanosine
NCT000022241	NCT00002224_1_T1	PHENOTYPE	24	25	stomach upset
NCT000022243	NCT00002224_3_T0	COMPOUND	8	8	stavudine
NCT000022243	NCT00002224_3_T1	COMPOUND	11	11	nelfinavir
NCT000022245	NCT00002224_5_T0	GENE	0	1	Group 1
NCT000022248	NCT00002224_8_T0	PHENOTYPE	14	14	HIV
NCT000022248	NCT00002224_8_T1	ORGAN	13	13	plasma
NCT000022254	NCT00002225_4_T0	COMPOUND	4	4	cisapride
NCT000022254	NCT00002225_4_T1	COMPOUND	11	11	terfenadine
NCT000022254	NCT00002225_4_T2	COMPOUND	14	14	vincristine
NCT000022254	NCT00002225_4_T3	COMPOUND	12	12	thalidomide
NCT000022254	NCT00002225_4_T4	COMPOUND	8	8	midazolam
NCT000022254	NCT00002225_4_T5	COMPOUND	9	9	rifabutin
NCT000022254	NCT00002225_4_T6	COMPOUND	6	6	ketoconazole
NCT000022254	NCT00002225_4_T7	COMPOUND	13	13	triazolam
NCT000022254	NCT00002225_4_T8	COMPOUND	7	7	itraconazole
NCT000022254	NCT00002225_4_T9	COMPOUND	5	5	clarithromycin
NCT000022254	NCT00002225_4_T10	COMPOUND	15	15	zalcitabine
NCT000022264	NCT00002226_4_T0	PHENOTYPE	5	5	toxicity
NCT000022264	NCT00002226_4_T1	PHENOTYPE	28	28	toxicity
NCT000022264	NCT00002226_4_T2	PHENOTYPE	30	31	tumor progression
NCT000022275	NCT00002227_5_T0	COMPOUND	14	14	vincristine
NCT000022275	NCT00002227_5_T1	COMPOUND	24	24	stavudine
NCT000022275	NCT00002227_5_T2	COMPOUND	9	9	rifabutin
NCT000022275	NCT00002227_5_T3	COMPOUND	13	13	triazolam
NCT000022275	NCT00002227_5_T4	COMPOUND	7	7	itraconazole
NCT000022275	NCT00002227_5_T5	COMPOUND	5	5	clarithromycin
NCT000022275	NCT00002227_5_T6	COMPOUND	4	4	cisapride
NCT000022275	NCT00002227_5_T7	COMPOUND	11	11	terfenadine
NCT000022275	NCT00002227_5_T8	COMPOUND	12	12	thalidomide
NCT000022275	NCT00002227_5_T9	COMPOUND	8	8	midazolam
NCT000022275	NCT00002227_5_T10	COMPOUND	6	6	ketoconazole
NCT000022275	NCT00002227_5_T11	COMPOUND	26	26	lamivudine
NCT000022275	NCT00002227_5_T12	COMPOUND	15	15	zalcitabine
NCT000022278	NCT00002227_8_T0	BIOLOGICAL_PROCESS	1	1	Behavior
NCT000022278	NCT00002227_8_T1	PHENOTYPE	7	8	drug use
NCT000022281	NCT00002228_1_T0	PHENOTYPE	3	3	HIV
NCT0000222810	NCT00002228_10_T0	ORGAN	5	5	allograft
NCT0000222811	NCT00002228_11_T0	PHENOTYPE	8	8	addiction
NCT0000222811	NCT00002228_11_T1	BIOLOGICAL_PROCESS	1	1	Behavior
NCT0000222811	NCT00002228_11_T2	PHENOTYPE	5	6	substance abuse
NCT000022301	NCT00002230_1_T0	GENE	12	12	HU
NCT000022301	NCT00002230_1_T1	PHENOTYPE	5	5	tolerance
NCT000022306	NCT00002230_6_T0	PHENOTYPE	3	3	Acute
NCT000022307	NCT00002230_7_T0	PHENOTYPE	0	0	Acute
NCT000022308	NCT00002230_8_T0	PHENOTYPE	8	8	symptoms
NCT000022308	NCT00002230_8_T1	PHENOTYPE	3	3	Condition
NCT000022308	NCT00002230_8_T2	PHENOTYPE	13	13	Malignancy
NCT0000223010	NCT00002230_10_T0	PHENOTYPE	13	13	toxicities
NCT0000223010	NCT00002230_10_T1	PHENOTYPE	12	12	recurrent
NCT0000223010	NCT00002230_10_T2	PHENOTYPE	32	32	anemia
NCT0000223012	NCT00002230_12_T0	GENE	6	6	HU
NCT0000223013	NCT00002230_13_T0	GENE	0	1	Protease inhibitor
NCT0000223015	NCT00002230_15_T0	BIOLOGICAL_PROCESS	1	1	Behavior
NCT0000223015	NCT00002230_15_T1	PHENOTYPE	4	5	ethanol abuse
NCT000022311	NCT00002231_1_T0	PHENOTYPE	9	9	affects
NCT000022311	NCT00002231_1_T1	ORGAN	11	12	immune system
NCT000022313	NCT00002231_3_T0	BIOLOGICAL_PROCESS	3	4	immune response
NCT000022325	NCT00002232_5_T0	PHENOTYPE	29	29	trauma
NCT000022325	NCT00002232_5_T1	PHENOTYPE	23	23	acute
NCT000022325	NCT00002232_5_T2	COMPOUND	19	19	aspirin
NCT000022325	NCT00002232_5_T3	PHENOTYPE	27	27	headache
NCT000022330	NCT00002233_0_T0	PHENOTYPE	12	13	HIV Infection
NCT000022332	NCT00002233_2_T0	PHENOTYPE	15	15	HIV
NCT000022332	NCT00002233_2_T1	ORGAN	9	10	immune system
NCT000022333	NCT00002233_3_T0	COMPOUND	6	6	amprenavir
NCT000022333	NCT00002233_3_T1	COMPOUND	8	8	indinavir
NCT000022333	NCT00002233_3_T2	COMPOUND	5	5	abacavir
NCT000022333	NCT00002233_3_T3	COMPOUND	4	4	lamivudine
NCT000022344	NCT00002234_4_T0	PHENOTYPE	3	4	virologic failure
NCT000022351	NCT00002235_1_T0	COMPOUND	22	22	nelfinavir
NCT000022351	NCT00002235_1_T1	COMPOUND	16	16	indinavir
NCT000022351	NCT00002235_1_T2	COMPOUND	29	29	efavirenz
NCT000022355	NCT00002235_5_T0	PHENOTYPE	3	4	virologic failure
NCT000022363	NCT00002236_3_T0	PHENOTYPE	0	1	Group B
NCT000022371	NCT00002237_1_T0	PHENOTYPE	14	14	HIV
NCT000022371	NCT00002237_1_T1	COMPOUND	9	9	peldesine
NCT000022373	NCT00002237_3_T0	ORGAN	0	0	Plasma
NCT000022373	NCT00002237_3_T1	GENE	8	8	MTD
NCT000022389	NCT00002238_9_T0	PHENOTYPE	3	4	alcohol abuse
NCT000022398	NCT00002239_8_T0	PHENOTYPE	32	32	pharmacokinetics
NCT000022398	NCT00002239_8_T1	ORGAN	29	29	plasma
NCT000022398	NCT00002239_8_T2	PHENOTYPE	18	19	adverse events
NCT000022400	NCT00002240_0_T0	GENE	4	4	Protease
NCT000022402	NCT00002240_2_T0	PHENOTYPE	10	10	HIV
NCT000022402	NCT00002240_2_T1	COMPOUND	12	12	stavudine
NCT000022402	NCT00002240_2_T2	COMPOUND	14	14	didanosine
NCT000022403	NCT00002240_3_T0	COMPOUND	13	13	nelfinavir
NCT000022403	NCT00002240_3_T1	GENE	15	16	protease inhibitor
NCT000022403	NCT00002240_3_T2	PHENOTYPE	5	6	HIV infection
NCT000022406	NCT00002240_6_T0	PHENOTYPE	4	4	HIV
NCT000022414	NCT00002241_4_T0	ORGAN	8	8	plasma
NCT000022433	NCT00002243_3_T0	COMPOUND	6	7	calanolide A
NCT000022434	NCT00002243_4_T0	PHENOTYPE	13	13	HIV
NCT000022440	NCT00002244_0_T0	PHENOTYPE	15	16	HIV Disease
NCT000022442	NCT00002244_2_T0	PHENOTYPE	12	13	HIV disease
NCT000022442	NCT00002244_2_T1	ORGAN	6	7	immune system
NCT000022442	NCT00002244_2_T2	PHENOTYPE	13	14	disease progression
NCT000022444	NCT00002244_4_T0	PHENOTYPE	9	9	progression
NCT000022444	NCT00002244_4_T1	GENE	28	28	CD8
NCT000022444	NCT00002244_4_T2	CELL	29	30	T cells
NCT000022444	NCT00002244_4_T3	GENE	25	26	CD38 antigen
NCT000022444	NCT00002244_4_T4	PHENOTYPE	18	20	quality of life
NCT000022462	NCT00002246_2_T0	GENE	12	12	ADC
NCT000022462	NCT00002246_2_T1	GENE	16	16	MSK
NCT000022463	NCT00002246_3_T0	PHENOTYPE	9	9	dementia
NCT000022465	NCT00002246_5_T0	GENE	10	10	CSF
NCT000022465	NCT00002246_5_T1	PHENOTYPE	5	5	pharmacokinetics
NCT000022472	NCT00002247_2_T0	PHENOTYPE	21	21	retinitis
NCT000022472	NCT00002247_2_T1	PHENOTYPE	19	19	progression
NCT000022472	NCT00002247_2_T2	COMPOUND	13	13	ganciclovir
NCT000022473	NCT00002247_3_T0	PHENOTYPE	10	10	retinitis
NCT000022473	NCT00002247_3_T1	PHENOTYPE	8	8	progression
NCT000022473	NCT00002247_3_T2	COMPOUND	17	17	ganciclovir
NCT000022473	NCT00002247_3_T3	PHENOTYPE	4	4	tolerance
NCT000022474	NCT00002247_4_T0	COMPOUND	18	18	zidovudine
NCT000022474	NCT00002247_4_T1	COMPOUND	8	8	ganciclovir
NCT000022474	NCT00002247_4_T2	PHENOTYPE	5	5	tolerance
NCT000022477	NCT00002247_7_T0	PHENOTYPE	30	30	retinitis
NCT000022477	NCT00002247_7_T1	COMPOUND	15	15	ganciclovir
NCT000022477	NCT00002247_7_T2	COMPOUND	22	22	ganciclovir
NCT000022477	NCT00002247_7_T3	COMPOUND	42	42	ganciclovir
NCT000022477	NCT00002247_7_T4	GENE	12	12	IV
NCT000022480	NCT00002248_0_T0	PHENOTYPE	22	22	Enteritis
NCT000022490	NCT00002249_0_T0	PHENOTYPE	8	8	Pharmacokinetics
NCT000022490	NCT00002249_0_T1	PHENOTYPE	16	17	HIV Infection
NCT0000225012	NCT00002250_12_T0	GENE	2	2	globulin
NCT0000225012	NCT00002250_12_T1	GENE	1	1	gamma
NCT0000225013	NCT00002250_13_T0	COMPOUND	1	1	acyclovir
NCT0000225020	NCT00002250_20_T0	COMPOUND	6	6	zidovudine
NCT0000225020	NCT00002250_20_T1	COMPOUND	9	9	acyclovir
NCT000022510	NCT00002251_0_T0	PHENOTYPE	4	4	Pharmacokinetics
NCT000022523	NCT00002252_3_T0	GENE	8	8	GI
NCT000022523	NCT00002252_3_T1	GENE	0	0	OR
NCT000022527	NCT00002252_7_T0	PHENOTYPE	1	3	intravenous drug abuse
NCT000022541	NCT00002254_1_T0	PHENOTYPE	4	4	pharmacokinetics
NCT000022541	NCT00002254_1_T1	GENE	6	6	FLT
NCT0000225412	NCT00002254_12_T0	PHENOTYPE	1	2	substance abuse
NCT000022554	NCT00002255_4_T0	GENE	22	22	p24
NCT000022554	NCT00002255_4_T1	PHENOTYPE	13	13	HIV
NCT000022554	NCT00002255_4_T2	PHENOTYPE	21	21	HIV
NCT000022554	NCT00002255_4_T3	PHENOTYPE	25	25	HIV
NCT000022554	NCT00002255_4_T4	PHENOTYPE	29	29	HIV
NCT000022554	NCT00002255_4_T5	GENE	11	11	EPO
NCT000022554	NCT00002255_4_T6	GENE	5	5	G-CSF
NCT000022554	NCT00002255_4_T7	ORGAN	24	24	plasma
NCT000022554	NCT00002255_4_T8	PHENOTYPE	26	26	viremia
NCT000022569	NCT00002256_9_T0	PHENOTYPE	21	22	peripheral neuropathy
NCT000022571	NCT00002257_1_T0	COMPOUND	8	8	ganciclovir
NCT000022571	NCT00002257_1_T1	COMPOUND	11	11	ganciclovir
NCT000022571	NCT00002257_1_T2	GENE	10	10	IV
NCT000022571	NCT00002257_1_T3	PHENOTYPE	5	5	tolerance
NCT000022572	NCT00002257_2_T0	COMPOUND	17	17	zidovudine
NCT000022572	NCT00002257_2_T1	COMPOUND	8	8	ganciclovir
NCT000022572	NCT00002257_2_T2	PHENOTYPE	5	5	tolerance
NCT000022576	NCT00002257_6_T0	PHENOTYPE	5	5	recruitment
NCT000022581	NCT00002258_1_T0	PHENOTYPE	17	17	HIV
NCT000022582	NCT00002258_2_T0	PHENOTYPE	14	14	HIV
NCT0000225811	NCT00002258_11_T0	PHENOTYPE	3	4	alcohol abuse
NCT000022614	NCT00002261_4_T0	PHENOTYPE	12	12	vaccinia
NCT000022614	NCT00002261_4_T1	PHENOTYPE	10	10	HIV
NCT0000226110	NCT00002261_10_T0	GENE	15	15	gp160
NCT0000226110	NCT00002261_10_T1	GENE	9	9	booster
NCT0000226115	NCT00002261_15_T0	PHENOTYPE	19	19	HIV
NCT0000226115	NCT00002261_15_T1	BIOLOGICAL_PROCESS	1	1	Behavior
NCT0000226117	NCT00002261_17_T0	PHENOTYPE	23	23	Smallpox
NCT0000226118	NCT00002261_18_T0	PHENOTYPE	15	15	HIV
NCT000022621	NCT00002262_1_T0	GENE	12	12	KS
NCT000022621	NCT00002262_1_T1	GENE	7	7	TNF
NCT000022621	NCT00002262_1_T2	PHENOTYPE	10	11	Kaposi's sarcoma
NCT000022631	NCT00002263_1_T0	GENE	9	9	GM-CSF
NCT000022632	NCT00002263_2_T0	PHENOTYPE	21	21	complications
NCT000022632	NCT00002263_2_T1	GENE	8	8	GM-CSF
NCT000022632	NCT00002263_2_T2	PHENOTYPE	16	17	HIV infection
NCT000022641	NCT00002264_1_T0	PHENOTYPE	1	1	secondary
NCT000022652	NCT00002265_2_T0	PHENOTYPE	28	28	toxic
NCT000022652	NCT00002265_2_T1	COMPOUND	11	11	pyrimethamine
NCT000022652	NCT00002265_2_T2	GENE	3	3	FOR
NCT000022652	NCT00002265_2_T3	COMPOUND	13	13	trimethoprim_sulfamethoxazole
NCT000022652	NCT00002265_2_T4	COMPOUND	14	14	ganciclovir
NCT000022652	NCT00002265_2_T5	COMPOUND	12	12	sulfadiazine
NCT000022652	NCT00002265_2_T6	COMPOUND	16	16	pentamidine
NCT000022652	NCT00002265_2_T7	COMPOUND	18	18	acyclovir
NCT000022652	NCT00002265_2_T8	COMPOUND	21	21	acyclovir
NCT000022652	NCT00002265_2_T9	ORGAN	24	25	bone marrow
NCT000022654	NCT00002265_4_T0	PHENOTYPE	18	18	toxicity
NCT000022654	NCT00002265_4_T1	PHENOTYPE	10	11	peripheral neuropathy
NCT000022655	NCT00002265_5_T0	PHENOTYPE	6	6	toxicity
NCT000022655	NCT00002265_5_T1	PHENOTYPE	19	19	acute
NCT000022655	NCT00002265_5_T2	PHENOTYPE	23	24	opportunistic infection
NCT000022657	NCT00002265_7_T0	PHENOTYPE	5	5	chronic
NCT0000226520	NCT00002265_20_T0	PHENOTYPE	3	4	alcohol abuse
NCT000022697	NCT00002269_7_T0	PHENOTYPE	1	2	drug abuse
NCT000022721	NCT00002272_1_T0	COMPOUND	10	10	foscarnet
NCT000022721	NCT00002272_1_T1	GENE	8	8	IV
NCT000022721	NCT00002272_1_T2	PHENOTYPE	14	15	recurrent disease
NCT000022722	NCT00002272_2_T0	PHENOTYPE	3	3	pharmacokinetics
NCT000022722	NCT00002272_2_T1	GENE	9	9	IV
NCT000022731	NCT00002273_1_T0	GENE	13	13	IV
NCT000022747	NCT00002274_7_T0	PHENOTYPE	9	10	intractable diarrhea
NCT000022748	NCT00002274_8_T0	GENE	12	12	7-10
NCT000022749	NCT00002274_9_T0	PHENOTYPE	6	6	severity
NCT000022749	NCT00002274_9_T1	PHENOTYPE	2	3	adverse effect
NCT0000227410	NCT00002274_10_T0	PHENOTYPE	14	15	adverse experience
NCT0000227411	NCT00002274_11_T0	ORGAN	52	52	liver
NCT0000227411	NCT00002274_11_T1	PHENOTYPE	24	24	disorders
NCT0000227411	NCT00002274_11_T2	PHENOTYPE	47	47	gout
NCT0000227411	NCT00002274_11_T3	PHENOTYPE	42	42	pancreatitis
NCT0000227411	NCT00002274_11_T4	PHENOTYPE	45	46	cardiac abnormalities
NCT0000227411	NCT00002274_11_T5	PHENOTYPE	40	41	peripheral neuropathy
NCT0000227411	NCT00002274_11_T6	PHENOTYPE	43	44	seizure disorder
NCT000022752	NCT00002275_2_T0	GENE	20	20	RT
NCT000022752	NCT00002275_2_T1	PHENOTYPE	10	10	HIV
NCT000022752	NCT00002275_2_T2	GENE	18	19	reverse transcriptase
NCT000022753	NCT00002275_3_T0	GENE	19	19	II
NCT000022753	NCT00002275_3_T1	PHENOTYPE	6	6	HIV
NCT000022753	NCT00002275_3_T2	GENE	24	24	III
NCT000022764	NCT00002276_4_T0	PHENOTYPE	8	8	symptoms
NCT000022764	NCT00002276_4_T1	PHENOTYPE	3	3	Condition
NCT000022764	NCT00002276_4_T2	PHENOTYPE	20	20	malignancy
NCT000022764	NCT00002276_4_T3	PHENOTYPE	15	16	opportunistic infection
NCT000022764	NCT00002276_4_T4	PHENOTYPE	17	18	bacterial infection
NCT000022766	NCT00002276_6_T0	PHENOTYPE	15	15	malignancy
NCT000022766	NCT00002276_6_T1	PHENOTYPE	10	11	opportunistic infection
NCT000022766	NCT00002276_6_T2	PHENOTYPE	12	13	bacterial infection
NCT000022771	NCT00002277_1_T0	PHENOTYPE	11	11	malignancy
NCT000022771	NCT00002277_1_T1	PHENOTYPE	0	1	HIV seropositive
NCT000022794	NCT00002279_4_T0	GENE	16	16	has
NCT000022803	NCT00002280_3_T0	COMPOUND	8	8	zidovudine
NCT000022813	NCT00002281_3_T0	GENE	22	22	p24
NCT000022813	NCT00002281_3_T1	PHENOTYPE	13	13	HIV
NCT000022813	NCT00002281_3_T2	PHENOTYPE	21	21	HIV
NCT000022813	NCT00002281_3_T3	PHENOTYPE	25	25	HIV
NCT000022813	NCT00002281_3_T4	PHENOTYPE	29	29	HIV
NCT000022813	NCT00002281_3_T5	GENE	11	11	EPO
NCT000022813	NCT00002281_3_T6	GENE	5	5	G-CSF
NCT000022813	NCT00002281_3_T7	ORGAN	24	24	plasma
NCT000022813	NCT00002281_3_T8	PHENOTYPE	26	26	viremia
NCT000022832	NCT00002283_2_T0	PHENOTYPE	2	2	toxicities
NCT000022841	NCT00002284_1_T0	GENE	9	9	III
NCT000022841	NCT00002284_1_T1	PHENOTYPE	12	13	drug levels
NCT000022844	NCT00002284_4_T0	ORGAN	8	8	transplant
NCT000022844	NCT00002284_4_T1	ORGAN	13	13	transplant
NCT000022851	NCT00002285_1_T0	PHENOTYPE	3	3	HIV
NCT000022851	NCT00002285_1_T1	PHENOTYPE	4	4	viremia
NCT000022854	NCT00002285_4_T0	PHENOTYPE	8	9	varicella zoster
NCT000022854	NCT00002285_4_T1	PHENOTYPE	11	12	herpes simplex
NCT000022854	NCT00002285_4_T2	ORGAN	1	3	central nervous system
NCT000022855	NCT00002285_5_T0	PHENOTYPE	2	3	CNS infection
NCT000022859	NCT00002285_9_T0	PHENOTYPE	8	9	varicella zoster
NCT000022859	NCT00002285_9_T1	PHENOTYPE	11	12	herpes simplex
NCT000022859	NCT00002285_9_T2	ORGAN	1	3	central nervous system
NCT0000228510	NCT00002285_10_T0	PHENOTYPE	2	3	CNS infection
NCT0000228514	NCT00002285_14_T0	GENE	21	21	III
NCT0000228514	NCT00002285_14_T1	PHENOTYPE	17	18	generalized lymphadenopathy
NCT0000228514	NCT00002285_14_T2	PHENOTYPE	9	10	Kaposi's sarcoma
NCT0000228516	NCT00002285_16_T0	PHENOTYPE	4	6	positive blood culture
NCT000022861	NCT00002286_1_T0	GENE	1	1	has
NCT000022869	NCT00002286_9_T0	COMPOUND	3	3	psoralen
NCT000022869	NCT00002286_9_T1	COMPOUND	1	1	methotrexate
NCT0000228610	NCT00002286_10_T0	PHENOTYPE	11	11	distal
NCT000022874	NCT00002287_4_T0	PHENOTYPE	8	8	HIV
NCT000022875	NCT00002287_5_T0	PHENOTYPE	18	18	HIV
NCT000022878	NCT00002287_8_T0	PHENOTYPE	4	4	needlesticks
NCT000022878	NCT00002287_8_T1	PHENOTYPE	6	6	cuts
NCT0000228710	NCT00002287_10_T0	PHENOTYPE	3	4	alcohol abuse
NCT000022891	NCT00002289_1_T0	PHENOTYPE	19	19	HIV
NCT000022891	NCT00002289_1_T1	PHENOTYPE	13	14	clinical findings
NCT000022891	NCT00002289_1_T2	ORGAN	8	9	immune system
NCT000022900	NCT00002290_0_T0	PHENOTYPE	12	13	HIV Infection
NCT000022903	NCT00002290_3_T0	BIOLOGICAL_PROCESS	13	14	viral replication
NCT000022919	NCT00002291_9_T0	PHENOTYPE	1	2	substance abuse
NCT000022960	NCT00002296_0_T0	ORGAN	10	11	Immune Systems
NCT000022960	NCT00002296_0_T1	PHENOTYPE	13	15	Lymph Node Disease
NCT000022967	NCT00002296_7_T0	GENE	0	0	IV
NCT000022967	NCT00002296_7_T1	PHENOTYPE	1	2	drug abuse
NCT000022970	NCT00002297_0_T0	PHENOTYPE	7	9	Lymph Node Disease
NCT000022974	NCT00002297_4_T0	PHENOTYPE	0	0	Infections
NCT000022974	NCT00002297_4_T1	PHENOTYPE	13	14	Herpes simplex
NCT000022974	NCT00002297_4_T2	PHENOTYPE	9	11	Pneumocystis carinii pneumonia
NCT000022978	NCT00002297_8_T0	PHENOTYPE	0	1	Critically ill
NCT0000229812	NCT00002298_12_T0	GENE	9	9	separated
NCT0000229813	NCT00002298_13_T0	CELL	17	17	lymphocyte
NCT000022991	NCT00002299_1_T0	PHENOTYPE	18	18	relapse
NCT000022991	NCT00002299_1_T1	PHENOTYPE	19	19	neutropenia
NCT000022992	NCT00002299_2_T0	PHENOTYPE	33	33	relapse
NCT000022992	NCT00002299_2_T1	GENE	18	18	reduced
NCT000022992	NCT00002299_2_T2	PHENOTYPE	36	36	neutropenia
NCT000022992	NCT00002299_2_T3	GENE	13	14	interferon beta
NCT000022992	NCT00002299_2_T4	GENE	29	30	interferon beta
NCT000022998	NCT00002299_8_T0	PHENOTYPE	3	3	Condition
NCT000023000	NCT00002300_0_T0	PHENOTYPE	14	14	Anorexia
NCT000023000	NCT00002300_0_T1	PHENOTYPE	16	16	Malnutrition
NCT000023002	NCT00002300_2_T0	PHENOTYPE	7	8	weight gain
NCT000023003	NCT00002300_3_T0	PHENOTYPE	17	17	cachexia
NCT000023003	NCT00002300_3_T1	COMPOUND	3	4	megestrol acetate
NCT000023004	NCT00002300_4_T0	CELL	16	16	lymphocytes
NCT000023004	NCT00002300_4_T1	COMPOUND	2	2	megestrol
NCT000023014	NCT00002301_4_T0	GENE	8	8	p24
NCT000023014	NCT00002301_4_T1	PHENOTYPE	7	7	HIV
NCT000023014	NCT00002301_4_T2	ORGAN	13	13	plasma
NCT000023021	NCT00002302_1_T0	PHENOTYPE	7	7	anemia
NCT000023047	NCT00002304_7_T0	PHENOTYPE	28	28	symptoms
NCT000023047	NCT00002304_7_T1	PHENOTYPE	16	16	malignancy
NCT000023047	NCT00002304_7_T2	PHENOTYPE	32	32	odynophagia
NCT000023047	NCT00002304_7_T3	PHENOTYPE	30	30	dysphagia
NCT000023047	NCT00002304_7_T4	ORGAN	18	18	transplant
NCT000023047	NCT00002304_7_T5	PHENOTYPE	25	25	candidiasis
NCT000023054	NCT00002305_4_T0	COMPOUND	13	14	amphotericin B
NCT000023071	NCT00002307_1_T0	GENE	15	15	p24
NCT000023071	NCT00002307_1_T1	PHENOTYPE	18	18	HIV
NCT000023071	NCT00002307_1_T2	ORGAN	12	12	plasma
NCT000023071	NCT00002307_1_T3	PHENOTYPE	19	19	viremia
NCT000023071	NCT00002307_1_T4	PHENOTYPE	38	39	HIV infection
NCT000023072	NCT00002307_2_T0	PHENOTYPE	14	15	HIV infection
NCT000023080	NCT00002308_0_T0	GENE	10	10	Had
NCT000023096	NCT00002309_6_T0	PHENOTYPE	13	13	tuberculosis
NCT000023096	NCT00002309_6_T1	GENE	14	14	MTb
NCT000023096	NCT00002309_6_T2	GENE	10	10	MAC
NCT000023101	NCT00002310_1_T0	COMPOUND	25	25	acyclovir
NCT000023101	NCT00002310_1_T1	PHENOTYPE	8	9	herpes simplex
NCT000023103	NCT00002310_3_T0	PHENOTYPE	7	7	resistant
NCT000023103	NCT00002310_3_T1	GENE	1	1	has
NCT000023103	NCT00002310_3_T2	PHENOTYPE	8	8	strains
NCT000023105	NCT00002310_5_T0	PHENOTYPE	7	7	resistant
NCT000023105	NCT00002310_5_T1	GENE	1	1	has
NCT000023105	NCT00002310_5_T2	PHENOTYPE	8	8	strains
NCT000023107	NCT00002310_7_T0	PHENOTYPE	5	6	herpes simplex
NCT000023111	NCT00002311_1_T0	PHENOTYPE	12	12	progression
NCT000023111	NCT00002311_1_T1	PHENOTYPE	14	15	HIV disease
NCT000023122	NCT00002312_2_T0	GENE	3	3	MTD
NCT0000231210	NCT00002312_10_T0	PHENOTYPE	6	6	practices
NCT0000231211	NCT00002312_11_T0	PHENOTYPE	1	2	substance abuse
NCT000023131	NCT00002313_1_T0	COMPOUND	10	10	nystatin
NCT000023131	NCT00002313_1_T1	COMPOUND	13	13	didanosine
NCT000023133	NCT00002313_3_T0	COMPOUND	12	12	nystatin
NCT000023133	NCT00002313_3_T1	COMPOUND	29	29	nystatin
NCT000023141	NCT00002314_1_T0	PHENOTYPE	8	8	HIV
NCT000023141	NCT00002314_1_T1	PHENOTYPE	5	5	tolerance
NCT000023142	NCT00002314_2_T0	PHENOTYPE	18	19	drug toxicity
NCT000023147	NCT00002314_7_T0	PHENOTYPE	11	12	adverse reactions
NCT000023149	NCT00002314_9_T0	PHENOTYPE	0	0	Localized
NCT0000231410	NCT00002314_10_T0	PHENOTYPE	3	3	localized
NCT0000231411	NCT00002314_11_T0	PHENOTYPE	3	4	alcohol abuse
NCT000023151	NCT00002315_1_T0	PHENOTYPE	5	5	tolerance
NCT000023153	NCT00002315_3_T0	PHENOTYPE	8	9	HIV infection
NCT000023161	NCT00002316_1_T0	GENE	7	7	CSF
NCT000023161	NCT00002316_1_T1	PHENOTYPE	3	3	pharmacokinetics
NCT000023161	NCT00002316_1_T2	COMPOUND	10	11	amphotericin B
NCT000023170	NCT00002317_0_T0	PHENOTYPE	9	11	Pneumocystis Carinii Pneumonia
NCT000023173	NCT00002317_3_T0	COMPOUND	10	11	trimetrexate glucuronate
NCT000023181	NCT00002318_1_T0	GENE	19	19	KS
NCT000023181	NCT00002318_1_T1	PHENOTYPE	5	5	tolerance
NCT000023184	NCT00002318_4_T0	PHENOTYPE	0	1	Kaposi's sarcoma
NCT000023185	NCT00002318_5_T0	GENE	9	9	KS
NCT000023191	NCT00002319_1_T0	PHENOTYPE	6	7	Kaposi's sarcoma
NCT000023193	NCT00002319_3_T0	GENE	0	0	KS
NCT000023205	NCT00002320_5_T0	PHENOTYPE	10	10	toxicity
NCT000023230	NCT00002323_0_T0	GENE	37	37	CD4
NCT000023230	NCT00002323_0_T1	CELL	38	38	Cell
NCT000023232	NCT00002323_2_T0	GENE	9	9	CD4
NCT000023232	NCT00002323_2_T1	CELL	10	10	T-cell
NCT000023234	NCT00002323_4_T0	PHENOTYPE	10	12	signs and symptoms
NCT000023235	NCT00002323_5_T0	PHENOTYPE	5	5	tolerance
NCT0000232313	NCT00002323_13_T0	PHENOTYPE	15	16	HIV infection
NCT000023241	NCT00002324_1_T0	COMPOUND	7	7	nevirapine
NCT000023241	NCT00002324_1_T1	PHENOTYPE	5	5	tolerance
NCT000023244	NCT00002324_4_T0	GENE	2	2	II
NCT000023244	NCT00002324_4_T1	COMPOUND	10	10	nevirapine
NCT000023245	NCT00002324_5_T0	COMPOUND	6	6	nevirapine
NCT000023262	NCT00002326_2_T0	GENE	1	1	MTD
NCT000023266	NCT00002326_6_T0	PHENOTYPE	6	6	malignancy
NCT0000232610	NCT00002326_10_T0	PHENOTYPE	11	12	Kaposi's sarcoma
NCT0000232612	NCT00002326_12_T0	COMPOUND	6	6	heroin
NCT0000232612	NCT00002326_12_T1	COMPOUND	8	8	cocaine
NCT0000232613	NCT00002326_13_T0	PHENOTYPE	0	0	Ingestion
NCT000023273	NCT00002327_3_T0	PHENOTYPE	16	16	toxicity
NCT000023275	NCT00002327_5_T0	PHENOTYPE	16	16	toxicity
NCT000023275	NCT00002327_5_T1	GENE	3	3	extended
NCT0000232711	NCT00002327_11_T0	PHENOTYPE	11	11	syphilis
NCT0000232711	NCT00002327_11_T1	PHENOTYPE	13	14	Bowenoid papulosis
NCT000023280	NCT00002328_0_T0	PHENOTYPE	5	5	Cryptosporidiosis
NCT000023280	NCT00002328_0_T1	GENE	11	11	Had
NCT000023283	NCT00002328_3_T0	COMPOUND	6	6	azithromycin
NCT000023284	NCT00002328_4_T0	COMPOUND	15	15	azithromycin
NCT000023284	NCT00002328_4_T1	GENE	6	6	IV
NCT000023284	NCT00002328_4_T2	GENE	14	14	IV
NCT000023284	NCT00002328_4_T3	PHENOTYPE	2	3	persistent diarrhea
NCT000023285	NCT00002328_5_T0	COMPOUND	36	36	azithromycin
NCT000023291	NCT00002329_1_T0	PHENOTYPE	6	6	acute
NCT000023291	NCT00002329_1_T1	GENE	3	3	MTD
NCT000023292	NCT00002329_2_T0	PHENOTYPE	18	18	acute
NCT000023292	NCT00002329_2_T1	COMPOUND	9	9	castanospermine
NCT000023301	NCT00002330_1_T0	COMPOUND	10	10	ganciclovir
NCT000023301	NCT00002330_1_T1	PHENOTYPE	5	5	tolerance
NCT000023311	NCT00002331_1_T0	PHENOTYPE	9	9	sterile
NCT000023312	NCT00002331_2_T0	PHENOTYPE	16	16	sterile
NCT000023326	NCT00002332_6_T0	PHENOTYPE	14	15	opportunistic infection
NCT000023333	NCT00002333_3_T0	GENE	5	5	CD4
NCT000023349	NCT00002334_9_T0	PHENOTYPE	10	11	Hodgkin's lymphoma
NCT000023353	NCT00002335_3_T0	PHENOTYPE	13	13	pharmacokinetics
NCT000023357	NCT00002335_7_T0	PHENOTYPE	11	11	pancreatitis
NCT000023357	NCT00002335_7_T1	PHENOTYPE	13	13	cardiomyopathy
NCT000023357	NCT00002335_7_T2	PHENOTYPE	10	10	hepatitis
NCT000023370	NCT00002337_0_T0	PHENOTYPE	9	10	HIV Disease
NCT0000233712	NCT00002337_12_T0	COMPOUND	9	9	heroin
NCT0000233712	NCT00002337_12_T1	COMPOUND	6	6	cocaine
NCT0000233712	NCT00002337_12_T2	COMPOUND	7	8	amyl nitrate
NCT000023385	NCT00002338_5_T0	PHENOTYPE	14	14	toxicity
NCT000023386	NCT00002338_6_T0	PHENOTYPE	7	7	toxicity
NCT0000233813	NCT00002338_13_T0	PHENOTYPE	15	15	hepatitis
NCT000023392	NCT00002339_2_T0	PHENOTYPE	13	13	symptoms
NCT000023398	NCT00002339_8_T0	COMPOUND	14	14	azoles
NCT000023398	NCT00002339_8_T1	PHENOTYPE	10	10	allergy
NCT000023400	NCT00002340_0_T0	PHENOTYPE	10	12	Pneumocystis Carinii Pneumonia
NCT000023402	NCT00002340_2_T0	PHENOTYPE	5	5	chronic
NCT000023402	NCT00002340_2_T1	PHENOTYPE	15	16	HIV disease
NCT000023410	NCT00002341_0_T0	GENE	17	17	Had
NCT000023410	NCT00002341_0_T1	PHENOTYPE	5	6	Fungal Infections
NCT000023423	NCT00002342_3_T0	GENE	1	1	punch
NCT000023423	NCT00002342_3_T1	PHENOTYPE	9	10	Kaposi's sarcoma
NCT000023431	NCT00002343_1_T0	COMPOUND	2	2	rifabutin
NCT000023431	NCT00002343_1_T1	COMPOUND	4	4	ethambutol
NCT000023431	NCT00002343_1_T2	PHENOTYPE	19	20	MAC bacteremia
NCT000023441	NCT00002344_1_T0	PHENOTYPE	15	15	HIV
NCT000023441	NCT00002344_1_T1	COMPOUND	9	9	azithromycin
NCT000023443	NCT00002344_3_T0	COMPOUND	5	5	azithromycin
NCT000023444	NCT00002344_4_T0	GENE	3	3	separated
NCT000023451	NCT00002345_1_T0	PHENOTYPE	12	13	weight gain
NCT000023468	NCT00002346_8_T0	PHENOTYPE	10	11	lactose intolerance
NCT0000234610	NCT00002346_10_T0	PHENOTYPE	11	12	Kaposi's sarcoma
NCT0000234611	NCT00002346_11_T0	PHENOTYPE	1	2	substance abuse
NCT0000234611	NCT00002346_11_T1	PHENOTYPE	10	12	positive drug screen
NCT000023470	NCT00002347_0_T0	PHENOTYPE	18	19	HIV Infection
NCT000023473	NCT00002347_3_T0	PHENOTYPE	7	8	HIV infection
NCT000023474	NCT00002347_4_T0	GENE	2	2	has
NCT000023476	NCT00002347_6_T0	GENE	2	2	has
NCT000023477	NCT00002347_7_T0	COMPOUND	12	12	nevirapine
NCT000023477	NCT00002347_7_T1	COMPOUND	5	5	AZT-ddC
NCT000023490	NCT00002349_0_T0	PHENOTYPE	23	24	HIV Infection
NCT000023491	NCT00002349_1_T0	PHENOTYPE	1	1	Infection
NCT000023493	NCT00002349_3_T0	PHENOTYPE	9	11	quality of life
NCT000023499	NCT00002349_9_T0	PHENOTYPE	10	10	bilateral
NCT000023499	NCT00002349_9_T1	PHENOTYPE	11	12	peripheral neuropathy
NCT000023503	NCT00002350_3_T0	CELL	1	1	cells
NCT000023503	NCT00002350_3_T1	CELL	25	25	T-cells
NCT000023503	NCT00002350_3_T2	CELL	28	28	T-cells
NCT000023507	NCT00002350_7_T0	CELL	1	1	cells
NCT000023507	NCT00002350_7_T1	CELL	25	25	T-cells
NCT000023507	NCT00002350_7_T2	CELL	28	28	T-cells
NCT000023512	NCT00002351_2_T0	ORGAN	3	3	plasma
NCT000023515	NCT00002351_5_T0	ORGAN	1	1	plasma
NCT000023533	NCT00002353_3_T0	PHENOTYPE	18	18	toxicity
NCT000023533	NCT00002353_3_T1	GENE	2	3	group 2
NCT000023570	NCT00002357_0_T0	PHENOTYPE	17	17	Mild
NCT000023570	NCT00002357_0_T1	PHENOTYPE	20	20	Symptoms
NCT0000235715	NCT00002357_15_T0	GENE	8	9	reverse transcriptase
NCT000023590	NCT00002359_0_T0	CELL	37	37	T-Lymphocytes
NCT000023590	NCT00002359_0_T1	GENE	36	36	CD4
NCT000023590	NCT00002359_0_T2	GENE	22	22	IFA
NCT000023590	NCT00002359_0_T3	GENE	4	4	III
NCT000023590	NCT00002359_0_T4	PHENOTYPE	33	34	HIV Infection
NCT0000235910	NCT00002359_10_T0	PHENOTYPE	6	6	practices
NCT000023601	NCT00002360_1_T0	PHENOTYPE	4	4	HIV
NCT000023609	NCT00002360_9_T0	GENE	0	1	Group 1
NCT0000236014	NCT00002360_14_T0	PHENOTYPE	5	6	adverse effects
NCT000023613	NCT00002361_3_T0	PHENOTYPE	7	7	experiences
NCT000023614	NCT00002361_4_T0	ORGAN	5	5	plasma
NCT0000236311	NCT00002363_11_T0	PHENOTYPE	3	3	Condition
NCT0000236415	NCT00002364_15_T0	BIOLOGICAL_PROCESS	1	1	Behavior
NCT0000236415	NCT00002364_15_T1	PHENOTYPE	9	10	drug use
NCT000023654	NCT00002365_4_T0	PHENOTYPE	3	3	Acute
NCT000023654	NCT00002365_4_T1	PHENOTYPE	12	12	infections
NCT000023654	NCT00002365_4_T2	PHENOTYPE	6	7	opportunistic infections
NCT000023658	NCT00002365_8_T0	PHENOTYPE	6	6	lymphoma
NCT000023658	NCT00002365_8_T1	PHENOTYPE	3	4	Kaposi's sarcoma
NCT0000236514	NCT00002365_14_T0	GENE	19	19	has
NCT0000236514	NCT00002365_14_T1	PHENOTYPE	20	20	diarrhea
NCT000023662	NCT00002366_2_T0	PHENOTYPE	3	3	Localized
NCT000023666	NCT00002366_6_T0	PHENOTYPE	5	6	Kaposi's sarcoma
NCT000023669	NCT00002366_9_T0	BIOLOGICAL_PROCESS	1	1	Behavior
NCT000023669	NCT00002366_9_T1	PHENOTYPE	4	5	substance abuse
NCT000023689	NCT00002368_9_T0	PHENOTYPE	9	9	symptoms
NCT000023689	NCT00002368_9_T1	PHENOTYPE	23	23	diseases
NCT0000236811	NCT00002368_11_T0	BIOLOGICAL_PROCESS	1	1	Behavior
NCT0000236811	NCT00002368_11_T1	PHENOTYPE	7	7	chronic
NCT000023695	NCT00002369_5_T0	PHENOTYPE	8	8	symptoms
NCT000023695	NCT00002369_5_T1	PHENOTYPE	3	3	Condition
NCT000023700	NCT00002370_0_T0	PHENOTYPE	7	8	HIV Infection
NCT000023703	NCT00002370_3_T0	COMPOUND	8	10	itraconazole oral solution
NCT000023706	NCT00002370_6_T0	GENE	7	7	has
NCT000023713	NCT00002371_3_T0	PHENOTYPE	3	3	HIV
NCT000023713	NCT00002371_3_T1	COMPOUND	20	20	indinavir
NCT000023713	NCT00002371_3_T2	ORGAN	2	2	plasma
NCT000023722	NCT00002372_2_T0	COMPOUND	9	9	nelfinavir
NCT000023722	NCT00002372_2_T1	COMPOUND	6	6	saquinavir
NCT000023722	NCT00002372_2_T2	COMPOUND	7	7	indinavir
NCT000023722	NCT00002372_2_T3	PHENOTYPE	4	4	pharmacokinetics
NCT000023723	NCT00002372_3_T0	COMPOUND	17	17	nelfinavir
NCT000023723	NCT00002372_3_T1	COMPOUND	14	14	saquinavir
NCT000023723	NCT00002372_3_T2	COMPOUND	15	15	indinavir
NCT000023725	NCT00002372_5_T0	COMPOUND	16	16	indinavir
NCT000023726	NCT00002372_6_T0	COMPOUND	14	14	indinavir
NCT0000237223	NCT00002372_23_T0	PHENOTYPE	4	5	drug use
NCT0000237311	NCT00002373_11_T0	PHENOTYPE	13	13	diseases
NCT0000237311	NCT00002373_11_T1	PHENOTYPE	9	10	HIV infection
NCT0000237313	NCT00002373_13_T0	PHENOTYPE	7	7	malignancy
NCT0000237314	NCT00002373_14_T0	PHENOTYPE	9	9	malignancy
NCT000023743	NCT00002374_3_T0	GENE	8	8	CD4
NCT000023743	NCT00002374_3_T1	ORGAN	4	4	plasma
NCT000023743	NCT00002374_3_T2	CELL	9	9	lymphocyte
NCT000023751	NCT00002375_1_T0	PHENOTYPE	15	15	HIV
NCT000023754	NCT00002375_4_T0	GENE	16	16	A1
NCT000023754	NCT00002375_4_T1	GENE	26	26	A2
NCT000023754	NCT00002375_4_T2	COMPOUND	14	14	nelfinavir
NCT000023754	NCT00002375_4_T3	COMPOUND	23	23	nelfinavir
NCT000023754	NCT00002375_4_T4	COMPOUND	12	12	indinavir
NCT000023754	NCT00002375_4_T5	COMPOUND	20	20	indinavir
NCT000023755	NCT00002375_5_T0	GENE	6	6	A1
NCT000023755	NCT00002375_5_T1	COMPOUND	9	9	nelfinavir
NCT000023756	NCT00002375_6_T0	PHENOTYPE	24	24	toxicity
NCT000023756	NCT00002375_6_T1	COMPOUND	4	4	nelfinavir
NCT000023756	NCT00002375_6_T2	PHENOTYPE	28	29	adverse events
NCT000023757	NCT00002375_7_T0	GENE	25	25	A1
NCT000023757	NCT00002375_7_T1	GENE	3	3	A2
NCT000023757	NCT00002375_7_T2	COMPOUND	18	18	nelfinavir
NCT000023757	NCT00002375_7_T3	COMPOUND	30	30	nelfinavir
NCT000023757	NCT00002375_7_T4	COMPOUND	16	16	indinavir
NCT000023757	NCT00002375_7_T5	COMPOUND	28	28	indinavir
NCT000023758	NCT00002375_8_T0	COMPOUND	19	19	nelfinavir
NCT000023758	NCT00002375_8_T1	COMPOUND	17	17	indinavir
NCT000023759	NCT00002375_9_T0	COMPOUND	17	17	nelfinavir
NCT000023759	NCT00002375_9_T1	COMPOUND	19	19	indinavir
NCT0000237511	NCT00002375_11_T0	COMPOUND	19	19	nelfinavir
NCT0000237511	NCT00002375_11_T1	COMPOUND	17	17	indinavir
NCT000023762	NCT00002376_2_T0	GENE	9	9	CD4
NCT000023762	NCT00002376_2_T1	GENE	37	37	CD4
NCT000023762	NCT00002376_2_T2	PHENOTYPE	5	5	HIV
NCT000023762	NCT00002376_2_T3	PHENOTYPE	33	33	decisions
NCT000023762	NCT00002376_2_T4	PHENOTYPE	46	46	decisions
NCT000023764	NCT00002376_4_T0	COMPOUND	21	21	1
NCT000023764	NCT00002376_4_T1	COMPOUND	27	27	2
NCT000023764	NCT00002376_4_T2	GENE	10	10	CD4
NCT000023765	NCT00002376_5_T0	GENE	5	5	CD4
NCT000023769	NCT00002376_9_T0	COMPOUND	20	20	zidovudine
NCT000023769	NCT00002376_9_T1	COMPOUND	17	17	stavudine
NCT000023769	NCT00002376_9_T2	COMPOUND	13	13	didanosine
NCT000023769	NCT00002376_9_T3	COMPOUND	15	15	lamivudine
NCT000023769	NCT00002376_9_T4	GENE	1	2	reverse transcriptase
NCT0000237612	NCT00002376_12_T0	COMPOUND	9	9	indinavir
NCT0000237614	NCT00002376_14_T0	COMPOUND	1	1	2
NCT0000237616	NCT00002376_16_T0	COMPOUND	1	1	2
NCT0000237618	NCT00002376_18_T0	COMPOUND	1	1	2
NCT0000237620	NCT00002376_20_T0	COMPOUND	1	1	2
NCT0000237622	NCT00002376_22_T0	COMPOUND	1	1	2
NCT0000237622	NCT00002376_22_T1	GENE	4	5	Group 1
NCT0000237624	NCT00002376_24_T0	GENE	56	56	fell
NCT0000237624	NCT00002376_24_T1	PHENOTYPE	21	21	falling
NCT0000237624	NCT00002376_24_T2	COMPOUND	1	1	2
NCT0000237624	NCT00002376_24_T3	GENE	10	10	CD4
NCT0000237624	NCT00002376_24_T4	GENE	38	38	CD4
NCT0000237624	NCT00002376_24_T5	GENE	54	54	CD4
NCT0000237626	NCT00002376_26_T0	COMPOUND	1	1	2
NCT000023772	NCT00002377_2_T0	PHENOTYPE	3	3	pharmacokinetics
NCT000023772	NCT00002377_2_T1	COMPOUND	5	5	ganciclovir
NCT000023781	NCT00002378_1_T0	ORGAN	6	6	plasma
NCT000023786	NCT00002378_6_T0	GENE	17	17	has
NCT000023786	NCT00002378_6_T1	GENE	10	11	reverse transcriptase
NCT0000237810	NCT00002378_10_T0	GENE	0	0	ARM
NCT0000237813	NCT00002378_13_T0	GENE	11	11	extended
NCT000023792	NCT00002379_2_T0	PHENOTYPE	11	11	falls
NCT000023792	NCT00002379_2_T1	ORGAN	7	7	plasma
NCT000023793	NCT00002379_3_T0	BIOLOGICAL_PROCESS	6	7	antiviral response
NCT000023795	NCT00002379_5_T0	COMPOUND	8	8	zidovudine
NCT000023795	NCT00002379_5_T1	COMPOUND	23	23	zidovudine
NCT000023795	NCT00002379_5_T2	COMPOUND	30	30	zidovudine
NCT000023795	NCT00002379_5_T3	COMPOUND	26	26	stavudine
NCT000023795	NCT00002379_5_T4	COMPOUND	7	7	indinavir
NCT000023795	NCT00002379_5_T5	COMPOUND	14	14	indinavir
NCT000023795	NCT00002379_5_T6	COMPOUND	29	29	indinavir
NCT000023795	NCT00002379_5_T7	COMPOUND	10	10	lamivudine
NCT000023795	NCT00002379_5_T8	COMPOUND	24	24	lamivudine
NCT000023795	NCT00002379_5_T9	COMPOUND	32	32	lamivudine
NCT000023795	NCT00002379_5_T10	COMPOUND	5	6	adefovir dipivoxil
NCT000023795	NCT00002379_5_T11	COMPOUND	12	13	adefovir dipivoxil
NCT0000237916	NCT00002379_16_T0	PHENOTYPE	5	6	substance abuse
NCT000023802	NCT00002380_2_T0	COMPOUND	11	11	saquinavir
NCT000023802	NCT00002380_2_T1	PHENOTYPE	0	0	Pharmacokinetics
NCT000023804	NCT00002380_4_T0	COMPOUND	10	10	saquinavir
NCT000023804	NCT00002380_4_T1	GENE	24	25	protease inhibitor
NCT000023805	NCT00002380_5_T0	COMPOUND	8	8	nelfinavir
NCT000023805	NCT00002380_5_T1	COMPOUND	3	3	saquinavir
NCT000023805	NCT00002380_5_T2	GENE	10	11	protease inhibitor
NCT000023806	NCT00002380_6_T0	PHENOTYPE	1	1	pharmacokinetics
NCT000023811	NCT00002381_1_T0	COMPOUND	9	9	nevirapine
NCT000023811	NCT00002381_1_T1	COMPOUND	10	10	nelfinavir
NCT000023811	NCT00002381_1_T2	GENE	26	27	protease inhibitor
NCT000023811	NCT00002381_1_T3	GENE	21	22	reverse transcriptase
NCT000023813	NCT00002381_3_T0	COMPOUND	13	13	nevirapine
NCT000023813	NCT00002381_3_T1	COMPOUND	15	15	nelfinavir
NCT000023814	NCT00002381_4_T0	GENE	1	1	II
NCT000023814	NCT00002381_4_T1	COMPOUND	14	14	nevirapine
NCT000023814	NCT00002381_4_T2	COMPOUND	16	16	nelfinavir
NCT000023816	NCT00002381_6_T0	COMPOUND	7	7	zidovudine
NCT000023816	NCT00002381_6_T1	COMPOUND	9	9	didanosine
NCT000023816	NCT00002381_6_T2	COMPOUND	8	8	lamivudine
NCT000023821	NCT00002382_1_T0	COMPOUND	17	17	saquinavir
NCT000023823	NCT00002382_3_T0	COMPOUND	23	23	saquinavir
NCT000023824	NCT00002382_4_T0	GENE	22	22	CD4
NCT000023824	NCT00002382_4_T1	GENE	42	42	CD4
NCT000023824	NCT00002382_4_T2	COMPOUND	2	2	saquinavir
NCT000023832	NCT00002383_2_T0	COMPOUND	1	1	2
NCT000023832	NCT00002383_2_T1	COMPOUND	5	5	saquinavir
NCT000023832	NCT00002383_2_T2	GENE	6	6	SGC
NCT000023833	NCT00002383_3_T0	COMPOUND	1	1	3
NCT000023833	NCT00002383_3_T1	COMPOUND	5	5	saquinavir
NCT000023833	NCT00002383_3_T2	GENE	6	6	SGC
NCT000023834	NCT00002383_4_T0	COMPOUND	5	5	saquinavir
NCT000023834	NCT00002383_4_T1	GENE	6	6	SGC
NCT000023835	NCT00002383_5_T0	PHENOTYPE	22	23	drug toxicity
NCT000023836	NCT00002383_6_T0	COMPOUND	14	14	saquinavir
NCT000023836	NCT00002383_6_T1	GENE	15	15	SGC
NCT000023837	NCT00002383_7_T0	GENE	18	18	CD4
NCT000023837	NCT00002383_7_T1	COMPOUND	27	27	saquinavir
NCT000023837	NCT00002383_7_T2	PHENOTYPE	15	16	drug toxicity
NCT0000238310	NCT00002383_10_T0	GENE	8	8	protease
NCT000023851	NCT00002385_1_T0	PHENOTYPE	3	4	adverse event
NCT000023852	NCT00002385_2_T0	PHENOTYPE	6	6	pharmacokinetics
NCT000023853	NCT00002385_3_T0	PHENOTYPE	3	4	adverse event
NCT0000238511	NCT00002385_11_T0	PHENOTYPE	6	6	malignancy
NCT000023862	NCT00002386_2_T0	PHENOTYPE	9	10	hemophilia A
NCT000023863	NCT00002386_3_T0	PHENOTYPE	10	11	hemophilia A
NCT000023864	NCT00002386_4_T0	COMPOUND	14	14	zidovudine
NCT000023864	NCT00002386_4_T1	COMPOUND	7	7	sulfate
NCT000023864	NCT00002386_4_T2	COMPOUND	20	20	stavudine
NCT000023864	NCT00002386_4_T3	COMPOUND	6	6	indinavir
NCT000023864	NCT00002386_4_T4	COMPOUND	16	16	didanosine
NCT000023864	NCT00002386_4_T5	COMPOUND	23	23	lamivudine
NCT000023864	NCT00002386_4_T6	COMPOUND	18	18	zalcitabine
NCT000023866	NCT00002386_6_T0	GENE	16	17	protease inhibitor
NCT0000238610	NCT00002386_10_T0	COMPOUND	14	14	1
NCT0000238610	NCT00002386_10_T1	GENE	27	27	half-life
NCT0000238610	NCT00002386_10_T2	GENE	22	22	VIII
NCT0000238610	NCT00002386_10_T3	GENE	24	24	IX
NCT0000238612	NCT00002386_12_T0	PHENOTYPE	10	10	bleeding
NCT0000238612	NCT00002386_12_T1	GENE	8	8	log
NCT0000238612	NCT00002386_12_T2	GENE	16	16	VIII
NCT0000238612	NCT00002386_12_T3	GENE	18	18	IX
NCT000023876	NCT00002387_6_T0	GENE	17	17	CD4
NCT000023876	NCT00002387_6_T1	ORGAN	13	13	serum
NCT0000238712	NCT00002387_12_T0	GENE	17	17	CD4
NCT0000238712	NCT00002387_12_T1	ORGAN	13	13	serum
NCT0000238713	NCT00002387_13_T0	BIOLOGICAL_PROCESS	14	14	DMP
NCT0000238713	NCT00002387_13_T1	BIOLOGICAL_PROCESS	23	23	DMP
NCT0000238713	NCT00002387_13_T2	COMPOUND	12	12	indinavir
NCT0000238713	NCT00002387_13_T3	COMPOUND	21	21	indinavir
NCT000023881	NCT00002388_1_T0	PHENOTYPE	15	15	HIV
NCT000023881	NCT00002388_1_T1	GENE	7	7	has
NCT000023881	NCT00002388_1_T2	ORGAN	9	9	plasma
NCT0000238814	NCT00002388_14_T0	PHENOTYPE	5	6	substance use
NCT000023893	NCT00002389_3_T0	PHENOTYPE	5	5	tolerance
NCT000023895	NCT00002389_5_T0	GENE	3	3	has
NCT000023895	NCT00002389_5_T1	GENE	22	22	has
NCT000023896	NCT00002389_6_T0	GENE	16	16	has
NCT000023896	NCT00002389_6_T1	GENE	5	5	met
NCT000023897	NCT00002389_7_T0	GENE	20	20	protease
NCT000023897	NCT00002389_7_T1	GENE	12	13	reverse transcriptase
NCT000023897	NCT00002389_7_T2	GENE	16	17	reverse transcriptase
NCT0000238913	NCT00002389_13_T0	PHENOTYPE	12	12	pancreatitis
NCT0000238913	NCT00002389_13_T1	PHENOTYPE	14	14	hepatitis
NCT0000238916	NCT00002389_16_T0	PHENOTYPE	4	5	drug use
NCT000023902	NCT00002390_2_T0	COMPOUND	22	22	zidovudine
NCT000023902	NCT00002390_2_T1	COMPOUND	25	25	lamivudine
NCT000023903	NCT00002390_3_T0	PHENOTYPE	4	4	falling
NCT000023903	NCT00002390_3_T1	GENE	5	5	CD4
NCT000023903	NCT00002390_3_T2	GENE	33	33	CD4
NCT000023903	NCT00002390_3_T3	PHENOTYPE	67	67	HIV
NCT000023903	NCT00002390_3_T4	PHENOTYPE	43	43	suppression
NCT000023903	NCT00002390_3_T5	PHENOTYPE	18	19	disease progression
NCT000023914	NCT00002391_4_T0	GENE	8	8	met
NCT000023927	NCT00002392_7_T0	BIOLOGICAL_PROCESS	1	1	Behavior
NCT000023927	NCT00002392_7_T1	PHENOTYPE	6	7	alcohol abuse
NCT000023928	NCT00002392_8_T0	COMPOUND	17	17	nelfinavir
NCT000023928	NCT00002392_8_T1	COMPOUND	19	19	indinavir
NCT000023934	NCT00002393_4_T0	BIOLOGICAL_PROCESS	15	15	DMP
NCT000023934	NCT00002393_4_T1	COMPOUND	18	18	indinavir
NCT000023943	NCT00002394_3_T0	PHENOTYPE	12	12	plaques
NCT000023953	NCT00002395_3_T0	GENE	11	11	Tat
NCT000023954	NCT00002395_4_T0	COMPOUND	8	8	topotecan
NCT000023955	NCT00002395_5_T0	COMPOUND	11	11	topotecan
NCT000023961	NCT00002396_1_T0	PHENOTYPE	16	16	HIV
NCT000023961	NCT00002396_1_T1	PHENOTYPE	3	3	pharmacokinetics
NCT000023964	NCT00002396_4_T0	GENE	3	3	1.7
NCT000023965	NCT00002396_5_T0	PHENOTYPE	8	8	toxicity
NCT0000239612	NCT00002396_12_T0	BIOLOGICAL_PROCESS	1	1	Behavior
NCT0000239612	NCT00002396_12_T1	PHENOTYPE	6	7	alcohol abuse
NCT0000239612	NCT00002396_12_T2	PHENOTYPE	28	29	substance abuse
NCT000023971	NCT00002397_1_T0	PHENOTYPE	11	12	kidney disease
NCT000023971	NCT00002397_1_T1	PHENOTYPE	14	15	progressing to
NCT000023972	NCT00002397_2_T0	PHENOTYPE	14	14	HIV
NCT000023973	NCT00002397_3_T0	PHENOTYPE	5	6	drug level
NCT000023973	NCT00002397_3_T1	PHENOTYPE	22	23	kidney disease
NCT000023975	NCT00002397_5_T0	ORGAN	13	13	kidney
NCT000023975	NCT00002397_5_T1	COMPOUND	18	18	creatine
NCT000023975	NCT00002397_5_T2	ORGAN	17	17	Serum
NCT000023975	NCT00002397_5_T3	GENE	15	16	Group 1
NCT000023977	NCT00002397_7_T0	COMPOUND	1	1	3
NCT000023977	NCT00002397_7_T1	COMPOUND	3	3	creatine
NCT000023977	NCT00002397_7_T2	ORGAN	2	2	Serum
NCT0000239711	NCT00002397_11_T0	ORGAN	4	4	kidney
NCT000023982	NCT00002398_2_T0	COMPOUND	6	6	adefovir
NCT000023983	NCT00002398_3_T0	PHENOTYPE	6	6	HIV
NCT000023984	NCT00002398_4_T0	PHENOTYPE	9	9	HIV
NCT000023986	NCT00002398_6_T0	PHENOTYPE	14	14	suppression
NCT000023986	NCT00002398_6_T1	GENE	8	8	has
NCT000023986	NCT00002398_6_T2	ORGAN	16	16	plasma
NCT000023987	NCT00002398_7_T0	COMPOUND	40	40	indinavir
NCT000023987	NCT00002398_7_T1	ORGAN	27	27	plasma
NCT000023987	NCT00002398_7_T2	GENE	36	37	reverse transcriptase
NCT000023988	NCT00002398_8_T0	ORGAN	8	8	plasma
NCT000023988	NCT00002398_8_T1	PHENOTYPE	17	17	understood
NCT0000239811	NCT00002398_11_T0	GENE	12	12	reduced
NCT0000239812	NCT00002398_12_T0	PHENOTYPE	19	19	toxicity
NCT000023995	NCT00002399_5_T0	PHENOTYPE	2	3	drug abuse
NCT000024003	NCT00002400_3_T0	GENE	9	9	opt
NCT000024005	NCT00002400_5_T0	COMPOUND	10	10	zidovudine
NCT000024011	NCT00002401_1_T0	COMPOUND	10	10	zidovudine
NCT000024011	NCT00002401_1_T1	COMPOUND	12	12	indinavir
NCT000024011	NCT00002401_1_T2	COMPOUND	15	15	lamivudine
NCT000024016	NCT00002401_6_T0	GENE	2	2	opt
NCT000024023	NCT00002402_3_T0	GENE	5	5	hr
NCT000024031	NCT00002403_1_T0	COMPOUND	0	0	Zintevir
NCT000024031	NCT00002403_1_T1	PHENOTYPE	7	7	HIV
NCT000024031	NCT00002403_1_T2	GENE	10	10	integrase
NCT000024033	NCT00002403_3_T0	GENE	0	0	Integrase
NCT000024033	NCT00002403_3_T1	PHENOTYPE	9	9	HIV
NCT000024033	NCT00002403_3_T2	GENE	3	3	integrase
NCT000024036	NCT00002403_6_T0	GENE	0	0	Integrase
NCT000024036	NCT00002403_6_T1	GENE	3	3	integrase
NCT000024041	NCT00002404_1_T0	PHENOTYPE	5	7	recurrent genital herpes
NCT000024045	NCT00002404_5_T0	PHENOTYPE	8	8	symptoms
NCT000024045	NCT00002404_5_T1	PHENOTYPE	3	3	Condition
NCT000024046	NCT00002404_6_T0	PHENOTYPE	0	1	Hepatic impairment
NCT000024048	NCT00002404_8_T0	COMPOUND	3	3	creatinine
NCT000024048	NCT00002404_8_T1	PHENOTYPE	0	2	Impaired renal function
NCT000024051	NCT00002405_1_T0	PHENOTYPE	12	12	HIV
NCT000024051	NCT00002405_1_T1	GENE	7	7	has
NCT000024053	NCT00002405_3_T0	GENE	14	14	protease
NCT000024053	NCT00002405_3_T1	PHENOTYPE	5	5	HIV
NCT000024053	NCT00002405_3_T2	GENE	25	25	PI
NCT000024055	NCT00002405_5_T0	GENE	6	6	has
NCT000024056	NCT00002405_6_T0	PHENOTYPE	23	23	HIV
NCT000024057	NCT00002405_7_T0	GENE	7	7	has
NCT000024057	NCT00002405_7_T1	GENE	18	19	protease inhibitor
NCT000024058	NCT00002405_8_T0	COMPOUND	10	10	1
NCT000024059	NCT00002405_9_T0	PHENOTYPE	6	7	associated conditions
NCT000024059	NCT00002405_9_T1	PHENOTYPE	9	10	adverse events
NCT0000240512	NCT00002405_12_T0	GENE	24	24	has
NCT0000240515	NCT00002405_15_T0	PHENOTYPE	12	12	pancreatitis
NCT0000240515	NCT00002405_15_T1	PHENOTYPE	14	14	hepatitis
NCT0000240517	NCT00002405_17_T0	BIOLOGICAL_PROCESS	1	1	Behavior
NCT0000240517	NCT00002405_17_T1	PHENOTYPE	9	10	drug use
NCT0000240518	NCT00002405_18_T0	COMPOUND	14	14	amprenavir
NCT0000240518	NCT00002405_18_T1	GENE	9	10	protease inhibitor
NCT000024063	NCT00002406_3_T0	ORGAN	0	0	Plasma
NCT000024074	NCT00002407_4_T0	PHENOTYPE	3	3	Condition
NCT000024074	NCT00002407_4_T1	PHENOTYPE	6	7	HIV disease
NCT000024075	NCT00002407_5_T0	PHENOTYPE	10	10	neuropathy
NCT000024080	NCT00002408_0_T0	PHENOTYPE	20	20	Diarrhea
NCT000024080	NCT00002408_0_T1	PHENOTYPE	22	24	Acquired Immunodeficiency Syndrome
NCT000024091	NCT00002409_1_T0	PHENOTYPE	12	12	HIV
NCT000024097	NCT00002409_7_T0	COMPOUND	5	5	foscarnet
NCT000024101	NCT00002410_1_T0	COMPOUND	14	14	zidovudine
NCT000024101	NCT00002410_1_T1	BIOLOGICAL_PROCESS	6	6	DMP
NCT000024101	NCT00002410_1_T2	BIOLOGICAL_PROCESS	11	11	DMP
NCT000024101	NCT00002410_1_T3	COMPOUND	9	9	indinavir
NCT000024101	NCT00002410_1_T4	COMPOUND	21	21	indinavir
NCT000024101	NCT00002410_1_T5	COMPOUND	5	5	efavirenz
NCT000024101	NCT00002410_1_T6	COMPOUND	17	17	lamivudine
NCT000024102	NCT00002410_2_T0	PHENOTYPE	6	6	HIV
NCT000024112	NCT00002411_2_T0	PHENOTYPE	17	17	HIV
NCT000024117	NCT00002411_7_T0	PHENOTYPE	10	10	acute
NCT000024117	NCT00002411_7_T1	PHENOTYPE	12	13	chronic pancreatitis
NCT000024140	NCT00002414_0_T0	COMPOUND	5	5	CPI-1189
NCT000024140	NCT00002414_0_T1	PHENOTYPE	10	11	AIDS Dementia
NCT000024143	NCT00002414_3_T0	COMPOUND	0	0	CPI-1189
NCT000024143	NCT00002414_3_T1	PHENOTYPE	6	7	AIDS dementia
NCT000024145	NCT00002414_5_T0	COMPOUND	0	0	CPI-1189
NCT000024145	NCT00002414_5_T1	PHENOTYPE	6	7	AIDS dementia
NCT000024146	NCT00002414_6_T0	COMPOUND	14	14	CPI-1189
NCT0000241410	NCT00002414_10_T0	COMPOUND	3	3	CPI-1189
NCT000024165	NCT00002416_5_T0	ORGAN	7	7	plasma
NCT000024166	NCT00002416_6_T0	COMPOUND	1	1	1
NCT000024166	NCT00002416_6_T1	GENE	6	6	PI
NCT000024166	NCT00002416_6_T2	GENE	7	8	protease inhibitor
NCT000024167	NCT00002416_7_T0	COMPOUND	1	1	2
NCT000024167	NCT00002416_7_T1	GENE	8	9	reverse transcriptase
NCT000024168	NCT00002416_8_T0	COMPOUND	1	1	3
NCT000024168	NCT00002416_8_T1	GENE	4	4	PI
NCT000024171	NCT00002417_1_T0	GENE	0	0	Protease
NCT000024172	NCT00002417_2_T0	PHENOTYPE	11	11	hyperlipidemia
NCT000024172	NCT00002417_2_T1	PHENOTYPE	21	21	lipodystrophy
NCT000024174	NCT00002417_4_T0	PHENOTYPE	16	16	HIV
NCT000024174	NCT00002417_4_T1	GENE	1	1	has
NCT000024174	NCT00002417_4_T2	ORGAN	11	11	plasma
NCT000024175	NCT00002417_5_T0	PHENOTYPE	8	8	complications
NCT000024177	NCT00002417_7_T0	PHENOTYPE	21	21	hyperlipidemia
NCT000024177	NCT00002417_7_T1	PHENOTYPE	16	16	complications
NCT000024177	NCT00002417_7_T2	PHENOTYPE	19	19	lipodystrophy
NCT000024177	NCT00002417_7_T3	PHENOTYPE	10	11	adverse effects
NCT000024178	NCT00002417_8_T0	GENE	15	15	protease
NCT000024178	NCT00002417_8_T1	PHENOTYPE	10	10	complications
NCT000024179	NCT00002417_9_T0	ORGAN	12	12	plasma
NCT0000241710	NCT00002417_10_T0	GENE	17	17	protease
NCT0000241717	NCT00002417_17_T0	GENE	7	8	protease inhibitor
NCT0000241718	NCT00002417_18_T0	PHENOTYPE	12	12	pancreatitis
NCT0000241718	NCT00002417_18_T1	PHENOTYPE	14	14	hepatitis
NCT0000241720	NCT00002417_20_T0	BIOLOGICAL_PROCESS	1	1	Behavior
NCT0000241721	NCT00002417_21_T0	GENE	7	8	protease inhibitor
NCT000024181	NCT00002418_1_T0	COMPOUND	11	11	nevirapine
NCT000024181	NCT00002418_1_T1	COMPOUND	8	8	stavudine
NCT000024181	NCT00002418_1_T2	COMPOUND	5	5	didanosine
NCT000024182	NCT00002418_2_T0	GENE	1	1	HU
NCT000024185	NCT00002418_5_T0	COMPOUND	10	10	hydroxyurea
NCT000024185	NCT00002418_5_T1	PHENOTYPE	3	4	virologic failure
NCT000024186	NCT00002418_6_T0	COMPOUND	14	14	nevirapine
NCT000024186	NCT00002418_6_T1	COMPOUND	20	20	hydroxyurea
NCT000024186	NCT00002418_6_T2	COMPOUND	13	13	stavudine
NCT000024186	NCT00002418_6_T3	COMPOUND	12	12	didanosine
NCT000024186	NCT00002418_6_T4	PHENOTYPE	31	31	experiences
NCT000024186	NCT00002418_6_T5	PHENOTYPE	32	33	virologic failure
NCT000024193	NCT00002419_3_T0	PHENOTYPE	3	4	virologic failure
NCT000024203	NCT00002420_3_T0	PHENOTYPE	3	3	pharmacokinetics
NCT000024204	NCT00002420_4_T0	COMPOUND	7	7	hydroxyurea
NCT000024204	NCT00002420_4_T1	PHENOTYPE	3	4	virologic failure
NCT000024205	NCT00002420_5_T0	COMPOUND	3	3	hydroxyurea
NCT000024205	NCT00002420_5_T1	PHENOTYPE	10	11	virologic failure
NCT000024206	NCT00002420_6_T0	ORGAN	17	17	plasma
NCT000024207	NCT00002420_7_T0	COMPOUND	3	3	hydroxyurea
NCT000024208	NCT00002420_8_T0	COMPOUND	14	14	hydroxyurea
NCT000024208	NCT00002420_8_T1	COMPOUND	7	7	delavirdine
NCT000024208	NCT00002420_8_T2	COMPOUND	6	6	stavudine
NCT000024208	NCT00002420_8_T3	COMPOUND	5	5	didanosine
NCT000024221	NCT00002422_1_T0	CELL	17	17	cells
NCT000024221	NCT00002422_1_T1	PHENOTYPE	13	13	HIV
NCT000024221	NCT00002422_1_T2	GENE	3	3	hormone
NCT000024229	NCT00002422_9_T0	PHENOTYPE	5	5	pharmacokinetics
NCT000024229	NCT00002422_9_T1	PHENOTYPE	2	2	tolerance
NCT000024232	NCT00002423_2_T0	PHENOTYPE	2	3	virologic failure
NCT000024243	NCT00002424_3_T0	GENE	1	2	Group 1
NCT000024244	NCT00002424_4_T0	GENE	19	20	Group 1
NCT000024248	NCT00002424_8_T0	PHENOTYPE	26	27	adverse events
NCT000024253	NCT00002425_3_T0	GENE	12	12	PI
NCT000024253	NCT00002425_3_T1	GENE	10	11	protease inhibitor
NCT000024263	NCT00002426_3_T0	COMPOUND	8	8	L-carnitine
NCT000024265	NCT00002426_5_T0	PHENOTYPE	7	8	virologic failure
NCT000024267	NCT00002426_7_T0	PHENOTYPE	0	1	Virologic failure
NCT000024268	NCT00002426_8_T0	PHENOTYPE	9	9	toxicity
NCT000024271	NCT00002427_1_T0	PHENOTYPE	10	10	HIV
NCT000024271	NCT00002427_1_T1	PHENOTYPE	17	17	HIV
NCT000024271	NCT00002427_1_T2	GENE	0	0	HU
NCT000024277	NCT00002427_7_T0	GENE	3	3	HU
NCT000024289	NCT00002428_9_T0	PHENOTYPE	0	0	Intermediate
NCT000024292	NCT00002429_2_T0	PHENOTYPE	12	12	HIV
NCT000024292	NCT00002429_2_T1	PHENOTYPE	21	21	HIV
NCT000024294	NCT00002429_4_T0	GENE	0	1	Group 1
NCT000024296	NCT00002429_6_T0	PHENOTYPE	10	10	HIV
NCT000024302	NCT00002430_2_T0	COMPOUND	5	5	indinavir
NCT000024304	NCT00002430_4_T0	GENE	0	1	Group 1
NCT000024331	NCT00002433_1_T0	GENE	8	8	IFN-gamma
NCT000024331	NCT00002433_1_T1	CELL	4	5	alveolar macrophages
NCT000024342	NCT00002434_2_T0	COMPOUND	10	11	trimetrexate glucuronate
NCT000024351	NCT00002435_1_T0	PHENOTYPE	14	14	progression
NCT000024351	NCT00002435_1_T1	CELL	9	9	T-cells
NCT000024351	NCT00002435_1_T2	GENE	6	6	gamma
NCT000024351	NCT00002435_1_T3	PHENOTYPE	10	12	quality of life
NCT000024357	NCT00002435_7_T0	PHENOTYPE	8	8	Myositis
NCT0000243510	NCT00002435_10_T0	PHENOTYPE	1	1	alcoholism
NCT0000243510	NCT00002435_10_T1	PHENOTYPE	2	3	drug abuse
NCT0000243510	NCT00002435_10_T2	PHENOTYPE	8	9	psychiatric problem
NCT000024365	NCT00002436_5_T0	PHENOTYPE	10	10	toxicity
NCT000024375	NCT00002437_5_T0	COMPOUND	21	21	probenecid
NCT000024375	NCT00002437_5_T1	GENE	5	5	IV
NCT000024375	NCT00002437_5_T2	GENE	23	23	IV
NCT000024376	NCT00002437_6_T0	PHENOTYPE	9	9	retinitis
NCT000024376	NCT00002437_6_T1	PHENOTYPE	25	25	retinitis
NCT000024376	NCT00002437_6_T2	PHENOTYPE	10	10	progression
NCT000024376	NCT00002437_6_T3	PHENOTYPE	26	26	progression
NCT000024376	NCT00002437_6_T4	PHENOTYPE	0	1	Group B
NCT000024381	NCT00002438_1_T0	COMPOUND	7	7	itraconazole
NCT000024381	NCT00002438_1_T1	PHENOTYPE	16	16	cryptococcosis
NCT000024381	NCT00002438_1_T2	PHENOTYPE	17	17	aspergillosis
NCT000024381	NCT00002438_1_T3	PHENOTYPE	24	24	recurrent
NCT000024381	NCT00002438_1_T4	PHENOTYPE	25	26	esophageal candidiasis
NCT000024381	NCT00002438_1_T5	PHENOTYPE	12	13	fungal infections
NCT000024381	NCT00002438_1_T6	PHENOTYPE	21	22	vaginal candidiasis
NCT000024385	NCT00002438_5_T0	COMPOUND	12	12	imidazole
NCT000024393	NCT00002439_3_T0	GENE	4	4	gel
NCT000024400	NCT00002440_0_T0	GENE	7	7	Protease
NCT000024406	NCT00002440_6_T0	PHENOTYPE	6	7	Kaposi's sarcoma
NCT0000244014	NCT00002440_14_T0	PHENOTYPE	3	4	drug use
NCT000024410	NCT00002441_0_T0	PHENOTYPE	3	3	HIV
NCT000024410	NCT00002441_0_T1	PHENOTYPE	16	17	HIV Infection
NCT000024412	NCT00002441_2_T0	PHENOTYPE	21	21	HIV
NCT000024416	NCT00002441_6_T0	PHENOTYPE	3	3	HIV
NCT000024423	NCT00002442_3_T0	GENE	0	1	Group 1
NCT000024424	NCT00002442_4_T0	GENE	4	4	bid
NCT000024425	NCT00002442_5_T0	PHENOTYPE	5	5	tolerance
NCT000024433	NCT00002443_3_T0	GENE	0	1	Group 1
NCT000024436	NCT00002443_6_T0	PHENOTYPE	13	13	experiences
NCT000024441	NCT00002444_1_T0	PHENOTYPE	4	4	concentrations
NCT000024443	NCT00002444_3_T0	PHENOTYPE	7	7	chronic
NCT000024443	NCT00002444_3_T1	PHENOTYPE	1	1	enterocolitis
NCT000024444	NCT00002444_4_T0	PHENOTYPE	2	3	antimicrobial activity
NCT000024446	NCT00002444_6_T0	PHENOTYPE	2	3	antimicrobial activity
NCT0000244411	NCT00002444_11_T0	PHENOTYPE	4	4	pharmacokinetics
NCT0000244413	NCT00002444_13_T0	ORGAN	11	11	plasma
NCT0000244419	NCT00002444_19_T0	PHENOTYPE	8	9	opportunistic infection
NCT0000244420	NCT00002444_20_T0	PHENOTYPE	22	22	toxicity
NCT0000244420	NCT00002444_20_T1	PHENOTYPE	8	8	symptoms
NCT0000244420	NCT00002444_20_T2	PHENOTYPE	3	3	Condition
NCT000024450	NCT00002445_0_T0	PHENOTYPE	10	11	Kaposi's Sarcoma
NCT000024454	NCT00002445_4_T0	PHENOTYPE	15	15	toxicity
NCT000024454	NCT00002445_4_T1	PHENOTYPE	11	12	disease progression
NCT000024455	NCT00002445_5_T0	PHENOTYPE	0	2	Quality of life
NCT000024458	NCT00002445_8_T0	PHENOTYPE	4	5	progressive disease
NCT000024461	NCT00002446_1_T0	PHENOTYPE	10	10	thrush
NCT000024477	NCT00002447_7_T0	PHENOTYPE	19	19	HIV
NCT000024477	NCT00002447_7_T1	ORGAN	18	18	plasma
NCT000024477	NCT00002447_7_T2	PHENOTYPE	28	28	experiences
NCT000024478	NCT00002447_8_T0	GENE	4	4	4-8
NCT000024484	NCT00002448_4_T0	COMPOUND	10	10	zidovudine
NCT000024484	NCT00002448_4_T1	COMPOUND	6	6	stavudine
NCT000024484	NCT00002448_4_T2	COMPOUND	8	8	didanosine
NCT000024484	NCT00002448_4_T3	COMPOUND	16	16	zalcitabine
NCT000024484	NCT00002448_4_T4	COMPOUND	12	12	lamivudine
NCT000024487	NCT00002448_7_T0	PHENOTYPE	11	11	lipodystrophy
NCT000024487	NCT00002448_7_T1	PHENOTYPE	2	3	adverse effects
NCT000024491	NCT00002449_1_T0	GENE	1	1	IL-2
NCT000024491	NCT00002449_1_T1	GENE	0	0	Interleukin-2
NCT000024491	NCT00002449_1_T2	CELL	10	12	white blood cells
NCT000024492	NCT00002449_2_T0	GENE	0	0	IL-2
NCT000024492	NCT00002449_2_T1	ORGAN	7	8	immune systems
NCT000024492	NCT00002449_2_T2	PHENOTYPE	12	13	HIV infection
NCT000024496	NCT00002449_6_T0	GENE	21	21	MTD
NCT000024497	NCT00002449_7_T0	GENE	17	17	ART
NCT000024497	NCT00002449_7_T1	GENE	27	27	ART
NCT000024497	NCT00002449_7_T2	GENE	30	30	ART
NCT000024498	NCT00002449_8_T0	GENE	5	5	SC
NCT000024499	NCT00002449_9_T0	GENE	5	5	receptor
NCT000024499	NCT00002449_9_T1	GENE	1	1	IL-2
NCT000024499	NCT00002449_9_T2	GENE	4	4	IL-2
NCT000024499	NCT00002449_9_T3	ORGAN	0	0	Serum
NCT000024505	NCT00002450_5_T0	COMPOUND	15	15	tenofovir
NCT000024508	NCT00002450_8_T0	COMPOUND	16	16	tenofovir
NCT000024508	NCT00002450_8_T1	GENE	10	10	rolled
NCT000024508	NCT00002450_8_T2	GENE	13	13	extended
NCT000024515	NCT00002451_5_T0	GENE	27	27	CD4
NCT000024517	NCT00002451_7_T0	PHENOTYPE	6	7	adverse events
NCT000024517	NCT00002451_7_T1	PHENOTYPE	10	11	adverse events
NCT000024524	NCT00002452_4_T0	ORGAN	0	0	Plasma
NCT000024530	NCT00002453_0_T0	PHENOTYPE	11	12	HIV Infection
NCT000024541	NCT00002454_1_T0	GENE	2	2	II
NCT000024541	NCT00002454_1_T1	ORGAN	21	21	larynx
NCT000024541	NCT00002454_1_T2	PHENOTYPE	9	9	papilloma
NCT000024541	NCT00002454_1_T3	PHENOTYPE	18	18	papilloma
NCT000024541	NCT00002454_1_T4	PHENOTYPE	17	17	recurrent
NCT000024543	NCT00002454_3_T0	ORGAN	11	11	larynx
NCT000024543	NCT00002454_3_T1	PHENOTYPE	21	21	tumor
NCT000024543	NCT00002454_3_T2	PHENOTYPE	8	8	papilloma
NCT000024543	NCT00002454_3_T3	BIOLOGICAL_PROCESS	2	3	immune response
NCT000024544	NCT00002454_4_T0	PHENOTYPE	4	4	papilloma
NCT000024551	NCT00002455_1_T0	PHENOTYPE	22	22	melanoma
NCT000024551	NCT00002455_1_T1	GENE	14	14	had
NCT000024551	NCT00002455_1_T2	PHENOTYPE	19	20	colon cancer
NCT000024551	NCT00002455_1_T3	PHENOTYPE	17	18	breast cancer
NCT000024552	NCT00002455_2_T0	GENE	2	2	III
NCT000024552	NCT00002455_2_T1	PHENOTYPE	26	26	melanoma
NCT000024552	NCT00002455_2_T2	PHENOTYPE	23	24	colon cancer
NCT000024552	NCT00002455_2_T3	PHENOTYPE	21	22	breast cancer
NCT000024556	NCT00002455_6_T0	GENE	10	10	P40
NCT000024562	NCT00002456_2_T0	COMPOUND	2	2	cyclosporine
NCT000024563	NCT00002456_3_T0	COMPOUND	13	13	cyclosporine
NCT000024563	NCT00002456_3_T1	GENE	2	2	III
NCT000024563	NCT00002456_3_T2	COMPOUND	11	11	methotrexate
NCT000024563	NCT00002456_3_T3	ORGAN	15	16	bone marrow
NCT000024563	NCT00002456_3_T4	PHENOTYPE	22	24	acute graft-versus-host disease
NCT000024566	NCT00002456_6_T0	COMPOUND	3	3	methotrexate
NCT000024566	NCT00002456_6_T1	GENE	4	4	IV
NCT000024567	NCT00002456_7_T0	COMPOUND	3	3	cyclosporine
NCT000024567	NCT00002456_7_T1	BIOLOGICAL_PROCESS	12	12	eating
NCT000024567	NCT00002456_7_T2	GENE	4	4	IV
NCT000024568	NCT00002456_8_T0	COMPOUND	4	4	1
NCT000024569	NCT00002456_9_T0	GENE	3	3	reduced
NCT000024581	NCT00002458_1_T0	GENE	2	2	II
NCT000024581	NCT00002458_1_T1	PHENOTYPE	19	19	remission
NCT000024581	NCT00002458_1_T2	PHENOTYPE	15	16	metastatic neuroblastoma
NCT000024583	NCT00002458_3_T0	COMPOUND	8	8	3F8
NCT000024583	NCT00002458_3_T1	PHENOTYPE	20	20	remission
NCT000024583	NCT00002458_3_T2	PHENOTYPE	17	17	neuroblastoma
NCT000024583	NCT00002458_3_T3	GENE	16	16	IV
NCT000024583	NCT00002458_3_T4	COMPOUND	4	5	ganglioside GD2
NCT000024585	NCT00002458_5_T0	COMPOUND	4	4	3F8
NCT000024585	NCT00002458_5_T1	COMPOUND	6	6	3F8
NCT000024596	NCT00002459_6_T0	PHENOTYPE	12	12	sarcoma
NCT000024596	NCT00002459_6_T1	PHENOTYPE	8	8	leiomyosarcoma
NCT000024596	NCT00002459_6_T2	PHENOTYPE	6	6	tumor
NCT000024596	NCT00002459_6_T3	PHENOTYPE	27	27	bilateral
NCT000024596	NCT00002459_6_T4	GENE	21	21	abdominal
NCT000024596	NCT00002459_6_T5	PHENOTYPE	14	16	endometrial stromal sarcoma
NCT000024602	NCT00002460_2_T0	COMPOUND	17	17	goserelin
NCT000024602	NCT00002460_2_T1	GENE	2	2	III
NCT000024602	NCT00002460_2_T2	COMPOUND	12	12	tamoxifen
NCT000024602	NCT00002460_2_T3	PHENOTYPE	27	30	stage II breast cancer
NCT000024604	NCT00002460_4_T0	PHENOTYPE	27	27	recurrence
NCT000024604	NCT00002460_4_T1	COMPOUND	15	15	tamoxifen
NCT000024604	NCT00002460_4_T2	PHENOTYPE	39	42	carcinoma of the breast
NCT000024606	NCT00002460_6_T0	PHENOTYPE	4	4	affects
NCT000024606	NCT00002460_6_T1	GENE	2	2	hormone
NCT000024609	NCT00002460_9_T0	COMPOUND	17	17	cyclophosphamide
NCT000024609	NCT00002460_9_T1	COMPOUND	24	24	cyclophosphamide
NCT000024609	NCT00002460_9_T2	COMPOUND	25	25	methotrexate
NCT0000246010	NCT00002460_10_T0	COMPOUND	15	15	tamoxifen
NCT0000246012	NCT00002460_12_T0	COMPOUND	4	4	tamoxifen
NCT0000246013	NCT00002460_13_T0	COMPOUND	7	7	goserelin
NCT0000246014	NCT00002460_14_T0	COMPOUND	7	7	goserelin
NCT0000246014	NCT00002460_14_T1	COMPOUND	10	10	tamoxifen
NCT000024611	NCT00002461_1_T0	CELL	9	9	cells
NCT000024615	NCT00002461_5_T0	GENE	34	34	G-CSF
NCT000024615	NCT00002461_5_T1	GENE	37	37	GM-CSF
NCT000024615	NCT00002461_5_T2	GENE	33	33	filgrastim
NCT000024615	NCT00002461_5_T3	COMPOUND	12	12	cyclophosphamide
NCT000024615	NCT00002461_5_T4	COMPOUND	8	8	etoposide
NCT000024615	NCT00002461_5_T5	COMPOUND	25	25	etoposide
NCT000024615	NCT00002461_5_T6	COMPOUND	10	10	cisplatin
NCT000024615	NCT00002461_5_T7	GENE	36	36	sargramostim
NCT000024615	NCT00002461_5_T8	ORGAN	18	19	bone marrow
NCT000024615	NCT00002461_5_T9	PHENOTYPE	46	47	Hodgkin's disease
NCT000024615	NCT00002461_5_T10	PHENOTYPE	49	50	Hodgkin's lymphoma
NCT000024615	NCT00002461_5_T11	CELL	27	30	peripheral blood stem cells
NCT000024617	NCT00002461_7_T0	PHENOTYPE	6	6	peripheral
NCT0000246111	NCT00002461_11_T0	COMPOUND	16	16	etoposide
NCT0000246111	NCT00002461_11_T1	ORGAN	1	2	bone marrow
NCT0000246113	NCT00002461_13_T0	PHENOTYPE	10	10	remission
NCT0000246113	NCT00002461_13_T1	ORGAN	3	4	bone marrow
NCT0000246113	NCT00002461_13_T2	ORGAN	8	9	bone marrow
NCT0000246115	NCT00002461_15_T0	GENE	6	6	filgrastim
NCT0000246115	NCT00002461_15_T1	GENE	7	7	G-CSF
NCT0000246115	NCT00002461_15_T2	GENE	4	4	GM-CSF
NCT0000246115	NCT00002461_15_T3	GENE	3	3	sargramostim
NCT0000246115	NCT00002461_15_T4	CELL	15	18	peripheral blood stem cells
NCT0000246116	NCT00002461_16_T0	GENE	24	24	14
NCT0000246116	NCT00002461_16_T1	GENE	22	22	17
NCT0000246116	NCT00002461_16_T2	GENE	16	16	cm
NCT0000246116	NCT00002461_16_T3	GENE	20	20	21
NCT0000246118	NCT00002461_18_T0	COMPOUND	7	7	cyclophosphamide
NCT0000246118	NCT00002461_18_T1	COMPOUND	5	5	cisplatin
NCT0000246118	NCT00002461_18_T2	GENE	8	8	IV
NCT0000246118	NCT00002461_18_T3	GENE	13	13	IV
NCT0000246118	NCT00002461_18_T4	GENE	22	22	IV
NCT0000246121	NCT00002461_21_T0	ORGAN	10	10	marrow
NCT0000246121	NCT00002461_21_T1	BIOLOGICAL_PROCESS	9	9	regeneration
NCT0000246121	NCT00002461_21_T2	ORGAN	2	3	bone marrow
NCT0000246122	NCT00002461_22_T0	CELL	3	3	granulocyte
NCT0000246122	NCT00002461_22_T1	PHENOTYPE	2	2	engraftment
NCT0000246122	NCT00002461_22_T2	CELL	10	10	platelets
NCT0000246125	NCT00002461_25_T0	PHENOTYPE	18	18	lymphoma
NCT0000246125	NCT00002461_25_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000246125	NCT00002461_25_T2	PHENOTYPE	16	17	high grade
NCT000024621	NCT00002462_1_T0	CELL	10	10	cells
NCT000024621	NCT00002462_1_T1	PHENOTYPE	9	9	tumor
NCT000024622	NCT00002462_2_T0	GENE	3	3	III
NCT000024622	NCT00002462_2_T1	GENE	26	26	IV
NCT000024622	NCT00002462_2_T2	PHENOTYPE	22	23	stage III
NCT000024622	NCT00002462_2_T3	PHENOTYPE	27	28	Hodgkin's disease
NCT000024624	NCT00002462_4_T0	PHENOTYPE	24	24	remission
NCT000024624	NCT00002462_4_T1	PHENOTYPE	11	12	Hodgkin's disease
NCT000024626	NCT00002462_6_T0	PHENOTYPE	10	11	Hodgkin's disease
NCT000024628	NCT00002462_8_T0	PHENOTYPE	14	15	Hodgkin's disease
NCT0000246213	NCT00002462_13_T0	GENE	4	4	VCR
NCT0000246213	NCT00002462_13_T1	COMPOUND	17	17	NSC-125066
NCT0000246213	NCT00002462_13_T2	GENE	7	7	PCB
NCT0000246213	NCT00002462_13_T3	GENE	1	1	NM
NCT000024631	NCT00002463_1_T0	CELL	9	9	cells
NCT000024631	NCT00002463_1_T1	PHENOTYPE	8	8	tumor
NCT000024632	NCT00002463_2_T0	GENE	2	2	II
NCT000024632	NCT00002463_2_T1	COMPOUND	11	11	vincristine
NCT000024632	NCT00002463_2_T2	PHENOTYPE	19	19	astrocytomas
NCT000024632	NCT00002463_2_T3	COMPOUND	9	9	methotrexate
NCT000024632	NCT00002463_2_T4	COMPOUND	12	12	procarbazine
NCT000024632	NCT00002463_2_T5	COMPOUND	14	14	prednisone
NCT000024632	NCT00002463_2_T6	PHENOTYPE	21	23	primitive neuroectodermal tumors
NCT000024634	NCT00002463_4_T0	COMPOUND	11	11	vincristine
NCT000024634	NCT00002463_4_T1	PHENOTYPE	27	27	medulloblastoma
NCT000024634	NCT00002463_4_T2	PHENOTYPE	25	25	PNET
NCT000024634	NCT00002463_4_T3	COMPOUND	5	5	methotrexate
NCT000024634	NCT00002463_4_T4	COMPOUND	14	14	procarbazine
NCT000024634	NCT00002463_4_T5	PHENOTYPE	35	35	astrocytoma
NCT000024634	NCT00002463_4_T6	PHENOTYPE	32	32	pineoblastoma
NCT000024634	NCT00002463_4_T7	COMPOUND	12	12	prednisone
NCT000024634	NCT00002463_4_T8	PHENOTYPE	30	30	ependymoblastoma
NCT000024634	NCT00002463_4_T9	PHENOTYPE	28	29	anaplastic ependymoma
NCT000024634	NCT00002463_4_T10	PHENOTYPE	22	24	primitive neuroectodermal tumors
NCT000024638	NCT00002463_8_T0	PHENOTYPE	13	13	metastasis
NCT000024638	NCT00002463_8_T1	PHENOTYPE	22	22	PNET
NCT0000246314	NCT00002463_14_T0	PHENOTYPE	14	14	PNET
NCT0000246314	NCT00002463_14_T1	PHENOTYPE	8	10	spinal cord disease
NCT0000246316	NCT00002463_16_T0	PHENOTYPE	13	13	PNET
NCT0000246316	NCT00002463_16_T1	ORGAN	5	6	spinal cord
NCT0000246317	NCT00002463_17_T0	PHENOTYPE	4	4	tumor
NCT0000246319	NCT00002463_19_T0	PHENOTYPE	9	10	pineal tumors
NCT0000246319	NCT00002463_19_T1	PHENOTYPE	12	13	glioblastoma multiforme
NCT0000246320	NCT00002463_20_T0	COMPOUND	5	5	methotrexate
NCT0000246320	NCT00002463_20_T1	GENE	7	7	IV
NCT0000246321	NCT00002463_21_T0	COMPOUND	9	9	calcium
NCT0000246321	NCT00002463_21_T1	COMPOUND	8	8	leucovorin
NCT0000246321	NCT00002463_21_T2	GENE	13	13	IV
NCT0000246324	NCT00002463_24_T0	COMPOUND	15	15	vincristine
NCT0000246324	NCT00002463_24_T1	COMPOUND	29	29	1_10
NCT0000246324	NCT00002463_24_T2	COMPOUND	26	26	prednisone
NCT0000246324	NCT00002463_24_T3	COMPOUND	34	34	prednisone
NCT0000246324	NCT00002463_24_T4	GENE	31	31	tapered
NCT0000246324	NCT00002463_24_T5	GENE	13	13	IV
NCT0000246324	NCT00002463_24_T6	GENE	16	16	IV
NCT0000246324	NCT00002463_24_T7	COMPOUND	23	23	procarbazine
NCT0000246326	NCT00002463_26_T0	PHENOTYPE	13	13	toxicity
NCT0000246326	NCT00002463_26_T1	PHENOTYPE	9	10	disease progression
NCT0000246327	NCT00002463_27_T0	PHENOTYPE	31	31	toxicity
NCT0000246327	NCT00002463_27_T1	PHENOTYPE	27	28	disease progression
NCT0000246328	NCT00002463_28_T0	PHENOTYPE	13	13	remission
NCT000024650	NCT00002465_0_T0	PHENOTYPE	12	12	Mesothelioma
NCT000024650	NCT00002465_0_T1	PHENOTYPE	9	10	Endometrial Cancer
NCT000024650	NCT00002465_0_T2	PHENOTYPE	6	8	Metastatic Breast Cancer
NCT000024652	NCT00002465_2_T0	COMPOUND	3	3	megestrol
NCT000024653	NCT00002465_3_T0	COMPOUND	10	10	megestrol
NCT000024653	NCT00002465_3_T1	PHENOTYPE	21	21	mesothelioma
NCT000024653	NCT00002465_3_T2	PHENOTYPE	18	19	endometrial cancer
NCT000024653	NCT00002465_3_T3	PHENOTYPE	15	17	metastatic breast cancer
NCT000024655	NCT00002465_5_T0	PHENOTYPE	10	10	regression
NCT000024655	NCT00002465_5_T1	COMPOUND	7	7	megestrol
NCT000024655	NCT00002465_5_T2	PHENOTYPE	23	23	mesothelioma
NCT000024655	NCT00002465_5_T3	PHENOTYPE	20	21	endometrial carcinoma
NCT000024657	NCT00002465_7_T0	PHENOTYPE	16	16	cachexia
NCT000024659	NCT00002465_9_T0	COMPOUND	14	14	megestrol
NCT0000246510	NCT00002465_10_T0	COMPOUND	12	12	megestrol
NCT0000246510	NCT00002465_10_T1	PHENOTYPE	0	1	Breast cancer
NCT0000246511	NCT00002465_11_T0	PHENOTYPE	4	4	tumor
NCT0000246511	NCT00002465_11_T1	COMPOUND	12	12	megestrol
NCT0000246512	NCT00002465_12_T0	COMPOUND	10	10	megestrol
NCT0000246513	NCT00002465_13_T0	COMPOUND	5	5	megestrol
NCT0000246514	NCT00002465_14_T0	PHENOTYPE	13	13	progression
NCT0000246516	NCT00002465_16_T0	PHENOTYPE	4	5	breast cancer
NCT000024660	NCT00002466_0_T0	PHENOTYPE	15	15	Tumor
NCT000024660	NCT00002466_0_T1	PHENOTYPE	17	18	Bone Cancer
NCT000024660	NCT00002466_0_T2	PHENOTYPE	12	13	Ewing's Sarcoma
NCT000024660	NCT00002466_0_T3	PHENOTYPE	9	11	Peripheral Neuroectodermal Tumors
NCT000024662	NCT00002466_2_T0	CELL	15	15	cells
NCT000024662	NCT00002466_2_T1	PHENOTYPE	14	14	tumor
NCT000024663	NCT00002466_3_T0	GENE	2	2	II
NCT000024663	NCT00002466_3_T1	PHENOTYPE	25	25	tumor
NCT000024663	NCT00002466_3_T2	PHENOTYPE	22	23	Ewing's sarcoma
NCT000024663	NCT00002466_3_T3	PHENOTYPE	27	28	bone cancer
NCT000024663	NCT00002466_3_T4	PHENOTYPE	19	21	peripheral neuroectodermal tumors
NCT000024665	NCT00002466_5_T0	COMPOUND	21	21	vincristine
NCT000024665	NCT00002466_5_T1	COMPOUND	24	24	ifosfamide
NCT000024665	NCT00002466_5_T2	COMPOUND	19	19	cyclophosphamide
NCT000024665	NCT00002466_5_T3	COMPOUND	22	22	etoposide
NCT000024665	NCT00002466_5_T4	COMPOUND	20	20	doxorubicin
NCT000024665	NCT00002466_5_T5	PHENOTYPE	15	16	Ewing's sarcoma
NCT000024665	NCT00002466_5_T6	PHENOTYPE	10	13	peripheral primitive neuroectodermal tumors
NCT000024668	NCT00002466_8_T0	PHENOTYPE	12	13	Ewing's sarcoma
NCT000024668	NCT00002466_8_T1	PHENOTYPE	8	10	primitive neuroectodermal tumor
NCT000024669	NCT00002466_9_T0	PHENOTYPE	34	34	toxicity
NCT000024669	NCT00002466_9_T1	GENE	11	11	1.3
NCT000024669	NCT00002466_9_T2	PHENOTYPE	30	31	disease progression
NCT0000246610	NCT00002466_10_T0	GENE	3	3	3.4
NCT0000246611	NCT00002466_11_T0	PHENOTYPE	11	11	tumor
NCT0000246611	NCT00002466_11_T1	PHENOTYPE	2	3	metastatic disease
NCT0000246612	NCT00002466_12_T0	PHENOTYPE	8	9	residual disease
NCT0000246613	NCT00002466_13_T0	PHENOTYPE	3	4	residual disease
NCT0000246614	NCT00002466_14_T0	COMPOUND	25	25	vincristine
NCT0000246614	NCT00002466_14_T1	COMPOUND	32	32	vincristine
NCT0000246614	NCT00002466_14_T2	GENE	30	30	1.3
NCT0000246614	NCT00002466_14_T3	COMPOUND	11	11	cyclophosphamide
NCT0000246614	NCT00002466_14_T4	COMPOUND	21	21	doxorubicin
NCT0000246614	NCT00002466_14_T5	GENE	12	12	IV
NCT0000246614	NCT00002466_14_T6	GENE	22	22	IV
NCT0000246614	NCT00002466_14_T7	GENE	26	26	IV
NCT0000246614	NCT00002466_14_T8	GENE	33	33	IV
NCT0000246615	NCT00002466_15_T0	COMPOUND	12	12	ifosfamide
NCT0000246615	NCT00002466_15_T1	GENE	19	19	1.5
NCT0000246615	NCT00002466_15_T2	COMPOUND	4	4	etoposide
NCT0000246615	NCT00002466_15_T3	GENE	5	5	IV
NCT0000246615	NCT00002466_15_T4	GENE	13	13	IV
NCT000024702	NCT00002470_2_T0	CELL	9	9	cells
NCT000024702	NCT00002470_2_T1	PHENOTYPE	8	8	tumor
NCT000024702	NCT00002470_2_T2	GENE	1	1	interferon
NCT000024703	NCT00002470_3_T0	GENE	2	2	II
NCT000024703	NCT00002470_3_T1	GENE	11	11	interferon
NCT000024703	NCT00002470_3_T2	PHENOTYPE	20	21	carcinoid tumors
NCT000024705	NCT00002470_5_T0	GENE	10	10	interferon
NCT000024705	NCT00002470_5_T1	GENE	4	4	IV
NCT000024706	NCT00002470_6_T0	PHENOTYPE	13	13	toxicity
NCT000024706	NCT00002470_6_T1	PHENOTYPE	9	10	disease progression
NCT000024707	NCT00002470_7_T0	PHENOTYPE	0	2	Quality of life
NCT000024711	NCT00002471_1_T0	CELL	9	9	cells
NCT000024712	NCT00002471_2_T0	GENE	2	2	II
NCT000024712	NCT00002471_2_T1	PHENOTYPE	18	18	leukemia
NCT000024712	NCT00002471_2_T2	PHENOTYPE	16	16	acute
NCT000024712	NCT00002471_2_T3	PHENOTYPE	20	20	recurrent
NCT000024712	NCT00002471_2_T4	PHENOTYPE	21	22	Hodgkin's lymphoma
NCT000024714	NCT00002471_4_T0	PHENOTYPE	14	14	leukemia
NCT000024714	NCT00002471_4_T1	PHENOTYPE	12	12	acute
NCT000024714	NCT00002471_4_T2	PHENOTYPE	10	10	lymphoma
NCT000024716	NCT00002471_6_T0	PHENOTYPE	2	2	toxicity
NCT0000247110	NCT00002471_10_T0	PHENOTYPE	0	0	Consolidation
NCT0000247111	NCT00002471_11_T0	GENE	7	7	MTX
NCT0000247111	NCT00002471_11_T1	GENE	8	8	VCR
NCT0000247111	NCT00002471_11_T2	GENE	5	5	ASP
NCT0000247115	NCT00002471_15_T0	PHENOTYPE	35	35	toxicity
NCT0000247115	NCT00002471_15_T1	PHENOTYPE	40	40	progression
NCT0000247115	NCT00002471_15_T2	PHENOTYPE	26	26	remission
NCT000024721	NCT00002472_1_T0	CELL	9	9	cells
NCT000024721	NCT00002472_1_T1	PHENOTYPE	8	8	tumor
NCT000024722	NCT00002472_2_T0	GENE	2	2	II
NCT000024722	NCT00002472_2_T1	PHENOTYPE	17	17	tumors
NCT000024722	NCT00002472_2_T2	COMPOUND	11	11	etoposide
NCT000024722	NCT00002472_2_T3	COMPOUND	9	9	cisplatin
NCT000024724	NCT00002472_4_T0	PHENOTYPE	6	6	germinoma
NCT000024725	NCT00002472_5_T0	GENE	16	16	1.5
NCT000024725	NCT00002472_5_T1	COMPOUND	9	9	etoposide
NCT000024725	NCT00002472_5_T2	COMPOUND	2	2	cisplatin
NCT000024725	NCT00002472_5_T3	GENE	3	3	IV
NCT000024725	NCT00002472_5_T4	GENE	10	10	IV
NCT000024726	NCT00002472_6_T0	PHENOTYPE	16	16	toxicity
NCT000024726	NCT00002472_6_T1	PHENOTYPE	12	13	disease progression
NCT000024727	NCT00002472_7_T0	PHENOTYPE	17	17	germinoma
NCT000024727	NCT00002472_7_T1	GENE	12	12	CR
NCT000024728	NCT00002472_8_T0	GENE	12	12	CR
NCT000024729	NCT00002472_9_T0	PHENOTYPE	7	7	toxicity
NCT000024729	NCT00002472_9_T1	PHENOTYPE	3	4	disease progression
NCT0000247210	NCT00002472_10_T0	PHENOTYPE	19	19	toxic
NCT0000247210	NCT00002472_10_T1	PHENOTYPE	33	33	localized
NCT0000247210	NCT00002472_10_T2	GENE	30	30	axis
NCT0000247210	NCT00002472_10_T3	PHENOTYPE	20	22	effects of chemotherapy
NCT0000247213	NCT00002472_13_T0	PHENOTYPE	8	8	germinoma
NCT000024731	NCT00002473_1_T0	ORGAN	10	10	kidney
NCT000024731	NCT00002473_1_T1	PHENOTYPE	14	15	kidney cancer
NCT000024732	NCT00002473_2_T0	ORGAN	15	15	kidney
NCT000024732	NCT00002473_2_T1	GENE	3	3	III
NCT000024732	NCT00002473_2_T2	PHENOTYPE	24	25	kidney cancer
NCT000024741	NCT00002474_1_T0	CELL	21	21	cells
NCT000024741	NCT00002474_1_T1	PHENOTYPE	20	20	tumor
NCT000024741	NCT00002474_1_T2	ORGAN	6	6	transplant
NCT000024741	NCT00002474_1_T3	ORGAN	4	5	bone marrow
NCT000024742	NCT00002474_2_T0	GENE	3	3	II
NCT000024742	NCT00002474_2_T1	ORGAN	14	14	transplant
NCT000024742	NCT00002474_2_T2	ORGAN	12	13	bone marrow
NCT000024742	NCT00002474_2_T3	PHENOTYPE	22	24	recurrent ovarian cancer
NCT000024744	NCT00002474_4_T0	ORGAN	2	3	bone marrow
NCT000024745	NCT00002474_5_T0	PHENOTYPE	34	34	toxicity
NCT000024745	NCT00002474_5_T1	COMPOUND	9	9	mitoxantrone
NCT000024745	NCT00002474_5_T2	COMPOUND	28	28	3
NCT000024745	NCT00002474_5_T3	COMPOUND	3	3	cyclophosphamide
NCT000024745	NCT00002474_5_T4	GENE	4	4	IV
NCT000024745	NCT00002474_5_T5	GENE	10	10	IV
NCT000024745	NCT00002474_5_T6	GENE	22	22	IV
NCT000024746	NCT00002474_6_T0	ORGAN	0	1	Bone marrow
NCT000024751	NCT00002475_1_T0	CELL	18	18	cells
NCT000024751	NCT00002475_1_T1	PHENOTYPE	5	5	tumor
NCT000024751	NCT00002475_1_T2	PHENOTYPE	17	17	tumor
NCT000024751	NCT00002475_1_T3	BIOLOGICAL_PROCESS	13	14	immune response
NCT000024752	NCT00002475_2_T0	CELL	9	9	cells
NCT000024752	NCT00002475_2_T1	PHENOTYPE	8	8	tumor
NCT000024756	NCT00002475_6_T0	PHENOTYPE	4	4	tumor
NCT000024757	NCT00002475_7_T0	PHENOTYPE	0	0	Tumor
NCT000024757	NCT00002475_7_T1	GENE	10	10	interferon
NCT000024757	NCT00002475_7_T2	GENE	13	14	interferon gamma
NCT000024758	NCT00002475_8_T0	CELL	3	3	cells
NCT000024758	NCT00002475_8_T1	CELL	14	14	cells
NCT000024758	NCT00002475_8_T2	PHENOTYPE	2	2	tumor
NCT000024759	NCT00002475_9_T0	COMPOUND	2	2	cyclophosphamide
NCT000024759	NCT00002475_9_T1	GENE	3	3	IV
NCT0000247511	NCT00002475_11_T0	GENE	4	4	GM-CSF
NCT0000247511	NCT00002475_11_T1	GENE	3	3	sargramostim
NCT0000247512	NCT00002475_12_T0	PHENOTYPE	13	13	toxicity
NCT000024760	NCT00002476_0_T0	PHENOTYPE	11	14	Head and Neck Cancer
NCT000024762	NCT00002476_2_T0	CELL	10	10	cells
NCT000024762	NCT00002476_2_T1	PHENOTYPE	9	9	tumor
NCT000024763	NCT00002476_3_T0	PHENOTYPE	22	25	head and neck cancer
NCT000024764	NCT00002476_4_T0	GENE	3	3	III
NCT000024764	NCT00002476_4_T1	PHENOTYPE	21	24	head and neck cancer
NCT000024766	NCT00002476_6_T0	GENE	6	6	MTX
NCT000024766	NCT00002476_6_T1	COMPOUND	5	5	methotrexate
NCT000024766	NCT00002476_6_T2	PHENOTYPE	14	18	carcinoma of the head and
NCT0000247610	NCT00002476_10_T0	ORGAN	14	14	oropharynx
NCT0000247610	NCT00002476_10_T1	ORGAN	11	12	oral cavity
NCT0000247615	NCT00002476_15_T0	TISSUE	5	6	lymph nodes
NCT0000247625	NCT00002476_25_T0	GENE	1	1	nodal
NCT000024771	NCT00002477_1_T0	CELL	9	9	cells
NCT000024772	NCT00002477_2_T0	GENE	3	3	III
NCT000024772	NCT00002477_2_T1	PHENOTYPE	27	29	ovarian epithelial cancer
NCT000024781	NCT00002478_1_T0	GENE	2	2	II
NCT000024781	NCT00002478_1_T1	COMPOUND	9	9	etoposide
NCT000024781	NCT00002478_1_T2	PHENOTYPE	16	16	recurrent
NCT000024781	NCT00002478_1_T3	PHENOTYPE	21	22	cervical cancer
NCT000024783	NCT00002478_3_T0	COMPOUND	6	6	etoposide
NCT000024783	NCT00002478_3_T1	PHENOTYPE	15	16	cervical cancer
NCT000024785	NCT00002478_5_T0	PHENOTYPE	4	4	severity
NCT000024785	NCT00002478_5_T1	PHENOTYPE	7	8	adverse effects
NCT000024786	NCT00002478_6_T0	COMPOUND	3	3	etoposide
NCT000024787	NCT00002478_7_T0	PHENOTYPE	19	19	toxicity
NCT000024787	NCT00002478_7_T1	PHENOTYPE	15	16	disease progression
NCT000024788	NCT00002478_8_T0	PHENOTYPE	19	19	toxicity
NCT000024788	NCT00002478_8_T1	PHENOTYPE	15	16	disease progression
NCT000024795	NCT00002479_5_T0	PHENOTYPE	4	4	toxicity
NCT000024795	NCT00002479_5_T1	GENE	6	6	TRA
NCT000024798	NCT00002479_8_T0	GENE	3	3	TRA
NCT000024808	NCT00002480_8_T0	GENE	5	5	4.5
NCT000024809	NCT00002480_9_T0	GENE	14	14	MTD
NCT0000248010	NCT00002480_10_T0	PHENOTYPE	17	17	toxicity
NCT0000248010	NCT00002480_10_T1	GENE	1	1	MTD
NCT000024811	NCT00002481_1_T0	CELL	8	8	cells
NCT000024812	NCT00002481_2_T0	CELL	19	19	cells
NCT000024812	NCT00002481_2_T1	ORGAN	0	1	Bone marrow
NCT000024813	NCT00002481_3_T0	GENE	2	2	II
NCT000024813	NCT00002481_3_T1	COMPOUND	12	12	cyclophosphamide
NCT000024813	NCT00002481_3_T2	COMPOUND	10	10	etoposide
NCT000024813	NCT00002481_3_T3	ORGAN	18	19	bone marrow
NCT000024813	NCT00002481_3_T4	PHENOTYPE	29	30	Hodgkin's lymphoma
NCT000024815	NCT00002481_5_T0	PHENOTYPE	2	2	toxicity
NCT000024815	NCT00002481_5_T1	PHENOTYPE	23	23	lymphoma
NCT000024815	NCT00002481_5_T2	COMPOUND	6	6	cyclophosphamide
NCT000024815	NCT00002481_5_T3	COMPOUND	7	7	etoposide
NCT000024815	NCT00002481_5_T4	ORGAN	13	14	bone marrow
NCT000024817	NCT00002481_7_T0	COMPOUND	14	14	dexamethasone
NCT000024817	NCT00002481_7_T1	COMPOUND	11	11	cytarabine
NCT000024817	NCT00002481_7_T2	COMPOUND	12	12	cisplatin
NCT000024819	NCT00002481_9_T0	PHENOTYPE	10	11	residual disease
NCT0000248111	NCT00002481_11_T0	ORGAN	1	2	bone marrow
NCT0000248112	NCT00002481_12_T0	ORGAN	2	2	marrow
NCT0000248112	NCT00002481_12_T1	ORGAN	6	6	marrow
NCT0000248112	NCT00002481_12_T2	ORGAN	14	15	bone marrow
NCT0000248113	NCT00002481_13_T0	COMPOUND	19	19	dexamethasone
NCT0000248113	NCT00002481_13_T1	COMPOUND	5	5	cytarabine
NCT0000248113	NCT00002481_13_T2	COMPOUND	13	13	cisplatin
NCT0000248113	NCT00002481_13_T3	GENE	6	6	IV
NCT0000248113	NCT00002481_13_T4	GENE	14	14	IV
NCT0000248114	NCT00002481_14_T0	PHENOTYPE	21	21	toxicity
NCT0000248114	NCT00002481_14_T1	PHENOTYPE	9	9	tumor
NCT0000248116	NCT00002481_16_T0	GENE	10	10	IV
NCT0000248116	NCT00002481_16_T1	GENE	19	19	IV
NCT0000248116	NCT00002481_16_T2	COMPOUND	43	43	1
NCT0000248116	NCT00002481_16_T3	COMPOUND	21	21	2
NCT0000248116	NCT00002481_16_T4	COMPOUND	38	38	2
NCT0000248116	NCT00002481_16_T5	COMPOUND	36	36	3
NCT0000248116	NCT00002481_16_T6	COMPOUND	18	18	cyclophosphamide
NCT0000248116	NCT00002481_16_T7	COMPOUND	9	9	etoposide
NCT0000248117	NCT00002481_17_T0	ORGAN	0	1	Bone marrow
NCT0000248118	NCT00002481_18_T0	PHENOTYPE	3	4	residual disease
NCT0000248118	NCT00002481_18_T1	PHENOTYPE	18	19	residual disease
NCT0000248121	NCT00002481_21_T0	PHENOTYPE	18	18	lymphoma
NCT0000248121	NCT00002481_21_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000248121	NCT00002481_21_T2	PHENOTYPE	16	17	high grade
NCT000024821	NCT00002482_1_T0	COMPOUND	12	12	cyclophosphamide
NCT000024821	NCT00002482_1_T1	PHENOTYPE	17	18	metastatic cancer
NCT000024823	NCT00002482_3_T0	PHENOTYPE	5	5	toxicity
NCT000024823	NCT00002482_3_T1	PHENOTYPE	18	18	malignancies
NCT000024823	NCT00002482_3_T2	COMPOUND	13	13	cyclophosphamide
NCT000024828	NCT00002482_8_T0	PHENOTYPE	8	8	Inhibition
NCT000024842	NCT00002484_2_T0	PHENOTYPE	12	12	tumor
NCT000024847	NCT00002484_7_T0	GENE	14	14	MTD
NCT000024848	NCT00002484_8_T0	PHENOTYPE	17	17	toxicity
NCT000024848	NCT00002484_8_T1	GENE	1	1	MTD
NCT000024850	NCT00002485_0_T0	PHENOTYPE	2	2	Strategies
NCT000024850	NCT00002485_0_T1	PHENOTYPE	12	12	Cancer
NCT000024852	NCT00002485_2_T0	PHENOTYPE	23	23	strategies
NCT000024852	NCT00002485_2_T1	PHENOTYPE	14	14	Oncology
NCT000024854	NCT00002485_4_T0	PHENOTYPE	16	16	Oncology
NCT000024856	NCT00002485_6_T0	PHENOTYPE	9	9	strategies
NCT000024859	NCT00002485_9_T0	GENE	13	13	POG
NCT000024859	NCT00002485_9_T1	PHENOTYPE	11	11	Oncology
NCT000024859	NCT00002485_9_T2	GENE	18	18	has
NCT0000248510	NCT00002485_10_T0	GENE	10	10	POG
NCT0000248510	NCT00002485_10_T1	GENE	15	15	has
NCT000024871	NCT00002487_1_T0	CELL	11	11	cells
NCT000024871	NCT00002487_1_T1	PHENOTYPE	10	10	tumor
NCT000024871	NCT00002487_1_T2	COMPOUND	6	6	methotrexate
NCT000024872	NCT00002487_2_T0	GENE	2	2	II
NCT000024872	NCT00002487_2_T1	COMPOUND	12	12	dipyridamole
NCT000024872	NCT00002487_2_T2	COMPOUND	10	10	methotrexate
NCT000024872	NCT00002487_2_T3	PHENOTYPE	22	22	recurrent
NCT000024872	NCT00002487_2_T4	PHENOTYPE	18	19	ovarian cancer
NCT000024874	NCT00002487_4_T0	PHENOTYPE	37	37	recurrent
NCT000024874	NCT00002487_4_T1	PHENOTYPE	33	34	ovarian carcinoma
NCT000024876	NCT00002487_6_T0	PHENOTYPE	5	5	toxicity
NCT000024879	NCT00002487_9_T0	GENE	1	1	MTX
NCT000024879	NCT00002487_9_T1	GENE	5	5	DP
NCT0000248711	NCT00002487_11_T0	GENE	18	18	cease
NCT000024880	NCT00002488_0_T0	PHENOTYPE	9	10	Non-Hodgkin's Lymphoma
NCT000024882	NCT00002488_2_T0	CELL	9	9	cells
NCT000024883	NCT00002488_3_T0	GENE	2	2	II
NCT000024883	NCT00002488_3_T1	COMPOUND	13	13	cyclophosphamide
NCT000024883	NCT00002488_3_T2	PHENOTYPE	32	32	resistant
NCT000024883	NCT00002488_3_T3	COMPOUND	14	14	etoposide
NCT000024883	NCT00002488_3_T4	COMPOUND	16	16	cisplatin
NCT000024883	NCT00002488_3_T5	PHENOTYPE	24	25	Hodgkin's lymphoma
NCT000024887	NCT00002488_7_T0	PHENOTYPE	2	2	toxicity
NCT0000248811	NCT00002488_11_T0	GENE	6	6	CR
NCT0000248812	NCT00002488_12_T0	PHENOTYPE	28	29	tumor progression
NCT000024890	NCT00002489_0_T0	PHENOTYPE	8	10	Germ Cell Tumors
NCT000024892	NCT00002489_2_T0	CELL	9	9	cells
NCT000024892	NCT00002489_2_T1	PHENOTYPE	8	8	tumor
NCT000024897	NCT00002489_7_T0	PHENOTYPE	2	4	quality of life
NCT0000248915	NCT00002489_15_T0	COMPOUND	7	7	cyclophosphamide
NCT0000248915	NCT00002489_15_T1	COMPOUND	13	13	methotrexate
NCT0000248915	NCT00002489_15_T2	COMPOUND	12	12	doxorubicin
NCT0000248915	NCT00002489_15_T3	PHENOTYPE	25	26	progressive disease
NCT0000248916	NCT00002489_16_T0	PHENOTYPE	12	12	tumor
NCT0000248916	NCT00002489_16_T1	GENE	39	39	2.4
NCT0000248916	NCT00002489_16_T2	COMPOUND	21	21	cyclophosphamide
NCT0000248916	NCT00002489_16_T3	COMPOUND	35	35	etoposide
NCT0000248916	NCT00002489_16_T4	GENE	22	22	IV
NCT0000248916	NCT00002489_16_T5	GENE	30	30	IV
NCT0000248916	NCT00002489_16_T6	GENE	36	36	IV
NCT0000248917	NCT00002489_17_T0	GENE	2	2	filgrastim
NCT0000248917	NCT00002489_17_T1	COMPOUND	15	15	etoposide
NCT0000248917	NCT00002489_17_T2	GENE	3	3	G-CSF
NCT0000248918	NCT00002489_18_T0	PHENOTYPE	12	13	disease progression
NCT0000248919	NCT00002489_19_T0	PHENOTYPE	14	15	residual disease
NCT0000248920	NCT00002489_20_T0	PHENOTYPE	3	4	residual disease
NCT0000248922	NCT00002489_22_T0	COMPOUND	17	17	vincristine
NCT0000248922	NCT00002489_22_T1	COMPOUND	34	34	vincristine
NCT0000248922	NCT00002489_22_T2	GENE	13	13	1.3
NCT0000248922	NCT00002489_22_T3	GENE	22	22	1.3
NCT0000248922	NCT00002489_22_T4	GENE	24	24	G-CSF
NCT0000248922	NCT00002489_22_T5	COMPOUND	14	14	doxorubicin
NCT0000248922	NCT00002489_22_T6	GENE	10	10	IV
NCT0000248922	NCT00002489_22_T7	GENE	15	15	IV
NCT0000248922	NCT00002489_22_T8	GENE	18	18	IV
NCT0000248923	NCT00002489_23_T0	COMPOUND	10	10	vincristine
NCT0000248923	NCT00002489_23_T1	GENE	9	9	1.2
NCT0000248923	NCT00002489_23_T2	GENE	18	18	1.3
NCT0000248923	NCT00002489_23_T3	COMPOUND	5	5	cyclophosphamide
NCT0000248923	NCT00002489_23_T4	GENE	20	20	G-CSF
NCT0000248923	NCT00002489_23_T5	COMPOUND	13	13	doxorubicin
NCT0000248923	NCT00002489_23_T6	GENE	6	6	IV
NCT0000248923	NCT00002489_23_T7	GENE	11	11	IV
NCT0000248923	NCT00002489_23_T8	GENE	14	14	IV
NCT0000248924	NCT00002489_24_T0	COMPOUND	12	12	calcium
NCT0000248924	NCT00002489_24_T1	COMPOUND	5	5	methotrexate
NCT0000248924	NCT00002489_24_T2	COMPOUND	29	29	methotrexate
NCT0000248924	NCT00002489_24_T3	COMPOUND	11	11	leucovorin
NCT0000248924	NCT00002489_24_T4	GENE	6	6	IV
NCT0000248924	NCT00002489_24_T5	GENE	15	15	IV
NCT000024901	NCT00002490_1_T0	CELL	10	10	cells
NCT000024901	NCT00002490_1_T1	PHENOTYPE	9	9	tumor
NCT000024902	NCT00002490_2_T0	CELL	9	9	cells
NCT000024902	NCT00002490_2_T1	PHENOTYPE	8	8	tumor
NCT000024903	NCT00002490_3_T0	PHENOTYPE	16	19	cancer of the bladder
NCT000024904	NCT00002490_4_T0	PHENOTYPE	16	16	tumor
NCT000024904	NCT00002490_4_T1	GENE	3	3	III
NCT000024904	NCT00002490_4_T2	PHENOTYPE	23	24	bladder cancer
NCT000024921	NCT00002492_1_T0	CELL	9	9	cells
NCT000024921	NCT00002492_1_T1	PHENOTYPE	8	8	tumor
NCT000024922	NCT00002492_2_T0	GENE	2	2	II
NCT000024922	NCT00002492_2_T1	COMPOUND	12	12	doxorubicin
NCT000024922	NCT00002492_2_T2	COMPOUND	10	10	cisplatin
NCT000024922	NCT00002492_2_T3	PHENOTYPE	18	20	soft tissue sarcoma
NCT000024924	NCT00002492_4_T0	GENE	19	19	IV
NCT000024924	NCT00002492_4_T1	GENE	28	28	IV
NCT000024924	NCT00002492_4_T2	GENE	31	31	IV
NCT000024924	NCT00002492_4_T3	COMPOUND	20	20	doxorubicin
NCT000024924	NCT00002492_4_T4	COMPOUND	32	32	doxorubicin
NCT000024924	NCT00002492_4_T5	COMPOUND	17	17	cisplatin
NCT000024924	NCT00002492_4_T6	COMPOUND	29	29	cisplatin
NCT000024924	NCT00002492_4_T7	ORGAN	12	12	extremity
NCT000024924	NCT00002492_4_T8	PHENOTYPE	7	9	soft tissue sarcoma
NCT000024926	NCT00002492_6_T0	PHENOTYPE	5	5	tumor
NCT000024927	NCT00002492_7_T0	GENE	30	30	1.3
NCT000024927	NCT00002492_7_T1	COMPOUND	18	18	doxorubicin
NCT000024927	NCT00002492_7_T2	COMPOUND	9	9	cisplatin
NCT000024927	NCT00002492_7_T3	COMPOUND	26	26	cisplatin
NCT000024927	NCT00002492_7_T4	GENE	19	19	IV
NCT000024928	NCT00002492_8_T0	PHENOTYPE	13	13	toxicity
NCT0000249211	NCT00002492_11_T0	PHENOTYPE	4	4	tumor
NCT0000249213	NCT00002492_13_T0	GENE	23	23	1.3
NCT0000249213	NCT00002492_13_T1	GENE	3	3	3.4
NCT0000249213	NCT00002492_13_T2	COMPOUND	18	18	doxorubicin
NCT0000249213	NCT00002492_13_T3	COMPOUND	9	9	cisplatin
NCT0000249213	NCT00002492_13_T4	GENE	10	10	IV
NCT0000249214	NCT00002492_14_T0	PHENOTYPE	18	18	toxicity
NCT0000249214	NCT00002492_14_T1	PHENOTYPE	12	13	disease progression
NCT0000249217	NCT00002492_17_T0	COMPOUND	4	4	iridium
NCT000024931	NCT00002493_1_T0	CELL	10	10	cells
NCT000024931	NCT00002493_1_T1	PHENOTYPE	9	9	tumor
NCT000024932	NCT00002493_2_T0	PHENOTYPE	12	13	endometrial cancer
NCT000024933	NCT00002493_3_T0	GENE	3	3	III
NCT000024933	NCT00002493_3_T1	PHENOTYPE	17	18	endometrial cancer
NCT000024935	NCT00002493_5_T0	PHENOTYPE	16	17	endometrial carcinoma
NCT000024937	NCT00002493_7_T0	PHENOTYPE	6	6	acute
NCT000024937	NCT00002493_7_T1	PHENOTYPE	9	10	adverse events
NCT000024939	NCT00002493_9_T0	PHENOTYPE	3	3	fatigue
NCT000024939	NCT00002493_9_T1	PHENOTYPE	7	7	impairment
NCT000024939	NCT00002493_9_T2	PHENOTYPE	4	4	elimination
NCT000024939	NCT00002493_9_T3	PHENOTYPE	11	13	quality of life
NCT0000249311	NCT00002493_11_T0	PHENOTYPE	9	11	quality of life
NCT0000249313	NCT00002493_13_T0	PHENOTYPE	1	1	quality-of-life
NCT000024941	NCT00002494_1_T0	CELL	9	9	cells
NCT000024942	NCT00002494_2_T0	GENE	2	2	II
NCT000024942	NCT00002494_2_T1	PHENOTYPE	21	22	Hodgkin's lymphoma
NCT000024942	NCT00002494_2_T2	PHENOTYPE	24	26	acute lymphocytic leukemia
NCT000024946	NCT00002494_6_T0	PHENOTYPE	2	2	toxicity
NCT000024946	NCT00002494_6_T1	PHENOTYPE	7	7	HIV
NCT000024948	NCT00002494_8_T0	COMPOUND	88	88	cytarabine
NCT000024948	NCT00002494_8_T1	COMPOUND	119	119	cytarabine
NCT000024948	NCT00002494_8_T2	GENE	136	136	29
NCT000024948	NCT00002494_8_T3	GENE	149	149	29
NCT000024948	NCT00002494_8_T4	GENE	201	201	29
NCT000024948	NCT00002494_8_T5	GENE	208	208	29
NCT000024948	NCT00002494_8_T6	COMPOUND	36	36	methotrexate
NCT000024948	NCT00002494_8_T7	COMPOUND	53	53	methotrexate
NCT000024948	NCT00002494_8_T8	COMPOUND	71	71	methotrexate
NCT000024948	NCT00002494_8_T9	COMPOUND	118	118	methotrexate
NCT000024948	NCT00002494_8_T10	COMPOUND	139	139	methotrexate
NCT000024948	NCT00002494_8_T11	COMPOUND	159	159	methotrexate
NCT000024948	NCT00002494_8_T12	COMPOUND	177	177	methotrexate
NCT000024948	NCT00002494_8_T13	COMPOUND	26	26	ifosfamide
NCT000024948	NCT00002494_8_T14	PHENOTYPE	51	51	initiation
NCT000024948	NCT00002494_8_T15	PHENOTYPE	157	157	initiation
NCT000024948	NCT00002494_8_T16	COMPOUND	2	2	cyclophosphamide
NCT000024948	NCT00002494_8_T17	COMPOUND	129	129	cyclophosphamide
NCT000024948	NCT00002494_8_T18	COMPOUND	189	189	doxorubicin
NCT000024948	NCT00002494_8_T19	GENE	138	138	33
NCT000024948	NCT00002494_8_T20	GENE	195	195	33
NCT000024948	NCT00002494_8_T21	GENE	203	203	33
NCT000024948	NCT00002494_8_T22	COMPOUND	106	106	dexamethasone
NCT000024948	NCT00002494_8_T23	COMPOUND	198	198	dexamethasone
NCT000024948	NCT00002494_8_T24	GENE	35	35	12
NCT000024948	NCT00002494_8_T25	GENE	103	103	12
NCT000024948	NCT00002494_8_T26	GENE	111	111	12
NCT000024948	NCT00002494_8_T27	GENE	126	126	12
NCT000024948	NCT00002494_8_T28	COMPOUND	83	83	vincristine
NCT000024948	NCT00002494_8_T29	COMPOUND	145	145	vincristine
NCT000024948	NCT00002494_8_T30	COMPOUND	45	45	calcium
NCT000024948	NCT00002494_8_T31	COMPOUND	151	151	calcium
NCT000024948	NCT00002494_8_T32	GENE	3	3	IV
NCT000024948	NCT00002494_8_T33	GENE	27	27	IV
NCT000024948	NCT00002494_8_T34	GENE	37	37	IV
NCT000024948	NCT00002494_8_T35	GENE	46	46	IV
NCT000024948	NCT00002494_8_T36	GENE	55	55	IV
NCT000024948	NCT00002494_8_T37	GENE	84	84	IV
NCT000024948	NCT00002494_8_T38	GENE	89	89	IV
NCT000024948	NCT00002494_8_T39	GENE	95	95	IV
NCT000024948	NCT00002494_8_T40	GENE	130	130	IV
NCT000024948	NCT00002494_8_T41	GENE	140	140	IV
NCT000024948	NCT00002494_8_T42	GENE	146	146	IV
NCT000024948	NCT00002494_8_T43	GENE	152	152	IV
NCT000024948	NCT00002494_8_T44	GENE	161	161	IV
NCT000024948	NCT00002494_8_T45	GENE	190	190	IV
NCT000024948	NCT00002494_8_T46	PHENOTYPE	5	5	5-10
NCT000024948	NCT00002494_8_T47	PHENOTYPE	132	132	5-10
NCT000024948	NCT00002494_8_T48	COMPOUND	121	121	hydrocortisone
NCT000024948	NCT00002494_8_T49	COMPOUND	94	94	etoposide
NCT000024948	NCT00002494_8_T50	COMPOUND	44	44	leucovorin
NCT000024948	NCT00002494_8_T51	COMPOUND	150	150	leucovorin
NCT000024948	NCT00002494_8_T52	ORGAN	70	70	serum
NCT000024948	NCT00002494_8_T53	ORGAN	176	176	serum
NCT000024948	NCT00002494_8_T54	COMPOUND	14	14	prednisone
NCT000024949	NCT00002494_9_T0	GENE	12	12	CSF
NCT0000249410	NCT00002494_10_T0	PHENOTYPE	6	6	initiation
NCT0000249412	NCT00002494_12_T0	PHENOTYPE	16	16	toxicity
NCT0000249412	NCT00002494_12_T1	PHENOTYPE	12	13	disease progression
NCT0000249413	NCT00002494_13_T0	GENE	6	6	had
NCT0000249413	NCT00002494_13_T1	ORGAN	8	9	bone marrow
NCT0000249414	NCT00002494_14_T0	ORGAN	19	19	transplant
NCT0000249414	NCT00002494_14_T1	ORGAN	17	18	bone marrow
NCT000024951	NCT00002495_1_T0	CELL	9	9	cells
NCT000024951	NCT00002495_1_T1	PHENOTYPE	8	8	tumor
NCT000024952	NCT00002495_2_T0	GENE	26	26	II
NCT000024952	NCT00002495_2_T1	COMPOUND	17	17	vinblastine
NCT000024952	NCT00002495_2_T2	GENE	3	3	III
NCT000024952	NCT00002495_2_T3	COMPOUND	15	15	doxorubicin
NCT000024952	NCT00002495_2_T4	PHENOTYPE	27	28	Hodgkin's disease
NCT000024954	NCT00002495_4_T0	GENE	26	26	nodal
NCT000024954	NCT00002495_4_T1	PHENOTYPE	11	12	Hodgkin's disease
NCT000024956	NCT00002495_6_T0	PHENOTYPE	10	10	toxicity
NCT000024956	NCT00002495_6_T1	PHENOTYPE	3	3	toxicities
NCT000024956	NCT00002495_6_T2	PHENOTYPE	14	14	infertility
NCT000024956	NCT00002495_6_T3	PHENOTYPE	11	12	secondary malignancies
NCT000024958	NCT00002495_8_T0	PHENOTYPE	8	8	tumor
NCT0000249511	NCT00002495_11_T0	GENE	1	1	nodal
NCT000024961	NCT00002496_1_T0	CELL	8	8	cells
NCT000024961	NCT00002496_1_T1	PHENOTYPE	7	7	tumor
NCT000024962	NCT00002496_2_T0	PHENOTYPE	21	22	advanced cancer
NCT000024962	NCT00002496_2_T1	PHENOTYPE	22	25	cancer of the larynx
NCT000024963	NCT00002496_3_T0	GENE	3	3	III
NCT000024963	NCT00002496_3_T1	PHENOTYPE	20	21	advanced cancer
NCT000024963	NCT00002496_3_T2	PHENOTYPE	21	24	cancer of the larynx
NCT000024969	NCT00002496_9_T0	PHENOTYPE	8	8	recurrence
NCT000024969	NCT00002496_9_T1	PHENOTYPE	4	4	relapse
NCT000024969	NCT00002496_9_T2	PHENOTYPE	11	11	metastasis
NCT0000249611	NCT00002496_11_T0	PHENOTYPE	5	6	primary tumors
NCT0000249613	NCT00002496_13_T0	PHENOTYPE	2	2	acute
NCT0000249613	NCT00002496_13_T1	PHENOTYPE	4	4	chronic
NCT0000249613	NCT00002496_13_T2	PHENOTYPE	5	6	adverse effects
NCT0000249617	NCT00002496_17_T0	PHENOTYPE	1	3	quality of life
NCT0000249619	NCT00002496_19_T0	PHENOTYPE	2	4	quality of life
NCT000024981	NCT00002498_1_T0	CELL	9	9	cells
NCT000024981	NCT00002498_1_T1	PHENOTYPE	8	8	tumor
NCT000024982	NCT00002498_2_T0	GENE	3	3	II
NCT000024982	NCT00002498_2_T1	COMPOUND	15	15	mitoxantrone
NCT000024982	NCT00002498_2_T2	COMPOUND	11	11	methotrexate
NCT000024982	NCT00002498_2_T3	COMPOUND	10	10	cyclophosphamide
NCT000024982	NCT00002498_2_T4	PHENOTYPE	21	21	recurrent
NCT000024982	NCT00002498_2_T5	PHENOTYPE	23	25	metastatic breast cancer
NCT000024984	NCT00002498_4_T0	COMPOUND	25	25	mitoxantrone
NCT000024984	NCT00002498_4_T1	GENE	26	26	DHAD
NCT000024984	NCT00002498_4_T2	PHENOTYPE	13	14	breast cancer
NCT000024986	NCT00002498_6_T0	GENE	6	6	DHAD
NCT000024988	NCT00002498_8_T0	PHENOTYPE	1	3	quality of life
NCT0000249811	NCT00002498_11_T0	COMPOUND	5	5	cyclophosphamide
NCT0000249811	NCT00002498_11_T1	COMPOUND	13	13	methotrexate
NCT0000249813	NCT00002498_13_T0	COMPOUND	5	5	mitoxantrone
NCT0000249815	NCT00002498_15_T0	ORGAN	10	11	bone marrow
NCT0000249816	NCT00002498_16_T0	PHENOTYPE	10	11	disease progression
NCT000024991	NCT00002499_1_T0	CELL	9	9	cells
NCT000024992	NCT00002499_2_T0	PHENOTYPE	16	18	acute lymphocytic leukemia
NCT000024996	NCT00002499_6_T0	PHENOTYPE	19	19	toxicity
NCT000024996	NCT00002499_6_T1	PHENOTYPE	12	12	remission
NCT000024998	NCT00002499_8_T0	GENE	13	13	II
NCT000024998	NCT00002499_8_T1	PHENOTYPE	4	4	toxicity
NCT000024998	NCT00002499_8_T2	PHENOTYPE	23	23	remission
NCT0000249910	NCT00002499_10_T0	PHENOTYPE	14	14	remission
NCT0000249910	NCT00002499_10_T1	ORGAN	4	5	bone marrow
NCT0000249912	NCT00002499_12_T0	PHENOTYPE	2	2	remission
NCT0000249912	NCT00002499_12_T1	PHENOTYPE	17	17	remission
NCT0000249912	NCT00002499_12_T2	PHENOTYPE	23	23	remission
NCT0000249914	NCT00002499_14_T0	GENE	1	1	VCR
NCT0000249914	NCT00002499_14_T1	GENE	15	15	IT
NCT0000249914	NCT00002499_14_T2	GENE	20	20	IT
NCT0000249914	NCT00002499_14_T3	GENE	7	7	ASP
NCT0000249916	NCT00002499_16_T0	GENE	3	3	MTX
NCT0000249916	NCT00002499_16_T1	GENE	0	0	VCR
NCT0000249916	NCT00002499_16_T2	GENE	1	1	ASP
NCT0000249918	NCT00002499_18_T0	GENE	1	1	II
NCT0000249918	NCT00002499_18_T1	GENE	11	11	MTX
NCT0000249918	NCT00002499_18_T2	GENE	9	9	VCR
NCT0000249918	NCT00002499_18_T3	GENE	13	13	IT
NCT0000249918	NCT00002499_18_T4	GENE	15	15	IT
NCT0000249918	NCT00002499_18_T5	GENE	3	3	ASP
NCT0000249918	NCT00002499_18_T6	GENE	10	10	ASP
NCT0000249920	NCT00002499_20_T0	GENE	1	1	ASP
NCT000025011	NCT00002501_1_T0	GENE	2	2	II
NCT000025011	NCT00002501_1_T1	GENE	11	11	filgrastim
NCT000025011	NCT00002501_1_T2	COMPOUND	9	9	cyclophosphamide
NCT000025011	NCT00002501_1_T3	GENE	17	17	IV
NCT000025011	NCT00002501_1_T4	PHENOTYPE	23	24	Hodgkin's lymphoma
NCT000025013	NCT00002501_3_T0	GENE	7	7	filgrastim
NCT000025013	NCT00002501_3_T1	COMPOUND	5	5	cyclophosphamide
NCT000025013	NCT00002501_3_T2	PHENOTYPE	16	16	progressive
NCT000025013	NCT00002501_3_T3	GENE	8	8	G-CSF
NCT000025013	NCT00002501_3_T4	GENE	13	13	IV
NCT000025013	NCT00002501_3_T5	PHENOTYPE	19	20	Hodgkin's lymphoma
NCT000025015	NCT00002501_5_T0	ORGAN	13	13	marrow
NCT000025015	NCT00002501_5_T1	PHENOTYPE	2	2	toxic
NCT000025017	NCT00002501_7_T0	PHENOTYPE	5	5	remission
NCT000025017	NCT00002501_7_T1	PHENOTYPE	9	9	remission
NCT000025017	NCT00002501_7_T2	GENE	6	6	CR
NCT000025019	NCT00002501_9_T0	GENE	13	13	polymerase
NCT000025019	NCT00002501_9_T1	GENE	8	8	bcl-2
NCT000025019	NCT00002501_9_T2	GENE	16	16	PCR
NCT0000250111	NCT00002501_11_T0	GENE	6	6	PCR
NCT0000250111	NCT00002501_11_T1	GENE	4	4	CR
NCT0000250113	NCT00002501_13_T0	GENE	11	11	filgrastim
NCT0000250113	NCT00002501_13_T1	COMPOUND	2	2	cyclophosphamide
NCT0000250113	NCT00002501_13_T2	GENE	12	12	G-CSF
NCT0000250113	NCT00002501_13_T3	GENE	3	3	IV
NCT0000250114	NCT00002501_14_T0	PHENOTYPE	12	13	disease progression
NCT0000250115	NCT00002501_15_T0	PHENOTYPE	4	4	remission
NCT0000250115	NCT00002501_15_T1	GENE	5	5	CR
NCT0000250116	NCT00002501_16_T0	GENE	5	5	PR
NCT0000250116	NCT00002501_16_T1	PHENOTYPE	4	4	remission
NCT0000250116	NCT00002501_16_T2	GENE	19	19	CR
NCT0000250119	NCT00002501_19_T0	PHENOTYPE	18	18	lymphoma
NCT0000250119	NCT00002501_19_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000250119	NCT00002501_19_T2	PHENOTYPE	16	17	high grade
NCT000025021	NCT00002502_1_T0	CELL	21	21	cells
NCT000025021	NCT00002502_1_T1	ORGAN	3	4	bone marrow
NCT000025025	NCT00002502_5_T0	ORGAN	9	9	Transplant
NCT000025025	NCT00002502_5_T1	ORGAN	7	8	Bone Marrow
NCT000025036	NCT00002503_6_T0	PHENOTYPE	2	4	quality of life
NCT000025038	NCT00002503_8_T0	PHENOTYPE	2	2	toxicity
NCT0000250313	NCT00002503_13_T0	COMPOUND	1	1	chloride
NCT0000250315	NCT00002503_15_T0	PHENOTYPE	3	3	unspecified
NCT000025042	NCT00002504_2_T0	CELL	9	9	cells
NCT000025042	NCT00002504_2_T1	GENE	1	1	interleukin-2
NCT000025042	NCT00002504_2_T2	GENE	3	3	interferon
NCT000025043	NCT00002504_3_T0	GENE	2	2	II
NCT000025043	NCT00002504_3_T1	GENE	9	9	interleukin-2
NCT000025043	NCT00002504_3_T2	GENE	11	11	interferon
NCT000025043	NCT00002504_3_T3	PHENOTYPE	17	18	metastatic cancer
NCT000025047	NCT00002504_7_T0	PHENOTYPE	2	2	toxicities
NCT0000250410	NCT00002504_10_T0	PHENOTYPE	8	8	malignancies
NCT0000250511	NCT00002505_11_T0	PHENOTYPE	7	7	tumor
NCT0000250511	NCT00002505_11_T1	PHENOTYPE	11	11	remission
NCT0000250511	NCT00002505_11_T2	PHENOTYPE	18	19	progressive disease
NCT000025061	NCT00002506_1_T0	COMPOUND	3	3	isotretinoin
NCT000025063	NCT00002506_3_T0	COMPOUND	1	1	isotretinoin
NCT000025063	NCT00002506_3_T1	PHENOTYPE	12	12	cancers
NCT000025063	NCT00002506_3_T2	GENE	3	3	interferon
NCT000025063	NCT00002506_3_T3	PHENOTYPE	11	11	recurrent
NCT000025064	NCT00002506_4_T0	GENE	2	2	II
NCT000025064	NCT00002506_4_T1	COMPOUND	12	12	isotretinoin
NCT000025064	NCT00002506_4_T2	GENE	9	9	interferon
NCT000025064	NCT00002506_4_T3	PHENOTYPE	17	18	recurrent cancer
NCT000025068	NCT00002506_8_T0	PHENOTYPE	2	2	toxicities
NCT0000250613	NCT00002506_13_T0	GENE	16	16	2/30
NCT0000250613	NCT00002506_13_T1	PHENOTYPE	9	9	tumor
NCT0000250613	NCT00002506_13_T2	PHENOTYPE	30	30	tumor
NCT000025070	NCT00002507_0_T0	PHENOTYPE	8	11	Head and Neck Cancer
NCT000025072	NCT00002507_2_T0	CELL	10	10	cells
NCT000025072	NCT00002507_2_T1	PHENOTYPE	9	9	tumor
NCT000025073	NCT00002507_3_T0	COMPOUND	9	9	porfiromycin
NCT000025073	NCT00002507_3_T1	PHENOTYPE	20	23	head and neck cancer
NCT000025074	NCT00002507_4_T0	COMPOUND	16	16	porfiromycin
NCT000025074	NCT00002507_4_T1	GENE	3	3	III
NCT000025074	NCT00002507_4_T2	PHENOTYPE	21	24	head and neck cancer
NCT000025076	NCT00002507_6_T0	COMPOUND	6	6	porfiromycin
NCT000025076	NCT00002507_6_T1	PHENOTYPE	16	17	epidermoid carcinomas
NCT0000250712	NCT00002507_12_T0	GENE	9	9	3.4
NCT000025080	NCT00002508_0_T0	CELL	7	8	Stem Cell
NCT000025080	NCT00002508_0_T1	ORGAN	4	5	Bone Marrow
NCT000025080	NCT00002508_0_T2	PHENOTYPE	17	19	Germ Cell Tumors
NCT000025086	NCT00002508_6_T0	ORGAN	8	9	bone marrow
NCT000025086	NCT00002508_6_T1	CELL	2	5	peripheral blood stem cells
NCT000025087	NCT00002508_7_T0	COMPOUND	15	15	3
NCT000025087	NCT00002508_7_T1	COMPOUND	6	6	etoposide
NCT000025087	NCT00002508_7_T2	GENE	3	3	IV
NCT000025087	NCT00002508_7_T3	GENE	7	7	IV
NCT000025088	NCT00002508_8_T0	ORGAN	3	4	bone marrow
NCT000025096	NCT00002509_6_T0	PHENOTYPE	8	8	toxicity
NCT000025097	NCT00002509_7_T0	ORGAN	18	18	marrow
NCT000025097	NCT00002509_7_T1	ORGAN	30	31	bone marrow
NCT000025097	NCT00002509_7_T2	CELL	8	11	peripheral blood stem cells
NCT000025098	NCT00002509_8_T0	CELL	21	21	granulocyte
NCT000025098	NCT00002509_8_T1	COMPOUND	3	3	cyclophosphamide
NCT000025098	NCT00002509_8_T2	COMPOUND	4	4	etoposide
NCT000025098	NCT00002509_8_T3	ORGAN	18	19	bone marrow
NCT000025099	NCT00002509_9_T0	PHENOTYPE	6	6	remission
NCT000025101	NCT00002510_1_T0	CELL	8	8	cells
NCT000025105	NCT00002510_5_T0	COMPOUND	16	16	etoposide
NCT000025105	NCT00002510_5_T1	PHENOTYPE	11	12	Hodgkin's lymphomas
NCT000025105	NCT00002510_5_T2	CELL	24	27	peripheral blood stem cells
NCT000025107	NCT00002510_7_T0	PHENOTYPE	2	2	toxicity
NCT000025109	NCT00002510_9_T0	PHENOTYPE	5	5	engraftment
NCT0000251010	NCT00002510_10_T0	GENE	16	16	cm
NCT0000251013	NCT00002510_13_T0	CELL	7	8	Stem Cell
NCT000025114	NCT00002511_4_T0	PHENOTYPE	1	1	relapse
NCT000025147	NCT00002514_7_T0	GENE	9	9	MTX
NCT000025147	NCT00002514_7_T1	PHENOTYPE	3	3	leukemia
NCT000025147	NCT00002514_7_T2	GENE	19	19	CSF
NCT000025147	NCT00002514_7_T3	COMPOUND	8	8	methotrexate
NCT000025147	NCT00002514_7_T4	GENE	11	11	IT
NCT000025149	NCT00002514_9_T0	PHENOTYPE	3	3	leukemia
NCT0000251410	NCT00002514_10_T0	GENE	7	7	MTX
NCT0000251410	NCT00002514_10_T1	PHENOTYPE	3	3	leukemia
NCT0000251410	NCT00002514_10_T2	GENE	8	8	IT
NCT0000251411	NCT00002514_11_T0	GENE	17	17	1.28
NCT0000251411	NCT00002514_11_T1	GENE	2	2	Ph
NCT0000251411	NCT00002514_11_T2	COMPOUND	7	7	imatinib
NCT0000251411	NCT00002514_11_T3	COMPOUND	8	8	mesylate
NCT0000251414	NCT00002514_14_T0	GENE	6	6	SC
NCT0000251414	NCT00002514_14_T1	GENE	3	3	filgrastim
NCT0000251414	NCT00002514_14_T2	GENE	4	4	G-CSF
NCT0000251416	NCT00002514_16_T0	PHENOTYPE	10	10	5-10
NCT0000251416	NCT00002514_16_T1	COMPOUND	28	28	3
NCT0000251416	NCT00002514_16_T2	COMPOUND	20	20	etoposide
NCT0000251416	NCT00002514_16_T3	GENE	22	22	IV
NCT0000251417	NCT00002514_17_T0	ORGAN	8	8	testes
NCT0000251423	NCT00002514_23_T0	PHENOTYPE	8	8	initiation
NCT0000251429	NCT00002514_29_T0	GENE	9	9	Ph
NCT0000251429	NCT00002514_29_T1	GENE	7	8	group II
NCT000025150	NCT00002515_0_T0	PHENOTYPE	12	12	Cancer
NCT000025150	NCT00002515_0_T1	ORGAN	4	5	Bone Marrow
NCT000025152	NCT00002515_2_T0	CELL	16	16	cells
NCT000025152	NCT00002515_2_T1	PHENOTYPE	15	15	tumor
NCT000025152	NCT00002515_2_T2	ORGAN	0	1	Bone marrow
NCT000025153	NCT00002515_3_T0	GENE	2	2	II
NCT000025153	NCT00002515_3_T1	COMPOUND	12	12	thiotepa
NCT000025153	NCT00002515_3_T2	PHENOTYPE	28	28	progressive
NCT000025153	NCT00002515_3_T3	COMPOUND	15	15	topotecan
NCT000025153	NCT00002515_3_T4	ORGAN	18	19	bone marrow
NCT000025155	NCT00002515_5_T0	ORGAN	2	3	bone marrow
NCT000025155	NCT00002515_5_T1	CELL	5	8	peripheral blood stem cells
NCT000025156	NCT00002515_6_T0	COMPOUND	6	6	3
NCT000025156	NCT00002515_6_T1	COMPOUND	22	22	3
NCT000025156	NCT00002515_6_T2	COMPOUND	3	3	thiotepa
NCT000025156	NCT00002515_6_T3	GENE	4	4	IV
NCT000025156	NCT00002515_6_T4	GENE	14	14	IV
NCT000025156	NCT00002515_6_T5	GENE	25	25	IV
NCT000025156	NCT00002515_6_T6	COMPOUND	24	24	topotecan
NCT000025157	NCT00002515_7_T0	ORGAN	1	2	bone marrow
NCT000025158	NCT00002515_8_T0	GENE	2	2	filgrastim
NCT000025158	NCT00002515_8_T1	GENE	3	3	G-CSF
NCT000025158	NCT00002515_8_T2	GENE	4	4	IV
NCT000025161	NCT00002516_1_T0	CELL	8	8	cells
NCT000025161	NCT00002516_1_T1	PHENOTYPE	7	7	tumor
NCT000025162	NCT00002516_2_T0	CELL	14	14	cells
NCT000025162	NCT00002516_2_T1	PHENOTYPE	13	13	tumor
NCT000025163	NCT00002516_3_T0	PHENOTYPE	16	17	Ewing's sarcoma
NCT000025164	NCT00002516_4_T0	GENE	3	3	III
NCT000025164	NCT00002516_4_T1	PHENOTYPE	21	22	Ewing's sarcoma
NCT000025168	NCT00002516_8_T0	PHENOTYPE	7	7	toxicity
NCT000025168	NCT00002516_8_T1	PHENOTYPE	15	15	PNET
NCT000025168	NCT00002516_8_T2	COMPOUND	20	20	etoposide
NCT000025168	NCT00002516_8_T3	PHENOTYPE	12	13	Ewing's sarcoma
NCT0000251614	NCT00002516_14_T0	COMPOUND	2	2	ifosfamide
NCT0000251614	NCT00002516_14_T1	PHENOTYPE	6	6	cardiotoxicity
NCT0000251614	NCT00002516_14_T2	PHENOTYPE	3	3	nephrotoxicity
NCT0000251614	NCT00002516_14_T3	COMPOUND	5	5	doxorubicin
NCT0000251619	NCT00002516_19_T0	PHENOTYPE	42	42	tumor
NCT000025171	NCT00002517_1_T0	CELL	9	9	cells
NCT000025179	NCT00002517_9_T0	GENE	3	3	CR
NCT000025192	NCT00002519_2_T0	CELL	9	9	cells
NCT000025192	NCT00002519_2_T1	PHENOTYPE	8	8	tumor
NCT000025197	NCT00002519_7_T0	COMPOUND	5	5	paclitaxel
NCT000025197	NCT00002519_7_T1	ORGAN	2	2	plasma
NCT0000251910	NCT00002519_10_T0	COMPOUND	7	7	paclitaxel
NCT0000251912	NCT00002519_12_T0	COMPOUND	2	2	paclitaxel
NCT0000251912	NCT00002519_12_T1	GENE	3	3	IV
NCT0000251913	NCT00002519_13_T0	PHENOTYPE	10	10	toxicity
NCT0000251913	NCT00002519_13_T1	PHENOTYPE	6	7	disease progression
NCT0000251914	NCT00002519_14_T0	COMPOUND	8	8	paclitaxel
NCT0000251914	NCT00002519_14_T1	GENE	2	2	3.5
NCT0000251914	NCT00002519_14_T2	GENE	14	14	MTD
NCT0000251915	NCT00002519_15_T0	PHENOTYPE	21	21	toxicity
NCT0000251915	NCT00002519_15_T1	GENE	1	1	MTD
NCT000025200	NCT00002520_0_T0	PHENOTYPE	9	9	Cancer
NCT000025208	NCT00002520_8_T0	COMPOUND	2	2	nicotine
NCT000025214	NCT00002521_4_T0	ORGAN	4	5	bone marrow
NCT000025214	NCT00002521_4_T1	CELL	8	11	peripheral blood stem cells
NCT000025215	NCT00002521_5_T0	ORGAN	1	2	bone marrow
NCT000025216	NCT00002521_6_T0	PHENOTYPE	19	19	hypocellular
NCT000025216	NCT00002521_6_T1	PHENOTYPE	10	10	lymphomatous
NCT000025216	NCT00002521_6_T2	ORGAN	14	15	bone marrow
NCT000025217	NCT00002521_7_T0	PHENOTYPE	10	10	lymphomatous
NCT000025217	NCT00002521_7_T1	ORGAN	14	15	bone marrow
NCT000025217	NCT00002521_7_T2	ORGAN	20	21	bone marrow
NCT000025218	NCT00002521_8_T0	COMPOUND	13	13	3
NCT000025218	NCT00002521_8_T1	PHENOTYPE	2	2	conditioning
NCT000025218	NCT00002521_8_T2	COMPOUND	4	4	cyclophosphamide
NCT000025218	NCT00002521_8_T3	COMPOUND	15	15	etoposide
NCT000025218	NCT00002521_8_T4	COMPOUND	24	24	cisplatin
NCT000025218	NCT00002521_8_T5	GENE	5	5	IV
NCT000025218	NCT00002521_8_T6	GENE	16	16	IV
NCT000025218	NCT00002521_8_T7	GENE	25	25	IV
NCT000025219	NCT00002521_9_T0	ORGAN	0	1	Bone marrow
NCT0000252110	NCT00002521_10_T0	COMPOUND	21	21	1
NCT0000252110	NCT00002521_10_T1	GENE	41	41	cm
NCT0000252110	NCT00002521_10_T2	CELL	7	8	stem cells
NCT0000252110	NCT00002521_10_T3	ORGAN	10	11	bone marrow
NCT0000252114	NCT00002521_14_T0	PHENOTYPE	18	18	lymphoma
NCT0000252114	NCT00002521_14_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000252114	NCT00002521_14_T2	PHENOTYPE	16	17	high grade
NCT000025224	NCT00002522_4_T0	ORGAN	4	5	bone marrow
NCT000025224	NCT00002522_4_T1	CELL	8	11	peripheral blood stem cells
NCT000025225	NCT00002522_5_T0	ORGAN	1	2	bone marrow
NCT000025226	NCT00002522_6_T0	PHENOTYPE	19	19	hypocellular
NCT000025226	NCT00002522_6_T1	PHENOTYPE	10	10	lymphomatous
NCT000025226	NCT00002522_6_T2	ORGAN	14	15	bone marrow
NCT000025227	NCT00002522_7_T0	PHENOTYPE	10	10	lymphomatous
NCT000025227	NCT00002522_7_T1	ORGAN	14	15	bone marrow
NCT000025227	NCT00002522_7_T2	ORGAN	20	21	bone marrow
NCT000025228	NCT00002522_8_T0	COMPOUND	13	13	3
NCT000025228	NCT00002522_8_T1	PHENOTYPE	2	2	conditioning
NCT000025228	NCT00002522_8_T2	COMPOUND	4	4	cyclophosphamide
NCT000025228	NCT00002522_8_T3	COMPOUND	15	15	etoposide
NCT000025228	NCT00002522_8_T4	COMPOUND	24	24	cisplatin
NCT000025228	NCT00002522_8_T5	GENE	5	5	IV
NCT000025228	NCT00002522_8_T6	GENE	16	16	IV
NCT000025228	NCT00002522_8_T7	GENE	25	25	IV
NCT000025229	NCT00002522_9_T0	ORGAN	0	1	Bone marrow
NCT0000252210	NCT00002522_10_T0	COMPOUND	21	21	1
NCT0000252210	NCT00002522_10_T1	GENE	41	41	cm
NCT0000252210	NCT00002522_10_T2	CELL	7	8	stem cells
NCT0000252210	NCT00002522_10_T3	ORGAN	10	11	bone marrow
NCT000025231	NCT00002523_1_T0	CELL	23	23	cells
NCT000025231	NCT00002523_1_T1	PHENOTYPE	22	22	tumor
NCT000025235	NCT00002523_5_T0	GENE	22	22	T4
NCT000025235	NCT00002523_5_T1	PHENOTYPE	7	7	tumor
NCT000025235	NCT00002523_5_T2	GENE	9	9	0.5
NCT000025235	NCT00002523_5_T3	GENE	14	14	cm
NCT000025235	NCT00002523_5_T4	GENE	20	20	T3
NCT000025237	NCT00002523_7_T0	GENE	1	1	3-10
NCT000025237	NCT00002523_7_T1	GENE	13	13	1.5
NCT000025241	NCT00002524_1_T0	CELL	9	9	cells
NCT000025242	NCT00002524_2_T0	GENE	2	2	II
NCT000025242	NCT00002524_2_T1	PHENOTYPE	16	16	lymphoma
NCT000025246	NCT00002524_6_T0	GENE	10	10	T4
NCT000025246	NCT00002524_6_T1	GENE	19	19	Ann
NCT000025246	NCT00002524_6_T2	GENE	23	23	ARL
NCT000025246	NCT00002524_6_T3	GENE	2	2	CR
NCT000025248	NCT00002524_8_T0	CELL	21	21	granulocyte
NCT000025248	NCT00002524_8_T1	COMPOUND	16	16	pentamidine
NCT000025248	NCT00002524_8_T2	COMPOUND	13	13	trimethoprim_sulfamethoxazole
NCT000025248	NCT00002524_8_T3	GENE	18	18	prn
NCT000025248	NCT00002524_8_T4	PHENOTYPE	5	5	outlook
NCT000025248	NCT00002524_8_T5	PHENOTYPE	25	26	severe myelosuppression
NCT000025249	NCT00002524_9_T0	GENE	28	28	Ann
NCT000025249	NCT00002524_9_T1	PHENOTYPE	21	21	immunosuppression
NCT000025249	NCT00002524_9_T2	GENE	46	46	LDH
NCT000025249	NCT00002524_9_T3	GENE	57	57	T4
NCT000025249	NCT00002524_9_T4	GENE	84	84	T4
NCT000025249	NCT00002524_9_T5	GENE	71	71	2.3
NCT000025249	NCT00002524_9_T6	GENE	44	44	cm
NCT000025249	NCT00002524_9_T7	PHENOTYPE	81	81	cavity
NCT000025249	NCT00002524_9_T8	PHENOTYPE	67	67	infiltration
NCT000025249	NCT00002524_9_T9	GENE	49	49	686
NCT000025249	NCT00002524_9_T10	ORGAN	78	78	rectum
NCT000025249	NCT00002524_9_T11	ORGAN	79	79	esophagus
NCT000025249	NCT00002524_9_T12	PHENOTYPE	53	54	opportunistic infection
NCT000025249	NCT00002524_9_T13	PHENOTYPE	35	36	immunoblastic lymphoma
NCT0000252411	NCT00002524_11_T0	GENE	13	13	T4
NCT0000252411	NCT00002524_11_T1	PHENOTYPE	22	23	opportunistic infection
NCT0000252411	NCT00002524_11_T2	PHENOTYPE	27	29	primary brain lymphoma
NCT0000252415	NCT00002524_15_T0	PHENOTYPE	18	19	localized disease
NCT0000252417	NCT00002524_17_T0	PHENOTYPE	9	10	localized disease
NCT0000252418	NCT00002524_18_T0	PHENOTYPE	6	8	primary brain lymphoma
NCT0000252420	NCT00002524_20_T0	GENE	28	28	cease
NCT0000252421	NCT00002524_21_T0	GENE	30	30	cease
NCT0000252421	NCT00002524_21_T1	PHENOTYPE	17	18	disease progression
NCT000025251	NCT00002525_1_T0	CELL	15	15	cells
NCT000025251	NCT00002525_1_T1	PHENOTYPE	14	14	tumor
NCT000025252	NCT00002525_2_T0	PHENOTYPE	15	16	colon cancer
NCT000025253	NCT00002525_3_T0	GENE	26	26	B3
NCT000025253	NCT00002525_3_T1	GENE	3	3	III
NCT000025253	NCT00002525_3_T2	PHENOTYPE	29	30	colon cancer
NCT000025256	NCT00002525_6_T0	GENE	41	41	B3
NCT000025256	NCT00002525_6_T1	ORGAN	18	18	colon
NCT000025256	NCT00002525_6_T2	PHENOTYPE	44	45	colon cancer
NCT000025259	NCT00002525_9_T0	GENE	19	19	B2
NCT000025259	NCT00002525_9_T1	PHENOTYPE	9	9	affects
NCT000025259	NCT00002525_9_T2	PHENOTYPE	20	21	colon cancer
NCT0000252510	NCT00002525_10_T0	GENE	7	7	III
NCT0000252511	NCT00002525_11_T0	ORGAN	3	3	colon
NCT0000252515	NCT00002525_15_T0	PHENOTYPE	9	12	stage IV colon cancer
NCT0000252516	NCT00002525_16_T0	GENE	6	6	III
NCT0000252516	NCT00002525_16_T1	PHENOTYPE	7	8	colon cancer
NCT0000252517	NCT00002525_17_T0	COMPOUND	14	14	calcium
NCT0000252517	NCT00002525_17_T1	GENE	25	25	1.5
NCT0000252517	NCT00002525_17_T2	GENE	10	10	III
NCT0000252517	NCT00002525_17_T3	COMPOUND	13	13	leucovorin
NCT0000252517	NCT00002525_17_T4	GENE	15	15	IV
NCT0000252517	NCT00002525_17_T5	GENE	21	21	IV
NCT0000252518	NCT00002525_18_T0	PHENOTYPE	19	19	toxicity
NCT0000252518	NCT00002525_18_T1	PHENOTYPE	15	16	disease progression
NCT0000252519	NCT00002525_19_T0	COMPOUND	12	12	calcium
NCT0000252519	NCT00002525_19_T1	COMPOUND	11	11	leucovorin
NCT0000252523	NCT00002525_23_T0	PHENOTYPE	2	3	intestinal obstruction
NCT000025261	NCT00002526_1_T0	CELL	9	9	cells
NCT000025261	NCT00002526_1_T1	PHENOTYPE	8	8	tumor
NCT000025262	NCT00002526_2_T0	GENE	2	2	II
NCT000025262	NCT00002526_2_T1	COMPOUND	13	13	ifosfamide
NCT000025262	NCT00002526_2_T2	PHENOTYPE	20	20	sarcoma
NCT000025262	NCT00002526_2_T3	COMPOUND	15	15	doxorubicin
NCT000025264	NCT00002526_4_T0	COMPOUND	22	22	ifosfamide
NCT000025264	NCT00002526_4_T1	PHENOTYPE	18	18	sarcoma
NCT000025264	NCT00002526_4_T2	COMPOUND	24	24	doxorubicin
NCT000025265	NCT00002526_5_T0	COMPOUND	3	3	ifosfamide
NCT000025265	NCT00002526_5_T1	GENE	14	14	1.3
NCT000025265	NCT00002526_5_T2	GENE	8	8	1.5
NCT000025265	NCT00002526_5_T3	COMPOUND	10	10	doxorubicin
NCT000025265	NCT00002526_5_T4	GENE	4	4	IV
NCT000025265	NCT00002526_5_T5	GENE	11	11	IV
NCT000025266	NCT00002526_6_T0	COMPOUND	12	12	ifosfamide
NCT000025266	NCT00002526_6_T1	GENE	1	1	G-CSF
NCT000025267	NCT00002526_7_T0	PHENOTYPE	13	13	toxicity
NCT000025267	NCT00002526_7_T1	PHENOTYPE	9	10	disease progression
NCT000025271	NCT00002527_1_T0	PHENOTYPE	12	12	recurrence
NCT000025271	NCT00002527_1_T1	PHENOTYPE	14	14	polyps
NCT000025271	NCT00002527_1_T2	COMPOUND	3	3	aspirin
NCT000025271	NCT00002527_1_T3	PHENOTYPE	16	17	colorectal cancer
NCT000025272	NCT00002527_2_T0	GENE	19	19	II
NCT000025272	NCT00002527_2_T1	GENE	3	3	III
NCT000025272	NCT00002527_2_T2	COMPOUND	10	10	aspirin
NCT000025272	NCT00002527_2_T3	GENE	26	26	has
NCT000025272	NCT00002527_2_T4	PHENOTYPE	21	24	stage III colorectal cancer
NCT000025274	NCT00002527_4_T0	PHENOTYPE	18	18	adenomas
NCT000025274	NCT00002527_4_T1	COMPOUND	2	2	aspirin
NCT000025274	NCT00002527_4_T2	PHENOTYPE	24	25	colorectal cancer
NCT000025276	NCT00002527_6_T0	COMPOUND	5	5	aspirin
NCT000025279	NCT00002527_9_T0	GENE	2	2	ASA
NCT000025281	NCT00002528_1_T0	TISSUE	17	18	lymph node
NCT000025281	NCT00002528_1_T1	PHENOTYPE	9	10	breast cancer
NCT000025282	NCT00002528_2_T0	GENE	3	3	III
NCT000025282	NCT00002528_2_T1	TISSUE	18	19	lymph nodes
NCT000025282	NCT00002528_2_T2	PHENOTYPE	28	31	stage IIA breast cancer
NCT000025287	NCT00002528_7_T0	COMPOUND	4	4	tamoxifen
NCT000025289	NCT00002528_9_T0	COMPOUND	4	4	tamoxifen
NCT0000252812	NCT00002528_12_T0	COMPOUND	1	1	tamoxifen
NCT0000252813	NCT00002528_13_T0	PHENOTYPE	0	2	Quality of life
NCT0000252814	NCT00002528_14_T0	COMPOUND	14	14	tamoxifen
NCT000025292	NCT00002529_2_T0	CELL	10	10	cells
NCT000025292	NCT00002529_2_T1	PHENOTYPE	9	9	tumor
NCT000025293	NCT00002529_3_T0	CELL	9	9	cells
NCT000025293	NCT00002529_3_T1	PHENOTYPE	8	8	tumor
NCT000025293	NCT00002529_3_T2	GENE	3	3	hormone
NCT000025294	NCT00002529_4_T0	PHENOTYPE	12	13	breast cancer
NCT000025295	NCT00002529_5_T0	GENE	30	30	II
NCT000025295	NCT00002529_5_T1	GENE	3	3	III
NCT000025295	NCT00002529_5_T2	GENE	10	10	hormone
NCT000025295	NCT00002529_5_T3	GENE	18	18	hormone
NCT000025295	NCT00002529_5_T4	PHENOTYPE	32	35	stage IIIA breast cancer
NCT000025297	NCT00002529_7_T0	COMPOUND	26	26	toremifene
NCT000025297	NCT00002529_7_T1	GENE	27	27	TOR
NCT000025297	NCT00002529_7_T2	GENE	29	29	peri
NCT000025297	NCT00002529_7_T3	COMPOUND	23	23	tamoxifen
NCT000025297	NCT00002529_7_T4	GENE	24	24	TMX
NCT000025297	NCT00002529_7_T5	PHENOTYPE	35	36	breast cancer
NCT0000252911	NCT00002529_11_T0	GENE	10	10	TOR
NCT0000252911	NCT00002529_11_T1	GENE	8	8	TMX
NCT0000252913	NCT00002529_13_T0	PHENOTYPE	2	4	quality of life
NCT0000252915	NCT00002529_15_T0	PHENOTYPE	2	2	toxic
NCT0000252919	NCT00002529_19_T0	COMPOUND	10	10	cyclophosphamide
NCT0000252919	NCT00002529_19_T1	COMPOUND	8	8	epirubicin
NCT0000252919	NCT00002529_19_T2	COMPOUND	6	6	doxorubicin
NCT0000252919	NCT00002529_19_T3	COMPOUND	22	22	tamoxifen
NCT0000252920	NCT00002529_20_T0	COMPOUND	11	11	tamoxifen
NCT0000252921	NCT00002529_21_T0	COMPOUND	7	7	tamoxifen
NCT0000252922	NCT00002529_22_T0	COMPOUND	18	18	toremifene
NCT0000252922	NCT00002529_22_T1	COMPOUND	14	14	tamoxifen
NCT0000252923	NCT00002529_23_T0	COMPOUND	18	18	toremifene
NCT0000252923	NCT00002529_23_T1	COMPOUND	14	14	tamoxifen
NCT0000252924	NCT00002529_24_T0	COMPOUND	7	7	toremifene
NCT0000252925	NCT00002529_25_T0	ORGAN	31	32	chest wall
NCT000025311	NCT00002531_1_T0	CELL	9	9	cells
NCT000025312	NCT00002531_2_T0	GENE	3	3	II
NCT000025312	NCT00002531_2_T1	PHENOTYPE	18	20	acute lymphocytic leukemia
NCT000025318	NCT00002531_8_T0	PHENOTYPE	4	4	remission
NCT0000253115	NCT00002531_15_T0	PHENOTYPE	4	4	remission
NCT0000253115	NCT00002531_15_T1	GENE	5	5	CR
NCT0000253117	NCT00002531_17_T0	GENE	17	17	2.4
NCT0000253117	NCT00002531_17_T1	GENE	3	3	CR
NCT0000253118	NCT00002531_18_T0	GENE	3	3	CR
NCT0000253118	NCT00002531_18_T1	GENE	10	11	group 3
NCT0000253120	NCT00002531_20_T0	GENE	5	5	MTX
NCT0000253120	NCT00002531_20_T1	COMPOUND	8	8	dexamethasone
NCT0000253121	NCT00002531_21_T0	GENE	15	15	VCR
NCT0000253121	NCT00002531_21_T1	GENE	13	13	1.7
NCT0000253121	NCT00002531_21_T2	COMPOUND	18	18	doxorubicin
NCT0000253121	NCT00002531_21_T3	GENE	16	16	IV
NCT0000253121	NCT00002531_21_T4	GENE	20	20	IV
NCT0000253123	NCT00002531_23_T0	GENE	10	10	MTX
NCT0000253123	NCT00002531_23_T1	GENE	21	21	MTX
NCT0000253123	NCT00002531_23_T2	GENE	35	35	45
NCT0000253123	NCT00002531_23_T3	GENE	6	6	MP
NCT0000253123	NCT00002531_23_T4	GENE	19	19	52
NCT0000253123	NCT00002531_23_T5	GENE	25	25	ASP
NCT0000253125	NCT00002531_25_T0	GENE	7	7	cm
NCT0000253125	NCT00002531_25_T1	PHENOTYPE	2	3	residual tumor
NCT0000253127	NCT00002531_27_T0	GENE	32	32	MTX
NCT0000253127	NCT00002531_27_T1	COMPOUND	18	18	mitoxantrone
NCT0000253127	NCT00002531_27_T2	GENE	29	29	13
NCT0000253127	NCT00002531_27_T3	GENE	37	37	MP
NCT0000253127	NCT00002531_27_T4	GENE	16	16	1.4
NCT0000253127	NCT00002531_27_T5	GENE	19	19	DHAD
NCT0000253127	NCT00002531_27_T6	GENE	26	26	3.5
NCT0000253127	NCT00002531_27_T7	GENE	7	7	IV
NCT0000253127	NCT00002531_27_T8	GENE	20	20	IV
NCT0000253127	NCT00002531_27_T9	GENE	35	35	ASP
NCT0000253132	NCT00002531_32_T0	GENE	15	15	1.4
NCT0000253132	NCT00002531_32_T1	GENE	17	17	DHAD
NCT0000253132	NCT00002531_32_T2	GENE	24	24	3.5
NCT0000253132	NCT00002531_32_T3	GENE	18	18	IV
NCT0000253137	NCT00002531_37_T0	GENE	1	1	1.3
NCT0000253137	NCT00002531_37_T1	GENE	11	11	CR
NCT0000253137	NCT00002531_37_T2	ORGAN	19	20	bone marrow
NCT0000253138	NCT00002531_38_T0	ORGAN	7	8	bone marrow
NCT0000253140	NCT00002531_40_T0	GENE	30	30	CSF
NCT0000253147	NCT00002531_47_T0	PHENOTYPE	6	6	blocks
NCT0000253148	NCT00002531_48_T0	GENE	7	7	MTX
NCT0000253148	NCT00002531_48_T1	COMPOUND	15	15	1
NCT0000253148	NCT00002531_48_T2	COMPOUND	19	19	1
NCT0000253148	NCT00002531_48_T3	COMPOUND	30	30	1
NCT0000253148	NCT00002531_48_T4	COMPOUND	36	36	1
NCT0000253148	NCT00002531_48_T5	COMPOUND	50	50	1
NCT0000253148	NCT00002531_48_T6	COMPOUND	16	16	ifosfamide
NCT0000253148	NCT00002531_48_T7	GENE	5	5	VCR
NCT0000253148	NCT00002531_48_T8	GENE	26	26	1.5
NCT0000253148	NCT00002531_48_T9	GENE	6	6	IV
NCT0000253148	NCT00002531_48_T10	GENE	8	8	IV
NCT0000253148	NCT00002531_48_T11	GENE	17	17	IV
NCT0000253148	NCT00002531_48_T12	GENE	28	28	IV
NCT0000253148	NCT00002531_48_T13	GENE	34	34	IV
NCT0000253150	NCT00002531_50_T0	PHENOTYPE	0	0	Blocks
NCT0000253151	NCT00002531_51_T0	COMPOUND	20	20	vindesine
NCT0000253151	NCT00002531_51_T1	COMPOUND	22	22	etoposide
NCT0000253151	NCT00002531_51_T2	GENE	5	5	CR
NCT0000253151	NCT00002531_51_T3	PHENOTYPE	12	13	disease progression
NCT0000253153	NCT00002531_53_T0	GENE	3	3	2.3
NCT0000253153	NCT00002531_53_T1	GENE	7	7	CSF
NCT000025321	NCT00002532_1_T0	CELL	9	9	cells
NCT000025322	NCT00002532_2_T0	GENE	2	2	II
NCT000025322	NCT00002532_2_T1	PHENOTYPE	19	21	acute lymphocytic leukemia
NCT0000253210	NCT00002532_10_T0	PHENOTYPE	8	8	remission
NCT0000253210	NCT00002532_10_T1	GENE	9	9	CR
NCT0000253211	NCT00002532_11_T0	GENE	8	8	CR
NCT0000253211	NCT00002532_11_T1	PHENOTYPE	4	5	relapsed disease
NCT0000253212	NCT00002532_12_T0	PHENOTYPE	3	3	relapse
NCT0000253212	NCT00002532_12_T1	GENE	6	6	CR
NCT0000253213	NCT00002532_13_T0	GENE	23	23	SC
NCT0000253213	NCT00002532_13_T1	COMPOUND	11	11	cytarabine
NCT0000253213	NCT00002532_13_T2	GENE	18	18	1.3
NCT0000253213	NCT00002532_13_T3	COMPOUND	4	4	idarubicin
NCT0000253213	NCT00002532_13_T4	GENE	20	20	filgrastim
NCT0000253213	NCT00002532_13_T5	GENE	21	21	G-CSF
NCT0000253213	NCT00002532_13_T6	GENE	5	5	IV
NCT0000253213	NCT00002532_13_T7	GENE	12	12	IV
NCT0000253215	NCT00002532_15_T0	COMPOUND	42	42	cytarabine
NCT0000253215	NCT00002532_15_T1	COMPOUND	28	28	calcium
NCT0000253215	NCT00002532_15_T2	GENE	16	16	1.4
NCT0000253215	NCT00002532_15_T3	COMPOUND	18	18	methotrexate
NCT0000253215	NCT00002532_15_T4	GENE	53	53	G-CSF
NCT0000253215	NCT00002532_15_T5	GENE	10	10	IV
NCT0000253215	NCT00002532_15_T6	GENE	19	19	IV
NCT0000253215	NCT00002532_15_T7	GENE	31	31	IV
NCT0000253215	NCT00002532_15_T8	GENE	43	43	IV
NCT0000253215	NCT00002532_15_T9	GENE	54	54	SC
NCT0000253215	NCT00002532_15_T10	COMPOUND	9	9	ifosfamide
NCT0000253215	NCT00002532_15_T11	COMPOUND	7	7	prednisolone
NCT0000253215	NCT00002532_15_T12	COMPOUND	30	30	etoposide
NCT0000253215	NCT00002532_15_T13	COMPOUND	27	27	leucovorin
NCT0000253216	NCT00002532_16_T0	COMPOUND	12	12	cytarabine
NCT0000253216	NCT00002532_16_T1	COMPOUND	10	10	etoposide
NCT000025330	NCT00002533_0_T0	PHENOTYPE	3	3	Mucositis
NCT000025330	NCT00002533_0_T1	PHENOTYPE	10	13	Head and Neck Cancer
NCT000025332	NCT00002533_2_T0	PHENOTYPE	13	13	mucositis
NCT000025332	NCT00002533_2_T1	COMPOUND	10	10	fluconazole
NCT000025332	NCT00002533_2_T2	PHENOTYPE	20	23	head and neck cancer
NCT000025341	NCT00002534_1_T0	CELL	21	21	cells
NCT000025341	NCT00002534_1_T1	ORGAN	3	4	bone marrow
NCT000025342	NCT00002534_2_T0	PHENOTYPE	29	29	remission
NCT000025342	NCT00002534_2_T1	GENE	3	3	III
NCT000025342	NCT00002534_2_T2	PHENOTYPE	23	24	acute leukemia
NCT000025342	NCT00002534_2_T3	ORGAN	10	11	bone marrow
NCT000025342	NCT00002534_2_T4	ORGAN	17	18	bone marrow
NCT000025344	NCT00002534_4_T0	PHENOTYPE	21	21	severity
NCT000025344	NCT00002534_4_T1	PHENOTYPE	27	27	engraftment
NCT000025344	NCT00002534_4_T2	PHENOTYPE	17	17	relapse
NCT000025344	NCT00002534_4_T3	ORGAN	8	8	marrow
NCT000025344	NCT00002534_4_T4	PHENOTYPE	44	44	remission
NCT000025344	NCT00002534_4_T5	PHENOTYPE	23	24	graft-versus-host disease
NCT000025344	NCT00002534_4_T6	PHENOTYPE	38	39	acute leukemia
NCT0000253410	NCT00002534_10_T0	GENE	9	9	2.4
NCT0000253410	NCT00002534_10_T1	GENE	7	7	IV
NCT0000253410	NCT00002534_10_T2	ORGAN	3	4	bone marrow
NCT0000253411	NCT00002534_11_T0	COMPOUND	10	10	cyclosporine
NCT0000253411	NCT00002534_11_T1	COMPOUND	12	12	methotrexate
NCT0000253411	NCT00002534_11_T2	PHENOTYPE	4	7	graft vs host disease
NCT0000253413	NCT00002534_13_T0	GENE	5	5	IV
NCT0000253413	NCT00002534_13_T1	CELL	2	2	T-cell
NCT0000253414	NCT00002534_14_T0	ORGAN	22	22	graft
NCT0000253414	NCT00002534_14_T1	COMPOUND	40	40	methylprednisolone
NCT0000253414	NCT00002534_14_T2	GENE	28	28	globulin
NCT0000253414	NCT00002534_14_T3	GENE	29	29	IV
NCT0000253414	NCT00002534_14_T4	ORGAN	5	6	bone marrow
NCT000025351	NCT00002535_1_T0	CELL	11	11	cells
NCT000025351	NCT00002535_1_T1	PHENOTYPE	10	10	tumor
NCT000025351	NCT00002535_1_T2	COMPOUND	6	6	cyclophosphamide
NCT000025351	NCT00002535_1_T3	COMPOUND	4	4	indomethacin
NCT000025352	NCT00002535_2_T0	GENE	2	2	II
NCT000025352	NCT00002535_2_T1	COMPOUND	16	16	cyclophosphamide
NCT000025352	NCT00002535_2_T2	PHENOTYPE	23	23	melanoma
NCT000025352	NCT00002535_2_T3	GENE	25	25	has
NCT000025352	NCT00002535_2_T4	COMPOUND	9	9	indomethacin
NCT000025358	NCT00002535_8_T0	GENE	8	8	TIL
NCT000025358	NCT00002535_8_T1	PHENOTYPE	15	15	tumor
NCT0000253510	NCT00002535_10_T0	GENE	8	8	TIL
NCT0000253510	NCT00002535_10_T1	PHENOTYPE	15	15	tumor
NCT0000253510	NCT00002535_10_T2	GENE	5	5	lymphokine
NCT0000253510	NCT00002535_10_T3	PHENOTYPE	2	2	lytic
NCT0000253512	NCT00002535_12_T0	GENE	14	14	TIL
NCT0000253512	NCT00002535_12_T1	GENE	27	27	TIL
NCT0000253512	NCT00002535_12_T2	CELL	5	6	LAK cells
NCT0000253512	NCT00002535_12_T3	CELL	20	21	LAK cells
NCT0000253513	NCT00002535_13_T0	PHENOTYPE	4	4	tumors
NCT0000253513	NCT00002535_13_T1	PHENOTYPE	19	19	tumors
NCT0000253513	NCT00002535_13_T2	GENE	10	10	TIL
NCT0000253513	NCT00002535_13_T3	GENE	22	22	TIL
NCT0000253516	NCT00002535_16_T0	PHENOTYPE	3	3	Inhibition
NCT0000253517	NCT00002535_17_T0	GENE	4	4	IL-2
NCT0000253517	NCT00002535_17_T1	GENE	3	3	LAK
NCT0000253519	NCT00002535_19_T0	GENE	29	29	cease
NCT000025362	NCT00002536_2_T0	GENE	3	3	III
NCT000025362	NCT00002536_2_T1	PHENOTYPE	17	20	stage IB cervical cancer
NCT000025364	NCT00002536_4_T0	COMPOUND	32	32	vincristine
NCT000025364	NCT00002536_4_T1	COMPOUND	34	34	cisplatin
NCT000025364	NCT00002536_4_T2	PHENOTYPE	15	18	carcinoma of the cervix
NCT000025364	NCT00002536_4_T3	PHENOTYPE	13	17	stage IB carcinoma of the
NCT000025366	NCT00002536_6_T0	COMPOUND	15	15	vincristine
NCT000025366	NCT00002536_6_T1	COMPOUND	17	17	cisplatin
NCT000025366	NCT00002536_6_T2	PHENOTYPE	1	2	adverse effects
NCT0000253611	NCT00002536_11_T0	PHENOTYPE	2	2	metastases
NCT0000253612	NCT00002536_12_T0	GENE	1	1	2.4
NCT0000253612	NCT00002536_12_T1	TISSUE	11	12	lymph nodes
NCT0000253612	NCT00002536_12_T2	TISSUE	14	16	positive surgical margins
NCT0000253614	NCT00002536_14_T0	COMPOUND	6	6	cisplatin
NCT0000253614	NCT00002536_14_T1	COMPOUND	23	23	cisplatin
NCT0000253614	NCT00002536_14_T2	GENE	7	7	IV
NCT0000253616	NCT00002536_16_T0	PHENOTYPE	18	18	toxicity
NCT0000253616	NCT00002536_16_T1	PHENOTYPE	14	15	disease progression
NCT0000253619	NCT00002536_19_T0	GENE	15	15	4.5
NCT000025372	NCT00002537_2_T0	CELL	10	10	cells
NCT000025372	NCT00002537_2_T1	PHENOTYPE	9	9	tumor
NCT000025373	NCT00002537_3_T0	CELL	9	9	cells
NCT000025373	NCT00002537_3_T1	PHENOTYPE	8	8	tumor
NCT000025377	NCT00002537_7_T0	PHENOTYPE	5	5	toxic
NCT0000253710	NCT00002537_10_T0	COMPOUND	8	8	topotecan
NCT0000253711	NCT00002537_11_T0	GENE	7	7	IV
NCT0000253711	NCT00002537_11_T1	COMPOUND	6	6	topotecan
NCT0000253712	NCT00002537_12_T0	GENE	17	17	MTD
NCT0000253712	NCT00002537_12_T1	COMPOUND	8	8	topotecan
NCT0000253713	NCT00002537_13_T0	PHENOTYPE	19	19	toxicity
NCT0000253713	NCT00002537_13_T1	GENE	1	1	MTD
NCT0000253714	NCT00002537_14_T0	GENE	7	7	MTD
NCT0000253715	NCT00002537_15_T0	GENE	23	23	IV
NCT0000253715	NCT00002537_15_T1	GENE	7	7	CR
NCT0000253715	NCT00002537_15_T2	PHENOTYPE	6	6	remission
NCT0000253715	NCT00002537_15_T3	GENE	34	34	MTD
NCT0000253715	NCT00002537_15_T4	COMPOUND	22	22	topotecan
NCT0000253715	NCT00002537_15_T5	PHENOTYPE	12	13	measurable disease
NCT0000253716	NCT00002537_16_T0	PHENOTYPE	10	10	toxicity
NCT000025385	NCT00002538_5_T0	PHENOTYPE	2	3	adverse effects
NCT000025387	NCT00002538_7_T0	TISSUE	5	6	lymph node
NCT000025389	NCT00002538_9_T0	PHENOTYPE	13	13	closed
NCT000025390	NCT00002539_0_T0	PHENOTYPE	12	12	Osteosarcoma
NCT000025390	NCT00002539_0_T1	GENE	7	7	G-CSF
NCT000025392	NCT00002539_2_T0	PHENOTYPE	17	17	peripheral
NCT000025392	NCT00002539_2_T1	GENE	4	4	G-CSF
NCT000025392	NCT00002539_2_T2	CELL	11	11	cells
NCT000025392	NCT00002539_2_T3	ORGAN	14	15	bone marrow
NCT000025392	NCT00002539_2_T4	ORGAN	24	25	immune system
NCT000025392	NCT00002539_2_T5	PHENOTYPE	30	32	effects of chemotherapy
NCT000025393	NCT00002539_3_T0	GENE	10	10	G-CSF
NCT000025393	NCT00002539_3_T1	PHENOTYPE	23	23	osteosarcoma
NCT000025394	NCT00002539_4_T0	GENE	3	3	III
NCT000025394	NCT00002539_4_T1	GENE	16	16	G-CSF
NCT000025394	NCT00002539_4_T2	PHENOTYPE	24	24	osteosarcoma
NCT0000253913	NCT00002539_13_T0	GENE	16	16	G-CSF
NCT0000253914	NCT00002539_14_T0	PHENOTYPE	3	4	disease progression
NCT000025409	NCT00002540_9_T0	PHENOTYPE	12	12	tumor
NCT0000254011	NCT00002540_11_T0	PHENOTYPE	11	11	carcinogenesis
NCT0000254014	NCT00002540_14_T0	GENE	0	0	ARM
NCT0000254017	NCT00002540_17_T0	COMPOUND	13	13	NCI
NCT0000254017	NCT00002540_17_T1	ORGAN	0	0	Serum
NCT0000254018	NCT00002540_18_T0	GENE	4	4	DRE
NCT000025422	NCT00002542_2_T0	CELL	7	7	cells
NCT000025422	NCT00002542_2_T1	PHENOTYPE	6	6	tumor
NCT000025423	NCT00002542_3_T0	GENE	30	30	II
NCT000025423	NCT00002542_3_T1	GENE	2	2	III
NCT000025423	NCT00002542_3_T2	PHENOTYPE	27	27	recurrence
NCT000025423	NCT00002542_3_T3	COMPOUND	9	9	tamoxifen
NCT000025423	NCT00002542_3_T4	PHENOTYPE	19	22	stage I breast cancer
NCT000025423	NCT00002542_3_T5	PHENOTYPE	32	35	stage III breast cancer
NCT000025425	NCT00002542_5_T0	GENE	56	56	CEF
NCT000025425	NCT00002542_5_T1	COMPOUND	48	48	methotrexate
NCT000025425	NCT00002542_5_T2	COMPOUND	53	53	epirubicin
NCT000025425	NCT00002542_5_T3	COMPOUND	47	47	cyclophosphamide
NCT000025425	NCT00002542_5_T4	COMPOUND	52	52	cyclophosphamide
NCT000025425	NCT00002542_5_T5	COMPOUND	60	60	cyclophosphamide
NCT000025425	NCT00002542_5_T6	COMPOUND	58	58	doxorubicin
NCT000025425	NCT00002542_5_T7	COMPOUND	66	66	tamoxifen
NCT000025425	NCT00002542_5_T8	PHENOTYPE	21	22	breast cancer
NCT000025427	NCT00002542_7_T0	PHENOTYPE	5	5	toxicity
NCT000025427	NCT00002542_7_T1	COMPOUND	9	9	tamoxifen
NCT0000254211	NCT00002542_11_T0	GENE	25	25	PR
NCT0000254211	NCT00002542_11_T1	GENE	30	30	PR
NCT0000254211	NCT00002542_11_T2	GENE	36	36	1.3
NCT0000254211	NCT00002542_11_T3	COMPOUND	13	13	methotrexate
NCT0000254211	NCT00002542_11_T4	COMPOUND	8	8	epirubicin
NCT0000254211	NCT00002542_11_T5	GENE	23	23	ER
NCT0000254211	NCT00002542_11_T6	GENE	28	28	ER
NCT0000254211	NCT00002542_11_T7	COMPOUND	7	7	cyclophosphamide
NCT0000254211	NCT00002542_11_T8	COMPOUND	12	12	cyclophosphamide
NCT0000254211	NCT00002542_11_T9	COMPOUND	17	17	cyclophosphamide
NCT0000254211	NCT00002542_11_T10	COMPOUND	19	19	doxorubicin
NCT0000254211	NCT00002542_11_T11	GENE	20	21	hormone receptor
NCT0000254213	NCT00002542_13_T0	COMPOUND	5	5	cyclophosphamide
NCT0000254213	NCT00002542_13_T1	COMPOUND	10	10	epirubicin
NCT0000254213	NCT00002542_13_T2	GENE	11	11	IV
NCT0000254213	NCT00002542_13_T3	GENE	14	14	IV
NCT0000254216	NCT00002542_16_T0	COMPOUND	5	5	cyclophosphamide
NCT0000254216	NCT00002542_16_T1	COMPOUND	10	10	cyclophosphamide
NCT0000254216	NCT00002542_16_T2	COMPOUND	17	17	methotrexate
NCT0000254216	NCT00002542_16_T3	GENE	11	11	IV
NCT0000254216	NCT00002542_16_T4	GENE	25	25	IV
NCT0000254219	NCT00002542_19_T0	COMPOUND	7	7	cyclophosphamide
NCT0000254219	NCT00002542_19_T1	COMPOUND	4	4	doxorubicin
NCT0000254219	NCT00002542_19_T2	GENE	5	5	IV
NCT0000254219	NCT00002542_19_T3	GENE	8	8	IV
NCT0000254221	NCT00002542_21_T0	COMPOUND	8	8	tamoxifen
NCT0000254222	NCT00002542_22_T0	PHENOTYPE	10	10	toxicity
NCT0000254222	NCT00002542_22_T1	PHENOTYPE	6	7	disease progression
NCT000025432	NCT00002543_2_T0	PHENOTYPE	20	20	neuroblastoma
NCT000025432	NCT00002543_2_T1	PHENOTYPE	21	21	rhabdomyosarcoma
NCT000025432	NCT00002543_2_T2	COMPOUND	10	11	gallium nitrate
NCT000025432	NCT00002543_2_T3	PHENOTYPE	26	27	solid tumor
NCT000025432	NCT00002543_2_T4	PHENOTYPE	18	19	brain tumors
NCT000025432	NCT00002543_2_T5	PHENOTYPE	22	23	Hodgkin's lymphoma
NCT000025441	NCT00002544_1_T0	COMPOUND	6	6	mitoxantrone
NCT000025441	NCT00002544_1_T1	COMPOUND	13	13	docetaxel
NCT000025442	NCT00002544_2_T0	COMPOUND	10	10	mitoxantrone
NCT000025442	NCT00002544_2_T1	GENE	3	3	III
NCT000025442	NCT00002544_2_T2	COMPOUND	14	14	docetaxel
NCT000025442	NCT00002544_2_T3	PHENOTYPE	20	22	metastatic breast cancer
NCT000025445	NCT00002544_5_T0	ORGAN	41	41	liver
NCT000025445	NCT00002544_5_T1	ORGAN	48	48	liver
NCT000025445	NCT00002544_5_T2	ORGAN	55	55	liver
NCT000025445	NCT00002544_5_T3	PHENOTYPE	60	61	lung metastases
NCT000025445	NCT00002544_5_T4	GENE	21	22	hormone receptor
NCT000025445	NCT00002544_5_T5	PHENOTYPE	39	40	liver metastases
NCT000025447	NCT00002544_7_T0	PHENOTYPE	9	9	toxicity
NCT000025447	NCT00002544_7_T1	PHENOTYPE	6	7	disease progression
NCT000025449	NCT00002544_9_T0	PHENOTYPE	19	19	toxicity
NCT000025449	NCT00002544_9_T1	PHENOTYPE	16	16	progression
NCT0000254410	NCT00002544_10_T0	PHENOTYPE	1	1	relapse
NCT0000254412	NCT00002544_12_T0	PHENOTYPE	0	2	Quality of life
NCT000025451	NCT00002545_1_T0	CELL	7	7	cells
NCT000025451	NCT00002545_1_T1	PHENOTYPE	6	6	tumor
NCT000025452	NCT00002545_2_T0	CELL	9	9	cells
NCT000025452	NCT00002545_2_T1	PHENOTYPE	8	8	tumor
NCT000025453	NCT00002545_3_T0	GENE	3	3	III
NCT000025453	NCT00002545_3_T1	PHENOTYPE	19	21	supratentorial glioblastoma multiforme
NCT000025455	NCT00002545_5_T0	COMPOUND	15	15	BCNU
NCT000025455	NCT00002545_5_T1	COMPOUND	24	24	BCNU
NCT000025455	NCT00002545_5_T2	PHENOTYPE	29	31	supratentorial glioblastoma multiforme
NCT000025457	NCT00002545_7_T0	PHENOTYPE	6	6	severity
NCT000025457	NCT00002545_7_T1	PHENOTYPE	8	8	toxicities
NCT000025459	NCT00002545_9_T0	PHENOTYPE	11	13	quality of life
NCT0000254512	NCT00002545_12_T0	COMPOUND	12	12	BCNU
NCT0000254512	NCT00002545_12_T1	PHENOTYPE	0	0	Tumor
NCT000025461	NCT00002546_1_T0	CELL	10	10	cells
NCT000025461	NCT00002546_1_T1	PHENOTYPE	9	9	tumor
NCT000025471	NCT00002547_1_T0	CELL	20	20	cells
NCT000025471	NCT00002547_1_T1	ORGAN	3	4	bone marrow
NCT000025476	NCT00002547_6_T0	ORGAN	22	22	marrow
NCT000025478	NCT00002547_8_T0	PHENOTYPE	5	5	toxic
NCT000025479	NCT00002547_9_T0	PHENOTYPE	7	7	remission
NCT000025479	NCT00002547_9_T1	GENE	8	8	CR
NCT000025479	NCT00002547_9_T2	GENE	11	11	CR
NCT0000254712	NCT00002547_12_T0	COMPOUND	2	2	methotrexate
NCT0000254712	NCT00002547_12_T1	GENE	3	3	IT
NCT0000254713	NCT00002547_13_T0	PHENOTYPE	25	25	leukemia
NCT0000254713	NCT00002547_13_T1	PHENOTYPE	2	2	initiation
NCT0000254713	NCT00002547_13_T2	CELL	26	26	cells
NCT0000254713	NCT00002547_13_T3	GENE	18	18	2.3
NCT0000254713	NCT00002547_13_T4	COMPOUND	15	15	methotrexate
NCT0000254713	NCT00002547_13_T5	GENE	16	16	IT
NCT0000254714	NCT00002547_14_T0	COMPOUND	10	10	methotrexate
NCT0000254715	NCT00002547_15_T0	GENE	22	22	IV
NCT0000254715	NCT00002547_15_T1	COMPOUND	5	5	busulfan
NCT0000254715	NCT00002547_15_T2	COMPOUND	24	24	2
NCT0000254715	NCT00002547_15_T3	COMPOUND	30	30	2
NCT0000254715	NCT00002547_15_T4	COMPOUND	28	28	3
NCT0000254715	NCT00002547_15_T5	COMPOUND	21	21	cyclophosphamide
NCT0000254716	NCT00002547_16_T0	ORGAN	1	2	bone marrow
NCT0000254717	NCT00002547_17_T0	COMPOUND	5	5	busulfan
NCT0000254718	NCT00002547_18_T0	COMPOUND	2	2	cytarabine
NCT0000254718	NCT00002547_18_T1	COMPOUND	19	19	2
NCT0000254718	NCT00002547_18_T2	COMPOUND	25	25	2
NCT0000254718	NCT00002547_18_T3	COMPOUND	23	23	3
NCT0000254718	NCT00002547_18_T4	COMPOUND	16	16	cyclophosphamide
NCT0000254718	NCT00002547_18_T5	GENE	3	3	IV
NCT0000254718	NCT00002547_18_T6	GENE	17	17	IV
NCT0000254719	NCT00002547_19_T0	ORGAN	1	2	bone marrow
NCT0000254720	NCT00002547_20_T0	COMPOUND	7	7	cyclosporine
NCT0000254720	NCT00002547_20_T1	COMPOUND	21	21	cyclosporine
NCT0000254720	NCT00002547_20_T2	COMPOUND	12	12	1
NCT0000254720	NCT00002547_20_T3	GENE	8	8	IV
NCT0000254720	NCT00002547_20_T4	PHENOTYPE	0	3	Graft versus host disease
NCT0000254721	NCT00002547_21_T0	COMPOUND	2	2	methotrexate
NCT0000254721	NCT00002547_21_T1	GENE	3	3	IV
NCT0000254722	NCT00002547_22_T0	COMPOUND	9	9	methotrexate
NCT0000254722	NCT00002547_22_T1	GENE	10	10	IT
NCT0000254723	NCT00002547_23_T0	COMPOUND	12	12	methotrexate
NCT0000254723	NCT00002547_23_T1	GENE	13	13	IT
NCT0000254725	NCT00002547_25_T0	GENE	14	14	2.7
NCT000025481	NCT00002548_1_T0	CELL	8	8	cells
NCT000025483	NCT00002548_3_T0	PHENOTYPE	12	13	multiple myeloma
NCT0000254814	NCT00002548_14_T0	PHENOTYPE	2	3	progressive disease
NCT0000254816	NCT00002548_16_T0	COMPOUND	5	5	1
NCT0000254816	NCT00002548_16_T1	COMPOUND	21	21	1
NCT0000254816	NCT00002548_16_T2	COMPOUND	2	2	melphalan
NCT0000254816	NCT00002548_16_T3	GENE	3	3	IV
NCT0000254822	NCT00002548_22_T0	GENE	2	2	interferon
NCT0000254823	NCT00002548_23_T0	PHENOTYPE	13	13	toxicity
NCT0000254823	NCT00002548_23_T1	PHENOTYPE	9	10	disease progression
NCT000025498	NCT00002549_8_T0	PHENOTYPE	3	3	relapse
NCT000025498	NCT00002549_8_T1	GENE	8	8	CR
NCT000025498	NCT00002549_8_T2	PHENOTYPE	39	39	remission
NCT000025498	NCT00002549_8_T3	ORGAN	25	25	transplant
NCT000025498	NCT00002549_8_T4	ORGAN	31	31	transplant
NCT000025498	NCT00002549_8_T5	ORGAN	23	24	bone marrow
NCT000025498	NCT00002549_8_T6	ORGAN	29	30	bone marrow
NCT000025498	NCT00002549_8_T7	CELL	16	19	peripheral blood stem cells
NCT0000254910	NCT00002549_10_T0	CELL	12	12	platelet
NCT0000254910	NCT00002549_10_T1	CELL	9	10	polymorphonuclear leukocyte
NCT0000254912	NCT00002549_12_T0	PHENOTYPE	8	8	toxicity
NCT0000254914	NCT00002549_14_T0	PHENOTYPE	2	4	quality of life
NCT0000254925	NCT00002549_25_T0	GENE	0	0	ICE
NCT0000254927	NCT00002549_27_T0	GENE	0	0	MICE
NCT0000254932	NCT00002549_32_T0	GENE	5	5	CI
NCT0000254932	NCT00002549_32_T1	GENE	6	6	IDA
NCT0000254934	NCT00002549_34_T0	GENE	0	0	G-CSF
NCT000025502	NCT00002550_2_T0	CELL	9	9	cells
NCT000025502	NCT00002550_2_T1	PHENOTYPE	8	8	tumor
NCT000025503	NCT00002550_3_T0	PHENOTYPE	18	19	lung cancer
NCT000025508	NCT00002550_8_T0	PHENOTYPE	12	12	tumor
NCT000025508	NCT00002550_8_T1	GENE	16	16	T2
NCT000025508	NCT00002550_8_T2	GENE	18	18	T3
NCT0000255010	NCT00002550_10_T0	PHENOTYPE	16	16	toxicity
NCT0000255010	NCT00002550_10_T1	PHENOTYPE	12	13	disease progression
NCT0000255011	NCT00002550_11_T0	PHENOTYPE	29	29	toxicity
NCT0000255011	NCT00002550_11_T1	PHENOTYPE	25	26	disease progression
NCT0000255012	NCT00002550_12_T0	PHENOTYPE	6	6	metastases
NCT0000255012	NCT00002550_12_T1	GENE	8	8	2.4
NCT0000255012	NCT00002550_12_T2	GENE	18	18	3.5
NCT0000255012	NCT00002550_12_T3	PHENOTYPE	3	3	progression
NCT0000255013	NCT00002550_13_T0	TISSUE	7	8	lymph nodes
NCT0000255014	NCT00002550_14_T0	TISSUE	22	22	pericardium
NCT0000255014	NCT00002550_14_T1	PHENOTYPE	14	14	tumor
NCT0000255014	NCT00002550_14_T2	GENE	10	10	en
NCT0000255014	NCT00002550_14_T3	ORGAN	24	24	diaphragm
NCT0000255014	NCT00002550_14_T4	ORGAN	20	21	chest wall
NCT0000255014	NCT00002550_14_T5	TISSUE	18	19	parietal pleura
NCT0000255017	NCT00002550_17_T0	PHENOTYPE	6	6	metastases
NCT0000255017	NCT00002550_17_T1	PHENOTYPE	3	3	progression
NCT0000255018	NCT00002550_18_T0	PHENOTYPE	5	5	progression
NCT000025511	NCT00002551_1_T0	CELL	8	8	cells
NCT000025511	NCT00002551_1_T1	PHENOTYPE	7	7	tumor
NCT000025512	NCT00002551_2_T0	PHENOTYPE	12	13	rectal cancer
NCT000025513	NCT00002551_3_T0	GENE	3	3	III
NCT000025513	NCT00002551_3_T1	GENE	26	26	has
NCT000025513	NCT00002551_3_T2	PHENOTYPE	23	24	rectal cancer
NCT000025516	NCT00002551_6_T0	GENE	11	11	II
NCT000025516	NCT00002551_6_T1	COMPOUND	60	60	calcium
NCT000025516	NCT00002551_6_T2	PHENOTYPE	4	4	relapse
NCT000025516	NCT00002551_6_T3	GENE	13	13	III
NCT000025516	NCT00002551_6_T4	COMPOUND	62	62	levamisole
NCT000025516	NCT00002551_6_T5	COMPOUND	59	59	leucovorin
NCT000025516	NCT00002551_6_T6	PHENOTYPE	14	15	rectal cancer
NCT000025518	NCT00002551_8_T0	PHENOTYPE	1	1	relapse
NCT000025518	NCT00002551_8_T1	PHENOTYPE	4	4	tolerance
NCT0000255110	NCT00002551_10_T0	GENE	29	29	T4a
NCT0000255110	NCT00002551_10_T1	PHENOTYPE	23	23	tumor
NCT0000255110	NCT00002551_10_T2	GENE	14	14	nodal
NCT0000255110	NCT00002551_10_T3	GENE	27	27	T3
NCT0000255114	NCT00002551_14_T0	GENE	13	13	1.5
NCT0000255114	NCT00002551_14_T1	GENE	10	10	IV
NCT0000255115	NCT00002551_15_T0	PHENOTYPE	17	17	toxicity
NCT0000255115	NCT00002551_15_T1	PHENOTYPE	13	14	disease progression
NCT0000255119	NCT00002551_19_T0	GENE	9	9	1.3
NCT0000255119	NCT00002551_19_T1	COMPOUND	4	4	levamisole
NCT0000255120	NCT00002551_20_T0	GENE	1	1	IV
NCT0000255120	NCT00002551_20_T1	GENE	4	4	IV
NCT0000255121	NCT00002551_21_T0	PHENOTYPE	39	39	toxicity
NCT0000255121	NCT00002551_21_T1	COMPOUND	21	21	levamisole
NCT0000255121	NCT00002551_21_T2	GENE	26	26	1.3
NCT0000255121	NCT00002551_21_T3	GENE	16	16	1.5
NCT0000255121	NCT00002551_21_T4	GENE	10	10	IV
NCT0000255121	NCT00002551_21_T5	GENE	13	13	IV
NCT0000255121	NCT00002551_21_T6	PHENOTYPE	35	36	disease progression
NCT000025521	NCT00002552_1_T0	CELL	19	19	cells
NCT000025521	NCT00002552_1_T1	PHENOTYPE	18	18	tumor
NCT000025521	NCT00002552_1_T2	ORGAN	1	2	bone marrow
NCT000025522	NCT00002552_2_T0	GENE	3	3	II
NCT000025522	NCT00002552_2_T1	ORGAN	15	15	transplant
NCT000025522	NCT00002552_2_T2	PHENOTYPE	36	37	multiple myeloma
NCT000025522	NCT00002552_2_T3	ORGAN	13	14	bone marrow
NCT000025522	NCT00002552_2_T4	PHENOTYPE	31	32	Hodgkin's lymphoma
NCT000025522	NCT00002552_2_T5	PHENOTYPE	33	34	Hodgkin's lymphoma
NCT000025524	NCT00002552_4_T0	PHENOTYPE	2	2	toxicities
NCT000025524	NCT00002552_4_T1	COMPOUND	12	12	cyclophosphamide
NCT000025524	NCT00002552_4_T2	COMPOUND	17	17	cyclophosphamide
NCT000025524	NCT00002552_4_T3	ORGAN	29	29	transplant
NCT000025524	NCT00002552_4_T4	COMPOUND	13	13	etoposide
NCT000025524	NCT00002552_4_T5	PHENOTYPE	41	42	multiple myeloma
NCT000025524	NCT00002552_4_T6	ORGAN	27	28	bone marrow
NCT000025524	NCT00002552_4_T7	PHENOTYPE	38	39	Hodgkin's disease
NCT000025524	NCT00002552_4_T8	PHENOTYPE	36	37	Hodgkin's lymphoma
NCT000025527	NCT00002552_7_T0	COMPOUND	37	37	3
NCT000025527	NCT00002552_7_T1	COMPOUND	10	10	cyclophosphamide
NCT000025527	NCT00002552_7_T2	COMPOUND	16	16	etoposide
NCT000025527	NCT00002552_7_T3	GENE	11	11	IV
NCT000025527	NCT00002552_7_T4	GENE	17	17	IV
NCT000025527	NCT00002552_7_T5	GENE	31	31	IV
NCT000025528	NCT00002552_8_T0	ORGAN	5	6	bone marrow
NCT000025529	NCT00002552_9_T0	COMPOUND	30	30	1
NCT000025529	NCT00002552_9_T1	COMPOUND	11	11	cyclophosphamide
NCT000025529	NCT00002552_9_T2	GENE	12	12	IV
NCT0000255210	NCT00002552_10_T0	ORGAN	5	6	bone marrow
NCT0000255211	NCT00002552_11_T0	COMPOUND	15	15	cytarabine
NCT0000255211	NCT00002552_11_T1	ORGAN	3	4	bone marrow
NCT0000255212	NCT00002552_12_T0	GENE	7	7	GM-CSF
NCT0000255212	NCT00002552_12_T1	GENE	6	6	sargramostim
NCT0000255213	NCT00002552_13_T0	CELL	20	20	cells
NCT0000255213	NCT00002552_13_T1	GENE	7	7	1.3
NCT0000255213	NCT00002552_13_T2	CELL	0	3	Peripheral blood stem cells
NCT0000255216	NCT00002552_16_T0	PHENOTYPE	18	18	lymphoma
NCT0000255216	NCT00002552_16_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000255216	NCT00002552_16_T2	PHENOTYPE	16	17	high grade
NCT000025531	NCT00002553_1_T0	CELL	8	8	cells
NCT000025531	NCT00002553_1_T1	PHENOTYPE	7	7	tumor
NCT000025532	NCT00002553_2_T0	CELL	9	9	cells
NCT000025532	NCT00002553_2_T1	CELL	22	22	cells
NCT000025532	NCT00002553_2_T2	PHENOTYPE	21	21	tumor
NCT000025532	NCT00002553_2_T3	ORGAN	0	1	Bone marrow
NCT000025533	NCT00002553_3_T0	GENE	2	2	II
NCT000025533	NCT00002553_3_T1	PHENOTYPE	22	23	hematologic cancer
NCT000025533	NCT00002553_3_T2	ORGAN	9	10	bone marrow
NCT000025533	NCT00002553_3_T3	ORGAN	14	15	bone marrow
NCT000025535	NCT00002553_5_T0	GENE	15	15	HLA-A
NCT000025535	NCT00002553_5_T1	PHENOTYPE	35	35	GVHD
NCT000025535	NCT00002553_5_T2	GENE	12	12	CREG
NCT000025535	NCT00002553_5_T3	GENE	46	46	CREG
NCT000025535	NCT00002553_5_T4	PHENOTYPE	31	34	graft versus host disease
NCT000025537	NCT00002553_7_T0	GENE	12	12	HLA-A
NCT000025537	NCT00002553_7_T1	PHENOTYPE	26	26	GVHD
NCT000025537	NCT00002553_7_T2	GENE	9	9	CREG
NCT000025539	NCT00002553_9_T0	GENE	4	4	HLA-A
NCT000025539	NCT00002553_9_T1	GENE	15	15	HLA-A
NCT000025539	NCT00002553_9_T2	ORGAN	10	10	transplants
NCT000025539	NCT00002553_9_T3	ORGAN	8	9	bone marrow
NCT0000255313	NCT00002553_13_T0	ORGAN	1	2	bone marrow
NCT000025541	NCT00002554_1_T0	CELL	18	18	cells
NCT000025541	NCT00002554_1_T1	ORGAN	11	12	bone marrow
NCT000025542	NCT00002554_2_T0	GENE	2	2	II
NCT000025542	NCT00002554_2_T1	ORGAN	15	16	bone marrow
NCT000025542	NCT00002554_2_T2	PHENOTYPE	22	24	acute myelogenous leukemia
NCT000025544	NCT00002554_4_T0	PHENOTYPE	7	7	toxicity
NCT000025544	NCT00002554_4_T1	PHENOTYPE	38	38	relapse
NCT000025544	NCT00002554_4_T2	ORGAN	22	22	marrow
NCT000025544	NCT00002554_4_T3	PHENOTYPE	34	34	remission
NCT000025544	NCT00002554_4_T4	ORGAN	23	23	transplant
NCT000025544	NCT00002554_4_T5	PHENOTYPE	27	29	acute myelogenous leukemia
NCT000025546	NCT00002554_6_T0	ORGAN	14	14	marrow
NCT000025546	NCT00002554_6_T1	CELL	23	23	cells
NCT000025548	NCT00002554_8_T0	PHENOTYPE	9	9	remission
NCT000025549	NCT00002554_9_T0	ORGAN	8	9	Bone Marrow
NCT0000255411	NCT00002554_11_T0	PHENOTYPE	16	16	relapse
NCT0000255411	NCT00002554_11_T1	PHENOTYPE	10	10	remission
NCT0000255411	NCT00002554_11_T2	PHENOTYPE	22	22	remission
NCT000025550	NCT00002555_0_T0	PHENOTYPE	11	14	Head and Neck Cancer
NCT000025552	NCT00002555_2_T0	CELL	10	10	cells
NCT000025552	NCT00002555_2_T1	PHENOTYPE	9	9	tumor
NCT000025553	NCT00002555_3_T0	PHENOTYPE	21	24	head and neck cancer
NCT000025554	NCT00002555_4_T0	GENE	3	3	III
NCT000025554	NCT00002555_4_T1	COMPOUND	19	19	cisplatin
NCT000025554	NCT00002555_4_T2	PHENOTYPE	24	27	head and neck cancer
NCT000025556	NCT00002555_6_T0	PHENOTYPE	28	28	recurrence
NCT000025556	NCT00002555_6_T1	PHENOTYPE	23	23	carcinomas
NCT000025556	NCT00002555_6_T2	COMPOUND	5	5	cisplatin
NCT0000255510	NCT00002555_10_T0	PHENOTYPE	16	16	recurrence
NCT0000255510	NCT00002555_10_T1	PHENOTYPE	4	5	primary tumor
NCT000025563	NCT00002556_3_T0	COMPOUND	14	14	cyclophosphamide
NCT000025563	NCT00002556_3_T1	PHENOTYPE	24	25	multiple myeloma
NCT000025563	NCT00002556_3_T2	COMPOUND	17	18	interferon alfa_2b
NCT000025565	NCT00002556_5_T0	PHENOTYPE	10	10	toxicity
NCT000025565	NCT00002556_5_T1	COMPOUND	20	20	melphalan
NCT000025565	NCT00002556_5_T2	COMPOUND	21	21	cyclophosphamide
NCT000025565	NCT00002556_5_T3	COMPOUND	29	29	cyclophosphamide
NCT000025565	NCT00002556_5_T4	COMPOUND	22	22	prednisone
NCT000025565	NCT00002556_5_T5	PHENOTYPE	43	44	multiple myeloma
NCT000025565	NCT00002556_5_T6	COMPOUND	34	35	interferon alfa_2b
NCT000025565	NCT00002556_5_T7	COMPOUND	17	18	vincristine sulfate
NCT000025568	NCT00002556_8_T0	COMPOUND	19	19	melphalan
NCT000025568	NCT00002556_8_T1	GENE	24	24	1.4
NCT000025568	NCT00002556_8_T2	COMPOUND	25	25	cyclophosphamide
NCT000025568	NCT00002556_8_T3	GENE	35	35	1.7
NCT000025568	NCT00002556_8_T4	COMPOUND	31	31	prednisone
NCT000025568	NCT00002556_8_T5	GENE	10	10	IV
NCT000025568	NCT00002556_8_T6	GENE	15	15	IV
NCT000025568	NCT00002556_8_T7	GENE	26	26	IV
NCT000025568	NCT00002556_8_T8	COMPOUND	7	8	vincristine sulfate
NCT000025569	NCT00002556_9_T0	PHENOTYPE	16	16	toxicity
NCT000025569	NCT00002556_9_T1	PHENOTYPE	12	13	disease progression
NCT0000255611	NCT00002556_11_T0	GENE	0	0	ARM
NCT0000255612	NCT00002556_12_T0	PHENOTYPE	13	13	toxicity
NCT0000255612	NCT00002556_12_T1	PHENOTYPE	9	10	disease progression
NCT0000255613	NCT00002556_13_T0	COMPOUND	8	8	melphalan
NCT0000255613	NCT00002556_13_T1	GENE	19	19	1.4
NCT0000255613	NCT00002556_13_T2	GENE	25	25	1.4
NCT0000255613	NCT00002556_13_T3	GENE	16	16	IV
NCT0000255613	NCT00002556_13_T4	COMPOUND	15	15	cyclophosphamide
NCT0000255613	NCT00002556_13_T5	GENE	0	0	ARM
NCT0000255613	NCT00002556_13_T6	COMPOUND	21	21	prednisone
NCT0000255613	NCT00002556_13_T7	COMPOUND	4	5	vincristine sulfate
NCT0000255615	NCT00002556_15_T0	GENE	6	6	SC
NCT0000255615	NCT00002556_15_T1	COMPOUND	3	4	interferon alfa_2b
NCT0000255616	NCT00002556_16_T0	PHENOTYPE	35	35	toxicity
NCT0000255616	NCT00002556_16_T1	GENE	7	7	3.5
NCT0000255616	NCT00002556_16_T2	PHENOTYPE	31	32	disease progression
NCT000025571	NCT00002557_1_T0	CELL	9	9	cells
NCT000025571	NCT00002557_1_T1	PHENOTYPE	8	8	tumor
NCT000025572	NCT00002557_2_T0	GENE	2	2	II
NCT000025572	NCT00002557_2_T1	COMPOUND	15	15	methotrexate
NCT000025572	NCT00002557_2_T2	COMPOUND	9	9	etoposide
NCT000025572	NCT00002557_2_T3	COMPOUND	13	13	doxorubicin
NCT000025572	NCT00002557_2_T4	PHENOTYPE	21	22	mycosis fungoides
NCT000025576	NCT00002557_6_T0	PHENOTYPE	10	10	tumor
NCT000025578	NCT00002557_8_T0	GENE	12	12	MTX
NCT000025578	NCT00002557_8_T1	COMPOUND	7	7	calcium
NCT000025580	NCT00002558_0_T0	CELL	3	5	Peripheral Stem Cell
NCT000025580	NCT00002558_0_T1	PHENOTYPE	11	13	Germ Cell Tumors
NCT000025583	NCT00002558_3_T0	GENE	21	21	G-CSF
NCT000025588	NCT00002558_8_T0	CELL	1	4	peripheral blood stem cells
NCT000025589	NCT00002558_9_T0	GENE	5	5	SC
NCT000025589	NCT00002558_9_T1	COMPOUND	14	14	paclitaxel
NCT000025589	NCT00002558_9_T2	COMPOUND	16	16	ifosfamide
NCT000025589	NCT00002558_9_T3	GENE	1	1	G-CSF
NCT0000255810	NCT00002558_10_T0	PHENOTYPE	16	16	toxicity
NCT0000255810	NCT00002558_10_T1	PHENOTYPE	12	13	disease progression
NCT0000255811	NCT00002558_11_T0	ORGAN	8	9	bone marrow
NCT0000255811	NCT00002558_11_T1	CELL	18	21	peripheral blood stem cells
NCT0000255814	NCT00002558_14_T0	GENE	3	3	SC
NCT0000255814	NCT00002558_14_T1	GENE	0	0	G-CSF
NCT0000255814	NCT00002558_14_T2	COMPOUND	12	12	etoposide
NCT0000255815	NCT00002558_15_T0	GENE	0	0	G-CSF
NCT0000255816	NCT00002558_16_T0	PHENOTYPE	16	16	toxicity
NCT0000255816	NCT00002558_16_T1	PHENOTYPE	12	13	disease progression
NCT0000255819	NCT00002558_19_T0	GENE	18	18	MTD
NCT0000255820	NCT00002558_20_T0	PHENOTYPE	17	17	toxicity
NCT0000255820	NCT00002558_20_T1	GENE	1	1	MTD
NCT000025591	NCT00002559_1_T0	CELL	9	9	cells
NCT000025591	NCT00002559_1_T1	PHENOTYPE	8	8	tumor
NCT000025594	NCT00002559_4_T0	COMPOUND	8	8	paclitaxel
NCT000025595	NCT00002559_5_T0	COMPOUND	2	2	paclitaxel
NCT000025595	NCT00002559_5_T1	COMPOUND	15	15	ifosfamide
NCT000025595	NCT00002559_5_T2	COMPOUND	9	9	cisplatin
NCT000025595	NCT00002559_5_T3	GENE	3	3	IV
NCT000025595	NCT00002559_5_T4	GENE	10	10	IV
NCT000025595	NCT00002559_5_T5	GENE	16	16	IV
NCT000025596	NCT00002559_6_T0	GENE	5	5	SC
NCT000025596	NCT00002559_6_T1	GENE	1	1	G-CSF
NCT000025597	NCT00002559_7_T0	PHENOTYPE	16	16	toxicity
NCT000025597	NCT00002559_7_T1	PHENOTYPE	12	13	disease progression
NCT000025598	NCT00002559_8_T0	COMPOUND	8	8	paclitaxel
NCT000025598	NCT00002559_8_T1	GENE	14	14	MTD
NCT000025599	NCT00002559_9_T0	PHENOTYPE	17	17	toxicity
NCT000025599	NCT00002559_9_T1	GENE	1	1	MTD
NCT0000255910	NCT00002559_10_T0	COMPOUND	3	3	paclitaxel
NCT0000255910	NCT00002559_10_T1	GENE	6	6	MTD
NCT000025601	NCT00002560_1_T0	PHENOTYPE	16	16	neuroblastoma
NCT000025601	NCT00002560_1_T1	GENE	5	5	sargramostim
NCT000025602	NCT00002560_2_T0	GENE	2	2	II
NCT000025602	NCT00002560_2_T1	COMPOUND	11	11	3F8
NCT000025602	NCT00002560_2_T2	PHENOTYPE	20	20	neuroblastoma
NCT000025602	NCT00002560_2_T3	GENE	13	13	sargramostim
NCT000025604	NCT00002560_4_T0	COMPOUND	14	14	7_11
NCT000025604	NCT00002560_4_T1	COMPOUND	5	5	3F8
NCT000025604	NCT00002560_4_T2	GENE	12	12	0.4
NCT000025604	NCT00002560_4_T3	GENE	8	8	1.5
NCT000025604	NCT00002560_4_T4	GENE	17	17	GM-CSF
NCT000025604	NCT00002560_4_T5	GENE	6	6	IV
NCT000025604	NCT00002560_4_T6	GENE	18	18	IV
NCT000025604	NCT00002560_4_T7	GENE	16	16	sargramostim
NCT000025605	NCT00002560_5_T0	PHENOTYPE	21	21	toxicity
NCT000025605	NCT00002560_5_T1	PHENOTYPE	15	16	progressive disease
NCT000025611	NCT00002561_1_T0	CELL	9	9	cells
NCT000025611	NCT00002561_1_T1	PHENOTYPE	8	8	tumor
NCT000025612	NCT00002561_2_T0	CELL	15	15	cells
NCT000025612	NCT00002561_2_T1	PHENOTYPE	14	14	tumor
NCT000025613	NCT00002561_3_T0	GENE	3	3	III
NCT000025613	NCT00002561_3_T1	PHENOTYPE	28	29	Hodgkin's disease
NCT000025615	NCT00002561_5_T0	COMPOUND	19	19	bleomycin
NCT000025615	NCT00002561_5_T1	COMPOUND	20	20	vinblastine
NCT000025615	NCT00002561_5_T2	COMPOUND	18	18	doxorubicin
NCT000025615	NCT00002561_5_T3	COMPOUND	22	22	dacarbazine
NCT000025617	NCT00002561_7_T0	PHENOTYPE	4	4	progression
NCT000025619	NCT00002561_9_T0	PHENOTYPE	7	7	secondary
NCT000025619	NCT00002561_9_T1	PHENOTYPE	3	3	remission
NCT000025619	NCT00002561_9_T2	PHENOTYPE	8	9	disease progression
NCT0000256111	NCT00002561_11_T0	PHENOTYPE	5	5	toxicity
NCT0000256113	NCT00002561_13_T0	PHENOTYPE	2	4	quality of life
NCT0000256116	NCT00002561_16_T0	PHENOTYPE	14	16	erythrocyte sedimentation rate
NCT0000256119	NCT00002561_19_T0	TISSUE	12	12	spleen
NCT0000256121	NCT00002561_21_T0	PHENOTYPE	19	19	toxicity
NCT0000256121	NCT00002561_21_T1	PHENOTYPE	15	16	disease progression
NCT0000256122	NCT00002561_22_T0	PHENOTYPE	3	3	remission
NCT0000256122	NCT00002561_22_T1	GENE	4	4	CR
NCT0000256122	NCT00002561_22_T2	GENE	13	13	CR
NCT0000256123	NCT00002561_23_T0	GENE	4	4	PR
NCT0000256123	NCT00002561_23_T1	GENE	13	13	PR
NCT0000256123	NCT00002561_23_T2	PHENOTYPE	3	3	remission
NCT0000256124	NCT00002561_24_T0	GENE	7	7	2.4
NCT0000256124	NCT00002561_24_T1	PHENOTYPE	4	4	remission
NCT0000256126	NCT00002561_26_T0	GENE	28	28	L2
NCT0000256126	NCT00002561_26_T1	ORGAN	23	23	abdomen
NCT0000256136	NCT00002561_36_T0	PHENOTYPE	15	15	enlargement
NCT0000256136	NCT00002561_36_T1	PHENOTYPE	13	13	Enlargement
NCT0000256137	NCT00002561_37_T0	PHENOTYPE	25	25	focal
NCT0000256137	NCT00002561_37_T1	TISSUE	10	10	spleen
NCT0000256138	NCT00002561_38_T0	GENE	14	14	III
NCT0000256139	NCT00002561_39_T0	PHENOTYPE	3	3	Lytic
NCT0000256139	NCT00002561_39_T1	PHENOTYPE	1	2	Bone Disease
NCT0000256140	NCT00002561_40_T0	GENE	9	9	IV
NCT0000256141	NCT00002561_41_T0	PHENOTYPE	12	12	ascites
NCT0000256141	NCT00002561_41_T1	PHENOTYPE	4	4	Ascites
NCT0000256141	NCT00002561_41_T2	PHENOTYPE	1	2	Pleural Effusion
NCT0000256141	NCT00002561_41_T3	PHENOTYPE	9	10	pleural effusion
NCT0000256142	NCT00002561_42_T0	GENE	7	7	probable
NCT0000256142	NCT00002561_42_T1	GENE	9	9	IV
NCT0000256143	NCT00002561_43_T0	PHENOTYPE	6	7	pleural thickening
NCT0000256146	NCT00002561_46_T0	PHENOTYPE	0	0	FVC
NCT0000256154	NCT00002561_54_T0	PHENOTYPE	19	19	toxicity
NCT0000256155	NCT00002561_55_T0	PHENOTYPE	2	4	quality of life
NCT0000256156	NCT00002561_56_T0	PHENOTYPE	6	8	quality of life
NCT000025621	NCT00002562_1_T0	GENE	2	2	II
NCT000025621	NCT00002562_1_T1	COMPOUND	9	9	paclitaxel
NCT000025621	NCT00002562_1_T2	PHENOTYPE	17	17	recurrent
NCT000025621	NCT00002562_1_T3	PHENOTYPE	20	21	vaginal cancer
NCT000025625	NCT00002562_5_T0	PHENOTYPE	4	4	severity
NCT000025625	NCT00002562_5_T1	PHENOTYPE	7	8	adverse effects
NCT000025627	NCT00002562_7_T0	GENE	1	1	TAX
NCT000025631	NCT00002563_1_T0	GENE	24	24	II
NCT000025631	NCT00002563_1_T1	PHENOTYPE	25	26	Hodgkin's disease
NCT000025631	NCT00002563_1_T2	PHENOTYPE	14	16	quality of life
NCT000025633	NCT00002563_3_T0	GENE	25	25	nodal
NCT000025633	NCT00002563_3_T1	PHENOTYPE	14	15	Hodgkin's disease
NCT000025633	NCT00002563_3_T2	PHENOTYPE	6	8	quality of life
NCT000025635	NCT00002563_5_T0	PHENOTYPE	24	24	fatigue
NCT000025635	NCT00002563_5_T1	PHENOTYPE	15	17	quality of life
NCT000025637	NCT00002563_7_T0	PHENOTYPE	17	17	quality-of-life
NCT000025638	NCT00002563_8_T0	PHENOTYPE	1	1	Quality-of-Life
NCT000025642	NCT00002564_2_T0	GENE	22	22	II
NCT000025642	NCT00002564_2_T1	GENE	29	29	has
NCT000025642	NCT00002564_2_T2	PHENOTYPE	24	27	stage IIIA breast cancer
NCT000025648	NCT00002564_8_T0	GENE	5	5	nodal
NCT000025648	NCT00002564_8_T1	GENE	7	7	ER
NCT000025651	NCT00002565_1_T0	CELL	9	9	cells
NCT000025652	NCT00002565_2_T0	PHENOTYPE	16	17	Hodgkin's lymphoma
NCT000025653	NCT00002565_3_T0	GENE	3	3	III
NCT000025653	NCT00002565_3_T1	PHENOTYPE	22	23	Hodgkin's lymphoma
NCT000025655	NCT00002565_5_T0	COMPOUND	55	55	mitoxantrone
NCT000025655	NCT00002565_5_T1	COMPOUND	43	43	cytarabine
NCT000025655	NCT00002565_5_T2	COMPOUND	48	48	bleomycin
NCT000025655	NCT00002565_5_T3	GENE	38	38	ATT
NCT000025655	NCT00002565_5_T4	COMPOUND	53	53	mesna
NCT000025655	NCT00002565_5_T5	COMPOUND	30	30	vincristine
NCT000025655	NCT00002565_5_T6	COMPOUND	47	47	vincristine
NCT000025655	NCT00002565_5_T7	COMPOUND	44	44	methylprednisolone
NCT000025655	NCT00002565_5_T8	COMPOUND	50	50	methylprednisolone
NCT000025655	NCT00002565_5_T9	COMPOUND	41	41	idarubicin
NCT000025655	NCT00002565_5_T10	COMPOUND	46	46	idarubicin
NCT000025655	NCT00002565_5_T11	COMPOUND	54	54	ifosfamide
NCT000025655	NCT00002565_5_T12	COMPOUND	28	28	cyclophosphamide
NCT000025655	NCT00002565_5_T13	COMPOUND	49	49	cyclophosphamide
NCT000025655	NCT00002565_5_T14	GENE	27	27	CHOP
NCT000025655	NCT00002565_5_T15	COMPOUND	56	56	etoposide
NCT000025655	NCT00002565_5_T16	COMPOUND	29	29	doxorubicin
NCT000025655	NCT00002565_5_T17	COMPOUND	31	31	prednisone
NCT000025655	NCT00002565_5_T18	COMPOUND	42	42	cisplatin
NCT000025655	NCT00002565_5_T19	PHENOTYPE	19	20	immunoblastic lymphoma
NCT000025657	NCT00002565_7_T0	GENE	7	7	ATT
NCT000025657	NCT00002565_7_T1	GENE	10	10	CHOP
NCT000025659	NCT00002565_9_T0	GENE	19	22	granulocyte colony stimulating factor
NCT0000256512	NCT00002565_12_T0	PHENOTYPE	1	1	Tumor
NCT0000256517	NCT00002565_17_T0	GENE	0	0	CHOP
NCT000025667	NCT00002566_7_T0	PHENOTYPE	7	7	remission
NCT000025667	NCT00002566_7_T1	PHENOTYPE	24	25	lung metastases
NCT000025668	NCT00002566_8_T0	ORGAN	1	2	bone marrow
NCT000025668	NCT00002566_8_T1	CELL	4	7	peripheral blood stem cells
NCT000025669	NCT00002566_9_T0	COMPOUND	25	25	bleomycin
NCT000025669	NCT00002566_9_T1	COMPOUND	33	33	bleomycin
NCT000025669	NCT00002566_9_T2	COMPOUND	13	13	vinblastine
NCT000025669	NCT00002566_9_T3	COMPOUND	23	23	vinblastine
NCT000025669	NCT00002566_9_T4	COMPOUND	31	31	vinblastine
NCT000025669	NCT00002566_9_T5	COMPOUND	29	29	cyclophosphamide
NCT000025669	NCT00002566_9_T6	COMPOUND	30	30	doxorubicin
NCT000025669	NCT00002566_9_T7	COMPOUND	22	22	cisplatin
NCT000025669	NCT00002566_9_T8	COMPOUND	28	28	cisplatin
NCT0000256610	NCT00002566_10_T0	COMPOUND	20	20	bleomycin
NCT0000256610	NCT00002566_10_T1	COMPOUND	10	10	etoposide
NCT0000256610	NCT00002566_10_T2	COMPOUND	23	23	cisplatin
NCT0000256611	NCT00002566_11_T0	COMPOUND	15	15	ifosfamide
NCT0000256611	NCT00002566_11_T1	GENE	22	22	1.5
NCT0000256611	NCT00002566_11_T2	COMPOUND	4	4	cisplatin
NCT0000256611	NCT00002566_11_T3	GENE	5	5	IV
NCT0000256611	NCT00002566_11_T4	GENE	10	10	IV
NCT0000256611	NCT00002566_11_T5	GENE	16	16	IV
NCT0000256612	NCT00002566_12_T0	COMPOUND	12	12	vinblastine
NCT0000256612	NCT00002566_12_T1	COMPOUND	6	6	etoposide
NCT0000256612	NCT00002566_12_T2	COMPOUND	4	4	cisplatin
NCT0000256612	NCT00002566_12_T3	GENE	13	13	IV
NCT000025678	NCT00002567_8_T0	CELL	2	3	Stem Cell
NCT000025679	NCT00002567_9_T0	CELL	0	0	Granulocyte
NCT000025679	NCT00002567_9_T1	GENE	5	5	G-CSF
NCT000025681	NCT00002568_1_T0	CELL	14	14	cells
NCT000025681	NCT00002568_1_T1	PHENOTYPE	13	13	tumor
NCT000025682	NCT00002568_2_T0	COMPOUND	14	14	paclitaxel
NCT000025682	NCT00002568_2_T1	GENE	3	3	III
NCT000025682	NCT00002568_2_T2	COMPOUND	16	16	cisplatin
NCT000025682	NCT00002568_2_T3	PHENOTYPE	25	29	stage III ovarian epithelial cancer
NCT000025684	NCT00002568_4_T0	PHENOTYPE	2	2	secondary
NCT000025684	NCT00002568_4_T1	PHENOTYPE	16	17	stage III
NCT000025684	NCT00002568_4_T2	PHENOTYPE	18	20	ovarian epithelial carcinoma
NCT000025686	NCT00002568_6_T0	PHENOTYPE	4	4	secondary
NCT000025688	NCT00002568_8_T0	PHENOTYPE	13	13	secondary
NCT000025688	NCT00002568_8_T1	PHENOTYPE	16	16	affects
NCT000025688	NCT00002568_8_T2	PHENOTYPE	6	6	QOL
NCT000025688	NCT00002568_8_T3	PHENOTYPE	17	17	QOL
NCT000025688	NCT00002568_8_T4	PHENOTYPE	3	5	quality of life
NCT0000256814	NCT00002568_14_T0	PHENOTYPE	4	5	residual disease
NCT000025691	NCT00002569_1_T0	CELL	8	8	cells
NCT000025691	NCT00002569_1_T1	PHENOTYPE	7	7	tumor
NCT000025692	NCT00002569_2_T0	CELL	9	9	cells
NCT000025692	NCT00002569_2_T1	PHENOTYPE	8	8	tumor
NCT000025693	NCT00002569_3_T0	GENE	3	3	III
NCT000025693	NCT00002569_3_T1	PHENOTYPE	21	22	anaplastic oligodendroglioma
NCT000025696	NCT00002569_6_T0	PHENOTYPE	18	18	tumor
NCT000025698	NCT00002569_8_T0	PHENOTYPE	16	16	toxicity
NCT000025698	NCT00002569_8_T1	PHENOTYPE	12	13	disease progression
NCT0000256910	NCT00002569_10_T0	GENE	12	12	MRI
NCT0000256910	NCT00002569_10_T1	PHENOTYPE	0	2	Quality of life
NCT000025701	NCT00002570_1_T0	CELL	9	9	cells
NCT000025701	NCT00002570_1_T1	PHENOTYPE	8	8	tumor
NCT000025702	NCT00002570_2_T0	PHENOTYPE	12	13	colorectal cancer
NCT000025703	NCT00002570_3_T0	PHENOTYPE	26	26	symptoms
NCT000025703	NCT00002570_3_T1	GENE	3	3	III
NCT000025703	NCT00002570_3_T2	COMPOUND	15	15	leucovorin
NCT000025703	NCT00002570_3_T3	PHENOTYPE	21	22	colorectal cancer
NCT000025705	NCT00002570_5_T0	PHENOTYPE	24	24	symptoms
NCT000025705	NCT00002570_5_T1	PHENOTYPE	11	12	colorectal cancer
NCT000025705	NCT00002570_5_T2	PHENOTYPE	3	5	quality of life
NCT000025708	NCT00002570_8_T0	COMPOUND	5	5	calcium
NCT000025711	NCT00002571_1_T0	CELL	8	8	cells
NCT000025712	NCT00002571_2_T0	PHENOTYPE	8	8	lymphoma
NCT000025713	NCT00002571_3_T0	GENE	2	2	II
NCT000025713	NCT00002571_3_T1	PHENOTYPE	22	22	lymphoma
NCT000025715	NCT00002571_5_T0	COMPOUND	13	13	cytarabine
NCT000025715	NCT00002571_5_T1	COMPOUND	14	14	bleomycin
NCT000025715	NCT00002571_5_T2	COMPOUND	15	15	vincristine
NCT000025715	NCT00002571_5_T3	PHENOTYPE	6	6	lymphoma
NCT000025715	NCT00002571_5_T4	COMPOUND	9	9	cyclophosphamide
NCT000025715	NCT00002571_5_T5	COMPOUND	16	16	methotrexate
NCT000025715	NCT00002571_5_T6	COMPOUND	11	11	etoposide
NCT000025715	NCT00002571_5_T7	COMPOUND	10	10	doxorubicin
NCT000025715	NCT00002571_5_T8	COMPOUND	12	12	prednisone
NCT000025717	NCT00002571_7_T0	PHENOTYPE	2	2	toxic
NCT000025717	NCT00002571_7_T1	PHENOTYPE	10	10	lymphoma
NCT000025719	NCT00002571_9_T0	GENE	5	5	filgrastim
NCT000025719	NCT00002571_9_T1	GENE	6	6	G-CSF
NCT0000257111	NCT00002571_11_T0	COMPOUND	7	7	cytarabine
NCT0000257111	NCT00002571_11_T1	PHENOTYPE	13	13	relapse
NCT0000257111	NCT00002571_11_T2	PHENOTYPE	17	17	lymphomatous
NCT0000257112	NCT00002571_12_T0	PHENOTYPE	17	17	lymphomas
NCT0000257112	NCT00002571_12_T1	PHENOTYPE	12	12	diffuse
NCT0000257112	NCT00002571_12_T2	ORGAN	55	55	marrow
NCT0000257112	NCT00002571_12_T3	GENE	50	50	protease
NCT0000257112	NCT00002571_12_T4	COMPOUND	43	43	2
NCT0000257112	NCT00002571_12_T5	GENE	21	21	CD4
NCT0000257112	NCT00002571_12_T6	PHENOTYPE	32	33	opportunistic infection
NCT0000257113	NCT00002571_13_T0	COMPOUND	15	15	bleomycin
NCT0000257113	NCT00002571_13_T1	COMPOUND	16	16	vincristine
NCT0000257113	NCT00002571_13_T2	COMPOUND	30	30	calcium
NCT0000257113	NCT00002571_13_T3	COMPOUND	18	18	methotrexate
NCT0000257113	NCT00002571_13_T4	GENE	44	44	G-CSF
NCT0000257113	NCT00002571_13_T5	GENE	10	10	IV
NCT0000257113	NCT00002571_13_T6	GENE	19	19	IV
NCT0000257113	NCT00002571_13_T7	GENE	43	43	filgrastim
NCT0000257113	NCT00002571_13_T8	COMPOUND	9	9	etoposide
NCT0000257113	NCT00002571_13_T9	COMPOUND	7	7	doxorubicin
NCT0000257113	NCT00002571_13_T10	COMPOUND	29	29	leucovorin
NCT0000257113	NCT00002571_13_T11	COMPOUND	24	24	prednisone
NCT0000257115	NCT00002571_15_T0	PHENOTYPE	2	3	progressive disease
NCT0000257117	NCT00002571_17_T0	PHENOTYPE	15	15	toxicity
NCT0000257117	NCT00002571_17_T1	PHENOTYPE	4	5	progressive disease
NCT0000257118	NCT00002571_18_T0	COMPOUND	18	18	cytarabine
NCT0000257118	NCT00002571_18_T1	ORGAN	3	4	bone marrow
NCT0000257119	NCT00002571_19_T0	COMPOUND	10	10	cytarabine
NCT0000257119	NCT00002571_19_T1	GENE	13	13	1.5
NCT0000257119	NCT00002571_19_T2	GENE	3	3	CSF
NCT0000257119	NCT00002571_19_T3	GENE	28	28	CSF
NCT0000257120	NCT00002571_20_T0	GENE	2	2	CSF
NCT0000257120	NCT00002571_20_T1	COMPOUND	15	15	methotrexate
NCT0000257121	NCT00002571_21_T0	COMPOUND	18	18	cytarabine
NCT0000257121	NCT00002571_21_T1	GENE	6	6	CSF
NCT0000257121	NCT00002571_21_T2	ORGAN	3	4	bone marrow
NCT0000257122	NCT00002571_22_T0	COMPOUND	13	13	cytarabine
NCT000025722	NCT00002572_2_T0	GENE	5	5	interleukin-2
NCT000025722	NCT00002572_2_T1	CELL	1	2	T cells
NCT000025722	NCT00002572_2_T2	PHENOTYPE	12	14	recurrent brain tumors
NCT000025723	NCT00002572_3_T0	GENE	13	13	interleukin-2
NCT000025723	NCT00002572_3_T1	CELL	10	11	T cells
NCT000025723	NCT00002572_3_T2	PHENOTYPE	18	20	recurrent brain tumors
NCT000025725	NCT00002572_5_T0	PHENOTYPE	2	2	toxicity
NCT000025725	NCT00002572_5_T1	GENE	8	8	CTL
NCT000025725	NCT00002572_5_T2	PHENOTYPE	18	18	recurrent
NCT000025725	NCT00002572_5_T3	CELL	6	7	T lymphocytes
NCT000025725	NCT00002572_5_T4	PHENOTYPE	19	21	primary brain tumors
NCT000025727	NCT00002572_7_T0	GENE	8	8	interleukin-2
NCT000025727	NCT00002572_7_T1	GENE	6	6	CTL
NCT000025729	NCT00002572_9_T0	PHENOTYPE	13	13	toxicity
NCT000025729	NCT00002572_9_T1	GENE	1	1	CTL
NCT0000257211	NCT00002572_11_T0	GENE	11	11	IL-2
NCT0000257211	NCT00002572_11_T1	GENE	9	9	Interleukin-2
NCT0000257211	NCT00002572_11_T2	PHENOTYPE	0	0	Tumor
NCT0000257211	NCT00002572_11_T3	GENE	7	7	CTL
NCT0000257211	NCT00002572_11_T4	CELL	5	6	T lymphocytes
NCT0000257212	NCT00002572_12_T0	CELL	9	9	lymphocytes
NCT0000257212	NCT00002572_12_T1	CELL	24	24	lymphocytes
NCT0000257212	NCT00002572_12_T2	GENE	12	12	IL-2
NCT0000257212	NCT00002572_12_T3	GENE	30	30	IL-2
NCT0000257212	NCT00002572_12_T4	GENE	16	16	OKT
NCT0000257212	NCT00002572_12_T5	GENE	19	19	OKT
NCT0000257212	NCT00002572_12_T6	GENE	0	0	CTL
NCT0000257214	NCT00002572_14_T0	PHENOTYPE	2	2	toxicity
NCT000025741	NCT00002574_1_T0	CELL	10	10	cells
NCT000025743	NCT00002574_3_T0	CELL	9	9	cells
NCT000025743	NCT00002574_3_T1	GENE	3	3	interferon
NCT000025747	NCT00002574_7_T0	GENE	4	4	Interferon
NCT000025752	NCT00002575_2_T0	PHENOTYPE	13	14	colon cancer
NCT000025753	NCT00002575_3_T0	GENE	3	3	III
NCT000025753	NCT00002575_3_T1	PHENOTYPE	20	21	colon cancer
NCT000025755	NCT00002575_5_T0	GENE	27	27	II
NCT000025755	NCT00002575_5_T1	ORGAN	17	17	sigmoid
NCT000025755	NCT00002575_5_T2	GENE	29	29	III
NCT000025755	NCT00002575_5_T3	PHENOTYPE	11	12	primary tumor
NCT000025761	NCT00002576_1_T0	CELL	9	9	cells
NCT000025761	NCT00002576_1_T1	PHENOTYPE	8	8	tumor
NCT000025762	NCT00002576_2_T0	COMPOUND	20	20	mitoxantrone
NCT000025762	NCT00002576_2_T1	COMPOUND	17	17	prednisolone
NCT000025762	NCT00002576_2_T2	COMPOUND	15	15	vincristine
NCT000025762	NCT00002576_2_T3	GENE	3	3	III
NCT000025762	NCT00002576_2_T4	COMPOUND	14	14	cyclophosphamide
NCT000025762	NCT00002576_2_T5	COMPOUND	22	22	doxorubicin
NCT000025762	NCT00002576_2_T6	PHENOTYPE	30	31	Hodgkin's lymphoma
NCT000025778	NCT00002577_8_T0	PHENOTYPE	9	12	carcinoma of the lung
NCT0000257710	NCT00002577_10_T0	GENE	15	15	Gy
NCT0000257711	NCT00002577_11_T0	PHENOTYPE	6	6	closed
NCT0000257712	NCT00002577_12_T0	GENE	12	12	6/7
NCT0000257713	NCT00002577_13_T0	GENE	18	18	MTD
NCT0000257714	NCT00002577_14_T0	PHENOTYPE	17	17	toxicity
NCT0000257714	NCT00002577_14_T1	GENE	1	1	MTD
NCT0000257717	NCT00002577_17_T0	PHENOTYPE	6	6	closed
NCT000025781	NCT00002578_1_T0	GENE	2	2	II
NCT000025781	NCT00002578_1_T1	COMPOUND	9	10	gallium nitrate
NCT000025781	NCT00002578_1_T2	PHENOTYPE	16	17	Hodgkin's lymphoma
NCT000025783	NCT00002578_3_T0	COMPOUND	16	17	gallium nitrate
NCT000025783	NCT00002578_3_T1	PHENOTYPE	12	13	Hodgkin's lymphoma
NCT000025785	NCT00002578_5_T0	PHENOTYPE	5	5	toxic
NCT000025788	NCT00002578_8_T0	GENE	9	9	1.7
NCT000025788	NCT00002578_8_T1	GENE	5	5	IV
NCT000025788	NCT00002578_8_T2	COMPOUND	3	4	gallium nitrate
NCT000025789	NCT00002578_9_T0	PHENOTYPE	13	13	toxicity
NCT000025789	NCT00002578_9_T1	PHENOTYPE	9	10	disease progression
NCT0000257810	NCT00002578_10_T0	PHENOTYPE	4	4	remission
NCT0000257810	NCT00002578_10_T1	GENE	5	5	CR
NCT0000257810	NCT00002578_10_T2	GENE	11	11	CR
NCT0000257811	NCT00002578_11_T0	PHENOTYPE	2	2	relapse
NCT0000257811	NCT00002578_11_T1	GENE	5	5	CR
NCT0000257811	NCT00002578_11_T2	PHENOTYPE	13	14	disease progression
NCT0000257812	NCT00002578_12_T0	PHENOTYPE	2	2	relapse
NCT0000257812	NCT00002578_12_T1	GENE	6	6	CR
NCT0000257813	NCT00002578_13_T0	COMPOUND	18	18	cytarabine
NCT0000257813	NCT00002578_13_T1	COMPOUND	15	15	calcium
NCT0000257813	NCT00002578_13_T2	COMPOUND	11	11	methotrexate
NCT0000257813	NCT00002578_13_T3	GENE	10	10	IT
NCT0000257813	NCT00002578_13_T4	GENE	17	17	IT
NCT0000257813	NCT00002578_13_T5	COMPOUND	14	14	leucovorin
NCT0000257813	NCT00002578_13_T6	GENE	13	13	IV
NCT0000257816	NCT00002578_16_T0	GENE	5	5	20.35
NCT0000257818	NCT00002578_18_T0	PHENOTYPE	18	18	lymphoma
NCT0000257818	NCT00002578_18_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000257818	NCT00002578_18_T2	PHENOTYPE	16	17	high grade
NCT0000257821	NCT00002578_21_T0	PHENOTYPE	18	18	lymphoma
NCT0000257821	NCT00002578_21_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000257821	NCT00002578_21_T2	PHENOTYPE	16	17	high grade
NCT000025792	NCT00002579_2_T0	CELL	10	10	cells
NCT000025792	NCT00002579_2_T1	PHENOTYPE	9	9	tumor
NCT000025792	NCT00002579_2_T2	GENE	4	4	hormone
NCT000025795	NCT00002579_5_T0	COMPOUND	9	9	tamoxifen
NCT000025795	NCT00002579_5_T1	PHENOTYPE	25	26	breast cancer
NCT000025799	NCT00002579_9_T0	COMPOUND	7	7	cyclophosphamide
NCT000025799	NCT00002579_9_T1	COMPOUND	8	8	methotrexate
NCT0000257911	NCT00002579_11_T0	COMPOUND	14	14	tamoxifen
NCT0000257913	NCT00002579_13_T0	GENE	12	12	hormone
NCT0000257913	NCT00002579_13_T1	PHENOTYPE	18	19	menopausal symptoms
NCT000025802	NCT00002580_2_T0	CELL	7	7	cells
NCT000025802	NCT00002580_2_T1	PHENOTYPE	6	6	tumor
NCT000025803	NCT00002580_3_T0	CELL	9	9	cells
NCT000025803	NCT00002580_3_T1	PHENOTYPE	8	8	tumor
NCT000025803	NCT00002580_3_T2	GENE	3	3	hormone
NCT000025804	NCT00002580_4_T0	PHENOTYPE	12	13	breast cancer
NCT000025805	NCT00002580_5_T0	GENE	27	27	II
NCT000025805	NCT00002580_5_T1	GENE	3	3	III
NCT000025805	NCT00002580_5_T2	COMPOUND	10	10	tamoxifen
NCT000025805	NCT00002580_5_T3	PHENOTYPE	29	32	stage IIIA breast cancer
NCT000025807	NCT00002580_7_T0	COMPOUND	14	14	methotrexate
NCT000025807	NCT00002580_7_T1	PHENOTYPE	24	24	unilateral
NCT000025807	NCT00002580_7_T2	PHENOTYPE	11	11	suppression
NCT000025807	NCT00002580_7_T3	COMPOUND	13	13	cyclophosphamide
NCT000025807	NCT00002580_7_T4	COMPOUND	6	6	tamoxifen
NCT000025807	NCT00002580_7_T5	PHENOTYPE	25	27	invasive breast cancer
NCT000025809	NCT00002580_9_T0	GENE	5	5	nodal
NCT0000258014	NCT00002580_14_T0	PHENOTYPE	13	13	toxicity
NCT0000258014	NCT00002580_14_T1	PHENOTYPE	9	10	disease progression
NCT0000258021	NCT00002580_21_T0	GENE	11	11	SC
NCT0000258021	NCT00002580_21_T1	GENE	14	14	SC
NCT0000258021	NCT00002580_21_T2	COMPOUND	9	9	goserelin
NCT0000258021	NCT00002580_21_T3	COMPOUND	13	13	leuprolide
NCT000025812	NCT00002581_2_T0	CELL	10	10	cells
NCT000025812	NCT00002581_2_T1	PHENOTYPE	9	9	tumor
NCT000025812	NCT00002581_2_T2	GENE	4	4	hormone
NCT000025815	NCT00002581_5_T0	COMPOUND	10	10	cyclophosphamide
NCT000025815	NCT00002581_5_T1	COMPOUND	11	11	methotrexate
NCT000025815	NCT00002581_5_T2	PHENOTYPE	21	21	unilateral
NCT000025815	NCT00002581_5_T3	COMPOUND	6	6	tamoxifen
NCT000025815	NCT00002581_5_T4	PHENOTYPE	22	24	invasive breast cancer
NCT000025817	NCT00002581_7_T0	GENE	5	5	nodal
NCT000025822	NCT00002582_2_T0	CELL	8	8	cells
NCT000025822	NCT00002582_2_T1	PHENOTYPE	7	7	tumor
NCT000025823	NCT00002582_3_T0	CELL	9	9	cells
NCT000025823	NCT00002582_3_T1	PHENOTYPE	8	8	tumor
NCT000025823	NCT00002582_3_T2	GENE	1	1	hormone
NCT000025824	NCT00002582_4_T0	GENE	25	25	II
NCT000025824	NCT00002582_4_T1	GENE	3	3	III
NCT000025824	NCT00002582_4_T2	COMPOUND	10	10	tamoxifen
NCT000025824	NCT00002582_4_T3	PHENOTYPE	27	30	stage IIIA breast cancer
NCT000025829	NCT00002582_9_T0	PHENOTYPE	10	10	judgement
NCT000025829	NCT00002582_9_T1	PHENOTYPE	18	18	suppression
NCT000025836	NCT00002583_6_T0	GENE	5	5	ras
NCT000025836	NCT00002583_6_T1	PHENOTYPE	11	12	primary tumor
NCT000025838	NCT00002583_8_T0	PHENOTYPE	19	19	NSCLC
NCT000025838	NCT00002583_8_T1	PHENOTYPE	3	3	tumor
NCT0000258312	NCT00002583_12_T0	PHENOTYPE	2	2	toxicity
NCT0000258314	NCT00002583_14_T0	PHENOTYPE	14	14	mutation
NCT0000258314	NCT00002583_14_T1	GENE	13	13	ras
NCT0000258314	NCT00002583_14_T2	GENE	7	7	nodal
NCT0000258314	NCT00002583_14_T3	PHENOTYPE	17	18	primary tumor
NCT0000258318	NCT00002583_18_T0	COMPOUND	3	3	cisplatin
NCT0000258318	NCT00002583_18_T1	GENE	4	4	IV
NCT0000258319	NCT00002583_19_T0	PHENOTYPE	10	10	toxicity
NCT0000258319	NCT00002583_19_T1	PHENOTYPE	6	7	disease progression
NCT0000258320	NCT00002583_20_T0	PHENOTYPE	7	7	centers
NCT0000258320	NCT00002583_20_T1	PHENOTYPE	0	2	Quality of life
NCT0000258321	NCT00002583_21_T0	PHENOTYPE	10	10	centers
NCT0000258321	NCT00002583_21_T1	PHENOTYPE	0	2	Quality of life
NCT000025851	NCT00002585_1_T0	GENE	2	2	II
NCT000025851	NCT00002585_1_T1	COMPOUND	9	9	pyrazoloacridine
NCT000025851	NCT00002585_1_T2	PHENOTYPE	14	16	metastatic breast cancer
NCT000025853	NCT00002585_3_T0	COMPOUND	4	4	pyrazoloacridine
NCT000025853	NCT00002585_3_T1	PHENOTYPE	13	15	metastatic breast cancer
NCT000025855	NCT00002585_5_T0	PHENOTYPE	5	5	toxicities
NCT000025858	NCT00002585_8_T0	PHENOTYPE	18	18	toxicity
NCT000025858	NCT00002585_8_T1	COMPOUND	5	5	pyrazoloacridine
NCT000025858	NCT00002585_8_T2	PHENOTYPE	14	15	progressive disease
NCT0000258510	NCT00002585_10_T0	PHENOTYPE	10	10	toxicity
NCT0000258511	NCT00002585_11_T0	GENE	11	11	CAF
NCT0000258513	NCT00002585_13_T0	CELL	1	1	granulocyte
NCT0000258514	NCT00002585_14_T0	GENE	10	10	7.12
NCT0000258515	NCT00002585_15_T0	GENE	16	16	cease
NCT000025862	NCT00002586_2_T0	GENE	4	4	II
NCT000025862	NCT00002586_2_T1	COMPOUND	17	18	vitamin E
NCT000025862	NCT00002586_2_T2	PHENOTYPE	32	33	lung cancer
NCT000025862	NCT00002586_2_T3	COMPOUND	12	13	retinoic acid
NCT000025868	NCT00002586_8_T0	GENE	16	16	OR
NCT000025868	NCT00002586_8_T1	PHENOTYPE	11	12	severe dysplasia
NCT000025868	NCT00002586_8_T2	PHENOTYPE	21	24	head and neck cancer
NCT000025869	NCT00002586_9_T0	PHENOTYPE	2	4	carcinoma in situ
NCT0000258630	NCT00002586_30_T0	PHENOTYPE	15	15	multifocal
NCT0000258630	NCT00002586_30_T1	PHENOTYPE	20	21	supraventricular tachycardias
NCT0000258630	NCT00002586_30_T2	PHENOTYPE	13	14	ventricular tachycardia
NCT0000258630	NCT00002586_30_T3	PHENOTYPE	4	5	cardiac dysrhythmia
NCT0000258630	NCT00002586_30_T4	PHENOTYPE	16	18	premature ventricular contractions
NCT0000258630	NCT00002586_30_T5	PHENOTYPE	24	26	rapid ventricular response
NCT0000258631	NCT00002586_31_T0	PHENOTYPE	2	3	atrial fibrillation
NCT0000258631	NCT00002586_31_T1	PHENOTYPE	7	9	premature ventricular contractions
NCT0000258632	NCT00002586_32_T0	PHENOTYPE	7	7	tumor
NCT0000258634	NCT00002586_34_T0	COMPOUND	5	6	vitamin A
NCT0000258635	NCT00002586_35_T0	COMPOUND	7	7	minocycline
NCT0000258635	NCT00002586_35_T1	COMPOUND	5	5	tetracycline
NCT0000258637	NCT00002586_37_T0	GENE	3	3	had
NCT000025870	NCT00002587_0_T0	PHENOTYPE	7	8	Solid Tumors
NCT000025872	NCT00002587_2_T0	CELL	10	10	cells
NCT000025872	NCT00002587_2_T1	PHENOTYPE	9	9	tumor
NCT000025873	NCT00002587_3_T0	CELL	9	9	cells
NCT000025873	NCT00002587_3_T1	PHENOTYPE	8	8	tumor
NCT000025875	NCT00002587_5_T0	PHENOTYPE	9	9	toxic
NCT000025875	NCT00002587_5_T1	COMPOUND	14	14	paclitaxel
NCT000025875	NCT00002587_5_T2	COMPOUND	12	12	topotecan
NCT000025875	NCT00002587_5_T3	PHENOTYPE	18	19	solid tumors
NCT000025878	NCT00002587_8_T0	COMPOUND	10	10	paclitaxel
NCT000025878	NCT00002587_8_T1	COMPOUND	8	8	topotecan
NCT000025879	NCT00002587_9_T0	COMPOUND	2	2	paclitaxel
NCT000025879	NCT00002587_9_T1	GENE	3	3	IV
NCT000025879	NCT00002587_9_T2	GENE	16	16	IV
NCT000025879	NCT00002587_9_T3	COMPOUND	15	15	topotecan
NCT0000258710	NCT00002587_10_T0	PHENOTYPE	13	13	toxicity
NCT0000258710	NCT00002587_10_T1	PHENOTYPE	9	10	disease progression
NCT0000258711	NCT00002587_11_T0	COMPOUND	10	10	paclitaxel
NCT0000258711	NCT00002587_11_T1	GENE	16	16	MTD
NCT0000258711	NCT00002587_11_T2	COMPOUND	8	8	topotecan
NCT0000258712	NCT00002587_12_T0	PHENOTYPE	18	18	toxicity
NCT0000258712	NCT00002587_12_T1	GENE	1	1	MTD
NCT000025881	NCT00002588_1_T0	CELL	9	9	cells
NCT000025882	NCT00002588_2_T0	PHENOTYPE	20	20	leukemia
NCT000025882	NCT00002588_2_T1	COMPOUND	11	11	etoposide
NCT000025882	NCT00002588_2_T2	PHENOTYPE	17	17	recurrent
NCT000025882	NCT00002588_2_T3	COMPOUND	9	9	topotecan
NCT000025884	NCT00002588_4_T0	COMPOUND	10	10	etoposide
NCT000025884	NCT00002588_4_T1	COMPOUND	6	6	topotecan
NCT000025884	NCT00002588_4_T2	PHENOTYPE	17	19	acute myelogenous leukemia
NCT000025884	NCT00002588_4_T3	PHENOTYPE	20	22	acute lymphoblastic leukemia
NCT000025884	NCT00002588_4_T4	PHENOTYPE	24	28	blastic phase chronic myelogenous leukemia
NCT000025886	NCT00002588_6_T0	PHENOTYPE	2	2	toxicity
NCT000025888	NCT00002588_8_T0	ORGAN	1	1	serum
NCT000025888	NCT00002588_8_T1	COMPOUND	4	4	topotecan
NCT000025888	NCT00002588_8_T2	GENE	15	16	topoisomerase II
NCT0000258810	NCT00002588_10_T0	GENE	21	21	II
NCT0000258810	NCT00002588_10_T1	PHENOTYPE	14	14	tumor
NCT0000258810	NCT00002588_10_T2	GENE	10	11	topoisomerase II
NCT0000258810	NCT00002588_10_T3	BIOLOGICAL_PROCESS	15	17	response to etoposide
NCT0000258812	NCT00002588_12_T0	GENE	10	10	II
NCT0000258812	NCT00002588_12_T1	CELL	13	13	cells
NCT0000258814	NCT00002588_14_T0	GENE	30	30	II
NCT0000258814	NCT00002588_14_T1	PHENOTYPE	25	25	tumor
NCT0000258814	NCT00002588_14_T2	PHENOTYPE	8	8	pharmacodynamic
NCT0000258819	NCT00002588_19_T0	PHENOTYPE	0	0	Consolidation
NCT000025891	NCT00002589_1_T0	GENE	3	3	II
NCT000025891	NCT00002589_1_T1	CELL	9	9	lymphocyte
NCT000025891	NCT00002589_1_T2	PHENOTYPE	16	17	stage III
NCT000025891	NCT00002589_1_T3	PHENOTYPE	19	22	stage IV kidney cancer
NCT000025893	NCT00002589_3_T0	CELL	30	30	lymphocyte
NCT000025893	NCT00002589_3_T1	TISSUE	19	20	lymph node
NCT000025894	NCT00002589_4_T0	CELL	1	1	cells
NCT000025894	NCT00002589_4_T1	GENE	12	12	interleukin-2
NCT000025895	NCT00002589_5_T0	CELL	5	5	lymphocytes
NCT000025896	NCT00002589_6_T0	PHENOTYPE	19	19	toxicity
NCT000025901	NCT00002590_1_T0	CELL	9	9	cells
NCT000025901	NCT00002590_1_T1	PHENOTYPE	8	8	tumor
NCT000025902	NCT00002590_2_T0	GENE	2	2	II
NCT000025902	NCT00002590_2_T1	PHENOTYPE	16	16	lymphoma
NCT000025908	NCT00002590_8_T0	PHENOTYPE	16	16	leukemia
NCT000025908	NCT00002590_8_T1	PHENOTYPE	10	11	lymphoblastic lymphoma
NCT0000259013	NCT00002590_13_T0	GENE	6	6	MTX
NCT0000259013	NCT00002590_13_T1	GENE	2	2	G-CSF
NCT0000259013	NCT00002590_13_T2	GENE	4	4	IT
NCT0000259014	NCT00002590_14_T0	PHENOTYPE	0	0	Consolidation
NCT0000259015	NCT00002590_15_T0	GENE	5	5	MTX
NCT0000259015	NCT00002590_15_T1	GENE	2	2	G-CSF
NCT0000259015	NCT00002590_15_T2	GENE	4	4	IT
NCT0000259016	NCT00002590_16_T0	COMPOUND	4	4	2
NCT0000259016	NCT00002590_16_T1	COMPOUND	5	5	3
NCT0000259016	NCT00002590_16_T2	COMPOUND	6	6	3
NCT0000259017	NCT00002590_17_T0	GENE	1	1	MTX
NCT0000259021	NCT00002590_21_T0	PHENOTYPE	4	4	toxic
NCT0000259021	NCT00002590_21_T1	PHENOTYPE	16	16	toxic
NCT0000259022	NCT00002590_22_T0	GENE	3	3	asparaginase
NCT0000259022	NCT00002590_22_T1	GENE	4	4	has
NCT0000259023	NCT00002590_23_T0	GENE	12	12	PEG
NCT000025921	NCT00002592_1_T0	CELL	22	22	cells
NCT000025921	NCT00002592_1_T1	ORGAN	4	5	bone marrow
NCT000025922	NCT00002592_2_T0	GENE	2	2	II
NCT000025922	NCT00002592_2_T1	ORGAN	13	14	bone marrow
NCT000025922	NCT00002592_2_T2	PHENOTYPE	20	22	chronic myelogenous leukemia
NCT000025924	NCT00002592_4_T0	GENE	4	4	c-myb
NCT000025924	NCT00002592_4_T1	GENE	46	46	c-myb
NCT000025924	NCT00002592_4_T2	ORGAN	43	43	marrow
NCT000025924	NCT00002592_4_T3	COMPOUND	33	33	busulfan
NCT000025924	NCT00002592_4_T4	CELL	18	18	cells
NCT000025924	NCT00002592_4_T5	PHENOTYPE	17	17	tumor
NCT000025924	NCT00002592_4_T6	COMPOUND	35	35	cyclophosphamide
NCT000025924	NCT00002592_4_T7	CELL	26	27	stem cells
NCT000025924	NCT00002592_4_T8	ORGAN	22	23	bone marrow
NCT000025924	NCT00002592_4_T9	ORGAN	39	40	bone marrow
NCT000025924	NCT00002592_4_T10	CELL	9	11	bone marrow cells
NCT000025924	NCT00002592_4_T11	PHENOTYPE	14	16	chronic myelogenous leukemia
NCT000025928	NCT00002592_8_T0	PHENOTYPE	2	2	toxicity
NCT000025929	NCT00002592_9_T0	ORGAN	3	4	bone marrow
NCT0000259210	NCT00002592_10_T0	GENE	6	6	c-myb
NCT0000259210	NCT00002592_10_T1	ORGAN	1	2	bone marrow
NCT0000259211	NCT00002592_11_T0	ORGAN	4	4	marrow
NCT0000259211	NCT00002592_11_T1	PHENOTYPE	11	11	engraftment
NCT0000259212	NCT00002592_12_T0	COMPOUND	3	3	busulfan
NCT0000259213	NCT00002592_13_T0	COMPOUND	11	11	2
NCT0000259213	NCT00002592_13_T1	COMPOUND	9	9	3
NCT0000259213	NCT00002592_13_T2	COMPOUND	2	2	cyclophosphamide
NCT0000259213	NCT00002592_13_T3	GENE	3	3	IV
NCT0000259214	NCT00002592_14_T0	ORGAN	0	1	Bone marrow
NCT0000259215	NCT00002592_15_T0	GENE	2	2	filgrastim
NCT0000259215	NCT00002592_15_T1	GENE	3	3	G-CSF
NCT0000259216	NCT00002592_16_T0	GENE	4	4	2.3
NCT000025931	NCT00002593_1_T0	CELL	15	15	cells
NCT000025932	NCT00002593_2_T0	GENE	22	22	II
NCT000025932	NCT00002593_2_T1	GENE	3	3	III
NCT000025932	NCT00002593_2_T2	PHENOTYPE	32	32	recurrence
NCT000025932	NCT00002593_2_T3	PHENOTYPE	24	27	stage III colon cancer
NCT000025934	NCT00002593_4_T0	GENE	12	12	II
NCT000025934	NCT00002593_4_T1	COMPOUND	26	26	calcium
NCT000025934	NCT00002593_4_T2	GENE	14	14	III
NCT000025934	NCT00002593_4_T3	COMPOUND	28	28	levamisole
NCT000025934	NCT00002593_4_T4	COMPOUND	34	34	levamisole
NCT000025934	NCT00002593_4_T5	COMPOUND	25	25	leucovorin
NCT000025934	NCT00002593_4_T6	PHENOTYPE	15	16	colon cancer
NCT000025936	NCT00002593_6_T0	GENE	14	14	T4a
NCT000025936	NCT00002593_6_T1	COMPOUND	15	15	N
NCT000025936	NCT00002593_6_T2	GENE	10	10	T2
NCT000025936	NCT00002593_6_T3	GENE	12	12	T3
NCT0000259312	NCT00002593_12_T0	PHENOTYPE	10	10	toxicity
NCT0000259312	NCT00002593_12_T1	PHENOTYPE	6	7	disease progression
NCT0000259314	NCT00002593_14_T0	GENE	15	15	5.5
NCT000025940	NCT00002594_0_T0	PHENOTYPE	15	16	Recurrent Medulloblastoma
NCT000025940	NCT00002594_0_T1	ORGAN	4	5	Bone Marrow
NCT000025940	NCT00002594_0_T2	PHENOTYPE	19	21	Germ Cell Tumors
NCT000025940	NCT00002594_0_T3	CELL	7	9	Peripheral Stem Cell
NCT000025944	NCT00002594_4_T0	ORGAN	2	3	bone marrow
NCT000025944	NCT00002594_4_T1	CELL	5	8	peripheral blood stem cells
NCT000025945	NCT00002594_5_T0	COMPOUND	24	24	2
NCT000025945	NCT00002594_5_T1	COMPOUND	15	15	melphalan
NCT000025945	NCT00002594_5_T2	COMPOUND	4	4	cyclophosphamide
NCT000025945	NCT00002594_5_T3	GENE	5	5	IV
NCT000025945	NCT00002594_5_T4	GENE	16	16	IV
NCT000025946	NCT00002594_6_T0	ORGAN	0	1	Bone marrow
NCT000025947	NCT00002594_7_T0	ORGAN	17	18	bone marrow
NCT000025948	NCT00002594_8_T0	GENE	1	1	GM-CSF
NCT000025948	NCT00002594_8_T1	GENE	4	4	IV
NCT000025952	NCT00002595_2_T0	GENE	2	2	II
NCT000025952	NCT00002595_2_T1	COMPOUND	9	9	toremifene
NCT000025952	NCT00002595_2_T2	PHENOTYPE	14	15	desmoid tumors
NCT000025954	NCT00002595_4_T0	COMPOUND	4	4	toremifene
NCT000025954	NCT00002595_4_T1	PHENOTYPE	8	8	tumor
NCT000025954	NCT00002595_4_T2	PHENOTYPE	17	18	desmoid tumors
NCT000025958	NCT00002595_8_T0	PHENOTYPE	2	4	quality of life
NCT0000259510	NCT00002595_10_T0	PHENOTYPE	18	18	toxicity
NCT0000259510	NCT00002595_10_T1	COMPOUND	3	3	toremifene
NCT0000259510	NCT00002595_10_T2	PHENOTYPE	14	15	disease progression
NCT0000259512	NCT00002595_12_T0	COMPOUND	22	22	toremifene
NCT0000259513	NCT00002595_13_T0	COMPOUND	12	12	toremifene
NCT0000259514	NCT00002595_14_T0	COMPOUND	13	13	toremifene
NCT0000259515	NCT00002595_15_T0	PHENOTYPE	0	2	Quality of life
NCT000025968	NCT00002596_8_T0	GENE	5	5	SC
NCT000025968	NCT00002596_8_T1	GENE	1	1	G-CSF
NCT000025969	NCT00002596_9_T0	PHENOTYPE	16	16	toxicity
NCT000025969	NCT00002596_9_T1	PHENOTYPE	12	13	disease progression
NCT0000259611	NCT00002596_11_T0	ORGAN	4	4	marrow
NCT0000259611	NCT00002596_11_T1	PHENOTYPE	7	7	tumor
NCT0000259611	NCT00002596_11_T2	ORGAN	12	13	bone marrow
NCT0000259612	NCT00002596_12_T0	PHENOTYPE	7	7	tumor
NCT0000259612	NCT00002596_12_T1	ORGAN	3	4	bone marrow
NCT0000259612	NCT00002596_12_T2	CELL	13	16	peripheral blood stem cells
NCT0000259613	NCT00002596_13_T0	COMPOUND	29	29	3
NCT0000259613	NCT00002596_13_T1	COMPOUND	20	20	cyclophosphamide
NCT0000259613	NCT00002596_13_T2	GENE	10	10	IV
NCT0000259613	NCT00002596_13_T3	GENE	15	15	IV
NCT0000259613	NCT00002596_13_T4	GENE	21	21	IV
NCT0000259614	NCT00002596_14_T0	ORGAN	1	2	bone marrow
NCT0000259615	NCT00002596_15_T0	GENE	3	3	SC
NCT0000259615	NCT00002596_15_T1	GENE	0	0	G-CSF
NCT0000259616	NCT00002596_16_T0	PHENOTYPE	48	48	toxicity
NCT0000259616	NCT00002596_16_T1	PHENOTYPE	15	15	toxic
NCT0000259616	NCT00002596_16_T2	GENE	1	1	1.3
NCT0000259616	NCT00002596_16_T3	PHENOTYPE	44	45	disease progression
NCT0000259616	NCT00002596_16_T4	ORGAN	35	36	bone marrow
NCT0000259622	NCT00002596_22_T0	PHENOTYPE	5	6	malignant tumor
NCT000025981	NCT00002598_1_T0	CELL	9	9	cells
NCT000025983	NCT00002598_3_T0	GENE	2	2	II
NCT000025983	NCT00002598_3_T1	GENE	12	12	interferon
NCT000025983	NCT00002598_3_T2	PHENOTYPE	18	20	chronic myelogenous leukemia
NCT000025986	NCT00002598_6_T0	GENE	5	5	SC
NCT000025986	NCT00002598_6_T1	GENE	1	1	GM-CSF
NCT000025986	NCT00002598_6_T2	GENE	7	7	IV
NCT000025987	NCT00002598_7_T0	ORGAN	9	10	bone marrow
NCT000025987	NCT00002598_7_T1	ORGAN	14	15	bone marrow
NCT000025989	NCT00002598_9_T0	GENE	3	3	SC
NCT000025989	NCT00002598_9_T1	GENE	0	0	GM-CSF
NCT000025989	NCT00002598_9_T2	GENE	5	5	IV
NCT0000259811	NCT00002598_11_T0	PHENOTYPE	14	14	toxicity
NCT0000259811	NCT00002598_11_T1	GENE	2	2	interferon
NCT0000259811	NCT00002598_11_T2	PHENOTYPE	10	11	disease progression
NCT0000259813	NCT00002598_13_T0	GENE	11	11	CSF
NCT0000259813	NCT00002598_13_T1	COMPOUND	3	3	methotrexate
NCT000025990	NCT00002599_0_T0	GENE	3	3	Interferon
NCT000025990	NCT00002599_0_T1	PHENOTYPE	19	19	Myeloma
NCT000025990	NCT00002599_0_T2	ORGAN	8	9	Bone Marrow
NCT000025990	NCT00002599_0_T3	CELL	11	13	Peripheral Stem Cell
NCT0000259913	NCT00002599_13_T0	PHENOTYPE	18	18	relapse
NCT0000259920	NCT00002599_20_T0	GENE	1	1	II
NCT0000259920	NCT00002599_20_T1	GENE	0	0	ARM
NCT0000259923	NCT00002599_23_T0	PHENOTYPE	0	0	Consolidation
NCT000026008	NCT00002600_8_T0	GENE	8	8	11
NCT000026008	NCT00002600_8_T1	GENE	17	17	11
NCT000026008	NCT00002600_8_T2	GENE	10	10	G-CSF
NCT000026008	NCT00002600_8_T3	GENE	14	14	SC
NCT000026008	NCT00002600_8_T4	GENE	9	9	filgrastim
NCT000026008	NCT00002600_8_T5	ORGAN	1	2	bone marrow
NCT000026008	NCT00002600_8_T6	CELL	22	25	peripheral blood stem cells
NCT000026009	NCT00002600_9_T0	COMPOUND	26	26	2
NCT000026009	NCT00002600_9_T1	COMPOUND	24	24	3
NCT000026009	NCT00002600_9_T2	COMPOUND	17	17	cyclophosphamide
NCT000026009	NCT00002600_9_T3	GENE	7	7	IV
NCT000026009	NCT00002600_9_T4	GENE	18	18	IV
NCT0000260010	NCT00002600_10_T0	GENE	16	16	SC
NCT0000260010	NCT00002600_10_T1	COMPOUND	5	5	1
NCT0000260010	NCT00002600_10_T2	GENE	13	13	G-CSF
NCT0000260011	NCT00002600_11_T0	GENE	2	2	2.4
NCT0000260011	NCT00002600_11_T1	GENE	14	14	MTD
NCT0000260012	NCT00002600_12_T0	PHENOTYPE	17	17	toxicity
NCT0000260012	NCT00002600_12_T1	GENE	1	1	MTD
NCT0000260013	NCT00002600_13_T0	GENE	9	9	MTD
NCT000026010	NCT00002601_0_T0	PHENOTYPE	11	11	Sarcoma
NCT000026010	NCT00002601_0_T1	CELL	3	5	Peripheral Stem Cell
NCT000026017	NCT00002601_7_T0	PHENOTYPE	2	2	toxic
NCT0000260111	NCT00002601_11_T0	GENE	7	7	G-CSF
NCT0000260112	NCT00002601_12_T0	CELL	6	6	cells
NCT0000260112	NCT00002601_12_T1	ORGAN	8	9	bone marrow
NCT0000260113	NCT00002601_13_T0	COMPOUND	5	5	ifosfamide
NCT0000260113	NCT00002601_13_T1	COMPOUND	8	8	doxorubicin
NCT0000260113	NCT00002601_13_T2	GENE	6	6	IV
NCT0000260113	NCT00002601_13_T3	GENE	9	9	IV
NCT0000260114	NCT00002601_14_T0	COMPOUND	10	10	2
NCT0000260114	NCT00002601_14_T1	ORGAN	4	5	bone marrow
NCT0000260115	NCT00002601_15_T0	GENE	2	2	G-CSF
NCT0000260115	NCT00002601_15_T1	GENE	3	3	IV
NCT0000260116	NCT00002601_16_T0	GENE	25	25	11
NCT0000260116	NCT00002601_16_T1	COMPOUND	16	16	melphalan
NCT0000260116	NCT00002601_16_T2	COMPOUND	21	21	cisplatin
NCT0000260116	NCT00002601_16_T3	GENE	17	17	IV
NCT0000260116	NCT00002601_16_T4	GENE	22	22	IV
NCT0000260117	NCT00002601_17_T0	GENE	2	2	G-CSF
NCT0000260117	NCT00002601_17_T1	GENE	3	3	IV
NCT0000260117	NCT00002601_17_T2	GENE	6	6	10
NCT0000260118	NCT00002601_18_T0	COMPOUND	10	10	3
NCT0000260118	NCT00002601_18_T1	ORGAN	4	5	bone marrow
NCT0000260119	NCT00002601_19_T0	GENE	2	2	G-CSF
NCT0000260119	NCT00002601_19_T1	GENE	3	3	IV
NCT000026025	NCT00002602_5_T0	PHENOTYPE	4	4	toxicity
NCT000026025	NCT00002602_5_T1	ORGAN	11	11	rectums
NCT0000260212	NCT00002602_12_T0	GENE	16	16	MTD
NCT0000260213	NCT00002602_13_T0	PHENOTYPE	16	16	toxicity
NCT0000260213	NCT00002602_13_T1	GENE	1	1	MTD
NCT000026040	NCT00002604_0_T0	PHENOTYPE	7	8	Solid Tumors
NCT000026042	NCT00002604_2_T0	CELL	9	9	cells
NCT000026042	NCT00002604_2_T1	PHENOTYPE	8	8	tumor
NCT000026043	NCT00002604_3_T0	COMPOUND	9	9	O(6)-benzylguanine
NCT000026043	NCT00002604_3_T1	PHENOTYPE	17	18	solid tumors
NCT000026046	NCT00002604_6_T0	PHENOTYPE	23	23	peripheral
NCT000026046	NCT00002604_6_T1	GENE	8	8	BG
NCT000026046	NCT00002604_6_T2	GENE	43	43	BG
NCT000026046	NCT00002604_6_T3	GENE	19	19	AGT
NCT000026046	NCT00002604_6_T4	CELL	26	26	cells
NCT000026046	NCT00002604_6_T5	PHENOTYPE	37	38	solid tumors
NCT000026048	NCT00002604_8_T0	GENE	8	8	BG
NCT000026048	NCT00002604_8_T1	GENE	30	30	BG
NCT000026048	NCT00002604_8_T2	MOLECULAR_FUNCTION	15	16	AGT activity
NCT000026048	NCT00002604_8_T3	PHENOTYPE	19	20	metastatic tumor
NCT0000260410	NCT00002604_10_T0	GENE	11	11	BG
NCT0000260410	NCT00002604_10_T1	COMPOUND	7	7	BCNU
NCT0000260412	NCT00002604_12_T0	GENE	4	4	BG
NCT0000260412	NCT00002604_12_T1	COMPOUND	6	6	BCNU
NCT0000260412	NCT00002604_12_T2	PHENOTYPE	2	2	toxicities
NCT0000260414	NCT00002604_14_T0	GENE	5	5	BG
NCT0000260414	NCT00002604_14_T1	GENE	17	17	BG
NCT0000260414	NCT00002604_14_T2	COMPOUND	15	15	BCNU
NCT0000260414	NCT00002604_14_T3	PHENOTYPE	18	18	pharmacokinetics
NCT0000260416	NCT00002604_16_T0	PHENOTYPE	8	9	solid tumors
NCT0000260418	NCT00002604_18_T0	GENE	14	14	BG
NCT0000260418	NCT00002604_18_T1	PHENOTYPE	24	24	tumor
NCT0000260418	NCT00002604_18_T2	MOLECULAR_FUNCTION	19	20	AGT activity
NCT0000260420	NCT00002604_20_T0	GENE	4	4	BG
NCT0000260420	NCT00002604_20_T1	PHENOTYPE	2	2	pharmacokinetics
NCT0000260421	NCT00002604_21_T0	GENE	9	9	BG
NCT0000260421	NCT00002604_21_T1	COMPOUND	12	12	BCNU
NCT0000260422	NCT00002604_22_T0	GENE	2	2	BG
NCT0000260422	NCT00002604_22_T1	GENE	12	12	BG
NCT0000260422	NCT00002604_22_T2	COMPOUND	22	22	BCNU
NCT0000260422	NCT00002604_22_T3	GENE	3	3	IV
NCT0000260422	NCT00002604_22_T4	GENE	13	13	IV
NCT0000260422	NCT00002604_22_T5	GENE	23	23	IV
NCT0000260423	NCT00002604_23_T0	PHENOTYPE	13	13	toxicity
NCT0000260423	NCT00002604_23_T1	PHENOTYPE	9	10	disease progression
NCT0000260424	NCT00002604_24_T0	GENE	2	2	1.3
NCT0000260424	NCT00002604_24_T1	GENE	8	8	BG
NCT0000260425	NCT00002604_25_T0	PHENOTYPE	17	17	peripheral
NCT0000260425	NCT00002604_25_T1	CELL	20	20	cells
NCT0000260425	NCT00002604_25_T2	GENE	30	30	BG
NCT0000260425	NCT00002604_25_T3	GENE	13	13	AGT
NCT0000260426	NCT00002604_26_T0	GENE	8	8	BG
NCT0000260427	NCT00002604_27_T0	GENE	25	25	BG
NCT0000260427	NCT00002604_27_T1	MOLECULAR_FUNCTION	9	10	AGT activity
NCT0000260427	NCT00002604_27_T2	PHENOTYPE	13	14	metastatic tumor
NCT0000260428	NCT00002604_28_T0	GENE	8	8	BG
NCT0000260429	NCT00002604_29_T0	GENE	24	24	BG
NCT0000260429	NCT00002604_29_T1	MOLECULAR_FUNCTION	9	10	AGT activity
NCT0000260429	NCT00002604_29_T2	PHENOTYPE	13	14	metastatic tumor
NCT0000260430	NCT00002604_30_T0	GENE	3	3	BG
NCT0000260430	NCT00002604_30_T1	COMPOUND	13	13	BCNU
NCT0000260430	NCT00002604_30_T2	GENE	4	4	IV
NCT0000260430	NCT00002604_30_T3	GENE	14	14	IV
NCT0000260431	NCT00002604_31_T0	PHENOTYPE	13	13	toxicity
NCT0000260431	NCT00002604_31_T1	PHENOTYPE	9	10	disease progression
NCT0000260432	NCT00002604_32_T0	GENE	11	11	BG
NCT0000260432	NCT00002604_32_T1	COMPOUND	8	8	BCNU
NCT0000260432	NCT00002604_32_T2	COMPOUND	22	22	BCNU
NCT0000260432	NCT00002604_32_T3	GENE	20	20	MTD
NCT0000260433	NCT00002604_33_T0	PHENOTYPE	22	22	toxicity
NCT0000260433	NCT00002604_33_T1	COMPOUND	3	3	BCNU
NCT0000260433	NCT00002604_33_T2	GENE	1	1	MTD
NCT0000260434	NCT00002604_34_T0	GENE	6	6	BG
NCT0000260434	NCT00002604_34_T1	GENE	18	18	BG
NCT0000260434	NCT00002604_34_T2	GENE	7	7	IV
NCT0000260434	NCT00002604_34_T3	GENE	19	19	IV
NCT0000260435	NCT00002604_35_T0	GENE	7	7	BG
NCT0000260435	NCT00002604_35_T1	GENE	22	22	BG
NCT0000260435	NCT00002604_35_T2	COMPOUND	13	13	BCNU
NCT0000260435	NCT00002604_35_T3	GENE	8	8	IV
NCT0000260435	NCT00002604_35_T4	GENE	14	14	IV
NCT000026080	NCT00002608_0_T0	PHENOTYPE	8	9	Solid Tumors
NCT000026084	NCT00002608_4_T0	CELL	8	8	cells
NCT000026084	NCT00002608_4_T1	PHENOTYPE	7	7	tumor
NCT000026084	NCT00002608_4_T2	COMPOUND	1	1	tamoxifen
NCT000026085	NCT00002608_5_T0	GENE	3	3	II
NCT000026085	NCT00002608_5_T1	COMPOUND	12	12	doxorubicin
NCT000026085	NCT00002608_5_T2	COMPOUND	10	10	cisplatin
NCT000026085	NCT00002608_5_T3	COMPOUND	15	15	tamoxifen
NCT000026085	NCT00002608_5_T4	PHENOTYPE	21	22	solid tumors
NCT000026087	NCT00002608_7_T0	GENE	6	6	1.2
NCT000026087	NCT00002608_7_T1	GENE	18	18	1.3
NCT000026087	NCT00002608_7_T2	COMPOUND	11	11	doxorubicin
NCT000026087	NCT00002608_7_T3	COMPOUND	3	3	cisplatin
NCT000026087	NCT00002608_7_T4	GENE	4	4	IV
NCT000026087	NCT00002608_7_T5	GENE	12	12	IV
NCT000026087	NCT00002608_7_T6	COMPOUND	21	21	tamoxifen
NCT000026088	NCT00002608_8_T0	PHENOTYPE	23	23	toxicity
NCT000026088	NCT00002608_8_T1	COMPOUND	12	12	doxorubicin
NCT000026088	NCT00002608_8_T2	PHENOTYPE	19	20	disease progression
NCT000026089	NCT00002608_9_T0	GENE	5	5	PR
NCT000026089	NCT00002608_9_T1	GENE	15	15	PR
NCT000026089	NCT00002608_9_T2	PHENOTYPE	4	4	remission
NCT000026089	NCT00002608_9_T3	PHENOTYPE	18	18	remission
NCT000026091	NCT00002609_1_T0	CELL	10	10	cells
NCT000026092	NCT00002609_2_T0	CELL	10	10	cells
NCT000026099	NCT00002609_9_T0	PHENOTYPE	4	4	toxicity
NCT0000260912	NCT00002609_12_T0	PHENOTYPE	13	13	remission
NCT0000260913	NCT00002609_13_T0	PHENOTYPE	16	16	relapse
NCT0000260913	NCT00002609_13_T1	PHENOTYPE	11	11	remission
NCT0000260914	NCT00002609_14_T0	GENE	3	3	IV
NCT0000260915	NCT00002609_15_T0	PHENOTYPE	3	3	toxicity
NCT0000260915	NCT00002609_15_T1	PHENOTYPE	7	7	remission
NCT0000260915	NCT00002609_15_T2	ORGAN	13	13	transplant
NCT0000260915	NCT00002609_15_T3	ORGAN	11	12	bone marrow
NCT0000260916	NCT00002609_16_T0	COMPOUND	11	11	cytarabine
NCT0000260916	NCT00002609_16_T1	GENE	9	9	1.3
NCT0000260916	NCT00002609_16_T2	GENE	16	16	1.5
NCT0000260916	NCT00002609_16_T3	COMPOUND	2	2	idarubicin
NCT0000260916	NCT00002609_16_T4	GENE	3	3	IV
NCT0000260916	NCT00002609_16_T5	GENE	12	12	IV
NCT0000260917	NCT00002609_17_T0	COMPOUND	22	22	cytarabine
NCT0000260917	NCT00002609_17_T1	GENE	20	20	1.2
NCT0000260917	NCT00002609_17_T2	GENE	27	27	1.4
NCT0000260917	NCT00002609_17_T3	COMPOUND	13	13	idarubicin
NCT0000260917	NCT00002609_17_T4	GENE	14	14	IV
NCT0000260917	NCT00002609_17_T5	GENE	23	23	IV
NCT0000260918	NCT00002609_18_T0	PHENOTYPE	5	5	toxicity
NCT0000260919	NCT00002609_19_T0	GENE	4	4	IV
NCT0000260923	NCT00002609_23_T0	GENE	14	14	2.3
NCT000026101	NCT00002610_1_T0	CELL	8	8	cells
NCT000026101	NCT00002610_1_T1	PHENOTYPE	7	7	tumor
NCT000026103	NCT00002610_3_T0	PHENOTYPE	15	16	kidney tumors
NCT000026108	NCT00002610_8_T0	PHENOTYPE	21	21	tumor
NCT000026109	NCT00002610_9_T0	PHENOTYPE	10	10	tumor
NCT0000261010	NCT00002610_10_T0	PHENOTYPE	10	10	tumor
NCT0000261010	NCT00002610_10_T1	GENE	14	15	group C
NCT0000261013	NCT00002610_13_T0	PHENOTYPE	4	4	recurrence
NCT0000261013	NCT00002610_13_T1	PHENOTYPE	13	13	recurrence
NCT0000261014	NCT00002610_14_T0	PHENOTYPE	6	6	recurrence
NCT0000261018	NCT00002610_18_T0	GENE	5	5	SC
NCT0000261018	NCT00002610_18_T1	GENE	1	1	G-CSF
NCT0000261019	NCT00002610_19_T0	PHENOTYPE	6	6	recurrence
NCT0000261019	NCT00002610_19_T1	PHENOTYPE	12	12	initiation
NCT0000261024	NCT00002610_24_T0	PHENOTYPE	12	13	disease progression
NCT0000261026	NCT00002610_26_T0	PHENOTYPE	10	11	disease progression
NCT000026111	NCT00002611_1_T0	CELL	9	9	cells
NCT000026111	NCT00002611_1_T1	PHENOTYPE	8	8	tumor
NCT000026112	NCT00002611_2_T0	PHENOTYPE	20	21	kidney cancer
NCT000026113	NCT00002611_3_T0	GENE	2	2	III
NCT000026113	NCT00002611_3_T1	PHENOTYPE	21	22	kidney cancer
NCT0000261110	NCT00002611_10_T0	GENE	5	5	SC
NCT0000261110	NCT00002611_10_T1	GENE	1	1	G-CSF
NCT0000261112	NCT00002611_12_T0	GENE	0	0	G-CSF
NCT0000261114	NCT00002611_14_T0	GENE	0	0	The
NCT0000261114	NCT00002611_14_T1	PHENOTYPE	4	4	closed
NCT0000261114	NCT00002611_14_T2	PHENOTYPE	1	2	rhabdoid tumor
NCT0000261115	NCT00002611_15_T0	PHENOTYPE	7	8	residual disease
NCT000026151	NCT00002615_1_T0	CELL	9	9	cells
NCT000026151	NCT00002615_1_T1	PHENOTYPE	8	8	tumor
NCT000026152	NCT00002615_2_T0	PHENOTYPE	20	21	stomach cancer
NCT000026153	NCT00002615_3_T0	GENE	3	3	III
NCT000026153	NCT00002615_3_T1	PHENOTYPE	21	22	stomach cancer
NCT0000261513	NCT00002615_13_T0	PHENOTYPE	0	2	Quality of life
NCT000026166	NCT00002616_6_T0	PHENOTYPE	2	2	engraftment
NCT000026166	NCT00002616_6_T1	COMPOUND	7	7	thiotepa
NCT000026166	NCT00002616_6_T2	COMPOUND	6	6	cyclophosphamide
NCT000026166	NCT00002616_6_T3	GENE	16	16	G-CSF
NCT000026166	NCT00002616_6_T4	GENE	11	11	STAMP
NCT000026168	NCT00002616_8_T0	PHENOTYPE	2	2	toxic
NCT000026168	NCT00002616_8_T1	GENE	6	6	IL-2
NCT000026168	NCT00002616_8_T2	GENE	8	8	G-CSF
NCT0000261612	NCT00002616_12_T0	CELL	12	12	CFU-GM
NCT0000261612	NCT00002616_12_T1	GENE	19	19	IL-2
NCT0000261612	NCT00002616_12_T2	GENE	24	24	G-CSF
NCT0000261612	NCT00002616_12_T3	GENE	29	29	G-CSF
NCT0000261612	NCT00002616_12_T4	GENE	11	11	CD34
NCT0000261612	NCT00002616_12_T5	CELL	8	10	hematopoietic progenitor cells
NCT0000261616	NCT00002616_16_T0	PHENOTYPE	3	3	toxicity
NCT0000261616	NCT00002616_16_T1	GENE	15	15	G-CSF
NCT0000261618	NCT00002616_18_T0	GENE	19	19	STAMP
NCT0000261618	NCT00002616_18_T1	PHENOTYPE	15	16	breast cancer
NCT0000261620	NCT00002616_20_T0	ORGAN	17	17	marrow
NCT0000261620	NCT00002616_20_T1	GENE	19	19	polymerase
NCT0000261620	NCT00002616_20_T2	GENE	4	4	cytokeratin
NCT0000261620	NCT00002616_20_T3	PHENOTYPE	10	11	residual disease
NCT0000261622	NCT00002616_22_T0	GENE	11	11	interleukin-2
NCT0000261622	NCT00002616_22_T1	GENE	12	12	IL-2
NCT0000261622	NCT00002616_22_T2	GENE	6	6	filgrastim
NCT0000261622	NCT00002616_22_T3	GENE	7	7	G-CSF
NCT0000261622	NCT00002616_22_T4	CELL	15	16	stem cells
NCT0000261628	NCT00002616_28_T0	PHENOTYPE	20	20	toxicity
NCT0000261629	NCT00002616_29_T0	PHENOTYPE	4	5	disease progression
NCT0000261630	NCT00002616_30_T0	GENE	30	30	IL-2
NCT0000261630	NCT00002616_30_T1	GENE	21	21	G-CSF
NCT000026181	NCT00002618_1_T0	CELL	10	10	cells
NCT0000261811	NCT00002618_11_T0	PHENOTYPE	3	3	remission
NCT0000261811	NCT00002618_11_T1	PHENOTYPE	13	13	remission
NCT0000261811	NCT00002618_11_T2	PHENOTYPE	23	24	residual disease
NCT0000261812	NCT00002618_12_T0	GENE	23	23	APO
NCT0000261812	NCT00002618_12_T1	COMPOUND	17	17	cytarabine
NCT0000261812	NCT00002618_12_T2	COMPOUND	13	13	calcium
NCT0000261813	NCT00002618_13_T0	GENE	16	16	APO
NCT0000261814	NCT00002618_14_T0	COMPOUND	26	26	cytarabine
NCT0000261814	NCT00002618_14_T1	COMPOUND	14	14	calcium
NCT0000261814	NCT00002618_14_T2	COMPOUND	5	5	methotrexate
NCT0000261814	NCT00002618_14_T3	COMPOUND	37	37	methotrexate
NCT0000261814	NCT00002618_14_T4	GENE	38	38	IT
NCT0000261814	NCT00002618_14_T5	COMPOUND	13	13	leucovorin
NCT0000261814	NCT00002618_14_T6	GENE	6	6	IV
NCT0000261814	NCT00002618_14_T7	GENE	15	15	IV
NCT0000261814	NCT00002618_14_T8	GENE	27	27	IV
NCT0000261815	NCT00002618_15_T0	GENE	1	1	G-CSF
NCT0000261816	NCT00002618_16_T0	GENE	1	1	APO
NCT0000261816	NCT00002618_16_T1	COMPOUND	4	4	vincristine
NCT0000261816	NCT00002618_16_T2	GENE	13	13	1.5
NCT0000261816	NCT00002618_16_T3	GENE	31	31	1.5
NCT0000261816	NCT00002618_16_T4	COMPOUND	14	14	doxorubicin
NCT0000261816	NCT00002618_16_T5	COMPOUND	24	24	prednisone
NCT0000261816	NCT00002618_16_T6	GENE	5	5	IV
NCT0000261816	NCT00002618_16_T7	GENE	15	15	IV
NCT0000261821	NCT00002618_21_T0	GENE	10	10	4.5
NCT0000261821	NCT00002618_21_T1	PHENOTYPE	13	14	residual tumor
NCT0000261822	NCT00002618_22_T0	GENE	12	12	3-1
NCT0000261824	NCT00002618_24_T0	GENE	15	15	5.4
NCT000026197	NCT00002619_7_T0	PHENOTYPE	2	2	toxicity
NCT000026197	NCT00002619_7_T1	COMPOUND	7	7	thiotepa
NCT000026199	NCT00002619_9_T0	PHENOTYPE	19	19	toxicity
NCT000026199	NCT00002619_9_T1	COMPOUND	9	9	triethylenephosphoramide
NCT0000261911	NCT00002619_11_T0	BIOLOGICAL_PROCESS	9	9	hematopoiesis
NCT0000261911	NCT00002619_11_T1	CELL	5	6	stem cells
NCT0000261913	NCT00002619_13_T0	GENE	12	12	G-CSF
NCT0000261913	NCT00002619_13_T1	ORGAN	7	8	Bone Marrow
NCT0000261913	NCT00002619_13_T2	GENE	13	15	Granulocyte Colony-Stimulating Factor
NCT0000261913	NCT00002619_13_T3	CELL	19	22	Peripheral Blood Stem Cells
NCT0000261914	NCT00002619_14_T0	GENE	7	7	G-CSF
NCT000026202	NCT00002620_2_T0	GENE	3	3	III
NCT000026202	NCT00002620_2_T1	PHENOTYPE	16	17	anaplastic astrocytomas
NCT000026204	NCT00002620_4_T0	PHENOTYPE	11	12	brain gliomas
NCT000026206	NCT00002620_6_T0	GENE	0	1	Group I
NCT000026208	NCT00002620_8_T0	GENE	1	1	II
NCT000026209	NCT00002620_9_T0	COMPOUND	13	13	BCNU
NCT000026209	NCT00002620_9_T1	GENE	3	4	Group I
NCT000026211	NCT00002621_1_T0	GENE	2	2	II
NCT000026211	NCT00002621_1_T1	PHENOTYPE	19	19	leukemia
NCT000026211	NCT00002621_1_T2	PHENOTYPE	23	23	lymphoma
NCT000026211	NCT00002621_1_T3	GENE	9	9	interferon
NCT000026211	NCT00002621_1_T4	PHENOTYPE	16	16	HIV
NCT000026211	NCT00002621_1_T5	PHENOTYPE	26	27	solid tumors
NCT000026211	NCT00002621_1_T6	PHENOTYPE	20	21	Hodgkin's lymphoma
NCT000026215	NCT00002621_5_T0	PHENOTYPE	16	16	toxicity
NCT000026215	NCT00002621_5_T1	PHENOTYPE	12	13	disease progression
NCT000026216	NCT00002621_6_T0	GENE	3	3	IT
NCT000026216	NCT00002621_6_T1	GENE	10	10	IT
NCT000026217	NCT00002621_7_T0	GENE	18	18	POG
NCT000026218	NCT00002621_8_T0	GENE	15	15	4.2
NCT000026221	NCT00002622_1_T0	PHENOTYPE	18	20	malignant pleural effusion
NCT000026222	NCT00002622_2_T0	GENE	3	3	III
NCT000026222	NCT00002622_2_T1	PHENOTYPE	19	21	malignant pleural effusion
NCT000026224	NCT00002622_4_T0	PHENOTYPE	17	17	MPE
NCT000026224	NCT00002622_4_T1	PHENOTYPE	14	16	malignant pleural effusion
NCT000026226	NCT00002622_6_T0	PHENOTYPE	10	10	MPE
NCT000026228	NCT00002622_8_T0	PHENOTYPE	4	4	recurrence
NCT000026228	NCT00002622_8_T1	PHENOTYPE	13	13	sclerosis
NCT000026228	NCT00002622_8_T2	PHENOTYPE	6	6	effusion
NCT000026228	NCT00002622_8_T3	PHENOTYPE	17	17	complications
NCT000026228	NCT00002622_8_T4	PHENOTYPE	19	19	toxicities
NCT0000262216	NCT00002622_16_T0	PHENOTYPE	5	5	sclerosis
NCT0000262219	NCT00002622_19_T0	GENE	10	10	ml_24
NCT0000262221	NCT00002622_21_T0	PHENOTYPE	14	14	visualization
NCT0000262223	NCT00002622_23_T0	GENE	21	21	ml_24
NCT0000262224	NCT00002622_24_T0	PHENOTYPE	6	7	disease progression
NCT0000262225	NCT00002622_25_T0	PHENOTYPE	8	8	relapse
NCT000026233	NCT00002623_3_T0	CELL	8	8	cells
NCT000026233	NCT00002623_3_T1	PHENOTYPE	7	7	tumor
NCT000026239	NCT00002623_9_T0	PHENOTYPE	21	21	toxicity
NCT000026239	NCT00002623_9_T1	COMPOUND	10	10	cisplatin
NCT000026239	NCT00002623_9_T2	PHENOTYPE	17	18	disease progression
NCT0000262311	NCT00002623_11_T0	GENE	9	9	cm
NCT0000262311	NCT00002623_11_T1	GENE	21	21	5.5
NCT0000262311	NCT00002623_11_T2	TISSUE	3	4	resection margins
NCT0000262313	NCT00002623_13_T0	PHENOTYPE	6	6	tumor
NCT0000262314	NCT00002623_14_T0	PHENOTYPE	3	3	tumor
NCT0000262314	NCT00002623_14_T1	PHENOTYPE	6	6	tumor
NCT0000262314	NCT00002623_14_T2	GENE	11	11	cm
NCT000026245	NCT00002624_5_T0	TISSUE	11	12	lymph nodes
NCT000026246	NCT00002624_6_T0	TISSUE	3	4	lymph nodes
NCT000026247	NCT00002624_7_T0	PHENOTYPE	2	2	tumor
NCT000026251	NCT00002625_1_T0	CELL	10	10	cells
NCT000026252	NCT00002625_2_T0	CELL	8	8	cells
NCT000026253	NCT00002625_3_T0	CELL	9	9	cells
NCT000026255	NCT00002625_5_T0	GENE	22	22	Gy
NCT000026255	NCT00002625_5_T1	PHENOTYPE	29	29	lymphoma
NCT000026255	NCT00002625_5_T2	COMPOUND	9	9	topotecan
NCT000026255	NCT00002625_5_T3	PHENOTYPE	26	27	solid tumor
NCT000026257	NCT00002625_7_T0	PHENOTYPE	8	8	toxic
NCT000026259	NCT00002625_9_T0	PHENOTYPE	6	6	concentrations
NCT000026259	NCT00002625_9_T1	PHENOTYPE	4	4	tumor
NCT000026259	NCT00002625_9_T2	ORGAN	11	11	plasma
NCT0000262511	NCT00002625_11_T0	GENE	3	3	blot
NCT0000262511	NCT00002625_11_T1	PHENOTYPE	16	16	peripheral
NCT0000262511	NCT00002625_11_T2	CELL	18	18	lymphocytes
NCT0000262511	NCT00002625_11_T3	GENE	19	19	PBL
NCT0000262511	NCT00002625_11_T4	GENE	12	13	topoisomerase I
NCT0000262515	NCT00002625_15_T0	PHENOTYPE	1	1	tumor
NCT0000262515	NCT00002625_15_T1	PHENOTYPE	11	12	DNA damage
NCT0000262515	NCT00002625_15_T2	GENE	8	9	topoisomerase I
NCT000026276	NCT00002627_6_T0	PHENOTYPE	3	3	toxicities
NCT0000262710	NCT00002627_10_T0	CELL	11	11	granulocyte
NCT0000262710	NCT00002627_10_T1	GENE	14	14	G-CSF
NCT0000262710	NCT00002627_10_T2	CELL	5	8	peripheral blood stem cells
NCT0000262711	NCT00002627_11_T0	COMPOUND	12	12	paclitaxel
NCT0000262711	NCT00002627_11_T1	GENE	2	2	3.5
NCT0000262711	NCT00002627_11_T2	GENE	18	18	MTD
NCT0000262712	NCT00002627_12_T0	COMPOUND	14	14	cyclophosphamide
NCT0000262713	NCT00002627_13_T0	GENE	7	7	G-CSF
NCT0000262714	NCT00002627_14_T0	GENE	6	6	MTD
NCT000026281	NCT00002628_1_T0	CELL	9	9	cells
NCT000026281	NCT00002628_1_T1	PHENOTYPE	8	8	tumor
NCT000026287	NCT00002628_7_T0	PHENOTYPE	3	3	toxic
NCT000026289	NCT00002628_9_T0	PHENOTYPE	13	15	metastatic breast cancer
NCT0000262811	NCT00002628_11_T0	CELL	11	11	granulocyte
NCT0000262811	NCT00002628_11_T1	GENE	14	14	G-CSF
NCT0000262811	NCT00002628_11_T2	CELL	5	8	peripheral blood stem cells
NCT0000262812	NCT00002628_12_T0	COMPOUND	12	12	paclitaxel
NCT0000262812	NCT00002628_12_T1	GENE	2	2	3.5
NCT0000262812	NCT00002628_12_T2	GENE	18	18	MTD
NCT0000262813	NCT00002628_13_T0	COMPOUND	14	14	cyclophosphamide
NCT0000262814	NCT00002628_14_T0	GENE	7	7	G-CSF
NCT0000262815	NCT00002628_15_T0	GENE	6	6	MTD
NCT000026301	NCT00002630_1_T0	CELL	8	8	cells
NCT000026301	NCT00002630_1_T1	PHENOTYPE	7	7	tumor
NCT000026309	NCT00002630_9_T0	PHENOTYPE	4	4	toxicity
NCT000026309	NCT00002630_9_T1	PHENOTYPE	12	13	multiple myeloma
NCT0000263012	NCT00002630_12_T0	PHENOTYPE	34	34	relapse
NCT0000263013	NCT00002630_13_T0	BIOLOGICAL_PROCESS	3	5	response to 3
NCT0000263016	NCT00002630_16_T0	CELL	6	7	Stem Cell
NCT000026311	NCT00002631_1_T0	CELL	8	8	cells
NCT000026311	NCT00002631_1_T1	PHENOTYPE	7	7	tumor
NCT000026312	NCT00002631_2_T0	PHENOTYPE	18	21	cancer of the esophagus
NCT000026313	NCT00002631_3_T0	GENE	3	3	III
NCT000026313	NCT00002631_3_T1	PHENOTYPE	22	25	cancer of the esophagus
NCT000026315	NCT00002631_5_T0	COMPOUND	19	19	5-FU-CDDP
NCT000026315	NCT00002631_5_T1	COMPOUND	24	24	5-FU-CDDP
NCT000026315	NCT00002631_5_T2	PHENOTYPE	28	29	esophageal cancer
NCT000026317	NCT00002631_7_T0	PHENOTYPE	2	2	tolerance
NCT000026317	NCT00002631_7_T1	PHENOTYPE	4	6	quality of life
NCT0000263110	NCT00002631_10_T0	PHENOTYPE	0	0	Tumor
NCT000026320	NCT00002632_0_T0	PHENOTYPE	7	10	Recurrent Salivary Gland Cancer
NCT000026322	NCT00002632_2_T0	GENE	2	2	II
NCT000026322	NCT00002632_2_T1	COMPOUND	9	9	paclitaxel
NCT000026322	NCT00002632_2_T2	PHENOTYPE	16	19	recurrent salivary gland cancer
NCT000026324	NCT00002632_4_T0	COMPOUND	15	15	paclitaxel
NCT000026324	NCT00002632_4_T1	GENE	17	17	TAX
NCT000026324	NCT00002632_4_T2	PHENOTYPE	9	12	recurrent salivary gland cancer
NCT000026326	NCT00002632_6_T0	PHENOTYPE	2	2	toxicity
NCT000026326	NCT00002632_6_T1	GENE	4	4	TAX
NCT000026328	NCT00002632_8_T0	GENE	3	3	TAX
NCT000026332	NCT00002633_2_T0	CELL	8	8	cells
NCT000026332	NCT00002633_2_T1	PHENOTYPE	7	7	tumor
NCT000026339	NCT00002633_9_T0	GENE	14	14	SC
NCT000026339	NCT00002633_9_T1	GENE	41	41	SC
NCT000026339	NCT00002633_9_T2	GENE	8	8	LHRH
NCT000026339	NCT00002633_9_T3	COMPOUND	40	40	buserelin
NCT000026339	NCT00002633_9_T4	COMPOUND	12	12	goserelin
NCT000026339	NCT00002633_9_T5	PHENOTYPE	5	5	bilateral
NCT000026339	NCT00002633_9_T6	COMPOUND	26	26	leuprolide
NCT0000263314	NCT00002633_14_T0	PHENOTYPE	0	2	Quality of life
NCT000026341	NCT00002634_1_T0	CELL	21	21	cells
NCT000026341	NCT00002634_1_T1	PHENOTYPE	20	20	tumor
NCT000026341	NCT00002634_1_T2	ORGAN	3	4	bone marrow
NCT000026342	NCT00002634_2_T0	CELL	8	8	cells
NCT000026342	NCT00002634_2_T1	PHENOTYPE	7	7	tumor
NCT000026344	NCT00002634_4_T0	GENE	2	2	II
NCT000026344	NCT00002634_4_T1	PHENOTYPE	22	22	neuroblastoma
NCT000026344	NCT00002634_4_T2	ORGAN	15	16	bone marrow
NCT000026346	NCT00002634_6_T0	PHENOTYPE	11	11	relapse
NCT000026346	NCT00002634_6_T1	COMPOUND	41	41	3F8
NCT000026346	NCT00002634_6_T2	COMPOUND	52	52	3F8
NCT000026346	NCT00002634_6_T3	PHENOTYPE	17	17	neuroblastoma
NCT000026346	NCT00002634_6_T4	PHENOTYPE	3	3	remission
NCT000026346	NCT00002634_6_T5	ORGAN	47	47	transplant
NCT000026346	NCT00002634_6_T6	COMPOUND	35	35	iodine
NCT000026346	NCT00002634_6_T7	ORGAN	45	46	bone marrow
NCT000026348	NCT00002634_8_T0	PHENOTYPE	16	16	malignancy
NCT0000263411	NCT00002634_11_T0	COMPOUND	14	14	vincristine
NCT0000263411	NCT00002634_11_T1	GENE	9	9	1.2
NCT0000263411	NCT00002634_11_T2	GENE	21	21	1.3
NCT0000263411	NCT00002634_11_T3	COMPOUND	2	2	cyclophosphamide
NCT0000263411	NCT00002634_11_T4	COMPOUND	11	11	doxorubicin
NCT0000263411	NCT00002634_11_T5	GENE	3	3	IV
NCT0000263411	NCT00002634_11_T6	GENE	12	12	IV
NCT0000263411	NCT00002634_11_T7	GENE	15	15	IV
NCT0000263412	NCT00002634_12_T0	COMPOUND	9	9	vincristine
NCT0000263412	NCT00002634_12_T1	GENE	16	16	1.3
NCT0000263412	NCT00002634_12_T2	GENE	7	7	1.4
NCT0000263412	NCT00002634_12_T3	GENE	1	1	IV
NCT0000263412	NCT00002634_12_T4	GENE	10	10	IV
NCT0000263414	NCT00002634_14_T0	ORGAN	11	11	marrow
NCT0000263414	NCT00002634_14_T1	CELL	16	16	cells
NCT0000263414	NCT00002634_14_T2	PHENOTYPE	15	15	tumor
NCT0000263414	NCT00002634_14_T3	ORGAN	1	2	bone marrow
NCT0000263417	NCT00002634_17_T0	COMPOUND	9	9	3F8
NCT0000263417	NCT00002634_17_T1	COMPOUND	11	11	3F8
NCT0000263417	NCT00002634_17_T2	GENE	19	19	1.5
NCT0000263417	NCT00002634_17_T3	COMPOUND	3	3	iodine
NCT0000263418	NCT00002634_18_T0	GENE	9	9	filgrastim
NCT0000263418	NCT00002634_18_T1	GENE	10	10	G-CSF
NCT0000263418	NCT00002634_18_T2	GENE	13	13	IV
NCT0000263418	NCT00002634_18_T3	ORGAN	1	2	bone marrow
NCT0000263419	NCT00002634_19_T0	COMPOUND	15	15	3F8
NCT0000263419	NCT00002634_19_T1	GENE	18	18	1.5
NCT0000263419	NCT00002634_19_T2	PHENOTYPE	8	8	allergy
NCT0000263419	NCT00002634_19_T3	GENE	16	16	IV
NCT0000263420	NCT00002634_20_T0	GENE	3	3	1.2
NCT000026351	NCT00002635_1_T0	GENE	2	2	II
NCT000026351	NCT00002635_1_T1	PHENOTYPE	15	17	cutaneous T-cell lymphoma
NCT000026353	NCT00002635_3_T0	PHENOTYPE	15	17	cutaneous T-cell lymphoma
NCT000026355	NCT00002635_5_T0	PHENOTYPE	2	2	toxic
NCT000026359	NCT00002635_9_T0	GENE	0	0	Probable
NCT000026379	NCT00002637_9_T0	PHENOTYPE	7	7	immunity
NCT0000263710	NCT00002637_10_T0	PHENOTYPE	1	1	Tumor
NCT0000263712	NCT00002637_12_T0	GENE	28	28	II
NCT0000263712	NCT00002637_12_T1	GENE	26	26	MTD
NCT000026384	NCT00002638_4_T0	COMPOUND	6	6	cytarabine
NCT000026384	NCT00002638_4_T1	GENE	13	13	1.5
NCT000026384	NCT00002638_4_T2	GENE	7	7	IV
NCT000026385	NCT00002638_5_T0	CELL	16	16	cells
NCT000026385	NCT00002638_5_T1	CELL	22	22	cells
NCT000026385	NCT00002638_5_T2	GENE	21	21	CD34
NCT000026385	NCT00002638_5_T3	CELL	18	19	colony-forming units
NCT000026385	NCT00002638_5_T4	CELL	5	8	peripheral blood stem cells
NCT000026386	NCT00002638_6_T0	COMPOUND	12	12	cytarabine
NCT000026386	NCT00002638_6_T1	GENE	6	6	IV
NCT000026386	NCT00002638_6_T2	GENE	13	13	IV
NCT000026386	NCT00002638_6_T3	GENE	19	19	IV
NCT000026386	NCT00002638_6_T4	GENE	30	30	IV
NCT000026386	NCT00002638_6_T5	COMPOUND	35	35	1
NCT000026386	NCT00002638_6_T6	COMPOUND	33	33	2
NCT000026386	NCT00002638_6_T7	COMPOUND	11	11	3
NCT000026386	NCT00002638_6_T8	COMPOUND	29	29	cyclophosphamide
NCT000026386	NCT00002638_6_T9	COMPOUND	18	18	etoposide
NCT000026388	NCT00002638_8_T0	GENE	2	2	filgrastim
NCT000026388	NCT00002638_8_T1	GENE	3	3	G-CSF
NCT000026388	NCT00002638_8_T2	GENE	6	6	GM-CSF
NCT000026388	NCT00002638_8_T3	GENE	5	5	sargramostim
NCT000026389	NCT00002638_9_T0	ORGAN	6	6	testes
NCT0000263810	NCT00002638_10_T0	PHENOTYPE	6	6	leukemia
NCT000026392	NCT00002639_2_T0	GENE	2	2	II
NCT000026392	NCT00002639_2_T1	COMPOUND	9	9	suramin
NCT000026392	NCT00002639_2_T2	PHENOTYPE	14	14	recurrent
NCT000026392	NCT00002639_2_T3	PHENOTYPE	15	17	primary brain tumors
NCT000026394	NCT00002639_4_T0	COMPOUND	4	4	suramin
NCT000026394	NCT00002639_4_T1	PHENOTYPE	19	19	progression
NCT000026394	NCT00002639_4_T2	PHENOTYPE	8	8	recurrent
NCT000026394	NCT00002639_4_T3	PHENOTYPE	9	11	primary brain tumors
NCT000026396	NCT00002639_6_T0	PHENOTYPE	2	2	toxic
NCT000026396	NCT00002639_6_T1	COMPOUND	5	5	suramin
NCT000026398	NCT00002639_8_T0	GENE	1	1	SUR
NCT000026399	NCT00002639_9_T0	PHENOTYPE	11	11	experiences
NCT000026411	NCT00002641_1_T0	PHENOTYPE	18	20	soft tissue sarcoma
NCT000026412	NCT00002641_2_T0	GENE	3	3	III
NCT000026412	NCT00002641_2_T1	PHENOTYPE	20	22	soft tissue sarcoma
NCT000026415	NCT00002641_5_T0	ORGAN	51	51	limb
NCT000026415	NCT00002641_5_T1	GENE	35	35	cm
NCT000026415	NCT00002641_5_T2	GENE	38	38	cm
NCT000026415	NCT00002641_5_T3	ORGAN	10	10	extremity
NCT000026415	NCT00002641_5_T4	PHENOTYPE	8	9	primary tumor
NCT000026415	NCT00002641_5_T5	PHENOTYPE	30	31	primary tumor
NCT000026416	NCT00002641_6_T0	ORGAN	4	4	limb
NCT0000264115	NCT00002641_15_T0	GENE	14	14	3.5
NCT000026422	NCT00002642_2_T0	CELL	8	8	cells
NCT000026422	NCT00002642_2_T1	PHENOTYPE	7	7	tumor
NCT000026423	NCT00002642_3_T0	CELL	9	9	cells
NCT000026423	NCT00002642_3_T1	PHENOTYPE	8	8	tumor
NCT000026426	NCT00002642_6_T0	PHENOTYPE	4	4	toxic
NCT000026426	NCT00002642_6_T1	GENE	34	34	nodal
NCT000026426	NCT00002642_6_T2	PHENOTYPE	28	29	Pancoast tumors
NCT000026428	NCT00002642_8_T0	PHENOTYPE	14	15	residual disease
NCT000026429	NCT00002642_9_T0	PHENOTYPE	13	13	progression
NCT0000264212	NCT00002642_12_T0	GENE	23	23	4.15
NCT0000264212	NCT00002642_12_T1	PHENOTYPE	10	10	tumor
NCT0000264214	NCT00002642_14_T0	PHENOTYPE	0	0	Tumor
NCT0000264217	NCT00002642_17_T0	GENE	8	8	2.4
NCT000026431	NCT00002643_1_T0	CELL	10	10	cells
NCT000026431	NCT00002643_1_T1	PHENOTYPE	9	9	tumor
NCT000026432	NCT00002643_2_T0	CELL	9	9	cells
NCT000026432	NCT00002643_2_T1	PHENOTYPE	8	8	tumor
NCT000026434	NCT00002643_4_T0	COMPOUND	25	25	vincristine
NCT000026434	NCT00002643_4_T1	COMPOUND	31	31	ifosfamide
NCT000026434	NCT00002643_4_T2	COMPOUND	27	27	cyclophosphamide
NCT000026434	NCT00002643_4_T3	COMPOUND	32	32	etoposide
NCT000026434	NCT00002643_4_T4	COMPOUND	26	26	doxorubicin
NCT000026434	NCT00002643_4_T5	GENE	30	30	IE
NCT000026434	NCT00002643_4_T6	PHENOTYPE	13	15	metastatic Ewing's sarcoma
NCT000026434	NCT00002643_4_T7	PHENOTYPE	17	19	primitive neuroectodermal tumor
NCT000026436	NCT00002643_6_T0	COMPOUND	11	11	cyclophosphamide
NCT000026436	NCT00002643_6_T1	COMPOUND	7	7	topotecan
NCT000026436	NCT00002643_6_T2	COMPOUND	9	9	topotecan
NCT000026438	NCT00002643_8_T0	PHENOTYPE	16	17	disease course
NCT0000264310	NCT00002643_10_T0	PHENOTYPE	11	11	toxicity
NCT0000264310	NCT00002643_10_T1	COMPOUND	5	5	ifosfamide
NCT0000264310	NCT00002643_10_T2	COMPOUND	7	7	cyclophosphamide
NCT0000264310	NCT00002643_10_T3	BIOLOGICAL_PROCESS	8	8	metabolism
NCT0000264312	NCT00002643_12_T0	GENE	12	12	filgrastim
NCT0000264312	NCT00002643_12_T1	GENE	13	13	G-CSF
NCT0000264312	NCT00002643_12_T2	CELL	6	6	neutrophil
NCT0000264312	NCT00002643_12_T3	ORGAN	25	26	bone marrow
NCT0000264314	NCT00002643_14_T0	PHENOTYPE	11	11	toxicities
NCT0000264314	NCT00002643_14_T1	COMPOUND	2	2	amifostine
NCT0000264317	NCT00002643_17_T0	GENE	14	14	1.5
NCT0000264317	NCT00002643_17_T1	COMPOUND	4	4	cyclophosphamide
NCT0000264317	NCT00002643_17_T2	GENE	5	5	IV
NCT0000264317	NCT00002643_17_T3	GENE	8	8	IV
NCT0000264317	NCT00002643_17_T4	COMPOUND	7	7	topotecan
NCT0000264320	NCT00002643_20_T0	COMPOUND	11	11	amifostine
NCT0000264321	NCT00002643_21_T0	COMPOUND	8	8	ifosfamide
NCT0000264321	NCT00002643_21_T1	GENE	15	15	1.5
NCT0000264321	NCT00002643_21_T2	COMPOUND	2	2	etoposide
NCT0000264321	NCT00002643_21_T3	GENE	3	3	IV
NCT0000264321	NCT00002643_21_T4	GENE	9	9	IV
NCT0000264322	NCT00002643_22_T0	COMPOUND	10	10	ifosfamide
NCT0000264322	NCT00002643_22_T1	GENE	1	1	IV
NCT0000264323	NCT00002643_23_T0	GENE	2	2	G-CSF
NCT0000264323	NCT00002643_23_T1	GENE	5	5	IV
NCT0000264326	NCT00002643_26_T0	COMPOUND	4	4	vincristine
NCT0000264326	NCT00002643_26_T1	COMPOUND	18	18	cyclophosphamide
NCT0000264326	NCT00002643_26_T2	GENE	35	35	G-CSF
NCT0000264326	NCT00002643_26_T3	COMPOUND	24	24	doxorubicin
NCT0000264326	NCT00002643_26_T4	COMPOUND	7	7	amifostine
NCT0000264326	NCT00002643_26_T5	GENE	5	5	IV
NCT0000264326	NCT00002643_26_T6	GENE	8	8	IV
NCT0000264326	NCT00002643_26_T7	GENE	19	19	IV
NCT0000264326	NCT00002643_26_T8	GENE	25	25	IV
NCT0000264327	NCT00002643_27_T0	COMPOUND	19	19	vincristine
NCT0000264327	NCT00002643_27_T1	GENE	50	50	1.3
NCT0000264327	NCT00002643_27_T2	COMPOUND	22	22	cyclophosphamide
NCT0000264327	NCT00002643_27_T3	COMPOUND	43	43	etoposide
NCT0000264327	NCT00002643_27_T4	COMPOUND	39	39	doxorubicin
NCT0000264327	NCT00002643_27_T5	GENE	44	44	IV
NCT0000264332	NCT00002643_32_T0	PHENOTYPE	3	3	metastases
NCT000026440	NCT00002644_0_T0	PHENOTYPE	5	6	Breast Cancer
NCT000026442	NCT00002644_2_T0	PHENOTYPE	16	16	centres
NCT000026442	NCT00002644_2_T1	PHENOTYPE	0	0	Recruitment
NCT000026444	NCT00002644_4_T0	COMPOUND	15	15	anastrozole
NCT000026444	NCT00002644_4_T1	COMPOUND	33	33	tamoxifen
NCT000026444	NCT00002644_4_T2	PHENOTYPE	20	21	breast cancer
NCT000026444	NCT00002644_4_T3	PHENOTYPE	27	28	breast cancer
NCT000026447	NCT00002644_7_T0	CELL	16	16	cells
NCT000026447	NCT00002644_7_T1	PHENOTYPE	8	9	breast cancer
NCT000026447	NCT00002644_7_T2	PHENOTYPE	11	14	ductal carcinoma in situ
NCT000026448	NCT00002644_8_T0	PHENOTYPE	0	0	Recruitment
NCT0000264411	NCT00002644_11_T0	GENE	7	7	reduced
NCT0000264411	NCT00002644_11_T1	COMPOUND	6	6	tamoxifen
NCT0000264411	NCT00002644_11_T2	PHENOTYPE	11	13	invasive breast cancer
NCT0000264412	NCT00002644_12_T0	COMPOUND	9	9	tamoxifen
NCT0000264412	NCT00002644_12_T1	PHENOTYPE	2	3	breast cancer
NCT0000264413	NCT00002644_13_T0	COMPOUND	13	13	tamoxifen
NCT0000264414	NCT00002644_14_T0	COMPOUND	5	5	tamoxifen
NCT0000264414	NCT00002644_14_T1	COMPOUND	15	15	tamoxifen
NCT0000264414	NCT00002644_14_T2	PHENOTYPE	8	9	breast cancer
NCT0000264414	NCT00002644_14_T3	PHENOTYPE	19	20	breast cancer
NCT0000264416	NCT00002644_16_T0	COMPOUND	1	1	tamoxifen
NCT0000264417	NCT00002644_17_T0	COMPOUND	9	9	tamoxifen
NCT0000264421	NCT00002644_21_T0	PHENOTYPE	5	6	breast cancer
NCT0000264422	NCT00002644_22_T0	PHENOTYPE	5	7	bilateral breast cancer
NCT0000264422	NCT00002644_22_T1	PHENOTYPE	6	8	breast cancer 3
NCT0000264423	NCT00002644_23_T0	PHENOTYPE	10	11	breast cancer
NCT0000264424	NCT00002644_24_T0	PHENOTYPE	8	9	breast cancer
NCT0000264425	NCT00002644_25_T0	PHENOTYPE	3	3	proliferative
NCT0000264425	NCT00002644_25_T1	PHENOTYPE	12	13	breast cancer
NCT0000264426	NCT00002644_26_T0	PHENOTYPE	0	3	Lobular carcinoma in situ
NCT000026462	NCT00002646_2_T0	CELL	9	9	cells
NCT000026462	NCT00002646_2_T1	PHENOTYPE	8	8	tumor
NCT000026462	NCT00002646_2_T2	GENE	3	3	hormone
NCT000026464	NCT00002646_4_T0	PHENOTYPE	12	12	recurrence
NCT000026464	NCT00002646_4_T1	COMPOUND	3	3	fenretinide
NCT000026464	NCT00002646_4_T2	PHENOTYPE	14	15	breast cancer
NCT000026465	NCT00002646_5_T0	COMPOUND	8	8	fenretinide
NCT000026465	NCT00002646_5_T1	COMPOUND	6	6	tamoxifen
NCT000026465	NCT00002646_5_T2	COMPOUND	13	13	tamoxifen
NCT000026465	NCT00002646_5_T3	PHENOTYPE	16	17	breast cancer
NCT000026466	NCT00002646_6_T0	GENE	23	23	II
NCT000026466	NCT00002646_6_T1	GENE	3	3	III
NCT000026466	NCT00002646_6_T2	COMPOUND	12	12	fenretinide
NCT000026466	NCT00002646_6_T3	COMPOUND	10	10	tamoxifen
NCT000026466	NCT00002646_6_T4	COMPOUND	14	14	tamoxifen
NCT000026466	NCT00002646_6_T5	PHENOTYPE	31	33	estrogen receptor positive
NCT000026466	NCT00002646_6_T6	PHENOTYPE	35	37	progesterone receptor positive
NCT000026466	NCT00002646_6_T7	PHENOTYPE	25	28	stage III breast cancer
NCT000026468	NCT00002646_8_T0	GENE	12	12	II
NCT000026468	NCT00002646_8_T1	GENE	23	23	HPR
NCT000026468	NCT00002646_8_T2	COMPOUND	22	22	fenretinide
NCT000026468	NCT00002646_8_T3	COMPOUND	19	19	tamoxifen
NCT000026468	NCT00002646_8_T4	GENE	20	20	TMX
NCT000026468	NCT00002646_8_T5	GENE	25	25	TMX
NCT000026468	NCT00002646_8_T6	PHENOTYPE	15	16	breast cancer
NCT0000264610	NCT00002646_10_T0	PHENOTYPE	7	7	toxicity
NCT0000264612	NCT00002646_12_T0	PHENOTYPE	1	1	tumor
NCT0000264614	NCT00002646_14_T0	GENE	24	24	1.3
NCT0000264614	NCT00002646_14_T1	GENE	34	34	1.5
NCT0000264615	NCT00002646_15_T0	COMPOUND	4	4	tamoxifen
NCT0000264616	NCT00002646_16_T0	COMPOUND	5	5	fenretinide
NCT000026472	NCT00002647_2_T0	PHENOTYPE	30	30	medulloblastoma
NCT000026472	NCT00002647_2_T1	PHENOTYPE	28	28	ependymoma
NCT000026472	NCT00002647_2_T2	PHENOTYPE	27	27	astrocytoma
NCT000026472	NCT00002647_2_T3	COMPOUND	17	18	porfimer sodium
NCT000026472	NCT00002647_2_T4	PHENOTYPE	24	25	brain tumors
NCT000026475	NCT00002647_5_T0	PHENOTYPE	5	5	tumor
NCT000026475	NCT00002647_5_T1	PHENOTYPE	13	14	brain tumors
NCT000026475	NCT00002647_5_T2	PHENOTYPE	7	9	posterior fossa tumors
NCT000026476	NCT00002647_6_T0	COMPOUND	2	2	benzoporphyrin
NCT000026476	NCT00002647_6_T1	COMPOUND	6	6	BPD-MA
NCT000026476	NCT00002647_6_T2	GENE	7	7	IV
NCT000026477	NCT00002647_7_T0	PHENOTYPE	13	13	tumor
NCT000026477	NCT00002647_7_T1	COMPOUND	4	4	BPD-MA
NCT000026478	NCT00002647_8_T0	PHENOTYPE	2	2	tumors
NCT000026478	NCT00002647_8_T1	PHENOTYPE	12	12	tumor
NCT000026478	NCT00002647_8_T2	GENE	6	6	cm
NCT000026479	NCT00002647_9_T0	COMPOUND	8	8	BPD-MA
NCT000026479	NCT00002647_9_T1	GENE	14	14	MTD
NCT0000264710	NCT00002647_10_T0	PHENOTYPE	22	22	toxicity
NCT0000264710	NCT00002647_10_T1	GENE	1	1	MTD
NCT0000264711	NCT00002647_11_T0	GENE	7	7	MTD
NCT000026491	NCT00002649_1_T0	CELL	12	12	cells
NCT000026491	NCT00002649_1_T1	GENE	0	0	Interleukin-2
NCT000026491	NCT00002649_1_T2	PHENOTYPE	10	11	Hodgkin's lymphoma
NCT000026491	NCT00002649_1_T3	CELL	5	7	white blood cells
NCT000026493	NCT00002649_3_T0	GENE	17	17	interleukin-2
NCT000026493	NCT00002649_3_T1	GENE	18	18	IL-2
NCT000026493	NCT00002649_3_T2	ORGAN	14	14	transplant
NCT000026493	NCT00002649_3_T3	PHENOTYPE	10	11	Hodgkin's lymphoma
NCT000026496	NCT00002649_6_T0	PHENOTYPE	7	7	toxicity
NCT000026496	NCT00002649_6_T1	PHENOTYPE	5	5	severity
NCT000026496	NCT00002649_6_T2	GENE	11	11	IL-2
NCT000026496	NCT00002649_6_T3	ORGAN	10	10	transplant
NCT000026499	NCT00002649_9_T0	CELL	3	6	peripheral blood stem cells
NCT0000264910	NCT00002649_10_T0	COMPOUND	30	30	2
NCT0000264910	NCT00002649_10_T1	COMPOUND	23	23	cyclophosphamide
NCT0000264910	NCT00002649_10_T2	COMPOUND	14	14	etoposide
NCT0000264910	NCT00002649_10_T3	GENE	15	15	IV
NCT0000264910	NCT00002649_10_T4	GENE	24	24	IV
NCT0000264911	NCT00002649_11_T0	GENE	8	8	filgrastim
NCT0000264911	NCT00002649_11_T1	GENE	18	18	0.21
NCT0000264911	NCT00002649_11_T2	GENE	9	9	G-CSF
NCT0000264911	NCT00002649_11_T3	GENE	15	15	IV
NCT000026501	NCT00002650_1_T0	PHENOTYPE	17	17	polyps
NCT000026501	NCT00002650_1_T1	PHENOTYPE	12	13	colorectal cancer
NCT000026501	NCT00002650_1_T2	COMPOUND	3	4	folic acid
NCT000026502	NCT00002650_2_T0	GENE	3	3	II
NCT000026502	NCT00002650_2_T1	PHENOTYPE	22	22	polyps
NCT000026502	NCT00002650_2_T2	GENE	21	21	had
NCT000026502	NCT00002650_2_T3	PHENOTYPE	15	16	colorectal cancer
NCT000026502	NCT00002650_2_T4	COMPOUND	11	12	folic acid
NCT000026504	NCT00002650_4_T0	PHENOTYPE	23	23	adenomas
NCT000026504	NCT00002650_4_T1	TISSUE	18	18	epithelium
NCT000026504	NCT00002650_4_T2	COMPOUND	3	4	folic acid
NCT000026504	NCT00002650_4_T3	BIOLOGICAL_PROCESS	7	8	DNA hypomethylation
NCT000026508	NCT00002650_8_T0	PHENOTYPE	7	7	adenomas
NCT000026508	NCT00002650_8_T1	TISSUE	15	15	mucosa
NCT000026508	NCT00002650_8_T2	BIOLOGICAL_PROCESS	10	11	DNA hypomethylation
NCT0000265010	NCT00002650_10_T0	PHENOTYPE	13	13	recurrence
NCT0000265010	NCT00002650_10_T1	PHENOTYPE	15	16	adenomatous polyps
NCT0000265010	NCT00002650_10_T2	COMPOUND	4	5	folic acid
NCT0000265012	NCT00002650_12_T0	PHENOTYPE	11	11	hyperplastic
NCT0000265016	NCT00002650_16_T0	PHENOTYPE	6	6	hyperplastic
NCT0000265016	NCT00002650_16_T1	PHENOTYPE	8	9	inflammatory polyps
NCT0000265112	NCT00002651_12_T0	PHENOTYPE	0	2	Quality of life
NCT000026521	NCT00002652_1_T0	GENE	2	2	II
NCT000026521	NCT00002652_1_T1	COMPOUND	9	9	suramin
NCT000026521	NCT00002652_1_T2	PHENOTYPE	18	19	multiple myeloma
NCT000026521	NCT00002652_1_T3	PHENOTYPE	21	22	Castleman's disease
NCT000026523	NCT00002652_3_T0	COMPOUND	17	17	suramin
NCT000026523	NCT00002652_3_T1	PHENOTYPE	2	2	tumor
NCT000026523	NCT00002652_3_T2	PHENOTYPE	10	11	multiple myeloma
NCT000026523	NCT00002652_3_T3	PHENOTYPE	13	14	Castleman's disease
NCT000026525	NCT00002652_5_T0	PHENOTYPE	8	8	symptoms
NCT000026525	NCT00002652_5_T1	PHENOTYPE	12	13	Castleman's disease
NCT000026527	NCT00002652_7_T0	PHENOTYPE	9	10	multiple myeloma
NCT000026529	NCT00002652_9_T0	PHENOTYPE	6	6	toxic
NCT0000265211	NCT00002652_11_T0	GENE	11	11	interleukin-6
NCT0000265211	NCT00002652_11_T1	GENE	15	15	receptor
NCT0000265211	NCT00002652_11_T2	GENE	12	12	IL-6
NCT0000265211	NCT00002652_11_T3	GENE	14	14	IL-6
NCT0000265211	NCT00002652_11_T4	GENE	18	18	gp130
NCT0000265211	NCT00002652_11_T5	ORGAN	10	10	serum
NCT0000265212	NCT00002652_12_T0	COMPOUND	3	3	suramin
NCT0000265212	NCT00002652_12_T1	GENE	6	6	1.5
NCT0000265213	NCT00002652_13_T0	COMPOUND	6	6	suramin
NCT0000265214	NCT00002652_14_T0	GENE	3	3	IV
NCT0000265216	NCT00002652_16_T0	PHENOTYPE	18	18	toxicity
NCT0000265218	NCT00002652_18_T0	PHENOTYPE	8	9	multiple myeloma
NCT0000265219	NCT00002652_19_T0	PHENOTYPE	6	7	Castleman's disease
NCT000026531	NCT00002653_1_T0	CELL	9	9	cells
NCT000026531	NCT00002653_1_T1	PHENOTYPE	8	8	tumor
NCT000026532	NCT00002653_2_T0	PHENOTYPE	17	18	multiple myeloma
NCT000026533	NCT00002653_3_T0	GENE	3	3	III
NCT000026533	NCT00002653_3_T1	COMPOUND	15	15	cyclophosphamide
NCT000026533	NCT00002653_3_T2	COMPOUND	17	17	prednisone
NCT000026533	NCT00002653_3_T3	PHENOTYPE	23	24	multiple myeloma
NCT000026538	NCT00002653_8_T0	PHENOTYPE	16	16	toxicity
NCT000026538	NCT00002653_8_T1	PHENOTYPE	12	13	disease progression
NCT0000265313	NCT00002653_13_T0	GENE	7	7	MRC
NCT0000265313	NCT00002653_13_T1	COMPOUND	10	11	interferon alfa_2b
NCT000026540	NCT00002654_0_T0	PHENOTYPE	11	14	Head and Neck Cancer
NCT000026542	NCT00002654_2_T0	CELL	10	10	cells
NCT000026542	NCT00002654_2_T1	PHENOTYPE	9	9	tumor
NCT000026543	NCT00002654_3_T0	PHENOTYPE	22	25	head and neck cancer
NCT000026544	NCT00002654_4_T0	GENE	3	3	III
NCT000026544	NCT00002654_4_T1	COMPOUND	13	13	cisplatin
NCT000026544	NCT00002654_4_T2	PHENOTYPE	23	26	head and neck cancer
NCT000026548	NCT00002654_8_T0	PHENOTYPE	10	10	toxicity
NCT000026548	NCT00002654_8_T1	PHENOTYPE	6	6	relapse
NCT0000265413	NCT00002654_13_T0	PHENOTYPE	2	2	tumor
NCT0000265413	NCT00002654_13_T1	ORGAN	22	23	oral cavity
NCT0000265413	NCT00002654_13_T2	PHENOTYPE	44	45	primary tumor
NCT000026551	NCT00002655_1_T0	PHENOTYPE	19	20	liver metastases
NCT000026551	NCT00002655_1_T1	PHENOTYPE	15	17	primary liver cancer
NCT000026553	NCT00002655_3_T0	PHENOTYPE	8	10	necrosis of liver
NCT000026557	NCT00002655_7_T0	PHENOTYPE	8	8	recurrence
NCT000026557	NCT00002655_7_T1	PHENOTYPE	11	12	malignant disease
NCT000026559	NCT00002655_9_T0	PHENOTYPE	4	4	tumor
NCT000026567	NCT00002656_7_T0	PHENOTYPE	5	5	toxicities
NCT000026569	NCT00002656_9_T0	PHENOTYPE	7	7	NSCLC
NCT000026572	NCT00002657_2_T0	GENE	2	2	II
NCT000026572	NCT00002657_2_T1	PHENOTYPE	10	10	immunosuppression
NCT000026572	NCT00002657_2_T2	GENE	13	13	interferon
NCT000026572	NCT00002657_2_T3	PHENOTYPE	23	24	malignant tumors
NCT000026572	NCT00002657_2_T4	ORGAN	28	29	organ transplant
NCT000026574	NCT00002657_4_T0	COMPOUND	43	43	cytarabine
NCT000026574	NCT00002657_4_T1	COMPOUND	44	44	bleomycin
NCT000026574	NCT00002657_4_T2	COMPOUND	45	45	vincristine
NCT000026574	NCT00002657_4_T3	PHENOTYPE	22	22	immunosuppression
NCT000026574	NCT00002657_4_T4	COMPOUND	46	46	methotrexate
NCT000026574	NCT00002657_4_T5	GENE	34	34	interferon
NCT000026574	NCT00002657_4_T6	PHENOTYPE	3	3	remission
NCT000026574	NCT00002657_4_T7	COMPOUND	39	39	cyclophosphamide
NCT000026574	NCT00002657_4_T8	GENE	10	10	lymphoproliferation
NCT000026574	NCT00002657_4_T9	COMPOUND	41	41	etoposide
NCT000026574	NCT00002657_4_T10	COMPOUND	40	40	doxorubicin
NCT000026574	NCT00002657_4_T11	COMPOUND	42	42	prednisone
NCT000026576	NCT00002657_6_T0	GENE	5	5	interferon
NCT000026577	NCT00002657_7_T0	GENE	7	7	reduced
NCT000026577	NCT00002657_7_T1	GENE	0	1	Group 1
NCT000026578	NCT00002657_8_T0	COMPOUND	1	1	2
NCT000026578	NCT00002657_8_T1	GENE	4	4	reduced
NCT0000265712	NCT00002657_12_T0	GENE	6	6	IFNA
NCT0000265712	NCT00002657_12_T1	GENE	12	12	1.28
NCT0000265712	NCT00002657_12_T2	GENE	0	0	Interferon
NCT0000265712	NCT00002657_12_T3	GENE	4	4	interferon
NCT0000265713	NCT00002657_13_T0	GENE	6	6	IFNA
NCT0000265715	NCT00002657_15_T0	COMPOUND	21	21	cytarabine
NCT0000265715	NCT00002657_15_T1	COMPOUND	23	23	bleomycin
NCT0000265715	NCT00002657_15_T2	COMPOUND	25	25	vincristine
NCT0000265715	NCT00002657_15_T3	COMPOUND	2	2	cyclophosphamide
NCT0000265715	NCT00002657_15_T4	COMPOUND	28	28	methotrexate
NCT0000265715	NCT00002657_15_T5	COMPOUND	7	7	etoposide
NCT0000265715	NCT00002657_15_T6	COMPOUND	4	4	doxorubicin
NCT0000265715	NCT00002657_15_T7	COMPOUND	16	16	prednisone
NCT0000265715	NCT00002657_15_T8	GENE	3	3	IV
NCT0000265715	NCT00002657_15_T9	GENE	5	5	IV
NCT0000265715	NCT00002657_15_T10	GENE	8	8	IV
NCT0000265715	NCT00002657_15_T11	GENE	22	22	IV
NCT0000265715	NCT00002657_15_T12	GENE	24	24	IV
NCT0000265715	NCT00002657_15_T13	GENE	26	26	IV
NCT0000265715	NCT00002657_15_T14	GENE	29	29	IV
NCT0000265717	NCT00002657_17_T0	COMPOUND	9	9	cytarabine
NCT0000265717	NCT00002657_17_T1	GENE	3	3	CSF
NCT0000265717	NCT00002657_17_T2	COMPOUND	7	7	methotrexate
NCT0000265720	NCT00002657_20_T0	GENE	14	14	4.5
NCT000026581	NCT00002658_1_T0	CELL	13	13	cells
NCT000026581	NCT00002658_1_T1	ORGAN	8	9	immune system
NCT000026582	NCT00002658_2_T0	CELL	21	21	cells
NCT000026582	NCT00002658_2_T1	ORGAN	3	4	bone marrow
NCT000026586	NCT00002658_6_T0	PHENOTYPE	21	21	secondary
NCT000026586	NCT00002658_6_T1	GENE	18	18	de
NCT000026589	NCT00002658_9_T0	GENE	9	9	CSF
NCT000026589	NCT00002658_9_T1	GENE	7	7	filgrastim
NCT000026589	NCT00002658_9_T2	PHENOTYPE	30	30	closed
NCT000026589	NCT00002658_9_T3	GENE	28	28	G-CSF
NCT0000265812	NCT00002658_12_T0	PHENOTYPE	14	14	remission
NCT0000265812	NCT00002658_12_T1	GENE	30	30	MRC
NCT0000265812	NCT00002658_12_T2	GENE	15	15	CR
NCT0000265813	NCT00002658_13_T0	GENE	3	3	CR
NCT0000265814	NCT00002658_14_T0	GENE	3	3	CR
NCT000026590	NCT00002659_0_T0	PHENOTYPE	7	7	Recurrent
NCT000026590	NCT00002659_0_T1	PHENOTYPE	10	13	Head and Neck Cancer
NCT000026592	NCT00002659_2_T0	CELL	9	9	cells
NCT000026592	NCT00002659_2_T1	PHENOTYPE	8	8	tumor
NCT000026593	NCT00002659_3_T0	COMPOUND	10	10	epinephrine
NCT000026593	NCT00002659_3_T1	COMPOUND	8	8	cisplatin
NCT000026593	NCT00002659_3_T2	PHENOTYPE	14	17	head and neck cancer
NCT000026594	NCT00002659_4_T0	GENE	4	4	III
NCT000026594	NCT00002659_4_T1	COMPOUND	13	13	epinephrine
NCT000026594	NCT00002659_4_T2	GENE	16	16	gel
NCT000026594	NCT00002659_4_T3	COMPOUND	11	11	cisplatin
NCT000026594	NCT00002659_4_T4	PHENOTYPE	23	23	recurrent
NCT000026594	NCT00002659_4_T5	PHENOTYPE	26	29	head and neck cancer
NCT0000265912	NCT00002659_12_T0	PHENOTYPE	13	13	tumor
NCT0000265912	NCT00002659_12_T1	PHENOTYPE	8	8	progression
NCT0000265912	NCT00002659_12_T2	GENE	22	22	gel
NCT0000265914	NCT00002659_14_T0	PHENOTYPE	7	9	quality of life
NCT0000265920	NCT00002659_20_T0	GENE	9	9	MP
NCT0000265920	NCT00002659_20_T1	GENE	7	7	collagen
NCT0000265920	NCT00002659_20_T2	GENE	8	8	gel
NCT0000265922	NCT00002659_22_T0	GENE	0	0	NS
NCT0000265922	NCT00002659_22_T1	GENE	4	4	collagen
NCT0000265922	NCT00002659_22_T2	GENE	5	5	gel
NCT000026621	NCT00002662_1_T0	COMPOUND	6	6	paclitaxel
NCT000026621	NCT00002662_1_T1	COMPOUND	11	11	docetaxel
NCT000026621	NCT00002662_1_T2	PHENOTYPE	13	14	breast cancer
NCT000026622	NCT00002662_2_T0	COMPOUND	10	10	paclitaxel
NCT000026622	NCT00002662_2_T1	COMPOUND	12	12	docetaxel
NCT000026622	NCT00002662_2_T2	GENE	3	3	III
NCT000026622	NCT00002662_2_T3	PHENOTYPE	20	22	metastatic breast cancer
NCT000026627	NCT00002662_7_T0	PHENOTYPE	13	13	toxicity
NCT000026627	NCT00002662_7_T1	PHENOTYPE	9	10	disease progression
NCT000026628	NCT00002662_8_T0	PHENOTYPE	0	2	Quality of life
NCT000026630	NCT00002663_0_T0	PHENOTYPE	13	13	Malignancies
NCT000026630	NCT00002663_0_T1	PHENOTYPE	9	9	Lymphoma
NCT000026630	NCT00002663_0_T2	PHENOTYPE	10	11	Lymphoproliferative Disease
NCT000026634	NCT00002663_4_T0	ORGAN	14	14	marrow
NCT000026634	NCT00002663_4_T1	PHENOTYPE	7	7	lymphomas
NCT000026634	NCT00002663_4_T2	ORGAN	15	15	transplant
NCT000026634	NCT00002663_4_T3	PHENOTYPE	9	10	lymphoproliferative disorders
NCT000026636	NCT00002663_6_T0	PHENOTYPE	7	7	lymphomas
NCT000026636	NCT00002663_6_T1	PHENOTYPE	9	10	lymphoproliferative disorders
NCT000026636	NCT00002663_6_T2	ORGAN	14	15	organ transplant
NCT0000266310	NCT00002663_10_T0	PHENOTYPE	12	12	profound
NCT0000266310	NCT00002663_10_T1	PHENOTYPE	13	13	immunodeficiencies
NCT0000266310	NCT00002663_10_T2	PHENOTYPE	4	4	lymphomas
NCT0000266310	NCT00002663_10_T3	PHENOTYPE	7	7	diseases
NCT0000266312	NCT00002663_12_T0	PHENOTYPE	25	25	leiomyosarcoma
NCT0000266312	NCT00002663_12_T1	PHENOTYPE	5	5	malignancies
NCT0000266312	NCT00002663_12_T2	PHENOTYPE	8	9	immune deficiency
NCT0000266312	NCT00002663_12_T3	PHENOTYPE	18	19	nasopharyngeal carcinoma
NCT0000266312	NCT00002663_12_T4	PHENOTYPE	21	22	hemophagocytic lymphohistiocytosis
NCT0000266312	NCT00002663_12_T5	PHENOTYPE	15	16	Hodgkin's disease
NCT000026641	NCT00002664_1_T0	PHENOTYPE	17	17	peripheral
NCT000026641	NCT00002664_1_T1	GENE	4	4	G-CSF
NCT000026641	NCT00002664_1_T2	CELL	11	11	cells
NCT000026641	NCT00002664_1_T3	CELL	29	29	cells
NCT000026641	NCT00002664_1_T4	PHENOTYPE	28	28	tumor
NCT000026641	NCT00002664_1_T5	ORGAN	14	15	bone marrow
NCT000026641	NCT00002664_1_T6	ORGAN	24	25	immune system
NCT000026642	NCT00002664_2_T0	GENE	2	2	II
NCT000026642	NCT00002664_2_T1	GENE	13	13	G-CSF
NCT000026642	NCT00002664_2_T2	GENE	22	22	has
NCT000026642	NCT00002664_2_T3	PHENOTYPE	18	20	metastatic colorectal cancer
NCT000026644	NCT00002664_4_T0	PHENOTYPE	23	24	colorectal cancer
NCT000026644	NCT00002664_4_T1	PHENOTYPE	24	25	cancer metastatic
NCT000026644	NCT00002664_4_T2	GENE	16	19	granulocyte-macrophage colony stimulating factor
NCT000026646	NCT00002664_6_T0	PHENOTYPE	2	2	toxicities
NCT000026648	NCT00002664_8_T0	PHENOTYPE	2	4	quality of life
NCT0000266410	NCT00002664_10_T0	GENE	14	14	GM-CSF
NCT000026651	NCT00002665_1_T0	CELL	21	21	cells
NCT000026651	NCT00002665_1_T1	ORGAN	3	4	bone marrow
NCT000026652	NCT00002665_2_T0	GENE	2	2	II
NCT000026652	NCT00002665_2_T1	ORGAN	14	15	bone marrow
NCT000026652	NCT00002665_2_T2	PHENOTYPE	22	24	acute lymphocytic leukemia
NCT000026656	NCT00002665_6_T0	PHENOTYPE	2	2	toxicity
NCT0000266513	NCT00002665_13_T0	GENE	22	22	2.3
NCT0000266513	NCT00002665_13_T1	GENE	17	17	65
NCT0000266513	NCT00002665_13_T2	ORGAN	29	30	bone marrow
NCT0000266514	NCT00002665_14_T0	COMPOUND	11	11	vincristine
NCT0000266514	NCT00002665_14_T1	GENE	24	24	1.28
NCT0000266514	NCT00002665_14_T2	GENE	30	30	IM
NCT0000266514	NCT00002665_14_T3	GENE	10	10	1.3
NCT0000266514	NCT00002665_14_T4	GENE	26	26	asparaginase
NCT0000266514	NCT00002665_14_T5	COMPOUND	21	21	prednisone
NCT0000266514	NCT00002665_14_T6	GENE	7	7	IV
NCT0000266514	NCT00002665_14_T7	GENE	12	12	IV
NCT0000266514	NCT00002665_14_T8	GENE	27	27	IV
NCT0000266514	NCT00002665_14_T9	COMPOUND	6	6	daunorubicin
NCT0000266515	NCT00002665_15_T0	PHENOTYPE	3	3	leukemia
NCT0000266515	NCT00002665_15_T1	COMPOUND	20	20	vincristine
NCT0000266515	NCT00002665_15_T2	COMPOUND	29	29	prednisone
NCT0000266515	NCT00002665_15_T3	GENE	14	14	IV
NCT0000266515	NCT00002665_15_T4	GENE	21	21	IV
NCT0000266515	NCT00002665_15_T5	COMPOUND	13	13	daunorubicin
NCT0000266516	NCT00002665_16_T0	PHENOTYPE	3	3	leukemia
NCT0000266516	NCT00002665_16_T1	COMPOUND	16	16	methotrexate
NCT0000266516	NCT00002665_16_T2	GENE	18	18	IT
NCT0000266517	NCT00002665_17_T0	COMPOUND	4	4	calcium
NCT0000266517	NCT00002665_17_T1	GENE	16	16	IT
NCT0000266517	NCT00002665_17_T2	COMPOUND	3	3	leucovorin
NCT0000266518	NCT00002665_18_T0	COMPOUND	8	8	methotrexate
NCT0000266518	NCT00002665_18_T1	GENE	9	9	IT
NCT0000266520	NCT00002665_20_T0	GENE	2	2	A1
NCT0000266520	NCT00002665_20_T1	ORGAN	3	4	bone marrow
NCT0000266522	NCT00002665_22_T0	GENE	32	32	IV
NCT0000266522	NCT00002665_22_T1	COMPOUND	16	16	3
NCT0000266522	NCT00002665_22_T2	COMPOUND	38	38	3
NCT0000266522	NCT00002665_22_T3	ORGAN	9	10	bone marrow
NCT0000266523	NCT00002665_23_T0	ORGAN	3	4	bone marrow
NCT0000266524	NCT00002665_24_T0	COMPOUND	24	24	methotrexate
NCT0000266524	NCT00002665_24_T1	ORGAN	9	10	bone marrow
NCT0000266526	NCT00002665_26_T0	COMPOUND	30	30	dexamethasone
NCT0000266526	NCT00002665_26_T1	COMPOUND	10	10	vincristine
NCT0000266526	NCT00002665_26_T2	GENE	33	33	1.28
NCT0000266526	NCT00002665_26_T3	COMPOUND	19	19	doxorubicin
NCT0000266526	NCT00002665_26_T4	GENE	11	11	IV
NCT0000266526	NCT00002665_26_T5	GENE	20	20	IV
NCT0000266527	NCT00002665_27_T0	COMPOUND	18	18	cytarabine
NCT0000266527	NCT00002665_27_T1	COMPOUND	7	7	cyclophosphamide
NCT0000266527	NCT00002665_27_T2	GENE	8	8	IV
NCT0000266527	NCT00002665_27_T3	GENE	19	19	IV
NCT0000266528	NCT00002665_28_T0	COMPOUND	11	11	methotrexate
NCT000026676	NCT00002667_6_T0	PHENOTYPE	11	12	lung cancer
NCT0000266719	NCT00002667_19_T0	PHENOTYPE	4	4	centers
NCT000026692	NCT00002669_2_T0	CELL	11	11	cells
NCT000026692	NCT00002669_2_T1	GENE	0	0	Interleukin-2
NCT000026692	NCT00002669_2_T2	PHENOTYPE	10	10	melanoma
NCT000026692	NCT00002669_2_T3	CELL	5	7	white blood cells
NCT000026693	NCT00002669_3_T0	PHENOTYPE	13	13	melanoma
NCT000026694	NCT00002669_4_T0	GENE	3	3	II
NCT000026694	NCT00002669_4_T1	GENE	19	19	interleukin-2
NCT000026694	NCT00002669_4_T2	GENE	16	16	interferon
NCT000026694	NCT00002669_4_T3	PHENOTYPE	25	26	metastatic melanoma
NCT000026699	NCT00002669_9_T0	GENE	11	11	interleukin-2
NCT000026699	NCT00002669_9_T1	GENE	9	9	1.5
NCT000026699	NCT00002669_9_T2	GENE	3	3	interferon
NCT000026699	NCT00002669_9_T3	GENE	14	14	IV
NCT000026701	NCT00002670_1_T0	CELL	10	10	cells
NCT000026701	NCT00002670_1_T1	PHENOTYPE	9	9	tumor
NCT000026702	NCT00002670_2_T0	COMPOUND	9	9	cisplatin
NCT000026702	NCT00002670_2_T1	PHENOTYPE	21	24	head and neck cancer
NCT000026703	NCT00002670_3_T0	GENE	3	3	III
NCT000026703	NCT00002670_3_T1	GENE	27	27	has
NCT000026703	NCT00002670_3_T2	COMPOUND	13	13	cisplatin
NCT000026703	NCT00002670_3_T3	PHENOTYPE	22	25	head and neck cancer
NCT000026707	NCT00002670_7_T0	PHENOTYPE	2	2	toxicity
NCT0000267010	NCT00002670_10_T0	GENE	4	4	1/6
NCT000026711	NCT00002671_1_T0	GENE	2	2	II
NCT000026711	NCT00002671_1_T1	GENE	21	21	has
NCT000026711	NCT00002671_1_T2	PHENOTYPE	14	14	recurrent
NCT000026711	NCT00002671_1_T3	PHENOTYPE	17	19	epithelial ovarian cancer
NCT000026713	NCT00002671_3_T0	PHENOTYPE	9	9	recurrent
NCT000026713	NCT00002671_3_T1	PHENOTYPE	12	14	ovarian epithelial cancer
NCT000026715	NCT00002671_5_T0	PHENOTYPE	2	2	toxic
NCT000026717	NCT00002671_7_T0	PHENOTYPE	10	10	tumors
NCT000026719	NCT00002671_9_T0	GENE	0	0	The
NCT000026719	NCT00002671_9_T1	GENE	16	16	1.3
NCT000026719	NCT00002671_9_T2	PHENOTYPE	4	4	closed
NCT000026719	NCT00002671_9_T3	GENE	12	12	IV
NCT000026719	NCT00002671_9_T4	PHENOTYPE	1	2	measurable disease
NCT0000267110	NCT00002671_10_T0	PHENOTYPE	13	13	toxicity
NCT0000267110	NCT00002671_10_T1	PHENOTYPE	9	10	disease progression
NCT0000267111	NCT00002671_11_T0	GENE	5	5	CR
NCT0000267111	NCT00002671_11_T1	GENE	11	11	CR
NCT000026737	NCT00002673_7_T0	ORGAN	0	1	Bone marrow
NCT000026741	NCT00002674_1_T0	CELL	9	9	cells
NCT000026741	NCT00002674_1_T1	CELL	19	19	cells
NCT000026741	NCT00002674_1_T2	ORGAN	0	1	Bone marrow
NCT000026746	NCT00002674_6_T0	PHENOTYPE	2	2	toxicity
NCT0000267411	NCT00002674_11_T0	GENE	9	9	DHAD
NCT0000267411	NCT00002674_11_T1	GENE	12	12	G-CSF
NCT0000267411	NCT00002674_11_T2	GENE	19	19	HU
NCT0000267411	NCT00002674_11_T3	GENE	13	15	Granulocyte Colony-Stimulating Factor
NCT0000267412	NCT00002674_12_T0	GENE	4	4	G-CSF
NCT0000267412	NCT00002674_12_T1	GENE	0	0	HU
NCT000026751	NCT00002675_1_T0	CELL	9	9	cells
NCT000026751	NCT00002675_1_T1	PHENOTYPE	8	8	tumor
NCT0000267512	NCT00002675_12_T0	PHENOTYPE	2	2	toxicity
NCT0000267514	NCT00002675_14_T0	ORGAN	5	5	eyes
NCT0000267516	NCT00002675_16_T0	GENE	3	3	IV
NCT0000267517	NCT00002675_17_T0	GENE	3	3	2.3
NCT0000267518	NCT00002675_18_T0	GENE	4	4	CR
NCT0000267519	NCT00002675_19_T0	GENE	3	3	CR
NCT0000267520	NCT00002675_20_T0	GENE	5	5	CR
NCT0000267521	NCT00002675_21_T0	GENE	6	6	CR
NCT0000267522	NCT00002675_22_T0	COMPOUND	6	6	vincristine
NCT0000267522	NCT00002675_22_T1	COMPOUND	31	31	cyclophosphamide
NCT0000267522	NCT00002675_22_T2	COMPOUND	22	22	etoposide
NCT0000267522	NCT00002675_22_T3	COMPOUND	14	14	cisplatin
NCT0000267522	NCT00002675_22_T4	GENE	7	7	IV
NCT0000267522	NCT00002675_22_T5	GENE	15	15	IV
NCT0000267522	NCT00002675_22_T6	GENE	23	23	IV
NCT0000267522	NCT00002675_22_T7	GENE	32	32	IV
NCT0000267523	NCT00002675_23_T0	GENE	2	2	filgrastim
NCT0000267523	NCT00002675_23_T1	GENE	3	3	G-CSF
NCT0000267524	NCT00002675_24_T0	GENE	3	3	2.4
NCT0000267524	NCT00002675_24_T1	GENE	9	9	CR
NCT000026761	NCT00002676_1_T0	CELL	8	8	cells
NCT000026761	NCT00002676_1_T1	PHENOTYPE	7	7	tumor
NCT000026762	NCT00002676_2_T0	CELL	9	9	cells
NCT000026762	NCT00002676_2_T1	PHENOTYPE	8	8	tumor
NCT000026762	NCT00002676_2_T2	PHENOTYPE	17	18	Hodgkin's lymphoma
NCT000026763	NCT00002676_3_T0	GENE	2	2	II
NCT000026763	NCT00002676_3_T1	PHENOTYPE	22	23	Hodgkin's lymphoma
NCT000026763	NCT00002676_3_T2	ORGAN	19	21	central nervous system
NCT000026765	NCT00002676_5_T0	COMPOUND	6	6	dexamethasone
NCT000026765	NCT00002676_5_T1	PHENOTYPE	22	22	PCNSL
NCT000026765	NCT00002676_5_T2	PHENOTYPE	20	21	Hodgkin's lymphoma
NCT000026765	NCT00002676_5_T3	ORGAN	17	19	central nervous system
NCT000026767	NCT00002676_7_T0	PHENOTYPE	2	2	toxic
NCT000026769	NCT00002676_9_T0	PHENOTYPE	6	6	PCNSL
NCT000026770	NCT00002677_0_T0	PHENOTYPE	6	7	Prostate Cancer
NCT000026770	NCT00002677_0_T1	PHENOTYPE	10	11	Solid Tumors
NCT000026772	NCT00002677_2_T0	CELL	10	10	cells
NCT000026772	NCT00002677_2_T1	PHENOTYPE	9	9	tumor
NCT000026776	NCT00002677_6_T0	PHENOTYPE	2	2	toxic
NCT000026776	NCT00002677_6_T1	COMPOUND	5	5	tributyrin
NCT000026778	NCT00002677_8_T0	CELL	21	21	cells
NCT000026778	NCT00002677_8_T1	COMPOUND	4	4	tributyrin
NCT000026778	NCT00002677_8_T2	PHENOTYPE	2	2	pharmacodynamics
NCT000026778	NCT00002677_8_T3	PHENOTYPE	8	8	tumor
NCT000026778	NCT00002677_8_T4	PHENOTYPE	13	13	remission
NCT000026778	NCT00002677_8_T5	GENE	25	25	hemoglobin
NCT0000267710	NCT00002677_10_T0	GENE	10	10	half-life
NCT0000267710	NCT00002677_10_T1	COMPOUND	23	23	butyrate
NCT0000267710	NCT00002677_10_T2	COMPOUND	4	4	tributyrin
NCT0000267710	NCT00002677_10_T3	PHENOTYPE	2	2	pharmacokinetics
NCT0000267710	NCT00002677_10_T4	ORGAN	7	7	plasma
NCT0000267712	NCT00002677_12_T0	PHENOTYPE	7	7	toxic
NCT0000267712	NCT00002677_12_T1	COMPOUND	13	13	butyrate
NCT0000267712	NCT00002677_12_T2	PHENOTYPE	5	5	pharmacokinetics
NCT0000267712	NCT00002677_12_T3	PHENOTYPE	10	10	pharmacodynamic
NCT0000267714	NCT00002677_14_T0	PHENOTYPE	23	23	toxicity
NCT0000267714	NCT00002677_14_T1	PHENOTYPE	15	15	concentrations
NCT0000267714	NCT00002677_14_T2	COMPOUND	14	14	butyrate
NCT0000267714	NCT00002677_14_T3	COMPOUND	2	2	tributyrin
NCT0000267714	NCT00002677_14_T4	GENE	22	22	reduced
NCT0000267714	NCT00002677_14_T5	PHENOTYPE	9	9	pharmacodynamic
NCT0000267716	NCT00002677_16_T0	COMPOUND	3	3	tributyrin
NCT0000267717	NCT00002677_17_T0	PHENOTYPE	16	16	toxicity
NCT0000267717	NCT00002677_17_T1	PHENOTYPE	12	13	disease progression
NCT0000267719	NCT00002677_19_T0	COMPOUND	8	8	tributyrin
NCT0000267719	NCT00002677_19_T1	GENE	14	14	MTD
NCT0000267720	NCT00002677_20_T0	PHENOTYPE	17	17	toxicity
NCT0000267720	NCT00002677_20_T1	GENE	1	1	MTD
NCT000026781	NCT00002678_1_T0	CELL	9	9	cells
NCT000026781	NCT00002678_1_T1	PHENOTYPE	8	8	tumor
NCT000026782	NCT00002678_2_T0	PHENOTYPE	16	17	multiple myeloma
NCT000026783	NCT00002678_3_T0	GENE	3	3	III
NCT000026783	NCT00002678_3_T1	PHENOTYPE	18	19	multiple myeloma
NCT0000267812	NCT00002678_12_T0	PHENOTYPE	18	18	toxicity
NCT0000267812	NCT00002678_12_T1	PHENOTYPE	14	15	disease progression
NCT0000267814	NCT00002678_14_T0	PHENOTYPE	4	5	disease progression
NCT0000267815	NCT00002678_15_T0	GENE	12	12	1.3
NCT0000267815	NCT00002678_15_T1	PHENOTYPE	0	2	Quality of life
NCT000026791	NCT00002679_1_T0	CELL	9	9	cells
NCT000026791	NCT00002679_1_T1	PHENOTYPE	8	8	tumor
NCT000026792	NCT00002679_2_T0	GENE	2	2	II
NCT000026792	NCT00002679_2_T1	GENE	20	20	II
NCT000026792	NCT00002679_2_T2	TISSUE	33	34	lymph nodes
NCT000026792	NCT00002679_2_T3	PHENOTYPE	22	25	stage III breast cancer
NCT000026794	NCT00002679_4_T0	COMPOUND	11	11	paclitaxel
NCT000026794	NCT00002679_4_T1	COMPOUND	13	13	cyclophosphamide
NCT000026794	NCT00002679_4_T2	COMPOUND	10	10	doxorubicin
NCT000026794	NCT00002679_4_T3	PHENOTYPE	20	21	breast cancer
NCT000026796	NCT00002679_6_T0	PHENOTYPE	2	2	toxicity
NCT000026797	NCT00002679_7_T0	COMPOUND	14	14	paclitaxel
NCT000026797	NCT00002679_7_T1	COMPOUND	16	16	cyclophosphamide
NCT000026797	NCT00002679_7_T2	COMPOUND	13	13	doxorubicin
NCT000026799	NCT00002679_9_T0	PHENOTYPE	11	11	tumors
NCT0000267910	NCT00002679_10_T0	GENE	8	8	receptor
NCT0000267910	NCT00002679_10_T1	COMPOUND	16	16	tamoxifen
NCT0000267910	NCT00002679_10_T2	GENE	3	4	hormone receptor
NCT000026806	NCT00002680_6_T0	COMPOUND	4	4	cyclophosphamide
NCT000026806	NCT00002680_6_T1	GENE	5	5	IV
NCT000026807	NCT00002680_7_T0	GENE	5	5	SC
NCT000026807	NCT00002680_7_T1	GENE	2	2	filgrastim
NCT000026807	NCT00002680_7_T2	COMPOUND	13	13	cyclophosphamide
NCT000026807	NCT00002680_7_T3	GENE	3	3	G-CSF
NCT000026807	NCT00002680_7_T4	CELL	18	21	peripheral blood stem cells
NCT000026808	NCT00002680_8_T0	PHENOTYPE	8	8	initiation
NCT000026808	NCT00002680_8_T1	COMPOUND	14	14	melphalan
NCT000026808	NCT00002680_8_T2	GENE	15	15	IV
NCT0000268010	NCT00002680_10_T0	GENE	3	3	SC
NCT0000268010	NCT00002680_10_T1	GENE	2	2	G-CSF
NCT0000268011	NCT00002680_11_T0	COMPOUND	14	14	thiotepa
NCT0000268011	NCT00002680_11_T1	PHENOTYPE	8	8	initiation
NCT0000268011	NCT00002680_11_T2	GENE	15	15	IV
NCT0000268013	NCT00002680_13_T0	GENE	3	3	SC
NCT0000268013	NCT00002680_13_T1	GENE	2	2	G-CSF
NCT0000268014	NCT00002680_14_T0	GENE	6	6	G-CSF
NCT0000268015	NCT00002680_15_T0	PHENOTYPE	10	10	tumors
NCT0000268015	NCT00002680_15_T1	COMPOUND	31	31	megestrol
NCT0000268015	NCT00002680_15_T2	COMPOUND	20	20	tamoxifen
NCT0000268015	NCT00002680_15_T3	COMPOUND	28	28	tamoxifen
NCT0000268015	NCT00002680_15_T4	GENE	8	8	hormone
NCT0000268016	NCT00002680_16_T0	GENE	8	8	nodal
NCT000026811	NCT00002681_1_T0	PHENOTYPE	10	10	leukemia
NCT000026811	NCT00002681_1_T1	CELL	13	13	cells
NCT000026811	NCT00002681_1_T2	GENE	0	0	Interleukin-2
NCT000026811	NCT00002681_1_T3	PHENOTYPE	12	12	lymphoma
NCT000026811	NCT00002681_1_T4	CELL	5	7	white blood cells
NCT000026812	NCT00002681_2_T0	PHENOTYPE	10	10	leukemia
NCT000026812	NCT00002681_2_T1	PHENOTYPE	12	12	lymphoma
NCT000026813	NCT00002681_3_T0	PHENOTYPE	19	19	leukemia
NCT000026813	NCT00002681_3_T1	GENE	13	13	interleukin-2
NCT000026813	NCT00002681_3_T2	PHENOTYPE	21	21	lymphoma
NCT000026815	NCT00002681_5_T0	PHENOTYPE	7	8	Hodgkin's lymphoma
NCT000026815	NCT00002681_5_T1	PHENOTYPE	10	12	acute myelogenous leukemia
NCT000026815	NCT00002681_5_T2	PHENOTYPE	14	16	chronic myelogenous leukemia
NCT000026816	NCT00002681_6_T0	GENE	23	23	interleukin-2
NCT000026816	NCT00002681_6_T1	GENE	3	3	TAC
NCT000026816	NCT00002681_6_T2	GENE	6	6	HAT
NCT000026816	NCT00002681_6_T3	GENE	7	7	IV
NCT000026816	NCT00002681_6_T4	GENE	15	15	IV
NCT000026821	NCT00002682_1_T0	PHENOTYPE	9	10	MALT lymphoma
NCT000026821	NCT00002682_1_T1	PHENOTYPE	10	13	lymphoma of the stomach
NCT000026822	NCT00002682_2_T0	GENE	2	2	II
NCT000026822	NCT00002682_2_T1	COMPOUND	12	12	amoxicillin
NCT000026822	NCT00002682_2_T2	COMPOUND	13	13	clarithromycin
NCT000026822	NCT00002682_2_T3	COMPOUND	14	14	tetracycline
NCT000026822	NCT00002682_2_T4	COMPOUND	16	16	metronidazole
NCT000026822	NCT00002682_2_T5	PHENOTYPE	22	23	MALT lymphoma
NCT000026822	NCT00002682_2_T6	PHENOTYPE	23	26	lymphoma of the stomach
NCT000026824	NCT00002682_4_T0	COMPOUND	19	19	amoxicillin
NCT000026824	NCT00002682_4_T1	COMPOUND	29	29	omeprazole
NCT000026824	NCT00002682_4_T2	COMPOUND	20	20	clarithromycin
NCT000026824	NCT00002682_4_T3	COMPOUND	21	21	tetracycline
NCT000026824	NCT00002682_4_T4	COMPOUND	23	23	metronidazole
NCT000026824	NCT00002682_4_T5	TISSUE	7	7	mucosa
NCT000026824	NCT00002682_4_T6	PHENOTYPE	10	10	MALT
NCT000026824	NCT00002682_4_T7	PHENOTYPE	4	5	gastric lymphoma
NCT000026824	NCT00002682_4_T8	COMPOUND	31	32	bismuth subsalicylate
NCT000026824	NCT00002682_4_T9	TISSUE	8	9	lymphoid tissue
NCT000026824	NCT00002682_4_T10	PHENOTYPE	14	16	Helicobacter pylori infection
NCT000026826	NCT00002682_6_T0	PHENOTYPE	4	4	tumor
NCT000026828	NCT00002682_8_T0	PHENOTYPE	11	12	MALT lymphoma
NCT000026829	NCT00002682_9_T0	COMPOUND	25	25	amoxicillin
NCT000026829	NCT00002682_9_T1	COMPOUND	10	10	tetracycline
NCT000026829	NCT00002682_9_T2	COMPOUND	31	31	tetracycline
NCT0000268210	NCT00002682_10_T0	PHENOTYPE	7	7	Inhibition
NCT0000268212	NCT00002682_12_T0	PHENOTYPE	7	7	Inhibition
NCT000026840	NCT00002684_0_T0	PHENOTYPE	6	8	Urinary Tract Cancer
NCT000026842	NCT00002684_2_T0	CELL	15	15	cells
NCT000026842	NCT00002684_2_T1	PHENOTYPE	14	14	tumor
NCT000026843	NCT00002684_3_T0	GENE	3	3	II
NCT000026843	NCT00002684_3_T1	PHENOTYPE	17	19	urinary tract cancer
NCT000026845	NCT00002684_5_T0	COMPOUND	3	3	paclitaxel
NCT000026845	NCT00002684_5_T1	COMPOUND	18	18	ifosfamide
NCT000026845	NCT00002684_5_T2	GENE	25	25	1.3
NCT000026845	NCT00002684_5_T3	COMPOUND	9	9	cisplatin
NCT000026845	NCT00002684_5_T4	GENE	4	4	IV
NCT000026845	NCT00002684_5_T5	GENE	10	10	IV
NCT000026845	NCT00002684_5_T6	GENE	19	19	IV
NCT000026846	NCT00002684_6_T0	GENE	1	1	G-CSF
NCT000026847	NCT00002684_7_T0	PHENOTYPE	17	18	progressive disease
NCT000026871	NCT00002687_1_T0	GENE	9	9	interleukin-2
NCT000026871	NCT00002687_1_T1	PHENOTYPE	15	16	mycosis fungoides
NCT000026874	NCT00002687_4_T0	GENE	2	2	interleukin-2
NCT000026874	NCT00002687_4_T1	GENE	3	3	IL-2
NCT000026874	NCT00002687_4_T2	GENE	10	10	1.3
NCT000026874	NCT00002687_4_T3	GENE	14	14	1.3
NCT000026874	NCT00002687_4_T4	GENE	7	7	1.5
NCT000026876	NCT00002687_6_T0	GENE	8	8	IL-2
NCT000026876	NCT00002687_6_T1	GENE	14	14	MTD
NCT000026877	NCT00002687_7_T0	PHENOTYPE	15	15	toxicity
NCT000026877	NCT00002687_7_T1	GENE	1	1	MTD
NCT000026878	NCT00002687_8_T0	GENE	4	4	IL-2
NCT000026878	NCT00002687_8_T1	GENE	11	11	MTD
NCT000026881	NCT00002688_1_T0	COMPOUND	1	1	cyclosporine
NCT000026881	NCT00002688_1_T1	CELL	14	14	cells
NCT000026884	NCT00002688_4_T0	COMPOUND	5	5	cyclosporine
NCT000026884	NCT00002688_4_T1	PHENOTYPE	30	30	AML
NCT000026884	NCT00002688_4_T2	COMPOUND	8	8	mitoxantrone
NCT000026884	NCT00002688_4_T3	GENE	6	6	CYSP
NCT000026884	NCT00002688_4_T4	GENE	9	9	DHAD
NCT000026884	NCT00002688_4_T5	COMPOUND	11	11	etoposide
NCT000026884	NCT00002688_4_T6	PHENOTYPE	27	29	acute myelogenous leukemia
NCT000026886	NCT00002688_6_T0	GENE	13	13	MDR
NCT000026886	NCT00002688_6_T1	GENE	9	9	P-glycoprotein
NCT000026886	NCT00002688_6_T2	GENE	25	25	CD34
NCT000026886	NCT00002688_6_T3	GENE	10	10	P-gp
NCT000026888	NCT00002688_8_T0	GENE	11	11	atypical
NCT000026888	NCT00002688_8_T1	GENE	12	12	MDR
NCT000026888	NCT00002688_8_T2	GENE	14	14	P-gp
NCT0000268810	NCT00002688_10_T0	PHENOTYPE	2	2	toxicity
NCT0000268810	NCT00002688_10_T1	PHENOTYPE	7	7	AML
NCT0000268812	NCT00002688_12_T0	GENE	6	6	DHAD
NCT0000268812	NCT00002688_12_T1	PHENOTYPE	9	9	pharmacokinetics
NCT0000268812	NCT00002688_12_T2	BIOLOGICAL_PROCESS	11	11	metabolism
NCT0000268812	NCT00002688_12_T3	GENE	4	4	CYSP
NCT0000268812	NCT00002688_12_T4	PHENOTYPE	16	17	drug accumulation
NCT0000268815	NCT00002688_15_T0	GENE	0	0	DHAD
NCT0000268817	NCT00002688_17_T0	GENE	0	0	DHAD
NCT0000268817	NCT00002688_17_T1	GENE	3	3	CYSP
NCT000026891	NCT00002689_1_T0	CELL	10	10	cells
NCT000026891	NCT00002689_1_T1	PHENOTYPE	9	9	tumor
NCT000026892	NCT00002689_2_T0	CELL	9	9	cells
NCT000026892	NCT00002689_2_T1	PHENOTYPE	8	8	tumor
NCT000026893	NCT00002689_3_T0	GENE	2	2	II
NCT000026893	NCT00002689_3_T1	PHENOTYPE	22	23	pancreatic cancer
NCT000026896	NCT00002689_6_T0	COMPOUND	2	2	dexamethasone
NCT000026896	NCT00002689_6_T1	GENE	6	6	albumin
NCT000026896	NCT00002689_6_T2	GENE	10	10	P32
NCT000026896	NCT00002689_6_T3	COMPOUND	9	9	phosphorus
NCT000026899	NCT00002689_9_T0	GENE	8	8	6.4
NCT0000268910	NCT00002689_10_T0	GENE	1	1	IV
NCT000026911	NCT00002691_1_T0	CELL	15	15	cells
NCT000026911	NCT00002691_1_T1	PHENOTYPE	14	14	tumor
NCT000026912	NCT00002691_2_T0	GENE	2	2	II
NCT000026912	NCT00002691_2_T1	GENE	20	20	IV
NCT000026912	NCT00002691_2_T2	PHENOTYPE	16	17	stage III
NCT000026912	NCT00002691_2_T3	PHENOTYPE	21	22	Hodgkin's lymphoma
NCT000026916	NCT00002691_6_T0	GENE	19	19	1.5
NCT000026916	NCT00002691_6_T1	COMPOUND	4	4	cyclophosphamide
NCT000026918	NCT00002691_8_T0	PHENOTYPE	31	31	relapse
NCT000026918	NCT00002691_8_T1	PHENOTYPE	3	3	remission
NCT000026918	NCT00002691_8_T2	COMPOUND	22	22	methotrexate
NCT000026918	NCT00002691_8_T3	ORGAN	28	30	central nervous system
NCT0000269114	NCT00002691_14_T0	GENE	9	9	II
NCT0000269114	NCT00002691_14_T1	GENE	23	23	MTX
NCT0000269114	NCT00002691_14_T2	GENE	4	4	IT
NCT0000269114	NCT00002691_14_T3	GENE	22	22	IT
NCT0000269114	NCT00002691_14_T4	CELL	17	17	T-cell
NCT0000269114	NCT00002691_14_T5	GENE	12	12	ASP
NCT0000269115	NCT00002691_15_T0	COMPOUND	1	1	2
NCT0000269115	NCT00002691_15_T1	COMPOUND	12	12	2
NCT0000269115	NCT00002691_15_T2	PHENOTYPE	0	0	Consolidation
NCT0000269116	NCT00002691_16_T0	GENE	18	18	II
NCT0000269116	NCT00002691_16_T1	CELL	11	11	T-cell
NCT0000269116	NCT00002691_16_T2	CELL	25	25	T-cell
NCT0000269116	NCT00002691_16_T3	GENE	6	6	ASP
NCT0000269119	NCT00002691_19_T0	GENE	11	11	II
NCT0000269119	NCT00002691_19_T1	GENE	2	2	MTX
NCT0000269119	NCT00002691_19_T2	GENE	7	7	MTX
NCT0000269119	NCT00002691_19_T3	GENE	16	16	III
NCT0000269119	NCT00002691_19_T4	GENE	6	6	IT
NCT0000269119	NCT00002691_19_T5	GENE	21	21	IV
NCT0000269121	NCT00002691_21_T0	GENE	13	13	has
NCT000026921	NCT00002692_1_T0	CELL	9	9	cells
NCT000026921	NCT00002692_1_T1	PHENOTYPE	8	8	tumor
NCT000026922	NCT00002692_2_T0	ORGAN	28	28	liver
NCT000026922	NCT00002692_2_T1	GENE	3	3	III
NCT000026922	NCT00002692_2_T2	COMPOUND	18	18	leucovorin
NCT000026922	NCT00002692_2_T3	PHENOTYPE	23	24	colorectal cancer
NCT000026922	NCT00002692_2_T4	PHENOTYPE	24	25	cancer metastatic
NCT000026924	NCT00002692_4_T0	PHENOTYPE	10	11	liver metastases
NCT000026926	NCT00002692_6_T0	PHENOTYPE	8	8	symptoms
NCT000026926	NCT00002692_6_T1	PHENOTYPE	10	12	quality of life
NCT0000269210	NCT00002692_10_T0	COMPOUND	5	5	calcium
NCT0000269215	NCT00002692_15_T0	GENE	10	10	3.4
NCT000026931	NCT00002693_1_T0	CELL	9	9	cells
NCT000026932	NCT00002693_2_T0	PHENOTYPE	23	23	recurrent
NCT000026932	NCT00002693_2_T1	COMPOUND	14	14	topotecan
NCT000026932	NCT00002693_2_T2	PHENOTYPE	24	25	acute leukemia
NCT000026932	NCT00002693_2_T3	PHENOTYPE	19	21	chronic myelogenous leukemia
NCT000026934	NCT00002693_4_T0	COMPOUND	8	8	topotecan
NCT000026936	NCT00002693_6_T0	GENE	4	4	filgrastim
NCT000026936	NCT00002693_6_T1	GENE	5	5	G-CSF
NCT000026937	NCT00002693_7_T0	ORGAN	6	6	marrow
NCT000026938	NCT00002693_8_T0	ORGAN	9	9	marrow
NCT000026939	NCT00002693_9_T0	PHENOTYPE	18	18	toxicity
NCT0000269310	NCT00002693_10_T0	GENE	8	8	G-CSF
NCT0000269311	NCT00002693_11_T0	GENE	2	2	1/6
NCT0000269311	NCT00002693_11_T1	GENE	14	14	MTD
NCT0000269311	NCT00002693_11_T2	COMPOUND	8	8	topotecan
NCT0000269312	NCT00002693_12_T0	PHENOTYPE	20	20	toxicity
NCT0000269312	NCT00002693_12_T1	GENE	1	1	MTD
NCT0000269314	NCT00002693_14_T0	PHENOTYPE	3	3	relapse
NCT0000269314	NCT00002693_14_T1	GENE	5	5	CR
NCT0000269315	NCT00002693_15_T0	ORGAN	13	14	bone marrow
NCT000026955	NCT00002695_5_T0	PHENOTYPE	4	4	tumor
NCT000026955	NCT00002695_5_T1	PHENOTYPE	13	14	neck disease
NCT000026955	NCT00002695_5_T2	PHENOTYPE	21	22	neck disease
NCT000026956	NCT00002695_6_T0	CELL	2	2	cells
NCT000026956	NCT00002695_6_T1	PHENOTYPE	6	7	p53 mutation
NCT0000269510	NCT00002695_10_T0	GENE	13	13	3.5
NCT000026961	NCT00002696_1_T0	CELL	9	9	cells
NCT000026961	NCT00002696_1_T1	PHENOTYPE	8	8	tumor
NCT000026962	NCT00002696_2_T0	GENE	3	3	III
NCT000026962	NCT00002696_2_T1	COMPOUND	13	13	methotrexate
NCT000026962	NCT00002696_2_T2	COMPOUND	7	7	cyclophosphamide
NCT000026962	NCT00002696_2_T3	COMPOUND	12	12	cyclophosphamide
NCT000026962	NCT00002696_2_T4	COMPOUND	8	8	doxorubicin
NCT000026962	NCT00002696_2_T5	PHENOTYPE	20	23	stage III breast cancer
NCT000026967	NCT00002696_7_T0	PHENOTYPE	12	13	disease progression
NCT000026969	NCT00002696_9_T0	PHENOTYPE	12	12	initiation
NCT000026969	NCT00002696_9_T1	PHENOTYPE	4	4	metastasis
NCT0000269611	NCT00002696_11_T0	PHENOTYPE	0	2	Quality of life
NCT0000269612	NCT00002696_12_T0	GENE	4	4	3.4
NCT0000269710	NCT00002697_10_T0	GENE	3	3	SC
NCT0000269710	NCT00002697_10_T1	GENE	2	2	G-CSF
NCT0000269711	NCT00002697_11_T0	GENE	11	11	G-CSF
NCT0000269712	NCT00002697_12_T0	PHENOTYPE	0	2	Quality of life
NCT0000269716	NCT00002697_16_T0	PHENOTYPE	5	6	aggressive lymphoma
NCT0000269716	NCT00002697_16_T1	PHENOTYPE	16	17	high grade
NCT000027001	NCT00002700_1_T0	CELL	9	9	cells
NCT000027001	NCT00002700_1_T1	PHENOTYPE	8	8	tumor
NCT000027003	NCT00002700_3_T0	GENE	3	3	III
NCT000027003	NCT00002700_3_T1	ORGAN	15	16	bone marrow
NCT000027003	NCT00002700_3_T2	PHENOTYPE	22	24	acute lymphoblastic leukemia
NCT0000270011	NCT00002700_11_T0	GENE	10	10	MTX
NCT0000270011	NCT00002700_11_T1	GENE	11	11	IT
NCT0000270012	NCT00002700_12_T0	GENE	13	13	MTX
NCT0000270012	NCT00002700_12_T1	GENE	11	11	IT
NCT0000270012	NCT00002700_12_T2	GENE	14	14	IT
NCT0000270014	NCT00002700_14_T0	GENE	3	3	CR
NCT0000270015	NCT00002700_15_T0	GENE	3	3	CR
NCT0000270015	NCT00002700_15_T1	ORGAN	12	13	bone marrow
NCT0000270019	NCT00002700_19_T0	ORGAN	1	2	bone marrow
NCT0000270020	NCT00002700_20_T0	COMPOUND	18	18	dexamethasone
NCT0000270020	NCT00002700_20_T1	COMPOUND	27	27	prednisolone
NCT0000270020	NCT00002700_20_T2	GENE	29	29	VAP
NCT0000270020	NCT00002700_20_T3	GENE	13	13	VCR
NCT0000270020	NCT00002700_20_T4	GENE	22	22	VCR
NCT0000270020	NCT00002700_20_T5	GENE	32	32	1.4
NCT0000270020	NCT00002700_20_T6	COMPOUND	15	15	doxorubicin
NCT0000270020	NCT00002700_20_T7	COMPOUND	24	24	doxorubicin
NCT0000270020	NCT00002700_20_T8	GENE	14	14	IV
NCT0000270020	NCT00002700_20_T9	GENE	16	16	IV
NCT0000270020	NCT00002700_20_T10	GENE	19	19	IV
NCT0000270020	NCT00002700_20_T11	GENE	23	23	IV
NCT0000270020	NCT00002700_20_T12	GENE	25	25	IV
NCT0000270020	NCT00002700_20_T13	GENE	28	28	IV
NCT0000270021	NCT00002700_21_T0	GENE	10	10	MTX
NCT0000270022	NCT00002700_22_T0	GENE	10	10	MTX
NCT0000270022	NCT00002700_22_T1	GENE	11	11	IT
NCT0000270024	NCT00002700_24_T0	GENE	2	2	MTX
NCT0000270024	NCT00002700_24_T1	GENE	38	38	MTX
NCT0000270024	NCT00002700_24_T2	COMPOUND	11	11	calcium
NCT0000270024	NCT00002700_24_T3	GENE	21	21	asparaginase
NCT0000270024	NCT00002700_24_T4	GENE	20	20	2.4
NCT0000270024	NCT00002700_24_T5	COMPOUND	10	10	leucovorin
NCT0000270024	NCT00002700_24_T6	GENE	3	3	IV
NCT0000270024	NCT00002700_24_T7	GENE	12	12	IV
NCT0000270024	NCT00002700_24_T8	GENE	22	22	IV
NCT0000270026	NCT00002700_26_T0	GENE	14	14	MTX
NCT0000270026	NCT00002700_26_T1	GENE	15	15	IT
NCT000027011	NCT00002701_1_T0	CELL	9	9	cells
NCT000027011	NCT00002701_1_T1	CELL	18	18	cells
NCT000027011	NCT00002701_1_T2	PHENOTYPE	17	17	tumor
NCT000027011	NCT00002701_1_T3	ORGAN	0	1	Bone marrow
NCT000027015	NCT00002701_5_T0	PHENOTYPE	19	19	toxicity
NCT000027015	NCT00002701_5_T1	PHENOTYPE	11	11	remission
NCT000027015	NCT00002701_5_T2	PHENOTYPE	32	32	remission
NCT000027015	NCT00002701_5_T3	GENE	12	12	CR
NCT000027015	NCT00002701_5_T4	PHENOTYPE	21	22	disease progression
NCT000027018	NCT00002701_8_T0	GENE	24	24	HLA-A
NCT000027018	NCT00002701_8_T1	GENE	16	16	CR
NCT000027018	NCT00002701_8_T2	ORGAN	4	5	bone marrow
NCT000027018	NCT00002701_8_T3	PHENOTYPE	29	31	chronic myelomonocytic leukemia
NCT000027019	NCT00002701_9_T0	GENE	13	13	CR
NCT0000270114	NCT00002701_14_T0	PHENOTYPE	14	14	initiation
NCT0000270114	NCT00002701_14_T1	ORGAN	3	4	bone marrow
NCT0000270115	NCT00002701_15_T0	PHENOTYPE	0	2	Quality of life
NCT000027021	NCT00002702_1_T0	CELL	8	8	cells
NCT000027021	NCT00002702_1_T1	PHENOTYPE	7	7	tumor
NCT000027022	NCT00002702_2_T0	GENE	6	6	interleukin-2
NCT000027023	NCT00002702_3_T0	GENE	25	25	interleukin-2
NCT000027023	NCT00002702_3_T1	GENE	4	4	III
NCT000027023	NCT00002702_3_T2	ORGAN	35	35	oropharynx
NCT000027023	NCT00002702_3_T3	PHENOTYPE	30	33	cancer of the mouth
NCT000027026	NCT00002702_6_T0	GENE	13	13	N3
NCT000027026	NCT00002702_6_T1	PHENOTYPE	7	7	tumor
NCT000027026	NCT00002702_6_T2	GENE	9	9	T2
NCT000027026	NCT00002702_6_T3	GENE	12	12	T2
NCT000027028	NCT00002702_8_T0	GENE	6	6	IL-2
NCT000027028	NCT00002702_8_T1	GENE	10	10	en
NCT000027028	NCT00002702_8_T2	PHENOTYPE	15	16	primary tumor
NCT0000270210	NCT00002702_10_T0	GENE	13	13	IL-2
NCT0000270210	NCT00002702_10_T1	GENE	30	30	1.5
NCT000027037	NCT00002703_7_T0	GENE	16	16	Gy
NCT000027037	NCT00002703_7_T1	ORGAN	4	4	bladder
NCT000027039	NCT00002703_9_T0	PHENOTYPE	7	7	blocks
NCT0000270318	NCT00002703_18_T0	GENE	2	2	3.5
NCT000027041	NCT00002704_1_T0	CELL	10	10	cells
NCT000027042	NCT00002704_2_T0	CELL	9	9	cells
NCT000027044	NCT00002704_4_T0	PHENOTYPE	4	4	toxicity
NCT000027044	NCT00002704_4_T1	ORGAN	11	13	central nervous system
NCT000027044	NCT00002704_4_T2	PHENOTYPE	19	21	acute lymphoblastic leukemia
NCT000027046	NCT00002704_6_T0	COMPOUND	5	5	thiotepa
NCT000027048	NCT00002704_8_T0	PHENOTYPE	2	2	toxicity
NCT000027048	NCT00002704_8_T1	COMPOUND	9	9	dexamethasone
NCT000027048	NCT00002704_8_T2	COMPOUND	10	10	vincristine
NCT000027048	NCT00002704_8_T3	COMPOUND	6	6	thiotepa
NCT000027048	NCT00002704_8_T4	COMPOUND	11	11	daunorubicin
NCT0000270410	NCT00002704_10_T0	COMPOUND	8	8	cytarabine
NCT0000270410	NCT00002704_10_T1	PHENOTYPE	21	21	relapse
NCT0000270410	NCT00002704_10_T2	PHENOTYPE	16	16	remission
NCT0000270410	NCT00002704_10_T3	ORGAN	14	15	bone marrow
NCT0000270412	NCT00002704_12_T0	PHENOTYPE	4	4	toxicity
NCT0000270413	NCT00002704_13_T0	PHENOTYPE	11	11	paresis
NCT0000270413	NCT00002704_13_T1	PHENOTYPE	7	7	seizures
NCT0000270413	NCT00002704_13_T2	PHENOTYPE	4	5	neurologic symptoms
NCT0000270413	NCT00002704_13_T3	PHENOTYPE	12	14	mental status changes
NCT0000270413	NCT00002704_13_T4	PHENOTYPE	8	10	cranial nerve palsy
NCT0000270423	NCT00002704_23_T0	GENE	1	1	II
NCT0000270426	NCT00002704_26_T0	ORGAN	12	13	spinal cord
NCT000027051	NCT00002705_1_T0	CELL	10	10	cells
NCT000027053	NCT00002705_3_T0	PHENOTYPE	12	12	toxicity
NCT000027053	NCT00002705_3_T1	PHENOTYPE	14	14	toxicity
NCT000027053	NCT00002705_3_T2	PHENOTYPE	24	24	leukemia
NCT000027053	NCT00002705_3_T3	PHENOTYPE	5	5	toxic
NCT000027053	NCT00002705_3_T4	PHENOTYPE	8	8	acute
NCT000027053	NCT00002705_3_T5	PHENOTYPE	10	10	chronic
NCT000027053	NCT00002705_3_T6	COMPOUND	34	34	topotecan
NCT000027055	NCT00002705_5_T0	PHENOTYPE	14	14	toxicity
NCT000027057	NCT00002705_7_T0	PHENOTYPE	25	25	toxicity
NCT0000270511	NCT00002705_11_T0	GENE	4	4	II
NCT0000270513	NCT00002705_13_T0	PHENOTYPE	23	24	drug accumulation
NCT0000270515	NCT00002705_15_T0	PHENOTYPE	10	10	toxicity
NCT000027062	NCT00002706_2_T0	PHENOTYPE	15	16	endometrial cancer
NCT000027064	NCT00002706_4_T0	GENE	16	16	IIa
NCT000027064	NCT00002706_4_T1	PHENOTYPE	5	5	complications
NCT000027064	NCT00002706_4_T2	GENE	34	34	abdominal
NCT000027064	NCT00002706_4_T3	PHENOTYPE	22	23	uterine cancer
NCT000027064	NCT00002706_4_T4	PHENOTYPE	19	20	endometrial cancer
NCT000027068	NCT00002706_8_T0	PHENOTYPE	2	4	quality of life
NCT0000270610	NCT00002706_10_T0	PHENOTYPE	7	7	recurrence
NCT0000270613	NCT00002706_13_T0	PHENOTYPE	7	7	bilateral
NCT0000270613	NCT00002706_13_T1	GENE	0	0	ARM
NCT0000270614	NCT00002706_14_T0	GENE	1	1	II
NCT0000270614	NCT00002706_14_T1	GENE	5	5	abdominal
NCT0000270614	NCT00002706_14_T2	GENE	0	0	ARM
NCT0000270616	NCT00002706_16_T0	PHENOTYPE	0	2	Quality of life
NCT000027071	NCT00002707_1_T0	COMPOUND	16	16	docetaxel
NCT000027071	NCT00002707_1_T1	PHENOTYPE	23	24	breast cancer
NCT000027072	NCT00002707_2_T0	GENE	25	25	II
NCT000027072	NCT00002707_2_T1	GENE	3	3	III
NCT000027072	NCT00002707_2_T2	COMPOUND	18	18	docetaxel
NCT000027072	NCT00002707_2_T3	COMPOUND	14	14	cyclophosphamide
NCT000027072	NCT00002707_2_T4	COMPOUND	12	12	doxorubicin
NCT000027072	NCT00002707_2_T5	PHENOTYPE	27	30	stage III breast cancer
NCT000027074	NCT00002707_4_T0	COMPOUND	31	31	docetaxel
NCT000027074	NCT00002707_4_T1	COMPOUND	21	21	cyclophosphamide
NCT000027074	NCT00002707_4_T2	COMPOUND	19	19	doxorubicin
NCT000027074	NCT00002707_4_T3	PHENOTYPE	9	12	adenocarcinoma of the breast
NCT000027076	NCT00002707_6_T0	PHENOTYPE	19	19	tumor
NCT0000270712	NCT00002707_12_T0	GENE	17	17	2.1
NCT0000270712	NCT00002707_12_T1	GENE	25	25	4.0
NCT0000270712	NCT00002707_12_T2	PHENOTYPE	13	13	tumor
NCT0000270712	NCT00002707_12_T3	GENE	18	18	cm
NCT0000270712	NCT00002707_12_T4	GENE	21	21	cm
NCT0000270712	NCT00002707_12_T5	GENE	26	26	cm
NCT0000270712	NCT00002707_12_T6	GENE	28	28	nodal
NCT0000270715	NCT00002707_15_T0	COMPOUND	3	3	tamoxifen
NCT0000270719	NCT00002707_19_T0	COMPOUND	3	3	tamoxifen
NCT0000270723	NCT00002707_23_T0	COMPOUND	3	3	tamoxifen
NCT0000270725	NCT00002707_25_T0	COMPOUND	3	3	docetaxel
NCT0000270725	NCT00002707_25_T1	GENE	4	4	IV
NCT0000270726	NCT00002707_26_T0	COMPOUND	2	2	docetaxel
NCT0000270727	NCT00002707_27_T0	PHENOTYPE	17	17	toxicity
NCT0000270727	NCT00002707_27_T1	PHENOTYPE	13	14	disease progression
NCT000027081	NCT00002708_1_T0	PHENOTYPE	20	21	brain metastases
NCT000027082	NCT00002708_2_T0	GENE	3	3	III
NCT000027082	NCT00002708_2_T1	PHENOTYPE	20	21	brain metastases
NCT0000270812	NCT00002708_12_T0	GENE	13	13	4.0
NCT0000270812	NCT00002708_12_T1	GENE	5	5	solitary
NCT0000270812	NCT00002708_12_T2	GENE	14	14	cm
NCT0000270817	NCT00002708_17_T0	GENE	8	8	solitary
NCT0000270817	NCT00002708_17_T1	PHENOTYPE	9	10	brain metastasis
NCT000027111	NCT00002711_1_T0	CELL	8	8	cells
NCT000027111	NCT00002711_1_T1	PHENOTYPE	7	7	tumor
NCT000027112	NCT00002711_2_T0	CELL	9	9	cells
NCT000027112	NCT00002711_2_T1	PHENOTYPE	8	8	tumor
NCT000027113	NCT00002711_3_T0	PHENOTYPE	18	21	cancer of the esophagus
NCT000027115	NCT00002711_5_T0	GENE	9	9	II
NCT000027115	NCT00002711_5_T1	COMPOUND	12	12	paclitaxel
NCT000027115	NCT00002711_5_T2	PHENOTYPE	36	36	localized
NCT000027115	NCT00002711_5_T3	GENE	13	13	TAX
NCT000027115	NCT00002711_5_T4	COMPOUND	28	28	cisplatin
NCT000027115	NCT00002711_5_T5	PHENOTYPE	37	38	esophageal cancer
NCT000027119	NCT00002711_9_T0	PHENOTYPE	2	2	toxic
NCT0000271111	NCT00002711_11_T0	GENE	9	9	CI
NCT0000271111	NCT00002711_11_T1	PHENOTYPE	2	2	pharmacokinetics
NCT0000271111	NCT00002711_11_T2	GENE	4	4	TAX
NCT0000271114	NCT00002711_14_T0	GENE	5	5	TAX
NCT0000271114	NCT00002711_14_T1	GENE	3	3	MTD
NCT0000271115	NCT00002711_15_T0	GENE	11	11	TAX
NCT000027141	NCT00002714_1_T0	CELL	8	8	cells
NCT000027141	NCT00002714_1_T1	PHENOTYPE	7	7	tumor
NCT000027142	NCT00002714_2_T0	CELL	13	13	cells
NCT000027142	NCT00002714_2_T1	PHENOTYPE	12	12	tumor
NCT000027143	NCT00002714_3_T0	GENE	2	2	II
NCT000027143	NCT00002714_3_T1	PHENOTYPE	21	22	Hodgkin's disease
NCT000027145	NCT00002714_5_T0	COMPOUND	23	23	bleomycin
NCT000027145	NCT00002714_5_T1	COMPOUND	22	22	vincristine
NCT000027145	NCT00002714_5_T2	COMPOUND	20	20	vinblastine
NCT000027145	NCT00002714_5_T3	COMPOUND	25	25	etoposide
NCT000027145	NCT00002714_5_T4	COMPOUND	19	19	doxorubicin
NCT000027145	NCT00002714_5_T5	COMPOUND	21	21	prednisone
NCT000027145	NCT00002714_5_T6	COMPOUND	14	15	Stanford V
NCT000027145	NCT00002714_5_T7	PHENOTYPE	36	37	Hodgkin's disease
NCT000027149	NCT00002714_9_T0	PHENOTYPE	16	16	toxicity
NCT000027149	NCT00002714_9_T1	PHENOTYPE	5	6	disease progression
NCT0000271411	NCT00002714_11_T0	PHENOTYPE	2	4	quality of life
NCT0000271412	NCT00002714_12_T0	COMPOUND	42	42	bleomycin
NCT0000271412	NCT00002714_12_T1	COMPOUND	39	39	vincristine
NCT0000271412	NCT00002714_12_T2	GENE	14	14	29
NCT0000271412	NCT00002714_12_T3	GENE	24	24	29
NCT0000271412	NCT00002714_12_T4	GENE	9	9	IV
NCT0000271412	NCT00002714_12_T5	GENE	16	16	IV
NCT0000271412	NCT00002714_12_T6	GENE	19	19	IV
NCT0000271412	NCT00002714_12_T7	GENE	40	40	IV
NCT0000271412	NCT00002714_12_T8	GENE	43	43	IV
NCT0000271412	NCT00002714_12_T9	GENE	53	53	IV
NCT0000271412	NCT00002714_12_T10	COMPOUND	18	18	vinblastine
NCT0000271412	NCT00002714_12_T11	COMPOUND	52	52	etoposide
NCT0000271412	NCT00002714_12_T12	COMPOUND	15	15	doxorubicin
NCT0000271412	NCT00002714_12_T13	GENE	50	50	50
NCT0000271412	NCT00002714_12_T14	COMPOUND	28	28	prednisone
NCT0000271412	NCT00002714_12_T15	GENE	37	37	tapered
NCT0000271412	NCT00002714_12_T16	GENE	26	26	43
NCT0000271412	NCT00002714_12_T17	GENE	58	58	43
NCT0000271412	NCT00002714_12_T18	COMPOUND	4	5	Stanford V
NCT0000271413	NCT00002714_13_T0	GENE	22	22	3.4
NCT0000271414	NCT00002714_14_T0	PHENOTYPE	0	2	Quality of life
NCT000027151	NCT00002715_1_T0	CELL	9	9	cells
NCT000027151	NCT00002715_1_T1	PHENOTYPE	8	8	tumor
NCT000027152	NCT00002715_2_T0	GENE	2	2	II
NCT000027152	NCT00002715_2_T1	PHENOTYPE	17	18	Hodgkin's lymphoma
NCT000027156	NCT00002715_6_T0	ORGAN	4	4	lungs
NCT000027156	NCT00002715_6_T1	TISSUE	5	5	pleura
NCT000027159	NCT00002715_9_T0	GENE	22	22	II
NCT000027161	NCT00002716_1_T0	CELL	9	9	cells
NCT000027162	NCT00002716_2_T0	PHENOTYPE	12	14	metastatic colorectal cancer
NCT000027163	NCT00002716_3_T0	COMPOUND	14	14	dexamethasone
NCT000027163	NCT00002716_3_T1	GENE	3	3	III
NCT000027163	NCT00002716_3_T2	COMPOUND	12	12	leucovorin
NCT000027163	NCT00002716_3_T3	COMPOUND	21	21	leucovorin
NCT000027163	NCT00002716_3_T4	PHENOTYPE	31	32	colorectal cancer
NCT000027163	NCT00002716_3_T5	PHENOTYPE	28	29	liver metastases
NCT000027166	NCT00002716_6_T0	COMPOUND	34	34	calcium
NCT000027166	NCT00002716_6_T1	ORGAN	8	8	liver
NCT000027166	NCT00002716_6_T2	GENE	14	14	MRI
NCT000027166	NCT00002716_6_T3	COMPOUND	40	40	levamisole
NCT000027166	NCT00002716_6_T4	COMPOUND	33	33	leucovorin
NCT000027171	NCT00002717_1_T0	CELL	9	9	cells
NCT000027171	NCT00002717_1_T1	PHENOTYPE	8	8	tumor
NCT000027172	NCT00002717_2_T0	PHENOTYPE	14	15	peritoneal cancer
NCT000027173	NCT00002717_3_T0	COMPOUND	13	13	paclitaxel
NCT000027173	NCT00002717_3_T1	GENE	3	3	III
NCT000027173	NCT00002717_3_T2	COMPOUND	15	15	cisplatin
NCT000027173	NCT00002717_3_T3	PHENOTYPE	27	28	stage III
NCT000027173	NCT00002717_3_T4	PHENOTYPE	21	22	residual disease
NCT000027173	NCT00002717_3_T5	PHENOTYPE	36	37	peritoneal cancer
NCT000027173	NCT00002717_3_T6	PHENOTYPE	30	33	stage IV ovarian cancer
NCT000027175	NCT00002717_5_T0	COMPOUND	35	35	paclitaxel
NCT000027175	NCT00002717_5_T1	PHENOTYPE	1	1	progression
NCT000027175	NCT00002717_5_T2	GENE	36	36	TAX
NCT000027175	NCT00002717_5_T3	GENE	17	17	IV
NCT000027175	NCT00002717_5_T4	COMPOUND	39	39	cisplatin
NCT000027175	NCT00002717_5_T5	PHENOTYPE	14	15	stage III
NCT000027175	NCT00002717_5_T6	PHENOTYPE	23	24	peritoneal cancer
NCT000027175	NCT00002717_5_T7	PHENOTYPE	18	20	ovarian epithelial cancer
NCT000027177	NCT00002717_7_T0	PHENOTYPE	4	4	severity
NCT000027177	NCT00002717_7_T1	GENE	20	20	TAX
NCT000027177	NCT00002717_7_T2	PHENOTYPE	12	13	drug toxicity
NCT000027177	NCT00002717_7_T3	PHENOTYPE	6	7	adverse events
NCT000027177	NCT00002717_7_T4	PHENOTYPE	9	10	catheter complications
NCT000027179	NCT00002717_9_T0	PHENOTYPE	7	7	toxicity
NCT000027179	NCT00002717_9_T1	PHENOTYPE	6	6	concentrations
NCT000027179	NCT00002717_9_T2	GENE	5	5	TAX
NCT000027179	NCT00002717_9_T3	ORGAN	4	4	plasma
NCT0000271711	NCT00002717_11_T0	PHENOTYPE	8	9	measurable disease
NCT0000271716	NCT00002717_16_T0	GENE	14	14	4.5
NCT000027184	NCT00002718_4_T0	CELL	18	18	cells
NCT000027184	NCT00002718_4_T1	GENE	5	5	filgrastim
NCT000027184	NCT00002718_4_T2	GENE	6	6	G-CSF
NCT000027184	NCT00002718_4_T3	GENE	17	17	CD34
NCT000027184	NCT00002718_4_T4	CELL	8	11	peripheral blood stem cells
NCT000027186	NCT00002718_6_T0	GENE	2	2	G-CSF
NCT000027186	NCT00002718_6_T1	GENE	3	3	IV
NCT000027188	NCT00002718_8_T0	PHENOTYPE	2	3	graft failure
NCT000027188	NCT00002718_8_T1	ORGAN	7	8	bone marrow
NCT000027191	NCT00002719_1_T0	PHENOTYPE	18	18	peripheral
NCT000027191	NCT00002719_1_T1	GENE	4	4	G-CSF
NCT000027191	NCT00002719_1_T2	CELL	11	11	cells
NCT000027191	NCT00002719_1_T3	ORGAN	15	16	bone marrow
NCT000027191	NCT00002719_1_T4	ORGAN	25	26	immune system
NCT000027192	NCT00002719_2_T0	CELL	15	15	cells
NCT000027195	NCT00002719_5_T0	PHENOTYPE	23	23	AML
NCT000027195	NCT00002719_5_T1	CELL	4	4	granulocyte
NCT000027195	NCT00002719_5_T2	PHENOTYPE	11	11	remission
NCT000027195	NCT00002719_5_T3	GENE	14	14	MICE
NCT000027195	NCT00002719_5_T4	PHENOTYPE	20	22	acute myelogenous leukemia
NCT000027197	NCT00002719_7_T0	GENE	21	21	mini-ICE
NCT000027197	NCT00002719_7_T1	PHENOTYPE	3	3	remission
NCT000027197	NCT00002719_7_T2	GENE	4	4	CR
NCT0000271913	NCT00002719_13_T0	PHENOTYPE	9	9	Consolidation
NCT0000271913	NCT00002719_13_T1	PHENOTYPE	32	32	Consolidation
NCT0000271913	NCT00002719_13_T2	PHENOTYPE	2	2	centers
NCT0000271913	NCT00002719_13_T3	GENE	5	5	CR
NCT0000271917	NCT00002719_17_T0	GENE	0	0	MICE
NCT0000271917	NCT00002719_17_T1	GENE	2	2	G-CSF
NCT0000271918	NCT00002719_18_T0	GENE	0	0	G-CSF
NCT0000271920	NCT00002719_20_T0	GENE	0	0	MICE
NCT0000271920	NCT00002719_20_T1	GENE	2	2	G-CSF
NCT0000271921	NCT00002719_21_T0	GENE	0	0	G-CSF
NCT0000271923	NCT00002719_23_T0	GENE	0	0	MICE
NCT0000271923	NCT00002719_23_T1	GENE	2	2	G-CSF
NCT0000271924	NCT00002719_24_T0	GENE	0	0	G-CSF
NCT0000271931	NCT00002719_31_T0	CELL	2	3	Stem Cell
NCT0000271931	NCT00002719_31_T1	CELL	12	13	Stem Cell
NCT0000271932	NCT00002719_32_T0	GENE	0	0	G-CSF
NCT0000271933	NCT00002719_33_T0	PHENOTYPE	19	19	Consolidation
NCT0000271934	NCT00002719_34_T0	PHENOTYPE	14	14	closed
NCT000027201	NCT00002720_1_T0	GENE	3	3	III
NCT000027201	NCT00002720_1_T1	TISSUE	15	16	lymph node
NCT000027201	NCT00002720_1_T2	PHENOTYPE	31	33	estrogen receptor positive
NCT000027201	NCT00002720_1_T3	PHENOTYPE	25	28	stage I breast cancer
NCT000027211	NCT00002721_1_T0	CELL	9	9	cells
NCT000027211	NCT00002721_1_T1	PHENOTYPE	8	8	tumor
NCT000027221	NCT00002722_1_T0	CELL	13	13	cells
NCT000027221	NCT00002722_1_T1	PHENOTYPE	12	12	tumor
NCT000027222	NCT00002722_2_T0	GENE	3	3	II
NCT000027222	NCT00002722_2_T1	PHENOTYPE	17	18	stomach cancer
NCT000027224	NCT00002722_4_T0	COMPOUND	19	19	leucovorin
NCT000027224	NCT00002722_4_T1	PHENOTYPE	8	9	gastric cancer
NCT000027226	NCT00002722_6_T0	PHENOTYPE	2	2	toxic
NCT0000272210	NCT00002722_10_T0	COMPOUND	14	14	2
NCT0000272215	NCT00002722_15_T0	PHENOTYPE	16	16	toxicity
NCT0000272215	NCT00002722_15_T1	PHENOTYPE	18	19	disease progression
NCT000027231	NCT00002723_1_T0	CELL	10	10	cells
NCT000027231	NCT00002723_1_T1	PHENOTYPE	9	9	tumor
NCT000027237	NCT00002723_7_T0	PHENOTYPE	2	2	toxic
NCT0000272313	NCT00002723_13_T0	PHENOTYPE	13	13	toxicity
NCT0000272313	NCT00002723_13_T1	PHENOTYPE	3	3	pharmacokinetics
NCT0000272315	NCT00002723_15_T0	PHENOTYPE	2	4	quality of life
NCT0000272321	NCT00002723_21_T0	COMPOUND	19	19	2
NCT0000272321	NCT00002723_21_T1	COMPOUND	27	27	2
NCT0000272321	NCT00002723_21_T2	COMPOUND	29	29	3
NCT0000272326	NCT00002723_26_T0	PHENOTYPE	41	41	toxicity
NCT0000272326	NCT00002723_26_T1	PHENOTYPE	3	3	progression
NCT0000272326	NCT00002723_26_T2	PHENOTYPE	37	38	disease progression
NCT0000272327	NCT00002723_27_T0	PHENOTYPE	0	2	Quality of life
NCT0000272328	NCT00002723_28_T0	PHENOTYPE	7	8	disease progression
NCT000027251	NCT00002725_1_T0	CELL	10	10	cells
NCT000027253	NCT00002725_3_T0	PHENOTYPE	16	17	Hodgkin's lymphoma
NCT000027253	NCT00002725_3_T1	COMPOUND	4	5	bryostatin 1
NCT000027255	NCT00002725_5_T0	PHENOTYPE	2	2	toxic
NCT000027259	NCT00002725_9_T0	PHENOTYPE	10	10	pharmacodynamics
NCT000027271	NCT00002727_1_T0	ORGAN	21	22	vocal cord
NCT000027271	NCT00002727_1_T1	PHENOTYPE	16	20	stage II cancer of the
NCT000027272	NCT00002727_2_T0	GENE	3	3	III
NCT000027272	NCT00002727_2_T1	ORGAN	22	23	vocal cord
NCT000027272	NCT00002727_2_T2	PHENOTYPE	17	21	stage II cancer of the
NCT000027279	NCT00002727_9_T0	GENE	14	14	3-2
NCT000027301	NCT00002730_1_T0	PHENOTYPE	1	1	tumors
NCT000027301	NCT00002730_1_T1	PHENOTYPE	3	3	resistant
NCT000027302	NCT00002730_2_T0	CELL	15	15	cells
NCT000027302	NCT00002730_2_T1	PHENOTYPE	14	14	tumor
NCT000027302	NCT00002730_2_T2	COMPOUND	1	2	buthionine sulfoximine
NCT000027303	NCT00002730_3_T0	COMPOUND	9	9	melphalan
NCT000027303	NCT00002730_3_T1	PHENOTYPE	19	19	neuroblastoma
NCT000027303	NCT00002730_3_T2	GENE	13	13	G-CSF
NCT000027303	NCT00002730_3_T3	PHENOTYPE	18	18	progressive
NCT000027303	NCT00002730_3_T4	GENE	21	21	has
NCT000027303	NCT00002730_3_T5	COMPOUND	10	11	buthionine sulfoximine
NCT000027305	NCT00002730_5_T0	PHENOTYPE	2	2	toxic
NCT000027305	NCT00002730_5_T1	COMPOUND	12	12	melphalan
NCT000027305	NCT00002730_5_T2	PHENOTYPE	19	19	neuroblastoma
NCT000027305	NCT00002730_5_T3	PHENOTYPE	18	18	progressive
NCT000027305	NCT00002730_5_T4	COMPOUND	8	9	buthionine sulfoximine
NCT000027307	NCT00002730_7_T0	PHENOTYPE	2	2	pharmacokinetics
NCT000027309	NCT00002730_9_T0	ORGAN	20	20	marrow
NCT000027309	NCT00002730_9_T1	PHENOTYPE	23	23	peripheral
NCT000027309	NCT00002730_9_T2	CELL	25	25	lymphocytes
NCT000027309	NCT00002730_9_T3	PHENOTYPE	13	13	tumor
NCT000027309	NCT00002730_9_T4	ORGAN	16	17	bone marrow
NCT0000273015	NCT00002730_15_T0	ORGAN	10	10	marrow
NCT0000273015	NCT00002730_15_T1	PHENOTYPE	7	7	tumor
NCT000027331	NCT00002733_1_T0	CELL	18	18	cells
NCT000027331	NCT00002733_1_T1	GENE	9	9	interleukin-2
NCT000027331	NCT00002733_1_T2	GENE	7	7	interferon
NCT000027331	NCT00002733_1_T3	CELL	11	13	tumor infiltrating lymphocytes
NCT000027332	NCT00002733_2_T0	GENE	2	2	II
NCT000027332	NCT00002733_2_T1	GENE	12	12	interferon
NCT000027332	NCT00002733_2_T2	GENE	14	14	interleukin-2
NCT000027332	NCT00002733_2_T3	PHENOTYPE	23	24	metastatic cancer
NCT000027332	NCT00002733_2_T4	CELL	16	18	tumor infiltrating lymphocytes
NCT000027336	NCT00002733_6_T0	PHENOTYPE	2	2	toxic
NCT000027338	NCT00002733_8_T0	GENE	20	20	IL-2
NCT000027338	NCT00002733_8_T1	GENE	9	9	TIL
NCT000027338	NCT00002733_8_T2	GENE	19	19	TIL
NCT000027338	NCT00002733_8_T3	GENE	22	22	TIL
NCT000027338	NCT00002733_8_T4	GENE	26	26	TIL
NCT000027338	NCT00002733_8_T5	COMPOUND	24	24	cimetidine
NCT0000273310	NCT00002733_10_T0	GENE	19	19	interferon
NCT0000273310	NCT00002733_10_T1	CELL	8	8	lymphocyte
NCT0000273310	NCT00002733_10_T2	PHENOTYPE	7	7	infiltrating
NCT0000273310	NCT00002733_10_T3	GENE	22	22	IL-2
NCT0000273310	NCT00002733_10_T4	PHENOTYPE	6	6	tumor
NCT0000273310	NCT00002733_10_T5	GENE	9	9	TIL
NCT0000273312	NCT00002733_12_T0	GENE	20	20	IL-2
NCT0000273312	NCT00002733_12_T1	GENE	26	26	IL-2
NCT0000273312	NCT00002733_12_T2	GENE	15	15	TIL
NCT0000273312	NCT00002733_12_T3	GENE	33	33	TIL
NCT0000273312	NCT00002733_12_T4	GENE	14	14	1.4
NCT0000273312	NCT00002733_12_T5	GENE	21	21	IV
NCT0000273312	NCT00002733_12_T6	GENE	27	27	IV
NCT0000273313	NCT00002733_13_T0	GENE	6	6	TIL
NCT0000273313	NCT00002733_13_T1	COMPOUND	12	12	cimetidine
NCT0000273314	NCT00002733_14_T0	GENE	17	17	TIL
NCT0000273314	NCT00002733_14_T1	PHENOTYPE	12	13	disease progression
NCT000027342	NCT00002734_2_T0	CELL	10	10	cells
NCT000027342	NCT00002734_2_T1	PHENOTYPE	9	9	tumor
NCT000027344	NCT00002734_4_T0	CELL	11	11	cells
NCT000027344	NCT00002734_4_T1	PHENOTYPE	10	10	tumor
NCT000027344	NCT00002734_4_T2	GENE	5	5	interferon
NCT000027346	NCT00002734_6_T0	COMPOUND	8	8	paclitaxel
NCT000027346	NCT00002734_6_T1	COMPOUND	19	19	lutetium
NCT000027346	NCT00002734_6_T2	GENE	5	5	MTD
NCT000027346	NCT00002734_6_T3	COMPOUND	10	10	topotecan
NCT000027346	NCT00002734_6_T4	COMPOUND	28	29	interferon alfa_2b
NCT000027346	NCT00002734_6_T5	PHENOTYPE	36	38	recurrent ovarian cancer
NCT000027348	NCT00002734_8_T0	PHENOTYPE	2	2	toxicity
NCT000027348	NCT00002734_8_T1	COMPOUND	6	6	paclitaxel
NCT000027348	NCT00002734_8_T2	COMPOUND	8	8	topotecan
NCT0000273410	NCT00002734_10_T0	COMPOUND	14	14	paclitaxel
NCT0000273410	NCT00002734_10_T1	PHENOTYPE	4	4	pharmacokinetics
NCT0000273414	NCT00002734_14_T0	COMPOUND	19	19	paclitaxel
NCT0000273414	NCT00002734_14_T1	COMPOUND	27	27	paclitaxel
NCT0000273414	NCT00002734_14_T2	COMPOUND	4	4	yttrium
NCT0000273414	NCT00002734_14_T3	GENE	2	2	MTD
NCT0000273414	NCT00002734_14_T4	GENE	23	23	MTD
NCT0000273417	NCT00002734_17_T0	COMPOUND	8	8	paclitaxel
NCT0000273417	NCT00002734_17_T1	COMPOUND	18	18	yttrium
NCT0000273417	NCT00002734_17_T2	COMPOUND	10	10	lutetium
NCT0000273417	NCT00002734_17_T3	COMPOUND	9	9	topotecan
NCT0000273418	NCT00002734_18_T0	COMPOUND	12	12	paclitaxel
NCT0000273418	NCT00002734_18_T1	GENE	2	2	interferon
NCT0000273418	NCT00002734_18_T2	COMPOUND	19	19	topotecan
NCT0000273419	NCT00002734_19_T0	PHENOTYPE	16	16	toxicity
NCT0000273419	NCT00002734_19_T1	PHENOTYPE	12	13	disease progression
NCT0000273420	NCT00002734_20_T0	COMPOUND	8	8	paclitaxel
NCT0000273420	NCT00002734_20_T1	GENE	2	2	3.5
NCT0000273420	NCT00002734_20_T2	GENE	19	19	MTD
NCT0000273421	NCT00002734_21_T0	PHENOTYPE	18	18	toxicity
NCT0000273421	NCT00002734_21_T1	GENE	1	1	MTD
NCT0000273422	NCT00002734_22_T0	COMPOUND	4	4	paclitaxel
NCT0000273422	NCT00002734_22_T1	GENE	2	2	MTD
NCT0000273423	NCT00002734_23_T0	GENE	2	2	MTD
NCT0000273424	NCT00002734_24_T0	COMPOUND	10	10	paclitaxel
NCT0000273424	NCT00002734_24_T1	GENE	1	1	MTD
NCT0000273425	NCT00002734_25_T0	COMPOUND	5	5	paclitaxel
NCT0000273425	NCT00002734_25_T1	GENE	9	9	MTD
NCT0000273425	NCT00002734_25_T2	GENE	20	20	MTD
NCT0000273425	NCT00002734_25_T3	GENE	13	13	interferon
NCT000027351	NCT00002735_1_T0	CELL	8	8	cells
NCT000027351	NCT00002735_1_T1	PHENOTYPE	7	7	tumor
NCT000027352	NCT00002735_2_T0	CELL	13	13	cells
NCT000027352	NCT00002735_2_T1	PHENOTYPE	12	12	tumor
NCT000027353	NCT00002735_3_T0	GENE	2	2	II
NCT000027353	NCT00002735_3_T1	PHENOTYPE	18	19	stage III
NCT000027353	NCT00002735_3_T2	PHENOTYPE	23	26	cancer of the hypopharynx
NCT000027353	NCT00002735_3_T3	PHENOTYPE	21	25	stage IV cancer of the
NCT000027355	NCT00002735_5_T0	COMPOUND	21	21	cisplatin
NCT000027355	NCT00002735_5_T1	PHENOTYPE	28	31	cancer of the hypopharynx
NCT0000273511	NCT00002735_11_T0	PHENOTYPE	7	7	tumor
NCT0000273511	NCT00002735_11_T1	ORGAN	9	9	hypopharynx
NCT0000273512	NCT00002735_12_T0	PHENOTYPE	4	4	closed
NCT0000273513	NCT00002735_13_T0	GENE	22	22	1.5
NCT0000273513	NCT00002735_13_T1	GENE	24	24	22.26
NCT0000273513	NCT00002735_13_T2	COMPOUND	4	4	cisplatin
NCT0000273513	NCT00002735_13_T3	GENE	5	5	IV
NCT0000273513	NCT00002735_13_T4	GENE	16	16	IV
NCT0000273514	NCT00002735_14_T0	GENE	9	9	has
NCT0000273517	NCT00002735_17_T0	GENE	4	4	3.4
NCT0000273517	NCT00002735_17_T1	COMPOUND	14	14	cisplatin
NCT0000273517	NCT00002735_17_T2	GENE	15	15	IV
NCT0000273521	NCT00002735_21_T0	PHENOTYPE	8	9	primary tumor
NCT0000273523	NCT00002735_23_T0	GENE	15	15	3.5
NCT000027371	NCT00002737_1_T0	CELL	5	5	cells
NCT000027371	NCT00002737_1_T1	CELL	9	9	cells
NCT000027371	NCT00002737_1_T2	PHENOTYPE	3	4	kidney cancer
NCT000027372	NCT00002737_2_T0	COMPOUND	9	9	isotretinoin
NCT000027372	NCT00002737_2_T1	GENE	6	6	interferon
NCT000027372	NCT00002737_2_T2	GENE	14	14	interferon
NCT000027372	NCT00002737_2_T3	PHENOTYPE	18	19	kidney cancer
NCT000027373	NCT00002737_3_T0	COMPOUND	15	15	isotretinoin
NCT000027373	NCT00002737_3_T1	GENE	3	3	III
NCT000027373	NCT00002737_3_T2	GENE	10	10	interferon
NCT000027373	NCT00002737_3_T3	PHENOTYPE	21	23	metastatic kidney cancer
NCT000027377	NCT00002737_7_T0	PHENOTYPE	2	2	toxic
NCT0000273715	NCT00002737_15_T0	PHENOTYPE	15	15	toxicity
NCT0000273715	NCT00002737_15_T1	PHENOTYPE	11	12	disease progression
NCT000027381	NCT00002738_1_T0	CELL	9	9	cells
NCT000027382	NCT00002738_2_T0	GENE	3	3	II
NCT000027382	NCT00002738_2_T1	PHENOTYPE	16	16	recurrent
NCT000027382	NCT00002738_2_T2	PHENOTYPE	20	21	recurrent osteosarcoma
NCT000027382	NCT00002738_2_T3	PHENOTYPE	24	25	Hodgkin's lymphoma
NCT000027382	NCT00002738_2_T4	PHENOTYPE	17	19	acute lymphoblastic leukemia
NCT000027384	NCT00002738_4_T0	PHENOTYPE	10	11	Hodgkin's lymphoma
NCT000027384	NCT00002738_4_T1	PHENOTYPE	13	14	osteogenic sarcoma
NCT000027384	NCT00002738_4_T2	PHENOTYPE	7	9	acute lymphocytic leukemia
NCT000027385	NCT00002738_5_T0	COMPOUND	16	16	calcium
NCT000027385	NCT00002738_5_T1	COMPOUND	15	15	leucovorin
NCT000027385	NCT00002738_5_T2	GENE	6	6	IV
NCT000027385	NCT00002738_5_T3	COMPOUND	2	3	trimetrexate glucuronate
NCT000027402	NCT00002740_2_T0	CELL	8	8	cells
NCT000027402	NCT00002740_2_T1	PHENOTYPE	7	7	tumor
NCT000027406	NCT00002740_6_T0	PHENOTYPE	5	5	toxic
NCT0000274012	NCT00002740_12_T0	CELL	13	13	CFU-GM
NCT0000274012	NCT00002740_12_T1	GENE	10	10	CD34
NCT0000274016	NCT00002740_16_T0	PHENOTYPE	14	14	neuroblastoma
NCT0000274016	NCT00002740_16_T1	PHENOTYPE	10	11	residual tumor
NCT0000274018	NCT00002740_18_T0	COMPOUND	6	6	vincristine
NCT0000274018	NCT00002740_18_T1	COMPOUND	11	11	cyclophosphamide
NCT0000274018	NCT00002740_18_T2	COMPOUND	17	17	doxorubicin
NCT0000274018	NCT00002740_18_T3	GENE	7	7	IV
NCT0000274018	NCT00002740_18_T4	GENE	12	12	IV
NCT0000274018	NCT00002740_18_T5	GENE	18	18	IV
NCT0000274019	NCT00002740_19_T0	GENE	2	2	filgrastim
NCT0000274019	NCT00002740_19_T1	GENE	3	3	G-CSF
NCT0000274019	NCT00002740_19_T2	GENE	7	7	IV
NCT0000274021	NCT00002740_21_T0	GENE	2	2	G-CSF
NCT0000274021	NCT00002740_21_T1	GENE	5	5	IV
NCT0000274022	NCT00002740_22_T0	GENE	5	5	1.3
NCT0000274023	NCT00002740_23_T0	ORGAN	4	5	bone marrow
NCT0000274024	NCT00002740_24_T0	COMPOUND	26	26	cyclophosphamide
NCT0000274024	NCT00002740_24_T1	COMPOUND	8	8	etoposide
NCT0000274024	NCT00002740_24_T2	GENE	9	9	IV
NCT0000274024	NCT00002740_24_T3	GENE	21	21	IV
NCT0000274024	NCT00002740_24_T4	GENE	27	27	IV
NCT0000274025	NCT00002740_25_T0	GENE	2	2	G-CSF
NCT0000274025	NCT00002740_25_T1	GENE	5	5	IV
NCT0000274027	NCT00002740_27_T0	PHENOTYPE	16	16	toxicity
NCT0000274027	NCT00002740_27_T1	PHENOTYPE	12	13	disease progression
NCT0000274028	NCT00002740_28_T0	PHENOTYPE	11	11	tumor
NCT0000274028	NCT00002740_28_T1	PHENOTYPE	8	9	disease progression
NCT0000274031	NCT00002740_31_T0	GENE	14	14	MTD
NCT0000274032	NCT00002740_32_T0	PHENOTYPE	22	22	toxicity
NCT0000274032	NCT00002740_32_T1	GENE	1	1	MTD
NCT000027421	NCT00002742_1_T0	PHENOTYPE	34	34	leukemia
NCT000027421	NCT00002742_1_T1	COMPOUND	7	7	nystatin
NCT000027421	NCT00002742_1_T2	PHENOTYPE	19	19	fever
NCT000027421	NCT00002742_1_T3	PHENOTYPE	21	21	neutropenia
NCT000027421	NCT00002742_1_T4	COMPOUND	13	14	amphotericin B
NCT000027421	NCT00002742_1_T5	PHENOTYPE	27	28	hematologic cancer
NCT000027421	NCT00002742_1_T6	ORGAN	30	31	bone marrow
NCT000027422	NCT00002742_2_T0	PHENOTYPE	34	34	leukemia
NCT000027422	NCT00002742_2_T1	COMPOUND	11	11	nystatin
NCT000027422	NCT00002742_2_T2	GENE	3	3	III
NCT000027422	NCT00002742_2_T3	PHENOTYPE	19	19	fever
NCT000027422	NCT00002742_2_T4	PHENOTYPE	21	21	neutropenia
NCT000027422	NCT00002742_2_T5	COMPOUND	15	16	amphotericin B
NCT000027422	NCT00002742_2_T6	PHENOTYPE	27	28	hematologic cancer
NCT000027422	NCT00002742_2_T7	ORGAN	30	31	bone marrow
NCT000027424	NCT00002742_4_T0	COMPOUND	5	5	nystatin
NCT000027424	NCT00002742_4_T1	PHENOTYPE	16	16	febrile
NCT000027424	NCT00002742_4_T2	COMPOUND	8	9	amphotericin B
NCT000027426	NCT00002742_6_T0	PHENOTYPE	10	10	toxicity
NCT000027426	NCT00002742_6_T1	COMPOUND	16	16	nystatin
NCT000027426	NCT00002742_6_T2	PHENOTYPE	7	7	impairment
NCT000027426	NCT00002742_6_T3	PHENOTYPE	4	5	drug toxicity
NCT000027426	NCT00002742_6_T4	COMPOUND	19	20	amphotericin B
NCT000027428	NCT00002742_8_T0	COMPOUND	5	5	nystatin
NCT000027428	NCT00002742_8_T1	PHENOTYPE	2	2	pharmacokinetics
NCT000027441	NCT00002744_1_T0	CELL	15	15	cells
NCT000027442	NCT00002744_2_T0	GENE	20	20	III
NCT000027442	NCT00002744_2_T1	PHENOTYPE	14	16	acute lymphoblastic leukemia
NCT000027442	NCT00002744_2_T2	PHENOTYPE	36	38	acute lymphoblastic leukemia
NCT000027446	NCT00002744_6_T0	ORGAN	15	15	marrow
NCT000027446	NCT00002744_6_T1	GENE	30	30	14
NCT000027446	NCT00002744_6_T2	GENE	40	40	14
NCT000027446	NCT00002744_6_T3	GENE	24	24	M2
NCT000027446	NCT00002744_6_T4	GENE	14	14	M3
NCT0000274410	NCT00002744_10_T0	ORGAN	9	9	marrow
NCT0000274410	NCT00002744_10_T1	GENE	16	16	fusion
NCT0000274416	NCT00002744_16_T0	GENE	8	8	MP
NCT0000274416	NCT00002744_16_T1	GENE	11	11	TG
NCT0000274416	NCT00002744_16_T2	PHENOTYPE	5	5	pharmacokinetics
NCT0000274420	NCT00002744_20_T0	GENE	4	5	thiopurine methyltransferase
NCT0000274420	NCT00002744_20_T1	GENE	7	10	hypoxanthine guanine phosphoribosyl transferase
NCT0000274422	NCT00002744_22_T0	GENE	17	17	MTX
NCT0000274422	NCT00002744_22_T1	PHENOTYPE	8	8	relapse
NCT0000274422	NCT00002744_22_T2	COMPOUND	16	16	methotrexate
NCT0000274422	NCT00002744_22_T3	ORGAN	4	6	central nervous system
NCT0000274430	NCT00002744_30_T0	GENE	8	8	MTX
NCT0000274430	NCT00002744_30_T1	GENE	1	1	IT
NCT0000274430	NCT00002744_30_T2	GENE	9	9	IT
NCT0000274433	NCT00002744_33_T0	GENE	13	13	MTX
NCT0000274433	NCT00002744_33_T1	GENE	8	8	MP
NCT0000274433	NCT00002744_33_T2	GENE	2	2	VCR
NCT0000274433	NCT00002744_33_T3	GENE	14	14	IT
NCT0000274433	NCT00002744_33_T4	GENE	3	3	IV
NCT0000274434	NCT00002744_34_T0	GENE	24	24	MTX
NCT0000274434	NCT00002744_34_T1	PHENOTYPE	7	7	Consolidation
NCT0000274434	NCT00002744_34_T2	GENE	38	38	MP
NCT0000274434	NCT00002744_34_T3	GENE	17	17	VCR
NCT0000274434	NCT00002744_34_T4	GENE	14	14	0.4
NCT0000274434	NCT00002744_34_T5	GENE	18	18	IV
NCT0000274436	NCT00002744_36_T0	COMPOUND	9	9	1
NCT0000274436	NCT00002744_36_T1	COMPOUND	17	17	1
NCT0000274437	NCT00002744_37_T0	GENE	15	15	MTX
NCT0000274437	NCT00002744_37_T1	COMPOUND	2	2	2
NCT0000274437	NCT00002744_37_T2	COMPOUND	9	9	2
NCT0000274437	NCT00002744_37_T3	GENE	16	16	IT
NCT0000274438	NCT00002744_38_T0	GENE	32	32	MTX
NCT0000274438	NCT00002744_38_T1	GENE	54	54	MTX
NCT0000274438	NCT00002744_38_T2	COMPOUND	7	7	2
NCT0000274438	NCT00002744_38_T3	GENE	27	27	MP
NCT0000274438	NCT00002744_38_T4	GENE	49	49	wk
NCT0000274438	NCT00002744_38_T5	GENE	18	18	VCR
NCT0000274438	NCT00002744_38_T6	GENE	14	14	0.4
NCT0000274438	NCT00002744_38_T7	GENE	51	51	IT
NCT0000274438	NCT00002744_38_T8	GENE	55	55	IT
NCT0000274438	NCT00002744_38_T9	GENE	19	19	IV
NCT0000274442	NCT00002744_42_T0	PHENOTYPE	1	1	secondary
NCT0000274442	NCT00002744_42_T1	GENE	5	5	MP
NCT0000274442	NCT00002744_42_T2	GENE	9	9	TG
NCT0000274442	NCT00002744_42_T3	PHENOTYPE	2	3	veno-occlusive disease
NCT0000274444	NCT00002744_44_T0	PHENOTYPE	1	1	secondary
NCT0000274444	NCT00002744_44_T1	GENE	5	5	MP
NCT0000274444	NCT00002744_44_T2	GENE	9	9	TG
NCT0000274444	NCT00002744_44_T3	PHENOTYPE	2	3	veno-occlusive disease
NCT0000274446	NCT00002744_46_T0	PHENOTYPE	10	10	Consolidation
NCT0000274446	NCT00002744_46_T1	ORGAN	3	4	bone marrow
NCT0000274447	NCT00002744_47_T0	PHENOTYPE	0	0	Consolidation
NCT0000274447	NCT00002744_47_T1	GENE	21	21	tapered
NCT0000274449	NCT00002744_49_T0	ORGAN	5	5	marrow
NCT0000274449	NCT00002744_49_T1	PHENOTYPE	9	9	leukemia
NCT0000274449	NCT00002744_49_T2	GENE	2	2	M1
NCT0000274449	NCT00002744_49_T3	GENE	4	4	M2
NCT0000274450	NCT00002744_50_T0	GENE	20	20	MTX
NCT0000274450	NCT00002744_50_T1	PHENOTYPE	7	7	Consolidation
NCT0000274450	NCT00002744_50_T2	GENE	32	32	IM
NCT0000274450	NCT00002744_50_T3	GENE	10	10	VCR
NCT0000274450	NCT00002744_50_T4	GENE	11	11	IV
NCT0000274450	NCT00002744_50_T5	GENE	21	21	IV
NCT0000274451	NCT00002744_51_T0	GENE	2	2	M1
NCT0000274451	NCT00002744_51_T1	ORGAN	3	4	bone marrow
NCT0000274453	NCT00002744_53_T0	GENE	19	19	MTX
NCT0000274453	NCT00002744_53_T1	COMPOUND	9	9	1
NCT0000274453	NCT00002744_53_T2	COMPOUND	17	17	1
NCT0000274453	NCT00002744_53_T3	GENE	20	20	IT
NCT0000274454	NCT00002744_54_T0	GENE	15	15	MTX
NCT0000274454	NCT00002744_54_T1	COMPOUND	2	2	2
NCT0000274454	NCT00002744_54_T2	COMPOUND	9	9	2
NCT0000274454	NCT00002744_54_T3	GENE	16	16	IT
NCT0000274456	NCT00002744_56_T0	PHENOTYPE	13	13	Consolidation
NCT0000274457	NCT00002744_57_T0	PHENOTYPE	6	6	initiation
NCT0000274457	NCT00002744_57_T1	PHENOTYPE	8	8	Consolidation
NCT0000274459	NCT00002744_59_T0	GENE	12	12	2.3
NCT0000274459	NCT00002744_59_T1	ORGAN	6	6	testes
NCT0000274461	NCT00002744_61_T0	GENE	14	14	3.5
NCT000027451	NCT00002745_1_T0	CELL	10	10	cells
NCT000027451	NCT00002745_1_T1	PHENOTYPE	9	9	tumor
NCT000027453	NCT00002745_3_T0	PHENOTYPE	17	18	Hodgkin's disease
NCT000027453	NCT00002745_3_T1	PHENOTYPE	20	21	Hodgkin's lymphoma
NCT000027455	NCT00002745_5_T0	PHENOTYPE	2	2	toxicity
NCT000027457	NCT00002745_7_T0	PHENOTYPE	13	13	toxicity
NCT000027457	NCT00002745_7_T1	GENE	9	9	albumin
NCT000027457	NCT00002745_7_T2	COMPOUND	11	11	bilirubin
NCT000027457	NCT00002745_7_T3	PHENOTYPE	3	3	pharmacodynamic
NCT000027459	NCT00002745_9_T0	PHENOTYPE	3	3	concentrations
NCT0000274511	NCT00002745_11_T0	GENE	7	7	1.3
NCT0000274511	NCT00002745_11_T1	GENE	3	3	IV
NCT0000274512	NCT00002745_12_T0	PHENOTYPE	19	19	toxicity
NCT0000274512	NCT00002745_12_T1	PHENOTYPE	15	16	disease progression
NCT0000274513	NCT00002745_13_T0	GENE	7	7	PR
NCT0000274513	NCT00002745_13_T1	GENE	25	25	PR
NCT0000274513	NCT00002745_13_T2	GENE	11	11	CR
NCT0000274513	NCT00002745_13_T3	GENE	27	27	CR
NCT0000274516	NCT00002745_16_T0	PHENOTYPE	18	18	lymphoma
NCT0000274516	NCT00002745_16_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000274516	NCT00002745_16_T2	PHENOTYPE	16	17	high grade
NCT000027463	NCT00002746_3_T0	GENE	1	1	IL-2
NCT000027465	NCT00002746_5_T0	GENE	4	4	IL-2
NCT000027466	NCT00002746_6_T0	GENE	6	6	IL-2
NCT000027468	NCT00002746_8_T0	PHENOTYPE	9	9	toxicity
NCT000027468	NCT00002746_8_T1	GENE	2	2	IL-2
NCT000027468	NCT00002746_8_T2	GENE	8	8	III
NCT000027469	NCT00002746_9_T0	PHENOTYPE	11	11	toxicity
NCT000027469	NCT00002746_9_T1	GENE	16	16	IL-2
NCT0000274610	NCT00002746_10_T0	PHENOTYPE	8	8	toxicity
NCT0000274610	NCT00002746_10_T1	GENE	15	15	IL-2
NCT0000274610	NCT00002746_10_T2	GENE	7	7	III
NCT000027470	NCT00002747_0_T0	PHENOTYPE	12	13	Mouth Cancer
NCT000027472	NCT00002747_2_T0	CELL	8	8	cells
NCT000027472	NCT00002747_2_T1	PHENOTYPE	7	7	tumor
NCT000027473	NCT00002747_3_T0	PHENOTYPE	19	20	mouth cancer
NCT000027474	NCT00002747_4_T0	GENE	23	23	II
NCT000027474	NCT00002747_4_T1	GENE	3	3	III
NCT000027474	NCT00002747_4_T2	GENE	28	28	IV
NCT000027474	NCT00002747_4_T3	PHENOTYPE	29	30	mouth cancer
NCT000027474	NCT00002747_4_T4	PHENOTYPE	24	25	stage III
NCT0000274710	NCT00002747_10_T0	PHENOTYPE	5	5	toxic
NCT0000274712	NCT00002747_12_T0	GENE	12	12	N3
NCT0000274712	NCT00002747_12_T1	GENE	6	6	nodal
NCT0000274715	NCT00002747_15_T0	PHENOTYPE	16	16	toxicity
NCT0000274715	NCT00002747_15_T1	PHENOTYPE	12	13	disease progression
NCT0000274716	NCT00002747_16_T0	PHENOTYPE	8	9	progressive disease
NCT0000274717	NCT00002747_17_T0	GENE	10	10	nodal
NCT0000274717	NCT00002747_17_T1	PHENOTYPE	5	6	primary tumor
NCT000027481	NCT00002748_1_T0	CELL	13	13	cells
NCT000027481	NCT00002748_1_T1	GENE	10	10	interleukin-2
NCT000027481	NCT00002748_1_T2	PHENOTYPE	12	12	neuroblastoma
NCT000027481	NCT00002748_1_T3	PHENOTYPE	21	22	recurrent neuroblastoma
NCT000027483	NCT00002748_3_T0	CELL	20	20	cells
NCT000027483	NCT00002748_3_T1	GENE	29	29	interleukin-2
NCT000027483	NCT00002748_3_T2	PHENOTYPE	19	19	neuroblastoma
NCT000027483	NCT00002748_3_T3	PHENOTYPE	6	7	recurrent neuroblastoma
NCT000027488	NCT00002748_8_T0	CELL	7	7	cells
NCT000027488	NCT00002748_8_T1	PHENOTYPE	6	6	neuroblastoma
NCT000027488	NCT00002748_8_T2	BIOLOGICAL_PROCESS	15	16	interleukin-2 production
NCT000027489	NCT00002748_9_T0	CELL	7	7	cells
NCT000027489	NCT00002748_9_T1	CELL	21	21	cells
NCT0000274810	NCT00002748_10_T0	GENE	2	2	3.4
NCT000027491	NCT00002749_1_T0	GENE	2	2	II
NCT000027491	NCT00002749_1_T1	PHENOTYPE	13	13	progressive
NCT000027491	NCT00002749_1_T2	PHENOTYPE	14	14	glioma
NCT000027493	NCT00002749_3_T0	PHENOTYPE	9	9	progressive
NCT000027493	NCT00002749_3_T1	PHENOTYPE	11	11	gliomas
NCT000027493	NCT00002749_3_T2	BIOLOGICAL_PROCESS	2	4	response to carboplatin
NCT000027500	NCT00002750_0_T0	PHENOTYPE	4	5	Neoplastic Meningitis
NCT000027502	NCT00002750_2_T0	COMPOUND	9	9	melphalan
NCT000027502	NCT00002750_2_T1	PHENOTYPE	15	15	recurrent
NCT000027502	NCT00002750_2_T2	PHENOTYPE	16	17	neoplastic meningitis
NCT000027504	NCT00002750_4_T0	COMPOUND	7	7	melphalan
NCT000027504	NCT00002750_4_T1	PHENOTYPE	12	13	neoplastic meningitis
NCT000027506	NCT00002750_6_T0	GENE	2	2	CSF
NCT000027506	NCT00002750_6_T1	PHENOTYPE	5	5	pharmacokinetics
NCT000027506	NCT00002750_6_T2	ORGAN	4	4	serum
NCT000027508	NCT00002750_8_T0	COMPOUND	2	2	melphalan
NCT000027508	NCT00002750_8_T1	GENE	5	5	IT
NCT000027509	NCT00002750_9_T0	COMPOUND	8	8	melphalan
NCT000027509	NCT00002750_9_T1	GENE	14	14	MTD
NCT0000275010	NCT00002750_10_T0	PHENOTYPE	17	17	toxicity
NCT0000275010	NCT00002750_10_T1	GENE	1	1	MTD
NCT0000275011	NCT00002750_11_T0	GENE	11	11	MTD
NCT0000275012	NCT00002750_12_T0	GENE	11	11	IT
NCT0000275013	NCT00002750_13_T0	PHENOTYPE	11	12	disease progression
NCT000027511	NCT00002751_1_T0	PHENOTYPE	17	18	brain metastases
NCT000027513	NCT00002751_3_T0	PHENOTYPE	2	2	toxicity
NCT000027513	NCT00002751_3_T1	GENE	11	11	fragment
NCT000027513	NCT00002751_3_T2	PHENOTYPE	19	19	neoplasms
NCT000027521	NCT00002752_1_T0	PHENOTYPE	20	22	metastatic brain cancer
NCT000027523	NCT00002752_3_T0	GENE	12	12	tenascin
NCT000027523	NCT00002752_3_T1	COMPOUND	8	8	iodine
NCT000027525	NCT00002752_5_T0	COMPOUND	2	2	iodine
NCT000027526	NCT00002752_6_T0	COMPOUND	8	8	iodine
NCT000027527	NCT00002752_7_T0	PHENOTYPE	18	18	toxicity
NCT000027527	NCT00002752_7_T1	GENE	1	1	MTD
NCT000027531	NCT00002753_1_T0	PHENOTYPE	16	16	gliomas
NCT000027531	NCT00002753_1_T1	PHENOTYPE	15	15	recurrent
NCT000027533	NCT00002753_3_T0	PHENOTYPE	2	2	toxic
NCT000027533	NCT00002753_3_T1	GENE	9	9	tenascin
NCT000027535	NCT00002753_5_T0	PHENOTYPE	14	14	gliomas
NCT000027535	NCT00002753_5_T1	PHENOTYPE	11	11	recurrent
NCT000027535	NCT00002753_5_T2	GENE	12	12	cystic
NCT000027542	NCT00002754_2_T0	PHENOTYPE	22	23	brain tumors
NCT000027542	NCT00002754_2_T1	PHENOTYPE	19	20	metastatic melanoma
NCT000027544	NCT00002754_4_T0	PHENOTYPE	2	2	toxicity
NCT000027544	NCT00002754_4_T1	GENE	11	11	fragment
NCT000027544	NCT00002754_4_T2	PHENOTYPE	19	19	recurrent
NCT000027544	NCT00002754_4_T3	PHENOTYPE	30	31	brain tumors
NCT000027544	NCT00002754_4_T4	PHENOTYPE	25	27	metastatic malignant melanoma
NCT000027547	NCT00002754_7_T0	GENE	10	10	fragment
NCT000027548	NCT00002754_8_T0	PHENOTYPE	22	23	disease progression
NCT000027549	NCT00002754_9_T0	PHENOTYPE	24	24	progression
NCT000027549	NCT00002754_9_T1	PHENOTYPE	2	3	recurrent disease
NCT000027552	NCT00002755_2_T0	PHENOTYPE	12	13	breast cancer
NCT0000275510	NCT00002755_10_T0	GENE	17	17	3.5
NCT0000275510	NCT00002755_10_T1	ORGAN	15	15	axilla
NCT0000275510	NCT00002755_10_T2	ORGAN	12	13	chest wall
NCT0000275511	NCT00002755_11_T0	COMPOUND	12	12	tamoxifen
NCT000027561	NCT00002756_1_T0	CELL	16	16	cells
NCT000027562	NCT00002756_2_T0	GENE	3	3	II
NCT000027562	NCT00002756_2_T1	PHENOTYPE	18	20	acute lymphocytic leukemia
NCT000027568	NCT00002756_8_T0	GENE	21	21	SC
NCT000027568	NCT00002756_8_T1	COMPOUND	10	10	cytarabine
NCT000027568	NCT00002756_8_T2	COMPOUND	8	8	hydrocortisone
NCT000027568	NCT00002756_8_T3	GENE	18	18	filgrastim
NCT000027568	NCT00002756_8_T4	COMPOUND	7	7	methotrexate
NCT000027568	NCT00002756_8_T5	GENE	19	19	G-CSF
NCT000027568	NCT00002756_8_T6	GENE	23	23	IV
NCT0000275610	NCT00002756_10_T0	COMPOUND	9	9	cyclophosphamide
NCT0000275610	NCT00002756_10_T1	COMPOUND	3	3	etoposide
NCT0000275610	NCT00002756_10_T2	GENE	4	4	IV
NCT0000275610	NCT00002756_10_T3	GENE	10	10	IV
NCT0000275611	NCT00002756_11_T0	GENE	3	3	SC
NCT0000275611	NCT00002756_11_T1	GENE	2	2	G-CSF
NCT0000275611	NCT00002756_11_T2	GENE	5	5	IV
NCT0000275612	NCT00002756_12_T0	GENE	31	31	IM
NCT0000275612	NCT00002756_12_T1	GENE	30	30	asparaginase
NCT0000275612	NCT00002756_12_T2	PHENOTYPE	3	3	remission
NCT0000275612	NCT00002756_12_T3	GENE	11	11	G-CSF
NCT0000275613	NCT00002756_13_T0	GENE	3	3	SC
NCT0000275613	NCT00002756_13_T1	GENE	2	2	G-CSF
NCT0000275613	NCT00002756_13_T2	GENE	5	5	IV
NCT0000275615	NCT00002756_15_T0	COMPOUND	10	10	cyclophosphamide
NCT0000275615	NCT00002756_15_T1	COMPOUND	3	3	etoposide
NCT0000275615	NCT00002756_15_T2	GENE	4	4	IV
NCT0000275615	NCT00002756_15_T3	GENE	11	11	IV
NCT0000275616	NCT00002756_16_T0	GENE	3	3	SC
NCT0000275616	NCT00002756_16_T1	GENE	2	2	G-CSF
NCT0000275616	NCT00002756_16_T2	GENE	5	5	IV
NCT0000275618	NCT00002756_18_T0	GENE	9	9	asparaginase
NCT0000275618	NCT00002756_18_T1	GENE	2	2	G-CSF
NCT0000275619	NCT00002756_19_T0	COMPOUND	22	22	1
NCT0000275619	NCT00002756_19_T1	COMPOUND	38	38	1
NCT0000275619	NCT00002756_19_T2	COMPOUND	18	18	vincristine
NCT0000275619	NCT00002756_19_T3	GENE	31	31	1.5
NCT0000275619	NCT00002756_19_T4	PHENOTYPE	3	3	remission
NCT0000275619	NCT00002756_19_T5	GENE	10	10	G-CSF
NCT0000275619	NCT00002756_19_T6	COMPOUND	24	24	prednisone
NCT0000275619	NCT00002756_19_T7	GENE	19	19	IV
NCT0000275620	NCT00002756_20_T0	GENE	4	4	IM
NCT0000275620	NCT00002756_20_T1	COMPOUND	3	3	methotrexate
NCT0000275621	NCT00002756_21_T0	GENE	24	24	SC
NCT0000275621	NCT00002756_21_T1	GENE	21	21	1.5
NCT0000275621	NCT00002756_21_T2	COMPOUND	13	13	cyclophosphamide
NCT0000275621	NCT00002756_21_T3	COMPOUND	5	5	etoposide
NCT0000275621	NCT00002756_21_T4	GENE	23	23	G-CSF
NCT0000275621	NCT00002756_21_T5	GENE	6	6	IV
NCT0000275621	NCT00002756_21_T6	GENE	14	14	IV
NCT0000275621	NCT00002756_21_T7	GENE	26	26	IV
NCT0000275623	NCT00002756_23_T0	COMPOUND	18	18	cyclophosphamide
NCT0000275623	NCT00002756_23_T1	COMPOUND	16	16	etoposide
NCT0000275625	NCT00002756_25_T0	GENE	12	12	2.1
NCT000027571	NCT00002757_1_T0	GENE	3	3	III
NCT000027571	NCT00002757_1_T1	PHENOTYPE	17	18	Hodgkin's lymphoma
NCT000027575	NCT00002757_5_T0	GENE	20	20	LDH
NCT000027575	NCT00002757_5_T1	GENE	1	1	III
NCT000027575	NCT00002757_5_T2	GENE	15	15	III
NCT000027575	NCT00002757_5_T3	PHENOTYPE	2	3	Group B
NCT000027577	NCT00002757_7_T0	GENE	9	9	II
NCT000027578	NCT00002757_8_T0	GENE	10	10	IV
NCT000027578	NCT00002757_8_T1	PHENOTYPE	5	6	stage III
NCT000027578	NCT00002757_8_T2	PHENOTYPE	24	25	Group B
NCT000027578	NCT00002757_8_T3	ORGAN	18	19	bone marrow
NCT000027579	NCT00002757_9_T0	GENE	14	14	L3
NCT000027579	NCT00002757_9_T1	GENE	17	17	CSF
NCT000027579	NCT00002757_9_T2	ORGAN	7	8	bone marrow
NCT000027579	NCT00002757_9_T3	PHENOTYPE	22	24	spinal cord compression
NCT000027579	NCT00002757_9_T4	PHENOTYPE	18	20	cranial nerve palsy
NCT0000275711	NCT00002757_11_T0	GENE	1	1	SC
NCT0000275711	NCT00002757_11_T1	GENE	0	0	G-CSF
NCT0000275716	NCT00002757_16_T0	GENE	0	0	G-CSF
NCT0000275718	NCT00002757_18_T0	GENE	0	0	G-CSF
NCT0000275721	NCT00002757_21_T0	GENE	11	11	CYM
NCT0000275724	NCT00002757_24_T0	GENE	0	0	G-CSF
NCT0000275727	NCT00002757_27_T0	GENE	0	0	G-CSF
NCT0000275729	NCT00002757_29_T0	GENE	2	2	MTX
NCT0000275729	NCT00002757_29_T1	GENE	3	3	IT
NCT0000275729	NCT00002757_29_T2	GENE	6	6	IT
NCT0000275731	NCT00002757_31_T0	GENE	0	0	G-CSF
NCT0000275734	NCT00002757_34_T0	PHENOTYPE	0	0	Tumor
NCT0000275734	NCT00002757_34_T1	PHENOTYPE	9	9	decisions
NCT0000275734	NCT00002757_34_T2	PHENOTYPE	18	19	Group B
NCT0000275735	NCT00002757_35_T0	GENE	18	18	MTX
NCT0000275735	NCT00002757_35_T1	GENE	19	19	IV
NCT0000275735	NCT00002757_35_T2	PHENOTYPE	13	14	Group B
NCT0000275736	NCT00002757_36_T0	GENE	0	0	G-CSF
NCT0000275739	NCT00002757_39_T0	GENE	0	0	G-CSF
NCT0000275741	NCT00002757_41_T0	GENE	0	0	G-CSF
NCT0000275745	NCT00002757_45_T0	GENE	0	0	G-CSF
NCT0000275750	NCT00002757_50_T0	PHENOTYPE	11	12	Group B
NCT000027591	NCT00002759_1_T0	CELL	10	10	cells
NCT000027592	NCT00002759_2_T0	COMPOUND	2	2	phenobarbital
NCT000027592	NCT00002759_2_T1	COMPOUND	8	8	irinotecan
NCT000027594	NCT00002759_4_T0	COMPOUND	12	12	cyclosporine
NCT000027594	NCT00002759_4_T1	COMPOUND	6	6	irinotecan
NCT000027594	NCT00002759_4_T2	PHENOTYPE	20	20	lymphoma
NCT000027594	NCT00002759_4_T3	GENE	13	13	CYSP
NCT000027594	NCT00002759_4_T4	PHENOTYPE	17	18	solid tumors
NCT000027596	NCT00002759_6_T0	PHENOTYPE	7	7	pharmacodynamics
NCT000027596	NCT00002759_6_T1	PHENOTYPE	5	5	pharmacokinetics
NCT000027596	NCT00002759_6_T2	GENE	2	2	CYSP
NCT000027598	NCT00002759_8_T0	COMPOUND	2	2	phenobarbital
NCT000027598	NCT00002759_8_T1	PHENOTYPE	7	7	pharmacodynamics
NCT000027598	NCT00002759_8_T2	PHENOTYPE	5	5	pharmacokinetics
NCT000027599	NCT00002759_9_T0	COMPOUND	8	8	irinotecan
NCT0000275911	NCT00002759_11_T0	COMPOUND	4	4	cyclosporine
NCT0000275911	NCT00002759_11_T1	COMPOUND	10	10	irinotecan
NCT0000275911	NCT00002759_11_T2	GENE	5	5	IV
NCT0000275911	NCT00002759_11_T3	GENE	11	11	IV
NCT0000275912	NCT00002759_12_T0	PHENOTYPE	10	10	toxicity
NCT0000275912	NCT00002759_12_T1	PHENOTYPE	12	13	disease progression
NCT0000275913	NCT00002759_13_T0	COMPOUND	8	8	irinotecan
NCT0000275913	NCT00002759_13_T1	GENE	2	2	3/12
NCT0000275913	NCT00002759_13_T2	GENE	14	14	MTD
NCT0000275914	NCT00002759_14_T0	PHENOTYPE	18	18	toxicity
NCT0000275914	NCT00002759_14_T1	GENE	1	1	MTD
NCT0000275914	NCT00002759_14_T2	GENE	19	19	DLT
NCT0000275915	NCT00002759_15_T0	PHENOTYPE	6	6	diarrhea
NCT0000275915	NCT00002759_15_T1	GENE	4	4	DLT
NCT0000275916	NCT00002759_16_T0	COMPOUND	4	4	cyclosporine
NCT0000275916	NCT00002759_16_T1	COMPOUND	3	3	phenobarbital
NCT0000275916	NCT00002759_16_T2	COMPOUND	10	10	irinotecan
NCT0000275916	NCT00002759_16_T3	GENE	13	13	MTD
NCT0000275917	NCT00002759_17_T0	GENE	11	11	MTD
NCT0000275918	NCT00002759_18_T0	PHENOTYPE	10	10	closed
NCT0000275918	NCT00002759_18_T1	GENE	2	2	DLT
NCT0000275918	NCT00002759_18_T2	PHENOTYPE	6	6	diarrhea
NCT0000275919	NCT00002759_19_T0	PHENOTYPE	6	6	neutropenia
NCT0000275919	NCT00002759_19_T1	GENE	4	4	DLT
NCT0000275920	NCT00002759_20_T0	COMPOUND	2	2	cyclosporine
NCT0000275920	NCT00002759_20_T1	COMPOUND	11	11	irinotecan
NCT0000275920	NCT00002759_20_T2	GENE	16	16	MTD
NCT0000275921	NCT00002759_21_T0	COMPOUND	19	19	cyclosporine
NCT0000275921	NCT00002759_21_T1	COMPOUND	18	18	phenobarbital
NCT0000275921	NCT00002759_21_T2	COMPOUND	21	21	irinotecan
NCT0000275921	NCT00002759_21_T3	GENE	1	1	III
NCT0000275921	NCT00002759_21_T4	PHENOTYPE	6	6	neutropenia
NCT0000275921	NCT00002759_21_T5	GENE	24	24	MTD
NCT0000275921	NCT00002759_21_T6	GENE	4	4	DLT
NCT0000275921	NCT00002759_21_T7	GENE	12	12	DLT
NCT0000275922	NCT00002759_22_T0	GENE	6	6	MTD
NCT0000276011	NCT00002760_11_T0	COMPOUND	18	18	androgen
NCT000027614	NCT00002761_4_T0	COMPOUND	5	5	cytarabine
NCT000027614	NCT00002761_4_T1	COMPOUND	3	3	idarubicin
NCT000027614	NCT00002761_4_T2	PHENOTYPE	25	25	chronic
NCT000027614	NCT00002761_4_T3	PHENOTYPE	21	23	chronic myelogenous leukemia
NCT000027614	NCT00002761_4_T4	CELL	13	16	peripheral blood stem cells
NCT000027616	NCT00002761_6_T0	PHENOTYPE	2	2	toxicity
NCT000027618	NCT00002761_8_T0	COMPOUND	9	9	cyclosporine
NCT000027618	NCT00002761_8_T1	GENE	11	12	interferon gamma
NCT0000276110	NCT00002761_10_T0	COMPOUND	15	15	busulfan
NCT0000276110	NCT00002761_10_T1	PHENOTYPE	12	12	conditioning
NCT0000276110	NCT00002761_10_T2	COMPOUND	17	17	cyclophosphamide
NCT0000276111	NCT00002761_11_T0	COMPOUND	6	6	cytarabine
NCT0000276111	NCT00002761_11_T1	GENE	13	13	1.3
NCT0000276111	NCT00002761_11_T2	COMPOUND	3	3	idarubicin
NCT0000276111	NCT00002761_11_T3	GENE	4	4	IV
NCT0000276111	NCT00002761_11_T4	GENE	7	7	IV
NCT0000276113	NCT00002761_13_T0	GENE	5	5	SC
NCT0000276113	NCT00002761_13_T1	COMPOUND	12	12	cytarabine
NCT0000276113	NCT00002761_13_T2	GENE	1	1	G-CSF
NCT0000276114	NCT00002761_14_T0	ORGAN	7	7	marrow
NCT0000276114	NCT00002761_14_T1	PHENOTYPE	10	10	peripheral
NCT0000276114	NCT00002761_14_T2	PHENOTYPE	24	24	conditioning
NCT0000276114	NCT00002761_14_T3	GENE	12	12	interferon
NCT0000276114	NCT00002761_14_T4	GENE	14	14	interferon
NCT0000276114	NCT00002761_14_T5	PHENOTYPE	20	21	clonal evolution
NCT0000276117	NCT00002761_17_T0	GENE	21	21	SC
NCT0000276117	NCT00002761_17_T1	COMPOUND	7	7	cyclosporine
NCT0000276117	NCT00002761_17_T2	PHENOTYPE	4	4	leukemia
NCT0000276117	NCT00002761_17_T3	ORGAN	2	2	graft
NCT0000276117	NCT00002761_17_T4	GENE	8	8	IV
NCT0000276117	NCT00002761_17_T5	GENE	19	20	interferon gamma
NCT0000276119	NCT00002761_19_T0	GENE	14	14	4-8
NCT000027621	NCT00002762_1_T0	BIOLOGICAL_PROCESS	13	14	menstrual cycle
NCT000027621	NCT00002762_1_T1	PHENOTYPE	31	34	stage II breast cancer
NCT000027624	NCT00002762_4_T0	PHENOTYPE	3	4	hormone levels
NCT000027628	NCT00002762_8_T0	GENE	4	4	21
NCT000027629	NCT00002762_9_T0	GENE	4	4	II
NCT000027629	NCT00002762_9_T1	PHENOTYPE	12	13	ductal carcinoma
NCT000027629	NCT00002762_9_T2	PHENOTYPE	5	6	breast cancer
NCT0000276210	NCT00002762_10_T0	ORGAN	2	2	serum
NCT000027630	NCT00002763_0_T0	PHENOTYPE	18	18	Melanoma
NCT000027630	NCT00002763_0_T1	GENE	17	17	III
NCT000027630	NCT00002763_0_T2	GENE	3	3	Interferon
NCT000027632	NCT00002763_2_T0	GENE	9	9	interferon
NCT000027632	NCT00002763_2_T1	PHENOTYPE	22	24	stage III melanoma
NCT000027633	NCT00002763_3_T0	GENE	3	3	III
NCT000027633	NCT00002763_3_T1	GENE	13	13	interferon
NCT000027633	NCT00002763_3_T2	PHENOTYPE	28	30	stage III melanoma
NCT000027637	NCT00002763_7_T0	PHENOTYPE	2	2	toxicity
NCT000027639	NCT00002763_9_T0	PHENOTYPE	2	4	quality of life
NCT0000276313	NCT00002763_13_T0	GENE	0	0	Interferon
NCT000027641	NCT00002764_1_T0	CELL	9	9	cells
NCT000027641	NCT00002764_1_T1	PHENOTYPE	8	8	tumor
NCT000027642	NCT00002764_2_T0	PHENOTYPE	20	21	lung metastases
NCT000027642	NCT00002764_2_T1	PHENOTYPE	23	25	soft tissue sarcoma
NCT000027643	NCT00002764_3_T0	GENE	3	3	III
NCT000027643	NCT00002764_3_T1	GENE	28	28	has
NCT000027643	NCT00002764_3_T2	PHENOTYPE	24	26	soft tissue sarcoma
NCT000027645	NCT00002764_5_T0	GENE	28	28	G-CSF
NCT000027645	NCT00002764_5_T1	PHENOTYPE	13	13	secondary
NCT000027645	NCT00002764_5_T2	COMPOUND	23	23	ifosfamide
NCT000027645	NCT00002764_5_T3	GENE	27	27	filgrastim
NCT000027645	NCT00002764_5_T4	COMPOUND	21	21	doxorubicin
NCT000027645	NCT00002764_5_T5	PHENOTYPE	11	12	lung metastases
NCT000027645	NCT00002764_5_T6	PHENOTYPE	15	17	soft tissue sarcoma
NCT000027649	NCT00002764_9_T0	PHENOTYPE	7	7	metastases
NCT000027649	NCT00002764_9_T1	PHENOTYPE	10	10	bilateral
NCT000027649	NCT00002764_9_T2	PHENOTYPE	8	8	unilateral
NCT0000276412	NCT00002764_12_T0	COMPOUND	8	8	ifosfamide
NCT0000276412	NCT00002764_12_T1	GENE	20	20	3/13
NCT0000276412	NCT00002764_12_T2	GENE	15	15	filgrastim
NCT0000276412	NCT00002764_12_T3	GENE	16	16	G-CSF
NCT0000276412	NCT00002764_12_T4	COMPOUND	5	5	doxorubicin
NCT0000276412	NCT00002764_12_T5	GENE	6	6	IV
NCT0000276412	NCT00002764_12_T6	GENE	9	9	IV
NCT0000276413	NCT00002764_13_T0	GENE	8	8	G-CSF
NCT000027651	NCT00002765_1_T0	PHENOTYPE	16	16	leukemia
NCT000027651	NCT00002765_1_T1	PHENOTYPE	18	18	lymphoma
NCT000027654	NCT00002765_4_T0	GENE	4	4	IV
NCT000027655	NCT00002765_5_T0	PHENOTYPE	20	20	toxicity
NCT000027655	NCT00002765_5_T1	PHENOTYPE	14	15	disease progression
NCT000027656	NCT00002765_6_T0	GENE	16	16	MTD
NCT000027657	NCT00002765_7_T0	PHENOTYPE	17	17	toxicity
NCT000027657	NCT00002765_7_T1	GENE	1	1	MTD
NCT000027657	NCT00002765_7_T2	PHENOTYPE	14	14	experiences
NCT000027661	NCT00002766_1_T0	CELL	9	9	cells
NCT000027661	NCT00002766_1_T1	PHENOTYPE	8	8	tumor
NCT000027662	NCT00002766_2_T0	PHENOTYPE	17	18	lymphoblastic lymphoma
NCT000027662	NCT00002766_2_T1	PHENOTYPE	20	22	chronic myelogenous leukemia
NCT000027662	NCT00002766_2_T2	PHENOTYPE	14	16	acute lymphoblastic leukemia
NCT000027663	NCT00002766_3_T0	GENE	4	4	III
NCT000027663	NCT00002766_3_T1	PHENOTYPE	28	29	lymphoblastic lymphoma
NCT000027663	NCT00002766_3_T2	PHENOTYPE	31	33	chronic myelogenous leukemia
NCT000027663	NCT00002766_3_T3	PHENOTYPE	25	27	acute lymphoblastic leukemia
NCT000027666	NCT00002766_6_T0	PHENOTYPE	10	11	blast crisis
NCT000027666	NCT00002766_6_T1	PHENOTYPE	13	15	chronic myelogenous leukemia
NCT000027671	NCT00002767_1_T0	PHENOTYPE	6	6	melanoma
NCT000027671	NCT00002767_1_T1	GENE	9	9	interferon
NCT000027671	NCT00002767_1_T2	GENE	15	15	interferon
NCT000027671	NCT00002767_1_T3	PHENOTYPE	22	23	metastatic melanoma
NCT000027672	NCT00002767_2_T0	GENE	3	3	III
NCT000027672	NCT00002767_2_T1	GENE	10	10	interferon
NCT000027672	NCT00002767_2_T2	PHENOTYPE	21	22	metastatic melanoma
NCT000027674	NCT00002767_4_T0	PHENOTYPE	7	7	melanoma
NCT000027674	NCT00002767_4_T1	COMPOUND	10	11	interferon alfa_2b
NCT000027674	NCT00002767_4_T2	PHENOTYPE	19	20	metastatic melanoma
NCT000027676	NCT00002767_6_T0	PHENOTYPE	4	4	toxicity
NCT000027676	NCT00002767_6_T1	PHENOTYPE	10	10	melanoma
NCT0000276710	NCT00002767_10_T0	PHENOTYPE	11	12	disease progression
NCT0000276712	NCT00002767_12_T0	PHENOTYPE	8	8	melanoma
NCT0000276712	NCT00002767_12_T1	PHENOTYPE	2	4	effects of immunotherapy
NCT0000276712	NCT00002767_12_T2	PHENOTYPE	16	18	quality of life
NCT0000276717	NCT00002767_17_T0	GENE	0	0	Interferon
NCT0000276719	NCT00002767_19_T0	PHENOTYPE	10	10	toxicity
NCT0000276719	NCT00002767_19_T1	PHENOTYPE	6	7	disease progression
NCT0000276721	NCT00002767_21_T0	PHENOTYPE	10	10	toxicity
NCT0000276721	NCT00002767_21_T1	PHENOTYPE	6	7	disease progression
NCT0000276722	NCT00002767_22_T0	PHENOTYPE	0	2	Quality of life
NCT0000276810	NCT00002768_10_T0	PHENOTYPE	2	2	engraftment
NCT0000276811	NCT00002768_11_T0	COMPOUND	4	4	cytarabine
NCT0000276811	NCT00002768_11_T1	GENE	18	18	1.4
NCT0000276811	NCT00002768_11_T2	COMPOUND	13	13	etoposide
NCT0000276811	NCT00002768_11_T3	GENE	5	5	IV
NCT0000276811	NCT00002768_11_T4	GENE	14	14	IV
NCT0000276812	NCT00002768_12_T0	GENE	5	5	SC
NCT0000276812	NCT00002768_12_T1	GENE	1	1	G-CSF
NCT0000276812	NCT00002768_12_T2	CELL	13	16	peripheral blood stem cells
NCT0000276813	NCT00002768_13_T0	CELL	11	11	cells
NCT0000276813	NCT00002768_13_T1	GENE	10	10	CD34
NCT0000276814	NCT00002768_14_T0	GENE	32	32	IV
NCT0000276814	NCT00002768_14_T1	COMPOUND	21	21	busulfan
NCT0000276814	NCT00002768_14_T2	COMPOUND	38	38	3
NCT0000276814	NCT00002768_14_T3	COMPOUND	31	31	etoposide
NCT0000276814	NCT00002768_14_T4	PHENOTYPE	0	0	Conditioning
NCT0000276816	NCT00002768_16_T0	GENE	3	3	SC
NCT0000276816	NCT00002768_16_T1	GENE	0	0	G-CSF
NCT0000276817	NCT00002768_17_T0	PHENOTYPE	7	7	relapse
NCT0000276817	NCT00002768_17_T1	COMPOUND	9	9	methotrexate
NCT000027711	NCT00002771_1_T0	CELL	21	21	cells
NCT000027711	NCT00002771_1_T1	ORGAN	3	4	bone marrow
NCT000027712	NCT00002771_2_T0	GENE	3	3	III
NCT000027712	NCT00002771_2_T1	ORGAN	15	16	bone marrow
NCT000027712	NCT00002771_2_T2	PHENOTYPE	22	24	chronic myelogenous leukemia
NCT000027715	NCT00002771_5_T0	ORGAN	10	11	bone marrow
NCT000027717	NCT00002771_7_T0	GENE	1	1	WBC
NCT000027717	NCT00002771_7_T1	GENE	10	10	HU
NCT000027718	NCT00002771_8_T0	GENE	6	6	IFN
NCT000027718	NCT00002771_8_T1	GENE	12	12	SC
NCT000027718	NCT00002771_8_T2	COMPOUND	10	10	cytarabine
NCT000027718	NCT00002771_8_T3	PHENOTYPE	2	3	disease progression
NCT0000277111	NCT00002771_11_T0	PHENOTYPE	4	4	remission
NCT0000277112	NCT00002771_12_T0	PHENOTYPE	4	4	remission
NCT0000277114	NCT00002771_14_T0	PHENOTYPE	10	10	remission
NCT0000277114	NCT00002771_14_T1	GENE	11	11	CR
NCT0000277115	NCT00002771_15_T0	PHENOTYPE	4	4	remission
NCT0000277116	NCT00002771_16_T0	PHENOTYPE	4	4	remission
NCT0000277117	NCT00002771_17_T0	GENE	11	11	CR
NCT0000277119	NCT00002771_19_T0	PHENOTYPE	4	4	remission
NCT0000277120	NCT00002771_20_T0	PHENOTYPE	4	4	remission
NCT0000277123	NCT00002771_23_T0	PHENOTYPE	0	0	Consolidation
NCT000027727	NCT00002772_7_T0	PHENOTYPE	2	2	toxic
NCT0000277211	NCT00002772_11_T0	PHENOTYPE	63	63	peripheral
NCT0000277211	NCT00002772_11_T1	COMPOUND	28	28	estrogen
NCT0000277211	NCT00002772_11_T2	GENE	38	38	N2
NCT0000277211	NCT00002772_11_T3	ORGAN	61	61	marrow
NCT0000277211	NCT00002772_11_T4	PHENOTYPE	23	23	menopausal
NCT0000277211	NCT00002772_11_T5	GENE	51	51	STAMP
NCT0000277211	NCT00002772_11_T6	GENE	54	54	STAMP
NCT0000277211	NCT00002772_11_T7	GENE	43	43	T3
NCT0000277211	NCT00002772_11_T8	CELL	59	60	progenitor cells
NCT0000277211	NCT00002772_11_T9	GENE	30	31	progesterone receptor
NCT0000277213	NCT00002772_13_T0	GENE	7	7	3-10
NCT0000277213	NCT00002772_13_T1	GENE	2	2	filgrastim
NCT0000277213	NCT00002772_13_T2	GENE	3	3	G-CSF
NCT0000277215	NCT00002772_15_T0	ORGAN	6	7	bone marrow
NCT0000277215	NCT00002772_15_T1	CELL	9	12	peripheral blood stem cells
NCT0000277217	NCT00002772_17_T0	GENE	8	8	OR
NCT0000277217	NCT00002772_17_T1	GENE	16	16	IV
NCT0000277217	NCT00002772_17_T2	GENE	22	22	IV
NCT0000277217	NCT00002772_17_T3	GENE	33	33	IV
NCT0000277217	NCT00002772_17_T4	COMPOUND	39	39	3
NCT0000277217	NCT00002772_17_T5	COMPOUND	15	15	cyclophosphamide
NCT0000277217	NCT00002772_17_T6	GENE	6	6	STAMP
NCT0000277217	NCT00002772_17_T7	GENE	9	9	STAMP
NCT0000277217	NCT00002772_17_T8	GENE	11	11	STAMP
NCT0000277217	NCT00002772_17_T9	COMPOUND	21	21	cisplatin
NCT0000277218	NCT00002772_18_T0	COMPOUND	15	15	thiotepa
NCT0000277218	NCT00002772_18_T1	COMPOUND	4	4	cyclophosphamide
NCT0000277218	NCT00002772_18_T2	GENE	0	0	STAMP
NCT0000277218	NCT00002772_18_T3	GENE	5	5	IV
NCT0000277218	NCT00002772_18_T4	GENE	10	10	IV
NCT0000277218	NCT00002772_18_T5	GENE	16	16	IV
NCT0000277219	NCT00002772_19_T0	ORGAN	2	3	bone marrow
NCT000027731	NCT00002773_1_T0	CELL	10	10	cells
NCT000027731	NCT00002773_1_T1	PHENOTYPE	9	9	tumor
NCT000027732	NCT00002773_2_T0	ORGAN	6	7	immune system
NCT000027732	NCT00002773_2_T1	PHENOTYPE	12	14	effects of chemotherapy
NCT000027733	NCT00002773_3_T0	CELL	7	7	cells
NCT000027733	NCT00002773_3_T1	PHENOTYPE	6	6	tumor
NCT000027734	NCT00002773_4_T0	GENE	2	2	II
NCT000027734	NCT00002773_4_T1	CELL	15	15	cells
NCT000027734	NCT00002773_4_T2	PHENOTYPE	14	14	tumor
NCT000027734	NCT00002773_4_T3	COMPOUND	24	24	cyclophosphamide
NCT000027734	NCT00002773_4_T4	GENE	26	26	GM-CSF
NCT000027734	NCT00002773_4_T5	GENE	18	18	interferon
NCT000027734	NCT00002773_4_T6	PHENOTYPE	32	33	pancreatic cancer
NCT000027736	NCT00002773_6_T0	PHENOTYPE	3	3	toxicity
NCT000027736	NCT00002773_6_T1	GENE	26	26	GM-CSF
NCT000027736	NCT00002773_6_T2	GENE	19	19	interferon
NCT000027736	NCT00002773_6_T3	CELL	16	16	cells
NCT000027736	NCT00002773_6_T4	COMPOUND	28	28	cyclophosphamide
NCT000027736	NCT00002773_6_T5	GENE	25	25	sargramostim
NCT000027736	NCT00002773_6_T6	PHENOTYPE	33	34	pancreatic adenocarcinoma
NCT000027736	NCT00002773_6_T7	PHENOTYPE	14	15	pancreatic cancer
NCT000027739	NCT00002773_9_T0	CELL	5	5	cells
NCT000027739	NCT00002773_9_T1	GENE	9	9	interferon
NCT000027739	NCT00002773_9_T2	PHENOTYPE	3	4	pancreatic cancer
NCT0000277311	NCT00002773_11_T0	CELL	1	1	cells
NCT0000277312	NCT00002773_12_T0	COMPOUND	6	6	3
NCT0000277312	NCT00002773_12_T1	COMPOUND	2	2	cyclophosphamide
NCT0000277312	NCT00002773_12_T2	GENE	13	13	0.8
NCT0000277312	NCT00002773_12_T3	GENE	9	9	GM-CSF
NCT0000277312	NCT00002773_12_T4	GENE	3	3	IV
NCT0000277312	NCT00002773_12_T5	GENE	8	8	sargramostim
NCT0000277313	NCT00002773_13_T0	GENE	9	9	dorsal
NCT0000277313	NCT00002773_13_T1	CELL	7	7	cells
NCT0000277313	NCT00002773_13_T2	PHENOTYPE	6	6	tumor
NCT0000277314	NCT00002773_14_T0	PHENOTYPE	19	19	toxicity
NCT0000277314	NCT00002773_14_T1	GENE	3	3	2.4
NCT0000277314	NCT00002773_14_T2	PHENOTYPE	15	16	disease progression
NCT0000277315	NCT00002773_15_T0	GENE	4	4	2.4
NCT000027740	NCT00002774_0_T0	GENE	10	10	III
NCT000027740	NCT00002774_0_T1	GENE	13	13	IV
NCT000027740	NCT00002774_0_T2	PHENOTYPE	14	17	Head and Neck Cancer
NCT000027742	NCT00002774_2_T0	CELL	11	11	cells
NCT000027742	NCT00002774_2_T1	PHENOTYPE	10	10	tumor
NCT000027743	NCT00002774_3_T0	CELL	9	9	cells
NCT000027743	NCT00002774_3_T1	PHENOTYPE	8	8	tumor
NCT000027744	NCT00002774_4_T0	CELL	8	8	cells
NCT000027744	NCT00002774_4_T1	PHENOTYPE	7	7	tumor
NCT000027745	NCT00002774_5_T0	CELL	13	13	cells
NCT000027745	NCT00002774_5_T1	PHENOTYPE	12	12	tumor
NCT000027748	NCT00002774_8_T0	COMPOUND	14	14	cisplatin
NCT000027748	NCT00002774_8_T1	COMPOUND	34	34	cisplatin
NCT0000277413	NCT00002774_13_T0	GENE	12	12	RT
NCT0000277416	NCT00002774_16_T0	GENE	13	13	PR
NCT0000277416	NCT00002774_16_T1	GENE	2	2	RT
NCT0000277416	NCT00002774_16_T2	GENE	9	9	had
NCT0000277416	NCT00002774_16_T3	GENE	11	11	CR
NCT0000277417	NCT00002774_17_T0	COMPOUND	6	6	1
NCT0000277417	NCT00002774_17_T1	GENE	10	10	5.5
NCT0000277418	NCT00002774_18_T0	PHENOTYPE	5	6	progressive disease
NCT000027751	NCT00002775_1_T0	CELL	9	9	cells
NCT000027751	NCT00002775_1_T1	PHENOTYPE	8	8	tumor
NCT000027756	NCT00002775_6_T0	GENE	10	10	II
NCT000027758	NCT00002775_8_T0	PHENOTYPE	18	19	disease progression
NCT0000277512	NCT00002775_12_T0	PHENOTYPE	4	6	quality of life
NCT0000277514	NCT00002775_14_T0	GENE	15	15	0.2
NCT0000277515	NCT00002775_15_T0	COMPOUND	12	12	docetaxel
NCT0000277515	NCT00002775_15_T1	COMPOUND	3	3	estramustine
NCT0000277516	NCT00002775_16_T0	COMPOUND	2	2	docetaxel
NCT0000277516	NCT00002775_16_T1	GENE	3	3	IV
NCT0000277517	NCT00002775_17_T0	COMPOUND	8	8	docetaxel
NCT0000277517	NCT00002775_17_T1	GENE	14	14	MTD
NCT0000277518	NCT00002775_18_T0	PHENOTYPE	18	18	toxicity
NCT0000277518	NCT00002775_18_T1	GENE	1	1	MTD
NCT0000277519	NCT00002775_19_T0	GENE	9	9	MTD
NCT0000277520	NCT00002775_20_T0	GENE	1	1	II
NCT0000277520	NCT00002775_20_T1	COMPOUND	4	4	docetaxel
NCT0000277520	NCT00002775_20_T2	GENE	8	8	MTD
NCT0000277520	NCT00002775_20_T3	GENE	5	5	IV
NCT0000277521	NCT00002775_21_T0	PHENOTYPE	10	10	toxicity
NCT0000277521	NCT00002775_21_T1	PHENOTYPE	6	7	disease progression
NCT0000277522	NCT00002775_22_T0	PHENOTYPE	0	2	Quality of life
NCT000027772	NCT00002777_2_T0	COMPOUND	10	10	exemestane
NCT000027772	NCT00002777_2_T1	PHENOTYPE	22	22	recurrent
NCT000027772	NCT00002777_2_T2	COMPOUND	14	14	tamoxifen
NCT000027772	NCT00002777_2_T3	PHENOTYPE	24	26	metastatic breast cancer
NCT000027775	NCT00002777_5_T0	GENE	1	1	II
NCT000027775	NCT00002777_5_T1	PHENOTYPE	5	5	closed
NCT000027776	NCT00002777_6_T0	PHENOTYPE	24	24	metastasis
NCT000027776	NCT00002777_6_T1	COMPOUND	8	8	tamoxifen
NCT000027776	NCT00002777_6_T2	PHENOTYPE	15	16	metastatic disease
NCT000027777	NCT00002777_7_T0	COMPOUND	7	7	exemestane
NCT000027777	NCT00002777_7_T1	COMPOUND	10	10	tamoxifen
NCT000027778	NCT00002777_8_T0	PHENOTYPE	10	10	toxicity
NCT000027778	NCT00002777_8_T1	PHENOTYPE	6	7	disease progression
NCT0000277710	NCT00002777_10_T0	GENE	14	14	4.7
NCT000027781	NCT00002778_1_T0	CELL	22	22	cells
NCT000027781	NCT00002778_1_T1	ORGAN	4	5	bone marrow
NCT000027782	NCT00002778_2_T0	PHENOTYPE	17	17	peripheral
NCT000027782	NCT00002778_2_T1	CELL	11	11	cells
NCT000027782	NCT00002778_2_T2	GENE	4	4	sargramostim
NCT000027782	NCT00002778_2_T3	ORGAN	14	15	bone marrow
NCT000027782	NCT00002778_2_T4	ORGAN	24	25	immune system
NCT000027782	NCT00002778_2_T5	PHENOTYPE	30	32	effects of chemotherapy
NCT000027783	NCT00002778_3_T0	GENE	2	2	II
NCT000027783	NCT00002778_3_T1	GENE	15	15	sargramostim
NCT000027783	NCT00002778_3_T2	ORGAN	10	11	bone marrow
NCT000027783	NCT00002778_3_T3	PHENOTYPE	21	23	chronic myelogenous leukemia
NCT000027785	NCT00002778_5_T0	COMPOUND	5	5	busulfan
NCT000027785	NCT00002778_5_T1	PHENOTYPE	3	3	myeloablation
NCT000027785	NCT00002778_5_T2	COMPOUND	7	7	cyclophosphamide
NCT000027786	NCT00002778_6_T0	GENE	10	10	CD34
NCT000027786	NCT00002778_6_T1	ORGAN	1	2	bone marrow
NCT000027787	NCT00002778_7_T0	CELL	0	0	T-cell
NCT000027787	NCT00002778_7_T1	ORGAN	4	5	bone marrow
NCT000027788	NCT00002778_8_T0	GENE	6	6	SC
NCT000027788	NCT00002778_8_T1	GENE	21	21	SC
NCT000027788	NCT00002778_8_T2	GENE	4	4	GM-CSF
NCT000027788	NCT00002778_8_T3	GENE	20	20	GM-CSF
NCT000027788	NCT00002778_8_T4	GENE	3	3	sargramostim
NCT000027789	NCT00002778_9_T0	PHENOTYPE	19	19	secondary
NCT000027789	NCT00002778_9_T1	PHENOTYPE	20	20	engraftment
NCT000027789	NCT00002778_9_T2	GENE	11	11	GM-CSF
NCT000027789	NCT00002778_9_T3	CELL	1	1	lymphocyte
NCT000027789	NCT00002778_9_T4	ORGAN	7	8	bone marrow
NCT000027791	NCT00002779_1_T0	CELL	9	9	cells
NCT000027792	NCT00002779_2_T0	GENE	2	2	II
NCT000027792	NCT00002779_2_T1	COMPOUND	9	9	fludarabine
NCT000027792	NCT00002779_2_T2	COMPOUND	11	11	octreotide
NCT000027792	NCT00002779_2_T3	PHENOTYPE	19	20	Hodgkin's lymphoma
NCT000027794	NCT00002779_4_T0	COMPOUND	9	9	fludarabine
NCT000027794	NCT00002779_4_T1	COMPOUND	12	12	octreotide
NCT000027794	NCT00002779_4_T2	COMPOUND	15	15	octreotide
NCT000027794	NCT00002779_4_T3	PHENOTYPE	22	23	Hodgkin's lymphoma
NCT000027798	NCT00002779_8_T0	PHENOTYPE	5	5	lymphoma
NCT000027798	NCT00002779_8_T1	GENE	1	2	somatostatin receptor
NCT000027799	NCT00002779_9_T0	GENE	10	10	1.5
NCT000027799	NCT00002779_9_T1	COMPOUND	3	3	fludarabine
NCT000027799	NCT00002779_9_T2	GENE	4	4	IV
NCT0000277910	NCT00002779_10_T0	COMPOUND	4	4	octreotide
NCT0000277910	NCT00002779_10_T1	COMPOUND	10	10	octreotide
NCT0000277910	NCT00002779_10_T2	COMPOUND	22	22	octreotide
NCT0000277912	NCT00002779_12_T0	COMPOUND	3	3	octreotide
NCT0000277913	NCT00002779_13_T0	COMPOUND	9	9	octreotide
NCT0000277914	NCT00002779_14_T0	PHENOTYPE	11	12	disease progression
NCT000027801	NCT00002780_1_T0	CELL	10	10	cells
NCT000027801	NCT00002780_1_T1	PHENOTYPE	9	9	tumor
NCT000027808	NCT00002780_8_T0	COMPOUND	25	25	3
NCT000027808	NCT00002780_8_T1	COMPOUND	19	19	thiotepa
NCT000027808	NCT00002780_8_T2	COMPOUND	14	14	cyclophosphamide
NCT000027808	NCT00002780_8_T3	GENE	15	15	IV
NCT000027808	NCT00002780_8_T4	GENE	17	17	IV
NCT000027808	NCT00002780_8_T5	GENE	20	20	IV
NCT000027808	NCT00002780_8_T6	ORGAN	4	5	bone marrow
NCT0000278010	NCT00002780_10_T0	GENE	26	26	interleukin-2
NCT0000278010	NCT00002780_10_T1	GENE	27	27	IL-2
NCT0000278010	NCT00002780_10_T2	GENE	34	34	GM-CSF
NCT0000278010	NCT00002780_10_T3	GENE	14	14	IV
NCT0000278010	NCT00002780_10_T4	GENE	28	28	IV
NCT0000278010	NCT00002780_10_T5	GENE	33	33	sargramostim
NCT0000278010	NCT00002780_10_T6	CELL	12	13	T lymphocytes
NCT0000278012	NCT00002780_12_T0	GENE	12	12	1.2
NCT000027810	NCT00002781_0_T0	COMPOUND	0	0	Boron
NCT000027810	NCT00002781_0_T1	PHENOTYPE	10	10	Melanoma
NCT000027810	NCT00002781_0_T2	GENE	9	9	III
NCT000027812	NCT00002781_2_T0	CELL	10	10	neuron
NCT000027812	NCT00002781_2_T1	COMPOUND	9	9	boron
NCT000027812	NCT00002781_2_T2	PHENOTYPE	17	19	stage III melanoma
NCT000027818	NCT00002781_8_T0	PHENOTYPE	1	1	tumor
NCT0000278110	NCT00002781_10_T0	PHENOTYPE	17	17	tumor
NCT0000278110	NCT00002781_10_T1	GENE	14	14	punch
NCT0000278113	NCT00002781_13_T0	GENE	21	21	has
NCT000027831	NCT00002783_1_T0	CELL	15	15	cells
NCT000027831	NCT00002783_1_T1	PHENOTYPE	14	14	tumor
NCT000027832	NCT00002783_2_T0	GENE	2	2	II
NCT000027832	NCT00002783_2_T1	PHENOTYPE	19	20	stomach cancer
NCT000027834	NCT00002783_4_T0	PHENOTYPE	4	4	toxicity
NCT000027834	NCT00002783_4_T1	PHENOTYPE	21	22	gastric cancer
NCT000027836	NCT00002783_6_T0	PHENOTYPE	2	4	quality of life
NCT0000278310	NCT00002783_10_T0	PHENOTYPE	4	4	mutated
NCT0000278310	NCT00002783_10_T1	PHENOTYPE	15	15	tumor
NCT0000278310	NCT00002783_10_T2	GENE	8	8	suppressor
NCT0000278310	NCT00002783_10_T3	GENE	7	7	p53
NCT0000278311	NCT00002783_11_T0	COMPOUND	11	11	calcium
NCT0000278312	NCT00002783_12_T0	GENE	9	9	D2
NCT000027846	NCT00002784_6_T0	GENE	31	31	G-CSF
NCT000027846	NCT00002784_6_T1	CELL	28	28	granulocyte
NCT000027846	NCT00002784_6_T2	PHENOTYPE	16	17	breast cancer
NCT000027846	NCT00002784_6_T3	CELL	34	37	peripheral blood stem cells
NCT000027848	NCT00002784_8_T0	PHENOTYPE	2	2	toxicity
NCT000027848	NCT00002784_8_T1	PHENOTYPE	10	10	toxicity
NCT000027848	NCT00002784_8_T2	PHENOTYPE	8	8	symptoms
NCT000027848	NCT00002784_8_T3	PHENOTYPE	12	14	quality of life
NCT0000278412	NCT00002784_12_T0	PHENOTYPE	8	8	menopausal
NCT0000278412	NCT00002784_12_T1	GENE	4	5	estrogen receptor
NCT0000278413	NCT00002784_13_T0	COMPOUND	16	16	cyclophosphamide
NCT0000278413	NCT00002784_13_T1	COMPOUND	26	26	cyclophosphamide
NCT0000278413	NCT00002784_13_T2	COMPOUND	27	27	methotrexate
NCT0000278413	NCT00002784_13_T3	COMPOUND	11	11	epirubicin
NCT0000278413	NCT00002784_13_T4	COMPOUND	14	14	doxorubicin
NCT0000278415	NCT00002784_15_T0	COMPOUND	4	4	tamoxifen
NCT000027851	NCT00002785_1_T0	CELL	9	9	cells
NCT000027852	NCT00002785_2_T0	CELL	17	17	cells
NCT000027852	NCT00002785_2_T1	ORGAN	0	1	Bone marrow
NCT000027853	NCT00002785_3_T0	CELL	8	8	cells
NCT000027854	NCT00002785_4_T0	GENE	2	2	II
NCT000027854	NCT00002785_4_T1	ORGAN	11	12	bone marrow
NCT000027854	NCT00002785_4_T2	PHENOTYPE	21	23	acute lymphoblastic leukemia
NCT000027858	NCT00002785_8_T0	ORGAN	6	7	bone marrow
NCT0000278514	NCT00002785_14_T0	PHENOTYPE	3	3	associations
NCT0000278515	NCT00002785_15_T0	PHENOTYPE	33	33	Consolidation
NCT0000278521	NCT00002785_21_T0	GENE	3	3	IT
NCT0000278523	NCT00002785_23_T0	GENE	6	6	IT
NCT0000278525	NCT00002785_25_T0	GENE	2	2	IT
NCT0000278527	NCT00002785_27_T0	GENE	3	3	MTX
NCT0000278527	NCT00002785_27_T1	GENE	2	2	IT
NCT0000278528	NCT00002785_28_T0	PHENOTYPE	13	13	GVHD
NCT000027861	NCT00002786_1_T0	PHENOTYPE	16	17	metastatic melanoma
NCT000027863	NCT00002786_3_T0	PHENOTYPE	2	2	peripheral
NCT000027863	NCT00002786_3_T1	CELL	14	14	clones
NCT000027863	NCT00002786_3_T2	GENE	20	20	ex
NCT000027863	NCT00002786_3_T3	CELL	5	5	cells
NCT000027863	NCT00002786_3_T4	GENE	10	10	CD8
NCT000027863	NCT00002786_3_T5	GENE	13	13	CTL
NCT000027864	NCT00002786_4_T0	CELL	9	9	clones
NCT000027864	NCT00002786_4_T1	GENE	7	7	CD8
NCT000027864	NCT00002786_4_T2	GENE	8	8	CTL
NCT000027865	NCT00002786_5_T0	GENE	3	3	interleukin-2
NCT000027865	NCT00002786_5_T1	GENE	13	13	2.3
NCT000027866	NCT00002786_6_T0	PHENOTYPE	16	16	toxicity
NCT000027866	NCT00002786_6_T1	PHENOTYPE	12	13	disease progression
NCT000027874	NCT00002787_4_T0	GENE	3	3	pre
NCT000027874	NCT00002787_4_T1	BIOLOGICAL_PROCESS	16	17	immune response
NCT000027874	NCT00002787_4_T2	ORGAN	6	7	bone marrow
NCT000027878	NCT00002787_8_T0	PHENOTYPE	10	10	tumor
NCT000027878	NCT00002787_8_T1	CELL	1	1	clone
NCT000027878	NCT00002787_8_T2	CELL	5	6	T cells
NCT0000278710	NCT00002787_10_T0	PHENOTYPE	1	1	myeloma
NCT0000278710	NCT00002787_10_T1	ORGAN	7	7	serum
NCT0000278710	NCT00002787_10_T2	ORGAN	4	5	bone marrow
NCT0000278713	NCT00002787_13_T0	GENE	12	12	SC
NCT0000278713	NCT00002787_13_T1	GENE	22	22	SC
NCT0000278713	NCT00002787_13_T2	GENE	10	10	sargramostim
NCT0000278713	NCT00002787_13_T3	GENE	21	21	sargramostim
NCT0000278714	NCT00002787_14_T0	GENE	5	5	SC
NCT0000278714	NCT00002787_14_T1	GENE	4	4	aldesleukin
NCT000027881	NCT00002788_1_T0	CELL	8	8	cells
NCT000027885	NCT00002788_5_T0	PHENOTYPE	1	1	engraftment
NCT000027885	NCT00002788_5_T1	PHENOTYPE	18	18	CLL
NCT000027885	NCT00002788_5_T2	GENE	5	5	CD34
NCT000027885	NCT00002788_5_T3	PHENOTYPE	15	17	chronic lymphocytic leukemia
NCT000027885	NCT00002788_5_T4	CELL	7	10	peripheral blood stem cells
NCT000027887	NCT00002788_7_T0	PHENOTYPE	8	8	CLL
NCT000027887	NCT00002788_7_T1	GENE	4	4	CD34
NCT000027887	NCT00002788_7_T2	PHENOTYPE	7	7	purging
NCT000027889	NCT00002788_9_T0	COMPOUND	10	10	dexamethasone
NCT000027889	NCT00002788_9_T1	CELL	13	13	granulocyte
NCT000027889	NCT00002788_9_T2	GENE	12	12	filgrastim
NCT000027889	NCT00002788_9_T3	COMPOUND	7	7	cyclophosphamide
NCT000027889	NCT00002788_9_T4	COMPOUND	8	8	etoposide
NCT0000278811	NCT00002788_11_T0	PHENOTYPE	1	1	toxicity
NCT0000278811	NCT00002788_11_T1	PHENOTYPE	7	7	conditioning
NCT0000278811	NCT00002788_11_T2	COMPOUND	14	14	cyclophosphamide
NCT0000278813	NCT00002788_13_T0	PHENOTYPE	9	9	remission
NCT0000278814	NCT00002788_14_T0	CELL	19	19	granulocyte
NCT0000278814	NCT00002788_14_T1	GENE	18	18	filgrastim
NCT0000278814	NCT00002788_14_T2	GENE	22	22	G-CSF
NCT0000278814	NCT00002788_14_T3	GENE	3	3	CD34
NCT0000278814	NCT00002788_14_T4	CELL	5	8	peripheral blood stem cells
NCT0000278816	NCT00002788_16_T0	GENE	5	5	1.2
NCT0000278817	NCT00002788_17_T0	GENE	9	9	1.3
NCT0000278818	NCT00002788_18_T0	GENE	0	0	G-CSF
NCT0000278819	NCT00002788_19_T0	ORGAN	13	13	transplant
NCT000027893	NCT00002789_3_T0	GENE	10	10	filgrastim
NCT000027893	NCT00002789_3_T1	CELL	0	1	Stem cells
NCT0000278912	NCT00002789_12_T0	PHENOTYPE	3	3	severity
NCT0000278912	NCT00002789_12_T1	PHENOTYPE	5	5	acute
NCT0000278912	NCT00002789_12_T2	PHENOTYPE	7	11	chronic graft versus host disease
NCT0000278912	NCT00002789_12_T3	PHENOTYPE	8	12	graft versus host disease in
NCT0000278918	NCT00002789_18_T0	ORGAN	1	2	bone marrow
NCT0000278919	NCT00002789_19_T0	COMPOUND	16	16	cyclosporine
NCT0000278919	NCT00002789_19_T1	COMPOUND	10	10	1
NCT0000278919	NCT00002789_19_T2	COMPOUND	28	28	1
NCT0000278919	NCT00002789_19_T3	GENE	19	19	1.4
NCT0000278919	NCT00002789_19_T4	COMPOUND	6	6	methotrexate
NCT0000278919	NCT00002789_19_T5	GENE	33	33	tapered
NCT0000278919	NCT00002789_19_T6	GENE	7	7	IV
NCT0000278919	NCT00002789_19_T7	GENE	17	17	IV
NCT0000278919	NCT00002789_19_T8	PHENOTYPE	2	3	graft-versus-host disease
NCT000027902	NCT00002790_2_T0	COMPOUND	5	5	cyclosporine
NCT000027902	NCT00002790_2_T1	COMPOUND	3	3	methotrexate
NCT000027903	NCT00002790_3_T0	COMPOUND	13	13	cyclosporine
NCT000027903	NCT00002790_3_T1	COMPOUND	11	11	methotrexate
NCT000027903	NCT00002790_3_T2	ORGAN	29	29	transplant
NCT000027903	NCT00002790_3_T3	PHENOTYPE	16	17	graft-versus-host disease
NCT000027903	NCT00002790_3_T4	ORGAN	27	28	bone marrow
NCT000027903	NCT00002790_3_T5	PHENOTYPE	21	22	hematologic malignancies
NCT000027907	NCT00002790_7_T0	COMPOUND	8	8	rapamycin
NCT000027907	NCT00002790_7_T1	COMPOUND	15	15	rapamycin
NCT000027908	NCT00002790_8_T0	COMPOUND	3	3	cyclosporine
NCT000027908	NCT00002790_8_T1	ORGAN	9	9	transplant
NCT000027908	NCT00002790_8_T2	ORGAN	13	13	transplant
NCT000027908	NCT00002790_8_T3	GENE	18	18	tapered
NCT000027909	NCT00002790_9_T0	ORGAN	9	9	transplant
NCT0000279011	NCT00002790_11_T0	ORGAN	0	1	Bone marrow
NCT0000279012	NCT00002790_12_T0	BIOLOGICAL_PROCESS	13	13	metabolism
NCT0000279012	NCT00002790_12_T1	GENE	16	16	FK506
NCT0000279012	NCT00002790_12_T2	COMPOUND	21	21	prednisone
NCT0000279012	NCT00002790_12_T3	COMPOUND	12	12	rapamycin
NCT000027911	NCT00002791_1_T0	CELL	8	8	cells
NCT000027911	NCT00002791_1_T1	PHENOTYPE	7	7	tumor
NCT000027912	NCT00002791_2_T0	CELL	13	13	cells
NCT000027912	NCT00002791_2_T1	PHENOTYPE	12	12	tumor
NCT000027913	NCT00002791_3_T0	GENE	2	2	II
NCT000027913	NCT00002791_3_T1	PHENOTYPE	22	24	soft tissue sarcoma
NCT000027915	NCT00002791_5_T0	PHENOTYPE	25	25	toxicity
NCT000027915	NCT00002791_5_T1	PHENOTYPE	27	27	complication
NCT000027915	NCT00002791_5_T2	GENE	8	8	STS
NCT000027915	NCT00002791_5_T3	PHENOTYPE	5	7	soft tissue sarcoma
NCT000027917	NCT00002791_7_T0	PHENOTYPE	5	5	complications
NCT000027919	NCT00002791_9_T0	PHENOTYPE	16	16	tumors
NCT000027919	NCT00002791_9_T1	GENE	6	6	STS
NCT0000279112	NCT00002791_12_T0	PHENOTYPE	16	16	unspecified
NCT0000279112	NCT00002791_12_T1	GENE	24	24	IFF
NCT0000279112	NCT00002791_12_T2	GENE	17	17	G-CSF
NCT0000279112	NCT00002791_12_T3	GENE	19	21	Granulocyte Colony-Stimulating Factor
NCT0000279113	NCT00002791_13_T0	PHENOTYPE	5	6	primary tumor
NCT000027924	NCT00002792_4_T0	COMPOUND	9	9	busulfan
NCT000027924	NCT00002792_4_T1	COMPOUND	24	24	2
NCT000027924	NCT00002792_4_T2	COMPOUND	22	22	3
NCT000027924	NCT00002792_4_T3	COMPOUND	19	19	cyclophosphamide
NCT000027925	NCT00002792_5_T0	ORGAN	4	5	bone marrow
NCT000027925	NCT00002792_5_T1	CELL	7	10	peripheral blood stem cells
NCT000027927	NCT00002792_7_T0	PHENOTYPE	10	10	GVHD
NCT000027927	NCT00002792_7_T1	PHENOTYPE	8	9	graft-versus-host disease
NCT000027928	NCT00002792_8_T0	ORGAN	2	2	marrow
NCT000027928	NCT00002792_8_T1	PHENOTYPE	10	10	GVHD
NCT000027929	NCT00002792_9_T0	ORGAN	9	9	transplant
NCT0000279210	NCT00002792_10_T0	GENE	15	15	3.5
NCT000027931	NCT00002793_1_T0	CELL	16	16	cells
NCT000027931	NCT00002793_1_T1	PHENOTYPE	15	15	tumor
NCT000027932	NCT00002793_2_T0	GENE	3	3	III
NCT000027932	NCT00002793_2_T1	PHENOTYPE	29	30	colorectal cancer
NCT000027932	NCT00002793_2_T2	PHENOTYPE	22	23	liver metastases
NCT000027934	NCT00002793_4_T0	PHENOTYPE	29	30	colorectal cancer
NCT000027934	NCT00002793_4_T1	PHENOTYPE	24	25	liver metastases
NCT000027936	NCT00002793_6_T0	PHENOTYPE	16	16	complications
NCT000027936	NCT00002793_6_T1	PHENOTYPE	9	11	quality of life
NCT000027941	NCT00002794_1_T0	CELL	9	9	cells
NCT000027941	NCT00002794_1_T1	PHENOTYPE	8	8	tumor
NCT000027949	NCT00002794_9_T0	COMPOUND	6	6	vincristine
NCT0000279410	NCT00002794_10_T0	PHENOTYPE	2	3	disease progression
NCT0000279411	NCT00002794_11_T0	GENE	16	16	3.4
NCT0000279412	NCT00002794_12_T0	GENE	14	14	4.5
NCT000027962	NCT00002796_2_T0	CELL	11	11	cells
NCT000027962	NCT00002796_2_T1	PHENOTYPE	10	10	tumor
NCT000027965	NCT00002796_5_T0	GENE	5	5	II
NCT000027965	NCT00002796_5_T1	GENE	14	14	PB
NCT000027965	NCT00002796_5_T2	COMPOUND	15	15	indomethacin
NCT000027965	NCT00002796_5_T3	GENE	10	10	FU
NCT000027965	NCT00002796_5_T4	PHENOTYPE	22	23	colorectal cancer
NCT000027967	NCT00002796_7_T0	COMPOUND	11	11	1
NCT000027967	NCT00002796_7_T1	GENE	5	5	IV
NCT000027967	NCT00002796_7_T2	GENE	13	13	IV
NCT000027967	NCT00002796_7_T3	COMPOUND	19	19	indomethacin
NCT000027967	NCT00002796_7_T4	GENE	25	26	interferon gamma
NCT000027968	NCT00002796_8_T0	PHENOTYPE	11	11	toxicity
NCT000027968	NCT00002796_8_T1	PHENOTYPE	7	8	disease progression
NCT000027969	NCT00002796_9_T0	GENE	14	14	MTD
NCT0000279610	NCT00002796_10_T0	PHENOTYPE	17	17	toxicity
NCT0000279610	NCT00002796_10_T1	GENE	1	1	MTD
NCT0000279610	NCT00002796_10_T2	GENE	18	18	DLT
NCT0000279611	NCT00002796_11_T0	GENE	1	1	II
NCT0000279611	NCT00002796_11_T1	GENE	16	16	MTD
NCT0000279611	NCT00002796_11_T2	COMPOUND	6	6	indomethacin
NCT0000279611	NCT00002796_11_T3	GENE	8	9	interferon gamma
NCT0000279613	NCT00002796_13_T0	GENE	28	28	II
NCT000027981	NCT00002798_1_T0	CELL	10	10	cells
NCT000027982	NCT00002798_2_T0	CELL	21	21	cells
NCT000027982	NCT00002798_2_T1	ORGAN	3	4	bone marrow
NCT000027984	NCT00002798_4_T0	GENE	33	33	M2
NCT000027984	NCT00002798_4_T1	GENE	15	15	IDA
NCT000027984	NCT00002798_4_T2	GENE	22	22	IDA
NCT000027984	NCT00002798_4_T3	ORGAN	38	38	marrow
NCT000027984	NCT00002798_4_T4	PHENOTYPE	2	2	remission
NCT000027984	NCT00002798_4_T5	PHENOTYPE	25	25	remission
NCT000027984	NCT00002798_4_T6	PHENOTYPE	29	29	remission
NCT000027984	NCT00002798_4_T7	COMPOUND	18	18	fludarabine
NCT000027984	NCT00002798_4_T8	COMPOUND	19	19	FAMP
NCT000027985	NCT00002798_5_T0	GENE	14	14	IDA
NCT000027985	NCT00002798_5_T1	GENE	20	20	IDA
NCT000027985	NCT00002798_5_T2	COMPOUND	17	17	FAMP
NCT000027986	NCT00002798_6_T0	GENE	15	15	II
NCT000027986	NCT00002798_6_T1	GENE	20	20	asparaginase
NCT000027986	NCT00002798_6_T2	ORGAN	27	28	bone marrow
NCT000027987	NCT00002798_7_T0	GENE	21	21	II
NCT000027987	NCT00002798_7_T1	GENE	12	12	interleukin-2
NCT000027987	NCT00002798_7_T2	GENE	13	13	IL-2
NCT000027988	NCT00002798_8_T0	PHENOTYPE	8	8	AML
NCT000027988	NCT00002798_8_T1	PHENOTYPE	27	29	minimal residual disease
NCT0000279810	NCT00002798_10_T0	GENE	13	13	receptor
NCT0000279810	NCT00002798_10_T1	GENE	11	11	IL-2
NCT0000279810	NCT00002798_10_T2	GENE	19	19	ALC
NCT0000279810	NCT00002798_10_T3	CELL	17	17	lymphocyte
NCT0000279812	NCT00002798_12_T0	PHENOTYPE	19	19	remission
NCT0000279812	NCT00002798_12_T1	PHENOTYPE	7	9	acute myelogenous leukemia
NCT0000279815	NCT00002798_15_T0	GENE	4	4	RA
NCT0000279815	NCT00002798_15_T1	GENE	6	6	RA
NCT0000279815	NCT00002798_15_T2	PHENOTYPE	2	3	refractory anemia
NCT0000279816	NCT00002798_16_T0	PHENOTYPE	3	4	myelodysplastic syndromes
NCT0000279818	NCT00002798_18_T0	COMPOUND	27	27	dexamethasone
NCT0000279818	NCT00002798_18_T1	COMPOUND	11	11	cytarabine
NCT0000279818	NCT00002798_18_T2	GENE	10	10	0.3
NCT0000279818	NCT00002798_18_T3	GENE	18	18	0.3
NCT0000279818	NCT00002798_18_T4	GENE	34	34	0.3
NCT0000279818	NCT00002798_18_T5	COMPOUND	3	3	idarubicin
NCT0000279818	NCT00002798_18_T6	COMPOUND	13	13	etoposide
NCT0000279818	NCT00002798_18_T7	GENE	4	4	IV
NCT0000279818	NCT00002798_18_T8	GENE	14	14	IV
NCT0000279819	NCT00002798_19_T0	GENE	26	26	SC
NCT0000279819	NCT00002798_19_T1	COMPOUND	12	12	dexamethasone
NCT0000279819	NCT00002798_19_T2	COMPOUND	8	8	cytarabine
NCT0000279819	NCT00002798_19_T3	GENE	23	23	filgrastim
NCT0000279819	NCT00002798_19_T4	COMPOUND	9	9	etoposide
NCT0000279819	NCT00002798_19_T5	GENE	24	24	G-CSF
NCT0000279819	NCT00002798_19_T6	GENE	17	17	IV
NCT0000279819	NCT00002798_19_T7	COMPOUND	16	16	daunorubicin
NCT0000279820	NCT00002798_20_T0	COMPOUND	7	7	cytarabine
NCT0000279820	NCT00002798_20_T1	GENE	9	9	IT
NCT0000279822	NCT00002798_22_T0	ORGAN	5	5	marrow
NCT0000279822	NCT00002798_22_T1	ORGAN	13	13	marrow
NCT0000279822	NCT00002798_22_T2	GENE	2	2	M1
NCT0000279822	NCT00002798_22_T3	GENE	4	4	M2
NCT0000279822	NCT00002798_22_T4	GENE	12	12	M3
NCT0000279822	NCT00002798_22_T5	PHENOTYPE	15	16	progressive disease
NCT0000279824	NCT00002798_24_T0	COMPOUND	11	11	cytarabine
NCT0000279824	NCT00002798_24_T1	GENE	1	1	CSF
NCT0000279824	NCT00002798_24_T2	GENE	12	12	IT
NCT0000279825	NCT00002798_25_T0	COMPOUND	11	11	cytarabine
NCT0000279825	NCT00002798_25_T1	COMPOUND	12	12	hydrocortisone
NCT0000279825	NCT00002798_25_T2	GENE	1	1	CSF
NCT0000279825	NCT00002798_25_T3	COMPOUND	13	13	methotrexate
NCT0000279827	NCT00002798_27_T0	GENE	0	0	G-CSF
NCT0000279828	NCT00002798_28_T0	COMPOUND	6	6	1
NCT0000279828	NCT00002798_28_T1	GENE	10	10	CSF
NCT0000279830	NCT00002798_30_T0	ORGAN	4	4	marrow
NCT0000279830	NCT00002798_30_T1	GENE	3	3	M1
NCT0000279831	NCT00002798_31_T0	GENE	2	2	II
NCT0000279831	NCT00002798_31_T1	COMPOUND	8	8	cytarabine
NCT0000279831	NCT00002798_31_T2	COMPOUND	5	5	1
NCT0000279831	NCT00002798_31_T3	COMPOUND	19	19	1
NCT0000279831	NCT00002798_31_T4	COMPOUND	28	28	1
NCT0000279831	NCT00002798_31_T5	GENE	25	25	IM
NCT0000279831	NCT00002798_31_T6	GENE	24	24	asparaginase
NCT0000279831	NCT00002798_31_T7	GENE	9	9	IV
NCT0000279832	NCT00002798_32_T0	COMPOUND	5	5	cytarabine
NCT0000279832	NCT00002798_32_T1	COMPOUND	1	1	2
NCT0000279832	NCT00002798_32_T2	GENE	6	6	IT
NCT0000279832	NCT00002798_32_T3	GENE	19	19	2.8
NCT0000279834	NCT00002798_34_T0	COMPOUND	4	4	busulfan
NCT0000279834	NCT00002798_34_T1	COMPOUND	23	23	2
NCT0000279834	NCT00002798_34_T2	COMPOUND	14	14	cyclophosphamide
NCT0000279834	NCT00002798_34_T3	GENE	15	15	IV
NCT0000279835	NCT00002798_35_T0	COMPOUND	14	14	cyclophosphamide
NCT0000279841	NCT00002798_41_T0	GENE	6	6	de
NCT0000279841	NCT00002798_41_T1	PHENOTYPE	8	10	acute myelogenous leukemia
NCT0000279843	NCT00002798_43_T0	PHENOTYPE	5	6	myelodysplastic syndromes
NCT000028001	NCT00002800_1_T0	CELL	9	9	cells
NCT000028004	NCT00002800_4_T0	PHENOTYPE	28	28	AML
NCT000028004	NCT00002800_4_T1	COMPOUND	12	12	cytarabine
NCT000028004	NCT00002800_4_T2	COMPOUND	19	19	idarubicin
NCT000028004	NCT00002800_4_T3	PHENOTYPE	25	27	acute myelogenous leukemia
NCT000028006	NCT00002800_6_T0	PHENOTYPE	7	7	AML
NCT000028006	NCT00002800_6_T1	PHENOTYPE	15	16	residual disease
NCT000028007	NCT00002800_7_T0	COMPOUND	6	6	cytarabine
NCT000028007	NCT00002800_7_T1	COMPOUND	11	11	idarubicin
NCT000028008	NCT00002800_8_T0	COMPOUND	13	13	cytarabine
NCT000028008	NCT00002800_8_T1	COMPOUND	26	26	cytarabine
NCT000028008	NCT00002800_8_T2	PHENOTYPE	5	5	remission
NCT000028008	NCT00002800_8_T3	COMPOUND	31	31	idarubicin
NCT000028008	NCT00002800_8_T4	COMPOUND	15	15	etoposide
NCT000028008	NCT00002800_8_T5	GENE	6	6	CR
NCT000028009	NCT00002800_9_T0	CELL	9	12	peripheral blood stem cells
NCT0000280010	NCT00002800_10_T0	PHENOTYPE	23	24	cytogenetic abnormality
NCT0000280010	NCT00002800_10_T1	ORGAN	9	10	bone marrow
NCT0000280011	NCT00002800_11_T0	GENE	0	0	G-CSF
NCT000028011	NCT00002801_1_T0	CELL	15	15	cells
NCT000028011	NCT00002801_1_T1	PHENOTYPE	14	14	tumor
NCT000028012	NCT00002801_2_T0	PHENOTYPE	32	32	tumor
NCT000028012	NCT00002801_2_T1	COMPOUND	15	15	leucovorin
NCT000028012	NCT00002801_2_T2	PHENOTYPE	23	24	colorectal cancer
NCT000028014	NCT00002801_4_T0	PHENOTYPE	7	7	toxicity
NCT000028014	NCT00002801_4_T1	COMPOUND	13	13	calcium
NCT000028014	NCT00002801_4_T2	COMPOUND	12	12	leucovorin
NCT000028014	NCT00002801_4_T3	PHENOTYPE	20	21	colorectal cancer
NCT000028016	NCT00002801_6_T0	PHENOTYPE	2	2	toxicity
NCT000028018	NCT00002801_8_T0	PHENOTYPE	4	4	tumors
NCT000028018	NCT00002801_8_T1	PHENOTYPE	8	9	measurable disease
NCT0000280110	NCT00002801_10_T0	GENE	22	22	1.28
NCT0000280110	NCT00002801_10_T1	COMPOUND	14	14	calcium
NCT0000280110	NCT00002801_10_T2	COMPOUND	13	13	leucovorin
NCT0000280111	NCT00002801_11_T0	PHENOTYPE	16	16	toxicity
NCT0000280111	NCT00002801_11_T1	PHENOTYPE	12	13	disease progression
NCT0000280112	NCT00002801_12_T0	PHENOTYPE	13	13	tumor
NCT0000280112	NCT00002801_12_T1	TISSUE	17	18	lymph nodes
NCT0000280112	NCT00002801_12_T2	PHENOTYPE	32	33	primary tumor
NCT0000280113	NCT00002801_13_T0	PHENOTYPE	21	21	toxic
NCT0000280114	NCT00002801_14_T0	PHENOTYPE	3	4	measurable disease
NCT0000280115	NCT00002801_15_T0	GENE	18	18	MTD
NCT0000280116	NCT00002801_16_T0	PHENOTYPE	15	15	toxicity
NCT0000280116	NCT00002801_16_T1	GENE	1	1	MTD
NCT000028021	NCT00002802_1_T0	CELL	21	21	cells
NCT000028021	NCT00002802_1_T1	PHENOTYPE	20	20	tumor
NCT000028021	NCT00002802_1_T2	ORGAN	3	4	bone marrow
NCT000028022	NCT00002802_2_T0	CELL	8	8	cells
NCT000028022	NCT00002802_2_T1	PHENOTYPE	7	7	tumor
NCT000028023	NCT00002802_3_T0	PHENOTYPE	22	22	neuroblastoma
NCT000028024	NCT00002802_4_T0	PHENOTYPE	22	22	neuroblastoma
NCT000028024	NCT00002802_4_T1	GENE	2	2	III
NCT000028026	NCT00002802_6_T0	PHENOTYPE	13	13	neuroblastoma
NCT000028028	NCT00002802_8_T0	PHENOTYPE	16	16	toxicity
NCT000028028	NCT00002802_8_T1	PHENOTYPE	12	12	remission
NCT000028028	NCT00002802_8_T2	PHENOTYPE	25	25	neuroblastoma
NCT0000280210	NCT00002802_10_T0	PHENOTYPE	13	13	tumor
NCT0000280210	NCT00002802_10_T1	PHENOTYPE	9	10	bone metastasis
NCT0000280210	NCT00002802_10_T2	PHENOTYPE	6	7	primary tumor
NCT0000280212	NCT00002802_12_T0	PHENOTYPE	9	9	conditioning
NCT0000280212	NCT00002802_12_T1	ORGAN	13	14	bone marrow
NCT0000280214	NCT00002802_14_T0	PHENOTYPE	18	18	neuroblastoma
NCT0000280214	NCT00002802_14_T1	PHENOTYPE	11	12	disease progression
NCT0000280216	NCT00002802_16_T0	PHENOTYPE	13	13	relapse
NCT0000280216	NCT00002802_16_T1	PHENOTYPE	22	22	neuroblastoma
NCT0000280218	NCT00002802_18_T0	GENE	5	5	LDH
NCT0000280218	NCT00002802_18_T1	COMPOUND	6	6	catecholamine
NCT0000280218	NCT00002802_18_T2	GENE	10	10	enolase
NCT0000280218	NCT00002802_18_T3	PHENOTYPE	3	3	tumor
NCT0000280218	NCT00002802_18_T4	PHENOTYPE	14	14	remission
NCT0000280218	NCT00002802_18_T5	CELL	9	9	neuron
NCT0000280218	NCT00002802_18_T6	ORGAN	2	2	serum
NCT0000280219	NCT00002802_19_T0	PHENOTYPE	8	8	Neuroblastoma
NCT0000280219	NCT00002802_19_T1	GENE	27	27	LDH
NCT0000280219	NCT00002802_19_T2	PHENOTYPE	29	29	tumor
NCT0000280219	NCT00002802_19_T3	ORGAN	26	26	serum
NCT0000280220	NCT00002802_20_T0	PHENOTYPE	22	22	tumor
NCT0000280221	NCT00002802_21_T0	PHENOTYPE	6	7	primary tumor
NCT0000280222	NCT00002802_22_T0	COMPOUND	22	22	ifosfamide
NCT0000280222	NCT00002802_22_T1	COMPOUND	20	20	vincristine
NCT0000280222	NCT00002802_22_T2	COMPOUND	15	15	vindesine
NCT0000280222	NCT00002802_22_T3	COMPOUND	14	14	etoposide
NCT0000280222	NCT00002802_22_T4	COMPOUND	23	23	doxorubicin
NCT0000280222	NCT00002802_22_T5	COMPOUND	13	13	cisplatin
NCT0000280222	NCT00002802_22_T6	COMPOUND	21	21	dacarbazine
NCT0000280222	NCT00002802_22_T7	PHENOTYPE	8	9	primary tumor
NCT0000280223	NCT00002802_23_T0	PHENOTYPE	3	3	remission
NCT0000280223	NCT00002802_23_T1	GENE	4	4	CR
NCT0000280223	NCT00002802_23_T2	GENE	12	12	CR
NCT0000280223	NCT00002802_23_T3	ORGAN	34	35	bone marrow
NCT0000280224	NCT00002802_24_T0	PHENOTYPE	18	18	metastases
NCT0000280224	NCT00002802_24_T1	ORGAN	28	29	bone marrow
NCT0000280225	NCT00002802_25_T0	ORGAN	1	1	marrow
NCT0000280225	NCT00002802_25_T1	PHENOTYPE	18	19	progressive disease
NCT0000280226	NCT00002802_26_T0	PHENOTYPE	11	12	primary tumor
NCT0000280226	NCT00002802_26_T1	PHENOTYPE	15	16	residual tumor
NCT0000280227	NCT00002802_27_T0	ORGAN	14	14	marrow
NCT0000280227	NCT00002802_27_T1	PHENOTYPE	9	9	remission
NCT0000280228	NCT00002802_28_T0	COMPOUND	10	10	melphalan
NCT0000280228	NCT00002802_28_T1	PHENOTYPE	0	0	Myeloablation
NCT0000280228	NCT00002802_28_T2	COMPOUND	11	11	etoposide
NCT0000280229	NCT00002802_29_T0	PHENOTYPE	19	19	initiation
NCT0000280230	NCT00002802_30_T0	COMPOUND	16	16	vincristine
NCT0000280230	NCT00002802_30_T1	COMPOUND	22	22	cyclophosphamide
NCT0000280233	NCT00002802_33_T0	COMPOUND	11	11	vincristine
NCT0000280233	NCT00002802_33_T1	GENE	12	12	AV
NCT0000280233	NCT00002802_33_T2	COMPOUND	9	9	doxorubicin
NCT0000280233	NCT00002802_33_T3	GENE	5	5	4-8
NCT0000280234	NCT00002802_34_T0	PHENOTYPE	2	3	tumor progression
NCT0000280235	NCT00002802_35_T0	PHENOTYPE	0	1	Primary tumor
NCT000028031	NCT00002803_1_T0	CELL	16	16	cells
NCT000028031	NCT00002803_1_T1	PHENOTYPE	11	11	tumor
NCT000028031	NCT00002803_1_T2	PHENOTYPE	15	15	tumor
NCT000028032	NCT00002803_2_T0	GENE	2	2	II
NCT000028032	NCT00002803_2_T1	PHENOTYPE	16	16	neuroblastoma
NCT000028034	NCT00002803_4_T0	PHENOTYPE	5	5	regression
NCT000028034	NCT00002803_4_T1	PHENOTYPE	7	8	localized neuroblastoma
NCT000028036	NCT00002803_6_T0	PHENOTYPE	5	5	neuroblastoma
NCT000028038	NCT00002803_8_T0	COMPOUND	10	10	catecholamine
NCT000028038	NCT00002803_8_T1	PHENOTYPE	5	5	regression
NCT0000280312	NCT00002803_12_T0	PHENOTYPE	4	4	toxicity
NCT0000280312	NCT00002803_12_T1	GENE	2	2	reduced
NCT0000280314	NCT00002803_14_T0	PHENOTYPE	2	3	drug levels
NCT0000280315	NCT00002803_15_T0	GENE	10	10	N-myc
NCT0000280315	NCT00002803_15_T1	PHENOTYPE	7	8	primary tumor
NCT0000280315	NCT00002803_15_T2	PHENOTYPE	18	19	critically ill
NCT0000280317	NCT00002803_17_T0	COMPOUND	11	11	vincristine
NCT0000280317	NCT00002803_17_T1	COMPOUND	13	13	cyclophosphamide
NCT0000280317	NCT00002803_17_T2	COMPOUND	10	10	doxorubicin
NCT0000280317	NCT00002803_17_T3	PHENOTYPE	5	6	critically ill
NCT0000280318	NCT00002803_18_T0	GENE	5	5	N-myc
NCT0000280320	NCT00002803_20_T0	PHENOTYPE	4	4	tumor
NCT0000280320	NCT00002803_20_T1	PHENOTYPE	5	5	regression
NCT000028041	NCT00002804_1_T0	CELL	8	8	cells
NCT000028041	NCT00002804_1_T1	PHENOTYPE	7	7	tumor
NCT000028042	NCT00002804_2_T0	CELL	13	13	cells
NCT000028042	NCT00002804_2_T1	PHENOTYPE	12	12	tumor
NCT000028043	NCT00002804_3_T0	GENE	2	2	II
NCT000028043	NCT00002804_3_T1	PHENOTYPE	21	23	soft tissue sarcoma
NCT000028045	NCT00002804_5_T0	CELL	7	7	granulocyte
NCT000028045	NCT00002804_5_T1	PHENOTYPE	19	19	rhabdomyosarcoma
NCT000028045	NCT00002804_5_T2	PHENOTYPE	20	22	soft tissue sarcomas
NCT000028049	NCT00002804_9_T0	PHENOTYPE	7	7	peripheral
NCT000028049	NCT00002804_9_T1	PHENOTYPE	5	5	tumor
NCT0000280410	NCT00002804_10_T0	GENE	22	22	VCR
NCT0000280410	NCT00002804_10_T1	GENE	15	15	IFF
NCT0000280410	NCT00002804_10_T2	GENE	9	9	G-CSF
NCT0000280410	NCT00002804_10_T3	GENE	10	12	Granulocyte Colony-Stimulating Factor
NCT0000280413	NCT00002804_13_T0	COMPOUND	30	30	iridium_192
NCT0000280413	NCT00002804_13_T1	PHENOTYPE	6	7	pulmonary metastases
NCT0000280413	NCT00002804_13_T2	PHENOTYPE	15	16	pulmonary metastases
NCT0000280413	NCT00002804_13_T3	PHENOTYPE	3	4	primary tumor
NCT0000280413	NCT00002804_13_T4	PHENOTYPE	12	13	primary tumor
NCT0000280416	NCT00002804_16_T0	GENE	11	11	2.7
NCT000028051	NCT00002805_1_T0	CELL	9	9	cells
NCT000028056	NCT00002805_6_T0	COMPOUND	18	18	CCG-201
NCT000028056	NCT00002805_6_T1	COMPOUND	17	17	CCG-243
NCT000028056	NCT00002805_6_T2	PHENOTYPE	2	2	remission
NCT000028058	NCT00002805_8_T0	PHENOTYPE	25	25	AML
NCT000028058	NCT00002805_8_T1	COMPOUND	30	30	CCG-213
NCT000028058	NCT00002805_8_T2	PHENOTYPE	20	20	remission
NCT000028058	NCT00002805_8_T3	COMPOUND	33	33	CCG-2891
NCT000028058	NCT00002805_8_T4	COMPOUND	29	29	CCG-251
NCT000028058	NCT00002805_8_T5	GENE	21	21	CR
NCT0000280510	NCT00002805_10_T0	GENE	7	7	mdr1
NCT0000280510	NCT00002805_10_T1	GENE	11	11	p53
NCT0000280510	NCT00002805_10_T2	GENE	12	13	topoisomerase II
NCT0000280510	NCT00002805_10_T3	GENE	15	16	deoxycytidine kinase
NCT0000280510	NCT00002805_10_T4	BIOLOGICAL_PROCESS	8	9	gene expression
NCT0000280512	NCT00002805_12_T0	GENE	10	10	CR
NCT0000280512	NCT00002805_12_T1	ORGAN	22	23	bone marrow
NCT0000280514	NCT00002805_14_T0	COMPOUND	22	22	mitoxantrone
NCT0000280514	NCT00002805_14_T1	COMPOUND	12	12	MUGA
NCT0000280518	NCT00002805_18_T0	PHENOTYPE	2	2	toxicity
NCT0000280518	NCT00002805_18_T1	PHENOTYPE	3	3	remission
NCT0000280518	NCT00002805_18_T2	GENE	17	17	CR
NCT0000280520	NCT00002805_20_T0	PHENOTYPE	4	4	toxicity
NCT0000280520	NCT00002805_20_T1	PHENOTYPE	20	20	AML
NCT0000280520	NCT00002805_20_T2	PHENOTYPE	5	5	remission
NCT0000280520	NCT00002805_20_T3	PHENOTYPE	23	24	second malignancy
NCT0000280521	NCT00002805_21_T0	ORGAN	7	7	marrow
NCT0000280522	NCT00002805_22_T0	PHENOTYPE	2	2	Consolidation
NCT0000280524	NCT00002805_24_T0	GENE	1	1	G-CSF
NCT0000280524	NCT00002805_24_T1	GENE	3	3	IT
NCT0000280528	NCT00002805_28_T0	PHENOTYPE	10	10	relapse
NCT0000280528	NCT00002805_28_T1	PHENOTYPE	12	12	chloromas
NCT0000280535	NCT00002805_35_T0	PHENOTYPE	4	4	closed
NCT000028061	NCT00002806_1_T0	CELL	8	8	cells
NCT000028061	NCT00002806_1_T1	PHENOTYPE	7	7	tumor
NCT000028062	NCT00002806_2_T0	CELL	9	9	cells
NCT000028062	NCT00002806_2_T1	PHENOTYPE	8	8	tumor
NCT000028063	NCT00002806_3_T0	GENE	2	2	II
NCT000028063	NCT00002806_3_T1	COMPOUND	12	12	vincristine
NCT000028063	NCT00002806_3_T2	PHENOTYPE	23	23	glioma
NCT000028063	NCT00002806_3_T3	COMPOUND	9	9	procarbazine
NCT000028063	NCT00002806_3_T4	COMPOUND	10	10	lomustine
NCT000028065	NCT00002806_5_T0	GENE	16	16	PCV
NCT000028065	NCT00002806_5_T1	PHENOTYPE	11	11	glioma
NCT000028067	NCT00002806_7_T0	PHENOTYPE	2	2	toxicity
NCT000028067	NCT00002806_7_T1	GENE	4	4	PCV
NCT000028069	NCT00002806_9_T0	GENE	10	10	PCV
NCT000028069	NCT00002806_9_T1	PHENOTYPE	4	5	disease progression
NCT0000280610	NCT00002806_10_T0	GENE	12	12	PCV
NCT0000280610	NCT00002806_10_T1	GENE	6	6	CCNU
NCT0000280610	NCT00002806_10_T2	GENE	9	9	PCB
NCT0000280611	NCT00002806_11_T0	GENE	0	0	PCV
NCT000028071	NCT00002807_1_T0	PHENOTYPE	18	19	endometrial cancer
NCT000028072	NCT00002807_2_T0	GENE	4	4	III
NCT000028072	NCT00002807_2_T1	PHENOTYPE	27	30	stage II endometrial cancer
NCT000028075	NCT00002807_5_T0	COMPOUND	11	11	3
NCT000028075	NCT00002807_5_T1	PHENOTYPE	5	5	tumor
NCT000028076	NCT00002807_6_T0	PHENOTYPE	10	10	bilateral
NCT000028076	NCT00002807_6_T1	GENE	7	7	abdominal
NCT000028091	NCT00002809_1_T0	CELL	8	8	cells
NCT000028092	NCT00002809_2_T0	CELL	25	25	cells
NCT000028092	NCT00002809_2_T1	ORGAN	9	9	transplant
NCT000028092	NCT00002809_2_T2	ORGAN	7	8	bone marrow
NCT000028093	NCT00002809_3_T0	GENE	3	3	II
NCT000028093	NCT00002809_3_T1	COMPOUND	19	19	cyclophosphamide
NCT000028093	NCT00002809_3_T2	ORGAN	12	12	transplant
NCT000028093	NCT00002809_3_T3	PHENOTYPE	28	29	hematologic cancer
NCT000028093	NCT00002809_3_T4	ORGAN	10	11	bone marrow
NCT000028095	NCT00002809_5_T0	COMPOUND	8	8	cyclophosphamide
NCT000028095	NCT00002809_5_T1	GENE	24	24	globulin
NCT000028095	NCT00002809_5_T2	PHENOTYPE	18	20	severe aplastic anemia
NCT000028096	NCT00002809_6_T0	ORGAN	4	5	bone marrow
NCT000028097	NCT00002809_7_T0	PHENOTYPE	8	8	engraftment
NCT000028097	NCT00002809_7_T1	ORGAN	5	5	transplant
NCT000028097	NCT00002809_7_T2	GENE	1	1	G-CSF
NCT000028098	NCT00002809_8_T0	GENE	1	1	GM-CSF
NCT000028098	NCT00002809_8_T1	PHENOTYPE	8	9	graft failure
NCT000028099	NCT00002809_9_T0	COMPOUND	7	7	tacrolimus
NCT000028099	NCT00002809_9_T1	COMPOUND	8	8	methotrexate
NCT000028099	NCT00002809_9_T2	PHENOTYPE	4	4	GVHD
NCT000028099	NCT00002809_9_T3	PHENOTYPE	3	3	graft-versus-host-disease
NCT000028099	NCT00002809_9_T4	GENE	11	11	globulin
NCT000028099	NCT00002809_9_T5	GENE	10	10	gamma
NCT0000280910	NCT00002809_10_T0	PHENOTYPE	1	1	GVHD
NCT0000280910	NCT00002809_10_T1	GENE	10	10	globulin
NCT0000280911	NCT00002809_11_T0	ORGAN	12	12	transplant
NCT000028100	NCT00002810_0_T0	PHENOTYPE	12	12	Amyloidosis
NCT000028100	NCT00002810_0_T1	ORGAN	6	7	Cell Transplant
NCT000028100	NCT00002810_0_T2	CELL	4	6	Peripheral Stem Cell
NCT000028103	NCT00002810_3_T0	CELL	5	6	plasma cells
NCT000028106	NCT00002810_6_T0	CELL	9	9	granulocyte
NCT000028106	NCT00002810_6_T1	GENE	12	12	G-CSF
NCT000028106	NCT00002810_6_T2	CELL	1	4	Peripheral blood stem cells
NCT000028107	NCT00002810_7_T0	COMPOUND	3	3	melphalan
NCT000028108	NCT00002810_8_T0	GENE	0	0	G-CSF
NCT000028108	NCT00002810_8_T1	CELL	10	10	neutrophil
NCT000028109	NCT00002810_9_T0	ORGAN	9	9	transplant
NCT0000281010	NCT00002810_10_T0	PHENOTYPE	14	14	5-10
NCT000028110	NCT00002811_0_T0	PHENOTYPE	9	10	Actinic Keratoses
NCT000028110	NCT00002811_0_T1	PHENOTYPE	14	15	Xeroderma Pigmentosum
NCT000028113	NCT00002811_3_T0	COMPOUND	2	2	lotion
NCT000028113	NCT00002811_3_T1	PHENOTYPE	10	11	skin damage
NCT000028113	NCT00002811_3_T2	PHENOTYPE	5	6	actinic keratoses
NCT000028113	NCT00002811_3_T3	PHENOTYPE	15	16	xeroderma pigmentosum
NCT000028114	NCT00002811_4_T0	GENE	4	4	III
NCT000028114	NCT00002811_4_T1	COMPOUND	12	12	lotion
NCT000028114	NCT00002811_4_T2	PHENOTYPE	24	25	skin damage
NCT000028114	NCT00002811_4_T3	PHENOTYPE	19	20	actinic keratoses
NCT000028114	NCT00002811_4_T4	PHENOTYPE	29	30	xeroderma pigmentosum
NCT000028116	NCT00002811_6_T0	COMPOUND	8	8	lotion
NCT000028116	NCT00002811_6_T1	COMPOUND	12	12	lotion
NCT000028116	NCT00002811_6_T2	PHENOTYPE	25	26	skin damage
NCT000028116	NCT00002811_6_T3	PHENOTYPE	18	19	actinic keratoses
NCT000028116	NCT00002811_6_T4	PHENOTYPE	30	31	xeroderma pigmentosum
NCT0000281110	NCT00002811_10_T0	GENE	3	3	T4
NCT0000281110	NCT00002811_10_T1	GENE	4	5	endonuclease V
NCT0000281110	NCT00002811_10_T2	GENE	5	6	V protein
NCT000028121	NCT00002812_1_T0	CELL	16	16	cells
NCT000028122	NCT00002812_2_T0	GENE	3	3	III
NCT000028122	NCT00002812_2_T1	PHENOTYPE	23	25	acute lymphocytic leukemia
NCT000028126	NCT00002812_6_T0	COMPOUND	8	8	dexamethasone
NCT000028126	NCT00002812_6_T1	PHENOTYPE	4	5	avascular necrosis
NCT000028128	NCT00002812_8_T0	ORGAN	6	6	marrow
NCT0000281212	NCT00002812_12_T0	ORGAN	8	8	marrow
NCT0000281212	NCT00002812_12_T1	ORGAN	15	15	marrow
NCT0000281215	NCT00002812_15_T0	COMPOUND	33	33	cytarabine
NCT0000281215	NCT00002812_15_T1	COMPOUND	10	10	vincristine
NCT0000281215	NCT00002812_15_T2	GENE	38	38	asparaginase
NCT0000281215	NCT00002812_15_T3	GENE	31	31	0.7
NCT0000281215	NCT00002812_15_T4	COMPOUND	27	27	prednisone
NCT0000281215	NCT00002812_15_T5	GENE	11	11	IV
NCT0000281215	NCT00002812_15_T6	GENE	14	14	IV
NCT0000281215	NCT00002812_15_T7	COMPOUND	13	13	daunorubicin
NCT0000281216	NCT00002812_16_T0	ORGAN	13	14	bone marrow
NCT0000281217	NCT00002812_17_T0	ORGAN	3	3	marrow
NCT0000281218	NCT00002812_18_T0	ORGAN	3	3	marrow
NCT0000281218	NCT00002812_18_T1	GENE	2	2	M3
NCT0000281219	NCT00002812_19_T0	GENE	0	1	Group 1
NCT0000281226	NCT00002812_26_T0	COMPOUND	2	2	methotrexate
NCT0000281227	NCT00002812_27_T0	COMPOUND	10	10	vincristine
NCT0000281227	NCT00002812_27_T1	GENE	4	4	asparaginase
NCT0000281230	NCT00002812_30_T0	GENE	9	9	asparaginase
NCT0000281230	NCT00002812_30_T1	GENE	3	3	BFM
NCT0000281234	NCT00002812_34_T0	COMPOUND	1	1	methotrexate
NCT0000281236	NCT00002812_36_T0	COMPOUND	11	11	idarubicin
NCT0000281236	NCT00002812_36_T1	COMPOUND	16	16	cyclophosphamide
NCT0000281236	NCT00002812_36_T2	COMPOUND	13	13	doxorubicin
NCT0000281238	NCT00002812_38_T0	GENE	1	1	MTX
NCT0000281241	NCT00002812_41_T0	PHENOTYPE	7	7	bilateral
NCT0000281241	NCT00002812_41_T1	PHENOTYPE	2	3	testicular leukemia
NCT0000281242	NCT00002812_42_T0	COMPOUND	3	3	2
NCT0000281242	NCT00002812_42_T1	COMPOUND	8	8	2
NCT000028131	NCT00002813_1_T0	CELL	9	9	cells
NCT000028131	NCT00002813_1_T1	PHENOTYPE	8	8	tumor
NCT000028136	NCT00002813_6_T0	COMPOUND	2	2	vinorelbine
NCT000028136	NCT00002813_6_T1	COMPOUND	24	24	vinorelbine
NCT000028136	NCT00002813_6_T2	COMPOUND	15	15	cisplatin
NCT000028136	NCT00002813_6_T3	GENE	3	3	IV
NCT000028136	NCT00002813_6_T4	GENE	16	16	IV
NCT000028137	NCT00002813_7_T0	PHENOTYPE	13	13	toxicity
NCT000028137	NCT00002813_7_T1	PHENOTYPE	9	10	disease progression
NCT000028142	NCT00002814_2_T0	CELL	9	9	cells
NCT000028142	NCT00002814_2_T1	PHENOTYPE	8	8	tumor
NCT000028143	NCT00002814_3_T0	GENE	2	2	II
NCT000028143	NCT00002814_3_T1	COMPOUND	12	12	paclitaxel
NCT000028143	NCT00002814_3_T2	GENE	16	16	G-CSF
NCT000028143	NCT00002814_3_T3	PHENOTYPE	30	30	recurrent
NCT000028143	NCT00002814_3_T4	COMPOUND	14	14	topotecan
NCT000028143	NCT00002814_3_T5	PHENOTYPE	21	22	glioblastoma multiforme
NCT000028143	NCT00002814_3_T6	PHENOTYPE	24	25	anaplastic astrocytoma
NCT000028145	NCT00002814_5_T0	COMPOUND	17	17	paclitaxel
NCT000028145	NCT00002814_5_T1	GENE	18	18	TAX
NCT000028145	NCT00002814_5_T2	GENE	26	26	G-CSF
NCT000028145	NCT00002814_5_T3	CELL	23	23	granulocyte
NCT000028145	NCT00002814_5_T4	PHENOTYPE	9	9	recurrent
NCT000028145	NCT00002814_5_T5	COMPOUND	20	20	topotecan
NCT000028145	NCT00002814_5_T6	PHENOTYPE	10	11	glioblastoma multiforme
NCT000028145	NCT00002814_5_T7	PHENOTYPE	13	14	anaplastic astrocytoma
NCT000028149	NCT00002814_9_T0	PHENOTYPE	2	2	toxicity
NCT0000281411	NCT00002814_11_T0	PHENOTYPE	1	1	tumor
NCT0000281411	NCT00002814_11_T1	GENE	2	2	p53
NCT0000281412	NCT00002814_12_T0	COMPOUND	4	4	paclitaxel
NCT0000281412	NCT00002814_12_T1	GENE	7	7	G-CSF
NCT0000281412	NCT00002814_12_T2	COMPOUND	5	5	topotecan
NCT0000281413	NCT00002814_13_T0	PHENOTYPE	14	14	relapse
NCT0000281414	NCT00002814_14_T0	GENE	13	13	1.3
NCT000028161	NCT00002816_1_T0	GENE	2	2	III
NCT000028161	NCT00002816_1_T1	PHENOTYPE	17	19	acute lymphoblastic leukemia
NCT000028165	NCT00002816_5_T0	ORGAN	29	29	marrow
NCT000028165	NCT00002816_5_T1	PHENOTYPE	8	8	leukemia
NCT000028165	NCT00002816_5_T2	PHENOTYPE	15	15	relapse
NCT000028165	NCT00002816_5_T3	PHENOTYPE	30	30	relapse
NCT0000281611	NCT00002816_11_T0	GENE	4	4	EFS
NCT0000281611	NCT00002816_11_T1	PHENOTYPE	18	18	relapse
NCT0000281613	NCT00002816_13_T0	GENE	1	1	EFS
NCT0000281613	NCT00002816_13_T1	PHENOTYPE	8	8	relapse
NCT0000281613	NCT00002816_13_T2	PHENOTYPE	15	15	relapse
NCT0000281615	NCT00002816_15_T0	PHENOTYPE	20	20	relapse
NCT0000281616	NCT00002816_16_T0	COMPOUND	12	12	dexamethasone
NCT0000281616	NCT00002816_16_T1	COMPOUND	30	30	dexamethasone
NCT0000281616	NCT00002816_16_T2	COMPOUND	13	13	vincristine
NCT0000281616	NCT00002816_16_T3	COMPOUND	31	31	vincristine
NCT0000281616	NCT00002816_16_T4	GENE	23	23	asparaginase
NCT0000281616	NCT00002816_16_T5	GENE	36	36	asparaginase
NCT0000281616	NCT00002816_16_T6	COMPOUND	39	39	methotrexate
NCT0000281616	NCT00002816_16_T7	COMPOUND	10	10	etoposide
NCT0000281616	NCT00002816_16_T8	COMPOUND	41	41	leucovorin
NCT0000281617	NCT00002816_17_T0	COMPOUND	19	19	dexamethasone
NCT0000281617	NCT00002816_17_T1	COMPOUND	34	34	dexamethasone
NCT0000281617	NCT00002816_17_T2	COMPOUND	24	24	cytarabine
NCT0000281617	NCT00002816_17_T3	COMPOUND	20	20	vincristine
NCT0000281617	NCT00002816_17_T4	COMPOUND	35	35	vincristine
NCT0000281617	NCT00002816_17_T5	GENE	31	31	asparaginase
NCT0000281617	NCT00002816_17_T6	COMPOUND	41	41	idarubicin
NCT0000281617	NCT00002816_17_T7	COMPOUND	25	25	etoposide
NCT0000281618	NCT00002816_18_T0	COMPOUND	17	17	vincristine
NCT0000281618	NCT00002816_18_T1	COMPOUND	19	19	methotrexate
NCT0000281620	NCT00002816_20_T0	PHENOTYPE	19	19	leukemia
NCT0000281620	NCT00002816_20_T1	PHENOTYPE	10	10	initiation
NCT0000281620	NCT00002816_20_T2	PHENOTYPE	4	4	relapse
NCT0000281622	NCT00002816_22_T0	PHENOTYPE	3	3	relapse
NCT0000281622	NCT00002816_22_T1	PHENOTYPE	5	5	bilateral
NCT0000281623	NCT00002816_23_T0	PHENOTYPE	20	20	relapse
NCT0000281623	NCT00002816_23_T1	PHENOTYPE	21	22	second malignancy
NCT0000281624	NCT00002816_24_T0	PHENOTYPE	3	3	quality-of-life
NCT000028171	NCT00002817_1_T0	PHENOTYPE	15	16	metastatic melanoma
NCT000028173	NCT00002817_3_T0	PHENOTYPE	2	2	toxicity
NCT000028173	NCT00002817_3_T1	PHENOTYPE	9	9	vaccinia
NCT000028173	NCT00002817_3_T2	GENE	16	16	GM-CSF
NCT000028173	NCT00002817_3_T3	PHENOTYPE	11	11	encoding
NCT000028173	NCT00002817_3_T4	GENE	15	15	sargramostim
NCT000028173	NCT00002817_3_T5	PHENOTYPE	20	21	metastatic melanoma
NCT000028177	NCT00002817_7_T0	PHENOTYPE	11	11	immunity
NCT000028179	NCT00002817_9_T0	PHENOTYPE	4	4	regression
NCT0000281710	NCT00002817_10_T0	PHENOTYPE	9	9	vaccinia
NCT0000281710	NCT00002817_10_T1	GENE	16	16	GM-CSF
NCT0000281710	NCT00002817_10_T2	PHENOTYPE	11	11	encoding
NCT0000281710	NCT00002817_10_T3	GENE	15	15	sargramostim
NCT0000281712	NCT00002817_12_T0	PHENOTYPE	4	4	vaccinia
NCT0000281712	NCT00002817_12_T1	GENE	3	3	pox
NCT0000281713	NCT00002817_13_T0	PHENOTYPE	6	6	progressive
NCT0000281714	NCT00002817_14_T0	PHENOTYPE	9	10	measurable lesion
NCT0000281716	NCT00002817_16_T0	GENE	15	15	MTD
NCT0000281717	NCT00002817_17_T0	GENE	6	6	MTD
NCT000028180	NCT00002818_0_T0	PHENOTYPE	12	13	Hematologic Malignancies
NCT000028180	NCT00002818_0_T1	PHENOTYPE	7	9	Acute Myelogenous Leukemia
NCT000028182	NCT00002818_2_T0	COMPOUND	10	10	cytarabine
NCT000028183	NCT00002818_3_T0	COMPOUND	10	10	cytarabine
NCT000028183	NCT00002818_3_T1	PHENOTYPE	27	27	leukemia
NCT000028183	NCT00002818_3_T2	PHENOTYPE	25	25	lymphoma
NCT000028183	NCT00002818_3_T3	COMPOUND	13	13	deoxycytidine
NCT000028183	NCT00002818_3_T4	PHENOTYPE	20	22	acute myelogenous leukemia
NCT000028187	NCT00002818_7_T0	PHENOTYPE	7	7	toxic
NCT000028189	NCT00002818_9_T0	PHENOTYPE	2	2	pharmacokinetics
NCT0000281811	NCT00002818_11_T0	PHENOTYPE	4	4	pharmacodynamics
NCT0000281815	NCT00002818_15_T0	COMPOUND	2	2	deoxycytidine
NCT0000281815	NCT00002818_15_T1	GENE	3	3	IV
NCT0000281816	NCT00002818_16_T0	COMPOUND	11	11	cytarabine
NCT0000281816	NCT00002818_16_T1	PHENOTYPE	4	4	initiation
NCT0000281816	NCT00002818_16_T2	COMPOUND	6	6	deoxycytidine
NCT0000281816	NCT00002818_16_T3	GENE	12	12	IV
NCT0000281818	NCT00002818_18_T0	PHENOTYPE	10	10	relapse
NCT0000281819	NCT00002818_19_T0	COMPOUND	12	12	cytarabine
NCT0000281819	NCT00002818_19_T1	COMPOUND	8	8	deoxycytidine
NCT0000281819	NCT00002818_19_T2	GENE	18	18	MTD
NCT0000281820	NCT00002818_20_T0	PHENOTYPE	18	18	toxicities
NCT0000281820	NCT00002818_20_T1	GENE	1	1	MTD
NCT000028195	NCT00002819_5_T0	COMPOUND	30	30	mitoxantrone
NCT000028195	NCT00002819_5_T1	COMPOUND	24	24	paclitaxel
NCT000028195	NCT00002819_5_T2	COMPOUND	32	32	cyclophosphamide
NCT000028195	NCT00002819_5_T3	PHENOTYPE	10	11	ovarian cancer
NCT000028195	NCT00002819_5_T4	ORGAN	35	36	bone marrow
NCT000028197	NCT00002819_7_T0	PHENOTYPE	2	2	toxic
NCT000028199	NCT00002819_9_T0	PHENOTYPE	5	7	quality of life
NCT0000281915	NCT00002819_15_T0	PHENOTYPE	26	27	disease progression
NCT0000281915	NCT00002819_15_T1	PHENOTYPE	0	2	Quality of life
NCT000028222	NCT00002822_2_T0	CELL	12	12	cells
NCT000028222	NCT00002822_2_T1	PHENOTYPE	11	11	tumor
NCT000028223	NCT00002822_3_T0	CELL	9	9	cells
NCT000028223	NCT00002822_3_T1	PHENOTYPE	8	8	tumor
NCT000028227	NCT00002822_7_T0	GENE	9	9	ACE
NCT000028227	NCT00002822_7_T1	GENE	12	12	PE
NCT000028228	NCT00002822_8_T0	COMPOUND	13	13	vincristine
NCT000028228	NCT00002822_8_T1	GENE	11	11	1.3
NCT0000282210	NCT00002822_10_T0	GENE	10	10	4.5
NCT0000282212	NCT00002822_12_T0	PHENOTYPE	2	2	relapse
NCT000028237	NCT00002823_7_T0	PHENOTYPE	8	8	toxic
NCT000028239	NCT00002823_9_T0	PHENOTYPE	8	8	toxic
NCT000028239	NCT00002823_9_T1	PHENOTYPE	5	6	second malignancies
NCT0000282312	NCT00002823_12_T0	COMPOUND	13	13	cisplatin
NCT0000282313	NCT00002823_13_T0	COMPOUND	10	10	vinorelbine
NCT0000282313	NCT00002823_13_T1	COMPOUND	8	8	vindesine
NCT0000282313	NCT00002823_13_T2	COMPOUND	9	9	vinblastine
NCT0000282313	NCT00002823_13_T3	GENE	14	14	3.4
NCT0000282313	NCT00002823_13_T4	GENE	17	17	3.4
NCT0000282313	NCT00002823_13_T5	COMPOUND	12	12	etoposide
NCT0000282313	NCT00002823_13_T6	COMPOUND	4	4	cisplatin
NCT0000282313	NCT00002823_13_T7	COMPOUND	24	24	cisplatin
NCT0000282315	NCT00002823_15_T0	GENE	25	25	N2
NCT0000282316	NCT00002823_16_T0	GENE	8	8	3.4
NCT000028242	NCT00002824_2_T0	PHENOTYPE	15	17	primary brain tumors
NCT000028244	NCT00002824_4_T0	COMPOUND	22	22	ganciclovir
NCT000028244	NCT00002824_4_T1	PHENOTYPE	26	26	recurrent
NCT000028244	NCT00002824_4_T2	GENE	15	16	thymidine kinase
NCT000028244	NCT00002824_4_T3	PHENOTYPE	27	28	malignant glioma
NCT000028244	NCT00002824_4_T4	PHENOTYPE	12	13	herpes simplex
NCT000028248	NCT00002824_8_T0	PHENOTYPE	2	2	toxic
NCT0000282412	NCT00002824_12_T0	COMPOUND	4	4	glucose
NCT0000282414	NCT00002824_14_T0	BIOLOGICAL_PROCESS	6	6	transduction
NCT0000282416	NCT00002824_16_T0	PHENOTYPE	4	4	toxicity
NCT0000282416	NCT00002824_16_T1	PHENOTYPE	14	14	tumors
NCT0000282418	NCT00002824_18_T0	GENE	15	16	thymidine kinase
NCT0000282418	NCT00002824_18_T1	PHENOTYPE	12	13	herpes simplex
NCT0000282421	NCT00002824_21_T0	PHENOTYPE	3	3	tumors
NCT0000282421	NCT00002824_21_T1	COMPOUND	5	5	ganciclovir
NCT0000282422	NCT00002824_22_T0	PHENOTYPE	3	3	tumors
NCT0000282422	NCT00002824_22_T1	COMPOUND	5	5	ganciclovir
NCT0000282422	NCT00002824_22_T2	COMPOUND	28	28	ganciclovir
NCT0000282424	NCT00002824_24_T0	PHENOTYPE	10	10	tumors
NCT0000282424	NCT00002824_24_T1	PHENOTYPE	15	15	tumors
NCT000028250	NCT00002825_0_T0	PHENOTYPE	5	5	Recurrent
NCT000028250	NCT00002825_0_T1	PHENOTYPE	6	7	Solid Tumors
NCT000028252	NCT00002825_2_T0	CELL	10	10	cells
NCT000028252	NCT00002825_2_T1	PHENOTYPE	9	9	tumor
NCT000028254	NCT00002825_4_T0	COMPOUND	5	5	docetaxel
NCT000028254	NCT00002825_4_T1	PHENOTYPE	10	10	sarcomas
NCT000028254	NCT00002825_4_T2	PHENOTYPE	9	9	recurrent
NCT000028254	NCT00002825_4_T3	PHENOTYPE	11	11	neuroblastomas
NCT000028254	NCT00002825_4_T4	PHENOTYPE	13	14	brain tumors
NCT000028256	NCT00002825_6_T0	PHENOTYPE	2	2	toxic
NCT000028256	NCT00002825_6_T1	COMPOUND	5	5	docetaxel
NCT000028257	NCT00002825_7_T0	COMPOUND	4	4	docetaxel
NCT000028257	NCT00002825_7_T1	GENE	6	6	G-CSF
NCT000028266	NCT00002826_6_T0	PHENOTYPE	2	2	toxicity
NCT000028271	NCT00002827_1_T0	CELL	8	8	cells
NCT000028272	NCT00002827_2_T0	CELL	9	9	cells
NCT000028273	NCT00002827_3_T0	COMPOUND	13	13	dexrazoxane
NCT000028273	NCT00002827_3_T1	PHENOTYPE	15	16	Hodgkin's disease
NCT000028274	NCT00002827_4_T0	GENE	30	30	II
NCT000028274	NCT00002827_4_T1	GENE	3	3	III
NCT000028274	NCT00002827_4_T2	COMPOUND	15	15	dexrazoxane
NCT000028274	NCT00002827_4_T3	PHENOTYPE	32	33	stage III
NCT000028274	NCT00002827_4_T4	PHENOTYPE	34	35	Hodgkin's disease
NCT000028276	NCT00002827_6_T0	PHENOTYPE	16	17	Hodgkin's disease
NCT000028278	NCT00002827_8_T0	COMPOUND	8	8	bleomycin
NCT000028278	NCT00002827_8_T1	COMPOUND	9	9	vincristine
NCT000028278	NCT00002827_8_T2	COMPOUND	11	11	etoposide
NCT000028278	NCT00002827_8_T3	COMPOUND	7	7	doxorubicin
NCT0000282710	NCT00002827_10_T0	PHENOTYPE	16	16	toxic
NCT0000282716	NCT00002827_16_T0	COMPOUND	24	24	dexrazoxane
NCT0000282716	NCT00002827_16_T1	GENE	19	19	reduced
NCT0000282716	NCT00002827_16_T2	ORGAN	15	15	serum
NCT0000282716	NCT00002827_16_T3	GENE	17	17	troponin-T
NCT0000282716	NCT00002827_16_T4	PHENOTYPE	7	8	myocardial injury
NCT0000282719	NCT00002827_19_T0	COMPOUND	7	7	bleomycin
NCT0000282719	NCT00002827_19_T1	COMPOUND	15	15	dexrazoxane
NCT0000282719	NCT00002827_19_T2	COMPOUND	8	8	vincristine
NCT0000282719	NCT00002827_19_T3	GENE	11	11	filgrastim
NCT0000282719	NCT00002827_19_T4	COMPOUND	9	9	etoposide
NCT0000282719	NCT00002827_19_T5	COMPOUND	6	6	doxorubicin
NCT0000282720	NCT00002827_20_T0	GENE	1	1	SC
NCT0000282720	NCT00002827_20_T1	GENE	7	7	filgrastim
NCT0000282721	NCT00002827_21_T0	GENE	16	16	ANC
NCT0000282725	NCT00002827_25_T0	PHENOTYPE	5	5	relapse
NCT000028281	NCT00002828_1_T0	CELL	9	9	cells
NCT000028281	NCT00002828_1_T1	PHENOTYPE	8	8	tumor
NCT000028282	NCT00002828_2_T0	COMPOUND	9	9	raltitrexed
NCT000028282	NCT00002828_2_T1	PHENOTYPE	22	22	recurrent
NCT000028282	NCT00002828_2_T2	PHENOTYPE	17	18	colorectal cancer
NCT000028284	NCT00002828_4_T0	COMPOUND	6	6	raltitrexed
NCT000028284	NCT00002828_4_T1	PHENOTYPE	15	16	colorectal carcinoma
NCT000028286	NCT00002828_6_T0	PHENOTYPE	2	2	toxicity
NCT000028289	NCT00002828_9_T0	COMPOUND	7	7	raltitrexed
NCT0000282810	NCT00002828_10_T0	COMPOUND	2	2	raltitrexed
NCT0000282810	NCT00002828_10_T1	GENE	3	3	IV
NCT0000282810	NCT00002828_10_T2	GENE	13	13	IV
NCT0000282811	NCT00002828_11_T0	PHENOTYPE	13	13	toxicity
NCT0000282811	NCT00002828_11_T1	PHENOTYPE	9	10	disease progression
NCT0000282812	NCT00002828_12_T0	COMPOUND	8	8	raltitrexed
NCT0000282812	NCT00002828_12_T1	GENE	14	14	MTD
NCT0000282813	NCT00002828_13_T0	PHENOTYPE	18	18	toxicity
NCT0000282813	NCT00002828_13_T1	GENE	1	1	MTD
NCT0000282814	NCT00002828_14_T0	GENE	8	8	MTD
NCT000028291	NCT00002829_1_T0	CELL	8	8	cells
NCT000028291	NCT00002829_1_T1	PHENOTYPE	16	16	lymphoma
NCT000028292	NCT00002829_2_T0	CELL	9	9	cells
NCT000028292	NCT00002829_2_T1	CELL	22	22	cells
NCT000028292	NCT00002829_2_T2	ORGAN	0	1	Bone marrow
NCT000028293	NCT00002829_3_T0	GENE	2	2	II
NCT000028293	NCT00002829_3_T1	PHENOTYPE	16	16	recurrent
NCT000028293	NCT00002829_3_T2	PHENOTYPE	19	20	low-grade lymphoma
NCT000028293	NCT00002829_3_T3	ORGAN	9	10	bone marrow
NCT000028295	NCT00002829_5_T0	COMPOUND	8	8	cyclophosphamide
NCT000028295	NCT00002829_5_T1	COMPOUND	7	7	etoposide
NCT000028295	NCT00002829_5_T2	PHENOTYPE	22	23	disease progression
NCT000028295	NCT00002829_5_T3	ORGAN	13	14	bone marrow
NCT000028297	NCT00002829_7_T0	PHENOTYPE	8	8	remission
NCT000028297	NCT00002829_7_T1	GENE	10	10	PCR
NCT0000282911	NCT00002829_11_T0	GENE	8	8	PCR
NCT0000282911	NCT00002829_11_T1	PHENOTYPE	6	6	purging
NCT0000282911	NCT00002829_11_T2	ORGAN	4	5	bone marrow
NCT0000282912	NCT00002829_12_T0	GENE	5	5	2.3
NCT0000282915	NCT00002829_15_T0	COMPOUND	2	2	mesna
NCT0000282915	NCT00002829_15_T1	PHENOTYPE	7	7	initiation
NCT0000282915	NCT00002829_15_T2	COMPOUND	10	10	cyclophosphamide
NCT0000282916	NCT00002829_16_T0	COMPOUND	12	12	1
NCT0000282916	NCT00002829_16_T1	COMPOUND	9	9	2
NCT0000282916	NCT00002829_16_T2	COMPOUND	8	8	3
NCT0000282917	NCT00002829_17_T0	ORGAN	6	7	bone marrow
NCT000028315	NCT00002831_5_T0	COMPOUND	10	10	busulfan
NCT000028315	NCT00002831_5_T1	COMPOUND	12	12	cyclophosphamide
NCT000028315	NCT00002831_5_T2	COMPOUND	6	6	decitabine
NCT000028315	NCT00002831_5_T3	PHENOTYPE	16	17	hematologic malignancies
NCT000028317	NCT00002831_7_T0	COMPOUND	6	6	busulfan
NCT000028317	NCT00002831_7_T1	PHENOTYPE	2	2	pharmacokinetics
NCT000028317	NCT00002831_7_T2	COMPOUND	4	4	decitabine
NCT0000283110	NCT00002831_10_T0	GENE	11	11	DAC
NCT0000283110	NCT00002831_10_T1	COMPOUND	10	10	decitabine
NCT0000283110	NCT00002831_10_T2	GENE	12	12	IV
NCT0000283113	NCT00002831_13_T0	PHENOTYPE	18	18	toxicity
NCT0000283113	NCT00002831_13_T1	GENE	5	5	DAC
NCT0000283116	NCT00002831_16_T0	ORGAN	8	8	marrow
NCT0000283116	NCT00002831_16_T1	CELL	4	4	cells
NCT0000283117	NCT00002831_17_T0	CELL	0	1	Stem cells
NCT0000283119	NCT00002831_19_T0	COMPOUND	5	5	cyclosporine
NCT0000283119	NCT00002831_19_T1	PHENOTYPE	16	16	engraftment
NCT0000283119	NCT00002831_19_T2	COMPOUND	10	10	2
NCT0000283119	NCT00002831_19_T3	COMPOUND	3	3	tacrolimus
NCT0000283119	NCT00002831_19_T4	GENE	6	6	IV
NCT0000283119	NCT00002831_19_T5	PHENOTYPE	14	14	tolerance
NCT0000283120	NCT00002831_20_T0	COMPOUND	3	3	methylprednisolone
NCT0000283120	NCT00002831_20_T1	PHENOTYPE	10	10	GVHD
NCT0000283121	NCT00002831_21_T0	COMPOUND	3	3	methotrexate
NCT0000283123	NCT00002831_23_T0	GENE	19	19	2.3
NCT000028324	NCT00002832_4_T0	PHENOTYPE	10	10	relapse
NCT000028324	NCT00002832_4_T1	ORGAN	15	15	transplant
NCT000028324	NCT00002832_4_T2	COMPOUND	6	6	decitabine
NCT000028324	NCT00002832_4_T3	ORGAN	13	14	bone marrow
NCT000028326	NCT00002832_6_T0	PHENOTYPE	2	2	toxicity
NCT000028326	NCT00002832_6_T1	GENE	8	8	G-CSF
NCT000028326	NCT00002832_6_T2	GENE	7	7	filgrastim
NCT000028326	NCT00002832_6_T3	COMPOUND	4	4	decitabine
NCT000028326	NCT00002832_6_T4	ORGAN	24	25	bone marrow
NCT000028326	NCT00002832_6_T5	CELL	11	14	peripheral blood stem cells
NCT000028328	NCT00002832_8_T0	PHENOTYPE	5	5	remission
NCT000028329	NCT00002832_9_T0	GENE	10	10	hr
NCT000028329	NCT00002832_9_T1	COMPOUND	3	3	decitabine
NCT000028329	NCT00002832_9_T2	GENE	4	4	IV
NCT0000283210	NCT00002832_10_T0	COMPOUND	13	13	decitabine
NCT0000283210	NCT00002832_10_T1	CELL	0	3	Peripheral blood stem cells
NCT0000283211	NCT00002832_11_T0	GENE	10	10	2.4
NCT0000283211	NCT00002832_11_T1	GENE	2	2	filgrastim
NCT0000283213	NCT00002832_13_T0	CELL	1	1	cells
NCT0000283213	NCT00002832_13_T1	COMPOUND	7	7	decitabine
NCT0000283214	NCT00002832_14_T0	GENE	2	2	filgrastim
NCT0000283215	NCT00002832_15_T0	COMPOUND	5	5	cyclosporine
NCT0000283215	NCT00002832_15_T1	COMPOUND	10	10	2
NCT0000283215	NCT00002832_15_T2	PHENOTYPE	1	1	GVHD
NCT0000283215	NCT00002832_15_T3	GENE	6	6	IV
NCT0000283216	NCT00002832_16_T0	COMPOUND	2	2	decitabine
NCT0000283217	NCT00002832_17_T0	PHENOTYPE	3	3	toxicity
NCT0000283219	NCT00002832_19_T0	PHENOTYPE	8	9	in remission
NCT000028332	NCT00002833_2_T0	PHENOTYPE	18	18	peripheral
NCT000028332	NCT00002833_2_T1	CELL	12	12	cells
NCT000028332	NCT00002833_2_T2	GENE	5	5	filgrastim
NCT000028332	NCT00002833_2_T3	ORGAN	15	16	bone marrow
NCT000028332	NCT00002833_2_T4	ORGAN	25	26	immune system
NCT000028332	NCT00002833_2_T5	PHENOTYPE	31	33	effects of chemotherapy
NCT000028338	NCT00002833_8_T0	PHENOTYPE	2	2	engraftment
NCT0000283310	NCT00002833_10_T0	PHENOTYPE	2	3	in remission
NCT0000283310	NCT00002833_10_T1	PHENOTYPE	11	12	in remission
NCT0000283310	NCT00002833_10_T2	GENE	16	17	group 2
NCT0000283312	NCT00002833_12_T0	COMPOUND	5	5	cytarabine
NCT0000283312	NCT00002833_12_T1	COMPOUND	18	18	3
NCT0000283312	NCT00002833_12_T2	COMPOUND	2	2	fludarabine
NCT0000283312	NCT00002833_12_T3	GENE	7	7	IV
NCT0000283313	NCT00002833_13_T0	COMPOUND	11	11	cladribine
NCT0000283314	NCT00002833_14_T0	COMPOUND	18	18	3
NCT0000283314	NCT00002833_14_T1	COMPOUND	3	3	fludarabine
NCT0000283314	NCT00002833_14_T2	COMPOUND	6	6	fludarabine
NCT0000283314	NCT00002833_14_T3	GENE	7	7	IV
NCT0000283315	NCT00002833_15_T0	COMPOUND	10	10	fludarabine
NCT0000283315	NCT00002833_15_T1	GENE	1	1	IV
NCT0000283316	NCT00002833_16_T0	GENE	1	1	IV
NCT0000283318	NCT00002833_18_T0	CELL	0	0	Cells
NCT0000283319	NCT00002833_19_T0	COMPOUND	6	6	cyclosporine
NCT0000283319	NCT00002833_19_T1	PHENOTYPE	1	1	GVHD
NCT0000283319	NCT00002833_19_T2	GENE	9	9	IV
NCT0000283320	NCT00002833_20_T0	COMPOUND	1	1	cyclosporine
NCT0000283321	NCT00002833_21_T0	COMPOUND	4	4	cyclosporine
NCT0000283321	NCT00002833_21_T1	GENE	6	6	tapered
NCT0000283322	NCT00002833_22_T0	GENE	9	9	tapered
NCT000028352	NCT00002835_2_T0	GENE	3	3	III
NCT000028352	NCT00002835_2_T1	PHENOTYPE	22	23	immunoblastic lymphoma
NCT000028355	NCT00002835_5_T0	PHENOTYPE	5	5	tumor
NCT000028356	NCT00002835_6_T0	COMPOUND	19	19	cytarabine
NCT000028356	NCT00002835_6_T1	GENE	18	18	1.4
NCT000028356	NCT00002835_6_T2	GENE	11	11	IDA
NCT000028356	NCT00002835_6_T3	GENE	37	37	1.5
NCT000028356	NCT00002835_6_T4	COMPOUND	29	29	methylprednisolone
NCT000028356	NCT00002835_6_T5	COMPOUND	10	10	idarubicin
NCT000028356	NCT00002835_6_T6	COMPOUND	13	13	cisplatin
NCT000028356	NCT00002835_6_T7	GENE	14	14	IV
NCT000028356	NCT00002835_6_T8	GENE	21	21	IV
NCT000028356	NCT00002835_6_T9	GENE	31	31	IV
NCT000028357	NCT00002835_7_T0	GENE	34	34	MTX
NCT000028357	NCT00002835_7_T1	COMPOUND	11	11	bleomycin
NCT000028357	NCT00002835_7_T2	COMPOUND	10	10	vincristine
NCT000028357	NCT00002835_7_T3	COMPOUND	45	45	calcium
NCT000028357	NCT00002835_7_T4	GENE	32	32	1.3
NCT000028357	NCT00002835_7_T5	GENE	21	21	IDA
NCT000028357	NCT00002835_7_T6	COMPOUND	13	13	cyclophosphamide
NCT000028357	NCT00002835_7_T7	COMPOUND	33	33	methotrexate
NCT000028357	NCT00002835_7_T8	COMPOUND	44	44	leucovorin
NCT000028357	NCT00002835_7_T9	GENE	14	14	IV
NCT000028357	NCT00002835_7_T10	GENE	22	22	IV
NCT000028357	NCT00002835_7_T11	GENE	26	26	IV
NCT000028357	NCT00002835_7_T12	GENE	35	35	IV
NCT000028358	NCT00002835_8_T0	PHENOTYPE	13	13	toxicity
NCT000028358	NCT00002835_8_T1	PHENOTYPE	9	10	disease progression
NCT0000283511	NCT00002835_11_T0	GENE	5	5	SC
NCT0000283511	NCT00002835_11_T1	CELL	30	30	cells
NCT0000283511	NCT00002835_11_T2	GENE	1	1	G-CSF
NCT0000283511	NCT00002835_11_T3	GENE	28	28	CD34
NCT0000283511	NCT00002835_11_T4	CELL	19	22	peripheral blood stem cells
NCT0000283514	NCT00002835_14_T0	GENE	3	3	SC
NCT0000283514	NCT00002835_14_T1	GENE	0	0	G-CSF
NCT0000283515	NCT00002835_15_T0	PHENOTYPE	13	13	toxicity
NCT0000283515	NCT00002835_15_T1	PHENOTYPE	9	10	disease progression
NCT0000283517	NCT00002835_17_T0	PHENOTYPE	13	13	toxicity
NCT0000283517	NCT00002835_17_T1	PHENOTYPE	9	10	disease progression
NCT0000283524	NCT00002835_24_T0	PHENOTYPE	18	18	lymphoma
NCT0000283524	NCT00002835_24_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000283524	NCT00002835_24_T2	PHENOTYPE	16	17	high grade
NCT000028361	NCT00002836_1_T0	PHENOTYPE	17	17	peripheral
NCT000028361	NCT00002836_1_T1	CELL	11	11	cells
NCT000028361	NCT00002836_1_T2	GENE	4	4	filgrastim
NCT000028361	NCT00002836_1_T3	ORGAN	14	15	bone marrow
NCT000028361	NCT00002836_1_T4	ORGAN	24	25	immune system
NCT000028361	NCT00002836_1_T5	PHENOTYPE	30	32	effects of chemotherapy
NCT000028363	NCT00002836_3_T0	PHENOTYPE	12	13	breast cancer
NCT0000283616	NCT00002836_16_T0	GENE	1	1	SC
NCT0000283617	NCT00002836_17_T0	GENE	6	6	SC
NCT0000283617	NCT00002836_17_T1	GENE	5	5	filgrastim
NCT0000283618	NCT00002836_18_T0	CELL	0	1	Stem cells
NCT0000283620	NCT00002836_20_T0	GENE	5	5	filgrastim
NCT0000283620	NCT00002836_20_T1	GENE	10	10	WBC
NCT0000283620	NCT00002836_20_T2	GENE	8	8	bid
NCT0000283621	NCT00002836_21_T0	PHENOTYPE	17	17	progression
NCT000028378	NCT00002837_8_T0	PHENOTYPE	8	8	progression
NCT0000283711	NCT00002837_11_T0	COMPOUND	7	7	paclitaxel
NCT0000283711	NCT00002837_11_T1	GENE	8	8	TAX
NCT0000283711	NCT00002837_11_T2	GENE	18	18	G-CSF
NCT0000283711	NCT00002837_11_T3	COMPOUND	4	4	doxorubicin
NCT0000283712	NCT00002837_12_T0	CELL	0	3	Peripheral blood stem cells
NCT0000283714	NCT00002837_14_T0	ORGAN	9	9	marrow
NCT0000283714	NCT00002837_14_T1	ORGAN	1	2	bone marrow
NCT0000283716	NCT00002837_16_T0	GENE	13	13	3.4
NCT0000283716	NCT00002837_16_T1	GENE	8	8	G-CSF
NCT0000283722	NCT00002837_22_T0	GENE	3	3	II
NCT000028386	NCT00002838_6_T0	PHENOTYPE	2	2	engraftment
NCT000028389	NCT00002838_9_T0	PHENOTYPE	24	24	engraftment
NCT000028389	NCT00002838_9_T1	COMPOUND	5	5	fludarabine
NCT000028389	NCT00002838_9_T2	COMPOUND	7	7	cyclophosphamide
NCT0000283810	NCT00002838_10_T0	CELL	6	7	stem cells
NCT000028391	NCT00002839_1_T0	CELL	8	8	cells
NCT000028391	NCT00002839_1_T1	PHENOTYPE	7	7	tumor
NCT000028392	NCT00002839_2_T0	CELL	9	9	cells
NCT000028392	NCT00002839_2_T1	PHENOTYPE	8	8	tumor
NCT000028393	NCT00002839_3_T0	ORGAN	26	26	larynx
NCT000028393	NCT00002839_3_T1	COMPOUND	8	8	cisplatin
NCT000028393	NCT00002839_3_T2	PHENOTYPE	21	24	cancer of the hypopharynx
NCT000028394	NCT00002839_4_T0	GENE	3	3	III
NCT000028394	NCT00002839_4_T1	ORGAN	23	23	larynx
NCT000028394	NCT00002839_4_T2	ORGAN	34	34	larynx
NCT000028394	NCT00002839_4_T3	COMPOUND	13	13	cisplatin
NCT000028394	NCT00002839_4_T4	PHENOTYPE	29	32	cancer of the hypopharynx
NCT000028397	NCT00002839_7_T0	PHENOTYPE	8	8	tumor
NCT0000283911	NCT00002839_11_T0	PHENOTYPE	6	6	remission
NCT0000283911	NCT00002839_11_T1	PHENOTYPE	13	13	remission
NCT0000283913	NCT00002839_13_T0	PHENOTYPE	18	18	remission
NCT0000283914	NCT00002839_14_T0	GENE	9	9	42
NCT0000283915	NCT00002839_15_T0	PHENOTYPE	4	5	progressive disease
NCT000028401	NCT00002840_1_T0	CELL	10	10	cells
NCT000028401	NCT00002840_1_T1	PHENOTYPE	9	9	tumor
NCT000028402	NCT00002840_2_T0	GENE	3	3	III
NCT000028402	NCT00002840_2_T1	PHENOTYPE	18	19	anaplastic oligodendroglioma
NCT000028404	NCT00002840_4_T0	GENE	23	23	PCV
NCT000028404	NCT00002840_4_T1	COMPOUND	22	22	vincristine
NCT000028404	NCT00002840_4_T2	PHENOTYPE	6	6	progression
NCT000028404	NCT00002840_4_T3	COMPOUND	19	19	procarbazine
NCT000028404	NCT00002840_4_T4	COMPOUND	20	20	lomustine
NCT000028404	NCT00002840_4_T5	PHENOTYPE	10	11	anaplastic oligodendroglioma
NCT000028406	NCT00002840_6_T0	GENE	4	4	PCV
NCT000028406	NCT00002840_6_T1	PHENOTYPE	6	8	quality of life
NCT000028408	NCT00002840_8_T0	PHENOTYPE	2	2	toxicity
NCT000028408	NCT00002840_8_T1	GENE	4	4	PCV
NCT0000284010	NCT00002840_10_T0	PHENOTYPE	10	10	mutation
NCT0000284010	NCT00002840_10_T1	GENE	7	7	p53
NCT0000284010	NCT00002840_10_T2	CELL	13	14	chromosome 7
NCT0000284010	NCT00002840_10_T3	PHENOTYPE	16	19	loss of chromosome 10
NCT0000284016	NCT00002840_16_T0	COMPOUND	13	13	vincristine
NCT0000284016	NCT00002840_16_T1	GENE	14	14	IV
NCT0000284016	NCT00002840_16_T2	COMPOUND	8	8	procarbazine
NCT0000284016	NCT00002840_16_T3	COMPOUND	3	3	lomustine
NCT0000284018	NCT00002840_18_T0	PHENOTYPE	3	3	recurrence
NCT000028421	NCT00002842_1_T0	CELL	15	15	cells
NCT000028421	NCT00002842_1_T1	PHENOTYPE	14	14	tumor
NCT000028422	NCT00002842_2_T0	GENE	2	2	II
NCT000028422	NCT00002842_2_T1	COMPOUND	17	17	leucovorin
NCT000028422	NCT00002842_2_T2	PHENOTYPE	25	26	colorectal cancer
NCT000028422	NCT00002842_2_T3	PHENOTYPE	22	23	liver metastases
NCT000028426	NCT00002842_6_T0	COMPOUND	5	5	calcium
NCT000028426	NCT00002842_6_T1	COMPOUND	4	4	leucovorin
NCT000028428	NCT00002842_8_T0	PHENOTYPE	2	3	metastatic disease
NCT000028441	NCT00002844_1_T0	CELL	21	21	cells
NCT000028441	NCT00002844_1_T1	ORGAN	3	4	bone marrow
NCT000028442	NCT00002844_2_T0	GENE	2	2	II
NCT000028442	NCT00002844_2_T1	ORGAN	9	10	bone marrow
NCT000028442	NCT00002844_2_T2	PHENOTYPE	16	18	chronic lymphocytic leukemia
NCT000028444	NCT00002844_4_T0	PHENOTYPE	19	19	exposures
NCT000028444	NCT00002844_4_T1	COMPOUND	7	7	cyclophosphamide
NCT000028445	NCT00002844_5_T0	ORGAN	10	11	bone marrow
NCT000028451	NCT00002845_1_T0	GENE	2	2	II
NCT000028451	NCT00002845_1_T1	GENE	9	9	interleukin-2
NCT000028451	NCT00002845_1_T2	PHENOTYPE	15	16	metastatic melanoma
NCT000028453	NCT00002845_3_T0	GENE	19	19	interleukin-2
NCT000028453	NCT00002845_3_T1	PHENOTYPE	9	10	metastatic melanoma
NCT000028455	NCT00002845_5_T0	PHENOTYPE	2	2	toxicity
NCT000028456	NCT00002845_6_T0	PHENOTYPE	20	20	toxicity
NCT000028456	NCT00002845_6_T1	GENE	5	5	interleukin-2
NCT000028456	NCT00002845_6_T2	GENE	12	12	interleukin-2
NCT000028458	NCT00002845_8_T0	PHENOTYPE	22	22	toxicity
NCT000028461	NCT00002846_1_T0	GENE	2	2	II
NCT000028461	NCT00002846_1_T1	GENE	10	10	interleukin-2
NCT000028461	NCT00002846_1_T2	PHENOTYPE	17	19	recurrent kidney cancer
NCT000028463	NCT00002846_3_T0	GENE	5	5	interleukin-2
NCT000028464	NCT00002846_4_T0	PHENOTYPE	13	13	initiation
NCT000028465	NCT00002846_5_T0	PHENOTYPE	9	9	toxicity
NCT000028466	NCT00002846_6_T0	ORGAN	3	3	kidney
NCT000028466	NCT00002846_6_T1	PHENOTYPE	9	9	tumor
NCT000028471	NCT00002847_1_T0	CELL	9	9	cells
NCT000028471	NCT00002847_1_T1	GENE	4	4	interleukin-2
NCT000028471	NCT00002847_1_T2	PHENOTYPE	8	8	tumor
NCT000028471	NCT00002847_1_T3	GENE	1	1	interferon
NCT000028472	NCT00002847_2_T0	GENE	2	2	II
NCT000028472	NCT00002847_2_T1	GENE	12	12	interleukin-2
NCT000028472	NCT00002847_2_T2	GENE	9	9	interferon
NCT000028472	NCT00002847_2_T3	PHENOTYPE	17	19	metastatic kidney cancer
NCT000028474	NCT00002847_4_T0	ORGAN	7	7	kidney
NCT000028474	NCT00002847_4_T1	PHENOTYPE	14	14	tumor
NCT000028475	NCT00002847_5_T0	GENE	10	10	interleukin-2
NCT000028475	NCT00002847_5_T1	GENE	25	25	interleukin-2
NCT000028475	NCT00002847_5_T2	GENE	13	13	3.5
NCT000028475	NCT00002847_5_T3	GENE	19	19	reduced
NCT000028475	NCT00002847_5_T4	GENE	4	4	interferon
NCT000028475	NCT00002847_5_T5	GENE	22	22	interferon
NCT000028477	NCT00002847_7_T0	PHENOTYPE	20	20	toxicity
NCT000028486	NCT00002848_6_T0	PHENOTYPE	16	16	imagery
NCT000028488	NCT00002848_8_T0	PHENOTYPE	24	24	thoughts
NCT000028488	NCT00002848_8_T1	PHENOTYPE	22	22	feelings
NCT000028489	NCT00002848_9_T0	PHENOTYPE	0	0	Quality-of-life
NCT000028490	NCT00002849_0_T0	GENE	3	3	Interferon
NCT000028490	NCT00002849_0_T1	PHENOTYPE	9	11	Primary Systemic Amyloidosis
NCT000028492	NCT00002849_2_T0	GENE	2	2	II
NCT000028492	NCT00002849_2_T1	COMPOUND	9	9	dexamethasone
NCT000028492	NCT00002849_2_T2	GENE	11	11	interferon
NCT000028492	NCT00002849_2_T3	PHENOTYPE	18	20	primary systemic amyloidosis
NCT000028494	NCT00002849_4_T0	PHENOTYPE	6	6	amyloidosis
NCT000028495	NCT00002849_5_T0	COMPOUND	7	7	dexamethasone
NCT000028495	NCT00002849_5_T1	GENE	10	10	1.4
NCT000028497	NCT00002849_7_T0	PHENOTYPE	23	23	toxicity
NCT000028497	NCT00002849_7_T1	COMPOUND	32	32	dexamethasone
NCT000028497	NCT00002849_7_T2	GENE	43	43	interferon
NCT000028497	NCT00002849_7_T3	PHENOTYPE	41	41	initiation
NCT000028497	NCT00002849_7_T4	PHENOTYPE	31	31	pulse
NCT000028497	NCT00002849_7_T5	ORGAN	9	9	serum
NCT000028498	NCT00002849_8_T0	PHENOTYPE	19	19	toxicity
NCT000028498	NCT00002849_8_T1	GENE	10	10	interferon
NCT000028499	NCT00002849_9_T0	GENE	11	11	interferon
NCT000028500	NCT00002850_0_T0	PHENOTYPE	9	10	Multiple Myeloma
NCT000028502	NCT00002850_2_T0	PHENOTYPE	25	26	multiple myeloma
NCT0000285013	NCT00002850_13_T0	PHENOTYPE	0	0	Myeloma
NCT0000285013	NCT00002850_13_T1	ORGAN	4	4	serum
NCT0000285014	NCT00002850_14_T0	PHENOTYPE	0	0	Myeloma
NCT0000285016	NCT00002850_16_T0	COMPOUND	11	11	dexamethasone
NCT000028511	NCT00002851_1_T0	GENE	28	28	II
NCT000028511	NCT00002851_1_T1	GENE	4	4	III
NCT000028511	NCT00002851_1_T2	GENE	35	35	has
NCT000028511	NCT00002851_1_T3	PHENOTYPE	30	33	stage III breast cancer
NCT000028514	NCT00002851_4_T0	PHENOTYPE	18	18	menopausal
NCT000028514	NCT00002851_4_T1	PHENOTYPE	6	6	tumor
NCT000028514	NCT00002851_4_T2	COMPOUND	16	16	N
NCT000028522	NCT00002852_2_T0	CELL	10	10	cells
NCT000028522	NCT00002852_2_T1	PHENOTYPE	9	9	tumor
NCT000028523	NCT00002852_3_T0	CELL	9	9	cells
NCT000028523	NCT00002852_3_T1	PHENOTYPE	8	8	tumor
NCT000028527	NCT00002852_7_T0	PHENOTYPE	11	13	stage I NSCLC
NCT000028529	NCT00002852_9_T0	PHENOTYPE	3	3	toxicities
NCT0000285211	NCT00002852_11_T0	PHENOTYPE	6	6	recurrence
NCT000028545	NCT00002854_5_T0	CELL	1	2	stem cells
NCT000028547	NCT00002854_7_T0	COMPOUND	8	8	cyclophosphamide
NCT000028547	NCT00002854_7_T1	COMPOUND	6	6	etoposide
NCT000028547	NCT00002854_7_T2	COMPOUND	5	5	cisplatin
NCT000028547	NCT00002854_7_T3	CELL	24	25	stem cells
NCT000028548	NCT00002854_8_T0	CELL	4	4	granulocyte
NCT000028548	NCT00002854_8_T1	GENE	0	0	G-CSF
NCT000028549	NCT00002854_9_T0	COMPOUND	22	22	paclitaxel
NCT000028549	NCT00002854_9_T1	COMPOUND	25	25	ifosfamide
NCT000028549	NCT00002854_9_T2	CELL	38	39	stem cells
NCT0000285410	NCT00002854_10_T0	CELL	4	4	granulocyte
NCT0000285410	NCT00002854_10_T1	GENE	0	0	G-CSF
NCT0000285411	NCT00002854_11_T0	COMPOUND	10	10	paclitaxel
NCT0000285413	NCT00002854_13_T0	COMPOUND	13	13	paclitaxel
NCT000028551	NCT00002855_1_T0	COMPOUND	6	6	androgen
NCT000028551	NCT00002855_1_T1	CELL	12	12	cells
NCT000028551	NCT00002855_1_T2	PHENOTYPE	11	11	tumor
NCT000028551	NCT00002855_1_T3	PHENOTYPE	7	7	suppression
NCT000028551	NCT00002855_1_T4	GENE	1	1	hormone
NCT000028557	NCT00002855_7_T0	COMPOUND	12	12	vinblastine
NCT000028557	NCT00002855_7_T1	COMPOUND	11	11	ketoconazole
NCT000028557	NCT00002855_7_T2	COMPOUND	10	10	doxorubicin
NCT000028557	NCT00002855_7_T3	COMPOUND	14	14	estramustine
NCT000028558	NCT00002855_8_T0	COMPOUND	6	6	hydrocortisone
NCT000028582	NCT00002858_2_T0	CELL	8	8	cells
NCT000028582	NCT00002858_2_T1	PHENOTYPE	7	7	tumor
NCT000028583	NCT00002858_3_T0	CELL	13	13	cells
NCT000028583	NCT00002858_3_T1	PHENOTYPE	12	12	tumor
NCT0000285810	NCT00002858_10_T0	COMPOUND	13	13	cyclophosphamide
NCT0000285810	NCT00002858_10_T1	COMPOUND	10	10	etoposide
NCT0000285810	NCT00002858_10_T2	COMPOUND	9	9	doxorubicin
NCT0000285810	NCT00002858_10_T3	COMPOUND	11	11	cisplatin
NCT0000285811	NCT00002858_11_T0	COMPOUND	13	13	cyclophosphamide
NCT0000285812	NCT00002858_12_T0	COMPOUND	10	10	cyclophosphamide
NCT000028601	NCT00002860_1_T0	GENE	3	3	II
NCT000028601	NCT00002860_1_T1	PHENOTYPE	15	16	metastatic melanoma
NCT000028605	NCT00002860_5_T0	PHENOTYPE	11	11	recurrence
NCT000028606	NCT00002860_6_T0	PHENOTYPE	5	6	residual disease
NCT000028608	NCT00002860_8_T0	GENE	8	8	interferon
NCT000028621	NCT00002862_1_T0	CELL	10	10	cells
NCT000028621	NCT00002862_1_T1	PHENOTYPE	9	9	tumor
NCT000028625	NCT00002862_5_T0	PHENOTYPE	2	2	toxic
NCT000028625	NCT00002862_5_T1	PHENOTYPE	5	5	pharmacokinetics
NCT000028627	NCT00002862_7_T0	COMPOUND	5	6	perillyl alcohol
NCT0000286210	NCT00002862_10_T0	COMPOUND	14	15	perillyl alcohol
NCT0000286212	NCT00002862_12_T0	PHENOTYPE	11	11	toxicity
NCT0000286212	NCT00002862_12_T1	PHENOTYPE	7	8	disease progression
NCT000028631	NCT00002863_1_T0	CELL	10	10	cells
NCT000028631	NCT00002863_1_T1	PHENOTYPE	9	9	tumor
NCT000028632	NCT00002863_2_T0	CELL	8	8	cells
NCT000028632	NCT00002863_2_T1	PHENOTYPE	7	7	tumor
NCT000028633	NCT00002863_3_T0	PHENOTYPE	19	21	soft tissue sarcoma
NCT000028635	NCT00002863_5_T0	ORGAN	17	17	extremity
NCT000028635	NCT00002863_5_T1	PHENOTYPE	12	14	soft tissue sarcomas
NCT000028637	NCT00002863_7_T0	GENE	22	22	2.3
NCT000028637	NCT00002863_7_T1	PHENOTYPE	2	3	high-grade sarcoma
NCT000028638	NCT00002863_8_T0	PHENOTYPE	7	8	high-grade sarcoma
NCT000028638	NCT00002863_8_T1	PHENOTYPE	2	3	low-grade sarcoma
NCT000028639	NCT00002863_9_T0	ORGAN	12	12	limb
NCT000028639	NCT00002863_9_T1	GENE	6	6	en
NCT0000286311	NCT00002863_11_T0	PHENOTYPE	13	13	sarcoma
NCT0000286311	NCT00002863_11_T1	PHENOTYPE	17	18	high-grade sarcoma
NCT0000286312	NCT00002863_12_T0	PHENOTYPE	9	9	complication
NCT0000286312	NCT00002863_12_T1	PHENOTYPE	20	20	neuropraxia
NCT0000286312	NCT00002863_12_T2	PHENOTYPE	34	35	wound complication
NCT0000286312	NCT00002863_12_T3	PHENOTYPE	45	46	deep wound
NCT0000286312	NCT00002863_12_T4	PHENOTYPE	46	47	wound infection
NCT000028642	NCT00002864_2_T0	PHENOTYPE	12	13	breast cancer
NCT000028643	NCT00002864_3_T0	GENE	24	24	II
NCT000028643	NCT00002864_3_T1	GENE	3	3	III
NCT000028643	NCT00002864_3_T2	COMPOUND	14	14	octreotide
NCT000028643	NCT00002864_3_T3	COMPOUND	10	10	tamoxifen
NCT000028643	NCT00002864_3_T4	PHENOTYPE	26	29	stage III breast cancer
NCT000028645	NCT00002864_5_T0	COMPOUND	15	15	octreotide
NCT000028645	NCT00002864_5_T1	COMPOUND	10	10	tamoxifen
NCT000028645	NCT00002864_5_T2	COMPOUND	13	13	tamoxifen
NCT000028645	NCT00002864_5_T3	PHENOTYPE	25	26	breast cancer
NCT000028647	NCT00002864_7_T0	PHENOTYPE	2	2	toxicity
NCT000028647	NCT00002864_7_T1	PHENOTYPE	4	6	quality of life
NCT0000286411	NCT00002864_11_T0	TISSUE	14	15	lymph node
NCT0000286411	NCT00002864_11_T1	GENE	18	19	hormone receptor
NCT0000286414	NCT00002864_14_T0	COMPOUND	17	17	octreotide
NCT0000286414	NCT00002864_14_T1	COMPOUND	7	7	tamoxifen
NCT0000286414	NCT00002864_14_T2	COMPOUND	15	15	tamoxifen
NCT0000286417	NCT00002864_17_T0	GENE	11	11	4.2
NCT000028651	NCT00002865_1_T0	CELL	9	9	cells
NCT000028651	NCT00002865_1_T1	PHENOTYPE	8	8	tumor
NCT000028652	NCT00002865_2_T0	GENE	2	2	II
NCT000028652	NCT00002865_2_T1	PHENOTYPE	19	21	acute lymphocytic leukemia
NCT000028656	NCT00002865_6_T0	PHENOTYPE	2	2	toxic
NCT000028657	NCT00002865_7_T0	COMPOUND	18	18	dexamethasone
NCT000028657	NCT00002865_7_T1	COMPOUND	32	32	dexamethasone
NCT000028657	NCT00002865_7_T2	COMPOUND	38	38	cytarabine
NCT000028657	NCT00002865_7_T3	COMPOUND	23	23	vincristine
NCT000028657	NCT00002865_7_T4	COMPOUND	37	37	vincristine
NCT000028657	NCT00002865_7_T5	GENE	10	10	3.4
NCT000028657	NCT00002865_7_T6	COMPOUND	19	19	methotrexate
NCT000028657	NCT00002865_7_T7	COMPOUND	33	33	methotrexate
NCT000028657	NCT00002865_7_T8	COMPOUND	16	16	cyclophosphamide
NCT000028657	NCT00002865_7_T9	COMPOUND	40	40	etoposide
NCT000028657	NCT00002865_7_T10	COMPOUND	25	25	doxorubicin
NCT000028657	NCT00002865_7_T11	COMPOUND	21	21	leucovorin
NCT000028657	NCT00002865_7_T12	COMPOUND	35	35	leucovorin
NCT000028658	NCT00002865_8_T0	GENE	0	0	G-CSF
NCT000028658	NCT00002865_8_T1	CELL	10	10	neutrophil
NCT0000286510	NCT00002865_10_T0	GENE	11	11	CSF
NCT000028661	NCT00002866_1_T0	PHENOTYPE	17	17	peripheral
NCT000028661	NCT00002866_1_T1	GENE	4	4	G-CSF
NCT000028661	NCT00002866_1_T2	CELL	11	11	cells
NCT000028661	NCT00002866_1_T3	ORGAN	14	15	bone marrow
NCT000028661	NCT00002866_1_T4	ORGAN	25	26	immune system
NCT000028661	NCT00002866_1_T5	PHENOTYPE	31	33	effects of chemotherapy
NCT000028662	NCT00002866_2_T0	COMPOUND	9	9	docetaxel
NCT000028662	NCT00002866_2_T1	COMPOUND	11	11	epirubicin
NCT000028662	NCT00002866_2_T2	GENE	15	15	G-CSF
NCT000028662	NCT00002866_2_T3	PHENOTYPE	20	22	metastatic breast cancer
NCT000028664	NCT00002866_4_T0	GENE	8	8	II
NCT000028664	NCT00002866_4_T1	GENE	29	29	II
NCT000028664	NCT00002866_4_T2	COMPOUND	15	15	epirubicin
NCT000028664	NCT00002866_4_T3	GENE	18	18	G-CSF
NCT000028664	NCT00002866_4_T4	COMPOUND	11	11	docetaxel
NCT000028664	NCT00002866_4_T5	GENE	17	17	filgrastim
NCT000028664	NCT00002866_4_T6	PHENOTYPE	30	30	closed
NCT000028664	NCT00002866_4_T7	PHENOTYPE	25	27	metastatic breast cancer
NCT000028666	NCT00002866_6_T0	COMPOUND	5	5	docetaxel
NCT000028666	NCT00002866_6_T1	COMPOUND	7	7	epirubicin
NCT000028668	NCT00002866_8_T0	PHENOTYPE	2	2	toxicity
NCT000028668	NCT00002866_8_T1	GENE	11	11	II
NCT0000286611	NCT00002866_11_T0	COMPOUND	10	10	docetaxel
NCT0000286611	NCT00002866_11_T1	COMPOUND	8	8	epirubicin
NCT0000286612	NCT00002866_12_T0	COMPOUND	9	9	docetaxel
NCT0000286612	NCT00002866_12_T1	COMPOUND	2	2	epirubicin
NCT0000286612	NCT00002866_12_T2	GENE	3	3	IV
NCT0000286612	NCT00002866_12_T3	GENE	10	10	IV
NCT0000286613	NCT00002866_13_T0	GENE	3	3	filgrastim
NCT0000286613	NCT00002866_13_T1	GENE	4	4	G-CSF
NCT0000286614	NCT00002866_14_T0	PHENOTYPE	18	18	toxicity
NCT0000286614	NCT00002866_14_T1	PHENOTYPE	14	15	disease progression
NCT0000286615	NCT00002866_15_T0	COMPOUND	10	10	docetaxel
NCT0000286615	NCT00002866_15_T1	COMPOUND	8	8	epirubicin
NCT0000286615	NCT00002866_15_T2	GENE	16	16	MTD
NCT0000286616	NCT00002866_16_T0	PHENOTYPE	17	17	toxicity
NCT0000286616	NCT00002866_16_T1	GENE	1	1	MTD
NCT0000286617	NCT00002866_17_T0	GENE	12	12	II
NCT0000286617	NCT00002866_17_T1	GENE	15	15	II
NCT0000286617	NCT00002866_17_T2	PHENOTYPE	16	16	closed
NCT0000286619	NCT00002866_19_T0	GENE	9	9	4.5
NCT0000286620	NCT00002866_20_T0	GENE	14	14	II
NCT0000286620	NCT00002866_20_T1	PHENOTYPE	19	19	closed
NCT000028681	NCT00002868_1_T0	CELL	10	10	cells
NCT0000286813	NCT00002868_13_T0	PHENOTYPE	3	3	remission
NCT0000286815	NCT00002868_15_T0	PHENOTYPE	5	5	remission
NCT0000286817	NCT00002868_17_T0	GENE	4	4	Ph
NCT0000286821	NCT00002868_21_T0	PHENOTYPE	1	3	quality of life
NCT0000286827	NCT00002868_27_T0	GENE	23	23	SC
NCT0000286827	NCT00002868_27_T1	COMPOUND	3	3	hydroxyurea
NCT0000286827	NCT00002868_27_T2	GENE	0	0	OR
NCT0000286827	NCT00002868_27_T3	GENE	22	22	G-CSF
NCT0000286827	NCT00002868_27_T4	GENE	4	4	IV
NCT0000286827	NCT00002868_27_T5	CELL	8	8	neutrophil
NCT0000286827	NCT00002868_27_T6	PHENOTYPE	15	16	platelet count
NCT0000286829	NCT00002868_29_T0	COMPOUND	8	8	busulfan
NCT0000286829	NCT00002868_29_T1	COMPOUND	13	13	2
NCT0000286830	NCT00002868_30_T0	CELL	1	4	peripheral blood stem cells
NCT0000286831	NCT00002868_31_T0	GENE	9	9	SC
NCT0000286831	NCT00002868_31_T1	GENE	7	7	interferon
NCT0000286831	NCT00002868_31_T2	PHENOTYPE	30	31	disease progression
NCT0000286832	NCT00002868_32_T0	GENE	12	12	SC
NCT0000286832	NCT00002868_32_T1	COMPOUND	11	11	cytarabine
NCT0000286832	NCT00002868_32_T2	GENE	26	26	interferon
NCT0000286834	NCT00002868_34_T0	PHENOTYPE	2	2	remission
NCT0000286834	NCT00002868_34_T1	GENE	8	8	interferon
NCT0000286834	NCT00002868_34_T2	PHENOTYPE	20	21	disease progression
NCT0000286836	NCT00002868_36_T0	PHENOTYPE	0	2	Quality of life
NCT000028691	NCT00002869_1_T0	GENE	3	3	interferon
NCT000028692	NCT00002869_2_T0	GENE	3	3	III
NCT000028692	NCT00002869_2_T1	GENE	13	13	interferon
NCT000028692	NCT00002869_2_T2	PHENOTYPE	22	24	chronic myelogenous leukemia
NCT000028694	NCT00002869_4_T0	GENE	12	12	interferon
NCT000028694	NCT00002869_4_T1	PHENOTYPE	4	4	chronic
NCT000028694	NCT00002869_4_T2	PHENOTYPE	23	23	chronic
NCT000028694	NCT00002869_4_T3	PHENOTYPE	19	21	chronic myelogenous leukemia
NCT000028696	NCT00002869_6_T0	PHENOTYPE	2	2	toxicity
NCT0000286912	NCT00002869_12_T0	COMPOUND	5	5	hydroxyurea
NCT0000286912	NCT00002869_12_T1	GENE	7	7	reduced
NCT0000286912	NCT00002869_12_T2	GENE	15	15	WBC
NCT0000286913	NCT00002869_13_T0	PHENOTYPE	3	4	disease progression
NCT0000286915	NCT00002869_15_T0	PHENOTYPE	20	20	toxicity
NCT0000286915	NCT00002869_15_T1	PHENOTYPE	16	17	disease progression
NCT000028707	NCT00002870_7_T0	PHENOTYPE	9	11	quality of life
NCT000028709	NCT00002870_9_T0	PHENOTYPE	1	1	tumor
NCT0000287011	NCT00002870_11_T0	GENE	5	5	hormone
NCT0000287012	NCT00002870_12_T0	COMPOUND	9	9	cyclophosphamide
NCT0000287012	NCT00002870_12_T1	COMPOUND	6	6	epirubicin
NCT0000287016	NCT00002870_16_T0	GENE	1	1	G-CSF
NCT0000287017	NCT00002870_17_T0	PHENOTYPE	12	12	tumors
NCT0000287017	NCT00002870_17_T1	PHENOTYPE	11	11	multifocal
NCT0000287018	NCT00002870_18_T0	PHENOTYPE	5	5	metastasis
NCT0000287019	NCT00002870_19_T0	PHENOTYPE	2	3	relapsed disease
NCT0000287020	NCT00002870_20_T0	PHENOTYPE	11	11	relapse
NCT000028721	NCT00002872_1_T0	COMPOUND	6	6	bleomycin
NCT000028721	NCT00002872_1_T1	COMPOUND	7	7	doxycycline
NCT000028721	NCT00002872_1_T2	PHENOTYPE	17	19	malignant pleural effusions
NCT000028722	NCT00002872_2_T0	COMPOUND	10	10	bleomycin
NCT000028722	NCT00002872_2_T1	GENE	3	3	III
NCT000028722	NCT00002872_2_T2	COMPOUND	11	11	doxycycline
NCT000028722	NCT00002872_2_T3	PHENOTYPE	18	20	malignant pleural effusions
NCT000028724	NCT00002872_4_T0	PHENOTYPE	19	19	recurrence
NCT000028724	NCT00002872_4_T1	COMPOUND	2	2	bleomycin
NCT000028724	NCT00002872_4_T2	PHENOTYPE	22	22	effusion
NCT000028724	NCT00002872_4_T3	COMPOUND	4	4	doxycycline
NCT000028724	NCT00002872_4_T4	PHENOTYPE	11	13	malignant pleural effusion
NCT000028726	NCT00002872_6_T0	PHENOTYPE	12	12	recurrent
NCT000028726	NCT00002872_6_T1	PHENOTYPE	13	13	effusions
NCT0000287212	NCT00002872_12_T0	PHENOTYPE	16	16	recurrence
NCT0000287212	NCT00002872_12_T1	PHENOTYPE	12	14	malignant pleural effusion
NCT0000287219	NCT00002872_19_T0	COMPOUND	8	8	bleomycin
NCT0000287219	NCT00002872_19_T1	COMPOUND	9	9	doxycycline
NCT000028731	NCT00002873_1_T0	PHENOTYPE	18	21	stage II breast cancer
NCT000028733	NCT00002873_3_T0	PHENOTYPE	8	8	complication
NCT000028733	NCT00002873_3_T1	GENE	51	51	nodal
NCT000028733	NCT00002873_3_T2	PHENOTYPE	11	12	local cancer
NCT000028733	NCT00002873_3_T3	PHENOTYPE	30	31	breast cancer
NCT000028733	NCT00002873_3_T4	TISSUE	39	41	negative surgical margins
NCT000028735	NCT00002873_5_T0	GENE	12	12	4.5
NCT000028737	NCT00002873_7_T0	COMPOUND	24	24	iridium_192
NCT000028737	NCT00002873_7_T1	GENE	21	21	cm
NCT000028737	NCT00002873_7_T2	PHENOTYPE	13	13	cavity
NCT000028751	NCT00002875_1_T0	CELL	10	10	cells
NCT000028751	NCT00002875_1_T1	PHENOTYPE	9	9	tumor
NCT000028752	NCT00002875_2_T0	CELL	9	9	cells
NCT000028752	NCT00002875_2_T1	PHENOTYPE	8	8	tumor
NCT000028753	NCT00002875_3_T0	PHENOTYPE	18	18	medulloblastoma
NCT000028754	NCT00002875_4_T0	PHENOTYPE	20	20	medulloblastoma
NCT000028754	NCT00002875_4_T1	GENE	3	3	III
NCT000028756	NCT00002875_6_T0	PHENOTYPE	21	21	medulloblastoma
NCT0000287510	NCT00002875_10_T0	PHENOTYPE	7	7	sequelae
NCT0000287510	NCT00002875_10_T1	PHENOTYPE	35	35	sequelae
NCT0000287510	NCT00002875_10_T2	COMPOUND	28	28	cyclophosphamide
NCT0000287510	NCT00002875_10_T3	COMPOUND	26	26	lomustine
NCT0000287512	NCT00002875_12_T0	PHENOTYPE	7	7	tumor
NCT0000287512	NCT00002875_12_T1	PHENOTYPE	29	30	disease relapse
NCT0000287514	NCT00002875_14_T0	ORGAN	14	14	spine
NCT0000287514	NCT00002875_14_T1	PHENOTYPE	18	19	recurrent disease
NCT0000287518	NCT00002875_18_T0	PHENOTYPE	12	13	primary tumor
NCT0000287519	NCT00002875_19_T0	COMPOUND	10	10	vincristine
NCT0000287519	NCT00002875_19_T1	PHENOTYPE	5	5	initiation
NCT0000287521	NCT00002875_21_T0	COMPOUND	7	7	vincristine
NCT000028760	NCT00002876_0_T0	PHENOTYPE	8	8	Ependymomas
NCT000028760	NCT00002876_0_T1	PHENOTYPE	7	7	Recurrent
NCT000028762	NCT00002876_2_T0	CELL	9	9	cells
NCT000028762	NCT00002876_2_T1	PHENOTYPE	8	8	tumor
NCT000028763	NCT00002876_3_T0	GENE	2	2	II
NCT000028763	NCT00002876_3_T1	PHENOTYPE	15	15	recurrent
NCT000028763	NCT00002876_3_T2	PHENOTYPE	16	16	ependymomas
NCT000028765	NCT00002876_5_T0	PHENOTYPE	4	4	toxicity
NCT000028765	NCT00002876_5_T1	COMPOUND	6	6	etoposide
NCT000028765	NCT00002876_5_T2	COMPOUND	8	8	cisplatin
NCT000028765	NCT00002876_5_T3	PHENOTYPE	12	12	recurrent
NCT000028765	NCT00002876_5_T4	PHENOTYPE	13	13	ependymomas
NCT000028766	NCT00002876_6_T0	GENE	10	10	1.3
NCT000028766	NCT00002876_6_T1	COMPOUND	7	7	etoposide
NCT000028766	NCT00002876_6_T2	COMPOUND	4	4	cisplatin
NCT000028767	NCT00002876_7_T0	PHENOTYPE	16	16	toxicity
NCT000028767	NCT00002876_7_T1	PHENOTYPE	12	13	disease progression
NCT000028769	NCT00002876_9_T0	GENE	14	14	4.5
NCT0000287610	NCT00002876_10_T0	GENE	17	17	3.8
NCT000028781	NCT00002878_1_T0	PHENOTYPE	1	1	tumors
NCT000028781	NCT00002878_1_T1	PHENOTYPE	3	3	resistant
NCT000028795	NCT00002879_5_T0	PHENOTYPE	13	13	peripheral
NCT000028795	NCT00002879_5_T1	PHENOTYPE	28	28	peripheral
NCT000028795	NCT00002879_5_T2	CELL	7	7	lymphocytes
NCT000028797	NCT00002879_7_T0	GENE	15	15	polymerase
NCT000028797	NCT00002879_7_T1	GENE	4	4	bcl-1
NCT000028797	NCT00002879_7_T2	GENE	32	32	bcl-1
NCT000028797	NCT00002879_7_T3	GENE	7	9	immunoglobulin heavy chain
NCT0000287911	NCT00002879_11_T0	PHENOTYPE	2	2	toxic
NCT0000287912	NCT00002879_12_T0	COMPOUND	3	3	cladribine
NCT0000287913	NCT00002879_13_T0	PHENOTYPE	3	3	remission
NCT0000287913	NCT00002879_13_T1	PHENOTYPE	15	16	disease progression
NCT000028801	NCT00002880_1_T0	GENE	2	2	II
NCT000028801	NCT00002880_1_T1	COMPOUND	9	9	etoposide
NCT000028801	NCT00002880_1_T2	PHENOTYPE	15	16	Hodgkin's lymphoma
NCT000028803	NCT00002880_3_T0	COMPOUND	18	18	etoposide
NCT000028803	NCT00002880_3_T1	PHENOTYPE	11	12	Hodgkin's lymphoma
NCT000028805	NCT00002880_5_T0	PHENOTYPE	2	2	toxic
NCT000028805	NCT00002880_5_T1	COMPOUND	7	7	etoposide
NCT000028807	NCT00002880_7_T0	PHENOTYPE	14	14	toxicity
NCT000028807	NCT00002880_7_T1	PHENOTYPE	8	8	concentrations
NCT000028807	NCT00002880_7_T2	COMPOUND	1	1	etoposide
NCT000028807	NCT00002880_7_T3	COMPOUND	7	7	etoposide
NCT000028808	NCT00002880_8_T0	COMPOUND	4	4	etoposide
NCT000028809	NCT00002880_9_T0	PHENOTYPE	14	14	toxicity
NCT000028809	NCT00002880_9_T1	PHENOTYPE	10	11	disease progression
NCT0000288010	NCT00002880_10_T0	PHENOTYPE	5	5	remission
NCT000028815	NCT00002881_5_T0	PHENOTYPE	10	10	toxic
NCT0000288111	NCT00002881_11_T0	COMPOUND	7	7	androgen
NCT0000288111	NCT00002881_11_T1	PHENOTYPE	8	8	suppression
NCT0000288112	NCT00002881_12_T0	COMPOUND	9	9	flutamide
NCT0000288113	NCT00002881_13_T0	GENE	9	9	LHRH
NCT0000288113	NCT00002881_13_T1	COMPOUND	15	15	goserelin
NCT0000288113	NCT00002881_13_T2	COMPOUND	13	13	leuprolide
NCT0000288114	NCT00002881_14_T0	COMPOUND	4	4	suramin
NCT0000288115	NCT00002881_15_T0	COMPOUND	6	6	suramin
NCT0000288115	NCT00002881_15_T1	COMPOUND	18	18	suramin
NCT0000288115	NCT00002881_15_T2	PHENOTYPE	22	23	disease progression
NCT000028821	NCT00002882_1_T0	CELL	11	11	cells
NCT000028821	NCT00002882_1_T1	GENE	0	0	Interleukin-2
NCT000028821	NCT00002882_1_T2	PHENOTYPE	10	10	melanoma
NCT000028821	NCT00002882_1_T3	CELL	5	7	white blood cells
NCT000028822	NCT00002882_2_T0	GENE	12	12	interleukin-2
NCT000028822	NCT00002882_2_T1	PHENOTYPE	24	24	melanoma
NCT000028822	NCT00002882_2_T2	GENE	6	6	interferon
NCT000028822	NCT00002882_2_T3	GENE	17	17	interferon
NCT000028823	NCT00002882_3_T0	GENE	18	18	interleukin-2
NCT000028823	NCT00002882_3_T1	GENE	3	3	III
NCT000028823	NCT00002882_3_T2	PHENOTYPE	23	23	melanoma
NCT000028823	NCT00002882_3_T3	GENE	10	10	interferon
NCT000028828	NCT00002882_8_T0	COMPOUND	3	4	interferon alfa_2b
NCT0000288211	NCT00002882_11_T0	COMPOUND	21	21	1
NCT0000288211	NCT00002882_11_T1	GENE	29	29	IL-2
NCT0000288211	NCT00002882_11_T2	COMPOUND	7	7	vinblastine
NCT0000288211	NCT00002882_11_T3	GENE	6	6	1.4
NCT0000288211	NCT00002882_11_T4	GENE	13	13	1.4
NCT0000288211	NCT00002882_11_T5	GENE	43	43	1.4
NCT0000288211	NCT00002882_11_T6	GENE	28	28	1.5
NCT0000288211	NCT00002882_11_T7	GENE	3	3	IV
NCT0000288211	NCT00002882_11_T8	COMPOUND	14	14	dacarbazine
NCT000028832	NCT00002883_2_T0	GENE	3	3	III
NCT000028832	NCT00002883_2_T1	PHENOTYPE	20	23	cancer of the esophagus
NCT000028835	NCT00002883_5_T0	PHENOTYPE	6	6	tumor
NCT000028836	NCT00002883_6_T0	GENE	20	20	R2
NCT000028836	NCT00002883_6_T1	PHENOTYPE	10	10	tumor
NCT000028836	NCT00002883_6_T2	GENE	25	25	nodal
NCT000028836	NCT00002883_6_T3	TISSUE	18	19	lymph nodes
NCT000028837	NCT00002883_7_T0	GENE	10	10	3.4
NCT000028837	NCT00002883_7_T1	COMPOUND	8	8	cisplatin
NCT000028837	NCT00002883_7_T2	COMPOUND	24	24	cisplatin
NCT000028838	NCT00002883_8_T0	PHENOTYPE	12	12	toxicity
NCT000028838	NCT00002883_8_T1	PHENOTYPE	0	0	Tumor
NCT0000288310	NCT00002883_10_T0	GENE	12	12	3.4
NCT0000288314	NCT00002883_14_T0	GENE	4	4	3.4
NCT000028841	NCT00002884_1_T0	CELL	8	8	cells
NCT000028841	NCT00002884_1_T1	PHENOTYPE	7	7	tumor
NCT000028843	NCT00002884_3_T0	GENE	25	25	II
NCT000028843	NCT00002884_3_T1	GENE	3	3	III
NCT000028843	NCT00002884_3_T2	PHENOTYPE	27	30	stage III esophageal cancer
NCT000028845	NCT00002884_5_T0	GENE	12	12	II
NCT000028845	NCT00002884_5_T1	PHENOTYPE	4	4	remission
NCT000028845	NCT00002884_5_T2	GENE	14	14	III
NCT000028845	NCT00002884_5_T3	PHENOTYPE	15	16	esophageal cancer
NCT000028847	NCT00002884_7_T0	PHENOTYPE	3	3	remission
NCT0000288411	NCT00002884_11_T0	PHENOTYPE	2	2	toxicity
NCT0000288411	NCT00002884_11_T1	PHENOTYPE	4	6	quality of life
NCT0000288413	NCT00002884_13_T0	PHENOTYPE	7	7	tumor
NCT0000288414	NCT00002884_14_T0	GENE	10	10	1.4
NCT0000288414	NCT00002884_14_T1	COMPOUND	12	12	cisplatin
NCT0000288414	NCT00002884_14_T2	GENE	4	4	IV
NCT0000288416	NCT00002884_16_T0	COMPOUND	4	4	Iridium
NCT0000288418	NCT00002884_18_T0	PHENOTYPE	0	2	Quality of life
NCT000028872	NCT00002887_2_T0	CELL	12	12	cells
NCT000028872	NCT00002887_2_T1	PHENOTYPE	11	11	tumor
NCT000028877	NCT00002887_7_T0	PHENOTYPE	2	2	toxicity
NCT0000288710	NCT00002887_10_T0	COMPOUND	12	12	hydroxyurea
NCT0000288710	NCT00002887_10_T1	GENE	10	10	MTD
NCT0000288712	NCT00002887_12_T0	PHENOTYPE	14	14	remission
NCT0000288712	NCT00002887_12_T1	PHENOTYPE	26	26	remission
NCT0000288713	NCT00002887_13_T0	PHENOTYPE	20	21	disease progression
NCT000028880	NCT00002888_0_T0	PHENOTYPE	7	10	Head and Neck Cancer
NCT000028882	NCT00002888_2_T0	CELL	9	9	cells
NCT000028882	NCT00002888_2_T1	PHENOTYPE	8	8	tumor
NCT000028883	NCT00002888_3_T0	COMPOUND	13	13	paclitaxel
NCT000028883	NCT00002888_3_T1	COMPOUND	6	6	cisplatin
NCT000028883	NCT00002888_3_T2	COMPOUND	15	15	cisplatin
NCT000028883	NCT00002888_3_T3	PHENOTYPE	21	24	head and neck cancer
NCT000028884	NCT00002888_4_T0	GENE	3	3	III
NCT000028884	NCT00002888_4_T1	PHENOTYPE	19	22	head and neck cancer
NCT000028886	NCT00002888_6_T0	PHENOTYPE	4	4	toxicity
NCT000028886	NCT00002888_6_T1	COMPOUND	23	23	paclitaxel
NCT000028886	NCT00002888_6_T2	PHENOTYPE	19	19	carcinomas
NCT000028886	NCT00002888_6_T3	COMPOUND	25	25	cisplatin
NCT000028886	NCT00002888_6_T4	COMPOUND	27	27	cisplatin
NCT000028886	NCT00002888_6_T5	PHENOTYPE	5	5	quality-of-life
NCT000028888	NCT00002888_8_T0	PHENOTYPE	15	15	toxicity
NCT000028888	NCT00002888_8_T1	PHENOTYPE	6	8	quality of life
NCT000028888	NCT00002888_8_T2	PHENOTYPE	11	13	quality of life
NCT0000288815	NCT00002888_15_T0	PHENOTYPE	13	13	toxicity
NCT0000288815	NCT00002888_15_T1	PHENOTYPE	9	10	disease progression
NCT0000288817	NCT00002888_17_T0	PHENOTYPE	13	13	toxicity
NCT0000288817	NCT00002888_17_T1	PHENOTYPE	9	10	disease progression
NCT0000288820	NCT00002888_20_T0	PHENOTYPE	7	8	disease progression
NCT000028903	NCT00002890_3_T0	PHENOTYPE	4	4	toxicity
NCT000028903	NCT00002890_3_T1	COMPOUND	6	6	yttrium_90
NCT000028903	NCT00002890_3_T2	PHENOTYPE	20	20	malignancies
NCT000028907	NCT00002890_7_T0	PHENOTYPE	14	15	antibody responses
NCT000028908	NCT00002890_8_T0	COMPOUND	12	12	yttrium_90
NCT000028908	NCT00002890_8_T1	GENE	10	10	MTD
NCT0000289010	NCT00002890_10_T0	COMPOUND	12	12	yttrium_90
NCT0000289010	NCT00002890_10_T1	GENE	15	15	MTD
NCT0000289011	NCT00002890_11_T0	ORGAN	12	12	marrow
NCT0000289011	NCT00002890_11_T1	PHENOTYPE	42	42	toxicity
NCT0000289011	NCT00002890_11_T2	PHENOTYPE	3	3	leukemia
NCT0000289011	NCT00002890_11_T3	GENE	43	43	has
NCT0000289011	NCT00002890_11_T4	GENE	24	24	4-8
NCT0000289011	NCT00002890_11_T5	PHENOTYPE	44	44	resolved
NCT0000289011	NCT00002890_11_T6	PHENOTYPE	38	39	antibody response
NCT000028921	NCT00002892_1_T0	PHENOTYPE	20	20	melanoma
NCT000028921	NCT00002892_1_T1	GENE	6	6	interferon
NCT000028922	NCT00002892_2_T0	GENE	23	23	II
NCT000028922	NCT00002892_2_T1	GENE	3	3	III
NCT000028922	NCT00002892_2_T2	GENE	10	10	interferon
NCT000028922	NCT00002892_2_T3	PHENOTYPE	24	25	stage III
NCT000028922	NCT00002892_2_T4	PHENOTYPE	27	28	recurrent melanoma
NCT000028924	NCT00002892_4_T0	PHENOTYPE	25	25	recurrence
NCT000028924	NCT00002892_4_T1	GENE	7	7	interferon
NCT000028924	NCT00002892_4_T2	PHENOTYPE	19	20	malignant melanoma
NCT000028926	NCT00002892_6_T0	GENE	12	12	interferon
NCT000028928	NCT00002892_8_T0	PHENOTYPE	2	2	toxic
NCT0000289210	NCT00002892_10_T0	GENE	7	7	interferon
NCT0000289213	NCT00002892_13_T0	PHENOTYPE	25	25	toxicity
NCT0000289213	NCT00002892_13_T1	GENE	9	9	interferon
NCT0000289213	NCT00002892_13_T2	PHENOTYPE	22	23	disease progression
NCT000028931	NCT00002893_1_T0	GENE	3	3	III
NCT000028931	NCT00002893_1_T1	PHENOTYPE	27	29	recurrent colorectal cancer
NCT000028931	NCT00002893_1_T2	PHENOTYPE	11	13	quality of life
NCT000028933	NCT00002893_3_T0	PHENOTYPE	12	14	recurrent colorectal cancer
NCT000028933	NCT00002893_3_T1	PHENOTYPE	4	6	quality of life
NCT000028935	NCT00002893_5_T0	PHENOTYPE	4	6	quality of life
NCT000028939	NCT00002893_9_T0	COMPOUND	4	4	leucovorin
NCT0000289312	NCT00002893_12_T0	PHENOTYPE	6	6	toxicity
NCT0000289312	NCT00002893_12_T1	PHENOTYPE	2	3	progressive disease
NCT0000289312	NCT00002893_12_T2	PHENOTYPE	39	40	disease progression
NCT000028941	NCT00002894_1_T0	CELL	9	9	cells
NCT000028941	NCT00002894_1_T1	PHENOTYPE	8	8	tumor
NCT000028942	NCT00002894_2_T0	COMPOUND	15	15	paclitaxel
NCT000028942	NCT00002894_2_T1	GENE	3	3	III
NCT000028942	NCT00002894_2_T2	PHENOTYPE	20	23	relapsed ovarian epithelial cancer
NCT000028947	NCT00002894_7_T0	PHENOTYPE	0	2	Quality of life
NCT000028956	NCT00002895_6_T0	GENE	6	6	CA
NCT000028956	NCT00002895_6_T1	PHENOTYPE	18	19	recurrent disease
NCT0000289510	NCT00002895_10_T0	PHENOTYPE	0	2	Quality of life
NCT000028961	NCT00002896_1_T0	CELL	21	21	cells
NCT000028961	NCT00002896_1_T1	PHENOTYPE	20	20	tumor
NCT000028962	NCT00002896_2_T0	GENE	3	3	III
NCT000028962	NCT00002896_2_T1	COMPOUND	15	15	leucovorin
NCT000028962	NCT00002896_2_T2	COMPOUND	24	24	leucovorin
NCT000028962	NCT00002896_2_T3	PHENOTYPE	32	33	rectal cancer
NCT000028964	NCT00002896_4_T0	PHENOTYPE	3	3	recurrence
NCT000028964	NCT00002896_4_T1	PHENOTYPE	11	11	toxicity
NCT000028964	NCT00002896_4_T2	PHENOTYPE	8	8	acute
NCT000028964	NCT00002896_4_T3	PHENOTYPE	25	28	adenocarcinoma of the rectum
NCT000028966	NCT00002896_6_T0	PHENOTYPE	2	2	relapse
NCT000028968	NCT00002896_8_T0	PHENOTYPE	4	4	tumor
NCT0000289610	NCT00002896_10_T0	PHENOTYPE	7	7	tumor
NCT000028971	NCT00002897_1_T0	PHENOTYPE	16	19	cancer of the esophagus
NCT000028972	NCT00002897_2_T0	GENE	20	20	II
NCT000028972	NCT00002897_2_T1	GENE	3	3	III
NCT000028972	NCT00002897_2_T2	PHENOTYPE	24	27	cancer of the esophagus
NCT000028972	NCT00002897_2_T3	PHENOTYPE	22	26	stage III cancer of the
NCT000028974	NCT00002897_4_T0	PHENOTYPE	9	10	esophageal cancer
NCT000028977	NCT00002897_7_T0	COMPOUND	4	4	cisplatin
NCT000028981	NCT00002898_1_T0	CELL	15	15	cells
NCT000028981	NCT00002898_1_T1	PHENOTYPE	14	14	tumor
NCT000028982	NCT00002898_2_T0	GENE	4	4	III
NCT000028982	NCT00002898_2_T1	PHENOTYPE	34	36	soft tissue sarcoma
NCT000028984	NCT00002898_4_T0	PHENOTYPE	11	11	sarcoma
NCT000028984	NCT00002898_4_T1	PHENOTYPE	28	29	stage III
NCT000028984	NCT00002898_4_T2	PHENOTYPE	26	27	orbital tumor
NCT000028985	NCT00002898_5_T0	PHENOTYPE	7	7	rhabdomyosarcoma
NCT000028988	NCT00002898_8_T0	PHENOTYPE	24	24	tumors
NCT0000289813	NCT00002898_13_T0	PHENOTYPE	13	13	tumors
NCT0000289814	NCT00002898_14_T0	PHENOTYPE	11	11	tumors
NCT0000289814	NCT00002898_14_T1	PHENOTYPE	17	17	tumors
NCT0000289817	NCT00002898_17_T0	COMPOUND	29	29	vincristine
NCT0000289821	NCT00002898_21_T0	GENE	5	5	CR
NCT0000289826	NCT00002898_26_T0	GENE	6	6	CR
NCT0000289829	NCT00002898_29_T0	GENE	16	16	CR
NCT0000289831	NCT00002898_31_T0	GENE	16	16	II
NCT0000289831	NCT00002898_31_T1	GENE	5	5	CR
NCT0000289834	NCT00002898_34_T0	PHENOTYPE	9	9	IVA
NCT0000289837	NCT00002898_37_T0	COMPOUND	11	11	vincristine
NCT0000289837	NCT00002898_37_T1	COMPOUND	14	14	etoposide
NCT0000289838	NCT00002898_38_T0	GENE	40	40	II
NCT0000289838	NCT00002898_38_T1	COMPOUND	15	15	vincristine
NCT0000289838	NCT00002898_38_T2	PHENOTYPE	19	19	relapse
NCT0000289838	NCT00002898_38_T3	PHENOTYPE	30	30	relapse
NCT0000289838	NCT00002898_38_T4	COMPOUND	17	17	cyclophosphamide
NCT0000289838	NCT00002898_38_T5	COMPOUND	13	13	etoposide
NCT000028991	NCT00002899_1_T0	CELL	8	8	cells
NCT000028991	NCT00002899_1_T1	PHENOTYPE	7	7	tumor
NCT000028991	NCT00002899_1_T2	PHENOTYPE	14	15	brain metastases
NCT000028992	NCT00002899_2_T0	GENE	4	4	III
NCT000028992	NCT00002899_2_T1	PHENOTYPE	29	30	brain metastases
NCT000028992	NCT00002899_2_T2	PHENOTYPE	34	35	solid tumors
NCT000028996	NCT00002899_6_T0	COMPOUND	30	30	2
NCT000028996	NCT00002899_6_T1	PHENOTYPE	8	9	brain metastases
NCT000028996	NCT00002899_6_T2	PHENOTYPE	15	16	primary tumor
NCT000028999	NCT00002899_9_T0	PHENOTYPE	0	2	Quality of life
NCT000029001	NCT00002900_1_T0	ORGAN	11	11	heart
NCT000029001	NCT00002900_1_T1	TISSUE	23	24	lymph nodes
NCT000029001	NCT00002900_1_T2	PHENOTYPE	18	19	breast cancer
NCT000029005	NCT00002900_5_T0	COMPOUND	3	3	MUGA
NCT000029011	NCT00002901_1_T0	COMPOUND	9	9	docetaxel
NCT000029011	NCT00002901_1_T1	PHENOTYPE	15	16	solid tumors
NCT000029013	NCT00002901_3_T0	COMPOUND	6	6	docetaxel
NCT000029013	NCT00002901_3_T1	PHENOTYPE	17	18	liver dysfunction
NCT000029013	NCT00002901_3_T2	PHENOTYPE	11	12	solid tumors
NCT000029015	NCT00002901_5_T0	PHENOTYPE	14	14	pharmacodynamics
NCT000029015	NCT00002901_5_T1	PHENOTYPE	12	12	pharmacokinetics
NCT000029015	NCT00002901_5_T2	ORGAN	11	11	plasma
NCT000029015	NCT00002901_5_T3	PHENOTYPE	4	5	liver dysfunction
NCT000029017	NCT00002901_7_T0	COMPOUND	16	16	docetaxel
NCT000029017	NCT00002901_7_T1	BIOLOGICAL_PROCESS	9	9	metabolism
NCT000029017	NCT00002901_7_T2	PHENOTYPE	14	14	elimination
NCT000029017	NCT00002901_7_T3	COMPOUND	8	8	lidocaine
NCT000029017	NCT00002901_7_T4	COMPOUND	4	5	indocyanine green
NCT000029019	NCT00002901_9_T0	ORGAN	5	5	liver
NCT0000290110	NCT00002901_10_T0	COMPOUND	2	2	docetaxel
NCT0000290110	NCT00002901_10_T1	GENE	3	3	IV
NCT0000290111	NCT00002901_11_T0	PHENOTYPE	13	13	toxicity
NCT0000290111	NCT00002901_11_T1	PHENOTYPE	9	10	disease progression
NCT0000290112	NCT00002901_12_T0	PHENOTYPE	4	4	remission
NCT0000290112	NCT00002901_12_T1	GENE	5	5	CR
NCT0000290112	NCT00002901_12_T2	GENE	11	11	CR
NCT0000290113	NCT00002901_13_T0	COMPOUND	14	14	docetaxel
NCT0000290113	NCT00002901_13_T1	PHENOTYPE	2	4	abnormal liver function
NCT0000290114	NCT00002901_14_T0	PHENOTYPE	17	17	toxicity
NCT0000290114	NCT00002901_14_T1	GENE	1	1	MTD
NCT0000290115	NCT00002901_15_T0	GENE	14	14	MTD
NCT0000290115	NCT00002901_15_T1	PHENOTYPE	2	4	abnormal liver function
NCT000029020	NCT00002902_0_T0	PHENOTYPE	9	10	Solid Tumors
NCT000029022	NCT00002902_2_T0	CELL	9	9	cells
NCT000029022	NCT00002902_2_T1	PHENOTYPE	8	8	tumor
NCT000029023	NCT00002902_3_T0	COMPOUND	9	9	irinotecan
NCT000029023	NCT00002902_3_T1	PHENOTYPE	18	19	solid tumors
NCT000029025	NCT00002902_5_T0	COMPOUND	12	12	irinotecan
NCT000029025	NCT00002902_5_T1	PHENOTYPE	22	22	malignancies
NCT000029025	NCT00002902_5_T2	GENE	8	8	TDX
NCT000029027	NCT00002902_7_T0	PHENOTYPE	2	2	pharmacokinetics
NCT000029027	NCT00002902_7_T1	GENE	4	4	TDX
NCT000029029	NCT00002902_9_T0	PHENOTYPE	15	15	toxicity
NCT000029029	NCT00002902_9_T1	PHENOTYPE	8	8	peripheral
NCT000029029	NCT00002902_9_T2	CELL	10	10	cells
NCT000029029	NCT00002902_9_T3	GENE	4	5	topoisomerase I
NCT0000290211	NCT00002902_11_T0	PHENOTYPE	10	10	tumor
NCT0000290211	NCT00002902_11_T1	GENE	6	7	thymidylate synthase
NCT0000290212	NCT00002902_12_T0	COMPOUND	21	21	irinotecan
NCT0000290212	NCT00002902_12_T1	GENE	16	16	TDX
NCT0000290212	NCT00002902_12_T2	GENE	12	12	MTD
NCT0000290214	NCT00002902_14_T0	PHENOTYPE	11	11	toxicity
NCT0000290214	NCT00002902_14_T1	PHENOTYPE	7	8	disease progression
NCT0000290215	NCT00002902_15_T0	GENE	31	31	II
NCT0000290215	NCT00002902_15_T1	GENE	8	8	TDX
NCT0000290215	NCT00002902_15_T2	GENE	11	11	MTD
NCT0000290215	NCT00002902_15_T3	GENE	23	23	MTD
NCT000029030	NCT00002903_0_T0	PHENOTYPE	5	5	Recurrent
NCT000029030	NCT00002903_0_T1	PHENOTYPE	8	10	Germ Cell Cancer
NCT000029036	NCT00002903_6_T0	PHENOTYPE	22	22	tumor
NCT000029038	NCT00002903_8_T0	PHENOTYPE	3	3	toxic
NCT000029039	NCT00002903_9_T0	PHENOTYPE	15	15	toxicity
NCT000029039	NCT00002903_9_T1	COMPOUND	4	4	docetaxel
NCT000029039	NCT00002903_9_T2	PHENOTYPE	12	13	disease progression
NCT000029040	NCT00002904_0_T0	PHENOTYPE	7	8	Solid Tumors
NCT000029042	NCT00002904_2_T0	PHENOTYPE	16	17	solid tumors
NCT000029044	NCT00002904_4_T0	GENE	5	5	MTD
NCT000029044	NCT00002904_4_T1	PHENOTYPE	22	23	solid tumors
NCT000029046	NCT00002904_6_T0	PHENOTYPE	5	5	toxic
NCT000029046	NCT00002904_6_T1	PHENOTYPE	21	21	toxic
NCT000029048	NCT00002904_8_T0	GENE	7	7	II
NCT000029048	NCT00002904_8_T1	GENE	12	12	MTD
NCT0000290410	NCT00002904_10_T0	PHENOTYPE	2	2	pharmacokinetics
NCT0000290414	NCT00002904_14_T0	GENE	4	4	IV
NCT0000290415	NCT00002904_15_T0	PHENOTYPE	10	10	toxicity
NCT0000290415	NCT00002904_15_T1	PHENOTYPE	6	7	disease progression
NCT0000290417	NCT00002904_17_T0	PHENOTYPE	11	12	disease progression
NCT000029051	NCT00002905_1_T0	CELL	9	9	cells
NCT000029052	NCT00002905_2_T0	GENE	2	2	II
NCT000029052	NCT00002905_2_T1	PHENOTYPE	15	15	HIV
NCT000029052	NCT00002905_2_T2	GENE	19	19	has
NCT000029052	NCT00002905_2_T3	GENE	22	22	has
NCT000029052	NCT00002905_2_T4	PHENOTYPE	16	17	Hodgkin's lymphoma
NCT000029058	NCT00002905_8_T0	PHENOTYPE	2	2	toxic
NCT0000290511	NCT00002905_11_T0	COMPOUND	7	7	zidovudine
NCT0000290511	NCT00002905_11_T1	COMPOUND	9	9	didanosine
NCT0000290512	NCT00002905_12_T0	GENE	0	0	G-CSF
NCT0000290514	NCT00002905_14_T0	GENE	5	5	CR
NCT0000290515	NCT00002905_15_T0	GENE	17	17	CR
NCT0000290516	NCT00002905_16_T0	PHENOTYPE	2	3	progressive disease
NCT000029071	NCT00002907_1_T0	GENE	2	2	II
NCT000029071	NCT00002907_1_T1	PHENOTYPE	16	17	multiple myeloma
NCT000029071	NCT00002907_1_T2	COMPOUND	9	10	bryostatin 1
NCT000029073	NCT00002907_3_T0	PHENOTYPE	16	17	multiple myeloma
NCT000029073	NCT00002907_3_T1	COMPOUND	4	5	bryostatin 1
NCT000029075	NCT00002907_5_T0	PHENOTYPE	5	5	toxic
NCT000029075	NCT00002907_5_T1	COMPOUND	8	9	bryostatin 1
NCT000029077	NCT00002907_7_T0	COMPOUND	8	9	bryostatin 1
NCT000029078	NCT00002907_8_T0	PHENOTYPE	21	21	remission
NCT000029078	NCT00002907_8_T1	PHENOTYPE	14	15	disease progression
NCT000029078	NCT00002907_8_T2	COMPOUND	4	5	bryostatin 1
NCT000029081	NCT00002908_1_T0	CELL	9	9	cells
NCT000029081	NCT00002908_1_T1	PHENOTYPE	8	8	tumor
NCT000029082	NCT00002908_2_T0	PHENOTYPE	17	18	Hodgkin's lymphoma
NCT000029082	NCT00002908_2_T1	COMPOUND	9	10	bryostatin 1
NCT000029082	NCT00002908_2_T2	PHENOTYPE	20	22	chronic lymphocytic leukemia
NCT000029084	NCT00002908_4_T0	PHENOTYPE	15	16	Hodgkin's lymphoma
NCT000029084	NCT00002908_4_T1	COMPOUND	4	5	bryostatin 1
NCT000029084	NCT00002908_4_T2	PHENOTYPE	18	20	chronic lymphocytic leukemia
NCT000029086	NCT00002908_6_T0	PHENOTYPE	4	4	toxicity
NCT000029086	NCT00002908_6_T1	COMPOUND	9	9	vincristine
NCT000029086	NCT00002908_6_T2	COMPOUND	14	15	bryostatin 1
NCT000029088	NCT00002908_8_T0	PHENOTYPE	5	5	toxic
NCT000029088	NCT00002908_8_T1	COMPOUND	8	9	bryostatin 1
NCT0000290810	NCT00002908_10_T0	COMPOUND	10	11	bryostatin 1
NCT0000290811	NCT00002908_11_T0	PHENOTYPE	24	24	remission
NCT0000290811	NCT00002908_11_T1	PHENOTYPE	14	15	disease progression
NCT0000290811	NCT00002908_11_T2	COMPOUND	4	5	bryostatin 1
NCT0000290813	NCT00002908_13_T0	COMPOUND	12	12	vincristine
NCT0000290813	NCT00002908_13_T1	PHENOTYPE	2	3	disease progression
NCT0000290813	NCT00002908_13_T2	COMPOUND	20	21	bryostatin 1
NCT0000290814	NCT00002908_14_T0	COMPOUND	8	8	vincristine
NCT0000290814	NCT00002908_14_T1	COMPOUND	15	16	bryostatin 1
NCT000029091	NCT00002909_1_T0	CELL	10	10	cells
NCT000029091	NCT00002909_1_T1	PHENOTYPE	9	9	tumor
NCT000029095	NCT00002909_5_T0	PHENOTYPE	2	2	pharmacokinetics
NCT000029095	NCT00002909_5_T1	PHENOTYPE	13	13	dependence
NCT000029099	NCT00002909_9_T0	PHENOTYPE	5	5	toxic
NCT0000290912	NCT00002909_12_T0	GENE	16	16	MTD
NCT0000290913	NCT00002909_13_T0	PHENOTYPE	7	7	toxicity
NCT0000290913	NCT00002909_13_T1	PHENOTYPE	3	4	disease progression
NCT000029116	NCT00002911_6_T0	COMPOUND	4	4	marimastat
NCT000029116	NCT00002911_6_T1	PHENOTYPE	8	9	disease progression
NCT000029118	NCT00002911_8_T0	COMPOUND	6	6	marimastat
NCT0000291112	NCT00002911_12_T0	COMPOUND	8	8	marimastat
NCT0000291113	NCT00002911_13_T0	PHENOTYPE	25	25	toxicity
NCT0000291113	NCT00002911_13_T1	PHENOTYPE	21	22	disease progression
NCT0000291116	NCT00002911_16_T0	PHENOTYPE	16	16	centers
NCT000029121	NCT00002912_1_T0	CELL	10	10	cells
NCT000029122	NCT00002912_2_T0	PHENOTYPE	1	1	cancers
NCT000029122	NCT00002912_2_T1	PHENOTYPE	3	3	resistant
NCT000029123	NCT00002912_3_T0	CELL	14	14	cells
NCT000029125	NCT00002912_5_T0	COMPOUND	10	10	mitoxantrone
NCT000029125	NCT00002912_5_T1	COMPOUND	12	12	etoposide
NCT000029125	NCT00002912_5_T2	PHENOTYPE	19	20	acute leukemia
NCT000029127	NCT00002912_7_T0	COMPOUND	6	6	mitoxantrone
NCT000029127	NCT00002912_7_T1	PHENOTYPE	9	9	pharmacokinetics
NCT000029127	NCT00002912_7_T2	COMPOUND	8	8	etoposide
NCT000029129	NCT00002912_9_T0	PHENOTYPE	12	12	leukemia
NCT000029129	NCT00002912_9_T1	GENE	1	1	MDR1
NCT000029129	NCT00002912_9_T2	GENE	5	5	MDR1
NCT000029129	NCT00002912_9_T3	CELL	13	13	cells
NCT000029129	NCT00002912_9_T4	GENE	6	6	P-glycoprotein
NCT000029129	NCT00002912_9_T5	BIOLOGICAL_PROCESS	2	3	gene expression
NCT0000291211	NCT00002912_11_T0	COMPOUND	9	9	mitoxantrone
NCT0000291211	NCT00002912_11_T1	GENE	13	13	1.5
NCT0000291211	NCT00002912_11_T2	COMPOUND	6	6	etoposide
NCT0000291211	NCT00002912_11_T3	GENE	7	7	IV
NCT0000291211	NCT00002912_11_T4	GENE	10	10	IV
NCT0000291212	NCT00002912_12_T0	GENE	4	4	IV
NCT0000291213	NCT00002912_13_T0	ORGAN	19	19	marrow
NCT0000291213	NCT00002912_13_T1	PHENOTYPE	21	21	hypocellular
NCT0000291216	NCT00002912_16_T0	PHENOTYPE	4	4	remission
NCT0000291216	NCT00002912_16_T1	PHENOTYPE	26	26	remission
NCT0000291217	NCT00002912_17_T0	PHENOTYPE	4	4	remission
NCT000029131	NCT00002913_1_T0	CELL	10	10	cells
NCT000029131	NCT00002913_1_T1	PHENOTYPE	9	9	tumor
NCT000029133	NCT00002913_3_T0	COMPOUND	6	6	paclitaxel
NCT000029133	NCT00002913_3_T1	GENE	15	15	filgrastim
NCT000029133	NCT00002913_3_T2	GENE	16	16	G-CSF
NCT000029133	NCT00002913_3_T3	COMPOUND	7	7	cisplatin
NCT000029133	NCT00002913_3_T4	COMPOUND	9	9	topotecan
NCT000029133	NCT00002913_3_T5	PHENOTYPE	23	24	ovarian cancer
NCT000029135	NCT00002913_5_T0	PHENOTYPE	5	5	toxic
NCT000029135	NCT00002913_5_T1	COMPOUND	11	11	paclitaxel
NCT000029135	NCT00002913_5_T2	GENE	18	18	G-CSF
NCT000029135	NCT00002913_5_T3	COMPOUND	12	12	cisplatin
NCT000029135	NCT00002913_5_T4	COMPOUND	14	14	topotecan
NCT000029138	NCT00002913_8_T0	COMPOUND	8	8	topotecan
NCT000029139	NCT00002913_9_T0	COMPOUND	2	2	paclitaxel
NCT000029139	NCT00002913_9_T1	GENE	22	22	1.3
NCT000029139	NCT00002913_9_T2	COMPOUND	8	8	cisplatin
NCT000029139	NCT00002913_9_T3	GENE	3	3	IV
NCT000029139	NCT00002913_9_T4	GENE	9	9	IV
NCT000029139	NCT00002913_9_T5	GENE	16	16	IV
NCT000029139	NCT00002913_9_T6	COMPOUND	15	15	topotecan
NCT0000291310	NCT00002913_10_T0	GENE	2	2	filgrastim
NCT0000291310	NCT00002913_10_T1	GENE	3	3	G-CSF
NCT0000291311	NCT00002913_11_T0	PHENOTYPE	13	13	toxicity
NCT0000291311	NCT00002913_11_T1	PHENOTYPE	9	10	disease progression
NCT0000291312	NCT00002913_12_T0	GENE	14	14	MTD
NCT0000291312	NCT00002913_12_T1	COMPOUND	8	8	topotecan
NCT0000291313	NCT00002913_13_T0	PHENOTYPE	18	18	toxicities
NCT0000291313	NCT00002913_13_T1	GENE	1	1	MTD
NCT000029141	NCT00002914_1_T0	GENE	2	2	II
NCT000029141	NCT00002914_1_T1	COMPOUND	9	9	piritrexim
NCT000029141	NCT00002914_1_T2	GENE	21	21	has
NCT000029141	NCT00002914_1_T3	PHENOTYPE	14	15	advanced cancer
NCT000029141	NCT00002914_1_T4	PHENOTYPE	15	19	cancer of the urinary tract
NCT000029143	NCT00002914_3_T0	COMPOUND	5	5	piritrexim
NCT000029143	NCT00002914_3_T1	PHENOTYPE	16	17	urothelial carcinoma
NCT000029145	NCT00002914_5_T0	PHENOTYPE	2	2	toxicity
NCT000029145	NCT00002914_5_T1	COMPOUND	4	4	piritrexim
NCT000029146	NCT00002914_6_T0	COMPOUND	3	3	piritrexim
NCT000029147	NCT00002914_7_T0	PHENOTYPE	13	13	toxicity
NCT000029147	NCT00002914_7_T1	PHENOTYPE	15	15	progression
NCT000029150	NCT00002915_0_T0	PHENOTYPE	6	7	Solid Tumors
NCT000029152	NCT00002915_2_T0	COMPOUND	9	9	penclomedine
NCT000029152	NCT00002915_2_T1	PHENOTYPE	16	17	solid tumors
NCT000029156	NCT00002915_6_T0	PHENOTYPE	4	4	toxic
NCT000029156	NCT00002915_6_T1	COMPOUND	7	7	penclomedine
NCT000029158	NCT00002915_8_T0	COMPOUND	7	7	penclomedine
NCT000029158	NCT00002915_8_T1	BIOLOGICAL_PROCESS	5	5	metabolism
NCT000029158	NCT00002915_8_T2	PHENOTYPE	13	13	pharmacodynamic
NCT0000291510	NCT00002915_10_T0	COMPOUND	5	5	penclomedine
NCT0000291512	NCT00002915_12_T0	COMPOUND	7	7	penclomedine
NCT0000291512	NCT00002915_12_T1	PHENOTYPE	11	12	advanced cancer
NCT0000291513	NCT00002915_13_T0	COMPOUND	14	14	penclomedine
NCT0000291513	NCT00002915_13_T1	GENE	12	12	MTD
NCT0000291514	NCT00002915_14_T0	GENE	11	11	MTD
NCT0000291515	NCT00002915_15_T0	COMPOUND	3	3	penclomedine
NCT0000291516	NCT00002915_16_T0	PHENOTYPE	5	5	toxicity
NCT0000291516	NCT00002915_16_T1	PHENOTYPE	1	2	tumor progression
NCT0000291517	NCT00002915_17_T0	GENE	19	19	II
NCT0000291517	NCT00002915_17_T1	GENE	15	15	MTD
NCT000029161	NCT00002916_1_T0	PHENOTYPE	12	13	cervical cancer
NCT000029162	NCT00002916_2_T0	GENE	3	3	II
NCT000029162	NCT00002916_2_T1	PHENOTYPE	21	22	cervical cancer
NCT000029165	NCT00002916_5_T0	PHENOTYPE	42	42	toxicity
NCT000029165	NCT00002916_5_T1	GENE	13	13	E6
NCT000029165	NCT00002916_5_T2	GENE	15	15	E7
NCT000029165	NCT00002916_5_T3	PHENOTYPE	7	7	papilloma
NCT000029166	NCT00002916_6_T0	GENE	10	10	4-8
NCT000029171	NCT00002917_1_T0	COMPOUND	9	9	paclitaxel
NCT000029171	NCT00002917_1_T1	PHENOTYPE	15	16	bladder cancer
NCT000029173	NCT00002917_3_T0	PHENOTYPE	1	1	toxicity
NCT000029173	NCT00002917_3_T1	COMPOUND	6	6	paclitaxel
NCT000029173	NCT00002917_3_T2	PHENOTYPE	10	12	superficial bladder cancer
NCT000029178	NCT00002917_8_T0	COMPOUND	6	6	paclitaxel
NCT000029191	NCT00002919_1_T0	CELL	9	9	cells
NCT000029191	NCT00002919_1_T1	PHENOTYPE	8	8	tumor
NCT000029192	NCT00002919_2_T0	GENE	2	2	II
NCT000029192	NCT00002919_2_T1	PHENOTYPE	17	20	stage II bladder cancer
NCT000029196	NCT00002919_6_T0	ORGAN	11	11	bladder
NCT000029197	NCT00002919_7_T0	PHENOTYPE	12	13	bladder tumor
NCT000029198	NCT00002919_8_T0	COMPOUND	12	12	vinblastine
NCT000029198	NCT00002919_8_T1	COMPOUND	11	11	methotrexate
NCT000029198	NCT00002919_8_T2	COMPOUND	13	13	doxorubicin
NCT000029198	NCT00002919_8_T3	COMPOUND	15	15	cisplatin
NCT000029199	NCT00002919_9_T0	GENE	1	1	G-CSF
NCT0000291910	NCT00002919_10_T0	PHENOTYPE	21	21	progression
NCT000029201	NCT00002920_1_T0	COMPOUND	46	46	tamoxifen
NCT000029201	NCT00002920_1_T1	GENE	3	3	III
NCT000029201	NCT00002920_1_T2	PHENOTYPE	13	14	endometrial disorder
NCT000029201	NCT00002920_1_T3	PHENOTYPE	33	36	stage I breast cancer
NCT000029201	NCT00002920_1_T4	PHENOTYPE	38	41	stage II breast cancer
NCT000029201	NCT00002920_1_T5	PHENOTYPE	20	23	ductal carcinoma in situ
NCT000029201	NCT00002920_1_T6	PHENOTYPE	24	27	lobular carcinoma in situ
NCT000029201	NCT00002920_1_T7	PHENOTYPE	28	32	Paget's disease of the nipple
NCT000029204	NCT00002920_4_T0	GENE	14	14	0.3
NCT000029212	NCT00002921_2_T0	GENE	2	2	II
NCT000029212	NCT00002921_2_T1	COMPOUND	9	9	suramin
NCT000029212	NCT00002921_2_T2	PHENOTYPE	14	15	stage III
NCT000029212	NCT00002921_2_T3	PHENOTYPE	17	20	stage IV adrenocortical cancer
NCT000029214	NCT00002921_4_T0	COMPOUND	10	10	suramin
NCT000029214	NCT00002921_4_T1	PHENOTYPE	6	7	adrenocortical carcinoma
NCT000029216	NCT00002921_6_T0	PHENOTYPE	5	5	toxic
NCT000029217	NCT00002921_7_T0	COMPOUND	15	15	mitotane
NCT000029218	NCT00002921_8_T0	COMPOUND	2	2	suramin
NCT000029218	NCT00002921_8_T1	GENE	3	3	IV
NCT000029220	NCT00002922_0_T0	PHENOTYPE	6	9	Head and Neck Cancer
NCT000029222	NCT00002922_2_T0	GENE	2	2	II
NCT000029222	NCT00002922_2_T1	COMPOUND	9	9	paclitaxel
NCT000029222	NCT00002922_2_T2	PHENOTYPE	14	14	recurrent
NCT000029222	NCT00002922_2_T3	PHENOTYPE	17	20	head and neck cancer
NCT000029225	NCT00002922_5_T0	COMPOUND	3	3	paclitaxel
NCT000029225	NCT00002922_5_T1	GENE	9	9	IV
NCT000029227	NCT00002922_7_T0	PHENOTYPE	10	10	toxicity
NCT000029227	NCT00002922_7_T1	PHENOTYPE	2	3	disease progression
NCT000029230	NCT00002923_0_T0	PHENOTYPE	6	7	Solid Tumors
NCT000029232	NCT00002923_2_T0	PHENOTYPE	15	16	solid tumors
NCT000029234	NCT00002923_4_T0	PHENOTYPE	6	6	toxicities
NCT000029234	NCT00002923_4_T1	PHENOTYPE	13	14	malignant tumors
NCT000029236	NCT00002923_6_T0	PHENOTYPE	3	3	pharmacokinetics
NCT0000292310	NCT00002923_10_T0	GENE	4	4	II
NCT0000292312	NCT00002923_12_T0	GENE	9	9	1.3
NCT0000292312	NCT00002923_12_T1	GENE	3	3	IV
NCT0000292314	NCT00002923_14_T0	PHENOTYPE	8	8	remission
NCT0000292314	NCT00002923_14_T1	PHENOTYPE	16	16	remission
NCT0000292316	NCT00002923_16_T0	PHENOTYPE	22	22	toxicity
NCT000029251	NCT00002925_1_T0	PHENOTYPE	1	1	cancers
NCT000029251	NCT00002925_1_T1	PHENOTYPE	4	4	resistant
NCT000029253	NCT00002925_3_T0	PHENOTYPE	10	10	leukemia
NCT000029253	NCT00002925_3_T1	CELL	11	11	cells
NCT000029253	NCT00002925_3_T2	GENE	0	0	Interleukin-2
NCT000029253	NCT00002925_3_T3	CELL	5	7	white blood cells
NCT000029258	NCT00002925_8_T0	COMPOUND	16	16	cytarabine
NCT000029258	NCT00002925_8_T1	COMPOUND	4	4	etoposide
NCT000029258	NCT00002925_8_T2	GENE	2	2	MTD
NCT000029258	NCT00002925_8_T3	COMPOUND	14	14	daunorubicin
NCT0000292514	NCT00002925_14_T0	GENE	10	10	interleukin-2
NCT0000292514	NCT00002925_14_T1	GENE	11	11	IL-2
NCT0000292514	NCT00002925_14_T2	GENE	19	19	IL-2
NCT0000292514	NCT00002925_14_T3	ORGAN	25	25	transplant
NCT0000292515	NCT00002925_15_T0	COMPOUND	21	21	etoposide
NCT0000292515	NCT00002925_15_T1	COMPOUND	8	8	daunorubicin
NCT0000292517	NCT00002925_17_T0	COMPOUND	4	4	cytarabine
NCT0000292517	NCT00002925_17_T1	GENE	27	27	1.3
NCT0000292517	NCT00002925_17_T2	GENE	12	12	1.7
NCT0000292517	NCT00002925_17_T3	COMPOUND	20	20	etoposide
NCT0000292517	NCT00002925_17_T4	GENE	5	5	IV
NCT0000292517	NCT00002925_17_T5	GENE	15	15	IV
NCT0000292517	NCT00002925_17_T6	GENE	21	21	IV
NCT0000292517	NCT00002925_17_T7	COMPOUND	14	14	daunorubicin
NCT0000292520	NCT00002925_20_T0	GENE	15	15	MTD
NCT0000292520	NCT00002925_20_T1	COMPOUND	9	9	daunorubicin
NCT0000292521	NCT00002925_21_T0	PHENOTYPE	16	16	toxicity
NCT0000292521	NCT00002925_21_T1	GENE	1	1	MTD
NCT0000292523	NCT00002925_23_T0	COMPOUND	10	10	etoposide
NCT0000292523	NCT00002925_23_T1	COMPOUND	15	15	daunorubicin
NCT0000292524	NCT00002925_24_T0	GENE	1	1	MTD
NCT0000292528	NCT00002925_28_T0	COMPOUND	5	5	cytarabine
NCT0000292528	NCT00002925_28_T1	GENE	12	12	1.4
NCT0000292528	NCT00002925_28_T2	GENE	21	21	1.4
NCT0000292528	NCT00002925_28_T3	GENE	23	23	filgrastim
NCT0000292528	NCT00002925_28_T4	COMPOUND	13	13	etoposide
NCT0000292528	NCT00002925_28_T5	GENE	24	24	G-CSF
NCT0000292528	NCT00002925_28_T6	GENE	6	6	IV
NCT0000292528	NCT00002925_28_T7	GENE	14	14	IV
NCT0000292530	NCT00002925_30_T0	COMPOUND	7	7	busulfan
NCT0000292530	NCT00002925_30_T1	GENE	14	14	1.4
NCT0000292530	NCT00002925_30_T2	COMPOUND	16	16	etoposide
NCT0000292530	NCT00002925_30_T3	GENE	17	17	IV
NCT0000292534	NCT00002925_34_T0	GENE	8	8	interleukin-2
NCT0000292534	NCT00002925_34_T1	GENE	9	9	IL-2
NCT0000292535	NCT00002925_35_T0	GENE	9	9	IL-2
NCT0000292536	NCT00002925_36_T0	GENE	5	5	IL-2
NCT0000292536	NCT00002925_36_T1	GENE	11	11	IL-2
NCT0000292536	NCT00002925_36_T2	GENE	17	17	IL-2
NCT0000292536	NCT00002925_36_T3	GENE	24	24	IL-2
NCT0000292536	NCT00002925_36_T4	GENE	34	34	IL-2
NCT0000292538	NCT00002925_38_T0	GENE	10	10	IL-2
NCT000029264	NCT00002926_4_T0	COMPOUND	4	4	idarubicin
NCT000029264	NCT00002926_4_T1	COMPOUND	14	14	etoposide
NCT000029264	NCT00002926_4_T2	GENE	13	13	10
NCT000029281	NCT00002928_1_T0	GENE	2	2	II
NCT000029281	NCT00002928_1_T1	COMPOUND	9	9	paclitaxel
NCT000029281	NCT00002928_1_T2	COMPOUND	23	23	paclitaxel
NCT000029281	NCT00002928_1_T3	PHENOTYPE	16	16	progressive
NCT000029281	NCT00002928_1_T4	PHENOTYPE	14	14	recurrent
NCT000029281	NCT00002928_1_T5	PHENOTYPE	18	20	epithelial ovarian cancer
NCT000029283	NCT00002928_3_T0	COMPOUND	4	4	paclitaxel
NCT000029283	NCT00002928_3_T1	COMPOUND	20	20	paclitaxel
NCT000029283	NCT00002928_3_T2	PHENOTYPE	15	16	ovarian cancer
NCT000029285	NCT00002928_5_T0	PHENOTYPE	2	2	toxic
NCT000029285	NCT00002928_5_T1	COMPOUND	5	5	paclitaxel
NCT000029287	NCT00002928_7_T0	PHENOTYPE	3	5	quality of life
NCT000029287	NCT00002928_7_T1	PHENOTYPE	14	16	quality of life
NCT0000292810	NCT00002928_10_T0	COMPOUND	7	7	paclitaxel
NCT0000292810	NCT00002928_10_T1	PHENOTYPE	3	3	allergy
NCT000029301	NCT00002930_1_T0	PHENOTYPE	25	26	lung cancer
NCT000029301	NCT00002930_1_T1	COMPOUND	9	11	fludeoxyglucose F 18
NCT000029305	NCT00002930_5_T0	GENE	20	20	MRI
NCT000029305	NCT00002930_5_T1	GENE	14	14	abdominal
NCT0000293010	NCT00002930_10_T0	PHENOTYPE	2	2	tumor
NCT0000293011	NCT00002930_11_T0	GENE	21	21	2.3
NCT0000293013	NCT00002930_13_T0	GENE	12	12	FDG
NCT0000293013	NCT00002930_13_T1	COMPOUND	9	11	fluorodeoxyglucose F 18
NCT0000293014	NCT00002930_14_T0	PHENOTYPE	7	8	lung cancer
NCT0000293014	NCT00002930_14_T1	PHENOTYPE	11	12	esophageal cancer
NCT000029310	NCT00002931_0_T0	CELL	3	5	Peripheral Stem Cell
NCT000029310	NCT00002931_0_T1	PHENOTYPE	12	14	Germ Cell Cancer
NCT000029316	NCT00002931_6_T0	GENE	5	5	SC
NCT000029316	NCT00002931_6_T1	GENE	3	3	filgrastim
NCT000029316	NCT00002931_6_T2	GENE	4	4	G-CSF
NCT000029316	NCT00002931_6_T3	GENE	7	7	IV
NCT000029316	NCT00002931_6_T4	CELL	12	15	peripheral blood stem cells
NCT000029317	NCT00002931_7_T0	CELL	8	9	stem cells
NCT000029317	NCT00002931_7_T1	ORGAN	1	2	bone marrow
NCT000029318	NCT00002931_8_T0	COMPOUND	13	13	paclitaxel
NCT000029318	NCT00002931_8_T1	GENE	14	14	IV
NCT000029319	NCT00002931_9_T0	COMPOUND	7	7	etoposide
NCT000029319	NCT00002931_9_T1	GENE	8	8	IV
NCT000029319	NCT00002931_9_T2	GENE	15	15	IV
NCT0000293110	NCT00002931_10_T0	COMPOUND	18	18	paclitaxel
NCT0000293110	NCT00002931_10_T1	COMPOUND	26	26	ifosfamide
NCT0000293110	NCT00002931_10_T2	GENE	19	19	IV
NCT0000293111	NCT00002931_11_T0	ORGAN	4	4	marrow
NCT0000293111	NCT00002931_11_T1	COMPOUND	8	8	2
NCT0000293111	NCT00002931_11_T2	COMPOUND	14	14	2
NCT0000293112	NCT00002931_12_T0	CELL	15	15	granulocytes
NCT0000293112	NCT00002931_12_T1	GENE	2	2	G-CSF
NCT0000293112	NCT00002931_12_T2	GENE	3	3	IV
NCT0000293113	NCT00002931_13_T0	CELL	3	4	stem cells
NCT0000293113	NCT00002931_13_T1	ORGAN	8	9	bone marrow
NCT000029321	NCT00002932_1_T0	CELL	8	8	cells
NCT000029321	NCT00002932_1_T1	PHENOTYPE	7	7	tumor
NCT000029322	NCT00002932_2_T0	CELL	9	9	cells
NCT000029322	NCT00002932_2_T1	PHENOTYPE	8	8	tumor
NCT000029323	NCT00002932_3_T0	GENE	2	2	II
NCT000029323	NCT00002932_3_T1	COMPOUND	9	9	cisplatin
NCT000029323	NCT00002932_3_T2	PHENOTYPE	17	21	stage IV cancer of the
NCT000029323	NCT00002932_3_T3	PHENOTYPE	19	23	cancer of the head and
NCT000029327	NCT00002932_7_T0	COMPOUND	8	8	cisplatin
NCT000029329	NCT00002932_9_T0	COMPOUND	7	7	cisplatin
NCT000029329	NCT00002932_9_T1	PHENOTYPE	4	5	adverse events
NCT0000293213	NCT00002932_13_T0	PHENOTYPE	6	6	recurrence
NCT0000293215	NCT00002932_15_T0	PHENOTYPE	1	3	quality of life
NCT0000293216	NCT00002932_16_T0	COMPOUND	7	7	cisplatin
NCT0000293217	NCT00002932_17_T0	GENE	10	10	3.5
NCT0000293217	NCT00002932_17_T1	COMPOUND	7	7	cisplatin
NCT0000293219	NCT00002932_19_T0	PHENOTYPE	13	13	toxicity
NCT0000293219	NCT00002932_19_T1	COMPOUND	2	2	cisplatin
NCT0000293220	NCT00002932_20_T0	COMPOUND	7	7	cisplatin
NCT000029331	NCT00002933_1_T0	GENE	2	2	II
NCT000029331	NCT00002933_1_T1	COMPOUND	9	9	irinotecan
NCT000029331	NCT00002933_1_T2	PHENOTYPE	17	19	recurrent colorectal cancer
NCT000029333	NCT00002933_3_T0	PHENOTYPE	10	10	toxicity
NCT000029333	NCT00002933_3_T1	PHENOTYPE	6	7	disease progression
NCT000029334	NCT00002933_4_T0	PHENOTYPE	0	0	Tumor
NCT000029337	NCT00002933_7_T0	COMPOUND	8	8	irinotecan
NCT000029337	NCT00002933_7_T1	PHENOTYPE	14	16	recurrent colorectal cancer
NCT000029339	NCT00002933_9_T0	COMPOUND	4	4	irinotecan
NCT000029339	NCT00002933_9_T1	PHENOTYPE	15	16	toxic effect
NCT0000293311	NCT00002933_11_T0	PHENOTYPE	7	7	proliferative
NCT0000293311	NCT00002933_11_T1	PHENOTYPE	1	1	tumor
NCT0000293311	NCT00002933_11_T2	PHENOTYPE	23	23	tumor
NCT0000293311	NCT00002933_11_T3	GENE	9	9	ki67
NCT0000293311	NCT00002933_11_T4	GENE	12	12	p53
NCT0000293311	NCT00002933_11_T5	GENE	4	5	topoisomerase I
NCT0000293313	NCT00002933_13_T0	COMPOUND	10	10	irinotecan
NCT0000293313	NCT00002933_13_T1	COMPOUND	26	26	irinotecan
NCT0000293313	NCT00002933_13_T2	COMPOUND	14	14	camptothecin
NCT0000293313	NCT00002933_13_T3	PHENOTYPE	4	4	inhibition
NCT0000293313	NCT00002933_13_T4	GENE	6	7	topoisomerase I
NCT0000293315	NCT00002933_15_T0	COMPOUND	7	7	irinotecan
NCT0000293315	NCT00002933_15_T1	PHENOTYPE	4	5	somatic mutations
NCT0000293316	NCT00002933_16_T0	COMPOUND	3	3	irinotecan
NCT0000293316	NCT00002933_16_T1	GENE	4	4	IV
NCT0000293317	NCT00002933_17_T0	PHENOTYPE	10	10	toxicity
NCT0000293317	NCT00002933_17_T1	PHENOTYPE	6	7	disease progression
NCT0000293318	NCT00002933_18_T0	PHENOTYPE	0	0	Tumor
NCT000029341	NCT00002934_1_T0	GENE	15	15	had
NCT000029341	NCT00002934_1_T1	PHENOTYPE	7	7	recurrence
NCT000029341	NCT00002934_1_T2	PHENOTYPE	9	10	breast cancer
NCT000029341	NCT00002934_1_T3	PHENOTYPE	18	21	ductal carcinoma in situ
NCT000029343	NCT00002934_3_T0	COMPOUND	17	17	tamoxifen
NCT000029345	NCT00002934_5_T0	PHENOTYPE	1	1	recurrence
NCT000029346	NCT00002934_6_T0	COMPOUND	5	5	tamoxifen
NCT000029347	NCT00002934_7_T0	PHENOTYPE	15	15	microcalcification
NCT000029351	NCT00002935_1_T0	PHENOTYPE	7	8	esophageal cancer
NCT000029352	NCT00002935_2_T0	GENE	2	2	II
NCT000029352	NCT00002935_2_T1	PHENOTYPE	15	16	Barrett's esophagus
NCT000029352	NCT00002935_2_T2	PHENOTYPE	21	22	esophageal cancer
NCT000029354	NCT00002935_4_T0	COMPOUND	10	10	Photofrin
NCT000029354	NCT00002935_4_T1	PHENOTYPE	23	24	Barrett's esophagus
NCT000029354	NCT00002935_4_T2	PHENOTYPE	29	30	Barrett's esophagus
NCT000029354	NCT00002935_4_T3	COMPOUND	8	9	porfimer sodium
NCT000029354	NCT00002935_4_T4	PHENOTYPE	26	27	severe dysplasia
NCT000029354	NCT00002935_4_T5	PHENOTYPE	19	21	carcinoma in situ
NCT000029358	NCT00002935_8_T0	GENE	3	3	IV
NCT000029358	NCT00002935_8_T1	COMPOUND	4	5	porfimer sodium
NCT000029361	NCT00002936_1_T0	CELL	9	9	cells
NCT000029361	NCT00002936_1_T1	PHENOTYPE	8	8	tumor
NCT000029362	NCT00002936_2_T0	PHENOTYPE	16	16	HIV
NCT000029362	NCT00002936_2_T1	COMPOUND	11	11	etoposide
NCT000029364	NCT00002936_4_T0	PHENOTYPE	1	1	toxic
NCT000029364	NCT00002936_4_T1	COMPOUND	9	9	etoposide
NCT000029364	NCT00002936_4_T2	GENE	15	15	MTD
NCT000029366	NCT00002936_6_T0	PHENOTYPE	15	15	HIV
NCT000029366	NCT00002936_6_T1	PHENOTYPE	16	16	malignancies
NCT000029366	NCT00002936_6_T2	PHENOTYPE	7	7	progression
NCT000029366	NCT00002936_6_T3	GENE	10	10	MTD
NCT000029368	NCT00002936_8_T0	ORGAN	8	9	immune systems
NCT0000293610	NCT00002936_10_T0	PHENOTYPE	8	10	quality of life
NCT0000293611	NCT00002936_11_T0	COMPOUND	8	8	etoposide
NCT0000293612	NCT00002936_12_T0	PHENOTYPE	19	19	progression
NCT0000293613	NCT00002936_13_T0	PHENOTYPE	5	5	remission
NCT0000293614	NCT00002936_14_T0	PHENOTYPE	11	11	toxic
NCT0000293615	NCT00002936_15_T0	PHENOTYPE	19	19	toxicity
NCT0000293615	NCT00002936_15_T1	GENE	1	1	MTD
NCT0000293616	NCT00002936_16_T0	PHENOTYPE	4	4	relapse
NCT000029371	NCT00002937_1_T0	CELL	9	9	cells
NCT000029371	NCT00002937_1_T1	PHENOTYPE	8	8	tumor
NCT000029378	NCT00002937_8_T0	PHENOTYPE	28	28	progression
NCT000029378	NCT00002937_8_T1	GENE	5	5	MDR
NCT0000293710	NCT00002937_10_T0	PHENOTYPE	16	16	progression
NCT0000293710	NCT00002937_10_T1	PHENOTYPE	25	26	evaluable disease
NCT000029383	NCT00002938_3_T0	PHENOTYPE	4	4	bilateral
NCT000029383	NCT00002938_3_T1	TISSUE	6	7	lymph node
NCT000029388	NCT00002938_8_T0	PHENOTYPE	0	2	Quality of life
NCT000029391	NCT00002939_1_T0	CELL	9	9	cells
NCT000029391	NCT00002939_1_T1	PHENOTYPE	8	8	tumor
NCT000029392	NCT00002939_2_T0	COMPOUND	11	11	paclitaxel
NCT000029392	NCT00002939_2_T1	COMPOUND	9	9	irinotecan
NCT000029392	NCT00002939_2_T2	PHENOTYPE	18	19	recurrent cancer
NCT000029394	NCT00002939_4_T0	COMPOUND	12	12	paclitaxel
NCT000029394	NCT00002939_4_T1	COMPOUND	7	7	irinotecan
NCT000029394	NCT00002939_4_T2	PHENOTYPE	19	19	malignancies
NCT000029394	NCT00002939_4_T3	GENE	5	5	MTD
NCT000029394	NCT00002939_4_T4	PHENOTYPE	18	18	recurrent
NCT000029396	NCT00002939_6_T0	PHENOTYPE	2	2	toxicity
NCT000029398	NCT00002939_8_T0	COMPOUND	9	9	paclitaxel
NCT000029398	NCT00002939_8_T1	COMPOUND	5	5	irinotecan
NCT000029398	NCT00002939_8_T2	COMPOUND	21	21	irinotecan
NCT000029398	NCT00002939_8_T3	PHENOTYPE	22	22	pharmacokinetics
NCT0000293910	NCT00002939_10_T0	COMPOUND	4	4	irinotecan
NCT0000293910	NCT00002939_10_T1	PHENOTYPE	1	1	pharmacodynamic
NCT0000293911	NCT00002939_11_T0	COMPOUND	8	8	irinotecan
NCT0000293912	NCT00002939_12_T0	COMPOUND	6	6	paclitaxel
NCT0000293912	NCT00002939_12_T1	COMPOUND	2	2	irinotecan
NCT0000293912	NCT00002939_12_T2	GENE	3	3	IV
NCT0000293912	NCT00002939_12_T3	GENE	7	7	IV
NCT0000293913	NCT00002939_13_T0	PHENOTYPE	18	18	toxicities
NCT0000293914	NCT00002939_14_T0	COMPOUND	8	8	irinotecan
NCT000029401	NCT00002940_1_T0	GENE	2	2	II
NCT000029401	NCT00002940_1_T1	COMPOUND	9	9	hydroxyurea
NCT000029401	NCT00002940_1_T2	PHENOTYPE	16	18	primary CNS lymphoma
NCT000029403	NCT00002940_3_T0	PHENOTYPE	6	6	PCNSL
NCT000029403	NCT00002940_3_T1	COMPOUND	12	12	hydroxyurea
NCT000029405	NCT00002940_5_T0	PHENOTYPE	18	18	PCNSL
NCT000029407	NCT00002940_7_T0	COMPOUND	3	3	hydroxyurea
NCT000029407	NCT00002940_7_T1	GENE	4	4	tid
NCT000029408	NCT00002940_8_T0	COMPOUND	3	3	hydroxyurea
NCT000029409	NCT00002940_9_T0	GENE	14	14	MRI
NCT000029409	NCT00002940_9_T1	PHENOTYPE	9	9	tumor
NCT0000294010	NCT00002940_10_T0	COMPOUND	11	11	hydroxyurea
NCT0000294010	NCT00002940_10_T1	PHENOTYPE	4	4	tumor
NCT0000294011	NCT00002940_11_T0	GENE	4	4	PR
NCT0000294011	NCT00002940_11_T1	GENE	2	2	CR
NCT0000294012	NCT00002940_12_T0	GENE	0	0	MRI
NCT0000294013	NCT00002940_13_T0	PHENOTYPE	2	3	progressive disease
NCT000029415	NCT00002941_5_T0	ORGAN	1	1	marrow
NCT000029424	NCT00002942_4_T0	PHENOTYPE	1	1	engraftment
NCT000029424	NCT00002942_4_T1	GENE	4	4	G-CSF
NCT000029424	NCT00002942_4_T2	GENE	10	10	PBCP
NCT000029424	NCT00002942_4_T3	PHENOTYPE	23	24	breast cancer
NCT000029424	NCT00002942_4_T4	ORGAN	7	8	bone marrow
NCT000029428	NCT00002942_8_T0	PHENOTYPE	41	41	engraftment
NCT000029428	NCT00002942_8_T1	GENE	2	2	IV
NCT000029428	NCT00002942_8_T2	GENE	16	16	IV
NCT000029428	NCT00002942_8_T3	CELL	35	36	progenitor cells
NCT000029428	NCT00002942_8_T4	ORGAN	7	8	bone marrow
NCT0000294211	NCT00002942_11_T0	GENE	5	5	G-CSF
NCT0000294213	NCT00002942_13_T0	GENE	8	8	ANC
NCT0000294213	NCT00002942_13_T1	GENE	0	0	G-CSF
NCT000029431	NCT00002943_1_T0	CELL	14	14	cells
NCT000029431	NCT00002943_1_T1	PHENOTYPE	13	13	tumor
NCT000029431	NCT00002943_1_T2	ORGAN	4	5	bone marrow
NCT000029434	NCT00002943_4_T0	COMPOUND	10	10	cyclophosphamide
NCT000029434	NCT00002943_4_T1	COMPOUND	5	5	etoposide
NCT000029435	NCT00002943_5_T0	PHENOTYPE	19	19	toxicity
NCT000029435	NCT00002943_5_T1	GENE	16	16	PR
NCT000029435	NCT00002943_5_T2	GENE	8	8	has
NCT000029435	NCT00002943_5_T3	GENE	12	12	CR
NCT000029436	NCT00002943_6_T0	PHENOTYPE	9	9	toxicity
NCT000029436	NCT00002943_6_T1	GENE	6	6	PR
NCT000029436	NCT00002943_6_T2	GENE	4	4	CR
NCT000029437	NCT00002943_7_T0	PHENOTYPE	6	7	disease progression
NCT000029442	NCT00002944_2_T0	CELL	9	9	cells
NCT000029442	NCT00002944_2_T1	PHENOTYPE	8	8	tumor
NCT000029443	NCT00002944_3_T0	PHENOTYPE	24	24	astrocytomas
NCT000029443	NCT00002944_3_T1	GENE	4	4	III
NCT000029443	NCT00002944_3_T2	PHENOTYPE	27	28	residual tumors
NCT000029446	NCT00002944_6_T0	PHENOTYPE	12	12	pathology
NCT000029452	NCT00002945_2_T0	PHENOTYPE	10	10	leukemia
NCT000029452	NCT00002945_2_T1	CELL	11	11	cells
NCT000029452	NCT00002945_2_T2	GENE	0	0	Interleukin-2
NCT000029452	NCT00002945_2_T3	CELL	5	7	white blood cells
NCT000029456	NCT00002945_6_T0	COMPOUND	8	8	cytarabine
NCT000029456	NCT00002945_6_T1	GENE	11	11	filgrastim
NCT000029456	NCT00002945_6_T2	GENE	12	12	G-CSF
NCT000029458	NCT00002945_8_T0	COMPOUND	8	8	cyclophosphamide
NCT000029458	NCT00002945_8_T1	GENE	11	11	G-CSF
NCT000029459	NCT00002945_9_T0	CELL	11	11	cells
NCT000029459	NCT00002945_9_T1	GENE	10	10	CD34
NCT000029459	NCT00002945_9_T2	CELL	0	3	Peripheral blood stem cells
NCT0000294510	NCT00002945_10_T0	COMPOUND	5	5	1
NCT0000294510	NCT00002945_10_T1	COMPOUND	20	20	1
NCT0000294510	NCT00002945_10_T2	COMPOUND	18	18	2
NCT0000294510	NCT00002945_10_T3	COMPOUND	17	17	3
NCT0000294510	NCT00002945_10_T4	COMPOUND	2	2	melphalan
NCT0000294510	NCT00002945_10_T5	GENE	3	3	IV
NCT0000294512	NCT00002945_12_T0	GENE	8	8	interleukin-2
NCT0000294512	NCT00002945_12_T1	GENE	17	17	interleukin-2
NCT0000294512	NCT00002945_12_T2	COMPOUND	12	12	1_10
NCT0000294513	NCT00002945_13_T0	PHENOTYPE	17	17	toxicity
NCT0000294513	NCT00002945_13_T1	GENE	0	0	Interleukin-2
NCT0000294513	NCT00002945_13_T2	PHENOTYPE	13	14	disease progression
NCT0000294514	NCT00002945_14_T0	GENE	8	8	interleukin-2
NCT000029461	NCT00002946_1_T0	CELL	10	10	cells
NCT000029461	NCT00002946_1_T1	PHENOTYPE	9	9	tumor
NCT000029463	NCT00002946_3_T0	GENE	8	8	II
NCT000029463	NCT00002946_3_T1	COMPOUND	12	12	penclomedine
NCT000029463	NCT00002946_3_T2	PHENOTYPE	16	16	malignancies
NCT000029463	NCT00002946_3_T3	GENE	5	5	MTD
NCT000029465	NCT00002946_5_T0	PHENOTYPE	2	2	toxic
NCT000029465	NCT00002946_5_T1	COMPOUND	6	6	penclomedine
NCT000029467	NCT00002946_7_T0	COMPOUND	5	5	penclomedine
NCT000029467	NCT00002946_7_T1	PHENOTYPE	2	2	pharmacokinetics
NCT000029469	NCT00002946_9_T0	COMPOUND	5	5	penclomedine
NCT0000294610	NCT00002946_10_T0	COMPOUND	15	15	penclomedine
NCT0000294610	NCT00002946_10_T1	GENE	14	14	IV
NCT0000294611	NCT00002946_11_T0	COMPOUND	9	9	penclomedine
NCT0000294612	NCT00002946_12_T0	PHENOTYPE	21	21	toxicity
NCT0000294612	NCT00002946_12_T1	COMPOUND	15	15	penclomedine
NCT0000294612	NCT00002946_12_T2	GENE	11	11	has
NCT0000294612	NCT00002946_12_T3	GENE	22	22	DLT
NCT0000294614	NCT00002946_14_T0	COMPOUND	4	4	penclomedine
NCT0000294616	NCT00002946_16_T0	GENE	1	1	MTD
NCT0000294616	NCT00002946_16_T1	GENE	15	15	DLT
NCT0000294617	NCT00002946_17_T0	PHENOTYPE	8	8	toxicity
NCT0000294617	NCT00002946_17_T1	PHENOTYPE	10	11	tumor progression
NCT000029471	NCT00002947_1_T0	CELL	10	10	cells
NCT000029471	NCT00002947_1_T1	PHENOTYPE	9	9	tumor
NCT000029472	NCT00002947_2_T0	COMPOUND	12	12	pentetreotide
NCT000029472	NCT00002947_2_T1	COMPOUND	9	9	indium
NCT000029472	NCT00002947_2_T2	PHENOTYPE	18	19	refractory cancer
NCT000029474	NCT00002947_4_T0	PHENOTYPE	6	6	toxic
NCT000029474	NCT00002947_4_T1	COMPOUND	17	17	pentetreotide
NCT000029474	NCT00002947_4_T2	COMPOUND	14	14	indium
NCT000029474	NCT00002947_4_T3	GENE	5	5	MTD
NCT000029476	NCT00002947_6_T0	COMPOUND	5	5	pentetreotide
NCT000029476	NCT00002947_6_T1	COMPOUND	2	2	indium
NCT000029476	NCT00002947_6_T2	GENE	4	4	III
NCT000029476	NCT00002947_6_T3	GENE	7	7	IV
NCT000029478	NCT00002947_8_T0	PHENOTYPE	17	17	toxicity
NCT000029478	NCT00002947_8_T1	PHENOTYPE	13	14	disease progression
NCT000029479	NCT00002947_9_T0	GENE	16	16	MTD
NCT0000294710	NCT00002947_10_T0	PHENOTYPE	18	18	toxicities
NCT0000294710	NCT00002947_10_T1	GENE	1	1	MTD
NCT000029489	NCT00002948_9_T0	PHENOTYPE	17	17	toxicity
NCT000029489	NCT00002948_9_T1	GENE	1	1	MTD
NCT0000294810	NCT00002948_10_T0	COMPOUND	14	14	topotecan
NCT0000294810	NCT00002948_10_T1	CELL	0	3	Peripheral blood stem cells
NCT0000294811	NCT00002948_11_T0	GENE	1	1	G-CSF
NCT000029491	NCT00002949_1_T0	CELL	10	10	cells
NCT000029491	NCT00002949_1_T1	PHENOTYPE	9	9	tumor
NCT000029492	NCT00002949_2_T0	COMPOUND	11	11	vinorelbine
NCT000029492	NCT00002949_2_T1	COMPOUND	13	13	paclitaxel
NCT000029492	NCT00002949_2_T2	ORGAN	26	26	pelvis
NCT000029492	NCT00002949_2_T3	PHENOTYPE	21	22	advanced cancer
NCT000029494	NCT00002949_4_T0	COMPOUND	5	5	vinorelbine
NCT000029494	NCT00002949_4_T1	PHENOTYPE	2	2	toxic
NCT000029496	NCT00002949_6_T0	COMPOUND	7	7	vinorelbine
NCT000029496	NCT00002949_6_T1	GENE	5	5	MTD
NCT000029498	NCT00002949_8_T0	COMPOUND	19	19	vinorelbine
NCT000029498	NCT00002949_8_T1	PHENOTYPE	2	2	toxic
NCT000029498	NCT00002949_8_T2	COMPOUND	5	5	paclitaxel
NCT000029498	NCT00002949_8_T3	GENE	17	17	MTD
NCT0000294910	NCT00002949_10_T0	COMPOUND	18	18	vinorelbine
NCT0000294910	NCT00002949_10_T1	COMPOUND	4	4	paclitaxel
NCT0000294910	NCT00002949_10_T2	GENE	2	2	MTD
NCT0000294910	NCT00002949_10_T3	GENE	16	16	MTD
NCT0000294911	NCT00002949_11_T0	GENE	4	4	IV
NCT0000294912	NCT00002949_12_T0	GENE	8	8	1.5
NCT0000294913	NCT00002949_13_T0	GENE	13	13	cm
NCT0000294915	NCT00002949_15_T0	COMPOUND	2	2	vinorelbine
NCT0000294915	NCT00002949_15_T1	GENE	16	16	MTD
NCT0000294916	NCT00002949_16_T0	GENE	1	1	II
NCT0000294916	NCT00002949_16_T1	COMPOUND	10	10	vinorelbine
NCT0000294916	NCT00002949_16_T2	GENE	13	13	MTD
NCT0000294917	NCT00002949_17_T0	COMPOUND	2	2	paclitaxel
NCT0000294917	NCT00002949_17_T1	GENE	14	14	MTD
NCT0000294918	NCT00002949_18_T0	GENE	14	14	II
NCT0000294918	NCT00002949_18_T1	GENE	8	8	MTD
NCT0000294919	NCT00002949_19_T0	PHENOTYPE	7	7	toxicities
NCT0000294919	NCT00002949_19_T1	PHENOTYPE	6	6	chronic
NCT000029501	NCT00002950_1_T0	PHENOTYPE	17	17	peripheral
NCT000029501	NCT00002950_1_T1	CELL	11	11	cells
NCT000029501	NCT00002950_1_T2	GENE	4	4	sargramostim
NCT000029501	NCT00002950_1_T3	ORGAN	14	15	bone marrow
NCT000029501	NCT00002950_1_T4	ORGAN	24	25	immune system
NCT000029501	NCT00002950_1_T5	PHENOTYPE	30	32	effects of chemotherapy
NCT000029502	NCT00002950_2_T0	COMPOUND	9	9	topotecan
NCT000029502	NCT00002950_2_T1	GENE	11	11	sargramostim
NCT000029502	NCT00002950_2_T2	PHENOTYPE	17	18	advanced cancer
NCT000029504	NCT00002950_4_T0	PHENOTYPE	26	26	malignancies
NCT000029504	NCT00002950_4_T1	GENE	6	6	GM-CSF
NCT000029504	NCT00002950_4_T2	GENE	5	5	sargramostim
NCT000029504	NCT00002950_4_T3	CELL	12	13	progenitor cells
NCT000029506	NCT00002950_6_T0	PHENOTYPE	6	6	toxic
NCT000029506	NCT00002950_6_T1	COMPOUND	9	9	topotecan
NCT000029506	NCT00002950_6_T2	GENE	13	13	sargramostim
NCT000029508	NCT00002950_8_T0	COMPOUND	9	9	topotecan
NCT000029509	NCT00002950_9_T0	COMPOUND	8	8	topotecan
NCT0000295010	NCT00002950_10_T0	COMPOUND	10	10	2
NCT0000295010	NCT00002950_10_T1	GENE	5	5	GM-CSF
NCT0000295010	NCT00002950_10_T2	GENE	4	4	sargramostim
NCT0000295011	NCT00002950_11_T0	GENE	4	4	IV
NCT0000295011	NCT00002950_11_T1	COMPOUND	3	3	topotecan
NCT0000295012	NCT00002950_12_T0	COMPOUND	8	8	topotecan
NCT0000295013	NCT00002950_13_T0	PHENOTYPE	20	20	toxicity
NCT0000295013	NCT00002950_13_T1	GENE	4	4	MTD
NCT0000295013	NCT00002950_13_T2	GENE	21	21	DLT
NCT0000295014	NCT00002950_14_T0	COMPOUND	6	6	topotecan
NCT0000295015	NCT00002950_15_T0	COMPOUND	4	4	topotecan
NCT000029510	NCT00002951_0_T0	PHENOTYPE	8	11	Head and Neck Cancer
NCT000029512	NCT00002951_2_T0	CELL	8	8	cells
NCT000029512	NCT00002951_2_T1	PHENOTYPE	7	7	tumor
NCT000029513	NCT00002951_3_T0	CELL	9	9	cells
NCT000029513	NCT00002951_3_T1	PHENOTYPE	8	8	tumor
NCT000029514	NCT00002951_4_T0	GENE	2	2	II
NCT000029514	NCT00002951_4_T1	PHENOTYPE	17	20	head and neck cancer
NCT000029516	NCT00002951_6_T0	PHENOTYPE	7	7	intent
NCT000029517	NCT00002951_7_T0	PHENOTYPE	6	7	residual disease
NCT000029518	NCT00002951_8_T0	COMPOUND	11	11	hydroxyurea
NCT000029518	NCT00002951_8_T1	GENE	17	17	0.5
NCT000029519	NCT00002951_9_T0	GENE	6	6	0.4
NCT000029519	NCT00002951_9_T1	GENE	3	3	IV
NCT0000295110	NCT00002951_10_T0	GENE	7	7	1/6
NCT0000295110	NCT00002951_10_T1	GENE	2	2	BID
NCT000029522	NCT00002952_2_T0	GENE	4	4	interleukin-12
NCT000029522	NCT00002952_2_T1	CELL	9	9	cells
NCT000029522	NCT00002952_2_T2	PHENOTYPE	8	8	melanoma
NCT000029523	NCT00002952_3_T0	GENE	12	12	interleukin-12
NCT000029523	NCT00002952_3_T1	PHENOTYPE	18	19	metastatic melanoma
NCT000029529	NCT00002952_9_T0	PHENOTYPE	5	5	tumor
NCT0000295212	NCT00002952_12_T0	GENE	13	13	interleukin-12
NCT0000295212	NCT00002952_12_T1	GENE	14	14	IL-12
NCT0000295212	NCT00002952_12_T2	GENE	19	19	IL-12
NCT0000295213	NCT00002952_13_T0	GENE	6	6	IL-12
NCT0000295213	NCT00002952_13_T1	GENE	16	16	IL-12
NCT0000295214	NCT00002952_14_T0	GENE	2	2	II
NCT0000295214	NCT00002952_14_T1	GENE	11	11	MTD
NCT0000295215	NCT00002952_15_T0	PHENOTYPE	4	4	tumor
NCT0000295215	NCT00002952_15_T1	PHENOTYPE	5	5	remission
NCT000029531	NCT00002953_1_T0	CELL	9	9	cells
NCT000029531	NCT00002953_1_T1	PHENOTYPE	8	8	tumor
NCT000029532	NCT00002953_2_T0	COMPOUND	16	16	paclitaxel
NCT000029532	NCT00002953_2_T1	GENE	3	3	III
NCT000029532	NCT00002953_2_T2	COMPOUND	12	12	cyclophosphamide
NCT000029532	NCT00002953_2_T3	COMPOUND	10	10	epirubicin
NCT000029532	NCT00002953_2_T4	COMPOUND	14	14	epirubicin
NCT000029532	NCT00002953_2_T5	PHENOTYPE	21	23	metastatic breast cancer
NCT000029534	NCT00002953_4_T0	PHENOTYPE	4	4	toxicity
NCT000029534	NCT00002953_4_T1	COMPOUND	14	14	paclitaxel
NCT000029534	NCT00002953_4_T2	COMPOUND	8	8	cyclophosphamide
NCT000029534	NCT00002953_4_T3	COMPOUND	6	6	epirubicin
NCT000029534	NCT00002953_4_T4	COMPOUND	12	12	epirubicin
NCT000029534	NCT00002953_4_T5	PHENOTYPE	18	20	metastatic breast cancer
NCT000029535	NCT00002953_5_T0	COMPOUND	13	13	paclitaxel
NCT000029535	NCT00002953_5_T1	COMPOUND	9	9	cyclophosphamide
NCT000029535	NCT00002953_5_T2	COMPOUND	7	7	epirubicin
NCT000029535	NCT00002953_5_T3	COMPOUND	11	11	epirubicin
NCT000029536	NCT00002953_6_T0	PHENOTYPE	19	19	toxicity
NCT000029536	NCT00002953_6_T1	PHENOTYPE	15	16	disease progression
NCT000029551	NCT00002955_1_T0	CELL	9	9	cells
NCT000029551	NCT00002955_1_T1	PHENOTYPE	8	8	tumor
NCT000029552	NCT00002955_2_T0	GENE	2	2	II
NCT000029552	NCT00002955_2_T1	PHENOTYPE	15	16	advanced cancer
NCT000029552	NCT00002955_2_T2	PHENOTYPE	16	19	cancer of the pancreas
NCT000029554	NCT00002955_4_T0	PHENOTYPE	1	1	tumor
NCT000029554	NCT00002955_4_T1	COMPOUND	8	8	leucovorin
NCT000029554	NCT00002955_4_T2	COMPOUND	5	5	trimetrexate
NCT000029554	NCT00002955_4_T3	PHENOTYPE	14	15	pancreatic carcinoma
NCT000029556	NCT00002955_6_T0	PHENOTYPE	2	2	toxicities
NCT000029556	NCT00002955_6_T1	PHENOTYPE	10	14	metastatic carcinoma of the pancreas
NCT000029557	NCT00002955_7_T0	COMPOUND	19	19	leucovorin
NCT000029557	NCT00002955_7_T1	COMPOUND	10	10	trimetrexate
NCT000029557	NCT00002955_7_T2	GENE	7	7	IV
NCT000029557	NCT00002955_7_T3	GENE	16	16	IV
NCT000029558	NCT00002955_8_T0	COMPOUND	5	5	leucovorin
NCT0000295510	NCT00002955_10_T0	PHENOTYPE	10	10	toxicity
NCT0000295510	NCT00002955_10_T1	PHENOTYPE	6	7	disease progression
NCT000029560	NCT00002956_0_T0	PHENOTYPE	3	3	Diseases
NCT000029560	NCT00002956_0_T1	ORGAN	13	14	Organ Transplants
NCT000029562	NCT00002956_2_T0	PHENOTYPE	23	23	diseases
NCT000029562	NCT00002956_2_T1	ORGAN	18	19	organ transplant
NCT000029562	NCT00002956_2_T2	CELL	11	12	T cells
NCT000029564	NCT00002956_4_T0	GENE	21	21	LPD
NCT000029564	NCT00002956_4_T1	PHENOTYPE	2	2	toxic
NCT000029564	NCT00002956_4_T2	PHENOTYPE	20	20	diseases
NCT000029564	NCT00002956_4_T3	GENE	13	13	CTL
NCT000029564	NCT00002956_4_T4	CELL	11	12	T lymphocytes
NCT000029564	NCT00002956_4_T5	ORGAN	23	24	organ transplant
NCT000029567	NCT00002956_7_T0	CELL	10	11	T lymphocytes
NCT000029568	NCT00002956_8_T0	CELL	7	8	T lymphocytes
NCT000029569	NCT00002956_9_T0	PHENOTYPE	8	8	remission
NCT000029569	NCT00002956_9_T1	PHENOTYPE	15	16	disease progression
NCT000029601	NCT00002960_1_T0	TISSUE	6	6	peritoneum
NCT000029601	NCT00002960_1_T1	CELL	11	11	cells
NCT000029606	NCT00002960_6_T0	GENE	10	10	p53
NCT000029606	NCT00002960_6_T1	BIOLOGICAL_PROCESS	11	12	gene expression
NCT000029608	NCT00002960_8_T0	PHENOTYPE	15	15	ascites
NCT0000296010	NCT00002960_10_T0	PHENOTYPE	2	2	pharmacokinetics
NCT0000296010	NCT00002960_10_T1	ORGAN	6	6	serum
NCT0000296014	NCT00002960_14_T0	GENE	8	8	1.5
NCT0000296015	NCT00002960_15_T0	PHENOTYPE	2	2	ascites
NCT0000296015	NCT00002960_15_T1	PHENOTYPE	5	5	tumor
NCT0000296016	NCT00002960_16_T0	PHENOTYPE	4	4	tumor
NCT0000296017	NCT00002960_17_T0	PHENOTYPE	15	15	toxicity
NCT000029611	NCT00002961_1_T0	CELL	21	21	cells
NCT000029611	NCT00002961_1_T1	ORGAN	3	4	bone marrow
NCT000029612	NCT00002961_2_T0	CELL	8	8	cells
NCT000029613	NCT00002961_3_T0	CELL	12	12	cells
NCT000029613	NCT00002961_3_T1	ORGAN	5	6	bone marrow
NCT000029614	NCT00002961_4_T0	GENE	3	3	III
NCT000029614	NCT00002961_4_T1	ORGAN	15	16	bone marrow
NCT000029614	NCT00002961_4_T2	PHENOTYPE	22	24	acute lymphoblastic leukemia
NCT0000296115	NCT00002961_15_T0	PHENOTYPE	10	10	toxicity
NCT0000296115	NCT00002961_15_T1	COMPOUND	5	5	busulfan
NCT0000296115	NCT00002961_15_T2	PHENOTYPE	8	8	relapse
NCT0000296115	NCT00002961_15_T3	ORGAN	4	4	plasma
NCT0000296121	NCT00002961_21_T0	COMPOUND	20	20	2
NCT0000296121	NCT00002961_21_T1	COMPOUND	18	18	3
NCT0000296121	NCT00002961_21_T2	COMPOUND	13	13	cyclophosphamide
NCT0000296121	NCT00002961_21_T3	COMPOUND	5	5	etoposide
NCT0000296121	NCT00002961_21_T4	GENE	15	15	IV
NCT0000296122	NCT00002961_22_T0	ORGAN	0	0	Marrow
NCT0000296123	NCT00002961_23_T0	COMPOUND	4	4	cyclosporine
NCT0000296123	NCT00002961_23_T1	COMPOUND	3	3	1
NCT0000296123	NCT00002961_23_T2	GENE	5	5	IV
NCT0000296124	NCT00002961_24_T0	GENE	1	1	IV
NCT000029632	NCT00002963_2_T0	PHENOTYPE	13	14	skin cancer
NCT000029633	NCT00002963_3_T0	GENE	4	4	II
NCT000029633	NCT00002963_3_T1	PHENOTYPE	17	18	skin cancer
NCT000029637	NCT00002963_7_T0	GENE	13	13	4.5
NCT000029639	NCT00002963_9_T0	PHENOTYPE	19	19	tumor
NCT000029639	NCT00002963_9_T1	GENE	5	5	has
NCT000029639	NCT00002963_9_T2	GENE	14	14	IX
NCT0000296310	NCT00002963_10_T0	PHENOTYPE	8	8	carcinoma
NCT000029640	NCT00002964_0_T0	COMPOUND	1	1	Sodium
NCT000029640	NCT00002964_0_T1	PHENOTYPE	6	9	Head and Neck Cancer
NCT000029642	NCT00002964_2_T0	GENE	2	2	II
NCT000029642	NCT00002964_2_T1	COMPOUND	9	10	porfimer sodium
NCT000029642	NCT00002964_2_T2	PHENOTYPE	15	18	head and neck cancer
NCT000029649	NCT00002964_9_T0	GENE	11	11	subdued
NCT000029649	NCT00002964_9_T1	GENE	5	5	IV
NCT000029649	NCT00002964_9_T2	COMPOUND	3	4	porfimer sodium
NCT000029650	NCT00002965_0_T0	GENE	0	0	Interferon
NCT000029650	NCT00002965_0_T1	PHENOTYPE	6	6	Recurrent
NCT000029650	NCT00002965_0_T2	PHENOTYPE	8	8	Meningiomas
NCT000029650	NCT00002965_0_T3	PHENOTYPE	10	11	Malignant Meningiomas
NCT000029652	NCT00002965_2_T0	GENE	2	2	II
NCT000029652	NCT00002965_2_T1	PHENOTYPE	17	17	meningiomas
NCT000029652	NCT00002965_2_T2	GENE	9	9	interferon
NCT000029652	NCT00002965_2_T3	PHENOTYPE	15	15	recurrent
NCT000029652	NCT00002965_2_T4	PHENOTYPE	19	20	malignant meningiomas
NCT000029659	NCT00002965_9_T0	PHENOTYPE	15	15	toxicity
NCT000029659	NCT00002965_9_T1	PHENOTYPE	13	13	progression
NCT000029659	NCT00002965_9_T2	PHENOTYPE	10	11	tumor recurrence
NCT0000296510	NCT00002965_10_T0	PHENOTYPE	16	16	toxic
NCT0000296510	NCT00002965_10_T1	GENE	20	20	III
NCT0000296511	NCT00002965_11_T0	PHENOTYPE	13	13	toxicity
NCT0000296511	NCT00002965_11_T1	GENE	16	16	III
NCT000029671	NCT00002967_1_T0	CELL	9	9	cells
NCT000029671	NCT00002967_1_T1	PHENOTYPE	8	8	tumor
NCT000029671	NCT00002967_1_T2	GENE	1	1	hormone
NCT000029672	NCT00002967_2_T0	GENE	3	3	III
NCT000029672	NCT00002967_2_T1	COMPOUND	11	11	octreotide
NCT000029672	NCT00002967_2_T2	COMPOUND	10	10	tamoxifen
NCT000029672	NCT00002967_2_T3	PHENOTYPE	22	25	stage II breast cancer
NCT000029674	NCT00002967_4_T0	GENE	30	30	ER
NCT000029674	NCT00002967_4_T1	PHENOTYPE	32	32	tumors
NCT000029674	NCT00002967_4_T2	COMPOUND	8	8	tamoxifen
NCT000029674	NCT00002967_4_T3	COMPOUND	12	12	tamoxifen
NCT000029674	NCT00002967_4_T4	GENE	28	29	estrogen receptor
NCT000029674	NCT00002967_4_T5	TISSUE	37	38	lymph nodes
NCT000029674	NCT00002967_4_T6	COMPOUND	5	6	octreotide pamoate
NCT000029674	NCT00002967_4_T7	TISSUE	42	44	sentinel lymph nodes
NCT000029674	NCT00002967_4_T8	PHENOTYPE	24	26	invasive breast cancer
NCT000029676	NCT00002967_6_T0	COMPOUND	9	9	tamoxifen
NCT000029676	NCT00002967_6_T1	COMPOUND	17	18	octreotide pamoate
NCT000029676	NCT00002967_6_T2	PHENOTYPE	5	6	endometrial cancer
NCT000029678	NCT00002967_8_T0	COMPOUND	8	8	tamoxifen
NCT000029678	NCT00002967_8_T1	COMPOUND	18	18	tamoxifen
NCT000029678	NCT00002967_8_T2	COMPOUND	5	6	octreotide pamoate
NCT000029678	NCT00002967_8_T3	PHENOTYPE	14	15	breast cancer
NCT0000296720	NCT00002967_20_T0	GENE	2	2	TMX
NCT0000296720	NCT00002967_20_T1	COMPOUND	4	5	octreotide pamoate
NCT000029683	NCT00002968_3_T0	PHENOTYPE	9	10	colon cancer
NCT000029685	NCT00002968_5_T0	GENE	30	30	II
NCT000029685	NCT00002968_5_T1	PHENOTYPE	31	32	colon cancer
NCT0000296811	NCT00002968_11_T0	PHENOTYPE	14	14	recurrence
NCT0000296815	NCT00002968_15_T0	PHENOTYPE	6	6	tumor
NCT0000296817	NCT00002968_17_T0	PHENOTYPE	10	10	proliferation
NCT0000296817	NCT00002968_17_T1	PHENOTYPE	6	6	tumor
NCT0000296817	NCT00002968_17_T2	PHENOTYPE	8	8	tumor
NCT0000296817	NCT00002968_17_T3	PHENOTYPE	12	12	tumor
NCT0000296817	NCT00002968_17_T4	PHENOTYPE	19	19	tumor
NCT0000296817	NCT00002968_17_T5	ORGAN	21	22	lymphatic vessel
NCT0000296819	NCT00002968_19_T0	GENE	27	27	5.0
NCT0000296819	NCT00002968_19_T1	GENE	32	32	5.0
NCT0000296819	NCT00002968_19_T2	ORGAN	23	23	serum
NCT0000296819	NCT00002968_19_T3	GENE	24	24	CEA
NCT000029694	NCT00002969_4_T0	COMPOUND	13	13	paclitaxel
NCT000029694	NCT00002969_4_T1	PHENOTYPE	10	11	bronchioloalveolar carcinoma
NCT000029696	NCT00002969_6_T0	PHENOTYPE	1	1	toxic
NCT000029696	NCT00002969_6_T1	COMPOUND	4	4	paclitaxel
NCT000029697	NCT00002969_7_T0	COMPOUND	6	6	paclitaxel
NCT000029697	NCT00002969_7_T1	GENE	8	8	IV
NCT000029699	NCT00002969_9_T0	PHENOTYPE	1	2	disease progression
NCT000029701	NCT00002970_1_T0	CELL	10	10	cells
NCT000029701	NCT00002970_1_T1	PHENOTYPE	9	9	tumor
NCT000029703	NCT00002970_3_T0	PHENOTYPE	23	23	malignancies
NCT000029703	NCT00002970_3_T1	PHENOTYPE	21	21	recurrent
NCT000029703	NCT00002970_3_T2	CELL	22	22	T-cell
NCT000029705	NCT00002970_5_T0	PHENOTYPE	2	2	toxicities
NCT000029707	NCT00002970_7_T0	PHENOTYPE	15	15	concentrations
NCT000029707	NCT00002970_7_T1	GENE	14	14	CSF
NCT000029709	NCT00002970_9_T0	PHENOTYPE	18	18	malignancies
NCT000029709	NCT00002970_9_T1	PHENOTYPE	16	16	recurrent
NCT000029709	NCT00002970_9_T2	CELL	17	17	T-cell
NCT0000297013	NCT00002970_13_T0	PHENOTYPE	21	22	disease progression
NCT0000297014	NCT00002970_14_T0	COMPOUND	18	18	cytarabine
NCT0000297014	NCT00002970_14_T1	COMPOUND	20	20	hydrocortisone
NCT0000297014	NCT00002970_14_T2	COMPOUND	17	17	methotrexate
NCT0000297016	NCT00002970_16_T0	COMPOUND	1	1	3
NCT0000297016	NCT00002970_16_T1	PHENOTYPE	19	20	disease progression
NCT0000297017	NCT00002970_17_T0	GENE	9	9	1.4
NCT000029711	NCT00002971_1_T0	COMPOUND	9	9	O(6)-benzylguanine
NCT000029711	NCT00002971_1_T1	PHENOTYPE	17	18	malignant glioma
NCT000029714	NCT00002971_4_T0	GENE	11	11	IV
NCT000029715	NCT00002971_5_T0	GENE	17	17	AGT
NCT000029715	NCT00002971_5_T1	MOLECULAR_FUNCTION	15	16	O6-alkylguanine-DNA alkyltransferase
NCT000029716	NCT00002971_6_T0	MOLECULAR_FUNCTION	12	13	AGT activity
NCT000029718	NCT00002971_8_T0	GENE	15	15	AGT
NCT000029719	NCT00002971_9_T0	GENE	11	11	AGT
NCT0000297110	NCT00002971_10_T0	MOLECULAR_FUNCTION	14	15	AGT activity
NCT0000297111	NCT00002971_11_T0	GENE	8	8	II
NCT0000297111	NCT00002971_11_T1	PHENOTYPE	2	2	closed
NCT0000297112	NCT00002971_12_T0	PHENOTYPE	7	7	closed
NCT000029722	NCT00002972_2_T0	GENE	2	2	II
NCT000029722	NCT00002972_2_T1	COMPOUND	9	9	paclitaxel
NCT000029722	NCT00002972_2_T2	GENE	19	19	IV
NCT000029722	NCT00002972_2_T3	PHENOTYPE	21	23	recurrent lung cancer
NCT000029725	NCT00002972_5_T0	COMPOUND	13	13	dextrose
NCT000029726	NCT00002972_6_T0	PHENOTYPE	11	11	toxicity
NCT000029726	NCT00002972_6_T1	PHENOTYPE	13	13	complication
NCT000029727	NCT00002972_7_T0	PHENOTYPE	8	8	progression
NCT000029727	NCT00002972_7_T1	PHENOTYPE	9	11	treatment side effects
NCT000029728	NCT00002972_8_T0	PHENOTYPE	17	17	toxicity
NCT000029728	NCT00002972_8_T1	PHENOTYPE	14	15	disease progression
NCT000029731	NCT00002973_1_T0	CELL	4	4	cells
NCT000029731	NCT00002973_1_T1	PHENOTYPE	3	3	tumor
NCT000029731	NCT00002973_1_T2	PHENOTYPE	0	0	Hyperthermia
NCT000029732	NCT00002973_2_T0	PHENOTYPE	1	1	hyperthermia
NCT000029732	NCT00002973_2_T1	CELL	8	8	cells
NCT000029732	NCT00002973_2_T2	PHENOTYPE	7	7	tumor
NCT000029733	NCT00002973_3_T0	GENE	2	2	II
NCT000029733	NCT00002973_3_T1	PHENOTYPE	12	12	hyperthermia
NCT000029733	NCT00002973_3_T2	COMPOUND	9	9	melphalan
NCT000029733	NCT00002973_3_T3	PHENOTYPE	18	18	melanoma
NCT000029735	NCT00002973_5_T0	PHENOTYPE	9	9	hyperthermia
NCT000029735	NCT00002973_5_T1	COMPOUND	12	12	melphalan
NCT000029735	NCT00002973_5_T2	PHENOTYPE	18	18	melanoma
NCT000029739	NCT00002973_9_T0	PHENOTYPE	3	3	toxicity
NCT0000297312	NCT00002973_12_T0	PHENOTYPE	6	6	hyperthermia
NCT0000297312	NCT00002973_12_T1	COMPOUND	9	9	melphalan
NCT0000297317	NCT00002973_17_T0	PHENOTYPE	2	3	progressive disease
NCT000029741	NCT00002974_1_T0	CELL	10	10	cells
NCT000029741	NCT00002974_1_T1	PHENOTYPE	9	9	tumor
NCT000029742	NCT00002974_2_T0	PHENOTYPE	4	4	hyperthermia
NCT000029742	NCT00002974_2_T1	CELL	9	9	cells
NCT000029742	NCT00002974_2_T2	PHENOTYPE	8	8	tumor
NCT000029743	NCT00002974_3_T0	GENE	2	2	II
NCT000029743	NCT00002974_3_T1	PHENOTYPE	10	10	hyperthermia
NCT000029743	NCT00002974_3_T2	PHENOTYPE	20	20	sarcoma
NCT000029745	NCT00002974_5_T0	PHENOTYPE	9	9	hyperthermia
NCT000029745	NCT00002974_5_T1	PHENOTYPE	19	19	sarcoma
NCT000029745	NCT00002974_5_T2	GENE	13	13	ICE
NCT000029749	NCT00002974_9_T0	PHENOTYPE	3	3	toxicity
NCT000029749	NCT00002974_9_T1	GENE	7	7	ICE
NCT0000297411	NCT00002974_11_T0	GENE	9	9	ICE
NCT0000297412	NCT00002974_12_T0	PHENOTYPE	5	5	hyperthermia
NCT0000297412	NCT00002974_12_T1	GENE	13	13	3.4
NCT0000297412	NCT00002974_12_T2	GENE	9	9	ICE
NCT0000297413	NCT00002974_13_T0	PHENOTYPE	17	17	hyperthermia
NCT0000297413	NCT00002974_13_T1	COMPOUND	6	6	ifosfamide
NCT0000297415	NCT00002974_15_T0	PHENOTYPE	9	9	hyperthermia
NCT0000297415	NCT00002974_15_T1	PHENOTYPE	17	17	hyperthermia
NCT0000297417	NCT00002974_17_T0	PHENOTYPE	4	5	disease progression
NCT000029752	NCT00002975_2_T0	PHENOTYPE	12	13	skin cancer
NCT000029753	NCT00002975_3_T0	GENE	4	4	II
NCT000029753	NCT00002975_3_T1	PHENOTYPE	21	22	skin cancer
NCT000029757	NCT00002975_7_T0	GENE	21	21	ALA
NCT000029757	NCT00002975_7_T1	GENE	13	13	4.5
NCT000029758	NCT00002975_8_T0	GENE	0	0	ALA
NCT000029759	NCT00002975_9_T0	GENE	15	15	dye
NCT000029759	NCT00002975_9_T1	GENE	5	5	ALA
NCT000029759	NCT00002975_9_T2	GENE	7	7	has
NCT000029761	NCT00002976_1_T0	COMPOUND	6	6	estrogen
NCT000029761	NCT00002976_1_T1	PHENOTYPE	11	12	cancer recurrence
NCT000029762	NCT00002976_2_T0	COMPOUND	11	11	estrogen
NCT000029762	NCT00002976_2_T1	GENE	4	4	III
NCT000029762	NCT00002976_2_T2	PHENOTYPE	22	25	stage II endometrial cancer
NCT000029765	NCT00002976_5_T0	GENE	13	13	II
NCT000029765	NCT00002976_5_T1	PHENOTYPE	7	8	endometrial cancer
NCT000029778	NCT00002977_8_T0	COMPOUND	9	9	melphalan
NCT000029778	NCT00002977_8_T1	PHENOTYPE	7	7	pharmacokinetics
NCT000029779	NCT00002977_9_T0	COMPOUND	8	8	thiotepa
NCT0000297710	NCT00002977_10_T0	GENE	12	12	filgrastim
NCT0000297710	NCT00002977_10_T1	GENE	13	13	G-CSF
NCT0000297710	NCT00002977_10_T2	CELL	6	9	peripheral blood stem cells
NCT0000297712	NCT00002977_12_T0	COMPOUND	23	23	3
NCT0000297712	NCT00002977_12_T1	COMPOUND	14	14	thiotepa
NCT0000297712	NCT00002977_12_T2	COMPOUND	3	3	melphalan
NCT0000297712	NCT00002977_12_T3	GENE	4	4	IV
NCT0000297712	NCT00002977_12_T4	GENE	15	15	IV
NCT0000297714	NCT00002977_14_T0	GENE	5	5	0.21
NCT0000297714	NCT00002977_14_T1	GENE	0	0	G-CSF
NCT0000297715	NCT00002977_15_T0	COMPOUND	9	9	thiotepa
NCT0000297715	NCT00002977_15_T1	GENE	15	15	MTD
NCT000029801	NCT00002980_1_T0	COMPOUND	9	9	decitabine
NCT000029801	NCT00002980_1_T1	GENE	25	25	has
NCT000029801	NCT00002980_1_T2	PHENOTYPE	14	15	stage III
NCT000029801	NCT00002980_1_T3	PHENOTYPE	22	23	advanced cancer
NCT000029801	NCT00002980_1_T4	PHENOTYPE	17	19	stage IV melanoma
NCT000029803	NCT00002980_3_T0	GENE	5	5	DAC
NCT000029803	NCT00002980_3_T1	COMPOUND	4	4	decitabine
NCT000029805	NCT00002980_5_T0	PHENOTYPE	5	5	toxicity
NCT000029805	NCT00002980_5_T1	GENE	7	7	DAC
NCT000029807	NCT00002980_7_T0	GENE	4	4	DAC
NCT000029807	NCT00002980_7_T1	ORGAN	5	5	serum
NCT000029809	NCT00002980_9_T0	GENE	5	5	DAC
NCT0000298010	NCT00002980_10_T0	GENE	10	10	DAC
NCT0000298010	NCT00002980_10_T1	COMPOUND	9	9	decitabine
NCT0000298010	NCT00002980_10_T2	GENE	17	17	MTD
NCT0000298012	NCT00002980_12_T0	PHENOTYPE	14	14	toxicity
NCT0000298012	NCT00002980_12_T1	GENE	15	15	DLT
NCT0000298013	NCT00002980_13_T0	GENE	1	1	DLT
NCT0000298014	NCT00002980_14_T0	GENE	6	6	DLT
NCT000029813	NCT00002981_3_T0	ORGAN	45	45	bladder
NCT000029813	NCT00002981_3_T1	TISSUE	30	31	lymph nodes
NCT000029813	NCT00002981_3_T2	ORGAN	8	9	urinary bladder
NCT000029813	NCT00002981_3_T3	ORGAN	34	35	pelvic bones
NCT000029816	NCT00002981_6_T0	GENE	12	12	FDG
NCT000029825	NCT00002982_5_T0	COMPOUND	8	8	ifosfamide
NCT000029825	NCT00002982_5_T1	COMPOUND	11	11	etoposide
NCT000029825	NCT00002982_5_T2	GENE	12	12	ICE
NCT000029827	NCT00002982_7_T0	COMPOUND	2	2	etoposide
NCT000029827	NCT00002982_7_T1	GENE	3	3	IV
NCT000029828	NCT00002982_8_T0	COMPOUND	2	2	ifosfamide
NCT000029828	NCT00002982_8_T1	GENE	8	8	IV
NCT000029829	NCT00002982_9_T0	GENE	9	9	SC
NCT000029829	NCT00002982_9_T1	GENE	25	25	ANC
NCT000029829	NCT00002982_9_T2	GENE	7	7	filgrastim
NCT000029829	NCT00002982_9_T3	GENE	8	8	G-CSF
NCT000029829	NCT00002982_9_T4	CELL	23	23	neutrophil
NCT0000298211	NCT00002982_11_T0	GENE	6	6	SC
NCT0000298211	NCT00002982_11_T1	GENE	3	3	G-CSF
NCT0000298212	NCT00002982_12_T0	CELL	11	12	stem cells
NCT0000298212	NCT00002982_12_T1	ORGAN	1	2	bone marrow
NCT0000298213	NCT00002982_13_T0	COMPOUND	26	26	cytarabine
NCT0000298213	NCT00002982_13_T1	COMPOUND	28	28	melphalan
NCT0000298213	NCT00002982_13_T2	COMPOUND	25	25	etoposide
NCT0000298213	NCT00002982_13_T3	PHENOTYPE	2	3	residual disease
NCT0000298214	NCT00002982_14_T0	GENE	3	3	IV
NCT0000298215	NCT00002982_15_T0	COMPOUND	2	2	cytarabine
NCT0000298215	NCT00002982_15_T1	COMPOUND	13	13	3
NCT0000298215	NCT00002982_15_T2	GENE	5	5	IV
NCT0000298216	NCT00002982_16_T0	COMPOUND	6	6	2
NCT0000298216	NCT00002982_16_T1	GENE	3	3	IV
NCT0000298217	NCT00002982_17_T0	GENE	15	15	ANC
NCT0000298217	NCT00002982_17_T1	GENE	0	0	G-CSF
NCT0000298218	NCT00002982_18_T0	GENE	17	17	SC
NCT0000298218	NCT00002982_18_T1	GENE	1	1	ANC
NCT0000298218	NCT00002982_18_T2	GENE	16	16	filgrastim
NCT0000298218	NCT00002982_18_T3	ORGAN	11	12	bone marrow
NCT000029841	NCT00002984_1_T0	CELL	8	8	cells
NCT000029841	NCT00002984_1_T1	PHENOTYPE	7	7	tumor
NCT000029842	NCT00002984_2_T0	CELL	15	15	cells
NCT000029842	NCT00002984_2_T1	PHENOTYPE	14	14	tumor
NCT000029843	NCT00002984_3_T0	PHENOTYPE	20	21	metastatic cancer
NCT000029843	NCT00002984_3_T1	PHENOTYPE	21	24	cancer of the esophagus
NCT000029845	NCT00002984_5_T0	COMPOUND	7	7	paclitaxel
NCT000029845	NCT00002984_5_T1	GENE	8	8	TAX
NCT000029845	NCT00002984_5_T2	GENE	5	5	MTD
NCT000029845	NCT00002984_5_T3	COMPOUND	19	19	cisplatin
NCT000029847	NCT00002984_7_T0	PHENOTYPE	2	2	toxicity
NCT000029847	NCT00002984_7_T1	GENE	5	5	TAX
NCT000029849	NCT00002984_9_T0	PHENOTYPE	36	36	recurrence
NCT000029849	NCT00002984_9_T1	GENE	5	5	TAX
NCT000029849	NCT00002984_9_T2	PHENOTYPE	21	22	esophageal cancer
NCT0000298410	NCT00002984_10_T0	PHENOTYPE	6	6	tumor
NCT0000298410	NCT00002984_10_T1	GENE	8	8	nodal
NCT0000298411	NCT00002984_11_T0	GENE	22	22	CI
NCT0000298411	NCT00002984_11_T1	GENE	53	53	CI
NCT0000298411	NCT00002984_11_T2	COMPOUND	5	5	cisplatin
NCT0000298412	NCT00002984_12_T0	PHENOTYPE	33	33	toxicity
NCT0000298412	NCT00002984_12_T1	COMPOUND	3	3	paclitaxel
NCT0000298412	NCT00002984_12_T2	GENE	4	4	TAX
NCT0000298413	NCT00002984_13_T0	GENE	0	0	TAX
NCT0000298414	NCT00002984_14_T0	PHENOTYPE	20	20	toxicity
NCT0000298414	NCT00002984_14_T1	GENE	3	3	TAX
NCT0000298414	NCT00002984_14_T2	GENE	1	1	MTD
NCT0000298414	NCT00002984_14_T3	PHENOTYPE	18	18	experiences
NCT0000298415	NCT00002984_15_T0	GENE	4	4	2.8
NCT0000298415	NCT00002984_15_T1	PHENOTYPE	30	31	metastatic disease
NCT0000298415	NCT00002984_15_T2	PHENOTYPE	16	17	disease progression
NCT0000298417	NCT00002984_17_T0	GENE	13	13	TAX
NCT0000298417	NCT00002984_17_T1	GENE	26	26	TAX
NCT0000298418	NCT00002984_18_T0	GENE	19	19	II
NCT0000298419	NCT00002984_19_T0	GENE	6	6	3.4
NCT000029851	NCT00002985_1_T0	COMPOUND	6	6	doxorubicin
NCT000029851	NCT00002985_1_T1	COMPOUND	11	11	daunorubicin
NCT000029851	NCT00002985_1_T2	PHENOTYPE	14	15	Kaposi's sarcoma
NCT000029852	NCT00002985_2_T0	GENE	4	4	III
NCT000029852	NCT00002985_2_T1	COMPOUND	9	9	doxorubicin
NCT000029852	NCT00002985_2_T2	COMPOUND	14	14	daunorubicin
NCT000029852	NCT00002985_2_T3	PHENOTYPE	21	22	Kaposi's sarcoma
NCT000029854	NCT00002985_4_T0	COMPOUND	6	6	HCl
NCT000029854	NCT00002985_4_T1	COMPOUND	5	5	doxorubicin
NCT000029854	NCT00002985_4_T2	PHENOTYPE	18	19	Kaposi's sarcoma
NCT000029856	NCT00002985_6_T0	PHENOTYPE	1	1	tumor
NCT0000298510	NCT00002985_10_T0	COMPOUND	7	7	HCl
NCT0000298510	NCT00002985_10_T1	GENE	15	15	3-1
NCT0000298510	NCT00002985_10_T2	COMPOUND	6	6	doxorubicin
NCT0000298510	NCT00002985_10_T3	COMPOUND	11	11	daunorubicin
NCT000029861	NCT00002986_1_T0	PHENOTYPE	15	15	recurrent
NCT000029861	NCT00002986_1_T1	COMPOUND	9	9	topotecan
NCT000029861	NCT00002986_1_T2	PHENOTYPE	17	18	malignant glioma
NCT000029865	NCT00002986_5_T0	PHENOTYPE	5	5	toxic
NCT000029865	NCT00002986_5_T1	PHENOTYPE	8	9	disease progression
NCT000029866	NCT00002986_6_T0	COMPOUND	16	16	topotecan
NCT000029867	NCT00002986_7_T0	PHENOTYPE	21	21	toxicity
NCT000029867	NCT00002986_7_T1	GENE	22	22	DLT
NCT000029867	NCT00002986_7_T2	GENE	36	36	DLT
NCT000029867	NCT00002986_7_T3	COMPOUND	11	11	topotecan
NCT000029868	NCT00002986_8_T0	GENE	1	1	MTD
NCT000029868	NCT00002986_8_T1	GENE	8	8	DLT
NCT000029871	NCT00002987_1_T0	CELL	9	9	cells
NCT000029871	NCT00002987_1_T1	PHENOTYPE	8	8	tumor
NCT000029872	NCT00002987_2_T0	GENE	3	3	III
NCT000029872	NCT00002987_2_T1	PHENOTYPE	24	25	Hodgkin's disease
NCT000029874	NCT00002987_4_T0	PHENOTYPE	2	2	recurrence
NCT000029874	NCT00002987_4_T1	PHENOTYPE	13	14	Hodgkin's disease
NCT000029876	NCT00002987_6_T0	COMPOUND	7	7	bleomycin
NCT000029877	NCT00002987_7_T0	COMPOUND	33	33	bleomycin
NCT000029877	NCT00002987_7_T1	COMPOUND	5	5	prednisolone
NCT000029877	NCT00002987_7_T2	COMPOUND	31	31	vincristine
NCT000029877	NCT00002987_7_T3	GENE	9	9	1/6
NCT000029877	NCT00002987_7_T4	COMPOUND	14	14	cyclophosphamide
NCT000029877	NCT00002987_7_T5	COMPOUND	22	22	etoposide
NCT000029877	NCT00002987_7_T6	COMPOUND	10	10	doxorubicin
NCT000029877	NCT00002987_7_T7	COMPOUND	19	19	doxorubicin
NCT000029877	NCT00002987_7_T8	GENE	11	11	IV
NCT000029877	NCT00002987_7_T9	GENE	15	15	IV
NCT000029877	NCT00002987_7_T10	GENE	20	20	IV
NCT000029877	NCT00002987_7_T11	GENE	34	34	IV
NCT0000298711	NCT00002987_11_T0	GENE	8	8	4.5
NCT000029881	NCT00002988_1_T0	COMPOUND	9	9	irinotecan
NCT000029881	NCT00002988_1_T1	PHENOTYPE	17	17	recurrent
NCT000029881	NCT00002988_1_T2	PHENOTYPE	19	20	malignant glioma
NCT000029883	NCT00002988_3_T0	COMPOUND	6	6	irinotecan
NCT000029883	NCT00002988_3_T1	PHENOTYPE	19	19	recurrent
NCT000029883	NCT00002988_3_T2	PHENOTYPE	21	22	malignant glioma
NCT000029885	NCT00002988_5_T0	PHENOTYPE	2	2	toxic
NCT000029885	NCT00002988_5_T1	COMPOUND	5	5	irinotecan
NCT000029886	NCT00002988_6_T0	COMPOUND	8	8	irinotecan
NCT000029887	NCT00002988_7_T0	COMPOUND	2	2	irinotecan
NCT000029887	NCT00002988_7_T1	GENE	10	10	1.4
NCT000029887	NCT00002988_7_T2	GENE	19	19	1/6
NCT000029887	NCT00002988_7_T3	GENE	3	3	IV
NCT000029887	NCT00002988_7_T4	GENE	13	13	IV
NCT000029888	NCT00002988_8_T0	PHENOTYPE	10	10	toxicity
NCT000029888	NCT00002988_8_T1	PHENOTYPE	6	7	disease progression
NCT000029889	NCT00002988_9_T0	COMPOUND	8	8	irinotecan
NCT000029889	NCT00002988_9_T1	GENE	14	14	MTD
NCT0000298810	NCT00002988_10_T0	PHENOTYPE	19	19	toxicities
NCT0000298810	NCT00002988_10_T1	GENE	1	1	MTD
NCT0000298810	NCT00002988_10_T2	PHENOTYPE	16	16	experiences
NCT000029896	NCT00002989_6_T0	BIOLOGICAL_PROCESS	8	8	PMN
NCT000029896	NCT00002989_6_T1	CELL	7	7	leukocyte
NCT000029896	NCT00002989_6_T2	CELL	10	10	platelet
NCT000029896	NCT00002989_6_T3	CELL	6	6	neutrophil
NCT000029898	NCT00002989_8_T0	PHENOTYPE	8	8	toxicity
NCT000029898	NCT00002989_8_T1	PHENOTYPE	10	10	mucositis
NCT000029898	NCT00002989_8_T2	GENE	7	7	3.4
NCT000029898	NCT00002989_8_T3	PHENOTYPE	17	17	fever
NCT0000298910	NCT00002989_10_T0	PHENOTYPE	4	4	acute
NCT0000298910	NCT00002989_10_T1	PHENOTYPE	11	11	GVHD
NCT0000298910	NCT00002989_10_T2	PHENOTYPE	6	10	chronic graft versus host disease
NCT0000298918	NCT00002989_18_T0	COMPOUND	10	10	melphalan
NCT0000298918	NCT00002989_18_T1	GENE	0	0	IDA
NCT0000298918	NCT00002989_18_T2	GENE	11	11	IV
NCT0000298919	NCT00002989_19_T0	CELL	0	1	Stem cells
NCT000029901	NCT00002990_1_T0	GENE	12	12	BCG
NCT000029901	NCT00002990_1_T1	GENE	4	4	III
NCT000029901	NCT00002990_1_T2	PHENOTYPE	27	28	bladder cancer
NCT000029908	NCT00002990_8_T0	GENE	6	6	BCG
NCT000029931	NCT00002993_1_T0	CELL	9	9	cells
NCT000029931	NCT00002993_1_T1	PHENOTYPE	8	8	tumor
NCT000029937	NCT00002993_7_T0	COMPOUND	4	4	doxorubicin
NCT000029937	NCT00002993_7_T1	COMPOUND	7	7	cisplatin
NCT000029937	NCT00002993_7_T2	GENE	3	3	IV
NCT000029940	NCT00002994_0_T0	GENE	0	0	Interleukin-2
NCT000029940	NCT00002994_0_T1	PHENOTYPE	9	10	Solid Tumors
NCT000029943	NCT00002994_3_T0	GENE	8	8	interleukin-2
NCT000029943	NCT00002994_3_T1	PHENOTYPE	17	18	solid tumors
NCT000029945	NCT00002994_5_T0	PHENOTYPE	2	2	toxic
NCT000029945	NCT00002994_5_T1	GENE	14	14	interleukin-2
NCT000029945	NCT00002994_5_T2	GENE	15	15	IL-2
NCT000029945	NCT00002994_5_T3	GENE	6	6	HER2
NCT000029945	NCT00002994_5_T4	PHENOTYPE	19	20	solid tumors
NCT000029949	NCT00002994_9_T0	CELL	3	3	cells
NCT000029949	NCT00002994_9_T1	GENE	19	19	IL-2
NCT0000299413	NCT00002994_13_T0	PHENOTYPE	36	36	toxicity
NCT0000299413	NCT00002994_13_T1	GENE	49	49	interleukin-2
NCT0000299413	NCT00002994_13_T2	GENE	50	50	IL-2
NCT0000299413	NCT00002994_13_T3	GENE	37	37	DLT
NCT0000299414	NCT00002994_14_T0	GENE	16	16	midway
NCT0000299414	NCT00002994_14_T1	GENE	6	6	DLT
NCT0000299416	NCT00002994_16_T0	GENE	5	5	IL-2
NCT0000299416	NCT00002994_16_T1	GENE	11	11	1.7
NCT0000299416	NCT00002994_16_T2	GENE	17	17	IV
NCT0000299416	NCT00002994_16_T3	GENE	14	14	HER-2
NCT0000299417	NCT00002994_17_T0	GENE	5	5	IL-2
NCT0000299417	NCT00002994_17_T1	GENE	13	13	IL-2
NCT0000299418	NCT00002994_18_T0	GENE	17	17	IL-2
NCT0000299418	NCT00002994_18_T1	GENE	26	26	IL-2
NCT0000299418	NCT00002994_18_T2	GENE	30	30	1.3
NCT0000299418	NCT00002994_18_T3	GENE	10	10	HER2
NCT0000299418	NCT00002994_18_T4	GENE	13	13	IV
NCT0000299419	NCT00002994_19_T0	GENE	4	4	IL-2
NCT0000299421	NCT00002994_21_T0	PHENOTYPE	12	12	progression
NCT000029951	NCT00002995_1_T0	CELL	8	8	cells
NCT000029951	NCT00002995_1_T1	PHENOTYPE	7	7	tumor
NCT000029952	NCT00002995_2_T0	PHENOTYPE	20	20	rhabdomyosarcoma
NCT000029953	NCT00002995_3_T0	GENE	2	2	III
NCT000029953	NCT00002995_3_T1	PHENOTYPE	21	21	rhabdomyosarcoma
NCT000029958	NCT00002995_8_T0	GENE	9	9	filgrastim
NCT000029958	NCT00002995_8_T1	COMPOUND	3	3	cyclophosphamide
NCT000029958	NCT00002995_8_T2	GENE	10	10	G-CSF
NCT000029958	NCT00002995_8_T3	GENE	13	13	GM-CSF
NCT000029958	NCT00002995_8_T4	GENE	4	4	IV
NCT000029958	NCT00002995_8_T5	GENE	12	12	sargramostim
NCT000029959	NCT00002995_9_T0	GENE	5	5	3.8
NCT000029959	NCT00002995_9_T1	GENE	14	15	group I
NCT0000299510	NCT00002995_10_T0	GENE	4	4	3.4
NCT0000299511	NCT00002995_11_T0	GENE	8	9	group I
NCT000029964	NCT00002996_4_T0	COMPOUND	6	6	flecainide
NCT000029965	NCT00002996_5_T0	COMPOUND	3	3	flecainide
NCT000029971	NCT00002997_1_T0	GENE	2	2	II
NCT000029971	NCT00002997_1_T1	PHENOTYPE	17	18	colorectal cancer
NCT000029971	NCT00002997_1_T2	PHENOTYPE	14	15	liver metastases
NCT000029973	NCT00002997_3_T0	PHENOTYPE	12	13	liver metastases
NCT000029975	NCT00002997_5_T0	PHENOTYPE	8	9	liver metastases
NCT000029977	NCT00002997_7_T0	ORGAN	12	12	liver
NCT000029977	NCT00002997_7_T1	PHENOTYPE	6	7	liver metastases
NCT000029979	NCT00002997_9_T0	PHENOTYPE	11	11	metastases
NCT0000299710	NCT00002997_10_T0	ORGAN	14	14	liver
NCT0000299710	NCT00002997_10_T1	GENE	6	6	portal
NCT0000299710	NCT00002997_10_T2	TISSUE	7	8	lymph node
NCT0000299712	NCT00002997_12_T0	PHENOTYPE	16	16	metastases
NCT0000299712	NCT00002997_12_T1	PHENOTYPE	9	10	metastatic tumor
NCT0000299713	NCT00002997_13_T0	PHENOTYPE	16	17	liver metastases
NCT0000299716	NCT00002997_16_T0	ORGAN	3	3	liver
NCT0000299716	NCT00002997_16_T1	ORGAN	20	20	liver
NCT0000299716	NCT00002997_16_T2	PHENOTYPE	16	17	disease progression
NCT0000299720	NCT00002997_20_T0	GENE	20	20	stops
NCT000029981	NCT00002998_1_T0	CELL	9	9	cells
NCT000029981	NCT00002998_1_T1	PHENOTYPE	8	8	tumor
NCT000029982	NCT00002998_2_T0	GENE	2	2	II
NCT000029982	NCT00002998_2_T1	COMPOUND	9	9	gemcitabine
NCT000029982	NCT00002998_2_T2	GENE	20	20	has
NCT000029982	NCT00002998_2_T3	COMPOUND	11	11	cisplatin
NCT000029982	NCT00002998_2_T4	PHENOTYPE	16	18	metastatic breast cancer
NCT000029984	NCT00002998_4_T0	COMPOUND	5	5	gemcitabine
NCT000029984	NCT00002998_4_T1	COMPOUND	7	7	cisplatin
NCT000029984	NCT00002998_4_T2	PHENOTYPE	12	14	metastatic breast cancer
NCT000029986	NCT00002998_6_T0	PHENOTYPE	3	3	progression
NCT000029988	NCT00002998_8_T0	PHENOTYPE	3	3	toxicity
NCT0000299810	NCT00002998_10_T0	COMPOUND	2	2	gemcitabine
NCT0000299810	NCT00002998_10_T1	COMPOUND	8	8	cisplatin
NCT0000299810	NCT00002998_10_T2	GENE	3	3	IV
NCT0000299810	NCT00002998_10_T3	GENE	9	9	IV
NCT0000299812	NCT00002998_12_T0	PHENOTYPE	10	10	toxicities
NCT0000299812	NCT00002998_12_T1	PHENOTYPE	6	7	disease progression
NCT000029992	NCT00002999_2_T0	CELL	8	8	cells
NCT000029992	NCT00002999_2_T1	PHENOTYPE	7	7	tumor
NCT000029993	NCT00002999_3_T0	CELL	15	15	cells
NCT000029993	NCT00002999_3_T1	PHENOTYPE	14	14	tumor
NCT000029998	NCT00002999_8_T0	PHENOTYPE	8	8	tumor
NCT0000299910	NCT00002999_10_T0	PHENOTYPE	4	4	toxicities
NCT0000299913	NCT00002999_13_T0	COMPOUND	3	3	cisplatin
NCT0000299917	NCT00002999_17_T0	COMPOUND	5	5	cisplatin
NCT000030007	NCT00003000_7_T0	GENE	8	8	NS
NCT000030007	NCT00003000_7_T1	COMPOUND	3	3	morphine
NCT000030007	NCT00003000_7_T2	GENE	0	1	Group 1
NCT000030009	NCT00003000_9_T0	GENE	5	5	NS
NCT0000300010	NCT00003000_10_T0	GENE	7	7	deltoid
NCT0000300010	NCT00003000_10_T1	COMPOUND	3	3	morphine
NCT0000300011	NCT00003000_11_T0	PHENOTYPE	5	5	analgesia
NCT0000300011	NCT00003000_11_T1	PHENOTYPE	10	10	analgesia
NCT0000300011	NCT00003000_11_T2	COMPOUND	4	4	fentanyl
NCT0000300011	NCT00003000_11_T3	GENE	3	3	IV
NCT0000300012	NCT00003000_12_T0	COMPOUND	4	4	fentanyl
NCT0000300012	NCT00003000_12_T1	GENE	3	3	IV
NCT000030011	NCT00003001_1_T0	CELL	9	9	cells
NCT000030011	NCT00003001_1_T1	PHENOTYPE	8	8	tumor
NCT000030012	NCT00003001_2_T0	COMPOUND	16	16	gemcitabine
NCT000030012	NCT00003001_2_T1	COMPOUND	14	14	leucovorin
NCT000030012	NCT00003001_2_T2	PHENOTYPE	21	21	recurrent
NCT000030012	NCT00003001_2_T3	PHENOTYPE	23	25	metastatic colorectal cancer
NCT000030014	NCT00003001_4_T0	COMPOUND	19	19	calcium
NCT000030014	NCT00003001_4_T1	COMPOUND	21	21	gemcitabine
NCT000030014	NCT00003001_4_T2	COMPOUND	18	18	leucovorin
NCT000030014	NCT00003001_4_T3	PHENOTYPE	9	9	recurrent
NCT000030014	NCT00003001_4_T4	PHENOTYPE	12	13	colorectal carcinoma
NCT000030016	NCT00003001_6_T0	COMPOUND	10	10	calcium
NCT000030016	NCT00003001_6_T1	COMPOUND	12	12	gemcitabine
NCT000030016	NCT00003001_6_T2	COMPOUND	9	9	leucovorin
NCT000030016	NCT00003001_6_T3	PHENOTYPE	4	5	toxic effect
NCT000030018	NCT00003001_8_T0	COMPOUND	4	4	calcium
NCT000030018	NCT00003001_8_T1	COMPOUND	16	16	gemcitabine
NCT000030018	NCT00003001_8_T2	COMPOUND	3	3	leucovorin
NCT000030019	NCT00003001_9_T0	GENE	17	17	3.4
NCT000030019	NCT00003001_9_T1	PHENOTYPE	18	18	toxicities
NCT000030019	NCT00003001_9_T2	COMPOUND	3	3	gemcitabine
NCT0000300110	NCT00003001_10_T0	GENE	1	1	II
NCT0000300110	NCT00003001_10_T1	GENE	19	19	3.4
NCT0000300110	NCT00003001_10_T2	PHENOTYPE	20	20	toxicities
NCT0000300112	NCT00003001_12_T0	PHENOTYPE	7	7	remission
NCT0000300113	NCT00003001_13_T0	PHENOTYPE	6	6	toxic
NCT0000300113	NCT00003001_13_T1	PHENOTYPE	2	3	disease progression
NCT000030022	NCT00003002_2_T0	PHENOTYPE	16	16	peripheral
NCT000030022	NCT00003002_2_T1	CELL	10	10	cells
NCT000030022	NCT00003002_2_T2	GENE	4	4	GM-CSF
NCT000030022	NCT00003002_2_T3	ORGAN	13	14	bone marrow
NCT0000300212	NCT00003002_12_T0	GENE	14	14	GM-CSF
NCT0000300212	NCT00003002_12_T1	GENE	6	6	HER-2/neu
NCT0000300212	NCT00003002_12_T2	GENE	13	13	sargramostim
NCT0000300214	NCT00003002_14_T0	PHENOTYPE	17	17	toxicity
NCT000030031	NCT00003003_1_T0	PHENOTYPE	1	1	cancers
NCT000030031	NCT00003003_1_T1	PHENOTYPE	3	3	resistant
NCT000030032	NCT00003003_2_T0	CELL	16	16	cells
NCT000030035	NCT00003003_5_T0	PHENOTYPE	22	22	leukemia
NCT000030035	NCT00003003_5_T1	CELL	23	23	cells
NCT000030035	NCT00003003_5_T2	COMPOUND	4	5	mitomycin C
NCT000030035	NCT00003003_5_T3	PHENOTYPE	28	30	acute myelogenous leukemia
NCT000030037	NCT00003003_7_T0	COMPOUND	20	20	mitoxantrone
NCT000030037	NCT00003003_7_T1	GENE	28	28	GM-CSF
NCT000030037	NCT00003003_7_T2	COMPOUND	9	10	mitomycin C
NCT000030037	NCT00003003_7_T3	PHENOTYPE	24	26	acute myelogenous leukemia
NCT000030039	NCT00003003_9_T0	PHENOTYPE	2	2	toxicity
NCT000030039	NCT00003003_9_T1	COMPOUND	13	13	mitoxantrone
NCT000030039	NCT00003003_9_T2	COMPOUND	10	11	mitomycin C
NCT0000300311	NCT00003003_11_T0	PHENOTYPE	14	14	resistant
NCT0000300311	NCT00003003_11_T1	PHENOTYPE	17	19	acute myelogenous leukemia
NCT0000300312	NCT00003003_12_T0	GENE	6	6	IV
NCT0000300312	NCT00003003_12_T1	COMPOUND	3	4	mitomycin C
NCT0000300313	NCT00003003_13_T0	COMPOUND	2	2	mitoxantrone
NCT0000300315	NCT00003003_15_T0	COMPOUND	3	3	mitoxantrone
NCT0000300315	NCT00003003_15_T1	PHENOTYPE	9	9	toxicity
NCT0000300316	NCT00003003_16_T0	PHENOTYPE	4	4	toxicity
NCT0000300316	NCT00003003_16_T1	PHENOTYPE	3	3	experiences
NCT0000300318	NCT00003003_18_T0	PHENOTYPE	5	5	toxicity
NCT0000300319	NCT00003003_19_T0	PHENOTYPE	7	7	toxicity
NCT0000300319	NCT00003003_19_T1	PHENOTYPE	6	6	experiences
NCT0000300320	NCT00003003_20_T0	PHENOTYPE	7	7	toxicity
NCT0000300320	NCT00003003_20_T1	PHENOTYPE	15	15	toxicity
NCT0000300320	NCT00003003_20_T2	GENE	14	14	has
NCT0000300320	NCT00003003_20_T3	PHENOTYPE	6	6	experiences
NCT0000300321	NCT00003003_21_T0	PHENOTYPE	5	5	toxicities
NCT0000300322	NCT00003003_22_T0	PHENOTYPE	10	10	toxicities
NCT0000300323	NCT00003003_23_T0	PHENOTYPE	21	21	leukemia
NCT0000300323	NCT00003003_23_T1	GENE	27	27	ANC
NCT0000300323	NCT00003003_23_T2	GENE	8	8	GM-CSF
NCT0000300323	NCT00003003_23_T3	GENE	22	22	GM-CSF
NCT0000300323	NCT00003003_23_T4	GENE	7	7	sargramostim
NCT0000300323	NCT00003003_23_T5	ORGAN	15	16	bone marrow
NCT0000300324	NCT00003003_24_T0	COMPOUND	7	8	mitomycin C
NCT0000300325	NCT00003003_25_T0	COMPOUND	9	9	mitoxantrone
NCT0000300325	NCT00003003_25_T1	COMPOUND	6	7	mitomycin C
NCT000030040	NCT00003004_0_T0	PHENOTYPE	8	8	Recurrent
NCT000030040	NCT00003004_0_T1	PHENOTYPE	9	10	Solid Tumors
NCT000030042	NCT00003004_2_T0	CELL	9	9	cells
NCT000030042	NCT00003004_2_T1	PHENOTYPE	8	8	tumor
NCT000030043	NCT00003004_3_T0	COMPOUND	12	12	paclitaxel
NCT000030043	NCT00003004_3_T1	COMPOUND	14	14	cisplatin
NCT000030043	NCT00003004_3_T2	PHENOTYPE	24	24	recurrent
NCT000030043	NCT00003004_3_T3	COMPOUND	16	16	flavopiridol
NCT000030043	NCT00003004_3_T4	PHENOTYPE	25	26	solid tumors
NCT000030045	NCT00003004_5_T0	COMPOUND	12	12	paclitaxel
NCT000030045	NCT00003004_5_T1	COMPOUND	14	14	cisplatin
NCT000030045	NCT00003004_5_T2	COMPOUND	6	6	flavopiridol
NCT000030045	NCT00003004_5_T3	PHENOTYPE	20	21	solid tumors
NCT000030047	NCT00003004_7_T0	COMPOUND	12	12	paclitaxel
NCT000030047	NCT00003004_7_T1	PHENOTYPE	3	3	pharmacokinetics
NCT000030047	NCT00003004_7_T2	COMPOUND	6	6	flavopiridol
NCT000030049	NCT00003004_9_T0	COMPOUND	14	14	paclitaxel
NCT000030049	NCT00003004_9_T1	COMPOUND	8	8	flavopiridol
NCT0000300413	NCT00003004_13_T0	COMPOUND	2	2	paclitaxel
NCT0000300413	NCT00003004_13_T1	GENE	3	3	IV
NCT0000300414	NCT00003004_14_T0	COMPOUND	5	5	cisplatin
NCT0000300414	NCT00003004_14_T1	GENE	6	6	IV
NCT0000300414	NCT00003004_14_T2	COMPOUND	17	17	flavopiridol
NCT0000300415	NCT00003004_15_T0	PHENOTYPE	14	14	toxicity
NCT0000300415	NCT00003004_15_T1	PHENOTYPE	10	11	disease progression
NCT0000300416	NCT00003004_16_T0	COMPOUND	12	12	cisplatin
NCT0000300416	NCT00003004_16_T1	COMPOUND	4	4	flavopiridol
NCT0000300417	NCT00003004_17_T0	GENE	14	14	MTD
NCT0000300418	NCT00003004_18_T0	PHENOTYPE	18	18	toxicity
NCT0000300418	NCT00003004_18_T1	GENE	1	1	MTD
NCT000030051	NCT00003005_1_T0	CELL	9	9	cells
NCT000030051	NCT00003005_1_T1	PHENOTYPE	8	8	tumor
NCT000030052	NCT00003005_2_T0	PHENOTYPE	20	20	acute
NCT000030052	NCT00003005_2_T1	COMPOUND	14	14	pentostatin
NCT000030052	NCT00003005_2_T2	COMPOUND	12	12	cordycepin
NCT000030052	NCT00003005_2_T3	PHENOTYPE	23	25	chronic myelogenous leukemia
NCT000030055	NCT00003005_5_T0	PHENOTYPE	31	31	leukemia
NCT000030055	NCT00003005_5_T1	GENE	29	29	TdT
NCT000030055	NCT00003005_5_T2	PHENOTYPE	9	9	toxicities
NCT000030055	NCT00003005_5_T3	COMPOUND	24	24	pentostatin
NCT000030055	NCT00003005_5_T4	COMPOUND	11	11	cordycepin
NCT000030055	NCT00003005_5_T5	PHENOTYPE	6	7	adverse effects
NCT000030055	NCT00003005_5_T6	COMPOUND	21	23	adenosine deaminase inhibitor
NCT000030057	NCT00003005_7_T0	COMPOUND	17	17	pentostatin
NCT000030057	NCT00003005_7_T1	PHENOTYPE	6	6	pharmacokinetics
NCT000030057	NCT00003005_7_T2	COMPOUND	8	8	cordycepin
NCT0000300511	NCT00003005_11_T0	PHENOTYPE	10	10	leukemia
NCT0000300511	NCT00003005_11_T1	GENE	8	8	TdT
NCT0000300514	NCT00003005_14_T0	COMPOUND	3	3	pentostatin
NCT0000300514	NCT00003005_14_T1	GENE	2	2	1.3
NCT0000300514	NCT00003005_14_T2	GENE	10	10	IV
NCT0000300514	NCT00003005_14_T3	GENE	24	24	IV
NCT0000300514	NCT00003005_14_T4	COMPOUND	23	23	cordycepin
NCT0000300515	NCT00003005_15_T0	COMPOUND	4	4	pentostatin
NCT0000300515	NCT00003005_15_T1	PHENOTYPE	20	20	inhibition
NCT0000300515	NCT00003005_15_T2	COMPOUND	12	12	cordycepin
NCT0000300515	NCT00003005_15_T3	GENE	18	19	adenosine deaminase
NCT0000300516	NCT00003005_16_T0	COMPOUND	24	24	pentostatin
NCT0000300516	NCT00003005_16_T1	GENE	18	18	MTD
NCT0000300516	NCT00003005_16_T2	COMPOUND	9	9	cordycepin
NCT0000300517	NCT00003005_17_T0	PHENOTYPE	13	13	toxicity
NCT0000300517	NCT00003005_17_T1	PHENOTYPE	19	19	toxicity
NCT0000300517	NCT00003005_17_T2	PHENOTYPE	16	16	severity
NCT0000300517	NCT00003005_17_T3	GENE	1	1	MTD
NCT000030064	NCT00003006_4_T0	PHENOTYPE	15	16	primary tumor
NCT000030064	NCT00003006_4_T1	ORGAN	13	14	bone marrow
NCT000030064	NCT00003006_4_T2	PHENOTYPE	18	20	intrathoracic lymph nodes
NCT000030065	NCT00003006_5_T0	PHENOTYPE	4	4	metastases
NCT000030065	NCT00003006_5_T1	TISSUE	9	10	lymph nodes
NCT000030065	NCT00003006_5_T2	ORGAN	6	7	bone marrow
NCT000030075	NCT00003007_5_T0	COMPOUND	10	10	melphalan
NCT000030075	NCT00003007_5_T1	PHENOTYPE	16	17	multiple myeloma
NCT000030075	NCT00003007_5_T2	COMPOUND	4	5	interferon alfa_2b
NCT000030077	NCT00003007_7_T0	COMPOUND	7	7	dexamethasone
NCT000030077	NCT00003007_7_T1	PHENOTYPE	17	18	multiple myeloma
NCT000030078	NCT00003007_8_T0	COMPOUND	5	5	dexamethasone
NCT000030078	NCT00003007_8_T1	GENE	8	8	1.4
NCT0000300711	NCT00003007_11_T0	COMPOUND	5	5	melphalan
NCT0000300715	NCT00003007_15_T0	PHENOTYPE	3	3	remission
NCT0000300716	NCT00003007_16_T0	PHENOTYPE	7	7	toxicity
NCT0000300716	NCT00003007_16_T1	CELL	13	13	neutrophil
NCT000030081	NCT00003008_1_T0	GENE	2	2	II
NCT000030081	NCT00003008_1_T1	COMPOUND	9	9	paclitaxel
NCT000030081	NCT00003008_1_T2	PHENOTYPE	15	16	Kaposi's sarcoma
NCT000030083	NCT00003008_3_T0	COMPOUND	13	13	paclitaxel
NCT000030083	NCT00003008_3_T1	COMPOUND	19	19	doxorubicin
NCT000030083	NCT00003008_3_T2	COMPOUND	21	21	daunorubicin
NCT000030083	NCT00003008_3_T3	GENE	6	7	protease inhibitor
NCT000030084	NCT00003008_4_T0	COMPOUND	2	2	paclitaxel
NCT000030084	NCT00003008_4_T1	GENE	3	3	IV
NCT000030085	NCT00003008_5_T0	PHENOTYPE	18	18	toxicity
NCT000030085	NCT00003008_5_T1	PHENOTYPE	14	15	disease progression
NCT000030086	NCT00003008_6_T0	COMPOUND	4	4	paclitaxel
NCT000030091	NCT00003009_1_T0	CELL	9	9	cells
NCT000030091	NCT00003009_1_T1	GENE	1	1	interleukin-2
NCT000030092	NCT00003009_2_T0	GENE	10	10	interleukin-2
NCT000030094	NCT00003009_4_T0	GENE	8	8	interleukin-2
NCT000030094	NCT00003009_4_T1	GENE	9	9	IL-2
NCT000030094	NCT00003009_4_T2	PHENOTYPE	4	4	tolerance
NCT000030096	NCT00003009_6_T0	CELL	13	13	cells
NCT000030096	NCT00003009_6_T1	GENE	4	4	IL-2
NCT000030096	NCT00003009_6_T2	GENE	18	18	IL-2
NCT0000300911	NCT00003009_11_T0	PHENOTYPE	34	34	toxicity
NCT0000300912	NCT00003009_12_T0	GENE	1	1	stops
NCT0000300912	NCT00003009_12_T1	GENE	6	6	MTD
NCT0000300915	NCT00003009_15_T0	PHENOTYPE	20	20	toxicity
NCT0000300915	NCT00003009_15_T1	PHENOTYPE	16	17	progressive disease
NCT000030100	NCT00003010_0_T0	GENE	13	13	Is
NCT000030100	NCT00003010_0_T1	PHENOTYPE	9	11	Metastatic Breast Cancer
NCT000030102	NCT00003010_2_T0	COMPOUND	12	12	marimastat
NCT000030102	NCT00003010_2_T1	PHENOTYPE	14	15	breast cancer
NCT000030103	NCT00003010_3_T0	COMPOUND	11	11	marimastat
NCT000030103	NCT00003010_3_T1	GENE	4	4	III
NCT000030103	NCT00003010_3_T2	PHENOTYPE	23	25	metastatic breast cancer
NCT000030105	NCT00003010_5_T0	COMPOUND	2	2	marimastat
NCT000030105	NCT00003010_5_T1	PHENOTYPE	9	11	metastatic breast cancer
NCT000030107	NCT00003010_7_T0	PHENOTYPE	2	2	toxic
NCT000030107	NCT00003010_7_T1	COMPOUND	5	5	marimastat
NCT000030107	NCT00003010_7_T2	PHENOTYPE	12	14	metastatic breast cancer
NCT000030109	NCT00003010_9_T0	PHENOTYPE	16	16	toxicity
NCT000030109	NCT00003010_9_T1	COMPOUND	8	8	marimastat
NCT000030109	NCT00003010_9_T2	PHENOTYPE	13	14	disease progression
NCT0000301011	NCT00003010_11_T0	PHENOTYPE	16	16	metastases
NCT0000301013	NCT00003010_13_T0	COMPOUND	3	3	marimastat
NCT0000301113	NCT00003011_13_T0	COMPOUND	5	5	marimastat
NCT0000301117	NCT00003011_17_T0	GENE	9	9	2.3
NCT000030121	NCT00003012_1_T0	PHENOTYPE	15	16	breast cancer
NCT000030122	NCT00003012_2_T0	GENE	3	3	III
NCT000030122	NCT00003012_2_T1	COMPOUND	15	15	methotrexate
NCT000030122	NCT00003012_2_T2	COMPOUND	21	21	epirubicin
NCT000030122	NCT00003012_2_T3	COMPOUND	14	14	cyclophosphamide
NCT000030122	NCT00003012_2_T4	PHENOTYPE	28	30	stage breast cancer
NCT000030124	NCT00003012_4_T0	COMPOUND	7	7	epirubicin
NCT000030124	NCT00003012_4_T1	PHENOTYPE	29	30	breast cancer
NCT000030126	NCT00003012_6_T0	PHENOTYPE	28	28	acute
NCT000030126	NCT00003012_6_T1	PHENOTYPE	31	31	toxicities
NCT000030126	NCT00003012_6_T2	COMPOUND	7	7	epirubicin
NCT000030126	NCT00003012_6_T3	PHENOTYPE	30	30	chronic
NCT000030128	NCT00003012_8_T0	COMPOUND	7	7	epirubicin
NCT000030128	NCT00003012_8_T1	PHENOTYPE	28	30	quality of life
NCT000030131	NCT00003013_1_T0	CELL	8	8	cells
NCT000030131	NCT00003013_1_T1	PHENOTYPE	7	7	tumor
NCT000030132	NCT00003013_2_T0	PHENOTYPE	12	13	breast cancer
NCT000030133	NCT00003013_3_T0	GENE	3	3	III
NCT000030133	NCT00003013_3_T1	PHENOTYPE	18	19	breast cancer
NCT000030136	NCT00003013_6_T0	GENE	15	15	receptor
NCT000030136	NCT00003013_6_T1	PHENOTYPE	5	5	tumor
NCT000030138	NCT00003013_8_T0	COMPOUND	11	11	cyclophosphamide
NCT000030138	NCT00003013_8_T1	COMPOUND	13	13	methotrexate
NCT000030138	NCT00003013_8_T2	COMPOUND	8	8	doxorubicin
NCT000030138	NCT00003013_8_T3	GENE	12	12	IV
NCT000030138	NCT00003013_8_T4	GENE	14	14	IV
NCT000030138	NCT00003013_8_T5	GENE	17	17	IV
NCT0000301310	NCT00003013_10_T0	COMPOUND	10	10	paclitaxel
NCT0000301310	NCT00003013_10_T1	COMPOUND	13	13	cyclophosphamide
NCT0000301310	NCT00003013_10_T2	COMPOUND	15	15	methotrexate
NCT0000301310	NCT00003013_10_T3	COMPOUND	8	8	doxorubicin
NCT0000301310	NCT00003013_10_T4	GENE	14	14	IV
NCT0000301310	NCT00003013_10_T5	GENE	16	16	IV
NCT0000301310	NCT00003013_10_T6	GENE	19	19	IV
NCT0000301311	NCT00003013_11_T0	PHENOTYPE	13	13	toxicity
NCT0000301311	NCT00003013_11_T1	PHENOTYPE	9	10	disease progression
NCT0000301312	NCT00003013_12_T0	TISSUE	12	13	surgical margins
NCT0000301313	NCT00003013_13_T0	TISSUE	0	1	Lymph node
NCT0000301318	NCT00003013_18_T0	ORGAN	14	15	chest wall
NCT000030141	NCT00003014_1_T0	CELL	8	8	cells
NCT000030141	NCT00003014_1_T1	PHENOTYPE	7	7	tumor
NCT000030142	NCT00003014_2_T0	PHENOTYPE	14	15	testicular cancer
NCT000030143	NCT00003014_3_T0	GENE	3	3	III
NCT000030143	NCT00003014_3_T1	PHENOTYPE	21	24	stage I testicular cancer
NCT000030145	NCT00003014_5_T0	PHENOTYPE	1	1	relapse
NCT000030145	NCT00003014_5_T1	PHENOTYPE	8	9	testicular seminoma
NCT000030147	NCT00003014_7_T0	PHENOTYPE	1	3	quality of life
NCT000030149	NCT00003014_9_T0	PHENOTYPE	2	2	acute
NCT000030149	NCT00003014_9_T1	GENE	5	5	1.2
NCT0000301411	NCT00003014_11_T0	PHENOTYPE	14	15	second malignancies
NCT0000301411	NCT00003014_11_T1	PHENOTYPE	9	10	bowel dysfunction
NCT000030150	NCT00003015_0_T0	PHENOTYPE	11	11	Glioma
NCT000030152	NCT00003015_2_T0	CELL	9	9	cells
NCT000030152	NCT00003015_2_T1	PHENOTYPE	8	8	tumor
NCT000030153	NCT00003015_3_T0	COMPOUND	12	12	vincristine
NCT000030153	NCT00003015_3_T1	GENE	3	3	III
NCT000030153	NCT00003015_3_T2	PHENOTYPE	21	21	glioma
NCT000030155	NCT00003015_5_T0	PHENOTYPE	13	13	glioma
NCT000030159	NCT00003015_9_T0	PHENOTYPE	5	5	relapse
NCT000030159	NCT00003015_9_T1	PHENOTYPE	4	4	tumor
NCT000030159	NCT00003015_9_T2	PHENOTYPE	6	6	progression
NCT0000301512	NCT00003015_12_T0	BIOLOGICAL_PROCESS	6	7	wound healing
NCT0000301512	NCT00003015_12_T1	PHENOTYPE	5	6	surgical wound
NCT0000301513	NCT00003015_13_T0	PHENOTYPE	13	13	tumor
NCT0000301515	NCT00003015_15_T0	PHENOTYPE	9	10	tumor progression
NCT0000301516	NCT00003015_16_T0	COMPOUND	12	12	1
NCT0000301517	NCT00003015_17_T0	COMPOUND	5	5	vincristine
NCT0000301517	NCT00003015_17_T1	GENE	6	6	IV
NCT0000301517	NCT00003015_17_T2	GENE	13	13	IV
NCT0000301518	NCT00003015_18_T0	COMPOUND	5	5	vincristine
NCT0000301518	NCT00003015_18_T1	GENE	6	6	IV
NCT0000301518	NCT00003015_18_T2	GENE	9	9	IV
NCT0000301519	NCT00003015_19_T0	PHENOTYPE	7	7	toxicity
NCT0000301519	NCT00003015_19_T1	PHENOTYPE	3	4	disease progression
NCT000030161	NCT00003016_1_T0	COMPOUND	13	13	estrogen
NCT000030161	NCT00003016_1_T1	COMPOUND	3	3	tamoxifen
NCT000030161	NCT00003016_1_T2	PHENOTYPE	6	7	breast cancer
NCT000030162	NCT00003016_2_T0	COMPOUND	7	7	tamoxifen
NCT000030162	NCT00003016_2_T1	COMPOUND	13	13	tamoxifen
NCT000030162	NCT00003016_2_T2	PHENOTYPE	19	20	breast cancer
NCT000030163	NCT00003016_3_T0	GENE	4	4	III
NCT000030163	NCT00003016_3_T1	GENE	37	37	had
NCT000030163	NCT00003016_3_T2	COMPOUND	9	9	tamoxifen
NCT000030163	NCT00003016_3_T3	COMPOUND	25	25	tamoxifen
NCT000030163	NCT00003016_3_T4	PHENOTYPE	39	40	breast tumor
NCT000030166	NCT00003016_6_T0	COMPOUND	6	6	tamoxifen
NCT000030166	NCT00003016_6_T1	COMPOUND	13	13	tamoxifen
NCT000030166	NCT00003016_6_T2	COMPOUND	19	19	tamoxifen
NCT000030171	NCT00003017_1_T0	GENE	2	2	II
NCT000030171	NCT00003017_1_T1	GENE	9	9	interleukin-12
NCT000030171	NCT00003017_1_T2	PHENOTYPE	17	21	recurrent cancer of the cervix
NCT000030173	NCT00003017_3_T0	GENE	20	20	interleukin-12
NCT000030173	NCT00003017_3_T1	PHENOTYPE	13	13	recurrent
NCT000030173	NCT00003017_3_T2	PHENOTYPE	16	17	cervical cancer
NCT000030175	NCT00003017_5_T0	PHENOTYPE	2	2	toxic
NCT000030175	NCT00003017_5_T1	GENE	6	6	interleukin-12
NCT000030177	NCT00003017_7_T0	PHENOTYPE	13	13	papilloma
NCT000030179	NCT00003017_9_T0	GENE	10	10	13
NCT000030179	NCT00003017_9_T1	GENE	3	3	interleukin-12
NCT000030179	NCT00003017_9_T2	GENE	16	16	1.5
NCT000030179	NCT00003017_9_T3	GENE	4	4	IV
NCT0000301710	NCT00003017_10_T0	PHENOTYPE	10	10	toxicity
NCT0000301710	NCT00003017_10_T1	PHENOTYPE	12	13	disease progression
NCT000030181	NCT00003018_1_T0	CELL	9	9	cells
NCT000030181	NCT00003018_1_T1	PHENOTYPE	8	8	tumor
NCT000030182	NCT00003018_2_T0	PHENOTYPE	9	10	pancreatic cancer
NCT000030183	NCT00003018_3_T0	GENE	2	2	II
NCT000030183	NCT00003018_3_T1	GENE	16	16	II
NCT000030183	NCT00003018_3_T2	GENE	23	23	has
NCT000030183	NCT00003018_3_T3	PHENOTYPE	18	21	stage III pancreatic cancer
NCT000030185	NCT00003018_5_T0	COMPOUND	20	20	dipyridamole
NCT000030185	NCT00003018_5_T1	COMPOUND	17	17	leucovorin
NCT000030185	NCT00003018_5_T2	PHENOTYPE	11	13	unresectable pancreatic cancer
NCT000030189	NCT00003018_9_T0	PHENOTYPE	4	4	severity
NCT000030189	NCT00003018_9_T1	PHENOTYPE	7	7	toxic
NCT0000301813	NCT00003018_13_T0	COMPOUND	21	21	dipyridamole
NCT0000301813	NCT00003018_13_T1	GENE	9	9	1.28
NCT0000301813	NCT00003018_13_T2	GENE	24	24	1.28
NCT0000301813	NCT00003018_13_T3	COMPOUND	11	11	calcium
NCT0000301813	NCT00003018_13_T4	COMPOUND	10	10	leucovorin
NCT0000301813	NCT00003018_13_T5	GENE	3	3	IV
NCT0000301813	NCT00003018_13_T6	GENE	12	12	IV
NCT0000301813	NCT00003018_13_T7	GENE	27	27	IV
NCT0000301816	NCT00003018_16_T0	GENE	4	4	4-8
NCT000030191	NCT00003019_1_T0	CELL	9	9	cells
NCT000030191	NCT00003019_1_T1	PHENOTYPE	8	8	tumor
NCT000030192	NCT00003019_2_T0	GENE	2	2	II
NCT000030192	NCT00003019_2_T1	COMPOUND	13	13	methotrexate
NCT000030192	NCT00003019_2_T2	COMPOUND	11	11	vinblastine
NCT000030192	NCT00003019_2_T3	PHENOTYPE	23	23	recurrent
NCT000030192	NCT00003019_2_T4	PHENOTYPE	19	20	desmoid tumors
NCT000030194	NCT00003019_4_T0	PHENOTYPE	4	4	toxicity
NCT000030194	NCT00003019_4_T1	COMPOUND	8	8	methotrexate
NCT000030194	NCT00003019_4_T2	COMPOUND	6	6	vinblastine
NCT000030194	NCT00003019_4_T3	PHENOTYPE	13	13	recurrent
NCT000030194	NCT00003019_4_T4	PHENOTYPE	14	15	desmoid tumors
NCT000030194	NCT00003019_4_T5	PHENOTYPE	15	17	tumors in children
NCT000030195	NCT00003019_5_T0	COMPOUND	3	3	vinblastine
NCT000030195	NCT00003019_5_T1	COMPOUND	5	5	methotrexate
NCT000030195	NCT00003019_5_T2	GENE	6	6	IV
NCT000030196	NCT00003019_6_T0	PHENOTYPE	13	13	toxicity
NCT000030196	NCT00003019_6_T1	PHENOTYPE	15	16	disease progression
NCT000030201	NCT00003020_1_T0	PHENOTYPE	18	18	metastases
NCT000030201	NCT00003020_1_T1	PHENOTYPE	16	17	leptomeningeal metastases
NCT000030203	NCT00003020_3_T0	PHENOTYPE	2	2	toxicity
NCT000030203	NCT00003020_3_T1	PHENOTYPE	10	11	leptomeningeal metastases
NCT000030208	NCT00003020_8_T0	GENE	32	32	II
NCT000030208	NCT00003020_8_T1	PHENOTYPE	33	33	toxicity
NCT000030208	NCT00003020_8_T2	GENE	19	19	CSF
NCT000030208	NCT00003020_8_T3	GENE	20	20	has
NCT000030208	NCT00003020_8_T4	GENE	26	26	has
NCT0000302010	NCT00003020_10_T0	GENE	8	8	MTD
NCT0000302011	NCT00003020_11_T0	PHENOTYPE	20	20	toxicity
NCT0000302011	NCT00003020_11_T1	PHENOTYPE	24	24	toxicity
NCT0000302011	NCT00003020_11_T2	GENE	1	1	MTD
NCT000030211	NCT00003021_1_T0	COMPOUND	9	9	bizelesin
NCT000030211	NCT00003021_1_T1	PHENOTYPE	15	16	advanced cancer
NCT000030213	NCT00003021_3_T0	COMPOUND	6	6	bizelesin
NCT000030213	NCT00003021_3_T1	PHENOTYPE	10	11	advanced cancer
NCT000030215	NCT00003021_5_T0	PHENOTYPE	5	5	toxic
NCT000030217	NCT00003021_7_T0	PHENOTYPE	2	2	pharmacokinetics
NCT000030219	NCT00003021_9_T0	GENE	9	9	II
NCT0000302113	NCT00003021_13_T0	COMPOUND	2	2	bizelesin
NCT0000302113	NCT00003021_13_T1	GENE	3	3	IV
NCT0000302114	NCT00003021_14_T0	PHENOTYPE	13	13	toxicity
NCT0000302114	NCT00003021_14_T1	PHENOTYPE	9	10	disease progression
NCT0000302115	NCT00003021_15_T0	COMPOUND	8	8	bizelesin
NCT0000302115	NCT00003021_15_T1	GENE	14	14	MTD
NCT0000302116	NCT00003021_16_T0	PHENOTYPE	19	19	toxicity
NCT0000302116	NCT00003021_16_T1	GENE	1	1	MTD
NCT000030221	NCT00003022_1_T0	PHENOTYPE	17	18	leptomeningeal metastases
NCT000030224	NCT00003022_4_T0	COMPOUND	14	14	3F8
NCT000030224	NCT00003022_4_T1	COMPOUND	9	9	iodine
NCT000030225	NCT00003022_5_T0	PHENOTYPE	11	11	toxicity
NCT000030225	NCT00003022_5_T1	PHENOTYPE	3	4	disease progression
NCT000030227	NCT00003022_7_T0	PHENOTYPE	5	5	toxicity
NCT000030228	NCT00003022_8_T0	PHENOTYPE	17	17	toxicity
NCT000030228	NCT00003022_8_T1	GENE	27	27	MTD
NCT0000302210	NCT00003022_10_T0	GENE	12	12	2.3
NCT000030230	NCT00003023_0_T0	GENE	4	4	BCG
NCT000030230	NCT00003023_0_T1	PHENOTYPE	9	9	Cancer
NCT000030232	NCT00003023_2_T0	CELL	10	10	cells
NCT000030232	NCT00003023_2_T1	PHENOTYPE	9	9	tumor
NCT000030232	NCT00003023_2_T2	GENE	5	5	BCG
NCT000030233	NCT00003023_3_T0	GENE	13	13	BCG
NCT000030235	NCT00003023_5_T0	GENE	17	17	BCG
NCT000030235	NCT00003023_5_T1	PHENOTYPE	9	9	sterile
NCT000030238	NCT00003023_8_T0	ORGAN	5	5	limbs
NCT000030238	NCT00003023_8_T1	TISSUE	8	9	lymph nodes
NCT000030239	NCT00003023_9_T0	GENE	8	8	BCG
NCT0000302310	NCT00003023_10_T0	GENE	11	11	BCG
NCT0000302313	NCT00003023_13_T0	PHENOTYPE	26	27	skin toxicity
NCT0000302314	NCT00003023_14_T0	PHENOTYPE	6	6	toxicity
NCT0000302314	NCT00003023_14_T1	PHENOTYPE	3	3	experiences
NCT0000302314	NCT00003023_14_T2	GENE	7	7	DLT
NCT0000302315	NCT00003023_15_T0	GENE	8	8	MTD
NCT0000302315	NCT00003023_15_T1	GENE	6	6	DLT
NCT000030251	NCT00003025_1_T0	PHENOTYPE	11	12	pancreatic cancer
NCT000030252	NCT00003025_2_T0	GENE	23	23	has
NCT000030252	NCT00003025_2_T1	PHENOTYPE	18	21	stage II pancreatic cancer
NCT000030254	NCT00003025_4_T0	PHENOTYPE	5	5	tumor
NCT000030254	NCT00003025_4_T1	GENE	7	7	gp96
NCT000030254	NCT00003025_4_T2	PHENOTYPE	18	19	pancreatic adenocarcinoma
NCT000030254	NCT00003025_4_T3	GENE	8	10	heat shock protein
NCT000030256	NCT00003025_6_T0	BIOLOGICAL_PROCESS	2	3	immune response
NCT000030258	NCT00003025_8_T0	PHENOTYPE	8	8	tumor
NCT000030258	NCT00003025_8_T1	GENE	10	10	gp96
NCT000030258	NCT00003025_8_T2	GENE	11	13	heat shock protein
NCT000030265	NCT00003026_5_T0	COMPOUND	21	21	androgen
NCT000030266	NCT00003026_6_T0	COMPOUND	3	3	bicalutamide
NCT000030267	NCT00003026_7_T0	COMPOUND	10	10	triptorelin
NCT000030271	NCT00003027_1_T0	CELL	11	11	cells
NCT000030271	NCT00003027_1_T1	GENE	0	0	Interleukin-2
NCT000030271	NCT00003027_1_T2	PHENOTYPE	10	10	melanoma
NCT000030271	NCT00003027_1_T3	CELL	5	7	white blood cells
NCT000030273	NCT00003027_3_T0	GENE	9	9	interleukin-2
NCT000030273	NCT00003027_3_T1	GENE	11	11	interferon
NCT000030273	NCT00003027_3_T2	PHENOTYPE	21	22	metastatic melanoma
NCT000030274	NCT00003027_4_T0	GENE	3	3	III
NCT000030274	NCT00003027_4_T1	GENE	14	14	interferon
NCT000030274	NCT00003027_4_T2	GENE	12	12	interleukin-2
NCT000030274	NCT00003027_4_T3	PHENOTYPE	21	22	metastatic melanoma
NCT000030277	NCT00003027_7_T0	COMPOUND	9	9	1
NCT000030277	NCT00003027_7_T1	GENE	11	11	interferon
NCT0000302710	NCT00003027_10_T0	GENE	15	15	SC
NCT0000302710	NCT00003027_10_T1	GENE	32	32	SC
NCT0000302710	NCT00003027_10_T2	GENE	5	5	IL-2
NCT0000302710	NCT00003027_10_T3	GENE	18	18	IL-2
NCT0000302710	NCT00003027_10_T4	GENE	24	24	IL-2
NCT0000302710	NCT00003027_10_T5	GENE	10	10	1.4
NCT0000302710	NCT00003027_10_T6	GENE	21	21	1.4
NCT0000302710	NCT00003027_10_T7	GENE	30	30	filgrastim
NCT0000302710	NCT00003027_10_T8	GENE	31	31	G-CSF
NCT0000302710	NCT00003027_10_T9	GENE	6	6	IV
NCT0000302710	NCT00003027_10_T10	GENE	3	4	interleukin 2
NCT0000302710	NCT00003027_10_T11	COMPOUND	12	13	interferon alfa_2b
NCT0000302711	NCT00003027_11_T0	PHENOTYPE	16	16	toxicity
NCT0000302711	NCT00003027_11_T1	PHENOTYPE	12	13	disease progression
NCT0000302713	NCT00003027_13_T0	GENE	14	14	3.5
NCT000030280	NCT00003028_0_T0	PHENOTYPE	5	5	Recurrent
NCT000030280	NCT00003028_0_T1	PHENOTYPE	8	9	Solid Tumors
NCT000030282	NCT00003028_2_T0	PHENOTYPE	15	15	recurrent
NCT000030282	NCT00003028_2_T1	PHENOTYPE	18	19	solid tumors
NCT000030284	NCT00003028_4_T0	GENE	5	5	MTD
NCT000030284	NCT00003028_4_T1	PHENOTYPE	11	11	recurrent
NCT000030284	NCT00003028_4_T2	PHENOTYPE	15	16	solid tumors
NCT000030286	NCT00003028_6_T0	PHENOTYPE	5	5	toxic
NCT000030286	NCT00003028_6_T1	PHENOTYPE	22	22	toxic
NCT000030288	NCT00003028_8_T0	GENE	6	6	II
NCT0000302810	NCT00003028_10_T0	PHENOTYPE	2	2	pharmacokinetics
NCT0000302814	NCT00003028_14_T0	PHENOTYPE	17	17	toxicity
NCT0000302815	NCT00003028_15_T0	PHENOTYPE	12	12	judgement
NCT0000302816	NCT00003028_16_T0	PHENOTYPE	9	9	toxicity
NCT0000302816	NCT00003028_16_T1	GENE	1	1	MTD
NCT0000302817	NCT00003028_17_T0	PHENOTYPE	8	9	cardiac toxicity
NCT0000302817	NCT00003028_17_T1	PHENOTYPE	10	11	disease progression
NCT000030291	NCT00003029_1_T0	CELL	15	15	cells
NCT000030291	NCT00003029_1_T1	PHENOTYPE	14	14	tumor
NCT000030292	NCT00003029_2_T0	COMPOUND	8	8	cisplatin
NCT000030292	NCT00003029_2_T1	PHENOTYPE	19	20	metastatic cancer
NCT000030292	NCT00003029_2_T2	PHENOTYPE	20	23	cancer of the pancreas
NCT000030293	NCT00003029_3_T0	GENE	3	3	III
NCT000030293	NCT00003029_3_T1	COMPOUND	14	14	cisplatin
NCT000030293	NCT00003029_3_T2	PHENOTYPE	22	23	metastatic cancer
NCT000030293	NCT00003029_3_T3	PHENOTYPE	23	26	cancer of the pancreas
NCT000030296	NCT00003029_6_T0	COMPOUND	28	28	cisplatin
NCT000030298	NCT00003029_8_T0	GENE	14	14	FU
NCT000030299	NCT00003029_9_T0	GENE	10	10	FU
NCT0000302910	NCT00003029_10_T0	GENE	12	12	FU
NCT0000302910	NCT00003029_10_T1	GENE	15	15	FU
NCT0000302911	NCT00003029_11_T0	GENE	2	2	FU
NCT0000302912	NCT00003029_12_T0	PHENOTYPE	7	7	toxicity
NCT0000302912	NCT00003029_12_T1	PHENOTYPE	10	10	remission
NCT0000302912	NCT00003029_12_T2	PHENOTYPE	4	5	disease progression
NCT000030311	NCT00003031_1_T0	COMPOUND	6	6	voriconazole
NCT000030311	NCT00003031_1_T1	PHENOTYPE	17	17	aspergillosis
NCT000030311	NCT00003031_1_T2	COMPOUND	11	12	amphotericin B
NCT000030312	NCT00003031_2_T0	COMPOUND	10	10	voriconazole
NCT000030312	NCT00003031_2_T1	PHENOTYPE	18	18	aspergillosis
NCT000030312	NCT00003031_2_T2	GENE	3	3	III
NCT000030312	NCT00003031_2_T3	COMPOUND	12	13	amphotericin B
NCT000030314	NCT00003031_4_T0	PHENOTYPE	16	16	acute
NCT000030314	NCT00003031_4_T1	COMPOUND	7	7	voriconazole
NCT000030314	NCT00003031_4_T2	GENE	11	11	CAB
NCT000030314	NCT00003031_4_T3	PHENOTYPE	17	18	invasive aspergillosis
NCT000030314	NCT00003031_4_T4	COMPOUND	9	10	amphotericin B
NCT000030316	NCT00003031_6_T0	PHENOTYPE	19	19	acute
NCT000030316	NCT00003031_6_T1	COMPOUND	7	7	voriconazole
NCT000030316	NCT00003031_6_T2	GENE	9	9	CAB
NCT000030316	NCT00003031_6_T3	PHENOTYPE	20	21	invasive aspergillosis
NCT000030318	NCT00003031_8_T0	COMPOUND	6	6	voriconazole
NCT000030318	NCT00003031_8_T1	GENE	8	8	CAB
NCT0000303110	NCT00003031_10_T0	COMPOUND	7	7	voriconazole
NCT0000303110	NCT00003031_10_T1	GENE	9	9	CAB
NCT0000303112	NCT00003031_12_T0	CELL	13	13	neutrophil
NCT0000303116	NCT00003031_16_T0	PHENOTYPE	8	8	toxicity
NCT000030322	NCT00003032_2_T0	PHENOTYPE	16	17	breast cancer
NCT0000303211	NCT00003032_11_T0	PHENOTYPE	3	5	quality of life
NCT0000303213	NCT00003032_13_T0	GENE	14	14	receptor
NCT0000303213	NCT00003032_13_T1	GENE	30	30	receptor
NCT0000303213	NCT00003032_13_T2	GENE	19	19	ER
NCT0000303213	NCT00003032_13_T3	GENE	21	21	ER
NCT0000303213	NCT00003032_13_T4	GENE	26	26	ER
NCT0000303213	NCT00003032_13_T5	COMPOUND	17	17	tamoxifen
NCT0000303213	NCT00003032_13_T6	COMPOUND	25	25	tamoxifen
NCT0000303213	NCT00003032_13_T7	COMPOUND	29	29	tamoxifen
NCT0000303214	NCT00003032_14_T0	PHENOTYPE	1	3	quality of life
NCT000030341	NCT00003034_1_T0	COMPOUND	8	8	doxorubicin
NCT000030341	NCT00003034_1_T1	COMPOUND	13	13	doxorubicin
NCT000030341	NCT00003034_1_T2	PHENOTYPE	19	20	malignant mesothelioma
NCT000030342	NCT00003034_2_T0	GENE	4	4	III
NCT000030342	NCT00003034_2_T1	COMPOUND	8	8	doxorubicin
NCT000030342	NCT00003034_2_T2	COMPOUND	18	18	doxorubicin
NCT000030342	NCT00003034_2_T3	PHENOTYPE	25	26	malignant mesothelioma
NCT000030345	NCT00003034_5_T0	GENE	13	13	1.4
NCT000030347	NCT00003034_7_T0	PHENOTYPE	15	15	progression
NCT000030349	NCT00003034_9_T0	PHENOTYPE	0	2	Quality of life
NCT000030351	NCT00003035_1_T0	CELL	16	16	cells
NCT000030351	NCT00003035_1_T1	PHENOTYPE	15	15	tumor
NCT000030352	NCT00003035_2_T0	GENE	3	3	II
NCT000030352	NCT00003035_2_T1	COMPOUND	12	12	paclitaxel
NCT000030352	NCT00003035_2_T2	COMPOUND	10	10	doxorubicin
NCT000030352	NCT00003035_2_T3	PHENOTYPE	20	21	breast cancer
NCT000030354	NCT00003035_4_T0	PHENOTYPE	15	16	breast cancer
NCT0000303512	NCT00003035_12_T0	PHENOTYPE	5	5	tumor
NCT0000303514	NCT00003035_14_T0	GENE	11	11	T4
NCT0000303514	NCT00003035_14_T1	GENE	4	4	pre
NCT0000303514	NCT00003035_14_T2	GENE	9	9	T3
NCT0000303516	NCT00003035_16_T0	GENE	15	15	ANC
NCT0000303516	NCT00003035_16_T1	CELL	13	13	neutrophil
NCT0000303516	NCT00003035_16_T2	PHENOTYPE	17	18	platelet count
NCT0000303517	NCT00003035_17_T0	COMPOUND	3	3	paclitaxel
NCT0000303517	NCT00003035_17_T1	GENE	20	20	ANC
NCT0000303517	NCT00003035_17_T2	GENE	4	4	IV
NCT0000303517	NCT00003035_17_T3	PHENOTYPE	22	23	platelet count
NCT0000303518	NCT00003035_18_T0	GENE	19	19	ANC
NCT0000303518	NCT00003035_18_T1	GENE	1	1	G-CSF
NCT0000303519	NCT00003035_19_T0	PHENOTYPE	9	9	aspirations
NCT0000303521	NCT00003035_21_T0	GENE	15	15	ANC
NCT0000303521	NCT00003035_21_T1	COMPOUND	6	6	doxorubicin
NCT0000303521	NCT00003035_21_T2	PHENOTYPE	17	18	platelet count
NCT0000303523	NCT00003035_23_T0	PHENOTYPE	9	9	aspirations
NCT0000303528	NCT00003035_28_T0	ORGAN	5	6	chest wall
NCT0000303529	NCT00003035_29_T0	COMPOUND	8	8	tamoxifen
NCT0000303529	NCT00003035_29_T1	GENE	2	3	hormone receptor
NCT000030372	NCT00003037_2_T0	CELL	9	9	cells
NCT000030372	NCT00003037_2_T1	PHENOTYPE	8	8	tumor
NCT000030379	NCT00003037_9_T0	GENE	7	7	IV
NCT0000303710	NCT00003037_10_T0	GENE	7	7	IV
NCT0000303711	NCT00003037_11_T0	GENE	7	7	IV
NCT0000303712	NCT00003037_12_T0	COMPOUND	20	20	docetaxel
NCT0000303712	NCT00003037_12_T1	GENE	2	2	G-CSF
NCT0000303714	NCT00003037_14_T0	PHENOTYPE	6	6	toxicity
NCT0000303714	NCT00003037_14_T1	PHENOTYPE	3	3	experiences
NCT0000303714	NCT00003037_14_T2	GENE	7	7	DLT
NCT0000303715	NCT00003037_15_T0	PHENOTYPE	3	3	experiences
NCT0000303715	NCT00003037_15_T1	GENE	4	4	DLT
NCT0000303716	NCT00003037_16_T0	GENE	16	16	MTD
NCT0000303716	NCT00003037_16_T1	GENE	6	6	DLT
NCT0000303717	NCT00003037_17_T0	GENE	7	7	II
NCT0000303717	NCT00003037_17_T1	GENE	2	2	MTD
NCT0000303717	NCT00003037_17_T2	GENE	25	25	MTD
NCT0000303718	NCT00003037_18_T0	PHENOTYPE	22	22	tumor
NCT0000303719	NCT00003037_19_T0	PHENOTYPE	8	8	toxicities
NCT0000303719	NCT00003037_19_T1	PHENOTYPE	4	5	disease progression
NCT000030380	NCT00003038_0_T0	PHENOTYPE	11	12	Solid Tumors
NCT000030382	NCT00003038_2_T0	CELL	9	9	cells
NCT000030382	NCT00003038_2_T1	PHENOTYPE	8	8	tumor
NCT000030383	NCT00003038_3_T0	COMPOUND	12	12	suramin
NCT000030383	NCT00003038_3_T1	COMPOUND	14	14	doxorubicin
NCT000030383	NCT00003038_3_T2	PHENOTYPE	20	21	solid tumors
NCT000030385	NCT00003038_5_T0	COMPOUND	7	7	suramin
NCT000030385	NCT00003038_5_T1	COMPOUND	10	10	doxorubicin
NCT000030385	NCT00003038_5_T2	GENE	5	5	MTD
NCT000030385	NCT00003038_5_T3	PHENOTYPE	15	16	solid tumors
NCT000030387	NCT00003038_7_T0	PHENOTYPE	2	2	toxic
NCT000030387	NCT00003038_7_T1	COMPOUND	5	5	suramin
NCT000030387	NCT00003038_7_T2	COMPOUND	10	10	doxorubicin
NCT0000303813	NCT00003038_13_T0	PHENOTYPE	9	9	neurotoxicity
NCT0000303813	NCT00003038_13_T1	COMPOUND	11	11	suramin
NCT0000303814	NCT00003038_14_T0	COMPOUND	7	7	doxorubicin
NCT0000303815	NCT00003038_15_T0	GENE	6	6	1.2
NCT0000303815	NCT00003038_15_T1	GENE	10	10	1.4
NCT0000303815	NCT00003038_15_T2	COMPOUND	2	2	suramin
NCT0000303815	NCT00003038_15_T3	COMPOUND	13	13	doxorubicin
NCT0000303815	NCT00003038_15_T4	GENE	3	3	IV
NCT0000303815	NCT00003038_15_T5	GENE	14	14	IV
NCT0000303816	NCT00003038_16_T0	PHENOTYPE	15	15	toxicity
NCT0000303816	NCT00003038_16_T1	PHENOTYPE	16	17	disease progression
NCT0000303817	NCT00003038_17_T0	COMPOUND	23	23	suramin
NCT0000303817	NCT00003038_17_T1	COMPOUND	9	9	doxorubicin
NCT0000303817	NCT00003038_17_T2	COMPOUND	25	25	doxorubicin
NCT0000303817	NCT00003038_17_T3	GENE	10	10	IV
NCT0000303818	NCT00003038_18_T0	COMPOUND	8	8	doxorubicin
NCT0000303818	NCT00003038_18_T1	GENE	14	14	MTD
NCT0000303819	NCT00003038_19_T0	PHENOTYPE	19	19	toxicity
NCT0000303819	NCT00003038_19_T1	GENE	1	1	MTD
NCT0000303820	NCT00003038_20_T0	COMPOUND	22	22	suramin
NCT0000303820	NCT00003038_20_T1	COMPOUND	16	16	doxorubicin
NCT0000303820	NCT00003038_20_T2	COMPOUND	19	19	doxorubicin
NCT000030391	NCT00003039_1_T0	CELL	10	10	cells
NCT000030395	NCT00003039_5_T0	PHENOTYPE	2	2	toxicity
NCT000030395	NCT00003039_5_T1	COMPOUND	4	4	flavopiridol
NCT000030397	NCT00003039_7_T0	PHENOTYPE	2	2	pharmacokinetics
NCT000030397	NCT00003039_7_T1	COMPOUND	4	4	flavopiridol
NCT0000303911	NCT00003039_11_T0	PHENOTYPE	11	11	toxicity
NCT0000303911	NCT00003039_11_T1	PHENOTYPE	13	14	disease progression
NCT000030401	NCT00003040_1_T0	CELL	8	8	cells
NCT000030401	NCT00003040_1_T1	PHENOTYPE	7	7	tumor
NCT000030402	NCT00003040_2_T0	CELL	10	10	cells
NCT000030402	NCT00003040_2_T1	PHENOTYPE	9	9	tumor
NCT000030403	NCT00003040_3_T0	GENE	2	2	II
NCT000030403	NCT00003040_3_T1	PHENOTYPE	20	23	cancer of the larynx
NCT000030407	NCT00003040_7_T0	PHENOTYPE	4	4	progression
NCT000030407	NCT00003040_7_T1	PHENOTYPE	12	13	disease progression
NCT000030408	NCT00003040_8_T0	COMPOUND	3	4	carbon dioxide
NCT0000304010	NCT00003040_10_T0	GENE	11	11	2.4
NCT0000304010	NCT00003040_10_T1	TISSUE	8	9	lymph node
NCT000030411	NCT00003041_1_T0	GENE	2	2	II
NCT000030411	NCT00003041_1_T1	COMPOUND	9	9	pyrazoloacridine
NCT000030411	NCT00003041_1_T2	PHENOTYPE	16	18	metastatic breast cancer
NCT000030413	NCT00003041_3_T0	COMPOUND	4	4	pyrazoloacridine
NCT000030413	NCT00003041_3_T1	PHENOTYPE	9	10	breast cancer
NCT000030415	NCT00003041_5_T0	PHENOTYPE	2	2	toxic
NCT000030415	NCT00003041_5_T1	COMPOUND	5	5	pyrazoloacridine
NCT000030416	NCT00003041_6_T0	COMPOUND	3	3	pyrazoloacridine
NCT000030416	NCT00003041_6_T1	GENE	4	4	IV
NCT000030417	NCT00003041_7_T0	PHENOTYPE	16	16	toxicity
NCT000030417	NCT00003041_7_T1	GENE	6	6	2.8
NCT000030417	NCT00003041_7_T2	PHENOTYPE	12	13	disease progression
NCT000030424	NCT00003042_4_T0	GENE	9	9	had
NCT000030424	NCT00003042_4_T1	GENE	24	24	had
NCT000030425	NCT00003042_5_T0	GENE	12	12	1.4
NCT000030425	NCT00003042_5_T1	COMPOUND	5	5	doxorubicin
NCT000030425	NCT00003042_5_T2	GENE	6	6	IV
NCT000030427	NCT00003042_7_T0	PHENOTYPE	6	6	5-10
NCT000030427	NCT00003042_7_T1	CELL	16	16	granulocyte
NCT000030427	NCT00003042_7_T2	GENE	1	1	G-CSF
NCT000030429	NCT00003042_9_T0	COMPOUND	9	9	paclitaxel
NCT000030429	NCT00003042_9_T1	COMPOUND	18	18	cyclophosphamide
NCT000030429	NCT00003042_9_T2	GENE	10	10	IV
NCT000030429	NCT00003042_9_T3	GENE	19	19	IV
NCT0000304211	NCT00003042_11_T0	CELL	0	1	Stem cells
NCT0000304213	NCT00003042_13_T0	COMPOUND	10	10	3
NCT0000304213	NCT00003042_13_T1	COMPOUND	4	4	doxorubicin
NCT0000304213	NCT00003042_13_T2	GENE	5	5	IV
NCT0000304214	NCT00003042_14_T0	COMPOUND	9	9	2
NCT0000304214	NCT00003042_14_T1	GENE	1	1	IV
NCT0000304215	NCT00003042_15_T0	CELL	12	12	granulocyte
NCT0000304215	NCT00003042_15_T1	COMPOUND	7	7	1
NCT0000304215	NCT00003042_15_T2	GENE	4	4	IV
NCT0000304216	NCT00003042_16_T0	CELL	0	2	Peripheral stem cells
NCT0000304217	NCT00003042_17_T0	GENE	19	19	11
NCT0000304217	NCT00003042_17_T1	COMPOUND	12	12	melphalan
NCT0000304217	NCT00003042_17_T2	COMPOUND	14	14	cisplatin
NCT0000304218	NCT00003042_18_T0	GENE	3	3	IV
NCT0000304218	NCT00003042_18_T1	GENE	6	6	10
NCT0000304219	NCT00003042_19_T0	COMPOUND	2	2	cisplatin
NCT0000304220	NCT00003042_20_T0	COMPOUND	6	6	3
NCT0000304220	NCT00003042_20_T1	CELL	0	1	Stem cells
NCT0000304221	NCT00003042_21_T0	CELL	6	6	granulocyte
NCT0000304222	NCT00003042_22_T0	GENE	4	4	4.7
NCT0000304223	NCT00003042_23_T0	PHENOTYPE	17	17	tumors
NCT0000304223	NCT00003042_23_T1	GENE	14	15	hormone receptor
NCT000030442	NCT00003044_2_T0	CELL	9	9	cells
NCT000030442	NCT00003044_2_T1	PHENOTYPE	8	8	tumor
NCT000030443	NCT00003044_3_T0	GENE	2	2	II
NCT000030443	NCT00003044_3_T1	COMPOUND	11	11	epinephrine
NCT000030443	NCT00003044_3_T2	PHENOTYPE	16	16	tumor
NCT000030443	NCT00003044_3_T3	COMPOUND	9	9	cisplatin
NCT000030443	NCT00003044_3_T4	PHENOTYPE	22	24	primary liver cancer
NCT000030445	NCT00003044_5_T0	GENE	8	8	gel
NCT000030445	NCT00003044_5_T1	PHENOTYPE	16	17	hepatocellular carcinoma
NCT000030449	NCT00003044_9_T0	BIOLOGICAL_PROCESS	11	11	necrosis
NCT000030449	NCT00003044_9_T1	PHENOTYPE	19	19	tumor
NCT0000304411	NCT00003044_11_T0	GENE	13	13	extended
NCT000030451	NCT00003045_1_T0	CELL	8	8	cells
NCT000030451	NCT00003045_1_T1	PHENOTYPE	7	7	tumor
NCT000030452	NCT00003045_2_T0	PHENOTYPE	1	1	hyperthermia
NCT000030452	NCT00003045_2_T1	CELL	9	9	cells
NCT000030452	NCT00003045_2_T2	PHENOTYPE	8	8	tumor
NCT000030455	NCT00003045_5_T0	PHENOTYPE	3	3	hyperthermia
NCT000030455	NCT00003045_5_T1	GENE	5	5	CEM
NCT000030457	NCT00003045_7_T0	PHENOTYPE	0	0	Hyperthermia
NCT000030457	NCT00003045_7_T1	PHENOTYPE	14	15	malignant tumors
NCT000030458	NCT00003045_8_T0	PHENOTYPE	12	12	tumors
NCT000030458	NCT00003045_8_T1	PHENOTYPE	8	8	tumor
NCT000030459	NCT00003045_9_T0	PHENOTYPE	5	5	hyperthermia
NCT000030459	NCT00003045_9_T1	PHENOTYPE	15	15	tumors
NCT0000304510	NCT00003045_10_T0	PHENOTYPE	6	6	hyperthermia
NCT0000304510	NCT00003045_10_T1	PHENOTYPE	13	13	tumors
NCT0000304510	NCT00003045_10_T2	GENE	7	7	has
NCT0000304510	NCT00003045_10_T3	ORGAN	17	18	urinary bladder
NCT0000304511	NCT00003045_11_T0	PHENOTYPE	5	5	tumor
NCT000030461	NCT00003046_1_T0	GENE	9	9	interleukin-12
NCT000030461	NCT00003046_1_T1	ORGAN	17	17	abdomen
NCT000030463	NCT00003046_3_T0	GENE	7	7	interleukin-12
NCT000030463	NCT00003046_3_T1	PHENOTYPE	12	12	carcinoma
NCT000030463	NCT00003046_3_T2	PHENOTYPE	13	13	closed
NCT000030463	NCT00003046_3_T3	PHENOTYPE	24	24	closed
NCT000030463	NCT00003046_3_T4	PHENOTYPE	19	20	gastrointestinal carcinoma
NCT000030463	NCT00003046_3_T5	PHENOTYPE	22	23	peritoneal mesothelioma
NCT000030465	NCT00003046_5_T0	PHENOTYPE	5	5	toxicity
NCT000030465	NCT00003046_5_T1	PHENOTYPE	9	9	toxicity
NCT000030467	NCT00003046_7_T0	GENE	3	3	interleukin-12
NCT000030468	NCT00003046_8_T0	PHENOTYPE	15	15	toxicity
NCT000030468	NCT00003046_8_T1	PHENOTYPE	17	18	disease progression
NCT0000304610	NCT00003046_10_T0	GENE	6	6	interleukin-12
NCT0000304610	NCT00003046_10_T1	GENE	12	12	MTD
NCT0000304611	NCT00003046_11_T0	PHENOTYPE	17	17	toxicity
NCT0000304611	NCT00003046_11_T1	GENE	1	1	MTD
NCT0000304612	NCT00003046_12_T0	GENE	11	11	interleukin-12
NCT0000304612	NCT00003046_12_T1	GENE	2	2	MTD
NCT000030487	NCT00003048_7_T0	COMPOUND	2	2	amifostine
NCT000030487	NCT00003048_7_T1	GENE	3	3	IV
NCT0000304810	NCT00003048_10_T0	PHENOTYPE	5	5	toxicity
NCT0000304811	NCT00003048_11_T0	PHENOTYPE	6	6	toxicity
NCT0000304811	NCT00003048_11_T1	PHENOTYPE	2	3	grade 1
NCT0000304812	NCT00003048_12_T0	PHENOTYPE	4	4	toxicity
NCT000030491	NCT00003049_1_T0	CELL	8	8	cells
NCT000030491	NCT00003049_1_T1	PHENOTYPE	7	7	tumor
NCT000030492	NCT00003049_2_T0	CELL	10	10	cells
NCT000030492	NCT00003049_2_T1	PHENOTYPE	9	9	tumor
NCT000030493	NCT00003049_3_T0	PHENOTYPE	12	15	cancer of the pancreas
NCT000030494	NCT00003049_4_T0	GENE	3	3	III
NCT000030494	NCT00003049_4_T1	ORGAN	14	14	pancreas
NCT000030494	NCT00003049_4_T2	TISSUE	26	27	lymph nodes
NCT000030494	NCT00003049_4_T3	ORGAN	20	21	small intestine
NCT000030494	NCT00003049_4_T4	PHENOTYPE	38	41	cancer of the pancreas
NCT000030496	NCT00003049_6_T0	GENE	12	12	extended
NCT000030496	NCT00003049_6_T1	TISSUE	13	14	lymph node
NCT000030497	NCT00003049_7_T0	PHENOTYPE	11	11	metastases
NCT000030499	NCT00003049_9_T0	COMPOUND	1	1	calcium
NCT000030499	NCT00003049_9_T1	GENE	16	16	1.4
NCT000030499	NCT00003049_9_T2	GENE	6	6	IV
NCT000030501	NCT00003050_1_T0	CELL	10	10	cells
NCT000030501	NCT00003050_1_T1	PHENOTYPE	9	9	tumor
NCT000030502	NCT00003050_2_T0	CELL	9	9	cells
NCT000030502	NCT00003050_2_T1	PHENOTYPE	8	8	tumor
NCT000030503	NCT00003050_3_T0	GENE	2	2	II
NCT000030503	NCT00003050_3_T1	COMPOUND	12	12	paclitaxel
NCT000030503	NCT00003050_3_T2	PHENOTYPE	20	23	stage III breast cancer
NCT000030505	NCT00003050_5_T0	COMPOUND	9	9	paclitaxel
NCT000030505	NCT00003050_5_T1	PHENOTYPE	18	19	breast cancer
NCT000030507	NCT00003050_7_T0	COMPOUND	5	5	paclitaxel
NCT000030507	NCT00003050_7_T1	PHENOTYPE	11	12	breast cancer
NCT000030509	NCT00003050_9_T0	COMPOUND	2	2	paclitaxel
NCT000030509	NCT00003050_9_T1	GENE	3	3	IV
NCT0000305010	NCT00003050_10_T0	PHENOTYPE	8	8	tumor
NCT0000305011	NCT00003050_11_T0	COMPOUND	14	14	paclitaxel
NCT0000305011	NCT00003050_11_T1	GENE	6	6	5.0
NCT0000305012	NCT00003050_12_T0	COMPOUND	24	24	cyclophosphamide
NCT0000305012	NCT00003050_12_T1	COMPOUND	21	21	doxorubicin
NCT0000305012	NCT00003050_12_T2	GENE	22	22	IV
NCT0000305012	NCT00003050_12_T3	GENE	25	25	IV
NCT0000305012	NCT00003050_12_T4	PHENOTYPE	4	5	progressive disease
NCT0000305014	NCT00003050_14_T0	COMPOUND	23	23	paclitaxel
NCT0000305014	NCT00003050_14_T1	COMPOUND	20	20	doxorubicin
NCT0000305014	NCT00003050_14_T2	GENE	21	21	IV
NCT0000305014	NCT00003050_14_T3	GENE	24	24	IV
NCT0000305015	NCT00003050_15_T0	PHENOTYPE	6	6	tumors
NCT0000305015	NCT00003050_15_T1	COMPOUND	8	8	tamoxifen
NCT0000305015	NCT00003050_15_T2	GENE	3	4	hormone receptor
NCT000030521	NCT00003052_1_T0	CELL	4	4	cells
NCT000030521	NCT00003052_1_T1	PHENOTYPE	3	3	tumor
NCT000030521	NCT00003052_1_T2	PHENOTYPE	0	0	Hyperthermia
NCT000030522	NCT00003052_2_T0	PHENOTYPE	8	8	hyperthermia
NCT000030522	NCT00003052_2_T1	PHENOTYPE	20	22	soft tissue sarcoma
NCT000030523	NCT00003052_3_T0	PHENOTYPE	22	22	hyperthermia
NCT000030523	NCT00003052_3_T1	GENE	4	4	III
NCT000030523	NCT00003052_3_T2	PHENOTYPE	28	30	soft tissue sarcoma
NCT0000305212	NCT00003052_12_T0	PHENOTYPE	25	25	hyperthermia
NCT0000305212	NCT00003052_12_T1	PHENOTYPE	9	9	tumors
NCT0000305212	NCT00003052_12_T2	PHENOTYPE	12	13	disease progression
NCT000030531	NCT00003053_1_T0	CELL	9	9	cells
NCT000030531	NCT00003053_1_T1	PHENOTYPE	8	8	tumor
NCT000030535	NCT00003053_5_T0	GENE	13	13	II
NCT000030536	NCT00003053_6_T0	GENE	7	7	1.3
NCT000030536	NCT00003053_6_T1	COMPOUND	4	4	etoposide
NCT000030536	NCT00003053_6_T2	COMPOUND	2	2	cisplatin
NCT000030545	NCT00003054_5_T0	PHENOTYPE	6	6	toxic
NCT000030545	NCT00003054_5_T1	COMPOUND	9	9	paclitaxel
NCT000030546	NCT00003054_6_T0	COMPOUND	7	7	paclitaxel
NCT000030547	NCT00003054_7_T0	COMPOUND	15	15	paclitaxel
NCT000030547	NCT00003054_7_T1	PHENOTYPE	3	3	remission
NCT000030547	NCT00003054_7_T2	PHENOTYPE	5	5	remission
NCT000030548	NCT00003054_8_T0	PHENOTYPE	6	7	adverse effects
NCT000030548	NCT00003054_8_T1	PHENOTYPE	3	4	disease progression
NCT000030551	NCT00003055_1_T0	CELL	9	9	cells
NCT000030551	NCT00003055_1_T1	PHENOTYPE	8	8	tumor
NCT000030552	NCT00003055_2_T0	GENE	2	2	II
NCT000030552	NCT00003055_2_T1	PHENOTYPE	21	22	gastric cancer
NCT000030554	NCT00003055_4_T0	COMPOUND	8	8	irinotecan
NCT000030554	NCT00003055_4_T1	COMPOUND	6	6	cisplatin
NCT000030554	NCT00003055_4_T2	PHENOTYPE	18	18	recurrent
NCT000030554	NCT00003055_4_T3	PHENOTYPE	21	22	gastric cancer
NCT000030556	NCT00003055_6_T0	PHENOTYPE	2	2	toxic
NCT000030556	NCT00003055_6_T1	COMPOUND	11	11	irinotecan
NCT000030556	NCT00003055_6_T2	COMPOUND	9	9	cisplatin
NCT0000305512	NCT00003055_12_T0	PHENOTYPE	16	16	dysphagia
NCT0000305512	NCT00003055_12_T1	PHENOTYPE	1	3	quality of life
NCT0000305513	NCT00003055_13_T0	COMPOUND	5	5	irinotecan
NCT0000305513	NCT00003055_13_T1	COMPOUND	3	3	cisplatin
NCT0000305515	NCT00003055_15_T0	PHENOTYPE	16	17	disease progression
NCT0000305517	NCT00003055_17_T0	PHENOTYPE	0	0	Tumor
NCT0000305520	NCT00003055_20_T0	PHENOTYPE	2	5	adenocarcinoma of the esophagus
NCT000030566	NCT00003056_6_T0	PHENOTYPE	24	24	toxicities
NCT000030566	NCT00003056_6_T1	PHENOTYPE	31	31	GVHD
NCT0000305610	NCT00003056_10_T0	CELL	11	11	cells
NCT0000305610	NCT00003056_10_T1	ORGAN	13	13	transplant
NCT0000305610	NCT00003056_10_T2	GENE	14	14	has
NCT0000305610	NCT00003056_10_T3	GENE	10	10	CD34
NCT0000305611	NCT00003056_11_T0	COMPOUND	31	31	cyclosporine
NCT0000305611	NCT00003056_11_T1	PHENOTYPE	21	21	GVHD
NCT0000305611	NCT00003056_11_T2	CELL	26	26	cells
NCT0000305611	NCT00003056_11_T3	GENE	25	25	CD34
NCT0000305611	NCT00003056_11_T4	PHENOTYPE	17	20	graft versus host disease
NCT0000305611	NCT00003056_11_T5	CELL	8	11	peripheral blood stem cells
NCT0000305612	NCT00003056_12_T0	COMPOUND	11	11	cyclosporine
NCT0000305612	NCT00003056_12_T1	COMPOUND	13	13	methotrexate
NCT0000305612	NCT00003056_12_T2	PHENOTYPE	4	4	GVHD
NCT0000305613	NCT00003056_13_T0	COMPOUND	1	1	cyclosporine
NCT0000305613	NCT00003056_13_T1	GENE	6	6	IV
NCT0000305614	NCT00003056_14_T0	GENE	4	4	IV
NCT0000305615	NCT00003056_15_T0	GENE	5	5	180
NCT0000305615	NCT00003056_15_T1	PHENOTYPE	12	12	GVHD
NCT0000305617	NCT00003056_17_T0	COMPOUND	1	1	cyclosporine
NCT0000305618	NCT00003056_18_T0	PHENOTYPE	6	6	acute
NCT0000305618	NCT00003056_18_T1	PHENOTYPE	9	9	GVHD
NCT0000305618	NCT00003056_18_T2	PHENOTYPE	8	8	chronic
NCT0000305619	NCT00003056_19_T0	ORGAN	8	8	transplant
NCT000030571	NCT00003057_1_T0	COMPOUND	13	13	hydrochloride
NCT000030571	NCT00003057_1_T1	COMPOUND	12	12	loperamide
NCT000030571	NCT00003057_1_T2	GENE	3	3	III
NCT000030571	NCT00003057_1_T3	COMPOUND	10	10	octreotide
NCT000030571	NCT00003057_1_T4	PHENOTYPE	19	19	diarrhea
NCT000030571	NCT00003057_1_T5	PHENOTYPE	24	25	colorectal cancer
NCT000030573	NCT00003057_3_T0	COMPOUND	13	13	hydrochloride
NCT000030573	NCT00003057_3_T1	COMPOUND	12	12	loperamide
NCT000030573	NCT00003057_3_T2	PHENOTYPE	23	23	malignancies
NCT000030573	NCT00003057_3_T3	PHENOTYPE	17	17	diarrhea
NCT000030573	NCT00003057_3_T4	COMPOUND	6	7	octreotide acetate
NCT000030575	NCT00003057_5_T0	COMPOUND	13	13	hydrochloride
NCT000030575	NCT00003057_5_T1	COMPOUND	12	12	loperamide
NCT000030575	NCT00003057_5_T2	PHENOTYPE	7	7	diarrhea
NCT000030575	NCT00003057_5_T3	COMPOUND	15	16	octreotide acetate
NCT000030579	NCT00003057_9_T0	GENE	10	10	bowel
NCT0000305711	NCT00003057_11_T0	PHENOTYPE	1	1	diarrhea
NCT000030580	NCT00003058_0_T0	PHENOTYPE	5	5	Liposarcoma
NCT000030584	NCT00003058_4_T0	COMPOUND	6	6	troglitazone
NCT000030584	NCT00003058_4_T1	PHENOTYPE	11	11	liposarcoma
NCT000030586	NCT00003058_6_T0	BIOLOGICAL_PROCESS	20	21	terminal differentiation
NCT000030588	NCT00003058_8_T0	COMPOUND	7	7	troglitazone
NCT000030588	NCT00003058_8_T1	PHENOTYPE	3	3	tolerance
NCT000030589	NCT00003058_9_T0	PHENOTYPE	13	13	liposarcoma
NCT0000305811	NCT00003058_11_T0	COMPOUND	11	11	troglitazone
NCT000030601	NCT00003060_1_T0	CELL	21	21	cells
NCT000030601	NCT00003060_1_T1	PHENOTYPE	20	20	tumor
NCT000030601	NCT00003060_1_T2	ORGAN	3	4	bone marrow
NCT000030602	NCT00003060_2_T0	GENE	20	20	has
NCT000030602	NCT00003060_2_T1	PHENOTYPE	17	18	metastatic melanoma
NCT000030602	NCT00003060_2_T2	ORGAN	10	11	bone marrow
NCT000030604	NCT00003060_4_T0	ORGAN	22	23	bone marrow
NCT000030604	NCT00003060_4_T1	PHENOTYPE	9	11	metastatic malignant melanoma
NCT000030606	NCT00003060_6_T0	COMPOUND	6	6	busulfan
NCT000030606	NCT00003060_6_T1	COMPOUND	8	8	cyclophosphamide
NCT000030608	NCT00003060_8_T0	COMPOUND	8	8	2
NCT000030608	NCT00003060_8_T1	COMPOUND	6	6	3
NCT000030608	NCT00003060_8_T2	GENE	1	1	IV
NCT000030609	NCT00003060_9_T0	ORGAN	0	1	Bone marrow
NCT0000306010	NCT00003060_10_T0	COMPOUND	4	4	1
NCT0000306011	NCT00003060_11_T0	GENE	1	1	IV
NCT0000306012	NCT00003060_12_T0	CELL	0	0	Granulocyte
NCT0000306012	NCT00003060_12_T1	GENE	8	8	IV
NCT0000306012	NCT00003060_12_T2	CELL	20	20	neutrophil
NCT0000306015	NCT00003060_15_T0	PHENOTYPE	5	5	melanoma
NCT000030610	NCT00003061_0_T0	PHENOTYPE	9	11	Primary CNS Lymphoma
NCT000030612	NCT00003061_2_T0	CELL	8	8	cells
NCT000030612	NCT00003061_2_T1	PHENOTYPE	7	7	tumor
NCT000030613	NCT00003061_3_T0	CELL	9	9	cells
NCT000030614	NCT00003061_4_T0	GENE	2	2	II
NCT000030614	NCT00003061_4_T1	COMPOUND	11	11	cytarabine
NCT000030614	NCT00003061_4_T2	COMPOUND	9	9	methotrexate
NCT000030614	NCT00003061_4_T3	PHENOTYPE	20	22	primary CNS lymphoma
NCT000030616	NCT00003061_6_T0	COMPOUND	6	6	cytarabine
NCT000030616	NCT00003061_6_T1	COMPOUND	4	4	methotrexate
NCT000030616	NCT00003061_6_T2	PHENOTYPE	19	23	primary central nervous system lymphoma
NCT0000306110	NCT00003061_10_T0	GENE	1	1	MTX
NCT0000306110	NCT00003061_10_T1	GENE	2	2	IV
NCT0000306112	NCT00003061_12_T0	ORGAN	11	12	bone marrow
NCT000030626	NCT00003062_6_T0	COMPOUND	6	6	temozolomide
NCT000030626	NCT00003062_6_T1	PHENOTYPE	2	2	acute
NCT0000306211	NCT00003062_11_T0	PHENOTYPE	10	10	progression
NCT0000306211	NCT00003062_11_T1	PHENOTYPE	23	23	progression
NCT0000306211	NCT00003062_11_T2	PHENOTYPE	2	3	brain metastases
NCT0000306211	NCT00003062_11_T3	PHENOTYPE	28	29	brain lesion
NCT0000306216	NCT00003062_16_T0	PHENOTYPE	27	27	toxicity
NCT0000306216	NCT00003062_16_T1	PHENOTYPE	24	25	disease progression
NCT000030631	NCT00003063_1_T0	CELL	9	9	cells
NCT000030631	NCT00003063_1_T1	PHENOTYPE	8	8	tumor
NCT000030632	NCT00003063_2_T0	GENE	30	30	II
NCT000030632	NCT00003063_2_T1	GENE	3	3	III
NCT000030632	NCT00003063_2_T2	GENE	16	16	interferon
NCT000030632	NCT00003063_2_T3	COMPOUND	12	12	levamisole
NCT000030632	NCT00003063_2_T4	COMPOUND	25	25	leucovorin
NCT000030632	NCT00003063_2_T5	PHENOTYPE	32	35	stage III colorectal cancer
NCT000030644	NCT00003064_4_T0	COMPOUND	8	8	topotecan
NCT000030646	NCT00003064_6_T0	GENE	1	1	filgrastim
NCT000030646	NCT00003064_6_T1	GENE	2	2	G-CSF
NCT000030647	NCT00003064_7_T0	CELL	3	6	peripheral blood stem cells
NCT000030648	NCT00003064_8_T0	COMPOUND	5	5	paclitaxel
NCT000030649	NCT00003064_9_T0	COMPOUND	10	10	topotecan
NCT000030649	NCT00003064_9_T1	COMPOUND	12	13	etoposide phosphate
NCT0000306410	NCT00003064_10_T0	COMPOUND	20	21	etoposide phosphate
NCT0000306411	NCT00003064_11_T0	COMPOUND	9	9	phosphate
NCT0000306412	NCT00003064_12_T0	COMPOUND	3	3	thiotepa
NCT0000306412	NCT00003064_12_T1	COMPOUND	16	16	topotecan
NCT0000306412	NCT00003064_12_T2	COMPOUND	18	19	etoposide phosphate
NCT0000306413	NCT00003064_13_T0	GENE	10	10	MTD
NCT0000306413	NCT00003064_13_T1	COMPOUND	3	3	topotecan
NCT0000306414	NCT00003064_14_T0	PHENOTYPE	18	18	toxicity
NCT0000306414	NCT00003064_14_T1	GENE	1	1	MTD
NCT0000306415	NCT00003064_15_T0	PHENOTYPE	16	16	progression
NCT0000306416	NCT00003064_16_T0	GENE	26	26	II
NCT000030651	NCT00003065_1_T0	CELL	9	9	cells
NCT000030651	NCT00003065_1_T1	PHENOTYPE	8	8	tumor
NCT000030652	NCT00003065_2_T0	GENE	2	2	II
NCT000030652	NCT00003065_2_T1	COMPOUND	11	11	paclitaxel
NCT000030652	NCT00003065_2_T2	PHENOTYPE	17	17	recurrent
NCT000030652	NCT00003065_2_T3	COMPOUND	9	9	topotecan
NCT000030652	NCT00003065_2_T4	PHENOTYPE	19	23	metastatic cancer of the cervix
NCT000030654	NCT00003065_4_T0	COMPOUND	3	3	paclitaxel
NCT000030654	NCT00003065_4_T1	GENE	19	19	1.5
NCT000030654	NCT00003065_4_T2	GENE	4	4	IV
NCT000030654	NCT00003065_4_T3	GENE	13	13	IV
NCT000030654	NCT00003065_4_T4	COMPOUND	12	12	topotecan
NCT000030655	NCT00003065_5_T0	GENE	1	1	G-CSF
NCT000030656	NCT00003065_6_T0	PHENOTYPE	19	19	toxicity
NCT000030656	NCT00003065_6_T1	PHENOTYPE	15	16	disease progression
NCT000030661	NCT00003066_1_T0	CELL	9	9	cells
NCT000030661	NCT00003066_1_T1	PHENOTYPE	8	8	tumor
NCT000030662	NCT00003066_2_T0	GENE	2	2	II
NCT000030662	NCT00003066_2_T1	COMPOUND	9	9	docetaxel
NCT000030662	NCT00003066_2_T2	COMPOUND	12	12	estramustine
NCT000030662	NCT00003066_2_T3	PHENOTYPE	17	19	metastatic breast cancer
NCT000030664	NCT00003066_4_T0	COMPOUND	16	16	docetaxel
NCT000030664	NCT00003066_4_T1	COMPOUND	18	18	estramustine
NCT000030664	NCT00003066_4_T2	PHENOTYPE	23	25	metastatic breast cancer
NCT000030664	NCT00003066_4_T3	PHENOTYPE	11	13	quality of life
NCT000030665	NCT00003066_5_T0	COMPOUND	3	3	estramustine
NCT000030666	NCT00003066_6_T0	COMPOUND	10	10	estramustine
NCT000030668	NCT00003066_8_T0	PHENOTYPE	11	11	tolerance
NCT000030668	NCT00003066_8_T1	PHENOTYPE	19	20	disease progression
NCT0000306610	NCT00003066_10_T0	PHENOTYPE	13	13	toxicity
NCT0000306610	NCT00003066_10_T1	PHENOTYPE	9	10	rapid progression
NCT000030671	NCT00003067_1_T0	CELL	11	11	cells
NCT000030671	NCT00003067_1_T1	GENE	0	0	Interleukin-2
NCT000030671	NCT00003067_1_T2	PHENOTYPE	18	18	glioma
NCT000030671	NCT00003067_1_T3	CELL	5	7	white blood cells
NCT000030672	NCT00003067_2_T0	GENE	11	11	interleukin-2
NCT000030672	NCT00003067_2_T1	PHENOTYPE	22	22	recurrent
NCT000030672	NCT00003067_2_T2	PHENOTYPE	25	26	malignant glioma
NCT000030672	NCT00003067_2_T3	CELL	13	15	lymphokine-activated killer cells
NCT000030674	NCT00003067_4_T0	PHENOTYPE	4	4	tumor
NCT000030675	NCT00003067_5_T0	GENE	13	13	ex
NCT000030675	NCT00003067_5_T1	CELL	10	10	cells
NCT000030675	NCT00003067_5_T2	GENE	16	16	interleukin-2
NCT000030675	NCT00003067_5_T3	GENE	17	17	IL-2
NCT000030676	NCT00003067_6_T0	CELL	3	3	cells
NCT000030676	NCT00003067_6_T1	GENE	5	5	IL-2
NCT000030676	NCT00003067_6_T2	GENE	2	2	LAK
NCT000030677	NCT00003067_7_T0	GENE	4	4	IL-2
NCT000030684	NCT00003068_4_T0	COMPOUND	6	6	mitoxantrone
NCT000030684	NCT00003068_4_T1	PHENOTYPE	35	35	cytoprotection
NCT000030684	NCT00003068_4_T2	COMPOUND	14	14	thiotepa
NCT000030684	NCT00003068_4_T3	COMPOUND	8	8	cyclophosphamide
NCT000030684	NCT00003068_4_T4	COMPOUND	19	19	amifostine
NCT000030684	NCT00003068_4_T5	COMPOUND	33	33	amifostine
NCT000030684	NCT00003068_4_T6	CELL	16	17	blood cells
NCT000030684	NCT00003068_4_T7	PHENOTYPE	27	29	metastatic breast cancer
NCT000030686	NCT00003068_6_T0	PHENOTYPE	4	4	toxicities
NCT000030686	NCT00003068_6_T1	PHENOTYPE	17	19	metastatic breast cancer
NCT0000306812	NCT00003068_12_T0	PHENOTYPE	11	13	quality of life
NCT0000306814	NCT00003068_14_T0	CELL	1	2	blood cells
NCT0000306815	NCT00003068_15_T0	COMPOUND	4	4	mitoxantrone
NCT0000306815	NCT00003068_15_T1	COMPOUND	6	6	thiotepa
NCT0000306815	NCT00003068_15_T2	COMPOUND	3	3	amifostine
NCT0000306815	NCT00003068_15_T3	GENE	2	2	IV
NCT0000306816	NCT00003068_16_T0	COMPOUND	7	7	thiotepa
NCT0000306816	NCT00003068_16_T1	COMPOUND	9	9	cyclophosphamide
NCT0000306816	NCT00003068_16_T2	COMPOUND	6	6	amifostine
NCT0000306816	NCT00003068_16_T3	GENE	5	5	IV
NCT0000306817	NCT00003068_17_T0	COMPOUND	5	5	3
NCT0000306817	NCT00003068_17_T1	COMPOUND	9	9	cyclophosphamide
NCT0000306817	NCT00003068_17_T2	COMPOUND	7	7	amifostine
NCT0000306817	NCT00003068_17_T3	GENE	6	6	IV
NCT0000306818	NCT00003068_18_T0	COMPOUND	11	11	1
NCT0000306818	NCT00003068_18_T1	COMPOUND	9	9	2
NCT0000306820	NCT00003068_20_T0	COMPOUND	9	9	mitoxantrone
NCT0000306820	NCT00003068_20_T1	COMPOUND	11	11	cyclophosphamide
NCT0000306821	NCT00003068_21_T0	PHENOTYPE	13	13	toxicity
NCT0000306821	NCT00003068_21_T1	PHENOTYPE	10	10	experiences
NCT0000306821	NCT00003068_21_T2	GENE	14	14	DLT
NCT0000306822	NCT00003068_22_T0	GENE	8	8	DLT
NCT000030701	NCT00003070_1_T0	PHENOTYPE	11	11	toxic
NCT000030701	NCT00003070_1_T1	CELL	8	8	cells
NCT000030701	NCT00003070_1_T2	COMPOUND	4	4	enalapril
NCT000030701	NCT00003070_1_T3	PHENOTYPE	12	14	effects of chemotherapy
NCT000030702	NCT00003070_2_T0	COMPOUND	5	5	enalapril
NCT000030702	NCT00003070_2_T1	ORGAN	14	14	heart
NCT000030702	NCT00003070_2_T2	PHENOTYPE	23	24	childhood cancer
NCT000030703	NCT00003070_3_T0	COMPOUND	11	11	enalapril
NCT000030703	NCT00003070_3_T1	GENE	4	4	III
NCT000030703	NCT00003070_3_T2	ORGAN	17	17	heart
NCT000030703	NCT00003070_3_T3	PHENOTYPE	26	27	childhood cancer
NCT000030705	NCT00003070_5_T0	COMPOUND	2	2	enalapril
NCT000030705	NCT00003070_5_T1	GENE	13	13	ventricular
NCT000030705	NCT00003070_5_T2	PHENOTYPE	19	20	childhood cancer
NCT000030707	NCT00003070_7_T0	PHENOTYPE	17	17	cardiotoxicity
NCT000030707	NCT00003070_7_T1	COMPOUND	8	8	enalapril
NCT000030707	NCT00003070_7_T2	GENE	4	4	ventricular
NCT000030709	NCT00003070_9_T0	COMPOUND	4	4	enalapril
NCT000030709	NCT00003070_9_T1	PHENOTYPE	7	9	quality of life
NCT0000307012	NCT00003070_12_T0	COMPOUND	3	3	enalapril
NCT0000307012	NCT00003070_12_T1	GENE	8	8	bid
NCT000030722	NCT00003072_2_T0	CELL	16	16	cells
NCT000030722	NCT00003072_2_T1	PHENOTYPE	15	15	tumor
NCT000030727	NCT00003072_7_T0	COMPOUND	6	6	amifostine
NCT000030728	NCT00003072_8_T0	COMPOUND	4	4	paclitaxel
NCT000030729	NCT00003072_9_T0	COMPOUND	21	21	paclitaxel
NCT000030729	NCT00003072_9_T1	COMPOUND	6	6	amifostine
NCT000030729	NCT00003072_9_T2	COMPOUND	10	10	amifostine
NCT0000307211	NCT00003072_11_T0	PHENOTYPE	13	13	toxic
NCT0000307211	NCT00003072_11_T1	PHENOTYPE	9	10	disease progression
NCT000030730	NCT00003073_0_T0	PHENOTYPE	6	6	Recurrent
NCT000030730	NCT00003073_0_T1	PHENOTYPE	11	11	Lymphoma
NCT000030730	NCT00003073_0_T2	PHENOTYPE	9	10	Meningeal Leukemia
NCT000030730	NCT00003073_0_T3	PHENOTYPE	13	14	Solid Tumors
NCT000030732	NCT00003073_2_T0	COMPOUND	10	10	cytarabine
NCT000030732	NCT00003073_2_T1	PHENOTYPE	22	22	lymphoma
NCT000030732	NCT00003073_2_T2	PHENOTYPE	17	17	recurrent
NCT000030732	NCT00003073_2_T3	PHENOTYPE	20	21	meningeal leukemia
NCT000030732	NCT00003073_2_T4	PHENOTYPE	24	25	solid tumors
NCT000030734	NCT00003073_4_T0	COMPOUND	11	11	cytarabine
NCT000030734	NCT00003073_4_T1	COMPOUND	14	14	cytarabine
NCT000030734	NCT00003073_4_T2	PHENOTYPE	5	5	toxic
NCT000030734	NCT00003073_4_T3	PHENOTYPE	25	25	malignancies
NCT000030734	NCT00003073_4_T4	PHENOTYPE	21	21	recurrent
NCT000030738	NCT00003073_8_T0	GENE	4	4	CSF
NCT000030738	NCT00003073_8_T1	PHENOTYPE	5	5	pharmacokinetics
NCT000030738	NCT00003073_8_T2	ORGAN	2	2	plasma
NCT0000307311	NCT00003073_11_T0	COMPOUND	8	8	cytarabine
NCT0000307311	NCT00003073_11_T1	COMPOUND	11	11	cytarabine
NCT0000307319	NCT00003073_19_T0	PHENOTYPE	16	16	relapse
NCT000030751	NCT00003075_1_T0	PHENOTYPE	7	7	neoplasia
NCT000030751	NCT00003075_1_T1	PHENOTYPE	10	11	cervical cancer
NCT000030752	NCT00003075_2_T0	GENE	4	4	III
NCT000030752	NCT00003075_2_T1	COMPOUND	11	11	fenretinide
NCT000030752	NCT00003075_2_T2	PHENOTYPE	19	19	neoplasia
NCT000030759	NCT00003075_9_T0	COMPOUND	6	6	fenretinide
NCT0000307510	NCT00003075_10_T0	COMPOUND	3	3	fenretinide
NCT000030761	NCT00003076_1_T0	PHENOTYPE	14	15	Barrett's esophagus
NCT000030762	NCT00003076_2_T0	GENE	4	4	II
NCT000030762	NCT00003076_2_T1	PHENOTYPE	18	19	Barrett's esophagus
NCT000030764	NCT00003076_4_T0	PHENOTYPE	28	28	dysplastic
NCT000030764	NCT00003076_4_T1	COMPOUND	4	4	DFMO
NCT000030764	NCT00003076_4_T2	GENE	15	15	Ki67
NCT000030764	NCT00003076_4_T3	PHENOTYPE	23	24	Barrett's esophagus
NCT000030764	NCT00003076_4_T4	PHENOTYPE	29	30	Barrett's esophagus
NCT000030766	NCT00003076_6_T0	PHENOTYPE	7	7	pathology
NCT000030766	NCT00003076_6_T1	COMPOUND	3	3	DFMO
NCT000030766	NCT00003076_6_T2	PHENOTYPE	11	12	Barrett's esophagus
NCT000030768	NCT00003076_8_T0	PHENOTYPE	18	18	dysplastic
NCT000030768	NCT00003076_8_T1	TISSUE	32	32	mucosa
NCT000030768	NCT00003076_8_T2	PHENOTYPE	19	20	Barrett's esophagus
NCT000030768	NCT00003076_8_T3	PHENOTYPE	25	26	Barrett's esophagus
NCT000030769	NCT00003076_9_T0	COMPOUND	2	2	DFMO
NCT0000307611	NCT00003076_11_T0	PHENOTYPE	23	23	dysplastic
NCT0000307611	NCT00003076_11_T1	CELL	2	2	cells
NCT0000307611	NCT00003076_11_T2	COMPOUND	27	27	DFMO
NCT0000307611	NCT00003076_11_T3	TISSUE	25	25	mucosa
NCT0000307611	NCT00003076_11_T4	GENE	5	5	p53
NCT0000307615	NCT00003076_15_T0	COMPOUND	12	12	DFMO
NCT0000307617	NCT00003076_17_T0	PHENOTYPE	5	5	dysplasia
NCT0000307617	NCT00003076_17_T1	PHENOTYPE	13	13	dysplastic
NCT0000307618	NCT00003076_18_T0	COMPOUND	9	9	DFMO
NCT0000307619	NCT00003076_19_T0	PHENOTYPE	12	12	toxicity
NCT000030770	NCT00003077_0_T0	PHENOTYPE	12	13	Weight Loss
NCT000030770	NCT00003077_0_T1	PHENOTYPE	7	8	Advanced Cancer
NCT000030772	NCT00003077_2_T0	PHENOTYPE	16	17	advanced cancer
NCT000030772	NCT00003077_2_T1	PHENOTYPE	21	22	weight loss
NCT000030776	NCT00003077_6_T0	PHENOTYPE	19	20	weight loss
NCT000030778	NCT00003077_8_T0	PHENOTYPE	34	34	toxicity
NCT000030778	NCT00003077_8_T1	GENE	4	4	MTD
NCT000030781	NCT00003078_1_T0	CELL	10	10	cells
NCT000030781	NCT00003078_1_T1	PHENOTYPE	9	9	tumor
NCT000030782	NCT00003078_2_T0	CELL	9	9	cells
NCT000030782	NCT00003078_2_T1	PHENOTYPE	8	8	tumor
NCT000030783	NCT00003078_3_T0	COMPOUND	9	9	cisplatin
NCT000030783	NCT00003078_3_T1	PHENOTYPE	23	26	cancer of the cervix
NCT000030784	NCT00003078_4_T0	GENE	3	3	III
NCT000030784	NCT00003078_4_T1	COMPOUND	13	13	cisplatin
NCT000030784	NCT00003078_4_T2	PHENOTYPE	28	31	cancer of the cervix
NCT000030784	NCT00003078_4_T3	PHENOTYPE	26	30	stage IVA cancer of the
NCT000030786	NCT00003078_6_T0	ORGAN	15	15	pelvis
NCT000030786	NCT00003078_6_T1	COMPOUND	24	24	cisplatin
NCT000030786	NCT00003078_6_T2	PHENOTYPE	10	11	cervical cancer
NCT000030787	NCT00003078_7_T0	GENE	5	5	II
NCT000030787	NCT00003078_7_T1	PHENOTYPE	3	3	closed
NCT000030788	NCT00003078_8_T0	PHENOTYPE	3	3	toxic
NCT000030788	NCT00003078_8_T1	COMPOUND	13	13	cisplatin
NCT000030788	NCT00003078_8_T2	PHENOTYPE	4	7	effects of radiation therapy
NCT000030789	NCT00003078_9_T0	PHENOTYPE	3	3	closed
NCT000030789	NCT00003078_9_T1	GENE	5	5	IV
NCT0000307810	NCT00003078_10_T0	ORGAN	15	15	pelvis
NCT0000307810	NCT00003078_10_T1	PHENOTYPE	10	11	cervical cancer
NCT0000307818	NCT00003078_18_T0	COMPOUND	4	4	cisplatin
NCT0000307818	NCT00003078_18_T1	GENE	3	3	IV
NCT0000307821	NCT00003078_21_T0	ORGAN	19	19	pelvis
NCT0000307822	NCT00003078_22_T0	COMPOUND	5	5	cisplatin
NCT000030791	NCT00003079_1_T0	CELL	9	9	cells
NCT000030792	NCT00003079_2_T0	COMPOUND	14	14	cytarabine
NCT000030792	NCT00003079_2_T1	PHENOTYPE	22	22	acute
NCT000030792	NCT00003079_2_T2	COMPOUND	9	10	bryostatin 1
NCT000030792	NCT00003079_2_T3	PHENOTYPE	35	36	lymphoblastic lymphoma
NCT000030792	NCT00003079_2_T4	PHENOTYPE	28	30	chronic myelogenous leukemia
NCT000030792	NCT00003079_2_T5	PHENOTYPE	25	27	acute lymphocytic leukemia
NCT000030794	NCT00003079_4_T0	COMPOUND	15	15	cytarabine
NCT000030794	NCT00003079_4_T1	GENE	5	5	MTD
NCT000030794	NCT00003079_4_T2	COMPOUND	7	8	bryostatin 1
NCT000030794	NCT00003079_4_T3	PHENOTYPE	36	37	lymphoblastic lymphoma
NCT000030794	NCT00003079_4_T4	PHENOTYPE	22	24	acute myelocytic leukemia
NCT000030794	NCT00003079_4_T5	PHENOTYPE	29	31	chronic myelogenous leukemia
NCT000030794	NCT00003079_4_T6	PHENOTYPE	26	28	acute lymphocytic leukemia
NCT000030796	NCT00003079_6_T0	COMPOUND	10	10	cytarabine
NCT000030796	NCT00003079_6_T1	PHENOTYPE	2	2	toxic
NCT000030796	NCT00003079_6_T2	COMPOUND	5	6	bryostatin 1
NCT0000307910	NCT00003079_10_T0	PHENOTYPE	3	3	pharmacokinetics
NCT0000307910	NCT00003079_10_T1	COMPOUND	1	2	bryostatin 1
NCT0000307914	NCT00003079_14_T0	COMPOUND	2	3	bryostatin 1
NCT0000307915	NCT00003079_15_T0	COMPOUND	11	11	cytarabine
NCT0000307915	NCT00003079_15_T1	GENE	21	21	2.4
NCT0000307915	NCT00003079_15_T2	GENE	12	12	IV
NCT0000307915	NCT00003079_15_T3	COMPOUND	5	6	bryostatin 1
NCT0000307916	NCT00003079_16_T0	COMPOUND	3	3	cytarabine
NCT0000307916	NCT00003079_16_T1	COMPOUND	18	19	bryostatin 1
NCT0000307917	NCT00003079_17_T0	PHENOTYPE	3	3	remission
NCT0000307918	NCT00003079_18_T0	COMPOUND	15	15	cytarabine
NCT0000307918	NCT00003079_18_T1	COMPOUND	27	27	cytarabine
NCT0000307918	NCT00003079_18_T2	PHENOTYPE	0	0	Consolidation
NCT0000307919	NCT00003079_19_T0	PHENOTYPE	3	3	remission
NCT0000307920	NCT00003079_20_T0	PHENOTYPE	6	6	toxicity
NCT0000307920	NCT00003079_20_T1	COMPOUND	22	23	bryostatin 1
NCT0000307921	NCT00003079_21_T0	PHENOTYPE	3	3	toxicity
NCT000030807	NCT00003080_7_T0	COMPOUND	8	8	thiotepa
NCT000030808	NCT00003080_8_T0	COMPOUND	18	18	paclitaxel
NCT000030808	NCT00003080_8_T1	COMPOUND	16	16	cyclophosphamide
NCT000030808	NCT00003080_8_T2	COMPOUND	21	21	cyclophosphamide
NCT000030808	NCT00003080_8_T3	COMPOUND	23	23	etoposide
NCT000030808	NCT00003080_8_T4	CELL	5	8	peripheral blood stem cells
NCT000030809	NCT00003080_9_T0	GENE	3	3	twins
NCT0000308011	NCT00003080_11_T0	GENE	8	8	cm
NCT0000308013	NCT00003080_13_T0	COMPOUND	2	2	mitoxantrone
NCT0000308013	NCT00003080_13_T1	GENE	3	3	IV
NCT0000308014	NCT00003080_14_T0	COMPOUND	8	8	3
NCT0000308014	NCT00003080_14_T1	GENE	1	1	IV
NCT0000308016	NCT00003080_16_T0	COMPOUND	12	12	3
NCT0000308016	NCT00003080_16_T1	COMPOUND	3	3	melphalan
NCT0000308016	NCT00003080_16_T2	GENE	4	4	IV
NCT0000308019	NCT00003080_19_T0	PHENOTYPE	5	5	toxicity
NCT0000308019	NCT00003080_19_T1	COMPOUND	17	17	thiotepa
NCT0000308019	NCT00003080_19_T2	GENE	6	6	DLT
NCT0000308020	NCT00003080_20_T0	GENE	1	1	DLT
NCT0000308022	NCT00003080_22_T0	PHENOTYPE	1	1	engraftment
NCT0000308022	NCT00003080_22_T1	PHENOTYPE	18	18	relapse
NCT0000308022	NCT00003080_22_T2	COMPOUND	3	3	melphalan
NCT0000308022	NCT00003080_22_T3	COMPOUND	7	7	tamoxifen
NCT000030812	NCT00003081_2_T0	CELL	8	8	cells
NCT000030812	NCT00003081_2_T1	PHENOTYPE	7	7	tumor
NCT000030817	NCT00003081_7_T0	PHENOTYPE	23	23	remission
NCT000030817	NCT00003081_7_T1	ORGAN	6	6	transplant
NCT000030817	NCT00003081_7_T2	PHENOTYPE	19	19	rhabdomyosarcoma
NCT000030817	NCT00003081_7_T3	PHENOTYPE	12	13	Ewing's sarcoma
NCT000030817	NCT00003081_7_T4	PHENOTYPE	14	17	peripheral primitive neuroectodermal tumor
NCT000030819	NCT00003081_9_T0	GENE	12	12	G-CSF
NCT000030819	NCT00003081_9_T1	CELL	0	3	Peripheral blood stem cells
NCT0000308111	NCT00003081_11_T0	ORGAN	12	12	marrow
NCT0000308111	NCT00003081_11_T1	GENE	14	14	TMI
NCT0000308112	NCT00003081_12_T0	ORGAN	0	0	Transplant
NCT0000308115	NCT00003081_15_T0	COMPOUND	5	5	2
NCT0000308115	NCT00003081_15_T1	COMPOUND	11	11	2
NCT0000308115	NCT00003081_15_T2	COMPOUND	9	9	3
NCT0000308117	NCT00003081_17_T0	PHENOTYPE	19	19	tumor
NCT0000308117	NCT00003081_17_T1	ORGAN	8	8	transplant
NCT0000308118	NCT00003081_18_T0	GENE	8	8	TMI
NCT0000308119	NCT00003081_19_T0	ORGAN	10	10	transplant
NCT0000308119	NCT00003081_19_T1	ORGAN	0	0	Transplant
NCT0000308120	NCT00003081_20_T0	COMPOUND	25	25	1
NCT0000308120	NCT00003081_20_T1	GENE	10	10	TMI
NCT0000308120	NCT00003081_20_T2	ORGAN	1	1	transplant
NCT0000308121	NCT00003081_21_T0	GENE	0	0	TMI
NCT0000308122	NCT00003081_22_T0	GENE	15	15	TMI
NCT0000308123	NCT00003081_23_T0	PHENOTYPE	20	20	toxicity
NCT0000308123	NCT00003081_23_T1	GENE	10	10	TMI
NCT0000308124	NCT00003081_24_T0	PHENOTYPE	6	6	toxicity
NCT0000308124	NCT00003081_24_T1	GENE	7	7	DLT
NCT0000308125	NCT00003081_25_T0	PHENOTYPE	6	6	experiences
NCT0000308125	NCT00003081_25_T1	GENE	7	7	DLT
NCT0000308126	NCT00003081_26_T0	GENE	2	2	DLT
NCT0000308127	NCT00003081_27_T0	GENE	17	17	MTD
NCT0000308127	NCT00003081_27_T1	GENE	7	7	DLT
NCT0000308128	NCT00003081_28_T0	GENE	25	25	MTD
NCT0000308128	NCT00003081_28_T1	GENE	11	11	DLT
NCT0000308130	NCT00003081_30_T0	PHENOTYPE	0	0	Tumor
NCT0000308130	NCT00003081_30_T1	ORGAN	8	8	transplant
NCT000030821	NCT00003082_1_T0	PHENOTYPE	16	17	advanced cancer
NCT000030823	NCT00003082_3_T0	GENE	10	10	receptor
NCT000030823	NCT00003082_3_T1	PHENOTYPE	2	2	toxicities
NCT000030825	NCT00003082_5_T0	PHENOTYPE	2	2	pharmacokinetics
NCT000030827	NCT00003082_7_T0	GENE	5	5	IV
NCT000030828	NCT00003082_8_T0	PHENOTYPE	4	4	initiation
NCT000030828	NCT00003082_8_T1	GENE	16	16	IV
NCT000030829	NCT00003082_9_T0	PHENOTYPE	7	7	toxic
NCT000030829	NCT00003082_9_T1	PHENOTYPE	22	22	remission
NCT0000308210	NCT00003082_10_T0	PHENOTYPE	7	8	progressive disease
NCT0000308211	NCT00003082_11_T0	PHENOTYPE	6	6	toxicity
NCT0000308212	NCT00003082_12_T0	PHENOTYPE	3	3	toxicity
NCT0000308212	NCT00003082_12_T1	GENE	27	27	MTD
NCT000030841	NCT00003084_1_T0	CELL	9	9	cells
NCT000030841	NCT00003084_1_T1	PHENOTYPE	8	8	tumor
NCT000030847	NCT00003084_7_T0	PHENOTYPE	14	14	toxic
NCT000030847	NCT00003084_7_T1	GENE	10	10	III
NCT000030849	NCT00003084_9_T0	ORGAN	28	28	skeleton
NCT000030849	NCT00003084_9_T1	PHENOTYPE	23	24	bone lesions
NCT000030849	NCT00003084_9_T2	PHENOTYPE	32	33	bone lesions
NCT0000308415	NCT00003084_15_T0	PHENOTYPE	10	10	toxicity
NCT0000308415	NCT00003084_15_T1	PHENOTYPE	6	7	disease progression
NCT000030851	NCT00003085_1_T0	GENE	2	2	II
NCT000030851	NCT00003085_1_T1	PHENOTYPE	18	21	stage II pancreatic cancer
NCT000030853	NCT00003085_3_T0	ORGAN	47	47	liver
NCT000030853	NCT00003085_3_T1	ORGAN	8	8	abdomen
NCT000030853	NCT00003085_3_T2	PHENOTYPE	30	30	localized
NCT000030853	NCT00003085_3_T3	PHENOTYPE	15	16	pancreatic cancer
NCT000030853	NCT00003085_3_T4	TISSUE	39	40	lymph node
NCT000030853	NCT00003085_3_T5	PHENOTYPE	32	33	pancreatic disease
NCT000030855	NCT00003085_5_T0	PHENOTYPE	16	17	pancreatic cancer
NCT000030857	NCT00003085_7_T0	PHENOTYPE	10	11	pancreatic cancer
NCT000030861	NCT00003086_1_T0	COMPOUND	19	19	samarium
NCT000030861	NCT00003086_1_T1	ORGAN	15	16	bone marrow
NCT000030861	NCT00003086_1_T2	PHENOTYPE	26	29	stage IV breast cancer
NCT000030863	NCT00003086_3_T0	COMPOUND	7	7	samarium
NCT000030863	NCT00003086_3_T1	GENE	5	5	MTD
NCT000030863	NCT00003086_3_T2	ORGAN	13	14	bone marrow
NCT000030863	NCT00003086_3_T3	PHENOTYPE	17	19	metastatic breast cancer
NCT000030868	NCT00003086_8_T0	PHENOTYPE	4	4	remission
NCT000030869	NCT00003086_9_T0	CELL	12	12	granulocyte
NCT000030869	NCT00003086_9_T1	GENE	11	11	filgrastim
NCT000030869	NCT00003086_9_T2	GENE	15	15	G-CSF
NCT000030869	NCT00003086_9_T3	CELL	0	3	Peripheral blood stem cells
NCT0000308612	NCT00003086_12_T0	GENE	1	1	IV
NCT0000308614	NCT00003086_14_T0	PHENOTYPE	21	21	remission
NCT0000308615	NCT00003086_15_T0	GENE	6	6	14
NCT0000308615	NCT00003086_15_T1	COMPOUND	0	0	Samarium
NCT0000308616	NCT00003086_16_T0	PHENOTYPE	26	26	toxicity
NCT0000308617	NCT00003086_17_T0	COMPOUND	1	1	thiotepa
NCT0000308618	NCT00003086_18_T0	GENE	8	8	G-CSF
NCT0000308618	NCT00003086_18_T1	GENE	9	9	IV
NCT0000308619	NCT00003086_19_T0	GENE	2	2	II
NCT0000308619	NCT00003086_19_T1	COMPOUND	5	5	samarium
NCT0000308619	NCT00003086_19_T2	GENE	13	13	MTD
NCT000030871	NCT00003087_1_T0	CELL	8	8	cells
NCT000030871	NCT00003087_1_T1	PHENOTYPE	7	7	tumor
NCT000030872	NCT00003087_2_T0	CELL	14	14	cells
NCT000030872	NCT00003087_2_T1	PHENOTYPE	13	13	tumor
NCT000030875	NCT00003087_5_T0	PHENOTYPE	17	18	esophageal cancer
NCT000030877	NCT00003087_7_T0	PHENOTYPE	2	2	toxic
NCT000030879	NCT00003087_9_T0	PHENOTYPE	2	4	quality of life
NCT0000308711	NCT00003087_11_T0	PHENOTYPE	9	10	p53 mutation
NCT0000308711	NCT00003087_11_T1	GENE	2	3	Jun oncogene
NCT0000308711	NCT00003087_11_T2	GENE	5	6	thymidylate synthase
NCT0000308713	NCT00003087_13_T0	PHENOTYPE	0	0	Adenocarcinoma
NCT0000308713	NCT00003087_13_T1	COMPOUND	10	10	paclitaxel
NCT0000308713	NCT00003087_13_T2	PHENOTYPE	2	2	closed
NCT0000308713	NCT00003087_13_T3	COMPOUND	17	17	cisplatin
NCT0000308713	NCT00003087_13_T4	GENE	11	11	IV
NCT0000308713	NCT00003087_13_T5	GENE	18	18	IV
NCT0000308714	NCT00003087_14_T0	COMPOUND	14	14	paclitaxel
NCT0000308714	NCT00003087_14_T1	COMPOUND	16	16	cisplatin
NCT0000308715	NCT00003087_15_T0	GENE	8	8	4-8
NCT0000308717	NCT00003087_17_T0	PHENOTYPE	0	2	Quality of life
NCT0000308718	NCT00003087_18_T0	PHENOTYPE	13	13	adenocarcinoma
NCT0000308718	NCT00003087_18_T1	PHENOTYPE	14	15	squamous carcinoma
NCT000030881	NCT00003088_1_T0	CELL	15	15	cells
NCT000030881	NCT00003088_1_T1	PHENOTYPE	14	14	tumor
NCT000030882	NCT00003088_2_T0	PHENOTYPE	12	13	breast cancer
NCT000030883	NCT00003088_3_T0	GENE	40	40	II
NCT000030883	NCT00003088_3_T1	COMPOUND	17	17	paclitaxel
NCT000030883	NCT00003088_3_T2	COMPOUND	34	34	paclitaxel
NCT000030883	NCT00003088_3_T3	GENE	3	3	III
NCT000030883	NCT00003088_3_T4	COMPOUND	15	15	cyclophosphamide
NCT000030883	NCT00003088_3_T5	COMPOUND	31	31	cyclophosphamide
NCT000030883	NCT00003088_3_T6	COMPOUND	14	14	doxorubicin
NCT000030883	NCT00003088_3_T7	COMPOUND	29	29	doxorubicin
NCT000030883	NCT00003088_3_T8	PHENOTYPE	42	45	stage IIIA breast cancer
NCT000030885	NCT00003088_5_T0	GENE	29	29	II
NCT000030885	NCT00003088_5_T1	COMPOUND	6	6	paclitaxel
NCT000030885	NCT00003088_5_T2	COMPOUND	16	16	paclitaxel
NCT000030885	NCT00003088_5_T3	COMPOUND	8	8	cyclophosphamide
NCT000030885	NCT00003088_5_T4	COMPOUND	13	13	cyclophosphamide
NCT000030885	NCT00003088_5_T5	COMPOUND	5	5	doxorubicin
NCT000030885	NCT00003088_5_T6	COMPOUND	11	11	doxorubicin
NCT000030885	NCT00003088_5_T7	PHENOTYPE	32	33	breast cancer
NCT000030889	NCT00003088_9_T0	PHENOTYPE	2	2	toxicity
NCT0000308812	NCT00003088_12_T0	PHENOTYPE	1	1	tumor
NCT0000308815	NCT00003088_15_T0	GENE	1	1	IV
NCT0000308816	NCT00003088_16_T0	GENE	1	1	IV
NCT0000308817	NCT00003088_17_T0	COMPOUND	12	12	paclitaxel
NCT0000308817	NCT00003088_17_T1	GENE	1	1	IV
NCT0000308819	NCT00003088_19_T0	GENE	1	1	IV
NCT0000308820	NCT00003088_20_T0	GENE	1	1	IV
NCT0000308821	NCT00003088_21_T0	COMPOUND	12	12	paclitaxel
NCT0000308821	NCT00003088_21_T1	GENE	1	1	IV
NCT0000308822	NCT00003088_22_T0	COMPOUND	15	15	paclitaxel
NCT0000308822	NCT00003088_22_T1	GENE	9	9	3-10
NCT0000308822	NCT00003088_22_T2	COMPOUND	17	17	cyclophosphamide
NCT0000308822	NCT00003088_22_T3	GENE	1	1	G-CSF
NCT0000308822	NCT00003088_22_T4	COMPOUND	14	14	doxorubicin
NCT0000308824	NCT00003088_24_T0	COMPOUND	4	4	cyclophosphamide
NCT0000308824	NCT00003088_24_T1	COMPOUND	1	1	doxorubicin
NCT0000308824	NCT00003088_24_T2	GENE	2	2	IV
NCT0000308824	NCT00003088_24_T3	GENE	5	5	IV
NCT0000308825	NCT00003088_25_T0	GENE	1	1	IV
NCT0000308827	NCT00003088_27_T0	COMPOUND	4	4	cyclophosphamide
NCT0000308827	NCT00003088_27_T1	COMPOUND	1	1	doxorubicin
NCT0000308827	NCT00003088_27_T2	GENE	2	2	IV
NCT0000308827	NCT00003088_27_T3	GENE	5	5	IV
NCT0000308828	NCT00003088_28_T0	GENE	1	1	IV
NCT0000308829	NCT00003088_29_T0	COMPOUND	19	19	paclitaxel
NCT0000308829	NCT00003088_29_T1	GENE	8	8	3-10
NCT0000308829	NCT00003088_29_T2	GENE	0	0	G-CSF
NCT0000308830	NCT00003088_30_T0	COMPOUND	7	7	tamoxifen
NCT0000308835	NCT00003088_35_T0	GENE	3	3	1.1
NCT0000308835	NCT00003088_35_T1	PHENOTYPE	1	1	Tumor
NCT0000308835	NCT00003088_35_T2	PHENOTYPE	9	9	adenocarcinoma
NCT0000308835	NCT00003088_35_T3	TISSUE	16	17	lymph nodes
NCT0000308835	NCT00003088_35_T4	PHENOTYPE	12	13	female breast
NCT0000308836	NCT00003088_36_T0	PHENOTYPE	14	15	sentinel node
NCT0000308837	NCT00003088_37_T0	PHENOTYPE	12	12	tumors
NCT0000308837	NCT00003088_37_T1	GENE	21	21	N2
NCT0000308837	NCT00003088_37_T2	TISSUE	9	10	lymph nodes
NCT0000308838	NCT00003088_38_T0	PHENOTYPE	2	3	metaplastic carcinoma
NCT0000308839	NCT00003088_39_T0	PHENOTYPE	0	0	Bilateral
NCT0000308840	NCT00003088_40_T0	GENE	0	0	1.2
NCT0000308840	NCT00003088_40_T1	PHENOTYPE	1	1	Tumors
NCT0000308842	NCT00003088_42_T0	GENE	18	18	T4
NCT0000308842	NCT00003088_42_T1	PHENOTYPE	2	2	tumors
NCT0000308842	NCT00003088_42_T2	PHENOTYPE	12	13	skin ulcerations
NCT0000308842	NCT00003088_42_T3	PHENOTYPE	8	9	peau d'orange
NCT0000308842	NCT00003088_42_T4	ORGAN	6	7	chest wall
NCT0000308843	NCT00003088_43_T0	PHENOTYPE	5	5	pathology
NCT0000308844	NCT00003088_44_T0	GENE	0	0	1.3
NCT0000308846	NCT00003088_46_T0	GENE	2	2	2.1
NCT0000308846	NCT00003088_46_T1	GENE	3	3	84
NCT0000308846	NCT00003088_46_T2	GENE	9	9	84
NCT0000308850	NCT00003088_50_T0	PHENOTYPE	1	1	tumor
NCT0000308850	NCT00003088_50_T1	TISSUE	5	6	resection margin
NCT0000308851	NCT00003088_51_T0	GENE	0	0	2.3
NCT0000308852	NCT00003088_52_T0	PHENOTYPE	7	7	malignancy
NCT0000308852	NCT00003088_52_T1	GENE	0	0	2.4
NCT0000308853	NCT00003088_53_T0	PHENOTYPE	8	8	DCIS
NCT0000308854	NCT00003088_54_T0	GENE	3	3	had
NCT0000308855	NCT00003088_55_T0	GENE	3	3	had
NCT0000308857	NCT00003088_57_T0	COMPOUND	3	3	tamoxifen
NCT0000308857	NCT00003088_57_T1	PHENOTYPE	19	20	breast cancer
NCT0000308857	NCT00003088_57_T2	PHENOTYPE	9	10	Breast Cancer
NCT000030892	NCT00003089_2_T0	CELL	8	8	cells
NCT000030892	NCT00003089_2_T1	COMPOUND	4	4	amifostine
NCT000030892	NCT00003089_2_T2	PHENOTYPE	12	14	effects of chemotherapy
NCT000030893	NCT00003089_3_T0	CELL	8	8	cells
NCT000030893	NCT00003089_3_T1	PHENOTYPE	7	7	tumor
NCT000030898	NCT00003089_8_T0	COMPOUND	9	9	paclitaxel
NCT0000308910	NCT00003089_10_T0	PHENOTYPE	22	23	weight loss
NCT0000308912	NCT00003089_12_T0	PHENOTYPE	11	11	toxic
NCT0000308912	NCT00003089_12_T1	PHENOTYPE	15	15	pneumonitis
NCT0000308912	NCT00003089_12_T2	PHENOTYPE	14	14	esophagitis
NCT0000308912	NCT00003089_12_T3	COMPOUND	4	4	amifostine
NCT0000308912	NCT00003089_12_T4	PHENOTYPE	17	18	radiation dermatitis
NCT0000308914	NCT00003089_14_T0	COMPOUND	5	5	paclitaxel
NCT0000308914	NCT00003089_14_T1	GENE	6	6	IV
NCT0000308914	NCT00003089_14_T2	GENE	13	13	IV
NCT0000308916	NCT00003089_16_T0	COMPOUND	10	10	paclitaxel
NCT0000308916	NCT00003089_16_T1	COMPOUND	3	3	amifostine
NCT0000308916	NCT00003089_16_T2	GENE	4	4	IV
NCT0000308916	NCT00003089_16_T3	GENE	11	11	IV
NCT0000308917	NCT00003089_17_T0	COMPOUND	9	9	amifostine
NCT0000308918	NCT00003089_18_T0	PHENOTYPE	15	16	disease progression
NCT000030906	NCT00003090_6_T0	GENE	8	8	IL-2
NCT000030908	NCT00003090_8_T0	PHENOTYPE	3	3	toxicity
NCT000030908	NCT00003090_8_T1	GENE	5	5	IL-2
NCT0000309010	NCT00003090_10_T0	GENE	3	3	interleukin-2
NCT0000309010	NCT00003090_10_T1	GENE	6	6	1.5
NCT0000309013	NCT00003090_13_T0	GENE	13	13	IL-2
NCT0000309015	NCT00003090_15_T0	PHENOTYPE	21	21	toxic
NCT0000309015	NCT00003090_15_T1	GENE	13	13	IL-2
NCT0000309015	NCT00003090_15_T2	PHENOTYPE	18	19	disease progression
NCT000030911	NCT00003091_1_T0	CELL	14	14	cells
NCT000030911	NCT00003091_1_T1	GENE	0	0	Interleukin-2
NCT000030911	NCT00003091_1_T2	PHENOTYPE	13	13	melanoma
NCT000030911	NCT00003091_1_T3	PHENOTYPE	10	11	kidney cancer
NCT000030911	NCT00003091_1_T4	CELL	5	7	white blood cells
NCT000030912	NCT00003091_2_T0	GENE	2	2	II
NCT000030912	NCT00003091_2_T1	GENE	13	13	interleukin-2
NCT000030912	NCT00003091_2_T2	PHENOTYPE	22	22	melanoma
NCT000030912	NCT00003091_2_T3	GENE	10	10	interferon
NCT000030912	NCT00003091_2_T4	PHENOTYPE	18	20	metastatic kidney cancer
NCT000030916	NCT00003091_6_T0	PHENOTYPE	2	2	toxic
NCT000030916	NCT00003091_6_T1	GENE	8	8	interleukin-2
NCT000030916	NCT00003091_6_T2	COMPOUND	5	6	interferon alfa_2b
NCT000030918	NCT00003091_8_T0	GENE	7	7	1.4
NCT000030918	NCT00003091_8_T1	COMPOUND	3	4	interferon alfa_2b
NCT000030919	NCT00003091_9_T0	GENE	8	8	interleukin-2
NCT000030919	NCT00003091_9_T1	GENE	9	9	IL-2
NCT000030919	NCT00003091_9_T2	GENE	17	17	5.7
NCT0000309110	NCT00003091_10_T0	GENE	8	8	IL-2
NCT0000309111	NCT00003091_11_T0	PHENOTYPE	7	8	disease progression
NCT000030920	NCT00003092_0_T0	PHENOTYPE	6	7	Solid Tumors
NCT000030922	NCT00003092_2_T0	COMPOUND	9	9	paclitaxel
NCT000030922	NCT00003092_2_T1	GENE	2	2	III
NCT000030922	NCT00003092_2_T2	PHENOTYPE	16	17	solid tumors
NCT000030924	NCT00003092_4_T0	COMPOUND	8	8	1
NCT000030924	NCT00003092_4_T1	COMPOUND	15	15	2
NCT000030924	NCT00003092_4_T2	COMPOUND	22	22	3
NCT000030931	NCT00003093_1_T0	CELL	9	9	cells
NCT000030931	NCT00003093_1_T1	PHENOTYPE	8	8	tumor
NCT000030932	NCT00003093_2_T0	PHENOTYPE	10	10	neuroblastoma
NCT000030933	NCT00003093_3_T0	PHENOTYPE	20	20	neuroblastoma
NCT000030933	NCT00003093_3_T1	GENE	3	3	III
NCT000030935	NCT00003093_5_T0	GENE	42	42	0.2
NCT000030935	NCT00003093_5_T1	COMPOUND	14	14	cyclophosphamide
NCT000030935	NCT00003093_5_T2	COMPOUND	35	35	etoposide
NCT000030935	NCT00003093_5_T3	COMPOUND	24	24	doxorubicin
NCT000030935	NCT00003093_5_T4	GENE	13	13	63
NCT000030935	NCT00003093_5_T5	GENE	33	33	63
NCT000030935	NCT00003093_5_T6	GENE	4	4	IV
NCT000030935	NCT00003093_5_T7	GENE	15	15	IV
NCT000030935	NCT00003093_5_T8	GENE	25	25	IV
NCT000030935	NCT00003093_5_T9	GENE	36	36	IV
NCT000030935	NCT00003093_5_T10	GENE	23	23	42
NCT000030936	NCT00003093_6_T0	GENE	8	8	filgrastim
NCT000030936	NCT00003093_6_T1	GENE	9	9	G-CSF
NCT000030936	NCT00003093_6_T2	GENE	12	12	GM-CSF
NCT000030936	NCT00003093_6_T3	GENE	11	11	sargramostim
NCT000030937	NCT00003093_7_T0	PHENOTYPE	9	9	remission
NCT000030937	NCT00003093_7_T1	PHENOTYPE	17	18	residual disease
NCT000030939	NCT00003093_9_T0	GENE	18	18	147
NCT000030939	NCT00003093_9_T1	GENE	49	49	147
NCT000030939	NCT00003093_9_T2	GENE	38	38	126
NCT000030939	NCT00003093_9_T3	COMPOUND	8	8	cyclophosphamide
NCT000030939	NCT00003093_9_T4	COMPOUND	19	19	etoposide
NCT000030939	NCT00003093_9_T5	COMPOUND	40	40	doxorubicin
NCT000030939	NCT00003093_9_T6	GENE	9	9	IV
NCT000030939	NCT00003093_9_T7	GENE	20	20	IV
NCT000030939	NCT00003093_9_T8	GENE	30	30	IV
NCT000030939	NCT00003093_9_T9	GENE	41	41	IV
NCT000030941	NCT00003094_1_T0	GENE	3	3	II
NCT000030941	NCT00003094_1_T1	PHENOTYPE	18	19	cervical dysplasia
NCT000030943	NCT00003094_3_T0	PHENOTYPE	25	25	dysplasia
NCT000030943	NCT00003094_3_T1	GENE	22	22	II
NCT000030943	NCT00003094_3_T2	PHENOTYPE	13	13	regression
NCT000030945	NCT00003094_5_T0	PHENOTYPE	3	3	regression
NCT000030945	NCT00003094_5_T1	PHENOTYPE	25	25	papilloma
NCT000030945	NCT00003094_5_T2	PHENOTYPE	11	11	reflected
NCT0000309410	NCT00003094_10_T0	PHENOTYPE	4	4	progression
NCT0000309410	NCT00003094_10_T1	PHENOTYPE	6	7	cervical dysplasia
NCT000030952	NCT00003095_2_T0	GENE	16	16	II
NCT000030952	NCT00003095_2_T1	TISSUE	27	28	lymph nodes
NCT000030952	NCT00003095_2_T2	PHENOTYPE	18	21	stage III breast cancer
NCT000030954	NCT00003095_4_T0	BIOLOGICAL_PROCESS	13	13	hematopoiesis
NCT000030954	NCT00003095_4_T1	GENE	20	20	HUMARA
NCT000030954	NCT00003095_4_T2	PHENOTYPE	38	39	breast cancer
NCT000030954	NCT00003095_4_T3	ORGAN	25	26	bone marrow
NCT000030954	NCT00003095_4_T4	GENE	17	18	androgen receptor
NCT000030956	NCT00003095_6_T0	GENE	16	16	defective
NCT000030956	NCT00003095_6_T1	PHENOTYPE	26	27	microsatellite instability
NCT000030956	NCT00003095_6_T2	BIOLOGICAL_PROCESS	18	19	mismatch repair
NCT000030956	NCT00003095_6_T3	PHENOTYPE	8	9	breast cancer
NCT000030958	NCT00003095_8_T0	GENE	8	8	fusion
NCT000030958	NCT00003095_8_T1	BIOLOGICAL_PROCESS	24	24	hematopoiesis
NCT000030958	NCT00003095_8_T2	GENE	15	15	HUMARA
NCT000030958	NCT00003095_8_T3	PHENOTYPE	5	6	lymphoid leukemia
NCT0000309510	NCT00003095_10_T0	GENE	10	10	N-RAS
NCT0000309510	NCT00003095_10_T1	GENE	4	4	RAS
NCT0000309510	NCT00003095_10_T2	PHENOTYPE	16	17	breast cancer
NCT0000309511	NCT00003095_11_T0	ORGAN	10	11	bone marrow
NCT0000309514	NCT00003095_14_T0	PHENOTYPE	10	11	second malignancy
NCT0000309515	NCT00003095_15_T0	ORGAN	6	7	bone marrow
NCT0000309516	NCT00003095_16_T0	GENE	3	3	HUMARA
NCT0000309517	NCT00003095_17_T0	GENE	15	15	BAT
NCT0000309517	NCT00003095_17_T1	PHENOTYPE	0	1	Microsatellite instability
NCT0000309519	NCT00003095_19_T0	GENE	9	9	N-RAS
NCT0000309519	NCT00003095_19_T1	GENE	5	5	RAS
NCT000030962	NCT00003096_2_T0	CELL	14	14	cells
NCT000030962	NCT00003096_2_T1	PHENOTYPE	18	19	brain tumors
NCT000030964	NCT00003096_4_T0	PHENOTYPE	13	13	aneuploidy
NCT000030966	NCT00003096_6_T0	GENE	12	12	FISH
NCT000030966	NCT00003096_6_T1	PHENOTYPE	0	0	Tumors
NCT000030966	NCT00003096_6_T2	PHENOTYPE	15	16	chromosomal rearrangements
NCT000030967	NCT00003096_7_T0	PHENOTYPE	3	3	PNETs
NCT000030967	NCT00003096_7_T1	PHENOTYPE	19	19	tumors
NCT000030967	NCT00003096_7_T2	PHENOTYPE	10	10	distal
NCT000030967	NCT00003096_7_T3	GENE	7	7	FISH
NCT000030967	NCT00003096_7_T4	PHENOTYPE	22	23	17p deletion
NCT000030967	NCT00003096_7_T5	PHENOTYPE	0	2	Primitive neuroectodermal tumors
NCT000030968	NCT00003096_8_T0	PHENOTYPE	2	2	tumors
NCT000030968	NCT00003096_8_T1	GENE	12	12	FISH
NCT000030968	NCT00003096_8_T2	PHENOTYPE	4	4	PNETs
NCT000030968	NCT00003096_8_T3	PHENOTYPE	7	8	17p deletion
NCT000030969	NCT00003096_9_T0	PHENOTYPE	14	14	tumors
NCT000030969	NCT00003096_9_T1	BIOLOGICAL_PROCESS	5	5	interphase
NCT000030969	NCT00003096_9_T2	GENE	6	6	FISH
NCT000030969	NCT00003096_9_T3	PHENOTYPE	0	0	PNETs
NCT000030969	NCT00003096_9_T4	CELL	10	11	chromosome 6
NCT000030972	NCT00003097_2_T0	GENE	3	3	II
NCT000030972	NCT00003097_2_T1	PHENOTYPE	22	23	skin cancer
NCT000030972	NCT00003097_2_T2	PHENOTYPE	16	17	disease progression
NCT000030974	NCT00003097_4_T0	PHENOTYPE	19	20	skin cancer
NCT000030974	NCT00003097_4_T1	PHENOTYPE	31	32	skin cancers
NCT000030976	NCT00003097_6_T0	PHENOTYPE	9	9	tumors
NCT000030978	NCT00003097_8_T0	PHENOTYPE	5	6	skin cancer
NCT0000309711	NCT00003097_11_T0	GENE	3	3	has
NCT0000309711	NCT00003097_11_T1	BIOLOGICAL_PROCESS	10	10	eating
NCT0000309712	NCT00003097_12_T0	GENE	5	5	has
NCT0000309712	NCT00003097_12_T1	BIOLOGICAL_PROCESS	12	12	eating
NCT0000309713	NCT00003097_13_T0	PHENOTYPE	7	9	of skin cancer
NCT000030981	NCT00003098_1_T0	BIOLOGICAL_PROCESS	21	22	estrogen metabolism
NCT000030985	NCT00003098_5_T0	BIOLOGICAL_PROCESS	7	8	steroid metabolism
NCT000030988	NCT00003098_8_T0	BIOLOGICAL_PROCESS	7	8	steroid metabolism
NCT0000309815	NCT00003098_15_T0	BIOLOGICAL_PROCESS	7	8	steroid metabolism
NCT0000309818	NCT00003098_18_T0	BIOLOGICAL_PROCESS	7	8	steroid metabolism
NCT000030992	NCT00003099_2_T0	GENE	3	3	II
NCT000030992	NCT00003099_2_T1	COMPOUND	10	10	fenretinide
NCT000030992	NCT00003099_2_T2	COMPOUND	12	12	tamoxifen
NCT000030992	NCT00003099_2_T3	PHENOTYPE	20	21	breast cancer
NCT000030995	NCT00003099_5_T0	PHENOTYPE	12	16	ductal carcinoma in situ and
NCT000030995	NCT00003099_5_T1	PHENOTYPE	11	15	breast ductal carcinoma in situ
NCT000030997	NCT00003099_7_T0	COMPOUND	4	4	fenretinide
NCT000030997	NCT00003099_7_T1	COMPOUND	6	6	tamoxifen
NCT000030999	NCT00003099_9_T0	PHENOTYPE	9	9	carcinoma
NCT000030999	NCT00003099_9_T1	PHENOTYPE	7	7	hyperplasia
NCT000031008	NCT00003100_8_T0	PHENOTYPE	8	8	menopausal
NCT000031009	NCT00003100_9_T0	GENE	2	2	II
NCT0000310012	NCT00003100_12_T0	COMPOUND	8	8	isoflavone
NCT0000310015	NCT00003100_15_T0	COMPOUND	8	8	isoflavone
NCT000031015	NCT00003101_5_T0	PHENOTYPE	13	13	toxicity
NCT000031015	NCT00003101_5_T1	PHENOTYPE	9	10	progressive disease
NCT000031016	NCT00003101_6_T0	GENE	9	9	PCV
NCT000031016	NCT00003101_6_T1	PHENOTYPE	21	21	tumor
NCT000031016	NCT00003101_6_T2	GENE	22	22	has
NCT000031017	NCT00003101_7_T0	GENE	27	27	PR
NCT000031017	NCT00003101_7_T1	GENE	11	11	PCV
NCT000031017	NCT00003101_7_T2	GENE	33	33	PCV
NCT000031017	NCT00003101_7_T3	GENE	22	22	CR
NCT0000310111	NCT00003101_11_T0	GENE	14	14	3.5
NCT000031021	NCT00003102_1_T0	PHENOTYPE	17	18	kidney cancer
NCT000031025	NCT00003102_5_T0	GENE	5	5	MTD
NCT000031027	NCT00003102_7_T0	PHENOTYPE	2	2	pharmacokinetics
NCT000031029	NCT00003102_9_T0	GENE	10	10	MTD
NCT0000310211	NCT00003102_11_T0	COMPOUND	8	8	iodine
NCT0000310211	NCT00003102_11_T1	GENE	7	7	IV
NCT0000310212	NCT00003102_12_T0	GENE	16	16	2.3
NCT0000310212	NCT00003102_12_T1	GENE	8	8	IV
NCT0000310214	NCT00003102_14_T0	PHENOTYPE	6	6	toxicity
NCT0000310215	NCT00003102_15_T0	PHENOTYPE	3	3	toxicity
NCT0000310215	NCT00003102_15_T1	GENE	31	31	MTD
NCT0000310216	NCT00003102_16_T0	PHENOTYPE	6	6	toxic
NCT0000310217	NCT00003102_17_T0	PHENOTYPE	3	3	remission
NCT0000310217	NCT00003102_17_T1	PHENOTYPE	5	5	remission
NCT0000310218	NCT00003102_18_T0	PHENOTYPE	3	4	disease progression
NCT000031030	NCT00003103_0_T0	PHENOTYPE	5	6	Solid Tumors
NCT000031032	NCT00003103_2_T0	PHENOTYPE	15	16	solid tumors
NCT000031034	NCT00003103_4_T0	COMPOUND	16	16	docetaxel
NCT000031034	NCT00003103_4_T1	ORGAN	4	4	plasma
NCT000031034	NCT00003103_4_T2	GENE	26	26	oncogene
NCT000031034	NCT00003103_4_T3	GENE	25	25	bcl-2
NCT000031034	NCT00003103_4_T4	PHENOTYPE	21	22	solid tumors
NCT000031036	NCT00003103_6_T0	COMPOUND	13	13	OBD
NCT000031036	NCT00003103_6_T1	ORGAN	2	2	plasma
NCT000031036	NCT00003103_6_T2	GENE	8	8	MTD
NCT0000310310	NCT00003103_10_T0	COMPOUND	10	10	docetaxel
NCT0000310310	NCT00003103_10_T1	GENE	8	8	1.5
NCT0000310310	NCT00003103_10_T2	GENE	5	5	IV
NCT0000310310	NCT00003103_10_T3	GENE	11	11	IV
NCT0000310311	NCT00003103_11_T0	PHENOTYPE	18	18	toxicity
NCT0000310311	NCT00003103_11_T1	PHENOTYPE	14	15	disease progression
NCT0000310312	NCT00003103_12_T0	GENE	14	14	MTD
NCT0000310313	NCT00003103_13_T0	PHENOTYPE	22	22	toxicity
NCT0000310313	NCT00003103_13_T1	GENE	1	1	MTD
NCT0000310314	NCT00003103_14_T0	GENE	1	1	II
NCT0000310314	NCT00003103_14_T1	COMPOUND	20	20	docetaxel
NCT0000310314	NCT00003103_14_T2	GENE	15	15	MTD
NCT0000310315	NCT00003103_15_T0	PHENOTYPE	17	17	toxicity
NCT0000310315	NCT00003103_15_T1	PHENOTYPE	13	14	disease progression
NCT0000310316	NCT00003103_16_T0	PHENOTYPE	7	8	disease progression
NCT0000310317	NCT00003103_17_T0	GENE	15	15	II
NCT000031041	NCT00003104_1_T0	PHENOTYPE	12	12	tumor
NCT000031051	NCT00003105_1_T0	CELL	9	9	cells
NCT000031051	NCT00003105_1_T1	PHENOTYPE	8	8	tumor
NCT000031052	NCT00003105_2_T0	PHENOTYPE	19	20	bladder cancer
NCT000031054	NCT00003105_4_T0	COMPOUND	7	7	gemcitabine
NCT000031055	NCT00003105_5_T0	GENE	17	17	SC
NCT000031055	NCT00003105_5_T1	GENE	14	14	filgrastim
NCT000031055	NCT00003105_5_T2	GENE	15	15	G-CSF
NCT000031055	NCT00003105_5_T3	COMPOUND	8	8	gemcitabine
NCT000031055	NCT00003105_5_T4	COMPOUND	2	2	doxorubicin
NCT000031055	NCT00003105_5_T5	GENE	3	3	IV
NCT000031055	NCT00003105_5_T6	GENE	9	9	IV
NCT000031057	NCT00003105_7_T0	GENE	32	32	SC
NCT000031057	NCT00003105_7_T1	COMPOUND	8	8	paclitaxel
NCT000031057	NCT00003105_7_T2	COMPOUND	22	22	ifosfamide
NCT000031057	NCT00003105_7_T3	GENE	29	29	1.3
NCT000031057	NCT00003105_7_T4	GENE	31	31	G-CSF
NCT000031057	NCT00003105_7_T5	COMPOUND	14	14	cisplatin
NCT000031057	NCT00003105_7_T6	GENE	9	9	IV
NCT000031057	NCT00003105_7_T7	GENE	15	15	IV
NCT000031057	NCT00003105_7_T8	GENE	23	23	IV
NCT000031058	NCT00003105_8_T0	GENE	3	3	3.4
NCT000031059	NCT00003105_9_T0	COMPOUND	8	8	gemcitabine
NCT000031059	NCT00003105_9_T1	GENE	14	14	MTD
NCT0000310510	NCT00003105_10_T0	PHENOTYPE	19	19	toxicity
NCT0000310510	NCT00003105_10_T1	GENE	1	1	MTD
NCT0000310511	NCT00003105_11_T0	GENE	2	2	MTD
NCT0000310511	NCT00003105_11_T1	GENE	11	11	MTD
NCT0000310512	NCT00003105_12_T0	GENE	24	24	II
NCT0000310512	NCT00003105_12_T1	GENE	26	26	2.3
NCT000031070	NCT00003107_0_T0	PHENOTYPE	6	6	Cancers
NCT000031070	NCT00003107_0_T1	PHENOTYPE	8	9	Solid Tumors
NCT000031072	NCT00003107_2_T0	GENE	9	9	interleukin-12
NCT000031072	NCT00003107_2_T1	PHENOTYPE	18	19	solid tumor
NCT000031072	NCT00003107_2_T2	PHENOTYPE	15	16	hematologic cancer
NCT000031076	NCT00003107_6_T0	GENE	7	7	IL-12
NCT000031078	NCT00003107_8_T0	GENE	2	2	interleukin-12
NCT000031078	NCT00003107_8_T1	GENE	3	3	IL-12
NCT000031078	NCT00003107_8_T2	GENE	4	4	IV
NCT000031079	NCT00003107_9_T0	GENE	3	3	IL-12
NCT000031079	NCT00003107_9_T1	GENE	4	4	IV
NCT0000310710	NCT00003107_10_T0	GENE	8	8	IL-12
NCT0000310710	NCT00003107_10_T1	GENE	2	2	3.5
NCT0000310710	NCT00003107_10_T2	GENE	14	14	MTD
NCT0000310711	NCT00003107_11_T0	PHENOTYPE	17	17	toxicity
NCT0000310711	NCT00003107_11_T1	GENE	1	1	MTD
NCT000031081	NCT00003108_1_T0	CELL	9	9	cells
NCT000031081	NCT00003108_1_T1	PHENOTYPE	8	8	tumor
NCT000031082	NCT00003108_2_T0	COMPOUND	9	9	cisplatin
NCT000031082	NCT00003108_2_T1	PHENOTYPE	18	19	advanced cancer
NCT000031082	NCT00003108_2_T2	COMPOUND	11	12	bryostatin 1
NCT000031084	NCT00003108_4_T0	PHENOTYPE	4	4	toxicity
NCT000031084	NCT00003108_4_T1	COMPOUND	14	14	cisplatin
NCT000031084	NCT00003108_4_T2	PHENOTYPE	21	22	solid tumors
NCT000031084	NCT00003108_4_T3	COMPOUND	11	12	bryostatin 1
NCT000031086	NCT00003108_6_T0	COMPOUND	11	11	cisplatin
NCT000031086	NCT00003108_6_T1	COMPOUND	35	35	cisplatin
NCT000031086	NCT00003108_6_T2	COMPOUND	17	18	bryostatin 1
NCT000031086	NCT00003108_6_T3	COMPOUND	28	29	bryostatin 1
NCT000031087	NCT00003108_7_T0	COMPOUND	4	4	cisplatin
NCT000031087	NCT00003108_7_T1	COMPOUND	20	21	bryostatin 1
NCT000031088	NCT00003108_8_T0	COMPOUND	10	10	cisplatin
NCT000031088	NCT00003108_8_T1	COMPOUND	4	5	bryostatin 1
NCT0000310810	NCT00003108_10_T0	GENE	8	8	MTD
NCT0000310811	NCT00003108_11_T0	PHENOTYPE	18	18	toxicity
NCT0000310811	NCT00003108_11_T1	GENE	1	1	MTD
NCT0000310812	NCT00003108_12_T0	GENE	2	2	MTD
NCT000031090	NCT00003109_0_T0	PHENOTYPE	8	9	Solid Tumors
NCT000031092	NCT00003109_2_T0	CELL	9	9	cells
NCT000031092	NCT00003109_2_T1	PHENOTYPE	8	8	tumor
NCT000031093	NCT00003109_3_T0	COMPOUND	9	9	irinotecan
NCT000031093	NCT00003109_3_T1	COMPOUND	11	11	raltitrexed
NCT000031093	NCT00003109_3_T2	PHENOTYPE	18	19	solid tumors
NCT000031095	NCT00003109_5_T0	COMPOUND	6	6	irinotecan
NCT000031095	NCT00003109_5_T1	COMPOUND	10	10	raltitrexed
NCT000031095	NCT00003109_5_T2	PHENOTYPE	15	16	solid tumors
NCT000031097	NCT00003109_7_T0	PHENOTYPE	4	4	toxic
NCT000031099	NCT00003109_9_T0	PHENOTYPE	2	2	pharmacokinetics
NCT0000310912	NCT00003109_12_T0	COMPOUND	8	8	irinotecan
NCT0000310912	NCT00003109_12_T1	COMPOUND	10	10	raltitrexed
NCT0000310913	NCT00003109_13_T0	COMPOUND	2	2	irinotecan
NCT0000310913	NCT00003109_13_T1	COMPOUND	14	14	raltitrexed
NCT0000310913	NCT00003109_13_T2	GENE	3	3	IV
NCT0000310913	NCT00003109_13_T3	GENE	15	15	IV
NCT0000310914	NCT00003109_14_T0	PHENOTYPE	13	13	toxicity
NCT0000310914	NCT00003109_14_T1	PHENOTYPE	9	10	disease progression
NCT0000310915	NCT00003109_15_T0	COMPOUND	9	9	irinotecan
NCT0000310915	NCT00003109_15_T1	COMPOUND	11	11	raltitrexed
NCT0000310915	NCT00003109_15_T2	GENE	17	17	MTD
NCT0000310916	NCT00003109_16_T0	PHENOTYPE	18	18	toxicities
NCT0000310916	NCT00003109_16_T1	GENE	1	1	MTD
NCT0000310917	NCT00003109_17_T0	COMPOUND	3	3	raltitrexed
NCT000031101	NCT00003110_1_T0	GENE	2	2	II
NCT000031101	NCT00003110_1_T1	COMPOUND	9	9	bleomycin
NCT000031101	NCT00003110_1_T2	PHENOTYPE	14	15	Hodgkin's lymphoma
NCT000031104	NCT00003110_4_T0	PHENOTYPE	4	4	remission
NCT000031106	NCT00003110_6_T0	COMPOUND	12	12	bleomycin
NCT000031106	NCT00003110_6_T1	PHENOTYPE	20	21	Hodgkin's lymphoma
NCT000031108	NCT00003110_8_T0	PHENOTYPE	4	4	toxicity
NCT0000311010	NCT00003110_10_T0	PHENOTYPE	11	12	Hodgkin's lymphoma
NCT0000311010	NCT00003110_10_T1	PHENOTYPE	2	4	quality of life
NCT0000311011	NCT00003110_11_T0	PHENOTYPE	14	14	HIV/AIDS
NCT0000311012	NCT00003110_12_T0	COMPOUND	2	2	bleomycin
NCT0000311014	NCT00003110_14_T0	PHENOTYPE	4	4	remission
NCT0000311015	NCT00003110_15_T0	PHENOTYPE	15	15	toxicity
NCT0000311015	NCT00003110_15_T1	PHENOTYPE	3	3	remission
NCT0000311015	NCT00003110_15_T2	PHENOTYPE	11	12	disease progression
NCT0000311016	NCT00003110_16_T0	PHENOTYPE	0	2	Quality of life
NCT0000311020	NCT00003110_20_T0	PHENOTYPE	18	18	lymphoma
NCT0000311020	NCT00003110_20_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000311020	NCT00003110_20_T2	PHENOTYPE	16	17	high grade
NCT000031112	NCT00003111_2_T0	CELL	9	9	cells
NCT000031112	NCT00003111_2_T1	PHENOTYPE	8	8	tumor
NCT000031115	NCT00003111_5_T0	COMPOUND	11	11	irinotecan
NCT000031115	NCT00003111_5_T1	COMPOUND	4	4	cisplatin
NCT000031115	NCT00003111_5_T2	GENE	3	3	IV
NCT000031115	NCT00003111_5_T3	GENE	10	10	IV
NCT000031116	NCT00003111_6_T0	PHENOTYPE	9	10	disease progression
NCT000031118	NCT00003111_8_T0	COMPOUND	14	14	paclitaxel
NCT000031118	NCT00003111_8_T1	GENE	11	11	IV
NCT000031119	NCT00003111_9_T0	COMPOUND	13	13	paclitaxel
NCT000031131	NCT00003113_1_T0	CELL	16	16	cells
NCT000031131	NCT00003113_1_T1	PHENOTYPE	15	15	tumor
NCT000031132	NCT00003113_2_T0	GENE	2	2	II
NCT000031132	NCT00003113_2_T1	GENE	13	13	G-CSF
NCT000031132	NCT00003113_2_T2	PHENOTYPE	21	22	Hodgkin's lymphomas
NCT000031135	NCT00003113_5_T0	GENE	5	5	1.3
NCT000031135	NCT00003113_5_T1	COMPOUND	7	7	cyclophosphamide
NCT000031135	NCT00003113_5_T2	COMPOUND	9	9	procarbazine
NCT000031137	NCT00003113_7_T0	CELL	1	1	granulocyte
NCT000031137	NCT00003113_7_T1	GENE	4	4	G-CSF
NCT000031138	NCT00003113_8_T0	PHENOTYPE	3	4	disease progression
NCT0000311310	NCT00003113_10_T0	GENE	5	5	PR
NCT0000311311	NCT00003113_11_T0	GENE	15	15	nodal
NCT0000311311	NCT00003113_11_T1	PHENOTYPE	7	8	residual disease
NCT0000311312	NCT00003113_12_T0	GENE	5	5	PR
NCT000031141	NCT00003114_1_T0	CELL	9	9	cells
NCT000031141	NCT00003114_1_T1	PHENOTYPE	8	8	tumor
NCT000031142	NCT00003114_2_T0	GENE	2	2	II
NCT000031142	NCT00003114_2_T1	GENE	27	27	IV
NCT000031142	NCT00003114_2_T2	COMPOUND	16	16	procarbazine
NCT000031142	NCT00003114_2_T3	COMPOUND	12	12	lomustine
NCT000031142	NCT00003114_2_T4	COMPOUND	14	14	cyclophosphamide
NCT000031142	NCT00003114_2_T5	COMPOUND	13	13	etoposide
NCT000031142	NCT00003114_2_T6	PHENOTYPE	23	24	stage III
NCT000031142	NCT00003114_2_T7	PHENOTYPE	29	30	Hodgkin's disease
NCT000031145	NCT00003114_5_T0	GENE	12	12	1.3
NCT000031145	NCT00003114_5_T1	COMPOUND	15	15	cyclophosphamide
NCT000031145	NCT00003114_5_T2	COMPOUND	9	9	etoposide
NCT000031145	NCT00003114_5_T3	COMPOUND	17	17	procarbazine
NCT000031145	NCT00003114_5_T4	COMPOUND	4	4	lomustine
NCT000031146	NCT00003114_6_T0	CELL	1	1	granulocyte
NCT000031153	NCT00003115_3_T0	COMPOUND	6	6	hydromorphone
NCT000031155	NCT00003115_5_T0	COMPOUND	13	13	hydromorphone
NCT000031155	NCT00003115_5_T1	PHENOTYPE	10	11	blood concentrations
NCT000031157	NCT00003115_7_T0	COMPOUND	7	7	hydromorphone
NCT000031158	NCT00003115_8_T0	COMPOUND	4	4	hydromorphone
NCT000031158	NCT00003115_8_T1	COMPOUND	19	19	hydromorphone
NCT000031158	NCT00003115_8_T2	PHENOTYPE	15	15	analgesia
NCT000031158	NCT00003115_8_T3	PHENOTYPE	30	30	analgesia
NCT000031164	NCT00003116_4_T0	COMPOUND	25	25	cyclosporine
NCT000031164	NCT00003116_4_T1	GENE	15	15	IV
NCT000031164	NCT00003116_4_T2	GENE	26	26	IV
NCT000031164	NCT00003116_4_T3	COMPOUND	5	5	busulfan
NCT000031164	NCT00003116_4_T4	COMPOUND	32	32	1
NCT000031164	NCT00003116_4_T5	COMPOUND	23	23	3
NCT000031164	NCT00003116_4_T6	COMPOUND	14	14	cyclophosphamide
NCT000031165	NCT00003116_5_T0	PHENOTYPE	1	1	peripheral
NCT000031165	NCT00003116_5_T1	GENE	5	5	IV
NCT000031165	NCT00003116_5_T2	CELL	3	4	progenitor cells
NCT000031167	NCT00003116_7_T0	PHENOTYPE	20	21	disease progression
NCT000031172	NCT00003117_2_T0	CELL	9	9	cells
NCT000031172	NCT00003117_2_T1	PHENOTYPE	8	8	tumor
NCT000031177	NCT00003117_7_T0	PHENOTYPE	2	4	quality of life
NCT000031179	NCT00003117_9_T0	PHENOTYPE	6	6	toxic
NCT0000311711	NCT00003117_11_T0	COMPOUND	25	25	2
NCT0000311711	NCT00003117_11_T1	PHENOTYPE	16	16	progressive
NCT0000311711	NCT00003117_11_T2	GENE	12	12	IV
NCT0000311711	NCT00003117_11_T3	PHENOTYPE	14	14	recurrent
NCT0000311715	NCT00003117_15_T0	PHENOTYPE	17	17	toxicity
NCT0000311715	NCT00003117_15_T1	PHENOTYPE	13	14	tumor progression
NCT0000311716	NCT00003117_16_T0	PHENOTYPE	0	2	Quality of life
NCT0000311717	NCT00003117_17_T0	PHENOTYPE	14	15	disease progression
NCT000031181	NCT00003118_1_T0	CELL	8	8	cells
NCT000031181	NCT00003118_1_T1	PHENOTYPE	7	7	tumor
NCT000031182	NCT00003118_2_T0	PHENOTYPE	18	21	cancer of the esophagus
NCT000031185	NCT00003118_5_T0	COMPOUND	12	12	cisplatin
NCT000031187	NCT00003118_7_T0	PHENOTYPE	4	4	toxicities
NCT000031189	NCT00003118_9_T0	PHENOTYPE	27	27	recurrence
NCT000031189	NCT00003118_9_T1	ORGAN	20	20	liver
NCT000031189	NCT00003118_9_T2	TISSUE	13	14	lymph nodes
NCT000031189	NCT00003118_9_T3	TISSUE	18	19	lymph node
NCT000031189	NCT00003118_9_T4	PHENOTYPE	21	22	peritoneal carcinomatosis
NCT0000311811	NCT00003118_11_T0	PHENOTYPE	16	16	recurrence
NCT0000311813	NCT00003118_13_T0	PHENOTYPE	13	13	tumors
NCT0000311815	NCT00003118_15_T0	PHENOTYPE	9	9	recurrence
NCT0000311815	NCT00003118_15_T1	TISSUE	4	5	lymph nodes
NCT0000311819	NCT00003118_19_T0	COMPOUND	3	3	cisplatin
NCT0000311819	NCT00003118_19_T1	GENE	7	7	IV
NCT0000311820	NCT00003118_20_T0	GENE	13	13	1.4
NCT0000311820	NCT00003118_20_T1	COMPOUND	19	19	cisplatin
NCT0000311820	NCT00003118_20_T2	GENE	6	6	IV
NCT0000311821	NCT00003118_21_T0	GENE	5	5	1.5
NCT0000311821	NCT00003118_21_T1	GENE	8	8	22.26
NCT0000311822	NCT00003118_22_T0	GENE	13	13	3.8
NCT0000311822	NCT00003118_22_T1	PHENOTYPE	4	5	disease progression
NCT0000311828	NCT00003118_28_T0	PHENOTYPE	4	5	metastatic disease
NCT0000311829	NCT00003118_29_T0	ORGAN	12	12	abdomen
NCT0000311831	NCT00003118_31_T0	GENE	5	6	alkaline phosphatase
NCT0000311833	NCT00003118_33_T0	ORGAN	16	16	bronchus
NCT0000311833	NCT00003118_33_T1	ORGAN	11	11	trachea
NCT0000311833	NCT00003118_33_T2	PHENOTYPE	5	6	primary tumor
NCT0000311836	NCT00003118_36_T0	GENE	16	16	axis
NCT0000311836	NCT00003118_36_T1	GENE	8	8	ts
NCT0000311837	NCT00003118_37_T0	PHENOTYPE	14	14	metastases
NCT0000311837	NCT00003118_37_T1	GENE	7	7	NX
NCT0000311837	NCT00003118_37_T2	PHENOTYPE	0	0	Tumors
NCT0000311837	NCT00003118_37_T3	TISSUE	11	12	lymph node
NCT0000311839	NCT00003118_39_T0	GENE	7	7	1.5
NCT0000311839	NCT00003118_39_T1	GENE	8	8	cm
NCT0000311839	NCT00003118_39_T2	TISSUE	3	4	lymph nodes
NCT0000311840	NCT00003118_40_T0	GENE	17	17	cm
NCT0000311840	NCT00003118_40_T1	GENE	12	12	axis
NCT0000311840	NCT00003118_40_T2	PHENOTYPE	2	4	lymph node metastases
NCT0000311841	NCT00003118_41_T0	PHENOTYPE	12	12	tumor
NCT0000311842	NCT00003118_42_T0	PHENOTYPE	18	18	tumor
NCT0000311842	NCT00003118_42_T1	PHENOTYPE	3	3	malignancies
NCT0000311842	NCT00003118_42_T2	GENE	11	11	had
NCT0000311844	NCT00003118_44_T0	PHENOTYPE	10	10	infections
NCT000031191	NCT00003119_1_T0	PHENOTYPE	16	16	neuroblastoma
NCT000031191	NCT00003119_1_T1	GENE	2	2	III
NCT000031194	NCT00003119_4_T0	GENE	7	7	MYCN
NCT000031195	NCT00003119_5_T0	PHENOTYPE	2	3	primary tumor
NCT000031196	NCT00003119_6_T0	PHENOTYPE	7	7	tumor
NCT000031199	NCT00003119_9_T0	GENE	8	8	filgrastim
NCT000031199	NCT00003119_9_T1	GENE	9	9	G-CSF
NCT000031199	NCT00003119_9_T2	GENE	12	12	GM-CSF
NCT000031199	NCT00003119_9_T3	GENE	11	11	sargramostim
NCT0000311910	NCT00003119_10_T0	PHENOTYPE	13	13	toxicity
NCT0000311911	NCT00003119_11_T0	PHENOTYPE	5	7	spinal cord compression
NCT0000311912	NCT00003119_12_T0	PHENOTYPE	2	2	progressive
NCT0000311912	NCT00003119_12_T1	PHENOTYPE	4	5	recurrent disease
NCT000031201	NCT00003120_1_T0	COMPOUND	7	7	paclitaxel
NCT000031201	NCT00003120_1_T1	PHENOTYPE	25	26	ovarian cancer
NCT000031206	NCT00003120_6_T0	PHENOTYPE	2	2	toxic
NCT000031206	NCT00003120_6_T1	COMPOUND	7	7	paclitaxel
NCT000031208	NCT00003120_8_T0	COMPOUND	18	18	paclitaxel
NCT000031208	NCT00003120_8_T1	GENE	14	14	IV
NCT000031208	NCT00003120_8_T2	PHENOTYPE	6	7	stage III
NCT000031208	NCT00003120_8_T3	PHENOTYPE	10	11	stage III
NCT0000312011	NCT00003120_11_T0	PHENOTYPE	16	16	toxicity
NCT0000312011	NCT00003120_11_T1	PHENOTYPE	12	13	disease progression
NCT0000312013	NCT00003120_13_T0	PHENOTYPE	16	16	toxicity
NCT0000312013	NCT00003120_13_T1	PHENOTYPE	12	13	disease progression
NCT0000312014	NCT00003120_14_T0	PHENOTYPE	7	8	disease progression
NCT000031221	NCT00003122_1_T0	GENE	3	3	II
NCT000031221	NCT00003122_1_T1	PHENOTYPE	15	15	neuroblastoma
NCT000031223	NCT00003122_3_T0	PHENOTYPE	5	5	tumors
NCT000031223	NCT00003122_3_T1	PHENOTYPE	3	3	localized
NCT000031225	NCT00003122_5_T0	GENE	14	14	II
NCT000031225	NCT00003122_5_T1	PHENOTYPE	8	8	tumors
NCT000031225	NCT00003122_5_T2	PHENOTYPE	15	15	tumors
NCT000031225	NCT00003122_5_T3	GENE	6	6	N-myc
NCT000031226	NCT00003122_6_T0	PHENOTYPE	20	20	relapse
NCT000031226	NCT00003122_6_T1	PHENOTYPE	17	18	disease progression
NCT000031235	NCT00003123_5_T0	PHENOTYPE	2	2	toxic
NCT000031235	NCT00003123_5_T1	COMPOUND	5	5	amifostine
NCT000031237	NCT00003123_7_T0	COMPOUND	3	3	amifostine
NCT0000312312	NCT00003123_12_T0	PHENOTYPE	2	2	relapse
NCT000031242	NCT00003124_2_T0	CELL	10	10	cells
NCT000031242	NCT00003124_2_T1	PHENOTYPE	9	9	tumor
NCT000031242	NCT00003124_2_T2	GENE	4	4	hormone
NCT000031246	NCT00003124_6_T0	COMPOUND	4	4	acetate
NCT000031246	NCT00003124_6_T1	COMPOUND	10	10	flutamide
NCT000031246	NCT00003124_6_T2	COMPOUND	3	3	leuprolide
NCT000031246	NCT00003124_6_T3	GENE	11	11	tid
NCT000031249	NCT00003124_9_T0	PHENOTYPE	4	5	disease progression
NCT0000312410	NCT00003124_10_T0	COMPOUND	12	12	flutamide
NCT0000312410	NCT00003124_10_T1	PHENOTYPE	8	8	initiation
NCT0000312410	NCT00003124_10_T2	COMPOUND	10	10	leuprolide
NCT0000312413	NCT00003124_13_T0	PHENOTYPE	12	13	class II
NCT000031251	NCT00003125_1_T0	CELL	11	11	cells
NCT000031251	NCT00003125_1_T1	GENE	4	4	sargramostim
NCT000031252	NCT00003125_2_T0	CELL	11	11	cells
NCT000031252	NCT00003125_2_T1	GENE	0	0	Interleukin-2
NCT000031252	NCT00003125_2_T2	CELL	5	7	white blood cells
NCT000031253	NCT00003125_3_T0	CELL	10	10	cells
NCT000031253	NCT00003125_3_T1	GENE	5	5	interleukin-2
NCT000031253	NCT00003125_3_T2	GENE	3	3	sargramostim
NCT000031254	NCT00003125_4_T0	GENE	3	3	II
NCT000031254	NCT00003125_4_T1	PHENOTYPE	21	21	tumors
NCT000031254	NCT00003125_4_T2	GENE	14	14	interleukin-2
NCT000031254	NCT00003125_4_T3	GENE	12	12	sargramostim
NCT000031256	NCT00003125_6_T0	PHENOTYPE	35	35	tumors
NCT000031256	NCT00003125_6_T1	GENE	28	28	interleukin-2
NCT000031256	NCT00003125_6_T2	GENE	29	29	IL-2
NCT000031256	NCT00003125_6_T3	GENE	24	24	GM-CSF
NCT000031256	NCT00003125_6_T4	GENE	8	8	CEA
NCT000031256	NCT00003125_6_T5	GENE	33	33	CEA
NCT000031256	NCT00003125_6_T6	GENE	23	23	sargramostim
NCT000031258	NCT00003125_8_T0	GENE	2	2	CEA
NCT000031258	NCT00003125_8_T1	BIOLOGICAL_PROCESS	3	5	cellular immune response
NCT0000312510	NCT00003125_10_T0	GENE	9	9	IL-2
NCT0000312510	NCT00003125_10_T1	GENE	5	5	GM-CSF
NCT0000312510	NCT00003125_10_T2	BIOLOGICAL_PROCESS	12	13	immune response
NCT0000312512	NCT00003125_12_T0	GENE	14	14	CEA
NCT0000312512	NCT00003125_12_T1	PHENOTYPE	10	10	cytotoxicity
NCT0000312512	NCT00003125_12_T2	CELL	16	16	lymphocyte
NCT0000312512	NCT00003125_12_T3	BIOLOGICAL_PROCESS	17	18	immune response
NCT0000312528	NCT00003125_28_T0	PHENOTYPE	10	10	toxic
NCT000031262	NCT00003126_2_T0	GENE	14	14	IL-2
NCT000031271	NCT00003127_1_T0	CELL	9	9	cells
NCT000031271	NCT00003127_1_T1	PHENOTYPE	8	8	tumor
NCT000031272	NCT00003127_2_T0	GENE	2	2	II
NCT000031272	NCT00003127_2_T1	PHENOTYPE	16	16	recurrent
NCT000031272	NCT00003127_2_T2	PHENOTYPE	19	20	endometrial cancer
NCT000031274	NCT00003127_4_T0	COMPOUND	4	4	paclitaxel
NCT000031274	NCT00003127_4_T1	PHENOTYPE	10	10	progression
NCT000031274	NCT00003127_4_T2	COMPOUND	8	8	amifostine
NCT000031274	NCT00003127_4_T3	PHENOTYPE	21	21	recurrent
NCT000031274	NCT00003127_4_T4	PHENOTYPE	23	24	endometrial carcinoma
NCT000031278	NCT00003127_8_T0	PHENOTYPE	6	6	toxicity
NCT000031279	NCT00003127_9_T0	COMPOUND	3	3	paclitaxel
NCT000031279	NCT00003127_9_T1	COMPOUND	9	9	amifostine
NCT000031279	NCT00003127_9_T2	GENE	4	4	IV
NCT000031279	NCT00003127_9_T3	GENE	10	10	IV
NCT000031279	NCT00003127_9_T4	GENE	20	20	IV
NCT0000312711	NCT00003127_11_T0	PHENOTYPE	9	10	disease progression
NCT000031286	NCT00003128_6_T0	CELL	10	10	granulocyte
NCT000031286	NCT00003128_6_T1	GENE	1	1	G-CSF
NCT000031287	NCT00003128_7_T0	COMPOUND	9	9	ifosfamide
NCT000031291	NCT00003129_1_T0	GENE	2	2	II
NCT000031291	NCT00003129_1_T1	GENE	22	22	BCG
NCT000031291	NCT00003129_1_T2	GENE	18	18	has
NCT000031291	NCT00003129_1_T3	PHENOTYPE	15	16	bladder cancer
NCT000031294	NCT00003129_4_T0	GENE	3	3	AD
NCT000031300	NCT00003130_0_T0	PHENOTYPE	5	5	Recurrent
NCT000031300	NCT00003130_0_T1	PHENOTYPE	6	7	Solid Tumors
NCT000031302	NCT00003130_2_T0	GENE	2	2	II
NCT000031302	NCT00003130_2_T1	COMPOUND	9	9	paclitaxel
NCT000031302	NCT00003130_2_T2	PHENOTYPE	15	15	recurrent
NCT000031302	NCT00003130_2_T3	PHENOTYPE	16	17	solid tumors
NCT000031304	NCT00003130_4_T0	COMPOUND	32	32	paclitaxel
NCT000031304	NCT00003130_4_T1	PHENOTYPE	9	9	toxic
NCT000031304	NCT00003130_4_T2	PHENOTYPE	17	17	toxic
NCT000031304	NCT00003130_4_T3	PHENOTYPE	13	13	pharmacokinetics
NCT000031304	NCT00003130_4_T4	PHENOTYPE	15	15	pharmacokinetics
NCT000031304	NCT00003130_4_T5	PHENOTYPE	22	22	recurrent
NCT000031304	NCT00003130_4_T6	PHENOTYPE	23	24	solid tumors
NCT000031306	NCT00003130_6_T0	PHENOTYPE	2	2	toxic
NCT000031306	NCT00003130_6_T1	COMPOUND	5	5	paclitaxel
NCT000031308	NCT00003130_8_T0	COMPOUND	4	4	paclitaxel
NCT000031308	NCT00003130_8_T1	PHENOTYPE	2	2	pharmacokinetics
NCT000031309	NCT00003130_9_T0	COMPOUND	7	7	paclitaxel
NCT0000313010	NCT00003130_10_T0	COMPOUND	9	9	paclitaxel
NCT0000313011	NCT00003130_11_T0	COMPOUND	4	4	paclitaxel
NCT000031317	NCT00003131_7_T0	GENE	3	3	IV
NCT000031319	NCT00003131_9_T0	PHENOTYPE	20	20	relapse
NCT000031319	NCT00003131_9_T1	PHENOTYPE	6	6	remission
NCT0000313111	NCT00003131_11_T0	GENE	4	4	extended
NCT000031321	NCT00003132_1_T0	CELL	9	9	cells
NCT000031321	NCT00003132_1_T1	PHENOTYPE	8	8	tumor
NCT000031322	NCT00003132_2_T0	COMPOUND	12	12	cisplatin
NCT000031322	NCT00003132_2_T1	COMPOUND	9	10	bryostatin 1
NCT000031324	NCT00003132_4_T0	PHENOTYPE	8	8	toxicity
NCT000031324	NCT00003132_4_T1	PHENOTYPE	20	20	malignancy
NCT000031324	NCT00003132_4_T2	COMPOUND	15	15	cisplatin
NCT000031324	NCT00003132_4_T3	COMPOUND	10	11	bryostatin 1
NCT000031326	NCT00003132_6_T0	GENE	4	4	II
NCT000031326	NCT00003132_6_T1	PHENOTYPE	22	22	toxicity
NCT000031326	NCT00003132_6_T2	PHENOTYPE	30	30	pharmacokinetics
NCT000031326	NCT00003132_6_T3	COMPOUND	10	10	cisplatin
NCT000031326	NCT00003132_6_T4	COMPOUND	7	8	bryostatin 1
NCT000031326	NCT00003132_6_T5	MOLECULAR_FUNCTION	25	28	protein kinase C activity
NCT000031328	NCT00003132_8_T0	PHENOTYPE	2	2	pharmacokinetics
NCT000031328	NCT00003132_8_T1	COMPOUND	4	5	bryostatin 1
NCT0000313210	NCT00003132_10_T0	PHENOTYPE	3	3	tumor
NCT0000313211	NCT00003132_11_T0	COMPOUND	8	9	bryostatin 1
NCT0000313212	NCT00003132_12_T0	GENE	1	1	1.7
NCT0000313212	NCT00003132_12_T1	COMPOUND	4	4	cisplatin
NCT0000313212	NCT00003132_12_T2	GENE	5	5	IV
NCT0000313213	NCT00003132_13_T0	PHENOTYPE	33	33	toxicity
NCT0000313213	NCT00003132_13_T1	COMPOUND	17	17	cisplatin
NCT0000313213	NCT00003132_13_T2	GENE	9	9	IV
NCT0000313213	NCT00003132_13_T3	GENE	18	18	IV
NCT0000313213	NCT00003132_13_T4	PHENOTYPE	29	30	disease progression
NCT0000313213	NCT00003132_13_T5	COMPOUND	7	8	bryostatin 1
NCT0000313214	NCT00003132_14_T0	GENE	8	8	1.7
NCT0000313214	NCT00003132_14_T1	COMPOUND	4	4	cisplatin
NCT0000313215	NCT00003132_15_T0	COMPOUND	15	15	cisplatin
NCT0000313215	NCT00003132_15_T1	GENE	9	9	IV
NCT0000313215	NCT00003132_15_T2	COMPOUND	7	8	bryostatin 1
NCT0000313216	NCT00003132_16_T0	GENE	1	1	11
NCT0000313216	NCT00003132_16_T1	COMPOUND	7	7	cisplatin
NCT0000313216	NCT00003132_16_T2	COMPOUND	4	5	bryostatin 1
NCT0000313217	NCT00003132_17_T0	COMPOUND	11	11	cisplatin
NCT0000313217	NCT00003132_17_T1	GENE	17	17	MTD
NCT0000313217	NCT00003132_17_T2	COMPOUND	8	9	bryostatin 1
NCT0000313218	NCT00003132_18_T0	GENE	1	1	MTD
NCT0000313218	NCT00003132_18_T1	GENE	20	20	DLT
NCT0000313219	NCT00003132_19_T0	GENE	3	3	II
NCT0000313219	NCT00003132_19_T1	GENE	13	13	MTD
NCT0000313220	NCT00003132_20_T0	COMPOUND	22	22	cisplatin
NCT000031331	NCT00003133_1_T0	CELL	9	9	cells
NCT000031331	NCT00003133_1_T1	PHENOTYPE	8	8	tumor
NCT000031332	NCT00003133_2_T0	GENE	2	2	II
NCT000031332	NCT00003133_2_T1	PHENOTYPE	18	19	bladder cancer
NCT000031337	NCT00003133_7_T0	COMPOUND	3	3	gemcitabine
NCT000031337	NCT00003133_7_T1	GENE	4	4	IV
NCT000031338	NCT00003133_8_T0	COMPOUND	11	11	gemcitabine
NCT000031339	NCT00003133_9_T0	COMPOUND	9	9	gemcitabine
NCT000031339	NCT00003133_9_T1	COMPOUND	16	16	doxorubicin
NCT0000313310	NCT00003133_10_T0	GENE	11	11	3-10
NCT0000313310	NCT00003133_10_T1	GENE	5	5	G-CSF
NCT0000313310	NCT00003133_10_T2	COMPOUND	16	16	doxorubicin
NCT0000313310	NCT00003133_10_T3	GENE	1	4	granulocyte colony stimulating factor
NCT0000313311	NCT00003133_11_T0	COMPOUND	18	18	paclitaxel
NCT0000313311	NCT00003133_11_T1	COMPOUND	9	9	doxorubicin
NCT0000313311	NCT00003133_11_T2	COMPOUND	24	24	cisplatin
NCT0000313311	NCT00003133_11_T3	GENE	19	19	IV
NCT0000313312	NCT00003133_12_T0	GENE	6	6	3-10
NCT0000313312	NCT00003133_12_T1	GENE	0	0	G-CSF
NCT000031341	NCT00003134_1_T0	GENE	2	2	II
NCT000031341	NCT00003134_1_T1	COMPOUND	9	9	irinotecan
NCT000031341	NCT00003134_1_T2	PHENOTYPE	16	16	glioma
NCT000031341	NCT00003134_1_T3	PHENOTYPE	15	15	recurrent
NCT000031343	NCT00003134_3_T0	COMPOUND	4	4	irinotecan
NCT000031343	NCT00003134_3_T1	PHENOTYPE	12	12	glioma
NCT000031343	NCT00003134_3_T2	PHENOTYPE	11	11	recurrent
NCT000031345	NCT00003134_5_T0	COMPOUND	4	4	irinotecan
NCT000031345	NCT00003134_5_T1	PHENOTYPE	2	2	toxicities
NCT000031347	NCT00003134_7_T0	PHENOTYPE	5	5	toxicity
NCT000031349	NCT00003134_9_T0	COMPOUND	6	6	nitrosourea
NCT000031351	NCT00003135_1_T0	CELL	10	10	cells
NCT000031351	NCT00003135_1_T1	PHENOTYPE	9	9	tumor
NCT000031352	NCT00003135_2_T0	PHENOTYPE	3	3	hyperthermia
NCT000031352	NCT00003135_2_T1	CELL	8	8	cells
NCT000031352	NCT00003135_2_T2	PHENOTYPE	7	7	tumor
NCT000031353	NCT00003135_3_T0	GENE	3	3	II
NCT000031353	NCT00003135_3_T1	PHENOTYPE	17	17	hyperthermia
NCT000031353	NCT00003135_3_T2	COMPOUND	13	13	doxorubicin
NCT000031353	NCT00003135_3_T3	PHENOTYPE	28	29	cervical cancer
NCT000031355	NCT00003135_5_T0	PHENOTYPE	8	8	hyperthermia
NCT000031356	NCT00003135_6_T0	COMPOUND	13	13	HCl
NCT000031356	NCT00003135_6_T1	GENE	10	10	1.5
NCT000031356	NCT00003135_6_T2	COMPOUND	12	12	doxorubicin
NCT000031356	NCT00003135_6_T3	GENE	3	3	IV
NCT000031356	NCT00003135_6_T4	GENE	15	15	IV
NCT000031358	NCT00003135_8_T0	GENE	3	3	4.5
NCT0000313510	NCT00003135_10_T0	GENE	13	13	II
NCT0000313510	NCT00003135_10_T1	PHENOTYPE	8	8	hyperthermia
NCT0000313511	NCT00003135_11_T0	GENE	3	3	II
NCT0000313511	NCT00003135_11_T1	PHENOTYPE	22	22	toxicity
NCT0000313511	NCT00003135_11_T2	PHENOTYPE	6	6	hyperthermia
NCT0000313511	NCT00003135_11_T3	PHENOTYPE	20	20	experiences
NCT0000313512	NCT00003135_12_T0	PHENOTYPE	2	2	closed
NCT000031366	NCT00003136_6_T0	CELL	5	5	granulocyte
NCT000031366	NCT00003136_6_T1	PHENOTYPE	1	1	engraftment
NCT000031366	NCT00003136_6_T2	CELL	7	7	platelet
NCT000031368	NCT00003136_8_T0	PHENOTYPE	2	2	toxic
NCT0000313610	NCT00003136_10_T0	PHENOTYPE	15	15	progression
NCT0000313612	NCT00003136_12_T0	GENE	4	4	2.4
NCT0000313612	NCT00003136_12_T1	CELL	8	11	peripheral blood stem cells
NCT0000313613	NCT00003136_13_T0	COMPOUND	3	3	amifostine
NCT0000313613	NCT00003136_13_T1	GENE	4	4	IV
NCT0000313614	NCT00003136_14_T0	COMPOUND	13	13	3
NCT0000313615	NCT00003136_15_T0	GENE	1	1	IV
NCT0000313617	NCT00003136_17_T0	GENE	1	1	G-CSF
NCT0000313620	NCT00003136_20_T0	PHENOTYPE	3	3	toxicity
NCT0000313620	NCT00003136_20_T1	PHENOTYPE	16	16	toxicity
NCT0000313620	NCT00003136_20_T2	GENE	4	4	DLT
NCT0000313621	NCT00003136_21_T0	GENE	4	4	MTD
NCT0000313621	NCT00003136_21_T1	GENE	13	13	DLT
NCT0000313622	NCT00003136_22_T0	GENE	8	8	MTD
NCT0000313623	NCT00003136_23_T0	GENE	8	8	2.3
NCT000031371	NCT00003137_1_T0	GENE	2	2	II
NCT000031371	NCT00003137_1_T1	COMPOUND	9	9	irinotecan
NCT000031371	NCT00003137_1_T2	PHENOTYPE	15	16	advanced cancer
NCT000031371	NCT00003137_1_T3	PHENOTYPE	16	19	cancer of the stomach
NCT000031373	NCT00003137_3_T0	PHENOTYPE	6	6	toxicity
NCT000031373	NCT00003137_3_T1	COMPOUND	22	22	irinotecan
NCT000031373	NCT00003137_3_T2	PHENOTYPE	15	17	metastatic gastric cancer
NCT000031375	NCT00003137_5_T0	COMPOUND	2	2	irinotecan
NCT000031375	NCT00003137_5_T1	GENE	5	5	IV
NCT000031376	NCT00003137_6_T0	PHENOTYPE	6	6	toxicity
NCT000031377	NCT00003137_7_T0	PHENOTYPE	18	18	toxic
NCT000031378	NCT00003137_8_T0	PHENOTYPE	11	11	toxic
NCT000031379	NCT00003137_9_T0	PHENOTYPE	15	15	toxicity
NCT000031379	NCT00003137_9_T1	PHENOTYPE	11	12	disease progression
NCT0000313711	NCT00003137_11_T0	PHENOTYPE	11	12	disease progression
NCT000031385	NCT00003138_5_T0	PHENOTYPE	8	8	nearest
NCT000031386	NCT00003138_6_T0	GENE	7	7	hematocrit
NCT000031389	NCT00003138_9_T0	GENE	9	9	RA
NCT000031389	NCT00003138_9_T1	GENE	11	11	RA
NCT000031389	NCT00003138_9_T2	GENE	16	16	RA
NCT000031389	NCT00003138_9_T3	GENE	26	26	erythropoietin
NCT000031389	NCT00003138_9_T4	PHENOTYPE	32	33	erythropoietin level
NCT000031389	NCT00003138_9_T5	PHENOTYPE	7	8	refractory anemia
NCT0000313816	NCT00003138_16_T0	GENE	11	11	G-CSF
NCT0000313816	NCT00003138_16_T1	GENE	12	12	SC
NCT0000313816	NCT00003138_16_T2	GENE	21	21	SC
NCT0000313816	NCT00003138_16_T3	GENE	10	10	filgrastim
NCT0000313816	NCT00003138_16_T4	GENE	20	20	erythropoietin
NCT0000313816	NCT00003138_16_T5	PHENOTYPE	4	5	progressive disease
NCT0000313817	NCT00003138_17_T0	GENE	8	8	erythropoietin
NCT0000313817	NCT00003138_17_T1	GENE	16	16	erythropoietin
NCT0000313817	NCT00003138_17_T2	BIOLOGICAL_PROCESS	3	5	response to G-CSF
NCT0000313818	NCT00003138_18_T0	PHENOTYPE	0	2	Quality of life
NCT000031390	NCT00003139_0_T0	PHENOTYPE	3	3	Mucositis
NCT000031390	NCT00003139_0_T1	PHENOTYPE	5	6	Dry Mouth
NCT000031390	NCT00003139_0_T2	PHENOTYPE	13	16	Head and Neck Cancer
NCT000031392	NCT00003139_2_T0	COMPOUND	3	3	pilocarpine
NCT000031392	NCT00003139_2_T1	CELL	7	7	cells
NCT000031392	NCT00003139_2_T2	PHENOTYPE	11	14	effects of radiation therapy
NCT000031393	NCT00003139_3_T0	COMPOUND	6	6	pilocarpine
NCT000031393	NCT00003139_3_T1	PHENOTYPE	12	12	mucositis
NCT000031393	NCT00003139_3_T2	PHENOTYPE	14	15	dry mouth
NCT000031393	NCT00003139_3_T3	PHENOTYPE	22	25	head and neck cancer
NCT000031394	NCT00003139_4_T0	GENE	4	4	III
NCT000031394	NCT00003139_4_T1	COMPOUND	11	11	pilocarpine
NCT000031394	NCT00003139_4_T2	PHENOTYPE	14	14	mucositis
NCT000031394	NCT00003139_4_T3	PHENOTYPE	16	17	dry mouth
NCT000031394	NCT00003139_4_T4	PHENOTYPE	24	27	head and neck cancer
NCT0000313912	NCT00003139_12_T0	COMPOUND	8	8	pilocarpine
NCT0000313912	NCT00003139_12_T1	PHENOTYPE	1	3	quality of life
NCT0000313914	NCT00003139_14_T0	PHENOTYPE	4	4	xerostomia
NCT0000313919	NCT00003139_19_T0	COMPOUND	15	15	pilocarpine
NCT0000313919	NCT00003139_19_T1	GENE	6	6	3.4
NCT000031401	NCT00003140_1_T0	COMPOUND	3	3	letrozole
NCT000031401	NCT00003140_1_T1	COMPOUND	13	13	estrogen
NCT000031401	NCT00003140_1_T2	PHENOTYPE	6	7	breast cancer
NCT000031402	NCT00003140_2_T0	COMPOUND	8	8	letrozole
NCT000031402	NCT00003140_2_T1	GENE	4	4	III
NCT000031402	NCT00003140_2_T2	COMPOUND	24	24	tamoxifen
NCT000031402	NCT00003140_2_T3	PHENOTYPE	19	20	breast cancer
NCT0000314013	NCT00003140_13_T0	COMPOUND	27	27	letrozole
NCT0000314013	NCT00003140_13_T1	TISSUE	5	6	lymph node
NCT0000314014	NCT00003140_14_T0	PHENOTYPE	33	33	toxicity
NCT0000314014	NCT00003140_14_T1	COMPOUND	16	16	letrozole
NCT0000314014	NCT00003140_14_T2	COMPOUND	37	37	letrozole
NCT0000314014	NCT00003140_14_T3	PHENOTYPE	13	13	pharmacodynamic
NCT0000314014	NCT00003140_14_T4	PHENOTYPE	7	7	encoding
NCT0000314015	NCT00003140_15_T0	PHENOTYPE	0	2	Quality of life
NCT000031416	NCT00003141_6_T0	PHENOTYPE	7	7	tumor
NCT000031417	NCT00003141_7_T0	COMPOUND	21	21	vincristine
NCT000031417	NCT00003141_7_T1	GENE	28	28	14
NCT000031417	NCT00003141_7_T2	GENE	45	45	0.2
NCT000031417	NCT00003141_7_T3	GENE	36	36	1.2
NCT000031417	NCT00003141_7_T4	COMPOUND	29	29	cyclophosphamide
NCT000031417	NCT00003141_7_T5	COMPOUND	38	38	etoposide
NCT000031417	NCT00003141_7_T6	COMPOUND	13	13	cisplatin
NCT000031417	NCT00003141_7_T7	GENE	14	14	IV
NCT000031417	NCT00003141_7_T8	GENE	22	22	IV
NCT000031417	NCT00003141_7_T9	GENE	30	30	IV
NCT000031417	NCT00003141_7_T10	GENE	39	39	IV
NCT000031419	NCT00003141_9_T0	PHENOTYPE	18	18	toxicity
NCT000031419	NCT00003141_9_T1	PHENOTYPE	14	15	disease progression
NCT0000314110	NCT00003141_10_T0	COMPOUND	25	25	thiotepa
NCT0000314110	NCT00003141_10_T1	GENE	12	12	IV
NCT0000314110	NCT00003141_10_T2	GENE	26	26	IV
NCT0000314112	NCT00003141_12_T0	GENE	3	3	SC
NCT0000314112	NCT00003141_12_T1	GENE	2	2	G-CSF
NCT0000314113	NCT00003141_13_T0	PHENOTYPE	18	18	toxicity
NCT0000314113	NCT00003141_13_T1	PHENOTYPE	14	15	disease progression
NCT0000314114	NCT00003141_14_T0	PHENOTYPE	3	3	toxicity
NCT0000314114	NCT00003141_14_T1	COMPOUND	6	6	thiotepa
NCT0000314115	NCT00003141_15_T0	PHENOTYPE	26	26	relapse
NCT000031431	NCT00003143_1_T0	CELL	8	8	cells
NCT000031431	NCT00003143_1_T1	COMPOUND	4	4	amifostine
NCT000031431	NCT00003143_1_T2	PHENOTYPE	12	14	effects of chemotherapy
NCT000031434	NCT00003143_4_T0	PHENOTYPE	8	8	toxicity
NCT000031434	NCT00003143_4_T1	PHENOTYPE	13	13	peripheral
NCT000031434	NCT00003143_4_T2	COMPOUND	31	31	platinum
NCT000031434	NCT00003143_4_T3	COMPOUND	4	4	amifostine
NCT000031434	NCT00003143_4_T4	PHENOTYPE	20	20	recurrent
NCT000031434	NCT00003143_4_T5	CELL	15	16	stem cells
NCT000031434	NCT00003143_4_T6	PHENOTYPE	26	27	Hodgkin's disease
NCT000031434	NCT00003143_4_T7	PHENOTYPE	23	24	Hodgkin's lymphoma
NCT000031436	NCT00003143_6_T0	COMPOUND	4	4	amifostine
NCT000031436	NCT00003143_6_T1	PHENOTYPE	7	8	renal toxicity
NCT000031438	NCT00003143_8_T0	COMPOUND	14	14	amifostine
NCT000031439	NCT00003143_9_T0	COMPOUND	9	9	cytarabine
NCT000031439	NCT00003143_9_T1	COMPOUND	2	2	cisplatin
NCT000031439	NCT00003143_9_T2	GENE	3	3	IV
NCT000031439	NCT00003143_9_T3	GENE	10	10	IV
NCT0000314310	NCT00003143_10_T0	COMPOUND	3	3	dexamethasone
NCT0000314310	NCT00003143_10_T1	GENE	6	6	IV
NCT0000314311	NCT00003143_11_T0	GENE	3	3	3.4
NCT000031440	NCT00003144_0_T0	PHENOTYPE	7	7	Recurrent
NCT000031440	NCT00003144_0_T1	PHENOTYPE	10	11	Solid Tumors
NCT000031442	NCT00003144_2_T0	CELL	8	8	cells
NCT000031442	NCT00003144_2_T1	COMPOUND	4	4	amifostine
NCT000031442	NCT00003144_2_T2	PHENOTYPE	13	15	effects of chemotherapy
NCT000031443	NCT00003144_3_T0	COMPOUND	10	10	amifostine
NCT000031443	NCT00003144_3_T1	PHENOTYPE	19	19	recurrent
NCT000031443	NCT00003144_3_T2	PHENOTYPE	22	23	solid tumors
NCT000031445	NCT00003144_5_T0	COMPOUND	11	11	gemcitabine
NCT000031445	NCT00003144_5_T1	COMPOUND	4	4	amifostine
NCT000031445	NCT00003144_5_T2	COMPOUND	13	13	cisplatin
NCT000031447	NCT00003144_7_T0	PHENOTYPE	4	4	toxicities
NCT000031447	NCT00003144_7_T1	COMPOUND	6	6	gemcitabine
NCT000031447	NCT00003144_7_T2	COMPOUND	13	13	amifostine
NCT000031447	NCT00003144_7_T3	COMPOUND	8	8	cisplatin
NCT000031449	NCT00003144_9_T0	COMPOUND	6	6	gemcitabine
NCT000031449	NCT00003144_9_T1	COMPOUND	11	11	amifostine
NCT000031449	NCT00003144_9_T2	COMPOUND	8	8	cisplatin
NCT0000314411	NCT00003144_11_T0	COMPOUND	7	7	gemcitabine
NCT0000314411	NCT00003144_11_T1	COMPOUND	9	9	cisplatin
NCT0000314414	NCT00003144_14_T0	GENE	12	12	GAP
NCT0000314414	NCT00003144_14_T1	GENE	15	15	GP
NCT0000314416	NCT00003144_16_T0	GENE	15	15	GAP
NCT0000314416	NCT00003144_16_T1	GENE	13	13	GP
NCT0000314418	NCT00003144_18_T0	PHENOTYPE	8	8	toxicity
NCT0000314418	NCT00003144_18_T1	PHENOTYPE	5	5	experiences
NCT0000314418	NCT00003144_18_T2	GENE	9	9	DLT
NCT0000314419	NCT00003144_19_T0	GENE	4	4	MTD
NCT0000314419	NCT00003144_19_T1	GENE	22	22	DLT
NCT0000314420	NCT00003144_20_T0	PHENOTYPE	6	6	toxicity
NCT0000314420	NCT00003144_20_T1	PHENOTYPE	8	9	tumor progression
NCT000031452	NCT00003145_2_T0	CELL	12	13	stem cells
NCT000031452	NCT00003145_2_T1	ORGAN	6	7	immune system
NCT000031453	NCT00003145_3_T0	CELL	30	30	platelets
NCT000031453	NCT00003145_3_T1	CELL	3	4	stem cells
NCT000031453	NCT00003145_3_T2	CELL	21	22	stem cells
NCT000031453	NCT00003145_3_T3	ORGAN	18	19	bone marrow
NCT000031453	NCT00003145_3_T4	CELL	23	25	red blood cells
NCT000031453	NCT00003145_3_T5	CELL	26	28	white blood cells
NCT000031455	NCT00003145_5_T0	COMPOUND	1	1	cyclosporine
NCT000031455	NCT00003145_5_T1	ORGAN	7	7	transplant
NCT000031455	NCT00003145_5_T2	COMPOUND	3	4	mycophenolate mofetil
NCT000031456	NCT00003145_6_T0	CELL	16	16	cells
NCT000031456	NCT00003145_6_T1	CELL	3	4	stem cells
NCT000031456	NCT00003145_6_T2	ORGAN	9	10	immune system
NCT000031457	NCT00003145_7_T0	CELL	10	10	lymphocyte
NCT000031457	NCT00003145_7_T1	CELL	6	8	white blood cells
NCT0000314514	NCT00003145_14_T0	COMPOUND	3	3	cyclosporine
NCT0000314514	NCT00003145_14_T1	COMPOUND	18	18	3
NCT0000314514	NCT00003145_14_T2	GENE	8	8	BID
NCT0000314514	NCT00003145_14_T3	GENE	11	11	BID
NCT0000314514	NCT00003145_14_T4	GENE	34	34	BID
NCT0000314514	NCT00003145_14_T5	GENE	10	10	IV
NCT0000314514	NCT00003145_14_T6	GENE	33	33	IV
NCT0000314514	NCT00003145_14_T7	GENE	15	15	TID
NCT0000314514	NCT00003145_14_T8	COMPOUND	29	30	mycophenolate mofetil
NCT000031464	NCT00003146_4_T0	PHENOTYPE	2	2	toxicity
NCT000031464	NCT00003146_4_T1	COMPOUND	11	11	busulfan
NCT000031464	NCT00003146_4_T2	COMPOUND	14	14	thiotepa
NCT000031464	NCT00003146_4_T3	COMPOUND	12	12	melphalan
NCT000031464	NCT00003146_4_T4	PHENOTYPE	18	19	multiple myeloma
NCT000031466	NCT00003146_6_T0	ORGAN	10	11	bone marrow
NCT000031466	NCT00003146_6_T1	CELL	0	3	Peripheral blood stem cells
NCT000031467	NCT00003146_7_T0	COMPOUND	3	3	busulfan
NCT000031468	NCT00003146_8_T0	GENE	5	5	IV
NCT000031469	NCT00003146_9_T0	COMPOUND	8	8	2
NCT000031469	NCT00003146_9_T1	COMPOUND	14	14	2
NCT000031469	NCT00003146_9_T2	COMPOUND	12	12	3
NCT000031469	NCT00003146_9_T3	GENE	5	5	IV
NCT0000314610	NCT00003146_10_T0	ORGAN	4	5	bone marrow
NCT000031471	NCT00003147_1_T0	PHENOTYPE	7	7	tumor
NCT000031471	NCT00003147_1_T1	GENE	2	2	p53
NCT000031471	NCT00003147_1_T2	PHENOTYPE	15	16	liver cancer
NCT000031473	NCT00003147_3_T0	GENE	5	5	p53
NCT000031473	NCT00003147_3_T1	PHENOTYPE	11	12	hepatocellular carcinoma
NCT000031477	NCT00003147_7_T0	GENE	3	3	p53
NCT000031479	NCT00003147_9_T0	PHENOTYPE	5	5	toxicity
NCT000031479	NCT00003147_9_T1	GENE	6	6	DLT
NCT0000314710	NCT00003147_10_T0	GENE	1	1	DLT
NCT0000314711	NCT00003147_11_T0	PHENOTYPE	8	9	disease progression
NCT0000314711	NCT00003147_11_T1	PHENOTYPE	12	13	adverse events
NCT000031481	NCT00003148_1_T0	GENE	2	2	II
NCT000031481	NCT00003148_1_T1	GENE	9	9	interleukin-2
NCT000031481	NCT00003148_1_T2	GENE	18	18	has
NCT000031481	NCT00003148_1_T3	PHENOTYPE	14	16	acute myelogenous leukemia
NCT000031485	NCT00003148_5_T0	PHENOTYPE	2	2	acute
NCT000031485	NCT00003148_5_T1	GENE	6	6	IL-2
NCT000031488	NCT00003148_8_T0	GENE	1	1	IL-2
NCT000031488	NCT00003148_8_T1	GENE	0	0	Interleukin-2
NCT000031489	NCT00003148_9_T0	GENE	7	7	has
NCT000031489	NCT00003148_9_T1	GENE	6	6	MTD
NCT000031489	NCT00003148_9_T2	GENE	17	17	MTD
NCT0000314811	NCT00003148_11_T0	GENE	7	7	IL-2
NCT0000314812	NCT00003148_12_T0	GENE	3	3	IL-2
NCT0000314813	NCT00003148_13_T0	PHENOTYPE	7	7	toxicity
NCT0000314813	NCT00003148_13_T1	PHENOTYPE	3	4	disease progression
NCT0000314814	NCT00003148_14_T0	PHENOTYPE	23	23	progression
NCT000031491	NCT00003149_1_T0	GENE	3	3	II
NCT000031491	NCT00003149_1_T1	GENE	10	10	interleukin-12
NCT000031491	NCT00003149_1_T2	PHENOTYPE	19	20	multiple myeloma
NCT000031493	NCT00003149_3_T0	GENE	5	5	interleukin-12
NCT000031493	NCT00003149_3_T1	GENE	6	6	IL-12
NCT000031493	NCT00003149_3_T2	PHENOTYPE	12	13	multiple myeloma
NCT000031495	NCT00003149_5_T0	PHENOTYPE	2	2	toxic
NCT000031495	NCT00003149_5_T1	GENE	5	5	IL-12
NCT000031497	NCT00003149_7_T0	GENE	4	4	IL-12
NCT000031499	NCT00003149_9_T0	ORGAN	5	6	bone marrow
NCT0000314912	NCT00003149_12_T0	GENE	4	4	interleukin-12
NCT0000314912	NCT00003149_12_T1	GENE	5	5	IL-12
NCT0000314913	NCT00003149_13_T0	GENE	11	11	IL-12
NCT0000314915	NCT00003149_15_T0	GENE	10	10	IL-12
NCT0000314915	NCT00003149_15_T1	GENE	5	5	1.4
NCT0000314916	NCT00003149_16_T0	GENE	11	11	IL-12
NCT000031502	NCT00003150_2_T0	PHENOTYPE	16	17	Hodgkin's lymphoma
NCT000031503	NCT00003150_3_T0	GENE	3	3	III
NCT000031503	NCT00003150_3_T1	PHENOTYPE	22	23	Hodgkin's lymphoma
NCT000031507	NCT00003150_7_T0	PHENOTYPE	26	26	toxicity
NCT0000315011	NCT00003150_11_T0	GENE	16	16	2.4
NCT0000315012	NCT00003150_12_T0	GENE	31	31	CHOP
NCT0000315012	NCT00003150_12_T1	GENE	33	33	CHOP
NCT0000315015	NCT00003150_15_T0	PHENOTYPE	10	10	toxicity
NCT0000315017	NCT00003150_17_T0	GENE	4	4	IV
NCT0000315020	NCT00003150_20_T0	PHENOTYPE	13	13	toxicity
NCT0000315022	NCT00003150_22_T0	GENE	5	5	PR
NCT0000315022	NCT00003150_22_T1	GENE	10	10	PR
NCT0000315022	NCT00003150_22_T2	GENE	9	9	OR
NCT0000315022	NCT00003150_22_T3	GENE	25	25	CHOP
NCT0000315022	NCT00003150_22_T4	GENE	16	16	CR
NCT0000315024	NCT00003150_24_T0	PHENOTYPE	5	6	disease progression
NCT0000315028	NCT00003150_28_T0	PHENOTYPE	18	18	lymphoma
NCT0000315028	NCT00003150_28_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000315028	NCT00003150_28_T2	PHENOTYPE	16	17	high grade
NCT000031511	NCT00003151_1_T0	GENE	2	2	II
NCT000031511	NCT00003151_1_T1	GENE	20	20	has
NCT000031511	NCT00003151_1_T2	PHENOTYPE	17	18	gastric lymphoma
NCT000031513	NCT00003151_3_T0	COMPOUND	9	9	omeprazole
NCT000031513	NCT00003151_3_T1	COMPOUND	13	13	tetracycline
NCT000031513	NCT00003151_3_T2	COMPOUND	15	15	metronidazole
NCT000031513	NCT00003151_3_T3	PHENOTYPE	21	22	gastric lymphoma
NCT000031513	NCT00003151_3_T4	PHENOTYPE	6	7	Helicobacter pylori
NCT000031513	NCT00003151_3_T5	COMPOUND	10	12	colloidal bismuth subcitrate
NCT000031515	NCT00003151_5_T0	PHENOTYPE	10	11	Helicobacter pylori
NCT000031517	NCT00003151_7_T0	PHENOTYPE	7	8	gastric lymphoma
NCT000031517	NCT00003151_7_T1	PHENOTYPE	12	13	Helicobacter pylori
NCT000031519	NCT00003151_9_T0	COMPOUND	3	3	omeprazole
NCT000031519	NCT00003151_9_T1	COMPOUND	7	7	1_10
NCT000031519	NCT00003151_9_T2	COMPOUND	13	13	tetracycline
NCT000031519	NCT00003151_9_T3	COMPOUND	20	20	metronidazole
NCT000031519	NCT00003151_9_T4	GENE	4	4	bid
NCT000031519	NCT00003151_9_T5	GENE	21	21	tid
NCT000031519	NCT00003151_9_T6	COMPOUND	9	9	bismuth
NCT0000315111	NCT00003151_11_T0	PHENOTYPE	4	4	remission
NCT000031522	NCT00003152_2_T0	CELL	8	8	cells
NCT000031529	NCT00003152_9_T0	COMPOUND	2	2	vincristine
NCT000031529	NCT00003152_9_T1	GENE	15	15	1.5
NCT000031529	NCT00003152_9_T2	COMPOUND	12	12	prednisone
NCT000031529	NCT00003152_9_T3	GENE	3	3	IV
NCT0000315211	NCT00003152_11_T0	ORGAN	34	35	bone marrow
NCT0000315214	NCT00003152_14_T0	GENE	14	14	2.3
NCT0000315214	NCT00003152_14_T1	CELL	3	3	leukocyte
NCT0000315214	NCT00003152_14_T2	GENE	11	11	3.4
NCT0000315214	NCT00003152_14_T3	CELL	4	4	platelet
NCT0000315214	NCT00003152_14_T4	GENE	6	6	CD34
NCT0000315215	NCT00003152_15_T0	PHENOTYPE	11	11	peripheral
NCT0000315215	NCT00003152_15_T1	CELL	5	6	stem cells
NCT0000315215	NCT00003152_15_T2	ORGAN	13	14	bone marrow
NCT0000315217	NCT00003152_17_T0	CELL	0	1	Stem cells
NCT000031531	NCT00003153_1_T0	GENE	3	3	II
NCT000031531	NCT00003153_1_T1	ORGAN	25	26	bone marrow
NCT000031531	NCT00003153_1_T2	CELL	11	13	white blood cells
NCT000031531	NCT00003153_1_T3	PHENOTYPE	19	21	recurrent multiple myeloma
NCT000031535	NCT00003153_5_T0	PHENOTYPE	30	30	toxicity
NCT000031535	NCT00003153_5_T1	GENE	20	20	CD3
NCT000031535	NCT00003153_5_T2	CELL	21	21	cells
NCT000031537	NCT00003153_7_T0	PHENOTYPE	2	3	disease progression
NCT000031545	NCT00003154_5_T0	PHENOTYPE	16	16	toxicity
NCT000031545	NCT00003154_5_T1	PHENOTYPE	8	8	tumor
NCT000031549	NCT00003154_9_T0	PHENOTYPE	2	2	toxicities
NCT0000315412	NCT00003154_12_T0	PHENOTYPE	16	16	toxicity
NCT0000315412	NCT00003154_12_T1	PHENOTYPE	8	8	tumor
NCT000031565	NCT00003156_5_T0	PHENOTYPE	6	6	toxic
NCT000031565	NCT00003156_5_T1	COMPOUND	9	9	topotecan
NCT000031566	NCT00003156_6_T0	GENE	4	4	IV
NCT000031566	NCT00003156_6_T1	COMPOUND	3	3	topotecan
NCT000031567	NCT00003156_7_T0	PHENOTYPE	19	19	toxicity
NCT000031567	NCT00003156_7_T1	PHENOTYPE	15	16	disease progression
NCT000031571	NCT00003157_1_T0	CELL	8	8	cells
NCT000031571	NCT00003157_1_T1	PHENOTYPE	7	7	tumor
NCT000031572	NCT00003157_2_T0	CELL	9	9	cells
NCT000031572	NCT00003157_2_T1	PHENOTYPE	8	8	tumor
NCT000031573	NCT00003157_3_T0	PHENOTYPE	18	21	cancer of the pancreas
NCT000031577	NCT00003157_7_T0	COMPOUND	4	4	gemcitabine
NCT000031577	NCT00003157_7_T1	COMPOUND	5	5	cisplatin
NCT000031577	NCT00003157_7_T2	PHENOTYPE	2	2	tolerance
NCT0000315711	NCT00003157_11_T0	PHENOTYPE	5	5	tumor
NCT0000315711	NCT00003157_11_T1	PHENOTYPE	17	17	tumor
NCT0000315711	NCT00003157_11_T2	TISSUE	7	8	lymph nodes
NCT0000315712	NCT00003157_12_T0	GENE	8	8	5.5
NCT0000315713	NCT00003157_13_T0	COMPOUND	3	3	gemcitabine
NCT0000315714	NCT00003157_14_T0	COMPOUND	7	7	gemcitabine
NCT0000315717	NCT00003157_17_T0	PHENOTYPE	3	3	toxicity
NCT0000315717	NCT00003157_17_T1	PHENOTYPE	20	20	toxic
NCT0000315717	NCT00003157_17_T2	GENE	4	4	DLT
NCT0000315718	NCT00003157_18_T0	PHENOTYPE	18	18	experiences
NCT0000315718	NCT00003157_18_T1	GENE	19	19	DLT
NCT0000315719	NCT00003157_19_T0	PHENOTYPE	12	12	toxic
NCT0000315719	NCT00003157_19_T1	PHENOTYPE	8	9	disease progression
NCT0000315720	NCT00003157_20_T0	PHENOTYPE	2	2	toxic
NCT0000315720	NCT00003157_20_T1	PHENOTYPE	6	7	disease progression
NCT000031582	NCT00003158_2_T0	CELL	8	8	cells
NCT000031582	NCT00003158_2_T1	PHENOTYPE	7	7	tumor
NCT000031583	NCT00003158_3_T0	CELL	13	13	cells
NCT000031583	NCT00003158_3_T1	PHENOTYPE	12	12	tumor
NCT000031588	NCT00003158_8_T0	PHENOTYPE	4	4	toxicities
NCT0000315810	NCT00003158_10_T0	PHENOTYPE	10	10	initiation
NCT0000315813	NCT00003158_13_T0	GENE	6	6	IV
NCT0000315814	NCT00003158_14_T0	GENE	13	13	1.4
NCT0000315814	NCT00003158_14_T1	GENE	9	9	IV
NCT0000315816	NCT00003158_16_T0	ORGAN	5	5	mediastinum
NCT0000315816	NCT00003158_16_T1	GENE	20	20	6.5
NCT0000315816	NCT00003158_16_T2	TISSUE	9	10	lymph nodes
NCT0000315816	NCT00003158_16_T3	PHENOTYPE	1	2	primary tumor
NCT0000315817	NCT00003158_17_T0	COMPOUND	23	23	paclitaxel
NCT0000315818	NCT00003158_18_T0	GENE	20	20	3.4
NCT0000315818	NCT00003158_18_T1	GENE	6	6	IV
NCT0000315910	NCT00003159_10_T0	PHENOTYPE	0	2	Quality of life
NCT000031601	NCT00003160_1_T0	CELL	10	10	cells
NCT000031601	NCT00003160_1_T1	PHENOTYPE	9	9	tumor
NCT000031602	NCT00003160_2_T0	GENE	2	2	II
NCT000031602	NCT00003160_2_T1	COMPOUND	9	9	paclitaxel
NCT000031602	NCT00003160_2_T2	COMPOUND	25	25	paclitaxel
NCT000031602	NCT00003160_2_T3	PHENOTYPE	14	15	stage III
NCT000031602	NCT00003160_2_T4	PHENOTYPE	17	20	stage IV ovarian cancer
NCT000031604	NCT00003160_4_T0	COMPOUND	6	6	paclitaxel
NCT000031604	NCT00003160_4_T1	GENE	22	22	IV
NCT000031604	NCT00003160_4_T2	PHENOTYPE	19	20	stage III
NCT000031604	NCT00003160_4_T3	PHENOTYPE	23	24	ovarian cancer
NCT000031606	NCT00003160_6_T0	COMPOUND	4	4	paclitaxel
NCT0000316010	NCT00003160_10_T0	PHENOTYPE	1	3	quality of life
NCT0000316012	NCT00003160_12_T0	COMPOUND	3	3	paclitaxel
NCT0000316012	NCT00003160_12_T1	GENE	8	8	IV
NCT0000316015	NCT00003160_15_T0	PHENOTYPE	9	9	toxicity
NCT0000316015	NCT00003160_15_T1	COMPOUND	2	2	paclitaxel
NCT0000316015	NCT00003160_15_T2	PHENOTYPE	5	6	disease progression
NCT0000316017	NCT00003160_17_T0	PHENOTYPE	0	2	Quality of life
NCT000031621	NCT00003162_1_T0	PHENOTYPE	13	14	bone metastases
NCT000031629	NCT00003162_9_T0	PHENOTYPE	4	6	quality of life
NCT000031636	NCT00003163_6_T0	ORGAN	5	6	bone marrow
NCT000031636	NCT00003163_6_T1	CELL	0	3	Peripheral blood stem cells
NCT000031637	NCT00003163_7_T0	GENE	1	1	G-CSF
NCT000031637	NCT00003163_7_T1	GENE	4	4	GM-CSF
NCT000031637	NCT00003163_7_T2	GENE	3	3	sargramostim
NCT000031639	NCT00003163_9_T0	GENE	3	3	IV
NCT0000316310	NCT00003163_10_T0	COMPOUND	18	18	1
NCT0000316310	NCT00003163_10_T1	COMPOUND	13	13	2
NCT0000316310	NCT00003163_10_T2	COMPOUND	11	11	3
NCT0000316314	NCT00003163_14_T0	COMPOUND	24	24	2
NCT0000316314	NCT00003163_14_T1	COMPOUND	22	22	3
NCT0000316314	NCT00003163_14_T2	COMPOUND	19	19	cyclophosphamide
NCT0000316315	NCT00003163_15_T0	CELL	0	2	Hematopoietic stem cells
NCT0000316316	NCT00003163_16_T0	ORGAN	2	2	transplant
NCT0000316316	NCT00003163_16_T1	ORGAN	15	15	transplant
NCT0000316318	NCT00003163_18_T0	COMPOUND	9	9	melphalan
NCT0000316318	NCT00003163_18_T1	COMPOUND	12	12	melphalan
NCT0000316318	NCT00003163_18_T2	COMPOUND	14	14	cyclophosphamide
NCT0000316320	NCT00003163_20_T0	CELL	0	2	Hematopoietic stem cells
NCT000031651	NCT00003165_1_T0	CELL	9	9	cells
NCT000031651	NCT00003165_1_T1	PHENOTYPE	8	8	tumor
NCT000031652	NCT00003165_2_T0	GENE	2	2	II
NCT000031652	NCT00003165_2_T1	COMPOUND	9	9	doxorubicin
NCT000031652	NCT00003165_2_T2	PHENOTYPE	15	17	metastatic breast cancer
NCT000031657	NCT00003165_7_T0	PHENOTYPE	14	14	toxicity
NCT000031657	NCT00003165_7_T1	PHENOTYPE	16	17	progressive disease
NCT000031660	NCT00003166_0_T0	PHENOTYPE	5	5	Malignancies
NCT000031660	NCT00003166_0_T1	CELL	4	4	B-Cell
NCT000031662	NCT00003166_2_T0	CELL	10	10	cells
NCT000031664	NCT00003166_4_T0	COMPOUND	15	15	vincristine
NCT000031664	NCT00003166_4_T1	COMPOUND	7	8	bryostatin 1
NCT000031668	NCT00003166_8_T0	COMPOUND	6	7	bryostatin 1
NCT0000316610	NCT00003166_10_T0	COMPOUND	13	13	vincristine
NCT0000316610	NCT00003166_10_T1	COMPOUND	10	11	bryostatin 1
NCT0000316611	NCT00003166_11_T0	COMPOUND	7	8	bryostatin 1
NCT0000316612	NCT00003166_12_T0	COMPOUND	11	11	vincristine
NCT0000316612	NCT00003166_12_T1	GENE	4	4	IV
NCT0000316612	NCT00003166_12_T2	GENE	12	12	IV
NCT0000316612	NCT00003166_12_T3	COMPOUND	2	3	bryostatin 1
NCT0000316613	NCT00003166_13_T0	PHENOTYPE	13	13	toxicity
NCT0000316613	NCT00003166_13_T1	PHENOTYPE	9	10	disease progression
NCT0000316615	NCT00003166_15_T0	COMPOUND	5	5	2
NCT0000316616	NCT00003166_16_T0	GENE	15	15	MTD
NCT0000316616	NCT00003166_16_T1	COMPOUND	8	9	bryostatin 1
NCT0000316617	NCT00003166_17_T0	PHENOTYPE	19	19	toxicity
NCT0000316617	NCT00003166_17_T1	GENE	1	1	MTD
NCT000031672	NCT00003167_2_T0	PHENOTYPE	4	4	toxicity
NCT000031672	NCT00003167_2_T1	GENE	7	7	p53
NCT000031672	NCT00003167_2_T2	PHENOTYPE	17	19	metastatic bladder cancer
NCT000031674	NCT00003167_4_T0	GENE	8	8	p53
NCT000031676	NCT00003167_6_T0	PHENOTYPE	5	5	tumor
NCT0000316710	NCT00003167_10_T0	PHENOTYPE	5	5	elimination
NCT0000316710	NCT00003167_10_T1	ORGAN	9	10	urinary bladder
NCT0000316712	NCT00003167_12_T0	GENE	5	5	p53
NCT0000316712	NCT00003167_12_T1	GENE	0	1	Group 1
NCT0000316713	NCT00003167_13_T0	PHENOTYPE	19	19	toxicity
NCT0000316713	NCT00003167_13_T1	PHENOTYPE	15	16	disease progression
NCT0000316715	NCT00003167_15_T0	PHENOTYPE	8	8	toxicity
NCT0000316716	NCT00003167_16_T0	PHENOTYPE	8	8	toxicity
NCT0000316716	NCT00003167_16_T1	PHENOTYPE	5	5	experiences
NCT0000316717	NCT00003167_17_T0	PHENOTYPE	8	8	toxicity
NCT0000316717	NCT00003167_17_T1	PHENOTYPE	17	17	toxicity
NCT0000316717	NCT00003167_17_T2	GENE	23	23	MTD
NCT0000316718	NCT00003167_18_T0	GENE	10	10	1.4
NCT0000316718	NCT00003167_18_T1	GENE	22	22	1.4
NCT0000316718	NCT00003167_18_T2	GENE	7	7	MTD
NCT0000316718	NCT00003167_18_T3	GENE	19	19	MTD
NCT0000316718	NCT00003167_18_T4	GENE	12	13	group 3
NCT0000316719	NCT00003167_19_T0	PHENOTYPE	15	16	disease progression
NCT0000316720	NCT00003167_20_T0	COMPOUND	17	17	1
NCT0000316720	NCT00003167_20_T1	GENE	13	13	3/12
NCT0000316720	NCT00003167_20_T2	GENE	21	22	group 2
NCT0000316720	NCT00003167_20_T3	GENE	27	28	group 3
NCT000031701	NCT00003170_1_T0	PHENOTYPE	7	8	acute diarrhea
NCT0000317011	NCT00003170_11_T0	GENE	9	9	bowel
NCT0000317015	NCT00003170_15_T0	PHENOTYPE	15	15	diarrhea
NCT000031715	NCT00003171_5_T0	PHENOTYPE	5	5	toxic
NCT000031715	NCT00003171_5_T1	COMPOUND	8	9	bryostatin 1
NCT000031719	NCT00003171_9_T0	COMPOUND	2	3	bryostatin 1
NCT0000317110	NCT00003171_10_T0	PHENOTYPE	13	13	toxicity
NCT0000317110	NCT00003171_10_T1	PHENOTYPE	9	10	disease progression
NCT000031721	NCT00003172_1_T0	CELL	17	17	cells
NCT000031721	NCT00003172_1_T1	PHENOTYPE	16	16	tumor
NCT000031721	NCT00003172_1_T2	GENE	12	12	G-CSF
NCT000031721	NCT00003172_1_T3	GENE	9	9	interferon
NCT000031722	NCT00003172_2_T0	GENE	3	3	II
NCT000031722	NCT00003172_2_T1	PHENOTYPE	19	20	stomach cancer
NCT000031724	NCT00003172_4_T0	GENE	29	29	interferon
NCT000031724	NCT00003172_4_T1	COMPOUND	20	20	hydroxyurea
NCT000031724	NCT00003172_4_T2	COMPOUND	39	39	docetaxel
NCT000031724	NCT00003172_4_T3	GENE	32	32	filgrastim
NCT000031724	NCT00003172_4_T4	COMPOUND	37	37	doxorubicin
NCT000031724	NCT00003172_4_T5	PHENOTYPE	13	14	gastric cancer
NCT000031726	NCT00003172_6_T0	PHENOTYPE	2	2	toxicities
NCT000031726	NCT00003172_6_T1	PHENOTYPE	6	6	toxicities
NCT000031726	NCT00003172_6_T2	PHENOTYPE	16	17	gastric cancer
NCT000031729	NCT00003172_9_T0	GENE	17	17	1/6
NCT0000317210	NCT00003172_10_T0	GENE	2	2	interferon
NCT0000317211	NCT00003172_11_T0	GENE	17	17	1/6
NCT0000317211	NCT00003172_11_T1	GENE	0	0	HU
NCT0000317212	NCT00003172_12_T0	GENE	13	13	1/6
NCT0000317212	NCT00003172_12_T1	GENE	0	0	G-CSF
NCT0000317216	NCT00003172_16_T0	PHENOTYPE	19	19	toxic
NCT0000317216	NCT00003172_16_T1	PHENOTYPE	15	16	disease progression
NCT000031730	NCT00003173_0_T0	PHENOTYPE	12	13	Solid Tumors
NCT000031730	NCT00003173_0_T1	CELL	3	5	Peripheral Stem Cell
NCT000031736	NCT00003173_6_T0	COMPOUND	10	10	thiotepa
NCT000031736	NCT00003173_6_T1	CELL	1	2	stem cells
NCT000031737	NCT00003173_7_T0	ORGAN	13	14	bone marrow
NCT000031737	NCT00003173_7_T1	CELL	5	8	peripheral blood stem cells
NCT000031739	NCT00003173_9_T0	COMPOUND	11	11	thiotepa
NCT000031739	NCT00003173_9_T1	CELL	0	1	Stem cells
NCT0000317310	NCT00003173_10_T0	CELL	8	9	stem cells
NCT0000317311	NCT00003173_11_T0	PHENOTYPE	27	27	toxicity
NCT0000317311	NCT00003173_11_T1	COMPOUND	4	4	thiotepa
NCT0000317311	NCT00003173_11_T2	CELL	22	23	stem cells
NCT000031741	NCT00003174_1_T0	CELL	9	9	cells
NCT000031741	NCT00003174_1_T1	PHENOTYPE	8	8	tumor
NCT000031742	NCT00003174_2_T0	COMPOUND	14	14	cladribine
NCT000031742	NCT00003174_2_T1	COMPOUND	18	19	bryostatin 1
NCT000031742	NCT00003174_2_T2	PHENOTYPE	24	27	relapsed chronic lymphocytic leukemia
NCT000031744	NCT00003174_4_T0	COMPOUND	8	8	cladribine
NCT000031745	NCT00003174_5_T0	GENE	8	8	1.3
NCT000031745	NCT00003174_5_T1	COMPOUND	12	12	cladribine
NCT000031745	NCT00003174_5_T2	GENE	4	4	IV
NCT000031745	NCT00003174_5_T3	GENE	13	13	IV
NCT000031745	NCT00003174_5_T4	GENE	17	17	4-8
NCT000031745	NCT00003174_5_T5	COMPOUND	2	3	bryostatin 1
NCT000031746	NCT00003174_6_T0	PHENOTYPE	13	13	toxicity
NCT000031746	NCT00003174_6_T1	PHENOTYPE	9	10	disease progression
NCT000031747	NCT00003174_7_T0	PHENOTYPE	4	4	remission
NCT000031747	NCT00003174_7_T1	GENE	5	5	CR
NCT000031747	NCT00003174_7_T2	GENE	11	11	CR
NCT000031748	NCT00003174_8_T0	COMPOUND	9	9	cladribine
NCT000031748	NCT00003174_8_T1	GENE	15	15	MTD
NCT000031749	NCT00003174_9_T0	PHENOTYPE	17	17	toxicity
NCT000031749	NCT00003174_9_T1	GENE	1	1	MTD
NCT000031751	NCT00003175_1_T0	GENE	2	2	II
NCT000031751	NCT00003175_1_T1	PHENOTYPE	19	19	recurrent
NCT000031751	NCT00003175_1_T2	PHENOTYPE	21	23	metastatic bladder cancer
NCT000031758	NCT00003175_8_T0	PHENOTYPE	6	6	toxic
NCT000031758	NCT00003175_8_T1	PHENOTYPE	2	3	disease progression
NCT000031761	NCT00003176_1_T0	CELL	9	9	cells
NCT000031761	NCT00003176_1_T1	PHENOTYPE	8	8	tumor
NCT000031762	NCT00003176_2_T0	COMPOUND	9	9	temozolomide
NCT000031762	NCT00003176_2_T1	GENE	2	2	II
NCT000031762	NCT00003176_2_T2	PHENOTYPE	17	17	glioma
NCT000031764	NCT00003176_4_T0	COMPOUND	13	13	temozolomide
NCT000031764	NCT00003176_4_T1	PHENOTYPE	16	16	glioblastoma
NCT000031764	NCT00003176_4_T2	PHENOTYPE	7	7	progression
NCT000031764	NCT00003176_4_T3	PHENOTYPE	15	15	recurrent
NCT000031766	NCT00003176_6_T0	PHENOTYPE	6	6	glioblastomas
NCT000031766	NCT00003176_6_T1	PHENOTYPE	5	5	recurrent
NCT000031768	NCT00003176_8_T0	PHENOTYPE	12	12	glioma
NCT000031768	NCT00003176_8_T1	PHENOTYPE	7	8	anaplastic astrocytomas
NCT0000317610	NCT00003176_10_T0	PHENOTYPE	5	5	toxicities
NCT0000317610	NCT00003176_10_T1	PHENOTYPE	13	13	gliomas
NCT0000317612	NCT00003176_12_T0	PHENOTYPE	6	6	glioblastoma
NCT0000317612	NCT00003176_12_T1	PHENOTYPE	13	13	glioma
NCT0000317612	NCT00003176_12_T2	PHENOTYPE	5	5	recurrent
NCT0000317612	NCT00003176_12_T3	PHENOTYPE	8	9	anaplastic astrocytoma
NCT0000317613	NCT00003176_13_T0	COMPOUND	11	11	temozolomide
NCT0000317616	NCT00003176_16_T0	PHENOTYPE	19	19	toxicity
NCT0000317616	NCT00003176_16_T1	PHENOTYPE	5	5	glioblastoma
NCT0000317616	NCT00003176_16_T2	PHENOTYPE	4	4	recurrent
NCT0000317616	NCT00003176_16_T3	PHENOTYPE	15	16	disease progression
NCT0000317617	NCT00003176_17_T0	PHENOTYPE	4	5	disease progression
NCT0000317618	NCT00003176_18_T0	PHENOTYPE	7	7	glioma
NCT0000317618	NCT00003176_18_T1	PHENOTYPE	2	3	anaplastic astrocytoma
NCT0000317620	NCT00003176_20_T0	PHENOTYPE	19	19	glioblastoma
NCT0000317620	NCT00003176_20_T1	PHENOTYPE	34	34	glioma
NCT0000317620	NCT00003176_20_T2	PHENOTYPE	18	18	recurrent
NCT0000317620	NCT00003176_20_T3	PHENOTYPE	29	30	anaplastic astrocytoma
NCT000031781	NCT00003178_1_T0	CELL	9	9	cells
NCT000031786	NCT00003178_6_T0	PHENOTYPE	1	1	AML
NCT000031786	NCT00003178_6_T1	COMPOUND	24	24	cladribine
NCT000031786	NCT00003178_6_T2	GENE	23	23	1.3
NCT000031786	NCT00003178_6_T3	GENE	31	31	1.5
NCT000031786	NCT00003178_6_T4	COMPOUND	16	16	idarubicin
NCT000031786	NCT00003178_6_T5	GENE	34	34	G-CSF
NCT000031786	NCT00003178_6_T6	GENE	17	17	IV
NCT000031786	NCT00003178_6_T7	GENE	25	25	IV
NCT000031786	NCT00003178_6_T8	GENE	33	33	filgrastim
NCT000031786	NCT00003178_6_T9	PHENOTYPE	3	3	closed
NCT000031786	NCT00003178_6_T10	PHENOTYPE	10	10	closed
NCT000031786	NCT00003178_6_T11	PHENOTYPE	7	8	Secondary AML
NCT000031787	NCT00003178_7_T0	PHENOTYPE	18	18	toxicity
NCT000031787	NCT00003178_7_T1	PHENOTYPE	14	15	disease progression
NCT000031788	NCT00003178_8_T0	ORGAN	16	17	bone marrow
NCT000031792	NCT00003179_2_T0	GENE	2	2	II
NCT000031792	NCT00003179_2_T1	PHENOTYPE	26	27	endometrial hyperplasia
NCT000031792	NCT00003179_2_T2	PHENOTYPE	20	21	endometrial cancer
NCT000031811	NCT00003181_1_T0	CELL	11	11	cells
NCT000031811	NCT00003181_1_T1	GENE	0	0	Interleukin-2
NCT000031811	NCT00003181_1_T2	CELL	5	7	white blood cells
NCT000031812	NCT00003181_2_T0	GENE	3	3	interleukin-2
NCT000031812	NCT00003181_2_T1	GENE	5	5	GM-CSF
NCT000031812	NCT00003181_2_T2	PHENOTYPE	13	14	kidney cancer
NCT000031813	NCT00003181_3_T0	GENE	2	2	II
NCT000031813	NCT00003181_3_T1	GENE	10	10	interleukin-2
NCT000031813	NCT00003181_3_T2	COMPOUND	11	11	vinblastine
NCT000031813	NCT00003181_3_T3	GENE	13	13	GM-CSF
NCT000031813	NCT00003181_3_T4	PHENOTYPE	18	20	metastatic kidney cancer
NCT000031817	NCT00003181_7_T0	PHENOTYPE	3	3	toxicities
NCT000031819	NCT00003181_9_T0	COMPOUND	2	2	vinblastine
NCT000031819	NCT00003181_9_T1	GENE	5	5	IV
NCT0000318110	NCT00003181_10_T0	GENE	0	0	Interleukin-2
NCT0000318110	NCT00003181_10_T1	GENE	8	8	1.5
NCT0000318111	NCT00003181_11_T0	GENE	12	12	1.5
NCT0000318111	NCT00003181_11_T1	GENE	4	4	GM-CSF
NCT0000318113	NCT00003181_13_T0	PHENOTYPE	14	15	disease progression
NCT0000318115	NCT00003181_15_T0	GENE	2	2	20.35
NCT000031821	NCT00003182_1_T0	CELL	9	9	cells
NCT000031821	NCT00003182_1_T1	PHENOTYPE	8	8	tumor
NCT000031826	NCT00003182_6_T0	PHENOTYPE	2	2	toxicity
NCT000031829	NCT00003182_9_T0	COMPOUND	8	8	gemcitabine
NCT0000318210	NCT00003182_10_T0	COMPOUND	2	2	gemcitabine
NCT0000318210	NCT00003182_10_T1	GENE	5	5	IV
NCT0000318212	NCT00003182_12_T0	PHENOTYPE	6	6	toxicity
NCT0000318212	NCT00003182_12_T1	COMPOUND	24	24	gemcitabine
NCT0000318212	NCT00003182_12_T2	GENE	7	7	DLT
NCT0000318213	NCT00003182_13_T0	PHENOTYPE	8	8	experiences
NCT0000318213	NCT00003182_13_T1	GENE	9	9	DLT
NCT0000318214	NCT00003182_14_T0	PHENOTYPE	5	5	experiences
NCT0000318214	NCT00003182_14_T1	GENE	6	6	DLT
NCT0000318216	NCT00003182_16_T0	PHENOTYPE	11	12	disease progression
NCT0000318217	NCT00003182_17_T0	GENE	20	20	II
NCT000031831	NCT00003183_1_T0	CELL	7	7	cells
NCT000031831	NCT00003183_1_T1	CELL	19	19	cells
NCT000031831	NCT00003183_1_T2	PHENOTYPE	6	6	tumor
NCT000031831	NCT00003183_1_T3	PHENOTYPE	18	18	tumor
NCT000031831	NCT00003183_1_T4	GENE	3	3	G-CSF
NCT000031836	NCT00003183_6_T0	COMPOUND	5	5	mitoxantrone
NCT0000318310	NCT00003183_10_T0	COMPOUND	8	8	mitoxantrone
NCT0000318311	NCT00003183_11_T0	CELL	10	10	granulocyte
NCT0000318311	NCT00003183_11_T1	GENE	9	9	filgrastim
NCT0000318311	NCT00003183_11_T2	GENE	13	13	G-CSF
NCT0000318312	NCT00003183_12_T0	PHENOTYPE	11	12	disease progression
NCT0000318313	NCT00003183_13_T0	COMPOUND	10	10	mitoxantrone
NCT0000318313	NCT00003183_13_T1	GENE	12	12	G-CSF
NCT0000318313	NCT00003183_13_T2	GENE	8	8	MTD
NCT0000318314	NCT00003183_14_T0	PHENOTYPE	18	18	toxicity
NCT0000318314	NCT00003183_14_T1	GENE	1	1	MTD
NCT0000318315	NCT00003183_15_T0	GENE	2	2	MTD
NCT0000318317	NCT00003183_17_T0	GENE	10	10	II
NCT000031841	NCT00003184_1_T0	CELL	14	14	cells
NCT000031841	NCT00003184_1_T1	PHENOTYPE	12	13	breast cancer
NCT000031841	NCT00003184_1_T2	PHENOTYPE	19	21	metastatic breast cancer
NCT000031844	NCT00003184_4_T0	CELL	6	6	cells
NCT000031844	NCT00003184_4_T1	GENE	16	16	BCG
NCT000031844	NCT00003184_4_T2	GENE	11	11	GM-CSF
NCT000031844	NCT00003184_4_T3	GENE	10	10	sargramostim
NCT000031846	NCT00003184_6_T0	GENE	9	9	GM-CSF
NCT000031847	NCT00003184_7_T0	GENE	0	0	GM-CSF
NCT0000318411	NCT00003184_11_T0	PHENOTYPE	28	29	disease progression
NCT000031851	NCT00003185_1_T0	GENE	2	2	II
NCT000031851	NCT00003185_1_T1	PHENOTYPE	15	16	glioblastoma multiforme
NCT000031855	NCT00003185_5_T0	PHENOTYPE	2	2	toxic
NCT000031856	NCT00003185_6_T0	CELL	8	8	cells
NCT000031856	NCT00003185_6_T1	PHENOTYPE	7	7	tumor
NCT000031856	NCT00003185_6_T2	ORGAN	19	19	groin
NCT000031856	NCT00003185_6_T3	GENE	11	11	GM-CSF
NCT000031856	NCT00003185_6_T4	GENE	10	10	sargramostim
NCT000031856	NCT00003185_6_T5	TISSUE	15	16	lymph nodes
NCT000031857	NCT00003185_7_T0	GENE	12	12	GM-CSF
NCT000031858	NCT00003185_8_T0	GENE	17	17	interleukin-2
NCT000031858	NCT00003185_8_T1	GENE	18	18	IL-2
NCT000031858	NCT00003185_8_T2	GENE	6	6	7-10
NCT000031858	NCT00003185_8_T3	GENE	15	15	SEA
NCT000031858	NCT00003185_8_T4	PHENOTYPE	0	2	Enlarged lymph nodes
NCT000031859	NCT00003185_9_T0	CELL	0	1	T cells
NCT0000318510	NCT00003185_10_T0	GENE	0	0	1.2
NCT0000318510	NCT00003185_10_T1	COMPOUND	6	6	cyclophosphamide
NCT0000318511	NCT00003185_11_T0	CELL	1	1	lymphocyte
NCT0000318512	NCT00003185_12_T0	CELL	15	15	cells
NCT0000318512	NCT00003185_12_T1	PHENOTYPE	14	14	tumor
NCT000031861	NCT00003186_1_T0	PHENOTYPE	16	18	metastatic colorectal cancer
NCT000031864	NCT00003186_4_T0	TISSUE	11	11	serosa
NCT000031864	NCT00003186_4_T1	PHENOTYPE	17	18	primary tumor
NCT000031864	NCT00003186_4_T2	COMPOUND	7	8	isosulfan blue
NCT000031865	NCT00003186_5_T0	TISSUE	13	13	mucosa
NCT000031866	NCT00003186_6_T0	ORGAN	1	1	mesentery
NCT000031866	NCT00003186_6_T1	COMPOUND	17	18	isosulfan blue
NCT000031867	NCT00003186_7_T0	GENE	1	1	sentinel
NCT000031868	NCT00003186_8_T0	COMPOUND	6	7	isosulfan blue
NCT000031869	NCT00003186_9_T0	PHENOTYPE	8	8	metastases
NCT000031869	NCT00003186_9_T1	ORGAN	4	4	liver
NCT000031869	NCT00003186_9_T2	COMPOUND	9	10	isosulfan blue
NCT000031872	NCT00003187_2_T0	CELL	7	7	cells
NCT000031872	NCT00003187_2_T1	CELL	2	3	T cells
NCT000031873	NCT00003187_3_T0	PHENOTYPE	25	25	leukemia
NCT000031873	NCT00003187_3_T1	PHENOTYPE	26	26	myelodysplasia
NCT000031873	NCT00003187_3_T2	ORGAN	11	12	bone marrow
NCT000031873	NCT00003187_3_T3	ORGAN	17	18	bone marrow
NCT000031873	NCT00003187_3_T4	PHENOTYPE	28	29	lymphoblastic lymphoma
NCT000031877	NCT00003187_7_T0	PHENOTYPE	9	9	acute
NCT000031877	NCT00003187_7_T1	PHENOTYPE	14	14	complications
NCT000031877	NCT00003187_7_T2	PHENOTYPE	21	21	relapse
NCT000031877	NCT00003187_7_T3	PHENOTYPE	6	6	secondary
NCT000031877	NCT00003187_7_T4	PHENOTYPE	11	11	chronic
NCT000031877	NCT00003187_7_T5	PHENOTYPE	18	19	interstitial pneumonitis
NCT000031877	NCT00003187_7_T6	PHENOTYPE	12	13	graft-vs-host disease
NCT000031877	NCT00003187_7_T7	PHENOTYPE	16	17	veno-occlusive disease
NCT000031877	NCT00003187_7_T8	PHENOTYPE	7	8	graft failure
NCT000031879	NCT00003187_9_T0	PHENOTYPE	10	10	myelodysplasia
NCT000031879	NCT00003187_9_T1	PHENOTYPE	5	5	malignancies
NCT000031879	NCT00003187_9_T2	ORGAN	9	9	transplant
NCT000031879	NCT00003187_9_T3	PHENOTYPE	6	7	lymphoproliferative disorders
NCT0000318716	NCT00003187_16_T0	ORGAN	0	1	Bone marrow
NCT0000318717	NCT00003187_17_T0	COMPOUND	2	2	cyclosporine
NCT0000318717	NCT00003187_17_T1	COMPOUND	6	6	1
NCT0000318717	NCT00003187_17_T2	COMPOUND	12	12	1
NCT0000318717	NCT00003187_17_T3	COMPOUND	8	8	methotrexate
NCT0000318717	NCT00003187_17_T4	GENE	9	9	IV
NCT0000318719	NCT00003187_19_T0	GENE	8	8	II
NCT0000318721	NCT00003187_21_T0	COMPOUND	4	4	cytarabine
NCT0000318721	NCT00003187_21_T1	COMPOUND	19	19	methylprednisolone
NCT0000318721	NCT00003187_21_T2	GENE	5	5	IV
NCT0000318721	NCT00003187_21_T3	GENE	12	12	IV
NCT0000318721	NCT00003187_21_T4	GENE	20	20	IV
NCT0000318721	NCT00003187_21_T5	COMPOUND	17	17	1
NCT0000318721	NCT00003187_21_T6	COMPOUND	15	15	2
NCT0000318721	NCT00003187_21_T7	COMPOUND	23	23	2
NCT0000318721	NCT00003187_21_T8	COMPOUND	10	10	3
NCT0000318721	NCT00003187_21_T9	COMPOUND	11	11	cyclophosphamide
NCT0000318722	NCT00003187_22_T0	ORGAN	0	1	Bone marrow
NCT0000318723	NCT00003187_23_T0	COMPOUND	4	4	1
NCT0000318724	NCT00003187_24_T0	GENE	1	1	II
NCT0000318724	NCT00003187_24_T1	COMPOUND	3	3	cytarabine
NCT0000318724	NCT00003187_24_T2	COMPOUND	11	11	cyclophosphamide
NCT0000318724	NCT00003187_24_T3	GENE	4	4	IV
NCT0000318725	NCT00003187_25_T0	COMPOUND	6	6	2
NCT0000318725	NCT00003187_25_T1	GENE	1	1	IV
NCT0000318726	NCT00003187_26_T0	ORGAN	0	1	Bone marrow
NCT0000318728	NCT00003187_28_T0	GENE	1	1	II
NCT0000318730	NCT00003187_30_T0	ORGAN	16	17	chest wall
NCT0000318731	NCT00003187_31_T0	COMPOUND	8	8	2
NCT0000318731	NCT00003187_31_T1	COMPOUND	6	6	3
NCT0000318731	NCT00003187_31_T2	GENE	1	1	IV
NCT0000318732	NCT00003187_32_T0	ORGAN	0	1	Bone marrow
NCT0000318734	NCT00003187_34_T0	ORGAN	0	1	Bone marrow
NCT0000318735	NCT00003187_35_T0	COMPOUND	2	2	methylprednisolone
NCT0000318735	NCT00003187_35_T1	GENE	6	6	hr
NCT0000318735	NCT00003187_35_T2	GENE	3	3	IV
NCT0000318736	NCT00003187_36_T0	COMPOUND	5	5	3
NCT000031901	NCT00003190_1_T0	PHENOTYPE	1	1	cancers
NCT000031901	NCT00003190_1_T1	PHENOTYPE	3	3	resistant
NCT000031905	NCT00003190_5_T0	PHENOTYPE	30	30	AML
NCT0000319014	NCT00003190_14_T0	PHENOTYPE	9	9	leukemia
NCT0000319014	NCT00003190_14_T1	ORGAN	14	15	bone marrow
NCT0000319015	NCT00003190_15_T0	COMPOUND	17	17	cytarabine
NCT0000319015	NCT00003190_15_T1	PHENOTYPE	5	5	remission
NCT0000319015	NCT00003190_15_T2	COMPOUND	28	28	etoposide
NCT0000319015	NCT00003190_15_T3	GENE	18	18	IV
NCT0000319015	NCT00003190_15_T4	GENE	25	25	IV
NCT0000319015	NCT00003190_15_T5	GENE	29	29	IV
NCT0000319015	NCT00003190_15_T6	COMPOUND	24	24	daunorubicin
NCT0000319015	NCT00003190_15_T7	GENE	6	6	CR
NCT0000319017	NCT00003190_17_T0	GENE	14	14	interleukin-2
NCT0000319017	NCT00003190_17_T1	GENE	15	15	IL-2
NCT0000319019	NCT00003190_19_T0	GENE	6	6	SC
NCT0000319019	NCT00003190_19_T1	GENE	20	20	SC
NCT0000319019	NCT00003190_19_T2	GENE	0	0	IL-2
NCT0000319019	NCT00003190_19_T3	GENE	7	7	IL-2
NCT0000319019	NCT00003190_19_T4	GENE	21	21	IL-2
NCT0000319020	NCT00003190_20_T0	PHENOTYPE	23	23	relapse
NCT000031910	NCT00003191_0_T0	PHENOTYPE	5	6	Solid Tumors
NCT000031912	NCT00003191_2_T0	CELL	10	10	cells
NCT000031912	NCT00003191_2_T1	PHENOTYPE	9	9	tumor
NCT000031914	NCT00003191_4_T0	COMPOUND	6	6	fenretinide
NCT000031914	NCT00003191_4_T1	GENE	7	7	HPR
NCT000031914	NCT00003191_4_T2	PHENOTYPE	13	14	solid tumors
NCT000031916	NCT00003191_6_T0	PHENOTYPE	2	2	toxicities
NCT000031916	NCT00003191_6_T1	GENE	4	4	HPR
NCT000031918	NCT00003191_8_T0	PHENOTYPE	2	2	pharmacokinetics
NCT000031918	NCT00003191_8_T1	GENE	4	4	HPR
NCT0000319110	NCT00003191_10_T0	GENE	2	2	CSF
NCT0000319110	NCT00003191_10_T1	GENE	5	5	HPR
NCT0000319112	NCT00003191_12_T0	GENE	4	4	HPR
NCT0000319112	NCT00003191_12_T1	ORGAN	6	6	plasma
NCT0000319114	NCT00003191_14_T0	GENE	4	4	HPR
NCT0000319116	NCT00003191_16_T0	PHENOTYPE	13	13	neuroblastoma
NCT0000319116	NCT00003191_16_T1	GENE	5	5	HPR
NCT0000319116	NCT00003191_16_T2	PHENOTYPE	9	11	bone marrow disease
NCT0000319118	NCT00003191_18_T0	GENE	10	10	1.7
NCT0000319118	NCT00003191_18_T1	COMPOUND	3	3	fenretinide
NCT0000319120	NCT00003191_20_T0	PHENOTYPE	16	17	residual tumor
NCT0000319121	NCT00003191_21_T0	PHENOTYPE	10	11	measurable disease
NCT0000319121	NCT00003191_21_T1	PHENOTYPE	2	3	recurrent neuroblastoma
NCT0000319122	NCT00003191_22_T0	COMPOUND	8	8	fenretinide
NCT0000319122	NCT00003191_22_T1	GENE	14	14	MTD
NCT0000319123	NCT00003191_23_T0	PHENOTYPE	18	18	toxicity
NCT0000319123	NCT00003191_23_T1	GENE	1	1	MTD
NCT000031921	NCT00003192_1_T0	GENE	2	2	II
NCT000031921	NCT00003192_1_T1	ORGAN	24	24	esophagus
NCT000031921	NCT00003192_1_T2	PHENOTYPE	18	22	recurrent cancer of the stomach
NCT000031923	NCT00003192_3_T0	ORGAN	24	25	gastroesophageal junction
NCT000031923	NCT00003192_3_T1	PHENOTYPE	19	22	adenocarcinoma of the stomach
NCT000031925	NCT00003192_5_T0	PHENOTYPE	5	5	toxicity
NCT000031927	NCT00003192_7_T0	PHENOTYPE	7	7	progression
NCT000031929	NCT00003192_9_T0	PHENOTYPE	4	4	pharmacodynamics
NCT000031929	NCT00003192_9_T1	PHENOTYPE	2	2	pharmacokinetics
NCT0000319211	NCT00003192_11_T0	GENE	12	12	1.5
NCT0000319212	NCT00003192_12_T0	PHENOTYPE	15	15	toxic
NCT0000319212	NCT00003192_12_T1	PHENOTYPE	19	20	disease progression
NCT0000319213	NCT00003192_13_T0	PHENOTYPE	14	14	toxicity
NCT000031930	NCT00003193_0_T0	GENE	13	13	III
NCT000031930	NCT00003193_0_T1	GENE	16	16	IV
NCT000031930	NCT00003193_0_T2	PHENOTYPE	17	20	Head and Neck Cancer
NCT000031932	NCT00003193_2_T0	CELL	8	8	cells
NCT000031932	NCT00003193_2_T1	PHENOTYPE	7	7	tumor
NCT000031933	NCT00003193_3_T0	CELL	8	8	cells
NCT000031933	NCT00003193_3_T1	COMPOUND	4	4	amifostine
NCT000031933	NCT00003193_3_T2	PHENOTYPE	12	14	effects of chemotherapy
NCT000031934	NCT00003193_4_T0	COMPOUND	9	9	paclitaxel
NCT000031934	NCT00003193_4_T1	GENE	25	25	IV
NCT000031934	NCT00003193_4_T2	COMPOUND	16	16	amifostine
NCT000031934	NCT00003193_4_T3	PHENOTYPE	21	22	stage III
NCT000031934	NCT00003193_4_T4	PHENOTYPE	26	29	head and neck cancer
NCT000031936	NCT00003193_6_T0	COMPOUND	7	7	paclitaxel
NCT000031936	NCT00003193_6_T1	COMPOUND	11	11	amifostine
NCT000031937	NCT00003193_7_T0	COMPOUND	2	2	paclitaxel
NCT000031937	NCT00003193_7_T1	GENE	3	3	IV
NCT000031938	NCT00003193_8_T0	COMPOUND	13	13	paclitaxel
NCT0000319310	NCT00003193_10_T0	PHENOTYPE	13	13	toxicity
NCT0000319310	NCT00003193_10_T1	GENE	9	9	2.3
NCT0000319310	NCT00003193_10_T2	GENE	1	1	MTD
NCT0000319311	NCT00003193_11_T0	GENE	8	8	MTD
NCT0000319313	NCT00003193_13_T0	COMPOUND	13	13	paclitaxel
NCT0000319313	NCT00003193_13_T1	GENE	3	3	MTD
NCT000031940	NCT00003194_0_T0	PHENOTYPE	11	11	Recurrent
NCT000031940	NCT00003194_0_T1	PHENOTYPE	14	15	Solid Tumors
NCT000031940	NCT00003194_0_T2	CELL	3	5	Peripheral Stem Cell
NCT000031945	NCT00003194_5_T0	COMPOUND	8	8	thiotepa
NCT000031947	NCT00003194_7_T0	COMPOUND	11	11	1
NCT000031947	NCT00003194_7_T1	COMPOUND	2	2	thiotepa
NCT000031947	NCT00003194_7_T2	GENE	19	19	0.4
NCT000031947	NCT00003194_7_T3	GENE	3	3	IV
NCT000031947	NCT00003194_7_T4	GENE	13	13	IV
NCT000031947	NCT00003194_7_T5	GENE	22	22	IV
NCT000031947	NCT00003194_7_T6	COMPOUND	12	12	topotecan
NCT000031948	NCT00003194_8_T0	GENE	3	3	G-CSF
NCT000031948	NCT00003194_8_T1	COMPOUND	15	15	topotecan
NCT000031949	NCT00003194_9_T0	COMPOUND	13	13	topotecan
NCT0000319411	NCT00003194_11_T0	COMPOUND	8	8	thiotepa
NCT0000319411	NCT00003194_11_T1	GENE	14	14	MTD
NCT0000319412	NCT00003194_12_T0	PHENOTYPE	17	17	toxicity
NCT0000319412	NCT00003194_12_T1	GENE	1	1	MTD
NCT000031951	NCT00003195_1_T0	CELL	10	10	cells
NCT000031957	NCT00003195_7_T0	ORGAN	3	3	marrow
NCT000031957	NCT00003195_7_T1	GENE	5	5	TMI
NCT000031957	NCT00003195_7_T2	GENE	6	6	bid
NCT000031958	NCT00003195_8_T0	COMPOUND	10	10	3
NCT0000319510	NCT00003195_10_T0	GENE	0	0	Interferon
NCT0000319511	NCT00003195_11_T0	GENE	0	0	Interferon
NCT0000319511	NCT00003195_11_T1	PHENOTYPE	13	14	disease progression
NCT0000319511	NCT00003195_11_T2	PHENOTYPE	8	11	graft versus host disease
NCT000031962	NCT00003196_2_T0	CELL	29	29	platelets
NCT000031962	NCT00003196_2_T1	CELL	2	3	stem cells
NCT000031962	NCT00003196_2_T2	CELL	20	21	stem cells
NCT000031962	NCT00003196_2_T3	ORGAN	17	18	bone marrow
NCT000031962	NCT00003196_2_T4	CELL	22	24	red blood cells
NCT000031962	NCT00003196_2_T5	CELL	25	27	white blood cells
NCT000031963	NCT00003196_3_T0	CELL	16	16	cells
NCT000031963	NCT00003196_3_T1	CELL	3	4	stem cells
NCT000031963	NCT00003196_3_T2	ORGAN	9	10	immune system
NCT000031964	NCT00003196_4_T0	CELL	10	10	lymphocyte
NCT000031964	NCT00003196_4_T1	CELL	6	8	white blood cells
NCT000031969	NCT00003196_9_T0	PHENOTYPE	13	13	tumor
NCT000031969	NCT00003196_9_T1	PHENOTYPE	7	7	malignancies
NCT0000319611	NCT00003196_11_T0	COMPOUND	3	3	cyclosporine
NCT0000319611	NCT00003196_11_T1	COMPOUND	11	11	1
NCT0000319611	NCT00003196_11_T2	GENE	8	8	BID
NCT0000319611	NCT00003196_11_T3	GENE	18	18	BID
NCT0000319611	NCT00003196_11_T4	GENE	5	5	IV
NCT0000319612	NCT00003196_12_T0	GENE	6	6	BID
NCT0000319612	NCT00003196_12_T1	COMPOUND	3	4	mycophenolate mofetil
NCT0000319613	NCT00003196_13_T0	PHENOTYPE	41	41	persistence
NCT0000319613	NCT00003196_13_T1	PHENOTYPE	15	15	GVHD
NCT0000319613	NCT00003196_13_T2	PHENOTYPE	36	36	GVHD
NCT0000319613	NCT00003196_13_T3	PHENOTYPE	13	14	graft-vs-host disease
NCT0000319613	NCT00003196_13_T4	PHENOTYPE	38	39	disease progression
NCT000031970	NCT00003197_0_T0	PHENOTYPE	8	9	Solid Tumors
NCT000031972	NCT00003197_2_T0	COMPOUND	10	11	tea extract
NCT000031972	NCT00003197_2_T1	PHENOTYPE	17	18	solid tumors
NCT000031974	NCT00003197_4_T0	COMPOUND	7	8	tea extract
NCT000031974	NCT00003197_4_T1	PHENOTYPE	14	15	solid tumors
NCT000031976	NCT00003197_6_T0	PHENOTYPE	4	4	chronic
NCT000031976	NCT00003197_6_T1	COMPOUND	9	10	tea extract
NCT000031978	NCT00003197_8_T0	COMPOUND	6	7	tea extract
NCT0000319711	NCT00003197_11_T0	COMPOUND	9	10	tea extract
NCT0000319712	NCT00003197_12_T0	COMPOUND	3	4	tea extract
NCT0000319714	NCT00003197_14_T0	GENE	2	2	II
NCT0000319714	NCT00003197_14_T1	PHENOTYPE	3	3	toxicities
NCT0000319715	NCT00003197_15_T0	PHENOTYPE	23	23	toxicity
NCT0000319716	NCT00003197_16_T0	PHENOTYPE	8	8	toxicity
NCT0000319716	NCT00003197_16_T1	GENE	24	24	MTD
NCT0000319717	NCT00003197_17_T0	GENE	8	8	MTD
NCT0000319718	NCT00003197_18_T0	PHENOTYPE	13	13	toxicity
NCT0000319718	NCT00003197_18_T1	PHENOTYPE	15	16	disease progression
NCT000031980	NCT00003198_0_T0	PHENOTYPE	8	9	Solid Tumors
NCT000031982	NCT00003198_2_T0	CELL	9	9	cells
NCT000031982	NCT00003198_2_T1	PHENOTYPE	8	8	tumor
NCT000031983	NCT00003198_3_T0	COMPOUND	11	11	ifosfamide
NCT000031983	NCT00003198_3_T1	COMPOUND	13	13	topotecan
NCT000031983	NCT00003198_3_T2	PHENOTYPE	19	20	solid tumors
NCT000031987	NCT00003198_7_T0	PHENOTYPE	1	1	toxicity
NCT000031987	NCT00003198_7_T1	COMPOUND	5	5	ifosfamide
NCT000031987	NCT00003198_7_T2	COMPOUND	3	3	topotecan
NCT000031989	NCT00003198_9_T0	PHENOTYPE	15	15	toxic
NCT000031989	NCT00003198_9_T1	COMPOUND	9	9	ifosfamide
NCT000031989	NCT00003198_9_T2	PHENOTYPE	2	2	pharmacokinetics
NCT000031989	NCT00003198_9_T3	COMPOUND	7	7	topotecan
NCT0000319813	NCT00003198_13_T0	COMPOUND	5	5	ifosfamide
NCT0000319813	NCT00003198_13_T1	COMPOUND	15	15	topotecan
NCT0000319815	NCT00003198_15_T0	COMPOUND	13	13	ifosfamide
NCT0000319815	NCT00003198_15_T1	COMPOUND	1	1	topotecan
NCT0000319816	NCT00003198_16_T0	COMPOUND	7	7	ifosfamide
NCT0000319816	NCT00003198_16_T1	COMPOUND	10	10	topotecan
NCT0000319819	NCT00003198_19_T0	CELL	1	1	granulocyte
NCT0000319819	NCT00003198_19_T1	CELL	17	17	granulocyte
NCT0000319819	NCT00003198_19_T2	GENE	4	4	G-CSF
NCT0000319819	NCT00003198_19_T3	GENE	19	19	has
NCT0000319820	NCT00003198_20_T0	PHENOTYPE	6	6	toxicity
NCT0000319820	NCT00003198_20_T1	GENE	7	7	DLT
NCT0000319821	NCT00003198_21_T0	PHENOTYPE	8	8	experiences
NCT0000319821	NCT00003198_21_T1	GENE	9	9	DLT
NCT0000319822	NCT00003198_22_T0	GENE	24	24	MTD
NCT0000319822	NCT00003198_22_T1	GENE	6	6	DLT
NCT0000319823	NCT00003198_23_T0	GENE	7	7	MTD
NCT0000319823	NCT00003198_23_T1	GENE	12	12	DLT
NCT0000319824	NCT00003198_24_T0	GENE	1	1	MTD
NCT000031993	NCT00003199_3_T0	CELL	12	12	cells
NCT000031993	NCT00003199_3_T1	PHENOTYPE	11	11	tumor
NCT000031994	NCT00003199_4_T0	CELL	11	11	cells
NCT000031994	NCT00003199_4_T1	PHENOTYPE	9	10	breast cancer
NCT000031994	NCT00003199_4_T2	CELL	4	6	white blood cells
NCT000031996	NCT00003199_6_T0	GENE	32	32	GM-CSF
NCT000031996	NCT00003199_6_T1	GENE	30	30	IL2
NCT000031996	NCT00003199_6_T2	PHENOTYPE	16	19	stage IV breast cancer
NCT000031997	NCT00003199_7_T0	GENE	2	2	II
NCT000031998	NCT00003199_8_T0	PHENOTYPE	3	3	toxicity
NCT000031998	NCT00003199_8_T1	GENE	9	9	IL-2
NCT000031998	NCT00003199_8_T2	GENE	15	15	HDC
NCT000031998	NCT00003199_8_T3	GENE	11	11	GM-CSF
NCT000031999	NCT00003199_9_T0	COMPOUND	18	18	melphalan
NCT000031999	NCT00003199_9_T1	GENE	19	19	IV
NCT000031999	NCT00003199_9_T2	GENE	30	30	IV
NCT000031999	NCT00003199_9_T3	COMPOUND	5	5	busulfan
NCT000031999	NCT00003199_9_T4	COMPOUND	32	32	2
NCT000031999	NCT00003199_9_T5	COMPOUND	38	38	2
NCT000031999	NCT00003199_9_T6	COMPOUND	36	36	3
NCT000031999	NCT00003199_9_T7	COMPOUND	29	29	thiotepa
NCT0000319911	NCT00003199_11_T0	COMPOUND	6	6	citrate
NCT0000319911	NCT00003199_11_T1	GENE	35	35	OR
NCT0000319911	NCT00003199_11_T2	PHENOTYPE	26	26	relapse
NCT0000319911	NCT00003199_11_T3	GENE	13	13	aldesleukin
NCT0000319911	NCT00003199_11_T4	GENE	17	17	GM-CSF
NCT0000319911	NCT00003199_11_T5	GENE	29	29	ER
NCT0000319911	NCT00003199_11_T6	GENE	14	14	IL-2
NCT0000319911	NCT00003199_11_T7	COMPOUND	5	5	tamoxifen
NCT0000319911	NCT00003199_11_T8	GENE	16	16	sargramostim
NCT0000319911	NCT00003199_11_T9	GENE	27	28	estrogen receptor
NCT0000319911	NCT00003199_11_T10	GENE	31	32	progesterone receptor
NCT0000319912	NCT00003199_12_T0	GENE	5	5	SC
NCT0000319912	NCT00003199_12_T1	GENE	9	9	SC
NCT0000319912	NCT00003199_12_T2	GENE	3	3	IL-2
NCT0000319912	NCT00003199_12_T3	GENE	8	8	GM-CSF
NCT0000319914	NCT00003199_14_T0	COMPOUND	10	10	citrate
NCT0000319914	NCT00003199_14_T1	PHENOTYPE	29	29	progression
NCT0000319914	NCT00003199_14_T2	COMPOUND	21	21	anastrozole
NCT0000319914	NCT00003199_14_T3	GENE	1	1	IV
NCT0000319914	NCT00003199_14_T4	COMPOUND	9	9	tamoxifen
NCT0000319914	NCT00003199_14_T5	COMPOUND	32	32	tamoxifen
NCT0000319915	NCT00003199_15_T0	GENE	0	0	For
NCT0000319915	NCT00003199_15_T1	COMPOUND	18	18	tamoxifen
NCT000032003	NCT00003200_3_T0	GENE	12	12	3.5
NCT000032004	NCT00003200_4_T0	PHENOTYPE	7	7	toxicities
NCT000032005	NCT00003200_5_T0	PHENOTYPE	23	23	tumors
NCT000032007	NCT00003200_7_T0	PHENOTYPE	6	6	tumors
NCT0000320014	NCT00003200_14_T0	PHENOTYPE	2	2	experiences
NCT0000320014	NCT00003200_14_T1	PHENOTYPE	4	5	weight loss
NCT000032022	NCT00003202_2_T0	CELL	8	8	cells
NCT000032022	NCT00003202_2_T1	PHENOTYPE	7	7	tumor
NCT000032023	NCT00003202_3_T0	CELL	9	9	cells
NCT000032023	NCT00003202_3_T1	PHENOTYPE	8	8	tumor
NCT0000320214	NCT00003202_14_T0	PHENOTYPE	3	3	toxicity
NCT0000320214	NCT00003202_14_T1	GENE	4	4	DLT
NCT0000320215	NCT00003202_15_T0	PHENOTYPE	22	22	toxicity
NCT0000320215	NCT00003202_15_T1	PHENOTYPE	36	36	toxicity
NCT0000320215	NCT00003202_15_T2	GENE	4	4	MTD
NCT0000320215	NCT00003202_15_T3	PHENOTYPE	19	19	experiences
NCT0000320215	NCT00003202_15_T4	GENE	37	37	DLT
NCT0000320218	NCT00003202_18_T0	GENE	13	13	1.2
NCT000032031	NCT00003203_1_T0	CELL	8	8	cells
NCT000032031	NCT00003203_1_T1	PHENOTYPE	7	7	tumor
NCT000032032	NCT00003203_2_T0	COMPOUND	3	3	vincristine
NCT000032032	NCT00003203_2_T1	CELL	15	15	cells
NCT000032032	NCT00003203_2_T2	PHENOTYPE	14	14	tumor
NCT000032033	NCT00003203_3_T0	GENE	3	3	II
NCT000032033	NCT00003203_3_T1	PHENOTYPE	28	29	embryonal tumors
NCT000032036	NCT00003203_6_T0	COMPOUND	15	15	vincristine
NCT000032036	NCT00003203_6_T1	COMPOUND	30	30	vincristine
NCT000032036	NCT00003203_6_T2	GENE	16	16	IV
NCT000032036	NCT00003203_6_T3	GENE	23	23	IV
NCT000032037	NCT00003203_7_T0	GENE	3	3	1.4
NCT000032038	NCT00003203_8_T0	GENE	14	14	MTD
NCT000032039	NCT00003203_9_T0	PHENOTYPE	18	18	toxicity
NCT000032039	NCT00003203_9_T1	GENE	1	1	MTD
NCT000032041	NCT00003204_1_T0	CELL	10	10	cells
NCT000032042	NCT00003204_2_T0	CELL	9	9	cells
NCT000032047	NCT00003204_7_T0	GENE	7	7	CD20
NCT000032047	NCT00003204_7_T1	PHENOTYPE	13	13	progression
NCT000032047	NCT00003204_7_T2	CELL	24	24	lymphocyte
NCT000032047	NCT00003204_7_T3	PHENOTYPE	29	30	immunoglobulin levels
NCT0000320411	NCT00003204_11_T0	GENE	3	3	AS
NCT0000320411	NCT00003204_11_T1	PHENOTYPE	2	2	CLOSED
NCT0000320411	NCT00003204_11_T2	GENE	24	24	1.5
NCT0000320411	NCT00003204_11_T3	COMPOUND	17	17	fludarabine
NCT0000320411	NCT00003204_11_T4	COMPOUND	8	8	cyclophosphamide
NCT0000320411	NCT00003204_11_T5	GENE	0	0	ARM
NCT0000320411	NCT00003204_11_T6	GENE	9	9	IV
NCT0000320411	NCT00003204_11_T7	GENE	18	18	IV
NCT0000320412	NCT00003204_12_T0	PHENOTYPE	9	10	disease progression
NCT0000320413	NCT00003204_13_T0	GENE	1	1	II
NCT0000320413	NCT00003204_13_T1	COMPOUND	10	10	vincristine
NCT0000320413	NCT00003204_13_T2	GENE	20	20	1.5
NCT0000320413	NCT00003204_13_T3	COMPOUND	4	4	cyclophosphamide
NCT0000320413	NCT00003204_13_T4	GENE	0	0	ARM
NCT0000320413	NCT00003204_13_T5	COMPOUND	17	17	prednisone
NCT0000320413	NCT00003204_13_T6	GENE	5	5	IV
NCT0000320413	NCT00003204_13_T7	GENE	11	11	IV
NCT0000320414	NCT00003204_14_T0	PHENOTYPE	9	10	disease progression
NCT0000320416	NCT00003204_16_T0	GENE	1	1	III
NCT0000320416	NCT00003204_16_T1	GENE	0	0	ARM
NCT0000320416	NCT00003204_16_T2	GENE	11	11	IV
NCT0000320419	NCT00003204_19_T0	GENE	0	0	ARM
NCT0000320419	NCT00003204_19_T1	GENE	1	1	IV
NCT000032051	NCT00003205_1_T0	GENE	2	2	II
NCT000032051	NCT00003205_1_T1	COMPOUND	9	10	bryostatin 1
NCT000032051	NCT00003205_1_T2	PHENOTYPE	15	18	stage IV breast cancer
NCT000032053	NCT00003205_3_T0	GENE	5	5	IV
NCT000032053	NCT00003205_3_T1	COMPOUND	3	4	bryostatin 1
NCT000032054	NCT00003205_4_T0	PHENOTYPE	11	11	toxicity
NCT000032054	NCT00003205_4_T1	PHENOTYPE	7	8	disease progression
NCT000032055	NCT00003205_5_T0	PHENOTYPE	7	7	tumor
NCT000032055	NCT00003205_5_T1	GENE	4	4	4-8
NCT000032061	NCT00003206_1_T0	GENE	2	2	II
NCT000032061	NCT00003206_1_T1	COMPOUND	11	11	paclitaxel
NCT000032061	NCT00003206_1_T2	PHENOTYPE	17	17	recurrent
NCT000032061	NCT00003206_1_T3	PHENOTYPE	19	21	metastatic nasopharyngeal cancer
NCT000032063	NCT00003206_3_T0	PHENOTYPE	4	4	toxicity
NCT000032063	NCT00003206_3_T1	COMPOUND	10	10	paclitaxel
NCT000032063	NCT00003206_3_T2	PHENOTYPE	15	15	recurrent
NCT000032063	NCT00003206_3_T3	PHENOTYPE	18	19	nasopharyngeal carcinoma
NCT000032064	NCT00003206_4_T0	COMPOUND	3	3	paclitaxel
NCT000032064	NCT00003206_4_T1	GENE	4	4	IV
NCT000032064	NCT00003206_4_T2	GENE	11	11	IV
NCT000032066	NCT00003206_6_T0	PHENOTYPE	11	11	toxicity
NCT000032066	NCT00003206_6_T1	PHENOTYPE	13	14	disease progression
NCT000032072	NCT00003207_2_T0	GENE	16	16	34.35
NCT000032072	NCT00003207_2_T1	PHENOTYPE	9	9	malignancies
NCT000032072	NCT00003207_2_T2	PHENOTYPE	14	15	ovarian cancer
NCT000032074	NCT00003207_4_T0	PHENOTYPE	9	9	pharmacokinetics
NCT000032074	NCT00003207_4_T1	GENE	13	13	MDR
NCT000032091	NCT00003209_1_T0	CELL	10	10	cells
NCT000032091	NCT00003209_1_T1	PHENOTYPE	9	9	tumor
NCT000032092	NCT00003209_2_T0	CELL	9	9	cells
NCT000032092	NCT00003209_2_T1	PHENOTYPE	8	8	tumor
NCT000032093	NCT00003209_3_T0	PHENOTYPE	24	25	cervical cancer
NCT000032094	NCT00003209_4_T0	GENE	3	3	III
NCT000032094	NCT00003209_4_T1	PHENOTYPE	25	28	stage IIA cervical cancer
NCT000032096	NCT00003209_6_T0	PHENOTYPE	1	1	relapse
NCT000032096	NCT00003209_6_T1	PHENOTYPE	26	27	cervical cancer
NCT000032098	NCT00003209_8_T0	PHENOTYPE	2	2	toxic
NCT0000320910	NCT00003209_10_T0	PHENOTYPE	12	12	relapse
NCT0000320912	NCT00003209_12_T0	TISSUE	14	15	resection margin
NCT0000320912	NCT00003209_12_T1	TISSUE	9	10	lymph node
NCT0000320912	NCT00003209_12_T2	PHENOTYPE	20	21	primary lesion
NCT0000320919	NCT00003209_19_T0	GENE	1	1	II
NCT0000320919	NCT00003209_19_T1	COMPOUND	11	11	ifosfamide
NCT0000320919	NCT00003209_19_T2	COMPOUND	9	9	cisplatin
NCT0000320921	NCT00003209_21_T0	COMPOUND	7	7	bleomycin
NCT0000320922	NCT00003209_22_T0	COMPOUND	14	14	bleomycin
NCT0000320922	NCT00003209_22_T1	COMPOUND	4	4	vindesine
NCT0000320922	NCT00003209_22_T2	GENE	17	17	2.4
NCT0000320922	NCT00003209_22_T3	GENE	1	1	III
NCT0000320922	NCT00003209_22_T4	COMPOUND	10	10	cisplatin
NCT0000320924	NCT00003209_24_T0	COMPOUND	11	11	bleomycin
NCT0000320924	NCT00003209_24_T1	COMPOUND	4	4	vinblastine
NCT0000320924	NCT00003209_24_T2	GENE	1	1	IV
NCT0000320926	NCT00003209_26_T0	COMPOUND	6	6	methotrexate
NCT0000320926	NCT00003209_26_T1	COMPOUND	4	4	cisplatin
NCT000032101	NCT00003210_1_T0	CELL	4	4	cells
NCT000032101	NCT00003210_1_T1	CELL	23	23	cells
NCT000032101	NCT00003210_1_T2	PHENOTYPE	3	3	tumor
NCT000032101	NCT00003210_1_T3	PHENOTYPE	11	11	tumor
NCT000032101	NCT00003210_1_T4	PHENOTYPE	22	22	lymphoma
NCT000032101	NCT00003210_1_T5	CELL	17	19	white blood cells
NCT000032103	NCT00003210_3_T0	GENE	5	5	interleukin-12
NCT000032103	NCT00003210_3_T1	PHENOTYPE	14	15	Hodgkin's disease
NCT000032103	NCT00003210_3_T2	PHENOTYPE	11	12	Hodgkin's lymphoma
NCT000032105	NCT00003210_5_T0	PHENOTYPE	16	16	peripheral
NCT000032105	NCT00003210_5_T1	GENE	8	8	interleukin-12
NCT000032105	NCT00003210_5_T2	CELL	18	18	lymphocytes
NCT000032105	NCT00003210_5_T3	GENE	12	12	FasL
NCT000032105	NCT00003210_5_T4	GENE	10	10	Fas
NCT000032107	NCT00003210_7_T0	GENE	2	2	interleukin-12
NCT000032108	NCT00003210_8_T0	PHENOTYPE	13	13	toxicity
NCT000032108	NCT00003210_8_T1	PHENOTYPE	9	10	disease progression
NCT000032119	NCT00003211_9_T0	COMPOUND	34	34	2
NCT000032119	NCT00003211_9_T1	COMPOUND	12	12	vincristine
NCT000032119	NCT00003211_9_T2	COMPOUND	32	32	3
NCT000032119	NCT00003211_9_T3	COMPOUND	25	25	cyclophosphamide
NCT000032119	NCT00003211_9_T4	COMPOUND	16	16	cisplatin
NCT000032119	NCT00003211_9_T5	GENE	13	13	IV
NCT000032119	NCT00003211_9_T6	GENE	17	17	IV
NCT000032119	NCT00003211_9_T7	GENE	26	26	IV
NCT0000321110	NCT00003211_10_T0	COMPOUND	2	2	amifostine
NCT0000321110	NCT00003211_10_T1	COMPOUND	14	14	cisplatin
NCT0000321110	NCT00003211_10_T2	COMPOUND	21	21	cisplatin
NCT0000321110	NCT00003211_10_T3	GENE	3	3	IV
NCT0000321112	NCT00003211_12_T0	GENE	3	3	SC
NCT0000321112	NCT00003211_12_T1	GENE	2	2	G-CSF
NCT0000321113	NCT00003211_13_T0	GENE	1	1	IV
NCT0000321114	NCT00003211_14_T0	GENE	0	0	G-CSF
NCT0000321117	NCT00003211_17_T0	COMPOUND	22	22	topotecan
NCT0000321118	NCT00003211_18_T0	COMPOUND	6	6	amifostine
NCT0000321119	NCT00003211_19_T0	PHENOTYPE	2	2	closed
NCT000032121	NCT00003212_1_T0	COMPOUND	6	6	ifosfamide
NCT000032121	NCT00003212_1_T1	COMPOUND	8	8	doxorubicin
NCT000032121	NCT00003212_1_T2	PHENOTYPE	16	18	soft tissue sarcoma
NCT000032122	NCT00003212_2_T0	COMPOUND	10	10	ifosfamide
NCT000032122	NCT00003212_2_T1	GENE	3	3	III
NCT000032122	NCT00003212_2_T2	COMPOUND	14	14	doxorubicin
NCT000032122	NCT00003212_2_T3	PHENOTYPE	23	25	soft tissue sarcoma
NCT000032124	NCT00003212_4_T0	COMPOUND	23	23	ifosfamide
NCT000032124	NCT00003212_4_T1	PHENOTYPE	2	2	progression
NCT000032124	NCT00003212_4_T2	COMPOUND	25	25	doxorubicin
NCT000032124	NCT00003212_4_T3	PHENOTYPE	12	14	soft tissue sarcoma
NCT000032126	NCT00003212_6_T0	PHENOTYPE	2	2	toxic
NCT000032129	NCT00003212_9_T0	PHENOTYPE	16	16	leiomyosarcoma
NCT000032129	NCT00003212_9_T1	COMPOUND	8	8	1
NCT000032129	NCT00003212_9_T2	COMPOUND	25	25	1
NCT000032129	NCT00003212_9_T3	ORGAN	9	9	liver
NCT000032129	NCT00003212_9_T4	PHENOTYPE	18	19	synovial sarcoma
NCT0000321215	NCT00003212_15_T0	PHENOTYPE	14	14	toxicity
NCT0000321215	NCT00003212_15_T1	PHENOTYPE	16	17	disease progression
NCT000032132	NCT00003213_2_T0	COMPOUND	6	6	dexamethasone
NCT000032132	NCT00003213_2_T1	COMPOUND	14	14	dexamethasone
NCT000032132	NCT00003213_2_T2	COMPOUND	16	16	metoclopramide
NCT000032132	NCT00003213_2_T3	COMPOUND	8	8	granisetron
NCT000032132	NCT00003213_2_T4	PHENOTYPE	21	23	effects of chemotherapy
NCT000032133	NCT00003213_3_T0	COMPOUND	10	10	dexamethasone
NCT000032133	NCT00003213_3_T1	COMPOUND	15	15	metoclopramide
NCT000032133	NCT00003213_3_T2	GENE	3	3	III
NCT000032133	NCT00003213_3_T3	COMPOUND	13	13	granisetron
NCT000032135	NCT00003213_5_T0	PHENOTYPE	35	35	acute
NCT000032135	NCT00003213_5_T1	PHENOTYPE	32	32	emesis
NCT000032135	NCT00003213_5_T2	PHENOTYPE	19	21	nausea and vomiting
NCT000032138	NCT00003213_8_T0	COMPOUND	2	2	dexamethasone
NCT000032138	NCT00003213_8_T1	COMPOUND	4	4	granisetron
NCT000032138	NCT00003213_8_T2	GENE	7	7	bid
NCT000032139	NCT00003213_9_T0	COMPOUND	11	11	dexamethasone
NCT000032139	NCT00003213_9_T1	COMPOUND	9	9	metoclopramide
NCT000032139	NCT00003213_9_T2	COMPOUND	7	7	granisetron
NCT0000321311	NCT00003213_11_T0	GENE	12	12	1.5
NCT0000321313	NCT00003213_13_T0	GENE	9	9	1.5
NCT000032141	NCT00003214_1_T0	GENE	3	3	III
NCT000032141	NCT00003214_1_T1	PHENOTYPE	18	19	stage III
NCT000032141	NCT00003214_1_T2	PHENOTYPE	21	24	stage IV ovarian cancer
NCT000032143	NCT00003214_3_T0	PHENOTYPE	15	15	progression
NCT000032143	NCT00003214_3_T1	PHENOTYPE	24	25	ovarian cancer
NCT000032145	NCT00003214_5_T0	PHENOTYPE	7	7	tumor
NCT000032149	NCT00003214_9_T0	GENE	4	4	3.4
NCT000032157	NCT00003215_7_T0	COMPOUND	10	10	vincristine
NCT000032157	NCT00003215_7_T1	COMPOUND	2	2	cyclophosphamide
NCT000032157	NCT00003215_7_T2	COMPOUND	7	7	doxorubicin
NCT000032157	NCT00003215_7_T3	GENE	3	3	IV
NCT000032157	NCT00003215_7_T4	GENE	8	8	IV
NCT000032157	NCT00003215_7_T5	GENE	11	11	IV
NCT000032158	NCT00003215_8_T0	GENE	7	7	1.5
NCT000032158	NCT00003215_8_T1	COMPOUND	3	3	prednisone
NCT0000321511	NCT00003215_11_T0	GENE	10	10	SC
NCT0000321511	NCT00003215_11_T1	GENE	7	7	filgrastim
NCT0000321511	NCT00003215_11_T2	GENE	8	8	G-CSF
NCT0000321511	NCT00003215_11_T3	ORGAN	3	4	bone marrow
NCT0000321511	NCT00003215_11_T4	CELL	20	23	peripheral blood stem cells
NCT0000321515	NCT00003215_15_T0	COMPOUND	2	2	methylprednisolone
NCT0000321515	NCT00003215_15_T1	GENE	3	3	IV
NCT0000321516	NCT00003215_16_T0	GENE	8	8	SC
NCT0000321516	NCT00003215_16_T1	GENE	7	7	G-CSF
NCT0000321516	NCT00003215_16_T2	ORGAN	3	4	bone marrow
NCT0000321517	NCT00003215_17_T0	GENE	8	8	SC
NCT0000321517	NCT00003215_17_T1	GENE	7	7	G-CSF
NCT0000321517	NCT00003215_17_T2	ORGAN	3	4	bone marrow
NCT0000321519	NCT00003215_19_T0	COMPOUND	2	2	mitoxantrone
NCT0000321519	NCT00003215_19_T1	COMPOUND	17	17	melphalan
NCT0000321519	NCT00003215_19_T2	GENE	3	3	IV
NCT0000321519	NCT00003215_19_T3	GENE	18	18	IV
NCT0000321520	NCT00003215_20_T0	COMPOUND	15	15	melphalan
NCT0000321521	NCT00003215_21_T0	GENE	3	3	SC
NCT0000321521	NCT00003215_21_T1	GENE	2	2	G-CSF
NCT0000321522	NCT00003215_22_T0	PHENOTYPE	7	8	residual disease
NCT0000321524	NCT00003215_24_T0	COMPOUND	3	3	cytarabine
NCT0000321524	NCT00003215_24_T1	GENE	12	12	1.2
NCT0000321524	NCT00003215_24_T2	COMPOUND	6	6	hydrocortisone
NCT0000321524	NCT00003215_24_T3	COMPOUND	10	10	hydrocortisone
NCT0000321524	NCT00003215_24_T4	COMPOUND	4	4	methotrexate
NCT0000321524	NCT00003215_24_T5	COMPOUND	8	8	methotrexate
NCT0000321526	NCT00003215_26_T0	GENE	12	12	4.5
NCT000032161	NCT00003216_1_T0	CELL	8	8	cells
NCT000032161	NCT00003216_1_T1	PHENOTYPE	7	7	tumor
NCT000032162	NCT00003216_2_T0	CELL	9	9	cells
NCT000032162	NCT00003216_2_T1	PHENOTYPE	8	8	tumor
NCT000032163	NCT00003216_3_T0	PHENOTYPE	12	13	pancreatic cancer
NCT000032164	NCT00003216_4_T0	GENE	3	3	III
NCT000032164	NCT00003216_4_T1	COMPOUND	12	12	gemcitabine
NCT000032164	NCT00003216_4_T2	PHENOTYPE	20	23	cancer of the pancreas
NCT000032167	NCT00003216_7_T0	PHENOTYPE	10	10	tumor
NCT000032167	NCT00003216_7_T1	GENE	15	15	cm
NCT000032167	NCT00003216_7_T2	GENE	18	18	cm
NCT000032167	NCT00003216_7_T3	GENE	5	5	nodal
NCT000032167	NCT00003216_7_T4	TISSUE	22	23	surgical margins
NCT000032169	NCT00003216_9_T0	GENE	1	1	1.2
NCT000032169	NCT00003216_9_T1	GENE	17	17	5.5
NCT000032169	NCT00003216_9_T2	GENE	7	7	IV
NCT0000321612	NCT00003216_12_T0	GENE	1	1	3.5
NCT0000321612	NCT00003216_12_T1	COMPOUND	9	9	gemcitabine
NCT0000321612	NCT00003216_12_T2	GENE	10	10	IV
NCT0000321614	NCT00003216_14_T0	GENE	14	14	8-6
NCT000032171	NCT00003217_1_T0	CELL	9	9	cells
NCT000032172	NCT00003217_2_T0	COMPOUND	13	13	methotrexate
NCT000032172	NCT00003217_2_T1	GENE	25	25	IV
NCT000032172	NCT00003217_2_T2	COMPOUND	15	15	cyclophosphamide
NCT000032172	NCT00003217_2_T3	PHENOTYPE	21	22	stage III
NCT000032172	NCT00003217_2_T4	PHENOTYPE	26	27	Hodgkin's lymphoma
NCT000032172	NCT00003217_2_T5	PHENOTYPE	29	31	acute lymphoblastic leukemia
NCT000032178	NCT00003217_8_T0	COMPOUND	3	3	cytarabine
NCT0000321713	NCT00003217_13_T0	GENE	12	12	1.5
NCT0000321713	NCT00003217_13_T1	GENE	4	4	IV
NCT0000321714	NCT00003217_14_T0	GENE	9	9	1.3
NCT0000321714	NCT00003217_14_T1	GENE	1	1	IV
NCT0000321715	NCT00003217_15_T0	COMPOUND	18	18	cyclophosphamide
NCT0000321715	NCT00003217_15_T1	GENE	1	1	IV
NCT0000321716	NCT00003217_16_T0	COMPOUND	4	4	vincristine
NCT0000321716	NCT00003217_16_T1	GENE	5	5	IV
NCT0000321717	NCT00003217_17_T0	CELL	3	3	granulocyte
NCT0000321717	NCT00003217_17_T1	GENE	2	2	filgrastim
NCT0000321717	NCT00003217_17_T2	GENE	6	6	G-CSF
NCT0000321717	NCT00003217_17_T3	GENE	9	9	IV
NCT0000321719	NCT00003217_19_T0	GENE	15	15	MTX
NCT0000321719	NCT00003217_19_T1	COMPOUND	8	8	methotrexate
NCT0000321719	NCT00003217_19_T2	GENE	14	14	IT
NCT0000321719	NCT00003217_19_T3	GENE	9	9	IV
NCT0000321720	NCT00003217_20_T0	GENE	12	12	1.5
NCT0000321720	NCT00003217_20_T1	GENE	4	4	IV
NCT0000321721	NCT00003217_21_T0	GENE	6	6	MTX
NCT0000321721	NCT00003217_21_T1	COMPOUND	10	10	cytarabine
NCT0000321721	NCT00003217_21_T2	GENE	5	5	IV
NCT0000321721	NCT00003217_21_T3	GENE	19	19	IV
NCT0000321722	NCT00003217_22_T0	GENE	2	2	G-CSF
NCT0000321722	NCT00003217_22_T1	GENE	5	5	IV
NCT0000321723	NCT00003217_23_T0	PHENOTYPE	4	4	remission
NCT0000321725	NCT00003217_25_T0	GENE	1	1	MTX
NCT0000321725	NCT00003217_25_T1	GENE	0	0	IT
NCT0000321725	NCT00003217_25_T2	GENE	3	3	IT
NCT0000321726	NCT00003217_26_T0	COMPOUND	7	7	vincristine
NCT0000321726	NCT00003217_26_T1	COMPOUND	10	10	doxorubicin
NCT0000321726	NCT00003217_26_T2	GENE	8	8	IV
NCT0000321726	NCT00003217_26_T3	GENE	11	11	IV
NCT0000321728	NCT00003217_28_T0	GENE	0	0	G-CSF
NCT0000321731	NCT00003217_31_T0	GENE	0	0	G-CSF
NCT000032191	NCT00003219_1_T0	GENE	2	2	II
NCT000032191	NCT00003219_1_T1	GENE	19	19	has
NCT000032191	NCT00003219_1_T2	COMPOUND	9	10	perillyl alcohol
NCT000032191	NCT00003219_1_T3	PHENOTYPE	15	17	metastatic breast cancer
NCT000032193	NCT00003219_3_T0	PHENOTYPE	6	6	tumor
NCT000032193	NCT00003219_3_T1	COMPOUND	15	16	perillyl alcohol
NCT000032193	NCT00003219_3_T2	PHENOTYPE	22	24	metastatic breast cancer
NCT000032195	NCT00003219_5_T0	PHENOTYPE	5	5	toxic
NCT000032195	NCT00003219_5_T1	PHENOTYPE	2	2	acute
NCT000032195	NCT00003219_5_T2	PHENOTYPE	4	4	chronic
NCT000032195	NCT00003219_5_T3	COMPOUND	8	9	perillyl alcohol
NCT000032197	NCT00003219_7_T0	PHENOTYPE	13	13	toxicity
NCT000032197	NCT00003219_7_T1	COMPOUND	3	4	perillyl alcohol
NCT000032198	NCT00003219_8_T0	PHENOTYPE	24	24	toxicity
NCT000032198	NCT00003219_8_T1	PHENOTYPE	14	15	progressive disease
NCT0000321910	NCT00003219_10_T0	GENE	4	4	2.4
NCT000032201	NCT00003220_1_T0	GENE	2	2	II
NCT000032201	NCT00003220_1_T1	COMPOUND	9	10	bryostatin 1
NCT000032201	NCT00003220_1_T2	PHENOTYPE	15	17	metastatic colorectal cancer
NCT000032203	NCT00003220_3_T0	PHENOTYPE	28	29	colorectal cancer
NCT000032203	NCT00003220_3_T1	COMPOUND	4	5	bryostatin 1
NCT000032205	NCT00003220_5_T0	PHENOTYPE	6	6	progression
NCT000032207	NCT00003220_7_T0	PHENOTYPE	5	5	toxic
NCT000032207	NCT00003220_7_T1	COMPOUND	8	9	bryostatin 1
NCT000032208	NCT00003220_8_T0	COMPOUND	5	6	bryostatin 1
NCT000032209	NCT00003220_9_T0	PHENOTYPE	11	11	toxicity
NCT000032209	NCT00003220_9_T1	PHENOTYPE	13	14	disease progression
NCT0000322010	NCT00003220_10_T0	PHENOTYPE	4	4	toxic
NCT0000322010	NCT00003220_10_T1	COMPOUND	20	21	bryostatin 1
NCT000032220	NCT00003222_0_T0	GENE	3	3	Interleukin-2
NCT000032220	NCT00003222_0_T1	PHENOTYPE	13	13	Melanoma
NCT000032220	NCT00003222_0_T2	GENE	9	9	III
NCT000032220	NCT00003222_0_T3	GENE	12	12	IV
NCT000032222	NCT00003222_2_T0	PHENOTYPE	18	18	peripheral
NCT000032222	NCT00003222_2_T1	CELL	11	11	cells
NCT000032222	NCT00003222_2_T2	GENE	4	4	GM-CSF
NCT000032222	NCT00003222_2_T3	ORGAN	15	16	bone marrow
NCT000032223	NCT00003222_3_T0	CELL	11	11	cells
NCT000032223	NCT00003222_3_T1	GENE	0	0	Interleukin-2
NCT000032223	NCT00003222_3_T2	PHENOTYPE	10	10	melanoma
NCT000032223	NCT00003222_3_T3	CELL	5	7	white blood cells
NCT000032224	NCT00003222_4_T0	CELL	12	12	cells
NCT000032224	NCT00003222_4_T1	GENE	6	6	interleukin-2
NCT000032224	NCT00003222_4_T2	PHENOTYPE	11	11	tumor
NCT000032224	NCT00003222_4_T3	GENE	4	4	GM-CSF
NCT000032225	NCT00003222_5_T0	GENE	2	2	II
NCT000032225	NCT00003222_5_T1	PHENOTYPE	12	12	melanoma
NCT000032225	NCT00003222_5_T2	GENE	17	17	GM-CSF
NCT000032225	NCT00003222_5_T3	CELL	13	13	cells
NCT000032225	NCT00003222_5_T4	GENE	20	20	interleukin-2
NCT000032225	NCT00003222_5_T5	PHENOTYPE	25	26	stage III
NCT000032225	NCT00003222_5_T6	PHENOTYPE	28	30	stage IV melanoma
NCT0000322210	NCT00003222_10_T0	PHENOTYPE	7	7	tumor
NCT0000322212	NCT00003222_12_T0	CELL	5	5	T-cell
NCT0000322215	NCT00003222_15_T0	GENE	22	22	SC
NCT0000322215	NCT00003222_15_T1	PHENOTYPE	12	12	tetanus
NCT0000322215	NCT00003222_15_T2	GENE	8	8	gp100
NCT0000322215	NCT00003222_15_T3	PHENOTYPE	6	6	melanoma
NCT0000322215	NCT00003222_15_T4	GENE	10	10	tyrosinase
NCT0000322215	NCT00003222_15_T5	GENE	19	19	IV
NCT0000322215	NCT00003222_15_T6	CELL	17	18	dendritic cells
NCT0000322217	NCT00003222_17_T0	GENE	20	20	SC
NCT0000322217	NCT00003222_17_T1	GENE	19	19	interleukin-2
NCT0000322218	NCT00003222_18_T0	PHENOTYPE	12	12	tumor
NCT000032232	NCT00003223_2_T0	GENE	2	2	II
NCT000032232	NCT00003223_2_T1	COMPOUND	9	9	fenretinide
NCT000032232	NCT00003223_2_T2	PHENOTYPE	17	17	neoplasia
NCT000032234	NCT00003223_4_T0	COMPOUND	4	4	fenretinide
NCT000032234	NCT00003223_4_T1	PHENOTYPE	9	10	intraepithelial neoplasia
NCT000032236	NCT00003223_6_T0	PHENOTYPE	2	2	toxicity
NCT000032236	NCT00003223_6_T1	COMPOUND	4	4	fenretinide
NCT000032237	NCT00003223_7_T0	COMPOUND	4	4	fenretinide
NCT000032239	NCT00003223_9_T0	PHENOTYPE	6	6	toxicities
NCT000032239	NCT00003223_9_T1	PHENOTYPE	2	3	disease progression
NCT000032241	NCT00003224_1_T0	PHENOTYPE	7	7	tetanus
NCT000032241	NCT00003224_1_T1	PHENOTYPE	22	23	metastatic melanoma
NCT000032242	NCT00003224_2_T0	PHENOTYPE	18	18	tetanus
NCT000032242	NCT00003224_2_T1	PHENOTYPE	37	37	melanoma
NCT000032242	NCT00003224_2_T2	PHENOTYPE	28	29	metastatic melanoma
NCT000032244	NCT00003224_4_T0	PHENOTYPE	14	14	tetanus
NCT000032244	NCT00003224_4_T1	PHENOTYPE	6	6	melanoma
NCT000032244	NCT00003224_4_T2	PHENOTYPE	16	16	melanoma
NCT000032244	NCT00003224_4_T3	PHENOTYPE	28	28	melanoma
NCT000032246	NCT00003224_6_T0	PHENOTYPE	14	14	tetanus
NCT000032246	NCT00003224_6_T1	PHENOTYPE	6	6	melanoma
NCT000032246	NCT00003224_6_T2	PHENOTYPE	16	16	melanoma
NCT000032246	NCT00003224_6_T3	PHENOTYPE	28	28	melanoma
NCT000032251	NCT00003225_1_T0	COMPOUND	11	11	irinotecan
NCT000032251	NCT00003225_1_T1	COMPOUND	9	9	amifostine
NCT000032251	NCT00003225_1_T2	PHENOTYPE	16	18	metastatic colorectal cancer
NCT000032255	NCT00003225_5_T0	PHENOTYPE	2	2	toxicity
NCT000032255	NCT00003225_5_T1	COMPOUND	5	5	irinotecan
NCT000032255	NCT00003225_5_T2	COMPOUND	7	7	amifostine
NCT000032255	NCT00003225_5_T3	PHENOTYPE	14	16	metastatic colorectal cancer
NCT000032259	NCT00003225_9_T0	PHENOTYPE	5	5	leukopenia
NCT000032259	NCT00003225_9_T1	COMPOUND	4	4	irinotecan
NCT000032259	NCT00003225_9_T2	PHENOTYPE	6	6	neutropenia
NCT000032259	NCT00003225_9_T3	PHENOTYPE	8	8	diarrhea
NCT0000322513	NCT00003225_13_T0	GENE	6	6	IV
NCT0000322514	NCT00003225_14_T0	COMPOUND	11	11	amifostine
NCT0000322514	NCT00003225_14_T1	GENE	4	4	IV
NCT0000322516	NCT00003225_16_T0	PHENOTYPE	10	11	disease progression
NCT0000322517	NCT00003225_17_T0	PHENOTYPE	16	16	toxic
NCT000032291	NCT00003229_1_T0	PHENOTYPE	18	18	melanoma
NCT000032291	NCT00003229_1_T1	CELL	19	19	cells
NCT000032291	NCT00003229_1_T2	PHENOTYPE	34	34	tumor
NCT000032291	NCT00003229_1_T3	PHENOTYPE	24	25	metastatic melanoma
NCT000032291	NCT00003229_1_T4	TISSUE	31	32	lymph node
NCT000032291	NCT00003229_1_T5	CELL	14	16	white blood cells
NCT0000322911	NCT00003229_11_T0	GENE	1	1	1.2
NCT0000322911	NCT00003229_11_T1	CELL	11	12	dendritic cells
NCT0000322912	NCT00003229_12_T0	GENE	25	25	A2
NCT0000322912	NCT00003229_12_T1	GENE	27	27	A3
NCT0000322912	NCT00003229_12_T2	PHENOTYPE	16	16	tumors
NCT0000322912	NCT00003229_12_T3	PHENOTYPE	7	7	tumor
NCT0000322912	NCT00003229_12_T4	PHENOTYPE	11	11	tumor
NCT0000322912	NCT00003229_12_T5	GENE	21	21	gp100
NCT0000322912	NCT00003229_12_T6	GENE	19	19	tyrosinase
NCT0000322914	NCT00003229_14_T0	PHENOTYPE	7	7	tumor
NCT0000322915	NCT00003229_15_T0	CELL	5	6	dendritic cells
NCT0000322917	NCT00003229_17_T0	PHENOTYPE	15	15	tumor
NCT0000322917	NCT00003229_17_T1	CELL	7	8	dendritic cells
NCT0000322920	NCT00003229_20_T0	GENE	12	12	interleukin-2
NCT000032301	NCT00003230_1_T0	COMPOUND	9	9	paclitaxel
NCT000032301	NCT00003230_1_T1	PHENOTYPE	16	16	recurrent
NCT000032301	NCT00003230_1_T2	PHENOTYPE	17	18	acute leukemia
NCT000032301	NCT00003230_1_T3	PHENOTYPE	20	22	chronic myelogenous leukemia
NCT000032303	NCT00003230_3_T0	COMPOUND	6	6	paclitaxel
NCT000032303	NCT00003230_3_T1	PHENOTYPE	20	20	recurrent
NCT000032303	NCT00003230_3_T2	PHENOTYPE	27	28	blast crisis
NCT000032303	NCT00003230_3_T3	PHENOTYPE	15	16	acute leukemia
NCT000032303	NCT00003230_3_T4	PHENOTYPE	41	42	acute leukemia
NCT000032303	NCT00003230_3_T5	PHENOTYPE	30	32	chronic myelogenous leukemia
NCT000032305	NCT00003230_5_T0	COMPOUND	9	9	paclitaxel
NCT000032305	NCT00003230_5_T1	PHENOTYPE	7	7	remissions
NCT000032307	NCT00003230_7_T0	PHENOTYPE	2	2	toxic
NCT000032307	NCT00003230_7_T1	COMPOUND	5	5	paclitaxel
NCT000032309	NCT00003230_9_T0	COMPOUND	6	6	paclitaxel
NCT000032309	NCT00003230_9_T1	PHENOTYPE	4	4	remission
NCT0000323011	NCT00003230_11_T0	COMPOUND	2	2	paclitaxel
NCT0000323012	NCT00003230_12_T0	PHENOTYPE	16	16	toxicity
NCT0000323013	NCT00003230_13_T0	PHENOTYPE	17	17	toxicity
NCT0000323013	NCT00003230_13_T1	COMPOUND	10	10	paclitaxel
NCT0000323013	NCT00003230_13_T2	GENE	18	18	DLT
NCT0000323014	NCT00003230_14_T0	GENE	7	7	DLT
NCT0000323015	NCT00003230_15_T0	GENE	13	13	stops
NCT0000323015	NCT00003230_15_T1	GENE	22	22	MTD
NCT0000323015	NCT00003230_15_T2	GENE	1	1	DLT
NCT0000323016	NCT00003230_16_T0	GENE	21	21	II
NCT0000323016	NCT00003230_16_T1	GENE	3	3	has
NCT0000323016	NCT00003230_16_T2	GENE	2	2	MTD
NCT0000323016	NCT00003230_16_T3	GENE	17	17	MTD
NCT000032312	NCT00003231_2_T0	CELL	11	11	cells
NCT000032312	NCT00003231_2_T1	PHENOTYPE	10	10	tumor
NCT0000323110	NCT00003231_10_T0	GENE	22	22	1.2
NCT0000323110	NCT00003231_10_T1	COMPOUND	5	5	docetaxel
NCT0000323110	NCT00003231_10_T2	COMPOUND	16	16	cisplatin
NCT0000323112	NCT00003231_12_T0	PHENOTYPE	2	2	tumor
NCT0000323112	NCT00003231_12_T1	TISSUE	6	7	lymph node
NCT0000323113	NCT00003231_13_T0	PHENOTYPE	13	13	tumor
NCT0000323113	NCT00003231_13_T1	TISSUE	16	17	resection margins
NCT0000323113	NCT00003231_13_T2	TISSUE	22	23	lymph node
NCT000032327	NCT00003232_7_T0	PHENOTYPE	5	7	quality of life
NCT0000323215	NCT00003232_15_T0	COMPOUND	13	13	clodronate
NCT0000323215	NCT00003232_15_T1	COMPOUND	8	8	prednisone
NCT0000323215	NCT00003232_15_T2	PHENOTYPE	17	18	disease progression
NCT0000323216	NCT00003232_16_T0	PHENOTYPE	0	2	Quality of life
NCT000032341	NCT00003234_1_T0	GENE	2	2	II
NCT000032341	NCT00003234_1_T1	COMPOUND	9	9	vinorelbine
NCT000032341	NCT00003234_1_T2	PHENOTYPE	14	14	recurrent
NCT000032341	NCT00003234_1_T3	PHENOTYPE	16	17	refractory cancer
NCT000032351	NCT00003235_1_T0	CELL	8	8	cells
NCT000032351	NCT00003235_1_T1	PHENOTYPE	7	7	tumor
NCT000032352	NCT00003235_2_T0	CELL	21	21	cells
NCT000032352	NCT00003235_2_T1	PHENOTYPE	20	20	tumor
NCT000032358	NCT00003235_8_T0	COMPOUND	13	13	1
NCT000032359	NCT00003235_9_T0	COMPOUND	7	7	paclitaxel
NCT000032359	NCT00003235_9_T1	GENE	8	8	IV
NCT000032359	NCT00003235_9_T2	GENE	15	15	IV
NCT0000323514	NCT00003235_14_T0	GENE	3	3	separated
NCT0000323517	NCT00003235_17_T0	GENE	12	12	3.5
NCT000032361	NCT00003236_1_T0	GENE	3	3	II
NCT000032361	NCT00003236_1_T1	GENE	24	24	has
NCT000032361	NCT00003236_1_T2	PHENOTYPE	20	22	metastatic breast cancer
NCT000032363	NCT00003236_3_T0	PHENOTYPE	13	13	progression
NCT000032363	NCT00003236_3_T1	PHENOTYPE	8	10	metastatic breast cancer
NCT000032367	NCT00003236_7_T0	PHENOTYPE	1	1	toxicities
NCT000032369	NCT00003236_9_T0	PHENOTYPE	10	12	metastatic breast cancer
NCT0000323612	NCT00003236_12_T0	PHENOTYPE	13	13	toxicity
NCT0000323612	NCT00003236_12_T1	PHENOTYPE	9	10	disease progression
NCT000032371	NCT00003237_1_T0	CELL	14	14	cells
NCT000032371	NCT00003237_1_T1	PHENOTYPE	13	13	tumor
NCT000032372	NCT00003237_2_T0	GENE	2	2	II
NCT000032372	NCT00003237_2_T1	COMPOUND	13	13	paclitaxel
NCT000032372	NCT00003237_2_T2	COMPOUND	15	15	cisplatin
NCT000032372	NCT00003237_2_T3	PHENOTYPE	23	26	cancer of the esophagus
NCT000032374	NCT00003237_4_T0	COMPOUND	22	22	paclitaxel
NCT000032374	NCT00003237_4_T1	ORGAN	18	18	cardia
NCT000032374	NCT00003237_4_T2	COMPOUND	24	24	cisplatin
NCT000032374	NCT00003237_4_T3	ORGAN	15	16	gastroesophageal junction
NCT000032374	NCT00003237_4_T4	PHENOTYPE	11	14	adenocarcinoma of the esophagus
NCT000032376	NCT00003237_6_T0	COMPOUND	3	3	paclitaxel
NCT000032376	NCT00003237_6_T1	COMPOUND	13	13	cisplatin
NCT000032378	NCT00003237_8_T0	PHENOTYPE	3	3	recurrence
NCT000032378	NCT00003237_8_T1	PHENOTYPE	6	6	toxic
NCT000032385	NCT00003238_5_T0	PHENOTYPE	2	2	toxicity
NCT000032386	NCT00003238_6_T0	COMPOUND	4	5	perillyl alcohol
NCT000032387	NCT00003238_7_T0	PHENOTYPE	8	8	toxicity
NCT000032387	NCT00003238_7_T1	PHENOTYPE	10	11	disease progression
NCT000032388	NCT00003238_8_T0	PHENOTYPE	9	10	disease progression
NCT000032391	NCT00003239_1_T0	CELL	9	9	cells
NCT000032392	NCT00003239_2_T0	GENE	2	2	II
NCT000032392	NCT00003239_2_T1	COMPOUND	11	11	cytarabine
NCT000032392	NCT00003239_2_T2	COMPOUND	13	13	homoharringtonine
NCT000032392	NCT00003239_2_T3	GENE	18	18	interferon
NCT000032392	NCT00003239_2_T4	PHENOTYPE	24	28	chronic phase chronic myelogenous leukemia
NCT000032399	NCT00003239_9_T0	PHENOTYPE	14	14	thrombocytosis
NCT000032399	NCT00003239_9_T1	PHENOTYPE	13	13	splenomegaly
NCT0000323910	NCT00003239_10_T0	COMPOUND	7	7	hydroxyurea
NCT0000323911	NCT00003239_11_T0	COMPOUND	6	6	cytarabine
NCT0000323911	NCT00003239_11_T1	GENE	3	3	interferon
NCT0000323912	NCT00003239_12_T0	GENE	8	8	1.5
NCT0000323914	NCT00003239_14_T0	PHENOTYPE	2	2	remission
NCT0000323914	NCT00003239_14_T1	CELL	5	8	peripheral blood stem cells
NCT000032402	NCT00003240_2_T0	PHENOTYPE	18	19	lung cancer
NCT0000324010	NCT00003240_10_T0	COMPOUND	34	34	vindesine
NCT0000324010	NCT00003240_10_T1	COMPOUND	27	27	cisplatin
NCT0000324010	NCT00003240_10_T2	GENE	28	28	IV
NCT0000324011	NCT00003240_11_T0	COMPOUND	5	5	ifosfamide
NCT0000324011	NCT00003240_11_T1	COMPOUND	7	7	cisplatin
NCT0000324012	NCT00003240_12_T0	COMPOUND	5	5	vinblastine
NCT0000324012	NCT00003240_12_T1	COMPOUND	7	7	cisplatin
NCT0000324013	NCT00003240_13_T0	COMPOUND	4	4	vinorelbine
NCT0000324013	NCT00003240_13_T1	COMPOUND	11	11	cisplatin
NCT000032412	NCT00003241_2_T0	GENE	2	2	II
NCT000032412	NCT00003241_2_T1	PHENOTYPE	16	16	progressive
NCT000032412	NCT00003241_2_T2	PHENOTYPE	14	14	recurrent
NCT000032412	NCT00003241_2_T3	PHENOTYPE	17	18	brain tumors
NCT000032414	NCT00003241_4_T0	PHENOTYPE	13	13	progression
NCT000032414	NCT00003241_4_T1	PHENOTYPE	19	19	progressive
NCT000032414	NCT00003241_4_T2	PHENOTYPE	17	17	recurrent
NCT000032414	NCT00003241_4_T3	PHENOTYPE	20	21	brain tumors
NCT000032414	NCT00003241_4_T4	PHENOTYPE	28	29	brain tumors
NCT000032416	NCT00003241_6_T0	PHENOTYPE	2	2	toxicity
NCT000032418	NCT00003241_8_T0	PHENOTYPE	10	10	toxicity
NCT000032418	NCT00003241_8_T1	ORGAN	4	4	serum
NCT000032419	NCT00003241_9_T0	PHENOTYPE	17	17	medulloblastoma
NCT000032419	NCT00003241_9_T1	PHENOTYPE	23	23	ependymoma
NCT000032419	NCT00003241_9_T2	PHENOTYPE	27	27	glioma
NCT000032419	NCT00003241_9_T3	PHENOTYPE	10	11	glioblastoma multiforme
NCT000032419	NCT00003241_9_T4	PHENOTYPE	7	8	anaplastic astrocytoma
NCT000032419	NCT00003241_9_T5	PHENOTYPE	19	21	primitive neuroectodermal tumors
NCT000032419	NCT00003241_9_T6	PHENOTYPE	13	15	brain stem glioma
NCT0000324110	NCT00003241_10_T0	GENE	10	10	1.28
NCT0000324112	NCT00003241_12_T0	PHENOTYPE	10	10	toxicity
NCT0000324112	NCT00003241_12_T1	PHENOTYPE	6	7	disease progression
NCT000032420	NCT00003242_0_T0	PHENOTYPE	11	12	Solid Tumors
NCT000032422	NCT00003242_2_T0	CELL	9	9	cells
NCT000032422	NCT00003242_2_T1	PHENOTYPE	8	8	tumor
NCT000032423	NCT00003242_3_T0	COMPOUND	14	14	paclitaxel
NCT000032423	NCT00003242_3_T1	COMPOUND	16	16	cisplatin
NCT000032423	NCT00003242_3_T2	PHENOTYPE	22	23	solid tumors
NCT000032423	NCT00003242_3_T3	COMPOUND	11	12	bryostatin 1
NCT000032425	NCT00003242_5_T0	COMPOUND	18	18	paclitaxel
NCT000032425	NCT00003242_5_T1	COMPOUND	20	20	cisplatin
NCT000032425	NCT00003242_5_T2	PHENOTYPE	25	26	solid tumors
NCT000032425	NCT00003242_5_T3	COMPOUND	7	8	bryostatin 1
NCT000032427	NCT00003242_7_T0	COMPOUND	6	6	paclitaxel
NCT000032427	NCT00003242_7_T1	PHENOTYPE	3	3	pharmacokinetics
NCT000032427	NCT00003242_7_T2	COMPOUND	12	13	bryostatin 1
NCT0000324211	NCT00003242_11_T0	COMPOUND	2	2	paclitaxel
NCT0000324211	NCT00003242_11_T1	GENE	3	3	IV
NCT0000324212	NCT00003242_12_T0	COMPOUND	14	14	cisplatin
NCT0000324212	NCT00003242_12_T1	GENE	7	7	IV
NCT0000324212	NCT00003242_12_T2	GENE	15	15	IV
NCT0000324212	NCT00003242_12_T3	COMPOUND	5	6	bryostatin 1
NCT0000324214	NCT00003242_14_T0	PHENOTYPE	10	10	toxicity
NCT0000324214	NCT00003242_14_T1	PHENOTYPE	6	7	disease progression
NCT0000324215	NCT00003242_15_T0	COMPOUND	14	14	paclitaxel
NCT0000324215	NCT00003242_15_T1	COMPOUND	11	12	bryostatin 1
NCT0000324216	NCT00003242_16_T0	PHENOTYPE	8	8	toxicity
NCT0000324216	NCT00003242_16_T1	GENE	20	20	MTD
NCT0000324216	NCT00003242_16_T2	GENE	9	9	DLT
NCT0000324217	NCT00003242_17_T0	COMPOUND	4	4	paclitaxel
NCT0000324217	NCT00003242_17_T1	GENE	8	8	has
NCT0000324217	NCT00003242_17_T2	COMPOUND	14	14	cisplatin
NCT0000324217	NCT00003242_17_T3	GENE	2	2	MTD
NCT0000324217	NCT00003242_17_T4	COMPOUND	6	7	bryostatin 1
NCT0000324218	NCT00003242_18_T0	COMPOUND	8	8	paclitaxel
NCT0000324218	NCT00003242_18_T1	COMPOUND	10	10	cisplatin
NCT0000324218	NCT00003242_18_T2	GENE	22	22	DLT
NCT0000324218	NCT00003242_18_T3	COMPOUND	14	15	bryostatin 1
NCT0000324219	NCT00003242_19_T0	GENE	21	21	has
NCT0000324219	NCT00003242_19_T1	COMPOUND	4	5	bryostatin 1
NCT0000324219	NCT00003242_19_T2	COMPOUND	13	14	bryostatin 1
NCT000032431	NCT00003243_1_T0	CELL	9	9	cells
NCT000032432	NCT00003243_2_T0	CELL	11	11	cells
NCT000032432	NCT00003243_2_T1	GENE	19	19	has
NCT000032432	NCT00003243_2_T2	PHENOTYPE	16	17	hematologic cancer
NCT000032432	NCT00003243_2_T3	ORGAN	22	23	bone marrow
NCT000032432	NCT00003243_2_T4	CELL	0	2	White blood cells
NCT000032433	NCT00003243_3_T0	GENE	26	26	has
NCT000032433	NCT00003243_3_T1	PHENOTYPE	23	24	hematologic cancer
NCT000032433	NCT00003243_3_T2	ORGAN	29	30	bone marrow
NCT000032433	NCT00003243_3_T3	CELL	15	17	white blood cells
NCT000032435	NCT00003243_5_T0	COMPOUND	10	10	HCl
NCT000032435	NCT00003243_5_T1	COMPOUND	9	9	doxorubicin
NCT000032439	NCT00003243_9_T0	GENE	14	14	MTD
NCT0000324310	NCT00003243_10_T0	GENE	1	1	MTD
NCT0000324310	NCT00003243_10_T1	GENE	16	16	DLT
NCT000032451	NCT00003245_1_T0	GENE	2	2	II
NCT000032451	NCT00003245_1_T1	COMPOUND	9	9	irinotecan
NCT000032451	NCT00003245_1_T2	PHENOTYPE	14	14	recurrent
NCT000032451	NCT00003245_1_T3	PHENOTYPE	17	18	Hodgkin's lymphoma
NCT000032455	NCT00003245_5_T0	GENE	4	4	PR
NCT000032455	NCT00003245_5_T1	GENE	2	2	CR
NCT000032456	NCT00003245_6_T0	ORGAN	3	4	bone marrow
NCT000032482	NCT00003248_2_T0	CELL	10	10	cells
NCT000032483	NCT00003248_3_T0	GENE	3	3	II
NCT000032483	NCT00003248_3_T1	COMPOUND	10	10	fludarabine
NCT000032483	NCT00003248_3_T2	PHENOTYPE	30	33	B-cell chronic lymphocytic leukemia
NCT000032485	NCT00003248_5_T0	GENE	12	12	CD20
NCT000032485	NCT00003248_5_T1	PHENOTYPE	5	5	toxicity
NCT000032485	NCT00003248_5_T2	COMPOUND	31	31	fludarabine
NCT000032485	NCT00003248_5_T3	PHENOTYPE	26	28	chronic lymphocytic leukemia
NCT000032487	NCT00003248_7_T0	COMPOUND	14	14	fludarabine
NCT000032487	NCT00003248_7_T1	GENE	4	4	CR
NCT000032489	NCT00003248_9_T0	GENE	9	9	PR
NCT000032489	NCT00003248_9_T1	GENE	18	18	PR
NCT000032489	NCT00003248_9_T2	GENE	12	12	CR
NCT000032489	NCT00003248_9_T3	GENE	20	20	CR
NCT0000324811	NCT00003248_11_T0	GENE	14	14	IgA
NCT0000324811	NCT00003248_11_T1	GENE	11	11	CD4
NCT0000324811	NCT00003248_11_T2	GENE	12	12	CD8
NCT0000324811	NCT00003248_11_T3	COMPOUND	6	6	fludarabine
NCT0000324811	NCT00003248_11_T4	GENE	13	13	IgG
NCT0000324811	NCT00003248_11_T5	GENE	16	16	IgM
NCT0000324815	NCT00003248_15_T0	GENE	8	8	II
NCT0000324815	NCT00003248_15_T1	GENE	10	10	III
NCT0000324815	NCT00003248_15_T2	GENE	12	12	IV
NCT0000324820	NCT00003248_20_T0	GENE	1	1	IV
NCT0000324821	NCT00003248_21_T0	COMPOUND	5	5	fludarabine
NCT0000324821	NCT00003248_21_T1	ORGAN	27	28	bone marrow
NCT000032491	NCT00003249_1_T0	CELL	10	10	cells
NCT000032491	NCT00003249_1_T1	PHENOTYPE	9	9	tumor
NCT000032492	NCT00003249_2_T0	CELL	9	9	cells
NCT000032492	NCT00003249_2_T1	PHENOTYPE	8	8	tumor
NCT000032494	NCT00003249_4_T0	COMPOUND	6	6	carboxyamidotriazole
NCT000032494	NCT00003249_4_T1	PHENOTYPE	16	16	malignancies
NCT000032494	NCT00003249_4_T2	COMPOUND	11	11	ketoconazole
NCT000032496	NCT00003249_6_T0	PHENOTYPE	2	2	toxic
NCT000032496	NCT00003249_6_T1	COMPOUND	12	12	ketoconazole
NCT000032498	NCT00003249_8_T0	COMPOUND	5	5	ketoconazole
NCT0000324910	NCT00003249_10_T0	COMPOUND	7	7	ketoconazole
NCT0000324910	NCT00003249_10_T1	PHENOTYPE	2	2	pharmacodynamic
NCT0000324912	NCT00003249_12_T0	COMPOUND	3	3	carboxyamidotriazole
NCT0000324913	NCT00003249_13_T0	COMPOUND	3	3	ketoconazole
NCT0000324913	NCT00003249_13_T1	COMPOUND	11	11	ketoconazole
NCT0000324914	NCT00003249_14_T0	COMPOUND	2	2	ketoconazole
NCT0000324916	NCT00003249_16_T0	PHENOTYPE	15	15	toxic
NCT0000324916	NCT00003249_16_T1	PHENOTYPE	11	12	disease progression
NCT0000324918	NCT00003249_18_T0	PHENOTYPE	11	11	toxicity
NCT0000324918	NCT00003249_18_T1	PHENOTYPE	8	8	experiences
NCT0000324918	NCT00003249_18_T2	GENE	12	12	DLT
NCT0000324919	NCT00003249_19_T0	GENE	6	6	DLT
NCT000032500	NCT00003250_0_T0	PHENOTYPE	5	6	Solid Tumors
NCT000032502	NCT00003250_2_T0	COMPOUND	9	9	fenretinide
NCT000032502	NCT00003250_2_T1	PHENOTYPE	15	16	solid tumors
NCT000032504	NCT00003250_4_T0	PHENOTYPE	6	6	toxicity
NCT000032504	NCT00003250_4_T1	COMPOUND	9	9	fenretinide
NCT000032504	NCT00003250_4_T2	PHENOTYPE	14	15	malignant tumors
NCT000032506	NCT00003250_6_T0	PHENOTYPE	2	2	pharmacokinetics
NCT000032506	NCT00003250_6_T1	COMPOUND	4	4	fenretinide
NCT000032508	NCT00003250_8_T0	COMPOUND	6	6	fenretinide
NCT0000325010	NCT00003250_10_T0	GENE	4	4	II
NCT0000325010	NCT00003250_10_T1	COMPOUND	8	8	fenretinide
NCT0000325014	NCT00003250_14_T0	GENE	19	19	2.7
NCT0000325014	NCT00003250_14_T1	COMPOUND	3	3	fenretinide
NCT0000325015	NCT00003250_15_T0	PHENOTYPE	13	13	toxicity
NCT0000325015	NCT00003250_15_T1	PHENOTYPE	9	10	disease progression
NCT0000325016	NCT00003250_16_T0	PHENOTYPE	9	9	remission
NCT0000325017	NCT00003250_17_T0	PHENOTYPE	1	1	tumors
NCT0000325018	NCT00003250_18_T0	COMPOUND	8	8	fenretinide
NCT0000325018	NCT00003250_18_T1	GENE	14	14	MTD
NCT0000325019	NCT00003250_19_T0	PHENOTYPE	18	18	toxicity
NCT0000325019	NCT00003250_19_T1	GENE	1	1	MTD
NCT000032510	NCT00003251_0_T0	PHENOTYPE	12	15	Head and Neck Cancer
NCT000032512	NCT00003251_2_T0	CELL	7	7	cells
NCT000032512	NCT00003251_2_T1	PHENOTYPE	6	6	tumor
NCT000032513	NCT00003251_3_T0	CELL	7	7	cells
NCT000032513	NCT00003251_3_T1	COMPOUND	3	3	amifostine
NCT000032513	NCT00003251_3_T2	PHENOTYPE	11	13	effects of chemotherapy
NCT000032514	NCT00003251_4_T0	COMPOUND	12	12	paclitaxel
NCT000032514	NCT00003251_4_T1	COMPOUND	9	9	amifostine
NCT000032514	NCT00003251_4_T2	COMPOUND	11	11	cisplatin
NCT000032514	NCT00003251_4_T3	PHENOTYPE	23	26	head and neck cancer
NCT000032516	NCT00003251_6_T0	PHENOTYPE	9	9	cytoprotection
NCT000032516	NCT00003251_6_T1	COMPOUND	6	6	amifostine
NCT000032516	NCT00003251_6_T2	PHENOTYPE	20	23	head and neck cancer
NCT000032518	NCT00003251_8_T0	PHENOTYPE	2	2	toxicity
NCT000032518	NCT00003251_8_T1	COMPOUND	7	7	paclitaxel
NCT000032518	NCT00003251_8_T2	BIOLOGICAL_PROCESS	4	6	response to cisplatin
NCT0000325110	NCT00003251_10_T0	PHENOTYPE	2	2	toxicity
NCT0000325110	NCT00003251_10_T1	COMPOUND	4	4	amifostine
NCT0000325112	NCT00003251_12_T0	COMPOUND	2	2	paclitaxel
NCT0000325112	NCT00003251_12_T1	GENE	8	8	0.3
NCT0000325113	NCT00003251_13_T0	GENE	9	9	1.5
NCT0000325113	NCT00003251_13_T1	GENE	1	1	IV
NCT0000325114	NCT00003251_14_T0	GENE	8	8	1.5
NCT0000325115	NCT00003251_15_T0	GENE	1	1	IV
NCT0000325117	NCT00003251_17_T0	PHENOTYPE	19	19	toxicity
NCT0000325117	NCT00003251_17_T1	PHENOTYPE	15	16	disease progression
NCT000032522	NCT00003252_2_T0	CELL	8	8	cells
NCT000032522	NCT00003252_2_T1	COMPOUND	4	4	amifostine
NCT000032522	NCT00003252_2_T2	PHENOTYPE	12	14	effects of chemotherapy
NCT000032523	NCT00003252_3_T0	COMPOUND	9	9	amifostine
NCT000032523	NCT00003252_3_T1	GENE	2	2	IV
NCT000032525	NCT00003252_5_T0	COMPOUND	7	7	amifostine
NCT000032527	NCT00003252_7_T0	COMPOUND	3	3	amifostine
NCT000032536	NCT00003253_6_T0	GENE	12	12	EDR
NCT000032536	NCT00003253_6_T1	BIOLOGICAL_PROCESS	1	3	response to paclitaxel
NCT000032538	NCT00003253_8_T0	COMPOUND	6	6	paclitaxel
NCT000032538	NCT00003253_8_T1	GENE	15	15	EDR
NCT000032538	NCT00003253_8_T2	PHENOTYPE	3	4	tumor progression
NCT0000325310	NCT00003253_10_T0	COMPOUND	27	27	paclitaxel
NCT0000325310	NCT00003253_10_T1	GENE	7	7	EDR
NCT0000325310	NCT00003253_10_T2	PHENOTYPE	19	19	tumor
NCT0000325310	NCT00003253_10_T3	PHENOTYPE	24	25	tumor progression
NCT0000325313	NCT00003253_13_T0	COMPOUND	12	12	paclitaxel
NCT0000325313	NCT00003253_13_T1	GENE	5	5	EDR
NCT0000325313	NCT00003253_13_T2	GENE	17	17	1.3
NCT0000325314	NCT00003253_14_T0	PHENOTYPE	12	12	toxicity
NCT0000325314	NCT00003253_14_T1	PHENOTYPE	8	9	tumor progression
NCT0000325315	NCT00003253_15_T0	GENE	14	14	EDR
NCT0000325315	NCT00003253_15_T1	BIOLOGICAL_PROCESS	2	4	response to paclitaxel
NCT000032540	NCT00003254_0_T0	PHENOTYPE	6	7	Colorectal Cancer
NCT000032542	NCT00003254_2_T0	CELL	7	7	cells
NCT000032542	NCT00003254_2_T1	CELL	11	11	cells
NCT000032542	NCT00003254_2_T2	PHENOTYPE	10	10	tumor
NCT000032543	NCT00003254_3_T0	GENE	2	2	II
NCT000032543	NCT00003254_3_T1	COMPOUND	11	11	ethynyluracil
NCT000032543	NCT00003254_3_T2	GENE	20	20	has
NCT000032543	NCT00003254_3_T3	PHENOTYPE	17	18	colorectal cancer
NCT000032545	NCT00003254_5_T0	COMPOUND	9	9	ethynyluracil
NCT000032545	NCT00003254_5_T1	PHENOTYPE	23	23	resistant
NCT000032545	NCT00003254_5_T2	GENE	18	18	has
NCT000032545	NCT00003254_5_T3	PHENOTYPE	14	16	metastatic colorectal cancer
NCT000032547	NCT00003254_7_T0	PHENOTYPE	3	3	progression
NCT000032549	NCT00003254_9_T0	PHENOTYPE	4	4	severity
NCT000032549	NCT00003254_9_T1	PHENOTYPE	6	6	toxicities
NCT0000325410	NCT00003254_10_T0	PHENOTYPE	6	6	relapse
NCT0000325410	NCT00003254_10_T1	PHENOTYPE	11	11	relapse
NCT0000325410	NCT00003254_10_T2	PHENOTYPE	20	20	relapse
NCT0000325411	NCT00003254_11_T0	COMPOUND	5	5	ethynyluracil
NCT0000325412	NCT00003254_12_T0	PHENOTYPE	13	13	toxicity
NCT0000325412	NCT00003254_12_T1	PHENOTYPE	9	10	disease progression
NCT000032551	NCT00003255_1_T0	CELL	9	9	cells
NCT000032551	NCT00003255_1_T1	PHENOTYPE	8	8	tumor
NCT000032552	NCT00003255_2_T0	GENE	2	2	II
NCT000032552	NCT00003255_2_T1	COMPOUND	12	12	topotecan
NCT000032552	NCT00003255_2_T2	PHENOTYPE	18	20	acute myelogenous leukemia
NCT000032554	NCT00003255_4_T0	PHENOTYPE	21	21	AML
NCT000032554	NCT00003255_4_T1	COMPOUND	11	11	topotecan
NCT000032554	NCT00003255_4_T2	PHENOTYPE	18	20	acute myelogenous leukemia
NCT000032556	NCT00003255_6_T0	PHENOTYPE	2	2	toxic
NCT000032557	NCT00003255_7_T0	COMPOUND	7	7	topotecan
NCT000032558	NCT00003255_8_T0	GENE	3	3	3.4
NCT000032561	NCT00003256_1_T0	CELL	10	10	cells
NCT000032561	NCT00003256_1_T1	PHENOTYPE	9	9	tumor
NCT000032565	NCT00003256_5_T0	PHENOTYPE	2	2	toxic
NCT000032565	NCT00003256_5_T1	COMPOUND	5	5	flavopiridol
NCT000032566	NCT00003256_6_T0	COMPOUND	4	4	flavopiridol
NCT000032567	NCT00003256_7_T0	PHENOTYPE	9	9	toxic
NCT000032570	NCT00003257_0_T0	PHENOTYPE	6	10	Recurrent Head and Neck Cancer
NCT000032572	NCT00003257_2_T0	GENE	2	2	II
NCT000032572	NCT00003257_2_T1	PHENOTYPE	16	20	recurrent head and neck cancer
NCT000032576	NCT00003257_6_T0	PHENOTYPE	7	8	disease progression
NCT0000325710	NCT00003257_10_T0	PHENOTYPE	2	4	quality of life
NCT0000325713	NCT00003257_13_T0	PHENOTYPE	9	10	local disease
NCT0000325713	NCT00003257_13_T1	PHENOTYPE	14	15	adverse events
NCT0000325713	NCT00003257_13_T2	PHENOTYPE	10	11	disease progression
NCT0000325715	NCT00003257_15_T0	PHENOTYPE	0	2	Quality of life
NCT000032595	NCT00003259_5_T0	PHENOTYPE	2	2	toxicity
NCT000032595	NCT00003259_5_T1	COMPOUND	4	4	vinorelbine
NCT000032598	NCT00003259_8_T0	PHENOTYPE	4	4	5-10
NCT000032598	NCT00003259_8_T1	COMPOUND	9	9	vinorelbine
NCT0000325910	NCT00003259_10_T0	PHENOTYPE	6	6	toxic
NCT0000325910	NCT00003259_10_T1	PHENOTYPE	2	3	disease progression
NCT0000325912	NCT00003259_12_T0	PHENOTYPE	7	8	disease progression
NCT000032601	NCT00003260_1_T0	CELL	16	16	cells
NCT000032601	NCT00003260_1_T1	PHENOTYPE	15	15	tumor
NCT000032602	NCT00003260_2_T0	COMPOUND	7	7	irinotecan
NCT000032602	NCT00003260_2_T1	COMPOUND	38	38	irinotecan
NCT000032602	NCT00003260_2_T2	GENE	31	31	III
NCT000032602	NCT00003260_2_T3	COMPOUND	17	17	oxaliplatin
NCT000032602	NCT00003260_2_T4	COMPOUND	40	40	oxaliplatin
NCT000032602	NCT00003260_2_T5	COMPOUND	11	11	leucovorin
NCT000032602	NCT00003260_2_T6	COMPOUND	21	21	leucovorin
NCT000032602	NCT00003260_2_T7	COMPOUND	45	45	leucovorin
NCT000032602	NCT00003260_2_T8	PHENOTYPE	24	24	recurrent
NCT000032602	NCT00003260_2_T9	PHENOTYPE	50	50	recurrent
NCT000032602	NCT00003260_2_T10	PHENOTYPE	25	27	metastatic colorectal cancer
NCT000032602	NCT00003260_2_T11	PHENOTYPE	51	53	metastatic colorectal cancer
NCT000032604	NCT00003260_4_T0	COMPOUND	5	5	calcium
NCT000032604	NCT00003260_4_T1	COMPOUND	10	10	irinotecan
NCT000032604	NCT00003260_4_T2	PHENOTYPE	16	16	progression
NCT000032604	NCT00003260_4_T3	COMPOUND	12	12	oxaliplatin
NCT000032604	NCT00003260_4_T4	COMPOUND	4	4	leucovorin
NCT000032604	NCT00003260_4_T5	PHENOTYPE	22	22	recurrent
NCT000032604	NCT00003260_4_T6	PHENOTYPE	23	25	metastatic colorectal cancer
NCT000032606	NCT00003260_6_T0	PHENOTYPE	3	3	tolerance
NCT000032606	NCT00003260_6_T1	PHENOTYPE	4	6	quality of life
NCT000032608	NCT00003260_8_T0	PHENOTYPE	9	10	evaluable disease
NCT000032609	NCT00003260_9_T0	COMPOUND	12	12	irinotecan
NCT000032609	NCT00003260_9_T1	COMPOUND	20	20	oxaliplatin
NCT0000326010	NCT00003260_10_T0	COMPOUND	10	10	calcium
NCT0000326010	NCT00003260_10_T1	COMPOUND	9	9	leucovorin
NCT0000326010	NCT00003260_10_T2	GENE	13	13	IV
NCT0000326012	NCT00003260_12_T0	PHENOTYPE	11	11	toxicity
NCT0000326012	NCT00003260_12_T1	PHENOTYPE	7	8	disease progression
NCT000032611	NCT00003261_1_T0	CELL	9	9	cells
NCT000032611	NCT00003261_1_T1	PHENOTYPE	8	8	tumor
NCT000032612	NCT00003261_2_T0	GENE	3	3	II
NCT000032612	NCT00003261_2_T1	COMPOUND	12	12	zidovudine
NCT000032612	NCT00003261_2_T2	COMPOUND	10	10	methotrexate
NCT000032612	NCT00003261_2_T3	PHENOTYPE	22	22	HIV
NCT000032612	NCT00003261_2_T4	PHENOTYPE	23	27	primary central nervous system lymphoma
NCT000032614	NCT00003261_4_T0	COMPOUND	15	15	zidovudine
NCT000032614	NCT00003261_4_T1	GENE	20	20	1.3
NCT000032614	NCT00003261_4_T2	COMPOUND	7	7	methotrexate
NCT000032614	NCT00003261_4_T3	GENE	8	8	IV
NCT000032614	NCT00003261_4_T4	GENE	16	16	IV
NCT000032620	NCT00003262_0_T0	PHENOTYPE	6	7	Hodgkin's Disease
NCT000032620	NCT00003262_0_T1	PHENOTYPE	9	10	HIV Infection
NCT000032622	NCT00003262_2_T0	CELL	9	9	cells
NCT000032622	NCT00003262_2_T1	PHENOTYPE	8	8	tumor
NCT000032623	NCT00003262_3_T0	GENE	2	2	II
NCT000032623	NCT00003262_3_T1	PHENOTYPE	17	18	Hodgkin's disease
NCT000032623	NCT00003262_3_T2	PHENOTYPE	20	21	HIV infection
NCT000032630	NCT00003263_0_T0	GENE	1	1	Interferon
NCT000032630	NCT00003263_0_T1	PHENOTYPE	11	13	Malignant Pleural Mesothelioma
NCT000032632	NCT00003263_2_T0	CELL	8	8	cells
NCT000032632	NCT00003263_2_T1	PHENOTYPE	7	7	tumor
NCT000032634	NCT00003263_4_T0	CELL	11	11	cells
NCT000032634	NCT00003263_4_T1	PHENOTYPE	10	10	tumor
NCT000032634	NCT00003263_4_T2	GENE	5	5	interferon
NCT000032635	NCT00003263_5_T0	COMPOUND	9	9	cisplatin
NCT000032635	NCT00003263_5_T1	GENE	11	11	interferon
NCT000032635	NCT00003263_5_T2	GENE	17	17	interferon
NCT000032635	NCT00003263_5_T3	PHENOTYPE	26	28	malignant pleural mesothelioma
NCT000032637	NCT00003263_7_T0	GENE	10	10	2b
NCT000032637	NCT00003263_7_T1	COMPOUND	14	14	cisplatin
NCT000032637	NCT00003263_7_T2	GENE	8	8	interferon
NCT000032637	NCT00003263_7_T3	GENE	5	5	MTD
NCT000032637	NCT00003263_7_T4	PHENOTYPE	18	20	malignant pleural mesothelioma
NCT000032639	NCT00003263_9_T0	COMPOUND	10	10	cisplatin
NCT000032639	NCT00003263_9_T1	GENE	2	2	MTD
NCT0000326311	NCT00003263_11_T0	PHENOTYPE	5	5	toxicity
NCT0000326311	NCT00003263_11_T1	COMPOUND	12	12	cisplatin
NCT0000326313	NCT00003263_13_T0	PHENOTYPE	2	2	toxicity
NCT0000326313	NCT00003263_13_T1	COMPOUND	7	7	cisplatin
NCT0000326315	NCT00003263_15_T0	PHENOTYPE	7	7	progression
NCT0000326317	NCT00003263_17_T0	GENE	12	12	2b
NCT0000326317	NCT00003263_17_T1	COMPOUND	6	6	cisplatin
NCT0000326317	NCT00003263_17_T2	GENE	10	10	interferon
NCT0000326317	NCT00003263_17_T3	GENE	7	7	IV
NCT0000326318	NCT00003263_18_T0	PHENOTYPE	6	6	tumor
NCT0000326319	NCT00003263_19_T0	PHENOTYPE	9	9	tumor
NCT0000326321	NCT00003263_21_T0	PHENOTYPE	3	3	tumors
NCT0000326321	NCT00003263_21_T1	GENE	7	7	2.4
NCT0000326323	NCT00003263_23_T0	COMPOUND	3	3	cisplatin
NCT0000326323	NCT00003263_23_T1	GENE	4	4	IV
NCT0000326325	NCT00003263_25_T0	GENE	5	5	MTD
NCT0000326326	NCT00003263_26_T0	PHENOTYPE	3	3	toxic
NCT0000326326	NCT00003263_26_T1	GENE	16	16	MTD
NCT0000326328	NCT00003263_28_T0	GENE	14	14	2.3
NCT000032640	NCT00003264_0_T0	CELL	8	9	Squamous Cell
NCT000032640	NCT00003264_0_T1	PHENOTYPE	10	13	Head and Neck Cancer
NCT000032642	NCT00003264_2_T0	CELL	9	9	cells
NCT000032642	NCT00003264_2_T1	PHENOTYPE	8	8	tumor
NCT000032646	NCT00003264_6_T0	PHENOTYPE	26	26	recurrence
NCT000032646	NCT00003264_6_T1	PHENOTYPE	59	59	recurrence
NCT000032646	NCT00003264_6_T2	PHENOTYPE	41	41	recurrent
NCT000032646	NCT00003264_6_T3	PHENOTYPE	45	46	metastatic disease
NCT000032647	NCT00003264_7_T0	COMPOUND	2	2	gemcitabine
NCT000032648	NCT00003264_8_T0	COMPOUND	10	10	gemcitabine
NCT0000326410	NCT00003264_10_T0	PHENOTYPE	4	5	metastatic disease
NCT000032661	NCT00003266_1_T0	COMPOUND	6	6	methylphenidate
NCT000032661	NCT00003266_1_T1	PHENOTYPE	19	19	melanoma
NCT000032662	NCT00003266_2_T0	COMPOUND	8	8	methylphenidate
NCT000032662	NCT00003266_2_T1	PHENOTYPE	20	20	fatigue
NCT000032662	NCT00003266_2_T2	GENE	3	3	III
NCT000032662	NCT00003266_2_T3	PHENOTYPE	22	22	drowsiness
NCT000032662	NCT00003266_2_T4	PHENOTYPE	27	27	melanoma
NCT000032662	NCT00003266_2_T5	GENE	32	32	interferon
NCT000032664	NCT00003266_4_T0	COMPOUND	2	2	methylphenidate
NCT000032664	NCT00003266_4_T1	PHENOTYPE	4	4	fatigue
NCT000032664	NCT00003266_4_T2	GENE	11	11	interferon
NCT000032664	NCT00003266_4_T3	PHENOTYPE	6	6	lethargy
NCT000032666	NCT00003266_6_T0	COMPOUND	5	5	methylphenidate
NCT000032666	NCT00003266_6_T1	PHENOTYPE	21	21	toxicities
NCT000032666	NCT00003266_6_T2	GENE	17	17	interferon
NCT000032666	NCT00003266_6_T3	PHENOTYPE	26	29	elevated liver function tests
NCT000032668	NCT00003266_8_T0	PHENOTYPE	4	4	toxicity
NCT000032668	NCT00003266_8_T1	COMPOUND	6	6	methylphenidate
NCT0000326610	NCT00003266_10_T0	PHENOTYPE	2	2	fatigue
NCT0000326610	NCT00003266_10_T1	PHENOTYPE	8	8	Fatigue
NCT0000326612	NCT00003266_12_T0	PHENOTYPE	6	6	fatigue
NCT0000326612	NCT00003266_12_T1	PHENOTYPE	14	14	tumor
NCT0000326616	NCT00003266_16_T0	PHENOTYPE	17	17	judgement
NCT0000326616	NCT00003266_16_T1	PHENOTYPE	28	29	drug withdrawal
NCT0000326618	NCT00003266_18_T0	PHENOTYPE	26	26	fatigue
NCT0000326618	NCT00003266_18_T1	PHENOTYPE	28	28	lethargy
NCT0000326619	NCT00003266_19_T0	PHENOTYPE	14	14	tiredness
NCT000032671	NCT00003267_1_T0	PHENOTYPE	26	27	vaginal cancer
NCT000032672	NCT00003267_2_T0	GENE	3	3	III
NCT000032672	NCT00003267_2_T1	PHENOTYPE	28	29	vaginal cancer
NCT000032674	NCT00003267_4_T0	GENE	24	24	cuff
NCT000032674	NCT00003267_4_T1	PHENOTYPE	1	2	postoperative complications
NCT000032676	NCT00003267_6_T0	TISSUE	25	25	fascia
NCT000032676	NCT00003267_6_T1	GENE	21	21	cuff
NCT000032681	NCT00003268_1_T0	CELL	9	9	cells
NCT000032681	NCT00003268_1_T1	PHENOTYPE	8	8	tumor
NCT000032682	NCT00003268_2_T0	CELL	8	8	cells
NCT000032682	NCT00003268_2_T1	COMPOUND	4	4	amifostine
NCT000032682	NCT00003268_2_T2	PHENOTYPE	12	14	effects of chemotherapy
NCT000032685	NCT00003268_5_T0	COMPOUND	8	8	idarubicin
NCT000032686	NCT00003268_6_T0	COMPOUND	2	2	amifostine
NCT000032686	NCT00003268_6_T1	GENE	3	3	IV
NCT000032687	NCT00003268_7_T0	GENE	9	9	1.3
NCT000032687	NCT00003268_7_T1	GENE	1	1	IV
NCT000032688	NCT00003268_8_T0	GENE	8	8	1.7
NCT0000326810	NCT00003268_10_T0	COMPOUND	12	12	idarubicin
NCT0000326811	NCT00003268_11_T0	PHENOTYPE	12	12	toxicity
NCT000032690	NCT00003269_0_T0	PHENOTYPE	10	11	Hematologic Cancer
NCT000032690	NCT00003269_0_T1	PHENOTYPE	13	14	Solid Tumors
NCT000032692	NCT00003269_2_T0	CELL	8	8	cells
NCT000032692	NCT00003269_2_T1	COMPOUND	4	4	amifostine
NCT000032692	NCT00003269_2_T2	PHENOTYPE	12	14	effects of chemotherapy
NCT000032693	NCT00003269_3_T0	GENE	3	3	II
NCT000032693	NCT00003269_3_T1	COMPOUND	10	10	amifostine
NCT000032693	NCT00003269_3_T2	PHENOTYPE	19	20	hematologic cancer
NCT000032693	NCT00003269_3_T3	PHENOTYPE	22	23	solid tumors
NCT000032695	NCT00003269_5_T0	COMPOUND	10	10	cyclophosphamide
NCT000032695	NCT00003269_5_T1	COMPOUND	11	11	etoposide
NCT000032695	NCT00003269_5_T2	COMPOUND	4	4	amifostine
NCT000032695	NCT00003269_5_T3	COMPOUND	13	13	cisplatin
NCT000032695	NCT00003269_5_T4	PHENOTYPE	18	19	hematologic malignancies
NCT000032695	NCT00003269_5_T5	PHENOTYPE	22	23	solid tumors
NCT000032697	NCT00003269_7_T0	GENE	17	17	0.2
NCT000032697	NCT00003269_7_T1	COMPOUND	3	3	amifostine
NCT000032698	NCT00003269_8_T0	COMPOUND	12	12	etoposide
NCT000032698	NCT00003269_8_T1	COMPOUND	23	23	cisplatin
NCT000032699	NCT00003269_9_T0	GENE	4	4	GM-CSF
NCT000032699	NCT00003269_9_T1	GENE	3	3	sargramostim
NCT0000326911	NCT00003269_11_T0	GENE	4	4	1.5
NCT000032701	NCT00003270_1_T0	CELL	8	8	cells
NCT000032702	NCT00003270_2_T0	CELL	20	20	cells
NCT000032702	NCT00003270_2_T1	ORGAN	0	2	Umbilical cord blood
NCT000032703	NCT00003270_3_T0	GENE	2	2	II
NCT000032703	NCT00003270_3_T1	PHENOTYPE	21	22	hematologic cancer
NCT000032703	NCT00003270_3_T2	ORGAN	13	15	umbilical cord blood
NCT000032708	NCT00003270_8_T0	COMPOUND	14	14	1
NCT000032708	NCT00003270_8_T1	COMPOUND	12	12	3
NCT000032708	NCT00003270_8_T2	GENE	4	4	globulin
NCT000032708	NCT00003270_8_T3	GENE	6	6	IV
NCT000032709	NCT00003270_9_T0	ORGAN	0	1	Cord blood
NCT0000327012	NCT00003270_12_T0	COMPOUND	3	3	cyclosporine
NCT0000327012	NCT00003270_12_T1	COMPOUND	6	6	2
NCT0000327012	NCT00003270_12_T2	COMPOUND	9	9	methylprednisolone
NCT0000327012	NCT00003270_12_T3	GENE	14	14	filgrastim
NCT0000327012	NCT00003270_12_T4	GENE	15	15	G-CSF
NCT0000327313	NCT00003273_13_T0	GENE	21	21	IV
NCT0000327313	NCT00003273_13_T1	GENE	34	34	IV
NCT0000327313	NCT00003273_13_T2	GENE	41	41	IV
NCT0000327313	NCT00003273_13_T3	COMPOUND	33	33	thiotepa
NCT0000327313	NCT00003273_13_T4	COMPOUND	36	36	3
NCT0000327313	NCT00003273_13_T5	COMPOUND	47	47	3
NCT0000327313	NCT00003273_13_T6	COMPOUND	40	40	etoposide
NCT0000327313	NCT00003273_13_T7	PHENOTYPE	11	12	disease progression
NCT0000327314	NCT00003273_14_T0	COMPOUND	13	13	etoposide
NCT0000327314	NCT00003273_14_T1	PHENOTYPE	6	6	diffuse
NCT0000327314	NCT00003273_14_T2	PHENOTYPE	8	9	pontine tumors
NCT0000327314	NCT00003273_14_T3	PHENOTYPE	2	3	malignant gliomas
NCT0000327316	NCT00003273_16_T0	PHENOTYPE	12	13	residual disease
NCT0000327317	NCT00003273_17_T0	GENE	21	21	2.4
NCT000032741	NCT00003274_1_T0	PHENOTYPE	15	15	melanoma
NCT000032744	NCT00003274_4_T0	GENE	21	21	gp100
NCT000032744	NCT00003274_4_T1	PHENOTYPE	13	13	melanoma
NCT000032744	NCT00003274_4_T2	GENE	34	34	GM-CSF
NCT000032744	NCT00003274_4_T3	GENE	18	18	tyrosinase
NCT000032744	NCT00003274_4_T4	GENE	33	33	sargramostim
NCT000032760	NCT00003276_0_T0	ORGAN	6	6	Gallbladder
NCT000032760	NCT00003276_0_T1	PHENOTYPE	8	10	Bile Duct Cancer
NCT000032762	NCT00003276_2_T0	GENE	2	2	II
NCT000032762	NCT00003276_2_T1	ORGAN	15	15	gallbladder
NCT000032762	NCT00003276_2_T2	COMPOUND	9	9	irinotecan
NCT000032762	NCT00003276_2_T3	PHENOTYPE	17	19	bile duct cancer
NCT000032764	NCT00003276_4_T0	PHENOTYPE	14	14	tumors
NCT000032764	NCT00003276_4_T1	ORGAN	10	10	gallbladder
NCT000032764	NCT00003276_4_T2	COMPOUND	17	17	irinotecan
NCT000032764	NCT00003276_4_T3	PHENOTYPE	3	3	tumor
NCT000032764	NCT00003276_4_T4	ORGAN	12	13	bile duct
NCT000032766	NCT00003276_6_T0	PHENOTYPE	4	4	toxic
NCT000032766	NCT00003276_6_T1	COMPOUND	8	8	irinotecan
NCT000032767	NCT00003276_7_T0	COMPOUND	9	9	irinotecan
NCT000032769	NCT00003276_9_T0	PHENOTYPE	11	11	toxicity
NCT000032769	NCT00003276_9_T1	PHENOTYPE	7	8	disease progression
NCT0000327611	NCT00003276_11_T0	GENE	12	12	2.4
NCT000032781	NCT00003278_1_T0	COMPOUND	8	8	dexamethasone
NCT000032781	NCT00003278_1_T1	PHENOTYPE	15	16	Hodgkin's lymphoma
NCT000032782	NCT00003278_2_T0	GENE	2	2	II
NCT000032782	NCT00003278_2_T1	COMPOUND	13	13	dexamethasone
NCT000032782	NCT00003278_2_T2	PHENOTYPE	21	22	Hodgkin's lymphoma
NCT000032784	NCT00003278_4_T0	GENE	12	12	4.5
NCT000032785	NCT00003278_5_T0	COMPOUND	10	10	dexamethasone
NCT000032785	NCT00003278_5_T1	GENE	14	14	1.5
NCT000032785	NCT00003278_5_T2	GENE	11	11	IV
NCT000032786	NCT00003278_6_T0	PHENOTYPE	13	13	toxicity
NCT000032786	NCT00003278_6_T1	PHENOTYPE	9	10	disease progression
NCT000032798	NCT00003279_8_T0	PHENOTYPE	4	6	quality of life
NCT0000327914	NCT00003279_14_T0	PHENOTYPE	18	18	toxicity
NCT0000327914	NCT00003279_14_T1	PHENOTYPE	20	21	disease progression
NCT0000327915	NCT00003279_15_T0	PHENOTYPE	0	2	Quality of life
NCT000032801	NCT00003280_1_T0	PHENOTYPE	12	12	lymphoma
NCT000032806	NCT00003280_6_T0	GENE	17	17	1.4
NCT000032806	NCT00003280_6_T1	GENE	10	10	3.5
NCT000032806	NCT00003280_6_T2	GENE	8	8	IV
NCT000032812	NCT00003281_2_T0	CELL	9	9	cells
NCT000032812	NCT00003281_2_T1	PHENOTYPE	8	8	tumor
NCT000032817	NCT00003281_7_T0	PHENOTYPE	2	2	closed
NCT000032818	NCT00003281_8_T0	COMPOUND	11	11	paclitaxel
NCT000032818	NCT00003281_8_T1	GENE	9	9	1.3
NCT000032818	NCT00003281_8_T2	GENE	3	3	IV
NCT000032818	NCT00003281_8_T3	GENE	12	12	IV
NCT000032818	NCT00003281_8_T4	COMPOUND	2	2	topotecan
NCT0000328110	NCT00003281_10_T0	PHENOTYPE	17	18	disease progression
NCT0000328111	NCT00003281_11_T0	PHENOTYPE	3	4	disease progression
NCT0000328112	NCT00003281_12_T0	PHENOTYPE	4	4	remission
NCT000032820	NCT00003282_0_T0	PHENOTYPE	5	6	Solid Tumors
NCT000032823	NCT00003282_3_T0	COMPOUND	5	5	etanidazole
NCT000032823	NCT00003282_3_T1	PHENOTYPE	20	21	solid tumors
NCT000032825	NCT00003282_5_T0	PHENOTYPE	2	2	toxic
NCT000032827	NCT00003282_7_T0	PHENOTYPE	2	2	pharmacokinetics
NCT0000328215	NCT00003282_15_T0	GENE	7	7	1.2
NCT0000328215	NCT00003282_15_T1	COMPOUND	2	2	etanidazole
NCT0000328215	NCT00003282_15_T2	GENE	5	5	IV
NCT0000328216	NCT00003282_16_T0	PHENOTYPE	0	0	Tumors
NCT0000328217	NCT00003282_17_T0	GENE	14	14	MTD
NCT0000328218	NCT00003282_18_T0	PHENOTYPE	17	17	toxicity
NCT0000328218	NCT00003282_18_T1	GENE	1	1	MTD
NCT0000328219	NCT00003282_19_T0	GENE	13	13	MTD
NCT000032831	NCT00003283_1_T0	GENE	2	2	II
NCT000032831	NCT00003283_1_T1	COMPOUND	9	9	octreotide
NCT000032831	NCT00003283_1_T2	COMPOUND	13	13	prednisone
NCT000032831	NCT00003283_1_T3	PHENOTYPE	20	21	recurrent thymoma
NCT000032833	NCT00003283_3_T0	COMPOUND	14	14	octreotide
NCT000032833	NCT00003283_3_T1	PHENOTYPE	10	11	recurrent thymoma
NCT000032835	NCT00003283_5_T0	PHENOTYPE	4	4	remission
NCT000032837	NCT00003283_7_T0	PHENOTYPE	2	2	toxicity
NCT000032837	NCT00003283_7_T1	COMPOUND	5	5	octreotide
NCT000032839	NCT00003283_9_T0	PHENOTYPE	9	9	toxicity
NCT000032839	NCT00003283_9_T1	PHENOTYPE	6	6	remission
NCT000032839	NCT00003283_9_T2	COMPOUND	14	14	octreotide
NCT000032839	NCT00003283_9_T3	COMPOUND	21	21	octreotide
NCT000032839	NCT00003283_9_T4	COMPOUND	11	11	prednisone
NCT0000328310	NCT00003283_10_T0	COMPOUND	4	4	octreotide
NCT0000328312	NCT00003283_12_T0	PHENOTYPE	21	21	toxicity
NCT0000328312	NCT00003283_12_T1	COMPOUND	7	7	octreotide
NCT0000328312	NCT00003283_12_T2	PHENOTYPE	23	24	disease progression
NCT0000328313	NCT00003283_13_T0	COMPOUND	8	8	octreotide
NCT0000328313	NCT00003283_13_T1	COMPOUND	16	16	octreotide
NCT0000328313	NCT00003283_13_T2	COMPOUND	12	12	prednisone
NCT0000328314	NCT00003283_14_T0	PHENOTYPE	22	22	toxicity
NCT0000328314	NCT00003283_14_T1	COMPOUND	8	8	octreotide
NCT0000328314	NCT00003283_14_T2	COMPOUND	10	10	prednisone
NCT0000328314	NCT00003283_14_T3	PHENOTYPE	24	25	disease progression
NCT000032848	NCT00003284_8_T0	COMPOUND	6	6	paclitaxel
NCT000032848	NCT00003284_8_T1	CELL	13	14	stem cells
NCT000032849	NCT00003284_9_T0	COMPOUND	8	8	ifosfamide
NCT000032849	NCT00003284_9_T1	GENE	2	2	3.4
NCT0000328411	NCT00003284_11_T0	CELL	0	1	Stem cells
NCT0000328412	NCT00003284_12_T0	CELL	1	1	granulocyte
NCT0000328412	NCT00003284_12_T1	GENE	4	4	G-CSF
NCT000032871	NCT00003287_1_T0	CELL	9	9	cells
NCT000032871	NCT00003287_1_T1	PHENOTYPE	8	8	tumor
NCT000032872	NCT00003287_2_T0	PHENOTYPE	17	17	recurrent
NCT000032872	NCT00003287_2_T1	PHENOTYPE	19	21	metastatic colorectal cancer
NCT000032873	NCT00003287_3_T0	GENE	3	3	III
NCT000032873	NCT00003287_3_T1	COMPOUND	14	14	oxaliplatin
NCT000032873	NCT00003287_3_T2	COMPOUND	12	12	leucovorin
NCT000032873	NCT00003287_3_T3	PHENOTYPE	22	22	recurrent
NCT000032873	NCT00003287_3_T4	PHENOTYPE	24	26	metastatic colorectal cancer
NCT000032875	NCT00003287_5_T0	PHENOTYPE	22	22	recurrent
NCT000032875	NCT00003287_5_T1	PHENOTYPE	24	26	metastatic colorectal cancer
NCT000032877	NCT00003287_7_T0	COMPOUND	10	10	calcium
NCT000032877	NCT00003287_7_T1	COMPOUND	12	12	oxaliplatin
NCT000032877	NCT00003287_7_T2	COMPOUND	9	9	leucovorin
NCT000032879	NCT00003287_9_T0	PHENOTYPE	5	5	toxicity
NCT0000328711	NCT00003287_11_T0	PHENOTYPE	2	4	quality of life
NCT0000328713	NCT00003287_13_T0	COMPOUND	10	10	2
NCT0000328713	NCT00003287_13_T1	ORGAN	13	13	liver
NCT0000328716	NCT00003287_16_T0	COMPOUND	11	11	calcium
NCT0000328716	NCT00003287_16_T1	COMPOUND	10	10	leucovorin
NCT0000328718	NCT00003287_18_T0	PHENOTYPE	0	2	Quality of life
NCT000032880	NCT00003288_0_T0	PHENOTYPE	8	9	Solid Tumors
NCT000032882	NCT00003288_2_T0	CELL	10	10	cells
NCT000032882	NCT00003288_2_T1	PHENOTYPE	9	9	tumor
NCT000032883	NCT00003288_3_T0	CELL	9	9	cells
NCT000032883	NCT00003288_3_T1	PHENOTYPE	8	8	tumor
NCT000032885	NCT00003288_5_T0	PHENOTYPE	9	9	toxicity
NCT000032885	NCT00003288_5_T1	COMPOUND	11	11	tirapazamine
NCT000032885	NCT00003288_5_T2	COMPOUND	15	15	cyclophosphamide
NCT000032885	NCT00003288_5_T3	PHENOTYPE	23	24	solid tumors
NCT000032887	NCT00003288_7_T0	PHENOTYPE	4	4	severity
NCT000032887	NCT00003288_7_T1	COMPOUND	9	9	tirapazamine
NCT000032887	NCT00003288_7_T2	COMPOUND	11	11	cyclophosphamide
NCT000032887	NCT00003288_7_T3	PHENOTYPE	7	7	toxicities
NCT000032889	NCT00003288_9_T0	GENE	14	14	II
NCT000032889	NCT00003288_9_T1	COMPOUND	7	7	tirapazamine
NCT000032889	NCT00003288_9_T2	COMPOUND	10	10	cyclophosphamide
NCT0000328811	NCT00003288_11_T0	COMPOUND	4	4	tirapazamine
NCT0000328811	NCT00003288_11_T1	COMPOUND	13	13	tirapazamine
NCT0000328811	NCT00003288_11_T2	PHENOTYPE	2	2	pharmacokinetics
NCT0000328811	NCT00003288_11_T3	COMPOUND	15	15	cyclophosphamide
NCT0000328813	NCT00003288_13_T0	COMPOUND	8	8	tirapazamine
NCT0000328813	NCT00003288_13_T1	COMPOUND	10	10	cyclophosphamide
NCT0000328815	NCT00003288_15_T0	GENE	9	9	0.2
NCT0000328815	NCT00003288_15_T1	COMPOUND	2	2	tirapazamine
NCT0000328815	NCT00003288_15_T2	COMPOUND	21	21	cyclophosphamide
NCT0000328817	NCT00003288_17_T0	COMPOUND	12	12	tirapazamine
NCT0000328818	NCT00003288_18_T0	PHENOTYPE	19	19	toxicity
NCT0000328818	NCT00003288_18_T1	COMPOUND	3	3	tirapazamine
NCT0000328818	NCT00003288_18_T2	GENE	15	15	has
NCT0000328818	NCT00003288_18_T3	GENE	20	20	DLT
NCT0000328819	NCT00003288_19_T0	GENE	1	1	DLT
NCT0000328820	NCT00003288_20_T0	PHENOTYPE	11	11	experiences
NCT0000328820	NCT00003288_20_T1	GENE	12	12	DLT
NCT0000328821	NCT00003288_21_T0	GENE	18	18	has
NCT0000328821	NCT00003288_21_T1	GENE	17	17	MTD
NCT0000328821	NCT00003288_21_T2	GENE	35	35	MTD
NCT0000328821	NCT00003288_21_T3	GENE	1	1	DLT
NCT0000328822	NCT00003288_22_T0	GENE	9	9	MTD
NCT0000328823	NCT00003288_23_T0	PHENOTYPE	6	6	neutropenia
NCT0000328823	NCT00003288_23_T1	GENE	1	1	DLT
NCT0000328824	NCT00003288_24_T0	CELL	16	16	granulocyte
NCT0000328824	NCT00003288_24_T1	GENE	15	15	filgrastim
NCT0000328824	NCT00003288_24_T2	COMPOUND	24	24	cyclophosphamide
NCT0000328824	NCT00003288_24_T3	PHENOTYPE	1	1	neutropenia
NCT0000328824	NCT00003288_24_T4	GENE	19	19	G-CSF
NCT0000328824	NCT00003288_24_T5	GENE	6	6	DLT
NCT0000328825	NCT00003288_25_T0	GENE	9	9	G-CSF
NCT0000328825	NCT00003288_25_T1	GENE	2	2	MTD
NCT000032891	NCT00003289_1_T0	GENE	17	17	has
NCT000032891	NCT00003289_1_T1	PHENOTYPE	14	15	advanced cancer
NCT000032893	NCT00003289_3_T0	PHENOTYPE	2	2	toxicity
NCT000032893	NCT00003289_3_T1	PHENOTYPE	6	6	toxicity
NCT000032893	NCT00003289_3_T2	PHENOTYPE	31	31	malignancies
NCT000032893	NCT00003289_3_T3	PHENOTYPE	33	33	chronic
NCT000032893	NCT00003289_3_T4	PHENOTYPE	34	35	lymphoproliferative disorders
NCT000032893	NCT00003289_3_T5	PHENOTYPE	29	30	solid tumor
NCT000032895	NCT00003289_5_T0	PHENOTYPE	5	5	pharmacodynamics
NCT000032895	NCT00003289_5_T1	PHENOTYPE	2	2	pharmacokinetics
NCT0000328911	NCT00003289_11_T0	PHENOTYPE	10	10	toxicity
NCT0000328913	NCT00003289_13_T0	PHENOTYPE	3	3	toxicity
NCT0000328913	NCT00003289_13_T1	GENE	4	4	DLT
NCT0000328914	NCT00003289_14_T0	GENE	11	11	has
NCT0000328914	NCT00003289_14_T1	GENE	6	6	DLT
NCT000032908	NCT00003290_8_T0	PHENOTYPE	0	2	Quality of life
NCT000032911	NCT00003291_1_T0	PHENOTYPE	21	23	acute lymphoblastic leukemia
NCT000032911	NCT00003291_1_T1	PHENOTYPE	17	19	cancer in children
NCT000032914	NCT00003291_4_T0	GENE	20	20	p14
NCT000032914	NCT00003291_4_T1	COMPOUND	8	8	CCG-1882
NCT000032914	NCT00003291_4_T2	GENE	18	18	p16
NCT000032914	NCT00003291_4_T3	PHENOTYPE	19	19	deletion
NCT000032914	NCT00003291_4_T4	PHENOTYPE	21	21	deletion
NCT000032914	NCT00003291_4_T5	PHENOTYPE	24	24	deletion
NCT000032914	NCT00003291_4_T6	GENE	23	23	p15
NCT000032914	NCT00003291_4_T7	ORGAN	0	1	Bone marrow
NCT000032921	NCT00003292_1_T0	GENE	2	2	II
NCT000032921	NCT00003292_1_T1	COMPOUND	9	9	ifosfamide
NCT000032921	NCT00003292_1_T2	PHENOTYPE	14	15	meningeal tumors
NCT000032923	NCT00003292_3_T0	COMPOUND	4	4	ifosfamide
NCT000032923	NCT00003292_3_T1	GENE	12	12	1.3
NCT000032923	NCT00003292_3_T2	GENE	5	5	IV
NCT000032926	NCT00003292_6_T0	PHENOTYPE	10	10	toxicity
NCT000032926	NCT00003292_6_T1	PHENOTYPE	6	7	disease progression
NCT000032931	NCT00003293_1_T0	COMPOUND	11	11	procarbazine
NCT000032931	NCT00003293_1_T1	PHENOTYPE	16	17	glioblastoma multiforme
NCT000032932	NCT00003293_2_T0	GENE	3	3	III
NCT000032932	NCT00003293_2_T1	GENE	22	22	has
NCT000032932	NCT00003293_2_T2	COMPOUND	14	14	procarbazine
NCT000032932	NCT00003293_2_T3	PHENOTYPE	19	20	glioblastoma multiforme
NCT000032934	NCT00003293_4_T0	COMPOUND	15	15	leflunomide
NCT000032934	NCT00003293_4_T1	PHENOTYPE	11	11	relapse
NCT000032934	NCT00003293_4_T2	COMPOUND	29	29	procarbazine
NCT000032934	NCT00003293_4_T3	PHENOTYPE	7	8	glioblastoma multiforme
NCT000032936	NCT00003293_6_T0	PHENOTYPE	5	5	progression
NCT0000329312	NCT00003293_12_T0	PHENOTYPE	3	5	quality of life
NCT0000329314	NCT00003293_14_T0	PHENOTYPE	25	25	recurrence
NCT0000329321	NCT00003293_21_T0	PHENOTYPE	5	5	quality-of-life
NCT0000329322	NCT00003293_22_T0	PHENOTYPE	15	15	toxicity
NCT0000329322	NCT00003293_22_T1	PHENOTYPE	17	18	disease progression
NCT000032941	NCT00003294_1_T0	CELL	8	8	cells
NCT000032941	NCT00003294_1_T1	COMPOUND	4	4	amifostine
NCT000032941	NCT00003294_1_T2	PHENOTYPE	12	14	effects of chemotherapy
NCT000032942	NCT00003294_2_T0	PHENOTYPE	17	17	peripheral
NCT000032942	NCT00003294_2_T1	CELL	11	11	cells
NCT000032942	NCT00003294_2_T2	GENE	4	4	filgrastim
NCT000032942	NCT00003294_2_T3	ORGAN	14	15	bone marrow
NCT000032942	NCT00003294_2_T4	ORGAN	24	25	immune system
NCT000032942	NCT00003294_2_T5	PHENOTYPE	30	32	effects of chemotherapy
NCT000032943	NCT00003294_3_T0	COMPOUND	13	13	paclitaxel
NCT000032943	NCT00003294_3_T1	GENE	20	20	filgrastim
NCT000032943	NCT00003294_3_T2	COMPOUND	18	18	amifostine
NCT000032943	NCT00003294_3_T3	PHENOTYPE	25	25	recurrent
NCT000032943	NCT00003294_3_T4	PHENOTYPE	27	28	metastatic cancer
NCT000032945	NCT00003294_5_T0	COMPOUND	7	7	paclitaxel
NCT000032945	NCT00003294_5_T1	GENE	16	16	G-CSF
NCT000032945	NCT00003294_5_T2	GENE	15	15	filgrastim
NCT000032945	NCT00003294_5_T3	COMPOUND	13	13	amifostine
NCT000032945	NCT00003294_5_T4	PHENOTYPE	20	20	recurrent
NCT000032945	NCT00003294_5_T5	PHENOTYPE	22	23	metastatic cancer
NCT000032947	NCT00003294_7_T0	PHENOTYPE	4	4	toxicity
NCT0000329410	NCT00003294_10_T0	COMPOUND	8	8	paclitaxel
NCT0000329411	NCT00003294_11_T0	COMPOUND	10	10	paclitaxel
NCT0000329411	NCT00003294_11_T1	COMPOUND	7	7	amifostine
NCT0000329412	NCT00003294_12_T0	GENE	1	1	G-CSF
NCT0000329413	NCT00003294_13_T0	PHENOTYPE	15	15	toxicity
NCT0000329413	NCT00003294_13_T1	PHENOTYPE	11	12	disease progression
NCT0000329414	NCT00003294_14_T0	PHENOTYPE	4	4	toxicity
NCT0000329414	NCT00003294_14_T1	GENE	5	5	DLT
NCT0000329416	NCT00003294_16_T0	COMPOUND	21	21	paclitaxel
NCT0000329416	NCT00003294_16_T1	GENE	4	4	DLT
NCT0000329417	NCT00003294_17_T0	GENE	1	1	DLT
NCT0000329418	NCT00003294_18_T0	GENE	14	14	MTD
NCT0000329418	NCT00003294_18_T1	GENE	1	1	DLT
NCT0000329418	NCT00003294_18_T2	GENE	16	16	DLT
NCT0000329419	NCT00003294_19_T0	GENE	16	16	MTD
NCT0000329419	NCT00003294_19_T1	GENE	1	1	DLT
NCT0000329420	NCT00003294_20_T0	PHENOTYPE	11	11	recruitment
NCT0000329420	NCT00003294_20_T1	GENE	6	6	DLT
NCT000032962	NCT00003296_2_T0	GENE	2	2	II
NCT000032962	NCT00003296_2_T1	ORGAN	15	15	liver
NCT000032962	NCT00003296_2_T2	COMPOUND	10	10	doxorubicin
NCT000032962	NCT00003296_2_T3	PHENOTYPE	17	19	bile duct cancer
NCT000032964	NCT00003296_4_T0	PHENOTYPE	5	5	toxicity
NCT000032964	NCT00003296_4_T1	COMPOUND	8	8	HCl
NCT000032964	NCT00003296_4_T2	ORGAN	16	16	liver
NCT000032964	NCT00003296_4_T3	PHENOTYPE	13	13	carcinomas
NCT000032964	NCT00003296_4_T4	COMPOUND	7	7	doxorubicin
NCT000032964	NCT00003296_4_T5	ORGAN	18	19	bile ducts
NCT000032965	NCT00003296_5_T0	COMPOUND	4	4	HCl
NCT000032965	NCT00003296_5_T1	COMPOUND	3	3	doxorubicin
NCT000032965	NCT00003296_5_T2	GENE	6	6	IV
NCT000032966	NCT00003296_6_T0	GENE	1	1	G-CSF
NCT000032968	NCT00003296_8_T0	PHENOTYPE	7	7	toxicity
NCT000032968	NCT00003296_8_T1	PHENOTYPE	9	10	disease progression
NCT000032977	NCT00003297_7_T0	COMPOUND	8	8	topotecan
NCT000032978	NCT00003297_8_T0	CELL	3	5	peripheral stem cells
NCT000032979	NCT00003297_9_T0	COMPOUND	11	11	mitoxantrone
NCT000032979	NCT00003297_9_T1	COMPOUND	13	13	thiotepa
NCT000032979	NCT00003297_9_T2	COMPOUND	3	3	topotecan
NCT0000329710	NCT00003297_10_T0	COMPOUND	12	12	mitoxantrone
NCT0000329710	NCT00003297_10_T1	COMPOUND	21	21	thiotepa
NCT0000329710	NCT00003297_10_T2	GENE	11	11	1.3
NCT0000329710	NCT00003297_10_T3	GENE	19	19	1.3
NCT0000329710	NCT00003297_10_T4	GENE	28	28	1.3
NCT0000329710	NCT00003297_10_T5	COMPOUND	2	2	topotecan
NCT0000329710	NCT00003297_10_T6	CELL	37	39	peripheral stem cells
NCT0000329712	NCT00003297_12_T0	GENE	16	16	MTD
NCT0000329712	NCT00003297_12_T1	COMPOUND	3	3	topotecan
NCT0000329713	NCT00003297_13_T0	PHENOTYPE	18	18	toxicity
NCT0000329713	NCT00003297_13_T1	GENE	1	1	MTD
NCT000032981	NCT00003298_1_T0	CELL	8	8	cells
NCT000032981	NCT00003298_1_T1	PHENOTYPE	7	7	tumor
NCT000032982	NCT00003298_2_T0	CELL	10	10	cells
NCT000032982	NCT00003298_2_T1	PHENOTYPE	9	9	tumor
NCT000032983	NCT00003298_3_T0	COMPOUND	23	23	paclitaxel
NCT000032983	NCT00003298_3_T1	COMPOUND	25	25	cisplatin
NCT000032983	NCT00003298_3_T2	PHENOTYPE	16	17	gastric cancer
NCT000032986	NCT00003298_6_T0	GENE	10	10	IV
NCT000032989	NCT00003298_9_T0	COMPOUND	14	14	paclitaxel
NCT000032989	NCT00003298_9_T1	PHENOTYPE	0	0	Secondary
NCT000032989	NCT00003298_9_T2	COMPOUND	12	12	cisplatin
NCT000032989	NCT00003298_9_T3	PHENOTYPE	8	9	gastric tumors
NCT0000329811	NCT00003298_11_T0	COMPOUND	15	15	paclitaxel
NCT0000329811	NCT00003298_11_T1	COMPOUND	7	7	cisplatin
NCT0000329812	NCT00003298_12_T0	COMPOUND	22	22	calcium
NCT0000329812	NCT00003298_12_T1	PHENOTYPE	5	5	tumor
NCT0000329812	NCT00003298_12_T2	COMPOUND	21	21	leucovorin
NCT0000329814	NCT00003298_14_T0	COMPOUND	12	12	calcium
NCT0000329814	NCT00003298_14_T1	COMPOUND	11	11	leucovorin
NCT000032992	NCT00003299_2_T0	CELL	9	9	cells
NCT000032992	NCT00003299_2_T1	PHENOTYPE	8	8	tumor
NCT000032998	NCT00003299_8_T0	PHENOTYPE	2	2	tumor
NCT0000329910	NCT00003299_10_T0	PHENOTYPE	4	4	toxic
NCT0000329916	NCT00003299_16_T0	GENE	3	3	filgrastim
NCT0000329916	NCT00003299_16_T1	GENE	4	4	G-CSF
NCT000033011	NCT00003301_1_T0	COMPOUND	9	9	irinotecan
NCT000033011	NCT00003301_1_T1	PHENOTYPE	14	14	recurrent
NCT000033011	NCT00003301_1_T2	PHENOTYPE	15	16	malignant glioma
NCT000033013	NCT00003301_3_T0	COMPOUND	7	7	irinotecan
NCT000033013	NCT00003301_3_T1	PHENOTYPE	17	17	recurrent
NCT000033013	NCT00003301_3_T2	PHENOTYPE	18	19	malignant gliomas
NCT000033015	NCT00003301_5_T0	COMPOUND	10	10	irinotecan
NCT000033015	NCT00003301_5_T1	PHENOTYPE	2	2	pharmacokinetics
NCT000033015	NCT00003301_5_T2	PHENOTYPE	30	30	pharmacokinetics
NCT000033017	NCT00003301_7_T0	COMPOUND	7	7	irinotecan
NCT000033019	NCT00003301_9_T0	PHENOTYPE	7	8	brain tumor
NCT000033019	NCT00003301_9_T1	GENE	3	4	topoisomerase I
NCT0000330115	NCT00003301_15_T0	PHENOTYPE	18	18	toxicity
NCT0000330116	NCT00003301_16_T0	PHENOTYPE	8	8	toxicity
NCT0000330116	NCT00003301_16_T1	PHENOTYPE	10	11	disease progression
NCT000033021	NCT00003302_1_T0	GENE	8	8	MRI
NCT000033021	NCT00003302_1_T1	GENE	17	17	had
NCT000033021	NCT00003302_1_T2	PHENOTYPE	11	12	breast tumors
NCT000033023	NCT00003302_3_T0	GENE	8	8	MRI
NCT000033025	NCT00003302_5_T0	GENE	6	6	MRI
NCT000033027	NCT00003302_7_T0	GENE	5	5	MRI
NCT000033029	NCT00003302_9_T0	GENE	11	11	MRI
NCT0000330212	NCT00003302_12_T0	PHENOTYPE	25	25	foci
NCT0000330215	NCT00003302_15_T0	GENE	9	9	MRI
NCT000033041	NCT00003304_1_T0	COMPOUND	9	9	temozolomide
NCT000033041	NCT00003304_1_T1	GENE	2	2	II
NCT000033041	NCT00003304_1_T2	PHENOTYPE	16	16	tumors
NCT000033041	NCT00003304_1_T3	PHENOTYPE	14	14	recurrent
NCT000033043	NCT00003304_3_T0	COMPOUND	12	12	temozolomide
NCT000033043	NCT00003304_3_T1	GENE	23	23	PCV
NCT000033043	NCT00003304_3_T2	PHENOTYPE	10	10	tumors
NCT000033043	NCT00003304_3_T3	PHENOTYPE	17	18	progressive disease
NCT000033045	NCT00003304_5_T0	PHENOTYPE	4	4	toxicity
NCT000033045	NCT00003304_5_T1	COMPOUND	6	6	temozolomide
NCT000033045	NCT00003304_5_T2	PHENOTYPE	9	9	PVC
NCT000033047	NCT00003304_7_T0	GENE	6	6	1.5
NCT000033051	NCT00003305_1_T0	COMPOUND	9	9	aminopterin
NCT000033051	NCT00003305_1_T1	GENE	2	2	II
NCT000033051	NCT00003305_1_T2	PHENOTYPE	16	16	leukemia
NCT000033053	NCT00003305_3_T0	COMPOUND	6	6	aminopterin
NCT000033053	NCT00003305_3_T1	PHENOTYPE	11	11	leukemia
NCT000033055	NCT00003305_5_T0	COMPOUND	5	5	aminopterin
NCT000033055	NCT00003305_5_T1	PHENOTYPE	11	11	acute
NCT000033055	NCT00003305_5_T2	GENE	21	21	has
NCT000033055	NCT00003305_5_T3	PHENOTYPE	14	16	acute lymphoblastic leukemia
NCT000033059	NCT00003305_9_T0	COMPOUND	5	5	aminopterin
NCT000033059	NCT00003305_9_T1	PHENOTYPE	10	10	pharmacokinetics
NCT0000330516	NCT00003305_16_T0	COMPOUND	19	19	aminopterin
NCT0000330516	NCT00003305_16_T1	COMPOUND	4	4	calcium
NCT0000330516	NCT00003305_16_T2	COMPOUND	3	3	leucovorin
NCT0000330517	NCT00003305_17_T0	COMPOUND	26	26	aminopterin
NCT0000330517	NCT00003305_17_T1	PHENOTYPE	1	1	toxicity
NCT0000330517	NCT00003305_17_T2	COMPOUND	12	12	calcium
NCT0000330517	NCT00003305_17_T3	COMPOUND	11	11	leucovorin
NCT0000330518	NCT00003305_18_T0	COMPOUND	11	11	calcium
NCT0000330518	NCT00003305_18_T1	COMPOUND	10	10	leucovorin
NCT0000330519	NCT00003305_19_T0	PHENOTYPE	16	16	toxicity
NCT0000330519	NCT00003305_19_T1	PHENOTYPE	12	13	disease progression
NCT000033071	NCT00003307_1_T0	CELL	4	4	cells
NCT000033071	NCT00003307_1_T1	PHENOTYPE	8	11	effects of radiation therapy
NCT000033076	NCT00003307_6_T0	PHENOTYPE	6	6	toxicity
NCT000033076	NCT00003307_6_T1	COMPOUND	9	9	amifostine
NCT000033078	NCT00003307_8_T0	PHENOTYPE	1	1	tumor
NCT000033081	NCT00003308_1_T0	GENE	2	2	II
NCT000033081	NCT00003308_1_T1	PHENOTYPE	24	24	sarcoma
NCT000033081	NCT00003308_1_T2	PHENOTYPE	22	22	melanoma
NCT000033081	NCT00003308_1_T3	PHENOTYPE	17	18	brain metastases
NCT000033081	NCT00003308_1_T4	PHENOTYPE	20	21	kidney cancer
NCT000033084	NCT00003308_4_T0	PHENOTYPE	6	6	tumor
NCT000033084	NCT00003308_4_T1	GENE	9	9	cm
NCT000033084	NCT00003308_4_T2	GENE	14	14	cm
NCT000033084	NCT00003308_4_T3	GENE	17	17	cm
NCT000033084	NCT00003308_4_T4	GENE	22	22	cm
NCT000033084	NCT00003308_4_T5	GENE	25	25	cm
NCT000033085	NCT00003308_5_T0	PHENOTYPE	10	10	tumor
NCT000033086	NCT00003308_6_T0	GENE	2	2	MRI
NCT000033086	NCT00003308_6_T1	PHENOTYPE	16	17	disease progression
NCT000033087	NCT00003308_7_T0	PHENOTYPE	23	23	progression
NCT000033087	NCT00003308_7_T1	PHENOTYPE	17	18	brain metastases
NCT000033089	NCT00003308_9_T0	GENE	14	14	7.2
NCT000033092	NCT00003309_2_T0	CELL	8	8	cells
NCT000033092	NCT00003309_2_T1	PHENOTYPE	7	7	tumor
NCT000033093	NCT00003309_3_T0	CELL	15	15	cells
NCT000033093	NCT00003309_3_T1	PHENOTYPE	14	14	tumor
NCT000033094	NCT00003309_4_T0	GENE	2	2	II
NCT000033094	NCT00003309_4_T1	PHENOTYPE	20	21	brain cancer
NCT000033096	NCT00003309_6_T0	COMPOUND	11	11	vincristine
NCT000033096	NCT00003309_6_T1	COMPOUND	38	38	vincristine
NCT000033096	NCT00003309_6_T2	GENE	14	14	1.2
NCT000033096	NCT00003309_6_T3	GENE	25	25	1.2
NCT000033096	NCT00003309_6_T4	GENE	41	41	1.2
NCT000033096	NCT00003309_6_T5	GENE	29	29	2.3
NCT000033096	NCT00003309_6_T6	GENE	31	31	G-CSF
NCT000033096	NCT00003309_6_T7	GENE	4	4	IV
NCT000033096	NCT00003309_6_T8	GENE	9	9	IV
NCT000033096	NCT00003309_6_T9	GENE	12	12	IV
NCT000033096	NCT00003309_6_T10	GENE	20	20	IV
NCT000033096	NCT00003309_6_T11	GENE	23	23	IV
NCT000033096	NCT00003309_6_T12	GENE	39	39	IV
NCT000033096	NCT00003309_6_T13	GENE	33	33	SC
NCT000033096	NCT00003309_6_T14	COMPOUND	18	18	1
NCT000033096	NCT00003309_6_T15	GENE	30	30	filgrastim
NCT000033096	NCT00003309_6_T16	COMPOUND	22	22	cyclophosphamide
NCT000033096	NCT00003309_6_T17	COMPOUND	8	8	etoposide
NCT000033096	NCT00003309_6_T18	COMPOUND	19	19	etoposide
NCT000033096	NCT00003309_6_T19	COMPOUND	3	3	cisplatin
NCT000033097	NCT00003309_7_T0	PHENOTYPE	18	18	toxicity
NCT000033097	NCT00003309_7_T1	PHENOTYPE	14	15	disease progression
NCT000033099	NCT00003309_9_T0	PHENOTYPE	19	19	5-10
NCT000033111	NCT00003311_1_T0	CELL	9	9	cells
NCT000033116	NCT00003311_6_T0	GENE	3	3	IV
NCT000033117	NCT00003311_7_T0	GENE	5	5	SC
NCT000033117	NCT00003311_7_T1	GENE	1	1	G-CSF
NCT000033119	NCT00003311_9_T0	GENE	3	3	IV
NCT0000331110	NCT00003311_10_T0	GENE	3	3	IV
NCT0000331111	NCT00003311_11_T0	GENE	8	8	1.4
NCT0000331111	NCT00003311_11_T1	GENE	5	5	IV
NCT0000331112	NCT00003311_12_T0	GENE	3	3	SC
NCT0000331112	NCT00003311_12_T1	GENE	0	0	G-CSF
NCT000033128	NCT00003312_8_T0	PHENOTYPE	2	4	quality of life
NCT0000331213	NCT00003312_13_T0	PHENOTYPE	10	10	progression
NCT0000331213	NCT00003312_13_T1	PHENOTYPE	18	18	progression
NCT0000331213	NCT00003312_13_T2	TISSUE	0	0	Prostate
NCT0000331214	NCT00003312_14_T0	PHENOTYPE	0	2	Quality of life
NCT000033137	NCT00003313_7_T0	PHENOTYPE	11	11	dysphagia
NCT000033137	NCT00003313_7_T1	COMPOUND	15	15	amifostine
NCT000033137	NCT00003313_7_T2	COMPOUND	20	20	amifostine
NCT000033137	NCT00003313_7_T3	PHENOTYPE	4	6	quality of life
NCT000033139	NCT00003313_9_T0	PHENOTYPE	21	21	esophagitis
NCT000033139	NCT00003313_9_T1	PHENOTYPE	14	16	quality of life
NCT0000331311	NCT00003313_11_T0	COMPOUND	7	7	paclitaxel
NCT0000331313	NCT00003313_13_T0	GENE	7	7	II
NCT0000331316	NCT00003313_16_T0	COMPOUND	10	10	paclitaxel
NCT0000331316	NCT00003313_16_T1	GENE	3	3	IV
NCT0000331317	NCT00003313_17_T0	COMPOUND	14	14	paclitaxel
NCT0000331317	NCT00003313_17_T1	GENE	2	2	filgrastim
NCT0000331317	NCT00003313_17_T2	GENE	3	3	G-CSF
NCT0000331319	NCT00003313_19_T0	COMPOUND	6	6	amifostine
NCT0000331319	NCT00003313_19_T1	GENE	9	9	5.7
NCT0000331319	NCT00003313_19_T2	GENE	7	7	IV
NCT0000331321	NCT00003313_21_T0	PHENOTYPE	0	2	Quality of life
NCT000033151	NCT00003315_1_T0	PHENOTYPE	17	17	peripheral
NCT000033151	NCT00003315_1_T1	CELL	11	11	cells
NCT000033151	NCT00003315_1_T2	GENE	4	4	sargramostim
NCT000033151	NCT00003315_1_T3	ORGAN	14	15	bone marrow
NCT000033151	NCT00003315_1_T4	ORGAN	24	25	immune system
NCT000033151	NCT00003315_1_T5	PHENOTYPE	30	32	effects of chemotherapy
NCT000033152	NCT00003315_2_T0	GENE	11	11	sargramostim
NCT000033152	NCT00003315_2_T1	PHENOTYPE	26	27	fungal infection
NCT000033152	NCT00003315_2_T2	COMPOUND	8	9	amphotericin B
NCT000033152	NCT00003315_2_T3	COMPOUND	18	19	amphotericin B
NCT000033153	NCT00003315_3_T0	GENE	4	4	III
NCT000033153	NCT00003315_3_T1	GENE	17	17	sargramostim
NCT000033153	NCT00003315_3_T2	PHENOTYPE	23	24	fungal infection
NCT000033153	NCT00003315_3_T3	COMPOUND	12	13	amphotericin B
NCT000033155	NCT00003315_5_T0	GENE	7	7	GM-CSF
NCT000033155	NCT00003315_5_T1	GENE	6	6	sargramostim
NCT000033155	NCT00003315_5_T2	COMPOUND	23	24	amphotericin B
NCT000033155	NCT00003315_5_T3	PHENOTYPE	13	14	fungal infections
NCT000033157	NCT00003315_7_T0	CELL	11	11	cells
NCT000033157	NCT00003315_7_T1	CELL	8	8	monocyte
NCT000033157	NCT00003315_7_T2	GENE	6	6	GM-CSF
NCT000033159	NCT00003315_9_T0	PHENOTYPE	8	9	fungal infection
NCT0000331510	NCT00003315_10_T0	COMPOUND	7	8	amphotericin B
NCT0000331513	NCT00003315_13_T0	PHENOTYPE	3	3	localized
NCT000033165	NCT00003316_5_T0	PHENOTYPE	2	2	toxicity
NCT000033165	NCT00003316_5_T1	COMPOUND	4	4	gemcitabine
NCT000033166	NCT00003316_6_T0	COMPOUND	3	3	gemcitabine
NCT000033166	NCT00003316_6_T1	GENE	4	4	IV
NCT000033167	NCT00003316_7_T0	PHENOTYPE	10	10	toxicity
NCT000033167	NCT00003316_7_T1	PHENOTYPE	12	13	disease progression
NCT000033172	NCT00003317_2_T0	CELL	9	9	cells
NCT000033172	NCT00003317_2_T1	PHENOTYPE	8	8	tumor
NCT000033173	NCT00003317_3_T0	CELL	8	8	cells
NCT000033173	NCT00003317_3_T1	PHENOTYPE	7	7	tumor
NCT0000331711	NCT00003317_11_T0	PHENOTYPE	7	7	recurrence
NCT0000331713	NCT00003317_13_T0	PHENOTYPE	2	2	toxicities
NCT0000331715	NCT00003317_15_T0	COMPOUND	9	9	paclitaxel
NCT0000331715	NCT00003317_15_T1	GENE	19	19	1.2
NCT0000331715	NCT00003317_15_T2	GENE	10	10	IV
NCT0000331715	NCT00003317_15_T3	GENE	17	17	IV
NCT000033201	NCT00003320_1_T0	PHENOTYPE	7	8	brain metastases
NCT000033201	NCT00003320_1_T1	PHENOTYPE	18	19	brain metastases
NCT000033202	NCT00003320_2_T0	PHENOTYPE	14	15	brain metastases
NCT000033204	NCT00003320_4_T0	PHENOTYPE	6	6	focal
NCT000033204	NCT00003320_4_T1	PHENOTYPE	16	17	cerebral metastases
NCT000033206	NCT00003320_6_T0	PHENOTYPE	3	3	relapse
NCT000033206	NCT00003320_6_T1	PHENOTYPE	17	18	cerebral metastases
NCT000033209	NCT00003320_9_T0	PHENOTYPE	8	9	cerebral metastases
NCT0000332012	NCT00003320_12_T0	GENE	32	32	3.5
NCT000033211	NCT00003321_1_T0	PHENOTYPE	5	5	quality-of-life
NCT000033211	NCT00003321_1_T1	PHENOTYPE	10	13	cancer of the esophagus
NCT000033213	NCT00003321_3_T0	GENE	16	16	3.0
NCT000033213	NCT00003321_3_T1	PHENOTYPE	12	12	quality-of-life
NCT000033213	NCT00003321_3_T2	PHENOTYPE	21	22	esophageal cancer
NCT000033213	NCT00003321_3_T3	PHENOTYPE	29	30	esophageal cancer
NCT000033217	NCT00003321_7_T0	PHENOTYPE	21	21	dysphagia
NCT000033218	NCT00003321_8_T0	PHENOTYPE	20	20	symptoms
NCT000033218	NCT00003321_8_T1	GENE	10	10	3.0
NCT000033218	NCT00003321_8_T2	PHENOTYPE	35	35	perceived
NCT000033218	NCT00003321_8_T3	PHENOTYPE	31	33	quality of life
NCT000033219	NCT00003321_9_T0	PHENOTYPE	19	19	symptoms
NCT000033219	NCT00003321_9_T1	PHENOTYPE	23	23	dysphagia
NCT000033219	NCT00003321_9_T2	PHENOTYPE	7	8	esophageal cancer
NCT000033219	NCT00003321_9_T3	PHENOTYPE	31	32	esophageal cancer
NCT0000332111	NCT00003321_11_T0	PHENOTYPE	10	11	metastatic disease
NCT000033221	NCT00003322_1_T0	CELL	15	15	cells
NCT000033221	NCT00003322_1_T1	PHENOTYPE	14	14	tumor
NCT000033222	NCT00003322_2_T0	PHENOTYPE	27	28	stage III
NCT000033222	NCT00003322_2_T1	PHENOTYPE	29	31	epithelial ovarian cancer
NCT000033223	NCT00003322_3_T0	GENE	3	3	III
NCT000033223	NCT00003322_3_T1	PHENOTYPE	29	30	stage III
NCT000033223	NCT00003322_3_T2	PHENOTYPE	31	33	epithelial ovarian cancer
NCT000033225	NCT00003322_5_T0	COMPOUND	23	23	paclitaxel
NCT000033225	NCT00003322_5_T1	COMPOUND	28	28	paclitaxel
NCT000033225	NCT00003322_5_T2	COMPOUND	35	35	paclitaxel
NCT000033225	NCT00003322_5_T3	GENE	22	22	IV
NCT000033225	NCT00003322_5_T4	GENE	27	27	IV
NCT000033225	NCT00003322_5_T5	COMPOUND	25	25	cisplatin
NCT000033225	NCT00003322_5_T6	COMPOUND	32	32	cisplatin
NCT000033225	NCT00003322_5_T7	PHENOTYPE	11	12	stage III
NCT000033225	NCT00003322_5_T8	PHENOTYPE	17	19	primary peritoneal carcinoma
NCT000033225	NCT00003322_5_T9	PHENOTYPE	13	15	epithelial ovarian cancer
NCT000033227	NCT00003322_7_T0	PHENOTYPE	2	2	toxic
NCT000033227	NCT00003322_7_T1	PHENOTYPE	5	5	complications
NCT000033229	NCT00003322_9_T0	GENE	7	7	BRCA1
NCT000033229	NCT00003322_9_T1	GENE	9	9	BRCA2
NCT0000332211	NCT00003322_11_T0	GENE	13	13	BRCA1
NCT0000332211	NCT00003322_11_T1	GENE	15	15	BRCA2
NCT0000332211	NCT00003322_11_T2	PHENOTYPE	16	17	ovarian cancer
NCT0000332211	NCT00003322_11_T3	PHENOTYPE	19	21	primary peritoneal carcinoma
NCT0000332213	NCT00003322_13_T0	PHENOTYPE	2	4	quality of life
NCT0000332215	NCT00003322_15_T0	PHENOTYPE	6	7	residual disease
NCT0000332222	NCT00003322_22_T0	PHENOTYPE	0	0	Quality-of-life
NCT000033235	NCT00003323_5_T0	COMPOUND	4	4	flutamide
NCT000033235	NCT00003323_5_T1	COMPOUND	2	2	finasteride
NCT000033237	NCT00003323_7_T0	PHENOTYPE	9	9	toxicity
NCT000033237	NCT00003323_7_T1	PHENOTYPE	11	12	disease progression
NCT000033238	NCT00003323_8_T0	PHENOTYPE	0	2	Quality of life
NCT0000332322	NCT00003323_22_T0	COMPOUND	6	6	finasteride
NCT0000332324	NCT00003323_24_T0	PHENOTYPE	5	5	malignancy
NCT0000332328	NCT00003323_28_T0	PHENOTYPE	9	10	adrenal failure
NCT0000332328	NCT00003323_28_T1	GENE	2	3	in excess
NCT0000332339	NCT00003323_39_T0	PHENOTYPE	5	5	recurrence
NCT0000332341	NCT00003323_41_T0	PHENOTYPE	1	2	metastatic disease
NCT0000332343	NCT00003323_43_T0	GENE	2	2	0.2
NCT000033241	NCT00003324_1_T0	PHENOTYPE	12	13	brain metastases
NCT000033242	NCT00003324_2_T0	PHENOTYPE	19	20	brain metastases
NCT000033245	NCT00003324_5_T0	PHENOTYPE	2	2	focal
NCT000033245	NCT00003324_5_T1	COMPOUND	34	34	sensitizer
NCT000033245	NCT00003324_5_T2	PHENOTYPE	5	6	cerebral metastases
NCT000033247	NCT00003324_7_T0	PHENOTYPE	0	2	Quality of life
NCT000033248	NCT00003324_8_T0	PHENOTYPE	16	16	metastases
NCT000033248	NCT00003324_8_T1	PHENOTYPE	7	7	focal
NCT000033248	NCT00003324_8_T2	PHENOTYPE	3	3	relapse
NCT000033248	NCT00003324_8_T3	PHENOTYPE	1	1	suffering
NCT000033253	NCT00003325_3_T0	PHENOTYPE	15	15	tumor
NCT000033253	NCT00003325_3_T1	ORGAN	9	9	dermis
NCT000033253	NCT00003325_3_T2	COMPOUND	5	6	isosulfan blue
NCT000033254	NCT00003325_4_T0	PHENOTYPE	15	15	bilateral
NCT000033254	NCT00003325_4_T1	PHENOTYPE	13	13	unilateral
NCT000033254	NCT00003325_4_T2	PHENOTYPE	6	7	sentinel node
NCT000033254	NCT00003325_4_T3	PHENOTYPE	23	24	primary tumor
NCT000033256	NCT00003325_6_T0	PHENOTYPE	21	21	recurrence
NCT000033261	NCT00003326_1_T0	GENE	2	2	II
NCT000033261	NCT00003326_1_T1	COMPOUND	9	9	paclitaxel
NCT000033261	NCT00003326_1_T2	PHENOTYPE	15	15	recurrent
NCT000033261	NCT00003326_1_T3	PHENOTYPE	18	21	cancer of the esophagus
NCT000033265	NCT00003326_5_T0	COMPOUND	4	4	paclitaxel
NCT000033267	NCT00003326_7_T0	PHENOTYPE	5	7	quality of life
NCT000033269	NCT00003326_9_T0	COMPOUND	3	3	paclitaxel
NCT0000332611	NCT00003326_11_T0	PHENOTYPE	8	8	toxic
NCT0000332611	NCT00003326_11_T1	PHENOTYPE	4	5	disease progression
NCT0000332613	NCT00003326_13_T0	PHENOTYPE	0	2	Quality of life
NCT000033270	NCT00003327_0_T0	PHENOTYPE	5	5	Recurrent
NCT000033270	NCT00003327_0_T1	PHENOTYPE	8	11	Head and Neck Cancer
NCT000033272	NCT00003327_2_T0	GENE	2	2	II
NCT000033272	NCT00003327_2_T1	COMPOUND	9	9	paclitaxel
NCT000033272	NCT00003327_2_T2	PHENOTYPE	14	14	recurrent
NCT000033272	NCT00003327_2_T3	PHENOTYPE	17	20	head and neck cancer
NCT000033274	NCT00003327_4_T0	COMPOUND	6	6	paclitaxel
NCT000033274	NCT00003327_4_T1	PHENOTYPE	13	13	recurrent
NCT000033274	NCT00003327_4_T2	PHENOTYPE	16	19	head and neck cancer
NCT000033276	NCT00003327_6_T0	COMPOUND	4	4	paclitaxel
NCT000033278	NCT00003327_8_T0	PHENOTYPE	5	7	quality of life
NCT0000332710	NCT00003327_10_T0	COMPOUND	3	3	paclitaxel
NCT0000332712	NCT00003327_12_T0	PHENOTYPE	8	8	toxic
NCT0000332712	NCT00003327_12_T1	PHENOTYPE	4	5	disease progression
NCT0000332714	NCT00003327_14_T0	PHENOTYPE	3	5	quality of life
NCT000033280	NCT00003328_0_T0	GENE	9	9	III
NCT000033280	NCT00003328_0_T1	GENE	12	12	IV
NCT000033280	NCT00003328_0_T2	PHENOTYPE	13	16	Head and Neck Cancer
NCT000033282	NCT00003328_2_T0	CELL	10	10	cells
NCT000033282	NCT00003328_2_T1	PHENOTYPE	9	9	tumor
NCT000033283	NCT00003328_3_T0	COMPOUND	10	10	porfiromycin
NCT000033283	NCT00003328_3_T1	PHENOTYPE	22	25	head and neck cancer
NCT000033284	NCT00003328_4_T0	GENE	4	4	III
NCT000033284	NCT00003328_4_T1	GENE	24	24	IV
NCT000033284	NCT00003328_4_T2	COMPOUND	15	15	porfiromycin
NCT000033284	NCT00003328_4_T3	PHENOTYPE	20	21	stage III
NCT000033284	NCT00003328_4_T4	PHENOTYPE	25	28	head and neck cancer
NCT000033286	NCT00003328_6_T0	GENE	12	12	IV
NCT000033286	NCT00003328_6_T1	PHENOTYPE	15	15	metastases
NCT000033286	NCT00003328_6_T2	COMPOUND	22	22	porfiromycin
NCT000033286	NCT00003328_6_T3	PHENOTYPE	9	10	stage III
NCT000033286	NCT00003328_6_T4	PHENOTYPE	4	5	tumor progression
NCT000033286	NCT00003328_6_T5	PHENOTYPE	16	19	head and neck cancer
NCT000033288	NCT00003328_8_T0	PHENOTYPE	6	7	tumor recurrence
NCT0000332812	NCT00003328_12_T0	COMPOUND	6	6	porfiromycin
NCT0000332812	NCT00003328_12_T1	PHENOTYPE	4	4	tolerance
NCT0000332814	NCT00003328_14_T0	ORGAN	12	12	larynx
NCT0000332814	NCT00003328_14_T1	ORGAN	10	10	pharynx
NCT0000332814	NCT00003328_14_T2	GENE	29	29	N3
NCT0000332814	NCT00003328_14_T3	COMPOUND	19	19	N
NCT0000332814	NCT00003328_14_T4	PHENOTYPE	5	6	primary tumor
NCT0000332818	NCT00003328_18_T0	COMPOUND	2	2	porfiromycin
NCT0000332820	NCT00003328_20_T0	GENE	3	3	N3
NCT0000332820	NCT00003328_20_T1	GENE	14	14	cm
NCT0000332820	NCT00003328_20_T2	PHENOTYPE	6	6	metastases
NCT0000332820	NCT00003328_20_T3	PHENOTYPE	4	5	neck disease
NCT0000332820	NCT00003328_20_T4	TISSUE	9	10	lymph node
NCT0000332821	NCT00003328_21_T0	GENE	8	8	N3
NCT0000332821	NCT00003328_21_T1	PHENOTYPE	15	16	residual disease
NCT0000332821	NCT00003328_21_T2	PHENOTYPE	9	10	neck disease
NCT000033290	NCT00003329_0_T0	PHENOTYPE	12	12	Cancer
NCT0000332911	NCT00003329_11_T0	PHENOTYPE	10	11	breast cancer
NCT0000332912	NCT00003329_12_T0	PHENOTYPE	11	12	breast cancer
NCT000033301	NCT00003330_1_T0	CELL	4	4	cells
NCT000033301	NCT00003330_1_T1	CELL	23	23	cells
NCT000033301	NCT00003330_1_T2	PHENOTYPE	3	3	tumor
NCT000033301	NCT00003330_1_T3	PHENOTYPE	11	11	tumor
NCT000033301	NCT00003330_1_T4	CELL	17	19	white blood cells
NCT000033303	NCT00003330_3_T0	PHENOTYPE	2	2	toxicity
NCT000033303	NCT00003330_3_T1	GENE	11	11	interleukin-12
NCT000033303	NCT00003330_3_T2	GENE	12	12	IL-12
NCT000033303	NCT00003330_3_T3	PHENOTYPE	33	33	malignancies
NCT000033303	NCT00003330_3_T4	GENE	8	8	MTD
NCT000033305	NCT00003330_5_T0	PHENOTYPE	16	16	secondary
NCT000033305	NCT00003330_5_T1	GENE	8	8	IL-12
NCT000033307	NCT00003330_7_T0	GENE	5	5	IL-12
NCT000033309	NCT00003330_9_T0	PHENOTYPE	8	8	toxicity
NCT000033309	NCT00003330_9_T1	ORGAN	24	24	liver
NCT000033309	NCT00003330_9_T2	PHENOTYPE	11	11	tumor
NCT000033309	NCT00003330_9_T3	PHENOTYPE	22	22	tumor
NCT000033309	NCT00003330_9_T4	GENE	10	10	MTD
NCT000033309	NCT00003330_9_T5	ORGAN	18	18	serum
NCT0000333011	NCT00003330_11_T0	GENE	6	6	interleukin-12
NCT0000333011	NCT00003330_11_T1	GENE	7	7	IL-12
NCT0000333012	NCT00003330_12_T0	PHENOTYPE	12	13	disease progression
NCT0000333013	NCT00003330_13_T0	GENE	3	3	IL-12
NCT0000333013	NCT00003330_13_T1	GENE	15	15	MTD
NCT0000333014	NCT00003330_14_T0	PHENOTYPE	18	18	toxicity
NCT0000333014	NCT00003330_14_T1	GENE	1	1	MTD
NCT0000333014	NCT00003330_14_T2	GENE	19	19	DLT
NCT0000333015	NCT00003330_15_T0	GENE	10	10	IL-12
NCT0000333016	NCT00003330_16_T0	GENE	6	6	IL-12
NCT0000333016	NCT00003330_16_T1	GENE	9	9	MTD
NCT0000333017	NCT00003330_17_T0	GENE	5	5	IL-12
NCT0000333017	NCT00003330_17_T1	GENE	12	12	MTD
NCT0000333018	NCT00003330_18_T0	GENE	10	10	MTD
NCT0000333019	NCT00003330_19_T0	GENE	1	1	MTD
NCT0000333019	NCT00003330_19_T1	GENE	16	16	DLT
NCT0000333020	NCT00003330_20_T0	GENE	5	5	IL-12
NCT0000333020	NCT00003330_20_T1	PHENOTYPE	10	11	measurable disease
NCT0000333020	NCT00003330_20_T2	PHENOTYPE	14	15	disease progression
NCT000033311	NCT00003331_1_T0	CELL	9	9	cells
NCT000033311	NCT00003331_1_T1	PHENOTYPE	8	8	tumor
NCT000033312	NCT00003331_2_T0	COMPOUND	13	13	leucovorin
NCT000033312	NCT00003331_2_T1	COMPOUND	10	10	topotecan
NCT000033312	NCT00003331_2_T2	PHENOTYPE	19	20	advanced cancer
NCT000033314	NCT00003331_4_T0	GENE	24	24	II
NCT000033314	NCT00003331_4_T1	PHENOTYPE	18	18	malignancy
NCT000033314	NCT00003331_4_T2	GENE	5	5	MTD
NCT000033314	NCT00003331_4_T3	GENE	29	29	MTD
NCT000033314	NCT00003331_4_T4	COMPOUND	9	9	topotecan
NCT000033316	NCT00003331_6_T0	PHENOTYPE	4	4	toxicity
NCT000033318	NCT00003331_8_T0	PHENOTYPE	3	3	pharmacodynamic
NCT0000333110	NCT00003331_10_T0	PHENOTYPE	3	3	tumor
NCT0000333111	NCT00003331_11_T0	COMPOUND	7	7	topotecan
NCT0000333112	NCT00003331_12_T0	COMPOUND	18	18	calcium
NCT0000333112	NCT00003331_12_T1	GENE	22	22	1.5
NCT0000333112	NCT00003331_12_T2	COMPOUND	17	17	leucovorin
NCT0000333112	NCT00003331_12_T3	GENE	15	15	IV
NCT0000333112	NCT00003331_12_T4	GENE	19	19	IV
NCT0000333112	NCT00003331_12_T5	COMPOUND	2	2	topotecan
NCT0000333113	NCT00003331_13_T0	PHENOTYPE	7	7	toxicity
NCT0000333113	NCT00003331_13_T1	PHENOTYPE	9	10	disease progression
NCT0000333114	NCT00003331_14_T0	PHENOTYPE	6	6	toxicity
NCT0000333114	NCT00003331_14_T1	GENE	7	7	DLT
NCT0000333115	NCT00003331_15_T0	GENE	1	1	DLT
NCT000033321	NCT00003332_1_T0	CELL	14	14	cells
NCT000033321	NCT00003332_1_T1	PHENOTYPE	13	13	tumor
NCT000033322	NCT00003332_2_T0	COMPOUND	13	13	gemcitabine
NCT000033322	NCT00003332_2_T1	COMPOUND	15	15	cisplatin
NCT000033322	NCT00003332_2_T2	PHENOTYPE	29	30	pancreatic cancer
NCT000033325	NCT00003332_5_T0	COMPOUND	2	2	gemcitabine
NCT000033325	NCT00003332_5_T1	GENE	3	3	IV
NCT000033326	NCT00003332_6_T0	COMPOUND	1	1	gemcitabine
NCT000033326	NCT00003332_6_T1	COMPOUND	4	4	cisplatin
NCT000033326	NCT00003332_6_T2	GENE	5	5	IV
NCT0000333211	NCT00003332_11_T0	COMPOUND	12	12	gemcitabine
NCT0000333211	NCT00003332_11_T1	COMPOUND	14	14	cisplatin
NCT0000333212	NCT00003332_12_T0	PHENOTYPE	27	27	toxicity
NCT0000333212	NCT00003332_12_T1	GENE	4	4	MTD
NCT0000333213	NCT00003332_13_T0	GENE	3	3	has
NCT0000333213	NCT00003332_13_T1	GENE	2	2	MTD
NCT0000333213	NCT00003332_13_T2	GENE	19	19	MTD
NCT0000333214	NCT00003332_14_T0	PHENOTYPE	12	12	tumor
NCT0000333214	NCT00003332_14_T1	COMPOUND	8	8	gemcitabine
NCT0000333214	NCT00003332_14_T2	COMPOUND	10	10	cisplatin
NCT0000333215	NCT00003332_15_T0	PHENOTYPE	2	2	tumor
NCT0000333215	NCT00003332_15_T1	COMPOUND	23	23	gemcitabine
NCT0000333215	NCT00003332_15_T2	COMPOUND	25	25	cisplatin
NCT0000333217	NCT00003332_17_T0	GENE	26	26	II
NCT000033341	NCT00003334_1_T0	CELL	9	9	cells
NCT000033341	NCT00003334_1_T1	PHENOTYPE	8	8	tumor
NCT000033344	NCT00003334_4_T0	PHENOTYPE	24	24	carcinosarcomas
NCT000033344	NCT00003334_4_T1	COMPOUND	13	13	paclitaxel
NCT000033344	NCT00003334_4_T2	COMPOUND	10	10	HCl
NCT000033344	NCT00003334_4_T3	PHENOTYPE	20	20	cancers
NCT000033344	NCT00003334_4_T4	PHENOTYPE	22	22	sarcomas
NCT000033344	NCT00003334_4_T5	PHENOTYPE	17	18	endometrial cancer
NCT000033344	NCT00003334_4_T6	PHENOTYPE	25	27	mixed mesodermal tumors
NCT000033344	NCT00003334_4_T7	BIOLOGICAL_PROCESS	7	9	response to doxorubicin
NCT000033346	NCT00003334_6_T0	COMPOUND	9	9	HCl
NCT000033346	NCT00003334_6_T1	COMPOUND	12	12	paclitaxel
NCT000033346	NCT00003334_6_T2	COMPOUND	8	8	doxorubicin
NCT000033348	NCT00003334_8_T0	PHENOTYPE	20	20	carcinosarcomas
NCT000033348	NCT00003334_8_T1	PHENOTYPE	10	10	cancers
NCT000033348	NCT00003334_8_T2	PHENOTYPE	18	18	sarcomas
NCT000033348	NCT00003334_8_T3	GENE	0	1	Group 1
NCT000033348	NCT00003334_8_T4	PHENOTYPE	21	23	mixed mesodermal tumors
NCT000033349	NCT00003334_9_T0	COMPOUND	3	3	HCl
NCT000033349	NCT00003334_9_T1	COMPOUND	2	2	doxorubicin
NCT0000333412	NCT00003334_12_T0	PHENOTYPE	7	7	toxic
NCT0000333412	NCT00003334_12_T1	PHENOTYPE	10	11	disease progression
NCT000033351	NCT00003335_1_T0	GENE	3	3	II
NCT000033351	NCT00003335_1_T1	PHENOTYPE	30	31	hematologic cancer
NCT000033351	NCT00003335_1_T2	ORGAN	8	10	umbilical cord blood
NCT000033355	NCT00003335_5_T0	ORGAN	5	7	umbilical cord blood
NCT000033357	NCT00003335_7_T0	COMPOUND	6	6	2
NCT000033357	NCT00003335_7_T1	COMPOUND	2	2	methylprednisolone
NCT000033360	NCT00003336_0_T0	ORGAN	5	5	Transplant
NCT000033362	NCT00003336_2_T0	GENE	3	3	II
NCT000033362	NCT00003336_2_T1	PHENOTYPE	24	24	myelodysplasia
NCT000033362	NCT00003336_2_T2	PHENOTYPE	21	22	malignant thymoma
NCT000033362	NCT00003336_2_T3	PHENOTYPE	18	20	severe aplastic anemia
NCT000033362	NCT00003336_2_T4	ORGAN	9	11	umbilical cord blood
NCT000033365	NCT00003336_5_T0	PHENOTYPE	8	8	conditioning
NCT000033365	NCT00003336_5_T1	ORGAN	18	18	transplant
NCT000033365	NCT00003336_5_T2	ORGAN	15	17	umbilical cord blood
NCT000033367	NCT00003336_7_T0	PHENOTYPE	4	4	conditioning
NCT000033371	NCT00003337_1_T0	GENE	2	2	III
NCT000033371	NCT00003337_1_T1	PHENOTYPE	21	22	Hodgkin's lymphoma
NCT000033373	NCT00003337_3_T0	GENE	11	11	LL2
NCT000033373	NCT00003337_3_T1	CELL	23	23	B-cell
NCT000033373	NCT00003337_3_T2	PHENOTYPE	24	25	Hodgkin's lymphoma
NCT000033373	NCT00003337_3_T3	PHENOTYPE	21	22	high grade
NCT000033373	NCT00003337_3_T4	COMPOUND	8	10	technetium Tc 99m
NCT000033375	NCT00003337_5_T0	GENE	11	11	LL2
NCT000033375	NCT00003337_5_T1	COMPOUND	8	10	technetium Tc 99m
NCT000033379	NCT00003337_9_T0	GENE	7	7	LL2
NCT000033379	NCT00003337_9_T1	COMPOUND	4	6	technetium Tc 99m
NCT0000333711	NCT00003337_11_T0	GENE	11	11	LL2
NCT0000333711	NCT00003337_11_T1	GENE	22	22	LL2
NCT0000333711	NCT00003337_11_T2	COMPOUND	8	10	technetium Tc 99m
NCT0000333711	NCT00003337_11_T3	COMPOUND	19	21	technetium Tc 99m
NCT0000333715	NCT00003337_15_T0	GENE	16	16	LL2
NCT0000333715	NCT00003337_15_T1	GENE	20	20	IV
NCT0000333715	NCT00003337_15_T2	COMPOUND	13	15	technetium Tc 99m
NCT0000333716	NCT00003337_16_T0	GENE	5	5	4-8
NCT0000333716	NCT00003337_16_T1	GENE	24	24	4-8
NCT0000333717	NCT00003337_17_T0	GENE	10	10	LL2
NCT0000333717	NCT00003337_17_T1	COMPOUND	7	9	technetium Tc 99m
NCT0000333721	NCT00003337_21_T0	PHENOTYPE	18	18	lymphoma
NCT0000333721	NCT00003337_21_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000333721	NCT00003337_21_T2	PHENOTYPE	16	17	high grade
NCT000033381	NCT00003338_1_T0	PHENOTYPE	13	14	residual disease
NCT000033381	NCT00003338_1_T1	PHENOTYPE	22	23	Hodgkin's lymphoma
NCT000033383	NCT00003338_3_T0	GENE	11	11	LL2
NCT000033383	NCT00003338_3_T1	CELL	18	18	B-cell
NCT000033383	NCT00003338_3_T2	GENE	5	5	2.3
NCT000033383	NCT00003338_3_T3	PHENOTYPE	19	20	Hodgkin's lymphoma
NCT000033383	NCT00003338_3_T4	COMPOUND	8	10	technetium Tc 99m
NCT000033389	NCT00003338_9_T0	PHENOTYPE	9	10	residual tumor
NCT0000333813	NCT00003338_13_T0	GENE	8	8	LL2
NCT0000333813	NCT00003338_13_T1	GENE	13	13	IV
NCT0000333813	NCT00003338_13_T2	COMPOUND	5	7	technetium Tc 99m
NCT0000333814	NCT00003338_14_T0	GENE	5	5	4-8
NCT0000333814	NCT00003338_14_T1	GENE	24	24	4-8
NCT0000333819	NCT00003338_19_T0	PHENOTYPE	18	18	lymphoma
NCT0000333819	NCT00003338_19_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000333819	NCT00003338_19_T2	PHENOTYPE	16	17	high grade
NCT000033390	NCT00003339_0_T0	PHENOTYPE	15	15	Melanoma
NCT000033390	NCT00003339_0_T1	GENE	11	11	III
NCT000033390	NCT00003339_0_T2	GENE	14	14	IV
NCT000033392	NCT00003339_2_T0	CELL	4	4	cells
NCT000033392	NCT00003339_2_T1	CELL	21	21	cells
NCT000033392	NCT00003339_2_T2	PHENOTYPE	3	3	tumor
NCT000033392	NCT00003339_2_T3	PHENOTYPE	11	11	tumor
NCT000033392	NCT00003339_2_T4	PHENOTYPE	20	20	melanoma
NCT000033392	NCT00003339_2_T5	CELL	15	17	white blood cells
NCT000033393	NCT00003339_3_T0	GENE	3	3	II
NCT000033393	NCT00003339_3_T1	GENE	14	14	interleukin-12
NCT000033393	NCT00003339_3_T2	PHENOTYPE	20	21	stage III
NCT000033393	NCT00003339_3_T3	PHENOTYPE	23	25	stage IV melanoma
NCT000033395	NCT00003339_5_T0	GENE	16	16	interleukin-12
NCT000033395	NCT00003339_5_T1	GENE	6	6	gp100
NCT000033395	NCT00003339_5_T2	PHENOTYPE	29	29	melanoma
NCT000033395	NCT00003339_5_T3	GENE	4	4	tyrosinase
NCT000033395	NCT00003339_5_T4	GENE	28	28	IV
NCT000033395	NCT00003339_5_T5	PHENOTYPE	25	26	stage III
NCT0000333910	NCT00003339_10_T0	GENE	4	4	2.4
NCT000033401	NCT00003340_1_T0	CELL	9	9	cells
NCT000033401	NCT00003340_1_T1	PHENOTYPE	8	8	tumor
NCT000033402	NCT00003340_2_T0	GENE	2	2	II
NCT000033402	NCT00003340_2_T1	COMPOUND	9	9	cyclophosphamide
NCT000033402	NCT00003340_2_T2	COMPOUND	11	11	topotecan
NCT000033402	NCT00003340_2_T3	PHENOTYPE	20	22	acute myelogenous leukemia
NCT000033404	NCT00003340_4_T0	COMPOUND	4	4	cyclophosphamide
NCT000033404	NCT00003340_4_T1	COMPOUND	7	7	topotecan
NCT000033404	NCT00003340_4_T2	PHENOTYPE	14	16	acute myelogenous leukemia
NCT000033407	NCT00003340_7_T0	COMPOUND	3	3	cyclophosphamide
NCT000033407	NCT00003340_7_T1	COMPOUND	26	26	cyclophosphamide
NCT000033407	NCT00003340_7_T2	COMPOUND	13	13	topotecan
NCT000033410	NCT00003341_0_T0	PHENOTYPE	4	4	Anemia
NCT000033410	NCT00003341_0_T1	PHENOTYPE	16	16	Anemia
NCT000033410	NCT00003341_0_T2	PHENOTYPE	8	8	Lymphoma
NCT000033410	NCT00003341_0_T3	PHENOTYPE	13	14	Multiple Myeloma
NCT000033410	NCT00003341_0_T4	PHENOTYPE	9	11	Chronic Lymphocytic Leukemia
NCT000033412	NCT00003341_2_T0	GENE	5	5	epoetin
NCT000033413	NCT00003341_3_T0	PHENOTYPE	18	18	lymphoma
NCT000033413	NCT00003341_3_T1	GENE	3	3	III
NCT000033413	NCT00003341_3_T2	PHENOTYPE	14	14	anemia
NCT000033413	NCT00003341_3_T3	GENE	10	10	epoetin
NCT000033413	NCT00003341_3_T4	PHENOTYPE	23	24	multiple myeloma
NCT000033413	NCT00003341_3_T5	PHENOTYPE	19	21	chronic lymphocytic leukemia
NCT000033416	NCT00003341_6_T0	PHENOTYPE	4	4	anemia
NCT000033419	NCT00003341_9_T0	GENE	9	9	epoetin
NCT000033419	NCT00003341_9_T1	GENE	6	6	9.0
NCT000033419	NCT00003341_9_T2	PHENOTYPE	2	3	hemoglobin levels
NCT0000334110	NCT00003341_10_T0	GENE	13	13	3.4
NCT0000334110	NCT00003341_10_T1	GENE	7	7	9.0
NCT0000334110	NCT00003341_10_T2	PHENOTYPE	2	3	hemoglobin levels
NCT0000334110	NCT00003341_10_T3	PHENOTYPE	17	18	hemoglobin levels
NCT0000334111	NCT00003341_11_T0	GENE	2	2	epoetin
NCT0000334116	NCT00003341_16_T0	PHENOTYPE	18	18	lymphoma
NCT0000334116	NCT00003341_16_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000334116	NCT00003341_16_T2	PHENOTYPE	16	17	high grade
NCT000033421	NCT00003342_1_T0	CELL	9	9	cells
NCT000033421	NCT00003342_1_T1	PHENOTYPE	8	8	tumor
NCT000033422	NCT00003342_2_T0	COMPOUND	15	15	paclitaxel
NCT000033422	NCT00003342_2_T1	ORGAN	30	30	kidney
NCT000033422	NCT00003342_2_T2	ORGAN	24	24	bladder
NCT000033422	NCT00003342_2_T3	COMPOUND	12	12	gemcitabine
NCT000033422	NCT00003342_2_T4	COMPOUND	13	13	doxorubicin
NCT000033422	NCT00003342_2_T5	PHENOTYPE	26	27	kidney cancer
NCT000033425	NCT00003342_5_T0	COMPOUND	2	2	gemcitabine
NCT000033425	NCT00003342_5_T1	COMPOUND	8	8	doxorubicin
NCT000033425	NCT00003342_5_T2	GENE	3	3	IV
NCT000033425	NCT00003342_5_T3	GENE	9	9	IV
NCT000033426	NCT00003342_6_T0	GENE	1	1	G-CSF
NCT000033427	NCT00003342_7_T0	COMPOUND	5	5	paclitaxel
NCT000033427	NCT00003342_7_T1	GENE	8	8	IV
NCT000033429	NCT00003342_9_T0	PHENOTYPE	6	6	toxicity
NCT000033429	NCT00003342_9_T1	PHENOTYPE	3	3	experiences
NCT000033429	NCT00003342_9_T2	GENE	7	7	DLT
NCT0000334210	NCT00003342_10_T0	GENE	13	13	has
NCT0000334210	NCT00003342_10_T1	GENE	4	4	DLT
NCT0000334310	NCT00003343_10_T0	PHENOTYPE	3	3	pharmacokinetics
NCT0000334312	NCT00003343_12_T0	GENE	3	4	matrix metalloprotease
NCT0000334312	NCT00003343_12_T1	MOLECULAR_FUNCTION	4	5	metalloprotease inhibitor
NCT0000334313	NCT00003343_13_T0	COMPOUND	2	2	mitoxantrone
NCT0000334313	NCT00003343_13_T1	COMPOUND	10	10	prednisone
NCT0000334314	NCT00003343_14_T0	PHENOTYPE	12	12	toxicity
NCT0000334315	NCT00003343_15_T0	COMPOUND	2	2	prednisone
NCT0000334316	NCT00003343_16_T0	PHENOTYPE	14	14	centers
NCT000033442	NCT00003344_2_T0	CELL	10	10	cells
NCT000033442	NCT00003344_2_T1	PHENOTYPE	9	9	tumor
NCT000033443	NCT00003344_3_T0	CELL	9	9	cells
NCT000033443	NCT00003344_3_T1	PHENOTYPE	8	8	tumor
NCT000033444	NCT00003344_4_T0	COMPOUND	12	12	irinotecan
NCT000033444	NCT00003344_4_T1	PHENOTYPE	21	21	recurrent
NCT000033444	NCT00003344_4_T2	PHENOTYPE	17	18	colon cancer
NCT000033446	NCT00003344_6_T0	PHENOTYPE	17	17	toxicity
NCT000033446	NCT00003344_6_T1	COMPOUND	8	8	irinotecan
NCT000033446	NCT00003344_6_T2	GENE	5	5	MTD
NCT000033448	NCT00003344_8_T0	GENE	14	14	MTD
NCT000033449	NCT00003344_9_T0	COMPOUND	3	3	irinotecan
NCT000033449	NCT00003344_9_T1	GENE	4	4	IV
NCT0000334411	NCT00003344_11_T0	GENE	12	12	has
NCT0000334411	NCT00003344_11_T1	GENE	11	11	MTD
NCT0000334412	NCT00003344_12_T0	PHENOTYPE	15	15	toxicity
NCT0000334412	NCT00003344_12_T1	GENE	1	1	MTD
NCT0000334413	NCT00003344_13_T0	COMPOUND	9	9	irinotecan
NCT0000334413	NCT00003344_13_T1	GENE	3	3	has
NCT0000334413	NCT00003344_13_T2	GENE	2	2	MTD
NCT0000334413	NCT00003344_13_T3	GENE	16	16	MTD
NCT0000334416	NCT00003344_16_T0	GENE	9	9	II
NCT000033451	NCT00003345_1_T0	CELL	9	9	cells
NCT000033451	NCT00003345_1_T1	PHENOTYPE	8	8	tumor
NCT000033456	NCT00003345_6_T0	PHENOTYPE	2	2	toxicity
NCT000033458	NCT00003345_8_T0	PHENOTYPE	2	4	quality of life
NCT000033459	NCT00003345_9_T0	COMPOUND	10	10	irinotecan
NCT000033459	NCT00003345_9_T1	COMPOUND	3	3	cisplatin
NCT000033459	NCT00003345_9_T2	GENE	4	4	IV
NCT000033459	NCT00003345_9_T3	GENE	11	11	IV
NCT0000334511	NCT00003345_11_T0	PHENOTYPE	18	18	toxicity
NCT0000334511	NCT00003345_11_T1	PHENOTYPE	14	15	disease progression
NCT0000334513	NCT00003345_13_T0	PHENOTYPE	0	2	Quality of life
NCT000033460	NCT00003346_0_T0	PHENOTYPE	11	11	Melanoma
NCT000033460	NCT00003346_0_T1	GENE	7	7	III
NCT000033460	NCT00003346_0_T2	GENE	10	10	IV
NCT000033462	NCT00003346_2_T0	CELL	9	9	cells
NCT000033462	NCT00003346_2_T1	PHENOTYPE	8	8	tumor
NCT000033463	NCT00003346_3_T0	PHENOTYPE	21	22	stage III
NCT000033463	NCT00003346_3_T1	PHENOTYPE	24	26	stage IV melanoma
NCT000033467	NCT00003346_7_T0	GENE	11	11	IV
NCT000033468	NCT00003346_8_T0	PHENOTYPE	13	13	toxicity
NCT000033468	NCT00003346_8_T1	PHENOTYPE	9	10	disease progression
NCT000033469	NCT00003346_9_T0	COMPOUND	16	16	OBD
NCT0000334610	NCT00003346_10_T0	COMPOUND	1	1	OBD
NCT0000334610	NCT00003346_10_T1	GENE	15	15	MTD
NCT0000334611	NCT00003346_11_T0	PHENOTYPE	18	18	toxicity
NCT0000334611	NCT00003346_11_T1	GENE	1	1	MTD
NCT0000334611	NCT00003346_11_T2	GENE	19	19	DLT
NCT0000334612	NCT00003346_12_T0	COMPOUND	2	2	OBD
NCT0000334613	NCT00003346_13_T0	GENE	1	1	MTD
NCT0000334615	NCT00003346_15_T0	COMPOUND	2	2	OBD
NCT0000334615	NCT00003346_15_T1	GENE	6	6	MTD
NCT0000334617	NCT00003346_17_T0	GENE	10	10	IV
NCT0000334617	NCT00003346_17_T1	GENE	15	15	IV
NCT0000334617	NCT00003346_17_T2	GENE	18	18	IV
NCT0000334618	NCT00003346_18_T0	PHENOTYPE	11	11	toxicity
NCT0000334618	NCT00003346_18_T1	PHENOTYPE	7	8	disease progression
NCT000033481	NCT00003348_1_T0	CELL	9	9	cells
NCT000033481	NCT00003348_1_T1	PHENOTYPE	8	8	tumor
NCT000033482	NCT00003348_2_T0	COMPOUND	11	11	O(6)-benzylguanine
NCT000033482	NCT00003348_2_T1	PHENOTYPE	19	19	progressive
NCT000033482	NCT00003348_2_T2	PHENOTYPE	20	20	gliomas
NCT000033482	NCT00003348_2_T3	PHENOTYPE	17	17	recurrent
NCT000033484	NCT00003348_4_T0	PHENOTYPE	17	17	progressive
NCT000033484	NCT00003348_4_T1	PHENOTYPE	20	20	gliomas
NCT000033484	NCT00003348_4_T2	PHENOTYPE	14	14	recurrent
NCT000033486	NCT00003348_6_T0	PHENOTYPE	2	2	toxic
NCT000033489	NCT00003348_9_T0	COMPOUND	7	7	nitrosourea
NCT0000334811	NCT00003348_11_T0	PHENOTYPE	15	15	toxicity
NCT0000334811	NCT00003348_11_T1	GENE	16	16	DLT
NCT0000334812	NCT00003348_12_T0	PHENOTYPE	18	18	experiences
NCT0000334812	NCT00003348_12_T1	GENE	19	19	DLT
NCT0000334813	NCT00003348_13_T0	PHENOTYPE	14	14	toxicity
NCT0000334813	NCT00003348_13_T1	PHENOTYPE	10	11	disease progression
NCT000033501	NCT00003350_1_T0	CELL	10	10	cells
NCT000033501	NCT00003350_1_T1	PHENOTYPE	9	9	tumor
NCT000033503	NCT00003350_3_T0	COMPOUND	7	7	paclitaxel
NCT000033503	NCT00003350_3_T1	COMPOUND	12	12	doxorubicin
NCT000033503	NCT00003350_3_T2	PHENOTYPE	21	23	quality of life
NCT000033505	NCT00003350_5_T0	PHENOTYPE	3	3	toxicity
NCT000033505	NCT00003350_5_T1	COMPOUND	7	7	paclitaxel
NCT000033505	NCT00003350_5_T2	COMPOUND	10	10	doxorubicin
NCT000033507	NCT00003350_7_T0	COMPOUND	10	10	paclitaxel
NCT000033507	NCT00003350_7_T1	COMPOUND	13	13	doxorubicin
NCT000033509	NCT00003350_9_T0	COMPOUND	6	6	paclitaxel
NCT000033509	NCT00003350_9_T1	GENE	29	29	CD4
NCT000033509	NCT00003350_9_T2	PHENOTYPE	34	34	HIV
NCT000033509	NCT00003350_9_T3	GENE	31	31	CD8
NCT000033509	NCT00003350_9_T4	COMPOUND	13	13	doxorubicin
NCT000033509	NCT00003350_9_T5	CELL	32	33	lymphocyte subsets
NCT000033509	NCT00003350_9_T6	PHENOTYPE	43	44	opportunistic infections
NCT000033509	NCT00003350_9_T7	PHENOTYPE	19	20	HIV infection
NCT0000335013	NCT00003350_13_T0	GENE	12	12	KS
NCT0000335013	NCT00003350_13_T1	GENE	26	26	KS
NCT0000335024	NCT00003350_24_T0	PHENOTYPE	0	2	Quality of life
NCT000033511	NCT00003351_1_T0	GENE	3	3	II
NCT000033511	NCT00003351_1_T1	COMPOUND	13	13	irinotecan
NCT000033511	NCT00003351_1_T2	PHENOTYPE	20	22	metastatic breast cancer
NCT000033513	NCT00003351_3_T0	PHENOTYPE	5	5	toxicity
NCT000033513	NCT00003351_3_T1	COMPOUND	11	11	irinotecan
NCT000033513	NCT00003351_3_T2	PHENOTYPE	37	38	metastatic disease
NCT000033513	NCT00003351_3_T3	PHENOTYPE	19	21	metastatic breast cancer
NCT000033515	NCT00003351_5_T0	COMPOUND	19	19	irinotecan
NCT000033515	NCT00003351_5_T1	PHENOTYPE	4	4	progression
NCT000033515	NCT00003351_5_T2	PHENOTYPE	7	9	quality of life
NCT000033517	NCT00003351_7_T0	COMPOUND	14	14	2
NCT000033519	NCT00003351_9_T0	PHENOTYPE	14	14	toxicity
NCT000033519	NCT00003351_9_T1	PHENOTYPE	10	11	disease progression
NCT0000335111	NCT00003351_11_T0	PHENOTYPE	14	14	toxicity
NCT0000335111	NCT00003351_11_T1	PHENOTYPE	10	11	disease progression
NCT0000335112	NCT00003351_12_T0	PHENOTYPE	0	2	Quality of life
NCT000033521	NCT00003352_1_T0	CELL	9	9	cells
NCT000033521	NCT00003352_1_T1	PHENOTYPE	8	8	tumor
NCT000033522	NCT00003352_2_T0	GENE	2	2	II
NCT000033522	NCT00003352_2_T1	COMPOUND	16	16	docetaxel
NCT000033522	NCT00003352_2_T2	COMPOUND	14	14	cyclophosphamide
NCT000033522	NCT00003352_2_T3	COMPOUND	13	13	doxorubicin
NCT000033522	NCT00003352_2_T4	PHENOTYPE	24	27	stage IV breast cancer
NCT000033526	NCT00003352_6_T0	PHENOTYPE	8	8	progression
NCT0000335211	NCT00003352_11_T0	COMPOUND	14	14	cyclophosphamide
NCT0000335211	NCT00003352_11_T1	COMPOUND	4	4	doxorubicin
NCT0000335212	NCT00003352_12_T0	COMPOUND	10	10	docetaxel
NCT0000335212	NCT00003352_12_T1	COMPOUND	7	7	doxorubicin
NCT0000335213	NCT00003352_13_T0	PHENOTYPE	11	11	toxic
NCT0000335213	NCT00003352_13_T1	PHENOTYPE	7	8	disease progression
NCT0000335214	NCT00003352_14_T0	COMPOUND	11	11	docetaxel
NCT0000335214	NCT00003352_14_T1	COMPOUND	13	13	cyclophosphamide
NCT0000335214	NCT00003352_14_T2	COMPOUND	5	5	doxorubicin
NCT0000335215	NCT00003352_15_T0	PHENOTYPE	4	5	breast cancer
NCT0000335219	NCT00003352_19_T0	PHENOTYPE	1	2	measurable disease
NCT0000335220	NCT00003352_20_T0	PHENOTYPE	6	6	metastases
NCT0000335220	NCT00003352_20_T1	ORGAN	2	4	central nervous system
NCT0000335222	NCT00003352_22_T0	PHENOTYPE	1	2	carcinomatous meningitis
NCT0000335223	NCT00003352_23_T0	PHENOTYPE	9	10	metastatic disease
NCT0000335223	NCT00003352_23_T1	PHENOTYPE	2	3	lung metastases
NCT0000335224	NCT00003352_24_T0	COMPOUND	4	4	estrogen
NCT0000335224	NCT00003352_24_T1	GENE	1	1	receptor
NCT0000335224	NCT00003352_24_T2	GENE	6	7	progesterone receptor
NCT0000335225	NCT00003352_25_T0	GENE	2	2	Age
NCT0000335227	NCT00003352_27_T0	PHENOTYPE	0	0	Menopausal
NCT0000335228	NCT00003352_28_T0	GENE	9	9	0.2
NCT0000335228	NCT00003352_28_T1	PHENOTYPE	4	4	Oncology
NCT0000335230	NCT00003352_30_T0	CELL	2	2	neutrophil
NCT0000335231	NCT00003352_31_T0	PHENOTYPE	0	1	Platelet count
NCT0000335233	NCT00003352_33_T0	GENE	1	1	phosphatase
NCT0000335236	NCT00003352_36_T0	GENE	5	5	1.2
NCT0000335237	NCT00003352_37_T0	GENE	4	4	1.5
NCT0000335238	NCT00003352_38_T0	COMPOUND	17	17	MUGA
NCT0000335238	NCT00003352_38_T1	GENE	1	1	ventricular
NCT0000335239	NCT00003352_39_T0	PHENOTYPE	1	2	myocardial infarction
NCT0000335241	NCT00003352_41_T0	PHENOTYPE	3	5	congestive heart failure
NCT0000335242	NCT00003352_42_T0	PHENOTYPE	2	2	arrhythmias
NCT0000335243	NCT00003352_43_T0	PHENOTYPE	10	10	hypertension
NCT0000335243	NCT00003352_43_T1	GENE	16	16	Hg
NCT0000335243	NCT00003352_43_T2	PHENOTYPE	1	2	vascular disease
NCT0000335244	NCT00003352_44_T0	PHENOTYPE	0	0	Other
NCT0000335246	NCT00003352_46_T0	PHENOTYPE	3	5	fasting blood sugar
NCT0000335247	NCT00003352_47_T0	PHENOTYPE	5	6	grade 1
NCT0000335247	NCT00003352_47_T1	PHENOTYPE	1	2	peripheral neuropathy
NCT0000335248	NCT00003352_48_T0	PHENOTYPE	4	4	disorders
NCT0000335248	NCT00003352_48_T1	PHENOTYPE	1	1	psychosis
NCT0000335250	NCT00003352_50_T0	PHENOTYPE	12	13	breast cancer
NCT0000335250	NCT00003352_50_T1	PHENOTYPE	8	10	metastatic breast cancer
NCT0000335251	NCT00003352_51_T0	PHENOTYPE	15	16	metastatic disease
NCT0000335251	NCT00003352_51_T1	PHENOTYPE	10	11	primary tumor
NCT0000335252	NCT00003352_52_T0	COMPOUND	10	10	doxorubicin
NCT0000335253	NCT00003352_53_T0	PHENOTYPE	0	0	Endocrine
NCT0000335253	NCT00003352_53_T1	GENE	8	8	hormone
NCT0000335253	NCT00003352_53_T2	GENE	10	10	hormone
NCT0000335253	NCT00003352_53_T3	PHENOTYPE	20	21	rapidly progressive
NCT0000335253	NCT00003352_53_T4	PHENOTYPE	21	22	progressive disease
NCT0000335253	NCT00003352_53_T5	PHENOTYPE	13	14	metastatic disease
NCT0000335257	NCT00003352_57_T0	ORGAN	7	8	bone marrow
NCT0000335258	NCT00003352_58_T0	ORGAN	3	4	chest wall
NCT000033530	NCT00003353_0_T0	CELL	3	5	Peripheral Stem Cell
NCT000033530	NCT00003353_0_T1	PHENOTYPE	11	13	Primary Systemic Amyloidosis
NCT000033536	NCT00003353_6_T0	PHENOTYPE	2	2	toxicity
NCT000033536	NCT00003353_6_T1	COMPOUND	6	6	melphalan
NCT0000335310	NCT00003353_10_T0	COMPOUND	12	12	1
NCT0000335310	NCT00003353_10_T1	COMPOUND	8	8	melphalan
NCT0000335310	NCT00003353_10_T2	GENE	9	9	IV
NCT0000335312	NCT00003353_12_T0	GENE	2	2	G-CSF
NCT000033541	NCT00003354_1_T0	PHENOTYPE	16	17	colorectal cancer
NCT000033542	NCT00003354_2_T0	GENE	4	4	III
NCT000033542	NCT00003354_2_T1	PHENOTYPE	24	25	colorectal cancer
NCT000033561	NCT00003356_1_T0	CELL	11	11	cells
NCT000033561	NCT00003356_1_T1	GENE	0	0	Interleukin-2
NCT000033561	NCT00003356_1_T2	CELL	5	7	white blood cells
NCT000033566	NCT00003356_6_T0	GENE	6	6	IL-2
NCT0000335611	NCT00003356_11_T0	GENE	3	3	interleukin-2
NCT0000335611	NCT00003356_11_T1	GENE	4	4	IL-2
NCT0000335611	NCT00003356_11_T2	GENE	8	8	1.5
NCT0000335611	NCT00003356_11_T3	GENE	11	11	IV
NCT0000335612	NCT00003356_12_T0	PHENOTYPE	16	16	toxicity
NCT0000335612	NCT00003356_12_T1	PHENOTYPE	12	13	disease progression
NCT0000335616	NCT00003356_16_T0	PHENOTYPE	18	18	lymphoma
NCT0000335616	NCT00003356_16_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000335616	NCT00003356_16_T2	PHENOTYPE	16	17	high grade
NCT000033571	NCT00003357_1_T0	PHENOTYPE	17	18	breast cancer
NCT000033573	NCT00003357_3_T0	GENE	16	16	GM2
NCT000033573	NCT00003357_3_T1	GENE	20	20	GM2
NCT000033573	NCT00003357_3_T2	PHENOTYPE	29	29	recurrence
NCT000033573	NCT00003357_3_T3	CELL	18	18	cells
NCT000033573	NCT00003357_3_T4	PHENOTYPE	31	32	breast cancer
NCT000033573	NCT00003357_3_T5	PHENOTYPE	13	14	antibody response
NCT000033581	NCT00003358_1_T0	CELL	9	9	cells
NCT000033581	NCT00003358_1_T1	PHENOTYPE	8	8	tumor
NCT000033588	NCT00003358_8_T0	PHENOTYPE	2	2	pharmacokinetics
NCT000033588	NCT00003358_8_T1	COMPOUND	5	5	gemcitabine
NCT000033588	NCT00003358_8_T2	COMPOUND	9	9	cisplatin
NCT000033589	NCT00003358_9_T0	COMPOUND	8	8	gemcitabine
NCT0000335810	NCT00003358_10_T0	COMPOUND	9	9	gemcitabine
NCT0000335810	NCT00003358_10_T1	COMPOUND	3	3	cisplatin
NCT0000335814	NCT00003358_14_T0	COMPOUND	3	3	gemcitabine
NCT0000335814	NCT00003358_14_T1	GENE	15	15	MTD
NCT0000335815	NCT00003358_15_T0	PHENOTYPE	19	19	toxicity
NCT0000335815	NCT00003358_15_T1	GENE	1	1	MTD
NCT0000335815	NCT00003358_15_T2	GENE	20	20	DLT
NCT000033591	NCT00003359_1_T0	COMPOUND	10	10	sodium
NCT000033591	NCT00003359_1_T1	PHENOTYPE	16	17	refractory cancer
NCT000033595	NCT00003359_5_T0	PHENOTYPE	6	6	toxicity
NCT000033595	NCT00003359_5_T1	COMPOUND	9	9	sodium
NCT000033599	NCT00003359_9_T0	COMPOUND	14	14	sodium
NCT0000335911	NCT00003359_11_T0	COMPOUND	3	3	sodium
NCT0000335911	NCT00003359_11_T1	GENE	5	5	IV
NCT0000335912	NCT00003359_12_T0	PHENOTYPE	24	24	toxicity
NCT0000335912	NCT00003359_12_T1	GENE	25	25	DLT
NCT0000335912	NCT00003359_12_T2	PHENOTYPE	19	20	disease progression
NCT0000335913	NCT00003359_13_T0	GENE	14	14	DLT
NCT0000335914	NCT00003359_14_T0	GENE	16	16	DLT
NCT000033601	NCT00003360_1_T0	PHENOTYPE	17	18	colorectal cancer
NCT000033603	NCT00003360_3_T0	PHENOTYPE	2	2	toxicity
NCT000033603	NCT00003360_3_T1	GENE	16	16	A33
NCT000033603	NCT00003360_3_T2	GENE	18	18	A33
NCT000033603	NCT00003360_3_T3	COMPOUND	10	10	iodine
NCT000033603	NCT00003360_3_T4	PHENOTYPE	23	24	colorectal cancer
NCT000033605	NCT00003360_5_T0	GENE	6	6	A33
NCT000033605	NCT00003360_5_T1	PHENOTYPE	1	1	pharmacokinetics
NCT000033607	NCT00003360_7_T0	GENE	14	14	A33
NCT000033607	NCT00003360_7_T1	PHENOTYPE	9	9	pharmacokinetics
NCT000033607	NCT00003360_7_T2	PHENOTYPE	6	7	antibody response
NCT0000336010	NCT00003360_10_T0	GENE	9	9	A33
NCT0000336010	NCT00003360_10_T1	GENE	11	11	A33
NCT0000336010	NCT00003360_10_T2	COMPOUND	3	3	iodine
NCT0000336010	NCT00003360_10_T3	GENE	13	13	IV
NCT0000336012	NCT00003360_12_T0	PHENOTYPE	8	8	toxicity
NCT0000336012	NCT00003360_12_T1	PHENOTYPE	4	5	disease progression
NCT0000336013	NCT00003360_13_T0	GENE	9	9	A33
NCT0000336013	NCT00003360_13_T1	GENE	16	16	MTD
NCT0000336014	NCT00003360_14_T0	PHENOTYPE	20	20	toxicity
NCT0000336014	NCT00003360_14_T1	GENE	1	1	MTD
NCT000033613	NCT00003361_3_T0	COMPOUND	13	13	decitabine
NCT000033613	NCT00003361_3_T1	PHENOTYPE	6	7	myelodysplastic syndromes
NCT000033613	NCT00003361_3_T2	PHENOTYPE	9	11	chronic myelomonocytic leukemia
NCT000033616	NCT00003361_6_T0	GENE	13	13	1.3
NCT000033616	NCT00003361_6_T1	COMPOUND	2	2	decitabine
NCT000033621	NCT00003362_1_T0	PHENOTYPE	21	21	melanoma
NCT000033621	NCT00003362_1_T1	GENE	8	8	GM-CSF
NCT000033622	NCT00003362_2_T0	GENE	3	3	II
NCT000033622	NCT00003362_2_T1	GENE	10	10	gp
NCT000033622	NCT00003362_2_T2	GENE	20	20	GM-CSF
NCT000033622	NCT00003362_2_T3	PHENOTYPE	30	31	stage III
NCT000033622	NCT00003362_2_T4	PHENOTYPE	33	35	stage IV melanoma
NCT000033624	NCT00003362_4_T0	PHENOTYPE	20	20	melanoma
NCT000033624	NCT00003362_4_T1	GENE	9	9	GM-CSF
NCT000033624	NCT00003362_4_T2	GENE	8	8	sargramostim
NCT000033626	NCT00003362_6_T0	PHENOTYPE	2	2	toxicity
NCT000033626	NCT00003362_6_T1	PHENOTYPE	6	6	melanoma
NCT000033628	NCT00003362_8_T0	PHENOTYPE	7	7	melanoma
NCT0000336212	NCT00003362_12_T0	COMPOUND	9	9	1_10
NCT0000336212	NCT00003362_12_T1	GENE	3	3	GM-CSF
NCT000033642	NCT00003364_2_T0	CELL	10	10	cells
NCT000033642	NCT00003364_2_T1	PHENOTYPE	9	9	tumor
NCT000033643	NCT00003364_3_T0	CELL	12	12	cells
NCT000033643	NCT00003364_3_T1	PHENOTYPE	11	11	tumor
NCT0000336412	NCT00003364_12_T0	COMPOUND	6	6	vincristine
NCT0000336412	NCT00003364_12_T1	COMPOUND	3	3	cyclophosphamide
NCT0000336412	NCT00003364_12_T2	COMPOUND	16	16	etoposide
NCT0000336412	NCT00003364_12_T3	COMPOUND	4	4	doxorubicin
NCT0000336412	NCT00003364_12_T4	COMPOUND	23	23	cisplatin
NCT0000336412	NCT00003364_12_T5	GENE	8	8	IV
NCT0000336412	NCT00003364_12_T6	GENE	17	17	IV
NCT0000336412	NCT00003364_12_T7	GENE	24	24	IV
NCT0000336416	NCT00003364_16_T0	PHENOTYPE	4	5	disease progression
NCT000033652	NCT00003365_2_T0	COMPOUND	3	3	sulindac
NCT000033652	NCT00003365_2_T1	PHENOTYPE	11	12	colon cancer
NCT000033653	NCT00003365_3_T0	BIOLOGICAL_PROCESS	0	0	Eating
NCT000033655	NCT00003365_5_T0	COMPOUND	9	9	sulindac
NCT000033655	NCT00003365_5_T1	COMPOUND	13	13	quercetin
NCT000033655	NCT00003365_5_T2	COMPOUND	11	11	rutin
NCT000033655	NCT00003365_5_T3	COMPOUND	10	10	curcumin
NCT000033655	NCT00003365_5_T4	PHENOTYPE	16	17	colon cancer
NCT0000336510	NCT00003365_10_T0	COMPOUND	10	10	quercetin
NCT0000336510	NCT00003365_10_T1	COMPOUND	9	9	rutin
NCT0000336510	NCT00003365_10_T2	COMPOUND	12	12	curcumin
NCT000033678	NCT00003367_8_T0	PHENOTYPE	8	10	quality of life
NCT0000336712	NCT00003367_12_T0	ORGAN	13	13	serum
NCT0000336712	NCT00003367_12_T1	PHENOTYPE	8	8	obesity
NCT0000336712	NCT00003367_12_T2	PHENOTYPE	9	11	high blood pressure
NCT0000336715	NCT00003367_15_T0	PHENOTYPE	3	5	quality of life
NCT000033681	NCT00003368_1_T0	ORGAN	11	11	kidney
NCT000033681	NCT00003368_1_T1	ORGAN	9	9	liver
NCT000033682	NCT00003368_2_T0	COMPOUND	9	9	irinotecan
NCT000033682	NCT00003368_2_T1	ORGAN	21	21	liver
NCT000033682	NCT00003368_2_T2	PHENOTYPE	17	17	lymphoma
NCT000033682	NCT00003368_2_T3	ORGAN	34	34	pelvis
NCT000033682	NCT00003368_2_T4	GENE	28	28	had
NCT000033682	NCT00003368_2_T5	ORGAN	23	23	kidney
NCT000033682	NCT00003368_2_T6	PHENOTYPE	14	15	solid tumors
NCT000033684	NCT00003368_4_T0	COMPOUND	6	6	irinotecan
NCT000033684	NCT00003368_4_T1	ORGAN	16	16	liver
NCT000033684	NCT00003368_4_T2	PHENOTYPE	13	13	lymphoma
NCT000033684	NCT00003368_4_T3	GENE	22	22	had
NCT000033684	NCT00003368_4_T4	PHENOTYPE	19	19	dysfunction
NCT000033684	NCT00003368_4_T5	PHENOTYPE	10	11	solid tumors
NCT000033686	NCT00003368_6_T0	COMPOUND	4	4	irinotecan
NCT000033686	NCT00003368_6_T1	PHENOTYPE	2	2	pharmacokinetics
NCT000033689	NCT00003368_9_T0	COMPOUND	14	14	creatinine
NCT000033689	NCT00003368_9_T1	GENE	11	11	AST
NCT000033689	NCT00003368_9_T2	COMPOUND	12	12	bilirubin
NCT0000336810	NCT00003368_10_T0	COMPOUND	2	2	irinotecan
NCT0000336810	NCT00003368_10_T1	GENE	3	3	IV
NCT0000336811	NCT00003368_11_T0	PHENOTYPE	15	15	toxicity
NCT0000336811	NCT00003368_11_T1	PHENOTYPE	11	12	disease progression
NCT0000336812	NCT00003368_12_T0	COMPOUND	10	10	irinotecan
NCT0000336813	NCT00003368_13_T0	GENE	11	11	MTD
NCT0000336814	NCT00003368_14_T0	PHENOTYPE	17	17	toxicity
NCT0000336814	NCT00003368_14_T1	GENE	1	1	MTD
NCT000033691	NCT00003369_1_T0	CELL	9	9	cells
NCT000033691	NCT00003369_1_T1	PHENOTYPE	8	8	tumor
NCT000033692	NCT00003369_2_T0	GENE	2	2	II
NCT000033692	NCT00003369_2_T1	COMPOUND	13	13	tirapazamine
NCT000033692	NCT00003369_2_T2	COMPOUND	15	15	cisplatin
NCT000033692	NCT00003369_2_T3	PHENOTYPE	22	22	recurrent
NCT000033692	NCT00003369_2_T4	PHENOTYPE	25	26	cervical cancer
NCT000033694	NCT00003369_4_T0	COMPOUND	21	21	tirapazamine
NCT000033694	NCT00003369_4_T1	COMPOUND	24	24	cisplatin
NCT000033694	NCT00003369_4_T2	PHENOTYPE	8	8	recurrent
NCT000033694	NCT00003369_4_T3	PHENOTYPE	12	13	adenosquamous carcinoma
NCT000033694	NCT00003369_4_T4	PHENOTYPE	13	16	carcinoma of the cervix
NCT000033696	NCT00003369_6_T0	PHENOTYPE	19	19	toxicity
NCT000033697	NCT00003369_7_T0	COMPOUND	3	3	tirapazamine
NCT000033697	NCT00003369_7_T1	COMPOUND	16	16	cisplatin
NCT000033699	NCT00003369_9_T0	PHENOTYPE	10	10	toxic
NCT000033699	NCT00003369_9_T1	PHENOTYPE	13	14	disease progression
NCT000033700	NCT00003370_0_T0	PHENOTYPE	5	5	Recurrent
NCT000033700	NCT00003370_0_T1	PHENOTYPE	8	9	Solid Tumors
NCT000033702	NCT00003370_2_T0	CELL	10	10	cells
NCT000033702	NCT00003370_2_T1	PHENOTYPE	9	9	tumor
NCT000033704	NCT00003370_4_T0	PHENOTYPE	8	8	toxicity
NCT000033704	NCT00003370_4_T1	PHENOTYPE	16	16	recurrent
NCT000033704	NCT00003370_4_T2	PHENOTYPE	19	20	solid tumors
NCT000033706	NCT00003370_6_T0	PHENOTYPE	4	4	severity
NCT000033706	NCT00003370_6_T1	PHENOTYPE	7	7	toxic
NCT000033708	NCT00003370_8_T0	GENE	13	13	II
NCT0000337010	NCT00003370_10_T0	PHENOTYPE	2	2	pharmacokinetics
NCT0000337012	NCT00003370_12_T0	PHENOTYPE	9	9	recurrent
NCT0000337012	NCT00003370_12_T1	PHENOTYPE	13	14	solid tumors
NCT0000337014	NCT00003370_14_T0	PHENOTYPE	4	4	toxicity
NCT0000337014	NCT00003370_14_T1	PHENOTYPE	14	14	closed
NCT0000337015	NCT00003370_15_T0	GENE	22	22	axis
NCT0000337015	NCT00003370_15_T1	ORGAN	25	26	bone marrow
NCT0000337015	NCT00003370_15_T2	ORGAN	33	34	bone marrow
NCT0000337017	NCT00003370_17_T0	PHENOTYPE	12	12	toxic
NCT0000337017	NCT00003370_17_T1	PHENOTYPE	8	9	disease progression
NCT0000337019	NCT00003370_19_T0	PHENOTYPE	3	3	toxicity
NCT000033722	NCT00003372_2_T0	GENE	2	2	II
NCT000033722	NCT00003372_2_T1	PHENOTYPE	14	14	recurrent
NCT000033722	NCT00003372_2_T2	COMPOUND	9	9	topotecan
NCT000033722	NCT00003372_2_T3	PHENOTYPE	15	16	brain tumor
NCT000033724	NCT00003372_4_T0	PHENOTYPE	8	8	recurrent
NCT000033724	NCT00003372_4_T1	COMPOUND	4	4	topotecan
NCT000033724	NCT00003372_4_T2	PHENOTYPE	13	14	mixed oligoastrocytoma
NCT000033724	NCT00003372_4_T3	PHENOTYPE	9	10	anaplastic oligodendroglioma
NCT000033726	NCT00003372_6_T0	PHENOTYPE	5	5	toxicity
NCT000033726	NCT00003372_6_T1	COMPOUND	7	7	topotecan
NCT000033728	NCT00003372_8_T0	COMPOUND	3	3	topotecan
NCT000033729	NCT00003372_9_T0	PHENOTYPE	10	10	toxicity
NCT000033729	NCT00003372_9_T1	PHENOTYPE	6	7	disease progression
NCT0000337211	NCT00003372_11_T0	GENE	11	11	2.3
NCT000033750	NCT00003375_0_T0	PHENOTYPE	14	14	Glioma
NCT000033752	NCT00003375_2_T0	CELL	10	10	cells
NCT000033752	NCT00003375_2_T1	PHENOTYPE	9	9	tumor
NCT000033753	NCT00003375_3_T0	PHENOTYPE	23	23	glioma
NCT000033754	NCT00003375_4_T0	PHENOTYPE	25	25	glioma
NCT000033757	NCT00003375_7_T0	PHENOTYPE	15	15	oligodendroglioma
NCT000033757	NCT00003375_7_T1	PHENOTYPE	7	7	astrocytoma
NCT000033757	NCT00003375_7_T2	PHENOTYPE	5	5	tumor
NCT000033757	NCT00003375_7_T3	GENE	21	21	40
NCT000033757	NCT00003375_7_T4	GENE	25	25	40
NCT0000337511	NCT00003375_11_T0	COMPOUND	8	8	vincristine
NCT0000337511	NCT00003375_11_T1	GENE	9	9	IV
NCT0000337511	NCT00003375_11_T2	COMPOUND	17	17	procarbazine
NCT0000337511	NCT00003375_11_T3	COMPOUND	4	4	lomustine
NCT000033761	NCT00003376_1_T0	CELL	9	9	cells
NCT000033761	NCT00003376_1_T1	PHENOTYPE	8	8	tumor
NCT000033762	NCT00003376_2_T0	TISSUE	22	22	urothelium
NCT000033762	NCT00003376_2_T1	PHENOTYPE	18	19	advanced cancer
NCT000033763	NCT00003376_3_T0	GENE	3	3	III
NCT000033763	NCT00003376_3_T1	TISSUE	28	28	urothelium
NCT000033763	NCT00003376_3_T2	PHENOTYPE	24	25	advanced cancer
NCT000033767	NCT00003376_7_T0	PHENOTYPE	3	3	toxic
NCT0000337611	NCT00003376_11_T0	PHENOTYPE	16	16	toxicity
NCT0000337611	NCT00003376_11_T1	PHENOTYPE	18	19	disease progression
NCT0000337613	NCT00003376_13_T0	PHENOTYPE	16	16	toxicity
NCT0000337613	NCT00003376_13_T1	PHENOTYPE	18	19	disease progression
NCT0000337614	NCT00003376_14_T0	PHENOTYPE	0	2	Quality of life
NCT0000337615	NCT00003376_15_T0	PHENOTYPE	15	16	disease progression
NCT0000337616	NCT00003376_16_T0	GENE	14	14	3.3
NCT000033771	NCT00003377_1_T0	CELL	14	14	cells
NCT000033771	NCT00003377_1_T1	PHENOTYPE	13	13	tumor
NCT000033771	NCT00003377_1_T2	COMPOUND	2	2	cisplatin
NCT000033772	NCT00003377_2_T0	CELL	10	10	cells
NCT000033772	NCT00003377_2_T1	PHENOTYPE	9	9	tumor
NCT000033773	NCT00003377_3_T0	CELL	9	9	cells
NCT000033773	NCT00003377_3_T1	PHENOTYPE	8	8	tumor
NCT000033774	NCT00003377_4_T0	COMPOUND	14	14	paclitaxel
NCT000033774	NCT00003377_4_T1	ORGAN	48	48	abdomen
NCT000033774	NCT00003377_4_T2	ORGAN	46	46	pelvis
NCT000033774	NCT00003377_4_T3	GENE	38	38	has
NCT000033774	NCT00003377_4_T4	COMPOUND	21	21	cisplatin
NCT000033774	NCT00003377_4_T5	TISSUE	42	43	lymph nodes
NCT000033774	NCT00003377_4_T6	PHENOTYPE	33	36	cancer of the cervix
NCT000033776	NCT00003377_6_T0	COMPOUND	8	8	paclitaxel
NCT000033777	NCT00003377_7_T0	GENE	5	5	RT
NCT000033777	NCT00003377_7_T1	GENE	17	17	RT
NCT000033777	NCT00003377_7_T2	PHENOTYPE	26	26	initiation
NCT000033777	NCT00003377_7_T3	ORGAN	12	12	pelvis
NCT000033778	NCT00003377_8_T0	GENE	5	5	RT
NCT000033778	NCT00003377_8_T1	GENE	10	10	1.5
NCT000033779	NCT00003377_9_T0	COMPOUND	7	7	paclitaxel
NCT000033779	NCT00003377_9_T1	GENE	4	4	RT
NCT000033779	NCT00003377_9_T2	COMPOUND	15	15	cisplatin
NCT000033779	NCT00003377_9_T3	GENE	8	8	IV
NCT000033779	NCT00003377_9_T4	GENE	16	16	IV
NCT0000337710	NCT00003377_10_T0	COMPOUND	8	8	paclitaxel
NCT0000337710	NCT00003377_10_T1	GENE	14	14	MTD
NCT0000337711	NCT00003377_11_T0	PHENOTYPE	19	19	toxicity
NCT0000337711	NCT00003377_11_T1	GENE	1	1	MTD
NCT0000337712	NCT00003377_12_T0	PHENOTYPE	24	24	recurrence
NCT000033781	NCT00003378_1_T0	CELL	9	9	cells
NCT000033781	NCT00003378_1_T1	PHENOTYPE	8	8	tumor
NCT000033782	NCT00003378_2_T0	GENE	21	21	IV
NCT000033782	NCT00003378_2_T1	PHENOTYPE	17	18	stage III
NCT000033782	NCT00003378_2_T2	PHENOTYPE	25	26	peritoneal cancer
NCT000033784	NCT00003378_4_T0	PHENOTYPE	21	23	ovarian epithelial carcinoma
NCT000033784	NCT00003378_4_T1	PHENOTYPE	25	27	primary peritoneal carcinoma
NCT000033786	NCT00003378_6_T0	PHENOTYPE	7	8	measurable disease
NCT000033788	NCT00003378_8_T0	COMPOUND	5	5	paclitaxel
NCT000033788	NCT00003378_8_T1	GENE	11	11	IV
NCT0000337810	NCT00003378_10_T0	PHENOTYPE	8	8	toxicity
NCT0000337810	NCT00003378_10_T1	PHENOTYPE	4	5	disease progression
NCT000033791	NCT00003379_1_T0	CELL	14	14	cells
NCT000033791	NCT00003379_1_T1	PHENOTYPE	13	13	tumor
NCT000033791	NCT00003379_1_T2	COMPOUND	2	2	cisplatin
NCT000033792	NCT00003379_2_T0	CELL	10	10	cells
NCT000033792	NCT00003379_2_T1	PHENOTYPE	9	9	tumor
NCT000033793	NCT00003379_3_T0	CELL	9	9	cells
NCT000033793	NCT00003379_3_T1	PHENOTYPE	8	8	tumor
NCT000033794	NCT00003379_4_T0	COMPOUND	15	15	paclitaxel
NCT000033794	NCT00003379_4_T1	ORGAN	13	13	pelvis
NCT000033794	NCT00003379_4_T2	COMPOUND	17	17	cisplatin
NCT000033794	NCT00003379_4_T3	PHENOTYPE	23	24	cervical cancer
NCT000033796	NCT00003379_6_T0	COMPOUND	8	8	paclitaxel
NCT000033797	NCT00003379_7_T0	GENE	5	5	RT
NCT000033797	NCT00003379_7_T1	GENE	16	16	1.5
NCT000033797	NCT00003379_7_T2	ORGAN	8	9	pelvic region
NCT000033798	NCT00003379_8_T0	COMPOUND	2	2	paclitaxel
NCT000033798	NCT00003379_8_T1	COMPOUND	10	10	cisplatin
NCT000033798	NCT00003379_8_T2	GENE	3	3	IV
NCT0000337910	NCT00003379_10_T0	GENE	21	21	RT
NCT0000337910	NCT00003379_10_T1	GENE	3	3	LDR
NCT0000337913	NCT00003379_13_T0	COMPOUND	8	8	paclitaxel
NCT0000337913	NCT00003379_13_T1	GENE	14	14	MTD
NCT0000337914	NCT00003379_14_T0	PHENOTYPE	21	21	toxicity
NCT0000337914	NCT00003379_14_T1	GENE	1	1	MTD
NCT0000337915	NCT00003379_15_T0	GENE	2	2	MTD
NCT0000337915	NCT00003379_15_T1	GENE	13	13	MTD
NCT0000337916	NCT00003379_16_T0	PHENOTYPE	23	23	recurrence
NCT0000337917	NCT00003379_17_T0	GENE	14	14	3.7
NCT000033801	NCT00003380_1_T0	CELL	9	9	cells
NCT000033801	NCT00003380_1_T1	PHENOTYPE	8	8	tumor
NCT000033804	NCT00003380_4_T0	COMPOUND	6	6	HCl
NCT000033804	NCT00003380_4_T1	COMPOUND	11	11	etoposide
NCT000033804	NCT00003380_4_T2	COMPOUND	5	5	doxorubicin
NCT000033804	NCT00003380_4_T3	PHENOTYPE	15	15	recurrent
NCT000033804	NCT00003380_4_T4	PHENOTYPE	21	22	peritoneal carcinoma
NCT000033806	NCT00003380_6_T0	PHENOTYPE	6	6	toxicity
NCT000033808	NCT00003380_8_T0	PHENOTYPE	7	8	measurable disease
NCT000033809	NCT00003380_9_T0	COMPOUND	12	12	HCl
NCT000033809	NCT00003380_9_T1	COMPOUND	9	9	etoposide
NCT000033809	NCT00003380_9_T2	COMPOUND	11	11	doxorubicin
NCT0000338010	NCT00003380_10_T0	COMPOUND	3	3	HCl
NCT0000338010	NCT00003380_10_T1	COMPOUND	15	15	etoposide
NCT0000338010	NCT00003380_10_T2	COMPOUND	2	2	doxorubicin
NCT0000338010	NCT00003380_10_T3	GENE	5	5	IV
NCT0000338011	NCT00003380_11_T0	PHENOTYPE	24	24	toxicity
NCT0000338011	NCT00003380_11_T1	PHENOTYPE	20	21	disease progression
NCT0000338013	NCT00003380_13_T0	PHENOTYPE	6	6	toxicity
NCT0000338013	NCT00003380_13_T1	COMPOUND	23	23	etoposide
NCT0000338013	NCT00003380_13_T2	GENE	7	7	DLT
NCT0000338014	NCT00003380_14_T0	COMPOUND	10	10	HCl
NCT0000338014	NCT00003380_14_T1	COMPOUND	5	5	etoposide
NCT0000338014	NCT00003380_14_T2	COMPOUND	9	9	doxorubicin
NCT0000338015	NCT00003380_15_T0	GENE	18	18	DLT
NCT000033810	NCT00003381_0_T0	PHENOTYPE	9	10	Esophageal Cancer
NCT000033810	NCT00003381_0_T1	PHENOTYPE	0	2	Quality of Life
NCT000033812	NCT00003381_2_T0	PHENOTYPE	15	16	esophageal cancer
NCT000033812	NCT00003381_2_T1	PHENOTYPE	7	9	quality of life
NCT000033814	NCT00003381_4_T0	PHENOTYPE	8	9	esophageal cancer
NCT000033814	NCT00003381_4_T1	PHENOTYPE	2	4	quality of life
NCT000033816	NCT00003381_6_T0	PHENOTYPE	17	18	esophageal cancer
NCT000033819	NCT00003381_9_T0	GENE	11	11	III
NCT0000338115	NCT00003381_15_T0	ORGAN	26	26	abdomen
NCT0000338115	NCT00003381_15_T1	PHENOTYPE	7	8	metastatic disease
NCT0000338117	NCT00003381_17_T0	PHENOTYPE	15	15	metastases
NCT0000338117	NCT00003381_17_T1	GENE	1	1	had
NCT0000338117	NCT00003381_17_T2	GENE	8	8	NX
NCT0000338117	NCT00003381_17_T3	PHENOTYPE	0	0	Tumors
NCT0000338117	NCT00003381_17_T4	TISSUE	12	13	lymph node
NCT0000338119	NCT00003381_19_T0	GENE	33	33	1.5
NCT0000338119	NCT00003381_19_T1	GENE	7	7	cm
NCT0000338119	NCT00003381_19_T2	GENE	34	34	cm
NCT0000338119	NCT00003381_19_T3	GENE	28	28	axis
NCT0000338119	NCT00003381_19_T4	TISSUE	3	4	lymph nodes
NCT0000338119	NCT00003381_19_T5	PHENOTYPE	18	20	lymph node metastases
NCT0000338121	NCT00003381_21_T0	PHENOTYPE	26	26	malignancy
NCT0000338121	NCT00003381_21_T1	PHENOTYPE	12	12	tumor
NCT0000338122	NCT00003381_22_T0	PHENOTYPE	3	3	malignancies
NCT0000338122	NCT00003381_22_T1	GENE	11	11	had
NCT0000338122	NCT00003381_22_T2	PHENOTYPE	18	19	tumor recurrence
NCT000033820	NCT00003382_0_T0	PHENOTYPE	13	13	Recurrent
NCT000033820	NCT00003382_0_T1	PHENOTYPE	16	18	Fallopian Tube Cancer
NCT000033822	NCT00003382_2_T0	CELL	9	9	cells
NCT000033822	NCT00003382_2_T1	PHENOTYPE	8	8	tumor
NCT000033826	NCT00003382_6_T0	GENE	20	20	2.4
NCT000033826	NCT00003382_6_T1	COMPOUND	2	2	gemcitabine
NCT000033826	NCT00003382_6_T2	GENE	3	3	IV
NCT000033826	NCT00003382_6_T3	GENE	14	14	IV
NCT000033826	NCT00003382_6_T4	COMPOUND	13	13	topotecan
NCT000033827	NCT00003382_7_T0	GENE	3	3	filgrastim
NCT000033827	NCT00003382_7_T1	GENE	4	4	G-CSF
NCT000033828	NCT00003382_8_T0	PHENOTYPE	8	8	5-10
NCT000033829	NCT00003382_9_T0	GENE	14	14	MTD
NCT000033829	NCT00003382_9_T1	COMPOUND	8	8	topotecan
NCT0000338210	NCT00003382_10_T0	PHENOTYPE	18	18	toxicity
NCT0000338210	NCT00003382_10_T1	GENE	1	1	MTD
NCT0000338210	NCT00003382_10_T2	GENE	19	19	DLT
NCT0000338211	NCT00003382_11_T0	COMPOUND	3	3	gemcitabine
NCT0000338211	NCT00003382_11_T1	GENE	13	13	MTD
NCT0000338212	NCT00003382_12_T0	GENE	1	1	MTD
NCT0000338212	NCT00003382_12_T1	GENE	16	16	DLT
NCT0000338213	NCT00003382_13_T0	GENE	4	4	2.3
NCT000033841	NCT00003384_1_T0	GENE	14	14	has
NCT000033841	NCT00003384_1_T1	PHENOTYPE	15	16	cervical dysplasia
NCT000033845	NCT00003384_5_T0	PHENOTYPE	7	7	pathology
NCT000033845	NCT00003384_5_T1	PHENOTYPE	13	13	AGUS
NCT0000338412	NCT00003384_12_T0	ORGAN	8	8	cervix
NCT0000338412	NCT00003384_12_T1	ORGAN	24	24	cervix
NCT000033850	NCT00003385_0_T0	PHENOTYPE	10	12	Fallopian Tube Cancer
NCT000033852	NCT00003385_2_T0	CELL	9	9	cells
NCT000033852	NCT00003385_2_T1	PHENOTYPE	8	8	tumor
NCT000033855	NCT00003385_5_T0	COMPOUND	8	8	HCl
NCT000033855	NCT00003385_5_T1	COMPOUND	7	7	doxorubicin
NCT000033856	NCT00003385_6_T0	COMPOUND	18	18	paclitaxel
NCT000033856	NCT00003385_6_T1	GENE	3	3	IV
NCT000033856	NCT00003385_6_T2	GENE	8	8	IV
NCT000033856	NCT00003385_6_T3	GENE	19	19	IV
NCT000033857	NCT00003385_7_T0	PHENOTYPE	13	13	toxicity
NCT000033857	NCT00003385_7_T1	PHENOTYPE	15	16	disease progression
NCT000033858	NCT00003385_8_T0	GENE	14	14	MTD
NCT000033859	NCT00003385_9_T0	PHENOTYPE	21	21	toxicity
NCT000033859	NCT00003385_9_T1	GENE	1	1	MTD
NCT0000338510	NCT00003385_10_T0	COMPOUND	14	14	paclitaxel
NCT0000338510	NCT00003385_10_T1	GENE	10	10	MTD
NCT000033861	NCT00003386_1_T0	GENE	2	2	II
NCT000033861	NCT00003386_1_T1	PHENOTYPE	16	17	stage III
NCT000033861	NCT00003386_1_T2	PHENOTYPE	19	23	stage IV ovarian epithelial cancer
NCT000033865	NCT00003386_5_T0	PHENOTYPE	2	2	toxic
NCT000033868	NCT00003386_8_T0	PHENOTYPE	9	9	tumor
NCT000033869	NCT00003386_9_T0	COMPOUND	11	11	paclitaxel
NCT000033869	NCT00003386_9_T1	COMPOUND	15	15	paclitaxel
NCT000033869	NCT00003386_9_T2	COMPOUND	13	13	cisplatin
NCT0000338612	NCT00003386_12_T0	GENE	1	1	IV
NCT000033871	NCT00003387_1_T0	CELL	8	8	cells
NCT000033871	NCT00003387_1_T1	PHENOTYPE	7	7	tumor
NCT000033879	NCT00003387_9_T0	PHENOTYPE	2	2	toxicity
NCT0000338711	NCT00003387_11_T0	PHENOTYPE	6	7	evaluable disease
NCT000033881	NCT00003388_1_T0	CELL	9	9	cells
NCT000033882	NCT00003388_2_T0	GENE	2	2	II
NCT000033882	NCT00003388_2_T1	COMPOUND	16	16	vincristine
NCT000033882	NCT00003388_2_T2	PHENOTYPE	24	24	lymphoma
NCT000033882	NCT00003388_2_T3	COMPOUND	15	15	cyclophosphamide
NCT000033882	NCT00003388_2_T4	COMPOUND	14	14	doxorubicin
NCT000033882	NCT00003388_2_T5	COMPOUND	18	18	prednisone
NCT000033884	NCT00003388_4_T0	COMPOUND	14	14	HCl
NCT000033884	NCT00003388_4_T1	PHENOTYPE	19	19	lymphoma
NCT000033884	NCT00003388_4_T2	COMPOUND	13	13	doxorubicin
NCT000033886	NCT00003388_6_T0	PHENOTYPE	2	2	toxicity
NCT000033888	NCT00003388_8_T0	PHENOTYPE	2	2	progression
NCT0000338810	NCT00003388_10_T0	GENE	12	12	CD4
NCT0000338810	NCT00003388_10_T1	GENE	10	10	mRNA
NCT0000338810	NCT00003388_10_T2	ORGAN	8	8	plasma
NCT0000338810	NCT00003388_10_T3	CELL	13	13	lymphocyte
NCT0000338810	NCT00003388_10_T4	PHENOTYPE	21	22	opportunistic infections
NCT0000338812	NCT00003388_12_T0	COMPOUND	9	9	HCl
NCT0000338812	NCT00003388_12_T1	COMPOUND	15	15	vincristine
NCT0000338812	NCT00003388_12_T2	COMPOUND	12	12	cyclophosphamide
NCT0000338812	NCT00003388_12_T3	COMPOUND	8	8	doxorubicin
NCT0000338812	NCT00003388_12_T4	GENE	11	11	IV
NCT0000338812	NCT00003388_12_T5	GENE	13	13	IV
NCT0000338812	NCT00003388_12_T6	GENE	16	16	IV
NCT0000338813	NCT00003388_13_T0	GENE	7	7	1.5
NCT0000338813	NCT00003388_13_T1	COMPOUND	4	4	prednisone
NCT0000338814	NCT00003388_14_T0	GENE	1	1	G-CSF
NCT0000338814	NCT00003388_14_T1	CELL	14	14	neutrophil
NCT0000338816	NCT00003388_16_T0	COMPOUND	11	11	cytarabine
NCT0000338816	NCT00003388_16_T1	PHENOTYPE	9	9	lymphoma
NCT0000338816	NCT00003388_16_T2	COMPOUND	13	13	methotrexate
NCT0000338816	NCT00003388_16_T3	PHENOTYPE	2	2	lymphomatous
NCT0000338816	NCT00003388_16_T4	ORGAN	3	4	bone marrow
NCT0000338817	NCT00003388_17_T0	PHENOTYPE	2	3	lymphomatous meningitis
NCT0000338819	NCT00003388_19_T0	PHENOTYPE	33	33	neutropenia
NCT0000338819	NCT00003388_19_T1	PHENOTYPE	7	8	progressive disease
NCT0000338824	NCT00003388_24_T0	PHENOTYPE	18	18	lymphoma
NCT0000338824	NCT00003388_24_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000338824	NCT00003388_24_T2	PHENOTYPE	16	17	high grade
NCT000033891	NCT00003389_1_T0	CELL	8	8	cells
NCT000033892	NCT00003389_2_T0	CELL	12	12	cells
NCT000033893	NCT00003389_3_T0	PHENOTYPE	14	15	Hodgkin's lymphoma
NCT000033894	NCT00003389_4_T0	GENE	4	4	III
NCT000033894	NCT00003389_4_T1	PHENOTYPE	28	29	Hodgkin's lymphoma
NCT000033897	NCT00003389_7_T0	GENE	10	10	0.2
NCT000033897	NCT00003389_7_T1	GENE	12	12	3.7
NCT0000338911	NCT00003389_11_T0	PHENOTYPE	5	5	remission
NCT0000338915	NCT00003389_15_T0	GENE	7	7	2.3
NCT0000338917	NCT00003389_17_T0	GENE	14	14	4.3
NCT000033901	NCT00003390_1_T0	GENE	2	2	II
NCT000033901	NCT00003390_1_T1	PHENOTYPE	14	16	metastatic kidney cancer
NCT000033907	NCT00003390_7_T0	PHENOTYPE	14	14	toxicity
NCT000033907	NCT00003390_7_T1	PHENOTYPE	10	11	disease progression
NCT000033915	NCT00003391_5_T0	PHENOTYPE	2	2	pharmacokinetics
NCT000033917	NCT00003391_7_T0	PHENOTYPE	4	5	antibody response
NCT0000339112	NCT00003391_12_T0	PHENOTYPE	0	0	Anterior
NCT0000339114	NCT00003391_14_T0	PHENOTYPE	14	15	disease progression
NCT0000339115	NCT00003391_15_T0	PHENOTYPE	10	11	antibody negative
NCT000033924	NCT00003392_4_T0	COMPOUND	14	14	paclitaxel
NCT000033924	NCT00003392_4_T1	COMPOUND	32	32	paclitaxel
NCT000033924	NCT00003392_4_T2	PHENOTYPE	20	20	peripheral
NCT000033924	NCT00003392_4_T3	COMPOUND	38	38	melphalan
NCT000033924	NCT00003392_4_T4	GENE	17	17	G-CSF
NCT000033924	NCT00003392_4_T5	GENE	44	44	G-CSF
NCT000033924	NCT00003392_4_T6	GENE	16	16	filgrastim
NCT000033924	NCT00003392_4_T7	COMPOUND	13	13	cyclophosphamide
NCT000033924	NCT00003392_4_T8	PHENOTYPE	48	48	recurrent
NCT000033924	NCT00003392_4_T9	PHENOTYPE	52	53	breast cancer
NCT000033924	NCT00003392_4_T10	CELL	22	23	progenitor cells
NCT0000339210	NCT00003392_10_T0	COMPOUND	13	13	paclitaxel
NCT0000339210	NCT00003392_10_T1	COMPOUND	27	27	paclitaxel
NCT0000339210	NCT00003392_10_T2	GENE	19	19	filgrastim
NCT0000339210	NCT00003392_10_T3	COMPOUND	6	6	cyclophosphamide
NCT0000339210	NCT00003392_10_T4	GENE	20	20	G-CSF
NCT0000339210	NCT00003392_10_T5	GENE	7	7	IV
NCT0000339210	NCT00003392_10_T6	GENE	14	14	IV
NCT0000339211	NCT00003392_11_T0	CELL	8	8	cells
NCT0000339211	NCT00003392_11_T1	GENE	7	7	CD34
NCT0000339213	NCT00003392_13_T0	PHENOTYPE	14	14	peripheral
NCT0000339213	NCT00003392_13_T1	GENE	19	19	G-CSF
NCT0000339213	NCT00003392_13_T2	CELL	16	17	progenitor cells
NCT000033941	NCT00003394_1_T0	CELL	9	9	cells
NCT000033941	NCT00003394_1_T1	PHENOTYPE	8	8	tumor
NCT000033946	NCT00003394_6_T0	COMPOUND	9	9	androgen
NCT000033946	NCT00003394_6_T1	COMPOUND	12	12	androgen
NCT000033948	NCT00003394_8_T0	PHENOTYPE	2	2	pharmacokinetics
NCT000033948	NCT00003394_8_T1	GENE	8	8	TAX
NCT000033949	NCT00003394_9_T0	COMPOUND	9	9	estramustine
NCT0000339410	NCT00003394_10_T0	GENE	1	1	II
NCT0000339410	NCT00003394_10_T1	COMPOUND	15	15	androgen
NCT0000339410	NCT00003394_10_T2	COMPOUND	17	17	androgen
NCT0000339410	NCT00003394_10_T3	COMPOUND	21	21	androgen
NCT0000339410	NCT00003394_10_T4	PHENOTYPE	16	16	dependence
NCT0000339411	NCT00003394_11_T0	COMPOUND	27	27	paclitaxel
NCT0000339411	NCT00003394_11_T1	GENE	28	28	TAX
NCT0000339411	NCT00003394_11_T2	COMPOUND	5	5	estramustine
NCT0000339411	NCT00003394_11_T3	GENE	6	6	IV
NCT0000339411	NCT00003394_11_T4	GENE	29	29	IV
NCT0000339412	NCT00003394_12_T0	GENE	11	11	TAX
NCT0000339412	NCT00003394_12_T1	GENE	1	1	IV
NCT0000339413	NCT00003394_13_T0	PHENOTYPE	10	10	toxicity
NCT0000339413	NCT00003394_13_T1	PHENOTYPE	6	7	disease progression
NCT0000339415	NCT00003394_15_T0	COMPOUND	14	14	goserelin
NCT0000339415	NCT00003394_15_T1	COMPOUND	16	16	leuprolide
NCT0000339415	NCT00003394_15_T2	GENE	11	11	GnRH
NCT0000339415	NCT00003394_15_T3	GENE	7	7	hormone
NCT0000339417	NCT00003394_17_T0	PHENOTYPE	6	6	toxicity
NCT0000339417	NCT00003394_17_T1	PHENOTYPE	3	3	experiences
NCT0000339417	NCT00003394_17_T2	GENE	7	7	DLT
NCT0000339418	NCT00003394_18_T0	PHENOTYPE	3	3	experiences
NCT0000339418	NCT00003394_18_T1	GENE	4	4	DLT
NCT0000339419	NCT00003394_19_T0	GENE	16	16	MTD
NCT0000339419	NCT00003394_19_T1	GENE	6	6	DLT
NCT0000339420	NCT00003394_20_T0	GENE	2	2	II
NCT0000339424	NCT00003394_24_T0	GENE	14	14	II
NCT000033951	NCT00003395_1_T0	COMPOUND	9	10	arsenic trioxide
NCT000033951	NCT00003395_1_T1	PHENOTYPE	17	18	hematologic cancer
NCT000033953	NCT00003395_3_T0	PHENOTYPE	18	18	cancers
NCT000033953	NCT00003395_3_T1	COMPOUND	7	8	arsenic trioxide
NCT000033955	NCT00003395_5_T0	PHENOTYPE	5	6	adverse experience
NCT000033959	NCT00003395_9_T0	GENE	6	6	1.4
NCT000033959	NCT00003395_9_T1	GENE	4	4	IV
NCT000033959	NCT00003395_9_T2	COMPOUND	2	3	arsenic trioxide
NCT0000339510	NCT00003395_10_T0	PHENOTYPE	13	13	toxicity
NCT0000339510	NCT00003395_10_T1	GENE	3	3	3.5
NCT0000339510	NCT00003395_10_T2	PHENOTYPE	9	10	disease progression
NCT0000339511	NCT00003395_11_T0	GENE	15	15	MTD
NCT0000339511	NCT00003395_11_T1	COMPOUND	8	9	arsenic trioxide
NCT0000339512	NCT00003395_12_T0	PHENOTYPE	18	18	toxicity
NCT0000339512	NCT00003395_12_T1	GENE	1	1	MTD
NCT0000339512	NCT00003395_12_T2	PHENOTYPE	16	16	experiences
NCT000033963	NCT00003396_3_T0	PHENOTYPE	10	11	graft-versus-host disease
NCT000033963	NCT00003396_3_T1	PHENOTYPE	23	24	hematologic malignancies
NCT000033963	NCT00003396_3_T2	CELL	5	8	peripheral blood stem cells
NCT000033967	NCT00003396_7_T0	ORGAN	14	14	testicles
NCT000033967	NCT00003396_7_T1	PHENOTYPE	3	5	acute lymphocytic leukemia
NCT000033969	NCT00003396_9_T0	COMPOUND	6	6	1
NCT000033969	NCT00003396_9_T1	COMPOUND	12	12	1
NCT000033969	NCT00003396_9_T2	COMPOUND	10	10	2
NCT000033969	NCT00003396_9_T3	COMPOUND	3	3	cyclophosphamide
NCT000033969	NCT00003396_9_T4	GENE	4	4	IV
NCT0000339610	NCT00003396_10_T0	COMPOUND	13	13	1
NCT0000339610	NCT00003396_10_T1	COMPOUND	11	11	2
NCT0000339610	NCT00003396_10_T2	GENE	1	1	globulin
NCT0000339610	NCT00003396_10_T3	GENE	5	5	IV
NCT0000339611	NCT00003396_11_T0	COMPOUND	8	8	cyclophosphamide
NCT0000339611	NCT00003396_11_T1	CELL	9	12	peripheral blood stem cells
NCT0000339612	NCT00003396_12_T0	ORGAN	8	8	transplant
NCT0000339612	NCT00003396_12_T1	PHENOTYPE	4	5	graft-versus-host disease
NCT000033975	NCT00003397_5_T0	GENE	39	39	CD20
NCT000033975	NCT00003397_5_T1	COMPOUND	30	30	melphalan
NCT000033975	NCT00003397_5_T2	CELL	21	21	B-cell
NCT000033975	NCT00003397_5_T3	COMPOUND	32	32	gemcitabine
NCT000033975	NCT00003397_5_T4	COMPOUND	52	52	gemcitabine
NCT000033975	NCT00003397_5_T5	GENE	43	43	sargramostim
NCT000033975	NCT00003397_5_T6	PHENOTYPE	22	23	Hodgkin's lymphoma
NCT000033975	NCT00003397_5_T7	PHENOTYPE	19	20	high grade
NCT000033977	NCT00003397_7_T0	PHENOTYPE	18	18	lymphoma
NCT000033977	NCT00003397_7_T1	GENE	11	11	GM-CSF
NCT000033977	NCT00003397_7_T2	GENE	10	10	sargramostim
NCT000033979	NCT00003397_9_T0	PHENOTYPE	10	11	secondary malignancies
NCT000033979	NCT00003397_9_T1	PHENOTYPE	1	3	quality of life
NCT0000339710	NCT00003397_10_T0	COMPOUND	22	22	2
NCT0000339710	NCT00003397_10_T1	COMPOUND	26	26	2
NCT0000339710	NCT00003397_10_T2	COMPOUND	5	5	gemcitabine
NCT0000339710	NCT00003397_10_T3	GENE	6	6	IV
NCT0000339710	NCT00003397_10_T4	GENE	20	20	IV
NCT0000339711	NCT00003397_11_T0	COMPOUND	2	2	1
NCT0000339711	NCT00003397_11_T1	COMPOUND	5	5	melphalan
NCT0000339711	NCT00003397_11_T2	GENE	6	6	IV
NCT0000339711	NCT00003397_11_T3	CELL	17	20	peripheral blood stem cells
NCT0000339712	NCT00003397_12_T0	CELL	11	11	granulocyte
NCT0000339712	NCT00003397_12_T1	GENE	4	4	GM-CSF
NCT0000339712	NCT00003397_12_T2	GENE	3	3	sargramostim
NCT0000339713	NCT00003397_13_T0	GENE	10	10	CD20
NCT0000339713	NCT00003397_13_T1	GENE	15	15	3.4
NCT0000339713	NCT00003397_13_T2	GENE	13	13	IV
NCT0000339714	NCT00003397_14_T0	GENE	11	11	GM-CSF
NCT0000339714	NCT00003397_14_T1	GENE	10	10	sargramostim
NCT0000339715	NCT00003397_15_T0	COMPOUND	9	9	dexamethasone
NCT0000339715	NCT00003397_15_T1	GENE	15	15	1.4
NCT0000339715	NCT00003397_15_T2	GENE	28	28	1.4
NCT0000339715	NCT00003397_15_T3	COMPOUND	17	17	cyclophosphamide
NCT0000339715	NCT00003397_15_T4	COMPOUND	18	18	etoposide
NCT0000339715	NCT00003397_15_T5	COMPOUND	30	30	gemcitabine
NCT0000339715	NCT00003397_15_T6	COMPOUND	20	20	cisplatin
NCT0000339715	NCT00003397_15_T7	GENE	31	31	IV
NCT0000339716	NCT00003397_16_T0	COMPOUND	9	9	paclitaxel
NCT0000339716	NCT00003397_16_T1	COMPOUND	18	18	cisplatin
NCT0000339716	NCT00003397_16_T2	GENE	10	10	IV
NCT0000339716	NCT00003397_16_T3	GENE	19	19	IV
NCT0000339720	NCT00003397_20_T0	PHENOTYPE	18	18	lymphoma
NCT0000339720	NCT00003397_20_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000339720	NCT00003397_20_T2	PHENOTYPE	16	17	high grade
NCT000033981	NCT00003398_1_T0	GENE	2	2	IV
NCT000033981	NCT00003398_1_T1	PHENOTYPE	15	16	hematologic cancer
NCT000033981	NCT00003398_1_T2	PHENOTYPE	9	10	graft-versus-host disease
NCT000033981	NCT00003398_1_T3	ORGAN	21	22	bone marrow
NCT000033983	NCT00003398_3_T0	PHENOTYPE	5	9	graft versus host disease in
NCT000033983	NCT00003398_3_T1	PHENOTYPE	4	8	acute graft versus host disease
NCT000033985	NCT00003398_5_T0	PHENOTYPE	4	4	engraftment
NCT000033985	NCT00003398_5_T1	GENE	6	6	CD4
NCT000033988	NCT00003398_8_T0	COMPOUND	15	15	1
NCT000033988	NCT00003398_8_T1	GENE	1	1	globulin
NCT000033988	NCT00003398_8_T2	GENE	5	5	IV
NCT000033989	NCT00003398_9_T0	ORGAN	4	5	bone marrow
NCT0000339810	NCT00003398_10_T0	CELL	9	9	T-cells
NCT0000339810	NCT00003398_10_T1	ORGAN	0	1	Bone marrow
NCT0000339811	NCT00003398_11_T0	GENE	2	2	filgrastim
NCT0000339811	NCT00003398_11_T1	GENE	3	3	G-CSF
NCT0000339812	NCT00003398_12_T0	GENE	12	12	3.4
NCT000033994	NCT00003399_4_T0	COMPOUND	21	21	melphalan
NCT000033994	NCT00003399_4_T1	PHENOTYPE	7	8	multiple myeloma
NCT000033994	NCT00003399_4_T2	CELL	11	14	peripheral blood stem cells
NCT000033999	NCT00003399_9_T0	COMPOUND	20	20	1
NCT000033999	NCT00003399_9_T1	COMPOUND	6	6	2
NCT000033999	NCT00003399_9_T2	COMPOUND	10	10	2
NCT000033999	NCT00003399_9_T3	COMPOUND	13	13	melphalan
NCT000033999	NCT00003399_9_T4	GENE	4	4	IV
NCT000033999	NCT00003399_9_T5	GENE	14	14	IV
NCT0000339910	NCT00003399_10_T0	GENE	3	3	CD34
NCT0000339910	NCT00003399_10_T1	CELL	4	7	peripheral blood stem cells
NCT0000339911	NCT00003399_11_T0	COMPOUND	15	15	dexamethasone
NCT0000339911	NCT00003399_11_T1	COMPOUND	12	12	cyclophosphamide
NCT0000339911	NCT00003399_11_T2	COMPOUND	16	16	etoposide
NCT0000339911	NCT00003399_11_T3	COMPOUND	19	19	cisplatin
NCT0000339911	NCT00003399_11_T4	GENE	13	13	IV
NCT0000339911	NCT00003399_11_T5	GENE	17	17	IV
NCT0000339911	NCT00003399_11_T6	GENE	20	20	IV
NCT0000339912	NCT00003399_12_T0	COMPOUND	17	17	dexamethasone
NCT0000339912	NCT00003399_12_T1	COMPOUND	21	21	paclitaxel
NCT0000339912	NCT00003399_12_T2	PHENOTYPE	10	10	peripheral
NCT0000339912	NCT00003399_12_T3	COMPOUND	14	14	creatinine
NCT0000339912	NCT00003399_12_T4	GENE	20	20	1.4
NCT0000339912	NCT00003399_12_T5	COMPOUND	30	30	cisplatin
NCT0000339912	NCT00003399_12_T6	GENE	22	22	IV
NCT0000339912	NCT00003399_12_T7	GENE	31	31	IV
NCT000034006	NCT00003400_6_T0	PHENOTYPE	2	2	toxic
NCT000034008	NCT00003400_8_T0	PHENOTYPE	2	4	quality of life
NCT000034009	NCT00003400_9_T0	PHENOTYPE	11	12	metastatic disease
NCT0000340010	NCT00003400_10_T0	GENE	3	3	filgrastim
NCT0000340010	NCT00003400_10_T1	GENE	4	4	G-CSF
NCT0000340010	NCT00003400_10_T2	CELL	10	13	peripheral blood stem cells
NCT0000340011	NCT00003400_11_T0	COMPOUND	19	19	1
NCT0000340011	NCT00003400_11_T1	COMPOUND	6	6	2
NCT0000340011	NCT00003400_11_T2	COMPOUND	10	10	2
NCT0000340011	NCT00003400_11_T3	COMPOUND	12	12	melphalan
NCT0000340011	NCT00003400_11_T4	GENE	4	4	IV
NCT0000340011	NCT00003400_11_T5	GENE	13	13	IV
NCT0000340013	NCT00003400_13_T0	COMPOUND	11	11	vinorelbine
NCT0000340013	NCT00003400_13_T1	ORGAN	8	8	transplant
NCT0000340013	NCT00003400_13_T2	COMPOUND	17	17	cisplatin
NCT0000340013	NCT00003400_13_T3	GENE	12	12	IV
NCT0000340013	NCT00003400_13_T4	GENE	18	18	IV
NCT000034014	NCT00003401_4_T0	COMPOUND	23	23	melphalan
NCT000034014	NCT00003401_4_T1	COMPOUND	17	17	gemcitabine
NCT000034014	NCT00003401_4_T2	COMPOUND	29	29	gemcitabine
NCT000034014	NCT00003401_4_T3	PHENOTYPE	7	8	multiple myeloma
NCT000034014	NCT00003401_4_T4	CELL	11	14	peripheral blood stem cells
NCT000034018	NCT00003401_8_T0	COMPOUND	6	6	gemcitabine
NCT000034019	NCT00003401_9_T0	COMPOUND	35	35	1
NCT000034019	NCT00003401_9_T1	COMPOUND	21	21	2
NCT000034019	NCT00003401_9_T2	COMPOUND	25	25	2
NCT000034019	NCT00003401_9_T3	COMPOUND	28	28	melphalan
NCT000034019	NCT00003401_9_T4	COMPOUND	3	3	gemcitabine
NCT000034019	NCT00003401_9_T5	GENE	4	4	IV
NCT000034019	NCT00003401_9_T6	GENE	19	19	IV
NCT000034019	NCT00003401_9_T7	GENE	29	29	IV
NCT0000340110	NCT00003401_10_T0	GENE	3	3	CD34
NCT0000340110	NCT00003401_10_T1	CELL	4	7	peripheral blood stem cells
NCT0000340111	NCT00003401_11_T0	COMPOUND	15	15	dexamethasone
NCT0000340111	NCT00003401_11_T1	COMPOUND	12	12	cyclophosphamide
NCT0000340111	NCT00003401_11_T2	COMPOUND	16	16	etoposide
NCT0000340111	NCT00003401_11_T3	COMPOUND	19	19	cisplatin
NCT0000340111	NCT00003401_11_T4	GENE	13	13	IV
NCT0000340111	NCT00003401_11_T5	GENE	17	17	IV
NCT0000340111	NCT00003401_11_T6	GENE	20	20	IV
NCT0000340112	NCT00003401_12_T0	COMPOUND	6	6	gemcitabine
NCT0000340113	NCT00003401_13_T0	COMPOUND	10	10	dexamethasone
NCT0000340113	NCT00003401_13_T1	COMPOUND	14	14	paclitaxel
NCT0000340113	NCT00003401_13_T2	GENE	13	13	1.4
NCT0000340113	NCT00003401_13_T3	ORGAN	6	6	autotransplant
NCT0000340113	NCT00003401_13_T4	COMPOUND	23	23	cisplatin
NCT0000340113	NCT00003401_13_T5	GENE	15	15	IV
NCT0000340113	NCT00003401_13_T6	GENE	24	24	IV
NCT000034028	NCT00003402_8_T0	PHENOTYPE	2	2	toxicity
NCT000034028	NCT00003402_8_T1	COMPOUND	9	9	dexamethasone
NCT000034028	NCT00003402_8_T2	COMPOUND	10	10	paclitaxel
NCT000034028	NCT00003402_8_T3	COMPOUND	12	12	cisplatin
NCT0000340210	NCT00003402_10_T0	COMPOUND	25	25	dexamethasone
NCT0000340210	NCT00003402_10_T1	COMPOUND	13	13	cyclophosphamide
NCT0000340210	NCT00003402_10_T2	COMPOUND	14	14	etoposide
NCT0000340210	NCT00003402_10_T3	COMPOUND	16	16	cisplatin
NCT0000340210	NCT00003402_10_T4	GENE	19	19	IV
NCT0000340211	NCT00003402_11_T0	COMPOUND	12	12	dexamethasone
NCT0000340211	NCT00003402_11_T1	COMPOUND	19	19	paclitaxel
NCT0000340211	NCT00003402_11_T2	COMPOUND	30	30	cisplatin
NCT0000340211	NCT00003402_11_T3	GENE	21	21	IV
NCT0000340211	NCT00003402_11_T4	GENE	32	32	IV
NCT0000340214	NCT00003402_14_T0	PHENOTYPE	18	18	lymphoma
NCT0000340214	NCT00003402_14_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000340214	NCT00003402_14_T2	PHENOTYPE	16	17	high grade
NCT000034030	NCT00003403_0_T0	PHENOTYPE	5	6	Solid Tumors
NCT000034032	NCT00003403_2_T0	PHENOTYPE	15	16	solid tumors
NCT000034034	NCT00003403_4_T0	PHENOTYPE	11	12	solid tumors
NCT000034036	NCT00003403_6_T0	PHENOTYPE	4	4	toxicity
NCT0000340310	NCT00003403_10_T0	GENE	3	3	IV
NCT0000340311	NCT00003403_11_T0	PHENOTYPE	15	15	toxicity
NCT0000340311	NCT00003403_11_T1	PHENOTYPE	10	11	disease progression
NCT0000340312	NCT00003403_12_T0	PHENOTYPE	18	18	progressing
NCT0000340312	NCT00003403_12_T1	COMPOUND	12	12	doxorubicin
NCT0000340315	NCT00003403_15_T0	PHENOTYPE	21	21	toxicity
NCT000034041	NCT00003404_1_T0	CELL	9	9	cells
NCT000034041	NCT00003404_1_T1	PHENOTYPE	8	8	tumor
NCT000034042	NCT00003404_2_T0	PHENOTYPE	11	15	phyllodes tumor of the breast
NCT000034047	NCT00003404_7_T0	PHENOTYPE	8	8	borderline
NCT000034047	NCT00003404_7_T1	PHENOTYPE	2	3	phyllodes tumors
NCT000034048	NCT00003404_8_T0	PHENOTYPE	11	11	infiltrating
NCT000034048	NCT00003404_8_T1	COMPOUND	13	13	2
NCT000034048	NCT00003404_8_T2	COMPOUND	15	15	2
NCT000034048	NCT00003404_8_T3	PHENOTYPE	0	0	Borderline
NCT000034048	NCT00003404_8_T4	PHENOTYPE	9	9	pushing
NCT000034048	NCT00003404_8_T5	GENE	3	3	5.9
NCT000034049	NCT00003404_9_T0	PHENOTYPE	9	9	infiltrating
NCT000034049	NCT00003404_9_T1	COMPOUND	16	16	2
NCT000034049	NCT00003404_9_T2	COMPOUND	18	18	2
NCT000034049	NCT00003404_9_T3	COMPOUND	12	12	3
NCT0000340411	NCT00003404_11_T0	PHENOTYPE	1	1	recurrence
NCT0000340411	NCT00003404_11_T1	PHENOTYPE	11	11	recurrence
NCT0000340411	NCT00003404_11_T2	PHENOTYPE	6	7	phyllodes tumor
NCT0000340412	NCT00003404_12_T0	PHENOTYPE	2	3	breast carcinoma
NCT0000340412	NCT00003404_12_T1	PHENOTYPE	5	8	ductal carcinoma in situ
NCT0000340413	NCT00003404_13_T0	GENE	1	1	receptor
NCT0000340414	NCT00003404_14_T0	GENE	0	0	Age
NCT0000340416	NCT00003404_16_T0	PHENOTYPE	0	0	Menopausal
NCT0000340422	NCT00003404_22_T0	PHENOTYPE	0	0	Other
NCT0000340424	NCT00003404_24_T0	PHENOTYPE	0	2	Negative pregnancy test
NCT0000340428	NCT00003404_28_T0	PHENOTYPE	0	0	Endocrine
NCT000034052	NCT00003405_2_T0	CELL	13	13	cells
NCT000034053	NCT00003405_3_T0	GENE	2	2	II
NCT000034053	NCT00003405_3_T1	COMPOUND	11	11	isotretinoin
NCT000034053	NCT00003405_3_T2	GENE	13	13	interferon
NCT000034053	NCT00003405_3_T3	PHENOTYPE	20	22	acute myelogenous leukemia
NCT000034055	NCT00003405_5_T0	PHENOTYPE	24	24	AML
NCT000034055	NCT00003405_5_T1	COMPOUND	8	8	mitoxantrone
NCT000034055	NCT00003405_5_T2	COMPOUND	6	6	cytarabine
NCT000034055	NCT00003405_5_T3	COMPOUND	10	10	amifostine
NCT000034055	NCT00003405_5_T4	PHENOTYPE	21	23	acute myelogenous leukemia
NCT000034057	NCT00003405_7_T0	PHENOTYPE	9	9	AML
NCT000034057	NCT00003405_7_T1	CELL	10	10	cells
NCT000034057	NCT00003405_7_T2	COMPOUND	4	4	amifostine
NCT000034059	NCT00003405_9_T0	PHENOTYPE	12	12	remission
NCT000034059	NCT00003405_9_T1	BIOLOGICAL_PROCESS	7	8	cytokine production
NCT0000340510	NCT00003405_10_T0	ORGAN	6	7	bone marrow
NCT0000340511	NCT00003405_11_T0	COMPOUND	2	2	3
NCT0000340511	NCT00003405_11_T1	GENE	6	6	IV
NCT0000340511	NCT00003405_11_T2	ORGAN	14	15	bone marrow
NCT0000340512	NCT00003405_12_T0	COMPOUND	3	3	amifostine
NCT0000340512	NCT00003405_12_T1	GENE	6	6	5.7
NCT0000340512	NCT00003405_12_T2	GENE	4	4	IV
NCT0000340513	NCT00003405_13_T0	GENE	9	9	IV
NCT0000340513	NCT00003405_13_T1	ORGAN	16	17	bone marrow
NCT0000340514	NCT00003405_14_T0	COMPOUND	19	19	mitoxantrone
NCT0000340514	NCT00003405_14_T1	COMPOUND	9	9	cytarabine
NCT0000340514	NCT00003405_14_T2	COMPOUND	30	30	cytarabine
NCT0000340514	NCT00003405_14_T3	COMPOUND	6	6	amifostine
NCT0000340514	NCT00003405_14_T4	GENE	10	10	IV
NCT0000340514	NCT00003405_14_T5	GENE	20	20	IV
NCT0000340515	NCT00003405_15_T0	ORGAN	9	10	bone marrow
NCT0000340516	NCT00003405_16_T0	COMPOUND	6	6	amifostine
NCT0000340518	NCT00003405_18_T0	COMPOUND	7	7	cytarabine
NCT0000340518	NCT00003405_18_T1	PHENOTYPE	0	0	Consolidation
NCT0000340518	NCT00003405_18_T2	COMPOUND	14	14	idarubicin
NCT0000340518	NCT00003405_18_T3	GENE	12	12	1.7
NCT0000340518	NCT00003405_18_T4	GENE	9	9	IV
NCT0000340518	NCT00003405_18_T5	GENE	15	15	IV
NCT0000340519	NCT00003405_19_T0	COMPOUND	5	5	cytarabine
NCT0000340519	NCT00003405_19_T1	PHENOTYPE	0	0	Consolidation
NCT0000340519	NCT00003405_19_T2	GENE	6	6	IV
NCT0000340520	NCT00003405_20_T0	COMPOUND	10	10	isotretinoin
NCT0000340520	NCT00003405_20_T1	GENE	15	15	interferon
NCT0000340521	NCT00003405_21_T0	GENE	2	2	interferon
NCT0000340522	NCT00003405_22_T0	PHENOTYPE	15	15	relapse
NCT0000340523	NCT00003405_23_T0	PHENOTYPE	3	3	remission
NCT000034065	NCT00003406_5_T0	COMPOUND	6	6	docetaxel
NCT000034066	NCT00003406_6_T0	GENE	12	12	IV
NCT000034066	NCT00003406_6_T1	GENE	30	30	IV
NCT000034066	NCT00003406_6_T2	GENE	37	37	IV
NCT000034066	NCT00003406_6_T3	COMPOUND	29	29	ifosfamide
NCT000034066	NCT00003406_6_T4	COMPOUND	48	48	3
NCT000034066	NCT00003406_6_T5	COMPOUND	11	11	docetaxel
NCT000034068	NCT00003406_8_T0	PHENOTYPE	10	10	toxicity
NCT000034068	NCT00003406_8_T1	GENE	11	11	DLT
NCT000034069	NCT00003406_9_T0	GENE	10	10	DLT
NCT0000340610	NCT00003406_10_T0	GENE	16	16	DLT
NCT0000340614	NCT00003406_14_T0	PHENOTYPE	18	18	lymphoma
NCT0000340614	NCT00003406_14_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000340614	NCT00003406_14_T2	PHENOTYPE	16	17	high grade
NCT000034071	NCT00003407_1_T0	CELL	8	8	cells
NCT000034071	NCT00003407_1_T1	COMPOUND	4	4	amifostine
NCT000034071	NCT00003407_1_T2	PHENOTYPE	12	14	effects of chemotherapy
NCT000034078	NCT00003407_8_T0	COMPOUND	4	4	amifostine
NCT000034078	NCT00003407_8_T1	GENE	5	5	IV
NCT000034079	NCT00003407_9_T0	COMPOUND	23	23	mitoxantrone
NCT000034079	NCT00003407_9_T1	COMPOUND	11	11	cytarabine
NCT000034079	NCT00003407_9_T2	COMPOUND	3	3	amifostine
NCT000034079	NCT00003407_9_T3	GENE	12	12	IV
NCT000034079	NCT00003407_9_T4	GENE	24	24	IV
NCT0000340710	NCT00003407_10_T0	PHENOTYPE	5	5	remission
NCT0000340711	NCT00003407_11_T0	PHENOTYPE	3	3	AML
NCT0000340713	NCT00003407_13_T0	PHENOTYPE	0	0	Consolidation
NCT0000340713	NCT00003407_13_T1	COMPOUND	4	4	amifostine
NCT0000340713	NCT00003407_13_T2	GENE	5	5	IV
NCT0000340714	NCT00003407_14_T0	COMPOUND	5	5	mitoxantrone
NCT0000340714	NCT00003407_14_T1	COMPOUND	3	3	cytarabine
NCT000034080	NCT00003408_0_T0	PHENOTYPE	13	13	Cancer
NCT000034080	NCT00003408_0_T1	CELL	5	7	Peripheral Stem Cell
NCT000034085	NCT00003408_5_T0	GENE	8	8	interleukin-2
NCT000034085	NCT00003408_5_T1	GENE	10	10	interferon
NCT000034087	NCT00003408_7_T0	GENE	7	7	interferon
NCT000034089	NCT00003408_9_T0	GENE	9	9	interleukin-2
NCT000034089	NCT00003408_9_T1	GENE	11	11	interferon
NCT000034089	NCT00003408_9_T2	GENE	18	18	MTD
NCT0000340810	NCT00003408_10_T0	PHENOTYPE	19	19	toxicity
NCT0000340810	NCT00003408_10_T1	GENE	1	1	MTD
NCT0000340811	NCT00003408_11_T0	PHENOTYPE	13	13	toxicity
NCT0000340811	NCT00003408_11_T1	GENE	6	6	2.4
NCT0000340814	NCT00003408_14_T0	PHENOTYPE	18	18	lymphoma
NCT0000340814	NCT00003408_14_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000340814	NCT00003408_14_T2	PHENOTYPE	16	17	high grade
NCT000034091	NCT00003409_1_T0	CELL	12	12	cells
NCT000034091	NCT00003409_1_T1	PHENOTYPE	11	11	tumor
NCT000034091	NCT00003409_1_T2	COMPOUND	1	1	gadolinium
NCT000034092	NCT00003409_2_T0	PHENOTYPE	21	22	glioblastoma multiforme
NCT000034092	NCT00003409_2_T1	COMPOUND	9	10	motexafin gadolinium
NCT000034094	NCT00003409_4_T0	PHENOTYPE	17	18	glioblastoma multiforme
NCT000034094	NCT00003409_4_T1	COMPOUND	6	7	motexafin gadolinium
NCT000034096	NCT00003409_6_T0	PHENOTYPE	6	6	pharmacokinetics
NCT000034097	NCT00003409_7_T0	COMPOUND	8	9	motexafin gadolinium
NCT000034098	NCT00003409_8_T0	GENE	15	15	1.5
NCT000034098	NCT00003409_8_T1	GENE	18	18	1.5
NCT000034098	NCT00003409_8_T2	GENE	9	9	IV
NCT000034098	NCT00003409_8_T3	COMPOUND	7	8	motexafin gadolinium
NCT000034099	NCT00003409_9_T0	GENE	21	21	6.5
NCT000034099	NCT00003409_9_T1	GENE	13	13	IV
NCT000034099	NCT00003409_9_T2	COMPOUND	11	12	motexafin gadolinium
NCT0000340910	NCT00003409_10_T0	GENE	11	11	6.5
NCT0000340911	NCT00003409_11_T0	GENE	18	18	MTD
NCT0000340911	NCT00003409_11_T1	COMPOUND	11	12	motexafin gadolinium
NCT0000340912	NCT00003409_12_T0	PHENOTYPE	17	17	toxicity
NCT0000340912	NCT00003409_12_T1	GENE	1	1	MTD
NCT000034101	NCT00003410_1_T0	PHENOTYPE	20	20	glioma
NCT000034101	NCT00003410_1_T1	COMPOUND	9	9	gadolinium
NCT000034103	NCT00003410_3_T0	GENE	11	11	retained
NCT000034103	NCT00003410_3_T1	GENE	15	15	MRI
NCT000034103	NCT00003410_3_T2	PHENOTYPE	10	10	tumor
NCT000034103	NCT00003410_3_T3	PHENOTYPE	26	26	glioma
NCT000034103	NCT00003410_3_T4	COMPOUND	6	6	gadolinium
NCT000034103	NCT00003410_3_T5	PHENOTYPE	24	25	high grade
NCT000034105	NCT00003410_5_T0	GENE	11	11	MRI
NCT000034105	NCT00003410_5_T1	PHENOTYPE	6	6	pharmacokinetics
NCT000034105	NCT00003410_5_T2	COMPOUND	8	8	gadolinium
NCT000034107	NCT00003410_7_T0	GENE	6	6	MRI
NCT000034107	NCT00003410_7_T1	COMPOUND	11	11	gadolinium
NCT000034107	NCT00003410_7_T2	COMPOUND	18	18	gadolinium
NCT000034109	NCT00003410_9_T0	PHENOTYPE	15	15	tumor
NCT000034109	NCT00003410_9_T1	PHENOTYPE	9	9	gliomas
NCT000034109	NCT00003410_9_T2	COMPOUND	24	24	proton
NCT000034109	NCT00003410_9_T3	COMPOUND	4	4	gadolinium
NCT000034109	NCT00003410_9_T4	PHENOTYPE	7	8	high grade
NCT0000341011	NCT00003410_11_T0	GENE	5	5	IV
NCT0000341011	NCT00003410_11_T1	COMPOUND	2	2	gadolinium
NCT0000341012	NCT00003410_12_T0	COMPOUND	9	9	gadolinium
NCT0000341014	NCT00003410_14_T0	GENE	15	15	stops
NCT000034111	NCT00003411_1_T0	CELL	12	12	cells
NCT000034111	NCT00003411_1_T1	PHENOTYPE	11	11	tumor
NCT000034111	NCT00003411_1_T2	COMPOUND	1	1	gadolinium
NCT000034112	NCT00003411_2_T0	ORGAN	20	20	gallbladder
NCT000034112	NCT00003411_2_T1	PHENOTYPE	22	23	pancreatic cancer
NCT000034112	NCT00003411_2_T2	ORGAN	18	19	bile duct
NCT000034112	NCT00003411_2_T3	COMPOUND	12	13	motexafin gadolinium
NCT000034114	NCT00003411_4_T0	PHENOTYPE	4	4	toxicity
NCT000034114	NCT00003411_4_T1	PHENOTYPE	24	24	tumors
NCT000034114	NCT00003411_4_T2	ORGAN	22	23	biliary tree
NCT000034114	NCT00003411_4_T3	COMPOUND	6	7	motexafin gadolinium
NCT000034116	NCT00003411_6_T0	PHENOTYPE	2	2	pharmacokinetics
NCT0000341113	NCT00003411_13_T0	COMPOUND	8	9	motexafin gadolinium
NCT0000341114	NCT00003411_14_T0	GENE	21	21	5.5
NCT0000341114	NCT00003411_14_T1	GENE	3	3	IV
NCT0000341116	NCT00003411_16_T0	GENE	14	14	MTD
NCT0000341117	NCT00003411_17_T0	PHENOTYPE	21	21	toxicity
NCT0000341117	NCT00003411_17_T1	GENE	1	1	MTD
NCT0000341118	NCT00003411_18_T0	GENE	11	11	II
NCT0000341119	NCT00003411_19_T0	GENE	3	3	II
NCT0000341119	NCT00003411_19_T1	GENE	13	13	MTD
NCT000034125	NCT00003412_5_T0	ORGAN	9	10	immune systems
NCT000034128	NCT00003412_8_T0	GENE	8	8	interleukin-12
NCT0000341211	NCT00003412_11_T0	PHENOTYPE	10	10	toxicity
NCT0000341211	NCT00003412_11_T1	PHENOTYPE	6	7	disease progression
NCT0000341213	NCT00003412_13_T0	PHENOTYPE	21	21	toxicity
NCT0000341213	NCT00003412_13_T1	PHENOTYPE	18	18	experiences
NCT0000341215	NCT00003412_15_T0	GENE	12	12	1.2
NCT000034134	NCT00003413_4_T0	COMPOUND	26	26	melphalan
NCT000034134	NCT00003413_4_T1	GENE	19	19	IV
NCT000034134	NCT00003413_4_T2	PHENOTYPE	16	17	stage III
NCT000034134	NCT00003413_4_T3	PHENOTYPE	20	22	ovarian epithelial cancer
NCT000034136	NCT00003413_6_T0	ORGAN	8	8	autotransplant
NCT000034138	NCT00003413_8_T0	PHENOTYPE	2	4	quality of life
NCT000034139	NCT00003413_9_T0	GENE	6	6	III
NCT000034139	NCT00003413_9_T1	GENE	17	17	cm
NCT000034139	NCT00003413_9_T2	GENE	22	22	cm
NCT000034139	NCT00003413_9_T3	GENE	8	8	IV
NCT000034139	NCT00003413_9_T4	PHENOTYPE	12	13	residual disease
NCT0000341311	NCT00003413_11_T0	COMPOUND	19	19	1
NCT0000341311	NCT00003413_11_T1	COMPOUND	6	6	2
NCT0000341311	NCT00003413_11_T2	COMPOUND	10	10	2
NCT0000341311	NCT00003413_11_T3	COMPOUND	12	12	melphalan
NCT0000341311	NCT00003413_11_T4	GENE	4	4	IV
NCT0000341311	NCT00003413_11_T5	GENE	13	13	IV
NCT0000341312	NCT00003413_12_T0	COMPOUND	9	9	melphalan
NCT0000341312	NCT00003413_12_T1	CELL	0	3	Peripheral blood stem cells
NCT0000341313	NCT00003413_13_T0	CELL	11	11	granulocytes
NCT0000341313	NCT00003413_13_T1	GENE	2	2	G-CSF
NCT0000341314	NCT00003413_14_T0	COMPOUND	11	11	paclitaxel
NCT0000341314	NCT00003413_14_T1	COMPOUND	20	20	cisplatin
NCT0000341314	NCT00003413_14_T2	GENE	12	12	IV
NCT0000341314	NCT00003413_14_T3	GENE	21	21	IV
NCT0000341315	NCT00003413_15_T0	PHENOTYPE	0	0	Consolidation
NCT0000341316	NCT00003413_16_T0	ORGAN	9	9	transplant
NCT0000341316	NCT00003413_16_T1	ORGAN	13	13	transplant
NCT0000341316	NCT00003413_16_T2	PHENOTYPE	0	2	Quality of life
NCT0000341318	NCT00003413_18_T0	GENE	13	13	3.4
NCT000034141	NCT00003414_1_T0	CELL	14	14	cells
NCT000034141	NCT00003414_1_T1	GENE	0	0	Interleukin-2
NCT000034141	NCT00003414_1_T2	GENE	2	3	interferon gamma
NCT000034141	NCT00003414_1_T3	PHENOTYPE	9	10	graft-versus-host disease
NCT000034142	NCT00003414_2_T0	PHENOTYPE	20	20	lymphoma
NCT000034142	NCT00003414_2_T1	GENE	3	3	III
NCT000034142	NCT00003414_2_T2	PHENOTYPE	17	17	recurrent
NCT000034142	NCT00003414_2_T3	PHENOTYPE	22	23	Hodgkin's disease
NCT000034142	NCT00003414_2_T4	PHENOTYPE	10	11	graft-versus-host disease
NCT000034144	NCT00003414_4_T0	PHENOTYPE	10	10	relapse
NCT000034144	NCT00003414_4_T1	PHENOTYPE	13	13	lymphoma
NCT000034144	NCT00003414_4_T2	PHENOTYPE	15	16	Hodgkin's disease
NCT000034144	NCT00003414_4_T3	ORGAN	19	20	bone marrow
NCT000034144	NCT00003414_4_T4	PHENOTYPE	2	6	autologous graft versus host disease
NCT000034146	NCT00003414_6_T0	CELL	0	1	Stem cells
NCT000034151	NCT00003415_1_T0	CELL	8	8	cells
NCT000034151	NCT00003415_1_T1	COMPOUND	4	4	amifostine
NCT000034151	NCT00003415_1_T2	PHENOTYPE	12	14	effects of chemotherapy
NCT000034154	NCT00003415_4_T0	COMPOUND	9	9	amifostine
NCT000034154	NCT00003415_4_T1	COMPOUND	11	11	topotecan
NCT000034154	NCT00003415_4_T2	PHENOTYPE	15	16	myelodysplastic syndromes
NCT000034156	NCT00003415_6_T0	PHENOTYPE	2	2	toxic
NCT000034158	NCT00003415_8_T0	ORGAN	7	8	bone marrow
NCT000034159	NCT00003415_9_T0	COMPOUND	8	8	topotecan
NCT0000341510	NCT00003415_10_T0	GENE	13	13	1.5
NCT0000341510	NCT00003415_10_T1	COMPOUND	2	2	amifostine
NCT0000341510	NCT00003415_10_T2	GENE	3	3	IV
NCT0000341510	NCT00003415_10_T3	GENE	7	7	IV
NCT0000341510	NCT00003415_10_T4	GENE	15	15	4-8
NCT0000341510	NCT00003415_10_T5	COMPOUND	6	6	topotecan
NCT0000341512	NCT00003415_12_T0	COMPOUND	11	11	topotecan
NCT0000341513	NCT00003415_13_T0	PHENOTYPE	21	21	toxicity
NCT000034167	NCT00003416_7_T0	PHENOTYPE	6	6	toxicities
NCT000034168	NCT00003416_8_T0	COMPOUND	3	3	dexamethasone
NCT000034168	NCT00003416_8_T1	COMPOUND	10	10	dexamethasone
NCT000034168	NCT00003416_8_T2	GENE	14	14	1.4
NCT0000341613	NCT00003416_13_T0	CELL	4	4	cells
NCT0000341613	NCT00003416_13_T1	ORGAN	9	9	transplant
NCT0000341613	NCT00003416_13_T2	GENE	2	2	had
NCT0000341614	NCT00003416_14_T0	PHENOTYPE	51	51	toxicity
NCT0000341614	NCT00003416_14_T1	PHENOTYPE	49	49	relapse
NCT0000341614	NCT00003416_14_T2	COMPOUND	30	30	melphalan
NCT0000341614	NCT00003416_14_T3	PHENOTYPE	19	19	toxicities
NCT0000341614	NCT00003416_14_T4	GENE	3	3	interferon
NCT0000341614	NCT00003416_14_T5	GENE	35	35	interferon
NCT0000341614	NCT00003416_14_T6	ORGAN	9	9	transplant
NCT0000341614	NCT00003416_14_T7	PHENOTYPE	47	48	disease progression
NCT000034171	NCT00003417_1_T0	PHENOTYPE	12	12	tumor
NCT000034172	NCT00003417_2_T0	CELL	10	10	cells
NCT000034172	NCT00003417_2_T1	PHENOTYPE	9	9	tumor
NCT000034173	NCT00003417_3_T0	CELL	9	9	cells
NCT000034173	NCT00003417_3_T1	PHENOTYPE	8	8	tumor
NCT000034174	NCT00003417_4_T0	GENE	12	12	has
NCT000034174	NCT00003417_4_T1	PHENOTYPE	25	26	glioblastoma multiforme
NCT000034177	NCT00003417_7_T0	GENE	19	19	cc
NCT000034177	NCT00003417_7_T1	GENE	24	24	cc
NCT000034177	NCT00003417_7_T2	PHENOTYPE	11	12	residual tumor
NCT000034179	NCT00003417_9_T0	GENE	2	2	Gy
NCT0000341710	NCT00003417_10_T0	PHENOTYPE	3	3	closed
NCT0000341711	NCT00003417_11_T0	PHENOTYPE	7	7	toxicity
NCT0000341711	NCT00003417_11_T1	PHENOTYPE	5	5	acute
NCT0000341712	NCT00003417_12_T0	GENE	6	6	1.2
NCT0000341712	NCT00003417_12_T1	GENE	11	11	1.3
NCT0000341712	NCT00003417_12_T2	GENE	4	4	IV
NCT000034182	NCT00003418_2_T0	COMPOUND	6	6	exemestane
NCT000034182	NCT00003418_2_T1	COMPOUND	11	11	tamoxifen
NCT000034182	NCT00003418_2_T2	PHENOTYPE	14	15	breast cancer
NCT000034183	NCT00003418_3_T0	COMPOUND	10	10	exemestane
NCT000034183	NCT00003418_3_T1	GENE	27	27	2.3
NCT000034183	NCT00003418_3_T2	GENE	3	3	III
NCT000034183	NCT00003418_3_T3	COMPOUND	14	14	tamoxifen
NCT000034183	NCT00003418_3_T4	COMPOUND	30	30	tamoxifen
NCT000034183	NCT00003418_3_T5	PHENOTYPE	21	22	breast cancer
NCT000034185	NCT00003418_5_T0	COMPOUND	13	13	exemestane
NCT000034185	NCT00003418_5_T1	GENE	37	37	2.3
NCT000034185	NCT00003418_5_T2	COMPOUND	18	18	tamoxifen
NCT000034185	NCT00003418_5_T3	COMPOUND	41	41	tamoxifen
NCT000034185	NCT00003418_5_T4	PHENOTYPE	31	32	breast cancer
NCT000034187	NCT00003418_7_T0	PHENOTYPE	9	11	contralateral breast cancer
NCT0000341811	NCT00003418_11_T0	PHENOTYPE	1	3	quality of life
NCT0000341813	NCT00003418_13_T0	PHENOTYPE	37	37	toxicity
NCT0000341813	NCT00003418_13_T1	COMPOUND	19	19	exemestane
NCT0000341813	NCT00003418_13_T2	GENE	1	1	2.3
NCT0000341813	NCT00003418_13_T3	COMPOUND	7	7	tamoxifen
NCT0000341813	NCT00003418_13_T4	COMPOUND	15	15	tamoxifen
NCT0000341813	NCT00003418_13_T5	PHENOTYPE	33	34	disease relapse
NCT0000341814	NCT00003418_14_T0	PHENOTYPE	7	7	centers
NCT0000341814	NCT00003418_14_T1	PHENOTYPE	0	2	Quality of life
NCT000034191	NCT00003419_1_T0	PHENOTYPE	5	5	HIV
NCT000034191	NCT00003419_1_T1	PHENOTYPE	14	15	Kaposi's sarcoma
NCT000034192	NCT00003419_2_T0	GENE	3	3	II
NCT000034192	NCT00003419_2_T1	PHENOTYPE	18	18	HIV
NCT000034192	NCT00003419_2_T2	PHENOTYPE	17	17	progressing
NCT000034192	NCT00003419_2_T3	PHENOTYPE	19	20	Kaposi's sarcoma
NCT000034194	NCT00003419_4_T0	GENE	10	10	protease
NCT000034194	NCT00003419_4_T1	GENE	12	12	PI
NCT000034196	NCT00003419_6_T0	PHENOTYPE	6	6	progression
NCT000034197	NCT00003419_7_T0	GENE	7	7	KS
NCT000034197	NCT00003419_7_T1	GENE	28	28	has
NCT000034197	NCT00003419_7_T2	GENE	43	43	has
NCT000034197	NCT00003419_7_T3	PHENOTYPE	4	4	regressing
NCT000034197	NCT00003419_7_T4	PHENOTYPE	5	6	Kaposi's sarcoma
NCT000034200	NCT00003420_0_T0	PHENOTYPE	6	9	Stage I Testicular Cancer
NCT000034202	NCT00003420_2_T0	PHENOTYPE	16	19	stage I testicular cancer
NCT000034203	NCT00003420_3_T0	PHENOTYPE	23	26	stage I testicular cancer
NCT000034211	NCT00003421_1_T0	CELL	9	9	cells
NCT000034211	NCT00003421_1_T1	PHENOTYPE	8	8	tumor
NCT000034212	NCT00003421_2_T0	PHENOTYPE	13	14	Hodgkin's disease
NCT000034213	NCT00003421_3_T0	GENE	3	3	III
NCT000034213	NCT00003421_3_T1	PHENOTYPE	16	17	Hodgkin's disease
NCT000034215	NCT00003421_5_T0	PHENOTYPE	22	23	Hodgkin's disease
NCT0000342115	NCT00003421_15_T0	PHENOTYPE	14	14	remission
NCT0000342115	NCT00003421_15_T1	PHENOTYPE	17	17	remission
NCT0000342116	NCT00003421_16_T0	PHENOTYPE	4	4	remission
NCT0000342116	NCT00003421_16_T1	PHENOTYPE	9	10	residual disease
NCT0000342117	NCT00003421_17_T0	PHENOTYPE	7	8	disease progression
NCT000034221	NCT00003422_1_T0	CELL	10	10	cells
NCT000034221	NCT00003422_1_T1	PHENOTYPE	9	9	tumor
NCT000034222	NCT00003422_2_T0	PHENOTYPE	26	27	rectal cancer
NCT0000342210	NCT00003422_10_T0	COMPOUND	14	14	calcium
NCT0000342210	NCT00003422_10_T1	COMPOUND	26	26	calcium
NCT0000342210	NCT00003422_10_T2	COMPOUND	13	13	leucovorin
NCT0000342210	NCT00003422_10_T3	COMPOUND	25	25	leucovorin
NCT0000342210	NCT00003422_10_T4	GENE	11	11	IV
NCT0000342210	NCT00003422_10_T5	GENE	15	15	IV
NCT0000342212	NCT00003422_12_T0	PHENOTYPE	0	2	Quality of life
NCT000034231	NCT00003423_1_T0	CELL	9	9	cells
NCT000034232	NCT00003423_2_T0	PHENOTYPE	13	14	Hodgkin's lymphoma
NCT000034233	NCT00003423_3_T0	GENE	3	3	III
NCT000034233	NCT00003423_3_T1	PHENOTYPE	22	23	Hodgkin's lymphoma
NCT000034239	NCT00003423_9_T0	COMPOUND	28	28	methotrexate
NCT000034239	NCT00003423_9_T1	PHENOTYPE	11	12	in remission
NCT0000342310	NCT00003423_10_T0	GENE	7	7	1.28
NCT0000342311	NCT00003423_11_T0	COMPOUND	4	4	prednisolone
NCT0000342311	NCT00003423_11_T1	COMPOUND	12	12	vincristine
NCT0000342311	NCT00003423_11_T2	GENE	22	22	asparaginase
NCT0000342311	NCT00003423_11_T3	GENE	11	11	1.4
NCT0000342311	NCT00003423_11_T4	COMPOUND	35	35	methotrexate
NCT0000342311	NCT00003423_11_T5	GENE	13	13	IV
NCT0000342313	NCT00003423_13_T0	COMPOUND	30	30	cytarabine
NCT0000342313	NCT00003423_13_T1	COMPOUND	6	6	prednisolone
NCT0000342313	NCT00003423_13_T2	COMPOUND	7	7	vincristine
NCT0000342313	NCT00003423_13_T3	GENE	29	29	1.5
NCT0000342313	NCT00003423_13_T4	GENE	40	40	1.5
NCT0000342313	NCT00003423_13_T5	GENE	46	46	1.5
NCT0000342313	NCT00003423_13_T6	COMPOUND	48	48	methotrexate
NCT0000342313	NCT00003423_13_T7	COMPOUND	22	22	etoposide
NCT0000342313	NCT00003423_13_T8	GENE	8	8	IV
NCT0000342313	NCT00003423_13_T9	GENE	13	13	IV
NCT0000342313	NCT00003423_13_T10	GENE	23	23	IV
NCT0000342313	NCT00003423_13_T11	GENE	31	31	IV
NCT0000342313	NCT00003423_13_T12	COMPOUND	12	12	daunorubicin
NCT0000342315	NCT00003423_15_T0	PHENOTYPE	4	4	remission
NCT0000342316	NCT00003423_16_T0	COMPOUND	4	4	methotrexate
NCT0000342317	NCT00003423_17_T0	COMPOUND	17	17	prednisolone
NCT0000342317	NCT00003423_17_T1	COMPOUND	11	11	vincristine
NCT0000342317	NCT00003423_17_T2	COMPOUND	9	9	methotrexate
NCT0000342317	NCT00003423_17_T3	COMPOUND	26	26	methotrexate
NCT0000342317	NCT00003423_17_T4	GENE	12	12	IV
NCT0000342319	NCT00003423_19_T0	COMPOUND	41	41	cytarabine
NCT0000342319	NCT00003423_19_T1	COMPOUND	16	16	vincristine
NCT0000342319	NCT00003423_19_T2	GENE	37	37	1.5
NCT0000342319	NCT00003423_19_T3	GENE	47	47	1.5
NCT0000342319	NCT00003423_19_T4	GENE	53	53	1.5
NCT0000342319	NCT00003423_19_T5	COMPOUND	56	56	methotrexate
NCT0000342319	NCT00003423_19_T6	GENE	21	21	IV
NCT0000342319	NCT00003423_19_T7	GENE	31	31	IV
NCT0000342319	NCT00003423_19_T8	COMPOUND	20	20	daunorubicin
NCT0000342319	NCT00003423_19_T9	COMPOUND	7	7	prednisolone
NCT0000342319	NCT00003423_19_T10	COMPOUND	30	30	etoposide
NCT0000342322	NCT00003423_22_T0	COMPOUND	11	11	dexamethasone
NCT0000342322	NCT00003423_22_T1	COMPOUND	51	51	cytarabine
NCT0000342322	NCT00003423_22_T2	COMPOUND	13	13	vincristine
NCT0000342322	NCT00003423_22_T3	GENE	21	21	asparaginase
NCT0000342322	NCT00003423_22_T4	GENE	37	37	39
NCT0000342322	NCT00003423_22_T5	GENE	45	45	39
NCT0000342322	NCT00003423_22_T6	GENE	58	58	39
NCT0000342322	NCT00003423_22_T7	GENE	55	55	1.4
NCT0000342322	NCT00003423_22_T8	COMPOUND	29	29	methotrexate
NCT0000342322	NCT00003423_22_T9	GENE	12	12	IV
NCT0000342322	NCT00003423_22_T10	GENE	38	38	IV
NCT0000342322	NCT00003423_22_T11	GENE	50	50	IV
NCT0000342322	NCT00003423_22_T12	COMPOUND	39	39	cyclophosphamide
NCT000034242	NCT00003424_2_T0	COMPOUND	13	13	estrogen
NCT000034242	NCT00003424_2_T1	COMPOUND	3	3	tamoxifen
NCT000034242	NCT00003424_2_T2	PHENOTYPE	6	7	liver cancer
NCT000034243	NCT00003424_3_T0	COMPOUND	7	7	tamoxifen
NCT000034243	NCT00003424_3_T1	PHENOTYPE	19	21	primary liver cancer
NCT000034244	NCT00003424_4_T0	GENE	3	3	III
NCT000034244	NCT00003424_4_T1	COMPOUND	8	8	tamoxifen
NCT000034244	NCT00003424_4_T2	PHENOTYPE	17	18	liver cancer
NCT000034246	NCT00003424_6_T0	COMPOUND	5	5	tamoxifen
NCT000034246	NCT00003424_6_T1	PHENOTYPE	10	11	hepatocellular carcinoma
NCT000034246	NCT00003424_6_T2	PHENOTYPE	18	20	quality of life
NCT0000342411	NCT00003424_11_T0	PHENOTYPE	0	2	Quality of life
NCT000034253	NCT00003425_3_T0	CELL	8	8	cells
NCT000034253	NCT00003425_3_T1	COMPOUND	4	4	amifostine
NCT000034253	NCT00003425_3_T2	PHENOTYPE	12	14	effects of chemotherapy
NCT000034259	NCT00003425_9_T0	COMPOUND	8	8	melphalan
NCT0000342510	NCT00003425_10_T0	PHENOTYPE	7	7	cytoprotection
NCT0000342510	NCT00003425_10_T1	COMPOUND	4	4	melphalan
NCT0000342510	NCT00003425_10_T2	COMPOUND	11	11	cyclophosphamide
NCT0000342510	NCT00003425_10_T3	COMPOUND	6	6	amifostine
NCT0000342510	NCT00003425_10_T4	GENE	12	12	IV
NCT0000342511	NCT00003425_11_T0	GENE	1	1	G-CSF
NCT0000342512	NCT00003425_12_T0	COMPOUND	4	4	melphalan
NCT0000342513	NCT00003425_13_T0	COMPOUND	8	8	1
NCT0000342513	NCT00003425_13_T1	COMPOUND	2	2	melphalan
NCT0000342513	NCT00003425_13_T2	GENE	5	5	IV
NCT0000342514	NCT00003425_14_T0	COMPOUND	8	8	1
NCT0000342514	NCT00003425_14_T1	COMPOUND	6	6	2
NCT0000342516	NCT00003425_16_T0	COMPOUND	5	5	melphalan
NCT0000342516	NCT00003425_16_T1	GENE	12	12	MTD
NCT0000342517	NCT00003425_17_T0	PHENOTYPE	18	18	toxicity
NCT0000342517	NCT00003425_17_T1	GENE	1	1	MTD
NCT0000342518	NCT00003425_18_T0	COMPOUND	6	6	melphalan
NCT0000342518	NCT00003425_18_T1	GENE	2	2	MTD
NCT0000342520	NCT00003425_20_T0	GENE	6	6	MTD
NCT000034261	NCT00003426_1_T0	CELL	10	10	cells
NCT000034261	NCT00003426_1_T1	PHENOTYPE	9	9	tumor
NCT000034262	NCT00003426_2_T0	CELL	9	9	cells
NCT000034262	NCT00003426_2_T1	PHENOTYPE	8	8	tumor
NCT000034265	NCT00003426_5_T0	COMPOUND	6	6	gemcitabine
NCT000034265	NCT00003426_5_T1	PHENOTYPE	19	22	adenocarcinoma of the pancreas
NCT000034267	NCT00003426_7_T0	PHENOTYPE	4	4	toxic
NCT000034269	NCT00003426_9_T0	COMPOUND	14	14	gemcitabine
NCT0000342612	NCT00003426_12_T0	COMPOUND	8	8	gemcitabine
NCT0000342613	NCT00003426_13_T0	COMPOUND	4	4	gemcitabine
NCT0000342614	NCT00003426_14_T0	GENE	1	1	II
NCT0000342614	NCT00003426_14_T1	GENE	3	3	IV
NCT0000342616	NCT00003426_16_T0	PHENOTYPE	5	5	toxicity
NCT0000342616	NCT00003426_16_T1	COMPOUND	23	23	gemcitabine
NCT0000342616	NCT00003426_16_T2	GENE	6	6	DLT
NCT0000342617	NCT00003426_17_T0	GENE	1	1	DLT
NCT0000342618	NCT00003426_18_T0	PHENOTYPE	6	6	toxicity
NCT0000342618	NCT00003426_18_T1	GENE	1	1	III
NCT0000342618	NCT00003426_18_T2	COMPOUND	12	12	gemcitabine
NCT0000342618	NCT00003426_18_T3	PHENOTYPE	8	9	disease progression
NCT0000342619	NCT00003426_19_T0	COMPOUND	1	1	gemcitabine
NCT000034271	NCT00003427_1_T0	CELL	9	9	cells
NCT000034271	NCT00003427_1_T1	PHENOTYPE	8	8	tumor
NCT000034272	NCT00003427_2_T0	COMPOUND	11	11	irinotecan
NCT000034272	NCT00003427_2_T1	COMPOUND	9	9	oxaliplatin
NCT000034272	NCT00003427_2_T2	GENE	22	22	has
NCT000034272	NCT00003427_2_T3	PHENOTYPE	19	20	gastrointestinal cancer
NCT000034274	NCT00003427_4_T0	COMPOUND	14	14	irinotecan
NCT000034274	NCT00003427_4_T1	COMPOUND	12	12	oxaliplatin
NCT000034274	NCT00003427_4_T2	GENE	5	5	MTD
NCT000034274	NCT00003427_4_T3	PHENOTYPE	36	37	gastrointestinal cancer
NCT000034276	NCT00003427_6_T0	PHENOTYPE	2	2	toxicities
NCT000034278	NCT00003427_8_T0	COMPOUND	4	4	platinum
NCT000034278	NCT00003427_8_T1	COMPOUND	6	6	irinotecan
NCT000034278	NCT00003427_8_T2	PHENOTYPE	2	2	pharmacokinetics
NCT000034278	NCT00003427_8_T3	GENE	9	9	MTD
NCT0000342710	NCT00003427_10_T0	COMPOUND	10	10	irinotecan
NCT0000342710	NCT00003427_10_T1	COMPOUND	2	2	oxaliplatin
NCT0000342710	NCT00003427_10_T2	GENE	3	3	IV
NCT0000342710	NCT00003427_10_T3	GENE	11	11	IV
NCT0000342712	NCT00003427_12_T0	PHENOTYPE	10	11	disease progression
NCT0000342713	NCT00003427_13_T0	COMPOUND	12	12	irinotecan
NCT0000342713	NCT00003427_13_T1	COMPOUND	4	4	oxaliplatin
NCT0000342714	NCT00003427_14_T0	GENE	14	14	MTD
NCT0000342715	NCT00003427_15_T0	PHENOTYPE	22	22	toxic
NCT0000342715	NCT00003427_15_T1	GENE	1	1	MTD
NCT0000342716	NCT00003427_16_T0	GENE	5	5	2.3
NCT000034281	NCT00003428_1_T0	COMPOUND	3	3	arzoxifene
NCT000034281	NCT00003428_1_T1	COMPOUND	4	4	hydrochloride
NCT000034281	NCT00003428_1_T2	COMPOUND	14	14	estrogen
NCT000034281	NCT00003428_1_T3	CELL	18	18	cells
NCT000034281	NCT00003428_1_T4	PHENOTYPE	17	17	tumor
NCT000034281	NCT00003428_1_T5	PHENOTYPE	7	8	breast cancer
NCT000034282	NCT00003428_2_T0	GENE	4	4	II
NCT000034282	NCT00003428_2_T1	COMPOUND	12	12	arzoxifene
NCT000034282	NCT00003428_2_T2	COMPOUND	13	13	hydrochloride
NCT000034282	NCT00003428_2_T3	PHENOTYPE	26	28	metastatic breast cancer
NCT000034284	NCT00003428_4_T0	COMPOUND	25	25	arzoxifene
NCT000034284	NCT00003428_4_T1	COMPOUND	26	26	hydrochloride
NCT000034284	NCT00003428_4_T2	PHENOTYPE	14	16	metastatic breast cancer
NCT000034288	NCT00003428_8_T0	PHENOTYPE	4	4	toxicity
NCT000034288	NCT00003428_8_T1	COMPOUND	10	10	arzoxifene
NCT000034288	NCT00003428_8_T2	COMPOUND	11	11	hydrochloride
NCT0000342810	NCT00003428_10_T0	COMPOUND	15	15	arzoxifene
NCT0000342810	NCT00003428_10_T1	COMPOUND	16	16	hydrochloride
NCT0000342810	NCT00003428_10_T2	PHENOTYPE	2	4	quality of life
NCT0000342812	NCT00003428_12_T0	PHENOTYPE	4	5	progressive disease
NCT0000342816	NCT00003428_16_T0	COMPOUND	16	16	tamoxifen
NCT0000342816	NCT00003428_16_T1	GENE	24	25	estrogen receptor
NCT0000342817	NCT00003428_17_T0	COMPOUND	10	10	arzoxifene
NCT0000342817	NCT00003428_17_T1	COMPOUND	11	11	hydrochloride
NCT0000342818	NCT00003428_18_T0	COMPOUND	2	2	arzoxifene
NCT0000342818	NCT00003428_18_T1	COMPOUND	3	3	hydrochloride
NCT0000342819	NCT00003428_19_T0	PHENOTYPE	6	6	toxicity
NCT0000342819	NCT00003428_19_T1	PHENOTYPE	8	9	disease progression
NCT0000342820	NCT00003428_20_T0	PHENOTYPE	0	2	Quality of life
NCT0000342821	NCT00003428_21_T0	GENE	18	18	2.3
NCT000034291	NCT00003429_1_T0	COMPOUND	8	10	fludeoxyglucose F 18
NCT000034291	NCT00003429_1_T1	PHENOTYPE	17	19	recurrent cervical cancer
NCT000034294	NCT00003429_4_T0	GENE	9	9	FDG
NCT000034294	NCT00003429_4_T1	PHENOTYPE	3	4	cervical cancer
NCT000034294	NCT00003429_4_T2	COMPOUND	6	8	fludeoxyglucose F 18
NCT000034295	NCT00003429_5_T0	ORGAN	8	8	abdomen
NCT000034295	NCT00003429_5_T1	ORGAN	10	10	pelvis
NCT000034297	NCT00003429_7_T0	ORGAN	13	13	thorax
NCT000034297	NCT00003429_7_T1	ORGAN	14	14	abdomen
NCT000034297	NCT00003429_7_T2	ORGAN	16	16	pelvis
NCT000034297	NCT00003429_7_T3	PHENOTYPE	2	4	recurrent cervical cancer
NCT000034299	NCT00003429_9_T0	PHENOTYPE	11	12	cervical cancer
NCT000034299	NCT00003429_9_T1	PHENOTYPE	17	19	recurrent cervical cancer
NCT000034300	NCT00003430_0_T0	PHENOTYPE	5	5	Recurrent
NCT000034300	NCT00003430_0_T1	PHENOTYPE	8	9	Solid Tumors
NCT000034302	NCT00003430_2_T0	PHENOTYPE	14	14	recurrent
NCT000034302	NCT00003430_2_T1	PHENOTYPE	17	18	solid tumors
NCT000034304	NCT00003430_4_T0	PHENOTYPE	10	10	recurrent
NCT000034304	NCT00003430_4_T1	PHENOTYPE	13	14	solid tumors
NCT000034306	NCT00003430_6_T0	PHENOTYPE	13	13	toxicity
NCT0000343010	NCT00003430_10_T0	PHENOTYPE	4	4	tumor
NCT0000343012	NCT00003430_12_T0	GENE	4	4	ras
NCT0000343014	NCT00003430_14_T0	ORGAN	4	4	plasma
NCT0000343014	NCT00003430_14_T1	PHENOTYPE	5	6	drug levels
NCT0000343017	NCT00003430_17_T0	PHENOTYPE	10	10	toxic
NCT0000343017	NCT00003430_17_T1	PHENOTYPE	6	7	disease progression
NCT0000343019	NCT00003430_19_T0	GENE	14	14	MTD
NCT0000343020	NCT00003430_20_T0	PHENOTYPE	18	18	toxicities
NCT0000343020	NCT00003430_20_T1	GENE	0	0	MTD
NCT0000343020	NCT00003430_20_T2	PHENOTYPE	15	15	experiences
NCT000034311	NCT00003431_1_T0	PHENOTYPE	18	18	metastases
NCT000034311	NCT00003431_1_T1	PHENOTYPE	20	21	colorectal cancer
NCT000034313	NCT00003431_3_T0	PHENOTYPE	15	16	colorectal cancer
NCT000034313	NCT00003431_3_T1	GENE	7	8	flt3 ligand
NCT000034313	NCT00003431_3_T2	PHENOTYPE	12	13	hepatic metastases
NCT000034314	NCT00003431_4_T0	GENE	3	4	flt3 ligand
NCT000034316	NCT00003431_6_T0	GENE	11	12	Flt3 ligand
NCT000034317	NCT00003431_7_T0	PHENOTYPE	4	4	metastasis
NCT000034324	NCT00003432_4_T0	GENE	8	8	CEA
NCT000034324	NCT00003432_4_T1	CELL	1	2	dendritic cells
NCT000034324	NCT00003432_4_T2	GENE	6	7	carcinoembryonic antigen
NCT000034332	NCT00003433_2_T0	PHENOTYPE	23	24	colon cancer
NCT000034332	NCT00003433_2_T1	PHENOTYPE	20	21	liver metastases
NCT000034332	NCT00003433_2_T2	CELL	12	14	white blood cells
NCT000034334	NCT00003433_4_T0	GENE	7	7	4.5
NCT000034334	NCT00003433_4_T1	CELL	11	12	dendritic cells
NCT000034335	NCT00003433_5_T0	GENE	1	1	separated
NCT000034335	NCT00003433_5_T1	GENE	9	9	CEA
NCT000034335	NCT00003433_5_T2	CELL	2	3	dendritic cells
NCT000034335	NCT00003433_5_T3	GENE	7	8	carcinoembryonic antigen
NCT000034336	NCT00003433_6_T0	GENE	2	2	CEA
NCT000034336	NCT00003433_6_T1	CELL	5	6	dendritic cells
NCT000034338	NCT00003433_8_T0	PHENOTYPE	26	26	toxicity
NCT000034338	NCT00003433_8_T1	GENE	13	13	CEA
NCT000034338	NCT00003433_8_T2	CELL	5	6	dendritic cells
NCT000034338	NCT00003433_8_T3	CELL	16	17	dendritic cells
NCT000034341	NCT00003434_1_T0	GENE	2	2	II
NCT000034341	NCT00003434_1_T1	GENE	23	23	II
NCT000034341	NCT00003434_1_T2	GENE	30	30	has
NCT000034341	NCT00003434_1_T3	GENE	13	14	carcinoembryonic antigen
NCT000034341	NCT00003434_1_T4	CELL	9	11	white blood cells
NCT000034341	NCT00003434_1_T5	PHENOTYPE	25	28	stage III pancreatic cancer
NCT000034346	NCT00003434_6_T0	GENE	7	7	4.5
NCT000034347	NCT00003434_7_T0	GENE	11	11	CEA
NCT000034347	NCT00003434_7_T1	CELL	4	5	dendritic cells
NCT000034347	NCT00003434_7_T2	GENE	9	10	carcinoembryonic antigen
NCT000034347	NCT00003434_7_T3	PHENOTYPE	20	21	hepatitis B
NCT000034348	NCT00003434_8_T0	GENE	3	3	CEA
NCT000034348	NCT00003434_8_T1	CELL	8	9	dendritic cells
NCT000034357	NCT00003435_7_T0	TISSUE	14	14	tissues
NCT000034357	NCT00003435_7_T1	PHENOTYPE	7	7	HIV
NCT000034357	NCT00003435_7_T2	ORGAN	12	12	serum
NCT0000343510	NCT00003435_10_T0	PHENOTYPE	17	17	initiation
NCT0000343510	NCT00003435_10_T1	PHENOTYPE	21	21	conditioning
NCT0000343511	NCT00003435_11_T0	COMPOUND	9	9	1
NCT0000343511	NCT00003435_11_T1	ORGAN	12	12	transplant
NCT0000343513	NCT00003435_13_T0	PHENOTYPE	22	22	conditioning
NCT0000343513	NCT00003435_13_T1	ORGAN	8	8	transplants
NCT0000343513	NCT00003435_13_T2	PHENOTYPE	29	30	graft failure
NCT0000343513	NCT00003435_13_T3	ORGAN	4	6	umbilical cord blood
NCT0000343513	NCT00003435_13_T4	CELL	13	16	peripheral blood stem cells
NCT0000343514	NCT00003435_14_T0	PHENOTYPE	14	14	conditioning
NCT0000343515	NCT00003435_15_T0	COMPOUND	26	26	2
NCT0000343515	NCT00003435_15_T1	COMPOUND	17	17	melphalan
NCT0000343515	NCT00003435_15_T2	PHENOTYPE	1	1	conditioning
NCT0000343515	NCT00003435_15_T3	GENE	18	18	IV
NCT0000343516	NCT00003435_16_T0	COMPOUND	15	15	1
NCT0000343516	NCT00003435_16_T1	COMPOUND	13	13	3
NCT0000343516	NCT00003435_16_T2	CELL	6	6	thymocyte
NCT0000343516	NCT00003435_16_T3	ORGAN	3	3	transplant
NCT0000343516	NCT00003435_16_T4	GENE	7	7	globulin
NCT0000343520	NCT00003435_20_T0	PHENOTYPE	18	18	lymphoma
NCT0000343520	NCT00003435_20_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000343520	NCT00003435_20_T2	PHENOTYPE	16	17	high grade
NCT000034361	NCT00003436_1_T0	CELL	19	19	cells
NCT000034361	NCT00003436_1_T1	ORGAN	3	4	bone marrow
NCT000034367	NCT00003436_7_T0	COMPOUND	15	15	cytarabine
NCT000034367	NCT00003436_7_T1	COMPOUND	17	17	hydrocortisone
NCT000034367	NCT00003436_7_T2	COMPOUND	14	14	methotrexate
NCT0000343610	NCT00003436_10_T0	GENE	22	22	MRC
NCT0000343611	NCT00003436_11_T0	COMPOUND	18	18	cytarabine
NCT0000343611	NCT00003436_11_T1	COMPOUND	1	1	3
NCT0000343611	NCT00003436_11_T2	COMPOUND	37	37	3
NCT0000343611	NCT00003436_11_T3	GENE	17	17	1.5
NCT0000343611	NCT00003436_11_T4	GENE	25	25	1.5
NCT0000343611	NCT00003436_11_T5	GENE	34	34	1.5
NCT0000343611	NCT00003436_11_T6	COMPOUND	27	27	etoposide
NCT0000343611	NCT00003436_11_T7	GENE	10	10	IV
NCT0000343611	NCT00003436_11_T8	GENE	20	20	IV
NCT0000343611	NCT00003436_11_T9	GENE	28	28	IV
NCT0000343611	NCT00003436_11_T10	COMPOUND	9	9	amsacrine
NCT000034371	NCT00003437_1_T0	CELL	10	10	cells
NCT000034372	NCT00003437_2_T0	CELL	9	9	cells
NCT000034372	NCT00003437_2_T1	GENE	1	1	hormone
NCT000034373	NCT00003437_3_T0	GENE	6	6	hormone
NCT000034373	NCT00003437_3_T1	PHENOTYPE	15	17	acute lymphoblastic leukemia
NCT000034374	NCT00003437_4_T0	GENE	3	3	III
NCT000034374	NCT00003437_4_T1	PHENOTYPE	21	23	acute lymphoblastic leukemia
NCT000034377	NCT00003437_7_T0	COMPOUND	9	9	dexamethasone
NCT000034377	NCT00003437_7_T1	COMPOUND	7	7	prednisolone
NCT000034379	NCT00003437_9_T0	GENE	23	23	WBC
NCT0000343710	NCT00003437_10_T0	COMPOUND	9	9	methotrexate
NCT0000343710	NCT00003437_10_T1	GENE	8	8	IT
NCT0000343711	NCT00003437_11_T0	COMPOUND	12	12	methotrexate
NCT0000343711	NCT00003437_11_T1	GENE	13	13	IT
NCT0000343712	NCT00003437_12_T0	COMPOUND	6	6	methotrexate
NCT0000343712	NCT00003437_12_T1	GENE	7	7	IT
NCT0000343713	NCT00003437_13_T0	ORGAN	14	14	testes
NCT0000343713	NCT00003437_13_T1	PHENOTYPE	3	3	infiltration
NCT0000343717	NCT00003437_17_T0	COMPOUND	30	30	vincristine
NCT0000343717	NCT00003437_17_T1	GENE	31	31	IV
NCT0000343719	NCT00003437_19_T0	GENE	4	4	IM
NCT0000343719	NCT00003437_19_T1	GENE	3	3	asparaginase
NCT0000343719	NCT00003437_19_T2	COMPOUND	19	19	methotrexate
NCT0000343719	NCT00003437_19_T3	GENE	20	20	IT
NCT0000343720	NCT00003437_20_T0	GENE	1	1	IV
NCT0000343723	NCT00003437_23_T0	GENE	1	1	IM
NCT0000343725	NCT00003437_25_T0	COMPOUND	18	18	vincristine
NCT0000343725	NCT00003437_25_T1	GENE	11	11	1.5
NCT0000343725	NCT00003437_25_T2	GENE	19	19	IV
NCT0000343726	NCT00003437_26_T0	GENE	1	1	IT
NCT0000343727	NCT00003437_27_T0	COMPOUND	4	4	methotrexate
NCT0000343733	NCT00003437_33_T0	GENE	4	4	IM
NCT0000343733	NCT00003437_33_T1	GENE	3	3	asparaginase
NCT0000343733	NCT00003437_33_T2	COMPOUND	19	19	methotrexate
NCT0000343733	NCT00003437_33_T3	GENE	20	20	IT
NCT0000343735	NCT00003437_35_T0	GENE	1	1	IM
NCT0000343738	NCT00003437_38_T0	COMPOUND	3	3	vincristine
NCT0000343738	NCT00003437_38_T1	GENE	4	4	IV
NCT0000343738	NCT00003437_38_T2	GENE	13	13	IV
NCT0000343738	NCT00003437_38_T3	COMPOUND	12	12	daunorubicin
NCT0000343739	NCT00003437_39_T0	GENE	1	1	IM
NCT0000343741	NCT00003437_41_T0	COMPOUND	3	3	vincristine
NCT0000343741	NCT00003437_41_T1	GENE	4	4	IV
NCT0000343741	NCT00003437_41_T2	GENE	7	7	IV
NCT0000343741	NCT00003437_41_T3	COMPOUND	6	6	daunorubicin
NCT0000343742	NCT00003437_42_T0	GENE	1	1	IM
NCT0000343746	NCT00003437_46_T0	GENE	1	1	IM
NCT000034391	NCT00003439_1_T0	CELL	4	4	cells
NCT000034391	NCT00003439_1_T1	CELL	23	23	cells
NCT000034391	NCT00003439_1_T2	PHENOTYPE	3	3	tumor
NCT000034391	NCT00003439_1_T3	PHENOTYPE	11	11	tumor
NCT000034391	NCT00003439_1_T4	CELL	17	19	white blood cells
NCT000034393	NCT00003439_3_T0	GENE	10	10	interleukin-12
NCT000034393	NCT00003439_3_T1	PHENOTYPE	26	26	diffuse
NCT000034393	NCT00003439_3_T2	PHENOTYPE	22	23	ovarian cancer
NCT000034393	NCT00003439_3_T3	PHENOTYPE	27	28	abdominal carcinomatosis
NCT000034399	NCT00003439_9_T0	GENE	12	12	interleukin-12
NCT0000343911	NCT00003439_11_T0	PHENOTYPE	7	7	toxicity
NCT0000343911	NCT00003439_11_T1	PHENOTYPE	9	10	disease progression
NCT0000343912	NCT00003439_12_T0	GENE	8	8	MTD
NCT0000343913	NCT00003439_13_T0	PHENOTYPE	21	21	toxicity
NCT0000343913	NCT00003439_13_T1	GENE	1	1	MTD
NCT0000343913	NCT00003439_13_T2	PHENOTYPE	18	18	experiences
NCT000034401	NCT00003440_1_T0	COMPOUND	6	6	paclitaxel
NCT000034401	NCT00003440_1_T1	CELL	13	13	cells
NCT000034401	NCT00003440_1_T2	PHENOTYPE	12	12	tumor
NCT000034403	NCT00003440_3_T0	COMPOUND	8	8	paclitaxel
NCT000034403	NCT00003440_3_T1	PHENOTYPE	20	21	breast cancer
NCT000034407	NCT00003440_7_T0	GENE	8	8	DD
NCT000034407	NCT00003440_7_T1	GENE	20	20	DD
NCT000034407	NCT00003440_7_T2	COMPOUND	11	11	paclitaxel
NCT000034407	NCT00003440_7_T3	COMPOUND	23	23	paclitaxel
NCT000034407	NCT00003440_7_T4	COMPOUND	34	34	1
NCT000034407	NCT00003440_7_T5	GENE	26	26	HER-2/neu
NCT000034407	NCT00003440_7_T6	PHENOTYPE	28	30	metastatic breast cancer
NCT000034409	NCT00003440_9_T0	GENE	19	19	HER-2/neu
NCT000034409	NCT00003440_9_T1	PHENOTYPE	21	23	metastatic breast cancer
NCT000034409	NCT00003440_9_T2	PHENOTYPE	12	14	quality of life
NCT0000344011	NCT00003440_11_T0	COMPOUND	20	20	paclitaxel
NCT0000344011	NCT00003440_11_T1	COMPOUND	31	31	paclitaxel
NCT0000344011	NCT00003440_11_T2	PHENOTYPE	11	13	metastatic breast cancer
NCT0000344011	NCT00003440_11_T3	PHENOTYPE	4	6	quality of life
NCT0000344016	NCT00003440_16_T0	PHENOTYPE	11	11	relapse
NCT0000344018	NCT00003440_18_T0	GENE	18	18	DD
NCT0000344018	NCT00003440_18_T1	COMPOUND	21	21	paclitaxel
NCT0000344018	NCT00003440_18_T2	PHENOTYPE	4	4	progression
NCT0000344018	NCT00003440_18_T3	GENE	10	10	HER-2
NCT0000344018	NCT00003440_18_T4	PHENOTYPE	12	14	metastatic breast cancer
NCT0000344020	NCT00003440_20_T0	GENE	18	18	DD
NCT0000344020	NCT00003440_20_T1	GENE	24	24	DD
NCT0000344020	NCT00003440_20_T2	COMPOUND	21	21	paclitaxel
NCT0000344020	NCT00003440_20_T3	COMPOUND	27	27	paclitaxel
NCT0000344020	NCT00003440_20_T4	PHENOTYPE	4	4	progression
NCT0000344020	NCT00003440_20_T5	GENE	10	10	HER-2
NCT0000344020	NCT00003440_20_T6	PHENOTYPE	12	14	metastatic breast cancer
NCT0000344022	NCT00003440_22_T0	PHENOTYPE	2	3	cardiac toxicity
NCT0000344025	NCT00003440_25_T0	COMPOUND	4	4	paclitaxel
NCT0000344025	NCT00003440_25_T1	GENE	0	0	ARM
NCT0000344025	NCT00003440_25_T2	GENE	6	6	IV
NCT0000344026	NCT00003440_26_T0	COMPOUND	4	4	paclitaxel
NCT0000344026	NCT00003440_26_T1	GENE	0	0	ARM
NCT0000344026	NCT00003440_26_T2	GENE	5	5	IV
NCT0000344028	NCT00003440_28_T0	GENE	4	4	IV
NCT000034411	NCT00003441_1_T0	GENE	2	2	II
NCT000034411	NCT00003441_1_T1	COMPOUND	9	9	irofulven
NCT000034411	NCT00003441_1_T2	PHENOTYPE	14	16	metastatic colorectal cancer
NCT000034416	NCT00003441_6_T0	ORGAN	25	25	rectum
NCT000034416	NCT00003441_6_T1	PHENOTYPE	19	20	metastatic adenocarcinoma
NCT000034416	NCT00003441_6_T2	PHENOTYPE	20	23	adenocarcinoma of the colon
NCT000034418	NCT00003441_8_T0	PHENOTYPE	5	5	toxicities
NCT000034419	NCT00003441_9_T0	GENE	5	5	IV
NCT0000344112	NCT00003441_12_T0	PHENOTYPE	8	8	toxic
NCT0000344112	NCT00003441_12_T1	PHENOTYPE	11	12	disease progression
NCT000034430	NCT00003443_0_T0	PHENOTYPE	8	12	Recurrent Head and Neck Cancer
NCT000034432	NCT00003443_2_T0	GENE	2	2	II
NCT000034432	NCT00003443_2_T1	COMPOUND	9	10	bryostatin 1
NCT000034432	NCT00003443_2_T2	PHENOTYPE	17	21	recurrent head and neck cancer
NCT000034436	NCT00003443_6_T0	PHENOTYPE	4	4	toxicity
NCT000034436	NCT00003443_6_T1	COMPOUND	6	7	bryostatin 1
NCT000034439	NCT00003443_9_T0	GENE	5	5	IV
NCT000034439	NCT00003443_9_T1	COMPOUND	3	4	bryostatin 1
NCT0000344310	NCT00003443_10_T0	PHENOTYPE	11	11	toxicity
NCT0000344310	NCT00003443_10_T1	PHENOTYPE	13	14	disease progression
NCT0000344312	NCT00003443_12_T0	GENE	12	12	1.2
NCT000034442	NCT00003444_2_T0	PHENOTYPE	22	22	melanoma
NCT000034442	NCT00003444_2_T1	COMPOUND	10	11	interferon alfa_2b
NCT000034442	NCT00003444_2_T2	COMPOUND	17	18	interferon alfa_2b
NCT000034445	NCT00003444_5_T0	PHENOTYPE	35	35	recurrence
NCT000034445	NCT00003444_5_T1	PHENOTYPE	16	16	relapse
NCT000034445	NCT00003444_5_T2	GENE	33	33	nodal
NCT000034445	NCT00003444_5_T3	GENE	12	12	interferon
NCT000034445	NCT00003444_5_T4	PHENOTYPE	20	21	malignant melanoma
NCT000034447	NCT00003444_7_T0	PHENOTYPE	8	8	relapse
NCT000034449	NCT00003444_9_T0	PHENOTYPE	2	2	toxicity
NCT0000344411	NCT00003444_11_T0	PHENOTYPE	8	8	recurrence
NCT0000344411	NCT00003444_11_T1	GENE	6	6	nodal
NCT0000344412	NCT00003444_12_T0	COMPOUND	8	9	interferon alfa_2b
NCT0000344412	NCT00003444_12_T1	COMPOUND	18	19	interferon alfa_2b
NCT0000344414	NCT00003444_14_T0	GENE	4	4	IV
NCT0000344414	NCT00003444_14_T1	COMPOUND	2	3	interferon alfa_2b
NCT000034451	NCT00003445_1_T0	GENE	2	2	II
NCT000034451	NCT00003445_1_T1	COMPOUND	9	9	docetaxel
NCT000034451	NCT00003445_1_T2	PHENOTYPE	14	15	advanced cancer
NCT000034451	NCT00003445_1_T3	PHENOTYPE	15	18	cancer of the cervix
NCT000034455	NCT00003445_5_T0	PHENOTYPE	2	2	tumor
NCT000034455	NCT00003445_5_T1	PHENOTYPE	4	5	toxic effect
NCT000034456	NCT00003445_6_T0	COMPOUND	3	3	docetaxel
NCT000034456	NCT00003445_6_T1	GENE	4	4	IV
NCT000034461	NCT00003446_1_T0	CELL	9	9	cells
NCT000034461	NCT00003446_1_T1	PHENOTYPE	8	8	tumor
NCT000034462	NCT00003446_2_T0	GENE	2	2	II
NCT000034462	NCT00003446_2_T1	COMPOUND	13	13	leucovorin
NCT000034462	NCT00003446_2_T2	PHENOTYPE	18	18	recurrent
NCT000034462	NCT00003446_2_T3	COMPOUND	9	10	trimetrexate glucuronate
NCT000034462	NCT00003446_2_T4	PHENOTYPE	20	22	metastatic colorectal cancer
NCT000034464	NCT00003446_4_T0	COMPOUND	28	28	calcium
NCT000034464	NCT00003446_4_T1	PHENOTYPE	1	1	tumor
NCT000034464	NCT00003446_4_T2	COMPOUND	27	27	leucovorin
NCT000034464	NCT00003446_4_T3	PHENOTYPE	15	15	recurrent
NCT000034464	NCT00003446_4_T4	COMPOUND	23	24	trimetrexate glucuronate
NCT000034464	NCT00003446_4_T5	PHENOTYPE	18	19	colorectal carcinoma
NCT000034465	NCT00003446_5_T0	GENE	6	6	IV
NCT000034465	NCT00003446_5_T1	COMPOUND	3	4	trimetrexate glucuronate
NCT000034466	NCT00003446_6_T0	COMPOUND	10	10	calcium
NCT000034466	NCT00003446_6_T1	COMPOUND	9	9	leucovorin
NCT000034466	NCT00003446_6_T2	GENE	12	12	IV
NCT000034467	NCT00003446_7_T0	GENE	11	11	IV
NCT000034469	NCT00003446_9_T0	PHENOTYPE	13	13	toxicity
NCT000034469	NCT00003446_9_T1	PHENOTYPE	9	10	disease progression
NCT000034472	NCT00003447_2_T0	CELL	9	9	cells
NCT000034472	NCT00003447_2_T1	PHENOTYPE	8	8	tumor
NCT000034477	NCT00003447_7_T0	PHENOTYPE	4	4	toxicity
NCT000034477	NCT00003447_7_T1	COMPOUND	11	11	vinorelbine
NCT000034477	NCT00003447_7_T2	COMPOUND	9	9	gemcitabine
NCT000034479	NCT00003447_9_T0	PHENOTYPE	5	7	quality of life
NCT0000344711	NCT00003447_11_T0	PHENOTYPE	6	6	progression
NCT0000344713	NCT00003447_13_T0	PHENOTYPE	2	2	toxicities
NCT0000344717	NCT00003447_17_T0	GENE	10	10	IV
NCT0000344719	NCT00003447_19_T0	COMPOUND	3	3	vinorelbine
NCT0000344719	NCT00003447_19_T1	COMPOUND	5	5	gemcitabine
NCT0000344719	NCT00003447_19_T2	GENE	4	4	IV
NCT0000344719	NCT00003447_19_T3	GENE	6	6	IV
NCT0000344721	NCT00003447_21_T0	PHENOTYPE	0	2	Quality of life
NCT000034491	NCT00003449_1_T0	CELL	9	9	cells
NCT000034491	NCT00003449_1_T1	PHENOTYPE	8	8	tumor
NCT000034492	NCT00003449_2_T0	GENE	2	2	II
NCT000034492	NCT00003449_2_T1	COMPOUND	9	9	dexamethasone
NCT000034492	NCT00003449_2_T2	COMPOUND	11	11	paclitaxel
NCT000034492	NCT00003449_2_T3	COMPOUND	13	13	gemcitabine
NCT000034492	NCT00003449_2_T4	PHENOTYPE	19	21	recurrent ovarian cancer
NCT000034494	NCT00003449_4_T0	COMPOUND	9	9	paclitaxel
NCT000034494	NCT00003449_4_T1	COMPOUND	18	18	paclitaxel
NCT000034494	NCT00003449_4_T2	COMPOUND	29	29	paclitaxel
NCT000034494	NCT00003449_4_T3	PHENOTYPE	12	12	relapse
NCT000034494	NCT00003449_4_T4	PHENOTYPE	23	23	relapse
NCT000034494	NCT00003449_4_T5	PHENOTYPE	20	21	progressive disease
NCT000034495	NCT00003449_5_T0	COMPOUND	2	2	dexamethasone
NCT000034495	NCT00003449_5_T1	COMPOUND	5	5	paclitaxel
NCT000034495	NCT00003449_5_T2	COMPOUND	9	9	gemcitabine
NCT000034495	NCT00003449_5_T3	GENE	3	3	IV
NCT000034495	NCT00003449_5_T4	GENE	6	6	IV
NCT000034495	NCT00003449_5_T5	GENE	10	10	IV
NCT000034496	NCT00003449_6_T0	PHENOTYPE	14	14	toxicity
NCT000034496	NCT00003449_6_T1	PHENOTYPE	10	11	disease progression
NCT000034501	NCT00003450_1_T0	PHENOTYPE	20	20	recurrent
NCT000034501	NCT00003450_1_T1	GENE	13	13	p53
NCT000034501	NCT00003450_1_T2	PHENOTYPE	23	24	ovarian cancer
NCT000034501	NCT00003450_1_T3	PHENOTYPE	27	29	peritoneal cavity cancer
NCT000034503	NCT00003450_3_T0	PHENOTYPE	6	6	toxicities
NCT000034503	NCT00003450_3_T1	PHENOTYPE	17	17	recurrent
NCT000034503	NCT00003450_3_T2	GENE	10	10	p53
NCT000034503	NCT00003450_3_T3	PHENOTYPE	20	21	ovarian carcinoma
NCT000034508	NCT00003450_8_T0	GENE	9	9	p53
NCT000034509	NCT00003450_9_T0	PHENOTYPE	4	4	ascites
NCT000034509	NCT00003450_9_T1	GENE	18	18	p53
NCT000034509	NCT00003450_9_T2	ORGAN	9	10	peritoneal cavity
NCT0000345010	NCT00003450_10_T0	PHENOTYPE	13	13	toxicity
NCT0000345010	NCT00003450_10_T1	PHENOTYPE	9	10	disease progression
NCT0000345012	NCT00003450_12_T0	GENE	11	11	p53
NCT0000345013	NCT00003450_13_T0	PHENOTYPE	21	21	toxicity
NCT0000345014	NCT00003450_14_T0	PHENOTYPE	7	7	toxicity
NCT0000345014	NCT00003450_14_T1	GENE	4	4	MTD
NCT000034511	NCT00003451_1_T0	CELL	11	11	cells
NCT000034511	NCT00003451_1_T1	CELL	5	7	white blood cells
NCT000034513	NCT00003451_3_T0	GENE	1	1	interleukin-12
NCT000034513	NCT00003451_3_T1	CELL	9	9	cells
NCT000034513	NCT00003451_3_T2	GENE	3	3	interferon
NCT000034515	NCT00003451_5_T0	GENE	15	15	interleukin-12
NCT000034515	NCT00003451_5_T1	PHENOTYPE	26	26	malignancies
NCT000034515	NCT00003451_5_T2	GENE	6	6	interferon
NCT000034515	NCT00003451_5_T3	PHENOTYPE	19	19	recurrent
NCT000034515	NCT00003451_5_T4	PHENOTYPE	21	22	metastatic melanoma
NCT000034517	NCT00003451_7_T0	GENE	5	5	interleukin-12
NCT000034517	NCT00003451_7_T1	GENE	16	16	interferon
NCT000034517	NCT00003451_7_T2	GENE	6	6	IV
NCT000034518	NCT00003451_8_T0	PHENOTYPE	16	16	toxicity
NCT000034518	NCT00003451_8_T1	PHENOTYPE	18	19	disease progression
NCT0000345110	NCT00003451_10_T0	PHENOTYPE	15	15	toxicity
NCT0000345110	NCT00003451_10_T1	GENE	3	3	interferon
NCT0000345110	NCT00003451_10_T2	GENE	16	16	DLT
NCT0000345111	NCT00003451_11_T0	PHENOTYPE	5	5	experiences
NCT0000345111	NCT00003451_11_T1	GENE	6	6	DLT
NCT0000345112	NCT00003451_12_T0	GENE	10	10	stops
NCT0000345112	NCT00003451_12_T1	GENE	6	6	DLT
NCT0000345113	NCT00003451_13_T0	GENE	21	21	DLT
NCT000034521	NCT00003452_1_T0	GENE	36	36	has
NCT000034521	NCT00003452_1_T1	GENE	17	17	IV
NCT000034521	NCT00003452_1_T2	GENE	41	41	IV
NCT000034521	NCT00003452_1_T3	PHENOTYPE	18	19	bladder cancer
NCT000034521	NCT00003452_1_T4	PHENOTYPE	42	43	bladder cancer
NCT000034523	NCT00003452_3_T0	GENE	4	4	A10
NCT000034524	NCT00003452_4_T0	GENE	6	6	A10
NCT000034526	NCT00003452_6_T0	PHENOTYPE	14	14	toxicity
NCT000034526	NCT00003452_6_T1	PHENOTYPE	10	11	disease progression
NCT000034530	NCT00003453_0_T0	GENE	7	7	IV
NCT000034530	NCT00003453_0_T1	PHENOTYPE	8	10	Adrenal Gland Cancer
NCT000034532	NCT00003453_2_T0	GENE	37	37	has
NCT000034532	NCT00003453_2_T1	GENE	17	17	IV
NCT000034532	NCT00003453_2_T2	GENE	42	42	IV
NCT000034532	NCT00003453_2_T3	PHENOTYPE	18	20	adrenal gland cancer
NCT000034532	NCT00003453_2_T4	PHENOTYPE	43	45	adrenal gland cancer
NCT000034534	NCT00003453_4_T0	GENE	4	4	A10
NCT000034535	NCT00003453_5_T0	GENE	6	6	A10
NCT000034537	NCT00003453_7_T0	PHENOTYPE	13	13	toxicity
NCT000034537	NCT00003453_7_T1	PHENOTYPE	9	10	disease progression
NCT000034542	NCT00003454_2_T0	GENE	3	3	II
NCT000034542	NCT00003454_2_T1	GENE	21	21	has
NCT000034542	NCT00003454_2_T2	PHENOTYPE	16	19	stage IV breast cancer
NCT000034544	NCT00003454_4_T0	GENE	4	4	A10
NCT000034545	NCT00003454_5_T0	GENE	6	6	A10
NCT000034547	NCT00003454_7_T0	PHENOTYPE	13	13	toxicity
NCT000034547	NCT00003454_7_T1	PHENOTYPE	9	10	disease progression
NCT000034552	NCT00003455_2_T0	GENE	3	3	II
NCT000034552	NCT00003455_2_T1	GENE	21	21	has
NCT000034552	NCT00003455_2_T2	PHENOTYPE	16	19	stage IV breast cancer
NCT000034557	NCT00003455_7_T0	PHENOTYPE	14	14	toxic
NCT000034557	NCT00003455_7_T1	PHENOTYPE	11	12	disease progression
NCT000034561	NCT00003456_1_T0	PHENOTYPE	16	17	brain tumors
NCT000034562	NCT00003456_2_T0	GENE	16	16	has
NCT000034562	NCT00003456_2_T1	PHENOTYPE	27	28	Glioblastoma Multiforme
NCT000034564	NCT00003456_4_T0	GENE	4	4	A10
NCT000034565	NCT00003456_5_T0	GENE	6	6	A10
NCT000034567	NCT00003456_7_T0	PHENOTYPE	15	15	toxicity
NCT000034567	NCT00003456_7_T1	PHENOTYPE	11	12	disease progression
NCT000034572	NCT00003457_2_T0	PHENOTYPE	20	22	recurrent brain tumors
NCT000034573	NCT00003457_3_T0	GENE	16	16	has
NCT000034573	NCT00003457_3_T1	PHENOTYPE	22	24	recurrent brain tumors
NCT000034577	NCT00003457_7_T0	PHENOTYPE	15	15	toxicity
NCT000034577	NCT00003457_7_T1	PHENOTYPE	11	12	disease progression
NCT000034579	NCT00003457_9_T0	GENE	9	9	MRI
NCT000034579	NCT00003457_9_T1	PHENOTYPE	4	4	tumor
NCT000034582	NCT00003458_2_T0	PHENOTYPE	16	18	childhood brain tumors
NCT000034586	NCT00003458_6_T0	PHENOTYPE	15	15	toxicity
NCT000034586	NCT00003458_6_T1	PHENOTYPE	11	12	disease progression
NCT000034592	NCT00003459_2_T0	PHENOTYPE	18	18	gliomas
NCT000034592	NCT00003459_2_T1	ORGAN	16	17	brain stem
NCT000034596	NCT00003459_6_T0	PHENOTYPE	15	15	toxicity
NCT000034596	NCT00003459_6_T1	PHENOTYPE	11	12	disease progression
NCT000034598	NCT00003459_8_T0	GENE	9	9	MRI
NCT000034598	NCT00003459_8_T1	PHENOTYPE	4	4	tumor
NCT000034601	NCT00003460_1_T0	PHENOTYPE	18	20	primitive neuroectodermal tumors
NCT000034606	NCT00003460_6_T0	PHENOTYPE	15	15	toxicity
NCT000034606	NCT00003460_6_T1	PHENOTYPE	11	12	disease progression
NCT000034608	NCT00003460_8_T0	GENE	9	9	MRI
NCT000034608	NCT00003460_8_T1	PHENOTYPE	4	4	tumor
NCT000034612	NCT00003461_2_T0	PHENOTYPE	9	10	brain tumors
NCT000034613	NCT00003461_3_T0	PHENOTYPE	20	21	brain tumors
NCT000034616	NCT00003461_6_T0	PHENOTYPE	6	6	tumor
NCT000034616	NCT00003461_6_T1	PHENOTYPE	14	14	cavity
NCT000034619	NCT00003461_9_T0	PHENOTYPE	20	20	toxicity
NCT000034621	NCT00003462_1_T0	CELL	19	19	cells
NCT000034621	NCT00003462_1_T1	PHENOTYPE	18	18	tumor
NCT000034621	NCT00003462_1_T2	ORGAN	11	12	spinal cord
NCT000034622	NCT00003462_2_T0	COMPOUND	10	10	busulfan
NCT000034622	NCT00003462_2_T1	PHENOTYPE	20	20	tumors
NCT000034622	NCT00003462_2_T2	PHENOTYPE	15	15	recurrent
NCT000034625	NCT00003462_5_T0	COMPOUND	3	3	busulfan
NCT000034626	NCT00003462_6_T0	PHENOTYPE	45	45	toxicity
NCT000034626	NCT00003462_6_T1	PHENOTYPE	41	42	disease progression
NCT000034627	NCT00003462_7_T0	COMPOUND	9	9	busulfan
NCT000034627	NCT00003462_7_T1	GENE	15	15	MTD
NCT000034628	NCT00003462_8_T0	PHENOTYPE	21	21	toxicity
NCT000034628	NCT00003462_8_T1	GENE	1	1	MTD
NCT000034629	NCT00003462_9_T0	PHENOTYPE	11	12	disease progression
NCT0000346210	NCT00003462_10_T0	GENE	14	14	1.2
NCT000034631	NCT00003463_1_T0	CELL	9	9	cells
NCT000034631	NCT00003463_1_T1	PHENOTYPE	8	8	tumor
NCT000034632	NCT00003463_2_T0	COMPOUND	12	12	irinotecan
NCT000034632	NCT00003463_2_T1	PHENOTYPE	21	21	gliomas
NCT000034632	NCT00003463_2_T2	PHENOTYPE	17	17	recurrent
NCT000034632	NCT00003463_2_T3	PHENOTYPE	19	20	high grade
NCT000034636	NCT00003463_6_T0	PHENOTYPE	17	17	tumor
NCT000034636	NCT00003463_6_T1	PHENOTYPE	18	18	cavity
NCT000034637	NCT00003463_7_T0	COMPOUND	9	9	irinotecan
NCT000034637	NCT00003463_7_T1	GENE	10	10	IV
NCT000034638	NCT00003463_8_T0	COMPOUND	9	9	irinotecan
NCT000034639	NCT00003463_9_T0	PHENOTYPE	6	6	toxicity
NCT000034639	NCT00003463_9_T1	PHENOTYPE	3	3	experiences
NCT000034639	NCT00003463_9_T2	GENE	7	7	DLT
NCT0000346310	NCT00003463_10_T0	GENE	10	10	has
NCT0000346310	NCT00003463_10_T1	GENE	9	9	MTD
NCT0000346310	NCT00003463_10_T2	GENE	4	4	DLT
NCT0000346311	NCT00003463_11_T0	GENE	1	1	MTD
NCT0000346311	NCT00003463_11_T1	PHENOTYPE	17	17	experiences
NCT0000346311	NCT00003463_11_T2	GENE	18	18	DLT
NCT0000346312	NCT00003463_12_T0	PHENOTYPE	12	12	toxicity
NCT0000346312	NCT00003463_12_T1	PHENOTYPE	14	15	disease progression
NCT000034641	NCT00003464_1_T0	COMPOUND	9	9	temozolomide
NCT000034641	NCT00003464_1_T1	GENE	2	2	II
NCT000034641	NCT00003464_1_T2	PHENOTYPE	18	19	glioblastoma multiforme
NCT000034643	NCT00003464_3_T0	COMPOUND	3	3	temozolomide
NCT000034643	NCT00003464_3_T1	GENE	9	9	1.5
NCT000034645	NCT00003464_5_T0	PHENOTYPE	7	7	toxicity
NCT000034645	NCT00003464_5_T1	PHENOTYPE	4	5	disease progression
NCT000034651	NCT00003465_1_T0	COMPOUND	9	9	temozolomide
NCT000034651	NCT00003465_1_T1	GENE	2	2	II
NCT000034651	NCT00003465_1_T2	PHENOTYPE	14	15	anaplastic oligodendroglioma
NCT000034653	NCT00003465_3_T0	COMPOUND	4	4	temozolomide
NCT000034653	NCT00003465_3_T1	PHENOTYPE	10	10	progressive
NCT000034653	NCT00003465_3_T2	PHENOTYPE	12	12	recurrent
NCT000034653	NCT00003465_3_T3	PHENOTYPE	13	14	anaplastic oligodendroglioma
NCT000034655	NCT00003465_5_T0	PHENOTYPE	2	2	toxicity
NCT000034656	NCT00003465_6_T0	PHENOTYPE	13	13	recurrent
NCT000034656	NCT00003465_6_T1	PHENOTYPE	10	11	anaplastic oligodendroglioma
NCT000034656	NCT00003465_6_T2	PHENOTYPE	14	15	anaplastic oligodendroglioma
NCT000034657	NCT00003465_7_T0	COMPOUND	3	3	temozolomide
NCT000034657	NCT00003465_7_T1	GENE	8	8	1.5
NCT000034659	NCT00003465_9_T0	PHENOTYPE	18	18	toxicity
NCT000034659	NCT00003465_9_T1	PHENOTYPE	2	2	progressive
NCT000034659	NCT00003465_9_T2	PHENOTYPE	14	15	disease progression
NCT000034659	NCT00003465_9_T3	PHENOTYPE	4	5	recurrent disease
NCT0000346510	NCT00003465_10_T0	PHENOTYPE	23	23	toxicity
NCT0000346510	NCT00003465_10_T1	PHENOTYPE	19	20	disease progression
NCT000034660	NCT00003466_0_T0	PHENOTYPE	5	5	Progressive
NCT000034660	NCT00003466_0_T1	PHENOTYPE	7	7	Glioma
NCT000034662	NCT00003466_2_T0	COMPOUND	9	9	temozolomide
NCT000034662	NCT00003466_2_T1	GENE	3	3	II
NCT000034662	NCT00003466_2_T2	PHENOTYPE	15	15	progressive
NCT000034662	NCT00003466_2_T3	PHENOTYPE	17	17	glioma
NCT000034664	NCT00003466_4_T0	PHENOTYPE	20	20	glioma
NCT000034664	NCT00003466_4_T1	PHENOTYPE	9	10	mixed glioma
NCT000034664	NCT00003466_4_T2	PHENOTYPE	11	12	well-differentiated oligodendroglioma
NCT000034664	NCT00003466_4_T3	PHENOTYPE	7	8	pilocytic astrocytoma
NCT000034664	NCT00003466_4_T4	PHENOTYPE	15	17	optic pathway glioma
NCT000034665	NCT00003466_5_T0	COMPOUND	2	2	temozolomide
NCT000034665	NCT00003466_5_T1	GENE	8	8	1.5
NCT000034667	NCT00003466_7_T0	PHENOTYPE	8	8	toxicity
NCT000034667	NCT00003466_7_T1	PHENOTYPE	15	15	tumor
NCT000034667	NCT00003466_7_T2	GENE	16	16	has
NCT000034667	NCT00003466_7_T3	PHENOTYPE	4	5	disease progression
NCT000034670	NCT00003467_0_T0	PHENOTYPE	8	8	Glioma
NCT000034670	NCT00003467_0_T1	PHENOTYPE	5	5	Recurrent
NCT000034672	NCT00003467_2_T0	GENE	2	2	II
NCT000034672	NCT00003467_2_T1	PHENOTYPE	17	17	glioma
NCT000034672	NCT00003467_2_T2	PHENOTYPE	14	14	recurrent
NCT000034674	NCT00003467_4_T0	PHENOTYPE	9	9	oligodendroglioma
NCT000034674	NCT00003467_4_T1	PHENOTYPE	11	12	mixed glioma
NCT000034674	NCT00003467_4_T2	PHENOTYPE	6	7	fibrillary astrocytoma
NCT000034675	NCT00003467_5_T0	PHENOTYPE	13	13	tumor
NCT000034675	NCT00003467_5_T1	PHENOTYPE	14	14	cavity
NCT000034680	NCT00003468_0_T0	PHENOTYPE	7	7	Astrocytoma
NCT000034686	NCT00003468_6_T0	PHENOTYPE	15	15	toxicity
NCT000034686	NCT00003468_6_T1	PHENOTYPE	11	12	disease progression
NCT000034688	NCT00003468_8_T0	GENE	9	9	MRI
NCT000034688	NCT00003468_8_T1	PHENOTYPE	4	4	tumor
NCT000034691	NCT00003469_1_T0	PHENOTYPE	18	18	tumors
NCT000034695	NCT00003469_5_T0	PHENOTYPE	15	15	toxicity
NCT000034695	NCT00003469_5_T1	PHENOTYPE	11	12	disease progression
NCT000034700	NCT00003470_0_T0	PHENOTYPE	6	7	Anaplastic Astrocytoma
NCT000034702	NCT00003470_2_T0	PHENOTYPE	18	19	anaplastic astrocytomas
NCT000034703	NCT00003470_3_T0	GENE	16	16	has
NCT000034703	NCT00003470_3_T1	PHENOTYPE	20	21	anaplastic astrocytomas
NCT000034705	NCT00003470_5_T0	GENE	4	4	A10
NCT000034706	NCT00003470_6_T0	GENE	6	6	A10
NCT000034708	NCT00003470_8_T0	PHENOTYPE	15	15	toxicity
NCT000034708	NCT00003470_8_T1	PHENOTYPE	11	12	disease progression
NCT0000347010	NCT00003470_10_T0	GENE	9	9	MRI
NCT0000347010	NCT00003470_10_T1	PHENOTYPE	4	4	tumor
NCT000034710	NCT00003471_0_T0	PHENOTYPE	7	7	Astrocytoma
NCT000034712	NCT00003471_2_T0	PHENOTYPE	18	20	low grade astrocytoma
NCT000034713	NCT00003471_3_T0	GENE	16	16	has
NCT000034713	NCT00003471_3_T1	PHENOTYPE	22	24	low grade astrocytoma
NCT000034715	NCT00003471_5_T0	GENE	4	4	A10
NCT000034716	NCT00003471_6_T0	GENE	6	6	A10
NCT000034718	NCT00003471_8_T0	PHENOTYPE	15	15	toxicity
NCT000034718	NCT00003471_8_T1	PHENOTYPE	11	12	disease progression
NCT000034721	NCT00003472_1_T0	PHENOTYPE	16	18	childhood brain tumors
NCT000034722	NCT00003472_2_T0	PHENOTYPE	20	20	oligodendrogliomas
NCT000034722	NCT00003472_2_T1	GENE	16	16	has
NCT000034725	NCT00003472_5_T0	PHENOTYPE	15	15	toxicity
NCT000034725	NCT00003472_5_T1	PHENOTYPE	11	12	disease progression
NCT000034731	NCT00003473_1_T0	PHENOTYPE	18	18	recurrent
NCT000034731	NCT00003473_1_T1	PHENOTYPE	21	22	mixed gliomas
NCT000034732	NCT00003473_2_T0	GENE	16	16	has
NCT000034732	NCT00003473_2_T1	PHENOTYPE	20	20	recurrent
NCT000034732	NCT00003473_2_T2	PHENOTYPE	23	24	mixed gliomas
NCT000034736	NCT00003473_6_T0	PHENOTYPE	15	15	toxicity
NCT000034736	NCT00003473_6_T1	PHENOTYPE	11	12	disease progression
NCT000034738	NCT00003473_8_T0	GENE	9	9	MRI
NCT000034738	NCT00003473_8_T1	PHENOTYPE	4	4	tumor
NCT000034741	NCT00003474_1_T0	PHENOTYPE	16	17	brain tumors
NCT000034742	NCT00003474_2_T0	GENE	16	16	has
NCT000034742	NCT00003474_2_T1	PHENOTYPE	26	27	Glioblastoma Multiforme
NCT000034744	NCT00003474_4_T0	GENE	4	4	A10
NCT000034745	NCT00003474_5_T0	GENE	6	6	A10
NCT000034747	NCT00003474_7_T0	PHENOTYPE	15	15	toxicity
NCT000034747	NCT00003474_7_T1	PHENOTYPE	11	12	disease progression
NCT000034752	NCT00003475_2_T0	PHENOTYPE	18	21	primary malignant brain tumors
NCT000034753	NCT00003475_3_T0	GENE	16	16	has
NCT000034753	NCT00003475_3_T1	PHENOTYPE	20	23	primary malignant brain tumors
NCT000034755	NCT00003475_5_T0	GENE	4	4	A10
NCT000034756	NCT00003475_6_T0	GENE	6	6	A10
NCT000034759	NCT00003475_9_T0	PHENOTYPE	15	15	toxicity
NCT000034759	NCT00003475_9_T1	PHENOTYPE	11	12	disease progression
NCT0000347511	NCT00003475_11_T0	GENE	9	9	MRI
NCT0000347511	NCT00003475_11_T1	PHENOTYPE	4	4	tumor
NCT000034762	NCT00003476_2_T0	PHENOTYPE	18	21	primary malignant brain tumors
NCT000034763	NCT00003476_3_T0	GENE	16	16	has
NCT000034763	NCT00003476_3_T1	PHENOTYPE	20	23	primary malignant brain tumors
NCT000034767	NCT00003476_7_T0	PHENOTYPE	15	15	toxicity
NCT000034767	NCT00003476_7_T1	PHENOTYPE	11	12	disease progression
NCT000034769	NCT00003476_9_T0	GENE	9	9	MRI
NCT000034769	NCT00003476_9_T1	PHENOTYPE	4	4	tumor
NCT000034771	NCT00003477_1_T0	PHENOTYPE	20	20	gliomas
NCT000034771	NCT00003477_1_T1	ORGAN	18	19	visual pathway
NCT000034772	NCT00003477_2_T0	GENE	16	16	has
NCT000034772	NCT00003477_2_T1	PHENOTYPE	22	22	gliomas
NCT000034772	NCT00003477_2_T2	ORGAN	20	21	visual pathway
NCT000034776	NCT00003477_6_T0	PHENOTYPE	15	15	toxicity
NCT000034776	NCT00003477_6_T1	PHENOTYPE	11	12	disease progression
NCT000034778	NCT00003477_8_T0	GENE	9	9	MRI
NCT000034778	NCT00003477_8_T1	PHENOTYPE	4	4	tumor
NCT000034782	NCT00003478_2_T0	PHENOTYPE	33	35	primary brain tumors
NCT000034785	NCT00003478_5_T0	COMPOUND	5	5	iodine
NCT000034788	NCT00003478_8_T0	GENE	29	29	MTD
NCT000034789	NCT00003478_9_T0	PHENOTYPE	18	18	toxicity
NCT000034789	NCT00003478_9_T1	GENE	1	1	MTD
NCT0000347810	NCT00003478_10_T0	PHENOTYPE	4	4	tumors
NCT0000347810	NCT00003478_10_T1	PHENOTYPE	15	16	glial tumors
NCT0000347811	NCT00003478_11_T0	PHENOTYPE	3	3	tumors
NCT0000347811	NCT00003478_11_T1	PHENOTYPE	9	9	tumor
NCT0000347811	NCT00003478_11_T2	PHENOTYPE	2	2	recurrent
NCT000034791	NCT00003479_1_T0	PHENOTYPE	18	18	ependymoma
NCT000034792	NCT00003479_2_T0	PHENOTYPE	20	20	ependymoma
NCT000034792	NCT00003479_2_T1	GENE	16	16	has
NCT000034795	NCT00003479_5_T0	PHENOTYPE	15	15	toxicity
NCT000034795	NCT00003479_5_T1	PHENOTYPE	11	12	disease progression
NCT000034797	NCT00003479_7_T0	GENE	9	9	MRI
NCT000034797	NCT00003479_7_T1	PHENOTYPE	4	4	tumor
NCT000034836	NCT00003483_6_T0	PHENOTYPE	15	15	toxicity
NCT000034836	NCT00003483_6_T1	PHENOTYPE	11	12	disease progression
NCT000034838	NCT00003483_8_T0	GENE	9	9	MRI
NCT000034838	NCT00003483_8_T1	PHENOTYPE	4	4	tumor
NCT000034844	NCT00003484_4_T0	COMPOUND	8	8	iodine
NCT000034845	NCT00003484_5_T0	PHENOTYPE	15	15	tumor
NCT000034845	NCT00003484_5_T1	GENE	1	1	2.4
NCT000034845	NCT00003484_5_T2	PHENOTYPE	26	26	cavity
NCT000034845	NCT00003484_5_T3	PHENOTYPE	17	18	brain metastasis
NCT000034847	NCT00003484_7_T0	GENE	17	17	MTD
NCT000034848	NCT00003484_8_T0	PHENOTYPE	18	18	toxicities
NCT000034848	NCT00003484_8_T1	GENE	1	1	MTD
NCT000034849	NCT00003484_9_T0	GENE	10	10	II
NCT000034849	NCT00003484_9_T1	GENE	3	3	has
NCT000034849	NCT00003484_9_T2	GENE	2	2	MTD
NCT0000348411	NCT00003484_11_T0	COMPOUND	11	11	irinotecan
NCT0000348411	NCT00003484_11_T1	GENE	3	3	IV
NCT0000348411	NCT00003484_11_T2	GENE	12	12	IV
NCT0000348412	NCT00003484_12_T0	PHENOTYPE	15	16	disease progression
NCT000034854	NCT00003485_4_T0	GENE	4	4	A10
NCT000034855	NCT00003485_5_T0	GENE	6	6	A10
NCT000034857	NCT00003485_7_T0	PHENOTYPE	13	13	toxicity
NCT000034857	NCT00003485_7_T1	PHENOTYPE	9	10	disease progression
NCT000034863	NCT00003486_3_T0	GENE	3	3	II
NCT000034863	NCT00003486_3_T1	PHENOTYPE	16	17	colon cancer
NCT000034866	NCT00003486_6_T0	GENE	8	8	A10
NCT000034866	NCT00003486_6_T1	GENE	13	13	6/7
NCT000034867	NCT00003486_7_T0	GENE	12	12	3.4
NCT000034867	NCT00003486_7_T1	GENE	3	3	has
NCT000034868	NCT00003486_8_T0	PHENOTYPE	14	14	toxicity
NCT000034868	NCT00003486_8_T1	PHENOTYPE	10	11	disease progression
NCT000034869	NCT00003486_9_T0	PHENOTYPE	0	0	Tumors
NCT000034872	NCT00003487_2_T0	GENE	3	3	II
NCT000034872	NCT00003487_2_T1	PHENOTYPE	16	19	cancer of the esophagus
NCT000034875	NCT00003487_5_T0	GENE	7	7	A10
NCT000034876	NCT00003487_6_T0	PHENOTYPE	15	15	toxicity
NCT000034876	NCT00003487_6_T1	PHENOTYPE	11	12	disease progression
NCT000034877	NCT00003487_7_T0	GENE	5	5	CR
NCT000034877	NCT00003487_7_T1	GENE	14	14	CR
NCT000034878	NCT00003487_8_T0	PHENOTYPE	11	12	disease progression
NCT000034879	NCT00003487_9_T0	PHENOTYPE	0	0	Tumors
NCT000034890	NCT00003489_0_T0	PHENOTYPE	7	10	Head and Neck Cancer
NCT000034892	NCT00003489_2_T0	PHENOTYPE	17	20	Head and Neck Cancer
NCT000034893	NCT00003489_3_T0	GENE	16	16	has
NCT000034893	NCT00003489_3_T1	PHENOTYPE	21	24	Head and Neck Cancer
NCT000034895	NCT00003489_5_T0	GENE	4	4	A10
NCT000034896	NCT00003489_6_T0	GENE	6	6	A10
NCT000034898	NCT00003489_8_T0	PHENOTYPE	13	13	toxicity
NCT000034898	NCT00003489_8_T1	PHENOTYPE	9	10	disease progression
NCT000034901	NCT00003490_1_T0	CELL	4	4	cells
NCT000034901	NCT00003490_1_T1	GENE	0	0	GM-CSF
NCT000034901	NCT00003490_1_T2	PHENOTYPE	9	11	effects of chemotherapy
NCT000034902	NCT00003490_2_T0	CELL	11	11	cells
NCT000034902	NCT00003490_2_T1	PHENOTYPE	10	10	tumor
NCT000034902	NCT00003490_2_T2	GENE	6	6	GM-CSF
NCT000034903	NCT00003490_3_T0	GENE	2	2	II
NCT000034903	NCT00003490_3_T1	COMPOUND	15	15	vincristine
NCT000034903	NCT00003490_3_T2	COMPOUND	13	13	cyclophosphamide
NCT000034903	NCT00003490_3_T3	GENE	25	25	has
NCT000034903	NCT00003490_3_T4	GENE	17	17	GM-CSF
NCT000034903	NCT00003490_3_T5	PHENOTYPE	22	23	multiple myeloma
NCT000034905	NCT00003490_5_T0	COMPOUND	13	13	vincristine
NCT000034905	NCT00003490_5_T1	PHENOTYPE	16	16	myeloma
NCT000034905	NCT00003490_5_T2	CELL	17	17	cells
NCT000034905	NCT00003490_5_T3	COMPOUND	11	11	cyclophosphamide
NCT000034905	NCT00003490_5_T4	GENE	20	20	GM-CSF
NCT000034905	NCT00003490_5_T5	GENE	19	19	sargramostim
NCT000034905	NCT00003490_5_T6	PHENOTYPE	5	6	multiple myeloma
NCT000034907	NCT00003490_7_T0	GENE	8	8	GM-CSF
NCT000034909	NCT00003490_9_T0	PHENOTYPE	2	2	toxicity
NCT000034909	NCT00003490_9_T1	GENE	4	4	GM-CSF
NCT0000349010	NCT00003490_10_T0	GENE	7	7	GM-CSF
NCT0000349010	NCT00003490_10_T1	GENE	6	6	sargramostim
NCT0000349011	NCT00003490_11_T0	COMPOUND	15	15	vincristine
NCT0000349011	NCT00003490_11_T1	GENE	30	30	1.4
NCT0000349011	NCT00003490_11_T2	COMPOUND	7	7	cyclophosphamide
NCT0000349011	NCT00003490_11_T3	COMPOUND	23	23	prednisone
NCT0000349011	NCT00003490_11_T4	GENE	8	8	IV
NCT0000349011	NCT00003490_11_T5	GENE	16	16	IV
NCT0000349012	NCT00003490_12_T0	GENE	6	6	GM-CSF
NCT0000349012	NCT00003490_12_T1	CELL	18	18	neutrophil
NCT0000349013	NCT00003490_13_T0	PHENOTYPE	19	19	toxicity
NCT0000349013	NCT00003490_13_T1	PHENOTYPE	15	16	disease progression
NCT0000349014	NCT00003490_14_T0	GENE	8	8	GM-CSF
NCT000034912	NCT00003491_2_T0	GENE	17	17	IV
NCT000034912	NCT00003491_2_T1	PHENOTYPE	18	19	lung cancer
NCT000034913	NCT00003491_3_T0	GENE	16	16	has
NCT000034913	NCT00003491_3_T1	GENE	21	21	IV
NCT000034913	NCT00003491_3_T2	PHENOTYPE	22	23	lung cancer
NCT000034915	NCT00003491_5_T0	GENE	4	4	A10
NCT000034916	NCT00003491_6_T0	GENE	6	6	A10
NCT000034918	NCT00003491_8_T0	PHENOTYPE	13	13	toxicity
NCT000034918	NCT00003491_8_T1	PHENOTYPE	9	10	disease progression
NCT000034922	NCT00003492_2_T0	PHENOTYPE	16	19	Stage IV Pancreatic Cancer
NCT000034925	NCT00003492_5_T0	GENE	4	4	A10
NCT000034926	NCT00003492_6_T0	GENE	6	6	A10
NCT000034928	NCT00003492_8_T0	PHENOTYPE	14	14	toxicity
NCT000034928	NCT00003492_8_T1	PHENOTYPE	10	11	disease progression
NCT0000349211	NCT00003492_11_T0	PHENOTYPE	14	14	toxicity
NCT0000349211	NCT00003492_11_T1	PHENOTYPE	10	11	disease progression
NCT000034931	NCT00003493_1_T0	CELL	9	9	cells
NCT000034931	NCT00003493_1_T1	PHENOTYPE	8	8	tumor
NCT000034932	NCT00003493_2_T0	GENE	2	2	II
NCT000034932	NCT00003493_2_T1	COMPOUND	17	17	dexamethasone
NCT000034932	NCT00003493_2_T2	COMPOUND	15	15	vincristine
NCT000034932	NCT00003493_2_T3	COMPOUND	14	14	doxorubicin
NCT000034932	NCT00003493_2_T4	PHENOTYPE	27	28	multiple myeloma
NCT000034934	NCT00003493_4_T0	COMPOUND	14	14	HCl
NCT000034934	NCT00003493_4_T1	COMPOUND	18	18	dexamethasone
NCT000034934	NCT00003493_4_T2	COMPOUND	16	16	vincristine
NCT000034934	NCT00003493_4_T3	COMPOUND	13	13	doxorubicin
NCT000034934	NCT00003493_4_T4	PHENOTYPE	9	10	multiple myeloma
NCT000034936	NCT00003493_6_T0	PHENOTYPE	5	5	toxic
NCT000034939	NCT00003493_9_T0	GENE	9	9	1.4
NCT000034939	NCT00003493_9_T1	GENE	6	6	IV
NCT0000349310	NCT00003493_10_T0	PHENOTYPE	20	20	toxic
NCT0000349310	NCT00003493_10_T1	PHENOTYPE	23	24	disease progression
NCT000034945	NCT00003494_5_T0	GENE	4	4	A10
NCT000034946	NCT00003494_6_T0	GENE	6	6	A10
NCT000034948	NCT00003494_8_T0	PHENOTYPE	14	14	toxicity
NCT000034948	NCT00003494_8_T1	PHENOTYPE	10	11	disease progression
NCT000034955	NCT00003495_5_T0	GENE	4	4	A10
NCT000034956	NCT00003495_6_T0	GENE	6	6	A10
NCT000034958	NCT00003495_8_T0	PHENOTYPE	13	13	toxicity
NCT000034958	NCT00003495_8_T1	PHENOTYPE	9	10	disease progression
NCT000034965	NCT00003496_5_T0	GENE	4	4	A10
NCT000034966	NCT00003496_6_T0	GENE	6	6	A10
NCT000034968	NCT00003496_8_T0	PHENOTYPE	13	13	toxicity
NCT000034968	NCT00003496_8_T1	PHENOTYPE	9	10	disease progression
NCT000034972	NCT00003497_2_T0	GENE	36	36	has
NCT000034972	NCT00003497_2_T1	GENE	17	17	IV
NCT000034972	NCT00003497_2_T2	GENE	41	41	IV
NCT000034972	NCT00003497_2_T3	PHENOTYPE	18	19	lung cancer
NCT000034972	NCT00003497_2_T4	PHENOTYPE	42	43	lung cancer
NCT000034974	NCT00003497_4_T0	PHENOTYPE	10	10	toxicity
NCT000034974	NCT00003497_4_T1	PHENOTYPE	17	17	toxicity
NCT000034974	NCT00003497_4_T2	PHENOTYPE	6	7	disease progression
NCT000034974	NCT00003497_4_T3	PHENOTYPE	13	14	disease progression
NCT000034976	NCT00003497_6_T0	PHENOTYPE	10	10	toxicity
NCT000034976	NCT00003497_6_T1	PHENOTYPE	6	7	disease progression
NCT000034981	NCT00003498_1_T0	PHENOTYPE	16	17	Non-Hodgkin's Lymphoma
NCT000034982	NCT00003498_2_T0	GENE	16	16	has
NCT000034982	NCT00003498_2_T1	PHENOTYPE	20	21	Non-Hodgkin's Lymphoma
NCT000034984	NCT00003498_4_T0	GENE	4	4	A10
NCT000034985	NCT00003498_5_T0	GENE	6	6	A10
NCT000034988	NCT00003498_8_T0	PHENOTYPE	14	14	toxicity
NCT000034988	NCT00003498_8_T1	PHENOTYPE	10	11	disease progression
NCT000034991	NCT00003499_1_T0	PHENOTYPE	17	18	Non-Hodgkin's Lymphoma
NCT000034992	NCT00003499_2_T0	GENE	16	16	has
NCT000034992	NCT00003499_2_T1	PHENOTYPE	21	22	Non-Hodgkin's Lymphoma
NCT000034994	NCT00003499_4_T0	GENE	4	4	A10
NCT000034995	NCT00003499_5_T0	GENE	6	6	A10
NCT000034997	NCT00003499_7_T0	PHENOTYPE	14	14	toxicity
NCT000034997	NCT00003499_7_T1	PHENOTYPE	10	11	disease progression
NCT0000349910	NCT00003499_10_T0	PHENOTYPE	18	18	lymphoma
NCT0000349910	NCT00003499_10_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000349910	NCT00003499_10_T2	PHENOTYPE	16	17	high grade
NCT000035004	NCT00003500_4_T0	GENE	4	4	A10
NCT000035005	NCT00003500_5_T0	GENE	6	6	A10
NCT000035007	NCT00003500_7_T0	PHENOTYPE	13	13	toxicity
NCT000035007	NCT00003500_7_T1	PHENOTYPE	9	10	disease progression
NCT0000350010	NCT00003500_10_T0	PHENOTYPE	18	18	lymphoma
NCT0000350010	NCT00003500_10_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000350010	NCT00003500_10_T2	PHENOTYPE	16	17	high grade
NCT000035014	NCT00003501_4_T0	GENE	4	4	A10
NCT000035015	NCT00003501_5_T0	GENE	6	6	A10
NCT000035017	NCT00003501_7_T0	PHENOTYPE	13	13	toxicity
NCT000035017	NCT00003501_7_T1	PHENOTYPE	9	10	disease progression
NCT0000350110	NCT00003501_10_T0	PHENOTYPE	18	18	lymphoma
NCT0000350110	NCT00003501_10_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000350110	NCT00003501_10_T2	PHENOTYPE	16	17	high grade
NCT000035025	NCT00003502_5_T0	GENE	7	7	A10
NCT000035026	NCT00003502_6_T0	PHENOTYPE	10	10	toxicity
NCT000035026	NCT00003502_6_T1	PHENOTYPE	6	7	disease progression
NCT000035027	NCT00003502_7_T0	PHENOTYPE	0	0	Tumors
NCT000035052	NCT00003505_2_T0	GENE	3	3	II
NCT000035052	NCT00003505_2_T1	PHENOTYPE	16	20	primary central nervous system lymphoma
NCT000035056	NCT00003505_6_T0	PHENOTYPE	15	15	toxicity
NCT000035056	NCT00003505_6_T1	PHENOTYPE	11	12	disease progression
NCT000035058	NCT00003505_8_T0	PHENOTYPE	0	0	Tumors
NCT000035080	NCT00003508_0_T0	PHENOTYPE	7	7	Mesothelioma
NCT000035083	NCT00003508_3_T0	GENE	3	3	II
NCT000035083	NCT00003508_3_T1	PHENOTYPE	17	17	mesothelioma
NCT000035086	NCT00003508_6_T0	PHENOTYPE	15	15	toxicity
NCT000035086	NCT00003508_6_T1	PHENOTYPE	11	12	disease progression
NCT000035088	NCT00003508_8_T0	GENE	4	4	CR
NCT000035088	NCT00003508_8_T1	GENE	13	13	CR
NCT000035090	NCT00003509_0_T0	PHENOTYPE	8	8	Melanoma
NCT000035090	NCT00003509_0_T1	GENE	7	7	IV
NCT000035092	NCT00003509_2_T0	PHENOTYPE	18	18	Melanoma
NCT000035092	NCT00003509_2_T1	GENE	17	17	IV
NCT000035093	NCT00003509_3_T0	PHENOTYPE	22	22	Melanoma
NCT000035093	NCT00003509_3_T1	GENE	16	16	has
NCT000035093	NCT00003509_3_T2	GENE	21	21	IV
NCT000035095	NCT00003509_5_T0	GENE	4	4	A10
NCT000035096	NCT00003509_6_T0	GENE	6	6	A10
NCT000035098	NCT00003509_8_T0	PHENOTYPE	14	14	toxicity
NCT000035098	NCT00003509_8_T1	PHENOTYPE	10	11	disease progression
NCT000035111	NCT00003511_1_T0	PHENOTYPE	16	17	Multiple Myeloma
NCT000035112	NCT00003511_2_T0	GENE	16	16	has
NCT000035112	NCT00003511_2_T1	PHENOTYPE	20	21	Multiple Myeloma
NCT000035114	NCT00003511_4_T0	GENE	4	4	A10
NCT000035115	NCT00003511_5_T0	GENE	6	6	A10
NCT000035117	NCT00003511_7_T0	PHENOTYPE	14	14	toxicity
NCT000035117	NCT00003511_7_T1	PHENOTYPE	10	11	disease progression
NCT000035121	NCT00003512_1_T0	PHENOTYPE	16	16	Recurrent
NCT000035121	NCT00003512_1_T1	PHENOTYPE	19	20	Waldenstrom's Macroglobulinemia
NCT000035122	NCT00003512_2_T0	PHENOTYPE	20	20	Recurrent
NCT000035122	NCT00003512_2_T1	GENE	16	16	has
NCT000035122	NCT00003512_2_T2	PHENOTYPE	23	24	Waldenstrom's Macroglobulinemia
NCT000035124	NCT00003512_4_T0	GENE	4	4	A10
NCT000035125	NCT00003512_5_T0	GENE	6	6	A10
NCT000035127	NCT00003512_7_T0	PHENOTYPE	14	14	toxicity
NCT000035127	NCT00003512_7_T1	PHENOTYPE	10	11	disease progression
NCT000035131	NCT00003513_1_T0	PHENOTYPE	17	17	Recurrent
NCT000035131	NCT00003513_1_T1	PHENOTYPE	20	20	Neuroblastoma
NCT000035132	NCT00003513_2_T0	PHENOTYPE	21	21	Recurrent
NCT000035132	NCT00003513_2_T1	GENE	16	16	has
NCT000035132	NCT00003513_2_T2	PHENOTYPE	24	24	Neuroblastoma
NCT000035134	NCT00003513_4_T0	GENE	4	4	A10
NCT000035135	NCT00003513_5_T0	GENE	6	6	A10
NCT000035137	NCT00003513_7_T0	PHENOTYPE	13	13	toxicity
NCT000035137	NCT00003513_7_T1	PHENOTYPE	9	10	disease progression
NCT000035142	NCT00003514_2_T0	GENE	3	3	II
NCT000035142	NCT00003514_2_T1	PHENOTYPE	16	17	neuroendocrine tumor
NCT000035145	NCT00003514_5_T0	GENE	7	7	A10
NCT000035146	NCT00003514_6_T0	PHENOTYPE	12	12	toxicity
NCT000035146	NCT00003514_6_T1	PHENOTYPE	14	15	disease progression
NCT000035147	NCT00003514_7_T0	GENE	4	4	CR
NCT000035147	NCT00003514_7_T1	GENE	14	14	CR
NCT000035148	NCT00003514_8_T0	PHENOTYPE	0	0	Tumors
NCT000035151	NCT00003515_1_T0	PHENOTYPE	17	17	Recurrent
NCT000035151	NCT00003515_1_T1	PHENOTYPE	20	22	Primitive Neuroectodermal Tumors
NCT000035152	NCT00003515_2_T0	PHENOTYPE	21	21	Recurrent
NCT000035152	NCT00003515_2_T1	GENE	16	16	has
NCT000035152	NCT00003515_2_T2	PHENOTYPE	24	26	Primitive Neuroectodermal Tumors
NCT000035154	NCT00003515_4_T0	GENE	4	4	A10
NCT000035155	NCT00003515_5_T0	GENE	6	6	A10
NCT000035157	NCT00003515_7_T0	PHENOTYPE	13	13	toxicity
NCT000035157	NCT00003515_7_T1	PHENOTYPE	9	10	disease progression
NCT000035161	NCT00003516_1_T0	GENE	17	17	III
NCT000035161	NCT00003516_1_T1	PHENOTYPE	19	22	Stage IV Prostate Cancer
NCT000035162	NCT00003516_2_T0	GENE	21	21	III
NCT000035162	NCT00003516_2_T1	GENE	16	16	has
NCT000035162	NCT00003516_2_T2	PHENOTYPE	23	26	Stage IV Prostate Cancer
NCT000035164	NCT00003516_4_T0	PHENOTYPE	10	10	toxicity
NCT000035164	NCT00003516_4_T1	PHENOTYPE	17	17	toxicity
NCT000035164	NCT00003516_4_T2	PHENOTYPE	6	7	disease progression
NCT000035164	NCT00003516_4_T3	PHENOTYPE	13	14	disease progression
NCT000035166	NCT00003516_6_T0	PHENOTYPE	10	10	toxicity
NCT000035166	NCT00003516_6_T1	PHENOTYPE	6	7	disease progression
NCT000035175	NCT00003517_5_T0	GENE	7	7	A10
NCT000035175	NCT00003517_5_T1	GENE	12	12	6/7
NCT000035176	NCT00003517_6_T0	PHENOTYPE	15	15	toxicity
NCT000035176	NCT00003517_6_T1	PHENOTYPE	11	12	disease progression
NCT000035177	NCT00003517_7_T0	COMPOUND	6	6	flutamide
NCT000035177	NCT00003517_7_T1	COMPOUND	7	7	leuprolide
NCT000035177	NCT00003517_7_T2	COMPOUND	9	9	bicalutamide
NCT000035178	NCT00003517_8_T0	PHENOTYPE	0	0	Tumors
NCT000035180	NCT00003518_0_T0	PHENOTYPE	9	11	Germ Cell Tumors
NCT000035182	NCT00003518_2_T0	CELL	9	9	cells
NCT000035182	NCT00003518_2_T1	PHENOTYPE	8	8	tumor
NCT000035187	NCT00003518_7_T0	PHENOTYPE	2	2	toxic
NCT000035188	NCT00003518_8_T0	COMPOUND	3	3	paclitaxel
NCT000035188	NCT00003518_8_T1	COMPOUND	10	10	gemcitabine
NCT000035188	NCT00003518_8_T2	GENE	4	4	IV
NCT000035188	NCT00003518_8_T3	GENE	11	11	IV
NCT000035189	NCT00003518_9_T0	PHENOTYPE	14	14	toxicity
NCT000035189	NCT00003518_9_T1	PHENOTYPE	16	17	disease progression
NCT000035191	NCT00003519_1_T0	CELL	9	9	cells
NCT000035191	NCT00003519_1_T1	PHENOTYPE	8	8	tumor
NCT000035192	NCT00003519_2_T0	PHENOTYPE	13	14	breast cancer
NCT000035193	NCT00003519_3_T0	PHENOTYPE	27	27	tumor
NCT000035193	NCT00003519_3_T1	GENE	3	3	III
NCT000035193	NCT00003519_3_T2	PHENOTYPE	18	19	breast cancer
NCT000035195	NCT00003519_5_T0	GENE	3	3	DD
NCT000035195	NCT00003519_5_T1	GENE	22	22	1.3
NCT000035195	NCT00003519_5_T2	PHENOTYPE	31	32	breast cancer
NCT000035195	NCT00003519_5_T3	TISSUE	19	20	lymph node
NCT000035195	NCT00003519_5_T4	TISSUE	28	29	lymph node
NCT000035197	NCT00003519_7_T0	PHENOTYPE	2	2	toxicity
NCT000035197	NCT00003519_7_T1	GENE	4	4	DD
NCT0000351912	NCT00003519_12_T0	COMPOUND	12	12	tamoxifen
NCT0000351912	NCT00003519_12_T1	GENE	4	5	estrogen receptor
NCT0000351912	NCT00003519_12_T2	PHENOTYPE	7	9	progesterone receptor positive
NCT000035201	NCT00003520_1_T0	PHENOTYPE	16	19	Stage IV Kidney Cancer
NCT000035202	NCT00003520_2_T0	GENE	16	16	has
NCT000035202	NCT00003520_2_T1	PHENOTYPE	20	23	Stage IV Kidney Cancer
NCT000035204	NCT00003520_4_T0	GENE	4	4	A10
NCT000035205	NCT00003520_5_T0	GENE	6	6	A10
NCT000035207	NCT00003520_7_T0	PHENOTYPE	13	13	toxicity
NCT000035207	NCT00003520_7_T1	PHENOTYPE	9	10	disease progression
NCT000035211	NCT00003521_1_T0	PHENOTYPE	16	18	Soft Tissue Sarcoma
NCT000035212	NCT00003521_2_T0	GENE	16	16	has
NCT000035212	NCT00003521_2_T1	PHENOTYPE	20	22	Soft Tissue Sarcoma
NCT000035214	NCT00003521_4_T0	GENE	4	4	A10
NCT000035215	NCT00003521_5_T0	GENE	6	6	A10
NCT000035217	NCT00003521_7_T0	PHENOTYPE	13	13	toxicity
NCT000035217	NCT00003521_7_T1	PHENOTYPE	9	10	disease progression
NCT000035224	NCT00003522_4_T0	GENE	4	4	A10
NCT000035225	NCT00003522_5_T0	GENE	6	6	A10
NCT000035227	NCT00003522_7_T0	PHENOTYPE	13	13	toxicity
NCT000035227	NCT00003522_7_T1	PHENOTYPE	9	10	disease progression
NCT000035231	NCT00003523_1_T0	GENE	2	2	II
NCT000035231	NCT00003523_1_T1	PHENOTYPE	14	14	recurrent
NCT000035231	NCT00003523_1_T2	PHENOTYPE	21	22	primary cancer
NCT000035231	NCT00003523_1_T3	PHENOTYPE	17	19	ovarian epithelial cancer
NCT000035231	NCT00003523_1_T4	PHENOTYPE	22	25	cancer of the peritoneum
NCT000035233	NCT00003523_3_T0	PHENOTYPE	12	12	recurrent
NCT000035233	NCT00003523_3_T1	PHENOTYPE	15	16	ovarian cancer
NCT000035233	NCT00003523_3_T2	PHENOTYPE	18	20	primary peritoneal carcinoma
NCT000035235	NCT00003523_5_T0	PHENOTYPE	6	6	toxicity
NCT000035236	NCT00003523_6_T0	GENE	6	6	IV
NCT000035237	NCT00003523_7_T0	PHENOTYPE	14	14	toxicity
NCT000035237	NCT00003523_7_T1	PHENOTYPE	10	11	disease progression
NCT000035244	NCT00003524_4_T0	GENE	4	4	A10
NCT000035245	NCT00003524_5_T0	GENE	6	6	A10
NCT000035247	NCT00003524_7_T0	PHENOTYPE	13	13	toxicity
NCT000035247	NCT00003524_7_T1	PHENOTYPE	9	10	disease progression
NCT000035254	NCT00003525_4_T0	GENE	4	4	A10
NCT000035255	NCT00003525_5_T0	GENE	6	6	A10
NCT000035257	NCT00003525_7_T0	PHENOTYPE	13	13	toxicity
NCT000035257	NCT00003525_7_T1	PHENOTYPE	9	10	disease progression
NCT000035262	NCT00003526_2_T0	GENE	16	16	has
NCT000035264	NCT00003526_4_T0	GENE	4	4	A10
NCT000035265	NCT00003526_5_T0	GENE	6	6	A10
NCT000035267	NCT00003526_7_T0	PHENOTYPE	14	14	toxicity
NCT000035267	NCT00003526_7_T1	PHENOTYPE	10	11	disease progression
NCT000035282	NCT00003528_2_T0	PHENOTYPE	8	8	toxicity
NCT000035282	NCT00003528_2_T1	COMPOUND	10	10	raltitrexed
NCT000035282	NCT00003528_2_T2	PHENOTYPE	19	20	acute leukemia
NCT000035284	NCT00003528_4_T0	PHENOTYPE	4	4	severity
NCT000035284	NCT00003528_4_T1	PHENOTYPE	7	7	toxic
NCT000035286	NCT00003528_6_T0	GENE	17	17	II
NCT000035286	NCT00003528_6_T1	COMPOUND	7	7	raltitrexed
NCT000035288	NCT00003528_8_T0	PHENOTYPE	2	2	pharmacokinetics
NCT0000352810	NCT00003528_10_T0	PHENOTYPE	10	10	toxicity
NCT0000352810	NCT00003528_10_T1	COMPOUND	3	3	2
NCT0000352810	NCT00003528_10_T2	PHENOTYPE	5	5	concentrations
NCT0000352810	NCT00003528_10_T3	COMPOUND	4	4	deoxyuridine
NCT0000352810	NCT00003528_10_T4	PHENOTYPE	12	12	pharmacokinetics
NCT0000352810	NCT00003528_10_T5	COMPOUND	9	9	raltitrexed
NCT0000352810	NCT00003528_10_T6	ORGAN	2	2	plasma
NCT0000352812	NCT00003528_12_T0	PHENOTYPE	8	8	leukemia
NCT0000352812	NCT00003528_12_T1	COMPOUND	5	5	raltitrexed
NCT0000352812	NCT00003528_12_T2	PHENOTYPE	7	7	recurrent
NCT0000352814	NCT00003528_14_T0	COMPOUND	2	2	raltitrexed
NCT0000352815	NCT00003528_15_T0	PHENOTYPE	10	10	toxicity
NCT0000352815	NCT00003528_15_T1	PHENOTYPE	6	7	disease progression
NCT0000352816	NCT00003528_16_T0	PHENOTYPE	5	5	toxicity
NCT0000352816	NCT00003528_16_T1	COMPOUND	25	25	raltitrexed
NCT0000352816	NCT00003528_16_T2	GENE	6	6	DLT
NCT0000352817	NCT00003528_17_T0	GENE	1	1	DLT
NCT000035303	NCT00003530_3_T0	GENE	16	16	has
NCT000035303	NCT00003530_3_T1	PHENOTYPE	21	24	Head and Neck Cancer
NCT000035305	NCT00003530_5_T0	GENE	4	4	A10
NCT000035306	NCT00003530_6_T0	GENE	6	6	A10
NCT000035308	NCT00003530_8_T0	PHENOTYPE	14	14	toxicity
NCT000035308	NCT00003530_8_T1	PHENOTYPE	10	11	disease progression
NCT000035311	NCT00003531_1_T0	PHENOTYPE	16	19	Stage IV Pancreatic Cancer
NCT000035312	NCT00003531_2_T0	GENE	16	16	has
NCT000035312	NCT00003531_2_T1	PHENOTYPE	20	23	Stage IV Pancreatic Cancer
NCT000035314	NCT00003531_4_T0	GENE	4	4	A10
NCT000035315	NCT00003531_5_T0	GENE	6	6	A10
NCT000035317	NCT00003531_7_T0	PHENOTYPE	14	14	toxicity
NCT000035317	NCT00003531_7_T1	PHENOTYPE	10	11	disease progression
NCT000035321	NCT00003532_1_T0	GENE	17	17	III
NCT000035321	NCT00003532_1_T1	GENE	19	19	IV
NCT000035321	NCT00003532_1_T2	PHENOTYPE	20	21	Ovarian Cancer
NCT000035322	NCT00003532_2_T0	GENE	21	21	III
NCT000035322	NCT00003532_2_T1	GENE	16	16	has
NCT000035322	NCT00003532_2_T2	GENE	23	23	IV
NCT000035322	NCT00003532_2_T3	PHENOTYPE	24	25	Ovarian Cancer
NCT000035324	NCT00003532_4_T0	GENE	4	4	A10
NCT000035325	NCT00003532_5_T0	GENE	6	6	A10
NCT000035327	NCT00003532_7_T0	PHENOTYPE	14	14	toxicity
NCT000035327	NCT00003532_7_T1	PHENOTYPE	10	11	disease progression
NCT000035331	NCT00003533_1_T0	PHENOTYPE	16	18	Metastatic Pancreatic Cancer
NCT000035332	NCT00003533_2_T0	GENE	16	16	has
NCT000035332	NCT00003533_2_T1	PHENOTYPE	20	22	Metastatic Pancreatic Cancer
NCT000035334	NCT00003533_4_T0	GENE	4	4	A10
NCT000035335	NCT00003533_5_T0	GENE	6	6	A10
NCT000035337	NCT00003533_7_T0	PHENOTYPE	14	14	toxicity
NCT000035337	NCT00003533_7_T1	PHENOTYPE	10	11	disease progression
NCT000035341	NCT00003534_1_T0	PHENOTYPE	17	20	Stage IV Prostate Cancer
NCT000035342	NCT00003534_2_T0	GENE	16	16	has
NCT000035342	NCT00003534_2_T1	PHENOTYPE	21	24	Stage IV Prostate Cancer
NCT000035344	NCT00003534_4_T0	GENE	4	4	A10
NCT000035345	NCT00003534_5_T0	GENE	6	6	A10
NCT000035347	NCT00003534_7_T0	PHENOTYPE	14	14	toxicity
NCT000035347	NCT00003534_7_T1	PHENOTYPE	10	11	disease progression
NCT000035350	NCT00003535_0_T0	PHENOTYPE	10	10	Glioma
NCT000035350	NCT00003535_0_T1	PHENOTYPE	6	6	Recurrent
NCT000035352	NCT00003535_2_T0	PHENOTYPE	21	21	gliomas
NCT000035352	NCT00003535_2_T1	PHENOTYPE	19	20	high grade
NCT000035357	NCT00003535_7_T0	PHENOTYPE	15	15	toxicity
NCT000035357	NCT00003535_7_T1	PHENOTYPE	11	12	disease progression
NCT000035359	NCT00003535_9_T0	GENE	9	9	MRI
NCT000035359	NCT00003535_9_T1	PHENOTYPE	4	4	tumor
NCT000035363	NCT00003536_3_T0	PHENOTYPE	21	22	breast cancer
NCT000035364	NCT00003536_4_T0	GENE	4	4	II
NCT000035364	NCT00003536_4_T1	COMPOUND	8	8	methotrexate
NCT000035364	NCT00003536_4_T2	COMPOUND	18	18	methotrexate
NCT000035364	NCT00003536_4_T3	PHENOTYPE	29	30	breast cancer
NCT000035368	NCT00003536_8_T0	PHENOTYPE	0	0	Tumors
NCT000035370	NCT00003537_0_T0	PHENOTYPE	7	8	Anaplastic Astrocytoma
NCT000035372	NCT00003537_2_T0	PHENOTYPE	18	19	anaplastic astrocytoma
NCT000035373	NCT00003537_3_T0	GENE	16	16	has
NCT000035373	NCT00003537_3_T1	PHENOTYPE	20	21	anaplastic astrocytoma
NCT000035377	NCT00003537_7_T0	PHENOTYPE	15	15	toxicity
NCT000035377	NCT00003537_7_T1	PHENOTYPE	11	12	disease progression
NCT000035379	NCT00003537_9_T0	GENE	9	9	MRI
NCT000035379	NCT00003537_9_T1	PHENOTYPE	4	4	tumor
NCT000035382	NCT00003538_2_T0	CELL	11	11	lymphocytes
NCT000035382	NCT00003538_2_T1	CELL	0	1	Stem cells
NCT000035383	NCT00003538_3_T0	PHENOTYPE	5	6	graft-versus-host disease
NCT000035383	NCT00003538_3_T1	ORGAN	10	11	bone marrow
NCT000035385	NCT00003538_5_T0	GENE	4	4	CD34
NCT000035385	NCT00003538_5_T1	ORGAN	7	8	bone marrow
NCT000035386	NCT00003538_6_T0	ORGAN	15	15	transplant
NCT000035386	NCT00003538_6_T1	ORGAN	0	1	Bone marrow
NCT000035392	NCT00003539_2_T0	CELL	10	10	cells
NCT000035393	NCT00003539_3_T0	GENE	2	2	II
NCT000035393	NCT00003539_3_T1	COMPOUND	9	9	paclitaxel
NCT000035393	NCT00003539_3_T2	PHENOTYPE	18	18	recurrent
NCT000035393	NCT00003539_3_T3	PHENOTYPE	20	22	metastatic breast cancer
NCT000035395	NCT00003539_5_T0	COMPOUND	5	5	paclitaxel
NCT000035395	NCT00003539_5_T1	GENE	11	11	HER2
NCT000035395	NCT00003539_5_T2	PHENOTYPE	16	16	recurrent
NCT000035395	NCT00003539_5_T3	PHENOTYPE	18	20	metastatic breast cancer
NCT000035398	NCT00003539_8_T0	PHENOTYPE	5	5	tumor
NCT000035398	NCT00003539_8_T1	GENE	8	8	HER2
NCT000035399	NCT00003539_9_T0	GENE	8	8	HER2
NCT0000353911	NCT00003539_11_T0	COMPOUND	6	6	paclitaxel
NCT0000353912	NCT00003539_12_T0	COMPOUND	11	11	paclitaxel
NCT0000353912	NCT00003539_12_T1	GENE	2	2	HER2
NCT0000353913	NCT00003539_13_T0	PHENOTYPE	10	10	toxicity
NCT0000353913	NCT00003539_13_T1	PHENOTYPE	6	7	disease progression
NCT000035401	NCT00003540_1_T0	GENE	2	2	II
NCT000035401	NCT00003540_1_T1	COMPOUND	22	22	paclitaxel
NCT000035401	NCT00003540_1_T2	COMPOUND	9	9	gemcitabine
NCT000035401	NCT00003540_1_T3	COMPOUND	20	20	doxorubicin
NCT000035401	NCT00003540_1_T4	PHENOTYPE	14	16	metastatic breast cancer
NCT000035403	NCT00003540_3_T0	COMPOUND	3	3	gemcitabine
NCT000035403	NCT00003540_3_T1	GENE	4	4	IV
NCT000035404	NCT00003540_4_T0	PHENOTYPE	13	13	toxic
NCT000035404	NCT00003540_4_T1	PHENOTYPE	9	10	disease progression
NCT000035411	NCT00003541_1_T0	CELL	8	8	cells
NCT000035419	NCT00003541_9_T0	COMPOUND	15	15	cyclophosphamide
NCT000035419	NCT00003541_9_T1	COMPOUND	17	17	etoposide
NCT000035419	NCT00003541_9_T2	GENE	6	6	ICE
NCT0000354111	NCT00003541_11_T0	CELL	7	7	cells
NCT0000354111	NCT00003541_11_T1	PHENOTYPE	6	6	lymphoma
NCT0000354111	NCT00003541_11_T2	GENE	13	13	G-CSF
NCT0000354112	NCT00003541_12_T0	COMPOUND	11	11	vincristine
NCT0000354112	NCT00003541_12_T1	GENE	23	23	filgrastim
NCT0000354112	NCT00003541_12_T2	COMPOUND	6	6	cyclophosphamide
NCT0000354112	NCT00003541_12_T3	GENE	24	24	G-CSF
NCT0000354112	NCT00003541_12_T4	COMPOUND	8	8	doxorubicin
NCT0000354112	NCT00003541_12_T5	COMPOUND	17	17	prednisone
NCT0000354112	NCT00003541_12_T6	GENE	7	7	IV
NCT0000354112	NCT00003541_12_T7	GENE	9	9	IV
NCT0000354112	NCT00003541_12_T8	GENE	12	12	IV
NCT0000354116	NCT00003541_16_T0	GENE	16	16	IV
NCT0000354116	NCT00003541_16_T1	GENE	28	28	IV
NCT0000354116	NCT00003541_16_T2	COMPOUND	34	34	2
NCT0000354116	NCT00003541_16_T3	COMPOUND	32	32	3
NCT0000354116	NCT00003541_16_T4	COMPOUND	27	27	cyclophosphamide
NCT0000354116	NCT00003541_16_T5	COMPOUND	15	15	etoposide
NCT0000354118	NCT00003541_18_T0	GENE	2	2	G-CSF
NCT0000354118	NCT00003541_18_T1	GENE	3	3	IV
NCT000035421	NCT00003542_1_T0	GENE	9	9	interferon
NCT000035421	NCT00003542_1_T1	PHENOTYPE	16	17	kidney cancer
NCT000035425	NCT00003542_5_T0	GENE	6	6	MTD
NCT000035427	NCT00003542_7_T0	PHENOTYPE	13	13	progression
NCT0000354210	NCT00003542_10_T0	GENE	10	10	MTD
NCT0000354211	NCT00003542_11_T0	PHENOTYPE	18	18	toxicity
NCT0000354211	NCT00003542_11_T1	GENE	1	1	MTD
NCT0000354212	NCT00003542_12_T0	GENE	2	2	MTD
NCT0000354213	NCT00003542_13_T0	PHENOTYPE	19	20	disease progression
NCT000035431	NCT00003543_1_T0	CELL	10	10	cells
NCT000035431	NCT00003543_1_T1	PHENOTYPE	9	9	tumor
NCT000035432	NCT00003543_2_T0	CELL	16	16	cells
NCT000035432	NCT00003543_2_T1	PHENOTYPE	15	15	tumor
NCT000035433	NCT00003543_3_T0	PHENOTYPE	20	21	colorectal cancer
NCT000035435	NCT00003543_5_T0	PHENOTYPE	1	1	toxicity
NCT000035435	NCT00003543_5_T1	GENE	11	11	A33
NCT000035435	NCT00003543_5_T2	GENE	13	13	A33
NCT000035435	NCT00003543_5_T3	COMPOUND	19	19	vincristine
NCT000035435	NCT00003543_5_T4	PHENOTYPE	26	27	colorectal cancer
NCT000035437	NCT00003543_7_T0	GENE	17	17	A33
NCT000035437	NCT00003543_7_T1	PHENOTYPE	13	13	pharmacokinetics
NCT000035437	NCT00003543_7_T2	PHENOTYPE	8	9	antibody response
NCT000035439	NCT00003543_9_T0	GENE	9	9	II
NCT000035439	NCT00003543_9_T1	GENE	4	4	A33
NCT0000354310	NCT00003543_10_T0	GENE	11	11	A33
NCT0000354310	NCT00003543_10_T1	GENE	13	13	A33
NCT0000354311	NCT00003543_11_T0	GENE	4	4	A33
NCT0000354311	NCT00003543_11_T1	GENE	5	5	IV
NCT0000354312	NCT00003543_12_T0	COMPOUND	20	20	vincristine
NCT0000354312	NCT00003543_12_T1	GENE	9	9	IV
NCT0000354312	NCT00003543_12_T2	GENE	14	14	IV
NCT0000354312	NCT00003543_12_T3	GENE	21	21	IV
NCT0000354312	NCT00003543_12_T4	GENE	29	29	IV
NCT0000354313	NCT00003543_13_T0	PHENOTYPE	13	13	toxicity
NCT0000354313	NCT00003543_13_T1	PHENOTYPE	9	10	disease progression
NCT0000354314	NCT00003543_14_T0	GENE	10	10	A33
NCT0000354315	NCT00003543_15_T0	PHENOTYPE	21	21	toxicity
NCT0000354316	NCT00003543_16_T0	GENE	12	12	2.9
NCT000035441	NCT00003544_1_T0	GENE	2	2	II
NCT000035441	NCT00003544_1_T1	COMPOUND	9	9	irinotecan
NCT000035441	NCT00003544_1_T2	PHENOTYPE	14	16	metastatic colorectal cancer
NCT000035443	NCT00003544_3_T0	COMPOUND	6	6	irinotecan
NCT000035443	NCT00003544_3_T1	PHENOTYPE	14	16	metastatic colorectal cancer
NCT000035445	NCT00003544_5_T0	COMPOUND	16	16	irinotecan
NCT000035447	NCT00003544_7_T0	COMPOUND	6	6	irinotecan
NCT000035447	NCT00003544_7_T1	GENE	11	11	putative
NCT000035449	NCT00003544_9_T0	COMPOUND	2	2	irinotecan
NCT000035449	NCT00003544_9_T1	GENE	3	3	IV
NCT0000354412	NCT00003544_12_T0	PHENOTYPE	21	21	toxicity
NCT0000354412	NCT00003544_12_T1	COMPOUND	12	12	irinotecan
NCT0000354412	NCT00003544_12_T2	GENE	1	1	4-8
NCT0000354412	NCT00003544_12_T3	PHENOTYPE	17	18	disease progression
NCT000035451	NCT00003545_1_T0	CELL	10	10	cells
NCT000035453	NCT00003545_3_T0	PHENOTYPE	5	5	remission
NCT000035453	NCT00003545_3_T1	PHENOTYPE	11	11	remission
NCT000035453	NCT00003545_3_T2	PHENOTYPE	24	25	lymphoblastic lymphoma
NCT000035453	NCT00003545_3_T3	PHENOTYPE	19	22	T-cell acute lymphoblastic leukemia
NCT000035455	NCT00003545_5_T0	PHENOTYPE	4	4	toxicity
NCT000035456	NCT00003545_6_T0	GENE	4	4	IV
NCT000035458	NCT00003545_8_T0	ORGAN	3	3	marrow
NCT000035458	NCT00003545_8_T1	PHENOTYPE	5	5	hypocellular
NCT000035458	NCT00003545_8_T2	ORGAN	9	10	bone marrow
NCT000035459	NCT00003545_9_T0	ORGAN	5	5	marrow
NCT000035461	NCT00003546_1_T0	CELL	8	8	cells
NCT000035461	NCT00003546_1_T1	PHENOTYPE	7	7	tumor
NCT000035462	NCT00003546_2_T0	CELL	9	9	cells
NCT000035462	NCT00003546_2_T1	PHENOTYPE	8	8	tumor
NCT000035463	NCT00003546_3_T0	GENE	2	2	II
NCT000035463	NCT00003546_3_T1	COMPOUND	9	9	gemcitabine
NCT000035463	NCT00003546_3_T2	PHENOTYPE	17	18	pancreatic cancer
NCT000035465	NCT00003546_5_T0	PHENOTYPE	3	3	progression
NCT000035465	NCT00003546_5_T1	COMPOUND	17	17	gemcitabine
NCT000035465	NCT00003546_5_T2	PHENOTYPE	11	14	adenocarcinoma of the pancreas
NCT0000354610	NCT00003546_10_T0	COMPOUND	11	11	gemcitabine
NCT0000354610	NCT00003546_10_T1	GENE	12	12	IV
NCT0000354611	NCT00003546_11_T0	COMPOUND	16	16	gemcitabine
NCT0000354612	NCT00003546_12_T0	PHENOTYPE	22	23	disease progression
NCT0000354613	NCT00003546_13_T0	PHENOTYPE	14	15	secondary malignancy
NCT0000354613	NCT00003546_13_T1	PHENOTYPE	3	4	disease progression
NCT000035481	NCT00003548_1_T0	PHENOTYPE	14	15	advanced cancer
NCT000035481	NCT00003548_1_T1	ORGAN	18	19	peritoneal cavity
NCT000035483	NCT00003548_3_T0	PHENOTYPE	5	5	toxicities
NCT000035483	NCT00003548_3_T1	PHENOTYPE	26	27	advanced cancer
NCT000035483	NCT00003548_3_T2	ORGAN	31	32	peritoneal cavity
NCT000035487	NCT00003548_7_T0	PHENOTYPE	11	12	drug toxicities
NCT0000354813	NCT00003548_13_T0	PHENOTYPE	10	10	toxic
NCT0000354813	NCT00003548_13_T1	PHENOTYPE	13	14	disease progression
NCT0000354814	NCT00003548_14_T0	GENE	16	16	MTD
NCT0000354815	NCT00003548_15_T0	PHENOTYPE	22	22	toxicity
NCT0000354815	NCT00003548_15_T1	GENE	1	1	MTD
NCT000035490	NCT00003549_0_T0	PHENOTYPE	7	9	Merkel Cell Cancer
NCT000035492	NCT00003549_2_T0	CELL	9	9	cells
NCT000035492	NCT00003549_2_T1	PHENOTYPE	8	8	tumor
NCT000035497	NCT00003549_7_T0	COMPOUND	15	15	cyclophosphamide
NCT000035497	NCT00003549_7_T1	COMPOUND	16	16	methotrexate
NCT000035498	NCT00003549_8_T0	PHENOTYPE	9	10	metastatic disease
NCT000035499	NCT00003549_9_T0	COMPOUND	4	4	methotrexate
NCT000035499	NCT00003549_9_T1	COMPOUND	2	2	cyclophosphamide
NCT000035499	NCT00003549_9_T2	GENE	3	3	IV
NCT000035499	NCT00003549_9_T3	GENE	5	5	IV
NCT000035499	NCT00003549_9_T4	GENE	8	8	IV
NCT0000354910	NCT00003549_10_T0	PHENOTYPE	18	18	toxicities
NCT0000354910	NCT00003549_10_T1	PHENOTYPE	14	15	disease progression
NCT000035511	NCT00003551_1_T0	GENE	2	2	II
NCT000035511	NCT00003551_1_T1	GENE	17	17	IV
NCT000035511	NCT00003551_1_T2	PHENOTYPE	14	15	stage III
NCT000035511	NCT00003551_1_T3	PHENOTYPE	19	21	recurrent kidney cancer
NCT000035515	NCT00003551_5_T0	PHENOTYPE	6	6	toxicity
NCT000035517	NCT00003551_7_T0	PHENOTYPE	15	15	toxicity
NCT000035517	NCT00003551_7_T1	PHENOTYPE	10	11	disease progression
NCT000035526	NCT00003552_6_T0	PHENOTYPE	4	4	toxicity
NCT000035528	NCT00003552_8_T0	PHENOTYPE	1	1	engraftment
NCT0000355210	NCT00003552_10_T0	PHENOTYPE	10	10	acute
NCT0000355210	NCT00003552_10_T1	PHENOTYPE	12	14	chronic graft-versus-host disease
NCT0000355212	NCT00003552_12_T0	CELL	4	4	lymphocyte
NCT0000355214	NCT00003552_14_T0	PHENOTYPE	11	12	tumor progression
NCT0000355215	NCT00003552_15_T0	PHENOTYPE	9	9	conditioning
NCT0000355217	NCT00003552_17_T0	COMPOUND	4	4	1
NCT0000355217	NCT00003552_17_T1	COMPOUND	9	9	1
NCT0000355217	NCT00003552_17_T2	COMPOUND	27	27	1
NCT0000355217	NCT00003552_17_T3	COMPOUND	17	17	fludarabine
NCT0000355217	NCT00003552_17_T4	COMPOUND	6	6	cyclophosphamide
NCT0000355217	NCT00003552_17_T5	GENE	7	7	IV
NCT0000355217	NCT00003552_17_T6	GENE	18	18	IV
NCT0000355218	NCT00003552_18_T0	GENE	29	29	globulin
NCT0000355218	NCT00003552_18_T1	GENE	7	7	IV
NCT0000355218	NCT00003552_18_T2	GENE	17	17	IV
NCT0000355218	NCT00003552_18_T3	COMPOUND	9	9	1
NCT0000355218	NCT00003552_18_T4	COMPOUND	26	26	1
NCT0000355218	NCT00003552_18_T5	COMPOUND	4	4	2
NCT0000355218	NCT00003552_18_T6	COMPOUND	35	35	2
NCT0000355218	NCT00003552_18_T7	COMPOUND	16	16	fludarabine
NCT0000355218	NCT00003552_18_T8	COMPOUND	6	6	cyclophosphamide
NCT0000355219	NCT00003552_19_T0	GENE	30	30	globulin
NCT0000355219	NCT00003552_19_T1	GENE	7	7	IV
NCT0000355219	NCT00003552_19_T2	GENE	18	18	IV
NCT0000355219	NCT00003552_19_T3	COMPOUND	9	9	1
NCT0000355219	NCT00003552_19_T4	COMPOUND	27	27	1
NCT0000355219	NCT00003552_19_T5	COMPOUND	36	36	2
NCT0000355219	NCT00003552_19_T6	COMPOUND	17	17	fludarabine
NCT0000355219	NCT00003552_19_T7	COMPOUND	6	6	cyclophosphamide
NCT0000355220	NCT00003552_20_T0	GENE	3	3	CD34
NCT0000355222	NCT00003552_22_T0	CELL	19	19	lymphocytes
NCT0000355222	NCT00003552_22_T1	PHENOTYPE	2	3	progressive disease
NCT0000355222	NCT00003552_22_T2	PHENOTYPE	13	14	graft-versus-host disease
NCT0000355223	NCT00003552_23_T0	CELL	2	2	lymphocyte
NCT000035531	NCT00003553_1_T0	CELL	12	13	stem cells
NCT000035531	NCT00003553_1_T1	ORGAN	6	7	immune system
NCT000035532	NCT00003553_2_T0	CELL	9	9	cells
NCT000035532	NCT00003553_2_T1	CELL	16	16	cells
NCT000035532	NCT00003553_2_T2	PHENOTYPE	15	15	tumor
NCT000035532	NCT00003553_2_T3	CELL	2	3	stem cells
NCT000035533	NCT00003553_3_T0	ORGAN	13	13	transplant
NCT000035533	NCT00003553_3_T1	CELL	9	9	lymphocyte
NCT000035533	NCT00003553_3_T2	CELL	6	7	T cells
NCT000035535	NCT00003553_5_T0	COMPOUND	1	1	cyclosporine
NCT000035535	NCT00003553_5_T1	COMPOUND	8	8	methotrexate
NCT000035535	NCT00003553_5_T2	ORGAN	11	11	transplant
NCT000035535	NCT00003553_5_T3	COMPOUND	5	6	mycophenolate mofetil
NCT0000355313	NCT00003553_13_T0	CELL	2	2	lymphocyte
NCT0000355319	NCT00003553_19_T0	PHENOTYPE	0	0	HIV
NCT0000355321	NCT00003553_21_T0	PHENOTYPE	3	3	dysfunction
NCT0000355323	NCT00003553_23_T0	PHENOTYPE	1	3	ventricular ejection fraction
NCT0000355328	NCT00003553_28_T0	GENE	3	3	G-CSF
NCT0000355328	NCT00003553_28_T1	CELL	6	9	peripheral blood stem cells
NCT0000355334	NCT00003553_34_T0	PHENOTYPE	3	4	mental deficiency
NCT0000355335	NCT00003553_35_T0	ORGAN	18	18	transplant
NCT0000355335	NCT00003553_35_T1	PHENOTYPE	4	5	organ failure
NCT0000355337	NCT00003553_37_T0	PHENOTYPE	1	3	ventricular ejection fraction
NCT0000355338	NCT00003553_38_T0	COMPOUND	1	1	creatinine
NCT0000355338	NCT00003553_38_T1	COMPOUND	6	6	creatinine
NCT0000355338	NCT00003553_38_T2	ORGAN	0	0	Serum
NCT0000355339	NCT00003553_39_T0	COMPOUND	1	1	bilirubin
NCT0000355339	NCT00003553_39_T1	ORGAN	0	0	Serum
NCT0000355340	NCT00003553_40_T0	PHENOTYPE	0	1	HIV positive
NCT0000355343	NCT00003553_43_T0	PHENOTYPE	4	5	progressive disease
NCT0000355345	NCT00003553_45_T0	PHENOTYPE	3	4	metastatic disease
NCT0000355346	NCT00003553_46_T0	ORGAN	7	7	liver
NCT0000355349	NCT00003553_49_T0	PHENOTYPE	1	1	HIV
NCT000035541	NCT00003554_1_T0	GENE	2	2	II
NCT000035541	NCT00003554_1_T1	PHENOTYPE	17	18	multiple myeloma
NCT000035545	NCT00003554_5_T0	COMPOUND	12	12	melphalan
NCT000035545	NCT00003554_5_T1	COMPOUND	14	14	prednisone
NCT000035547	NCT00003554_7_T0	PHENOTYPE	5	6	residual disease
NCT000035549	NCT00003554_9_T0	PHENOTYPE	2	2	toxic
NCT0000355410	NCT00003554_10_T0	GENE	4	4	IV
NCT0000355413	NCT00003554_13_T0	COMPOUND	4	4	melphalan
NCT0000355413	NCT00003554_13_T1	COMPOUND	6	6	prednisone
NCT000035550	NCT00003555_0_T0	PHENOTYPE	9	9	Recurrent
NCT000035550	NCT00003555_0_T1	PHENOTYPE	12	13	Solid Tumors
NCT000035552	NCT00003555_2_T0	CELL	8	8	cells
NCT000035552	NCT00003555_2_T1	COMPOUND	4	4	amifostine
NCT000035552	NCT00003555_2_T2	PHENOTYPE	12	14	effects of chemotherapy
NCT000035553	NCT00003555_3_T0	COMPOUND	9	9	paclitaxel
NCT000035553	NCT00003555_3_T1	COMPOUND	13	13	amifostine
NCT000035553	NCT00003555_3_T2	PHENOTYPE	18	18	recurrent
NCT000035553	NCT00003555_3_T3	PHENOTYPE	21	22	solid tumors
NCT000035555	NCT00003555_5_T0	COMPOUND	9	9	amifostine
NCT000035555	NCT00003555_5_T1	PHENOTYPE	13	13	recurrent
NCT000035555	NCT00003555_5_T2	PHENOTYPE	16	17	solid tumors
NCT000035555	NCT00003555_5_T3	COMPOUND	6	7	weekly paclitaxel
NCT000035557	NCT00003555_7_T0	PHENOTYPE	1	1	tumor
NCT000035558	NCT00003555_8_T0	COMPOUND	8	8	paclitaxel
NCT000035559	NCT00003555_9_T0	COMPOUND	14	14	paclitaxel
NCT000035559	NCT00003555_9_T1	COMPOUND	2	2	amifostine
NCT000035559	NCT00003555_9_T2	GENE	3	3	IV
NCT000035559	NCT00003555_9_T3	GENE	15	15	IV
NCT0000355511	NCT00003555_11_T0	COMPOUND	9	9	paclitaxel
NCT0000355511	NCT00003555_11_T1	GENE	2	2	3.5
NCT0000355512	NCT00003555_12_T0	PHENOTYPE	23	23	toxicity
NCT0000355512	NCT00003555_12_T1	GENE	18	18	3.5
NCT000035561	NCT00003556_1_T0	CELL	13	13	cells
NCT000035561	NCT00003556_1_T1	PHENOTYPE	12	12	tumor
NCT000035561	NCT00003556_1_T2	BIOLOGICAL_PROCESS	7	8	immune response
NCT000035562	NCT00003556_2_T0	CELL	9	9	cells
NCT000035562	NCT00003556_2_T1	PHENOTYPE	8	8	tumor
NCT000035564	NCT00003556_4_T0	PHENOTYPE	2	2	toxic
NCT000035564	NCT00003556_4_T1	PHENOTYPE	17	17	melanoma
NCT000035566	NCT00003556_6_T0	GENE	4	4	lymphokine
NCT0000355610	NCT00003556_10_T0	PHENOTYPE	10	10	toxicity
NCT0000355610	NCT00003556_10_T1	PHENOTYPE	6	7	disease progression
NCT0000355612	NCT00003556_12_T0	PHENOTYPE	23	23	toxicity
NCT0000355612	NCT00003556_12_T1	PHENOTYPE	20	20	experiences
NCT000035571	NCT00003557_1_T0	GENE	2	2	II
NCT000035571	NCT00003557_1_T1	ORGAN	18	18	liver
NCT000035571	NCT00003557_1_T2	PHENOTYPE	17	17	recurrent
NCT000035571	NCT00003557_1_T3	PHENOTYPE	22	23	gallbladder cancer
NCT000035571	NCT00003557_1_T4	COMPOUND	9	10	dolastatin 10
NCT000035571	NCT00003557_1_T5	ORGAN	19	20	bile duct
NCT000035573	NCT00003557_3_T0	PHENOTYPE	7	7	progression
NCT000035573	NCT00003557_3_T1	COMPOUND	20	21	dolastatin 10
NCT000035575	NCT00003557_5_T0	PHENOTYPE	2	2	toxicity
NCT000035577	NCT00003557_7_T0	GENE	4	4	IV
NCT000035577	NCT00003557_7_T1	COMPOUND	2	3	dolastatin 10
NCT000035578	NCT00003557_8_T0	PHENOTYPE	13	13	toxicity
NCT000035578	NCT00003557_8_T1	PHENOTYPE	15	16	disease progression
NCT000035581	NCT00003558_1_T0	CELL	9	9	cells
NCT000035581	NCT00003558_1_T1	PHENOTYPE	8	8	tumor
NCT000035582	NCT00003558_2_T0	PHENOTYPE	13	17	cancer of unknown primary origin
NCT000035583	NCT00003558_3_T0	GENE	3	3	III
NCT000035583	NCT00003558_3_T1	PHENOTYPE	20	24	cancer of unknown primary origin
NCT000035586	NCT00003558_6_T0	PHENOTYPE	10	11	liver metastases
NCT000035586	NCT00003558_6_T1	PHENOTYPE	8	10	absence of liver
NCT0000355811	NCT00003558_11_T0	PHENOTYPE	0	2	Quality of life
NCT000035601	NCT00003560_1_T0	CELL	9	9	cells
NCT000035601	NCT00003560_1_T1	PHENOTYPE	8	8	tumor
NCT000035605	NCT00003560_5_T0	COMPOUND	2	2	docetaxel
NCT000035605	NCT00003560_5_T1	GENE	3	3	IV
NCT000035605	NCT00003560_5_T2	GENE	9	9	IV
NCT000035606	NCT00003560_6_T0	PHENOTYPE	18	18	toxicity
NCT000035606	NCT00003560_6_T1	PHENOTYPE	14	15	disease progression
NCT000035607	NCT00003560_7_T0	PHENOTYPE	0	2	Quality of life
NCT000035611	NCT00003561_1_T0	PHENOTYPE	17	17	peripheral
NCT000035611	NCT00003561_1_T1	CELL	11	11	cells
NCT000035611	NCT00003561_1_T2	GENE	4	4	sargramostim
NCT000035611	NCT00003561_1_T3	ORGAN	14	15	bone marrow
NCT000035611	NCT00003561_1_T4	ORGAN	24	25	immune system
NCT000035612	NCT00003561_2_T0	CELL	9	9	cells
NCT000035612	NCT00003561_2_T1	GENE	3	3	interferon
NCT000035612	NCT00003561_2_T2	GENE	1	1	sargramostim
NCT000035613	NCT00003561_3_T0	GENE	2	2	II
NCT000035613	NCT00003561_3_T1	GENE	16	16	interferon
NCT000035613	NCT00003561_3_T2	GENE	9	9	sargramostim
NCT000035613	NCT00003561_3_T3	PHENOTYPE	26	27	in remission
NCT000035613	NCT00003561_3_T4	PHENOTYPE	19	23	chronic phase chronic myelogenous leukemia
NCT000035617	NCT00003561_7_T0	PHENOTYPE	5	5	toxic
NCT000035617	NCT00003561_7_T1	GENE	8	8	GM-CSF
NCT000035617	NCT00003561_7_T2	GENE	10	10	interferon
NCT000035618	NCT00003561_8_T0	PHENOTYPE	6	6	remission
NCT000035618	NCT00003561_8_T1	GENE	9	9	interferon
NCT000035619	NCT00003561_9_T0	GENE	12	12	has
NCT000035619	NCT00003561_9_T1	GENE	22	22	GM-CSF
NCT000035619	NCT00003561_9_T2	GENE	9	9	interferon
NCT000035619	NCT00003561_9_T3	GENE	21	21	sargramostim
NCT000035619	NCT00003561_9_T4	PHENOTYPE	2	4	complete hematologic response
NCT000035622	NCT00003562_2_T0	CELL	9	9	cells
NCT000035622	NCT00003562_2_T1	PHENOTYPE	8	8	tumor
NCT000035627	NCT00003562_7_T0	PHENOTYPE	5	5	toxicity
NCT000035627	NCT00003562_7_T1	COMPOUND	8	8	docetaxel
NCT000035629	NCT00003562_9_T0	COMPOUND	2	2	docetaxel
NCT000035629	NCT00003562_9_T1	GENE	3	3	IV
NCT000035629	NCT00003562_9_T2	GENE	10	10	IV
NCT0000356211	NCT00003562_11_T0	PHENOTYPE	9	9	toxicity
NCT0000356211	NCT00003562_11_T1	PHENOTYPE	11	12	disease progression
NCT000035631	NCT00003563_1_T0	CELL	12	12	cells
NCT000035631	NCT00003563_1_T1	PHENOTYPE	11	11	tumor
NCT000035631	NCT00003563_1_T2	COMPOUND	0	0	Gadolinium
NCT000035632	NCT00003563_2_T0	COMPOUND	7	7	gadolinium
NCT000035632	NCT00003563_2_T1	PHENOTYPE	21	22	brain metastases
NCT000035633	NCT00003563_3_T0	GENE	3	3	III
NCT000035633	NCT00003563_3_T1	COMPOUND	15	15	gadolinium
NCT000035633	NCT00003563_3_T2	PHENOTYPE	22	23	brain metastases
NCT000035635	NCT00003563_5_T0	COMPOUND	4	4	gadolinium
NCT000035635	NCT00003563_5_T1	PHENOTYPE	15	16	brain metastases
NCT000035637	NCT00003563_7_T0	PHENOTYPE	4	4	toxicity
NCT000035637	NCT00003563_7_T1	COMPOUND	12	12	gadolinium
NCT000035639	NCT00003563_9_T0	PHENOTYPE	2	4	quality of life
NCT0000356311	NCT00003563_11_T0	GENE	10	10	RPA
NCT0000356311	NCT00003563_11_T1	PHENOTYPE	17	17	tumor
NCT0000356312	NCT00003563_12_T0	PHENOTYPE	10	10	5-10
NCT0000356312	NCT00003563_12_T1	GENE	8	8	IV
NCT0000356312	NCT00003563_12_T2	COMPOUND	6	6	gadolinium
NCT0000356317	NCT00003563_17_T0	PHENOTYPE	0	2	Quality of life
NCT000035641	NCT00003564_1_T0	CELL	9	9	cells
NCT000035641	NCT00003564_1_T1	PHENOTYPE	8	8	tumor
NCT000035642	NCT00003564_2_T0	COMPOUND	11	11	isotretinoin
NCT000035642	NCT00003564_2_T1	PHENOTYPE	16	16	recurrent
NCT000035642	NCT00003564_2_T2	COMPOUND	7	7	procarbazine
NCT000035642	NCT00003564_2_T3	PHENOTYPE	18	19	malignant glioma
NCT000035643	NCT00003564_3_T0	COMPOUND	14	14	isotretinoin
NCT000035643	NCT00003564_3_T1	GENE	3	3	III
NCT000035643	NCT00003564_3_T2	PHENOTYPE	19	19	recurrent
NCT000035643	NCT00003564_3_T3	COMPOUND	10	10	procarbazine
NCT000035643	NCT00003564_3_T4	PHENOTYPE	21	22	malignant gliomas
NCT000035648	NCT00003564_8_T0	PHENOTYPE	2	2	toxicity
NCT0000356410	NCT00003564_10_T0	COMPOUND	11	11	isotretinoin
NCT0000356410	NCT00003564_10_T1	COMPOUND	5	5	procarbazine
NCT0000356412	NCT00003564_12_T0	COMPOUND	1	1	isotretinoin
NCT0000356413	NCT00003564_13_T0	PHENOTYPE	26	26	toxicity
NCT0000356413	NCT00003564_13_T1	COMPOUND	11	11	isotretinoin
NCT0000356413	NCT00003564_13_T2	PHENOTYPE	22	23	disease progression
NCT0000356415	NCT00003564_15_T0	PHENOTYPE	17	17	toxicity
NCT0000356415	NCT00003564_15_T1	PHENOTYPE	13	14	disease progression
NCT000035650	NCT00003565_0_T0	PHENOTYPE	5	6	Solid Tumors
NCT000035652	NCT00003565_2_T0	GENE	2	2	II
NCT000035652	NCT00003565_2_T1	COMPOUND	9	9	docetaxel
NCT000035652	NCT00003565_2_T2	PHENOTYPE	19	20	solid tumors
NCT000035654	NCT00003565_4_T0	COMPOUND	3	3	docetaxel
NCT000035654	NCT00003565_4_T1	GENE	4	4	IV
NCT000035655	NCT00003565_5_T0	COMPOUND	11	11	docetaxel
NCT000035665	NCT00003566_5_T0	PHENOTYPE	3	3	secondary
NCT000035668	NCT00003566_8_T0	PHENOTYPE	0	0	Secondary
NCT000035669	NCT00003566_9_T0	GENE	23	23	N2
NCT000035669	NCT00003566_9_T1	PHENOTYPE	24	24	NSCLC
NCT000035669	NCT00003566_9_T2	GENE	22	22	III
NCT0000356616	NCT00003566_16_T0	GENE	21	21	Gy
NCT0000356616	NCT00003566_16_T1	GENE	31	31	Gy
NCT0000356618	NCT00003566_18_T0	PHENOTYPE	5	6	local disease
NCT0000356618	NCT00003566_18_T1	PHENOTYPE	2	3	metastatic disease
NCT0000356618	NCT00003566_18_T2	PHENOTYPE	6	7	disease progression
NCT0000356619	NCT00003566_19_T0	PHENOTYPE	5	6	local disease
NCT0000356620	NCT00003566_20_T0	PHENOTYPE	12	12	tumor
NCT0000356620	NCT00003566_20_T1	PHENOTYPE	21	22	malignant disease
NCT0000356620	NCT00003566_20_T2	PHENOTYPE	2	3	local disease
NCT0000356620	NCT00003566_20_T3	PHENOTYPE	3	4	disease progression
NCT000035671	NCT00003567_1_T0	CELL	10	10	cells
NCT000035671	NCT00003567_1_T1	PHENOTYPE	9	9	tumor
NCT000035672	NCT00003567_2_T0	PHENOTYPE	27	28	Hodgkin's lymphoma
NCT000035672	NCT00003567_2_T1	PHENOTYPE	24	25	solid tumors
NCT000035674	NCT00003567_4_T0	GENE	7	7	CD34
NCT000035674	NCT00003567_4_T1	CELL	8	9	stem cells
NCT000035675	NCT00003567_5_T0	GENE	19	19	1.5
NCT000035675	NCT00003567_5_T1	GENE	12	12	G-CSF
NCT000035675	NCT00003567_5_T2	GENE	21	21	G-CSF
NCT000035675	NCT00003567_5_T3	GENE	26	26	4.5
NCT000035675	NCT00003567_5_T4	GENE	9	9	GM-CSF
NCT000035675	NCT00003567_5_T5	GENE	14	14	SC
NCT000035675	NCT00003567_5_T6	GENE	11	11	filgrastim
NCT000035675	NCT00003567_5_T7	GENE	8	8	sargramostim
NCT000035675	NCT00003567_5_T8	ORGAN	3	4	bone marrow
NCT000035678	NCT00003567_8_T0	PHENOTYPE	24	24	peripheral
NCT000035678	NCT00003567_8_T1	GENE	3	3	BG
NCT000035678	NCT00003567_8_T2	GENE	4	4	IV
NCT000035678	NCT00003567_8_T3	GENE	11	11	IV
NCT000035679	NCT00003567_9_T0	PHENOTYPE	21	21	5-10
NCT000035679	NCT00003567_9_T1	CELL	17	19	hematopoietic stem cells
NCT0000356710	NCT00003567_10_T0	COMPOUND	18	18	temozolomide
NCT0000356710	NCT00003567_10_T1	PHENOTYPE	36	36	toxicity
NCT0000356710	NCT00003567_10_T2	GENE	6	6	BG
NCT0000356710	NCT00003567_10_T3	GENE	11	11	BG
NCT0000356710	NCT00003567_10_T4	GENE	12	12	IV
NCT0000356710	NCT00003567_10_T5	GENE	19	19	IV
NCT0000356711	NCT00003567_11_T0	GENE	23	23	II
NCT0000356711	NCT00003567_11_T1	PHENOTYPE	19	19	toxicity
NCT0000356711	NCT00003567_11_T2	GENE	8	8	BG
NCT0000356711	NCT00003567_11_T3	PHENOTYPE	15	16	disease progression
NCT0000356712	NCT00003567_12_T0	GENE	8	8	CD34
NCT0000356712	NCT00003567_12_T1	CELL	9	10	stem cells
NCT0000356712	NCT00003567_12_T2	PHENOTYPE	13	14	retroviral infection
NCT000035681	NCT00003568_1_T0	CELL	11	11	cells
NCT000035681	NCT00003568_1_T1	GENE	0	0	Interleukin-2
NCT000035681	NCT00003568_1_T2	PHENOTYPE	10	10	melanoma
NCT000035681	NCT00003568_1_T3	CELL	5	7	white blood cells
NCT000035682	NCT00003568_2_T0	GENE	3	3	II
NCT000035682	NCT00003568_2_T1	GENE	13	13	interleukin-2
NCT000035682	NCT00003568_2_T2	PHENOTYPE	18	19	metastatic melanoma
NCT000035685	NCT00003568_5_T0	COMPOUND	23	23	1
NCT000035685	NCT00003568_5_T1	COMPOUND	30	30	1
NCT000035685	NCT00003568_5_T2	COMPOUND	34	34	1
NCT000035685	NCT00003568_5_T3	GENE	8	8	interferon
NCT0000356811	NCT00003568_11_T0	PHENOTYPE	3	3	toxicity
NCT0000356812	NCT00003568_12_T0	GENE	5	5	IL-2
NCT000035691	NCT00003569_1_T0	CELL	8	8	cells
NCT000035691	NCT00003569_1_T1	PHENOTYPE	12	14	effects of chemotherapy
NCT000035692	NCT00003569_2_T0	COMPOUND	26	26	paclitaxel
NCT000035692	NCT00003569_2_T1	COMPOUND	24	24	cisplatin
NCT000035692	NCT00003569_2_T2	PHENOTYPE	19	20	solid tumors
NCT000035695	NCT00003569_5_T0	GENE	10	10	IV
NCT000035696	NCT00003569_6_T0	COMPOUND	3	3	paclitaxel
NCT000035696	NCT00003569_6_T1	COMPOUND	18	18	cisplatin
NCT000035696	NCT00003569_6_T2	GENE	4	4	IV
NCT000035696	NCT00003569_6_T3	GENE	11	11	IV
NCT000035696	NCT00003569_6_T4	GENE	19	19	IV
NCT000035697	NCT00003569_7_T0	PHENOTYPE	19	19	toxicity
NCT000035697	NCT00003569_7_T1	COMPOUND	4	4	paclitaxel
NCT000035697	NCT00003569_7_T2	COMPOUND	7	7	cisplatin
NCT000035697	NCT00003569_7_T3	PHENOTYPE	15	16	disease progression
NCT000035698	NCT00003569_8_T0	GENE	18	18	MTD
NCT000035699	NCT00003569_9_T0	PHENOTYPE	20	20	toxicity
NCT000035699	NCT00003569_9_T1	GENE	1	1	MTD
NCT000035699	NCT00003569_9_T2	PHENOTYPE	17	17	experiences
NCT000035699	NCT00003569_9_T3	GENE	21	21	DLT
NCT0000356910	NCT00003569_10_T0	GENE	9	9	II
NCT0000356910	NCT00003569_10_T1	GENE	18	18	pre
NCT0000356910	NCT00003569_10_T2	GENE	26	26	reduced
NCT0000356910	NCT00003569_10_T3	GENE	1	1	MTD
NCT0000356910	NCT00003569_10_T4	COMPOUND	21	21	cisplatin
NCT0000356911	NCT00003569_11_T0	GENE	1	1	MTD
NCT0000356911	NCT00003569_11_T1	COMPOUND	4	4	cisplatin
NCT0000356911	NCT00003569_11_T2	GENE	23	23	DLT
NCT000035712	NCT00003571_2_T0	PHENOTYPE	13	14	colon cancer
NCT000035721	NCT00003572_1_T0	CELL	9	9	cells
NCT000035721	NCT00003572_1_T1	CELL	21	21	cells
NCT000035721	NCT00003572_1_T2	PHENOTYPE	20	20	tumor
NCT000035721	NCT00003572_1_T3	ORGAN	0	1	Bone marrow
NCT000035723	NCT00003572_3_T0	COMPOUND	3	3	tacrolimus
NCT000035723	NCT00003572_3_T1	PHENOTYPE	10	11	graft-versus-host disease
NCT000035723	NCT00003572_3_T2	ORGAN	14	15	bone marrow
NCT000035724	NCT00003572_4_T0	GENE	2	2	II
NCT000035724	NCT00003572_4_T1	COMPOUND	11	11	tacrolimus
NCT000035724	NCT00003572_4_T2	PHENOTYPE	24	24	cancers
NCT000035724	NCT00003572_4_T3	COMPOUND	13	14	mycophenolate mofetil
NCT000035724	NCT00003572_4_T4	ORGAN	16	17	bone marrow
NCT000035728	NCT00003572_8_T0	PHENOTYPE	3	3	toxicities
NCT0000357212	NCT00003572_12_T0	CELL	11	11	leukocyte
NCT0000357212	NCT00003572_12_T1	PHENOTYPE	4	4	aplasia
NCT0000357212	NCT00003572_12_T2	PHENOTYPE	6	7	graft-versus-host disease
NCT0000357213	NCT00003572_13_T0	COMPOUND	12	12	1
NCT0000357216	NCT00003572_16_T0	ORGAN	3	4	bone marrow
NCT000035731	NCT00003573_1_T0	CELL	8	8	cells
NCT000035731	NCT00003573_1_T1	PHENOTYPE	7	7	tumor
NCT000035732	NCT00003573_2_T0	CELL	9	9	cells
NCT000035732	NCT00003573_2_T1	PHENOTYPE	8	8	tumor
NCT000035733	NCT00003573_3_T0	GENE	2	2	II
NCT000035733	NCT00003573_3_T1	PHENOTYPE	24	24	medulloblastoma
NCT000035733	NCT00003573_3_T2	COMPOUND	9	9	etoposide
NCT000035736	NCT00003573_6_T0	PHENOTYPE	21	21	metastasis
NCT000035736	NCT00003573_6_T1	ORGAN	10	10	spine
NCT000035737	NCT00003573_7_T0	GENE	20	20	1.3
NCT000035737	NCT00003573_7_T1	COMPOUND	7	7	etoposide
NCT000035737	NCT00003573_7_T2	GENE	22	22	5.7
NCT000035738	NCT00003573_8_T0	COMPOUND	63	63	vincristine
NCT000035738	NCT00003573_8_T1	GENE	36	36	19
NCT000035738	NCT00003573_8_T2	GENE	45	45	filgrastim
NCT000035738	NCT00003573_8_T3	COMPOUND	37	37	cyclophosphamide
NCT000035738	NCT00003573_8_T4	GENE	46	46	G-CSF
NCT000035738	NCT00003573_8_T5	COMPOUND	21	21	etoposide
NCT000035738	NCT00003573_8_T6	COMPOUND	7	7	cisplatin
NCT000035738	NCT00003573_8_T7	GENE	8	8	IV
NCT000035738	NCT00003573_8_T8	GENE	38	38	IV
NCT000035738	NCT00003573_8_T9	GENE	64	64	IV
NCT000035742	NCT00003574_2_T0	CELL	10	10	cells
NCT000035742	NCT00003574_2_T1	PHENOTYPE	9	9	tumor
NCT000035743	NCT00003574_3_T0	GENE	2	2	II
NCT000035743	NCT00003574_3_T1	PHENOTYPE	20	20	progressive
NCT000035743	NCT00003574_3_T2	PHENOTYPE	22	22	recurrent
NCT000035743	NCT00003574_3_T3	PHENOTYPE	24	25	brain tumors
NCT000035749	NCT00003574_9_T0	PHENOTYPE	6	6	tumor
NCT000035749	NCT00003574_9_T1	PHENOTYPE	18	18	cavity
NCT0000357410	NCT00003574_10_T0	COMPOUND	14	14	iodine
NCT0000357411	NCT00003574_11_T0	GENE	7	7	5.7
NCT000035751	NCT00003575_1_T0	CELL	10	10	cells
NCT000035751	NCT00003575_1_T1	PHENOTYPE	9	9	tumor
NCT000035752	NCT00003575_2_T0	CELL	4	4	cells
NCT000035752	NCT00003575_2_T1	CELL	23	23	cells
NCT000035752	NCT00003575_2_T2	PHENOTYPE	3	3	tumor
NCT000035752	NCT00003575_2_T3	PHENOTYPE	11	11	tumor
NCT000035752	NCT00003575_2_T4	CELL	17	19	white blood cells
NCT000035754	NCT00003575_4_T0	GENE	4	4	interleukin-12
NCT000035754	NCT00003575_4_T1	COMPOUND	20	20	ifosfamide
NCT000035754	NCT00003575_4_T2	PHENOTYPE	26	26	HIV
NCT000035754	NCT00003575_4_T3	GENE	5	5	IL-12
NCT000035754	NCT00003575_4_T4	PHENOTYPE	11	11	remission
NCT000035754	NCT00003575_4_T5	COMPOUND	22	22	etoposide
NCT000035754	NCT00003575_4_T6	PHENOTYPE	27	28	Hodgkin's lymphoma
NCT000035756	NCT00003575_6_T0	GENE	4	4	IL-12
NCT0000357510	NCT00003575_10_T0	ORGAN	1	1	serum
NCT0000357512	NCT00003575_12_T0	PHENOTYPE	6	6	HIV
NCT0000357512	NCT00003575_12_T1	GENE	4	4	IL-12
NCT0000357512	NCT00003575_12_T2	CELL	12	12	T-cell
NCT0000357514	NCT00003575_14_T0	GENE	4	4	IL-12
NCT0000357516	NCT00003575_16_T0	GENE	26	26	SC
NCT0000357516	NCT00003575_16_T1	COMPOUND	3	3	ifosfamide
NCT0000357516	NCT00003575_16_T2	GENE	23	23	filgrastim
NCT0000357516	NCT00003575_16_T3	COMPOUND	11	11	etoposide
NCT0000357516	NCT00003575_16_T4	GENE	24	24	G-CSF
NCT0000357516	NCT00003575_16_T5	GENE	4	4	IV
NCT0000357516	NCT00003575_16_T6	GENE	12	12	IV
NCT0000357518	NCT00003575_18_T0	GENE	21	21	SC
NCT0000357518	NCT00003575_18_T1	GENE	20	20	interleukin-12
NCT0000357518	NCT00003575_18_T2	PHENOTYPE	6	6	remission
NCT0000357518	NCT00003575_18_T3	PHENOTYPE	40	41	disease progression
NCT0000357522	NCT00003575_22_T0	PHENOTYPE	18	18	lymphoma
NCT0000357522	NCT00003575_22_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000357522	NCT00003575_22_T2	PHENOTYPE	16	17	high grade
NCT000035761	NCT00003576_1_T0	CELL	10	10	cells
NCT000035761	NCT00003576_1_T1	PHENOTYPE	9	9	tumor
NCT000035762	NCT00003576_2_T0	PHENOTYPE	19	22	head and neck cancer
NCT000035767	NCT00003576_7_T0	PHENOTYPE	16	16	tumor
NCT000035767	NCT00003576_7_T1	GENE	11	11	6.5
NCT000035768	NCT00003576_8_T0	COMPOUND	2	2	cisplatin
NCT000035769	NCT00003576_9_T0	COMPOUND	6	6	cisplatin
NCT0000357612	NCT00003576_12_T0	GENE	10	10	4.5
NCT000035771	NCT00003577_1_T0	CELL	9	9	cells
NCT000035771	NCT00003577_1_T1	PHENOTYPE	8	8	tumor
NCT000035772	NCT00003577_2_T0	COMPOUND	9	9	epirubicin
NCT000035772	NCT00003577_2_T1	PHENOTYPE	21	24	stage II breast cancer
NCT000035773	NCT00003577_3_T0	GENE	4	4	III
NCT000035773	NCT00003577_3_T1	COMPOUND	22	22	epirubicin
NCT000035773	NCT00003577_3_T2	PHENOTYPE	41	41	tumor
NCT000035773	NCT00003577_3_T3	PHENOTYPE	30	33	stage II breast cancer
NCT000035776	NCT00003577_6_T0	GENE	14	14	1.3
NCT000035776	NCT00003577_6_T1	PHENOTYPE	28	28	tumor
NCT000035776	NCT00003577_6_T2	GENE	20	20	50
NCT000035776	NCT00003577_6_T3	GENE	25	25	50
NCT000035776	NCT00003577_6_T4	GENE	10	10	nodal
NCT0000357710	NCT00003577_10_T0	PHENOTYPE	10	10	toxicity
NCT0000357710	NCT00003577_10_T1	PHENOTYPE	6	7	disease progression
NCT0000357711	NCT00003577_11_T0	PHENOTYPE	0	2	Quality of life
NCT000035781	NCT00003578_1_T0	CELL	17	17	cells
NCT000035781	NCT00003578_1_T1	ORGAN	0	1	Bone marrow
NCT000035782	NCT00003578_2_T0	PHENOTYPE	25	26	Hodgkin's lymphoma
NCT000035782	NCT00003578_2_T1	ORGAN	10	11	bone marrow
NCT000035783	NCT00003578_3_T0	GENE	3	3	III
NCT000035783	NCT00003578_3_T1	PHENOTYPE	27	28	Hodgkin's lymphoma
NCT000035783	NCT00003578_3_T2	ORGAN	16	17	bone marrow
NCT000035787	NCT00003578_7_T0	ORGAN	11	12	bone marrow
NCT000035788	NCT00003578_8_T0	COMPOUND	6	6	vincristine
NCT000035788	NCT00003578_8_T1	GENE	14	14	1.5
NCT000035788	NCT00003578_8_T2	COMPOUND	3	3	cyclophosphamide
NCT000035788	NCT00003578_8_T3	COMPOUND	4	4	doxorubicin
NCT000035788	NCT00003578_8_T4	COMPOUND	11	11	prednisone
NCT0000357810	NCT00003578_10_T0	PHENOTYPE	17	17	toxicity
NCT0000357810	NCT00003578_10_T1	PHENOTYPE	13	14	disease progression
NCT0000357813	NCT00003578_13_T0	GENE	1	1	IV
NCT0000357814	NCT00003578_14_T0	ORGAN	3	4	bone marrow
NCT0000357814	NCT00003578_14_T1	CELL	6	9	peripheral blood stem cells
NCT0000357819	NCT00003578_19_T0	PHENOTYPE	18	18	lymphoma
NCT0000357819	NCT00003578_19_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000357819	NCT00003578_19_T2	PHENOTYPE	16	17	high grade
NCT000035800	NCT00003580_0_T0	PHENOTYPE	16	19	Head and Neck Cancer
NCT000035802	NCT00003580_2_T0	CELL	10	10	cells
NCT000035802	NCT00003580_2_T1	PHENOTYPE	9	9	tumor
NCT000035803	NCT00003580_3_T0	CELL	7	7	cells
NCT000035803	NCT00003580_3_T1	COMPOUND	3	3	amifostine
NCT000035803	NCT00003580_3_T2	PHENOTYPE	11	13	effects of chemotherapy
NCT000035804	NCT00003580_4_T0	GENE	2	2	II
NCT000035804	NCT00003580_4_T1	COMPOUND	9	9	amifostine
NCT000035804	NCT00003580_4_T2	COMPOUND	22	22	cisplatin
NCT000035804	NCT00003580_4_T3	PHENOTYPE	25	28	head and neck cancer
NCT000035808	NCT00003580_8_T0	COMPOUND	4	4	amifostine
NCT000035809	NCT00003580_9_T0	COMPOUND	9	9	amifostine
NCT0000358011	NCT00003580_11_T0	GENE	19	19	3.5
NCT0000358011	NCT00003580_11_T1	COMPOUND	5	5	amifostine
NCT0000358011	NCT00003580_11_T2	COMPOUND	14	14	cisplatin
NCT0000358011	NCT00003580_11_T3	COMPOUND	16	16	cisplatin
NCT0000358011	NCT00003580_11_T4	GENE	6	6	IV
NCT0000358012	NCT00003580_12_T0	COMPOUND	2	2	amifostine
NCT000035820	NCT00003582_0_T0	PHENOTYPE	10	13	Head and Neck Cancer
NCT000035822	NCT00003582_2_T0	CELL	10	10	cells
NCT000035822	NCT00003582_2_T1	PHENOTYPE	9	9	tumor
NCT000035823	NCT00003582_3_T0	CELL	8	8	cells
NCT000035823	NCT00003582_3_T1	COMPOUND	4	4	amifostine
NCT000035823	NCT00003582_3_T2	PHENOTYPE	12	15	effects of radiation therapy
NCT000035824	NCT00003582_4_T0	GENE	22	22	II
NCT000035824	NCT00003582_4_T1	GENE	27	27	IV
NCT000035824	NCT00003582_4_T2	COMPOUND	15	15	amifostine
NCT000035824	NCT00003582_4_T3	PHENOTYPE	23	24	stage III
NCT000035824	NCT00003582_4_T4	PHENOTYPE	28	31	head and neck cancer
NCT000035826	NCT00003582_6_T0	COMPOUND	18	18	paclitaxel
NCT000035826	NCT00003582_6_T1	PHENOTYPE	7	7	acute
NCT000035826	NCT00003582_6_T2	PHENOTYPE	29	29	acute
NCT000035826	NCT00003582_6_T3	PHENOTYPE	34	34	acute
NCT000035826	NCT00003582_6_T4	GENE	43	43	IV
NCT000035826	NCT00003582_6_T5	PHENOTYPE	30	30	mucositis
NCT000035826	NCT00003582_6_T6	PHENOTYPE	32	32	dermatitis
NCT000035826	NCT00003582_6_T7	COMPOUND	4	4	amifostine
NCT000035826	NCT00003582_6_T8	COMPOUND	20	20	amifostine
NCT000035826	NCT00003582_6_T9	COMPOUND	16	16	cisplatin
NCT000035826	NCT00003582_6_T10	PHENOTYPE	8	8	tolerance
NCT000035826	NCT00003582_6_T11	PHENOTYPE	36	36	tolerance
NCT000035826	NCT00003582_6_T12	PHENOTYPE	40	41	stage III
NCT000035826	NCT00003582_6_T13	PHENOTYPE	45	48	head and neck carcinoma
NCT0000358210	NCT00003582_10_T0	PHENOTYPE	5	5	toxic
NCT0000358210	NCT00003582_10_T1	GENE	15	15	PEG
NCT0000358210	NCT00003582_10_T2	PHENOTYPE	16	16	dependency
NCT0000358210	NCT00003582_10_T3	PHENOTYPE	18	18	xerostomia
NCT0000358210	NCT00003582_10_T4	PHENOTYPE	4	4	chronic
NCT0000358210	NCT00003582_10_T5	PHENOTYPE	14	14	dysfunction
NCT0000358212	NCT00003582_12_T0	PHENOTYPE	2	4	quality of life
NCT0000358216	NCT00003582_16_T0	COMPOUND	6	6	paclitaxel
NCT0000358216	NCT00003582_16_T1	COMPOUND	17	17	amifostine
NCT0000358216	NCT00003582_16_T2	COMPOUND	15	15	cisplatin
NCT0000358218	NCT00003582_18_T0	CELL	5	5	chromosome
NCT0000358218	NCT00003582_18_T1	GENE	4	4	p53
NCT0000358220	NCT00003582_20_T0	PHENOTYPE	1	1	tumor
NCT0000358221	NCT00003582_21_T0	COMPOUND	7	7	paclitaxel
NCT0000358222	NCT00003582_22_T0	PHENOTYPE	8	8	tumor
NCT0000358222	NCT00003582_22_T1	GENE	12	12	p53
NCT0000358223	NCT00003582_23_T0	COMPOUND	2	2	amifostine
NCT0000358223	NCT00003582_23_T1	GENE	3	3	IV
NCT0000358223	NCT00003582_23_T2	GENE	17	17	5.7
NCT0000358224	NCT00003582_24_T0	COMPOUND	8	8	paclitaxel
NCT0000358224	NCT00003582_24_T1	GENE	32	32	1.4
NCT0000358224	NCT00003582_24_T2	COMPOUND	4	4	amifostine
NCT0000358224	NCT00003582_24_T3	COMPOUND	13	13	cisplatin
NCT0000358224	NCT00003582_24_T4	GENE	9	9	IV
NCT0000358224	NCT00003582_24_T5	GENE	14	14	IV
NCT0000358224	NCT00003582_24_T6	GENE	26	26	IV
NCT0000358225	NCT00003582_25_T0	COMPOUND	16	16	amifostine
NCT0000358225	NCT00003582_25_T1	GENE	13	13	6.5
NCT0000358225	NCT00003582_25_T2	GENE	17	17	IV
NCT0000358225	NCT00003582_25_T3	GENE	19	19	5.7
NCT0000358226	NCT00003582_26_T0	COMPOUND	9	9	paclitaxel
NCT0000358227	NCT00003582_27_T0	PHENOTYPE	0	2	Quality of life
NCT000035832	NCT00003583_2_T0	CELL	7	7	cells
NCT000035832	NCT00003583_2_T1	COMPOUND	3	3	amifostine
NCT000035832	NCT00003583_2_T2	PHENOTYPE	11	13	effects of chemotherapy
NCT0000358311	NCT00003583_11_T0	GENE	13	13	1.3
NCT0000358311	NCT00003583_11_T1	COMPOUND	8	8	etoposide
NCT0000358311	NCT00003583_11_T2	COMPOUND	2	2	cisplatin
NCT0000358311	NCT00003583_11_T3	GENE	3	3	IV
NCT0000358311	NCT00003583_11_T4	GENE	9	9	IV
NCT0000358314	NCT00003583_14_T0	GENE	17	17	1.3
NCT0000358314	NCT00003583_14_T1	COMPOUND	2	2	amifostine
NCT0000358314	NCT00003583_14_T2	GENE	3	3	IV
NCT000035841	NCT00003584_1_T0	CELL	9	9	cells
NCT000035841	NCT00003584_1_T1	PHENOTYPE	8	8	tumor
NCT000035842	NCT00003584_2_T0	PHENOTYPE	5	5	symptoms
NCT000035842	NCT00003584_2_T1	PHENOTYPE	9	9	recurrent
NCT000035842	NCT00003584_2_T2	PHENOTYPE	11	13	metastatic kidney cancer
NCT000035843	NCT00003584_3_T0	GENE	2	2	II
NCT000035843	NCT00003584_3_T1	COMPOUND	13	13	vinorelbine
NCT000035843	NCT00003584_3_T2	COMPOUND	15	15	estramustine
NCT000035843	NCT00003584_3_T3	COMPOUND	19	19	prednisone
NCT000035843	NCT00003584_3_T4	PHENOTYPE	25	25	recurrent
NCT000035843	NCT00003584_3_T5	PHENOTYPE	27	29	metastatic kidney cancer
NCT000035847	NCT00003584_7_T0	PHENOTYPE	15	15	symptoms
NCT000035847	NCT00003584_7_T1	PHENOTYPE	20	20	tolerance
NCT000035849	NCT00003584_9_T0	COMPOUND	2	2	vinorelbine
NCT000035849	NCT00003584_9_T1	GENE	3	3	IV
NCT0000358411	NCT00003584_11_T0	COMPOUND	5	5	prednisone
NCT0000358411	NCT00003584_11_T1	GENE	1	1	tapered
NCT0000358411	NCT00003584_11_T2	PHENOTYPE	12	15	elevated erythrocyte sedimentation rate
NCT0000358414	NCT00003584_14_T0	GENE	21	21	interleukin-2
NCT000035851	NCT00003585_1_T0	CELL	10	10	cells
NCT000035851	NCT00003585_1_T1	PHENOTYPE	9	9	tumor
NCT000035852	NCT00003585_2_T0	CELL	9	9	cells
NCT000035852	NCT00003585_2_T1	PHENOTYPE	8	8	tumor
NCT000035853	NCT00003585_3_T0	PHENOTYPE	19	21	recurrent kidney cancer
NCT000035859	NCT00003585_9_T0	PHENOTYPE	4	4	tumor
NCT0000358510	NCT00003585_10_T0	GENE	36	36	hormone
NCT0000358510	NCT00003585_10_T1	COMPOUND	9	9	1
NCT0000358510	NCT00003585_10_T2	PHENOTYPE	19	21	lymph node metastases
NCT0000358511	NCT00003585_11_T0	COMPOUND	10	11	interferon alfa_2b
NCT0000358512	NCT00003585_12_T0	COMPOUND	14	14	isotretinoin
NCT0000358512	NCT00003585_12_T1	GENE	7	7	interleukin-2
NCT0000358514	NCT00003585_14_T0	PHENOTYPE	15	15	toxicity
NCT0000358514	NCT00003585_14_T1	PHENOTYPE	11	12	disease progression
NCT000035872	NCT00003587_2_T0	CELL	9	9	cells
NCT000035872	NCT00003587_2_T1	PHENOTYPE	8	8	tumor
NCT000035876	NCT00003587_6_T0	PHENOTYPE	7	7	toxicities
NCT0000358711	NCT00003587_11_T0	COMPOUND	10	10	paclitaxel
NCT0000358711	NCT00003587_11_T1	COMPOUND	7	7	gemcitabine
NCT0000358711	NCT00003587_11_T2	GENE	11	11	IV
NCT0000358714	NCT00003587_14_T0	COMPOUND	7	7	vinorelbine
NCT0000358714	NCT00003587_14_T1	COMPOUND	10	10	docetaxel
NCT0000358714	NCT00003587_14_T2	COMPOUND	5	5	cisplatin
NCT0000358714	NCT00003587_14_T3	GENE	11	11	IV
NCT0000358715	NCT00003587_15_T0	PHENOTYPE	8	9	disease progression
NCT000035881	NCT00003588_1_T0	CELL	8	8	cells
NCT000035881	NCT00003588_1_T1	CELL	21	21	cells
NCT000035881	NCT00003588_1_T2	GENE	2	2	p53
NCT000035883	NCT00003588_3_T0	COMPOUND	11	11	platinum
NCT000035883	NCT00003588_3_T1	GENE	7	7	p53
NCT000035883	NCT00003588_3_T2	PHENOTYPE	14	16	ovarian epithelial cancer
NCT000035885	NCT00003588_5_T0	PHENOTYPE	5	5	toxic
NCT000035887	NCT00003588_7_T0	PHENOTYPE	3	3	tumor
NCT0000358811	NCT00003588_11_T0	GENE	4	4	p53
NCT0000358812	NCT00003588_12_T0	GENE	7	7	p53
NCT0000358813	NCT00003588_13_T0	PHENOTYPE	14	14	toxicity
NCT0000358813	NCT00003588_13_T1	PHENOTYPE	10	11	disease progression
NCT0000358815	NCT00003588_15_T0	PHENOTYPE	21	21	toxicity
NCT0000358815	NCT00003588_15_T1	PHENOTYPE	18	18	experiences
NCT000035892	NCT00003589_2_T0	CELL	9	9	cells
NCT000035892	NCT00003589_2_T1	PHENOTYPE	8	8	tumor
NCT0000358913	NCT00003589_13_T0	PHENOTYPE	5	5	toxicity
NCT0000358913	NCT00003589_13_T1	PHENOTYPE	7	8	disease progression
NCT0000358914	NCT00003589_14_T0	PHENOTYPE	18	19	disease progression
NCT0000358914	NCT00003589_14_T1	PHENOTYPE	0	2	Quality of life
NCT0000358915	NCT00003589_15_T0	PHENOTYPE	7	8	disease progression
NCT000035903	NCT00003590_3_T0	PHENOTYPE	18	18	toxicity
NCT000035903	NCT00003590_3_T1	COMPOUND	4	4	hydroxyurea
NCT000035903	NCT00003590_3_T2	PHENOTYPE	14	15	disease progression
NCT000035911	NCT00003591_1_T0	CELL	10	10	cells
NCT000035911	NCT00003591_1_T1	PHENOTYPE	9	9	tumor
NCT000035912	NCT00003591_2_T0	CELL	9	9	cells
NCT000035912	NCT00003591_2_T1	PHENOTYPE	8	8	tumor
NCT000035913	NCT00003591_3_T0	GENE	2	2	II
NCT000035913	NCT00003591_3_T1	COMPOUND	12	12	paclitaxel
NCT000035913	NCT00003591_3_T2	PHENOTYPE	19	21	unresectable pancreatic cancer
NCT000035915	NCT00003591_5_T0	COMPOUND	16	17	weekly paclitaxel
NCT000035915	NCT00003591_5_T1	PHENOTYPE	8	10	unresectable pancreatic cancer
NCT000035919	NCT00003591_9_T0	PHENOTYPE	2	2	acute
NCT000035919	NCT00003591_9_T1	COMPOUND	8	8	paclitaxel
NCT0000359111	NCT00003591_11_T0	GENE	1	1	p53
NCT0000359113	NCT00003591_13_T0	PHENOTYPE	16	17	hepatic metastases
NCT0000359114	NCT00003591_14_T0	COMPOUND	2	2	paclitaxel
NCT0000359114	NCT00003591_14_T1	GENE	16	16	1.5
NCT0000359114	NCT00003591_14_T2	GENE	29	29	5.5
NCT0000359114	NCT00003591_14_T3	GENE	3	3	IV
NCT0000359115	NCT00003591_15_T0	GENE	6	6	abdominal
NCT0000359117	NCT00003591_17_T0	GENE	21	21	3.5
NCT000035920	NCT00003592_0_T0	PHENOTYPE	9	12	Head and Neck Cancer
NCT000035922	NCT00003592_2_T0	COMPOUND	8	8	paclitaxel
NCT000035922	NCT00003592_2_T1	COMPOUND	6	6	methotrexate
NCT000035922	NCT00003592_2_T2	PHENOTYPE	17	20	head and neck cancer
NCT000035923	NCT00003592_3_T0	COMPOUND	14	14	paclitaxel
NCT000035923	NCT00003592_3_T1	GENE	3	3	III
NCT000035923	NCT00003592_3_T2	COMPOUND	10	10	methotrexate
NCT000035923	NCT00003592_3_T3	COMPOUND	30	30	cisplatin
NCT000035923	NCT00003592_3_T4	PHENOTYPE	21	24	head and neck cancer
NCT0000359216	NCT00003592_16_T0	PHENOTYPE	17	17	toxicity
NCT0000359216	NCT00003592_16_T1	PHENOTYPE	13	14	disease progression
NCT0000359218	NCT00003592_18_T0	GENE	12	12	2.4
NCT000035931	NCT00003593_1_T0	CELL	9	9	cells
NCT000035931	NCT00003593_1_T1	PHENOTYPE	8	8	tumor
NCT0000359310	NCT00003593_10_T0	COMPOUND	8	8	cytarabine
NCT0000359310	NCT00003593_10_T1	GENE	10	10	IT
NCT0000359311	NCT00003593_11_T0	COMPOUND	7	7	cytarabine
NCT0000359311	NCT00003593_11_T1	GENE	8	8	IT
NCT0000359312	NCT00003593_12_T0	COMPOUND	14	14	cytarabine
NCT0000359312	NCT00003593_12_T1	COMPOUND	16	16	hydrocortisone
NCT0000359312	NCT00003593_12_T2	COMPOUND	19	19	methotrexate
NCT0000359312	NCT00003593_12_T3	GENE	15	15	IT
NCT0000359312	NCT00003593_12_T4	GENE	17	17	IT
NCT0000359312	NCT00003593_12_T5	GENE	20	20	IT
NCT0000359313	NCT00003593_13_T0	PHENOTYPE	3	3	remission
NCT0000359314	NCT00003593_14_T0	COMPOUND	6	6	cytarabine
NCT0000359314	NCT00003593_14_T1	GENE	7	7	IV
NCT0000359315	NCT00003593_15_T0	GENE	3	3	asparaginase
NCT0000359317	NCT00003593_17_T0	COMPOUND	19	19	cytarabine
NCT0000359317	NCT00003593_17_T1	GENE	20	20	IT
NCT0000359317	NCT00003593_17_T2	PHENOTYPE	11	11	resolved
NCT0000359318	NCT00003593_18_T0	COMPOUND	12	12	cytarabine
NCT0000359318	NCT00003593_18_T1	COMPOUND	14	14	hydrocortisone
NCT0000359318	NCT00003593_18_T2	COMPOUND	17	17	methotrexate
NCT0000359318	NCT00003593_18_T3	GENE	13	13	IT
NCT0000359318	NCT00003593_18_T4	GENE	15	15	IT
NCT0000359318	NCT00003593_18_T5	GENE	18	18	IT
NCT0000359321	NCT00003593_21_T0	PHENOTYPE	11	11	remission
NCT0000359321	NCT00003593_21_T1	PHENOTYPE	6	8	transient myeloproliferative disorder
NCT000035941	NCT00003594_1_T0	CELL	9	9	cells
NCT000035941	NCT00003594_1_T1	PHENOTYPE	8	8	tumor
NCT000035942	NCT00003594_2_T0	PHENOTYPE	16	17	colorectal cancer
NCT000035943	NCT00003594_3_T0	GENE	3	3	III
NCT000035943	NCT00003594_3_T1	PHENOTYPE	20	20	recurrent
NCT000035943	NCT00003594_3_T2	PHENOTYPE	22	24	metastatic colorectal cancer
NCT000035946	NCT00003594_6_T0	COMPOUND	10	10	2
NCT000035951	NCT00003595_1_T0	CELL	10	10	cells
NCT000035953	NCT00003595_3_T0	PHENOTYPE	21	21	HIV
NCT000035953	NCT00003595_3_T1	PHENOTYPE	22	23	Hodgkin's lymphoma
NCT000035955	NCT00003595_5_T0	COMPOUND	7	7	vincristine
NCT000035955	NCT00003595_5_T1	PHENOTYPE	19	19	HIV
NCT000035955	NCT00003595_5_T2	GENE	4	4	CHOP
NCT000035955	NCT00003595_5_T3	COMPOUND	5	5	cyclophosphamide
NCT000035955	NCT00003595_5_T4	COMPOUND	6	6	doxorubicin
NCT000035955	NCT00003595_5_T5	COMPOUND	9	9	prednisone
NCT000035955	NCT00003595_5_T6	PHENOTYPE	20	21	Hodgkin's lymphoma
NCT000035957	NCT00003595_7_T0	PHENOTYPE	9	9	remission
NCT000035957	NCT00003595_7_T1	GENE	12	12	CHOP
NCT000035959	NCT00003595_9_T0	PHENOTYPE	10	10	HIV
NCT000035959	NCT00003595_9_T1	ORGAN	7	8	immune system
NCT0000359511	NCT00003595_11_T0	CELL	14	14	cells
NCT0000359511	NCT00003595_11_T1	PHENOTYPE	13	13	tumor
NCT0000359511	NCT00003595_11_T2	PHENOTYPE	12	12	lymphoma
NCT0000359513	NCT00003595_13_T0	GENE	4	4	CHOP
NCT0000359518	NCT00003595_18_T0	PHENOTYPE	25	25	toxicity
NCT0000359518	NCT00003595_18_T1	PHENOTYPE	21	22	disease progression
NCT0000359519	NCT00003595_19_T0	GENE	11	11	II
NCT0000359519	NCT00003595_19_T1	GENE	13	13	IIE
NCT0000359519	NCT00003595_19_T2	GENE	5	5	IE
NCT0000359520	NCT00003595_20_T0	GENE	17	17	IV
NCT0000359524	NCT00003595_24_T0	GENE	11	11	II
NCT0000359524	NCT00003595_24_T1	GENE	13	13	IIE
NCT0000359524	NCT00003595_24_T2	GENE	5	5	IE
NCT0000359529	NCT00003595_29_T0	PHENOTYPE	18	18	lymphoma
NCT0000359529	NCT00003595_29_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000359529	NCT00003595_29_T2	PHENOTYPE	16	17	high grade
NCT000035960	NCT00003596_0_T0	GENE	9	9	II
NCT000035960	NCT00003596_0_T1	PHENOTYPE	11	14	Stage III Anal Cancer
NCT000035962	NCT00003596_2_T0	CELL	15	15	cells
NCT000035962	NCT00003596_2_T1	PHENOTYPE	14	14	tumor
NCT000035963	NCT00003596_3_T0	COMPOUND	18	18	cisplatin
NCT000035963	NCT00003596_3_T1	PHENOTYPE	23	24	anal cancer
NCT000035964	NCT00003596_4_T0	GENE	33	33	II
NCT000035964	NCT00003596_4_T1	GENE	4	4	III
NCT000035964	NCT00003596_4_T2	COMPOUND	24	24	cisplatin
NCT000035964	NCT00003596_4_T3	PHENOTYPE	35	38	stage III anal cancer
NCT000035967	NCT00003596_7_T0	GENE	18	18	cm
NCT000035967	NCT00003596_7_T1	GENE	21	21	cm
NCT000035967	NCT00003596_7_T2	GENE	26	26	cm
NCT000035967	NCT00003596_7_T3	GENE	6	6	nodal
NCT000035967	NCT00003596_7_T4	PHENOTYPE	12	13	primary tumor
NCT0000359611	NCT00003596_11_T0	GENE	3	3	T4
NCT0000359611	NCT00003596_11_T1	GENE	18	18	reduced
NCT0000359611	NCT00003596_11_T2	COMPOUND	5	5	N
NCT0000359611	NCT00003596_11_T3	GENE	8	8	T2
NCT0000359611	NCT00003596_11_T4	GENE	2	2	T3
NCT0000359611	NCT00003596_11_T5	PHENOTYPE	11	12	residual disease
NCT000035970	NCT00003597_0_T0	PHENOTYPE	6	6	Recurrent
NCT000035970	NCT00003597_0_T1	PHENOTYPE	9	10	Solid Tumors
NCT000035972	NCT00003597_2_T0	GENE	4	4	thrombopoietin
NCT000035972	NCT00003597_2_T1	PHENOTYPE	19	19	peripheral
NCT000035972	NCT00003597_2_T2	GENE	6	6	G-CSF
NCT000035972	NCT00003597_2_T3	CELL	13	13	cells
NCT000035972	NCT00003597_2_T4	ORGAN	16	17	bone marrow
NCT000035972	NCT00003597_2_T5	ORGAN	26	27	immune system
NCT000035972	NCT00003597_2_T6	PHENOTYPE	32	34	effects of chemotherapy
NCT000035973	NCT00003597_3_T0	PHENOTYPE	16	16	recurrent
NCT000035973	NCT00003597_3_T1	PHENOTYPE	19	20	solid tumors
NCT000035975	NCT00003597_5_T0	GENE	10	10	thrombopoietin
NCT000035976	NCT00003597_6_T0	COMPOUND	19	19	ifosfamide
NCT000035976	NCT00003597_6_T1	GENE	26	26	0.4
NCT000035976	NCT00003597_6_T2	COMPOUND	17	17	etoposide
NCT000035976	NCT00003597_6_T3	GENE	7	7	IV
NCT000035976	NCT00003597_6_T4	GENE	20	20	IV
NCT000035977	NCT00003597_7_T0	PHENOTYPE	11	11	toxicity
NCT000035977	NCT00003597_7_T1	PHENOTYPE	7	8	disease progression
NCT000035978	NCT00003597_8_T0	GENE	11	11	thrombopoietin
NCT000035978	NCT00003597_8_T1	GENE	26	26	MTD
NCT000035978	NCT00003597_8_T2	GENE	12	12	IV
NCT000035979	NCT00003597_9_T0	PHENOTYPE	16	16	toxicity
NCT000035979	NCT00003597_9_T1	GENE	1	1	MTD
NCT0000359710	NCT00003597_10_T0	GENE	2	2	MTD
NCT0000359711	NCT00003597_11_T0	GENE	2	2	filgrastim
NCT0000359711	NCT00003597_11_T1	GENE	3	3	G-CSF
NCT0000359711	NCT00003597_11_T2	CELL	13	13	neutrophil
NCT000035981	NCT00003598_1_T0	PHENOTYPE	21	21	neoplasia
NCT000035981	NCT00003598_1_T1	PHENOTYPE	15	16	cervical cancer
NCT000035982	NCT00003598_2_T0	PHENOTYPE	13	13	neoplasia
NCT000035982	NCT00003598_2_T1	PHENOTYPE	17	18	cervical cancer
NCT000035988	NCT00003598_8_T0	GENE	9	9	II
NCT000035988	NCT00003598_8_T1	GENE	11	11	III
NCT000035988	NCT00003598_8_T2	PHENOTYPE	5	7	cervical intraepithelial neoplasia
NCT000035992	NCT00003599_2_T0	COMPOUND	3	3	isotretinoin
NCT000035992	NCT00003599_2_T1	PHENOTYPE	11	12	lung cancer
NCT000035993	NCT00003599_3_T0	COMPOUND	8	8	isotretinoin
NCT000035994	NCT00003599_4_T0	COMPOUND	17	17	isotretinoin
NCT000035994	NCT00003599_4_T1	COMPOUND	26	26	isotretinoin
NCT000035994	NCT00003599_4_T2	PHENOTYPE	29	30	lung cancer
NCT000035994	NCT00003599_4_T3	COMPOUND	9	10	vitamin E
NCT000035996	NCT00003599_6_T0	GENE	16	16	II
NCT000035996	NCT00003599_6_T1	PHENOTYPE	19	19	toxicity
NCT000035996	NCT00003599_6_T2	COMPOUND	10	10	isotretinoin
NCT000035996	NCT00003599_6_T3	COMPOUND	21	21	isotretinoin
NCT000035996	NCT00003599_6_T4	GENE	6	6	AT
NCT000035996	NCT00003599_6_T5	COMPOUND	7	8	vitamin E
NCT000035998	NCT00003599_8_T0	COMPOUND	5	5	isotretinoin
NCT000035998	NCT00003599_8_T1	GENE	14	14	AT
NCT0000359910	NCT00003599_10_T0	GENE	12	12	AT
NCT0000359912	NCT00003599_12_T0	COMPOUND	4	4	isotretinoin
NCT0000359912	NCT00003599_12_T1	ORGAN	7	7	serum
NCT000036000	NCT00003600_0_T0	PHENOTYPE	4	4	Anemia
NCT000036002	NCT00003600_2_T0	GENE	6	6	epoetin
NCT000036002	NCT00003600_2_T1	PHENOTYPE	16	16	anemia
NCT000036003	NCT00003600_3_T0	GENE	5	5	III
NCT000036003	NCT00003600_3_T1	GENE	12	12	epoetin
NCT000036003	NCT00003600_3_T2	PHENOTYPE	19	19	anemia
NCT000036005	NCT00003600_5_T0	PHENOTYPE	19	19	malignancy
NCT000036005	NCT00003600_5_T1	GENE	2	2	epoetin
NCT000036005	NCT00003600_5_T2	PHENOTYPE	7	9	quality of life
NCT000036007	NCT00003600_7_T0	GENE	2	2	epoetin
NCT000036007	NCT00003600_7_T1	PHENOTYPE	5	6	hemoglobin levels
NCT0000360011	NCT00003600_11_T0	PHENOTYPE	10	10	nephrotoxicity
NCT0000360011	NCT00003600_11_T1	GENE	15	15	epoetin
NCT0000360013	NCT00003600_13_T0	PHENOTYPE	30	30	anemia
NCT0000360013	NCT00003600_13_T1	PHENOTYPE	5	6	malignant disease
NCT0000360015	NCT00003600_15_T0	PHENOTYPE	0	2	Quality of life
NCT000036014	NCT00003601_4_T0	PHENOTYPE	8	8	regression
NCT000036014	NCT00003601_4_T1	COMPOUND	16	16	fenretinide
NCT000036014	NCT00003601_4_T2	PHENOTYPE	20	21	dysplastic nevi
NCT000036014	NCT00003601_4_T3	PHENOTYPE	28	29	cutaneous melanoma
NCT000036016	NCT00003601_6_T0	PHENOTYPE	8	9	cutaneous melanoma
NCT000036016	NCT00003601_6_T1	PHENOTYPE	14	15	cutaneous melanoma
NCT000036021	NCT00003602_1_T0	CELL	9	9	cells
NCT000036026	NCT00003602_6_T0	PHENOTYPE	15	15	remission
NCT000036027	NCT00003602_7_T0	COMPOUND	13	13	cytarabine
NCT000036027	NCT00003602_7_T1	GENE	11	11	1.3
NCT000036027	NCT00003602_7_T2	COMPOUND	7	7	idarubicin
NCT000036027	NCT00003602_7_T3	GENE	20	20	1.7
NCT000036027	NCT00003602_7_T4	GENE	8	8	IV
NCT000036027	NCT00003602_7_T5	GENE	14	14	IV
NCT000036028	NCT00003602_8_T0	GENE	2	2	1.2
NCT000036028	NCT00003602_8_T1	PHENOTYPE	10	10	remission
NCT0000360210	NCT00003602_10_T0	PHENOTYPE	0	2	Quality of life
NCT000036031	NCT00003603_1_T0	CELL	9	9	cells
NCT000036032	NCT00003603_2_T0	COMPOUND	3	3	dexamethasone
NCT000036032	NCT00003603_2_T1	COMPOUND	5	5	prednisolone
NCT000036032	NCT00003603_2_T2	PHENOTYPE	13	15	effects of chemotherapy
NCT000036033	NCT00003603_3_T0	PHENOTYPE	19	20	multiple myeloma
NCT000036034	NCT00003603_4_T0	GENE	3	3	III
NCT000036034	NCT00003603_4_T1	GENE	25	25	has
NCT000036034	NCT00003603_4_T2	PHENOTYPE	22	23	multiple myeloma
NCT000036037	NCT00003603_7_T0	ORGAN	6	7	autologous transplant
NCT0000360310	NCT00003603_10_T0	PHENOTYPE	14	14	toxicity
NCT0000360310	NCT00003603_10_T1	PHENOTYPE	16	17	disease progression
NCT0000360312	NCT00003603_12_T0	PHENOTYPE	0	2	Quality of life
NCT000036040	NCT00003604_0_T0	GENE	0	0	Interleukin-2
NCT000036040	NCT00003604_0_T1	GENE	6	6	III
NCT000036040	NCT00003604_0_T2	PHENOTYPE	8	11	Stage IV Kidney Cancer
NCT000036042	NCT00003604_2_T0	GENE	2	2	II
NCT000036042	NCT00003604_2_T1	GENE	9	9	interleukin-2
NCT000036042	NCT00003604_2_T2	GENE	22	22	has
NCT000036042	NCT00003604_2_T3	PHENOTYPE	14	15	stage III
NCT000036042	NCT00003604_2_T4	PHENOTYPE	17	20	stage IV kidney cancer
NCT000036044	NCT00003604_4_T0	GENE	20	20	interleukin-2
NCT000036044	NCT00003604_4_T1	GENE	15	15	IV
NCT000036044	NCT00003604_4_T2	PHENOTYPE	12	13	stage III
NCT000036044	NCT00003604_4_T3	PHENOTYPE	16	17	renal cancer
NCT000036046	NCT00003604_6_T0	PHENOTYPE	5	5	lymphocytosis
NCT000036048	NCT00003604_8_T0	GENE	2	2	interleukin-2
NCT000036048	NCT00003604_8_T1	GENE	3	3	IV
NCT000036051	NCT00003605_1_T0	CELL	10	10	cells
NCT000036052	NCT00003605_2_T0	CELL	10	10	cells
NCT000036053	NCT00003605_3_T0	GENE	2	2	II
NCT000036053	NCT00003605_3_T1	COMPOUND	11	11	cyclophosphamide
NCT000036053	NCT00003605_3_T2	GENE	22	22	IV
NCT000036053	NCT00003605_3_T3	PHENOTYPE	18	19	stage III
NCT000036053	NCT00003605_3_T4	PHENOTYPE	23	24	Hodgkin's lymphoma
NCT000036055	NCT00003605_5_T0	PHENOTYPE	2	2	toxicity
NCT000036055	NCT00003605_5_T1	GENE	21	21	IV
NCT000036055	NCT00003605_5_T2	COMPOUND	5	5	cyclophosphamide
NCT000036055	NCT00003605_5_T3	PHENOTYPE	18	19	stage III
NCT000036055	NCT00003605_5_T4	PHENOTYPE	23	24	B-cell lymphoma
NCT000036057	NCT00003605_7_T0	PHENOTYPE	3	3	tumor
NCT0000360511	NCT00003605_11_T0	PHENOTYPE	10	11	indolent lymphoma
NCT0000360513	NCT00003605_13_T0	PHENOTYPE	2	4	quality of life
NCT0000360515	NCT00003605_15_T0	COMPOUND	3	3	cyclophosphamide
NCT0000360515	NCT00003605_15_T1	GENE	10	10	IV
NCT0000360516	NCT00003605_16_T0	COMPOUND	4	4	cyclophosphamide
NCT0000360516	NCT00003605_16_T1	GENE	8	8	IV
NCT000036062	NCT00003606_2_T0	CELL	9	9	cells
NCT000036062	NCT00003606_2_T1	PHENOTYPE	8	8	tumor
NCT000036068	NCT00003606_8_T0	COMPOUND	9	9	etoposide
NCT000036068	NCT00003606_8_T1	COMPOUND	7	7	cisplatin
NCT0000360610	NCT00003606_10_T0	PHENOTYPE	8	10	quality of life
NCT0000360612	NCT00003606_12_T0	PHENOTYPE	2	2	toxic
NCT0000360619	NCT00003606_19_T0	COMPOUND	7	7	etoposide
NCT0000360619	NCT00003606_19_T1	PHENOTYPE	2	3	residual tumor
NCT000036078	NCT00003607_8_T0	PHENOTYPE	0	2	Quality of life
NCT000036101	NCT00003610_1_T0	PHENOTYPE	15	15	mucositis
NCT000036101	NCT00003610_1_T1	COMPOUND	6	6	capsaicin
NCT000036102	NCT00003610_2_T0	PHENOTYPE	16	16	mucositis
NCT000036102	NCT00003610_2_T1	COMPOUND	10	10	capsaicin
NCT000036102	NCT00003610_2_T2	GENE	3	3	III
NCT000036106	NCT00003610_6_T0	PHENOTYPE	2	2	toxicity
NCT000036108	NCT00003610_8_T0	COMPOUND	34	34	fluoride
NCT000036108	NCT00003610_8_T1	TISSUE	42	43	oral mucosa
NCT000036109	NCT00003610_9_T0	COMPOUND	6	6	capsaicin
NCT000036112	NCT00003611_2_T0	COMPOUND	9	9	acitretin
NCT000036112	NCT00003611_2_T1	PHENOTYPE	12	13	skin cancers
NCT000036112	NCT00003611_2_T2	PHENOTYPE	22	23	skin cancers
NCT000036115	NCT00003611_5_T0	PHENOTYPE	56	56	sunburn
NCT000036115	NCT00003611_5_T1	PHENOTYPE	44	45	skin cancer
NCT000036115	NCT00003611_5_T2	PHENOTYPE	64	65	skin damage
NCT000036115	NCT00003611_5_T3	PHENOTYPE	27	28	skin cancers
NCT000036116	NCT00003611_6_T0	COMPOUND	4	4	acitretin
NCT000036121	NCT00003612_1_T0	CELL	9	9	cells
NCT000036121	NCT00003612_1_T1	PHENOTYPE	8	8	tumor
NCT000036123	NCT00003612_3_T0	GENE	2	2	II
NCT000036123	NCT00003612_3_T1	COMPOUND	10	10	paclitaxel
NCT000036123	NCT00003612_3_T2	GENE	24	24	HER2
NCT000036123	NCT00003612_3_T3	PHENOTYPE	19	21	metastatic breast cancer
NCT000036127	NCT00003612_7_T0	GENE	26	26	PR
NCT000036127	NCT00003612_7_T1	GENE	48	48	pre
NCT000036127	NCT00003612_7_T2	GENE	21	21	ER
NCT000036127	NCT00003612_7_T3	GENE	31	31	ER
NCT000036127	NCT00003612_7_T4	GENE	37	37	ER
NCT000036127	NCT00003612_7_T5	GENE	41	41	ER
NCT000036127	NCT00003612_7_T6	PHENOTYPE	46	46	menopausal
NCT000036127	NCT00003612_7_T7	GENE	19	20	estrogen receptor
NCT000036127	NCT00003612_7_T8	GENE	24	25	progesterone receptor
NCT000036129	NCT00003612_9_T0	PHENOTYPE	18	18	toxicity
NCT000036129	NCT00003612_9_T1	PHENOTYPE	15	15	progression
NCT0000361210	NCT00003612_10_T0	GENE	4	4	IV
NCT0000361210	NCT00003612_10_T1	PHENOTYPE	12	13	disease progression
NCT0000361212	NCT00003612_12_T0	PHENOTYPE	18	18	toxicity
NCT0000361212	NCT00003612_12_T1	PHENOTYPE	14	15	disease progression
NCT0000361213	NCT00003612_13_T0	GENE	4	4	IV
NCT0000361213	NCT00003612_13_T1	PHENOTYPE	12	13	disease progression
NCT0000361216	NCT00003612_16_T0	PHENOTYPE	2	2	closed
NCT000036131	NCT00003613_1_T0	CELL	10	10	cells
NCT000036135	NCT00003613_5_T0	PHENOTYPE	3	3	toxicity
NCT000036135	NCT00003613_5_T1	COMPOUND	7	7	BCNU
NCT000036137	NCT00003613_7_T0	GENE	3	3	IV
NCT000036138	NCT00003613_8_T0	PHENOTYPE	10	10	toxicity
NCT000036138	NCT00003613_8_T1	PHENOTYPE	6	7	disease progression
NCT000036139	NCT00003613_9_T0	GENE	14	14	MTD
NCT0000361310	NCT00003613_10_T0	PHENOTYPE	17	17	toxicity
NCT0000361310	NCT00003613_10_T1	GENE	1	1	MTD
NCT000036141	NCT00003614_1_T0	CELL	9	9	cells
NCT000036141	NCT00003614_1_T1	PHENOTYPE	8	8	tumor
NCT000036146	NCT00003614_6_T0	PHENOTYPE	2	2	toxic
NCT0000361410	NCT00003614_10_T0	PHENOTYPE	12	13	measurable disease
NCT0000361411	NCT00003614_11_T0	GENE	10	10	1.3
NCT0000361411	NCT00003614_11_T1	COMPOUND	3	3	estramustine
NCT0000361412	NCT00003614_12_T0	COMPOUND	3	3	paclitaxel
NCT0000361412	NCT00003614_12_T1	GENE	4	4	IV
NCT0000361413	NCT00003614_13_T0	PHENOTYPE	10	10	toxicity
NCT0000361413	NCT00003614_13_T1	PHENOTYPE	12	13	disease progression
NCT0000361414	NCT00003614_14_T0	PHENOTYPE	0	2	Quality of life
NCT000036151	NCT00003615_1_T0	PHENOTYPE	7	8	Hodgkin's lymphoma
NCT000036152	NCT00003615_2_T0	GENE	2	2	II
NCT000036152	NCT00003615_2_T1	GENE	19	19	has
NCT000036152	NCT00003615_2_T2	PHENOTYPE	16	17	Hodgkin's lymphoma
NCT000036154	NCT00003615_4_T0	GENE	12	12	II
NCT000036154	NCT00003615_4_T1	CELL	19	19	B-cell
NCT000036154	NCT00003615_4_T2	GENE	13	13	III
NCT000036154	NCT00003615_4_T3	GENE	15	15	IV
NCT000036154	NCT00003615_4_T4	PHENOTYPE	20	21	Hodgkin's lymphoma
NCT000036156	NCT00003615_6_T0	PHENOTYPE	7	7	remission
NCT000036156	NCT00003615_6_T1	PHENOTYPE	4	4	progression
NCT000036158	NCT00003615_8_T0	PHENOTYPE	2	2	toxicity
NCT0000361510	NCT00003615_10_T0	GENE	6	6	receptor
NCT0000361511	NCT00003615_11_T0	GENE	7	7	receptor
NCT0000361511	NCT00003615_11_T1	GENE	6	6	interleukin-2
NCT0000361512	NCT00003615_12_T0	GENE	13	13	1.5
NCT0000361512	NCT00003615_12_T1	GENE	7	7	IV
NCT0000361513	NCT00003615_13_T0	PHENOTYPE	16	16	toxicity
NCT0000361513	NCT00003615_13_T1	PHENOTYPE	12	13	disease progression
NCT0000361515	NCT00003615_15_T0	GENE	12	12	interleukin-2
NCT0000361515	NCT00003615_15_T1	GENE	13	13	IL-2
NCT0000361515	NCT00003615_15_T2	GENE	27	27	IL-2
NCT0000361517	NCT00003615_17_T0	PHENOTYPE	18	18	lymphoma
NCT0000361517	NCT00003615_17_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000361517	NCT00003615_17_T2	PHENOTYPE	16	17	high grade
NCT000036161	NCT00003616_1_T0	COMPOUND	9	9	irinotecan
NCT000036161	NCT00003616_1_T1	PHENOTYPE	15	15	progressive
NCT000036161	NCT00003616_1_T2	PHENOTYPE	17	17	recurrent
NCT000036161	NCT00003616_1_T3	PHENOTYPE	18	19	malignant glioma
NCT000036163	NCT00003616_3_T0	COMPOUND	11	11	irinotecan
NCT000036163	NCT00003616_3_T1	PHENOTYPE	9	9	toxicities
NCT000036163	NCT00003616_3_T2	PHENOTYPE	15	15	progressive
NCT000036163	NCT00003616_3_T3	PHENOTYPE	17	17	recurrent
NCT000036163	NCT00003616_3_T4	PHENOTYPE	18	19	malignant glioma
NCT000036165	NCT00003616_5_T0	COMPOUND	10	10	irinotecan
NCT0000361611	NCT00003616_11_T0	COMPOUND	4	4	irinotecan
NCT0000361611	NCT00003616_11_T1	PHENOTYPE	17	17	tumor
NCT0000361613	NCT00003616_13_T0	GENE	12	12	II
NCT0000361613	NCT00003616_13_T1	COMPOUND	6	6	irinotecan
NCT0000361616	NCT00003616_16_T0	COMPOUND	6	6	irinotecan
NCT0000361616	NCT00003616_16_T1	GENE	7	7	IV
NCT0000361618	NCT00003616_18_T0	PHENOTYPE	21	21	toxicities
NCT0000361618	NCT00003616_18_T1	GENE	4	4	MTD
NCT0000361619	NCT00003616_19_T0	GENE	14	14	II
NCT0000361619	NCT00003616_19_T1	GENE	3	3	MTD
NCT0000361620	NCT00003616_20_T0	PHENOTYPE	18	18	toxicity
NCT0000361620	NCT00003616_20_T1	PHENOTYPE	14	15	disease progression
NCT0000361621	NCT00003616_21_T0	PHENOTYPE	26	27	disease progression
NCT0000361624	NCT00003616_24_T0	GENE	10	10	II
NCT000036171	NCT00003617_1_T0	COMPOUND	6	6	chlorambucil
NCT000036171	NCT00003617_1_T1	PHENOTYPE	14	15	low-grade lymphoma
NCT000036171	NCT00003617_1_T2	PHENOTYPE	15	18	lymphoma of the stomach
NCT000036172	NCT00003617_2_T0	GENE	3	3	III
NCT000036172	NCT00003617_2_T1	COMPOUND	10	10	chlorambucil
NCT000036172	NCT00003617_2_T2	PHENOTYPE	24	25	low-grade lymphoma
NCT000036172	NCT00003617_2_T3	PHENOTYPE	25	28	lymphoma of the stomach
NCT000036174	NCT00003617_4_T0	PHENOTYPE	23	24	gastric lymphoma
NCT000036174	NCT00003617_4_T1	PHENOTYPE	11	12	Helicobacter pylori
NCT000036176	NCT00003617_6_T0	PHENOTYPE	9	9	relapse
NCT000036176	NCT00003617_6_T1	COMPOUND	4	4	chlorambucil
NCT000036176	NCT00003617_6_T2	PHENOTYPE	18	19	gastric lymphoma
NCT000036178	NCT00003617_8_T0	PHENOTYPE	11	12	gastric lymphoma
NCT0000361710	NCT00003617_10_T0	COMPOUND	5	5	chlorambucil
NCT0000361711	NCT00003617_11_T0	COMPOUND	2	2	omeprazole
NCT0000361712	NCT00003617_12_T0	COMPOUND	2	2	tinidazole
NCT0000361713	NCT00003617_13_T0	GENE	4	4	2.3
NCT0000361714	NCT00003617_14_T0	GENE	11	11	2.3
NCT0000361716	NCT00003617_16_T0	COMPOUND	14	14	chlorambucil
NCT000036192	NCT00003619_2_T0	CELL	4	4	cells
NCT000036192	NCT00003619_2_T1	CELL	8	10	white blood cells
NCT000036197	NCT00003619_7_T0	COMPOUND	6	6	topotecan
NCT000036199	NCT00003619_9_T0	PHENOTYPE	3	3	remission
NCT0000361911	NCT00003619_11_T0	COMPOUND	12	12	cytarabine
NCT0000361911	NCT00003619_11_T1	GENE	24	24	filgrastim
NCT0000361911	NCT00003619_11_T2	COMPOUND	5	5	etoposide
NCT0000361911	NCT00003619_11_T3	GENE	25	25	G-CSF
NCT0000361911	NCT00003619_11_T4	GENE	7	7	IV
NCT0000361911	NCT00003619_11_T5	GENE	13	13	IV
NCT0000361912	NCT00003619_12_T0	CELL	0	3	Peripheral blood stem cells
NCT0000361913	NCT00003619_13_T0	COMPOUND	4	4	busulfan
NCT0000361913	NCT00003619_13_T1	COMPOUND	21	21	3
NCT0000361913	NCT00003619_13_T2	COMPOUND	14	14	etoposide
NCT0000361913	NCT00003619_13_T3	GENE	15	15	IV
NCT0000361915	NCT00003619_15_T0	COMPOUND	5	5	isotretinoin
NCT0000361915	NCT00003619_15_T1	GENE	1	1	65
NCT0000361915	NCT00003619_15_T2	COMPOUND	7	8	vitamin E
NCT0000361916	NCT00003619_16_T0	PHENOTYPE	10	10	toxicity
NCT0000361916	NCT00003619_16_T1	PHENOTYPE	6	7	disease progression
NCT0000361918	NCT00003619_18_T0	GENE	14	14	3.4
NCT000036202	NCT00003620_2_T0	PHENOTYPE	2	2	toxicity
NCT000036204	NCT00003620_4_T0	CELL	7	7	T-cell
NCT000036204	NCT00003620_4_T1	COMPOUND	4	4	flavopiridol
NCT000036204	NCT00003620_4_T2	PHENOTYPE	10	11	immunoglobulin levels
NCT000036206	NCT00003620_6_T0	GENE	10	10	1.3
NCT000036206	NCT00003620_6_T1	GENE	6	6	IV
NCT000036206	NCT00003620_6_T2	COMPOUND	5	5	flavopiridol
NCT000036207	NCT00003620_7_T0	PHENOTYPE	19	19	toxicity
NCT000036207	NCT00003620_7_T1	PHENOTYPE	15	16	disease progression
NCT000036208	NCT00003620_8_T0	GENE	13	13	1.3
NCT000036208	NCT00003620_8_T1	GENE	6	6	IV
NCT000036208	NCT00003620_8_T2	COMPOUND	5	5	flavopiridol
NCT000036209	NCT00003620_9_T0	PHENOTYPE	19	19	toxicity
NCT000036209	NCT00003620_9_T1	PHENOTYPE	15	16	disease progression
NCT000036210	NCT00003621_0_T0	PHENOTYPE	9	10	Anaplastic Astrocytoma
NCT000036212	NCT00003621_2_T0	CELL	8	8	cells
NCT000036212	NCT00003621_2_T1	PHENOTYPE	7	7	tumor
NCT000036213	NCT00003621_3_T0	CELL	12	12	cells
NCT000036213	NCT00003621_3_T1	PHENOTYPE	11	11	tumor
NCT000036214	NCT00003621_4_T0	GENE	2	2	II
NCT000036214	NCT00003621_4_T1	PHENOTYPE	21	22	anaplastic astrocytoma
NCT000036216	NCT00003621_6_T0	COMPOUND	7	7	etoposide
NCT000036216	NCT00003621_6_T1	COMPOUND	5	5	cisplatin
NCT000036216	NCT00003621_6_T2	PHENOTYPE	17	18	anaplastic astrocytoma
NCT000036218	NCT00003621_8_T0	PHENOTYPE	2	2	toxic
NCT0000362110	NCT00003621_10_T0	PHENOTYPE	6	6	fatigue
NCT0000362110	NCT00003621_10_T1	PHENOTYPE	12	14	quality of life
NCT0000362110	NCT00003621_10_T2	PHENOTYPE	8	10	excessive daytime somnolence
NCT0000362111	NCT00003621_11_T0	GENE	22	22	1.2
NCT0000362111	NCT00003621_11_T1	GENE	10	10	1.3
NCT0000362111	NCT00003621_11_T2	GENE	26	26	1.3
NCT0000362111	NCT00003621_11_T3	COMPOUND	12	12	etoposide
NCT0000362111	NCT00003621_11_T4	COMPOUND	19	19	cisplatin
NCT0000362111	NCT00003621_11_T5	GENE	4	4	IV
NCT0000362111	NCT00003621_11_T6	GENE	20	20	IV
NCT0000362114	NCT00003621_14_T0	PHENOTYPE	0	2	Quality of life
NCT000036227	NCT00003622_7_T0	PHENOTYPE	8	8	remission
NCT000036227	NCT00003622_7_T1	PHENOTYPE	12	13	measurable disease
NCT0000362213	NCT00003622_13_T0	COMPOUND	2	2	vinorelbine
NCT0000362213	NCT00003622_13_T1	COMPOUND	23	23	vinorelbine
NCT0000362213	NCT00003622_13_T2	COMPOUND	14	14	paclitaxel
NCT0000362213	NCT00003622_13_T3	GENE	3	3	IV
NCT0000362213	NCT00003622_13_T4	GENE	15	15	IV
NCT0000362214	NCT00003622_14_T0	PHENOTYPE	13	13	toxicity
NCT0000362214	NCT00003622_14_T1	PHENOTYPE	9	10	disease progression
NCT0000362215	NCT00003622_15_T0	PHENOTYPE	0	2	Quality of life
NCT000036231	NCT00003623_1_T0	PHENOTYPE	13	13	recurrence
NCT000036231	NCT00003623_1_T1	PHENOTYPE	16	18	stage bladder cancer
NCT000036232	NCT00003623_2_T0	PHENOTYPE	21	22	bladder cancer
NCT000036233	NCT00003623_3_T0	PHENOTYPE	19	19	recurrence
NCT000036233	NCT00003623_3_T1	GENE	4	4	III
NCT000036233	NCT00003623_3_T2	PHENOTYPE	26	28	stage bladder cancer
NCT000036241	NCT00003624_1_T0	CELL	8	8	cells
NCT000036241	NCT00003624_1_T1	COMPOUND	4	4	amifostine
NCT000036241	NCT00003624_1_T2	PHENOTYPE	12	14	effects of chemotherapy
NCT000036246	NCT00003624_6_T0	PHENOTYPE	11	12	peripheral neuropathy
NCT000036248	NCT00003624_8_T0	PHENOTYPE	3	3	toxicity
NCT000036249	NCT00003624_9_T0	COMPOUND	3	3	paclitaxel
NCT000036249	NCT00003624_9_T1	COMPOUND	8	8	amifostine
NCT000036249	NCT00003624_9_T2	COMPOUND	14	14	cisplatin
NCT000036249	NCT00003624_9_T3	GENE	4	4	IV
NCT000036249	NCT00003624_9_T4	GENE	9	9	IV
NCT000036249	NCT00003624_9_T5	GENE	15	15	IV
NCT0000362410	NCT00003624_10_T0	PHENOTYPE	16	16	toxicity
NCT0000362410	NCT00003624_10_T1	PHENOTYPE	12	13	disease progression
NCT0000362411	NCT00003624_11_T0	PHENOTYPE	0	0	Neurotoxicity
NCT0000362411	NCT00003624_11_T1	PHENOTYPE	4	5	vibration perception
NCT000036252	NCT00003625_2_T0	CELL	8	8	cells
NCT000036252	NCT00003625_2_T1	PHENOTYPE	7	7	tumor
NCT000036253	NCT00003625_3_T0	CELL	13	13	cells
NCT000036253	NCT00003625_3_T1	PHENOTYPE	12	12	tumor
NCT000036254	NCT00003625_4_T0	PHENOTYPE	20	22	brain stem glioma
NCT000036256	NCT00003625_6_T0	PHENOTYPE	8	8	toxicity
NCT000036256	NCT00003625_6_T1	COMPOUND	22	22	cyclosporine
NCT000036256	NCT00003625_6_T2	COMPOUND	10	10	vincristine
NCT000036256	NCT00003625_6_T3	GENE	14	14	IV
NCT000036256	NCT00003625_6_T4	COMPOUND	25	25	etoposide
NCT000036256	NCT00003625_6_T5	PHENOTYPE	39	41	brain stem glioma
NCT000036258	NCT00003625_8_T0	PHENOTYPE	4	4	severity
NCT000036258	NCT00003625_8_T1	COMPOUND	9	9	vincristine
NCT000036258	NCT00003625_8_T2	PHENOTYPE	7	7	toxicities
NCT0000362510	NCT00003625_10_T0	GENE	16	16	II
NCT0000362510	NCT00003625_10_T1	COMPOUND	7	7	vincristine
NCT0000362513	NCT00003625_13_T0	COMPOUND	7	7	vincristine
NCT0000362515	NCT00003625_15_T0	COMPOUND	20	20	cyclosporine
NCT0000362515	NCT00003625_15_T1	COMPOUND	4	4	vincristine
NCT0000362515	NCT00003625_15_T2	COMPOUND	27	27	vincristine
NCT0000362515	NCT00003625_15_T3	COMPOUND	12	12	etoposide
NCT0000362515	NCT00003625_15_T4	GENE	5	5	IV
NCT0000362515	NCT00003625_15_T5	GENE	21	21	IV
NCT0000362516	NCT00003625_16_T0	COMPOUND	8	8	vincristine
NCT0000362517	NCT00003625_17_T0	PHENOTYPE	3	3	toxicity
NCT0000362517	NCT00003625_17_T1	GENE	18	18	has
NCT0000362517	NCT00003625_17_T2	GENE	17	17	MTD
NCT0000362517	NCT00003625_17_T3	GENE	28	28	MTD
NCT0000362517	NCT00003625_17_T4	GENE	4	4	DLT
NCT0000362518	NCT00003625_18_T0	COMPOUND	8	8	cyclosporine
NCT0000362518	NCT00003625_18_T1	COMPOUND	17	17	vincristine
NCT0000362518	NCT00003625_18_T2	COMPOUND	25	25	etoposide
NCT0000362518	NCT00003625_18_T3	GENE	9	9	IV
NCT0000362518	NCT00003625_18_T4	GENE	18	18	IV
NCT000036265	NCT00003626_5_T0	PHENOTYPE	2	2	toxicity
NCT000036266	NCT00003626_6_T0	GENE	5	5	IV
NCT000036266	NCT00003626_6_T1	COMPOUND	3	4	dolastatin 10
NCT000036267	NCT00003626_7_T0	PHENOTYPE	13	13	toxicity
NCT000036267	NCT00003626_7_T1	PHENOTYPE	15	16	disease progression
NCT000036270	NCT00003627_0_T0	ORGAN	17	17	Hypopharynx
NCT000036270	NCT00003627_0_T1	PHENOTYPE	11	12	Advanced Cancer
NCT000036270	NCT00003627_0_T2	PHENOTYPE	12	15	Cancer of the Oropharynx
NCT000036272	NCT00003627_2_T0	CELL	10	10	cells
NCT000036272	NCT00003627_2_T1	PHENOTYPE	9	9	tumor
NCT000036273	NCT00003627_3_T0	CELL	9	9	cells
NCT000036273	NCT00003627_3_T1	PHENOTYPE	8	8	tumor
NCT000036274	NCT00003627_4_T0	ORGAN	25	25	hypopharynx
NCT000036274	NCT00003627_4_T1	PHENOTYPE	20	23	cancer of the oropharynx
NCT000036275	NCT00003627_5_T0	GENE	3	3	III
NCT000036275	NCT00003627_5_T1	ORGAN	31	31	hypopharynx
NCT000036275	NCT00003627_5_T2	COMPOUND	13	13	cisplatin
NCT000036275	NCT00003627_5_T3	PHENOTYPE	25	26	advanced cancer
NCT000036275	NCT00003627_5_T4	PHENOTYPE	26	29	cancer of the oropharynx
NCT0000362710	NCT00003627_10_T0	GENE	9	9	2.3
NCT0000362711	NCT00003627_11_T0	GENE	15	15	4.5
NCT000036300	NCT00003630_0_T0	PHENOTYPE	7	8	Solid Tumors
NCT000036302	NCT00003630_2_T0	COMPOUND	9	10	arsenic trioxide
NCT000036302	NCT00003630_2_T1	PHENOTYPE	17	18	solid tumors
NCT000036304	NCT00003630_4_T0	GENE	5	5	MTD
NCT000036304	NCT00003630_4_T1	COMPOUND	7	8	arsenic trioxide
NCT000036304	NCT00003630_4_T2	PHENOTYPE	16	17	solid tumors
NCT000036306	NCT00003630_6_T0	COMPOUND	8	9	arsenic trioxide
NCT000036306	NCT00003630_6_T1	PHENOTYPE	5	6	adverse experience
NCT0000363011	NCT00003630_11_T0	GENE	6	6	1.2
NCT0000363011	NCT00003630_11_T1	GENE	4	4	IV
NCT0000363011	NCT00003630_11_T2	COMPOUND	2	3	arsenic trioxide
NCT0000363012	NCT00003630_12_T0	PHENOTYPE	27	27	toxicity
NCT0000363012	NCT00003630_12_T1	PHENOTYPE	23	24	disease progression
NCT0000363013	NCT00003630_13_T0	GENE	12	12	MTD
NCT0000363013	NCT00003630_13_T1	COMPOUND	5	6	arsenic trioxide
NCT0000363014	NCT00003630_14_T0	PHENOTYPE	21	21	toxicity
NCT0000363014	NCT00003630_14_T1	GENE	1	1	MTD
NCT000036311	NCT00003631_1_T0	CELL	8	8	cells
NCT000036311	NCT00003631_1_T1	PHENOTYPE	7	7	tumor
NCT000036312	NCT00003631_2_T0	CELL	9	9	cells
NCT000036312	NCT00003631_2_T1	PHENOTYPE	8	8	tumor
NCT000036314	NCT00003631_4_T0	GENE	2	2	II
NCT000036314	NCT00003631_4_T1	PHENOTYPE	20	21	Hodgkin's lymphoma
NCT000036318	NCT00003631_8_T0	GENE	8	8	1.3
NCT000036318	NCT00003631_8_T1	GENE	1	1	IV
NCT000036319	NCT00003631_9_T0	GENE	3	3	filgrastim
NCT000036319	NCT00003631_9_T1	GENE	4	4	G-CSF
NCT000036319	NCT00003631_9_T2	GENE	7	7	IV
NCT0000363110	NCT00003631_10_T0	GENE	7	7	2.3
NCT0000363110	NCT00003631_10_T1	GENE	5	5	ICE
NCT0000363111	NCT00003631_11_T0	GENE	4	4	WBC
NCT0000363111	NCT00003631_11_T1	CELL	13	16	peripheral blood stem cells
NCT0000363112	NCT00003631_12_T0	GENE	22	22	10
NCT0000363113	NCT00003631_13_T0	GENE	1	1	IV
NCT0000363114	NCT00003631_14_T0	COMPOUND	13	13	2
NCT0000363114	NCT00003631_14_T1	GENE	1	1	IV
NCT0000363115	NCT00003631_15_T0	GENE	3	3	had
NCT0000363116	NCT00003631_16_T0	GENE	1	1	IV
NCT0000363117	NCT00003631_17_T0	COMPOUND	13	13	3
NCT0000363117	NCT00003631_17_T1	GENE	1	1	IV
NCT0000363118	NCT00003631_18_T0	COMPOUND	6	6	2
NCT0000363118	NCT00003631_18_T1	GENE	1	1	IV
NCT0000363119	NCT00003631_19_T0	CELL	0	3	Peripheral blood stem cells
NCT0000363121	NCT00003631_21_T0	CELL	13	13	cells
NCT0000363121	NCT00003631_21_T1	GENE	4	4	WBC
NCT0000363122	NCT00003631_22_T0	GENE	4	4	ICE
NCT0000363123	NCT00003631_23_T0	GENE	10	10	1.2
NCT0000363125	NCT00003631_25_T0	GENE	1	1	IV
NCT0000363126	NCT00003631_26_T0	GENE	2	2	G-CSF
NCT0000363127	NCT00003631_27_T0	GENE	16	16	10
NCT0000363128	NCT00003631_28_T0	COMPOUND	12	12	2
NCT0000363128	NCT00003631_28_T1	GENE	1	1	IV
NCT0000363129	NCT00003631_29_T0	COMPOUND	13	13	2
NCT0000363129	NCT00003631_29_T1	GENE	1	1	IV
NCT0000363130	NCT00003631_30_T0	GENE	3	3	had
NCT0000363131	NCT00003631_31_T0	COMPOUND	11	11	3
NCT0000363131	NCT00003631_31_T1	GENE	1	1	IV
NCT0000363132	NCT00003631_32_T0	COMPOUND	13	13	3
NCT0000363132	NCT00003631_32_T1	GENE	1	1	IV
NCT0000363133	NCT00003631_33_T0	COMPOUND	6	6	2
NCT0000363133	NCT00003631_33_T1	GENE	1	1	IV
NCT0000363134	NCT00003631_34_T0	CELL	0	3	Peripheral blood stem cells
NCT0000363136	NCT00003631_36_T0	CELL	6	6	cells
NCT0000363138	NCT00003631_38_T0	GENE	1	1	IV
NCT0000363140	NCT00003631_40_T0	GENE	1	1	IV
NCT0000363143	NCT00003631_43_T0	CELL	0	3	Peripheral blood stem cells
NCT0000363144	NCT00003631_44_T0	GENE	0	0	G-CSF
NCT0000363146	NCT00003631_46_T0	CELL	14	14	cells
NCT0000363147	NCT00003631_47_T0	COMPOUND	3	3	cytarabine
NCT0000363147	NCT00003631_47_T1	COMPOUND	16	16	3
NCT0000363147	NCT00003631_47_T2	GENE	1	1	IV
NCT0000363147	NCT00003631_47_T3	GENE	4	4	IV
NCT0000363148	NCT00003631_48_T0	COMPOUND	6	6	2
NCT0000363148	NCT00003631_48_T1	GENE	1	1	IV
NCT0000363150	NCT00003631_50_T0	GENE	1	1	IV
NCT0000363151	NCT00003631_51_T0	COMPOUND	3	3	cytarabine
NCT0000363151	NCT00003631_51_T1	COMPOUND	16	16	3
NCT0000363151	NCT00003631_51_T2	GENE	1	1	IV
NCT0000363151	NCT00003631_51_T3	GENE	4	4	IV
NCT0000363152	NCT00003631_52_T0	COMPOUND	6	6	2
NCT0000363152	NCT00003631_52_T1	GENE	1	1	IV
NCT0000363153	NCT00003631_53_T0	CELL	0	3	Peripheral blood stem cells
NCT0000363154	NCT00003631_54_T0	GENE	0	0	G-CSF
NCT0000363155	NCT00003631_55_T0	GENE	16	16	3.5
NCT0000363211	NCT00003632_11_T0	GENE	6	6	MTX
NCT0000363211	NCT00003632_11_T1	COMPOUND	5	5	methotrexate
NCT0000363211	NCT00003632_11_T2	GENE	7	7	IV
NCT0000363212	NCT00003632_12_T0	GENE	10	10	MTX
NCT0000363212	NCT00003632_12_T1	GENE	28	28	MTX
NCT0000363212	NCT00003632_12_T2	COMPOUND	16	16	cytarabine
NCT0000363212	NCT00003632_12_T3	GENE	18	18	IV
NCT0000363213	NCT00003632_13_T0	GENE	1	1	G-CSF
NCT0000363213	NCT00003632_13_T1	CELL	18	21	peripheral blood stem cells
NCT0000363214	NCT00003632_14_T0	GENE	7	7	IV
NCT0000363215	NCT00003632_15_T0	GENE	0	0	G-CSF
NCT0000363216	NCT00003632_16_T0	GENE	16	16	1.2
NCT0000363216	NCT00003632_16_T1	COMPOUND	41	41	melphalan
NCT0000363216	NCT00003632_16_T2	GENE	14	14	IV
NCT0000363216	NCT00003632_16_T3	GENE	22	22	IV
NCT0000363216	NCT00003632_16_T4	GENE	31	31	IV
NCT0000363216	NCT00003632_16_T5	GENE	42	42	IV
NCT0000363216	NCT00003632_16_T6	COMPOUND	45	45	2
NCT0000363216	NCT00003632_16_T7	COMPOUND	39	39	3
NCT0000363216	NCT00003632_16_T8	COMPOUND	21	21	etoposide
NCT0000363218	NCT00003632_18_T0	GENE	2	2	G-CSF
NCT000036331	NCT00003633_1_T0	CELL	9	9	cells
NCT000036331	NCT00003633_1_T1	PHENOTYPE	8	8	tumor
NCT000036334	NCT00003633_4_T0	COMPOUND	8	8	mitoxantrone
NCT000036334	NCT00003633_4_T1	COMPOUND	10	10	docetaxel
NCT000036336	NCT00003633_6_T0	COMPOUND	18	18	mitoxantrone
NCT000036336	NCT00003633_6_T1	GENE	9	9	0.3
NCT000036336	NCT00003633_6_T2	COMPOUND	25	25	docetaxel
NCT000036336	NCT00003633_6_T3	GENE	17	17	1.5
NCT000036336	NCT00003633_6_T4	COMPOUND	11	11	estramustine
NCT000036336	NCT00003633_6_T5	COMPOUND	4	4	prednisone
NCT000036336	NCT00003633_6_T6	GENE	19	19	IV
NCT000036336	NCT00003633_6_T7	GENE	26	26	IV
NCT000036337	NCT00003633_7_T0	PHENOTYPE	10	10	toxicity
NCT000036337	NCT00003633_7_T1	PHENOTYPE	12	13	disease progression
NCT0000363311	NCT00003633_11_T0	PHENOTYPE	12	12	toxicity
NCT0000363311	NCT00003633_11_T1	PHENOTYPE	9	9	experiences
NCT0000363311	NCT00003633_11_T2	GENE	13	13	DLT
NCT0000363312	NCT00003633_12_T0	GENE	14	14	stops
NCT0000363312	NCT00003633_12_T1	GENE	20	20	MTD
NCT0000363312	NCT00003633_12_T2	GENE	10	10	DLT
NCT0000363313	NCT00003633_13_T0	GENE	9	9	MTD
NCT000036340	NCT00003634_0_T0	GENE	11	11	III
NCT000036340	NCT00003634_0_T1	GENE	14	14	IV
NCT000036340	NCT00003634_0_T2	PHENOTYPE	20	21	Peritoneal Cancer
NCT000036340	NCT00003634_0_T3	ORGAN	17	18	Fallopian Tube
NCT000036340	NCT00003634_0_T4	PHENOTYPE	7	8	Residual Disease
NCT000036345	NCT00003634_5_T0	GENE	30	30	OR
NCT000036345	NCT00003634_5_T1	PHENOTYPE	23	23	adenocarcinoma
NCT000036345	NCT00003634_5_T2	GENE	17	17	IV
NCT000036345	NCT00003634_5_T3	PHENOTYPE	14	15	stage III
NCT000036345	NCT00003634_5_T4	PHENOTYPE	4	5	disease relapse
NCT000036345	NCT00003634_5_T5	PHENOTYPE	8	10	quality of life
NCT000036349	NCT00003634_9_T0	BIOLOGICAL_PROCESS	2	3	immune response
NCT0000363411	NCT00003634_11_T0	COMPOUND	5	5	platinum
NCT0000363413	NCT00003634_13_T0	PHENOTYPE	24	24	toxicity
NCT0000363413	NCT00003634_13_T1	PHENOTYPE	20	21	disease progression
NCT0000363416	NCT00003634_16_T0	PHENOTYPE	3	3	relapse
NCT0000363417	NCT00003634_17_T0	PHENOTYPE	0	2	Quality of life
NCT000036351	NCT00003635_1_T0	GENE	2	2	II
NCT000036351	NCT00003635_1_T1	COMPOUND	22	22	fludarabine
NCT000036351	NCT00003635_1_T2	GENE	18	18	has
NCT000036351	NCT00003635_1_T3	PHENOTYPE	14	16	chronic lymphocytic leukemia
NCT000036353	NCT00003635_3_T0	COMPOUND	14	14	fludarabine
NCT000036353	NCT00003635_3_T1	PHENOTYPE	9	12	chronic lymphocytic leukemia refractory
NCT000036357	NCT00003635_7_T0	PHENOTYPE	2	2	pharmacokinetics
NCT000036357	NCT00003635_7_T1	PHENOTYPE	11	11	pharmacokinetics
NCT000036357	NCT00003635_7_T2	COMPOUND	13	13	ara-GTP
NCT0000363514	NCT00003635_14_T0	GENE	3	3	IV
NCT0000363515	NCT00003635_15_T0	PHENOTYPE	19	19	toxicity
NCT0000363515	NCT00003635_15_T1	PHENOTYPE	15	16	disease progression
NCT0000363516	NCT00003635_16_T0	PHENOTYPE	15	16	disease progression
NCT0000363517	NCT00003635_17_T0	PHENOTYPE	1	2	disease progression
NCT000036360	NCT00003636_0_T0	GENE	8	8	III
NCT000036360	NCT00003636_0_T1	GENE	11	11	IV
NCT000036360	NCT00003636_0_T2	PHENOTYPE	15	17	Fallopian Tube Cancer
NCT000036362	NCT00003636_2_T0	CELL	8	8	cells
NCT000036362	NCT00003636_2_T1	PHENOTYPE	7	7	tumor
NCT000036367	NCT00003636_7_T0	PHENOTYPE	12	12	tumor
NCT000036367	NCT00003636_7_T1	PHENOTYPE	17	17	intent
NCT0000363613	NCT00003636_13_T0	PHENOTYPE	3	3	QOL
NCT0000363613	NCT00003636_13_T1	PHENOTYPE	0	2	Quality of life
NCT0000363614	NCT00003636_14_T0	PHENOTYPE	9	9	QOL
NCT000036372	NCT00003637_2_T0	CELL	10	10	cells
NCT000036372	NCT00003637_2_T1	PHENOTYPE	9	9	tumor
NCT0000363710	NCT00003637_10_T0	COMPOUND	2	2	cisplatin
NCT0000363710	NCT00003637_10_T1	GENE	3	3	IV
NCT0000363710	NCT00003637_10_T2	GENE	6	6	IV
NCT000036381	NCT00003638_1_T0	CELL	12	12	cells
NCT000036381	NCT00003638_1_T1	PHENOTYPE	11	11	tumor
NCT000036381	NCT00003638_1_T2	BIOLOGICAL_PROCESS	7	8	immune response
NCT000036382	NCT00003638_2_T0	PHENOTYPE	18	20	metastatic breast cancer
NCT000036383	NCT00003638_3_T0	GENE	5	5	III
NCT000036383	NCT00003638_3_T1	PHENOTYPE	26	28	metastatic breast cancer
NCT000036385	NCT00003638_5_T0	PHENOTYPE	3	4	disease progression
NCT0000363811	NCT00003638_11_T0	COMPOUND	5	5	KLH
NCT0000363811	NCT00003638_11_T1	GENE	3	3	OSM
NCT0000363811	NCT00003638_11_T2	PHENOTYPE	6	7	antibody titers
NCT0000363813	NCT00003638_13_T0	PHENOTYPE	9	11	quality of life
NCT0000363816	NCT00003638_16_T0	PHENOTYPE	16	16	nonprogressive
NCT0000363816	NCT00003638_16_T1	PHENOTYPE	28	29	metastatic disease
NCT0000363820	NCT00003638_20_T0	PHENOTYPE	3	3	toxic
NCT0000363820	NCT00003638_20_T1	PHENOTYPE	6	7	disease progression
NCT000036392	NCT00003639_2_T0	GENE	13	13	interferon
NCT000036392	NCT00003639_2_T1	PHENOTYPE	26	27	Hodgkin's lymphoma
NCT000036393	NCT00003639_3_T0	GENE	3	3	III
NCT000036393	NCT00003639_3_T1	GENE	15	15	interferon
NCT000036393	NCT00003639_3_T2	PHENOTYPE	22	23	Hodgkin's lymphoma
NCT000036395	NCT00003639_5_T0	PHENOTYPE	6	6	toxicity
NCT000036395	NCT00003639_5_T1	COMPOUND	10	10	dexamethasone
NCT000036395	NCT00003639_5_T2	PHENOTYPE	2	2	remission
NCT000036395	NCT00003639_5_T3	COMPOUND	14	14	idarubicin
NCT000036395	NCT00003639_5_T4	COMPOUND	8	8	chlorambucil
NCT000036395	NCT00003639_5_T5	PHENOTYPE	22	23	Hodgkin's lymphoma
NCT000036397	NCT00003639_7_T0	GENE	13	13	interferon
NCT000036397	NCT00003639_7_T1	GENE	18	18	interferon
NCT0000363921	NCT00003639_21_T0	PHENOTYPE	18	18	lymphoma
NCT0000363921	NCT00003639_21_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000363921	NCT00003639_21_T2	PHENOTYPE	16	17	high grade
NCT000036401	NCT00003640_1_T0	CELL	10	10	cells
NCT000036401	NCT00003640_1_T1	PHENOTYPE	9	9	tumor
NCT000036402	NCT00003640_2_T0	GENE	2	2	II
NCT000036402	NCT00003640_2_T1	GENE	20	20	II
NCT000036402	NCT00003640_2_T2	PHENOTYPE	22	25	stage III bladder cancer
NCT000036406	NCT00003640_6_T0	ORGAN	16	16	bladder
NCT000036406	NCT00003640_6_T1	COMPOUND	9	9	M-VAC
NCT0000364013	NCT00003640_13_T0	COMPOUND	10	10	vinblastine
NCT0000364013	NCT00003640_13_T1	COMPOUND	3	3	methotrexate
NCT0000364013	NCT00003640_13_T2	COMPOUND	12	12	doxorubicin
NCT0000364013	NCT00003640_13_T3	COMPOUND	15	15	cisplatin
NCT0000364013	NCT00003640_13_T4	GENE	4	4	IV
NCT0000364013	NCT00003640_13_T5	GENE	11	11	IV
NCT0000364013	NCT00003640_13_T6	GENE	13	13	IV
NCT0000364013	NCT00003640_13_T7	GENE	16	16	IV
NCT0000364014	NCT00003640_14_T0	GENE	1	1	G-CSF
NCT000036410	NCT00003641_0_T0	GENE	8	8	II
NCT000036410	NCT00003641_0_T1	PHENOTYPE	12	12	Melanoma
NCT000036410	NCT00003641_0_T2	GENE	11	11	III
NCT000036410	NCT00003641_0_T3	GENE	1	1	Interferon
NCT000036412	NCT00003641_2_T0	GENE	18	18	II
NCT000036412	NCT00003641_2_T1	GENE	24	24	has
NCT000036412	NCT00003641_2_T2	GENE	8	8	interferon
NCT000036412	NCT00003641_2_T3	PHENOTYPE	20	22	stage III melanoma
NCT000036413	NCT00003641_3_T0	GENE	27	27	II
NCT000036413	NCT00003641_3_T1	GENE	4	4	III
NCT000036413	NCT00003641_3_T2	GENE	10	10	interferon
NCT000036413	NCT00003641_3_T3	GENE	33	33	has
NCT000036413	NCT00003641_3_T4	PHENOTYPE	29	31	stage III melanoma
NCT000036419	NCT00003641_9_T0	PHENOTYPE	11	11	toxicity
NCT0000364110	NCT00003641_10_T0	PHENOTYPE	0	2	Quality of life
NCT000036421	NCT00003642_1_T0	CELL	10	10	cells
NCT000036421	NCT00003642_1_T1	PHENOTYPE	9	9	tumor
NCT000036422	NCT00003642_2_T0	CELL	15	15	cells
NCT000036422	NCT00003642_2_T1	PHENOTYPE	14	14	tumor
NCT000036423	NCT00003642_3_T0	GENE	2	2	II
NCT000036423	NCT00003642_3_T1	GENE	22	22	II
NCT000036423	NCT00003642_3_T2	COMPOUND	15	15	cisplatin
NCT000036423	NCT00003642_3_T3	PHENOTYPE	24	27	stage III bladder cancer
NCT000036427	NCT00003642_7_T0	PHENOTYPE	7	7	recurrence
NCT0000364211	NCT00003642_11_T0	PHENOTYPE	3	3	recurrent
NCT0000364214	NCT00003642_14_T0	GENE	28	28	1.5
NCT0000364214	NCT00003642_14_T1	COMPOUND	12	12	cisplatin
NCT0000364214	NCT00003642_14_T2	GENE	13	13	IV
NCT000036432	NCT00003643_2_T0	CELL	9	9	cells
NCT000036432	NCT00003643_2_T1	PHENOTYPE	8	8	tumor
NCT000036438	NCT00003643_8_T0	PHENOTYPE	6	6	seminoma
NCT000036438	NCT00003643_8_T1	PHENOTYPE	8	8	seminoma
NCT0000364310	NCT00003643_10_T0	GENE	3	3	filgrastim
NCT0000364310	NCT00003643_10_T1	GENE	4	4	G-CSF
NCT0000364312	NCT00003643_12_T0	PHENOTYPE	0	2	Quality of life
NCT000036441	NCT00003644_1_T0	CELL	9	9	cells
NCT000036441	NCT00003644_1_T1	PHENOTYPE	8	8	tumor
NCT000036442	NCT00003644_2_T0	COMPOUND	10	10	paclitaxel
NCT000036442	NCT00003644_2_T1	COMPOUND	14	14	paclitaxel
NCT000036442	NCT00003644_2_T2	COMPOUND	21	21	paclitaxel
NCT000036442	NCT00003644_2_T3	PHENOTYPE	25	26	ovarian cancer
NCT000036443	NCT00003644_3_T0	COMPOUND	10	10	paclitaxel
NCT000036443	NCT00003644_3_T1	COMPOUND	22	22	paclitaxel
NCT000036443	NCT00003644_3_T2	COMPOUND	27	27	paclitaxel
NCT000036443	NCT00003644_3_T3	GENE	4	4	III
NCT000036443	NCT00003644_3_T4	PHENOTYPE	33	34	ovarian cancer
NCT0000364412	NCT00003644_12_T0	GENE	14	14	5.5
NCT000036452	NCT00003645_2_T0	COMPOUND	9	9	flutamide
NCT000036452	NCT00003645_2_T1	COMPOUND	7	7	leuprolide
NCT000036457	NCT00003645_7_T0	PHENOTYPE	0	2	Quality of life
NCT000036458	NCT00003645_8_T0	PHENOTYPE	0	2	Quality of life
NCT0000364513	NCT00003645_13_T0	PHENOTYPE	3	3	bilateral
NCT0000364513	NCT00003645_13_T1	TISSUE	4	5	lymph node
NCT0000364515	NCT00003645_15_T0	PHENOTYPE	16	16	pathology
NCT0000364515	NCT00003645_15_T1	ORGAN	29	30	Seminal vesicle
NCT0000364515	NCT00003645_15_T2	TISSUE	36	38	positive surgical margins
NCT0000364518	NCT00003645_18_T0	PHENOTYPE	3	4	metastatic disease
NCT0000364523	NCT00003645_23_T0	ORGAN	2	2	liver
NCT000036460	NCT00003646_0_T0	PHENOTYPE	11	11	Melanoma
NCT000036460	NCT00003646_0_T1	GENE	7	7	III
NCT000036460	NCT00003646_0_T2	GENE	10	10	IV
NCT000036462	NCT00003646_2_T0	GENE	2	2	II
NCT000036462	NCT00003646_2_T1	GENE	23	23	has
NCT000036462	NCT00003646_2_T2	PHENOTYPE	16	17	stage III
NCT000036462	NCT00003646_2_T3	PHENOTYPE	19	21	stage IV melanoma
NCT000036464	NCT00003646_4_T0	PHENOTYPE	26	26	melanoma
NCT000036464	NCT00003646_4_T1	GENE	25	25	IV
NCT000036464	NCT00003646_4_T2	PHENOTYPE	22	23	stage III
NCT000036470	NCT00003647_0_T0	PHENOTYPE	14	14	Melanoma
NCT000036470	NCT00003647_0_T1	GENE	10	10	III
NCT000036470	NCT00003647_0_T2	GENE	13	13	IV
NCT000036472	NCT00003647_2_T0	CELL	6	6	cells
NCT000036472	NCT00003647_2_T1	CELL	19	19	cells
NCT000036472	NCT00003647_2_T2	PHENOTYPE	18	18	tumor
NCT000036472	NCT00003647_2_T3	PHENOTYPE	5	5	melanoma
NCT000036472	NCT00003647_2_T4	BIOLOGICAL_PROCESS	13	14	immune response
NCT000036473	NCT00003647_3_T0	GENE	3	3	III
NCT000036473	NCT00003647_3_T1	COMPOUND	10	10	dacarbazine
NCT000036473	NCT00003647_3_T2	PHENOTYPE	20	21	stage III
NCT000036473	NCT00003647_3_T3	PHENOTYPE	23	25	stage IV melanoma
NCT000036475	NCT00003647_5_T0	GENE	26	26	OR
NCT000036475	NCT00003647_5_T1	PHENOTYPE	57	57	melanoma
NCT000036475	NCT00003647_5_T2	GENE	56	56	IV
NCT000036475	NCT00003647_5_T3	COMPOUND	59	59	dacarbazine
NCT000036475	NCT00003647_5_T4	COMPOUND	67	67	dacarbazine
NCT000036475	NCT00003647_5_T5	PHENOTYPE	53	54	stage III
NCT000036475	NCT00003647_5_T6	PHENOTYPE	9	10	disease progression
NCT000036475	NCT00003647_5_T7	PHENOTYPE	48	49	disease progression
NCT000036479	NCT00003647_9_T0	GENE	13	13	nodal
NCT000036481	NCT00003648_1_T0	PHENOTYPE	12	13	colorectal cancer
NCT000036481	NCT00003648_1_T1	PHENOTYPE	23	24	colorectal cancer
NCT000036487	NCT00003648_7_T0	GENE	23	23	hMSH2
NCT000036487	NCT00003648_7_T1	GENE	25	25	hMLH1
NCT000036487	NCT00003648_7_T2	GENE	4	4	defective
NCT000036487	NCT00003648_7_T3	PHENOTYPE	12	13	colon cancer
NCT000036487	NCT00003648_7_T4	BIOLOGICAL_PROCESS	6	7	mismatch repair
NCT000036487	NCT00003648_7_T5	PHENOTYPE	16	17	colon cancers
NCT000036489	NCT00003648_9_T0	GENE	8	8	extended
NCT000036489	NCT00003648_9_T1	GENE	12	12	extended
NCT0000364810	NCT00003648_10_T0	GENE	14	14	hMSH2
NCT0000364810	NCT00003648_10_T1	PHENOTYPE	2	2	tumor
NCT0000364811	NCT00003648_11_T0	PHENOTYPE	15	15	practices
NCT000036494	NCT00003649_4_T0	GENE	6	6	p53
NCT000036496	NCT00003649_6_T0	PHENOTYPE	11	11	toxicity
NCT000036498	NCT00003649_8_T0	GENE	12	12	p53
NCT000036499	NCT00003649_9_T0	PHENOTYPE	9	9	toxicity
NCT000036499	NCT00003649_9_T1	GENE	10	10	DLT
NCT0000364910	NCT00003649_10_T0	PHENOTYPE	12	12	toxicity
NCT0000364910	NCT00003649_10_T1	PHENOTYPE	9	9	experiences
NCT0000364910	NCT00003649_10_T2	GENE	13	13	DLT
NCT0000364911	NCT00003649_11_T0	GENE	17	17	MTD
NCT0000364911	NCT00003649_11_T1	GENE	8	8	DLT
NCT0000364912	NCT00003649_12_T0	GENE	8	8	MTD
NCT000036501	NCT00003650_1_T0	CELL	9	9	cells
NCT000036502	NCT00003650_2_T0	GENE	2	2	III
NCT000036502	NCT00003650_2_T1	PHENOTYPE	16	17	Hodgkin's lymphoma
NCT000036505	NCT00003650_5_T0	COMPOUND	24	24	vincristine
NCT000036505	NCT00003650_5_T1	GENE	16	16	1.28
NCT000036505	NCT00003650_5_T2	GENE	55	55	IM
NCT000036505	NCT00003650_5_T3	GENE	52	52	asparaginase
NCT000036505	NCT00003650_5_T4	GENE	32	32	29
NCT000036505	NCT00003650_5_T5	GENE	51	51	29
NCT000036505	NCT00003650_5_T6	COMPOUND	68	68	methotrexate
NCT000036505	NCT00003650_5_T7	GENE	10	10	IV
NCT000036505	NCT00003650_5_T8	GENE	25	25	IV
NCT000036505	NCT00003650_5_T9	GENE	34	34	IV
NCT000036505	NCT00003650_5_T10	GENE	42	42	IV
NCT000036505	NCT00003650_5_T11	GENE	53	53	IV
NCT000036505	NCT00003650_5_T12	GENE	69	69	IV
NCT000036505	NCT00003650_5_T13	COMPOUND	41	41	daunorubicin
NCT000036505	NCT00003650_5_T14	COMPOUND	33	33	cyclophosphamide
NCT000036505	NCT00003650_5_T15	COMPOUND	9	9	prednisone
NCT000036505	NCT00003650_5_T16	GENE	66	66	32
NCT000036506	NCT00003650_6_T0	COMPOUND	5	5	methylprednisolone
NCT000036506	NCT00003650_6_T1	COMPOUND	3	3	methotrexate
NCT000036506	NCT00003650_6_T2	GENE	7	7	IT
NCT000036507	NCT00003650_7_T0	GENE	8	8	4-8
NCT000036509	NCT00003650_9_T0	COMPOUND	5	5	methylprednisolone
NCT000036509	NCT00003650_9_T1	COMPOUND	3	3	methotrexate
NCT000036509	NCT00003650_9_T2	GENE	6	6	IT
NCT0000365010	NCT00003650_10_T0	PHENOTYPE	4	4	remission
NCT0000365011	NCT00003650_11_T0	BIOLOGICAL_PROCESS	6	6	interphase
NCT0000365011	NCT00003650_11_T1	COMPOUND	30	30	methylprednisolone
NCT0000365011	NCT00003650_11_T2	COMPOUND	17	17	methotrexate
NCT0000365011	NCT00003650_11_T3	COMPOUND	28	28	methotrexate
NCT0000365011	NCT00003650_11_T4	GENE	31	31	IT
NCT0000365011	NCT00003650_11_T5	GENE	18	18	IV
NCT0000365014	NCT00003650_14_T0	GENE	35	35	22
NCT0000365014	NCT00003650_14_T1	COMPOUND	19	19	vincristine
NCT0000365014	NCT00003650_14_T2	GENE	44	44	IM
NCT0000365014	NCT00003650_14_T3	GENE	43	43	asparaginase
NCT0000365014	NCT00003650_14_T4	COMPOUND	38	38	methylprednisolone
NCT0000365014	NCT00003650_14_T5	COMPOUND	24	24	methotrexate
NCT0000365014	NCT00003650_14_T6	COMPOUND	36	36	methotrexate
NCT0000365014	NCT00003650_14_T7	GENE	39	39	IT
NCT0000365014	NCT00003650_14_T8	GENE	20	20	IV
NCT0000365014	NCT00003650_14_T9	GENE	25	25	IV
NCT0000365014	NCT00003650_14_T10	GENE	46	46	IV
NCT0000365014	NCT00003650_14_T11	COMPOUND	12	12	1
NCT0000365014	NCT00003650_14_T12	COMPOUND	23	23	1
NCT0000365014	NCT00003650_14_T13	COMPOUND	31	31	1
NCT0000365014	NCT00003650_14_T14	COMPOUND	42	42	2
NCT0000365014	NCT00003650_14_T15	COMPOUND	49	49	2
NCT0000365016	NCT00003650_16_T0	GENE	27	27	22
NCT0000365016	NCT00003650_16_T1	COMPOUND	11	11	cytarabine
NCT0000365016	NCT00003650_16_T2	GENE	18	18	1.4
NCT0000365016	NCT00003650_16_T3	GENE	10	10	1.5
NCT0000365016	NCT00003650_16_T4	COMPOUND	19	19	methotrexate
NCT0000365016	NCT00003650_16_T5	COMPOUND	4	4	prednisone
NCT0000365016	NCT00003650_16_T6	GENE	20	20	IV
NCT0000365017	NCT00003650_17_T0	COMPOUND	9	9	methotrexate
NCT0000365018	NCT00003650_18_T0	GENE	4	4	II
NCT0000365018	NCT00003650_18_T1	GENE	6	6	III
NCT0000365018	NCT00003650_18_T2	GENE	18	18	IV
NCT0000365022	NCT00003650_22_T0	COMPOUND	49	49	mitoxantrone
NCT0000365022	NCT00003650_22_T1	COMPOUND	33	33	dexamethasone
NCT0000365022	NCT00003650_22_T2	COMPOUND	37	37	cytarabine
NCT0000365022	NCT00003650_22_T3	GENE	74	74	IM
NCT0000365022	NCT00003650_22_T4	GENE	68	68	asparaginase
NCT0000365022	NCT00003650_22_T5	GENE	36	36	1.5
NCT0000365022	NCT00003650_22_T6	GENE	66	66	3.5
NCT0000365022	NCT00003650_22_T7	GENE	13	13	4-8
NCT0000365022	NCT00003650_22_T8	GENE	50	50	IV
NCT0000365022	NCT00003650_22_T9	GENE	60	60	IV
NCT0000365022	NCT00003650_22_T10	GENE	69	69	IV
NCT0000365022	NCT00003650_22_T11	PHENOTYPE	22	22	recurrence
NCT0000365022	NCT00003650_22_T12	COMPOUND	48	48	2
NCT0000365022	NCT00003650_22_T13	PHENOTYPE	11	11	remission
NCT0000365022	NCT00003650_22_T14	COMPOUND	59	59	etoposide
NCT0000365023	NCT00003650_23_T0	COMPOUND	7	7	cytarabine
NCT0000365023	NCT00003650_23_T1	COMPOUND	9	9	methylprednisolone
NCT0000365023	NCT00003650_23_T2	COMPOUND	6	6	methotrexate
NCT000036520	NCT00003652_0_T0	GENE	10	10	II
NCT000036520	NCT00003652_0_T1	PHENOTYPE	12	15	Stage III Anal Cancer
NCT000036522	NCT00003652_2_T0	CELL	8	8	cells
NCT000036522	NCT00003652_2_T1	PHENOTYPE	7	7	tumor
NCT000036523	NCT00003652_3_T0	CELL	9	9	cells
NCT000036523	NCT00003652_3_T1	PHENOTYPE	8	8	tumor
NCT000036524	NCT00003652_4_T0	GENE	29	29	II
NCT000036524	NCT00003652_4_T1	GENE	4	4	III
NCT000036524	NCT00003652_4_T2	PHENOTYPE	31	34	stage III anal cancer
NCT000036529	NCT00003652_9_T0	GENE	11	11	1.4
NCT000036529	NCT00003652_9_T1	COMPOUND	13	13	cisplatin
NCT000036529	NCT00003652_9_T2	GENE	5	5	IV
NCT000036529	NCT00003652_9_T3	GENE	14	14	IV
NCT0000365211	NCT00003652_11_T0	PHENOTYPE	9	9	tumors
NCT0000365212	NCT00003652_12_T0	PHENOTYPE	4	4	tumors
NCT0000365213	NCT00003652_13_T0	PHENOTYPE	0	2	Quality of life
NCT000036535	NCT00003653_5_T0	GENE	5	5	LHRH
NCT000036535	NCT00003653_5_T1	ORGAN	15	15	Appendix
NCT000036535	NCT00003653_5_T2	GENE	16	16	IX
NCT000036537	NCT00003653_7_T0	GENE	8	8	LHRH
NCT000036537	NCT00003653_7_T1	ORGAN	17	17	Appendix
NCT000036537	NCT00003653_7_T2	GENE	18	18	IX
NCT0000365314	NCT00003653_14_T0	COMPOUND	19	19	flutamide
NCT0000365314	NCT00003653_14_T1	COMPOUND	7	7	buserelin
NCT0000365314	NCT00003653_14_T2	COMPOUND	9	9	goserelin
NCT0000365314	NCT00003653_14_T3	COMPOUND	21	21	bicalutamide
NCT0000365314	NCT00003653_14_T4	GENE	5	5	LHRH
NCT0000365314	NCT00003653_14_T5	COMPOUND	12	12	leuprolide
NCT0000365314	NCT00003653_14_T6	COMPOUND	17	17	nilutamide
NCT0000365314	NCT00003653_14_T7	COMPOUND	24	25	cyproterone acetate
NCT0000365314	NCT00003653_14_T8	GENE	2	4	luteinizing hormone-releasing hormone
NCT0000365315	NCT00003653_15_T0	GENE	6	6	SC
NCT0000365315	NCT00003653_15_T1	GENE	2	2	LHRH
NCT0000365315	NCT00003653_15_T2	GENE	30	30	LHRH
NCT0000365315	NCT00003653_15_T3	GENE	9	9	IM
NCT0000365315	NCT00003653_15_T4	GENE	23	23	1.3
NCT0000365315	NCT00003653_15_T5	GENE	12	12	1.4
NCT0000365320	NCT00003653_20_T0	GENE	2	2	LHRH
NCT0000365320	NCT00003653_20_T1	GENE	16	16	OR
NCT0000365320	NCT00003653_20_T2	PHENOTYPE	18	18	bilateral
NCT0000365321	NCT00003653_21_T0	GENE	5	5	SC
NCT0000365321	NCT00003653_21_T1	GENE	2	2	LHRH
NCT0000365321	NCT00003653_21_T2	GENE	28	28	LHRH
NCT0000365321	NCT00003653_21_T3	GENE	7	7	IM
NCT0000365321	NCT00003653_21_T4	GENE	21	21	1.3
NCT0000365321	NCT00003653_21_T5	GENE	10	10	1.4
NCT0000365323	NCT00003653_23_T0	GENE	3	3	hormone
NCT000036545	NCT00003654_5_T0	GENE	16	16	dye
NCT000036545	NCT00003654_5_T1	GENE	18	18	gamma
NCT000036545	NCT00003654_5_T2	COMPOUND	13	14	patent blue
NCT000036545	NCT00003654_5_T3	TISSUE	9	11	sentinel lymph nodes
NCT000036546	NCT00003654_6_T0	GENE	6	6	dye
NCT000036546	NCT00003654_6_T1	COMPOUND	3	4	patent blue
NCT000036548	NCT00003654_8_T0	PHENOTYPE	1	1	tumors
NCT000036548	NCT00003654_8_T1	PHENOTYPE	4	4	localized
NCT000036549	NCT00003654_9_T0	GENE	8	8	II
NCT000036549	NCT00003654_9_T1	TISSUE	9	10	lymph node
NCT000036562	NCT00003656_2_T0	GENE	2	2	II
NCT000036562	NCT00003656_2_T1	GENE	12	12	interferon
NCT000036562	NCT00003656_2_T2	PHENOTYPE	19	21	metastatic kidney cancer
NCT000036564	NCT00003656_4_T0	COMPOUND	15	16	interferon alfa_2b
NCT000036565	NCT00003656_5_T0	PHENOTYPE	2	2	closed
NCT000036565	NCT00003656_5_T1	GENE	12	12	IV
NCT000036565	NCT00003656_5_T2	COMPOUND	19	20	interferon alfa_2b
NCT000036566	NCT00003656_6_T0	PHENOTYPE	13	13	toxicity
NCT000036566	NCT00003656_6_T1	PHENOTYPE	9	10	disease progression
NCT000036567	NCT00003656_7_T0	GENE	16	16	has
NCT000036567	NCT00003656_7_T1	GENE	15	15	MTD
NCT000036568	NCT00003656_8_T0	PHENOTYPE	21	21	toxicity
NCT000036568	NCT00003656_8_T1	GENE	1	1	MTD
NCT000036569	NCT00003656_9_T0	GENE	2	2	MTD
NCT0000365610	NCT00003656_10_T0	PHENOTYPE	2	2	closed
NCT0000365610	NCT00003656_10_T1	COMPOUND	18	19	interferon alfa_2b
NCT0000365611	NCT00003656_11_T0	COMPOUND	12	13	interferon alfa_2b
NCT0000365612	NCT00003656_12_T0	PHENOTYPE	2	2	closed
NCT0000365613	NCT00003656_13_T0	PHENOTYPE	20	20	closed
NCT0000365614	NCT00003656_14_T0	GENE	11	11	II
NCT000036571	NCT00003657_1_T0	TISSUE	8	8	tissues
NCT000036571	NCT00003657_1_T1	PHENOTYPE	11	11	toxicities
NCT000036571	NCT00003657_1_T2	GENE	18	18	reduced
NCT000036571	NCT00003657_1_T3	GENE	17	17	has
NCT000036571	NCT00003657_1_T4	PHENOTYPE	21	23	effects of chemotherapy
NCT000036582	NCT00003658_2_T0	CELL	10	10	cells
NCT000036583	NCT00003658_3_T0	GENE	2	2	II
NCT000036583	NCT00003658_3_T1	COMPOUND	10	10	pentostatin
NCT000036583	NCT00003658_3_T2	CELL	24	24	B-cell
NCT000036583	NCT00003658_3_T3	PHENOTYPE	25	25	cancers
NCT000036583	NCT00003658_3_T4	COMPOUND	11	11	cyclophosphamide
NCT000036583	NCT00003658_3_T5	PHENOTYPE	19	21	chronic lymphocytic leukemia
NCT000036587	NCT00003658_7_T0	GENE	3	3	filgrastim
NCT000036587	NCT00003658_7_T1	GENE	4	4	G-CSF
NCT000036589	NCT00003658_9_T0	GENE	3	3	G-CSF
NCT0000365810	NCT00003658_10_T0	PHENOTYPE	16	16	toxicity
NCT0000365810	NCT00003658_10_T1	PHENOTYPE	12	13	disease progression
NCT0000365813	NCT00003658_13_T0	PHENOTYPE	19	19	toxicity
NCT0000365813	NCT00003658_13_T1	GENE	1	1	MTD
NCT0000365819	NCT00003658_19_T0	PHENOTYPE	18	18	lymphoma
NCT0000365819	NCT00003658_19_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000365819	NCT00003658_19_T2	PHENOTYPE	16	17	high grade
NCT000036591	NCT00003659_1_T0	CELL	9	9	cells
NCT000036593	NCT00003659_3_T0	GENE	2	2	II
NCT000036593	NCT00003659_3_T1	COMPOUND	9	9	fludarabine
NCT000036593	NCT00003659_3_T2	COMPOUND	12	12	cyclophosphamide
NCT000036593	NCT00003659_3_T3	PHENOTYPE	22	24	chronic lymphocytic leukemia
NCT000036596	NCT00003659_6_T0	COMPOUND	2	2	fludarabine
NCT000036596	NCT00003659_6_T1	GENE	3	3	IV
NCT000036598	NCT00003659_8_T0	GENE	8	8	2.3
NCT000036598	NCT00003659_8_T1	COMPOUND	3	3	cyclophosphamide
NCT000036599	NCT00003659_9_T0	GENE	1	1	G-CSF
NCT0000365910	NCT00003659_10_T0	COMPOUND	8	8	cyclophosphamide
NCT000036611	NCT00003661_1_T0	CELL	8	8	cells
NCT000036612	NCT00003661_2_T0	CELL	9	9	cells
NCT000036612	NCT00003661_2_T1	ORGAN	0	2	Umbilical cord blood
NCT000036613	NCT00003661_3_T0	GENE	2	2	II
NCT000036613	NCT00003661_3_T1	PHENOTYPE	22	23	hematologic cancer
NCT000036613	NCT00003661_3_T2	ORGAN	13	15	umbilical cord blood
NCT000036617	NCT00003661_7_T0	PHENOTYPE	4	5	graft-versus-host disease
NCT000036619	NCT00003661_9_T0	CELL	9	9	cells
NCT000036619	NCT00003661_9_T1	ORGAN	4	6	umbilical cord blood
NCT0000366111	NCT00003661_11_T0	PHENOTYPE	5	5	relapse
NCT0000366113	NCT00003661_13_T0	PHENOTYPE	7	7	secondary
NCT0000366113	NCT00003661_13_T1	PHENOTYPE	5	5	infections
NCT0000366113	NCT00003661_13_T2	PHENOTYPE	9	9	diseases
NCT0000366116	NCT00003661_16_T0	ORGAN	5	6	bone marrow
NCT0000366119	NCT00003661_19_T0	ORGAN	5	7	umbilical cord blood
NCT0000366120	NCT00003661_20_T0	COMPOUND	6	6	2
NCT0000366120	NCT00003661_20_T1	COMPOUND	2	2	methylprednisolone
NCT0000366121	NCT00003661_21_T0	PHENOTYPE	8	8	toxicity
NCT000036621	NCT00003662_1_T0	GENE	2	2	II
NCT000036621	NCT00003662_1_T1	PHENOTYPE	24	25	metabolic diseases
NCT000036621	NCT00003662_1_T2	PHENOTYPE	18	19	hematologic cancer
NCT000036621	NCT00003662_1_T3	ORGAN	9	11	umbilical cord blood
NCT000036625	NCT00003662_5_T0	PHENOTYPE	4	4	severity
NCT000036625	NCT00003662_5_T1	PHENOTYPE	6	6	acute
NCT000036625	NCT00003662_5_T2	PHENOTYPE	8	10	chronic graft-versus-host disease
NCT0000366213	NCT00003662_13_T0	PHENOTYPE	7	8	high weight
NCT0000366215	NCT00003662_15_T0	ORGAN	5	7	umbilical cord blood
NCT0000366216	NCT00003662_16_T0	COMPOUND	32	32	melphalan
NCT0000366216	NCT00003662_16_T1	COMPOUND	49	49	methylprednisolone
NCT0000366216	NCT00003662_16_T2	GENE	22	22	IV
NCT0000366216	NCT00003662_16_T3	GENE	33	33	IV
NCT0000366216	NCT00003662_16_T4	GENE	44	44	IV
NCT0000366216	NCT00003662_16_T5	GENE	50	50	IV
NCT0000366216	NCT00003662_16_T6	COMPOUND	12	12	busulfan
NCT0000366216	NCT00003662_16_T7	PHENOTYPE	9	9	disorders
NCT0000366216	NCT00003662_16_T8	COMPOUND	24	24	1
NCT0000366216	NCT00003662_16_T9	COMPOUND	52	52	1
NCT0000366216	NCT00003662_16_T10	COMPOUND	58	58	1
NCT0000366216	NCT00003662_16_T11	COMPOUND	30	30	2
NCT0000366216	NCT00003662_16_T12	COMPOUND	41	41	2
NCT0000366216	NCT00003662_16_T13	COMPOUND	56	56	3
NCT0000366216	NCT00003662_16_T14	COMPOUND	21	21	cyclophosphamide
NCT0000366216	NCT00003662_16_T15	PHENOTYPE	2	5	inborn errors of metabolism
NCT0000366218	NCT00003662_18_T0	COMPOUND	11	11	methylprednisolone
NCT0000366218	NCT00003662_18_T1	GENE	6	6	IV
NCT0000366218	NCT00003662_18_T2	GENE	12	12	IV
NCT0000366218	NCT00003662_18_T3	GENE	22	22	IV
NCT0000366218	NCT00003662_18_T4	COMPOUND	14	14	1
NCT0000366218	NCT00003662_18_T5	COMPOUND	20	20	1
NCT0000366218	NCT00003662_18_T6	COMPOUND	24	24	1
NCT0000366218	NCT00003662_18_T7	COMPOUND	35	35	1
NCT0000366218	NCT00003662_18_T8	COMPOUND	30	30	2
NCT0000366218	NCT00003662_18_T9	COMPOUND	21	21	cyclophosphamide
NCT0000366218	NCT00003662_18_T10	PHENOTYPE	2	3	Fanconi's anemia
NCT0000366219	NCT00003662_19_T0	COMPOUND	3	3	cyclosporine
NCT0000366219	NCT00003662_19_T1	COMPOUND	9	9	2
NCT0000366219	NCT00003662_19_T2	COMPOUND	5	5	methylprednisolone
NCT0000366219	NCT00003662_19_T3	PHENOTYPE	15	16	graft-versus-host disease
NCT0000366220	NCT00003662_20_T0	PHENOTYPE	8	8	toxicity
NCT000036631	NCT00003663_1_T0	COMPOUND	6	6	dexamethasone
NCT000036631	NCT00003663_1_T1	CELL	11	11	cells
NCT000036632	NCT00003663_2_T0	GENE	2	2	II
NCT000036632	NCT00003663_2_T1	COMPOUND	11	11	dexamethasone
NCT000036632	NCT00003663_2_T2	PHENOTYPE	16	16	recurrent
NCT000036632	NCT00003663_2_T3	PHENOTYPE	20	21	Hodgkin's lymphoma
NCT000036634	NCT00003663_4_T0	COMPOUND	7	7	dexamethasone
NCT000036634	NCT00003663_4_T1	PHENOTYPE	2	2	toxic
NCT000036634	NCT00003663_4_T2	PHENOTYPE	11	11	recurrent
NCT000036634	NCT00003663_4_T3	PHENOTYPE	15	16	Hodgkin's lymphoma
NCT000036636	NCT00003663_6_T0	PHENOTYPE	14	14	initiation
NCT000036636	NCT00003663_6_T1	PHENOTYPE	3	3	tumor
NCT000036636	NCT00003663_6_T2	PHENOTYPE	23	24	progressive disease
NCT000036638	NCT00003663_8_T0	PHENOTYPE	8	8	progression
NCT0000366312	NCT00003663_12_T0	COMPOUND	23	23	dexamethasone
NCT0000366313	NCT00003663_13_T0	COMPOUND	3	3	dexamethasone
NCT0000366313	NCT00003663_13_T1	GENE	4	4	IV
NCT0000366313	NCT00003663_13_T2	GENE	8	8	IV
NCT0000366314	NCT00003663_14_T0	PHENOTYPE	9	10	disease progression
NCT0000366315	NCT00003663_15_T0	COMPOUND	9	9	dexamethasone
NCT0000366316	NCT00003663_16_T0	GENE	15	15	3.4
NCT000036641	NCT00003664_1_T0	CELL	12	12	cells
NCT000036641	NCT00003664_1_T1	GENE	0	0	Interleukin-2
NCT000036641	NCT00003664_1_T2	PHENOTYPE	10	11	kidney cancer
NCT000036641	NCT00003664_1_T3	CELL	5	7	white blood cells
NCT000036643	NCT00003664_3_T0	CELL	9	9	cells
NCT000036644	NCT00003664_4_T0	GENE	2	2	II
NCT000036644	NCT00003664_4_T1	PHENOTYPE	18	19	kidney cancer
NCT0000366410	NCT00003664_10_T0	PHENOTYPE	9	11	quality of life
NCT0000366411	NCT00003664_11_T0	COMPOUND	14	14	gemcitabine
NCT0000366411	NCT00003664_11_T1	GENE	4	4	IV
NCT0000366411	NCT00003664_11_T2	GENE	15	15	IV
NCT0000366412	NCT00003664_12_T0	GENE	0	0	Interferon
NCT0000366413	NCT00003664_13_T0	GENE	4	4	interleukin-2
NCT0000366414	NCT00003664_14_T0	PHENOTYPE	16	16	toxic
NCT0000366414	NCT00003664_14_T1	PHENOTYPE	19	20	disease progression
NCT0000366416	NCT00003664_16_T0	GENE	3	3	interferon
NCT0000366416	NCT00003664_16_T1	PHENOTYPE	14	15	disease progression
NCT0000366417	NCT00003664_17_T0	PHENOTYPE	1	3	quality of life
NCT000036650	NCT00003665_0_T0	PHENOTYPE	8	8	Melanoma
NCT000036650	NCT00003665_0_T1	GENE	7	7	IV
NCT000036652	NCT00003665_2_T0	CELL	12	12	cells
NCT000036652	NCT00003665_2_T1	PHENOTYPE	11	11	tumor
NCT000036652	NCT00003665_2_T2	BIOLOGICAL_PROCESS	7	8	immune response
NCT0000366511	NCT00003665_11_T0	PHENOTYPE	22	22	toxicity
NCT0000366511	NCT00003665_11_T1	GENE	4	4	MTD
NCT0000366612	NCT00003666_12_T0	PHENOTYPE	2	2	toxicity
NCT0000366614	NCT00003666_14_T0	GENE	3	3	IV
NCT0000366616	NCT00003666_16_T0	PHENOTYPE	24	24	toxic
NCT0000366616	NCT00003666_16_T1	PHENOTYPE	27	28	disease progression
NCT000036671	NCT00003667_1_T0	CELL	13	13	cells
NCT000036671	NCT00003667_1_T1	ORGAN	8	9	immune system
NCT000036672	NCT00003667_2_T0	CELL	9	9	cells
NCT000036672	NCT00003667_2_T1	PHENOTYPE	8	8	tumor
NCT000036673	NCT00003667_3_T0	GENE	3	3	II
NCT000036673	NCT00003667_3_T1	PHENOTYPE	25	26	Ewing's sarcoma
NCT000036675	NCT00003667_5_T0	COMPOUND	12	12	dexrazoxane
NCT000036675	NCT00003667_5_T1	COMPOUND	8	8	vincristine
NCT000036675	NCT00003667_5_T2	COMPOUND	10	10	cyclophosphamide
NCT000036675	NCT00003667_5_T3	COMPOUND	9	9	doxorubicin
NCT000036675	NCT00003667_5_T4	COMPOUND	18	19	muramyl dipeptide
NCT000036675	NCT00003667_5_T5	PHENOTYPE	34	35	Ewing's sarcoma
NCT000036677	NCT00003667_7_T0	PHENOTYPE	6	6	toxicity
NCT0000366711	NCT00003667_11_T0	PHENOTYPE	8	9	bony metastases
NCT0000366713	NCT00003667_13_T0	COMPOUND	3	3	dexrazoxane
NCT0000366713	NCT00003667_13_T1	COMPOUND	18	18	vincristine
NCT0000366713	NCT00003667_13_T2	COMPOUND	24	24	cyclophosphamide
NCT0000366713	NCT00003667_13_T3	COMPOUND	10	10	doxorubicin
NCT0000366713	NCT00003667_13_T4	GENE	4	4	IV
NCT0000366713	NCT00003667_13_T5	GENE	11	11	IV
NCT0000366713	NCT00003667_13_T6	GENE	19	19	IV
NCT0000366713	NCT00003667_13_T7	GENE	25	25	IV
NCT0000366714	NCT00003667_14_T0	PHENOTYPE	17	17	toxicity
NCT0000366714	NCT00003667_14_T1	PHENOTYPE	13	14	disease progression
NCT000036691	NCT00003669_1_T0	GENE	23	23	II
NCT000036691	NCT00003669_1_T1	COMPOUND	3	3	arzoxifene
NCT000036691	NCT00003669_1_T2	COMPOUND	29	29	arzoxifene
NCT000036691	NCT00003669_1_T3	COMPOUND	15	15	estrogen
NCT000036691	NCT00003669_1_T4	COMPOUND	4	4	hydrochloride
NCT000036691	NCT00003669_1_T5	COMPOUND	30	30	hydrochloride
NCT000036691	NCT00003669_1_T6	CELL	19	19	cells
NCT000036691	NCT00003669_1_T7	PHENOTYPE	18	18	tumor
NCT000036691	NCT00003669_1_T8	PHENOTYPE	36	36	recurrent
NCT000036691	NCT00003669_1_T9	PHENOTYPE	8	9	endometrial cancer
NCT000036691	NCT00003669_1_T10	PHENOTYPE	39	41	metastatic endometrial cancer
NCT000036693	NCT00003669_3_T0	COMPOUND	12	12	arzoxifene
NCT000036693	NCT00003669_3_T1	COMPOUND	13	13	hydrochloride
NCT000036693	NCT00003669_3_T2	PHENOTYPE	3	3	tumor
NCT000036693	NCT00003669_3_T3	PHENOTYPE	17	17	recurrent
NCT000036693	NCT00003669_3_T4	PHENOTYPE	20	21	endometrial cancer
NCT000036695	NCT00003669_5_T0	COMPOUND	23	23	arzoxifene
NCT000036695	NCT00003669_5_T1	COMPOUND	24	24	hydrochloride
NCT000036695	NCT00003669_5_T2	PHENOTYPE	17	17	recurrent
NCT000036695	NCT00003669_5_T3	PHENOTYPE	4	5	progressive disease
NCT000036695	NCT00003669_5_T4	PHENOTYPE	20	21	endometrial cancer
NCT0000366910	NCT00003669_10_T0	COMPOUND	4	4	arzoxifene
NCT0000366910	NCT00003669_10_T1	COMPOUND	5	5	hydrochloride
NCT0000366911	NCT00003669_11_T0	PHENOTYPE	7	7	toxicity
NCT0000366911	NCT00003669_11_T1	PHENOTYPE	9	10	disease progression
NCT0000366912	NCT00003669_12_T0	COMPOUND	12	12	Eli
NCT0000366912	NCT00003669_12_T1	COMPOUND	7	7	NCI
NCT0000366913	NCT00003669_13_T0	COMPOUND	0	0	NCI
NCT0000366914	NCT00003669_14_T0	COMPOUND	3	3	NCI
NCT000036701	NCT00003670_1_T0	COMPOUND	3	3	arzoxifene
NCT000036701	NCT00003670_1_T1	COMPOUND	4	4	hydrochloride
NCT000036701	NCT00003670_1_T2	COMPOUND	16	16	estrogen
NCT000036701	NCT00003670_1_T3	CELL	20	20	cells
NCT000036701	NCT00003670_1_T4	PHENOTYPE	19	19	tumor
NCT000036701	NCT00003670_1_T5	PHENOTYPE	9	10	peritoneal cancer
NCT000036702	NCT00003670_2_T0	GENE	3	3	II
NCT000036702	NCT00003670_2_T1	COMPOUND	9	9	arzoxifene
NCT000036702	NCT00003670_2_T2	COMPOUND	10	10	hydrochloride
NCT000036702	NCT00003670_2_T3	PHENOTYPE	18	19	ovarian cancer
NCT000036702	NCT00003670_2_T4	PHENOTYPE	22	23	peritoneal cancer
NCT000036704	NCT00003670_4_T0	COMPOUND	4	4	arzoxifene
NCT000036704	NCT00003670_4_T1	COMPOUND	5	5	hydrochloride
NCT000036704	NCT00003670_4_T2	PHENOTYPE	16	17	peritoneal cancer
NCT000036704	NCT00003670_4_T3	PHENOTYPE	11	13	ovarian epithelial cancer
NCT000036706	NCT00003670_6_T0	PHENOTYPE	4	5	progressive disease
NCT0000367011	NCT00003670_11_T0	COMPOUND	4	4	arzoxifene
NCT0000367011	NCT00003670_11_T1	COMPOUND	5	5	hydrochloride
NCT0000367012	NCT00003670_12_T0	PHENOTYPE	7	7	toxicity
NCT0000367012	NCT00003670_12_T1	PHENOTYPE	9	10	disease progression
NCT0000367013	NCT00003670_13_T0	COMPOUND	12	12	Eli
NCT0000367013	NCT00003670_13_T1	COMPOUND	7	7	NCI
NCT0000367014	NCT00003670_14_T0	COMPOUND	0	0	NCI
NCT0000367015	NCT00003670_15_T0	COMPOUND	3	3	NCI
NCT000036711	NCT00003671_1_T0	CELL	9	9	cells
NCT000036712	NCT00003671_2_T0	GENE	2	2	II
NCT000036712	NCT00003671_2_T1	PHENOTYPE	18	20	acute lymphocytic leukemia
NCT000036718	NCT00003671_8_T0	COMPOUND	4	4	dexamethasone
NCT000036718	NCT00003671_8_T1	COMPOUND	10	10	vincristine
NCT000036718	NCT00003671_8_T2	GENE	22	22	IM
NCT000036718	NCT00003671_8_T3	GENE	20	20	asparaginase
NCT000036718	NCT00003671_8_T4	GENE	11	11	IV
NCT000036719	NCT00003671_9_T0	COMPOUND	2	2	methotrexate
NCT000036719	NCT00003671_9_T1	GENE	4	4	IT
NCT0000367110	NCT00003671_10_T0	COMPOUND	7	7	methotrexate
NCT0000367110	NCT00003671_10_T1	GENE	8	8	IT
NCT0000367111	NCT00003671_11_T0	GENE	2	2	M1
NCT0000367111	NCT00003671_11_T1	ORGAN	3	4	bone marrow
NCT0000367112	NCT00003671_12_T0	COMPOUND	10	10	dexamethasone
NCT0000367112	NCT00003671_12_T1	COMPOUND	16	16	vincristine
NCT0000367112	NCT00003671_12_T2	GENE	31	31	IM
NCT0000367112	NCT00003671_12_T3	GENE	2	2	M2
NCT0000367112	NCT00003671_12_T4	GENE	30	30	asparaginase
NCT0000367112	NCT00003671_12_T5	GENE	17	17	IV
NCT0000367112	NCT00003671_12_T6	GENE	20	20	IV
NCT0000367112	NCT00003671_12_T7	COMPOUND	19	19	daunorubicin
NCT0000367112	NCT00003671_12_T8	ORGAN	3	4	bone marrow
NCT0000367113	NCT00003671_13_T0	GENE	9	9	M2
NCT0000367113	NCT00003671_13_T1	GENE	2	2	M3
NCT0000367113	NCT00003671_13_T2	GENE	11	11	M3
NCT0000367113	NCT00003671_13_T3	ORGAN	3	4	bone marrow
NCT0000367113	NCT00003671_13_T4	ORGAN	12	13	bone marrow
NCT0000367114	NCT00003671_14_T0	PHENOTYPE	0	0	Consolidation
NCT0000367114	NCT00003671_14_T1	COMPOUND	22	22	calcium
NCT0000367114	NCT00003671_14_T2	GENE	51	51	IM
NCT0000367114	NCT00003671_14_T3	GENE	50	50	asparaginase
NCT0000367114	NCT00003671_14_T4	COMPOUND	3	3	methotrexate
NCT0000367114	NCT00003671_14_T5	COMPOUND	36	36	methotrexate
NCT0000367114	NCT00003671_14_T6	COMPOUND	38	38	methotrexate
NCT0000367114	NCT00003671_14_T7	GENE	39	39	IT
NCT0000367114	NCT00003671_14_T8	COMPOUND	21	21	leucovorin
NCT0000367114	NCT00003671_14_T9	GENE	4	4	IV
NCT0000367116	NCT00003671_16_T0	COMPOUND	25	25	calcium
NCT0000367116	NCT00003671_16_T1	COMPOUND	5	5	methotrexate
NCT0000367116	NCT00003671_16_T2	COMPOUND	40	40	methotrexate
NCT0000367116	NCT00003671_16_T3	COMPOUND	24	24	leucovorin
NCT0000367117	NCT00003671_17_T0	COMPOUND	18	18	dexamethasone
NCT0000367117	NCT00003671_17_T1	COMPOUND	8	8	vincristine
NCT0000367117	NCT00003671_17_T2	COMPOUND	26	26	vincristine
NCT0000367117	NCT00003671_17_T3	COMPOUND	3	3	methotrexate
NCT0000367117	NCT00003671_17_T4	GENE	4	4	IT
NCT0000367117	NCT00003671_17_T5	GENE	9	9	IV
NCT0000367119	NCT00003671_19_T0	COMPOUND	34	34	dexamethasone
NCT0000367119	NCT00003671_19_T1	COMPOUND	24	24	vincristine
NCT0000367119	NCT00003671_19_T2	COMPOUND	42	42	vincristine
NCT0000367119	NCT00003671_19_T3	COMPOUND	5	5	methotrexate
NCT0000367119	NCT00003671_19_T4	COMPOUND	13	13	methotrexate
NCT0000367119	NCT00003671_19_T5	COMPOUND	19	19	methotrexate
NCT0000367119	NCT00003671_19_T6	GENE	14	14	IT
NCT0000367119	NCT00003671_19_T7	GENE	20	20	IT
NCT0000367119	NCT00003671_19_T8	GENE	25	25	IV
NCT0000367120	NCT00003671_20_T0	PHENOTYPE	15	15	toxicity
NCT0000367120	NCT00003671_20_T1	PHENOTYPE	11	12	disease progression
NCT000036737	NCT00003673_7_T0	GENE	6	6	IV
NCT0000367310	NCT00003673_10_T0	PHENOTYPE	21	21	relapse
NCT0000367312	NCT00003673_12_T0	GENE	4	4	extended
NCT000036744	NCT00003674_4_T0	COMPOUND	7	7	heparin
NCT000036744	NCT00003674_4_T1	COMPOUND	8	8	dalteparin
NCT000036744	NCT00003674_4_T2	PHENOTYPE	25	25	cancers
NCT000036746	NCT00003674_6_T0	PHENOTYPE	2	2	toxic
NCT000036746	NCT00003674_6_T1	PHENOTYPE	12	14	quality of life
NCT000036748	NCT00003674_8_T0	PHENOTYPE	12	12	DVT
NCT000036748	NCT00003674_8_T1	GENE	15	15	PE
NCT000036748	NCT00003674_8_T2	PHENOTYPE	13	14	pulmonary embolus
NCT000036748	NCT00003674_8_T3	PHENOTYPE	9	11	deep venous thrombosis
NCT0000367411	NCT00003674_11_T0	COMPOUND	8	8	heparin
NCT0000367411	NCT00003674_11_T1	COMPOUND	9	9	dalteparin
NCT000036753	NCT00003675_3_T0	PHENOTYPE	4	4	remission
NCT000036753	NCT00003675_3_T1	COMPOUND	13	13	topotecan
NCT000036753	NCT00003675_3_T2	PHENOTYPE	32	33	myelodysplastic syndromes
NCT000036755	NCT00003675_5_T0	PHENOTYPE	4	4	toxicity
NCT000036755	NCT00003675_5_T1	COMPOUND	7	7	topotecan
NCT000036757	NCT00003675_7_T0	PHENOTYPE	10	11	myelodysplastic syndromes
NCT000036759	NCT00003675_9_T0	CELL	10	10	cells
NCT000036759	NCT00003675_9_T1	ORGAN	7	8	bone marrow
NCT0000367513	NCT00003675_13_T0	GENE	5	5	FAB
NCT0000367514	NCT00003675_14_T0	PHENOTYPE	0	4	Refractory anemia with excess blasts
NCT0000367515	NCT00003675_15_T0	PHENOTYPE	0	4	Refractory anemia with excess blasts
NCT0000367516	NCT00003675_16_T0	PHENOTYPE	0	2	Chronic myelomonocytic leukemia
NCT0000367517	NCT00003675_17_T0	COMPOUND	19	19	topotecan
NCT0000367517	NCT00003675_17_T1	PHENOTYPE	0	1	Refractory anemia
NCT0000367517	NCT00003675_17_T2	PHENOTYPE	8	12	refractory cytopenia with multilineage dysplasia
NCT0000367517	NCT00003675_17_T3	PHENOTYPE	2	6	refractory anemia with ringed sideroblasts
NCT0000367522	NCT00003675_22_T0	PHENOTYPE	21	21	progression
NCT000036771	NCT00003677_1_T0	GENE	2	2	II
NCT000036771	NCT00003677_1_T1	COMPOUND	9	10	dolastatin 10
NCT000036771	NCT00003677_1_T2	PHENOTYPE	16	18	metastatic pancreatic cancer
NCT000036774	NCT00003677_4_T0	COMPOUND	5	6	dolastatin 10
NCT000036774	NCT00003677_4_T1	PHENOTYPE	10	11	metastatic adenocarcinoma
NCT000036774	NCT00003677_4_T2	PHENOTYPE	11	14	adenocarcinoma of the pancreas
NCT000036776	NCT00003677_6_T0	PHENOTYPE	5	5	toxic
NCT0000367710	NCT00003677_10_T0	GENE	4	4	IV
NCT0000367710	NCT00003677_10_T1	COMPOUND	2	3	dolastatin 10
NCT0000367711	NCT00003677_11_T0	PHENOTYPE	10	10	toxicity
NCT0000367711	NCT00003677_11_T1	PHENOTYPE	6	7	disease progression
NCT0000367713	NCT00003677_13_T0	GENE	9	9	18.5
NCT000036782	NCT00003678_2_T0	GENE	3	3	III
NCT000036782	NCT00003678_2_T1	GENE	32	32	has
NCT000036782	NCT00003678_2_T2	COMPOUND	15	15	tamoxifen
NCT000036782	NCT00003678_2_T3	COMPOUND	23	23	tamoxifen
NCT000036782	NCT00003678_2_T4	PHENOTYPE	29	30	breast cancer
NCT000036785	NCT00003678_5_T0	GENE	13	13	2.3
NCT000036785	NCT00003678_5_T1	GENE	16	16	4.5
NCT000036785	NCT00003678_5_T2	GENE	46	46	nodal
NCT000036785	NCT00003678_5_T3	GENE	19	19	6/7
NCT000036785	NCT00003678_5_T4	PHENOTYPE	41	41	tumor
NCT000036785	NCT00003678_5_T5	GENE	35	35	50
NCT000036785	NCT00003678_5_T6	COMPOUND	9	9	tamoxifen
NCT000036785	NCT00003678_5_T7	GENE	48	49	estrogen receptor
NCT000036791	NCT00003679_1_T0	CELL	9	9	cells
NCT000036791	NCT00003679_1_T1	PHENOTYPE	8	8	tumor
NCT000036792	NCT00003679_2_T0	COMPOUND	8	8	docetaxel
NCT000036792	NCT00003679_2_T1	COMPOUND	15	15	cyclophosphamide
NCT000036792	NCT00003679_2_T2	COMPOUND	6	6	doxorubicin
NCT000036792	NCT00003679_2_T3	COMPOUND	13	13	doxorubicin
NCT000036792	NCT00003679_2_T4	PHENOTYPE	17	18	breast cancer
NCT000036793	NCT00003679_3_T0	GENE	3	3	III
NCT000036793	NCT00003679_3_T1	COMPOUND	15	15	docetaxel
NCT000036793	NCT00003679_3_T2	COMPOUND	17	17	cyclophosphamide
NCT000036793	NCT00003679_3_T3	COMPOUND	10	10	doxorubicin
NCT000036793	NCT00003679_3_T4	PHENOTYPE	27	29	inflammatory breast cancer
NCT000036795	NCT00003679_5_T0	PHENOTYPE	6	6	toxicity
NCT000036795	NCT00003679_5_T1	COMPOUND	13	13	docetaxel
NCT000036795	NCT00003679_5_T2	COMPOUND	15	15	cyclophosphamide
NCT000036795	NCT00003679_5_T3	COMPOUND	8	8	doxorubicin
NCT000036795	NCT00003679_5_T4	PHENOTYPE	26	28	inflammatory breast cancer
NCT0000367911	NCT00003679_11_T0	PHENOTYPE	17	17	toxicity
NCT0000367911	NCT00003679_11_T1	PHENOTYPE	13	14	disease progression
NCT0000367912	NCT00003679_12_T0	COMPOUND	28	28	estrogen
NCT0000367912	NCT00003679_12_T1	COMPOUND	17	17	tamoxifen
NCT000036805	NCT00003680_5_T0	GENE	17	17	cm
NCT000036805	NCT00003680_5_T1	TISSUE	22	23	lymph nodes
NCT000036805	NCT00003680_5_T2	PHENOTYPE	12	13	breast cancer
NCT000036807	NCT00003680_7_T0	PHENOTYPE	5	7	quality of life
NCT000036809	NCT00003680_9_T0	TISSUE	11	12	lymph nodes
NCT0000368013	NCT00003680_13_T0	GENE	1	1	IV
NCT0000368015	NCT00003680_15_T0	PHENOTYPE	0	0	Peripheral
NCT0000368015	NCT00003680_15_T1	CELL	2	3	progenitor cells
NCT0000368016	NCT00003680_16_T0	COMPOUND	10	10	tamoxifen
NCT0000368017	NCT00003680_17_T0	COMPOUND	6	6	tamoxifen
NCT0000368017	NCT00003680_17_T1	PHENOTYPE	0	2	Estrogen receptor negative
NCT0000368018	NCT00003680_18_T0	PHENOTYPE	0	2	Quality of life
NCT000036818	NCT00003681_8_T0	PHENOTYPE	5	5	toxicity
NCT000036818	NCT00003681_8_T1	COMPOUND	7	7	amifostine
NCT0000368112	NCT00003681_12_T0	PHENOTYPE	6	7	disease progression
NCT0000368114	NCT00003681_14_T0	COMPOUND	29	29	amifostine
NCT0000368114	NCT00003681_14_T1	GENE	16	16	hemoglobin
NCT0000368114	NCT00003681_14_T2	GENE	12	13	Group 1
NCT0000368119	NCT00003681_19_T0	GENE	14	14	1.3
NCT000036828	NCT00003682_8_T0	PHENOTYPE	2	2	toxicity
NCT0000368217	NCT00003682_17_T0	PHENOTYPE	0	2	Quality of life
NCT000036831	NCT00003683_1_T0	CELL	10	10	cells
NCT000036831	NCT00003683_1_T1	PHENOTYPE	9	9	tumor
NCT000036832	NCT00003683_2_T0	GENE	2	2	II
NCT000036832	NCT00003683_2_T1	COMPOUND	12	12	ifosfamide
NCT000036832	NCT00003683_2_T2	COMPOUND	10	10	doxorubicin
NCT000036832	NCT00003683_2_T3	PHENOTYPE	18	20	metastatic kidney cancer
NCT000036836	NCT00003683_6_T0	PHENOTYPE	2	2	toxicity
NCT0000368310	NCT00003683_10_T0	COMPOUND	8	8	ifosfamide
NCT0000368310	NCT00003683_10_T1	COMPOUND	2	2	doxorubicin
NCT0000368310	NCT00003683_10_T2	GENE	3	3	IV
NCT0000368310	NCT00003683_10_T3	GENE	9	9	IV
NCT0000368311	NCT00003683_11_T0	PHENOTYPE	19	19	toxicity
NCT0000368311	NCT00003683_11_T1	PHENOTYPE	15	16	disease progression
NCT000036841	NCT00003684_1_T0	COMPOUND	6	6	theophylline
NCT000036841	NCT00003684_1_T1	PHENOTYPE	15	17	shortness of breath
NCT000036842	NCT00003684_2_T0	COMPOUND	10	10	theophylline
NCT000036842	NCT00003684_2_T1	GENE	3	3	III
NCT000036842	NCT00003684_2_T2	PHENOTYPE	13	15	shortness of breath
NCT000036844	NCT00003684_4_T0	COMPOUND	2	2	theophylline
NCT000036844	NCT00003684_4_T1	PHENOTYPE	6	6	dyspnea
NCT000036844	NCT00003684_4_T2	GENE	14	16	short of breath
NCT000036844	NCT00003684_4_T3	PHENOTYPE	21	23	respiratory muscle weakness
NCT000036848	NCT00003684_8_T0	PHENOTYPE	13	13	FVC
NCT000036848	NCT00003684_8_T1	PHENOTYPE	9	10	lung function
NCT0000368410	NCT00003684_10_T0	COMPOUND	4	4	theophylline
NCT0000368410	NCT00003684_10_T1	ORGAN	3	3	serum
NCT0000368412	NCT00003684_12_T0	PHENOTYPE	10	12	quality of life
NCT0000368415	NCT00003684_15_T0	COMPOUND	4	4	theophylline
NCT0000368416	NCT00003684_16_T0	PHENOTYPE	6	6	toxicity
NCT0000368416	NCT00003684_16_T1	GENE	7	7	DLT
NCT0000368417	NCT00003684_17_T0	GENE	4	4	DLT
NCT0000368418	NCT00003684_18_T0	PHENOTYPE	26	26	toxic
NCT0000368419	NCT00003684_19_T0	PHENOTYPE	0	2	Quality of life
NCT000036857	NCT00003685_7_T0	PHENOTYPE	2	2	toxicity
NCT000036859	NCT00003685_9_T0	PHENOTYPE	2	4	quality of life
NCT0000368511	NCT00003685_11_T0	PHENOTYPE	6	7	weight loss
NCT0000368513	NCT00003685_13_T0	PHENOTYPE	0	2	Quality of life
NCT000036861	NCT00003686_1_T0	COMPOUND	6	6	pilocarpine
NCT000036862	NCT00003686_2_T0	COMPOUND	10	10	pilocarpine
NCT000036862	NCT00003686_2_T1	GENE	3	3	III
NCT000036862	NCT00003686_2_T2	PHENOTYPE	16	17	dry mouth
NCT000036866	NCT00003686_6_T0	COMPOUND	5	5	pilocarpine
NCT000036866	NCT00003686_6_T1	PHENOTYPE	2	3	adverse effects
NCT000036868	NCT00003686_8_T0	PHENOTYPE	2	2	constipation
NCT000036868	NCT00003686_8_T1	COMPOUND	11	11	pilocarpine
NCT000036868	NCT00003686_8_T2	PHENOTYPE	7	7	nausea
NCT000036868	NCT00003686_8_T3	PHENOTYPE	4	5	poor appetite
NCT0000368610	NCT00003686_10_T0	COMPOUND	4	4	pilocarpine
NCT0000368610	NCT00003686_10_T1	PHENOTYPE	6	8	quality of life
NCT0000368612	NCT00003686_12_T0	COMPOUND	9	9	pilocarpine
NCT0000368615	NCT00003686_15_T0	COMPOUND	16	16	pilocarpine
NCT0000368616	NCT00003686_16_T0	PHENOTYPE	0	2	Quality of life
NCT000036881	NCT00003688_1_T0	GENE	2	2	II
NCT000036881	NCT00003688_1_T1	PHENOTYPE	17	17	recurrent
NCT000036881	NCT00003688_1_T2	PHENOTYPE	18	20	gestational trophoblastic neoplasia
NCT000036884	NCT00003688_4_T0	GENE	3	3	IV
NCT000036885	NCT00003688_5_T0	PHENOTYPE	10	10	toxicity
NCT000036900	NCT00003690_0_T0	PHENOTYPE	10	11	Solid Tumors
NCT000036902	NCT00003690_2_T0	CELL	9	9	cells
NCT000036902	NCT00003690_2_T1	PHENOTYPE	8	8	tumor
NCT000036903	NCT00003690_3_T0	COMPOUND	11	11	cisplatin
NCT000036903	NCT00003690_3_T1	COMPOUND	9	9	flavopiridol
NCT000036903	NCT00003690_3_T2	PHENOTYPE	20	21	solid tumors
NCT000036908	NCT00003690_8_T0	COMPOUND	5	5	cisplatin
NCT000036908	NCT00003690_8_T1	GENE	6	6	IV
NCT000036908	NCT00003690_8_T2	GENE	14	14	IV
NCT000036908	NCT00003690_8_T3	COMPOUND	13	13	flavopiridol
NCT000036909	NCT00003690_9_T0	PHENOTYPE	12	12	toxicity
NCT000036909	NCT00003690_9_T1	PHENOTYPE	14	15	disease progression
NCT0000369010	NCT00003690_10_T0	COMPOUND	12	12	cisplatin
NCT0000369010	NCT00003690_10_T1	COMPOUND	4	4	flavopiridol
NCT0000369011	NCT00003690_11_T0	GENE	17	17	MTD
NCT0000369011	NCT00003690_11_T1	COMPOUND	11	11	cisplatin
NCT0000369011	NCT00003690_11_T2	COMPOUND	8	8	flavopiridol
NCT0000369013	NCT00003690_13_T0	GENE	4	4	IV
NCT0000369013	NCT00003690_13_T1	GENE	12	12	IV
NCT0000369013	NCT00003690_13_T2	COMPOUND	11	11	flavopiridol
NCT0000369014	NCT00003690_14_T0	PHENOTYPE	10	10	toxicity
NCT0000369014	NCT00003690_14_T1	PHENOTYPE	12	13	disease progression
NCT0000369015	NCT00003690_15_T0	GENE	11	11	MTD
NCT0000369016	NCT00003690_16_T0	GENE	1	1	MTD
NCT000036911	NCT00003691_1_T0	CELL	9	9	cells
NCT000036911	NCT00003691_1_T1	PHENOTYPE	8	8	tumor
NCT000036912	NCT00003691_2_T0	COMPOUND	20	20	paclitaxel
NCT000036912	NCT00003691_2_T1	GENE	3	3	III
NCT000036912	NCT00003691_2_T2	GENE	22	22	G-CSF
NCT000036912	NCT00003691_2_T3	GENE	31	31	IV
NCT000036912	NCT00003691_2_T4	COMPOUND	14	14	doxorubicin
NCT000036912	NCT00003691_2_T5	COMPOUND	16	16	cisplatin
NCT000036912	NCT00003691_2_T6	PHENOTYPE	28	29	stage III
NCT000036912	NCT00003691_2_T7	PHENOTYPE	33	35	recurrent endometrial cancer
NCT000036916	NCT00003691_6_T0	COMPOUND	5	5	paclitaxel
NCT000036916	NCT00003691_6_T1	GENE	6	6	IV
NCT000036917	NCT00003691_7_T0	GENE	3	3	filgrastim
NCT000036917	NCT00003691_7_T1	GENE	4	4	G-CSF
NCT000036919	NCT00003691_9_T0	PHENOTYPE	15	15	toxicity
NCT000036919	NCT00003691_9_T1	PHENOTYPE	11	12	disease progression
NCT000036928	NCT00003692_8_T0	PHENOTYPE	2	2	complications
NCT0000369214	NCT00003692_14_T0	GENE	4	4	lobe
NCT0000369214	NCT00003692_14_T1	TISSUE	12	13	lymph nodes
NCT0000369214	NCT00003692_14_T2	TISSUE	17	18	lymph nodes
NCT0000369215	NCT00003692_15_T0	GENE	8	8	lobe
NCT000036934	NCT00003693_4_T0	PHENOTYPE	8	8	toxicity
NCT000036934	NCT00003693_4_T1	COMPOUND	10	11	dolastatin 10
NCT000036934	NCT00003693_4_T2	PHENOTYPE	19	20	blast phase
NCT000036934	NCT00003693_4_T3	PHENOTYPE	27	28	myelodysplastic syndromes
NCT000036934	NCT00003693_4_T4	PHENOTYPE	24	25	acute leukemia
NCT000036934	NCT00003693_4_T5	PHENOTYPE	15	17	chronic myelogenous leukemia
NCT000036938	NCT00003693_8_T0	GENE	5	5	IV
NCT000036938	NCT00003693_8_T1	COMPOUND	2	3	dolastatin 10
NCT000036939	NCT00003693_9_T0	PHENOTYPE	14	14	toxicity
NCT000036939	NCT00003693_9_T1	GENE	2	2	2.12
NCT000036939	NCT00003693_9_T2	PHENOTYPE	10	11	disease progression
NCT0000369310	NCT00003693_10_T0	PHENOTYPE	6	6	toxicity
NCT0000369310	NCT00003693_10_T1	GENE	7	7	DLT
NCT0000369310	NCT00003693_10_T2	COMPOUND	25	26	dolastatin 10
NCT0000369311	NCT00003693_11_T0	GENE	1	1	DLT
NCT000036941	NCT00003694_1_T0	CELL	10	10	cells
NCT000036942	NCT00003694_2_T0	CELL	9	9	cells
NCT000036946	NCT00003694_6_T0	PHENOTYPE	3	3	toxicity
NCT000036948	NCT00003694_8_T0	PHENOTYPE	10	10	progression
NCT0000369414	NCT00003694_14_T0	ORGAN	10	10	marrow
NCT0000369414	NCT00003694_14_T1	GENE	4	4	blot
NCT0000369417	NCT00003694_17_T0	COMPOUND	3	3	cytarabine
NCT0000369417	NCT00003694_17_T1	COMPOUND	5	5	homoharringtonine
NCT0000369419	NCT00003694_19_T0	PHENOTYPE	17	17	toxicity
NCT0000369419	NCT00003694_19_T1	PHENOTYPE	13	14	disease progression
NCT0000369420	NCT00003694_20_T0	GENE	15	15	interferon
NCT0000369421	NCT00003694_21_T0	GENE	6	6	interferon
NCT0000369421	NCT00003694_21_T1	GENE	20	20	interferon
NCT000036951	NCT00003695_1_T0	CELL	8	8	cells
NCT000036951	NCT00003695_1_T1	PHENOTYPE	7	7	tumor
NCT000036952	NCT00003695_2_T0	GENE	20	20	II
NCT000036952	NCT00003695_2_T1	PHENOTYPE	22	25	stage III ovarian cancer
NCT000036953	NCT00003695_3_T0	GENE	20	20	II
NCT000036953	NCT00003695_3_T1	GENE	3	3	III
NCT000036953	NCT00003695_3_T2	PHENOTYPE	22	25	stage III ovarian cancer
NCT000036955	NCT00003695_5_T0	GENE	23	23	II
NCT000036955	NCT00003695_5_T1	GENE	25	25	III
NCT000036955	NCT00003695_5_T2	GENE	35	35	cm
NCT000036955	NCT00003695_5_T3	PHENOTYPE	26	27	ovarian cancer
NCT000036955	NCT00003695_5_T4	PHENOTYPE	14	16	quality of life
NCT0000369510	NCT00003695_10_T0	PHENOTYPE	15	15	initiation
NCT0000369510	NCT00003695_10_T1	PHENOTYPE	4	5	disease progression
NCT0000369513	NCT00003695_13_T0	PHENOTYPE	0	2	Quality of life
NCT000036962	NCT00003696_2_T0	CELL	9	9	cells
NCT000036962	NCT00003696_2_T1	PHENOTYPE	8	8	tumor
NCT000036967	NCT00003696_7_T0	GENE	11	11	2.3
NCT000036970	NCT00003697_0_T0	COMPOUND	1	1	Acetic
NCT000036970	NCT00003697_0_T1	PHENOTYPE	7	8	Solid Tumors
NCT000036972	NCT00003697_2_T0	COMPOUND	9	9	dimethylxanthenone
NCT000036972	NCT00003697_2_T1	COMPOUND	10	11	acetic acid
NCT000036972	NCT00003697_2_T2	PHENOTYPE	16	17	solid tumors
NCT000036974	NCT00003697_4_T0	PHENOTYPE	2	2	toxicity
NCT000036974	NCT00003697_4_T1	COMPOUND	4	4	dimethylxanthenone
NCT000036974	NCT00003697_4_T2	COMPOUND	7	7	DMXAA
NCT000036974	NCT00003697_4_T3	COMPOUND	5	6	acetic acid
NCT000036974	NCT00003697_4_T4	PHENOTYPE	11	12	solid tumors
NCT000036978	NCT00003697_8_T0	PHENOTYPE	2	2	pharmacokinetics
NCT000036978	NCT00003697_8_T1	COMPOUND	4	4	DMXAA
NCT0000369714	NCT00003697_14_T0	GENE	15	15	MRI
NCT0000369714	NCT00003697_14_T1	PHENOTYPE	7	8	tumor vasculature
NCT0000369716	NCT00003697_16_T0	COMPOUND	2	2	dimethylxanthenone
NCT0000369716	NCT00003697_16_T1	COMPOUND	5	5	DMXAA
NCT0000369716	NCT00003697_16_T2	GENE	6	6	IV
NCT0000369716	NCT00003697_16_T3	COMPOUND	3	4	acetic acid
NCT0000369717	NCT00003697_17_T0	PHENOTYPE	13	13	toxicity
NCT0000369717	NCT00003697_17_T1	PHENOTYPE	15	16	disease progression
NCT0000369718	NCT00003697_18_T0	GENE	14	14	MTD
NCT0000369718	NCT00003697_18_T1	COMPOUND	8	8	DMXAA
NCT0000369719	NCT00003697_19_T0	PHENOTYPE	18	18	toxicity
NCT0000369719	NCT00003697_19_T1	GENE	1	1	MTD
NCT000036980	NCT00003698_0_T0	PHENOTYPE	5	6	Solid Tumors
NCT000036982	NCT00003698_2_T0	COMPOUND	9	9	combretastatin
NCT000036982	NCT00003698_2_T1	GENE	10	10	A4
NCT000036982	NCT00003698_2_T2	COMPOUND	11	11	phosphate
NCT000036982	NCT00003698_2_T3	PHENOTYPE	19	20	solid tumors
NCT000036984	NCT00003698_4_T0	PHENOTYPE	2	2	toxicity
NCT000036984	NCT00003698_4_T1	PHENOTYPE	7	7	toxicity
NCT000036984	NCT00003698_4_T2	COMPOUND	14	14	combretastatin
NCT000036984	NCT00003698_4_T3	GENE	15	15	A4
NCT000036984	NCT00003698_4_T4	COMPOUND	16	16	phosphate
NCT000036984	NCT00003698_4_T5	GENE	12	12	MTD
NCT000036984	NCT00003698_4_T6	PHENOTYPE	22	23	malignant tumors
NCT000036986	NCT00003698_6_T0	COMPOUND	4	4	combretastatin
NCT000036986	NCT00003698_6_T1	GENE	5	5	A4
NCT000036986	NCT00003698_6_T2	PHENOTYPE	2	2	pharmacokinetics
NCT000036986	NCT00003698_6_T3	COMPOUND	6	6	phosphate
NCT000036988	NCT00003698_8_T0	COMPOUND	4	4	combretastatin
NCT000036988	NCT00003698_8_T1	GENE	5	5	A4
NCT000036988	NCT00003698_8_T2	GENE	14	14	MRI
NCT000036988	NCT00003698_8_T3	PHENOTYPE	8	8	tumor
NCT000036988	NCT00003698_8_T4	COMPOUND	6	6	phosphate
NCT0000369810	NCT00003698_10_T0	GENE	9	9	II
NCT0000369810	NCT00003698_10_T1	COMPOUND	4	4	combretastatin
NCT0000369810	NCT00003698_10_T2	GENE	5	5	A4
NCT0000369810	NCT00003698_10_T3	PHENOTYPE	13	13	tumor
NCT0000369810	NCT00003698_10_T4	COMPOUND	6	6	phosphate
NCT0000369810	NCT00003698_10_T5	GENE	19	19	MTD
NCT0000369814	NCT00003698_14_T0	COMPOUND	3	3	combretastatin
NCT0000369814	NCT00003698_14_T1	GENE	4	4	A4
NCT0000369814	NCT00003698_14_T2	COMPOUND	5	5	phosphate
NCT0000369814	NCT00003698_14_T3	GENE	2	2	IV
NCT0000369815	NCT00003698_15_T0	PHENOTYPE	4	4	toxic
NCT0000369816	NCT00003698_16_T0	PHENOTYPE	10	10	toxicity
NCT0000369816	NCT00003698_16_T1	GENE	2	2	stops
NCT0000369816	NCT00003698_16_T2	GENE	11	11	DLT
NCT0000369817	NCT00003698_17_T0	GENE	1	1	DLT
NCT000037001	NCT00003700_1_T0	CELL	9	9	cells
NCT000037002	NCT00003700_2_T0	GENE	2	2	II
NCT000037002	NCT00003700_2_T1	PHENOTYPE	17	19	acute lymphoblastic leukemia
NCT000037005	NCT00003700_5_T0	ORGAN	5	6	bone marrow
NCT000037006	NCT00003700_6_T0	GENE	10	10	II
NCT000037006	NCT00003700_6_T1	GENE	3	3	M1
NCT000037006	NCT00003700_6_T2	GENE	5	5	M2
NCT000037008	NCT00003700_8_T0	ORGAN	0	1	Bone marrow
NCT000037009	NCT00003700_9_T0	GENE	16	16	II
NCT000037009	NCT00003700_9_T1	GENE	4	4	M1
NCT000037009	NCT00003700_9_T2	PHENOTYPE	13	13	relapse
NCT000037009	NCT00003700_9_T3	GENE	20	20	III
NCT0000370010	NCT00003700_10_T0	GENE	17	17	II
NCT0000370010	NCT00003700_10_T1	GENE	13	13	M1
NCT0000370010	NCT00003700_10_T2	GENE	2	2	M2
NCT0000370010	NCT00003700_10_T3	GENE	4	4	M3
NCT0000370010	NCT00003700_10_T4	GENE	22	22	III
NCT0000370012	NCT00003700_12_T0	COMPOUND	3	3	calcium
NCT0000370012	NCT00003700_12_T1	COMPOUND	22	22	calcium
NCT0000370012	NCT00003700_12_T2	COMPOUND	28	28	calcium
NCT0000370012	NCT00003700_12_T3	COMPOUND	11	11	methotrexate
NCT0000370012	NCT00003700_12_T4	COMPOUND	2	2	leucovorin
NCT0000370012	NCT00003700_12_T5	COMPOUND	21	21	leucovorin
NCT0000370012	NCT00003700_12_T6	COMPOUND	27	27	leucovorin
NCT0000370012	NCT00003700_12_T7	GENE	4	4	IV
NCT0000370012	NCT00003700_12_T8	GENE	29	29	IV
NCT0000370013	NCT00003700_13_T0	COMPOUND	5	5	calcium
NCT0000370013	NCT00003700_13_T1	COMPOUND	4	4	leucovorin
NCT0000370014	NCT00003700_14_T0	GENE	5	5	M1
NCT0000370014	NCT00003700_14_T1	GENE	12	12	III
NCT0000370017	NCT00003700_17_T0	PHENOTYPE	2	3	testicular disease
NCT0000370018	NCT00003700_18_T0	GENE	3	3	halted
NCT0000370022	NCT00003700_22_T0	COMPOUND	9	9	2
NCT0000370022	NCT00003700_22_T1	PHENOTYPE	3	3	illnesses
NCT0000370024	NCT00003700_24_T0	PHENOTYPE	3	4	cardiovascular disease
NCT0000370026	NCT00003700_26_T0	PHENOTYPE	2	2	pancreatitis
NCT0000370026	NCT00003700_26_T1	PHENOTYPE	5	5	coagulopathy
NCT0000370026	NCT00003700_26_T2	PHENOTYPE	10	10	hemorrhage
NCT0000370026	NCT00003700_26_T3	PHENOTYPE	7	8	cerebrovascular accident
NCT0000370026	NCT00003700_26_T4	PHENOTYPE	11	13	transient ischemic attack
NCT0000370026	NCT00003700_26_T5	PHENOTYPE	15	17	deep venous thrombosis
NCT0000370028	NCT00003700_28_T0	COMPOUND	3	3	creatinine
NCT0000370028	NCT00003700_28_T1	COMPOUND	2	2	bilirubin
NCT0000370028	NCT00003700_28_T2	GENE	5	5	amylase
NCT0000370028	NCT00003700_28_T3	PHENOTYPE	24	24	tolerance
NCT0000370030	NCT00003700_30_T0	PHENOTYPE	11	12	malignant disease
NCT000037011	NCT00003701_1_T0	CELL	9	9	cells
NCT000037011	NCT00003701_1_T1	PHENOTYPE	8	8	tumor
NCT000037012	NCT00003701_2_T0	PHENOTYPE	18	19	bladder cancer
NCT000037013	NCT00003701_3_T0	GENE	3	3	III
NCT000037013	NCT00003701_3_T1	PHENOTYPE	19	20	bladder cancer
NCT000037015	NCT00003701_5_T0	COMPOUND	24	24	paclitaxel
NCT000037015	NCT00003701_5_T1	PHENOTYPE	37	37	relapse
NCT000037015	NCT00003701_5_T2	COMPOUND	13	13	methotrexate
NCT000037015	NCT00003701_5_T3	COMPOUND	18	18	M-VAC
NCT000037015	NCT00003701_5_T4	PHENOTYPE	2	2	recurrence
NCT000037015	NCT00003701_5_T5	COMPOUND	14	14	vinblastine
NCT000037015	NCT00003701_5_T6	COMPOUND	15	15	doxorubicin
NCT000037015	NCT00003701_5_T7	COMPOUND	17	17	cisplatin
NCT000037015	NCT00003701_5_T8	PHENOTYPE	30	31	bladder cancer
NCT000037017	NCT00003701_7_T0	COMPOUND	12	12	paclitaxel
NCT000037017	NCT00003701_7_T1	PHENOTYPE	3	3	toxicities
NCT000037017	NCT00003701_7_T2	COMPOUND	6	6	M-VAC
NCT0000370111	NCT00003701_11_T0	COMPOUND	4	4	N
NCT0000370111	NCT00003701_11_T1	COMPOUND	8	8	N
NCT0000370117	NCT00003701_17_T0	PHENOTYPE	0	2	Quality of life
NCT000037021	NCT00003702_1_T0	CELL	10	10	cells
NCT000037021	NCT00003702_1_T1	PHENOTYPE	9	9	tumor
NCT000037022	NCT00003702_2_T0	COMPOUND	6	6	methotrexate
NCT000037022	NCT00003702_2_T1	PHENOTYPE	16	18	gestational trophoblastic neoplasia
NCT000037024	NCT00003702_4_T0	COMPOUND	4	4	methotrexate
NCT000037024	NCT00003702_4_T1	PHENOTYPE	17	19	gestational trophoblastic neoplasia
NCT000037026	NCT00003702_6_T0	PHENOTYPE	2	2	toxicity
NCT0000370211	NCT00003702_11_T0	PHENOTYPE	16	16	toxicity
NCT0000370211	NCT00003702_11_T1	COMPOUND	4	4	methotrexate
NCT0000370211	NCT00003702_11_T2	GENE	0	0	ARM
NCT0000370211	NCT00003702_11_T3	PHENOTYPE	12	13	disease progression
NCT0000370212	NCT00003702_12_T0	PHENOTYPE	20	20	toxicity
NCT0000370212	NCT00003702_12_T1	GENE	1	1	II
NCT0000370212	NCT00003702_12_T2	GENE	0	0	ARM
NCT0000370212	NCT00003702_12_T3	GENE	5	5	IV
NCT0000370212	NCT00003702_12_T4	PHENOTYPE	16	17	disease progression
NCT000037030	NCT00003703_0_T0	PHENOTYPE	6	7	Solid Tumors
NCT000037032	NCT00003703_2_T0	PHENOTYPE	17	18	solid tumors
NCT000037034	NCT00003703_4_T0	PHENOTYPE	12	12	malignancies
NCT000037034	NCT00003703_4_T1	COMPOUND	6	6	SarCNU
NCT000037036	NCT00003703_6_T0	PHENOTYPE	2	2	toxic
NCT000037036	NCT00003703_6_T1	COMPOUND	5	5	SarCNU
NCT0000370312	NCT00003703_12_T0	COMPOUND	3	3	SarCNU
NCT0000370313	NCT00003703_13_T0	PHENOTYPE	13	13	toxicity
NCT0000370313	NCT00003703_13_T1	PHENOTYPE	9	10	disease progression
NCT0000370314	NCT00003703_14_T0	COMPOUND	8	8	SarCNU
NCT0000370314	NCT00003703_14_T1	GENE	14	14	MTD
NCT0000370315	NCT00003703_15_T0	PHENOTYPE	17	17	toxicity
NCT0000370315	NCT00003703_15_T1	GENE	1	1	MTD
NCT0000370316	NCT00003703_16_T0	GENE	2	2	MTD
NCT0000370316	NCT00003703_16_T1	GENE	11	11	MTD
NCT000037041	NCT00003704_1_T0	CELL	7	7	cells
NCT000037041	NCT00003704_1_T1	PHENOTYPE	6	6	tumor
NCT000037042	NCT00003704_2_T0	COMPOUND	3	3	capecitabine
NCT000037042	NCT00003704_2_T1	CELL	8	8	cells
NCT000037042	NCT00003704_2_T2	PHENOTYPE	7	7	tumor
NCT000037043	NCT00003704_3_T0	COMPOUND	9	9	capecitabine
NCT000037043	NCT00003704_3_T1	ORGAN	29	29	pelvis
NCT000037043	NCT00003704_3_T2	PHENOTYPE	23	25	recurrent colorectal cancer
NCT000037045	NCT00003704_5_T0	COMPOUND	7	7	capecitabine
NCT000037045	NCT00003704_5_T1	PHENOTYPE	23	23	localized
NCT000037045	NCT00003704_5_T2	ORGAN	26	26	pelvis
NCT000037045	NCT00003704_5_T3	PHENOTYPE	20	22	locally recurrent cancer
NCT000037047	NCT00003704_7_T0	PHENOTYPE	2	2	tolerance
NCT0000370410	NCT00003704_10_T0	COMPOUND	7	7	capecitabine
NCT0000370411	NCT00003704_11_T0	COMPOUND	3	3	capecitabine
NCT0000370412	NCT00003704_12_T0	COMPOUND	11	11	capecitabine
NCT0000370412	NCT00003704_12_T1	PHENOTYPE	9	9	initiation
NCT0000370413	NCT00003704_13_T0	COMPOUND	8	8	capecitabine
NCT0000370413	NCT00003704_13_T1	GENE	14	14	MTD
NCT0000370414	NCT00003704_14_T0	PHENOTYPE	17	17	toxicity
NCT0000370414	NCT00003704_14_T1	GENE	1	1	MTD
NCT000037050	NCT00003705_0_T0	COMPOUND	0	0	BMS-184476
NCT000037050	NCT00003705_0_T1	PHENOTYPE	6	7	Solid Tumors
NCT000037052	NCT00003705_2_T0	COMPOUND	9	9	BMS-184476
NCT000037052	NCT00003705_2_T1	PHENOTYPE	16	17	solid tumors
NCT000037054	NCT00003705_4_T0	GENE	10	10	II
NCT000037054	NCT00003705_4_T1	PHENOTYPE	7	7	toxicity
NCT000037054	NCT00003705_4_T2	COMPOUND	15	15	BMS-184476
NCT000037054	NCT00003705_4_T3	PHENOTYPE	20	21	solid tumors
NCT000037056	NCT00003705_6_T0	COMPOUND	5	5	BMS-184476
NCT000037058	NCT00003705_8_T0	COMPOUND	7	7	BMS-184476
NCT0000370510	NCT00003705_10_T0	COMPOUND	2	2	BMS-184476
NCT0000370510	NCT00003705_10_T1	GENE	3	3	IV
NCT0000370511	NCT00003705_11_T0	PHENOTYPE	14	14	toxicity
NCT0000370511	NCT00003705_11_T1	PHENOTYPE	10	11	disease progression
NCT0000370512	NCT00003705_12_T0	COMPOUND	9	9	BMS-184476
NCT0000370512	NCT00003705_12_T1	GENE	10	10	IV
NCT0000370513	NCT00003705_13_T0	COMPOUND	10	10	BMS-184476
NCT0000370514	NCT00003705_14_T0	PHENOTYPE	20	20	toxicity
NCT0000370515	NCT00003705_15_T0	PHENOTYPE	7	7	toxicity
NCT0000370515	NCT00003705_15_T1	PHENOTYPE	9	9	resolved
NCT000037061	NCT00003706_1_T0	ORGAN	12	12	kidney
NCT000037062	NCT00003706_2_T0	ORGAN	25	25	kidney
NCT000037062	NCT00003706_2_T1	PHENOTYPE	19	20	solid tumors
NCT000037064	NCT00003706_4_T0	PHENOTYPE	2	2	toxic
NCT000037064	NCT00003706_4_T1	GENE	8	8	MTD
NCT000037064	NCT00003706_4_T2	PHENOTYPE	18	19	solid tumors
NCT000037068	NCT00003706_8_T0	PHENOTYPE	8	8	pharmacokinetics
NCT000037068	NCT00003706_8_T1	PHENOTYPE	5	5	dysfunction
NCT0000370610	NCT00003706_10_T0	PHENOTYPE	4	6	impaired renal function
NCT0000370617	NCT00003706_17_T0	GENE	0	1	Group 1
NCT0000370617	NCT00003706_17_T1	PHENOTYPE	23	24	renal impairment
NCT0000370618	NCT00003706_18_T0	GENE	4	4	IV
NCT0000370619	NCT00003706_19_T0	PHENOTYPE	10	10	toxicity
NCT0000370619	NCT00003706_19_T1	PHENOTYPE	6	7	disease progression
NCT0000370621	NCT00003706_21_T0	PHENOTYPE	3	3	toxicity
NCT0000370621	NCT00003706_21_T1	GENE	4	4	DLT
NCT0000370622	NCT00003706_22_T0	GENE	19	19	DLT
NCT000037071	NCT00003707_1_T0	CELL	9	9	cells
NCT000037072	NCT00003707_2_T0	COMPOUND	12	12	gemcitabine
NCT000037072	NCT00003707_2_T1	PHENOTYPE	17	18	advanced cancer
NCT000037074	NCT00003707_4_T0	COMPOUND	7	7	tipifarnib
NCT000037075	NCT00003707_5_T0	COMPOUND	2	2	gemcitabine
NCT000037075	NCT00003707_5_T1	COMPOUND	15	15	tipifarnib
NCT000037075	NCT00003707_5_T2	GENE	3	3	IV
NCT000037076	NCT00003707_6_T0	PHENOTYPE	13	13	toxicity
NCT000037076	NCT00003707_6_T1	PHENOTYPE	9	10	disease progression
NCT000037077	NCT00003707_7_T0	COMPOUND	9	9	tipifarnib
NCT000037077	NCT00003707_7_T1	GENE	15	15	MTD
NCT000037078	NCT00003707_8_T0	PHENOTYPE	19	19	toxicity
NCT000037078	NCT00003707_8_T1	GENE	1	1	MTD
NCT000037079	NCT00003707_9_T0	PHENOTYPE	0	2	Quality of life
NCT000037080	NCT00003708_0_T0	PHENOTYPE	6	7	Solid Tumors
NCT000037082	NCT00003708_2_T0	COMPOUND	9	9	temozolomide
NCT000037082	NCT00003708_2_T1	PHENOTYPE	16	17	solid tumors
NCT000037084	NCT00003708_4_T0	PHENOTYPE	13	13	toxicity
NCT000037084	NCT00003708_4_T1	PHENOTYPE	9	10	disease progression
NCT000037085	NCT00003708_5_T0	COMPOUND	10	10	temozolomide
NCT000037086	NCT00003708_6_T0	PHENOTYPE	21	21	toxicity
NCT000037086	NCT00003708_6_T1	PHENOTYPE	18	18	experiences
NCT000037086	NCT00003708_6_T2	GENE	22	22	DLT
NCT000037086	NCT00003708_6_T3	GENE	34	34	DLT
NCT000037088	NCT00003708_8_T0	PHENOTYPE	10	10	toxicity
NCT000037088	NCT00003708_8_T1	COMPOUND	12	12	temozolomide
NCT000037088	NCT00003708_8_T2	PHENOTYPE	18	18	malignancies
NCT0000370810	NCT00003708_10_T0	COMPOUND	7	7	temozolomide
NCT0000370810	NCT00003708_10_T1	PHENOTYPE	5	5	pharmacokinetics
NCT0000370812	NCT00003708_12_T0	COMPOUND	4	4	temozolomide
NCT0000370814	NCT00003708_14_T0	COMPOUND	3	3	temozolomide
NCT0000370815	NCT00003708_15_T0	PHENOTYPE	13	13	toxicity
NCT0000370815	NCT00003708_15_T1	PHENOTYPE	9	10	disease progression
NCT0000370816	NCT00003708_16_T0	COMPOUND	10	10	temozolomide
NCT0000370817	NCT00003708_17_T0	PHENOTYPE	21	21	toxicity
NCT0000370817	NCT00003708_17_T1	PHENOTYPE	18	18	experiences
NCT0000370817	NCT00003708_17_T2	GENE	22	22	DLT
NCT0000370817	NCT00003708_17_T3	GENE	34	34	DLT
NCT000037090	NCT00003709_0_T0	PHENOTYPE	6	7	Solid Tumors
NCT000037092	NCT00003709_2_T0	COMPOUND	9	9	carbendazim
NCT000037092	NCT00003709_2_T1	PHENOTYPE	16	17	solid tumors
NCT000037094	NCT00003709_4_T0	PHENOTYPE	14	14	toxic
NCT000037094	NCT00003709_4_T1	PHENOTYPE	10	11	disease progression
NCT000037095	NCT00003709_5_T0	COMPOUND	8	8	carbendazim
NCT000037096	NCT00003709_6_T0	PHENOTYPE	3	3	toxicity
NCT000037096	NCT00003709_6_T1	GENE	4	4	DLT
NCT000037097	NCT00003709_7_T0	GENE	8	8	MTD
NCT000037098	NCT00003709_8_T0	GENE	1	1	MTD
NCT000037098	NCT00003709_8_T1	GENE	16	16	DLT
NCT0000370910	NCT00003709_10_T0	COMPOUND	7	7	carbendazim
NCT0000370910	NCT00003709_10_T1	PHENOTYPE	12	13	solid tumors
NCT0000370912	NCT00003709_12_T0	COMPOUND	9	9	carbendazim
NCT0000370912	NCT00003709_12_T1	PHENOTYPE	5	5	toxic
NCT0000370914	NCT00003709_14_T0	COMPOUND	6	6	carbendazim
NCT0000370916	NCT00003709_16_T0	GENE	12	12	II
NCT0000370916	NCT00003709_16_T1	COMPOUND	6	6	carbendazim
NCT0000370920	NCT00003709_20_T0	COMPOUND	3	3	carbendazim
NCT0000370921	NCT00003709_21_T0	PHENOTYPE	14	14	toxic
NCT0000370921	NCT00003709_21_T1	PHENOTYPE	10	11	disease progression
NCT0000370922	NCT00003709_22_T0	COMPOUND	8	8	carbendazim
NCT0000370923	NCT00003709_23_T0	PHENOTYPE	3	3	toxicity
NCT0000370923	NCT00003709_23_T1	GENE	4	4	DLT
NCT0000370924	NCT00003709_24_T0	GENE	8	8	MTD
NCT0000370925	NCT00003709_25_T0	GENE	1	1	MTD
NCT0000370925	NCT00003709_25_T1	GENE	16	16	DLT
NCT000037100	NCT00003710_0_T0	PHENOTYPE	8	9	Solid Tumors
NCT000037102	NCT00003710_2_T0	CELL	9	9	cells
NCT000037102	NCT00003710_2_T1	PHENOTYPE	8	8	tumor
NCT000037103	NCT00003710_3_T0	COMPOUND	9	9	irinotecan
NCT000037103	NCT00003710_3_T1	PHENOTYPE	24	24	recurrent
NCT000037103	NCT00003710_3_T2	PHENOTYPE	18	19	solid tumors
NCT000037105	NCT00003710_5_T0	PHENOTYPE	13	13	toxicity
NCT000037105	NCT00003710_5_T1	PHENOTYPE	9	10	disease progression
NCT000037106	NCT00003710_6_T0	COMPOUND	13	13	irinotecan
NCT000037106	NCT00003710_6_T1	GENE	19	19	MTD
NCT000037107	NCT00003710_7_T0	PHENOTYPE	19	19	toxicity
NCT000037107	NCT00003710_7_T1	GENE	1	1	MTD
NCT000037107	NCT00003710_7_T2	PHENOTYPE	16	16	experiences
NCT000037109	NCT00003710_9_T0	COMPOUND	10	10	irinotecan
NCT000037109	NCT00003710_9_T1	PHENOTYPE	15	16	solid tumors
NCT0000371011	NCT00003710_11_T0	COMPOUND	6	6	irinotecan
NCT0000371013	NCT00003710_13_T0	COMPOUND	4	4	irinotecan
NCT0000371013	NCT00003710_13_T1	GENE	14	15	Topo I
NCT0000371017	NCT00003710_17_T0	COMPOUND	13	13	irinotecan
NCT0000371017	NCT00003710_17_T1	GENE	3	3	IV
NCT0000371017	NCT00003710_17_T2	GENE	14	14	IV
NCT0000371018	NCT00003710_18_T0	PHENOTYPE	13	13	toxicity
NCT0000371018	NCT00003710_18_T1	PHENOTYPE	9	10	disease progression
NCT0000371019	NCT00003710_19_T0	COMPOUND	13	13	irinotecan
NCT0000371019	NCT00003710_19_T1	GENE	19	19	MTD
NCT0000371020	NCT00003710_20_T0	PHENOTYPE	19	19	toxicity
NCT0000371020	NCT00003710_20_T1	GENE	1	1	MTD
NCT0000371020	NCT00003710_20_T2	PHENOTYPE	16	16	experiences
NCT000037110	NCT00003711_0_T0	PHENOTYPE	7	8	Solid Tumors
NCT000037112	NCT00003711_2_T0	CELL	9	9	cells
NCT000037112	NCT00003711_2_T1	PHENOTYPE	8	8	tumor
NCT000037113	NCT00003711_3_T0	COMPOUND	13	13	disodium
NCT000037113	NCT00003711_3_T1	COMPOUND	12	12	pemetrexed
NCT000037113	NCT00003711_3_T2	COMPOUND	15	15	irinotecan
NCT000037113	NCT00003711_3_T3	PHENOTYPE	22	23	solid tumors
NCT000037115	NCT00003711_5_T0	COMPOUND	9	9	irinotecan
NCT000037115	NCT00003711_5_T1	PHENOTYPE	13	14	metastatic cancer
NCT000037117	NCT00003711_7_T0	PHENOTYPE	5	5	toxicity
NCT000037117	NCT00003711_7_T1	COMPOUND	11	11	irinotecan
NCT000037119	NCT00003711_9_T0	PHENOTYPE	2	2	pharmacokinetics
NCT000037119	NCT00003711_9_T1	ORGAN	1	1	plasma
NCT0000371113	NCT00003711_13_T0	COMPOUND	9	9	irinotecan
NCT0000371113	NCT00003711_13_T1	GENE	3	3	IV
NCT0000371113	NCT00003711_13_T2	GENE	10	10	IV
NCT0000371114	NCT00003711_14_T0	PHENOTYPE	13	13	toxicity
NCT0000371114	NCT00003711_14_T1	PHENOTYPE	9	10	disease progression
NCT0000371115	NCT00003711_15_T0	COMPOUND	11	11	irinotecan
NCT0000371116	NCT00003711_16_T0	PHENOTYPE	13	13	toxicity
NCT0000371116	NCT00003711_16_T1	GENE	14	14	DLT
NCT0000371117	NCT00003711_17_T0	GENE	20	20	DLT
NCT0000371118	NCT00003711_18_T0	GENE	1	1	DLT
NCT0000371119	NCT00003711_19_T0	GENE	19	19	DLT
NCT000037120	NCT00003712_0_T0	PHENOTYPE	6	7	Solid Tumors
NCT000037122	NCT00003712_2_T0	PHENOTYPE	16	17	solid tumors
NCT000037124	NCT00003712_4_T0	PHENOTYPE	14	14	toxicity
NCT000037124	NCT00003712_4_T1	PHENOTYPE	10	11	disease progression
NCT000037125	NCT00003712_5_T0	PHENOTYPE	21	21	toxicity
NCT000037126	NCT00003712_6_T0	GENE	1	1	II
NCT000037127	NCT00003712_7_T0	PHENOTYPE	4	4	tumors
NCT000037127	NCT00003712_7_T1	GENE	16	16	MTD
NCT0000371210	NCT00003712_10_T0	PHENOTYPE	14	14	toxicity
NCT0000371210	NCT00003712_10_T1	PHENOTYPE	11	11	progression
NCT0000371212	NCT00003712_12_T0	PHENOTYPE	4	4	tumors
NCT0000371212	NCT00003712_12_T1	GENE	16	16	MTD
NCT0000371213	NCT00003712_13_T0	GENE	12	12	II
NCT0000371214	NCT00003712_14_T0	GENE	25	25	II
NCT000037130	NCT00003713_0_T0	PHENOTYPE	8	9	Solid Tumors
NCT000037132	NCT00003713_2_T0	COMPOUND	9	9	intoplicine
NCT000037132	NCT00003713_2_T1	PHENOTYPE	18	19	solid tumors
NCT000037134	NCT00003713_4_T0	COMPOUND	6	6	intoplicine
NCT000037134	NCT00003713_4_T1	PHENOTYPE	13	14	metastatic cancer
NCT000037136	NCT00003713_6_T0	GENE	3	3	II
NCT000037136	NCT00003713_6_T1	COMPOUND	6	6	intoplicine
NCT000037138	NCT00003713_8_T0	COMPOUND	8	8	intoplicine
NCT000037138	NCT00003713_8_T1	PHENOTYPE	6	6	toxicities
NCT000037138	NCT00003713_8_T2	PHENOTYPE	20	20	toxicities
NCT0000371310	NCT00003713_10_T0	PHENOTYPE	19	19	toxicity
NCT0000371310	NCT00003713_10_T1	PHENOTYPE	5	5	concentrations
NCT0000371310	NCT00003713_10_T2	ORGAN	4	4	plasma
NCT0000371312	NCT00003713_12_T0	COMPOUND	7	7	intoplicine
NCT0000371314	NCT00003713_14_T0	COMPOUND	5	5	intoplicine
NCT0000371314	NCT00003713_14_T1	GENE	6	6	IV
NCT0000371315	NCT00003713_15_T0	PHENOTYPE	14	14	toxicity
NCT0000371315	NCT00003713_15_T1	PHENOTYPE	10	11	disease progression
NCT0000371316	NCT00003713_16_T0	COMPOUND	9	9	intoplicine
NCT0000371317	NCT00003713_17_T0	PHENOTYPE	23	23	toxicity
NCT0000371318	NCT00003713_18_T0	GENE	5	5	20.35
NCT000037141	NCT00003714_1_T0	GENE	2	2	II
NCT000037141	NCT00003714_1_T1	COMPOUND	9	9	pyrazoloacridine
NCT000037141	NCT00003714_1_T2	GENE	22	22	has
NCT000037141	NCT00003714_1_T3	PHENOTYPE	18	20	metastatic kidney cancer
NCT000037143	NCT00003714_3_T0	COMPOUND	16	16	pyrazoloacridine
NCT000037143	NCT00003714_3_T1	PHENOTYPE	12	13	hepatocellular carcinoma
NCT000037145	NCT00003714_5_T0	PHENOTYPE	7	7	toxic
NCT000037146	NCT00003714_6_T0	COMPOUND	3	3	pyrazoloacridine
NCT000037146	NCT00003714_6_T1	GENE	4	4	IV
NCT000037147	NCT00003714_7_T0	PHENOTYPE	8	8	tumor
NCT000037148	NCT00003714_8_T0	GENE	8	8	PR
NCT000037148	NCT00003714_8_T1	GENE	15	15	PR
NCT000037148	NCT00003714_8_T2	PHENOTYPE	3	3	remission
NCT000037148	NCT00003714_8_T3	PHENOTYPE	7	7	remission
NCT000037148	NCT00003714_8_T4	GENE	4	4	CR
NCT000037148	NCT00003714_8_T5	GENE	23	23	CR
NCT000037150	NCT00003715_0_T0	PHENOTYPE	12	12	Melanoma
NCT000037150	NCT00003715_0_T1	GENE	11	11	III
NCT000037150	NCT00003715_0_T2	GENE	4	4	Interferon
NCT000037153	NCT00003715_3_T0	GENE	3	3	III
NCT000037153	NCT00003715_3_T1	PHENOTYPE	10	10	melanoma
NCT000037153	NCT00003715_3_T2	GENE	26	26	has
NCT000037153	NCT00003715_3_T3	COMPOUND	15	16	interferon alfa_2b
NCT000037153	NCT00003715_3_T4	TISSUE	30	31	lymph nodes
NCT000037153	NCT00003715_3_T5	PHENOTYPE	22	24	stage III melanoma
NCT000037155	NCT00003715_5_T0	PHENOTYPE	16	16	tumor
NCT000037155	NCT00003715_5_T1	COMPOUND	19	20	interferon alfa_2b
NCT000037155	NCT00003715_5_T2	PHENOTYPE	10	12	stage III melanoma
NCT000037159	NCT00003715_9_T0	COMPOUND	11	11	1
NCT000037159	NCT00003715_9_T1	COMPOUND	15	15	1
NCT000037159	NCT00003715_9_T2	COMPOUND	27	27	1
NCT000037159	NCT00003715_9_T3	PHENOTYPE	33	33	metastases
NCT000037159	NCT00003715_9_T4	TISSUE	19	20	lymph nodes
NCT000037159	NCT00003715_9_T5	TISSUE	8	9	lymph node
NCT0000371512	NCT00003715_12_T0	GENE	0	0	BCG
NCT0000371512	NCT00003715_12_T1	GENE	11	11	2.8
NCT0000371513	NCT00003715_13_T0	COMPOUND	3	3	cyclophosphamide
NCT000037161	NCT00003716_1_T0	GENE	2	2	II
NCT000037161	NCT00003716_1_T1	PHENOTYPE	21	21	immunosuppression
NCT000037161	NCT00003716_1_T2	PHENOTYPE	15	16	lymphoproliferative disorder
NCT000037163	NCT00003716_3_T0	ORGAN	20	20	allograft
NCT000037163	NCT00003716_3_T1	CELL	8	8	B-cell
NCT000037163	NCT00003716_3_T2	PHENOTYPE	23	24	autoimmune disease
NCT000037163	NCT00003716_3_T3	PHENOTYPE	9	10	lymphoproliferative disorders
NCT000037163	NCT00003716_3_T4	PHENOTYPE	14	15	immune suppression
NCT000037165	NCT00003716_5_T0	PHENOTYPE	5	5	toxicity
NCT000037165	NCT00003716_5_T1	PHENOTYPE	16	17	opportunistic infections
NCT000037167	NCT00003716_7_T0	PHENOTYPE	2	2	secondary
NCT000037167	NCT00003716_7_T1	PHENOTYPE	25	25	severity
NCT000037167	NCT00003716_7_T2	ORGAN	20	20	graft
NCT000037167	NCT00003716_7_T3	ORGAN	22	22	graft
NCT000037167	NCT00003716_7_T4	PHENOTYPE	27	28	autoimmune disease
NCT000037168	NCT00003716_8_T0	GENE	4	4	IV
NCT0000371610	NCT00003716_10_T0	PHENOTYPE	14	14	relapse
NCT000037171	NCT00003717_1_T0	CELL	9	9	cells
NCT000037171	NCT00003717_1_T1	PHENOTYPE	8	8	tumor
NCT000037176	NCT00003717_6_T0	PHENOTYPE	4	6	quality of life
NCT000037177	NCT00003717_7_T0	COMPOUND	3	3	paclitaxel
NCT000037177	NCT00003717_7_T1	GENE	4	4	IV
NCT000037178	NCT00003717_8_T0	COMPOUND	14	14	paclitaxel
NCT000037178	NCT00003717_8_T1	COMPOUND	3	3	estramustine
NCT000037179	NCT00003717_9_T0	PHENOTYPE	10	10	toxicity
NCT000037179	NCT00003717_9_T1	PHENOTYPE	12	13	disease progression
NCT0000371710	NCT00003717_10_T0	PHENOTYPE	14	14	initiation
NCT0000371710	NCT00003717_10_T1	PHENOTYPE	1	3	quality of life
NCT000037181	NCT00003718_1_T0	COMPOUND	9	9	temozolomide
NCT000037181	NCT00003718_1_T1	GENE	2	2	II
NCT000037181	NCT00003718_1_T2	PHENOTYPE	16	18	soft tissue sarcoma
NCT000037183	NCT00003718_3_T0	COMPOUND	10	10	temozolomide
NCT000037183	NCT00003718_3_T1	GENE	16	16	IV
NCT000037183	NCT00003718_3_T2	PHENOTYPE	18	18	recurrent
NCT000037183	NCT00003718_3_T3	PHENOTYPE	19	21	soft tissue sarcoma
NCT000037185	NCT00003718_5_T0	PHENOTYPE	5	5	toxicities
NCT000037185	NCT00003718_5_T1	PHENOTYPE	10	10	tolerance
NCT000037186	NCT00003718_6_T0	COMPOUND	11	11	2
NCT000037186	NCT00003718_6_T1	COMPOUND	30	30	2
NCT000037187	NCT00003718_7_T0	COMPOUND	3	3	temozolomide
NCT000037188	NCT00003718_8_T0	PHENOTYPE	15	15	toxicity
NCT000037188	NCT00003718_8_T1	PHENOTYPE	17	18	disease progression
NCT000037191	NCT00003719_1_T0	GENE	2	2	II
NCT000037191	NCT00003719_1_T1	COMPOUND	9	9	irinotecan
NCT000037191	NCT00003719_1_T2	GENE	16	16	IV
NCT000037191	NCT00003719_1_T3	GENE	23	23	has
NCT000037191	NCT00003719_1_T4	PHENOTYPE	18	18	recurrent
NCT000037191	NCT00003719_1_T5	PHENOTYPE	19	21	soft tissue sarcoma
NCT000037193	NCT00003719_3_T0	COMPOUND	4	4	irinotecan
NCT000037193	NCT00003719_3_T1	PHENOTYPE	9	9	recurrent
NCT000037193	NCT00003719_3_T2	PHENOTYPE	16	18	soft tissue sarcoma
NCT000037195	NCT00003719_5_T0	PHENOTYPE	5	5	toxic
NCT000037195	NCT00003719_5_T1	PHENOTYPE	9	9	tolerance
NCT000037196	NCT00003719_6_T0	COMPOUND	3	3	irinotecan
NCT000037196	NCT00003719_6_T1	GENE	4	4	IV
NCT000037197	NCT00003719_7_T0	PHENOTYPE	13	13	toxicity
NCT000037197	NCT00003719_7_T1	PHENOTYPE	9	10	disease progression
NCT000037201	NCT00003720_1_T0	PHENOTYPE	16	17	Kaposi's sarcoma
NCT000037203	NCT00003720_3_T0	PHENOTYPE	11	12	Kaposi's sarcoma
NCT000037205	NCT00003720_5_T0	PHENOTYPE	2	2	pharmacokinetics
NCT000037209	NCT00003720_9_T0	PHENOTYPE	7	7	HIV
NCT0000372012	NCT00003720_12_T0	PHENOTYPE	18	18	toxicity
NCT0000372012	NCT00003720_12_T1	PHENOTYPE	14	15	disease progression
NCT0000372013	NCT00003720_13_T0	PHENOTYPE	6	6	toxicity
NCT0000372013	NCT00003720_13_T1	GENE	7	7	DLT
NCT0000372014	NCT00003720_14_T0	GENE	28	28	MTD
NCT0000372014	NCT00003720_14_T1	GENE	1	1	DLT
NCT0000372015	NCT00003720_15_T0	GENE	7	7	MTD
NCT000037210	NCT00003721_0_T0	PHENOTYPE	6	7	Solid Tumors
NCT000037212	NCT00003721_2_T0	PHENOTYPE	16	17	solid tumors
NCT000037215	NCT00003721_5_T0	PHENOTYPE	10	10	toxic
NCT000037215	NCT00003721_5_T1	PHENOTYPE	6	7	disease progression
NCT000037217	NCT00003721_7_T0	PHENOTYPE	19	19	toxicity
NCT000037217	NCT00003721_7_T1	GENE	20	20	DLT
NCT000037218	NCT00003721_8_T0	GENE	8	8	MTD
NCT0000372110	NCT00003721_10_T0	PHENOTYPE	11	12	solid tumors
NCT0000372112	NCT00003721_12_T0	PHENOTYPE	4	4	toxicity
NCT0000372114	NCT00003721_14_T0	PHENOTYPE	4	4	pharmacodynamics
NCT0000372114	NCT00003721_14_T1	PHENOTYPE	2	2	pharmacokinetics
NCT0000372119	NCT00003721_19_T0	PHENOTYPE	10	10	toxic
NCT0000372119	NCT00003721_19_T1	PHENOTYPE	6	7	disease progression
NCT0000372121	NCT00003721_21_T0	PHENOTYPE	19	19	toxicity
NCT0000372121	NCT00003721_21_T1	GENE	20	20	DLT
NCT0000372122	NCT00003721_22_T0	GENE	8	8	MTD
NCT0000372123	NCT00003721_23_T0	GENE	1	1	MTD
NCT0000372123	NCT00003721_23_T1	GENE	18	18	DLT
NCT000037231	NCT00003723_1_T0	CELL	9	9	cells
NCT000037231	NCT00003723_1_T1	PHENOTYPE	8	8	tumor
NCT000037232	NCT00003723_2_T0	GENE	2	2	II
NCT000037232	NCT00003723_2_T1	COMPOUND	9	9	gemcitabine
NCT000037232	NCT00003723_2_T2	COMPOUND	11	11	cisplatin
NCT000037232	NCT00003723_2_T3	PHENOTYPE	16	20	malignant mesothelioma of the pleura
NCT000037234	NCT00003723_4_T0	COMPOUND	22	22	gemcitabine
NCT000037234	NCT00003723_4_T1	COMPOUND	24	24	cisplatin
NCT000037234	NCT00003723_4_T2	PHENOTYPE	15	19	malignant mesothelioma of the pleura
NCT000037236	NCT00003723_6_T0	PHENOTYPE	5	5	toxicities
NCT000037237	NCT00003723_7_T0	COMPOUND	3	3	gemcitabine
NCT000037237	NCT00003723_7_T1	COMPOUND	11	11	cisplatin
NCT000037237	NCT00003723_7_T2	GENE	4	4	IV
NCT000037237	NCT00003723_7_T3	GENE	12	12	IV
NCT000037239	NCT00003723_9_T0	PHENOTYPE	7	7	toxicity
NCT000037239	NCT00003723_9_T1	PHENOTYPE	9	10	disease progression
NCT000037241	NCT00003724_1_T0	PHENOTYPE	16	17	lung metastases
NCT000037242	NCT00003724_2_T0	GENE	3	3	III
NCT000037242	NCT00003724_2_T1	PHENOTYPE	22	23	lung metastases
NCT000037244	NCT00003724_4_T0	PHENOTYPE	12	13	pulmonary metastases
NCT000037246	NCT00003724_6_T0	PHENOTYPE	3	3	recurrence
NCT000037246	NCT00003724_6_T1	PHENOTYPE	17	17	recurrence
NCT000037248	NCT00003724_8_T0	PHENOTYPE	4	4	complications
NCT0000372410	NCT00003724_10_T0	PHENOTYPE	13	15	quality of life
NCT0000372414	NCT00003724_14_T0	PHENOTYPE	3	3	recurrence
NCT0000372416	NCT00003724_16_T0	PHENOTYPE	0	2	Quality of life
NCT000037251	NCT00003725_1_T0	CELL	10	10	cells
NCT000037251	NCT00003725_1_T1	PHENOTYPE	9	9	tumor
NCT000037252	NCT00003725_2_T0	GENE	9	9	AD
NCT000037252	NCT00003725_2_T1	PHENOTYPE	19	20	bladder cancer
NCT000037253	NCT00003725_3_T0	GENE	15	15	AD
NCT000037253	NCT00003725_3_T1	GENE	3	3	III
NCT000037253	NCT00003725_3_T2	PHENOTYPE	31	33	recurrent bladder cancer
NCT000037257	NCT00003725_7_T0	PHENOTYPE	2	2	toxicity
NCT000037257	NCT00003725_7_T1	GENE	4	4	AD
NCT000037259	NCT00003725_9_T0	GENE	7	7	AD
NCT0000372511	NCT00003725_11_T0	GENE	0	0	AD
NCT0000372511	NCT00003725_11_T1	ORGAN	8	8	bladder
NCT0000372512	NCT00003725_12_T0	GENE	4	4	AD
NCT0000372512	NCT00003725_12_T1	ORGAN	9	9	bladder
NCT0000372514	NCT00003725_14_T0	GENE	8	8	BCG
NCT0000372514	NCT00003725_14_T1	GENE	4	4	Tis
NCT000037266	NCT00003726_6_T0	GENE	12	12	3.4
NCT000037269	NCT00003726_9_T0	PHENOTYPE	10	10	toxicity
NCT000037269	NCT00003726_9_T1	PHENOTYPE	6	7	disease progression
NCT0000372610	NCT00003726_10_T0	GENE	5	5	20.35
NCT0000372615	NCT00003726_15_T0	GENE	5	5	has
NCT0000372615	NCT00003726_15_T1	PHENOTYPE	2	3	evaluable disease
NCT0000372616	NCT00003726_16_T0	ORGAN	8	8	serum
NCT0000372616	NCT00003726_16_T1	PHENOTYPE	1	2	pleural effusions
NCT0000372616	NCT00003726_16_T2	PHENOTYPE	5	6	brain metastases
NCT0000372616	NCT00003726_16_T3	PHENOTYPE	3	4	bone metastases
NCT0000372618	NCT00003726_18_T0	GENE	0	0	Age
NCT0000372621	NCT00003726_21_T0	GENE	1	1	WBC
NCT0000372621	NCT00003726_21_T1	PHENOTYPE	5	6	Platelet count
NCT0000372622	NCT00003726_22_T0	GENE	5	5	2.0
NCT0000372623	NCT00003726_23_T0	GENE	7	7	OR
NCT0000372623	NCT00003726_23_T1	GENE	5	5	1.5
NCT0000372625	NCT00003726_25_T0	PHENOTYPE	0	0	Other
NCT0000372625	NCT00003726_25_T1	PHENOTYPE	5	7	Negative pregnancy test
NCT0000372626	NCT00003726_26_T0	PHENOTYPE	8	8	symptoms
NCT0000372626	NCT00003726_26_T1	PHENOTYPE	10	10	bleeding
NCT0000372626	NCT00003726_26_T2	PHENOTYPE	14	14	bleeding
NCT0000372627	NCT00003726_27_T0	PHENOTYPE	1	2	bacterial endocarditis
NCT0000372630	NCT00003726_30_T0	PHENOTYPE	0	0	Endocrine
NCT0000372631	NCT00003726_31_T0	PHENOTYPE	8	8	trauma
NCT000037272	NCT00003727_2_T0	CELL	13	13	cells
NCT000037272	NCT00003727_2_T1	ORGAN	8	9	immune system
NCT000037276	NCT00003727_6_T0	GENE	5	5	interferon
NCT000037277	NCT00003727_7_T0	GENE	20	20	SC
NCT000037277	NCT00003727_7_T1	GENE	29	29	SC
NCT000037277	NCT00003727_7_T2	GENE	27	27	filgrastim
NCT000037277	NCT00003727_7_T3	COMPOUND	2	2	cyclophosphamide
NCT000037277	NCT00003727_7_T4	COMPOUND	10	10	etoposide
NCT000037277	NCT00003727_7_T5	GENE	28	28	G-CSF
NCT000037277	NCT00003727_7_T6	GENE	19	19	GM-CSF
NCT000037277	NCT00003727_7_T7	GENE	3	3	IV
NCT000037277	NCT00003727_7_T8	GENE	11	11	IV
NCT000037277	NCT00003727_7_T9	GENE	18	18	sargramostim
NCT000037279	NCT00003727_9_T0	GENE	1	1	2.3
NCT0000372710	NCT00003727_10_T0	COMPOUND	34	34	1
NCT0000372710	NCT00003727_10_T1	COMPOUND	13	13	2
NCT0000372710	NCT00003727_10_T2	COMPOUND	17	17	2
NCT0000372710	NCT00003727_10_T3	COMPOUND	27	27	melphalan
NCT0000372710	NCT00003727_10_T4	COMPOUND	2	2	gemcitabine
NCT0000372710	NCT00003727_10_T5	COMPOUND	23	23	gemcitabine
NCT0000372710	NCT00003727_10_T6	GENE	3	3	IV
NCT0000372710	NCT00003727_10_T7	GENE	11	11	IV
NCT0000372710	NCT00003727_10_T8	GENE	24	24	IV
NCT0000372710	NCT00003727_10_T9	GENE	28	28	IV
NCT0000372711	NCT00003727_11_T0	COMPOUND	13	13	melphalan
NCT0000372711	NCT00003727_11_T1	GENE	0	0	CD34
NCT0000372713	NCT00003727_13_T0	GENE	3	3	ex
NCT0000372713	NCT00003727_13_T1	CELL	7	8	T cells
NCT0000372714	NCT00003727_14_T0	GENE	0	0	Interferon
NCT000037281	NCT00003728_1_T0	CELL	9	9	cells
NCT000037281	NCT00003728_1_T1	PHENOTYPE	8	8	tumor
NCT000037282	NCT00003728_2_T0	PHENOTYPE	22	23	Hodgkin's lymphoma
NCT000037282	NCT00003728_2_T1	PHENOTYPE	17	19	acute lymphoblastic leukemia
NCT000037283	NCT00003728_3_T0	GENE	3	3	III
NCT000037283	NCT00003728_3_T1	PHENOTYPE	28	29	Hodgkin's lymphoma
NCT000037283	NCT00003728_3_T2	PHENOTYPE	23	25	acute lymphoblastic leukemia
NCT0000372810	NCT00003728_10_T0	GENE	3	3	AR1
NCT0000372810	NCT00003728_10_T1	GENE	19	19	II
NCT0000372810	NCT00003728_10_T2	GENE	5	5	AR2
NCT0000372819	NCT00003728_19_T0	GENE	14	14	5.5
NCT0000372821	NCT00003728_21_T0	PHENOTYPE	18	18	lymphoma
NCT0000372821	NCT00003728_21_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000372821	NCT00003728_21_T2	PHENOTYPE	16	17	high grade
NCT000037291	NCT00003729_1_T0	CELL	9	9	cells
NCT000037291	NCT00003729_1_T1	PHENOTYPE	8	8	tumor
NCT000037292	NCT00003729_2_T0	GENE	2	2	II
NCT000037292	NCT00003729_2_T1	PHENOTYPE	19	21	acute lymphocytic leukemia
NCT000037294	NCT00003729_4_T0	COMPOUND	10	10	cytarabine
NCT000037294	NCT00003729_4_T1	COMPOUND	8	8	idarubicin
NCT000037294	NCT00003729_4_T2	COMPOUND	7	7	fludarabine
NCT000037294	NCT00003729_4_T3	PHENOTYPE	17	19	acute lymphocytic leukemia
NCT000037296	NCT00003729_6_T0	PHENOTYPE	4	4	tolerance
NCT000037298	NCT00003729_8_T0	PHENOTYPE	4	4	progression
NCT0000372910	NCT00003729_10_T0	GENE	9	9	1.3
NCT0000372910	NCT00003729_10_T1	COMPOUND	2	2	idarubicin
NCT0000372910	NCT00003729_10_T2	GENE	3	3	IV
NCT0000372911	NCT00003729_11_T0	GENE	9	9	1.5
NCT0000372911	NCT00003729_11_T1	GENE	1	1	IV
NCT0000372912	NCT00003729_12_T0	GENE	9	9	1.5
NCT0000372912	NCT00003729_12_T1	GENE	1	1	IV
NCT0000372914	NCT00003729_14_T0	PHENOTYPE	13	13	toxicity
NCT0000372914	NCT00003729_14_T1	PHENOTYPE	9	10	disease progression
NCT0000372915	NCT00003729_15_T0	GENE	1	1	IV
NCT0000372916	NCT00003729_16_T0	COMPOUND	9	9	cytarabine
NCT0000372916	NCT00003729_16_T1	GENE	16	16	1.5
NCT0000372916	NCT00003729_16_T2	GENE	1	1	IV
NCT0000372916	NCT00003729_16_T3	GENE	10	10	IV
NCT000037301	NCT00003730_1_T0	CELL	9	9	cells
NCT000037301	NCT00003730_1_T1	PHENOTYPE	8	8	tumor
NCT000037302	NCT00003730_2_T0	COMPOUND	9	9	vinorelbine
NCT000037302	NCT00003730_2_T1	GENE	21	21	has
NCT000037302	NCT00003730_2_T2	PHENOTYPE	17	19	metastatic breast cancer
NCT000037306	NCT00003730_6_T0	COMPOUND	7	7	vinorelbine
NCT000037307	NCT00003730_7_T0	COMPOUND	2	2	vinorelbine
NCT000037307	NCT00003730_7_T1	GENE	35	35	1.4
NCT000037307	NCT00003730_7_T2	GENE	3	3	IV
NCT000037307	NCT00003730_7_T3	GENE	14	14	IV
NCT000037308	NCT00003730_8_T0	PHENOTYPE	15	15	toxicity
NCT000037311	NCT00003731_1_T0	COMPOUND	9	9	temozolomide
NCT000037311	NCT00003731_1_T1	GENE	2	2	II
NCT000037311	NCT00003731_1_T2	PHENOTYPE	16	16	tumors
NCT000037311	NCT00003731_1_T3	PHENOTYPE	14	14	recurrent
NCT000037313	NCT00003731_3_T0	COMPOUND	5	5	temozolomide
NCT000037313	NCT00003731_3_T1	PHENOTYPE	15	15	tumors
NCT000037313	NCT00003731_3_T2	PHENOTYPE	13	13	recurrent
NCT000037317	NCT00003731_7_T0	COMPOUND	6	6	temozolomide
NCT000037317	NCT00003731_7_T1	PHENOTYPE	2	2	acute
NCT000037319	NCT00003731_9_T0	COMPOUND	3	3	temozolomide
NCT000037319	NCT00003731_9_T1	GENE	6	6	1.5
NCT0000373111	NCT00003731_11_T0	PHENOTYPE	13	13	toxicity
NCT0000373111	NCT00003731_11_T1	PHENOTYPE	15	16	disease progression
NCT0000373112	NCT00003731_12_T0	PHENOTYPE	7	8	disease progression
NCT000037321	NCT00003732_1_T0	CELL	9	9	cells
NCT000037322	NCT00003732_2_T0	GENE	21	21	II
NCT000037322	NCT00003732_2_T1	COMPOUND	14	14	paclitaxel
NCT000037322	NCT00003732_2_T2	COMPOUND	9	9	topotecan
NCT000037322	NCT00003732_2_T3	PHENOTYPE	22	23	stage III
NCT000037322	NCT00003732_2_T4	PHENOTYPE	25	28	stage IV ovarian cancer
NCT000037324	NCT00003732_4_T0	COMPOUND	8	8	topotecan
NCT000037325	NCT00003732_5_T0	COMPOUND	8	8	paclitaxel
NCT000037325	NCT00003732_5_T1	GENE	6	6	1.5
NCT000037325	NCT00003732_5_T2	GENE	9	9	IV
NCT000037325	NCT00003732_5_T3	GENE	16	16	IV
NCT000037325	NCT00003732_5_T4	COMPOUND	3	3	topotecan
NCT000037331	NCT00003733_1_T0	CELL	10	10	cells
NCT000037331	NCT00003733_1_T1	PHENOTYPE	9	9	tumor
NCT000037332	NCT00003733_2_T0	GENE	2	2	II
NCT000037332	NCT00003733_2_T1	PHENOTYPE	22	23	stage III
NCT000037332	NCT00003733_2_T2	PHENOTYPE	15	16	residual disease
NCT000037332	NCT00003733_2_T3	PHENOTYPE	25	28	stage IV ovarian cancer
NCT000037334	NCT00003733_4_T0	COMPOUND	6	6	paclitaxel
NCT000037334	NCT00003733_4_T1	PHENOTYPE	16	16	progression
NCT000037334	NCT00003733_4_T2	PHENOTYPE	19	19	progression
NCT000037334	NCT00003733_4_T3	COMPOUND	8	8	topotecan
NCT000037334	NCT00003733_4_T4	PHENOTYPE	27	28	stage III
NCT000037334	NCT00003733_4_T5	PHENOTYPE	30	34	stage IV ovarian epithelial cancer
NCT000037336	NCT00003733_6_T0	PHENOTYPE	2	2	toxicity
NCT000037337	NCT00003733_7_T0	GENE	4	4	IV
NCT000037338	NCT00003733_8_T0	COMPOUND	3	3	paclitaxel
NCT000037338	NCT00003733_8_T1	GENE	4	4	IV
NCT000037338	NCT00003733_8_T2	GENE	15	15	IV
NCT000037338	NCT00003733_8_T3	COMPOUND	14	14	topotecan
NCT000037339	NCT00003733_9_T0	PHENOTYPE	10	10	toxicity
NCT000037339	NCT00003733_9_T1	PHENOTYPE	6	7	disease progression
NCT000037341	NCT00003734_1_T0	COMPOUND	5	5	flutamide
NCT000037341	NCT00003734_1_T1	COMPOUND	3	3	triptorelin
NCT000037348	NCT00003734_8_T0	COMPOUND	10	10	flutamide
NCT000037348	NCT00003734_8_T1	COMPOUND	3	3	triptorelin
NCT000037348	NCT00003734_8_T2	GENE	4	4	IM
NCT0000373411	NCT00003734_11_T0	COMPOUND	29	29	flutamide
NCT0000373411	NCT00003734_11_T1	COMPOUND	20	20	triptorelin
NCT000037355	NCT00003735_5_T0	PHENOTYPE	2	2	toxic
NCT000037355	NCT00003735_5_T1	PHENOTYPE	5	5	pharmacokinetics
NCT000037357	NCT00003735_7_T0	COMPOUND	3	3	topotecan
NCT000037358	NCT00003735_8_T0	PHENOTYPE	18	18	toxicity
NCT000037358	NCT00003735_8_T1	GENE	13	13	M3
NCT000037358	NCT00003735_8_T2	ORGAN	14	15	bone marrow
NCT000037361	NCT00003736_1_T0	GENE	4	4	MRI
NCT000037361	NCT00003736_1_T1	PHENOTYPE	11	12	breast cancer
NCT000037362	NCT00003736_2_T0	GENE	10	10	MRI
NCT000037362	NCT00003736_2_T1	PHENOTYPE	21	22	breast cancer
NCT000037364	NCT00003736_4_T0	GENE	12	12	MRI
NCT000037366	NCT00003736_6_T0	GENE	3	3	MRI
NCT000037366	NCT00003736_6_T1	COMPOUND	5	5	gadolinium
NCT000037367	NCT00003736_7_T0	GENE	10	10	MRI
NCT000037371	NCT00003737_1_T0	GENE	2	2	II
NCT000037371	NCT00003737_1_T1	PHENOTYPE	19	19	neuroblastoma
NCT000037371	NCT00003737_1_T2	COMPOUND	9	10	rebeccamycin analog
NCT000037373	NCT00003737_3_T0	GENE	12	12	1.5
NCT000037373	NCT00003737_3_T1	GENE	5	5	IV
NCT000037373	NCT00003737_3_T2	COMPOUND	3	3	rebeccamycin
NCT000037374	NCT00003737_4_T0	PHENOTYPE	18	18	toxicity
NCT000037374	NCT00003737_4_T1	PHENOTYPE	14	15	disease progression
NCT000037375	NCT00003737_5_T0	GENE	11	11	1.5
NCT000037390	NCT00003739_0_T0	GENE	5	5	G-CSF
NCT000037390	NCT00003739_0_T1	PHENOTYPE	12	12	Fever
NCT000037390	NCT00003739_0_T2	PHENOTYPE	10	10	Neutropenia
NCT000037392	NCT00003739_2_T0	PHENOTYPE	17	17	peripheral
NCT000037392	NCT00003739_2_T1	GENE	4	4	G-CSF
NCT000037392	NCT00003739_2_T2	CELL	11	11	cells
NCT000037392	NCT00003739_2_T3	ORGAN	14	15	bone marrow
NCT000037392	NCT00003739_2_T4	ORGAN	24	25	immune system
NCT000037392	NCT00003739_2_T5	PHENOTYPE	30	32	effects of chemotherapy
NCT000037393	NCT00003739_3_T0	GENE	9	9	G-CSF
NCT000037394	NCT00003739_4_T0	GENE	3	3	III
NCT000037394	NCT00003739_4_T1	PHENOTYPE	23	23	fever
NCT000037394	NCT00003739_4_T2	PHENOTYPE	21	21	neutropenia
NCT000037394	NCT00003739_4_T3	GENE	15	15	G-CSF
NCT000037398	NCT00003739_8_T0	GENE	3	3	filgrastim
NCT000037398	NCT00003739_8_T1	GENE	4	4	G-CSF
NCT000037398	NCT00003739_8_T2	GENE	7	7	IV
NCT000037398	NCT00003739_8_T3	CELL	22	22	neutrophil
NCT000037408	NCT00003740_8_T0	GENE	4	4	IV
NCT000037409	NCT00003740_9_T0	PHENOTYPE	13	13	toxicity
NCT000037409	NCT00003740_9_T1	PHENOTYPE	15	16	disease progression
NCT0000374010	NCT00003740_10_T0	PHENOTYPE	6	6	progression
NCT000037414	NCT00003741_4_T0	GENE	5	5	IV
NCT000037417	NCT00003741_7_T0	GENE	2	2	3.4
NCT000037417	NCT00003741_7_T1	GENE	16	16	MTD
NCT000037418	NCT00003741_8_T0	PHENOTYPE	17	17	toxicity
NCT000037418	NCT00003741_8_T1	GENE	1	1	MTD
NCT000037420	NCT00003742_0_T0	PHENOTYPE	10	11	Solid Tumors
NCT000037422	NCT00003742_2_T0	CELL	9	9	cells
NCT000037422	NCT00003742_2_T1	PHENOTYPE	8	8	tumor
NCT000037423	NCT00003742_3_T0	PHENOTYPE	19	20	solid tumors
NCT000037425	NCT00003742_5_T0	COMPOUND	6	6	paclitaxel
NCT000037425	NCT00003742_5_T1	COMPOUND	12	12	irinotecan
NCT000037425	NCT00003742_5_T2	COMPOUND	10	10	cisplatin
NCT000037425	NCT00003742_5_T3	PHENOTYPE	20	21	solid tumors
NCT000037427	NCT00003742_7_T0	PHENOTYPE	4	4	toxicity
NCT000037427	NCT00003742_7_T1	COMPOUND	6	6	paclitaxel
NCT000037427	NCT00003742_7_T2	COMPOUND	12	12	irinotecan
NCT000037427	NCT00003742_7_T3	COMPOUND	10	10	cisplatin
NCT000037429	NCT00003742_9_T0	GENE	4	4	II
NCT0000374211	NCT00003742_11_T0	PHENOTYPE	11	11	malignancies
NCT0000374211	NCT00003742_11_T1	PHENOTYPE	9	10	solid tumor
NCT0000374212	NCT00003742_12_T0	COMPOUND	8	8	paclitaxel
NCT0000374213	NCT00003742_13_T0	COMPOUND	3	3	paclitaxel
NCT0000374213	NCT00003742_13_T1	COMPOUND	16	16	irinotecan
NCT0000374213	NCT00003742_13_T2	COMPOUND	9	9	cisplatin
NCT0000374213	NCT00003742_13_T3	GENE	4	4	IV
NCT0000374213	NCT00003742_13_T4	GENE	10	10	IV
NCT0000374213	NCT00003742_13_T5	GENE	17	17	IV
NCT0000374214	NCT00003742_14_T0	PHENOTYPE	19	19	toxicity
NCT0000374214	NCT00003742_14_T1	PHENOTYPE	15	16	disease progression
NCT0000374215	NCT00003742_15_T0	COMPOUND	8	8	paclitaxel
NCT0000374216	NCT00003742_16_T0	PHENOTYPE	8	8	toxicity
NCT0000374216	NCT00003742_16_T1	GENE	22	22	MTD
NCT0000374216	NCT00003742_16_T2	GENE	9	9	DLT
NCT0000374312	NCT00003743_12_T0	GENE	0	0	IL-2
NCT0000374313	NCT00003743_13_T0	GENE	11	11	IL-2
NCT0000374313	NCT00003743_13_T1	GENE	17	17	MTD
NCT0000374314	NCT00003743_14_T0	PHENOTYPE	16	16	toxicity
NCT0000374314	NCT00003743_14_T1	GENE	1	1	MTD
NCT0000374315	NCT00003743_15_T0	GENE	1	1	II
NCT0000374315	NCT00003743_15_T1	GENE	5	5	IL-2
NCT0000374315	NCT00003743_15_T2	GENE	12	12	MTD
NCT0000374316	NCT00003743_16_T0	COMPOUND	21	21	busulfan
NCT0000374316	NCT00003743_16_T1	COMPOUND	8	8	melphalan
NCT0000374316	NCT00003743_16_T2	COMPOUND	19	19	melphalan
NCT000037441	NCT00003744_1_T0	GENE	13	13	has
NCT000037441	NCT00003744_1_T1	PHENOTYPE	17	19	salivary gland cancer
NCT000037442	NCT00003744_2_T0	GENE	1	1	has
NCT000037442	NCT00003744_2_T1	PHENOTYPE	25	26	ovarian cancer
NCT000037442	NCT00003744_2_T2	PHENOTYPE	18	19	breast cancer
NCT000037442	NCT00003744_2_T3	PHENOTYPE	23	24	lung cancer
NCT000037442	NCT00003744_2_T4	PHENOTYPE	16	17	bladder cancer
NCT000037442	NCT00003744_2_T5	PHENOTYPE	28	29	pancreas cancer
NCT000037446	NCT00003744_6_T0	COMPOUND	2	2	gemcitabine
NCT000037446	NCT00003744_6_T1	GENE	3	3	IV
NCT000037448	NCT00003744_8_T0	PHENOTYPE	12	12	toxicity
NCT000037448	NCT00003744_8_T1	PHENOTYPE	8	9	disease progression
NCT000037451	NCT00003745_1_T0	CELL	10	10	cells
NCT000037451	NCT00003745_1_T1	PHENOTYPE	9	9	tumor
NCT000037453	NCT00003745_3_T0	PHENOTYPE	12	12	sarcomas
NCT000037453	NCT00003745_3_T1	PHENOTYPE	7	7	recurrent
NCT000037453	NCT00003745_3_T2	PHENOTYPE	14	14	neuroblastomas
NCT000037453	NCT00003745_3_T3	COMPOUND	17	17	topotecan
NCT000037453	NCT00003745_3_T4	PHENOTYPE	10	11	brain tumors
NCT000037455	NCT00003745_5_T0	PHENOTYPE	2	2	toxicity
NCT000037457	NCT00003745_7_T0	GENE	3	3	IV
NCT000037457	NCT00003745_7_T1	COMPOUND	2	2	topotecan
NCT000037458	NCT00003745_8_T0	PHENOTYPE	12	12	toxicity
NCT000037458	NCT00003745_8_T1	PHENOTYPE	14	15	disease progression
NCT000037466	NCT00003746_6_T0	PHENOTYPE	23	23	relapse
NCT000037466	NCT00003746_6_T1	PHENOTYPE	5	5	remission
NCT000037466	NCT00003746_6_T2	PHENOTYPE	25	26	disease progression
NCT000037471	NCT00003747_1_T0	CELL	9	9	cells
NCT000037471	NCT00003747_1_T1	PHENOTYPE	8	8	tumor
NCT000037472	NCT00003747_2_T0	COMPOUND	12	12	temozolomide
NCT000037472	NCT00003747_2_T1	PHENOTYPE	20	21	metastatic melanoma
NCT000037474	NCT00003747_4_T0	COMPOUND	8	8	temozolomide
NCT000037474	NCT00003747_4_T1	PHENOTYPE	14	15	metastatic melanoma
NCT0000374710	NCT00003747_10_T0	COMPOUND	3	3	temozolomide
NCT0000374710	NCT00003747_10_T1	GENE	8	8	1.5
NCT0000374711	NCT00003747_11_T0	GENE	1	1	IV
NCT0000374713	NCT00003747_13_T0	PHENOTYPE	12	12	toxicity
NCT0000374713	NCT00003747_13_T1	PHENOTYPE	14	15	disease progression
NCT0000374714	NCT00003747_14_T0	COMPOUND	10	10	temozolomide
NCT0000374714	NCT00003747_14_T1	COMPOUND	25	25	temozolomide
NCT0000374715	NCT00003747_15_T0	GENE	14	14	MTD
NCT0000374716	NCT00003747_16_T0	PHENOTYPE	22	22	toxic
NCT0000374716	NCT00003747_16_T1	GENE	1	1	MTD
NCT0000374717	NCT00003747_17_T0	COMPOUND	11	11	temozolomide
NCT0000374717	NCT00003747_17_T1	COMPOUND	30	30	temozolomide
NCT0000374717	NCT00003747_17_T2	PHENOTYPE	15	15	toxic
NCT000037481	NCT00003748_1_T0	GENE	2	2	II
NCT000037481	NCT00003748_1_T1	COMPOUND	9	9	irinotecan
NCT000037481	NCT00003748_1_T2	PHENOTYPE	17	18	stomach cancer
NCT000037485	NCT00003748_5_T0	COMPOUND	5	5	irinotecan
NCT000037485	NCT00003748_5_T1	ORGAN	15	15	cardia
NCT000037485	NCT00003748_5_T2	PHENOTYPE	9	12	adenocarcinoma of the esophagus
NCT000037487	NCT00003748_7_T0	PHENOTYPE	2	2	toxicities
NCT000037489	NCT00003748_9_T0	COMPOUND	2	2	irinotecan
NCT000037489	NCT00003748_9_T1	GENE	4	4	IV
NCT0000374810	NCT00003748_10_T0	PHENOTYPE	7	7	toxicity
NCT0000374810	NCT00003748_10_T1	PHENOTYPE	9	10	disease progression
NCT000037491	NCT00003749_1_T0	CELL	8	8	cells
NCT000037491	NCT00003749_1_T1	PHENOTYPE	7	7	tumor
NCT000037492	NCT00003749_2_T0	PHENOTYPE	20	21	endometrial cancer
NCT000037493	NCT00003749_3_T0	GENE	3	3	III
NCT000037493	NCT00003749_3_T1	PHENOTYPE	24	25	endometrial cancer
NCT000037499	NCT00003749_9_T0	PHENOTYPE	0	2	Quality of life
NCT000037500	NCT00003750_0_T0	PHENOTYPE	12	12	Tumors
NCT000037500	NCT00003750_0_T1	PHENOTYPE	8	9	Recurrent Neuroblastoma
NCT000037502	NCT00003750_2_T0	PHENOTYPE	23	23	tumors
NCT000037502	NCT00003750_2_T1	GENE	10	11	fusion protein
NCT000037502	NCT00003750_2_T2	PHENOTYPE	19	20	recurrent neuroblastoma
NCT000037505	NCT00003750_5_T0	GENE	14	14	1.3
NCT000037505	NCT00003750_5_T1	GENE	4	5	fusion protein
NCT000037505	NCT00003750_5_T2	GENE	5	6	protein IV
NCT000037506	NCT00003750_6_T0	PHENOTYPE	18	18	toxicity
NCT000037506	NCT00003750_6_T1	PHENOTYPE	14	15	disease progression
NCT000037507	NCT00003750_7_T0	GENE	16	16	MTD
NCT000037507	NCT00003750_7_T1	GENE	9	10	fusion protein
NCT000037508	NCT00003750_8_T0	PHENOTYPE	23	23	toxicity
NCT000037508	NCT00003750_8_T1	GENE	1	1	MTD
NCT000037510	NCT00003751_0_T0	PHENOTYPE	11	11	Glioblastoma
NCT000037510	NCT00003751_0_T1	PHENOTYPE	1	2	Low Copper
NCT000037513	NCT00003751_3_T0	CELL	8	8	cells
NCT000037513	NCT00003751_3_T1	PHENOTYPE	7	7	tumor
NCT000037514	NCT00003751_4_T0	PHENOTYPE	8	8	glioblastoma
NCT000037515	NCT00003751_5_T0	GENE	2	2	II
NCT000037515	NCT00003751_5_T1	PHENOTYPE	24	24	glioblastoma
NCT000037515	NCT00003751_5_T2	COMPOUND	9	9	penicillamine
NCT000037515	NCT00003751_5_T3	PHENOTYPE	11	12	low copper
NCT000037517	NCT00003751_7_T0	PHENOTYPE	19	19	glioblastoma
NCT000037517	NCT00003751_7_T1	COMPOUND	4	4	penicillamine
NCT000037517	NCT00003751_7_T2	PHENOTYPE	13	13	progression
NCT000037517	NCT00003751_7_T3	COMPOUND	6	6	copper
NCT000037519	NCT00003751_9_T0	COMPOUND	4	4	penicillamine
NCT000037519	NCT00003751_9_T1	COMPOUND	10	10	copper
NCT000037519	NCT00003751_9_T2	ORGAN	9	9	serum
NCT0000375111	NCT00003751_11_T0	PHENOTYPE	10	10	edema
NCT0000375111	NCT00003751_11_T1	PHENOTYPE	5	5	tumor
NCT0000375111	NCT00003751_11_T2	COMPOUND	2	2	penicillamine
NCT0000375112	NCT00003751_12_T0	COMPOUND	10	10	1
NCT0000375112	NCT00003751_12_T1	COMPOUND	14	14	2
NCT0000375112	NCT00003751_12_T2	COMPOUND	19	19	3
NCT0000375112	NCT00003751_12_T3	COMPOUND	4	4	penicillamine
NCT0000375113	NCT00003751_13_T0	COMPOUND	4	4	pyridoxine
NCT0000375113	NCT00003751_13_T1	GENE	15	15	0.5
NCT0000375113	NCT00003751_13_T2	PHENOTYPE	9	10	low copper
NCT0000375114	NCT00003751_14_T0	PHENOTYPE	17	17	toxicity
NCT0000375114	NCT00003751_14_T1	PHENOTYPE	13	14	disease progression
NCT0000375115	NCT00003751_15_T0	COMPOUND	11	11	penicillamine
NCT0000375116	NCT00003751_16_T0	GENE	6	6	MRI
NCT000037521	NCT00003752_1_T0	GENE	3	3	II
NCT000037521	NCT00003752_1_T1	COMPOUND	10	10	bexarotene
NCT000037521	NCT00003752_1_T2	PHENOTYPE	16	18	metastatic breast cancer
NCT000037523	NCT00003752_3_T0	COMPOUND	5	5	bexarotene
NCT000037523	NCT00003752_3_T1	PHENOTYPE	16	17	breast cancer
NCT000037529	NCT00003752_9_T0	PHENOTYPE	8	9	metastatic disease
NCT0000375211	NCT00003752_11_T0	COMPOUND	4	4	bexarotene
NCT0000375212	NCT00003752_12_T0	PHENOTYPE	10	10	toxicity
NCT0000375212	NCT00003752_12_T1	PHENOTYPE	6	7	disease progression
NCT000037531	NCT00003753_1_T0	ORGAN	12	12	liver
NCT000037532	NCT00003753_2_T0	CELL	15	15	cells
NCT000037532	NCT00003753_2_T1	PHENOTYPE	14	14	tumor
NCT000037533	NCT00003753_3_T0	GENE	2	2	II
NCT000037533	NCT00003753_3_T1	COMPOUND	18	18	dexamethasone
NCT000037533	NCT00003753_3_T2	COMPOUND	9	9	irinotecan
NCT000037533	NCT00003753_3_T3	PHENOTYPE	29	30	colorectal cancer
NCT000037533	NCT00003753_3_T4	PHENOTYPE	26	27	liver metastases
NCT000037536	NCT00003753_6_T0	COMPOUND	9	9	irinotecan
NCT000037537	NCT00003753_7_T0	ORGAN	9	9	abdomen
NCT000037538	NCT00003753_8_T0	COMPOUND	7	7	irinotecan
NCT000037538	NCT00003753_8_T1	GENE	8	8	IV
NCT000037539	NCT00003753_9_T0	COMPOUND	5	5	dexamethasone
NCT0000375310	NCT00003753_10_T0	PHENOTYPE	13	13	toxicity
NCT0000375310	NCT00003753_10_T1	PHENOTYPE	15	16	disease progression
NCT0000375311	NCT00003753_11_T0	COMPOUND	4	4	irinotecan
NCT0000375312	NCT00003753_12_T0	COMPOUND	8	8	irinotecan
NCT0000375313	NCT00003753_13_T0	PHENOTYPE	20	20	toxicity
NCT0000375313	NCT00003753_13_T1	GENE	3	3	II
NCT0000375313	NCT00003753_13_T2	GENE	1	1	MTD
NCT0000375314	NCT00003753_14_T0	GENE	1	1	The
NCT0000375314	NCT00003753_14_T1	COMPOUND	4	4	irinotecan
NCT0000375314	NCT00003753_14_T2	GENE	34	34	2.4
NCT0000375314	NCT00003753_14_T3	PHENOTYPE	15	15	closed
NCT0000375315	NCT00003753_15_T0	PHENOTYPE	23	23	closed
NCT0000375316	NCT00003753_16_T0	GENE	15	15	II
NCT000037541	NCT00003754_1_T0	CELL	10	10	cells
NCT000037541	NCT00003754_1_T1	PHENOTYPE	9	9	tumor
NCT000037542	NCT00003754_2_T0	CELL	8	8	cells
NCT000037542	NCT00003754_2_T1	COMPOUND	1	1	thalidomide
NCT000037542	NCT00003754_2_T2	PHENOTYPE	7	7	tumor
NCT000037543	NCT00003754_3_T0	GENE	2	2	II
NCT000037543	NCT00003754_3_T1	COMPOUND	10	10	thalidomide
NCT000037543	NCT00003754_3_T2	PHENOTYPE	22	22	cancers
NCT000037543	NCT00003754_3_T3	COMPOUND	12	12	cyclophosphamide
NCT000037543	NCT00003754_3_T4	PHENOTYPE	18	18	recurrent
NCT000037545	NCT00003754_5_T0	PHENOTYPE	4	4	toxic
NCT000037545	NCT00003754_5_T1	COMPOUND	7	7	thalidomide
NCT000037545	NCT00003754_5_T2	PHENOTYPE	17	17	malignancies
NCT000037545	NCT00003754_5_T3	COMPOUND	9	9	cyclophosphamide
NCT000037545	NCT00003754_5_T4	PHENOTYPE	13	13	recurrent
NCT000037546	NCT00003754_6_T0	COMPOUND	4	4	thalidomide
NCT000037547	NCT00003754_7_T0	COMPOUND	17	17	thalidomide
NCT000037547	NCT00003754_7_T1	GENE	3	3	IV
NCT000037548	NCT00003754_8_T0	PHENOTYPE	7	7	toxicity
NCT000037548	NCT00003754_8_T1	PHENOTYPE	9	10	disease progression
NCT000037549	NCT00003754_9_T0	PHENOTYPE	0	0	Tumor
NCT000037550	NCT00003755_0_T0	PHENOTYPE	10	11	Solid Tumor
NCT000037552	NCT00003755_2_T0	PHENOTYPE	20	21	solid tumor
NCT000037554	NCT00003755_4_T0	PHENOTYPE	11	12	solid tumors
NCT000037556	NCT00003755_6_T0	PHENOTYPE	2	2	toxicity
NCT000037558	NCT00003755_8_T0	PHENOTYPE	2	2	pharmacokinetics
NCT0000375516	NCT00003755_16_T0	GENE	3	3	DLT
NCT0000375518	NCT00003755_18_T0	GENE	14	14	DLT
NCT0000375519	NCT00003755_19_T0	GENE	6	6	DLT
NCT0000375520	NCT00003755_20_T0	PHENOTYPE	16	16	toxicity
NCT0000375520	NCT00003755_20_T1	PHENOTYPE	12	13	disease progression
NCT0000375521	NCT00003755_21_T0	PHENOTYPE	11	12	disease progression
NCT000037574	NCT00003757_4_T0	GENE	3	3	IV
NCT000037581	NCT00003758_1_T0	CELL	9	9	cells
NCT000037582	NCT00003758_2_T0	GENE	2	2	II
NCT000037582	NCT00003758_2_T1	COMPOUND	13	13	cytarabine
NCT000037582	NCT00003758_2_T2	COMPOUND	15	15	idarubicin
NCT000037582	NCT00003758_2_T3	PHENOTYPE	22	24	acute myelogenous leukemia
NCT000037584	NCT00003758_4_T0	COMPOUND	8	8	cytarabine
NCT000037584	NCT00003758_4_T1	COMPOUND	15	15	cytarabine
NCT000037584	NCT00003758_4_T2	COMPOUND	10	10	idarubicin
NCT000037584	NCT00003758_4_T3	PHENOTYPE	20	22	acute myelogenous leukemia
NCT000037586	NCT00003758_6_T0	COMPOUND	4	4	cytarabine
NCT000037586	NCT00003758_6_T1	COMPOUND	29	29	cytarabine
NCT000037586	NCT00003758_6_T2	GENE	14	14	1.5
NCT000037586	NCT00003758_6_T3	COMPOUND	15	15	idarubicin
NCT000037586	NCT00003758_6_T4	GENE	5	5	IV
NCT000037586	NCT00003758_6_T5	GENE	16	16	IV
NCT000037586	NCT00003758_6_T6	GENE	30	30	IV
NCT000037587	NCT00003758_7_T0	PHENOTYPE	4	4	remission
NCT000037588	NCT00003758_8_T0	PHENOTYPE	4	4	remission
NCT000037588	NCT00003758_8_T1	COMPOUND	18	18	idarubicin
NCT000037589	NCT00003758_9_T0	PHENOTYPE	6	6	remission
NCT0000375811	NCT00003758_11_T0	ORGAN	11	11	transplant
NCT0000375811	NCT00003758_11_T1	ORGAN	15	16	autologous transplant
NCT000037591	NCT00003759_1_T0	CELL	16	16	cells
NCT000037591	NCT00003759_1_T1	GENE	4	4	BCG
NCT000037591	NCT00003759_1_T2	ORGAN	11	12	immune system
NCT000037592	NCT00003759_2_T0	GENE	6	6	AD
NCT000037592	NCT00003759_2_T1	GENE	14	14	BCG
NCT000037592	NCT00003759_2_T2	PHENOTYPE	18	20	superficial bladder cancer
NCT000037593	NCT00003759_3_T0	GENE	3	3	II
NCT000037593	NCT00003759_3_T1	GENE	10	10	AD
NCT000037593	NCT00003759_3_T2	GENE	15	15	BCG
NCT000037593	NCT00003759_3_T3	PHENOTYPE	26	26	recurrent
NCT000037593	NCT00003759_3_T4	PHENOTYPE	27	29	superficial bladder cancer
NCT000037596	NCT00003759_6_T0	PHENOTYPE	8	9	bladder tumors
NCT000037597	NCT00003759_7_T0	GENE	0	0	AD
NCT000037597	NCT00003759_7_T1	ORGAN	8	8	bladder
NCT000037598	NCT00003759_8_T0	GENE	4	4	AD
NCT000037598	NCT00003759_8_T1	ORGAN	8	8	bladder
NCT000037601	NCT00003760_1_T0	GENE	2	2	II
NCT000037601	NCT00003760_1_T1	COMPOUND	9	9	irofulven
NCT000037601	NCT00003760_1_T2	PHENOTYPE	15	16	stage III
NCT000037601	NCT00003760_1_T3	PHENOTYPE	18	21	stage IV pancreatic cancer
NCT000037603	NCT00003760_3_T0	PHENOTYPE	14	14	toxicity
NCT000037603	NCT00003760_3_T1	PHENOTYPE	10	11	disease progression
NCT000037605	NCT00003760_5_T0	GENE	13	13	IV
NCT000037605	NCT00003760_5_T1	GENE	22	22	MGI
NCT000037605	NCT00003760_5_T2	PHENOTYPE	10	11	stage III
NCT000037605	NCT00003760_5_T3	PHENOTYPE	15	18	adenocarcinoma of the pancreas
NCT000037607	NCT00003760_7_T0	PHENOTYPE	3	3	tumor
NCT000037607	NCT00003760_7_T1	PHENOTYPE	9	9	tumor
NCT000037607	NCT00003760_7_T2	COMPOUND	30	30	gemcitabine
NCT000037607	NCT00003760_7_T3	PHENOTYPE	25	26	tumor progression
NCT0000376013	NCT00003760_13_T0	PHENOTYPE	5	5	toxic
NCT0000376015	NCT00003760_15_T0	GENE	11	11	1.5
NCT0000376015	NCT00003760_15_T1	GENE	5	5	IV
NCT0000376015	NCT00003760_15_T2	GENE	3	3	MGI
NCT0000376016	NCT00003760_16_T0	PHENOTYPE	14	14	toxicity
NCT0000376016	NCT00003760_16_T1	PHENOTYPE	10	11	disease progression
NCT0000376017	NCT00003760_17_T0	PHENOTYPE	11	11	initiation
NCT000037615	NCT00003761_5_T0	PHENOTYPE	2	2	toxicity
NCT000037615	NCT00003761_5_T1	PHENOTYPE	9	9	vaccinia
NCT000037615	NCT00003761_5_T2	PHENOTYPE	16	18	metastatic breast cancer
NCT000037617	NCT00003761_7_T0	PHENOTYPE	12	12	immunity
NCT0000376111	NCT00003761_11_T0	PHENOTYPE	3	3	vaccinia
NCT0000376112	NCT00003761_12_T0	PHENOTYPE	15	15	toxicity
NCT0000376112	NCT00003761_12_T1	PHENOTYPE	11	12	disease progression
NCT0000376113	NCT00003761_13_T0	GENE	16	16	MTD
NCT0000376114	NCT00003761_14_T0	PHENOTYPE	18	18	toxicity
NCT0000376114	NCT00003761_14_T1	GENE	1	1	MTD
NCT0000376116	NCT00003761_16_T0	GENE	14	14	1.2
NCT0000376119	NCT00003761_19_T0	PHENOTYPE	10	11	metastatic disease
NCT0000376121	NCT00003761_21_T0	PHENOTYPE	3	3	HIV
NCT000037622	NCT00003762_2_T0	CELL	9	9	cells
NCT000037622	NCT00003762_2_T1	PHENOTYPE	8	8	tumor
NCT000037627	NCT00003762_7_T0	PHENOTYPE	2	2	toxicity
NCT000037629	NCT00003762_9_T0	PHENOTYPE	2	4	quality of life
NCT0000376213	NCT00003762_13_T0	GENE	9	9	IV
NCT0000376217	NCT00003762_17_T0	PHENOTYPE	17	17	toxicity
NCT0000376217	NCT00003762_17_T1	PHENOTYPE	19	20	disease progression
NCT0000376219	NCT00003762_19_T0	PHENOTYPE	0	2	Quality of life
NCT000037631	NCT00003763_1_T0	PHENOTYPE	15	16	ovarian cancer
NCT000037631	NCT00003763_1_T1	COMPOUND	9	10	folic acid
NCT000037633	NCT00003763_3_T0	COMPOUND	8	8	indium
NCT000037633	NCT00003763_3_T1	PHENOTYPE	13	14	ovarian cancer
NCT000037633	NCT00003763_3_T2	PHENOTYPE	17	18	metastatic disease
NCT000037633	NCT00003763_3_T3	COMPOUND	4	5	folic acid
NCT000037635	NCT00003763_5_T0	COMPOUND	9	9	indium
NCT000037635	NCT00003763_5_T1	COMPOUND	5	6	folic acid
NCT000037641	NCT00003764_1_T0	CELL	9	9	cells
NCT000037642	NCT00003764_2_T0	COMPOUND	9	9	fludarabine
NCT000037642	NCT00003764_2_T1	COMPOUND	14	14	fludarabine
NCT000037642	NCT00003764_2_T2	COMPOUND	7	7	cyclophosphamide
NCT000037642	NCT00003764_2_T3	PHENOTYPE	18	20	chronic lymphocytic leukemia
NCT000037643	NCT00003764_3_T0	GENE	3	3	III
NCT000037643	NCT00003764_3_T1	COMPOUND	10	10	fludarabine
NCT000037643	NCT00003764_3_T2	COMPOUND	14	14	cyclophosphamide
NCT000037643	NCT00003764_3_T3	GENE	24	24	has
NCT000037643	NCT00003764_3_T4	PHENOTYPE	20	22	chronic lymphocytic leukemia
NCT000037648	NCT00003764_8_T0	PHENOTYPE	18	18	toxicity
NCT000037648	NCT00003764_8_T1	PHENOTYPE	14	15	disease progression
NCT000037649	NCT00003764_9_T0	PHENOTYPE	15	16	disease progression
NCT000037651	NCT00003765_1_T0	CELL	10	10	cells
NCT000037651	NCT00003765_1_T1	PHENOTYPE	9	9	tumor
NCT000037652	NCT00003765_2_T0	CELL	9	9	cells
NCT000037652	NCT00003765_2_T1	PHENOTYPE	8	8	tumor
NCT000037654	NCT00003765_4_T0	PHENOTYPE	9	9	toxicity
NCT000037654	NCT00003765_4_T1	PHENOTYPE	21	21	tumors
NCT000037656	NCT00003765_6_T0	GENE	16	16	II
NCT000037658	NCT00003765_8_T0	PHENOTYPE	2	2	pharmacokinetics
NCT000037658	NCT00003765_8_T1	COMPOUND	8	8	O6-benzyl-8-oxoguanine
NCT0000376512	NCT00003765_12_T0	PHENOTYPE	9	9	toxicity
NCT0000376512	NCT00003765_12_T1	PHENOTYPE	2	2	acute
NCT0000376512	NCT00003765_12_T2	PHENOTYPE	5	5	toxicities
NCT0000376512	NCT00003765_12_T3	PHENOTYPE	4	4	chronic
NCT0000376514	NCT00003765_14_T0	GENE	3	3	IV
NCT0000376514	NCT00003765_14_T1	GENE	12	12	IV
NCT0000376515	NCT00003765_15_T0	PHENOTYPE	19	19	toxicity
NCT0000376515	NCT00003765_15_T1	PHENOTYPE	15	16	disease progression
NCT0000376516	NCT00003765_16_T0	GENE	15	15	MTD
NCT0000376517	NCT00003765_17_T0	PHENOTYPE	19	19	toxicity
NCT0000376517	NCT00003765_17_T1	GENE	1	1	MTD
NCT0000376517	NCT00003765_17_T2	GENE	20	20	DLT
NCT0000376518	NCT00003765_18_T0	PHENOTYPE	8	8	closed
NCT0000376518	NCT00003765_18_T1	GENE	4	4	DLT
NCT0000376519	NCT00003765_19_T0	GENE	10	10	filgrastim
NCT0000376519	NCT00003765_19_T1	PHENOTYPE	1	1	neutropenia
NCT0000376519	NCT00003765_19_T2	GENE	11	11	G-CSF
NCT0000376519	NCT00003765_19_T3	GENE	4	4	DLT
NCT000037664	NCT00003766_4_T0	PHENOTYPE	9	9	tumor
NCT000037664	NCT00003766_4_T1	PHENOTYPE	28	29	solid tumors
NCT000037666	NCT00003766_6_T0	PHENOTYPE	9	9	peripheral
NCT000037666	NCT00003766_6_T1	CELL	12	12	cells
NCT000037666	NCT00003766_6_T2	PHENOTYPE	1	1	tumor
NCT000037666	NCT00003766_6_T3	GENE	3	3	AGT
NCT000037666	NCT00003766_6_T4	GENE	6	6	AGT
NCT000037668	NCT00003766_8_T0	GENE	8	8	IV
NCT0000376611	NCT00003766_11_T0	GENE	7	7	AGT
NCT0000376612	NCT00003766_12_T0	COMPOUND	4	4	OBD
NCT0000376612	NCT00003766_12_T1	MOLECULAR_FUNCTION	21	22	AGT activity
NCT000037680	NCT00003768_0_T0	GENE	1	1	A4
NCT000037680	NCT00003768_0_T1	PHENOTYPE	8	9	Solid Tumors
NCT000037682	NCT00003768_2_T0	COMPOUND	9	9	combretastatin
NCT000037682	NCT00003768_2_T1	GENE	10	10	A4
NCT000037682	NCT00003768_2_T2	COMPOUND	11	11	phosphate
NCT000037682	NCT00003768_2_T3	PHENOTYPE	18	19	solid tumors
NCT000037684	NCT00003768_4_T0	COMPOUND	6	6	combretastatin
NCT000037684	NCT00003768_4_T1	GENE	7	7	A4
NCT000037684	NCT00003768_4_T2	COMPOUND	8	8	phosphate
NCT000037684	NCT00003768_4_T3	PHENOTYPE	21	22	solid tumors
NCT000037686	NCT00003768_6_T0	PHENOTYPE	3	3	toxicity
NCT000037686	NCT00003768_6_T1	PHENOTYPE	7	7	toxicity
NCT000037688	NCT00003768_8_T0	COMPOUND	7	7	combretastatin
NCT000037688	NCT00003768_8_T1	COMPOUND	10	10	combretastatin
NCT000037688	NCT00003768_8_T2	GENE	8	8	A4
NCT000037688	NCT00003768_8_T3	GENE	11	11	A4
NCT000037688	NCT00003768_8_T4	PHENOTYPE	5	5	pharmacokinetics
NCT000037688	NCT00003768_8_T5	COMPOUND	12	12	phosphate
NCT000037688	NCT00003768_8_T6	ORGAN	2	2	plasma
NCT0000376810	NCT00003768_10_T0	PHENOTYPE	11	12	measurable disease
NCT0000376812	NCT00003768_12_T0	COMPOUND	2	2	combretastatin
NCT0000376812	NCT00003768_12_T1	GENE	3	3	A4
NCT0000376812	NCT00003768_12_T2	COMPOUND	4	4	phosphate
NCT0000376812	NCT00003768_12_T3	GENE	5	5	IV
NCT0000376813	NCT00003768_13_T0	PHENOTYPE	10	10	toxicity
NCT0000376813	NCT00003768_13_T1	PHENOTYPE	12	13	disease progression
NCT0000376814	NCT00003768_14_T0	COMPOUND	8	8	combretastatin
NCT0000376814	NCT00003768_14_T1	GENE	9	9	A4
NCT0000376814	NCT00003768_14_T2	COMPOUND	10	10	phosphate
NCT0000376814	NCT00003768_14_T3	GENE	16	16	MTD
NCT0000376815	NCT00003768_15_T0	PHENOTYPE	22	22	toxicity
NCT0000376815	NCT00003768_15_T1	GENE	1	1	MTD
NCT000037692	NCT00003769_2_T0	GENE	2	2	II
NCT000037692	NCT00003769_2_T1	GENE	20	20	II
NCT000037692	NCT00003769_2_T2	COMPOUND	9	10	perillyl alcohol
NCT000037692	NCT00003769_2_T3	PHENOTYPE	22	25	stage III pancreatic cancer
NCT000037694	NCT00003769_4_T0	GENE	13	13	II
NCT000037694	NCT00003769_4_T1	PHENOTYPE	17	18	pancreatic adenocarcinoma
NCT000037694	NCT00003769_4_T2	PHENOTYPE	15	16	stage III
NCT000037694	NCT00003769_4_T3	COMPOUND	5	6	perillyl alcohol
NCT000037696	NCT00003769_6_T0	PHENOTYPE	3	3	toxicity
NCT000037696	NCT00003769_6_T1	PHENOTYPE	2	2	acute
NCT0000376910	NCT00003769_10_T0	ORGAN	4	4	plasma
NCT0000376910	NCT00003769_10_T1	COMPOUND	7	8	perillyl alcohol
NCT0000376911	NCT00003769_11_T0	COMPOUND	4	5	perillyl alcohol
NCT0000376913	NCT00003769_13_T0	COMPOUND	5	6	perillyl alcohol
NCT000037711	NCT00003771_1_T0	GENE	6	6	hormone
NCT000037711	NCT00003771_1_T1	PHENOTYPE	13	14	breast cancer
NCT000037711	NCT00003771_1_T2	PHENOTYPE	14	15	cancer recurrence
NCT000037711	NCT00003771_1_T3	PHENOTYPE	22	24	stage breast cancer
NCT000037715	NCT00003771_5_T0	COMPOUND	13	13	tamoxifen
NCT000037715	NCT00003771_5_T1	GENE	6	6	hormone
NCT0000377111	NCT00003771_11_T0	PHENOTYPE	0	2	Quality of life
NCT0000377113	NCT00003771_13_T0	PHENOTYPE	0	1	Breast cancer
NCT000037721	NCT00003772_1_T0	PHENOTYPE	12	13	ovarian cancer
NCT000037721	NCT00003772_1_T1	PHENOTYPE	6	8	quality of life
NCT000037723	NCT00003772_3_T0	PHENOTYPE	8	9	ovarian cancer
NCT000037723	NCT00003772_3_T1	PHENOTYPE	31	33	ovarian epithelial cancer
NCT000037725	NCT00003772_5_T0	PHENOTYPE	20	21	ovarian cancer
NCT0000377211	NCT00003772_11_T0	GENE	30	31	Group 1
NCT0000377211	NCT00003772_11_T1	PHENOTYPE	19	21	quality of life
NCT0000377212	NCT00003772_12_T0	COMPOUND	1	1	2
NCT0000377213	NCT00003772_13_T0	COMPOUND	1	1	3
NCT0000377213	NCT00003772_13_T1	COMPOUND	18	18	3
NCT0000377214	NCT00003772_14_T0	GENE	29	29	OR
NCT0000377214	NCT00003772_14_T1	GENE	40	40	OR
NCT000037731	NCT00003773_1_T0	PHENOTYPE	15	17	recurrent ovarian cancer
NCT000037733	NCT00003773_3_T0	PHENOTYPE	12	14	recurrent ovarian cancer
NCT000037735	NCT00003773_5_T0	PHENOTYPE	2	2	toxicity
NCT0000377312	NCT00003773_12_T0	PHENOTYPE	10	10	toxicity
NCT0000377312	NCT00003773_12_T1	PHENOTYPE	12	13	disease progression
NCT0000377314	NCT00003773_14_T0	GENE	16	16	MTD
NCT0000377315	NCT00003773_15_T0	PHENOTYPE	22	22	toxicity
NCT0000377315	NCT00003773_15_T1	GENE	1	1	MTD
NCT000037751	NCT00003775_1_T0	GENE	2	2	II
NCT000037751	NCT00003775_1_T1	COMPOUND	9	9	leflunomide
NCT000037751	NCT00003775_1_T2	PHENOTYPE	19	19	relapse
NCT000037751	NCT00003775_1_T3	PHENOTYPE	15	16	anaplastic astrocytoma
NCT000037753	NCT00003775_3_T0	COMPOUND	25	25	leflunomide
NCT000037753	NCT00003775_3_T1	PHENOTYPE	21	21	relapse
NCT000037753	NCT00003775_3_T2	PHENOTYPE	5	5	progression
NCT000037753	NCT00003775_3_T3	PHENOTYPE	17	18	anaplastic oligoastrocytoma
NCT000037753	NCT00003775_3_T4	PHENOTYPE	14	15	anaplastic astrocytoma
NCT000037757	NCT00003775_7_T0	PHENOTYPE	3	5	quality of life
NCT000037759	NCT00003775_9_T0	COMPOUND	2	2	leflunomide
NCT000037759	NCT00003775_9_T1	GENE	10	10	1.4
NCT000037759	NCT00003775_9_T2	GENE	4	4	IV
NCT0000377510	NCT00003775_10_T0	GENE	4	4	IV
NCT0000377511	NCT00003775_11_T0	PHENOTYPE	24	24	toxicity
NCT0000377511	NCT00003775_11_T1	PHENOTYPE	20	21	disease progression
NCT0000377512	NCT00003775_12_T0	GENE	5	5	IV
NCT0000377513	NCT00003775_13_T0	PHENOTYPE	0	2	Quality of life
NCT0000377514	NCT00003775_14_T0	PHENOTYPE	8	9	tumor progression
NCT000037760	NCT00003776_0_T0	PHENOTYPE	10	11	Metastatic Osteosarcoma
NCT000037762	NCT00003776_2_T0	CELL	14	14	cells
NCT000037762	NCT00003776_2_T1	PHENOTYPE	13	13	tumor
NCT000037763	NCT00003776_3_T0	GENE	2	2	II
NCT000037763	NCT00003776_3_T1	PHENOTYPE	20	21	metastatic osteosarcoma
NCT000037765	NCT00003776_5_T0	COMPOUND	10	10	calcium
NCT000037765	NCT00003776_5_T1	COMPOUND	9	9	leucovorin
NCT000037765	NCT00003776_5_T2	COMPOUND	5	6	trimetrexate glucuronate
NCT000037765	NCT00003776_5_T3	PHENOTYPE	17	19	metastatic osteogenic sarcoma
NCT000037767	NCT00003776_7_T0	PHENOTYPE	2	2	toxicity
NCT000037767	NCT00003776_7_T1	PHENOTYPE	17	18	osteogenic sarcoma
NCT000037769	NCT00003776_9_T0	PHENOTYPE	10	10	tumor
NCT0000377610	NCT00003776_10_T0	GENE	20	20	0.2
NCT0000377610	NCT00003776_10_T1	COMPOUND	12	12	calcium
NCT0000377610	NCT00003776_10_T2	COMPOUND	11	11	leucovorin
NCT0000377610	NCT00003776_10_T3	COMPOUND	7	8	trimetrexate glucuronate
NCT0000377611	NCT00003776_11_T0	COMPOUND	3	3	calcium
NCT0000377611	NCT00003776_11_T1	COMPOUND	2	2	leucovorin
NCT0000377612	NCT00003776_12_T0	COMPOUND	13	13	calcium
NCT0000377612	NCT00003776_12_T1	COMPOUND	12	12	leucovorin
NCT0000377612	NCT00003776_12_T2	GENE	10	10	IV
NCT0000377612	NCT00003776_12_T3	GENE	14	14	IV
NCT0000377613	NCT00003776_13_T0	GENE	4	4	7-10
NCT0000377614	NCT00003776_14_T0	PHENOTYPE	4	5	metastatic disease
NCT0000377615	NCT00003776_15_T0	COMPOUND	18	18	ifosfamide
NCT0000377615	NCT00003776_15_T1	COMPOUND	45	45	ifosfamide
NCT0000377615	NCT00003776_15_T2	GENE	37	37	1.2
NCT0000377615	NCT00003776_15_T3	GENE	28	28	1.4
NCT0000377615	NCT00003776_15_T4	COMPOUND	30	30	doxorubicin
NCT0000377615	NCT00003776_15_T5	GENE	19	19	IV
NCT0000377615	NCT00003776_15_T6	GENE	31	31	IV
NCT0000377616	NCT00003776_16_T0	COMPOUND	11	11	doxorubicin
NCT0000377616	NCT00003776_16_T1	COMPOUND	2	2	cisplatin
NCT0000377616	NCT00003776_16_T2	COMPOUND	29	29	cisplatin
NCT0000377616	NCT00003776_16_T3	GENE	3	3	IV
NCT0000377616	NCT00003776_16_T4	GENE	12	12	IV
NCT0000377617	NCT00003776_17_T0	COMPOUND	2	2	cisplatin
NCT0000377618	NCT00003776_18_T0	COMPOUND	18	18	ifosfamide
NCT0000377618	NCT00003776_18_T1	GENE	2	2	filgrastim
NCT0000377618	NCT00003776_18_T2	COMPOUND	20	20	cisplatin
NCT0000377619	NCT00003776_19_T0	COMPOUND	13	13	calcium
NCT0000377619	NCT00003776_19_T1	COMPOUND	2	2	methotrexate
NCT0000377619	NCT00003776_19_T2	COMPOUND	30	30	methotrexate
NCT0000377619	NCT00003776_19_T3	COMPOUND	12	12	leucovorin
NCT0000377619	NCT00003776_19_T4	GENE	3	3	IV
NCT0000377620	NCT00003776_20_T0	COMPOUND	6	6	calcium
NCT0000377620	NCT00003776_20_T1	COMPOUND	5	5	leucovorin
NCT0000377620	NCT00003776_20_T2	GENE	7	7	IV
NCT0000377623	NCT00003776_23_T0	GENE	14	14	2.3
NCT000037770	NCT00003777_0_T0	PHENOTYPE	10	14	Recurrent Head and Neck Cancer
NCT000037772	NCT00003777_2_T0	CELL	8	8	cells
NCT000037772	NCT00003777_2_T1	PHENOTYPE	7	7	tumor
NCT000037773	NCT00003777_3_T0	COMPOUND	3	3	amifostine
NCT000037773	NCT00003777_3_T1	PHENOTYPE	8	11	effects of radiation therapy
NCT000037774	NCT00003777_4_T0	CELL	17	17	cells
NCT000037774	NCT00003777_4_T1	PHENOTYPE	16	16	tumor
NCT000037775	NCT00003777_5_T0	GENE	2	2	II
NCT000037775	NCT00003777_5_T1	GENE	27	27	has
NCT000037775	NCT00003777_5_T2	PHENOTYPE	21	25	recurrent head and neck cancer
NCT000037779	NCT00003777_9_T0	GENE	6	6	1.3
NCT000037779	NCT00003777_9_T1	COMPOUND	1	1	cisplatin
NCT0000377710	NCT00003777_10_T0	COMPOUND	1	1	amifostine
NCT0000377710	NCT00003777_10_T1	COMPOUND	10	10	cisplatin
NCT0000377711	NCT00003777_11_T0	GENE	7	7	1.4
NCT0000377711	NCT00003777_11_T1	GENE	3	3	IV
NCT000037781	NCT00003778_1_T0	CELL	10	10	cells
NCT000037781	NCT00003778_1_T1	PHENOTYPE	9	9	tumor
NCT000037783	NCT00003778_3_T0	PHENOTYPE	7	7	recurrent
NCT000037783	NCT00003778_3_T1	COMPOUND	15	16	dolastatin 10
NCT000037783	NCT00003778_3_T2	PHENOTYPE	10	12	soft tissue sarcomas
NCT000037785	NCT00003778_5_T0	PHENOTYPE	2	2	toxicity
NCT000037787	NCT00003778_7_T0	PHENOTYPE	20	20	recurrent
NCT000037788	NCT00003778_8_T0	GENE	4	4	IV
NCT000037788	NCT00003778_8_T1	COMPOUND	2	3	dolastatin 10
NCT000037789	NCT00003778_9_T0	PHENOTYPE	13	13	toxicity
NCT000037789	NCT00003778_9_T1	PHENOTYPE	9	10	disease progression
NCT000037791	NCT00003779_1_T0	GENE	8	8	BCG
NCT000037791	NCT00003779_1_T1	PHENOTYPE	13	14	bladder cancer
NCT000037792	NCT00003779_2_T0	GENE	14	14	BCG
NCT000037792	NCT00003779_2_T1	GENE	3	3	III
NCT000037792	NCT00003779_2_T2	PHENOTYPE	20	21	bladder cancer
NCT000037794	NCT00003779_4_T0	PHENOTYPE	13	13	relapse
NCT000037794	NCT00003779_4_T1	GENE	4	4	BCG
NCT000037794	NCT00003779_4_T2	PHENOTYPE	2	2	strains
NCT000037794	NCT00003779_4_T3	ORGAN	35	36	urinary bladder
NCT000037794	NCT00003779_4_T4	PHENOTYPE	23	24	papillary carcinoma
NCT000037794	NCT00003779_4_T5	PHENOTYPE	30	34	carcinoma in situ of the
NCT000037794	NCT00003779_4_T6	PHENOTYPE	24	28	carcinoma of the urinary bladder
NCT000037796	NCT00003779_6_T0	GENE	10	10	BCG
NCT000037798	NCT00003779_8_T0	GENE	11	11	BCG
NCT000037798	NCT00003779_8_T1	PHENOTYPE	4	4	fever
NCT0000377912	NCT00003779_12_T0	PHENOTYPE	10	10	progression
NCT0000377914	NCT00003779_14_T0	PHENOTYPE	1	3	quality of life
NCT0000377917	NCT00003779_17_T0	PHENOTYPE	9	10	bladder tumors
NCT0000377919	NCT00003779_19_T0	GENE	10	10	2.4
NCT0000377922	NCT00003779_22_T0	GENE	4	4	BCG
NCT0000377922	NCT00003779_22_T1	ORGAN	7	7	bladder
NCT0000377923	NCT00003779_23_T0	GENE	0	0	BCG
NCT0000377924	NCT00003779_24_T0	PHENOTYPE	0	2	Quality of life
NCT000037801	NCT00003780_1_T0	CELL	13	13	cells
NCT000037801	NCT00003780_1_T1	ORGAN	8	9	immune system
NCT000037802	NCT00003780_2_T0	PHENOTYPE	17	20	cancer of the pancreas
NCT000037803	NCT00003780_3_T0	GENE	3	3	II
NCT000037803	NCT00003780_3_T1	COMPOUND	10	10	gemcitabine
NCT000037803	NCT00003780_3_T2	PHENOTYPE	19	22	cancer of the pancreas
NCT000037805	NCT00003780_5_T0	PHENOTYPE	9	9	peripheral
NCT000037805	NCT00003780_5_T1	CELL	12	12	cells
NCT000037805	NCT00003780_5_T2	COMPOUND	22	22	gemcitabine
NCT000037805	NCT00003780_5_T3	CELL	19	19	lymphocyte
NCT000037805	NCT00003780_5_T4	PHENOTYPE	30	32	metastatic pancreatic cancer
NCT000037807	NCT00003780_7_T0	PHENOTYPE	8	8	tumor
NCT000037807	NCT00003780_7_T1	PHENOTYPE	4	4	progression
NCT000037807	NCT00003780_7_T2	PHENOTYPE	15	17	quality of life
NCT000037809	NCT00003780_9_T0	PHENOTYPE	4	4	toxicities
NCT000037809	NCT00003780_9_T1	COMPOUND	8	8	gemcitabine
NCT0000378013	NCT00003780_13_T0	COMPOUND	6	6	gemcitabine
NCT0000378013	NCT00003780_13_T1	GENE	7	7	IV
NCT0000378014	NCT00003780_14_T0	PHENOTYPE	14	14	toxicity
NCT0000378014	NCT00003780_14_T1	PHENOTYPE	10	11	disease progression
NCT0000378016	NCT00003780_16_T0	CELL	1	1	lymphocytes
NCT0000378016	NCT00003780_16_T1	CELL	6	6	lymphocytes
NCT0000378017	NCT00003780_17_T0	PHENOTYPE	6	6	tumor
NCT0000378018	NCT00003780_18_T0	CELL	12	12	lymphocytes
NCT0000378019	NCT00003780_19_T0	PHENOTYPE	12	14	quality of life
NCT000037817	NCT00003781_7_T0	PHENOTYPE	7	9	quality of life
NCT000037819	NCT00003781_9_T0	PHENOTYPE	4	4	toxicities
NCT0000378110	NCT00003781_10_T0	COMPOUND	3	3	docetaxel
NCT0000378110	NCT00003781_10_T1	GENE	4	4	IV
NCT0000378112	NCT00003781_12_T0	PHENOTYPE	10	10	toxicity
NCT0000378112	NCT00003781_12_T1	PHENOTYPE	6	7	disease progression
NCT0000378114	NCT00003781_14_T0	PHENOTYPE	10	10	toxicity
NCT000037820	NCT00003782_0_T0	GENE	9	9	II
NCT000037820	NCT00003782_0_T1	TISSUE	21	22	Lymph Nodes
NCT000037820	NCT00003782_0_T2	PHENOTYPE	16	17	Breast Cancer
NCT000037822	NCT00003782_2_T0	CELL	9	9	cells
NCT000037822	NCT00003782_2_T1	PHENOTYPE	8	8	tumor
NCT000037823	NCT00003782_3_T0	TISSUE	20	21	lymph nodes
NCT000037823	NCT00003782_3_T1	PHENOTYPE	15	16	breast cancer
NCT000037824	NCT00003782_4_T0	GENE	26	26	II
NCT000037824	NCT00003782_4_T1	GENE	3	3	III
NCT000037824	NCT00003782_4_T2	TISSUE	35	36	lymph nodes
NCT000037824	NCT00003782_4_T3	PHENOTYPE	28	31	stage IIIA breast cancer
NCT000037828	NCT00003782_8_T0	GENE	11	11	1.3
NCT000037828	NCT00003782_8_T1	COMPOUND	21	21	anastrozole
NCT000037828	NCT00003782_8_T2	COMPOUND	19	19	tamoxifen
NCT000037828	NCT00003782_8_T3	GENE	17	17	10
NCT0000378214	NCT00003782_14_T0	PHENOTYPE	0	2	Quality of life
NCT0000378215	NCT00003782_15_T0	PHENOTYPE	4	4	closed
NCT0000378215	NCT00003782_15_T1	PHENOTYPE	0	2	Quality of life
NCT0000378216	NCT00003782_16_T0	GENE	14	14	4.5
NCT000037831	NCT00003783_1_T0	CELL	15	15	cells
NCT000037832	NCT00003783_2_T0	GENE	2	2	II
NCT000037832	NCT00003783_2_T1	PHENOTYPE	18	20	acute lymphocytic leukemia
NCT000037834	NCT00003783_4_T0	PHENOTYPE	20	22	acute lymphocytic leukemia
NCT000037836	NCT00003783_6_T0	PHENOTYPE	2	2	tolerance
NCT000037836	NCT00003783_6_T1	PHENOTYPE	5	6	in remission
NCT000037837	NCT00003783_7_T0	GENE	7	7	1.4
NCT000037838	NCT00003783_8_T0	GENE	20	20	22
NCT000037838	NCT00003783_8_T1	GENE	28	28	22
NCT000037838	NCT00003783_8_T2	COMPOUND	12	12	vincristine
NCT000037838	NCT00003783_8_T3	GENE	11	11	1.28
NCT000037838	NCT00003783_8_T4	GENE	31	31	IM
NCT000037838	NCT00003783_8_T5	GENE	30	30	asparaginase
NCT000037838	NCT00003783_8_T6	COMPOUND	4	4	prednisone
NCT000037838	NCT00003783_8_T7	GENE	13	13	IV
NCT000037838	NCT00003783_8_T8	GENE	22	22	IV
NCT000037838	NCT00003783_8_T9	COMPOUND	21	21	daunorubicin
NCT000037839	NCT00003783_9_T0	COMPOUND	3	3	methotrexate
NCT000037839	NCT00003783_9_T1	GENE	5	5	IT
NCT0000378310	NCT00003783_10_T0	COMPOUND	9	9	methotrexate
NCT0000378310	NCT00003783_10_T1	GENE	10	10	IT
NCT0000378311	NCT00003783_11_T0	COMPOUND	19	19	vincristine
NCT0000378311	NCT00003783_11_T1	GENE	31	31	36
NCT0000378311	NCT00003783_11_T2	GENE	39	39	36
NCT0000378311	NCT00003783_11_T3	GENE	34	34	IM
NCT0000378311	NCT00003783_11_T4	GENE	3	3	M2
NCT0000378311	NCT00003783_11_T5	GENE	33	33	asparaginase
NCT0000378311	NCT00003783_11_T6	GENE	20	20	IV
NCT0000378311	NCT00003783_11_T7	GENE	23	23	IV
NCT0000378311	NCT00003783_11_T8	COMPOUND	22	22	daunorubicin
NCT0000378311	NCT00003783_11_T9	COMPOUND	11	11	prednisone
NCT0000378311	NCT00003783_11_T10	ORGAN	4	5	bone marrow
NCT0000378312	NCT00003783_12_T0	GENE	9	9	M2
NCT0000378312	NCT00003783_12_T1	GENE	4	4	M3
NCT0000378312	NCT00003783_12_T2	GENE	11	11	M3
NCT0000378312	NCT00003783_12_T3	ORGAN	1	2	bone marrow
NCT0000378314	NCT00003783_14_T0	COMPOUND	37	37	cytarabine
NCT0000378314	NCT00003783_14_T1	COMPOUND	20	20	calcium
NCT0000378314	NCT00003783_14_T2	COMPOUND	44	44	idarubicin
NCT0000378314	NCT00003783_14_T3	GENE	53	53	filgrastim
NCT0000378314	NCT00003783_14_T4	COMPOUND	5	5	methotrexate
NCT0000378314	NCT00003783_14_T5	GENE	54	54	G-CSF
NCT0000378314	NCT00003783_14_T6	COMPOUND	19	19	leucovorin
NCT0000378314	NCT00003783_14_T7	GENE	6	6	IV
NCT0000378314	NCT00003783_14_T8	GENE	21	21	IV
NCT0000378314	NCT00003783_14_T9	GENE	38	38	IV
NCT0000378314	NCT00003783_14_T10	GENE	45	45	IV
NCT0000378315	NCT00003783_15_T0	COMPOUND	9	9	cyclophosphamide
NCT0000378315	NCT00003783_15_T1	COMPOUND	2	2	etoposide
NCT0000378315	NCT00003783_15_T2	GENE	18	18	G-CSF
NCT0000378315	NCT00003783_15_T3	GENE	3	3	IV
NCT0000378315	NCT00003783_15_T4	GENE	10	10	IV
NCT0000378316	NCT00003783_16_T0	GENE	1	1	IT
NCT0000378318	NCT00003783_18_T0	COMPOUND	14	14	dexamethasone
NCT0000378318	NCT00003783_18_T1	COMPOUND	2	2	vincristine
NCT0000378318	NCT00003783_18_T2	GENE	20	20	1.7
NCT0000378318	NCT00003783_18_T3	COMPOUND	7	7	methotrexate
NCT0000378318	NCT00003783_18_T4	GENE	8	8	IT
NCT0000378318	NCT00003783_18_T5	GENE	3	3	IV
NCT0000378318	NCT00003783_18_T6	GENE	5	5	IV
NCT0000378318	NCT00003783_18_T7	COMPOUND	4	4	daunorubicin
NCT0000378319	NCT00003783_19_T0	COMPOUND	5	5	cytarabine
NCT0000378319	NCT00003783_19_T1	COMPOUND	27	27	cytarabine
NCT0000378319	NCT00003783_19_T2	GENE	19	19	IM
NCT0000378319	NCT00003783_19_T3	GENE	18	18	asparaginase
NCT0000378319	NCT00003783_19_T4	GENE	6	6	IV
NCT0000378320	NCT00003783_20_T0	GENE	4	4	IM
NCT0000378320	NCT00003783_20_T1	COMPOUND	3	3	methotrexate
NCT0000378321	NCT00003783_21_T0	GENE	5	5	1.2
NCT0000378321	NCT00003783_21_T1	COMPOUND	9	9	cyclophosphamide
NCT0000378321	NCT00003783_21_T2	COMPOUND	2	2	etoposide
NCT0000378321	NCT00003783_21_T3	GENE	3	3	IV
NCT0000378321	NCT00003783_21_T4	GENE	10	10	IV
NCT0000378323	NCT00003783_23_T0	COMPOUND	3	3	cyclophosphamide
NCT0000378323	NCT00003783_23_T1	GENE	1	1	IV
NCT0000378323	NCT00003783_23_T2	GENE	4	4	IV
NCT0000378324	NCT00003783_24_T0	COMPOUND	4	4	dexamethasone
NCT0000378324	NCT00003783_24_T1	COMPOUND	23	23	cytarabine
NCT0000378324	NCT00003783_24_T2	GENE	24	24	IV
NCT0000378325	NCT00003783_25_T0	GENE	18	18	IM
NCT0000378325	NCT00003783_25_T1	COMPOUND	17	17	methotrexate
NCT0000378326	NCT00003783_26_T0	GENE	1	1	IT
NCT0000378328	NCT00003783_28_T0	COMPOUND	6	6	methotrexate
NCT0000378328	NCT00003783_28_T1	GENE	7	7	IT
NCT000037841	NCT00003784_1_T0	CELL	9	9	cells
NCT000037843	NCT00003784_3_T0	GENE	2	2	II
NCT000037843	NCT00003784_3_T1	PHENOTYPE	24	25	Hodgkin's lymphoma
NCT000037849	NCT00003784_9_T0	PHENOTYPE	2	2	toxicity
NCT0000378411	NCT00003784_11_T0	PHENOTYPE	13	13	peripheral
NCT0000378411	NCT00003784_11_T1	CELL	6	6	cells
NCT0000378411	NCT00003784_11_T2	ORGAN	16	17	bone marrow
NCT0000378412	NCT00003784_12_T0	COMPOUND	11	11	vincristine
NCT0000378412	NCT00003784_12_T1	GENE	21	21	1.5
NCT0000378412	NCT00003784_12_T2	COMPOUND	3	3	cyclophosphamide
NCT0000378412	NCT00003784_12_T3	COMPOUND	8	8	doxorubicin
NCT0000378412	NCT00003784_12_T4	COMPOUND	18	18	prednisone
NCT0000378412	NCT00003784_12_T5	GENE	4	4	IV
NCT0000378412	NCT00003784_12_T6	GENE	9	9	IV
NCT0000378412	NCT00003784_12_T7	GENE	12	12	IV
NCT0000378414	NCT00003784_14_T0	GENE	1	1	4-8
NCT0000378414	NCT00003784_14_T1	ORGAN	22	23	bone marrow
NCT000037861	NCT00003786_1_T0	GENE	2	2	II
NCT000037861	NCT00003786_1_T1	COMPOUND	9	9	irofulven
NCT000037861	NCT00003786_1_T2	PHENOTYPE	16	18	recurrent colorectal cancer
NCT000037863	NCT00003786_3_T0	ORGAN	17	17	rectum
NCT000037863	NCT00003786_3_T1	PHENOTYPE	11	11	recurrent
NCT000037863	NCT00003786_3_T2	PHENOTYPE	12	15	adenocarcinoma of the colon
NCT000037865	NCT00003786_5_T0	PHENOTYPE	2	2	toxicity
NCT000037867	NCT00003786_7_T0	PHENOTYPE	1	1	pharmacokinetics
NCT000037869	NCT00003786_9_T0	PHENOTYPE	11	11	toxicity
NCT000037869	NCT00003786_9_T1	PHENOTYPE	4	4	pharmacokinetics
NCT0000378611	NCT00003786_11_T0	GENE	4	4	IV
NCT0000378613	NCT00003786_13_T0	PHENOTYPE	13	13	toxic
NCT0000378613	NCT00003786_13_T1	PHENOTYPE	16	17	disease progression
NCT000037870	NCT00003787_0_T0	BIOLOGICAL_PROCESS	2	2	Eating
NCT000037872	NCT00003787_2_T0	GENE	31	31	II
NCT000037872	NCT00003787_2_T1	PHENOTYPE	33	36	stage III breast cancer
NCT000037874	NCT00003787_4_T0	PHENOTYPE	19	20	breast cancer
NCT000037874	NCT00003787_4_T1	PHENOTYPE	24	25	breast cancer
NCT000037876	NCT00003787_6_T0	PHENOTYPE	5	6	breast cancer
NCT0000378710	NCT00003787_10_T0	COMPOUND	22	22	estrogen
NCT0000378710	NCT00003787_10_T1	PHENOTYPE	19	19	concentrations
NCT0000378710	NCT00003787_10_T2	PHENOTYPE	23	23	concentrations
NCT0000378710	NCT00003787_10_T3	PHENOTYPE	6	7	secondary cancer
NCT0000378712	NCT00003787_12_T0	PHENOTYPE	18	18	tumor
NCT0000378712	NCT00003787_12_T1	GENE	25	25	cm
NCT000037881	NCT00003788_1_T0	PHENOTYPE	29	29	gliomas
NCT000037882	NCT00003788_2_T0	GENE	3	3	III
NCT000037882	NCT00003788_2_T1	PHENOTYPE	31	31	gliomas
NCT000037882	NCT00003788_2_T2	PHENOTYPE	28	28	recurrent
NCT000037887	NCT00003788_7_T0	PHENOTYPE	2	2	tumor
NCT0000378810	NCT00003788_10_T0	COMPOUND	5	5	nitrosourea
NCT0000378810	NCT00003788_10_T1	COMPOUND	8	8	lomustine
NCT0000378813	NCT00003788_13_T0	GENE	9	9	2.4
NCT0000378813	NCT00003788_13_T1	COMPOUND	4	4	procarbazine
NCT0000378814	NCT00003788_14_T0	PHENOTYPE	13	13	toxicity
NCT0000378814	NCT00003788_14_T1	PHENOTYPE	9	10	disease progression
NCT0000378816	NCT00003788_16_T0	PHENOTYPE	10	10	tumor
NCT000037891	NCT00003789_1_T0	CELL	10	10	cells
NCT000037891	NCT00003789_1_T1	PHENOTYPE	9	9	tumor
NCT000037892	NCT00003789_2_T0	CELL	22	22	cells
NCT000037892	NCT00003789_2_T1	COMPOUND	1	1	melphalan
NCT000037892	NCT00003789_2_T2	PHENOTYPE	17	17	tumor
NCT000037892	NCT00003789_2_T3	PHENOTYPE	21	21	tumor
NCT000037897	NCT00003789_7_T0	PHENOTYPE	8	8	symptoms
NCT000037897	NCT00003789_7_T1	PHENOTYPE	11	11	tumor
NCT000037899	NCT00003789_9_T0	PHENOTYPE	2	2	toxicity
NCT0000378911	NCT00003789_11_T0	COMPOUND	12	12	melphalan
NCT0000378911	NCT00003789_11_T1	PHENOTYPE	5	5	tumor
NCT0000378911	NCT00003789_11_T2	GENE	16	16	nodal
NCT0000378911	NCT00003789_11_T3	PHENOTYPE	11	11	reperfusion
NCT0000378913	NCT00003789_13_T0	PHENOTYPE	4	4	hyperthermic
NCT0000378913	NCT00003789_13_T1	GENE	0	0	ARM
NCT0000378913	NCT00003789_13_T2	ORGAN	9	10	lower limb
NCT0000378917	NCT00003789_17_T0	MOLECULAR_FUNCTION	0	2	Tumor necrosis factor
NCT000037905	NCT00003790_5_T0	CELL	6	6	cells
NCT000037905	NCT00003790_5_T1	GENE	13	13	polymerase
NCT000037905	NCT00003790_5_T2	GENE	9	9	MDF
NCT000037905	NCT00003790_5_T3	GENE	16	16	PCR
NCT000037907	NCT00003790_7_T0	PHENOTYPE	12	12	leukemia
NCT000037907	NCT00003790_7_T1	CELL	9	9	cells
NCT000037907	NCT00003790_7_T2	GENE	17	17	PCR
NCT0000379012	NCT00003790_12_T0	ORGAN	8	8	transplant
NCT0000379012	NCT00003790_12_T1	ORGAN	6	7	bone marrow
NCT0000379013	NCT00003790_13_T0	GENE	3	3	interleukin-2
NCT0000379013	NCT00003790_13_T1	GENE	4	4	IL-2
NCT0000379014	NCT00003790_14_T0	PHENOTYPE	10	10	engraftment
NCT0000379014	NCT00003790_14_T1	GENE	27	27	IL-2
NCT0000379014	NCT00003790_14_T2	GENE	31	31	IL-2
NCT0000379014	NCT00003790_14_T3	ORGAN	6	6	transplant
NCT0000379014	NCT00003790_14_T4	ORGAN	15	15	transplant
NCT0000379014	NCT00003790_14_T5	ORGAN	13	14	bone marrow
NCT0000379015	NCT00003790_15_T0	PHENOTYPE	1	1	relapse
NCT0000379016	NCT00003790_16_T0	GENE	16	16	PCR
NCT0000379016	NCT00003790_16_T1	ORGAN	7	8	bone marrow
NCT0000379016	NCT00003790_16_T2	PHENOTYPE	3	5	minimal residual disease
NCT000037921	NCT00003792_1_T0	PHENOTYPE	16	17	metastatic melanoma
NCT000037928	NCT00003792_8_T0	GENE	14	14	2.3
NCT000037928	NCT00003792_8_T1	GENE	9	9	1/6
NCT000037928	NCT00003792_8_T2	GENE	3	3	filgrastim
NCT000037928	NCT00003792_8_T3	GENE	4	4	G-CSF
NCT0000379210	NCT00003792_10_T0	CELL	3	4	dendritic cells
NCT000037931	NCT00003793_1_T0	PHENOTYPE	24	24	leukemia
NCT000037931	NCT00003793_1_T1	PHENOTYPE	31	31	sarcoma
NCT000037931	NCT00003793_1_T2	PHENOTYPE	14	14	rhabdomyosarcoma
NCT000037931	NCT00003793_1_T3	PHENOTYPE	10	12	soft tissue sarcoma
NCT000037941	NCT00003794_1_T0	PHENOTYPE	14	15	ovarian cancer
NCT000037941	NCT00003794_1_T1	PHENOTYPE	6	8	quality of life
NCT000037945	NCT00003794_5_T0	PHENOTYPE	1	3	quality of life
NCT000037947	NCT00003794_7_T0	PHENOTYPE	23	25	quality of life
NCT000037951	NCT00003795_1_T0	PHENOTYPE	13	14	gynecologic cancer
NCT000037951	NCT00003795_1_T1	PHENOTYPE	7	9	quality of life
NCT000037957	NCT00003795_7_T0	PHENOTYPE	8	9	endometrial cancer
NCT000037957	NCT00003795_7_T1	PHENOTYPE	14	16	stage ovarian cancer
NCT000037961	NCT00003796_1_T0	CELL	10	10	cells
NCT000037961	NCT00003796_1_T1	PHENOTYPE	9	9	tumor
NCT000037963	NCT00003796_3_T0	COMPOUND	20	20	irofulven
NCT000037963	NCT00003796_3_T1	PHENOTYPE	13	14	metastatic adenocarcinoma
NCT000037963	NCT00003796_3_T2	PHENOTYPE	14	17	adenocarcinoma of the breast
NCT000037965	NCT00003796_5_T0	PHENOTYPE	5	5	toxic
NCT000037967	NCT00003796_7_T0	PHENOTYPE	3	3	pharmacokinetics
NCT000037969	NCT00003796_9_T0	COMPOUND	2	2	irofulven
NCT000037969	NCT00003796_9_T1	GENE	3	3	IV
NCT0000379610	NCT00003796_10_T0	PHENOTYPE	13	13	toxicity
NCT0000379610	NCT00003796_10_T1	PHENOTYPE	9	10	disease progression
NCT000037972	NCT00003797_2_T0	CELL	10	10	cells
NCT000037972	NCT00003797_2_T1	PHENOTYPE	9	9	tumor
NCT000037973	NCT00003797_3_T0	GENE	2	2	II
NCT000037973	NCT00003797_3_T1	COMPOUND	9	9	gemcitabine
NCT000037973	NCT00003797_3_T2	PHENOTYPE	17	18	metastatic cancer
NCT000037973	NCT00003797_3_T3	PHENOTYPE	18	21	cancer of the pancreas
NCT000037976	NCT00003797_6_T0	GENE	11	11	1.7
NCT000037976	NCT00003797_6_T1	COMPOUND	2	2	gemcitabine
NCT000037976	NCT00003797_6_T2	GENE	3	3	IV
NCT000037977	NCT00003797_7_T0	GENE	21	21	2.8
NCT000037977	NCT00003797_7_T1	GENE	3	3	IV
NCT000037977	NCT00003797_7_T2	GENE	13	13	IV
NCT000037978	NCT00003797_8_T0	GENE	16	16	1.3
NCT000037978	NCT00003797_8_T1	GENE	27	27	1.4
NCT000037978	NCT00003797_8_T2	COMPOUND	7	7	gemcitabine
NCT000037978	NCT00003797_8_T3	GENE	8	8	IV
NCT000037978	NCT00003797_8_T4	GENE	19	19	IV
NCT000037979	NCT00003797_9_T0	PHENOTYPE	13	13	toxicity
NCT000037979	NCT00003797_9_T1	PHENOTYPE	9	10	disease progression
NCT000037981	NCT00003798_1_T0	CELL	9	9	cells
NCT000037981	NCT00003798_1_T1	PHENOTYPE	8	8	tumor
NCT000037981	NCT00003798_1_T2	COMPOUND	3	3	gadolinium
NCT000037982	NCT00003798_2_T0	COMPOUND	9	9	gadolinium
NCT000037982	NCT00003798_2_T1	PHENOTYPE	19	22	cancer of the pancreas
NCT000037984	NCT00003798_4_T0	COMPOUND	6	6	gadolinium
NCT000037984	NCT00003798_4_T1	PHENOTYPE	16	17	periampullary adenocarcinoma
NCT000037986	NCT00003798_6_T0	PHENOTYPE	2	2	toxic
NCT000037986	NCT00003798_6_T1	COMPOUND	5	5	gadolinium
NCT0000379811	NCT00003798_11_T0	COMPOUND	10	10	gadolinium
NCT0000379812	NCT00003798_12_T0	PHENOTYPE	15	15	toxicity
NCT000037991	NCT00003799_1_T0	CELL	10	10	cells
NCT000037991	NCT00003799_1_T1	PHENOTYPE	9	9	tumor
NCT000037992	NCT00003799_2_T0	CELL	8	8	cells
NCT000037992	NCT00003799_2_T1	PHENOTYPE	7	7	tumor
NCT000037994	NCT00003799_4_T0	PHENOTYPE	9	9	toxicity
NCT000037994	NCT00003799_4_T1	COMPOUND	12	12	oxaliplatin
NCT000037994	NCT00003799_4_T2	GENE	5	5	MTD
NCT000037994	NCT00003799_4_T3	GENE	10	10	DLT
NCT000037998	NCT00003799_8_T0	PHENOTYPE	10	10	recurrence
NCT0000379910	NCT00003799_10_T0	GENE	7	7	op
NCT0000379911	NCT00003799_11_T0	COMPOUND	8	8	oxaliplatin
NCT0000379912	NCT00003799_12_T0	GENE	9	9	5.5
NCT0000379912	NCT00003799_12_T1	GENE	3	3	IV
NCT0000379913	NCT00003799_13_T0	COMPOUND	3	3	oxaliplatin
NCT0000379913	NCT00003799_13_T1	GENE	4	4	IV
NCT0000379914	NCT00003799_14_T0	COMPOUND	9	9	oxaliplatin
NCT0000379914	NCT00003799_14_T1	GENE	15	15	MTD
NCT0000379915	NCT00003799_15_T0	PHENOTYPE	19	19	toxicity
NCT0000379915	NCT00003799_15_T1	GENE	1	1	MTD
NCT0000379916	NCT00003799_16_T0	GENE	6	6	MTD
NCT0000379918	NCT00003799_18_T0	PHENOTYPE	10	10	tumor
NCT0000379920	NCT00003799_20_T0	COMPOUND	10	10	calcium
NCT0000379920	NCT00003799_20_T1	GENE	16	16	1.5
NCT0000379920	NCT00003799_20_T2	COMPOUND	9	9	leucovorin
NCT0000379920	NCT00003799_20_T3	GENE	13	13	IV
NCT000038001	NCT00003800_1_T0	PHENOTYPE	8	9	recurrent disease
NCT000038001	NCT00003800_1_T1	PHENOTYPE	14	17	stage I testicular cancer
NCT000038003	NCT00003800_3_T0	TISSUE	5	6	lymph node
NCT000038005	NCT00003800_5_T0	TISSUE	5	6	lymph nodes
NCT000038008	NCT00003800_8_T0	GENE	8	8	II
NCT000038008	NCT00003800_8_T1	GENE	36	36	3.5
NCT000038009	NCT00003800_9_T0	GENE	6	6	II
NCT000038009	NCT00003800_9_T1	GENE	31	31	3.5
NCT0000380010	NCT00003800_10_T0	GENE	23	23	3.5
NCT000038011	NCT00003801_1_T0	PHENOTYPE	15	15	rhabdomyosarcoma
NCT000038012	NCT00003801_2_T0	PHENOTYPE	21	21	Rhabdomyosarcoma
NCT000038012	NCT00003801_2_T1	PHENOTYPE	17	17	rhabdomyosarcoma
NCT000038014	NCT00003801_4_T0	GENE	29	29	II
NCT000038014	NCT00003801_4_T1	PHENOTYPE	23	23	Rhabdomyosarcoma
NCT000038014	NCT00003801_4_T2	GENE	30	30	III
NCT000038014	NCT00003801_4_T3	PHENOTYPE	12	12	rhabdomyosarcoma
NCT000038014	NCT00003801_4_T4	GENE	32	32	IV
NCT000038018	NCT00003801_8_T0	PHENOTYPE	12	12	rhabdomyosarcoma
NCT000038018	NCT00003801_8_T1	PHENOTYPE	7	8	second malignancy
NCT0000380110	NCT00003801_10_T0	COMPOUND	16	16	cyclophosphamide
NCT0000380112	NCT00003801_12_T0	PHENOTYPE	13	16	head and neck cancer
NCT0000380114	NCT00003801_14_T0	COMPOUND	6	6	doxorubicin
NCT000038024	NCT00003802_4_T0	PHENOTYPE	7	8	ocular melanoma
NCT000038025	NCT00003802_5_T0	COMPOUND	2	2	pyrazoloacridine
NCT000038025	NCT00003802_5_T1	GENE	3	3	IV
NCT000038026	NCT00003802_6_T0	PHENOTYPE	13	13	toxicity
NCT000038026	NCT00003802_6_T1	PHENOTYPE	9	10	disease progression
NCT000038031	NCT00003803_1_T0	CELL	8	8	cells
NCT000038031	NCT00003803_1_T1	PHENOTYPE	7	7	tumor
NCT000038036	NCT00003803_6_T0	COMPOUND	9	9	1
NCT000038036	NCT00003803_6_T1	GENE	10	10	TNM
NCT0000380310	NCT00003803_10_T0	GENE	18	18	Gy
NCT0000380311	NCT00003803_11_T0	PHENOTYPE	0	2	Quality of life
NCT0000380312	NCT00003803_12_T0	GENE	6	6	6/7
NCT000038040	NCT00003804_0_T0	PHENOTYPE	14	14	Tumor
NCT000038042	NCT00003804_2_T0	PHENOTYPE	16	16	tumor
NCT000038043	NCT00003804_3_T0	PHENOTYPE	27	27	tumor
NCT000038043	NCT00003804_3_T1	GENE	3	3	III
NCT000038045	NCT00003804_5_T0	PHENOTYPE	44	44	tumor
NCT000038047	NCT00003804_7_T0	GENE	6	6	reduced
NCT000038049	NCT00003804_9_T0	COMPOUND	10	10	vincristine
NCT000038049	NCT00003804_9_T1	GENE	6	6	1.3
NCT000038049	NCT00003804_9_T2	GENE	3	3	IV
NCT000038049	NCT00003804_9_T3	GENE	11	11	IV
NCT0000380411	NCT00003804_11_T0	COMPOUND	4	4	vincristine
NCT0000380411	NCT00003804_11_T1	GENE	5	5	IV
NCT0000380411	NCT00003804_11_T2	GENE	15	15	IV
NCT000038052	NCT00003805_2_T0	PHENOTYPE	22	22	leukemia
NCT000038052	NCT00003805_2_T1	PHENOTYPE	23	23	lymphoma
NCT000038052	NCT00003805_2_T2	GENE	3	3	III
NCT000038052	NCT00003805_2_T3	PHENOTYPE	17	17	fever
NCT000038052	NCT00003805_2_T4	COMPOUND	14	14	vancomycin
NCT000038052	NCT00003805_2_T5	COMPOUND	10	10	piperacillin_tazobactam
NCT000038052	NCT00003805_2_T6	PHENOTYPE	25	26	Hodgkin's disease
NCT000038054	NCT00003805_4_T0	COMPOUND	6	6	tazobactam
NCT000038054	NCT00003805_4_T1	COMPOUND	10	10	vancomycin
NCT000038054	NCT00003805_4_T2	PHENOTYPE	13	13	fever
NCT000038054	NCT00003805_4_T3	COMPOUND	4	4	piperacillin
NCT000038054	NCT00003805_4_T4	PHENOTYPE	22	22	granulocytopenia
NCT000038054	NCT00003805_4_T5	PHENOTYPE	21	21	febrile
NCT000038054	NCT00003805_4_T6	PHENOTYPE	17	18	hematological malignancies
NCT000038056	NCT00003805_6_T0	COMPOUND	2	2	piperacillin_tazobactam
NCT000038056	NCT00003805_6_T1	GENE	3	3	IV
NCT000038057	NCT00003805_7_T0	COMPOUND	13	13	piperacillin_tazobactam
NCT000038058	NCT00003805_8_T0	PHENOTYPE	18	18	fever
NCT000038059	NCT00003805_9_T0	COMPOUND	19	19	vancomycin
NCT000038059	NCT00003805_9_T1	PHENOTYPE	4	4	febrile
NCT000038059	NCT00003805_9_T2	COMPOUND	15	15	piperacillin_tazobactam
NCT0000380510	NCT00003805_10_T0	GENE	1	1	IV
NCT0000380511	NCT00003805_11_T0	PHENOTYPE	12	13	persistent fever
NCT0000380512	NCT00003805_12_T0	GENE	4	4	7-10
NCT000038081	NCT00003808_1_T0	GENE	2	2	II
NCT000038081	NCT00003808_1_T1	COMPOUND	9	9	theophylline
NCT000038081	NCT00003808_1_T2	PHENOTYPE	20	24	stage II chronic lymphocytic leukemia
NCT000038083	NCT00003808_3_T0	GENE	12	12	II
NCT000038083	NCT00003808_3_T1	COMPOUND	19	19	theophylline
NCT000038083	NCT00003808_3_T2	PHENOTYPE	8	9	stage 0
NCT000038083	NCT00003808_3_T3	PHENOTYPE	13	16	B-cell chronic lymphocytic leukemia
NCT000038085	NCT00003808_5_T0	PHENOTYPE	2	2	toxicity
NCT000038086	NCT00003808_6_T0	COMPOUND	4	4	theophylline
NCT000038087	NCT00003808_7_T0	PHENOTYPE	17	17	toxicity
NCT000038087	NCT00003808_7_T1	PHENOTYPE	13	14	disease progression
NCT000038090	NCT00003809_0_T0	PHENOTYPE	13	17	Recurrent Head and Neck Cancer
NCT000038093	NCT00003809_3_T0	COMPOUND	6	6	cisplatin
NCT000038093	NCT00003809_3_T1	COMPOUND	15	15	cisplatin
NCT000038093	NCT00003809_3_T2	PHENOTYPE	20	24	recurrent head and neck cancer
NCT000038094	NCT00003809_4_T0	GENE	4	4	III
NCT000038094	NCT00003809_4_T1	COMPOUND	11	11	cisplatin
NCT000038094	NCT00003809_4_T2	PHENOTYPE	24	28	recurrent head and neck cancer
NCT0000380910	NCT00003809_10_T0	ORGAN	4	4	serum
NCT0000380910	NCT00003809_10_T1	COMPOUND	9	9	C225
NCT0000380910	NCT00003809_10_T2	PHENOTYPE	15	16	antibody response
NCT0000380912	NCT00003809_12_T0	PHENOTYPE	10	10	recurrent
NCT0000380915	NCT00003809_15_T0	COMPOUND	2	2	C225
NCT0000380918	NCT00003809_18_T0	PHENOTYPE	18	18	toxicity
NCT0000380918	NCT00003809_18_T1	PHENOTYPE	14	15	disease progression
NCT0000380920	NCT00003809_20_T0	PHENOTYPE	14	15	disease progression
NCT000038101	NCT00003810_1_T0	CELL	9	9	cells
NCT000038101	NCT00003810_1_T1	PHENOTYPE	8	8	tumor
NCT000038102	NCT00003810_2_T0	GENE	2	2	II
NCT000038102	NCT00003810_2_T1	COMPOUND	12	12	docetaxel
NCT000038102	NCT00003810_2_T2	COMPOUND	10	10	gemcitabine
NCT000038102	NCT00003810_2_T3	PHENOTYPE	21	22	metastatic cancer
NCT000038102	NCT00003810_2_T4	PHENOTYPE	22	25	cancer of the pancreas
NCT000038104	NCT00003810_4_T0	COMPOUND	15	15	docetaxel
NCT000038104	NCT00003810_4_T1	COMPOUND	13	13	gemcitabine
NCT000038104	NCT00003810_4_T2	PHENOTYPE	8	9	pancreatic adenocarcinoma
NCT000038106	NCT00003810_6_T0	PHENOTYPE	2	2	toxicity
NCT000038109	NCT00003810_9_T0	COMPOUND	3	3	docetaxel
NCT000038109	NCT00003810_9_T1	COMPOUND	10	10	gemcitabine
NCT000038109	NCT00003810_9_T2	GENE	4	4	IV
NCT000038109	NCT00003810_9_T3	GENE	11	11	IV
NCT0000381011	NCT00003810_11_T0	PHENOTYPE	9	9	toxicity
NCT0000381011	NCT00003810_11_T1	PHENOTYPE	11	12	disease progression
NCT000038110	NCT00003811_0_T0	PHENOTYPE	9	11	Germ Cell Tumors
NCT000038112	NCT00003811_2_T0	CELL	8	8	cells
NCT000038112	NCT00003811_2_T1	COMPOUND	4	4	amifostine
NCT000038112	NCT00003811_2_T2	PHENOTYPE	12	14	effects of chemotherapy
NCT0000381111	NCT00003811_11_T0	COMPOUND	3	3	bleomycin
NCT0000381111	NCT00003811_11_T1	GENE	30	30	1.5
NCT0000381111	NCT00003811_11_T2	COMPOUND	12	12	etoposide
NCT0000381111	NCT00003811_11_T3	COMPOUND	17	17	amifostine
NCT0000381111	NCT00003811_11_T4	COMPOUND	23	23	cisplatin
NCT0000381111	NCT00003811_11_T5	GENE	4	4	IV
NCT0000381111	NCT00003811_11_T6	GENE	13	13	IV
NCT0000381111	NCT00003811_11_T7	GENE	18	18	IV
NCT0000381111	NCT00003811_11_T8	GENE	24	24	IV
NCT0000381112	NCT00003811_12_T0	PHENOTYPE	13	13	toxicity
NCT0000381112	NCT00003811_12_T1	GENE	3	3	3.4
NCT0000381112	NCT00003811_12_T2	PHENOTYPE	15	16	disease progression
NCT0000381114	NCT00003811_14_T0	PHENOTYPE	3	4	residual disease
NCT0000381115	NCT00003811_15_T0	PHENOTYPE	7	7	tumor
NCT0000381116	NCT00003811_16_T0	PHENOTYPE	5	5	tumor
NCT000038122	NCT00003812_2_T0	CELL	8	8	cells
NCT000038122	NCT00003812_2_T1	PHENOTYPE	7	7	tumor
NCT000038128	NCT00003812_8_T0	PHENOTYPE	2	2	toxic
NCT0000381210	NCT00003812_10_T0	PHENOTYPE	4	4	relapse
NCT0000381210	NCT00003812_10_T1	PHENOTYPE	10	10	relapse
NCT0000381213	NCT00003812_13_T0	COMPOUND	9	9	paclitaxel
NCT0000381213	NCT00003812_13_T1	GENE	7	7	1.5
NCT0000381213	NCT00003812_13_T2	GENE	4	4	IV
NCT0000381213	NCT00003812_13_T3	GENE	10	10	IV
NCT0000381213	NCT00003812_13_T4	COMPOUND	3	3	topotecan
NCT0000381214	NCT00003812_14_T0	GENE	1	1	G-CSF
NCT0000381217	NCT00003812_17_T0	COMPOUND	17	17	etoposide
NCT0000381217	NCT00003812_17_T1	GENE	10	10	IV
NCT0000381217	NCT00003812_17_T2	GENE	18	18	IV
NCT000038141	NCT00003814_1_T0	PHENOTYPE	16	17	bladder cancer
NCT000038142	NCT00003814_2_T0	GENE	3	3	III
NCT000038142	NCT00003814_2_T1	PHENOTYPE	19	21	recurrent bladder cancer
NCT000038146	NCT00003814_6_T0	PHENOTYPE	4	4	severity
NCT000038146	NCT00003814_6_T1	PHENOTYPE	6	6	toxicities
NCT000038148	NCT00003814_8_T0	PHENOTYPE	22	22	multifocal
NCT000038148	NCT00003814_8_T1	GENE	17	17	G1
NCT000038148	NCT00003814_8_T2	GENE	19	19	G2
NCT000038148	NCT00003814_8_T3	PHENOTYPE	10	10	recurrent
NCT0000381410	NCT00003814_10_T0	PHENOTYPE	13	13	toxicity
NCT0000381410	NCT00003814_10_T1	PHENOTYPE	9	10	disease progression
NCT000038151	NCT00003815_1_T0	CELL	8	8	cells
NCT000038152	NCT00003815_2_T0	CELL	17	17	cells
NCT000038152	NCT00003815_2_T1	ORGAN	0	1	Bone marrow
NCT000038153	NCT00003815_3_T0	GENE	3	3	III
NCT000038153	NCT00003815_3_T1	PHENOTYPE	24	25	Hodgkin's lymphoma
NCT000038153	NCT00003815_3_T2	ORGAN	15	16	bone marrow
NCT000038157	NCT00003815_7_T0	CELL	7	8	stem cells
NCT000038157	NCT00003815_7_T1	ORGAN	5	6	bone marrow
NCT000038158	NCT00003815_8_T0	GENE	6	6	CHOP
NCT000038161	NCT00003816_1_T0	CELL	12	13	stem cells
NCT000038161	NCT00003816_1_T1	ORGAN	6	7	immune system
NCT000038162	NCT00003816_2_T0	CELL	30	30	platelets
NCT000038162	NCT00003816_2_T1	CELL	3	4	stem cells
NCT000038162	NCT00003816_2_T2	CELL	21	22	stem cells
NCT000038162	NCT00003816_2_T3	ORGAN	18	19	bone marrow
NCT000038162	NCT00003816_2_T4	CELL	23	25	red blood cells
NCT000038162	NCT00003816_2_T5	CELL	26	28	white blood cells
NCT000038166	NCT00003816_6_T0	PHENOTYPE	8	8	relapse
NCT000038166	NCT00003816_6_T1	PHENOTYPE	27	27	relapse
NCT000038166	NCT00003816_6_T2	PHENOTYPE	23	23	lymphoma
NCT000038166	NCT00003816_6_T3	PHENOTYPE	15	15	remission
NCT000038166	NCT00003816_6_T4	PHENOTYPE	30	30	remission
NCT000038166	NCT00003816_6_T5	PHENOTYPE	21	21	chronic
NCT000038166	NCT00003816_6_T6	PHENOTYPE	10	11	acute leukemia
NCT000038166	NCT00003816_6_T7	PHENOTYPE	38	40	severe aplastic anemia
NCT000038166	NCT00003816_6_T8	PHENOTYPE	16	18	chronic myelogenous leukemia
NCT000038166	NCT00003816_6_T9	PHENOTYPE	33	35	untreated myelodysplastic syndromes
NCT000038169	NCT00003816_9_T0	ORGAN	9	9	transplant
NCT000038169	NCT00003816_9_T1	GENE	6	6	4-8
NCT0000381613	NCT00003816_13_T0	PHENOTYPE	18	18	lymphoma
NCT0000381613	NCT00003816_13_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000381613	NCT00003816_13_T2	PHENOTYPE	16	17	high grade
NCT000038170	NCT00003817_0_T0	ORGAN	3	3	Wrist
NCT000038170	NCT00003817_0_T1	PHENOTYPE	9	11	Nausea and Vomiting
NCT000038172	NCT00003817_2_T0	GENE	3	3	II
NCT000038172	NCT00003817_2_T1	ORGAN	13	13	wrist
NCT000038172	NCT00003817_2_T2	PHENOTYPE	17	19	nausea and vomiting
NCT000038174	NCT00003817_4_T0	PHENOTYPE	15	15	acute
NCT000038174	NCT00003817_4_T1	GENE	23	23	1.4
NCT000038174	NCT00003817_4_T2	COMPOUND	31	31	doxorubicin
NCT000038174	NCT00003817_4_T3	COMPOUND	29	29	cisplatin
NCT000038174	NCT00003817_4_T4	PHENOTYPE	16	16	nausea
NCT000038174	NCT00003817_4_T5	PHENOTYPE	22	22	nausea
NCT000038176	NCT00003817_6_T0	PHENOTYPE	9	9	acute
NCT000038176	NCT00003817_6_T1	PHENOTYPE	12	12	vomiting
NCT000038176	NCT00003817_6_T2	PHENOTYPE	16	18	quality of life
NCT0000381714	NCT00003817_14_T0	ORGAN	11	11	wrists
NCT0000381714	NCT00003817_14_T1	ORGAN	7	7	wrist
NCT0000381716	NCT00003817_16_T0	ORGAN	11	11	wrists
NCT0000381716	NCT00003817_16_T1	ORGAN	7	7	wrist
NCT0000381717	NCT00003817_17_T0	COMPOUND	20	20	doxorubicin
NCT0000381717	NCT00003817_17_T1	COMPOUND	18	18	cisplatin
NCT0000381717	NCT00003817_17_T2	PHENOTYPE	8	8	nausea
NCT0000381719	NCT00003817_19_T0	PHENOTYPE	15	15	emesis
NCT0000381719	NCT00003817_19_T1	PHENOTYPE	13	13	nausea
NCT0000381719	NCT00003817_19_T2	PHENOTYPE	25	27	quality of life
NCT0000381910	NCT00003819_10_T0	PHENOTYPE	17	18	antibody response
NCT000038202	NCT00003820_2_T0	PHENOTYPE	9	9	diseases
NCT000038202	NCT00003820_2_T1	CELL	2	2	B-cells
NCT000038202	NCT00003820_2_T2	CELL	17	17	B-cells
NCT000038202	NCT00003820_2_T3	CELL	19	19	B-cells
NCT000038202	NCT00003820_2_T4	CELL	22	22	B-cells
NCT000038203	NCT00003820_3_T0	PHENOTYPE	4	4	leukemias
NCT000038203	NCT00003820_3_T1	PHENOTYPE	3	3	lymphomas
NCT000038203	NCT00003820_3_T2	ORGAN	5	5	transplant
NCT000038203	NCT00003820_3_T3	PHENOTYPE	8	9	autoimmune disorders
NCT000038205	NCT00003820_5_T0	GENE	5	5	IV
NCT000038206	NCT00003820_6_T0	PHENOTYPE	13	13	Secondary
NCT000038207	NCT00003820_7_T0	PHENOTYPE	28	28	Secondary
NCT000038207	NCT00003820_7_T1	PHENOTYPE	11	11	intent
NCT000038211	NCT00003821_1_T0	COMPOUND	9	9	aminopterin
NCT000038211	NCT00003821_1_T1	GENE	2	2	II
NCT000038211	NCT00003821_1_T2	PHENOTYPE	17	19	recurrent endometrial cancer
NCT000038213	NCT00003821_3_T0	COMPOUND	5	5	aminopterin
NCT000038213	NCT00003821_3_T1	PHENOTYPE	10	10	recurrent
NCT000038213	NCT00003821_3_T2	PHENOTYPE	13	14	endometrial carcinoma
NCT000038215	NCT00003821_5_T0	COMPOUND	8	8	aminopterin
NCT000038215	NCT00003821_5_T1	PHENOTYPE	5	5	toxic
NCT000038217	NCT00003821_7_T0	PHENOTYPE	8	8	progression
NCT0000382110	NCT00003821_10_T0	COMPOUND	4	4	aminopterin
NCT0000382111	NCT00003821_11_T0	PHENOTYPE	15	15	toxicity
NCT0000382111	NCT00003821_11_T1	PHENOTYPE	11	12	disease progression
NCT000038220	NCT00003822_0_T0	PHENOTYPE	6	7	Solid Tumors
NCT000038222	NCT00003822_2_T0	PHENOTYPE	16	17	solid tumors
NCT000038224	NCT00003822_4_T0	PHENOTYPE	14	15	solid tumors
NCT000038226	NCT00003822_6_T0	PHENOTYPE	3	3	toxic
NCT0000382214	NCT00003822_14_T0	PHENOTYPE	13	13	toxicity
NCT0000382214	NCT00003822_14_T1	PHENOTYPE	9	10	disease progression
NCT0000382215	NCT00003822_15_T0	GENE	14	14	MTD
NCT0000382216	NCT00003822_16_T0	PHENOTYPE	18	18	toxicity
NCT0000382216	NCT00003822_16_T1	GENE	1	1	MTD
NCT000038241	NCT00003824_1_T0	COMPOUND	11	11	cephalexin
NCT000038241	NCT00003824_1_T1	COMPOUND	6	6	ciprofloxacin
NCT000038241	NCT00003824_1_T2	PHENOTYPE	24	25	bladder cancer
NCT000038241	NCT00003824_1_T3	PHENOTYPE	14	15	cancer recurrence
NCT000038242	NCT00003824_2_T0	PHENOTYPE	17	17	recurrence
NCT000038242	NCT00003824_2_T1	COMPOUND	14	14	cephalexin
NCT000038242	NCT00003824_2_T2	GENE	3	3	III
NCT000038242	NCT00003824_2_T3	COMPOUND	10	10	ciprofloxacin
NCT000038242	NCT00003824_2_T4	PHENOTYPE	27	28	bladder cancer
NCT000038246	NCT00003824_6_T0	PHENOTYPE	10	11	recurrent disease
NCT000038247	NCT00003824_7_T0	COMPOUND	10	10	cephalexin
NCT000038247	NCT00003824_7_T1	COMPOUND	7	7	ciprofloxacin
NCT000038248	NCT00003824_8_T0	COMPOUND	5	5	penicillin
NCT000038249	NCT00003824_9_T0	PHENOTYPE	7	8	bladder tumors
NCT000038251	NCT00003825_1_T0	COMPOUND	6	7	pentosan polysulfate
NCT000038252	NCT00003825_2_T0	ORGAN	33	33	abdomen
NCT000038252	NCT00003825_2_T1	GENE	3	3	III
NCT000038252	NCT00003825_2_T2	ORGAN	35	35	pelvis
NCT000038252	NCT00003825_2_T3	PHENOTYPE	21	21	diarrhea
NCT000038252	NCT00003825_2_T4	PHENOTYPE	17	17	inflammation
NCT000038252	NCT00003825_2_T5	ORGAN	20	20	rectum
NCT000038252	NCT00003825_2_T6	COMPOUND	10	11	pentosan polysulfate
NCT000038254	NCT00003825_4_T0	PHENOTYPE	11	11	sequelae
NCT000038254	NCT00003825_4_T1	ORGAN	16	16	abdomen
NCT000038254	NCT00003825_4_T2	ORGAN	18	18	pelvis
NCT000038254	NCT00003825_4_T3	ORGAN	9	10	gastrointestinal tract
NCT000038254	NCT00003825_4_T4	COMPOUND	4	5	pentosan polysulfate
NCT000038256	NCT00003825_6_T0	PHENOTYPE	2	2	toxic
NCT000038258	NCT00003825_8_T0	PHENOTYPE	7	7	symptoms
NCT000038258	NCT00003825_8_T1	PHENOTYPE	9	11	quality of life
NCT0000382514	NCT00003825_14_T0	PHENOTYPE	0	2	Quality of life
NCT000038271	NCT00003827_1_T0	CELL	9	9	cells
NCT000038272	NCT00003827_2_T0	CELL	8	8	cells
NCT000038272	NCT00003827_2_T1	COMPOUND	4	4	amifostine
NCT000038272	NCT00003827_2_T2	PHENOTYPE	12	14	effects of chemotherapy
NCT000038275	NCT00003827_5_T0	COMPOUND	11	11	cytarabine
NCT000038275	NCT00003827_5_T1	GENE	18	18	1.5
NCT000038275	NCT00003827_5_T2	GENE	6	6	IV
NCT000038275	NCT00003827_5_T3	GENE	12	12	IV
NCT000038275	NCT00003827_5_T4	COMPOUND	3	3	topotecan
NCT000038276	NCT00003827_6_T0	COMPOUND	2	2	amifostine
NCT000038276	NCT00003827_6_T1	GENE	3	3	IV
NCT000038279	NCT00003827_9_T0	GENE	14	14	1.5
NCT000038280	NCT00003828_0_T0	PHENOTYPE	8	8	Melanoma
NCT000038280	NCT00003828_0_T1	GENE	7	7	IV
NCT000038282	NCT00003828_2_T0	GENE	2	2	II
NCT000038282	NCT00003828_2_T1	COMPOUND	9	9	vinorelbine
NCT000038282	NCT00003828_2_T2	GENE	19	19	has
NCT000038282	NCT00003828_2_T3	PHENOTYPE	15	17	stage IV melanoma
NCT000038284	NCT00003828_4_T0	COMPOUND	16	16	vinorelbine
NCT000038284	NCT00003828_4_T1	PHENOTYPE	11	13	stage IV melanoma
NCT000038286	NCT00003828_6_T0	COMPOUND	8	8	vinorelbine
NCT000038286	NCT00003828_6_T1	PHENOTYPE	5	5	toxic
NCT000038287	NCT00003828_7_T0	COMPOUND	3	3	vinorelbine
NCT000038287	NCT00003828_7_T1	GENE	5	5	IV
NCT000038288	NCT00003828_8_T0	PHENOTYPE	9	9	toxicity
NCT000038288	NCT00003828_8_T1	PHENOTYPE	6	7	disease progression
NCT000038291	NCT00003829_1_T0	CELL	11	11	cells
NCT000038292	NCT00003829_2_T0	GENE	2	2	II
NCT000038292	NCT00003829_2_T1	COMPOUND	9	9	fludarabine
NCT000038292	NCT00003829_2_T2	COMPOUND	12	12	cyclophosphamide
NCT000038292	NCT00003829_2_T3	PHENOTYPE	20	22	chronic lymphocytic leukemia
NCT000038294	NCT00003829_4_T0	COMPOUND	25	25	fludarabine
NCT000038294	NCT00003829_4_T1	COMPOUND	27	27	cyclophosphamide
NCT000038294	NCT00003829_4_T2	PHENOTYPE	9	9	remissions
NCT000038294	NCT00003829_4_T3	PHENOTYPE	15	18	B-cell chronic lymphocytic leukemia
NCT000038296	NCT00003829_6_T0	PHENOTYPE	3	3	toxicity
NCT000038298	NCT00003829_8_T0	PHENOTYPE	8	8	peripheral
NCT000038298	NCT00003829_8_T1	PHENOTYPE	15	15	remission
NCT000038298	NCT00003829_8_T2	CELL	9	10	blood cells
NCT0000382910	NCT00003829_10_T0	CELL	6	6	chromosomes
NCT0000382910	NCT00003829_10_T1	GENE	1	1	FISH
NCT0000382910	NCT00003829_10_T2	PHENOTYPE	16	16	progression
NCT0000382911	NCT00003829_11_T0	COMPOUND	6	6	fludarabine
NCT0000382911	NCT00003829_11_T1	COMPOUND	8	8	cyclophosphamide
NCT0000382912	NCT00003829_12_T0	GENE	9	9	1.5
NCT0000382912	NCT00003829_12_T1	GENE	3	3	IV
NCT0000382913	NCT00003829_13_T0	GENE	3	3	IV
NCT0000382915	NCT00003829_15_T0	GENE	5	5	CCR
NCT0000382915	NCT00003829_15_T1	PHENOTYPE	4	4	remission
NCT0000382916	NCT00003829_16_T0	PHENOTYPE	3	3	remission
NCT0000382917	NCT00003829_17_T0	GENE	5	5	CCR
NCT000038301	NCT00003830_1_T0	ORGAN	26	26	armpit
NCT000038301	NCT00003830_1_T1	PHENOTYPE	29	30	breast cancer
NCT000038301	NCT00003830_1_T2	TISSUE	22	23	lymph nodes
NCT000038301	NCT00003830_1_T3	TISSUE	10	12	sentinel lymph nodes
NCT000038302	NCT00003830_2_T0	ORGAN	26	26	armpit
NCT000038302	NCT00003830_2_T1	GENE	3	3	III
NCT000038302	NCT00003830_2_T2	PHENOTYPE	32	33	breast cancer
NCT000038302	NCT00003830_2_T3	TISSUE	22	23	lymph nodes
NCT000038302	NCT00003830_2_T4	TISSUE	14	16	sentinel lymph nodes
NCT000038307	NCT00003830_7_T0	GENE	27	27	2.0
NCT000038307	NCT00003830_7_T1	PHENOTYPE	22	22	tumor
NCT000038307	NCT00003830_7_T2	GENE	28	28	cm
NCT000038307	NCT00003830_7_T3	GENE	31	31	cm
NCT000038307	NCT00003830_7_T4	GENE	36	36	cm
NCT0000383010	NCT00003830_10_T0	GENE	8	8	dye
NCT0000383010	NCT00003830_10_T1	PHENOTYPE	11	11	tumor
NCT0000383010	NCT00003830_10_T2	PHENOTYPE	14	14	cavity
NCT0000383010	NCT00003830_10_T3	GENE	23	23	gamma
NCT0000383010	NCT00003830_10_T4	COMPOUND	6	7	isosulfan blue
NCT0000383010	NCT00003830_10_T5	PHENOTYPE	17	18	hot spot
NCT0000383012	NCT00003830_12_T0	GENE	3	3	sentinel
NCT0000383012	NCT00003830_12_T1	PHENOTYPE	9	10	sentinel node
NCT0000383013	NCT00003830_13_T0	GENE	4	4	sentinel
NCT0000383015	NCT00003830_15_T0	GENE	4	4	sentinel
NCT0000383015	NCT00003830_15_T1	PHENOTYPE	11	12	sentinel node
NCT0000383015	NCT00003830_15_T2	PHENOTYPE	20	21	sentinel node
NCT0000383016	NCT00003830_16_T0	GENE	5	5	sentinel
NCT0000383016	NCT00003830_16_T1	PHENOTYPE	11	12	sentinel node
NCT0000383017	NCT00003830_17_T0	PHENOTYPE	4	4	tumor
NCT0000383018	NCT00003830_18_T0	PHENOTYPE	20	20	recurrence
NCT0000383018	NCT00003830_18_T1	GENE	9	9	1.3
NCT0000383018	NCT00003830_18_T2	PHENOTYPE	0	2	Quality of life
NCT0000383113	NCT00003831_13_T0	ORGAN	16	16	liver
NCT0000383113	NCT00003831_13_T1	ORGAN	13	13	abdomen
NCT0000383113	NCT00003831_13_T2	ORGAN	18	19	adrenal glands
NCT0000383117	NCT00003831_17_T0	PHENOTYPE	10	10	carcinoma
NCT0000383121	NCT00003831_21_T0	GENE	13	13	met
NCT0000383122	NCT00003831_22_T0	PHENOTYPE	9	9	malignancies
NCT0000383122	NCT00003831_22_T1	GENE	1	1	has
NCT0000383124	NCT00003831_24_T0	PHENOTYPE	13	13	recurrence
NCT0000383124	NCT00003831_24_T1	PHENOTYPE	16	16	malignancies
NCT0000383126	NCT00003831_26_T0	PHENOTYPE	2	2	right-sided
NCT0000383126	NCT00003831_26_T1	GENE	8	8	nodal
NCT0000383126	NCT00003831_26_T2	GENE	11	11	4R
NCT0000383129	NCT00003831_29_T0	GENE	8	8	nodal
NCT0000383129	NCT00003831_29_T1	GENE	14	14	10L
NCT0000383129	NCT00003831_29_T2	PHENOTYPE	2	2	left-sided
NCT0000383134	NCT00003831_34_T0	GENE	5	5	NOT
NCT0000383135	NCT00003831_35_T0	GENE	2	2	N2
NCT0000383135	NCT00003831_35_T1	GENE	1	1	has
NCT0000383137	NCT00003831_37_T0	GENE	4	4	T4
NCT0000383137	NCT00003831_37_T1	PHENOTYPE	5	5	tumor
NCT0000383137	NCT00003831_37_T2	GENE	1	1	has
NCT0000383137	NCT00003831_37_T3	GENE	2	2	T3
NCT0000383141	NCT00003831_41_T0	GENE	1	1	has
NCT000038325	NCT00003832_5_T0	COMPOUND	10	10	1
NCT000038325	NCT00003832_5_T1	GENE	4	4	IV
NCT000038327	NCT00003832_7_T0	PHENOTYPE	17	17	tumor
NCT000038327	NCT00003832_7_T1	PHENOTYPE	0	0	Tumor
NCT000038332	NCT00003833_2_T0	GENE	12	12	II
NCT000038332	NCT00003833_2_T1	PHENOTYPE	14	17	stage III colon cancer
NCT000038334	NCT00003833_4_T0	PHENOTYPE	4	4	tumor
NCT000038334	NCT00003833_4_T1	PHENOTYPE	20	20	localized
NCT000038334	NCT00003833_4_T2	PHENOTYPE	10	11	allelic imbalance
NCT000038341	NCT00003834_1_T0	CELL	9	9	cells
NCT000038341	NCT00003834_1_T1	PHENOTYPE	8	8	tumor
NCT000038342	NCT00003834_2_T0	GENE	2	2	II
NCT000038342	NCT00003834_2_T1	PHENOTYPE	18	19	colorectal cancer
NCT000038342	NCT00003834_2_T2	PHENOTYPE	15	16	liver metastases
NCT000038344	NCT00003834_4_T0	COMPOUND	10	10	calcium
NCT000038344	NCT00003834_4_T1	ORGAN	27	27	liver
NCT000038344	NCT00003834_4_T2	COMPOUND	6	6	oxaliplatin
NCT000038344	NCT00003834_4_T3	COMPOUND	9	9	leucovorin
NCT000038344	NCT00003834_4_T4	PHENOTYPE	22	23	colorectal carcinoma
NCT000038346	NCT00003834_6_T0	PHENOTYPE	8	8	toxicity
NCT000038347	NCT00003834_7_T0	COMPOUND	13	13	calcium
NCT000038347	NCT00003834_7_T1	COMPOUND	3	3	oxaliplatin
NCT000038347	NCT00003834_7_T2	COMPOUND	12	12	leucovorin
NCT000038347	NCT00003834_7_T3	GENE	4	4	IV
NCT000038347	NCT00003834_7_T4	GENE	14	14	IV
NCT000038347	NCT00003834_7_T5	GENE	20	20	IV
NCT000038347	NCT00003834_7_T6	GENE	25	25	IV
NCT000038349	NCT00003834_9_T0	PHENOTYPE	14	14	toxicity
NCT000038349	NCT00003834_9_T1	PHENOTYPE	10	11	disease progression
NCT0000383412	NCT00003834_12_T0	GENE	6	6	PR
NCT0000383412	NCT00003834_12_T1	GENE	4	4	CR
NCT000038352	NCT00003835_2_T0	CELL	9	9	cells
NCT000038352	NCT00003835_2_T1	PHENOTYPE	8	8	tumor
NCT000038353	NCT00003835_3_T0	PHENOTYPE	12	15	stage III colon cancer
NCT000038354	NCT00003835_4_T0	COMPOUND	15	15	irinotecan
NCT000038354	NCT00003835_4_T1	GENE	2	2	III
NCT000038354	NCT00003835_4_T2	COMPOUND	11	11	leucovorin
NCT000038354	NCT00003835_4_T3	PHENOTYPE	24	27	stage III colon cancer
NCT000038356	NCT00003835_6_T0	COMPOUND	20	20	calcium
NCT000038356	NCT00003835_6_T1	COMPOUND	24	24	irinotecan
NCT000038356	NCT00003835_6_T2	COMPOUND	19	19	leucovorin
NCT000038356	NCT00003835_6_T3	PHENOTYPE	10	13	stage III colon cancer
NCT0000383510	NCT00003835_10_T0	PHENOTYPE	15	16	cancer recurrence
NCT0000383512	NCT00003835_12_T0	PHENOTYPE	13	13	toxicity
NCT0000383512	NCT00003835_12_T1	PHENOTYPE	5	5	obesity
NCT0000383514	NCT00003835_14_T0	PHENOTYPE	9	9	proliferation
NCT0000383514	NCT00003835_14_T1	PHENOTYPE	5	5	tumor
NCT0000383514	NCT00003835_14_T2	PHENOTYPE	7	7	tumor
NCT0000383514	NCT00003835_14_T3	PHENOTYPE	11	11	tumor
NCT0000383514	NCT00003835_14_T4	PHENOTYPE	19	19	tumor
NCT0000383514	NCT00003835_14_T5	ORGAN	21	22	lymphatic vessel
NCT0000383516	NCT00003835_16_T0	GENE	8	8	1.3
NCT0000383516	NCT00003835_16_T1	GENE	29	29	5.0
NCT0000383516	NCT00003835_16_T2	GENE	34	34	5.0
NCT0000383516	NCT00003835_16_T3	ORGAN	25	25	serum
NCT0000383516	NCT00003835_16_T4	GENE	26	26	CEA
NCT0000383516	NCT00003835_16_T5	TISSUE	5	6	lymph node
NCT0000383520	NCT00003835_20_T0	GENE	1	1	II
NCT0000383520	NCT00003835_20_T1	COMPOUND	4	4	irinotecan
NCT0000383520	NCT00003835_20_T2	COMPOUND	12	12	calcium
NCT0000383520	NCT00003835_20_T3	GENE	0	0	ARM
NCT0000383520	NCT00003835_20_T4	COMPOUND	11	11	leucovorin
NCT0000383520	NCT00003835_20_T5	GENE	5	5	IV
NCT0000383520	NCT00003835_20_T6	GENE	13	13	IV
NCT0000383520	NCT00003835_20_T7	GENE	18	18	IV
NCT000038371	NCT00003837_1_T0	CELL	22	22	T-cell
NCT000038371	NCT00003837_1_T1	PHENOTYPE	23	24	lymphoblastic lymphoma
NCT000038371	NCT00003837_1_T2	PHENOTYPE	17	20	T-cell acute lymphoblastic leukemia
NCT000038374	NCT00003837_4_T0	PHENOTYPE	16	16	toxicity
NCT000038374	NCT00003837_4_T1	PHENOTYPE	18	19	disease progression
NCT000038380	NCT00003838_0_T0	PHENOTYPE	5	5	Cancers
NCT000038380	NCT00003838_0_T1	ORGAN	2	3	Cell Transplants
NCT000038380	NCT00003838_0_T2	CELL	1	2	Blood Cell
NCT000038380	NCT00003838_0_T3	ORGAN	10	11	Bone Marrow
NCT000038384	NCT00003838_4_T0	PHENOTYPE	3	3	relapse
NCT000038386	NCT00003838_6_T0	CELL	3	3	cells
NCT000038386	NCT00003838_6_T1	ORGAN	1	1	transplants
NCT000038387	NCT00003838_7_T0	CELL	14	14	cells
NCT000038387	NCT00003838_7_T1	ORGAN	1	1	transplant
NCT000038388	NCT00003838_8_T0	CELL	5	7	bone marrow cells
NCT000038389	NCT00003838_9_T0	CELL	6	7	stem cells
NCT0000383810	NCT00003838_10_T0	CELL	11	11	cells
NCT0000383810	NCT00003838_10_T1	CELL	13	13	cells
NCT0000383810	NCT00003838_10_T2	CELL	15	15	platelets
NCT0000383810	NCT00003838_10_T3	CELL	1	2	stem cells
NCT0000383810	NCT00003838_10_T4	ORGAN	8	9	bone marrow
NCT0000383811	NCT00003838_11_T0	CELL	4	4	cells
NCT0000383811	NCT00003838_11_T1	CELL	25	25	cells
NCT0000383812	NCT00003838_12_T0	PHENOTYPE	14	14	toxic
NCT0000383813	NCT00003838_13_T0	PHENOTYPE	5	5	complications
NCT0000383813	NCT00003838_13_T1	PHENOTYPE	18	18	cancers
NCT0000383813	NCT00003838_13_T2	ORGAN	23	24	bone marrow
NCT0000383819	NCT00003838_19_T0	PHENOTYPE	15	15	tumor
NCT0000383819	NCT00003838_19_T1	GENE	3	3	has
NCT0000383819	NCT00003838_19_T2	ORGAN	22	22	allograft
NCT0000383819	NCT00003838_19_T3	ORGAN	17	18	bone marrow
NCT0000383820	NCT00003838_20_T0	PHENOTYPE	18	18	toxicity
NCT0000383820	NCT00003838_20_T1	PHENOTYPE	10	10	recurrence
NCT0000383820	NCT00003838_20_T2	PHENOTYPE	3	3	conditioning
NCT0000383820	NCT00003838_20_T3	GENE	11	11	has
NCT0000383821	NCT00003838_21_T0	CELL	25	25	cells
NCT0000383821	NCT00003838_21_T1	CELL	7	7	T-cells
NCT0000383825	NCT00003838_25_T0	PHENOTYPE	22	22	leukemia
NCT0000383825	NCT00003838_25_T1	GENE	10	10	CD4
NCT0000383825	NCT00003838_25_T2	CELL	12	14	CD8 positive lymphocytes
NCT0000383826	NCT00003838_26_T0	CELL	1	1	cells
NCT0000383828	NCT00003838_28_T0	PHENOTYPE	5	5	leukemia
NCT0000383828	NCT00003838_28_T1	PHENOTYPE	40	40	engraftment
NCT0000383828	NCT00003838_28_T2	CELL	9	9	cells
NCT0000383828	NCT00003838_28_T3	CELL	26	26	cells
NCT0000383828	NCT00003838_28_T4	ORGAN	30	30	transplant
NCT0000383828	NCT00003838_28_T5	CELL	17	17	T-cells
NCT0000383830	NCT00003838_30_T0	PHENOTYPE	28	28	toxicity
NCT0000383830	NCT00003838_30_T1	PHENOTYPE	24	24	engraftment
NCT0000383831	NCT00003838_31_T0	PHENOTYPE	17	17	complications
NCT0000383831	NCT00003838_31_T1	ORGAN	16	16	transplant
NCT0000383832	NCT00003838_32_T0	PHENOTYPE	5	5	complications
NCT0000383832	NCT00003838_32_T1	PHENOTYPE	32	32	complications
NCT0000383832	NCT00003838_32_T2	ORGAN	4	4	transplant
NCT0000383832	NCT00003838_32_T3	ORGAN	14	14	transplant
NCT0000383832	NCT00003838_32_T4	ORGAN	9	9	transplants
NCT0000383834	NCT00003838_34_T0	PHENOTYPE	30	30	disorders
NCT0000383836	NCT00003838_36_T0	PHENOTYPE	16	16	complications
NCT0000383836	NCT00003838_36_T1	PHENOTYPE	25	25	diseases
NCT0000383836	NCT00003838_36_T2	ORGAN	14	14	transplant
NCT0000383836	NCT00003838_36_T3	PHENOTYPE	4	5	hematologic malignancies
NCT0000383837	NCT00003838_37_T0	PHENOTYPE	29	29	closed
NCT0000383837	NCT00003838_37_T1	GENE	13	13	longevity
NCT0000383837	NCT00003838_37_T2	PHENOTYPE	0	1	Group B
NCT0000383837	NCT00003838_37_T3	PHENOTYPE	4	5	hematologic diseases
NCT0000383838	NCT00003838_38_T0	ORGAN	44	44	marrow
NCT0000383838	NCT00003838_38_T1	PHENOTYPE	41	41	malignancy
NCT0000383838	NCT00003838_38_T2	ORGAN	48	48	graft
NCT0000383838	NCT00003838_38_T3	PHENOTYPE	28	28	myeloablation
NCT0000383838	NCT00003838_38_T4	PHENOTYPE	37	37	toxicities
NCT0000383838	NCT00003838_38_T5	ORGAN	11	11	transplant
NCT0000383838	NCT00003838_38_T6	ORGAN	35	35	transplant
NCT0000383840	NCT00003838_40_T0	CELL	0	0	T-cell
NCT0000383840	NCT00003838_40_T1	GENE	3	6	granulocyte colony stimulating factor
NCT0000383841	NCT00003838_41_T0	CELL	4	4	lymphocytes
NCT0000383841	NCT00003838_41_T1	ORGAN	19	19	graft
NCT0000383841	NCT00003838_41_T2	CELL	12	12	T-cell
NCT0000383842	NCT00003838_42_T0	ORGAN	7	7	transplant
NCT0000383843	NCT00003838_43_T0	PHENOTYPE	4	4	engraftment
NCT0000383843	NCT00003838_43_T1	PHENOTYPE	11	11	acute
NCT0000383843	NCT00003838_43_T2	PHENOTYPE	18	18	GVHD
NCT0000383843	NCT00003838_43_T3	ORGAN	19	19	transplant
NCT0000383843	NCT00003838_43_T4	PHENOTYPE	13	17	chronic graft versus host disease
NCT0000383848	NCT00003838_48_T0	ORGAN	22	22	marrow
NCT0000383848	NCT00003838_48_T1	ORGAN	25	25	transplant
NCT0000383848	NCT00003838_48_T2	PHENOTYPE	29	29	resistant
NCT0000383848	NCT00003838_48_T3	PHENOTYPE	5	7	small lymphocytic lymphoma
NCT0000383857	NCT00003838_57_T0	PHENOTYPE	1	3	ventricular ejection fraction
NCT000038405	NCT00003840_5_T0	PHENOTYPE	3	3	toxic
NCT000038407	NCT00003840_7_T0	PHENOTYPE	2	2	pharmacokinetics
NCT0000384015	NCT00003840_15_T0	ORGAN	5	5	serum
NCT0000384015	NCT00003840_15_T1	PHENOTYPE	9	10	antibody titer
NCT0000384016	NCT00003840_16_T0	GENE	11	11	1.5
NCT0000384016	NCT00003840_16_T1	GENE	3	4	fusion protein
NCT0000384016	NCT00003840_16_T2	GENE	4	5	protein IV
NCT0000384018	NCT00003840_18_T0	GENE	16	16	MTD
NCT0000384018	NCT00003840_18_T1	GENE	9	10	fusion protein
NCT0000384019	NCT00003840_19_T0	PHENOTYPE	21	21	toxicity
NCT0000384019	NCT00003840_19_T1	GENE	1	1	MTD
NCT0000384020	NCT00003840_20_T0	GENE	2	2	MTD
NCT0000384020	NCT00003840_20_T1	GENE	18	18	MTD
NCT0000384020	NCT00003840_20_T2	GENE	14	15	fusion protein
NCT0000384021	NCT00003840_21_T0	PHENOTYPE	5	6	disease progression
NCT000038420	NCT00003842_0_T0	PHENOTYPE	6	6	Recurrent
NCT000038420	NCT00003842_0_T1	PHENOTYPE	7	8	Malignant Astrocytoma
NCT000038422	NCT00003842_2_T0	PHENOTYPE	7	7	recurrent
NCT000038422	NCT00003842_2_T1	PHENOTYPE	8	9	malignant astrocytoma
NCT000038423	NCT00003842_3_T0	PHENOTYPE	16	16	recurrent
NCT000038423	NCT00003842_3_T1	PHENOTYPE	17	18	malignant astrocytoma
NCT000038425	NCT00003842_5_T0	PHENOTYPE	13	13	recurrent
NCT000038425	NCT00003842_5_T1	PHENOTYPE	14	15	malignant astrocytoma
NCT0000384212	NCT00003842_12_T0	PHENOTYPE	6	6	tumor
NCT0000384213	NCT00003842_13_T0	GENE	8	8	toxin
NCT0000384213	NCT00003842_13_T1	GENE	7	7	IL-4
NCT0000384214	NCT00003842_14_T0	GENE	2	2	toxin
NCT0000384214	NCT00003842_14_T1	GENE	1	1	IL-4
NCT0000384216	NCT00003842_16_T0	GENE	10	10	toxin
NCT0000384216	NCT00003842_16_T1	GENE	9	9	IL-4
NCT0000384216	NCT00003842_16_T2	GENE	16	16	MTD
NCT0000384217	NCT00003842_17_T0	PHENOTYPE	19	19	toxicity
NCT0000384217	NCT00003842_17_T1	GENE	1	1	MTD
NCT000038431	NCT00003843_1_T0	GENE	2	2	II
NCT000038431	NCT00003843_1_T1	COMPOUND	9	9	irinotecan
NCT000038431	NCT00003843_1_T2	PHENOTYPE	15	16	colorectal cancer
NCT000038433	NCT00003843_3_T0	GENE	13	13	UGT1
NCT000038434	NCT00003843_4_T0	GENE	5	5	UGT1
NCT000038435	NCT00003843_5_T0	COMPOUND	2	2	irinotecan
NCT000038436	NCT00003843_6_T0	PHENOTYPE	13	13	toxicity
NCT000038436	NCT00003843_6_T1	PHENOTYPE	9	10	disease progression
NCT000038461	NCT00003846_1_T0	CELL	10	10	cells
NCT000038461	NCT00003846_1_T1	PHENOTYPE	9	9	tumor
NCT000038467	NCT00003846_7_T0	COMPOUND	2	2	vincristine
NCT000038467	NCT00003846_7_T1	GENE	3	3	IV
NCT000038469	NCT00003846_9_T0	GENE	35	35	SC
NCT000038469	NCT00003846_9_T1	COMPOUND	10	10	vincristine
NCT000038469	NCT00003846_9_T2	COMPOUND	25	25	thiotepa
NCT000038469	NCT00003846_9_T3	GENE	32	32	2.4
NCT000038469	NCT00003846_9_T4	GENE	34	34	G-CSF
NCT000038469	NCT00003846_9_T5	GENE	11	11	IV
NCT000038469	NCT00003846_9_T6	GENE	16	16	IV
NCT000038469	NCT00003846_9_T7	GENE	26	26	IV
NCT0000384611	NCT00003846_11_T0	GENE	31	31	SC
NCT0000384611	NCT00003846_11_T1	COMPOUND	4	4	vincristine
NCT0000384611	NCT00003846_11_T2	COMPOUND	19	19	cyclophosphamide
NCT0000384611	NCT00003846_11_T3	GENE	30	30	G-CSF
NCT0000384611	NCT00003846_11_T4	GENE	5	5	IV
NCT0000384611	NCT00003846_11_T5	GENE	10	10	IV
NCT0000384611	NCT00003846_11_T6	GENE	20	20	IV
NCT0000384614	NCT00003846_14_T0	COMPOUND	12	12	thiotepa
NCT0000384614	NCT00003846_14_T1	GENE	18	18	MTD
NCT0000384615	NCT00003846_15_T0	PHENOTYPE	18	18	toxicity
NCT0000384615	NCT00003846_15_T1	GENE	1	1	MTD
NCT000038472	NCT00003847_2_T0	CELL	9	9	cells
NCT000038472	NCT00003847_2_T1	PHENOTYPE	8	8	tumor
NCT000038477	NCT00003847_7_T0	PHENOTYPE	3	3	pharmacokinetics
NCT000038477	NCT00003847_7_T1	ORGAN	2	2	plasma
NCT0000384713	NCT00003847_13_T0	COMPOUND	14	14	vincristine
NCT0000384713	NCT00003847_13_T1	COMPOUND	11	11	doxorubicin
NCT0000384713	NCT00003847_13_T2	GENE	5	5	IV
NCT0000384713	NCT00003847_13_T3	GENE	12	12	IV
NCT0000384713	NCT00003847_13_T4	GENE	15	15	IV
NCT0000384715	NCT00003847_15_T0	PHENOTYPE	12	12	toxicity
NCT0000384715	NCT00003847_15_T1	COMPOUND	24	24	vincristine
NCT0000384716	NCT00003847_16_T0	PHENOTYPE	21	21	toxicity
NCT0000384717	NCT00003847_17_T0	GENE	1	1	II
NCT0000384717	NCT00003847_17_T1	COMPOUND	16	16	vincristine
NCT0000384717	NCT00003847_17_T2	COMPOUND	11	11	doxorubicin
NCT0000384717	NCT00003847_17_T3	GENE	5	5	IV
NCT0000384717	NCT00003847_17_T4	GENE	12	12	IV
NCT0000384717	NCT00003847_17_T5	GENE	17	17	IV
NCT0000384718	NCT00003847_18_T0	PHENOTYPE	18	18	toxicity
NCT0000384718	NCT00003847_18_T1	PHENOTYPE	14	15	disease progression
NCT000038491	NCT00003849_1_T0	GENE	2	2	II
NCT000038491	NCT00003849_1_T1	PHENOTYPE	18	19	Hodgkin's disease
NCT000038491	NCT00003849_1_T2	PHENOTYPE	15	16	Hodgkin's lymphoma
NCT000038495	NCT00003849_5_T0	GENE	13	13	CD20
NCT000038495	NCT00003849_5_T1	PHENOTYPE	14	15	Hodgkin's disease
NCT000038497	NCT00003849_7_T0	PHENOTYPE	4	4	progression
NCT000038499	NCT00003849_9_T0	GENE	3	3	IV
NCT000038500	NCT00003850_0_T0	PHENOTYPE	5	5	Recurrent
NCT000038500	NCT00003850_0_T1	PHENOTYPE	8	11	Head and Neck Cancer
NCT000038508	NCT00003850_8_T0	PHENOTYPE	2	2	toxic
NCT000038508	NCT00003850_8_T1	COMPOUND	5	5	thalidomide
NCT0000385011	NCT00003850_11_T0	COMPOUND	7	7	thalidomide
NCT0000385013	NCT00003850_13_T0	PHENOTYPE	10	10	toxicity
NCT0000385013	NCT00003850_13_T1	PHENOTYPE	6	7	disease progression
NCT000038511	NCT00003851_1_T0	CELL	6	6	cells
NCT000038512	NCT00003851_2_T0	COMPOUND	6	6	gemcitabine
NCT000038512	NCT00003851_2_T1	PHENOTYPE	18	19	pancreatic cancer
NCT000038513	NCT00003851_3_T0	GENE	27	27	II
NCT000038513	NCT00003851_3_T1	COMPOUND	9	9	gemcitabine
NCT000038513	NCT00003851_3_T2	PHENOTYPE	28	29	stage III
NCT000038513	NCT00003851_3_T3	PHENOTYPE	31	34	stage IV pancreatic cancer
NCT000038516	NCT00003851_6_T0	GENE	6	6	II
NCT000038516	NCT00003851_6_T1	PHENOTYPE	23	23	malnourished
NCT000038516	NCT00003851_6_T2	PHENOTYPE	26	26	malnourished
NCT000038516	NCT00003851_6_T3	GENE	8	8	III
NCT000038516	NCT00003851_6_T4	PHENOTYPE	25	25	severely
NCT000038516	NCT00003851_6_T5	GENE	10	10	IV
NCT000038518	NCT00003851_8_T0	COMPOUND	2	3	magnesium citrate
NCT0000385110	NCT00003851_10_T0	PHENOTYPE	8	8	relapse
NCT0000385112	NCT00003851_12_T0	COMPOUND	18	19	castor oil
NCT000038520	NCT00003852_0_T0	CELL	3	5	Peripheral Stem Cell
NCT000038520	NCT00003852_0_T1	PHENOTYPE	11	13	Germ Cell Tumors
NCT000038529	NCT00003852_9_T0	PHENOTYPE	2	2	toxic
NCT0000385211	NCT00003852_11_T0	PHENOTYPE	21	21	toxic
NCT0000385211	NCT00003852_11_T1	PHENOTYPE	2	2	pharmacokinetics
NCT0000385211	NCT00003852_11_T2	PHENOTYPE	11	11	pharmacokinetics
NCT0000385213	NCT00003852_13_T0	COMPOUND	8	8	paclitaxel
NCT0000385213	NCT00003852_13_T1	GENE	17	17	filgrastim
NCT0000385213	NCT00003852_13_T2	COMPOUND	2	2	epirubicin
NCT0000385213	NCT00003852_13_T3	GENE	18	18	G-CSF
NCT0000385213	NCT00003852_13_T4	GENE	3	3	IV
NCT0000385213	NCT00003852_13_T5	GENE	9	9	IV
NCT0000385214	NCT00003852_14_T0	CELL	0	3	Peripheral blood stem cells
NCT0000385217	NCT00003852_17_T0	COMPOUND	7	7	thiotepa
NCT0000385217	NCT00003852_17_T1	COMPOUND	4	4	cyclophosphamide
NCT0000385217	NCT00003852_17_T2	GENE	5	5	IV
NCT0000385217	NCT00003852_17_T3	GENE	8	8	IV
NCT0000385219	NCT00003852_19_T0	GENE	1	1	II
NCT0000385219	NCT00003852_19_T1	COMPOUND	9	9	ifosfamide
NCT0000385219	NCT00003852_19_T2	COMPOUND	4	4	etoposide
NCT0000385219	NCT00003852_19_T3	GENE	5	5	IV
NCT0000385219	NCT00003852_19_T4	GENE	10	10	IV
NCT0000385219	NCT00003852_19_T5	GENE	16	16	IV
NCT0000385220	NCT00003852_20_T0	GENE	8	8	G-CSF
NCT0000385221	NCT00003852_21_T0	GENE	14	14	II
NCT0000385221	NCT00003852_21_T1	COMPOUND	5	5	ifosfamide
NCT0000385221	NCT00003852_21_T2	GENE	1	1	III
NCT0000385221	NCT00003852_21_T3	COMPOUND	4	4	etoposide
NCT0000385222	NCT00003852_22_T0	GENE	8	8	G-CSF
NCT000038530	NCT00003853_0_T0	PHENOTYPE	5	7	Primary Systemic Amyloidosis
NCT000038532	NCT00003853_2_T0	GENE	2	2	II
NCT000038532	NCT00003853_2_T1	PHENOTYPE	15	17	primary systemic amyloidosis
NCT000038534	NCT00003853_4_T0	PHENOTYPE	10	10	symptoms
NCT000038534	NCT00003853_4_T1	PHENOTYPE	19	19	infiltration
NCT000038534	NCT00003853_4_T2	PHENOTYPE	15	15	dysfunction
NCT000038534	NCT00003853_4_T3	PHENOTYPE	25	27	primary systemic amyloidosis
NCT000038538	NCT00003853_8_T0	PHENOTYPE	8	8	symptoms
NCT000038538	NCT00003853_8_T1	PHENOTYPE	6	6	amyloidosis
NCT000038538	NCT00003853_8_T2	PHENOTYPE	4	4	progression
NCT000038538	NCT00003853_8_T3	PHENOTYPE	11	11	dysfunction
NCT000038539	NCT00003853_9_T0	GENE	4	4	IV
NCT0000385311	NCT00003853_11_T0	PHENOTYPE	15	15	toxicity
NCT0000385311	NCT00003853_11_T1	PHENOTYPE	11	12	disease progression
NCT000038546	NCT00003854_6_T0	GENE	7	7	II
NCT000038546	NCT00003854_6_T1	PHENOTYPE	15	15	tumor
NCT000038546	NCT00003854_6_T2	GENE	10	10	T2
NCT000038548	NCT00003854_8_T0	PHENOTYPE	7	9	invasive breast carcinoma
NCT0000385411	NCT00003854_11_T0	PHENOTYPE	16	17	breast carcinoma
NCT0000385411	NCT00003854_11_T1	PHENOTYPE	9	11	invasive breast carcinoma
NCT0000385413	NCT00003854_13_T0	GENE	3	3	had
NCT0000385414	NCT00003854_14_T0	PHENOTYPE	5	5	pathology
NCT0000385420	NCT00003854_20_T0	PHENOTYPE	8	8	malignancy
NCT0000385421	NCT00003854_21_T0	GENE	11	11	met
NCT0000385422	NCT00003854_22_T0	PHENOTYPE	10	10	malignancies
NCT0000385422	NCT00003854_22_T1	GENE	2	2	has
NCT0000385425	NCT00003854_25_T0	PHENOTYPE	14	14	recurrence
NCT0000385425	NCT00003854_25_T1	PHENOTYPE	17	17	malignancies
NCT0000385428	NCT00003854_28_T0	ORGAN	8	8	serum
NCT0000385433	NCT00003854_33_T0	GENE	1	1	has
NCT0000385433	NCT00003854_33_T1	GENE	7	8	estrogen receptor
NCT0000385433	NCT00003854_33_T2	GENE	14	15	estrogen receptor
NCT0000385433	NCT00003854_33_T3	PHENOTYPE	22	24	invasive breast cancer
NCT0000385435	NCT00003854_35_T0	GENE	1	1	has
NCT0000385438	NCT00003854_38_T0	PHENOTYPE	11	12	systemic disease
NCT0000385440	NCT00003854_40_T0	PHENOTYPE	3	3	bilateral
NCT0000385440	NCT00003854_40_T1	PHENOTYPE	6	6	malignancies
NCT0000385440	NCT00003854_40_T2	GENE	1	1	has
NCT0000385445	NCT00003854_45_T0	GENE	1	1	has
NCT0000385447	NCT00003854_47_T0	ORGAN	12	12	lymph
NCT0000385447	NCT00003854_47_T1	GENE	2	2	had
NCT0000385447	NCT00003854_47_T2	GENE	1	1	has
NCT0000385447	NCT00003854_47_T3	PHENOTYPE	16	16	hidradenitis
NCT000038551	NCT00003855_1_T0	ORGAN	15	15	armpit
NCT000038551	NCT00003855_1_T1	GENE	3	3	III
NCT000038551	NCT00003855_1_T2	TISSUE	11	12	lymph nodes
NCT000038551	NCT00003855_1_T3	PHENOTYPE	24	27	stage IIA breast cancer
NCT0000385513	NCT00003855_13_T0	PHENOTYPE	7	7	tumor
NCT0000385513	NCT00003855_13_T1	PHENOTYPE	35	35	tumor
NCT0000385513	NCT00003855_13_T2	GENE	12	12	cm
NCT0000385513	NCT00003855_13_T3	GENE	25	25	T2
NCT0000385513	NCT00003855_13_T4	PHENOTYPE	21	22	metastatic disease
NCT0000385515	NCT00003855_15_T0	PHENOTYPE	7	9	invasive breast carcinoma
NCT0000385518	NCT00003855_18_T0	PHENOTYPE	15	15	carcinoma
NCT0000385518	NCT00003855_18_T1	PHENOTYPE	8	10	invasive breast carcinoma
NCT0000385520	NCT00003855_20_T0	GENE	3	3	had
NCT0000385521	NCT00003855_21_T0	PHENOTYPE	6	6	pathology
NCT0000385527	NCT00003855_27_T0	ORGAN	8	8	serum
NCT0000385531	NCT00003855_31_T0	PHENOTYPE	8	8	malignancy
NCT0000385532	NCT00003855_32_T0	GENE	11	11	met
NCT0000385533	NCT00003855_33_T0	PHENOTYPE	10	10	malignancies
NCT0000385533	NCT00003855_33_T1	GENE	2	2	has
NCT0000385535	NCT00003855_35_T0	PHENOTYPE	14	14	recurrence
NCT0000385542	NCT00003855_42_T0	GENE	1	1	has
NCT0000385542	NCT00003855_42_T1	GENE	7	8	estrogen receptor
NCT0000385542	NCT00003855_42_T2	GENE	14	15	estrogen receptor
NCT0000385542	NCT00003855_42_T3	PHENOTYPE	22	24	invasive breast cancer
NCT0000385544	NCT00003855_44_T0	GENE	1	1	has
NCT0000385547	NCT00003855_47_T0	PHENOTYPE	4	4	bilateral
NCT0000385547	NCT00003855_47_T1	PHENOTYPE	6	6	malignancies
NCT0000385547	NCT00003855_47_T2	GENE	1	1	has
NCT0000385549	NCT00003855_49_T0	GENE	1	1	has
NCT0000385551	NCT00003855_51_T0	ORGAN	12	12	lymph
NCT0000385551	NCT00003855_51_T1	GENE	2	2	had
NCT0000385551	NCT00003855_51_T2	GENE	1	1	has
NCT0000385551	NCT00003855_51_T3	PHENOTYPE	16	16	hidradenitis
NCT0000385553	NCT00003855_53_T0	GENE	1	1	has
NCT0000385553	NCT00003855_53_T1	PHENOTYPE	18	19	systemic disease
NCT0000385557	NCT00003855_57_T0	GENE	6	6	sentinel
NCT0000385557	NCT00003855_57_T1	GENE	12	12	prep
NCT0000385557	NCT00003855_57_T2	GENE	1	1	has
NCT000038561	NCT00003856_1_T0	PHENOTYPE	8	11	head and neck cancer
NCT000038562	NCT00003856_2_T0	GENE	2	2	II
NCT000038562	NCT00003856_2_T1	PHENOTYPE	18	18	recurrent
NCT000038562	NCT00003856_2_T2	PHENOTYPE	23	26	head and neck cancer
NCT000038566	NCT00003856_6_T0	PHENOTYPE	10	12	quality of life
NCT000038568	NCT00003856_8_T0	PHENOTYPE	2	2	toxic
NCT0000385610	NCT00003856_10_T0	PHENOTYPE	5	5	tumor
NCT0000385610	NCT00003856_10_T1	PHENOTYPE	3	3	pharmacokinetics
NCT0000385612	NCT00003856_12_T0	GENE	2	2	IV
NCT0000385615	NCT00003856_15_T0	PHENOTYPE	0	2	Quality of life
NCT000038573	NCT00003857_3_T0	COMPOUND	16	16	tamoxifen
NCT000038573	NCT00003857_3_T1	PHENOTYPE	19	22	ductal carcinoma in situ
NCT000038574	NCT00003857_4_T0	GENE	3	3	III
NCT000038574	NCT00003857_4_T1	COMPOUND	19	19	tamoxifen
NCT000038574	NCT00003857_4_T2	PHENOTYPE	25	28	ductal carcinoma in situ
NCT000038581	NCT00003858_1_T0	CELL	8	8	cells
NCT000038581	NCT00003858_1_T1	PHENOTYPE	7	7	tumor
NCT000038591	NCT00003859_1_T0	CELL	8	8	cells
NCT000038591	NCT00003859_1_T1	PHENOTYPE	7	7	tumor
NCT000038592	NCT00003859_2_T0	PHENOTYPE	19	21	primitive neuroectodermal tumors
NCT000038593	NCT00003859_3_T0	GENE	3	3	III
NCT000038593	NCT00003859_3_T1	PHENOTYPE	23	25	primitive neuroectodermal tumors
NCT000038595	NCT00003859_5_T0	COMPOUND	5	5	vincristine
NCT000038595	NCT00003859_5_T1	COMPOUND	6	6	cyclophosphamide
NCT000038595	NCT00003859_5_T2	COMPOUND	8	8	etoposide
NCT000038595	NCT00003859_5_T3	PHENOTYPE	15	17	primitive neuroectodermal tumors
NCT000038595	NCT00003859_5_T4	ORGAN	20	22	central nervous system
NCT000038595	NCT00003859_5_T5	PHENOTYPE	17	21	tumors of the central nervous
NCT0000385911	NCT00003859_11_T0	PHENOTYPE	6	7	primary tumor
NCT0000385916	NCT00003859_16_T0	GENE	1	1	IV
NCT0000385917	NCT00003859_17_T0	GENE	9	9	1.3
NCT0000385917	NCT00003859_17_T1	GENE	1	1	IV
NCT0000385918	NCT00003859_18_T0	GENE	1	1	IV
NCT0000385920	NCT00003859_20_T0	PHENOTYPE	0	2	Quality of life
NCT000038609	NCT00003860_9_T0	PHENOTYPE	2	2	progression
NCT0000386011	NCT00003860_11_T0	COMPOUND	9	9	ifosfamide
NCT0000386011	NCT00003860_11_T1	COMPOUND	24	24	etoposide
NCT0000386011	NCT00003860_11_T2	GENE	10	10	IV
NCT0000386011	NCT00003860_11_T3	GENE	16	16	IV
NCT0000386011	NCT00003860_11_T4	GENE	25	25	IV
NCT0000386014	NCT00003860_14_T0	CELL	0	3	Peripheral blood stem cells
NCT000038621	NCT00003862_1_T0	CELL	8	8	cells
NCT000038621	NCT00003862_1_T1	PHENOTYPE	7	7	tumor
NCT000038622	NCT00003862_2_T0	CELL	9	9	cells
NCT000038622	NCT00003862_2_T1	PHENOTYPE	8	8	tumor
NCT000038623	NCT00003862_3_T0	GENE	2	2	II
NCT000038623	NCT00003862_3_T1	PHENOTYPE	18	19	stomach cancer
NCT000038625	NCT00003862_5_T0	COMPOUND	21	21	calcium
NCT000038625	NCT00003862_5_T1	GENE	18	18	1.5
NCT000038625	NCT00003862_5_T2	COMPOUND	20	20	leucovorin
NCT000038625	NCT00003862_5_T3	COMPOUND	11	11	cisplatin
NCT000038625	NCT00003862_5_T4	GENE	4	4	IV
NCT000038625	NCT00003862_5_T5	GENE	12	12	IV
NCT000038625	NCT00003862_5_T6	GENE	22	22	IV
NCT000038628	NCT00003862_8_T0	COMPOUND	18	18	paclitaxel
NCT000038628	NCT00003862_8_T1	GENE	3	3	IV
NCT000038628	NCT00003862_8_T2	GENE	19	19	IV
NCT000038629	NCT00003862_9_T0	GENE	1	1	4.5
NCT000038629	NCT00003862_9_T1	PHENOTYPE	10	11	metastatic disease
NCT000038631	NCT00003863_1_T0	PHENOTYPE	13	14	Hodgkin's lymphoma
NCT000038634	NCT00003863_4_T0	PHENOTYPE	32	32	relapse
NCT000038634	NCT00003863_4_T1	PHENOTYPE	22	22	remission
NCT000038634	NCT00003863_4_T2	PHENOTYPE	39	39	remission
NCT000038635	NCT00003863_5_T0	GENE	9	9	BCL6
NCT000038635	NCT00003863_5_T1	GENE	7	7	MYC
NCT000038635	NCT00003863_5_T2	GENE	8	8	BCL2
NCT000038635	NCT00003863_5_T3	GENE	11	11	IGH
NCT000038636	NCT00003863_6_T0	CELL	20	20	cells
NCT000038636	NCT00003863_6_T1	PHENOTYPE	19	19	tumor
NCT000038641	NCT00003864_1_T0	CELL	9	9	cells
NCT000038642	NCT00003864_2_T0	GENE	2	2	II
NCT000038642	NCT00003864_2_T1	COMPOUND	9	9	docetaxel
NCT000038642	NCT00003864_2_T2	PHENOTYPE	17	18	advanced cancer
NCT000038642	NCT00003864_2_T3	PHENOTYPE	18	21	cancer of the esophagus
NCT000038646	NCT00003864_6_T0	PHENOTYPE	2	2	toxicity
NCT000038648	NCT00003864_8_T0	PHENOTYPE	4	4	progression
NCT000038649	NCT00003864_9_T0	COMPOUND	3	3	docetaxel
NCT000038649	NCT00003864_9_T1	GENE	4	4	IV
NCT000038649	NCT00003864_9_T2	GENE	14	14	IV
NCT0000386410	NCT00003864_10_T0	PHENOTYPE	17	17	toxicity
NCT0000386410	NCT00003864_10_T1	PHENOTYPE	13	14	disease progression
NCT000038651	NCT00003865_1_T0	COMPOUND	13	13	estrogen
NCT000038651	NCT00003865_1_T1	COMPOUND	3	3	toremifene
NCT000038651	NCT00003865_1_T2	PHENOTYPE	6	7	ovarian cancer
NCT000038652	NCT00003865_2_T0	GENE	3	3	II
NCT000038652	NCT00003865_2_T1	COMPOUND	10	10	toremifene
NCT000038652	NCT00003865_2_T2	PHENOTYPE	16	16	recurrent
NCT000038652	NCT00003865_2_T3	PHENOTYPE	19	20	ovarian cancer
NCT000038655	NCT00003865_5_T0	COMPOUND	8	8	toremifene
NCT000038656	NCT00003865_6_T0	PHENOTYPE	10	10	toxicity
NCT000038656	NCT00003865_6_T1	PHENOTYPE	6	7	disease progression
NCT000038657	NCT00003865_7_T0	PHENOTYPE	0	2	Quality of life
NCT000038659	NCT00003865_9_T0	PHENOTYPE	5	5	closed
NCT000038670	NCT00003867_0_T0	PHENOTYPE	7	8	Solid Tumors
NCT000038672	NCT00003867_2_T0	CELL	9	9	cells
NCT000038672	NCT00003867_2_T1	PHENOTYPE	8	8	tumor
NCT000038673	NCT00003867_3_T0	COMPOUND	11	11	capecitabine
NCT000038673	NCT00003867_3_T1	COMPOUND	9	9	irinotecan
NCT000038673	NCT00003867_3_T2	PHENOTYPE	17	18	solid tumors
NCT000038675	NCT00003867_5_T0	COMPOUND	12	12	capecitabine
NCT000038675	NCT00003867_5_T1	PHENOTYPE	6	6	toxic
NCT000038675	NCT00003867_5_T2	COMPOUND	9	9	irinotecan
NCT000038675	NCT00003867_5_T3	PHENOTYPE	19	20	solid tumors
NCT000038677	NCT00003867_7_T0	GENE	7	7	II
NCT000038677	NCT00003867_7_T1	PHENOTYPE	20	20	toxic
NCT000038677	NCT00003867_7_T2	PHENOTYPE	17	17	tumor
NCT000038677	NCT00003867_7_T3	COMPOUND	10	10	thymidine
NCT000038677	NCT00003867_7_T4	GENE	13	14	thymidine phosphorylase
NCT000038679	NCT00003867_9_T0	COMPOUND	3	3	capecitabine
NCT000038679	NCT00003867_9_T1	COMPOUND	14	14	irinotecan
NCT000038679	NCT00003867_9_T2	GENE	13	13	IV
NCT0000386710	NCT00003867_10_T0	PHENOTYPE	15	15	toxicity
NCT0000386710	NCT00003867_10_T1	PHENOTYPE	11	12	disease progression
NCT0000386711	NCT00003867_11_T0	COMPOUND	3	3	capecitabine
NCT0000386711	NCT00003867_11_T1	COMPOUND	5	5	irinotecan
NCT0000386711	NCT00003867_11_T2	GENE	18	18	MTD
NCT0000386712	NCT00003867_12_T0	PHENOTYPE	16	16	toxicity
NCT0000386712	NCT00003867_12_T1	GENE	1	1	MTD
NCT000038681	NCT00003868_1_T0	CELL	11	11	cells
NCT000038682	NCT00003868_2_T0	CELL	8	8	cells
NCT000038688	NCT00003868_8_T0	GENE	29	29	12
NCT000038688	NCT00003868_8_T1	COMPOUND	6	6	iodine
NCT000038688	NCT00003868_8_T2	GENE	15	15	IV
NCT000038688	NCT00003868_8_T3	GENE	24	24	IV
NCT0000386810	NCT00003868_10_T0	COMPOUND	8	8	2
NCT0000386810	NCT00003868_10_T1	COMPOUND	6	6	3
NCT0000386810	NCT00003868_10_T2	COMPOUND	2	2	cyclophosphamide
NCT0000386810	NCT00003868_10_T3	GENE	3	3	IV
NCT0000386811	NCT00003868_11_T0	CELL	0	2	Bone marrow cells
NCT0000386811	NCT00003868_11_T1	CELL	4	7	peripheral blood stem cells
NCT0000386812	NCT00003868_12_T0	COMPOUND	7	7	methotrexate
NCT0000386814	NCT00003868_14_T0	COMPOUND	9	9	iodine
NCT0000386814	NCT00003868_14_T1	GENE	26	26	MTD
NCT0000386815	NCT00003868_15_T0	GENE	1	1	MTD
NCT0000386815	NCT00003868_15_T1	PHENOTYPE	19	20	graft failure
NCT000038699	NCT00003869_9_T0	PHENOTYPE	6	6	progression
NCT0000386913	NCT00003869_13_T0	PHENOTYPE	12	13	evaluable disease
NCT0000386917	NCT00003869_17_T0	GENE	21	21	IV
NCT0000386919	NCT00003869_19_T0	COMPOUND	5	5	carboxyamidotriazole
NCT0000386919	NCT00003869_19_T1	GENE	0	0	ARM
NCT0000386920	NCT00003869_20_T0	GENE	1	1	II
NCT0000386920	NCT00003869_20_T1	GENE	0	0	ARM
NCT0000386921	NCT00003869_21_T0	PHENOTYPE	10	10	toxicity
NCT0000386921	NCT00003869_21_T1	PHENOTYPE	6	7	disease progression
NCT0000386922	NCT00003869_22_T0	PHENOTYPE	0	2	Quality of life
NCT000038701	NCT00003870_1_T0	CELL	10	10	cells
NCT000038702	NCT00003870_2_T0	CELL	8	8	cells
NCT000038706	NCT00003870_6_T0	PHENOTYPE	4	4	toxicity
NCT000038706	NCT00003870_6_T1	COMPOUND	12	12	cyclophosphamide
NCT000038706	NCT00003870_6_T2	COMPOUND	6	6	iodine
NCT000038706	NCT00003870_6_T3	ORGAN	32	33	bone marrow
NCT000038706	NCT00003870_6_T4	PHENOTYPE	21	23	acute lymphocytic leukemia
NCT000038708	NCT00003870_8_T0	COMPOUND	7	7	iodine
NCT000038708	NCT00003870_8_T1	GENE	5	5	MTD
NCT0000387010	NCT00003870_10_T0	ORGAN	15	15	marrow
NCT0000387010	NCT00003870_10_T1	COMPOUND	7	7	iodine
NCT0000387010	NCT00003870_10_T2	GENE	2	2	MTD
NCT0000387012	NCT00003870_12_T0	ORGAN	4	4	marrow
NCT0000387012	NCT00003870_12_T1	CELL	12	12	cells
NCT0000387012	NCT00003870_12_T2	COMPOUND	24	24	iodine
NCT0000387014	NCT00003870_14_T0	COMPOUND	7	7	iodine
NCT0000387014	NCT00003870_14_T1	GENE	15	15	IV
NCT0000387015	NCT00003870_15_T0	GENE	17	17	11
NCT0000387015	NCT00003870_15_T1	GENE	11	11	IV
NCT0000387015	NCT00003870_15_T2	GENE	34	34	IV
NCT0000387015	NCT00003870_15_T3	COMPOUND	42	42	2
NCT0000387015	NCT00003870_15_T4	COMPOUND	40	40	3
NCT0000387015	NCT00003870_15_T5	COMPOUND	33	33	cyclophosphamide
NCT0000387015	NCT00003870_15_T6	COMPOUND	6	6	iodine
NCT0000387016	NCT00003870_16_T0	ORGAN	3	4	bone marrow
NCT0000387017	NCT00003870_17_T0	COMPOUND	3	3	methotrexate
NCT0000387018	NCT00003870_18_T0	COMPOUND	8	8	iodine
NCT0000387018	NCT00003870_18_T1	GENE	18	18	MTD
NCT0000387019	NCT00003870_19_T0	PHENOTYPE	17	17	toxicity
NCT0000387019	NCT00003870_19_T1	GENE	1	1	MTD
NCT000038715	NCT00003871_5_T0	PHENOTYPE	4	4	toxicity
NCT000038717	NCT00003871_7_T0	PHENOTYPE	12	12	immunity
NCT000038731	NCT00003873_1_T0	CELL	10	10	cells
NCT000038731	NCT00003873_1_T1	PHENOTYPE	9	9	tumor
NCT000038733	NCT00003873_3_T0	COMPOUND	20	20	eniluracil
NCT000038733	NCT00003873_3_T1	PHENOTYPE	12	13	colorectal cancer
NCT000038735	NCT00003873_5_T0	PHENOTYPE	2	2	toxicity
NCT000038737	NCT00003873_7_T0	GENE	9	9	1.2
NCT000038737	NCT00003873_7_T1	PHENOTYPE	11	12	measurable disease
NCT000038739	NCT00003873_9_T0	GENE	0	0	ARM
NCT000038739	NCT00003873_9_T1	GENE	5	5	IV
NCT0000387310	NCT00003873_10_T0	GENE	1	1	II
NCT0000387310	NCT00003873_10_T1	GENE	0	0	ARM
NCT0000387311	NCT00003873_11_T0	PHENOTYPE	13	13	toxicity
NCT0000387311	NCT00003873_11_T1	PHENOTYPE	9	10	disease progression
NCT000038741	NCT00003874_1_T0	PHENOTYPE	19	19	leukemia
NCT000038741	NCT00003874_1_T1	PHENOTYPE	17	17	lymphoma
NCT000038747	NCT00003874_7_T0	GENE	16	16	CD34
NCT000038749	NCT00003874_9_T0	CELL	7	7	cells
NCT000038749	NCT00003874_9_T1	GENE	6	6	CD34
NCT0000387410	NCT00003874_10_T0	CELL	11	11	cells
NCT0000387410	NCT00003874_10_T1	GENE	10	10	CD34
NCT0000387410	NCT00003874_10_T2	CELL	0	3	Peripheral blood stem cells
NCT0000387411	NCT00003874_11_T0	GENE	5	5	CD20
NCT0000387411	NCT00003874_11_T1	CELL	11	11	cells
NCT0000387411	NCT00003874_11_T2	CELL	17	17	cells
NCT0000387411	NCT00003874_11_T3	GENE	3	3	CD19
NCT0000387411	NCT00003874_11_T4	PHENOTYPE	16	16	tumor
NCT0000387411	NCT00003874_11_T5	GENE	10	10	CD34
NCT0000387412	NCT00003874_12_T0	ORGAN	9	9	transplant
NCT0000387413	NCT00003874_13_T0	PHENOTYPE	9	9	engraftment
NCT0000387413	NCT00003874_13_T1	GENE	5	5	interleukin-2
NCT000038752	NCT00003875_2_T0	CELL	8	8	cells
NCT000038753	NCT00003875_3_T0	CELL	12	12	cells
NCT000038754	NCT00003875_4_T0	CELL	10	10	cells
NCT000038754	NCT00003875_4_T1	CELL	4	6	white blood cells
NCT000038755	NCT00003875_5_T0	PHENOTYPE	16	16	AML
NCT000038755	NCT00003875_5_T1	COMPOUND	1	1	busulfan
NCT000038755	NCT00003875_5_T2	GENE	9	9	aldesleukin
NCT000038755	NCT00003875_5_T3	COMPOUND	3	3	etoposide
NCT000038757	NCT00003875_7_T0	PHENOTYPE	3	3	toxicity
NCT000038757	NCT00003875_7_T1	PHENOTYPE	23	23	AML
NCT000038757	NCT00003875_7_T2	GENE	19	19	aldesleukin
NCT000038757	NCT00003875_7_T3	ORGAN	15	15	transplant
NCT000038757	NCT00003875_7_T4	COMPOUND	12	12	etoposide
NCT000038759	NCT00003875_9_T0	PHENOTYPE	5	5	relapse
NCT0000387510	NCT00003875_10_T0	COMPOUND	5	5	busulfan
NCT0000387510	NCT00003875_10_T1	COMPOUND	27	27	3
NCT0000387510	NCT00003875_10_T2	COMPOUND	23	23	etoposide
NCT0000387510	NCT00003875_10_T3	GENE	7	7	IV
NCT0000387510	NCT00003875_10_T4	GENE	24	24	IV
NCT0000387511	NCT00003875_11_T0	GENE	1	1	CELL
NCT0000387512	NCT00003875_12_T0	GENE	13	13	SC
NCT0000387512	NCT00003875_12_T1	GENE	11	11	aldesleukin
NCT0000387512	NCT00003875_12_T2	ORGAN	7	7	transplant
NCT000038761	NCT00003876_1_T0	CELL	10	10	cells
NCT000038761	NCT00003876_1_T1	PHENOTYPE	9	9	tumor
NCT000038762	NCT00003876_2_T0	CELL	11	11	cells
NCT000038762	NCT00003876_2_T1	PHENOTYPE	10	10	tumor
NCT000038763	NCT00003876_3_T0	PHENOTYPE	20	20	recurrent
NCT000038763	NCT00003876_3_T1	PHENOTYPE	23	24	malignant glioma
NCT000038765	NCT00003876_5_T0	PHENOTYPE	2	2	toxic
NCT000038765	NCT00003876_5_T1	COMPOUND	7	7	iodine
NCT000038765	NCT00003876_5_T2	PHENOTYPE	24	24	recurrent
NCT000038765	NCT00003876_5_T3	PHENOTYPE	27	28	malignant glioma
NCT000038767	NCT00003876_7_T0	PHENOTYPE	9	9	progression
NCT000038769	NCT00003876_9_T0	PHENOTYPE	7	9	quality of life
NCT0000387611	NCT00003876_11_T0	PHENOTYPE	3	4	tumor progression
NCT0000387613	NCT00003876_13_T0	PHENOTYPE	10	10	proliferative
NCT0000387613	NCT00003876_13_T1	GENE	9	9	MIB-1
NCT0000387613	NCT00003876_13_T2	PHENOTYPE	4	4	progression
NCT0000387613	NCT00003876_13_T3	PHENOTYPE	15	16	malignant glioma
NCT0000387615	NCT00003876_15_T0	PHENOTYPE	13	13	tumor
NCT0000387615	NCT00003876_15_T1	PHENOTYPE	5	5	intent
NCT0000387616	NCT00003876_16_T0	PHENOTYPE	2	2	tumor
NCT0000387616	NCT00003876_16_T1	PHENOTYPE	24	24	tumor
NCT0000387616	NCT00003876_16_T2	COMPOUND	4	4	iodine
NCT0000387616	NCT00003876_16_T3	PHENOTYPE	25	25	cavity
NCT0000387617	NCT00003876_17_T0	PHENOTYPE	14	14	tumor
NCT0000387617	NCT00003876_17_T1	PHENOTYPE	15	15	cavity
NCT0000387618	NCT00003876_18_T0	PHENOTYPE	13	14	tumor progression
NCT0000387618	NCT00003876_18_T1	PHENOTYPE	0	2	Quality of life
NCT000038774	NCT00003877_4_T0	GENE	12	12	CD34
NCT000038774	NCT00003877_4_T1	CELL	5	7	mesenchymal stem cells
NCT000038774	NCT00003877_4_T2	PHENOTYPE	25	27	metastatic breast cancer
NCT000038774	NCT00003877_4_T3	CELL	13	16	peripheral blood stem cells
NCT000038776	NCT00003877_6_T0	PHENOTYPE	7	7	engraftment
NCT000038776	NCT00003877_6_T1	CELL	6	6	platelet
NCT000038776	NCT00003877_6_T2	CELL	4	4	neutrophil
NCT0000387711	NCT00003877_11_T0	COMPOUND	17	17	paclitaxel
NCT0000387711	NCT00003877_11_T1	GENE	26	26	filgrastim
NCT0000387711	NCT00003877_11_T2	COMPOUND	11	11	cyclophosphamide
NCT0000387711	NCT00003877_11_T3	GENE	27	27	G-CSF
NCT0000387711	NCT00003877_11_T4	GENE	12	12	IV
NCT0000387711	NCT00003877_11_T5	GENE	18	18	IV
NCT0000387711	NCT00003877_11_T6	CELL	5	8	peripheral blood stem cells
NCT0000387712	NCT00003877_12_T0	CELL	10	10	cells
NCT0000387712	NCT00003877_12_T1	GENE	8	8	CD34
NCT0000387712	NCT00003877_12_T2	CELL	2	4	bone marrow cells
NCT0000387714	NCT00003877_14_T0	COMPOUND	11	11	thiotepa
NCT0000387714	NCT00003877_14_T1	GENE	1	1	IV
NCT0000387714	NCT00003877_14_T2	GENE	6	6	IV
NCT0000387714	NCT00003877_14_T3	GENE	12	12	IV
NCT0000387715	NCT00003877_15_T0	COMPOUND	18	18	1
NCT0000387715	NCT00003877_15_T1	GENE	20	20	CD34
NCT0000387715	NCT00003877_15_T2	GENE	15	15	IV
NCT0000387715	NCT00003877_15_T3	GENE	23	23	IV
NCT0000387715	NCT00003877_15_T4	CELL	11	13	mesenchymal stem cells
NCT000038781	NCT00003878_1_T0	CELL	10	10	cells
NCT000038781	NCT00003878_1_T1	PHENOTYPE	9	9	tumor
NCT000038782	NCT00003878_2_T0	GENE	2	2	II
NCT000038782	NCT00003878_2_T1	PHENOTYPE	27	27	tumor
NCT000038782	NCT00003878_2_T2	PHENOTYPE	17	18	brain metastases
NCT000038784	NCT00003878_4_T0	PHENOTYPE	17	17	tumor
NCT000038784	NCT00003878_4_T1	PHENOTYPE	18	18	cavity
NCT000038801	NCT00003880_1_T0	CELL	11	11	cells
NCT000038801	NCT00003880_1_T1	PHENOTYPE	10	10	tumor
NCT000038802	NCT00003880_2_T0	COMPOUND	10	10	paclitaxel
NCT000038802	NCT00003880_2_T1	PHENOTYPE	41	41	tumor
NCT000038802	NCT00003880_2_T2	PHENOTYPE	24	25	stage III
NCT000038802	NCT00003880_2_T3	PHENOTYPE	28	29	stage III
NCT000038802	NCT00003880_2_T4	PHENOTYPE	34	35	residual disease
NCT000038802	NCT00003880_2_T5	PHENOTYPE	31	32	peritoneal cancer
NCT000038806	NCT00003880_6_T0	COMPOUND	5	5	paclitaxel
NCT000038806	NCT00003880_6_T1	GENE	4	4	IV
NCT000038806	NCT00003880_6_T2	GENE	7	7	IV
NCT0000388012	NCT00003880_12_T0	PHENOTYPE	22	23	disease progression
NCT000038812	NCT00003881_2_T0	CELL	10	10	cells
NCT000038812	NCT00003881_2_T1	PHENOTYPE	9	9	tumor
NCT000038813	NCT00003881_3_T0	CELL	10	10	cells
NCT000038813	NCT00003881_3_T1	PHENOTYPE	9	9	tumor
NCT000038818	NCT00003881_8_T0	PHENOTYPE	4	4	progression
NCT000038818	NCT00003881_8_T1	PHENOTYPE	10	10	progression
NCT0000388111	NCT00003881_11_T0	COMPOUND	3	3	paclitaxel
NCT0000388111	NCT00003881_11_T1	GENE	21	21	HER2
NCT0000388111	NCT00003881_11_T2	GENE	4	4	IV
NCT0000388111	NCT00003881_11_T3	GENE	12	12	IV
NCT0000388111	NCT00003881_11_T4	GENE	22	22	IV
NCT0000388112	NCT00003881_12_T0	GENE	5	5	HER2
NCT0000388114	NCT00003881_14_T0	PHENOTYPE	25	25	toxicity
NCT0000388114	NCT00003881_14_T1	GENE	10	10	HER2
NCT0000388114	NCT00003881_14_T2	PHENOTYPE	21	22	disease progression
NCT0000388115	NCT00003881_15_T0	PHENOTYPE	21	22	disease progression
NCT000038820	NCT00003882_0_T0	PHENOTYPE	6	6	Recurrent
NCT000038820	NCT00003882_0_T1	PHENOTYPE	7	8	Solid Tumors
NCT000038822	NCT00003882_2_T0	COMPOUND	9	9	anhydrovinblastine
NCT000038822	NCT00003882_2_T1	PHENOTYPE	16	16	recurrent
NCT000038822	NCT00003882_2_T2	PHENOTYPE	17	18	solid tumors
NCT000038824	NCT00003882_4_T0	PHENOTYPE	8	8	toxicity
NCT000038824	NCT00003882_4_T1	COMPOUND	10	10	anhydrovinblastine
NCT000038824	NCT00003882_4_T2	PHENOTYPE	16	17	solid tumors
NCT000038826	NCT00003882_6_T0	PHENOTYPE	3	3	pharmacokinetics
NCT000038828	NCT00003882_8_T0	COMPOUND	2	2	anhydrovinblastine
NCT000038828	NCT00003882_8_T1	GENE	3	3	IV
NCT0000388210	NCT00003882_10_T0	PHENOTYPE	10	10	toxicity
NCT0000388210	NCT00003882_10_T1	PHENOTYPE	6	7	disease progression
NCT0000388211	NCT00003882_11_T0	COMPOUND	3	3	anhydrovinblastine
NCT0000388211	NCT00003882_11_T1	GENE	9	9	1/6
NCT0000388211	NCT00003882_11_T2	GENE	16	16	MTD
NCT0000388212	NCT00003882_12_T0	PHENOTYPE	20	20	toxicity
NCT0000388212	NCT00003882_12_T1	GENE	1	1	MTD
NCT000038831	NCT00003883_1_T0	COMPOUND	11	11	fluconazole
NCT000038831	NCT00003883_1_T1	PHENOTYPE	14	14	infections
NCT000038831	NCT00003883_1_T2	COMPOUND	6	6	itraconazole
NCT000038836	NCT00003883_6_T0	PHENOTYPE	6	6	infections
NCT000038838	NCT00003883_8_T0	PHENOTYPE	2	2	toxic
NCT0000388315	NCT00003883_15_T0	COMPOUND	3	3	itraconazole
NCT0000388315	NCT00003883_15_T1	GENE	6	6	IV
NCT000038841	NCT00003884_1_T0	PHENOTYPE	16	16	symptoms
NCT000038841	NCT00003884_1_T1	PHENOTYPE	18	19	bone metastases
NCT000038841	NCT00003884_1_T2	PHENOTYPE	22	23	disease progression
NCT000038842	NCT00003884_2_T0	GENE	3	3	III
NCT000038842	NCT00003884_2_T1	PHENOTYPE	16	17	solid tumors
NCT000038846	NCT00003884_6_T0	PHENOTYPE	12	12	hypercalcemia
NCT000038846	NCT00003884_6_T1	PHENOTYPE	10	10	tumor
NCT000038846	NCT00003884_6_T2	PHENOTYPE	28	28	progression
NCT000038846	NCT00003884_6_T3	PHENOTYPE	30	31	bone metastases
NCT000038846	NCT00003884_6_T4	PHENOTYPE	38	39	disease progression
NCT0000388410	NCT00003884_10_T0	PHENOTYPE	17	17	cancers
NCT0000388410	NCT00003884_10_T1	PHENOTYPE	8	9	lung cancer
NCT0000388410	NCT00003884_10_T2	PHENOTYPE	15	16	solid tumor
NCT0000388414	NCT00003884_14_T0	COMPOUND	4	4	calcium
NCT0000388415	NCT00003884_15_T0	PHENOTYPE	0	2	Quality of life
NCT000038855	NCT00003885_5_T0	PHENOTYPE	4	4	progression
NCT000038857	NCT00003885_7_T0	PHENOTYPE	2	2	toxic
NCT000038859	NCT00003885_9_T0	GENE	6	6	2.3
NCT000038859	NCT00003885_9_T1	GENE	2	2	IV
NCT000038859	NCT00003885_9_T2	COMPOUND	3	4	arsenic trioxide
NCT0000388510	NCT00003885_10_T0	PHENOTYPE	6	7	disease progression
NCT0000388512	NCT00003885_12_T0	PHENOTYPE	14	15	in remission
NCT000038871	NCT00003887_1_T0	GENE	2	2	II
NCT000038871	NCT00003887_1_T1	ORGAN	24	25	bone marrow
NCT000038871	NCT00003887_1_T2	PHENOTYPE	18	19	relapsed cancer
NCT000038871	NCT00003887_1_T3	CELL	10	12	white blood cells
NCT000038871	NCT00003887_1_T4	CELL	27	29	peripheral stem cells
NCT000038874	NCT00003887_4_T0	PHENOTYPE	3	4	rapidly progressive
NCT000038874	NCT00003887_4_T1	PHENOTYPE	4	5	progressive disease
NCT000038875	NCT00003887_5_T0	CELL	1	1	lymphocyte
NCT000038880	NCT00003888_0_T0	PHENOTYPE	10	13	Head and Neck Cancer
NCT000038882	NCT00003888_2_T0	CELL	8	8	cells
NCT000038882	NCT00003888_2_T1	PHENOTYPE	7	7	tumor
NCT000038883	NCT00003888_3_T0	CELL	15	15	cells
NCT000038883	NCT00003888_3_T1	PHENOTYPE	14	14	tumor
NCT000038884	NCT00003888_4_T0	PHENOTYPE	15	18	head and neck cancer
NCT000038885	NCT00003888_5_T0	GENE	3	3	III
NCT000038885	NCT00003888_5_T1	PHENOTYPE	24	27	head and neck cancer
NCT000038889	NCT00003888_9_T0	PHENOTYPE	8	8	symptoms
NCT000038889	NCT00003888_9_T1	PHENOTYPE	6	6	toxicity
NCT000038889	NCT00003888_9_T2	PHENOTYPE	12	13	disease progression
NCT0000388811	NCT00003888_11_T0	PHENOTYPE	2	4	quality of life
NCT0000388813	NCT00003888_13_T0	ORGAN	15	15	larynx
NCT0000388813	NCT00003888_13_T1	ORGAN	13	13	hypopharynx
NCT0000388813	NCT00003888_13_T2	ORGAN	11	11	oropharynx
NCT0000388813	NCT00003888_13_T3	ORGAN	8	9	oral cavity
NCT0000388813	NCT00003888_13_T4	PHENOTYPE	5	6	primary tumor
NCT0000388817	NCT00003888_17_T0	PHENOTYPE	16	16	toxicity
NCT0000388817	NCT00003888_17_T1	PHENOTYPE	12	13	disease progression
NCT0000388820	NCT00003888_20_T0	PHENOTYPE	0	2	Quality of life
NCT000038900	NCT00003890_0_T0	PHENOTYPE	6	7	Solid Tumors
NCT000038902	NCT00003890_2_T0	PHENOTYPE	16	17	solid tumors
NCT000038905	NCT00003890_5_T0	GENE	3	3	IV
NCT000038907	NCT00003890_7_T0	PHENOTYPE	10	10	toxicity
NCT000038907	NCT00003890_7_T1	PHENOTYPE	6	7	disease progression
NCT000038908	NCT00003890_8_T0	GENE	9	9	1/6
NCT000038908	NCT00003890_8_T1	GENE	16	16	MTD
NCT000038909	NCT00003890_9_T0	PHENOTYPE	22	22	toxicity
NCT000038909	NCT00003890_9_T1	GENE	1	1	MTD
NCT0000389010	NCT00003890_10_T0	PHENOTYPE	13	13	relapse
NCT000038910	NCT00003891_0_T0	PHENOTYPE	7	8	Solid Tumors
NCT000038912	NCT00003891_2_T0	COMPOUND	9	9	lurtotecan
NCT000038912	NCT00003891_2_T1	PHENOTYPE	17	18	solid tumors
NCT000038914	NCT00003891_4_T0	COMPOUND	11	11	lurtotecan
NCT000038914	NCT00003891_4_T1	GENE	5	5	MTD
NCT000038914	NCT00003891_4_T2	PHENOTYPE	17	18	solid tumors
NCT000038916	NCT00003891_6_T0	PHENOTYPE	2	2	toxicity
NCT000038916	NCT00003891_6_T1	PHENOTYPE	4	4	pharmacokinetics
NCT000038918	NCT00003891_8_T0	PHENOTYPE	9	10	measurable disease
NCT0000389110	NCT00003891_10_T0	COMPOUND	2	2	lurtotecan
NCT0000389110	NCT00003891_10_T1	GENE	5	5	IV
NCT0000389112	NCT00003891_12_T0	PHENOTYPE	12	12	toxicity
NCT0000389112	NCT00003891_12_T1	PHENOTYPE	14	15	disease progression
NCT0000389113	NCT00003891_13_T0	GENE	16	16	MTD
NCT0000389114	NCT00003891_14_T0	PHENOTYPE	18	18	toxicity
NCT0000389114	NCT00003891_14_T1	GENE	1	1	MTD
NCT000038921	NCT00003892_1_T0	GENE	2	2	II
NCT000038921	NCT00003892_1_T1	GENE	22	22	has
NCT000038921	NCT00003892_1_T2	PHENOTYPE	18	20	recurrent ovarian cancer
NCT000038924	NCT00003892_4_T0	PHENOTYPE	17	20	recurrent ovarian epithelial cancer
NCT000038926	NCT00003892_6_T0	PHENOTYPE	5	5	toxicity
NCT000038928	NCT00003892_8_T0	GENE	4	4	IV
NCT0000389210	NCT00003892_10_T0	PHENOTYPE	16	16	toxicity
NCT0000389210	NCT00003892_10_T1	PHENOTYPE	12	13	disease progression
NCT0000389213	NCT00003892_13_T0	PHENOTYPE	14	14	progression
NCT0000389213	NCT00003892_13_T1	PHENOTYPE	11	12	disease relapse
NCT000038931	NCT00003893_1_T0	PHENOTYPE	7	7	tumors
NCT000038931	NCT00003893_1_T1	CELL	8	8	cells
NCT000038932	NCT00003893_2_T0	CELL	9	9	cells
NCT000038932	NCT00003893_2_T1	PHENOTYPE	8	8	tumor
NCT000038933	NCT00003893_3_T0	PHENOTYPE	16	18	early-stage breast cancer
NCT000038934	NCT00003893_4_T0	GENE	3	3	III
NCT000038934	NCT00003893_4_T1	PHENOTYPE	24	26	early-stage breast cancer
NCT000038937	NCT00003893_7_T0	COMPOUND	22	22	cyclophosphamide
NCT000038937	NCT00003893_7_T1	COMPOUND	23	23	methotrexate
NCT000038937	NCT00003893_7_T2	PHENOTYPE	14	14	intent
NCT000038937	NCT00003893_7_T3	PHENOTYPE	21	21	intent
NCT000038939	NCT00003893_9_T0	COMPOUND	8	8	methotrexate
NCT000038939	NCT00003893_9_T1	COMPOUND	7	7	cyclophosphamide
NCT0000389310	NCT00003893_10_T0	COMPOUND	7	7	mitoxantrone
NCT0000389310	NCT00003893_10_T1	COMPOUND	5	5	epirubicin
NCT0000389310	NCT00003893_10_T2	COMPOUND	6	6	doxorubicin
NCT0000389313	NCT00003893_13_T0	GENE	4	4	3.5
NCT0000389315	NCT00003893_15_T0	GENE	7	7	2.3
NCT0000389315	NCT00003893_15_T1	PHENOTYPE	0	2	Quality of life
NCT000038941	NCT00003894_1_T0	GENE	3	3	II
NCT000038941	NCT00003894_1_T1	COMPOUND	10	10	thalidomide
NCT000038941	NCT00003894_1_T2	ORGAN	20	21	bone marrow
NCT000038941	NCT00003894_1_T3	PHENOTYPE	16	18	chronic graft-versus-host disease
NCT000038943	NCT00003894_3_T0	COMPOUND	4	4	thalidomide
NCT000038943	NCT00003894_3_T1	ORGAN	22	22	transplant
NCT000038943	NCT00003894_3_T2	PHENOTYPE	12	12	chronic
NCT000038943	NCT00003894_3_T3	ORGAN	20	21	bone marrow
NCT000038943	NCT00003894_3_T4	PHENOTYPE	13	16	graft vs host disease
NCT000038945	NCT00003894_5_T0	PHENOTYPE	2	2	toxicity
NCT000038947	NCT00003894_7_T0	ORGAN	10	10	transplant
NCT000038947	NCT00003894_7_T1	PHENOTYPE	20	20	chronic
NCT000038947	NCT00003894_7_T2	ORGAN	8	9	bone marrow
NCT000038947	NCT00003894_7_T3	PHENOTYPE	21	24	graft vs host disease
NCT000038948	NCT00003894_8_T0	COMPOUND	4	4	thalidomide
NCT000038948	NCT00003894_8_T1	GENE	7	7	2.4
NCT000038949	NCT00003894_9_T0	GENE	4	4	tapered
NCT0000389412	NCT00003894_12_T0	GENE	7	7	tapered
NCT000038951	NCT00003895_1_T0	CELL	16	16	cells
NCT000038951	NCT00003895_1_T1	PHENOTYPE	15	15	tumor
NCT000038951	NCT00003895_1_T2	BIOLOGICAL_PROCESS	11	12	immune response
NCT000038955	NCT00003895_5_T0	GENE	18	18	gp100
NCT000038955	NCT00003895_5_T1	GENE	16	16	glycoprotein
NCT000038955	NCT00003895_5_T2	CELL	3	3	T-cell
NCT000038957	NCT00003895_7_T0	PHENOTYPE	18	18	papilloma
NCT000038957	NCT00003895_7_T1	CELL	9	9	leukocyte
NCT000038957	NCT00003895_7_T2	GENE	15	15	CTL
NCT000038957	NCT00003895_7_T3	CELL	3	3	T-cell
NCT000038959	NCT00003895_9_T0	GENE	37	37	LDA
NCT000038959	NCT00003895_9_T1	CELL	6	6	T-cells
NCT000038959	NCT00003895_9_T2	BIOLOGICAL_PROCESS	42	43	cytokine production
NCT000038959	NCT00003895_9_T3	BIOLOGICAL_PROCESS	18	19	immune response
NCT0000389511	NCT00003895_11_T0	GENE	24	24	E7
NCT0000389511	NCT00003895_11_T1	GENE	19	19	gp100
NCT0000389511	NCT00003895_11_T2	CELL	13	13	T-cell
NCT0000389513	NCT00003895_13_T0	BIOLOGICAL_PROCESS	3	4	immune response
NCT0000389515	NCT00003895_15_T0	GENE	17	17	SC
NCT0000389515	NCT00003895_15_T1	GENE	0	0	ARM
NCT0000389516	NCT00003895_16_T0	PHENOTYPE	10	10	toxicity
NCT0000389516	NCT00003895_16_T1	PHENOTYPE	6	7	disease progression
NCT0000389517	NCT00003895_17_T0	GENE	16	16	SC
NCT0000389517	NCT00003895_17_T1	GENE	0	0	ARM
NCT0000389518	NCT00003895_18_T0	PHENOTYPE	10	10	toxicity
NCT0000389518	NCT00003895_18_T1	PHENOTYPE	6	7	disease progression
NCT0000389520	NCT00003895_20_T0	TISSUE	3	4	lymph nodes
NCT0000389520	NCT00003895_20_T1	TISSUE	7	8	lymph node
NCT000038961	NCT00003896_1_T0	CELL	9	9	cells
NCT000038961	NCT00003896_1_T1	PHENOTYPE	8	8	tumor
NCT000038965	NCT00003896_5_T0	COMPOUND	29	29	HCl
NCT000038965	NCT00003896_5_T1	COMPOUND	2	2	paclitaxel
NCT000038965	NCT00003896_5_T2	COMPOUND	20	20	paclitaxel
NCT000038965	NCT00003896_5_T3	COMPOUND	28	28	doxorubicin
NCT000038965	NCT00003896_5_T4	COMPOUND	12	12	cisplatin
NCT000038965	NCT00003896_5_T5	GENE	3	3	IV
NCT000038965	NCT00003896_5_T6	GENE	31	31	IV
NCT000038966	NCT00003896_6_T0	COMPOUND	8	8	paclitaxel
NCT000038966	NCT00003896_6_T1	COMPOUND	11	11	cisplatin
NCT000038966	NCT00003896_6_T2	GENE	9	9	IV
NCT000038966	NCT00003896_6_T3	GENE	12	12	IV
NCT000038967	NCT00003896_7_T0	PHENOTYPE	16	16	toxicity
NCT000038967	NCT00003896_7_T1	PHENOTYPE	12	13	disease progression
NCT000038971	NCT00003897_1_T0	GENE	12	12	gp100
NCT000038971	NCT00003897_1_T1	GENE	14	14	sargramostim
NCT000038971	NCT00003897_1_T2	PHENOTYPE	20	21	malignant melanoma
NCT000038973	NCT00003897_3_T0	PHENOTYPE	4	4	toxicity
NCT000038973	NCT00003897_3_T1	PHENOTYPE	35	35	melanoma
NCT000038973	NCT00003897_3_T2	GENE	28	28	GM-CSF
NCT000038973	NCT00003897_3_T3	GENE	18	18	gp100
NCT000038973	NCT00003897_3_T4	GENE	16	16	cDNA
NCT000038973	NCT00003897_3_T5	GENE	25	25	cDNA
NCT000038973	NCT00003897_3_T6	GENE	27	27	sargramostim
NCT000038975	NCT00003897_5_T0	GENE	6	6	gp100
NCT000038977	NCT00003897_7_T0	CELL	2	2	lymphocyte
NCT000038977	NCT00003897_7_T1	CELL	6	6	lymphocyte
NCT000038979	NCT00003897_9_T0	GENE	1	1	gp100
NCT000038979	NCT00003897_9_T1	GENE	26	26	gp100
NCT000038979	NCT00003897_9_T2	GENE	33	33	gp100
NCT000038979	NCT00003897_9_T3	GENE	16	16	cDNA
NCT000038979	NCT00003897_9_T4	GENE	24	24	cDNA
NCT000038979	NCT00003897_9_T5	GENE	18	18	GM-CSF
NCT000038979	NCT00003897_9_T6	CELL	8	8	lymphocyte
NCT000038979	NCT00003897_9_T7	CELL	12	12	lymphocyte
NCT0000389711	NCT00003897_11_T0	PHENOTYPE	13	13	inflammation
NCT0000389711	NCT00003897_11_T1	BIOLOGICAL_PROCESS	15	15	necrosis
NCT0000389711	NCT00003897_11_T2	PHENOTYPE	7	7	tumor
NCT0000389711	NCT00003897_11_T3	PHENOTYPE	12	12	tumor
NCT0000389714	NCT00003897_14_T0	GENE	10	10	gp100
NCT0000389714	NCT00003897_14_T1	GENE	0	1	Group I
NCT0000389718	NCT00003897_18_T0	GENE	1	1	II
NCT0000389718	NCT00003897_18_T1	GENE	12	12	1.5
NCT0000389718	NCT00003897_18_T2	GENE	7	7	GM-CSF
NCT0000389718	NCT00003897_18_T3	GENE	6	6	sargramostim
NCT0000389719	NCT00003897_19_T0	GENE	2	2	gp100
NCT0000389719	NCT00003897_19_T1	GENE	6	6	2.4
NCT0000389720	NCT00003897_20_T0	GENE	3	3	gp100
NCT0000389723	NCT00003897_23_T0	GENE	10	10	gp100
NCT0000389723	NCT00003897_23_T1	GENE	1	1	III
NCT0000389723	NCT00003897_23_T2	GENE	6	6	GM-CSF
NCT0000389724	NCT00003897_24_T0	GENE	5	6	group I
NCT0000389726	NCT00003897_26_T0	GENE	17	17	MTD
NCT0000389727	NCT00003897_27_T0	PHENOTYPE	18	18	toxicity
NCT0000389727	NCT00003897_27_T1	GENE	1	1	MTD
NCT000038989	NCT00003898_9_T0	PHENOTYPE	12	12	conditioning
NCT000038990	NCT00003899_0_T0	PHENOTYPE	13	13	Recurrent
NCT000038990	NCT00003899_0_T1	ORGAN	2	3	Bone Marrow
NCT000038990	NCT00003899_0_T2	PHENOTYPE	16	17	Solid Tumors
NCT000038990	NCT00003899_0_T3	CELL	5	7	Peripheral Stem Cell
NCT000038995	NCT00003899_5_T0	COMPOUND	6	6	melphalan
NCT000038995	NCT00003899_5_T1	PHENOTYPE	12	12	recurrent
NCT000038995	NCT00003899_5_T2	PHENOTYPE	15	16	solid tumors
NCT000038999	NCT00003899_9_T0	COMPOUND	11	11	paclitaxel
NCT000038999	NCT00003899_9_T1	GENE	24	24	filgrastim
NCT000038999	NCT00003899_9_T2	COMPOUND	2	2	cyclophosphamide
NCT000038999	NCT00003899_9_T3	GENE	25	25	G-CSF
NCT000038999	NCT00003899_9_T4	GENE	3	3	IV
NCT000038999	NCT00003899_9_T5	GENE	12	12	IV
NCT0000389910	NCT00003899_10_T0	GENE	13	13	5.7
NCT0000389910	NCT00003899_10_T1	ORGAN	7	8	bone marrow
NCT0000389910	NCT00003899_10_T2	CELL	0	3	Peripheral blood stem cells
NCT0000389911	NCT00003899_11_T0	COMPOUND	7	7	melphalan
NCT0000389911	NCT00003899_11_T1	GENE	8	8	IV
NCT0000389911	NCT00003899_11_T2	GENE	19	19	IV
NCT0000389911	NCT00003899_11_T3	COMPOUND	21	21	2
NCT0000389911	NCT00003899_11_T4	COMPOUND	27	27	2
NCT0000389911	NCT00003899_11_T5	COMPOUND	25	25	3
NCT0000389911	NCT00003899_11_T6	COMPOUND	18	18	thiotepa
NCT0000389911	NCT00003899_11_T7	ORGAN	31	32	bone marrow
NCT0000389912	NCT00003899_12_T0	COMPOUND	12	12	thiotepa
NCT0000389912	NCT00003899_12_T1	COMPOUND	4	4	melphalan
NCT0000389913	NCT00003899_13_T0	GENE	14	14	MTD
NCT0000389914	NCT00003899_14_T0	PHENOTYPE	28	28	toxicity
NCT0000389914	NCT00003899_14_T1	GENE	1	1	MTD
NCT000039002	NCT00003900_2_T0	CELL	9	9	cells
NCT000039002	NCT00003900_2_T1	PHENOTYPE	8	8	tumor
NCT000039007	NCT00003900_7_T0	PHENOTYPE	2	2	toxicity
NCT0000390010	NCT00003900_10_T0	COMPOUND	3	3	irinotecan
NCT0000390010	NCT00003900_10_T1	COMPOUND	11	11	docetaxel
NCT0000390010	NCT00003900_10_T2	GENE	4	4	IV
NCT0000390010	NCT00003900_10_T3	GENE	12	12	IV
NCT0000390011	NCT00003900_11_T0	PHENOTYPE	17	17	toxicity
NCT0000390011	NCT00003900_11_T1	PHENOTYPE	13	14	disease progression
NCT0000390110	NCT00003901_10_T0	GENE	5	5	N2
NCT0000390111	NCT00003901_11_T0	GENE	9	9	N3
NCT0000390113	NCT00003901_13_T0	PHENOTYPE	10	10	NSCLC
NCT0000390115	NCT00003901_15_T0	PHENOTYPE	17	17	NSCLC
NCT0000390116	NCT00003901_16_T0	ORGAN	19	19	abdomen
NCT0000390116	NCT00003901_16_T1	ORGAN	22	23	adrenal glands
NCT0000390120	NCT00003901_20_T0	PHENOTYPE	10	10	carcinoma
NCT0000390125	NCT00003901_25_T0	PHENOTYPE	9	9	malignancies
NCT0000390125	NCT00003901_25_T1	GENE	1	1	has
NCT0000390127	NCT00003901_27_T0	PHENOTYPE	13	13	recurrence
NCT0000390127	NCT00003901_27_T1	PHENOTYPE	16	16	malignancies
NCT0000390129	NCT00003901_29_T0	GENE	1	1	has
NCT0000390129	NCT00003901_29_T1	PHENOTYPE	4	5	pleural effusion
NCT0000390131	NCT00003901_31_T0	GENE	2	2	had
NCT0000390131	NCT00003901_31_T1	GENE	1	1	has
NCT0000390133	NCT00003901_33_T0	GENE	1	1	has
NCT0000390135	NCT00003901_35_T0	PHENOTYPE	10	11	systemic disease
NCT000039020	NCT00003902_0_T0	PHENOTYPE	9	11	Metastatic Breast Cancer
NCT000039022	NCT00003902_2_T0	CELL	9	9	cells
NCT000039022	NCT00003902_2_T1	PHENOTYPE	8	8	tumor
NCT000039023	NCT00003902_3_T0	COMPOUND	16	16	vinorelbine
NCT000039023	NCT00003902_3_T1	COMPOUND	14	14	capecitabine
NCT000039023	NCT00003902_3_T2	PHENOTYPE	29	31	metastatic breast cancer
NCT000039025	NCT00003902_5_T0	COMPOUND	9	9	vinorelbine
NCT000039025	NCT00003902_5_T1	COMPOUND	7	7	capecitabine
NCT000039027	NCT00003902_7_T0	PHENOTYPE	19	19	toxicity
NCT000039027	NCT00003902_7_T1	PHENOTYPE	15	16	disease progression
NCT000039028	NCT00003902_8_T0	COMPOUND	10	10	vinorelbine
NCT000039028	NCT00003902_8_T1	COMPOUND	8	8	capecitabine
NCT000039028	NCT00003902_8_T2	GENE	16	16	MTD
NCT0000390210	NCT00003902_10_T0	GENE	7	7	II
NCT0000390210	NCT00003902_10_T1	GENE	23	23	2.4
NCT0000390210	NCT00003902_10_T2	PHENOTYPE	0	2	Quality of life
NCT0000390211	NCT00003902_11_T0	PHENOTYPE	7	8	disease progression
NCT000039033	NCT00003903_3_T0	COMPOUND	7	7	androgen
NCT000039033	NCT00003903_3_T1	PHENOTYPE	14	15	metastatic disease
NCT000039035	NCT00003903_5_T0	COMPOUND	4	4	androgen
NCT000039035	NCT00003903_5_T1	PHENOTYPE	12	14	increased bone resorption
NCT000039036	NCT00003903_6_T0	PHENOTYPE	13	13	metastases
NCT000039036	NCT00003903_6_T1	COMPOUND	5	5	androgen
NCT000039036	NCT00003903_6_T2	BIOLOGICAL_PROCESS	9	10	bone resorption
NCT000039062	NCT00003906_2_T0	COMPOUND	10	10	raloxifene
NCT000039062	NCT00003906_2_T1	COMPOUND	14	14	tamoxifen
NCT000039062	NCT00003906_2_T2	PHENOTYPE	17	18	breast cancer
NCT000039064	NCT00003906_4_T0	PHENOTYPE	4	4	closed
NCT000039064	NCT00003906_4_T1	PHENOTYPE	0	2	Quality of life
NCT000039065	NCT00003906_5_T0	GENE	51	51	2.0
NCT000039065	NCT00003906_5_T1	GENE	11	11	59
NCT000039065	NCT00003906_5_T2	GENE	14	14	59
NCT000039065	NCT00003906_5_T3	GENE	57	57	5.0
NCT000039065	NCT00003906_5_T4	PHENOTYPE	40	42	invasive breast cancer
NCT000039065	NCT00003906_5_T5	PHENOTYPE	23	26	lobular carcinoma in situ
NCT000039067	NCT00003906_7_T0	PHENOTYPE	7	7	centers
NCT000039068	NCT00003906_8_T0	PHENOTYPE	4	4	closed
NCT000039068	NCT00003906_8_T1	PHENOTYPE	0	2	Quality of life
NCT000039071	NCT00003907_1_T0	GENE	2	2	II
NCT000039071	NCT00003907_1_T1	PHENOTYPE	19	19	metastases
NCT000039071	NCT00003907_1_T2	ORGAN	22	22	liver
NCT000039071	NCT00003907_1_T3	PHENOTYPE	15	17	primary liver cancer
NCT000039074	NCT00003907_4_T0	PHENOTYPE	11	12	hepatic metastases
NCT000039074	NCT00003907_4_T1	PHENOTYPE	7	8	hepatocellular carcinoma
NCT000039076	NCT00003907_6_T0	GENE	16	16	lobe
NCT000039076	NCT00003907_6_T1	COMPOUND	2	2	doxorubicin
NCT000039076	NCT00003907_6_T2	COMPOUND	5	5	cisplatin
NCT000039078	NCT00003907_8_T0	GENE	2	2	lobe
NCT000039078	NCT00003907_8_T1	GENE	15	15	lobe
NCT000039078	NCT00003907_8_T2	GENE	8	8	3.5
NCT000039079	NCT00003907_9_T0	PHENOTYPE	5	5	toxicity
NCT000039079	NCT00003907_9_T1	GENE	8	8	lobe
NCT0000390710	NCT00003907_10_T0	PHENOTYPE	16	16	recurrence
NCT0000390710	NCT00003907_10_T1	GENE	11	11	lobe
NCT0000390710	NCT00003907_10_T2	GENE	33	33	lobe
NCT000039080	NCT00003908_0_T0	PHENOTYPE	10	14	Recurrent Head and Neck Cancer
NCT000039082	NCT00003908_2_T0	GENE	2	2	II
NCT000039082	NCT00003908_2_T1	COMPOUND	9	9	docetaxel
NCT000039082	NCT00003908_2_T2	PHENOTYPE	19	23	recurrent head and neck cancer
NCT000039088	NCT00003908_8_T0	PHENOTYPE	2	2	toxicities
NCT000039089	NCT00003908_9_T0	COMPOUND	3	3	docetaxel
NCT000039089	NCT00003908_9_T1	GENE	4	4	IV
NCT000039089	NCT00003908_9_T2	GENE	12	12	IV
NCT0000390810	NCT00003908_10_T0	PHENOTYPE	10	10	toxicity
NCT0000390810	NCT00003908_10_T1	PHENOTYPE	12	13	disease progression
NCT000039092	NCT00003909_2_T0	CELL	9	9	cells
NCT000039092	NCT00003909_2_T1	PHENOTYPE	8	8	tumor
NCT000039092	NCT00003909_2_T2	COMPOUND	3	4	motexafin gadolinium
NCT000039094	NCT00003909_4_T0	GENE	5	5	MTD
NCT000039094	NCT00003909_4_T1	COMPOUND	9	10	motexafin gadolinium
NCT000039094	NCT00003909_4_T2	PHENOTYPE	20	23	diffuse intrinsic pontine glioma
NCT000039096	NCT00003909_6_T0	PHENOTYPE	2	2	toxic
NCT000039096	NCT00003909_6_T1	GENE	10	10	MTD
NCT000039098	NCT00003909_8_T0	GENE	13	13	MRI
NCT000039099	NCT00003909_9_T0	COMPOUND	7	8	motexafin gadolinium
NCT0000390912	NCT00003909_12_T0	GENE	12	12	MTD
NCT0000390912	NCT00003909_12_T1	COMPOUND	8	9	motexafin gadolinium
NCT0000390913	NCT00003909_13_T0	COMPOUND	4	5	motexafin gadolinium
NCT0000390913	NCT00003909_13_T1	COMPOUND	17	18	motexafin gadolinium
NCT0000390913	NCT00003909_13_T2	COMPOUND	30	31	motexafin gadolinium
NCT0000390914	NCT00003909_14_T0	PHENOTYPE	21	21	toxicity
NCT0000390914	NCT00003909_14_T1	GENE	1	1	MTD
NCT000039101	NCT00003910_1_T0	GENE	2	2	II
NCT000039101	NCT00003910_1_T1	COMPOUND	13	13	cyclophosphamide
NCT000039101	NCT00003910_1_T2	PHENOTYPE	22	22	neutropenia
NCT000039101	NCT00003910_1_T3	COMPOUND	9	9	methotrexate
NCT000039101	NCT00003910_1_T4	PHENOTYPE	24	24	anemia
NCT000039101	NCT00003910_1_T5	PHENOTYPE	19	20	lymphocytic leukemia
NCT000039105	NCT00003910_5_T0	PHENOTYPE	4	4	neutropenia
NCT000039105	NCT00003910_5_T1	PHENOTYPE	5	5	anemia
NCT000039105	NCT00003910_5_T2	PHENOTYPE	7	8	rheumatoid arthritis
NCT000039109	NCT00003910_9_T0	GENE	4	4	has
NCT0000391010	NCT00003910_10_T0	GENE	3	3	MTX
NCT0000391010	NCT00003910_10_T1	PHENOTYPE	14	14	neutropenia
NCT0000391010	NCT00003910_10_T2	GENE	4	4	has
NCT0000391011	NCT00003910_11_T0	GENE	3	3	MTX
NCT0000391011	NCT00003910_11_T1	CELL	11	11	neutrophil
NCT0000391012	NCT00003910_12_T0	GENE	13	13	MTX
NCT0000391012	NCT00003910_12_T1	PHENOTYPE	3	3	remission
NCT0000391013	NCT00003910_13_T0	GENE	2	2	has
NCT0000391013	NCT00003910_13_T1	PHENOTYPE	14	14	anemia
NCT0000391015	NCT00003910_15_T0	GENE	16	16	MTX
NCT0000391015	NCT00003910_15_T1	CELL	29	29	clone
NCT0000391015	NCT00003910_15_T2	PHENOTYPE	20	20	remissions
NCT000039111	NCT00003911_1_T0	CELL	6	6	cells
NCT000039111	NCT00003911_1_T1	PHENOTYPE	5	5	tumor
NCT000039112	NCT00003911_2_T0	GENE	2	2	II
NCT000039112	NCT00003911_2_T1	PHENOTYPE	23	24	malignant melanoma
NCT000039112	NCT00003911_2_T2	PHENOTYPE	20	21	brain metastases
NCT000039114	NCT00003911_4_T0	PHENOTYPE	5	5	progression
NCT000039114	NCT00003911_4_T1	PHENOTYPE	20	21	malignant melanoma
NCT000039114	NCT00003911_4_T2	PHENOTYPE	17	18	brain metastases
NCT000039116	NCT00003911_6_T0	PHENOTYPE	5	5	toxic
NCT000039117	NCT00003911_7_T0	GENE	14	14	3.5
NCT000039122	NCT00003912_2_T0	PHENOTYPE	15	16	liver cancer
NCT000039123	NCT00003912_3_T0	GENE	3	3	III
NCT000039123	NCT00003912_3_T1	COMPOUND	14	14	doxorubicin
NCT000039123	NCT00003912_3_T2	COMPOUND	23	23	doxorubicin
NCT000039123	NCT00003912_3_T3	COMPOUND	10	10	cisplatin
NCT000039123	NCT00003912_3_T4	COMPOUND	20	20	cisplatin
NCT000039123	NCT00003912_3_T5	PHENOTYPE	29	30	liver cancer
NCT000039126	NCT00003912_6_T0	PHENOTYPE	1	1	hepatoblastoma
NCT000039127	NCT00003912_7_T0	PHENOTYPE	0	0	Hepatoblastoma
NCT000039128	NCT00003912_8_T0	COMPOUND	2	2	cisplatin
NCT000039128	NCT00003912_8_T1	GENE	3	3	IV
NCT0000391212	NCT00003912_12_T0	PHENOTYPE	0	0	Tumor
NCT0000391213	NCT00003912_13_T0	PHENOTYPE	20	20	tumors
NCT0000391214	NCT00003912_14_T0	PHENOTYPE	2	2	tumors
NCT0000391217	NCT00003912_17_T0	PHENOTYPE	0	0	Tumor
NCT0000391218	NCT00003912_18_T0	COMPOUND	9	9	cisplatin
NCT0000391219	NCT00003912_19_T0	PHENOTYPE	3	3	tumors
NCT0000391219	NCT00003912_19_T1	COMPOUND	17	17	cisplatin
NCT0000391220	NCT00003912_20_T0	PHENOTYPE	2	2	tumors
NCT0000391220	NCT00003912_20_T1	PHENOTYPE	20	20	tumors
NCT0000391220	NCT00003912_20_T2	COMPOUND	14	14	cisplatin
NCT0000391222	NCT00003912_22_T0	PHENOTYPE	3	3	tumors
NCT0000391222	NCT00003912_22_T1	ORGAN	11	11	liver
NCT0000391222	NCT00003912_22_T2	ORGAN	12	12	transplant
NCT0000391223	NCT00003912_23_T0	PHENOTYPE	4	4	hepatoblastoma
NCT0000391223	NCT00003912_23_T1	COMPOUND	29	29	doxorubicin
NCT0000391223	NCT00003912_23_T2	COMPOUND	10	10	cisplatin
NCT0000391223	NCT00003912_23_T3	GENE	11	11	IV
NCT0000391223	NCT00003912_23_T4	GENE	23	23	IV
NCT0000391223	NCT00003912_23_T5	GENE	30	30	IV
NCT0000391223	NCT00003912_23_T6	PHENOTYPE	7	8	hepatocellular carcinoma
NCT0000391224	NCT00003912_24_T0	COMPOUND	29	29	doxorubicin
NCT0000391224	NCT00003912_24_T1	COMPOUND	42	42	cisplatin
NCT0000391227	NCT00003912_27_T0	ORGAN	21	21	liver
NCT0000391227	NCT00003912_27_T1	PHENOTYPE	9	9	tumor
NCT0000391227	NCT00003912_27_T2	ORGAN	22	22	transplant
NCT0000391228	NCT00003912_28_T0	COMPOUND	18	18	doxorubicin
NCT0000391228	NCT00003912_28_T1	COMPOUND	33	33	doxorubicin
NCT0000391228	NCT00003912_28_T2	COMPOUND	14	14	cisplatin
NCT0000391228	NCT00003912_28_T3	COMPOUND	26	26	cisplatin
NCT0000391228	NCT00003912_28_T4	PHENOTYPE	3	5	resectable hepatocellular carcinoma
NCT0000391229	NCT00003912_29_T0	GENE	4	4	2.3
NCT000039131	NCT00003913_1_T0	CELL	10	10	cells
NCT000039131	NCT00003913_1_T1	CELL	26	26	cells
NCT000039131	NCT00003913_1_T2	ORGAN	0	2	Umbilical cord blood
NCT000039132	NCT00003913_2_T0	GENE	2	2	II
NCT000039132	NCT00003913_2_T1	PHENOTYPE	21	22	hematologic cancer
NCT000039132	NCT00003913_2_T2	PHENOTYPE	25	26	hematologic disease
NCT000039132	NCT00003913_2_T3	ORGAN	9	11	umbilical cord blood
NCT0000391310	NCT00003913_10_T0	GENE	7	7	IV
NCT0000391310	NCT00003913_10_T1	ORGAN	5	6	cord blood
NCT0000391311	NCT00003913_11_T0	GENE	20	20	filgrastim
NCT0000391311	NCT00003913_11_T1	GENE	21	21	G-CSF
NCT0000391311	NCT00003913_11_T2	GENE	4	4	IV
NCT0000391311	NCT00003913_11_T3	GENE	22	22	IV
NCT0000391311	NCT00003913_11_T4	ORGAN	16	17	cord blood
NCT000039141	NCT00003914_1_T0	GENE	2	2	II
NCT000039141	NCT00003914_1_T1	PHENOTYPE	16	17	kidney cancer
NCT000039141	NCT00003914_1_T2	COMPOUND	9	10	dolastatin 10
NCT000039145	NCT00003914_5_T0	PHENOTYPE	2	2	toxicities
NCT000039149	NCT00003914_9_T0	PHENOTYPE	9	9	toxicity
NCT000039149	NCT00003914_9_T1	PHENOTYPE	5	5	pharmacokinetics
NCT0000391410	NCT00003914_10_T0	GENE	5	5	IV
NCT0000391410	NCT00003914_10_T1	COMPOUND	3	4	dolastatin 10
NCT0000391411	NCT00003914_11_T0	PHENOTYPE	15	15	toxicity
NCT0000391411	NCT00003914_11_T1	PHENOTYPE	11	12	disease progression
NCT0000391412	NCT00003914_12_T0	PHENOTYPE	18	18	progression
NCT0000391414	NCT00003914_14_T0	GENE	14	14	4.15
NCT000039160	NCT00003916_0_T0	PHENOTYPE	13	13	Glioma
NCT000039162	NCT00003916_2_T0	PHENOTYPE	12	12	tumor
NCT000039164	NCT00003916_4_T0	GENE	3	3	III
NCT000039164	NCT00003916_4_T1	PHENOTYPE	24	24	glioma
NCT000039166	NCT00003916_6_T0	PHENOTYPE	21	21	glioma
NCT000039166	NCT00003916_6_T1	PHENOTYPE	19	20	high grade
NCT000039168	NCT00003916_8_T0	PHENOTYPE	2	4	quality of life
NCT0000391610	NCT00003916_10_T0	GENE	8	8	III
NCT0000391610	NCT00003916_10_T1	GENE	10	10	IV
NCT0000391614	NCT00003916_14_T0	PHENOTYPE	0	2	Quality of life
NCT000039172	NCT00003917_2_T0	COMPOUND	6	6	topotecan
NCT000039177	NCT00003917_7_T0	PHENOTYPE	5	5	toxicities
NCT000039179	NCT00003917_9_T0	PHENOTYPE	2	4	quality of life
NCT0000391711	NCT00003917_11_T0	PHENOTYPE	6	7	liver metastases
NCT0000391715	NCT00003917_15_T0	PHENOTYPE	10	10	toxicity
NCT0000391716	NCT00003917_16_T0	PHENOTYPE	8	8	progression
NCT0000391718	NCT00003917_18_T0	PHENOTYPE	0	2	Quality of life
NCT000039206	NCT00003920_6_T0	PHENOTYPE	12	12	pharmacokinetics
NCT000039206	NCT00003920_6_T1	COMPOUND	3	3	indium
NCT000039206	NCT00003920_6_T2	PHENOTYPE	21	23	metastatic breast cancer
NCT000039208	NCT00003920_8_T0	COMPOUND	5	5	yttrium
NCT000039208	NCT00003920_8_T1	TISSUE	23	23	tissues
NCT0000392012	NCT00003920_12_T0	COMPOUND	11	11	cyclosporine
NCT0000392012	NCT00003920_12_T1	PHENOTYPE	5	5	tumor
NCT0000392012	NCT00003920_12_T2	CELL	14	16	peripheral stem cells
NCT0000392013	NCT00003920_13_T0	COMPOUND	8	8	yttrium
NCT0000392016	NCT00003920_16_T0	GENE	7	7	G-CSF
NCT0000392017	NCT00003920_17_T0	COMPOUND	3	3	cyclosporine
NCT0000392018	NCT00003920_18_T0	COMPOUND	19	19	indium
NCT0000392018	NCT00003920_18_T1	GENE	10	10	IV
NCT0000392018	NCT00003920_18_T2	GENE	28	28	IV
NCT0000392019	NCT00003920_19_T0	GENE	14	14	1.4
NCT0000392020	NCT00003920_20_T0	GENE	5	5	IV
NCT0000392020	NCT00003920_20_T1	GENE	23	23	IV
NCT000039231	NCT00003923_1_T0	ORGAN	11	11	gallbladder
NCT000039231	NCT00003923_1_T1	ORGAN	13	13	pancreas
NCT000039231	NCT00003923_1_T2	PHENOTYPE	6	10	cancer of the bile duct
NCT000039232	NCT00003923_2_T0	GENE	2	2	II
NCT000039232	NCT00003923_2_T1	ORGAN	21	21	gallbladder
NCT000039232	NCT00003923_2_T2	ORGAN	23	23	pancreas
NCT000039232	NCT00003923_2_T3	PHENOTYPE	16	20	cancer of the bile duct
NCT000039234	NCT00003923_4_T0	COMPOUND	9	10	porfimer sodium
NCT000039234	NCT00003923_4_T1	PHENOTYPE	16	18	bile duct obstruction
NCT000039235	NCT00003923_5_T0	PHENOTYPE	10	10	distal
NCT000039235	NCT00003923_5_T1	PHENOTYPE	6	6	tumor
NCT000039235	NCT00003923_5_T2	PHENOTYPE	8	8	proximal
NCT000039236	NCT00003923_6_T0	GENE	6	6	3.5
NCT000039236	NCT00003923_6_T1	GENE	4	4	IV
NCT000039236	NCT00003923_6_T2	COMPOUND	2	3	porfimer sodium
NCT000039237	NCT00003923_7_T0	PHENOTYPE	15	15	cholangitis
NCT000039237	NCT00003923_7_T1	PHENOTYPE	12	13	total bilirubin
NCT000039246	NCT00003924_6_T0	COMPOUND	14	15	interferon alfa_2b
NCT000039246	NCT00003924_6_T1	PHENOTYPE	4	5	disease progression
NCT0000392410	NCT00003924_10_T0	PHENOTYPE	5	5	lymphoma
NCT0000392414	NCT00003924_14_T0	PHENOTYPE	13	13	toxicity
NCT0000392414	NCT00003924_14_T1	PHENOTYPE	9	10	disease progression
NCT0000392415	NCT00003924_15_T0	PHENOTYPE	7	8	disease progression
NCT000039251	NCT00003925_1_T0	CELL	9	9	cells
NCT000039251	NCT00003925_1_T1	PHENOTYPE	8	8	tumor
NCT000039252	NCT00003925_2_T0	COMPOUND	10	10	gemcitabine
NCT000039252	NCT00003925_2_T1	GENE	22	22	has
NCT000039252	NCT00003925_2_T2	COMPOUND	13	13	leucovorin
NCT000039252	NCT00003925_2_T3	PHENOTYPE	19	20	advanced cancer
NCT000039254	NCT00003925_4_T0	COMPOUND	8	8	gemcitabine
NCT000039255	NCT00003925_5_T0	COMPOUND	2	2	gemcitabine
NCT000039255	NCT00003925_5_T1	GENE	3	3	IV
NCT000039256	NCT00003925_6_T0	COMPOUND	4	4	calcium
NCT000039256	NCT00003925_6_T1	COMPOUND	3	3	leucovorin
NCT000039258	NCT00003925_8_T0	PHENOTYPE	10	10	toxicity
NCT000039258	NCT00003925_8_T1	PHENOTYPE	6	7	disease progression
NCT000039259	NCT00003925_9_T0	COMPOUND	8	8	gemcitabine
NCT000039259	NCT00003925_9_T1	GENE	16	16	MTD
NCT0000392510	NCT00003925_10_T0	PHENOTYPE	18	18	toxicities
NCT0000392510	NCT00003925_10_T1	GENE	1	1	MTD
NCT000039260	NCT00003926_0_T0	PHENOTYPE	12	13	Solid Tumors
NCT000039263	NCT00003926_3_T0	CELL	8	8	cells
NCT000039263	NCT00003926_3_T1	COMPOUND	4	4	amifostine
NCT000039266	NCT00003926_6_T0	COMPOUND	8	8	amifostine
NCT000039268	NCT00003926_8_T0	COMPOUND	7	7	amifostine
NCT0000392610	NCT00003926_10_T0	GENE	3	3	filgrastim
NCT0000392610	NCT00003926_10_T1	GENE	4	4	G-CSF
NCT0000392610	NCT00003926_10_T2	GENE	5	5	IV
NCT0000392612	NCT00003926_12_T0	COMPOUND	14	14	melphalan
NCT0000392612	NCT00003926_12_T1	GENE	15	15	IV
NCT0000392612	NCT00003926_12_T2	GENE	26	26	IV
NCT0000392612	NCT00003926_12_T3	COMPOUND	3	3	busulfan
NCT0000392612	NCT00003926_12_T4	COMPOUND	28	28	2
NCT0000392612	NCT00003926_12_T5	COMPOUND	34	34	2
NCT0000392612	NCT00003926_12_T6	COMPOUND	32	32	3
NCT0000392612	NCT00003926_12_T7	COMPOUND	25	25	thiotepa
NCT0000392613	NCT00003926_13_T0	COMPOUND	20	20	1
NCT0000392613	NCT00003926_13_T1	COMPOUND	14	14	thiotepa
NCT0000392613	NCT00003926_13_T2	COMPOUND	12	12	melphalan
NCT0000392613	NCT00003926_13_T3	COMPOUND	2	2	amifostine
NCT0000392613	NCT00003926_13_T4	GENE	3	3	IV
NCT0000392615	NCT00003926_15_T0	COMPOUND	8	8	amifostine
NCT0000392616	NCT00003926_16_T0	PHENOTYPE	21	21	toxicity
NCT0000392616	NCT00003926_16_T1	GENE	1	1	MTD
NCT0000392617	NCT00003926_17_T0	GENE	5	5	50
NCT000039272	NCT00003927_2_T0	CELL	4	4	cells
NCT000039272	NCT00003927_2_T1	PHENOTYPE	8	10	effects of chemotherapy
NCT000039275	NCT00003927_5_T0	COMPOUND	8	8	paclitaxel
NCT000039275	NCT00003927_5_T1	COMPOUND	7	7	cyclophosphamide
NCT000039275	NCT00003927_5_T2	COMPOUND	6	6	doxorubicin
NCT000039275	NCT00003927_5_T3	COMPOUND	10	10	amifostine
NCT000039275	NCT00003927_5_T4	GENE	21	21	IV
NCT000039275	NCT00003927_5_T5	PHENOTYPE	23	24	breast cancer
NCT000039277	NCT00003927_7_T0	COMPOUND	5	5	paclitaxel
NCT000039277	NCT00003927_7_T1	COMPOUND	8	8	amifostine
NCT000039279	NCT00003927_9_T0	PHENOTYPE	2	2	toxicity
NCT0000392711	NCT00003927_11_T0	COMPOUND	36	36	paclitaxel
NCT0000392711	NCT00003927_11_T1	COMPOUND	21	21	cyclophosphamide
NCT0000392711	NCT00003927_11_T2	COMPOUND	8	8	doxorubicin
NCT0000392711	NCT00003927_11_T3	COMPOUND	30	30	amifostine
NCT0000392711	NCT00003927_11_T4	GENE	9	9	IV
NCT0000392711	NCT00003927_11_T5	GENE	22	22	IV
NCT0000392711	NCT00003927_11_T6	GENE	31	31	IV
NCT0000392711	NCT00003927_11_T7	GENE	37	37	IV
NCT0000392712	NCT00003927_12_T0	COMPOUND	2	2	2
NCT0000392712	NCT00003927_12_T1	GENE	17	17	G-CSF
NCT0000392712	NCT00003927_12_T2	GENE	20	20	IV
NCT000039281	NCT00003928_1_T0	GENE	3	3	II
NCT000039281	NCT00003928_1_T1	COMPOUND	9	9	gemcitabine
NCT000039281	NCT00003928_1_T2	COMPOUND	11	11	cisplatin
NCT000039281	NCT00003928_1_T3	PHENOTYPE	17	19	metastatic kidney cancer
NCT000039284	NCT00003928_4_T0	COMPOUND	3	3	gemcitabine
NCT000039284	NCT00003928_4_T1	COMPOUND	15	15	cisplatin
NCT000039284	NCT00003928_4_T2	GENE	4	4	IV
NCT000039284	NCT00003928_4_T3	GENE	16	16	IV
NCT000039285	NCT00003928_5_T0	PHENOTYPE	13	13	toxicity
NCT000039285	NCT00003928_5_T1	PHENOTYPE	9	10	disease progression
NCT000039291	NCT00003929_1_T0	CELL	8	8	cells
NCT000039292	NCT00003929_2_T0	CELL	9	9	cells
NCT000039293	NCT00003929_3_T0	CELL	18	18	cells
NCT000039293	NCT00003929_3_T1	GENE	4	4	filgrastim
NCT000039294	NCT00003929_4_T0	GENE	2	2	II
NCT000039294	NCT00003929_4_T1	COMPOUND	10	10	procarbazine
NCT000039294	NCT00003929_4_T2	COMPOUND	9	9	lomustine
NCT000039294	NCT00003929_4_T3	GENE	11	11	filgrastim
NCT000039294	NCT00003929_4_T4	PHENOTYPE	20	24	primary central nervous system lymphoma
NCT000039297	NCT00003929_7_T0	GENE	26	26	G-CSF
NCT000039297	NCT00003929_7_T1	COMPOUND	24	24	procarbazine
NCT000039297	NCT00003929_7_T2	COMPOUND	22	22	lomustine
NCT000039297	NCT00003929_7_T3	GENE	25	25	filgrastim
NCT000039297	NCT00003929_7_T4	PHENOTYPE	13	17	primary central nervous system lymphoma
NCT000039299	NCT00003929_9_T0	PHENOTYPE	1	1	toxicity
NCT0000392911	NCT00003929_11_T0	PHENOTYPE	1	3	quality of life
NCT0000392912	NCT00003929_12_T0	GENE	5	5	CD4
NCT0000392913	NCT00003929_13_T0	COMPOUND	12	12	1_10
NCT0000392913	NCT00003929_13_T1	COMPOUND	9	9	procarbazine
NCT0000392913	NCT00003929_13_T2	COMPOUND	3	3	lomustine
NCT0000392914	NCT00003929_14_T0	GENE	1	1	G-CSF
NCT0000392914	NCT00003929_14_T1	CELL	14	14	neutrophil
NCT0000392916	NCT00003929_16_T0	PHENOTYPE	8	9	disease progression
NCT0000392917	NCT00003929_17_T0	GENE	10	10	1.3
NCT0000392918	NCT00003929_18_T0	PHENOTYPE	0	2	Quality of life
NCT000039301	NCT00003930_1_T0	CELL	10	10	cells
NCT000039301	NCT00003930_1_T1	PHENOTYPE	9	9	tumor
NCT000039302	NCT00003930_2_T0	CELL	11	11	cells
NCT000039302	NCT00003930_2_T1	PHENOTYPE	10	10	tumor
NCT000039305	NCT00003930_5_T0	COMPOUND	14	14	paclitaxel
NCT000039305	NCT00003930_5_T1	GENE	45	45	1.5
NCT000039305	NCT00003930_5_T2	COMPOUND	25	25	cisplatin
NCT000039305	NCT00003930_5_T3	GENE	15	15	IV
NCT000039305	NCT00003930_5_T4	GENE	26	26	IV
NCT000039307	NCT00003930_7_T0	COMPOUND	13	13	paclitaxel
NCT000039307	NCT00003930_7_T1	GENE	1	1	1.2
NCT000039307	NCT00003930_7_T2	GENE	41	41	1.5
NCT000039307	NCT00003930_7_T3	COMPOUND	23	23	cisplatin
NCT000039307	NCT00003930_7_T4	GENE	14	14	IV
NCT000039307	NCT00003930_7_T5	GENE	24	24	IV
NCT000039308	NCT00003930_8_T0	PHENOTYPE	3	3	tumor
NCT000039309	NCT00003930_9_T0	COMPOUND	16	16	gemcitabine
NCT000039309	NCT00003930_9_T1	COMPOUND	23	23	cisplatin
NCT000039309	NCT00003930_9_T2	GENE	17	17	IV
NCT000039309	NCT00003930_9_T3	GENE	24	24	IV
NCT0000393010	NCT00003930_10_T0	PHENOTYPE	16	16	toxicity
NCT0000393010	NCT00003930_10_T1	PHENOTYPE	12	13	disease progression
NCT000039314	NCT00003931_4_T0	ORGAN	4	5	bone marrow
NCT000039315	NCT00003931_5_T0	PHENOTYPE	4	6	Southern blot analysis
NCT000039331	NCT00003933_1_T0	PHENOTYPE	19	21	acute lymphocytic leukemia
NCT000039333	NCT00003933_3_T0	CELL	2	2	cells
NCT000039334	NCT00003933_4_T0	GENE	17	17	p16
NCT000039334	NCT00003933_4_T1	GENE	19	19	p15
NCT000039334	NCT00003933_4_T2	PHENOTYPE	6	8	Southern blot analysis
NCT000039341	NCT00003934_1_T0	COMPOUND	7	7	cytarabine
NCT000039341	NCT00003934_1_T1	COMPOUND	9	9	methotrexate
NCT000039341	NCT00003934_1_T2	COMPOUND	6	6	daunorubicin
NCT000039341	NCT00003934_1_T3	CELL	20	20	cells
NCT000039341	NCT00003934_1_T4	COMPOUND	11	12	arsenic trioxide
NCT000039342	NCT00003934_2_T0	PHENOTYPE	3	3	leukemia
NCT000039342	NCT00003934_2_T1	CELL	4	4	cells
NCT000039342	NCT00003934_2_T2	CELL	8	10	white blood cells
NCT000039349	NCT00003934_9_T0	GENE	5	5	CD56
NCT0000393411	NCT00003934_11_T0	COMPOUND	7	7	daunorubicin
NCT0000393411	NCT00003934_11_T1	PHENOTYPE	3	4	cardiac toxicity
NCT0000393415	NCT00003934_15_T0	COMPOUND	7	8	arsenic trioxide
NCT0000393417	NCT00003934_17_T0	COMPOUND	9	9	cytarabine
NCT0000393417	NCT00003934_17_T1	GENE	4	4	IV
NCT0000393417	NCT00003934_17_T2	GENE	10	10	IV
NCT0000393417	NCT00003934_17_T3	COMPOUND	3	3	daunorubicin
NCT0000393424	NCT00003934_24_T0	COMPOUND	10	11	arsenic trioxide
NCT0000393426	NCT00003934_26_T0	GENE	5	5	PR
NCT0000393426	NCT00003934_26_T1	GENE	3	3	CR
NCT0000393430	NCT00003934_30_T0	COMPOUND	10	10	methotrexate
NCT0000393431	NCT00003934_31_T0	PHENOTYPE	13	13	toxicity
NCT000039352	NCT00003935_2_T0	CELL	8	8	cells
NCT000039352	NCT00003935_2_T1	PHENOTYPE	7	7	tumor
NCT000039353	NCT00003935_3_T0	CELL	12	12	cells
NCT000039353	NCT00003935_3_T1	PHENOTYPE	11	11	tumor
NCT000039354	NCT00003935_4_T0	COMPOUND	9	9	vincristine
NCT000039354	NCT00003935_4_T1	COMPOUND	11	11	etoposide
NCT000039354	NCT00003935_4_T2	PHENOTYPE	22	24	brain stem glioma
NCT000039356	NCT00003935_6_T0	COMPOUND	4	4	vincristine
NCT000039356	NCT00003935_6_T1	COMPOUND	6	6	etoposide
NCT000039356	NCT00003935_6_T2	PHENOTYPE	19	19	diffuse
NCT000039356	NCT00003935_6_T3	PHENOTYPE	21	23	brain stem glioma
NCT000039358	NCT00003935_8_T0	PHENOTYPE	2	2	toxicity
NCT000039359	NCT00003935_9_T0	COMPOUND	11	11	vincristine
NCT000039359	NCT00003935_9_T1	COMPOUND	5	5	etoposide
NCT000039359	NCT00003935_9_T2	GENE	12	12	IV
NCT0000393512	NCT00003935_12_T0	COMPOUND	8	8	vincristine
NCT0000393512	NCT00003935_12_T1	COMPOUND	17	17	etoposide
NCT0000393512	NCT00003935_12_T2	GENE	9	9	IV
NCT0000393513	NCT00003935_13_T0	PHENOTYPE	16	16	toxicity
NCT0000393513	NCT00003935_13_T1	PHENOTYPE	12	13	disease progression
NCT000039361	NCT00003936_1_T0	GENE	2	2	II
NCT000039361	NCT00003936_1_T1	PHENOTYPE	16	16	recurrent
NCT000039361	NCT00003936_1_T2	PHENOTYPE	19	20	Hodgkin's disease
NCT000039361	NCT00003936_1_T3	COMPOUND	9	10	bryostatin 1
NCT000039363	NCT00003936_3_T0	PHENOTYPE	7	7	recurrent
NCT000039363	NCT00003936_3_T1	PHENOTYPE	10	11	Hodgkin's disease
NCT000039363	NCT00003936_3_T2	COMPOUND	14	15	bryostatin 1
NCT000039365	NCT00003936_5_T0	PHENOTYPE	4	4	toxicities
NCT000039365	NCT00003936_5_T1	COMPOUND	6	7	bryostatin 1
NCT000039368	NCT00003936_8_T0	GENE	7	7	IV
NCT000039368	NCT00003936_8_T1	COMPOUND	3	4	bryostatin 1
NCT000039369	NCT00003936_9_T0	PHENOTYPE	13	13	toxicity
NCT000039369	NCT00003936_9_T1	PHENOTYPE	9	10	disease progression
NCT0000393610	NCT00003936_10_T0	GENE	5	5	CR
NCT0000393610	NCT00003936_10_T1	GENE	13	13	CR
NCT000039370	NCT00003937_0_T0	PHENOTYPE	11	11	Osteosarcoma
NCT000039372	NCT00003937_2_T0	CELL	9	9	cells
NCT000039372	NCT00003937_2_T1	PHENOTYPE	8	8	tumor
NCT000039373	NCT00003937_3_T0	COMPOUND	4	4	dexrazoxane
NCT000039373	NCT00003937_3_T1	CELL	8	8	cells
NCT000039373	NCT00003937_3_T2	PHENOTYPE	12	14	effects of chemotherapy
NCT000039374	NCT00003937_4_T0	COMPOUND	14	14	dexrazoxane
NCT000039374	NCT00003937_4_T1	GENE	2	2	III
NCT000039374	NCT00003937_4_T2	PHENOTYPE	23	23	osteosarcoma
NCT000039376	NCT00003937_6_T0	COMPOUND	11	11	ifosfamide
NCT000039376	NCT00003937_6_T1	COMPOUND	15	15	ifosfamide
NCT000039376	NCT00003937_6_T2	COMPOUND	17	17	etoposide
NCT000039376	NCT00003937_6_T3	COMPOUND	7	7	doxorubicin
NCT000039376	NCT00003937_6_T4	COMPOUND	9	9	doxorubicin
NCT000039376	NCT00003937_6_T5	COMPOUND	13	13	doxorubicin
NCT000039376	NCT00003937_6_T6	PHENOTYPE	26	26	osteosarcoma
NCT0000393710	NCT00003937_10_T0	COMPOUND	4	4	dexrazoxane
NCT0000393714	NCT00003937_14_T0	COMPOUND	15	15	ifosfamide
NCT0000393714	NCT00003937_14_T1	COMPOUND	4	4	dexrazoxane
NCT0000393714	NCT00003937_14_T2	COMPOUND	7	7	doxorubicin
NCT0000393714	NCT00003937_14_T3	COMPOUND	11	11	cisplatin
NCT0000393714	NCT00003937_14_T4	COMPOUND	13	13	cisplatin
NCT0000393716	NCT00003937_16_T0	COMPOUND	4	4	dexrazoxane
NCT0000393716	NCT00003937_16_T1	PHENOTYPE	6	6	cytotoxicity
NCT0000393716	NCT00003937_16_T2	PHENOTYPE	10	11	tumor necrosis
NCT0000393718	NCT00003937_18_T0	COMPOUND	12	12	ifosfamide
NCT0000393718	NCT00003937_18_T1	COMPOUND	7	7	dexrazoxane
NCT0000393718	NCT00003937_18_T2	COMPOUND	23	23	methotrexate
NCT0000393718	NCT00003937_18_T3	COMPOUND	14	14	etoposide
NCT0000393718	NCT00003937_18_T4	COMPOUND	5	5	doxorubicin
NCT0000393718	NCT00003937_18_T5	COMPOUND	25	25	cisplatin
NCT0000393721	NCT00003937_21_T0	ORGAN	23	23	limb
NCT0000393721	NCT00003937_21_T1	BIOLOGICAL_PROCESS	21	21	necrosis
NCT0000393721	NCT00003937_21_T2	PHENOTYPE	6	7	primary tumor
NCT0000393722	NCT00003937_22_T0	COMPOUND	1	1	1
NCT0000393722	NCT00003937_22_T1	COMPOUND	28	28	1
NCT0000393722	NCT00003937_22_T2	COMPOUND	33	33	1
NCT0000393722	NCT00003937_22_T3	COMPOUND	10	10	dexrazoxane
NCT0000393722	NCT00003937_22_T4	PHENOTYPE	2	2	Closed
NCT0000393722	NCT00003937_22_T5	COMPOUND	15	15	doxorubicin
NCT0000393722	NCT00003937_22_T6	COMPOUND	21	21	cisplatin
NCT0000393722	NCT00003937_22_T7	GENE	11	11	IV
NCT0000393722	NCT00003937_22_T8	GENE	16	16	IV
NCT0000393722	NCT00003937_22_T9	GENE	22	22	IV
NCT0000393723	NCT00003937_23_T0	GENE	1	1	IV
NCT0000393726	NCT00003937_26_T0	COMPOUND	9	9	methotrexate
NCT0000393726	NCT00003937_26_T1	GENE	10	10	IV
NCT0000393726	NCT00003937_26_T2	GENE	0	1	Group 1
NCT0000393727	NCT00003937_27_T0	COMPOUND	3	3	dexrazoxane
NCT0000393727	NCT00003937_27_T1	COMPOUND	5	5	doxorubicin
NCT0000393728	NCT00003937_28_T0	COMPOUND	9	9	dexrazoxane
NCT0000393728	NCT00003937_28_T1	COMPOUND	11	11	doxorubicin
NCT0000393729	NCT00003937_29_T0	COMPOUND	17	17	dexrazoxane
NCT0000393729	NCT00003937_29_T1	COMPOUND	9	9	methotrexate
NCT0000393729	NCT00003937_29_T2	COMPOUND	19	19	doxorubicin
NCT0000393729	NCT00003937_29_T3	COMPOUND	11	11	cisplatin
NCT0000393730	NCT00003937_30_T0	COMPOUND	1	1	2
NCT0000393730	NCT00003937_30_T1	COMPOUND	8	8	dexrazoxane
NCT0000393730	NCT00003937_30_T2	COMPOUND	11	11	methotrexate
NCT0000393730	NCT00003937_30_T3	COMPOUND	9	9	doxorubicin
NCT0000393731	NCT00003937_31_T0	GENE	10	10	1.5
NCT0000393731	NCT00003937_31_T1	GENE	1	1	IV
NCT0000393733	NCT00003937_33_T0	COMPOUND	11	11	1
NCT0000393733	NCT00003937_33_T1	COMPOUND	13	13	1
NCT0000393733	NCT00003937_33_T2	COMPOUND	5	5	dexrazoxane
NCT0000393733	NCT00003937_33_T3	COMPOUND	4	4	methotrexate
NCT0000393733	NCT00003937_33_T4	COMPOUND	7	7	doxorubicin
NCT0000393733	NCT00003937_33_T5	GENE	0	1	Group 1
NCT0000393736	NCT00003937_36_T0	COMPOUND	1	1	2
NCT0000393736	NCT00003937_36_T1	COMPOUND	5	5	dexrazoxane
NCT0000393736	NCT00003937_36_T2	COMPOUND	4	4	methotrexate
NCT0000393736	NCT00003937_36_T3	COMPOUND	7	7	doxorubicin
NCT0000393736	NCT00003937_36_T4	GENE	12	13	group 2
NCT0000393739	NCT00003937_39_T0	COMPOUND	17	17	ifosfamide
NCT0000393739	NCT00003937_39_T1	COMPOUND	15	15	dexrazoxane
NCT0000393739	NCT00003937_39_T2	COMPOUND	1	1	3
NCT0000393739	NCT00003937_39_T3	COMPOUND	14	14	methotrexate
NCT0000393739	NCT00003937_39_T4	COMPOUND	16	16	doxorubicin
NCT0000393739	NCT00003937_39_T5	COMPOUND	19	19	cisplatin
NCT0000393741	NCT00003937_41_T0	COMPOUND	15	15	1
NCT0000393741	NCT00003937_41_T1	COMPOUND	7	7	ifosfamide
NCT0000393741	NCT00003937_41_T2	COMPOUND	5	5	dexrazoxane
NCT0000393741	NCT00003937_41_T3	COMPOUND	4	4	methotrexate
NCT0000393741	NCT00003937_41_T4	COMPOUND	6	6	doxorubicin
NCT0000393741	NCT00003937_41_T5	COMPOUND	9	9	cisplatin
NCT0000393741	NCT00003937_41_T6	GENE	0	1	Group 1
NCT0000393742	NCT00003937_42_T0	COMPOUND	1	1	2
NCT0000393742	NCT00003937_42_T1	COMPOUND	16	16	ifosfamide
NCT0000393742	NCT00003937_42_T2	GENE	25	25	1.5
NCT0000393742	NCT00003937_42_T3	COMPOUND	4	4	methotrexate
NCT0000393742	NCT00003937_42_T4	COMPOUND	18	18	etoposide
NCT0000393742	NCT00003937_42_T5	COMPOUND	33	33	cisplatin
NCT0000393742	NCT00003937_42_T6	GENE	19	19	IV
NCT0000393743	NCT00003937_43_T0	COMPOUND	2	2	doxorubicin
NCT000039381	NCT00003938_1_T0	COMPOUND	9	10	amphotericin B
NCT000039382	NCT00003938_2_T0	GENE	3	3	III
NCT000039382	NCT00003938_2_T1	PHENOTYPE	20	20	fever
NCT000039382	NCT00003938_2_T2	PHENOTYPE	18	18	granulocytopenia
NCT000039382	NCT00003938_2_T3	COMPOUND	14	15	amphotericin B
NCT000039387	NCT00003938_7_T0	GENE	14	14	has
NCT000039387	NCT00003938_7_T1	PHENOTYPE	15	15	resolved
NCT000039387	NCT00003938_7_T2	PHENOTYPE	8	9	fungal infection
NCT000039387	NCT00003938_7_T3	PHENOTYPE	12	13	febrile neutropenia
NCT000039387	NCT00003938_7_T4	PHENOTYPE	3	5	signs and symptoms
NCT000039391	NCT00003939_1_T0	GENE	2	2	II
NCT000039391	NCT00003939_1_T1	PHENOTYPE	17	19	soft tissue sarcoma
NCT000039393	NCT00003939_3_T0	PHENOTYPE	11	13	soft tissue sarcomas
NCT000039397	NCT00003939_7_T0	PHENOTYPE	2	2	acute
NCT000039399	NCT00003939_9_T0	GENE	5	5	IV
NCT0000393910	NCT00003939_10_T0	PHENOTYPE	15	15	toxicity
NCT0000393910	NCT00003939_10_T1	PHENOTYPE	11	12	disease progression
NCT0000393911	NCT00003939_11_T0	PHENOTYPE	7	8	disease progression
NCT0000393911	NCT00003939_11_T1	PHENOTYPE	14	15	disease progression
NCT000039412	NCT00003941_2_T0	CELL	9	9	cells
NCT0000394111	NCT00003941_11_T0	CELL	0	3	Peripheral blood stem cells
NCT0000394112	NCT00003941_12_T0	GENE	4	4	filgrastim
NCT0000394112	NCT00003941_12_T1	GENE	5	5	G-CSF
NCT0000394113	NCT00003941_13_T0	COMPOUND	22	22	ifosfamide
NCT0000394113	NCT00003941_13_T1	COMPOUND	31	31	2
NCT0000394113	NCT00003941_13_T2	COMPOUND	9	9	etoposide
NCT0000394113	NCT00003941_13_T3	COMPOUND	16	16	cisplatin
NCT0000394113	NCT00003941_13_T4	GENE	10	10	IV
NCT0000394113	NCT00003941_13_T5	GENE	17	17	IV
NCT0000394113	NCT00003941_13_T6	GENE	23	23	IV
NCT0000394115	NCT00003941_15_T0	GENE	3	3	G-CSF
NCT0000394116	NCT00003941_16_T0	PHENOTYPE	16	16	toxicity
NCT0000394116	NCT00003941_16_T1	PHENOTYPE	12	13	disease progression
NCT0000394117	NCT00003941_17_T0	PHENOTYPE	0	2	Quality of life
NCT000039425	NCT00003942_5_T0	PHENOTYPE	9	9	peripheral
NCT000039425	NCT00003942_5_T1	CELL	4	4	lymphocytes
NCT000039425	NCT00003942_5_T2	CELL	6	7	myeloid cells
NCT000039425	NCT00003942_5_T3	ORGAN	11	12	bone marrow
NCT000039425	NCT00003942_5_T4	TISSUE	14	15	lymph nodes
NCT0000394210	NCT00003942_10_T0	COMPOUND	9	9	1
NCT0000394211	NCT00003942_11_T0	CELL	4	6	hematopoietic stem cells
NCT0000394212	NCT00003942_12_T0	CELL	2	5	peripheral blood stem cells
NCT000039430	NCT00003943_0_T0	GENE	13	13	atic
NCT000039430	NCT00003943_0_T1	PHENOTYPE	14	14	Cancer
NCT000039430	NCT00003943_0_T2	PHENOTYPE	11	12	Metastatic Cancer
NCT000039430	NCT00003943_0_T3	CELL	3	5	Peripheral Stem Cell
NCT000039438	NCT00003943_8_T0	COMPOUND	10	10	paclitaxel
NCT000039438	NCT00003943_8_T1	GENE	19	19	filgrastim
NCT000039438	NCT00003943_8_T2	COMPOUND	3	3	cyclophosphamide
NCT000039438	NCT00003943_8_T3	GENE	20	20	G-CSF
NCT000039438	NCT00003943_8_T4	GENE	4	4	IV
NCT000039438	NCT00003943_8_T5	GENE	11	11	IV
NCT000039439	NCT00003943_9_T0	GENE	8	8	3.5
NCT000039439	NCT00003943_9_T1	CELL	0	3	Peripheral blood stem cells
NCT0000394310	NCT00003943_10_T0	COMPOUND	8	8	paclitaxel
NCT0000394310	NCT00003943_10_T1	GENE	34	34	G-CSF
NCT0000394310	NCT00003943_10_T2	GENE	9	9	IV
NCT0000394310	NCT00003943_10_T3	GENE	20	20	IV
NCT0000394310	NCT00003943_10_T4	GENE	26	26	IV
NCT0000394310	NCT00003943_10_T5	COMPOUND	25	25	topotecan
NCT0000394312	NCT00003943_12_T0	GENE	2	2	1.3
NCT0000394313	NCT00003943_13_T0	PHENOTYPE	13	13	toxicity
NCT000039447	NCT00003944_7_T0	COMPOUND	15	15	paclitaxel
NCT000039447	NCT00003944_7_T1	COMPOUND	5	5	cyclophosphamide
NCT000039447	NCT00003944_7_T2	GENE	6	6	IV
NCT000039447	NCT00003944_7_T3	GENE	16	16	IV
NCT000039449	NCT00003944_9_T0	CELL	11	11	cells
NCT000039449	NCT00003944_9_T1	GENE	10	10	CD34
NCT000039449	NCT00003944_9_T2	CELL	0	3	Peripheral blood stem cells
NCT0000394411	NCT00003944_11_T0	COMPOUND	2	2	paclitaxel
NCT0000394411	NCT00003944_11_T1	GENE	3	3	IV
NCT0000394411	NCT00003944_11_T2	GENE	11	11	IV
NCT0000394411	NCT00003944_11_T3	GENE	21	21	IV
NCT0000394411	NCT00003944_11_T4	COMPOUND	20	20	topotecan
NCT0000394412	NCT00003944_12_T0	GENE	0	0	G-CSF
NCT0000394414	NCT00003944_14_T0	PHENOTYPE	18	18	toxicity
NCT0000394414	NCT00003944_14_T1	PHENOTYPE	14	15	disease progression
NCT000039451	NCT00003945_1_T0	CELL	9	9	cells
NCT000039451	NCT00003945_1_T1	PHENOTYPE	8	8	tumor
NCT000039452	NCT00003945_2_T0	PHENOTYPE	12	13	cervical cancer
NCT000039453	NCT00003945_3_T0	GENE	3	3	III
NCT000039453	NCT00003945_3_T1	PHENOTYPE	20	20	recurrent
NCT000039453	NCT00003945_3_T2	PHENOTYPE	23	24	cervical cancer
NCT000039461	NCT00003946_1_T0	GENE	2	2	II
NCT000039461	NCT00003946_1_T1	COMPOUND	9	9	danazol
NCT000039461	NCT00003946_1_T2	PHENOTYPE	16	18	recurrent endometrial cancer
NCT000039463	NCT00003946_3_T0	COMPOUND	5	5	danazol
NCT000039463	NCT00003946_3_T1	PHENOTYPE	11	13	recurrent endometrial cancer
NCT000039465	NCT00003946_5_T0	PHENOTYPE	4	4	toxicity
NCT000039465	NCT00003946_5_T1	COMPOUND	6	6	danazol
NCT000039467	NCT00003946_7_T0	PHENOTYPE	19	19	toxicity
NCT000039467	NCT00003946_7_T1	PHENOTYPE	15	16	disease progression
NCT000039501	NCT00003950_1_T0	COMPOUND	7	7	irinotecan
NCT000039501	NCT00003950_1_T1	PHENOTYPE	4	4	diarrhea
NCT000039502	NCT00003950_2_T0	GENE	2	2	II
NCT000039502	NCT00003950_2_T1	COMPOUND	11	11	cyclosporine
NCT000039502	NCT00003950_2_T2	COMPOUND	9	9	irinotecan
NCT000039502	NCT00003950_2_T3	GENE	25	25	has
NCT000039502	NCT00003950_2_T4	PHENOTYPE	21	23	recurrent colorectal cancer
NCT000039504	NCT00003950_4_T0	COMPOUND	24	24	cyclosporine
NCT000039504	NCT00003950_4_T1	COMPOUND	22	22	irinotecan
NCT000039504	NCT00003950_4_T2	ORGAN	19	19	rectum
NCT000039504	NCT00003950_4_T3	PHENOTYPE	11	11	recurrent
NCT000039504	NCT00003950_4_T4	PHENOTYPE	14	17	adenocarcinoma of the colon
NCT000039506	NCT00003950_6_T0	PHENOTYPE	6	6	toxicity
NCT000039506	NCT00003950_6_T1	PHENOTYPE	4	4	tolerance
NCT000039508	NCT00003950_8_T0	COMPOUND	2	2	cyclosporine
NCT000039508	NCT00003950_8_T1	COMPOUND	8	8	irinotecan
NCT000039508	NCT00003950_8_T2	GENE	3	3	IV
NCT000039508	NCT00003950_8_T3	GENE	9	9	IV
NCT0000395010	NCT00003950_10_T0	PHENOTYPE	14	14	toxicity
NCT0000395010	NCT00003950_10_T1	PHENOTYPE	10	11	disease progression
NCT000039511	NCT00003951_1_T0	GENE	2	2	II
NCT000039511	NCT00003951_1_T1	GENE	21	21	has
NCT000039511	NCT00003951_1_T2	GENE	28	28	has
NCT000039511	NCT00003951_1_T3	PHENOTYPE	15	16	metastatic cancer
NCT000039511	NCT00003951_1_T4	PHENOTYPE	16	19	cancer of the pancreas
NCT000039513	NCT00003951_3_T0	PHENOTYPE	8	9	metastatic carcinoma
NCT000039513	NCT00003951_3_T1	TISSUE	12	13	exocrine pancreas
NCT000039515	NCT00003951_5_T0	PHENOTYPE	4	5	tumor progression
NCT000039519	NCT00003951_9_T0	PHENOTYPE	5	5	toxicities
NCT0000395111	NCT00003951_11_T0	PHENOTYPE	2	2	pharmacokinetics
NCT0000395112	NCT00003951_12_T0	GENE	4	4	IV
NCT0000395114	NCT00003951_14_T0	PHENOTYPE	7	7	toxicity
NCT0000395114	NCT00003951_14_T1	PHENOTYPE	9	10	disease progression
NCT000039531	NCT00003953_1_T0	GENE	2	2	II
NCT000039531	NCT00003953_1_T1	GENE	21	21	II
NCT000039531	NCT00003953_1_T2	COMPOUND	11	11	docetaxel
NCT000039531	NCT00003953_1_T3	COMPOUND	9	9	doxorubicin
NCT000039531	NCT00003953_1_T4	PHENOTYPE	23	26	stage III breast cancer
NCT000039534	NCT00003953_4_T0	COMPOUND	23	23	docetaxel
NCT000039534	NCT00003953_4_T1	COMPOUND	21	21	doxorubicin
NCT000039534	NCT00003953_4_T2	PHENOTYPE	12	13	breast cancer
NCT000039536	NCT00003953_6_T0	PHENOTYPE	4	4	toxicity
NCT0000395310	NCT00003953_10_T0	COMPOUND	8	8	docetaxel
NCT0000395310	NCT00003953_10_T1	COMPOUND	13	13	doxorubicin
NCT0000395312	NCT00003953_12_T0	CELL	2	4	circulating tumor cells
NCT0000395314	NCT00003953_14_T0	PHENOTYPE	2	2	tumor
NCT0000395314	NCT00003953_14_T1	PHENOTYPE	10	11	primary tumor
NCT0000395315	NCT00003953_15_T0	COMPOUND	13	13	docetaxel
NCT0000395315	NCT00003953_15_T1	COMPOUND	3	3	doxorubicin
NCT0000395315	NCT00003953_15_T2	GENE	4	4	IV
NCT0000395315	NCT00003953_15_T3	GENE	14	14	IV
NCT0000395316	NCT00003953_16_T0	GENE	7	7	3-10
NCT0000395316	NCT00003953_16_T1	GENE	1	1	G-CSF
NCT0000395317	NCT00003953_17_T0	TISSUE	19	20	lymph node
NCT0000395318	NCT00003953_18_T0	PHENOTYPE	2	3	disease progression
NCT0000395319	NCT00003953_19_T0	COMPOUND	25	25	cyclophosphamide
NCT0000395319	NCT00003953_19_T1	COMPOUND	26	26	methotrexate
NCT0000395319	NCT00003953_19_T2	PHENOTYPE	16	18	lymph node metastases
NCT0000395320	NCT00003953_20_T0	GENE	1	1	II
NCT0000395320	NCT00003953_20_T1	GENE	4	4	1.3
NCT0000395320	NCT00003953_20_T2	PHENOTYPE	5	7	lymph node metastases
NCT0000395323	NCT00003953_23_T0	GENE	15	15	T4
NCT0000395323	NCT00003953_23_T1	GENE	17	17	N2
NCT0000395323	NCT00003953_23_T2	GENE	14	14	T3
NCT0000395323	NCT00003953_23_T3	ORGAN	4	5	chest wall
NCT0000395324	NCT00003953_24_T0	GENE	12	12	N3
NCT0000395324	NCT00003953_24_T1	TISSUE	9	10	lymph nodes
NCT0000395325	NCT00003953_25_T0	GENE	8	8	5.5
NCT0000395326	NCT00003953_26_T0	COMPOUND	3	3	estrogen
NCT0000395326	NCT00003953_26_T1	COMPOUND	5	5	progesterone
NCT0000395326	NCT00003953_26_T2	COMPOUND	9	9	tamoxifen
NCT0000395331	NCT00003953_31_T0	COMPOUND	9	9	tamoxifen
NCT0000395336	NCT00003953_36_T0	PHENOTYPE	5	5	LCIS
NCT0000395336	NCT00003953_36_T1	PHENOTYPE	3	3	DCIS
NCT000039543	NCT00003954_3_T0	PHENOTYPE	2	2	relapse
NCT000039545	NCT00003954_5_T0	PHENOTYPE	12	12	progression
NCT000039546	NCT00003954_6_T0	COMPOUND	14	14	2
NCT000039546	NCT00003954_6_T1	COMPOUND	6	6	melphalan
NCT000039546	NCT00003954_6_T2	PHENOTYPE	1	1	CONDITIONING
NCT000039546	NCT00003954_6_T3	GENE	8	8	IV
NCT000039547	NCT00003954_7_T0	ORGAN	4	5	bone marrow
NCT0000395410	NCT00003954_10_T0	COMPOUND	3	3	cyclosporine
NCT0000395410	NCT00003954_10_T1	COMPOUND	10	10	1
NCT0000395410	NCT00003954_10_T2	PHENOTYPE	31	31	GVHD
NCT0000395410	NCT00003954_10_T3	GENE	7	7	BID
NCT0000395410	NCT00003954_10_T4	GENE	16	16	BID
NCT0000395410	NCT00003954_10_T5	GENE	4	4	IV
NCT0000395410	NCT00003954_10_T6	PHENOTYPE	29	30	graft-versus-host disease
NCT0000395411	NCT00003954_11_T0	GENE	6	6	BID
NCT0000395411	NCT00003954_11_T1	COMPOUND	3	4	mycophenolate mofetil
NCT0000395412	NCT00003954_12_T0	PHENOTYPE	9	9	immunosuppression
NCT0000395412	NCT00003954_12_T1	PHENOTYPE	14	15	progressive disease
NCT000039551	NCT00003955_1_T0	CELL	8	8	cells
NCT000039551	NCT00003955_1_T1	PHENOTYPE	7	7	tumor
NCT000039552	NCT00003955_2_T0	CELL	13	13	cells
NCT000039552	NCT00003955_2_T1	PHENOTYPE	12	12	tumor
NCT000039553	NCT00003955_3_T0	GENE	2	2	II
NCT000039553	NCT00003955_3_T1	PHENOTYPE	23	23	sarcoma
NCT000039553	NCT00003955_3_T2	PHENOTYPE	21	21	rhabdomyosarcoma
NCT000039559	NCT00003955_9_T0	COMPOUND	40	40	vincristine
NCT000039559	NCT00003955_9_T1	COMPOUND	3	3	irinotecan
NCT000039559	NCT00003955_9_T2	COMPOUND	65	65	cyclophosphamide
NCT000039559	NCT00003955_9_T3	GENE	4	4	IV
NCT000039559	NCT00003955_9_T4	GENE	46	46	IV
NCT000039559	NCT00003955_9_T5	GENE	66	66	IV
NCT0000395513	NCT00003955_13_T0	GENE	15	15	0.6
NCT0000395515	NCT00003955_15_T0	GENE	9	9	SC
NCT0000395515	NCT00003955_15_T1	GENE	3	3	filgrastim
NCT0000395515	NCT00003955_15_T2	GENE	4	4	G-CSF
NCT0000395515	NCT00003955_15_T3	GENE	7	7	GM-CSF
NCT0000395515	NCT00003955_15_T4	GENE	6	6	sargramostim
NCT0000395516	NCT00003955_16_T0	GENE	5	5	SC
NCT0000395516	NCT00003955_16_T1	COMPOUND	4	4	pegfilgrastim
NCT0000395518	NCT00003955_18_T0	GENE	14	14	9-24
NCT000039561	NCT00003956_1_T0	CELL	9	9	cells
NCT0000395613	NCT00003956_13_T0	COMPOUND	3	3	calcium
NCT0000395613	NCT00003956_13_T1	GENE	6	6	1.2
NCT0000395613	NCT00003956_13_T2	GENE	14	14	1.2
NCT0000395613	NCT00003956_13_T3	COMPOUND	2	2	leucovorin
NCT0000395613	NCT00003956_13_T4	GENE	4	4	IV
NCT0000395613	NCT00003956_13_T5	GENE	12	12	IV
NCT0000395614	NCT00003956_14_T0	PHENOTYPE	13	13	toxicity
NCT0000395614	NCT00003956_14_T1	PHENOTYPE	9	10	disease progression
NCT0000395616	NCT00003956_16_T0	PHENOTYPE	21	21	toxicity
NCT0000395616	NCT00003956_16_T1	PHENOTYPE	18	18	experiences
NCT0000395616	NCT00003956_16_T2	GENE	22	22	DLT
NCT0000395616	NCT00003956_16_T3	GENE	32	32	DLT
NCT000039574	NCT00003957_4_T0	GENE	23	23	CD34
NCT000039574	NCT00003957_4_T1	PHENOTYPE	8	9	Hodgkin's lymphoma
NCT000039579	NCT00003957_9_T0	COMPOUND	10	10	paclitaxel
NCT000039579	NCT00003957_9_T1	COMPOUND	3	3	cyclophosphamide
NCT000039579	NCT00003957_9_T2	GENE	4	4	IV
NCT000039579	NCT00003957_9_T3	GENE	11	11	IV
NCT0000395711	NCT00003957_11_T0	GENE	8	8	3.5
NCT0000395711	NCT00003957_11_T1	CELL	0	3	Peripheral blood stem cells
NCT0000395712	NCT00003957_12_T0	COMPOUND	8	8	cytarabine
NCT0000395712	NCT00003957_12_T1	COMPOUND	20	20	3
NCT0000395712	NCT00003957_12_T2	GENE	9	9	IV
NCT0000395713	NCT00003957_13_T0	GENE	1	1	IV
NCT0000395714	NCT00003957_14_T0	GENE	0	0	CD34
NCT0000395715	NCT00003957_15_T0	COMPOUND	22	22	1
NCT0000395715	NCT00003957_15_T1	COMPOUND	12	12	2
NCT0000395715	NCT00003957_15_T2	COMPOUND	14	14	melphalan
NCT0000395715	NCT00003957_15_T3	COMPOUND	5	5	etoposide
NCT0000395715	NCT00003957_15_T4	GENE	6	6	IV
NCT0000395715	NCT00003957_15_T5	GENE	15	15	IV
NCT0000395716	NCT00003957_16_T0	GENE	0	0	CD34
NCT0000395717	NCT00003957_17_T0	GENE	1	1	G-CSF
NCT000039581	NCT00003958_1_T0	COMPOUND	8	8	vincristine
NCT000039581	NCT00003958_1_T1	CELL	17	17	cells
NCT000039581	NCT00003958_1_T2	PHENOTYPE	16	16	tumor
NCT000039581	NCT00003958_1_T3	COMPOUND	7	7	cyclophosphamide
NCT000039581	NCT00003958_1_T4	COMPOUND	10	10	topotecan
NCT000039582	NCT00003958_2_T0	PHENOTYPE	14	14	rhabdomyosarcoma
NCT000039584	NCT00003958_4_T0	COMPOUND	19	19	vincristine
NCT000039584	NCT00003958_4_T1	COMPOUND	28	28	vincristine
NCT000039584	NCT00003958_4_T2	COMPOUND	22	22	cyclophosphamide
NCT000039584	NCT00003958_4_T3	COMPOUND	31	31	cyclophosphamide
NCT000039584	NCT00003958_4_T4	PHENOTYPE	13	13	rhabdomyosarcoma
NCT000039584	NCT00003958_4_T5	COMPOUND	29	29	topotecan
NCT000039586	NCT00003958_6_T0	PHENOTYPE	2	2	acute
NCT000039586	NCT00003958_6_T1	PHENOTYPE	4	5	late effects
NCT000039588	NCT00003958_8_T0	PHENOTYPE	28	28	tumor
NCT000039588	NCT00003958_8_T1	PHENOTYPE	33	33	tumor
NCT000039588	NCT00003958_8_T2	GENE	18	18	III
NCT000039588	NCT00003958_8_T3	PHENOTYPE	11	12	residual tumor
NCT0000395810	NCT00003958_10_T0	GENE	18	18	III
NCT0000395810	NCT00003958_10_T1	PHENOTYPE	11	12	residual tumors
NCT0000395812	NCT00003958_12_T0	GENE	20	20	III
NCT0000395812	NCT00003958_12_T1	PHENOTYPE	15	16	residual disease
NCT0000395814	NCT00003958_14_T0	GENE	9	9	II
NCT0000395814	NCT00003958_14_T1	GENE	45	45	II
NCT0000395814	NCT00003958_14_T2	GENE	50	50	II
NCT0000395814	NCT00003958_14_T3	GENE	11	11	III
NCT0000395814	NCT00003958_14_T4	GENE	14	14	III
NCT0000395814	NCT00003958_14_T5	GENE	47	47	III
NCT0000395814	NCT00003958_14_T6	GENE	52	52	III
NCT0000395814	NCT00003958_14_T7	GENE	20	20	IV
NCT0000395814	NCT00003958_14_T8	PHENOTYPE	30	31	undifferentiated sarcoma
NCT0000395814	NCT00003958_14_T9	PHENOTYPE	41	42	undifferentiated sarcoma
NCT0000395814	NCT00003958_14_T10	GENE	36	37	Group I
NCT0000395817	NCT00003958_17_T0	GENE	1	1	IV
NCT0000395818	NCT00003958_18_T0	GENE	1	1	IV
NCT0000395819	NCT00003958_19_T0	PHENOTYPE	9	9	tumor
NCT0000395821	NCT00003958_21_T0	GENE	6	6	0.6
NCT0000395824	NCT00003958_24_T0	PHENOTYPE	5	5	tumors
NCT0000395824	NCT00003958_24_T1	PHENOTYPE	25	25	initiation
NCT0000395824	NCT00003958_24_T2	GENE	4	4	III
NCT0000395825	NCT00003958_25_T0	GENE	4	4	II
NCT0000395825	NCT00003958_25_T1	GENE	10	10	III
NCT0000395825	NCT00003958_25_T2	PHENOTYPE	6	6	tumors
NCT0000395825	NCT00003958_25_T3	PHENOTYPE	12	12	tumors
NCT0000395825	NCT00003958_25_T4	PHENOTYPE	17	17	erosion
NCT0000395825	NCT00003958_25_T5	PHENOTYPE	19	21	cranial nerve palsy
NCT0000395825	NCT00003958_25_T6	ORGAN	14	16	base of skull
NCT0000395826	NCT00003958_26_T0	PHENOTYPE	9	9	metastases
NCT0000395826	NCT00003958_26_T1	PHENOTYPE	6	6	tumors
NCT0000395826	NCT00003958_26_T2	GENE	4	4	IV
NCT0000395827	NCT00003958_27_T0	PHENOTYPE	3	3	metastases
NCT0000395827	NCT00003958_27_T1	PHENOTYPE	30	30	initiation
NCT0000395829	NCT00003958_29_T0	GENE	3	3	filgrastim
NCT0000395829	NCT00003958_29_T1	GENE	4	4	G-CSF
NCT0000395829	NCT00003958_29_T2	GENE	7	7	GM-CSF
NCT0000395829	NCT00003958_29_T3	GENE	6	6	sargramostim
NCT0000395830	NCT00003958_30_T0	GENE	4	4	1.2
NCT000039591	NCT00003959_1_T0	CELL	9	9	cells
NCT000039591	NCT00003959_1_T1	GENE	4	4	sargramostim
NCT000039596	NCT00003959_6_T0	GENE	19	19	ras
NCT000039599	NCT00003959_9_T0	COMPOUND	8	8	1_10
NCT000039599	NCT00003959_9_T1	GENE	4	4	GM-CSF
NCT000039599	NCT00003959_9_T2	GENE	3	3	sargramostim
NCT0000395911	NCT00003959_11_T0	PHENOTYPE	18	18	toxicity
NCT0000395911	NCT00003959_11_T1	PHENOTYPE	14	15	disease progression
NCT000039601	NCT00003960_1_T0	CELL	18	18	cells
NCT000039601	NCT00003960_1_T1	PHENOTYPE	17	17	tumor
NCT000039601	NCT00003960_1_T2	ORGAN	0	1	Bone marrow
NCT000039602	NCT00003960_2_T0	GENE	2	2	II
NCT000039602	NCT00003960_2_T1	PHENOTYPE	21	22	hematologic cancer
NCT000039602	NCT00003960_2_T2	ORGAN	13	14	bone marrow
NCT000039604	NCT00003960_4_T0	PHENOTYPE	8	9	hematologic malignancies
NCT000039604	NCT00003960_4_T1	ORGAN	15	16	bone marrow
NCT000039605	NCT00003960_5_T0	COMPOUND	25	25	methylprednisolone
NCT000039605	NCT00003960_5_T1	GENE	15	15	IV
NCT000039605	NCT00003960_5_T2	GENE	26	26	IV
NCT000039605	NCT00003960_5_T3	COMPOUND	4	4	busulfan
NCT000039605	NCT00003960_5_T4	COMPOUND	17	17	1
NCT000039605	NCT00003960_5_T5	COMPOUND	23	23	1
NCT000039605	NCT00003960_5_T6	COMPOUND	28	28	1
NCT000039605	NCT00003960_5_T7	COMPOUND	35	35	2
NCT000039605	NCT00003960_5_T8	COMPOUND	14	14	cyclophosphamide
NCT000039607	NCT00003960_7_T0	GENE	12	12	tapered
NCT000039607	NCT00003960_7_T1	GENE	3	3	IV
NCT000039614	NCT00003961_4_T0	GENE	3	3	GM-CSF
NCT000039614	NCT00003961_4_T1	GENE	2	2	sargramostim
NCT000039616	NCT00003961_6_T0	GENE	14	14	3.4
NCT000039621	NCT00003962_1_T0	GENE	9	9	interleukin-2
NCT000039621	NCT00003962_1_T1	PHENOTYPE	24	24	relapse
NCT000039621	NCT00003962_1_T2	PHENOTYPE	19	20	hematologic cancer
NCT000039621	NCT00003962_1_T3	ORGAN	11	12	bone marrow
NCT000039623	NCT00003962_3_T0	PHENOTYPE	2	2	toxicity
NCT000039623	NCT00003962_3_T1	PHENOTYPE	25	25	relapse
NCT000039623	NCT00003962_3_T2	CELL	11	11	T-cell
NCT000039623	NCT00003962_3_T3	GENE	8	8	interleukin-2
NCT000039623	NCT00003962_3_T4	ORGAN	15	15	transplant
NCT000039623	NCT00003962_3_T5	ORGAN	13	14	bone marrow
NCT000039623	NCT00003962_3_T6	PHENOTYPE	19	20	hematologic malignancies
NCT000039628	NCT00003962_8_T0	GENE	3	3	interleukin-2
NCT000039628	NCT00003962_8_T1	GENE	4	4	IL-2
NCT000039629	NCT00003962_9_T0	PHENOTYPE	11	11	toxicity
NCT0000396210	NCT00003962_10_T0	GENE	8	8	IL-2
NCT0000396210	NCT00003962_10_T1	GENE	14	14	MTD
NCT0000396211	NCT00003962_11_T0	PHENOTYPE	16	16	toxicity
NCT0000396211	NCT00003962_11_T1	GENE	1	1	MTD
NCT000039631	NCT00003963_1_T0	CELL	10	10	cells
NCT000039632	NCT00003963_2_T0	CELL	10	10	cells
NCT000039638	NCT00003963_8_T0	COMPOUND	15	15	vinorelbine
NCT000039638	NCT00003963_8_T1	GENE	8	8	1.4
NCT000039638	NCT00003963_8_T2	GENE	19	19	2.4
NCT000039638	NCT00003963_8_T3	GENE	4	4	IV
NCT000039638	NCT00003963_8_T4	GENE	16	16	IV
NCT000039639	NCT00003963_9_T0	COMPOUND	8	8	vinorelbine
NCT000039639	NCT00003963_9_T1	PHENOTYPE	13	14	disease progression
NCT0000396310	NCT00003963_10_T0	PHENOTYPE	4	5	disease progression
NCT000039664	NCT00003966_4_T0	GENE	9	9	IV
NCT000039670	NCT00003967_0_T0	PHENOTYPE	7	7	Recurrent
NCT000039670	NCT00003967_0_T1	PHENOTYPE	11	13	Fallopian Tube Cancer
NCT000039672	NCT00003967_2_T0	CELL	9	9	cells
NCT000039672	NCT00003967_2_T1	PHENOTYPE	8	8	tumor
NCT000039675	NCT00003967_5_T0	COMPOUND	11	11	etoposide
NCT000039675	NCT00003967_5_T1	PHENOTYPE	19	19	recurrent
NCT000039675	NCT00003967_5_T2	COMPOUND	8	8	topotecan
NCT000039677	NCT00003967_7_T0	PHENOTYPE	6	6	toxicity
NCT000039679	NCT00003967_9_T0	PHENOTYPE	7	8	disease progression
NCT0000396711	NCT00003967_11_T0	GENE	7	7	1.5
NCT0000396711	NCT00003967_11_T1	COMPOUND	10	10	etoposide
NCT0000396711	NCT00003967_11_T2	COMPOUND	3	3	topotecan
NCT0000396712	NCT00003967_12_T0	PHENOTYPE	9	10	disease progression
NCT0000396714	NCT00003967_14_T0	COMPOUND	7	7	etoposide
NCT0000396714	NCT00003967_14_T1	GENE	18	18	MTD
NCT0000396714	NCT00003967_14_T2	COMPOUND	5	5	topotecan
NCT0000396715	NCT00003967_15_T0	PHENOTYPE	19	19	toxicity
NCT0000396715	NCT00003967_15_T1	GENE	1	1	MTD
NCT0000396715	NCT00003967_15_T2	PHENOTYPE	16	16	experiences
NCT000039681	NCT00003968_1_T0	CELL	10	10	cells
NCT000039681	NCT00003968_1_T1	PHENOTYPE	9	9	tumor
NCT000039685	NCT00003968_5_T0	PHENOTYPE	2	2	toxicities
NCT000039687	NCT00003968_7_T0	PHENOTYPE	4	5	disease progression
NCT0000396810	NCT00003968_10_T0	GENE	5	5	IV
NCT0000396810	NCT00003968_10_T1	COMPOUND	3	4	bryostatin 1
NCT0000396811	NCT00003968_11_T0	PHENOTYPE	10	10	toxicity
NCT000039691	NCT00003969_1_T0	COMPOUND	15	15	geldanamycin
NCT000039691	NCT00003969_1_T1	PHENOTYPE	21	22	advanced cancer
NCT000039694	NCT00003969_4_T0	GENE	6	6	AAG
NCT000039694	NCT00003969_4_T1	COMPOUND	3	3	geldanamycin
NCT000039694	NCT00003969_4_T2	COMPOUND	5	5	17_allylamino_17_demethoxygeldanamycin
NCT000039694	NCT00003969_4_T3	GENE	7	7	IV
NCT000039695	NCT00003969_5_T0	PHENOTYPE	10	10	toxicity
NCT000039695	NCT00003969_5_T1	PHENOTYPE	6	7	disease progression
NCT000039696	NCT00003969_6_T0	GENE	8	8	AAG
NCT000039696	NCT00003969_6_T1	GENE	14	14	MTD
NCT000039697	NCT00003969_7_T0	PHENOTYPE	19	19	toxicity
NCT000039697	NCT00003969_7_T1	GENE	1	1	MTD
NCT000039701	NCT00003970_1_T0	CELL	10	10	cells
NCT000039703	NCT00003970_3_T0	GENE	9	9	UGT1A1
NCT000039703	NCT00003970_3_T1	PHENOTYPE	6	6	lymphoma
NCT000039703	NCT00003970_3_T2	PHENOTYPE	17	17	mutation
NCT000039703	NCT00003970_3_T3	GENE	11	11	TATA
NCT000039703	NCT00003970_3_T4	PHENOTYPE	3	4	solid tumors
NCT000039703	NCT00003970_3_T5	GENE	19	20	CYP3A4 promoter
NCT000039705	NCT00003970_5_T0	COMPOUND	5	5	irinotecan
NCT000039705	NCT00003970_5_T1	GENE	1	1	UGT1A1
NCT000039707	NCT00003970_7_T0	COMPOUND	24	24	irinotecan
NCT000039707	NCT00003970_7_T1	GENE	4	4	UGT1A1
NCT000039707	NCT00003970_7_T2	PHENOTYPE	10	10	mutation
NCT000039707	NCT00003970_7_T3	PHENOTYPE	22	22	pharmacokinetics
NCT000039707	NCT00003970_7_T4	GENE	12	13	CYP3A4 promoter
NCT000039707	NCT00003970_7_T5	PHENOTYPE	18	20	bone marrow toxicity
NCT000039709	NCT00003970_9_T0	COMPOUND	4	4	irinotecan
NCT000039709	NCT00003970_9_T1	PHENOTYPE	2	2	pharmacokinetics
NCT0000397010	NCT00003970_10_T0	GENE	5	5	UGT1A1
NCT0000397010	NCT00003970_10_T1	GENE	13	13	6/7
NCT0000397010	NCT00003970_10_T2	GENE	11	11	7.7
NCT0000397011	NCT00003970_11_T0	PHENOTYPE	9	9	mutation
NCT0000397011	NCT00003970_11_T1	GENE	6	6	UGT1A1
NCT0000397011	NCT00003970_11_T2	GENE	12	13	CYP3A4 promoter
NCT0000397012	NCT00003970_12_T0	COMPOUND	13	13	irinotecan
NCT0000397013	NCT00003970_13_T0	COMPOUND	2	2	irinotecan
NCT0000397013	NCT00003970_13_T1	GENE	3	3	IV
NCT0000397014	NCT00003970_14_T0	PHENOTYPE	15	15	toxicity
NCT0000397014	NCT00003970_14_T1	PHENOTYPE	11	12	disease progression
NCT000039722	NCT00003972_2_T0	PHENOTYPE	14	15	breast cancer
NCT000039727	NCT00003972_7_T0	PHENOTYPE	2	2	toxicity
NCT000039729	NCT00003972_9_T0	GENE	9	9	II
NCT000039729	NCT00003972_9_T1	GENE	28	29	hormone receptor
NCT000039729	NCT00003972_9_T2	TISSUE	13	14	lymph node
NCT000039729	NCT00003972_9_T3	PHENOTYPE	31	33	estrogen receptor positive
NCT000039729	NCT00003972_9_T4	PHENOTYPE	43	45	progesterone receptor negative
NCT000039729	NCT00003972_9_T5	PHENOTYPE	39	41	estrogen receptor negative
NCT000039729	NCT00003972_9_T6	PHENOTYPE	35	37	progesterone receptor positive
NCT0000397210	NCT00003972_10_T0	COMPOUND	16	16	paclitaxel
NCT0000397210	NCT00003972_10_T1	GENE	10	10	1.2
NCT0000397210	NCT00003972_10_T2	COMPOUND	7	7	cyclophosphamide
NCT0000397210	NCT00003972_10_T3	GENE	8	8	IV
NCT0000397210	NCT00003972_10_T4	GENE	17	17	IV
NCT0000397211	NCT00003972_11_T0	GENE	6	6	filgrastim
NCT0000397211	NCT00003972_11_T1	GENE	7	7	G-CSF
NCT0000397211	NCT00003972_11_T2	GENE	10	10	GM-CSF
NCT0000397211	NCT00003972_11_T3	GENE	9	9	sargramostim
NCT0000397212	NCT00003972_12_T0	CELL	4	7	peripheral blood stem cells
NCT0000397219	NCT00003972_19_T0	COMPOUND	16	16	estrogen
NCT0000397219	NCT00003972_19_T1	COMPOUND	4	4	tamoxifen
NCT0000397219	NCT00003972_19_T2	PHENOTYPE	18	20	progesterone receptor positive
NCT000039746	NCT00003974_6_T0	PHENOTYPE	8	9	immune status
NCT000039748	NCT00003974_8_T0	COMPOUND	7	7	cyclophosphamide
NCT000039748	NCT00003974_8_T1	GENE	8	8	IV
NCT000039749	NCT00003974_9_T0	PHENOTYPE	8	8	TAA
NCT0000397410	NCT00003974_10_T0	GENE	1	1	2.3
NCT0000397411	NCT00003974_11_T0	CELL	23	24	T cells
NCT0000397411	NCT00003974_11_T1	PHENOTYPE	6	8	positive skin test
NCT000039760	NCT00003976_0_T0	PHENOTYPE	5	6	Solid Tumors
NCT000039762	NCT00003976_2_T0	PHENOTYPE	15	16	solid tumors
NCT000039764	NCT00003976_4_T0	PHENOTYPE	10	11	solid tumors
NCT000039766	NCT00003976_6_T0	PHENOTYPE	5	5	toxicity
NCT000039768	NCT00003976_8_T0	GENE	6	6	II
NCT0000397610	NCT00003976_10_T0	PHENOTYPE	2	2	pharmacokinetics
NCT0000397614	NCT00003976_14_T0	GENE	3	3	IV
NCT0000397615	NCT00003976_15_T0	PHENOTYPE	15	15	toxicity
NCT0000397615	NCT00003976_15_T1	PHENOTYPE	11	12	disease progression
NCT0000397616	NCT00003976_16_T0	GENE	14	14	MTD
NCT0000397617	NCT00003976_17_T0	PHENOTYPE	20	20	toxicity
NCT0000397617	NCT00003976_17_T1	GENE	1	1	MTD
NCT000039771	NCT00003977_1_T0	PHENOTYPE	15	15	recurrent
NCT000039771	NCT00003977_1_T1	PHENOTYPE	18	19	cervical cancer
NCT000039773	NCT00003977_3_T0	GENE	11	11	E7
NCT000039773	NCT00003977_3_T1	GENE	13	13	E7
NCT000039774	NCT00003977_4_T0	PHENOTYPE	5	5	peripheral
NCT000039774	NCT00003977_4_T1	CELL	8	8	cells
NCT000039774	NCT00003977_4_T2	CELL	12	13	dendritic cells
NCT000039775	NCT00003977_5_T0	GENE	4	4	E7
NCT000039775	NCT00003977_5_T1	GENE	16	16	E7
NCT000039775	NCT00003977_5_T2	GENE	19	19	IV
NCT000039776	NCT00003977_6_T0	PHENOTYPE	10	10	toxicity
NCT000039776	NCT00003977_6_T1	PHENOTYPE	6	7	disease progression
NCT000039778	NCT00003977_8_T0	GENE	10	10	E7
NCT000039779	NCT00003977_9_T0	PHENOTYPE	20	20	toxicity
NCT000039795	NCT00003979_5_T0	PHENOTYPE	15	15	toxicity
NCT000039795	NCT00003979_5_T1	PHENOTYPE	11	12	disease progression
NCT000039797	NCT00003979_7_T0	PHENOTYPE	16	16	toxicity
NCT000039797	NCT00003979_7_T1	GENE	1	1	MTD
NCT000039800	NCT00003980_0_T0	PHENOTYPE	6	7	Solid Tumors
NCT000039802	NCT00003980_2_T0	PHENOTYPE	16	17	solid tumors
NCT000039804	NCT00003980_4_T0	PHENOTYPE	12	13	solid tumors
NCT000039806	NCT00003980_6_T0	PHENOTYPE	4	4	toxicities
NCT000039808	NCT00003980_8_T0	PHENOTYPE	11	11	toxicities
NCT0000398010	NCT00003980_10_T0	GENE	12	12	II
NCT0000398012	NCT00003980_12_T0	PHENOTYPE	2	2	pharmacokinetics
NCT0000398016	NCT00003980_16_T0	GENE	4	4	IV
NCT0000398018	NCT00003980_18_T0	PHENOTYPE	18	18	toxicity
NCT0000398018	NCT00003980_18_T1	PHENOTYPE	14	15	disease progression
NCT0000398020	NCT00003980_20_T0	PHENOTYPE	14	14	toxicity
NCT0000398020	NCT00003980_20_T1	GENE	4	4	MTD
NCT000039810	NCT00003981_0_T0	PHENOTYPE	5	6	Solid Tumors
NCT000039812	NCT00003981_2_T0	PHENOTYPE	15	16	solid tumors
NCT000039815	NCT00003981_5_T0	GENE	3	3	IV
NCT000039816	NCT00003981_6_T0	PHENOTYPE	15	15	toxicity
NCT000039816	NCT00003981_6_T1	PHENOTYPE	17	18	disease progression
NCT000039817	NCT00003981_7_T0	GENE	16	16	MTD
NCT000039818	NCT00003981_8_T0	PHENOTYPE	18	18	toxicity
NCT000039818	NCT00003981_8_T1	GENE	1	1	MTD
NCT000039820	NCT00003982_0_T0	PHENOTYPE	5	6	Solid Tumors
NCT000039822	NCT00003982_2_T0	PHENOTYPE	15	16	solid tumors
NCT000039824	NCT00003982_4_T0	PHENOTYPE	10	11	solid tumors
NCT000039826	NCT00003982_6_T0	PHENOTYPE	5	5	toxic
NCT000039826	NCT00003982_6_T1	PHENOTYPE	23	23	toxic
NCT000039828	NCT00003982_8_T0	GENE	6	6	II
NCT0000398210	NCT00003982_10_T0	PHENOTYPE	2	2	pharmacokinetics
NCT0000398214	NCT00003982_14_T0	GENE	3	3	IV
NCT0000398215	NCT00003982_15_T0	PHENOTYPE	9	9	toxicity
NCT0000398216	NCT00003982_16_T0	PHENOTYPE	12	12	toxicity
NCT0000398216	NCT00003982_16_T1	PHENOTYPE	14	15	disease progression
NCT0000398217	NCT00003982_17_T0	GENE	14	14	MTD
NCT0000398218	NCT00003982_18_T0	PHENOTYPE	18	18	toxicity
NCT0000398218	NCT00003982_18_T1	GENE	1	1	MTD
NCT000039847	NCT00003984_7_T0	PHENOTYPE	2	2	toxicity
NCT000039848	NCT00003984_8_T0	GENE	12	12	1.4
NCT000039848	NCT00003984_8_T1	GENE	6	6	IV
NCT000039849	NCT00003984_9_T0	PHENOTYPE	16	16	toxicity
NCT000039849	NCT00003984_9_T1	PHENOTYPE	12	13	disease progression
NCT0000398410	NCT00003984_10_T0	PHENOTYPE	2	3	progressive disease
NCT000039850	NCT00003985_0_T0	PHENOTYPE	5	6	Solid Tumors
NCT000039852	NCT00003985_2_T0	PHENOTYPE	15	16	solid tumors
NCT000039854	NCT00003985_4_T0	PHENOTYPE	13	14	solid tumors
NCT000039858	NCT00003985_8_T0	PHENOTYPE	2	2	pharmacokinetics
NCT0000398513	NCT00003985_13_T0	PHENOTYPE	18	18	toxicity
NCT0000398513	NCT00003985_13_T1	PHENOTYPE	14	15	disease progression
NCT0000398514	NCT00003985_14_T0	GENE	15	15	MTD
NCT0000398515	NCT00003985_15_T0	PHENOTYPE	18	18	toxicity
NCT0000398515	NCT00003985_15_T1	GENE	1	1	MTD
NCT000039898	NCT00003989_8_T0	GENE	4	4	IV
NCT000039899	NCT00003989_9_T0	PHENOTYPE	13	13	toxicity
NCT000039899	NCT00003989_9_T1	PHENOTYPE	9	10	disease progression
NCT000039916	NCT00003991_6_T0	GENE	16	16	interleukin-2
NCT000039916	NCT00003991_6_T1	PHENOTYPE	2	2	relapse
NCT000039916	NCT00003991_6_T2	PHENOTYPE	7	9	quality of life
NCT000039918	NCT00003991_8_T0	PHENOTYPE	2	2	remission
NCT000039918	NCT00003991_8_T1	GENE	9	9	CR
NCT0000399110	NCT00003991_10_T0	PHENOTYPE	6	6	remission
NCT0000399113	NCT00003991_13_T0	PHENOTYPE	24	24	toxicity
NCT0000399113	NCT00003991_13_T1	PHENOTYPE	20	21	disease relapse
NCT0000399115	NCT00003991_15_T0	PHENOTYPE	0	2	Quality of life
NCT000039921	NCT00003992_1_T0	CELL	10	10	cells
NCT000039921	NCT00003992_1_T1	PHENOTYPE	9	9	tumor
NCT000039923	NCT00003992_3_T0	CELL	10	10	cells
NCT000039923	NCT00003992_3_T1	PHENOTYPE	9	9	tumor
NCT000039925	NCT00003992_5_T0	GENE	18	18	II
NCT000039925	NCT00003992_5_T1	COMPOUND	4	4	paclitaxel
NCT000039925	NCT00003992_5_T2	GENE	20	20	IIIa
NCT000039925	NCT00003992_5_T3	GENE	24	24	HER2
NCT000039925	NCT00003992_5_T4	PHENOTYPE	21	22	breast cancer
NCT000039929	NCT00003992_9_T0	ORGAN	13	14	chest wall
NCT0000399211	NCT00003992_11_T0	COMPOUND	4	4	paclitaxel
NCT0000399211	NCT00003992_11_T1	GENE	0	0	ARM
NCT0000399211	NCT00003992_11_T2	GENE	5	5	IV
NCT0000399211	NCT00003992_11_T3	GENE	14	14	IV
NCT0000399213	NCT00003992_13_T0	COMPOUND	4	4	paclitaxel
NCT0000399213	NCT00003992_13_T1	COMPOUND	13	13	cyclophosphamide
NCT0000399213	NCT00003992_13_T2	COMPOUND	10	10	doxorubicin
NCT0000399213	NCT00003992_13_T3	GENE	11	11	IV
NCT0000399213	NCT00003992_13_T4	GENE	14	14	IV
NCT0000399214	NCT00003992_14_T0	GENE	9	9	PR
NCT0000399214	NCT00003992_14_T1	GENE	4	4	ER
NCT0000399214	NCT00003992_14_T2	COMPOUND	14	14	tamoxifen
NCT0000399214	NCT00003992_14_T3	GENE	2	3	estrogen receptor
NCT0000399214	NCT00003992_14_T4	GENE	7	8	progesterone receptor
NCT0000399217	NCT00003992_17_T0	COMPOUND	5	5	cyclophosphamide
NCT0000399217	NCT00003992_17_T1	COMPOUND	3	3	doxorubicin
NCT0000399218	NCT00003992_18_T0	PHENOTYPE	10	10	toxicity
NCT0000399218	NCT00003992_18_T1	PHENOTYPE	6	7	disease progression
NCT000039931	NCT00003993_1_T0	CELL	11	11	cells
NCT000039931	NCT00003993_1_T1	GENE	0	0	Interleukin-2
NCT000039931	NCT00003993_1_T2	CELL	5	7	white blood cells
NCT000039932	NCT00003993_2_T0	CELL	8	8	cells
NCT000039932	NCT00003993_2_T1	GENE	3	3	interleukin-2
NCT000039933	NCT00003993_3_T0	GENE	14	14	interleukin-2
NCT000039933	NCT00003993_3_T1	PHENOTYPE	29	29	lymphoma
NCT000039933	NCT00003993_3_T2	PHENOTYPE	26	27	solid tumors
NCT000039933	NCT00003993_3_T3	COMPOUND	19	20	bryostatin 1
NCT000039935	NCT00003993_5_T0	GENE	8	8	interleukin-2
NCT000039936	NCT00003993_6_T0	GENE	14	14	interleukin-2
NCT000039936	NCT00003993_6_T1	GENE	18	18	1.5
NCT000039936	NCT00003993_6_T2	GENE	4	4	IV
NCT000039936	NCT00003993_6_T3	COMPOUND	2	3	bryostatin 1
NCT000039937	NCT00003993_7_T0	PHENOTYPE	13	13	toxicity
NCT000039937	NCT00003993_7_T1	PHENOTYPE	9	10	disease progression
NCT000039938	NCT00003993_8_T0	GENE	8	8	interleukin-2
NCT000039938	NCT00003993_8_T1	GENE	14	14	MTD
NCT000039939	NCT00003993_9_T0	PHENOTYPE	17	17	toxicity
NCT000039939	NCT00003993_9_T1	GENE	1	1	MTD
NCT000039942	NCT00003994_2_T0	CELL	9	9	cells
NCT000039942	NCT00003994_2_T1	PHENOTYPE	8	8	tumor
NCT000039943	NCT00003994_3_T0	CELL	8	8	cells
NCT000039943	NCT00003994_3_T1	COMPOUND	4	4	amifostine
NCT000039943	NCT00003994_3_T2	PHENOTYPE	12	14	effects of chemotherapy
NCT000039944	NCT00003994_4_T0	PHENOTYPE	17	18	liver cancer
NCT000039945	NCT00003994_5_T0	GENE	3	3	III
NCT000039945	NCT00003994_5_T1	COMPOUND	12	12	amifostine
NCT000039945	NCT00003994_5_T2	PHENOTYPE	28	29	liver cancer
NCT000039947	NCT00003994_7_T0	PHENOTYPE	13	13	toxicity
NCT000039947	NCT00003994_7_T1	COMPOUND	16	16	platinum
NCT000039947	NCT00003994_7_T2	COMPOUND	7	7	amifostine
NCT000039947	NCT00003994_7_T3	COMPOUND	8	8	amifostine
NCT000039947	NCT00003994_7_T4	COMPOUND	9	9	trihydrate
NCT000039949	NCT00003994_9_T0	COMPOUND	8	8	amifostine
NCT000039949	NCT00003994_9_T1	COMPOUND	19	19	amifostine
NCT0000399413	NCT00003994_13_T0	PHENOTYPE	9	9	toxicity
NCT0000399413	NCT00003994_13_T1	PHENOTYPE	17	17	tumors
NCT0000399413	NCT00003994_13_T2	COMPOUND	5	5	amifostine
NCT0000399413	NCT00003994_13_T3	COMPOUND	28	28	amifostine
NCT0000399415	NCT00003994_15_T0	PHENOTYPE	37	37	hepatoblastoma
NCT0000399415	NCT00003994_15_T1	PHENOTYPE	2	2	tumor
NCT0000399419	NCT00003994_19_T0	GENE	19	19	II
NCT0000399419	NCT00003994_19_T1	GENE	21	21	II
NCT0000399419	NCT00003994_19_T2	GENE	34	34	III
NCT0000399419	NCT00003994_19_T3	GENE	32	32	IV
NCT0000399419	NCT00003994_19_T4	GENE	36	36	IV
NCT0000399419	NCT00003994_19_T5	PHENOTYPE	22	22	closed
NCT0000399419	NCT00003994_19_T6	PHENOTYPE	37	37	closed
NCT0000399419	NCT00003994_19_T7	PHENOTYPE	29	30	stage III
NCT0000399422	NCT00003994_22_T0	PHENOTYPE	7	7	tumor
NCT0000399429	NCT00003994_29_T0	GENE	8	8	III
NCT0000399429	NCT00003994_29_T1	PHENOTYPE	11	11	closed
NCT0000399429	NCT00003994_29_T2	GENE	5	5	IV
NCT0000399429	NCT00003994_29_T3	GENE	10	10	IV
NCT0000399429	NCT00003994_29_T4	PHENOTYPE	2	3	stage III
NCT0000399431	NCT00003994_31_T0	GENE	14	14	5.5
NCT000039952	NCT00003995_2_T0	CELL	10	10	cells
NCT000039952	NCT00003995_2_T1	PHENOTYPE	9	9	tumor
NCT000039953	NCT00003995_3_T0	CELL	10	10	cells
NCT000039953	NCT00003995_3_T1	PHENOTYPE	9	9	tumor
NCT000039955	NCT00003995_5_T0	COMPOUND	6	6	irinotecan
NCT000039955	NCT00003995_5_T1	GENE	18	18	HER2
NCT000039955	NCT00003995_5_T2	GENE	17	17	p185
NCT000039955	NCT00003995_5_T3	PHENOTYPE	12	15	stage IV colorectal cancer
NCT000039957	NCT00003995_7_T0	PHENOTYPE	4	4	toxic
NCT000039959	NCT00003995_9_T0	PHENOTYPE	7	7	progression
NCT0000399511	NCT00003995_11_T0	COMPOUND	8	8	irinotecan
NCT0000399511	NCT00003995_11_T1	PHENOTYPE	2	2	pharmacokinetics
NCT0000399515	NCT00003995_15_T0	GENE	7	7	IV
NCT0000399516	NCT00003995_16_T0	COMPOUND	2	2	irinotecan
NCT0000399516	NCT00003995_16_T1	GENE	3	3	IV
NCT0000399517	NCT00003995_17_T0	PHENOTYPE	14	14	toxicity
NCT0000399517	NCT00003995_17_T1	PHENOTYPE	10	11	disease progression
NCT000039961	NCT00003996_1_T0	CELL	8	8	cells
NCT000039961	NCT00003996_1_T1	PHENOTYPE	7	7	tumor
NCT000039962	NCT00003996_2_T0	CELL	13	13	cells
NCT000039962	NCT00003996_2_T1	PHENOTYPE	12	12	tumor
NCT000039963	NCT00003996_3_T0	GENE	2	2	II
NCT000039963	NCT00003996_3_T1	PHENOTYPE	21	22	glioblastoma multiforme
NCT000039965	NCT00003996_5_T0	COMPOUND	7	7	etoposide
NCT000039965	NCT00003996_5_T1	COMPOUND	5	5	cisplatin
NCT000039965	NCT00003996_5_T2	PHENOTYPE	21	22	glioblastoma multiforme
NCT000039965	NCT00003996_5_T3	PHENOTYPE	19	20	high grade
NCT000039967	NCT00003996_7_T0	PHENOTYPE	2	2	toxicities
NCT000039969	NCT00003996_9_T0	PHENOTYPE	23	23	symptoms
NCT000039969	NCT00003996_9_T1	PHENOTYPE	1	1	fatigue
NCT000039969	NCT00003996_9_T2	PHENOTYPE	16	16	tumor
NCT000039969	NCT00003996_9_T3	PHENOTYPE	18	18	tumor
NCT000039969	NCT00003996_9_T4	PHENOTYPE	4	6	excessive daytime somnolence
NCT0000399611	NCT00003996_11_T0	PHENOTYPE	2	4	quality of life
NCT0000399612	NCT00003996_12_T0	GENE	29	29	1.2
NCT0000399612	NCT00003996_12_T1	GENE	14	14	1.3
NCT0000399612	NCT00003996_12_T2	GENE	33	33	1.3
NCT0000399612	NCT00003996_12_T3	COMPOUND	17	17	etoposide
NCT0000399612	NCT00003996_12_T4	COMPOUND	26	26	cisplatin
NCT0000399612	NCT00003996_12_T5	GENE	8	8	IV
NCT0000399612	NCT00003996_12_T6	GENE	27	27	IV
NCT0000399615	NCT00003996_15_T0	GENE	6	6	1.2
NCT0000399615	NCT00003996_15_T1	GENE	4	4	IV
NCT0000399616	NCT00003996_16_T0	PHENOTYPE	10	10	toxicity
NCT0000399616	NCT00003996_16_T1	PHENOTYPE	6	7	disease progression
NCT0000399617	NCT00003996_17_T0	PHENOTYPE	0	2	Quality of life
NCT000039971	NCT00003997_1_T0	CELL	10	10	cells
NCT000039975	NCT00003997_5_T0	PHENOTYPE	5	5	toxicities
NCT000039977	NCT00003997_7_T0	PHENOTYPE	10	10	toxicities
NCT0000399713	NCT00003997_13_T0	GENE	10	10	1.5
NCT0000399713	NCT00003997_13_T1	GENE	4	4	IV
NCT0000399714	NCT00003997_14_T0	PHENOTYPE	18	18	toxicity
NCT0000399714	NCT00003997_14_T1	GENE	3	3	3.4
NCT0000399714	NCT00003997_14_T2	PHENOTYPE	14	15	disease progression
NCT0000399716	NCT00003997_16_T0	PHENOTYPE	13	13	toxicity
NCT000039981	NCT00003998_1_T0	CELL	9	9	cells
NCT000039982	NCT00003998_2_T0	PHENOTYPE	14	16	ovarian epithelial cancer
NCT000039983	NCT00003998_3_T0	COMPOUND	12	12	paclitaxel
NCT000039983	NCT00003998_3_T1	COMPOUND	18	18	docetaxel
NCT000039983	NCT00003998_3_T2	GENE	3	3	III
NCT000039983	NCT00003998_3_T3	PHENOTYPE	24	26	ovarian epithelial cancer
NCT000039985	NCT00003998_5_T0	COMPOUND	20	20	paclitaxel
NCT000039985	NCT00003998_5_T1	COMPOUND	24	24	docetaxel
NCT000039985	NCT00003998_5_T2	PHENOTYPE	2	2	progression
NCT000039985	NCT00003998_5_T3	PHENOTYPE	12	14	ovarian epithelial cancer
NCT000039987	NCT00003998_7_T0	PHENOTYPE	2	2	toxic
NCT000039989	NCT00003998_9_T0	GENE	8	8	CA125
NCT0000399811	NCT00003998_11_T0	PHENOTYPE	2	4	quality of life
NCT0000399813	NCT00003998_13_T0	GENE	15	15	cm
NCT0000399813	NCT00003998_13_T1	GENE	22	22	cm
NCT0000399813	NCT00003998_13_T2	COMPOUND	14	14	2
NCT0000399813	NCT00003998_13_T3	COMPOUND	21	21	2
NCT0000399813	NCT00003998_13_T4	COMPOUND	34	34	2
NCT0000399813	NCT00003998_13_T5	PHENOTYPE	35	35	tumor
NCT0000399813	NCT00003998_13_T6	GENE	58	58	CA125
NCT0000399813	NCT00003998_13_T7	PHENOTYPE	4	5	residual disease
NCT0000399813	NCT00003998_13_T8	PHENOTYPE	67	68	peritoneal cancer
NCT0000399820	NCT00003998_20_T0	PHENOTYPE	13	13	toxicity
NCT0000399820	NCT00003998_20_T1	PHENOTYPE	9	10	disease progression
NCT0000399822	NCT00003998_22_T0	PHENOTYPE	22	23	disease progression
NCT0000399822	NCT00003998_22_T1	PHENOTYPE	0	2	Quality of life
NCT000040011	NCT00004001_1_T0	CELL	15	15	cells
NCT000040011	NCT00004001_1_T1	PHENOTYPE	14	14	tumor
NCT000040019	NCT00004001_9_T0	PHENOTYPE	0	2	Quality of life
NCT000040021	NCT00004002_1_T0	PHENOTYPE	19	19	lymphoma
NCT000040021	NCT00004002_1_T1	PHENOTYPE	16	17	solid tumors
NCT000040023	NCT00004002_3_T0	PHENOTYPE	3	3	toxicity
NCT000040023	NCT00004002_3_T1	PHENOTYPE	17	17	lymphoma
NCT000040023	NCT00004002_3_T2	PHENOTYPE	14	15	solid tumors
NCT000040025	NCT00004002_5_T0	PHENOTYPE	2	2	pharmacodynamics
NCT000040025	NCT00004002_5_T1	PHENOTYPE	10	10	inhibition
NCT000040025	NCT00004002_5_T2	GENE	8	9	20S proteasome
NCT000040027	NCT00004002_7_T0	GENE	5	5	P27
NCT000040027	NCT00004002_7_T1	PHENOTYPE	15	15	lymphoma
NCT000040027	NCT00004002_7_T2	GENE	8	8	E2F-1
NCT000040027	NCT00004002_7_T3	GENE	3	3	P53
NCT000040027	NCT00004002_7_T4	GENE	10	11	cyclin E
NCT000040029	NCT00004002_9_T0	PHENOTYPE	2	2	tumor
NCT0000400211	NCT00004002_11_T0	PHENOTYPE	4	4	toxicity
NCT0000400211	NCT00004002_11_T1	PHENOTYPE	14	14	tumor
NCT0000400211	NCT00004002_11_T2	PHENOTYPE	8	8	inhibition
NCT0000400211	NCT00004002_11_T3	GENE	6	7	20S proteasome
NCT0000400213	NCT00004002_13_T0	PHENOTYPE	12	13	evaluable disease
NCT0000400215	NCT00004002_15_T0	GENE	3	3	IV
NCT0000400216	NCT00004002_16_T0	PHENOTYPE	15	15	toxicity
NCT0000400216	NCT00004002_16_T1	PHENOTYPE	17	18	disease progression
NCT0000400218	NCT00004002_18_T0	GENE	14	14	MTD
NCT0000400219	NCT00004002_19_T0	PHENOTYPE	17	17	toxicity
NCT0000400219	NCT00004002_19_T1	GENE	1	1	MTD
NCT000040031	NCT00004003_1_T0	CELL	9	9	cells
NCT000040031	NCT00004003_1_T1	PHENOTYPE	8	8	tumor
NCT000040032	NCT00004003_2_T0	GENE	2	2	II
NCT000040032	NCT00004003_2_T1	PHENOTYPE	17	18	stage III
NCT000040032	NCT00004003_2_T2	PHENOTYPE	20	23	stage IV pancreatic cancer
NCT000040034	NCT00004003_4_T0	COMPOUND	16	16	gemcitabine
NCT000040034	NCT00004003_4_T1	COMPOUND	17	17	cisplatin
NCT000040034	NCT00004003_4_T2	GENE	11	11	IV
NCT000040034	NCT00004003_4_T3	PHENOTYPE	12	13	pancreatic adenocarcinoma
NCT000040034	NCT00004003_4_T4	PHENOTYPE	8	9	stage III
NCT000040036	NCT00004003_6_T0	PHENOTYPE	6	6	intent
NCT000040036	NCT00004003_6_T1	PHENOTYPE	13	14	pancreatic adenocarcinoma
NCT000040036	NCT00004003_6_T2	PHENOTYPE	11	12	stage III
NCT000040038	NCT00004003_8_T0	PHENOTYPE	4	4	toxicity
NCT0000400310	NCT00004003_10_T0	PHENOTYPE	14	15	disease progression
NCT0000400312	NCT00004003_12_T0	PHENOTYPE	2	4	quality of life
NCT0000400313	NCT00004003_13_T0	COMPOUND	3	3	gemcitabine
NCT0000400313	NCT00004003_13_T1	COMPOUND	16	16	cisplatin
NCT0000400313	NCT00004003_13_T2	GENE	4	4	IV
NCT0000400313	NCT00004003_13_T3	GENE	17	17	IV
NCT0000400316	NCT00004003_16_T0	PHENOTYPE	0	2	Quality of life
NCT000040042	NCT00004004_2_T0	PHENOTYPE	19	19	oligodendroglioma
NCT000040042	NCT00004004_2_T1	PHENOTYPE	18	18	astrocytoma
NCT000040042	NCT00004004_2_T2	PHENOTYPE	15	15	progressive
NCT000040042	NCT00004004_2_T3	PHENOTYPE	17	17	recurrent
NCT000040042	NCT00004004_2_T4	COMPOUND	9	9	procarbazine
NCT000040042	NCT00004004_2_T5	PHENOTYPE	21	22	glioblastoma multiforme
NCT000040046	NCT00004004_6_T0	PHENOTYPE	13	13	toxicity
NCT000040046	NCT00004004_6_T1	PHENOTYPE	9	10	disease progression
NCT000040051	NCT00004005_1_T0	CELL	8	8	cells
NCT000040051	NCT00004005_1_T1	PHENOTYPE	7	7	tumor
NCT000040052	NCT00004005_2_T0	CELL	13	13	cells
NCT000040052	NCT00004005_2_T1	PHENOTYPE	12	12	tumor
NCT000040053	NCT00004005_3_T0	GENE	3	3	II
NCT000040053	NCT00004005_3_T1	GENE	25	25	IV
NCT000040053	NCT00004005_3_T2	PHENOTYPE	21	22	stage III
NCT000040053	NCT00004005_3_T3	PHENOTYPE	30	31	refractory carcinoma
NCT000040053	NCT00004005_3_T4	PHENOTYPE	26	27	colorectal carcinoma
NCT000040053	NCT00004005_3_T5	PHENOTYPE	34	35	metastatic adenocarcinoma
NCT000040055	NCT00004005_5_T0	COMPOUND	11	11	irinotecan
NCT000040055	NCT00004005_5_T1	GENE	18	18	1.5
NCT000040055	NCT00004005_5_T2	GENE	12	12	IV
NCT000040055	NCT00004005_5_T3	PHENOTYPE	3	4	stage III
NCT000040055	NCT00004005_5_T4	PHENOTYPE	5	6	colorectal carcinoma
NCT000040057	NCT00004005_7_T0	COMPOUND	9	9	calcium
NCT000040057	NCT00004005_7_T1	COMPOUND	25	25	calcium
NCT000040057	NCT00004005_7_T2	GENE	29	29	1.5
NCT000040057	NCT00004005_7_T3	COMPOUND	8	8	leucovorin
NCT000040057	NCT00004005_7_T4	COMPOUND	24	24	leucovorin
NCT000040057	NCT00004005_7_T5	GENE	10	10	IV
NCT000040057	NCT00004005_7_T6	GENE	16	16	IV
NCT0000400510	NCT00004005_10_T0	COMPOUND	23	23	irinotecan
NCT0000400510	NCT00004005_10_T1	COMPOUND	27	27	calcium
NCT0000400510	NCT00004005_10_T2	GENE	3	3	IV
NCT0000400510	NCT00004005_10_T3	PHENOTYPE	11	11	adenocarcinomas
NCT0000400510	NCT00004005_10_T4	PHENOTYPE	8	8	carcinomas
NCT0000400510	NCT00004005_10_T5	COMPOUND	26	26	leucovorin
NCT0000400510	NCT00004005_10_T6	PHENOTYPE	4	5	colorectal carcinoma
NCT0000400511	NCT00004005_11_T0	PHENOTYPE	23	23	tumor
NCT0000400511	NCT00004005_11_T1	PHENOTYPE	24	24	regression
NCT0000400511	NCT00004005_11_T2	GENE	11	11	4.5
NCT0000400511	NCT00004005_11_T3	PHENOTYPE	6	7	primary tumor
NCT0000400512	NCT00004005_12_T0	PHENOTYPE	13	13	symptoms
NCT0000400512	NCT00004005_12_T1	PHENOTYPE	17	18	primary tumor
NCT0000400513	NCT00004005_13_T0	PHENOTYPE	34	34	toxicity
NCT0000400513	NCT00004005_13_T1	GENE	8	8	PR
NCT0000400513	NCT00004005_13_T2	GENE	4	4	CR
NCT0000400513	NCT00004005_13_T3	PHENOTYPE	30	31	disease progression
NCT0000400515	NCT00004005_15_T0	PHENOTYPE	41	41	toxicity
NCT0000400515	NCT00004005_15_T1	GENE	17	17	PR
NCT0000400515	NCT00004005_15_T2	COMPOUND	12	12	irinotecan
NCT0000400515	NCT00004005_15_T3	COMPOUND	22	22	calcium
NCT0000400515	NCT00004005_15_T4	GENE	15	15	CR
NCT0000400515	NCT00004005_15_T5	COMPOUND	21	21	leucovorin
NCT0000400515	NCT00004005_15_T6	PHENOTYPE	6	7	progressive disease
NCT0000400515	NCT00004005_15_T7	PHENOTYPE	37	38	disease progression
NCT000040061	NCT00004006_1_T0	CELL	8	8	cells
NCT000040061	NCT00004006_1_T1	PHENOTYPE	7	7	tumor
NCT000040062	NCT00004006_2_T0	CELL	18	18	cells
NCT000040062	NCT00004006_2_T1	PHENOTYPE	17	17	tumor
NCT000040062	NCT00004006_2_T2	ORGAN	0	1	Bone marrow
NCT000040065	NCT00004006_5_T0	GENE	17	17	1.3
NCT000040065	NCT00004006_5_T1	COMPOUND	25	25	cyclophosphamide
NCT000040065	NCT00004006_5_T2	GENE	32	32	1.7
NCT000040065	NCT00004006_5_T3	COMPOUND	9	9	etoposide
NCT000040065	NCT00004006_5_T4	COMPOUND	33	33	doxorubicin
NCT000040065	NCT00004006_5_T5	GENE	4	4	IV
NCT000040065	NCT00004006_5_T6	GENE	10	10	IV
NCT000040065	NCT00004006_5_T7	GENE	26	26	IV
NCT000040065	NCT00004006_5_T8	GENE	34	34	IV
NCT000040065	NCT00004006_5_T9	GENE	40	40	IV
NCT000040067	NCT00004006_7_T0	COMPOUND	5	5	topotecan
NCT000040068	NCT00004006_8_T0	GENE	9	9	filgrastim
NCT000040068	NCT00004006_8_T1	GENE	10	10	G-CSF
NCT000040069	NCT00004006_9_T0	ORGAN	2	3	bone marrow
NCT0000400610	NCT00004006_10_T0	COMPOUND	13	13	cyclophosphamide
NCT0000400610	NCT00004006_10_T1	COMPOUND	15	15	topotecan
NCT0000400610	NCT00004006_10_T2	ORGAN	18	19	bone marrow
NCT000040081	NCT00004008_1_T0	GENE	2	2	II
NCT000040081	NCT00004008_1_T1	GENE	20	20	has
NCT000040081	NCT00004008_1_T2	COMPOUND	9	10	bryostatin 1
NCT000040081	NCT00004008_1_T3	PHENOTYPE	16	18	ovarian epithelial cancer
NCT000040084	NCT00004008_4_T0	GENE	4	4	IV
NCT000040084	NCT00004008_4_T1	COMPOUND	2	3	bryostatin 1
NCT000040085	NCT00004008_5_T0	PHENOTYPE	14	14	toxicity
NCT000040085	NCT00004008_5_T1	PHENOTYPE	10	11	disease progression
NCT000040091	NCT00004009_1_T0	PHENOTYPE	17	17	recurrent
NCT000040091	NCT00004009_1_T1	PHENOTYPE	18	19	acute leukemia
NCT000040091	NCT00004009_1_T2	PHENOTYPE	21	23	chronic myelogenous leukemia
NCT000040093	NCT00004009_3_T0	PHENOTYPE	1	1	toxicities
NCT000040093	NCT00004009_3_T1	PHENOTYPE	3	3	pharmacokinetics
NCT000040093	NCT00004009_3_T2	PHENOTYPE	11	12	acute leukemia
NCT000040093	NCT00004009_3_T3	PHENOTYPE	16	20	blastic phase chronic myelogenous leukemia
NCT000040095	NCT00004009_5_T0	PHENOTYPE	8	8	leukemia
NCT000040095	NCT00004009_5_T1	CELL	9	9	cells
NCT000040097	NCT00004009_7_T0	PHENOTYPE	10	10	leukemia
NCT000040097	NCT00004009_7_T1	CELL	11	11	cells
NCT0000400910	NCT00004009_10_T0	GENE	9	9	PR
NCT0000400910	NCT00004009_10_T1	GENE	11	11	1.4
NCT0000400910	NCT00004009_10_T2	GENE	5	5	CR
NCT0000400912	NCT00004009_12_T0	GENE	3	3	PR
NCT0000400912	NCT00004009_12_T1	GENE	1	1	CR
NCT0000400913	NCT00004009_13_T0	GENE	14	14	MTD
NCT0000400914	NCT00004009_14_T0	PHENOTYPE	18	18	toxicity
NCT0000400914	NCT00004009_14_T1	GENE	1	1	MTD
NCT000040101	NCT00004010_1_T0	CELL	9	9	cells
NCT000040102	NCT00004010_2_T0	CELL	8	8	cells
NCT000040103	NCT00004010_3_T0	PHENOTYPE	11	12	Hodgkin's disease
NCT000040104	NCT00004010_4_T0	GENE	2	2	II
NCT000040104	NCT00004010_4_T1	GENE	22	22	II
NCT000040104	NCT00004010_4_T2	GENE	27	27	IV
NCT000040104	NCT00004010_4_T3	PHENOTYPE	23	24	stage III
NCT000040104	NCT00004010_4_T4	PHENOTYPE	28	29	Hodgkin's disease
NCT000040106	NCT00004010_6_T0	GENE	23	23	II
NCT000040106	NCT00004010_6_T1	PHENOTYPE	4	4	toxicity
NCT000040106	NCT00004010_6_T2	COMPOUND	6	6	bleomycin
NCT000040106	NCT00004010_6_T3	COMPOUND	10	10	vincristine
NCT000040106	NCT00004010_6_T4	GENE	28	28	IV
NCT000040106	NCT00004010_6_T5	COMPOUND	11	11	procarbazine
NCT000040106	NCT00004010_6_T6	COMPOUND	9	9	cyclophosphamide
NCT000040106	NCT00004010_6_T7	COMPOUND	7	7	etoposide
NCT000040106	NCT00004010_6_T8	COMPOUND	8	8	doxorubicin
NCT000040106	NCT00004010_6_T9	COMPOUND	13	13	prednisone
NCT000040106	NCT00004010_6_T10	PHENOTYPE	24	25	stage III
NCT000040106	NCT00004010_6_T11	PHENOTYPE	29	30	Hodgkin's disease
NCT000040108	NCT00004010_8_T0	COMPOUND	30	30	gallium
NCT000040108	NCT00004010_8_T1	GENE	25	25	nodal
NCT0000401010	NCT00004010_10_T0	COMPOUND	2	2	thallium
NCT0000401017	NCT00004010_17_T0	COMPOUND	7	7	cyclophosphamide
NCT0000401017	NCT00004010_17_T1	COMPOUND	17	17	etoposide
NCT0000401017	NCT00004010_17_T2	COMPOUND	12	12	doxorubicin
NCT0000401017	NCT00004010_17_T3	COMPOUND	23	23	prednisone
NCT0000401017	NCT00004010_17_T4	GENE	8	8	IV
NCT0000401017	NCT00004010_17_T5	GENE	13	13	IV
NCT0000401017	NCT00004010_17_T6	GENE	18	18	IV
NCT0000401017	NCT00004010_17_T7	COMPOUND	29	29	procarbazine
NCT0000401018	NCT00004010_18_T0	COMPOUND	7	7	etoposide
NCT0000401018	NCT00004010_18_T1	COMPOUND	13	13	prednisone
NCT0000401018	NCT00004010_18_T2	GENE	8	8	IV
NCT0000401018	NCT00004010_18_T3	COMPOUND	19	19	procarbazine
NCT0000401019	NCT00004010_19_T0	COMPOUND	6	6	prednisone
NCT0000401019	NCT00004010_19_T1	COMPOUND	12	12	procarbazine
NCT0000401020	NCT00004010_20_T0	COMPOUND	7	7	bleomycin
NCT0000401020	NCT00004010_20_T1	COMPOUND	5	5	vincristine
NCT0000401020	NCT00004010_20_T2	COMPOUND	14	14	prednisone
NCT0000401020	NCT00004010_20_T3	GENE	6	6	IV
NCT0000401020	NCT00004010_20_T4	GENE	8	8	IV
NCT0000401021	NCT00004010_21_T0	COMPOUND	6	6	prednisone
NCT0000401022	NCT00004010_22_T0	GENE	6	6	filgrastim
NCT0000401022	NCT00004010_22_T1	GENE	7	7	G-CSF
NCT0000401022	NCT00004010_22_T2	CELL	11	11	neutrophil
NCT0000401023	NCT00004010_23_T0	PHENOTYPE	16	16	toxicity
NCT0000401023	NCT00004010_23_T1	PHENOTYPE	12	13	disease progression
NCT0000401024	NCT00004010_24_T0	PHENOTYPE	0	0	Consolidation
NCT0000401026	NCT00004010_26_T0	GENE	2	2	1/6
NCT0000401026	NCT00004010_26_T1	COMPOUND	6	6	prednisone
NCT0000401026	NCT00004010_26_T2	COMPOUND	12	12	procarbazine
NCT0000401027	NCT00004010_27_T0	COMPOUND	7	7	bleomycin
NCT0000401027	NCT00004010_27_T1	COMPOUND	5	5	vinblastine
NCT0000401027	NCT00004010_27_T2	COMPOUND	12	12	doxorubicin
NCT0000401027	NCT00004010_27_T3	COMPOUND	19	19	prednisone
NCT0000401027	NCT00004010_27_T4	GENE	6	6	IV
NCT0000401027	NCT00004010_27_T5	GENE	8	8	IV
NCT0000401027	NCT00004010_27_T6	GENE	13	13	IV
NCT0000401028	NCT00004010_28_T0	COMPOUND	6	6	prednisone
NCT0000401029	NCT00004010_29_T0	PHENOTYPE	19	19	toxicity
NCT0000401029	NCT00004010_29_T1	PHENOTYPE	15	16	disease progression
NCT0000401031	NCT00004010_31_T0	PHENOTYPE	19	19	toxicity
NCT0000401031	NCT00004010_31_T1	PHENOTYPE	15	16	disease progression
NCT0000401033	NCT00004010_33_T0	GENE	10	10	PR-2
NCT0000401033	NCT00004010_33_T1	PHENOTYPE	36	36	toxicity
NCT0000401033	NCT00004010_33_T2	PHENOTYPE	0	0	Consolidation
NCT0000401033	NCT00004010_33_T3	PHENOTYPE	32	33	disease progression
NCT0000401034	NCT00004010_34_T0	GENE	6	6	G-CSF
NCT0000401035	NCT00004010_35_T0	GENE	4	4	G-CSF
NCT000040112	NCT00004011_2_T0	CELL	9	9	cells
NCT000040112	NCT00004011_2_T1	PHENOTYPE	8	8	tumor
NCT0000401110	NCT00004011_10_T0	PHENOTYPE	19	19	toxicity
NCT0000401110	NCT00004011_10_T1	PHENOTYPE	15	16	disease progression
NCT000040126	NCT00004012_6_T0	COMPOUND	4	4	capecitabine
NCT000040127	NCT00004012_7_T0	PHENOTYPE	13	13	toxicity
NCT000040127	NCT00004012_7_T1	PHENOTYPE	9	10	disease progression
NCT0000401311	NCT00004013_11_T0	GENE	12	12	IV
NCT0000401312	NCT00004013_12_T0	PHENOTYPE	22	22	toxicity
NCT0000401312	NCT00004013_12_T1	COMPOUND	2	2	paclitaxel
NCT0000401312	NCT00004013_12_T2	PHENOTYPE	18	19	disease progression
NCT0000401314	NCT00004013_14_T0	COMPOUND	12	12	anastrozole
NCT0000401314	NCT00004013_14_T1	COMPOUND	10	10	tamoxifen
NCT0000401314	NCT00004013_14_T2	GENE	2	3	hormone receptor
NCT0000401315	NCT00004013_15_T0	PHENOTYPE	3	3	metastasis
NCT0000401315	NCT00004013_15_T1	PHENOTYPE	8	9	bone lesion
NCT000040143	NCT00004014_3_T0	PHENOTYPE	10	10	toxicity
NCT000040143	NCT00004014_3_T1	PHENOTYPE	6	7	disease progression
NCT000040147	NCT00004014_7_T0	PHENOTYPE	2	2	toxic
NCT000040147	NCT00004014_7_T1	PHENOTYPE	7	7	cardiotoxicity
NCT0000401410	NCT00004014_10_T0	COMPOUND	4	4	HCl
NCT0000401410	NCT00004014_10_T1	COMPOUND	3	3	doxorubicin
NCT0000401410	NCT00004014_10_T2	GENE	6	6	IV
NCT0000401411	NCT00004014_11_T0	PHENOTYPE	10	10	toxicity
NCT0000401411	NCT00004014_11_T1	PHENOTYPE	6	7	disease progression
NCT0000401412	NCT00004014_12_T0	PHENOTYPE	0	2	Quality of life
NCT000040151	NCT00004015_1_T0	COMPOUND	14	14	boron
NCT000040151	NCT00004015_1_T1	PHENOTYPE	24	25	glioblastoma multiforme
NCT000040154	NCT00004015_4_T0	COMPOUND	8	8	sodium
NCT000040157	NCT00004015_7_T0	PHENOTYPE	20	20	toxicity
NCT000040160	NCT00004016_0_T0	GENE	0	0	Interferon
NCT000040160	NCT00004016_0_T1	PHENOTYPE	6	6	Recurrent
NCT000040160	NCT00004016_0_T2	PHENOTYPE	8	9	Metastatic Melanoma
NCT000040160	NCT00004016_0_T3	PHENOTYPE	12	13	Solid Tumors
NCT000040162	NCT00004016_2_T0	PHENOTYPE	15	15	recurrent
NCT000040162	NCT00004016_2_T1	GENE	9	10	interferon gamma
NCT000040162	NCT00004016_2_T2	PHENOTYPE	21	22	solid tumors
NCT000040162	NCT00004016_2_T3	PHENOTYPE	17	18	metastatic melanoma
NCT000040164	NCT00004016_4_T0	PHENOTYPE	16	16	recurrent
NCT000040164	NCT00004016_4_T1	GENE	10	11	interferon gamma
NCT000040164	NCT00004016_4_T2	PHENOTYPE	18	19	metastatic melanoma
NCT000040164	NCT00004016_4_T3	PHENOTYPE	22	23	solid tumors
NCT0000401610	NCT00004016_10_T0	GENE	14	15	interferon gamma
NCT0000401612	NCT00004016_12_T0	GENE	3	4	interferon gamma
NCT0000401614	NCT00004016_14_T0	GENE	18	18	MTD
NCT0000401614	NCT00004016_14_T1	GENE	11	12	interferon gamma
NCT0000401615	NCT00004016_15_T0	PHENOTYPE	18	18	toxicity
NCT0000401615	NCT00004016_15_T1	GENE	1	1	MTD
NCT000040170	NCT00004017_0_T0	PHENOTYPE	7	8	Glioblastoma Multiforme
NCT000040170	NCT00004017_0_T1	PHENOTYPE	10	11	Anaplastic Astrocytoma
NCT000040172	NCT00004017_2_T0	PHENOTYPE	10	11	brain tumors
NCT000040173	NCT00004017_3_T0	GENE	2	2	II
NCT000040173	NCT00004017_3_T1	PHENOTYPE	17	18	glioblastoma multiforme
NCT000040173	NCT00004017_3_T2	PHENOTYPE	20	21	anaplastic astrocytoma
NCT000040176	NCT00004017_6_T0	PHENOTYPE	10	10	tumor
NCT000040177	NCT00004017_7_T0	COMPOUND	5	5	iodine
NCT000040178	NCT00004017_8_T0	PHENOTYPE	2	2	centers
NCT0000401710	NCT00004017_10_T0	GENE	3	3	MRI
NCT0000401710	NCT00004017_10_T1	COMPOUND	1	1	gadolinium
NCT0000401712	NCT00004017_12_T0	PHENOTYPE	8	8	toxicity
NCT0000401712	NCT00004017_12_T1	PHENOTYPE	4	5	progressive disease
NCT0000401713	NCT00004017_13_T0	PHENOTYPE	6	7	disease progression
NCT0000401714	NCT00004017_14_T0	PHENOTYPE	4	5	disease progression
NCT0000401715	NCT00004017_15_T0	PHENOTYPE	15	15	GBM
NCT0000401715	NCT00004017_15_T1	PHENOTYPE	20	20	GBM
NCT0000401715	NCT00004017_15_T2	PHENOTYPE	19	19	recurrent
NCT0000401715	NCT00004017_15_T3	PHENOTYPE	25	25	recurrent
NCT0000401715	NCT00004017_15_T4	PHENOTYPE	13	14	glioblastoma multiforme
NCT0000401715	NCT00004017_15_T5	PHENOTYPE	26	27	anaplastic astrocytoma
NCT000040220	NCT00004022_0_T0	PHENOTYPE	13	13	Melanoma
NCT000040220	NCT00004022_0_T1	GENE	9	9	III
NCT000040220	NCT00004022_0_T2	GENE	12	12	IV
NCT000040222	NCT00004022_2_T0	CELL	10	10	cells
NCT000040222	NCT00004022_2_T1	PHENOTYPE	9	9	tumor
NCT000040223	NCT00004022_3_T0	GENE	2	2	II
NCT000040223	NCT00004022_3_T1	PHENOTYPE	18	19	stage III
NCT000040223	NCT00004022_3_T2	PHENOTYPE	21	23	stage IV melanoma
NCT000040225	NCT00004022_5_T0	COMPOUND	20	20	1
NCT000040226	NCT00004022_6_T0	PHENOTYPE	5	5	tumor
NCT000040227	NCT00004022_7_T0	CELL	12	12	cells
NCT000040227	NCT00004022_7_T1	GENE	1	1	1.2
NCT000040227	NCT00004022_7_T2	PHENOTYPE	11	11	tumor
NCT000040227	NCT00004022_7_T3	GENE	15	15	GM-CSF
NCT000040227	NCT00004022_7_T4	GENE	18	18	GM-CSF
NCT000040227	NCT00004022_7_T5	GENE	14	14	sargramostim
NCT0000402210	NCT00004022_10_T0	PHENOTYPE	0	0	Peripheral
NCT0000402210	NCT00004022_10_T1	CELL	3	3	cells
NCT0000402210	NCT00004022_10_T2	GENE	7	7	CD3
NCT0000402210	NCT00004022_10_T3	GENE	12	12	interleukin-2
NCT0000402210	NCT00004022_10_T4	CELL	15	16	T lymphocytes
NCT0000402211	NCT00004022_11_T0	GENE	15	15	interleukin-2
NCT0000402211	NCT00004022_11_T1	GENE	8	8	1/6
NCT0000402211	NCT00004022_11_T2	GENE	6	6	IV
NCT0000402211	NCT00004022_11_T3	GENE	16	16	IV
NCT0000402211	NCT00004022_11_T4	CELL	2	3	T lymphocytes
NCT0000402212	NCT00004022_12_T0	PHENOTYPE	10	10	toxicity
NCT0000402212	NCT00004022_12_T1	PHENOTYPE	6	7	disease progression
NCT000040241	NCT00004024_1_T0	CELL	10	10	cells
NCT000040241	NCT00004024_1_T1	PHENOTYPE	9	9	tumor
NCT000040242	NCT00004024_2_T0	GENE	2	2	II
NCT000040242	NCT00004024_2_T1	PHENOTYPE	26	26	oligodendroglioma
NCT000040242	NCT00004024_2_T2	PHENOTYPE	24	24	astrocytoma
NCT000040242	NCT00004024_2_T3	PHENOTYPE	23	23	recurrent
NCT000040244	NCT00004024_4_T0	COMPOUND	19	19	1
NCT000040244	NCT00004024_4_T1	PHENOTYPE	11	12	antigen response
NCT000040245	NCT00004024_5_T0	PHENOTYPE	2	2	tumor
NCT000040246	NCT00004024_6_T0	GENE	9	9	2.8
NCT000040246	NCT00004024_6_T1	PHENOTYPE	2	3	recurrent disease
NCT000040247	NCT00004024_7_T0	CELL	10	10	cells
NCT000040247	NCT00004024_7_T1	PHENOTYPE	9	9	tumor
NCT000040247	NCT00004024_7_T2	GENE	13	13	GM-CSF
NCT000040247	NCT00004024_7_T3	GENE	17	17	GM-CSF
NCT000040247	NCT00004024_7_T4	GENE	12	12	sargramostim
NCT0000402410	NCT00004024_10_T0	PHENOTYPE	10	10	toxicity
NCT0000402410	NCT00004024_10_T1	PHENOTYPE	6	7	disease progression
NCT000040250	NCT00004025_0_T0	GENE	5	5	Interleukin-2
NCT000040250	NCT00004025_0_T1	PHENOTYPE	15	15	Melanoma
NCT000040250	NCT00004025_0_T2	GENE	11	11	III
NCT000040250	NCT00004025_0_T3	GENE	14	14	IV
NCT000040252	NCT00004025_2_T0	CELL	11	11	cells
NCT000040252	NCT00004025_2_T1	GENE	0	0	Interleukin-2
NCT000040252	NCT00004025_2_T2	PHENOTYPE	10	10	melanoma
NCT000040252	NCT00004025_2_T3	CELL	5	7	white blood cells
NCT000040253	NCT00004025_3_T0	GENE	4	4	interleukin-2
NCT000040253	NCT00004025_3_T1	PHENOTYPE	11	12	stage III
NCT000040253	NCT00004025_3_T2	PHENOTYPE	14	16	stage IV melanoma
NCT000040254	NCT00004025_4_T0	GENE	14	14	interleukin-2
NCT000040254	NCT00004025_4_T1	PHENOTYPE	20	21	stage III
NCT000040254	NCT00004025_4_T2	PHENOTYPE	23	25	stage IV melanoma
NCT000040256	NCT00004025_6_T0	PHENOTYPE	4	4	toxicity
NCT000040256	NCT00004025_6_T1	PHENOTYPE	21	21	melanoma
NCT000040256	NCT00004025_6_T2	PHENOTYPE	34	34	melanoma
NCT000040256	NCT00004025_6_T3	PHENOTYPE	16	16	encoding
NCT000040256	NCT00004025_6_T4	GENE	33	33	IV
NCT000040256	NCT00004025_6_T5	GENE	26	26	interleukin-2
NCT000040256	NCT00004025_6_T6	GENE	20	20	gp100
NCT000040256	NCT00004025_6_T7	GENE	18	18	MART-1
NCT000040256	NCT00004025_6_T8	PHENOTYPE	30	31	stage III
NCT000040256	NCT00004025_6_T9	CELL	11	12	dendritic cells
NCT0000402511	NCT00004025_11_T0	GENE	13	13	interleukin-2
NCT0000402511	NCT00004025_11_T1	GENE	14	14	IV
NCT0000402511	NCT00004025_11_T2	CELL	4	5	dendritic cells
NCT0000402512	NCT00004025_12_T0	PHENOTYPE	19	19	toxicity
NCT0000402512	NCT00004025_12_T1	PHENOTYPE	15	16	disease progression
NCT0000402513	NCT00004025_13_T0	GENE	14	14	interleukin-2
NCT0000402513	NCT00004025_13_T1	GENE	20	20	MTD
NCT0000402513	NCT00004025_13_T2	CELL	9	10	dendritic cells
NCT0000402514	NCT00004025_14_T0	PHENOTYPE	17	17	toxicity
NCT0000402514	NCT00004025_14_T1	GENE	1	1	MTD
NCT000040268	NCT00004026_8_T0	PHENOTYPE	13	13	toxicity
NCT000040268	NCT00004026_8_T1	PHENOTYPE	9	10	disease progression
NCT000040281	NCT00004028_1_T0	PHENOTYPE	18	18	recurrent
NCT000040281	NCT00004028_1_T1	PHENOTYPE	19	20	malignant glioma
NCT000040284	NCT00004028_4_T0	PHENOTYPE	4	4	tumor
NCT000040285	NCT00004028_5_T0	PHENOTYPE	25	25	cavity
NCT000040286	NCT00004028_6_T0	PHENOTYPE	7	8	glioblastoma multiforme
NCT000040286	NCT00004028_6_T1	PHENOTYPE	10	11	anaplastic astrocytoma
NCT000040291	NCT00004029_1_T0	CELL	12	12	cells
NCT000040291	NCT00004029_1_T1	PHENOTYPE	11	11	tumor
NCT000040291	NCT00004029_1_T2	BIOLOGICAL_PROCESS	7	8	immune response
NCT000040295	NCT00004029_5_T0	PHENOTYPE	15	15	immunity
NCT000040297	NCT00004029_7_T0	PHENOTYPE	8	8	tumor
NCT000040299	NCT00004029_9_T0	PHENOTYPE	13	13	immunity
NCT000040299	NCT00004029_9_T1	GENE	6	6	has
NCT000040299	NCT00004029_9_T2	GENE	23	23	has
NCT000040299	NCT00004029_9_T3	GENE	5	5	GM-CSF
NCT000040299	NCT00004029_9_T4	GENE	22	22	GM-CSF
NCT0000402911	NCT00004029_11_T0	PHENOTYPE	27	27	toxicity
NCT0000402911	NCT00004029_11_T1	PHENOTYPE	23	24	disease progression
NCT0000402914	NCT00004029_14_T0	PHENOTYPE	3	3	toxicity
NCT0000402914	NCT00004029_14_T1	GENE	26	26	MTD
NCT0000402916	NCT00004029_16_T0	PHENOTYPE	13	13	toxicity
NCT0000402916	NCT00004029_16_T1	GENE	42	42	GM-CSF
NCT0000402916	NCT00004029_16_T2	PHENOTYPE	26	27	disease progression
NCT000040300	NCT00004030_0_T0	PHENOTYPE	5	6	Solid Tumors
NCT000040302	NCT00004030_2_T0	COMPOUND	21	21	doxorubicin
NCT000040302	NCT00004030_2_T1	PHENOTYPE	15	16	solid tumors
NCT000040304	NCT00004030_4_T0	COMPOUND	11	11	HCl
NCT000040304	NCT00004030_4_T1	COMPOUND	10	10	doxorubicin
NCT000040304	NCT00004030_4_T2	PHENOTYPE	19	20	solid tumors
NCT000040306	NCT00004030_6_T0	COMPOUND	13	13	HCl
NCT000040306	NCT00004030_6_T1	COMPOUND	12	12	doxorubicin
NCT000040308	NCT00004030_8_T0	PHENOTYPE	15	15	pharmacokinetics
NCT000040308	NCT00004030_8_T1	PHENOTYPE	2	3	blood concentrations
NCT0000403010	NCT00004030_10_T0	COMPOUND	9	9	HCl
NCT0000403010	NCT00004030_10_T1	COMPOUND	8	8	doxorubicin
NCT0000403013	NCT00004030_13_T0	PHENOTYPE	13	13	toxicity
NCT0000403013	NCT00004030_13_T1	PHENOTYPE	9	10	disease progression
NCT0000403014	NCT00004030_14_T0	GENE	14	14	MTD
NCT0000403015	NCT00004030_15_T0	PHENOTYPE	20	20	toxicity
NCT0000403015	NCT00004030_15_T1	GENE	1	1	MTD
NCT000040311	NCT00004031_1_T0	CELL	8	8	cells
NCT000040318	NCT00004031_8_T0	COMPOUND	13	13	vincristine
NCT000040318	NCT00004031_8_T1	GENE	23	23	1.5
NCT000040318	NCT00004031_8_T2	GENE	2	2	CHOP
NCT000040318	NCT00004031_8_T3	COMPOUND	5	5	cyclophosphamide
NCT000040318	NCT00004031_8_T4	COMPOUND	10	10	doxorubicin
NCT000040318	NCT00004031_8_T5	COMPOUND	20	20	prednisone
NCT000040318	NCT00004031_8_T6	GENE	6	6	IV
NCT000040318	NCT00004031_8_T7	GENE	11	11	IV
NCT000040318	NCT00004031_8_T8	GENE	14	14	IV
NCT000040319	NCT00004031_9_T0	GENE	7	7	IV
NCT0000403110	NCT00004031_10_T0	PHENOTYPE	16	16	toxicity
NCT0000403110	NCT00004031_10_T1	PHENOTYPE	12	13	disease progression
NCT0000403113	NCT00004031_13_T0	PHENOTYPE	22	22	relapse
NCT0000403113	NCT00004031_13_T1	CELL	11	14	peripheral blood stem cells
NCT0000403115	NCT00004031_15_T0	CELL	7	7	cells
NCT0000403115	NCT00004031_15_T1	GENE	6	6	CD34
NCT0000403117	NCT00004031_17_T0	COMPOUND	13	13	cyclophosphamide
NCT0000403117	NCT00004031_17_T1	COMPOUND	11	11	etoposide
NCT0000403119	NCT00004031_19_T0	COMPOUND	8	8	cyclophosphamide
NCT0000403120	NCT00004031_20_T0	ORGAN	2	3	bone marrow
NCT0000403120	NCT00004031_20_T1	ORGAN	8	9	bone marrow
NCT0000403124	NCT00004031_24_T0	PHENOTYPE	18	18	lymphoma
NCT0000403124	NCT00004031_24_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000403124	NCT00004031_24_T2	PHENOTYPE	16	17	high grade
NCT000040321	NCT00004032_1_T0	CELL	6	6	cells
NCT000040321	NCT00004032_1_T1	CELL	20	20	cells
NCT000040321	NCT00004032_1_T2	PHENOTYPE	19	19	tumor
NCT000040321	NCT00004032_1_T3	BIOLOGICAL_PROCESS	13	14	immune response
NCT000040323	NCT00004032_3_T0	PHENOTYPE	19	19	toxicity
NCT000040323	NCT00004032_3_T1	CELL	9	9	cells
NCT000040323	NCT00004032_3_T2	GENE	15	16	interferon gamma
NCT000040323	NCT00004032_3_T3	PHENOTYPE	6	8	epithelial ovarian carcinoma
NCT000040323	NCT00004032_3_T4	PHENOTYPE	29	31	ovarian epithelial cancer
NCT000040324	NCT00004032_4_T0	CELL	10	10	cells
NCT000040324	NCT00004032_4_T1	PHENOTYPE	9	9	tumor
NCT000040325	NCT00004032_5_T0	CELL	5	5	cells
NCT000040325	NCT00004032_5_T1	PHENOTYPE	4	4	tumor
NCT000040326	NCT00004032_6_T0	GENE	3	4	interferon gamma
NCT000040327	NCT00004032_7_T0	PHENOTYPE	4	5	disease progression
NCT000040329	NCT00004032_9_T0	CELL	13	13	cells
NCT000040329	NCT00004032_9_T1	PHENOTYPE	12	12	tumor
NCT000040329	NCT00004032_9_T2	GENE	19	19	MTD
NCT0000403210	NCT00004032_10_T0	PHENOTYPE	18	18	toxicity
NCT0000403210	NCT00004032_10_T1	GENE	1	1	MTD
NCT0000403211	NCT00004032_11_T0	PHENOTYPE	7	8	disease progression
NCT000040330	NCT00004033_0_T0	COMPOUND	2	2	L-NDDP
NCT000040330	NCT00004033_0_T1	PHENOTYPE	7	9	Malignant Pleural Mesothelioma
NCT000040332	NCT00004033_2_T0	COMPOUND	8	8	L-NDDP
NCT000040332	NCT00004033_2_T1	PHENOTYPE	17	19	malignant pleural mesothelioma
NCT000040334	NCT00004033_4_T0	PHENOTYPE	4	4	progression
NCT000040336	NCT00004033_6_T0	PHENOTYPE	5	5	toxicity
NCT000040336	NCT00004033_6_T1	COMPOUND	8	8	L-NDDP
NCT000040337	NCT00004033_7_T0	PHENOTYPE	8	8	anesthesia
NCT000040338	NCT00004033_8_T0	PHENOTYPE	13	13	cavity
NCT000040339	NCT00004033_9_T0	COMPOUND	6	6	L-NDDP
NCT0000403310	NCT00004033_10_T0	COMPOUND	6	6	L-NDDP
NCT0000403311	NCT00004033_11_T0	PHENOTYPE	4	4	toxic
NCT0000403311	NCT00004033_11_T1	PHENOTYPE	7	8	disease progression
NCT000040361	NCT00004036_1_T0	CELL	8	8	cells
NCT000040361	NCT00004036_1_T1	COMPOUND	4	4	amifostine
NCT000040361	NCT00004036_1_T2	PHENOTYPE	12	14	effects of chemotherapy
NCT000040362	NCT00004036_2_T0	COMPOUND	9	9	amifostine
NCT000040362	NCT00004036_2_T1	PHENOTYPE	17	18	advanced cancer
NCT000040364	NCT00004036_4_T0	CELL	9	9	thrombocyte
NCT000040364	NCT00004036_4_T1	CELL	7	7	granulocyte
NCT000040364	NCT00004036_4_T2	PHENOTYPE	22	22	malignancies
NCT000040364	NCT00004036_4_T3	COMPOUND	15	15	cyclophosphamide
NCT000040366	NCT00004036_6_T0	CELL	9	9	thrombocyte
NCT000040366	NCT00004036_6_T1	CELL	7	7	granulocyte
NCT000040366	NCT00004036_6_T2	COMPOUND	4	4	amifostine
NCT000040366	NCT00004036_6_T3	GENE	19	19	sargramostim
NCT000040366	NCT00004036_6_T4	CELL	21	22	progenitor cells
NCT0000403610	NCT00004036_10_T0	COMPOUND	13	13	cyclophosphamide
NCT0000403610	NCT00004036_10_T1	COMPOUND	3	3	amifostine
NCT0000403611	NCT00004036_11_T0	COMPOUND	8	8	2
NCT0000403611	NCT00004036_11_T1	CELL	17	17	neutrophil
NCT0000403612	NCT00004036_12_T0	PHENOTYPE	11	11	toxic
NCT0000403612	NCT00004036_12_T1	PHENOTYPE	7	8	disease progression
NCT0000403615	NCT00004036_15_T0	COMPOUND	8	8	cyclophosphamide
NCT0000403615	NCT00004036_15_T1	GENE	16	16	MTD
NCT0000403616	NCT00004036_16_T0	PHENOTYPE	3	3	toxicity
NCT0000403616	NCT00004036_16_T1	GENE	28	28	MTD
NCT0000403616	NCT00004036_16_T2	GENE	4	4	DLT
NCT000040371	NCT00004037_1_T0	GENE	2	2	II
NCT000040371	NCT00004037_1_T1	COMPOUND	9	9	docetaxel
NCT000040371	NCT00004037_1_T2	PHENOTYPE	14	14	recurrent
NCT000040371	NCT00004037_1_T3	PHENOTYPE	20	21	peritoneal cancer
NCT000040373	NCT00004037_3_T0	COMPOUND	9	9	paclitaxel
NCT000040373	NCT00004037_3_T1	COMPOUND	5	5	docetaxel
NCT000040373	NCT00004037_3_T2	PHENOTYPE	12	12	recurrent
NCT000040373	NCT00004037_3_T3	PHENOTYPE	19	20	peritoneal cancer
NCT000040375	NCT00004037_5_T0	PHENOTYPE	6	6	toxicity
NCT000040375	NCT00004037_5_T1	COMPOUND	8	8	docetaxel
NCT000040376	NCT00004037_6_T0	COMPOUND	3	3	docetaxel
NCT000040378	NCT00004037_8_T0	PHENOTYPE	7	7	toxic
NCT000040378	NCT00004037_8_T1	PHENOTYPE	10	11	disease progression
NCT000040381	NCT00004038_1_T0	CELL	8	8	cells
NCT000040381	NCT00004038_1_T1	GENE	2	2	p53
NCT000040382	NCT00004038_2_T0	CELL	9	9	cells
NCT000040382	NCT00004038_2_T1	PHENOTYPE	8	8	tumor
NCT000040386	NCT00004038_6_T0	GENE	14	14	polymerase
NCT000040386	NCT00004038_6_T1	GENE	1	1	p53
NCT000040386	NCT00004038_6_T2	GENE	12	13	reverse transcriptase
NCT0000403812	NCT00004038_12_T0	PHENOTYPE	2	2	toxicities
NCT0000403812	NCT00004038_12_T1	PHENOTYPE	23	25	metastatic breast cancer
NCT0000403815	NCT00004038_15_T0	PHENOTYPE	9	9	nodules
NCT0000403816	NCT00004038_16_T0	COMPOUND	17	17	phosphate
NCT0000403816	NCT00004038_16_T1	PHENOTYPE	8	8	nodule
NCT0000403816	NCT00004038_16_T2	PHENOTYPE	14	14	nodule
NCT0000403818	NCT00004038_18_T0	PHENOTYPE	9	9	nodules
NCT000040390	NCT00004039_0_T0	GENE	12	12	III
NCT000040390	NCT00004039_0_T1	GENE	3	3	Interferon
NCT000040390	NCT00004039_0_T2	GENE	15	15	IV
NCT000040390	NCT00004039_0_T3	PHENOTYPE	16	16	Lymphoma
NCT000040392	NCT00004039_2_T0	CELL	14	14	cells
NCT000040392	NCT00004039_2_T1	GENE	1	1	interferon
NCT000040393	NCT00004039_3_T0	GENE	2	2	II
NCT000040393	NCT00004039_3_T1	PHENOTYPE	28	28	lymphoma
NCT000040393	NCT00004039_3_T2	GENE	12	12	interferon
NCT000040393	NCT00004039_3_T3	GENE	27	27	IV
NCT000040393	NCT00004039_3_T4	PHENOTYPE	23	24	stage III
NCT000040395	NCT00004039_5_T0	PHENOTYPE	2	2	toxicity
NCT000040395	NCT00004039_5_T1	COMPOUND	6	6	vincristine
NCT000040395	NCT00004039_5_T2	GENE	12	12	interferon
NCT000040395	NCT00004039_5_T3	GENE	22	22	IV
NCT000040395	NCT00004039_5_T4	COMPOUND	4	4	cyclophosphamide
NCT000040395	NCT00004039_5_T5	GENE	9	9	CHOP
NCT000040395	NCT00004039_5_T6	COMPOUND	5	5	doxorubicin
NCT000040395	NCT00004039_5_T7	COMPOUND	8	8	prednisone
NCT000040395	NCT00004039_5_T8	PHENOTYPE	19	20	stage III
NCT000040395	NCT00004039_5_T9	PHENOTYPE	28	29	B-cell lymphoma
NCT000040397	NCT00004039_7_T0	PHENOTYPE	3	3	tumor
NCT0000403913	NCT00004039_13_T0	PHENOTYPE	2	2	toxicities
NCT0000403915	NCT00004039_15_T0	PHENOTYPE	2	4	quality of life
NCT0000403919	NCT00004039_19_T0	PHENOTYPE	18	18	toxicity
NCT0000403919	NCT00004039_19_T1	PHENOTYPE	14	15	disease progression
NCT0000403920	NCT00004039_20_T0	PHENOTYPE	0	2	Quality of life
NCT000040400	NCT00004040_0_T0	PHENOTYPE	14	15	Multiple Myeloma
NCT000040400	NCT00004040_0_T1	PHENOTYPE	10	12	Chronic Lymphocytic Leukemia
NCT000040402	NCT00004040_2_T0	CELL	17	17	cells
NCT000040402	NCT00004040_2_T1	COMPOUND	4	5	interferon alfa_2b
NCT000040402	NCT00004040_2_T2	ORGAN	12	13	immune system
NCT000040403	NCT00004040_3_T0	GENE	2	2	II
NCT000040403	NCT00004040_3_T1	PHENOTYPE	24	25	in remission
NCT000040403	NCT00004040_3_T2	PHENOTYPE	22	23	multiple myeloma
NCT000040403	NCT00004040_3_T3	COMPOUND	11	12	interferon alfa_2b
NCT000040403	NCT00004040_3_T4	PHENOTYPE	18	20	chronic lymphocytic leukemia
NCT000040405	NCT00004040_5_T0	PHENOTYPE	2	2	toxicity
NCT000040405	NCT00004040_5_T1	PHENOTYPE	19	20	in remission
NCT000040405	NCT00004040_5_T2	PHENOTYPE	17	18	multiple myeloma
NCT000040405	NCT00004040_5_T3	COMPOUND	6	7	interferon alfa_2b
NCT000040405	NCT00004040_5_T4	PHENOTYPE	13	15	chronic lymphocytic leukemia
NCT000040407	NCT00004040_7_T0	PHENOTYPE	2	2	progression
NCT0000404011	NCT00004040_11_T0	PHENOTYPE	2	4	quality of life
NCT0000404014	NCT00004040_14_T0	PHENOTYPE	0	2	Quality of life
NCT000040411	NCT00004041_1_T0	PHENOTYPE	16	16	recurrent
NCT000040411	NCT00004041_1_T1	PHENOTYPE	17	18	malignant gliomas
NCT000040413	NCT00004041_3_T0	PHENOTYPE	21	21	glioma
NCT000040413	NCT00004041_3_T1	GENE	13	13	p53
NCT000040417	NCT00004041_7_T0	PHENOTYPE	5	5	toxicity
NCT000040419	NCT00004041_9_T0	GENE	9	9	p53
NCT0000404110	NCT00004041_10_T0	PHENOTYPE	5	5	toxicity
NCT0000404110	NCT00004041_10_T1	PHENOTYPE	14	14	tumor
NCT0000404110	NCT00004041_10_T2	PHENOTYPE	28	28	tumor
NCT0000404110	NCT00004041_10_T3	PHENOTYPE	29	29	cavity
NCT0000404112	NCT00004041_12_T0	PHENOTYPE	12	12	toxicity
NCT0000404112	NCT00004041_12_T1	GENE	13	13	DLT
NCT000040421	NCT00004042_1_T0	PHENOTYPE	19	20	metastatic cancer
NCT000040423	NCT00004042_3_T0	PHENOTYPE	2	2	toxicity
NCT000040423	NCT00004042_3_T1	PHENOTYPE	27	28	colorectal cancer
NCT000040423	NCT00004042_3_T2	BIOLOGICAL_PROCESS	24	25	fibroblast activation
NCT000040425	NCT00004042_5_T0	PHENOTYPE	4	4	toxicity
NCT000040429	NCT00004042_9_T0	PHENOTYPE	2	2	pharmacokinetics
NCT0000404211	NCT00004042_11_T0	PHENOTYPE	1	1	tumor
NCT0000404213	NCT00004042_13_T0	GENE	6	6	IV
NCT0000404214	NCT00004042_14_T0	COMPOUND	9	9	iodine
NCT0000404216	NCT00004042_16_T0	GENE	16	16	MTD
NCT0000404217	NCT00004042_17_T0	PHENOTYPE	22	22	toxicity
NCT0000404217	NCT00004042_17_T1	GENE	1	1	MTD
NCT000040437	NCT00004043_7_T0	PHENOTYPE	5	5	toxic
NCT000040439	NCT00004043_9_T0	PHENOTYPE	8	10	quality of life
NCT0000404310	NCT00004043_10_T0	COMPOUND	7	7	calcium
NCT0000404310	NCT00004043_10_T1	GENE	6	6	reduced
NCT0000404311	NCT00004043_11_T0	BIOLOGICAL_PROCESS	7	7	drinking
NCT0000404312	NCT00004043_12_T0	COMPOUND	3	3	calcitriol
NCT0000404313	NCT00004043_13_T0	PHENOTYPE	10	10	toxicity
NCT0000404313	NCT00004043_13_T1	PHENOTYPE	6	7	disease progression
NCT0000404314	NCT00004043_14_T0	PHENOTYPE	0	2	Quality of life
NCT000040455	NCT00004045_5_T0	PHENOTYPE	14	15	measurable disease
NCT000040457	NCT00004045_7_T0	PHENOTYPE	5	5	toxicities
NCT000040459	NCT00004045_9_T0	PHENOTYPE	2	2	pharmacokinetics
NCT0000404511	NCT00004045_11_T0	GENE	3	3	IV
NCT0000404513	NCT00004045_13_T0	PHENOTYPE	7	7	toxicity
NCT0000404513	NCT00004045_13_T1	PHENOTYPE	9	10	disease progression
NCT000040461	NCT00004046_1_T0	GENE	2	2	II
NCT000040461	NCT00004046_1_T1	GENE	19	19	has
NCT000040461	NCT00004046_1_T2	PHENOTYPE	15	17	metastatic breast cancer
NCT000040463	NCT00004046_3_T0	PHENOTYPE	9	10	metastatic adenocarcinoma
NCT000040463	NCT00004046_3_T1	PHENOTYPE	10	13	adenocarcinoma of the breast
NCT000040465	NCT00004046_5_T0	PHENOTYPE	5	5	toxicities
NCT000040467	NCT00004046_7_T0	PHENOTYPE	2	2	pharmacokinetics
NCT000040468	NCT00004046_8_T0	GENE	4	4	IV
NCT0000404610	NCT00004046_10_T0	PHENOTYPE	7	7	toxicity
NCT0000404610	NCT00004046_10_T1	PHENOTYPE	9	10	disease progression
NCT000040471	NCT00004047_1_T0	PHENOTYPE	15	16	hematologic cancer
NCT000040473	NCT00004047_3_T0	PHENOTYPE	14	14	acute
NCT000040473	NCT00004047_3_T1	PHENOTYPE	21	21	transformed
NCT000040473	NCT00004047_3_T2	PHENOTYPE	17	18	lymphocytic leukemia
NCT000040473	NCT00004047_3_T3	PHENOTYPE	30	31	blastic phase
NCT000040473	NCT00004047_3_T4	PHENOTYPE	11	12	myelodysplastic syndromes
NCT000040473	NCT00004047_3_T5	PHENOTYPE	26	28	chronic myelogenous leukemia
NCT000040473	NCT00004047_3_T6	PHENOTYPE	22	24	chronic lymphocytic leukemia
NCT000040475	NCT00004047_5_T0	PHENOTYPE	5	5	toxic
NCT000040479	NCT00004047_9_T0	PHENOTYPE	2	2	pharmacokinetics
NCT0000404711	NCT00004047_11_T0	GENE	3	3	IV
NCT0000404712	NCT00004047_12_T0	PHENOTYPE	18	18	toxicity
NCT0000404712	NCT00004047_12_T1	PHENOTYPE	14	15	disease progression
NCT0000404713	NCT00004047_13_T0	GENE	14	14	MTD
NCT0000404714	NCT00004047_14_T0	PHENOTYPE	20	20	toxicity
NCT0000404714	NCT00004047_14_T1	GENE	1	1	MTD
NCT000040481	NCT00004048_1_T0	CELL	7	7	cells
NCT000040481	NCT00004048_1_T1	PHENOTYPE	6	6	tumor
NCT000040487	NCT00004048_7_T0	PHENOTYPE	6	6	toxicity
NCT000040487	NCT00004048_7_T1	PHENOTYPE	3	3	tumor
NCT0000404811	NCT00004048_11_T0	COMPOUND	5	5	doxorubicin
NCT0000404812	NCT00004048_12_T0	GENE	8	8	11
NCT0000404812	NCT00004048_12_T1	GENE	2	2	filgrastim
NCT0000404812	NCT00004048_12_T2	GENE	3	3	G-CSF
NCT0000404813	NCT00004048_13_T0	CELL	6	6	cells
NCT0000404813	NCT00004048_13_T1	GENE	5	5	CD34
NCT0000404813	NCT00004048_13_T2	ORGAN	10	11	bone marrow
NCT0000404814	NCT00004048_14_T0	COMPOUND	6	6	indium
NCT0000404815	NCT00004048_15_T0	PHENOTYPE	4	4	tumor
NCT0000404816	NCT00004048_16_T0	GENE	3	3	IV
NCT0000404817	NCT00004048_17_T0	COMPOUND	4	4	doxorubicin
NCT0000404817	NCT00004048_17_T1	GENE	5	5	IV
NCT0000404818	NCT00004048_18_T0	ORGAN	2	3	bone marrow
NCT0000404819	NCT00004048_19_T0	GENE	3	3	G-CSF
NCT0000404819	NCT00004048_19_T1	GENE	6	6	IV
NCT0000404820	NCT00004048_20_T0	GENE	15	15	MTD
NCT0000404821	NCT00004048_21_T0	PHENOTYPE	20	20	toxicity
NCT0000404821	NCT00004048_21_T1	ORGAN	30	30	liver
NCT0000404821	NCT00004048_21_T2	ORGAN	27	27	lungs
NCT0000404821	NCT00004048_21_T3	ORGAN	28	28	kidneys
NCT0000404821	NCT00004048_21_T4	GENE	1	1	MTD
NCT0000404821	NCT00004048_21_T5	PHENOTYPE	17	17	experiences
NCT000040490	NCT00004049_0_T0	PHENOTYPE	9	10	Solid Tumors
NCT000040492	NCT00004049_2_T0	PHENOTYPE	19	20	solid tumors
NCT000040494	NCT00004049_4_T0	PHENOTYPE	14	15	solid tumors
NCT000040496	NCT00004049_6_T0	PHENOTYPE	5	5	toxic
NCT000040498	NCT00004049_8_T0	PHENOTYPE	5	5	pharmacokinetics
NCT000040498	NCT00004049_8_T1	ORGAN	2	2	plasma
NCT0000404913	NCT00004049_13_T0	PHENOTYPE	13	13	toxicity
NCT0000404913	NCT00004049_13_T1	PHENOTYPE	9	10	disease progression
NCT0000404914	NCT00004049_14_T0	GENE	14	14	MTD
NCT0000404915	NCT00004049_15_T0	PHENOTYPE	18	18	toxicity
NCT0000404915	NCT00004049_15_T1	GENE	1	1	MTD
NCT000040510	NCT00004051_0_T0	PHENOTYPE	6	7	Solid Tumors
NCT000040512	NCT00004051_2_T0	COMPOUND	9	9	irinotecan
NCT000040512	NCT00004051_2_T1	PHENOTYPE	16	17	solid tumors
NCT000040514	NCT00004051_4_T0	PHENOTYPE	7	7	toxicity
NCT000040514	NCT00004051_4_T1	COMPOUND	13	13	irinotecan
NCT000040514	NCT00004051_4_T2	PHENOTYPE	18	19	solid tumors
NCT000040516	NCT00004051_6_T0	COMPOUND	9	9	irinotecan
NCT000040516	NCT00004051_6_T1	PHENOTYPE	6	6	pharmacokinetics
NCT000040516	NCT00004051_6_T2	COMPOUND	15	16	SN-38 glucuronide
NCT0000405110	NCT00004051_10_T0	COMPOUND	3	3	irinotecan
NCT0000405111	NCT00004051_11_T0	PHENOTYPE	13	13	toxicity
NCT0000405111	NCT00004051_11_T1	PHENOTYPE	9	10	disease progression
NCT0000405112	NCT00004051_12_T0	COMPOUND	8	8	irinotecan
NCT0000405112	NCT00004051_12_T1	GENE	14	14	MTD
NCT0000405113	NCT00004051_13_T0	PHENOTYPE	20	20	toxicity
NCT0000405113	NCT00004051_13_T1	GENE	1	1	MTD
NCT000040521	NCT00004052_1_T0	GENE	2	2	II
NCT000040521	NCT00004052_1_T1	PHENOTYPE	16	18	chronic myelogenous leukemia
NCT000040523	NCT00004052_3_T0	GENE	15	15	1.3
NCT000040523	NCT00004052_3_T1	GENE	3	3	bcr/abl
NCT000040524	NCT00004052_4_T0	PHENOTYPE	10	10	toxicity
NCT000040524	NCT00004052_4_T1	PHENOTYPE	6	7	disease progression
NCT000040542	NCT00004054_2_T0	CELL	8	8	cells
NCT000040542	NCT00004054_2_T1	PHENOTYPE	7	7	tumor
NCT000040543	NCT00004054_3_T0	CELL	10	10	cells
NCT000040543	NCT00004054_3_T1	PHENOTYPE	9	9	tumor
NCT0000405412	NCT00004054_12_T0	GENE	10	10	LHRH
NCT0000405412	NCT00004054_12_T1	COMPOUND	15	15	flutamide
NCT0000405412	NCT00004054_12_T2	COMPOUND	3	3	androgen
NCT0000405412	NCT00004054_12_T3	GENE	14	14	OR
NCT0000405412	NCT00004054_12_T4	PHENOTYPE	4	4	suppression
NCT0000405412	NCT00004054_12_T5	COMPOUND	13	13	bicalutamide
NCT0000405412	NCT00004054_12_T6	GENE	7	9	luteinizing hormone-releasing hormone
NCT0000405413	NCT00004054_13_T0	COMPOUND	7	7	androgen
NCT0000405413	NCT00004054_13_T1	PHENOTYPE	5	5	initiation
NCT0000405413	NCT00004054_13_T2	PHENOTYPE	8	8	suppression
NCT0000405415	NCT00004054_15_T0	COMPOUND	16	16	paclitaxel
NCT0000405415	NCT00004054_15_T1	COMPOUND	9	9	etoposide
NCT0000405415	NCT00004054_15_T2	COMPOUND	3	3	estramustine
NCT0000405415	NCT00004054_15_T3	GENE	17	17	IV
NCT000040552	NCT00004055_2_T0	PHENOTYPE	17	17	peripheral
NCT000040552	NCT00004055_2_T1	CELL	11	11	cells
NCT000040552	NCT00004055_2_T2	GENE	4	4	filgrastim
NCT000040552	NCT00004055_2_T3	ORGAN	14	15	bone marrow
NCT000040552	NCT00004055_2_T4	ORGAN	24	25	immune system
NCT000040552	NCT00004055_2_T5	PHENOTYPE	30	32	effects of chemotherapy
NCT000040558	NCT00004055_8_T0	COMPOUND	10	10	paclitaxel
NCT000040558	NCT00004055_8_T1	GENE	7	7	1.5
NCT000040558	NCT00004055_8_T2	GENE	11	11	IV
NCT000040558	NCT00004055_8_T3	COMPOUND	4	4	topotecan
NCT000040559	NCT00004055_9_T0	GENE	7	7	filgrastim
NCT000040559	NCT00004055_9_T1	GENE	8	8	G-CSF
NCT0000405510	NCT00004055_10_T0	PHENOTYPE	12	13	disease progression
NCT0000405511	NCT00004055_11_T0	PHENOTYPE	4	5	progressive disease
NCT000040568	NCT00004056_8_T0	COMPOUND	12	12	cytarabine
NCT000040568	NCT00004056_8_T1	COMPOUND	25	25	cytarabine
NCT000040568	NCT00004056_8_T2	GENE	11	11	1.3
NCT000040568	NCT00004056_8_T3	GENE	17	17	1.7
NCT000040568	NCT00004056_8_T4	GENE	23	23	1.7
NCT000040568	NCT00004056_8_T5	GENE	27	27	IT
NCT000040568	NCT00004056_8_T6	GENE	5	5	IV
NCT000040568	NCT00004056_8_T7	GENE	13	13	IV
NCT000040568	NCT00004056_8_T8	COMPOUND	4	4	daunorubicin
NCT000040569	NCT00004056_9_T0	GENE	1	1	IV
NCT0000405610	NCT00004056_10_T0	GENE	1	1	G-CSF
NCT0000405610	NCT00004056_10_T1	GENE	4	4	IV
NCT0000405611	NCT00004056_11_T0	ORGAN	7	8	bone marrow
NCT0000405612	NCT00004056_12_T0	GENE	5	5	M1
NCT0000405612	NCT00004056_12_T1	GENE	15	15	5.5
NCT0000405612	NCT00004056_12_T2	ORGAN	27	28	bone marrow
NCT0000405614	NCT00004056_14_T0	COMPOUND	14	14	cytarabine
NCT0000405614	NCT00004056_14_T1	COMPOUND	1	1	1
NCT0000405614	NCT00004056_14_T2	COMPOUND	11	11	1
NCT0000405614	NCT00004056_14_T3	COMPOUND	24	24	1
NCT0000405614	NCT00004056_14_T4	PHENOTYPE	0	0	Consolidation
NCT0000405614	NCT00004056_14_T5	GENE	30	30	asparaginase
NCT0000405614	NCT00004056_14_T6	GENE	5	5	IV
NCT0000405614	NCT00004056_14_T7	GENE	15	15	IV
NCT0000405614	NCT00004056_14_T8	COMPOUND	4	4	daunorubicin
NCT0000405615	NCT00004056_15_T0	GENE	0	0	G-CSF
NCT0000405615	NCT00004056_15_T1	GENE	1	1	IV
NCT0000405616	NCT00004056_16_T0	COMPOUND	4	4	cytarabine
NCT0000405616	NCT00004056_16_T1	COMPOUND	1	1	2
NCT0000405616	NCT00004056_16_T2	PHENOTYPE	0	0	Consolidation
NCT0000405616	NCT00004056_16_T3	GENE	5	5	IV
NCT0000405617	NCT00004056_17_T0	GENE	0	0	G-CSF
NCT0000405617	NCT00004056_17_T1	GENE	1	1	IV
NCT0000405618	NCT00004056_18_T0	CELL	0	3	Peripheral blood stem cells
NCT0000405619	NCT00004056_19_T0	PHENOTYPE	0	0	Consolidation
NCT0000405619	NCT00004056_19_T1	COMPOUND	1	1	3
NCT0000405620	NCT00004056_20_T0	PHENOTYPE	5	5	remission
NCT0000405621	NCT00004056_21_T0	COMPOUND	9	9	2
NCT0000405621	NCT00004056_21_T1	COMPOUND	2	2	melphalan
NCT0000405621	NCT00004056_21_T2	GENE	3	3	IV
NCT0000405622	NCT00004056_22_T0	GENE	0	0	G-CSF
NCT0000405622	NCT00004056_22_T1	GENE	1	1	IV
NCT000040571	NCT00004057_1_T0	CELL	9	9	cells
NCT000040572	NCT00004057_2_T0	COMPOUND	10	10	paclitaxel
NCT000040572	NCT00004057_2_T1	PHENOTYPE	24	24	lymphomas
NCT000040572	NCT00004057_2_T2	PHENOTYPE	18	18	recurrent
NCT000040572	NCT00004057_2_T3	PHENOTYPE	21	22	solid tumors
NCT000040574	NCT00004057_4_T0	COMPOUND	10	10	paclitaxel
NCT000040574	NCT00004057_4_T1	PHENOTYPE	20	20	lymphomas
NCT000040574	NCT00004057_4_T2	PHENOTYPE	14	14	recurrent
NCT000040574	NCT00004057_4_T3	PHENOTYPE	17	18	solid tumors
NCT000040576	NCT00004057_6_T0	PHENOTYPE	7	7	toxicity
NCT000040578	NCT00004057_8_T0	COMPOUND	12	12	paclitaxel
NCT000040578	NCT00004057_8_T1	PHENOTYPE	4	4	concentrations
NCT000040578	NCT00004057_8_T2	ORGAN	3	3	plasma
NCT0000405710	NCT00004057_10_T0	PHENOTYPE	3	3	tumor
NCT0000405712	NCT00004057_12_T0	GENE	4	4	ras
NCT0000405714	NCT00004057_14_T0	COMPOUND	2	2	paclitaxel
NCT0000405714	NCT00004057_14_T1	GENE	3	3	IV
NCT0000405714	NCT00004057_14_T2	GENE	13	13	IV
NCT0000405715	NCT00004057_15_T0	PHENOTYPE	13	13	toxicity
NCT0000405715	NCT00004057_15_T1	PHENOTYPE	9	10	disease progression
NCT0000405717	NCT00004057_17_T0	GENE	2	2	1.3
NCT0000405717	NCT00004057_17_T1	GENE	14	14	MTD
NCT0000405718	NCT00004057_18_T0	PHENOTYPE	16	16	toxicity
NCT0000405718	NCT00004057_18_T1	GENE	1	1	MTD
NCT000040581	NCT00004058_1_T0	GENE	26	26	has
NCT000040581	NCT00004058_1_T1	PHENOTYPE	19	20	hematologic cancer
NCT000040581	NCT00004058_1_T2	PHENOTYPE	22	24	bone marrow disorder
NCT000040584	NCT00004058_4_T0	GENE	3	3	TPA
NCT000040584	NCT00004058_4_T1	GENE	4	4	IV
NCT000040585	NCT00004058_5_T0	PHENOTYPE	10	10	toxicity
NCT000040585	NCT00004058_5_T1	PHENOTYPE	6	7	disease progression
NCT000040586	NCT00004058_6_T0	GENE	8	8	TPA
NCT000040586	NCT00004058_6_T1	GENE	14	14	MTD
NCT000040587	NCT00004058_7_T0	PHENOTYPE	19	19	toxicity
NCT000040587	NCT00004058_7_T1	GENE	1	1	MTD
NCT000040587	NCT00004058_7_T2	PHENOTYPE	16	16	experiences
NCT000040590	NCT00004059_0_T0	PHENOTYPE	10	11	Solid Tumors
NCT000040592	NCT00004059_2_T0	CELL	12	12	cells
NCT000040592	NCT00004059_2_T1	PHENOTYPE	11	11	tumor
NCT000040593	NCT00004059_3_T0	PHENOTYPE	20	21	solid tumors
NCT000040596	NCT00004059_6_T0	GENE	3	3	IV
NCT000040597	NCT00004059_7_T0	GENE	7	7	IV
NCT000040597	NCT00004059_7_T1	GENE	22	22	IV
NCT000040598	NCT00004059_8_T0	PHENOTYPE	18	18	toxicity
NCT000040598	NCT00004059_8_T1	PHENOTYPE	14	15	disease progression
NCT000040599	NCT00004059_9_T0	GENE	14	14	MTD
NCT0000405910	NCT00004059_10_T0	PHENOTYPE	18	18	toxicity
NCT0000405910	NCT00004059_10_T1	GENE	1	1	MTD
NCT000040603	NCT00004060_3_T0	COMPOUND	22	22	platinum
NCT000040603	NCT00004060_3_T1	PHENOTYPE	9	9	recurrent
NCT000040603	NCT00004060_3_T2	COMPOUND	25	25	topotecan
NCT000040603	NCT00004060_3_T3	PHENOTYPE	16	17	peritoneal carcinoma
NCT000040605	NCT00004060_5_T0	PHENOTYPE	5	5	toxic
NCT000040607	NCT00004060_7_T0	PHENOTYPE	2	2	pharmacokinetics
NCT0000406010	NCT00004060_10_T0	PHENOTYPE	13	13	toxicity
NCT0000406010	NCT00004060_10_T1	PHENOTYPE	9	10	disease progression
NCT000040615	NCT00004061_5_T0	GENE	22	22	2.4
NCT000040615	NCT00004061_5_T1	PHENOTYPE	23	23	diarrhea
NCT000040615	NCT00004061_5_T2	PHENOTYPE	5	6	oral mucositis
NCT000040617	NCT00004061_7_T0	PHENOTYPE	2	4	quality of life
NCT000040619	NCT00004061_9_T0	PHENOTYPE	4	5	febrile neutropenia
NCT0000406115	NCT00004061_15_T0	COMPOUND	27	27	ifosfamide
NCT0000406115	NCT00004061_15_T1	COMPOUND	18	18	2
NCT0000406115	NCT00004061_15_T2	COMPOUND	11	11	cyclophosphamide
NCT0000406115	NCT00004061_15_T3	COMPOUND	2	2	etoposide
NCT0000406115	NCT00004061_15_T4	COMPOUND	40	40	etoposide
NCT0000406115	NCT00004061_15_T5	GENE	3	3	IV
NCT0000406115	NCT00004061_15_T6	GENE	12	12	IV
NCT0000406115	NCT00004061_15_T7	GENE	28	28	IV
NCT0000406115	NCT00004061_15_T8	GENE	41	41	IV
NCT0000406116	NCT00004061_16_T0	GENE	1	1	G-CSF
NCT0000406117	NCT00004061_17_T0	CELL	1	4	peripheral blood stem cells
NCT0000406123	NCT00004061_23_T0	PHENOTYPE	0	2	Quality of life
NCT000040621	NCT00004062_1_T0	COMPOUND	12	12	iodine
NCT000040622	NCT00004062_2_T0	PHENOTYPE	12	13	thyroid function
NCT000040622	NCT00004062_2_T1	PHENOTYPE	21	23	metastatic thyroid cancer
NCT000040628	NCT00004062_8_T0	COMPOUND	6	6	iodine
NCT0000406210	NCT00004062_10_T0	COMPOUND	9	9	sodium
NCT0000406210	NCT00004062_10_T1	GENE	14	14	1.4
NCT0000406210	NCT00004062_10_T2	COMPOUND	18	18	iodine
NCT0000406210	NCT00004062_10_T3	GENE	22	22	4.7
NCT0000406211	NCT00004062_11_T0	COMPOUND	9	9	iodine
NCT0000406212	NCT00004062_12_T0	COMPOUND	13	13	sodium
NCT0000406212	NCT00004062_12_T1	COMPOUND	28	28	7_11
NCT0000406212	NCT00004062_12_T2	COMPOUND	32	32	iodine
NCT0000406213	NCT00004062_13_T0	COMPOUND	18	18	iodine
NCT0000406216	NCT00004062_16_T0	PHENOTYPE	18	18	toxicity
NCT0000406216	NCT00004062_16_T1	GENE	1	1	MTD
NCT000040632	NCT00004063_2_T0	CELL	4	4	cells
NCT000040632	NCT00004063_2_T1	PHENOTYPE	3	3	tumor
NCT000040632	NCT00004063_2_T2	PHENOTYPE	0	0	Hyperthermia
NCT000040633	NCT00004063_3_T0	PHENOTYPE	1	1	hyperthermia
NCT000040633	NCT00004063_3_T1	CELL	11	11	cells
NCT000040633	NCT00004063_3_T2	PHENOTYPE	10	10	tumor
NCT000040633	NCT00004063_3_T3	GENE	5	5	interferon
NCT000040634	NCT00004063_4_T0	PHENOTYPE	17	17	hyperthermia
NCT000040634	NCT00004063_4_T1	GENE	13	13	interferon
NCT000040634	NCT00004063_4_T2	COMPOUND	12	12	gemcitabine
NCT000040634	NCT00004063_4_T3	COMPOUND	11	11	cisplatin
NCT000040634	NCT00004063_4_T4	PHENOTYPE	28	28	recurrent
NCT000040634	NCT00004063_4_T5	PHENOTYPE	30	31	refractory cancer
NCT000040637	NCT00004063_7_T0	COMPOUND	2	2	cisplatin
NCT000040637	NCT00004063_7_T1	GENE	13	13	interferon
NCT000040637	NCT00004063_7_T2	GENE	3	3	IV
NCT000040638	NCT00004063_8_T0	PHENOTYPE	7	7	hyperthermia
NCT000040638	NCT00004063_8_T1	COMPOUND	12	12	gemcitabine
NCT0000406310	NCT00004063_10_T0	PHENOTYPE	24	24	toxicity
NCT0000406310	NCT00004063_10_T1	GENE	1	1	MTD
NCT0000406311	NCT00004063_11_T0	GENE	8	8	II
NCT0000406311	NCT00004063_11_T1	COMPOUND	3	3	cisplatin
NCT0000406311	NCT00004063_11_T2	GENE	1	1	MTD
NCT000040645	NCT00004064_5_T0	GENE	8	8	CA
NCT000040645	NCT00004064_5_T1	PHENOTYPE	4	5	disease progression
NCT000040645	NCT00004064_5_T2	PHENOTYPE	14	16	quality of life
NCT0000406410	NCT00004064_10_T0	PHENOTYPE	2	3	disease progression
NCT0000406411	NCT00004064_11_T0	PHENOTYPE	0	2	Quality of life
NCT000040651	NCT00004065_1_T0	PHENOTYPE	25	25	cancers
NCT000040651	NCT00004065_1_T1	PHENOTYPE	21	22	solid tumors
NCT000040655	NCT00004065_5_T0	GENE	4	4	IV
NCT000040657	NCT00004065_7_T0	PHENOTYPE	21	21	toxicity
NCT000040657	NCT00004065_7_T1	GENE	1	1	MTD
NCT000040661	NCT00004066_1_T0	PHENOTYPE	17	17	peripheral
NCT000040661	NCT00004066_1_T1	CELL	11	11	cells
NCT000040661	NCT00004066_1_T2	GENE	4	4	filgrastim
NCT000040661	NCT00004066_1_T3	ORGAN	14	15	bone marrow
NCT000040661	NCT00004066_1_T4	ORGAN	24	25	immune system
NCT000040661	NCT00004066_1_T5	PHENOTYPE	30	32	effects of chemotherapy
NCT000040662	NCT00004066_2_T0	GENE	2	2	II
NCT000040662	NCT00004066_2_T1	PHENOTYPE	22	22	leiomyosarcoma
NCT000040662	NCT00004066_2_T2	COMPOUND	11	11	docetaxel
NCT000040662	NCT00004066_2_T3	GENE	13	13	filgrastim
NCT000040662	NCT00004066_2_T4	COMPOUND	10	10	gemcitabine
NCT000040662	NCT00004066_2_T5	PHENOTYPE	19	19	recurrent
NCT000040662	NCT00004066_2_T6	PHENOTYPE	24	26	soft tissue sarcoma
NCT000040664	NCT00004066_4_T0	ORGAN	10	10	pelvis
NCT000040665	NCT00004066_5_T0	COMPOUND	14	14	docetaxel
NCT000040665	NCT00004066_5_T1	GENE	23	23	filgrastim
NCT000040665	NCT00004066_5_T2	COMPOUND	2	2	gemcitabine
NCT000040665	NCT00004066_5_T3	GENE	24	24	G-CSF
NCT000040665	NCT00004066_5_T4	GENE	3	3	IV
NCT000040665	NCT00004066_5_T5	GENE	15	15	IV
NCT000040666	NCT00004066_6_T0	PHENOTYPE	16	16	toxicity
NCT000040666	NCT00004066_6_T1	PHENOTYPE	12	13	disease progression
NCT000040668	NCT00004066_8_T0	PHENOTYPE	11	12	disease progression
NCT000040669	NCT00004066_9_T0	PHENOTYPE	9	10	uterine leiomyosarcoma
NCT000040669	NCT00004066_9_T1	PHENOTYPE	15	17	soft tissue sarcoma
NCT000040672	NCT00004067_2_T0	PHENOTYPE	19	20	breast cancer
NCT000040673	NCT00004067_3_T0	GENE	28	28	II
NCT000040673	NCT00004067_3_T1	GENE	4	4	III
NCT000040673	NCT00004067_3_T2	GENE	36	36	HER2
NCT000040673	NCT00004067_3_T3	PHENOTYPE	30	33	stage IIIA breast cancer
NCT000040677	NCT00004067_7_T0	COMPOUND	46	46	paclitaxel
NCT000040677	NCT00004067_7_T1	GENE	9	9	1.3
NCT000040677	NCT00004067_7_T2	COMPOUND	22	22	anastrozole
NCT000040677	NCT00004067_7_T3	COMPOUND	20	20	tamoxifen
NCT0000406711	NCT00004067_11_T0	GENE	4	4	IV
NCT0000406712	NCT00004067_12_T0	COMPOUND	3	3	estrogen
NCT0000406712	NCT00004067_12_T1	PHENOTYPE	7	7	tumors
NCT0000406712	NCT00004067_12_T2	GENE	18	18	3/12
NCT0000406712	NCT00004067_12_T3	COMPOUND	5	5	progesterone
NCT0000406713	NCT00004067_13_T0	GENE	27	27	PI
NCT0000406713	NCT00004067_13_T1	COMPOUND	5	5	tamoxifen
NCT0000406713	NCT00004067_13_T2	COMPOUND	13	13	tamoxifen
NCT0000406714	NCT00004067_14_T0	COMPOUND	15	15	tamoxifen
NCT0000406714	NCT00004067_14_T1	PHENOTYPE	1	1	Other
NCT0000406723	NCT00004067_23_T0	GENE	7	7	FISH
NCT0000406731	NCT00004067_31_T0	GENE	3	3	had
NCT0000406733	NCT00004067_33_T0	PHENOTYPE	10	10	tumors
NCT0000406733	NCT00004067_33_T1	GENE	13	13	cm
NCT0000406734	NCT00004067_34_T0	PHENOTYPE	12	12	tumor
NCT0000406734	NCT00004067_34_T1	PHENOTYPE	14	14	DCIS
NCT0000406735	NCT00004067_35_T0	PHENOTYPE	7	7	tumor
NCT0000406736	NCT00004067_36_T0	GENE	7	7	has
NCT0000406737	NCT00004067_37_T0	PHENOTYPE	3	3	tumor
NCT0000406749	NCT00004067_49_T0	PHENOTYPE	11	11	toxicity
NCT0000406749	NCT00004067_49_T1	COMPOUND	14	14	tamoxifen
NCT0000406750	NCT00004067_50_T0	COMPOUND	4	4	tamoxifen
NCT0000406750	NCT00004067_50_T1	PHENOTYPE	7	8	fetal deaths
NCT0000406750	NCT00004067_50_T2	PHENOTYPE	14	15	vaginal bleeding
NCT0000406750	NCT00004067_50_T3	PHENOTYPE	11	12	spontaneous abortions
NCT0000406750	NCT00004067_50_T4	PHENOTYPE	9	10	birth defects
NCT0000406754	NCT00004067_54_T0	ORGAN	7	7	Appendix
NCT000040682	NCT00004068_2_T0	CELL	8	8	cells
NCT000040682	NCT00004068_2_T1	PHENOTYPE	7	7	tumor
NCT000040683	NCT00004068_3_T0	CELL	9	9	cells
NCT000040683	NCT00004068_3_T1	PHENOTYPE	8	8	tumor
NCT000040684	NCT00004068_4_T0	COMPOUND	15	15	temozolomide
NCT000040684	NCT00004068_4_T1	GENE	2	2	II
NCT000040684	NCT00004068_4_T2	COMPOUND	9	9	irinotecan
NCT000040684	NCT00004068_4_T3	PHENOTYPE	23	24	brain tumor
NCT000040686	NCT00004068_6_T0	COMPOUND	4	4	irinotecan
NCT000040686	NCT00004068_6_T1	GENE	15	15	1.2
NCT000040686	NCT00004068_6_T2	GENE	5	5	IV
NCT000040688	NCT00004068_8_T0	COMPOUND	3	3	irinotecan
NCT0000406810	NCT00004068_10_T0	GENE	6	6	3.5
NCT0000406810	NCT00004068_10_T1	GENE	7	7	cm
NCT0000406810	NCT00004068_10_T2	PHENOTYPE	2	3	residual tumor
NCT0000406811	NCT00004068_11_T0	COMPOUND	10	10	temozolomide
NCT000040700	NCT00004070_0_T0	PHENOTYPE	7	7	Recurrent
NCT000040700	NCT00004070_0_T1	PHENOTYPE	10	13	Head and Neck Cancer
NCT000040702	NCT00004070_2_T0	GENE	11	11	interleukin-12
NCT000040702	NCT00004070_2_T1	CELL	16	16	cells
NCT000040702	NCT00004070_2_T2	CELL	32	32	cells
NCT000040702	NCT00004070_2_T3	PHENOTYPE	31	31	tumor
NCT000040702	NCT00004070_2_T4	PHENOTYPE	19	19	anticipation
NCT000040702	NCT00004070_2_T5	BIOLOGICAL_PROCESS	26	27	immune response
NCT000040711	NCT00004071_1_T0	CELL	9	9	cells
NCT000040711	NCT00004071_1_T1	PHENOTYPE	8	8	tumor
NCT000040719	NCT00004071_9_T0	COMPOUND	6	6	mitoxantrone
NCT0000407111	NCT00004071_11_T0	PHENOTYPE	4	6	quality of life
NCT0000407115	NCT00004071_15_T0	COMPOUND	3	3	prednisone
NCT0000407119	NCT00004071_19_T0	COMPOUND	7	7	leflunomide
NCT0000407119	NCT00004071_19_T1	GENE	11	11	4.5
NCT0000407119	NCT00004071_19_T2	GENE	9	9	IV
NCT0000407120	NCT00004071_20_T0	COMPOUND	5	5	mitoxantrone
NCT0000407121	NCT00004071_21_T0	COMPOUND	10	10	mitoxantrone
NCT0000407122	NCT00004071_22_T0	PHENOTYPE	0	2	Quality of life
NCT000040721	NCT00004072_1_T0	CELL	9	9	cells
NCT000040721	NCT00004072_1_T1	PHENOTYPE	8	8	tumor
NCT000040722	NCT00004072_2_T0	GENE	2	2	II
NCT000040722	NCT00004072_2_T1	PHENOTYPE	23	24	multiple myeloma
NCT000040724	NCT00004072_4_T0	PHENOTYPE	13	13	toxicity
NCT000040724	NCT00004072_4_T1	PHENOTYPE	9	10	disease progression
NCT000040726	NCT00004072_6_T0	GENE	4	4	IV
NCT000040726	NCT00004072_6_T1	GENE	14	14	IV
NCT000040727	NCT00004072_7_T0	PHENOTYPE	13	13	toxicity
NCT000040727	NCT00004072_7_T1	PHENOTYPE	9	10	disease progression
NCT000040731	NCT00004073_1_T0	CELL	8	8	cells
NCT000040731	NCT00004073_1_T1	PHENOTYPE	7	7	tumor
NCT000040732	NCT00004073_2_T0	COMPOUND	1	1	suramin
NCT000040732	NCT00004073_2_T1	PHENOTYPE	12	13	glioblastoma multiforme
NCT000040733	NCT00004073_3_T0	GENE	2	2	II
NCT000040733	NCT00004073_3_T1	COMPOUND	9	9	suramin
NCT000040733	NCT00004073_3_T2	PHENOTYPE	20	21	glioblastoma multiforme
NCT000040735	NCT00004073_5_T0	PHENOTYPE	2	2	toxicity
NCT000040735	NCT00004073_5_T1	COMPOUND	4	4	suramin
NCT000040735	NCT00004073_5_T2	PHENOTYPE	19	20	glioblastoma multiforme
NCT000040735	NCT00004073_5_T3	PHENOTYPE	17	18	high grade
NCT000040738	NCT00004073_8_T0	COMPOUND	3	3	suramin
NCT000040738	NCT00004073_8_T1	GENE	4	4	IV
NCT000040739	NCT00004073_9_T0	COMPOUND	6	6	suramin
NCT000040739	NCT00004073_9_T1	GENE	15	15	2.7
NCT000040739	NCT00004073_9_T2	GENE	7	7	IV
NCT0000407310	NCT00004073_10_T0	COMPOUND	11	11	suramin
NCT0000407311	NCT00004073_11_T0	PHENOTYPE	10	10	toxicity
NCT0000407311	NCT00004073_11_T1	PHENOTYPE	6	7	disease progression
NCT0000407312	NCT00004073_12_T0	PHENOTYPE	7	8	disease progression
NCT0000407313	NCT00004073_13_T0	GENE	14	14	1.5
NCT000040743	NCT00004074_3_T0	GENE	6	6	interleukin-12
NCT000040743	NCT00004074_3_T1	GENE	7	7	IL-12
NCT000040743	NCT00004074_3_T2	PHENOTYPE	17	17	malignancies
NCT000040747	NCT00004074_7_T0	TISSUE	8	8	tissues
NCT000040747	NCT00004074_7_T1	PHENOTYPE	7	7	tumor
NCT000040747	NCT00004074_7_T2	GENE	4	4	interferon
NCT000040749	NCT00004074_9_T0	BIOLOGICAL_PROCESS	3	4	cytokine production
NCT0000407411	NCT00004074_11_T0	ORGAN	1	1	serum
NCT0000407411	NCT00004074_11_T1	GENE	2	3	interferon gamma
NCT0000407412	NCT00004074_12_T0	GENE	8	8	interleukin-12
NCT0000407412	NCT00004074_12_T1	GENE	9	9	IL-12
NCT0000407413	NCT00004074_13_T0	GENE	8	8	IV
NCT0000407413	NCT00004074_13_T1	GENE	25	25	IV
NCT0000407414	NCT00004074_14_T0	GENE	2	2	IL-12
NCT0000407414	NCT00004074_14_T1	GENE	3	3	IV
NCT0000407415	NCT00004074_15_T0	PHENOTYPE	19	19	toxicity
NCT0000407415	NCT00004074_15_T1	GENE	5	5	IL-12
NCT0000407415	NCT00004074_15_T2	PHENOTYPE	15	16	disease progression
NCT0000407417	NCT00004074_17_T0	GENE	8	8	IL-12
NCT0000407417	NCT00004074_17_T1	GENE	14	14	MTD
NCT0000407418	NCT00004074_18_T0	PHENOTYPE	18	18	toxicity
NCT0000407418	NCT00004074_18_T1	GENE	1	1	MTD
NCT000040751	NCT00004075_1_T0	PHENOTYPE	19	20	solid tumors
NCT000040756	NCT00004075_6_T0	PHENOTYPE	13	13	toxicity
NCT000040756	NCT00004075_6_T1	PHENOTYPE	9	10	disease progression
NCT000040757	NCT00004075_7_T0	GENE	2	2	1/6
NCT000040757	NCT00004075_7_T1	GENE	16	16	MTD
NCT000040757	NCT00004075_7_T2	PHENOTYPE	3	4	solid tumor
NCT000040758	NCT00004075_8_T0	PHENOTYPE	17	17	toxicity
NCT000040758	NCT00004075_8_T1	GENE	1	1	MTD
NCT000040759	NCT00004075_9_T0	PHENOTYPE	9	9	lymphoma
NCT000040759	NCT00004075_9_T1	GENE	2	2	MTD
NCT000040759	NCT00004075_9_T2	GENE	25	25	MTD
NCT000040759	NCT00004075_9_T3	GENE	21	22	group II
NCT000040759	NCT00004075_9_T4	PHENOTYPE	12	13	solid tumors
NCT0000407511	NCT00004075_11_T0	GENE	9	10	group I
NCT0000407511	NCT00004075_11_T1	GENE	14	15	group II
NCT000040760	NCT00004076_0_T0	PHENOTYPE	7	8	Solid Tumors
NCT000040762	NCT00004076_2_T0	PHENOTYPE	17	18	solid tumors
NCT000040764	NCT00004076_4_T0	PHENOTYPE	10	10	toxicities
NCT000040764	NCT00004076_4_T1	PHENOTYPE	19	20	solid tumors
NCT000040766	NCT00004076_6_T0	GENE	10	10	II
NCT000040768	NCT00004076_8_T0	COMPOUND	17	17	camptothecin
NCT0000407612	NCT00004076_12_T0	GENE	4	4	IV
NCT0000407613	NCT00004076_13_T0	PHENOTYPE	16	16	toxicity
NCT0000407613	NCT00004076_13_T1	PHENOTYPE	12	13	disease progression
NCT0000407614	NCT00004076_14_T0	GENE	15	15	MTD
NCT0000407615	NCT00004076_15_T0	PHENOTYPE	18	18	toxicity
NCT0000407615	NCT00004076_15_T1	GENE	1	1	MTD
NCT0000407616	NCT00004076_16_T0	PHENOTYPE	23	23	attributable
NCT0000407616	NCT00004076_16_T1	PHENOTYPE	14	15	adverse events
NCT000040771	NCT00004077_1_T0	CELL	9	9	cells
NCT000040771	NCT00004077_1_T1	PHENOTYPE	8	8	tumor
NCT000040772	NCT00004077_2_T0	GENE	2	2	II
NCT000040772	NCT00004077_2_T1	COMPOUND	10	10	paclitaxel
NCT000040772	NCT00004077_2_T2	COMPOUND	11	11	ifosfamide
NCT000040772	NCT00004077_2_T3	GENE	23	23	has
NCT000040772	NCT00004077_2_T4	COMPOUND	13	13	cisplatin
NCT000040772	NCT00004077_2_T5	PHENOTYPE	19	21	metastatic testicular cancer
NCT000040774	NCT00004077_4_T0	COMPOUND	2	2	paclitaxel
NCT000040774	NCT00004077_4_T1	COMPOUND	8	8	ifosfamide
NCT000040774	NCT00004077_4_T2	COMPOUND	11	11	cisplatin
NCT000040774	NCT00004077_4_T3	GENE	3	3	IV
NCT000040774	NCT00004077_4_T4	GENE	9	9	IV
NCT000040774	NCT00004077_4_T5	GENE	12	12	IV
NCT000040775	NCT00004077_5_T0	PHENOTYPE	22	22	toxicity
NCT000040775	NCT00004077_5_T1	PHENOTYPE	18	19	disease progression
NCT000040780	NCT00004078_0_T0	PHENOTYPE	6	7	Solid Tumors
NCT000040782	NCT00004078_2_T0	CELL	10	10	cells
NCT000040782	NCT00004078_2_T1	PHENOTYPE	9	9	tumor
NCT000040784	NCT00004078_4_T0	COMPOUND	4	4	irinotecan
NCT000040784	NCT00004078_4_T1	PHENOTYPE	11	12	solid tumors
NCT000040786	NCT00004078_6_T0	PHENOTYPE	2	2	toxicity
NCT000040786	NCT00004078_6_T1	PHENOTYPE	5	5	pharmacodynamics
NCT000040786	NCT00004078_6_T2	PHENOTYPE	3	3	pharmacokinetics
NCT000040788	NCT00004078_8_T0	PHENOTYPE	8	8	toxicity
NCT000040788	NCT00004078_8_T1	GENE	2	2	UGT1A1
NCT000040789	NCT00004078_9_T0	PHENOTYPE	12	12	neuroblastoma
NCT000040789	NCT00004078_9_T1	PHENOTYPE	22	22	lymphomas
NCT000040789	NCT00004078_9_T2	PHENOTYPE	35	35	ependymoma
NCT000040789	NCT00004078_9_T3	PHENOTYPE	39	39	tumors
NCT000040789	NCT00004078_9_T4	PHENOTYPE	16	16	rhabdomyosarcoma
NCT000040789	NCT00004078_9_T5	PHENOTYPE	14	14	osteosarcoma
NCT000040789	NCT00004078_9_T6	PHENOTYPE	8	9	solid tumor
NCT000040789	NCT00004078_9_T7	PHENOTYPE	27	28	brain tumor
NCT000040789	NCT00004078_9_T8	PHENOTYPE	19	20	solid tumors
NCT000040789	NCT00004078_9_T9	PHENOTYPE	24	25	brain tumors
NCT000040789	NCT00004078_9_T10	PHENOTYPE	31	33	brain stem glioma
NCT0000407810	NCT00004078_10_T0	COMPOUND	2	2	irinotecan
NCT0000407810	NCT00004078_10_T1	GENE	9	9	1.5
NCT0000407810	NCT00004078_10_T2	GENE	3	3	IV
NCT0000407811	NCT00004078_11_T0	PHENOTYPE	18	18	toxicity
NCT0000407811	NCT00004078_11_T1	PHENOTYPE	14	15	disease progression
NCT0000407812	NCT00004078_12_T0	GENE	20	20	POG
NCT000040790	NCT00004079_0_T0	PHENOTYPE	9	10	Solid Tumors
NCT000040793	NCT00004079_3_T0	COMPOUND	11	11	SarCNU
NCT000040793	NCT00004079_3_T1	GENE	5	5	MTD
NCT000040795	NCT00004079_5_T0	GENE	9	9	II
NCT000040795	NCT00004079_5_T1	COMPOUND	6	6	SarCNU
NCT000040797	NCT00004079_7_T0	PHENOTYPE	3	3	toxicities
NCT000040797	NCT00004079_7_T1	COMPOUND	6	6	SarCNU
NCT000040799	NCT00004079_9_T0	COMPOUND	5	5	SarCNU
NCT0000407911	NCT00004079_11_T0	PHENOTYPE	3	3	pharmacokinetics
NCT0000407911	NCT00004079_11_T1	COMPOUND	5	5	SarCNU
NCT0000407911	NCT00004079_11_T2	ORGAN	2	2	plasma
NCT0000407913	NCT00004079_13_T0	COMPOUND	16	16	BCNU
NCT0000407913	NCT00004079_13_T1	COMPOUND	9	9	isocyanate
NCT0000407913	NCT00004079_13_T2	COMPOUND	2	2	SarCNU
NCT0000407913	NCT00004079_13_T3	PHENOTYPE	17	18	pulmonary toxicity
NCT0000407915	NCT00004079_15_T0	COMPOUND	5	5	SarCNU
NCT0000407915	NCT00004079_15_T1	PHENOTYPE	11	12	evaluable disease
NCT0000407917	NCT00004079_17_T0	PHENOTYPE	8	8	toxicity
NCT0000407917	NCT00004079_17_T1	PHENOTYPE	3	3	pharmacodynamic
NCT0000407919	NCT00004079_19_T0	COMPOUND	5	5	SarCNU
NCT0000407919	NCT00004079_19_T1	COMPOUND	4	4	nitrosourea
NCT0000407919	NCT00004079_19_T2	COMPOUND	3	3	sarcosinamide
NCT0000407920	NCT00004079_20_T0	PHENOTYPE	13	13	toxicity
NCT0000407920	NCT00004079_20_T1	PHENOTYPE	9	10	disease progression
NCT0000407921	NCT00004079_21_T0	COMPOUND	8	8	SarCNU
NCT0000407921	NCT00004079_21_T1	GENE	14	14	MTD
NCT0000407922	NCT00004079_22_T0	PHENOTYPE	21	21	toxicity
NCT0000407922	NCT00004079_22_T1	GENE	1	1	MTD
NCT0000407923	NCT00004079_23_T0	GENE	4	4	4.5
NCT000040806	NCT00004080_6_T0	GENE	7	7	p53
NCT000040808	NCT00004080_8_T0	PHENOTYPE	4	4	tumor
NCT000040808	NCT00004080_8_T1	PHENOTYPE	17	17	tumor
NCT000040808	NCT00004080_8_T2	GENE	6	6	p53
NCT000040808	NCT00004080_8_T3	GENE	11	11	p53
NCT0000408010	NCT00004080_10_T0	PHENOTYPE	4	4	tumor
NCT0000408010	NCT00004080_10_T1	PHENOTYPE	11	11	tumor
NCT0000408010	NCT00004080_10_T2	PHENOTYPE	19	19	tumor
NCT0000408010	NCT00004080_10_T3	GENE	6	6	p53
NCT0000408010	NCT00004080_10_T4	BIOLOGICAL_PROCESS	12	13	immune response
NCT0000408012	NCT00004080_12_T0	PHENOTYPE	8	8	tumor
NCT0000408013	NCT00004080_13_T0	PHENOTYPE	2	2	tumor
NCT0000408013	NCT00004080_13_T1	PHENOTYPE	11	11	tumor
NCT0000408014	NCT00004080_14_T0	GENE	14	14	MTD
NCT0000408015	NCT00004080_15_T0	PHENOTYPE	19	19	toxicity
NCT0000408015	NCT00004080_15_T1	GENE	1	1	MTD
NCT0000408016	NCT00004080_16_T0	PHENOTYPE	23	24	disease progression
NCT000040811	NCT00004081_1_T0	GENE	2	2	II
NCT000040811	NCT00004081_1_T1	COMPOUND	9	9	docetaxel
NCT000040811	NCT00004081_1_T2	GENE	23	23	has
NCT000040811	NCT00004081_1_T3	PHENOTYPE	20	21	peritoneal cancer
NCT000040811	NCT00004081_1_T4	PHENOTYPE	15	17	ovarian epithelial cancer
NCT000040813	NCT00004081_3_T0	COMPOUND	3	3	docetaxel
NCT000040813	NCT00004081_3_T1	GENE	4	4	IV
NCT000040814	NCT00004081_4_T0	PHENOTYPE	13	13	toxicity
NCT000040814	NCT00004081_4_T1	PHENOTYPE	9	10	disease progression
NCT000040815	NCT00004081_5_T0	GENE	4	4	CR
NCT000040815	NCT00004081_5_T1	GENE	17	17	CR
NCT000040821	NCT00004082_1_T0	CELL	9	9	cells
NCT000040821	NCT00004082_1_T1	PHENOTYPE	8	8	tumor
NCT000040822	NCT00004082_2_T0	COMPOUND	10	10	docetaxel
NCT000040822	NCT00004082_2_T1	COMPOUND	13	13	gemcitabine
NCT000040824	NCT00004082_4_T0	COMPOUND	6	6	docetaxel
NCT000040824	NCT00004082_4_T1	COMPOUND	9	9	gemcitabine
NCT000040825	NCT00004082_5_T0	COMPOUND	7	7	docetaxel
NCT000040825	NCT00004082_5_T1	COMPOUND	9	9	gemcitabine
NCT000040826	NCT00004082_6_T0	COMPOUND	2	2	docetaxel
NCT000040826	NCT00004082_6_T1	COMPOUND	8	8	gemcitabine
NCT000040826	NCT00004082_6_T2	GENE	3	3	IV
NCT000040826	NCT00004082_6_T3	GENE	9	9	IV
NCT000040827	NCT00004082_7_T0	GENE	1	1	IV
NCT000040828	NCT00004082_8_T0	PHENOTYPE	18	18	toxicity
NCT000040828	NCT00004082_8_T1	PHENOTYPE	14	15	disease progression
NCT000040829	NCT00004082_9_T0	COMPOUND	8	8	docetaxel
NCT000040829	NCT00004082_9_T1	GENE	2	2	3.5
NCT000040829	NCT00004082_9_T2	COMPOUND	10	10	gemcitabine
NCT0000408210	NCT00004082_10_T0	PHENOTYPE	21	21	toxicity
NCT0000408210	NCT00004082_10_T1	GENE	1	1	MTD
NCT000040831	NCT00004083_1_T0	GENE	2	2	II
NCT000040831	NCT00004083_1_T1	COMPOUND	10	10	cisplatin
NCT000040831	NCT00004083_1_T2	PHENOTYPE	16	18	recurrent ovarian cancer
NCT000040833	NCT00004083_3_T0	COMPOUND	9	9	platinum
NCT000040833	NCT00004083_3_T1	COMPOUND	16	16	cisplatin
NCT000040833	NCT00004083_3_T2	PHENOTYPE	8	8	recurrent
NCT000040833	NCT00004083_3_T3	PHENOTYPE	11	13	ovarian epithelial cancer
NCT000040835	NCT00004083_5_T0	PHENOTYPE	10	10	progression
NCT000040838	NCT00004083_8_T0	COMPOUND	3	3	cisplatin
NCT000040838	NCT00004083_8_T1	GENE	6	6	IV
NCT000040839	NCT00004083_9_T0	PHENOTYPE	16	16	toxicity
NCT000040839	NCT00004083_9_T1	PHENOTYPE	12	13	disease progression
NCT000040841	NCT00004084_1_T0	PHENOTYPE	20	20	leukemia
NCT000040841	NCT00004084_1_T1	PHENOTYPE	18	18	lymphoma
NCT000040841	NCT00004084_1_T2	GENE	22	22	has
NCT000040843	NCT00004084_3_T0	PHENOTYPE	8	8	toxicity
NCT000040843	NCT00004084_3_T1	COMPOUND	10	10	yttrium
NCT000040843	NCT00004084_3_T2	CELL	22	22	B-cell
NCT000040843	NCT00004084_3_T3	PHENOTYPE	23	23	malignancies
NCT000040843	NCT00004084_3_T4	GENE	18	18	IgG
NCT000040843	NCT00004084_3_T5	GENE	14	14	CD22
NCT000040845	NCT00004084_5_T0	GENE	10	10	LL2
NCT000040845	NCT00004084_5_T1	GENE	12	12	IgG
NCT000040845	NCT00004084_5_T2	PHENOTYPE	2	2	pharmacokinetics
NCT000040845	NCT00004084_5_T3	COMPOUND	6	6	indium
NCT000040847	NCT00004084_7_T0	GENE	8	8	IgG
NCT000040849	NCT00004084_9_T0	GENE	9	9	LL2
NCT000040849	NCT00004084_9_T1	PHENOTYPE	19	19	tumor
NCT000040849	NCT00004084_9_T2	GENE	3	3	IgG
NCT000040849	NCT00004084_9_T3	GENE	10	10	IgG
NCT000040849	NCT00004084_9_T4	GENE	24	24	IgG
NCT000040849	NCT00004084_9_T5	COMPOUND	5	5	indium
NCT000040849	NCT00004084_9_T6	GENE	11	11	has
NCT0000408412	NCT00004084_12_T0	GENE	9	9	LL2
NCT0000408412	NCT00004084_12_T1	GENE	10	10	IgG
NCT0000408412	NCT00004084_12_T2	COMPOUND	5	5	indium
NCT0000408412	NCT00004084_12_T3	GENE	11	11	IV
NCT0000408413	NCT00004084_13_T0	GENE	9	9	LL2
NCT0000408413	NCT00004084_13_T1	COMPOUND	2	2	yttrium
NCT0000408413	NCT00004084_13_T2	GENE	11	11	IV
NCT0000408413	NCT00004084_13_T3	GENE	6	6	CD22
NCT0000408414	NCT00004084_14_T0	GENE	14	14	MTD
NCT0000408415	NCT00004084_15_T0	PHENOTYPE	23	23	toxicity
NCT0000408415	NCT00004084_15_T1	GENE	1	1	MTD
NCT0000408417	NCT00004084_17_T0	GENE	14	14	1.2
NCT000040856	NCT00004085_6_T0	PHENOTYPE	14	14	tumors
NCT000040858	NCT00004085_8_T0	PHENOTYPE	2	3	antibody response
NCT0000408512	NCT00004085_12_T0	PHENOTYPE	9	9	tumors
NCT0000408515	NCT00004085_15_T0	CELL	6	6	cells
NCT0000408515	NCT00004085_15_T1	GENE	5	5	CD34
NCT0000408515	NCT00004085_15_T2	ORGAN	10	11	bone marrow
NCT0000408516	NCT00004085_16_T0	COMPOUND	5	5	indium
NCT0000408516	NCT00004085_16_T1	GENE	11	11	IV
NCT0000408517	NCT00004085_17_T0	COMPOUND	2	2	yttrium
NCT0000408517	NCT00004085_17_T1	GENE	11	11	IV
NCT0000408518	NCT00004085_18_T0	ORGAN	2	3	bone marrow
NCT0000408519	NCT00004085_19_T0	GENE	3	3	SC
NCT0000408519	NCT00004085_19_T1	GENE	2	2	G-CSF
NCT0000408519	NCT00004085_19_T2	GENE	5	5	IV
NCT0000408520	NCT00004085_20_T0	GENE	16	16	MTD
NCT0000408521	NCT00004085_21_T0	PHENOTYPE	17	17	toxicity
NCT0000408521	NCT00004085_21_T1	GENE	1	1	MTD
NCT000040861	NCT00004086_1_T0	CELL	10	10	cells
NCT000040869	NCT00004086_9_T0	PHENOTYPE	6	6	tumor
NCT0000408610	NCT00004086_10_T0	GENE	15	15	LL2
NCT0000408610	NCT00004086_10_T1	COMPOUND	8	8	yttrium
NCT0000408610	NCT00004086_10_T2	GENE	12	12	CD22
NCT0000408611	NCT00004086_11_T0	GENE	2	2	filgrastim
NCT0000408611	NCT00004086_11_T1	GENE	3	3	G-CSF
NCT0000408611	NCT00004086_11_T2	CELL	13	16	peripheral blood stem cells
NCT0000408612	NCT00004086_12_T0	CELL	6	6	cells
NCT0000408612	NCT00004086_12_T1	GENE	5	5	CD34
NCT0000408612	NCT00004086_12_T2	ORGAN	11	12	bone marrow
NCT0000408613	NCT00004086_13_T0	GENE	3	3	filgrastim
NCT0000408614	NCT00004086_14_T0	GENE	9	9	LL2
NCT0000408614	NCT00004086_14_T1	COMPOUND	5	5	indium
NCT0000408616	NCT00004086_16_T0	COMPOUND	13	13	cytarabine
NCT0000408616	NCT00004086_16_T1	COMPOUND	2	2	ifosfamide
NCT0000408616	NCT00004086_16_T2	COMPOUND	7	7	cisplatin
NCT0000408616	NCT00004086_16_T3	GENE	3	3	IV
NCT0000408616	NCT00004086_16_T4	GENE	8	8	IV
NCT0000408616	NCT00004086_16_T5	GENE	14	14	IV
NCT0000408617	NCT00004086_17_T0	GENE	7	7	1.7
NCT0000408617	NCT00004086_17_T1	COMPOUND	1	1	etoposide
NCT0000408618	NCT00004086_18_T0	ORGAN	2	3	bone marrow
NCT0000408619	NCT00004086_19_T0	GENE	16	16	MTD
NCT0000408620	NCT00004086_20_T0	PHENOTYPE	22	22	toxicity
NCT0000408620	NCT00004086_20_T1	GENE	1	1	MTD
NCT000040876	NCT00004087_6_T0	PHENOTYPE	2	2	tumor
NCT000040876	NCT00004087_6_T1	COMPOUND	10	10	iodine
NCT0000408711	NCT00004087_11_T0	COMPOUND	7	7	yttrium
NCT0000408714	NCT00004087_14_T0	CELL	6	6	cells
NCT0000408714	NCT00004087_14_T1	GENE	5	5	CD34
NCT0000408714	NCT00004087_14_T2	ORGAN	10	11	bone marrow
NCT0000408715	NCT00004087_15_T0	COMPOUND	5	5	indium
NCT0000408715	NCT00004087_15_T1	GENE	12	12	IV
NCT0000408718	NCT00004087_18_T0	GENE	2	2	G-CSF
NCT0000408719	NCT00004087_19_T0	GENE	14	14	MTD
NCT0000408720	NCT00004087_20_T0	PHENOTYPE	20	20	toxicity
NCT0000408720	NCT00004087_20_T1	GENE	1	1	MTD
NCT0000408721	NCT00004087_21_T0	GENE	4	4	1.4
NCT000040882	NCT00004088_2_T0	CELL	17	17	cells
NCT000040882	NCT00004088_2_T1	GENE	4	4	interferon
NCT000040882	NCT00004088_2_T2	ORGAN	12	13	immune system
NCT000040884	NCT00004088_4_T0	PHENOTYPE	11	12	multiple myeloma
NCT000040887	NCT00004088_7_T0	GENE	13	13	G-CSF
NCT000040887	NCT00004088_7_T1	GENE	4	4	IV
NCT000040887	NCT00004088_7_T2	GENE	17	17	IV
NCT000040887	NCT00004088_7_T3	GENE	15	15	SC
NCT000040887	NCT00004088_7_T4	GENE	12	12	filgrastim
NCT000040887	NCT00004088_7_T5	COMPOUND	3	3	cyclophosphamide
NCT000040887	NCT00004088_7_T6	CELL	28	31	peripheral blood stem cells
NCT000040889	NCT00004088_9_T0	COMPOUND	7	7	1
NCT000040889	NCT00004088_9_T1	COMPOUND	3	3	melphalan
NCT000040889	NCT00004088_9_T2	GENE	4	4	IV
NCT0000408811	NCT00004088_11_T0	GENE	5	5	SC
NCT0000408811	NCT00004088_11_T1	GENE	0	0	G-CSF
NCT0000408811	NCT00004088_11_T2	GENE	3	3	IV
NCT0000408812	NCT00004088_12_T0	COMPOUND	9	9	busulfan
NCT0000408812	NCT00004088_12_T1	COMPOUND	23	23	2
NCT0000408812	NCT00004088_12_T2	COMPOUND	29	29	2
NCT0000408812	NCT00004088_12_T3	COMPOUND	27	27	3
NCT0000408812	NCT00004088_12_T4	COMPOUND	20	20	cyclophosphamide
NCT0000408812	NCT00004088_12_T5	GENE	10	10	IV
NCT0000408812	NCT00004088_12_T6	GENE	21	21	IV
NCT0000408813	NCT00004088_13_T0	GENE	12	12	SC
NCT0000408813	NCT00004088_13_T1	GENE	7	7	G-CSF
NCT0000408813	NCT00004088_13_T2	GENE	10	10	IV
NCT0000408814	NCT00004088_14_T0	GENE	12	12	interferon
NCT0000408815	NCT00004088_15_T0	GENE	4	4	SC
NCT0000408815	NCT00004088_15_T1	GENE	0	0	Interferon
NCT0000408816	NCT00004088_16_T0	COMPOUND	3	3	pamidronate
NCT0000408816	NCT00004088_16_T1	GENE	4	4	IV
NCT0000408816	NCT00004088_16_T2	PHENOTYPE	9	10	disease progression
NCT0000408817	NCT00004088_17_T0	COMPOUND	19	19	thalidomide
NCT0000408817	NCT00004088_17_T1	PHENOTYPE	6	6	remission
NCT0000408817	NCT00004088_17_T2	GENE	7	7	CR
NCT0000408817	NCT00004088_17_T3	GENE	33	33	CR
NCT000040891	NCT00004089_1_T0	CELL	8	8	cells
NCT000040891	NCT00004089_1_T1	PHENOTYPE	7	7	tumor
NCT000040892	NCT00004089_2_T0	CELL	9	9	cells
NCT000040892	NCT00004089_2_T1	PHENOTYPE	8	8	tumor
NCT000040893	NCT00004089_3_T0	GENE	2	2	II
NCT000040893	NCT00004089_3_T1	PHENOTYPE	21	23	anaplastic thyroid cancer
NCT000040895	NCT00004089_5_T0	PHENOTYPE	18	18	progression
NCT000040895	NCT00004089_5_T1	PHENOTYPE	25	26	primary tumors
NCT000040895	NCT00004089_5_T2	PHENOTYPE	35	37	anaplastic thyroid cancer
NCT000040897	NCT00004089_7_T0	COMPOUND	13	13	paclitaxel
NCT000040897	NCT00004089_7_T1	COMPOUND	3	3	hydroxyurea
NCT000040897	NCT00004089_7_T2	GENE	9	9	0.5
NCT000040897	NCT00004089_7_T3	GENE	18	18	1.5
NCT000040897	NCT00004089_7_T4	GENE	26	26	1.5
NCT000040897	NCT00004089_7_T5	GENE	11	11	IV
NCT000040897	NCT00004089_7_T6	GENE	14	14	IV
NCT000040898	NCT00004089_8_T0	GENE	2	2	filgrastim
NCT000040898	NCT00004089_8_T1	GENE	3	3	G-CSF
NCT0000408910	NCT00004089_10_T0	GENE	17	17	nodal
NCT0000408910	NCT00004089_10_T1	GENE	22	22	nodal
NCT0000408910	NCT00004089_10_T2	PHENOTYPE	28	29	residual disease
NCT0000408911	NCT00004089_11_T0	PHENOTYPE	3	4	residual disease
NCT0000408912	NCT00004089_12_T0	PHENOTYPE	6	6	recurrence
NCT0000408912	NCT00004089_12_T1	PHENOTYPE	3	4	progressive disease
NCT000040900	NCT00004090_0_T0	PHENOTYPE	9	9	Recurrent
NCT000040900	NCT00004090_0_T1	PHENOTYPE	10	11	Solid Tumors
NCT000040902	NCT00004090_2_T0	CELL	9	9	cells
NCT000040902	NCT00004090_2_T1	PHENOTYPE	8	8	tumor
NCT000040903	NCT00004090_3_T0	COMPOUND	9	9	gemcitabine
NCT000040903	NCT00004090_3_T1	COMPOUND	11	11	cisplatin
NCT000040903	NCT00004090_3_T2	PHENOTYPE	19	19	recurrent
NCT000040903	NCT00004090_3_T3	PHENOTYPE	20	21	solid tumors
NCT000040905	NCT00004090_5_T0	PHENOTYPE	2	2	toxicity
NCT000040905	NCT00004090_5_T1	PHENOTYPE	18	18	malignancies
NCT000040905	NCT00004090_5_T2	COMPOUND	8	8	gemcitabine
NCT000040905	NCT00004090_5_T3	COMPOUND	10	10	cisplatin
NCT000040905	NCT00004090_5_T4	PHENOTYPE	16	16	recurrent
NCT000040906	NCT00004090_6_T0	COMPOUND	8	8	gemcitabine
NCT000040907	NCT00004090_7_T0	COMPOUND	2	2	gemcitabine
NCT000040907	NCT00004090_7_T1	COMPOUND	12	12	cisplatin
NCT000040907	NCT00004090_7_T2	GENE	3	3	IV
NCT000040907	NCT00004090_7_T3	GENE	13	13	IV
NCT000040908	NCT00004090_8_T0	PHENOTYPE	18	18	toxicity
NCT000040908	NCT00004090_8_T1	PHENOTYPE	14	15	disease progression
NCT000040909	NCT00004090_9_T0	GENE	2	2	3.5
NCT000040909	NCT00004090_9_T1	COMPOUND	8	8	gemcitabine
NCT000040909	NCT00004090_9_T2	GENE	14	14	MTD
NCT0000409010	NCT00004090_10_T0	PHENOTYPE	20	20	toxicity
NCT0000409010	NCT00004090_10_T1	GENE	1	1	MTD
NCT000040916	NCT00004091_6_T0	CELL	1	2	epithelial cells
NCT000040917	NCT00004091_7_T0	CELL	0	0	Cells
NCT000040921	NCT00004092_1_T0	CELL	9	9	cells
NCT000040921	NCT00004092_1_T1	PHENOTYPE	8	8	tumor
NCT000040922	NCT00004092_2_T0	GENE	4	4	II
NCT000040922	NCT00004092_2_T1	GENE	30	30	II
NCT000040922	NCT00004092_2_T2	PHENOTYPE	32	35	stage III breast cancer
NCT000040927	NCT00004092_7_T0	GENE	10	10	filgrastim
NCT000040927	NCT00004092_7_T1	GENE	11	11	G-CSF
NCT000040927	NCT00004092_7_T2	GENE	15	15	IV
NCT000040927	NCT00004092_7_T3	CELL	0	3	Peripheral blood stem cells
NCT000040928	NCT00004092_8_T0	COMPOUND	10	10	cyclophosphamide
NCT000040928	NCT00004092_8_T1	COMPOUND	8	8	doxorubicin
NCT000040928	NCT00004092_8_T2	GENE	9	9	IV
NCT000040928	NCT00004092_8_T3	GENE	11	11	IV
NCT000040928	NCT00004092_8_T4	GENE	14	14	IV
NCT0000409211	NCT00004092_11_T0	COMPOUND	5	5	2
NCT0000409214	NCT00004092_14_T0	COMPOUND	11	11	estrogen
NCT0000409214	NCT00004092_14_T1	PHENOTYPE	16	16	tumors
NCT0000409214	NCT00004092_14_T2	COMPOUND	19	19	tamoxifen
NCT0000409214	NCT00004092_14_T3	PHENOTYPE	13	15	progesterone receptor positive
NCT0000409215	NCT00004092_15_T0	COMPOUND	9	9	pamidronate
NCT0000409215	NCT00004092_15_T1	GENE	10	10	IV
NCT0000409216	NCT00004092_16_T0	PHENOTYPE	0	2	Quality of life
NCT000040932	NCT00004093_2_T0	CELL	8	8	cells
NCT000040932	NCT00004093_2_T1	PHENOTYPE	7	7	tumor
NCT000040933	NCT00004093_3_T0	CELL	9	9	cells
NCT000040933	NCT00004093_3_T1	PHENOTYPE	8	8	tumor
NCT000040938	NCT00004093_8_T0	PHENOTYPE	8	8	toxicities
NCT0000409310	NCT00004093_10_T0	COMPOUND	11	11	gemcitabine
NCT0000409314	NCT00004093_14_T0	PHENOTYPE	4	4	progression
NCT0000409314	NCT00004093_14_T1	PHENOTYPE	8	10	quality of life
NCT0000409315	NCT00004093_15_T0	COMPOUND	8	8	vinorelbine
NCT0000409316	NCT00004093_16_T0	COMPOUND	16	16	gemcitabine
NCT0000409316	NCT00004093_16_T1	GENE	7	7	IV
NCT0000409316	NCT00004093_16_T2	GENE	17	17	IV
NCT0000409318	NCT00004093_18_T0	COMPOUND	10	10	vinorelbine
NCT0000409318	NCT00004093_18_T1	COMPOUND	17	17	paclitaxel
NCT0000409318	NCT00004093_18_T2	GENE	34	34	1/6
NCT0000409318	NCT00004093_18_T3	GENE	11	11	IV
NCT0000409318	NCT00004093_18_T4	GENE	18	18	IV
NCT0000409319	NCT00004093_19_T0	GENE	14	14	2.4
NCT0000409319	NCT00004093_19_T1	COMPOUND	19	19	gemcitabine
NCT0000409321	NCT00004093_21_T0	COMPOUND	8	8	vinorelbine
NCT0000409321	NCT00004093_21_T1	GENE	14	14	MTD
NCT0000409322	NCT00004093_22_T0	PHENOTYPE	22	22	toxicity
NCT0000409322	NCT00004093_22_T1	GENE	1	1	MTD
NCT0000409323	NCT00004093_23_T0	PHENOTYPE	0	2	Quality of life
NCT000040942	NCT00004094_2_T0	CELL	8	8	cells
NCT000040942	NCT00004094_2_T1	PHENOTYPE	7	7	tumor
NCT000040943	NCT00004094_3_T0	CELL	9	9	cells
NCT000040943	NCT00004094_3_T1	PHENOTYPE	8	8	tumor
NCT000040944	NCT00004094_4_T0	GENE	2	2	II
NCT000040944	NCT00004094_4_T1	ORGAN	28	28	larynx
NCT000040944	NCT00004094_4_T2	ORGAN	26	26	pharynx
NCT000040944	NCT00004094_4_T3	PHENOTYPE	21	22	advanced cancer
NCT000040944	NCT00004094_4_T4	PHENOTYPE	22	25	cancer of the mouth
NCT000040946	NCT00004094_6_T0	COMPOUND	6	6	paclitaxel
NCT000040946	NCT00004094_6_T1	GENE	7	7	IV
NCT000040946	NCT00004094_6_T2	GENE	14	14	IV
NCT000040948	NCT00004094_8_T0	COMPOUND	31	31	paclitaxel
NCT000040948	NCT00004094_8_T1	COMPOUND	11	11	hydroxyurea
NCT000040948	NCT00004094_8_T2	GENE	1	1	1.2
NCT000040948	NCT00004094_8_T3	GENE	23	23	1.5
NCT000040948	NCT00004094_8_T4	GENE	29	29	1.5
NCT000040948	NCT00004094_8_T5	GENE	17	17	1/6
NCT000040948	NCT00004094_8_T6	GENE	19	19	IV
NCT000040948	NCT00004094_8_T7	GENE	32	32	IV
NCT0000409410	NCT00004094_10_T0	GENE	3	3	nodal
NCT0000409410	NCT00004094_10_T1	GENE	8	8	nodal
NCT0000409410	NCT00004094_10_T2	PHENOTYPE	15	16	residual disease
NCT0000409411	NCT00004094_11_T0	PHENOTYPE	2	3	residual disease
NCT0000409412	NCT00004094_12_T0	PHENOTYPE	6	6	recurrence
NCT0000409412	NCT00004094_12_T1	PHENOTYPE	2	3	disease progression
NCT0000409413	NCT00004094_13_T0	GENE	15	15	1.5
NCT0000409413	NCT00004094_13_T1	PHENOTYPE	0	2	Quality of life
NCT000040950	NCT00004095_0_T0	PHENOTYPE	10	11	Solid Tumors
NCT000040952	NCT00004095_2_T0	CELL	9	9	cells
NCT000040952	NCT00004095_2_T1	PHENOTYPE	8	8	tumor
NCT000040953	NCT00004095_3_T0	COMPOUND	10	10	irinotecan
NCT000040953	NCT00004095_3_T1	COMPOUND	12	12	gemcitabine
NCT000040953	NCT00004095_3_T2	PHENOTYPE	21	22	solid tumors
NCT000040956	NCT00004095_6_T0	COMPOUND	2	2	irinotecan
NCT000040956	NCT00004095_6_T1	COMPOUND	9	9	gemcitabine
NCT000040956	NCT00004095_6_T2	GENE	3	3	IV
NCT000040956	NCT00004095_6_T3	GENE	10	10	IV
NCT000040957	NCT00004095_7_T0	PHENOTYPE	13	13	toxicity
NCT000040957	NCT00004095_7_T1	PHENOTYPE	9	10	disease progression
NCT000040958	NCT00004095_8_T0	GENE	5	5	MTD
NCT000040958	NCT00004095_8_T1	GENE	23	23	MTD
NCT000040959	NCT00004095_9_T0	COMPOUND	8	8	irinotecan
NCT000040959	NCT00004095_9_T1	COMPOUND	10	10	gemcitabine
NCT000040959	NCT00004095_9_T2	GENE	13	13	MTD
NCT0000409510	NCT00004095_10_T0	PHENOTYPE	22	22	toxicities
NCT0000409510	NCT00004095_10_T1	GENE	1	1	MTD
NCT000040962	NCT00004096_2_T0	CELL	9	9	cells
NCT000040962	NCT00004096_2_T1	PHENOTYPE	8	8	tumor
NCT000040967	NCT00004096_7_T0	PHENOTYPE	8	8	toxicities
NCT0000409610	NCT00004096_10_T0	COMPOUND	8	8	vinorelbine
NCT0000409611	NCT00004096_11_T0	COMPOUND	9	9	vinorelbine
NCT0000409611	NCT00004096_11_T1	GENE	3	3	IV
NCT0000409611	NCT00004096_11_T2	GENE	10	10	IV
NCT0000409612	NCT00004096_12_T0	PHENOTYPE	10	10	toxicity
NCT0000409612	NCT00004096_12_T1	PHENOTYPE	12	13	disease progression
NCT0000409613	NCT00004096_13_T0	COMPOUND	8	8	vinorelbine
NCT0000409613	NCT00004096_13_T1	GENE	14	14	MTD
NCT0000409614	NCT00004096_14_T0	PHENOTYPE	19	19	toxicity
NCT0000409614	NCT00004096_14_T1	GENE	1	1	MTD
NCT000040970	NCT00004097_0_T0	PHENOTYPE	11	15	Recurrent Head and Neck Cancer
NCT000040972	NCT00004097_2_T0	CELL	8	8	cells
NCT000040972	NCT00004097_2_T1	PHENOTYPE	7	7	tumor
NCT000040973	NCT00004097_3_T0	CELL	9	9	cells
NCT000040973	NCT00004097_3_T1	PHENOTYPE	8	8	tumor
NCT000040974	NCT00004097_4_T0	PHENOTYPE	21	25	recurrent head and neck cancer
NCT000040976	NCT00004097_6_T0	PHENOTYPE	8	8	toxicity
NCT000040976	NCT00004097_6_T1	COMPOUND	15	15	paclitaxel
NCT000040976	NCT00004097_6_T2	GENE	9	9	DLT
NCT000040976	NCT00004097_6_T3	COMPOUND	11	11	gemcitabine
NCT000040976	NCT00004097_6_T4	GENE	5	5	MTD
NCT000040976	NCT00004097_6_T5	PHENOTYPE	27	31	recurrent head and neck cancer
NCT000040978	NCT00004097_8_T0	COMPOUND	6	6	gemcitabine
NCT000040978	NCT00004097_8_T1	GENE	2	2	MTD
NCT000040978	NCT00004097_8_T2	GENE	4	4	DLT
NCT0000409710	NCT00004097_10_T0	PHENOTYPE	11	11	progression
NCT0000409710	NCT00004097_10_T1	PHENOTYPE	21	22	measurable disease
NCT0000409712	NCT00004097_12_T0	PHENOTYPE	4	4	pharmacokinetics
NCT0000409712	NCT00004097_12_T1	COMPOUND	1	1	gemcitabine
NCT0000409713	NCT00004097_13_T0	COMPOUND	8	8	gemcitabine
NCT0000409714	NCT00004097_14_T0	COMPOUND	10	10	paclitaxel
NCT0000409714	NCT00004097_14_T1	GENE	9	9	1.5
NCT0000409714	NCT00004097_14_T2	GENE	25	25	1.5
NCT0000409714	NCT00004097_14_T3	GENE	5	5	IV
NCT0000409714	NCT00004097_14_T4	GENE	11	11	IV
NCT0000409715	NCT00004097_15_T0	COMPOUND	22	22	paclitaxel
NCT0000409715	NCT00004097_15_T1	COMPOUND	11	11	gemcitabine
NCT0000409715	NCT00004097_15_T2	GENE	12	12	IV
NCT0000409718	NCT00004097_18_T0	COMPOUND	8	8	gemcitabine
NCT0000409718	NCT00004097_18_T1	GENE	14	14	MTD
NCT0000409719	NCT00004097_19_T0	PHENOTYPE	15	15	toxicity
NCT0000409719	NCT00004097_19_T1	GENE	1	1	MTD
NCT0000409720	NCT00004097_20_T0	COMPOUND	26	26	paclitaxel
NCT0000409720	NCT00004097_20_T1	COMPOUND	6	6	gemcitabine
NCT0000409720	NCT00004097_20_T2	COMPOUND	16	16	gemcitabine
NCT0000409720	NCT00004097_20_T3	GENE	4	4	MTD
NCT0000409721	NCT00004097_21_T0	GENE	1	1	MTD
NCT000040991	NCT00004099_1_T0	PHENOTYPE	18	19	stomach cancer
NCT000040992	NCT00004099_2_T0	GENE	22	22	II
NCT000040992	NCT00004099_2_T1	GENE	3	3	III
NCT000040992	NCT00004099_2_T2	PHENOTYPE	23	24	stage III
NCT000040992	NCT00004099_2_T3	PHENOTYPE	26	29	stage IV stomach cancer
NCT000040997	NCT00004099_7_T0	COMPOUND	4	4	calcium
NCT000040997	NCT00004099_7_T1	COMPOUND	3	3	leucovorin
NCT000040997	NCT00004099_7_T2	GENE	5	5	IV
NCT000040997	NCT00004099_7_T3	GENE	12	12	IV
NCT000040998	NCT00004099_8_T0	PHENOTYPE	17	17	toxicity
NCT000040998	NCT00004099_8_T1	PHENOTYPE	13	14	disease progression
NCT0000409910	NCT00004099_10_T0	PHENOTYPE	0	2	Quality of life
NCT000041009	NCT00004100_9_T0	PHENOTYPE	2	2	toxic
NCT0000410013	NCT00004100_13_T0	GENE	11	11	IV
NCT0000410018	NCT00004100_18_T0	PHENOTYPE	0	2	Quality of life
NCT000041013	NCT00004101_3_T0	PHENOTYPE	14	15	Hodgkin's lymphoma
NCT000041017	NCT00004101_7_T0	PHENOTYPE	2	2	pharmacokinetics
NCT0000410111	NCT00004101_11_T0	GENE	7	7	2.4
NCT0000410111	NCT00004101_11_T1	GENE	5	5	IV
NCT0000410112	NCT00004101_12_T0	PHENOTYPE	10	10	toxicity
NCT0000410112	NCT00004101_12_T1	PHENOTYPE	6	7	disease progression
NCT0000410113	NCT00004101_13_T0	GENE	16	16	MTD
NCT0000410114	NCT00004101_14_T0	PHENOTYPE	18	18	toxicity
NCT0000410114	NCT00004101_14_T1	GENE	1	1	MTD
NCT0000410115	NCT00004101_15_T0	GENE	19	19	1.5
NCT0000410115	NCT00004101_15_T1	GENE	15	15	2.4
NCT0000410115	NCT00004101_15_T2	GENE	2	2	MTD
NCT0000410115	NCT00004101_15_T3	GENE	13	13	IV
NCT0000410116	NCT00004101_16_T0	PHENOTYPE	12	13	disease progression
NCT000041021	NCT00004102_1_T0	CELL	9	9	cells
NCT000041021	NCT00004102_1_T1	PHENOTYPE	8	8	tumor
NCT000041022	NCT00004102_2_T0	CELL	10	10	cells
NCT000041022	NCT00004102_2_T1	PHENOTYPE	9	9	tumor
NCT000041023	NCT00004102_3_T0	GENE	2	2	II
NCT000041023	NCT00004102_3_T1	COMPOUND	13	13	oxaliplatin
NCT000041023	NCT00004102_3_T2	COMPOUND	16	16	leucovorin
NCT000041023	NCT00004102_3_T3	PHENOTYPE	22	23	colorectal cancer
NCT000041025	NCT00004102_5_T0	COMPOUND	13	13	calcium
NCT000041025	NCT00004102_5_T1	PHENOTYPE	5	5	toxicities
NCT000041025	NCT00004102_5_T2	COMPOUND	7	7	oxaliplatin
NCT000041025	NCT00004102_5_T3	ORGAN	23	23	rectum
NCT000041025	NCT00004102_5_T4	COMPOUND	12	12	leucovorin
NCT000041025	NCT00004102_5_T5	PHENOTYPE	18	21	adenocarcinoma of the colon
NCT000041026	NCT00004102_6_T0	COMPOUND	4	4	calcium
NCT000041026	NCT00004102_6_T1	COMPOUND	3	3	leucovorin
NCT000041026	NCT00004102_6_T2	GENE	5	5	IV
NCT000041026	NCT00004102_6_T3	GENE	15	15	IV
NCT000041027	NCT00004102_7_T0	COMPOUND	10	10	calcium
NCT000041027	NCT00004102_7_T1	COMPOUND	2	2	oxaliplatin
NCT000041027	NCT00004102_7_T2	COMPOUND	9	9	leucovorin
NCT000041027	NCT00004102_7_T3	GENE	3	3	IV
NCT000041028	NCT00004102_8_T0	PHENOTYPE	16	16	toxicity
NCT000041028	NCT00004102_8_T1	PHENOTYPE	12	13	disease progression
NCT000041031	NCT00004103_1_T0	CELL	14	14	cells
NCT000041031	NCT00004103_1_T1	PHENOTYPE	13	13	tumor
NCT000041032	NCT00004103_2_T0	GENE	3	3	II
NCT000041032	NCT00004103_2_T1	COMPOUND	9	9	irinotecan
NCT000041032	NCT00004103_2_T2	COMPOUND	11	11	cisplatin
NCT000041032	NCT00004103_2_T3	COMPOUND	17	17	cisplatin
NCT000041032	NCT00004103_2_T4	PHENOTYPE	23	24	stomach cancer
NCT000041034	NCT00004103_4_T0	COMPOUND	6	6	irinotecan
NCT000041034	NCT00004103_4_T1	COMPOUND	3	3	cisplatin
NCT000041034	NCT00004103_4_T2	GENE	4	4	IV
NCT000041034	NCT00004103_4_T3	GENE	7	7	IV
NCT000041036	NCT00004103_6_T0	PHENOTYPE	6	6	remission
NCT000041038	NCT00004103_8_T0	GENE	10	10	1.3
NCT000041038	NCT00004103_8_T1	COMPOUND	15	15	cisplatin
NCT000041040	NCT00004104_0_T0	GENE	3	3	Interleukin-2
NCT000041040	NCT00004104_0_T1	PHENOTYPE	15	15	Melanoma
NCT000041040	NCT00004104_0_T2	GENE	14	14	III
NCT000041040	NCT00004104_0_T3	GENE	7	7	Interferon
NCT000041042	NCT00004104_2_T0	CELL	11	11	cells
NCT000041042	NCT00004104_2_T1	GENE	0	0	Interleukin-2
NCT000041042	NCT00004104_2_T2	PHENOTYPE	10	10	tumor
NCT000041042	NCT00004104_2_T3	CELL	5	7	white blood cells
NCT000041044	NCT00004104_4_T0	GENE	3	3	II
NCT000041044	NCT00004104_4_T1	GENE	13	13	interleukin-2
NCT000041044	NCT00004104_4_T2	COMPOUND	17	18	interferon alfa_2b
NCT000041044	NCT00004104_4_T3	PHENOTYPE	24	26	stage III melanoma
NCT000041046	NCT00004104_6_T0	GENE	25	25	interleukin-2
NCT000041046	NCT00004104_6_T1	PHENOTYPE	22	22	melanoma
NCT000041046	NCT00004104_6_T2	PHENOTYPE	29	30	stage III
NCT000041046	NCT00004104_6_T3	PHENOTYPE	31	32	malignant melanoma
NCT000041046	NCT00004104_6_T4	COMPOUND	4	5	interferon alfa_2b
NCT000041048	NCT00004104_8_T0	GENE	5	5	interferon
NCT0000410410	NCT00004104_10_T0	PHENOTYPE	2	2	toxicity
NCT0000410413	NCT00004104_13_T0	GENE	8	8	interleukin-2
NCT0000410413	NCT00004104_13_T1	PHENOTYPE	4	4	melanoma
NCT0000410414	NCT00004104_14_T0	PHENOTYPE	28	29	disease progression
NCT000041051	NCT00004105_1_T0	CELL	9	9	cells
NCT000041052	NCT00004105_2_T0	COMPOUND	9	9	vinorelbine
NCT000041052	NCT00004105_2_T1	COMPOUND	10	10	paclitaxel
NCT000041052	NCT00004105_2_T2	GENE	21	21	has
NCT000041052	NCT00004105_2_T3	COMPOUND	12	12	estramustine
NCT000041052	NCT00004105_2_T4	PHENOTYPE	18	19	advanced cancer
NCT000041056	NCT00004105_6_T0	PHENOTYPE	2	2	toxicity
NCT000041058	NCT00004105_8_T0	GENE	18	18	II
NCT0000410511	NCT00004105_11_T0	COMPOUND	9	9	vinorelbine
NCT0000410511	NCT00004105_11_T1	COMPOUND	11	11	paclitaxel
NCT0000410512	NCT00004105_12_T0	COMPOUND	13	13	vinorelbine
NCT0000410512	NCT00004105_12_T1	COMPOUND	21	21	paclitaxel
NCT0000410512	NCT00004105_12_T2	GENE	9	9	0.2
NCT0000410512	NCT00004105_12_T3	COMPOUND	3	3	estramustine
NCT0000410512	NCT00004105_12_T4	GENE	14	14	IV
NCT0000410512	NCT00004105_12_T5	GENE	22	22	IV
NCT0000410514	NCT00004105_14_T0	PHENOTYPE	20	20	toxicity
NCT0000410514	NCT00004105_14_T1	PHENOTYPE	16	17	disease progression
NCT0000410515	NCT00004105_15_T0	COMPOUND	8	8	vinorelbine
NCT0000410515	NCT00004105_15_T1	COMPOUND	10	10	paclitaxel
NCT0000410515	NCT00004105_15_T2	GENE	16	16	MTD
NCT0000410516	NCT00004105_16_T0	PHENOTYPE	19	19	toxicity
NCT0000410516	NCT00004105_16_T1	GENE	1	1	MTD
NCT0000410517	NCT00004105_17_T0	GENE	3	3	II
NCT0000410517	NCT00004105_17_T1	COMPOUND	6	6	vinorelbine
NCT0000410517	NCT00004105_17_T2	COMPOUND	8	8	paclitaxel
NCT0000410517	NCT00004105_17_T3	GENE	17	17	MTD
NCT0000410518	NCT00004105_18_T0	GENE	30	30	II
NCT000041064	NCT00004106_4_T0	COMPOUND	3	3	temozolomide
NCT000041064	NCT00004106_4_T1	GENE	8	8	1.5
NCT000041065	NCT00004106_5_T0	PHENOTYPE	13	13	toxicity
NCT000041065	NCT00004106_5_T1	PHENOTYPE	9	10	disease progression
NCT000041076	NCT00004107_6_T0	PHENOTYPE	12	12	toxicity
NCT000041076	NCT00004107_6_T1	PHENOTYPE	4	4	tumor
NCT000041078	NCT00004107_8_T0	GENE	7	7	LL2
NCT0000410713	NCT00004107_13_T0	GENE	5	5	SC
NCT0000410713	NCT00004107_13_T1	GENE	2	2	filgrastim
NCT0000410713	NCT00004107_13_T2	GENE	3	3	G-CSF
NCT0000410713	NCT00004107_13_T3	CELL	14	17	peripheral blood stem cells
NCT0000410714	NCT00004107_14_T0	CELL	6	6	cells
NCT0000410714	NCT00004107_14_T1	GENE	5	5	CD34
NCT0000410714	NCT00004107_14_T2	ORGAN	11	12	bone marrow
NCT0000410715	NCT00004107_15_T0	COMPOUND	5	5	indium
NCT0000410715	NCT00004107_15_T1	GENE	12	12	IV
NCT0000410716	NCT00004107_16_T0	GENE	19	19	LL2
NCT0000410716	NCT00004107_16_T1	COMPOUND	12	12	yttrium
NCT0000410716	NCT00004107_16_T2	PHENOTYPE	4	4	tumor
NCT0000410716	NCT00004107_16_T3	GENE	23	23	IV
NCT0000410716	NCT00004107_16_T4	GENE	16	16	CD22
NCT0000410717	NCT00004107_17_T0	ORGAN	2	3	bone marrow
NCT0000410718	NCT00004107_18_T0	GENE	4	4	SC
NCT0000410718	NCT00004107_18_T1	GENE	3	3	G-CSF
NCT0000410719	NCT00004107_19_T0	GENE	16	16	MTD
NCT0000410720	NCT00004107_20_T0	PHENOTYPE	18	18	toxicity
NCT0000410720	NCT00004107_20_T1	GENE	1	1	MTD
NCT000041082	NCT00004108_2_T0	GENE	2	2	II
NCT000041082	NCT00004108_2_T1	PHENOTYPE	15	16	liver cancer
NCT000041084	NCT00004108_4_T0	PHENOTYPE	18	19	hepatocellular carcinoma
NCT000041086	NCT00004108_6_T0	PHENOTYPE	5	5	toxicities
NCT000041088	NCT00004108_8_T0	PHENOTYPE	2	2	pharmacokinetics
NCT000041088	NCT00004108_8_T1	ORGAN	6	6	plasma
NCT000041089	NCT00004108_9_T0	GENE	4	4	IV
NCT0000410810	NCT00004108_10_T0	PHENOTYPE	18	18	toxicity
NCT0000410810	NCT00004108_10_T1	PHENOTYPE	14	15	disease progression
NCT000041091	NCT00004109_1_T0	CELL	8	8	cells
NCT000041091	NCT00004109_1_T1	PHENOTYPE	7	7	tumor
NCT000041092	NCT00004109_2_T0	CELL	9	9	cells
NCT000041092	NCT00004109_2_T1	PHENOTYPE	8	8	tumor
NCT000041093	NCT00004109_3_T0	COMPOUND	9	9	doxorubicin
NCT000041093	NCT00004109_3_T1	PHENOTYPE	19	21	soft tissue sarcoma
NCT000041095	NCT00004109_5_T0	PHENOTYPE	2	2	toxicity
NCT000041095	NCT00004109_5_T1	COMPOUND	8	8	doxorubicin
NCT000041095	NCT00004109_5_T2	ORGAN	25	25	extremity
NCT000041095	NCT00004109_5_T3	PHENOTYPE	20	22	soft tissue sarcomas
NCT000041097	NCT00004109_7_T0	PHENOTYPE	18	19	measurable disease
NCT000041098	NCT00004109_8_T0	COMPOUND	8	8	doxorubicin
NCT000041099	NCT00004109_9_T0	PHENOTYPE	24	24	toxicity
NCT000041099	NCT00004109_9_T1	COMPOUND	2	2	doxorubicin
NCT000041099	NCT00004109_9_T2	COMPOUND	9	9	doxorubicin
NCT000041099	NCT00004109_9_T3	GENE	4	4	IV
NCT000041099	NCT00004109_9_T4	GENE	10	10	IV
NCT0000410910	NCT00004109_10_T0	COMPOUND	17	17	doxorubicin
NCT0000410910	NCT00004109_10_T1	PHENOTYPE	2	3	measurable disease
NCT0000410911	NCT00004109_11_T0	GENE	11	11	4.7
NCT0000410911	NCT00004109_11_T1	PHENOTYPE	2	3	measurable disease
NCT0000410913	NCT00004109_13_T0	COMPOUND	8	8	doxorubicin
NCT0000410913	NCT00004109_13_T1	GENE	14	14	MTD
NCT0000410917	NCT00004109_17_T0	GENE	10	10	mc
NCT0000410917	NCT00004109_17_T1	GENE	12	12	III
NCT0000410917	NCT00004109_17_T2	ORGAN	19	19	extremity
NCT0000410917	NCT00004109_17_T3	PHENOTYPE	14	16	soft tissue sarcoma
NCT0000410918	NCT00004109_18_T0	GENE	13	13	II
NCT0000410918	NCT00004109_18_T1	PHENOTYPE	11	11	tumors
NCT0000410920	NCT00004109_20_T0	PHENOTYPE	5	6	measurable disease
NCT0000410922	NCT00004109_22_T0	GENE	3	3	had
NCT0000410922	NCT00004109_22_T1	COMPOUND	5	5	doxorubicin
NCT0000410922	NCT00004109_22_T2	COMPOUND	10	10	doxorubicin
NCT0000410924	NCT00004109_24_T0	PHENOTYPE	7	7	malignancy
NCT0000410926	NCT00004109_26_T0	GENE	8	8	70
NCT000041101	NCT00004110_1_T0	CELL	10	10	cells
NCT000041101	NCT00004110_1_T1	PHENOTYPE	9	9	tumor
NCT000041102	NCT00004110_2_T0	CELL	10	10	cells
NCT000041102	NCT00004110_2_T1	PHENOTYPE	9	9	tumor
NCT000041103	NCT00004110_3_T0	GENE	2	2	II
NCT000041103	NCT00004110_3_T1	PHENOTYPE	19	19	neuroblastoma
NCT000041103	NCT00004110_3_T2	COMPOUND	13	13	etoposide
NCT000041106	NCT00004110_6_T0	COMPOUND	4	4	3F8
NCT000041106	NCT00004110_6_T1	COMPOUND	6	6	3F8
NCT000041106	NCT00004110_6_T2	GENE	9	9	1.5
NCT000041106	NCT00004110_6_T3	COMPOUND	15	15	1_10
NCT000041106	NCT00004110_6_T4	COMPOUND	18	18	etoposide
NCT000041106	NCT00004110_6_T5	GENE	7	7	IV
NCT000041107	NCT00004110_7_T0	PHENOTYPE	21	21	toxicity
NCT000041107	NCT00004110_7_T1	PHENOTYPE	12	13	disease progression
NCT000041108	NCT00004110_8_T0	COMPOUND	12	12	3F8
NCT000041108	NCT00004110_8_T1	COMPOUND	18	18	3F8
NCT000041108	NCT00004110_8_T2	GENE	21	21	1.5
NCT000041109	NCT00004110_9_T0	COMPOUND	18	18	isotretinoin
NCT000041109	NCT00004110_9_T1	COMPOUND	10	10	3F8
NCT000041109	NCT00004110_9_T2	COMPOUND	7	7	etoposide
NCT000041122	NCT00004112_2_T0	PHENOTYPE	18	19	Hodgkin's lymphoma
NCT000041123	NCT00004112_3_T0	GENE	3	3	III
NCT000041123	NCT00004112_3_T1	GENE	26	26	has
NCT000041123	NCT00004112_3_T2	PHENOTYPE	23	24	Hodgkin's lymphoma
NCT000041125	NCT00004112_5_T0	COMPOUND	9	9	vincristine
NCT000041125	NCT00004112_5_T1	CELL	25	25	B-cell
NCT000041125	NCT00004112_5_T2	COMPOUND	7	7	cyclophosphamide
NCT000041125	NCT00004112_5_T3	GENE	12	12	CHOP
NCT000041125	NCT00004112_5_T4	COMPOUND	8	8	doxorubicin
NCT000041125	NCT00004112_5_T5	COMPOUND	11	11	prednisone
NCT000041125	NCT00004112_5_T6	PHENOTYPE	26	27	Hodgkin's lymphoma
NCT000041127	NCT00004112_7_T0	PHENOTYPE	8	8	toxicity
NCT000041127	NCT00004112_7_T1	GENE	12	12	CHOP
NCT0000411212	NCT00004112_12_T0	PHENOTYPE	18	18	toxicity
NCT0000411212	NCT00004112_12_T1	PHENOTYPE	14	15	disease progression
NCT000041131	NCT00004113_1_T0	COMPOUND	9	9	temozolomide
NCT000041131	NCT00004113_1_T1	GENE	2	2	II
NCT000041131	NCT00004113_1_T2	PHENOTYPE	15	15	recurrent
NCT000041131	NCT00004113_1_T3	PHENOTYPE	16	17	malignant glioma
NCT000041133	NCT00004113_3_T0	COMPOUND	6	6	temozolomide
NCT000041133	NCT00004113_3_T1	PHENOTYPE	10	10	recurrent
NCT000041133	NCT00004113_3_T2	PHENOTYPE	11	12	malignant glioma
NCT000041137	NCT00004113_7_T0	PHENOTYPE	4	5	tumor progression
NCT000041139	NCT00004113_9_T0	PHENOTYPE	2	4	quality of life
NCT0000411310	NCT00004113_10_T0	COMPOUND	4	4	temozolomide
NCT0000411311	NCT00004113_11_T0	PHENOTYPE	18	18	toxicity
NCT0000411311	NCT00004113_11_T1	PHENOTYPE	14	15	disease progression
NCT0000411312	NCT00004113_12_T0	GENE	6	6	1.2
NCT0000411312	NCT00004113_12_T1	PHENOTYPE	0	2	Quality of life
NCT0000411313	NCT00004113_13_T0	GENE	4	4	3.4
NCT0000411314	NCT00004113_14_T0	GENE	5	5	20.35
NCT000041146	NCT00004114_6_T0	PHENOTYPE	2	2	toxicities
NCT000041146	NCT00004114_6_T1	PHENOTYPE	7	10	graft versus host disease
NCT000041147	NCT00004114_7_T0	COMPOUND	24	24	cytarabine
NCT000041147	NCT00004114_7_T1	COMPOUND	33	33	3
NCT000041147	NCT00004114_7_T2	COMPOUND	3	3	fludarabine
NCT000041147	NCT00004114_7_T3	COMPOUND	13	13	cyclophosphamide
NCT000041147	NCT00004114_7_T4	GENE	4	4	IV
NCT000041147	NCT00004114_7_T5	GENE	14	14	IV
NCT000041147	NCT00004114_7_T6	GENE	25	25	IV
NCT000041148	NCT00004114_8_T0	CELL	1	4	peripheral blood stem cells
NCT000041149	NCT00004114_9_T0	GENE	1	1	G-CSF
NCT000041149	NCT00004114_9_T1	GENE	4	4	IV
NCT000041150	NCT00004115_0_T0	PHENOTYPE	7	8	Ovarian Cancer
NCT000041150	NCT00004115_0_T1	PHENOTYPE	11	12	Peritoneal Cancer
NCT000041152	NCT00004115_2_T0	PHENOTYPE	23	24	in remission
NCT000041152	NCT00004115_2_T1	PHENOTYPE	15	16	ovarian cancer
NCT000041152	NCT00004115_2_T2	PHENOTYPE	19	20	peritoneal cancer
NCT000041153	NCT00004115_3_T0	GENE	3	3	III
NCT000041153	NCT00004115_3_T1	PHENOTYPE	28	29	in remission
NCT000041153	NCT00004115_3_T2	PHENOTYPE	22	23	ovarian cancer
NCT000041153	NCT00004115_3_T3	PHENOTYPE	26	27	peritoneal cancer
NCT000041157	NCT00004115_7_T0	PHENOTYPE	0	2	Quality of life
NCT000041222	NCT00004122_2_T0	PHENOTYPE	9	10	bladder cancer
NCT000041223	NCT00004122_3_T0	GENE	2	2	II
NCT000041223	NCT00004122_3_T1	GENE	13	13	2b
NCT000041223	NCT00004122_3_T2	GENE	9	9	BCG
NCT000041223	NCT00004122_3_T3	GENE	11	11	interferon
NCT000041223	NCT00004122_3_T4	PHENOTYPE	19	20	bladder cancer
NCT000041225	NCT00004122_5_T0	GENE	9	9	2b
NCT000041225	NCT00004122_5_T1	GENE	4	4	BCG
NCT000041225	NCT00004122_5_T2	GENE	7	7	interferon
NCT000041225	NCT00004122_5_T3	PHENOTYPE	13	15	superficial bladder cancer
NCT000041227	NCT00004122_7_T0	PHENOTYPE	6	6	toxicities
NCT000041227	NCT00004122_7_T1	PHENOTYPE	14	16	quality of life
NCT000041229	NCT00004122_9_T0	GENE	4	4	BCG
NCT000041229	NCT00004122_9_T1	GENE	17	17	extended
NCT000041229	NCT00004122_9_T2	PHENOTYPE	11	11	tolerance
NCT0000412211	NCT00004122_11_T0	GENE	6	6	BCG
NCT0000412211	NCT00004122_11_T1	GENE	9	9	BCG
NCT0000412211	NCT00004122_11_T2	GENE	13	13	BCG
NCT0000412211	NCT00004122_11_T3	GENE	17	17	BCG
NCT0000412211	NCT00004122_11_T4	GENE	19	19	BCG
NCT0000412211	NCT00004122_11_T5	GENE	23	23	BCG
NCT0000412211	NCT00004122_11_T6	GENE	29	29	BCG
NCT0000412211	NCT00004122_11_T7	GENE	25	25	interferon
NCT0000412211	NCT00004122_11_T8	PHENOTYPE	10	10	tolerance
NCT0000412212	NCT00004122_12_T0	GENE	9	9	BCG
NCT0000412212	NCT00004122_12_T1	GENE	11	11	interferon
NCT0000412213	NCT00004122_13_T0	PHENOTYPE	3	3	recurrence
NCT0000412215	NCT00004122_15_T0	GENE	17	17	BCG
NCT0000412215	NCT00004122_15_T1	GENE	19	19	interferon
NCT0000412217	NCT00004122_17_T0	PHENOTYPE	0	2	Quality of life
NCT0000412218	NCT00004122_18_T0	GENE	13	13	1.5
NCT000041231	NCT00004123_1_T0	CELL	10	10	cells
NCT000041231	NCT00004123_1_T1	PHENOTYPE	9	9	tumor
NCT000041232	NCT00004123_2_T0	CELL	9	9	cells
NCT000041232	NCT00004123_2_T1	PHENOTYPE	8	8	tumor
NCT000041233	NCT00004123_3_T0	COMPOUND	12	12	doxorubicin
NCT000041233	NCT00004123_3_T1	PHENOTYPE	21	21	recurrent
NCT000041233	NCT00004123_3_T2	PHENOTYPE	23	25	soft tissue sarcoma
NCT000041236	NCT00004123_6_T0	PHENOTYPE	2	2	toxicity
NCT000041236	NCT00004123_6_T1	COMPOUND	15	15	doxorubicin
NCT000041236	NCT00004123_6_T2	PHENOTYPE	27	27	recurrent
NCT000041236	NCT00004123_6_T3	PHENOTYPE	28	30	soft tissue sarcoma
NCT0000412310	NCT00004123_10_T0	COMPOUND	2	2	doxorubicin
NCT0000412310	NCT00004123_10_T1	COMPOUND	8	8	doxorubicin
NCT0000412310	NCT00004123_10_T2	GENE	3	3	IV
NCT0000412310	NCT00004123_10_T3	GENE	9	9	IV
NCT0000412311	NCT00004123_11_T0	PHENOTYPE	10	11	primary tumor
NCT0000412313	NCT00004123_13_T0	GENE	16	16	MTD
NCT0000412314	NCT00004123_14_T0	PHENOTYPE	18	18	toxicity
NCT0000412314	NCT00004123_14_T1	GENE	1	1	MTD
NCT000041242	NCT00004124_2_T0	CELL	10	10	cells
NCT000041242	NCT00004124_2_T1	PHENOTYPE	9	9	tumor
NCT000041249	NCT00004124_9_T0	PHENOTYPE	16	16	toxicity
NCT000041249	NCT00004124_9_T1	PHENOTYPE	12	13	disease progression
NCT000041250	NCT00004125_0_T0	GENE	7	7	II
NCT000041250	NCT00004125_0_T1	TISSUE	18	19	Lymph Nodes
NCT000041250	NCT00004125_0_T2	PHENOTYPE	9	12	Stage IIIA Breast Cancer
NCT000041252	NCT00004125_2_T0	PHENOTYPE	13	14	breast cancer
NCT000041253	NCT00004125_3_T0	GENE	22	22	II
NCT000041253	NCT00004125_3_T1	GENE	3	3	III
NCT000041253	NCT00004125_3_T2	GENE	29	29	has
NCT000041253	NCT00004125_3_T3	TISSUE	33	34	lymph nodes
NCT000041253	NCT00004125_3_T4	PHENOTYPE	24	27	stage IIIA breast cancer
NCT000041256	NCT00004125_6_T0	GENE	19	19	1.3
NCT000041256	NCT00004125_6_T1	PHENOTYPE	32	32	tumor
NCT000041256	NCT00004125_6_T2	GENE	38	38	cm
NCT000041256	NCT00004125_6_T3	GENE	43	43	cm
NCT000041256	NCT00004125_6_T4	GENE	13	13	nodal
NCT000041256	NCT00004125_6_T5	GENE	5	6	estrogen receptor
NCT0000412511	NCT00004125_11_T0	COMPOUND	6	6	docetaxel
NCT0000412511	NCT00004125_11_T1	GENE	7	7	IV
NCT0000412512	NCT00004125_12_T0	COMPOUND	9	9	estrogen
NCT0000412512	NCT00004125_12_T1	PHENOTYPE	14	14	tumors
NCT0000412512	NCT00004125_12_T2	COMPOUND	17	17	tamoxifen
NCT0000412512	NCT00004125_12_T3	PHENOTYPE	11	13	progesterone receptor positive
NCT000041262	NCT00004126_2_T0	CELL	9	9	cells
NCT000041262	NCT00004126_2_T1	PHENOTYPE	8	8	tumor
NCT000041267	NCT00004126_7_T0	PHENOTYPE	9	9	toxicities
NCT000041267	NCT00004126_7_T1	PHENOTYPE	6	7	tumor progression
NCT000041269	NCT00004126_9_T0	PHENOTYPE	3	3	toxicity
NCT000041269	NCT00004126_9_T1	COMPOUND	12	12	creatinine
NCT0000412611	NCT00004126_11_T0	COMPOUND	2	2	paclitaxel
NCT0000412611	NCT00004126_11_T1	COMPOUND	9	9	oxaliplatin
NCT0000412611	NCT00004126_11_T2	GENE	3	3	IV
NCT0000412611	NCT00004126_11_T3	GENE	10	10	IV
NCT0000412612	NCT00004126_12_T0	PHENOTYPE	13	13	toxicity
NCT0000412612	NCT00004126_12_T1	PHENOTYPE	9	10	disease progression
NCT000041271	NCT00004127_1_T0	CELL	9	9	cells
NCT000041271	NCT00004127_1_T1	PHENOTYPE	8	8	tumor
NCT000041272	NCT00004127_2_T0	GENE	2	2	II
NCT000041272	NCT00004127_2_T1	COMPOUND	10	10	oxaliplatin
NCT000041272	NCT00004127_2_T2	COMPOUND	14	14	leucovorin
NCT000041272	NCT00004127_2_T3	PHENOTYPE	20	20	recurrent
NCT000041272	NCT00004127_2_T4	PHENOTYPE	22	23	metastatic cancer
NCT000041272	NCT00004127_2_T5	PHENOTYPE	23	26	cancer of the esophagus
NCT000041274	NCT00004127_4_T0	COMPOUND	25	25	calcium
NCT000041274	NCT00004127_4_T1	ORGAN	16	16	cardia
NCT000041274	NCT00004127_4_T2	COMPOUND	21	21	oxaliplatin
NCT000041274	NCT00004127_4_T3	COMPOUND	24	24	leucovorin
NCT000041274	NCT00004127_4_T4	PHENOTYPE	7	7	recurrent
NCT000041274	NCT00004127_4_T5	PHENOTYPE	9	13	metastatic carcinoma of the esophagus
NCT000041278	NCT00004127_8_T0	PHENOTYPE	2	2	toxicity
NCT000041278	NCT00004127_8_T1	PHENOTYPE	4	4	neurotoxicity
NCT0000412710	NCT00004127_10_T0	COMPOUND	12	12	calcium
NCT0000412710	NCT00004127_10_T1	COMPOUND	2	2	oxaliplatin
NCT0000412710	NCT00004127_10_T2	COMPOUND	11	11	leucovorin
NCT0000412710	NCT00004127_10_T3	GENE	3	3	IV
NCT0000412710	NCT00004127_10_T4	GENE	13	13	IV
NCT0000412710	NCT00004127_10_T5	GENE	19	19	IV
NCT0000412710	NCT00004127_10_T6	GENE	24	24	IV
NCT0000412711	NCT00004127_11_T0	PHENOTYPE	19	19	toxicity
NCT0000412711	NCT00004127_11_T1	PHENOTYPE	15	16	disease progression
NCT000041281	NCT00004128_1_T0	CELL	2	3	stem cells
NCT000041281	NCT00004128_1_T1	ORGAN	11	12	bone marrow
NCT000041283	NCT00004128_3_T0	CELL	13	13	cells
NCT000041283	NCT00004128_3_T1	CELL	1	2	stem cells
NCT000041284	NCT00004128_4_T0	CELL	11	11	cells
NCT000041284	NCT00004128_4_T1	GENE	0	0	Interleukin-2
NCT000041284	NCT00004128_4_T2	CELL	5	7	white blood cells
NCT000041288	NCT00004128_8_T0	GENE	10	10	WBC
NCT000041288	NCT00004128_8_T1	GENE	28	28	60
NCT0000412811	NCT00004128_11_T0	ORGAN	1	2	bone marrow
NCT000041291	NCT00004129_1_T0	COMPOUND	14	14	phosphorus
NCT000041291	NCT00004129_1_T1	PHENOTYPE	20	21	glioblastoma multiforme
NCT000041294	NCT00004129_4_T0	GENE	5	5	P32
NCT000041294	NCT00004129_4_T1	GENE	7	7	P32
NCT000041294	NCT00004129_4_T2	COMPOUND	4	4	phosphorus
NCT000041295	NCT00004129_5_T0	PHENOTYPE	13	13	toxicity
NCT000041295	NCT00004129_5_T1	PHENOTYPE	9	10	disease progression
NCT000041296	NCT00004129_6_T0	GENE	15	15	MTD
NCT000041296	NCT00004129_6_T1	GENE	9	9	P32
NCT000041297	NCT00004129_7_T0	PHENOTYPE	14	14	toxicity
NCT000041297	NCT00004129_7_T1	GENE	1	1	MTD
NCT000041325	NCT00004132_5_T0	GENE	10	10	2.4
NCT000041325	NCT00004132_5_T1	PHENOTYPE	11	11	diarrhea
NCT000041325	NCT00004132_5_T2	PHENOTYPE	7	8	oral mucositis
NCT000041325	NCT00004132_5_T3	PHENOTYPE	13	14	febrile neutropenia
NCT000041327	NCT00004132_7_T0	PHENOTYPE	20	20	infections
NCT000041327	NCT00004132_7_T1	GENE	12	12	IV
NCT000041327	NCT00004132_7_T2	PHENOTYPE	17	18	febrile neutropenia
NCT000041329	NCT00004132_9_T0	PHENOTYPE	2	4	quality of life
NCT0000413216	NCT00004132_16_T0	PHENOTYPE	5	5	conditioning
NCT0000413217	NCT00004132_17_T0	GENE	11	11	11
NCT0000413217	NCT00004132_17_T1	PHENOTYPE	1	1	conditioning
NCT0000413217	NCT00004132_17_T2	GENE	12	12	10
NCT0000413220	NCT00004132_20_T0	GENE	4	4	SC
NCT0000413220	NCT00004132_20_T1	GENE	1	1	G-CSF
NCT0000413220	NCT00004132_20_T2	GENE	2	2	IV
NCT0000413221	NCT00004132_21_T0	GENE	13	13	11
NCT0000413221	NCT00004132_21_T1	GENE	12	12	12
NCT0000413221	NCT00004132_21_T2	GENE	11	11	13
NCT0000413221	NCT00004132_21_T3	PHENOTYPE	0	0	Secondary
NCT0000413221	NCT00004132_21_T4	PHENOTYPE	1	1	conditioning
NCT0000413223	NCT00004132_23_T0	COMPOUND	2	2	ifosfamide
NCT0000413223	NCT00004132_23_T1	COMPOUND	17	17	2
NCT0000413223	NCT00004132_23_T2	COMPOUND	9	9	etoposide
NCT0000413223	NCT00004132_23_T3	GENE	3	3	IV
NCT0000413224	NCT00004132_24_T0	GENE	3	3	SC
NCT0000413224	NCT00004132_24_T1	GENE	0	0	G-CSF
NCT0000413224	NCT00004132_24_T2	GENE	1	1	IV
NCT0000413225	NCT00004132_25_T0	GENE	9	9	11
NCT0000413225	NCT00004132_25_T1	PHENOTYPE	0	2	Quality of life
NCT000041354	NCT00004135_4_T0	COMPOUND	23	23	2
NCT000041354	NCT00004135_4_T1	COMPOUND	21	21	3
NCT000041354	NCT00004135_4_T2	COMPOUND	3	3	fludarabine
NCT000041354	NCT00004135_4_T3	COMPOUND	14	14	cyclophosphamide
NCT000041354	NCT00004135_4_T4	GENE	4	4	IV
NCT000041354	NCT00004135_4_T5	GENE	15	15	IV
NCT000041355	NCT00004135_5_T0	CELL	27	27	cells
NCT000041355	NCT00004135_5_T1	GENE	14	14	IV
NCT000041355	NCT00004135_5_T2	CELL	9	12	peripheral blood stem cells
NCT000041356	NCT00004135_6_T0	GENE	2	2	filgrastim
NCT000041356	NCT00004135_6_T1	GENE	3	3	G-CSF
NCT000041357	NCT00004135_7_T0	GENE	34	34	IV
NCT000041357	NCT00004135_7_T1	PHENOTYPE	20	20	recurrence
NCT000041357	NCT00004135_7_T2	BIOLOGICAL_PROCESS	25	25	hematopoiesis
NCT000041357	NCT00004135_7_T3	GENE	6	6	has
NCT000041357	NCT00004135_7_T4	CELL	32	33	T lymphocytes
NCT000041357	NCT00004135_7_T5	PHENOTYPE	17	18	disease progression
NCT000041357	NCT00004135_7_T6	PHENOTYPE	2	5	graft versus host disease
NCT000041358	NCT00004135_8_T0	CELL	8	9	T lymphocytes
NCT000041362	NCT00004136_2_T0	GENE	2	2	II
NCT000041362	NCT00004136_2_T1	PHENOTYPE	19	21	metastatic liver cancer
NCT000041364	NCT00004136_4_T0	PHENOTYPE	11	13	metastatic liver cancer
NCT000041366	NCT00004136_6_T0	PHENOTYPE	5	5	recurrence
NCT000041366	NCT00004136_6_T1	PHENOTYPE	14	14	recurrence
NCT000041367	NCT00004136_7_T0	PHENOTYPE	12	12	tumors
NCT000041368	NCT00004136_8_T0	PHENOTYPE	0	0	Tumors
NCT000041369	NCT00004136_9_T0	GENE	4	4	cm
NCT0000413610	NCT00004136_10_T0	PHENOTYPE	5	5	tumor
NCT000041372	NCT00004137_2_T0	CELL	9	9	cells
NCT000041372	NCT00004137_2_T1	PHENOTYPE	8	8	tumor
NCT000041373	NCT00004137_3_T0	PHENOTYPE	17	17	peripheral
NCT000041373	NCT00004137_3_T1	CELL	11	11	cells
NCT000041373	NCT00004137_3_T2	GENE	4	4	filgrastim
NCT000041373	NCT00004137_3_T3	ORGAN	14	15	bone marrow
NCT000041373	NCT00004137_3_T4	ORGAN	24	25	immune system
NCT000041373	NCT00004137_3_T5	PHENOTYPE	30	32	effects of chemotherapy
NCT000041378	NCT00004137_8_T0	PHENOTYPE	5	5	toxicity
NCT000041379	NCT00004137_9_T0	COMPOUND	12	12	paclitaxel
NCT000041379	NCT00004137_9_T1	GENE	10	10	1.4
NCT000041379	NCT00004137_9_T2	GENE	4	4	IV
NCT000041379	NCT00004137_9_T3	GENE	13	13	IV
NCT000041379	NCT00004137_9_T4	GENE	20	20	IV
NCT000041379	NCT00004137_9_T5	COMPOUND	3	3	topotecan
NCT000041379	NCT00004137_9_T6	COMPOUND	26	26	topotecan
NCT0000413710	NCT00004137_10_T0	GENE	2	2	filgrastim
NCT0000413710	NCT00004137_10_T1	GENE	3	3	G-CSF
NCT0000413711	NCT00004137_11_T0	GENE	0	0	G-CSF
NCT0000413712	NCT00004137_12_T0	PHENOTYPE	16	16	toxicity
NCT0000413712	NCT00004137_12_T1	PHENOTYPE	12	13	disease progression
NCT000041384	NCT00004138_4_T0	PHENOTYPE	0	0	Secondary
NCT000041385	NCT00004138_5_T0	GENE	5	5	FDG
NCT000041385	NCT00004138_5_T1	GENE	6	6	IV
NCT000041385	NCT00004138_5_T2	COMPOUND	2	4	fludeoxyglucose F 18
NCT000041387	NCT00004138_7_T0	PHENOTYPE	7	7	metastases
NCT000041387	NCT00004138_7_T1	GENE	4	4	nodal
NCT0000413812	NCT00004138_12_T0	GENE	0	0	OR
NCT0000413812	NCT00004138_12_T1	PHENOTYPE	29	30	lung tumor
NCT0000413817	NCT00004138_17_T0	GENE	12	12	II
NCT0000413817	NCT00004138_17_T1	GENE	14	14	IIIa
NCT0000413823	NCT00004138_23_T0	COMPOUND	36	36	furosemide
NCT0000413823	NCT00004138_23_T1	ORGAN	9	9	serum
NCT0000413823	NCT00004138_23_T2	PHENOTYPE	29	30	radiation exposure
NCT0000413829	NCT00004138_29_T0	PHENOTYPE	11	11	NSCLC
NCT0000413829	NCT00004138_29_T1	GENE	2	2	had
NCT0000413829	NCT00004138_29_T2	GENE	1	1	has
NCT0000413831	NCT00004138_31_T0	GENE	24	24	MRI
NCT0000413831	NCT00004138_31_T1	ORGAN	20	20	abdomen
NCT0000413831	NCT00004138_31_T2	GENE	1	1	has
NCT0000413831	NCT00004138_31_T3	GENE	7	7	IV
NCT000041392	NCT00004139_2_T0	CELL	9	9	cells
NCT000041392	NCT00004139_2_T1	PHENOTYPE	8	8	tumor
NCT000041397	NCT00004139_7_T0	PHENOTYPE	11	11	toxicity
NCT000041399	NCT00004139_9_T0	GENE	11	11	IV
NCT000041399	NCT00004139_9_T1	GENE	17	17	IV
NCT0000413913	NCT00004139_13_T0	PHENOTYPE	13	13	toxicity
NCT0000413913	NCT00004139_13_T1	PHENOTYPE	9	10	disease progression
NCT0000413915	NCT00004139_15_T0	PHENOTYPE	20	21	disease progression
NCT000041412	NCT00004141_2_T0	CELL	15	15	cells
NCT000041412	NCT00004141_2_T1	PHENOTYPE	14	14	tumor
NCT000041413	NCT00004141_3_T0	GENE	2	2	II
NCT000041413	NCT00004141_3_T1	PHENOTYPE	19	20	metastatic melanoma
NCT000041415	NCT00004141_5_T0	GENE	23	23	SC
NCT000041415	NCT00004141_5_T1	GENE	28	28	SC
NCT000041415	NCT00004141_5_T2	GENE	35	35	SC
NCT000041415	NCT00004141_5_T3	GENE	27	27	interleukin-2
NCT000041415	NCT00004141_5_T4	GENE	26	26	2.7
NCT000041415	NCT00004141_5_T5	GENE	21	21	GM-CSF
NCT000041415	NCT00004141_5_T6	COMPOUND	3	3	cisplatin
NCT000041415	NCT00004141_5_T7	GENE	33	33	interferon
NCT000041415	NCT00004141_5_T8	GENE	4	4	IV
NCT000041415	NCT00004141_5_T9	GENE	10	10	IV
NCT000041415	NCT00004141_5_T10	GENE	20	20	sargramostim
NCT000041415	NCT00004141_5_T11	COMPOUND	9	9	dacarbazine
NCT000041416	NCT00004141_6_T0	PHENOTYPE	13	13	toxicity
NCT000041416	NCT00004141_6_T1	PHENOTYPE	9	10	disease progression
NCT000041417	NCT00004141_7_T0	PHENOTYPE	7	8	disease progression
NCT000041421	NCT00004142_1_T0	CELL	10	10	cells
NCT000041421	NCT00004142_1_T1	PHENOTYPE	9	9	tumor
NCT000041422	NCT00004142_2_T0	PHENOTYPE	13	13	tumors
NCT000041422	NCT00004142_2_T1	ORGAN	9	9	liver
NCT000041422	NCT00004142_2_T2	ORGAN	5	6	blood vessels
NCT000041423	NCT00004142_3_T0	ORGAN	16	16	liver
NCT000041423	NCT00004142_3_T1	GENE	12	12	has
NCT000041423	NCT00004142_3_T2	PHENOTYPE	9	10	colorectal cancer
NCT000041424	NCT00004142_4_T0	GENE	2	2	II
NCT000041424	NCT00004142_4_T1	ORGAN	22	22	liver
NCT000041424	NCT00004142_4_T2	ORGAN	35	35	liver
NCT000041424	NCT00004142_4_T3	GENE	31	31	has
NCT000041424	NCT00004142_4_T4	PHENOTYPE	28	29	colorectal cancer
NCT000041424	NCT00004142_4_T5	ORGAN	18	19	blood vessels
NCT000041428	NCT00004142_8_T0	ORGAN	26	26	liver
NCT000041428	NCT00004142_8_T1	PHENOTYPE	21	22	colorectal cancer
NCT000041428	NCT00004142_8_T2	PHENOTYPE	22	23	cancer metastatic
NCT000041429	NCT00004142_9_T0	ORGAN	13	13	liver
NCT000041429	NCT00004142_9_T1	PHENOTYPE	10	10	tumor
NCT000041429	NCT00004142_9_T2	PHENOTYPE	27	27	tumor
NCT0000414210	NCT00004142_10_T0	GENE	14	14	1.7
NCT000041434	NCT00004143_4_T0	PHENOTYPE	18	18	disorders
NCT000041434	NCT00004143_4_T1	ORGAN	16	17	bone marrow
NCT0000414311	NCT00004143_11_T0	PHENOTYPE	0	0	Secondary
NCT0000414314	NCT00004143_14_T0	PHENOTYPE	7	7	engraftment
NCT0000414319	NCT00004143_19_T0	PHENOTYPE	0	0	HIV
NCT0000414319	NCT00004143_19_T1	PHENOTYPE	1	2	antibody negative
NCT0000414323	NCT00004143_23_T0	PHENOTYPE	17	17	thalassemia
NCT0000414323	NCT00004143_23_T1	PHENOTYPE	3	4	cerebrovascular accident
NCT0000414325	NCT00004143_25_T0	COMPOUND	20	20	MUGA
NCT0000414325	NCT00004143_25_T1	ORGAN	4	4	transplant
NCT0000414325	NCT00004143_25_T2	PHENOTYPE	14	16	left ventricular dysfunction
NCT0000414326	NCT00004143_26_T0	GENE	0	0	II
NCT0000414326	NCT00004143_26_T1	PHENOTYPE	4	4	Disorders
NCT0000414326	NCT00004143_26_T2	PHENOTYPE	1	3	Bone marrow failure
NCT0000414327	NCT00004143_27_T0	CELL	14	14	neutrophil
NCT0000414327	NCT00004143_27_T1	PHENOTYPE	3	3	Cytopenia
NCT0000414327	NCT00004143_27_T2	COMPOUND	12	12	3
NCT0000414327	NCT00004143_27_T3	PHENOTYPE	25	26	reticulocyte count
NCT0000414327	NCT00004143_27_T4	PHENOTYPE	19	20	platelet count
NCT0000414327	NCT00004143_27_T5	PHENOTYPE	0	2	Severe Aplastic Anemia
NCT000041441	NCT00004144_1_T0	CELL	9	9	cells
NCT000041441	NCT00004144_1_T1	PHENOTYPE	8	8	tumor
NCT000041442	NCT00004144_2_T0	COMPOUND	12	12	gemcitabine
NCT000041442	NCT00004144_2_T1	GENE	21	21	has
NCT000041442	NCT00004144_2_T2	PHENOTYPE	18	19	advanced cancer
NCT000041442	NCT00004144_2_T3	COMPOUND	9	10	bryostatin 1
NCT000041445	NCT00004144_5_T0	COMPOUND	2	2	gemcitabine
NCT000041445	NCT00004144_5_T1	GENE	3	3	IV
NCT000041445	NCT00004144_5_T2	GENE	12	12	IV
NCT000041445	NCT00004144_5_T3	COMPOUND	10	11	bryostatin 1
NCT000041446	NCT00004144_6_T0	PHENOTYPE	10	10	toxicity
NCT000041446	NCT00004144_6_T1	PHENOTYPE	12	13	disease progression
NCT000041447	NCT00004144_7_T0	COMPOUND	8	8	gemcitabine
NCT000041447	NCT00004144_7_T1	GENE	17	17	MTD
NCT000041447	NCT00004144_7_T2	COMPOUND	10	11	bryostatin 1
NCT000041448	NCT00004144_8_T0	PHENOTYPE	18	18	toxic
NCT000041448	NCT00004144_8_T1	GENE	1	1	MTD
NCT000041452	NCT00004145_2_T0	CELL	3	3	cells
NCT000041452	NCT00004145_2_T1	TISSUE	10	10	tissues
NCT000041453	NCT00004145_3_T0	GENE	1	1	globulin
NCT000041458	NCT00004145_8_T0	PHENOTYPE	2	2	toxicities
NCT0000414512	NCT00004145_12_T0	PHENOTYPE	4	4	toxicity
NCT0000414512	NCT00004145_12_T1	PHENOTYPE	10	10	relapse
NCT0000414512	NCT00004145_12_T2	CELL	7	7	leukocyte
NCT0000414517	NCT00004145_17_T0	COMPOUND	32	32	2
NCT0000414517	NCT00004145_17_T1	COMPOUND	3	3	fludarabine
NCT0000414517	NCT00004145_17_T2	COMPOUND	13	13	cyclophosphamide
NCT0000414517	NCT00004145_17_T3	GENE	23	23	globulin
NCT0000414517	NCT00004145_17_T4	GENE	4	4	IV
NCT0000414517	NCT00004145_17_T5	GENE	14	14	IV
NCT0000414517	NCT00004145_17_T6	GENE	24	24	IV
NCT0000414518	NCT00004145_18_T0	CELL	1	4	peripheral blood stem cells
NCT0000414519	NCT00004145_19_T0	PHENOTYPE	8	8	relapse
NCT0000414519	NCT00004145_19_T1	CELL	22	22	leukocyte
NCT0000414519	NCT00004145_19_T2	PHENOTYPE	4	4	remission
NCT0000414519	NCT00004145_19_T3	GENE	5	5	CR
NCT0000414519	NCT00004145_19_T4	GENE	16	16	CR
NCT0000414524	NCT00004145_24_T0	PHENOTYPE	18	18	lymphoma
NCT0000414524	NCT00004145_24_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000414524	NCT00004145_24_T2	PHENOTYPE	16	17	high grade
NCT000041461	NCT00004146_1_T0	CELL	8	8	cells
NCT000041461	NCT00004146_1_T1	PHENOTYPE	7	7	tumor
NCT000041462	NCT00004146_2_T0	CELL	9	9	cells
NCT000041462	NCT00004146_2_T1	PHENOTYPE	8	8	tumor
NCT000041463	NCT00004146_3_T0	GENE	1	1	II
NCT000041463	NCT00004146_3_T1	COMPOUND	8	8	carboxyamidotriazole
NCT000041463	NCT00004146_3_T2	PHENOTYPE	19	21	supratentorial glioblastoma multiforme
NCT000041465	NCT00004146_5_T0	COMPOUND	9	9	carboxyamidotriazole
NCT000041465	NCT00004146_5_T1	PHENOTYPE	18	19	glioblastoma multiforme
NCT000041467	NCT00004146_7_T0	PHENOTYPE	3	3	toxicity
NCT000041469	NCT00004146_9_T0	PHENOTYPE	12	12	toxicity
NCT0000414611	NCT00004146_11_T0	PHENOTYPE	6	6	progression
NCT0000414613	NCT00004146_13_T0	COMPOUND	15	15	carboxyamidotriazole
NCT0000414613	NCT00004146_13_T1	COMPOUND	23	23	carboxyamidotriazole
NCT0000414614	NCT00004146_14_T0	PHENOTYPE	18	18	toxicity
NCT0000414614	NCT00004146_14_T1	COMPOUND	4	4	carboxyamidotriazole
NCT0000414614	NCT00004146_14_T2	PHENOTYPE	14	15	disease progression
NCT0000414616	NCT00004146_16_T0	GENE	14	14	1.5
NCT000041472	NCT00004147_2_T0	PHENOTYPE	15	15	progressive
NCT000041472	NCT00004147_2_T1	PHENOTYPE	17	19	recurrent brain tumors
NCT000041476	NCT00004147_6_T0	PHENOTYPE	13	13	toxicity
NCT000041476	NCT00004147_6_T1	PHENOTYPE	9	10	disease progression
NCT000041477	NCT00004147_7_T0	GENE	14	14	MTD
NCT000041481	NCT00004148_1_T0	CELL	12	12	cells
NCT000041481	NCT00004148_1_T1	PHENOTYPE	11	11	tumor
NCT000041481	NCT00004148_1_T2	BIOLOGICAL_PROCESS	7	8	immune response
NCT000041483	NCT00004148_3_T0	PHENOTYPE	20	20	toxicity
NCT000041483	NCT00004148_3_T1	BIOLOGICAL_PROCESS	13	14	immune response
NCT000041483	NCT00004148_3_T2	PHENOTYPE	25	26	metastatic melanoma
NCT000041485	NCT00004148_5_T0	PHENOTYPE	3	3	toxicities
NCT0000414811	NCT00004148_11_T0	PHENOTYPE	8	8	immunity
NCT0000414811	NCT00004148_11_T1	CELL	7	7	T-cell
NCT0000414815	NCT00004148_15_T0	PHENOTYPE	1	3	quality of life
NCT0000414818	NCT00004148_18_T0	PHENOTYPE	10	10	toxicity
NCT0000414818	NCT00004148_18_T1	PHENOTYPE	12	13	disease progression
NCT0000414819	NCT00004148_19_T0	GENE	14	14	MTD
NCT0000414820	NCT00004148_20_T0	PHENOTYPE	22	22	toxicities
NCT0000414820	NCT00004148_20_T1	GENE	1	1	MTD
NCT0000414821	NCT00004148_21_T0	PHENOTYPE	0	2	Quality of life
NCT000041493	NCT00004149_3_T0	GENE	11	11	1.5
NCT000041493	NCT00004149_3_T1	GENE	5	5	IV
NCT000041493	NCT00004149_3_T2	COMPOUND	3	4	arsenic trioxide
NCT000041502	NCT00004150_2_T0	PHENOTYPE	12	13	colon cancer
NCT000041503	NCT00004150_3_T0	GENE	4	4	III
NCT000041503	NCT00004150_3_T1	COMPOUND	13	13	leucovorin
NCT000041503	NCT00004150_3_T2	COMPOUND	25	25	leucovorin
NCT000041503	NCT00004150_3_T3	PHENOTYPE	34	37	stage III colon cancer
NCT000041506	NCT00004150_6_T0	GENE	15	15	N2
NCT000041506	NCT00004150_6_T1	GENE	10	10	1.3
NCT000041506	NCT00004150_6_T2	TISSUE	12	13	lymph nodes
NCT000041506	NCT00004150_6_T3	TISSUE	20	21	lymph nodes
NCT000041506	NCT00004150_6_T4	TISSUE	6	7	lymph node
NCT0000415014	NCT00004150_14_T0	GENE	10	10	4.5
NCT000041516	NCT00004151_6_T0	PHENOTYPE	4	4	pharmacokinetics
NCT000041516	NCT00004151_6_T1	PHENOTYPE	2	2	toxicities
NCT000041518	NCT00004151_8_T0	GENE	4	4	IV
NCT000041518	NCT00004151_8_T1	COMPOUND	2	3	acridine carboxamide
NCT000041519	NCT00004151_9_T0	PHENOTYPE	19	19	toxicity
NCT000041519	NCT00004151_9_T1	PHENOTYPE	15	16	disease progression
NCT0000415110	NCT00004151_10_T0	PHENOTYPE	7	8	disease progression
NCT000041520	NCT00004152_0_T0	PHENOTYPE	13	13	Melanoma
NCT000041520	NCT00004152_0_T1	GENE	9	9	III
NCT000041520	NCT00004152_0_T2	GENE	12	12	IV
NCT000041522	NCT00004152_2_T0	GENE	2	2	II
NCT000041522	NCT00004152_2_T1	PHENOTYPE	21	22	stage III
NCT000041522	NCT00004152_2_T2	PHENOTYPE	15	16	metastatic disease
NCT000041522	NCT00004152_2_T3	PHENOTYPE	24	26	stage IV melanoma
NCT000041524	NCT00004152_4_T0	GENE	10	10	FDG
NCT000041524	NCT00004152_4_T1	PHENOTYPE	27	27	melanoma
NCT000041524	NCT00004152_4_T2	GENE	26	26	IV
NCT000041524	NCT00004152_4_T3	PHENOTYPE	23	24	stage III
NCT000041524	NCT00004152_4_T4	PHENOTYPE	18	19	metastatic disease
NCT000041524	NCT00004152_4_T5	COMPOUND	7	9	fludeoxyglucose F 18
NCT000041526	NCT00004152_6_T0	GENE	13	13	FDG
NCT000041528	NCT00004152_8_T0	GENE	3	3	FDG
NCT000041528	NCT00004152_8_T1	GENE	6	6	IV
NCT000041529	NCT00004152_9_T0	GENE	2	2	dye
NCT000041529	NCT00004152_9_T1	ORGAN	18	18	abdomen
NCT000041529	NCT00004152_9_T2	ORGAN	20	20	pelvis
NCT000041529	NCT00004152_9_T3	GENE	6	6	IV
NCT0000415210	NCT00004152_10_T0	ORGAN	11	11	abdomen
NCT0000415210	NCT00004152_10_T1	GENE	2	2	FDG
NCT0000415210	NCT00004152_10_T2	ORGAN	13	13	pelvis
NCT0000415211	NCT00004152_11_T0	PHENOTYPE	13	14	biopsy findings
NCT000041531	NCT00004153_1_T0	PHENOTYPE	12	12	peripheral
NCT000041531	NCT00004153_1_T1	PHENOTYPE	5	5	melanoma
NCT000041531	NCT00004153_1_T2	PHENOTYPE	18	18	melanoma
NCT000041531	NCT00004153_1_T3	TISSUE	9	10	lymph nodes
NCT000041533	NCT00004153_3_T0	PHENOTYPE	5	5	peripheral
NCT000041533	NCT00004153_3_T1	TISSUE	1	2	Lymph node
NCT000041534	NCT00004153_4_T0	PHENOTYPE	15	15	tumor
NCT000041534	NCT00004153_4_T1	GENE	5	5	nested
NCT000041541	NCT00004154_1_T0	PHENOTYPE	16	16	recurrence
NCT000041541	NCT00004154_1_T1	PHENOTYPE	25	25	tumor
NCT000041541	NCT00004154_1_T2	COMPOUND	6	6	fenretinide
NCT000041541	NCT00004154_1_T3	PHENOTYPE	18	19	bladder cancer
NCT000041542	NCT00004154_2_T0	GENE	4	4	III
NCT000041542	NCT00004154_2_T1	PHENOTYPE	35	35	tumor
NCT000041542	NCT00004154_2_T2	COMPOUND	8	8	fenretinide
NCT000041542	NCT00004154_2_T3	PHENOTYPE	27	29	recurrent bladder cancer
NCT000041546	NCT00004154_6_T0	PHENOTYPE	7	7	multifocal
NCT000041546	NCT00004154_6_T1	GENE	9	9	solitary
NCT000041548	NCT00004154_8_T0	COMPOUND	4	4	fenretinide
NCT000041563	NCT00004156_3_T0	GENE	24	24	1.3
NCT000041563	NCT00004156_3_T1	GENE	4	4	MUC-1
NCT000041563	NCT00004156_3_T2	GENE	12	12	limpet
NCT000041570	NCT00004157_0_T0	PHENOTYPE	16	17	Breast Cancer
NCT000041570	NCT00004157_0_T1	PHENOTYPE	14	15	Hodgkin's Disease
NCT000041570	NCT00004157_0_T2	PHENOTYPE	20	21	Solid Tumors
NCT000041570	NCT00004157_0_T3	PHENOTYPE	12	13	Non-Hodgkin's Lymphoma
NCT000041570	NCT00004157_0_T4	CELL	5	7	Peripheral Stem Cell
NCT000041575	NCT00004157_5_T0	GENE	8	8	G-CSF
NCT000041575	NCT00004157_5_T1	GENE	5	5	IL-11
NCT000041575	NCT00004157_5_T2	GENE	7	7	filgrastim
NCT000041575	NCT00004157_5_T3	GENE	4	4	interleukin-11
NCT000041575	NCT00004157_5_T4	PHENOTYPE	16	17	breast cancer
NCT000041575	NCT00004157_5_T5	PHENOTYPE	20	21	solid tumors
NCT000041575	NCT00004157_5_T6	PHENOTYPE	14	15	Hodgkin's disease
NCT000041575	NCT00004157_5_T7	PHENOTYPE	12	13	Hodgkin's lymphoma
NCT000041577	NCT00004157_7_T0	CELL	6	6	cells
NCT000041577	NCT00004157_7_T1	CELL	21	21	cells
NCT000041577	NCT00004157_7_T2	GENE	5	5	CD34
NCT000041577	NCT00004157_7_T3	GENE	20	20	CD34
NCT0000415710	NCT00004157_10_T0	GENE	4	4	IL-11
NCT0000415710	NCT00004157_10_T1	GENE	11	11	filgrastim
NCT0000415710	NCT00004157_10_T2	COMPOUND	9	9	1_10
NCT0000415710	NCT00004157_10_T3	GENE	12	12	G-CSF
NCT0000415710	NCT00004157_10_T4	GENE	3	3	interleukin-11
NCT000041581	NCT00004158_1_T0	CELL	10	10	cells
NCT000041587	NCT00004158_7_T0	PHENOTYPE	7	7	progression
NCT000041589	NCT00004158_9_T0	CELL	16	16	cells
NCT000041589	NCT00004158_9_T1	GENE	15	15	CD34
NCT000041589	NCT00004158_9_T2	CELL	5	8	peripheral blood stem cells
NCT0000415812	NCT00004158_12_T0	PHENOTYPE	19	19	falls
NCT0000415812	NCT00004158_12_T1	COMPOUND	10	10	melphalan
NCT0000415812	NCT00004158_12_T2	ORGAN	17	18	bone marrow
NCT0000415814	NCT00004158_14_T0	PHENOTYPE	18	18	toxicity
NCT0000415814	NCT00004158_14_T1	GENE	1	1	MTD
NCT000041592	NCT00004159_2_T0	CELL	9	9	cells
NCT000041592	NCT00004159_2_T1	PHENOTYPE	8	8	tumor
NCT000041599	NCT00004159_9_T0	COMPOUND	2	2	paclitaxel
NCT000041599	NCT00004159_9_T1	COMPOUND	12	12	gemcitabine
NCT000041599	NCT00004159_9_T2	GENE	3	3	IV
NCT000041599	NCT00004159_9_T3	GENE	13	13	IV
NCT0000415911	NCT00004159_11_T0	COMPOUND	8	8	paclitaxel
NCT0000415911	NCT00004159_11_T1	GENE	2	2	3.5
NCT0000415911	NCT00004159_11_T2	COMPOUND	10	10	gemcitabine
NCT0000415911	NCT00004159_11_T3	GENE	16	16	MTD
NCT0000415912	NCT00004159_12_T0	PHENOTYPE	18	18	toxicity
NCT0000415912	NCT00004159_12_T1	GENE	1	1	MTD
NCT0000415913	NCT00004159_13_T0	GENE	20	20	II
NCT0000415913	NCT00004159_13_T1	PHENOTYPE	13	13	NSCLC
NCT0000415913	NCT00004159_13_T2	GENE	2	2	MTD
NCT0000415915	NCT00004159_15_T0	GENE	27	27	II
NCT000041601	NCT00004160_1_T0	CELL	8	8	cells
NCT000041601	NCT00004160_1_T1	PHENOTYPE	7	7	tumor
NCT000041602	NCT00004160_2_T0	CELL	9	9	cells
NCT000041602	NCT00004160_2_T1	PHENOTYPE	8	8	tumor
NCT000041609	NCT00004160_9_T0	COMPOUND	6	6	paclitaxel
NCT000041609	NCT00004160_9_T1	PHENOTYPE	2	2	pharmacokinetics
NCT000041609	NCT00004160_9_T2	COMPOUND	4	4	gemcitabine
NCT0000416010	NCT00004160_10_T0	COMPOUND	8	8	gemcitabine
NCT0000416011	NCT00004160_11_T0	COMPOUND	4	4	gemcitabine
NCT0000416011	NCT00004160_11_T1	COMPOUND	15	15	cisplatin
NCT0000416011	NCT00004160_11_T2	GENE	5	5	IV
NCT0000416011	NCT00004160_11_T3	GENE	16	16	IV
NCT0000416013	NCT00004160_13_T0	COMPOUND	4	4	paclitaxel
NCT0000416013	NCT00004160_13_T1	COMPOUND	19	19	paclitaxel
NCT0000416013	NCT00004160_13_T2	COMPOUND	10	10	gemcitabine
NCT0000416013	NCT00004160_13_T3	GENE	5	5	IV
NCT0000416013	NCT00004160_13_T4	GENE	11	11	IV
NCT0000416015	NCT00004160_15_T0	GENE	2	2	3.5
NCT0000416015	NCT00004160_15_T1	COMPOUND	8	8	gemcitabine
NCT0000416015	NCT00004160_15_T2	GENE	14	14	MTD
NCT0000416016	NCT00004160_16_T0	PHENOTYPE	18	18	toxicity
NCT0000416016	NCT00004160_16_T1	GENE	1	1	MTD
NCT000041611	NCT00004161_1_T0	PHENOTYPE	8	8	leukoplakia
NCT000041612	NCT00004161_2_T0	GENE	3	3	II
NCT000041612	NCT00004161_2_T1	COMPOUND	10	10	fenretinide
NCT000041612	NCT00004161_2_T2	PHENOTYPE	16	19	leukoplakia of the mouth
NCT000041614	NCT00004161_4_T0	PHENOTYPE	16	16	dysplastic
NCT000041614	NCT00004161_4_T1	PHENOTYPE	11	11	carcinogenesis
NCT000041614	NCT00004161_4_T2	PHENOTYPE	17	17	leukoplakia
NCT000041614	NCT00004161_4_T3	COMPOUND	3	3	fenretinide
NCT000041616	NCT00004161_6_T0	PHENOTYPE	16	16	dysplastic
NCT000041616	NCT00004161_6_T1	PHENOTYPE	17	17	leukoplakia
NCT000041616	NCT00004161_6_T2	PHENOTYPE	13	13	regression
NCT000041616	NCT00004161_6_T3	COMPOUND	2	2	fenretinide
NCT000041618	NCT00004161_8_T0	COMPOUND	4	4	fenretinide
NCT0000416110	NCT00004161_10_T0	PHENOTYPE	4	4	recurrence
NCT0000416110	NCT00004161_10_T1	PHENOTYPE	7	7	dysplastic
NCT0000416110	NCT00004161_10_T2	PHENOTYPE	8	8	leukoplakia
NCT0000416110	NCT00004161_10_T3	COMPOUND	13	13	fenretinide
NCT0000416114	NCT00004161_14_T0	GENE	8	8	1.3
NCT0000416114	NCT00004161_14_T1	COMPOUND	4	4	fenretinide
NCT000041621	NCT00004162_1_T0	CELL	9	9	cells
NCT000041622	NCT00004162_2_T0	COMPOUND	10	10	doxorubicin
NCT000041622	NCT00004162_2_T1	PHENOTYPE	20	21	Hodgkin's lymphoma
NCT000041624	NCT00004162_4_T0	PHENOTYPE	2	2	toxicity
NCT000041624	NCT00004162_4_T1	COMPOUND	9	9	HCl
NCT000041624	NCT00004162_4_T2	COMPOUND	8	8	doxorubicin
NCT000041624	NCT00004162_4_T3	PHENOTYPE	20	21	Hodgkin's lymphoma
NCT000041626	NCT00004162_6_T0	GENE	4	4	II
NCT000041626	NCT00004162_6_T1	COMPOUND	8	8	HCl
NCT000041626	NCT00004162_6_T2	COMPOUND	7	7	doxorubicin
NCT000041628	NCT00004162_8_T0	PHENOTYPE	7	7	HIV
NCT0000416211	NCT00004162_11_T0	COMPOUND	9	9	HCl
NCT0000416211	NCT00004162_11_T1	COMPOUND	8	8	doxorubicin
NCT0000416213	NCT00004162_13_T0	COMPOUND	3	3	HCl
NCT0000416213	NCT00004162_13_T1	COMPOUND	6	6	vincristine
NCT0000416213	NCT00004162_13_T2	GENE	20	20	1.5
NCT0000416213	NCT00004162_13_T3	COMPOUND	9	9	methotrexate
NCT0000416213	NCT00004162_13_T4	COMPOUND	2	2	doxorubicin
NCT0000416213	NCT00004162_13_T5	COMPOUND	17	17	prednisone
NCT0000416213	NCT00004162_13_T6	GENE	5	5	IV
NCT0000416213	NCT00004162_13_T7	GENE	7	7	IV
NCT0000416214	NCT00004162_14_T0	GENE	1	1	GM-CSF
NCT0000416215	NCT00004162_15_T0	PHENOTYPE	18	18	toxicity
NCT0000416215	NCT00004162_15_T1	PHENOTYPE	14	15	disease progression
NCT0000416216	NCT00004162_16_T0	COMPOUND	9	9	HCl
NCT0000416216	NCT00004162_16_T1	COMPOUND	8	8	doxorubicin
NCT0000416216	NCT00004162_16_T2	GENE	16	16	MTD
NCT0000416217	NCT00004162_17_T0	PHENOTYPE	16	16	toxicity
NCT0000416217	NCT00004162_17_T1	GENE	1	1	MTD
NCT000041630	NCT00004163_0_T0	PHENOTYPE	6	8	Salivary Gland Cancer
NCT000041632	NCT00004163_2_T0	GENE	2	2	II
NCT000041632	NCT00004163_2_T1	PHENOTYPE	16	18	salivary gland cancer
NCT000041638	NCT00004163_8_T0	PHENOTYPE	11	14	metastatic salivary gland cancer
NCT0000416310	NCT00004163_10_T0	PHENOTYPE	4	4	progression
NCT0000416312	NCT00004163_12_T0	PHENOTYPE	2	2	toxicity
NCT0000416316	NCT00004163_16_T0	PHENOTYPE	28	28	recurrence
NCT0000416316	NCT00004163_16_T1	PHENOTYPE	11	11	tumor
NCT0000416318	NCT00004163_18_T0	COMPOUND	3	3	2
NCT0000416318	NCT00004163_18_T1	COMPOUND	5	5	3
NCT000041642	NCT00004164_2_T0	CELL	9	9	cells
NCT000041645	NCT00004164_5_T0	COMPOUND	13	13	calcium
NCT000041645	NCT00004164_5_T1	COMPOUND	8	8	docetaxel
NCT000041645	NCT00004164_5_T2	COMPOUND	12	12	leucovorin
NCT000041645	NCT00004164_5_T3	COMPOUND	9	9	cisplatin
NCT000041645	NCT00004164_5_T4	PHENOTYPE	19	20	nasopharyngeal cancer
NCT000041648	NCT00004164_8_T0	COMPOUND	23	23	calcium
NCT000041648	NCT00004164_8_T1	COMPOUND	3	3	docetaxel
NCT000041648	NCT00004164_8_T2	COMPOUND	22	22	leucovorin
NCT000041648	NCT00004164_8_T3	COMPOUND	13	13	cisplatin
NCT000041648	NCT00004164_8_T4	GENE	4	4	IV
NCT000041648	NCT00004164_8_T5	GENE	14	14	IV
NCT000041648	NCT00004164_8_T6	GENE	20	20	IV
NCT000041648	NCT00004164_8_T7	GENE	24	24	IV
NCT000041649	NCT00004164_9_T0	GENE	1	1	G-CSF
NCT0000416412	NCT00004164_12_T0	PHENOTYPE	8	8	remission
NCT000041654	NCT00004165_4_T0	PHENOTYPE	9	9	remission
NCT000041654	NCT00004165_4_T1	PHENOTYPE	3	4	in remission
NCT000041656	NCT00004165_6_T0	COMPOUND	13	13	melphalan
NCT000041656	NCT00004165_6_T1	GENE	14	14	IV
NCT000041657	NCT00004165_7_T0	COMPOUND	6	6	melphalan
NCT000041657	NCT00004165_7_T1	GENE	14	14	G-CSF
NCT000041658	NCT00004165_8_T0	COMPOUND	26	26	melphalan
NCT000041658	NCT00004165_8_T1	PHENOTYPE	17	18	disease progression
NCT000041660	NCT00004166_0_T0	PHENOTYPE	5	7	Ovarian Epithelial Cancer
NCT000041662	NCT00004166_2_T0	CELL	8	8	cells
NCT000041662	NCT00004166_2_T1	COMPOUND	4	4	amifostine
NCT000041662	NCT00004166_2_T2	PHENOTYPE	12	14	effects of chemotherapy
NCT000041663	NCT00004166_3_T0	GENE	3	3	III
NCT000041663	NCT00004166_3_T1	COMPOUND	10	10	amifostine
NCT000041663	NCT00004166_3_T2	PHENOTYPE	16	18	ovarian epithelial cancer
NCT000041665	NCT00004166_5_T0	COMPOUND	17	17	amifostine
NCT000041665	NCT00004166_5_T1	PHENOTYPE	4	6	ovarian epithelial cancer
NCT000041667	NCT00004166_7_T0	PHENOTYPE	24	24	thrombocytopenia
NCT000041667	NCT00004166_7_T1	PHENOTYPE	14	14	neutropenia
NCT000041667	NCT00004166_7_T2	PHENOTYPE	22	22	anemia
NCT000041667	NCT00004166_7_T3	PHENOTYPE	21	21	leukopenia
NCT000041667	NCT00004166_7_T4	PHENOTYPE	31	31	infections
NCT000041667	NCT00004166_7_T5	PHENOTYPE	11	11	neuropathy
NCT000041667	NCT00004166_7_T6	COMPOUND	1	1	amifostine
NCT000041667	NCT00004166_7_T7	PHENOTYPE	33	35	quality of life
NCT0000416612	NCT00004166_12_T0	PHENOTYPE	16	16	toxicity
NCT0000416612	NCT00004166_12_T1	PHENOTYPE	12	13	disease progression
NCT0000416613	NCT00004166_13_T0	PHENOTYPE	0	2	Quality of life
NCT000041691	NCT00004169_1_T0	CELL	8	8	cells
NCT000041697	NCT00004169_7_T0	COMPOUND	12	12	cyclophosphamide
NCT000041697	NCT00004169_7_T1	COMPOUND	6	6	etoposide
NCT000041698	NCT00004169_8_T0	COMPOUND	8	8	etoposide
NCT000041699	NCT00004169_9_T0	GENE	15	15	24
NCT000041699	NCT00004169_9_T1	GENE	10	10	35
NCT000041699	NCT00004169_9_T2	GENE	27	27	17
NCT000041699	NCT00004169_9_T3	GENE	13	13	28
NCT000041699	NCT00004169_9_T4	GENE	3	3	nodal
NCT000041699	NCT00004169_9_T5	GENE	12	12	31
NCT000041699	NCT00004169_9_T6	GENE	25	25	21
NCT0000416910	NCT00004169_10_T0	COMPOUND	19	19	2
NCT0000416910	NCT00004169_10_T1	COMPOUND	25	25	2
NCT0000416910	NCT00004169_10_T2	COMPOUND	23	23	3
NCT0000416910	NCT00004169_10_T3	COMPOUND	16	16	cyclophosphamide
NCT0000416910	NCT00004169_10_T4	COMPOUND	3	3	etoposide
NCT0000416910	NCT00004169_10_T5	GENE	4	4	IV
NCT0000416910	NCT00004169_10_T6	GENE	8	8	IV
NCT0000416910	NCT00004169_10_T7	GENE	17	17	IV
NCT0000416911	NCT00004169_11_T0	CELL	1	4	peripheral blood stem cells
NCT0000416913	NCT00004169_13_T0	COMPOUND	8	8	etoposide
NCT0000416913	NCT00004169_13_T1	GENE	14	14	MTD
NCT0000416913	NCT00004169_13_T2	GENE	2	2	4-8
NCT0000416914	NCT00004169_14_T0	PHENOTYPE	20	20	toxicity
NCT0000416914	NCT00004169_14_T1	GENE	1	1	MTD
NCT0000416915	NCT00004169_15_T0	GENE	4	4	1.3
NCT000041715	NCT00004171_5_T0	COMPOUND	4	4	busulfan
NCT000041715	NCT00004171_5_T1	COMPOUND	17	17	2
NCT000041715	NCT00004171_5_T2	COMPOUND	23	23	2
NCT000041715	NCT00004171_5_T3	COMPOUND	14	14	cyclophosphamide
NCT000041715	NCT00004171_5_T4	GENE	15	15	IV
NCT000041716	NCT00004171_6_T0	CELL	1	4	peripheral blood stem cells
NCT000041719	NCT00004171_9_T0	PHENOTYPE	18	18	lymphoma
NCT000041719	NCT00004171_9_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT000041719	NCT00004171_9_T2	PHENOTYPE	16	17	high grade
NCT000041721	NCT00004172_1_T0	PHENOTYPE	17	17	peripheral
NCT000041721	NCT00004172_1_T1	CELL	11	11	cells
NCT000041721	NCT00004172_1_T2	GENE	4	4	filgrastim
NCT000041721	NCT00004172_1_T3	ORGAN	14	15	bone marrow
NCT000041721	NCT00004172_1_T4	ORGAN	24	25	immune system
NCT000041721	NCT00004172_1_T5	PHENOTYPE	30	32	effects of chemotherapy
NCT000041723	NCT00004172_3_T0	CELL	8	8	cells
NCT000041723	NCT00004172_3_T1	PHENOTYPE	7	7	tumor
NCT000041728	NCT00004172_8_T0	PHENOTYPE	2	2	toxicity
NCT0000417210	NCT00004172_10_T0	GENE	11	11	filgrastim
NCT0000417210	NCT00004172_10_T1	COMPOUND	9	9	cyclophosphamide
NCT0000417210	NCT00004172_10_T2	GENE	12	12	G-CSF
NCT0000417210	NCT00004172_10_T3	GENE	14	14	G-CSF
NCT0000417212	NCT00004172_12_T0	COMPOUND	1	1	2
NCT0000417212	NCT00004172_12_T1	GENE	4	4	G-CSF
NCT0000417213	NCT00004172_13_T0	COMPOUND	9	9	cyclophosphamide
NCT0000417214	NCT00004172_14_T0	COMPOUND	7	7	ifosfamide
NCT0000417214	NCT00004172_14_T1	COMPOUND	22	22	3
NCT0000417214	NCT00004172_14_T2	COMPOUND	13	13	thiotepa
NCT0000417214	NCT00004172_14_T3	GENE	5	5	IV
NCT0000417214	NCT00004172_14_T4	GENE	8	8	IV
NCT0000417214	NCT00004172_14_T5	GENE	14	14	IV
NCT0000417216	NCT00004172_16_T0	GENE	2	2	G-CSF
NCT0000417217	NCT00004172_17_T0	PHENOTYPE	3	3	metastases
NCT0000417217	NCT00004172_17_T1	GENE	7	7	cm
NCT000041731	NCT00004173_1_T0	CELL	9	9	cells
NCT000041731	NCT00004173_1_T1	PHENOTYPE	8	8	tumor
NCT000041732	NCT00004173_2_T0	COMPOUND	11	11	paclitaxel
NCT000041732	NCT00004173_2_T1	COMPOUND	9	9	oxaliplatin
NCT000041735	NCT00004173_5_T0	COMPOUND	9	9	paclitaxel
NCT000041735	NCT00004173_5_T1	COMPOUND	2	2	oxaliplatin
NCT000041735	NCT00004173_5_T2	GENE	3	3	IV
NCT000041735	NCT00004173_5_T3	GENE	10	10	IV
NCT000041736	NCT00004173_6_T0	PHENOTYPE	13	13	toxicity
NCT000041736	NCT00004173_6_T1	PHENOTYPE	9	10	disease progression
NCT000041737	NCT00004173_7_T0	COMPOUND	10	10	paclitaxel
NCT000041737	NCT00004173_7_T1	COMPOUND	8	8	oxaliplatin
NCT000041737	NCT00004173_7_T2	GENE	16	16	MTD
NCT000041738	NCT00004173_8_T0	PHENOTYPE	19	19	toxicity
NCT000041738	NCT00004173_8_T1	GENE	1	1	MTD
NCT000041738	NCT00004173_8_T2	PHENOTYPE	16	16	experiences
NCT000041746	NCT00004174_6_T0	PHENOTYPE	5	5	toxicity
NCT000041747	NCT00004174_7_T0	COMPOUND	8	8	paclitaxel
NCT000041748	NCT00004174_8_T0	CELL	7	10	peripheral blood stem cells
NCT000041749	NCT00004174_9_T0	CELL	7	7	cells
NCT000041749	NCT00004174_9_T1	GENE	6	6	CD34
NCT0000417410	NCT00004174_10_T0	CELL	6	6	cells
NCT0000417410	NCT00004174_10_T1	GENE	5	5	CD34
NCT0000417410	NCT00004174_10_T2	ORGAN	11	12	bone marrow
NCT0000417411	NCT00004174_11_T0	COMPOUND	4	4	paclitaxel
NCT0000417411	NCT00004174_11_T1	COMPOUND	34	34	paclitaxel
NCT0000417411	NCT00004174_11_T2	COMPOUND	18	18	2
NCT0000417411	NCT00004174_11_T3	COMPOUND	26	26	2
NCT0000417411	NCT00004174_11_T4	COMPOUND	38	38	2
NCT0000417411	NCT00004174_11_T5	COMPOUND	15	15	thiotepa
NCT0000417411	NCT00004174_11_T6	COMPOUND	23	23	cyclophosphamide
NCT0000417411	NCT00004174_11_T7	GENE	5	5	IV
NCT0000417411	NCT00004174_11_T8	GENE	16	16	IV
NCT0000417411	NCT00004174_11_T9	GENE	24	24	IV
NCT0000417412	NCT00004174_12_T0	COMPOUND	8	8	paclitaxel
NCT0000417412	NCT00004174_12_T1	GENE	14	14	MTD
NCT0000417413	NCT00004174_13_T0	PHENOTYPE	22	22	toxicity
NCT0000417413	NCT00004174_13_T1	GENE	1	1	MTD
NCT0000417415	NCT00004174_15_T0	GENE	2	2	filgrastim
NCT0000417415	NCT00004174_15_T1	GENE	3	3	G-CSF
NCT0000417416	NCT00004174_16_T0	PHENOTYPE	3	3	metastases
NCT0000417416	NCT00004174_16_T1	GENE	7	7	cm
NCT000041751	NCT00004175_1_T0	CELL	9	9	cells
NCT000041751	NCT00004175_1_T1	PHENOTYPE	8	8	tumor
NCT000041752	NCT00004175_2_T0	GENE	2	2	II
NCT000041752	NCT00004175_2_T1	COMPOUND	10	10	docetaxel
NCT000041752	NCT00004175_2_T2	COMPOUND	13	13	cyclophosphamide
NCT000041752	NCT00004175_2_T3	COMPOUND	11	11	doxorubicin
NCT000041752	NCT00004175_2_T4	PHENOTYPE	21	24	stage III breast cancer
NCT000041754	NCT00004175_4_T0	COMPOUND	6	6	docetaxel
NCT000041754	NCT00004175_4_T1	COMPOUND	9	9	cyclophosphamide
NCT000041754	NCT00004175_4_T2	COMPOUND	7	7	doxorubicin
NCT000041754	NCT00004175_4_T3	PHENOTYPE	16	19	stage III breast cancer
NCT000041758	NCT00004175_8_T0	PHENOTYPE	5	5	toxicity
NCT0000417510	NCT00004175_10_T0	PHENOTYPE	5	5	5-10
NCT0000417510	NCT00004175_10_T1	PHENOTYPE	12	12	5-10
NCT0000417510	NCT00004175_10_T2	COMPOUND	15	15	docetaxel
NCT0000417510	NCT00004175_10_T3	COMPOUND	9	9	cyclophosphamide
NCT0000417510	NCT00004175_10_T4	COMPOUND	2	2	doxorubicin
NCT0000417510	NCT00004175_10_T5	GENE	3	3	IV
NCT0000417510	NCT00004175_10_T6	GENE	10	10	IV
NCT0000417510	NCT00004175_10_T7	GENE	16	16	IV
NCT0000417511	NCT00004175_11_T0	PHENOTYPE	16	16	toxicity
NCT0000417511	NCT00004175_11_T1	PHENOTYPE	12	13	disease progression
NCT0000417512	NCT00004175_12_T0	GENE	21	21	nodal
NCT0000417513	NCT00004175_13_T0	PHENOTYPE	4	4	tumor
NCT000041762	NCT00004176_2_T0	CELL	8	8	cells
NCT000041762	NCT00004176_2_T1	PHENOTYPE	7	7	tumor
NCT000041763	NCT00004176_3_T0	CELL	7	7	cells
NCT000041763	NCT00004176_3_T1	COMPOUND	3	3	amifostine
NCT000041763	NCT00004176_3_T2	PHENOTYPE	11	13	effects of chemotherapy
NCT000041768	NCT00004176_8_T0	PHENOTYPE	2	2	tumor
NCT000041769	NCT00004176_9_T0	COMPOUND	2	2	1
NCT000041769	NCT00004176_9_T1	COMPOUND	5	5	amifostine
NCT000041769	NCT00004176_9_T2	GENE	6	6	IV
NCT0000417610	NCT00004176_10_T0	COMPOUND	11	11	etoposide
NCT0000417610	NCT00004176_10_T1	COMPOUND	2	2	cisplatin
NCT0000417610	NCT00004176_10_T2	GENE	3	3	IV
NCT0000417610	NCT00004176_10_T3	GENE	12	12	IV
NCT0000417611	NCT00004176_11_T0	GENE	1	1	2.4
NCT0000417611	NCT00004176_11_T1	COMPOUND	19	19	etoposide
NCT0000417611	NCT00004176_11_T2	COMPOUND	4	4	amifostine
NCT0000417611	NCT00004176_11_T3	COMPOUND	13	13	cisplatin
NCT0000417611	NCT00004176_11_T4	GENE	14	14	IV
NCT0000417611	NCT00004176_11_T5	GENE	20	20	IV
NCT0000417613	NCT00004176_13_T0	GENE	12	12	1.2
NCT000041774	NCT00004177_4_T0	COMPOUND	8	8	yttrium
NCT000041774	NCT00004177_4_T1	PHENOTYPE	5	5	tumor
NCT000041774	NCT00004177_4_T2	COMPOUND	15	15	indium
NCT000041774	NCT00004177_4_T3	PHENOTYPE	27	29	ovarian epithelial cancer
NCT000041777	NCT00004177_7_T0	COMPOUND	8	8	yttrium
NCT000041778	NCT00004177_8_T0	GENE	18	18	12
NCT000041778	NCT00004177_8_T1	GENE	10	10	13
NCT000041778	NCT00004177_8_T2	GENE	16	16	14
NCT000041778	NCT00004177_8_T3	GENE	8	8	17
NCT000041778	NCT00004177_8_T4	GENE	2	2	filgrastim
NCT000041778	NCT00004177_8_T5	GENE	3	3	G-CSF
NCT000041779	NCT00004177_9_T0	CELL	6	6	cells
NCT000041779	NCT00004177_9_T1	GENE	5	5	CD34
NCT000041779	NCT00004177_9_T2	ORGAN	10	11	bone marrow
NCT0000417710	NCT00004177_10_T0	COMPOUND	6	6	indium
NCT0000417711	NCT00004177_11_T0	PHENOTYPE	4	4	tumor
NCT0000417712	NCT00004177_12_T0	GENE	4	4	IV
NCT0000417714	NCT00004177_14_T0	GENE	2	2	G-CSF
NCT0000417714	NCT00004177_14_T1	GENE	5	5	IV
NCT0000417715	NCT00004177_15_T0	GENE	15	15	MTD
NCT0000417716	NCT00004177_16_T0	PHENOTYPE	20	20	toxicity
NCT0000417716	NCT00004177_16_T1	ORGAN	28	28	kidney
NCT0000417716	NCT00004177_16_T2	ORGAN	30	30	liver
NCT0000417716	NCT00004177_16_T3	ORGAN	27	27	lungs
NCT0000417716	NCT00004177_16_T4	GENE	1	1	MTD
NCT0000417716	NCT00004177_16_T5	PHENOTYPE	17	17	experiences
NCT000041780	NCT00004178_0_T0	PHENOTYPE	6	6	Cancer
NCT000041782	NCT00004178_2_T0	GENE	18	18	has
NCT000041785	NCT00004178_5_T0	CELL	2	2	lymphocytes
NCT000041785	NCT00004178_5_T1	PHENOTYPE	0	0	Peripheral
NCT000041785	NCT00004178_5_T2	GENE	3	3	PBL
NCT000041788	NCT00004178_8_T0	PHENOTYPE	19	19	toxicity
NCT000041788	NCT00004178_8_T1	GENE	5	5	MTD
NCT000041789	NCT00004178_9_T0	GENE	2	2	MTD
NCT000041789	NCT00004178_9_T1	CELL	22	23	T cells
NCT000041792	NCT00004179_2_T0	PHENOTYPE	16	17	Hodgkin's lymphoma
NCT000041793	NCT00004179_3_T0	GENE	4	4	III
NCT000041793	NCT00004179_3_T1	PHENOTYPE	28	29	Hodgkin's lymphoma
NCT0000417913	NCT00004179_13_T0	PHENOTYPE	18	18	lymphoma
NCT0000417913	NCT00004179_13_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000417913	NCT00004179_13_T2	PHENOTYPE	16	17	high grade
NCT000041800	NCT00004180_0_T0	PHENOTYPE	5	5	Liposarcoma
NCT000041802	NCT00004180_2_T0	GENE	2	2	II
NCT000041802	NCT00004180_2_T1	COMPOUND	9	9	rosiglitazone
NCT000041802	NCT00004180_2_T2	PHENOTYPE	15	15	liposarcoma
NCT000041805	NCT00004180_5_T0	COMPOUND	3	3	rosiglitazone
NCT000041806	NCT00004180_6_T0	PHENOTYPE	10	10	toxicity
NCT000041806	NCT00004180_6_T1	PHENOTYPE	6	7	disease progression
NCT000041807	NCT00004180_7_T0	GENE	4	4	1.3
NCT000041813	NCT00004181_3_T0	PHENOTYPE	5	5	remission
NCT000041814	NCT00004181_4_T0	COMPOUND	28	28	1
NCT000041814	NCT00004181_4_T1	COMPOUND	8	8	cyclophosphamide
NCT000041814	NCT00004181_4_T2	GENE	9	9	IV
NCT000041815	NCT00004181_5_T0	ORGAN	1	2	bone marrow
NCT000041816	NCT00004181_6_T0	GENE	23	23	IV
NCT000041816	NCT00004181_6_T1	COMPOUND	8	8	busulfan
NCT000041816	NCT00004181_6_T2	COMPOUND	25	25	2
NCT000041816	NCT00004181_6_T3	COMPOUND	31	31	2
NCT000041816	NCT00004181_6_T4	COMPOUND	20	20	3
NCT000041816	NCT00004181_6_T5	COMPOUND	29	29	3
NCT000041816	NCT00004181_6_T6	COMPOUND	22	22	cyclophosphamide
NCT000041817	NCT00004181_7_T0	ORGAN	1	2	bone marrow
NCT000041821	NCT00004182_1_T0	GENE	2	2	II
NCT000041821	NCT00004182_1_T1	COMPOUND	9	9	irinotecan
NCT000041821	NCT00004182_1_T2	PHENOTYPE	17	19	recurrent breast cancer
NCT000041823	NCT00004182_3_T0	COMPOUND	6	6	irinotecan
NCT000041823	NCT00004182_3_T1	PHENOTYPE	23	24	metastatic disease
NCT000041823	NCT00004182_3_T2	PHENOTYPE	10	12	metastatic breast cancer
NCT000041825	NCT00004182_5_T0	COMPOUND	4	4	irinotecan
NCT000041825	NCT00004182_5_T1	PHENOTYPE	2	2	toxicities
NCT000041828	NCT00004182_8_T0	COMPOUND	3	3	irinotecan
NCT000041828	NCT00004182_8_T1	GENE	4	4	IV
NCT000041829	NCT00004182_9_T0	PHENOTYPE	13	13	toxicity
NCT000041829	NCT00004182_9_T1	PHENOTYPE	9	10	disease progression
NCT000041830	NCT00004183_0_T0	PHENOTYPE	5	6	Malignant Mesothelioma
NCT000041832	NCT00004183_2_T0	GENE	2	2	II
NCT000041832	NCT00004183_2_T1	COMPOUND	9	9	capecitabine
NCT000041832	NCT00004183_2_T2	PHENOTYPE	15	16	malignant mesothelioma
NCT000041834	NCT00004183_4_T0	COMPOUND	17	17	capecitabine
NCT000041834	NCT00004183_4_T1	PHENOTYPE	13	14	malignant mesothelioma
NCT000041836	NCT00004183_6_T0	PHENOTYPE	2	2	toxicity
NCT000041838	NCT00004183_8_T0	COMPOUND	3	3	capecitabine
NCT000041839	NCT00004183_9_T0	PHENOTYPE	19	19	toxicity
NCT000041839	NCT00004183_9_T1	PHENOTYPE	15	16	disease progression
NCT000041840	NCT00004184_0_T0	PHENOTYPE	12	12	Melanoma
NCT000041840	NCT00004184_0_T1	GENE	8	8	III
NCT000041840	NCT00004184_0_T2	GENE	11	11	IV
NCT000041842	NCT00004184_2_T0	PHENOTYPE	27	27	recurrence
NCT000041842	NCT00004184_2_T1	PHENOTYPE	33	33	tumor
NCT000041842	NCT00004184_2_T2	PHENOTYPE	17	18	stage III
NCT000041842	NCT00004184_2_T3	PHENOTYPE	20	22	stage IV melanoma
NCT000041844	NCT00004184_4_T0	PHENOTYPE	2	2	toxicity
NCT000041844	NCT00004184_4_T1	PHENOTYPE	24	24	melanoma
NCT000041844	NCT00004184_4_T2	GENE	14	14	GM-CSF
NCT000041844	NCT00004184_4_T3	GENE	23	23	IV
NCT000041844	NCT00004184_4_T4	PHENOTYPE	29	29	recurrence
NCT000041844	NCT00004184_4_T5	GENE	13	13	sargramostim
NCT000041844	NCT00004184_4_T6	PHENOTYPE	20	21	stage III
NCT000041848	NCT00004184_8_T0	PHENOTYPE	13	13	melanoma
NCT000041848	NCT00004184_8_T1	BIOLOGICAL_PROCESS	3	4	immune response
NCT0000418413	NCT00004184_13_T0	GENE	2	2	GM-CSF
NCT0000418415	NCT00004184_15_T0	PHENOTYPE	19	19	toxicity
NCT000041862	NCT00004186_2_T0	CELL	9	9	cells
NCT000041862	NCT00004186_2_T1	PHENOTYPE	8	8	tumor
NCT000041867	NCT00004186_7_T0	PHENOTYPE	8	8	toxicity
NCT000041867	NCT00004186_7_T1	PHENOTYPE	10	10	tumor
NCT000041867	NCT00004186_7_T2	PHENOTYPE	2	2	pharmacokinetics
NCT000041867	NCT00004186_7_T3	COMPOUND	4	4	topotecan
NCT0000418614	NCT00004186_14_T0	COMPOUND	8	8	topotecan
NCT0000418615	NCT00004186_15_T0	GENE	17	17	II
NCT0000418616	NCT00004186_16_T0	COMPOUND	10	10	ifosfamide
NCT0000418616	NCT00004186_16_T1	GENE	5	5	IV
NCT0000418616	NCT00004186_16_T2	GENE	11	11	IV
NCT0000418616	NCT00004186_16_T3	COMPOUND	4	4	topotecan
NCT0000418617	NCT00004186_17_T0	PHENOTYPE	17	18	progressive disease
NCT0000418618	NCT00004186_18_T0	PHENOTYPE	17	17	toxicity
NCT0000418618	NCT00004186_18_T1	PHENOTYPE	13	14	disease progression
NCT0000418619	NCT00004186_19_T0	GENE	16	16	MTD
NCT0000418619	NCT00004186_19_T1	COMPOUND	10	10	topotecan
NCT0000418620	NCT00004186_20_T0	PHENOTYPE	18	18	toxicity
NCT0000418620	NCT00004186_20_T1	GENE	1	1	MTD
NCT0000418621	NCT00004186_21_T0	COMPOUND	17	17	etoposide
NCT0000418621	NCT00004186_21_T1	GENE	9	9	IV
NCT0000418621	NCT00004186_21_T2	GENE	18	18	IV
NCT0000418625	NCT00004186_25_T0	GENE	20	20	II
NCT000041871	NCT00004187_1_T0	CELL	9	9	cells
NCT000041871	NCT00004187_1_T1	PHENOTYPE	8	8	tumor
NCT000041872	NCT00004187_2_T0	COMPOUND	10	10	capecitabine
NCT000041872	NCT00004187_2_T1	COMPOUND	12	12	oxaliplatin
NCT000041872	NCT00004187_2_T2	PHENOTYPE	20	22	metastatic colorectal cancer
NCT000041874	NCT00004187_4_T0	COMPOUND	6	6	capecitabine
NCT000041874	NCT00004187_4_T1	COMPOUND	10	10	oxaliplatin
NCT000041874	NCT00004187_4_T2	GENE	17	18	thymidylate synthase
NCT000041874	NCT00004187_4_T3	PHENOTYPE	24	26	metastatic colorectal cancer
NCT000041876	NCT00004187_6_T0	PHENOTYPE	4	4	toxicity
NCT000041878	NCT00004187_8_T0	PHENOTYPE	5	5	remission
NCT000041879	NCT00004187_9_T0	COMPOUND	9	9	capecitabine
NCT0000418710	NCT00004187_10_T0	GENE	12	13	thymidylate synthase
NCT0000418712	NCT00004187_12_T0	PHENOTYPE	13	13	toxicity
NCT0000418712	NCT00004187_12_T1	PHENOTYPE	9	10	disease progression
NCT0000418713	NCT00004187_13_T0	COMPOUND	8	8	capecitabine
NCT0000418713	NCT00004187_13_T1	GENE	14	14	MTD
NCT0000418714	NCT00004187_14_T0	PHENOTYPE	19	19	toxicity
NCT0000418714	NCT00004187_14_T1	GENE	1	1	MTD
NCT0000418715	NCT00004187_15_T0	GENE	1	1	II
NCT0000418715	NCT00004187_15_T1	COMPOUND	4	4	capecitabine
NCT0000418716	NCT00004187_16_T0	GENE	11	11	MTD
NCT0000418718	NCT00004187_18_T0	GENE	36	36	II
NCT0000418718	NCT00004187_18_T1	GENE	21	22	thymidylate synthase
NCT000041887	NCT00004188_7_T0	COMPOUND	19	19	vincristine
NCT000041887	NCT00004188_7_T1	GENE	27	27	0.2
NCT000041887	NCT00004188_7_T2	GENE	30	30	G-CSF
NCT000041887	NCT00004188_7_T3	GENE	7	7	IV
NCT000041887	NCT00004188_7_T4	GENE	17	17	IV
NCT000041887	NCT00004188_7_T5	GENE	20	20	IV
NCT000041887	NCT00004188_7_T6	GENE	34	34	IV
NCT000041887	NCT00004188_7_T7	GENE	32	32	SC
NCT000041887	NCT00004188_7_T8	GENE	29	29	filgrastim
NCT000041887	NCT00004188_7_T9	COMPOUND	6	6	cyclophosphamide
NCT000041887	NCT00004188_7_T10	COMPOUND	16	16	doxorubicin
NCT000041888	NCT00004188_8_T0	GENE	26	26	SC
NCT000041888	NCT00004188_8_T1	GENE	15	15	0.2
NCT000041888	NCT00004188_8_T2	GENE	23	23	0.3
NCT000041888	NCT00004188_8_T3	COMPOUND	8	8	etoposide
NCT000041888	NCT00004188_8_T4	GENE	25	25	G-CSF
NCT000041888	NCT00004188_8_T5	COMPOUND	16	16	cisplatin
NCT000041888	NCT00004188_8_T6	GENE	9	9	IV
NCT000041888	NCT00004188_8_T7	GENE	17	17	IV
NCT000041888	NCT00004188_8_T8	GENE	28	28	IV
NCT000041889	NCT00004188_9_T0	PHENOTYPE	19	19	toxicity
NCT000041889	NCT00004188_9_T1	PHENOTYPE	15	16	disease progression
NCT0000418812	NCT00004188_12_T0	ORGAN	8	9	bone marrow
NCT0000418813	NCT00004188_13_T0	PHENOTYPE	8	9	residual tumor
NCT0000418814	NCT00004188_14_T0	COMPOUND	18	18	melphalan
NCT0000418814	NCT00004188_14_T1	COMPOUND	30	30	etoposide
NCT0000418814	NCT00004188_14_T2	GENE	19	19	IV
NCT0000418814	NCT00004188_14_T3	GENE	28	28	IV
NCT0000418814	NCT00004188_14_T4	GENE	31	31	IV
NCT0000418815	NCT00004188_15_T0	GENE	19	19	SC
NCT0000418815	NCT00004188_15_T1	GENE	18	18	G-CSF
NCT0000418815	NCT00004188_15_T2	GENE	21	21	IV
NCT0000418815	NCT00004188_15_T3	ORGAN	10	11	bone marrow
NCT0000418816	NCT00004188_16_T0	COMPOUND	7	7	isotretinoin
NCT0000418819	NCT00004188_19_T0	GENE	29	29	0.4
NCT0000418819	NCT00004188_19_T1	COMPOUND	15	15	cyclophosphamide
NCT0000418819	NCT00004188_19_T2	GENE	16	16	IV
NCT0000418819	NCT00004188_19_T3	GENE	23	23	IV
NCT0000418819	NCT00004188_19_T4	COMPOUND	22	22	topotecan
NCT0000418820	NCT00004188_20_T0	GENE	3	3	SC
NCT0000418820	NCT00004188_20_T1	GENE	2	2	G-CSF
NCT0000418820	NCT00004188_20_T2	GENE	5	5	IV
NCT0000418823	NCT00004188_23_T0	COMPOUND	4	4	isotretinoin
NCT0000418825	NCT00004188_25_T0	COMPOUND	6	6	1
NCT0000418825	NCT00004188_25_T1	PHENOTYPE	0	2	Quality of life
NCT0000418826	NCT00004188_26_T0	PHENOTYPE	21	22	disease progression
NCT000041891	NCT00004189_1_T0	CELL	10	10	cells
NCT000041891	NCT00004189_1_T1	PHENOTYPE	9	9	tumor
NCT000041892	NCT00004189_2_T0	CELL	9	9	cells
NCT000041892	NCT00004189_2_T1	PHENOTYPE	8	8	tumor
NCT000041893	NCT00004189_3_T0	PHENOTYPE	17	17	peripheral
NCT000041893	NCT00004189_3_T1	CELL	11	11	cells
NCT000041893	NCT00004189_3_T2	GENE	4	4	filgrastim
NCT000041893	NCT00004189_3_T3	ORGAN	14	15	bone marrow
NCT000041893	NCT00004189_3_T4	ORGAN	24	25	immune system
NCT000041893	NCT00004189_3_T5	PHENOTYPE	30	32	effects of chemotherapy
NCT000041895	NCT00004189_5_T0	PHENOTYPE	20	20	malignancies
NCT000041895	NCT00004189_5_T1	GENE	14	14	filgrastim
NCT000041895	NCT00004189_5_T2	GENE	15	15	G-CSF
NCT000041895	NCT00004189_5_T3	COMPOUND	10	10	cisplatin
NCT000041895	NCT00004189_5_T4	COMPOUND	7	7	rebeccamycin
NCT000041897	NCT00004189_7_T0	PHENOTYPE	5	5	toxicities
NCT000041899	NCT00004189_9_T0	PHENOTYPE	3	3	pharmacokinetics
NCT000041899	NCT00004189_9_T1	COMPOUND	11	11	cisplatin
NCT000041899	NCT00004189_9_T2	COMPOUND	6	6	rebeccamycin
NCT0000418912	NCT00004189_12_T0	COMPOUND	12	12	cisplatin
NCT0000418912	NCT00004189_12_T1	COMPOUND	9	9	rebeccamycin
NCT0000418913	NCT00004189_13_T0	COMPOUND	15	15	cisplatin
NCT0000418913	NCT00004189_13_T1	GENE	16	16	IV
NCT0000418913	NCT00004189_13_T2	GENE	28	28	IV
NCT0000418913	NCT00004189_13_T3	COMPOUND	26	26	rebeccamycin
NCT0000418917	NCT00004189_17_T0	PHENOTYPE	16	16	toxicity
NCT0000418917	NCT00004189_17_T1	PHENOTYPE	12	13	disease progression
NCT0000418918	NCT00004189_18_T0	GENE	6	6	filgrastim
NCT0000418918	NCT00004189_18_T1	GENE	7	7	G-CSF
NCT0000418919	NCT00004189_19_T0	GENE	18	18	MTD
NCT0000418919	NCT00004189_19_T1	COMPOUND	12	12	cisplatin
NCT0000418919	NCT00004189_19_T2	COMPOUND	9	9	rebeccamycin
NCT0000418920	NCT00004189_20_T0	PHENOTYPE	19	19	toxicity
NCT0000418920	NCT00004189_20_T1	GENE	1	1	MTD
NCT0000418920	NCT00004189_20_T2	GENE	20	20	DLT
NCT0000418921	NCT00004189_21_T0	GENE	16	16	G-CSF
NCT0000418921	NCT00004189_21_T1	GENE	8	8	DLT
NCT0000418922	NCT00004189_22_T0	GENE	2	2	G-CSF
NCT0000418923	NCT00004189_23_T0	COMPOUND	12	12	cisplatin
NCT0000418923	NCT00004189_23_T1	COMPOUND	9	9	rebeccamycin
NCT0000418924	NCT00004189_24_T0	GENE	1	1	MTD
NCT0000418925	NCT00004189_25_T0	GENE	1	1	II
NCT0000418925	NCT00004189_25_T1	GENE	21	21	MTD
NCT0000418925	NCT00004189_25_T2	COMPOUND	13	13	cisplatin
NCT0000418925	NCT00004189_25_T3	COMPOUND	10	10	rebeccamycin
NCT000041901	NCT00004190_1_T0	CELL	9	9	cells
NCT000041901	NCT00004190_1_T1	PHENOTYPE	8	8	tumor
NCT000041902	NCT00004190_2_T0	GENE	2	2	II
NCT000041902	NCT00004190_2_T1	COMPOUND	12	12	oxaliplatin
NCT000041902	NCT00004190_2_T2	COMPOUND	10	10	gemcitabine
NCT000041902	NCT00004190_2_T3	PHENOTYPE	22	24	metastatic pancreatic cancer
NCT000041904	NCT00004190_4_T0	PHENOTYPE	25	25	closed
NCT000041904	NCT00004190_4_T1	COMPOUND	8	8	oxaliplatin
NCT000041904	NCT00004190_4_T2	COMPOUND	6	6	gemcitabine
NCT000041904	NCT00004190_4_T3	PHENOTYPE	17	18	pancreatic cancer
NCT000041906	NCT00004190_6_T0	PHENOTYPE	3	3	tumor
NCT000041908	NCT00004190_8_T0	COMPOUND	15	15	oxaliplatin
NCT000041908	NCT00004190_8_T1	COMPOUND	2	2	gemcitabine
NCT000041908	NCT00004190_8_T2	GENE	3	3	IV
NCT000041908	NCT00004190_8_T3	GENE	16	16	IV
NCT0000419012	NCT00004190_12_T0	PHENOTYPE	2	2	closed
NCT0000419012	NCT00004190_12_T1	COMPOUND	16	16	oxaliplatin
NCT0000419012	NCT00004190_12_T2	COMPOUND	14	14	gemcitabine
NCT0000419012	NCT00004190_12_T3	GENE	22	22	MTD
NCT0000419013	NCT00004190_13_T0	PHENOTYPE	18	18	toxicity
NCT0000419013	NCT00004190_13_T1	GENE	1	1	MTD
NCT0000419014	NCT00004190_14_T0	GENE	1	1	II
NCT0000419014	NCT00004190_14_T1	COMPOUND	9	9	oxaliplatin
NCT0000419014	NCT00004190_14_T2	COMPOUND	7	7	gemcitabine
NCT0000419014	NCT00004190_14_T3	GENE	5	5	MTD
NCT0000419016	NCT00004190_16_T0	GENE	22	22	II
NCT0000419016	NCT00004190_16_T1	PHENOTYPE	14	14	closed
NCT000041921	NCT00004192_1_T0	GENE	3	3	II
NCT000041921	NCT00004192_1_T1	GENE	14	14	filgrastim
NCT000041921	NCT00004192_1_T2	PHENOTYPE	18	18	neutropenia
NCT000041921	NCT00004192_1_T3	PHENOTYPE	26	27	Hodgkin's lymphoma
NCT000041923	NCT00004192_3_T0	GENE	9	9	filgrastim
NCT000041923	NCT00004192_3_T1	PHENOTYPE	15	15	neutropenia
NCT000041923	NCT00004192_3_T2	GENE	10	10	G-CSF
NCT000041923	NCT00004192_3_T3	PHENOTYPE	25	25	recurrent
NCT000041923	NCT00004192_3_T4	PHENOTYPE	26	27	Hodgkin's lymphoma
NCT000041925	NCT00004192_5_T0	GENE	19	19	1.4
NCT000041925	NCT00004192_5_T1	GENE	26	26	1.4
NCT000041925	NCT00004192_5_T2	GENE	16	16	ANC
NCT000041925	NCT00004192_5_T3	GENE	22	22	ANC
NCT000041925	NCT00004192_5_T4	GENE	12	12	2.4
NCT000041925	NCT00004192_5_T5	PHENOTYPE	9	9	neutropenia
NCT000041925	NCT00004192_5_T6	CELL	14	14	neutrophil
NCT0000419210	NCT00004192_10_T0	COMPOUND	26	26	cytarabine
NCT0000419210	NCT00004192_10_T1	GENE	10	10	1.4
NCT0000419210	NCT00004192_10_T2	GENE	16	16	1.4
NCT0000419210	NCT00004192_10_T3	GENE	24	24	1.5
NCT0000419210	NCT00004192_10_T4	COMPOUND	17	17	methylprednisolone
NCT0000419210	NCT00004192_10_T5	COMPOUND	3	3	etoposide
NCT0000419210	NCT00004192_10_T6	COMPOUND	11	11	cisplatin
NCT0000419210	NCT00004192_10_T7	GENE	4	4	IV
NCT0000419210	NCT00004192_10_T8	GENE	12	12	IV
NCT0000419210	NCT00004192_10_T9	GENE	18	18	IV
NCT0000419210	NCT00004192_10_T10	GENE	27	27	IV
NCT000041931	NCT00004193_1_T0	GENE	2	2	II
NCT000041931	NCT00004193_1_T1	PHENOTYPE	19	21	recurrent colorectal cancer
NCT000041933	NCT00004193_3_T0	PHENOTYPE	10	10	progression
NCT000041933	NCT00004193_3_T1	GENE	32	32	H-ras
NCT000041933	NCT00004193_3_T2	ORGAN	23	23	rectum
NCT000041933	NCT00004193_3_T3	PHENOTYPE	17	17	recurrent
NCT000041933	NCT00004193_3_T4	PHENOTYPE	18	21	adenocarcinoma of the colon
NCT000041937	NCT00004193_7_T0	GENE	4	4	IV
NCT000041938	NCT00004193_8_T0	PHENOTYPE	13	13	toxicity
NCT000041938	NCT00004193_8_T1	PHENOTYPE	9	10	disease progression
NCT000041940	NCT00004194_0_T0	PHENOTYPE	6	6	Chronic
NCT000041940	NCT00004194_0_T1	PHENOTYPE	9	9	Disease
NCT000041940	NCT00004194_0_T2	ORGAN	7	7	Graft
NCT000041942	NCT00004194_2_T0	COMPOUND	9	9	fludarabine
NCT000041942	NCT00004194_2_T1	GENE	19	19	has
NCT000041942	NCT00004194_2_T2	PHENOTYPE	15	17	chronic graft-versus-host disease
NCT000041944	NCT00004194_4_T0	PHENOTYPE	5	5	toxicity
NCT000041944	NCT00004194_4_T1	COMPOUND	9	9	fludarabine
NCT000041944	NCT00004194_4_T2	PHENOTYPE	14	14	resistant
NCT000041944	NCT00004194_4_T3	PHENOTYPE	15	19	chronic graft versus host disease
NCT000041946	NCT00004194_6_T0	GENE	12	12	1.3
NCT000041946	NCT00004194_6_T1	COMPOUND	4	4	fludarabine
NCT000041946	NCT00004194_6_T2	GENE	5	5	IV
NCT000041947	NCT00004194_7_T0	PHENOTYPE	23	23	toxicity
NCT000041947	NCT00004194_7_T1	PHENOTYPE	18	18	malignancy
NCT000041947	NCT00004194_7_T2	ORGAN	19	19	graft
NCT000041947	NCT00004194_7_T3	PHENOTYPE	14	14	relapse
NCT000041948	NCT00004194_8_T0	PHENOTYPE	2	2	progressive
NCT000041948	NCT00004194_8_T1	PHENOTYPE	3	6	graft versus host disease
NCT0000419411	NCT00004194_11_T0	COMPOUND	7	7	fludarabine
NCT0000419411	NCT00004194_11_T1	GENE	13	13	MTD
NCT0000419412	NCT00004194_12_T0	PHENOTYPE	18	18	toxicity
NCT0000419412	NCT00004194_12_T1	GENE	1	1	MTD
NCT0000419413	NCT00004194_13_T0	GENE	1	1	II
NCT0000419413	NCT00004194_13_T1	COMPOUND	4	4	fludarabine
NCT0000419413	NCT00004194_13_T2	GENE	7	7	MTD
NCT000041951	NCT00004195_1_T0	GENE	3	3	II
NCT000041951	NCT00004195_1_T1	COMPOUND	10	10	eniluracil
NCT000041951	NCT00004195_1_T2	PHENOTYPE	21	23	metastatic colorectal cancer
NCT000041953	NCT00004195_3_T0	PHENOTYPE	9	9	peripheral
NCT000041953	NCT00004195_3_T1	ORGAN	18	18	liver
NCT000041953	NCT00004195_3_T2	GENE	6	6	dehydrogenase
NCT000041953	NCT00004195_3_T3	CELL	12	12	cells
NCT000041953	NCT00004195_3_T4	GENE	7	7	DPD
NCT000041953	NCT00004195_3_T5	TISSUE	15	15	mucosa
NCT000041953	NCT00004195_3_T6	PHENOTYPE	24	26	metastatic colorectal cancer
NCT000041955	NCT00004195_5_T0	COMPOUND	4	4	eniluracil
NCT000041955	NCT00004195_5_T1	PHENOTYPE	10	10	tumor
NCT000041955	NCT00004195_5_T2	GENE	7	7	DPD
NCT000041957	NCT00004195_7_T0	GENE	1	1	DPD
NCT000041957	NCT00004195_7_T1	COMPOUND	4	4	uracil
NCT000041959	NCT00004195_9_T0	PHENOTYPE	6	6	tumor
NCT0000419516	NCT00004195_16_T0	PHENOTYPE	9	10	colorectal carcinoma
NCT0000419518	NCT00004195_18_T0	GENE	0	0	Age
NCT0000419522	NCT00004195_22_T0	COMPOUND	10	10	capecitabine
NCT0000419522	NCT00004195_22_T1	PHENOTYPE	15	15	Endocrine
NCT0000419522	NCT00004195_22_T2	GENE	2	2	had
NCT0000419522	NCT00004195_22_T3	GENE	1	1	has
NCT0000419524	NCT00004195_24_T0	PHENOTYPE	8	8	obstruction
NCT0000419525	NCT00004195_25_T0	COMPOUND	19	19	flucytosine
NCT0000419525	NCT00004195_25_T1	GENE	11	11	dehydrogenase
NCT0000419526	NCT00004195_26_T0	CELL	2	3	Blood Cell
NCT0000419527	NCT00004195_27_T0	PHENOTYPE	0	0	Fever
NCT0000419528	NCT00004195_28_T0	PHENOTYPE	0	0	Sepsis
NCT0000419530	NCT00004195_30_T0	ORGAN	2	2	serum
NCT0000419532	NCT00004195_32_T0	COMPOUND	4	4	eniluracil
NCT000041961	NCT00004196_1_T0	GENE	3	3	III
NCT000041961	NCT00004196_1_T1	PHENOTYPE	17	17	melanoma
NCT000041961	NCT00004196_1_T2	COMPOUND	10	11	interferon alfa_2b
NCT000041961	NCT00004196_1_T3	PHENOTYPE	20	22	lymph node metastasis
NCT000041964	NCT00004196_4_T0	PHENOTYPE	28	28	ulceration
NCT000041964	NCT00004196_4_T1	GENE	16	16	1.2
NCT000041964	NCT00004196_4_T2	PHENOTYPE	14	14	tumor
NCT000041964	NCT00004196_4_T3	PHENOTYPE	27	27	tumor
NCT000041964	NCT00004196_4_T4	GENE	19	19	3.4
NCT000041965	NCT00004196_5_T0	PHENOTYPE	5	5	tumor
NCT000041965	NCT00004196_5_T1	PHENOTYPE	11	12	sentinel node
NCT000041966	NCT00004196_6_T0	PHENOTYPE	2	2	tumors
NCT000041966	NCT00004196_6_T1	PHENOTYPE	11	11	tumor
NCT000041971	NCT00004197_1_T0	CELL	12	12	cells
NCT000041971	NCT00004197_1_T1	BIOLOGICAL_PROCESS	7	8	immune response
NCT000041972	NCT00004197_2_T0	PHENOTYPE	17	17	peripheral
NCT000041972	NCT00004197_2_T1	CELL	11	11	cells
NCT000041972	NCT00004197_2_T2	GENE	4	4	sargramostim
NCT000041972	NCT00004197_2_T3	ORGAN	14	15	bone marrow
NCT000041972	NCT00004197_2_T4	ORGAN	24	25	immune system
NCT000041972	NCT00004197_2_T5	PHENOTYPE	30	32	effects of chemotherapy
NCT000041973	NCT00004197_3_T0	GENE	2	2	II
NCT000041973	NCT00004197_3_T1	GENE	8	8	sargramostim
NCT000041973	NCT00004197_3_T2	PHENOTYPE	19	20	Hodgkin's lymphoma
NCT000041977	NCT00004197_7_T0	PHENOTYPE	4	4	toxicity
NCT000041978	NCT00004197_8_T0	COMPOUND	15	15	mitoxantrone
NCT000041978	NCT00004197_8_T1	COMPOUND	9	9	vincristine
NCT000041978	NCT00004197_8_T2	COMPOUND	16	16	vincristine
NCT000041978	NCT00004197_8_T3	COMPOUND	7	7	cyclophosphamide
NCT000041978	NCT00004197_8_T4	COMPOUND	14	14	cyclophosphamide
NCT000041978	NCT00004197_8_T5	GENE	12	12	CHOP
NCT000041978	NCT00004197_8_T6	COMPOUND	8	8	doxorubicin
NCT000041978	NCT00004197_8_T7	COMPOUND	11	11	prednisone
NCT000041978	NCT00004197_8_T8	COMPOUND	18	18	prednisone
NCT0000419710	NCT00004197_10_T0	PHENOTYPE	17	17	tumor
NCT0000419710	NCT00004197_10_T1	GENE	23	23	limpet
NCT0000419710	NCT00004197_10_T2	GENE	31	31	GM-CSF
NCT0000419710	NCT00004197_10_T3	GENE	30	30	sargramostim
NCT0000419711	NCT00004197_11_T0	GENE	6	6	2.4
NCT0000419711	NCT00004197_11_T1	GENE	2	2	GM-CSF
NCT0000419713	NCT00004197_13_T0	PHENOTYPE	20	21	disease progression
NCT000041981	NCT00004198_1_T0	CELL	12	12	cells
NCT000041981	NCT00004198_1_T1	PHENOTYPE	11	11	tumor
NCT000041981	NCT00004198_1_T2	BIOLOGICAL_PROCESS	7	8	immune response
NCT000041982	NCT00004198_2_T0	CELL	12	12	cells
NCT000041982	NCT00004198_2_T1	PHENOTYPE	11	11	tumor
NCT000041982	NCT00004198_2_T2	ORGAN	5	6	immune system
NCT000041983	NCT00004198_3_T0	GENE	2	2	II
NCT000041983	NCT00004198_3_T1	GENE	24	24	IV
NCT000041983	NCT00004198_3_T2	GENE	12	12	sargramostim
NCT000041983	NCT00004198_3_T3	PHENOTYPE	20	21	stage III
NCT000041983	NCT00004198_3_T4	PHENOTYPE	25	26	Hodgkin's lymphoma
NCT000041987	NCT00004198_7_T0	PHENOTYPE	4	4	toxicity
NCT000041988	NCT00004198_8_T0	COMPOUND	9	9	vincristine
NCT000041988	NCT00004198_8_T1	COMPOUND	8	8	cyclophosphamide
NCT000041988	NCT00004198_8_T2	COMPOUND	11	11	prednisone
NCT0000419810	NCT00004198_10_T0	COMPOUND	17	17	vincristine
NCT0000419810	NCT00004198_10_T1	COMPOUND	15	15	cyclophosphamide
NCT0000419810	NCT00004198_10_T2	COMPOUND	16	16	doxorubicin
NCT0000419810	NCT00004198_10_T3	COMPOUND	19	19	prednisone
NCT0000419811	NCT00004198_11_T0	PHENOTYPE	22	22	tumor
NCT0000419811	NCT00004198_11_T1	GENE	28	28	limpet
NCT0000419811	NCT00004198_11_T2	GENE	40	40	GM-CSF
NCT0000419811	NCT00004198_11_T3	GENE	39	39	sargramostim
NCT0000419812	NCT00004198_12_T0	GENE	6	6	2.4
NCT0000419812	NCT00004198_12_T1	GENE	2	2	GM-CSF
NCT0000419814	NCT00004198_14_T0	PHENOTYPE	20	21	disease progression
NCT0000419816	NCT00004198_16_T0	PHENOTYPE	18	18	lymphoma
NCT0000419816	NCT00004198_16_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000419816	NCT00004198_16_T2	PHENOTYPE	16	17	high grade
NCT000041992	NCT00004199_2_T0	CELL	6	6	cells
NCT000041992	NCT00004199_2_T1	PHENOTYPE	5	5	tumor
NCT000041999	NCT00004199_9_T0	PHENOTYPE	2	4	quality of life
NCT0000419913	NCT00004199_13_T0	COMPOUND	3	3	prinomastat
NCT0000419913	NCT00004199_13_T1	COMPOUND	14	14	gemcitabine
NCT0000419913	NCT00004199_13_T2	COMPOUND	22	22	cisplatin
NCT0000419913	NCT00004199_13_T3	GENE	15	15	IV
NCT0000419913	NCT00004199_13_T4	GENE	23	23	IV
NCT000042001	NCT00004200_1_T0	CELL	6	6	cells
NCT000042001	NCT00004200_1_T1	PHENOTYPE	5	5	tumor
NCT000042002	NCT00004200_2_T0	COMPOUND	12	12	temozolomide
NCT000042002	NCT00004200_2_T1	GENE	3	3	II
NCT000042002	NCT00004200_2_T2	COMPOUND	10	10	prinomastat
NCT000042002	NCT00004200_2_T3	PHENOTYPE	20	21	glioblastoma multiforme
NCT000042004	NCT00004200_4_T0	COMPOUND	24	24	temozolomide
NCT000042004	NCT00004200_4_T1	COMPOUND	19	19	prinomastat
NCT000042004	NCT00004200_4_T2	PHENOTYPE	7	7	progression
NCT000042004	NCT00004200_4_T3	PHENOTYPE	15	16	glioblastoma multiforme
NCT000042008	NCT00004200_8_T0	PHENOTYPE	2	4	quality of life
NCT0000420010	NCT00004200_10_T0	COMPOUND	12	12	temozolomide
NCT0000420010	NCT00004200_10_T1	COMPOUND	3	3	prinomastat
NCT0000420010	NCT00004200_10_T2	GENE	16	16	1.5
NCT0000420011	NCT00004200_11_T0	PHENOTYPE	13	13	toxicity
NCT0000420011	NCT00004200_11_T1	PHENOTYPE	9	10	disease progression
NCT000042012	NCT00004201_2_T0	CELL	9	9	cells
NCT000042012	NCT00004201_2_T1	PHENOTYPE	8	8	tumor
NCT000042017	NCT00004201_7_T0	PHENOTYPE	2	2	toxicity
NCT000042019	NCT00004201_9_T0	PHENOTYPE	4	4	progression
NCT0000420115	NCT00004201_15_T0	PHENOTYPE	18	18	toxicity
NCT0000420115	NCT00004201_15_T1	PHENOTYPE	14	15	disease progression
NCT000042022	NCT00004202_2_T0	CELL	8	8	cells
NCT000042022	NCT00004202_2_T1	PHENOTYPE	7	7	tumor
NCT000042023	NCT00004202_3_T0	CELL	7	7	cells
NCT000042023	NCT00004202_3_T1	PHENOTYPE	6	6	tumor
NCT000042028	NCT00004202_8_T0	PHENOTYPE	8	8	progression
NCT000042028	NCT00004202_8_T1	GENE	15	15	portal
NCT0000420210	NCT00004202_10_T0	GENE	10	10	portal
NCT0000420210	NCT00004202_10_T1	PHENOTYPE	4	5	disease progression
NCT0000420212	NCT00004202_12_T0	PHENOTYPE	2	2	toxic
NCT0000420212	NCT00004202_12_T1	PHENOTYPE	5	6	adverse events
NCT0000420214	NCT00004202_14_T0	COMPOUND	4	4	paclitaxel
NCT0000420214	NCT00004202_14_T1	GENE	5	5	IV
NCT0000420214	NCT00004202_14_T2	GENE	11	11	IV
NCT0000420215	NCT00004202_15_T0	GENE	12	12	IV
NCT0000420215	NCT00004202_15_T1	GENE	24	24	6/7
NCT0000420216	NCT00004202_16_T0	PHENOTYPE	14	15	disease progression
NCT000042031	NCT00004203_1_T0	GENE	2	2	II
NCT000042031	NCT00004203_1_T1	COMPOUND	9	9	oxaliplatin
NCT000042031	NCT00004203_1_T2	PHENOTYPE	15	17	metastatic bladder cancer
NCT000042033	NCT00004203_3_T0	COMPOUND	18	18	oxaliplatin
NCT000042033	NCT00004203_3_T1	PHENOTYPE	14	15	urothelial carcinoma
NCT000042035	NCT00004203_5_T0	PHENOTYPE	2	2	toxicity
NCT000042035	NCT00004203_5_T1	PHENOTYPE	7	7	neurotoxicity
NCT000042035	NCT00004203_5_T2	COMPOUND	9	9	oxaliplatin
NCT000042037	NCT00004203_7_T0	COMPOUND	4	4	platinum
NCT000042037	NCT00004203_7_T1	COMPOUND	7	7	platinum
NCT000042037	NCT00004203_7_T2	COMPOUND	10	10	platinum
NCT000042037	NCT00004203_7_T3	PHENOTYPE	11	11	resistant
NCT000042038	NCT00004203_8_T0	COMPOUND	2	2	oxaliplatin
NCT000042038	NCT00004203_8_T1	GENE	3	3	IV
NCT000042039	NCT00004203_9_T0	PHENOTYPE	22	22	toxicity
NCT000042039	NCT00004203_9_T1	PHENOTYPE	9	10	disease progression
NCT000042041	NCT00004204_1_T0	COMPOUND	9	9	temozolomide
NCT000042041	NCT00004204_1_T1	GENE	2	2	II
NCT000042041	NCT00004204_1_T2	PHENOTYPE	17	17	progressive
NCT000042041	NCT00004204_1_T3	PHENOTYPE	15	15	recurrent
NCT000042041	NCT00004204_1_T4	PHENOTYPE	18	19	malignant glioma
NCT000042043	NCT00004204_3_T0	PHENOTYPE	11	11	closed
NCT000042043	NCT00004204_3_T1	PHENOTYPE	8	8	recurrent
NCT000042043	NCT00004204_3_T2	PHENOTYPE	16	16	recurrent
NCT000042043	NCT00004204_3_T3	PHENOTYPE	20	20	recurrent
NCT000042043	NCT00004204_3_T4	PHENOTYPE	9	10	glioblastoma multiforme
NCT000042043	NCT00004204_3_T5	PHENOTYPE	17	18	anaplastic astrocytoma
NCT000042043	NCT00004204_3_T6	PHENOTYPE	21	22	anaplastic oligodendroglioma
NCT000042044	NCT00004204_4_T0	COMPOUND	3	3	temozolomide
NCT000042045	NCT00004204_5_T0	PHENOTYPE	18	18	toxicity
NCT000042045	NCT00004204_5_T1	PHENOTYPE	14	15	disease progression
NCT000042051	NCT00004205_1_T0	COMPOUND	3	3	letrozole
NCT000042051	NCT00004205_1_T1	COMPOUND	13	13	estrogen
NCT000042051	NCT00004205_1_T2	PHENOTYPE	6	7	breast cancer
NCT000042053	NCT00004205_3_T0	PHENOTYPE	12	13	breast cancer
NCT000042054	NCT00004205_4_T0	COMPOUND	11	11	letrozole
NCT000042054	NCT00004205_4_T1	GENE	4	4	III
NCT000042054	NCT00004205_4_T2	GENE	25	25	has
NCT000042054	NCT00004205_4_T3	COMPOUND	15	15	tamoxifen
NCT000042054	NCT00004205_4_T4	PHENOTYPE	22	23	breast cancer
NCT000042061	NCT00004206_1_T0	CELL	9	9	cells
NCT000042061	NCT00004206_1_T1	PHENOTYPE	8	8	tumor
NCT000042062	NCT00004206_2_T0	GENE	2	2	II
NCT000042062	NCT00004206_2_T1	COMPOUND	10	10	oxaliplatin
NCT000042062	NCT00004206_2_T2	PHENOTYPE	18	20	recurrent ovarian cancer
NCT000042064	NCT00004206_4_T0	COMPOUND	4	4	oxaliplatin
NCT000042064	NCT00004206_4_T1	PHENOTYPE	16	17	tumor progression
NCT000042064	NCT00004206_4_T2	PHENOTYPE	24	26	recurrent ovarian cancer
NCT000042068	NCT00004206_8_T0	COMPOUND	16	16	calcium
NCT000042068	NCT00004206_8_T1	COMPOUND	2	2	oxaliplatin
NCT000042068	NCT00004206_8_T2	COMPOUND	15	15	leucovorin
NCT000042068	NCT00004206_8_T3	GENE	3	3	IV
NCT000042068	NCT00004206_8_T4	GENE	13	13	IV
NCT000042068	NCT00004206_8_T5	GENE	17	17	IV
NCT000042069	NCT00004206_9_T0	PHENOTYPE	16	16	toxicity
NCT000042069	NCT00004206_9_T1	PHENOTYPE	12	13	disease progression
NCT0000420610	NCT00004206_10_T0	PHENOTYPE	20	21	disease relapse
NCT000042071	NCT00004207_1_T0	COMPOUND	10	10	daunorubicin
NCT000042071	NCT00004207_1_T1	PHENOTYPE	16	18	metastatic breast cancer
NCT000042073	NCT00004207_3_T0	COMPOUND	6	6	daunorubicin
NCT000042073	NCT00004207_3_T1	PHENOTYPE	11	13	metastatic breast cancer
NCT000042077	NCT00004207_7_T0	GENE	4	4	IV
NCT000042077	NCT00004207_7_T1	COMPOUND	2	2	daunorubicin
NCT000042078	NCT00004207_8_T0	PHENOTYPE	19	19	toxicity
NCT000042078	NCT00004207_8_T1	PHENOTYPE	15	16	disease progression
NCT000042079	NCT00004207_9_T0	GENE	15	15	MTD
NCT000042079	NCT00004207_9_T1	COMPOUND	8	8	daunorubicin
NCT0000420710	NCT00004207_10_T0	PHENOTYPE	16	16	toxicity
NCT0000420710	NCT00004207_10_T1	GENE	1	1	MTD
NCT000042092	NCT00004209_2_T0	CELL	9	9	cells
NCT000042092	NCT00004209_2_T1	PHENOTYPE	8	8	tumor
NCT000042098	NCT00004209_8_T0	GENE	10	10	IV
NCT0000420910	NCT00004209_10_T0	PHENOTYPE	16	16	toxicity
NCT0000420910	NCT00004209_10_T1	PHENOTYPE	12	13	disease progression
NCT0000420913	NCT00004209_13_T0	PHENOTYPE	16	16	toxicity
NCT0000420913	NCT00004209_13_T1	PHENOTYPE	12	13	disease progression
NCT0000421010	NCT00004210_10_T0	PHENOTYPE	0	0	Tumors
NCT0000421010	NCT00004210_10_T1	PHENOTYPE	13	14	microsatellite instability
NCT000042117	NCT00004211_7_T0	PHENOTYPE	8	8	peripheral
NCT000042117	NCT00004211_7_T1	CELL	10	11	T lymphocytes
NCT0000421117	NCT00004211_17_T0	PHENOTYPE	18	18	toxicity
NCT0000421117	NCT00004211_17_T1	GENE	1	1	MTD
NCT000042121	NCT00004212_1_T0	PHENOTYPE	19	19	lymphomas
NCT000042121	NCT00004212_1_T1	PHENOTYPE	16	17	solid tumors
NCT000042123	NCT00004212_3_T0	COMPOUND	8	8	mesylate
NCT000042123	NCT00004212_3_T1	COMPOUND	7	7	exatecan
NCT000042125	NCT00004212_5_T0	COMPOUND	3	3	mesylate
NCT000042125	NCT00004212_5_T1	COMPOUND	2	2	exatecan
NCT000042125	NCT00004212_5_T2	GENE	4	4	IV
NCT000042126	NCT00004212_6_T0	GENE	9	9	filgrastim
NCT000042126	NCT00004212_6_T1	GENE	10	10	G-CSF
NCT000042127	NCT00004212_7_T0	PHENOTYPE	13	13	toxicity
NCT000042127	NCT00004212_7_T1	PHENOTYPE	9	10	disease progression
NCT000042128	NCT00004212_8_T0	GENE	2	2	1/6
NCT000042128	NCT00004212_8_T1	COMPOUND	9	9	mesylate
NCT000042128	NCT00004212_8_T2	GENE	13	13	G-CSF
NCT000042128	NCT00004212_8_T3	COMPOUND	8	8	exatecan
NCT000042128	NCT00004212_8_T4	GENE	19	19	MTD
NCT000042129	NCT00004212_9_T0	PHENOTYPE	23	23	toxicity
NCT000042129	NCT00004212_9_T1	GENE	1	1	MTD
NCT000042130	NCT00004213_0_T0	PHENOTYPE	6	7	Solid Tumors
NCT000042132	NCT00004213_2_T0	COMPOUND	9	10	3_aminopyridine_2_carboxaldehyde thiosemicarbazone
NCT000042132	NCT00004213_2_T1	PHENOTYPE	16	17	solid tumors
NCT000042134	NCT00004213_4_T0	GENE	27	27	II
NCT000042134	NCT00004213_4_T1	PHENOTYPE	31	31	tumor
NCT000042134	NCT00004213_4_T2	PHENOTYPE	29	29	pharmacokinetics
NCT000042134	NCT00004213_4_T3	GENE	21	21	MTD
NCT000042134	NCT00004213_4_T4	PHENOTYPE	10	11	solid tumors
NCT000042134	NCT00004213_4_T5	COMPOUND	4	5	3_aminopyridine_2_carboxaldehyde thiosemicarbazone
NCT000042136	NCT00004213_6_T0	GENE	11	11	1.5
NCT000042136	NCT00004213_6_T1	GENE	5	5	IV
NCT000042136	NCT00004213_6_T2	COMPOUND	2	3	3_aminopyridine_2_carboxaldehyde thiosemicarbazone
NCT000042137	NCT00004213_7_T0	PHENOTYPE	13	13	toxicity
NCT000042137	NCT00004213_7_T1	PHENOTYPE	9	10	disease progression
NCT000042138	NCT00004213_8_T0	GENE	2	2	1/6
NCT000042138	NCT00004213_8_T1	GENE	14	14	MTD
NCT000042139	NCT00004213_9_T0	PHENOTYPE	18	18	toxicity
NCT000042139	NCT00004213_9_T1	GENE	1	1	MTD
NCT000042151	NCT00004215_1_T0	PHENOTYPE	18	18	peripheral
NCT000042151	NCT00004215_1_T1	CELL	12	12	cells
NCT000042151	NCT00004215_1_T2	GENE	6	6	filgrastim
NCT000042151	NCT00004215_1_T3	ORGAN	15	16	bone marrow
NCT000042151	NCT00004215_1_T4	ORGAN	25	26	immune system
NCT000042151	NCT00004215_1_T5	PHENOTYPE	31	33	effects of chemotherapy
NCT000042156	NCT00004215_6_T0	PHENOTYPE	11	11	neutropenia
NCT000042156	NCT00004215_6_T1	GENE	10	10	IV
NCT0000421510	NCT00004215_10_T0	PHENOTYPE	12	12	thrombocytopenia
NCT0000421510	NCT00004215_10_T1	GENE	6	6	filgrastim
NCT0000421510	NCT00004215_10_T2	GENE	7	7	G-CSF
NCT0000421510	NCT00004215_10_T3	GENE	21	21	IV
NCT0000421515	NCT00004215_15_T0	COMPOUND	16	16	cytarabine
NCT0000421515	NCT00004215_15_T1	GENE	14	14	1.3
NCT0000421515	NCT00004215_15_T2	GENE	21	21	1.7
NCT0000421515	NCT00004215_15_T3	GENE	8	8	IV
NCT0000421515	NCT00004215_15_T4	GENE	17	17	IV
NCT0000421515	NCT00004215_15_T5	COMPOUND	7	7	daunorubicin
NCT0000421516	NCT00004215_16_T0	PHENOTYPE	5	5	aplasia
NCT0000421518	NCT00004215_18_T0	GENE	19	19	HAD
NCT0000421518	NCT00004215_18_T1	GENE	20	20	has
NCT0000421518	NCT00004215_18_T2	GENE	14	14	MTD
NCT0000421519	NCT00004215_19_T0	PHENOTYPE	22	22	toxicities
NCT0000421519	NCT00004215_19_T1	GENE	1	1	MTD
NCT0000421520	NCT00004215_20_T0	COMPOUND	9	9	cytarabine
NCT0000421520	NCT00004215_20_T1	PHENOTYPE	0	0	Consolidation
NCT0000421520	NCT00004215_20_T2	GENE	32	32	1/6
NCT0000421520	NCT00004215_20_T3	GENE	10	10	IV
NCT0000421527	NCT00004215_27_T0	GENE	15	15	II
NCT000042161	NCT00004216_1_T0	PHENOTYPE	18	19	solid tumors
NCT000042163	NCT00004216_3_T0	PHENOTYPE	20	21	solid tumors
NCT000042168	NCT00004216_8_T0	PHENOTYPE	1	1	tumor
NCT000042169	NCT00004216_9_T0	COMPOUND	20	20	OBD
NCT000042169	NCT00004216_9_T1	GENE	14	14	MTD
NCT0000421610	NCT00004216_10_T0	PHENOTYPE	22	22	toxicity
NCT0000421610	NCT00004216_10_T1	GENE	1	1	MTD
NCT0000421610	NCT00004216_10_T2	PHENOTYPE	20	20	experiences
NCT0000421610	NCT00004216_10_T3	GENE	23	23	DLT
NCT0000421612	NCT00004216_12_T0	COMPOUND	4	4	OBD
NCT0000421613	NCT00004216_13_T0	PHENOTYPE	5	5	tumor
NCT0000421613	NCT00004216_13_T1	GENE	7	7	4.5
NCT0000421615	NCT00004216_15_T0	PHENOTYPE	71	71	initiation
NCT0000421615	NCT00004216_15_T1	COMPOUND	47	47	cefixime
NCT0000421615	NCT00004216_15_T2	GENE	13	13	DLT
NCT0000421615	NCT00004216_15_T3	GENE	22	22	IV
NCT0000421615	NCT00004216_15_T4	GENE	42	42	IV
NCT0000421615	NCT00004216_15_T5	PHENOTYPE	11	12	progressive disease
NCT000042176	NCT00004217_6_T0	PHENOTYPE	4	4	severity
NCT000042176	NCT00004217_6_T1	PHENOTYPE	6	6	toxicities
NCT000042178	NCT00004217_8_T0	PHENOTYPE	13	13	pharmacokinetics
NCT000042178	NCT00004217_8_T1	GENE	9	9	P-glycoprotein
NCT0000421711	NCT00004217_11_T0	GENE	1	1	G-CSF
NCT0000421711	NCT00004217_11_T1	GENE	4	4	GM-CSF
NCT0000421711	NCT00004217_11_T2	GENE	10	10	IV
NCT0000421711	NCT00004217_11_T3	GENE	3	3	sargramostim
NCT0000421712	NCT00004217_12_T0	PHENOTYPE	6	6	remission
NCT000042181	NCT00004218_1_T0	PHENOTYPE	13	15	chronic lymphocytic leukemia
NCT000042182	NCT00004218_2_T0	GENE	4	4	III
NCT000042182	NCT00004218_2_T1	COMPOUND	17	17	fludarabine
NCT000042182	NCT00004218_2_T2	COMPOUND	21	21	fludarabine
NCT000042182	NCT00004218_2_T3	COMPOUND	19	19	cyclophosphamide
NCT000042182	NCT00004218_2_T4	COMPOUND	8	8	chlorambucil
NCT000042182	NCT00004218_2_T5	PHENOTYPE	29	31	chronic lymphocytic leukemia
NCT000042189	NCT00004218_9_T0	GENE	6	6	3.8
NCT0000421810	NCT00004218_10_T0	PHENOTYPE	2	2	relapse
NCT0000421810	NCT00004218_10_T1	PHENOTYPE	5	6	in remission
NCT0000421813	NCT00004218_13_T0	PHENOTYPE	0	2	Quality of life
NCT0000421815	NCT00004218_15_T0	GENE	14	14	6/7
NCT000042191	NCT00004219_1_T0	COMPOUND	11	11	granisetron
NCT000042191	NCT00004219_1_T1	COMPOUND	6	6	lerisetron
NCT000042191	NCT00004219_1_T2	PHENOTYPE	14	16	nausea and vomiting
NCT0000421910	NCT00004219_10_T0	GENE	1	1	1.2
NCT000042201	NCT00004220_1_T0	CELL	9	9	cells
NCT000042201	NCT00004220_1_T1	PHENOTYPE	8	8	tumor
NCT000042202	NCT00004220_2_T0	COMPOUND	9	9	oxaliplatin
NCT000042202	NCT00004220_2_T1	COMPOUND	11	11	gemcitabine
NCT000042202	NCT00004220_2_T2	PHENOTYPE	17	18	advanced cancer
NCT000042204	NCT00004220_4_T0	PHENOTYPE	19	19	malignancies
NCT000042204	NCT00004220_4_T1	PHENOTYPE	8	8	toxicities
NCT000042204	NCT00004220_4_T2	COMPOUND	14	14	oxaliplatin
NCT000042204	NCT00004220_4_T3	COMPOUND	10	10	gemcitabine
NCT000042206	NCT00004220_6_T0	PHENOTYPE	2	2	pharmacokinetics
NCT000042206	NCT00004220_6_T1	COMPOUND	4	4	oxaliplatin
NCT000042206	NCT00004220_6_T2	COMPOUND	6	6	gemcitabine
NCT000042207	NCT00004220_7_T0	COMPOUND	9	9	gemcitabine
NCT000042208	NCT00004220_8_T0	COMPOUND	2	2	oxaliplatin
NCT000042208	NCT00004220_8_T1	COMPOUND	11	11	gemcitabine
NCT000042208	NCT00004220_8_T2	GENE	3	3	IV
NCT000042208	NCT00004220_8_T3	GENE	12	12	IV
NCT000042209	NCT00004220_9_T0	PHENOTYPE	13	13	toxicity
NCT000042209	NCT00004220_9_T1	PHENOTYPE	9	10	disease progression
NCT0000422010	NCT00004220_10_T0	COMPOUND	16	16	oxaliplatin
NCT0000422010	NCT00004220_10_T1	COMPOUND	8	8	gemcitabine
NCT0000422010	NCT00004220_10_T2	GENE	22	22	MTD
NCT0000422011	NCT00004220_11_T0	PHENOTYPE	19	19	toxicity
NCT0000422011	NCT00004220_11_T1	GENE	1	1	MTD
NCT0000422011	NCT00004220_11_T2	PHENOTYPE	16	16	experiences
NCT000042211	NCT00004221_1_T0	CELL	10	10	cells
NCT000042211	NCT00004221_1_T1	PHENOTYPE	9	9	tumor
NCT000042218	NCT00004221_8_T0	COMPOUND	21	21	paclitaxel
NCT000042218	NCT00004221_8_T1	COMPOUND	11	11	cyclophosphamide
NCT000042218	NCT00004221_8_T2	GENE	12	12	IV
NCT000042218	NCT00004221_8_T3	GENE	22	22	IV
NCT000042219	NCT00004221_9_T0	COMPOUND	13	13	paclitaxel
NCT000042219	NCT00004221_9_T1	CELL	34	34	cells
NCT000042219	NCT00004221_9_T2	GENE	2	2	filgrastim
NCT000042219	NCT00004221_9_T3	GENE	3	3	G-CSF
NCT000042219	NCT00004221_9_T4	GENE	33	33	CD34
NCT000042219	NCT00004221_9_T5	CELL	23	26	peripheral blood stem cells
NCT0000422110	NCT00004221_10_T0	COMPOUND	12	12	paclitaxel
NCT0000422110	NCT00004221_10_T1	GENE	13	13	IV
NCT0000422110	NCT00004221_10_T2	GENE	25	25	IV
NCT0000422110	NCT00004221_10_T3	GENE	33	33	IV
NCT0000422110	NCT00004221_10_T4	COMPOUND	32	32	topotecan
NCT0000422111	NCT00004221_11_T0	GENE	2	2	G-CSF
NCT0000422111	NCT00004221_11_T1	COMPOUND	12	12	topotecan
NCT0000422112	NCT00004221_12_T0	COMPOUND	13	13	topotecan
NCT0000422113	NCT00004221_13_T0	PHENOTYPE	16	16	toxicity
NCT0000422113	NCT00004221_13_T1	PHENOTYPE	12	13	disease progression
NCT0000422116	NCT00004221_16_T0	PHENOTYPE	23	23	recurrence
NCT000042231	NCT00004223_1_T0	CELL	9	9	cells
NCT000042231	NCT00004223_1_T1	PHENOTYPE	8	8	tumor
NCT000042232	NCT00004223_2_T0	GENE	2	2	II
NCT000042232	NCT00004223_2_T1	COMPOUND	9	9	docetaxel
NCT000042232	NCT00004223_2_T2	PHENOTYPE	17	17	progressive
NCT000042232	NCT00004223_2_T3	COMPOUND	11	11	gemcitabine
NCT000042232	NCT00004223_2_T4	PHENOTYPE	20	22	metastatic bladder cancer
NCT000042236	NCT00004223_6_T0	PHENOTYPE	2	2	toxicities
NCT000042238	NCT00004223_8_T0	COMPOUND	2	2	docetaxel
NCT000042238	NCT00004223_8_T1	COMPOUND	9	9	gemcitabine
NCT000042238	NCT00004223_8_T2	GENE	3	3	IV
NCT000042238	NCT00004223_8_T3	GENE	10	10	IV
NCT000042239	NCT00004223_9_T0	PHENOTYPE	32	32	toxicity
NCT000042239	NCT00004223_9_T1	PHENOTYPE	28	29	disease progression
NCT0000422310	NCT00004223_10_T0	PHENOTYPE	20	21	disease progression
NCT000042241	NCT00004224_1_T0	CELL	8	8	cells
NCT000042241	NCT00004224_1_T1	PHENOTYPE	7	7	tumor
NCT000042242	NCT00004224_2_T0	CELL	15	15	cells
NCT000042242	NCT00004224_2_T1	PHENOTYPE	14	14	tumor
NCT000042243	NCT00004224_3_T0	GENE	3	3	II
NCT000042243	NCT00004224_3_T1	PHENOTYPE	23	23	ependymoma
NCT000042243	NCT00004224_3_T2	PHENOTYPE	22	22	localized
NCT000042246	NCT00004224_6_T0	PHENOTYPE	8	8	tumor
NCT000042247	NCT00004224_7_T0	PHENOTYPE	2	3	residual disease
NCT000042247	NCT00004224_7_T1	PHENOTYPE	11	12	residual disease
NCT000042248	NCT00004224_8_T0	COMPOUND	10	10	vincristine
NCT000042248	NCT00004224_8_T1	GENE	34	34	1.3
NCT000042248	NCT00004224_8_T2	COMPOUND	18	18	cyclophosphamide
NCT000042248	NCT00004224_8_T3	COMPOUND	27	27	etoposide
NCT000042248	NCT00004224_8_T4	GENE	11	11	IV
NCT000042248	NCT00004224_8_T5	GENE	19	19	IV
NCT000042248	NCT00004224_8_T6	GENE	28	28	IV
NCT0000422411	NCT00004224_11_T0	PHENOTYPE	1	2	residual disease
NCT0000422414	NCT00004224_14_T0	GENE	14	14	2.3
NCT000042252	NCT00004225_2_T0	CELL	8	8	cells
NCT000042252	NCT00004225_2_T1	PHENOTYPE	7	7	tumor
NCT000042257	NCT00004225_7_T0	PHENOTYPE	14	14	tumors
NCT000042257	NCT00004225_7_T1	PHENOTYPE	18	18	punctures
NCT000042257	NCT00004225_7_T2	PHENOTYPE	0	0	Adenovirus
NCT000042257	NCT00004225_7_T3	GENE	1	1	p53
NCT000042261	NCT00004226_1_T0	PHENOTYPE	18	18	recurrent
NCT000042261	NCT00004226_1_T1	PHENOTYPE	20	22	second primary cancer
NCT000042261	NCT00004226_1_T2	PHENOTYPE	22	26	cancer of the head and
NCT000042264	NCT00004226_4_T0	GENE	25	25	2.3
NCT000042264	NCT00004226_4_T1	GENE	31	31	4.5
NCT000042264	NCT00004226_4_T2	PHENOTYPE	0	2	Quality of life
NCT000042265	NCT00004226_5_T0	GENE	24	24	3.5
NCT000042273	NCT00004227_3_T0	ORGAN	22	22	larynx
NCT000042273	NCT00004227_3_T1	ORGAN	20	20	hypopharynx
NCT000042273	NCT00004227_3_T2	PHENOTYPE	16	19	cancer of the oropharynx
NCT000042274	NCT00004227_4_T0	GENE	3	3	III
NCT000042274	NCT00004227_4_T1	ORGAN	32	32	larynx
NCT000042274	NCT00004227_4_T2	ORGAN	30	30	hypopharynx
NCT000042274	NCT00004227_4_T3	PHENOTYPE	21	22	stage III
NCT000042274	NCT00004227_4_T4	PHENOTYPE	26	29	cancer of the oropharynx
NCT000042274	NCT00004227_4_T5	PHENOTYPE	24	28	stage IV cancer of the
NCT000042277	NCT00004227_7_T0	GENE	19	19	T4
NCT000042277	NCT00004227_7_T1	PHENOTYPE	15	15	tumor
NCT000042277	NCT00004227_7_T2	GENE	10	10	nodal
NCT000042277	NCT00004227_7_T3	COMPOUND	14	14	N
NCT0000422710	NCT00004227_10_T0	GENE	15	15	IV
NCT0000422710	NCT00004227_10_T1	PHENOTYPE	7	8	anaphylactic reaction
NCT0000422711	NCT00004227_11_T0	GENE	4	4	IV
NCT0000422715	NCT00004227_15_T0	GENE	13	13	4-8
NCT0000422715	NCT00004227_15_T1	PHENOTYPE	5	6	neck disease
NCT0000422716	NCT00004227_16_T0	PHENOTYPE	6	6	initiation
NCT0000422716	NCT00004227_16_T1	PHENOTYPE	0	2	Quality of life
NCT000042281	NCT00004228_1_T0	PHENOTYPE	14	15	lymphoblastic lymphoma
NCT000042282	NCT00004228_2_T0	GENE	4	4	III
NCT000042282	NCT00004228_2_T1	GENE	31	31	IV
NCT000042282	NCT00004228_2_T2	PHENOTYPE	27	28	stage III
NCT000042282	NCT00004228_2_T3	PHENOTYPE	32	33	lymphoblastic lymphoma
NCT000042287	NCT00004228_7_T0	PHENOTYPE	2	2	localized
NCT000042287	NCT00004228_7_T1	PHENOTYPE	5	5	closed
NCT000042287	NCT00004228_7_T2	PHENOTYPE	3	4	lymphoblastic lymphoma
NCT0000422818	NCT00004228_18_T0	GENE	14	14	1.2
NCT0000422819	NCT00004228_19_T0	GENE	17	17	1.5
NCT000042290	NCT00004229_0_T0	COMPOUND	0	0	Endostatin
NCT000042290	NCT00004229_0_T1	PHENOTYPE	6	7	Solid Tumors
NCT000042294	NCT00004229_4_T0	GENE	6	6	endostatin
NCT000042294	NCT00004229_4_T1	PHENOTYPE	11	12	solid tumors
NCT000042298	NCT00004229_8_T0	PHENOTYPE	7	7	tumor
NCT0000422912	NCT00004229_12_T0	GENE	4	4	II
NCT0000422915	NCT00004229_15_T0	GENE	2	2	endostatin
NCT0000422915	NCT00004229_15_T1	GENE	3	3	IV
NCT0000422916	NCT00004229_16_T0	GENE	6	6	endostatin
NCT0000422916	NCT00004229_16_T1	GENE	4	4	1/6
NCT0000422917	NCT00004229_17_T0	GENE	6	6	endostatin
NCT0000422918	NCT00004229_18_T0	PHENOTYPE	13	13	toxicity
NCT0000422918	NCT00004229_18_T1	PHENOTYPE	9	10	disease progression
NCT0000422919	NCT00004229_19_T0	GENE	8	8	endostatin
NCT0000422919	NCT00004229_19_T1	GENE	14	14	MTD
NCT0000422920	NCT00004229_20_T0	PHENOTYPE	18	18	toxicity
NCT0000422920	NCT00004229_20_T1	GENE	1	1	MTD
NCT000042305	NCT00004230_5_T0	PHENOTYPE	5	6	lung injury
NCT000042307	NCT00004230_7_T0	COMPOUND	11	11	cyclophosphamide
NCT000042312	NCT00004231_2_T0	CELL	13	13	cells
NCT000042312	NCT00004231_2_T1	ORGAN	8	9	immune system
NCT000042316	NCT00004231_6_T0	COMPOUND	35	35	cytarabine
NCT000042316	NCT00004231_6_T1	COMPOUND	24	24	vincristine
NCT000042316	NCT00004231_6_T2	COMPOUND	55	55	calcium
NCT000042316	NCT00004231_6_T3	COMPOUND	11	11	teniposide
NCT000042316	NCT00004231_6_T4	GENE	23	23	1.5
NCT000042316	NCT00004231_6_T5	COMPOUND	27	27	methotrexate
NCT000042316	NCT00004231_6_T6	COMPOUND	66	66	methotrexate
NCT000042316	NCT00004231_6_T7	GENE	7	7	IV
NCT000042316	NCT00004231_6_T8	GENE	9	9	IV
NCT000042316	NCT00004231_6_T9	GENE	12	12	IV
NCT000042316	NCT00004231_6_T10	GENE	25	25	IV
NCT000042316	NCT00004231_6_T11	GENE	28	28	IV
NCT000042316	NCT00004231_6_T12	GENE	36	36	IV
NCT000042316	NCT00004231_6_T13	COMPOUND	6	6	cyclophosphamide
NCT000042316	NCT00004231_6_T14	COMPOUND	8	8	doxorubicin
NCT000042316	NCT00004231_6_T15	COMPOUND	54	54	leucovorin
NCT000042316	NCT00004231_6_T16	COMPOUND	20	20	prednisone
NCT0000423110	NCT00004231_10_T0	ORGAN	11	12	bone marrow
NCT0000423111	NCT00004231_11_T0	COMPOUND	2	2	busulfan
NCT0000423111	NCT00004231_11_T1	GENE	20	20	3.5
NCT0000423111	NCT00004231_11_T2	GENE	3	3	IV
NCT0000423112	NCT00004231_12_T0	COMPOUND	8	8	busulfan
NCT0000423112	NCT00004231_12_T1	COMPOUND	11	11	cyclophosphamide
NCT0000423112	NCT00004231_12_T2	GENE	12	12	IV
NCT0000423113	NCT00004231_13_T0	ORGAN	3	4	bone marrow
NCT0000423115	NCT00004231_15_T0	COMPOUND	10	10	teniposide
NCT0000423115	NCT00004231_15_T1	COMPOUND	7	7	cyclophosphamide
NCT0000423115	NCT00004231_15_T2	COMPOUND	8	8	doxorubicin
NCT0000423117	NCT00004231_17_T0	CELL	2	3	stem cells
NCT0000423117	NCT00004231_17_T1	ORGAN	10	11	bone marrow
NCT0000423117	NCT00004231_17_T2	ORGAN	15	16	bone marrow
NCT0000423118	NCT00004231_18_T0	COMPOUND	7	7	busulfan
NCT0000423118	NCT00004231_18_T1	PHENOTYPE	3	3	conditioning
NCT0000423118	NCT00004231_18_T2	COMPOUND	9	9	cyclophosphamide
NCT0000423119	NCT00004231_19_T0	GENE	12	12	filgrastim
NCT0000423119	NCT00004231_19_T1	GENE	13	13	G-CSF
NCT0000423119	NCT00004231_19_T2	ORGAN	3	4	bone marrow
NCT0000423120	NCT00004231_20_T0	GENE	14	14	interleukin-2
NCT0000423120	NCT00004231_20_T1	GENE	10	10	interferon
NCT0000423124	NCT00004231_24_T0	ORGAN	7	7	transplant
NCT000042323	NCT00004232_3_T0	GENE	10	10	filgrastim
NCT000042323	NCT00004232_3_T1	GENE	12	12	CD34
NCT000042323	NCT00004232_3_T2	ORGAN	7	8	bone marrow
NCT000042323	NCT00004232_3_T3	CELL	14	17	peripheral blood stem cells
NCT000042324	NCT00004232_4_T0	COMPOUND	6	6	cyclosporine
NCT000042324	NCT00004232_4_T1	COMPOUND	13	13	1
NCT000042324	NCT00004232_4_T2	COMPOUND	15	15	methylprednisolone
NCT000042324	NCT00004232_4_T3	COMPOUND	19	19	prednisone
NCT000042324	NCT00004232_4_T4	GENE	7	7	IV
NCT000042324	NCT00004232_4_T5	GENE	16	16	IV
NCT000042324	NCT00004232_4_T6	PHENOTYPE	2	3	graft-vs-host disease
NCT000042325	NCT00004232_5_T0	GENE	3	3	G-CSF
NCT000042331	NCT00004233_1_T0	CELL	8	8	cells
NCT000042331	NCT00004233_1_T1	COMPOUND	4	4	triacetyluridine
NCT000042331	NCT00004233_1_T2	PHENOTYPE	12	14	effects of chemotherapy
NCT000042332	NCT00004233_2_T0	GENE	2	2	II
NCT000042332	NCT00004233_2_T1	COMPOUND	9	9	triacetyluridine
NCT000042332	NCT00004233_2_T2	COMPOUND	12	12	leucovorin
NCT000042332	NCT00004233_2_T3	PHENOTYPE	22	23	metastatic cancer
NCT000042332	NCT00004233_2_T4	PHENOTYPE	23	26	cancer of the esophagus
NCT000042335	NCT00004233_5_T0	COMPOUND	3	3	calcium
NCT000042335	NCT00004233_5_T1	COMPOUND	19	19	calcium
NCT000042335	NCT00004233_5_T2	COMPOUND	2	2	leucovorin
NCT000042335	NCT00004233_5_T3	COMPOUND	18	18	leucovorin
NCT000042335	NCT00004233_5_T4	GENE	4	4	IV
NCT000042335	NCT00004233_5_T5	GENE	10	10	IV
NCT000042336	NCT00004233_6_T0	GENE	9	9	1.3
NCT000042336	NCT00004233_6_T1	COMPOUND	3	3	triacetyluridine
NCT000042337	NCT00004233_7_T0	PHENOTYPE	13	13	toxicity
NCT000042337	NCT00004233_7_T1	PHENOTYPE	9	10	disease progression
NCT000042342	NCT00004234_2_T0	PHENOTYPE	19	19	mucositis
NCT000042343	NCT00004234_3_T0	ORGAN	21	21	larynx
NCT000042343	NCT00004234_3_T1	PHENOTYPE	10	10	mucositis
NCT000042343	NCT00004234_3_T2	ORGAN	19	19	pharynx
NCT000042343	NCT00004234_3_T3	GENE	3	3	III
NCT000042343	NCT00004234_3_T4	PHENOTYPE	15	18	cancer of the mouth
NCT000042348	NCT00004234_8_T0	PHENOTYPE	16	16	toxicity
NCT000042348	NCT00004234_8_T1	PHENOTYPE	18	19	disease progression
NCT000042349	NCT00004234_9_T0	PHENOTYPE	16	16	mucositis
NCT000042349	NCT00004234_9_T1	PHENOTYPE	28	28	mucositis
NCT000042349	NCT00004234_9_T2	PHENOTYPE	0	0	Toxicity
NCT000042349	NCT00004234_9_T3	GENE	17	17	has
NCT000042349	NCT00004234_9_T4	GENE	29	29	has
NCT0000423410	NCT00004234_10_T0	PHENOTYPE	12	12	toxicity
NCT0000423410	NCT00004234_10_T1	PHENOTYPE	22	22	toxicity
NCT0000423410	NCT00004234_10_T2	PHENOTYPE	28	28	mucositis
NCT0000423410	NCT00004234_10_T3	GENE	13	13	has
NCT0000423410	NCT00004234_10_T4	PHENOTYPE	0	2	Quality of life
NCT0000423411	NCT00004234_11_T0	GENE	5	5	2.3
NCT000042351	NCT00004235_1_T0	GENE	2	2	II
NCT000042351	NCT00004235_1_T1	COMPOUND	12	12	irinotecan
NCT000042351	NCT00004235_1_T2	COMPOUND	10	10	docetaxel
NCT000042351	NCT00004235_1_T3	PHENOTYPE	18	19	advanced cancer
NCT000042351	NCT00004235_1_T4	PHENOTYPE	19	22	cancer of the esophagus
NCT000042353	NCT00004235_3_T0	COMPOUND	24	24	irinotecan
NCT000042353	NCT00004235_3_T1	ORGAN	19	19	cardia
NCT000042353	NCT00004235_3_T2	COMPOUND	22	22	docetaxel
NCT000042353	NCT00004235_3_T3	PHENOTYPE	3	3	tumor
NCT000042353	NCT00004235_3_T4	PHENOTYPE	10	10	adenocarcinoma
NCT000042353	NCT00004235_3_T5	ORGAN	14	14	esophagus
NCT000042353	NCT00004235_3_T6	ORGAN	15	16	esophagogastric junction
NCT000042355	NCT00004235_5_T0	PHENOTYPE	3	3	progression
NCT000042357	NCT00004235_7_T0	PHENOTYPE	2	2	toxic
NCT000042359	NCT00004235_9_T0	PHENOTYPE	12	12	anorexia
NCT000042359	NCT00004235_9_T1	PHENOTYPE	11	11	dysphagia
NCT000042361	NCT00004236_1_T0	GENE	2	2	II
NCT000042361	NCT00004236_1_T1	COMPOUND	10	10	doxorubicin
NCT000042361	NCT00004236_1_T2	PHENOTYPE	17	18	stomach cancer
NCT000042363	NCT00004236_3_T0	COMPOUND	26	26	HCl
NCT000042363	NCT00004236_3_T1	COMPOUND	25	25	doxorubicin
NCT000042363	NCT00004236_3_T2	PHENOTYPE	20	21	gastric adenocarcinoma
NCT000042363	NCT00004236_3_T3	PHENOTYPE	5	6	disease progression
NCT000042363	NCT00004236_3_T4	PHENOTYPE	13	15	quality of life
NCT000042364	NCT00004236_4_T0	COMPOUND	4	4	HCl
NCT000042364	NCT00004236_4_T1	COMPOUND	3	3	doxorubicin
NCT000042364	NCT00004236_4_T2	GENE	6	6	IV
NCT000042365	NCT00004236_5_T0	PHENOTYPE	12	12	toxicity
NCT000042365	NCT00004236_5_T1	PHENOTYPE	14	15	disease progression
NCT000042366	NCT00004236_6_T0	PHENOTYPE	13	14	disease progression
NCT000042367	NCT00004236_7_T0	PHENOTYPE	0	2	Quality of life
NCT000042371	NCT00004237_1_T0	CELL	9	9	cells
NCT000042371	NCT00004237_1_T1	PHENOTYPE	8	8	tumor
NCT000042372	NCT00004237_2_T0	GENE	4	4	II
NCT000042372	NCT00004237_2_T1	PHENOTYPE	26	29	stage II breast cancer
NCT000042377	NCT00004237_7_T0	PHENOTYPE	13	13	toxicity
NCT000042377	NCT00004237_7_T1	PHENOTYPE	16	16	progression
NCT000042378	NCT00004237_8_T0	COMPOUND	12	12	estrogen
NCT000042378	NCT00004237_8_T1	PHENOTYPE	10	10	tumors
NCT000042378	NCT00004237_8_T2	GENE	13	13	receptor
NCT000042378	NCT00004237_8_T3	COMPOUND	18	18	tamoxifen
NCT000042386	NCT00004238_6_T0	PHENOTYPE	2	2	toxicity
NCT0000423810	NCT00004238_10_T0	PHENOTYPE	1	3	quality of life
NCT0000423811	NCT00004238_11_T0	GENE	4	4	IV
NCT0000423812	NCT00004238_12_T0	PHENOTYPE	10	10	toxicity
NCT0000423812	NCT00004238_12_T1	PHENOTYPE	12	13	disease progression
NCT0000423813	NCT00004238_13_T0	PHENOTYPE	0	2	Quality of life
NCT0000423814	NCT00004238_14_T0	PHENOTYPE	7	8	disease progression
NCT000042391	NCT00004239_1_T0	ORGAN	18	18	kidney
NCT000042391	NCT00004239_1_T1	ORGAN	20	20	liver
NCT000042391	NCT00004239_1_T2	PHENOTYPE	21	21	impairment
NCT000042391	NCT00004239_1_T3	PHENOTYPE	15	16	hematologic cancer
NCT000042393	NCT00004239_3_T0	PHENOTYPE	15	16	hepatic impairment
NCT000042393	NCT00004239_3_T1	PHENOTYPE	10	11	hematologic malignancies
NCT000042397	NCT00004239_7_T0	PHENOTYPE	4	4	pharmacokinetics
NCT000042397	NCT00004239_7_T1	PHENOTYPE	2	2	toxicities
NCT000042398	NCT00004239_8_T0	GENE	64	64	IV
NCT000042398	NCT00004239_8_T1	COMPOUND	70	70	1
NCT000042398	NCT00004239_8_T2	COMPOUND	23	23	2
NCT000042398	NCT00004239_8_T3	COMPOUND	66	66	2
NCT000042398	NCT00004239_8_T4	COMPOUND	32	32	3
NCT000042398	NCT00004239_8_T5	COMPOUND	71	71	3
NCT000042398	NCT00004239_8_T6	GENE	13	14	Group 1
NCT000042398	NCT00004239_8_T7	GENE	59	60	Group 1
NCT000042398	NCT00004239_8_T8	PHENOTYPE	57	58	hepatic impairment
NCT000042398	NCT00004239_8_T9	PHENOTYPE	25	26	renal impairment
NCT000042398	NCT00004239_8_T10	PHENOTYPE	34	35	renal impairment
NCT000042398	NCT00004239_8_T11	PHENOTYPE	44	45	renal impairment
NCT0000423911	NCT00004239_11_T0	GENE	14	14	MTD
NCT0000423912	NCT00004239_12_T0	PHENOTYPE	22	22	toxicities
NCT0000423912	NCT00004239_12_T1	GENE	1	1	MTD
NCT0000423913	NCT00004239_13_T0	PHENOTYPE	16	16	toxicity
NCT0000423913	NCT00004239_13_T1	PHENOTYPE	18	19	disease progression
NCT000042412	NCT00004241_2_T0	PHENOTYPE	3	3	toxicity
NCT000042412	NCT00004241_2_T1	PHENOTYPE	20	20	sarcoma
NCT000042412	NCT00004241_2_T2	PHENOTYPE	17	18	malignant lymphoma
NCT000042414	NCT00004241_4_T0	PHENOTYPE	3	3	toxic
NCT000042418	NCT00004241_8_T0	PHENOTYPE	2	2	pharmacokinetics
NCT0000424111	NCT00004241_11_T0	GENE	8	8	1.2
NCT0000424111	NCT00004241_11_T1	GENE	6	6	IV
NCT0000424112	NCT00004241_12_T0	PHENOTYPE	13	13	toxicity
NCT0000424112	NCT00004241_12_T1	PHENOTYPE	9	10	disease progression
NCT0000424113	NCT00004241_13_T0	GENE	7	7	1.2
NCT0000424113	NCT00004241_13_T1	GENE	5	5	IV
NCT0000424114	NCT00004241_14_T0	PHENOTYPE	13	13	toxicity
NCT0000424114	NCT00004241_14_T1	PHENOTYPE	9	10	disease progression
NCT0000424115	NCT00004241_15_T0	GENE	17	17	MTD
NCT0000424116	NCT00004241_16_T0	PHENOTYPE	17	17	toxicity
NCT0000424116	NCT00004241_16_T1	GENE	1	1	MTD
NCT0000424117	NCT00004241_17_T0	GENE	8	8	MTD
NCT000042420	NCT00004242_0_T0	PHENOTYPE	9	10	Solid Tumors
NCT000042422	NCT00004242_2_T0	CELL	10	10	cells
NCT000042422	NCT00004242_2_T1	PHENOTYPE	9	9	tumor
NCT000042423	NCT00004242_3_T0	CELL	9	9	cells
NCT000042423	NCT00004242_3_T1	PHENOTYPE	8	8	tumor
NCT000042425	NCT00004242_5_T0	GENE	7	7	II
NCT000042425	NCT00004242_5_T1	PHENOTYPE	11	11	toxic
NCT000042425	NCT00004242_5_T2	COMPOUND	24	24	oxaliplatin
NCT000042425	NCT00004242_5_T3	COMPOUND	22	22	gemcitabine
NCT000042425	NCT00004242_5_T4	PHENOTYPE	31	32	solid tumors
NCT000042427	NCT00004242_7_T0	PHENOTYPE	3	3	toxic
NCT000042427	NCT00004242_7_T1	PHENOTYPE	11	11	pharmacodynamic
NCT000042428	NCT00004242_8_T0	COMPOUND	7	7	oxaliplatin
NCT000042428	NCT00004242_8_T1	COMPOUND	9	9	gemcitabine
NCT000042429	NCT00004242_9_T0	COMPOUND	11	11	oxaliplatin
NCT000042429	NCT00004242_9_T1	COMPOUND	21	21	gemcitabine
NCT000042429	NCT00004242_9_T2	GENE	12	12	IV
NCT000042429	NCT00004242_9_T3	GENE	22	22	IV
NCT000042429	NCT00004242_9_T4	GENE	34	34	IV
NCT0000424210	NCT00004242_10_T0	COMPOUND	21	21	oxaliplatin
NCT0000424210	NCT00004242_10_T1	COMPOUND	15	15	gemcitabine
NCT0000424211	NCT00004242_11_T0	PHENOTYPE	10	10	toxicity
NCT0000424211	NCT00004242_11_T1	PHENOTYPE	12	13	disease progression
NCT0000424212	NCT00004242_12_T0	GENE	2	2	1/6
NCT0000424212	NCT00004242_12_T1	COMPOUND	8	8	oxaliplatin
NCT0000424212	NCT00004242_12_T2	COMPOUND	10	10	gemcitabine
NCT0000424212	NCT00004242_12_T3	GENE	16	16	MTD
NCT0000424213	NCT00004242_13_T0	PHENOTYPE	17	17	toxicity
NCT0000424213	NCT00004242_13_T1	GENE	1	1	MTD
NCT0000424214	NCT00004242_14_T0	GENE	3	3	II
NCT0000424214	NCT00004242_14_T1	GENE	12	12	MTD
NCT0000424216	NCT00004242_16_T0	COMPOUND	7	7	oxaliplatin
NCT0000424216	NCT00004242_16_T1	COMPOUND	8	8	gemcitabine
NCT0000424216	NCT00004242_16_T2	COMPOUND	16	17	I dose
NCT0000424217	NCT00004242_17_T0	PHENOTYPE	4	5	disease progression
NCT000042430	NCT00004243_0_T0	PHENOTYPE	9	9	Recurrent
NCT000042430	NCT00004243_0_T1	PHENOTYPE	10	11	Solid Tumor
NCT000042432	NCT00004243_2_T0	CELL	9	9	cells
NCT000042432	NCT00004243_2_T1	PHENOTYPE	8	8	tumor
NCT000042433	NCT00004243_3_T0	COMPOUND	9	9	docetaxel
NCT000042433	NCT00004243_3_T1	COMPOUND	11	11	oxaliplatin
NCT000042433	NCT00004243_3_T2	PHENOTYPE	19	19	recurrent
NCT000042433	NCT00004243_3_T3	PHENOTYPE	20	21	solid tumor
NCT000042435	NCT00004243_5_T0	COMPOUND	6	6	docetaxel
NCT000042435	NCT00004243_5_T1	COMPOUND	10	10	oxaliplatin
NCT000042435	NCT00004243_5_T2	PHENOTYPE	16	16	recurrent
NCT000042435	NCT00004243_5_T3	PHENOTYPE	17	18	solid tumors
NCT000042437	NCT00004243_7_T0	PHENOTYPE	2	2	toxicities
NCT000042439	NCT00004243_9_T0	PHENOTYPE	4	4	pharmacodynamics
NCT000042439	NCT00004243_9_T1	PHENOTYPE	2	2	pharmacokinetics
NCT0000424310	NCT00004243_10_T0	COMPOUND	8	8	docetaxel
NCT0000424311	NCT00004243_11_T0	COMPOUND	2	2	docetaxel
NCT0000424311	NCT00004243_11_T1	COMPOUND	9	9	oxaliplatin
NCT0000424311	NCT00004243_11_T2	GENE	3	3	IV
NCT0000424311	NCT00004243_11_T3	GENE	10	10	IV
NCT0000424312	NCT00004243_12_T0	PHENOTYPE	7	7	toxicity
NCT0000424312	NCT00004243_12_T1	PHENOTYPE	9	10	disease progression
NCT0000424313	NCT00004243_13_T0	COMPOUND	8	8	docetaxel
NCT0000424313	NCT00004243_13_T1	GENE	14	14	MTD
NCT0000424314	NCT00004243_14_T0	PHENOTYPE	18	18	toxicities
NCT0000424314	NCT00004243_14_T1	GENE	1	1	MTD
NCT0000424315	NCT00004243_15_T0	PHENOTYPE	4	5	disease progression
NCT000042441	NCT00004244_1_T0	CELL	4	4	cells
NCT000042441	NCT00004244_1_T1	CELL	23	23	cells
NCT000042441	NCT00004244_1_T2	PHENOTYPE	3	3	tumor
NCT000042441	NCT00004244_1_T3	PHENOTYPE	11	11	tumor
NCT000042441	NCT00004244_1_T4	CELL	17	19	white blood cells
NCT000042443	NCT00004244_3_T0	GENE	1	1	interleukin-12
NCT000042443	NCT00004244_3_T1	CELL	9	9	cells
NCT000042443	NCT00004244_3_T2	GENE	3	3	interferon
NCT0000424411	NCT00004244_11_T0	GENE	4	4	SC
NCT0000424411	NCT00004244_11_T1	GENE	11	11	SC
NCT0000424411	NCT00004244_11_T2	GENE	2	2	interleukin-12
NCT0000424411	NCT00004244_11_T3	GENE	9	9	interferon
NCT0000424412	NCT00004244_12_T0	PHENOTYPE	7	7	toxicity
NCT0000424412	NCT00004244_12_T1	PHENOTYPE	9	10	disease progression
NCT0000424413	NCT00004244_13_T0	GENE	8	8	interleukin-12
NCT0000424413	NCT00004244_13_T1	GENE	10	10	interferon
NCT0000424413	NCT00004244_13_T2	GENE	17	17	MTD
NCT0000424414	NCT00004244_14_T0	PHENOTYPE	22	22	toxicities
NCT0000424414	NCT00004244_14_T1	GENE	1	1	MTD
NCT0000424416	NCT00004244_16_T0	GENE	1	1	II
NCT0000424416	NCT00004244_16_T1	GENE	6	6	SC
NCT0000424416	NCT00004244_16_T2	GENE	18	18	interleukin-12
NCT0000424416	NCT00004244_16_T3	GENE	0	0	ARM
NCT0000424416	NCT00004244_16_T4	GENE	4	4	interferon
NCT0000424416	NCT00004244_16_T5	GENE	22	22	interferon
NCT0000424417	NCT00004244_17_T0	GENE	6	6	interleukin-12
NCT0000424417	NCT00004244_17_T1	GENE	1	1	III
NCT0000424417	NCT00004244_17_T2	GENE	0	0	ARM
NCT0000424417	NCT00004244_17_T3	GENE	10	10	interferon
NCT0000424417	NCT00004244_17_T4	GENE	14	14	MTD
NCT000042453	NCT00004245_3_T0	COMPOUND	4	4	sodium
NCT000042453	NCT00004245_3_T1	COMPOUND	5	5	salicylate
NCT000042455	NCT00004245_5_T0	PHENOTYPE	12	12	toxicity
NCT000042455	NCT00004245_5_T1	PHENOTYPE	14	15	disease progression
NCT000042456	NCT00004245_6_T0	COMPOUND	6	6	sodium
NCT000042456	NCT00004245_6_T1	COMPOUND	7	7	salicylate
NCT000042457	NCT00004245_7_T0	PHENOTYPE	2	4	acute myelogenous leukemia
NCT000042462	NCT00004246_2_T0	CELL	10	10	cells
NCT000042462	NCT00004246_2_T1	PHENOTYPE	9	9	tumor
NCT000042463	NCT00004246_3_T0	CELL	9	9	cells
NCT000042463	NCT00004246_3_T1	PHENOTYPE	8	8	tumor
NCT000042464	NCT00004246_4_T0	ORGAN	26	26	larynx
NCT000042464	NCT00004246_4_T1	ORGAN	24	24	pharynx
NCT000042464	NCT00004246_4_T2	COMPOUND	12	12	fludarabine
NCT000042464	NCT00004246_4_T3	PHENOTYPE	18	20	locally advanced cancer
NCT000042464	NCT00004246_4_T4	PHENOTYPE	20	23	cancer of the mouth
NCT000042469	NCT00004246_9_T0	PHENOTYPE	5	5	toxicity
NCT0000424610	NCT00004246_10_T0	COMPOUND	8	8	fludarabine
NCT0000424611	NCT00004246_11_T0	GENE	5	5	1.5
NCT0000424612	NCT00004246_12_T0	GENE	6	6	1.5
NCT0000424612	NCT00004246_12_T1	COMPOUND	2	2	fludarabine
NCT0000424612	NCT00004246_12_T2	GENE	3	3	IV
NCT0000424613	NCT00004246_13_T0	GENE	3	3	3.4
NCT0000424614	NCT00004246_14_T0	COMPOUND	8	8	fludarabine
NCT0000424614	NCT00004246_14_T1	GENE	14	14	MTD
NCT0000424615	NCT00004246_15_T0	PHENOTYPE	11	11	toxicity
NCT0000424615	NCT00004246_15_T1	GENE	1	1	MTD
NCT0000424615	NCT00004246_15_T2	PHENOTYPE	13	13	nearest
NCT0000424616	NCT00004246_16_T0	PHENOTYPE	12	12	acute
NCT0000424616	NCT00004246_16_T1	PHENOTYPE	15	15	resolved
NCT0000424617	NCT00004246_17_T0	GENE	14	14	1.5
NCT000042481	NCT00004248_1_T0	CELL	12	12	cells
NCT000042481	NCT00004248_1_T1	GENE	0	0	Interleukin-2
NCT000042481	NCT00004248_1_T2	PHENOTYPE	10	11	liver cancer
NCT000042481	NCT00004248_1_T3	CELL	5	7	white blood cells
NCT000042482	NCT00004248_2_T0	GENE	2	2	II
NCT000042482	NCT00004248_2_T1	COMPOUND	9	9	doxorubicin
NCT000042482	NCT00004248_2_T2	PHENOTYPE	18	19	liver cancer
NCT000042484	NCT00004248_4_T0	PHENOTYPE	23	23	peripheral
NCT000042484	NCT00004248_4_T1	GENE	9	9	interleukin-2
NCT000042484	NCT00004248_4_T2	CELL	19	20	T cells
NCT000042484	NCT00004248_4_T3	PHENOTYPE	15	16	hepatocellular carcinoma
NCT000042484	NCT00004248_4_T4	PHENOTYPE	29	30	hepatocellular carcinoma
NCT000042484	NCT00004248_4_T5	BIOLOGICAL_PROCESS	3	5	response to doxorubicin
NCT000042486	NCT00004248_6_T0	PHENOTYPE	2	2	toxicity
NCT0000424810	NCT00004248_10_T0	PHENOTYPE	2	2	progression
NCT0000424812	NCT00004248_12_T0	PHENOTYPE	6	6	tumor
NCT0000424812	NCT00004248_12_T1	PHENOTYPE	8	8	progression
NCT0000424813	NCT00004248_13_T0	GENE	13	13	interleukin-2
NCT0000424813	NCT00004248_13_T1	GENE	14	14	IL-2
NCT0000424813	NCT00004248_13_T2	GENE	6	6	3.5
NCT0000424813	NCT00004248_13_T3	COMPOUND	3	3	doxorubicin
NCT0000424813	NCT00004248_13_T4	GENE	4	4	IV
NCT0000424813	NCT00004248_13_T5	GENE	15	15	IV
NCT0000424814	NCT00004248_14_T0	GENE	22	22	IL-2
NCT0000424815	NCT00004248_15_T0	GENE	21	21	IL-2
NCT0000424815	NCT00004248_15_T1	COMPOUND	13	13	doxorubicin
NCT0000424816	NCT00004248_16_T0	GENE	13	13	IL-2
NCT0000424816	NCT00004248_16_T1	PHENOTYPE	6	7	progressive disease
NCT000042491	NCT00004249_1_T0	CELL	16	16	cells
NCT000042491	NCT00004249_1_T1	ORGAN	11	12	immune system
NCT000042496	NCT00004249_6_T0	PHENOTYPE	3	3	toxicities
NCT000042496	NCT00004249_6_T1	BIOLOGICAL_PROCESS	11	12	immune response
NCT000042497	NCT00004249_7_T0	GENE	22	22	1.4
NCT000042497	NCT00004249_7_T1	GENE	6	6	limpet
NCT000042497	NCT00004249_7_T2	COMPOUND	3	4	polysialic acid
NCT000042501	NCT00004250_1_T0	CELL	11	11	cells
NCT000042501	NCT00004250_1_T1	TISSUE	18	18	tissues
NCT000042501	NCT00004250_1_T2	PHENOTYPE	4	4	tumor
NCT000042501	NCT00004250_1_T3	PHENOTYPE	10	10	tumor
NCT000042504	NCT00004250_4_T0	ORGAN	14	14	extremity
NCT000042505	NCT00004250_5_T0	ORGAN	2	2	limb
NCT000042505	NCT00004250_5_T1	ORGAN	14	14	limb
NCT000042505	NCT00004250_5_T2	COMPOUND	5	5	melphalan
NCT000042508	NCT00004250_8_T0	GENE	4	4	1.2
NCT000042508	NCT00004250_8_T1	GENE	6	6	3.4
NCT000042511	NCT00004251_1_T0	GENE	2	2	II
NCT000042511	NCT00004251_1_T1	COMPOUND	9	9	letrozole
NCT000042511	NCT00004251_1_T2	PHENOTYPE	15	15	recurrent
NCT000042511	NCT00004251_1_T3	PHENOTYPE	17	19	metastatic endometrial cancer
NCT000042513	NCT00004251_3_T0	COMPOUND	4	4	letrozole
NCT000042513	NCT00004251_3_T1	PHENOTYPE	9	9	tumor
NCT000042513	NCT00004251_3_T2	PHENOTYPE	14	14	progression
NCT000042513	NCT00004251_3_T3	PHENOTYPE	18	18	recurrent
NCT000042513	NCT00004251_3_T4	PHENOTYPE	20	22	metastatic endometrial cancer
NCT000042515	NCT00004251_5_T0	PHENOTYPE	2	2	toxicity
NCT000042515	NCT00004251_5_T1	COMPOUND	4	4	letrozole
NCT000042517	NCT00004251_7_T0	GENE	5	5	receptor
NCT000042517	NCT00004251_7_T1	PHENOTYPE	4	4	tumor
NCT000042517	NCT00004251_7_T2	PHENOTYPE	9	9	tumor
NCT000042517	NCT00004251_7_T3	PHENOTYPE	13	13	tumor
NCT000042517	NCT00004251_7_T4	MOLECULAR_FUNCTION	10	11	aromatase activity
NCT000042518	NCT00004251_8_T0	COMPOUND	5	5	letrozole
NCT000042519	NCT00004251_9_T0	PHENOTYPE	14	14	toxicity
NCT000042519	NCT00004251_9_T1	PHENOTYPE	10	11	disease progression
NCT000042522	NCT00004252_2_T0	PHENOTYPE	16	18	metastatic colorectal cancer
NCT000042523	NCT00004252_3_T0	GENE	3	3	III
NCT000042523	NCT00004252_3_T1	COMPOUND	10	10	leucovorin
NCT000042523	NCT00004252_3_T2	PHENOTYPE	22	24	metastatic colorectal cancer
NCT000042525	NCT00004252_5_T0	COMPOUND	15	15	calcium
NCT000042525	NCT00004252_5_T1	COMPOUND	14	14	leucovorin
NCT000042525	NCT00004252_5_T2	PHENOTYPE	7	9	metastatic colorectal cancer
NCT000042527	NCT00004252_7_T0	PHENOTYPE	4	4	progression
NCT0000425213	NCT00004252_13_T0	PHENOTYPE	4	6	quality of life
NCT0000425217	NCT00004252_17_T0	COMPOUND	9	9	calcium
NCT0000425217	NCT00004252_17_T1	COMPOUND	8	8	leucovorin
NCT0000425219	NCT00004252_19_T0	COMPOUND	10	10	1
NCT0000425219	NCT00004252_19_T1	COMPOUND	31	31	1
NCT0000425219	NCT00004252_19_T2	ORGAN	15	15	colon
NCT0000425219	NCT00004252_19_T3	ORGAN	17	17	rectum
NCT0000425219	NCT00004252_19_T4	PHENOTYPE	20	21	evaluable disease
NCT0000425222	NCT00004252_22_T0	PHENOTYPE	13	13	toxicity
NCT0000425222	NCT00004252_22_T1	PHENOTYPE	9	10	disease progression
NCT0000425223	NCT00004252_23_T0	PHENOTYPE	0	2	Quality of life
NCT000042531	NCT00004253_1_T0	CELL	18	18	cells
NCT000042531	NCT00004253_1_T1	PHENOTYPE	12	12	tumor
NCT000042531	NCT00004253_1_T2	PHENOTYPE	17	17	tumor
NCT000042535	NCT00004253_5_T0	COMPOUND	2	2	paclitaxel
NCT000042535	NCT00004253_5_T1	GENE	3	3	IV
NCT000042535	NCT00004253_5_T2	GENE	11	11	IV
NCT000042538	NCT00004253_8_T0	PHENOTYPE	0	2	Quality of life
NCT000042541	NCT00004254_1_T0	GENE	2	2	II
NCT000042541	NCT00004254_1_T1	COMPOUND	9	9	raltitrexed
NCT000042541	NCT00004254_1_T2	PHENOTYPE	15	16	malignant mesothelioma
NCT000042543	NCT00004254_3_T0	PHENOTYPE	5	5	toxicities
NCT000042543	NCT00004254_3_T1	COMPOUND	7	7	raltitrexed
NCT000042543	NCT00004254_3_T2	PHENOTYPE	12	13	malignant mesothelioma
NCT000042547	NCT00004254_7_T0	COMPOUND	8	8	raltitrexed
NCT000042547	NCT00004254_7_T1	GENE	9	9	IV
NCT000042548	NCT00004254_8_T0	PHENOTYPE	19	19	toxicity
NCT000042548	NCT00004254_8_T1	PHENOTYPE	15	16	disease progression
NCT000042549	NCT00004254_9_T0	PHENOTYPE	7	8	disease progression
NCT000042551	NCT00004255_1_T0	PHENOTYPE	26	26	acute
NCT000042551	NCT00004255_1_T1	PHENOTYPE	28	29	chronic leukemia
NCT000042551	NCT00004255_1_T2	PHENOTYPE	21	22	graft-versus-host disease
NCT000042551	NCT00004255_1_T3	ORGAN	11	12	bone marrow
NCT000042551	NCT00004255_1_T4	ORGAN	17	18	bone marrow
NCT000042551	NCT00004255_1_T5	ORGAN	33	34	bone marrow
NCT000042554	NCT00004255_4_T0	PHENOTYPE	13	13	acute
NCT000042554	NCT00004255_4_T1	PHENOTYPE	11	11	chronic
NCT000042555	NCT00004255_5_T0	PHENOTYPE	10	11	myelodysplastic syndromes
NCT000042555	NCT00004255_5_T1	PHENOTYPE	0	2	Acute myelogenous leukemia
NCT000042557	NCT00004255_7_T0	GENE	20	20	globulin
NCT000042557	NCT00004255_7_T1	GENE	8	8	IV
NCT000042557	NCT00004255_7_T2	GENE	13	13	IV
NCT000042557	NCT00004255_7_T3	GENE	21	21	IV
NCT000042557	NCT00004255_7_T4	COMPOUND	26	26	2
NCT000042557	NCT00004255_7_T5	COMPOUND	33	33	3
NCT000042557	NCT00004255_7_T6	PHENOTYPE	4	4	conditioning
NCT000042557	NCT00004255_7_T7	CELL	19	19	thymocyte
NCT000042557	NCT00004255_7_T8	COMPOUND	7	7	fludarabine
NCT000042557	NCT00004255_7_T9	COMPOUND	12	12	cyclophosphamide
NCT000042558	NCT00004255_8_T0	COMPOUND	13	13	2
NCT000042558	NCT00004255_8_T1	COMPOUND	3	3	methylprednisolone
NCT000042558	NCT00004255_8_T2	GENE	4	4	IV
NCT000042559	NCT00004255_9_T0	COMPOUND	7	7	1
NCT000042559	NCT00004255_9_T1	GENE	1	1	IV
NCT000042559	NCT00004255_9_T2	GENE	13	13	IV
NCT0000425510	NCT00004255_10_T0	ORGAN	0	1	Bone marrow
NCT000042561	NCT00004256_1_T0	CELL	7	7	cells
NCT000042561	NCT00004256_1_T1	GENE	3	3	sargramostim
NCT000042561	NCT00004256_1_T2	PHENOTYPE	11	14	effects of radiation therapy
NCT000042562	NCT00004256_2_T0	GENE	3	3	II
NCT000042562	NCT00004256_2_T1	PHENOTYPE	13	13	mucositis
NCT000042562	NCT00004256_2_T2	GENE	10	10	sargramostim
NCT000042562	NCT00004256_2_T3	PHENOTYPE	22	23	laryngeal cancer
NCT000042567	NCT00004256_7_T0	PHENOTYPE	5	5	mucositis
NCT000042571	NCT00004257_1_T0	CELL	8	8	cells
NCT000042571	NCT00004257_1_T1	PHENOTYPE	7	7	tumor
NCT000042572	NCT00004257_2_T0	CELL	15	15	cells
NCT000042572	NCT00004257_2_T1	PHENOTYPE	14	14	tumor
NCT000042573	NCT00004257_3_T0	COMPOUND	10	10	oxaliplatin
NCT000042573	NCT00004257_3_T1	PHENOTYPE	24	25	stomach cancer
NCT000042575	NCT00004257_5_T0	COMPOUND	7	7	oxaliplatin
NCT000042576	NCT00004257_6_T0	COMPOUND	2	2	oxaliplatin
NCT000042576	NCT00004257_6_T1	GENE	3	3	IV
NCT000042576	NCT00004257_6_T2	GENE	15	15	IV
NCT000042578	NCT00004257_8_T0	GENE	18	18	3.4
NCT000042579	NCT00004257_9_T0	COMPOUND	3	3	oxaliplatin
NCT0000425710	NCT00004257_10_T0	COMPOUND	8	8	oxaliplatin
NCT0000425710	NCT00004257_10_T1	GENE	16	16	MTD
NCT0000425711	NCT00004257_11_T0	PHENOTYPE	21	21	toxicity
NCT0000425711	NCT00004257_11_T1	GENE	1	1	MTD
NCT000042588	NCT00004258_8_T0	PHENOTYPE	11	11	toxicity
NCT000042589	NCT00004258_9_T0	PHENOTYPE	15	16	disease progression
NCT0000425811	NCT00004258_11_T0	PHENOTYPE	22	22	toxicities
NCT0000425811	NCT00004258_11_T1	GENE	1	1	MTD
NCT0000425812	NCT00004258_12_T0	PHENOTYPE	17	18	disease progression
NCT000042591	NCT00004259_1_T0	COMPOUND	6	6	temozolomide
NCT000042591	NCT00004259_1_T1	CELL	16	16	cells
NCT000042591	NCT00004259_1_T2	PHENOTYPE	15	15	tumor
NCT000042591	NCT00004259_1_T3	COMPOUND	9	9	lomustine
NCT000042592	NCT00004259_2_T0	CELL	9	9	cells
NCT000042592	NCT00004259_2_T1	PHENOTYPE	8	8	tumor
NCT000042593	NCT00004259_3_T0	COMPOUND	11	11	temozolomide
NCT000042593	NCT00004259_3_T1	GENE	4	4	III
NCT000042593	NCT00004259_3_T2	COMPOUND	25	25	lomustine
NCT000042593	NCT00004259_3_T3	PHENOTYPE	33	34	mixed gliomas
NCT000042593	NCT00004259_3_T4	PHENOTYPE	30	31	anaplastic astrocytoma
NCT0000425910	NCT00004259_10_T0	COMPOUND	3	3	temozolomide
NCT0000425910	NCT00004259_10_T1	GENE	6	6	1.5
NCT0000425912	NCT00004259_12_T0	GENE	8	8	1.2
NCT0000425912	NCT00004259_12_T1	GENE	12	12	1.3
NCT0000425912	NCT00004259_12_T2	GENE	3	3	IV
NCT0000425912	NCT00004259_12_T3	GENE	6	6	IV
NCT0000425912	NCT00004259_12_T4	COMPOUND	5	5	lomustine
NCT0000425914	NCT00004259_14_T0	COMPOUND	15	15	temozolomide
NCT0000425914	NCT00004259_14_T1	GENE	27	27	1.5
NCT0000425914	NCT00004259_14_T2	GENE	3	3	IV
NCT0000425914	NCT00004259_14_T3	GENE	6	6	IV
NCT0000425914	NCT00004259_14_T4	COMPOUND	5	5	lomustine
NCT0000425914	NCT00004259_14_T5	COMPOUND	23	23	lomustine
NCT000042602	NCT00004260_2_T0	GENE	9	9	interleukin-12
NCT000042602	NCT00004260_2_T1	PHENOTYPE	17	18	Hodgkin's lymphoma
NCT000042604	NCT00004260_4_T0	GENE	6	6	interleukin-12
NCT000042604	NCT00004260_4_T1	PHENOTYPE	16	17	Hodgkin's lymphoma
NCT000042606	NCT00004260_6_T0	PHENOTYPE	2	2	toxicities
NCT000042608	NCT00004260_8_T0	PHENOTYPE	2	2	pharmacodynamics
NCT0000426011	NCT00004260_11_T0	GENE	8	8	interleukin-12
NCT0000426012	NCT00004260_12_T0	GENE	3	3	IV
NCT0000426013	NCT00004260_13_T0	GENE	7	7	SC
NCT0000426013	NCT00004260_13_T1	GENE	6	6	interleukin-12
NCT0000426014	NCT00004260_14_T0	GENE	4	4	SC
NCT0000426014	NCT00004260_14_T1	GENE	3	3	interleukin-12
NCT0000426015	NCT00004260_15_T0	GENE	10	10	interleukin-12
NCT0000426015	NCT00004260_15_T1	PHENOTYPE	20	21	disease progression
NCT0000426016	NCT00004260_16_T0	GENE	8	8	interleukin-12
NCT0000426018	NCT00004260_18_T0	GENE	16	16	SC
NCT0000426018	NCT00004260_18_T1	GENE	15	15	interleukin-12
NCT0000426019	NCT00004260_19_T0	PHENOTYPE	22	23	disease progression
NCT0000426022	NCT00004260_22_T0	PHENOTYPE	18	18	lymphoma
NCT0000426022	NCT00004260_22_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000426022	NCT00004260_22_T2	PHENOTYPE	16	17	high grade
NCT000042615	NCT00004261_5_T0	PHENOTYPE	2	2	toxic
NCT000042617	NCT00004261_7_T0	GENE	7	7	1.2
NCT000042617	NCT00004261_7_T1	COMPOUND	2	2	etanidazole
NCT000042617	NCT00004261_7_T2	GENE	5	5	IV
NCT000042618	NCT00004261_8_T0	PHENOTYPE	13	13	tumor
NCT000042619	NCT00004261_9_T0	GENE	14	14	MTD
NCT0000426110	NCT00004261_10_T0	PHENOTYPE	17	17	toxicity
NCT0000426110	NCT00004261_10_T1	GENE	1	1	MTD
NCT000042621	NCT00004262_1_T0	CELL	8	8	cells
NCT000042621	NCT00004262_1_T1	PHENOTYPE	7	7	tumor
NCT000042622	NCT00004262_2_T0	CELL	9	9	cells
NCT000042622	NCT00004262_2_T1	PHENOTYPE	8	8	tumor
NCT000042622	NCT00004262_2_T2	COMPOUND	3	3	gadolinium
NCT000042624	NCT00004262_4_T0	PHENOTYPE	6	6	toxicity
NCT000042624	NCT00004262_4_T1	COMPOUND	8	8	gadolinium
NCT000042624	NCT00004262_4_T2	PHENOTYPE	20	22	supratentorial glioblastoma multiforme
NCT000042626	NCT00004262_6_T0	PHENOTYPE	7	7	concentrations
NCT000042626	NCT00004262_6_T1	GENE	17	17	MRI
NCT000042626	NCT00004262_6_T2	PHENOTYPE	2	2	tumor
NCT000042626	NCT00004262_6_T3	GENE	13	13	1.5
NCT000042626	NCT00004262_6_T4	ORGAN	6	6	plasma
NCT000042628	NCT00004262_8_T0	PHENOTYPE	23	23	tumor
NCT000042628	NCT00004262_8_T1	GENE	11	11	1.5
NCT0000426211	NCT00004262_11_T0	GENE	11	11	IV
NCT0000426211	NCT00004262_11_T1	COMPOUND	9	9	gadolinium
NCT0000426212	NCT00004262_12_T0	PHENOTYPE	5	5	tumor
NCT0000426212	NCT00004262_12_T1	GENE	14	14	IV
NCT0000426212	NCT00004262_12_T2	COMPOUND	12	12	gadolinium
NCT0000426213	NCT00004262_13_T0	GENE	15	15	MTD
NCT0000426213	NCT00004262_13_T1	COMPOUND	8	8	gadolinium
NCT0000426214	NCT00004262_14_T0	PHENOTYPE	22	22	toxicity
NCT0000426214	NCT00004262_14_T1	GENE	1	1	MTD
NCT000042631	NCT00004263_1_T0	COMPOUND	8	8	cytarabine
NCT000042631	NCT00004263_1_T1	CELL	4	4	cells
NCT000042638	NCT00004263_8_T0	PHENOTYPE	4	4	toxicity
NCT000042638	NCT00004263_8_T1	PHENOTYPE	7	7	pharmacodynamics
NCT000042638	NCT00004263_8_T2	PHENOTYPE	5	5	pharmacokinetics
NCT0000426311	NCT00004263_11_T0	COMPOUND	9	9	cytarabine
NCT0000426312	NCT00004263_12_T0	COMPOUND	2	2	cytarabine
NCT0000426312	NCT00004263_12_T1	GENE	9	9	1.4
NCT0000426312	NCT00004263_12_T2	GENE	3	3	IV
NCT0000426313	NCT00004263_13_T0	GENE	9	9	2.4
NCT0000426313	NCT00004263_13_T1	GENE	3	3	IV
NCT0000426314	NCT00004263_14_T0	PHENOTYPE	19	19	toxicity
NCT0000426314	NCT00004263_14_T1	PHENOTYPE	15	16	disease progression
NCT0000426315	NCT00004263_15_T0	COMPOUND	8	8	cytarabine
NCT0000426315	NCT00004263_15_T1	GENE	14	14	MTD
NCT0000426316	NCT00004263_16_T0	PHENOTYPE	16	16	toxicity
NCT0000426316	NCT00004263_16_T1	GENE	1	1	MTD
NCT0000426320	NCT00004263_20_T0	PHENOTYPE	13	13	RAEB-T
NCT0000426320	NCT00004263_20_T1	PHENOTYPE	11	11	RAEB
NCT0000426320	NCT00004263_20_T2	PHENOTYPE	9	10	myelodysplastic syndromes
NCT0000426320	NCT00004263_20_T3	PHENOTYPE	5	7	acute myelogenous leukemia
NCT0000426329	NCT00004263_29_T0	PHENOTYPE	18	18	toxic
NCT0000426329	NCT00004263_29_T1	PHENOTYPE	28	29	rapidly progressive
NCT0000426329	NCT00004263_29_T2	PHENOTYPE	29	30	progressive disease
NCT0000426332	NCT00004263_32_T0	COMPOUND	2	2	creatinine
NCT0000426332	NCT00004263_32_T1	COMPOUND	4	4	creatinine
NCT0000426344	NCT00004263_44_T0	PHENOTYPE	1	1	proliferative
NCT0000426349	NCT00004263_49_T0	ORGAN	6	6	marrow
NCT0000426349	NCT00004263_49_T1	ORGAN	7	7	transplant
NCT0000426349	NCT00004263_49_T2	ORGAN	16	16	transplant
NCT000042642	NCT00004264_2_T0	CELL	8	8	cells
NCT000042642	NCT00004264_2_T1	COMPOUND	4	4	amifostine
NCT000042642	NCT00004264_2_T2	PHENOTYPE	12	14	effects of chemotherapy
NCT0000426410	NCT00004264_10_T0	COMPOUND	9	9	docetaxel
NCT0000426411	NCT00004264_11_T0	COMPOUND	10	10	docetaxel
NCT0000426411	NCT00004264_11_T1	COMPOUND	2	2	amifostine
NCT0000426411	NCT00004264_11_T2	COMPOUND	20	20	amifostine
NCT0000426411	NCT00004264_11_T3	COMPOUND	28	28	cisplatin
NCT0000426411	NCT00004264_11_T4	GENE	3	3	IV
NCT0000426411	NCT00004264_11_T5	GENE	11	11	IV
NCT0000426411	NCT00004264_11_T6	GENE	29	29	IV
NCT0000426412	NCT00004264_12_T0	PHENOTYPE	13	13	toxicity
NCT0000426412	NCT00004264_12_T1	PHENOTYPE	9	10	disease progression
NCT0000426413	NCT00004264_13_T0	COMPOUND	7	7	docetaxel
NCT000042656	NCT00004265_6_T0	PHENOTYPE	5	5	toxicities
NCT000042656	NCT00004265_6_T1	PHENOTYPE	14	15	recurrent NSCLC
NCT000042659	NCT00004265_9_T0	COMPOUND	3	3	paclitaxel
NCT000042659	NCT00004265_9_T1	GENE	4	4	IV
NCT0000426510	NCT00004265_10_T0	PHENOTYPE	13	13	toxicity
NCT0000426510	NCT00004265_10_T1	PHENOTYPE	9	10	disease progression
NCT000042665	NCT00004266_5_T0	PHENOTYPE	13	13	strategies
NCT000042665	NCT00004266_5_T1	COMPOUND	4	4	simvastatin
NCT000042665	NCT00004266_5_T2	PHENOTYPE	23	23	nephropathy
NCT000042665	NCT00004266_5_T3	PHENOTYPE	25	26	vascular diseases
NCT000042665	NCT00004266_5_T4	GENE	6	9	3-hydroxy-3-methylglutaryl coenzyme A reductase
NCT000042668	NCT00004266_8_T0	COMPOUND	5	5	nifedipine
NCT000042668	NCT00004266_8_T1	PHENOTYPE	11	13	high blood pressure
NCT0000426610	NCT00004266_10_T0	COMPOUND	2	2	doxazosin
NCT0000426611	NCT00004266_11_T0	COMPOUND	5	5	lisinopril
NCT0000426611	NCT00004266_11_T1	PHENOTYPE	11	13	high blood pressure
NCT0000426613	NCT00004266_13_T0	COMPOUND	2	2	doxazosin
NCT0000426614	NCT00004266_14_T0	COMPOUND	5	5	nifedipine
NCT0000426614	NCT00004266_14_T1	COMPOUND	15	15	simvastatin
NCT0000426614	NCT00004266_14_T2	PHENOTYPE	11	13	high blood pressure
NCT0000426615	NCT00004266_15_T0	COMPOUND	1	1	cholestyramine
NCT0000426616	NCT00004266_16_T0	COMPOUND	1	1	cholestyramine
NCT0000426616	NCT00004266_16_T1	COMPOUND	14	14	cholestyramine
NCT0000426616	NCT00004266_16_T2	COMPOUND	10	10	gemfibrozil
NCT0000426617	NCT00004266_17_T0	COMPOUND	4	4	lisinopril
NCT0000426617	NCT00004266_17_T1	COMPOUND	14	14	simvastatin
NCT0000426617	NCT00004266_17_T2	PHENOTYPE	10	12	high blood pressure
NCT000042680	NCT00004268_0_T0	GENE	1	1	II
NCT000042680	NCT00004268_0_T1	PHENOTYPE	7	8	Orthostatic Hypotension
NCT000042682	NCT00004268_2_T0	COMPOUND	10	10	midodrine
NCT000042682	NCT00004268_2_T1	PHENOTYPE	15	16	orthostatic hypotension
NCT000042684	NCT00004268_4_T0	PHENOTYPE	2	4	quality of life
NCT000042686	NCT00004268_6_T0	COMPOUND	3	3	midodrine
NCT000042686	NCT00004268_6_T1	COMPOUND	16	16	midodrine
NCT000042686	NCT00004268_6_T2	GENE	12	12	3.5
NCT000042687	NCT00004268_7_T0	PHENOTYPE	0	2	Quality of life
NCT000042756	NCT00004275_6_T0	GENE	0	0	GH
NCT000042756	NCT00004275_6_T1	COMPOUND	8	8	oxandrolone
NCT000042757	NCT00004275_7_T0	COMPOUND	5	5	estrogen
NCT000042760	NCT00004276_0_T0	GENE	1	1	II
NCT000042760	NCT00004276_0_T1	PHENOTYPE	12	13	HIV Infections
NCT000042762	NCT00004276_2_T0	PHENOTYPE	4	4	toxic
NCT000042762	NCT00004276_2_T1	COMPOUND	2	2	thalidomide
NCT000042762	NCT00004276_2_T2	PHENOTYPE	6	7	inflammatory responses
NCT000042766	NCT00004276_6_T0	COMPOUND	2	2	thalidomide
NCT000042766	NCT00004276_6_T1	PHENOTYPE	8	8	HIV
NCT000042766	NCT00004276_6_T2	PHENOTYPE	4	4	immunity
NCT000042766	NCT00004276_6_T3	PHENOTYPE	10	11	mycobacterial infections
NCT000042769	NCT00004276_9_T0	COMPOUND	6	6	thalidomide
NCT000042784	NCT00004278_4_T0	COMPOUND	10	10	ganciclovir
NCT000042845	NCT00004284_5_T0	COMPOUND	9	9	potassium
NCT000042845	NCT00004284_5_T1	COMPOUND	10	10	citrate
NCT000042845	NCT00004284_5_T2	COMPOUND	4	5	potassium phosphate
NCT000042848	NCT00004284_8_T0	COMPOUND	5	5	potassium
NCT000042848	NCT00004284_8_T1	COMPOUND	6	6	citrate
NCT000042848	NCT00004284_8_T2	COMPOUND	2	3	potassium phosphate
NCT000042850	NCT00004285_0_T0	TISSUE	5	5	Membrane
NCT000042852	NCT00004285_2_T0	GENE	13	13	1.05
NCT000042852	NCT00004285_2_T1	GENE	15	15	1.45
NCT000042852	NCT00004285_2_T2	COMPOUND	8	8	urea
NCT000042852	NCT00004285_2_T3	PHENOTYPE	23	26	end stage renal disease
NCT000042854	NCT00004285_4_T0	TISSUE	9	9	membranes
NCT000042858	NCT00004285_8_T0	GENE	7	7	1.05
NCT000042858	NCT00004285_8_T1	GENE	12	12	1.45
NCT000042859	NCT00004285_9_T0	COMPOUND	15	15	urea
NCT0000428512	NCT00004285_12_T0	TISSUE	9	9	membranes
NCT000042861	NCT00004286_1_T0	GENE	11	11	globulin
NCT000042861	NCT00004286_1_T1	PHENOTYPE	20	23	chronic inflammatory demyelinating polyneuropathy
NCT000042863	NCT00004286_3_T0	GENE	6	6	globulin
NCT000042871	NCT00004287_1_T0	PHENOTYPE	17	18	cystic fibrosis
NCT000042873	NCT00004287_3_T0	PHENOTYPE	9	9	concentrations
NCT000042880	NCT00004288_0_T0	GENE	1	1	II
NCT000042880	NCT00004288_0_T1	PHENOTYPE	7	8	Ankylosing Spondylitis
NCT000042886	NCT00004288_6_T0	COMPOUND	1	1	sulfasalazine
NCT000042931	NCT00004293_1_T0	PHENOTYPE	4	4	toxicity
NCT000042931	NCT00004293_1_T1	GENE	6	6	glucocerebrosidase
NCT000042931	NCT00004293_1_T2	PHENOTYPE	12	13	Gaucher disease
NCT000042933	NCT00004293_3_T0	PHENOTYPE	6	6	severity
NCT000042941	NCT00004294_1_T0	GENE	3	3	glucocerebrosidase
NCT000042941	NCT00004294_1_T1	GENE	4	4	GC
NCT000042941	NCT00004294_1_T2	PHENOTYPE	18	19	Gaucher disease
NCT000042941	NCT00004294_1_T3	CELL	7	10	peripheral blood stem cells
NCT000042943	NCT00004294_3_T0	ORGAN	0	0	Transplant
NCT000042945	NCT00004294_5_T0	PHENOTYPE	13	13	peripheral
NCT000042945	NCT00004294_5_T1	CELL	15	15	leukocytes
NCT000042949	NCT00004294_9_T0	PHENOTYPE	15	15	peripheral
NCT000042949	NCT00004294_9_T1	CELL	16	16	leukocytes
NCT000042949	NCT00004294_9_T2	GENE	10	10	glucocerebrosidase
NCT000042949	NCT00004294_9_T3	ORGAN	6	6	transplants
NCT0000429410	NCT00004294_10_T0	GENE	1	1	G-CSF
NCT0000429410	NCT00004294_10_T1	CELL	7	8	stem cells
NCT0000429411	NCT00004294_11_T0	CELL	0	1	Stem cells
NCT000042961	NCT00004296_1_T0	PHENOTYPE	12	13	cystic fibrosis
NCT000042965	NCT00004296_5_T0	PHENOTYPE	15	16	Cystic Fibrosis
NCT000042967	NCT00004296_7_T0	GENE	4	4	NTM
NCT000042970	NCT00004297_0_T0	GENE	1	1	III
NCT000042970	NCT00004297_0_T1	PHENOTYPE	14	15	Status Epilepticus
NCT000042972	NCT00004297_2_T0	PHENOTYPE	9	9	complications
NCT000042972	NCT00004297_2_T1	COMPOUND	11	11	diazepam
NCT000042972	NCT00004297_2_T2	COMPOUND	13	13	lorazepam
NCT000042972	NCT00004297_2_T3	PHENOTYPE	22	23	status epilepticus
NCT000042974	NCT00004297_4_T0	PHENOTYPE	10	11	status epilepticus
NCT000042976	NCT00004297_6_T0	PHENOTYPE	12	12	affects
NCT000042979	NCT00004297_9_T0	GENE	8	8	San
NCT0000429710	NCT00004297_10_T0	PHENOTYPE	6	7	impaired consciousness
NCT0000429711	NCT00004297_11_T0	COMPOUND	3	3	diazepam
NCT0000429711	NCT00004297_11_T1	COMPOUND	4	4	lorazepam
NCT0000429711	NCT00004297_11_T2	BIOLOGICAL_PROCESS	8	8	transport
NCT0000429712	NCT00004297_12_T0	PHENOTYPE	6	6	seizure
NCT0000429713	NCT00004297_13_T0	PHENOTYPE	10	11	status epilepticus
NCT000043001	NCT00004300_1_T0	PHENOTYPE	20	20	pathophysiology
NCT000043001	NCT00004300_1_T1	ORGAN	18	19	basal ganglia
NCT000043001	NCT00004300_1_T2	PHENOTYPE	6	7	behavior disorders
NCT000043003	NCT00004300_3_T0	COMPOUND	4	4	bromocriptine
NCT000043003	NCT00004300_3_T1	COMPOUND	6	6	dopamine
NCT000043003	NCT00004300_3_T2	PHENOTYPE	12	13	stereotyped behavior
NCT000043003	NCT00004300_3_T3	PHENOTYPE	16	17	behavior disorders
NCT000043009	NCT00004300_9_T0	PHENOTYPE	2	2	reflecting
NCT000043009	NCT00004300_9_T1	COMPOUND	7	7	dopamine
NCT000043009	NCT00004300_9_T2	ORGAN	5	6	basal ganglia
NCT0000430015	NCT00004300_15_T0	PHENOTYPE	24	24	compulsions
NCT0000430015	NCT00004300_15_T1	COMPOUND	11	11	sertraline
NCT0000430015	NCT00004300_15_T2	PHENOTYPE	18	18	stereotypy
NCT0000430015	NCT00004300_15_T3	PHENOTYPE	21	22	self injury
NCT000043053	NCT00004305_3_T0	PHENOTYPE	16	17	adult onset
NCT000043055	NCT00004305_5_T0	GENE	7	7	C4
NCT000043055	NCT00004305_5_T1	GENE	31	31	C4
NCT000043055	NCT00004305_5_T2	GENE	15	15	receptor
NCT000043055	NCT00004305_5_T3	GENE	19	19	receptor
NCT000043055	NCT00004305_5_T4	ORGAN	30	30	plasma
NCT000043055	NCT00004305_5_T5	BIOLOGICAL_PROCESS	26	27	complement activation
NCT000043063	NCT00004306_3_T0	PHENOTYPE	9	9	ataxias
NCT000043065	NCT00004306_5_T0	ORGAN	18	19	brain stem
NCT000043071	NCT00004307_1_T0	PHENOTYPE	2	2	disorders
NCT000043071	NCT00004307_1_T1	PHENOTYPE	5	5	disorders
NCT000043071	NCT00004307_1_T2	PHENOTYPE	18	18	bloodstream
NCT000043071	NCT00004307_1_T3	COMPOUND	15	15	ammonia
NCT000043071	NCT00004307_1_T4	BIOLOGICAL_PROCESS	0	1	Urea cycle
NCT000043073	NCT00004307_3_T0	PHENOTYPE	10	10	disorders
NCT000043073	NCT00004307_3_T1	PHENOTYPE	20	20	disorders
NCT000043073	NCT00004307_3_T2	BIOLOGICAL_PROCESS	4	4	metabolism
NCT000043073	NCT00004307_3_T3	BIOLOGICAL_PROCESS	8	9	urea cycle
NCT000043074	NCT00004307_4_T0	PHENOTYPE	16	16	disorders
NCT000043074	NCT00004307_4_T1	BIOLOGICAL_PROCESS	9	9	metabolism
NCT000043074	NCT00004307_4_T2	BIOLOGICAL_PROCESS	14	15	urea cycle
NCT000043077	NCT00004307_7_T0	PHENOTYPE	15	15	deletion
NCT000043077	NCT00004307_7_T1	PHENOTYPE	19	19	deletion
NCT000043077	NCT00004307_7_T2	GENE	14	14	E1
NCT000043077	NCT00004307_7_T3	GENE	18	18	E3
NCT000043077	NCT00004307_7_T4	GENE	25	25	OTC
NCT000043077	NCT00004307_7_T5	GENE	23	24	ornithine transcarbamylase
NCT0000430710	NCT00004307_10_T0	COMPOUND	4	4	arginine
NCT0000430710	NCT00004307_10_T1	COMPOUND	7	7	benzoate
NCT0000430711	NCT00004307_11_T0	GENE	18	18	OTC
NCT0000430713	NCT00004307_13_T0	PHENOTYPE	9	9	closed
NCT0000430715	NCT00004307_15_T0	PHENOTYPE	43	43	severely
NCT0000430715	NCT00004307_15_T1	GENE	10	10	OTC
NCT0000430715	NCT00004307_15_T2	GENE	13	13	OTC
NCT0000430715	NCT00004307_15_T3	GENE	26	26	OTC
NCT0000430715	NCT00004307_15_T4	GENE	38	38	OTC
NCT0000430715	NCT00004307_15_T5	PHENOTYPE	23	24	enzyme deficiency
NCT0000430715	NCT00004307_15_T6	MOLECULAR_FUNCTION	36	37	enzyme activity
NCT0000430715	NCT00004307_15_T7	PHENOTYPE	7	9	ornithine transcarbamylase deficiency
NCT0000430715	NCT00004307_15_T8	PHENOTYPE	16	18	autosomal recessive disorder
NCT0000430715	NCT00004307_15_T9	PHENOTYPE	51	53	autosomal recessive disorder
NCT000043101	NCT00004310_1_T0	COMPOUND	10	10	clomipramine
NCT000043101	NCT00004310_1_T1	PHENOTYPE	7	7	pulse
NCT000043101	NCT00004310_1_T2	PHENOTYPE	23	25	obsessive compulsive disorder
NCT000043107	NCT00004310_7_T0	PHENOTYPE	15	15	pulse
NCT000043116	NCT00004311_6_T0	COMPOUND	11	11	acetate
NCT000043116	NCT00004311_6_T1	COMPOUND	10	10	leuprolide
NCT000043116	NCT00004311_6_T2	COMPOUND	13	13	spironolactone
NCT000043120	NCT00004312_0_T0	PHENOTYPE	10	11	Nephropathic Cystinosis
NCT000043122	NCT00004312_2_T0	PHENOTYPE	11	11	cystinosis
NCT000043122	NCT00004312_2_T1	COMPOUND	14	14	cysteamine
NCT000043124	NCT00004312_4_T0	ORGAN	7	7	transplant
NCT000043124	NCT00004312_4_T1	ORGAN	12	12	transplants
NCT000043127	NCT00004312_7_T0	ORGAN	3	3	kidney
NCT000043127	NCT00004312_7_T1	PHENOTYPE	7	7	initiation
NCT000043131	NCT00004313_1_T0	COMPOUND	5	5	DHEA
NCT000043131	NCT00004313_1_T1	COMPOUND	7	7	androgen
NCT000043131	NCT00004313_1_T2	COMPOUND	4	4	dehydroepiandrosterone
NCT000043131	NCT00004313_1_T3	GENE	9	9	hormone
NCT000043131	NCT00004313_1_T4	PHENOTYPE	16	17	Addison's disease
NCT000043131	NCT00004313_1_T5	PHENOTYPE	13	15	primary adrenal insufficiency
NCT000043134	NCT00004313_4_T0	COMPOUND	11	11	DHEA
NCT000043134	NCT00004313_4_T1	COMPOUND	5	5	androgen
NCT000043134	NCT00004313_4_T2	COMPOUND	10	10	dehydroepiandrosterone
NCT000043135	NCT00004313_5_T0	COMPOUND	8	8	DHEA
NCT000043136	NCT00004313_6_T0	COMPOUND	8	9	conjugated estrogens
NCT000043141	NCT00004314_1_T0	GENE	7	7	AICAR
NCT000043143	NCT00004314_3_T0	GENE	7	7	AICAR
NCT000043145	NCT00004314_5_T0	GENE	4	4	AICAR
NCT000043147	NCT00004314_7_T0	COMPOUND	3	3	folate
NCT000043147	NCT00004314_7_T1	COMPOUND	1	1	allopurinol
NCT000043151	NCT00004315_1_T0	PHENOTYPE	21	21	chronic
NCT000043151	NCT00004315_1_T1	COMPOUND	8	9	ursodeoxycholic acid
NCT000043151	NCT00004315_1_T2	PHENOTYPE	22	24	cholestatic liver disease
NCT000043151	NCT00004315_1_T3	PHENOTYPE	16	19	cystic fibrosis liver disease
NCT000043153	NCT00004315_3_T0	PHENOTYPE	4	4	pruritus
NCT000043153	NCT00004315_3_T1	ORGAN	8	8	liver
NCT000043153	NCT00004315_3_T2	PHENOTYPE	5	6	weight gain
NCT000043160	NCT00004316_0_T0	PHENOTYPE	8	9	Interstitial Cystitis
NCT000043160	NCT00004316_0_T1	PHENOTYPE	11	12	Vulvar Vestibulitis
NCT000043162	NCT00004316_2_T0	COMPOUND	7	7	capsaicin
NCT000043162	NCT00004316_2_T1	PHENOTYPE	11	12	interstitial cystitis
NCT000043166	NCT00004316_6_T0	COMPOUND	4	4	capsaicin
NCT000043166	NCT00004316_6_T1	ORGAN	11	11	bladder
NCT000043166	NCT00004316_6_T2	TISSUE	12	12	mucosa
NCT000043166	NCT00004316_6_T3	CELL	8	9	nerve fibers
NCT000043168	NCT00004316_8_T0	COMPOUND	11	11	histamine
NCT000043168	NCT00004316_8_T1	COMPOUND	13	13	prostaglandin
NCT000043168	NCT00004316_8_T2	CELL	4	5	C fiber
NCT0000431611	NCT00004316_11_T0	COMPOUND	6	6	capsaicin
NCT0000431612	NCT00004316_12_T0	COMPOUND	9	9	capsaicin
NCT0000431616	NCT00004316_16_T0	COMPOUND	4	4	capsaicin
NCT0000431617	NCT00004316_17_T0	PHENOTYPE	6	6	burning
NCT0000431617	NCT00004316_17_T1	PHENOTYPE	7	7	discomfort
NCT0000431619	NCT00004316_19_T0	COMPOUND	9	9	capsaicin
NCT0000431619	NCT00004316_19_T1	PHENOTYPE	2	3	vulvar vestibulitis
NCT000043171	NCT00004317_1_T0	PHENOTYPE	5	5	symptoms
NCT000043171	NCT00004317_1_T1	PHENOTYPE	8	8	symptoms
NCT000043171	NCT00004317_1_T2	ORGAN	22	22	ears
NCT000043171	NCT00004317_1_T3	ORGAN	17	17	eyes
NCT000043171	NCT00004317_1_T4	ORGAN	18	19	nervous system
NCT000043174	NCT00004317_4_T0	COMPOUND	10	10	pyrimethamine
NCT000043174	NCT00004317_4_T1	COMPOUND	19	19	leucovorin
NCT000043174	NCT00004317_4_T2	GENE	3	3	IV
NCT000043174	NCT00004317_4_T3	COMPOUND	17	17	sulfadiazine
NCT000043174	NCT00004317_4_T4	PHENOTYPE	25	26	congenital toxoplasmosis
NCT000043176	NCT00004317_6_T0	PHENOTYPE	5	5	severity
NCT000043176	NCT00004317_6_T1	PHENOTYPE	6	6	chorioretinitis
NCT000043177	NCT00004317_7_T0	COMPOUND	12	12	pyrimethamine
NCT000043178	NCT00004317_8_T0	COMPOUND	3	3	calcium
NCT000043178	NCT00004317_8_T1	COMPOUND	2	2	leucovorin
NCT000043179	NCT00004317_9_T0	COMPOUND	1	1	pyrimethamine
NCT0000431710	NCT00004317_10_T0	COMPOUND	12	12	pyrimethamine
NCT0000431711	NCT00004317_11_T0	COMPOUND	3	3	calcium
NCT0000431711	NCT00004317_11_T1	COMPOUND	2	2	leucovorin
NCT0000431712	NCT00004317_12_T0	COMPOUND	15	15	calcium
NCT0000431712	NCT00004317_12_T1	COMPOUND	11	11	pyrimethamine
NCT0000431712	NCT00004317_12_T2	COMPOUND	14	14	leucovorin
NCT0000431712	NCT00004317_12_T3	COMPOUND	12	12	sulfadiazine
NCT0000431714	NCT00004317_14_T0	PHENOTYPE	5	5	inflammation
NCT0000431714	NCT00004317_14_T1	COMPOUND	1	1	prednisone
NCT0000431714	NCT00004317_14_T2	PHENOTYPE	7	10	elevated cerebrospinal fluid protein
NCT0000431719	NCT00004317_19_T0	PHENOTYPE	6	6	chorioretinitis
NCT0000431720	NCT00004317_20_T0	GENE	10	10	3.5
NCT000043235	NCT00004323_5_T0	PHENOTYPE	11	12	systemic reaction
NCT000043236	NCT00004323_6_T0	COMPOUND	12	12	methotrexate
NCT000043237	NCT00004323_7_T0	COMPOUND	5	5	cyclosporine
NCT000043240	NCT00004324_0_T0	PHENOTYPE	7	8	Tourette Syndrome
NCT000043240	NCT00004324_0_T1	PHENOTYPE	3	5	Obsessive Compulsive Disorder
NCT000043255	NCT00004325_5_T0	GENE	4	4	neuropeptide
NCT000043255	NCT00004325_5_T1	GENE	14	14	putative
NCT000043255	NCT00004325_5_T2	BIOLOGICAL_PROCESS	16	17	gene expression
NCT000043257	NCT00004325_7_T0	PHENOTYPE	7	8	systemic disease
NCT000043259	NCT00004325_9_T0	PHENOTYPE	8	8	symptoms
NCT000043259	NCT00004325_9_T1	PHENOTYPE	3	3	experiences
NCT000043267	NCT00004326_7_T0	GENE	5	5	structural
NCT000043267	NCT00004326_7_T1	PHENOTYPE	11	12	cortisol levels
NCT000043267	NCT00004326_7_T2	PHENOTYPE	8	9	cognitive dysfunction
NCT0000432610	NCT00004326_10_T0	COMPOUND	3	3	dexamethasone
NCT0000432610	NCT00004326_10_T1	PHENOTYPE	0	0	Endocrine
NCT0000432610	NCT00004326_10_T2	GENE	6	6	hormone
NCT0000432612	NCT00004326_12_T0	PHENOTYPE	8	8	initiation
NCT000043271	NCT00004327_1_T0	PHENOTYPE	22	22	ectasia
NCT000043271	NCT00004327_1_T1	GENE	6	6	somatostatin
NCT000043271	NCT00004327_1_T2	COMPOUND	4	4	octreotide
NCT000043271	NCT00004327_1_T3	PHENOTYPE	11	12	gastrointestinal bleeding
NCT000043271	NCT00004327_1_T4	PHENOTYPE	17	19	hereditary hemorrhagic telangiectasia
NCT000043274	NCT00004327_4_T0	GENE	15	15	hemoglobin
NCT000043275	NCT00004327_5_T0	PHENOTYPE	6	6	bleeding
NCT000043281	NCT00004328_1_T0	COMPOUND	2	2	sodium
NCT000043281	NCT00004328_1_T1	COMPOUND	4	4	potassium
NCT000043281	NCT00004328_1_T2	PHENOTYPE	16	16	pseudohypoaldosteronism
NCT000043283	NCT00004328_3_T0	PHENOTYPE	13	13	tolerance
NCT000043283	NCT00004328_3_T1	PHENOTYPE	8	9	serum potassium
NCT000043283	NCT00004328_3_T2	CELL	4	5	extracellular fluid
NCT000043287	NCT00004328_7_T0	ORGAN	16	16	serum
NCT000043288	NCT00004328_8_T0	PHENOTYPE	1	1	tolerance
NCT000043289	NCT00004328_9_T0	COMPOUND	2	2	potassium
NCT000043289	NCT00004328_9_T1	COMPOUND	0	0	Sodium
NCT000043289	NCT00004328_9_T2	COMPOUND	8	8	enalapril
NCT000043289	NCT00004328_9_T3	COMPOUND	10	11	polystyrene sulfonate
NCT0000432810	NCT00004328_10_T0	PHENOTYPE	1	1	tolerance
NCT000043290	NCT00004329_0_T0	PHENOTYPE	5	5	Dysfunction
NCT000043290	NCT00004329_0_T1	PHENOTYPE	8	8	Lipoatrophy
NCT000043290	NCT00004329_0_T2	GENE	2	2	Alpha-2
NCT000043292	NCT00004329_2_T0	COMPOUND	5	5	norepinephrine
NCT000043292	NCT00004329_2_T1	PHENOTYPE	28	28	lipoatrophy
NCT000043292	NCT00004329_2_T2	COMPOUND	13	13	clonidine
NCT000043292	NCT00004329_2_T3	COMPOUND	17	17	yohimbine
NCT000043292	NCT00004329_2_T4	COMPOUND	9	9	glycerol
NCT000043292	NCT00004329_2_T5	ORGAN	4	4	plasma
NCT000043292	NCT00004329_2_T6	ORGAN	8	8	plasma
NCT000043292	NCT00004329_2_T7	GENE	20	22	alpha-2 adrenergic receptor
NCT000043294	NCT00004329_4_T0	PHENOTYPE	15	15	peripheral
NCT000043294	NCT00004329_4_T1	GENE	9	9	structural
NCT000043294	NCT00004329_4_T2	CELL	17	17	leukocytes
NCT000043294	NCT00004329_4_T3	GENE	6	8	alpha-2 adrenergic receptor
NCT000043296	NCT00004329_6_T0	COMPOUND	7	7	clonidine
NCT000043296	NCT00004329_6_T1	COMPOUND	11	11	yohimbine
NCT000043298	NCT00004329_8_T0	COMPOUND	3	3	norepinephrine
NCT000043298	NCT00004329_8_T1	COMPOUND	4	4	glycerol
NCT000043302	NCT00004330_2_T0	BIOLOGICAL_PROCESS	9	10	menstrual cycle
NCT000043303	NCT00004330_3_T0	COMPOUND	1	1	estrogen
NCT000043304	NCT00004330_4_T0	COMPOUND	6	6	calcium
NCT000043311	NCT00004331_1_T0	PHENOTYPE	9	9	porphyria
NCT000043313	NCT00004331_3_T0	PHENOTYPE	8	8	porphyria
NCT000043317	NCT00004331_7_T0	ORGAN	7	7	plasma
NCT000043317	NCT00004331_7_T1	CELL	2	2	erythrocyte
NCT000043317	NCT00004331_7_T2	CELL	5	5	erythrocyte
NCT000043317	NCT00004331_7_T3	GENE	3	4	porphobilinogen deaminase
NCT000043318	NCT00004331_8_T0	COMPOUND	6	6	porphyrin
NCT000043323	NCT00004332_3_T0	GENE	9	9	GH
NCT000043323	NCT00004332_3_T1	GENE	4	4	hormone
NCT000043326	NCT00004332_6_T0	GENE	12	12	hormone
NCT000043326	NCT00004332_6_T1	GENE	8	9	thyrotropin-releasing hormone
NCT000043332	NCT00004333_2_T0	COMPOUND	4	4	NTBC
NCT000043333	NCT00004333_3_T0	COMPOUND	10	10	NTBC
NCT000043333	NCT00004333_3_T1	PHENOTYPE	8	8	attributable
NCT000043345	NCT00004334_5_T0	COMPOUND	15	15	dexamethasone
NCT000043345	NCT00004334_5_T1	COMPOUND	13	13	metyrapone
NCT000043345	NCT00004334_5_T2	BIOLOGICAL_PROCESS	9	12	response to corticotropin-releasing hormone
NCT000043346	NCT00004334_6_T0	PHENOTYPE	4	4	electroencephalograms
NCT000043359	NCT00004335_9_T0	MOLECULAR_FUNCTION	0	1	Growth hormone
NCT0000433510	NCT00004335_10_T0	COMPOUND	12	12	naloxone
NCT0000433510	NCT00004335_10_T1	GENE	10	10	E2
NCT0000433511	NCT00004335_11_T0	GENE	4	4	E2
NCT0000433511	NCT00004335_11_T1	BIOLOGICAL_PROCESS	11	12	follicular phase
NCT0000433511	NCT00004335_11_T2	BIOLOGICAL_PROCESS	15	16	menstrual cycle
NCT000043363	NCT00004336_3_T0	PHENOTYPE	7	9	mode of inheritance
NCT000043381	NCT00004338_1_T0	COMPOUND	8	8	zinc
NCT000043381	NCT00004338_1_T1	GENE	6	6	extended
NCT000043383	NCT00004338_3_T0	COMPOUND	5	5	zinc
NCT000043385	NCT00004338_5_T0	COMPOUND	5	5	zinc
NCT000043387	NCT00004338_7_T0	COMPOUND	5	5	zinc
NCT000043389	NCT00004338_9_T0	PHENOTYPE	10	10	toxicity
NCT000043389	NCT00004338_9_T1	COMPOUND	5	5	copper
NCT000043395	NCT00004339_5_T0	GENE	7	7	TM
NCT000043395	NCT00004339_5_T1	COMPOUND	12	12	zinc
NCT000043395	NCT00004339_5_T2	COMPOUND	26	26	zinc
NCT000043407	NCT00004340_7_T0	PHENOTYPE	4	5	bone lesion
NCT000043407	NCT00004340_7_T1	PHENOTYPE	8	9	secondary hyperparathyroidism
NCT000043409	NCT00004340_9_T0	COMPOUND	8	8	calcitriol
NCT0000434113	NCT00004341_13_T0	PHENOTYPE	6	6	disorders
NCT0000434113	NCT00004341_13_T1	PHENOTYPE	5	5	X-linked
NCT000043420	NCT00004342_0_T0	PHENOTYPE	4	5	Chronic Neutropenia
NCT000043422	NCT00004342_2_T0	GENE	8	8	SCN
NCT000043422	NCT00004342_2_T1	PHENOTYPE	6	7	chronic neutropenia
NCT000043424	NCT00004342_4_T0	GENE	10	10	SCN
NCT0000434212	NCT00004342_12_T0	GENE	9	9	SCN
NCT000043433	NCT00004343_3_T0	COMPOUND	6	6	dexamethasone
NCT000043433	NCT00004343_3_T1	PHENOTYPE	7	7	suppression
NCT000043434	NCT00004343_4_T0	PHENOTYPE	3	3	tumors
NCT000043434	NCT00004343_4_T1	GENE	2	2	ACTH
NCT000043442	NCT00004344_2_T0	PHENOTYPE	0	1	Hormone levels
NCT0000434510	NCT00004345_10_T0	BIOLOGICAL_PROCESS	3	3	eating
NCT0000434511	NCT00004345_11_T0	GENE	14	14	3.7
NCT000043465	NCT00004346_5_T0	COMPOUND	7	7	cholestanol
NCT000043466	NCT00004346_6_T0	COMPOUND	16	16	lovastatin
NCT000043466	NCT00004346_6_T1	COMPOUND	18	19	chenodeoxycholic acid
NCT000043467	NCT00004346_7_T0	COMPOUND	15	15	lovastatin
NCT000043467	NCT00004346_7_T1	COMPOUND	17	18	chenodeoxycholic acid
NCT000043473	NCT00004347_3_T0	COMPOUND	8	8	sterol
NCT000043473	NCT00004347_3_T1	ORGAN	7	7	plasma
NCT000043479	NCT00004347_9_T0	COMPOUND	9	9	7_dehydrocholesterol
NCT000043479	NCT00004347_9_T1	ORGAN	7	7	plasma
NCT0000434712	NCT00004347_12_T0	BIOLOGICAL_PROCESS	3	3	metabolism
NCT0000434712	NCT00004347_12_T1	ORGAN	9	9	plasma
NCT0000434713	NCT00004347_13_T0	COMPOUND	10	10	deuterium
NCT0000434713	NCT00004347_13_T1	COMPOUND	18	18	7_dehydrocholesterol
NCT0000434713	NCT00004347_13_T2	ORGAN	12	12	plasma
NCT000043481	NCT00004348_1_T0	PHENOTYPE	9	9	disorders
NCT000043519	NCT00004351_9_T0	PHENOTYPE	19	19	imprinted
NCT0000435113	NCT00004351_13_T0	CELL	11	11	chromosome
NCT0000435116	NCT00004351_16_T0	COMPOUND	9	9	melatonin
NCT0000435118	NCT00004351_18_T0	CELL	3	3	chromosome
NCT000043531	NCT00004353_1_T0	BIOLOGICAL_PROCESS	2	2	metabolism
NCT000043531	NCT00004353_1_T1	COMPOUND	4	4	pyruvate
NCT000043531	NCT00004353_1_T2	PHENOTYPE	11	12	lactic acidemia
NCT000043535	NCT00004353_5_T0	GENE	0	0	Glucagon
NCT000043535	NCT00004353_5_T1	GENE	1	1	IM
NCT000043537	NCT00004353_7_T0	COMPOUND	5	5	alanine
NCT000043537	NCT00004353_7_T1	COMPOUND	7	8	lactic acid
NCT000043539	NCT00004353_9_T0	GENE	0	0	Glucagon
NCT000043539	NCT00004353_9_T1	GENE	1	1	IM
NCT000043541	NCT00004354_1_T0	PHENOTYPE	6	6	GRA
NCT000043541	NCT00004354_1_T1	PHENOTYPE	17	17	GRA
NCT000043541	NCT00004354_1_T2	PHENOTYPE	4	5	glucocorticoid-remediable aldosteronism
NCT000043543	NCT00004354_3_T0	PHENOTYPE	7	7	GRA
NCT000043547	NCT00004354_7_T0	PHENOTYPE	4	4	GRA
NCT000043549	NCT00004354_9_T0	GENE	5	5	MRI
NCT000043549	NCT00004354_9_T1	PHENOTYPE	8	9	intracranial aneurysm
NCT0000435412	NCT00004354_12_T0	PHENOTYPE	17	17	GRA
NCT000043563	NCT00004356_3_T0	COMPOUND	2	2	homocysteine
NCT000043563	NCT00004356_3_T1	COMPOUND	7	7	methionine
NCT000043563	NCT00004356_3_T2	PHENOTYPE	3	4	metabolic rates
NCT000043566	NCT00004356_6_T0	COMPOUND	27	27	homocysteine
NCT000043566	NCT00004356_6_T1	COMPOUND	10	10	methionine
NCT000043566	NCT00004356_6_T2	ORGAN	23	23	plasma
NCT000043566	NCT00004356_6_T3	ORGAN	26	26	plasma
NCT000043571	NCT00004357_1_T0	COMPOUND	12	12	prednisolone
NCT000043571	NCT00004357_1_T1	COMPOUND	16	16	methylprednisolone
NCT000043571	NCT00004357_1_T2	GENE	15	15	IV
NCT000043579	NCT00004357_9_T0	COMPOUND	4	4	prednisolone
NCT000043579	NCT00004357_9_T1	COMPOUND	10	10	methylprednisolone
NCT000043579	NCT00004357_9_T2	GENE	9	9	IV
NCT0000435712	NCT00004357_12_T0	COMPOUND	19	19	neopterin
NCT0000435712	NCT00004357_12_T1	GENE	15	17	von Willebrand factor
NCT0000435713	NCT00004357_13_T0	PHENOTYPE	20	20	vasculitis
NCT000043581	NCT00004358_1_T0	GENE	7	7	calcitonin
NCT000043581	NCT00004358_1_T1	PHENOTYPE	11	11	hyperphosphatemia
NCT000043581	NCT00004358_1_T2	PHENOTYPE	9	9	phosphaturia
NCT000043581	NCT00004358_1_T3	GENE	15	16	parathyroid hormone
NCT000043581	NCT00004358_1_T4	PHENOTYPE	21	22	tumoral calcinosis
NCT000043581	NCT00004358_1_T5	PHENOTYPE	16	17	hormone levels
NCT000043583	NCT00004358_3_T0	GENE	2	2	calcitonin
NCT000043583	NCT00004358_3_T1	PHENOTYPE	6	7	tumor recurrence
NCT000043585	NCT00004358_5_T0	PHENOTYPE	2	2	hyperphosphatemia
NCT000043585	NCT00004358_5_T1	ORGAN	9	9	serum
NCT000043585	NCT00004358_5_T2	COMPOUND	10	10	phosphorus
NCT000043587	NCT00004358_7_T0	GENE	3	3	calcitonin
NCT000043587	NCT00004358_7_T1	BIOLOGICAL_PROCESS	11	11	metabolism
NCT000043587	NCT00004358_7_T2	PHENOTYPE	16	17	tumoral calcinosis
NCT0000435810	NCT00004358_10_T0	PHENOTYPE	7	8	tumor recurrence
NCT0000435810	NCT00004358_10_T1	PHENOTYPE	4	5	disease progression
NCT000043591	NCT00004359_1_T0	GENE	5	5	ECP
NCT000043591	NCT00004359_1_T1	PHENOTYPE	9	11	epidermolysis bullosa acquisita
NCT000043593	NCT00004359_3_T0	GENE	4	4	ECP
NCT000043593	NCT00004359_3_T1	CELL	6	6	lymphocyte
NCT000043595	NCT00004359_5_T0	CELL	2	2	cells
NCT000043597	NCT00004359_7_T0	GENE	18	18	has
NCT000043605	NCT00004360_5_T0	COMPOUND	13	13	creatinine
NCT000043605	NCT00004360_5_T1	GENE	15	15	vasopressin
NCT000043606	NCT00004360_6_T0	GENE	7	7	AMP
NCT000043606	NCT00004360_6_T1	GENE	24	24	vasopressin
NCT000043606	NCT00004360_6_T2	GENE	8	8	GMP
NCT000043606	NCT00004360_6_T3	ORGAN	5	5	plasma
NCT000043606	NCT00004360_6_T4	GENE	12	13	Factor VIII
NCT000043606	NCT00004360_6_T5	PHENOTYPE	9	10	von Willebrand
NCT000043609	NCT00004360_9_T0	COMPOUND	0	0	Sodium
NCT0000436011	NCT00004360_11_T0	PHENOTYPE	14	16	de novo mutations
NCT0000436012	NCT00004360_12_T0	PHENOTYPE	2	2	mutation
NCT0000436012	NCT00004360_12_T1	PHENOTYPE	10	10	transmitted
NCT0000436012	NCT00004360_12_T2	PHENOTYPE	13	13	X-linked
NCT000043611	NCT00004361_1_T0	PHENOTYPE	20	20	hypocalcemia
NCT000043611	NCT00004361_1_T1	PHENOTYPE	2	2	hypoparathyroidism
NCT000043611	NCT00004361_1_T2	ORGAN	14	15	parathyroid gland
NCT000043611	NCT00004361_1_T3	PHENOTYPE	9	11	conotruncal cardiac defects
NCT000043616	NCT00004361_6_T0	COMPOUND	6	7	calcium gluconate
NCT000043633	NCT00004363_3_T0	GENE	3	3	AVP-NPII
NCT000043633	NCT00004363_3_T1	CELL	10	10	neurons
NCT000043635	NCT00004363_5_T0	GENE	22	22	II
NCT000043637	NCT00004363_7_T0	COMPOUND	12	12	sodium
NCT000043637	NCT00004363_7_T1	GENE	18	18	oxytocin
NCT000043637	NCT00004363_7_T2	COMPOUND	11	11	creatinine
NCT000043637	NCT00004363_7_T3	COMPOUND	15	15	glucose
NCT000043637	NCT00004363_7_T4	COMPOUND	13	13	potassium
NCT000043637	NCT00004363_7_T5	GENE	17	17	AVP
NCT000043637	NCT00004363_7_T6	COMPOUND	14	14	urea
NCT000043639	NCT00004363_9_T0	COMPOUND	13	13	chlorpropamide
NCT000043639	NCT00004363_9_T1	COMPOUND	10	10	desmopressin
NCT0000436310	NCT00004363_10_T0	COMPOUND	15	15	gadolinium
NCT0000436313	NCT00004363_13_T0	PHENOTYPE	11	11	symptoms
NCT0000436313	NCT00004363_13_T1	GENE	9	9	de
NCT0000436314	NCT00004363_14_T0	GENE	2	2	II
NCT000043643	NCT00004364_3_T0	GENE	12	12	vasopressin
NCT000043643	NCT00004364_3_T1	ORGAN	11	11	plasma
NCT000043644	NCT00004364_4_T0	GENE	10	10	renin
NCT000043644	NCT00004364_4_T1	ORGAN	7	7	plasma
NCT000043646	NCT00004364_6_T0	COMPOUND	8	8	desmopressin
NCT000043651	NCT00004365_1_T0	GENE	10	10	MRI
NCT000043651	NCT00004365_1_T1	PHENOTYPE	14	14	dwarfs
NCT000043655	NCT00004365_5_T0	GENE	3	3	MRI
NCT000043660	NCT00004366_0_T0	PHENOTYPE	7	8	Panic Disorder
NCT000043660	NCT00004366_0_T1	PHENOTYPE	10	11	Vestibular Dysfunction
NCT000043662	NCT00004366_2_T0	PHENOTYPE	11	11	symptoms
NCT000043662	NCT00004366_2_T1	PHENOTYPE	20	20	agoraphobia
NCT000043662	NCT00004366_2_T2	PHENOTYPE	24	24	dysfunction
NCT000043662	NCT00004366_2_T3	PHENOTYPE	15	16	panic disorder
NCT000043664	NCT00004366_4_T0	PHENOTYPE	7	8	anxiety disorder
NCT000043668	NCT00004366_8_T0	PHENOTYPE	25	25	symptoms
NCT000043670	NCT00004367_0_T0	PHENOTYPE	11	11	Agoraphobia
NCT000043670	NCT00004367_0_T1	PHENOTYPE	6	7	Panic Disorder
NCT000043670	NCT00004367_0_T2	PHENOTYPE	0	1	Vestibular Dysfunction
NCT000043672	NCT00004367_2_T0	PHENOTYPE	25	26	anxiety disorder
NCT000043672	NCT00004367_2_T1	PHENOTYPE	21	22	panic disorder
NCT000043672	NCT00004367_2_T2	PHENOTYPE	14	17	panic disorder with agoraphobia
NCT000043674	NCT00004367_4_T0	ORGAN	12	12	brainstem
NCT000043674	NCT00004367_4_T1	PHENOTYPE	23	24	anxiety disorder
NCT000043674	NCT00004367_4_T2	PHENOTYPE	17	20	panic disorder without agoraphobia
NCT0000436710	NCT00004367_10_T0	PHENOTYPE	9	9	focused
NCT0000436710	NCT00004367_10_T1	PHENOTYPE	11	12	anxiety disorders
NCT0000436713	NCT00004367_13_T0	ORGAN	17	17	brainstem
NCT0000436713	NCT00004367_13_T1	PHENOTYPE	12	13	speech recognition
NCT0000436713	NCT00004367_13_T2	PHENOTYPE	24	25	masking level
NCT000043683	NCT00004368_3_T0	COMPOUND	7	7	colchicine
NCT000043730	NCT00004373_0_T0	GENE	1	1	II
NCT000043730	NCT00004373_0_T1	PHENOTYPE	14	14	Anxiety
NCT000043732	NCT00004373_2_T0	COMPOUND	4	4	alprazolam
NCT000043732	NCT00004373_2_T1	PHENOTYPE	9	9	anxious
NCT000043732	NCT00004373_2_T2	COMPOUND	3	3	benzodiazepine
NCT000043734	NCT00004373_4_T0	PHENOTYPE	19	19	dependence
NCT000043734	NCT00004373_4_T1	PHENOTYPE	10	10	reinforcement
NCT000043734	NCT00004373_4_T2	PHENOTYPE	16	17	drug abuse
NCT000043736	NCT00004373_6_T0	PHENOTYPE	8	9	drug use
NCT0000437310	NCT00004373_10_T0	COMPOUND	7	7	alprazolam
NCT000043741	NCT00004374_1_T0	PHENOTYPE	11	11	secondary
NCT000043741	NCT00004374_1_T1	PHENOTYPE	12	12	myeloma
NCT000043741	NCT00004374_1_T2	PHENOTYPE	14	15	hereditary amyloidosis
NCT000043741	NCT00004374_1_T3	PHENOTYPE	5	6	amyloid deposition
NCT000043745	NCT00004374_5_T0	PHENOTYPE	14	15	systemic amyloidosis
NCT000043745	NCT00004374_5_T1	PHENOTYPE	4	5	hereditary amyloidosis
NCT0000437412	NCT00004374_12_T0	PHENOTYPE	6	6	fixation
NCT0000437412	NCT00004374_12_T1	ORGAN	8	8	serum
NCT0000437414	NCT00004374_14_T0	GENE	9	9	II
NCT0000437414	NCT00004374_14_T1	PHENOTYPE	7	7	polyneuropathy
NCT0000437414	NCT00004374_14_T2	ORGAN	19	19	wrist
NCT000043751	NCT00004375_1_T0	PHENOTYPE	11	13	systemic lupus erythematosus
NCT000043765	NCT00004376_5_T0	COMPOUND	5	5	guanfacine
NCT000043768	NCT00004376_8_T0	COMPOUND	8	8	guanfacine
NCT000043783	NCT00004378_3_T0	PHENOTYPE	10	10	arrested
NCT000043786	NCT00004378_6_T0	COMPOUND	19	19	2
NCT000043786	NCT00004378_6_T1	COMPOUND	13	13	cyclophosphamide
NCT000043786	NCT00004378_6_T2	GENE	14	14	IV
NCT000043787	NCT00004378_7_T0	COMPOUND	4	4	1
NCT000043788	NCT00004378_8_T0	ORGAN	2	3	bone marrow
NCT000043789	NCT00004378_9_T0	COMPOUND	5	5	methotrexate
NCT000043789	NCT00004378_9_T1	PHENOTYPE	1	1	GVHD
NCT0000437810	NCT00004378_10_T0	COMPOUND	5	5	2
NCT0000437810	NCT00004378_10_T1	GENE	1	1	IV
NCT0000437811	NCT00004378_11_T0	COMPOUND	4	4	cyclosporine
NCT0000437813	NCT00004378_13_T0	COMPOUND	13	13	methylprednisolone
NCT0000437813	NCT00004378_13_T1	PHENOTYPE	10	10	GVHD
NCT0000437813	NCT00004378_13_T2	GENE	14	14	IV
NCT0000437813	NCT00004378_13_T3	CELL	6	7	stem cells
NCT0000437814	NCT00004378_14_T0	GENE	3	3	tapered
NCT0000437815	NCT00004378_15_T0	COMPOUND	8	8	methylprednisolone
NCT0000437815	NCT00004378_15_T1	COMPOUND	11	11	methotrexate
NCT0000437815	NCT00004378_15_T2	CELL	5	6	stem cells
NCT0000437815	NCT00004378_15_T3	ORGAN	3	4	cord blood
NCT0000437818	NCT00004378_18_T0	PHENOTYPE	2	2	engraftment
NCT0000437818	NCT00004378_18_T1	COMPOUND	11	11	1
NCT0000437818	NCT00004378_18_T2	GENE	6	6	IM
NCT0000437818	NCT00004378_18_T3	GENE	15	15	ANC
NCT0000437818	NCT00004378_18_T4	GENE	5	5	filgrastim
NCT000043801	NCT00004380_1_T0	PHENOTYPE	21	21	scleroderma
NCT000043801	NCT00004380_1_T1	GENE	3	3	relaxin
NCT000043801	NCT00004380_1_T2	PHENOTYPE	13	13	ulcers
NCT000043801	NCT00004380_1_T3	PHENOTYPE	7	8	Raynaud's phenomenon
NCT000043801	NCT00004380_1_T4	PHENOTYPE	18	20	progressive systemic sclerosis
NCT000043803	NCT00004380_3_T0	CELL	7	7	fibroblasts
NCT000043803	NCT00004380_3_T1	GENE	4	4	collagen
NCT000043803	NCT00004380_3_T2	GENE	2	2	relaxin
NCT000043805	NCT00004380_5_T0	GENE	9	9	relaxin
NCT000043806	NCT00004380_6_T0	GENE	6	6	extended
NCT000043827	NCT00004382_7_T0	COMPOUND	8	8	bilirubin
NCT000043827	NCT00004382_7_T1	ORGAN	7	7	plasma
NCT000043829	NCT00004382_9_T0	COMPOUND	9	9	bilirubin
NCT000043829	NCT00004382_9_T1	ORGAN	8	8	plasma
NCT000043862	NCT00004386_2_T0	ORGAN	10	10	liver
NCT000043871	NCT00004387_1_T0	PHENOTYPE	10	11	Parkinson's disease
NCT000043874	NCT00004387_4_T0	ORGAN	9	10	substantia nigra
NCT000043875	NCT00004387_5_T0	PHENOTYPE	0	1	Group B
NCT000043878	NCT00004387_8_T0	ORGAN	1	1	transplant
NCT000043878	NCT00004387_8_T1	ORGAN	17	17	transplant
NCT000043878	NCT00004387_8_T2	PHENOTYPE	6	7	Parkinson's disease
NCT000043903	NCT00004390_3_T0	PHENOTYPE	10	11	cognitive functions
NCT000043909	NCT00004390_9_T0	COMPOUND	3	3	nortriptyline
NCT000043909	NCT00004390_9_T1	COMPOUND	4	4	morphine
NCT0000439010	NCT00004390_10_T0	COMPOUND	6	6	nortriptyline
NCT0000439010	NCT00004390_10_T1	COMPOUND	14	14	methadone
NCT0000439010	NCT00004390_10_T2	COMPOUND	12	12	desipramine
NCT0000439010	NCT00004390_10_T3	COMPOUND	8	8	morphine
NCT0000439014	NCT00004390_14_T0	GENE	4	4	tapered
NCT000043927	NCT00004392_7_T0	GENE	5	5	CPR
NCT000043933	NCT00004393_3_T0	GENE	5	5	RIS
NCT000043936	NCT00004393_6_T0	COMPOUND	7	7	risperidone
NCT000043936	NCT00004393_6_T1	GENE	8	8	RIS
NCT000043937	NCT00004393_7_T0	GENE	3	3	RIS
NCT000043938	NCT00004393_8_T0	GENE	2	2	RIS
NCT0000439611	NCT00004396_11_T0	PHENOTYPE	2	3	adverse reactions
NCT000043979	NCT00004397_9_T0	PHENOTYPE	15	15	porphyria
NCT000043979	NCT00004397_9_T1	GENE	6	6	reduced
NCT000043990	NCT00004399_0_T0	PHENOTYPE	12	12	Seizures
NCT000043990	NCT00004399_0_T1	PHENOTYPE	16	17	Severe Preeclampsia
NCT000043992	NCT00004399_2_T0	COMPOUND	7	7	sulfate
NCT000043992	NCT00004399_2_T1	COMPOUND	4	4	nimodipine
NCT000043992	NCT00004399_2_T2	PHENOTYPE	13	13	seizures
NCT000043992	NCT00004399_2_T3	COMPOUND	6	6	magnesium
NCT000043992	NCT00004399_2_T4	PHENOTYPE	17	18	severe preeclampsia
NCT000043994	NCT00004399_4_T0	COMPOUND	9	9	sulfate
NCT000043994	NCT00004399_4_T1	COMPOUND	6	6	nimodipine
NCT000043994	NCT00004399_4_T2	COMPOUND	8	8	magnesium
NCT000044003	NCT00004400_3_T0	GENE	7	7	fat-free
NCT000044003	NCT00004400_3_T1	COMPOUND	4	4	testosterone
NCT000044009	NCT00004400_9_T0	PHENOTYPE	10	11	adverse reaction
NCT0000440011	NCT00004400_11_T0	PHENOTYPE	0	2	Quality of life
NCT000044016	NCT00004401_6_T0	GENE	2	2	BIG
NCT000044016	NCT00004401_6_T1	GENE	3	3	IV
NCT000044017	NCT00004401_7_T0	PHENOTYPE	7	7	severity
NCT000044017	NCT00004401_7_T1	PHENOTYPE	8	8	complications
NCT000044023	NCT00004402_3_T0	PHENOTYPE	10	11	disease progression
NCT000044023	NCT00004402_3_T1	PHENOTYPE	4	5	adverse events
NCT000044025	NCT00004402_5_T0	BIOLOGICAL_PROCESS	7	7	hematopoiesis
NCT000044025	NCT00004402_5_T1	GENE	4	5	interferon gamma
NCT000044025	NCT00004402_5_T2	ORGAN	8	9	cranial nerve
NCT000044029	NCT00004402_9_T0	GENE	0	0	Interferon
NCT000044029	NCT00004402_9_T1	GENE	1	1	gamma
NCT0000440211	NCT00004402_11_T0	PHENOTYPE	8	8	toxicity
NCT0000440211	NCT00004402_11_T1	PHENOTYPE	10	11	disease progression
NCT0000440212	NCT00004402_12_T0	COMPOUND	18	18	calcitriol
NCT0000440212	NCT00004402_12_T1	GENE	13	14	interferon gamma
NCT0000440212	NCT00004402_12_T2	PHENOTYPE	1	2	disease progression
NCT000044031	NCT00004403_1_T0	PHENOTYPE	14	14	epilepsy
NCT000044031	NCT00004403_1_T1	PHENOTYPE	10	10	severity
NCT000044031	NCT00004403_1_T2	COMPOUND	7	7	albendazole
NCT000044031	NCT00004403_1_T3	PHENOTYPE	17	17	neurocysticercosis
NCT000044033	NCT00004403_3_T0	COMPOUND	8	8	albendazole
NCT000044033	NCT00004403_3_T1	PHENOTYPE	12	12	cysts
NCT000044033	NCT00004403_3_T2	COMPOUND	11	11	solium
NCT000044035	NCT00004403_5_T0	PHENOTYPE	3	3	regression
NCT000044035	NCT00004403_5_T1	PHENOTYPE	8	8	cysts
NCT000044035	NCT00004403_5_T2	COMPOUND	7	7	solium
NCT000044037	NCT00004403_7_T0	COMPOUND	8	8	dexamethasone
NCT000044037	NCT00004403_7_T1	COMPOUND	6	6	albendazole
NCT000044038	NCT00004403_8_T0	PHENOTYPE	11	11	seizure
NCT000044038	NCT00004403_8_T1	COMPOUND	2	2	phenytoin
NCT000044039	NCT00004403_9_T0	COMPOUND	2	2	dexamethasone
NCT000044065	NCT00004406_5_T0	PHENOTYPE	6	6	toxicities
NCT000044070	NCT00004407_0_T0	PHENOTYPE	10	10	Proximal
NCT000044070	NCT00004407_0_T1	PHENOTYPE	9	9	Subacute
NCT000044070	NCT00004407_0_T2	PHENOTYPE	11	12	Diabetic Neuropathy
NCT000044072	NCT00004407_2_T0	PHENOTYPE	12	12	proximal
NCT000044072	NCT00004407_2_T1	PHENOTYPE	13	14	diabetic neuropathy
NCT000044078	NCT00004407_8_T0	GENE	15	15	2.4
NCT000044080	NCT00004408_0_T0	GENE	1	1	III
NCT000044080	NCT00004408_0_T1	PHENOTYPE	8	9	Vaso-Occlusive Crisis
NCT000044080	NCT00004408_0_T2	PHENOTYPE	11	13	Sickle Cell Disease
NCT000044086	NCT00004408_6_T0	COMPOUND	5	5	hydroxyurea
NCT000044092	NCT00004409_2_T0	GENE	7	7	collagenase
NCT000044093	NCT00004409_3_T0	GENE	19	19	collagenase
NCT000044093	NCT00004409_3_T1	GENE	21	21	IgE
NCT000044103	NCT00004410_3_T0	GENE	14	14	TPN
NCT000044103	NCT00004410_3_T1	GENE	19	19	TPN
NCT000044103	NCT00004410_3_T2	PHENOTYPE	21	21	cholestasis
NCT000044103	NCT00004410_3_T3	COMPOUND	26	26	TUDCA
NCT0000441011	NCT00004410_11_T0	COMPOUND	0	0	TUDCA
NCT0000441011	NCT00004410_11_T1	PHENOTYPE	8	8	gastrostomy
NCT0000441013	NCT00004410_13_T0	ORGAN	5	5	liver
NCT0000441013	NCT00004410_13_T1	ORGAN	7	8	biliary tract
NCT0000441013	NCT00004410_13_T2	ORGAN	27	28	biliary tract
NCT000044120	NCT00004412_0_T0	GENE	1	1	II
NCT000044120	NCT00004412_0_T1	PHENOTYPE	15	15	Ulcers
NCT000044124	NCT00004412_4_T0	COMPOUND	4	4	arginine
NCT000044124	NCT00004412_4_T1	COMPOUND	5	5	butyrate
NCT000044124	NCT00004412_4_T2	PHENOTYPE	14	14	inhibition
NCT000044124	NCT00004412_4_T3	BIOLOGICAL_PROCESS	16	17	wound healing
NCT0000441211	NCT00004412_11_T0	COMPOUND	6	6	arginine
NCT0000441211	NCT00004412_11_T1	COMPOUND	7	7	butyrate
NCT0000441211	NCT00004412_11_T2	GENE	8	8	3.4
NCT0000441211	NCT00004412_11_T3	PHENOTYPE	3	3	progressive
NCT0000441212	NCT00004412_12_T0	COMPOUND	1	1	butyrate
NCT0000441212	NCT00004412_12_T1	PHENOTYPE	13	14	medical complication
NCT000044140	NCT00004414_0_T0	PHENOTYPE	15	15	Cholestasis
NCT000044140	NCT00004414_0_T1	COMPOUND	1	2	Cholecystokinin Octapeptide
NCT000044142	NCT00004414_2_T0	PHENOTYPE	10	10	severely
NCT000044142	NCT00004414_2_T1	ORGAN	5	5	serum
NCT000044142	NCT00004414_2_T2	PHENOTYPE	2	3	bilirubin levels
NCT000044142	NCT00004414_2_T3	GENE	6	7	bile acid
NCT000044148	NCT00004414_8_T0	PHENOTYPE	5	5	prematurity
NCT000044149	NCT00004414_9_T0	GENE	9	9	IV
NCT000044161	NCT00004416_1_T0	GENE	8	8	toxin
NCT000044161	NCT00004416_1_T1	PHENOTYPE	13	13	achalasia
NCT000044167	NCT00004416_7_T0	GENE	1	1	toxin
NCT000044167	NCT00004416_7_T1	ORGAN	6	8	lower esophageal sphincter
NCT000044168	NCT00004416_8_T0	PHENOTYPE	13	13	relapse
NCT000044169	NCT00004416_9_T0	GENE	12	12	1.2
NCT000044169	NCT00004416_9_T1	GENE	9	9	1/6
NCT000044181	NCT00004418_1_T0	PHENOTYPE	17	18	X-linked adrenoleukodystrophy
NCT000044183	NCT00004418_3_T0	PHENOTYPE	4	4	severity
NCT000044183	NCT00004418_3_T1	PHENOTYPE	6	7	neurological disability
NCT000044186	NCT00004418_6_T0	GENE	2	2	2.4
NCT000044187	NCT00004418_7_T0	PHENOTYPE	9	10	neurological disability
NCT0000441913	NCT00004419_13_T0	COMPOUND	10	10	glucose
NCT000044201	NCT00004420_1_T0	PHENOTYPE	12	13	childhood arthritis
NCT000044203	NCT00004420_3_T0	PHENOTYPE	6	8	juvenile rheumatoid arthritis
NCT000044212	NCT00004421_2_T0	PHENOTYPE	7	7	symptoms
NCT000044212	NCT00004421_2_T1	GENE	5	5	lessen
NCT000044212	NCT00004421_2_T2	PHENOTYPE	9	9	dystonia
NCT000044213	NCT00004421_3_T0	PHENOTYPE	17	17	dystonia
NCT000044215	NCT00004421_5_T0	GENE	3	3	has
NCT000044222	NCT00004422_2_T0	GENE	11	11	globulin
NCT000044222	NCT00004422_2_T1	PHENOTYPE	9	9	pertussis
NCT000044231	NCT00004423_1_T0	GENE	17	17	bowel
NCT000044231	NCT00004423_1_T1	PHENOTYPE	12	13	Crohn's disease
NCT000044241	NCT00004424_1_T0	PHENOTYPE	4	4	amnesia
NCT000044241	NCT00004424_1_T1	PHENOTYPE	16	16	experiences
NCT000044243	NCT00004424_3_T0	COMPOUND	6	6	propofol
NCT000044243	NCT00004424_3_T1	COMPOUND	20	20	midazolam
NCT000044243	NCT00004424_3_T2	COMPOUND	18	18	fentanyl
NCT000044245	NCT00004424_5_T0	COMPOUND	6	6	propofol
NCT000044247	NCT00004424_7_T0	COMPOUND	10	10	propofol
NCT000044247	NCT00004424_7_T1	COMPOUND	19	19	midazolam
NCT000044247	NCT00004424_7_T2	COMPOUND	17	17	fentanyl
NCT000044248	NCT00004424_8_T0	GENE	4	4	reduced
NCT000044249	NCT00004424_9_T0	PHENOTYPE	17	17	toxicity
NCT000044261	NCT00004426_1_T0	COMPOUND	10	10	leuprolide
NCT000044263	NCT00004426_3_T0	COMPOUND	6	6	acetate
NCT000044263	NCT00004426_3_T1	COMPOUND	5	5	leuprolide
NCT000044263	NCT00004426_3_T2	GENE	11	11	GnRH
NCT000044263	NCT00004426_3_T3	GENE	10	10	hormone
NCT000044264	NCT00004426_4_T0	COMPOUND	7	7	acetate
NCT000044264	NCT00004426_4_T1	COMPOUND	6	6	leuprolide
NCT000044264	NCT00004426_4_T2	GENE	9	9	GnRH
NCT000044266	NCT00004426_6_T0	COMPOUND	9	9	acetate
NCT000044266	NCT00004426_6_T1	COMPOUND	8	8	leuprolide
NCT000044301	NCT00004430_1_T0	GENE	8	8	DHP
NCT000044301	NCT00004430_1_T1	PHENOTYPE	17	18	corneal neovascularization
NCT000044303	NCT00004430_3_T0	PHENOTYPE	16	17	corneal neovascularization
NCT000044303	NCT00004430_3_T1	PHENOTYPE	3	5	mechanism of action
NCT000044305	NCT00004430_5_T0	PHENOTYPE	8	8	photosensitizing
NCT000044305	NCT00004430_5_T1	GENE	5	5	DHP
NCT0000443011	NCT00004430_11_T0	COMPOUND	7	8	prednisolone phosphate
NCT000044311	NCT00004431_1_T0	PHENOTYPE	9	10	trigeminal neuralgia
NCT000044313	NCT00004431_3_T0	PHENOTYPE	4	4	tolerance
NCT000044333	NCT00004433_3_T0	COMPOUND	5	5	pergolide
NCT000044337	NCT00004433_7_T0	COMPOUND	8	8	pergolide
NCT000044338	NCT00004433_8_T0	GENE	1	1	II
NCT000044338	NCT00004433_8_T1	COMPOUND	12	12	pergolide
NCT000044339	NCT00004433_9_T0	GENE	1	1	III
NCT000044339	NCT00004433_9_T1	COMPOUND	9	9	pergolide
NCT000044361	NCT00004436_1_T0	COMPOUND	5	5	leuprolide
NCT000044361	NCT00004436_1_T1	PHENOTYPE	19	19	hemangiomas
NCT000044361	NCT00004436_1_T2	GENE	7	8	gonadotropin-releasing hormone
NCT000044368	NCT00004436_8_T0	COMPOUND	4	4	prednisone
NCT000044369	NCT00004436_9_T0	GENE	10	10	IM
NCT000044369	NCT00004436_9_T1	COMPOUND	9	9	leuprolide
NCT000044369	NCT00004436_9_T2	COMPOUND	17	17	prednisone
NCT0000443610	NCT00004436_10_T0	PHENOTYPE	0	0	Tumors
NCT0000443611	NCT00004436_11_T0	PHENOTYPE	2	2	tumor
NCT0000443611	NCT00004436_11_T1	COMPOUND	7	7	leuprolide
NCT0000443612	NCT00004436_12_T0	PHENOTYPE	0	0	Tumors
NCT0000443614	NCT00004436_14_T0	PHENOTYPE	2	2	tumor
NCT0000443614	NCT00004436_14_T1	COMPOUND	7	7	leuprolide
NCT0000443615	NCT00004436_15_T0	PHENOTYPE	2	2	tumors
NCT0000443615	NCT00004436_15_T1	COMPOUND	15	15	leuprolide
NCT0000443615	NCT00004436_15_T2	COMPOUND	17	17	prednisone
NCT000044371	NCT00004437_1_T0	ORGAN	5	6	brain stem
NCT000044371	NCT00004437_1_T1	ORGAN	17	18	brain stem
NCT000044382	NCT00004438_2_T0	PHENOTYPE	14	14	hypogonadotropism
NCT000044382	NCT00004438_2_T1	COMPOUND	8	8	leuprolide
NCT000044384	NCT00004438_4_T0	COMPOUND	3	3	leuprolide
NCT000044401	NCT00004440_1_T0	COMPOUND	7	7	ibuprofen
NCT000044401	NCT00004440_1_T1	CELL	9	9	neutrophil
NCT000044401	NCT00004440_1_T2	BIOLOGICAL_PROCESS	12	12	PMN
NCT000044401	NCT00004440_1_T3	TISSUE	19	20	oral mucosa
NCT000044401	NCT00004440_1_T4	CELL	10	11	polymorphonuclear leukocyte
NCT000044401	NCT00004440_1_T5	PHENOTYPE	24	25	cystic fibrosis
NCT000044403	NCT00004440_3_T0	BIOLOGICAL_PROCESS	12	12	PMN
NCT000044403	NCT00004440_3_T1	COMPOUND	10	10	ibuprofen
NCT000044406	NCT00004440_6_T0	GENE	16	16	1.3
NCT000044406	NCT00004440_6_T1	GENE	19	19	3/12
NCT000044411	NCT00004441_1_T0	COMPOUND	7	7	TUDCA
NCT000044411	NCT00004441_1_T1	PHENOTYPE	16	19	cystic fibrosis liver disease
NCT000044413	NCT00004441_3_T0	COMPOUND	4	4	TUDCA
NCT000044413	NCT00004441_3_T1	COMPOUND	9	9	UDCA
NCT000044413	NCT00004441_3_T2	BIOLOGICAL_PROCESS	18	18	metabolism
NCT000044413	NCT00004441_3_T3	ORGAN	19	19	serum
NCT000044413	NCT00004441_3_T4	COMPOUND	7	8	ursodeoxycholic acid
NCT000044413	NCT00004441_3_T5	GENE	14	15	bile acid
NCT000044413	NCT00004441_3_T6	PHENOTYPE	21	22	fat absorption
NCT000044415	NCT00004441_5_T0	COMPOUND	12	12	TUDCA
NCT000044416	NCT00004441_6_T0	GENE	1	1	II
NCT000044416	NCT00004441_6_T1	COMPOUND	17	17	TUDCA
NCT000044417	NCT00004441_7_T0	COMPOUND	6	6	TUDCA
NCT000044426	NCT00004442_6_T0	ORGAN	9	9	liver
NCT000044427	NCT00004442_7_T0	PHENOTYPE	8	8	toxic
NCT000044427	NCT00004442_7_T1	PHENOTYPE	4	5	disease progression
NCT000044431	NCT00004443_1_T0	COMPOUND	6	6	NTBC
NCT000044431	NCT00004443_1_T1	PHENOTYPE	10	10	tyrosinemia
NCT000044435	NCT00004443_5_T0	COMPOUND	3	3	NTBC
NCT000044436	NCT00004443_6_T0	PHENOTYPE	7	7	toxicity
NCT000044440	NCT00004444_0_T0	PHENOTYPE	10	11	Pulmonary Tuberculosis
NCT000044442	NCT00004444_2_T0	PHENOTYPE	2	2	pharmacokinetics
NCT000044442	NCT00004444_2_T1	COMPOUND	8	8	paromomycin
NCT000044442	NCT00004444_2_T2	COMPOUND	11	11	streptomycin
NCT000044442	NCT00004444_2_T3	PHENOTYPE	17	18	pulmonary tuberculosis
NCT000044442	NCT00004444_2_T4	PHENOTYPE	5	6	bactericidal activity
NCT000044446	NCT00004444_6_T0	COMPOUND	15	15	paromomycin
NCT000044446	NCT00004444_6_T1	ORGAN	5	5	serum
NCT000044446	NCT00004444_6_T2	COMPOUND	17	17	streptomycin
NCT000044446	NCT00004444_6_T3	PHENOTYPE	12	13	bactericidal activity
NCT0000444411	NCT00004444_11_T0	PHENOTYPE	10	10	tuberculosis
NCT000044451	NCT00004445_1_T0	GENE	12	12	neuromuscular
NCT000044451	NCT00004445_1_T1	PHENOTYPE	28	28	paraplegia
NCT000044451	NCT00004445_1_T2	PHENOTYPE	26	26	tetraplegia
NCT000044457	NCT00004445_7_T0	ORGAN	14	14	abdomen
NCT000044458	NCT00004445_8_T0	GENE	16	16	neuromuscular
NCT000044462	NCT00004446_2_T0	PHENOTYPE	6	6	acute
NCT000044463	NCT00004446_3_T0	PHENOTYPE	2	2	acute
NCT000044463	NCT00004446_3_T1	COMPOUND	8	8	fluoxetine
NCT000044467	NCT00004446_7_T0	PHENOTYPE	7	7	acute
NCT000044467	NCT00004446_7_T1	COMPOUND	13	13	fluoxetine
NCT000044480	NCT00004448_0_T0	PHENOTYPE	11	13	Immunoglobulin A Nephropathy
NCT000044488	NCT00004448_8_T0	COMPOUND	4	4	enalapril
NCT000044488	NCT00004448_8_T1	PHENOTYPE	6	6	hypertension
NCT000044490	NCT00004449_0_T0	PHENOTYPE	12	12	Autism
NCT000044492	NCT00004449_2_T0	PHENOTYPE	25	25	autism
NCT000044497	NCT00004449_7_T0	PHENOTYPE	7	7	autism
NCT000044506	NCT00004450_6_T0	COMPOUND	8	8	thalidomide
NCT000044506	NCT00004450_6_T1	GENE	2	3	interferon beta
NCT000044507	NCT00004450_7_T0	COMPOUND	10	11	Lorenzo's oil
NCT000044512	NCT00004451_2_T0	COMPOUND	10	10	glucose
NCT000044512	NCT00004451_2_T1	COMPOUND	12	12	saccharin
NCT000044543	NCT00004454_3_T0	CELL	15	15	lymphocytes
NCT000044543	NCT00004454_3_T1	GENE	4	4	iduronate-2-sulfatase
NCT000044543	NCT00004454_3_T2	GENE	28	28	iduronate-2-sulfatase
NCT000044545	NCT00004454_5_T0	CELL	8	8	cells
NCT000044549	NCT00004454_9_T0	CELL	10	10	lymphocytes
NCT000044571	NCT00004457_1_T0	PHENOTYPE	24	24	severity
NCT000044571	NCT00004457_1_T1	PHENOTYPE	18	20	amyotrophic lateral sclerosis
NCT000044574	NCT00004457_4_T0	MOLECULAR_FUNCTION	16	17	antioxidant activity
NCT000044581	NCT00004458_1_T0	PHENOTYPE	13	13	interests
NCT000044581	NCT00004458_1_T1	PHENOTYPE	23	23	autistic
NCT000044581	NCT00004458_1_T2	PHENOTYPE	21	21	autism
NCT000044581	NCT00004458_1_T3	PHENOTYPE	4	5	language acquisition
NCT000044581	NCT00004458_1_T4	PHENOTYPE	17	19	childhood disintegrative disorder
NCT000044641	NCT00004464_1_T0	COMPOUND	11	11	cyclophosphamide
NCT000044641	NCT00004464_1_T1	PHENOTYPE	15	17	severe aplastic anemia
NCT000044643	NCT00004464_3_T0	GENE	5	5	filgrastim
NCT000044643	NCT00004464_3_T1	COMPOUND	10	10	cyclophosphamide
NCT000044643	NCT00004464_3_T2	GENE	6	6	G-CSF
NCT000044645	NCT00004464_5_T0	PHENOTYPE	8	10	paroxysmal nocturnal hemoglobinuria
NCT000044647	NCT00004464_7_T0	GENE	6	6	filgrastim
NCT000044647	NCT00004464_7_T1	GENE	7	7	G-CSF
NCT000044647	NCT00004464_7_T2	CELL	11	11	neutrophil
NCT000044650	NCT00004465_0_T0	GENE	1	1	III
NCT000044663	NCT00004466_3_T0	COMPOUND	6	6	atorvastatin
NCT000044665	NCT00004466_5_T0	PHENOTYPE	21	21	progression
NCT000044665	NCT00004466_5_T1	PHENOTYPE	23	24	renal insufficiency
NCT000044665	NCT00004466_5_T2	PHENOTYPE	13	14	cholesterol levels
NCT000044669	NCT00004466_9_T0	COMPOUND	9	9	atorvastatin
NCT000044669	NCT00004466_9_T1	GENE	16	16	extended
NCT000044671	NCT00004467_1_T0	PHENOTYPE	17	19	acute liver failure
NCT000044676	NCT00004467_6_T0	ORGAN	12	12	liver
NCT000044676	NCT00004467_6_T1	GENE	5	5	III
NCT000044676	NCT00004467_6_T2	PHENOTYPE	8	8	encephalopathy
NCT000044676	NCT00004467_6_T3	GENE	7	7	IV
NCT0000446713	NCT00004467_13_T0	ORGAN	2	4	fresh frozen plasma
NCT0000446717	NCT00004467_17_T0	GENE	0	0	ALF
NCT0000446717	NCT00004467_17_T1	PHENOTYPE	5	6	mushroom poisoning
NCT0000446718	NCT00004467_18_T0	GENE	8	8	NAC
NCT0000446720	NCT00004467_20_T0	PHENOTYPE	8	8	hepatopathy
NCT0000446720	NCT00004467_20_T1	ORGAN	6	6	liver
NCT0000446721	NCT00004467_21_T0	PHENOTYPE	0	1	Heat stroke
NCT0000446724	NCT00004467_24_T0	GENE	3	3	NAC
NCT0000446724	NCT00004467_24_T1	GENE	10	10	has
NCT0000446724	NCT00004467_24_T2	PHENOTYPE	17	18	liver diseases
NCT0000446726	NCT00004467_26_T0	PHENOTYPE	2	2	secondary
NCT0000446726	NCT00004467_26_T1	PHENOTYPE	5	5	malignancy
NCT0000446726	NCT00004467_26_T2	GENE	0	0	ALF
NCT0000446727	NCT00004467_27_T0	PHENOTYPE	3	3	malignancy
NCT0000446727	NCT00004467_27_T1	ORGAN	12	12	transplant
NCT0000446727	NCT00004467_27_T2	GENE	5	5	ALF
NCT0000446729	NCT00004467_29_T0	PHENOTYPE	5	6	cerebral herniation
NCT0000446731	NCT00004467_31_T0	PHENOTYPE	7	8	arterial hypotension
NCT0000446733	NCT00004467_33_T0	PHENOTYPE	7	7	bacteremia
NCT0000446733	NCT00004467_33_T1	PHENOTYPE	0	1	Severe sepsis
NCT000044685	NCT00004468_5_T0	COMPOUND	3	3	calcitriol
NCT000044685	NCT00004468_5_T1	COMPOUND	8	8	calcitriol
NCT0000446810	NCT00004468_10_T0	GENE	19	19	1.3
NCT0000446810	NCT00004468_10_T1	GENE	7	7	2.4
NCT0000446813	NCT00004468_13_T0	GENE	6	6	2.4
NCT000044712	NCT00004471_2_T0	GENE	14	14	2.3
NCT000044741	NCT00004474_1_T0	GENE	26	26	globulin
NCT000044741	NCT00004474_1_T1	PHENOTYPE	29	29	conditioning
NCT000044741	NCT00004474_1_T2	COMPOUND	21	21	cyclophosphamide
NCT000044741	NCT00004474_1_T3	ORGAN	16	16	transplants
NCT000044741	NCT00004474_1_T4	PHENOTYPE	3	4	graft failure
NCT000044741	NCT00004474_1_T5	ORGAN	14	15	bone marrow
NCT000044741	NCT00004474_1_T6	PHENOTYPE	18	19	aplastic anemia
NCT000044741	NCT00004474_1_T7	PHENOTYPE	5	8	graft versus host disease
NCT000044743	NCT00004474_3_T0	COMPOUND	14	14	2
NCT000044743	NCT00004474_3_T1	COMPOUND	5	5	cyclophosphamide
NCT000044743	NCT00004474_3_T2	GENE	19	19	globulin
NCT000044743	NCT00004474_3_T3	GENE	6	6	IV
NCT000044743	NCT00004474_3_T4	GENE	20	20	IV
NCT000044744	NCT00004474_4_T0	COMPOUND	19	19	cyclophosphamide
NCT000044744	NCT00004474_4_T1	ORGAN	4	5	bone marrow
NCT000044750	NCT00004475_0_T0	PHENOTYPE	4	5	Hereditary Pancreatitis
NCT000044753	NCT00004475_3_T0	PHENOTYPE	3	4	autosomal dominant
NCT000044754	NCT00004475_4_T0	PHENOTYPE	15	15	chronic
NCT000044754	NCT00004475_4_T1	PHENOTYPE	0	0	Symptoms
NCT000044754	NCT00004475_4_T2	PHENOTYPE	17	18	recurrent pancreatitis
NCT000044756	NCT00004475_6_T0	GENE	12	12	HP
NCT000044758	NCT00004475_8_T0	GENE	12	12	HP
NCT000044759	NCT00004475_9_T0	PHENOTYPE	24	24	insights
NCT000044759	NCT00004475_9_T1	GENE	3	3	HP
NCT000044759	NCT00004475_9_T2	PHENOTYPE	29	30	pancreatic cancer
NCT000044759	NCT00004475_9_T3	PHENOTYPE	9	12	adenocarcinoma of the pancreas
NCT0000447515	NCT00004475_15_T0	COMPOUND	11	11	1st
NCT0000447515	NCT00004475_15_T1	GENE	24	24	OR
NCT0000447515	NCT00004475_15_T2	PHENOTYPE	2	2	pancreatitis
NCT0000447515	NCT00004475_15_T3	PHENOTYPE	20	20	pancreatitis
NCT0000447515	NCT00004475_15_T4	PHENOTYPE	22	23	pancreatic cancer
NCT0000447516	NCT00004475_16_T0	COMPOUND	6	6	1st
NCT0000447516	NCT00004475_16_T1	GENE	16	16	OR
NCT0000447516	NCT00004475_16_T2	PHENOTYPE	15	15	pancreatitis
NCT0000447516	NCT00004475_16_T3	PHENOTYPE	2	3	pancreatic cancer
NCT0000447516	NCT00004475_16_T4	PHENOTYPE	12	13	pancreatic cancer
NCT0000447517	NCT00004475_17_T0	GENE	12	12	OR
NCT0000447517	NCT00004475_17_T1	PHENOTYPE	2	3	pancreatic insufficiency
NCT000044780	NCT00004478_0_T0	PHENOTYPE	6	6	Hypotension
NCT000044782	NCT00004478_2_T0	PHENOTYPE	2	2	hypotension
NCT000044782	NCT00004478_2_T1	BIOLOGICAL_PROCESS	24	24	eating
NCT000044782	NCT00004478_2_T2	PHENOTYPE	20	21	standing position
NCT000044782	NCT00004478_2_T3	PHENOTYPE	16	17	lying down
NCT000044784	NCT00004478_4_T0	PHENOTYPE	1	1	hypotension
NCT000044784	NCT00004478_4_T1	ORGAN	19	19	heart
NCT000044784	NCT00004478_4_T2	ORGAN	12	13	nervous system
NCT000044785	NCT00004478_5_T0	PHENOTYPE	15	15	hypotension
NCT000044785	NCT00004478_5_T1	PHENOTYPE	5	7	increase blood pressure
NCT000044786	NCT00004478_6_T0	PHENOTYPE	15	15	hypotension
NCT000044788	NCT00004478_8_T0	PHENOTYPE	10	11	standing positions
NCT000044792	NCT00004479_2_T0	COMPOUND	6	6	midodrine
NCT000044801	NCT00004480_1_T0	PHENOTYPE	15	15	hyperhidrosis
NCT000044801	NCT00004480_1_T1	GENE	6	6	toxin
NCT000044801	NCT00004480_1_T2	PHENOTYPE	10	10	sweating
NCT000044803	NCT00004480_3_T0	COMPOUND	3	3	iodine
NCT000044803	NCT00004480_3_T1	COMPOUND	4	4	starch
NCT000044803	NCT00004480_3_T2	PHENOTYPE	9	10	skin response
NCT000044804	NCT00004480_4_T0	PHENOTYPE	9	9	sweating
NCT000044813	NCT00004481_3_T0	CELL	11	11	chromosome
NCT000044820	NCT00004482_0_T0	GENE	1	1	II
NCT000044820	NCT00004482_0_T1	PHENOTYPE	13	15	Giant Cell Myocarditis
NCT0000448210	NCT00004482_10_T0	COMPOUND	1	1	cyclosporine
NCT0000448210	NCT00004482_10_T1	COMPOUND	8	8	prednisone
NCT000044850	NCT00004485_0_T0	ORGAN	0	1	Bone Marrow
NCT000044850	NCT00004485_0_T1	PHENOTYPE	7	9	Sickle Cell Disease
NCT000044852	NCT00004485_2_T0	CELL	25	25	platelets
NCT000044852	NCT00004485_2_T1	TISSUE	16	16	bones
NCT000044852	NCT00004485_2_T2	ORGAN	29	30	bone marrow
NCT000044852	NCT00004485_2_T3	ORGAN	0	1	Bone marrow
NCT000044852	NCT00004485_2_T4	CELL	21	23	red blood cells
NCT000044852	NCT00004485_2_T5	CELL	18	20	white blood cells
NCT000044856	NCT00004485_6_T0	ORGAN	11	12	bone marrow
NCT000044857	NCT00004485_7_T0	COMPOUND	7	7	cyclosporine
NCT000044857	NCT00004485_7_T1	COMPOUND	14	14	1
NCT000044857	NCT00004485_7_T2	COMPOUND	16	16	1
NCT000044857	NCT00004485_7_T3	COMPOUND	3	3	fludarabine
NCT000044857	NCT00004485_7_T4	GENE	4	4	IV
NCT000044857	NCT00004485_7_T5	GENE	8	8	IV
NCT000044858	NCT00004485_8_T0	COMPOUND	4	4	cyclosporine
NCT000044858	NCT00004485_8_T1	COMPOUND	10	11	mycophenolate mofetil
NCT000044860	NCT00004486_0_T0	PHENOTYPE	9	9	Autism
NCT000044862	NCT00004486_2_T0	PHENOTYPE	11	11	severity
NCT000044862	NCT00004486_2_T1	COMPOUND	4	4	fluoxetine
NCT000044862	NCT00004486_2_T2	PHENOTYPE	20	20	autism
NCT000044866	NCT00004486_6_T0	PHENOTYPE	4	4	severity
NCT000044869	NCT00004486_9_T0	COMPOUND	7	7	fluoxetine
NCT000044869	NCT00004486_9_T1	GENE	14	14	1.8
NCT000044871	NCT00004487_1_T0	CELL	6	6	chondrocyte
NCT000044871	NCT00004487_1_T1	GENE	8	8	gel
NCT000044871	NCT00004487_1_T2	PHENOTYPE	14	15	vesicoureteral reflux
NCT000044875	NCT00004487_5_T0	PHENOTYPE	6	6	avoidance
NCT000044879	NCT00004487_9_T0	CELL	8	8	chondrocytes
NCT000044879	NCT00004487_9_T1	ORGAN	5	6	auricular cartilage
NCT0000448710	NCT00004487_10_T0	CELL	0	0	Chondrocyte
NCT0000448710	NCT00004487_10_T1	ORGAN	11	11	bladder
NCT0000448710	NCT00004487_10_T2	GENE	2	2	gel
NCT0000448711	NCT00004487_11_T0	PHENOTYPE	6	6	reflux
NCT000044881	NCT00004488_1_T0	PHENOTYPE	8	8	osteopenia
NCT000044881	NCT00004488_1_T1	COMPOUND	5	5	sodium
NCT000044881	NCT00004488_1_T2	PHENOTYPE	9	9	generalized
NCT000044881	NCT00004488_1_T3	PHENOTYPE	13	13	focal
NCT000044881	NCT00004488_1_T4	COMPOUND	4	4	alendronate
NCT000044881	NCT00004488_1_T5	PHENOTYPE	19	20	Gaucher's disease
NCT000044881	NCT00004488_1_T6	PHENOTYPE	14	15	bone lesions
NCT000044883	NCT00004488_3_T0	COMPOUND	4	4	calcium
NCT000044883	NCT00004488_3_T1	COMPOUND	5	5	carbonate
NCT000044884	NCT00004488_4_T0	COMPOUND	7	7	sodium
NCT000044884	NCT00004488_4_T1	COMPOUND	6	6	alendronate
NCT000044890	NCT00004489_0_T0	PHENOTYPE	11	11	Osteoporosis
NCT000044890	NCT00004489_0_T1	PHENOTYPE	8	9	Cystic Fibrosis
NCT000044892	NCT00004489_2_T0	BIOLOGICAL_PROCESS	10	10	metabolism
NCT000044892	NCT00004489_2_T1	COMPOUND	7	7	alendronate
NCT000044892	NCT00004489_2_T2	PHENOTYPE	14	15	cystic fibrosis
NCT000044894	NCT00004489_4_T0	PHENOTYPE	11	11	osteoporosis
NCT000044896	NCT00004489_6_T0	PHENOTYPE	13	13	severity
NCT000044896	NCT00004489_6_T1	PHENOTYPE	11	11	osteoporosis
NCT000044898	NCT00004489_8_T0	COMPOUND	10	10	alendronate
NCT000044901	NCT00004490_1_T0	COMPOUND	4	4	sodium
NCT000044901	NCT00004490_1_T1	COMPOUND	5	5	dichloroacetate
NCT000044901	NCT00004490_1_T2	PHENOTYPE	12	14	congenital lactic acidosis
NCT000044903	NCT00004490_3_T0	PHENOTYPE	2	4	quality of life
NCT000044905	NCT00004490_5_T0	PHENOTYPE	2	2	pharmacokinetics
NCT000044909	NCT00004490_9_T0	PHENOTYPE	0	2	Quality of life
NCT000044920	NCT00004492_0_T0	PHENOTYPE	13	15	Sickle Cell Anemia
NCT000044931	NCT00004493_1_T0	COMPOUND	4	4	sodium
NCT000044931	NCT00004493_1_T1	COMPOUND	5	5	dichloroacetate
NCT000044931	NCT00004493_1_T2	PHENOTYPE	2	2	pharmacokinetics
NCT000044931	NCT00004493_1_T3	PHENOTYPE	11	12	lactic acidemia
NCT000044935	NCT00004493_5_T0	COMPOUND	12	12	sodium
NCT000044935	NCT00004493_5_T1	COMPOUND	13	13	dichloroacetate
NCT000044943	NCT00004494_3_T0	PHENOTYPE	4	4	pharmacodynamic
NCT000044945	NCT00004494_5_T0	GENE	5	5	VIP
NCT000044945	NCT00004494_5_T1	GENE	6	6	IV
NCT000044945	NCT00004494_5_T2	GENE	2	4	vasoactive intestinal peptide
NCT000044946	NCT00004494_6_T0	GENE	9	9	VIP
NCT000044950	NCT00004495_0_T0	PHENOTYPE	7	7	Hyperhomocysteinemia
NCT000044950	NCT00004495_0_T1	PHENOTYPE	11	14	End Stage Renal Disease
NCT000044952	NCT00004495_2_T0	COMPOUND	13	13	homocysteine
NCT000044952	NCT00004495_2_T1	PHENOTYPE	28	28	hyperhomocysteinemia
NCT000044952	NCT00004495_2_T2	ORGAN	11	11	plasma
NCT000044952	NCT00004495_2_T3	COMPOUND	7	8	folic acid
NCT000044952	NCT00004495_2_T4	PHENOTYPE	18	21	end stage renal disease
NCT000044958	NCT00004495_8_T0	COMPOUND	6	6	homocysteine
NCT000044959	NCT00004495_9_T0	COMPOUND	18	18	pyridoxine
NCT000044959	NCT00004495_9_T1	COMPOUND	20	20	cyanocobalamin
NCT000044959	NCT00004495_9_T2	COMPOUND	13	14	folic acid
NCT0000449613	NCT00004496_13_T0	GENE	12	12	MTD
NCT0000449613	NCT00004496_13_T1	GENE	9	9	MED
NCT000044970	NCT00004497_0_T0	GENE	1	1	III
NCT000044970	NCT00004497_0_T1	PHENOTYPE	9	11	Primary Pulmonary Hypertension
NCT000044972	NCT00004497_2_T0	PHENOTYPE	12	14	primary pulmonary hypertension
NCT000044981	NCT00004498_1_T0	ORGAN	16	16	liver
NCT000044981	NCT00004498_1_T1	PHENOTYPE	21	23	ornithine transcarbamylase deficiency
NCT000045331	NCT00004533_1_T0	PHENOTYPE	13	14	cystic fibrosis
NCT000045337	NCT00004533_7_T0	GENE	2	2	CFTR
NCT000045337	NCT00004533_7_T1	BIOLOGICAL_PROCESS	3	4	gene expression
NCT000045339	NCT00004533_9_T0	GENE	5	5	CFTR
NCT000045339	NCT00004533_9_T1	BIOLOGICAL_PROCESS	6	7	gene expression
NCT0000453311	NCT00004533_11_T0	GENE	6	6	CFTR
NCT0000453311	NCT00004533_11_T1	BIOLOGICAL_PROCESS	2	3	immune response
NCT0000453314	NCT00004533_14_T0	GENE	5	5	10
NCT0000453314	NCT00004533_14_T1	PHENOTYPE	14	15	virus infections
NCT0000453315	NCT00004533_15_T0	ORGAN	12	12	turbinates
NCT0000453316	NCT00004533_16_T0	GENE	19	19	lobe
NCT0000453317	NCT00004533_17_T0	GENE	2	2	2.4
NCT0000453317	NCT00004533_17_T1	GENE	16	16	MTD
NCT0000453318	NCT00004533_18_T0	PHENOTYPE	21	21	toxicity
NCT0000453318	NCT00004533_18_T1	GENE	1	1	MTD
NCT000045470	NCT00004547_0_T0	PHENOTYPE	2	3	Peritoneal Cancer
NCT000045472	NCT00004547_2_T0	PHENOTYPE	6	6	tumors
NCT000045472	NCT00004547_2_T1	ORGAN	11	11	abdomen
NCT000045472	NCT00004547_2_T2	PHENOTYPE	3	4	peritoneal cancer
NCT000045473	NCT00004547_3_T0	GENE	22	22	MRI
NCT000045473	NCT00004547_3_T1	ORGAN	25	25	abdomen
NCT000045474	NCT00004547_4_T0	PHENOTYPE	7	7	tumor
NCT000045475	NCT00004547_5_T0	TISSUE	9	9	spleen
NCT000045475	NCT00004547_5_T1	ORGAN	4	4	pancreas
NCT000045475	NCT00004547_5_T2	ORGAN	3	3	intestines
NCT000045476	NCT00004547_6_T0	ORGAN	17	17	abdomen
NCT000045476	NCT00004547_6_T1	PHENOTYPE	4	4	tumor
NCT000045476	NCT00004547_6_T2	GENE	5	5	has
NCT000045477	NCT00004547_7_T0	ORGAN	27	27	abdomen
NCT000045477	NCT00004547_7_T1	COMPOUND	7	7	cisplatin
NCT000045479	NCT00004547_9_T0	ORGAN	6	6	abdomen
NCT000045479	NCT00004547_9_T1	ORGAN	16	16	abdomen
NCT0000454710	NCT00004547_10_T0	ORGAN	10	10	abdomen
NCT0000454711	NCT00004547_11_T0	COMPOUND	12	12	paclitaxel
NCT0000454715	NCT00004547_15_T0	PHENOTYPE	9	9	affects
NCT0000454716	NCT00004547_16_T0	PHENOTYPE	6	6	quality-of-life
NCT0000454716	NCT00004547_16_T1	PHENOTYPE	7	7	QOL
NCT0000454719	NCT00004547_19_T0	TISSUE	9	9	spleen
NCT0000454719	NCT00004547_19_T1	ORGAN	4	4	pancreas
NCT0000454719	NCT00004547_19_T2	ORGAN	3	3	intestines
NCT0000454721	NCT00004547_21_T0	PHENOTYPE	13	13	hyperthermic
NCT0000454721	NCT00004547_21_T1	COMPOUND	28	28	paclitaxel
NCT0000454721	NCT00004547_21_T2	COMPOUND	18	18	cisplatin
NCT0000454721	NCT00004547_21_T3	PHENOTYPE	33	34	peritoneal carcinomatosis
NCT0000454722	NCT00004547_22_T0	PHENOTYPE	15	15	hyperthermic
NCT0000454722	NCT00004547_22_T1	COMPOUND	29	29	paclitaxel
NCT0000454722	NCT00004547_22_T2	COMPOUND	19	19	cisplatin
NCT0000454724	NCT00004547_24_T0	PHENOTYPE	22	22	hyperthermic
NCT0000454724	NCT00004547_24_T1	COMPOUND	9	9	paclitaxel
NCT0000454724	NCT00004547_24_T2	COMPOUND	36	36	paclitaxel
NCT0000454724	NCT00004547_24_T3	PHENOTYPE	1	1	secondary
NCT0000454724	NCT00004547_24_T4	PHENOTYPE	7	7	pharmacokinetics
NCT0000454724	NCT00004547_24_T5	GENE	37	37	has
NCT0000454724	NCT00004547_24_T6	COMPOUND	26	26	cisplatin
NCT0000454724	NCT00004547_24_T7	ORGAN	15	16	peritoneal cavity
NCT0000454724	NCT00004547_24_T8	PHENOTYPE	42	44	quality of life
NCT0000454726	NCT00004547_26_T0	PHENOTYPE	41	41	adenocarcinoma
NCT0000454726	NCT00004547_26_T1	PHENOTYPE	37	37	borderline
NCT0000454726	NCT00004547_26_T2	PHENOTYPE	35	35	neoplasms
NCT0000454726	NCT00004547_26_T3	ORGAN	43	44	gastrointestinal tract
NCT0000454726	NCT00004547_26_T4	PHENOTYPE	29	30	mucinous adenocarcinoma
NCT0000454726	NCT00004547_26_T5	ORGAN	59	60	peritoneal cavity
NCT0000454726	NCT00004547_26_T6	PHENOTYPE	14	15	peritoneal carcinomatosis
NCT0000454726	NCT00004547_26_T7	PHENOTYPE	52	53	pancreatic cancer
NCT0000454726	NCT00004547_26_T8	PHENOTYPE	24	25	peritoneal mesothelioma
NCT0000454727	NCT00004547_27_T0	PHENOTYPE	19	19	toxicity
NCT0000454727	NCT00004547_27_T1	GENE	4	4	had
NCT0000454728	NCT00004547_28_T0	PHENOTYPE	13	13	disorders
NCT0000454729	NCT00004547_29_T0	COMPOUND	7	7	platinum
NCT0000454730	NCT00004547_30_T0	COMPOUND	10	10	cisplatin
NCT0000454731	NCT00004547_31_T0	ORGAN	9	10	peritoneal cavity
NCT0000454734	NCT00004547_34_T0	PHENOTYPE	0	0	Tumor
NCT0000454736	NCT00004547_36_T0	PHENOTYPE	11	11	tumor
NCT0000454736	NCT00004547_36_T1	ORGAN	20	20	abdomen
NCT0000454736	NCT00004547_36_T2	ORGAN	22	22	pelvis
NCT0000454736	NCT00004547_36_T3	PHENOTYPE	24	24	QOL
NCT0000454737	NCT00004547_37_T0	PHENOTYPE	27	27	tumors
NCT0000454738	NCT00004547_38_T0	PHENOTYPE	4	4	tumors
NCT0000454740	NCT00004547_40_T0	PHENOTYPE	9	9	adenocarcinoma
NCT0000454740	NCT00004547_40_T1	PHENOTYPE	23	24	mucinous adenocarcinoma
NCT0000454740	NCT00004547_40_T2	PHENOTYPE	30	31	peritoneal mesothelioma
NCT0000454741	NCT00004547_41_T0	PHENOTYPE	12	12	recurrence
NCT0000454743	NCT00004547_43_T0	PHENOTYPE	19	19	borderline
NCT0000454743	NCT00004547_43_T1	PHENOTYPE	24	24	adenocarcinoma
NCT0000454743	NCT00004547_43_T2	PHENOTYPE	17	17	neoplasms
NCT0000454743	NCT00004547_43_T3	PHENOTYPE	11	12	mucinous adenocarcinoma
NCT0000454743	NCT00004547_43_T4	PHENOTYPE	6	7	peritoneal mesothelioma
NCT0000454745	NCT00004547_45_T0	ORGAN	11	12	peritoneal cavity
NCT0000454749	NCT00004547_49_T0	PHENOTYPE	6	6	toxicity
NCT0000454751	NCT00004547_51_T0	PHENOTYPE	41	41	ischemia
NCT0000454751	NCT00004547_51_T1	PHENOTYPE	10	10	dysfunction
NCT0000454751	NCT00004547_51_T2	COMPOUND	45	45	thallium
NCT0000454751	NCT00004547_51_T3	PHENOTYPE	18	18	hypertension
NCT0000454751	NCT00004547_51_T4	PHENOTYPE	5	7	coronary artery disease
NCT0000454751	NCT00004547_51_T5	PHENOTYPE	24	26	coronary artery disease
NCT0000454752	NCT00004547_52_T0	GENE	40	40	1.2
NCT0000454752	NCT00004547_52_T1	PHENOTYPE	46	46	ventilation
NCT0000454752	NCT00004547_52_T2	PHENOTYPE	18	18	chronic
NCT0000454752	NCT00004547_52_T3	PHENOTYPE	15	16	pulmonary disease
NCT0000454752	NCT00004547_52_T4	PHENOTYPE	3	5	shortness of breath
NCT0000454753	NCT00004547_53_T0	PHENOTYPE	6	6	toxicity
NCT0000454753	NCT00004547_53_T1	COMPOUND	24	24	paclitaxel
NCT0000454753	NCT00004547_53_T2	COMPOUND	22	22	platinum
NCT0000454753	NCT00004547_53_T3	PHENOTYPE	19	19	neurotoxicity
NCT0000454754	NCT00004547_54_T0	COMPOUND	8	8	creatinine
NCT0000454754	NCT00004547_54_T1	COMPOUND	15	15	creatinine
NCT0000454754	NCT00004547_54_T2	GENE	12	12	1.5
NCT000045492	NCT00004549_2_T0	PHENOTYPE	17	17	atherosclerosis
NCT000045492	NCT00004549_2_T1	PHENOTYPE	11	11	inflammation
NCT000045492	NCT00004549_2_T2	ORGAN	13	13	arteries
NCT000045492	NCT00004549_2_T3	PHENOTYPE	19	20	disease progression
NCT000045496	NCT00004549_6_T0	GENE	4	4	MRI
NCT000045498	NCT00004549_8_T0	GENE	11	11	MRI
NCT000045499	NCT00004549_9_T0	GENE	7	7	coil
NCT000045499	NCT00004549_9_T1	GENE	6	6	MRI
NCT0000454910	NCT00004549_10_T0	COMPOUND	7	7	gadolinium
NCT0000454911	NCT00004549_11_T0	COMPOUND	0	0	Gadolinium
NCT0000454911	NCT00004549_11_T1	ORGAN	6	7	blood vessels
NCT0000454914	NCT00004549_14_T0	PHENOTYPE	13	15	peripheral vascular disease
NCT0000454915	NCT00004549_15_T0	GENE	16	16	2.4
NCT0000454916	NCT00004549_16_T0	GENE	4	4	paired
NCT0000454921	NCT00004549_21_T0	PHENOTYPE	7	7	claustrophobia
NCT0000454923	NCT00004549_23_T0	COMPOUND	5	5	creatinine
NCT0000454923	NCT00004549_23_T1	GENE	9	9	2.0
NCT0000454923	NCT00004549_23_T2	ORGAN	4	4	serum
NCT0000454925	NCT00004549_25_T0	PHENOTYPE	11	11	arthritis
NCT0000454925	NCT00004549_25_T1	PHENOTYPE	4	5	inflammatory disorder
NCT0000454925	NCT00004549_25_T2	PHENOTYPE	14	15	Reiter's Syndrome
NCT0000454925	NCT00004549_25_T3	PHENOTYPE	12	13	polyarteritis nodosa
NCT0000454925	NCT00004549_25_T4	PHENOTYPE	7	9	systemic lupus erythematosus
NCT000045501	NCT00004550_1_T0	PHENOTYPE	13	13	disorders
NCT000045501	NCT00004550_1_T1	PHENOTYPE	10	10	OCD
NCT000045501	NCT00004550_1_T2	PHENOTYPE	12	12	OCD
NCT000045505	NCT00004550_5_T0	PHENOTYPE	15	15	OCD
NCT000045506	NCT00004550_6_T0	PHENOTYPE	15	15	centers
NCT000045508	NCT00004550_8_T0	PHENOTYPE	19	19	pathophysiology
NCT000045508	NCT00004550_8_T1	PHENOTYPE	22	24	course of illness
NCT000045509	NCT00004550_9_T0	GENE	26	26	II
NCT000045509	NCT00004550_9_T1	PHENOTYPE	22	22	SCID
NCT000045509	NCT00004550_9_T2	PHENOTYPE	25	25	SCID
NCT0000455010	NCT00004550_10_T0	GENE	18	18	MRI
NCT0000455013	NCT00004550_13_T0	PHENOTYPE	14	14	disorders
NCT0000455013	NCT00004550_13_T1	PHENOTYPE	11	11	OCD
NCT0000455013	NCT00004550_13_T2	PHENOTYPE	13	13	OCD
NCT0000455015	NCT00004550_15_T0	PHENOTYPE	5	6	decision making
NCT000045521	NCT00004552_1_T0	COMPOUND	13	13	acamprosate
NCT000045523	NCT00004552_3_T0	BIOLOGICAL_PROCESS	1	1	drinking
NCT000045532	NCT00004553_2_T0	PHENOTYPE	9	10	disease progression
NCT000045533	NCT00004553_3_T0	PHENOTYPE	10	10	weakness
NCT000045533	NCT00004553_3_T1	PHENOTYPE	4	5	neurological disorders
NCT000045536	NCT00004553_6_T0	PHENOTYPE	4	4	tense
NCT000045537	NCT00004553_7_T0	PHENOTYPE	14	14	tense
NCT0000455311	NCT00004553_11_T0	PHENOTYPE	14	14	shocks
NCT0000455311	NCT00004553_11_T1	CELL	20	21	nerve fiber
NCT0000455313	NCT00004553_13_T0	PHENOTYPE	7	7	neurophysiology
NCT0000455317	NCT00004553_17_T0	PHENOTYPE	2	2	Anticoagulation
NCT0000455317	NCT00004553_17_T1	PHENOTYPE	5	6	bleeding disorder
NCT000045541	NCT00004554_1_T0	PHENOTYPE	1	1	secondary
NCT000045541	NCT00004554_1_T1	COMPOUND	15	15	naltrexone
NCT000045541	NCT00004554_1_T2	COMPOUND	14	14	sertraline
NCT000045545	NCT00004554_5_T0	COMPOUND	16	16	sertraline
NCT000045566	NCT00004556_6_T0	GENE	14	14	separated
NCT0000455613	NCT00004556_13_T0	BIOLOGICAL_PROCESS	19	19	metabolism
NCT0000455613	NCT00004556_13_T1	BIOLOGICAL_PROCESS	26	26	aging
NCT0000455613	NCT00004556_13_T2	PHENOTYPE	15	16	individual differences
NCT0000455620	NCT00004556_20_T0	GENE	5	5	II
NCT0000455624	NCT00004556_24_T0	GENE	6	6	II
NCT0000455626	NCT00004556_26_T0	PHENOTYPE	10	10	illnesses
NCT0000455626	NCT00004556_26_T1	PHENOTYPE	18	18	hypertension
NCT0000455626	NCT00004556_26_T2	PHENOTYPE	5	6	cardiovascular disease
NCT0000455626	NCT00004556_26_T3	PHENOTYPE	11	12	substance abuse
NCT0000455626	NCT00004556_26_T4	PHENOTYPE	14	16	recreational drug use
NCT0000455627	NCT00004556_27_T0	PHENOTYPE	5	6	pulse rate
NCT000045571	NCT00004557_1_T0	GENE	9	9	AD
NCT000045571	NCT00004557_1_T1	GENE	1	1	has
NCT000045572	NCT00004557_2_T0	GENE	2	2	has
NCT000045573	NCT00004557_3_T0	GENE	3	3	AD
NCT000045573	NCT00004557_3_T1	PHENOTYPE	9	9	naming
NCT000045574	NCT00004557_4_T0	GENE	19	19	AD
NCT000045574	NCT00004557_4_T1	GENE	11	11	has
NCT000045575	NCT00004557_5_T0	GENE	14	14	AD
NCT000045575	NCT00004557_5_T1	BIOLOGICAL_PROCESS	28	28	degradation
NCT000045576	NCT00004557_6_T0	GENE	25	25	AD
NCT0000455710	NCT00004557_10_T0	GENE	9	9	AD
NCT0000455710	NCT00004557_10_T1	GENE	1	1	has
NCT0000455711	NCT00004557_11_T0	GENE	2	2	has
NCT0000455712	NCT00004557_12_T0	GENE	3	3	AD
NCT0000455712	NCT00004557_12_T1	PHENOTYPE	9	9	naming
NCT0000455713	NCT00004557_13_T0	GENE	19	19	AD
NCT0000455713	NCT00004557_13_T1	GENE	11	11	has
NCT0000455714	NCT00004557_14_T0	GENE	14	14	AD
NCT0000455714	NCT00004557_14_T1	BIOLOGICAL_PROCESS	28	28	degradation
NCT0000455715	NCT00004557_15_T0	GENE	25	25	AD
NCT0000455719	NCT00004557_19_T0	PHENOTYPE	9	10	Huntington's disease
NCT0000455719	NCT00004557_19_T1	PHENOTYPE	7	8	Korsakoff's disease
NCT000045583	NCT00004558_3_T0	PHENOTYPE	6	7	heart disease
NCT000045583	NCT00004558_3_T1	PHENOTYPE	10	12	coronary artery disease
NCT000045584	NCT00004558_4_T0	PHENOTYPE	16	17	coronary disease
NCT000045585	NCT00004558_5_T0	PHENOTYPE	15	17	coronary artery disease
NCT000045586	NCT00004558_6_T0	COMPOUND	27	28	docosahexaenoic acids
NCT000045588	NCT00004558_8_T0	GENE	2	2	VT
NCT000045595	NCT00004559_5_T0	PHENOTYPE	16	16	arrhythmias
NCT000045602	NCT00004560_2_T0	BIOLOGICAL_PROCESS	14	14	transport
NCT000045605	NCT00004560_5_T0	GENE	24	24	EMS
NCT0000456010	NCT00004560_10_T0	GENE	39	39	Las
NCT0000456014	NCT00004560_14_T0	PHENOTYPE	27	28	medical emergencies
NCT0000456018	NCT00004560_18_T0	PHENOTYPE	0	0	Secondary
NCT0000456018	NCT00004560_18_T1	PHENOTYPE	15	17	quality of life
NCT0000456019	NCT00004560_19_T0	GENE	26	26	0.6
NCT0000456019	NCT00004560_19_T1	PHENOTYPE	28	30	out-of-hospital cardiac arrests
NCT0000456022	NCT00004560_22_T0	PHENOTYPE	6	6	strategies
NCT000045610	NCT00004561_0_T0	PHENOTYPE	2	2	Hypertension
NCT000045610	NCT00004561_0_T1	PHENOTYPE	6	6	Intensities
NCT000045613	NCT00004561_3_T0	PHENOTYPE	25	25	hypertension
NCT000045615	NCT00004561_5_T0	COMPOUND	27	27	enalapril
NCT000045615	NCT00004561_5_T1	GENE	22	22	had
NCT000045616	NCT00004561_6_T0	COMPOUND	2	2	V02
NCT000045617	NCT00004561_7_T0	COMPOUND	30	30	V02
NCT000045617	NCT00004561_7_T1	COMPOUND	47	47	V02
NCT000045617	NCT00004561_7_T2	ORGAN	24	24	heart
NCT000045617	NCT00004561_7_T3	ORGAN	42	42	heart
NCT000045619	NCT00004561_9_T0	PHENOTYPE	6	6	withdrawn
NCT0000456110	NCT00004561_10_T0	COMPOUND	69	69	V02
NCT0000456110	NCT00004561_10_T1	PHENOTYPE	52	53	essential hypertension
NCT000045620	NCT00004562_0_T0	GENE	3	3	OAT
NCT000045620	NCT00004562_0_T1	PHENOTYPE	0	0	Occluded
NCT000045620	NCT00004562_0_T2	ORGAN	1	1	Artery
NCT000045626	NCT00004562_6_T0	PHENOTYPE	3	3	strategies
NCT000045626	NCT00004562_6_T1	ORGAN	22	22	arteries
NCT000045626	NCT00004562_6_T2	PHENOTYPE	20	20	occluded
NCT000045626	NCT00004562_6_T3	PHENOTYPE	21	21	infarct
NCT000045626	NCT00004562_6_T4	PHENOTYPE	8	8	reperfusion
NCT000045627	NCT00004562_7_T0	PHENOTYPE	16	16	acute
NCT000045627	NCT00004562_7_T1	PHENOTYPE	4	4	reperfusion
NCT000045629	NCT00004562_9_T0	GENE	1	1	lines
NCT000045629	NCT00004562_9_T1	PHENOTYPE	10	10	reperfusion
NCT0000456215	NCT00004562_15_T0	GENE	14	14	IV
NCT0000456215	NCT00004562_15_T1	PHENOTYPE	6	6	recurrent
NCT0000456215	NCT00004562_15_T2	PHENOTYPE	7	8	myocardial infarction
NCT0000456215	NCT00004562_15_T3	PHENOTYPE	15	17	congestive heart failure
NCT000045636	NCT00004563_6_T0	PHENOTYPE	30	31	systemic sclerosis
NCT000045636	NCT00004563_6_T1	PHENOTYPE	18	19	interstitial fibrosis
NCT000045636	NCT00004563_6_T2	PHENOTYPE	15	17	restrictive lung disease
NCT000045637	NCT00004563_7_T0	PHENOTYPE	2	2	alveolitis
NCT000045637	NCT00004563_7_T1	PHENOTYPE	14	15	systemic sclerosis
NCT000045637	NCT00004563_7_T2	PHENOTYPE	10	12	interstitial pulmonary fibrosis
NCT000045638	NCT00004563_8_T0	GENE	8	8	has
NCT000045638	NCT00004563_8_T1	PHENOTYPE	5	7	interstitial lung disease
NCT0000456311	NCT00004563_11_T0	PHENOTYPE	1	1	scleroderma
NCT0000456312	NCT00004563_12_T0	COMPOUND	9	9	cyclophosphamide
NCT0000456312	NCT00004563_12_T1	GENE	10	10	has
NCT0000456312	NCT00004563_12_T2	PHENOTYPE	15	16	pulmonary fibrosis
NCT0000456313	NCT00004563_13_T0	COMPOUND	8	8	cyclophosphamide
NCT0000456315	NCT00004563_15_T0	PHENOTYPE	6	6	centers
NCT0000456315	NCT00004563_15_T1	COMPOUND	13	13	cyclophosphamide
NCT0000456317	NCT00004563_17_T0	COMPOUND	4	4	cyclophosphamide
NCT0000456317	NCT00004563_17_T1	COMPOUND	10	10	azathioprine
NCT0000456318	NCT00004563_18_T0	PHENOTYPE	9	11	forced vital capacity
NCT0000456319	NCT00004563_19_T0	PHENOTYPE	0	0	Secondary
NCT0000456319	NCT00004563_19_T1	PHENOTYPE	8	8	dyspnea
NCT0000456319	NCT00004563_19_T2	COMPOUND	11	12	carbon monoxide
NCT0000456319	NCT00004563_19_T3	PHENOTYPE	3	5	quality of life
NCT0000456320	NCT00004563_20_T0	PHENOTYPE	0	0	Recruitment
NCT0000456323	NCT00004563_23_T0	PHENOTYPE	6	6	scleroderma
NCT0000456323	NCT00004563_23_T1	PHENOTYPE	0	0	Onset
NCT0000456323	NCT00004563_23_T2	PHENOTYPE	9	10	Raynaud's phenomenon
NCT0000456324	NCT00004563_24_T0	PHENOTYPE	1	1	FVC
NCT0000456325	NCT00004563_25_T0	PHENOTYPE	12	12	Dyspnea
NCT0000456325	NCT00004563_25_T1	PHENOTYPE	2	3	exertional dyspnea
NCT0000456327	NCT00004563_27_T0	COMPOUND	2	3	carbon monoxide
NCT0000456329	NCT00004563_29_T0	PHENOTYPE	2	3	pulmonary hypertension
NCT000045641	NCT00004564_1_T0	PHENOTYPE	12	12	strokes
NCT000045641	NCT00004564_1_T1	GENE	7	7	has
NCT000045641	NCT00004564_1_T2	PHENOTYPE	14	15	heart attacks
NCT000045642	NCT00004564_2_T0	COMPOUND	3	4	cholesterol lowering
NCT000045644	NCT00004564_4_T0	COMPOUND	5	5	clopidogrel
NCT000045644	NCT00004564_4_T1	COMPOUND	16	16	atorvastatin
NCT000045645	NCT00004564_5_T0	COMPOUND	11	11	clopidogrel
NCT000045645	NCT00004564_5_T1	COMPOUND	4	4	atorvastatin
NCT000045646	NCT00004564_6_T0	ORGAN	22	22	liver
NCT000045646	NCT00004564_6_T1	COMPOUND	5	5	erythromycin
NCT000045647	NCT00004564_7_T0	CELL	8	8	platelet
NCT000045648	NCT00004564_8_T0	COMPOUND	18	18	erythromycin
NCT000045648	NCT00004564_8_T1	PHENOTYPE	15	16	allergic reaction
NCT000045648	NCT00004564_8_T2	PHENOTYPE	24	25	liver disease
NCT000045648	NCT00004564_8_T3	PHENOTYPE	29	30	kidney disease
NCT000045648	NCT00004564_8_T4	PHENOTYPE	27	28	lung disease
NCT000045648	NCT00004564_8_T5	PHENOTYPE	22	23	bleeding problems
NCT000045649	NCT00004564_9_T0	PHENOTYPE	3	3	impairment
NCT000045649	NCT00004564_9_T1	PHENOTYPE	8	9	substance abuse
NCT0000456411	NCT00004564_11_T0	COMPOUND	6	7	cholesterol lowering
NCT000045652	NCT00004565_2_T0	PHENOTYPE	12	13	breast cancer
NCT000045653	NCT00004565_3_T0	COMPOUND	42	42	nicotine
NCT000045653	NCT00004565_3_T1	COMPOUND	44	44	estrogen
NCT000045653	NCT00004565_3_T2	PHENOTYPE	9	10	breast cancer
NCT000045653	NCT00004565_3_T3	PHENOTYPE	30	31	breast cancer
NCT000045653	NCT00004565_3_T4	PHENOTYPE	47	48	breast cancer
NCT000045654	NCT00004565_4_T0	ORGAN	25	25	nipple
NCT000045654	NCT00004565_4_T1	PHENOTYPE	14	14	aspirated
NCT000045654	NCT00004565_4_T2	CELL	8	8	cells
NCT000045654	NCT00004565_4_T3	PHENOTYPE	37	38	breast cancer
NCT000045656	NCT00004565_6_T0	PHENOTYPE	17	18	breast cancer
NCT000045657	NCT00004565_7_T0	ORGAN	0	0	Nipple
NCT000045657	NCT00004565_7_T1	PHENOTYPE	1	1	aspirations
NCT000045658	NCT00004565_8_T0	ORGAN	12	12	breasts
NCT0000456514	NCT00004565_14_T0	GENE	22	22	BRCA1
NCT0000456514	NCT00004565_14_T1	GENE	24	24	BRCA2
NCT0000456514	NCT00004565_14_T2	PHENOTYPE	20	21	breast cancer
NCT0000456514	NCT00004565_14_T3	PHENOTYPE	35	36	breast cancer
NCT0000456516	NCT00004565_16_T0	PHENOTYPE	20	21	breast cancer
NCT0000456518	NCT00004565_18_T0	BIOLOGICAL_PROCESS	15	16	estrogen metabolism
NCT0000456518	NCT00004565_18_T1	PHENOTYPE	6	7	breast cancer
NCT0000456519	NCT00004565_19_T0	BIOLOGICAL_PROCESS	15	16	estrogen metabolism
NCT0000456520	NCT00004565_20_T0	ORGAN	6	6	nipple
NCT0000456523	NCT00004565_23_T0	PHENOTYPE	18	19	breast cancer
NCT0000456523	NCT00004565_23_T1	PHENOTYPE	30	31	breast cancer
NCT0000456526	NCT00004565_26_T0	ORGAN	13	13	nipple
NCT0000456528	NCT00004565_28_T0	COMPOUND	0	0	1
NCT0000456529	NCT00004565_29_T0	PHENOTYPE	6	8	invasive breast cancer
NCT0000456530	NCT00004565_30_T0	COMPOUND	0	0	2
NCT0000456531	NCT00004565_31_T0	PHENOTYPE	6	9	ductal carcinoma in situ
NCT0000456533	NCT00004565_33_T0	COMPOUND	0	0	1
NCT0000456535	NCT00004565_35_T0	PHENOTYPE	8	8	mutation
NCT0000456535	NCT00004565_35_T1	GENE	5	5	BRCA1
NCT0000456535	NCT00004565_35_T2	GENE	7	7	BRCA2
NCT0000456536	NCT00004565_36_T0	COMPOUND	0	0	2
NCT0000456544	NCT00004565_44_T0	PHENOTYPE	20	20	practices
NCT0000456546	NCT00004565_46_T0	PHENOTYPE	7	7	malignancy
NCT0000456546	NCT00004565_46_T1	PHENOTYPE	12	12	melanoma
NCT0000456546	NCT00004565_46_T2	PHENOTYPE	9	10	skin cancers
NCT0000456546	NCT00004565_46_T3	PHENOTYPE	14	15	cervical cancer
NCT0000456546	NCT00004565_46_T4	PHENOTYPE	15	17	cancer in situ
NCT0000456551	NCT00004565_51_T0	PHENOTYPE	13	14	breast cancer
NCT0000456553	NCT00004565_53_T0	PHENOTYPE	6	6	malignancy
NCT0000456553	NCT00004565_53_T1	PHENOTYPE	11	11	melanoma
NCT0000456553	NCT00004565_53_T2	PHENOTYPE	8	9	skin cancers
NCT0000456553	NCT00004565_53_T3	PHENOTYPE	13	14	cervical cancer
NCT0000456553	NCT00004565_53_T4	PHENOTYPE	14	16	cancer in situ
NCT0000456557	NCT00004565_57_T0	GENE	5	5	BRCA1
NCT0000456557	NCT00004565_57_T1	GENE	7	7	BRCA2
NCT0000456557	NCT00004565_57_T2	PHENOTYPE	2	3	deleterious mutation
NCT0000456561	NCT00004565_61_T0	PHENOTYPE	6	6	LCIS
NCT0000456561	NCT00004565_61_T1	PHENOTYPE	2	5	lobular carcinoma in situ
NCT0000456563	NCT00004565_63_T0	GENE	2	2	atypical
NCT0000456563	NCT00004565_63_T1	PHENOTYPE	6	6	hyperplasia
NCT000045663	NCT00004566_3_T0	PHENOTYPE	23	23	sucking
NCT000045663	NCT00004566_3_T1	PHENOTYPE	37	38	feeding problems
NCT000045663	NCT00004566_3_T2	PHENOTYPE	46	47	feeding difficulties
NCT000045668	NCT00004566_8_T0	PHENOTYPE	5	5	sucking
NCT0000456617	NCT00004566_17_T0	GENE	4	4	has
NCT0000456622	NCT00004566_22_T0	PHENOTYPE	4	4	insights
NCT0000456622	NCT00004566_22_T1	PHENOTYPE	12	13	feeding difficulties
NCT0000456624	NCT00004566_24_T0	PHENOTYPE	10	10	decisions
NCT000045671	NCT00004567_1_T0	COMPOUND	13	13	cyclophosphamide
NCT000045671	NCT00004567_1_T1	COMPOUND	11	11	prednisone
NCT000045672	NCT00004567_2_T0	PHENOTYPE	15	15	relapse
NCT000045672	NCT00004567_2_T1	PHENOTYPE	11	11	remission
NCT000045674	NCT00004567_4_T0	PHENOTYPE	13	13	remission
NCT000045675	NCT00004567_5_T0	PHENOTYPE	9	9	disorders
NCT000045675	NCT00004567_5_T1	ORGAN	7	8	blood vessel
NCT000045675	NCT00004567_5_T2	PHENOTYPE	2	3	Wegener's granulomatosis
NCT000045676	NCT00004567_6_T0	COMPOUND	11	11	cyclophosphamide
NCT000045676	NCT00004567_6_T1	COMPOUND	9	9	prednisone
NCT000045677	NCT00004567_7_T0	PHENOTYPE	9	9	symptoms
NCT000045677	NCT00004567_7_T1	GENE	3	3	reduced
NCT000045678	NCT00004567_8_T0	PHENOTYPE	7	8	in remission
NCT000045679	NCT00004567_9_T0	COMPOUND	15	15	methotrexate
NCT000045679	NCT00004567_9_T1	PHENOTYPE	1	2	in remission
NCT0000456713	NCT00004567_13_T0	GENE	6	6	reduced
NCT0000456714	NCT00004567_14_T0	PHENOTYPE	8	8	relapse
NCT0000456715	NCT00004567_15_T0	PHENOTYPE	18	18	recurrence
NCT0000456715	NCT00004567_15_T1	PHENOTYPE	15	15	severity
NCT0000456715	NCT00004567_15_T2	PHENOTYPE	24	26	drug side effects
NCT0000456716	NCT00004567_16_T0	PHENOTYPE	24	26	drug side effects
NCT0000456719	NCT00004567_19_T0	COMPOUND	29	29	methotrexate
NCT0000456719	NCT00004567_19_T1	PHENOTYPE	16	16	remission
NCT0000456719	NCT00004567_19_T2	PHENOTYPE	34	34	remission
NCT0000456719	NCT00004567_19_T3	COMPOUND	9	9	cyclophosphamide
NCT0000456719	NCT00004567_19_T4	COMPOUND	17	17	cyclophosphamide
NCT0000456719	NCT00004567_19_T5	COMPOUND	31	32	mycophenolate mofetil
NCT0000456720	NCT00004567_20_T0	GENE	21	21	tapered
NCT0000456721	NCT00004567_21_T0	PHENOTYPE	11	12	drug toxicity
NCT0000456721	NCT00004567_21_T1	PHENOTYPE	8	9	disease relapse
NCT0000456722	NCT00004567_22_T0	PHENOTYPE	11	11	remission
NCT0000456722	NCT00004567_22_T1	PHENOTYPE	24	25	adverse events
NCT0000456722	NCT00004567_22_T2	PHENOTYPE	17	18	disease relapse
NCT0000456724	NCT00004567_24_T0	GENE	4	4	WG
NCT0000456724	NCT00004567_24_T1	PHENOTYPE	9	9	vasculitis
NCT0000456724	NCT00004567_24_T2	PHENOTYPE	20	20	vasculitis
NCT0000456724	NCT00004567_24_T3	PHENOTYPE	2	3	Wegener's granulomatosis
NCT0000456725	NCT00004567_25_T0	PHENOTYPE	9	9	vasculitis
NCT0000456725	NCT00004567_25_T1	PHENOTYPE	33	33	vasculitides
NCT0000456725	NCT00004567_25_T2	GENE	28	28	WG
NCT0000456725	NCT00004567_25_T3	PHENOTYPE	23	24	autoimmune diseases
NCT0000456728	NCT00004567_28_T0	PHENOTYPE	29	29	infiltrates
NCT0000456728	NCT00004567_28_T1	PHENOTYPE	34	34	inflammation
NCT0000456728	NCT00004567_28_T2	PHENOTYPE	27	27	nodules
NCT0000456728	NCT00004567_28_T3	CELL	4	4	neutrophil
NCT0000456728	NCT00004567_28_T4	PHENOTYPE	14	15	granulomatous inflammation
NCT0000456734	NCT00004567_34_T0	PHENOTYPE	21	21	vasculitis
NCT0000456738	NCT00004567_38_T0	PHENOTYPE	5	7	negative pregnancy test
NCT000045681	NCT00004568_1_T0	PHENOTYPE	30	30	disorders
NCT000045681	NCT00004568_1_T1	PHENOTYPE	15	15	diseases
NCT000045681	NCT00004568_1_T2	PHENOTYPE	5	5	symptoms
NCT000045681	NCT00004568_1_T3	PHENOTYPE	24	24	myopathies
NCT000045681	NCT00004568_1_T4	PHENOTYPE	31	32	mitochondrial myopathies
NCT000045681	NCT00004568_1_T5	PHENOTYPE	34	35	neurocognitive disorders
NCT000045681	NCT00004568_1_T6	PHENOTYPE	6	7	disease progression
NCT000045681	NCT00004568_1_T7	PHENOTYPE	21	22	peripheral neuropathies
NCT000045681	NCT00004568_1_T8	PHENOTYPE	25	26	muscular dystrophies
NCT000045681	NCT00004568_1_T9	CELL	28	29	motor neuron
NCT000045681	NCT00004568_1_T10	PHENOTYPE	37	38	neurological disorders
NCT000045682	NCT00004568_2_T0	TISSUE	10	10	muscles
NCT000045682	NCT00004568_2_T1	PHENOTYPE	3	3	diseases
NCT000045682	NCT00004568_2_T2	PHENOTYPE	17	17	understood
NCT000045682	NCT00004568_2_T3	ORGAN	8	9	spinal cord
NCT000045683	NCT00004568_3_T0	PHENOTYPE	9	10	neurological disorders
NCT000045687	NCT00004568_7_T0	PHENOTYPE	6	6	symptoms
NCT000045687	NCT00004568_7_T1	GENE	14	14	MRI
NCT000045688	NCT00004568_8_T0	PHENOTYPE	15	15	disorders
NCT0000456811	NCT00004568_11_T0	GENE	7	7	NGB
NCT0000456811	NCT00004568_11_T1	PHENOTYPE	22	23	neurological disorders
NCT0000456812	NCT00004568_12_T0	PHENOTYPE	14	14	diseases
NCT0000456813	NCT00004568_13_T0	PHENOTYPE	5	5	ideas
NCT0000456814	NCT00004568_14_T0	GENE	10	10	saliva
NCT0000456816	NCT00004568_16_T0	PHENOTYPE	13	13	pathophysiology
NCT0000456816	NCT00004568_16_T1	PHENOTYPE	10	10	diseases
NCT000045691	NCT00004569_1_T0	PHENOTYPE	3	5	quality of life
NCT000045693	NCT00004569_3_T0	PHENOTYPE	20	20	airflow
NCT000045693	NCT00004569_3_T1	GENE	2	2	has
NCT000045703	NCT00004570_3_T0	PHENOTYPE	9	10	language impairment
NCT000045704	NCT00004570_4_T0	PHENOTYPE	11	11	listening
NCT000045707	NCT00004570_7_T0	PHENOTYPE	6	7	language disorders
NCT0000457011	NCT00004570_11_T0	GENE	6	6	twins
NCT0000457012	NCT00004570_12_T0	GENE	25	25	twins
NCT0000457016	NCT00004570_16_T0	GENE	18	18	twins
NCT0000457018	NCT00004570_18_T0	PHENOTYPE	11	11	heredity
NCT0000457019	NCT00004570_19_T0	GENE	15	15	twins
NCT000045711	NCT00004571_1_T0	PHENOTYPE	0	0	Schizophrenia
NCT000045711	NCT00004571_1_T1	CELL	13	13	neurons
NCT000045711	NCT00004571_1_T2	PHENOTYPE	3	4	brain disorder
NCT000045712	NCT00004571_2_T0	PHENOTYPE	5	5	localized
NCT000045715	NCT00004571_5_T0	PHENOTYPE	27	27	disorders
NCT000045715	NCT00004571_5_T1	GENE	7	7	MRI
NCT000045715	NCT00004571_5_T2	PHENOTYPE	21	21	schizophrenia
NCT000045715	NCT00004571_5_T3	PHENOTYPE	15	15	neurophysiology
NCT000045717	NCT00004571_7_T0	PHENOTYPE	7	7	physiology
NCT000045718	NCT00004571_8_T0	PHENOTYPE	13	13	schizophrenia
NCT000045718	NCT00004571_8_T1	PHENOTYPE	16	17	brain disorder
NCT0000457114	NCT00004571_14_T0	BIOLOGICAL_PROCESS	40	40	digestion
NCT0000457115	NCT00004571_15_T0	PHENOTYPE	15	15	schizophrenia
NCT0000457116	NCT00004571_16_T0	GENE	4	4	endo
NCT0000457124	NCT00004571_24_T0	PHENOTYPE	1	1	Schizophrenia
NCT0000457124	NCT00004571_24_T1	GENE	10	10	IV
NCT0000457125	NCT00004571_25_T0	GENE	8	8	IV
NCT0000457125	NCT00004571_25_T1	PHENOTYPE	0	1	Bipolar Disorder
NCT0000457126	NCT00004571_26_T0	PHENOTYPE	1	2	Mood Disorder
NCT0000457127	NCT00004571_27_T0	PHENOTYPE	0	0	Mild
NCT0000457127	NCT00004571_27_T1	GENE	9	9	1.3
NCT0000457127	NCT00004571_27_T2	PHENOTYPE	3	4	Parkinson's Disease
NCT0000457128	NCT00004571_28_T0	PHENOTYPE	0	1	Williams Syndrome
NCT0000457129	NCT00004571_29_T0	PHENOTYPE	2	3	Multiple Sclerosis
NCT0000457132	NCT00004571_32_T0	PHENOTYPE	15	15	impairment
NCT0000457132	NCT00004571_32_T1	PHENOTYPE	21	22	head trauma
NCT0000457132	NCT00004571_32_T2	PHENOTYPE	0	1	Head trauma
NCT0000457132	NCT00004571_32_T3	PHENOTYPE	3	5	loss of consciousness
NCT0000457133	NCT00004571_33_T0	GENE	37	37	MRI
NCT0000457134	NCT00004571_34_T0	COMPOUND	4	4	nicotine
NCT0000457134	NCT00004571_34_T1	PHENOTYPE	9	10	substance use
NCT0000457134	NCT00004571_34_T2	PHENOTYPE	14	15	substance dependence
NCT0000457135	NCT00004571_35_T0	COMPOUND	6	6	nicotine
NCT0000457135	NCT00004571_35_T1	PHENOTYPE	26	27	in remission
NCT0000457135	NCT00004571_35_T2	PHENOTYPE	15	16	substance abuse
NCT0000457135	NCT00004571_35_T3	GENE	18	19	in excess
NCT0000457136	NCT00004571_36_T0	PHENOTYPE	5	6	mental illness
NCT0000457140	NCT00004571_40_T0	GENE	8	8	MRI
NCT0000457140	NCT00004571_40_T1	PHENOTYPE	0	1	Involuntary movements
NCT000045725	NCT00004572_5_T0	PHENOTYPE	5	5	obesity
NCT0000457210	NCT00004572_10_T0	GENE	9	9	insulin
NCT000045730	NCT00004573_0_T0	GENE	11	11	PCR
NCT000045732	NCT00004573_2_T0	PHENOTYPE	27	27	resistant
NCT000045735	NCT00004573_5_T0	COMPOUND	11	11	ganciclovir
NCT000045736	NCT00004573_6_T0	GENE	22	22	II
NCT000045736	NCT00004573_6_T1	PHENOTYPE	8	8	decisions
NCT000045737	NCT00004573_7_T0	PHENOTYPE	0	0	Strains
NCT000045741	NCT00004574_1_T0	PHENOTYPE	23	23	bloodstream
NCT000045741	NCT00004574_1_T1	PHENOTYPE	0	0	Abetalipoproteinemia
NCT000045741	NCT00004574_1_T2	ORGAN	30	30	liver
NCT000045741	NCT00004574_1_T3	ORGAN	20	20	intestines
NCT000045741	NCT00004574_1_T4	GENE	27	27	secreted
NCT000045745	NCT00004574_5_T0	GENE	5	5	bypass
NCT000045745	NCT00004574_5_T1	ORGAN	7	8	digestive tract
NCT0000457410	NCT00004574_10_T0	PHENOTYPE	8	8	bloodstream
NCT0000457410	NCT00004574_10_T1	ORGAN	5	5	intestine
NCT0000457410	NCT00004574_10_T2	GENE	2	2	secreted
NCT0000457413	NCT00004574_13_T0	GENE	7	7	mega
NCT0000457413	NCT00004574_13_T1	PHENOTYPE	2	3	vitamin deficiency
NCT0000457414	NCT00004574_14_T0	PHENOTYPE	7	7	symptoms
NCT000045751	NCT00004575_1_T0	ORGAN	9	9	arteries
NCT000045751	NCT00004575_1_T1	GENE	1	1	stops
NCT000045752	NCT00004575_2_T0	CELL	5	5	cells
NCT000045752	NCT00004575_2_T1	ORGAN	8	9	blood vessels
NCT000045755	NCT00004575_5_T0	COMPOUND	6	6	miconazole
NCT000045755	NCT00004575_5_T1	ORGAN	12	13	blood vessels
NCT000045756	NCT00004575_6_T0	COMPOUND	5	5	aspirin
NCT0000457511	NCT00004575_11_T0	COMPOUND	7	7	miconazole
NCT0000457511	NCT00004575_11_T1	COMPOUND	5	6	sodium nitroprusside
NCT0000457513	NCT00004575_13_T0	COMPOUND	0	0	Sodium
NCT0000457513	NCT00004575_13_T1	COMPOUND	1	1	nitroprusside
NCT0000457513	NCT00004575_13_T2	PHENOTYPE	16	17	heart failure
NCT0000457513	NCT00004575_13_T3	ORGAN	3	4	blood vessels
NCT0000457513	NCT00004575_13_T4	PHENOTYPE	12	14	high blood pressure
NCT0000457515	NCT00004575_15_T0	ORGAN	20	20	bladder
NCT0000457515	NCT00004575_15_T1	ORGAN	16	16	lungs
NCT0000457515	NCT00004575_15_T2	ORGAN	18	18	kidneys
NCT0000457515	NCT00004575_15_T3	PHENOTYPE	9	10	fungal infections
NCT0000457516	NCT00004575_16_T0	CELL	12	12	cells
NCT0000457516	NCT00004575_16_T1	COMPOUND	4	5	nitric oxide
NCT0000457516	NCT00004575_16_T2	ORGAN	14	15	blood vessels
NCT0000457519	NCT00004575_19_T0	GENE	11	11	bradykinin
NCT0000457519	NCT00004575_19_T1	GENE	5	5	receptor
NCT0000457519	NCT00004575_19_T2	COMPOUND	9	9	acetylcholine
NCT0000457519	NCT00004575_19_T3	CELL	20	22	smooth muscle cells
NCT0000457521	NCT00004575_21_T0	TISSUE	9	9	tissues
NCT0000457522	NCT00004575_22_T0	COMPOUND	2	2	miconazole
NCT0000457522	NCT00004575_22_T1	GENE	3	3	has
NCT0000457523	NCT00004575_23_T0	PHENOTYPE	20	20	inhibition
NCT0000457523	NCT00004575_23_T1	GENE	10	10	has
NCT0000457528	NCT00004575_28_T0	PHENOTYPE	1	1	hypertension
NCT0000457530	NCT00004575_30_T0	PHENOTYPE	1	1	hypercholesterolemia
NCT0000457532	NCT00004575_32_T0	COMPOUND	3	3	creatinine
NCT0000457532	NCT00004575_32_T1	GENE	6	6	1.4
NCT0000457532	NCT00004575_32_T2	PHENOTYPE	1	2	renal failure
NCT0000457533	NCT00004575_33_T0	PHENOTYPE	1	1	allergies
NCT0000457533	NCT00004575_33_T1	COMPOUND	8	8	aspirin
NCT0000457533	NCT00004575_33_T2	COMPOUND	3	3	miconazole
NCT0000457533	NCT00004575_33_T3	COMPOUND	5	6	castor oil
NCT0000457534	NCT00004575_34_T0	PHENOTYPE	1	2	bleeding disorders
NCT000045761	NCT00004576_1_T0	GENE	5	5	II
NCT000045761	NCT00004576_1_T1	GENE	7	7	IV
NCT000045762	NCT00004576_2_T0	GENE	22	22	MRI
NCT000045763	NCT00004576_3_T0	PHENOTYPE	5	5	parkinsonism
NCT000045763	NCT00004576_3_T1	COMPOUND	8	8	levodopa
NCT000045764	NCT00004576_4_T0	COMPOUND	15	15	levodopa
NCT000045767	NCT00004576_7_T0	COMPOUND	10	10	levodopa
NCT000045768	NCT00004576_8_T0	COMPOUND	15	15	levodopa
NCT0000457612	NCT00004576_12_T0	COMPOUND	29	29	levodopa
NCT0000457613	NCT00004576_13_T0	COMPOUND	7	7	levodopa
NCT0000457615	NCT00004576_15_T0	COMPOUND	9	9	levodopa
NCT0000457616	NCT00004576_16_T0	PHENOTYPE	4	4	symptoms
NCT0000457616	NCT00004576_16_T1	PHENOTYPE	3	3	parkinsonism
NCT0000457616	NCT00004576_16_T2	PHENOTYPE	6	6	dyskinesias
NCT0000457616	NCT00004576_16_T3	PHENOTYPE	19	20	drug levels
NCT0000457618	NCT00004576_18_T0	PHENOTYPE	15	16	motor function
NCT0000457621	NCT00004576_21_T0	PHENOTYPE	7	8	Parkinson's disease
NCT0000457622	NCT00004576_22_T0	GENE	10	10	II
NCT0000457622	NCT00004576_22_T1	PHENOTYPE	17	17	complications
NCT0000457622	NCT00004576_22_T2	PHENOTYPE	20	20	fluctuations
NCT0000457622	NCT00004576_22_T3	COMPOUND	14	14	levodopa
NCT0000457622	NCT00004576_22_T4	PHENOTYPE	23	23	dyskinesias
NCT0000457622	NCT00004576_22_T5	GENE	12	12	IV
NCT0000457624	NCT00004576_24_T0	ORGAN	6	6	liver
NCT0000457624	NCT00004576_24_T1	PHENOTYPE	19	19	neutropenia
NCT0000457624	NCT00004576_24_T2	GENE	20	20	WBC
NCT0000457624	NCT00004576_24_T3	PHENOTYPE	3	4	laboratory abnormalities
NCT0000457625	NCT00004576_25_T0	PHENOTYPE	11	11	dystonia
NCT0000457625	NCT00004576_25_T1	PHENOTYPE	8	8	dyskinesias
NCT0000457625	NCT00004576_25_T2	PHENOTYPE	1	2	parkinson`s disease
NCT0000457627	NCT00004576_27_T0	COMPOUND	9	9	levodopa_carbidopa
NCT0000457627	NCT00004576_27_T1	COMPOUND	16	16	dopamine
NCT0000457628	NCT00004576_28_T0	COMPOUND	7	7	amantadine
NCT0000457629	NCT00004576_29_T0	ORGAN	24	25	reproductive organs
NCT000045771	NCT00004577_1_T0	GENE	0	0	MRI
NCT000045771	NCT00004577_1_T1	PHENOTYPE	12	12	physiology
NCT000045772	NCT00004577_2_T0	GENE	5	5	MRI
NCT000045773	NCT00004577_3_T0	GENE	1	1	MRI
NCT000045776	NCT00004577_6_T0	GENE	6	6	MRI
NCT000045778	NCT00004577_8_T0	GENE	5	5	coil
NCT0000457714	NCT00004577_14_T0	GENE	3	3	MRI
NCT0000457714	NCT00004577_14_T1	GENE	8	8	MRI
NCT0000457714	NCT00004577_14_T2	GENE	17	17	structural
NCT0000457715	NCT00004577_15_T0	GENE	9	9	MRI
NCT0000457720	NCT00004577_20_T0	CELL	19	19	myelin
NCT0000457720	NCT00004577_20_T1	PHENOTYPE	24	24	concentrations
NCT0000457720	NCT00004577_20_T2	GENE	15	15	structural
NCT0000457721	NCT00004577_21_T0	GENE	13	13	MRI
NCT000045801	NCT00004580_1_T0	PHENOTYPE	11	11	HIV
NCT000045804	NCT00004580_4_T0	GENE	7	7	had
NCT000045804	NCT00004580_4_T1	GENE	6	6	has
NCT000045804	NCT00004580_4_T2	GENE	17	18	reverse transcriptase
NCT000045804	NCT00004580_4_T3	GENE	27	28	reverse transcriptase
NCT000045812	NCT00004581_2_T0	COMPOUND	4	4	nevirapine
NCT000045812	NCT00004581_2_T1	GENE	18	18	PI
NCT000045812	NCT00004581_2_T2	GENE	16	17	protease inhibitor
NCT000045812	NCT00004581_2_T3	GENE	8	9	reverse transcriptase
NCT000045813	NCT00004581_3_T0	COMPOUND	14	14	ritonavir
NCT000045813	NCT00004581_3_T1	GENE	6	7	protease inhibitor
NCT000045830	NCT00004583_0_T0	GENE	2	2	III
NCT000045832	NCT00004583_2_T0	CELL	11	11	cells
NCT000045832	NCT00004583_2_T1	PHENOTYPE	7	7	HIV
NCT000045832	NCT00004583_2_T2	GENE	1	1	PI
NCT000045832	NCT00004583_2_T3	GENE	6	6	stops
NCT000045833	NCT00004583_3_T0	COMPOUND	16	16	nelfinavir
NCT000045833	NCT00004583_3_T1	COMPOUND	11	11	ritonavir
NCT000045833	NCT00004583_3_T2	GENE	6	6	PI
NCT000045833	NCT00004583_3_T3	GENE	15	15	PI
NCT000045834	NCT00004583_4_T0	PHENOTYPE	17	18	HIV infection
NCT000045841	NCT00004584_1_T0	PHENOTYPE	4	4	HIV
NCT000045841	NCT00004584_1_T1	COMPOUND	16	16	ritonavir
NCT000045851	NCT00004585_1_T0	COMPOUND	9	9	zidovudine
NCT000045851	NCT00004585_1_T1	COMPOUND	13	13	abacavir
NCT000045851	NCT00004585_1_T2	COMPOUND	15	15	efavirenz
NCT000045851	NCT00004585_1_T3	COMPOUND	7	7	lamivudine
NCT000045854	NCT00004585_4_T0	GENE	0	0	CD4
NCT000045856	NCT00004585_6_T0	GENE	5	5	1.1
NCT000045858	NCT00004585_8_T0	PHENOTYPE	5	5	HIV
NCT000045858	NCT00004585_8_T1	ORGAN	4	4	plasma
NCT000046041	NCT00004604_1_T0	GENE	19	19	has
NCT000046041	NCT00004604_1_T1	PHENOTYPE	16	17	metastatic cancer
NCT000046043	NCT00004604_3_T0	PHENOTYPE	6	6	toxicity
NCT000046043	NCT00004604_3_T1	GENE	20	20	CEA
NCT000046043	NCT00004604_3_T2	GENE	28	28	CEA
NCT000046043	NCT00004604_3_T3	CELL	14	15	dendritic cells
NCT000046043	NCT00004604_3_T4	GENE	18	19	carcinoembryonic antigen
NCT000046043	NCT00004604_3_T5	PHENOTYPE	25	26	metastatic adenocarcinoma
NCT000046045	NCT00004604_5_T0	GENE	7	7	CEA
NCT000046045	NCT00004604_5_T1	BIOLOGICAL_PROCESS	2	4	cellular immune response
NCT000046049	NCT00004604_9_T0	GENE	12	12	CEA
NCT000046049	NCT00004604_9_T1	CELL	15	16	dendritic cells
NCT000046049	NCT00004604_9_T2	GENE	10	11	carcinoembryonic antigen
NCT0000460410	NCT00004604_10_T0	PHENOTYPE	6	6	toxicity
NCT0000460410	NCT00004604_10_T1	GENE	7	7	DLT
NCT0000460410	NCT00004604_10_T2	BIOLOGICAL_PROCESS	8	9	immune response
NCT0000460411	NCT00004604_11_T0	GENE	4	4	DLT
NCT0000460411	NCT00004604_11_T1	GENE	20	20	CEA
NCT0000460412	NCT00004604_12_T0	GENE	2	2	DLT
NCT0000460412	NCT00004604_12_T1	GENE	22	22	CEA
NCT0000460413	NCT00004604_13_T0	GENE	1	1	1.2
NCT0000460413	NCT00004604_13_T1	GENE	4	4	DLT
NCT0000460414	NCT00004604_14_T0	GENE	3	3	DLT
NCT0000460415	NCT00004604_15_T0	PHENOTYPE	4	4	toxic
NCT0000460416	NCT00004604_16_T0	GENE	1	1	MTD
NCT0000460416	NCT00004604_16_T1	GENE	20	20	DLT
NCT000046356	NCT00004635_6_T0	COMPOUND	5	5	goserelin
NCT000046356	NCT00004635_6_T1	COMPOUND	14	14	goserelin
NCT000046356	NCT00004635_6_T2	COMPOUND	8	8	thalidomide
NCT000046356	NCT00004635_6_T3	COMPOUND	3	3	leuprolide
NCT000046356	NCT00004635_6_T4	COMPOUND	12	12	leuprolide
NCT000046357	NCT00004635_7_T0	COMPOUND	10	10	goserelin
NCT000046357	NCT00004635_7_T1	COMPOUND	8	8	leuprolide
NCT0000463512	NCT00004635_12_T0	PHENOTYPE	14	14	tumor
NCT0000463514	NCT00004635_14_T0	TISSUE	10	10	muscles
NCT0000463514	NCT00004635_14_T1	TISSUE	22	22	muscles
NCT0000463516	NCT00004635_16_T0	PHENOTYPE	10	10	toxicity
NCT0000463522	NCT00004635_22_T0	COMPOUND	6	6	testosterone
NCT0000463522	NCT00004635_22_T1	COMPOUND	8	8	dihydrotestosterone
NCT0000463523	NCT00004635_23_T0	PHENOTYPE	6	6	toxicity
NCT0000463523	NCT00004635_23_T1	COMPOUND	10	10	thalidomide
NCT0000463523	NCT00004635_23_T2	PHENOTYPE	1	1	complications
NCT0000463523	NCT00004635_23_T3	PHENOTYPE	9	9	chronic
NCT0000463526	NCT00004635_26_T0	COMPOUND	15	15	NCI
NCT0000463526	NCT00004635_26_T1	PHENOTYPE	9	9	blocks
NCT000046371	NCT00004637_1_T0	PHENOTYPE	5	5	epilepsy
NCT000046371	NCT00004637_1_T1	PHENOTYPE	10	10	seizure
NCT000046372	NCT00004637_2_T0	PHENOTYPE	6	6	epilepsy
NCT000046374	NCT00004637_4_T0	PHENOTYPE	13	13	epilepsy
NCT000046374	NCT00004637_4_T1	PHENOTYPE	7	7	seizure
NCT000046375	NCT00004637_5_T0	PHENOTYPE	11	11	seizure
NCT000046375	NCT00004637_5_T1	COMPOUND	7	8	vitamin E
NCT000046376	NCT00004637_6_T0	PHENOTYPE	11	11	seizures
NCT000046376	NCT00004637_6_T1	COMPOUND	7	8	vitamin E
NCT000046377	NCT00004637_7_T0	PHENOTYPE	12	12	seizures
NCT000046377	NCT00004637_7_T1	COMPOUND	14	15	vitamin E
NCT000046378	NCT00004637_8_T0	PHENOTYPE	19	19	epilepsy
NCT000046379	NCT00004637_9_T0	PHENOTYPE	8	8	Epilepsy
NCT0000463710	NCT00004637_10_T0	PHENOTYPE	8	8	epilepsy
NCT0000463714	NCT00004637_14_T0	PHENOTYPE	6	6	feels
NCT0000463715	NCT00004637_15_T0	PHENOTYPE	10	10	seizure
NCT0000463717	NCT00004637_17_T0	COMPOUND	6	7	vitamin E
NCT0000463718	NCT00004637_18_T0	COMPOUND	4	5	vitamin E
NCT0000463719	NCT00004637_19_T0	GENE	16	16	dice
NCT0000463719	NCT00004637_19_T1	COMPOUND	4	5	vitamin E
NCT0000463721	NCT00004637_21_T0	COMPOUND	12	13	vitamin E
NCT0000463723	NCT00004637_23_T0	PHENOTYPE	1	3	quality of life
NCT0000463724	NCT00004637_24_T0	PHENOTYPE	0	0	Seizure
NCT000046382	NCT00004638_2_T0	PHENOTYPE	19	20	acute sinusitis
NCT000046382	NCT00004638_2_T1	PHENOTYPE	11	12	chronic sinusitis
NCT000046382	NCT00004638_2_T2	PHENOTYPE	23	24	chronic sinusitis
NCT000046385	NCT00004638_5_T0	CELL	15	15	leukocyte
NCT000046385	NCT00004638_5_T1	ORGAN	23	24	maxillary sinus
NCT000046386	NCT00004638_6_T0	PHENOTYPE	33	33	secondary
NCT000046386	NCT00004638_6_T1	PHENOTYPE	23	23	sinusitis
NCT000046386	NCT00004638_6_T2	PHENOTYPE	16	17	acute sinusitis
NCT000046386	NCT00004638_6_T3	PHENOTYPE	11	12	chronic sinusitis
NCT000046386	NCT00004638_6_T4	PHENOTYPE	30	31	chronic sinusitis
NCT000046390	NCT00004639_0_T0	BIOLOGICAL_PROCESS	5	5	Development
NCT000046390	NCT00004639_0_T1	PHENOTYPE	0	1	Cleft Palate
NCT000046407	NCT00004640_7_T0	PHENOTYPE	29	29	recession
NCT000046407	NCT00004640_7_T1	PHENOTYPE	30	30	caries
NCT000046407	NCT00004640_7_T2	PHENOTYPE	10	11	tooth loss
NCT000046408	NCT00004640_8_T0	PHENOTYPE	16	18	quality of life
NCT000046423	NCT00004642_3_T0	PHENOTYPE	5	5	concentrations
NCT000046423	NCT00004642_3_T1	ORGAN	4	4	plasma
NCT000046425	NCT00004642_5_T0	PHENOTYPE	6	7	antibody response
NCT000046428	NCT00004642_8_T0	PHENOTYPE	6	7	systemic infection
NCT000046431	NCT00004643_1_T0	PHENOTYPE	2	2	toxicity
NCT000046431	NCT00004643_1_T1	COMPOUND	4	4	cytarabine
NCT000046431	NCT00004643_1_T2	PHENOTYPE	9	11	systemic lupus erythematosus
NCT000046433	NCT00004643_3_T0	ORGAN	5	5	serum
NCT000046433	NCT00004643_3_T1	PHENOTYPE	16	16	lupus
NCT000046433	NCT00004643_3_T2	PHENOTYPE	9	10	antibody titers
NCT000046435	NCT00004643_5_T0	PHENOTYPE	14	14	relapse
NCT000046441	NCT00004644_1_T0	PHENOTYPE	5	5	acute
NCT000046441	NCT00004644_1_T1	PHENOTYPE	22	22	HSV
NCT000046441	NCT00004644_1_T2	COMPOUND	3	3	acyclovir
NCT000046441	NCT00004644_1_T3	PHENOTYPE	19	20	herpes simplex
NCT000046441	NCT00004644_1_T4	ORGAN	14	16	central nervous system
NCT000046443	NCT00004644_3_T0	COMPOUND	3	3	acyclovir
NCT0000464411	NCT00004644_11_T0	GENE	13	13	CSF
NCT0000464411	NCT00004644_11_T1	PHENOTYPE	7	7	HSV
NCT0000464413	NCT00004644_13_T0	GENE	8	8	CSF
NCT000046451	NCT00004645_1_T0	PHENOTYPE	10	10	acute
NCT000046451	NCT00004645_1_T1	ORGAN	4	4	plasma
NCT000046451	NCT00004645_1_T2	PHENOTYPE	15	16	demyelinating disease
NCT000046455	NCT00004645_5_T0	ORGAN	6	6	plasma
NCT000046469	NCT00004646_9_T0	COMPOUND	5	5	prednisone
NCT0000464610	NCT00004646_10_T0	COMPOUND	7	7	prednisone
NCT0000464610	NCT00004646_10_T1	GENE	10	10	tapered
NCT000046470	NCT00004647_0_T0	GENE	1	1	III
NCT000046470	NCT00004647_0_T1	PHENOTYPE	9	11	Painful Diabetic Neuropathy
NCT000046475	NCT00004647_5_T0	COMPOUND	5	5	mexiletine
NCT000046481	NCT00004648_1_T0	GENE	12	12	endoglin
NCT000046481	NCT00004648_1_T1	PHENOTYPE	6	7	arteriovenous malformation
NCT0000464810	NCT00004648_10_T0	PHENOTYPE	10	10	pulse
NCT0000464810	NCT00004648_10_T1	PHENOTYPE	22	23	arteriovenous malformations
NCT0000464811	NCT00004648_11_T0	GENE	8	8	MRI
NCT0000464811	NCT00004648_11_T1	PHENOTYPE	16	16	AVM
NCT0000464811	NCT00004648_11_T2	COMPOUND	10	10	gadolinium
NCT0000464811	NCT00004648_11_T3	PHENOTYPE	22	24	cerebral arteriovenous malformations
NCT0000464813	NCT00004648_13_T0	PHENOTYPE	11	12	arteriovenous malformations
NCT0000464814	NCT00004648_14_T0	ORGAN	12	12	liver
NCT0000464814	NCT00004648_14_T1	ORGAN	1	1	abdomen
NCT0000464814	NCT00004648_14_T2	PHENOTYPE	9	9	AVM
NCT0000464815	NCT00004648_15_T0	ORGAN	14	15	heart valve
NCT000046501	NCT00004650_1_T0	PHENOTYPE	2	4	alveolar bone loss
NCT000046503	NCT00004650_3_T0	COMPOUND	4	4	estrogen
NCT000046503	NCT00004650_3_T1	PHENOTYPE	6	8	alveolar bone loss
NCT000046507	NCT00004650_7_T0	COMPOUND	8	9	conjugated estrogens
NCT000046508	NCT00004650_8_T0	COMPOUND	3	3	calcium
NCT000046527	NCT00004652_7_T0	COMPOUND	4	4	pimozide
NCT000046527	NCT00004652_7_T1	COMPOUND	8	8	pimozide
NCT000046528	NCT00004652_8_T0	COMPOUND	1	1	pimozide
NCT000046529	NCT00004652_9_T0	COMPOUND	5	5	pimozide
NCT000046529	NCT00004652_9_T1	COMPOUND	8	8	pimozide
NCT0000465210	NCT00004652_10_T0	PHENOTYPE	11	11	tics
NCT0000465210	NCT00004652_10_T1	PHENOTYPE	13	14	behavioral symptoms
NCT0000465211	NCT00004652_11_T0	PHENOTYPE	8	8	tics
NCT000046543	NCT00004654_3_T0	PHENOTYPE	9	9	severity
NCT000046543	NCT00004654_3_T1	GENE	2	2	soy
NCT000046543	NCT00004654_3_T2	PHENOTYPE	11	11	epistaxis
NCT000046543	NCT00004654_3_T3	PHENOTYPE	13	14	gastrointestinal bleeding
NCT000046545	NCT00004654_5_T0	GENE	7	7	soy
NCT000046563	NCT00004656_3_T0	PHENOTYPE	4	5	metabolic rates
NCT000046567	NCT00004656_7_T0	COMPOUND	11	11	oxygen
NCT000046567	NCT00004656_7_T1	ORGAN	6	6	heart
NCT0000465611	NCT00004656_11_T0	COMPOUND	7	7	potassium
NCT0000465615	NCT00004656_15_T0	PHENOTYPE	9	10	metabolic rate
NCT0000465615	NCT00004656_15_T1	TISSUE	4	5	body fat
NCT000046583	NCT00004658_3_T0	COMPOUND	5	5	ribose
NCT000046585	NCT00004658_5_T0	COMPOUND	5	5	ribose
NCT000046588	NCT00004658_8_T0	COMPOUND	6	6	uridine
NCT000046588	NCT00004658_8_T1	GENE	10	10	TDR
NCT000046588	NCT00004658_8_T2	COMPOUND	9	9	thymidine
NCT000046589	NCT00004658_9_T0	COMPOUND	9	9	ribose
NCT0000465812	NCT00004658_12_T0	GENE	3	3	TDR
NCT0000465812	NCT00004658_12_T1	GENE	8	8	tapered
NCT000046592	NCT00004659_2_T0	PHENOTYPE	16	17	brain tumors
NCT000046592	NCT00004659_2_T1	PHENOTYPE	19	20	systemic disease
NCT000046594	NCT00004659_4_T0	PHENOTYPE	6	6	tumor
NCT000046596	NCT00004659_6_T0	PHENOTYPE	0	0	Tumor
NCT0000465911	NCT00004659_11_T0	PHENOTYPE	6	6	tumors
NCT0000465914	NCT00004659_14_T0	PHENOTYPE	10	10	tumors
NCT000046607	NCT00004660_7_T0	PHENOTYPE	4	5	radiation retinopathy
NCT000046612	NCT00004661_2_T0	COMPOUND	3	3	calcium
NCT000046612	NCT00004661_2_T1	GENE	6	7	parathyroid hormone
NCT000046621	NCT00004662_1_T0	COMPOUND	7	7	dehydroepiandrosterone
NCT000046621	NCT00004662_1_T1	PHENOTYPE	13	15	systemic lupus erythematosus
NCT000046624	NCT00004662_4_T0	COMPOUND	7	7	dehydroepiandrosterone
NCT000046626	NCT00004662_6_T0	COMPOUND	3	3	estrogen
NCT000046626	NCT00004662_6_T1	COMPOUND	13	13	folate
NCT000046626	NCT00004662_6_T2	COMPOUND	15	15	hydroxychloroquine
NCT000046626	NCT00004662_6_T3	COMPOUND	10	10	azathioprine
NCT000046626	NCT00004662_6_T4	COMPOUND	11	11	methotrexate
NCT000046626	NCT00004662_6_T5	COMPOUND	9	9	prednisone
NCT000046631	NCT00004663_1_T0	PHENOTYPE	9	9	affects
NCT000046631	NCT00004663_1_T1	PHENOTYPE	15	17	systemic lupus erythematosus
NCT000046636	NCT00004663_6_T0	PHENOTYPE	15	15	Lupus
NCT000046636	NCT00004663_6_T1	GENE	18	18	SLAM
NCT0000466310	NCT00004663_10_T0	GENE	15	15	SLAM
NCT000046648	NCT00004664_8_T0	PHENOTYPE	5	6	bioelectrical impedance
NCT0000466410	NCT00004664_10_T0	PHENOTYPE	7	9	quality of life
NCT0000466412	NCT00004664_12_T0	PHENOTYPE	13	14	energy expenditure
NCT0000466415	NCT00004664_15_T0	COMPOUND	5	6	megestrol acetate
NCT0000466418	NCT00004664_18_T0	COMPOUND	13	13	oxygen
NCT0000466418	NCT00004664_18_T1	ORGAN	6	6	heart
NCT000046651	NCT00004665_1_T0	COMPOUND	11	11	dehydroepiandrosterone
NCT000046651	NCT00004665_1_T1	PHENOTYPE	5	5	tolerance
NCT000046651	NCT00004665_1_T2	PHENOTYPE	16	18	systemic lupus erythematosus
NCT000046653	NCT00004665_3_T0	PHENOTYPE	9	9	tolerance
NCT000046671	NCT00004667_1_T0	GENE	18	18	half-life
NCT000046671	NCT00004667_1_T1	PHENOTYPE	11	12	bleeding time
NCT000046671	NCT00004667_1_T2	GENE	6	8	von Willebrand factor
NCT000046671	NCT00004667_1_T3	PHENOTYPE	26	28	von Willebrand's disease
NCT000046673	NCT00004667_3_T0	GENE	4	6	von Willebrand factor
NCT000046691	NCT00004669_1_T0	COMPOUND	4	4	cortisol
NCT000046691	NCT00004669_1_T1	PHENOTYPE	17	18	bronchopulmonary dysplasia
NCT000046693	NCT00004669_3_T0	COMPOUND	4	4	cortisol
NCT000046693	NCT00004669_3_T1	PHENOTYPE	11	13	acute adrenal insufficiency
NCT000046695	NCT00004669_5_T0	COMPOUND	4	4	cortisol
NCT000046695	NCT00004669_5_T1	PHENOTYPE	10	10	concentrations
NCT000046695	NCT00004669_5_T2	GENE	22	22	ACTH
NCT000046695	NCT00004669_5_T3	GENE	9	9	hormone
NCT000046695	NCT00004669_5_T4	ORGAN	17	18	adrenal gland
NCT000046697	NCT00004669_7_T0	PHENOTYPE	16	16	peripheral
NCT000046697	NCT00004669_7_T1	PHENOTYPE	10	10	inflammation
NCT000046697	NCT00004669_7_T2	CELL	18	18	leukocytes
NCT000046699	NCT00004669_9_T0	GENE	2	2	IV
NCT0000466911	NCT00004669_11_T0	PHENOTYPE	19	19	concentrations
NCT0000466912	NCT00004669_12_T0	GENE	7	7	ACTH
NCT000046701	NCT00004670_1_T0	PHENOTYPE	25	26	Parkinson disease
NCT000046703	NCT00004670_3_T0	CELL	14	14	cells
NCT000046703	NCT00004670_3_T1	ORGAN	17	18	globus pallidus
NCT000046821	NCT00004682_1_T0	PHENOTYPE	14	15	myasthenia gravis
NCT000046823	NCT00004682_3_T0	PHENOTYPE	16	17	Myasthenia Gravis
NCT000046824	NCT00004682_4_T0	COMPOUND	14	14	azathioprine
NCT000046824	NCT00004682_4_T1	GENE	2	3	group 2
NCT000046825	NCT00004682_5_T0	GENE	14	14	albumin
NCT000046826	NCT00004682_6_T0	GENE	9	9	albumin
NCT000046851	NCT00004685_1_T0	PHENOTYPE	16	16	contraction
NCT000046851	NCT00004685_1_T1	PHENOTYPE	9	9	dystrophy
NCT000046863	NCT00004686_3_T0	PHENOTYPE	2	2	relapse
NCT000046863	NCT00004686_3_T1	PHENOTYPE	1	1	remission
NCT000046863	NCT00004686_3_T2	COMPOUND	13	13	methotrexate
NCT000046865	NCT00004686_5_T0	COMPOUND	5	5	methotrexate
NCT000046869	NCT00004686_9_T0	COMPOUND	16	16	methotrexate
NCT000046869	NCT00004686_9_T1	COMPOUND	7	7	prednisone
NCT000046869	NCT00004686_9_T2	COMPOUND	12	12	prednisone
NCT0000468612	NCT00004686_12_T0	PHENOTYPE	18	18	toxicity
NCT0000468612	NCT00004686_12_T1	COMPOUND	3	3	methotrexate
NCT0000468612	NCT00004686_12_T2	GENE	1	1	MTD
NCT0000468613	NCT00004686_13_T0	PHENOTYPE	5	5	remission
NCT0000468613	NCT00004686_13_T1	COMPOUND	8	8	methotrexate
NCT0000468613	NCT00004686_13_T2	GENE	12	12	tapered
NCT0000468614	NCT00004686_14_T0	GENE	4	4	1/6
NCT000046881	NCT00004688_1_T0	PHENOTYPE	9	9	recurrent
NCT000046881	NCT00004688_1_T1	PHENOTYPE	10	11	brain neoplasms
NCT000046891	NCT00004689_1_T0	GENE	10	10	MAC
NCT000046891	NCT00004689_1_T1	PHENOTYPE	11	12	pulmonary disease
NCT000046891	NCT00004689_1_T2	PHENOTYPE	7	9	Mycobacterium avium complex
NCT000046893	NCT00004689_3_T0	GENE	12	12	MAC
NCT000046895	NCT00004689_5_T0	PHENOTYPE	8	8	chronic
NCT000046895	NCT00004689_5_T1	PHENOTYPE	4	4	tolerance
NCT000046897	NCT00004689_7_T0	COMPOUND	7	7	ethambutol
NCT000046897	NCT00004689_7_T1	COMPOUND	8	8	kanamycin
NCT000046897	NCT00004689_7_T2	COMPOUND	4	4	clarithromycin
NCT000046897	NCT00004689_7_T3	GENE	16	16	MAC
NCT000046897	NCT00004689_7_T4	COMPOUND	5	5	streptomycin
NCT000046899	NCT00004689_9_T0	COMPOUND	7	7	clarithromycin
NCT000046899	NCT00004689_9_T1	COMPOUND	9	9	streptomycin
NCT0000468913	NCT00004689_13_T0	PHENOTYPE	12	12	complications
NCT0000468913	NCT00004689_13_T1	PHENOTYPE	9	9	relapse
NCT000046901	NCT00004690_1_T0	COMPOUND	6	6	monolaurin
NCT000046901	NCT00004690_1_T1	PHENOTYPE	18	21	nonbullous congenital ichthyosiform erythroderma
NCT000046905	NCT00004690_5_T0	COMPOUND	6	6	monolaurin
NCT000046907	NCT00004690_7_T0	COMPOUND	13	13	monolaurin
NCT000046909	NCT00004690_9_T0	COMPOUND	11	11	monolaurin
NCT000046941	NCT00004694_1_T0	COMPOUND	10	10	heparin
NCT000046941	NCT00004694_1_T1	PHENOTYPE	15	16	hereditary angioedema
NCT000046943	NCT00004694_3_T0	PHENOTYPE	23	23	symptoms
NCT000046944	NCT00004694_4_T0	COMPOUND	6	6	heparin
NCT000046944	NCT00004694_4_T1	COMPOUND	10	10	heparin
NCT000046955	NCT00004695_5_T0	GENE	6	7	interleukin 2
NCT000046960	NCT00004696_0_T0	PHENOTYPE	9	9	Ventilation
NCT000046962	NCT00004696_2_T0	COMPOUND	6	6	morphine
NCT000046966	NCT00004696_6_T0	PHENOTYPE	1	1	ventilation
NCT000046966	NCT00004696_6_T1	PHENOTYPE	15	15	ventilation
NCT000046966	NCT00004696_6_T2	GENE	5	5	CO2
NCT0000469611	NCT00004696_11_T0	GENE	2	2	II
NCT0000469611	NCT00004696_11_T1	GENE	22	22	IV
NCT0000469611	NCT00004696_11_T2	COMPOUND	10	10	morphine
NCT000046971	NCT00004697_1_T0	COMPOUND	3	3	choline
NCT000046971	NCT00004697_1_T1	ORGAN	12	12	liver
NCT000046971	NCT00004697_1_T2	PHENOTYPE	8	9	hepatic steatosis
NCT000046973	NCT00004697_3_T0	COMPOUND	4	4	choline
NCT000046973	NCT00004697_3_T1	GENE	11	11	TPN
NCT000046973	NCT00004697_3_T2	GENE	16	16	TPN
NCT000046973	NCT00004697_3_T3	COMPOUND	5	5	chloride
NCT000046974	NCT00004697_4_T0	GENE	1	1	TPN
NCT000046976	NCT00004697_6_T0	COMPOUND	6	6	choline
NCT000046976	NCT00004697_6_T1	COMPOUND	15	15	choline
NCT000046976	NCT00004697_6_T2	ORGAN	13	13	plasma
NCT000046976	NCT00004697_6_T3	PHENOTYPE	19	19	tolerance
NCT000046994	NCT00004699_4_T0	GENE	0	0	IGF-I
NCT000046995	NCT00004699_5_T0	GENE	3	3	IGF-I
NCT000046996	NCT00004699_6_T0	PHENOTYPE	8	8	hypoglycemia
NCT000047051	NCT00004705_1_T0	BIOLOGICAL_PROCESS	10	10	metabolism
NCT000047051	NCT00004705_1_T1	PHENOTYPE	21	22	cystic fibrosis
NCT000047051	NCT00004705_1_T2	COMPOUND	4	5	uridine triphosphate
NCT000047053	NCT00004705_3_T0	PHENOTYPE	2	2	acute
NCT000047053	NCT00004705_3_T1	PHENOTYPE	12	13	cystic fibrosis
NCT000047056	NCT00004705_6_T0	COMPOUND	8	9	uridine triphosphate
NCT0000470510	NCT00004705_10_T0	COMPOUND	2	2	amiloride
NCT0000470512	NCT00004705_12_T0	COMPOUND	4	4	technetium
NCT0000470512	NCT00004705_12_T1	COMPOUND	7	8	iron oxide
NCT0000470513	NCT00004705_13_T0	ORGAN	5	5	lungs
NCT0000470514	NCT00004705_14_T0	COMPOUND	12	12	amiloride
NCT0000470514	NCT00004705_14_T1	COMPOUND	16	16	amiloride
NCT000047271	NCT00004727_1_T0	PHENOTYPE	14	14	symptoms
NCT000047277	NCT00004727_7_T0	PHENOTYPE	18	18	secondary
NCT000047277	NCT00004727_7_T1	COMPOUND	10	10	ticlopidine
NCT000047277	NCT00004727_7_T2	COMPOUND	15	15	aspirin
NCT000047277	NCT00004727_7_T3	PHENOTYPE	33	34	adverse events
NCT000047278	NCT00004727_8_T0	COMPOUND	10	10	hydrochloride
NCT000047278	NCT00004727_8_T1	COMPOUND	9	9	ticlopidine
NCT000047278	NCT00004727_8_T2	COMPOUND	13	13	aspirin
NCT000047278	NCT00004727_8_T3	PHENOTYPE	21	22	ischemic stroke
NCT000047279	NCT00004727_9_T0	COMPOUND	12	12	ticlopidine
NCT000047279	NCT00004727_9_T1	COMPOUND	14	14	aspirin
NCT000047279	NCT00004727_9_T2	PHENOTYPE	22	22	recurrent
NCT000047279	NCT00004727_9_T3	PHENOTYPE	27	28	myocardial infarction
NCT0000472710	NCT00004727_10_T0	PHENOTYPE	1	1	experiences
NCT0000472712	NCT00004727_12_T0	GENE	6	6	3.5
NCT0000472714	NCT00004727_14_T0	PHENOTYPE	9	9	secondary
NCT0000472714	NCT00004727_14_T1	GENE	15	15	has
NCT0000472716	NCT00004727_16_T0	PHENOTYPE	11	12	cerebrovascular disease
NCT000047283	NCT00004728_3_T0	ORGAN	30	30	arteries
NCT000047283	NCT00004728_3_T1	COMPOUND	14	14	warfarin
NCT000047283	NCT00004728_3_T2	COMPOUND	16	16	aspirin
NCT000047283	NCT00004728_3_T3	PHENOTYPE	24	24	narrowing
NCT000047284	NCT00004728_4_T0	PHENOTYPE	9	9	TIA
NCT000047284	NCT00004728_4_T1	PHENOTYPE	6	8	transient ischemic attack
NCT000047292	NCT00004729_2_T0	PHENOTYPE	11	11	seizures
NCT000047293	NCT00004729_3_T0	PHENOTYPE	17	17	seizure
NCT000047293	NCT00004729_3_T1	PHENOTYPE	19	20	medication toxicity
NCT000047293	NCT00004729_3_T2	PHENOTYPE	23	25	quality of life
NCT000047295	NCT00004729_5_T0	PHENOTYPE	8	8	seizures
NCT000047296	NCT00004729_6_T0	PHENOTYPE	19	20	drop seizures
NCT000047297	NCT00004729_7_T0	PHENOTYPE	6	7	drop seizures
NCT000047299	NCT00004729_9_T0	PHENOTYPE	13	13	seizure
NCT000047303	NCT00004730_3_T0	PHENOTYPE	26	27	head injury
NCT000047304	NCT00004730_4_T0	PHENOTYPE	15	15	epilepsy
NCT000047304	NCT00004730_4_T1	COMPOUND	5	5	magnesium
NCT000047304	NCT00004730_4_T2	PHENOTYPE	14	14	seizures
NCT000047304	NCT00004730_4_T3	PHENOTYPE	25	27	traumatic brain injury
NCT000047305	NCT00004730_5_T0	COMPOUND	13	13	sulfate
NCT000047305	NCT00004730_5_T1	COMPOUND	12	12	magnesium
NCT000047308	NCT00004730_8_T0	COMPOUND	5	5	sulfate
NCT000047308	NCT00004730_8_T1	COMPOUND	4	4	magnesium
NCT0000473010	NCT00004730_10_T0	COMPOUND	1	1	magnesium
NCT0000473010	NCT00004730_10_T1	PHENOTYPE	14	15	Magnesium blood
NCT0000473012	NCT00004730_12_T0	COMPOUND	13	13	magnesium
NCT0000473013	NCT00004730_13_T0	GENE	28	28	had
NCT0000473013	NCT00004730_13_T1	PHENOTYPE	30	30	seizures
NCT0000473013	NCT00004730_13_T2	PHENOTYPE	42	43	head injury
NCT0000473016	NCT00004730_16_T0	PHENOTYPE	14	15	problem solving
NCT0000473017	NCT00004730_17_T0	GENE	8	8	has
NCT0000473018	NCT00004730_18_T0	PHENOTYPE	16	16	moods
NCT000047310	NCT00004731_0_T0	GENE	5	5	Q10
NCT000047310	NCT00004731_0_T1	COMPOUND	4	4	Coenzyme
NCT000047310	NCT00004731_0_T2	PHENOTYPE	0	1	Parkinson's Disease
NCT000047315	NCT00004731_5_T0	COMPOUND	10	10	levodopa
NCT000047318	NCT00004731_8_T0	PHENOTYPE	8	9	one side
NCT000047323	NCT00004732_3_T0	PHENOTYPE	11	12	heart disease
NCT000047324	NCT00004732_4_T0	GENE	20	20	scaffold
NCT000047324	NCT00004732_4_T1	ORGAN	26	27	carotid artery
NCT000047325	NCT00004732_5_T0	ORGAN	17	18	carotid artery
NCT000047326	NCT00004732_6_T0	ORGAN	20	21	carotid artery
NCT000047327	NCT00004732_7_T0	ORGAN	8	8	arteries
NCT000047327	NCT00004732_7_T1	PHENOTYPE	11	11	narrowing
NCT000047328	NCT00004732_8_T0	PHENOTYPE	5	5	closed
NCT000047329	NCT00004732_9_T0	PHENOTYPE	10	10	plaque
NCT000047329	NCT00004732_9_T1	ORGAN	16	16	artery
NCT000047329	NCT00004732_9_T2	GENE	0	0	CEA
NCT0000473211	NCT00004732_11_T0	PHENOTYPE	8	8	plaque
NCT0000473211	NCT00004732_11_T1	ORGAN	12	12	artery
NCT0000473214	NCT00004732_14_T0	PHENOTYPE	12	12	secondary
NCT0000473214	NCT00004732_14_T1	PHENOTYPE	17	17	restenosis
NCT0000473214	NCT00004732_14_T2	GENE	19	19	viability
NCT0000473216	NCT00004732_16_T0	PHENOTYPE	3	3	restenosis
NCT0000473216	NCT00004732_16_T1	GENE	5	5	viability
NCT0000473217	NCT00004732_17_T0	GENE	2	2	has
NCT0000473219	NCT00004732_19_T0	GENE	2	2	CREST
NCT0000473219	NCT00004732_19_T1	GENE	18	18	CREST
NCT0000473219	NCT00004732_19_T2	GENE	21	21	CMS
NCT0000473219	NCT00004732_19_T3	GENE	6	6	FOR
NCT0000473220	NCT00004732_20_T0	PHENOTYPE	23	23	strategies
NCT0000473220	NCT00004732_20_T1	PHENOTYPE	29	29	strategies
NCT000047332	NCT00004733_2_T0	PHENOTYPE	12	12	fluctuations
NCT000047332	NCT00004733_2_T1	COMPOUND	6	6	levodopa
NCT000047332	NCT00004733_2_T2	PHENOTYPE	14	15	involuntary movements
NCT000047334	NCT00004733_4_T0	COMPOUND	5	5	levodopa
NCT000047334	NCT00004733_4_T1	CELL	14	15	dopamine neurons
NCT000047335	NCT00004733_5_T0	PHENOTYPE	31	31	toxicity
NCT000047335	NCT00004733_5_T1	CELL	13	13	cells
NCT000047335	NCT00004733_5_T2	COMPOUND	30	30	levodopa
NCT000047335	NCT00004733_5_T3	CELL	9	9	glia
NCT000047335	NCT00004733_5_T4	CELL	24	24	glia
NCT000047335	NCT00004733_5_T5	CELL	21	22	nerve cells
NCT000047336	NCT00004733_6_T0	PHENOTYPE	17	17	toxic
NCT000047336	NCT00004733_6_T1	COMPOUND	13	13	levodopa
NCT000047336	NCT00004733_6_T2	GENE	9	9	has
NCT000047336	NCT00004733_6_T3	CELL	1	1	glia
NCT000047338	NCT00004733_8_T0	PHENOTYPE	8	8	toxic
NCT000047338	NCT00004733_8_T1	PHENOTYPE	18	18	toxic
NCT000047338	NCT00004733_8_T2	COMPOUND	6	6	levodopa
NCT000047338	NCT00004733_8_T3	COMPOUND	15	15	levodopa
NCT000047338	NCT00004733_8_T4	CELL	10	10	neurons
NCT000047339	NCT00004733_9_T0	COMPOUND	9	9	levodopa
NCT000047339	NCT00004733_9_T1	PHENOTYPE	10	10	damages
NCT000047339	NCT00004733_9_T2	CELL	11	12	dopamine neurons
NCT0000473310	NCT00004733_10_T0	CELL	14	14	cells
NCT0000473310	NCT00004733_10_T1	COMPOUND	6	6	levodopa
NCT0000473310	NCT00004733_10_T2	COMPOUND	33	33	levodopa
NCT0000473310	NCT00004733_10_T3	PHENOTYPE	38	38	progression
NCT0000473310	NCT00004733_10_T4	COMPOUND	13	13	dopamine
NCT0000473311	NCT00004733_11_T0	PHENOTYPE	3	3	Progression
NCT000047343	NCT00004734_3_T0	COMPOUND	9	9	homocysteine
NCT000047343	NCT00004734_3_T1	ORGAN	16	16	arteries
NCT000047343	NCT00004734_3_T2	ORGAN	21	21	heart
NCT000047343	NCT00004734_3_T3	PHENOTYPE	29	30	heart attack
NCT000047346	NCT00004734_6_T0	PHENOTYPE	6	6	complication
NCT000047346	NCT00004734_6_T1	PHENOTYPE	0	1	Myocardial infarction
NCT000047346	NCT00004734_6_T2	PHENOTYPE	2	3	heart attack
NCT000047347	NCT00004734_7_T0	COMPOUND	1	1	homocysteine
NCT000047347	NCT00004734_7_T1	PHENOTYPE	22	22	recurrent
NCT000047347	NCT00004734_7_T2	PHENOTYPE	24	25	myocardial infarction
NCT000047348	NCT00004734_8_T0	COMPOUND	43	43	homocysteine
NCT000047348	NCT00004734_8_T1	COMPOUND	17	17	cyanocobalamin
NCT000047348	NCT00004734_8_T2	PHENOTYPE	30	30	recurrence
NCT000047348	NCT00004734_8_T3	COMPOUND	15	15	pyridoxine
NCT000047348	NCT00004734_8_T4	PHENOTYPE	36	37	myocardial infarction
NCT000047348	NCT00004734_8_T5	COMPOUND	13	14	folic acid
NCT000047351	NCT00004735_1_T0	PHENOTYPE	21	21	tetanus
NCT000047351	NCT00004735_1_T1	GENE	10	10	CD4
NCT000047351	NCT00004735_1_T2	CELL	11	11	cells
NCT000047351	NCT00004735_1_T3	PHENOTYPE	18	19	hepatitis A
NCT000047351	NCT00004735_1_T4	BIOLOGICAL_PROCESS	15	16	immune response
NCT000047352	NCT00004735_2_T0	GENE	12	12	CD4
NCT000047352	NCT00004735_2_T1	CELL	13	13	cells
NCT000047354	NCT00004735_4_T0	GENE	15	15	CD4
NCT000047356	NCT00004735_6_T0	GENE	1	1	CD4
NCT000047356	NCT00004735_6_T1	CELL	2	2	cells
NCT000047356	NCT00004735_6_T2	ORGAN	5	6	immune system
NCT000047357	NCT00004735_7_T0	GENE	13	13	CD4
NCT000047357	NCT00004735_7_T1	CELL	14	14	cells
NCT000047357	NCT00004735_7_T2	PHENOTYPE	1	1	HIV
NCT000047359	NCT00004735_9_T0	GENE	7	7	CD4
NCT000047359	NCT00004735_9_T1	PHENOTYPE	11	11	HIV
NCT0000473510	NCT00004735_10_T0	PHENOTYPE	0	0	HIV
NCT0000473516	NCT00004735_16_T0	GENE	14	14	Td
NCT0000473516	NCT00004735_16_T1	PHENOTYPE	6	6	tetanus
NCT0000473516	NCT00004735_16_T2	PHENOTYPE	22	23	hepatitis A
NCT0000473516	NCT00004735_16_T3	GENE	2	3	Group 1
NCT0000473517	NCT00004735_17_T0	PHENOTYPE	16	16	tetanus
NCT0000473517	NCT00004735_17_T1	PHENOTYPE	6	7	hepatitis A
NCT0000473519	NCT00004735_19_T0	GENE	16	16	booster
NCT0000473519	NCT00004735_19_T1	PHENOTYPE	13	14	hepatitis A
NCT0000473520	NCT00004735_20_T0	GENE	15	15	booster
NCT0000473521	NCT00004735_21_T0	GENE	13	13	booster
NCT0000473521	NCT00004735_21_T1	PHENOTYPE	10	11	hepatitis A
NCT0000473524	NCT00004735_24_T0	GENE	8	9	protease inhibitor
NCT0000473524	NCT00004735_24_T1	GENE	13	14	reverse transcriptase
NCT000047360	NCT00004736_0_T0	PHENOTYPE	9	9	Tuberculosis
NCT000047363	NCT00004736_3_T0	GENE	10	10	CD4
NCT000047363	NCT00004736_3_T1	CELL	11	11	cells
NCT000047363	NCT00004736_3_T2	PHENOTYPE	6	6	HIV
NCT000047363	NCT00004736_3_T3	GENE	1	1	has
NCT000047364	NCT00004736_4_T0	PHENOTYPE	4	4	HIV
NCT000047367	NCT00004736_7_T0	PHENOTYPE	10	11	opportunistic infection
NCT000047368	NCT00004736_8_T0	PHENOTYPE	0	0	HIV
NCT000047368	NCT00004736_8_T1	COMPOUND	10	10	rifabutin
NCT000047369	NCT00004736_9_T0	ORGAN	0	0	Plasma
NCT000047369	NCT00004736_9_T1	PHENOTYPE	29	29	initiation
NCT000047369	NCT00004736_9_T2	COMPOUND	4	4	rifabutin
NCT0000473610	NCT00004736_10_T0	COMPOUND	19	19	nelfinavir
NCT0000473610	NCT00004736_10_T1	COMPOUND	13	13	rifabutin
NCT0000473610	NCT00004736_10_T2	COMPOUND	21	21	rifabutin
NCT0000473610	NCT00004736_10_T3	PHENOTYPE	22	22	pharmacokinetics
NCT0000473610	NCT00004736_10_T4	BIOLOGICAL_PROCESS	14	14	metabolism
NCT0000473611	NCT00004736_11_T0	COMPOUND	10	10	zidovudine
NCT0000473611	NCT00004736_11_T1	COMPOUND	13	13	stavudine
NCT0000473611	NCT00004736_11_T2	COMPOUND	4	4	nelfinavir
NCT0000473611	NCT00004736_11_T3	COMPOUND	6	6	lamivudine
NCT0000473612	NCT00004736_12_T0	PHENOTYPE	1	1	initiation
NCT0000473616	NCT00004736_16_T0	PHENOTYPE	49	49	adenopathy
NCT0000473616	NCT00004736_16_T1	PHENOTYPE	41	41	lymphadenopathy
NCT0000473616	NCT00004736_16_T2	PHENOTYPE	10	10	symptoms
NCT0000473616	NCT00004736_16_T3	PHENOTYPE	88	88	symptoms
NCT0000473616	NCT00004736_16_T4	PHENOTYPE	58	58	tuberculous
NCT0000473616	NCT00004736_16_T5	PHENOTYPE	17	17	fevers
NCT0000473616	NCT00004736_16_T6	PHENOTYPE	42	43	pulmonary infiltrates
NCT0000473616	NCT00004736_16_T7	PHENOTYPE	75	77	signs and symptoms
NCT000047380	NCT00004738_0_T0	PHENOTYPE	4	6	Chiari I Malformation
NCT000047382	NCT00004738_2_T0	ORGAN	10	10	skull
NCT000047383	NCT00004738_3_T0	TISSUE	12	12	tonsils
NCT000047383	NCT00004738_3_T1	ORGAN	23	23	skull
NCT000047383	NCT00004738_3_T2	ORGAN	26	27	spinal canal
NCT000047384	NCT00004738_4_T0	PHENOTYPE	14	14	malformation
NCT000047386	NCT00004738_6_T0	PHENOTYPE	7	9	Chiari I malformation
NCT000047388	NCT00004738_8_T0	GENE	6	6	MRI
NCT000047388	NCT00004738_8_T1	PHENOTYPE	32	32	syringomyelia
NCT000047388	NCT00004738_8_T2	ORGAN	13	14	spinal cord
NCT000047388	NCT00004738_8_T3	PHENOTYPE	28	30	Chiari I malformation
NCT000047389	NCT00004738_9_T0	PHENOTYPE	16	18	Chiari I malformation
NCT0000473811	NCT00004738_11_T0	PHENOTYPE	10	12	Chiari I malformation
NCT0000473813	NCT00004738_13_T0	PHENOTYPE	21	21	syringomyelia
NCT0000473813	NCT00004738_13_T1	GENE	12	12	MRI
NCT0000473813	NCT00004738_13_T2	PHENOTYPE	18	20	Chiari I malformation
NCT0000473814	NCT00004738_14_T0	GENE	9	9	MRI
NCT0000473815	NCT00004738_15_T0	GENE	9	9	caudal
NCT0000473815	NCT00004738_15_T1	TISSUE	14	14	tonsils
NCT0000473815	NCT00004738_15_T2	TISSUE	75	75	bones
NCT0000473815	NCT00004738_15_T3	GENE	44	44	CSF
NCT0000473815	NCT00004738_15_T4	PHENOTYPE	28	28	underdevelopment
NCT0000473815	NCT00004738_15_T5	ORGAN	78	79	skull base
NCT0000473815	NCT00004738_15_T6	ORGAN	25	26	foramen magnum
NCT0000473816	NCT00004738_16_T0	PHENOTYPE	20	22	small posterior fossa
NCT0000473817	NCT00004738_17_T0	GENE	1	1	lod
NCT0000473817	NCT00004738_17_T1	GENE	4	4	3.0
NCT0000473819	NCT00004738_19_T0	GENE	11	11	has
NCT0000473820	NCT00004738_20_T0	GENE	13	13	MRI
NCT0000473821	NCT00004738_21_T0	GENE	0	0	Is
NCT0000473822	NCT00004738_22_T0	GENE	0	0	Is
NCT000047397	NCT00004739_7_T0	GENE	18	18	protease
NCT000047397	NCT00004739_7_T1	GENE	32	32	protease
NCT000047397	NCT00004739_7_T2	PHENOTYPE	12	12	HIV
NCT000047397	NCT00004739_7_T3	PHENOTYPE	9	10	insulin resistance
NCT000047398	NCT00004739_8_T0	GENE	8	8	protease
NCT000047398	NCT00004739_8_T1	PHENOTYPE	17	18	insulin sensitivity
NCT0000473913	NCT00004739_13_T0	GENE	8	9	protease inhibitor
NCT0000473916	NCT00004739_16_T0	GENE	18	19	protease inhibitor
NCT0000473919	NCT00004739_19_T0	PHENOTYPE	3	3	HIV
NCT0000473920	NCT00004739_20_T0	PHENOTYPE	3	3	HIV
NCT0000473921	NCT00004739_21_T0	PHENOTYPE	13	13	HIV
NCT000047401	NCT00004740_1_T0	COMPOUND	14	14	isoniazid
NCT000047401	NCT00004740_1_T1	PHENOTYPE	6	7	positive tuberculin
NCT000047403	NCT00004740_3_T0	COMPOUND	5	5	isoniazid
NCT000047408	NCT00004740_8_T0	PHENOTYPE	1	1	attitudes
NCT000047408	NCT00004740_8_T1	PHENOTYPE	6	6	tuberculosis
NCT0000474010	NCT00004740_10_T0	PHENOTYPE	1	1	attitudes
NCT0000474010	NCT00004740_10_T1	PHENOTYPE	38	38	attitudes
NCT0000474010	NCT00004740_10_T2	PHENOTYPE	5	5	tuberculosis
NCT0000474010	NCT00004740_10_T3	PHENOTYPE	16	16	self-efficacy
NCT0000474012	NCT00004740_12_T0	COMPOUND	7	7	isoniazid
NCT0000474014	NCT00004740_14_T0	COMPOUND	7	7	isoniazid
NCT0000474015	NCT00004740_15_T0	PHENOTYPE	8	8	ingestion
NCT0000474017	NCT00004740_17_T0	COMPOUND	7	7	isoniazid
NCT0000474019	NCT00004740_19_T0	PHENOTYPE	13	13	compensation
NCT0000474020	NCT00004740_20_T0	PHENOTYPE	1	1	compensation
NCT0000474020	NCT00004740_20_T1	PHENOTYPE	18	18	compensation
NCT0000474021	NCT00004740_21_T0	COMPOUND	12	12	isoniazid
NCT000047441	NCT00004744_1_T0	GENE	5	5	globulin
NCT000047441	NCT00004744_1_T1	PHENOTYPE	21	22	multiple sclerosis
NCT000047445	NCT00004744_5_T0	GENE	6	6	globulin
NCT000047471	NCT00004747_1_T0	PHENOTYPE	23	23	acute
NCT000047471	NCT00004747_1_T1	GENE	11	11	globulin
NCT000047471	NCT00004747_1_T2	GENE	12	12	MEP
NCT000047471	NCT00004747_1_T3	PHENOTYPE	34	35	pulmonary disease
NCT000047471	NCT00004747_1_T4	PHENOTYPE	29	30	cystic fibrosis
NCT000047473	NCT00004747_3_T0	GENE	4	4	MEP
NCT000047473	NCT00004747_3_T1	PHENOTYPE	16	18	quality of life
NCT000047475	NCT00004747_5_T0	GENE	5	5	MEP
NCT000047477	NCT00004747_7_T0	PHENOTYPE	4	4	pharmacokinetics
NCT000047477	NCT00004747_7_T1	GENE	2	2	MEP
NCT000047477	NCT00004747_7_T2	PHENOTYPE	6	6	chronic
NCT0000474710	NCT00004747_10_T0	GENE	17	17	MEP
NCT0000474710	NCT00004747_10_T1	GENE	20	20	MEP
NCT0000474710	NCT00004747_10_T2	GENE	16	16	globulin
NCT0000474713	NCT00004747_13_T0	PHENOTYPE	1	1	chronic
NCT000047483	NCT00004748_3_T0	GENE	7	7	MTX
NCT000047488	NCT00004748_8_T0	COMPOUND	9	9	methotrexate
NCT000047489	NCT00004748_9_T0	COMPOUND	10	10	colchicine
NCT0000474812	NCT00004748_12_T0	ORGAN	12	12	liver
NCT0000474812	NCT00004748_12_T1	PHENOTYPE	2	3	disease progression
NCT000047513	NCT00004751_3_T0	ORGAN	11	11	feet
NCT000047516	NCT00004751_6_T0	GENE	6	6	dorsal
NCT000047531	NCT00004753_1_T0	PHENOTYPE	10	11	Huntington's disease
NCT000047531	NCT00004753_1_T1	BIOLOGICAL_PROCESS	5	6	glucose metabolism
NCT0000475310	NCT00004753_10_T0	COMPOUND	6	6	fluorodeoxyglucose
NCT000047540	NCT00004754_0_T0	PHENOTYPE	4	4	Chronic
NCT000047540	NCT00004754_0_T1	GENE	1	1	IV
NCT000047540	NCT00004754_0_T2	PHENOTYPE	9	11	Primary Pulmonary Hypertension
NCT000047542	NCT00004754_2_T0	COMPOUND	3	3	prostaglandin
NCT000047542	NCT00004754_2_T1	COMPOUND	1	1	epoprostenol
NCT000047542	NCT00004754_2_T2	PHENOTYPE	6	6	chronic
NCT000047542	NCT00004754_2_T3	PHENOTYPE	12	14	primary pulmonary hypertension
NCT000047544	NCT00004754_4_T0	COMPOUND	7	7	epoprostenol
NCT000047548	NCT00004754_8_T0	PHENOTYPE	24	24	experiences
NCT000047549	NCT00004754_9_T0	PHENOTYPE	6	6	chronic
NCT000047555	NCT00004755_5_T0	PHENOTYPE	2	3	progressive disease
NCT000047556	NCT00004755_6_T0	COMPOUND	8	8	allopurinol
NCT000047558	NCT00004755_8_T0	PHENOTYPE	4	5	progressive disease
NCT000047559	NCT00004755_9_T0	PHENOTYPE	5	5	closed
NCT0000475510	NCT00004755_10_T0	COMPOUND	4	4	allopurinol
NCT000047566	NCT00004756_6_T0	GENE	14	14	1.5
NCT000047566	NCT00004756_6_T1	PHENOTYPE	25	25	reinforcement
NCT000047573	NCT00004757_3_T0	PHENOTYPE	5	5	recurrent
NCT000047577	NCT00004757_7_T0	PHENOTYPE	5	5	recurrent
NCT0000475712	NCT00004757_12_T0	COMPOUND	6	6	acyclovir
NCT0000475713	NCT00004757_13_T0	GENE	16	16	met
NCT0000475713	NCT00004757_13_T1	GENE	40	40	met
NCT0000475713	NCT00004757_13_T2	PHENOTYPE	18	19	systemic disease
NCT0000475714	NCT00004757_14_T0	COMPOUND	11	11	acyclovir
NCT0000475715	NCT00004757_15_T0	COMPOUND	6	6	acyclovir
NCT0000475716	NCT00004757_16_T0	PHENOTYPE	10	10	toxicity
NCT0000475716	NCT00004757_16_T1	PHENOTYPE	17	17	recurrences
NCT0000475716	NCT00004757_16_T2	PHENOTYPE	11	12	systemic disease
NCT000047581	NCT00004758_1_T0	PHENOTYPE	20	21	infantile spasms
NCT000047588	NCT00004758_8_T0	COMPOUND	14	14	nitrazepam
NCT000047588	NCT00004758_8_T1	COMPOUND	8	8	pyridoxine
NCT000047588	NCT00004758_8_T2	GENE	9	9	corticotropin
NCT000047588	NCT00004758_8_T3	COMPOUND	12	12	carbamazepine
NCT0000475812	NCT00004758_12_T0	PHENOTYPE	6	6	hemiparesis
NCT0000475812	NCT00004758_12_T1	PHENOTYPE	8	8	diffuse
NCT0000475812	NCT00004758_12_T2	PHENOTYPE	10	10	dysfunction
NCT0000475813	NCT00004758_13_T0	PHENOTYPE	1	1	seizures
NCT0000475813	NCT00004758_13_T1	PHENOTYPE	17	17	seizures
NCT0000475814	NCT00004758_14_T0	PHENOTYPE	3	3	seizures
NCT0000475815	NCT00004758_15_T0	PHENOTYPE	4	4	seizures
NCT0000475815	NCT00004758_15_T1	PHENOTYPE	10	10	seizures
NCT000047592	NCT00004759_2_T0	GENE	6	6	24
NCT000047592	NCT00004759_2_T1	COMPOUND	11	11	methylprednisolone
NCT000047592	NCT00004759_2_T2	PHENOTYPE	18	21	acute spinal cord injury
NCT000047594	NCT00004759_4_T0	GENE	4	4	24
NCT000047599	NCT00004759_9_T0	COMPOUND	5	5	methylprednisolone
NCT000047601	NCT00004760_1_T0	PHENOTYPE	18	19	Parkinson disease
NCT000047611	NCT00004761_1_T0	PHENOTYPE	13	15	acquired epidermolysis bullosa
NCT0000476111	NCT00004761_11_T0	PHENOTYPE	7	8	epidermolysis bullosa
NCT000047620	NCT00004762_0_T0	GENE	1	1	II
NCT000047620	NCT00004762_0_T1	PHENOTYPE	11	13	Primary Sclerosing Cholangitis
NCT000047622	NCT00004762_2_T0	COMPOUND	4	4	cladribine
NCT000047622	NCT00004762_2_T1	PHENOTYPE	18	20	primary sclerosing cholangitis
NCT000047631	NCT00004763_1_T0	PHENOTYPE	21	21	hyperandrogenism
NCT000047631	NCT00004763_1_T1	COMPOUND	5	5	leuprolide
NCT000047633	NCT00004763_3_T0	COMPOUND	9	9	leuprolide
NCT000047633	NCT00004763_3_T1	COMPOUND	16	16	leuprolide
NCT000047671	NCT00004767_1_T0	PHENOTYPE	20	20	disorders
NCT000047671	NCT00004767_1_T1	COMPOUND	6	6	sodium
NCT000047671	NCT00004767_1_T2	COMPOUND	8	8	sodium
NCT000047671	NCT00004767_1_T3	COMPOUND	10	10	sodium
NCT000047671	NCT00004767_1_T4	COMPOUND	9	9	benzoate
NCT000047671	NCT00004767_1_T5	BIOLOGICAL_PROCESS	18	19	urea cycle
NCT000047673	NCT00004767_3_T0	COMPOUND	3	3	phosphate
NCT000047673	NCT00004767_3_T1	COMPOUND	25	25	sodium
NCT000047673	NCT00004767_3_T2	COMPOUND	37	37	arginine
NCT000047673	NCT00004767_3_T3	COMPOUND	35	35	citrulline
NCT000047673	NCT00004767_3_T4	PHENOTYPE	19	20	neonatal onset
NCT000047673	NCT00004767_3_T5	PHENOTYPE	6	8	ornithine transcarbamylase deficiency
NCT000047674	NCT00004767_4_T0	COMPOUND	15	15	sodium
NCT000047674	NCT00004767_4_T1	COMPOUND	25	25	arginine
NCT000047674	NCT00004767_4_T2	PHENOTYPE	4	5	synthetase deficiency
NCT000047675	NCT00004767_5_T0	COMPOUND	14	14	arginine
NCT000047675	NCT00004767_5_T1	PHENOTYPE	2	3	argininosuccinic aciduria
NCT000047676	NCT00004767_6_T0	COMPOUND	11	11	sodium
NCT000047676	NCT00004767_6_T1	COMPOUND	13	13	sodium
NCT000047676	NCT00004767_6_T2	COMPOUND	17	17	hydrochloride
NCT000047676	NCT00004767_6_T3	COMPOUND	16	16	arginine
NCT000047676	NCT00004767_6_T4	PHENOTYPE	6	6	hyperammonemia
NCT000047676	NCT00004767_6_T5	COMPOUND	12	12	benzoate
NCT000047676	NCT00004767_6_T6	COMPOUND	18	18	benzoate
NCT000047677	NCT00004767_7_T0	COMPOUND	1	1	ammonium
NCT000047678	NCT00004767_8_T0	COMPOUND	7	7	ammonium
NCT000047679	NCT00004767_9_T0	COMPOUND	3	3	ondansetron
NCT000047679	NCT00004767_9_T1	COMPOUND	8	8	mannitol
NCT000047679	NCT00004767_9_T2	PHENOTYPE	10	12	elevated intracranial pressure
NCT000047691	NCT00004769_1_T0	PHENOTYPE	10	11	myotonic dystrophy
NCT000047691	NCT00004769_1_T1	BIOLOGICAL_PROCESS	13	14	gene expression
NCT000047691	NCT00004769_1_T2	PHENOTYPE	4	5	muscle wasting
NCT000047693	NCT00004769_3_T0	PHENOTYPE	2	3	insulin resistance
NCT000047697	NCT00004769_7_T0	PHENOTYPE	12	12	5-10
NCT000047697	NCT00004769_7_T1	TISSUE	9	9	muscles
NCT000047699	NCT00004769_9_T0	COMPOUND	25	25	glucose
NCT000047699	NCT00004769_9_T1	COMPOUND	26	26	dextrose
NCT000047699	NCT00004769_9_T2	GENE	23	23	insulin
NCT000047699	NCT00004769_9_T3	PHENOTYPE	10	11	glucose tolerance
NCT000047699	NCT00004769_9_T4	PHENOTYPE	15	16	glucose tolerance
NCT000047699	NCT00004769_9_T5	PHENOTYPE	32	33	insulin resistance
NCT0000476910	NCT00004769_10_T0	COMPOUND	11	11	potassium
NCT0000476913	NCT00004769_13_T0	COMPOUND	15	15	glucose
NCT0000476913	NCT00004769_13_T1	GENE	12	12	insulin
NCT0000476913	NCT00004769_13_T2	COMPOUND	19	19	glycerol
NCT0000476915	NCT00004769_15_T0	COMPOUND	7	7	glucose
NCT0000476915	NCT00004769_15_T1	GENE	12	12	insulin
NCT0000476915	NCT00004769_15_T2	COMPOUND	10	10	phenylalanine
NCT000047701	NCT00004770_1_T0	PHENOTYPE	12	13	mitochondrial myopathy
NCT000047703	NCT00004770_3_T0	PHENOTYPE	2	2	experiences
NCT000047721	NCT00004772_1_T0	GENE	15	15	globulin
NCT000047721	NCT00004772_1_T1	PHENOTYPE	8	11	chronic inflammatory demyelinating polyneuropathy
NCT000047723	NCT00004772_3_T0	GENE	6	6	globulin
NCT000047723	NCT00004772_3_T1	GENE	13	13	21
NCT000047725	NCT00004772_5_T0	GENE	5	5	globulin
NCT000047733	NCT00004773_3_T0	BIOLOGICAL_PROCESS	3	4	cardiac conduction
NCT000047735	NCT00004773_5_T0	PHENOTYPE	1	1	arrhythmias
NCT000047735	NCT00004773_5_T1	ORGAN	2	2	heart
NCT000047735	NCT00004773_5_T2	ORGAN	6	8	autonomic nervous system
NCT000047737	NCT00004773_7_T0	PHENOTYPE	21	21	seizure
NCT000047737	NCT00004773_7_T1	PHENOTYPE	5	5	seizures
NCT000047737	NCT00004773_7_T2	PHENOTYPE	8	8	electroencephalogram
NCT0000477311	NCT00004773_11_T0	PHENOTYPE	4	4	seizures
NCT0000477315	NCT00004773_15_T0	GENE	2	2	II
NCT0000477316	NCT00004773_16_T0	PHENOTYPE	8	8	seizure
NCT0000477316	NCT00004773_16_T1	PHENOTYPE	11	11	seizure
NCT0000477316	NCT00004773_16_T2	PHENOTYPE	34	34	seizure
NCT0000477316	NCT00004773_16_T3	GENE	35	35	log
NCT0000477316	NCT00004773_16_T4	COMPOUND	29	29	oxygen
NCT0000477316	NCT00004773_16_T5	COMPOUND	26	27	carbon dioxide
NCT000047763	NCT00004776_3_T0	COMPOUND	11	11	topiramate
NCT000047765	NCT00004776_5_T0	COMPOUND	1	1	topiramate
NCT000047781	NCT00004778_1_T0	PHENOTYPE	9	9	severity
NCT000047781	NCT00004778_1_T1	GENE	6	6	TRH
NCT000047781	NCT00004778_1_T2	PHENOTYPE	12	13	lung disease
NCT000047781	NCT00004778_1_T3	GENE	4	5	thyrotropin-releasing hormone
NCT000047781	NCT00004778_1_T4	PHENOTYPE	27	28	premature delivery
NCT000047781	NCT00004778_1_T5	PHENOTYPE	17	19	chronic lung disease
NCT000047783	NCT00004778_3_T0	PHENOTYPE	10	10	severity
NCT000047783	NCT00004778_3_T1	GENE	7	7	TRH
NCT000047783	NCT00004778_3_T2	PHENOTYPE	14	16	chronic lung disease
NCT000047789	NCT00004778_9_T0	COMPOUND	16	16	dexamethasone
NCT000047789	NCT00004778_9_T1	GENE	9	9	TRH
NCT000047789	NCT00004778_9_T2	COMPOUND	14	14	betamethasone
NCT000047789	NCT00004778_9_T3	GENE	7	8	thyrotropin-releasing hormone
NCT0000477810	NCT00004778_10_T0	GENE	9	9	TRH
NCT0000477811	NCT00004778_11_T0	COMPOUND	7	7	indomethacin
NCT000047795	NCT00004779_5_T0	ORGAN	5	6	nasal cavity
NCT000047795	NCT00004779_5_T1	ORGAN	16	17	nasal cavity
NCT000047810	NCT00004781_0_T0	PHENOTYPE	0	1	Oral Manifestations
NCT000047810	NCT00004781_0_T1	PHENOTYPE	3	6	Human Immunodeficiency Virus Infection
NCT000047816	NCT00004781_6_T0	ORGAN	6	7	oral cavity
NCT000047818	NCT00004781_8_T0	GENE	4	4	saliva
NCT000047841	NCT00004784_1_T0	PHENOTYPE	12	12	pruritus
NCT000047841	NCT00004784_1_T1	PHENOTYPE	21	21	severity
NCT000047841	NCT00004784_1_T2	COMPOUND	10	10	methotrexate
NCT000047841	NCT00004784_1_T3	ORGAN	16	16	serum
NCT000047841	NCT00004784_1_T4	COMPOUND	5	6	ursodeoxycholic acid
NCT000047841	NCT00004784_1_T5	PHENOTYPE	25	27	primary biliary cirrhosis
NCT000047845	NCT00004784_5_T0	PHENOTYPE	2	2	toxicity
NCT000047848	NCT00004784_8_T0	COMPOUND	8	8	UDCA
NCT000047848	NCT00004784_8_T1	COMPOUND	6	7	ursodeoxycholic acid
NCT000047849	NCT00004784_9_T0	GENE	6	6	met
NCT000047851	NCT00004785_1_T0	COMPOUND	4	4	dexamethasone
NCT000047851	NCT00004785_1_T1	PHENOTYPE	25	26	premature infants
NCT000047851	NCT00004785_1_T2	PHENOTYPE	29	30	bronchopulmonary dysplasia
NCT000047853	NCT00004785_3_T0	PHENOTYPE	2	2	toxicities
NCT000047858	NCT00004785_8_T0	COMPOUND	5	5	dexamethasone
NCT000047858	NCT00004785_8_T1	GENE	6	6	tapered
NCT000047859	NCT00004785_9_T0	COMPOUND	6	6	dexamethasone
NCT000047859	NCT00004785_9_T1	COMPOUND	12	12	methylprednisolone
NCT000047859	NCT00004785_9_T2	GENE	14	14	tapered
NCT0000478512	NCT00004785_12_T0	COMPOUND	7	7	dexamethasone
NCT000047861	NCT00004786_1_T0	PHENOTYPE	16	16	secondary
NCT000047861	NCT00004786_1_T1	COMPOUND	7	7	iloprost
NCT000047861	NCT00004786_1_T2	COMPOUND	9	9	prostacyclin
NCT000047861	NCT00004786_1_T3	PHENOTYPE	14	15	Raynaud's phenomenon
NCT000047861	NCT00004786_1_T4	PHENOTYPE	18	19	systemic sclerosis
NCT000047863	NCT00004786_3_T0	PHENOTYPE	8	9	cutaneous ulcers
NCT000047864	NCT00004786_4_T0	COMPOUND	3	3	iloprost
NCT000047865	NCT00004786_5_T0	COMPOUND	5	5	heparin
NCT000047866	NCT00004786_6_T0	PHENOTYPE	16	16	ischemia
NCT000047866	NCT00004786_6_T1	GENE	10	11	calcium channel
NCT000047866	NCT00004786_6_T2	GENE	3	4	angiotensin-converting enzyme
NCT000047871	NCT00004787_1_T0	GENE	9	9	G-CSF
NCT000047871	NCT00004787_1_T1	CELL	14	14	neutrophil
NCT000047871	NCT00004787_1_T2	CELL	6	6	granulocyte
NCT000047871	NCT00004787_1_T3	PHENOTYPE	16	17	platelet count
NCT000047871	NCT00004787_1_T4	PHENOTYPE	19	20	hemoglobin level
NCT000047871	NCT00004787_1_T5	PHENOTYPE	25	28	bone marrow failure syndromes
NCT000047873	NCT00004787_3_T0	GENE	5	5	reduced
NCT000047873	NCT00004787_3_T1	GENE	14	14	G-CSF
NCT000047875	NCT00004787_5_T0	PHENOTYPE	2	2	toxic
NCT000047875	NCT00004787_5_T1	GENE	5	5	G-CSF
NCT000047877	NCT00004787_7_T0	GENE	8	8	G-CSF
NCT000047877	NCT00004787_7_T1	ORGAN	1	2	bone marrow
NCT000047879	NCT00004787_9_T0	ORGAN	4	4	marrow
NCT000047879	NCT00004787_9_T1	CELL	2	2	cells
NCT000047879	NCT00004787_9_T2	GENE	10	10	G-CSF
NCT0000478711	NCT00004787_11_T0	GENE	17	17	G-CSF
NCT0000478711	NCT00004787_11_T1	GENE	10	10	tapered
NCT0000478712	NCT00004787_12_T0	CELL	8	8	neutrophil
NCT0000478713	NCT00004787_13_T0	ORGAN	25	25	marrow
NCT0000478713	NCT00004787_13_T1	PHENOTYPE	17	17	toxicity
NCT0000478713	NCT00004787_13_T2	PHENOTYPE	30	30	leukemia
NCT000047881	NCT00004788_1_T0	PHENOTYPE	14	16	acute intermittent porphyria
NCT000047883	NCT00004788_3_T0	PHENOTYPE	3	3	porphyria
NCT000047883	NCT00004788_3_T1	BIOLOGICAL_PROCESS	9	10	luteal phase
NCT000047887	NCT00004788_7_T0	COMPOUND	20	20	pyridoxine
NCT000047887	NCT00004788_7_T1	COMPOUND	18	18	zinc
NCT000047887	NCT00004788_7_T2	PHENOTYPE	7	9	acute intermittent porphyria
NCT0000478811	NCT00004788_11_T0	PHENOTYPE	13	14	acute porphyria
NCT0000478814	NCT00004788_14_T0	PHENOTYPE	9	10	energy metabolism
NCT0000478815	NCT00004788_15_T0	PHENOTYPE	3	4	metabolic rates
NCT0000478815	NCT00004788_15_T1	PHENOTYPE	7	8	metabolic rates
NCT0000478815	NCT00004788_15_T2	PHENOTYPE	0	1	Energy expenditure
NCT0000478816	NCT00004788_16_T0	GENE	3	3	hormone
NCT0000478818	NCT00004788_18_T0	CELL	9	9	erythrocyte
NCT0000478818	NCT00004788_18_T1	COMPOUND	15	15	porphobilinogen
NCT0000478818	NCT00004788_18_T2	GENE	10	11	porphobilinogen deaminase
NCT0000478818	NCT00004788_18_T3	PHENOTYPE	3	5	acute intermittent porphyria
NCT0000478819	NCT00004788_19_T0	PHENOTYPE	3	3	acute
NCT0000478819	NCT00004788_19_T1	PHENOTYPE	6	6	porphyria
NCT0000478819	NCT00004788_19_T2	COMPOUND	16	16	hematin
NCT000047891	NCT00004789_1_T0	PHENOTYPE	15	15	acute
NCT000047891	NCT00004789_1_T1	PHENOTYPE	18	18	porphyria
NCT000047891	NCT00004789_1_T2	COMPOUND	6	7	heme arginate
NCT000047893	NCT00004789_3_T0	PHENOTYPE	13	14	acute porphyria
NCT000047893	NCT00004789_3_T1	COMPOUND	6	7	heme arginate
NCT000047895	NCT00004789_5_T0	GENE	9	9	1.0
NCT000047895	NCT00004789_5_T1	COMPOUND	15	15	porphyrin
NCT000047895	NCT00004789_5_T2	GENE	11	11	3.0
NCT000047895	NCT00004789_5_T3	GENE	8	8	0.3
NCT000047895	NCT00004789_5_T4	PHENOTYPE	25	26	in remission
NCT000047895	NCT00004789_5_T5	COMPOUND	6	7	heme arginate
NCT000047895	NCT00004789_5_T6	PHENOTYPE	22	24	acute intermittent porphyria
NCT000047899	NCT00004789_9_T0	PHENOTYPE	6	6	acute
NCT000047899	NCT00004789_9_T1	PHENOTYPE	9	9	porphyria
NCT000047899	NCT00004789_9_T2	COMPOUND	12	13	heme arginate
NCT0000478910	NCT00004789_10_T0	GENE	3	3	extended
NCT0000478911	NCT00004789_11_T0	COMPOUND	9	10	heme arginate
NCT0000478912	NCT00004789_12_T0	GENE	3	3	extended
NCT0000478913	NCT00004789_13_T0	PHENOTYPE	2	2	acute
NCT0000478913	NCT00004789_13_T1	COMPOUND	13	14	heme arginate
NCT0000478915	NCT00004789_15_T0	COMPOUND	16	17	heme arginate
NCT0000478917	NCT00004789_17_T0	COMPOUND	9	10	heme arginate
NCT0000478919	NCT00004789_19_T0	COMPOUND	14	15	heme arginate
NCT0000478921	NCT00004789_21_T0	COMPOUND	11	11	porphyrin
NCT0000478921	NCT00004789_21_T1	PHENOTYPE	9	9	fluctuations
NCT000047911	NCT00004791_1_T0	PHENOTYPE	11	12	epidermolysis bullosa
NCT000047911	NCT00004791_1_T1	PHENOTYPE	4	5	metabolic profile
NCT000047915	NCT00004791_5_T0	PHENOTYPE	10	11	energy expenditure
NCT000047919	NCT00004791_9_T0	COMPOUND	16	16	potassium
NCT000047935	NCT00004793_5_T0	PHENOTYPE	0	0	Pituitary
NCT000047935	NCT00004793_5_T1	GENE	8	9	gonadotropin-releasing hormone
NCT000047935	NCT00004793_5_T2	PHENOTYPE	16	17	short stature
NCT000047941	NCT00004794_1_T0	PHENOTYPE	12	12	peripheral
NCT000047941	NCT00004794_1_T1	COMPOUND	7	7	cidofovir
NCT000047941	NCT00004794_1_T2	PHENOTYPE	13	14	cytomegalovirus retinitis
NCT000047943	NCT00004794_3_T0	COMPOUND	10	10	cidofovir
NCT000047947	NCT00004794_7_T0	PHENOTYPE	8	9	disease progression
NCT000047948	NCT00004794_8_T0	PHENOTYPE	8	8	judgement
NCT000047948	NCT00004794_8_T1	COMPOUND	14	14	cidofovir
NCT000047949	NCT00004794_9_T0	PHENOTYPE	26	26	toxicity
NCT000047949	NCT00004794_9_T1	COMPOUND	6	6	cidofovir
NCT000047949	NCT00004794_9_T2	PHENOTYPE	28	29	disease progression
NCT0000479410	NCT00004794_10_T0	PHENOTYPE	20	20	toxicity
NCT0000479410	NCT00004794_10_T1	COMPOUND	6	6	cidofovir
NCT0000479410	NCT00004794_10_T2	PHENOTYPE	22	23	disease progression
NCT0000479411	NCT00004794_11_T0	COMPOUND	8	8	cidofovir
NCT0000479412	NCT00004794_12_T0	PHENOTYPE	4	4	progression
NCT0000479413	NCT00004794_13_T0	PHENOTYPE	1	2	disease progression
NCT000047951	NCT00004795_1_T0	COMPOUND	7	7	dehydroepiandrosterone
NCT000047951	NCT00004795_1_T1	COMPOUND	12	12	prednisone
NCT000047951	NCT00004795_1_T2	PHENOTYPE	13	15	systemic lupus erythematosus
NCT000047953	NCT00004795_3_T0	PHENOTYPE	2	2	pharmacokinetics
NCT000047956	NCT00004795_6_T0	COMPOUND	11	11	dehydroepiandrosterone
NCT000047957	NCT00004795_7_T0	COMPOUND	1	1	prednisone
NCT000047958	NCT00004795_8_T0	COMPOUND	5	5	prednisone
NCT000047963	NCT00004796_3_T0	COMPOUND	6	6	melatonin
NCT000047965	NCT00004796_5_T0	COMPOUND	12	12	lactulose
NCT000047970	NCT00004797_0_T0	PHENOTYPE	5	7	Sickle Cell Crisis
NCT000047974	NCT00004797_4_T0	COMPOUND	8	8	fructose
NCT000047976	NCT00004797_6_T0	COMPOUND	3	3	fructose
NCT000047977	NCT00004797_7_T0	GENE	11	11	1.1
NCT000047977	NCT00004797_7_T1	COMPOUND	13	13	fructose
NCT000047978	NCT00004797_8_T0	COMPOUND	3	3	fructose
NCT0000479710	NCT00004797_10_T0	PHENOTYPE	2	2	symptoms
NCT0000479710	NCT00004797_10_T1	PHENOTYPE	23	23	symptoms
NCT0000479710	NCT00004797_10_T2	COMPOUND	10	10	fructose
NCT0000479710	NCT00004797_10_T3	COMPOUND	18	18	fructose
NCT000047991	NCT00004799_1_T0	PHENOTYPE	13	13	pertussis
NCT000047993	NCT00004799_3_T0	GENE	8	8	atypical
NCT000047993	NCT00004799_3_T1	PHENOTYPE	11	11	pertussis
NCT0000479910	NCT00004799_10_T0	PHENOTYPE	6	6	pertussis
NCT0000479912	NCT00004799_12_T0	GENE	9	9	2.3
NCT0000479913	NCT00004799_13_T0	GENE	8	8	2.3
NCT000048001	NCT00004800_1_T0	PHENOTYPE	6	6	pertussis
NCT000048001	NCT00004800_1_T1	PHENOTYPE	10	10	pertussis
NCT000048003	NCT00004800_3_T0	PHENOTYPE	16	16	pertussis
NCT000048009	NCT00004800_9_T0	PHENOTYPE	4	5	adverse events
NCT0000480011	NCT00004800_11_T0	PHENOTYPE	6	6	attributable
NCT0000480011	NCT00004800_11_T1	PHENOTYPE	9	9	pertussis
NCT0000480011	NCT00004800_11_T2	PHENOTYPE	4	5	adverse events
NCT0000480013	NCT00004800_13_T0	PHENOTYPE	6	6	pertussis
NCT0000480013	NCT00004800_13_T1	PHENOTYPE	18	19	antibody response
NCT0000480013	NCT00004800_13_T2	BIOLOGICAL_PROCESS	12	14	mucosal immune response
NCT0000480020	NCT00004800_20_T0	GENE	4	4	DPT
NCT0000480020	NCT00004800_20_T1	PHENOTYPE	7	7	pertussis
NCT0000480023	NCT00004800_23_T0	GENE	14	14	globulin
NCT0000480023	NCT00004800_23_T1	PHENOTYPE	9	10	hepatitis B
NCT0000480024	NCT00004800_24_T0	GENE	5	5	booster
NCT000048010	NCT00004801_0_T0	GENE	6	6	IX
NCT000048010	NCT00004801_0_T1	PHENOTYPE	9	11	Factor IX Deficiency
NCT000048013	NCT00004801_3_T0	PHENOTYPE	11	11	bleeding
NCT000048021	NCT00004802_1_T0	PHENOTYPE	10	10	weakness
NCT000048021	NCT00004802_1_T1	COMPOUND	4	4	dichlorphenamide
NCT000048021	NCT00004802_1_T2	PHENOTYPE	18	19	paramyotonia congenita
NCT000048021	NCT00004802_1_T3	PHENOTYPE	21	22	periodic paralysis
NCT000048021	NCT00004802_1_T4	PHENOTYPE	24	26	hypokalemic periodic paralysis
NCT000048021	NCT00004802_1_T5	PHENOTYPE	15	17	hyperkalemic periodic paralysis
NCT000048024	NCT00004802_4_T0	PHENOTYPE	13	13	initiation
NCT000048025	NCT00004802_5_T0	GENE	7	7	DCP
NCT000048025	NCT00004802_5_T1	COMPOUND	6	6	dichlorphenamide
NCT000048026	NCT00004802_6_T0	GENE	2	2	DCP
NCT000048026	NCT00004802_6_T1	GENE	18	18	DCP
NCT000048026	NCT00004802_6_T2	COMPOUND	12	12	acetazolamide
NCT000048026	NCT00004802_6_T3	GENE	13	13	ACZ
NCT000048026	NCT00004802_6_T4	GENE	26	26	ACZ
NCT000048040	NCT00004804_0_T0	GENE	1	1	III
NCT000048040	NCT00004804_0_T1	GENE	10	10	Interferon
NCT000048040	NCT00004804_0_T2	PHENOTYPE	13	15	Chronic Hepatitis C
NCT000048046	NCT00004804_6_T0	GENE	7	7	interferon
NCT000048050	NCT00004805_0_T0	PHENOTYPE	21	22	Sudden Death
NCT000048054	NCT00004805_4_T0	GENE	7	7	CPR
NCT000048056	NCT00004805_6_T0	GENE	18	18	CPR
NCT0000480514	NCT00004805_14_T0	GENE	9	9	CPR
NCT0000480518	NCT00004805_18_T0	GENE	6	6	CPR
NCT000048062	NCT00004806_2_T0	GENE	2	2	CFTR
NCT000048063	NCT00004806_3_T0	GENE	10	10	CFTR
NCT000048064	NCT00004806_4_T0	GENE	17	17	2.3
NCT000048064	NCT00004806_4_T1	GENE	5	5	2.12
NCT000048064	NCT00004806_4_T2	GENE	11	11	3.4
NCT000048079	NCT00004807_9_T0	PHENOTYPE	3	3	malnutrition
NCT0000480711	NCT00004807_11_T0	PHENOTYPE	6	6	hyperventilation
NCT0000480711	NCT00004807_11_T1	PHENOTYPE	3	3	seizures
NCT0000480711	NCT00004807_11_T2	PHENOTYPE	8	8	progressive
NCT0000480711	NCT00004807_11_T3	PHENOTYPE	9	9	rigidity
NCT0000480711	NCT00004807_11_T4	COMPOUND	14	14	dextromethorphan
NCT0000480711	NCT00004807_11_T5	COMPOUND	16	16	topiramate
NCT0000480712	NCT00004807_12_T0	COMPOUND	1	1	dextromethorphan
NCT0000480713	NCT00004807_13_T0	COMPOUND	1	1	topiramate
NCT0000480715	NCT00004807_15_T0	PHENOTYPE	3	3	constipation
NCT0000480715	NCT00004807_15_T1	PHENOTYPE	4	4	scoliosis
NCT0000480715	NCT00004807_15_T2	PHENOTYPE	6	7	weight loss
NCT000048081	NCT00004808_1_T0	PHENOTYPE	10	10	acute
NCT000048081	NCT00004808_1_T1	PHENOTYPE	18	18	sporotrichosis
NCT000048081	NCT00004808_1_T2	COMPOUND	4	4	fluconazole
NCT000048081	NCT00004808_1_T3	PHENOTYPE	13	13	blastomycosis
NCT000048081	NCT00004808_1_T4	PHENOTYPE	11	11	histoplasmosis
NCT000048083	NCT00004808_3_T0	COMPOUND	6	6	fluconazole
NCT000048086	NCT00004808_6_T0	COMPOUND	11	11	fluconazole
NCT000048086	NCT00004808_6_T1	PHENOTYPE	2	2	blastomycosis
NCT000048088	NCT00004808_8_T0	COMPOUND	10	10	fluconazole
NCT000048089	NCT00004808_9_T0	PHENOTYPE	4	4	sporotrichosis
NCT000048089	NCT00004808_9_T1	COMPOUND	10	10	fluconazole
NCT000048089	NCT00004808_9_T2	PHENOTYPE	2	2	histoplasmosis
NCT0000480812	NCT00004808_12_T0	CELL	7	7	lymphocyte
NCT000048091	NCT00004809_1_T0	CELL	15	15	hepatocytes
NCT000048091	NCT00004809_1_T1	PHENOTYPE	8	9	familial hypercholesterolemia
NCT000048091	NCT00004809_1_T2	GENE	20	22	low-density lipoprotein receptor
NCT000048094	NCT00004809_4_T0	CELL	18	18	hepatocyte
NCT000048101	NCT00004810_1_T0	PHENOTYPE	15	16	ulcerative colitis
NCT000048106	NCT00004810_6_T0	COMPOUND	4	4	sulfasalazine
NCT000048106	NCT00004810_6_T1	COMPOUND	5	5	prednisone
NCT000048111	NCT00004811_1_T0	PHENOTYPE	9	9	sporotrichosis
NCT000048111	NCT00004811_1_T1	PHENOTYPE	6	6	blastomycosis
NCT000048111	NCT00004811_1_T2	COMPOUND	14	14	itraconazole
NCT000048111	NCT00004811_1_T3	PHENOTYPE	7	7	histoplasmosis
NCT000048111	NCT00004811_1_T4	PHENOTYPE	2	2	tolerance
NCT000048113	NCT00004811_3_T0	COMPOUND	3	3	itraconazole
NCT000048113	NCT00004811_3_T1	ORGAN	5	5	serum
NCT000048115	NCT00004811_5_T0	COMPOUND	6	6	itraconazole
NCT000048115	NCT00004811_5_T1	PHENOTYPE	2	4	course of illness
NCT000048117	NCT00004811_7_T0	COMPOUND	4	4	itraconazole
NCT000048119	NCT00004811_9_T0	COMPOUND	9	9	itraconazole
NCT0000481111	NCT00004811_11_T0	PHENOTYPE	2	3	progressive disease
NCT000048122	NCT00004812_2_T0	PHENOTYPE	12	15	thoracic spinal cord injury
NCT000048126	NCT00004812_6_T0	ORGAN	7	7	limbs
NCT0000481214	NCT00004812_14_T0	ORGAN	12	12	limb
NCT0000481214	NCT00004812_14_T1	PHENOTYPE	13	13	progression
NCT0000481214	NCT00004812_14_T2	PHENOTYPE	19	19	hyperextension
NCT0000481216	NCT00004812_16_T0	COMPOUND	24	24	cyproheptadine
NCT0000481216	NCT00004812_16_T1	COMPOUND	33	33	cyproheptadine
NCT0000481216	NCT00004812_16_T2	COMPOUND	10	10	clonidine
NCT0000481216	NCT00004812_16_T3	COMPOUND	17	17	clonidine
NCT0000481217	NCT00004812_17_T0	COMPOUND	8	8	cyproheptadine
NCT0000481217	NCT00004812_17_T1	COMPOUND	6	6	clonidine
NCT0000481219	NCT00004812_19_T0	ORGAN	6	7	lower extremities
NCT0000481220	NCT00004812_20_T0	PHENOTYPE	3	3	spasticity
NCT000048141	NCT00004814_1_T0	PHENOTYPE	1	1	tolerance
NCT000048141	NCT00004814_1_T1	PHENOTYPE	19	21	relapsing-remitting multiple sclerosis
NCT000048153	NCT00004815_3_T0	ORGAN	7	7	serum
NCT000048153	NCT00004815_3_T1	PHENOTYPE	8	9	hormone level
NCT000048154	NCT00004815_4_T0	COMPOUND	9	9	estradiol
NCT000048154	NCT00004815_4_T1	COMPOUND	6	7	calcium citrate
NCT000048161	NCT00004816_1_T0	GENE	15	15	CD4
NCT000048161	NCT00004816_1_T1	PHENOTYPE	21	22	multiple sclerosis
NCT000048163	NCT00004816_3_T0	PHENOTYPE	2	2	pharmacokinetics
NCT000048168	NCT00004816_8_T0	GENE	19	19	IV
NCT000048169	NCT00004816_9_T0	GENE	8	8	IV
NCT0000481610	NCT00004816_10_T0	GENE	3	3	CD4
NCT0000481610	NCT00004816_10_T1	CELL	4	4	cells
NCT0000481611	NCT00004816_11_T0	GENE	6	6	CD4
NCT0000481611	NCT00004816_11_T1	CELL	7	7	cells
NCT000048171	NCT00004817_1_T0	COMPOUND	7	7	valproate
NCT000048171	NCT00004817_1_T1	COMPOUND	8	8	sodium
NCT000048171	NCT00004817_1_T2	PHENOTYPE	15	15	seizures
NCT000048171	NCT00004817_1_T3	PHENOTYPE	21	22	head injury
NCT000048173	NCT00004817_3_T0	COMPOUND	4	4	valproate
NCT000048173	NCT00004817_3_T1	COMPOUND	11	11	valproate
NCT000048173	NCT00004817_3_T2	ORGAN	33	33	limbs
NCT000048173	NCT00004817_3_T3	PHENOTYPE	35	36	head injury
NCT000048175	NCT00004817_5_T0	COMPOUND	5	5	phenytoin
NCT000048175	NCT00004817_5_T1	GENE	6	6	IV
NCT000048176	NCT00004817_6_T0	COMPOUND	11	11	phenytoin
NCT000048177	NCT00004817_7_T0	GENE	9	9	IV
NCT000048178	NCT00004817_8_T0	COMPOUND	11	11	valproate
NCT000048178	NCT00004817_8_T1	COMPOUND	12	12	sodium
NCT0000481710	NCT00004817_10_T0	COMPOUND	11	11	valproate
NCT0000481710	NCT00004817_10_T1	GENE	12	12	IV
NCT0000481712	NCT00004817_12_T0	COMPOUND	9	9	valproate
NCT0000481712	NCT00004817_12_T1	GENE	10	10	IV
NCT0000481713	NCT00004817_13_T0	COMPOUND	14	14	valproate
NCT0000481713	NCT00004817_13_T1	PHENOTYPE	3	3	seizure
NCT0000481713	NCT00004817_13_T2	GENE	19	19	tapered
NCT000048253	NCT00004825_3_T0	GENE	6	6	IGF-I
NCT000048253	NCT00004825_3_T1	PHENOTYPE	10	12	blood sugar levels
NCT000048255	NCT00004825_5_T0	GENE	6	6	IGF-I
NCT000048255	NCT00004825_5_T1	GENE	13	13	insulin
NCT000048257	NCT00004825_7_T0	GENE	15	15	insulin
NCT000048261	NCT00004826_1_T0	COMPOUND	6	6	clozapine
NCT000048261	NCT00004826_1_T1	PHENOTYPE	9	9	psychosis
NCT000048261	NCT00004826_1_T2	PHENOTYPE	14	15	Parkinson's disease
NCT000048263	NCT00004826_3_T0	COMPOUND	5	5	clozapine
NCT000048263	NCT00004826_3_T1	PHENOTYPE	2	3	adverse effects
NCT000048263	NCT00004826_3_T2	PHENOTYPE	7	8	motor function
NCT000048265	NCT00004826_5_T0	COMPOUND	4	4	clozapine
NCT000048267	NCT00004826_7_T0	PHENOTYPE	4	6	drug induced psychosis
NCT0000482610	NCT00004826_10_T0	COMPOUND	10	10	clozapine
NCT0000482612	NCT00004826_12_T0	PHENOTYPE	11	11	parkinsonism
NCT0000482612	NCT00004826_12_T1	PHENOTYPE	6	6	psychosis
NCT0000482612	NCT00004826_12_T2	PHENOTYPE	15	16	adverse effects
NCT0000482614	NCT00004826_14_T0	COMPOUND	14	14	clozapine
NCT0000482615	NCT00004826_15_T0	PHENOTYPE	9	9	parkinsonism
NCT000048271	NCT00004827_1_T0	PHENOTYPE	23	23	progression
NCT000048271	NCT00004827_1_T1	PHENOTYPE	33	33	X-linked
NCT000048271	NCT00004827_1_T2	COMPOUND	5	6	docosahexaenoic acid
NCT000048271	NCT00004827_1_T3	PHENOTYPE	34	35	retinitis pigmentosa
NCT000048271	NCT00004827_1_T4	CELL	16	18	red blood cells
NCT000048281	NCT00004828_1_T0	PHENOTYPE	2	2	pharmacokinetics
NCT000048283	NCT00004828_3_T0	PHENOTYPE	12	12	concentrations
NCT000048283	NCT00004828_3_T1	ORGAN	10	10	serum
NCT000048285	NCT00004828_5_T0	PHENOTYPE	3	3	toxicity
NCT000048288	NCT00004828_8_T0	PHENOTYPE	3	3	toxicity
NCT000048291	NCT00004829_1_T0	COMPOUND	6	6	tobramycin
NCT000048291	NCT00004829_1_T1	PHENOTYPE	10	11	cystic fibrosis
NCT000048295	NCT00004829_5_T0	COMPOUND	2	2	tobramycin
NCT000048313	NCT00004831_3_T0	COMPOUND	12	12	hydrochloride
NCT000048314	NCT00004831_4_T0	COMPOUND	4	4	hydrochloride
NCT000048314	NCT00004831_4_T1	PHENOTYPE	7	7	ingestion
NCT000048314	NCT00004831_4_T2	GENE	0	1	Group 1
NCT000048314	NCT00004831_4_T3	GENE	14	15	period 2
NCT000048314	NCT00004831_4_T4	GENE	8	9	period 1
NCT000048315	NCT00004831_5_T0	COMPOUND	10	10	hydrochloride
NCT000048315	NCT00004831_5_T1	GENE	12	13	period 2
NCT000048315	NCT00004831_5_T2	GENE	5	6	period 1
NCT000048316	NCT00004831_6_T0	PHENOTYPE	2	2	ingest
NCT000048317	NCT00004831_7_T0	PHENOTYPE	2	2	ingestion
NCT000048319	NCT00004831_9_T0	PHENOTYPE	12	12	ingestion
NCT000048323	NCT00004832_3_T0	GENE	7	7	DAP
NCT000048325	NCT00004832_5_T0	GENE	6	6	DAP
NCT000048325	NCT00004832_5_T1	COMPOUND	5	5	3_4_diaminopyridine
NCT000048326	NCT00004832_6_T0	GENE	15	15	DAP
NCT000048338	NCT00004833_8_T0	PHENOTYPE	17	17	5-10
NCT000048344	NCT00004834_4_T0	COMPOUND	15	15	1_10
NCT0000483411	NCT00004834_11_T0	COMPOUND	10	11	carbon dioxide
NCT000048385	NCT00004838_5_T0	PHENOTYPE	44	45	lead levels
NCT000048387	NCT00004838_7_T0	GENE	4	4	3.4
NCT000048401	NCT00004840_1_T0	GENE	9	10	thyrotropin-releasing hormone
NCT000048401	NCT00004840_1_T1	PHENOTYPE	14	15	premature labor
NCT000048403	NCT00004840_3_T0	GENE	6	7	thyrotropin-releasing hormone
NCT000048404	NCT00004840_4_T0	GENE	2	3	thyrotropin-releasing hormone
NCT000048405	NCT00004840_5_T0	PHENOTYPE	6	8	chronic lung disease
NCT000048420	NCT00004842_0_T0	PHENOTYPE	7	9	Primary Sclerosing Cholangitis
NCT000048422	NCT00004842_2_T0	COMPOUND	6	6	budesonide
NCT000048422	NCT00004842_2_T1	COMPOUND	22	23	ursodeoxycholic acid
NCT000048422	NCT00004842_2_T2	PHENOTYPE	14	16	primary biliary cirrhosis
NCT000048422	NCT00004842_2_T3	PHENOTYPE	10	12	primary sclerosing cholangitis
NCT000048426	NCT00004842_6_T0	ORGAN	1	1	liver
NCT000048426	NCT00004842_6_T1	GENE	7	7	reduced
NCT000048431	NCT00004843_1_T0	PHENOTYPE	13	14	primary hyperparathyroidism
NCT000048433	NCT00004843_3_T0	PHENOTYPE	2	4	quality of life
NCT000048438	NCT00004843_8_T0	PHENOTYPE	0	2	Quality of life
NCT000048447	NCT00004844_7_T0	ORGAN	10	10	putamen
NCT000048450	NCT00004845_0_T0	PHENOTYPE	8	9	Alzheimer's Disease
NCT000048453	NCT00004845_3_T0	COMPOUND	12	12	naproxen
NCT000048453	NCT00004845_3_T1	COMPOUND	10	10	rofecoxib
NCT000048454	NCT00004845_4_T0	COMPOUND	13	13	naproxen
NCT000048454	NCT00004845_4_T1	COMPOUND	12	12	rofecoxib
NCT000048456	NCT00004845_6_T0	COMPOUND	5	5	estrogen
NCT000048456	NCT00004845_6_T1	GENE	3	3	cholinesterase
NCT000048456	NCT00004845_6_T2	COMPOUND	8	8	aspirin
NCT000048456	NCT00004845_6_T3	COMPOUND	10	11	vitamin E
NCT000048457	NCT00004845_7_T0	PHENOTYPE	3	3	diseases
NCT000048458	NCT00004845_8_T0	PHENOTYPE	16	17	Alzheimer's Disease
NCT000048459	NCT00004845_9_T0	PHENOTYPE	10	10	secondary
NCT0000484510	NCT00004845_10_T0	GENE	5	5	CDR
NCT0000484510	NCT00004845_10_T1	PHENOTYPE	1	1	secondary
NCT0000484510	NCT00004845_10_T2	GENE	15	15	ADCS
NCT0000484511	NCT00004845_11_T0	CELL	5	5	Leukocyte
NCT0000484511	NCT00004845_11_T1	PHENOTYPE	10	10	progression
NCT000048460	NCT00004846_0_T0	GENE	4	4	NAT
NCT000048460	NCT00004846_0_T1	PHENOTYPE	2	2	Amplification
NCT000048460	NCT00004846_0_T2	PHENOTYPE	11	11	HIV
NCT000048460	NCT00004846_0_T3	COMPOUND	9	9	HCV
NCT000048463	NCT00004846_3_T0	GENE	26	26	NAT
NCT000048463	NCT00004846_3_T1	BIOLOGICAL_PROCESS	20	20	transcription
NCT000048464	NCT00004846_4_T0	GENE	11	11	NAT
NCT000048464	NCT00004846_4_T1	PHENOTYPE	7	7	HIV
NCT000048464	NCT00004846_4_T2	COMPOUND	9	9	HCV
NCT000048466	NCT00004846_6_T0	PHENOTYPE	12	12	HIV
NCT000048466	NCT00004846_6_T1	COMPOUND	14	14	HCV
NCT000048469	NCT00004846_9_T0	GENE	4	4	NAT
NCT000048469	NCT00004846_9_T1	PHENOTYPE	12	12	HIV
NCT000048469	NCT00004846_9_T2	COMPOUND	29	29	HCV
NCT0000484610	NCT00004846_10_T0	PHENOTYPE	14	14	diseases
NCT0000484613	NCT00004846_13_T0	GENE	5	5	NAT
NCT0000484613	NCT00004846_13_T1	PHENOTYPE	14	14	HIV
NCT0000484613	NCT00004846_13_T2	COMPOUND	16	16	HCV
NCT0000484614	NCT00004846_14_T0	GENE	18	18	has
NCT0000484615	NCT00004846_15_T0	GENE	0	0	NAT
NCT0000484615	NCT00004846_15_T1	GENE	8	8	IND
NCT0000484616	NCT00004846_16_T0	GENE	1	1	IND
NCT0000484617	NCT00004846_17_T0	GENE	22	22	NAT
NCT0000484618	NCT00004846_18_T0	GENE	12	12	NAT
NCT0000484622	NCT00004846_22_T0	GENE	26	26	NAT
NCT0000484622	NCT00004846_22_T1	PHENOTYPE	31	31	HIV
NCT0000484622	NCT00004846_22_T2	COMPOUND	29	29	HCV
NCT0000484622	NCT00004846_22_T3	GENE	8	8	has
NCT000048471	NCT00004847_1_T0	PHENOTYPE	1	1	tumors
NCT000048471	NCT00004847_1_T1	ORGAN	7	8	adrenal glands
NCT000048472	NCT00004847_2_T0	PHENOTYPE	0	0	Pheochromocytomas
NCT000048472	NCT00004847_2_T1	PHENOTYPE	6	8	high blood pressure
NCT000048474	NCT00004847_4_T0	PHENOTYPE	2	2	pheochromocytoma
NCT000048476	NCT00004847_6_T0	PHENOTYPE	13	13	pheochromocytoma
NCT000048477	NCT00004847_7_T0	PHENOTYPE	2	2	tumor
NCT000048478	NCT00004847_8_T0	PHENOTYPE	10	11	multiple tumors
NCT000048479	NCT00004847_9_T0	PHENOTYPE	2	2	tumor
NCT000048479	NCT00004847_9_T1	PHENOTYPE	18	18	tumor
NCT0000484715	NCT00004847_15_T0	PHENOTYPE	11	11	pheochromocytoma
NCT0000484723	NCT00004847_23_T0	PHENOTYPE	8	9	neuroendocrine tumors
NCT0000484724	NCT00004847_24_T0	PHENOTYPE	4	4	tumors
NCT0000484724	NCT00004847_24_T1	COMPOUND	14	14	dopamine
NCT0000484724	NCT00004847_24_T2	PHENOTYPE	1	1	heterogeneous
NCT0000484724	NCT00004847_24_T3	PHENOTYPE	24	24	vesicles
NCT0000484725	NCT00004847_25_T0	COMPOUND	8	8	norepinephrine
NCT0000484725	NCT00004847_25_T1	COMPOUND	10	10	epinephrine
NCT0000484725	NCT00004847_25_T2	COMPOUND	7	7	dopamine
NCT0000484726	NCT00004847_26_T0	COMPOUND	3	3	dopamine
NCT0000484726	NCT00004847_26_T1	GENE	8	11	aromatic amino acid decarboxylase
NCT0000484729	NCT00004847_29_T0	GENE	11	11	MRI
NCT0000484731	NCT00004847_31_T0	COMPOUND	13	13	norepinephrine
NCT0000484731	NCT00004847_31_T1	COMPOUND	15	15	epinephrine
NCT0000484734	NCT00004847_34_T0	COMPOUND	11	11	metaiodobenzylguanidine
NCT0000484734	NCT00004847_34_T1	ORGAN	0	0	Plasma
NCT0000484734	NCT00004847_34_T2	PHENOTYPE	22	22	tumor
NCT0000484735	NCT00004847_35_T0	GENE	7	7	MRI
NCT0000484739	NCT00004847_39_T0	GENE	31	31	MRI
NCT0000484739	NCT00004847_39_T1	COMPOUND	18	18	DOTATATE
NCT0000484741	NCT00004847_41_T0	COMPOUND	8	8	methoxytyramine
NCT0000484750	NCT00004847_50_T0	PHENOTYPE	2	3	metastatic disease
NCT0000484754	NCT00004847_54_T0	PHENOTYPE	2	2	dysfunction
NCT0000484756	NCT00004847_56_T0	PHENOTYPE	13	15	positive pregnancy test
NCT0000484766	NCT00004847_66_T0	PHENOTYPE	8	8	acute
NCT0000484766	NCT00004847_66_T1	COMPOUND	14	14	gadolinium
NCT0000484766	NCT00004847_66_T2	PHENOTYPE	10	12	chronic renal insufficiency
NCT0000484767	NCT00004847_67_T0	ORGAN	3	3	kidney
NCT0000484767	NCT00004847_67_T1	COMPOUND	11	11	creatinine
NCT0000484768	NCT00004847_68_T0	GENE	18	18	MRI
NCT0000484768	NCT00004847_68_T1	PHENOTYPE	32	32	allergy
NCT0000484768	NCT00004847_68_T2	PHENOTYPE	9	9	claustrophobia
NCT0000484768	NCT00004847_68_T3	COMPOUND	34	34	gadolinium
NCT000048482	NCT00004848_2_T0	PHENOTYPE	23	23	hepatitis
NCT000048484	NCT00004848_4_T0	PHENOTYPE	38	38	inflammation
NCT000048484	NCT00004848_4_T1	PHENOTYPE	25	25	hepatitis
NCT000048487	NCT00004848_7_T0	PHENOTYPE	23	23	hepatitis
NCT000048489	NCT00004848_9_T0	PHENOTYPE	38	38	inflammation
NCT000048489	NCT00004848_9_T1	PHENOTYPE	25	25	hepatitis
NCT0000484811	NCT00004848_11_T0	PHENOTYPE	15	16	chronic hepatitis
NCT0000484811	NCT00004848_11_T1	PHENOTYPE	6	7	hepatitis B
NCT0000484811	NCT00004848_11_T2	PHENOTYPE	3	4	hepatitis C
NCT0000484813	NCT00004848_13_T0	PHENOTYPE	9	9	hepatitis
NCT0000484820	NCT00004848_20_T0	PHENOTYPE	2	2	alcoholism
NCT0000484820	NCT00004848_20_T1	ORGAN	6	6	liver
NCT0000484820	NCT00004848_20_T2	PHENOTYPE	9	11	biliary tract disease
NCT000048501	NCT00004850_1_T0	GENE	17	17	had
NCT000048501	NCT00004850_1_T1	COMPOUND	1	1	HCV
NCT000048501	NCT00004850_1_T2	PHENOTYPE	14	14	hepatitis
NCT000048503	NCT00004850_3_T0	COMPOUND	8	8	HCV
NCT000048503	NCT00004850_3_T1	COMPOUND	21	21	HCV
NCT000048503	NCT00004850_3_T2	PHENOTYPE	27	28	liver disease
NCT000048505	NCT00004850_5_T0	PHENOTYPE	16	16	practices
NCT000048506	NCT00004850_6_T0	GENE	5	5	ml
NCT000048506	NCT00004850_6_T1	GENE	17	17	ml
NCT000048507	NCT00004850_7_T0	ORGAN	10	10	plasma
NCT0000485011	NCT00004850_11_T0	GENE	6	6	saliva
NCT0000485015	NCT00004850_15_T0	ORGAN	7	7	liver
NCT0000485020	NCT00004850_20_T0	PHENOTYPE	33	33	acute
NCT0000485020	NCT00004850_20_T1	COMPOUND	5	5	HCV
NCT0000485020	NCT00004850_20_T2	COMPOUND	18	18	HCV
NCT0000485020	NCT00004850_20_T3	COMPOUND	29	29	HCV
NCT0000485020	NCT00004850_20_T4	COMPOUND	42	42	HCV
NCT0000485020	NCT00004850_20_T5	COMPOUND	50	50	HCV
NCT0000485020	NCT00004850_20_T6	COMPOUND	68	68	HCV
NCT0000485020	NCT00004850_20_T7	PHENOTYPE	65	65	chronic
NCT0000485020	NCT00004850_20_T8	PHENOTYPE	35	37	chronic liver disease
NCT0000485021	NCT00004850_21_T0	COMPOUND	8	8	HCV
NCT0000485022	NCT00004850_22_T0	COMPOUND	7	7	HCV
NCT0000485022	NCT00004850_22_T1	PHENOTYPE	29	30	hepatitis C
NCT0000485022	NCT00004850_22_T2	PHENOTYPE	31	32	virus infection
NCT0000485022	NCT00004850_22_T3	PHENOTYPE	28	29	acute hepatitis
NCT0000485024	NCT00004850_24_T0	COMPOUND	18	18	HCV
NCT0000485024	NCT00004850_24_T1	PHENOTYPE	26	26	coinfection
NCT0000485024	NCT00004850_24_T2	PHENOTYPE	8	8	HBV
NCT0000485024	NCT00004850_24_T3	PHENOTYPE	20	20	HBV
NCT0000485026	NCT00004850_26_T0	COMPOUND	11	11	HCV
NCT0000485027	NCT00004850_27_T0	GENE	29	29	Or
NCT0000485027	NCT00004850_27_T1	COMPOUND	9	9	1
NCT0000485027	NCT00004850_27_T2	COMPOUND	50	50	2
NCT0000485027	NCT00004850_27_T3	COMPOUND	12	12	HCV
NCT0000485027	NCT00004850_27_T4	COMPOUND	48	48	HCV
NCT0000485027	NCT00004850_27_T5	PHENOTYPE	32	32	HBV
NCT0000485027	NCT00004850_27_T6	PHENOTYPE	42	42	HBV
NCT0000485027	NCT00004850_27_T7	PHENOTYPE	25	26	hepatitis C
NCT0000485027	NCT00004850_27_T8	PHENOTYPE	27	28	virus infection
NCT0000485027	NCT00004850_27_T9	PHENOTYPE	24	25	acute hepatitis
NCT000048510	NCT00004851_0_T0	COMPOUND	14	14	HCV
NCT000048510	NCT00004851_0_T1	BIOLOGICAL_PROCESS	11	12	Immune Response
NCT000048510	NCT00004851_0_T2	ORGAN	5	6	Bone Marrow
NCT000048513	NCT00004851_3_T0	BIOLOGICAL_PROCESS	12	13	viral replication
NCT000048516	NCT00004851_6_T0	BIOLOGICAL_PROCESS	12	13	viral replication
NCT000048532	NCT00004853_2_T0	GENE	6	6	filgrastim
NCT000048532	NCT00004853_2_T1	PHENOTYPE	12	12	neutropenia
NCT000048532	NCT00004853_2_T2	GENE	17	17	has
NCT000048533	NCT00004853_3_T0	CELL	18	18	granulocyte
NCT000048533	NCT00004853_3_T1	GENE	11	11	filgrastim
NCT000048534	NCT00004853_4_T0	GENE	5	5	II
NCT000048534	NCT00004853_4_T1	GENE	22	22	filgrastim
NCT000048534	NCT00004853_4_T2	GENE	28	28	has
NCT000048534	NCT00004853_4_T3	CELL	25	25	neutrophil
NCT000048534	NCT00004853_4_T4	PHENOTYPE	31	32	adverse event
NCT000048535	NCT00004853_5_T0	PHENOTYPE	28	28	centers
NCT000048535	NCT00004853_5_T1	GENE	7	7	has
NCT000048535	NCT00004853_5_T2	GENE	6	6	IE
NCT000048535	NCT00004853_5_T3	PHENOTYPE	20	20	sarcomas
NCT000048535	NCT00004853_5_T4	PHENOTYPE	26	27	other cancer
NCT000048535	NCT00004853_5_T5	PHENOTYPE	16	17	Ewing's sarcoma
NCT000048536	NCT00004853_6_T0	COMPOUND	13	13	mesna
NCT000048536	NCT00004853_6_T1	COMPOUND	18	18	dexrazoxane
NCT000048536	NCT00004853_6_T2	PHENOTYPE	22	22	cardiotoxicity
NCT000048536	NCT00004853_6_T3	GENE	24	24	filgrastim
NCT000048536	NCT00004853_6_T4	PHENOTYPE	30	30	neutropenia
NCT000048536	NCT00004853_6_T5	COMPOUND	21	21	doxorubicin
NCT000048537	NCT00004853_7_T0	PHENOTYPE	13	13	toxicity
NCT000048537	NCT00004853_7_T1	PHENOTYPE	35	35	sarcoma
NCT000048537	NCT00004853_7_T2	GENE	29	29	filgrastim
NCT000048537	NCT00004853_7_T3	PHENOTYPE	12	12	tolerance
NCT000048538	NCT00004853_8_T0	PHENOTYPE	1	1	pharmacokinetics
NCT000048538	NCT00004853_8_T1	PHENOTYPE	10	10	pharmacokinetics
NCT000048538	NCT00004853_8_T2	GENE	12	12	filgrastim
NCT000048539	NCT00004853_9_T0	PHENOTYPE	13	13	tumors
NCT0000485310	NCT00004853_10_T0	ORGAN	19	19	transplant
NCT000048543	NCT00004854_3_T0	GENE	13	13	Ace
NCT000048543	NCT00004854_3_T1	PHENOTYPE	7	8	heart failure
NCT000048545	NCT00004854_5_T0	GENE	6	6	1.2
NCT000048546	NCT00004854_6_T0	PHENOTYPE	0	0	Secondary
NCT000048546	NCT00004854_6_T1	PHENOTYPE	9	9	tolerance
NCT000048546	NCT00004854_6_T2	PHENOTYPE	5	7	quality of life
NCT000048550	NCT00004855_0_T0	ORGAN	8	9	Immune Systems
NCT000048552	NCT00004855_2_T0	GENE	3	3	protease
NCT000048552	NCT00004855_2_T1	PHENOTYPE	9	9	HIV
NCT000048553	NCT00004855_3_T0	GENE	26	26	CD4
NCT000048553	NCT00004855_3_T1	CELL	27	27	cells
NCT000048553	NCT00004855_3_T2	GENE	18	18	has
NCT000048553	NCT00004855_3_T3	GENE	13	14	protease inhibitor
NCT000048554	NCT00004855_4_T0	GENE	0	0	CD4
NCT000048554	NCT00004855_4_T1	CELL	1	1	cells
NCT000048554	NCT00004855_4_T2	CELL	3	3	cells
NCT000048554	NCT00004855_4_T3	ORGAN	6	7	immune system
NCT000048557	NCT00004855_7_T0	GENE	23	23	CD4
NCT000048557	NCT00004855_7_T1	GENE	30	31	protease inhibitor
NCT000048557	NCT00004855_7_T2	GENE	8	9	reverse transcriptase
NCT000048557	NCT00004855_7_T3	GENE	15	16	reverse transcriptase
NCT000048559	NCT00004855_9_T0	GENE	5	5	CD4
NCT0000485514	NCT00004855_14_T0	PHENOTYPE	0	0	HIV
NCT0000485515	NCT00004855_15_T0	GENE	6	6	1.0
NCT0000485515	NCT00004855_15_T1	PHENOTYPE	12	12	HIV
NCT0000485516	NCT00004855_16_T0	GENE	7	7	1.0
NCT0000485519	NCT00004855_19_T0	GENE	9	9	CD4
NCT0000485519	NCT00004855_19_T1	PHENOTYPE	5	5	HIV
NCT0000485519	NCT00004855_19_T2	GENE	11	11	CD8
NCT0000485519	NCT00004855_19_T3	CELL	15	15	telomere
NCT0000485523	NCT00004855_23_T0	ORGAN	1	1	plasma
NCT0000485524	NCT00004855_24_T0	ORGAN	0	0	Plasma
NCT0000485524	NCT00004855_24_T1	PHENOTYPE	1	1	HIV
NCT000048568	NCT00004856_8_T0	GENE	9	9	IV
NCT000048569	NCT00004856_9_T0	GENE	7	7	IV
NCT0000485610	NCT00004856_10_T0	PHENOTYPE	13	13	toxicity
NCT0000485610	NCT00004856_10_T1	PHENOTYPE	15	16	disease progression
NCT000048572	NCT00004857_2_T0	GENE	2	2	II
NCT000048572	NCT00004857_2_T1	COMPOUND	9	9	fludarabine
NCT000048572	NCT00004857_2_T2	PHENOTYPE	18	20	chronic lymphocytic leukemia
NCT000048574	NCT00004857_4_T0	GENE	12	12	II
NCT000048574	NCT00004857_4_T1	GENE	13	13	III
NCT000048574	NCT00004857_4_T2	GENE	15	15	IV
NCT000048574	NCT00004857_4_T3	COMPOUND	23	23	fludarabine
NCT000048574	NCT00004857_4_T4	PHENOTYPE	16	19	B-cell chronic lymphocytic leukemia
NCT000048576	NCT00004857_6_T0	PHENOTYPE	3	3	toxic
NCT000048578	NCT00004857_8_T0	PHENOTYPE	3	3	toxic
NCT0000485713	NCT00004857_13_T0	COMPOUND	3	3	fludarabine
NCT0000485713	NCT00004857_13_T1	GENE	4	4	IV
NCT0000485714	NCT00004857_14_T0	PHENOTYPE	12	13	disease progression
NCT0000485715	NCT00004857_15_T0	COMPOUND	10	10	fludarabine
NCT0000485721	NCT00004857_21_T0	PHENOTYPE	9	9	unilateral
NCT0000485721	NCT00004857_21_T1	ORGAN	1	2	Bone marrow
NCT0000485724	NCT00004857_24_T0	GENE	17	17	CD20
NCT0000485724	NCT00004857_24_T1	GENE	22	22	CD5
NCT0000485724	NCT00004857_24_T2	CELL	9	9	B-cell
NCT0000485724	NCT00004857_24_T3	CELL	14	14	B-cell
NCT0000485724	NCT00004857_24_T4	GENE	16	16	CD19
NCT0000485724	NCT00004857_24_T5	GENE	19	19	CD24
NCT0000485724	NCT00004857_24_T6	GENE	18	18	CD23
NCT0000485724	NCT00004857_24_T7	CELL	3	3	lymphocyte
NCT0000485725	NCT00004857_25_T0	CELL	2	2	B-cells
NCT0000485726	NCT00004857_26_T0	GENE	8	8	CD23
NCT0000485726	NCT00004857_26_T1	PHENOTYPE	4	5	immunoglobulin levels
NCT0000485730	NCT00004857_30_T0	PHENOTYPE	6	6	CLL
NCT0000485730	NCT00004857_30_T1	PHENOTYPE	20	20	CLL
NCT0000485730	NCT00004857_30_T2	PHENOTYPE	10	10	autoimmune
NCT0000485730	NCT00004857_30_T3	PHENOTYPE	11	11	complications
NCT0000485732	NCT00004857_32_T0	PHENOTYPE	4	4	chronic
NCT0000485738	NCT00004857_38_T0	PHENOTYPE	1	2	HIV disease
NCT0000485739	NCT00004857_39_T0	PHENOTYPE	8	8	HIV
NCT0000485739	NCT00004857_39_T1	PHENOTYPE	5	5	immunity
NCT000048581	NCT00004858_1_T0	PHENOTYPE	17	17	recurrent
NCT000048581	NCT00004858_1_T1	PHENOTYPE	22	23	Hodgkin's lymphoma
NCT000048581	NCT00004858_1_T2	PHENOTYPE	18	20	acute lymphoblastic leukemia
NCT000048583	NCT00004858_3_T0	PHENOTYPE	11	11	recurrent
NCT000048583	NCT00004858_3_T1	PHENOTYPE	17	18	Hodgkin's lymphoma
NCT000048583	NCT00004858_3_T2	PHENOTYPE	12	15	B-cell acute lymphoblastic leukemia
NCT0000485811	NCT00004858_11_T0	GENE	10	10	1.3
NCT0000485811	NCT00004858_11_T1	GENE	4	4	IV
NCT0000485812	NCT00004858_12_T0	PHENOTYPE	10	10	toxicity
NCT0000485812	NCT00004858_12_T1	PHENOTYPE	13	14	disease progression
NCT0000485813	NCT00004858_13_T0	GENE	15	15	MTD
NCT0000485814	NCT00004858_14_T0	PHENOTYPE	18	18	toxicity
NCT0000485814	NCT00004858_14_T1	GENE	1	1	MTD
NCT000048592	NCT00004859_2_T0	CELL	10	10	cells
NCT000048592	NCT00004859_2_T1	PHENOTYPE	9	9	tumor
NCT000048594	NCT00004859_4_T0	COMPOUND	17	17	thalidomide
NCT000048599	NCT00004859_9_T0	PHENOTYPE	2	2	toxicity
NCT0000485915	NCT00004859_15_T0	COMPOUND	14	14	1
NCT0000485917	NCT00004859_17_T0	COMPOUND	4	4	paclitaxel
NCT0000485917	NCT00004859_17_T1	GENE	0	0	ARM
NCT0000485917	NCT00004859_17_T2	GENE	6	6	IV
NCT0000485917	NCT00004859_17_T3	GENE	14	14	IV
NCT0000485918	NCT00004859_18_T0	PHENOTYPE	10	10	toxicity
NCT0000485918	NCT00004859_18_T1	PHENOTYPE	12	13	disease progression
NCT0000485920	NCT00004859_20_T0	COMPOUND	4	4	thalidomide
NCT0000485920	NCT00004859_20_T1	COMPOUND	8	8	aspirin
NCT0000485920	NCT00004859_20_T2	PHENOTYPE	23	24	disease progression
NCT000048601	NCT00004860_1_T0	CELL	9	9	cells
NCT000048601	NCT00004860_1_T1	PHENOTYPE	8	8	tumor
NCT000048602	NCT00004860_2_T0	GENE	2	2	II
NCT000048602	NCT00004860_2_T1	COMPOUND	11	11	leucovorin
NCT000048602	NCT00004860_2_T2	PHENOTYPE	18	20	metastatic colorectal cancer
NCT000048604	NCT00004860_4_T0	COMPOUND	16	16	calcium
NCT000048604	NCT00004860_4_T1	COMPOUND	15	15	leucovorin
NCT000048604	NCT00004860_4_T2	PHENOTYPE	8	10	metastatic colorectal cancer
NCT000048606	NCT00004860_6_T0	PHENOTYPE	2	2	toxicity
NCT000048608	NCT00004860_8_T0	GENE	13	13	III
NCT000048609	NCT00004860_9_T0	COMPOUND	8	8	calcium
NCT000048609	NCT00004860_9_T1	COMPOUND	7	7	leucovorin
NCT0000486010	NCT00004860_10_T0	PHENOTYPE	10	10	toxicity
NCT0000486010	NCT00004860_10_T1	PHENOTYPE	12	13	disease progression
NCT000048611	NCT00004861_1_T0	CELL	15	15	cells
NCT000048611	NCT00004861_1_T1	PHENOTYPE	14	14	tumor
NCT000048612	NCT00004861_2_T0	GENE	3	3	II
NCT000048612	NCT00004861_2_T1	COMPOUND	10	10	gemcitabine
NCT000048612	NCT00004861_2_T2	PHENOTYPE	21	22	pancreatic cancer
NCT000048614	NCT00004861_4_T0	COMPOUND	11	11	gemcitabine
NCT000048614	NCT00004861_4_T1	COMPOUND	14	14	gemcitabine
NCT000048614	NCT00004861_4_T2	PHENOTYPE	23	24	pancreatic cancer
NCT000048615	NCT00004861_5_T0	PHENOTYPE	8	9	pancreatic cancer
NCT000048616	NCT00004861_6_T0	COMPOUND	2	2	gemcitabine
NCT000048617	NCT00004861_7_T0	COMPOUND	17	17	gemcitabine
NCT000048618	NCT00004861_8_T0	PHENOTYPE	9	9	tolerance
NCT000048621	NCT00004862_1_T0	CELL	10	10	cells
NCT000048622	NCT00004862_2_T0	CELL	8	8	cells
NCT000048623	NCT00004862_3_T0	CELL	11	11	cells
NCT000048627	NCT00004862_7_T0	PHENOTYPE	5	5	toxic
NCT0000486211	NCT00004862_11_T0	ORGAN	11	11	marrow
NCT0000486211	NCT00004862_11_T1	PHENOTYPE	12	12	leukemia
NCT0000486211	NCT00004862_11_T2	CELL	13	13	cells
NCT0000486211	NCT00004862_11_T3	GENE	1	1	bcl-2
NCT0000486215	NCT00004862_15_T0	GENE	5	5	bcl-2
NCT0000486221	NCT00004862_21_T0	COMPOUND	6	6	cytarabine
NCT0000486221	NCT00004862_21_T1	COMPOUND	4	4	fludarabine
NCT0000486221	NCT00004862_21_T2	PHENOTYPE	2	2	pharmacokinetics
NCT0000486223	NCT00004862_23_T0	COMPOUND	6	6	cytarabine
NCT0000486223	NCT00004862_23_T1	CELL	10	10	cells
NCT0000486223	NCT00004862_23_T2	COMPOUND	4	4	fludarabine
NCT0000486223	NCT00004862_23_T3	PHENOTYPE	1	1	pharmacodynamic
NCT0000486224	NCT00004862_24_T0	COMPOUND	9	9	cytarabine
NCT0000486224	NCT00004862_24_T1	COMPOUND	7	7	fludarabine
NCT0000486225	NCT00004862_25_T0	GENE	9	9	filgrastim
NCT0000486225	NCT00004862_25_T1	COMPOUND	7	7	1_10
NCT0000486225	NCT00004862_25_T2	GENE	10	10	G-CSF
NCT0000486225	NCT00004862_25_T3	GENE	3	3	IV
NCT0000486226	NCT00004862_26_T0	COMPOUND	12	12	cytarabine
NCT0000486226	NCT00004862_26_T1	COMPOUND	2	2	fludarabine
NCT0000486226	NCT00004862_26_T2	GENE	8	8	3.5
NCT0000486226	NCT00004862_26_T3	GENE	3	3	IV
NCT0000486226	NCT00004862_26_T4	GENE	13	13	IV
NCT0000486227	NCT00004862_27_T0	GENE	5	5	CR
NCT0000486228	NCT00004862_28_T0	GENE	3	3	CR
NCT0000486228	NCT00004862_28_T1	ORGAN	11	12	bone marrow
NCT0000486228	NCT00004862_28_T2	ORGAN	17	18	bone marrow
NCT0000486229	NCT00004862_29_T0	COMPOUND	10	10	cytarabine
NCT0000486229	NCT00004862_29_T1	COMPOUND	8	8	fludarabine
NCT0000486229	NCT00004862_29_T2	GENE	16	16	MTD
NCT0000486230	NCT00004862_30_T0	PHENOTYPE	17	17	toxicity
NCT0000486230	NCT00004862_30_T1	GENE	1	1	MTD
NCT000048630	NCT00004863_0_T0	PHENOTYPE	8	8	Recurrent
NCT000048630	NCT00004863_0_T1	GENE	2	2	GEM
NCT000048630	NCT00004863_0_T2	PHENOTYPE	11	12	Solid Tumors
NCT000048632	NCT00004863_2_T0	CELL	9	9	cells
NCT000048632	NCT00004863_2_T1	PHENOTYPE	8	8	tumor
NCT000048633	NCT00004863_3_T0	COMPOUND	9	9	paclitaxel
NCT000048633	NCT00004863_3_T1	PHENOTYPE	18	18	recurrent
NCT000048633	NCT00004863_3_T2	GENE	11	11	GEM
NCT000048633	NCT00004863_3_T3	PHENOTYPE	21	22	solid tumors
NCT000048635	NCT00004863_5_T0	COMPOUND	11	11	paclitaxel
NCT000048635	NCT00004863_5_T1	PHENOTYPE	15	15	recurrent
NCT000048635	NCT00004863_5_T2	GENE	8	8	GEM
NCT000048635	NCT00004863_5_T3	PHENOTYPE	18	19	solid tumors
NCT000048638	NCT00004863_8_T0	GENE	8	8	GEM
NCT000048639	NCT00004863_9_T0	COMPOUND	2	2	paclitaxel
NCT000048639	NCT00004863_9_T1	GENE	3	3	IV
NCT000048639	NCT00004863_9_T2	GENE	13	13	GEM
NCT0000486310	NCT00004863_10_T0	PHENOTYPE	13	13	toxicity
NCT0000486310	NCT00004863_10_T1	PHENOTYPE	9	10	disease progression
NCT0000486311	NCT00004863_11_T0	COMPOUND	12	12	paclitaxel
NCT0000486311	NCT00004863_11_T1	GENE	24	24	MTD
NCT0000486311	NCT00004863_11_T2	GENE	17	17	GEM
NCT0000486312	NCT00004863_12_T0	PHENOTYPE	19	19	toxicity
NCT0000486312	NCT00004863_12_T1	GENE	1	1	MTD
NCT000048640	NCT00004864_0_T0	PHENOTYPE	8	8	Recurrent
NCT000048640	NCT00004864_0_T1	GENE	2	2	GEM
NCT000048640	NCT00004864_0_T2	PHENOTYPE	11	12	Solid Tumors
NCT000048643	NCT00004864_3_T0	COMPOUND	10	10	docetaxel
NCT000048643	NCT00004864_3_T1	PHENOTYPE	19	19	recurrent
NCT000048643	NCT00004864_3_T2	GENE	12	12	GEM
NCT000048643	NCT00004864_3_T3	PHENOTYPE	22	23	solid tumors
NCT000048645	NCT00004864_5_T0	COMPOUND	8	8	docetaxel
NCT000048645	NCT00004864_5_T1	PHENOTYPE	15	15	recurrent
NCT000048645	NCT00004864_5_T2	GENE	10	10	GEM
NCT000048645	NCT00004864_5_T3	PHENOTYPE	18	19	solid tumors
NCT000048647	NCT00004864_7_T0	GENE	6	6	GEM
NCT000048648	NCT00004864_8_T0	COMPOUND	11	11	docetaxel
NCT000048648	NCT00004864_8_T1	GENE	8	8	GEM
NCT000048649	NCT00004864_9_T0	COMPOUND	2	2	docetaxel
NCT000048649	NCT00004864_9_T1	GENE	3	3	IV
NCT000048649	NCT00004864_9_T2	GENE	15	15	IV
NCT000048649	NCT00004864_9_T3	GENE	13	13	GEM
NCT0000486410	NCT00004864_10_T0	PHENOTYPE	13	13	toxicity
NCT0000486410	NCT00004864_10_T1	PHENOTYPE	9	10	disease progression
NCT0000486411	NCT00004864_11_T0	COMPOUND	13	13	docetaxel
NCT0000486411	NCT00004864_11_T1	GENE	19	19	MTD
NCT0000486411	NCT00004864_11_T2	GENE	10	10	GEM
NCT0000486412	NCT00004864_12_T0	PHENOTYPE	19	19	toxicity
NCT0000486412	NCT00004864_12_T1	GENE	1	1	MTD
NCT000048650	NCT00004865_0_T0	PHENOTYPE	9	10	Recurrent Cancer
NCT000048650	NCT00004865_0_T1	PHENOTYPE	10	14	Cancer of the Head and
NCT000048652	NCT00004865_2_T0	CELL	10	10	cells
NCT000048652	NCT00004865_2_T1	PHENOTYPE	9	9	tumor
NCT000048653	NCT00004865_3_T0	CELL	10	10	cells
NCT000048653	NCT00004865_3_T1	PHENOTYPE	9	9	tumor
NCT000048654	NCT00004865_4_T0	GENE	2	2	II
NCT000048654	NCT00004865_4_T1	GENE	27	27	has
NCT000048654	NCT00004865_4_T2	COMPOUND	11	11	cisplatin
NCT000048654	NCT00004865_4_T3	PHENOTYPE	19	20	recurrent cancer
NCT000048654	NCT00004865_4_T4	PHENOTYPE	20	24	cancer of the head and
NCT000048658	NCT00004865_8_T0	PHENOTYPE	5	5	toxicity
NCT0000486510	NCT00004865_10_T0	PHENOTYPE	2	4	quality of life
NCT0000486512	NCT00004865_12_T0	COMPOUND	26	26	paclitaxel
NCT0000486512	NCT00004865_12_T1	COMPOUND	5	5	2
NCT0000486512	NCT00004865_12_T2	COMPOUND	12	12	2
NCT0000486512	NCT00004865_12_T3	GENE	43	43	1.4
NCT0000486512	NCT00004865_12_T4	COMPOUND	24	24	cisplatin
NCT0000486512	NCT00004865_12_T5	COMPOUND	29	29	cisplatin
NCT0000486512	NCT00004865_12_T6	GENE	30	30	IV
NCT0000486512	NCT00004865_12_T7	GENE	39	39	IV
NCT0000486512	NCT00004865_12_T8	GENE	21	22	Group 1
NCT0000486513	NCT00004865_13_T0	COMPOUND	14	14	paclitaxel
NCT0000486513	NCT00004865_13_T1	COMPOUND	3	3	cisplatin
NCT0000486513	NCT00004865_13_T2	COMPOUND	8	8	cisplatin
NCT0000486513	NCT00004865_13_T3	GENE	9	9	IV
NCT0000486513	NCT00004865_13_T4	GENE	15	15	IV
NCT0000486516	NCT00004865_16_T0	GENE	15	15	II
NCT0000486516	NCT00004865_16_T1	PHENOTYPE	5	6	disease progression
NCT0000486517	NCT00004865_17_T0	GENE	1	1	II
NCT0000486517	NCT00004865_17_T1	PHENOTYPE	17	18	disease progression
NCT0000486518	NCT00004865_18_T0	GENE	7	7	IV
NCT0000486519	NCT00004865_19_T0	GENE	15	15	IV
NCT0000486519	NCT00004865_19_T1	PHENOTYPE	7	8	anaphylactic reaction
NCT0000486520	NCT00004865_20_T0	COMPOUND	2	2	cisplatin
NCT0000486520	NCT00004865_20_T1	GENE	3	3	IV
NCT0000486521	NCT00004865_21_T0	GENE	4	4	IV
NCT0000486524	NCT00004865_24_T0	PHENOTYPE	21	22	disease progression
NCT0000486525	NCT00004865_25_T0	PHENOTYPE	0	2	Quality of life
NCT000048661	NCT00004866_1_T0	GENE	2	2	II
NCT000048661	NCT00004866_1_T1	PHENOTYPE	17	21	recurrent cancer of the cervix
NCT000048664	NCT00004866_4_T0	GENE	3	3	IV
NCT000048665	NCT00004866_5_T0	PHENOTYPE	13	13	toxicity
NCT000048665	NCT00004866_5_T1	PHENOTYPE	9	10	disease progression
NCT000048671	NCT00004867_1_T0	PHENOTYPE	15	15	tumor
NCT000048671	NCT00004867_1_T1	PHENOTYPE	20	21	esophageal cancer
NCT000048671	NCT00004867_1_T2	COMPOUND	8	10	fludeoxyglucose F 18
NCT000048673	NCT00004867_3_T0	PHENOTYPE	0	0	Secondary
NCT0000486712	NCT00004867_12_T0	PHENOTYPE	32	32	tumors
NCT0000486712	NCT00004867_12_T1	PHENOTYPE	27	27	tumor
NCT0000486716	NCT00004867_16_T0	COMPOUND	37	37	furosemide
NCT0000486716	NCT00004867_16_T1	ORGAN	9	9	serum
NCT0000486716	NCT00004867_16_T2	PHENOTYPE	30	31	radiation exposure
NCT0000486724	NCT00004867_24_T0	GENE	8	8	cm
NCT0000486724	NCT00004867_24_T1	PHENOTYPE	2	2	proximal
NCT0000486724	NCT00004867_24_T2	GENE	1	1	has
NCT0000486724	NCT00004867_24_T3	ORGAN	10	10	incisors
NCT0000486724	NCT00004867_24_T4	PHENOTYPE	3	4	esophageal cancer
NCT0000486726	NCT00004867_26_T0	GENE	19	19	T4
NCT0000486726	NCT00004867_26_T1	GENE	1	1	has
NCT0000486726	NCT00004867_26_T2	PHENOTYPE	11	12	metastatic disease
NCT0000486730	NCT00004867_30_T0	GENE	2	2	had
NCT0000486730	NCT00004867_30_T1	GENE	1	1	has
NCT0000486730	NCT00004867_30_T2	PHENOTYPE	11	12	esophageal cancer
NCT0000486734	NCT00004867_34_T0	GENE	1	1	has
NCT000048681	NCT00004868_1_T0	PHENOTYPE	16	16	astrocytoma
NCT000048681	NCT00004868_1_T1	GENE	21	21	has
NCT000048681	NCT00004868_1_T2	PHENOTYPE	15	15	recurrent
NCT000048681	NCT00004868_1_T3	PHENOTYPE	18	19	mixed glioma
NCT000048686	NCT00004868_6_T0	GENE	3	3	IV
NCT000048687	NCT00004868_7_T0	PHENOTYPE	10	10	toxicity
NCT000048687	NCT00004868_7_T1	PHENOTYPE	12	13	disease progression
NCT000048688	NCT00004868_8_T0	GENE	14	14	MTD
NCT000048689	NCT00004868_9_T0	PHENOTYPE	21	21	toxicity
NCT000048689	NCT00004868_9_T1	GENE	1	1	MTD
NCT0000486810	NCT00004868_10_T0	GENE	13	13	II
NCT0000486810	NCT00004868_10_T1	GENE	3	3	has
NCT0000486810	NCT00004868_10_T2	GENE	2	2	MTD
NCT0000486811	NCT00004868_11_T0	GENE	14	14	MTD
NCT0000486811	NCT00004868_11_T1	GENE	4	4	IV
NCT0000486814	NCT00004868_14_T0	GENE	19	19	II
NCT0000486814	NCT00004868_14_T1	PHENOTYPE	12	12	glioma
NCT0000486814	NCT00004868_14_T2	PHENOTYPE	6	7	glioblastoma multiforme
NCT000048701	NCT00004870_1_T0	CELL	8	8	cells
NCT000048701	NCT00004870_1_T1	PHENOTYPE	7	7	tumor
NCT000048702	NCT00004870_2_T0	COMPOUND	1	1	irinotecan
NCT000048702	NCT00004870_2_T1	CELL	8	8	cells
NCT000048702	NCT00004870_2_T2	PHENOTYPE	7	7	tumor
NCT000048703	NCT00004870_3_T0	COMPOUND	12	12	irinotecan
NCT000048703	NCT00004870_3_T1	PHENOTYPE	20	22	recurrent colorectal cancer
NCT000048705	NCT00004870_5_T0	PHENOTYPE	3	3	toxic
NCT000048705	NCT00004870_5_T1	COMPOUND	16	16	irinotecan
NCT000048705	NCT00004870_5_T2	PHENOTYPE	23	25	recurrent colorectal cancer
NCT000048707	NCT00004870_7_T0	PHENOTYPE	5	5	toxicity
NCT000048709	NCT00004870_9_T0	PHENOTYPE	3	3	pharmacokinetics
NCT000048709	NCT00004870_9_T1	ORGAN	2	2	plasma
NCT0000487011	NCT00004870_11_T0	GENE	14	14	II
NCT0000487013	NCT00004870_13_T0	PHENOTYPE	8	8	tumor
NCT0000487013	NCT00004870_13_T1	PHENOTYPE	26	26	pharmacodynamic
NCT0000487015	NCT00004870_15_T0	COMPOUND	10	10	irinotecan
NCT0000487015	NCT00004870_15_T1	GENE	8	8	1.7
NCT0000487015	NCT00004870_15_T2	GENE	4	4	IV
NCT0000487015	NCT00004870_15_T3	GENE	11	11	IV
NCT0000487016	NCT00004870_16_T0	PHENOTYPE	10	10	toxicity
NCT0000487016	NCT00004870_16_T1	PHENOTYPE	12	13	disease progression
NCT0000487017	NCT00004870_17_T0	COMPOUND	10	10	irinotecan
NCT0000487017	NCT00004870_17_T1	GENE	16	16	MTD
NCT0000487018	NCT00004870_18_T0	PHENOTYPE	17	17	toxicity
NCT0000487018	NCT00004870_18_T1	GENE	1	1	MTD
NCT0000487019	NCT00004870_19_T0	GENE	20	20	II
NCT0000487019	NCT00004870_19_T1	COMPOUND	15	15	irinotecan
NCT0000487019	NCT00004870_19_T2	GENE	2	2	MTD
NCT0000487020	NCT00004870_20_T0	PHENOTYPE	7	7	toxicity
NCT0000487022	NCT00004870_22_T0	GENE	11	11	II
NCT000048714	NCT00004871_4_T0	GENE	7	7	1.5
NCT000048714	NCT00004871_4_T1	GENE	13	13	IV
NCT000048715	NCT00004871_5_T0	PHENOTYPE	11	12	disease progression
NCT000048717	NCT00004871_7_T0	GENE	15	15	MEPD
NCT000048718	NCT00004871_8_T0	GENE	1	1	MEPD
NCT000048718	NCT00004871_8_T1	PHENOTYPE	23	24	enzyme inhibition
NCT000048719	NCT00004871_9_T0	PHENOTYPE	4	4	toxicity
NCT000048719	NCT00004871_9_T1	GENE	2	2	MEPD
NCT000048720	NCT00004872_0_T0	COMPOUND	0	0	Endostatin
NCT000048720	NCT00004872_0_T1	PHENOTYPE	7	8	Solid Tumors
NCT000048722	NCT00004872_2_T0	GENE	9	9	endostatin
NCT000048722	NCT00004872_2_T1	PHENOTYPE	17	18	solid tumors
NCT000048724	NCT00004872_4_T0	GENE	8	8	II
NCT000048724	NCT00004872_4_T1	GENE	11	11	endostatin
NCT000048724	NCT00004872_4_T2	GENE	5	5	MTD
NCT000048724	NCT00004872_4_T3	PHENOTYPE	17	18	solid tumors
NCT000048726	NCT00004872_6_T0	GENE	11	11	endostatin
NCT000048726	NCT00004872_6_T1	PHENOTYPE	8	8	toxicities
NCT000048728	NCT00004872_8_T0	GENE	7	7	endostatin
NCT000048728	NCT00004872_8_T1	PHENOTYPE	3	3	pharmacokinetics
NCT000048728	NCT00004872_8_T2	BIOLOGICAL_PROCESS	5	5	metabolism
NCT000048728	NCT00004872_8_T3	GENE	14	14	EIA
NCT000048728	NCT00004872_8_T4	ORGAN	11	11	plasma
NCT0000487210	NCT00004872_10_T0	PHENOTYPE	7	7	toxicity
NCT0000487214	NCT00004872_14_T0	GENE	2	2	endostatin
NCT0000487214	NCT00004872_14_T1	GENE	3	3	IV
NCT0000487215	NCT00004872_15_T0	PHENOTYPE	15	15	toxicity
NCT0000487215	NCT00004872_15_T1	PHENOTYPE	11	12	disease progression
NCT0000487216	NCT00004872_16_T0	GENE	8	8	endostatin
NCT0000487216	NCT00004872_16_T1	GENE	14	14	MTD
NCT0000487217	NCT00004872_17_T0	PHENOTYPE	18	18	toxicities
NCT0000487217	NCT00004872_17_T1	GENE	1	1	MTD
NCT000048731	NCT00004873_1_T0	CELL	9	9	cells
NCT000048731	NCT00004873_1_T1	PHENOTYPE	8	8	tumor
NCT000048732	NCT00004873_2_T0	PHENOTYPE	15	16	stomach cancer
NCT000048733	NCT00004873_3_T0	GENE	3	3	II
NCT000048733	NCT00004873_3_T1	PHENOTYPE	21	22	stomach cancer
NCT000048736	NCT00004873_6_T0	COMPOUND	10	10	1
NCT000048736	NCT00004873_6_T1	ORGAN	12	12	liver
NCT000048738	NCT00004873_8_T0	PHENOTYPE	20	20	toxicity
NCT000048738	NCT00004873_8_T1	PHENOTYPE	16	17	disease progression
NCT000048739	NCT00004873_9_T0	PHENOTYPE	0	2	Quality of life
NCT000048741	NCT00004874_1_T0	GENE	2	2	III
NCT000048741	NCT00004874_1_T1	PHENOTYPE	20	21	Hodgkin's lymphoma
NCT000048745	NCT00004874_5_T0	GENE	11	11	14
NCT0000487412	NCT00004874_12_T0	PHENOTYPE	18	18	lymphoma
NCT0000487412	NCT00004874_12_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000487412	NCT00004874_12_T2	PHENOTYPE	16	17	high grade
NCT000048750	NCT00004875_0_T0	PHENOTYPE	6	6	Cancer
NCT000048752	NCT00004875_2_T0	COMPOUND	9	9	heparin
NCT000048754	NCT00004875_4_T0	PHENOTYPE	17	17	anticoagulation
NCT000048754	NCT00004875_4_T1	GENE	8	8	TFPI
NCT000048754	NCT00004875_4_T2	COMPOUND	18	18	heparin
NCT000048754	NCT00004875_4_T3	PHENOTYPE	12	12	tumor
NCT000048754	NCT00004875_4_T4	GENE	4	7	tissue factor pathway inhibitor
NCT000048756	NCT00004875_6_T0	GENE	10	10	TFPI
NCT000048758	NCT00004875_8_T0	PHENOTYPE	2	2	anticoagulation
NCT000048758	NCT00004875_8_T1	GENE	9	9	TFPI
NCT000048762	NCT00004876_2_T0	GENE	4	4	II
NCT000048762	NCT00004876_2_T1	COMPOUND	14	14	thalidomide
NCT000048762	NCT00004876_2_T2	PHENOTYPE	24	26	ovarian epithelial cancer
NCT000048767	NCT00004876_7_T0	COMPOUND	2	2	thalidomide
NCT000048770	NCT00004877_0_T0	PHENOTYPE	6	7	Solid Tumors
NCT000048772	NCT00004877_2_T0	PHENOTYPE	16	17	solid tumors
NCT000048774	NCT00004877_4_T0	GENE	10	10	II
NCT000048774	NCT00004877_4_T1	PHENOTYPE	7	7	toxicity
NCT000048774	NCT00004877_4_T2	PHENOTYPE	20	21	solid tumors
NCT000048776	NCT00004877_6_T0	PHENOTYPE	2	2	pharmacokinetics
NCT0000487712	NCT00004877_12_T0	GENE	3	3	IV
NCT0000487714	NCT00004877_14_T0	PHENOTYPE	13	13	toxicity
NCT0000487714	NCT00004877_14_T1	PHENOTYPE	9	10	disease progression
NCT0000487715	NCT00004877_15_T0	GENE	14	14	MTD
NCT0000487716	NCT00004877_16_T0	PHENOTYPE	18	18	toxicity
NCT0000487716	NCT00004877_16_T1	GENE	1	1	MTD
NCT0000487717	NCT00004877_17_T0	PHENOTYPE	7	7	toxicities
NCT000048782	NCT00004878_2_T0	CELL	1	1	lymphocytes
NCT000048787	NCT00004878_7_T0	PHENOTYPE	9	9	remission
NCT000048787	NCT00004878_7_T1	PHENOTYPE	13	13	GVHD
NCT000048789	NCT00004878_9_T0	GENE	5	5	HDM
NCT000048789	NCT00004878_9_T1	CELL	16	16	lymphocytes
NCT000048789	NCT00004878_9_T2	CELL	13	13	cells
NCT000048789	NCT00004878_9_T3	GENE	4	4	CD8
NCT000048789	NCT00004878_9_T4	GENE	12	12	CD8
NCT0000487811	NCT00004878_11_T0	PHENOTYPE	4	4	toxicity
NCT0000487814	NCT00004878_14_T0	CELL	12	12	cells
NCT0000487814	NCT00004878_14_T1	GENE	11	11	CD34
NCT0000487814	NCT00004878_14_T2	CELL	1	4	peripheral blood stem cells
NCT0000487815	NCT00004878_15_T0	COMPOUND	10	10	cytarabine
NCT0000487815	NCT00004878_15_T1	COMPOUND	28	28	3
NCT0000487815	NCT00004878_15_T2	PHENOTYPE	1	1	conditioning
NCT0000487815	NCT00004878_15_T3	GENE	33	33	1.5
NCT0000487815	NCT00004878_15_T4	COMPOUND	30	30	idarubicin
NCT0000487815	NCT00004878_15_T5	COMPOUND	4	4	fludarabine
NCT0000487815	NCT00004878_15_T6	COMPOUND	22	22	fludarabine
NCT0000487815	NCT00004878_15_T7	GENE	5	5	IV
NCT0000487815	NCT00004878_15_T8	GENE	11	11	IV
NCT0000487815	NCT00004878_15_T9	GENE	31	31	IV
NCT0000487816	NCT00004878_16_T0	COMPOUND	9	9	2
NCT0000487816	NCT00004878_16_T1	GENE	1	1	G-CSF
NCT0000487817	NCT00004878_17_T0	COMPOUND	8	8	2
NCT0000487817	NCT00004878_17_T1	COMPOUND	11	11	tacrolimus
NCT0000487817	NCT00004878_17_T2	GENE	12	12	IV
NCT0000487817	NCT00004878_17_T3	PHENOTYPE	0	3	Graft versus host disease
NCT0000487818	NCT00004878_18_T0	COMPOUND	2	2	tacrolimus
NCT0000487818	NCT00004878_18_T1	COMPOUND	6	6	methotrexate
NCT0000487819	NCT00004878_19_T0	COMPOUND	8	8	tacrolimus
NCT0000487819	NCT00004878_19_T1	GENE	10	10	tapered
NCT0000487824	NCT00004878_24_T0	GENE	4	4	IV
NCT000048794	NCT00004879_4_T0	GENE	35	35	OR
NCT000048794	NCT00004879_4_T1	GENE	47	47	OR
NCT000048794	NCT00004879_4_T2	GENE	13	13	0.3
NCT000048794	NCT00004879_4_T3	GENE	5	5	IV
NCT000048795	NCT00004879_5_T0	GENE	19	19	3.5
NCT000048796	NCT00004879_6_T0	PHENOTYPE	1	1	All
NCT000048797	NCT00004879_7_T0	GENE	2	2	2.8
NCT000048797	NCT00004879_7_T1	GENE	16	16	MTD
NCT000048798	NCT00004879_8_T0	PHENOTYPE	19	19	toxicity
NCT000048798	NCT00004879_8_T1	GENE	1	1	MTD
NCT000048801	NCT00004880_1_T0	PHENOTYPE	17	18	kidney cancer
NCT000048809	NCT00004880_9_T0	PHENOTYPE	7	8	primary tumor
NCT0000488010	NCT00004880_10_T0	PHENOTYPE	2	3	primary tumor
NCT000048811	NCT00004881_1_T0	PHENOTYPE	16	17	advanced cancer
NCT000048813	NCT00004881_3_T0	GENE	13	13	MUC1
NCT000048813	NCT00004881_3_T1	PHENOTYPE	3	3	tolerance
NCT000048813	NCT00004881_3_T2	PHENOTYPE	15	16	advanced cancer
NCT000048817	NCT00004881_7_T0	GENE	3	3	IM
NCT000048818	NCT00004881_8_T0	PHENOTYPE	10	10	toxicity
NCT000048818	NCT00004881_8_T1	PHENOTYPE	12	13	disease progression
NCT000048819	NCT00004881_9_T0	GENE	14	14	MTD
NCT0000488110	NCT00004881_10_T0	PHENOTYPE	20	20	toxicity
NCT0000488110	NCT00004881_10_T1	GENE	1	1	MTD
NCT0000488111	NCT00004881_11_T0	PHENOTYPE	6	6	toxicity
NCT0000488111	NCT00004881_11_T1	GENE	14	14	MTD
NCT0000488111	NCT00004881_11_T2	PHENOTYPE	3	3	experiences
NCT000048836	NCT00004883_6_T0	PHENOTYPE	2	2	toxicity
NCT000048838	NCT00004883_8_T0	GENE	4	4	HER2
NCT000048838	NCT00004883_8_T1	GENE	8	8	HER2
NCT0000488311	NCT00004883_11_T0	GENE	5	5	IV
NCT0000488312	NCT00004883_12_T0	PHENOTYPE	13	13	toxicity
NCT0000488312	NCT00004883_12_T1	PHENOTYPE	9	10	disease progression
NCT0000488313	NCT00004883_13_T0	PHENOTYPE	7	8	disease progression
NCT000048841	NCT00004884_1_T0	CELL	9	9	cells
NCT000048841	NCT00004884_1_T1	PHENOTYPE	8	8	tumor
NCT000048842	NCT00004884_2_T0	COMPOUND	6	6	docetaxel
NCT000048842	NCT00004884_2_T1	COMPOUND	13	13	docetaxel
NCT000048842	NCT00004884_2_T2	COMPOUND	8	8	gemcitabine
NCT000048842	NCT00004884_2_T3	COMPOUND	15	15	cisplatin
NCT000048842	NCT00004884_2_T4	PHENOTYPE	19	20	pancreatic cancer
NCT000048843	NCT00004884_3_T0	GENE	3	3	II
NCT000048843	NCT00004884_3_T1	COMPOUND	10	10	docetaxel
NCT000048843	NCT00004884_3_T2	COMPOUND	16	16	docetaxel
NCT000048843	NCT00004884_3_T3	COMPOUND	12	12	gemcitabine
NCT000048843	NCT00004884_3_T4	COMPOUND	18	18	cisplatin
NCT000048843	NCT00004884_3_T5	PHENOTYPE	28	29	pancreatic cancer
NCT000048845	NCT00004884_5_T0	COMPOUND	4	4	docetaxel
NCT000048845	NCT00004884_5_T1	COMPOUND	8	8	docetaxel
NCT000048845	NCT00004884_5_T2	COMPOUND	6	6	gemcitabine
NCT000048845	NCT00004884_5_T3	COMPOUND	10	10	cisplatin
NCT000048845	NCT00004884_5_T4	PHENOTYPE	18	19	pancreatic cancer
NCT000048847	NCT00004884_7_T0	PHENOTYPE	2	2	toxicity
NCT000048847	NCT00004884_7_T1	PHENOTYPE	10	10	progression
NCT0000488412	NCT00004884_12_T0	PHENOTYPE	17	17	toxicity
NCT0000488412	NCT00004884_12_T1	PHENOTYPE	13	14	disease progression
NCT0000488413	NCT00004884_13_T0	PHENOTYPE	7	8	disease progression
NCT000048851	NCT00004885_1_T0	COMPOUND	10	10	irinotecan
NCT000048851	NCT00004885_1_T1	COMPOUND	8	8	leucovorin
NCT000048851	NCT00004885_1_T2	COMPOUND	17	17	leucovorin
NCT000048851	NCT00004885_1_T3	PHENOTYPE	20	21	colorectal cancer
NCT000048852	NCT00004885_2_T0	COMPOUND	16	16	irinotecan
NCT000048852	NCT00004885_2_T1	GENE	3	3	III
NCT000048852	NCT00004885_2_T2	COMPOUND	12	12	leucovorin
NCT000048852	NCT00004885_2_T3	PHENOTYPE	22	24	metastatic colorectal cancer
NCT000048854	NCT00004885_4_T0	PHENOTYPE	4	4	toxicity
NCT000048854	NCT00004885_4_T1	COMPOUND	10	10	calcium
NCT000048854	NCT00004885_4_T2	COMPOUND	14	14	irinotecan
NCT000048854	NCT00004885_4_T3	ORGAN	24	24	rectum
NCT000048854	NCT00004885_4_T4	COMPOUND	9	9	leucovorin
NCT000048854	NCT00004885_4_T5	PHENOTYPE	18	19	metastatic adenocarcinoma
NCT000048854	NCT00004885_4_T6	PHENOTYPE	19	22	adenocarcinoma of the colon
NCT000048858	NCT00004885_8_T0	PHENOTYPE	1	3	quality of life
NCT0000488516	NCT00004885_16_T0	PHENOTYPE	26	27	disease progression
NCT0000488516	NCT00004885_16_T1	PHENOTYPE	0	2	Quality of life
NCT0000488517	NCT00004885_17_T0	PHENOTYPE	7	8	disease progression
NCT000048860	NCT00004886_0_T0	GENE	0	0	MS
NCT000048860	NCT00004886_0_T1	PHENOTYPE	9	10	Solid Tumors
NCT000048862	NCT00004886_2_T0	CELL	9	9	cells
NCT000048862	NCT00004886_2_T1	PHENOTYPE	8	8	tumor
NCT000048863	NCT00004886_3_T0	COMPOUND	12	12	docetaxel
NCT000048863	NCT00004886_3_T1	GENE	9	9	MS
NCT000048863	NCT00004886_3_T2	PHENOTYPE	19	20	solid tumors
NCT000048866	NCT00004886_6_T0	COMPOUND	2	2	docetaxel
NCT000048866	NCT00004886_6_T1	GENE	3	3	IV
NCT000048867	NCT00004886_7_T0	COMPOUND	13	13	docetaxel
NCT000048867	NCT00004886_7_T1	GENE	14	14	IV
NCT000048868	NCT00004886_8_T0	COMPOUND	12	12	docetaxel
NCT000048868	NCT00004886_8_T1	GENE	7	7	4.7
NCT000048869	NCT00004886_9_T0	PHENOTYPE	10	10	toxicity
NCT000048869	NCT00004886_9_T1	PHENOTYPE	6	7	disease progression
NCT0000488610	NCT00004886_10_T0	GENE	14	14	MTD
NCT0000488611	NCT00004886_11_T0	PHENOTYPE	20	20	toxicities
NCT0000488611	NCT00004886_11_T1	GENE	1	1	MTD
NCT000048875	NCT00004887_5_T0	GENE	13	13	IV
NCT000048877	NCT00004887_7_T0	PHENOTYPE	18	18	toxicity
NCT000048877	NCT00004887_7_T1	PHENOTYPE	14	15	disease progression
NCT000048878	NCT00004887_8_T0	PHENOTYPE	0	2	Quality of life
NCT000048881	NCT00004888_1_T0	CELL	10	10	cells
NCT000048881	NCT00004888_1_T1	PHENOTYPE	9	9	tumor
NCT000048884	NCT00004888_4_T0	PHENOTYPE	23	23	cardiotoxicity
NCT000048884	NCT00004888_4_T1	COMPOUND	11	11	doxorubicin
NCT000048886	NCT00004888_6_T0	PHENOTYPE	19	21	metastatic breast cancer
NCT000048888	NCT00004888_8_T0	PHENOTYPE	4	4	toxicity
NCT000048888	NCT00004888_8_T1	PHENOTYPE	15	16	breast cancer
NCT0000488810	NCT00004888_10_T0	PHENOTYPE	25	25	CHF
NCT0000488810	NCT00004888_10_T1	GENE	12	12	cTnT
NCT0000488810	NCT00004888_10_T2	ORGAN	9	9	plasma
NCT0000488810	NCT00004888_10_T3	PHENOTYPE	23	24	cardiac event
NCT0000488810	NCT00004888_10_T4	GENE	13	15	cardiac troponin T
NCT0000488810	NCT00004888_10_T5	GENE	18	20	brain natriuretic peptide
NCT0000488812	NCT00004888_12_T0	PHENOTYPE	18	18	toxicity
NCT0000488812	NCT00004888_12_T1	ORGAN	4	4	plasma
NCT0000488812	NCT00004888_12_T2	GENE	7	7	HER2
NCT0000488815	NCT00004888_15_T0	PHENOTYPE	17	17	toxicity
NCT0000488815	NCT00004888_15_T1	PHENOTYPE	13	14	disease progression
NCT0000488816	NCT00004888_16_T0	COMPOUND	6	6	docetaxel
NCT0000488816	NCT00004888_16_T1	GENE	7	7	IV
NCT0000488817	NCT00004888_17_T0	PHENOTYPE	10	10	toxicity
NCT0000488817	NCT00004888_17_T1	PHENOTYPE	6	7	disease progression
NCT0000488819	NCT00004888_19_T0	COMPOUND	3	3	HCl
NCT0000488819	NCT00004888_19_T1	COMPOUND	11	11	docetaxel
NCT0000488819	NCT00004888_19_T2	COMPOUND	2	2	doxorubicin
NCT0000488819	NCT00004888_19_T3	GENE	5	5	IV
NCT0000488819	NCT00004888_19_T4	GENE	12	12	IV
NCT0000488821	NCT00004888_21_T0	COMPOUND	14	14	docetaxel
NCT0000488821	NCT00004888_21_T1	GENE	7	7	IV
NCT0000488821	NCT00004888_21_T2	GENE	15	15	IV
NCT0000488822	NCT00004888_22_T0	PHENOTYPE	10	10	toxicity
NCT0000488822	NCT00004888_22_T1	PHENOTYPE	6	7	disease progression
NCT000048891	NCT00004889_1_T0	GENE	2	2	II
NCT000048891	NCT00004889_1_T1	PHENOTYPE	15	16	Waldenstrom's macroglobulinemia
NCT000048895	NCT00004889_5_T0	PHENOTYPE	9	9	toxicity
NCT000048895	NCT00004889_5_T1	PHENOTYPE	13	14	Waldenstrom's macroglobulinemia
NCT000048897	NCT00004889_7_T0	GENE	7	7	CD20
NCT000048897	NCT00004889_7_T1	CELL	13	13	B-cells
NCT000048897	NCT00004889_7_T2	CELL	10	11	plasma cells
NCT000048899	NCT00004889_9_T0	GENE	3	3	IV
NCT000048901	NCT00004890_1_T0	CELL	5	5	cells
NCT000048901	NCT00004890_1_T1	GENE	11	11	interleukin-2
NCT000048902	NCT00004890_2_T0	GENE	15	15	interleukin-2
NCT000048902	NCT00004890_2_T1	PHENOTYPE	17	18	kidney cancer
NCT000048906	NCT00004890_6_T0	PHENOTYPE	32	32	toxicity
NCT000048906	NCT00004890_6_T1	PHENOTYPE	13	13	severity
NCT000048906	NCT00004890_6_T2	GENE	15	15	IL-2
NCT000048906	NCT00004890_6_T3	GENE	25	25	IL-2
NCT000048906	NCT00004890_6_T4	GENE	30	30	IL-2
NCT000048906	NCT00004890_6_T5	PHENOTYPE	17	17	toxicities
NCT000048908	NCT00004890_8_T0	GENE	10	10	interleukin-2
NCT000048908	NCT00004890_8_T1	GENE	14	14	1.5
NCT000048908	NCT00004890_8_T2	GENE	11	11	IV
NCT000048909	NCT00004890_9_T0	GENE	15	15	MTD
NCT0000489010	NCT00004890_10_T0	PHENOTYPE	20	20	toxicities
NCT0000489010	NCT00004890_10_T1	GENE	1	1	MTD
NCT000048914	NCT00004891_4_T0	ORGAN	18	18	thorax
NCT000048914	NCT00004891_4_T1	GENE	1	1	1.2
NCT000048914	NCT00004891_4_T2	ORGAN	19	19	abdomen
NCT000048914	NCT00004891_4_T3	ORGAN	21	21	pelvis
NCT000048915	NCT00004891_5_T0	GENE	5	5	FDG
NCT000048915	NCT00004891_5_T1	GENE	6	6	IV
NCT000048915	NCT00004891_5_T2	COMPOUND	2	4	fludeoxyglucose F 18
NCT000048916	NCT00004891_6_T0	ORGAN	8	8	abdomen
NCT000048916	NCT00004891_6_T1	ORGAN	10	10	pelvis
NCT0000489110	NCT00004891_10_T0	GENE	4	4	1.2
NCT000048921	NCT00004892_1_T0	CELL	15	15	cells
NCT000048921	NCT00004892_1_T1	PHENOTYPE	14	14	tumor
NCT000048922	NCT00004892_2_T0	PHENOTYPE	19	19	recurrent
NCT000048922	NCT00004892_2_T1	PHENOTYPE	20	21	malignant glioma
NCT000048924	NCT00004892_4_T0	PHENOTYPE	13	13	recurrent
NCT000048924	NCT00004892_4_T1	GENE	8	8	AGT
NCT000048924	NCT00004892_4_T2	PHENOTYPE	14	15	malignant glioma
NCT000048926	NCT00004892_6_T0	PHENOTYPE	24	24	tumor
NCT000048926	NCT00004892_6_T1	PHENOTYPE	4	4	tolerance
NCT000048926	NCT00004892_6_T2	MOLECULAR_FUNCTION	25	26	AGT activity
NCT000048928	NCT00004892_8_T0	GENE	7	7	IV
NCT000048929	NCT00004892_9_T0	PHENOTYPE	19	19	tumor
NCT000048929	NCT00004892_9_T1	PHENOTYPE	20	20	cavity
NCT0000489210	NCT00004892_10_T0	PHENOTYPE	20	20	suppression
NCT0000489210	NCT00004892_10_T1	GENE	22	22	AGT
NCT0000489211	NCT00004892_11_T0	GENE	9	9	has
NCT0000489211	NCT00004892_11_T1	GENE	16	16	IV
NCT0000489211	NCT00004892_11_T2	GENE	8	8	AGT
NCT0000489213	NCT00004892_13_T0	GENE	16	16	MTD
NCT0000489214	NCT00004892_14_T0	PHENOTYPE	22	22	toxicities
NCT0000489214	NCT00004892_14_T1	GENE	1	1	MTD
NCT0000489216	NCT00004892_16_T0	GENE	14	14	9.5
NCT000048931	NCT00004893_1_T0	GENE	3	3	II
NCT000048931	NCT00004893_1_T1	GENE	10	10	interleukin-12
NCT000048931	NCT00004893_1_T2	PHENOTYPE	18	20	recurrent breast cancer
NCT000048933	NCT00004893_3_T0	GENE	4	4	interleukin-12
NCT000048937	NCT00004893_7_T0	PHENOTYPE	3	3	progression
NCT000048939	NCT00004893_9_T0	PHENOTYPE	13	13	metastases
NCT000048939	NCT00004893_9_T1	GENE	23	24	estrogen receptor
NCT0000489312	NCT00004893_12_T0	GENE	2	2	interleukin-12
NCT0000489313	NCT00004893_13_T0	PHENOTYPE	10	10	toxicity
NCT0000489313	NCT00004893_13_T1	PHENOTYPE	6	7	disease progression
NCT0000489315	NCT00004893_15_T0	PHENOTYPE	15	15	symptoms
NCT0000489315	NCT00004893_15_T1	PHENOTYPE	2	2	progression
NCT0000489319	NCT00004893_19_T0	PHENOTYPE	10	10	toxicity
NCT0000489319	NCT00004893_19_T1	PHENOTYPE	6	7	disease progression
NCT0000489320	NCT00004893_20_T0	PHENOTYPE	4	4	toxicity
NCT0000489320	NCT00004893_20_T1	GENE	7	7	interleukin-12
NCT000048951	NCT00004895_1_T0	GENE	2	2	II
NCT000048951	NCT00004895_1_T1	COMPOUND	9	9	octreotide
NCT000048951	NCT00004895_1_T2	PHENOTYPE	19	20	bowel obstruction
NCT000048954	NCT00004895_4_T0	COMPOUND	8	8	octreotide
NCT000048961	NCT00004896_1_T0	CELL	22	22	cells
NCT000048961	NCT00004896_1_T1	ORGAN	4	5	bone marrow
NCT000048964	NCT00004896_4_T0	COMPOUND	5	5	busulfan
NCT000048964	NCT00004896_4_T1	COMPOUND	29	29	2
NCT000048964	NCT00004896_4_T2	COMPOUND	20	20	cyclophosphamide
NCT000048964	NCT00004896_4_T3	GENE	21	21	IV
NCT000048965	NCT00004896_5_T0	ORGAN	1	2	bone marrow
NCT000048966	NCT00004896_6_T0	GENE	4	4	had
NCT000048966	NCT00004896_6_T1	GENE	10	10	IV
NCT000048966	NCT00004896_6_T2	COMPOUND	5	5	1
NCT000048966	NCT00004896_6_T3	COMPOUND	26	26	1
NCT000048966	NCT00004896_6_T4	COMPOUND	9	9	cyclophosphamide
NCT000048966	NCT00004896_6_T5	ORGAN	6	6	transplant
NCT000048966	NCT00004896_6_T6	ORGAN	29	30	bone marrow
NCT000048967	NCT00004896_7_T0	PHENOTYPE	5	8	graft versus host disease
NCT000048972	NCT00004897_2_T0	CELL	8	8	cells
NCT000048972	NCT00004897_2_T1	PHENOTYPE	7	7	tumor
NCT000048973	NCT00004897_3_T0	CELL	19	19	cells
NCT000048973	NCT00004897_3_T1	PHENOTYPE	18	18	tumor
NCT000048973	NCT00004897_3_T2	GENE	9	9	interferon
NCT000048974	NCT00004897_4_T0	GENE	2	2	II
NCT000048974	NCT00004897_4_T1	GENE	28	28	II
NCT000048974	NCT00004897_4_T2	GENE	12	12	interferon
NCT000048974	NCT00004897_4_T3	PHENOTYPE	30	33	stage III esophageal cancer
NCT000048976	NCT00004897_6_T0	COMPOUND	25	25	calcium
NCT000048976	NCT00004897_6_T1	COMPOUND	24	24	leucovorin
NCT000048976	NCT00004897_6_T2	COMPOUND	19	19	cisplatin
NCT000048976	NCT00004897_6_T3	GENE	21	21	interferon
NCT000048976	NCT00004897_6_T4	PHENOTYPE	14	15	esophageal cancer
NCT000048978	NCT00004897_8_T0	PHENOTYPE	1	1	toxicities
NCT0000489710	NCT00004897_10_T0	PHENOTYPE	1	1	relapse
NCT0000489712	NCT00004897_12_T0	PHENOTYPE	9	9	relapse
NCT0000489714	NCT00004897_14_T0	PHENOTYPE	2	2	toxicities
NCT0000489716	NCT00004897_16_T0	PHENOTYPE	1	1	recurrence
NCT0000489720	NCT00004897_20_T0	PHENOTYPE	25	25	tumor
NCT0000489720	NCT00004897_20_T1	PHENOTYPE	28	28	tumor
NCT0000489720	NCT00004897_20_T2	GENE	23	23	nodal
NCT0000489720	NCT00004897_20_T3	TISSUE	14	16	negative surgical margins
NCT0000489722	NCT00004897_22_T0	PHENOTYPE	5	5	complications
NCT0000489722	NCT00004897_22_T1	PHENOTYPE	16	17	blood loss
NCT0000489723	NCT00004897_23_T0	COMPOUND	4	4	calcium
NCT0000489723	NCT00004897_23_T1	GENE	31	31	1.5
NCT0000489723	NCT00004897_23_T2	GENE	16	16	1/6
NCT0000489723	NCT00004897_23_T3	COMPOUND	3	3	leucovorin
NCT0000489723	NCT00004897_23_T4	COMPOUND	17	17	cisplatin
NCT0000489723	NCT00004897_23_T5	GENE	10	10	interferon
NCT0000489723	NCT00004897_23_T6	GENE	5	5	IV
NCT0000489723	NCT00004897_23_T7	GENE	18	18	IV
NCT0000489723	NCT00004897_23_T8	GENE	27	27	IV
NCT0000489724	NCT00004897_24_T0	PHENOTYPE	13	13	toxicity
NCT0000489725	NCT00004897_25_T0	PHENOTYPE	20	20	metastases
NCT0000489725	NCT00004897_25_T1	PHENOTYPE	16	17	esophageal cancer
NCT0000489726	NCT00004897_26_T0	PHENOTYPE	4	5	residual disease
NCT0000489728	NCT00004897_28_T0	COMPOUND	3	3	hydroxyurea
NCT0000489728	NCT00004897_28_T1	GENE	9	9	0.5
NCT0000489728	NCT00004897_28_T2	GENE	16	16	1.5
NCT0000489728	NCT00004897_28_T3	GENE	12	12	IV
NCT0000489729	NCT00004897_29_T0	GENE	8	8	1.5
NCT0000489729	NCT00004897_29_T1	ORGAN	4	4	esophagus
NCT0000489730	NCT00004897_30_T0	PHENOTYPE	13	13	toxicity
NCT000048981	NCT00004898_1_T0	CELL	10	10	cells
NCT0000489811	NCT00004898_11_T0	PHENOTYPE	11	12	lymphoblastic lymphoma
NCT0000489816	NCT00004898_16_T0	COMPOUND	8	8	etoposide
NCT0000489818	NCT00004898_18_T0	COMPOUND	30	30	2
NCT0000489818	NCT00004898_18_T1	COMPOUND	19	19	3
NCT0000489818	NCT00004898_18_T2	COMPOUND	12	12	cyclophosphamide
NCT0000489818	NCT00004898_18_T3	COMPOUND	2	2	etoposide
NCT0000489818	NCT00004898_18_T4	COMPOUND	26	26	etoposide
NCT0000489818	NCT00004898_18_T5	GENE	3	3	IV
NCT0000489818	NCT00004898_18_T6	GENE	13	13	IV
NCT0000489819	NCT00004898_19_T0	CELL	0	3	Peripheral blood stem cells
NCT0000489820	NCT00004898_20_T0	GENE	2	2	filgrastim
NCT0000489820	NCT00004898_20_T1	GENE	3	3	G-CSF
NCT0000489821	NCT00004898_21_T0	COMPOUND	8	8	etoposide
NCT0000489821	NCT00004898_21_T1	GENE	14	14	MTD
NCT0000489822	NCT00004898_22_T0	PHENOTYPE	18	18	toxicity
NCT0000489822	NCT00004898_22_T1	GENE	1	1	MTD
NCT0000489826	NCT00004898_26_T0	PHENOTYPE	18	18	lymphoma
NCT0000489826	NCT00004898_26_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000489826	NCT00004898_26_T2	PHENOTYPE	16	17	high grade
NCT000048991	NCT00004899_1_T0	CELL	8	8	cells
NCT000048991	NCT00004899_1_T1	ORGAN	0	1	Bone marrow
NCT000048992	NCT00004899_2_T0	PHENOTYPE	17	17	peripheral
NCT000048992	NCT00004899_2_T1	CELL	11	11	cells
NCT000048992	NCT00004899_2_T2	GENE	4	4	filgrastim
NCT000048992	NCT00004899_2_T3	ORGAN	14	15	bone marrow
NCT000048992	NCT00004899_2_T4	ORGAN	24	25	immune system
NCT000048992	NCT00004899_2_T5	PHENOTYPE	30	32	effects of chemotherapy
NCT000048995	NCT00004899_5_T0	PHENOTYPE	10	10	remission
NCT000048996	NCT00004899_6_T0	ORGAN	2	3	bone marrow
NCT000048997	NCT00004899_7_T0	COMPOUND	3	3	busulfan
NCT000048997	NCT00004899_7_T1	COMPOUND	16	16	2
NCT000048997	NCT00004899_7_T2	COMPOUND	14	14	3
NCT000048998	NCT00004899_8_T0	COMPOUND	12	12	2
NCT000048998	NCT00004899_8_T1	COMPOUND	10	10	3
NCT000048998	NCT00004899_8_T2	COMPOUND	2	2	etoposide
NCT000048998	NCT00004899_8_T3	GENE	3	3	IV
NCT000048999	NCT00004899_9_T0	COMPOUND	11	11	etoposide
NCT000048999	NCT00004899_9_T1	ORGAN	0	1	Bone marrow
NCT0000489910	NCT00004899_10_T0	GENE	7	7	2.4
NCT0000489910	NCT00004899_10_T1	GENE	2	2	filgrastim
NCT0000489910	NCT00004899_10_T2	GENE	3	3	G-CSF
NCT0000489910	NCT00004899_10_T3	GENE	4	4	IV
NCT0000489910	NCT00004899_10_T4	ORGAN	10	11	bone marrow
NCT000049004	NCT00004900_4_T0	PHENOTYPE	2	2	toxicity
NCT000049004	NCT00004900_4_T1	PHENOTYPE	17	19	metastatic breast cancer
NCT000049006	NCT00004900_6_T0	ORGAN	26	26	autograft
NCT000049006	NCT00004900_6_T1	GENE	13	13	CD34
NCT000049006	NCT00004900_6_T2	GENE	18	18	CD34
NCT000049009	NCT00004900_9_T0	COMPOUND	3	3	cyclophosphamide
NCT000049009	NCT00004900_9_T1	COMPOUND	10	10	etoposide
NCT000049009	NCT00004900_9_T2	COMPOUND	13	13	cisplatin
NCT000049009	NCT00004900_9_T3	GENE	4	4	IV
NCT000049009	NCT00004900_9_T4	GENE	11	11	IV
NCT000049009	NCT00004900_9_T5	GENE	14	14	IV
NCT0000490010	NCT00004900_10_T0	GENE	1	1	G-CSF
NCT0000490011	NCT00004900_11_T0	CELL	3	6	peripheral blood stem cells
NCT0000490012	NCT00004900_12_T0	COMPOUND	10	10	thiotepa
NCT0000490012	NCT00004900_12_T1	COMPOUND	8	8	cyclophosphamide
NCT0000490012	NCT00004900_12_T2	GENE	9	9	IV
NCT0000490012	NCT00004900_12_T3	GENE	11	11	IV
NCT0000490012	NCT00004900_12_T4	GENE	14	14	IV
NCT0000490013	NCT00004900_13_T0	GENE	0	0	CD34
NCT0000490014	NCT00004900_14_T0	GENE	7	7	G-CSF
NCT0000490016	NCT00004900_16_T0	ORGAN	10	10	transplant
NCT0000490016	NCT00004900_16_T1	PHENOTYPE	19	20	disease progression
NCT000049010	NCT00004901_0_T0	PHENOTYPE	10	11	Mouth Cancer
NCT000049012	NCT00004901_2_T0	CELL	8	8	cells
NCT000049012	NCT00004901_2_T1	PHENOTYPE	7	7	tumor
NCT000049013	NCT00004901_3_T0	CELL	13	13	cells
NCT000049013	NCT00004901_3_T1	PHENOTYPE	12	12	tumor
NCT000049014	NCT00004901_4_T0	PHENOTYPE	20	21	mouth cancer
NCT000049016	NCT00004901_6_T0	COMPOUND	7	7	ethynyluracil
NCT000049016	NCT00004901_6_T1	PHENOTYPE	17	18	oral cancer
NCT000049018	NCT00004901_8_T0	PHENOTYPE	8	8	toxicities
NCT000049018	NCT00004901_8_T1	GENE	5	5	MTD
NCT000049019	NCT00004901_9_T0	COMPOUND	10	10	hydroxyurea
NCT0000490110	NCT00004901_10_T0	COMPOUND	3	3	ethynyluracil
NCT0000490110	NCT00004901_10_T1	GENE	9	9	1.7
NCT0000490112	NCT00004901_12_T0	PHENOTYPE	10	10	toxicity
NCT0000490112	NCT00004901_12_T1	GENE	3	3	5.7
NCT0000490113	NCT00004901_13_T0	GENE	14	14	MTD
NCT0000490114	NCT00004901_14_T0	PHENOTYPE	18	18	toxicities
NCT0000490114	NCT00004901_14_T1	GENE	1	1	MTD
NCT0000490115	NCT00004901_15_T0	COMPOUND	7	7	hydroxyurea
NCT0000490115	NCT00004901_15_T1	GENE	2	2	MTD
NCT0000490117	NCT00004901_17_T0	COMPOUND	4	4	hydroxyurea
NCT0000490117	NCT00004901_17_T1	GENE	13	13	1/6
NCT0000490119	NCT00004901_19_T0	COMPOUND	8	8	hydroxyurea
NCT0000490119	NCT00004901_19_T1	GENE	11	11	MTD
NCT0000490121	NCT00004901_21_T0	PHENOTYPE	7	7	toxicity
NCT000049021	NCT00004902_1_T0	GENE	2	2	II
NCT000049021	NCT00004902_1_T1	PHENOTYPE	15	15	recurrent
NCT000049021	NCT00004902_1_T2	PHENOTYPE	17	19	refractory multiple myeloma
NCT000049023	NCT00004902_3_T0	PHENOTYPE	11	11	recurrent
NCT000049023	NCT00004902_3_T1	COMPOUND	5	6	adenosine monophosphate
NCT000049023	NCT00004902_3_T2	PHENOTYPE	13	15	refractory multiple myeloma
NCT000049027	NCT00004902_7_T0	PHENOTYPE	2	2	pharmacokinetics
NCT000049028	NCT00004902_8_T0	COMPOUND	4	5	adenosine monophosphate
NCT000049029	NCT00004902_9_T0	PHENOTYPE	19	20	disease progression
NCT000049036	NCT00004903_6_T0	PHENOTYPE	7	7	toxicities
NCT000049038	NCT00004903_8_T0	COMPOUND	9	9	melphalan
NCT0000490312	NCT00004903_12_T0	PHENOTYPE	4	4	relapse
NCT0000490314	NCT00004903_14_T0	PHENOTYPE	5	5	attributable
NCT0000490314	NCT00004903_14_T1	PHENOTYPE	4	4	toxicities
NCT0000490314	NCT00004903_14_T2	GENE	7	7	interferon
NCT0000490314	NCT00004903_14_T3	GENE	14	14	interferon
NCT0000490316	NCT00004903_16_T0	COMPOUND	2	2	cyclophosphamide
NCT0000490316	NCT00004903_16_T1	GENE	3	3	IV
NCT0000490317	NCT00004903_17_T0	COMPOUND	10	10	cyclophosphamide
NCT0000490317	NCT00004903_17_T1	GENE	1	1	G-CSF
NCT0000490318	NCT00004903_18_T0	CELL	3	6	peripheral blood stem cells
NCT0000490320	NCT00004903_20_T0	COMPOUND	6	6	melphalan
NCT0000490320	NCT00004903_20_T1	GENE	7	7	IV
NCT0000490321	NCT00004903_21_T0	COMPOUND	9	9	melphalan
NCT0000490322	NCT00004903_22_T0	GENE	0	0	G-CSF
NCT0000490323	NCT00004903_23_T0	COMPOUND	11	11	melphalan
NCT0000490323	NCT00004903_23_T1	COMPOUND	17	17	melphalan
NCT0000490323	NCT00004903_23_T2	PHENOTYPE	2	3	in remission
NCT0000490324	NCT00004903_24_T0	GENE	1	1	IV
NCT0000490325	NCT00004903_25_T0	PHENOTYPE	16	16	relapse
NCT0000490325	NCT00004903_25_T1	ORGAN	6	6	transplant
NCT0000490325	NCT00004903_25_T2	GENE	9	9	interferon
NCT000049045	NCT00004904_5_T0	PHENOTYPE	4	4	severity
NCT000049045	NCT00004904_5_T1	PHENOTYPE	6	6	acute
NCT000049045	NCT00004904_5_T2	GENE	26	26	HSC
NCT000049045	NCT00004904_5_T3	PHENOTYPE	10	10	chronic
NCT000049045	NCT00004904_5_T4	CELL	22	22	T-cell
NCT000049045	NCT00004904_5_T5	PHENOTYPE	14	18	graft versus host disease in
NCT000049046	NCT00004904_6_T0	ORGAN	2	3	Bone marrow
NCT000049046	NCT00004904_6_T1	CELL	5	8	peripheral blood stem cells
NCT000049047	NCT00004904_7_T0	CELL	5	5	cells
NCT000049047	NCT00004904_7_T1	CELL	7	7	T-cells
NCT000049047	NCT00004904_7_T2	GENE	4	4	CD34
NCT000049048	NCT00004904_8_T0	PHENOTYPE	0	0	Conditioning
NCT000049048	NCT00004904_8_T1	GENE	10	10	10
NCT000049049	NCT00004904_9_T0	COMPOUND	2	2	cladribine
NCT000049049	NCT00004904_9_T1	COMPOUND	32	32	methylprednisolone
NCT000049049	NCT00004904_9_T2	GENE	25	25	globulin
NCT000049049	NCT00004904_9_T3	GENE	3	3	IV
NCT000049049	NCT00004904_9_T4	GENE	11	11	IV
NCT000049049	NCT00004904_9_T5	GENE	20	20	IV
NCT000049049	NCT00004904_9_T6	GENE	27	27	IV
NCT000049049	NCT00004904_9_T7	GENE	33	33	IV
NCT000049049	NCT00004904_9_T8	COMPOUND	13	13	2
NCT000049049	NCT00004904_9_T9	COMPOUND	22	22	2
NCT000049049	NCT00004904_9_T10	COMPOUND	41	41	2
NCT000049049	NCT00004904_9_T11	COMPOUND	19	19	cyclophosphamide
NCT000049049	NCT00004904_9_T12	COMPOUND	10	10	etoposide
NCT000049049	NCT00004904_9_T13	GENE	7	7	10
NCT0000490410	NCT00004904_10_T0	CELL	1	1	T-cell
NCT0000490410	NCT00004904_10_T1	ORGAN	5	6	bone marrow
NCT0000490411	NCT00004904_11_T0	GENE	2	2	G-CSF
NCT0000490412	NCT00004904_12_T0	COMPOUND	15	15	2
NCT0000490412	NCT00004904_12_T1	COMPOUND	7	7	tacrolimus
NCT0000490412	NCT00004904_12_T2	GENE	8	8	IV
NCT0000490412	NCT00004904_12_T3	PHENOTYPE	0	3	Graft versus host disease
NCT0000490413	NCT00004904_13_T0	COMPOUND	8	8	methylprednisolone
NCT0000490413	NCT00004904_13_T1	COMPOUND	21	21	methylprednisolone
NCT0000490413	NCT00004904_13_T2	GENE	3	3	IV
NCT0000490413	NCT00004904_13_T3	GENE	9	9	IV
NCT000049054	NCT00004905_4_T0	PHENOTYPE	3	3	toxicity
NCT000049054	NCT00004905_4_T1	ORGAN	7	7	transplant
NCT000049054	NCT00004905_4_T2	PHENOTYPE	17	18	acute leukemia
NCT000049054	NCT00004905_4_T3	PHENOTYPE	12	14	chronic myelogenous leukemia
NCT000049056	NCT00004905_6_T0	CELL	26	27	progenitor cells
NCT000049056	NCT00004905_6_T1	CELL	4	7	peripheral blood stem cells
NCT000049058	NCT00004905_8_T0	PHENOTYPE	7	7	peripheral
NCT000049058	NCT00004905_8_T1	PHENOTYPE	17	17	progression
NCT000049058	NCT00004905_8_T2	ORGAN	10	11	bone marrow
NCT0000490510	NCT00004905_10_T0	PHENOTYPE	10	12	acute lymphoblastic leukemia
NCT0000490510	NCT00004905_10_T1	PHENOTYPE	14	16	acute myelogenous leukemia
NCT0000490510	NCT00004905_10_T2	PHENOTYPE	6	8	chronic myelogenous leukemia
NCT0000490511	NCT00004905_11_T0	PHENOTYPE	16	16	5-10
NCT0000490511	NCT00004905_11_T1	COMPOUND	2	2	cytarabine
NCT0000490511	NCT00004905_11_T2	COMPOUND	13	13	idarubicin
NCT0000490511	NCT00004905_11_T3	COMPOUND	7	7	etoposide
NCT0000490511	NCT00004905_11_T4	GENE	3	3	IV
NCT0000490511	NCT00004905_11_T5	GENE	8	8	IV
NCT0000490511	NCT00004905_11_T6	GENE	14	14	IV
NCT0000490512	NCT00004905_12_T0	GENE	5	5	SC
NCT0000490512	NCT00004905_12_T1	GENE	1	1	G-CSF
NCT0000490513	NCT00004905_13_T0	PHENOTYPE	19	19	peripheral
NCT0000490513	NCT00004905_13_T1	CELL	28	28	cells
NCT0000490513	NCT00004905_13_T2	ORGAN	9	10	bone marrow
NCT0000490513	NCT00004905_13_T3	PHENOTYPE	0	2	Chronic myelogenous leukemia
NCT0000490514	NCT00004905_14_T0	CELL	7	7	cells
NCT0000490515	NCT00004905_15_T0	PHENOTYPE	5	6	progressive disease
NCT0000490516	NCT00004905_16_T0	PHENOTYPE	18	18	peripheral
NCT0000490516	NCT00004905_16_T1	CELL	25	25	cells
NCT0000490516	NCT00004905_16_T2	PHENOTYPE	0	1	Acute leukemia
NCT0000490516	NCT00004905_16_T3	ORGAN	8	9	bone marrow
NCT0000490517	NCT00004905_17_T0	PHENOTYPE	7	7	remission
NCT0000490518	NCT00004905_18_T0	GENE	7	7	G-CSF
NCT0000490519	NCT00004905_19_T0	CELL	8	11	peripheral blood stem cells
NCT0000490521	NCT00004905_21_T0	COMPOUND	29	29	2
NCT0000490521	NCT00004905_21_T1	COMPOUND	33	33	2
NCT0000490521	NCT00004905_21_T2	PHENOTYPE	4	4	conditioning
NCT0000490521	NCT00004905_21_T3	COMPOUND	26	26	cyclophosphamide
NCT0000490521	NCT00004905_21_T4	COMPOUND	17	17	etoposide
NCT0000490521	NCT00004905_21_T5	GENE	18	18	IV
NCT0000490521	NCT00004905_21_T6	GENE	27	27	IV
NCT0000490523	NCT00004905_23_T0	GENE	1	1	SC
NCT0000490523	NCT00004905_23_T1	GENE	0	0	G-CSF
NCT0000490524	NCT00004905_24_T0	GENE	7	7	SC
NCT0000490524	NCT00004905_24_T1	GENE	5	5	interferon
NCT000049064	NCT00004906_4_T0	PHENOTYPE	2	2	toxicity
NCT000049064	NCT00004906_4_T1	COMPOUND	10	10	docetaxel
NCT000049064	NCT00004906_4_T2	COMPOUND	12	12	doxorubicin
NCT000049064	NCT00004906_4_T3	PHENOTYPE	18	20	metastatic breast cancer
NCT000049066	NCT00004906_6_T0	PHENOTYPE	2	2	toxicity
NCT000049066	NCT00004906_6_T1	PHENOTYPE	17	19	metastatic breast cancer
NCT0000490610	NCT00004906_10_T0	PHENOTYPE	2	2	toxicity
NCT0000490612	NCT00004906_12_T0	COMPOUND	18	18	docetaxel
NCT0000490612	NCT00004906_12_T1	COMPOUND	13	13	doxorubicin
NCT0000490612	NCT00004906_12_T2	GENE	14	14	IV
NCT0000490612	NCT00004906_12_T3	GENE	19	19	IV
NCT0000490612	NCT00004906_12_T4	PHENOTYPE	6	7	metastatic disease
NCT0000490613	NCT00004906_13_T0	GENE	2	2	filgrastim
NCT0000490613	NCT00004906_13_T1	GENE	3	3	G-CSF
NCT0000490615	NCT00004906_15_T0	COMPOUND	16	16	cyclophosphamide
NCT0000490615	NCT00004906_15_T1	COMPOUND	22	22	etoposide
NCT0000490615	NCT00004906_15_T2	COMPOUND	25	25	cisplatin
NCT0000490615	NCT00004906_15_T3	GENE	17	17	IV
NCT0000490615	NCT00004906_15_T4	GENE	23	23	IV
NCT0000490615	NCT00004906_15_T5	GENE	26	26	IV
NCT0000490616	NCT00004906_16_T0	GENE	9	9	G-CSF
NCT0000490616	NCT00004906_16_T1	CELL	18	21	peripheral blood stem cells
NCT0000490617	NCT00004906_17_T0	COMPOUND	12	12	thiotepa
NCT0000490617	NCT00004906_17_T1	COMPOUND	10	10	cyclophosphamide
NCT0000490617	NCT00004906_17_T2	GENE	11	11	IV
NCT0000490617	NCT00004906_17_T3	GENE	13	13	IV
NCT0000490617	NCT00004906_17_T4	GENE	16	16	IV
NCT0000490618	NCT00004906_18_T0	GENE	13	13	G-CSF
NCT0000490618	NCT00004906_18_T1	GENE	2	2	CD34
NCT0000490619	NCT00004906_19_T0	COMPOUND	22	22	anastrozole
NCT0000490619	NCT00004906_19_T1	PHENOTYPE	25	26	disease progression
NCT0000490620	NCT00004906_20_T0	COMPOUND	6	6	pamidronate
NCT0000490620	NCT00004906_20_T1	GENE	7	7	IV
NCT000049071	NCT00004907_1_T0	CELL	8	8	cells
NCT000049075	NCT00004907_5_T0	ORGAN	8	9	bone marrow
NCT000049075	NCT00004907_5_T1	CELL	11	14	peripheral blood stem cells
NCT000049077	NCT00004907_7_T0	GENE	55	55	PR
NCT000049077	NCT00004907_7_T1	GENE	10	10	IV
NCT000049077	NCT00004907_7_T2	GENE	22	22	IV
NCT000049077	NCT00004907_7_T3	GENE	74	74	IV
NCT000049077	NCT00004907_7_T4	GENE	53	53	CR
NCT000049077	NCT00004907_7_T5	COMPOUND	62	62	busulfan
NCT000049077	NCT00004907_7_T6	COMPOUND	12	12	1
NCT000049077	NCT00004907_7_T7	COMPOUND	41	41	1
NCT000049077	NCT00004907_7_T8	COMPOUND	76	76	1
NCT000049077	NCT00004907_7_T9	COMPOUND	82	82	2
NCT000049077	NCT00004907_7_T10	COMPOUND	80	80	3
NCT000049077	NCT00004907_7_T11	COMPOUND	9	9	cyclophosphamide
NCT000049077	NCT00004907_7_T12	COMPOUND	73	73	cyclophosphamide
NCT000049077	NCT00004907_7_T13	COMPOUND	21	21	etoposide
NCT000049077	NCT00004907_7_T14	PHENOTYPE	43	44	Group B
NCT000049078	NCT00004907_8_T0	GENE	22	22	IV
NCT000049078	NCT00004907_8_T1	GENE	34	34	IV
NCT000049078	NCT00004907_8_T2	COMPOUND	10	10	busulfan
NCT000049078	NCT00004907_8_T3	COMPOUND	41	41	3
NCT000049078	NCT00004907_8_T4	COMPOUND	21	21	cyclophosphamide
NCT000049078	NCT00004907_8_T5	COMPOUND	33	33	etoposide
NCT000049078	NCT00004907_8_T6	ORGAN	45	46	Bone marrow
NCT000049079	NCT00004907_9_T0	GENE	8	8	cm
NCT000049079	NCT00004907_9_T1	GENE	3	3	nodal
NCT0000490712	NCT00004907_12_T0	PHENOTYPE	18	18	lymphoma
NCT0000490712	NCT00004907_12_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000490712	NCT00004907_12_T2	PHENOTYPE	16	17	high grade
NCT000049081	NCT00004908_1_T0	CELL	10	10	cells
NCT000049088	NCT00004908_8_T0	GENE	8	8	16
NCT000049089	NCT00004908_9_T0	COMPOUND	2	2	cyclophosphamide
NCT000049089	NCT00004908_9_T1	GENE	3	3	IV
NCT0000490810	NCT00004908_10_T0	COMPOUND	11	11	1
NCT0000490811	NCT00004908_11_T0	CELL	1	4	peripheral blood stem cells
NCT0000490814	NCT00004908_14_T0	PHENOTYPE	18	18	lymphoma
NCT0000490814	NCT00004908_14_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000490814	NCT00004908_14_T2	PHENOTYPE	16	17	high grade
NCT000049091	NCT00004909_1_T0	PHENOTYPE	6	8	effects of chemotherapy
NCT000049091	NCT00004909_1_T1	PHENOTYPE	18	20	quality of life
NCT000049091	NCT00004909_1_T2	PHENOTYPE	24	27	recurrent ovarian epithelial cancer
NCT000049093	NCT00004909_3_T0	PHENOTYPE	12	12	QOL
NCT000049093	NCT00004909_3_T1	PHENOTYPE	9	11	quality of life
NCT000049093	NCT00004909_3_T2	PHENOTYPE	16	19	recurrent ovarian epithelial cancer
NCT000049095	NCT00004909_5_T0	PHENOTYPE	2	2	QOL
NCT000049097	NCT00004909_7_T0	PHENOTYPE	5	5	symptoms
NCT000049097	NCT00004909_7_T1	PHENOTYPE	15	15	QOL
NCT000049097	NCT00004909_7_T2	PHENOTYPE	6	8	treatment side effects
NCT000049098	NCT00004909_8_T0	PHENOTYPE	8	8	QOL
NCT000049098	NCT00004909_8_T1	PHENOTYPE	24	25	recurrent disease
NCT000049098	NCT00004909_8_T2	PHENOTYPE	5	7	quality of life
NCT000049099	NCT00004909_9_T0	GENE	8	8	IV
NCT0000490910	NCT00004909_10_T0	PHENOTYPE	0	0	QOL
NCT0000490912	NCT00004909_12_T0	PHENOTYPE	2	2	withdrawn
NCT0000490912	NCT00004909_12_T1	GENE	13	13	IV
NCT0000490912	NCT00004909_12_T2	GENE	16	16	IV
NCT000049100	NCT00004910_0_T0	PHENOTYPE	9	9	Cancer
NCT000049100	NCT00004910_0_T1	PHENOTYPE	11	12	Duodenal Obstruction
NCT000049102	NCT00004910_2_T0	PHENOTYPE	20	20	obstruction
NCT000049102	NCT00004910_2_T1	ORGAN	23	23	duodenum
NCT000049104	NCT00004910_4_T0	ORGAN	14	14	duodenum
NCT000049105	NCT00004910_5_T0	PHENOTYPE	0	2	Quality of life
NCT000049110	NCT00004911_0_T0	PHENOTYPE	9	10	Bowel Obstruction
NCT000049112	NCT00004911_2_T0	PHENOTYPE	21	22	bowel obstruction
NCT000049114	NCT00004911_4_T0	ORGAN	21	22	large intestine
NCT000049115	NCT00004911_5_T0	PHENOTYPE	0	2	Quality of life
NCT000049120	NCT00004912_0_T0	PHENOTYPE	8	9	Weight Loss
NCT000049122	NCT00004912_2_T0	PHENOTYPE	3	4	cancer fatigue
NCT000049122	NCT00004912_2_T1	TISSUE	11	12	muscle tissue
NCT000049123	NCT00004912_3_T0	COMPOUND	2	2	megestrol
NCT000049123	NCT00004912_3_T1	PHENOTYPE	9	10	weight loss
NCT000049124	NCT00004912_4_T0	GENE	2	2	II
NCT000049124	NCT00004912_4_T1	PHENOTYPE	23	23	fatigue
NCT000049124	NCT00004912_4_T2	COMPOUND	9	9	megestrol
NCT000049124	NCT00004912_4_T3	PHENOTYPE	29	30	weight loss
NCT000049126	NCT00004912_6_T0	PHENOTYPE	20	20	fatigue
NCT000049126	NCT00004912_6_T1	PHENOTYPE	29	29	malignancy
NCT000049126	NCT00004912_6_T2	COMPOUND	4	4	megestrol
NCT000049126	NCT00004912_6_T3	PHENOTYPE	6	6	progressive
NCT000049126	NCT00004912_6_T4	PHENOTYPE	24	25	weight loss
NCT000049128	NCT00004912_8_T0	COMPOUND	3	3	megestrol
NCT000049129	NCT00004912_9_T0	PHENOTYPE	3	3	progressive
NCT0000491210	NCT00004912_10_T0	PHENOTYPE	10	10	toxicity
NCT0000491210	NCT00004912_10_T1	PHENOTYPE	12	12	progressive
NCT0000491210	NCT00004912_10_T2	PHENOTYPE	13	14	weight loss
NCT000049130	NCT00004913_0_T0	PHENOTYPE	7	8	Solid Tumors
NCT000049132	NCT00004913_2_T0	CELL	9	9	cells
NCT000049132	NCT00004913_2_T1	PHENOTYPE	8	8	tumor
NCT000049133	NCT00004913_3_T0	PHENOTYPE	17	18	solid tumors
NCT000049135	NCT00004913_5_T0	COMPOUND	15	15	calcium
NCT000049135	NCT00004913_5_T1	COMPOUND	6	6	docetaxel
NCT000049135	NCT00004913_5_T2	COMPOUND	14	14	leucovorin
NCT000049135	NCT00004913_5_T3	COMPOUND	11	11	cisplatin
NCT000049135	NCT00004913_5_T4	PHENOTYPE	20	21	solid tumors
NCT000049137	NCT00004913_7_T0	PHENOTYPE	2	2	toxicities
NCT0000491310	NCT00004913_10_T0	COMPOUND	8	8	docetaxel
NCT0000491311	NCT00004913_11_T0	COMPOUND	20	20	calcium
NCT0000491311	NCT00004913_11_T1	COMPOUND	2	2	docetaxel
NCT0000491311	NCT00004913_11_T2	GENE	29	29	1.5
NCT0000491311	NCT00004913_11_T3	COMPOUND	19	19	leucovorin
NCT0000491311	NCT00004913_11_T4	COMPOUND	10	10	cisplatin
NCT0000491311	NCT00004913_11_T5	GENE	3	3	IV
NCT0000491311	NCT00004913_11_T6	GENE	11	11	IV
NCT0000491311	NCT00004913_11_T7	GENE	21	21	IV
NCT0000491311	NCT00004913_11_T8	GENE	26	26	IV
NCT0000491312	NCT00004913_12_T0	PHENOTYPE	9	10	disease progression
NCT0000491313	NCT00004913_13_T0	COMPOUND	8	8	docetaxel
NCT0000491313	NCT00004913_13_T1	GENE	2	2	3.5
NCT0000491313	NCT00004913_13_T2	GENE	16	16	MTD
NCT0000491314	NCT00004913_14_T0	PHENOTYPE	24	24	toxicity
NCT0000491314	NCT00004913_14_T1	GENE	1	1	MTD
NCT000049141	NCT00004914_1_T0	PHENOTYPE	6	6	anemia
NCT000049141	NCT00004914_1_T1	PHENOTYPE	10	12	quality of life
NCT000049142	NCT00004914_2_T0	PHENOTYPE	10	10	fatigue
NCT000049142	NCT00004914_2_T1	GENE	2	2	epoetin
NCT000049142	NCT00004914_2_T2	PHENOTYPE	9	9	anemia
NCT000049143	NCT00004914_3_T0	GENE	2	2	II
NCT000049143	NCT00004914_3_T1	PHENOTYPE	20	20	fatigue
NCT000049143	NCT00004914_3_T2	GENE	11	11	epoetin
NCT000049143	NCT00004914_3_T3	PHENOTYPE	19	19	anemia
NCT000049145	NCT00004914_5_T0	PHENOTYPE	14	14	fatigue
NCT000049145	NCT00004914_5_T1	PHENOTYPE	29	29	fatigue
NCT000049145	NCT00004914_5_T2	GENE	8	8	epoetin
NCT000049145	NCT00004914_5_T3	PHENOTYPE	4	4	progressive
NCT000049145	NCT00004914_5_T4	PHENOTYPE	16	16	tolerance
NCT000049145	NCT00004914_5_T5	PHENOTYPE	27	27	anemia
NCT000049147	NCT00004914_7_T0	GENE	15	15	PRT
NCT000049148	NCT00004914_8_T0	GENE	2	2	PRT
NCT000049149	NCT00004914_9_T0	PHENOTYPE	16	16	toxicity
NCT000049149	NCT00004914_9_T1	GENE	3	3	epoetin
NCT000049151	NCT00004915_1_T0	COMPOUND	13	13	estrogen
NCT000049151	NCT00004915_1_T1	COMPOUND	3	3	raloxifene
NCT000049151	NCT00004915_1_T2	PHENOTYPE	6	7	endometrial cancer
NCT000049152	NCT00004915_2_T0	GENE	2	2	II
NCT000049152	NCT00004915_2_T1	COMPOUND	9	9	raloxifene
NCT000049152	NCT00004915_2_T2	PHENOTYPE	17	19	recurrent endometrial cancer
NCT000049154	NCT00004915_4_T0	COMPOUND	16	16	raloxifene
NCT000049154	NCT00004915_4_T1	PHENOTYPE	6	7	disease progression
NCT000049154	NCT00004915_4_T2	PHENOTYPE	11	13	recurrent endometrial cancer
NCT000049158	NCT00004915_8_T0	PHENOTYPE	2	2	toxicity
NCT000049158	NCT00004915_8_T1	COMPOUND	4	4	raloxifene
NCT000049159	NCT00004915_9_T0	COMPOUND	4	4	raloxifene
NCT0000491510	NCT00004915_10_T0	PHENOTYPE	11	11	toxicity
NCT0000491510	NCT00004915_10_T1	PHENOTYPE	7	8	disease progression
NCT000049161	NCT00004916_1_T0	CELL	9	9	cells
NCT000049162	NCT00004916_2_T0	COMPOUND	12	12	paclitaxel
NCT000049162	NCT00004916_2_T1	COMPOUND	9	9	ifosfamide
NCT000049162	NCT00004916_2_T2	COMPOUND	10	10	teniposide
NCT000049162	NCT00004916_2_T3	PHENOTYPE	19	20	Hodgkin's lymphoma
NCT000049164	NCT00004916_4_T0	COMPOUND	8	8	teniposide
NCT000049166	NCT00004916_6_T0	COMPOUND	25	25	paclitaxel
NCT000049166	NCT00004916_6_T1	COMPOUND	2	2	ifosfamide
NCT000049166	NCT00004916_6_T2	GENE	5	5	1.2
NCT000049166	NCT00004916_6_T3	COMPOUND	13	13	teniposide
NCT000049166	NCT00004916_6_T4	GENE	9	9	1.3
NCT000049166	NCT00004916_6_T5	GENE	3	3	IV
NCT000049166	NCT00004916_6_T6	GENE	14	14	IV
NCT000049166	NCT00004916_6_T7	GENE	26	26	IV
NCT000049169	NCT00004916_9_T0	ORGAN	12	13	autologous transplant
NCT000049169	NCT00004916_9_T1	CELL	0	3	Peripheral blood stem cells
NCT0000491610	NCT00004916_10_T0	ORGAN	14	14	transplant
NCT0000491610	NCT00004916_10_T1	ORGAN	0	0	Transplant
NCT0000491611	NCT00004916_11_T0	COMPOUND	8	8	teniposide
NCT0000491611	NCT00004916_11_T1	GENE	2	2	3.5
NCT0000491611	NCT00004916_11_T2	GENE	14	14	MTD
NCT0000491612	NCT00004916_12_T0	PHENOTYPE	22	22	toxicities
NCT0000491612	NCT00004916_12_T1	GENE	1	1	MTD
NCT0000491616	NCT00004916_16_T0	PHENOTYPE	18	18	lymphoma
NCT0000491616	NCT00004916_16_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000491616	NCT00004916_16_T2	PHENOTYPE	16	17	high grade
NCT000049170	NCT00004917_0_T0	PHENOTYPE	12	15	Head and Neck Cancer
NCT000049173	NCT00004917_3_T0	GENE	10	10	epoetin
NCT000049173	NCT00004917_3_T1	PHENOTYPE	24	27	head and neck cancer
NCT000049174	NCT00004917_4_T0	GENE	3	3	III
NCT000049174	NCT00004917_4_T1	GENE	15	15	epoetin
NCT000049174	NCT00004917_4_T2	PHENOTYPE	23	26	head and neck cancer
NCT000049178	NCT00004917_8_T0	GENE	22	22	11.5
NCT000049178	NCT00004917_8_T1	GENE	25	25	11.5
NCT000049178	NCT00004917_8_T2	GENE	18	18	9.0
NCT000049178	NCT00004917_8_T3	GENE	27	27	13.5
NCT000049178	NCT00004917_8_T4	PHENOTYPE	16	17	hemoglobin level
NCT0000491711	NCT00004917_11_T0	GENE	7	7	epoetin
NCT0000491711	NCT00004917_11_T1	GENE	1	1	7-10
NCT0000491712	NCT00004917_12_T0	GENE	11	11	1.2
NCT0000491712	NCT00004917_12_T1	COMPOUND	8	8	cisplatin
NCT0000491712	NCT00004917_12_T2	GENE	9	9	IV
NCT000049183	NCT00004918_3_T0	PHENOTYPE	3	3	toxicity
NCT000049183	NCT00004918_3_T1	PHENOTYPE	12	12	leukemia
NCT000049183	NCT00004918_3_T2	GENE	9	9	PR1
NCT000049183	NCT00004918_3_T3	GENE	11	11	PR1
NCT000049183	NCT00004918_3_T4	BIOLOGICAL_PROCESS	5	6	immune response
NCT000049185	NCT00004918_5_T0	GENE	18	18	VG
NCT000049185	NCT00004918_5_T1	GENE	12	12	ISA
NCT000049185	NCT00004918_5_T2	GENE	16	16	ISA
NCT000049185	NCT00004918_5_T3	GENE	6	6	PR1
NCT000049185	NCT00004918_5_T4	PHENOTYPE	26	27	myeloid leukemias
NCT000049186	NCT00004918_6_T0	GENE	17	17	II
NCT000049186	NCT00004918_6_T1	PHENOTYPE	10	10	leukemia
NCT000049186	NCT00004918_6_T2	GENE	9	9	PR1
NCT000049187	NCT00004918_7_T0	GENE	11	11	SC
NCT000049187	NCT00004918_7_T1	PHENOTYPE	3	3	leukemia
NCT000049187	NCT00004918_7_T2	GENE	2	2	PR1
NCT000049188	NCT00004918_8_T0	GENE	5	5	SC
NCT000049188	NCT00004918_8_T1	GENE	4	4	GM-CSF
NCT000049188	NCT00004918_8_T2	GENE	3	3	sargramostim
NCT000049189	NCT00004918_9_T0	PHENOTYPE	9	9	leukemia
NCT000049189	NCT00004918_9_T1	GENE	17	17	MTD
NCT000049189	NCT00004918_9_T2	GENE	8	8	PR1
NCT0000491810	NCT00004918_10_T0	PHENOTYPE	17	17	toxicity
NCT0000491810	NCT00004918_10_T1	GENE	1	1	MTD
NCT0000491811	NCT00004918_11_T0	GENE	7	7	II
NCT0000491811	NCT00004918_11_T1	PHENOTYPE	24	24	leukemia
NCT0000491811	NCT00004918_11_T2	GENE	23	23	PR1
NCT0000491815	NCT00004918_15_T0	COMPOUND	13	14	I dose
NCT000049191	NCT00004919_1_T0	CELL	8	8	cells
NCT000049191	NCT00004919_1_T1	COMPOUND	4	4	amifostine
NCT000049191	NCT00004919_1_T2	PHENOTYPE	12	14	effects of chemotherapy
NCT000049192	NCT00004919_2_T0	COMPOUND	8	8	irinotecan
NCT000049192	NCT00004919_2_T1	COMPOUND	14	14	amifostine
NCT000049192	NCT00004919_2_T2	COMPOUND	10	10	cisplatin
NCT000049192	NCT00004919_2_T3	PHENOTYPE	20	21	solid tumors
NCT000049194	NCT00004919_4_T0	COMPOUND	7	7	irinotecan
NCT000049194	NCT00004919_4_T1	COMPOUND	15	15	amifostine
NCT000049194	NCT00004919_4_T2	GENE	5	5	MTD
NCT000049194	NCT00004919_4_T3	COMPOUND	11	11	cisplatin
NCT000049194	NCT00004919_4_T4	PHENOTYPE	20	21	solid tumors
NCT000049196	NCT00004919_6_T0	COMPOUND	9	9	irinotecan
NCT000049196	NCT00004919_6_T1	PHENOTYPE	4	4	toxicities
NCT000049196	NCT00004919_6_T2	COMPOUND	15	15	amifostine
NCT000049196	NCT00004919_6_T3	COMPOUND	11	11	cisplatin
NCT000049198	NCT00004919_8_T0	PHENOTYPE	2	2	pharmacokinetics
NCT000049198	NCT00004919_8_T1	COMPOUND	8	8	amifostine
NCT000049198	NCT00004919_8_T2	COMPOUND	4	4	cisplatin
NCT0000491912	NCT00004919_12_T0	GENE	17	17	II
NCT0000491913	NCT00004919_13_T0	COMPOUND	8	8	irinotecan
NCT0000491914	NCT00004919_14_T0	COMPOUND	12	12	irinotecan
NCT0000491914	NCT00004919_14_T1	COMPOUND	4	4	cisplatin
NCT0000491914	NCT00004919_14_T2	GENE	5	5	IV
NCT0000491914	NCT00004919_14_T3	GENE	13	13	IV
NCT0000491916	NCT00004919_16_T0	PHENOTYPE	13	13	toxicity
NCT0000491916	NCT00004919_16_T1	PHENOTYPE	15	16	disease progression
NCT0000491918	NCT00004919_18_T0	COMPOUND	2	2	amifostine
NCT0000491918	NCT00004919_18_T1	COMPOUND	11	11	cisplatin
NCT0000491918	NCT00004919_18_T2	GENE	3	3	IV
NCT0000491919	NCT00004919_19_T0	COMPOUND	8	8	irinotecan
NCT0000491919	NCT00004919_19_T1	GENE	14	14	MTD
NCT0000491920	NCT00004919_20_T0	PHENOTYPE	22	22	toxicities
NCT0000491920	NCT00004919_20_T1	GENE	1	1	MTD
NCT0000491921	NCT00004919_21_T0	GENE	2	2	MTD
NCT0000491921	NCT00004919_21_T1	GENE	15	15	MTD
NCT0000491922	NCT00004919_22_T0	PHENOTYPE	6	6	toxicity
NCT000049201	NCT00004920_1_T0	COMPOUND	9	9	raltitrexed
NCT000049201	NCT00004920_1_T1	COMPOUND	7	7	cisplatin
NCT000049201	NCT00004920_1_T2	COMPOUND	14	14	cisplatin
NCT000049201	NCT00004920_1_T3	PHENOTYPE	17	18	malignant mesothelioma
NCT000049202	NCT00004920_2_T0	GENE	3	3	III
NCT000049202	NCT00004920_2_T1	COMPOUND	14	14	raltitrexed
NCT000049202	NCT00004920_2_T2	COMPOUND	10	10	cisplatin
NCT000049202	NCT00004920_2_T3	PHENOTYPE	20	24	malignant mesothelioma of the pleura
NCT000049205	NCT00004920_5_T0	GENE	9	9	1.2
NCT000049205	NCT00004920_5_T1	GENE	11	11	WBC
NCT000049207	NCT00004920_7_T0	PHENOTYPE	13	13	toxicity
NCT000049207	NCT00004920_7_T1	PHENOTYPE	9	10	disease progression
NCT000049208	NCT00004920_8_T0	PHENOTYPE	0	2	Quality of life
NCT000049211	NCT00004921_1_T0	CELL	9	9	cells
NCT000049211	NCT00004921_1_T1	PHENOTYPE	8	8	tumor
NCT000049212	NCT00004921_2_T0	PHENOTYPE	12	14	ovarian epithelial cancer
NCT000049213	NCT00004921_3_T0	GENE	4	4	III
NCT000049213	NCT00004921_3_T1	GENE	33	33	has
NCT000049213	NCT00004921_3_T2	PHENOTYPE	24	25	stage III
NCT000049213	NCT00004921_3_T3	PHENOTYPE	27	31	stage IV ovarian epithelial cancer
NCT0000492111	NCT00004921_11_T0	COMPOUND	5	5	epirubicin
NCT0000492111	NCT00004921_11_T1	COMPOUND	3	3	doxorubicin
NCT0000492112	NCT00004921_12_T0	PHENOTYPE	0	2	Quality of life
NCT000049221	NCT00004922_1_T0	GENE	2	2	II
NCT000049221	NCT00004922_1_T1	COMPOUND	9	9	irinotecan
NCT000049221	NCT00004922_1_T2	PHENOTYPE	16	17	neuroendocrine tumors
NCT000049223	NCT00004922_3_T0	COMPOUND	3	3	irinotecan
NCT000049223	NCT00004922_3_T1	GENE	4	4	IV
NCT000049224	NCT00004922_4_T0	PHENOTYPE	13	13	toxicity
NCT000049224	NCT00004922_4_T1	PHENOTYPE	9	10	disease progression
NCT000049230	NCT00004923_0_T0	PHENOTYPE	8	9	Solid Tumors
NCT000049232	NCT00004923_2_T0	CELL	9	9	cells
NCT000049232	NCT00004923_2_T1	PHENOTYPE	8	8	tumor
NCT000049233	NCT00004923_3_T0	COMPOUND	11	11	irinotecan
NCT000049233	NCT00004923_3_T1	COMPOUND	9	9	docetaxel
NCT000049233	NCT00004923_3_T2	PHENOTYPE	18	19	solid tumors
NCT000049235	NCT00004923_5_T0	COMPOUND	6	6	irinotecan
NCT000049235	NCT00004923_5_T1	COMPOUND	10	10	docetaxel
NCT000049235	NCT00004923_5_T2	PHENOTYPE	16	16	malignancies
NCT000049237	NCT00004923_7_T0	PHENOTYPE	4	4	toxicity
NCT0000492310	NCT00004923_10_T0	COMPOUND	9	9	irinotecan
NCT0000492311	NCT00004923_11_T0	COMPOUND	10	10	irinotecan
NCT0000492311	NCT00004923_11_T1	COMPOUND	2	2	docetaxel
NCT0000492311	NCT00004923_11_T2	GENE	3	3	IV
NCT0000492311	NCT00004923_11_T3	GENE	11	11	IV
NCT0000492312	NCT00004923_12_T0	PHENOTYPE	13	13	toxicity
NCT0000492312	NCT00004923_12_T1	PHENOTYPE	9	10	disease progression
NCT0000492313	NCT00004923_13_T0	COMPOUND	8	8	irinotecan
NCT0000492313	NCT00004923_13_T1	GENE	14	14	MTD
NCT0000492314	NCT00004923_14_T0	PHENOTYPE	18	18	toxicity
NCT0000492314	NCT00004923_14_T1	GENE	1	1	MTD
NCT000049242	NCT00004924_2_T0	CELL	9	9	cells
NCT000049242	NCT00004924_2_T1	PHENOTYPE	8	8	tumor
NCT000049245	NCT00004924_5_T0	COMPOUND	3	3	paclitaxel
NCT000049245	NCT00004924_5_T1	COMPOUND	11	11	irinotecan
NCT000049245	NCT00004924_5_T2	GENE	4	4	IV
NCT000049245	NCT00004924_5_T3	GENE	12	12	IV
NCT000049247	NCT00004924_7_T0	PHENOTYPE	14	14	toxicity
NCT000049247	NCT00004924_7_T1	PHENOTYPE	10	11	disease progression
NCT000049252	NCT00004925_2_T0	COMPOUND	10	10	doxorubicin
NCT000049252	NCT00004925_2_T1	PHENOTYPE	22	24	metastatic breast cancer
NCT000049255	NCT00004925_5_T0	COMPOUND	3	3	HCl
NCT000049255	NCT00004925_5_T1	COMPOUND	2	2	doxorubicin
NCT000049255	NCT00004925_5_T2	GENE	5	5	IV
NCT000049255	NCT00004925_5_T3	GENE	16	16	IV
NCT000049256	NCT00004925_6_T0	PHENOTYPE	10	10	toxicity
NCT000049256	NCT00004925_6_T1	PHENOTYPE	12	13	disease progression
NCT000049261	NCT00004926_1_T0	PHENOTYPE	15	16	solid tumors
NCT000049263	NCT00004926_3_T0	GENE	8	8	II
NCT000049263	NCT00004926_3_T1	PHENOTYPE	16	17	solid tumors
NCT000049265	NCT00004926_5_T0	PHENOTYPE	6	6	toxicities
NCT0000492610	NCT00004926_10_T0	PHENOTYPE	13	13	toxicity
NCT0000492610	NCT00004926_10_T1	PHENOTYPE	9	10	disease progression
NCT0000492611	NCT00004926_11_T0	GENE	14	14	MTD
NCT0000492612	NCT00004926_12_T0	PHENOTYPE	22	22	toxicity
NCT0000492612	NCT00004926_12_T1	GENE	1	1	MTD
NCT000049271	NCT00004927_1_T0	PHENOTYPE	16	17	solid tumors
NCT000049273	NCT00004927_3_T0	GENE	13	13	II
NCT000049273	NCT00004927_3_T1	PHENOTYPE	7	7	toxicities
NCT000049273	NCT00004927_3_T2	PHENOTYPE	30	31	solid tumors
NCT000049275	NCT00004927_5_T0	PHENOTYPE	3	3	pharmacokinetics
NCT000049275	NCT00004927_5_T1	ORGAN	2	2	plasma
NCT000049279	NCT00004927_9_T0	GENE	3	3	IV
NCT0000492710	NCT00004927_10_T0	PHENOTYPE	13	13	toxicity
NCT0000492710	NCT00004927_10_T1	PHENOTYPE	15	16	disease progression
NCT0000492711	NCT00004927_11_T0	GENE	14	14	MTD
NCT0000492712	NCT00004927_12_T0	PHENOTYPE	22	22	toxicities
NCT0000492712	NCT00004927_12_T1	GENE	1	1	MTD
NCT000049285	NCT00004928_5_T0	COMPOUND	7	7	calcitriol
NCT000049286	NCT00004928_6_T0	COMPOUND	3	3	calcitriol
NCT000049286	NCT00004928_6_T1	GENE	11	11	IV
NCT000049287	NCT00004928_7_T0	PHENOTYPE	7	7	toxicity
NCT000049287	NCT00004928_7_T1	PHENOTYPE	9	10	disease progression
NCT000049288	NCT00004928_8_T0	COMPOUND	8	8	calcitriol
NCT000049288	NCT00004928_8_T1	GENE	14	14	MTD
NCT000049289	NCT00004928_9_T0	PHENOTYPE	21	21	toxicity
NCT000049289	NCT00004928_9_T1	GENE	1	1	MTD
NCT0000492910	NCT00004929_10_T0	GENE	22	22	1.3
NCT0000492910	NCT00004929_10_T1	GENE	10	10	limpet
NCT0000492910	NCT00004929_10_T2	GENE	6	6	MUC-2
NCT0000492911	NCT00004929_11_T0	PHENOTYPE	11	12	disease progression
NCT000049301	NCT00004930_1_T0	COMPOUND	10	10	doxorubicin
NCT000049301	NCT00004930_1_T1	PHENOTYPE	17	18	lung cancer
NCT000049301	NCT00004930_1_T2	PHENOTYPE	20	21	lung metastases
NCT000049304	NCT00004930_4_T0	COMPOUND	3	3	doxorubicin
NCT000049305	NCT00004930_5_T0	PHENOTYPE	13	13	toxicity
NCT000049305	NCT00004930_5_T1	PHENOTYPE	15	16	disease progression
NCT000049307	NCT00004930_7_T0	COMPOUND	8	8	doxorubicin
NCT000049307	NCT00004930_7_T1	GENE	14	14	MTD
NCT000049308	NCT00004930_8_T0	PHENOTYPE	21	21	toxicity
NCT000049308	NCT00004930_8_T1	GENE	1	1	MTD
NCT000049312	NCT00004931_2_T0	CELL	10	10	cells
NCT000049312	NCT00004931_2_T1	PHENOTYPE	9	9	tumor
NCT000049313	NCT00004931_3_T0	CELL	9	9	cells
NCT000049313	NCT00004931_3_T1	PHENOTYPE	8	8	tumor
NCT0000493110	NCT00004931_10_T0	COMPOUND	5	5	calcium
NCT0000493110	NCT00004931_10_T1	COMPOUND	19	19	calcium
NCT0000493110	NCT00004931_10_T2	GENE	0	0	ARM
NCT0000493110	NCT00004931_10_T3	COMPOUND	4	4	leucovorin
NCT0000493110	NCT00004931_10_T4	COMPOUND	18	18	leucovorin
NCT0000493110	NCT00004931_10_T5	GENE	6	6	IV
NCT0000493110	NCT00004931_10_T6	GENE	12	12	IV
NCT000049321	NCT00004932_1_T0	PHENOTYPE	17	17	leukemia
NCT000049321	NCT00004932_1_T1	COMPOUND	9	9	imatinib
NCT000049321	NCT00004932_1_T2	COMPOUND	10	10	mesylate
NCT000049321	NCT00004932_1_T3	PHENOTYPE	16	16	recurrent
NCT000049324	NCT00004932_4_T0	COMPOUND	3	3	imatinib
NCT000049324	NCT00004932_4_T1	COMPOUND	4	4	mesylate
NCT000049325	NCT00004932_5_T0	PHENOTYPE	7	7	toxicity
NCT000049325	NCT00004932_5_T1	PHENOTYPE	9	10	disease progression
NCT000049326	NCT00004932_6_T0	GENE	14	14	MTD
NCT000049327	NCT00004932_7_T0	PHENOTYPE	23	23	toxicity
NCT000049327	NCT00004932_7_T1	GENE	1	1	MTD
NCT000049329	NCT00004932_9_T0	GENE	14	14	3.5
NCT000049331	NCT00004933_1_T0	COMPOUND	6	6	homoharringtonine
NCT000049331	NCT00004933_1_T1	GENE	21	21	interferon
NCT000049331	NCT00004933_1_T2	COMPOUND	11	11	hydroxyurea
NCT000049331	NCT00004933_1_T3	GENE	17	17	has
NCT000049331	NCT00004933_1_T4	PHENOTYPE	13	15	chronic myelogenous leukemia
NCT000049332	NCT00004933_2_T0	GENE	3	3	III
NCT000049332	NCT00004933_2_T1	COMPOUND	10	10	homoharringtonine
NCT000049332	NCT00004933_2_T2	GENE	28	28	interferon
NCT000049332	NCT00004933_2_T3	COMPOUND	14	14	hydroxyurea
NCT000049332	NCT00004933_2_T4	GENE	24	24	has
NCT000049332	NCT00004933_2_T5	PHENOTYPE	20	22	chronic myelogenous leukemia
NCT000049334	NCT00004933_4_T0	COMPOUND	19	19	hydroxyurea
NCT000049334	NCT00004933_4_T1	COMPOUND	14	14	homoharringtonine
NCT000049334	NCT00004933_4_T2	GENE	5	5	interferon
NCT000049334	NCT00004933_4_T3	PHENOTYPE	7	10	refractory chronic myelogenous leukemia
NCT000049336	NCT00004933_6_T0	PHENOTYPE	4	4	progression
NCT0000493313	NCT00004933_13_T0	COMPOUND	3	3	homoharringtonine
NCT0000493313	NCT00004933_13_T1	GENE	4	4	IV
NCT0000493316	NCT00004933_16_T0	COMPOUND	4	4	hydroxyurea
NCT0000493328	NCT00004933_28_T0	GENE	15	15	interferon
NCT0000493328	NCT00004933_28_T1	GENE	11	11	HU
NCT0000493329	NCT00004933_29_T0	GENE	9	9	HU
NCT0000493334	NCT00004933_34_T0	PHENOTYPE	6	7	atrial fibrillation
NCT0000493334	NCT00004933_34_T1	PHENOTYPE	12	13	ventricular tachycardias
NCT0000493334	NCT00004933_34_T2	PHENOTYPE	9	10	supraventricular tachycardia
NCT000049345	NCT00004934_5_T0	GENE	25	25	III
NCT000049345	NCT00004934_5_T1	GENE	31	31	cm
NCT000049345	NCT00004934_5_T2	GENE	42	42	cm
NCT000049345	NCT00004934_5_T3	GENE	38	38	IV
NCT000049345	NCT00004934_5_T4	PHENOTYPE	26	27	residual tumor
NCT000049345	NCT00004934_5_T5	PHENOTYPE	39	40	residual tumor
NCT000049351	NCT00004935_1_T0	PHENOTYPE	24	25	breast cancer
NCT000049353	NCT00004935_3_T0	PHENOTYPE	4	4	toxicity
NCT000049353	NCT00004935_3_T1	PHENOTYPE	16	16	progression
NCT000049353	NCT00004935_3_T2	GENE	34	34	HER2
NCT000049353	NCT00004935_3_T3	PHENOTYPE	36	37	breast cancer
NCT000049353	NCT00004935_3_T4	PHENOTYPE	6	8	quality of life
NCT000049361	NCT00004936_1_T0	GENE	8	8	MRI
NCT000049361	NCT00004936_1_T1	PHENOTYPE	14	16	invasive cervical cancer
NCT000049364	NCT00004936_4_T0	GENE	9	9	dye
NCT000049364	NCT00004936_4_T1	COMPOUND	22	22	gadopentetate
NCT000049371	NCT00004937_1_T0	GENE	2	2	II
NCT000049371	NCT00004937_1_T1	PHENOTYPE	16	16	recurrent
NCT000049371	NCT00004937_1_T2	PHENOTYPE	17	18	glioblastoma multiforme
NCT000049371	NCT00004937_1_T3	COMPOUND	9	10	acridine carboxamide
NCT000049373	NCT00004937_3_T0	COMPOUND	3	3	acridine
NCT000049373	NCT00004937_3_T1	PHENOTYPE	17	18	glioblastoma multiforme
NCT000049375	NCT00004937_5_T0	PHENOTYPE	2	2	toxicities
NCT000049377	NCT00004937_7_T0	GENE	8	8	1.5
NCT000049377	NCT00004937_7_T1	GENE	4	4	IV
NCT000049377	NCT00004937_7_T2	COMPOUND	2	3	acridine carboxamide
NCT000049378	NCT00004937_8_T0	PHENOTYPE	26	26	toxicity
NCT000049378	NCT00004937_8_T1	PHENOTYPE	22	23	disease progression
NCT000049379	NCT00004937_9_T0	PHENOTYPE	7	8	disease progression
NCT000049381	NCT00004938_1_T0	PHENOTYPE	11	11	sporotrichosis
NCT000049381	NCT00004938_1_T1	COMPOUND	4	4	fluconazole
NCT000049391	NCT00004939_1_T0	COMPOUND	4	4	3_4_diaminopyridine
NCT000049391	NCT00004939_1_T1	PHENOTYPE	9	9	chronic
NCT000049391	NCT00004939_1_T2	PHENOTYPE	10	11	demyelinating polyneuropathy
NCT000049393	NCT00004939_3_T0	COMPOUND	6	6	3_4_diaminopyridine
NCT000049411	NCT00004941_1_T0	PHENOTYPE	19	20	Crohn's disease
NCT000049781	NCT00004978_1_T0	PHENOTYPE	19	20	HIV disease
NCT000049781	NCT00004978_1_T1	PHENOTYPE	20	21	disease progression
NCT000049782	NCT00004978_2_T0	PHENOTYPE	18	18	HIV
NCT000049782	NCT00004978_2_T1	GENE	2	2	has
NCT000049782	NCT00004978_2_T2	PHENOTYPE	8	9	HIV positive
NCT000049783	NCT00004978_3_T0	PHENOTYPE	1	1	HIV
NCT000049783	NCT00004978_3_T1	ORGAN	13	14	immune system
NCT000049783	NCT00004978_3_T2	PHENOTYPE	20	21	HIV positive
NCT000049784	NCT00004978_4_T0	GENE	6	6	interleukin-2
NCT000049784	NCT00004978_4_T1	PHENOTYPE	12	12	HIV
NCT000049784	NCT00004978_4_T2	ORGAN	18	19	immune systems
NCT000049785	NCT00004978_5_T0	GENE	3	3	hormone
NCT000049785	NCT00004978_5_T1	BIOLOGICAL_PROCESS	11	12	immune response
NCT0000497810	NCT00004978_10_T0	PHENOTYPE	7	7	initiation
NCT0000497810	NCT00004978_10_T1	PHENOTYPE	17	17	HIV
NCT0000497811	NCT00004978_11_T0	GENE	8	8	CD4
NCT0000497811	NCT00004978_11_T1	CELL	9	9	lymphocytes
NCT0000497812	NCT00004978_12_T0	GENE	26	26	CD4
NCT0000497812	NCT00004978_12_T1	CELL	27	27	cells
NCT0000497812	NCT00004978_12_T2	PHENOTYPE	21	21	HIV
NCT0000497812	NCT00004978_12_T3	GENE	2	2	has
NCT0000497812	NCT00004978_12_T4	PHENOTYPE	20	20	purging
NCT0000497814	NCT00004978_14_T0	GENE	6	6	SC
NCT0000497817	NCT00004978_17_T0	GENE	4	4	SC
NCT0000497817	NCT00004978_17_T1	GENE	1	1	IL-2
NCT0000497817	NCT00004978_17_T2	PHENOTYPE	18	18	toxicities
NCT0000497822	NCT00004978_22_T0	GENE	7	7	SC
NCT000049792	NCT00004979_2_T0	CELL	9	9	cells
NCT000049792	NCT00004979_2_T1	PHENOTYPE	8	8	tumor
NCT000049795	NCT00004979_5_T0	COMPOUND	15	15	paclitaxel
NCT000049795	NCT00004979_5_T1	PHENOTYPE	23	23	NSCLC
NCT000049795	NCT00004979_5_T2	GENE	5	5	MTD
NCT000049795	NCT00004979_5_T3	COMPOUND	8	8	topotecan
NCT000049795	NCT00004979_5_T4	PHENOTYPE	27	28	solid tumors
NCT000049795	NCT00004979_5_T5	PHENOTYPE	20	21	small lung
NCT000049795	NCT00004979_5_T6	PHENOTYPE	21	22	lung cancer
NCT000049797	NCT00004979_7_T0	COMPOUND	17	17	paclitaxel
NCT000049797	NCT00004979_7_T1	PHENOTYPE	5	5	NSCLC
NCT000049797	NCT00004979_7_T2	GENE	10	10	MTD
NCT000049797	NCT00004979_7_T3	COMPOUND	13	13	topotecan
NCT000049799	NCT00004979_9_T0	PHENOTYPE	4	4	toxicities
NCT0000497910	NCT00004979_10_T0	GENE	1	1	II
NCT0000497910	NCT00004979_10_T1	GENE	2	2	IV
NCT0000497911	NCT00004979_11_T0	PHENOTYPE	12	12	NSCLC
NCT0000497911	NCT00004979_11_T1	PHENOTYPE	2	2	toxicities
NCT0000497911	NCT00004979_11_T2	GENE	8	8	MTD
NCT0000497913	NCT00004979_13_T0	PHENOTYPE	18	18	NSCLC
NCT0000497913	NCT00004979_13_T1	PHENOTYPE	9	9	progression
NCT0000497913	NCT00004979_13_T2	GENE	25	25	MTD
NCT0000497915	NCT00004979_15_T0	PHENOTYPE	7	7	NSCLC
NCT0000497915	NCT00004979_15_T1	GENE	14	14	MTD
NCT0000497916	NCT00004979_16_T0	COMPOUND	8	8	topotecan
NCT0000497917	NCT00004979_17_T0	COMPOUND	8	8	paclitaxel
NCT0000497917	NCT00004979_17_T1	GENE	6	6	1.5
NCT0000497917	NCT00004979_17_T2	GENE	9	9	IV
NCT0000497917	NCT00004979_17_T3	COMPOUND	3	3	topotecan
NCT0000497918	NCT00004979_18_T0	PHENOTYPE	10	10	toxicity
NCT0000497918	NCT00004979_18_T1	PHENOTYPE	12	13	disease progression
NCT0000497919	NCT00004979_19_T0	GENE	14	14	MTD
NCT0000497919	NCT00004979_19_T1	COMPOUND	8	8	topotecan
NCT0000497920	NCT00004979_20_T0	PHENOTYPE	22	22	toxicities
NCT0000497920	NCT00004979_20_T1	GENE	1	1	MTD
NCT0000497922	NCT00004979_22_T0	GENE	8	8	II
NCT0000497922	NCT00004979_22_T1	PHENOTYPE	0	2	Quality of life
NCT0000497924	NCT00004979_24_T0	COMPOUND	13	14	I dose
NCT000049801	NCT00004980_1_T0	PHENOTYPE	16	16	schizophrenia
NCT000049801	NCT00004980_1_T1	PHENOTYPE	11	12	auditory hallucinations
NCT000049804	NCT00004980_4_T0	COMPOUND	11	11	rTMS
NCT000049804	NCT00004980_4_T1	COMPOUND	18	18	rTMS
NCT000049804	NCT00004980_4_T2	GENE	0	1	Group I
NCT000049807	NCT00004980_7_T0	GENE	1	1	II
NCT000049811	NCT00004981_1_T0	COMPOUND	2	2	lamivudine
NCT000049812	NCT00004981_2_T0	COMPOUND	10	10	abacavir
NCT000049821	NCT00004982_1_T0	PHENOTYPE	11	12	excess iron
NCT000049848	NCT00004984_8_T0	PHENOTYPE	4	5	antibody titer
NCT000049848	NCT00004984_8_T1	PHENOTYPE	8	9	Juvenile Diabetes
NCT000049849	NCT00004984_9_T0	COMPOUND	17	17	glucose
NCT000049849	NCT00004984_9_T1	GENE	8	8	insulin
NCT000049849	NCT00004984_9_T2	GENE	13	13	insulin
NCT000049849	NCT00004984_9_T3	PHENOTYPE	20	21	glucose tolerance
NCT0000498411	NCT00004984_11_T0	GENE	8	8	insulin
NCT0000498411	NCT00004984_11_T1	GENE	15	15	insulin
NCT0000498411	NCT00004984_11_T2	GENE	46	46	insulin
NCT0000498411	NCT00004984_11_T3	GENE	12	12	had
NCT0000498411	NCT00004984_11_T4	PHENOTYPE	22	23	glucose tolerance
NCT0000498413	NCT00004984_13_T0	PHENOTYPE	1	1	tolerance
NCT000049852	NCT00004985_2_T0	COMPOUND	7	7	nelfinavir
NCT000049852	NCT00004985_2_T1	COMPOUND	8	8	mesylate
NCT000049853	NCT00004985_3_T0	GENE	11	11	has
NCT000049855	NCT00004985_5_T0	GENE	17	17	CD4
NCT000049855	NCT00004985_5_T1	PHENOTYPE	13	13	HIV
NCT000049855	NCT00004985_5_T2	GENE	19	19	CD8
NCT000049855	NCT00004985_5_T3	PHENOTYPE	15	15	pharmacokinetics
NCT000049855	NCT00004985_5_T4	ORGAN	12	12	plasma
NCT000049860	NCT00004986_0_T0	PHENOTYPE	9	9	Cryptosporidiosis
NCT000049865	NCT00004986_5_T0	CELL	12	12	oocysts
NCT000049865	NCT00004986_5_T1	COMPOUND	26	26	nitazoxanide
NCT000049866	NCT00004986_6_T0	PHENOTYPE	36	36	Cryptosporidiosis
NCT000049866	NCT00004986_6_T1	COMPOUND	23	23	nitazoxanide
NCT000049872	NCT00004987_2_T0	COMPOUND	19	19	sulphate
NCT000049872	NCT00004987_2_T1	GENE	20	20	DS
NCT000049874	NCT00004987_4_T0	GENE	19	19	has
NCT000049874	NCT00004987_4_T1	GENE	18	18	DS
NCT000049885	NCT00004988_5_T0	PHENOTYPE	13	13	tumor
NCT000049887	NCT00004988_7_T0	PHENOTYPE	4	5	metastatic cancer
NCT0000498812	NCT00004988_12_T0	GENE	12	12	1.2
NCT0000498812	NCT00004988_12_T1	GENE	17	17	4.5
NCT0000498813	NCT00004988_13_T0	PHENOTYPE	2	2	tumors
NCT0000498813	NCT00004988_13_T1	PHENOTYPE	18	18	tumors
NCT0000498814	NCT00004988_14_T0	PHENOTYPE	20	20	tumor
NCT0000498814	NCT00004988_14_T1	GENE	6	6	4.5
NCT0000498815	NCT00004988_15_T0	PHENOTYPE	2	2	tumor
NCT0000498816	NCT00004988_16_T0	PHENOTYPE	2	2	tumor
NCT0000498819	NCT00004988_19_T0	PHENOTYPE	16	16	tumor
NCT0000498832	NCT00004988_32_T0	PHENOTYPE	33	33	tumor
NCT0000498832	NCT00004988_32_T1	PHENOTYPE	4	5	solid tumor
NCT0000498833	NCT00004988_33_T0	PHENOTYPE	6	7	metastatic disease
NCT0000498834	NCT00004988_34_T0	PHENOTYPE	7	7	tumor
NCT0000498835	NCT00004988_35_T0	PHENOTYPE	12	12	discomfort
NCT0000498842	NCT00004988_42_T0	GENE	12	12	DPA
NCT0000498844	NCT00004988_44_T0	PHENOTYPE	5	5	toxicities
NCT0000498844	NCT00004988_44_T1	PHENOTYPE	15	16	other cancer
NCT0000498846	NCT00004988_46_T0	PHENOTYPE	19	19	lymphoma
NCT0000498846	NCT00004988_46_T1	PHENOTYPE	22	23	hematologic malignancy
NCT0000498847	NCT00004988_47_T0	ORGAN	11	11	hips
NCT0000498847	NCT00004988_47_T1	PHENOTYPE	21	21	nidus
NCT0000498847	NCT00004988_47_T2	ORGAN	8	9	heart valves
NCT0000498848	NCT00004988_48_T0	PHENOTYPE	7	7	arteriosclerosis
NCT0000498848	NCT00004988_48_T1	PHENOTYPE	3	4	valvular disease
NCT0000498849	NCT00004988_49_T0	PHENOTYPE	4	4	murmur
NCT0000498850	NCT00004988_50_T0	PHENOTYPE	14	15	venous malformations
NCT0000498850	NCT00004988_50_T1	PHENOTYPE	5	7	peripheral vascular disease
NCT0000498851	NCT00004988_51_T0	PHENOTYPE	13	13	thrombus
NCT0000498851	NCT00004988_51_T1	PHENOTYPE	2	3	atrial fibrillation
NCT0000498852	NCT00004988_52_T0	ORGAN	10	10	gallbladders
NCT0000498853	NCT00004988_53_T0	PHENOTYPE	8	8	obstruction
NCT0000498853	NCT00004988_53_T1	PHENOTYPE	6	6	cholelithiasis
NCT0000498854	NCT00004988_54_T0	ORGAN	10	10	kidneys
NCT0000498855	NCT00004988_55_T0	PHENOTYPE	2	2	urolithiasis
NCT0000498856	NCT00004988_56_T0	PHENOTYPE	6	7	Hepatitis B
NCT0000498856	NCT00004988_56_T1	PHENOTYPE	9	11	chronic viral hepatitis
NCT0000498857	NCT00004988_57_T0	PHENOTYPE	1	2	Salmonella infections
NCT0000498859	NCT00004988_59_T0	PHENOTYPE	2	2	tumor
NCT0000498859	NCT00004988_59_T1	PHENOTYPE	3	3	fever
NCT0000498859	NCT00004988_59_T2	PHENOTYPE	5	8	fever of unknown origin
NCT0000498860	NCT00004988_60_T0	PHENOTYPE	2	3	bleeding disorder
NCT0000498862	NCT00004988_62_T0	PHENOTYPE	9	9	toxic
NCT0000498862	NCT00004988_62_T1	PHENOTYPE	11	11	severely
NCT0000498866	NCT00004988_66_T0	PHENOTYPE	4	5	brain metastases
NCT0000498867	NCT00004988_67_T0	PHENOTYPE	10	10	recurrence
NCT0000498867	NCT00004988_67_T1	PHENOTYPE	4	5	brain metastases
NCT000049904	NCT00004990_4_T0	PHENOTYPE	8	8	proteinuria
NCT000049904	NCT00004990_4_T1	COMPOUND	4	4	cyclosporin
NCT000049904	NCT00004990_4_T2	COMPOUND	6	6	cyclophosphamide
NCT000049905	NCT00004990_5_T0	PHENOTYPE	17	17	toxicity
NCT000049905	NCT00004990_5_T1	PHENOTYPE	14	14	remission
NCT000049905	NCT00004990_5_T2	PHENOTYPE	7	7	pulse
NCT000049907	NCT00004990_7_T0	COMPOUND	4	4	dexamethasone
NCT0000499015	NCT00004990_15_T0	ORGAN	6	6	hips
NCT0000499015	NCT00004990_15_T1	GENE	3	3	MRI
NCT0000499021	NCT00004990_21_T0	PHENOTYPE	7	7	remission
NCT0000499021	NCT00004990_21_T1	GENE	39	39	3.4
NCT0000499021	NCT00004990_21_T2	COMPOUND	25	25	prednisone
NCT0000499023	NCT00004990_23_T0	PHENOTYPE	26	26	remission
NCT0000499025	NCT00004990_25_T0	COMPOUND	10	10	dexamethasone
NCT0000499026	NCT00004990_26_T0	PHENOTYPE	8	8	remission
NCT0000499027	NCT00004990_27_T0	PHENOTYPE	9	9	toxicity
NCT0000499032	NCT00004990_32_T0	GENE	10	10	GFR
NCT0000499032	NCT00004990_32_T1	COMPOUND	19	19	creatinine
NCT0000499032	NCT00004990_32_T2	ORGAN	18	18	serum
NCT0000499032	NCT00004990_32_T3	BIOLOGICAL_PROCESS	0	1	Glomerular filtration
NCT0000499033	NCT00004990_33_T0	GENE	13	13	GFR
NCT0000499033	NCT00004990_33_T1	GENE	2	2	has
NCT0000499034	NCT00004990_34_T0	GENE	13	13	GFR
NCT0000499034	NCT00004990_34_T1	GENE	2	2	has
NCT0000499035	NCT00004990_35_T0	GENE	12	12	3.5
NCT0000499035	NCT00004990_35_T1	PHENOTYPE	0	2	Nephrotic range proteinuria
NCT0000499037	NCT00004990_37_T0	GENE	7	7	BP
NCT0000499037	NCT00004990_37_T1	GENE	15	15	Hg
NCT0000499042	NCT00004990_42_T0	PHENOTYPE	2	2	chronic
NCT0000499043	NCT00004990_43_T0	PHENOTYPE	11	11	HIV
NCT0000499043	NCT00004990_43_T1	PHENOTYPE	7	8	hepatitis B
NCT0000499043	NCT00004990_43_T2	PHENOTYPE	9	10	hepatitis C
NCT0000499043	NCT00004990_43_T3	PHENOTYPE	14	15	mycobacterial infection
NCT0000499048	NCT00004990_48_T0	PHENOTYPE	2	4	other psychiatric disorders
NCT000049914	NCT00004991_4_T0	PHENOTYPE	27	27	stuttering
NCT000049914	NCT00004991_4_T1	PHENOTYPE	32	32	chronic
NCT000049914	NCT00004991_4_T2	PHENOTYPE	29	30	phonological disorders
NCT000049915	NCT00004991_5_T0	PHENOTYPE	7	8	speech disorders
NCT000049916	NCT00004991_6_T0	PHENOTYPE	18	19	speech disorder
NCT000049918	NCT00004991_8_T0	PHENOTYPE	19	19	listening
NCT000049919	NCT00004991_9_T0	GENE	7	7	MRI
NCT000049919	NCT00004991_9_T1	PHENOTYPE	10	11	brain activity
NCT0000499111	NCT00004991_11_T0	PHENOTYPE	12	12	listening
NCT0000499111	NCT00004991_11_T1	GENE	2	2	MRI
NCT0000499115	NCT00004991_15_T0	PHENOTYPE	27	27	stuttering
NCT0000499115	NCT00004991_15_T1	PHENOTYPE	32	32	chronic
NCT0000499115	NCT00004991_15_T2	GENE	38	38	span
NCT0000499115	NCT00004991_15_T3	PHENOTYPE	29	30	phonological disorders
NCT0000499116	NCT00004991_16_T0	PHENOTYPE	13	13	disorders
NCT0000499116	NCT00004991_16_T1	GENE	1	1	MRI
NCT0000499116	NCT00004991_16_T2	GENE	4	4	MEG
NCT0000499117	NCT00004991_17_T0	PHENOTYPE	28	28	stuttering
NCT0000499117	NCT00004991_17_T1	GENE	5	5	MEG
NCT0000499117	NCT00004991_17_T2	PHENOTYPE	30	31	phonological disorders
NCT0000499119	NCT00004991_19_T0	PHENOTYPE	13	13	diffuse
NCT0000499119	NCT00004991_19_T1	PHENOTYPE	22	22	stuttering
NCT0000499119	NCT00004991_19_T2	PHENOTYPE	21	21	chronic
NCT0000499119	NCT00004991_19_T3	PHENOTYPE	24	25	phonological disorders
NCT0000499123	NCT00004991_23_T0	PHENOTYPE	13	13	disorders
NCT0000499123	NCT00004991_23_T1	PHENOTYPE	9	9	stuttering
NCT0000499127	NCT00004991_27_T0	GENE	0	0	Dr
NCT000049922	NCT00004992_2_T0	PHENOTYPE	8	8	Diabetes
NCT000049922	NCT00004992_2_T1	PHENOTYPE	12	13	Kidney Diseases
NCT000049932	NCT00004993_2_T0	PHENOTYPE	13	14	osteoporotic fractures
NCT000049932	NCT00004993_2_T1	PHENOTYPE	10	11	bone loss
NCT000049933	NCT00004993_3_T0	GENE	9	9	has
NCT000049933	NCT00004993_3_T1	PHENOTYPE	0	0	Parathyroid
NCT000049933	NCT00004993_3_T2	GENE	1	1	hormone
NCT000049936	NCT00004993_6_T0	PHENOTYPE	17	17	osteopenia
NCT000049936	NCT00004993_6_T1	COMPOUND	19	19	DXA
NCT000049936	NCT00004993_6_T2	COMPOUND	11	11	prednisone
NCT000049936	NCT00004993_6_T3	PHENOTYPE	8	8	chronic
NCT000049936	NCT00004993_6_T4	PHENOTYPE	15	16	bone loss
NCT000049937	NCT00004993_7_T0	COMPOUND	23	23	estrogen
NCT000049937	NCT00004993_7_T1	GENE	8	8	PTH
NCT000049937	NCT00004993_7_T2	COMPOUND	27	27	alendronate
NCT000049941	NCT00004994_1_T0	PHENOTYPE	7	7	affects
NCT000049941	NCT00004994_1_T1	PHENOTYPE	20	21	emotional state
NCT000049943	NCT00004994_3_T0	CELL	4	5	stem cells
NCT000049943	NCT00004994_3_T1	ORGAN	2	3	bone marrow
NCT000049944	NCT00004994_4_T0	COMPOUND	15	15	1
NCT000049944	NCT00004994_4_T1	COMPOUND	22	22	2
NCT000049944	NCT00004994_4_T2	ORGAN	26	26	transplant
NCT000049945	NCT00004994_5_T0	ORGAN	4	4	transplant
NCT000049946	NCT00004994_6_T0	ORGAN	4	4	transplant
NCT0000499416	NCT00004994_16_T0	PHENOTYPE	11	11	regression
NCT0000499419	NCT00004994_19_T0	PHENOTYPE	0	1	Hematological disease
NCT000049961	NCT00004996_1_T0	PHENOTYPE	6	6	blisters
NCT000049961	NCT00004996_1_T1	PHENOTYPE	10	10	blistering
NCT000049962	NCT00004996_2_T0	PHENOTYPE	23	23	infections
NCT000049962	NCT00004996_2_T1	ORGAN	13	14	immune system
NCT000049963	NCT00004996_3_T0	PHENOTYPE	5	5	acute
NCT000049963	NCT00004996_3_T1	PHENOTYPE	11	11	infections
NCT000049964	NCT00004996_4_T0	CELL	14	14	cells
NCT000049964	NCT00004996_4_T1	PHENOTYPE	11	11	blistering
NCT000049965	NCT00004996_5_T0	ORGAN	11	11	thigh
NCT000049965	NCT00004996_5_T1	PHENOTYPE	2	2	blister
NCT000049967	NCT00004996_7_T0	PHENOTYPE	17	17	blisters
NCT000049968	NCT00004996_8_T0	PHENOTYPE	1	1	blister
NCT000049968	NCT00004996_8_T1	PHENOTYPE	6	6	sterile
NCT000049969	NCT00004996_9_T0	GENE	1	1	blistered
NCT0000499610	NCT00004996_10_T0	PHENOTYPE	21	21	blister
NCT0000499614	NCT00004996_14_T0	PHENOTYPE	6	6	blisters
NCT0000499614	NCT00004996_14_T1	PHENOTYPE	10	10	blistering
NCT0000499615	NCT00004996_15_T0	PHENOTYPE	23	23	infections
NCT0000499615	NCT00004996_15_T1	ORGAN	13	14	immune system
NCT0000499616	NCT00004996_16_T0	PHENOTYPE	5	5	acute
NCT0000499616	NCT00004996_16_T1	PHENOTYPE	11	11	infections
NCT0000499617	NCT00004996_17_T0	CELL	14	14	cells
NCT0000499617	NCT00004996_17_T1	PHENOTYPE	11	11	blistering
NCT0000499618	NCT00004996_18_T0	ORGAN	11	11	thigh
NCT0000499618	NCT00004996_18_T1	PHENOTYPE	2	2	blister
NCT0000499620	NCT00004996_20_T0	PHENOTYPE	17	17	blisters
NCT0000499621	NCT00004996_21_T0	PHENOTYPE	1	1	blister
NCT0000499621	NCT00004996_21_T1	PHENOTYPE	6	6	sterile
NCT0000499622	NCT00004996_22_T0	GENE	1	1	blistered
NCT0000499623	NCT00004996_23_T0	PHENOTYPE	21	21	blister
NCT0000499632	NCT00004996_32_T0	PHENOTYPE	2	2	malignancy
NCT0000499632	NCT00004996_32_T1	PHENOTYPE	10	10	vasculitis
NCT0000499632	NCT00004996_32_T2	PHENOTYPE	11	12	pyoderma gangrenosum
NCT0000499632	NCT00004996_32_T3	PHENOTYPE	4	5	autoimmune disease
NCT0000499632	NCT00004996_32_T4	PHENOTYPE	8	9	rheumatoid arthritis
NCT0000499634	NCT00004996_34_T0	PHENOTYPE	7	7	blistering
NCT0000499635	NCT00004996_35_T0	PHENOTYPE	3	4	acute infection
NCT000049973	NCT00004997_3_T0	PHENOTYPE	23	23	infections
NCT000049973	NCT00004997_3_T1	PHENOTYPE	9	9	bleed
NCT000049973	NCT00004997_3_T2	CELL	3	3	platelets
NCT000049973	NCT00004997_3_T3	PHENOTYPE	21	21	susceptible
NCT000049973	NCT00004997_3_T4	CELL	16	17	blood cells
NCT000049978	NCT00004997_8_T0	COMPOUND	8	9	folic acid
NCT000049979	NCT00004997_9_T0	COMPOUND	11	11	leucovorin
NCT0000499713	NCT00004997_13_T0	ORGAN	13	13	marrow
NCT0000499713	NCT00004997_13_T1	PHENOTYPE	4	4	transforming
NCT0000499713	NCT00004997_13_T2	PHENOTYPE	6	7	acute leukemia
NCT0000499717	NCT00004997_17_T0	ORGAN	6	6	transplant
NCT0000499717	NCT00004997_17_T1	ORGAN	4	5	bone marrow
NCT0000499719	NCT00004997_19_T0	PHENOTYPE	4	5	HIV positive
NCT000049983	NCT00004998_3_T0	PHENOTYPE	13	13	peripheral
NCT000049983	NCT00004998_3_T1	GENE	9	9	CD4
NCT000049983	NCT00004998_3_T2	PHENOTYPE	23	23	concentrations
NCT000049983	NCT00004998_3_T3	CELL	16	16	cells
NCT000049983	NCT00004998_3_T4	GENE	11	11	CD8
NCT000049983	NCT00004998_3_T5	ORGAN	22	22	plasma
NCT000049993	NCT00004999_3_T0	PHENOTYPE	15	15	peripheral
NCT000049993	NCT00004999_3_T1	GENE	10	10	CD4
NCT000049993	NCT00004999_3_T2	CELL	18	18	cells
NCT000049993	NCT00004999_3_T3	GENE	12	12	CD8
NCT000049993	NCT00004999_3_T4	ORGAN	7	7	plasma
NCT000049995	NCT00004999_5_T0	PHENOTYPE	10	10	pharmacokinetics
NCT000050002	NCT00005000_2_T0	PHENOTYPE	20	20	HIV
NCT000050003	NCT00005000_3_T0	ORGAN	10	11	immune system
NCT000050005	NCT00005000_5_T0	COMPOUND	4	4	zidovudine
NCT000050005	NCT00005000_5_T1	COMPOUND	7	7	lamivudine
NCT000050006	NCT00005000_6_T0	PHENOTYPE	13	13	HIV
NCT000050006	NCT00005000_6_T1	COMPOUND	34	34	KLH
NCT000050007	NCT00005000_7_T0	GENE	6	6	met
NCT000050008	NCT00005000_8_T0	GENE	11	11	R2
NCT000050008	NCT00005000_8_T1	GENE	4	4	met
NCT000050009	NCT00005000_9_T0	GENE	0	0	R2
NCT000050009	NCT00005000_9_T1	COMPOUND	20	20	stavudine
NCT000050009	NCT00005000_9_T2	COMPOUND	23	23	didanosine
NCT000050012	NCT00005001_2_T0	GENE	8	8	IFA
NCT000050014	NCT00005001_4_T0	GENE	9	9	IFA
NCT000050014	NCT00005001_4_T1	ORGAN	12	12	plasma
NCT000050016	NCT00005001_6_T0	ORGAN	3	3	plasma
NCT000050017	NCT00005001_7_T0	ORGAN	2	2	plasma
NCT000050017	NCT00005001_7_T1	ORGAN	29	29	plasma
NCT000050022	NCT00005002_2_T0	GENE	26	26	IFA
NCT000050022	NCT00005002_2_T1	ORGAN	3	3	plasma
NCT000050023	NCT00005002_3_T0	ORGAN	6	6	plasma
NCT000050024	NCT00005002_4_T0	COMPOUND	14	14	nelfinavir
NCT000050025	NCT00005002_5_T0	GENE	5	5	IFA
NCT000050026	NCT00005002_6_T0	PHENOTYPE	27	27	relapse
NCT000050027	NCT00005002_7_T0	GENE	36	36	IFA
NCT000050027	NCT00005002_7_T1	ORGAN	8	8	plasma
NCT000050037	NCT00005003_7_T0	GENE	5	5	kit
NCT000050038	NCT00005003_8_T0	CELL	15	15	cells
NCT0000500313	NCT00005003_13_T0	GENE	2	2	II
NCT000050045	NCT00005004_5_T0	BIOLOGICAL_PROCESS	6	6	aging
NCT000050047	NCT00005004_7_T0	PHENOTYPE	10	10	trauma
NCT000050047	NCT00005004_7_T1	PHENOTYPE	8	8	dysfunction
NCT000050047	NCT00005004_7_T2	PHENOTYPE	4	7	central nervous system disease
NCT000050049	NCT00005004_9_T0	GENE	12	12	MRI
NCT000050049	NCT00005004_9_T1	GENE	7	7	had
NCT000050049	NCT00005004_9_T2	PHENOTYPE	2	3	neurological damage
NCT0000500415	NCT00005004_15_T0	PHENOTYPE	13	13	suppression
NCT0000500416	NCT00005004_16_T0	PHENOTYPE	1	1	secondary
NCT0000500416	NCT00005004_16_T1	PHENOTYPE	7	8	cognitive processes
NCT0000500426	NCT00005004_26_T0	GENE	2	2	BD
NCT0000500427	NCT00005004_27_T0	GENE	6	6	al
NCT0000500427	NCT00005004_27_T1	GENE	5	5	et
NCT0000500428	NCT00005004_28_T0	GENE	2	2	BD
NCT0000500428	NCT00005004_28_T1	PHENOTYPE	8	8	focal
NCT0000500429	NCT00005004_29_T0	GENE	16	16	MRI
NCT0000500430	NCT00005004_30_T0	PHENOTYPE	17	18	neurological damage
NCT0000500430	NCT00005004_30_T1	PHENOTYPE	5	7	penetrating head injury
NCT0000500431	NCT00005004_31_T0	PHENOTYPE	5	5	tumor
NCT0000500433	NCT00005004_33_T0	GENE	6	6	BD
NCT000050050	NCT00005005_0_T0	PHENOTYPE	7	7	Osteoporosis
NCT000050050	NCT00005005_0_T1	PHENOTYPE	2	2	Parathyroid
NCT000050053	NCT00005005_3_T0	GENE	8	8	PTH
NCT000050053	NCT00005005_3_T1	GENE	14	14	PTH
NCT000050053	NCT00005005_3_T2	COMPOUND	10	10	alendronate
NCT000050053	NCT00005005_3_T3	COMPOUND	11	11	alendronate
NCT000050056	NCT00005005_6_T0	GENE	15	15	PTH
NCT000050056	NCT00005005_6_T1	GENE	26	26	PTH
NCT000050056	NCT00005005_6_T2	GENE	45	45	PTH
NCT000050056	NCT00005005_6_T3	COMPOUND	21	21	alendronate
NCT000050056	NCT00005005_6_T4	COMPOUND	28	28	alendronate
NCT000050056	NCT00005005_6_T5	COMPOUND	34	34	alendronate
NCT000050056	NCT00005005_6_T6	COMPOUND	39	39	alendronate
NCT000050059	NCT00005005_9_T0	ORGAN	12	12	calcaneus
NCT000050059	NCT00005005_9_T1	GENE	5	5	PTH
NCT000050059	NCT00005005_9_T2	PHENOTYPE	7	7	affects
NCT000050060	NCT00005006_0_T0	PHENOTYPE	6	6	Osteoporosis
NCT000050060	NCT00005006_0_T1	GENE	2	2	PTH
NCT000050060	NCT00005006_0_T2	PHENOTYPE	0	0	Parathyroid
NCT000050063	NCT00005006_3_T0	GENE	13	13	PTH
NCT000050063	NCT00005006_3_T1	GENE	21	21	PTH
NCT000050066	NCT00005006_6_T0	GENE	23	23	PTH
NCT000050066	NCT00005006_6_T1	GENE	29	29	PTH
NCT000050066	NCT00005006_6_T2	GENE	46	46	PTH
NCT000050066	NCT00005006_6_T3	COMPOUND	18	18	alendronate
NCT000050066	NCT00005006_6_T4	COMPOUND	25	25	alendronate
NCT000050066	NCT00005006_6_T5	COMPOUND	49	49	alendronate
NCT000050068	NCT00005006_8_T0	GENE	11	11	calcitonin
NCT000050068	NCT00005006_8_T1	COMPOUND	8	8	bisphosphonates
NCT000050068	NCT00005006_8_T2	COMPOUND	9	9	raloxifene
NCT000050068	NCT00005006_8_T3	PHENOTYPE	4	4	osteoporosis
NCT000050068	NCT00005006_8_T4	PHENOTYPE	15	16	bone loss
NCT0000500611	NCT00005006_11_T0	GENE	7	7	PTH
NCT0000500611	NCT00005006_11_T1	GENE	5	6	parathyroid hormone
NCT0000500612	NCT00005006_12_T0	GENE	21	21	PTH
NCT0000500612	NCT00005006_12_T1	PHENOTYPE	15	16	vertebral fracture
NCT0000500614	NCT00005006_14_T0	GENE	8	8	PTH
NCT0000500614	NCT00005006_14_T1	COMPOUND	17	17	alendronate
NCT0000500620	NCT00005006_20_T0	PHENOTYPE	10	10	osteoporosis
NCT0000500620	NCT00005006_20_T1	COMPOUND	26	26	alendronate
NCT0000500620	NCT00005006_20_T2	PHENOTYPE	18	19	osteoporotic fracture
NCT0000500623	NCT00005006_23_T0	ORGAN	13	13	skeleton
NCT0000500624	NCT00005006_24_T0	GENE	15	15	PTH
NCT0000500624	NCT00005006_24_T1	GENE	21	21	PTH
NCT0000500624	NCT00005006_24_T2	GENE	38	38	PTH
NCT0000500624	NCT00005006_24_T3	GENE	41	41	PTH
NCT0000500624	NCT00005006_24_T4	COMPOUND	10	10	alendronate
NCT0000500624	NCT00005006_24_T5	COMPOUND	17	17	alendronate
NCT0000500624	NCT00005006_24_T6	COMPOUND	49	49	alendronate
NCT000050071	NCT00005007_1_T0	GENE	19	19	WG
NCT000050071	NCT00005007_1_T1	PHENOTYPE	1	1	blocks
NCT000050071	NCT00005007_1_T2	GENE	5	7	tumor necrosis factor-alpha
NCT000050072	NCT00005007_2_T0	GENE	13	13	WG
NCT000050072	NCT00005007_2_T1	PHENOTYPE	2	2	centers
NCT000050074	NCT00005007_4_T0	GENE	8	8	WG
NCT000050076	NCT00005007_6_T0	PHENOTYPE	6	7	in remission
NCT000050077	NCT00005007_7_T0	TISSUE	10	10	tissues
NCT000050077	NCT00005007_7_T1	GENE	28	28	WG
NCT000050077	NCT00005007_7_T2	PHENOTYPE	34	35	disease progression
NCT000050079	NCT00005007_9_T0	GENE	33	33	WG
NCT000050079	NCT00005007_9_T1	PHENOTYPE	27	27	remissions
NCT000050079	NCT00005007_9_T2	PHENOTYPE	31	32	Wegener's granulomatosis
NCT0000500710	NCT00005007_10_T0	PHENOTYPE	1	1	secondary
NCT0000500710	NCT00005007_10_T1	GENE	33	33	WG
NCT0000500710	NCT00005007_10_T2	PHENOTYPE	29	29	pathophysiology
NCT0000500710	NCT00005007_10_T3	ORGAN	10	10	serum
NCT0000500710	NCT00005007_10_T4	ORGAN	11	11	plasma
NCT0000500712	NCT00005007_12_T0	GENE	15	15	1.1
NCT0000500713	NCT00005007_13_T0	GENE	17	17	WG
NCT0000500713	NCT00005007_13_T1	PHENOTYPE	21	21	severity
NCT0000500714	NCT00005007_14_T0	GENE	6	6	WG
NCT0000500714	NCT00005007_14_T1	GENE	15	15	WG
NCT0000500714	NCT00005007_14_T2	COMPOUND	17	17	cyclophosphamide
NCT0000500714	NCT00005007_14_T3	COMPOUND	8	8	methotrexate
NCT0000500715	NCT00005007_15_T0	PHENOTYPE	48	48	remissions
NCT0000500717	NCT00005007_17_T0	PHENOTYPE	10	10	centers
NCT0000500718	NCT00005007_18_T0	PHENOTYPE	8	8	severity
NCT000050091	NCT00005009_1_T0	PHENOTYPE	17	17	zoster
NCT000050091	NCT00005009_1_T1	COMPOUND	8	8	VZV
NCT000050091	NCT00005009_1_T2	PHENOTYPE	13	13	chickenpox
NCT000050091	NCT00005009_1_T3	PHENOTYPE	16	16	shingles
NCT000050091	NCT00005009_1_T4	PHENOTYPE	14	14	varicella
NCT000050091	NCT00005009_1_T5	PHENOTYPE	5	6	varicella zoster
NCT000050092	NCT00005009_2_T0	PHENOTYPE	11	11	chickenpox
NCT000050093	NCT00005009_3_T0	ORGAN	3	3	kidney
NCT000050093	NCT00005009_3_T1	ORGAN	4	4	transplants
NCT000050095	NCT00005009_5_T0	ORGAN	20	20	kidney
NCT000050095	NCT00005009_5_T1	COMPOUND	13	13	VZV
NCT000050095	NCT00005009_5_T2	PHENOTYPE	14	14	infections
NCT000050095	NCT00005009_5_T3	GENE	19	19	had
NCT000050095	NCT00005009_5_T4	ORGAN	21	21	transplants
NCT0000500910	NCT00005009_10_T0	GENE	1	1	has
NCT0000500910	NCT00005009_10_T1	GENE	12	12	has
NCT0000500913	NCT00005009_13_T0	COMPOUND	22	22	VZV
NCT0000500913	NCT00005009_13_T1	ORGAN	17	17	transplant
NCT0000500913	NCT00005009_13_T2	ORGAN	37	37	transplant
NCT0000500913	NCT00005009_13_T3	PHENOTYPE	29	29	immunosuppression
NCT0000500913	NCT00005009_13_T4	PHENOTYPE	20	20	susceptible
NCT0000500914	NCT00005009_14_T0	ORGAN	19	19	graft
NCT0000500914	NCT00005009_14_T1	PHENOTYPE	16	16	varicella
NCT0000500916	NCT00005009_16_T0	PHENOTYPE	14	14	centers
NCT0000500916	NCT00005009_16_T1	PHENOTYPE	10	11	adverse reaction
NCT0000500917	NCT00005009_17_T0	PHENOTYPE	17	17	centers
NCT0000500917	NCT00005009_17_T1	GENE	8	8	had
NCT0000500917	NCT00005009_17_T2	PHENOTYPE	11	12	adverse reactions
NCT0000500918	NCT00005009_18_T0	PHENOTYPE	26	26	centers
NCT0000500920	NCT00005009_20_T0	ORGAN	22	22	graft
NCT0000500920	NCT00005009_20_T1	ORGAN	24	24	liver
NCT0000500920	NCT00005009_20_T2	PHENOTYPE	31	32	varicella infection
NCT0000500926	NCT00005009_26_T0	COMPOUND	21	21	VZV
NCT0000500926	NCT00005009_26_T1	PHENOTYPE	16	17	varicella infection
NCT0000500926	NCT00005009_26_T2	PHENOTYPE	22	23	antibody responses
NCT000050101	NCT00005010_1_T0	ORGAN	1	1	kidney
NCT000050101	NCT00005010_1_T1	ORGAN	2	2	transplant
NCT000050101	NCT00005010_1_T2	PHENOTYPE	8	8	chronic
NCT000050107	NCT00005010_7_T0	ORGAN	19	19	kidney
NCT000050107	NCT00005010_7_T1	GENE	14	14	TGF-beta
NCT000050107	NCT00005010_7_T2	GENE	16	16	PDGF
NCT000050107	NCT00005010_7_T3	PHENOTYPE	5	5	chronic
NCT000050108	NCT00005010_8_T0	PHENOTYPE	5	5	chronic
NCT000050108	NCT00005010_8_T1	PHENOTYPE	12	13	renal diseases
NCT000050108	NCT00005010_8_T2	MOLECULAR_FUNCTION	2	3	cytokine activity
NCT000050109	NCT00005010_9_T0	GENE	6	7	HMG-CoA reductase
NCT000050109	NCT00005010_9_T1	MOLECULAR_FUNCTION	0	2	Angiotensin converting enzyme
NCT0000501010	NCT00005010_10_T0	GENE	23	23	TGF-beta
NCT0000501010	NCT00005010_10_T1	GENE	25	25	PDGF
NCT0000501010	NCT00005010_10_T2	ORGAN	12	12	transplant
NCT0000501010	NCT00005010_10_T3	PHENOTYPE	5	5	fibrosis
NCT0000501010	NCT00005010_10_T4	PHENOTYPE	15	15	chronic
NCT0000501011	NCT00005010_11_T0	COMPOUND	6	6	irbesartan
NCT0000501011	NCT00005010_11_T1	GENE	29	29	TGF-beta
NCT0000501011	NCT00005010_11_T2	COMPOUND	16	16	pravastatin
NCT0000501011	NCT00005010_11_T3	PHENOTYPE	20	20	progression
NCT0000501011	NCT00005010_11_T4	ORGAN	39	39	kidney
NCT0000501011	NCT00005010_11_T5	GENE	30	30	PDGF
NCT0000501011	NCT00005010_11_T6	PHENOTYPE	22	22	chronic
NCT0000501011	NCT00005010_11_T7	TISSUE	32	33	connective tissue
NCT0000501012	NCT00005010_12_T0	GENE	26	26	TGF-beta
NCT0000501012	NCT00005010_12_T1	GENE	23	23	mRNA
NCT0000501012	NCT00005010_12_T2	ORGAN	17	17	allograft
NCT0000501012	NCT00005010_12_T3	GENE	27	27	PDGF
NCT0000501012	NCT00005010_12_T4	ORGAN	6	6	transplant
NCT0000501012	NCT00005010_12_T5	PHENOTYPE	18	18	nephropathy
NCT0000501012	NCT00005010_12_T6	PHENOTYPE	15	15	chronic
NCT0000501012	NCT00005010_12_T7	TISSUE	32	33	connective tissue
NCT0000501016	NCT00005010_16_T0	ORGAN	16	16	kidney
NCT0000501016	NCT00005010_16_T1	COMPOUND	6	6	creatinine
NCT0000501016	NCT00005010_16_T2	COMPOUND	8	8	potassium
NCT0000501016	NCT00005010_16_T3	ORGAN	5	5	serum
NCT0000501017	NCT00005010_17_T0	COMPOUND	16	16	creatinine
NCT0000501017	NCT00005010_17_T1	PHENOTYPE	6	6	toxicities
NCT0000501017	NCT00005010_17_T2	ORGAN	15	15	serum
NCT0000501017	NCT00005010_17_T3	PHENOTYPE	8	9	adverse events
NCT0000501018	NCT00005010_18_T0	ORGAN	19	19	kidney
NCT0000501018	NCT00005010_18_T1	COMPOUND	6	6	creatinine
NCT0000501018	NCT00005010_18_T2	GENE	10	10	5.0
NCT0000501018	NCT00005010_18_T3	ORGAN	18	18	transplant
NCT0000501018	NCT00005010_18_T4	GENE	7	7	has
NCT0000501018	NCT00005010_18_T5	ORGAN	5	5	serum
NCT0000501019	NCT00005010_19_T0	GENE	7	7	mRNA
NCT0000501019	NCT00005010_19_T1	PHENOTYPE	2	4	chronic allograft nephropathy
NCT0000501020	NCT00005010_20_T0	PHENOTYPE	9	9	initiation
NCT0000501020	NCT00005010_20_T1	PHENOTYPE	5	6	renal failure
NCT000050113	NCT00005011_3_T0	GENE	4	4	hormone
NCT000050114	NCT00005011_4_T0	COMPOUND	18	18	estrogen
NCT000050114	NCT00005011_4_T1	COMPOUND	33	33	estrogen
NCT000050114	NCT00005011_4_T2	COMPOUND	20	20	progesterone
NCT000050114	NCT00005011_4_T3	COMPOUND	35	35	progesterone
NCT000050116	NCT00005011_6_T0	COMPOUND	7	7	acetate
NCT000050116	NCT00005011_6_T1	COMPOUND	6	6	leuprolide
NCT000050117	NCT00005011_7_T0	PHENOTYPE	5	5	symptoms
NCT000050117	NCT00005011_7_T1	COMPOUND	15	15	estrogen
NCT000050117	NCT00005011_7_T2	COMPOUND	31	31	progesterone
NCT000050119	NCT00005011_9_T0	PHENOTYPE	24	25	hormone levels
NCT0000501111	NCT00005011_11_T0	GENE	5	5	hormone
NCT0000501112	NCT00005011_12_T0	PHENOTYPE	41	41	symptoms
NCT0000501112	NCT00005011_12_T1	GENE	8	8	hormone
NCT0000501112	NCT00005011_12_T2	GENE	18	18	hormone
NCT0000501112	NCT00005011_12_T3	GENE	27	27	hormone
NCT0000501112	NCT00005011_12_T4	PHENOTYPE	3	5	symptoms of depression
NCT0000501113	NCT00005011_13_T0	COMPOUND	34	34	progesterone
NCT0000501113	NCT00005011_13_T1	COMPOUND	23	23	acetate
NCT0000501113	NCT00005011_13_T2	PHENOTYPE	14	14	suppression
NCT0000501113	NCT00005011_13_T3	COMPOUND	22	22	leuprolide
NCT0000501113	NCT00005011_13_T4	COMPOUND	32	32	estradiol
NCT0000501113	NCT00005011_13_T5	PHENOTYPE	56	57	mood disorder
NCT0000501116	NCT00005011_16_T0	PHENOTYPE	15	16	behavioral disturbances
NCT0000501117	NCT00005011_17_T0	PHENOTYPE	0	0	Symptoms
NCT0000501117	NCT00005011_17_T1	BIOLOGICAL_PROCESS	12	13	follicular phase
NCT0000501122	NCT00005011_22_T0	PHENOTYPE	40	40	severity
NCT0000501122	NCT00005011_22_T1	PHENOTYPE	25	26	mood disorder
NCT0000501122	NCT00005011_22_T2	BIOLOGICAL_PROCESS	33	34	menstrual cycle
NCT0000501124	NCT00005011_24_T0	PHENOTYPE	19	19	IUD
NCT0000501126	NCT00005011_26_T0	PHENOTYPE	3	4	psychiatric diagnosis
NCT0000501127	NCT00005011_27_T0	PHENOTYPE	2	2	endometriosis
NCT0000501128	NCT00005011_28_T0	PHENOTYPE	8	9	ovarian enlargement
NCT0000501129	NCT00005011_29_T0	PHENOTYPE	0	1	Hepatic disease
NCT0000501129	NCT00005011_29_T1	PHENOTYPE	5	8	abnormal liver function tests
NCT0000501130	NCT00005011_30_T0	PHENOTYPE	2	3	mammary carcinoma
NCT0000501131	NCT00005011_31_T0	PHENOTYPE	5	5	phlebothrombosis
NCT0000501131	NCT00005011_31_T1	PHENOTYPE	2	3	pulmonary embolism
NCT0000501132	NCT00005011_32_T0	PHENOTYPE	1	2	vaginal bleeding
NCT0000501134	NCT00005011_34_T0	PHENOTYPE	0	0	Diabetes
NCT0000501136	NCT00005011_36_T0	PHENOTYPE	0	0	Cholecystitis
NCT000050123	NCT00005012_3_T0	GENE	6	6	log
NCT000050123	NCT00005012_3_T1	GENE	5	5	0.5
NCT000050123	NCT00005012_3_T2	PHENOTYPE	11	11	HIV
NCT000050130	NCT00005013_0_T0	PHENOTYPE	2	3	Major Depression
NCT000050135	NCT00005013_5_T0	PHENOTYPE	1	1	toxicity
NCT000050137	NCT00005013_7_T0	PHENOTYPE	3	3	acute
NCT000050139	NCT00005013_9_T0	GENE	14	14	has
NCT000050139	NCT00005013_9_T1	PHENOTYPE	22	23	clinical depression
NCT0000501313	NCT00005013_13_T0	PHENOTYPE	9	9	symptoms
NCT0000501319	NCT00005013_19_T0	COMPOUND	12	12	sertraline
NCT000050140	NCT00005014_0_T0	PHENOTYPE	2	2	Autism
NCT000050142	NCT00005014_2_T0	PHENOTYPE	16	16	centers
NCT000050145	NCT00005014_5_T0	COMPOUND	19	19	risperidone
NCT000050147	NCT00005014_7_T0	COMPOUND	9	9	risperidone
NCT000050148	NCT00005014_8_T0	COMPOUND	15	15	risperidone
NCT0000501410	NCT00005014_10_T0	COMPOUND	4	4	risperidone
NCT0000501410	NCT00005014_10_T1	COMPOUND	11	11	risperidone
NCT0000501410	NCT00005014_10_T2	GENE	9	9	tapered
NCT0000501411	NCT00005014_11_T0	PHENOTYPE	16	16	recurrence
NCT0000501411	NCT00005014_11_T1	PHENOTYPE	20	20	symptoms
NCT0000501412	NCT00005014_12_T0	COMPOUND	23	23	risperidone
NCT0000501416	NCT00005014_16_T0	PHENOTYPE	9	10	weight gain
NCT0000501418	NCT00005014_18_T0	COMPOUND	4	4	risperidone
NCT0000501420	NCT00005014_20_T0	COMPOUND	4	4	risperidone
NCT0000501421	NCT00005014_21_T0	COMPOUND	4	4	risperidone
NCT0000501423	NCT00005014_23_T0	PHENOTYPE	9	10	adverse events
NCT0000501428	NCT00005014_28_T0	GENE	19	19	II
NCT0000501429	NCT00005014_29_T0	GENE	6	6	reduced
NCT000050151	NCT00005015_1_T0	COMPOUND	11	11	fluoxetine
NCT000050151	NCT00005015_1_T1	PHENOTYPE	18	19	Bipolar Disorder
NCT000050151	NCT00005015_1_T2	PHENOTYPE	26	27	major depression
NCT000050153	NCT00005015_3_T0	COMPOUND	8	8	lithium
NCT000050153	NCT00005015_3_T1	COMPOUND	10	10	valproate
NCT000050153	NCT00005015_3_T2	COMPOUND	24	24	fluoxetine
NCT000050156	NCT00005015_6_T0	PHENOTYPE	4	4	recurrent
NCT000050156	NCT00005015_6_T1	PHENOTYPE	22	22	mania
NCT000050156	NCT00005015_6_T2	PHENOTYPE	12	13	mood swings
NCT000050156	NCT00005015_6_T3	PHENOTYPE	0	1	Bipolar disorder
NCT000050157	NCT00005015_7_T0	PHENOTYPE	1	2	mood swings
NCT000050157	NCT00005015_7_T1	PHENOTYPE	4	5	associated symptoms
NCT000050157	NCT00005015_7_T2	PHENOTYPE	12	13	mood changes
NCT000050158	NCT00005015_8_T0	PHENOTYPE	2	2	suffering
NCT000050158	NCT00005015_8_T1	PHENOTYPE	14	14	experiences
NCT000050158	NCT00005015_8_T2	PHENOTYPE	13	13	mania
NCT000050158	NCT00005015_8_T3	PHENOTYPE	4	5	bipolar disorder
NCT0000501511	NCT00005015_11_T0	PHENOTYPE	7	8	bipolar disorder
NCT0000501512	NCT00005015_12_T0	PHENOTYPE	1	2	bipolar disorder
NCT0000501514	NCT00005015_14_T0	COMPOUND	9	9	lithium
NCT0000501514	NCT00005015_14_T1	COMPOUND	11	11	valproate
NCT0000501514	NCT00005015_14_T2	PHENOTYPE	16	17	mood swings
NCT0000501514	NCT00005015_14_T3	PHENOTYPE	0	1	Bipolar disorder
NCT0000501515	NCT00005015_15_T0	PHENOTYPE	3	4	bipolar disorder
NCT0000501516	NCT00005015_16_T0	PHENOTYPE	14	15	depressive symptoms
NCT0000501520	NCT00005015_20_T0	COMPOUND	5	5	fluoxetine
NCT0000501520	NCT00005015_20_T1	GENE	2	2	has
NCT0000501520	NCT00005015_20_T2	PHENOTYPE	32	33	bipolar disorders
NCT0000501521	NCT00005015_21_T0	COMPOUND	14	14	lithium
NCT0000501521	NCT00005015_21_T1	COMPOUND	17	17	valproate
NCT0000501521	NCT00005015_21_T2	COMPOUND	28	28	fluoxetine
NCT0000501521	NCT00005015_21_T3	COMPOUND	15	15	carbonate
NCT0000501524	NCT00005015_24_T0	COMPOUND	4	4	fluoxetine
NCT0000501524	NCT00005015_24_T1	COMPOUND	11	11	fluoxetine
NCT0000501525	NCT00005015_25_T0	COMPOUND	12	12	fluoxetine
NCT0000501526	NCT00005015_26_T0	COMPOUND	25	25	lithium
NCT0000501526	NCT00005015_26_T1	COMPOUND	27	27	valproate
NCT0000501526	NCT00005015_26_T2	COMPOUND	14	14	fluoxetine
NCT0000501528	NCT00005015_28_T0	COMPOUND	6	6	lithium
NCT0000501528	NCT00005015_28_T1	COMPOUND	4	4	valproate
NCT0000501529	NCT00005015_29_T0	PHENOTYPE	6	7	bipolar disorder
NCT0000501529	NCT00005015_29_T1	PHENOTYPE	3	4	major depression
NCT0000501534	NCT00005015_34_T0	PHENOTYPE	0	1	Substance abuse
NCT0000501536	NCT00005015_36_T0	COMPOUND	8	8	fluoxetine
NCT000050162	NCT00005016_2_T0	PHENOTYPE	1	1	severity
NCT000050162	NCT00005016_2_T1	PHENOTYPE	3	3	symptoms
NCT0000501617	NCT00005016_17_T0	PHENOTYPE	15	15	focused
NCT0000501617	NCT00005016_17_T1	PHENOTYPE	19	19	experiences
NCT0000501618	NCT00005016_18_T0	PHENOTYPE	6	6	experiences
NCT0000501619	NCT00005016_19_T0	PHENOTYPE	4	4	experiences
NCT0000501621	NCT00005016_21_T0	PHENOTYPE	22	22	experiences
NCT0000501622	NCT00005016_22_T0	PHENOTYPE	1	1	perceived
NCT0000501623	NCT00005016_23_T0	PHENOTYPE	3	3	thoughts
NCT0000501625	NCT00005016_25_T0	PHENOTYPE	20	20	severity
NCT0000501625	NCT00005016_25_T1	PHENOTYPE	19	19	perceived
NCT0000501625	NCT00005016_25_T2	PHENOTYPE	11	11	tolerance
NCT0000501629	NCT00005016_29_T0	PHENOTYPE	4	4	experiences
NCT0000501629	NCT00005016_29_T1	PHENOTYPE	45	46	fetal anomaly
NCT000050172	NCT00005017_2_T0	ORGAN	9	9	plasma
NCT000050173	NCT00005017_3_T0	COMPOUND	6	6	2
NCT000050173	NCT00005017_3_T1	COMPOUND	12	12	3
NCT000050173	NCT00005017_3_T2	GENE	0	1	Group 1
NCT000050175	NCT00005017_5_T0	GENE	10	10	CD4
NCT000050175	NCT00005017_5_T1	PHENOTYPE	7	7	HIV
NCT000050175	NCT00005017_5_T2	ORGAN	6	6	plasma
NCT000050176	NCT00005017_6_T0	PHENOTYPE	15	15	secondary
NCT000050176	NCT00005017_6_T1	PHENOTYPE	6	6	suppression
NCT000050176	NCT00005017_6_T2	PHENOTYPE	8	9	virologic failure
NCT000050179	NCT00005017_9_T0	PHENOTYPE	3	3	HIV
NCT0000501710	NCT00005017_10_T0	PHENOTYPE	6	6	HIV
NCT0000501710	NCT00005017_10_T1	PHENOTYPE	19	20	Kaposi's sarcoma
NCT0000501714	NCT00005017_14_T0	PHENOTYPE	14	15	muscle weakness
NCT0000501715	NCT00005017_15_T0	ORGAN	4	4	pancreas
NCT0000501715	NCT00005017_15_T1	GENE	1	1	had
NCT0000501715	NCT00005017_15_T2	PHENOTYPE	2	2	pancreatitis
NCT0000501715	NCT00005017_15_T3	PHENOTYPE	6	6	hepatitis
NCT0000501716	NCT00005017_16_T0	GENE	1	1	had
NCT0000501717	NCT00005017_17_T0	PHENOTYPE	4	4	sarcoma
NCT0000501718	NCT00005017_18_T0	ORGAN	10	11	immune system
NCT0000501719	NCT00005017_19_T0	PHENOTYPE	3	3	HIV
NCT000050184	NCT00005018_4_T0	ORGAN	7	7	plasma
NCT000050189	NCT00005018_9_T0	GENE	8	8	protease
NCT000050200	NCT00005020_0_T0	PHENOTYPE	4	5	HIV Infection
NCT000050202	NCT00005020_2_T0	PHENOTYPE	12	12	acute
NCT000050202	NCT00005020_2_T1	PHENOTYPE	6	6	HIV
NCT000050202	NCT00005020_2_T2	PHENOTYPE	15	16	HIV infection
NCT000050208	NCT00005020_8_T0	PHENOTYPE	8	8	HIV
NCT000050208	NCT00005020_8_T1	GENE	12	12	CTL
NCT000050208	NCT00005020_8_T2	CELL	11	11	lymphocyte
NCT000050208	NCT00005020_8_T3	BIOLOGICAL_PROCESS	17	18	viral replication
NCT000050208	NCT00005020_8_T4	BIOLOGICAL_PROCESS	13	14	immune response
NCT000050209	NCT00005020_9_T0	CELL	5	5	cells
NCT000050209	NCT00005020_9_T1	PHENOTYPE	4	4	HIV
NCT000050209	NCT00005020_9_T2	PHENOTYPE	12	12	HIV
NCT000050209	NCT00005020_9_T3	ORGAN	11	11	plasma
NCT0000502010	NCT00005020_10_T0	PHENOTYPE	19	19	HIV
NCT0000502010	NCT00005020_10_T1	TISSUE	16	17	lymph nodes
NCT0000502014	NCT00005020_14_T0	TISSUE	9	10	lymphoid tissue
NCT0000502015	NCT00005020_15_T0	PHENOTYPE	0	0	Compensation
NCT0000502016	NCT00005020_16_T0	GENE	1	1	II
NCT0000502017	NCT00005020_17_T0	PHENOTYPE	5	5	HIV
NCT0000502017	NCT00005020_17_T1	ORGAN	4	4	plasma
NCT0000502019	NCT00005020_19_T0	TISSUE	9	10	lymphoid tissue
NCT0000502020	NCT00005020_20_T0	COMPOUND	13	13	glucose
NCT000050211	NCT00005021_1_T0	CELL	21	21	cells
NCT000050212	NCT00005021_2_T0	COMPOUND	10	10	paclitaxel
NCT000050212	NCT00005021_2_T1	PHENOTYPE	26	26	lymphoma
NCT000050212	NCT00005021_2_T2	GENE	16	16	filgrastim
NCT000050212	NCT00005021_2_T3	GENE	28	28	has
NCT000050212	NCT00005021_2_T4	COMPOUND	9	9	topotecan
NCT000050212	NCT00005021_2_T5	PHENOTYPE	23	24	solid tumor
NCT000050214	NCT00005021_4_T0	COMPOUND	8	8	paclitaxel
NCT000050214	NCT00005021_4_T1	PHENOTYPE	24	24	lymphomas
NCT000050214	NCT00005021_4_T2	GENE	15	15	filgrastim
NCT000050214	NCT00005021_4_T3	GENE	16	16	G-CSF
NCT000050214	NCT00005021_4_T4	COMPOUND	7	7	topotecan
NCT000050214	NCT00005021_4_T5	PHENOTYPE	21	22	solid tumors
NCT000050216	NCT00005021_6_T0	PHENOTYPE	2	2	toxic
NCT000050218	NCT00005021_8_T0	PHENOTYPE	2	2	pharmacokinetics
NCT000050218	NCT00005021_8_T1	PHENOTYPE	11	11	pharmacokinetics
NCT0000502113	NCT00005021_13_T0	COMPOUND	10	10	paclitaxel
NCT0000502113	NCT00005021_13_T1	GENE	8	8	1.3
NCT0000502113	NCT00005021_13_T2	GENE	5	5	IV
NCT0000502113	NCT00005021_13_T3	GENE	11	11	IV
NCT0000502113	NCT00005021_13_T4	GENE	17	17	IV
NCT0000502113	NCT00005021_13_T5	COMPOUND	4	4	topotecan
NCT0000502114	NCT00005021_14_T0	GENE	1	1	II
NCT0000502114	NCT00005021_14_T1	COMPOUND	5	5	paclitaxel
NCT0000502114	NCT00005021_14_T2	GENE	13	13	filgrastim
NCT0000502114	NCT00005021_14_T3	GENE	14	14	G-CSF
NCT0000502114	NCT00005021_14_T4	COMPOUND	4	4	topotecan
NCT0000502115	NCT00005021_15_T0	PHENOTYPE	13	13	toxicity
NCT0000502115	NCT00005021_15_T1	GENE	28	28	MTD
NCT0000502115	NCT00005021_15_T2	PHENOTYPE	9	10	disease progression
NCT0000502116	NCT00005021_16_T0	PHENOTYPE	18	18	toxicity
NCT0000502116	NCT00005021_16_T1	GENE	1	1	MTD
NCT000050222	NCT00005022_2_T0	CELL	8	8	cells
NCT000050222	NCT00005022_2_T1	PHENOTYPE	7	7	tumor
NCT000050223	NCT00005022_3_T0	CELL	13	13	cells
NCT000050223	NCT00005022_3_T1	PHENOTYPE	12	12	tumor
NCT0000502210	NCT00005022_10_T0	PHENOTYPE	2	2	toxic
NCT0000502210	NCT00005022_10_T1	ORGAN	9	9	lungs
NCT0000502210	NCT00005022_10_T2	ORGAN	7	7	esophagus
NCT0000502213	NCT00005022_13_T0	COMPOUND	2	2	1
NCT0000502214	NCT00005022_14_T0	COMPOUND	6	6	2
NCT0000502214	NCT00005022_14_T1	PHENOTYPE	0	0	Closed
NCT0000502215	NCT00005022_15_T0	COMPOUND	6	6	3
NCT0000502215	NCT00005022_15_T1	PHENOTYPE	0	0	Closed
NCT0000502216	NCT00005022_16_T0	PHENOTYPE	0	0	Closed
NCT0000502218	NCT00005022_18_T0	PHENOTYPE	0	0	Closed
NCT0000502219	NCT00005022_19_T0	PHENOTYPE	7	7	toxicity
NCT0000502219	NCT00005022_19_T1	PHENOTYPE	3	3	experiences
NCT0000502219	NCT00005022_19_T2	GENE	8	8	DLT
NCT0000502221	NCT00005022_21_T0	COMPOUND	5	5	etoposide
NCT0000502221	NCT00005022_21_T1	COMPOUND	14	14	etoposide
NCT0000502221	NCT00005022_21_T2	COMPOUND	2	2	cisplatin
NCT0000502221	NCT00005022_21_T3	GENE	3	3	IV
NCT0000502221	NCT00005022_21_T4	GENE	6	6	IV
NCT0000502223	NCT00005022_23_T0	PHENOTYPE	14	14	5-10
NCT000050231	NCT00005023_1_T0	PHENOTYPE	16	16	peripheral
NCT000050231	NCT00005023_1_T1	CELL	10	10	cells
NCT000050231	NCT00005023_1_T2	GENE	4	4	sargramostim
NCT000050231	NCT00005023_1_T3	ORGAN	13	14	bone marrow
NCT000050232	NCT00005023_2_T0	GENE	22	22	IV
NCT000050232	NCT00005023_2_T1	GENE	12	12	sargramostim
NCT000050232	NCT00005023_2_T2	PHENOTYPE	18	19	stage III
NCT000050234	NCT00005023_4_T0	PHENOTYPE	32	32	cancers
NCT000050234	NCT00005023_4_T1	GENE	17	17	PLG
NCT000050234	NCT00005023_4_T2	GENE	22	22	GM-CSF
NCT000050234	NCT00005023_4_T3	GENE	29	29	IV
NCT000050234	NCT00005023_4_T4	GENE	10	10	HER-2
NCT000050234	NCT00005023_4_T5	GENE	30	30	HER-2
NCT000050234	NCT00005023_4_T6	GENE	21	21	sargramostim
NCT000050234	NCT00005023_4_T7	PHENOTYPE	26	27	stage III
NCT000050238	NCT00005023_8_T0	GENE	15	15	CTL
NCT000050238	NCT00005023_8_T1	GENE	13	13	HER-2
NCT0000502310	NCT00005023_10_T0	PHENOTYPE	10	10	affects
NCT0000502310	NCT00005023_10_T1	GENE	8	8	PLG
NCT0000502310	NCT00005023_10_T2	BIOLOGICAL_PROCESS	12	13	immune response
NCT0000502315	NCT00005023_15_T0	PHENOTYPE	15	15	toxicity
NCT000050241	NCT00005024_1_T0	GENE	3	3	III
NCT000050241	NCT00005024_1_T1	COMPOUND	10	10	granisetron
NCT000050241	NCT00005024_1_T2	PHENOTYPE	27	28	malignant disease
NCT000050241	NCT00005024_1_T3	PHENOTYPE	18	20	nausea and vomiting
NCT000050243	NCT00005024_3_T0	COMPOUND	7	7	granisetron
NCT000050243	NCT00005024_3_T1	PHENOTYPE	34	35	malignant disease
NCT000050243	NCT00005024_3_T2	PHENOTYPE	12	14	nausea and vomiting
NCT000050247	NCT00005024_7_T0	COMPOUND	8	8	granisetron
NCT000050249	NCT00005024_9_T0	COMPOUND	16	16	granisetron
NCT000050254	NCT00005025_4_T0	CELL	9	9	cells
NCT000050254	NCT00005025_4_T1	PHENOTYPE	10	10	VPC
NCT000050254	NCT00005025_4_T2	COMPOUND	20	20	ganciclovir
NCT000050254	NCT00005025_4_T3	GENE	21	21	IV
NCT000050254	NCT00005025_4_T4	GENE	4	5	thymidine kinase
NCT000050254	NCT00005025_4_T5	PHENOTYPE	2	3	herpes simplex
NCT000050261	NCT00005026_1_T0	CELL	9	9	cells
NCT000050261	NCT00005026_1_T1	PHENOTYPE	8	8	tumor
NCT000050262	NCT00005026_2_T0	GENE	20	20	IV
NCT000050262	NCT00005026_2_T1	PHENOTYPE	16	17	stage III
NCT000050262	NCT00005026_2_T2	PHENOTYPE	25	26	peritoneal cancer
NCT000050264	NCT00005026_4_T0	COMPOUND	10	10	topotecan
NCT000050264	NCT00005026_4_T1	PHENOTYPE	26	28	primary peritoneal carcinoma
NCT000050268	NCT00005026_8_T0	PHENOTYPE	3	3	pharmacodynamic
NCT000050268	NCT00005026_8_T1	COMPOUND	12	12	topotecan
NCT0000502610	NCT00005026_10_T0	GENE	21	21	1.3
NCT0000502610	NCT00005026_10_T1	GENE	5	5	IV
NCT0000502610	NCT00005026_10_T2	GENE	15	15	IV
NCT0000502610	NCT00005026_10_T3	COMPOUND	14	14	topotecan
NCT0000502611	NCT00005026_11_T0	PHENOTYPE	16	16	toxicity
NCT0000502611	NCT00005026_11_T1	PHENOTYPE	12	13	disease progression
NCT0000502612	NCT00005026_12_T0	COMPOUND	3	3	paclitaxel
NCT0000502612	NCT00005026_12_T1	GENE	4	4	IV
NCT0000502612	NCT00005026_12_T2	GENE	11	11	IV
NCT0000502613	NCT00005026_13_T0	PHENOTYPE	16	16	toxicity
NCT0000502613	NCT00005026_13_T1	PHENOTYPE	12	13	disease progression
NCT0000502614	NCT00005026_14_T0	GENE	1	1	II
NCT0000502614	NCT00005026_14_T1	GENE	11	11	1.3
NCT0000502614	NCT00005026_14_T2	GENE	5	5	IV
NCT0000502614	NCT00005026_14_T3	GENE	15	15	IV
NCT0000502614	NCT00005026_14_T4	COMPOUND	4	4	topotecan
NCT0000502615	NCT00005026_15_T0	PHENOTYPE	16	16	toxicity
NCT0000502615	NCT00005026_15_T1	PHENOTYPE	12	13	disease progression
NCT0000502616	NCT00005026_16_T0	COMPOUND	3	3	paclitaxel
NCT0000502616	NCT00005026_16_T1	GENE	4	4	IV
NCT0000502616	NCT00005026_16_T2	GENE	11	11	IV
NCT0000502617	NCT00005026_17_T0	PHENOTYPE	16	16	toxicity
NCT0000502617	NCT00005026_17_T1	PHENOTYPE	12	13	disease progression
NCT0000502618	NCT00005026_18_T0	GENE	11	11	1.5
NCT0000502618	NCT00005026_18_T1	GENE	1	1	III
NCT0000502618	NCT00005026_18_T2	GENE	5	5	IV
NCT0000502618	NCT00005026_18_T3	GENE	15	15	IV
NCT0000502618	NCT00005026_18_T4	COMPOUND	4	4	topotecan
NCT0000502619	NCT00005026_19_T0	PHENOTYPE	16	16	toxicity
NCT0000502619	NCT00005026_19_T1	PHENOTYPE	12	13	disease progression
NCT0000502620	NCT00005026_20_T0	COMPOUND	3	3	paclitaxel
NCT0000502620	NCT00005026_20_T1	GENE	4	4	IV
NCT0000502620	NCT00005026_20_T2	GENE	11	11	IV
NCT0000502621	NCT00005026_21_T0	PHENOTYPE	16	16	toxicity
NCT0000502621	NCT00005026_21_T1	PHENOTYPE	12	13	disease progression
NCT000050271	NCT00005027_1_T0	GENE	2	2	II
NCT000050271	NCT00005027_1_T1	PHENOTYPE	17	18	kidney cancer
NCT000050271	NCT00005027_1_T2	COMPOUND	9	10	rebeccamycin analog
NCT000050273	NCT00005027_3_T0	GENE	5	5	IV
NCT000050273	NCT00005027_3_T1	COMPOUND	3	3	rebeccamycin
NCT000050274	NCT00005027_4_T0	PHENOTYPE	13	13	toxicity
NCT000050274	NCT00005027_4_T1	PHENOTYPE	9	10	disease progression
NCT000050281	NCT00005028_1_T0	CELL	10	10	cells
NCT000050281	NCT00005028_1_T1	PHENOTYPE	9	9	tumor
NCT000050282	NCT00005028_2_T0	CELL	9	9	cells
NCT000050282	NCT00005028_2_T1	PHENOTYPE	8	8	tumor
NCT000050286	NCT00005028_6_T0	PHENOTYPE	2	2	toxicity
NCT0000502810	NCT00005028_10_T0	COMPOUND	2	2	paclitaxel
NCT0000502810	NCT00005028_10_T1	GENE	3	3	IV
NCT0000502810	NCT00005028_10_T2	GENE	16	16	IV
NCT0000502810	NCT00005028_10_T3	COMPOUND	14	15	bryostatin 1
NCT0000502811	NCT00005028_11_T0	PHENOTYPE	13	13	toxicity
NCT0000502811	NCT00005028_11_T1	PHENOTYPE	9	10	disease progression
NCT000050291	NCT00005029_1_T0	GENE	2	2	II
NCT000050291	NCT00005029_1_T1	PHENOTYPE	15	15	recurrent
NCT000050291	NCT00005029_1_T2	COMPOUND	9	9	topotecan
NCT000050291	NCT00005029_1_T3	PHENOTYPE	20	21	peritoneal cancer
NCT000050293	NCT00005029_3_T0	COMPOUND	10	10	platinum
NCT000050293	NCT00005029_3_T1	PHENOTYPE	9	9	recurrent
NCT000050293	NCT00005029_3_T2	COMPOUND	5	5	topotecan
NCT000050293	NCT00005029_3_T3	PHENOTYPE	16	17	peritoneal cancer
NCT000050295	NCT00005029_5_T0	PHENOTYPE	6	6	toxicity
NCT000050296	NCT00005029_6_T0	GENE	10	10	1.3
NCT000050296	NCT00005029_6_T1	GENE	4	4	IV
NCT000050296	NCT00005029_6_T2	COMPOUND	3	3	topotecan
NCT000050297	NCT00005029_7_T0	PHENOTYPE	13	13	toxicity
NCT000050297	NCT00005029_7_T1	PHENOTYPE	9	10	disease progression
NCT000050311	NCT00005031_1_T0	GENE	2	2	II
NCT000050311	NCT00005031_1_T1	COMPOUND	9	9	irofulven
NCT000050311	NCT00005031_1_T2	PHENOTYPE	17	17	recurrent
NCT000050311	NCT00005031_1_T3	PHENOTYPE	19	20	endometrial cancer
NCT000050313	NCT00005031_3_T0	PHENOTYPE	11	11	recurrent
NCT000050313	NCT00005031_3_T1	PHENOTYPE	13	14	endometrial carcinoma
NCT000050315	NCT00005031_5_T0	PHENOTYPE	6	6	toxicity
NCT000050317	NCT00005031_7_T0	GENE	9	9	1.4
NCT000050317	NCT00005031_7_T1	GENE	3	3	IV
NCT000050318	NCT00005031_8_T0	PHENOTYPE	13	13	toxicity
NCT000050318	NCT00005031_8_T1	PHENOTYPE	9	10	disease progression
NCT000050322	NCT00005032_2_T0	CELL	15	15	cells
NCT000050322	NCT00005032_2_T1	PHENOTYPE	14	14	tumor
NCT000050322	NCT00005032_2_T2	GENE	0	0	Bcl-2
NCT000050329	NCT00005032_9_T0	GENE	4	4	bcl-2
NCT0000503211	NCT00005032_11_T0	GENE	10	10	1/6
NCT0000503211	NCT00005032_11_T1	GENE	2	2	bcl-2
NCT0000503211	NCT00005032_11_T2	GENE	6	6	IV
NCT0000503212	NCT00005032_12_T0	GENE	1	1	IV
NCT0000503213	NCT00005032_13_T0	PHENOTYPE	16	16	toxicity
NCT0000503213	NCT00005032_13_T1	PHENOTYPE	12	13	disease progression
NCT000050330	NCT00005033_0_T0	PHENOTYPE	5	6	Recurrent Osteosarcoma
NCT000050332	NCT00005033_2_T0	GENE	2	2	II
NCT000050332	NCT00005033_2_T1	PHENOTYPE	15	16	recurrent osteosarcoma
NCT000050335	NCT00005033_5_T0	GENE	4	4	IV
NCT000050336	NCT00005033_6_T0	PHENOTYPE	15	15	toxicity
NCT000050336	NCT00005033_6_T1	PHENOTYPE	11	12	disease progression
NCT000050350	NCT00005035_0_T0	PHENOTYPE	6	9	Head and Neck Cancer
NCT000050352	NCT00005035_2_T0	GENE	2	2	II
NCT000050352	NCT00005035_2_T1	COMPOUND	9	9	oxaliplatin
NCT000050352	NCT00005035_2_T2	PHENOTYPE	16	19	head and neck cancer
NCT000050356	NCT00005035_6_T0	PHENOTYPE	4	4	pharmacokinetics
NCT000050356	NCT00005035_6_T1	PHENOTYPE	2	2	toxicities
NCT000050358	NCT00005035_8_T0	PHENOTYPE	7	7	progression
NCT0000503510	NCT00005035_10_T0	COMPOUND	2	2	oxaliplatin
NCT0000503510	NCT00005035_10_T1	GENE	3	3	IV
NCT0000503511	NCT00005035_11_T0	PHENOTYPE	10	10	toxicity
NCT0000503511	NCT00005035_11_T1	PHENOTYPE	12	13	disease progression
NCT0000503512	NCT00005035_12_T0	PHENOTYPE	4	4	toxicity
NCT0000503513	NCT00005035_13_T0	GENE	5	5	34.74
NCT000050361	NCT00005036_1_T0	CELL	10	10	cells
NCT000050361	NCT00005036_1_T1	PHENOTYPE	9	9	tumor
NCT000050362	NCT00005036_2_T0	CELL	9	9	cells
NCT000050362	NCT00005036_2_T1	PHENOTYPE	8	8	tumor
NCT000050363	NCT00005036_3_T0	PHENOTYPE	12	13	colorectal cancer
NCT000050367	NCT00005036_7_T0	PHENOTYPE	10	10	toxicity
NCT000050367	NCT00005036_7_T1	PHENOTYPE	4	5	tumor progression
NCT000050369	NCT00005036_9_T0	PHENOTYPE	2	2	quality-of-life
NCT0000503611	NCT00005036_11_T0	COMPOUND	10	10	2
NCT0000503611	NCT00005036_11_T1	COMPOUND	32	32	2
NCT0000503611	NCT00005036_11_T2	COMPOUND	36	36	2
NCT0000503611	NCT00005036_11_T3	GENE	28	29	alkaline phosphatase
NCT0000503613	NCT00005036_13_T0	COMPOUND	4	4	irinotecan
NCT0000503613	NCT00005036_13_T1	GENE	0	0	ARM
NCT0000503613	NCT00005036_13_T2	GENE	5	5	IV
NCT0000503614	NCT00005036_14_T0	PHENOTYPE	13	13	toxicity
NCT0000503614	NCT00005036_14_T1	PHENOTYPE	9	10	disease progression
NCT0000503615	NCT00005036_15_T0	GENE	1	1	II
NCT0000503615	NCT00005036_15_T1	COMPOUND	13	13	calcium
NCT0000503615	NCT00005036_15_T2	COMPOUND	4	4	oxaliplatin
NCT0000503615	NCT00005036_15_T3	GENE	0	0	ARM
NCT0000503615	NCT00005036_15_T4	COMPOUND	12	12	leucovorin
NCT0000503615	NCT00005036_15_T5	GENE	5	5	IV
NCT0000503615	NCT00005036_15_T6	GENE	14	14	IV
NCT0000503615	NCT00005036_15_T7	GENE	25	25	IV
NCT0000503615	NCT00005036_15_T8	GENE	29	29	IV
NCT0000503616	NCT00005036_16_T0	PHENOTYPE	13	13	toxicity
NCT0000503616	NCT00005036_16_T1	PHENOTYPE	9	10	disease progression
NCT0000503617	NCT00005036_17_T0	PHENOTYPE	5	5	toxicity
NCT0000503617	NCT00005036_17_T1	PHENOTYPE	3	3	progression
NCT0000503619	NCT00005036_19_T0	PHENOTYPE	0	2	Quality of life
NCT000050376	NCT00005037_6_T0	PHENOTYPE	4	4	progression
NCT000050377	NCT00005037_7_T0	PHENOTYPE	8	8	closed
NCT000050378	NCT00005037_8_T0	COMPOUND	3	3	temozolomide
NCT000050379	NCT00005037_9_T0	PHENOTYPE	18	18	toxicity
NCT000050379	NCT00005037_9_T1	PHENOTYPE	14	15	disease progression
NCT000050381	NCT00005038_1_T0	COMPOUND	1	1	dihydrochloride
NCT000050381	NCT00005038_1_T1	PHENOTYPE	7	9	quality of life
NCT000050381	NCT00005038_1_T2	PHENOTYPE	13	15	metastatic kidney cancer
NCT000050382	NCT00005038_2_T0	GENE	3	3	II
NCT000050382	NCT00005038_2_T1	COMPOUND	14	14	histamine
NCT000050382	NCT00005038_2_T2	COMPOUND	15	15	dihydrochloride
NCT000050382	NCT00005038_2_T3	GENE	10	10	interleukin-2
NCT000050382	NCT00005038_2_T4	PHENOTYPE	21	23	metastatic kidney cancer
NCT0000503910	NCT00005039_10_T0	GENE	15	15	IM
NCT0000503912	NCT00005039_12_T0	PHENOTYPE	5	5	toxicity
NCT0000503913	NCT00005039_13_T0	PHENOTYPE	5	5	toxicity
NCT0000503914	NCT00005039_14_T0	PHENOTYPE	22	22	toxicity
NCT0000503914	NCT00005039_14_T1	GENE	4	4	MTD
NCT0000503914	NCT00005039_14_T2	PHENOTYPE	16	16	experiences
NCT0000503920	NCT00005039_20_T0	PHENOTYPE	9	10	disease progression
NCT000050401	NCT00005040_1_T0	GENE	2	2	II
NCT000050401	NCT00005040_1_T1	COMPOUND	9	10	arsenic trioxide
NCT000050401	NCT00005040_1_T2	PHENOTYPE	19	20	Hodgkin's lymphoma
NCT000050403	NCT00005040_3_T0	PHENOTYPE	30	30	lymphoma
NCT000050403	NCT00005040_3_T1	PHENOTYPE	13	13	progression
NCT000050403	NCT00005040_3_T2	COMPOUND	33	34	arsenic trioxide
NCT000050403	NCT00005040_3_T3	PHENOTYPE	28	29	high grade
NCT000050405	NCT00005040_5_T0	PHENOTYPE	2	2	toxicity
NCT000050406	NCT00005040_6_T0	GENE	7	7	2.4
NCT000050406	NCT00005040_6_T1	GENE	22	22	3.4
NCT000050406	NCT00005040_6_T2	GENE	5	5	IV
NCT000050406	NCT00005040_6_T3	COMPOUND	3	4	arsenic trioxide
NCT000050407	NCT00005040_7_T0	PHENOTYPE	19	19	toxicity
NCT000050407	NCT00005040_7_T1	PHENOTYPE	15	16	disease progression
NCT000050408	NCT00005040_8_T0	PHENOTYPE	5	5	tumor
NCT000050408	NCT00005040_8_T1	PHENOTYPE	6	6	regression
NCT0000504012	NCT00005040_12_T0	PHENOTYPE	18	18	lymphoma
NCT0000504012	NCT00005040_12_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000504012	NCT00005040_12_T2	PHENOTYPE	16	17	high grade
NCT000050416	NCT00005041_6_T0	PHENOTYPE	4	5	disease progression
NCT000050416	NCT00005041_6_T1	PHENOTYPE	8	10	quality of life
NCT0000504110	NCT00005041_10_T0	GENE	4	4	ras
NCT0000504110	NCT00005041_10_T1	PHENOTYPE	12	12	blocks
NCT0000504113	NCT00005041_13_T0	PHENOTYPE	7	7	toxicity
NCT0000504113	NCT00005041_13_T1	PHENOTYPE	9	10	disease progression
NCT0000504114	NCT00005041_14_T0	PHENOTYPE	0	2	Quality of life
NCT000050421	NCT00005042_1_T0	GENE	2	2	II
NCT000050421	NCT00005042_1_T1	PHENOTYPE	16	17	Kaposi's sarcoma
NCT000050423	NCT00005042_3_T0	PHENOTYPE	13	14	Kaposi's sarcoma
NCT000050427	NCT00005042_7_T0	PHENOTYPE	2	2	pharmacokinetics
NCT000050429	NCT00005042_9_T0	PHENOTYPE	7	7	HIV
NCT0000504211	NCT00005042_11_T0	PHENOTYPE	14	14	symptoms
NCT0000504211	NCT00005042_11_T1	PHENOTYPE	12	12	tumor
NCT0000504211	NCT00005042_11_T2	PHENOTYPE	8	10	quality of life
NCT0000504213	NCT00005042_13_T0	GENE	3	3	IV
NCT0000504214	NCT00005042_14_T0	PHENOTYPE	15	15	toxicity
NCT0000504214	NCT00005042_14_T1	PHENOTYPE	11	12	disease progression
NCT0000504215	NCT00005042_15_T0	PHENOTYPE	0	2	Quality of life
NCT000050442	NCT00005044_2_T0	CELL	8	8	cells
NCT000050442	NCT00005044_2_T1	PHENOTYPE	7	7	tumor
NCT0000504410	NCT00005044_10_T0	GENE	4	4	LHRH
NCT0000504410	NCT00005044_10_T1	COMPOUND	14	14	flutamide
NCT0000504410	NCT00005044_10_T2	GENE	13	13	OR
NCT0000504410	NCT00005044_10_T3	GENE	9	9	1.3
NCT0000504410	NCT00005044_10_T4	COMPOUND	12	12	bicalutamide
NCT0000504410	NCT00005044_10_T5	GENE	1	3	luteinizing hormone-releasing hormone
NCT0000504417	NCT00005044_17_T0	PHENOTYPE	0	0	Adenocarcinoma
NCT0000504419	NCT00005044_19_T0	GENE	5	5	II
NCT0000504419	NCT00005044_19_T1	ORGAN	4	4	Appendix
NCT0000504421	NCT00005044_21_T0	GENE	10	10	VI
NCT0000504421	NCT00005044_21_T1	PHENOTYPE	2	2	tumor
NCT0000504421	NCT00005044_21_T2	ORGAN	9	9	Appendix
NCT0000504425	NCT00005044_25_T0	GENE	5	5	LN
NCT0000504425	NCT00005044_25_T1	GENE	19	19	LN
NCT0000504425	NCT00005044_25_T2	GENE	16	16	LAG
NCT0000504425	NCT00005044_25_T3	GENE	14	14	MRI
NCT0000504425	NCT00005044_25_T4	GENE	12	12	abdominal
NCT0000504425	NCT00005044_25_T5	GENE	21	21	nodal
NCT0000504425	NCT00005044_25_T6	TISSUE	3	4	lymph nodes
NCT0000504426	NCT00005044_26_T0	GENE	7	7	LAG
NCT0000504426	NCT00005044_26_T1	PHENOTYPE	42	42	malignancy
NCT0000504426	NCT00005044_26_T2	GENE	5	5	MRI
NCT0000504426	NCT00005044_26_T3	GENE	16	16	nodal
NCT0000504426	NCT00005044_26_T4	PHENOTYPE	36	37	neoplastic process
NCT0000504427	NCT00005044_27_T0	GENE	9	9	1.5
NCT0000504427	NCT00005044_27_T1	GENE	10	10	cm
NCT0000504427	NCT00005044_27_T2	GENE	6	6	nodal
NCT0000504429	NCT00005044_29_T0	PHENOTYPE	3	3	metastases
NCT0000504437	NCT00005044_37_T0	ORGAN	8	8	Appendix
NCT0000504443	NCT00005044_43_T0	GENE	5	5	T1a
NCT0000504445	NCT00005044_45_T0	GENE	18	18	M1
NCT0000504445	NCT00005044_45_T1	PHENOTYPE	5	5	tumor
NCT0000504445	NCT00005044_45_T2	TISSUE	9	10	lymph nodes
NCT0000504445	NCT00005044_45_T3	PHENOTYPE	16	17	metastatic disease
NCT0000504449	NCT00005044_49_T0	GENE	19	19	10
NCT0000504456	NCT00005044_56_T0	PHENOTYPE	3	4	psychiatric illness
NCT000050451	NCT00005045_1_T0	GENE	2	2	II
NCT000050451	NCT00005045_1_T1	COMPOUND	9	9	carboxyamidotriazole
NCT000050451	NCT00005045_1_T2	GENE	19	19	has
NCT000050451	NCT00005045_1_T3	PHENOTYPE	16	17	kidney cancer
NCT000050455	NCT00005045_5_T0	PHENOTYPE	2	2	progression
NCT000050457	NCT00005045_7_T0	PHENOTYPE	2	3	toxic effect
NCT000050458	NCT00005045_8_T0	COMPOUND	4	4	carboxyamidotriazole
NCT000050459	NCT00005045_9_T0	PHENOTYPE	13	13	toxicity
NCT000050459	NCT00005045_9_T1	PHENOTYPE	9	10	disease progression
NCT000050461	NCT00005046_1_T0	COMPOUND	9	9	paclitaxel
NCT000050461	NCT00005046_1_T1	PHENOTYPE	15	15	recurrent
NCT000050461	NCT00005046_1_T2	PHENOTYPE	21	22	peritoneal cancer
NCT000050463	NCT00005046_3_T0	COMPOUND	9	9	paclitaxel
NCT000050463	NCT00005046_3_T1	PHENOTYPE	15	15	recurrent
NCT000050463	NCT00005046_3_T2	PHENOTYPE	20	22	primary peritoneal carcinoma
NCT000050467	NCT00005046_7_T0	COMPOUND	2	2	paclitaxel
NCT000050467	NCT00005046_7_T1	PHENOTYPE	3	3	concentrations
NCT000050467	NCT00005046_7_T2	ORGAN	1	1	plasma
NCT000050469	NCT00005046_9_T0	COMPOUND	3	3	paclitaxel
NCT0000504610	NCT00005046_10_T0	COMPOUND	9	9	paclitaxel
NCT0000504610	NCT00005046_10_T1	GENE	2	2	1.3
NCT0000504610	NCT00005046_10_T2	GENE	17	17	MTD
NCT0000504611	NCT00005046_11_T0	PHENOTYPE	18	18	toxicities
NCT0000504611	NCT00005046_11_T1	GENE	1	1	MTD
NCT0000504612	NCT00005046_12_T0	GENE	2	2	probable
NCT0000504612	NCT00005046_12_T1	GENE	3	3	MTD
NCT0000504612	NCT00005046_12_T2	GENE	17	17	MTD
NCT0000504613	NCT00005046_13_T0	GENE	1	1	MTD
NCT000050471	NCT00005047_1_T0	CELL	9	9	cells
NCT000050471	NCT00005047_1_T1	PHENOTYPE	8	8	tumor
NCT000050472	NCT00005047_2_T0	PHENOTYPE	16	17	bladder cancer
NCT000050473	NCT00005047_3_T0	GENE	4	4	III
NCT000050473	NCT00005047_3_T1	PHENOTYPE	24	25	bladder cancer
NCT000050481	NCT00005048_1_T0	CELL	9	9	cells
NCT000050481	NCT00005048_1_T1	PHENOTYPE	8	8	tumor
NCT000050486	NCT00005048_6_T0	PHENOTYPE	2	2	toxicity
NCT000050486	NCT00005048_6_T1	COMPOUND	10	10	paclitaxel
NCT000050486	NCT00005048_6_T2	GENE	8	8	MTD
NCT000050488	NCT00005048_8_T0	PHENOTYPE	3	3	tumor
NCT000050489	NCT00005048_9_T0	COMPOUND	8	8	paclitaxel
NCT0000504810	NCT00005048_10_T0	COMPOUND	9	9	paclitaxel
NCT0000504810	NCT00005048_10_T1	GENE	7	7	1.3
NCT0000504810	NCT00005048_10_T2	COMPOUND	3	3	estramustine
NCT0000504810	NCT00005048_10_T3	GENE	10	10	IV
NCT0000504811	NCT00005048_11_T0	PHENOTYPE	12	12	toxicity
NCT0000504811	NCT00005048_11_T1	PHENOTYPE	14	15	disease progression
NCT0000504812	NCT00005048_12_T0	COMPOUND	8	8	paclitaxel
NCT0000504812	NCT00005048_12_T1	GENE	14	14	MTD
NCT0000504813	NCT00005048_13_T0	PHENOTYPE	18	18	toxicities
NCT0000504813	NCT00005048_13_T1	GENE	1	1	MTD
NCT000050491	NCT00005049_1_T0	CELL	15	15	cells
NCT000050491	NCT00005049_1_T1	PHENOTYPE	14	14	tumor
NCT000050492	NCT00005049_2_T0	GENE	2	2	II
NCT000050492	NCT00005049_2_T1	PHENOTYPE	23	24	gastrointestinal cancer
NCT000050492	NCT00005049_2_T2	PHENOTYPE	17	21	stage III ovarian epithelial cancer
NCT000050494	NCT00005049_4_T0	GENE	22	22	0.5
NCT000050494	NCT00005049_4_T1	GENE	27	27	0.5
NCT000050494	NCT00005049_4_T2	GENE	23	23	cm
NCT000050494	NCT00005049_4_T3	GENE	28	28	cm
NCT000050494	NCT00005049_4_T4	GENE	34	34	cm
NCT000050494	NCT00005049_4_T5	PHENOTYPE	8	9	residual disease
NCT000050495	NCT00005049_5_T0	GENE	6	6	1.3
NCT000050495	NCT00005049_5_T1	COMPOUND	10	10	cisplatin
NCT000050496	NCT00005049_6_T0	PHENOTYPE	16	16	toxicity
NCT000050496	NCT00005049_6_T1	PHENOTYPE	12	13	disease progression
NCT000050501	NCT00005050_1_T0	CELL	9	9	cells
NCT000050501	NCT00005050_1_T1	PHENOTYPE	8	8	tumor
NCT000050502	NCT00005050_2_T0	COMPOUND	10	10	eniluracil
NCT000050502	NCT00005050_2_T1	COMPOUND	13	13	oxaliplatin
NCT000050502	NCT00005050_2_T2	GENE	23	23	has
NCT000050502	NCT00005050_2_T3	PHENOTYPE	20	21	colorectal cancer
NCT000050504	NCT00005050_4_T0	GENE	11	11	II
NCT000050504	NCT00005050_4_T1	PHENOTYPE	7	7	toxicity
NCT000050504	NCT00005050_4_T2	COMPOUND	14	14	eniluracil
NCT000050504	NCT00005050_4_T3	COMPOUND	17	17	oxaliplatin
NCT000050504	NCT00005050_4_T4	PHENOTYPE	24	25	colorectal cancer
NCT000050507	NCT00005050_7_T0	COMPOUND	8	8	eniluracil
NCT000050508	NCT00005050_8_T0	COMPOUND	3	3	eniluracil
NCT000050509	NCT00005050_9_T0	COMPOUND	2	2	oxaliplatin
NCT000050509	NCT00005050_9_T1	GENE	3	3	IV
NCT0000505010	NCT00005050_10_T0	PHENOTYPE	13	13	toxicity
NCT0000505010	NCT00005050_10_T1	PHENOTYPE	9	10	disease progression
NCT0000505012	NCT00005050_12_T0	COMPOUND	8	8	eniluracil
NCT0000505012	NCT00005050_12_T1	GENE	16	16	MTD
NCT0000505013	NCT00005050_13_T0	PHENOTYPE	22	22	toxicity
NCT0000505013	NCT00005050_13_T1	GENE	1	1	MTD
NCT0000505014	NCT00005050_14_T0	GENE	3	3	II
NCT0000505014	NCT00005050_14_T1	GENE	14	14	MTD
NCT0000505016	NCT00005050_16_T0	GENE	26	26	II
NCT000050511	NCT00005051_1_T0	CELL	9	9	cells
NCT000050511	NCT00005051_1_T1	PHENOTYPE	8	8	tumor
NCT000050512	NCT00005051_2_T0	GENE	2	2	II
NCT000050512	NCT00005051_2_T1	PHENOTYPE	17	19	ovarian epithelial cancer
NCT000050515	NCT00005051_5_T0	GENE	1	1	IV
NCT000050516	NCT00005051_6_T0	COMPOUND	1	1	topotecan
NCT000050520	NCT00005052_0_T0	PHENOTYPE	7	9	Stage II Melanoma
NCT000050522	NCT00005052_2_T0	PHENOTYPE	15	15	melanoma
NCT000050523	NCT00005052_3_T0	GENE	4	4	III
NCT000050523	NCT00005052_3_T1	PHENOTYPE	25	27	stage II melanoma
NCT000050526	NCT00005052_6_T0	PHENOTYPE	28	28	ulceration
NCT000050526	NCT00005052_6_T1	GENE	13	13	3.0
NCT000050526	NCT00005052_6_T2	GENE	18	18	3.0
NCT000050526	NCT00005052_6_T3	GENE	20	20	4.0
NCT000050526	NCT00005052_6_T4	GENE	25	25	4.0
NCT000050526	NCT00005052_6_T5	PHENOTYPE	7	7	tumor
NCT000050526	NCT00005052_6_T6	GENE	11	11	1.5
NCT000050526	NCT00005052_6_T7	TISSUE	40	41	lymph nodes
NCT000050531	NCT00005053_1_T0	ORGAN	7	7	kidney
NCT000050531	NCT00005053_1_T1	CELL	8	8	cells
NCT000050531	NCT00005053_1_T2	PHENOTYPE	12	14	effects of chemotherapy
NCT000050532	NCT00005053_2_T0	GENE	3	3	II
NCT000050532	NCT00005053_2_T1	COMPOUND	10	10	glufosfamide
NCT000050532	NCT00005053_2_T2	PHENOTYPE	20	21	pancreatic cancer
NCT000050534	NCT00005053_4_T0	COMPOUND	4	4	glufosfamide
NCT000050534	NCT00005053_4_T1	PHENOTYPE	18	19	pancreatic cancer
NCT0000505310	NCT00005053_10_T0	PHENOTYPE	2	2	toxic
NCT0000505312	NCT00005053_12_T0	PHENOTYPE	7	7	toxicity
NCT0000505316	NCT00005053_16_T0	COMPOUND	18	18	glufosfamide
NCT0000505317	NCT00005053_17_T0	PHENOTYPE	13	13	toxicity
NCT0000505317	NCT00005053_17_T1	PHENOTYPE	9	10	disease progression
NCT0000505319	NCT00005053_19_T0	PHENOTYPE	7	8	disease progression
NCT000050541	NCT00005054_1_T0	COMPOUND	9	9	temozolomide
NCT000050541	NCT00005054_1_T1	GENE	2	2	II
NCT000050541	NCT00005054_1_T2	PHENOTYPE	16	17	breast cancer
NCT000050543	NCT00005054_3_T0	COMPOUND	5	5	temozolomide
NCT000050543	NCT00005054_3_T1	PHENOTYPE	9	9	tumor
NCT000050543	NCT00005054_3_T2	PHENOTYPE	11	11	progression
NCT000050543	NCT00005054_3_T3	PHENOTYPE	20	21	breast cancer
NCT000050545	NCT00005054_5_T0	PHENOTYPE	11	11	peripheral
NCT000050545	NCT00005054_5_T1	PHENOTYPE	27	27	tumor
NCT000050545	NCT00005054_5_T2	GENE	4	4	ATase
NCT000050545	NCT00005054_5_T3	BIOLOGICAL_PROCESS	7	8	DNA methylation
NCT000050546	NCT00005054_6_T0	COMPOUND	4	4	temozolomide
NCT000050547	NCT00005054_7_T0	PHENOTYPE	22	22	toxicity
NCT000050547	NCT00005054_7_T1	PHENOTYPE	24	25	disease progression
NCT000050552	NCT00005055_2_T0	ORGAN	6	6	kidney
NCT000050552	NCT00005055_2_T1	CELL	7	7	cells
NCT000050552	NCT00005055_2_T2	PHENOTYPE	11	13	effects of chemotherapy
NCT0000505511	NCT00005055_11_T0	PHENOTYPE	2	2	toxicities
NCT0000505513	NCT00005055_13_T0	PHENOTYPE	9	9	toxicity
NCT0000505517	NCT00005055_17_T0	COMPOUND	5	5	glufosfamide
NCT0000505520	NCT00005055_20_T0	COMPOUND	17	17	glufosfamide
NCT0000505523	NCT00005055_23_T0	PHENOTYPE	7	8	disease progression
NCT000050562	NCT00005056_2_T0	PHENOTYPE	7	7	progressive
NCT000050562	NCT00005056_2_T1	PHENOTYPE	8	8	hypernephroma
NCT000050562	NCT00005056_2_T2	COMPOUND	11	12	bryostatin 1
NCT000050564	NCT00005056_4_T0	PHENOTYPE	2	2	toxicity
NCT000050566	NCT00005056_6_T0	GENE	4	4	IV
NCT000050566	NCT00005056_6_T1	COMPOUND	2	3	bryostatin 1
NCT000050568	NCT00005056_8_T0	PHENOTYPE	25	25	toxicity
NCT000050568	NCT00005056_8_T1	PHENOTYPE	21	22	disease progression
NCT000050570	NCT00005057_0_T0	PHENOTYPE	10	10	Melanoma
NCT000050570	NCT00005057_0_T1	GENE	9	9	IV
NCT000050572	NCT00005057_2_T0	PHENOTYPE	16	18	stage IV melanoma
NCT000050574	NCT00005057_4_T0	COMPOUND	6	6	ganciclovir
NCT000050574	NCT00005057_4_T1	GENE	8	8	IV
NCT000050574	NCT00005057_4_T2	PHENOTYPE	31	33	metastatic malignant melanoma
NCT000050576	NCT00005057_6_T0	PHENOTYPE	4	4	toxicities
NCT000050578	NCT00005057_8_T0	COMPOUND	15	15	ganciclovir
NCT000050578	NCT00005057_8_T1	COMPOUND	26	26	ganciclovir
NCT000050579	NCT00005057_9_T0	COMPOUND	8	8	ganciclovir
NCT0000505710	NCT00005057_10_T0	PHENOTYPE	12	13	metastatic disease
NCT0000505712	NCT00005057_12_T0	GENE	9	9	3-10
NCT0000505712	NCT00005057_12_T1	GENE	1	1	IV
NCT0000505713	NCT00005057_13_T0	GENE	5	5	PR
NCT0000505713	NCT00005057_13_T1	GENE	17	17	PR
NCT0000505713	NCT00005057_13_T2	GENE	9	9	CR
NCT0000505713	NCT00005057_13_T3	GENE	19	19	CR
NCT0000505714	NCT00005057_14_T0	COMPOUND	8	8	ganciclovir
NCT0000505714	NCT00005057_14_T1	GENE	14	14	MTD
NCT0000505715	NCT00005057_15_T0	PHENOTYPE	18	18	toxicities
NCT0000505715	NCT00005057_15_T1	GENE	1	1	MTD
NCT0000505716	NCT00005057_16_T0	GENE	23	23	1.5
NCT000050581	NCT00005058_1_T0	PHENOTYPE	13	14	breast cancer
NCT000050583	NCT00005058_3_T0	TISSUE	9	10	lymph nodes
NCT000050583	NCT00005058_3_T1	PHENOTYPE	30	31	breast cancer
NCT000050587	NCT00005058_7_T0	PHENOTYPE	6	6	tumor
NCT000050587	NCT00005058_7_T1	ORGAN	2	2	microvessel
NCT000050587	NCT00005058_7_T2	PHENOTYPE	15	17	lymph node metastases
NCT0000505811	NCT00005058_11_T0	PHENOTYPE	1	1	tumor
NCT0000505813	NCT00005058_13_T0	GENE	5	5	IV
NCT0000505815	NCT00005058_15_T0	TISSUE	12	13	lymph nodes
NCT0000505816	NCT00005058_16_T0	TISSUE	22	23	lymph nodes
NCT0000505817	NCT00005058_17_T0	TISSUE	14	15	lymph nodes
NCT000050592	NCT00005059_2_T0	CELL	9	9	cells
NCT000050592	NCT00005059_2_T1	PHENOTYPE	8	8	tumor
NCT000050597	NCT00005059_7_T0	PHENOTYPE	2	2	toxicity
NCT000050599	NCT00005059_9_T0	PHENOTYPE	10	10	recruitment
NCT0000505911	NCT00005059_11_T0	PHENOTYPE	15	15	toxicity
NCT000050601	NCT00005060_1_T0	CELL	12	12	cells
NCT000050601	NCT00005060_1_T1	PHENOTYPE	11	11	tumor
NCT000050602	NCT00005060_2_T0	PHENOTYPE	19	20	stomach cancer
NCT000050603	NCT00005060_3_T0	GENE	4	4	III
NCT000050603	NCT00005060_3_T1	PHENOTYPE	32	33	stomach cancer
NCT000050606	NCT00005060_6_T0	GENE	15	15	II
NCT000050606	NCT00005060_6_T1	ORGAN	12	12	cardia
NCT000050606	NCT00005060_6_T2	PHENOTYPE	13	13	carcinoma
NCT000050606	NCT00005060_6_T3	PHENOTYPE	7	7	tumor
NCT000050606	NCT00005060_6_T4	GENE	17	17	III
NCT000050606	NCT00005060_6_T5	GENE	24	24	nodal
NCT000050608	NCT00005060_8_T0	PHENOTYPE	9	10	progressive disease
NCT000050609	NCT00005060_9_T0	PHENOTYPE	14	14	toxicity
NCT000050609	NCT00005060_9_T1	PHENOTYPE	16	17	disease progression
NCT0000506012	NCT00005060_12_T0	PHENOTYPE	0	2	Quality of life
NCT000050610	NCT00005061_0_T0	PHENOTYPE	10	11	Solid Tumors
NCT000050612	NCT00005061_2_T0	PHENOTYPE	20	21	solid tumors
NCT000050614	NCT00005061_4_T0	GENE	9	9	VEGF
NCT000050614	NCT00005061_4_T1	GENE	11	11	VEGF
NCT000050614	NCT00005061_4_T2	PHENOTYPE	18	18	progressive
NCT000050614	NCT00005061_4_T3	PHENOTYPE	19	20	solid tumors
NCT000050616	NCT00005061_6_T0	GENE	8	8	VEGF
NCT000050618	NCT00005061_8_T0	GENE	7	7	VEGF
NCT0000506110	NCT00005061_10_T0	GENE	6	6	VEGF
NCT0000506112	NCT00005061_12_T0	PHENOTYPE	4	4	toxicity
NCT0000506112	NCT00005061_12_T1	PHENOTYPE	6	6	pharmacokinetics
NCT0000506116	NCT00005061_16_T0	GENE	4	4	VEGF
NCT0000506116	NCT00005061_16_T1	GENE	6	6	VEGF
NCT0000506116	NCT00005061_16_T2	GENE	7	7	IV
NCT0000506117	NCT00005061_17_T0	PHENOTYPE	35	35	toxicity
NCT0000506117	NCT00005061_17_T1	GENE	4	4	PR
NCT0000506117	NCT00005061_17_T2	GENE	7	7	CR
NCT0000506117	NCT00005061_17_T3	PHENOTYPE	31	32	disease progression
NCT0000506118	NCT00005061_18_T0	GENE	9	9	VEGF
NCT0000506118	NCT00005061_18_T1	GENE	15	15	MTD
NCT0000506119	NCT00005061_19_T0	PHENOTYPE	16	16	toxicity
NCT0000506119	NCT00005061_19_T1	GENE	1	1	MTD
NCT0000506119	NCT00005061_19_T2	PHENOTYPE	13	13	experiences
NCT0000506121	NCT00005061_21_T0	GENE	2	2	PR
NCT0000506121	NCT00005061_21_T1	PHENOTYPE	15	15	initiation
NCT0000506121	NCT00005061_21_T2	GENE	3	3	CR
NCT0000506121	NCT00005061_21_T3	PHENOTYPE	12	13	disease progression
NCT0000506122	NCT00005061_22_T0	PHENOTYPE	7	7	toxicity
NCT0000506122	NCT00005061_22_T1	PHENOTYPE	16	16	toxicity
NCT0000506123	NCT00005061_23_T0	PHENOTYPE	16	16	toxicity
NCT0000506123	NCT00005061_23_T1	GENE	10	10	VEGF
NCT000050625	NCT00005062_5_T0	GENE	8	8	60
NCT000050625	NCT00005062_5_T1	GENE	13	13	60
NCT000050627	NCT00005062_7_T0	PHENOTYPE	0	2	Quality of life
NCT000050648	NCT00005064_8_T0	GENE	3	3	IV
NCT000050649	NCT00005064_9_T0	PHENOTYPE	13	13	toxicity
NCT000050649	NCT00005064_9_T1	PHENOTYPE	15	16	disease progression
NCT0000506410	NCT00005064_10_T0	GENE	14	14	MTD
NCT0000506411	NCT00005064_11_T0	PHENOTYPE	10	10	toxicity
NCT0000506411	NCT00005064_11_T1	GENE	14	14	0.2
NCT0000506411	NCT00005064_11_T2	GENE	1	1	MTD
NCT000050652	NCT00005065_2_T0	CELL	10	10	cells
NCT000050652	NCT00005065_2_T1	PHENOTYPE	9	9	tumor
NCT000050653	NCT00005065_3_T0	CELL	8	8	cells
NCT000050653	NCT00005065_3_T1	PHENOTYPE	7	7	tumor
NCT000050654	NCT00005065_4_T0	CELL	9	9	cells
NCT000050654	NCT00005065_4_T1	PHENOTYPE	8	8	tumor
NCT000050654	NCT00005065_4_T2	COMPOUND	3	3	gadolinium
NCT000050655	NCT00005065_5_T0	CELL	10	10	cells
NCT000050655	NCT00005065_5_T1	PHENOTYPE	9	9	tumor
NCT000050659	NCT00005065_9_T0	PHENOTYPE	9	9	concentrations
NCT000050659	NCT00005065_9_T1	GENE	24	24	MRI
NCT000050659	NCT00005065_9_T2	GENE	22	22	1.5
NCT000050659	NCT00005065_9_T3	PHENOTYPE	2	2	tumor
NCT000050659	NCT00005065_9_T4	COMPOUND	11	11	gadolinium
NCT000050659	NCT00005065_9_T5	TISSUE	4	5	lymph nodes
NCT0000506510	NCT00005065_10_T0	COMPOUND	8	8	gadolinium
NCT0000506511	NCT00005065_11_T0	COMPOUND	2	2	paclitaxel
NCT0000506511	NCT00005065_11_T1	GENE	12	12	1.2
NCT0000506511	NCT00005065_11_T2	GENE	3	3	IV
NCT0000506511	NCT00005065_11_T3	GENE	10	10	IV
NCT0000506512	NCT00005065_12_T0	GENE	10	10	IV
NCT0000506514	NCT00005065_14_T0	GENE	1	1	3.5
NCT0000506515	NCT00005065_15_T0	PHENOTYPE	21	21	toxicity
NCT0000506516	NCT00005065_16_T0	GENE	4	4	MRI
NCT0000506517	NCT00005065_17_T0	PHENOTYPE	2	2	tumor
NCT0000506518	NCT00005065_18_T0	GENE	14	14	MTD
NCT0000506519	NCT00005065_19_T0	PHENOTYPE	22	22	toxicities
NCT0000506519	NCT00005065_19_T1	GENE	1	1	MTD
NCT000050661	NCT00005066_1_T0	CELL	9	9	cells
NCT000050661	NCT00005066_1_T1	PHENOTYPE	8	8	tumor
NCT000050662	NCT00005066_2_T0	GENE	2	2	II
NCT000050662	NCT00005066_2_T1	PHENOTYPE	18	18	recurrent
NCT000050662	NCT00005066_2_T2	PHENOTYPE	23	25	soft tissue sarcoma
NCT000050664	NCT00005066_4_T0	PHENOTYPE	8	8	recurrent
NCT000050664	NCT00005066_4_T1	PHENOTYPE	13	15	soft tissue sarcoma
NCT000050666	NCT00005066_6_T0	PHENOTYPE	2	2	toxicity
NCT000050668	NCT00005066_8_T0	PHENOTYPE	7	7	progression
NCT000050669	NCT00005066_9_T0	GENE	4	4	IV
NCT000050669	NCT00005066_9_T1	GENE	14	14	IV
NCT0000506610	NCT00005066_10_T0	PHENOTYPE	16	16	toxicity
NCT0000506610	NCT00005066_10_T1	PHENOTYPE	18	19	disease progression
NCT0000506611	NCT00005066_11_T0	PHENOTYPE	2	3	progressive disease
NCT0000506612	NCT00005066_12_T0	PHENOTYPE	2	3	progressive disease
NCT000050671	NCT00005067_1_T0	CELL	9	9	cells
NCT000050671	NCT00005067_1_T1	CELL	17	17	cells
NCT000050671	NCT00005067_1_T2	PHENOTYPE	16	16	tumor
NCT0000506710	NCT00005067_10_T0	PHENOTYPE	16	16	relapse
NCT0000506710	NCT00005067_10_T1	PHENOTYPE	6	6	progression
NCT0000506710	NCT00005067_10_T2	PHENOTYPE	20	20	progression
NCT0000506711	NCT00005067_11_T0	COMPOUND	7	7	lutetium
NCT0000506712	NCT00005067_12_T0	COMPOUND	2	2	lutetium
NCT0000506712	NCT00005067_12_T1	GENE	4	4	IV
NCT0000506716	NCT00005067_16_T0	COMPOUND	8	8	lutetium
NCT0000506716	NCT00005067_16_T1	GENE	18	18	MTD
NCT0000506717	NCT00005067_17_T0	PHENOTYPE	18	18	toxicity
NCT0000506717	NCT00005067_17_T1	GENE	1	1	MTD
NCT000050680	NCT00005068_0_T0	PHENOTYPE	9	10	Solid Tumors
NCT000050682	NCT00005068_2_T0	CELL	9	9	cells
NCT000050682	NCT00005068_2_T1	PHENOTYPE	8	8	tumor
NCT000050683	NCT00005068_3_T0	PHENOTYPE	23	24	solid tumors
NCT000050687	NCT00005068_7_T0	COMPOUND	4	4	irinotecan
NCT000050687	NCT00005068_7_T1	COMPOUND	9	9	oxaliplatin
NCT0000506811	NCT00005068_11_T0	PHENOTYPE	10	11	solid tumors
NCT0000506818	NCT00005068_18_T0	PHENOTYPE	18	18	toxicity
NCT0000506818	NCT00005068_18_T1	GENE	1	1	MTD
NCT000050691	NCT00005069_1_T0	GENE	2	2	II
NCT000050691	NCT00005069_1_T1	COMPOUND	9	10	arsenic trioxide
NCT000050691	NCT00005069_1_T2	PHENOTYPE	16	18	metastatic kidney cancer
NCT000050696	NCT00005069_6_T0	GENE	7	7	1.4
NCT000050696	NCT00005069_6_T1	GENE	5	5	IV
NCT000050696	NCT00005069_6_T2	COMPOUND	3	4	arsenic trioxide
NCT000050697	NCT00005069_7_T0	PHENOTYPE	19	19	toxicity
NCT000050697	NCT00005069_7_T1	PHENOTYPE	15	16	disease progression
NCT000050701	NCT00005070_1_T0	GENE	2	2	II
NCT000050701	NCT00005070_1_T1	COMPOUND	9	9	irofulven
NCT000050701	NCT00005070_1_T2	PHENOTYPE	18	20	recurrent cervical cancer
NCT000050703	NCT00005070_3_T0	PHENOTYPE	11	13	recurrent cervical carcinoma
NCT000050706	NCT00005070_6_T0	GENE	4	4	IV
NCT000050707	NCT00005070_7_T0	PHENOTYPE	10	10	toxicity
NCT000050707	NCT00005070_7_T1	PHENOTYPE	12	13	disease progression
NCT000050712	NCT00005071_2_T0	PHENOTYPE	23	24	lung cancer
NCT000050714	NCT00005071_4_T0	PHENOTYPE	8	9	lung cancer
NCT0000507117	NCT00005071_17_T0	PHENOTYPE	0	2	Quality of life
NCT000050725	NCT00005072_5_T0	PHENOTYPE	21	21	recurrence
NCT000050725	NCT00005072_5_T1	PHENOTYPE	12	13	disease progression
NCT000050729	NCT00005072_9_T0	PHENOTYPE	29	29	toxicity
NCT000050729	NCT00005072_9_T1	GENE	6	6	1/6
NCT000050729	NCT00005072_9_T2	PHENOTYPE	25	26	disease progression
NCT0000507210	NCT00005072_10_T0	PHENOTYPE	21	22	disease progression
NCT0000507217	NCT00005072_17_T0	PHENOTYPE	1	1	metastasis
NCT0000507218	NCT00005072_18_T0	ORGAN	2	4	central nervous system
NCT0000507219	NCT00005072_19_T0	GENE	2	2	Age
NCT0000507220	NCT00005072_20_T0	GENE	4	4	OR
NCT0000507220	NCT00005072_20_T1	PHENOTYPE	7	7	Oncology
NCT0000507223	NCT00005072_23_T0	PHENOTYPE	0	1	Platelet count
NCT0000507224	NCT00005072_24_T0	GENE	3	3	9.0
NCT0000507226	NCT00005072_26_T0	ORGAN	0	0	Serum
NCT0000507226	NCT00005072_26_T1	ORGAN	6	6	serum
NCT0000507228	NCT00005072_28_T0	GENE	5	5	thromboplastin
NCT0000507229	NCT00005072_29_T0	PHENOTYPE	0	1	Hepatitis B
NCT0000507231	NCT00005072_31_T0	PHENOTYPE	3	3	hypertension
NCT0000507232	NCT00005072_32_T0	PHENOTYPE	24	24	infarction
NCT0000507232	NCT00005072_32_T1	PHENOTYPE	12	12	Symptoms
NCT0000507232	NCT00005072_32_T2	PHENOTYPE	20	21	ventricular arrhythmia
NCT0000507232	NCT00005072_32_T3	PHENOTYPE	7	8	ventricular dysfunction
NCT0000507232	NCT00005072_32_T4	PHENOTYPE	14	16	coronary artery disease
NCT0000507232	NCT00005072_32_T5	PHENOTYPE	9	11	Congestive heart failure
NCT0000507233	NCT00005072_33_T0	PHENOTYPE	1	1	HIV
NCT0000507233	NCT00005072_33_T1	PHENOTYPE	0	0	Other
NCT0000507235	NCT00005072_35_T0	PHENOTYPE	2	2	autoimmune
NCT0000507236	NCT00005072_36_T0	GENE	4	4	IV
NCT0000507238	NCT00005072_38_T0	PHENOTYPE	2	3	psychiatric disorder
NCT0000507241	NCT00005072_41_T0	COMPOUND	13	13	hydroxyurea
NCT0000507247	NCT00005072_47_T0	PHENOTYPE	0	0	Other
NCT000050730	NCT00005073_0_T0	PHENOTYPE	23	23	Symptoms
NCT000050730	NCT00005073_0_T1	PHENOTYPE	12	13	Bone Metastases
NCT000050730	NCT00005073_0_T2	PHENOTYPE	17	19	Recurrent Prostate Cancer
NCT000050737	NCT00005073_7_T0	PHENOTYPE	8	9	pathological fractures
NCT000050737	NCT00005073_7_T1	PHENOTYPE	15	16	pathological fractures
NCT000050737	NCT00005073_7_T2	PHENOTYPE	17	19	spinal cord compression
NCT0000507311	NCT00005073_11_T0	GENE	19	19	LHRH
NCT0000507311	NCT00005073_11_T1	PHENOTYPE	17	17	initiation
NCT0000507311	NCT00005073_11_T2	GENE	29	29	1.2
NCT0000507316	NCT00005073_16_T0	COMPOUND	4	4	calcium
NCT0000507316	NCT00005073_16_T1	COMPOUND	7	8	vitamin D
NCT0000507317	NCT00005073_17_T0	GENE	3	3	LHRH
NCT0000507317	NCT00005073_17_T1	GENE	13	13	LHRH
NCT000050744	NCT00005074_4_T0	GENE	3	3	IV
NCT000050744	NCT00005074_4_T1	COMPOUND	2	2	flavopiridol
NCT000050745	NCT00005074_5_T0	PHENOTYPE	10	10	toxicity
NCT000050745	NCT00005074_5_T1	PHENOTYPE	12	13	disease progression
NCT000050746	NCT00005074_6_T0	GENE	5	5	CR
NCT000050746	NCT00005074_6_T1	GENE	12	12	CR
NCT000050747	NCT00005074_7_T0	PHENOTYPE	12	12	tumor
NCT000050749	NCT00005074_9_T0	PHENOTYPE	12	12	relapse
NCT000050758	NCT00005075_8_T0	ORGAN	6	6	rectum
NCT0000507510	NCT00005075_10_T0	PHENOTYPE	7	7	initiation
NCT0000507510	NCT00005075_10_T1	PHENOTYPE	0	2	Quality of life
NCT000050761	NCT00005076_1_T0	CELL	10	10	cells
NCT000050761	NCT00005076_1_T1	PHENOTYPE	9	9	tumor
NCT000050762	NCT00005076_2_T0	GENE	2	2	II
NCT000050762	NCT00005076_2_T1	COMPOUND	11	11	irinotecan
NCT000050762	NCT00005076_2_T2	GENE	21	21	has
NCT000050762	NCT00005076_2_T3	PHENOTYPE	18	19	colorectal cancer
NCT000050764	NCT00005076_4_T0	COMPOUND	22	22	irinotecan
NCT000050764	NCT00005076_4_T1	PHENOTYPE	10	10	progression
NCT000050764	NCT00005076_4_T2	PHENOTYPE	16	17	colorectal carcinoma
NCT000050766	NCT00005076_6_T0	PHENOTYPE	4	4	toxicity
NCT000050768	NCT00005076_8_T0	PHENOTYPE	2	4	quality of life
NCT0000507612	NCT00005076_12_T0	PHENOTYPE	13	14	disease progression
NCT0000507612	NCT00005076_12_T1	BIOLOGICAL_PROCESS	4	6	response to irinotecan
NCT0000507613	NCT00005076_13_T0	GENE	7	7	IV
NCT0000507614	NCT00005076_14_T0	GENE	15	15	IV
NCT0000507614	NCT00005076_14_T1	PHENOTYPE	7	8	anaphylactic reaction
NCT0000507615	NCT00005076_15_T0	GENE	4	4	IV
NCT0000507616	NCT00005076_16_T0	COMPOUND	2	2	irinotecan
NCT0000507616	NCT00005076_16_T1	COMPOUND	29	29	irinotecan
NCT0000507616	NCT00005076_16_T2	GENE	3	3	IV
NCT0000507617	NCT00005076_17_T0	GENE	12	12	OR
NCT0000507618	NCT00005076_18_T0	PHENOTYPE	13	13	toxicity
NCT0000507618	NCT00005076_18_T1	PHENOTYPE	9	10	disease progression
NCT0000507619	NCT00005076_19_T0	PHENOTYPE	3	3	toxicity
NCT0000507619	NCT00005076_19_T1	COMPOUND	5	5	irinotecan
NCT0000507620	NCT00005076_20_T0	PHENOTYPE	6	6	initiation
NCT0000507620	NCT00005076_20_T1	PHENOTYPE	0	2	Quality of life
NCT000050772	NCT00005077_2_T0	COMPOUND	9	9	oxaliplatin
NCT000050772	NCT00005077_2_T1	PHENOTYPE	15	16	advanced cancer
NCT000050772	NCT00005077_2_T2	PHENOTYPE	18	19	liver dysfunction
NCT000050774	NCT00005077_4_T0	PHENOTYPE	11	11	malignancies
NCT000050774	NCT00005077_4_T1	COMPOUND	6	6	oxaliplatin
NCT000050774	NCT00005077_4_T2	PHENOTYPE	16	17	liver dysfunction
NCT000050776	NCT00005077_6_T0	PHENOTYPE	11	11	pharmacodynamics
NCT000050776	NCT00005077_6_T1	PHENOTYPE	9	9	pharmacokinetics
NCT000050776	NCT00005077_6_T2	COMPOUND	13	13	oxaliplatin
NCT000050776	NCT00005077_6_T3	ORGAN	8	8	plasma
NCT000050776	NCT00005077_6_T4	PHENOTYPE	4	5	hepatic dysfunction
NCT000050779	NCT00005077_9_T0	PHENOTYPE	13	13	toxicity
NCT000050779	NCT00005077_9_T1	PHENOTYPE	9	10	disease progression
NCT0000507710	NCT00005077_10_T0	COMPOUND	14	14	oxaliplatin
NCT0000507710	NCT00005077_10_T1	GENE	20	20	MTD
NCT0000507711	NCT00005077_11_T0	PHENOTYPE	18	18	toxicity
NCT0000507711	NCT00005077_11_T1	GENE	1	1	MTD
NCT0000507712	NCT00005077_12_T0	GENE	12	12	1.5
NCT000050780	NCT00005078_0_T0	PHENOTYPE	10	11	Solid Tumors
NCT000050782	NCT00005078_2_T0	CELL	9	9	cells
NCT000050782	NCT00005078_2_T1	PHENOTYPE	8	8	tumor
NCT000050783	NCT00005078_3_T0	COMPOUND	13	13	paclitaxel
NCT000050783	NCT00005078_3_T1	COMPOUND	10	10	tirapazamine
NCT000050783	NCT00005078_3_T2	PHENOTYPE	21	22	solid tumors
NCT000050785	NCT00005078_5_T0	COMPOUND	7	7	tirapazamine
NCT000050787	NCT00005078_7_T0	COMPOUND	7	7	paclitaxel
NCT000050787	NCT00005078_7_T1	COMPOUND	2	2	tirapazamine
NCT000050787	NCT00005078_7_T2	GENE	3	3	IV
NCT000050787	NCT00005078_7_T3	GENE	8	8	IV
NCT000050787	NCT00005078_7_T4	GENE	14	14	IV
NCT000050788	NCT00005078_8_T0	PHENOTYPE	16	16	toxicity
NCT000050788	NCT00005078_8_T1	PHENOTYPE	18	19	disease progression
NCT000050789	NCT00005078_9_T0	PHENOTYPE	10	10	toxicity
NCT0000507810	NCT00005078_10_T0	COMPOUND	8	8	tirapazamine
NCT0000507810	NCT00005078_10_T1	GENE	14	14	MTD
NCT0000507811	NCT00005078_11_T0	PHENOTYPE	17	17	toxicity
NCT0000507811	NCT00005078_11_T1	GENE	1	1	MTD
NCT0000507812	NCT00005078_12_T0	GENE	13	13	MTD
NCT000050791	NCT00005079_1_T0	BIOLOGICAL_PROCESS	18	19	menstrual cycle
NCT000050792	NCT00005079_2_T0	GENE	23	23	II
NCT000050792	NCT00005079_2_T1	GENE	2	2	III
NCT000050792	NCT00005079_2_T2	BIOLOGICAL_PROCESS	9	11	menstrual cycle phase
NCT000050792	NCT00005079_2_T3	PHENOTYPE	25	28	stage III breast cancer
NCT000050796	NCT00005079_6_T0	ORGAN	2	2	serum
NCT000050797	NCT00005079_7_T0	PHENOTYPE	20	21	environmental exposures
NCT000050798	NCT00005079_8_T0	BIOLOGICAL_PROCESS	18	19	menstrual cycle
NCT000050802	NCT00005080_2_T0	PHENOTYPE	5	5	remission
NCT000050802	NCT00005080_2_T1	PHENOTYPE	8	8	remission
NCT000050802	NCT00005080_2_T2	PHENOTYPE	13	15	cutaneous T-cell lymphoma
NCT000050802	NCT00005080_2_T3	PHENOTYPE	21	23	peripheral T-cell lymphoma
NCT000050804	NCT00005080_4_T0	PHENOTYPE	4	4	toxicity
NCT000050805	NCT00005080_5_T0	GENE	4	4	IV
NCT000050806	NCT00005080_6_T0	PHENOTYPE	18	18	toxicity
NCT000050806	NCT00005080_6_T1	PHENOTYPE	14	15	disease progression
NCT000050808	NCT00005080_8_T0	PHENOTYPE	19	19	relapse
NCT000050809	NCT00005080_9_T0	GENE	5	5	34.74
NCT000050811	NCT00005081_1_T0	CELL	9	9	cells
NCT000050811	NCT00005081_1_T1	PHENOTYPE	8	8	tumor
NCT000050812	NCT00005081_2_T0	GENE	2	2	II
NCT000050812	NCT00005081_2_T1	PHENOTYPE	21	21	glioma
NCT000050812	NCT00005081_2_T2	PHENOTYPE	20	20	progressive
NCT000050812	NCT00005081_2_T3	PHENOTYPE	18	18	recurrent
NCT000050814	NCT00005081_4_T0	PHENOTYPE	18	18	gliosarcoma
NCT000050814	NCT00005081_4_T1	PHENOTYPE	19	19	resistant
NCT000050814	NCT00005081_4_T2	PHENOTYPE	12	12	progressive
NCT000050814	NCT00005081_4_T3	COMPOUND	21	21	nitrosourea
NCT000050814	NCT00005081_4_T4	PHENOTYPE	10	10	recurrent
NCT000050814	NCT00005081_4_T5	PHENOTYPE	13	14	glioblastoma multiforme
NCT000050814	NCT00005081_4_T6	PHENOTYPE	15	16	anaplastic astrocytoma
NCT000050816	NCT00005081_6_T0	PHENOTYPE	2	2	toxic
NCT000050817	NCT00005081_7_T0	GENE	4	4	IV
NCT000050817	NCT00005081_7_T1	GENE	14	14	IV
NCT000050818	NCT00005081_8_T0	PHENOTYPE	13	13	toxicity
NCT000050818	NCT00005081_8_T1	PHENOTYPE	9	10	disease progression
NCT000050821	NCT00005082_1_T0	PHENOTYPE	19	19	glioma
NCT000050826	NCT00005082_6_T0	GENE	19	19	MRI
NCT000050826	NCT00005082_6_T1	COMPOUND	20	20	proton
NCT000050826	NCT00005082_6_T2	PHENOTYPE	12	13	brain tumor
NCT000050827	NCT00005082_7_T0	GENE	3	3	MRI
NCT000050829	NCT00005082_9_T0	GENE	1	1	II
NCT000050829	NCT00005082_9_T1	GENE	16	16	II
NCT000050829	NCT00005082_9_T2	COMPOUND	10	10	dexamethasone
NCT0000508211	NCT00005082_11_T0	COMPOUND	18	18	dexamethasone
NCT0000508211	NCT00005082_11_T1	GENE	3	3	MRI
NCT0000508211	NCT00005082_11_T2	GENE	13	13	4.7
NCT0000508212	NCT00005082_12_T0	COMPOUND	10	10	dexamethasone
NCT000050832	NCT00005083_2_T0	GENE	2	2	II
NCT000050832	NCT00005083_2_T1	PHENOTYPE	26	27	brain tumors
NCT000050834	NCT00005083_4_T0	PHENOTYPE	32	33	brain tumors
NCT000050838	NCT00005083_8_T0	PHENOTYPE	8	8	progression
NCT000050838	NCT00005083_8_T1	COMPOUND	13	13	choline
NCT000050838	NCT00005083_8_T2	COMPOUND	17	17	N-acetylaspartate
NCT000050838	NCT00005083_8_T3	PHENOTYPE	5	6	tumor recurrence
NCT000050838	NCT00005083_8_T4	ORGAN	32	33	white matter
NCT000050839	NCT00005083_9_T0	GENE	18	18	MRI
NCT000050840	NCT00005084_0_T0	PHENOTYPE	7	7	Progressive
NCT000050840	NCT00005084_0_T1	PHENOTYPE	9	9	Astrocytoma
NCT000050842	NCT00005084_2_T0	GENE	2	2	II
NCT000050842	NCT00005084_2_T1	PHENOTYPE	19	19	astrocytoma
NCT000050842	NCT00005084_2_T2	PHENOTYPE	17	17	progressive
NCT000050846	NCT00005084_6_T0	PHENOTYPE	2	4	quality of life
NCT000050851	NCT00005085_1_T0	CELL	10	10	cells
NCT000050851	NCT00005085_1_T1	PHENOTYPE	9	9	tumor
NCT000050853	NCT00005085_3_T0	COMPOUND	16	16	rebeccamycin
NCT000050853	NCT00005085_3_T1	PHENOTYPE	11	13	recurrent colorectal cancer
NCT000050855	NCT00005085_5_T0	PHENOTYPE	2	2	toxicity
NCT000050859	NCT00005085_9_T0	GENE	4	4	IV
NCT000050859	NCT00005085_9_T1	COMPOUND	2	2	rebeccamycin
NCT0000508510	NCT00005085_10_T0	PHENOTYPE	16	16	toxicity
NCT0000508510	NCT00005085_10_T1	PHENOTYPE	18	19	disease progression
NCT000050861	NCT00005086_1_T0	CELL	9	9	cells
NCT000050861	NCT00005086_1_T1	PHENOTYPE	8	8	tumor
NCT000050862	NCT00005086_2_T0	GENE	2	2	II
NCT000050862	NCT00005086_2_T1	GENE	17	17	IV
NCT000050862	NCT00005086_2_T2	PHENOTYPE	21	23	metastatic bladder cancer
NCT000050864	NCT00005086_4_T0	COMPOUND	11	11	docetaxel
NCT000050864	NCT00005086_4_T1	COMPOUND	3	3	methotrexate
NCT000050864	NCT00005086_4_T2	GENE	4	4	IV
NCT000050864	NCT00005086_4_T3	GENE	12	12	IV
NCT000050865	NCT00005086_5_T0	COMPOUND	12	12	gemcitabine
NCT000050865	NCT00005086_5_T1	COMPOUND	3	3	cisplatin
NCT000050865	NCT00005086_5_T2	GENE	4	4	IV
NCT000050865	NCT00005086_5_T3	GENE	13	13	IV
NCT000050867	NCT00005086_7_T0	PHENOTYPE	7	7	toxicity
NCT000050867	NCT00005086_7_T1	PHENOTYPE	9	10	disease progression
NCT000050869	NCT00005086_9_T0	GENE	14	14	9-24
NCT000050870	NCT00005087_0_T0	PHENOTYPE	13	17	Recurrent Head and Neck Cancer
NCT000050872	NCT00005087_2_T0	PHENOTYPE	17	17	peripheral
NCT000050872	NCT00005087_2_T1	CELL	11	11	cells
NCT000050872	NCT00005087_2_T2	GENE	4	4	filgrastim
NCT000050872	NCT00005087_2_T3	ORGAN	14	15	bone marrow
NCT000050872	NCT00005087_2_T4	ORGAN	24	25	immune system
NCT000050872	NCT00005087_2_T5	PHENOTYPE	30	32	effects of chemotherapy
NCT000050873	NCT00005087_3_T0	CELL	8	8	cells
NCT000050873	NCT00005087_3_T1	PHENOTYPE	7	7	tumor
NCT000050874	NCT00005087_4_T0	GENE	2	2	II
NCT000050874	NCT00005087_4_T1	COMPOUND	9	9	paclitaxel
NCT000050874	NCT00005087_4_T2	GENE	12	12	filgrastim
NCT000050874	NCT00005087_4_T3	COMPOUND	10	10	cisplatin
NCT000050874	NCT00005087_4_T4	PHENOTYPE	23	27	recurrent head and neck cancer
NCT000050876	NCT00005087_6_T0	GENE	11	11	1.5
NCT000050877	NCT00005087_7_T0	COMPOUND	2	2	paclitaxel
NCT000050877	NCT00005087_7_T1	GENE	32	32	1.5
NCT000050877	NCT00005087_7_T2	GENE	3	3	IV
NCT000050878	NCT00005087_8_T0	COMPOUND	12	12	paclitaxel
NCT000050878	NCT00005087_8_T1	GENE	16	16	1.5
NCT000050878	NCT00005087_8_T2	GENE	18	18	filgrastim
NCT000050878	NCT00005087_8_T3	GENE	19	19	G-CSF
NCT000050878	NCT00005087_8_T4	COMPOUND	2	2	cisplatin
NCT000050878	NCT00005087_8_T5	GENE	3	3	IV
NCT000050879	NCT00005087_9_T0	PHENOTYPE	16	16	toxicity
NCT000050879	NCT00005087_9_T1	PHENOTYPE	12	13	disease progression
NCT000050880	NCT00005088_0_T0	PHENOTYPE	9	12	Head and Neck Cancer
NCT000050882	NCT00005088_2_T0	CELL	10	10	cells
NCT000050882	NCT00005088_2_T1	PHENOTYPE	9	9	tumor
NCT000050883	NCT00005088_3_T0	CELL	9	9	cells
NCT000050883	NCT00005088_3_T1	PHENOTYPE	8	8	tumor
NCT000050884	NCT00005088_4_T0	GENE	2	2	II
NCT000050884	NCT00005088_4_T1	COMPOUND	12	12	cisplatin
NCT000050884	NCT00005088_4_T2	PHENOTYPE	19	22	head and neck cancer
NCT000050886	NCT00005088_6_T0	PHENOTYPE	6	6	recurrence
NCT000050886	NCT00005088_6_T1	COMPOUND	23	23	cisplatin
NCT000050886	NCT00005088_6_T2	PHENOTYPE	14	17	head and neck cancer
NCT000050888	NCT00005088_8_T0	PHENOTYPE	9	9	acute
NCT000050888	NCT00005088_8_T1	PHENOTYPE	12	12	toxicities
NCT000050888	NCT00005088_8_T2	PHENOTYPE	7	7	tolerance
NCT0000508810	NCT00005088_10_T0	PHENOTYPE	9	9	relapse
NCT0000508811	NCT00005088_11_T0	GENE	5	5	1.2
NCT0000508811	NCT00005088_11_T1	GENE	19	19	1.2
NCT0000508811	NCT00005088_11_T2	COMPOUND	16	16	cisplatin
NCT0000508811	NCT00005088_11_T3	GENE	17	17	IV
NCT000050892	NCT00005089_2_T0	CELL	8	8	cells
NCT000050893	NCT00005089_3_T0	CELL	13	13	cells
NCT000050894	NCT00005089_4_T0	GENE	2	2	II
NCT000050894	NCT00005089_4_T1	GENE	25	25	II
NCT000050894	NCT00005089_4_T2	PHENOTYPE	26	27	Hodgkin's lymphoma
NCT000050897	NCT00005089_7_T0	GENE	29	29	II
NCT000050897	NCT00005089_7_T1	COMPOUND	11	11	vincristine
NCT000050897	NCT00005089_7_T2	GENE	31	31	IIE
NCT000050897	NCT00005089_7_T3	PHENOTYPE	34	34	localized
NCT000050897	NCT00005089_7_T4	PHENOTYPE	3	3	progression
NCT000050897	NCT00005089_7_T5	COMPOUND	9	9	cyclophosphamide
NCT000050897	NCT00005089_7_T6	GENE	14	14	CHOP
NCT000050897	NCT00005089_7_T7	COMPOUND	10	10	doxorubicin
NCT000050897	NCT00005089_7_T8	GENE	25	25	IE
NCT000050897	NCT00005089_7_T9	COMPOUND	13	13	prednisone
NCT000050897	NCT00005089_7_T10	PHENOTYPE	39	40	Hodgkin's lymphoma
NCT000050897	NCT00005089_7_T11	PHENOTYPE	37	38	high grade
NCT000050899	NCT00005089_9_T0	PHENOTYPE	2	2	toxicity
NCT0000508910	NCT00005089_10_T0	GENE	4	4	IV
NCT0000508911	NCT00005089_11_T0	COMPOUND	10	10	vincristine
NCT0000508911	NCT00005089_11_T1	GENE	5	5	1.2
NCT0000508911	NCT00005089_11_T2	COMPOUND	2	2	cyclophosphamide
NCT0000508911	NCT00005089_11_T3	COMPOUND	7	7	doxorubicin
NCT0000508911	NCT00005089_11_T4	GENE	3	3	IV
NCT0000508911	NCT00005089_11_T5	GENE	8	8	IV
NCT0000508911	NCT00005089_11_T6	GENE	11	11	IV
NCT0000508912	NCT00005089_12_T0	GENE	14	14	3.7
NCT0000508912	NCT00005089_12_T1	COMPOUND	3	3	prednisone
NCT0000508913	NCT00005089_13_T0	PHENOTYPE	16	16	toxicity
NCT0000508913	NCT00005089_13_T1	PHENOTYPE	12	13	disease progression
NCT0000508914	NCT00005089_14_T0	GENE	11	11	4.5
NCT0000508918	NCT00005089_18_T0	PHENOTYPE	18	18	lymphoma
NCT0000508918	NCT00005089_18_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000508918	NCT00005089_18_T2	PHENOTYPE	16	17	high grade
NCT000050908	NCT00005090_8_T0	GENE	19	19	III
NCT000050908	NCT00005090_8_T1	GENE	21	21	IV
NCT000050909	NCT00005090_9_T0	COMPOUND	11	11	bleomycin
NCT000050909	NCT00005090_9_T1	COMPOUND	16	16	vinblastine
NCT000050909	NCT00005090_9_T2	COMPOUND	6	6	doxorubicin
NCT000050909	NCT00005090_9_T3	GENE	7	7	IV
NCT000050909	NCT00005090_9_T4	GENE	12	12	IV
NCT000050909	NCT00005090_9_T5	GENE	17	17	IV
NCT000050909	NCT00005090_9_T6	GENE	23	23	IV
NCT000050909	NCT00005090_9_T7	COMPOUND	22	22	dacarbazine
NCT0000509010	NCT00005090_10_T0	PHENOTYPE	16	16	toxicity
NCT0000509010	NCT00005090_10_T1	PHENOTYPE	12	13	disease progression
NCT0000509012	NCT00005090_12_T0	COMPOUND	9	9	2
NCT0000509012	NCT00005090_12_T1	COMPOUND	29	29	2
NCT0000509012	NCT00005090_12_T2	COMPOUND	25	25	cyclophosphamide
NCT0000509012	NCT00005090_12_T3	COMPOUND	16	16	etoposide
NCT0000509012	NCT00005090_12_T4	GENE	7	7	IV
NCT0000509012	NCT00005090_12_T5	GENE	17	17	IV
NCT0000509012	NCT00005090_12_T6	GENE	26	26	IV
NCT000050916	NCT00005091_6_T0	PHENOTYPE	5	5	toxic
NCT000050918	NCT00005091_8_T0	PHENOTYPE	2	2	pharmacokinetics
NCT0000509110	NCT00005091_10_T0	PHENOTYPE	4	4	progression
NCT0000509112	NCT00005091_12_T0	GENE	3	3	IV
NCT0000509113	NCT00005091_13_T0	PHENOTYPE	19	19	toxicity
NCT0000509113	NCT00005091_13_T1	PHENOTYPE	15	16	disease progression
NCT000050921	NCT00005092_1_T0	CELL	3	3	cells
NCT000050921	NCT00005092_1_T1	TISSUE	10	10	tissues
NCT000050922	NCT00005092_2_T0	CELL	2	2	cells
NCT000050922	NCT00005092_2_T1	COMPOUND	8	8	psoralen
NCT000050927	NCT00005092_7_T0	PHENOTYPE	2	2	toxicity
NCT000050929	NCT00005092_9_T0	PHENOTYPE	15	15	malignancy
NCT000050929	NCT00005092_9_T1	PHENOTYPE	8	11	graft versus host disease
NCT0000509210	NCT00005092_10_T0	COMPOUND	13	13	psoralen
NCT0000509210	NCT00005092_10_T1	CELL	9	9	T-cells
NCT0000509211	NCT00005092_11_T0	COMPOUND	2	2	thiotepa
NCT0000509211	NCT00005092_11_T1	COMPOUND	10	10	cyclophosphamide
NCT0000509211	NCT00005092_11_T2	GENE	3	3	IV
NCT0000509211	NCT00005092_11_T3	GENE	11	11	IV
NCT0000509213	NCT00005092_13_T0	CELL	10	10	T-cells
NCT0000509213	NCT00005092_13_T1	GENE	16	16	MTD
NCT0000509214	NCT00005092_14_T0	PHENOTYPE	20	20	toxicities
NCT0000509214	NCT00005092_14_T1	GENE	1	1	MTD
NCT0000509310	NCT00005093_10_T0	PHENOTYPE	16	16	toxicity
NCT0000509310	NCT00005093_10_T1	PHENOTYPE	12	13	disease progression
NCT000050946	NCT00005094_6_T0	PHENOTYPE	13	13	sporadic
NCT000050946	NCT00005094_6_T1	GENE	16	16	SAP
NCT000050946	NCT00005094_6_T2	GENE	30	30	SAP
NCT000050946	NCT00005094_6_T3	COMPOUND	6	6	celecoxib
NCT000050946	NCT00005094_6_T4	ORGAN	19	19	colon
NCT000050946	NCT00005094_6_T5	ORGAN	21	21	rectum
NCT000050946	NCT00005094_6_T6	PHENOTYPE	14	15	adenomatous polyps
NCT0000509411	NCT00005094_11_T0	PHENOTYPE	5	6	colorectal polyps
NCT000050951	NCT00005095_1_T0	PHENOTYPE	19	20	ovarian cancer
NCT000050955	NCT00005095_5_T0	PHENOTYPE	12	12	ascites
NCT000050955	NCT00005095_5_T1	PHENOTYPE	27	27	tumor
NCT000050955	NCT00005095_5_T2	PHENOTYPE	34	36	recurrent ovarian cancer
NCT000050957	NCT00005095_7_T0	PHENOTYPE	7	8	experimental tumor
NCT000050957	NCT00005095_7_T1	PHENOTYPE	18	20	stage ovarian cancer
NCT000050958	NCT00005095_8_T0	PHENOTYPE	21	22	ovarian cancer
NCT000050958	NCT00005095_8_T1	PHENOTYPE	41	42	ovarian cancer
NCT000050965	NCT00005096_5_T0	PHENOTYPE	2	2	toxicity
NCT000050968	NCT00005096_8_T0	COMPOUND	3	3	docetaxel
NCT000050968	NCT00005096_8_T1	GENE	4	4	IV
NCT000050969	NCT00005096_9_T0	PHENOTYPE	13	13	toxicity
NCT000050969	NCT00005096_9_T1	PHENOTYPE	9	10	disease progression
NCT000050971	NCT00005097_1_T0	GENE	3	3	II
NCT000050971	NCT00005097_1_T1	COMPOUND	11	12	tea extract
NCT000050971	NCT00005097_1_T2	PHENOTYPE	18	19	actinic keratosis
NCT000050977	NCT00005097_7_T0	PHENOTYPE	20	20	regression
NCT000050977	NCT00005097_7_T1	COMPOUND	8	8	epigallocatechin
NCT000050977	NCT00005097_7_T2	COMPOUND	6	7	tea extract
NCT000050977	NCT00005097_7_T3	PHENOTYPE	24	25	actinic keratoses
NCT000050979	NCT00005097_9_T0	PHENOTYPE	10	10	regression
NCT0000509711	NCT00005097_11_T0	PHENOTYPE	6	7	actinic keratoses
NCT0000509713	NCT00005097_13_T0	PHENOTYPE	9	10	skin cancer
NCT0000509716	NCT00005097_16_T0	PHENOTYPE	13	14	actinic keratoses
NCT0000509720	NCT00005097_20_T0	PHENOTYPE	38	38	acute
NCT0000509720	NCT00005097_20_T1	PHENOTYPE	20	20	CLL
NCT0000509720	NCT00005097_20_T2	PHENOTYPE	3	4	invasive cancer
NCT0000509720	NCT00005097_20_T3	PHENOTYPE	33	34	metabolic disorders
NCT0000509720	NCT00005097_20_T4	PHENOTYPE	21	22	stage 0
NCT0000509720	NCT00005097_20_T5	PHENOTYPE	40	41	chronic disease
NCT0000509720	NCT00005097_20_T6	PHENOTYPE	9	11	melanoma skin cancer
NCT0000509720	NCT00005097_20_T7	PHENOTYPE	17	19	chronic lymphocytic leukemia
NCT0000509720	NCT00005097_20_T8	PHENOTYPE	12	15	stage I cervical cancer
NCT0000509728	NCT00005097_28_T0	COMPOUND	28	29	lactic acid
NCT0000509728	NCT00005097_28_T1	COMPOUND	26	27	glycolic acid
NCT0000509729	NCT00005097_29_T0	COMPOUND	15	15	5_fluorouracil
NCT0000509729	NCT00005097_29_T1	PHENOTYPE	11	11	peels
NCT0000509729	NCT00005097_29_T2	PHENOTYPE	23	24	actinic keratoses
NCT0000509733	NCT00005097_33_T0	PHENOTYPE	8	8	HIV
NCT0000509733	NCT00005097_33_T1	PHENOTYPE	5	5	tuberculosis
NCT0000509733	NCT00005097_33_T2	PHENOTYPE	1	2	infectious diseases
NCT0000509733	NCT00005097_33_T3	ORGAN	20	21	immune system
NCT0000509734	NCT00005097_34_T0	PHENOTYPE	5	5	sinusitis
NCT0000509734	NCT00005097_34_T1	PHENOTYPE	2	2	infections
NCT0000509734	NCT00005097_34_T2	PHENOTYPE	0	0	Localized
NCT0000509734	NCT00005097_34_T3	PHENOTYPE	10	11	otitis media
NCT0000509734	NCT00005097_34_T4	PHENOTYPE	7	9	urinary tract infection
NCT000051005	NCT00005100_5_T0	GENE	10	10	GH
NCT000051005	NCT00005100_5_T1	GENE	8	8	IGFBP-3
NCT000051005	NCT00005100_5_T2	GENE	6	6	IGF-I
NCT000051007	NCT00005100_7_T0	GENE	9	9	GH
NCT000051007	NCT00005100_7_T1	PHENOTYPE	15	15	progression
NCT000051009	NCT00005100_9_T0	COMPOUND	16	16	glucose
NCT000051009	NCT00005100_9_T1	MOLECULAR_FUNCTION	0	1	Growth hormone
NCT0000510010	NCT00005100_10_T0	COMPOUND	1	1	glucose
NCT0000510010	NCT00005100_10_T1	COMPOUND	15	15	glucose
NCT0000510010	NCT00005100_10_T2	COMPOUND	11	11	dextrose
NCT0000510010	NCT00005100_10_T3	ORGAN	0	0	Serum
NCT0000510010	NCT00005100_10_T4	GENE	16	16	hexokinase
NCT000051011	NCT00005101_1_T0	PHENOTYPE	5	6	bone loss
NCT000051023	NCT00005102_3_T0	PHENOTYPE	12	12	deletion
NCT000051023	NCT00005102_3_T1	CELL	10	11	chromosome 22
NCT000051028	NCT00005102_8_T0	PHENOTYPE	15	15	tetanus
NCT000051028	NCT00005102_8_T1	CELL	8	8	lymphocytes
NCT000051028	NCT00005102_8_T2	PHENOTYPE	17	17	diphtheria
NCT000051029	NCT00005102_9_T0	GENE	8	8	IgA
NCT000051029	NCT00005102_9_T1	GENE	7	7	IgG
NCT000051029	NCT00005102_9_T2	GENE	10	10	IgM
NCT000051029	NCT00005102_9_T3	CELL	5	6	lymphocyte subset
NCT0000510210	NCT00005102_10_T0	PHENOTYPE	9	9	influenza
NCT0000510210	NCT00005102_10_T1	PHENOTYPE	7	7	tetanus
NCT0000510210	NCT00005102_10_T2	PHENOTYPE	6	6	diphtheria
NCT0000510210	NCT00005102_10_T3	PHENOTYPE	3	4	antibody titers
NCT0000510210	NCT00005102_10_T4	PHENOTYPE	11	12	hepatitis B
NCT000051037	NCT00005103_7_T0	PHENOTYPE	1	2	hepatitis C
NCT000051037	NCT00005103_7_T1	PHENOTYPE	3	4	virus infections
NCT0000510315	NCT00005103_15_T0	GENE	10	10	CYP
NCT0000510321	NCT00005103_21_T0	COMPOUND	4	4	HCV
NCT0000510321	NCT00005103_21_T1	COMPOUND	7	7	HCV
NCT0000510321	NCT00005103_21_T2	PHENOTYPE	0	1	Serum hepatitis
NCT0000510321	NCT00005103_21_T3	PHENOTYPE	1	2	hepatitis C
NCT0000510322	NCT00005103_22_T0	ORGAN	1	1	liver
NCT0000510322	NCT00005103_22_T1	ORGAN	5	5	liver
NCT0000510323	NCT00005103_23_T0	COMPOUND	5	6	ascorbic acid
NCT0000510326	NCT00005103_26_T0	COMPOUND	18	18	chloroquine
NCT0000510327	NCT00005103_27_T0	COMPOUND	2	2	HCV
NCT0000510327	NCT00005103_27_T1	COMPOUND	7	8	interferon alfa_2b
NCT000051044	NCT00005104_4_T0	COMPOUND	3	3	metformin
NCT000051045	NCT00005104_5_T0	PHENOTYPE	2	2	anovulatory
NCT000051045	NCT00005104_5_T1	COMPOUND	7	7	metformin
NCT000051045	NCT00005104_5_T2	COMPOUND	15	16	clomiphene citrate
NCT000051046	NCT00005104_6_T0	PHENOTYPE	19	19	anovulation
NCT000051046	NCT00005104_6_T1	COMPOUND	7	7	metformin
NCT000051046	NCT00005104_6_T2	BIOLOGICAL_PROCESS	1	1	ovulation
NCT000051046	NCT00005104_6_T3	COMPOUND	4	5	clomiphene citrate
NCT000051050	NCT00005105_0_T0	PHENOTYPE	11	13	Intrauterine Growth Retardation
NCT000051062	NCT00005106_2_T0	ORGAN	10	10	plasma
NCT000051063	NCT00005106_3_T0	BIOLOGICAL_PROCESS	19	20	lipid metabolism
NCT000051063	NCT00005106_3_T1	TISSUE	6	7	body fat
NCT000051064	NCT00005106_4_T0	PHENOTYPE	3	5	quality of life
NCT000051070	NCT00005107_0_T0	PHENOTYPE	5	5	Cirrhosis
NCT000051070	NCT00005107_0_T1	PHENOTYPE	11	11	Function
NCT000051073	NCT00005107_3_T0	PHENOTYPE	19	19	cirrhosis
NCT000051074	NCT00005107_4_T0	PHENOTYPE	7	7	cirrhosis
NCT000051076	NCT00005107_6_T0	ORGAN	10	10	heart
NCT0000510710	NCT00005107_10_T0	ORGAN	11	11	kidney
NCT0000510710	NCT00005107_10_T1	COMPOUND	0	0	Inulin
NCT000051083	NCT00005108_3_T0	PHENOTYPE	13	13	inflammation
NCT000051084	NCT00005108_4_T0	COMPOUND	8	8	estrogen
NCT000051084	NCT00005108_4_T1	PHENOTYPE	12	12	inflammation
NCT000051084	NCT00005108_4_T2	ORGAN	10	10	artery
NCT000051084	NCT00005108_4_T3	PHENOTYPE	14	14	stiffness
NCT000051086	NCT00005108_6_T0	ORGAN	11	11	heart
NCT000051088	NCT00005108_8_T0	GENE	41	41	hormone
NCT000051089	NCT00005108_9_T0	PHENOTYPE	18	18	inflammation
NCT000051089	NCT00005108_9_T1	PHENOTYPE	20	20	stiffness
NCT000051089	NCT00005108_9_T2	ORGAN	16	17	blood vessel
NCT0000510816	NCT00005108_16_T0	GENE	6	6	coil
NCT0000510816	NCT00005108_16_T1	ORGAN	18	18	ears
NCT0000510816	NCT00005108_16_T2	GENE	5	5	MRI
NCT0000510818	NCT00005108_18_T0	COMPOUND	0	0	Gadolinium
NCT0000510819	NCT00005108_19_T0	COMPOUND	11	11	estrogen
NCT0000510819	NCT00005108_19_T1	PHENOTYPE	15	15	inflammation
NCT0000510820	NCT00005108_20_T0	PHENOTYPE	12	12	decisions
NCT0000510820	NCT00005108_20_T1	PHENOTYPE	14	14	chronic
NCT0000510820	NCT00005108_20_T2	GENE	15	15	hormone
NCT0000510822	NCT00005108_22_T0	PHENOTYPE	4	5	vascular inflammation
NCT0000510824	NCT00005108_24_T0	PHENOTYPE	18	18	plaques
NCT0000510824	NCT00005108_24_T1	GENE	0	0	MMP-9
NCT0000510824	NCT00005108_24_T2	GENE	2	2	secreted
NCT0000510824	NCT00005108_24_T3	CELL	4	4	macrophages
NCT0000510824	NCT00005108_24_T4	CELL	7	9	smooth muscle cells
NCT0000510827	NCT00005108_27_T0	COMPOUND	12	12	estrogen
NCT0000510827	NCT00005108_27_T1	PHENOTYPE	16	17	vascular inflammation
NCT0000510827	NCT00005108_27_T2	ORGAN	26	27	carotid arteries
NCT0000510829	NCT00005108_29_T0	COMPOUND	3	3	estrogen
NCT0000510830	NCT00005108_30_T0	COMPOUND	8	8	estrogen
NCT0000510830	NCT00005108_30_T1	PHENOTYPE	9	9	tumor
NCT0000510830	NCT00005108_30_T2	PHENOTYPE	5	6	uterine cancer
NCT0000510830	NCT00005108_30_T3	PHENOTYPE	3	4	breast cancer
NCT0000510836	NCT00005108_36_T0	PHENOTYPE	3	5	coronary artery disease
NCT0000510837	NCT00005108_37_T0	PHENOTYPE	2	5	of carotid artery disease
NCT0000510838	NCT00005108_38_T0	PHENOTYPE	3	3	pancreatitis
NCT0000510839	NCT00005108_39_T0	PHENOTYPE	3	3	claustrophobia
NCT0000510841	NCT00005108_41_T0	GENE	1	1	MRI
NCT0000510841	NCT00005108_41_T1	BIOLOGICAL_PROCESS	11	11	AICD
NCT0000510842	NCT00005108_42_T0	PHENOTYPE	10	10	lupus
NCT0000510842	NCT00005108_42_T1	PHENOTYPE	2	3	inflammatory disorder
NCT0000510842	NCT00005108_42_T2	PHENOTYPE	7	8	periarteritis nodosa
NCT0000510842	NCT00005108_42_T3	PHENOTYPE	12	13	temporal arteritis
NCT0000510842	NCT00005108_42_T4	PHENOTYPE	5	6	rheumatoid arthritis
NCT000051111	NCT00005111_1_T0	PHENOTYPE	6	7	Fabry disease
NCT000051112	NCT00005111_2_T0	GENE	12	12	MRI
NCT000051112	NCT00005111_2_T1	BIOLOGICAL_PROCESS	17	17	metabolism
NCT000051113	NCT00005111_3_T0	PHENOTYPE	5	6	Fabry disease
NCT000051116	NCT00005111_6_T0	TISSUE	15	15	tissues
NCT000051118	NCT00005111_8_T0	GENE	11	11	FDG
NCT0000511114	NCT00005111_14_T0	TISSUE	18	18	tissues
NCT0000511114	NCT00005111_14_T1	GENE	13	13	structural
NCT0000511115	NCT00005111_15_T0	PHENOTYPE	11	12	Fabry disease
NCT0000511118	NCT00005111_18_T0	COMPOUND	13	13	glucose
NCT0000511118	NCT00005111_18_T1	PHENOTYPE	20	21	Fabry disease
NCT0000511118	NCT00005111_18_T2	PHENOTYPE	10	11	metabolic rate
NCT0000511119	NCT00005111_19_T0	GENE	8	8	lines
NCT0000511119	NCT00005111_19_T1	ORGAN	17	17	heart
NCT0000511119	NCT00005111_19_T2	ORGAN	13	14	left ventricle
NCT000051122	NCT00005112_2_T0	GENE	11	11	GH
NCT000051122	NCT00005112_2_T1	GENE	42	42	GH
NCT000051122	NCT00005112_2_T2	GENE	52	52	GH
NCT000051122	NCT00005112_2_T3	PHENOTYPE	47	49	quality of life
NCT000051123	NCT00005112_3_T0	GENE	3	3	GH
NCT000051123	NCT00005112_3_T1	PHENOTYPE	15	17	quality of life
NCT000051124	NCT00005112_4_T0	GENE	30	30	GH
NCT000051126	NCT00005112_6_T0	GENE	9	9	GH
NCT000051129	NCT00005112_9_T0	GENE	39	39	The
NCT000051129	NCT00005112_9_T1	PHENOTYPE	31	31	QOL
NCT000051129	NCT00005112_9_T2	PHENOTYPE	34	34	QOL
NCT000051129	NCT00005112_9_T3	PHENOTYPE	40	41	Cystic Fibrosis
NCT000051129	NCT00005112_9_T4	ORGAN	18	19	respiratory muscle
NCT000051129	NCT00005112_9_T5	PHENOTYPE	28	30	quality of life
NCT0000511211	NCT00005112_11_T0	GENE	36	36	GH
NCT0000511211	NCT00005112_11_T1	PHENOTYPE	21	21	centers
NCT000051131	NCT00005113_1_T0	GENE	0	0	SRL
NCT000051131	NCT00005113_1_T1	ORGAN	10	11	immune system
NCT000051131	NCT00005113_1_T2	ORGAN	14	15	organ transplants
NCT000051132	NCT00005113_2_T0	ORGAN	3	3	kidney
NCT000051132	NCT00005113_2_T1	ORGAN	10	10	kidney
NCT000051132	NCT00005113_2_T2	ORGAN	23	23	kidney
NCT000051132	NCT00005113_2_T3	ORGAN	4	4	transplant
NCT000051132	NCT00005113_2_T4	ORGAN	18	19	immune system
NCT000051134	NCT00005113_4_T0	ORGAN	6	6	kidney
NCT000051134	NCT00005113_4_T1	ORGAN	8	8	transplant
NCT000051134	NCT00005113_4_T2	BIOLOGICAL_PROCESS	19	20	immune response
NCT000051135	NCT00005113_5_T0	COMPOUND	2	2	tacrolimus
NCT000051135	NCT00005113_5_T1	ORGAN	11	11	transplant
NCT000051137	NCT00005113_7_T0	ORGAN	19	19	kidney
NCT000051137	NCT00005113_7_T1	ORGAN	12	12	transplant
NCT000051137	NCT00005113_7_T2	GENE	6	6	has
NCT000051137	NCT00005113_7_T3	GENE	0	0	SRL
NCT000051138	NCT00005113_8_T0	GENE	11	11	SRL
NCT0000511312	NCT00005113_12_T0	PHENOTYPE	4	4	immunosuppression
NCT0000511313	NCT00005113_13_T0	GENE	7	7	masking
NCT0000511313	NCT00005113_13_T1	PHENOTYPE	4	5	drug toxicity
NCT0000511315	NCT00005113_15_T0	PHENOTYPE	6	6	toxicity
NCT0000511315	NCT00005113_15_T1	PHENOTYPE	11	11	acute
NCT0000511315	NCT00005113_15_T2	ORGAN	21	21	graft
NCT0000511315	NCT00005113_15_T3	ORGAN	33	33	transplant
NCT0000511316	NCT00005113_16_T0	PHENOTYPE	11	11	acute
NCT0000511316	NCT00005113_16_T1	GENE	0	0	SRL
NCT0000511316	NCT00005113_16_T2	ORGAN	13	13	allograft
NCT0000511317	NCT00005113_17_T0	GENE	1	1	has
NCT0000511317	NCT00005113_17_T1	GENE	0	0	SRL
NCT0000511317	NCT00005113_17_T2	PHENOTYPE	4	6	mechanism of action
NCT0000511319	NCT00005113_19_T0	GENE	4	4	II
NCT0000511319	NCT00005113_19_T1	GENE	8	8	SRL
NCT0000511319	NCT00005113_19_T2	GENE	28	28	SRL
NCT0000511320	NCT00005113_20_T0	GENE	22	22	GFR
NCT0000511320	NCT00005113_20_T1	BIOLOGICAL_PROCESS	19	20	glomerular filtration
NCT0000511321	NCT00005113_21_T0	GENE	14	14	2.1
NCT0000511321	NCT00005113_21_T1	GENE	19	19	SRL
NCT0000511322	NCT00005113_22_T0	GENE	0	0	SRL
NCT0000511326	NCT00005113_26_T0	PHENOTYPE	10	10	acute
NCT0000511326	NCT00005113_26_T1	PHENOTYPE	12	13	graft loss
NCT0000511327	NCT00005113_27_T0	PHENOTYPE	9	10	graft loss
NCT000051164	NCT00005116_4_T0	PHENOTYPE	12	12	Diabetes
NCT000051165	NCT00005116_5_T0	COMPOUND	4	4	3
NCT000051165	NCT00005116_5_T1	COMPOUND	15	15	3
NCT000051165	NCT00005116_5_T2	GENE	13	13	booster
NCT000051171	NCT00005117_1_T0	ORGAN	17	18	blood vessel
NCT000051171	NCT00005117_1_T1	PHENOTYPE	4	5	cholesterol levels
NCT000051172	NCT00005117_2_T0	GENE	1	1	has
NCT000051172	NCT00005117_2_T1	ORGAN	13	14	blood vessel
NCT000051172	NCT00005117_2_T2	PHENOTYPE	17	18	endothelial dysfunction
NCT000051173	NCT00005117_3_T0	COMPOUND	5	5	pravastatin
NCT000051173	NCT00005117_3_T1	ORGAN	11	12	blood vessel
NCT000051173	NCT00005117_3_T2	GENE	7	8	HMG-CoA reductase
NCT000051175	NCT00005117_5_T0	COMPOUND	12	12	pravastatin
NCT000051176	NCT00005117_6_T0	PHENOTYPE	26	26	occlusion
NCT000051176	NCT00005117_6_T1	ORGAN	20	20	artery
NCT000051176	NCT00005117_6_T2	ORGAN	19	19	forearm
NCT000051176	NCT00005117_6_T3	ORGAN	0	1	Blood vessel
NCT000051178	NCT00005117_8_T0	COMPOUND	7	7	pravastatin
NCT000051178	NCT00005117_8_T1	PHENOTYPE	12	12	dysfunction
NCT000051178	NCT00005117_8_T2	ORGAN	10	11	blood vessel
NCT000051179	NCT00005117_9_T0	PHENOTYPE	0	0	Secondary
NCT000051179	NCT00005117_9_T1	GENE	8	8	mediator
NCT000051179	NCT00005117_9_T2	ORGAN	10	11	blood vessel
NCT0000511710	NCT00005117_10_T0	PHENOTYPE	20	20	acute
NCT0000511710	NCT00005117_10_T1	PHENOTYPE	27	27	strokes
NCT0000511710	NCT00005117_10_T2	COMPOUND	1	1	pravastatin
NCT0000511710	NCT00005117_10_T3	PHENOTYPE	24	25	heart attacks
NCT0000511710	NCT00005117_10_T4	PHENOTYPE	4	5	endothelial dysfunction
NCT000051192	NCT00005119_2_T0	PHENOTYPE	9	9	osteoporosis
NCT000051204	NCT00005120_4_T0	PHENOTYPE	16	16	HIV
NCT000051204	NCT00005120_4_T1	GENE	3	3	has
NCT000051210	NCT00005121_0_T0	ORGAN	1	1	Heart
NCT000051212	NCT00005121_2_T0	PHENOTYPE	15	17	coronary heart disease
NCT000051214	NCT00005121_4_T0	GENE	14	14	had
NCT000051215	NCT00005121_5_T0	GENE	2	2	has
NCT000051216	NCT00005121_6_T0	PHENOTYPE	18	18	estimation
NCT000051216	NCT00005121_6_T1	PHENOTYPE	13	14	cardiovascular disease
NCT000051216	NCT00005121_6_T2	PHENOTYPE	27	28	cardiovascular disease
NCT000051217	NCT00005121_7_T0	PHENOTYPE	33	34	cardiovascular disease
NCT000051218	NCT00005121_8_T0	PHENOTYPE	5	6	cardiovascular disease
NCT000051218	NCT00005121_8_T1	PHENOTYPE	27	28	cardiovascular disease
NCT0000512110	NCT00005121_10_T0	GENE	7	7	lipoprotein
NCT0000512110	NCT00005121_10_T1	GENE	10	10	apoprotein
NCT0000512110	NCT00005121_10_T2	PHENOTYPE	28	29	cardiovascular disease
NCT0000512111	NCT00005121_11_T0	PHENOTYPE	9	10	cardiovascular disease
NCT0000512112	NCT00005121_12_T0	PHENOTYPE	21	21	CVD
NCT0000512113	NCT00005121_13_T0	PHENOTYPE	9	10	cardiovascular diseases
NCT0000512114	NCT00005121_14_T0	ORGAN	16	16	Heart
NCT0000512114	NCT00005121_14_T1	BIOLOGICAL_PROCESS	6	6	Aging
NCT0000512114	NCT00005121_14_T2	PHENOTYPE	11	12	senile dementia
NCT0000512115	NCT00005121_15_T0	PHENOTYPE	16	16	suffering
NCT0000512115	NCT00005121_15_T1	PHENOTYPE	18	18	dementia
NCT0000512115	NCT00005121_15_T2	PHENOTYPE	36	36	dementia
NCT0000512115	NCT00005121_15_T3	PHENOTYPE	29	30	senile dementia
NCT0000512117	NCT00005121_17_T0	ORGAN	6	6	Heart
NCT0000512119	NCT00005121_19_T0	PHENOTYPE	7	7	Center
NCT0000512122	NCT00005121_22_T0	PHENOTYPE	6	6	hypertension
NCT0000512122	NCT00005121_22_T1	PHENOTYPE	7	9	congestive heart failure
NCT0000512122	NCT00005121_22_T2	PHENOTYPE	11	13	peripheral arterial disease
NCT0000512122	NCT00005121_22_T3	PHENOTYPE	2	4	coronary heart disease
NCT0000512126	NCT00005121_26_T0	GENE	3	3	has
NCT0000512130	NCT00005121_30_T0	PHENOTYPE	30	31	myocardial infarction
NCT0000512130	NCT00005121_30_T1	PHENOTYPE	43	45	heart valve disorders
NCT0000512130	NCT00005121_30_T2	PHENOTYPE	34	36	left ventricular hypertrophy
NCT0000512130	NCT00005121_30_T3	PHENOTYPE	22	24	coronary heart disease
NCT0000512131	NCT00005121_31_T0	PHENOTYPE	0	0	Initiation
NCT0000512132	NCT00005121_32_T0	ORGAN	13	13	Heart
NCT000051222	NCT00005122_2_T0	PHENOTYPE	30	30	hypertension
NCT000051222	NCT00005122_2_T1	PHENOTYPE	26	28	coronary heart disease
NCT000051223	NCT00005122_3_T0	GENE	35	35	had
NCT000051223	NCT00005122_3_T1	PHENOTYPE	39	39	hypertension
NCT000051223	NCT00005122_3_T2	PHENOTYPE	14	16	coronary heart disease
NCT000051223	NCT00005122_3_T3	PHENOTYPE	25	27	coronary heart disease
NCT000051225	NCT00005122_5_T0	PHENOTYPE	16	17	cardiovascular diseases
NCT000051225	NCT00005122_5_T1	PHENOTYPE	25	27	coronary heart disease
NCT0000512211	NCT00005122_11_T0	GENE	1	1	Lipoprotein
NCT0000512211	NCT00005122_11_T1	PHENOTYPE	23	25	coronary heart disease
NCT0000512214	NCT00005122_14_T0	PHENOTYPE	7	7	Hypertension
NCT000051233	NCT00005123_3_T0	ORGAN	2	2	Heart
NCT000051234	NCT00005123_4_T0	GENE	9	9	San
NCT000051238	NCT00005123_8_T0	COMPOUND	17	17	glucose
NCT000051238	NCT00005123_8_T1	GENE	11	11	hematocrit
NCT000051238	NCT00005123_8_T2	ORGAN	12	12	serum
NCT000051238	NCT00005123_8_T3	ORGAN	6	7	cardiovascular system
NCT000051238	NCT00005123_8_T4	COMPOUND	15	16	uric acid
NCT0000512316	NCT00005123_16_T0	PHENOTYPE	11	11	hypertension
NCT0000512318	NCT00005123_18_T0	PHENOTYPE	10	12	coronary heart disease
NCT0000512319	NCT00005123_19_T0	GENE	13	13	lipoprotein
NCT0000512319	NCT00005123_19_T1	GENE	12	12	had
NCT0000512319	NCT00005123_19_T2	GENE	21	21	Lipoprotein
NCT0000512320	NCT00005123_20_T0	GENE	3	3	lipoprotein
NCT0000512321	NCT00005123_21_T0	PHENOTYPE	16	18	coronary heart disease
NCT0000512323	NCT00005123_23_T0	PHENOTYPE	18	19	chronic diseases
NCT0000512323	NCT00005123_23_T1	PHENOTYPE	13	14	respiratory disease
NCT0000512324	NCT00005123_24_T0	ORGAN	24	24	Heart
NCT0000512324	NCT00005123_24_T1	BIOLOGICAL_PROCESS	13	13	Aging
NCT0000512324	NCT00005123_24_T2	PHENOTYPE	21	21	dementia
NCT0000512324	NCT00005123_24_T3	BIOLOGICAL_PROCESS	19	19	aging
NCT0000512327	NCT00005123_27_T0	PHENOTYPE	14	15	myocardial infarction
NCT0000512331	NCT00005123_31_T0	GENE	7	7	had
NCT0000512332	NCT00005123_32_T0	BIOLOGICAL_PROCESS	22	22	Aging
NCT0000512333	NCT00005123_33_T0	PHENOTYPE	10	10	dementia
NCT0000512335	NCT00005123_35_T0	GENE	25	25	MD
NCT0000512337	NCT00005123_37_T0	PHENOTYPE	17	17	diseases
NCT0000512337	NCT00005123_37_T1	BIOLOGICAL_PROCESS	47	47	aging
NCT0000512337	NCT00005123_37_T2	PHENOTYPE	31	32	cardiovascular disease
NCT0000512339	NCT00005123_39_T0	PHENOTYPE	20	21	chronic diseases
NCT0000512339	NCT00005123_39_T1	PHENOTYPE	14	16	coronary heart disease
NCT0000512341	NCT00005123_41_T0	GENE	1	1	sera
NCT0000512341	NCT00005123_41_T1	PHENOTYPE	8	8	ideas
NCT000051242	NCT00005124_2_T0	GENE	7	7	twins
NCT000051242	NCT00005124_2_T1	GENE	24	24	twins
NCT000051244	NCT00005124_4_T0	GENE	6	6	twins
NCT000051244	NCT00005124_4_T1	PHENOTYPE	14	14	centers
NCT000051246	NCT00005124_6_T0	GENE	9	9	II
NCT000051246	NCT00005124_6_T1	GENE	11	11	twins
NCT000051247	NCT00005124_7_T0	GENE	5	5	twins
NCT000051248	NCT00005124_8_T0	GENE	3	3	II
NCT000051248	NCT00005124_8_T1	GENE	22	22	San
NCT000051248	NCT00005124_8_T2	PHENOTYPE	16	16	centers
NCT0000512411	NCT00005124_11_T0	GENE	16	16	had
NCT0000512417	NCT00005124_17_T0	GENE	0	0	HDL
NCT0000512419	NCT00005124_19_T0	PHENOTYPE	30	31	cardiovascular disease
NCT0000512419	NCT00005124_19_T1	PHENOTYPE	15	16	pulmonary diseases
NCT0000512425	NCT00005124_25_T0	GENE	24	24	twins
NCT0000512425	NCT00005124_25_T1	GENE	32	32	twins
NCT0000512425	NCT00005124_25_T2	PHENOTYPE	35	36	cardiovascular disease
NCT0000512427	NCT00005124_27_T0	GENE	59	59	MRI
NCT0000512427	NCT00005124_27_T1	PHENOTYPE	45	46	cognitive function
NCT0000512429	NCT00005124_29_T0	PHENOTYPE	43	43	CVD
NCT0000512429	NCT00005124_29_T1	PHENOTYPE	41	41	associations
NCT0000512429	NCT00005124_29_T2	PHENOTYPE	16	17	cardiovascular disease
NCT0000512431	NCT00005124_31_T0	PHENOTYPE	24	24	obesity
NCT0000512434	NCT00005124_34_T0	PHENOTYPE	18	18	CVD
NCT000051252	NCT00005125_2_T0	GENE	5	5	has
NCT000051253	NCT00005125_3_T0	GENE	21	21	twins
NCT000051256	NCT00005125_6_T0	GENE	10	10	II
NCT000051256	NCT00005125_6_T1	GENE	2	2	has
NCT000051257	NCT00005125_7_T0	GENE	8	8	II
NCT000051257	NCT00005125_7_T1	GENE	20	20	twins
NCT000051258	NCT00005125_8_T0	GENE	26	26	twins
NCT000051258	NCT00005125_8_T1	GENE	18	18	has
NCT0000512511	NCT00005125_11_T0	GENE	19	19	twins
NCT000051264	NCT00005126_4_T0	GENE	9	9	twins
NCT000051266	NCT00005126_6_T0	GENE	14	14	twins
NCT000051267	NCT00005126_7_T0	GENE	20	20	II
NCT000051268	NCT00005126_8_T0	PHENOTYPE	30	31	drug use
NCT000051269	NCT00005126_9_T0	PHENOTYPE	11	12	blood diseases
NCT0000512610	NCT00005126_10_T0	ORGAN	16	16	heart
NCT0000512610	NCT00005126_10_T1	PHENOTYPE	19	20	blood diseases
NCT0000512612	NCT00005126_12_T0	GENE	21	21	QVR
NCT000051270	NCT00005127_0_T0	ORGAN	1	1	Heart
NCT000051274	NCT00005127_4_T0	ORGAN	5	5	Heart
NCT000051276	NCT00005127_6_T0	PHENOTYPE	16	17	cardiovascular disease
NCT000051277	NCT00005127_7_T0	PHENOTYPE	8	9	cardiovascular disease
NCT0000512710	NCT00005127_10_T0	ORGAN	2	2	Heart
NCT0000512710	NCT00005127_10_T1	PHENOTYPE	17	17	Arteriosclerosis
NCT0000512712	NCT00005127_12_T0	ORGAN	2	2	Heart
NCT0000512714	NCT00005127_14_T0	PHENOTYPE	51	51	conditioning
NCT0000512714	NCT00005127_14_T1	GENE	4	4	ventricular
NCT0000512714	NCT00005127_14_T2	GENE	17	17	ventricular
NCT0000512714	NCT00005127_14_T3	GENE	29	29	ventricular
NCT0000512715	NCT00005127_15_T0	GENE	12	12	ventricular
NCT0000512715	NCT00005127_15_T1	GENE	27	27	ventricular
NCT0000512715	NCT00005127_15_T2	PHENOTYPE	19	21	high blood pressure
NCT0000512717	NCT00005127_17_T0	GENE	15	15	had
NCT0000512718	NCT00005127_18_T0	PHENOTYPE	36	38	high blood pressure
NCT0000512719	NCT00005127_19_T0	PHENOTYPE	16	17	mental stress
NCT0000512719	NCT00005127_19_T1	PHENOTYPE	6	8	systemic vascular resistance
NCT0000512720	NCT00005127_20_T0	GENE	33	33	ventricular
NCT0000512720	NCT00005127_20_T1	PHENOTYPE	21	22	mental stress
NCT0000512722	NCT00005127_22_T0	GENE	6	6	structural
NCT0000512722	NCT00005127_22_T1	PHENOTYPE	9	10	vascular resistance
NCT0000512722	NCT00005127_22_T2	PHENOTYPE	14	15	mental stress
NCT0000512724	NCT00005127_24_T0	PHENOTYPE	25	25	associations
NCT0000512724	NCT00005127_24_T1	GENE	31	31	lipoprotein
NCT0000512724	NCT00005127_24_T2	GENE	17	18	apolipoprotein A-I
NCT0000512724	NCT00005127_24_T3	PHENOTYPE	36	38	coronary artery disease
NCT0000512727	NCT00005127_27_T0	ORGAN	4	4	serum
NCT0000512727	NCT00005127_27_T1	ORGAN	6	6	serum
NCT0000512728	NCT00005127_28_T0	GENE	10	10	had
NCT000051283	NCT00005128_3_T0	PHENOTYPE	43	43	atherosclerosis
NCT000051283	NCT00005128_3_T1	PHENOTYPE	12	12	hyperlipoproteinemia
NCT000051283	NCT00005128_3_T2	PHENOTYPE	27	27	hyperlipoproteinemia
NCT000051283	NCT00005128_3_T3	PHENOTYPE	48	48	hyperlipoproteinemia
NCT000051283	NCT00005128_3_T4	PHENOTYPE	60	62	coronary heart disease
NCT000051287	NCT00005128_7_T0	PHENOTYPE	3	4	Cardiovascular Diseases
NCT0000512814	NCT00005128_14_T0	PHENOTYPE	13	13	dyslipidemia
NCT0000512816	NCT00005128_16_T0	GENE	12	12	had
NCT0000512818	NCT00005128_18_T0	PHENOTYPE	25	25	associations
NCT0000512818	NCT00005128_18_T1	GENE	21	21	lipoprotein
NCT0000512818	NCT00005128_18_T2	GENE	49	49	lipoprotein
NCT0000512818	NCT00005128_18_T3	PHENOTYPE	13	13	dyslipoproteinemia
NCT0000512818	NCT00005128_18_T4	GENE	78	78	hormone
NCT0000512818	NCT00005128_18_T5	PHENOTYPE	12	12	secondary
NCT0000512818	NCT00005128_18_T6	PHENOTYPE	31	32	vascular diseases
NCT0000512818	NCT00005128_18_T7	PHENOTYPE	27	29	coronary heart disease
NCT0000512818	NCT00005128_18_T8	PHENOTYPE	38	40	coronary heart disease
NCT0000512820	NCT00005128_20_T0	ORGAN	16	16	plasma
NCT0000512822	NCT00005128_22_T0	ORGAN	6	6	plasma
NCT0000512825	NCT00005128_25_T0	GENE	10	10	HDL
NCT0000512825	NCT00005128_25_T1	ORGAN	8	8	plasma
NCT0000512825	NCT00005128_25_T2	PHENOTYPE	16	17	cardiovascular disease
NCT0000512825	NCT00005128_25_T3	PHENOTYPE	22	24	coronary heart disease
NCT0000512827	NCT00005128_27_T0	COMPOUND	8	8	estrogen
NCT0000512827	NCT00005128_27_T1	GENE	29	29	lipoprotein
NCT0000512827	NCT00005128_27_T2	PHENOTYPE	14	15	cardiovascular disease
NCT0000512827	NCT00005128_27_T3	PHENOTYPE	16	18	coronary heart disease
NCT000051290	NCT00005129_0_T0	ORGAN	1	1	Heart
NCT000051293	NCT00005129_3_T0	PHENOTYPE	25	26	cardiovascular disease
NCT000051296	NCT00005129_6_T0	ORGAN	2	2	Heart
NCT000051296	NCT00005129_6_T1	PHENOTYPE	13	13	Centers
NCT000051296	NCT00005129_6_T2	GENE	4	4	had
NCT000051299	NCT00005129_9_T0	ORGAN	5	5	Heart
NCT0000512912	NCT00005129_12_T0	ORGAN	15	15	serum
NCT0000512912	NCT00005129_12_T1	GENE	12	12	hemoglobin
NCT0000512915	NCT00005129_15_T0	PHENOTYPE	17	17	attitudes
NCT0000512916	NCT00005129_16_T0	ORGAN	20	20	heart
NCT0000512917	NCT00005129_17_T0	PHENOTYPE	14	16	Type A behavior
NCT0000512918	NCT00005129_18_T0	ORGAN	2	2	Heart
NCT0000512919	NCT00005129_19_T0	GENE	8	8	had
NCT0000512921	NCT00005129_21_T0	PHENOTYPE	21	21	concentrations
NCT0000512921	NCT00005129_21_T1	GENE	20	20	lipoprotein
NCT0000512921	NCT00005129_21_T2	ORGAN	17	17	serum
NCT0000512923	NCT00005129_23_T0	ORGAN	26	26	Heart
NCT0000512925	NCT00005129_25_T0	GENE	7	7	extended
NCT0000512926	NCT00005129_26_T0	PHENOTYPE	14	15	cardiovascular disease
NCT0000512928	NCT00005129_28_T0	ORGAN	24	24	Heart
NCT0000512928	NCT00005129_28_T1	GENE	17	17	had
NCT0000512932	NCT00005129_32_T0	ORGAN	7	7	Heart
NCT0000512933	NCT00005129_33_T0	GENE	29	29	ventricular
NCT0000512933	NCT00005129_33_T1	PHENOTYPE	22	23	myocardial infarction
NCT0000512933	NCT00005129_33_T2	PHENOTYPE	6	7	childhood obesity
NCT0000512935	NCT00005129_35_T0	GENE	48	48	had
NCT0000512935	NCT00005129_35_T1	GENE	7	7	extended
NCT0000512936	NCT00005129_36_T0	ORGAN	17	18	cardiovascular system
NCT0000512938	NCT00005129_38_T0	COMPOUND	10	10	homocysteine
NCT0000512938	NCT00005129_38_T1	GENE	12	12	fibrinogen
NCT0000512938	NCT00005129_38_T2	PHENOTYPE	4	4	obesity
NCT0000512938	NCT00005129_38_T3	PHENOTYPE	17	18	von Willebrand
NCT0000512938	NCT00005129_38_T4	GENE	13	15	plasminogen activator inhibitor-1
NCT0000512943	NCT00005129_43_T0	ORGAN	22	22	Heart
NCT0000512943	NCT00005129_43_T1	PHENOTYPE	14	14	Arteriosclerosis
NCT000051301	NCT00005130_1_T0	GENE	8	8	span
NCT000051303	NCT00005130_3_T0	PHENOTYPE	9	11	coronary heart disease
NCT000051304	NCT00005130_4_T0	GENE	4	4	has
NCT000051306	NCT00005130_6_T0	GENE	29	29	lipoprotein
NCT000051306	NCT00005130_6_T1	PHENOTYPE	6	7	weight gain
NCT000051307	NCT00005130_7_T0	PHENOTYPE	9	9	adiposity
NCT000051308	NCT00005130_8_T0	GENE	20	20	lipoprotein
NCT000051308	NCT00005130_8_T1	GENE	42	42	span
NCT000051308	NCT00005130_8_T2	PHENOTYPE	17	18	weight gain
NCT000051308	NCT00005130_8_T3	PHENOTYPE	31	32	weight gain
NCT0000513011	NCT00005130_11_T0	GENE	0	0	Is
NCT0000513014	NCT00005130_14_T0	PHENOTYPE	4	5	Heart Disease
NCT0000513021	NCT00005130_21_T0	PHENOTYPE	11	12	psychological factors
NCT0000513022	NCT00005130_22_T0	COMPOUND	10	10	glucose
NCT0000513022	NCT00005130_22_T1	GENE	9	9	insulin
NCT0000513022	NCT00005130_22_T2	ORGAN	15	15	serum
NCT0000513022	NCT00005130_22_T3	PHENOTYPE	11	12	liver enzymes
NCT0000513024	NCT00005130_24_T0	ORGAN	7	7	plasma
NCT0000513025	NCT00005130_25_T0	COMPOUND	62	62	creatinine
NCT0000513025	NCT00005130_25_T1	PHENOTYPE	77	77	microalbuminuria
NCT0000513025	NCT00005130_25_T2	COMPOUND	32	32	2
NCT0000513025	NCT00005130_25_T3	GENE	26	26	20
NCT0000513025	NCT00005130_25_T4	GENE	83	83	20
NCT0000513025	NCT00005130_25_T5	GENE	92	92	20
NCT0000513025	NCT00005130_25_T6	GENE	100	100	20
NCT0000513025	NCT00005130_25_T7	PHENOTYPE	59	60	urine sodium
NCT0000513025	NCT00005130_25_T8	PHENOTYPE	73	74	glucose tolerance
NCT0000513030	NCT00005130_30_T0	PHENOTYPE	10	10	centers
NCT000051311	NCT00005131_1_T0	PHENOTYPE	11	11	atherosclerosis
NCT000051311	NCT00005131_1_T1	PHENOTYPE	13	15	coronary heart disease
NCT000051315	NCT00005131_5_T0	PHENOTYPE	28	29	arterial diseases
NCT000051316	NCT00005131_6_T0	PHENOTYPE	13	13	strategies
NCT000051317	NCT00005131_7_T0	PHENOTYPE	12	12	atherosclerosis
NCT000051317	NCT00005131_7_T1	PHENOTYPE	13	14	cardiovascular symptoms
NCT000051318	NCT00005131_8_T0	PHENOTYPE	4	4	atherosclerosis
NCT000051318	NCT00005131_8_T1	PHENOTYPE	16	16	centers
NCT000051318	NCT00005131_8_T2	PHENOTYPE	6	7	cardiovascular diseases
NCT000051319	NCT00005131_9_T0	PHENOTYPE	17	18	Heart Disease
NCT000051319	NCT00005131_9_T1	PHENOTYPE	7	9	Coronary Heart Disease
NCT0000513111	NCT00005131_11_T0	GENE	1	1	II
NCT0000513119	NCT00005131_19_T0	PHENOTYPE	0	0	Atherosclerosis
NCT0000513120	NCT00005131_20_T0	PHENOTYPE	0	0	Arteriosclerosis
NCT0000513121	NCT00005131_21_T0	GENE	5	5	MRI
NCT0000513121	NCT00005131_21_T1	PHENOTYPE	0	1	Cerebrovascular disease
NCT0000513122	NCT00005131_22_T0	GENE	6	6	lipoprotein
NCT0000513122	NCT00005131_22_T1	ORGAN	45	45	heart
NCT0000513122	NCT00005131_22_T2	ORGAN	10	10	plasma
NCT0000513122	NCT00005131_22_T3	PHENOTYPE	22	23	inflammatory disease
NCT0000513122	NCT00005131_22_T4	PHENOTYPE	41	42	insulin levels
NCT0000513122	NCT00005131_22_T5	PHENOTYPE	37	39	fasting blood glucose
NCT0000513123	NCT00005131_23_T0	GENE	5	5	nested
NCT0000513125	NCT00005131_25_T0	PHENOTYPE	13	14	myocardial infarction
NCT0000513125	NCT00005131_25_T1	PHENOTYPE	16	18	coronary heart disease
NCT0000513126	NCT00005131_26_T0	GENE	2	2	has
NCT0000513126	NCT00005131_26_T1	GENE	4	4	extended
NCT0000513127	NCT00005131_27_T0	PHENOTYPE	7	8	cardiovascular disease
NCT0000513129	NCT00005131_29_T0	GENE	15	15	CHD
NCT000051324	NCT00005132_4_T0	PHENOTYPE	10	12	coronary heart disease
NCT000051325	NCT00005132_5_T0	PHENOTYPE	2	2	obesity
NCT000051325	NCT00005132_5_T1	PHENOTYPE	4	5	weight reduction
NCT000051325	NCT00005132_5_T2	PHENOTYPE	15	17	coronary heart disease
NCT000051326	NCT00005132_6_T0	PHENOTYPE	7	7	obesity
NCT000051327	NCT00005132_7_T0	PHENOTYPE	0	0	Obesity
NCT000051327	NCT00005132_7_T1	PHENOTYPE	8	8	maturation
NCT000051328	NCT00005132_8_T0	PHENOTYPE	5	5	pathophysiology
NCT000051328	NCT00005132_8_T1	PHENOTYPE	7	7	obesity
NCT000051328	NCT00005132_8_T2	PHENOTYPE	38	38	obesity
NCT0000513210	NCT00005132_10_T0	PHENOTYPE	14	16	Coronary Heart Disease
NCT0000513211	NCT00005132_11_T0	PHENOTYPE	15	15	obesity
NCT0000513212	NCT00005132_12_T0	PHENOTYPE	28	28	imbalance
NCT0000513212	NCT00005132_12_T1	PHENOTYPE	10	10	Arteriosclerosis
NCT0000513214	NCT00005132_14_T0	PHENOTYPE	14	14	centers
NCT0000513216	NCT00005132_16_T0	GENE	16	16	II
NCT0000513217	NCT00005132_17_T0	GENE	9	9	III
NCT0000513219	NCT00005132_19_T0	GENE	18	18	lipoprotein
NCT000051334	NCT00005133_4_T0	GENE	2	2	has
NCT000051334	NCT00005133_4_T1	PHENOTYPE	8	9	cardiovascular diseases
NCT000051335	NCT00005133_5_T0	GENE	2	2	2.8
NCT000051335	NCT00005133_5_T1	PHENOTYPE	15	17	coronary heart disease
NCT0000513313	NCT00005133_13_T0	PHENOTYPE	24	24	overweight
NCT0000513313	NCT00005133_13_T1	GENE	36	36	ml
NCT0000513313	NCT00005133_13_T2	PHENOTYPE	30	32	serum cholesterol level
NCT0000513314	NCT00005133_14_T0	GENE	2	2	SHEP
NCT0000513314	NCT00005133_14_T1	PHENOTYPE	25	25	hypertension
NCT0000513315	NCT00005133_15_T0	PHENOTYPE	1	2	systolic hypertension
NCT0000513317	NCT00005133_17_T0	GENE	2	2	has
NCT0000513317	NCT00005133_17_T1	PHENOTYPE	16	17	cardiovascular diseases
NCT0000513317	NCT00005133_17_T2	PHENOTYPE	13	14	physical disability
NCT0000513318	NCT00005133_18_T0	GENE	8	8	has
NCT0000513318	NCT00005133_18_T1	PHENOTYPE	5	7	coronary heart disease
NCT0000513319	NCT00005133_19_T0	PHENOTYPE	5	6	heart disease
NCT0000513322	NCT00005133_22_T0	PHENOTYPE	7	8	chronic illness
NCT0000513324	NCT00005133_24_T0	GENE	4	4	sparse
NCT0000513324	NCT00005133_24_T1	PHENOTYPE	18	19	cardiovascular disease
NCT0000513332	NCT00005133_32_T0	PHENOTYPE	2	2	associations
NCT0000513332	NCT00005133_32_T1	GENE	10	10	CHD
NCT0000513334	NCT00005133_34_T0	PHENOTYPE	3	3	associations
NCT0000513334	NCT00005133_34_T1	GENE	14	14	CHD
NCT0000513336	NCT00005133_36_T0	PHENOTYPE	3	3	associations
NCT0000513338	NCT00005133_38_T0	GENE	6	6	CHD
NCT0000513340	NCT00005133_40_T0	GENE	16	16	CHD
NCT0000513341	NCT00005133_41_T0	PHENOTYPE	12	12	CVD
NCT0000513342	NCT00005133_42_T0	GENE	13	13	CHD
NCT0000513343	NCT00005133_43_T0	PHENOTYPE	1	1	atherosclerosis
NCT0000513343	NCT00005133_43_T1	PHENOTYPE	10	10	focused
NCT0000513344	NCT00005133_44_T0	PHENOTYPE	19	19	symptoms
NCT0000513347	NCT00005133_47_T0	GENE	4	4	MRI
NCT0000513349	NCT00005133_49_T0	PHENOTYPE	2	2	associations
NCT0000513353	NCT00005133_53_T0	PHENOTYPE	12	13	myocardial infarction
NCT0000513353	NCT00005133_53_T1	PHENOTYPE	17	18	myocardial ischemia
NCT0000513355	NCT00005133_55_T0	PHENOTYPE	4	4	5-10
NCT0000513355	NCT00005133_55_T1	PHENOTYPE	10	10	CVD
NCT0000513355	NCT00005133_55_T2	GENE	8	8	1.3
NCT0000513357	NCT00005133_57_T0	PHENOTYPE	14	14	symptoms
NCT0000513357	NCT00005133_57_T1	PHENOTYPE	4	4	progression
NCT0000513361	NCT00005133_61_T0	PHENOTYPE	9	9	CVD
NCT0000513362	NCT00005133_62_T0	GENE	24	24	MRI
NCT0000513362	NCT00005133_62_T1	PHENOTYPE	5	5	centers
NCT0000513362	NCT00005133_62_T2	PHENOTYPE	12	12	centers
NCT0000513367	NCT00005133_67_T0	PHENOTYPE	5	5	focused
NCT0000513372	NCT00005133_72_T0	GENE	2	2	has
NCT0000513372	NCT00005133_72_T1	GENE	4	4	extended
NCT000051340	NCT00005134_0_T0	ORGAN	1	1	Heart
NCT000051344	NCT00005134_4_T0	PHENOTYPE	10	11	cardiovascular disease
NCT000051345	NCT00005134_5_T0	PHENOTYPE	14	14	severity
NCT000051345	NCT00005134_5_T1	PHENOTYPE	16	17	cardiovascular disease
NCT000051347	NCT00005134_7_T0	PHENOTYPE	15	16	cardiovascular disease
NCT0000513413	NCT00005134_13_T0	PHENOTYPE	3	3	concentrations
NCT0000513413	NCT00005134_13_T1	PHENOTYPE	25	26	cardiovascular disease
NCT0000513413	NCT00005134_13_T2	PHENOTYPE	28	29	cardiovascular disease
NCT0000513415	NCT00005134_15_T0	PHENOTYPE	7	8	cardiovascular disease
NCT0000513416	NCT00005134_16_T0	PHENOTYPE	7	8	cardiovascular disease
NCT0000513417	NCT00005134_17_T0	PHENOTYPE	13	13	secondary
NCT0000513417	NCT00005134_17_T1	PHENOTYPE	6	7	heart disease
NCT0000513417	NCT00005134_17_T2	PHENOTYPE	15	16	myocardial infarction
NCT0000513417	NCT00005134_17_T3	PHENOTYPE	23	26	chronic ischemic heart disease
NCT0000513418	NCT00005134_18_T0	PHENOTYPE	7	8	heart disease
NCT0000513419	NCT00005134_19_T0	PHENOTYPE	10	12	congenital heart disease
NCT0000513420	NCT00005134_20_T0	PHENOTYPE	16	17	cardiovascular disease
NCT0000513421	NCT00005134_21_T0	PHENOTYPE	41	42	cardiovascular disease
NCT0000513422	NCT00005134_22_T0	PHENOTYPE	26	27	cardiovascular disease
NCT0000513424	NCT00005134_24_T0	PHENOTYPE	6	6	secondary
NCT0000513425	NCT00005134_25_T0	PHENOTYPE	6	6	generalizations
NCT0000513425	NCT00005134_25_T1	PHENOTYPE	11	12	cardiovascular disease
NCT0000513429	NCT00005134_29_T0	PHENOTYPE	39	40	cardiovascular disease
NCT0000513430	NCT00005134_30_T0	PHENOTYPE	9	10	cardiovascular disease
NCT0000513430	NCT00005134_30_T1	PHENOTYPE	23	24	cardiovascular disease
NCT0000513430	NCT00005134_30_T2	PHENOTYPE	14	15	cardiac disease
NCT0000513437	NCT00005134_37_T0	PHENOTYPE	17	17	asthma
NCT0000513437	NCT00005134_37_T1	PHENOTYPE	12	13	arterial stiffness
NCT0000513437	NCT00005134_37_T2	PHENOTYPE	10	11	carotid atherosclerosis
NCT0000513439	NCT00005134_39_T0	PHENOTYPE	12	12	asthma
NCT0000513441	NCT00005134_41_T0	GENE	7	7	FY
NCT0000513441	NCT00005134_41_T1	GENE	1	1	IV
NCT0000513444	NCT00005134_44_T0	GENE	2	2	IV
NCT0000513444	NCT00005134_44_T1	PHENOTYPE	18	19	arterial stiffness
NCT0000513446	NCT00005134_46_T0	PHENOTYPE	15	15	gallstone
NCT0000513446	NCT00005134_46_T1	PHENOTYPE	4	4	Diabetes
NCT0000513446	NCT00005134_46_T2	PHENOTYPE	8	9	Kidney Diseases
NCT000051352	NCT00005135_2_T0	PHENOTYPE	11	11	adiposity
NCT000051352	NCT00005135_2_T1	PHENOTYPE	7	8	insulin resistance
NCT000051354	NCT00005135_4_T0	PHENOTYPE	8	8	understood
NCT000051359	NCT00005135_9_T0	PHENOTYPE	8	8	associations
NCT000051359	NCT00005135_9_T1	PHENOTYPE	30	30	localizing
NCT000051359	NCT00005135_9_T2	GENE	14	14	insulin
NCT000051359	NCT00005135_9_T3	PHENOTYPE	17	18	insulin resistance
NCT0000513510	NCT00005135_10_T0	PHENOTYPE	13	14	cardiovascular disease
NCT0000513510	NCT00005135_10_T1	PHENOTYPE	24	25	insulin levels
NCT0000513511	NCT00005135_11_T0	PHENOTYPE	10	10	hyperinsulinemia
NCT0000513511	NCT00005135_11_T1	PHENOTYPE	19	20	insulin resistance
NCT0000513513	NCT00005135_13_T0	PHENOTYPE	10	11	cardiovascular disease
NCT0000513514	NCT00005135_14_T0	PHENOTYPE	11	12	cardiovascular disease
NCT0000513514	NCT00005135_14_T1	PHENOTYPE	7	8	insulin resistance
NCT0000513515	NCT00005135_15_T0	GENE	3	3	IRAS
NCT0000513515	NCT00005135_15_T1	GENE	10	10	had
NCT0000513515	NCT00005135_15_T2	PHENOTYPE	8	9	insulin resistance
NCT0000513516	NCT00005135_16_T0	GENE	3	3	IRAS
NCT0000513516	NCT00005135_16_T1	PHENOTYPE	20	21	cardiovascular disease
NCT0000513516	NCT00005135_16_T2	PHENOTYPE	16	17	insulin resistance
NCT0000513517	NCT00005135_17_T0	GENE	1	1	IRAS
NCT0000513520	NCT00005135_20_T0	GENE	3	3	extended
NCT0000513523	NCT00005135_23_T0	GENE	8	8	IRAS
NCT0000513526	NCT00005135_26_T0	PHENOTYPE	8	8	atherosclerosis
NCT0000513526	NCT00005135_26_T1	ORGAN	1	2	carotid artery
NCT0000513527	NCT00005135_27_T0	PHENOTYPE	1	2	cardiovascular disease
NCT0000513528	NCT00005135_28_T0	GENE	1	1	IRAS
NCT0000513530	NCT00005135_30_T0	GENE	7	7	06
NCT0000513530	NCT00005135_30_T1	PHENOTYPE	23	23	NIDDM
NCT0000513530	NCT00005135_30_T2	PHENOTYPE	18	19	insulin sensitivity
NCT0000513531	NCT00005135_31_T0	GENE	13	13	IRAS
NCT0000513531	NCT00005135_31_T1	PHENOTYPE	16	16	NIDDM
NCT0000513531	NCT00005135_31_T2	PHENOTYPE	8	9	insulin sensitivity
NCT0000513532	NCT00005135_32_T0	GENE	3	3	IRAS
NCT0000513534	NCT00005135_34_T0	GENE	25	25	IRAS
NCT0000513536	NCT00005135_36_T0	GENE	28	28	IRAS
NCT0000513536	NCT00005135_36_T1	PHENOTYPE	4	5	insulin resistance
NCT0000513536	NCT00005135_36_T2	PHENOTYPE	21	22	insulin resistance
NCT0000513537	NCT00005135_37_T0	GENE	22	22	IRAS
NCT0000513537	NCT00005135_37_T1	GENE	2	2	has
NCT0000513537	NCT00005135_37_T2	PHENOTYPE	17	18	vascular resistance
NCT0000513537	NCT00005135_37_T3	PHENOTYPE	11	12	glucose tolerance
NCT0000513538	NCT00005135_38_T0	PHENOTYPE	8	9	insulin resistance
NCT0000513539	NCT00005135_39_T0	GENE	1	1	IRAS
NCT0000513539	NCT00005135_39_T1	GENE	12	12	IRAS
NCT0000513540	NCT00005135_40_T0	PHENOTYPE	24	24	adiposity
NCT0000513540	NCT00005135_40_T1	PHENOTYPE	27	28	cardiovascular disease
NCT0000513540	NCT00005135_40_T2	PHENOTYPE	12	13	abdominal obesity
NCT0000513540	NCT00005135_40_T3	PHENOTYPE	9	10	insulin resistance
NCT0000513540	NCT00005135_40_T4	PHENOTYPE	21	22	insulin resistance
NCT0000513541	NCT00005135_41_T0	GENE	13	13	IRAS
NCT0000513544	NCT00005135_44_T0	PHENOTYPE	1	2	cardiovascular disease
NCT0000513545	NCT00005135_45_T0	PHENOTYPE	34	34	adiposity
NCT0000513545	NCT00005135_45_T1	PHENOTYPE	30	31	insulin resistance
NCT0000513549	NCT00005135_49_T0	BIOLOGICAL_PROCESS	6	6	eating
NCT000051362	NCT00005136_2_T0	GENE	17	17	II
NCT000051362	NCT00005136_2_T1	GENE	26	26	III
NCT000051368	NCT00005136_8_T0	ORGAN	19	19	Heart
NCT000051368	NCT00005136_8_T1	ORGAN	46	46	Heart
NCT000051368	NCT00005136_8_T2	GENE	6	6	II
NCT000051369	NCT00005136_9_T0	GENE	15	15	CHD
NCT0000513611	NCT00005136_11_T0	GENE	9	9	CHD
NCT0000513613	NCT00005136_13_T0	PHENOTYPE	20	20	hostility
NCT0000513614	NCT00005136_14_T0	GENE	3	3	II
NCT0000513614	NCT00005136_14_T1	PHENOTYPE	7	7	centers
NCT0000513615	NCT00005136_15_T0	GENE	33	33	II
NCT0000513615	NCT00005136_15_T1	GENE	4	4	III
NCT0000513616	NCT00005136_16_T0	GENE	1	1	III
NCT0000513618	NCT00005136_18_T0	PHENOTYPE	25	25	atherosclerosis
NCT0000513618	NCT00005136_18_T1	PHENOTYPE	21	23	coronary heart disease
NCT0000513619	NCT00005136_19_T0	PHENOTYPE	14	14	atherosclerosis
NCT0000513620	NCT00005136_20_T0	PHENOTYPE	6	6	centers
NCT0000513620	NCT00005136_20_T1	GENE	1	1	III
NCT0000513622	NCT00005136_22_T0	ORGAN	18	18	Heart
NCT0000513622	NCT00005136_22_T1	PHENOTYPE	34	34	atherosclerosis
NCT0000513622	NCT00005136_22_T2	COMPOUND	25	25	calcium
NCT0000513623	NCT00005136_23_T0	PHENOTYPE	15	15	Hypertension
NCT000051377	NCT00005137_7_T0	ORGAN	0	0	Plasma
NCT000051377	NCT00005137_7_T1	COMPOUND	13	13	glucose
NCT000051377	NCT00005137_7_T2	GENE	8	8	insulin
NCT000051377	NCT00005137_7_T3	ORGAN	15	15	plasma
NCT000051377	NCT00005137_7_T4	PHENOTYPE	5	6	glucose tolerance
NCT000051377	NCT00005137_7_T5	TISSUE	27	28	body fat
NCT0000513717	NCT00005137_17_T0	TISSUE	4	5	skeletal muscle
NCT0000513718	NCT00005137_18_T0	PHENOTYPE	25	25	NIDDM
NCT000051382	NCT00005138_2_T0	PHENOTYPE	16	16	hypertension
NCT000051382	NCT00005138_2_T1	PHENOTYPE	3	5	High Blood Pressure
NCT000051383	NCT00005138_3_T0	PHENOTYPE	11	11	Centers
NCT000051383	NCT00005138_3_T1	PHENOTYPE	19	21	high blood pressure
NCT000051387	NCT00005138_7_T0	GENE	12	12	had
NCT000051387	NCT00005138_7_T1	PHENOTYPE	29	29	hypertension
NCT0000513810	NCT00005138_10_T0	GENE	15	15	had
NCT0000513810	NCT00005138_10_T1	PHENOTYPE	5	5	hypertension
NCT0000513810	NCT00005138_10_T2	PHENOTYPE	20	20	hypertension
NCT0000513818	NCT00005138_18_T0	ORGAN	0	0	Plasma
NCT0000513818	NCT00005138_18_T1	COMPOUND	5	5	aldosterone
NCT0000513818	NCT00005138_18_T2	GENE	30	30	axis
NCT0000513818	NCT00005138_18_T3	ORGAN	4	4	plasma
NCT0000513818	NCT00005138_18_T4	PHENOTYPE	37	37	hypertension
NCT0000513818	NCT00005138_18_T5	MOLECULAR_FUNCTION	1	2	renin activity
NCT0000513818	NCT00005138_18_T6	PHENOTYPE	22	24	low blood pressures
NCT0000513819	NCT00005138_19_T0	PHENOTYPE	11	11	hypertension
NCT0000513819	NCT00005138_19_T1	PHENOTYPE	31	33	high blood pressure
NCT0000513819	NCT00005138_19_T2	PHENOTYPE	22	24	elevated blood pressure
NCT000051391	NCT00005139_1_T0	PHENOTYPE	5	5	syndromes
NCT000051391	NCT00005139_1_T1	PHENOTYPE	8	9	coronary disease
NCT000051398	NCT00005139_8_T0	PHENOTYPE	8	8	founders
NCT0000513910	NCT00005139_10_T0	GENE	13	13	1.2
NCT0000513916	NCT00005139_16_T0	GENE	12	12	apo
NCT0000513916	NCT00005139_16_T1	GENE	14	14	apo
NCT0000513916	NCT00005139_16_T2	GENE	17	17	apo
NCT0000513916	NCT00005139_16_T3	GENE	11	11	lipoprotein
NCT0000513921	NCT00005139_21_T0	GENE	14	14	had
NCT0000513921	NCT00005139_21_T1	PHENOTYPE	16	18	coronary heart disease
NCT0000513924	NCT00005139_24_T0	PHENOTYPE	31	32	coronary disease
NCT0000513924	NCT00005139_24_T1	PHENOTYPE	20	22	coronary heart disease
NCT0000513926	NCT00005139_26_T0	PHENOTYPE	11	13	coronary heart disease
NCT000051404	NCT00005140_4_T0	PHENOTYPE	27	28	cardiovascular disease
NCT000051404	NCT00005140_4_T1	PHENOTYPE	22	24	coronary heart disease
NCT000051405	NCT00005140_5_T0	ORGAN	29	29	Heart
NCT000051406	NCT00005140_6_T0	PHENOTYPE	24	25	chronic diseases
NCT000051407	NCT00005140_7_T0	ORGAN	3	3	Heart
NCT0000514013	NCT00005140_13_T0	COMPOUND	36	36	glucose
NCT0000514013	NCT00005140_13_T1	ORGAN	10	10	serum
NCT0000514013	NCT00005140_13_T2	ORGAN	38	38	serum
NCT0000514013	NCT00005140_13_T3	ORGAN	14	14	heart
NCT0000514013	NCT00005140_13_T4	COMPOUND	39	40	uric acid
NCT0000514015	NCT00005140_15_T0	PHENOTYPE	7	9	coronary heart disease
NCT0000514016	NCT00005140_16_T0	PHENOTYPE	6	8	coronary heart disease
NCT0000514017	NCT00005140_17_T0	ORGAN	11	11	Heart
NCT0000514018	NCT00005140_18_T0	GENE	9	9	hemoglobin
NCT0000514018	NCT00005140_18_T1	GENE	20	21	lipoprotein lipase
NCT0000514018	NCT00005140_18_T2	PHENOTYPE	22	23	glucose level
NCT0000514018	NCT00005140_18_T3	PHENOTYPE	12	13	cholesterol levels
NCT0000514019	NCT00005140_19_T0	GENE	5	5	FY
NCT0000514019	NCT00005140_19_T1	GENE	10	10	FY
NCT0000514022	NCT00005140_22_T0	ORGAN	16	16	Heart
NCT0000514022	NCT00005140_22_T1	GENE	2	2	has
NCT0000514022	NCT00005140_22_T2	GENE	4	4	extended
NCT000051411	NCT00005141_1_T0	PHENOTYPE	11	11	obesity
NCT000051413	NCT00005141_3_T0	PHENOTYPE	0	0	Hypertension
NCT000051413	NCT00005141_3_T1	PHENOTYPE	24	24	hypertension
NCT000051415	NCT00005141_5_T0	PHENOTYPE	4	6	High Blood Pressure
NCT000051416	NCT00005141_6_T0	PHENOTYPE	31	31	hypertension
NCT000051423	NCT00005142_3_T0	GENE	7	7	had
NCT000051423	NCT00005142_3_T1	PHENOTYPE	4	6	peripheral arterial disease
NCT000051425	NCT00005142_5_T0	PHENOTYPE	28	28	hyperlipidemia
NCT000051426	NCT00005142_6_T0	PHENOTYPE	22	23	cardiovascular disease
NCT000051427	NCT00005142_7_T0	PHENOTYPE	29	29	pulse
NCT000051427	NCT00005142_7_T1	PHENOTYPE	26	27	reactive hyperemia
NCT000051427	NCT00005142_7_T2	PHENOTYPE	9	11	peripheral arterial disease
NCT000051427	NCT00005142_7_T3	PHENOTYPE	17	19	segmental blood pressure
NCT000051428	NCT00005142_8_T0	PHENOTYPE	7	9	peripheral arterial disease
NCT000051428	NCT00005142_8_T1	PHENOTYPE	13	15	peripheral arterial disease
NCT000051435	NCT00005143_5_T0	PHENOTYPE	23	23	strategies
NCT000051435	NCT00005143_5_T1	PHENOTYPE	28	29	cardiovascular disease
NCT000051436	NCT00005143_6_T0	GENE	15	15	FCP
NCT000051438	NCT00005143_8_T0	PHENOTYPE	12	13	Heart Disease
NCT0000514311	NCT00005143_11_T0	PHENOTYPE	16	17	Heart Disease
NCT0000514313	NCT00005143_13_T0	PHENOTYPE	0	1	Heart Disease
NCT0000514315	NCT00005143_15_T0	GENE	23	23	San
NCT0000514315	NCT00005143_15_T1	GENE	4	4	had
NCT0000514323	NCT00005143_23_T0	GENE	3	3	has
NCT0000514326	NCT00005143_26_T0	PHENOTYPE	18	19	heart disease
NCT0000514328	NCT00005143_28_T0	COMPOUND	28	28	sodium
NCT0000514328	NCT00005143_28_T1	COMPOUND	31	31	creatinine
NCT0000514328	NCT00005143_28_T2	COMPOUND	29	29	potassium
NCT0000514328	NCT00005143_28_T3	GENE	21	21	lipoprotein
NCT0000514328	NCT00005143_28_T4	ORGAN	12	12	plasma
NCT0000514328	NCT00005143_28_T5	COMPOUND	13	13	thiocyanate
NCT0000514328	NCT00005143_28_T6	ORGAN	10	10	heart
NCT0000514328	NCT00005143_28_T7	COMPOUND	25	26	carbon dioxide
NCT0000514329	NCT00005143_29_T0	GENE	14	14	lipoprotein
NCT0000514329	NCT00005143_29_T1	ORGAN	5	5	plasma
NCT0000514329	NCT00005143_29_T2	GENE	6	7	apolipoprotein A-1
NCT0000514331	NCT00005143_31_T0	PHENOTYPE	18	19	myocardial infarction
NCT0000514331	NCT00005143_31_T1	PHENOTYPE	21	22	myocardial infarction
NCT0000514332	NCT00005143_32_T0	ORGAN	14	14	Heart
NCT0000514332	NCT00005143_32_T1	ORGAN	20	20	Heart
NCT0000514333	NCT00005143_33_T0	PHENOTYPE	2	3	cardiovascular disease
NCT0000514333	NCT00005143_33_T1	PHENOTYPE	14	15	myocardial infarction
NCT0000514337	NCT00005143_37_T0	PHENOTYPE	5	5	severity
NCT0000514338	NCT00005143_38_T0	PHENOTYPE	1	1	Acute
NCT0000514340	NCT00005143_40_T0	GENE	63	63	nested
NCT0000514340	NCT00005143_40_T1	GENE	70	70	HDL
NCT0000514340	NCT00005143_40_T2	GENE	34	34	FCP
NCT0000514340	NCT00005143_40_T3	GENE	57	57	FCP
NCT0000514340	NCT00005143_40_T4	ORGAN	53	53	plasma
NCT0000514340	NCT00005143_40_T5	PHENOTYPE	78	79	cardiovascular disease
NCT0000514343	NCT00005143_43_T0	PHENOTYPE	11	11	CVD
NCT000051441	NCT00005144_1_T0	PHENOTYPE	10	10	Hostility
NCT000051441	NCT00005144_1_T1	PHENOTYPE	17	19	Type A behavior
NCT000051443	NCT00005144_3_T0	ORGAN	54	54	serum
NCT000051443	NCT00005144_3_T1	PHENOTYPE	25	27	Type A behavior
NCT000051443	NCT00005144_3_T2	PHENOTYPE	35	37	coronary heart disease
NCT000051444	NCT00005144_4_T0	PHENOTYPE	56	56	associations
NCT000051444	NCT00005144_4_T1	PHENOTYPE	65	65	severity
NCT000051444	NCT00005144_4_T2	GENE	5	5	met
NCT000051444	NCT00005144_4_T3	PHENOTYPE	67	69	coronary artery disease
NCT000051444	NCT00005144_4_T4	PHENOTYPE	12	14	Type A behavior
NCT000051444	NCT00005144_4_T5	PHENOTYPE	37	39	Type A behavior
NCT000051444	NCT00005144_4_T6	PHENOTYPE	60	62	Type A behavior
NCT000051444	NCT00005144_4_T7	PHENOTYPE	17	19	coronary heart disease
NCT000051444	NCT00005144_4_T8	PHENOTYPE	46	48	coronary heart disease
NCT000051445	NCT00005144_5_T0	COMPOUND	12	12	JAS
NCT000051445	NCT00005144_5_T1	PHENOTYPE	15	17	Type A behavior
NCT000051445	NCT00005144_5_T2	PHENOTYPE	38	40	Type A behavior
NCT000051446	NCT00005144_6_T0	GENE	5	5	had
NCT000051446	NCT00005144_6_T1	PHENOTYPE	20	22	Type A behavior
NCT000051446	NCT00005144_6_T2	PHENOTYPE	28	30	coronary heart disease
NCT000051449	NCT00005144_9_T0	PHENOTYPE	28	29	myocardial infarction
NCT000051449	NCT00005144_9_T1	PHENOTYPE	13	15	Type A behavior
NCT0000514410	NCT00005144_10_T0	PHENOTYPE	22	24	Type A behavior
NCT0000514410	NCT00005144_10_T1	PHENOTYPE	30	32	coronary heart disease
NCT0000514411	NCT00005144_11_T0	PHENOTYPE	9	9	associations
NCT0000514411	NCT00005144_11_T1	GENE	2	2	had
NCT0000514411	NCT00005144_11_T2	GENE	7	7	had
NCT0000514411	NCT00005144_11_T3	PHENOTYPE	18	20	Type A behavior
NCT0000514411	NCT00005144_11_T4	PHENOTYPE	11	13	coronary heart disease
NCT0000514412	NCT00005144_12_T0	PHENOTYPE	20	20	Hostility
NCT0000514412	NCT00005144_12_T1	PHENOTYPE	4	6	Type A behavior
NCT0000514412	NCT00005144_12_T2	PHENOTYPE	27	29	coronary heart disease
NCT0000514414	NCT00005144_14_T0	PHENOTYPE	18	20	Type A behavior
NCT0000514414	NCT00005144_14_T1	PHENOTYPE	24	26	coronary heart disease
NCT0000514415	NCT00005144_15_T0	GENE	11	11	had
NCT0000514415	NCT00005144_15_T1	ORGAN	19	19	heart
NCT0000514417	NCT00005144_17_T0	PHENOTYPE	15	15	Hostility
NCT0000514418	NCT00005144_18_T0	GENE	2	2	II
NCT0000514419	NCT00005144_19_T0	PHENOTYPE	21	21	attitudes
NCT0000514420	NCT00005144_20_T0	PHENOTYPE	38	38	Hostility
NCT0000514420	NCT00005144_20_T1	PHENOTYPE	44	46	coronary heart disease
NCT0000514421	NCT00005144_21_T0	PHENOTYPE	22	22	judgement
NCT0000514421	NCT00005144_21_T1	PHENOTYPE	14	14	Intensity
NCT0000514421	NCT00005144_21_T2	PHENOTYPE	13	13	Content
NCT0000514421	NCT00005144_21_T3	PHENOTYPE	6	6	Hostility
NCT0000514421	NCT00005144_21_T4	PHENOTYPE	27	27	Hostility
NCT0000514421	NCT00005144_21_T5	GENE	2	2	had
NCT0000514422	NCT00005144_22_T0	PHENOTYPE	5	5	Hostility
NCT0000514425	NCT00005144_25_T0	PHENOTYPE	10	10	Hostility
NCT0000514425	NCT00005144_25_T1	PHENOTYPE	4	4	regressions
NCT000051452	NCT00005145_2_T0	PHENOTYPE	10	11	cardiovascular diseases
NCT000051453	NCT00005145_3_T0	GENE	15	15	had
NCT000051453	NCT00005145_3_T1	GENE	28	28	had
NCT000051453	NCT00005145_3_T2	PHENOTYPE	20	21	cerebrovascular disease
NCT000051453	NCT00005145_3_T3	PHENOTYPE	6	8	coronary heart disease
NCT000051454	NCT00005145_4_T0	PHENOTYPE	25	25	hypertension
NCT000051455	NCT00005145_5_T0	ORGAN	2	2	Heart
NCT000051455	NCT00005145_5_T1	PHENOTYPE	21	22	myocardial infarction
NCT000051455	NCT00005145_5_T2	PHENOTYPE	8	10	coronary heart disease
NCT000051457	NCT00005145_7_T0	GENE	2	2	FY
NCT000051459	NCT00005145_9_T0	PHENOTYPE	3	3	hypertension
NCT000051459	NCT00005145_9_T1	PHENOTYPE	11	12	renal disease
NCT000051459	NCT00005145_9_T2	PHENOTYPE	5	7	coronary heart disease
NCT0000514510	NCT00005145_10_T0	GENE	0	0	Age
NCT0000514512	NCT00005145_12_T0	PHENOTYPE	13	15	coronary heart disease
NCT0000514513	NCT00005145_13_T0	PHENOTYPE	10	10	acute
NCT0000514513	NCT00005145_13_T1	PHENOTYPE	12	12	chronic
NCT0000514513	NCT00005145_13_T2	PHENOTYPE	14	15	heart disease
NCT0000514515	NCT00005145_15_T0	GENE	7	7	probable
NCT0000514515	NCT00005145_15_T1	PHENOTYPE	10	11	myocardial infarction
NCT0000514516	NCT00005145_16_T0	GENE	25	25	bypass
NCT0000514516	NCT00005145_16_T1	ORGAN	23	24	coronary artery
NCT0000514517	NCT00005145_17_T0	PHENOTYPE	14	16	coronary heart disease
NCT0000514518	NCT00005145_18_T0	PHENOTYPE	8	9	myocardial infarction
NCT0000514519	NCT00005145_19_T0	GENE	20	20	lipoprotein
NCT0000514519	NCT00005145_19_T1	PHENOTYPE	30	30	attitudes
NCT0000514519	NCT00005145_19_T2	ORGAN	15	15	serum
NCT0000514519	NCT00005145_19_T3	ORGAN	17	17	serum
NCT0000514522	NCT00005145_22_T0	GENE	1	1	nested
NCT0000514522	NCT00005145_22_T1	PHENOTYPE	13	14	cardiovascular disease
NCT0000514522	NCT00005145_22_T2	PHENOTYPE	19	21	coronary heart disease
NCT0000514524	NCT00005145_24_T0	PHENOTYPE	22	24	congestive heart failure
NCT0000514524	NCT00005145_24_T1	PHENOTYPE	19	21	coronary heart disease
NCT000051460	NCT00005146_0_T0	ORGAN	9	9	Heart
NCT000051460	NCT00005146_0_T1	GENE	7	7	San
NCT000051460	NCT00005146_0_T2	PHENOTYPE	0	0	Diabetes
NCT000051462	NCT00005146_2_T0	PHENOTYPE	10	10	adiposity
NCT000051462	NCT00005146_2_T1	GENE	16	16	insulin
NCT000051462	NCT00005146_2_T2	PHENOTYPE	17	17	resistant
NCT000051462	NCT00005146_2_T3	PHENOTYPE	23	24	insulin resistance
NCT000051468	NCT00005146_8_T0	GENE	13	13	lipoprotein
NCT000051468	NCT00005146_8_T1	PHENOTYPE	7	7	hypertriglyceridemia
NCT000051468	NCT00005146_8_T2	PHENOTYPE	4	4	obesity
NCT000051468	NCT00005146_8_T3	PHENOTYPE	5	6	glucose intolerance
NCT0000514615	NCT00005146_15_T0	GENE	10	10	insulin
NCT0000514615	NCT00005146_15_T1	GENE	11	11	hemoglobin
NCT0000514615	NCT00005146_15_T2	GENE	15	15	HDL
NCT0000514615	NCT00005146_15_T3	GENE	16	16	LDL
NCT0000514615	NCT00005146_15_T4	GENE	18	18	VLDL
NCT0000514615	NCT00005146_15_T5	ORGAN	9	9	plasma
NCT0000514615	NCT00005146_15_T6	ORGAN	12	12	serum
NCT0000514615	NCT00005146_15_T7	PHENOTYPE	7	8	plasma glucose
NCT0000514621	NCT00005146_21_T0	PHENOTYPE	8	8	obesity
NCT0000514621	NCT00005146_21_T1	TISSUE	9	10	body fat
NCT0000514622	NCT00005146_22_T0	COMPOUND	15	15	glucose
NCT0000514622	NCT00005146_22_T1	PHENOTYPE	18	18	concentrations
NCT0000514622	NCT00005146_22_T2	GENE	17	17	insulin
NCT0000514622	NCT00005146_22_T3	PHENOTYPE	10	11	glucose tolerance
NCT0000514625	NCT00005146_25_T0	PHENOTYPE	6	6	obesity
NCT0000514625	NCT00005146_25_T1	TISSUE	7	8	body fat
NCT0000514629	NCT00005146_29_T0	GENE	7	7	6.5
NCT000051472	NCT00005147_2_T0	GENE	2	2	has
NCT000051472	NCT00005147_2_T1	PHENOTYPE	20	22	coronary artery disease
NCT000051473	NCT00005147_3_T0	GENE	19	19	has
NCT000051473	NCT00005147_3_T1	PHENOTYPE	43	44	familial hypercholesterolemia
NCT000051473	NCT00005147_3_T2	PHENOTYPE	15	17	coronary heart disease
NCT000051475	NCT00005147_5_T0	BIOLOGICAL_PROCESS	23	24	lipid metabolism
NCT000051476	NCT00005147_6_T0	GENE	13	13	apo
NCT000051476	NCT00005147_6_T1	GENE	33	33	apo
NCT000051476	NCT00005147_6_T2	GENE	39	39	apo
NCT000051476	NCT00005147_6_T3	GENE	52	52	apo
NCT000051476	NCT00005147_6_T4	GENE	42	42	HDL
NCT000051476	NCT00005147_6_T5	PHENOTYPE	29	29	obesity
NCT000051476	NCT00005147_6_T6	PHENOTYPE	16	18	coronary artery disease
NCT000051476	NCT00005147_6_T7	PHENOTYPE	71	73	coronary artery disease
NCT000051476	NCT00005147_6_T8	PHENOTYPE	48	50	mode of inheritance
NCT000051477	NCT00005147_7_T0	ORGAN	12	12	Heart
NCT000051477	NCT00005147_7_T1	PHENOTYPE	16	16	recruitment
NCT000051478	NCT00005147_8_T0	PHENOTYPE	4	4	recruitment
NCT000051479	NCT00005147_9_T0	GENE	9	9	had
NCT0000514713	NCT00005147_13_T0	PHENOTYPE	9	11	coronary artery disease
NCT0000514714	NCT00005147_14_T0	PHENOTYPE	20	20	diseases
NCT0000514714	NCT00005147_14_T1	PHENOTYPE	7	7	symptoms
NCT0000514714	NCT00005147_14_T2	PHENOTYPE	14	15	cerebrovascular disease
NCT0000514714	NCT00005147_14_T3	PHENOTYPE	12	13	arteriosclerosis obliterans
NCT0000514714	NCT00005147_14_T4	PHENOTYPE	9	11	coronary artery disease
NCT0000514715	NCT00005147_15_T0	GENE	10	10	apo
NCT0000514715	NCT00005147_15_T1	GENE	12	12	apo
NCT0000514715	NCT00005147_15_T2	GENE	14	14	apo
NCT0000514715	NCT00005147_15_T3	GENE	16	16	apo
NCT0000514715	NCT00005147_15_T4	GENE	18	18	apo
NCT0000514715	NCT00005147_15_T5	GENE	20	20	apo
NCT0000514715	NCT00005147_15_T6	GENE	22	22	apo
NCT0000514715	NCT00005147_15_T7	GENE	25	25	apo
NCT0000514715	NCT00005147_15_T8	GENE	28	28	apo
NCT0000514715	NCT00005147_15_T9	GENE	6	6	HDL
NCT0000514715	NCT00005147_15_T10	GENE	27	27	HDL
NCT0000514715	NCT00005147_15_T11	GENE	8	8	LDL
NCT0000514715	NCT00005147_15_T12	GENE	24	24	LDL
NCT0000514716	NCT00005147_16_T0	GENE	1	1	lipoprotein
NCT0000514716	NCT00005147_16_T1	PHENOTYPE	11	11	RFLP
NCT0000514716	NCT00005147_16_T2	PHENOTYPE	18	20	coronary artery disease
NCT0000514716	NCT00005147_16_T3	PHENOTYPE	7	10	restriction fragment length polymorphisms
NCT0000514718	NCT00005147_18_T0	PHENOTYPE	1	1	RFLP
NCT000051482	NCT00005148_2_T0	ORGAN	2	2	Heart
NCT000051482	NCT00005148_2_T1	PHENOTYPE	16	18	coronary heart disease
NCT000051487	NCT00005148_7_T0	PHENOTYPE	35	37	coronary heart disease
NCT0000514811	NCT00005148_11_T0	PHENOTYPE	21	21	satisfied
NCT0000514813	NCT00005148_13_T0	GENE	6	6	met
NCT0000514814	NCT00005148_14_T0	GENE	2	2	abstract
NCT0000514815	NCT00005148_15_T0	GENE	1	1	abstract
NCT0000514815	NCT00005148_15_T1	PHENOTYPE	10	10	hypertension
NCT0000514815	NCT00005148_15_T2	PHENOTYPE	11	11	hypertension
NCT0000514816	NCT00005148_16_T0	PHENOTYPE	2	3	myocardial infarction
NCT0000514816	NCT00005148_16_T1	PHENOTYPE	23	24	myocardial infarction
NCT0000514816	NCT00005148_16_T2	PHENOTYPE	27	28	myocardial infarction
NCT0000514816	NCT00005148_16_T3	PHENOTYPE	7	9	coronary heart disease
NCT0000514816	NCT00005148_16_T4	PHENOTYPE	18	20	coronary heart disease
NCT0000514820	NCT00005148_20_T0	PHENOTYPE	10	12	coronary heart disease
NCT0000514825	NCT00005148_25_T0	ORGAN	11	11	heart
NCT0000514825	NCT00005148_25_T1	ORGAN	18	19	coronary arteries
NCT0000514825	NCT00005148_25_T2	PHENOTYPE	6	8	age at death
NCT0000514825	NCT00005148_25_T3	PHENOTYPE	25	27	old myocardial infarction
NCT0000514826	NCT00005148_26_T0	PHENOTYPE	10	12	coronary heart disease
NCT0000514827	NCT00005148_27_T0	PHENOTYPE	3	5	valvular heart disease
NCT0000514828	NCT00005148_28_T0	GENE	7	7	DRG
NCT0000514828	NCT00005148_28_T1	PHENOTYPE	14	16	valvular heart disease
NCT0000514829	NCT00005148_29_T0	GENE	9	9	retained
NCT0000514829	NCT00005148_29_T1	GENE	4	4	DRG
NCT0000514831	NCT00005148_31_T0	GENE	51	51	1976
NCT0000514831	NCT00005148_31_T1	GENE	73	73	1976
NCT0000514831	NCT00005148_31_T2	GENE	54	54	bypass
NCT0000514831	NCT00005148_31_T3	GENE	44	44	balloon
NCT0000514831	NCT00005148_31_T4	ORGAN	52	53	coronary artery
NCT000051490	NCT00005149_0_T0	PHENOTYPE	5	5	Hypertension
NCT000051493	NCT00005149_3_T0	PHENOTYPE	0	1	Essential hypertension
NCT000051494	NCT00005149_4_T0	PHENOTYPE	1	1	syndromes
NCT000051494	NCT00005149_4_T1	PHENOTYPE	4	4	hypertension
NCT000051495	NCT00005149_5_T0	GENE	19	19	extended
NCT000051496	NCT00005149_6_T0	PHENOTYPE	23	23	Hypertension
NCT000051496	NCT00005149_6_T1	PHENOTYPE	28	30	high blood pressure
NCT000051496	NCT00005149_6_T2	PHENOTYPE	14	16	coronary heart disease
NCT000051499	NCT00005149_9_T0	GENE	12	12	kallikrein
NCT000051499	NCT00005149_9_T1	ORGAN	7	7	plasma
NCT000051499	NCT00005149_9_T2	MOLECULAR_FUNCTION	8	9	renin activity
NCT0000514912	NCT00005149_12_T0	PHENOTYPE	7	9	high blood pressure
NCT0000514913	NCT00005149_13_T0	PHENOTYPE	17	19	high blood pressure
NCT0000514914	NCT00005149_14_T0	PHENOTYPE	21	21	hypertension
NCT000051503	NCT00005150_3_T0	PHENOTYPE	24	24	associations
NCT000051503	NCT00005150_3_T1	PHENOTYPE	7	8	cardiovascular diseases
NCT000051504	NCT00005150_4_T0	PHENOTYPE	16	16	inference
NCT000051505	NCT00005150_5_T0	PHENOTYPE	23	23	strategies
NCT000051506	NCT00005150_6_T0	PHENOTYPE	14	14	hypertension
NCT000051506	NCT00005150_6_T1	GENE	20	20	CHD
NCT000051506	NCT00005150_6_T2	PHENOTYPE	17	19	coronary heart disease
NCT000051507	NCT00005150_7_T0	ORGAN	12	12	Heart
NCT000051507	NCT00005150_7_T1	GENE	15	15	contrasted
NCT000051509	NCT00005150_9_T0	PHENOTYPE	7	7	attributable
NCT000051509	NCT00005150_9_T1	PHENOTYPE	11	12	cardiovascular disease
NCT0000515010	NCT00005150_10_T0	PHENOTYPE	2	2	learned
NCT0000515010	NCT00005150_10_T1	PHENOTYPE	10	11	cardiovascular disease
NCT0000515014	NCT00005150_14_T0	GENE	9	9	Paul
NCT0000515016	NCT00005150_16_T0	PHENOTYPE	12	12	Falls
NCT0000515016	NCT00005150_16_T1	PHENOTYPE	18	18	centers
NCT0000515016	NCT00005150_16_T2	GENE	9	9	paired
NCT0000515017	NCT00005150_17_T0	PHENOTYPE	6	6	centers
NCT0000515020	NCT00005150_20_T0	PHENOTYPE	11	12	cholesterol levels
NCT0000515026	NCT00005150_26_T0	PHENOTYPE	11	11	attitudes
NCT0000515027	NCT00005150_27_T0	GENE	5	5	had
NCT0000515028	NCT00005150_28_T0	GENE	11	11	HDL
NCT0000515028	NCT00005150_28_T1	ORGAN	8	8	serum
NCT0000515028	NCT00005150_28_T2	ORGAN	14	14	serum
NCT0000515028	NCT00005150_28_T3	COMPOUND	15	15	thiocyanate
NCT0000515030	NCT00005150_30_T0	ORGAN	16	16	Heart
NCT0000515030	NCT00005150_30_T1	PHENOTYPE	5	6	myocardial infarction
NCT0000515031	NCT00005150_31_T0	ORGAN	9	9	Heart
NCT0000515032	NCT00005150_32_T0	PHENOTYPE	17	18	cardiovascular disease
NCT0000515032	NCT00005150_32_T1	PHENOTYPE	4	5	myocardial infarction
NCT000051511	NCT00005151_1_T0	PHENOTYPE	10	10	obesity
NCT000051511	NCT00005151_1_T1	PHENOTYPE	4	6	high blood pressure
NCT000051514	NCT00005151_4_T0	PHENOTYPE	13	13	secondary
NCT000051514	NCT00005151_4_T1	PHENOTYPE	20	22	coronary heart disease
NCT000051515	NCT00005151_5_T0	PHENOTYPE	18	20	coronary heart disease
NCT000051516	NCT00005151_6_T0	ORGAN	2	2	Heart
NCT000051519	NCT00005151_9_T0	ORGAN	21	21	Heart
NCT0000515116	NCT00005151_16_T0	COMPOUND	59	59	sodium
NCT0000515120	NCT00005151_20_T0	PHENOTYPE	22	23	cardiovascular disease
NCT0000515121	NCT00005151_21_T0	COMPOUND	15	15	cotinine
NCT0000515121	NCT00005151_21_T1	ORGAN	14	14	serum
NCT0000515127	NCT00005151_27_T0	PHENOTYPE	10	12	coronary heart disease
NCT0000515129	NCT00005151_29_T0	ORGAN	8	8	Heart
NCT0000515129	NCT00005151_29_T1	ORGAN	21	21	Heart
NCT000051529	NCT00005152_9_T0	GENE	2	2	has
NCT0000515218	NCT00005152_18_T0	GENE	17	17	6.0
NCT0000515218	NCT00005152_18_T1	PHENOTYPE	6	8	coronary heart disease
NCT0000515223	NCT00005152_23_T0	PHENOTYPE	6	7	cardiovascular disease
NCT0000515225	NCT00005152_25_T0	PHENOTYPE	10	10	menopausal
NCT0000515225	NCT00005152_25_T1	PHENOTYPE	17	17	menopausal
NCT0000515225	NCT00005152_25_T2	GENE	18	18	hormone
NCT0000515229	NCT00005152_29_T0	COMPOUND	22	22	estrogen
NCT0000515229	NCT00005152_29_T1	PHENOTYPE	21	21	menopausal
NCT0000515229	NCT00005152_29_T2	ORGAN	30	30	plasma
NCT0000515230	NCT00005152_30_T0	PHENOTYPE	3	4	cardiovascular disease
NCT0000515231	NCT00005152_31_T0	GENE	24	24	kin
NCT0000515233	NCT00005152_33_T0	GENE	5	5	FY
NCT0000515235	NCT00005152_35_T0	PHENOTYPE	37	37	exposures
NCT0000515235	NCT00005152_35_T1	PHENOTYPE	13	13	menopausal
NCT0000515235	NCT00005152_35_T2	GENE	47	47	prothrombin
NCT0000515235	NCT00005152_35_T3	GENE	14	14	hormone
NCT0000515235	NCT00005152_35_T4	PHENOTYPE	10	11	cardiovascular disease
NCT0000515236	NCT00005152_36_T0	PHENOTYPE	24	25	cardiovascular disease
NCT0000515236	NCT00005152_36_T1	PHENOTYPE	13	15	coronary heart disease
NCT0000515237	NCT00005152_37_T0	COMPOUND	21	21	L-carnitine
NCT0000515237	NCT00005152_37_T1	COMPOUND	19	19	choline
NCT0000515237	NCT00005152_37_T2	COMPOUND	17	17	trimethylamine
NCT0000515237	NCT00005152_37_T3	ORGAN	6	6	plasma
NCT0000515237	NCT00005152_37_T4	PHENOTYPE	23	25	coronary heart disease
NCT000051533	NCT00005153_3_T0	PHENOTYPE	8	8	malformations
NCT000051533	NCT00005153_3_T1	PHENOTYPE	16	17	Birth Defects
NCT000051533	NCT00005153_3_T2	PHENOTYPE	0	2	Congenital heart disease
NCT000051534	NCT00005153_4_T0	PHENOTYPE	4	6	congenital heart disease
NCT000051536	NCT00005153_6_T0	PHENOTYPE	8	9	cardiac defects
NCT000051538	NCT00005153_8_T0	PHENOTYPE	11	13	congenital heart disease
NCT000051539	NCT00005153_9_T0	PHENOTYPE	20	20	pathology
NCT000051539	NCT00005153_9_T1	PHENOTYPE	8	8	centers
NCT0000515310	NCT00005153_10_T0	PHENOTYPE	18	20	congenital heart disease
NCT0000515311	NCT00005153_11_T0	PHENOTYPE	30	30	transmitted
NCT0000515311	NCT00005153_11_T1	PHENOTYPE	22	23	environmental exposures
NCT0000515312	NCT00005153_12_T0	PHENOTYPE	6	7	drug use
NCT0000515315	NCT00005153_15_T0	PHENOTYPE	6	6	exposures
NCT0000515315	NCT00005153_15_T1	PHENOTYPE	21	23	congenital heart disease
NCT0000515316	NCT00005153_16_T0	PHENOTYPE	16	17	environmental exposures
NCT0000515316	NCT00005153_16_T1	PHENOTYPE	3	5	congenital heart disease
NCT0000515318	NCT00005153_18_T0	PHENOTYPE	7	7	recurrence
NCT0000515318	NCT00005153_18_T1	PHENOTYPE	5	5	estimation
NCT0000515318	NCT00005153_18_T2	PHENOTYPE	31	32	pregnancy loss
NCT0000515318	NCT00005153_18_T3	PHENOTYPE	28	29	birth defect
NCT0000515318	NCT00005153_18_T4	PHENOTYPE	18	19	cardiac defect
NCT0000515318	NCT00005153_18_T5	PHENOTYPE	21	22	cardiac defect
NCT0000515318	NCT00005153_18_T6	PHENOTYPE	12	14	congenital heart disease
NCT0000515319	NCT00005153_19_T0	PHENOTYPE	12	13	genetic disorders
NCT0000515319	NCT00005153_19_T1	PHENOTYPE	8	9	birth defects
NCT0000515324	NCT00005153_24_T0	COMPOUND	6	7	vitamin A
NCT000051540	NCT00005154_0_T0	GENE	6	6	IV
NCT000051540	NCT00005154_0_T1	GENE	8	8	IV
NCT000051545	NCT00005154_5_T0	BIOLOGICAL_PROCESS	6	6	Aging
NCT000051546	NCT00005154_6_T0	PHENOTYPE	12	14	coronary heart disease
NCT000051547	NCT00005154_7_T0	ORGAN	6	6	serum
NCT000051547	NCT00005154_7_T1	PHENOTYPE	14	16	coronary heart disease
NCT000051548	NCT00005154_8_T0	PHENOTYPE	6	8	coronary heart disease
NCT000051549	NCT00005154_9_T0	PHENOTYPE	15	17	coronary heart disease
NCT0000515411	NCT00005154_11_T0	GENE	7	7	III
NCT0000515411	NCT00005154_11_T1	GENE	14	14	IV
NCT0000515412	NCT00005154_12_T0	GENE	1	1	III
NCT0000515414	NCT00005154_14_T0	ORGAN	12	12	heart
NCT0000515414	NCT00005154_14_T1	PHENOTYPE	16	17	blood diseases
NCT0000515415	NCT00005154_15_T0	PHENOTYPE	22	22	generalized
NCT0000515416	NCT00005154_16_T0	ORGAN	30	30	Heart
NCT0000515416	NCT00005154_16_T1	PHENOTYPE	23	23	Atherosclerosis
NCT0000515416	NCT00005154_16_T2	GENE	10	10	III
NCT0000515416	NCT00005154_16_T3	PHENOTYPE	13	15	Coronary Heart Disease
NCT0000515417	NCT00005154_17_T0	GENE	4	4	III
NCT0000515421	NCT00005154_21_T0	ORGAN	17	17	heart
NCT0000515421	NCT00005154_21_T1	PHENOTYPE	20	21	blood diseases
NCT0000515423	NCT00005154_23_T0	PHENOTYPE	21	21	ischemia
NCT0000515423	NCT00005154_23_T1	PHENOTYPE	13	15	premature ventricular contractions
NCT0000515428	NCT00005154_28_T0	GENE	8	8	IV
NCT0000515429	NCT00005154_29_T0	GENE	1	1	IV
NCT0000515430	NCT00005154_30_T0	GENE	42	42	IV
NCT0000515431	NCT00005154_31_T0	ORGAN	12	12	heart
NCT0000515431	NCT00005154_31_T1	PHENOTYPE	16	17	blood diseases
NCT0000515432	NCT00005154_32_T0	GENE	10	10	HIS
NCT0000515435	NCT00005154_35_T0	PHENOTYPE	49	49	associations
NCT0000515435	NCT00005154_35_T1	PHENOTYPE	54	54	diseases
NCT0000515435	NCT00005154_35_T2	GENE	4	4	IV
NCT0000515435	NCT00005154_35_T3	ORGAN	11	11	heart
NCT0000515435	NCT00005154_35_T4	ORGAN	42	42	heart
NCT0000515435	NCT00005154_35_T5	ORGAN	72	72	heart
NCT0000515435	NCT00005154_35_T6	ORGAN	82	82	heart
NCT0000515435	NCT00005154_35_T7	PHENOTYPE	139	139	generalized
NCT0000515435	NCT00005154_35_T8	PHENOTYPE	75	76	blood diseases
NCT0000515435	NCT00005154_35_T9	PHENOTYPE	85	86	blood diseases
NCT0000515435	NCT00005154_35_T10	PHENOTYPE	15	16	blood disease
NCT0000515435	NCT00005154_35_T11	PHENOTYPE	46	47	blood disease
NCT0000515436	NCT00005154_36_T0	GENE	17	17	HDL
NCT0000515436	NCT00005154_36_T1	GENE	23	23	IV
NCT0000515436	NCT00005154_36_T2	GENE	34	34	IV
NCT0000515438	NCT00005154_38_T0	GENE	1	1	II
NCT0000515438	NCT00005154_38_T1	GENE	5	5	IV
NCT000051552	NCT00005155_2_T0	PHENOTYPE	16	18	Type A behavior
NCT000051552	NCT00005155_2_T1	PHENOTYPE	10	12	Coronary Heart Disease
NCT000051552	NCT00005155_2_T2	PHENOTYPE	27	29	coronary heart disease
NCT000051553	NCT00005155_3_T0	PHENOTYPE	14	16	coronary heart disease
NCT000051555	NCT00005155_5_T0	PHENOTYPE	12	12	hostility
NCT000051555	NCT00005155_5_T1	PHENOTYPE	21	21	generalized
NCT000051555	NCT00005155_5_T2	PHENOTYPE	20	20	chronic
NCT000051555	NCT00005155_5_T3	PHENOTYPE	23	23	arousal
NCT000051555	NCT00005155_5_T4	PHENOTYPE	4	6	Type A behavior
NCT000051556	NCT00005155_6_T0	PHENOTYPE	9	11	Type A behavior
NCT000051558	NCT00005155_8_T0	PHENOTYPE	22	23	coronary disease
NCT000051559	NCT00005155_9_T0	PHENOTYPE	6	8	Type A behavior
NCT0000515510	NCT00005155_10_T0	PHENOTYPE	11	11	hostility
NCT0000515514	NCT00005155_14_T0	PHENOTYPE	24	24	acute
NCT0000515514	NCT00005155_14_T1	ORGAN	36	36	heart
NCT0000515514	NCT00005155_14_T2	ORGAN	41	41	pupil
NCT0000515514	NCT00005155_14_T3	GENE	9	9	SI
NCT0000515514	NCT00005155_14_T4	CELL	32	32	platelet
NCT0000515514	NCT00005155_14_T5	ORGAN	34	34	plasma
NCT0000515514	NCT00005155_14_T6	PHENOTYPE	22	22	chronic
NCT0000515514	NCT00005155_14_T7	PHENOTYPE	13	15	Type A behavior
NCT0000515514	NCT00005155_14_T8	ORGAN	25	27	sympathetic nervous system
NCT0000515515	NCT00005155_15_T0	ORGAN	3	3	heart
NCT0000515515	NCT00005155_15_T1	ORGAN	5	5	pupil
NCT0000515515	NCT00005155_15_T2	COMPOUND	14	14	catecholamine
NCT0000515515	NCT00005155_15_T3	CELL	13	13	platelet
NCT0000515515	NCT00005155_15_T4	ORGAN	11	11	plasma
NCT0000515515	NCT00005155_15_T5	PHENOTYPE	26	27	chronic disease
NCT0000515516	NCT00005155_16_T0	PHENOTYPE	9	10	chronic disease
NCT0000515516	NCT00005155_16_T1	PHENOTYPE	20	22	Type A behavior
NCT0000515517	NCT00005155_17_T0	PHENOTYPE	10	10	acute
NCT0000515517	NCT00005155_17_T1	ORGAN	22	22	heart
NCT0000515517	NCT00005155_17_T2	ORGAN	20	20	pupil
NCT0000515517	NCT00005155_17_T3	CELL	16	16	platelet
NCT0000515517	NCT00005155_17_T4	ORGAN	18	18	plasma
NCT0000515517	NCT00005155_17_T5	PHENOTYPE	8	8	chronic
NCT000051566	NCT00005156_6_T0	ORGAN	11	11	serum
NCT000051567	NCT00005156_7_T0	PHENOTYPE	11	11	Center
NCT000051567	NCT00005156_7_T1	PHENOTYPE	7	7	transmitted
NCT0000515610	NCT00005156_10_T0	PHENOTYPE	27	27	Diseases
NCT0000515612	NCT00005156_12_T0	PHENOTYPE	8	9	systolic hypertension
NCT0000515612	NCT00005156_12_T1	PHENOTYPE	13	15	coronary heart disease
NCT000051571	NCT00005157_1_T0	PHENOTYPE	11	13	Type A behavior
NCT000051571	NCT00005157_1_T1	PHENOTYPE	18	20	coronary heart disease
NCT000051574	NCT00005157_4_T0	PHENOTYPE	17	19	coronary heart disease
NCT000051575	NCT00005157_5_T0	PHENOTYPE	8	10	Type A behavior
NCT000051575	NCT00005157_5_T1	PHENOTYPE	29	31	Type A behavior
NCT000051579	NCT00005157_9_T0	PHENOTYPE	8	10	Type A behavior
NCT0000515710	NCT00005157_10_T0	PHENOTYPE	2	4	Type A behavior
NCT0000515710	NCT00005157_10_T1	PHENOTYPE	14	16	coronary heart disease
NCT0000515711	NCT00005157_11_T0	PHENOTYPE	6	8	Type A behavior
NCT0000515711	NCT00005157_11_T1	PHENOTYPE	13	15	coronary heart disease
NCT0000515715	NCT00005157_15_T0	PHENOTYPE	2	2	regression
NCT000051580	NCT00005158_0_T0	PHENOTYPE	3	3	Hypertension
NCT000051583	NCT00005158_3_T0	PHENOTYPE	5	5	hypertension
NCT000051583	NCT00005158_3_T1	PHENOTYPE	14	15	autosomal dominant
NCT000051584	NCT00005158_4_T0	PHENOTYPE	4	4	hypertension
NCT000051586	NCT00005158_6_T0	GENE	1	1	has
NCT0000515810	NCT00005158_10_T0	PHENOTYPE	4	4	said
NCT0000515813	NCT00005158_13_T0	PHENOTYPE	24	24	generalization
NCT0000515814	NCT00005158_14_T0	GENE	2	2	has
NCT0000515814	NCT00005158_14_T1	PHENOTYPE	11	12	polygenic inheritance
NCT0000515815	NCT00005158_15_T0	GENE	2	2	has
NCT0000515815	NCT00005158_15_T1	GENE	4	4	extended
NCT0000515816	NCT00005158_16_T0	PHENOTYPE	7	7	hypercholesterolemia
NCT0000515816	NCT00005158_16_T1	GENE	8	8	dopamine-beta-hydroxylase
NCT0000515818	NCT00005158_18_T0	PHENOTYPE	19	20	polygenic inheritance
NCT0000515819	NCT00005158_19_T0	PHENOTYPE	12	13	polygenic inheritance
NCT0000515820	NCT00005158_20_T0	GENE	2	2	has
NCT0000515820	NCT00005158_20_T1	GENE	4	4	extended
NCT0000515824	NCT00005158_24_T0	PHENOTYPE	25	25	hypertension
NCT000051597	NCT00005159_7_T0	GENE	20	20	2.4
NCT0000515916	NCT00005159_16_T0	GENE	5	5	CMS
NCT000051608	NCT00005160_8_T0	GENE	2	2	had
NCT000051609	NCT00005160_9_T0	COMPOUND	6	6	glucose
NCT000051609	NCT00005160_9_T1	GENE	8	8	insulin
NCT000051609	NCT00005160_9_T2	PHENOTYPE	9	9	obesity
NCT0000516012	NCT00005160_12_T0	PHENOTYPE	32	32	plaque
NCT0000516013	NCT00005160_13_T0	PHENOTYPE	22	22	atherosclerosis
NCT0000516013	NCT00005160_13_T1	GENE	15	15	insulin
NCT0000516014	NCT00005160_14_T0	ORGAN	23	23	abdomen
NCT0000516014	NCT00005160_14_T1	TISSUE	14	15	body fat
NCT0000516015	NCT00005160_15_T0	GENE	2	2	has
NCT000051613	NCT00005161_3_T0	GENE	19	19	twins
NCT000051615	NCT00005161_5_T0	GENE	5	5	twins
NCT000051616	NCT00005161_6_T0	GENE	11	11	twins
NCT000051618	NCT00005161_8_T0	GENE	4	4	twins
NCT0000516113	NCT00005161_13_T0	PHENOTYPE	11	12	blood group
NCT000051623	NCT00005162_3_T0	GENE	2	2	has
NCT000051624	NCT00005162_4_T0	GENE	2	2	has
NCT000051625	NCT00005162_5_T0	PHENOTYPE	3	5	coronary heart disease
NCT000051626	NCT00005162_6_T0	PHENOTYPE	7	9	coronary heart disease
NCT000051628	NCT00005162_8_T0	PHENOTYPE	21	21	symptoms
NCT000051628	NCT00005162_8_T1	PHENOTYPE	8	9	sudden death
NCT0000516210	NCT00005162_10_T0	PHENOTYPE	23	23	practices
NCT0000516210	NCT00005162_10_T1	PHENOTYPE	10	12	coronary heart disease
NCT0000516214	NCT00005162_14_T0	PHENOTYPE	21	21	diseases
NCT0000516214	NCT00005162_14_T1	PHENOTYPE	12	13	sudden death
NCT0000516214	NCT00005162_14_T2	PHENOTYPE	18	19	heart disease
NCT000051633	NCT00005163_3_T0	PHENOTYPE	1	1	HRA
NCT000051637	NCT00005163_7_T0	GENE	29	29	had
NCT000051638	NCT00005163_8_T0	ORGAN	27	27	Heart
NCT000051638	NCT00005163_8_T1	PHENOTYPE	42	43	physiological values
NCT000051645	NCT00005164_5_T0	PHENOTYPE	14	14	Hypertension
NCT0000516411	NCT00005164_11_T0	PHENOTYPE	5	6	insulin resistance
NCT0000516414	NCT00005164_14_T0	PHENOTYPE	0	0	Peripheral
NCT0000516414	NCT00005164_14_T1	ORGAN	8	8	forearm
NCT0000516414	NCT00005164_14_T2	ORGAN	12	12	forearm
NCT0000516414	NCT00005164_14_T3	PHENOTYPE	13	14	vascular resistance
NCT0000516415	NCT00005164_15_T0	PHENOTYPE	2	2	peripheral
NCT0000516415	NCT00005164_15_T1	COMPOUND	10	10	sodium
NCT0000516415	NCT00005164_15_T2	COMPOUND	13	13	potassium
NCT000051651	NCT00005165_1_T0	PHENOTYPE	30	31	cardiovascular disease
NCT000051653	NCT00005165_3_T0	GENE	1	1	has
NCT000051653	NCT00005165_3_T1	GENE	31	31	has
NCT000051653	NCT00005165_3_T2	PHENOTYPE	28	28	hypertension
NCT000051653	NCT00005165_3_T3	PHENOTYPE	7	9	coronary heart disease
NCT000051654	NCT00005165_4_T0	PHENOTYPE	11	13	coronary heart disease
NCT000051657	NCT00005165_7_T0	ORGAN	2	2	Heart
NCT0000516511	NCT00005165_11_T0	ORGAN	16	16	Heart
NCT0000516512	NCT00005165_12_T0	ORGAN	14	14	Heart
NCT0000516515	NCT00005165_15_T0	GENE	5	6	type A
NCT0000516516	NCT00005165_16_T0	PHENOTYPE	2	4	coronary heart disease
NCT0000516518	NCT00005165_18_T0	ORGAN	9	9	heart
NCT0000516519	NCT00005165_19_T0	COMPOUND	1	1	glucose
NCT0000516522	NCT00005165_22_T0	PHENOTYPE	9	9	obesity
NCT000051662	NCT00005166_2_T0	ORGAN	28	28	Heart
NCT000051662	NCT00005166_2_T1	PHENOTYPE	17	18	essential hypertension
NCT000051664	NCT00005166_4_T0	PHENOTYPE	10	10	hypertension
NCT000051664	NCT00005166_4_T1	PHENOTYPE	15	16	cardiovascular morbidity
NCT000051665	NCT00005166_5_T0	PHENOTYPE	12	12	said
NCT000051665	NCT00005166_5_T1	PHENOTYPE	15	16	essential hypertension
NCT000051667	NCT00005166_7_T0	GENE	9	9	had
NCT000051667	NCT00005166_7_T1	PHENOTYPE	18	19	essential hypertension
NCT000051669	NCT00005166_9_T0	COMPOUND	11	11	sodium
NCT000051669	NCT00005166_9_T1	COMPOUND	38	38	sodium
NCT000051669	NCT00005166_9_T2	BIOLOGICAL_PROCESS	9	9	metabolism
NCT000051669	NCT00005166_9_T3	PHENOTYPE	53	54	essential hypertension
NCT000051669	NCT00005166_9_T4	BIOLOGICAL_PROCESS	43	44	sodium transport
NCT000051669	NCT00005166_9_T5	CELL	47	49	red blood cells
NCT000051669	NCT00005166_9_T6	PHENOTYPE	27	29	elevated blood pressure
NCT0000516610	NCT00005166_10_T0	BIOLOGICAL_PROCESS	9	10	sodium transport
NCT0000516610	NCT00005166_10_T1	CELL	16	18	red blood cells
NCT0000516610	NCT00005166_10_T2	TISSUE	32	34	vascular smooth muscle
NCT0000516610	NCT00005166_10_T3	PHENOTYPE	22	24	elevated blood pressure
NCT0000516612	NCT00005166_12_T0	COMPOUND	9	9	sodium_lithium
NCT0000516612	NCT00005166_12_T1	PHENOTYPE	20	21	essential hypertension
NCT0000516612	NCT00005166_12_T2	CELL	14	16	red blood cells
NCT0000516613	NCT00005166_13_T0	PHENOTYPE	6	6	secondary
NCT0000516613	NCT00005166_13_T1	COMPOUND	1	1	sodium_lithium
NCT0000516613	NCT00005166_13_T2	PHENOTYPE	9	9	hypertension
NCT0000516613	NCT00005166_13_T3	PHENOTYPE	14	15	essential hypertension
NCT0000516614	NCT00005166_14_T0	PHENOTYPE	13	14	essential hypertension
NCT0000516615	NCT00005166_15_T0	PHENOTYPE	34	35	primary hypertension
NCT0000516615	NCT00005166_15_T1	BIOLOGICAL_PROCESS	19	20	sodium transport
NCT0000516615	NCT00005166_15_T2	CELL	23	25	red blood cells
NCT0000516621	NCT00005166_21_T0	COMPOUND	19	19	sodium_lithium
NCT0000516622	NCT00005166_22_T0	COMPOUND	4	4	sodium_lithium
NCT0000516622	NCT00005166_22_T1	PHENOTYPE	11	12	primary hypertension
NCT0000516624	NCT00005166_24_T0	ORGAN	34	34	Heart
NCT0000516624	NCT00005166_24_T1	PHENOTYPE	23	24	essential hypertension
NCT0000516626	NCT00005166_26_T0	PHENOTYPE	11	12	essential hypertension
NCT000051673	NCT00005167_3_T0	COMPOUND	16	16	calcium
NCT000051673	NCT00005167_3_T1	PHENOTYPE	25	26	cholesterol levels
NCT000051674	NCT00005167_4_T0	COMPOUND	10	10	calcium
NCT000051675	NCT00005167_5_T0	COMPOUND	10	10	calcium
NCT000051676	NCT00005167_6_T0	COMPOUND	18	18	sodium
NCT000051676	NCT00005167_6_T1	COMPOUND	20	21	linoleic acid
NCT000051677	NCT00005167_7_T0	COMPOUND	16	16	sodium
NCT000051677	NCT00005167_7_T1	COMPOUND	20	20	sodium
NCT000051677	NCT00005167_7_T2	GENE	32	32	reduced
NCT0000516710	NCT00005167_10_T0	COMPOUND	6	6	sodium
NCT0000516713	NCT00005167_13_T0	COMPOUND	15	15	calcium
NCT0000516715	NCT00005167_15_T0	COMPOUND	4	4	calcium
NCT0000516716	NCT00005167_16_T0	PHENOTYPE	26	28	increased bone density
NCT0000516716	NCT00005167_16_T1	PHENOTYPE	22	24	lower blood cholesterol
NCT000051682	NCT00005168_2_T0	GENE	1	1	has
NCT000051682	NCT00005168_2_T1	PHENOTYPE	11	13	coronary artery disease
NCT000051683	NCT00005168_3_T0	ORGAN	26	26	plasma
NCT000051683	NCT00005168_3_T1	PHENOTYPE	23	23	hypertension
NCT000051683	NCT00005168_3_T2	PHENOTYPE	16	18	coronary artery disease
NCT000051684	NCT00005168_4_T0	PHENOTYPE	6	6	pathophysiology
NCT000051684	NCT00005168_4_T1	PHENOTYPE	8	10	coronary artery disease
NCT000051687	NCT00005168_7_T0	PHENOTYPE	20	20	xanthomata
NCT000051687	NCT00005168_7_T1	GENE	15	15	insulin
NCT000051687	NCT00005168_7_T2	PHENOTYPE	22	22	xanthelasma
NCT000051687	NCT00005168_7_T3	PHENOTYPE	18	19	corneal arcus
NCT000051688	NCT00005168_8_T0	PHENOTYPE	18	19	coronary disease
NCT000051688	NCT00005168_8_T1	PHENOTYPE	31	32	coronary disease
NCT000051688	NCT00005168_8_T2	GENE	4	5	apolipoprotein B
NCT000051689	NCT00005168_9_T0	GENE	3	4	apolipoprotein B
NCT0000516810	NCT00005168_10_T0	PHENOTYPE	26	26	hyperalphalipoproteinemia
NCT0000516810	NCT00005168_10_T1	GENE	14	15	apolipoprotein B
NCT000051691	NCT00005169_1_T0	PHENOTYPE	21	22	cardiovascular morbidity
NCT000051693	NCT00005169_3_T0	PHENOTYPE	23	25	coronary heart disease
NCT000051694	NCT00005169_4_T0	PHENOTYPE	21	21	enthusiasm
NCT000051694	NCT00005169_4_T1	PHENOTYPE	9	9	intensities
NCT000051696	NCT00005169_6_T0	ORGAN	11	11	Heart
NCT000051696	NCT00005169_6_T1	GENE	16	16	has
NCT0000516919	NCT00005169_19_T0	GENE	4	4	CHD
NCT0000516920	NCT00005169_20_T0	GENE	1	1	CHD
NCT0000516921	NCT00005169_21_T0	PHENOTYPE	53	53	CVD
NCT0000516921	NCT00005169_21_T1	PHENOTYPE	25	26	energy expenditure
NCT0000516922	NCT00005169_22_T0	PHENOTYPE	8	8	CVD
NCT000051702	NCT00005170_2_T0	COMPOUND	10	10	sodium
NCT000051702	NCT00005170_2_T1	PHENOTYPE	13	14	weight gain
NCT000051703	NCT00005170_3_T0	GENE	2	2	probable
NCT000051703	NCT00005170_3_T1	PHENOTYPE	11	11	hypertension
NCT000051706	NCT00005170_6_T0	ORGAN	5	7	sympathetic nervous system
NCT0000517010	NCT00005170_10_T0	GENE	18	18	has
NCT0000517010	NCT00005170_10_T1	PHENOTYPE	9	9	hypertension
NCT0000517012	NCT00005170_12_T0	PHENOTYPE	6	6	hypertension
NCT0000517013	NCT00005170_13_T0	PHENOTYPE	4	4	strategies
NCT0000517014	NCT00005170_14_T0	PHENOTYPE	2	4	white coat hypertension
NCT0000517016	NCT00005170_16_T0	PHENOTYPE	18	19	adverse effect
NCT0000517016	NCT00005170_16_T1	PHENOTYPE	4	5	job strain
NCT0000517017	NCT00005170_17_T0	PHENOTYPE	21	21	hypertension
NCT0000517017	NCT00005170_17_T1	PHENOTYPE	1	2	job strain
NCT0000517020	NCT00005170_20_T0	PHENOTYPE	6	8	white coat hypertension
NCT0000517021	NCT00005170_21_T0	PHENOTYPE	17	17	hypertension
NCT0000517022	NCT00005170_22_T0	PHENOTYPE	4	5	Job Strain
NCT0000517023	NCT00005170_23_T0	PHENOTYPE	0	0	Generalization
NCT0000517025	NCT00005170_25_T0	GENE	45	45	ventricular
NCT0000517025	NCT00005170_25_T1	GENE	42	42	ABP
NCT0000517025	NCT00005170_25_T2	PHENOTYPE	23	24	job strain
NCT0000517025	NCT00005170_25_T3	PHENOTYPE	33	35	hypertensive cardiovascular disease
NCT0000517026	NCT00005170_26_T0	PHENOTYPE	22	23	job strain
NCT0000517027	NCT00005170_27_T0	PHENOTYPE	10	10	hypertension
NCT0000517029	NCT00005170_29_T0	PHENOTYPE	16	16	progressive
NCT0000517029	NCT00005170_29_T1	GENE	19	19	ABP
NCT0000517029	NCT00005170_29_T2	PHENOTYPE	13	14	job strain
NCT0000517031	NCT00005170_31_T0	PHENOTYPE	20	20	atherosclerosis
NCT0000517031	NCT00005170_31_T1	GENE	17	17	structural
NCT0000517031	NCT00005170_31_T2	ORGAN	12	13	carotid artery
NCT0000517032	NCT00005170_32_T0	GENE	7	7	ABP
NCT0000517033	NCT00005170_33_T0	GENE	8	8	had
NCT0000517033	NCT00005170_33_T1	PHENOTYPE	14	15	cardiovascular morbidity
NCT0000517033	NCT00005170_33_T2	PHENOTYPE	22	23	job strain
NCT0000517034	NCT00005170_34_T0	PHENOTYPE	7	7	perceived
NCT0000517034	NCT00005170_34_T1	PHENOTYPE	11	12	job strain
NCT0000517035	NCT00005170_35_T0	COMPOUND	9	9	cortisol
NCT0000517035	NCT00005170_35_T1	PHENOTYPE	3	4	job strain
NCT0000517035	NCT00005170_35_T2	PHENOTYPE	21	22	job strain
NCT0000517035	NCT00005170_35_T3	ORGAN	31	33	sympathetic nervous system
NCT0000517036	NCT00005170_36_T0	PHENOTYPE	15	15	atherosclerosis
NCT0000517037	NCT00005170_37_T0	GENE	25	25	ABP
NCT0000517037	NCT00005170_37_T1	PHENOTYPE	32	33	cardiovascular disease
NCT0000517037	NCT00005170_37_T2	PHENOTYPE	38	39	carotid atherosclerosis
NCT0000517037	NCT00005170_37_T3	PHENOTYPE	13	14	job strain
NCT0000517037	NCT00005170_37_T4	PHENOTYPE	34	36	left ventricular hypertrophy
NCT000051712	NCT00005171_2_T0	GENE	9	9	contrasted
NCT000051714	NCT00005171_4_T0	PHENOTYPE	13	13	focused
NCT000051714	NCT00005171_4_T1	PHENOTYPE	9	11	coronary heart disease
NCT000051715	NCT00005171_5_T0	ORGAN	25	25	serum
NCT000051715	NCT00005171_5_T1	PHENOTYPE	35	37	coronary heart disease
NCT000051718	NCT00005171_8_T0	GENE	14	14	had
NCT0000517110	NCT00005171_10_T0	ORGAN	6	6	serum
NCT0000517111	NCT00005171_11_T0	ORGAN	4	4	serum
NCT0000517111	NCT00005171_11_T1	PHENOTYPE	9	9	obesity
NCT0000517112	NCT00005171_12_T0	GENE	22	22	II
NCT0000517112	NCT00005171_12_T1	GENE	11	11	III
NCT0000517113	NCT00005171_13_T0	GENE	8	8	contrasted
NCT0000517115	NCT00005171_15_T0	GENE	12	12	contrasted
NCT0000517116	NCT00005171_16_T0	PHENOTYPE	17	17	strategies
NCT0000517116	NCT00005171_16_T1	PHENOTYPE	34	34	strategies
NCT000051722	NCT00005172_2_T0	GENE	36	36	relaxed
NCT000051722	NCT00005172_2_T1	PHENOTYPE	44	44	suppression
NCT000051724	NCT00005172_4_T0	PHENOTYPE	27	29	high blood pressure
NCT000051729	NCT00005172_9_T0	COMPOUND	30	30	sodium
NCT000051729	NCT00005172_9_T1	COMPOUND	31	31	potassium
NCT000051729	NCT00005172_9_T2	COMPOUND	32	32	calcium
NCT0000517210	NCT00005172_10_T0	PHENOTYPE	14	14	regression
NCT0000517214	NCT00005172_14_T0	COMPOUND	17	17	sodium
NCT0000517214	NCT00005172_14_T1	COMPOUND	20	20	calcium
NCT0000517214	NCT00005172_14_T2	COMPOUND	18	18	potassium
NCT0000517214	NCT00005172_14_T3	COMPOUND	29	29	BMI
NCT0000517215	NCT00005172_15_T0	PHENOTYPE	15	16	weight gain
NCT0000517215	NCT00005172_15_T1	TISSUE	22	23	body fat
NCT0000517216	NCT00005172_16_T0	PHENOTYPE	2	2	regression
NCT0000517217	NCT00005172_17_T0	PHENOTYPE	19	19	associations
NCT0000517217	NCT00005172_17_T1	PHENOTYPE	21	21	obesity
NCT0000517217	NCT00005172_17_T2	PHENOTYPE	15	16	insulin resistance
NCT000051732	NCT00005173_2_T0	PHENOTYPE	23	24	myocardial infarction
NCT000051738	NCT00005173_8_T0	PHENOTYPE	28	29	myocardial infarction
NCT000051738	NCT00005173_8_T1	PHENOTYPE	25	26	drug use
NCT000051742	NCT00005174_2_T0	PHENOTYPE	10	11	heart disease
NCT000051745	NCT00005174_5_T0	GENE	31	31	lipoprotein
NCT000051745	NCT00005174_5_T1	PHENOTYPE	25	26	corneal arcus
NCT000051746	NCT00005174_6_T0	COMPOUND	11	11	caffeine
NCT000051747	NCT00005174_7_T0	GENE	4	4	8.5
NCT000051748	NCT00005174_8_T0	GENE	2	2	8.5
NCT000051748	NCT00005174_8_T1	PHENOTYPE	5	7	coronary heart disease
NCT000051748	NCT00005174_8_T2	PHENOTYPE	21	23	coronary heart disease
NCT000051749	NCT00005174_9_T0	PHENOTYPE	3	4	coronary disease
NCT0000517410	NCT00005174_10_T0	ORGAN	9	9	serum
NCT0000517411	NCT00005174_11_T0	GENE	27	27	2.1
NCT0000517411	NCT00005174_11_T1	PHENOTYPE	5	7	Type A behavior
NCT0000517411	NCT00005174_11_T2	PHENOTYPE	21	23	coronary heart disease
NCT0000517412	NCT00005174_12_T0	PHENOTYPE	7	7	David
NCT0000517412	NCT00005174_12_T1	GENE	2	2	Dr
NCT0000517412	NCT00005174_12_T2	GENE	6	6	Dr
NCT0000517413	NCT00005174_13_T0	GENE	36	36	had
NCT0000517417	NCT00005174_17_T0	PHENOTYPE	8	9	cardiovascular disease
NCT0000517417	NCT00005174_17_T1	PHENOTYPE	18	20	coronary heart disease
NCT0000517418	NCT00005174_18_T0	BIOLOGICAL_PROCESS	40	40	aging
NCT0000517418	NCT00005174_18_T1	PHENOTYPE	8	9	cardiovascular disease
NCT0000517419	NCT00005174_19_T0	GENE	3	3	extended
NCT0000517419	NCT00005174_19_T1	PHENOTYPE	14	15	cardiovascular disease
NCT0000517420	NCT00005174_20_T0	PHENOTYPE	16	18	Type A behavior
NCT0000517421	NCT00005174_21_T0	PHENOTYPE	18	19	cardiovascular pathology
NCT000051753	NCT00005175_3_T0	PHENOTYPE	18	20	coronary heart disease
NCT000051755	NCT00005175_5_T0	GENE	2	2	has
NCT000051755	NCT00005175_5_T1	PHENOTYPE	22	24	coronary heart disease
NCT000051756	NCT00005175_6_T0	GENE	11	11	has
NCT000051757	NCT00005175_7_T0	GENE	7	7	has
NCT000051757	NCT00005175_7_T1	PHENOTYPE	6	6	hypertension
NCT000051757	NCT00005175_7_T2	PHENOTYPE	12	13	rare disease
NCT000051758	NCT00005175_8_T0	PHENOTYPE	11	11	hypertension
NCT000051758	NCT00005175_8_T1	PHENOTYPE	16	17	cardiovascular disease
NCT0000517512	NCT00005175_12_T0	BIOLOGICAL_PROCESS	29	29	drinking
NCT0000517512	NCT00005175_12_T1	PHENOTYPE	25	25	practices
NCT0000517512	NCT00005175_12_T2	ORGAN	7	7	heart
NCT0000517513	NCT00005175_13_T0	GENE	6	6	had
NCT0000517514	NCT00005175_14_T0	COMPOUND	10	10	sodium
NCT0000517514	NCT00005175_14_T1	COMPOUND	12	12	potassium
NCT0000517517	NCT00005175_17_T0	COMPOUND	27	27	sodium
NCT0000517517	NCT00005175_17_T1	COMPOUND	29	29	potassium
NCT0000517520	NCT00005175_20_T0	PHENOTYPE	1	1	regression
NCT000051764	NCT00005176_4_T0	PHENOTYPE	8	10	autosomal recessive inheritance
NCT000051766	NCT00005176_6_T0	PHENOTYPE	31	31	arrhythmias
NCT000051767	NCT00005176_7_T0	PHENOTYPE	21	22	congenital deafness
NCT000051767	NCT00005176_7_T1	PHENOTYPE	17	19	Long QT Syndrome
NCT000051767	NCT00005176_7_T2	PHENOTYPE	41	44	Jervell and Lange-Nielsen Syndrome
NCT000051768	NCT00005176_8_T0	PHENOTYPE	22	23	Romano-Ward Syndrome
NCT000051768	NCT00005176_8_T1	PHENOTYPE	3	5	Long QT Syndrome
NCT0000517610	NCT00005176_10_T0	GENE	10	10	had
NCT0000517610	NCT00005176_10_T1	GENE	27	27	had
NCT0000517610	NCT00005176_10_T2	PHENOTYPE	33	34	autonomic dysfunction
NCT0000517612	NCT00005176_12_T0	GENE	2	2	had
NCT0000517613	NCT00005176_13_T0	GENE	35	35	Harvey-ras
NCT0000517613	NCT00005176_13_T1	PHENOTYPE	3	4	genetic heterogeneity
NCT0000517614	NCT00005176_14_T0	PHENOTYPE	22	23	malignant disease
NCT0000517615	NCT00005176_15_T0	ORGAN	31	31	heart
NCT0000517617	NCT00005176_17_T0	GENE	21	21	Harvey-ras
NCT0000517617	NCT00005176_17_T1	GENE	34	34	Harvey-ras
NCT0000517617	NCT00005176_17_T2	BIOLOGICAL_PROCESS	15	16	ventricular repolarization
NCT0000517618	NCT00005176_18_T0	PHENOTYPE	36	36	severity
NCT0000517618	NCT00005176_18_T1	PHENOTYPE	55	55	syncope
NCT0000517618	NCT00005176_18_T2	PHENOTYPE	57	58	sudden death
NCT0000517619	NCT00005176_19_T0	PHENOTYPE	72	72	associations
NCT0000517619	NCT00005176_19_T1	GENE	2	2	has
NCT0000517619	NCT00005176_19_T2	PHENOTYPE	68	69	cardiac events
NCT0000517620	NCT00005176_20_T0	PHENOTYPE	9	9	centers
NCT000051770	NCT00005177_0_T0	ORGAN	2	2	Heart
NCT000051773	NCT00005177_3_T0	PHENOTYPE	14	15	weight loss
NCT000051774	NCT00005177_4_T0	PHENOTYPE	9	9	severity
NCT000051774	NCT00005177_4_T1	PHENOTYPE	19	19	overweight
NCT000051774	NCT00005177_4_T2	PHENOTYPE	6	6	obesity
NCT000051774	NCT00005177_4_T3	PHENOTYPE	24	24	obesity
NCT0000517713	NCT00005177_13_T0	ORGAN	15	15	Heart
NCT000051787	NCT00005178_7_T0	GENE	4	4	has
NCT000051787	NCT00005178_7_T1	PHENOTYPE	9	11	coronary heart disease
NCT000051788	NCT00005178_8_T0	GENE	11	11	reduced
NCT000051788	NCT00005178_8_T1	GENE	2	2	has
NCT000051788	NCT00005178_8_T2	PHENOTYPE	14	15	myocardial infarctions
NCT000051789	NCT00005178_9_T0	PHENOTYPE	23	23	hypertriglyceridemia
NCT000051789	NCT00005178_9_T1	GENE	29	29	HDL
NCT000051789	NCT00005178_9_T2	GENE	3	3	has
NCT000051789	NCT00005178_9_T3	PHENOTYPE	22	22	hypertension
NCT000051789	NCT00005178_9_T4	PHENOTYPE	14	14	obesity
NCT000051789	NCT00005178_9_T5	PHENOTYPE	25	26	glucose intolerance
NCT000051789	NCT00005178_9_T6	PHENOTYPE	30	31	cholesterol levels
NCT0000517811	NCT00005178_11_T0	PHENOTYPE	10	12	coronary heart disease
NCT0000517812	NCT00005178_12_T0	GENE	8	9	type A
NCT0000517819	NCT00005178_19_T0	ORGAN	33	33	heart
NCT0000517819	NCT00005178_19_T1	PHENOTYPE	43	45	coronary heart disease
NCT0000517821	NCT00005178_21_T0	ORGAN	12	12	serum
NCT0000517822	NCT00005178_22_T0	PHENOTYPE	11	11	attitudes
NCT0000517823	NCT00005178_23_T0	PHENOTYPE	28	30	coronary heart disease
NCT0000517826	NCT00005178_26_T0	BIOLOGICAL_PROCESS	0	0	Eating
NCT0000517828	NCT00005178_28_T0	ORGAN	17	17	Heart
NCT0000517832	NCT00005178_32_T0	GENE	7	7	FY
NCT0000517832	NCT00005178_32_T1	GENE	12	12	FY
NCT0000517833	NCT00005178_33_T0	GENE	11	11	III
NCT000051792	NCT00005179_2_T0	PHENOTYPE	11	12	cardiovascular disease
NCT000051795	NCT00005179_5_T0	PHENOTYPE	3	3	pulse
NCT000051795	NCT00005179_5_T1	ORGAN	7	7	plasma
NCT000051795	NCT00005179_5_T2	PHENOTYPE	11	13	Type A behavior
NCT0000517910	NCT00005179_10_T0	GENE	18	18	3.4
NCT000051800	NCT00005180_0_T0	PHENOTYPE	4	5	Essential Hypertension
NCT000051803	NCT00005180_3_T0	PHENOTYPE	5	5	pathology
NCT000051803	NCT00005180_3_T1	PHENOTYPE	25	25	retinopathy
NCT000051803	NCT00005180_3_T2	PHENOTYPE	8	8	hypertension
NCT000051803	NCT00005180_3_T3	PHENOTYPE	22	23	renal failure
NCT000051803	NCT00005180_3_T4	PHENOTYPE	18	20	peripheral artery disease
NCT000051803	NCT00005180_3_T5	PHENOTYPE	13	15	ischemic heart disease
NCT000051803	NCT00005180_3_T6	PHENOTYPE	10	12	congestive heart failure
NCT000051804	NCT00005180_4_T0	PHENOTYPE	18	18	complications
NCT000051804	NCT00005180_4_T1	GENE	3	3	has
NCT000051804	NCT00005180_4_T2	GENE	9	9	has
NCT000051804	NCT00005180_4_T3	PHENOTYPE	14	15	essential hypertension
NCT000051805	NCT00005180_5_T0	PHENOTYPE	30	30	complications
NCT000051805	NCT00005180_5_T1	PHENOTYPE	8	10	elevated blood pressure
NCT0000518011	NCT00005180_11_T0	GENE	8	8	had
NCT0000518012	NCT00005180_12_T0	COMPOUND	19	19	fluorescein
NCT0000518012	NCT00005180_12_T1	GENE	9	9	ventricular
NCT0000518012	NCT00005180_12_T2	PHENOTYPE	25	26	retinal vascular
NCT0000518012	NCT00005180_12_T3	PHENOTYPE	26	27	vascular abnormalities
NCT0000518013	NCT00005180_13_T0	GENE	40	40	hemoglobin
NCT0000518013	NCT00005180_13_T1	COMPOUND	32	32	sodium
NCT0000518013	NCT00005180_13_T2	ORGAN	42	42	plasma
NCT0000518013	NCT00005180_13_T3	ORGAN	45	45	plasma
NCT0000518013	NCT00005180_13_T4	PHENOTYPE	27	27	hypertension
NCT0000518013	NCT00005180_13_T5	PHENOTYPE	11	11	obesity
NCT0000518013	NCT00005180_13_T6	MOLECULAR_FUNCTION	43	44	renin activity
NCT0000518013	NCT00005180_13_T7	PHENOTYPE	50	51	mental stress
NCT0000518013	NCT00005180_13_T8	PHENOTYPE	37	39	fasting blood glucose
NCT0000518013	NCT00005180_13_T9	PHENOTYPE	16	18	increased blood pressure
NCT0000518014	NCT00005180_14_T0	COMPOUND	19	19	creatinine
NCT0000518014	NCT00005180_14_T1	PHENOTYPE	1	1	regression
NCT0000518014	NCT00005180_14_T2	GENE	17	17	ventricular
NCT0000518014	NCT00005180_14_T3	PHENOTYPE	22	23	retinal vascular
NCT0000518014	NCT00005180_14_T4	PHENOTYPE	23	24	vascular abnormality
NCT000051815	NCT00005181_5_T0	GENE	9	9	had
NCT000051815	NCT00005181_5_T1	GENE	20	20	had
NCT000051815	NCT00005181_5_T2	PHENOTYPE	19	19	hypertension
NCT000051817	NCT00005181_7_T0	PHENOTYPE	20	20	Hypertension
NCT000051818	NCT00005181_8_T0	COMPOUND	6	6	norepinephrine
NCT000051818	NCT00005181_8_T1	COMPOUND	4	4	aldosterone
NCT0000518112	NCT00005181_12_T0	PHENOTYPE	3	3	hypertension
NCT0000518114	NCT00005181_14_T0	PHENOTYPE	8	8	maturation
NCT0000518114	NCT00005181_14_T1	PHENOTYPE	13	16	increase in blood pressure
NCT0000518118	NCT00005181_18_T0	COMPOUND	10	10	potassium
NCT0000518118	NCT00005181_18_T1	COMPOUND	13	13	aldosterone
NCT0000518120	NCT00005181_20_T0	GENE	17	17	6-16
NCT0000518123	NCT00005181_23_T0	COMPOUND	19	19	potassium
NCT0000518123	NCT00005181_23_T1	COMPOUND	25	25	aldosterone
NCT0000518124	NCT00005181_24_T0	PHENOTYPE	10	10	hypertension
NCT0000518126	NCT00005181_26_T0	PHENOTYPE	21	21	secondary
NCT0000518126	NCT00005181_26_T1	COMPOUND	5	5	potassium
NCT0000518126	NCT00005181_26_T2	COMPOUND	27	27	potassium
NCT0000518126	NCT00005181_26_T3	COMPOUND	28	28	potassium
NCT0000518126	NCT00005181_26_T4	COMPOUND	18	18	aldosterone
NCT0000518126	NCT00005181_26_T5	COMPOUND	34	34	aldosterone
NCT0000518126	NCT00005181_26_T6	GENE	3	3	had
NCT0000518127	NCT00005181_27_T0	COMPOUND	12	12	potassium
NCT0000518127	NCT00005181_27_T1	COMPOUND	27	27	potassium
NCT0000518127	NCT00005181_27_T2	GENE	24	24	reduced
NCT0000518128	NCT00005181_28_T0	PHENOTYPE	22	24	mode of inheritance
NCT0000518132	NCT00005181_32_T0	ORGAN	22	22	kidney
NCT0000518132	NCT00005181_32_T1	COMPOUND	19	19	sodium
NCT0000518132	NCT00005181_32_T2	COMPOUND	30	30	sodium
NCT0000518132	NCT00005181_32_T3	GENE	5	5	FY
NCT0000518132	NCT00005181_32_T4	PHENOTYPE	12	12	hypertension
NCT0000518133	NCT00005181_33_T0	ORGAN	4	4	nephron
NCT000051822	NCT00005182_2_T0	GENE	25	25	had
NCT000051822	NCT00005182_2_T1	PHENOTYPE	15	16	heart disease
NCT000051825	NCT00005182_5_T0	PHENOTYPE	15	17	coronary heart disease
NCT000051826	NCT00005182_6_T0	PHENOTYPE	10	10	understood
NCT000051828	NCT00005182_8_T0	COMPOUND	27	27	chromium
NCT000051828	NCT00005182_8_T1	COMPOUND	24	24	calcium
NCT000051828	NCT00005182_8_T2	GENE	11	11	nested
NCT000051828	NCT00005182_8_T3	COMPOUND	25	25	selenium
NCT000051828	NCT00005182_8_T4	PHENOTYPE	15	17	coronary heart disease
NCT0000518210	NCT00005182_10_T0	PHENOTYPE	16	16	pathology
NCT0000518210	NCT00005182_10_T1	PHENOTYPE	5	6	myocardial infarction
NCT0000518216	NCT00005182_16_T0	GENE	13	13	6.0
NCT0000518216	NCT00005182_16_T1	PHENOTYPE	5	6	cardiovascular disease
NCT000051831	NCT00005183_1_T0	GENE	33	33	Apo
NCT000051831	NCT00005183_1_T1	GENE	12	12	HDL
NCT000051831	NCT00005183_1_T2	PHENOTYPE	18	19	coronary disease
NCT000051831	NCT00005183_1_T3	PHENOTYPE	28	29	coronary disease
NCT000051833	NCT00005183_3_T0	GENE	0	0	HDL
NCT000051833	NCT00005183_3_T1	CELL	9	9	cells
NCT000051833	NCT00005183_3_T2	GENE	1	1	has
NCT000051833	NCT00005183_3_T3	BIOLOGICAL_PROCESS	6	7	cholesterol efflux
NCT000051834	NCT00005183_4_T0	PHENOTYPE	19	19	atherosclerosis
NCT000051834	NCT00005183_4_T1	GENE	7	7	Apo
NCT000051834	NCT00005183_4_T2	PHENOTYPE	2	2	concentrations
NCT000051834	NCT00005183_4_T3	GENE	4	4	HDL
NCT000051834	NCT00005183_4_T4	ORGAN	1	1	plasma
NCT000051834	NCT00005183_4_T5	PHENOTYPE	13	16	premature coronary artery disease
NCT000051835	NCT00005183_5_T0	GENE	2	2	HDL
NCT000051835	NCT00005183_5_T1	PHENOTYPE	14	17	premature coronary artery disease
NCT000051836	NCT00005183_6_T0	GENE	3	3	Apo
NCT000051836	NCT00005183_6_T1	GENE	5	5	has
NCT000051837	NCT00005183_7_T0	GENE	6	6	Apo
NCT000051837	NCT00005183_7_T1	GENE	45	45	HDL
NCT000051837	NCT00005183_7_T2	BIOLOGICAL_PROCESS	16	16	digestion
NCT000051837	NCT00005183_7_T3	PHENOTYPE	28	31	premature coronary artery disease
NCT000051838	NCT00005183_8_T0	GENE	1	1	Apo
NCT000051838	NCT00005183_8_T1	GENE	12	12	Apo
NCT000051838	NCT00005183_8_T2	GENE	14	14	Apo
NCT000051838	NCT00005183_8_T3	GENE	27	27	Apo
NCT000051838	NCT00005183_8_T4	COMPOUND	20	20	3
NCT000051839	NCT00005183_9_T0	PHENOTYPE	27	27	atherosclerosis
NCT000051839	NCT00005183_9_T1	PHENOTYPE	21	21	insights
NCT000051839	NCT00005183_9_T2	PHENOTYPE	14	15	coronary disease
NCT0000518311	NCT00005183_11_T0	GENE	6	6	lipoprotein
NCT0000518314	NCT00005183_14_T0	GENE	10	10	Apo
NCT0000518314	NCT00005183_14_T1	GENE	21	21	Apo
NCT0000518314	NCT00005183_14_T2	GENE	24	24	HDL
NCT0000518314	NCT00005183_14_T3	ORGAN	20	20	plasma
NCT0000518315	NCT00005183_15_T0	GENE	10	10	Apo
NCT0000518315	NCT00005183_15_T1	GENE	25	25	Apo
NCT0000518315	NCT00005183_15_T2	GENE	28	28	HDL
NCT0000518315	NCT00005183_15_T3	ORGAN	24	24	plasma
NCT0000518315	NCT00005183_15_T4	PHENOTYPE	17	18	coronary disease
NCT0000518316	NCT00005183_16_T0	GENE	9	9	Apo
NCT0000518316	NCT00005183_16_T1	GENE	11	11	Apo
NCT0000518316	NCT00005183_16_T2	GENE	29	29	Apo
NCT0000518316	NCT00005183_16_T3	GENE	20	20	HDL
NCT0000518316	NCT00005183_16_T4	PHENOTYPE	23	24	coronary disease
NCT0000518316	NCT00005183_16_T5	GENE	13	14	Apo A-IV
NCT000051842	NCT00005184_2_T0	PHENOTYPE	7	8	coronary disease
NCT000051843	NCT00005184_3_T0	BIOLOGICAL_PROCESS	0	2	Major histocompatibility complex
NCT000051847	NCT00005184_7_T0	GENE	2	2	had
NCT0000518410	NCT00005184_10_T0	PHENOTYPE	23	23	severity
NCT000051850	NCT00005185_0_T0	PHENOTYPE	0	1	Myocardial Infarction
NCT000051854	NCT00005185_4_T0	GENE	4	4	has
NCT000051854	NCT00005185_4_T1	PHENOTYPE	17	17	osteoporosis
NCT000051855	NCT00005185_5_T0	PHENOTYPE	23	24	endometrial cancer
NCT000051856	NCT00005185_6_T0	COMPOUND	16	16	progestins
NCT000051856	NCT00005185_6_T1	PHENOTYPE	11	12	myocardial infarction
NCT000051857	NCT00005185_7_T0	PHENOTYPE	2	3	myocardial infarction
NCT000051857	NCT00005185_7_T1	PHENOTYPE	27	28	myocardial infarction
NCT000051859	NCT00005185_9_T0	PHENOTYPE	11	12	myocardial infarction
NCT000051860	NCT00005186_0_T0	PHENOTYPE	2	3	Cardiovascular Diseases
NCT000051864	NCT00005186_4_T0	PHENOTYPE	1	2	cardiovascular disease
NCT000051867	NCT00005186_7_T0	PHENOTYPE	13	14	cardiovascular disease
NCT0000518611	NCT00005186_11_T0	PHENOTYPE	12	13	cardiovascular disease
NCT0000518613	NCT00005186_13_T0	PHENOTYPE	19	19	disorders
NCT0000518618	NCT00005186_18_T0	GENE	7	7	had
NCT0000518618	NCT00005186_18_T1	GENE	15	15	had
NCT0000518620	NCT00005186_20_T0	PHENOTYPE	0	1	Cardiovascular disease
NCT0000518621	NCT00005186_21_T0	PHENOTYPE	7	8	cardiovascular disease
NCT0000518622	NCT00005186_22_T0	PHENOTYPE	4	5	cardiovascular disease
NCT0000518624	NCT00005186_24_T0	PHENOTYPE	0	0	Regression
NCT0000518624	NCT00005186_24_T1	PHENOTYPE	22	23	cardiovascular disease
NCT000051876	NCT00005187_6_T0	GENE	31	31	apo
NCT000051878	NCT00005187_8_T0	PHENOTYPE	6	7	gallbladder disease
NCT0000518717	NCT00005187_17_T0	PHENOTYPE	7	7	blocks
NCT0000518718	NCT00005187_18_T0	PHENOTYPE	6	6	blocks
NCT000051883	NCT00005188_3_T0	PHENOTYPE	6	6	heterogeneous
NCT000051884	NCT00005188_4_T0	GENE	7	7	had
NCT000051885	NCT00005188_5_T0	ORGAN	0	0	Plasma
NCT000051885	NCT00005188_5_T1	PHENOTYPE	5	5	heterogeneous
NCT000051888	NCT00005188_8_T0	PHENOTYPE	15	15	dyslipoproteinemias
NCT0000518810	NCT00005188_10_T0	PHENOTYPE	23	24	glucose levels
NCT0000518810	NCT00005188_10_T1	COMPOUND	20	21	uric acid
NCT0000518811	NCT00005188_11_T0	GENE	2	2	had
NCT0000518812	NCT00005188_12_T0	PHENOTYPE	18	19	primary hypoalphalipoproteinemia
NCT0000518812	NCT00005188_12_T1	PHENOTYPE	13	15	familial combined hyperlipidemia
NCT0000518812	NCT00005188_12_T2	PHENOTYPE	9	11	mode of inheritance
NCT0000518814	NCT00005188_14_T0	PHENOTYPE	10	10	associations
NCT000051891	NCT00005189_1_T0	PHENOTYPE	6	6	progression
NCT000051891	NCT00005189_1_T1	PHENOTYPE	19	19	progression
NCT000051891	NCT00005189_1_T2	PHENOTYPE	21	22	carotid atherosclerosis
NCT000051891	NCT00005189_1_T3	PHENOTYPE	7	10	of carotid artery disease
NCT000051893	NCT00005189_3_T0	PHENOTYPE	41	41	atherosclerosis
NCT000051893	NCT00005189_3_T1	PHENOTYPE	48	48	sequelae
NCT000051893	NCT00005189_3_T2	PHENOTYPE	54	55	myocardial infarction
NCT000051893	NCT00005189_3_T3	ORGAN	8	9	carotid arteries
NCT000051893	NCT00005189_3_T4	ORGAN	22	23	carotid arteries
NCT000051893	NCT00005189_3_T5	ORGAN	39	40	carotid artery
NCT000051894	NCT00005189_4_T0	PHENOTYPE	15	16	carotid atherosclerosis
NCT000051897	NCT00005189_7_T0	GENE	5	5	3.5
NCT000051897	NCT00005189_7_T1	GENE	7	7	8.5
NCT000051898	NCT00005189_8_T0	PHENOTYPE	17	18	myocardial infarction
NCT000051899	NCT00005189_9_T0	PHENOTYPE	11	12	carotid atherosclerosis
NCT0000518911	NCT00005189_11_T0	GENE	9	9	had
NCT0000518913	NCT00005189_13_T0	PHENOTYPE	27	27	5-10
NCT0000518913	NCT00005189_13_T1	PHENOTYPE	21	23	coronary artery disease
NCT0000518914	NCT00005189_14_T0	PHENOTYPE	55	55	progression
NCT0000518914	NCT00005189_14_T1	COMPOUND	21	21	2
NCT0000518914	NCT00005189_14_T2	PHENOTYPE	7	9	coronary artery disease
NCT0000518914	NCT00005189_14_T3	PHENOTYPE	33	35	coronary artery disease
NCT0000518914	NCT00005189_14_T4	PHENOTYPE	0	2	Coronary artery disease
NCT000051903	NCT00005190_3_T0	PHENOTYPE	18	20	congenital heart defects
NCT000051906	NCT00005190_6_T0	BIOLOGICAL_PROCESS	6	6	reproduction
NCT0000519021	NCT00005190_21_T0	BIOLOGICAL_PROCESS	9	9	reproduction
NCT0000519022	NCT00005190_22_T0	PHENOTYPE	4	4	recurrent
NCT0000519022	NCT00005190_22_T1	GENE	5	5	CHD
NCT000051910	NCT00005191_0_T0	PHENOTYPE	3	5	Coronary Artery Disease
NCT000051913	NCT00005191_3_T0	PHENOTYPE	11	13	coronary artery disease
NCT000051915	NCT00005191_5_T0	PHENOTYPE	27	27	hypertension
NCT000051915	NCT00005191_5_T1	PHENOTYPE	7	9	coronary artery disease
NCT000051919	NCT00005191_9_T0	PHENOTYPE	16	16	hyperlipidemia
NCT0000519114	NCT00005191_14_T0	PHENOTYPE	4	6	left ventricular hypertrophy
NCT0000519117	NCT00005191_17_T0	GENE	32	32	bypass
NCT0000519117	NCT00005191_17_T1	PHENOTYPE	21	21	hypertension
NCT0000519117	NCT00005191_17_T2	ORGAN	30	31	coronary artery
NCT0000519117	NCT00005191_17_T3	PHENOTYPE	23	25	coronary artery disease
NCT0000519120	NCT00005191_20_T0	GENE	41	41	ventricular
NCT0000519120	NCT00005191_20_T1	PHENOTYPE	52	52	obesity
NCT0000519120	NCT00005191_20_T2	PHENOTYPE	21	21	LVH
NCT0000519120	NCT00005191_20_T3	PHENOTYPE	18	20	left ventricular hypertrophy
NCT0000519120	NCT00005191_20_T4	PHENOTYPE	31	33	coronary heart disease
NCT0000519121	NCT00005191_21_T0	PHENOTYPE	23	23	Center
NCT0000519121	NCT00005191_21_T1	GENE	21	21	LSU
NCT0000519122	NCT00005191_22_T0	PHENOTYPE	13	13	LVH
NCT000051923	NCT00005192_3_T0	PHENOTYPE	7	7	Hypertension
NCT000051923	NCT00005192_3_T1	GENE	24	24	had
NCT000051923	NCT00005192_3_T2	GENE	12	12	36.2
NCT000051924	NCT00005192_4_T0	PHENOTYPE	7	7	hypertension
NCT000051925	NCT00005192_5_T0	PHENOTYPE	4	4	hypertension
NCT000051927	NCT00005192_7_T0	PHENOTYPE	16	16	hypertension
NCT0000519210	NCT00005192_10_T0	PHENOTYPE	26	27	borderline hypertension
NCT0000519211	NCT00005192_11_T0	CELL	31	31	cells
NCT0000519212	NCT00005192_12_T0	PHENOTYPE	24	26	Type A behavior
NCT0000519213	NCT00005192_13_T0	COMPOUND	20	20	cortisol
NCT0000519213	NCT00005192_13_T1	COMPOUND	21	21	aldosterone
NCT0000519213	NCT00005192_13_T2	GENE	19	19	renin
NCT0000519213	NCT00005192_13_T3	GENE	23	23	vasopressin
NCT0000519213	NCT00005192_13_T4	ORGAN	17	17	plasma
NCT0000519213	NCT00005192_13_T5	ORGAN	7	7	heart
NCT0000519214	NCT00005192_14_T0	PHENOTYPE	8	8	hostility
NCT0000519216	NCT00005192_16_T0	COMPOUND	7	7	sodium
NCT0000519216	NCT00005192_16_T1	PHENOTYPE	6	6	acute
NCT0000519217	NCT00005192_17_T0	CELL	18	18	cells
NCT0000519220	NCT00005192_20_T0	COMPOUND	13	13	sodium
NCT0000519220	NCT00005192_20_T1	PHENOTYPE	17	18	sodium depletion
NCT0000519223	NCT00005192_23_T0	PHENOTYPE	16	16	Hypertension
NCT0000519224	NCT00005192_24_T0	GENE	1	1	had
NCT0000519232	NCT00005192_32_T0	PHENOTYPE	12	14	high blood pressure
NCT0000519233	NCT00005192_33_T0	PHENOTYPE	18	18	adiposity
NCT0000519233	NCT00005192_33_T1	GENE	14	14	insulin
NCT0000519233	NCT00005192_33_T2	PHENOTYPE	16	17	glucose tolerance
NCT0000519234	NCT00005192_34_T0	GENE	7	7	FY
NCT0000519235	NCT00005192_35_T0	GENE	7	7	FY
NCT0000519235	NCT00005192_35_T1	PHENOTYPE	13	14	myocardial infarction
NCT000051933	NCT00005193_3_T0	PHENOTYPE	20	20	gangrene
NCT000051933	NCT00005193_3_T1	GENE	2	2	mid
NCT000051933	NCT00005193_3_T2	GENE	6	6	had
NCT000051934	NCT00005193_4_T0	GENE	5	5	2.3
NCT000051935	NCT00005193_5_T0	PHENOTYPE	3	5	coronary heart disease
NCT000051937	NCT00005193_7_T0	PHENOTYPE	20	20	Diabetes
NCT000051937	NCT00005193_7_T1	PHENOTYPE	17	18	Vascular Disease
NCT000051939	NCT00005193_9_T0	PHENOTYPE	10	10	proteinuria
NCT000051939	NCT00005193_9_T1	ORGAN	5	5	plasma
NCT000051939	NCT00005193_9_T2	ORGAN	7	7	plasma
NCT0000519316	NCT00005193_16_T0	GENE	13	13	II
NCT0000519318	NCT00005193_18_T0	PHENOTYPE	18	18	Diabetes
NCT0000519318	NCT00005193_18_T1	PHENOTYPE	15	16	Vascular Disease
NCT0000519320	NCT00005193_20_T0	PHENOTYPE	9	9	complications
NCT000051944	NCT00005194_4_T0	GENE	13	13	Hg
NCT000051944	NCT00005194_4_T1	GENE	22	22	Hg
NCT0000519412	NCT00005194_12_T0	PHENOTYPE	0	0	Obesity
NCT0000519412	NCT00005194_12_T1	PHENOTYPE	16	16	hyperinsulinemia
NCT0000519412	NCT00005194_12_T2	PHENOTYPE	2	3	abdominal obesity
NCT0000519412	NCT00005194_12_T3	PHENOTYPE	13	14	insulin resistance
NCT0000519414	NCT00005194_14_T0	PHENOTYPE	17	18	Cardiovascular Disease
NCT0000519416	NCT00005194_16_T0	BIOLOGICAL_PROCESS	11	11	Aging
NCT0000519417	NCT00005194_17_T0	PHENOTYPE	19	19	hyperinsulinism
NCT0000519417	NCT00005194_17_T1	PHENOTYPE	14	14	obesity
NCT0000519417	NCT00005194_17_T2	PHENOTYPE	45	46	myocardial infarction
NCT0000519419	NCT00005194_19_T0	PHENOTYPE	10	11	insulin resistance
NCT0000519419	NCT00005194_19_T1	ORGAN	12	14	sympathetic nervous system
NCT000051952	NCT00005195_2_T0	GENE	2	2	has
NCT000051953	NCT00005195_3_T0	GENE	15	15	al
NCT000051953	NCT00005195_3_T1	GENE	19	19	al
NCT000051953	NCT00005195_3_T2	GENE	14	14	et
NCT000051953	NCT00005195_3_T3	GENE	18	18	et
NCT000051954	NCT00005195_4_T0	PHENOTYPE	11	12	ventricular tachycardia
NCT000051957	NCT00005195_7_T0	PHENOTYPE	29	29	complication
NCT000051957	NCT00005195_7_T1	PHENOTYPE	25	25	anesthesia
NCT0000519512	NCT00005195_12_T0	PHENOTYPE	9	9	centers
NCT0000519512	NCT00005195_12_T1	PHENOTYPE	28	29	ventricular tachycardia
NCT0000519512	NCT00005195_12_T2	PHENOTYPE	24	26	accessory atrioventricular pathways
NCT0000519516	NCT00005195_16_T0	PHENOTYPE	19	20	heart disease
NCT0000519517	NCT00005195_17_T0	PHENOTYPE	23	23	symptoms
NCT0000519517	NCT00005195_17_T1	PHENOTYPE	30	30	complications
NCT0000519517	NCT00005195_17_T2	PHENOTYPE	13	13	arrhythmias
NCT0000519517	NCT00005195_17_T3	PHENOTYPE	26	27	adverse effects
NCT0000519517	NCT00005195_17_T4	PHENOTYPE	16	19	third degree atrioventricular block
NCT000051962	NCT00005196_2_T0	GENE	9	9	has
NCT000051962	NCT00005196_2_T1	PHENOTYPE	6	8	coronary heart disease
NCT000051963	NCT00005196_3_T0	PHENOTYPE	23	25	coronary heart disease
NCT000051964	NCT00005196_4_T0	PHENOTYPE	17	17	practices
NCT000051964	NCT00005196_4_T1	PHENOTYPE	26	28	coronary heart disease
NCT000051965	NCT00005196_5_T0	PHENOTYPE	8	10	coronary heart disease
NCT000051966	NCT00005196_6_T0	PHENOTYPE	19	21	coronary heart disease
NCT000051967	NCT00005196_7_T0	PHENOTYPE	53	53	acute
NCT000051967	NCT00005196_7_T1	PHENOTYPE	10	12	coronary heart disease
NCT000051969	NCT00005196_9_T0	ORGAN	49	49	serum
NCT000051969	NCT00005196_9_T1	PHENOTYPE	43	43	hypertension
NCT000051969	NCT00005196_9_T2	PHENOTYPE	50	51	cholesterol levels
NCT000051969	NCT00005196_9_T3	PHENOTYPE	7	9	coronary heart disease
NCT0000519610	NCT00005196_10_T0	PHENOTYPE	35	35	secondary
NCT0000519610	NCT00005196_10_T1	PHENOTYPE	6	8	coronary heart disease
NCT0000519611	NCT00005196_11_T0	PHENOTYPE	38	40	coronary heart disease
NCT0000519611	NCT00005196_11_T1	PHENOTYPE	33	35	acute myocardial infarction
NCT0000519611	NCT00005196_11_T2	PHENOTYPE	62	64	acute myocardial infarction
NCT0000519611	NCT00005196_11_T3	PHENOTYPE	75	77	acute myocardial infarction
NCT0000519612	NCT00005196_12_T0	PHENOTYPE	20	22	acute myocardial infarction
NCT0000519614	NCT00005196_14_T0	PHENOTYPE	8	8	acute
NCT0000519614	NCT00005196_14_T1	GENE	20	20	extended
NCT0000519615	NCT00005196_15_T0	PHENOTYPE	4	4	recurrent
NCT0000519615	NCT00005196_15_T1	PHENOTYPE	8	10	acute myocardial infarction
NCT0000519616	NCT00005196_16_T0	PHENOTYPE	18	20	acute myocardial infarction
NCT0000519619	NCT00005196_19_T0	PHENOTYPE	16	18	coronary heart disease
NCT0000519620	NCT00005196_20_T0	PHENOTYPE	33	33	AMI
NCT0000519620	NCT00005196_20_T1	PHENOTYPE	49	49	AMI
NCT0000519620	NCT00005196_20_T2	GENE	38	38	CHD
NCT0000519621	NCT00005196_21_T0	PHENOTYPE	28	28	AMI
NCT000051972	NCT00005197_2_T0	PHENOTYPE	34	35	cardiac events
NCT000051972	NCT00005197_2_T1	PHENOTYPE	19	20	myocardial infarction
NCT000051972	NCT00005197_2_T2	PHENOTYPE	8	10	coronary artery disease
NCT000051975	NCT00005197_5_T0	PHENOTYPE	22	22	anesthesia
NCT000051976	NCT00005197_6_T0	PHENOTYPE	0	1	Myocardial ischemia
NCT000051977	NCT00005197_7_T0	PHENOTYPE	11	11	Ischemia
NCT000051983	NCT00005198_3_T0	PHENOTYPE	15	15	recurrence
NCT000051983	NCT00005198_3_T1	PHENOTYPE	17	18	myocardial infarction
NCT000051983	NCT00005198_3_T2	PHENOTYPE	22	23	myocardial infarction
NCT000051983	NCT00005198_3_T3	PHENOTYPE	33	34	myocardial infarction
NCT000051984	NCT00005198_4_T0	PHENOTYPE	65	65	practices
NCT000051984	NCT00005198_4_T1	PHENOTYPE	33	33	recurrence
NCT000051984	NCT00005198_4_T2	PHENOTYPE	16	16	estimation
NCT000051984	NCT00005198_4_T3	PHENOTYPE	28	29	myocardial infarction
NCT000051984	NCT00005198_4_T4	PHENOTYPE	39	40	myocardial infarction
NCT000051984	NCT00005198_4_T5	PHENOTYPE	68	69	myocardial infarction
NCT000051984	NCT00005198_4_T6	PHENOTYPE	94	96	coronary heart disease
NCT000051985	NCT00005198_5_T0	PHENOTYPE	5	5	acute
NCT000051985	NCT00005198_5_T1	PHENOTYPE	12	12	acute
NCT000051985	NCT00005198_5_T2	GENE	9	9	CHD
NCT000051985	NCT00005198_5_T3	PHENOTYPE	6	8	coronary heart disease
NCT000051987	NCT00005198_7_T0	PHENOTYPE	47	47	practices
NCT000051987	NCT00005198_7_T1	PHENOTYPE	36	36	recurrent
NCT000051987	NCT00005198_7_T2	PHENOTYPE	37	38	myocardial infarction
NCT000051987	NCT00005198_7_T3	PHENOTYPE	7	9	acute myocardial infarction
NCT000051988	NCT00005198_8_T0	PHENOTYPE	15	16	myocardial infarction
NCT000051988	NCT00005198_8_T1	PHENOTYPE	8	10	coronary heart disease
NCT000051989	NCT00005198_9_T0	PHENOTYPE	7	7	recurrence
NCT000051989	NCT00005198_9_T1	PHENOTYPE	40	40	recurrence
NCT000051989	NCT00005198_9_T2	PHENOTYPE	9	10	myocardial infarction
NCT000051989	NCT00005198_9_T3	PHENOTYPE	16	17	myocardial infarction
NCT000051989	NCT00005198_9_T4	PHENOTYPE	38	39	myocardial infarction
NCT0000519810	NCT00005198_10_T0	GENE	20	20	bypass
NCT0000519810	NCT00005198_10_T1	GENE	13	13	CHD
NCT0000519811	NCT00005198_11_T0	GENE	25	25	CHD
NCT0000519812	NCT00005198_12_T0	GENE	8	8	CHD
NCT000051992	NCT00005199_2_T0	ORGAN	9	10	mitral valves
NCT0000519912	NCT00005199_12_T0	ORGAN	9	10	aortic valves
NCT0000519919	NCT00005199_19_T0	PHENOTYPE	5	8	coarctation of the aorta
NCT0000519921	NCT00005199_21_T0	PHENOTYPE	11	11	anesthesia
NCT0000519922	NCT00005199_22_T0	GENE	1	1	balloon
NCT0000519922	NCT00005199_22_T1	PHENOTYPE	12	12	circulation
NCT0000519922	NCT00005199_22_T2	ORGAN	24	25	atrial septum
NCT0000519922	NCT00005199_22_T3	ORGAN	18	19	mitral valve
NCT0000519924	NCT00005199_24_T0	PHENOTYPE	4	4	closed
NCT0000519925	NCT00005199_25_T0	GENE	15	15	balloon
NCT0000519925	NCT00005199_25_T1	GENE	3	3	has
NCT0000519925	NCT00005199_25_T2	PHENOTYPE	7	7	severely
NCT0000519925	NCT00005199_25_T3	PHENOTYPE	8	8	stenotic
NCT0000519925	NCT00005199_25_T4	ORGAN	9	10	aortic valves
NCT0000519925	NCT00005199_25_T5	ORGAN	18	19	mitral valve
NCT0000519928	NCT00005199_28_T0	GENE	9	9	balloon
NCT0000519932	NCT00005199_32_T0	GENE	6	6	balloon
NCT0000519932	NCT00005199_32_T1	PHENOTYPE	23	23	recruitment
NCT0000519934	NCT00005199_34_T0	PHENOTYPE	12	12	Center
NCT000052002	NCT00005200_2_T0	ORGAN	20	20	heart
NCT000052002	NCT00005200_2_T1	PHENOTYPE	8	10	nervous system abnormality
NCT000052002	NCT00005200_2_T2	ORGAN	7	9	sympathetic nervous system
NCT000052003	NCT00005200_3_T0	PHENOTYPE	9	9	inhibition
NCT000052003	NCT00005200_3_T1	PHENOTYPE	24	24	borderline
NCT000052003	NCT00005200_3_T2	PHENOTYPE	15	15	circulation
NCT000052003	NCT00005200_3_T3	GENE	14	14	hyperkinetic
NCT000052003	NCT00005200_3_T4	PHENOTYPE	25	26	essential hypertension
NCT000052003	NCT00005200_3_T5	ORGAN	2	4	sympathetic nervous system
NCT000052004	NCT00005200_4_T0	ORGAN	4	4	heart
NCT000052006	NCT00005200_6_T0	PHENOTYPE	15	16	essential hypertension
NCT000052006	NCT00005200_6_T1	PHENOTYPE	0	2	Increased blood pressure
NCT000052007	NCT00005200_7_T0	ORGAN	6	8	sympathetic nervous system
NCT000052008	NCT00005200_8_T0	GENE	3	3	defective
NCT000052008	NCT00005200_8_T1	PHENOTYPE	9	10	problem solving
NCT000052009	NCT00005200_9_T0	PHENOTYPE	11	11	pathophysiology
NCT0000520010	NCT00005200_10_T0	GENE	5	5	reduced
NCT0000520010	NCT00005200_10_T1	PHENOTYPE	0	1	Essential hypertension
NCT0000520011	NCT00005200_11_T0	PHENOTYPE	17	17	pathophysiology
NCT0000520011	NCT00005200_11_T1	PHENOTYPE	19	20	essential hypertension
NCT0000520011	NCT00005200_11_T2	ORGAN	10	12	sympathetic nervous system
NCT0000520013	NCT00005200_13_T0	COMPOUND	18	18	sodium
NCT0000520013	NCT00005200_13_T1	PHENOTYPE	23	25	left ventricular hypertrophy
NCT0000520017	NCT00005200_17_T0	COMPOUND	20	20	sodium
NCT000052012	NCT00005201_2_T0	GENE	4	4	had
NCT000052012	NCT00005201_2_T1	PHENOTYPE	16	17	genetic diseases
NCT000052012	NCT00005201_2_T2	PHENOTYPE	7	8	dilated cardiomyopathy
NCT000052014	NCT00005201_4_T0	PHENOTYPE	7	7	sporadic
NCT000052016	NCT00005201_6_T0	GENE	25	25	ANP
NCT000052016	NCT00005201_6_T1	TISSUE	35	35	myocardium
NCT000052016	NCT00005201_6_T2	PHENOTYPE	15	16	dilated cardiomyopathy
NCT000052016	NCT00005201_6_T3	PHENOTYPE	38	40	idiopathic dilated cardiomyopathy
NCT0000520110	NCT00005201_10_T0	GENE	3	3	had
NCT0000520111	NCT00005201_11_T0	GENE	9	9	ANP
NCT0000520111	NCT00005201_11_T1	GENE	6	8	atrial natriuretic peptide
NCT0000520112	NCT00005201_12_T0	GENE	16	16	ANP
NCT0000520112	NCT00005201_12_T1	PHENOTYPE	7	8	drug use
NCT0000520115	NCT00005201_15_T0	PHENOTYPE	0	0	Heterogeneity
NCT0000520115	NCT00005201_15_T1	GENE	9	9	ANP
NCT0000520115	NCT00005201_15_T2	PHENOTYPE	23	25	idiopathic dilated cardiomyopathy
NCT0000520115	NCT00005201_15_T3	PHENOTYPE	30	32	idiopathic dilated cardiomyopathy
NCT000052020	NCT00005202_0_T0	PHENOTYPE	5	5	Syncope
NCT000052023	NCT00005202_3_T0	PHENOTYPE	11	11	syncope
NCT000052024	NCT00005202_4_T0	PHENOTYPE	18	18	disorders
NCT000052024	NCT00005202_4_T1	PHENOTYPE	3	3	diseases
NCT000052024	NCT00005202_4_T2	PHENOTYPE	7	7	syncope
NCT000052025	NCT00005202_5_T0	PHENOTYPE	13	13	syncope
NCT000052028	NCT00005202_8_T0	PHENOTYPE	10	10	syncope
NCT000052029	NCT00005202_9_T0	PHENOTYPE	14	14	syncope
NCT0000520210	NCT00005202_10_T0	PHENOTYPE	12	12	arrhythmias
NCT0000520210	NCT00005202_10_T1	PHENOTYPE	9	9	syncope
NCT0000520210	NCT00005202_10_T2	PHENOTYPE	18	18	syncope
NCT0000520212	NCT00005202_12_T0	PHENOTYPE	21	21	arrhythmias
NCT0000520212	NCT00005202_12_T1	PHENOTYPE	6	6	syncope
NCT0000520212	NCT00005202_12_T2	PHENOTYPE	18	18	syncope
NCT0000520212	NCT00005202_12_T3	PHENOTYPE	27	27	syncope
NCT0000520213	NCT00005202_13_T0	PHENOTYPE	21	21	arrhythmias
NCT0000520213	NCT00005202_13_T1	GENE	4	4	has
NCT0000520214	NCT00005202_14_T0	PHENOTYPE	8	8	arrhythmias
NCT0000520214	NCT00005202_14_T1	PHENOTYPE	22	22	arrhythmias
NCT0000520214	NCT00005202_14_T2	PHENOTYPE	10	10	syncope
NCT0000520216	NCT00005202_16_T0	PHENOTYPE	4	4	arrhythmias
NCT0000520217	NCT00005202_17_T0	PHENOTYPE	7	7	arrhythmias
NCT0000520217	NCT00005202_17_T1	PHENOTYPE	13	13	decisions
NCT0000520218	NCT00005202_18_T0	PHENOTYPE	4	4	arrhythmias
NCT0000520219	NCT00005202_19_T0	PHENOTYPE	7	7	arrhythmias
NCT0000520220	NCT00005202_20_T0	PHENOTYPE	4	4	arrhythmias
NCT0000520220	NCT00005202_20_T1	PHENOTYPE	10	11	sudden death
NCT0000520222	NCT00005202_22_T0	PHENOTYPE	21	21	arrhythmias
NCT0000520222	NCT00005202_22_T1	PHENOTYPE	14	15	sudden death
NCT0000520223	NCT00005202_23_T0	PHENOTYPE	16	16	syncope
NCT0000520223	NCT00005202_23_T1	PHENOTYPE	5	6	sudden death
NCT0000520225	NCT00005202_25_T0	PHENOTYPE	16	16	syncope
NCT0000520225	NCT00005202_25_T1	PHENOTYPE	6	6	arrhythmias
NCT0000520225	NCT00005202_25_T2	PHENOTYPE	32	33	ventricular tachycardia
NCT0000520226	NCT00005202_26_T0	PHENOTYPE	2	2	syncope
NCT0000520228	NCT00005202_28_T0	PHENOTYPE	5	5	syncope
NCT0000520229	NCT00005202_29_T0	PHENOTYPE	3	4	sudden death
NCT000052032	NCT00005203_2_T0	GENE	8	8	lipoprotein
NCT000052032	NCT00005203_2_T1	PHENOTYPE	11	13	coronary heart disease
NCT000052033	NCT00005203_3_T0	GENE	7	7	lipoprotein
NCT000052033	NCT00005203_3_T1	GENE	8	8	VLDL
NCT000052033	NCT00005203_3_T2	ORGAN	11	11	plasma
NCT000052033	NCT00005203_3_T3	PHENOTYPE	19	20	cardiovascular disease
NCT000052034	NCT00005203_4_T0	GENE	30	30	AI
NCT000052034	NCT00005203_4_T1	GENE	36	36	HDL
NCT000052034	NCT00005203_4_T2	GENE	22	22	LDL
NCT000052034	NCT00005203_4_T3	GENE	16	16	apoprotein
NCT000052034	NCT00005203_4_T4	GENE	29	29	apoprotein
NCT000052034	NCT00005203_4_T5	ORGAN	13	13	plasma
NCT000052034	NCT00005203_4_T6	PHENOTYPE	9	11	coronary heart disease
NCT000052035	NCT00005203_5_T0	GENE	3	3	has
NCT000052035	NCT00005203_5_T1	ORGAN	7	7	plasma
NCT000052036	NCT00005203_6_T0	GENE	8	8	lipoprotein
NCT000052036	NCT00005203_6_T1	GENE	10	10	apoprotein
NCT000052036	NCT00005203_6_T2	PHENOTYPE	21	23	coronary heart disease
NCT000052037	NCT00005203_7_T0	GENE	20	20	lipoprotein
NCT000052037	NCT00005203_7_T1	PHENOTYPE	0	1	Cardiovascular disease
NCT000052038	NCT00005203_8_T0	PHENOTYPE	8	9	heart disease
NCT000052038	NCT00005203_8_T1	PHENOTYPE	24	25	cholesterol levels
NCT0000520310	NCT00005203_10_T0	PHENOTYPE	6	7	rare disorder
NCT0000520310	NCT00005203_10_T1	PHENOTYPE	1	2	familial hypercholesterolemia
NCT0000520311	NCT00005203_11_T0	GENE	13	13	lipoprotein
NCT0000520311	NCT00005203_11_T1	PHENOTYPE	4	4	understood
NCT0000520311	NCT00005203_11_T2	PHENOTYPE	21	23	coronary heart disease
NCT0000520313	NCT00005203_13_T0	PHENOTYPE	1	1	recruitment
NCT0000520314	NCT00005203_14_T0	PHENOTYPE	1	1	recruitment
NCT0000520315	NCT00005203_15_T0	GENE	7	7	LDL
NCT0000520315	NCT00005203_15_T1	GENE	14	14	apoprotein
NCT0000520317	NCT00005203_17_T0	GENE	7	7	LDL
NCT0000520317	NCT00005203_17_T1	GENE	20	20	LDL
NCT0000520317	NCT00005203_17_T2	GENE	25	25	LDL
NCT0000520317	NCT00005203_17_T3	GENE	22	22	defective
NCT0000520317	NCT00005203_17_T4	PHENOTYPE	15	15	hypercholesterolemia
NCT0000520318	NCT00005203_18_T0	GENE	3	3	LDL
NCT0000520319	NCT00005203_19_T0	GENE	4	4	LDL
NCT0000520319	NCT00005203_19_T1	GENE	14	14	LDL
NCT0000520319	NCT00005203_19_T2	GENE	18	18	apoprotein
NCT0000520319	NCT00005203_19_T3	BIOLOGICAL_PROCESS	21	22	LDL clearance
NCT0000520320	NCT00005203_20_T0	GENE	15	15	LDL
NCT000052043	NCT00005204_3_T0	PHENOTYPE	19	19	hypertension
NCT000052044	NCT00005204_4_T0	ORGAN	13	13	kidney
NCT000052044	NCT00005204_4_T1	PHENOTYPE	15	15	excrete
NCT000052044	NCT00005204_4_T2	PHENOTYPE	4	4	hypertension
NCT0000520410	NCT00005204_10_T0	PHENOTYPE	29	29	excretions
NCT0000520418	NCT00005204_18_T0	PHENOTYPE	19	21	high blood pressure
NCT000052056	NCT00005205_6_T0	GENE	13	13	lipoprotein
NCT000052056	NCT00005205_6_T1	PHENOTYPE	7	7	hypertriglyceridemia
NCT000052056	NCT00005205_6_T2	PHENOTYPE	4	4	obesity
NCT000052056	NCT00005205_6_T3	PHENOTYPE	5	6	glucose intolerance
NCT0000520511	NCT00005205_11_T0	ORGAN	21	21	Heart
NCT0000520511	NCT00005205_11_T1	GENE	19	19	San
NCT0000520511	NCT00005205_11_T2	GENE	5	5	has
NCT0000520512	NCT00005205_12_T0	ORGAN	12	12	Heart
NCT0000520512	NCT00005205_12_T1	GENE	10	10	San
NCT0000520528	NCT00005205_28_T0	GENE	21	21	San
NCT000052062	NCT00005206_2_T0	COMPOUND	7	7	calcium
NCT000052062	NCT00005206_2_T1	COMPOUND	13	13	calcium
NCT000052062	NCT00005206_2_T2	BIOLOGICAL_PROCESS	14	14	metabolism
NCT000052062	NCT00005206_2_T3	BIOLOGICAL_PROCESS	24	24	gestation
NCT000052063	NCT00005206_3_T0	PHENOTYPE	11	12	pregnancy hypertension
NCT000052065	NCT00005206_5_T0	COMPOUND	9	9	calcium
NCT000052065	NCT00005206_5_T1	BIOLOGICAL_PROCESS	10	10	metabolism
NCT000052066	NCT00005206_6_T0	COMPOUND	4	4	calcium
NCT000052066	NCT00005206_6_T1	BIOLOGICAL_PROCESS	8	8	gestation
NCT000052067	NCT00005206_7_T0	COMPOUND	25	25	potassium
NCT000052067	NCT00005206_7_T1	PHENOTYPE	26	26	concentrations
NCT000052067	NCT00005206_7_T2	COMPOUND	4	4	calcium
NCT000052067	NCT00005206_7_T3	COMPOUND	13	13	calcium
NCT000052067	NCT00005206_7_T4	GENE	16	16	calcitonin
NCT000052067	NCT00005206_7_T5	COMPOUND	21	21	magnesium
NCT000052067	NCT00005206_7_T6	COMPOUND	23	23	sodium
NCT000052067	NCT00005206_7_T7	BIOLOGICAL_PROCESS	5	5	metabolism
NCT000052067	NCT00005206_7_T8	ORGAN	1	1	serum
NCT000052067	NCT00005206_7_T9	ORGAN	9	9	serum
NCT000052067	NCT00005206_7_T10	ORGAN	20	20	serum
NCT000052067	NCT00005206_7_T11	COMPOUND	22	22	phosphorus
NCT000052067	NCT00005206_7_T12	GENE	14	15	parathyroid hormone
NCT000052067	NCT00005206_7_T13	COMPOUND	17	18	vitamin D
NCT000052074	NCT00005207_4_T0	ORGAN	10	10	kidney
NCT000052074	NCT00005207_4_T1	ORGAN	11	11	ovary
NCT000052078	NCT00005207_8_T0	BIOLOGICAL_PROCESS	4	5	glomerular filtration
NCT000052078	NCT00005207_8_T1	PHENOTYPE	7	9	renal plasma flow
NCT000052079	NCT00005207_9_T0	BIOLOGICAL_PROCESS	11	11	fertilization
NCT000052079	NCT00005207_9_T1	GENE	17	17	had
NCT000052079	NCT00005207_9_T2	ORGAN	22	22	plasma
NCT000052079	NCT00005207_9_T3	PHENOTYPE	13	14	ovarian failure
NCT000052083	NCT00005208_3_T0	PHENOTYPE	7	7	hypoxia
NCT000052083	NCT00005208_3_T1	PHENOTYPE	20	20	hypoxia
NCT000052083	NCT00005208_3_T2	PHENOTYPE	12	12	adaptation
NCT000052083	NCT00005208_3_T3	PHENOTYPE	16	17	oxygen extraction
NCT000052084	NCT00005208_4_T0	PHENOTYPE	2	2	circulation
NCT000052085	NCT00005208_5_T0	COMPOUND	8	8	thromboxane
NCT000052085	NCT00005208_5_T1	PHENOTYPE	1	1	imbalance
NCT000052085	NCT00005208_5_T2	COMPOUND	4	4	prostacyclin
NCT000052085	NCT00005208_5_T3	GENE	5	5	PGI2
NCT000052085	NCT00005208_5_T4	BIOLOGICAL_PROCESS	16	16	vasoconstriction
NCT000052085	NCT00005208_5_T5	GENE	19	19	PIH
NCT000052087	NCT00005208_7_T0	PHENOTYPE	22	22	imbalance
NCT000052087	NCT00005208_7_T1	PHENOTYPE	36	36	circulation
NCT000052087	NCT00005208_7_T2	BIOLOGICAL_PROCESS	38	38	vasoconstriction
NCT000052087	NCT00005208_7_T3	PHENOTYPE	4	4	circulations
NCT000052088	NCT00005208_8_T0	PHENOTYPE	11	11	hypoxia
NCT000052088	NCT00005208_8_T1	PHENOTYPE	8	8	hypocalcemia
NCT000052088	NCT00005208_8_T2	PHENOTYPE	10	10	hypomagnesemia
NCT000052092	NCT00005209_2_T0	PHENOTYPE	0	0	Recruitment
NCT000052094	NCT00005209_4_T0	PHENOTYPE	11	13	coronary heart disease
NCT000052095	NCT00005209_5_T0	PHENOTYPE	4	7	diseases of the heart
NCT000052096	NCT00005209_6_T0	PHENOTYPE	12	12	attributable
NCT000052096	NCT00005209_6_T1	PHENOTYPE	14	16	coronary heart disease
NCT000052097	NCT00005209_7_T0	PHENOTYPE	23	25	coronary heart disease
NCT0000520911	NCT00005209_11_T0	PHENOTYPE	9	9	progression
NCT0000520911	NCT00005209_11_T1	BIOLOGICAL_PROCESS	0	1	Lipid metabolism
NCT0000520912	NCT00005209_12_T0	GENE	33	33	lipoprotein
NCT0000520912	NCT00005209_12_T1	COMPOUND	21	21	cholestyramine
NCT0000520912	NCT00005209_12_T2	GENE	34	34	LDL
NCT0000520912	NCT00005209_12_T3	ORGAN	30	30	plasma
NCT0000520912	NCT00005209_12_T4	PHENOTYPE	9	11	coronary heart disease
NCT0000520912	NCT00005209_12_T5	PHENOTYPE	44	46	coronary heart disease
NCT0000520913	NCT00005209_13_T0	PHENOTYPE	5	5	focused
NCT0000520914	NCT00005209_14_T0	GENE	15	15	lipoprotein
NCT0000520915	NCT00005209_15_T0	BIOLOGICAL_PROCESS	32	33	lipid metabolism
NCT0000520915	NCT00005209_15_T1	PHENOTYPE	35	37	coronary heart disease
NCT0000520916	NCT00005209_16_T0	PHENOTYPE	6	8	coronary heart disease
NCT0000520917	NCT00005209_17_T0	PHENOTYPE	10	10	strategies
NCT0000520918	NCT00005209_18_T0	PHENOTYPE	14	16	coronary heart disease
NCT0000520919	NCT00005209_19_T0	PHENOTYPE	29	30	protein level
NCT0000520919	NCT00005209_19_T1	PHENOTYPE	22	25	restriction fragment length polymorphisms
NCT0000520920	NCT00005209_20_T0	GENE	14	14	lipoprotein
NCT0000520920	NCT00005209_20_T1	PHENOTYPE	31	31	obesity
NCT0000520920	NCT00005209_20_T2	PHENOTYPE	28	29	drug use
NCT0000520921	NCT00005209_21_T0	PHENOTYPE	12	12	attributable
NCT0000520923	NCT00005209_23_T0	GENE	17	17	apo
NCT0000520923	NCT00005209_23_T1	GENE	50	50	lipoprotein
NCT0000520923	NCT00005209_23_T2	PHENOTYPE	25	27	coronary heart disease
NCT0000520925	NCT00005209_25_T0	GENE	12	12	fragment
NCT0000520927	NCT00005209_27_T0	PHENOTYPE	5	6	phenotypic variability
NCT0000520928	NCT00005209_28_T0	PHENOTYPE	44	46	coronary artery disease
NCT0000520928	NCT00005209_28_T1	PHENOTYPE	58	60	coronary artery disease
NCT0000520928	NCT00005209_28_T2	BIOLOGICAL_PROCESS	22	24	reverse cholesterol transport
NCT0000520929	NCT00005209_29_T0	PHENOTYPE	4	6	coronary artery disease
NCT0000520929	NCT00005209_29_T1	PHENOTYPE	27	29	coronary artery disease
NCT0000520931	NCT00005209_31_T0	PHENOTYPE	9	11	coronary artery disease
NCT0000520934	NCT00005209_34_T0	PHENOTYPE	13	15	coronary artery disease
NCT0000520936	NCT00005209_36_T0	PHENOTYPE	10	12	coronary artery disease
NCT0000520937	NCT00005209_37_T0	ORGAN	46	46	plasma
NCT0000520937	NCT00005209_37_T1	PHENOTYPE	21	23	coronary artery disease
NCT000052102	NCT00005210_2_T0	COMPOUND	28	28	androgen
NCT000052102	NCT00005210_2_T1	GENE	9	9	had
NCT000052102	NCT00005210_2_T2	GENE	15	15	had
NCT000052103	NCT00005210_3_T0	GENE	3	3	had
NCT000052103	NCT00005210_3_T1	PHENOTYPE	11	13	coronary heart disease
NCT000052105	NCT00005210_5_T0	COMPOUND	7	7	androgen
NCT000052105	NCT00005210_5_T1	PHENOTYPE	15	15	obesity
NCT000052112	NCT00005211_2_T0	PHENOTYPE	10	12	atherosclerotic heart disease
NCT000052113	NCT00005211_3_T0	PHENOTYPE	12	14	atherosclerotic heart disease
NCT000052115	NCT00005211_5_T0	PHENOTYPE	13	13	atherogenesis
NCT000052115	NCT00005211_5_T1	PHENOTYPE	16	16	atherosclerosis
NCT000052115	NCT00005211_5_T2	CELL	7	7	platelet
NCT000052115	NCT00005211_5_T3	BIOLOGICAL_PROCESS	20	21	lipid metabolism
NCT000052116	NCT00005211_6_T0	PHENOTYPE	7	8	sudden death
NCT000052116	NCT00005211_6_T1	PHENOTYPE	15	16	ventricular fibrillation
NCT000052117	NCT00005211_7_T0	PHENOTYPE	36	36	atherogenesis
NCT000052117	NCT00005211_7_T1	PHENOTYPE	12	12	hypoxia
NCT000052117	NCT00005211_7_T2	TISSUE	15	15	myocardium
NCT000052117	NCT00005211_7_T3	PHENOTYPE	46	47	cardiovascular disease
NCT000052117	NCT00005211_7_T4	PHENOTYPE	22	23	myocardial ischemia
NCT0000521110	NCT00005211_10_T0	PHENOTYPE	5	7	carbon monoxide exposure
NCT0000521117	NCT00005211_17_T0	PHENOTYPE	22	22	estimation
NCT0000521117	NCT00005211_17_T1	PHENOTYPE	13	14	occupational exposure
NCT0000521118	NCT00005211_18_T0	COMPOUND	1	2	carbon monoxide
NCT0000521119	NCT00005211_19_T0	GENE	9	9	nested
NCT0000521119	NCT00005211_19_T1	PHENOTYPE	31	32	cardiovascular disease
NCT0000521119	NCT00005211_19_T2	PHENOTYPE	34	35	occupational exposure
NCT0000521119	NCT00005211_19_T3	PHENOTYPE	22	24	other cardiovascular disease
NCT0000521119	NCT00005211_19_T4	PHENOTYPE	35	38	exposure to carbon monoxide
NCT0000521120	NCT00005211_20_T0	GENE	21	21	QVR
NCT000052122	NCT00005212_2_T0	GENE	20	20	reduced
NCT000052122	NCT00005212_2_T1	GENE	2	2	has
NCT000052122	NCT00005212_2_T2	GENE	19	19	has
NCT000052122	NCT00005212_2_T3	PHENOTYPE	17	17	hypertension
NCT000052122	NCT00005212_2_T4	PHENOTYPE	24	25	cardiovascular disease
NCT000052123	NCT00005212_3_T0	PHENOTYPE	16	17	cardiovascular disease
NCT000052124	NCT00005212_4_T0	PHENOTYPE	3	4	cardiovascular disease
NCT000052127	NCT00005212_7_T0	GENE	12	12	ULF
NCT000052128	NCT00005212_8_T0	GENE	1	1	ULF
NCT0000521213	NCT00005212_13_T0	PHENOTYPE	1	1	regression
NCT000052130	NCT00005213_0_T0	COMPOUND	0	0	Lithium
NCT000052133	NCT00005213_3_T0	PHENOTYPE	1	1	centers
NCT000052135	NCT00005213_5_T0	PHENOTYPE	24	24	hypertension
NCT000052135	NCT00005213_5_T1	PHENOTYPE	30	31	cardiovascular morbidity
NCT000052136	NCT00005213_6_T0	PHENOTYPE	2	2	centers
NCT0000521310	NCT00005213_10_T0	PHENOTYPE	4	5	cardiovascular morbidity
NCT0000521313	NCT00005213_13_T0	COMPOUND	27	27	sodium
NCT0000521313	NCT00005213_13_T1	CELL	5	5	erythrocytes
NCT0000521313	NCT00005213_13_T2	CELL	7	7	leukocytes
NCT0000521313	NCT00005213_13_T3	BIOLOGICAL_PROCESS	22	22	metabolism
NCT0000521316	NCT00005213_16_T0	COMPOUND	9	9	lithium
NCT0000521316	NCT00005213_16_T1	COMPOUND	8	8	sodium
NCT0000521316	NCT00005213_16_T2	GENE	11	11	LCT
NCT0000521317	NCT00005213_17_T0	GENE	8	8	LCT
NCT0000521319	NCT00005213_19_T0	GENE	7	7	has
NCT0000521319	NCT00005213_19_T1	GENE	3	3	LCT
NCT0000521322	NCT00005213_22_T0	GENE	4	4	LCT
NCT0000521324	NCT00005213_24_T0	GENE	7	7	had
NCT0000521325	NCT00005213_25_T0	GENE	12	12	LCT
NCT0000521327	NCT00005213_27_T0	COMPOUND	39	39	glucose
NCT0000521327	NCT00005213_27_T1	COMPOUND	52	52	calcium
NCT0000521327	NCT00005213_27_T2	GENE	44	44	lipoprotein
NCT0000521327	NCT00005213_27_T3	COMPOUND	14	14	lithium
NCT0000521327	NCT00005213_27_T4	PHENOTYPE	33	33	pulse
NCT0000521327	NCT00005213_27_T5	ORGAN	38	38	serum
NCT0000521327	NCT00005213_27_T6	COMPOUND	46	47	uric acid
NCT0000521328	NCT00005213_28_T0	COMPOUND	10	10	lithium
NCT0000521328	NCT00005213_28_T1	PHENOTYPE	16	16	hypertension
NCT0000521329	NCT00005213_29_T0	CELL	5	5	erythrocytes
NCT0000521329	NCT00005213_29_T1	COMPOUND	0	0	Lithium
NCT000052143	NCT00005214_3_T0	PHENOTYPE	12	13	chronic diseases
NCT000052143	NCT00005214_3_T1	BIOLOGICAL_PROCESS	8	9	lipid metabolism
NCT000052145	NCT00005214_5_T0	PHENOTYPE	31	31	gallstones
NCT000052145	NCT00005214_5_T1	BIOLOGICAL_PROCESS	4	5	lipid metabolism
NCT000052145	NCT00005214_5_T2	PHENOTYPE	11	12	gallbladder disease
NCT000052146	NCT00005214_6_T0	GENE	14	14	lipoprotein
NCT000052146	NCT00005214_6_T1	PHENOTYPE	19	19	attributable
NCT000052146	NCT00005214_6_T2	ORGAN	12	12	plasma
NCT000052147	NCT00005214_7_T0	BIOLOGICAL_PROCESS	24	24	metabolism
NCT000052148	NCT00005214_8_T0	PHENOTYPE	21	22	chronic diseases
NCT0000521411	NCT00005214_11_T0	GENE	19	20	E protein
NCT0000521411	NCT00005214_11_T1	GENE	18	19	apolipoprotein E
NCT0000521411	NCT00005214_11_T2	GENE	12	13	apolipoprotein B
NCT0000521411	NCT00005214_11_T3	PHENOTYPE	4	7	restriction fragment length polymorphisms
NCT0000521412	NCT00005214_12_T0	BIOLOGICAL_PROCESS	15	16	lipid metabolism
NCT0000521412	NCT00005214_12_T1	GENE	4	5	apolipoprotein E
NCT0000521412	NCT00005214_12_T2	GENE	1	2	apolipoprotein B
NCT0000521413	NCT00005214_13_T0	GENE	39	39	apo
NCT0000521413	NCT00005214_13_T1	GENE	42	42	apo
NCT0000521413	NCT00005214_13_T2	GENE	45	45	apo-E
NCT0000521413	NCT00005214_13_T3	GENE	22	23	apolipoprotein B
NCT0000521414	NCT00005214_14_T0	GENE	19	20	apolipoprotein E
NCT0000521414	NCT00005214_14_T1	BIOLOGICAL_PROCESS	6	7	DNA restriction
NCT0000521414	NCT00005214_14_T2	GENE	12	13	apolipoprotein B
NCT0000521415	NCT00005214_15_T0	GENE	13	14	apolipoprotein B
NCT0000521417	NCT00005214_17_T0	BIOLOGICAL_PROCESS	23	24	lipid metabolism
NCT0000521417	NCT00005214_17_T1	GENE	8	9	apolipoprotein E
NCT000052153	NCT00005215_3_T0	GENE	5	5	Dr
NCT000052154	NCT00005215_4_T0	PHENOTYPE	6	6	Circulation
NCT000052156	NCT00005215_6_T0	GENE	13	13	lipoprotein
NCT000052156	NCT00005215_6_T1	GENE	4	4	Dr
NCT000052159	NCT00005215_9_T0	GENE	14	14	lipoprotein
NCT000052159	NCT00005215_9_T1	GENE	5	5	Dr
NCT0000521511	NCT00005215_11_T0	GENE	0	0	Dr
NCT0000521512	NCT00005215_12_T0	PHENOTYPE	7	8	coronary disease
NCT0000521514	NCT00005215_14_T0	GENE	6	6	Dr
NCT0000521515	NCT00005215_15_T0	GENE	11	11	lipoprotein
NCT0000521515	NCT00005215_15_T1	PHENOTYPE	14	15	coronary disease
NCT000052166	NCT00005216_6_T0	PHENOTYPE	8	9	myocardial ischemia
NCT000052167	NCT00005216_7_T0	PHENOTYPE	24	24	outlook
NCT000052167	NCT00005216_7_T1	PHENOTYPE	28	29	coronary disease
NCT000052167	NCT00005216_7_T2	PHENOTYPE	16	17	myocardial ischemia
NCT000052168	NCT00005216_8_T0	GENE	14	14	sparse
NCT000052168	NCT00005216_8_T1	GENE	12	12	scattered
NCT000052169	NCT00005216_9_T0	PHENOTYPE	17	17	acute
NCT0000521610	NCT00005216_10_T0	PHENOTYPE	9	9	generalization
NCT0000521610	NCT00005216_10_T1	PHENOTYPE	6	6	centers
NCT0000521611	NCT00005216_11_T0	PHENOTYPE	11	11	severity
NCT0000521611	NCT00005216_11_T1	PHENOTYPE	24	25	myocardial ischemia
NCT0000521611	NCT00005216_11_T2	PHENOTYPE	16	17	ST depression
NCT0000521612	NCT00005216_12_T0	COMPOUND	19	19	thallium
NCT0000521612	NCT00005216_12_T1	PHENOTYPE	47	48	myocardial ischemia
NCT0000521612	NCT00005216_12_T2	PHENOTYPE	7	9	ST segment depression
NCT0000521614	NCT00005216_14_T0	PHENOTYPE	14	14	symptoms
NCT0000521614	NCT00005216_14_T1	PHENOTYPE	16	17	drug usage
NCT0000521617	NCT00005216_17_T0	PHENOTYPE	26	26	associations
NCT0000521617	NCT00005216_17_T1	PHENOTYPE	30	30	severity
NCT0000521617	NCT00005216_17_T2	COMPOUND	50	50	oxygen
NCT0000521617	NCT00005216_17_T3	PHENOTYPE	65	66	ventricular arrhythmias
NCT0000521617	NCT00005216_17_T4	PHENOTYPE	39	40	myocardial ischemia
NCT0000521617	NCT00005216_17_T5	PHENOTYPE	54	55	myocardial ischemia
NCT0000521617	NCT00005216_17_T6	PHENOTYPE	62	63	myocardial ischemia
NCT0000521617	NCT00005216_17_T7	PHENOTYPE	18	20	coronary heart disease
NCT0000521618	NCT00005216_18_T0	PHENOTYPE	29	30	Myocardial Ischemia
NCT0000521619	NCT00005216_19_T0	TISSUE	24	24	myocardium
NCT0000521619	NCT00005216_19_T1	PHENOTYPE	29	30	cardiac events
NCT0000521621	NCT00005216_21_T0	PHENOTYPE	30	30	regression
NCT0000521621	NCT00005216_21_T1	GENE	14	14	kappa
NCT0000521621	NCT00005216_21_T2	PHENOTYPE	10	11	ST depression
NCT0000521622	NCT00005216_22_T0	PHENOTYPE	2	2	centers
NCT0000521623	NCT00005216_23_T0	COMPOUND	16	16	Thallium
NCT0000521623	NCT00005216_23_T1	PHENOTYPE	22	22	Center
NCT0000521623	NCT00005216_23_T2	GENE	6	6	Lab
NCT0000521623	NCT00005216_23_T3	GENE	10	10	Lab
NCT0000521623	NCT00005216_23_T4	GENE	14	14	Lab
NCT0000521623	NCT00005216_23_T5	GENE	18	18	Lab
NCT000052173	NCT00005217_3_T0	PHENOTYPE	3	3	ischemia
NCT000052173	NCT00005217_3_T1	PHENOTYPE	12	13	ST depression
NCT000052178	NCT00005217_8_T0	GENE	15	15	had
NCT000052178	NCT00005217_8_T1	PHENOTYPE	16	17	myocardial infarction
NCT000052178	NCT00005217_8_T2	PHENOTYPE	3	4	transient ischemia
NCT0000521711	NCT00005217_11_T0	COMPOUND	12	12	propranolol
NCT0000521711	NCT00005217_11_T1	PHENOTYPE	16	18	acute myocardial infarction
NCT0000521713	NCT00005217_13_T0	COMPOUND	12	12	propranolol
NCT0000521713	NCT00005217_13_T1	PHENOTYPE	21	21	asthma
NCT0000521713	NCT00005217_13_T2	GENE	8	8	had
NCT0000521713	NCT00005217_13_T3	GENE	28	28	had
NCT0000521713	NCT00005217_13_T4	PHENOTYPE	17	19	congestive heart failure
NCT0000521715	NCT00005217_15_T0	GENE	13	13	had
NCT0000521717	NCT00005217_17_T0	PHENOTYPE	15	16	myocardial infarction
NCT0000521719	NCT00005217_19_T0	COMPOUND	9	9	propranolol
NCT0000521719	NCT00005217_19_T1	GENE	10	10	has
NCT0000521726	NCT00005217_26_T0	COMPOUND	6	6	propranolol
NCT0000521726	NCT00005217_26_T1	GENE	20	20	had
NCT0000521731	NCT00005217_31_T0	GENE	0	0	Dr
NCT000052182	NCT00005218_2_T0	PHENOTYPE	1	3	coronary heart disease
NCT000052186	NCT00005218_6_T0	PHENOTYPE	12	13	cardiovascular disease
NCT000052194	NCT00005219_4_T0	GENE	5	5	San
NCT000052198	NCT00005219_8_T0	PHENOTYPE	16	16	perceived
NCT000052198	NCT00005219_8_T1	PHENOTYPE	1	1	regression
NCT000052198	NCT00005219_8_T2	PHENOTYPE	13	13	self-efficacy
NCT000052199	NCT00005219_9_T0	GENE	3	3	separated
NCT0000521912	NCT00005219_12_T0	PHENOTYPE	0	1	Cardiovascular Disease
NCT000052200	NCT00005220_0_T0	PHENOTYPE	4	4	Stroke
NCT000052203	NCT00005220_3_T0	ORGAN	5	5	endometrium
NCT000052204	NCT00005220_4_T0	PHENOTYPE	9	10	myocardial infarction
NCT000052207	NCT00005220_7_T0	PHENOTYPE	25	26	myocardial infarction
NCT0000522013	NCT00005220_13_T0	PHENOTYPE	3	3	regression
NCT000052216	NCT00005221_6_T0	GENE	2	2	has
NCT0000522110	NCT00005221_10_T0	GENE	1	1	has
NCT0000522112	NCT00005221_12_T0	PHENOTYPE	38	40	High Blood Pressure
NCT0000522115	NCT00005221_15_T0	BIOLOGICAL_PROCESS	39	39	Aging
NCT0000522115	NCT00005221_15_T1	PHENOTYPE	12	13	Respiratory Disease
NCT0000522116	NCT00005221_16_T0	PHENOTYPE	30	30	regression
NCT0000522116	NCT00005221_16_T1	PHENOTYPE	10	10	fitted
NCT0000522117	NCT00005221_17_T0	PHENOTYPE	40	40	estimation
NCT0000522122	NCT00005221_22_T0	GENE	1	1	has
NCT0000522127	NCT00005221_27_T0	GENE	71	71	K4
NCT0000522127	NCT00005221_27_T1	GENE	86	86	DBF
NCT0000522127	NCT00005221_27_T2	GENE	73	73	K5
NCT0000522127	NCT00005221_27_T3	GENE	85	85	K5
NCT0000522127	NCT00005221_27_T4	PHENOTYPE	43	43	hypertension
NCT0000522127	NCT00005221_27_T5	PHENOTYPE	45	45	obesity
NCT0000522128	NCT00005221_28_T0	PHENOTYPE	9	11	high blood pressure
NCT000052223	NCT00005222_3_T0	PHENOTYPE	4	5	cardiovascular disease
NCT000052227	NCT00005222_7_T0	GENE	8	8	has
NCT000052227	NCT00005222_7_T1	PHENOTYPE	5	6	cardiovascular disease
NCT000052227	NCT00005222_7_T2	PHENOTYPE	14	16	quality of life
NCT000052229	NCT00005222_9_T0	PHENOTYPE	23	24	cardiovascular disease
NCT0000522210	NCT00005222_10_T0	PHENOTYPE	16	16	severity
NCT0000522210	NCT00005222_10_T1	GENE	64	64	reduced
NCT0000522210	NCT00005222_10_T2	PHENOTYPE	49	49	progression
NCT0000522210	NCT00005222_10_T3	PHENOTYPE	61	61	recurrence
NCT0000522210	NCT00005222_10_T4	PHENOTYPE	69	69	sequelae
NCT0000522212	NCT00005222_12_T0	GENE	26	26	had
NCT0000522212	NCT00005222_12_T1	PHENOTYPE	56	56	chronic
NCT0000522213	NCT00005222_13_T0	PHENOTYPE	6	6	recurrent
NCT0000522213	NCT00005222_13_T1	PHENOTYPE	7	8	cardiovascular disease
NCT000052232	NCT00005223_2_T0	PHENOTYPE	0	2	Coronary heart disease
NCT000052234	NCT00005223_4_T0	PHENOTYPE	9	11	coronary heart disease
NCT000052235	NCT00005223_5_T0	PHENOTYPE	14	16	coronary heart disease
NCT000052236	NCT00005223_6_T0	PHENOTYPE	5	7	coronary heart disease
NCT000052237	NCT00005223_7_T0	PHENOTYPE	18	18	atherosclerosis
NCT0000522310	NCT00005223_10_T0	PHENOTYPE	25	27	coronary heart disease
NCT0000522311	NCT00005223_11_T0	PHENOTYPE	11	13	coronary heart disease
NCT0000522313	NCT00005223_13_T0	PHENOTYPE	11	11	Center
NCT0000522315	NCT00005223_15_T0	GENE	8	8	apoprotein
NCT000052245	NCT00005224_5_T0	GENE	13	13	5-1
NCT000052245	NCT00005224_5_T1	PHENOTYPE	5	6	heart disease
NCT000052249	NCT00005224_9_T0	PHENOTYPE	14	16	coronary heart disease
NCT0000522414	NCT00005224_14_T0	PHENOTYPE	19	21	coronary heart disease
NCT0000522415	NCT00005224_15_T0	GENE	26	26	had
NCT0000522415	NCT00005224_15_T1	PHENOTYPE	10	10	hostility
NCT0000522415	NCT00005224_15_T2	PHENOTYPE	7	9	Type A behavior
NCT0000522415	NCT00005224_15_T3	PHENOTYPE	23	25	coronary heart disease
NCT0000522417	NCT00005224_17_T0	ORGAN	7	7	plasma
NCT0000522417	NCT00005224_17_T1	ORGAN	14	14	heart
NCT0000522421	NCT00005224_21_T0	PHENOTYPE	6	7	heart disease
NCT0000522421	NCT00005224_21_T1	PHENOTYPE	8	10	Type A behavior
NCT000052252	NCT00005225_2_T0	PHENOTYPE	28	30	coronary heart disease
NCT000052254	NCT00005225_4_T0	GENE	19	19	had
NCT000052254	NCT00005225_4_T1	PHENOTYPE	16	18	coronary heart disease
NCT000052255	NCT00005225_5_T0	GENE	4	4	had
NCT000052257	NCT00005225_7_T0	PHENOTYPE	25	25	occlusion
NCT000052259	NCT00005225_9_T0	GENE	31	31	apo
NCT000052259	NCT00005225_9_T1	GENE	33	33	apo
NCT000052259	NCT00005225_9_T2	GENE	36	36	apo
NCT000052259	NCT00005225_9_T3	GENE	16	16	HDL
NCT000052259	NCT00005225_9_T4	GENE	18	18	LDL
NCT000052259	NCT00005225_9_T5	GENE	20	20	VLDL
NCT0000522510	NCT00005225_10_T0	GENE	23	23	apo
NCT0000522510	NCT00005225_10_T1	GENE	26	26	apo
NCT0000522510	NCT00005225_10_T2	GENE	27	27	AIV
NCT0000522512	NCT00005225_12_T0	PHENOTYPE	10	10	obesity
NCT0000522513	NCT00005225_13_T0	PHENOTYPE	8	9	cardiovascular disease
NCT0000522514	NCT00005225_14_T0	PHENOTYPE	11	12	coronary disease
NCT000052261	NCT00005226_1_T0	PHENOTYPE	13	13	atherosclerosis
NCT000052264	NCT00005226_4_T0	PHENOTYPE	9	10	cardiovascular disease
NCT000052264	NCT00005226_4_T1	PHENOTYPE	6	7	myocardial infarction
NCT000052268	NCT00005226_8_T0	PHENOTYPE	30	30	peripheral
NCT000052268	NCT00005226_8_T1	PHENOTYPE	24	24	visualization
NCT000052268	NCT00005226_8_T2	ORGAN	20	21	popliteal artery
NCT000052269	NCT00005226_9_T0	PHENOTYPE	13	14	carotid atherosclerosis
NCT0000522612	NCT00005226_12_T0	ORGAN	3	3	plasma
NCT0000522612	NCT00005226_12_T1	ORGAN	16	16	plasma
NCT0000522613	NCT00005226_13_T0	ORGAN	28	28	plasma
NCT0000522615	NCT00005226_15_T0	ORGAN	7	7	plasma
NCT0000522615	NCT00005226_15_T1	ORGAN	11	11	plasma
NCT0000522616	NCT00005226_16_T0	ORGAN	8	8	plasma
NCT0000522616	NCT00005226_16_T1	GENE	1	1	nested
NCT0000522616	NCT00005226_16_T2	PHENOTYPE	16	17	carotid atherosclerosis
NCT0000522617	NCT00005226_17_T0	ORGAN	7	7	plasma
NCT0000522617	NCT00005226_17_T1	PHENOTYPE	16	17	myocardial infarction
NCT000052271	NCT00005227_1_T0	PHENOTYPE	3	3	immunopathology
NCT000052271	NCT00005227_1_T1	TISSUE	12	12	tissues
NCT000052273	NCT00005227_3_T0	PHENOTYPE	10	11	Heart Disease
NCT000052277	NCT00005227_7_T0	PHENOTYPE	16	16	chronic
NCT000052277	NCT00005227_7_T1	PHENOTYPE	18	19	pulmonary infection
NCT000052277	NCT00005227_7_T2	PHENOTYPE	21	23	Pneumocystis carinii pneumonia
NCT000052278	NCT00005227_8_T0	COMPOUND	6	6	trimetrexate
NCT000052279	NCT00005227_9_T0	PHENOTYPE	14	14	complication
NCT000052279	NCT00005227_9_T1	PHENOTYPE	7	8	cardiac diseases
NCT0000522711	NCT00005227_11_T0	PHENOTYPE	4	4	cardiomyopathy
NCT0000522711	NCT00005227_11_T1	PHENOTYPE	16	16	cardiomyopathy
NCT0000522712	NCT00005227_12_T0	PHENOTYPE	6	6	immunopathology
NCT0000522712	NCT00005227_12_T1	TISSUE	13	13	tissues
NCT0000522719	NCT00005227_19_T0	GENE	9	9	sera
NCT0000522719	NCT00005227_19_T1	PHENOTYPE	15	15	autoimmunity
NCT0000522719	NCT00005227_19_T2	ORGAN	14	14	heart
NCT000052282	NCT00005228_2_T0	GENE	34	34	had
NCT000052282	NCT00005228_2_T1	PHENOTYPE	8	8	cardiomyopathy
NCT000052282	NCT00005228_2_T2	PHENOTYPE	12	12	left-sided
NCT000052282	NCT00005228_2_T3	PHENOTYPE	2	3	cardiac tamponade
NCT000052282	NCT00005228_2_T4	PHENOTYPE	0	1	Pericardial effusion
NCT000052282	NCT00005228_2_T5	PHENOTYPE	13	15	congestive heart failure
NCT000052285	NCT00005228_5_T0	CELL	9	9	macrophage
NCT000052285	NCT00005228_5_T1	PHENOTYPE	10	10	immunity
NCT000052285	NCT00005228_5_T2	PHENOTYPE	28	28	immunity
NCT000052285	NCT00005228_5_T3	CELL	8	8	T-cell
NCT000052285	NCT00005228_5_T4	CELL	21	21	lymphocyte
NCT000052285	NCT00005228_5_T5	PHENOTYPE	5	5	profound
NCT000052285	NCT00005228_5_T6	CELL	20	20	B-cell
NCT000052285	NCT00005228_5_T7	PHENOTYPE	6	6	suppression
NCT000052285	NCT00005228_5_T8	PHENOTYPE	34	34	superinfections
NCT000052285	NCT00005228_5_T9	PHENOTYPE	1	2	HIV infection
NCT000052286	NCT00005228_6_T0	PHENOTYPE	18	18	myocarditis
NCT000052286	NCT00005228_6_T1	PHENOTYPE	8	8	cryptococcosis
NCT000052286	NCT00005228_6_T2	PHENOTYPE	43	43	HIV
NCT000052286	NCT00005228_6_T3	PHENOTYPE	9	9	toxoplasmosis
NCT000052286	NCT00005228_6_T4	PHENOTYPE	16	16	pericarditis
NCT000052286	NCT00005228_6_T5	PHENOTYPE	11	11	histoplasmosis
NCT000052286	NCT00005228_6_T6	PHENOTYPE	5	6	herpes simplex
NCT000052286	NCT00005228_6_T7	PHENOTYPE	29	30	myocardial disease
NCT0000522810	NCT00005228_10_T0	PHENOTYPE	11	11	HIV
NCT0000522811	NCT00005228_11_T0	PHENOTYPE	17	18	cardiac abnormalities
NCT0000522811	NCT00005228_11_T1	PHENOTYPE	10	13	drug and alcohol abuse
NCT0000522812	NCT00005228_12_T0	PHENOTYPE	36	36	superinfection
NCT0000522812	NCT00005228_12_T1	PHENOTYPE	7	7	HIV
NCT0000522812	NCT00005228_12_T2	PHENOTYPE	33	34	HIV infection
NCT0000522813	NCT00005228_13_T0	PHENOTYPE	10	11	Heart Disease
NCT0000522816	NCT00005228_16_T0	GENE	14	14	San
NCT0000522819	NCT00005228_19_T0	PHENOTYPE	4	5	cardiac disease
NCT0000522820	NCT00005228_20_T0	GENE	22	22	ventricular
NCT0000522820	NCT00005228_20_T1	PHENOTYPE	10	12	left ventricular failure
NCT000052293	NCT00005229_3_T0	GENE	7	7	had
NCT000052293	NCT00005229_3_T1	GENE	24	24	had
NCT000052293	NCT00005229_3_T2	PHENOTYPE	13	14	heart disease
NCT000052293	NCT00005229_3_T3	PHENOTYPE	16	18	quality of life
NCT000052294	NCT00005229_4_T0	PHENOTYPE	3	3	pathology
NCT000052294	NCT00005229_4_T1	PHENOTYPE	7	8	heart disease
NCT000052294	NCT00005229_4_T2	PHENOTYPE	15	16	cardiac disease
NCT000052295	NCT00005229_5_T0	PHENOTYPE	38	38	HIV
NCT000052295	NCT00005229_5_T1	PHENOTYPE	53	54	disease course
NCT000052295	NCT00005229_5_T2	PHENOTYPE	8	9	heart disease
NCT000052295	NCT00005229_5_T3	PHENOTYPE	15	16	heart disease
NCT000052296	NCT00005229_6_T0	PHENOTYPE	10	11	Heart Disease
NCT0000522910	NCT00005229_10_T0	PHENOTYPE	31	31	Center
NCT0000522910	NCT00005229_10_T1	COMPOUND	22	22	Ampligen
NCT0000522915	NCT00005229_15_T0	PHENOTYPE	25	25	arrhythmias
NCT0000522915	NCT00005229_15_T1	PHENOTYPE	7	8	congestive cardiomyopathy
NCT0000522915	NCT00005229_15_T2	PHENOTYPE	19	20	pericardial effusions
NCT0000522915	NCT00005229_15_T3	PHENOTYPE	14	16	left ventricular dysfunction
NCT0000522917	NCT00005229_17_T0	PHENOTYPE	16	16	HIV
NCT0000522917	NCT00005229_17_T1	PHENOTYPE	8	9	pericardial effusions
NCT0000522920	NCT00005229_20_T0	ORGAN	9	9	heart
NCT0000522920	NCT00005229_20_T1	PHENOTYPE	15	16	HIV infection
NCT0000522921	NCT00005229_21_T0	PHENOTYPE	6	6	HIV
NCT000052303	NCT00005230_3_T0	PHENOTYPE	4	5	systolic hypertension
NCT000052303	NCT00005230_3_T1	PHENOTYPE	13	14	heart attack
NCT000052304	NCT00005230_4_T0	GENE	2	2	has
NCT000052304	NCT00005230_4_T1	PHENOTYPE	14	15	carotid disease
NCT000052304	NCT00005230_4_T2	PHENOTYPE	19	20	arterial disease
NCT000052304	NCT00005230_4_T3	ORGAN	17	18	lower extremity
NCT000052307	NCT00005230_7_T0	GENE	14	14	SHEP
NCT000052307	NCT00005230_7_T1	PHENOTYPE	8	9	Systolic Hypertension
NCT000052308	NCT00005230_8_T0	GENE	3	3	SHEP
NCT0000523010	NCT00005230_10_T0	PHENOTYPE	0	1	Carotid disease
NCT0000523011	NCT00005230_11_T0	GENE	24	24	insulin
NCT0000523011	NCT00005230_11_T1	GENE	21	21	lipoprotein
NCT0000523011	NCT00005230_11_T2	GENE	30	30	hematocrit
NCT0000523011	NCT00005230_11_T3	GENE	28	28	hemoglobin
NCT0000523011	NCT00005230_11_T4	ORGAN	3	3	ankle
NCT0000523011	NCT00005230_11_T5	PHENOTYPE	26	27	glucose levels
NCT0000523011	NCT00005230_11_T6	PHENOTYPE	12	13	arterial disease
NCT0000523011	NCT00005230_11_T7	ORGAN	10	11	lower extremity
NCT0000523015	NCT00005230_15_T0	PHENOTYPE	26	27	disease progression
NCT0000523016	NCT00005230_16_T0	GENE	4	4	FY
NCT0000523016	NCT00005230_16_T1	GENE	11	11	FY
NCT0000523018	NCT00005230_18_T0	PHENOTYPE	12	12	atherosclerosis
NCT0000523018	NCT00005230_18_T1	GENE	16	16	SHEP
NCT0000523019	NCT00005230_19_T0	GENE	7	7	SHEP
NCT0000523020	NCT00005230_20_T0	PHENOTYPE	17	17	pulse
NCT0000523020	NCT00005230_20_T1	PHENOTYPE	27	28	cognitive function
NCT0000523020	NCT00005230_20_T2	PHENOTYPE	9	10	aortic calcification
NCT0000523021	NCT00005230_21_T0	GENE	3	3	SHEP
NCT0000523021	NCT00005230_21_T1	GENE	27	27	SHEP
NCT0000523022	NCT00005230_22_T0	COMPOUND	8	8	calcium
NCT0000523022	NCT00005230_22_T1	ORGAN	23	24	coronary arteries
NCT0000523023	NCT00005230_23_T0	PHENOTYPE	4	4	calcification
NCT0000523024	NCT00005230_24_T0	PHENOTYPE	12	12	atherosclerosis
NCT0000523024	NCT00005230_24_T1	PHENOTYPE	4	5	vascular stiffness
NCT000052310	NCT00005231_0_T0	BIOLOGICAL_PROCESS	0	0	Development
NCT000052314	NCT00005231_4_T0	GENE	3	3	had
NCT000052316	NCT00005231_6_T0	PHENOTYPE	44	45	cardiovascular disease
NCT000052318	NCT00005231_8_T0	PHENOTYPE	9	9	estimation
NCT000052318	NCT00005231_8_T1	PHENOTYPE	35	36	cardiovascular disease
NCT000052319	NCT00005231_9_T0	PHENOTYPE	0	1	Essential hypertension
NCT0000523110	NCT00005231_10_T0	PHENOTYPE	18	18	borderline
NCT0000523110	NCT00005231_10_T1	PHENOTYPE	21	21	hypertension
NCT0000523111	NCT00005231_11_T0	PHENOTYPE	16	18	elevated blood pressure
NCT0000523112	NCT00005231_12_T0	PHENOTYPE	18	18	pathology
NCT0000523112	NCT00005231_12_T1	ORGAN	16	17	nervous system
NCT0000523112	NCT00005231_12_T2	PHENOTYPE	9	11	elevated blood pressure
NCT0000523114	NCT00005231_14_T0	PHENOTYPE	7	9	coronary heart disease
NCT0000523115	NCT00005231_15_T0	PHENOTYPE	27	27	atherosclerosis
NCT0000523115	NCT00005231_15_T1	GENE	17	17	had
NCT0000523115	NCT00005231_15_T2	ORGAN	30	30	heart
NCT0000523115	NCT00005231_15_T3	ORGAN	15	16	coronary arteries
NCT0000523115	NCT00005231_15_T4	PHENOTYPE	35	37	low heart rate
NCT0000523116	NCT00005231_16_T0	PHENOTYPE	15	15	atherosclerosis
NCT0000523116	NCT00005231_16_T1	ORGAN	5	5	heart
NCT0000523116	NCT00005231_16_T2	PHENOTYPE	11	11	arousal
NCT0000523117	NCT00005231_17_T0	GENE	4	4	had
NCT0000523118	NCT00005231_18_T0	GENE	12	12	had
NCT0000523118	NCT00005231_18_T1	PHENOTYPE	21	22	cardiovascular disease
NCT0000523124	NCT00005231_24_T0	PHENOTYPE	25	25	arousal
NCT0000523124	NCT00005231_24_T1	ORGAN	22	24	autonomic nervous system
NCT0000523131	NCT00005231_31_T0	GENE	16	16	ventricular
NCT0000523131	NCT00005231_31_T1	ORGAN	5	5	heart
NCT0000523131	NCT00005231_31_T2	PHENOTYPE	9	10	peripheral resistance
NCT0000523132	NCT00005231_32_T0	PHENOTYPE	12	12	impedance
NCT0000523135	NCT00005231_35_T0	PHENOTYPE	6	6	impedance
NCT000052323	NCT00005232_3_T0	PHENOTYPE	20	21	cardiovascular diseases
NCT000052326	NCT00005232_6_T0	GENE	7	7	di
NCT0000523210	NCT00005232_10_T0	COMPOUND	34	34	glucose
NCT0000523210	NCT00005232_10_T1	COMPOUND	13	13	lithium
NCT0000523210	NCT00005232_10_T2	ORGAN	31	31	plasma
NCT0000523210	NCT00005232_10_T3	COMPOUND	32	33	uric acid
NCT0000523211	NCT00005232_11_T0	COMPOUND	10	10	lithium
NCT0000523213	NCT00005232_13_T0	PHENOTYPE	0	2	Coronary heart disease
NCT000052333	NCT00005233_3_T0	GENE	15	15	had
NCT000052333	NCT00005233_3_T1	GENE	37	37	had
NCT000052335	NCT00005233_5_T0	PHENOTYPE	38	38	hyperlipidemia
NCT000052335	NCT00005233_5_T1	PHENOTYPE	28	28	hypertension
NCT000052335	NCT00005233_5_T2	PHENOTYPE	25	26	cardiovascular disease
NCT000052337	NCT00005233_7_T0	ORGAN	0	0	Plasma
NCT0000523311	NCT00005233_11_T0	ORGAN	7	7	capillary
NCT000052342	NCT00005234_2_T0	PHENOTYPE	14	15	cardiovascular disease
NCT000052343	NCT00005234_3_T0	PHENOTYPE	14	14	hypertension
NCT000052343	NCT00005234_3_T1	PHENOTYPE	17	18	cardiovascular diseases
NCT000052343	NCT00005234_3_T2	PHENOTYPE	11	13	coronary artery disease
NCT000052352	NCT00005235_2_T0	PHENOTYPE	1	2	ventricular arrhythmias
NCT000052352	NCT00005235_2_T1	PHENOTYPE	23	24	ventricular arrhythmias
NCT000052352	NCT00005235_2_T2	ORGAN	27	29	autonomic nervous system
NCT000052352	NCT00005235_2_T3	PHENOTYPE	4	6	coronary heart disease
NCT000052354	NCT00005235_4_T0	PHENOTYPE	9	11	ventricular ejection fraction
NCT000052355	NCT00005235_5_T0	ORGAN	2	2	heart
NCT000052355	NCT00005235_5_T1	ORGAN	12	12	heart
NCT000052355	NCT00005235_5_T2	ORGAN	15	15	heart
NCT000052355	NCT00005235_5_T3	ORGAN	34	36	autonomic nervous system
NCT000052356	NCT00005235_6_T0	ORGAN	13	13	heart
NCT000052356	NCT00005235_6_T1	GENE	4	4	has
NCT000052356	NCT00005235_6_T2	PHENOTYPE	36	37	myocardial infarction
NCT000052356	NCT00005235_6_T3	PHENOTYPE	54	55	ventricular arrhythmias
NCT000052356	NCT00005235_6_T4	PHENOTYPE	49	51	left ventricular dysfunction
NCT000052358	NCT00005235_8_T0	ORGAN	7	7	heart
NCT000052358	NCT00005235_8_T1	ORGAN	10	10	heart
NCT000052359	NCT00005235_9_T0	ORGAN	13	13	heart
NCT000052359	NCT00005235_9_T1	ORGAN	17	17	heart
NCT000052359	NCT00005235_9_T2	PHENOTYPE	23	24	myocardial infarction
NCT0000523511	NCT00005235_11_T0	ORGAN	0	0	Heart
NCT0000523511	NCT00005235_11_T1	ORGAN	3	3	heart
NCT0000523511	NCT00005235_11_T2	PHENOTYPE	28	29	ventricular arrhythmias
NCT0000523511	NCT00005235_11_T3	PHENOTYPE	8	9	myocardial infarction
NCT000052363	NCT00005236_3_T0	ORGAN	9	9	liver
NCT000052363	NCT00005236_3_T1	ORGAN	4	4	aortas
NCT000052363	NCT00005236_3_T2	TISSUE	6	7	adipose tissue
NCT000052363	NCT00005236_3_T3	ORGAN	2	3	Coronary arteries
NCT000052364	NCT00005236_4_T0	PHENOTYPE	21	21	atherosclerosis
NCT000052364	NCT00005236_4_T1	ORGAN	23	23	arteries
NCT000052366	NCT00005236_6_T0	TISSUE	9	9	tissues
NCT000052366	NCT00005236_6_T1	PHENOTYPE	3	5	coronary artery disease
NCT000052367	NCT00005236_7_T0	PHENOTYPE	0	0	Hypertension
NCT000052367	NCT00005236_7_T1	ORGAN	7	7	kidney
NCT000052367	NCT00005236_7_T2	ORGAN	8	8	arterioles
NCT000052369	NCT00005236_9_T0	PHENOTYPE	28	28	Atherosclerosis
NCT000052370	NCT00005237_0_T0	PHENOTYPE	3	3	Arrhythmias
NCT000052373	NCT00005237_3_T0	PHENOTYPE	11	11	tachycardias
NCT000052373	NCT00005237_3_T1	PHENOTYPE	29	29	tachycardias
NCT000052374	NCT00005237_4_T0	PHENOTYPE	13	13	tachycardia
NCT000052374	NCT00005237_4_T1	PHENOTYPE	22	23	paroxysmal tachycardias
NCT000052376	NCT00005237_6_T0	PHENOTYPE	8	9	paroxysmal tachycardias
NCT000052377	NCT00005237_7_T0	PHENOTYPE	14	14	arrhythmias
NCT000052377	NCT00005237_7_T1	PHENOTYPE	7	7	tachycardia
NCT000052378	NCT00005237_8_T0	PHENOTYPE	20	21	supraventricular tachycardia
NCT000052379	NCT00005237_9_T0	GENE	2	2	had
NCT0000523710	NCT00005237_10_T0	PHENOTYPE	6	7	atrial fibrillation
NCT0000523711	NCT00005237_11_T0	PHENOTYPE	21	21	arrhythmia
NCT0000523713	NCT00005237_13_T0	PHENOTYPE	15	15	tachycardia
NCT0000523714	NCT00005237_14_T0	PHENOTYPE	13	13	tachycardia
NCT0000523714	NCT00005237_14_T1	PHENOTYPE	7	8	paroxysmal tachycardias
NCT0000523716	NCT00005237_16_T0	PHENOTYPE	15	15	tachycardia
NCT000052382	NCT00005238_2_T0	PHENOTYPE	6	7	essential hypertension
NCT000052384	NCT00005238_4_T0	PHENOTYPE	25	25	hostility
NCT000052384	NCT00005238_4_T1	PHENOTYPE	21	21	feelings
NCT000052384	NCT00005238_4_T2	PHENOTYPE	6	7	essential hypertension
NCT000052386	NCT00005238_6_T0	PHENOTYPE	19	19	chronic
NCT000052386	NCT00005238_6_T1	PHENOTYPE	20	22	elevated blood pressure
NCT000052387	NCT00005238_7_T0	GENE	3	3	has
NCT000052389	NCT00005238_9_T0	PHENOTYPE	30	30	hypertension
NCT000052389	NCT00005238_9_T1	PHENOTYPE	14	15	essential hypertension
NCT0000523812	NCT00005238_12_T0	PHENOTYPE	27	27	hostility
NCT0000523813	NCT00005238_13_T0	COMPOUND	18	18	sodium
NCT0000523813	NCT00005238_13_T1	PHENOTYPE	11	11	hypertension
NCT0000523813	NCT00005238_13_T2	PHENOTYPE	16	17	cholesterol level
NCT000052390	NCT00005239_0_T0	PHENOTYPE	3	5	Coronary Heart Disease
NCT000052392	NCT00005239_2_T0	GENE	6	6	lipoprotein
NCT000052392	NCT00005239_2_T1	GENE	7	7	LDL
NCT000052392	NCT00005239_2_T2	ORGAN	10	10	plasma
NCT000052392	NCT00005239_2_T3	PHENOTYPE	17	18	serum insulin
NCT000052392	NCT00005239_2_T4	PHENOTYPE	18	19	insulin levels
NCT000052392	NCT00005239_2_T5	TISSUE	13	14	body fat
NCT000052395	NCT00005239_5_T0	GENE	6	6	twins
NCT000052395	NCT00005239_5_T1	PHENOTYPE	17	19	coronary heart disease
NCT000052396	NCT00005239_6_T0	ORGAN	10	10	plasma
NCT000052396	NCT00005239_6_T1	ORGAN	13	13	serum
NCT000052396	NCT00005239_6_T2	ORGAN	30	30	serum
NCT000052396	NCT00005239_6_T3	COMPOUND	31	31	thiocyanate
NCT000052396	NCT00005239_6_T4	COMPOUND	27	28	carbon monoxide
NCT000052399	NCT00005239_9_T0	PHENOTYPE	9	11	coronary heart disease
NCT0000523917	NCT00005239_17_T0	PHENOTYPE	17	18	serum insulin
NCT0000523917	NCT00005239_17_T1	PHENOTYPE	18	19	insulin levels
NCT0000523917	NCT00005239_17_T2	TISSUE	4	5	body fat
NCT0000523917	NCT00005239_17_T3	PHENOTYPE	9	11	coronary heart disease
NCT0000523918	NCT00005239_18_T0	PHENOTYPE	21	22	insulin levels
NCT0000523918	NCT00005239_18_T1	PHENOTYPE	12	14	coronary heart disease
NCT0000523919	NCT00005239_19_T0	GENE	0	0	Lipoprotein
NCT000052401	NCT00005240_1_T0	PHENOTYPE	10	11	hypertensive emergency
NCT000052401	NCT00005240_1_T1	PHENOTYPE	22	23	hypertensive emergency
NCT000052404	NCT00005240_4_T0	PHENOTYPE	14	14	Diseases
NCT000052404	NCT00005240_4_T1	PHENOTYPE	19	20	malignant hypertension
NCT000052404	NCT00005240_4_T2	PHENOTYPE	3	4	hypertensive emergency
NCT000052404	NCT00005240_4_T3	PHENOTYPE	32	33	hypertensive emergency
NCT000052405	NCT00005240_5_T0	GENE	1	1	had
NCT000052405	NCT00005240_5_T1	PHENOTYPE	8	9	hypertensive emergency
NCT000052413	NCT00005241_3_T0	PHENOTYPE	8	8	practices
NCT000052414	NCT00005241_4_T0	PHENOTYPE	0	1	Myocardial infarction
NCT000052414	NCT00005241_4_T1	PHENOTYPE	6	7	cardiovascular disease
NCT000052414	NCT00005241_4_T2	PHENOTYPE	26	27	myocardial infarction
NCT000052416	NCT00005241_6_T0	PHENOTYPE	17	18	myocardial infarction
NCT000052417	NCT00005241_7_T0	PHENOTYPE	18	19	myocardial infarction
NCT000052417	NCT00005241_7_T1	PHENOTYPE	11	12	drug use
NCT0000524111	NCT00005241_11_T0	COMPOUND	12	12	estrogen
NCT0000524112	NCT00005241_12_T0	PHENOTYPE	2	2	regression
NCT0000524112	NCT00005241_12_T1	PHENOTYPE	8	8	regression
NCT000052423	NCT00005242_3_T0	PHENOTYPE	17	19	small airways disease
NCT000052423	NCT00005242_3_T1	PHENOTYPE	12	15	lower respiratory tract infections
NCT000052426	NCT00005242_6_T0	GENE	4	4	twins
NCT000052427	NCT00005242_7_T0	COMPOUND	42	42	cotinine
NCT000052427	NCT00005242_7_T1	GENE	36	36	hematocrit
NCT000052427	NCT00005242_7_T2	COMPOUND	43	43	thiocyanate
NCT000052427	NCT00005242_7_T3	COMPOUND	34	34	oxygen
NCT000052427	NCT00005242_7_T4	GENE	31	31	ventricular
NCT000052427	NCT00005242_7_T5	ORGAN	26	26	heart
NCT000052427	NCT00005242_7_T6	GENE	45	45	erythropoietin
NCT000052430	NCT00005243_0_T0	PHENOTYPE	2	3	Ventricular Arrhythmias
NCT000052433	NCT00005243_3_T0	PHENOTYPE	13	13	pathophysiology
NCT000052433	NCT00005243_3_T1	PHENOTYPE	15	16	myocardial infarction
NCT000052433	NCT00005243_3_T2	PHENOTYPE	35	36	myocardial infarction
NCT000052435	NCT00005243_5_T0	PHENOTYPE	11	13	acute myocardial infarction
NCT000052436	NCT00005243_6_T0	PHENOTYPE	17	18	myocardial infarction
NCT000052437	NCT00005243_7_T0	PHENOTYPE	8	9	myocardial infarction
NCT000052437	NCT00005243_7_T1	PHENOTYPE	14	15	myocardial ischemia
NCT000052437	NCT00005243_7_T2	PHENOTYPE	10	12	sudden cardiac death
NCT0000524310	NCT00005243_10_T0	PHENOTYPE	9	9	Infarct
NCT0000524310	NCT00005243_10_T1	PHENOTYPE	23	24	myocardial infarction
NCT0000524312	NCT00005243_12_T0	GENE	2	2	has
NCT0000524312	NCT00005243_12_T1	PHENOTYPE	15	15	infarct
NCT0000524312	NCT00005243_12_T2	GENE	19	20	creatine kinase
NCT0000524313	NCT00005243_13_T0	PHENOTYPE	9	10	myocardial infarction
NCT0000524314	NCT00005243_14_T0	PHENOTYPE	4	4	infarction
NCT0000524319	NCT00005243_19_T0	GENE	9	9	FY
NCT0000524319	NCT00005243_19_T1	PHENOTYPE	3	4	Ventricular Arrhythmias
NCT0000524321	NCT00005243_21_T0	GENE	14	14	had
NCT0000524321	NCT00005243_21_T1	PHENOTYPE	5	5	Onset
NCT0000524321	NCT00005243_21_T2	PHENOTYPE	3	4	Myocardial Infarction
NCT0000524324	NCT00005243_24_T0	PHENOTYPE	35	35	infarct
NCT0000524327	NCT00005243_27_T0	PHENOTYPE	10	11	myocardial infarction
NCT0000524327	NCT00005243_27_T1	PHENOTYPE	22	23	myocardial infarction
NCT0000524328	NCT00005243_28_T0	PHENOTYPE	19	19	Onset
NCT0000524328	NCT00005243_28_T1	PHENOTYPE	17	18	Myocardial Infarction
NCT0000524329	NCT00005243_29_T0	PHENOTYPE	5	5	pathophysiology
NCT0000524329	NCT00005243_29_T1	PHENOTYPE	31	31	Onset
NCT0000524329	NCT00005243_29_T2	PHENOTYPE	29	30	Myocardial Infarction
NCT0000524329	NCT00005243_29_T3	PHENOTYPE	7	9	acute myocardial infarction
NCT0000524330	NCT00005243_30_T0	PHENOTYPE	17	17	acute
NCT0000524337	NCT00005243_37_T0	GENE	7	7	nested
NCT000052440	NCT00005244_0_T0	PHENOTYPE	4	6	Coronary Heart Disease
NCT000052444	NCT00005244_4_T0	PHENOTYPE	21	21	perceived
NCT000052445	NCT00005244_5_T0	PHENOTYPE	11	11	hostility
NCT000052447	NCT00005244_7_T0	PHENOTYPE	15	15	perceived
NCT000052448	NCT00005244_8_T0	ORGAN	24	24	serum
NCT000052452	NCT00005245_2_T0	PHENOTYPE	6	8	ischemic heart disease
NCT000052457	NCT00005245_7_T0	PHENOTYPE	21	22	cardiovascular disease
NCT000052457	NCT00005245_7_T1	PHENOTYPE	14	16	ischemic heart disease
NCT0000524511	NCT00005245_11_T0	PHENOTYPE	7	9	ischemic heart disease
NCT0000524512	NCT00005245_12_T0	PHENOTYPE	17	19	ischemic heart disease
NCT0000524514	NCT00005245_14_T0	PHENOTYPE	1	1	associations
NCT0000524514	NCT00005245_14_T1	PHENOTYPE	5	6	cardiovascular disease
NCT0000524515	NCT00005245_15_T0	PHENOTYPE	3	3	associations
NCT0000524515	NCT00005245_15_T1	PHENOTYPE	13	13	associations
NCT0000524515	NCT00005245_15_T2	PHENOTYPE	16	17	cardiovascular disease
NCT0000524515	NCT00005245_15_T3	PHENOTYPE	5	7	ischemic heart disease
NCT0000524516	NCT00005245_16_T0	PHENOTYPE	8	8	associations
NCT000052463	NCT00005246_3_T0	GENE	4	4	had
NCT000052463	NCT00005246_3_T1	ORGAN	1	1	serum
NCT000052464	NCT00005246_4_T0	GENE	11	11	extended
NCT000052465	NCT00005246_5_T0	PHENOTYPE	10	10	atherosclerosis
NCT000052465	NCT00005246_5_T1	GENE	3	3	insulin
NCT000052466	NCT00005246_6_T0	ORGAN	2	2	serum
NCT000052466	NCT00005246_6_T1	ORGAN	11	11	serum
NCT000052466	NCT00005246_6_T2	PHENOTYPE	48	49	glucose levels
NCT000052466	NCT00005246_6_T3	PHENOTYPE	23	24	insulin levels
NCT000052466	NCT00005246_6_T4	PHENOTYPE	26	28	coronary heart disease
NCT000052467	NCT00005246_7_T0	COMPOUND	15	15	DHEA
NCT000052467	NCT00005246_7_T1	GENE	0	0	DHEAS
NCT000052467	NCT00005246_7_T2	GENE	7	7	hormone
NCT000052467	NCT00005246_7_T3	GENE	23	24	glucose-6-phosphate dehydrogenase
NCT000052468	NCT00005246_8_T0	PHENOTYPE	15	15	atherosclerosis
NCT000052468	NCT00005246_8_T1	GENE	7	7	DHEAS
NCT000052468	NCT00005246_8_T2	PHENOTYPE	9	9	obesity
NCT000052468	NCT00005246_8_T3	BIOLOGICAL_PROCESS	10	11	lipid metabolism
NCT000052468	NCT00005246_8_T4	PHENOTYPE	12	13	cellular proliferation
NCT0000524610	NCT00005246_10_T0	GENE	6	6	DHEAS
NCT0000524610	NCT00005246_10_T1	BIOLOGICAL_PROCESS	13	13	aging
NCT0000524610	NCT00005246_10_T2	ORGAN	18	18	serum
NCT0000524610	NCT00005246_10_T3	PHENOTYPE	15	15	obesity
NCT0000524610	NCT00005246_10_T4	PHENOTYPE	19	20	cholesterol levels
NCT0000524611	NCT00005246_11_T0	GENE	3	3	nested
NCT0000524611	NCT00005246_11_T1	ORGAN	11	12	blood serum
NCT0000524614	NCT00005246_14_T0	GENE	0	0	DHEAS
NCT0000524615	NCT00005246_15_T0	GENE	7	7	DHEAS
NCT0000524615	NCT00005246_15_T1	GENE	5	5	insulin
NCT0000524616	NCT00005246_16_T0	PHENOTYPE	13	14	myocardial infarction
NCT0000524616	NCT00005246_16_T1	PHENOTYPE	7	9	coronary heart disease
NCT0000524617	NCT00005246_17_T0	GENE	18	18	DHEAS
NCT0000524617	NCT00005246_17_T1	PHENOTYPE	15	16	serum insulin
NCT0000524617	NCT00005246_17_T2	PHENOTYPE	8	10	coronary heart disease
NCT0000524618	NCT00005246_18_T0	GENE	18	18	HDL
NCT0000524618	NCT00005246_18_T1	COMPOUND	30	30	glucose
NCT0000524618	NCT00005246_18_T2	GENE	20	20	LDL
NCT0000524618	NCT00005246_18_T3	ORGAN	7	7	serum
NCT0000524618	NCT00005246_18_T4	ORGAN	16	16	serum
NCT0000524618	NCT00005246_18_T5	COMPOUND	17	17	thiocyanate
NCT0000524620	NCT00005246_20_T0	GENE	5	5	DHEAS
NCT0000524620	NCT00005246_20_T1	GENE	3	3	insulin
NCT0000524620	NCT00005246_20_T2	PHENOTYPE	7	9	coronary heart disease
NCT000052472	NCT00005247_2_T0	PHENOTYPE	5	5	atherosclerosis
NCT000052472	NCT00005247_2_T1	GENE	9	9	has
NCT000052473	NCT00005247_3_T0	PHENOTYPE	42	42	atherosclerosis
NCT000052473	NCT00005247_3_T1	ORGAN	38	38	serum
NCT000052473	NCT00005247_3_T2	PHENOTYPE	8	8	ingestion
NCT000052477	NCT00005247_7_T0	ORGAN	22	22	serum
NCT000052477	NCT00005247_7_T1	PHENOTYPE	26	28	coronary heart disease
NCT000052478	NCT00005247_8_T0	PHENOTYPE	11	11	weaknesses
NCT000052478	NCT00005247_8_T1	ORGAN	15	15	serum
NCT000052479	NCT00005247_9_T0	GENE	78	78	lipoprotein
NCT0000524710	NCT00005247_10_T0	PHENOTYPE	35	35	atherogenesis
NCT0000524710	NCT00005247_10_T1	PHENOTYPE	23	24	heart disease
NCT0000524710	NCT00005247_10_T2	PHENOTYPE	42	43	heart disease
NCT0000524711	NCT00005247_11_T0	PHENOTYPE	3	3	associations
NCT0000524711	NCT00005247_11_T1	PHENOTYPE	13	13	dyslipidemia
NCT0000524711	NCT00005247_11_T2	PHENOTYPE	21	21	overweight
NCT0000524711	NCT00005247_11_T3	PHENOTYPE	17	19	impaired glucose tolerance
NCT0000524711	NCT00005247_11_T4	PHENOTYPE	14	16	elevated blood pressure
NCT0000524712	NCT00005247_12_T0	PHENOTYPE	11	12	cardiovascular morbidity
NCT0000524714	NCT00005247_14_T0	PHENOTYPE	10	10	associations
NCT000052484	NCT00005248_4_T0	ORGAN	2	2	Heart
NCT000052486	NCT00005248_6_T0	PHENOTYPE	18	19	plasma glucose
NCT000052486	NCT00005248_6_T1	PHENOTYPE	23	24	physical disability
NCT000052489	NCT00005248_9_T0	ORGAN	19	19	umbilicus
NCT0000524810	NCT00005248_10_T0	ORGAN	16	16	hips
NCT0000524810	NCT00005248_10_T1	ORGAN	11	11	thigh
NCT0000524814	NCT00005248_14_T0	PHENOTYPE	19	20	cardiovascular disease
NCT0000524814	NCT00005248_14_T1	PHENOTYPE	16	18	coronary heart disease
NCT000052493	NCT00005249_3_T0	GENE	9	9	has
NCT000052493	NCT00005249_3_T1	PHENOTYPE	8	8	hypertension
NCT000052493	NCT00005249_3_T2	MOLECULAR_FUNCTION	4	6	sodium:hydrogen exchange activity
NCT000052494	NCT00005249_4_T0	COMPOUND	12	12	sodium_lithium
NCT000052494	NCT00005249_4_T1	GENE	7	7	insulin
NCT000052494	NCT00005249_4_T2	BIOLOGICAL_PROCESS	3	3	transport
NCT000052498	NCT00005249_8_T0	PHENOTYPE	17	17	regressions
NCT000052499	NCT00005249_9_T0	COMPOUND	48	48	sodium_lithium
NCT000052499	NCT00005249_9_T1	COMPOUND	65	65	calcium
NCT000052499	NCT00005249_9_T2	GENE	18	18	insulin
NCT000052499	NCT00005249_9_T3	GENE	63	63	pH
NCT000052499	NCT00005249_9_T4	PHENOTYPE	11	11	obesity
NCT000052499	NCT00005249_9_T5	BIOLOGICAL_PROCESS	24	25	ion transport
NCT000052499	NCT00005249_9_T6	BIOLOGICAL_PROCESS	29	30	ion transport
NCT000052499	NCT00005249_9_T7	PHENOTYPE	53	55	increased blood pressure
NCT000052504	NCT00005250_4_T0	GENE	17	17	had
NCT000052505	NCT00005250_5_T0	PHENOTYPE	13	15	mode of inheritance
NCT000052512	NCT00005251_2_T0	GENE	15	15	ventricular
NCT000052513	NCT00005251_3_T0	CELL	2	2	cells
NCT000052514	NCT00005251_4_T0	PHENOTYPE	5	5	cardiomyopathy
NCT000052514	NCT00005251_4_T1	GENE	11	11	ventricular
NCT000052514	NCT00005251_4_T2	ORGAN	19	19	heart
NCT000052514	NCT00005251_4_T3	PHENOTYPE	7	8	diastolic dysfunction
NCT000052516	NCT00005251_6_T0	PHENOTYPE	10	10	thromboembolism
NCT000052516	NCT00005251_6_T1	PHENOTYPE	0	0	Complications
NCT000052516	NCT00005251_6_T2	PHENOTYPE	14	15	sudden death
NCT000052516	NCT00005251_6_T3	PHENOTYPE	5	6	atrial fibrillation
NCT000052516	NCT00005251_6_T4	PHENOTYPE	7	9	congestive heart failure
NCT0000525111	NCT00005251_11_T0	PHENOTYPE	16	18	familial hypertrophic cardiomyopathy
NCT0000525111	NCT00005251_11_T1	PHENOTYPE	0	3	Restriction fragment length polymorphism
NCT0000525112	NCT00005251_12_T0	PHENOTYPE	7	9	familial hypertrophic cardiomyopathy
NCT000052523	NCT00005252_3_T0	COMPOUND	15	15	aspirin
NCT000052523	NCT00005252_3_T1	COMPOUND	30	30	aspirin
NCT000052523	NCT00005252_3_T2	PHENOTYPE	36	37	myocardial infarction
NCT000052526	NCT00005252_6_T0	GENE	8	8	AMA
NCT0000525310	NCT00005253_10_T0	PHENOTYPE	16	16	severity
NCT0000525310	NCT00005253_10_T1	PHENOTYPE	18	18	hypertension
NCT0000525313	NCT00005253_13_T0	GENE	7	7	nested
NCT0000525315	NCT00005253_15_T0	PHENOTYPE	17	18	heart disease
NCT0000525317	NCT00005253_17_T0	PHENOTYPE	15	15	severity
NCT0000525317	NCT00005253_17_T1	PHENOTYPE	17	18	heart disease
NCT0000525318	NCT00005253_18_T0	PHENOTYPE	11	12	heart disease
NCT0000525318	NCT00005253_18_T1	PHENOTYPE	26	27	heart disease
NCT0000525321	NCT00005253_21_T0	BIOLOGICAL_PROCESS	12	13	cardiac conduction
NCT0000525321	NCT00005253_21_T1	PHENOTYPE	18	19	drug disposition
NCT000052545	NCT00005254_5_T0	PHENOTYPE	15	15	pulse
NCT000052545	NCT00005254_5_T1	PHENOTYPE	12	13	reactive hyperemia
NCT000052545	NCT00005254_5_T2	PHENOTYPE	3	5	segmental blood pressure
NCT000052550	NCT00005255_0_T0	PHENOTYPE	8	8	Distribution
NCT000052550	NCT00005255_0_T1	PHENOTYPE	0	2	Ischemic Heart Disease
NCT000052555	NCT00005255_5_T0	PHENOTYPE	17	19	ischemic heart disease
NCT000052557	NCT00005255_7_T0	GENE	9	9	abdominal
NCT000052559	NCT00005255_9_T0	PHENOTYPE	9	11	ischemic heart disease
NCT000052563	NCT00005256_3_T0	PHENOTYPE	21	21	plaque
NCT000052563	NCT00005256_3_T1	GENE	7	7	had
NCT000052565	NCT00005256_5_T0	GENE	26	26	3.5
NCT000052565	NCT00005256_5_T1	PHENOTYPE	12	14	coronary heart disease
NCT000052566	NCT00005256_6_T0	PHENOTYPE	20	20	regression
NCT000052572	NCT00005257_2_T0	PHENOTYPE	19	19	dyslipidemia
NCT000052572	NCT00005257_2_T1	PHENOTYPE	18	18	hypertension
NCT000052572	NCT00005257_2_T2	PHENOTYPE	44	45	heart disease
NCT000052572	NCT00005257_2_T3	PHENOTYPE	21	22	glucose intolerance
NCT000052573	NCT00005257_3_T0	PHENOTYPE	18	20	coronary heart disease
NCT000052574	NCT00005257_4_T0	PHENOTYPE	20	22	coronary heart disease
NCT000052583	NCT00005258_3_T0	PHENOTYPE	18	19	cardiovascular malformations
NCT000052587	NCT00005258_7_T0	PHENOTYPE	3	4	cardiac defects
NCT000052588	NCT00005258_8_T0	ORGAN	3	3	heart
NCT000052589	NCT00005258_9_T0	PHENOTYPE	8	8	malformations
NCT0000525810	NCT00005258_10_T0	PHENOTYPE	4	4	centers
NCT000052592	NCT00005259_2_T0	GENE	12	12	has
NCT000052592	NCT00005259_2_T1	PHENOTYPE	4	6	coronary heart disease
NCT000052593	NCT00005259_3_T0	PHENOTYPE	18	20	coronary heart disease
NCT000052596	NCT00005259_6_T0	GENE	2	2	PUFA
NCT000052596	NCT00005259_6_T1	PHENOTYPE	11	13	coronary heart disease
NCT000052597	NCT00005259_7_T0	PHENOTYPE	19	21	coronary heart disease
NCT000052598	NCT00005259_8_T0	PHENOTYPE	15	17	coronary heart disease
NCT0000525911	NCT00005259_11_T0	GENE	4	4	has
NCT0000525928	NCT00005259_28_T0	GENE	2	2	has
NCT000052602	NCT00005260_2_T0	PHENOTYPE	20	20	hostility
NCT000052602	NCT00005260_2_T1	PHENOTYPE	15	16	job strain
NCT000052602	NCT00005260_2_T2	PHENOTYPE	17	19	Type A behavior
NCT000052602	NCT00005260_2_T3	PHENOTYPE	8	10	ischemic heart disease
NCT000052603	NCT00005260_3_T0	PHENOTYPE	12	14	Ischemic Heart Disease
NCT000052604	NCT00005260_4_T0	PHENOTYPE	15	17	ischemic heart disease
NCT000052608	NCT00005260_8_T0	GENE	12	12	II
NCT000052608	NCT00005260_8_T1	ORGAN	6	7	carotid arteries
NCT000052609	NCT00005260_9_T0	PHENOTYPE	10	11	job strain
NCT000052609	NCT00005260_9_T1	PHENOTYPE	12	14	Type A behavior
NCT0000526010	NCT00005260_10_T0	GENE	4	4	II
NCT0000526012	NCT00005260_12_T0	PHENOTYPE	2	4	ischemic heart disease
NCT0000526015	NCT00005260_15_T0	PHENOTYPE	19	19	atherosclerosis
NCT0000526015	NCT00005260_15_T1	PHENOTYPE	34	34	progression
NCT0000526015	NCT00005260_15_T2	PHENOTYPE	23	24	myocardial infarctions
NCT0000526018	NCT00005260_18_T0	GENE	2	2	had
NCT0000526019	NCT00005260_19_T0	GENE	9	9	FY
NCT000052612	NCT00005261_2_T0	GENE	9	9	kallikrein
NCT000052612	NCT00005261_2_T1	PHENOTYPE	19	19	hypertension
NCT000052612	NCT00005261_2_T2	PHENOTYPE	22	23	coronary disease
NCT000052613	NCT00005261_3_T0	GENE	18	18	kallikrein
NCT000052613	NCT00005261_3_T1	PHENOTYPE	11	11	inferred
NCT000052615	NCT00005261_5_T0	PHENOTYPE	20	20	hypertension
NCT000052616	NCT00005261_6_T0	GENE	11	11	structural
NCT000052616	NCT00005261_6_T1	GENE	12	12	kallikrein
NCT000052616	NCT00005261_6_T2	GENE	19	19	kallikrein
NCT000052617	NCT00005261_7_T0	GENE	11	11	twins
NCT000052618	NCT00005261_8_T0	COMPOUND	7	7	prostaglandin
NCT000052618	NCT00005261_8_T1	COMPOUND	5	5	aldosterone
NCT000052618	NCT00005261_8_T2	GENE	4	4	kallikrein
NCT000052618	NCT00005261_8_T3	GENE	16	16	had
NCT000052619	NCT00005261_9_T0	PHENOTYPE	20	20	hypertension
NCT000052622	NCT00005262_2_T0	PHENOTYPE	12	12	symptoms
NCT000052622	NCT00005262_2_T1	PHENOTYPE	6	6	hypertrophic
NCT000052622	NCT00005262_2_T2	PHENOTYPE	19	19	left-sided
NCT000052622	NCT00005262_2_T3	PHENOTYPE	0	1	Dilated cardiomyopathy
NCT000052622	NCT00005262_2_T4	PHENOTYPE	8	9	restrictive cardiomyopathy
NCT000052622	NCT00005262_2_T5	PHENOTYPE	22	24	right-sided heart failure
NCT000052623	NCT00005262_3_T0	PHENOTYPE	12	12	hypertrophy
NCT000052623	NCT00005262_3_T1	CELL	11	11	myocyte
NCT000052623	NCT00005262_3_T2	PHENOTYPE	8	9	myocardial fibrosis
NCT000052624	NCT00005262_4_T0	PHENOTYPE	15	15	secondary
NCT000052624	NCT00005262_4_T1	PHENOTYPE	7	8	generalized disease
NCT000052624	NCT00005262_4_T2	PHENOTYPE	16	17	dilated cardiomyopathy
NCT000052625	NCT00005262_5_T0	PHENOTYPE	3	3	cardiomyopathy
NCT000052625	NCT00005262_5_T1	PHENOTYPE	19	19	cardiomyopathy
NCT000052626	NCT00005262_6_T0	GENE	4	4	had
NCT000052627	NCT00005262_7_T0	PHENOTYPE	6	8	idiopathic dilated cardiomyopathy
NCT000052628	NCT00005262_8_T0	PHENOTYPE	1	1	acute
NCT0000526213	NCT00005262_13_T0	PHENOTYPE	3	3	hypertension
NCT0000526214	NCT00005262_14_T0	PHENOTYPE	9	9	regression
NCT0000526216	NCT00005262_16_T0	PHENOTYPE	0	1	Dilated Cardiomyopathy
NCT0000526217	NCT00005262_17_T0	GENE	0	0	Dr
NCT000052632	NCT00005263_2_T0	PHENOTYPE	15	15	atherosclerosis
NCT000052634	NCT00005263_4_T0	GENE	19	19	LDL
NCT000052634	NCT00005263_4_T1	GENE	24	25	apolipoprotein B
NCT000052635	NCT00005263_5_T0	PHENOTYPE	23	23	concentrations
NCT000052636	NCT00005263_6_T0	PHENOTYPE	11	11	associations
NCT000052636	NCT00005263_6_T1	GENE	3	3	had
NCT0000526311	NCT00005263_11_T0	COMPOUND	15	15	thallium
NCT0000526312	NCT00005263_12_T0	PHENOTYPE	11	11	ingestion
NCT0000526313	NCT00005263_13_T0	ORGAN	0	0	Plasma
NCT0000526313	NCT00005263_13_T1	COMPOUND	9	9	glucose
NCT0000526313	NCT00005263_13_T2	GENE	11	11	insulin
NCT0000526314	NCT00005263_14_T0	GENE	0	0	Apo
NCT0000526314	NCT00005263_14_T1	GENE	4	4	LDL
NCT0000526317	NCT00005263_17_T0	COMPOUND	15	16	vitamin A
NCT0000526319	NCT00005263_19_T0	GENE	8	8	3.5
NCT000052644	NCT00005264_4_T0	PHENOTYPE	29	29	inferred
NCT000052647	NCT00005264_7_T0	ORGAN	9	9	heart
NCT0000526410	NCT00005264_10_T0	PHENOTYPE	6	6	recruitment
NCT0000526412	NCT00005264_12_T0	GENE	2	2	has
NCT0000526412	NCT00005264_12_T1	GENE	0	0	Dr
NCT000052653	NCT00005265_3_T0	PHENOTYPE	13	13	recurrent
NCT000052653	NCT00005265_3_T1	PHENOTYPE	11	12	sudden death
NCT000052653	NCT00005265_3_T2	PHENOTYPE	16	17	myocardial infarction
NCT000052653	NCT00005265_3_T3	PHENOTYPE	20	22	congestive heart failure
NCT000052657	NCT00005265_7_T0	PHENOTYPE	6	6	suffering
NCT000052657	NCT00005265_7_T1	PHENOTYPE	15	15	suffering
NCT000052657	NCT00005265_7_T2	PHENOTYPE	18	18	infarction
NCT000052657	NCT00005265_7_T3	PHENOTYPE	9	10	myocardial infarction
NCT000052662	NCT00005266_2_T0	PHENOTYPE	10	11	chronic diseases
NCT000052673	NCT00005267_3_T0	GENE	1	1	has
NCT000052674	NCT00005267_4_T0	PHENOTYPE	21	21	pathophysiology
NCT000052674	NCT00005267_4_T1	PHENOTYPE	24	24	circulation
NCT000052674	NCT00005267_4_T2	PHENOTYPE	9	11	high blood pressure
NCT000052676	NCT00005267_6_T0	PHENOTYPE	25	25	strategies
NCT000052679	NCT00005267_9_T0	PHENOTYPE	10	12	high blood pressure
NCT0000526712	NCT00005267_12_T0	PHENOTYPE	7	7	Hypertension
NCT0000526712	NCT00005267_12_T1	PHENOTYPE	6	6	Arteriosclerosis
NCT0000526712	NCT00005267_12_T2	BIOLOGICAL_PROCESS	9	10	Lipid Metabolism
NCT0000526716	NCT00005267_16_T0	PHENOTYPE	8	8	centers
NCT0000526718	NCT00005267_18_T0	PHENOTYPE	30	30	centers
NCT0000526719	NCT00005267_19_T0	PHENOTYPE	6	8	left ventricular hypertrophy
NCT0000526720	NCT00005267_20_T0	GENE	11	11	structural
NCT0000526720	NCT00005267_20_T1	GENE	4	4	ventricular
NCT0000526720	NCT00005267_20_T2	GENE	10	10	ventricular
NCT0000526720	NCT00005267_20_T3	PHENOTYPE	23	25	left ventricular hypertrophy
NCT0000526720	NCT00005267_20_T4	PHENOTYPE	28	30	left ventricular hypertrophy
NCT0000526721	NCT00005267_21_T0	GENE	14	14	ventricular
NCT0000526722	NCT00005267_22_T0	GENE	19	19	ventricular
NCT0000526723	NCT00005267_23_T0	COMPOUND	17	17	glucose
NCT0000526723	NCT00005267_23_T1	GENE	16	16	insulin
NCT0000526723	NCT00005267_23_T2	PHENOTYPE	31	31	obesity
NCT0000526723	NCT00005267_23_T3	PHENOTYPE	12	14	left ventricular hypertrophy
NCT0000526726	NCT00005267_26_T0	GENE	10	10	FY
NCT0000526729	NCT00005267_29_T0	PHENOTYPE	23	23	hypertension
NCT0000526730	NCT00005267_30_T0	ORGAN	18	18	heart
NCT0000526730	NCT00005267_30_T1	PHENOTYPE	20	21	kidney diseases
NCT0000526731	NCT00005267_31_T0	PHENOTYPE	26	26	interests
NCT0000526734	NCT00005267_34_T0	PHENOTYPE	15	17	left ventricular hypertrophy
NCT0000526735	NCT00005267_35_T0	PHENOTYPE	0	1	Environmental exposures
NCT0000526737	NCT00005267_37_T0	PHENOTYPE	15	15	hypertension
NCT0000526737	NCT00005267_37_T1	GENE	3	3	extended
NCT0000526738	NCT00005267_38_T0	PHENOTYPE	30	30	complications
NCT0000526738	NCT00005267_38_T1	PHENOTYPE	24	24	hypertension
NCT0000526739	NCT00005267_39_T0	PHENOTYPE	30	30	localizing
NCT0000526739	NCT00005267_39_T1	PHENOTYPE	31	31	hypertension
NCT0000526740	NCT00005267_40_T0	PHENOTYPE	28	28	hypertension
NCT0000526742	NCT00005267_42_T0	PHENOTYPE	32	32	microalbuminuria
NCT0000526742	NCT00005267_42_T1	PHENOTYPE	24	24	complications
NCT0000526742	NCT00005267_42_T2	PHENOTYPE	19	19	reflecting
NCT0000526742	NCT00005267_42_T3	PHENOTYPE	7	7	hypertension
NCT0000526742	NCT00005267_42_T4	PHENOTYPE	26	26	hypertension
NCT0000526742	NCT00005267_42_T5	GENE	29	29	ventricular
NCT0000526743	NCT00005267_43_T0	PHENOTYPE	29	29	complications
NCT0000526743	NCT00005267_43_T1	PHENOTYPE	11	11	hypertension
NCT0000526743	NCT00005267_43_T2	PHENOTYPE	24	24	hypertension
NCT0000526745	NCT00005267_45_T0	PHENOTYPE	0	0	Hypertension
NCT0000526745	NCT00005267_45_T1	PHENOTYPE	21	21	hypertension
NCT0000526745	NCT00005267_45_T2	GENE	6	6	BP
NCT0000526745	NCT00005267_45_T3	GENE	10	10	BP
NCT000052684	NCT00005268_4_T0	GENE	1	1	has
NCT000052685	NCT00005268_5_T0	PHENOTYPE	21	21	pathophysiology
NCT000052685	NCT00005268_5_T1	PHENOTYPE	24	24	circulation
NCT000052685	NCT00005268_5_T2	PHENOTYPE	9	11	high blood pressure
NCT000052687	NCT00005268_7_T0	PHENOTYPE	25	25	strategies
NCT0000526810	NCT00005268_10_T0	PHENOTYPE	10	12	high blood pressure
NCT0000526813	NCT00005268_13_T0	PHENOTYPE	7	7	Hypertension
NCT0000526813	NCT00005268_13_T1	PHENOTYPE	6	6	Arteriosclerosis
NCT0000526813	NCT00005268_13_T2	BIOLOGICAL_PROCESS	9	10	Lipid Metabolism
NCT0000526817	NCT00005268_17_T0	PHENOTYPE	7	7	centers
NCT0000526817	NCT00005268_17_T1	PHENOTYPE	10	10	centers
NCT0000526819	NCT00005268_19_T0	PHENOTYPE	15	15	hypertension
NCT0000526824	NCT00005268_24_T0	PHENOTYPE	15	15	hypertension
NCT0000526826	NCT00005268_26_T0	PHENOTYPE	12	12	hypertension
NCT0000526829	NCT00005268_29_T0	PHENOTYPE	23	23	hypertension
NCT0000526830	NCT00005268_30_T0	ORGAN	18	18	heart
NCT0000526830	NCT00005268_30_T1	PHENOTYPE	20	21	kidney diseases
NCT0000526831	NCT00005268_31_T0	PHENOTYPE	26	26	interests
NCT0000526832	NCT00005268_32_T0	GENE	3	3	has
NCT0000526833	NCT00005268_33_T0	PHENOTYPE	15	15	strains
NCT0000526834	NCT00005268_34_T0	PHENOTYPE	24	24	hypertension
NCT0000526835	NCT00005268_35_T0	PHENOTYPE	30	30	complications
NCT0000526835	NCT00005268_35_T1	PHENOTYPE	24	24	hypertension
NCT0000526836	NCT00005268_36_T0	PHENOTYPE	30	30	localizing
NCT0000526836	NCT00005268_36_T1	PHENOTYPE	31	31	hypertension
NCT0000526837	NCT00005268_37_T0	PHENOTYPE	28	28	hypertension
NCT0000526839	NCT00005268_39_T0	PHENOTYPE	32	32	microalbuminuria
NCT0000526839	NCT00005268_39_T1	PHENOTYPE	24	24	complications
NCT0000526839	NCT00005268_39_T2	PHENOTYPE	19	19	reflecting
NCT0000526839	NCT00005268_39_T3	PHENOTYPE	7	7	hypertension
NCT0000526839	NCT00005268_39_T4	PHENOTYPE	26	26	hypertension
NCT0000526839	NCT00005268_39_T5	GENE	29	29	ventricular
NCT0000526840	NCT00005268_40_T0	PHENOTYPE	29	29	complications
NCT0000526840	NCT00005268_40_T1	PHENOTYPE	11	11	hypertension
NCT0000526840	NCT00005268_40_T2	PHENOTYPE	24	24	hypertension
NCT000052693	NCT00005269_3_T0	GENE	1	1	has
NCT000052694	NCT00005269_4_T0	PHENOTYPE	21	21	pathophysiology
NCT000052694	NCT00005269_4_T1	PHENOTYPE	24	24	circulation
NCT000052694	NCT00005269_4_T2	PHENOTYPE	9	11	high blood pressure
NCT000052696	NCT00005269_6_T0	PHENOTYPE	25	25	strategies
NCT000052699	NCT00005269_9_T0	PHENOTYPE	10	12	high blood pressure
NCT0000526912	NCT00005269_12_T0	PHENOTYPE	7	7	Hypertension
NCT0000526912	NCT00005269_12_T1	PHENOTYPE	6	6	Arteriosclerosis
NCT0000526912	NCT00005269_12_T2	BIOLOGICAL_PROCESS	9	10	Lipid Metabolism
NCT0000526916	NCT00005269_16_T0	PHENOTYPE	8	8	Arteriopathy
NCT0000526916	NCT00005269_16_T1	PHENOTYPE	16	16	centers
NCT0000526916	NCT00005269_16_T2	PHENOTYPE	38	39	essential hypertension
NCT0000526916	NCT00005269_16_T3	PHENOTYPE	32	33	individual differences
NCT0000526919	NCT00005269_19_T0	PHENOTYPE	12	12	localize
NCT0000526919	NCT00005269_19_T1	PHENOTYPE	19	21	high blood pressure
NCT0000526920	NCT00005269_20_T0	PHENOTYPE	24	24	localize
NCT0000526920	NCT00005269_20_T1	PHENOTYPE	33	34	essential hypertension
NCT0000526921	NCT00005269_21_T0	ORGAN	25	25	Heart
NCT0000526921	NCT00005269_21_T1	PHENOTYPE	28	28	localize
NCT0000526921	NCT00005269_21_T2	PHENOTYPE	32	33	essential hypertension
NCT0000526922	NCT00005269_22_T0	GENE	4	4	1.3
NCT0000526923	NCT00005269_23_T0	GENE	35	35	BP
NCT0000526923	NCT00005269_23_T1	PHENOTYPE	38	39	essential hypertension
NCT0000526924	NCT00005269_24_T0	PHENOTYPE	13	14	essential hypertension
NCT0000526925	NCT00005269_25_T0	GENE	10	10	lines
NCT0000526926	NCT00005269_26_T0	PHENOTYPE	22	24	coronary artery calcification
NCT0000526926	NCT00005269_26_T1	PHENOTYPE	11	13	coronary heart disease
NCT0000526927	NCT00005269_27_T0	PHENOTYPE	32	34	coronary artery calcification
NCT0000526928	NCT00005269_28_T0	PHENOTYPE	34	36	coronary artery calcification
NCT0000526929	NCT00005269_29_T0	PHENOTYPE	17	17	localize
NCT0000526929	NCT00005269_29_T1	PHENOTYPE	10	10	regression
NCT0000526929	NCT00005269_29_T2	GENE	5	5	extended
NCT0000526930	NCT00005269_30_T0	GENE	11	11	FY
NCT0000526930	NCT00005269_30_T1	PHENOTYPE	26	26	hypertension
NCT0000526931	NCT00005269_31_T0	PHENOTYPE	30	30	complications
NCT0000526931	NCT00005269_31_T1	PHENOTYPE	24	24	hypertension
NCT0000526932	NCT00005269_32_T0	PHENOTYPE	30	30	localizing
NCT0000526932	NCT00005269_32_T1	PHENOTYPE	31	31	hypertension
NCT0000526933	NCT00005269_33_T0	PHENOTYPE	28	28	hypertension
NCT0000526935	NCT00005269_35_T0	PHENOTYPE	32	32	microalbuminuria
NCT0000526935	NCT00005269_35_T1	PHENOTYPE	24	24	complications
NCT0000526935	NCT00005269_35_T2	PHENOTYPE	19	19	reflecting
NCT0000526935	NCT00005269_35_T3	PHENOTYPE	7	7	hypertension
NCT0000526935	NCT00005269_35_T4	PHENOTYPE	26	26	hypertension
NCT0000526935	NCT00005269_35_T5	GENE	29	29	ventricular
NCT0000526936	NCT00005269_36_T0	PHENOTYPE	29	29	complications
NCT0000526936	NCT00005269_36_T1	PHENOTYPE	11	11	hypertension
NCT0000526936	NCT00005269_36_T2	PHENOTYPE	24	24	hypertension
NCT000052704	NCT00005270_4_T0	GENE	1	1	has
NCT000052705	NCT00005270_5_T0	PHENOTYPE	21	21	pathophysiology
NCT000052705	NCT00005270_5_T1	PHENOTYPE	24	24	circulation
NCT000052705	NCT00005270_5_T2	PHENOTYPE	9	11	high blood pressure
NCT000052707	NCT00005270_7_T0	PHENOTYPE	25	25	strategies
NCT0000527010	NCT00005270_10_T0	PHENOTYPE	10	12	high blood pressure
NCT0000527013	NCT00005270_13_T0	PHENOTYPE	7	7	Hypertension
NCT0000527013	NCT00005270_13_T1	PHENOTYPE	6	6	Arteriosclerosis
NCT0000527013	NCT00005270_13_T2	BIOLOGICAL_PROCESS	9	10	Lipid Metabolism
NCT0000527017	NCT00005270_17_T0	PHENOTYPE	4	5	focused attention
NCT0000527018	NCT00005270_18_T0	GENE	9	9	San
NCT0000527024	NCT00005270_24_T0	PHENOTYPE	25	25	hypertension
NCT0000527025	NCT00005270_25_T0	PHENOTYPE	22	22	hyperinsulinemia
NCT0000527025	NCT00005270_25_T1	GENE	6	6	had
NCT0000527025	NCT00005270_25_T2	PHENOTYPE	16	16	Syndrome
NCT0000527025	NCT00005270_25_T3	PHENOTYPE	12	12	dyslipidemia
NCT0000527025	NCT00005270_25_T4	PHENOTYPE	11	11	hypertension
NCT0000527025	NCT00005270_25_T5	PHENOTYPE	14	15	glucose intolerance
NCT0000527026	NCT00005270_26_T0	GENE	24	24	II
NCT0000527026	NCT00005270_26_T1	GENE	22	22	renin
NCT0000527026	NCT00005270_26_T2	PHENOTYPE	19	19	pathophysiology
NCT0000527026	NCT00005270_26_T3	GENE	23	23	Ang
NCT0000527026	NCT00005270_26_T4	PHENOTYPE	1	1	hypertension
NCT0000527026	NCT00005270_26_T5	PHENOTYPE	18	18	hypertension
NCT0000527026	NCT00005270_26_T6	PHENOTYPE	6	7	insulin sensitivity
NCT0000527027	NCT00005270_27_T0	PHENOTYPE	22	22	hypertension
NCT0000527028	NCT00005270_28_T0	BIOLOGICAL_PROCESS	28	28	meiosis
NCT0000527028	NCT00005270_28_T1	PHENOTYPE	13	13	hypertension
NCT0000527031	NCT00005270_31_T0	GENE	29	29	had
NCT0000527032	NCT00005270_32_T0	GENE	12	12	FY
NCT0000527035	NCT00005270_35_T0	PHENOTYPE	23	23	hypertension
NCT0000527036	NCT00005270_36_T0	ORGAN	18	18	heart
NCT0000527036	NCT00005270_36_T1	PHENOTYPE	20	21	kidney diseases
NCT0000527037	NCT00005270_37_T0	PHENOTYPE	26	26	interests
NCT0000527038	NCT00005270_38_T0	PHENOTYPE	27	28	plasma glucose
NCT0000527038	NCT00005270_38_T1	PHENOTYPE	21	22	glucose tolerance
NCT0000527038	NCT00005270_38_T2	PHENOTYPE	16	17	insulin resistance
NCT0000527039	NCT00005270_39_T0	ORGAN	27	27	plasma
NCT0000527040	NCT00005270_40_T0	PHENOTYPE	25	25	hypertension
NCT0000527041	NCT00005270_41_T0	PHENOTYPE	30	30	complications
NCT0000527041	NCT00005270_41_T1	PHENOTYPE	24	24	hypertension
NCT0000527042	NCT00005270_42_T0	PHENOTYPE	30	30	localizing
NCT0000527042	NCT00005270_42_T1	PHENOTYPE	31	31	hypertension
NCT0000527043	NCT00005270_43_T0	PHENOTYPE	28	28	hypertension
NCT0000527045	NCT00005270_45_T0	PHENOTYPE	32	32	microalbuminuria
NCT0000527045	NCT00005270_45_T1	PHENOTYPE	24	24	complications
NCT0000527045	NCT00005270_45_T2	PHENOTYPE	19	19	reflecting
NCT0000527045	NCT00005270_45_T3	PHENOTYPE	7	7	hypertension
NCT0000527045	NCT00005270_45_T4	PHENOTYPE	26	26	hypertension
NCT0000527045	NCT00005270_45_T5	GENE	29	29	ventricular
NCT0000527046	NCT00005270_46_T0	PHENOTYPE	29	29	complications
NCT0000527046	NCT00005270_46_T1	PHENOTYPE	11	11	hypertension
NCT0000527046	NCT00005270_46_T2	PHENOTYPE	24	24	hypertension
NCT000052713	NCT00005271_3_T0	PHENOTYPE	19	19	hypertension
NCT000052715	NCT00005271_5_T0	PHENOTYPE	6	6	centers
NCT000052716	NCT00005271_6_T0	COMPOUND	26	26	caffeine
NCT000052716	NCT00005271_6_T1	COMPOUND	21	21	calcium
NCT000052716	NCT00005271_6_T2	COMPOUND	22	22	magnesium
NCT000052717	NCT00005271_7_T0	COMPOUND	63	63	starch
NCT000052717	NCT00005271_7_T1	COMPOUND	9	9	BMI
NCT000052718	NCT00005271_8_T0	COMPOUND	12	12	sodium
NCT000052718	NCT00005271_8_T1	COMPOUND	13	13	potassium
NCT000052718	NCT00005271_8_T2	COMPOUND	14	14	creatine
NCT000052718	NCT00005271_8_T3	COMPOUND	16	16	urea
NCT0000527112	NCT00005271_12_T0	PHENOTYPE	22	22	Center
NCT0000527113	NCT00005271_13_T0	PHENOTYPE	11	11	Center
NCT0000527114	NCT00005271_14_T0	PHENOTYPE	0	0	Recruitment
NCT0000527115	NCT00005271_15_T0	PHENOTYPE	7	7	regression
NCT0000527116	NCT00005271_16_T0	GENE	5	5	FY
NCT0000527116	NCT00005271_16_T1	GENE	9	9	FY
NCT000052721	NCT00005272_1_T0	GENE	22	22	II
NCT000052721	NCT00005272_1_T1	COMPOUND	13	13	glucose
NCT000052724	NCT00005272_4_T0	GENE	10	10	ANOVA
NCT000052725	NCT00005272_5_T0	GENE	10	10	II
NCT000052725	NCT00005272_5_T1	COMPOUND	25	25	glucose
NCT000052730	NCT00005273_0_T0	PHENOTYPE	0	1	Pulmonary Complications
NCT000052730	NCT00005273_0_T1	PHENOTYPE	3	4	HIV Infection
NCT000052734	NCT00005273_4_T0	GENE	9	9	had
NCT000052734	NCT00005273_4_T1	PHENOTYPE	23	24	pulmonary complications
NCT000052734	NCT00005273_4_T2	PHENOTYPE	27	28	HIV infection
NCT000052735	NCT00005273_5_T0	PHENOTYPE	23	23	tuberculosis
NCT000052735	NCT00005273_5_T1	PHENOTYPE	11	11	infections
NCT000052735	NCT00005273_5_T2	GENE	24	24	had
NCT000052737	NCT00005273_7_T0	PHENOTYPE	1	2	interstitial pneumonitis
NCT000052738	NCT00005273_8_T0	PHENOTYPE	0	1	Legionella pneumonia
NCT000052739	NCT00005273_9_T0	PHENOTYPE	7	7	tuberculosis
NCT000052739	NCT00005273_9_T1	GENE	20	20	had
NCT000052739	NCT00005273_9_T2	PHENOTYPE	18	19	pulmonary complications
NCT0000527314	NCT00005273_14_T0	GENE	10	10	FY
NCT0000527314	NCT00005273_14_T1	GENE	3	3	extended
NCT0000527317	NCT00005273_17_T0	PHENOTYPE	10	11	lung diseases
NCT0000527317	NCT00005273_17_T1	PHENOTYPE	16	17	HIV infection
NCT0000527318	NCT00005273_18_T0	PHENOTYPE	2	2	centers
NCT0000527319	NCT00005273_19_T0	PHENOTYPE	30	30	strategies
NCT0000527319	NCT00005273_19_T1	PHENOTYPE	7	8	pulmonary disease
NCT0000527319	NCT00005273_19_T2	PHENOTYPE	0	1	HIV seropositive
NCT0000527323	NCT00005273_23_T0	PHENOTYPE	11	11	complications
NCT0000527323	NCT00005273_23_T1	PHENOTYPE	31	31	HIV
NCT0000527323	NCT00005273_23_T2	GENE	16	16	had
NCT000052746	NCT00005274_6_T0	PHENOTYPE	8	9	cardiac disorders
NCT000052748	NCT00005274_8_T0	GENE	21	21	II
NCT000052748	NCT00005274_8_T1	GENE	13	14	Group I
NCT000052749	NCT00005274_9_T0	GENE	30	30	The
NCT000052749	NCT00005274_9_T1	PHENOTYPE	16	16	recruitment
NCT000052749	NCT00005274_9_T2	PHENOTYPE	29	29	illnesses
NCT0000527514	NCT00005275_14_T0	PHENOTYPE	14	15	cardiovascular disease
NCT0000527515	NCT00005275_15_T0	PHENOTYPE	22	23	cerebrovascular disease
NCT0000527515	NCT00005275_15_T1	PHENOTYPE	12	14	coronary heart disease
NCT0000527515	NCT00005275_15_T2	PHENOTYPE	8	10	acute myocardial infarction
NCT0000527516	NCT00005275_16_T0	PHENOTYPE	7	7	hypertension
NCT0000527516	NCT00005275_16_T1	PHENOTYPE	18	20	quality of life
NCT0000527518	NCT00005275_18_T0	PHENOTYPE	7	8	cognitive functioning
NCT000052761	NCT00005276_1_T0	PHENOTYPE	7	7	sarcoidosis
NCT000052762	NCT00005276_2_T0	PHENOTYPE	7	7	sarcoidosis
NCT000052762	NCT00005276_2_T1	ORGAN	29	29	plasma
NCT000052762	NCT00005276_2_T2	ORGAN	31	31	serum
NCT000052762	NCT00005276_2_T3	CELL	27	28	blood cells
NCT000052767	NCT00005276_7_T0	PHENOTYPE	3	4	chronic disease
NCT000052768	NCT00005276_8_T0	PHENOTYPE	12	12	sarcoidosis
NCT000052769	NCT00005276_9_T0	PHENOTYPE	14	14	sarcoidosis
NCT0000527613	NCT00005276_13_T0	PHENOTYPE	10	10	sarcoidosis
NCT0000527616	NCT00005276_16_T0	PHENOTYPE	15	15	sarcoidosis
NCT0000527617	NCT00005276_17_T0	PHENOTYPE	4	4	sarcoidosis
NCT0000527618	NCT00005276_18_T0	PHENOTYPE	36	36	recurrence
NCT0000527618	NCT00005276_18_T1	PHENOTYPE	5	5	sarcoidosis
NCT0000527618	NCT00005276_18_T2	GENE	16	16	has
NCT0000527618	NCT00005276_18_T3	GENE	29	29	has
NCT0000527618	NCT00005276_18_T4	GENE	40	40	has
NCT0000527618	NCT00005276_18_T5	PHENOTYPE	15	15	alveolitis
NCT0000527618	NCT00005276_18_T6	PHENOTYPE	21	22	granulomatous inflammation
NCT0000527618	NCT00005276_18_T7	PHENOTYPE	38	39	granulomatous inflammation
NCT000052770	NCT00005277_0_T0	PHENOTYPE	7	9	Sickle Cell Disease
NCT000052774	NCT00005277_4_T0	PHENOTYPE	8	8	symptoms
NCT000052775	NCT00005277_5_T0	PHENOTYPE	19	19	acute
NCT000052775	NCT00005277_5_T1	PHENOTYPE	20	20	illnesses
NCT000052777	NCT00005277_7_T0	PHENOTYPE	14	14	remissions
NCT0000527710	NCT00005277_10_T0	PHENOTYPE	13	13	severity
NCT0000527713	NCT00005277_13_T0	PHENOTYPE	1	2	Hemolytic Disease
NCT0000527713	NCT00005277_13_T1	PHENOTYPE	9	10	Blood Diseases
NCT0000527714	NCT00005277_14_T0	PHENOTYPE	2	4	Sickle Cell Disease
NCT0000527715	NCT00005277_15_T0	PHENOTYPE	10	11	Blood Diseases
NCT0000527719	NCT00005277_19_T0	GENE	1	1	II
NCT0000527720	NCT00005277_20_T0	GENE	5	5	extended
NCT0000527726	NCT00005277_26_T0	PHENOTYPE	44	44	centers
NCT0000527726	NCT00005277_26_T1	GENE	5	5	had
NCT0000527733	NCT00005277_33_T0	TISSUE	5	5	spleen
NCT0000527733	NCT00005277_33_T1	ORGAN	9	9	liver
NCT0000527733	NCT00005277_33_T2	ORGAN	4	4	lungs
NCT0000527733	NCT00005277_33_T3	ORGAN	6	6	kidneys
NCT0000527733	NCT00005277_33_T4	ORGAN	7	7	eyes
NCT000052784	NCT00005278_4_T0	PHENOTYPE	17	18	blood supply
NCT000052787	NCT00005278_7_T0	PHENOTYPE	2	2	transforming
NCT000052789	NCT00005278_9_T0	PHENOTYPE	11	11	malignancy
NCT000052789	NCT00005278_9_T1	GENE	14	14	ATL
NCT000052789	NCT00005278_9_T2	CELL	10	10	T-cell
NCT0000527810	NCT00005278_10_T0	PHENOTYPE	14	15	T-cell lymphoma/leukemia
NCT0000527815	NCT00005278_15_T0	GENE	18	18	T4
NCT0000527815	NCT00005278_15_T1	GENE	19	19	CD4
NCT0000527815	NCT00005278_15_T2	CELL	20	20	lymphocytes
NCT0000527815	NCT00005278_15_T3	PHENOTYPE	10	10	HIV
NCT0000527815	NCT00005278_15_T4	CELL	26	26	T-cell
NCT0000527816	NCT00005278_16_T0	PHENOTYPE	8	8	proliferation
NCT0000527816	NCT00005278_16_T1	CELL	22	22	T-cell
NCT0000527816	NCT00005278_16_T2	GENE	29	29	CD4
NCT0000527816	NCT00005278_16_T3	CELL	30	30	cells
NCT0000527816	NCT00005278_16_T4	PHENOTYPE	18	18	HIV
NCT0000527816	NCT00005278_16_T5	PHENOTYPE	14	15	T-cell lymphoma/leukemia
NCT0000527816	NCT00005278_16_T6	CELL	10	11	T Lymphocytes
NCT0000527817	NCT00005278_17_T0	PHENOTYPE	3	3	HIV
NCT0000527818	NCT00005278_18_T0	PHENOTYPE	7	7	HIV
NCT0000527819	NCT00005278_19_T0	CELL	4	4	platelets
NCT0000527819	NCT00005278_19_T1	CELL	1	3	red blood cells
NCT0000527819	NCT00005278_19_T2	ORGAN	6	8	fresh frozen plasma
NCT0000527820	NCT00005278_20_T0	PHENOTYPE	15	15	HIV
NCT0000527822	NCT00005278_22_T0	PHENOTYPE	18	18	HIV
NCT0000527822	NCT00005278_22_T1	PHENOTYPE	27	28	blood supply
NCT0000527825	NCT00005278_25_T0	PHENOTYPE	11	11	exposures
NCT0000527825	NCT00005278_25_T1	PHENOTYPE	34	34	HIV
NCT0000527825	NCT00005278_25_T2	PHENOTYPE	15	16	retroviral infection
NCT0000527825	NCT00005278_25_T3	PHENOTYPE	24	25	drug use
NCT0000527828	NCT00005278_28_T0	PHENOTYPE	11	11	centers
NCT0000527828	NCT00005278_28_T1	GENE	16	16	had
NCT0000527829	NCT00005278_29_T0	GENE	10	10	had
NCT0000527830	NCT00005278_30_T0	PHENOTYPE	4	4	infections
NCT000052794	NCT00005279_4_T0	PHENOTYPE	9	9	bronchitis
NCT000052794	NCT00005279_4_T1	PHENOTYPE	12	12	asthma
NCT000052794	NCT00005279_4_T2	PHENOTYPE	7	7	COLD
NCT000052794	NCT00005279_4_T3	PHENOTYPE	3	3	chronic
NCT000052794	NCT00005279_4_T4	PHENOTYPE	10	10	emphysema
NCT000052794	NCT00005279_4_T5	PHENOTYPE	4	6	obstructive lung diseases
NCT000052795	NCT00005279_5_T0	GENE	8	8	had
NCT000052795	NCT00005279_5_T1	PHENOTYPE	7	7	emphysema
NCT000052798	NCT00005279_8_T0	GENE	5	5	had
NCT000052799	NCT00005279_9_T0	PHENOTYPE	27	27	diseases
NCT0000527910	NCT00005279_10_T0	GENE	10	10	span
NCT0000527910	NCT00005279_10_T1	PHENOTYPE	23	25	obstructive lung disease
NCT0000527912	NCT00005279_12_T0	PHENOTYPE	15	18	chronic obstructive lung disease
NCT0000527913	NCT00005279_13_T0	ORGAN	10	11	respiratory tract
NCT0000527914	NCT00005279_14_T0	PHENOTYPE	14	14	disorders
NCT0000527916	NCT00005279_16_T0	PHENOTYPE	17	19	chronic respiratory disease
NCT0000527916	NCT00005279_16_T1	PHENOTYPE	11	14	lower respiratory tract infections
NCT0000527918	NCT00005279_18_T0	GENE	4	4	had
NCT0000527921	NCT00005279_21_T0	GENE	6	6	alpha-1-antitrypsin
NCT0000527922	NCT00005279_22_T0	PHENOTYPE	3	4	allergy skin
NCT0000527925	NCT00005279_25_T0	PHENOTYPE	15	16	Chronic Diseases
NCT0000527929	NCT00005279_29_T0	PHENOTYPE	0	0	Cord
NCT0000527930	NCT00005279_30_T0	PHENOTYPE	13	13	illnesses
NCT0000527930	NCT00005279_30_T1	ORGAN	11	12	respiratory tract
NCT0000527931	NCT00005279_31_T0	PHENOTYPE	12	12	mycoplasma
NCT0000527931	NCT00005279_31_T1	ORGAN	2	3	respiratory tract
NCT000052803	NCT00005280_3_T0	PHENOTYPE	3	3	Exposures
NCT000052803	NCT00005280_3_T1	COMPOUND	35	35	formaldehyde
NCT000052803	NCT00005280_3_T2	COMPOUND	27	27	ammonia
NCT000052803	NCT00005280_3_T3	COMPOUND	29	29	phosgene
NCT000052803	NCT00005280_3_T4	COMPOUND	28	28	chlorine
NCT000052803	NCT00005280_3_T5	COMPOUND	33	34	nitrous oxide
NCT000052803	NCT00005280_3_T6	PHENOTYPE	10	11	lung function
NCT000052806	NCT00005280_6_T0	PHENOTYPE	15	15	silicosis
NCT000052806	NCT00005280_6_T1	COMPOUND	29	29	chloride
NCT000052806	NCT00005280_6_T2	PHENOTYPE	14	14	asbestosis
NCT000052809	NCT00005280_9_T0	PHENOTYPE	3	4	chemical accidents
NCT0000528010	NCT00005280_10_T0	PHENOTYPE	24	24	accidents
NCT0000528010	NCT00005280_10_T1	PHENOTYPE	10	11	chemical accidents
NCT0000528012	NCT00005280_12_T0	PHENOTYPE	10	12	acute lung injury
NCT0000528013	NCT00005280_13_T0	PHENOTYPE	0	0	Byssinosis
NCT0000528013	NCT00005280_13_T1	GENE	1	1	has
NCT0000528013	NCT00005280_13_T2	PHENOTYPE	6	7	respiratory disorder
NCT0000528014	NCT00005280_14_T0	PHENOTYPE	8	8	symptoms
NCT0000528014	NCT00005280_14_T1	PHENOTYPE	21	22	lung function
NCT0000528014	NCT00005280_14_T2	PHENOTYPE	1	2	respiratory disorder
NCT0000528015	NCT00005280_15_T0	PHENOTYPE	0	0	Byssinosis
NCT0000528017	NCT00005280_17_T0	PHENOTYPE	20	20	impairment
NCT0000528018	NCT00005280_18_T0	PHENOTYPE	5	5	Exposures
NCT0000528019	NCT00005280_19_T0	GENE	2	2	IgE
NCT0000528019	NCT00005280_19_T1	PHENOTYPE	19	20	lung function
NCT0000528020	NCT00005280_20_T0	PHENOTYPE	28	28	affects
NCT0000528020	NCT00005280_20_T1	PHENOTYPE	33	33	affects
NCT0000528020	NCT00005280_20_T2	PHENOTYPE	37	38	respiratory symptoms
NCT0000528020	NCT00005280_20_T3	PHENOTYPE	29	30	lung function
NCT0000528020	NCT00005280_20_T4	PHENOTYPE	17	18	lung injury
NCT0000528020	NCT00005280_20_T5	PHENOTYPE	26	27	lung injury
NCT0000528023	NCT00005280_23_T0	GENE	3	3	IgE
NCT0000528024	NCT00005280_24_T0	GENE	3	3	had
NCT0000528027	NCT00005280_27_T0	PHENOTYPE	8	8	atopic
NCT000052812	NCT00005281_2_T0	BIOLOGICAL_PROCESS	27	27	menarche
NCT000052812	NCT00005281_2_T1	PHENOTYPE	1	2	lung function
NCT000052812	NCT00005281_2_T2	PHENOTYPE	23	24	cardiac disease
NCT000052817	NCT00005281_7_T0	PHENOTYPE	24	24	asthma
NCT000052817	NCT00005281_7_T1	PHENOTYPE	19	19	chronic
NCT000052817	NCT00005281_7_T2	PHENOTYPE	20	21	respiratory symptoms
NCT000052817	NCT00005281_7_T3	PHENOTYPE	31	32	lung function
NCT000052818	NCT00005281_8_T0	GENE	6	6	had
NCT0000528110	NCT00005281_10_T0	PHENOTYPE	20	21	lung function
NCT0000528111	NCT00005281_11_T0	PHENOTYPE	17	17	exposures
NCT0000528111	NCT00005281_11_T1	PHENOTYPE	15	15	diseases
NCT0000528111	NCT00005281_11_T2	PHENOTYPE	13	14	respiratory symptoms
NCT0000528112	NCT00005281_12_T0	GENE	23	23	WBC
NCT0000528112	NCT00005281_12_T1	CELL	26	26	eosinophil
NCT0000528113	NCT00005281_13_T0	PHENOTYPE	29	29	symptoms
NCT0000528113	NCT00005281_13_T1	PHENOTYPE	9	9	wheeze
NCT0000528113	NCT00005281_13_T2	PHENOTYPE	8	8	asthma
NCT0000528113	NCT00005281_13_T3	PHENOTYPE	13	13	asthma
NCT0000528113	NCT00005281_13_T4	GENE	45	45	had
NCT0000528114	NCT00005281_14_T0	PHENOTYPE	6	6	insights
NCT0000528115	NCT00005281_15_T0	PHENOTYPE	30	30	strategies
NCT0000528115	NCT00005281_15_T1	PHENOTYPE	49	51	chronic respiratory disease
NCT0000528115	NCT00005281_15_T2	PHENOTYPE	12	15	chronic obstructive lung disease
NCT000052825	NCT00005282_5_T0	PHENOTYPE	41	41	symptoms
NCT000052825	NCT00005282_5_T1	PHENOTYPE	13	14	lung function
NCT000052827	NCT00005282_7_T0	GENE	3	3	had
NCT0000528210	NCT00005282_10_T0	PHENOTYPE	12	13	Chronic Diseases
NCT0000528212	NCT00005282_12_T0	GENE	12	12	5.9
NCT0000528215	NCT00005282_15_T0	PHENOTYPE	33	33	symptoms
NCT0000528215	NCT00005282_15_T1	PHENOTYPE	26	26	exposures
NCT0000528215	NCT00005282_15_T2	PHENOTYPE	32	32	chronic
NCT0000528215	NCT00005282_15_T3	PHENOTYPE	16	18	chronic airflow obstruction
NCT0000528220	NCT00005282_20_T0	COMPOUND	3	3	isoproterenol
NCT0000528220	NCT00005282_20_T1	PHENOTYPE	12	14	forced vital capacity
NCT0000528221	NCT00005282_21_T0	PHENOTYPE	6	6	allergy
NCT0000528225	NCT00005282_25_T0	PHENOTYPE	11	11	chronic
NCT0000528225	NCT00005282_25_T1	PHENOTYPE	12	13	respiratory symptoms
NCT0000528226	NCT00005282_26_T0	PHENOTYPE	23	23	symptoms
NCT0000528226	NCT00005282_26_T1	PHENOTYPE	22	22	chronic
NCT0000528227	NCT00005282_27_T0	PHENOTYPE	11	11	inflammation
NCT0000528228	NCT00005282_28_T0	PHENOTYPE	12	12	narrowing
NCT0000528229	NCT00005282_29_T0	PHENOTYPE	15	16	Chronic Diseases
NCT000052833	NCT00005283_3_T0	PHENOTYPE	10	11	allergic symptoms
NCT000052833	NCT00005283_3_T1	PHENOTYPE	14	16	laboratory animal allergy
NCT000052834	NCT00005283_4_T0	PHENOTYPE	22	22	asthma
NCT000052834	NCT00005283_4_T1	GENE	21	21	had
NCT000052834	NCT00005283_4_T2	PHENOTYPE	0	0	Asthma
NCT000052835	NCT00005283_5_T0	PHENOTYPE	7	7	asthma
NCT000052835	NCT00005283_5_T1	PHENOTYPE	3	5	laboratory animal allergy
NCT000052836	NCT00005283_6_T0	PHENOTYPE	2	2	Recruitment
NCT000052837	NCT00005283_7_T0	PHENOTYPE	24	24	allergy
NCT000052837	NCT00005283_7_T1	PHENOTYPE	19	19	asthma
NCT000052837	NCT00005283_7_T2	PHENOTYPE	16	18	laboratory animal allergy
NCT000052838	NCT00005283_8_T0	GENE	7	7	IgE
NCT000052838	NCT00005283_8_T1	GENE	9	9	IgG
NCT000052838	NCT00005283_8_T2	ORGAN	5	5	serum
NCT000052839	NCT00005283_9_T0	COMPOUND	5	5	methacholine
NCT0000528311	NCT00005283_11_T0	COMPOUND	12	12	methacholine
NCT000052843	NCT00005284_3_T0	GENE	4	4	had
NCT000052844	NCT00005284_4_T0	PHENOTYPE	8	8	atopy
NCT000052845	NCT00005284_5_T0	PHENOTYPE	17	17	NAS
NCT000052845	NCT00005284_5_T1	BIOLOGICAL_PROCESS	15	15	Aging
NCT000052847	NCT00005284_7_T0	PHENOTYPE	1	1	NAS
NCT000052847	NCT00005284_7_T1	PHENOTYPE	11	12	respiratory symptom
NCT000052848	NCT00005284_8_T0	PHENOTYPE	26	26	NAS
NCT000052848	NCT00005284_8_T1	GENE	24	24	IgE
NCT000052848	NCT00005284_8_T2	PHENOTYPE	14	14	atopy
NCT000052848	NCT00005284_8_T3	PHENOTYPE	21	21	eosinophilia
NCT000052848	NCT00005284_8_T4	ORGAN	23	23	serum
NCT000052848	NCT00005284_8_T5	COMPOUND	11	11	methacholine
NCT000052849	NCT00005284_9_T0	PHENOTYPE	11	11	atopy
NCT000052849	NCT00005284_9_T1	PHENOTYPE	16	17	respiratory symptoms
NCT0000528410	NCT00005284_10_T0	PHENOTYPE	30	30	asthma
NCT0000528410	NCT00005284_10_T1	PHENOTYPE	28	28	COLD
NCT0000528410	NCT00005284_10_T2	PHENOTYPE	24	27	chronic obstructive lung disease
NCT0000528412	NCT00005284_12_T0	GENE	4	4	allergen
NCT0000528412	NCT00005284_12_T1	PHENOTYPE	13	13	obstruction
NCT0000528412	NCT00005284_12_T2	PHENOTYPE	12	12	airflow
NCT0000528413	NCT00005284_13_T0	GENE	20	20	II
NCT0000528413	NCT00005284_13_T1	GENE	13	13	fI
NCT0000528413	NCT00005284_13_T2	GENE	9	9	Der
NCT0000528413	NCT00005284_13_T3	GENE	12	12	Der
NCT0000528413	NCT00005284_13_T4	PHENOTYPE	26	26	fungi
NCT0000528413	NCT00005284_13_T5	GENE	15	15	Bla
NCT0000528413	NCT00005284_13_T6	GENE	18	18	Bla
NCT0000528413	NCT00005284_13_T7	GENE	22	24	Fel d I
NCT0000528415	NCT00005284_15_T0	GENE	38	38	allergen
NCT0000528415	NCT00005284_15_T1	PHENOTYPE	45	45	NAS
NCT0000528415	NCT00005284_15_T2	PHENOTYPE	11	11	illnesses
NCT0000528415	NCT00005284_15_T3	GENE	26	26	IgE
NCT0000528415	NCT00005284_15_T4	PHENOTYPE	29	29	inflammation
NCT0000528415	NCT00005284_15_T5	CELL	30	30	eosinophil
NCT0000528415	NCT00005284_15_T6	GENE	136	136	II
NCT0000528415	NCT00005284_15_T7	PHENOTYPE	35	35	peripheral
NCT0000528415	NCT00005284_15_T8	PHENOTYPE	20	20	atopy
NCT0000528415	NCT00005284_15_T9	PHENOTYPE	90	90	affects
NCT0000528415	NCT00005284_15_T10	PHENOTYPE	123	123	fungi
NCT0000528415	NCT00005284_15_T11	GENE	131	131	Bla
NCT0000528415	NCT00005284_15_T12	GENE	134	134	Bla
NCT0000528415	NCT00005284_15_T13	CELL	32	32	leukocyte
NCT0000528415	NCT00005284_15_T14	PHENOTYPE	8	9	respiratory symptoms
NCT0000528415	NCT00005284_15_T15	GENE	139	141	Fel d I
NCT000052853	NCT00005285_3_T0	PHENOTYPE	8	9	occupational exposures
NCT000052854	NCT00005285_4_T0	GENE	11	11	has
NCT000052854	NCT00005285_4_T1	PHENOTYPE	16	17	lung function
NCT000052856	NCT00005285_6_T0	PHENOTYPE	33	33	illnesses
NCT000052856	NCT00005285_6_T1	GENE	3	3	pointed
NCT000052858	NCT00005285_8_T0	COMPOUND	8	8	cotinine
NCT000052859	NCT00005285_9_T0	ORGAN	19	20	respiratory system
NCT000052863	NCT00005286_3_T0	PHENOTYPE	5	5	dyspnea
NCT000052863	NCT00005286_3_T1	PHENOTYPE	2	2	choking
NCT000052863	NCT00005286_3_T2	PHENOTYPE	0	0	Snoring
NCT000052863	NCT00005286_3_T3	PHENOTYPE	15	17	Sleep Apnea Syndrome
NCT000052863	NCT00005286_3_T4	PHENOTYPE	10	12	upper airway obstruction
NCT000052865	NCT00005286_5_T0	PHENOTYPE	9	10	pulmonary hypertension
NCT000052865	NCT00005286_5_T1	PHENOTYPE	4	5	cardiovascular complications
NCT000052865	NCT00005286_5_T2	PHENOTYPE	12	13	cardiac arrhythmias
NCT000052866	NCT00005286_6_T0	PHENOTYPE	12	12	chronic
NCT000052866	NCT00005286_6_T1	PHENOTYPE	22	23	sudden death
NCT000052866	NCT00005286_6_T2	PHENOTYPE	15	16	respiratory failure
NCT000052867	NCT00005286_7_T0	GENE	3	3	disabled
NCT000052867	NCT00005286_7_T1	PHENOTYPE	9	9	sleepiness
NCT000052868	NCT00005286_8_T0	PHENOTYPE	8	10	Sleep Apnea Syndrome
NCT000052869	NCT00005286_9_T0	PHENOTYPE	8	8	severely
NCT0000528610	NCT00005286_10_T0	PHENOTYPE	6	6	symptoms
NCT0000528610	NCT00005286_10_T1	PHENOTYPE	11	13	Sleep Apnea Syndrome
NCT0000528612	NCT00005286_12_T0	PHENOTYPE	13	15	Sleep Apnea Syndrome
NCT0000528612	NCT00005286_12_T1	PHENOTYPE	9	11	signs and symptoms
NCT0000528614	NCT00005286_14_T0	PHENOTYPE	13	13	recruitment
NCT0000528615	NCT00005286_15_T0	PHENOTYPE	9	11	Sleep Apnea Syndrome
NCT0000528618	NCT00005286_18_T0	PHENOTYPE	7	9	Sleep Apnea Syndrome
NCT000052876	NCT00005287_6_T0	PHENOTYPE	2	4	left ventricular hypertrophy
NCT000052876	NCT00005287_6_T1	PHENOTYPE	0	2	Right and left
NCT000052877	NCT00005287_7_T0	PHENOTYPE	1	3	right ventricular pressure
NCT000052878	NCT00005287_8_T0	PHENOTYPE	1	1	atopic
NCT000052883	NCT00005288_3_T0	PHENOTYPE	11	11	accidents
NCT000052885	NCT00005288_5_T0	PHENOTYPE	5	5	disorders
NCT000052887	NCT00005288_7_T0	COMPOUND	10	10	ammonia
NCT000052887	NCT00005288_7_T1	COMPOUND	12	13	hydrogen sulfide
NCT0000528812	NCT00005288_12_T0	GENE	3	3	nested
NCT0000528814	NCT00005288_14_T0	COMPOUND	19	19	methacholine
NCT0000528815	NCT00005288_15_T0	GENE	11	11	had
NCT0000528818	NCT00005288_18_T0	PHENOTYPE	26	26	atopy
NCT000052892	NCT00005289_2_T0	PHENOTYPE	10	10	BPD
NCT000052892	NCT00005289_2_T1	PHENOTYPE	14	14	chronic
NCT000052892	NCT00005289_2_T2	PHENOTYPE	3	4	premature infants
NCT000052892	NCT00005289_2_T3	PHENOTYPE	15	16	respiratory disorder
NCT000052893	NCT00005289_3_T0	PHENOTYPE	4	4	BPD
NCT000052893	NCT00005289_3_T1	PHENOTYPE	7	10	very low birth weight
NCT000052894	NCT00005289_4_T0	PHENOTYPE	4	6	low birth weight
NCT000052894	NCT00005289_4_T1	PHENOTYPE	16	19	very low birth weight
NCT000052895	NCT00005289_5_T0	GENE	2	2	had
NCT000052895	NCT00005289_5_T1	PHENOTYPE	7	8	neonatal death
NCT000052896	NCT00005289_6_T0	GENE	4	4	had
NCT000052896	NCT00005289_6_T1	PHENOTYPE	7	7	chronic
NCT000052896	NCT00005289_6_T2	PHENOTYPE	8	9	pulmonary disease
NCT000052897	NCT00005289_7_T0	GENE	29	29	3.5
NCT000052897	NCT00005289_7_T1	PHENOTYPE	6	9	very low birth weight
NCT000052899	NCT00005289_9_T0	GENE	4	4	had
NCT000052899	NCT00005289_9_T1	GENE	6	6	nested
NCT0000528910	NCT00005289_10_T0	PHENOTYPE	21	21	severity
NCT0000528910	NCT00005289_10_T1	PHENOTYPE	10	10	BPD
NCT0000528911	NCT00005289_11_T0	PHENOTYPE	5	8	very low birth weight
NCT0000528914	NCT00005289_14_T0	PHENOTYPE	16	16	prematurity
NCT0000528914	NCT00005289_14_T1	PHENOTYPE	5	5	diseases
NCT0000528914	NCT00005289_14_T2	PHENOTYPE	9	10	respiratory diseases
NCT0000528914	NCT00005289_14_T3	PHENOTYPE	24	25	environmental exposures
NCT0000528915	NCT00005289_15_T0	GENE	12	12	log
NCT0000528915	NCT00005289_15_T1	PHENOTYPE	0	0	Severity
NCT0000528916	NCT00005289_16_T0	PHENOTYPE	5	5	BPD
NCT0000528916	NCT00005289_16_T1	PHENOTYPE	9	9	BPD
NCT0000528918	NCT00005289_18_T0	GENE	12	12	4.5
NCT0000528919	NCT00005289_19_T0	PHENOTYPE	9	12	very low birth weight
NCT0000528920	NCT00005289_20_T0	GENE	20	20	had
NCT0000528924	NCT00005289_24_T0	PHENOTYPE	23	23	focused
NCT0000528924	NCT00005289_24_T1	PHENOTYPE	10	13	very low birth weight
NCT0000528928	NCT00005289_28_T0	PHENOTYPE	40	40	centers
NCT0000528929	NCT00005289_29_T0	PHENOTYPE	14	17	very low birth weight
NCT0000528932	NCT00005289_32_T0	PHENOTYPE	15	16	respiratory disease
NCT0000528933	NCT00005289_33_T0	GENE	36	36	has
NCT0000528933	NCT00005289_33_T1	PHENOTYPE	34	35	respiratory problems
NCT0000528934	NCT00005289_34_T0	PHENOTYPE	25	26	respiratory symptoms
NCT0000528934	NCT00005289_34_T1	PHENOTYPE	18	19	respiratory function
NCT000052903	NCT00005290_3_T0	PHENOTYPE	21	23	interstitial lung diseases
NCT000052904	NCT00005290_4_T0	PHENOTYPE	11	13	interstitial lung diseases
NCT000052906	NCT00005290_6_T0	PHENOTYPE	11	11	physiology
NCT000052906	NCT00005290_6_T1	PHENOTYPE	17	19	interstitial lung diseases
NCT000052907	NCT00005290_7_T0	PHENOTYPE	8	8	Tumor
NCT000052907	NCT00005290_7_T1	PHENOTYPE	17	19	interstitial lung disease
NCT000052909	NCT00005290_9_T0	GENE	7	7	had
NCT000052909	NCT00005290_9_T1	PHENOTYPE	21	21	symptoms
NCT000052909	NCT00005290_9_T2	BIOLOGICAL_PROCESS	27	27	phlebotomy
NCT000052909	NCT00005290_9_T3	ORGAN	31	31	serum
NCT000052909	NCT00005290_9_T4	PHENOTYPE	4	6	interstitial lung disease
NCT000052912	NCT00005291_2_T0	PHENOTYPE	3	3	asthma
NCT000052913	NCT00005291_3_T0	PHENOTYPE	28	28	asthma
NCT000052914	NCT00005291_4_T0	PHENOTYPE	24	24	asthma
NCT000052914	NCT00005291_4_T1	PHENOTYPE	48	48	asthma
NCT000052914	NCT00005291_4_T2	PHENOTYPE	54	54	asthma
NCT000052914	NCT00005291_4_T3	PHENOTYPE	26	27	asthma disorders
NCT000052923	NCT00005292_3_T0	ORGAN	10	10	plasma
NCT000052924	NCT00005292_4_T0	GENE	2	2	had
NCT000052925	NCT00005292_5_T0	PHENOTYPE	32	33	congenital deficiency
NCT000052925	NCT00005292_5_T1	PHENOTYPE	36	37	lung function
NCT000052928	NCT00005292_8_T0	PHENOTYPE	24	25	lung function
NCT000052929	NCT00005292_9_T0	PHENOTYPE	30	31	congenital deficiency
NCT000052929	NCT00005292_9_T1	PHENOTYPE	25	26	lung function
NCT0000529211	NCT00005292_11_T0	PHENOTYPE	15	16	lung function
NCT0000529212	NCT00005292_12_T0	PHENOTYPE	16	16	initiation
NCT0000529212	NCT00005292_12_T1	GENE	6	6	had
NCT0000529212	NCT00005292_12_T2	ORGAN	23	23	serum
NCT0000529212	NCT00005292_12_T3	PHENOTYPE	8	9	lung function
NCT0000529213	NCT00005292_13_T0	PHENOTYPE	1	1	recruitment
NCT000052932	NCT00005293_2_T0	GENE	16	16	had
NCT000052932	NCT00005293_2_T1	PHENOTYPE	19	20	intraventricular hemorrhage
NCT000052934	NCT00005293_4_T0	PHENOTYPE	5	6	Intraventricular Hemorrhage
NCT000052938	NCT00005293_8_T0	PHENOTYPE	5	5	prematurity
NCT000052938	NCT00005293_8_T1	PHENOTYPE	2	3	pulmonary disease
NCT0000529312	NCT00005293_12_T0	PHENOTYPE	9	9	BPD
NCT0000529312	NCT00005293_12_T1	COMPOUND	17	17	oxygen
NCT0000529313	NCT00005293_13_T0	GENE	3	3	had
NCT0000529316	NCT00005293_16_T0	GENE	3	3	structural
NCT0000529316	NCT00005293_16_T1	PHENOTYPE	11	11	severely
NCT0000529320	NCT00005293_20_T0	PHENOTYPE	26	27	bronchopulmonary dysplasia
NCT0000529320	NCT00005293_20_T1	PHENOTYPE	15	17	acute respiratory disease
NCT0000529321	NCT00005293_21_T0	PHENOTYPE	7	8	premature infants
NCT0000529321	NCT00005293_21_T1	PHENOTYPE	11	12	bronchopulmonary dysplasia
NCT0000529324	NCT00005293_24_T0	COMPOUND	19	19	oxygen
NCT0000529325	NCT00005293_25_T0	GENE	12	12	II
NCT0000529325	NCT00005293_25_T1	PHENOTYPE	24	24	prematurity
NCT0000529325	NCT00005293_25_T2	GENE	13	13	III
NCT0000529325	NCT00005293_25_T3	GENE	15	15	IV
NCT0000529325	NCT00005293_25_T4	PHENOTYPE	21	22	pulmonary disease
NCT000052942	NCT00005294_2_T0	PHENOTYPE	27	27	sequelae
NCT000052952	NCT00005295_2_T0	PHENOTYPE	5	5	diseases
NCT000052952	NCT00005295_2_T1	PHENOTYPE	11	13	idiopathic pulmonary fibrosis
NCT000052953	NCT00005295_3_T0	PHENOTYPE	14	14	centers
NCT000052954	NCT00005295_4_T0	PHENOTYPE	18	18	exposures
NCT000052954	NCT00005295_4_T1	PHENOTYPE	15	16	occupational exposure
NCT000052955	NCT00005295_5_T0	PHENOTYPE	24	26	interstitial lung fibrosis
NCT000052955	NCT00005295_5_T1	PHENOTYPE	9	12	diseases of the lung
NCT000052962	NCT00005296_2_T0	PHENOTYPE	12	13	mental health
NCT000052962	NCT00005296_2_T1	PHENOTYPE	19	20	cardiovascular abnormalities
NCT000052962	NCT00005296_2_T2	PHENOTYPE	22	23	cognitive impairment
NCT000052962	NCT00005296_2_T3	PHENOTYPE	1	2	sleep apnea
NCT000052962	NCT00005296_2_T4	PHENOTYPE	16	18	excessive daytime sleepiness
NCT000052963	NCT00005296_3_T0	PHENOTYPE	5	6	sleep apnea
NCT000052975	NCT00005297_5_T0	PHENOTYPE	0	0	Hypopneas
NCT000052975	NCT00005297_5_T1	PHENOTYPE	3	3	airflow
NCT000052975	NCT00005297_5_T2	PHENOTYPE	14	14	snoring
NCT000052975	NCT00005297_5_T3	PHENOTYPE	21	21	apneas
NCT000052976	NCT00005297_6_T0	PHENOTYPE	3	3	hypopneas
NCT000052976	NCT00005297_6_T1	PHENOTYPE	11	11	somnolence
NCT000052976	NCT00005297_6_T2	PHENOTYPE	1	1	apneas
NCT000052978	NCT00005297_8_T0	GENE	7	7	San
NCT0000529713	NCT00005297_13_T0	PHENOTYPE	5	5	snoring
NCT0000529713	NCT00005297_13_T1	COMPOUND	1	1	oxygen
NCT0000529713	NCT00005297_13_T2	PHENOTYPE	3	4	pulse rate
NCT0000529714	NCT00005297_14_T0	PHENOTYPE	2	2	pulse
NCT0000529717	NCT00005297_17_T0	PHENOTYPE	0	0	Associations
NCT000052982	NCT00005298_2_T0	PHENOTYPE	18	18	atopy
NCT000052982	NCT00005298_2_T1	PHENOTYPE	10	10	asthma
NCT000052982	NCT00005298_2_T2	TISSUE	44	45	smooth muscle
NCT000052982	NCT00005298_2_T3	PHENOTYPE	1	2	chronic bronchitis
NCT000052986	NCT00005298_6_T0	PHENOTYPE	6	6	insights
NCT000052986	NCT00005298_6_T1	PHENOTYPE	12	12	asthma
NCT000052986	NCT00005298_6_T2	PHENOTYPE	14	15	chronic bronchitis
NCT000052988	NCT00005298_8_T0	PHENOTYPE	7	7	NAS
NCT000052988	NCT00005298_8_T1	PHENOTYPE	19	19	illnesses
NCT000052988	NCT00005298_8_T2	PHENOTYPE	16	17	respiratory symptoms
NCT000052990	NCT00005299_0_T0	PHENOTYPE	6	7	Sleep Apnea
NCT000052993	NCT00005299_3_T0	PHENOTYPE	8	8	hypoxemia
NCT000052993	NCT00005299_3_T1	PHENOTYPE	6	6	apneas
NCT000052993	NCT00005299_3_T2	PHENOTYPE	15	16	pulmonary hypertension
NCT000052993	NCT00005299_3_T3	PHENOTYPE	17	18	cor pulmonale
NCT000052993	NCT00005299_3_T4	PHENOTYPE	20	22	excessive daytime sleepiness
NCT000052994	NCT00005299_4_T0	PHENOTYPE	0	1	Systemic hypertension
NCT000052994	NCT00005299_4_T1	PHENOTYPE	8	10	obstructive sleep apnea
NCT000052996	NCT00005299_6_T0	PHENOTYPE	1	1	snoring
NCT000052996	NCT00005299_6_T1	PHENOTYPE	6	7	sleep apnea
NCT000052996	NCT00005299_6_T2	PHENOTYPE	13	15	ischemic heart disease
NCT000052997	NCT00005299_7_T0	PHENOTYPE	3	4	systemic hypertension
NCT0000529911	NCT00005299_11_T0	PHENOTYPE	6	6	symptoms
NCT0000529911	NCT00005299_11_T1	PHENOTYPE	10	10	exposures
NCT0000529913	NCT00005299_13_T0	PHENOTYPE	0	0	Airflow
NCT0000529913	NCT00005299_13_T1	COMPOUND	4	4	oxygen
NCT0000529913	NCT00005299_13_T2	ORGAN	7	7	heart
NCT0000529913	NCT00005299_13_T3	ORGAN	1	2	chest wall
NCT0000529914	NCT00005299_14_T0	GENE	7	7	extended
NCT0000529915	NCT00005299_15_T0	GENE	2	2	had
NCT0000529918	NCT00005299_18_T0	GENE	5	5	FY
NCT0000529921	NCT00005299_21_T0	PHENOTYPE	8	8	apnea
NCT0000529921	NCT00005299_21_T1	TISSUE	12	13	body fat
NCT0000529922	NCT00005299_22_T0	GENE	6	6	extended
NCT0000529923	NCT00005299_23_T0	GENE	1	1	nested
NCT0000529925	NCT00005299_25_T0	GENE	5	5	FY
NCT0000529926	NCT00005299_26_T0	GENE	11	11	had
NCT0000529927	NCT00005299_27_T0	GENE	14	14	had
NCT0000529927	NCT00005299_27_T1	PHENOTYPE	39	40	cardiovascular disease
NCT0000529927	NCT00005299_27_T2	PHENOTYPE	9	10	sleep apnea
NCT0000529927	NCT00005299_27_T3	PHENOTYPE	35	36	sleep apnea
NCT0000529929	NCT00005299_29_T0	PHENOTYPE	40	40	severity
NCT0000529929	NCT00005299_29_T1	PHENOTYPE	16	17	cardiovascular disease
NCT0000529929	NCT00005299_29_T2	PHENOTYPE	25	26	sleep apnea
NCT0000529929	NCT00005299_29_T3	PHENOTYPE	37	38	sleep apnea
NCT000053000	NCT00005300_0_T0	PHENOTYPE	10	12	Sickle Cell Disease
NCT000053003	NCT00005300_3_T0	GENE	4	4	had
NCT000053005	NCT00005300_5_T0	PHENOTYPE	14	14	dysfunction
NCT000053005	NCT00005300_5_T1	CELL	6	8	red blood cells
NCT000053007	NCT00005300_7_T0	GENE	10	10	has
NCT000053007	NCT00005300_7_T1	PHENOTYPE	0	1	Growth retardation
NCT000053009	NCT00005300_9_T0	GENE	23	23	has
NCT0000530010	NCT00005300_10_T0	PHENOTYPE	16	16	severity
NCT0000530010	NCT00005300_10_T1	PHENOTYPE	23	23	severity
NCT0000530018	NCT00005300_18_T0	PHENOTYPE	14	14	severity
NCT0000530020	NCT00005300_20_T0	GENE	1	1	had
NCT0000530022	NCT00005300_22_T0	GENE	15	15	longevity
NCT0000530023	NCT00005300_23_T0	COMPOUND	24	24	MUGA
NCT0000530023	NCT00005300_23_T1	ORGAN	21	21	serum
NCT000053015	NCT00005301_5_T0	PHENOTYPE	9	9	hemophilia
NCT000053018	NCT00005301_8_T0	PHENOTYPE	18	18	chronic
NCT0000530115	NCT00005301_15_T0	PHENOTYPE	1	1	progression
NCT0000530117	NCT00005301_17_T0	PHENOTYPE	6	6	HIV
NCT0000530117	NCT00005301_17_T1	ORGAN	3	3	serum
NCT0000530118	NCT00005301_18_T0	GENE	31	31	San
NCT0000530118	NCT00005301_18_T1	ORGAN	10	10	serum
NCT0000530119	NCT00005301_19_T0	GENE	19	19	San
NCT0000530120	NCT00005301_20_T0	PHENOTYPE	20	21	HIV infection
NCT0000530121	NCT00005301_21_T0	GENE	2	2	sera
NCT0000530121	NCT00005301_21_T1	GENE	4	4	separated
NCT0000530123	NCT00005301_23_T0	PHENOTYPE	14	14	HIV
NCT0000530123	NCT00005301_23_T1	ORGAN	5	5	serum
NCT0000530129	NCT00005301_29_T0	GENE	7	7	San
NCT0000530129	NCT00005301_29_T1	PHENOTYPE	3	3	centers
NCT0000530131	NCT00005301_31_T0	PHENOTYPE	37	37	Center
NCT0000530136	NCT00005301_36_T0	GENE	1	1	aminotransferase
NCT0000530137	NCT00005301_37_T0	PHENOTYPE	5	5	hepatitis
NCT0000530138	NCT00005301_38_T0	PHENOTYPE	2	3	immune status
NCT0000530138	NCT00005301_38_T1	PHENOTYPE	6	7	globulin levels
NCT000053025	NCT00005302_5_T0	PHENOTYPE	35	35	associations
NCT000053025	NCT00005302_5_T1	PHENOTYPE	27	27	suspicion
NCT000053025	NCT00005302_5_T2	PHENOTYPE	18	18	dyscrasia
NCT000053026	NCT00005302_6_T0	PHENOTYPE	15	15	associations
NCT000053026	NCT00005302_6_T1	PHENOTYPE	27	27	attributable
NCT000053026	NCT00005302_6_T2	PHENOTYPE	31	31	exposures
NCT000053026	NCT00005302_6_T3	GENE	33	33	sparse
NCT000053028	NCT00005302_8_T0	PHENOTYPE	4	4	associations
NCT000053028	NCT00005302_8_T1	COMPOUND	10	10	chloramphenicol
NCT000053028	NCT00005302_8_T2	PHENOTYPE	7	8	aplastic anemia
NCT000053029	NCT00005302_9_T0	PHENOTYPE	15	15	dyscrasia
NCT0000530210	NCT00005302_10_T0	PHENOTYPE	11	11	dyscrasia
NCT0000530211	NCT00005302_11_T0	COMPOUND	29	29	phenothiazine
NCT0000530211	NCT00005302_11_T1	COMPOUND	8	8	phenylbutazone
NCT0000530211	NCT00005302_11_T2	COMPOUND	9	9	oxyphenbutazone
NCT0000530211	NCT00005302_11_T3	PHENOTYPE	26	26	agranulocytosis
NCT0000530211	NCT00005302_11_T4	COMPOUND	7	7	chloramphenicol
NCT0000530211	NCT00005302_11_T5	COMPOUND	18	18	chloramphenicol
NCT0000530211	NCT00005302_11_T6	PHENOTYPE	4	5	aplastic anemia
NCT0000530212	NCT00005302_12_T0	COMPOUND	18	18	quinidine
NCT0000530212	NCT00005302_12_T1	PHENOTYPE	7	7	thrombocytopenia
NCT0000530212	NCT00005302_12_T2	GENE	9	9	had
NCT0000530213	NCT00005302_13_T0	PHENOTYPE	17	18	drug use
NCT0000530218	NCT00005302_18_T0	PHENOTYPE	6	6	agranulocytosis
NCT0000530218	NCT00005302_18_T1	PHENOTYPE	3	4	aplastic anemia
NCT0000530222	NCT00005302_22_T0	PHENOTYPE	4	5	drug use
NCT0000530223	NCT00005302_23_T0	PHENOTYPE	7	7	associations
NCT0000530223	NCT00005302_23_T1	PHENOTYPE	21	21	associations
NCT0000530223	NCT00005302_23_T2	PHENOTYPE	27	27	associations
NCT0000530223	NCT00005302_23_T3	PHENOTYPE	13	14	drug use
NCT0000530224	NCT00005302_24_T0	PHENOTYPE	7	7	attributable
NCT0000530224	NCT00005302_24_T1	PHENOTYPE	6	6	agranulocytosis
NCT0000530224	NCT00005302_24_T2	PHENOTYPE	3	4	aplastic anemia
NCT000053032	NCT00005303_2_T0	PHENOTYPE	18	18	HIV
NCT000053032	NCT00005303_2_T1	GENE	25	25	EIA
NCT000053033	NCT00005303_3_T0	PHENOTYPE	10	10	HIV
NCT000053034	NCT00005303_4_T0	PHENOTYPE	4	4	HIV
NCT000053034	NCT00005303_4_T1	PHENOTYPE	38	38	HIV
NCT000053034	NCT00005303_4_T2	GENE	21	21	VIII
NCT000053034	NCT00005303_4_T3	GENE	35	35	VIII
NCT000053034	NCT00005303_4_T4	PHENOTYPE	41	42	antibody positive
NCT000053035	NCT00005303_5_T0	GENE	14	14	VIII
NCT000053035	NCT00005303_5_T1	GENE	29	29	VIII
NCT000053035	NCT00005303_5_T2	PHENOTYPE	3	4	HIV positive
NCT000053035	NCT00005303_5_T3	PHENOTYPE	42	44	HIV antibody positive
NCT0000530310	NCT00005303_10_T0	GENE	6	6	San
NCT0000530310	NCT00005303_10_T1	GENE	34	34	San
NCT0000530310	NCT00005303_10_T2	PHENOTYPE	25	25	HIV
NCT0000530310	NCT00005303_10_T3	PHENOTYPE	14	15	HIV infection
NCT0000530313	NCT00005303_13_T0	PHENOTYPE	24	24	HIV
NCT0000530314	NCT00005303_14_T0	ORGAN	11	11	Heart
NCT0000530315	NCT00005303_15_T0	ORGAN	1	1	serum
NCT000053043	NCT00005304_3_T0	PHENOTYPE	15	15	hepatitis
NCT000053043	NCT00005304_3_T1	GENE	25	25	defective
NCT000053043	NCT00005304_3_T2	PHENOTYPE	32	32	coinfection
NCT000053043	NCT00005304_3_T3	PHENOTYPE	34	34	HBV
NCT000053043	NCT00005304_3_T4	PHENOTYPE	17	18	hepatitis B
NCT000053043	NCT00005304_3_T5	PHENOTYPE	1	2	chronic hepatitis
NCT000053043	NCT00005304_3_T6	PHENOTYPE	21	22	delta hepatitis
NCT000053043	NCT00005304_3_T7	PHENOTYPE	11	12	persistent infection
NCT000053044	NCT00005304_4_T0	PHENOTYPE	6	6	acute
NCT000053044	NCT00005304_4_T1	PHENOTYPE	2	2	HBV
NCT000053044	NCT00005304_4_T2	PHENOTYPE	20	20	HBV
NCT000053044	NCT00005304_4_T3	PHENOTYPE	7	8	delta hepatitis
NCT000053045	NCT00005304_5_T0	PHENOTYPE	5	6	delta hepatitis
NCT000053046	NCT00005304_6_T0	PHENOTYPE	0	0	Transmission
NCT000053046	NCT00005304_6_T1	PHENOTYPE	15	15	HBV
NCT000053046	NCT00005304_6_T2	PHENOTYPE	3	4	delta hepatitis
NCT000053047	NCT00005304_7_T0	PHENOTYPE	10	10	HBV
NCT000053047	NCT00005304_7_T1	PHENOTYPE	19	20	delta hepatitis
NCT000053049	NCT00005304_9_T0	GENE	6	6	had
NCT000053049	NCT00005304_9_T1	PHENOTYPE	7	8	delta hepatitis
NCT0000530410	NCT00005304_10_T0	PHENOTYPE	8	9	delta infection
NCT0000530410	NCT00005304_10_T1	PHENOTYPE	7	8	hepatitis delta
NCT0000530410	NCT00005304_10_T2	PHENOTYPE	15	19	chronic liver disease and cirrhosis
NCT0000530411	NCT00005304_11_T0	GENE	43	43	delta
NCT0000530411	NCT00005304_11_T1	PHENOTYPE	46	46	infections
NCT0000530411	NCT00005304_11_T2	PHENOTYPE	45	45	HBV
NCT0000530411	NCT00005304_11_T3	PHENOTYPE	35	35	chronic
NCT0000530411	NCT00005304_11_T4	PHENOTYPE	42	42	chronic
NCT0000530411	NCT00005304_11_T5	PHENOTYPE	37	38	hepatitis B
NCT0000530411	NCT00005304_11_T6	PHENOTYPE	14	15	delta infection
NCT0000530411	NCT00005304_11_T7	PHENOTYPE	13	14	hepatitis delta
NCT0000530411	NCT00005304_11_T8	PHENOTYPE	28	30	chronic liver disease
NCT0000530412	NCT00005304_12_T0	PHENOTYPE	21	22	Delta Infection
NCT0000530412	NCT00005304_12_T1	PHENOTYPE	20	21	Hepatitis Delta
NCT0000530414	NCT00005304_14_T0	PHENOTYPE	14	14	centers
NCT0000530416	NCT00005304_16_T0	ORGAN	6	6	liver
NCT0000530417	NCT00005304_17_T0	PHENOTYPE	27	28	liver disease
NCT0000530418	NCT00005304_18_T0	PHENOTYPE	10	11	delta hepatitis
NCT0000530420	NCT00005304_20_T0	GENE	4	4	delta
NCT0000530420	NCT00005304_20_T1	PHENOTYPE	8	9	liver disease
NCT0000530420	NCT00005304_20_T2	PHENOTYPE	5	6	virus infection
NCT0000530420	NCT00005304_20_T3	PHENOTYPE	11	12	hepatitis delta
NCT000053050	NCT00005305_0_T0	PHENOTYPE	2	2	Infections
NCT000053050	NCT00005305_0_T1	PHENOTYPE	0	1	Hepatitis Delta
NCT000053053	NCT00005305_3_T0	PHENOTYPE	16	16	hepatitis
NCT000053053	NCT00005305_3_T1	GENE	26	26	defective
NCT000053053	NCT00005305_3_T2	PHENOTYPE	33	33	coinfection
NCT000053053	NCT00005305_3_T3	PHENOTYPE	35	35	HBV
NCT000053053	NCT00005305_3_T4	PHENOTYPE	18	19	hepatitis B
NCT000053053	NCT00005305_3_T5	PHENOTYPE	1	2	chronic hepatitis
NCT000053053	NCT00005305_3_T6	PHENOTYPE	22	23	delta hepatitis
NCT000053053	NCT00005305_3_T7	PHENOTYPE	11	12	persistent infection
NCT000053054	NCT00005305_4_T0	PHENOTYPE	6	6	acute
NCT000053054	NCT00005305_4_T1	PHENOTYPE	2	2	HBV
NCT000053054	NCT00005305_4_T2	PHENOTYPE	20	20	HBV
NCT000053054	NCT00005305_4_T3	PHENOTYPE	7	8	delta hepatitis
NCT000053055	NCT00005305_5_T0	PHENOTYPE	5	6	delta hepatitis
NCT000053056	NCT00005305_6_T0	PHENOTYPE	0	0	Transmission
NCT000053056	NCT00005305_6_T1	PHENOTYPE	15	15	HBV
NCT000053056	NCT00005305_6_T2	PHENOTYPE	3	4	delta hepatitis
NCT000053057	NCT00005305_7_T0	PHENOTYPE	10	10	HBV
NCT000053057	NCT00005305_7_T1	PHENOTYPE	19	20	delta hepatitis
NCT000053059	NCT00005305_9_T0	GENE	6	6	had
NCT000053059	NCT00005305_9_T1	PHENOTYPE	7	8	delta hepatitis
NCT0000530510	NCT00005305_10_T0	PHENOTYPE	8	9	delta infection
NCT0000530510	NCT00005305_10_T1	PHENOTYPE	7	8	hepatitis delta
NCT0000530510	NCT00005305_10_T2	PHENOTYPE	15	19	chronic liver disease and cirrhosis
NCT0000530511	NCT00005305_11_T0	GENE	33	33	delta
NCT0000530511	NCT00005305_11_T1	PHENOTYPE	25	25	hepatitis
NCT0000530511	NCT00005305_11_T2	PHENOTYPE	36	36	infections
NCT0000530511	NCT00005305_11_T3	PHENOTYPE	22	22	chronic
NCT0000530511	NCT00005305_11_T4	PHENOTYPE	32	32	chronic
NCT0000530511	NCT00005305_11_T5	PHENOTYPE	35	35	HBV
NCT0000530511	NCT00005305_11_T6	PHENOTYPE	27	28	hepatitis B
NCT0000530511	NCT00005305_11_T7	PHENOTYPE	14	15	delta infection
NCT0000530511	NCT00005305_11_T8	PHENOTYPE	13	14	hepatitis delta
NCT0000530511	NCT00005305_11_T9	PHENOTYPE	26	27	chronic hepatitis
NCT0000530512	NCT00005305_12_T0	PHENOTYPE	21	22	Delta Infection
NCT0000530512	NCT00005305_12_T1	PHENOTYPE	20	21	Hepatitis Delta
NCT0000530514	NCT00005305_14_T0	PHENOTYPE	10	10	hemophilia
NCT0000530514	NCT00005305_14_T1	PHENOTYPE	17	17	Hemophilia
NCT0000530514	NCT00005305_14_T2	PHENOTYPE	12	12	centers
NCT0000530515	NCT00005305_15_T0	PHENOTYPE	19	19	hemophilia
NCT0000530515	NCT00005305_15_T1	PHENOTYPE	22	23	drug abuse
NCT0000530517	NCT00005305_17_T0	PHENOTYPE	16	16	persistence
NCT0000530517	NCT00005305_17_T1	GENE	6	6	had
NCT0000530517	NCT00005305_17_T2	GENE	29	29	cDNA
NCT0000530517	NCT00005305_17_T3	ORGAN	22	22	serum
NCT0000530518	NCT00005305_18_T0	GENE	1	1	blot
NCT0000530518	NCT00005305_18_T1	PHENOTYPE	7	8	antibody responses
NCT0000530520	NCT00005305_20_T0	PHENOTYPE	20	20	infections
NCT0000530520	NCT00005305_20_T1	PHENOTYPE	29	29	progression
NCT0000530520	NCT00005305_20_T2	PHENOTYPE	17	17	HBV
NCT0000530520	NCT00005305_20_T3	PHENOTYPE	31	32	liver disease
NCT0000530521	NCT00005305_21_T0	GENE	4	4	had
NCT0000530521	NCT00005305_21_T1	PHENOTYPE	21	21	HBV
NCT0000530521	NCT00005305_21_T2	PHENOTYPE	32	33	viral infections
NCT000053063	NCT00005306_3_T0	PHENOTYPE	12	12	hepatitis
NCT000053064	NCT00005306_4_T0	GENE	10	10	had
NCT000053065	NCT00005306_5_T0	GENE	8	8	PTH
NCT000053065	NCT00005306_5_T1	GENE	11	11	reduced
NCT000053069	NCT00005306_9_T0	PHENOTYPE	0	1	Acute hepatitis
NCT000053069	NCT00005306_9_T1	PHENOTYPE	36	37	hepatitis A
NCT000053069	NCT00005306_9_T2	PHENOTYPE	15	16	fulminant hepatitis
NCT000053069	NCT00005306_9_T3	PHENOTYPE	35	36	acute hepatitis
NCT0000530610	NCT00005306_10_T0	PHENOTYPE	16	16	acute
NCT0000530610	NCT00005306_10_T1	GENE	18	18	PTH
NCT0000530610	NCT00005306_10_T2	PHENOTYPE	7	8	chronic hepatitis
NCT0000530611	NCT00005306_11_T0	PHENOTYPE	43	43	alcoholism
NCT0000530611	NCT00005306_11_T1	PHENOTYPE	2	2	hepatitis
NCT0000530611	NCT00005306_11_T2	PHENOTYPE	0	0	Chronic
NCT0000530611	NCT00005306_11_T3	PHENOTYPE	26	27	hepatitis A
NCT0000530611	NCT00005306_11_T4	PHENOTYPE	23	24	hepatitis B
NCT0000530611	NCT00005306_11_T5	PHENOTYPE	41	42	drug toxicity
NCT0000530611	NCT00005306_11_T6	PHENOTYPE	45	46	heart failure
NCT0000530611	NCT00005306_11_T7	PHENOTYPE	9	11	chronic liver disease
NCT0000530612	NCT00005306_12_T0	PHENOTYPE	25	26	hepatitis B
NCT0000530612	NCT00005306_12_T1	PHENOTYPE	4	6	chronic liver disease
NCT0000530613	NCT00005306_13_T0	PHENOTYPE	14	14	cirrhosis
NCT0000530613	NCT00005306_13_T1	PHENOTYPE	10	12	chronic active hepatitis
NCT0000530614	NCT00005306_14_T0	PHENOTYPE	2	2	sequelae
NCT0000530614	NCT00005306_14_T1	PHENOTYPE	5	5	hepatitis
NCT0000530614	NCT00005306_14_T2	PHENOTYPE	1	1	chronic
NCT0000530614	NCT00005306_14_T3	PHENOTYPE	14	15	acute illness
NCT0000530615	NCT00005306_15_T0	PHENOTYPE	4	4	profound
NCT0000530616	NCT00005306_16_T0	GENE	5	5	had
NCT0000530616	NCT00005306_16_T1	PHENOTYPE	33	33	hepatitis
NCT0000530616	NCT00005306_16_T2	PHENOTYPE	31	31	chronic
NCT0000530618	NCT00005306_18_T0	PHENOTYPE	21	21	Hepatitis
NCT0000530619	NCT00005306_19_T0	GENE	3	3	II
NCT0000530619	NCT00005306_19_T1	PHENOTYPE	0	0	Initiation
NCT0000530620	NCT00005306_20_T0	GENE	2	2	II
NCT0000530621	NCT00005306_21_T0	ORGAN	14	14	liver
NCT0000530625	NCT00005306_25_T0	PHENOTYPE	18	20	chronic liver disease
NCT0000530626	NCT00005306_26_T0	PHENOTYPE	11	13	chronic liver disease
NCT0000530626	NCT00005306_26_T1	PHENOTYPE	20	22	chronic liver disease
NCT0000530629	NCT00005306_29_T0	ORGAN	7	7	liver
NCT0000530629	NCT00005306_29_T1	MOLECULAR_FUNCTION	1	2	aminotransferase activity
NCT0000530630	NCT00005306_30_T0	PHENOTYPE	9	11	chronic liver disease
NCT0000530631	NCT00005306_31_T0	GENE	6	6	had
NCT0000530631	NCT00005306_31_T1	PHENOTYPE	22	23	liver disease
NCT0000530631	NCT00005306_31_T2	PHENOTYPE	3	5	chronic liver disease
NCT0000530631	NCT00005306_31_T3	PHENOTYPE	12	14	chronic liver disease
NCT0000530633	NCT00005306_33_T0	PHENOTYPE	30	32	chronic liver disease
NCT0000530634	NCT00005306_34_T0	PHENOTYPE	23	24	liver disease
NCT0000530635	NCT00005306_35_T0	PHENOTYPE	5	6	liver disease
NCT000053072	NCT00005307_2_T0	PHENOTYPE	13	13	exposures
NCT000053078	NCT00005307_8_T0	PHENOTYPE	0	1	Adverse effects
NCT0000530711	NCT00005307_11_T0	COMPOUND	21	21	allopurinol
NCT000053080	NCT00005308_0_T0	PHENOTYPE	0	0	Anemia
NCT000053083	NCT00005308_3_T0	PHENOTYPE	11	11	hepatitis
NCT000053083	NCT00005308_3_T1	PHENOTYPE	4	6	hemolytic transfusion reactions
NCT000053085	NCT00005308_5_T0	PHENOTYPE	24	24	anemia
NCT000053085	NCT00005308_5_T1	PHENOTYPE	18	19	blood loss
NCT000053085	NCT00005308_5_T2	PHENOTYPE	29	30	hemoglobin level
NCT000053088	NCT00005308_8_T0	PHENOTYPE	23	24	blood loss
NCT000053089	NCT00005308_9_T0	GENE	25	25	hemoglobin
NCT0000530811	NCT00005308_11_T0	PHENOTYPE	9	9	associations
NCT0000530811	NCT00005308_11_T1	PHENOTYPE	12	12	anemia
NCT0000530817	NCT00005308_17_T0	PHENOTYPE	17	18	hemoglobin levels
NCT0000530817	NCT00005308_17_T1	PHENOTYPE	21	22	blood loss
NCT0000530818	NCT00005308_18_T0	PHENOTYPE	16	16	diseases
NCT000053090	NCT00005309_0_T0	PHENOTYPE	3	4	HIV Infection
NCT000053094	NCT00005309_4_T0	PHENOTYPE	5	5	hepatitis
NCT000053094	NCT00005309_4_T1	PHENOTYPE	27	28	rapid progression
NCT000053094	NCT00005309_4_T2	PHENOTYPE	22	23	chronic disease
NCT000053094	NCT00005309_4_T3	PHENOTYPE	30	31	HIV infection
NCT000053095	NCT00005309_5_T0	PHENOTYPE	8	8	HIV
NCT000053096	NCT00005309_6_T0	PHENOTYPE	13	13	hepatitis
NCT000053096	NCT00005309_6_T1	PHENOTYPE	11	11	chronic
NCT000053097	NCT00005309_7_T0	ORGAN	8	8	plasma
NCT000053097	NCT00005309_7_T1	PHENOTYPE	11	12	antibody titers
NCT000053097	NCT00005309_7_T2	BIOLOGICAL_PROCESS	0	1	Host-virus interaction
NCT000053099	NCT00005309_9_T0	PHENOTYPE	25	25	HIV
NCT000053099	NCT00005309_9_T1	PHENOTYPE	10	10	seronegative
NCT000053110	NCT00005311_0_T0	PHENOTYPE	0	0	Hypertension
NCT000053115	NCT00005311_5_T0	PHENOTYPE	14	14	hypertension
NCT000053116	NCT00005311_6_T0	PHENOTYPE	6	6	Hypertension
NCT000053116	NCT00005311_6_T1	GENE	22	22	had
NCT000053117	NCT00005311_7_T0	PHENOTYPE	9	9	hypertension
NCT000053118	NCT00005311_8_T0	PHENOTYPE	27	27	hypertension
NCT0000531112	NCT00005311_12_T0	PHENOTYPE	3	3	Hypertension
NCT0000531112	NCT00005311_12_T1	PHENOTYPE	27	27	hypertension
NCT000053121	NCT00005312_1_T0	PHENOTYPE	6	6	bilateral
NCT000053121	NCT00005312_1_T1	GENE	11	11	had
NCT000053124	NCT00005312_4_T0	GENE	1	1	FY
NCT000053124	NCT00005312_4_T1	PHENOTYPE	26	26	bilateral
NCT000053125	NCT00005312_5_T0	PHENOTYPE	13	13	bilateral
NCT000053125	NCT00005312_5_T1	GENE	2	2	has
NCT000053126	NCT00005312_6_T0	PHENOTYPE	7	7	insights
NCT000053132	NCT00005313_2_T0	PHENOTYPE	27	27	hyperlipidemia
NCT000053132	NCT00005313_2_T1	PHENOTYPE	21	21	regression
NCT000053132	NCT00005313_2_T2	BIOLOGICAL_PROCESS	14	15	lipoprotein metabolism
NCT000053132	NCT00005313_2_T3	PHENOTYPE	18	19	disease progression
NCT000053133	NCT00005313_3_T0	PHENOTYPE	41	41	homocysteinemia
NCT000053133	NCT00005313_3_T1	PHENOTYPE	31	31	hypercholesterolemia
NCT000053133	NCT00005313_3_T2	PHENOTYPE	4	4	focused
NCT000053133	NCT00005313_3_T3	PHENOTYPE	15	15	dyslipoproteinemias
NCT000053133	NCT00005313_3_T4	PHENOTYPE	26	28	familial combined hyperlipidemia
NCT000053133	NCT00005313_3_T5	PHENOTYPE	18	21	premature coronary artery disease
NCT000053135	NCT00005313_5_T0	GENE	26	26	lipoprotein
NCT0000531310	NCT00005313_10_T0	GENE	7	7	has
NCT000053144	NCT00005314_4_T0	PHENOTYPE	21	21	hostility
NCT000053145	NCT00005314_5_T0	PHENOTYPE	6	6	hostility
NCT000053145	NCT00005314_5_T1	GENE	13	13	CHD
NCT000053146	NCT00005314_6_T0	ORGAN	31	31	Heart
NCT000053146	NCT00005314_6_T1	PHENOTYPE	6	6	hostility
NCT000053146	NCT00005314_6_T2	GENE	18	18	CHD
NCT000053148	NCT00005314_8_T0	GENE	2	2	extended
NCT0000531410	NCT00005314_10_T0	PHENOTYPE	34	34	atherogenesis
NCT0000531410	NCT00005314_10_T1	PHENOTYPE	19	19	hostility
NCT0000531411	NCT00005314_11_T0	GENE	15	15	mediator
NCT0000531411	NCT00005314_11_T1	ORGAN	7	9	central nervous system
NCT0000531413	NCT00005314_13_T0	ORGAN	24	26	sympathetic nervous system
NCT0000531413	NCT00005314_13_T1	ORGAN	37	39	peripheral nervous system
NCT0000531414	NCT00005314_14_T0	PHENOTYPE	17	18	cardiovascular disease
NCT0000531415	NCT00005314_15_T0	PHENOTYPE	8	9	early experience
NCT0000531416	NCT00005314_16_T0	GENE	5	5	FY
NCT0000531417	NCT00005314_17_T0	PHENOTYPE	19	20	cardiovascular disease
NCT0000531420	NCT00005314_20_T0	PHENOTYPE	12	12	hostility
NCT0000531420	NCT00005314_20_T1	PHENOTYPE	14	15	cardiovascular disease
NCT0000531420	NCT00005314_20_T2	BIOLOGICAL_PROCESS	10	11	glucose metabolism
NCT0000531421	NCT00005314_21_T0	PHENOTYPE	6	6	hostility
NCT000053152	NCT00005315_2_T0	PHENOTYPE	19	19	acute
NCT000053154	NCT00005315_4_T0	PHENOTYPE	7	8	Job Strain
NCT000053157	NCT00005315_7_T0	GENE	9	9	structural
NCT000053157	NCT00005315_7_T1	ORGAN	13	13	heart
NCT000053157	NCT00005315_7_T2	ORGAN	15	16	carotid arteries
NCT000053159	NCT00005315_9_T0	PHENOTYPE	15	16	cardiovascular morbidity
NCT0000531510	NCT00005315_10_T0	PHENOTYPE	15	15	hypertension
NCT0000531510	NCT00005315_10_T1	PHENOTYPE	3	5	white coat hypertension
NCT0000531511	NCT00005315_11_T0	PHENOTYPE	7	8	job strain
NCT0000531514	NCT00005315_14_T0	PHENOTYPE	7	8	job strain
NCT0000531514	NCT00005315_14_T1	PHENOTYPE	12	14	white coat hypertension
NCT0000531515	NCT00005315_15_T0	GENE	5	5	FY
NCT0000531515	NCT00005315_15_T1	GENE	9	9	FY
NCT000053163	NCT00005316_3_T0	PHENOTYPE	9	9	hypertension
NCT000053164	NCT00005316_4_T0	PHENOTYPE	3	5	white coat hypertension
NCT000053165	NCT00005316_5_T0	PHENOTYPE	26	26	hypertension
NCT000053165	NCT00005316_5_T1	PHENOTYPE	9	11	white coat hypertension
NCT000053167	NCT00005316_7_T0	PHENOTYPE	11	12	urine albumin
NCT000053173	NCT00005317_3_T0	CELL	9	9	macrophages
NCT000053173	NCT00005317_3_T1	CELL	8	8	lymphocytes
NCT000053173	NCT00005317_3_T2	CELL	10	10	fibroblast
NCT000053173	NCT00005317_3_T3	CELL	7	7	neutrophils
NCT000053173	NCT00005317_3_T4	CELL	12	13	epithelial cells
NCT000053175	NCT00005317_5_T0	PHENOTYPE	3	5	idiopathic pulmonary fibrosis
NCT000053176	NCT00005317_6_T0	CELL	16	16	monocyte
NCT000053176	NCT00005317_6_T1	CELL	14	14	neutrophil
NCT000053177	NCT00005317_7_T0	PHENOTYPE	6	6	progression
NCT0000531712	NCT00005317_12_T0	GENE	21	21	QVR
NCT000053186	NCT00005318_6_T0	PHENOTYPE	18	18	ARDS
NCT000053186	NCT00005318_6_T1	PHENOTYPE	31	32	lung injury
NCT0000531810	NCT00005318_10_T0	PHENOTYPE	2	2	inflammation
NCT0000531918	NCT00005319_18_T0	PHENOTYPE	17	17	Center
NCT000053203	NCT00005320_3_T0	GENE	4	4	SRRD
NCT000053204	NCT00005320_4_T0	PHENOTYPE	10	10	sleepiness
NCT000053204	NCT00005320_4_T1	PHENOTYPE	49	49	profound
NCT000053204	NCT00005320_4_T2	COMPOUND	23	23	RDI
NCT000053204	NCT00005320_4_T3	GENE	24	24	30
NCT000053204	NCT00005320_4_T4	PHENOTYPE	30	31	sleep disorders
NCT000053204	NCT00005320_4_T5	PHENOTYPE	17	19	obstructive sleep apnea
NCT000053205	NCT00005320_5_T0	GENE	30	30	SRRD
NCT000053205	NCT00005320_5_T1	PHENOTYPE	11	12	sleep apnea
NCT000053206	NCT00005320_6_T0	PHENOTYPE	19	19	apneic
NCT000053206	NCT00005320_6_T1	COMPOUND	24	24	RDI
NCT000053206	NCT00005320_6_T2	COMPOUND	29	29	RDI
NCT000053206	NCT00005320_6_T3	PHENOTYPE	5	5	sleepiness
NCT000053208	NCT00005320_8_T0	GENE	23	23	CPAP
NCT000053208	NCT00005320_8_T1	GENE	14	14	CMT
NCT000053208	NCT00005320_8_T2	GENE	16	16	CMT
NCT0000532010	NCT00005320_10_T0	GENE	22	22	CPAP
NCT0000532010	NCT00005320_10_T1	GENE	14	14	SRRD
NCT0000532010	NCT00005320_10_T2	PHENOTYPE	6	7	sleep apnea
NCT0000532011	NCT00005320_11_T0	GENE	21	21	QVR
NCT0000532111	NCT00005321_11_T0	GENE	21	21	QVR
NCT000053224	NCT00005322_4_T0	PHENOTYPE	28	29	Cardiovascular Disease
NCT000053224	NCT00005322_4_T1	PHENOTYPE	10	12	endocardial cushion defects
NCT000053227	NCT00005322_7_T0	COMPOUND	9	9	1st
NCT000053228	NCT00005322_8_T0	CELL	30	30	chromosomes
NCT000053228	NCT00005322_8_T1	BIOLOGICAL_PROCESS	35	35	embryogenesis
NCT000053228	NCT00005322_8_T2	CELL	22	23	chromosome 21
NCT000053229	NCT00005322_9_T0	PHENOTYPE	2	2	focused
NCT000053229	NCT00005322_9_T1	PHENOTYPE	27	27	deformities
NCT000053229	NCT00005322_9_T2	PHENOTYPE	30	31	atrioventricular canal
NCT000053229	NCT00005322_9_T3	PHENOTYPE	10	12	endocardial cushion defects
NCT0000532217	NCT00005322_17_T0	GENE	14	14	had
NCT0000532217	NCT00005322_17_T1	PHENOTYPE	20	22	other congenital anomalies
NCT0000532217	NCT00005322_17_T2	PHENOTYPE	15	17	congenital heart defects
NCT0000532218	NCT00005322_18_T0	COMPOUND	11	11	1st
NCT0000532219	NCT00005322_19_T0	GENE	21	21	QVR
NCT000053234	NCT00005323_4_T0	PHENOTYPE	8	8	PPHN
NCT000053235	NCT00005323_5_T0	PHENOTYPE	40	40	associations
NCT000053235	NCT00005323_5_T1	PHENOTYPE	51	51	hypoxia
NCT000053235	NCT00005323_5_T2	COMPOUND	79	79	nicotine
NCT000053235	NCT00005323_5_T3	PHENOTYPE	24	24	PPHN
NCT000053235	NCT00005323_5_T4	PHENOTYPE	38	38	PPHN
NCT000053235	NCT00005323_5_T5	PHENOTYPE	42	42	PPHN
NCT000053235	NCT00005323_5_T6	PHENOTYPE	68	68	PPHN
NCT000053235	NCT00005323_5_T7	PHENOTYPE	73	73	PPHN
NCT000053235	NCT00005323_5_T8	COMPOUND	32	32	prostaglandin
NCT000053235	NCT00005323_5_T9	PHENOTYPE	14	14	exposures
NCT000053235	NCT00005323_5_T10	PHENOTYPE	47	48	drug use
NCT000053242	NCT00005324_2_T0	PHENOTYPE	8	8	Arteriosclerosis
NCT000053242	NCT00005324_2_T1	GENE	10	10	had
NCT000053245	NCT00005324_5_T0	GENE	7	7	putative
NCT000053245	NCT00005324_5_T1	BIOLOGICAL_PROCESS	23	24	lipid metabolism
NCT000053246	NCT00005324_6_T0	GENE	18	18	apo
NCT000053246	NCT00005324_6_T1	GENE	20	21	lipoprotein lipase
NCT000053246	NCT00005324_6_T2	GENE	8	9	apolipoprotein A1
NCT000053249	NCT00005324_9_T0	GENE	21	21	QVR
NCT000053252	NCT00005325_2_T0	PHENOTYPE	27	27	recruitment
NCT000053252	NCT00005325_2_T1	PHENOTYPE	7	7	pathophysiology
NCT000053252	NCT00005325_2_T2	PHENOTYPE	11	11	hypertension
NCT000053253	NCT00005325_3_T0	PHENOTYPE	16	16	Hypertension
NCT000053253	NCT00005325_3_T1	PHENOTYPE	7	7	Centers
NCT000053255	NCT00005325_5_T0	PHENOTYPE	23	23	Hypertension
NCT000053257	NCT00005325_7_T0	PHENOTYPE	8	8	Hypertension
NCT000053257	NCT00005325_7_T1	GENE	14	14	had
NCT000053259	NCT00005325_9_T0	PHENOTYPE	17	17	5-10
NCT000053259	NCT00005325_9_T1	CELL	22	22	chromosome
NCT0000532511	NCT00005325_11_T0	GENE	13	13	lod
NCT0000532513	NCT00005325_13_T0	PHENOTYPE	19	19	associations
NCT0000532514	NCT00005325_14_T0	PHENOTYPE	12	12	hypertension
NCT0000532515	NCT00005325_15_T0	ORGAN	7	7	Heart
NCT0000532515	NCT00005325_15_T1	PHENOTYPE	14	14	hypertension
NCT0000532517	NCT00005325_17_T0	ORGAN	46	46	marrow
NCT000053264	NCT00005326_4_T0	PHENOTYPE	30	30	focal
NCT000053264	NCT00005326_4_T1	PHENOTYPE	34	34	occlusion
NCT000053269	NCT00005326_9_T0	GENE	7	7	MRI
NCT000053269	NCT00005326_9_T1	PHENOTYPE	12	12	MRA
NCT0000532611	NCT00005326_11_T0	PHENOTYPE	17	17	strokes
NCT0000532611	NCT00005326_11_T1	PHENOTYPE	13	13	suffered
NCT0000532615	NCT00005326_15_T0	PHENOTYPE	15	15	dementia
NCT0000532615	NCT00005326_15_T1	PHENOTYPE	12	13	chronic encephalopathy
NCT0000532616	NCT00005326_16_T0	PHENOTYPE	16	17	cognitive deficits
NCT0000532617	NCT00005326_17_T0	GENE	5	5	FY
NCT0000532617	NCT00005326_17_T1	GENE	10	10	FY
NCT0000532618	NCT00005326_18_T0	GENE	10	10	FY
NCT0000532618	NCT00005326_18_T1	GENE	4	4	PI
NCT000053276	NCT00005327_6_T0	GENE	17	17	SS
NCT000053276	NCT00005327_6_T1	PHENOTYPE	3	4	cerebral infarction
NCT000053276	NCT00005327_6_T2	ORGAN	11	12	bone marrow
NCT000053283	NCT00005328_3_T0	GENE	9	9	extended
NCT000053285	NCT00005328_5_T0	ORGAN	22	24	autonomic nervous system
NCT000053286	NCT00005328_6_T0	COMPOUND	26	26	glucose
NCT000053286	NCT00005328_6_T1	GENE	25	25	insulin
NCT000053286	NCT00005328_6_T2	PHENOTYPE	37	37	hostility
NCT000053286	NCT00005328_6_T3	GENE	18	18	ventricular
NCT000053286	NCT00005328_6_T4	PHENOTYPE	35	35	conceptualization
NCT000053286	NCT00005328_6_T5	TISSUE	14	15	body fat
NCT000053287	NCT00005328_7_T0	GENE	19	19	pubescent
NCT000053287	NCT00005328_7_T1	GENE	26	26	pubescent
NCT000053288	NCT00005328_8_T0	PHENOTYPE	37	37	hostility
NCT000053288	NCT00005328_8_T1	ORGAN	26	28	autonomic nervous system
NCT000053289	NCT00005328_9_T0	PHENOTYPE	30	30	intentions
NCT000053289	NCT00005328_9_T1	GENE	9	9	ventricular
NCT0000532810	NCT00005328_10_T0	PHENOTYPE	36	36	CVD
NCT0000532810	NCT00005328_10_T1	GENE	2	2	has
NCT0000532810	NCT00005328_10_T2	GENE	4	4	extended
NCT0000532810	NCT00005328_10_T3	PHENOTYPE	34	35	cardiovascular disease
NCT0000532815	NCT00005328_15_T0	PHENOTYPE	32	33	endothelial dysfunction
NCT000053292	NCT00005329_2_T0	GENE	8	8	reduced
NCT000053292	NCT00005329_2_T1	PHENOTYPE	3	5	acute myocardial infarction
NCT000053293	NCT00005329_3_T0	PHENOTYPE	11	12	myocardial infarction
NCT000053295	NCT00005329_5_T0	PHENOTYPE	19	20	myocardial infarction
NCT000053297	NCT00005329_7_T0	PHENOTYPE	10	11	myocardial infarction
NCT0000532910	NCT00005329_10_T0	PHENOTYPE	23	24	myocardial infarction
NCT0000532911	NCT00005329_11_T0	GENE	6	6	had
NCT0000532911	NCT00005329_11_T1	PHENOTYPE	20	21	myocardial infarction
NCT0000532912	NCT00005329_12_T0	GENE	14	14	fragment
NCT0000532912	NCT00005329_12_T1	GENE	13	13	prothrombin
NCT0000532912	NCT00005329_12_T2	PHENOTYPE	30	31	myocardial infarction
NCT0000532913	NCT00005329_13_T0	PHENOTYPE	16	17	myocardial infarction
NCT000053304	NCT00005330_4_T0	ORGAN	18	18	Heart
NCT000053305	NCT00005330_5_T0	GENE	11	11	has
NCT000053306	NCT00005330_6_T0	ORGAN	28	28	Heart
NCT000053307	NCT00005330_7_T0	ORGAN	20	20	Heart
NCT000053308	NCT00005330_8_T0	GENE	4	4	3.5
NCT000053309	NCT00005330_9_T0	GENE	1	1	has
NCT0000533011	NCT00005330_11_T0	GENE	1	1	FCS
NCT0000533012	NCT00005330_12_T0	GENE	4	4	had
NCT0000533014	NCT00005330_14_T0	GENE	4	4	FCS
NCT0000533014	NCT00005330_14_T1	BIOLOGICAL_PROCESS	9	9	eating
NCT0000533014	NCT00005330_14_T2	PHENOTYPE	42	42	obesity
NCT000053313	NCT00005331_3_T0	GENE	6	6	midway
NCT000053315	NCT00005331_5_T0	COMPOUND	11	12	carbon monoxide
NCT0000533111	NCT00005331_11_T0	GENE	6	6	midway
NCT0000533112	NCT00005331_12_T0	GENE	16	16	1.2
NCT0000533112	NCT00005331_12_T1	GENE	19	19	1.2
NCT0000533113	NCT00005331_13_T0	COMPOUND	11	12	carbon monoxide
NCT0000533114	NCT00005331_14_T0	PHENOTYPE	18	18	self-perception
NCT0000533114	NCT00005331_14_T1	PHENOTYPE	10	10	strategies
NCT0000533114	NCT00005331_14_T2	PHENOTYPE	26	26	strategies
NCT0000533114	NCT00005331_14_T3	PHENOTYPE	38	38	strategies
NCT0000533114	NCT00005331_14_T4	GENE	17	17	dissonance
NCT000053323	NCT00005332_3_T0	PHENOTYPE	21	23	High Blood Pressure
NCT000053324	NCT00005332_4_T0	COMPOUND	18	18	calcium
NCT000053324	NCT00005332_4_T1	PHENOTYPE	16	16	hypertension
NCT000053326	NCT00005332_6_T0	GENE	4	4	had
NCT000053326	NCT00005332_6_T1	PHENOTYPE	20	22	coronary heart disease
NCT000053327	NCT00005332_7_T0	PHENOTYPE	12	12	hypertension
NCT000053327	NCT00005332_7_T1	PHENOTYPE	19	21	coronary heart disease
NCT000053328	NCT00005332_8_T0	PHENOTYPE	56	56	hypertension
NCT000053329	NCT00005332_9_T0	GENE	4	4	has
NCT0000533212	NCT00005332_12_T0	GENE	11	11	met
NCT0000533213	NCT00005332_13_T0	PHENOTYPE	10	10	hypertension
NCT0000533216	NCT00005332_16_T0	PHENOTYPE	19	19	regression
NCT0000533217	NCT00005332_17_T0	GENE	2	2	has
NCT000053331	NCT00005333_1_T0	PHENOTYPE	9	10	weight gain
NCT000053333	NCT00005333_3_T0	PHENOTYPE	18	18	hypertension
NCT000053334	NCT00005333_4_T0	COMPOUND	26	26	sodium
NCT000053334	NCT00005333_4_T1	COMPOUND	43	43	potassium
NCT000053334	NCT00005333_4_T2	GENE	42	42	reduced
NCT000053334	NCT00005333_4_T3	PHENOTYPE	4	4	hypertension
NCT000053336	NCT00005333_6_T0	COMPOUND	7	7	sodium
NCT000053336	NCT00005333_6_T1	COMPOUND	8	8	potassium
NCT000053336	NCT00005333_6_T2	PHENOTYPE	14	15	serum insulin
NCT000053337	NCT00005333_7_T0	GENE	1	1	FY
NCT0000533310	NCT00005333_10_T0	PHENOTYPE	2	2	hypertension
NCT0000533310	NCT00005333_10_T1	ORGAN	12	14	sympathetic nervous system
NCT0000533313	NCT00005333_13_T0	PHENOTYPE	8	9	weight gain
NCT0000533314	NCT00005333_14_T0	PHENOTYPE	3	4	weight gain
NCT0000533315	NCT00005333_15_T0	PHENOTYPE	6	8	left ventricular hypertrophy
NCT0000533316	NCT00005333_16_T0	PHENOTYPE	9	9	microalbuminuria
NCT0000533318	NCT00005333_18_T0	COMPOUND	57	57	glucose
NCT0000533318	NCT00005333_18_T1	COMPOUND	48	48	potassium
NCT0000533318	NCT00005333_18_T2	GENE	56	56	insulin
NCT0000533318	NCT00005333_18_T3	COMPOUND	47	47	sodium
NCT0000533318	NCT00005333_18_T4	COMPOUND	49	49	creatinine
NCT0000533318	NCT00005333_18_T5	COMPOUND	59	59	creatinine
NCT0000533318	NCT00005333_18_T6	ORGAN	28	28	hips
NCT0000533318	NCT00005333_18_T7	PHENOTYPE	39	39	menopausal
NCT0000533318	NCT00005333_18_T8	ORGAN	53	53	serum
NCT000053342	NCT00005334_2_T0	PHENOTYPE	6	7	accelerated atherosclerosis
NCT000053343	NCT00005334_3_T0	COMPOUND	6	6	CABS
NCT000053344	NCT00005334_4_T0	PHENOTYPE	8	9	life quality
NCT000053345	NCT00005334_5_T0	COMPOUND	7	7	CABS
NCT000053345	NCT00005334_5_T1	COMPOUND	27	27	CABS
NCT000053345	NCT00005334_5_T2	PHENOTYPE	23	25	quality of life
NCT000053346	NCT00005334_6_T0	COMPOUND	11	11	CABS
NCT000053346	NCT00005334_6_T1	PHENOTYPE	24	26	quality of life
NCT000053347	NCT00005334_7_T0	PHENOTYPE	6	6	optimism
NCT000053347	NCT00005334_7_T1	PHENOTYPE	14	14	hostility
NCT000053348	NCT00005334_8_T0	GENE	30	30	CHD
NCT000053348	NCT00005334_8_T1	PHENOTYPE	27	29	coronary heart disease
NCT0000533416	NCT00005334_16_T0	PHENOTYPE	6	6	optimism
NCT0000533416	NCT00005334_16_T1	PHENOTYPE	20	20	neuroticism
NCT0000533416	NCT00005334_16_T2	PHENOTYPE	9	9	hostility
NCT0000533418	NCT00005334_18_T0	PHENOTYPE	22	22	recurrent
NCT0000533419	NCT00005334_19_T0	PHENOTYPE	8	8	perceptions
NCT000053354	NCT00005335_4_T0	PHENOTYPE	9	9	RFLP
NCT000053355	NCT00005335_5_T0	GENE	8	8	APO
NCT000053355	NCT00005335_5_T1	GENE	3	4	apolipoprotein B
NCT000053356	NCT00005335_6_T0	GENE	11	11	HDL
NCT000053356	NCT00005335_6_T1	GENE	14	14	HDL
NCT000053356	NCT00005335_6_T2	GENE	12	12	LDL
NCT000053357	NCT00005335_7_T0	GENE	17	17	lipoprotein
NCT000053358	NCT00005335_8_T0	PHENOTYPE	6	6	RFLPs
NCT0000533510	NCT00005335_10_T0	GENE	4	4	San
NCT0000533513	NCT00005335_13_T0	PHENOTYPE	10	10	mutation
NCT0000533513	NCT00005335_13_T1	GENE	24	24	HDL
NCT0000533513	NCT00005335_13_T2	GENE	15	15	LPL
NCT0000533513	NCT00005335_13_T3	ORGAN	21	21	plasma
NCT0000533513	NCT00005335_13_T4	GENE	13	14	lipoprotein lipase
NCT0000533514	NCT00005335_14_T0	GENE	83	83	CETP
NCT0000533514	NCT00005335_14_T1	GENE	84	84	HL
NCT0000533514	NCT00005335_14_T2	GENE	27	27	LPL
NCT0000533514	NCT00005335_14_T3	GENE	90	90	LCAT
NCT0000533514	NCT00005335_14_T4	GENE	85	85	LRP
NCT0000533514	NCT00005335_14_T5	BIOLOGICAL_PROCESS	57	57	mutagenesis
NCT0000533514	NCT00005335_14_T6	GENE	146	146	gel
NCT0000533514	NCT00005335_14_T7	PHENOTYPE	88	88	COA
NCT0000533514	NCT00005335_14_T8	GENE	86	86	APOD
NCT0000533514	NCT00005335_14_T9	GENE	87	87	HMG
NCT0000533514	NCT00005335_14_T10	GENE	22	22	putative
NCT0000533514	NCT00005335_14_T11	GENE	68	68	putative
NCT0000533514	NCT00005335_14_T12	PHENOTYPE	16	16	SSCP
NCT0000533514	NCT00005335_14_T13	GENE	92	92	PON
NCT0000533514	NCT00005335_14_T14	PHENOTYPE	75	75	mutation
NCT0000533514	NCT00005335_14_T15	GENE	12	12	PCR
NCT0000533514	NCT00005335_14_T16	GENE	96	96	PCR
NCT0000533514	NCT00005335_14_T17	GENE	149	149	PCR
NCT000053363	NCT00005336_3_T0	GENE	2	2	had
NCT000053365	NCT00005336_5_T0	GENE	22	22	10.5
NCT000053365	NCT00005336_5_T1	GENE	20	20	4.5
NCT000053366	NCT00005336_6_T0	GENE	4	4	lipoprotein
NCT000053367	NCT00005336_7_T0	ORGAN	16	16	serum
NCT000053373	NCT00005337_3_T0	GENE	10	10	SNS
NCT000053373	NCT00005337_3_T1	PHENOTYPE	2	2	hostility
NCT000053373	NCT00005337_3_T2	PHENOTYPE	33	33	hostility
NCT000053373	NCT00005337_3_T3	GENE	37	37	CHD
NCT000053373	NCT00005337_3_T4	ORGAN	14	14	heart
NCT000053374	NCT00005337_4_T0	PHENOTYPE	13	14	myocardial ischemia
NCT000053374	NCT00005337_4_T1	PHENOTYPE	19	21	coronary heart disease
NCT000053381	NCT00005338_1_T0	COMPOUND	16	16	homocysteine
NCT000053381	NCT00005338_1_T1	ORGAN	15	15	plasma
NCT000053381	NCT00005338_1_T2	COMPOUND	11	12	folic acid
NCT000053381	NCT00005338_1_T3	PHENOTYPE	18	20	peripheral vascular disease
NCT000053384	NCT00005338_4_T0	PHENOTYPE	12	12	atherosclerosis
NCT000053384	NCT00005338_4_T1	COMPOUND	2	2	homocysteine
NCT000053384	NCT00005338_4_T2	ORGAN	1	1	plasma
NCT000053385	NCT00005338_5_T0	PHENOTYPE	23	23	atherosclerosis
NCT000053385	NCT00005338_5_T1	PHENOTYPE	27	27	toxic
NCT000053385	NCT00005338_5_T2	PHENOTYPE	7	7	progression
NCT000053385	NCT00005338_5_T3	COMPOUND	1	1	folate
NCT000053385	NCT00005338_5_T4	PHENOTYPE	9	11	peripheral vascular disease
NCT000053386	NCT00005338_6_T0	PHENOTYPE	5	5	Progression
NCT000053386	NCT00005338_6_T1	COMPOUND	30	30	homocysteine
NCT000053386	NCT00005338_6_T2	PHENOTYPE	43	43	progression
NCT000053386	NCT00005338_6_T3	PHENOTYPE	7	7	Atherosclerosis
NCT000053386	NCT00005338_6_T4	ORGAN	29	29	plasma
NCT000053387	NCT00005338_7_T0	PHENOTYPE	20	20	CVD
NCT000053387	NCT00005338_7_T1	GENE	16	16	LED
NCT000053387	NCT00005338_7_T2	PHENOTYPE	18	19	cerebrovascular disease
NCT000053387	NCT00005338_7_T3	ORGAN	14	15	lower extremity
NCT000053388	NCT00005338_8_T0	COMPOUND	21	21	homocysteine
NCT000053388	NCT00005338_8_T1	PHENOTYPE	14	14	progression
NCT000053388	NCT00005338_8_T2	ORGAN	20	20	plasma
NCT000053388	NCT00005338_8_T3	PHENOTYPE	16	18	peripheral vascular disease
NCT000053389	NCT00005338_9_T0	COMPOUND	20	20	homocysteine
NCT000053389	NCT00005338_9_T1	COMPOUND	39	39	homocysteine
NCT000053389	NCT00005338_9_T2	PHENOTYPE	24	24	progression
NCT000053389	NCT00005338_9_T3	ORGAN	19	19	plasma
NCT000053389	NCT00005338_9_T4	ORGAN	38	38	plasma
NCT000053389	NCT00005338_9_T5	PHENOTYPE	14	16	peripheral vascular disease
NCT000053389	NCT00005338_9_T6	PHENOTYPE	26	28	peripheral vascular disease
NCT000053389	NCT00005338_9_T7	PHENOTYPE	33	35	peripheral vascular disease
NCT0000533811	NCT00005338_11_T0	COMPOUND	13	13	homocysteine
NCT0000533811	NCT00005338_11_T1	ORGAN	12	12	plasma
NCT0000533812	NCT00005338_12_T0	COMPOUND	25	25	homocysteine
NCT0000533812	NCT00005338_12_T1	ORGAN	24	24	plasma
NCT0000533812	NCT00005338_12_T2	COMPOUND	19	20	folic acid
NCT0000533813	NCT00005338_13_T0	COMPOUND	13	13	homocysteine
NCT0000533813	NCT00005338_13_T1	GENE	3	3	has
NCT0000533813	NCT00005338_13_T2	ORGAN	12	12	plasma
NCT0000533814	NCT00005338_14_T0	COMPOUND	17	17	homocysteine
NCT0000533814	NCT00005338_14_T1	COMPOUND	39	39	homocysteine
NCT0000533814	NCT00005338_14_T2	COMPOUND	20	20	folate
NCT0000533814	NCT00005338_14_T3	PHENOTYPE	24	24	progression
NCT0000533814	NCT00005338_14_T4	ORGAN	16	16	plasma
NCT0000533814	NCT00005338_14_T5	ORGAN	38	38	plasma
NCT0000533814	NCT00005338_14_T6	PHENOTYPE	11	13	peripheral vascular disease
NCT0000533814	NCT00005338_14_T7	PHENOTYPE	26	28	peripheral vascular disease
NCT0000533814	NCT00005338_14_T8	PHENOTYPE	33	35	peripheral vascular disease
NCT0000533815	NCT00005338_15_T0	GENE	25	25	III
NCT0000533816	NCT00005338_16_T0	GENE	5	5	FY
NCT000053393	NCT00005339_3_T0	PHENOTYPE	16	16	cirrhosis
NCT000053393	NCT00005339_3_T1	PHENOTYPE	7	8	chronic hepatitis
NCT000053394	NCT00005339_4_T0	GENE	2	2	had
NCT000053394	NCT00005339_4_T1	PHENOTYPE	0	1	Hepatocellular carcinoma
NCT000053395	NCT00005339_5_T0	PHENOTYPE	26	26	NANBH
NCT000053395	NCT00005339_5_T1	COMPOUND	13	13	HCV
NCT000053395	NCT00005339_5_T2	COMPOUND	19	19	HCV
NCT000053396	NCT00005339_6_T0	COMPOUND	11	11	HCV
NCT000053397	NCT00005339_7_T0	COMPOUND	8	8	HCV
NCT000053397	NCT00005339_7_T1	PHENOTYPE	13	13	seronegative
NCT000053399	NCT00005339_9_T0	COMPOUND	5	5	HCV
NCT000053399	NCT00005339_9_T1	COMPOUND	16	16	HCV
NCT000053399	NCT00005339_9_T2	ORGAN	9	9	serum
NCT0000533910	NCT00005339_10_T0	GENE	6	6	sera
NCT0000533911	NCT00005339_11_T0	COMPOUND	10	10	HCV
NCT0000533911	NCT00005339_11_T1	COMPOUND	32	32	HCV
NCT0000533912	NCT00005339_12_T0	COMPOUND	12	12	HCV
NCT0000533913	NCT00005339_13_T0	COMPOUND	6	6	HCV
NCT0000533915	NCT00005339_15_T0	PHENOTYPE	14	14	regression
NCT000053403	NCT00005340_3_T0	PHENOTYPE	14	14	hypertension
NCT000053407	NCT00005340_7_T0	PHENOTYPE	5	5	hypertension
NCT000053409	NCT00005340_9_T0	GENE	9	9	extended
NCT0000534012	NCT00005340_12_T0	PHENOTYPE	17	17	hypertension
NCT0000534015	NCT00005340_15_T0	PHENOTYPE	5	5	hypertension
NCT0000534017	NCT00005340_17_T0	PHENOTYPE	0	0	Hypertension
NCT0000534018	NCT00005340_18_T0	PHENOTYPE	10	10	attributable
NCT0000534018	NCT00005340_18_T1	PHENOTYPE	13	13	hypertension
NCT0000534022	NCT00005340_22_T0	PHENOTYPE	11	11	hypertension
NCT0000534023	NCT00005340_23_T0	COMPOUND	24	24	sodium
NCT0000534023	NCT00005340_23_T1	GENE	5	5	FY
NCT0000534023	NCT00005340_23_T2	PHENOTYPE	26	26	obesity
NCT0000534024	NCT00005340_24_T0	COMPOUND	15	15	sodium
NCT0000534025	NCT00005340_25_T0	COMPOUND	5	5	sodium
NCT0000534026	NCT00005340_26_T0	TISSUE	22	23	body fat
NCT0000534028	NCT00005340_28_T0	PHENOTYPE	8	8	sequelae
NCT0000534028	NCT00005340_28_T1	PHENOTYPE	7	7	hypertension
NCT000053410	NCT00005341_0_T0	PHENOTYPE	4	4	Recruitment
NCT000053413	NCT00005341_3_T0	CELL	21	21	platelet
NCT000053413	NCT00005341_3_T1	ORGAN	19	19	plasma
NCT000053414	NCT00005341_4_T0	GENE	2	2	had
NCT000053416	NCT00005341_6_T0	PHENOTYPE	22	23	clinical findings
NCT000053417	NCT00005341_7_T0	PHENOTYPE	15	16	immune status
NCT0000534110	NCT00005341_10_T0	GENE	8	8	FY
NCT0000534110	NCT00005341_10_T1	GENE	3	3	extended
NCT000053423	NCT00005342_3_T0	PHENOTYPE	15	15	concentrations
NCT000053423	NCT00005342_3_T1	ORGAN	13	13	plasma
NCT000053424	NCT00005342_4_T0	GENE	8	8	had
NCT000053424	NCT00005342_4_T1	GENE	0	0	HDL
NCT000053424	NCT00005342_4_T2	GENE	37	37	PA
NCT000053424	NCT00005342_4_T3	PHENOTYPE	1	2	cholesterol levels
NCT000053425	NCT00005342_5_T0	GENE	1	1	PA
NCT000053425	NCT00005342_5_T1	PHENOTYPE	12	12	Diabetes
NCT000053425	NCT00005342_5_T2	PHENOTYPE	16	17	Kidney Diseases
NCT000053427	NCT00005342_7_T0	GENE	20	20	lipoprotein
NCT000053427	NCT00005342_7_T1	GENE	33	33	lipoprotein
NCT000053427	NCT00005342_7_T2	PHENOTYPE	39	40	weight loss
NCT000053432	NCT00005343_2_T0	ORGAN	17	17	serum
NCT000053432	NCT00005343_2_T1	PHENOTYPE	9	11	coronary heart disease
NCT000053435	NCT00005343_5_T0	GENE	10	10	has
NCT000053437	NCT00005343_7_T0	ORGAN	17	17	serum
NCT000053438	NCT00005343_8_T0	GENE	17	17	kin
NCT000053439	NCT00005343_9_T0	PHENOTYPE	1	1	regression
NCT000053442	NCT00005344_2_T0	GENE	39	39	ventricular
NCT000053442	NCT00005344_2_T1	PHENOTYPE	53	54	myocardial infarction
NCT000053442	NCT00005344_2_T2	PHENOTYPE	12	13	coronary disease
NCT000053442	NCT00005344_2_T3	PHENOTYPE	47	48	cardiac event
NCT000053442	NCT00005344_2_T4	PHENOTYPE	29	30	Group B
NCT000053442	NCT00005344_2_T5	PHENOTYPE	33	35	coronary artery disease
NCT000053443	NCT00005344_3_T0	GENE	6	6	structural
NCT000053443	NCT00005344_3_T1	PHENOTYPE	26	28	coronary artery disease
NCT000053443	NCT00005344_3_T2	PHENOTYPE	19	21	quality of life
NCT000053444	NCT00005344_4_T0	PHENOTYPE	6	6	perceived
NCT000053444	NCT00005344_4_T1	PHENOTYPE	16	16	hostility
NCT000053444	NCT00005344_4_T2	PHENOTYPE	24	25	Group B
NCT000053445	NCT00005344_5_T0	PHENOTYPE	29	30	Group B
NCT000053447	NCT00005344_7_T0	PHENOTYPE	0	1	Group B
NCT000053448	NCT00005344_8_T0	ORGAN	29	29	heart
NCT000053449	NCT00005344_9_T0	PHENOTYPE	0	1	Group B
NCT0000534410	NCT00005344_10_T0	GENE	4	4	had
NCT0000534412	NCT00005344_12_T0	PHENOTYPE	5	6	myocardial infarction
NCT0000534413	NCT00005344_13_T0	PHENOTYPE	37	37	severity
NCT0000534413	NCT00005344_13_T1	PHENOTYPE	7	7	regression
NCT000053453	NCT00005345_3_T0	GENE	3	3	had
NCT000053453	NCT00005345_3_T1	PHENOTYPE	19	19	obesity
NCT000053453	NCT00005345_3_T2	BIOLOGICAL_PROCESS	16	17	lipid metabolism
NCT000053455	NCT00005345_5_T0	PHENOTYPE	39	39	maturation
NCT000053455	NCT00005345_5_T1	TISSUE	24	25	body fat
NCT000053458	NCT00005345_8_T0	PHENOTYPE	31	31	obesity
NCT000053458	NCT00005345_8_T1	BIOLOGICAL_PROCESS	28	29	lipid metabolism
NCT0000534511	NCT00005345_11_T0	PHENOTYPE	36	36	maturation
NCT0000534511	NCT00005345_11_T1	PHENOTYPE	38	38	adiposity
NCT0000534511	NCT00005345_11_T2	TISSUE	25	26	body fat
NCT000053460	NCT00005346_0_T0	GENE	4	4	BP
NCT000053463	NCT00005346_3_T0	PHENOTYPE	10	12	increase blood pressure
NCT000053464	NCT00005346_4_T0	COMPOUND	10	10	sodium
NCT000053465	NCT00005346_5_T0	COMPOUND	8	8	sodium
NCT000053466	NCT00005346_6_T0	GENE	8	8	reduced
NCT000053466	NCT00005346_6_T1	PHENOTYPE	9	9	fluctuation
NCT000053466	NCT00005346_6_T2	GENE	12	12	extended
NCT000053466	NCT00005346_6_T3	PHENOTYPE	15	17	increased blood pressure
NCT000053468	NCT00005346_8_T0	COMPOUND	17	17	sodium
NCT0000534610	NCT00005346_10_T0	COMPOUND	21	21	sodium
NCT000053472	NCT00005347_2_T0	GENE	15	15	III
NCT000053474	NCT00005347_4_T0	COMPOUND	14	14	glucose
NCT000053474	NCT00005347_4_T1	GENE	28	28	CHD
NCT000053481	NCT00005348_1_T0	GENE	11	11	had
NCT000053481	NCT00005348_1_T1	PHENOTYPE	8	9	carotid atherosclerosis
NCT000053481	NCT00005348_1_T2	TISSUE	13	14	intra-abdominal fat
NCT000053481	NCT00005348_1_T3	TISSUE	20	21	intra-abdominal fat
NCT000053481	NCT00005348_1_T4	TISSUE	25	26	subcutaneous fat
NCT000053485	NCT00005348_5_T0	TISSUE	6	7	intra-abdominal fat
NCT000053485	NCT00005348_5_T1	TISSUE	29	30	intra-abdominal fat
NCT000053492	NCT00005349_2_T0	PHENOTYPE	7	7	atherosclerosis
NCT000053492	NCT00005349_2_T1	PHENOTYPE	16	16	plaques
NCT000053493	NCT00005349_3_T0	GENE	30	30	clot
NCT000053493	NCT00005349_3_T1	PHENOTYPE	26	26	rupture
NCT000053493	NCT00005349_3_T2	PHENOTYPE	18	18	symptoms
NCT000053493	NCT00005349_3_T3	PHENOTYPE	12	13	myocardial infarction
NCT000053495	NCT00005349_5_T0	COMPOUND	3	3	calcium
NCT000053496	NCT00005349_6_T0	GENE	21	21	CAC
NCT000053497	NCT00005349_7_T0	PHENOTYPE	22	22	atherosclerosis
NCT000053497	NCT00005349_7_T1	PHENOTYPE	35	35	symptoms
NCT000053497	NCT00005349_7_T2	PHENOTYPE	37	39	coronary artery disease
NCT000053497	NCT00005349_7_T3	PHENOTYPE	15	17	coronary artery calcification
NCT000053498	NCT00005349_8_T0	GENE	16	16	CAC
NCT000053498	NCT00005349_8_T1	GENE	37	37	CAC
NCT000053498	NCT00005349_8_T2	GENE	54	54	CAC
NCT000053498	NCT00005349_8_T3	GENE	62	62	CAC
NCT000053498	NCT00005349_8_T4	PHENOTYPE	72	72	symptoms
NCT000053498	NCT00005349_8_T5	BIOLOGICAL_PROCESS	9	10	lipid metabolism
NCT000053498	NCT00005349_8_T6	BIOLOGICAL_PROCESS	48	49	lipid metabolism
NCT000053498	NCT00005349_8_T7	PHENOTYPE	74	76	coronary artery disease
NCT000053499	NCT00005349_9_T0	GENE	20	20	CAC
NCT0000534910	NCT00005349_10_T0	GENE	12	12	CAC
NCT0000534910	NCT00005349_10_T1	GENE	28	28	CAC
NCT0000534910	NCT00005349_10_T2	PHENOTYPE	37	39	coronary artery disease
NCT0000534911	NCT00005349_11_T0	GENE	24	24	sub
NCT0000534911	NCT00005349_11_T1	GENE	17	17	CAC
NCT0000534912	NCT00005349_12_T0	GENE	8	8	fibrinogen
NCT0000534912	NCT00005349_12_T1	GENE	9	10	C-reactive protein
NCT0000534914	NCT00005349_14_T0	GENE	12	12	had
NCT0000534914	NCT00005349_14_T1	GENE	14	14	had
NCT0000534914	NCT00005349_14_T2	ORGAN	18	18	heart
NCT000053505	NCT00005350_5_T0	PHENOTYPE	81	81	strategies
NCT000053505	NCT00005350_5_T1	PHENOTYPE	13	15	coronary heart disease
NCT000053505	NCT00005350_5_T2	PHENOTYPE	18	20	coronary heart disease
NCT000053506	NCT00005350_6_T0	ORGAN	4	4	Heart
NCT000053506	NCT00005350_6_T1	PHENOTYPE	14	15	cholesterol levels
NCT000053507	NCT00005350_7_T0	PHENOTYPE	14	15	cholesterol levels
NCT0000535010	NCT00005350_10_T0	PHENOTYPE	12	12	projections
NCT0000535010	NCT00005350_10_T1	PHENOTYPE	18	18	strategies
NCT000053511	NCT00005351_1_T0	PHENOTYPE	2	2	DVT
NCT000053511	NCT00005351_1_T1	GENE	4	4	PE
NCT000053513	NCT00005351_3_T0	PHENOTYPE	6	6	embolism
NCT000053513	NCT00005351_3_T1	PHENOTYPE	32	32	embolism
NCT000053514	NCT00005351_4_T0	PHENOTYPE	14	14	embolism
NCT000053514	NCT00005351_4_T1	PHENOTYPE	19	19	embolism
NCT000053515	NCT00005351_5_T0	COMPOUND	6	6	1
NCT000053515	NCT00005351_5_T1	GENE	29	29	had
NCT000053515	NCT00005351_5_T2	GENE	41	41	had
NCT000053515	NCT00005351_5_T3	GENE	56	56	had
NCT000053515	NCT00005351_5_T4	PHENOTYPE	28	28	embolism
NCT000053515	NCT00005351_5_T5	PHENOTYPE	40	40	embolism
NCT000053515	NCT00005351_5_T6	PHENOTYPE	55	55	embolism
NCT000053516	NCT00005351_6_T0	COMPOUND	0	0	2
NCT000053516	NCT00005351_6_T1	PHENOTYPE	10	10	embolism
NCT000053516	NCT00005351_6_T2	PHENOTYPE	27	27	embolism
NCT000053517	NCT00005351_7_T0	COMPOUND	0	0	3
NCT000053517	NCT00005351_7_T1	PHENOTYPE	8	8	embolism
NCT000053519	NCT00005351_9_T0	PHENOTYPE	34	34	embolism
NCT000053519	NCT00005351_9_T1	PHENOTYPE	6	7	pulmonary embolism
NCT000053519	NCT00005351_9_T2	PHENOTYPE	12	13	pulmonary embolism
NCT000053519	NCT00005351_9_T3	PHENOTYPE	39	40	pulmonary embolism
NCT0000535110	NCT00005351_10_T0	PHENOTYPE	23	23	embolism
NCT000053523	NCT00005352_3_T0	GENE	29	29	shutdown
NCT000053528	NCT00005352_8_T0	PHENOTYPE	5	5	chronic
NCT000053529	NCT00005352_9_T0	PHENOTYPE	0	0	Perceptions
NCT000053529	NCT00005352_9_T1	PHENOTYPE	16	16	chronic
NCT000053533	NCT00005353_3_T0	PHENOTYPE	9	9	HIV
NCT000053533	NCT00005353_3_T1	PHENOTYPE	2	2	dysautonomia
NCT000053534	NCT00005353_4_T0	PHENOTYPE	27	27	Infection
NCT000053534	NCT00005353_4_T1	PHENOTYPE	26	26	HIV
NCT000053534	NCT00005353_4_T2	PHENOTYPE	24	24	Immunodeficiency
NCT000053534	NCT00005353_4_T3	PHENOTYPE	22	22	Transmitted
NCT000053534	NCT00005353_4_T4	PHENOTYPE	18	19	Cardiovascular Complications
NCT000053535	NCT00005353_5_T0	PHENOTYPE	41	41	dysautonomia
NCT000053535	NCT00005353_5_T1	GENE	27	27	had
NCT000053535	NCT00005353_5_T2	PHENOTYPE	23	23	HIV
NCT000053535	NCT00005353_5_T3	PHENOTYPE	14	15	HIV infection
NCT000053535	NCT00005353_5_T4	PHENOTYPE	44	45	HIV infection
NCT000053536	NCT00005353_6_T0	PHENOTYPE	16	16	dysautonomia
NCT000053536	NCT00005353_6_T1	PHENOTYPE	6	7	HIV infection
NCT000053536	NCT00005353_6_T2	PHENOTYPE	22	23	HIV infection
NCT000053537	NCT00005353_7_T0	ORGAN	0	0	Heart
NCT000053537	NCT00005353_7_T1	PHENOTYPE	20	20	centers
NCT000053537	NCT00005353_7_T2	ORGAN	39	39	heart
NCT000053537	NCT00005353_7_T3	ORGAN	32	34	parasympathetic nervous system
NCT000053538	NCT00005353_8_T0	ORGAN	9	9	heart
NCT000053538	NCT00005353_8_T1	ORGAN	23	25	parasympathetic nervous system
NCT000053541	NCT00005354_1_T0	PHENOTYPE	11	13	coronary artery calcification
NCT000053542	NCT00005354_2_T0	GENE	2	2	has
NCT000053542	NCT00005354_2_T1	GENE	4	4	extended
NCT000053542	NCT00005354_2_T2	PHENOTYPE	26	28	coronary artery calcification
NCT000053544	NCT00005354_4_T0	COMPOUND	2	2	calcium
NCT000053544	NCT00005354_4_T1	PHENOTYPE	7	7	atheromatous
NCT000053544	NCT00005354_4_T2	ORGAN	20	20	aorta
NCT000053544	NCT00005354_4_T3	ORGAN	16	17	coronary arteries
NCT000053545	NCT00005354_5_T0	GENE	20	20	CAC
NCT000053545	NCT00005354_5_T1	PHENOTYPE	17	19	coronary artery calcification
NCT000053547	NCT00005354_7_T0	GENE	3	3	CAC
NCT000053548	NCT00005354_8_T0	PHENOTYPE	18	19	aortic calcification
NCT000053548	NCT00005354_8_T1	ORGAN	15	16	coronary artery
NCT0000535411	NCT00005354_11_T0	PHENOTYPE	41	43	coronary artery calcification
NCT0000535412	NCT00005354_12_T0	GENE	12	12	ventricular
NCT0000535412	NCT00005354_12_T1	COMPOUND	9	9	homocyst_e_ine
NCT0000535413	NCT00005354_13_T0	PHENOTYPE	15	17	coronary artery calcification
NCT000053552	NCT00005355_2_T0	PHENOTYPE	13	13	resolved
NCT000053553	NCT00005355_3_T0	GENE	13	13	twins
NCT000053564	NCT00005356_4_T0	GENE	6	6	thrombin
NCT000053564	NCT00005356_4_T1	PHENOTYPE	16	16	thrombosis
NCT000053564	NCT00005356_4_T2	GENE	7	7	III
NCT000053565	NCT00005356_5_T0	GENE	15	15	has
NCT000053566	NCT00005356_6_T0	GENE	4	4	plasminogen
NCT000053566	NCT00005356_6_T1	CELL	2	2	Platelet
NCT000053566	NCT00005356_6_T2	GENE	7	7	fibrinogen
NCT000053566	NCT00005356_6_T3	GENE	12	12	VII
NCT000053567	NCT00005356_7_T0	PHENOTYPE	18	19	carotid atherosclerosis
NCT000053567	NCT00005356_7_T1	PHENOTYPE	47	48	cardiac death
NCT000053567	NCT00005356_7_T2	PHENOTYPE	44	45	myocardial infarction
NCT000053574	NCT00005357_4_T0	GENE	18	18	PPH
NCT000053575	NCT00005357_5_T0	GENE	7	7	has
NCT000053575	NCT00005357_5_T1	PHENOTYPE	19	20	incomplete penetrance
NCT000053575	NCT00005357_5_T2	PHENOTYPE	22	23	genetic anticipation
NCT000053575	NCT00005357_5_T3	PHENOTYPE	15	17	autosomal dominant disorder
NCT000053576	NCT00005357_6_T0	CELL	10	10	chromosome
NCT000053576	NCT00005357_6_T1	PHENOTYPE	15	16	genetic heterogeneity
NCT000053577	NCT00005357_7_T0	GENE	10	10	PPH
NCT000053578	NCT00005357_8_T0	PHENOTYPE	32	33	autosomal dominant
NCT000053578	NCT00005357_8_T1	PHENOTYPE	21	23	mode of inheritance
NCT000053579	NCT00005357_9_T0	GENE	19	19	PPH
NCT0000535710	NCT00005357_10_T0	CELL	11	11	lymphocytes
NCT0000535710	NCT00005357_10_T1	PHENOTYPE	10	10	transformed
NCT0000535710	NCT00005357_10_T2	PHENOTYPE	17	18	pulmonary hypertension
NCT0000535712	NCT00005357_12_T0	PHENOTYPE	16	16	deletion
NCT0000535712	NCT00005357_12_T1	CELL	7	7	chromosome
NCT0000535712	NCT00005357_12_T2	PHENOTYPE	13	14	chromosomal translocation
NCT0000535713	NCT00005357_13_T0	CELL	8	8	leukocyte
NCT0000535713	NCT00005357_13_T1	GENE	15	15	PPH
NCT0000535716	NCT00005357_16_T0	PHENOTYPE	20	20	localize
NCT0000535716	NCT00005357_16_T1	CELL	22	22	clone
NCT0000535716	NCT00005357_16_T2	GENE	17	17	PPH
NCT0000535716	NCT00005357_16_T3	GENE	24	24	PPH
NCT0000535717	NCT00005357_17_T0	GENE	18	18	PPH
NCT0000535717	NCT00005357_17_T1	GENE	6	6	mediator
NCT0000535718	NCT00005357_18_T0	PHENOTYPE	18	18	diseases
NCT0000535718	NCT00005357_18_T1	GENE	10	10	PPH
NCT0000535719	NCT00005357_19_T0	PHENOTYPE	9	9	sporadic
NCT0000535719	NCT00005357_19_T1	GENE	4	4	broadened
NCT0000535719	NCT00005357_19_T2	GENE	10	10	PPH
NCT0000535719	NCT00005357_19_T3	GENE	15	15	had
NCT000053584	NCT00005358_4_T0	PHENOTYPE	0	0	Secondary
NCT000053584	NCT00005358_4_T1	GENE	35	35	had
NCT000053593	NCT00005359_3_T0	PHENOTYPE	20	20	understood
NCT000053594	NCT00005359_4_T0	PHENOTYPE	7	7	asthma
NCT000053595	NCT00005359_5_T0	GENE	3	3	Dr
NCT000053599	NCT00005359_9_T0	PHENOTYPE	16	16	asthma
NCT000053599	NCT00005359_9_T1	COMPOUND	14	14	BHR
NCT000053599	NCT00005359_9_T2	PHENOTYPE	12	13	bronchial hyperresponsiveness
NCT0000535910	NCT00005359_10_T0	PHENOTYPE	19	19	atopy
NCT0000535910	NCT00005359_10_T1	PHENOTYPE	1	1	allergy
NCT0000535910	NCT00005359_10_T2	PHENOTYPE	6	6	asthma
NCT0000535911	NCT00005359_11_T0	GENE	15	15	IgE
NCT0000535911	NCT00005359_11_T1	PHENOTYPE	19	19	eosinophilia
NCT0000535911	NCT00005359_11_T2	ORGAN	11	11	serum
NCT0000535912	NCT00005359_12_T0	PHENOTYPE	11	11	allergy
NCT0000535912	NCT00005359_12_T1	PHENOTYPE	8	8	asthma
NCT0000535912	NCT00005359_12_T2	COMPOUND	9	9	BHR
NCT000053603	NCT00005360_3_T0	CELL	1	1	cells
NCT000053603	NCT00005360_3_T1	GENE	3	3	sera
NCT000053606	NCT00005360_6_T0	ORGAN	6	6	serum
NCT000053607	NCT00005360_7_T0	PHENOTYPE	20	20	progression
NCT000053613	NCT00005361_3_T0	PHENOTYPE	18	19	lung function
NCT000053615	NCT00005361_5_T0	PHENOTYPE	7	8	lung function
NCT000053616	NCT00005361_6_T0	PHENOTYPE	1	1	exposures
NCT000053618	NCT00005361_8_T0	PHENOTYPE	14	14	FVC
NCT000053618	NCT00005361_8_T1	PHENOTYPE	29	29	FVC
NCT000053618	NCT00005361_8_T2	PHENOTYPE	3	4	lung function
NCT000053619	NCT00005361_9_T0	PHENOTYPE	1	2	lung function
NCT0000536110	NCT00005361_10_T0	PHENOTYPE	25	25	exposures
NCT0000536110	NCT00005361_10_T1	PHENOTYPE	30	31	lung function
NCT000053623	NCT00005362_3_T0	PHENOTYPE	15	15	concentrations
NCT000053623	NCT00005362_3_T1	GENE	9	9	toxin
NCT000053624	NCT00005362_4_T0	BIOLOGICAL_PROCESS	13	13	metabolism
NCT000053625	NCT00005362_5_T0	PHENOTYPE	18	18	concentrations
NCT000053625	NCT00005362_5_T1	GENE	9	9	toxin
NCT000053626	NCT00005362_6_T0	PHENOTYPE	49	49	symptoms
NCT000053626	NCT00005362_6_T1	COMPOUND	37	38	sodium borate
NCT000053627	NCT00005362_7_T0	PHENOTYPE	17	17	focused
NCT000053632	NCT00005363_2_T0	GENE	28	28	ventricular
NCT000053633	NCT00005363_3_T0	COMPOUND	6	6	BMI
NCT000053634	NCT00005363_4_T0	PHENOTYPE	12	13	myocardial infarction
NCT000053634	NCT00005363_4_T1	ORGAN	19	20	coronary artery
NCT000053634	NCT00005363_4_T2	PHENOTYPE	15	17	congestive heart failure
NCT000053634	NCT00005363_4_T3	PHENOTYPE	9	11	sudden cardiac death
NCT000053635	NCT00005363_5_T0	PHENOTYPE	46	46	hypertension
NCT000053635	NCT00005363_5_T1	PHENOTYPE	23	25	white coat hypertension
NCT000053636	NCT00005363_6_T0	ORGAN	34	34	serum
NCT000053643	NCT00005364_3_T0	COMPOUND	17	17	IEF
NCT000053647	NCT00005364_7_T0	PHENOTYPE	6	6	RFLP
NCT000053652	NCT00005365_2_T0	GENE	4	4	has
NCT000053652	NCT00005365_2_T1	PHENOTYPE	7	7	Syndrome
NCT000053653	NCT00005365_3_T0	PHENOTYPE	4	4	Syndrome
NCT000053663	NCT00005366_3_T0	PHENOTYPE	13	14	cardiovascular morbidity
NCT000053663	NCT00005366_3_T1	PHENOTYPE	1	3	left ventricular hypertrophy
NCT000053663	NCT00005366_3_T2	PHENOTYPE	17	19	high blood pressure
NCT000053664	NCT00005366_4_T0	GENE	20	20	ventricular
NCT000053664	NCT00005366_4_T1	PHENOTYPE	7	9	left ventricular hypertrophy
NCT000053666	NCT00005366_6_T0	PHENOTYPE	12	14	left ventricular hypertrophy
NCT000053669	NCT00005366_9_T0	GENE	15	15	ventricular
NCT000053669	NCT00005366_9_T1	PHENOTYPE	1	3	systemic vascular resistance
NCT0000536611	NCT00005366_11_T0	PHENOTYPE	19	21	hypertensive heart disease
NCT000053672	NCT00005367_2_T0	PHENOTYPE	4	5	ventricular fibrillation
NCT000053673	NCT00005367_3_T0	GENE	33	33	SE
NCT000053673	NCT00005367_3_T1	PHENOTYPE	6	6	inferred
NCT000053676	NCT00005367_6_T0	PHENOTYPE	25	25	hypokalemia
NCT000053676	NCT00005367_6_T1	COMPOUND	13	13	thiamine
NCT000053681	NCT00005368_1_T0	GENE	30	30	apo
NCT000053681	NCT00005368_1_T1	GENE	35	35	apo
NCT000053681	NCT00005368_1_T2	GENE	9	9	lipoprotein
NCT000053681	NCT00005368_1_T3	GENE	18	18	ALP
NCT000053681	NCT00005368_1_T4	GENE	16	16	Lipoprotein
NCT000053681	NCT00005368_1_T5	GENE	25	25	LDL
NCT000053681	NCT00005368_1_T6	ORGAN	32	32	plasma
NCT000053681	NCT00005368_1_T7	GENE	13	13	CHD
NCT000053683	NCT00005368_3_T0	GENE	24	24	CHD
NCT000053683	NCT00005368_3_T1	PHENOTYPE	44	45	familial hypertriglyceridemia
NCT000053683	NCT00005368_3_T2	PHENOTYPE	40	42	familial combined hyperlipidemia
NCT000053684	NCT00005368_4_T0	ORGAN	8	8	plasma
NCT000053684	NCT00005368_4_T1	GENE	14	14	CHD
NCT000053686	NCT00005368_6_T0	ORGAN	8	8	plasma
NCT000053686	NCT00005368_6_T1	CELL	4	6	white blood cells
NCT000053687	NCT00005368_7_T0	GENE	24	24	CHD
NCT000053689	NCT00005368_9_T0	GENE	5	5	FY
NCT000053692	NCT00005369_2_T0	PHENOTYPE	17	19	Coronary Heart Disease
NCT000053694	NCT00005369_4_T0	GENE	4	4	had
NCT000053694	NCT00005369_4_T1	PHENOTYPE	9	10	coronary disease
NCT000053694	NCT00005369_4_T2	PHENOTYPE	15	16	coronary disease
NCT000053695	NCT00005369_5_T0	COMPOUND	28	28	glucose
NCT000053695	NCT00005369_5_T1	GENE	31	31	fibrinogen
NCT000053695	NCT00005369_5_T2	GENE	29	29	insulin
NCT000053695	NCT00005369_5_T3	COMPOUND	39	39	thallium
NCT000053695	NCT00005369_5_T4	GENE	25	25	A1
NCT000053695	NCT00005369_5_T5	PHENOTYPE	13	14	coronary disease
NCT000053695	NCT00005369_5_T6	PHENOTYPE	44	45	coronary disease
NCT000053696	NCT00005369_6_T0	CELL	0	0	Platelet
NCT000053696	NCT00005369_6_T1	GENE	10	10	receptor
NCT000053696	NCT00005369_6_T2	ORGAN	13	13	serum
NCT000053696	NCT00005369_6_T3	COMPOUND	14	15	thromboxane B2
NCT000053697	NCT00005369_7_T0	GENE	13	13	ventricular
NCT000053697	NCT00005369_7_T1	ORGAN	34	34	heart
NCT000053697	NCT00005369_7_T2	PHENOTYPE	32	32	ischemia
NCT000053697	NCT00005369_7_T3	GENE	18	18	QRS
NCT000053697	NCT00005369_7_T4	PHENOTYPE	27	28	ventricular arrhythmias
NCT000053697	NCT00005369_7_T5	PHENOTYPE	3	5	sudden cardiac death
NCT000053699	NCT00005369_9_T0	PHENOTYPE	16	16	severity
NCT000053699	NCT00005369_9_T1	TISSUE	32	32	endothelium
NCT000053699	NCT00005369_9_T2	COMPOUND	30	30	acetylcholine
NCT000053699	NCT00005369_9_T3	COMPOUND	7	7	thallium
NCT000053699	NCT00005369_9_T4	PHENOTYPE	19	20	coronary disease
NCT0000536910	NCT00005369_10_T0	ORGAN	28	28	arteries
NCT0000536910	NCT00005369_10_T1	PHENOTYPE	27	27	proximal
NCT0000536910	NCT00005369_10_T2	COMPOUND	15	15	acetylcholine
NCT0000536910	NCT00005369_10_T3	ORGAN	1	2	coronary arteries
NCT0000536910	NCT00005369_10_T4	PHENOTYPE	10	11	vascular resistance
NCT000053701	NCT00005370_1_T0	COMPOUND	9	9	cortisol
NCT000053701	NCT00005370_1_T1	PHENOTYPE	10	10	concentrations
NCT000053701	NCT00005370_1_T2	BIOLOGICAL_PROCESS	29	29	aging
NCT000053701	NCT00005370_1_T3	ORGAN	8	8	plasma
NCT000053703	NCT00005370_3_T0	BIOLOGICAL_PROCESS	8	8	Aging
NCT000053706	NCT00005370_6_T0	CELL	9	9	leukocyte
NCT000053706	NCT00005370_6_T1	COMPOUND	12	12	methacholine
NCT000053715	NCT00005371_5_T0	PHENOTYPE	12	12	Center
NCT000053726	NCT00005372_6_T0	PHENOTYPE	8	8	atherosclerosis
NCT000053726	NCT00005372_6_T1	GENE	15	15	LDL
NCT000053726	NCT00005372_6_T2	ORGAN	19	19	serum
NCT000053729	NCT00005372_9_T0	PHENOTYPE	32	33	myocardial infarction
NCT0000537212	NCT00005372_12_T0	COMPOUND	9	9	carotene
NCT0000537212	NCT00005372_12_T1	COMPOUND	6	6	ascorbate
NCT0000537212	NCT00005372_12_T2	ORGAN	12	12	plasma
NCT0000537212	NCT00005372_12_T3	GENE	8	8	beta
NCT0000537213	NCT00005372_13_T0	ORGAN	0	0	Plasma
NCT0000537213	NCT00005372_13_T1	GENE	5	5	LDL
NCT0000537213	NCT00005372_13_T2	PHENOTYPE	17	17	progressing
NCT0000537213	NCT00005372_13_T3	PHENOTYPE	32	32	progressing
NCT0000537214	NCT00005372_14_T0	PHENOTYPE	12	12	atherosclerosis
NCT0000537214	NCT00005372_14_T1	PHENOTYPE	6	7	arterial stiffness
NCT0000537215	NCT00005372_15_T0	PHENOTYPE	41	41	stiffness
NCT0000537215	NCT00005372_15_T1	PHENOTYPE	30	30	dysfunction
NCT0000537215	NCT00005372_15_T2	PHENOTYPE	3	3	Atherosclerosis
NCT0000537215	NCT00005372_15_T3	GENE	6	6	has
NCT0000537215	NCT00005372_15_T4	ORGAN	36	37	brachial artery
NCT0000537215	NCT00005372_15_T5	ORGAN	44	46	common carotid artery
NCT000053732	NCT00005373_2_T0	PHENOTYPE	31	31	physiology
NCT000053732	NCT00005373_2_T1	PHENOTYPE	26	26	diseases
NCT000053732	NCT00005373_2_T2	PHENOTYPE	9	10	myocardial ischemia
NCT000053732	NCT00005373_2_T3	PHENOTYPE	17	19	coronary artery atherosclerosis
NCT000053735	NCT00005373_5_T0	PHENOTYPE	13	14	coronary disease
NCT000053735	NCT00005373_5_T1	PHENOTYPE	10	11	ventricular hypertrophy
NCT000053739	NCT00005373_9_T0	PHENOTYPE	10	10	autoregulation
NCT000053739	NCT00005373_9_T1	PHENOTYPE	12	12	chronic
NCT000053739	NCT00005373_9_T2	PHENOTYPE	13	13	hypertension
NCT000053739	NCT00005373_9_T3	ORGAN	8	9	coronary artery
NCT0000537310	NCT00005373_10_T0	PHENOTYPE	9	9	autoregulation
NCT0000537310	NCT00005373_10_T1	PHENOTYPE	27	27	ischemia
NCT000053741	NCT00005374_1_T0	GENE	5	5	had
NCT000053741	NCT00005374_1_T1	GENE	18	18	CHD
NCT000053741	NCT00005374_1_T2	PHENOTYPE	15	17	coronary heart disease
NCT000053743	NCT00005374_3_T0	GENE	14	14	CHD
NCT000053746	NCT00005374_6_T0	PHENOTYPE	33	33	associations
NCT000053746	NCT00005374_6_T1	ORGAN	2	2	plasma
NCT000053746	NCT00005374_6_T2	ORGAN	55	55	plasma
NCT000053747	NCT00005374_7_T0	CELL	9	9	cells
NCT000053747	NCT00005374_7_T1	GENE	21	21	CHD
NCT000053748	NCT00005374_8_T0	PHENOTYPE	29	29	Diabetes
NCT0000537410	NCT00005374_10_T0	GENE	4	4	has
NCT000053750	NCT00005375_0_T0	PHENOTYPE	1	1	Onset
NCT000053753	NCT00005375_3_T0	PHENOTYPE	15	15	initiation
NCT000053753	NCT00005375_3_T1	PHENOTYPE	28	28	initiation
NCT000053754	NCT00005375_4_T0	PHENOTYPE	9	9	initiation
NCT000053756	NCT00005375_6_T0	GENE	5	5	has
NCT000053757	NCT00005375_7_T0	GENE	26	26	has
NCT0000537510	NCT00005375_10_T0	GENE	0	0	Dr
NCT0000537511	NCT00005375_11_T0	GENE	4	4	Eck
NCT0000537511	NCT00005375_11_T1	GENE	2	2	Dr
NCT0000537511	NCT00005375_11_T2	PHENOTYPE	17	18	metabolic rate
NCT0000537512	NCT00005375_12_T0	GENE	6	6	FY
NCT0000537512	NCT00005375_12_T1	GENE	0	0	Dr
NCT0000537514	NCT00005375_14_T0	PHENOTYPE	45	46	late onset
NCT000053762	NCT00005376_2_T0	GENE	8	8	fold
NCT000053762	NCT00005376_2_T1	GENE	4	4	has
NCT000053762	NCT00005376_2_T2	GENE	24	24	has
NCT000053762	NCT00005376_2_T3	PHENOTYPE	17	18	bronchopulmonary dysplasia
NCT0000537610	NCT00005376_10_T0	PHENOTYPE	13	14	lung function
NCT0000537611	NCT00005376_11_T0	PHENOTYPE	38	38	strategies
NCT0000537611	NCT00005376_11_T1	PHENOTYPE	25	26	premature infants
NCT0000537611	NCT00005376_11_T2	ORGAN	4	5	respiratory system
NCT000053770	NCT00005377_0_T0	PHENOTYPE	3	4	Essential Hypertension
NCT000053773	NCT00005377_3_T0	PHENOTYPE	3	3	localize
NCT000053773	NCT00005377_3_T1	PHENOTYPE	27	28	essential hypertension
NCT000053773	NCT00005377_3_T2	PHENOTYPE	30	32	coronary artery disease
NCT000053774	NCT00005377_4_T0	GENE	4	4	has
NCT000053776	NCT00005377_6_T0	PHENOTYPE	15	15	physiology
NCT000053776	NCT00005377_6_T1	BIOLOGICAL_PROCESS	22	23	lipid metabolism
NCT000053776	NCT00005377_6_T2	BIOLOGICAL_PROCESS	12	13	ion transport
NCT000053777	NCT00005377_7_T0	GENE	10	10	has
NCT000053778	NCT00005377_8_T0	PHENOTYPE	21	21	localize
NCT000053779	NCT00005377_9_T0	PHENOTYPE	27	28	essential hypertension
NCT0000537710	NCT00005377_10_T0	PHENOTYPE	30	31	essential hypertension
NCT0000537710	NCT00005377_10_T1	PHENOTYPE	16	18	coronary artery disease
NCT0000537711	NCT00005377_11_T0	PHENOTYPE	18	19	essential hypertension
NCT0000537711	NCT00005377_11_T1	PHENOTYPE	21	23	coronary artery disease
NCT0000537712	NCT00005377_12_T0	GENE	5	5	FY
NCT000053786	NCT00005378_6_T0	PHENOTYPE	9	9	NAS
NCT000053786	NCT00005378_6_T1	BIOLOGICAL_PROCESS	7	7	Aging
NCT000053788	NCT00005378_8_T0	PHENOTYPE	3	5	quality of life
NCT000053793	NCT00005379_3_T0	PHENOTYPE	17	17	centers
NCT000053793	NCT00005379_3_T1	PHENOTYPE	25	26	cardiovascular diseases
NCT000053796	NCT00005379_6_T0	PHENOTYPE	35	35	Center
NCT000053799	NCT00005379_9_T0	PHENOTYPE	5	6	HIV disease
NCT0000537910	NCT00005379_10_T0	PHENOTYPE	4	4	RFLP
NCT000053801	NCT00005380_1_T0	GENE	7	7	se
NCT000053801	NCT00005380_1_T1	PHENOTYPE	5	5	hyperinsulinemia
NCT000053801	NCT00005380_1_T2	PHENOTYPE	13	14	cardiovascular disease
NCT000053802	NCT00005380_2_T0	PHENOTYPE	19	19	hyperinsulinemia
NCT000053809	NCT00005380_9_T0	PHENOTYPE	17	17	centers
NCT000053809	NCT00005380_9_T1	PHENOTYPE	25	26	cardiovascular disease
NCT0000538012	NCT00005380_12_T0	PHENOTYPE	14	14	hyperinsulinemia
NCT0000538013	NCT00005380_13_T0	COMPOUND	6	6	androgen
NCT0000538013	NCT00005380_13_T1	PHENOTYPE	3	3	hyperinsulinemia
NCT0000538013	NCT00005380_13_T2	ORGAN	17	17	serum
NCT0000538013	NCT00005380_13_T3	PHENOTYPE	12	14	impaired glucose tolerance
NCT0000538013	NCT00005380_13_T4	PHENOTYPE	9	11	high blood pressure
NCT0000538018	NCT00005380_18_T0	GENE	9	9	Dr
NCT0000538018	NCT00005380_18_T1	GENE	14	14	Dr
NCT0000538018	NCT00005380_18_T2	GENE	19	19	Dr
NCT000053815	NCT00005381_5_T0	GENE	8	8	2.2
NCT000053815	NCT00005381_5_T1	PHENOTYPE	18	19	sleep apnea
NCT000053818	NCT00005381_8_T0	PHENOTYPE	10	10	snoring
NCT000053818	NCT00005381_8_T1	PHENOTYPE	8	8	obesity
NCT0000538112	NCT00005381_12_T0	PHENOTYPE	4	5	sleep apnea
NCT000053823	NCT00005382_3_T0	PHENOTYPE	24	24	FVC
NCT000053823	NCT00005382_3_T1	GENE	12	12	contrasted
NCT000053824	NCT00005382_4_T0	PHENOTYPE	2	2	Thoracic
NCT000053829	NCT00005382_9_T0	PHENOTYPE	10	10	asthmatics
NCT000053832	NCT00005383_2_T0	COMPOUND	19	19	glucose
NCT000053832	NCT00005383_2_T1	GENE	17	17	insulin
NCT000053832	NCT00005383_2_T2	GENE	15	15	BP
NCT000053832	NCT00005383_2_T3	PHENOTYPE	23	24	central obesity
NCT000053838	NCT00005383_8_T0	PHENOTYPE	32	32	perceived
NCT000053838	NCT00005383_8_T1	PHENOTYPE	44	44	chronic
NCT000053847	NCT00005384_7_T0	GENE	5	5	San
NCT000053848	NCT00005384_8_T0	PHENOTYPE	35	35	CVD
NCT0000538410	NCT00005384_10_T0	COMPOUND	22	22	sodium
NCT0000538411	NCT00005384_11_T0	PHENOTYPE	20	20	adiposity
NCT0000538411	NCT00005384_11_T1	ORGAN	24	24	serum
NCT0000538411	NCT00005384_11_T2	PHENOTYPE	10	10	practices
NCT0000538412	NCT00005384_12_T0	COMPOUND	20	20	sodium
NCT000053852	NCT00005385_2_T0	GENE	3	3	has
NCT000053853	NCT00005385_3_T0	GENE	19	19	lipoprotein
NCT000053853	NCT00005385_3_T1	GENE	22	22	lipoprotein
NCT000053853	NCT00005385_3_T2	GENE	24	24	lipoprotein
NCT000053853	NCT00005385_3_T3	GENE	31	31	lipoprotein
NCT000053853	NCT00005385_3_T4	GENE	27	27	AI
NCT000053856	NCT00005385_6_T0	ORGAN	4	4	serum
NCT000053856	NCT00005385_6_T1	CELL	10	10	platelets
NCT000053856	NCT00005385_6_T2	COMPOUND	23	23	BMI
NCT0000538510	NCT00005385_10_T0	PHENOTYPE	22	22	regression
NCT000053860	NCT00005386_0_T0	PHENOTYPE	3	3	Obesity
NCT000053864	NCT00005386_4_T0	PHENOTYPE	0	0	Obesity
NCT000053864	NCT00005386_4_T1	PHENOTYPE	11	11	hypertension
NCT000053864	NCT00005386_4_T2	PHENOTYPE	7	8	cardiovascular disease
NCT000053865	NCT00005386_5_T0	PHENOTYPE	0	0	Obesity
NCT000053867	NCT00005386_7_T0	PHENOTYPE	14	15	metabolic rate
NCT000053867	NCT00005386_7_T1	TISSUE	23	24	body fat
NCT000053868	NCT00005386_8_T0	PHENOTYPE	9	9	adiposity
NCT000053873	NCT00005387_3_T0	GENE	3	3	angiotensinogen
NCT000053874	NCT00005387_4_T0	GENE	6	6	RAS
NCT000053874	NCT00005387_4_T1	GENE	14	14	RAS
NCT000053874	NCT00005387_4_T2	PHENOTYPE	23	23	hypertension
NCT000053875	NCT00005387_5_T0	GENE	10	10	RAS
NCT000053875	NCT00005387_5_T1	PHENOTYPE	25	25	hypertension
NCT000053876	NCT00005387_6_T0	PHENOTYPE	21	21	hypertension
NCT000053877	NCT00005387_7_T0	GENE	19	19	RAS
NCT000053877	NCT00005387_7_T1	GENE	29	29	RAS
NCT000053877	NCT00005387_7_T2	GENE	60	60	RAS
NCT000053877	NCT00005387_7_T3	GENE	87	87	RAS
NCT000053877	NCT00005387_7_T4	GENE	94	94	RAS
NCT000053877	NCT00005387_7_T5	PHENOTYPE	108	108	reflected
NCT000053877	NCT00005387_7_T6	PHENOTYPE	83	83	hypertension
NCT000053877	NCT00005387_7_T7	PHENOTYPE	91	91	hypertension
NCT000053877	NCT00005387_7_T8	PHENOTYPE	104	104	hypertension
NCT0000538712	NCT00005387_12_T0	GENE	5	5	FY
NCT0000538713	NCT00005387_13_T0	COMPOUND	21	21	sodium
NCT0000538713	NCT00005387_13_T1	PHENOTYPE	19	19	obesity
NCT0000538715	NCT00005387_15_T0	GENE	7	7	adducin
NCT0000538715	NCT00005387_15_T1	GENE	9	11	beta-2 adrenergic receptor
NCT000053880	NCT00005388_0_T0	GENE	5	5	CHD
NCT000053880	NCT00005388_0_T1	TISSUE	0	1	Visceral Fat
NCT000053883	NCT00005388_3_T0	PHENOTYPE	12	12	understood
NCT000053883	NCT00005388_3_T1	PHENOTYPE	9	9	obesity
NCT000053887	NCT00005388_7_T0	GENE	26	26	CHD
NCT000053887	NCT00005388_7_T1	PHENOTYPE	23	25	coronary heart disease
NCT000053887	NCT00005388_7_T2	TISSUE	9	11	visceral adipose tissue
NCT000053888	NCT00005388_8_T0	GENE	7	7	had
NCT000053888	NCT00005388_8_T1	TISSUE	18	19	body fat
NCT000053888	NCT00005388_8_T2	TISSUE	9	11	visceral adipose tissue
NCT000053889	NCT00005388_9_T0	GENE	11	11	CHD
NCT000053889	NCT00005388_9_T1	TISSUE	4	6	visceral adipose tissue
NCT0000538810	NCT00005388_10_T0	PHENOTYPE	7	7	obesity
NCT0000538810	NCT00005388_10_T1	GENE	9	9	CHD
NCT0000538813	NCT00005388_13_T0	TISSUE	17	19	visceral adipose tissue
NCT0000538814	NCT00005388_14_T0	PHENOTYPE	17	17	adiposity
NCT0000538814	NCT00005388_14_T1	PHENOTYPE	19	20	thyroid function
NCT0000538814	NCT00005388_14_T2	PHENOTYPE	14	15	metabolic rate
NCT0000538814	NCT00005388_14_T3	PHENOTYPE	28	29	energy expenditure
NCT0000538815	NCT00005388_15_T0	COMPOUND	15	15	glucose
NCT0000538815	NCT00005388_15_T1	GENE	14	14	insulin
NCT0000538815	NCT00005388_15_T2	TISSUE	30	31	body fat
NCT0000538815	NCT00005388_15_T3	PHENOTYPE	6	8	cardiovascular risk factor
NCT000053893	NCT00005389_3_T0	PHENOTYPE	0	2	Coronary heart disease
NCT000053894	NCT00005389_4_T0	PHENOTYPE	12	13	myocardial infarction
NCT000053895	NCT00005389_5_T0	PHENOTYPE	12	13	myocardial infarction
NCT000053898	NCT00005389_8_T0	PHENOTYPE	22	22	suffered
NCT000053898	NCT00005389_8_T1	PHENOTYPE	25	26	heart attack
NCT0000538913	NCT00005389_13_T0	COMPOUND	26	26	estrogen
NCT0000538913	NCT00005389_13_T1	COMPOUND	20	20	angiotensin
NCT0000538913	NCT00005389_13_T2	PHENOTYPE	17	18	myocardial infarction
NCT000053902	NCT00005390_2_T0	PHENOTYPE	19	19	asthma
NCT000053902	NCT00005390_2_T1	PHENOTYPE	22	22	asthma
NCT000053903	NCT00005390_3_T0	PHENOTYPE	16	16	asthma
NCT000053912	NCT00005391_2_T0	PHENOTYPE	6	6	cardiomyopathy
NCT000053913	NCT00005391_3_T0	PHENOTYPE	2	2	cardiomyopathy
NCT000053914	NCT00005391_4_T0	PHENOTYPE	25	25	diseases
NCT0000539111	NCT00005391_11_T0	PHENOTYPE	4	4	centers
NCT0000539112	NCT00005391_12_T0	PHENOTYPE	38	38	associations
NCT0000539112	NCT00005391_12_T1	PHENOTYPE	14	14	cardiomyopathy
NCT0000539112	NCT00005391_12_T2	PHENOTYPE	29	29	cardiomyopathy
NCT0000539112	NCT00005391_12_T3	PHENOTYPE	45	45	cardiomyopathy
NCT0000539114	NCT00005391_14_T0	ORGAN	21	21	Heart
NCT0000539114	NCT00005391_14_T1	PHENOTYPE	15	15	Cardiomyopathy
NCT0000539114	NCT00005391_14_T2	PHENOTYPE	8	8	cardiomyopathy
NCT0000539114	NCT00005391_14_T3	PHENOTYPE	39	39	cardiomyopathy
NCT0000539114	NCT00005391_14_T4	ORGAN	22	22	Transplant
NCT0000539115	NCT00005391_15_T0	PHENOTYPE	11	11	cardiomyopathy
NCT0000539116	NCT00005391_16_T0	PHENOTYPE	13	13	cardiomyopathy
NCT0000539117	NCT00005391_17_T0	PHENOTYPE	12	12	cardiomyopathy
NCT0000539117	NCT00005391_17_T1	ORGAN	20	20	heart
NCT0000539118	NCT00005391_18_T0	PHENOTYPE	19	19	cardiomyopathy
NCT0000539119	NCT00005391_19_T0	PHENOTYPE	24	24	Cardiomyopathy
NCT0000539119	NCT00005391_19_T1	PHENOTYPE	12	12	cardiomyopathy
NCT000053922	NCT00005392_2_T0	PHENOTYPE	10	11	cardiovascular disease
NCT000053922	NCT00005392_2_T1	PHENOTYPE	14	15	venous disease
NCT000053923	NCT00005392_3_T0	GENE	9	9	has
NCT000053923	NCT00005392_3_T1	PHENOTYPE	7	8	venous disease
NCT000053924	NCT00005392_4_T0	PHENOTYPE	4	4	peripheral
NCT000053924	NCT00005392_4_T1	PHENOTYPE	5	6	venous disease
NCT000053924	NCT00005392_4_T2	PHENOTYPE	11	13	symptoms and signs
NCT000053925	NCT00005392_5_T0	PHENOTYPE	8	8	peripheral
NCT000053925	NCT00005392_5_T1	PHENOTYPE	9	10	venous disease
NCT000053927	NCT00005392_7_T0	ORGAN	13	13	veins
NCT000053927	NCT00005392_7_T1	PHENOTYPE	22	22	obstruction
NCT000053927	NCT00005392_7_T2	PHENOTYPE	30	30	obstruction
NCT000053927	NCT00005392_7_T3	PHENOTYPE	9	9	telangiectasias
NCT000053927	NCT00005392_7_T4	PHENOTYPE	19	20	valvular incompetence
NCT000053927	NCT00005392_7_T5	PHENOTYPE	27	28	valvular incompetence
NCT000053927	NCT00005392_7_T6	PHENOTYPE	4	5	venous disease
NCT000053927	NCT00005392_7_T7	PHENOTYPE	15	16	venous disease
NCT000053927	NCT00005392_7_T8	PHENOTYPE	24	25	venous disease
NCT000053929	NCT00005392_9_T0	PHENOTYPE	25	26	valvular incompetence
NCT000053929	NCT00005392_9_T1	PHENOTYPE	28	29	venous obstruction
NCT0000539210	NCT00005392_10_T0	PHENOTYPE	20	21	venous disease
NCT0000539210	NCT00005392_10_T1	PHENOTYPE	29	30	venous disease
NCT0000539210	NCT00005392_10_T2	PHENOTYPE	16	18	signs and symptoms
NCT0000539211	NCT00005392_11_T0	PHENOTYPE	9	9	edema
NCT0000539211	NCT00005392_11_T1	BIOLOGICAL_PROCESS	15	15	pigmentation
NCT0000539211	NCT00005392_11_T2	PHENOTYPE	16	16	induration
NCT0000539211	NCT00005392_11_T3	PHENOTYPE	6	6	itching
NCT0000539211	NCT00005392_11_T4	PHENOTYPE	5	5	aching
NCT0000539211	NCT00005392_11_T5	PHENOTYPE	11	11	cramps
NCT0000539211	NCT00005392_11_T6	PHENOTYPE	17	17	ulcers
NCT0000539211	NCT00005392_11_T7	PHENOTYPE	13	14	restless legs
NCT0000539211	NCT00005392_11_T8	PHENOTYPE	0	2	Signs and symptoms
NCT0000539212	NCT00005392_12_T0	PHENOTYPE	11	12	venous disease
NCT0000539214	NCT00005392_14_T0	GENE	33	33	San
NCT0000539214	NCT00005392_14_T1	PHENOTYPE	17	18	venous disease
NCT000053931	NCT00005393_1_T0	PHENOTYPE	9	10	endothelial dysfunction
NCT000053931	NCT00005393_1_T1	PHENOTYPE	6	7	oxidative stress
NCT000053934	NCT00005393_4_T0	PHENOTYPE	4	4	concentrations
NCT000053934	NCT00005393_4_T1	PHENOTYPE	8	8	understood
NCT000053936	NCT00005393_6_T0	ORGAN	7	7	serum
NCT000053937	NCT00005393_7_T0	ORGAN	5	5	serum
NCT000053939	NCT00005393_9_T0	PHENOTYPE	2	2	concentrations
NCT000053939	NCT00005393_9_T1	ORGAN	4	4	serum
NCT000053939	NCT00005393_9_T2	ORGAN	19	19	serum
NCT0000539311	NCT00005393_11_T0	ORGAN	7	7	serum
NCT0000539312	NCT00005393_12_T0	ORGAN	23	23	serum
NCT0000539313	NCT00005393_13_T0	ORGAN	2	2	plasma
NCT0000539313	NCT00005393_13_T1	COMPOUND	3	4	ascorbic acid
NCT0000539315	NCT00005393_15_T0	GENE	32	32	ICAM
NCT0000539315	NCT00005393_15_T1	BIOLOGICAL_PROCESS	12	12	glycosylation
NCT0000539315	NCT00005393_15_T2	PHENOTYPE	30	30	adhesion
NCT0000539315	NCT00005393_15_T3	GENE	34	34	P-selectin
NCT0000539315	NCT00005393_15_T4	GENE	22	22	PAF
NCT0000539315	NCT00005393_15_T5	CELL	19	19	platelet
NCT0000539315	NCT00005393_15_T6	COMPOUND	18	18	tyrosine
NCT0000539315	NCT00005393_15_T7	GENE	14	14	AGE
NCT0000539315	NCT00005393_15_T8	PHENOTYPE	26	27	DNA damage
NCT0000539316	NCT00005393_16_T0	PHENOTYPE	18	18	microalbuminuria
NCT0000539316	NCT00005393_16_T1	PHENOTYPE	9	11	coronary artery calcification
NCT0000539318	NCT00005393_18_T0	GENE	16	16	F2
NCT0000539318	NCT00005393_18_T1	GENE	18	19	phospholipase A2
NCT0000539318	NCT00005393_18_T2	GENE	20	21	superoxide dismutase
NCT0000539321	NCT00005393_21_T0	PHENOTYPE	9	10	oxidative stress
NCT000053940	NCT00005394_0_T0	PHENOTYPE	5	5	Hypertension
NCT000053940	NCT00005394_0_T1	PHENOTYPE	4	4	Aldosteronism
NCT000053944	NCT00005394_4_T0	PHENOTYPE	14	14	hypokalemia
NCT000053944	NCT00005394_4_T1	PHENOTYPE	6	6	GRA
NCT000053944	NCT00005394_4_T2	PHENOTYPE	2	2	physiology
NCT000053944	NCT00005394_4_T3	PHENOTYPE	18	19	mineralocorticoid excess
NCT000053945	NCT00005394_5_T0	COMPOUND	55	55	potassium
NCT000053945	NCT00005394_5_T1	PHENOTYPE	15	15	GRA
NCT000053945	NCT00005394_5_T2	PHENOTYPE	34	34	GRA
NCT000053945	NCT00005394_5_T3	PHENOTYPE	60	60	GRA
NCT000053945	NCT00005394_5_T4	PHENOTYPE	68	68	GRA
NCT000053945	NCT00005394_5_T5	PHENOTYPE	45	45	hypertension
NCT000053945	NCT00005394_5_T6	GENE	79	80	aldosterone synthase
NCT000053958	NCT00005395_8_T0	PHENOTYPE	10	11	brain infarction
NCT000053959	NCT00005395_9_T0	PHENOTYPE	13	13	regression
NCT000053963	NCT00005396_3_T0	PHENOTYPE	35	35	illnesses
NCT000053963	NCT00005396_3_T1	GENE	30	30	reduced
NCT000053966	NCT00005396_6_T0	COMPOUND	30	30	nicotine
NCT000053966	NCT00005396_6_T1	PHENOTYPE	28	28	concentrations
NCT000053967	NCT00005396_7_T0	COMPOUND	7	7	3
NCT000053968	NCT00005396_8_T0	COMPOUND	4	4	nicotine
NCT000053968	NCT00005396_8_T1	PHENOTYPE	5	5	concentrations
NCT000053969	NCT00005396_9_T0	GENE	33	33	had
NCT000053969	NCT00005396_9_T1	GENE	32	32	has
NCT000053969	NCT00005396_9_T2	PHENOTYPE	39	39	chronic
NCT000053974	NCT00005397_4_T0	GENE	19	19	has
NCT000053974	NCT00005397_4_T1	PHENOTYPE	33	34	cardiovascular disease
NCT000053975	NCT00005397_5_T0	ORGAN	5	5	Heart
NCT000053978	NCT00005397_8_T0	ORGAN	15	15	Heart
NCT000053978	NCT00005397_8_T1	GENE	5	5	FY
NCT0000539710	NCT00005397_10_T0	PHENOTYPE	18	18	atherosclerosis
NCT0000539710	NCT00005397_10_T1	GENE	3	3	extended
NCT0000539710	NCT00005397_10_T2	PHENOTYPE	20	20	distal
NCT0000539710	NCT00005397_10_T3	ORGAN	21	22	abdominal aorta
NCT0000539710	NCT00005397_10_T4	ORGAN	28	29	carotid artery
NCT0000539711	NCT00005397_11_T0	PHENOTYPE	33	33	progression
NCT000053980	NCT00005398_0_T0	ORGAN	5	5	Heart
NCT000053984	NCT00005398_4_T0	PHENOTYPE	13	13	suffering
NCT000053985	NCT00005398_5_T0	ORGAN	6	6	Heart
NCT000053985	NCT00005398_5_T1	PHENOTYPE	14	14	associations
NCT000053985	NCT00005398_5_T2	PHENOTYPE	33	33	hostility
NCT000053985	NCT00005398_5_T3	PHENOTYPE	52	52	hostility
NCT000053985	NCT00005398_5_T4	GENE	57	57	CHD
NCT000053985	NCT00005398_5_T5	PHENOTYPE	30	31	individual differences
NCT000053988	NCT00005398_8_T0	ORGAN	10	10	Heart
NCT000053988	NCT00005398_8_T1	GENE	8	8	UNC
NCT000053989	NCT00005398_9_T0	PHENOTYPE	4	4	hostility
NCT000053989	NCT00005398_9_T1	PHENOTYPE	19	21	coronary heart disease
NCT0000539810	NCT00005398_10_T0	PHENOTYPE	24	24	hostility
NCT0000539810	NCT00005398_10_T1	PHENOTYPE	18	18	practices
NCT0000539811	NCT00005398_11_T0	PHENOTYPE	20	20	hostility
NCT0000539811	NCT00005398_11_T1	GENE	16	16	span
NCT0000539812	NCT00005398_12_T0	PHENOTYPE	19	19	hostility
NCT0000539813	NCT00005398_13_T0	PHENOTYPE	7	7	associations
NCT0000539813	NCT00005398_13_T1	PHENOTYPE	9	9	hostility
NCT0000539813	NCT00005398_13_T2	PHENOTYPE	19	20	job strain
NCT0000539814	NCT00005398_14_T0	GENE	8	8	broadened
NCT0000539814	NCT00005398_14_T1	PHENOTYPE	21	21	practices
NCT0000539814	NCT00005398_14_T2	PHENOTYPE	11	12	individual differences
NCT0000539815	NCT00005398_15_T0	PHENOTYPE	39	39	associations
NCT0000539815	NCT00005398_15_T1	GENE	29	29	hormone
NCT0000539815	NCT00005398_15_T2	PHENOTYPE	24	24	menopausal
NCT0000539815	NCT00005398_15_T3	PHENOTYPE	9	10	coronary disease
NCT000053990	NCT00005399_0_T0	ORGAN	3	3	Heart
NCT000053992	NCT00005399_2_T0	PHENOTYPE	37	37	progression
NCT000053992	NCT00005399_2_T1	PHENOTYPE	24	24	Atherosclerosis
NCT000053992	NCT00005399_2_T2	PHENOTYPE	50	50	hypertension
NCT000053992	NCT00005399_2_T3	PHENOTYPE	39	40	carotid atherosclerosis
NCT000053992	NCT00005399_2_T4	PHENOTYPE	14	16	ischemic heart disease
NCT000053996	NCT00005399_6_T0	GENE	6	6	had
NCT000053997	NCT00005399_7_T0	PHENOTYPE	28	28	sequelae
NCT000053998	NCT00005399_8_T0	PHENOTYPE	15	16	pulmonary diseases
NCT0000539910	NCT00005399_10_T0	ORGAN	17	17	heart
NCT0000539911	NCT00005399_11_T0	ORGAN	4	4	heart
NCT0000539913	NCT00005399_13_T0	ORGAN	30	30	heart
NCT0000539913	NCT00005399_13_T1	ORGAN	35	35	heart
NCT000054002	NCT00005400_2_T0	PHENOTYPE	16	16	pathophysiology
NCT000054002	NCT00005400_2_T1	GENE	3	3	has
NCT000054002	NCT00005400_2_T2	PHENOTYPE	20	22	complications of pregnancy
NCT000054003	NCT00005400_3_T0	PHENOTYPE	27	27	preeclampsia
NCT000054003	NCT00005400_3_T1	GENE	16	16	angiotensinogen
NCT000054003	NCT00005400_3_T2	COMPOUND	17	18	renin substrate
NCT000054005	NCT00005400_5_T0	PHENOTYPE	23	23	pathophysiology
NCT000054005	NCT00005400_5_T1	PHENOTYPE	25	25	preeclampsia
NCT000054005	NCT00005400_5_T2	GENE	17	17	angiotensinogen
NCT000054006	NCT00005400_6_T0	PHENOTYPE	28	28	secondary
NCT000054006	NCT00005400_6_T1	GENE	11	11	angiotensinogen
NCT000054006	NCT00005400_6_T2	PHENOTYPE	8	9	genetic alteration
NCT000054008	NCT00005400_8_T0	ORGAN	3	3	plasma
NCT000054009	NCT00005400_9_T0	PHENOTYPE	4	4	strategies
NCT0000540010	NCT00005400_10_T0	PHENOTYPE	20	20	disorders
NCT0000540011	NCT00005400_11_T0	PHENOTYPE	30	30	physiology
NCT0000540011	NCT00005400_11_T1	PHENOTYPE	45	46	adverse effect
NCT0000540012	NCT00005400_12_T0	PHENOTYPE	16	16	preeclampsia
NCT0000540012	NCT00005400_12_T1	GENE	28	28	angiotensinogen
NCT0000540013	NCT00005400_13_T0	GENE	12	12	angiotensinogen
NCT0000540014	NCT00005400_14_T0	ORGAN	21	21	artery
NCT0000540014	NCT00005400_14_T1	ORGAN	26	26	plasma
NCT0000540014	NCT00005400_14_T2	GENE	16	16	angiotensinogen
NCT000054016	NCT00005401_6_T0	GENE	17	17	San
NCT000054017	NCT00005401_7_T0	GENE	6	6	hormone
NCT000054018	NCT00005401_8_T0	PHENOTYPE	14	14	severity
NCT000054020	NCT00005402_0_T0	COMPOUND	2	2	HCV
NCT000054024	NCT00005402_4_T0	PHENOTYPE	12	12	sequelae
NCT000054024	NCT00005402_4_T1	PHENOTYPE	6	6	progression
NCT000054024	NCT00005402_4_T2	PHENOTYPE	11	11	chronic
NCT000054026	NCT00005402_6_T0	GENE	40	40	IV
NCT000054026	NCT00005402_6_T1	PHENOTYPE	41	42	drug use
NCT000054028	NCT00005402_8_T0	ORGAN	25	25	serum
NCT000054029	NCT00005402_9_T0	COMPOUND	19	19	HCV
NCT000054029	NCT00005402_9_T1	PHENOTYPE	25	26	hepatitis G
NCT0000540212	NCT00005402_12_T0	COMPOUND	13	13	HCV
NCT0000540212	NCT00005402_12_T1	ORGAN	1	1	serum
NCT0000540212	NCT00005402_12_T2	PHENOTYPE	20	21	posttransfusion hepatitis
NCT0000540213	NCT00005402_13_T0	COMPOUND	9	9	HCV
NCT0000540213	NCT00005402_13_T1	PHENOTYPE	30	30	hepatitis
NCT0000540213	NCT00005402_13_T2	PHENOTYPE	31	32	virus infection
NCT0000540213	NCT00005402_13_T3	PHENOTYPE	32	34	infection in children
NCT0000540214	NCT00005402_14_T0	PHENOTYPE	26	26	persistence
NCT0000540215	NCT00005402_15_T0	ORGAN	4	4	liver
NCT0000540216	NCT00005402_16_T0	PHENOTYPE	1	2	persistent infection
NCT0000540216	NCT00005402_16_T1	PHENOTYPE	4	6	chronic liver disease
NCT000054030	NCT00005403_0_T0	PHENOTYPE	0	1	Heart Disease
NCT000054035	NCT00005403_5_T0	PHENOTYPE	17	18	heart disease
NCT000054036	NCT00005403_6_T0	GENE	27	27	has
NCT000054043	NCT00005404_3_T0	COMPOUND	8	8	aspirin
NCT000054043	NCT00005404_3_T1	COMPOUND	17	17	aspirin
NCT000054043	NCT00005404_3_T2	COMPOUND	23	23	aspirin
NCT000054043	NCT00005404_3_T3	CELL	10	10	platelet
NCT000054044	NCT00005404_4_T0	COMPOUND	2	2	aspirin
NCT000054044	NCT00005404_4_T1	COMPOUND	28	28	aspirin
NCT000054044	NCT00005404_4_T2	PHENOTYPE	34	35	myocardial infarction
NCT000054045	NCT00005404_5_T0	COMPOUND	9	9	aspirin
NCT000054045	NCT00005404_5_T1	GENE	29	29	had
NCT000054046	NCT00005404_6_T0	COMPOUND	11	11	aspirin
NCT000054046	NCT00005404_6_T1	COMPOUND	26	26	aspirin
NCT000054046	NCT00005404_6_T2	CELL	28	28	platelet
NCT000054047	NCT00005404_7_T0	COMPOUND	16	16	aspirin
NCT000054047	NCT00005404_7_T1	COMPOUND	31	31	aspirin
NCT000054048	NCT00005404_8_T0	COMPOUND	10	10	aspirin
NCT000054048	NCT00005404_8_T1	CELL	12	12	platelet
NCT0000540410	NCT00005404_10_T0	COMPOUND	7	7	aspirin
NCT0000540411	NCT00005404_11_T0	COMPOUND	4	4	aspirin
NCT0000540411	NCT00005404_11_T1	PHENOTYPE	10	11	myocardial infarction
NCT000054053	NCT00005405_3_T0	PHENOTYPE	12	12	associations
NCT000054053	NCT00005405_3_T1	GENE	10	10	mediator
NCT000054053	NCT00005405_3_T2	ORGAN	3	3	serum
NCT000054054	NCT00005405_4_T0	PHENOTYPE	5	5	associations
NCT000054055	NCT00005405_5_T0	PHENOTYPE	0	0	Secondary
NCT000054057	NCT00005405_7_T0	GENE	0	0	HDL
NCT000054057	NCT00005405_7_T1	GENE	1	1	LDL
NCT000054060	NCT00005406_0_T0	PHENOTYPE	2	4	Coronary Heart Disease
NCT000054065	NCT00005406_5_T0	PHENOTYPE	4	4	insights
NCT000054065	NCT00005406_5_T1	PHENOTYPE	9	11	coronary heart disease
NCT000054066	NCT00005406_6_T0	GENE	5	5	had
NCT000054074	NCT00005407_4_T0	PHENOTYPE	6	6	hypertension
NCT000054074	NCT00005407_4_T1	PHENOTYPE	26	26	hypertension
NCT000054075	NCT00005407_5_T0	GENE	9	9	had
NCT000054075	NCT00005407_5_T1	GENE	22	22	had
NCT000054083	NCT00005408_3_T0	GENE	55	55	ACE
NCT000054084	NCT00005408_4_T0	GENE	4	4	ACE
NCT000054084	NCT00005408_4_T1	PHENOTYPE	7	7	fitted
NCT000054085	NCT00005408_5_T0	GENE	3	3	extended
NCT000054086	NCT00005408_6_T0	PHENOTYPE	12	12	estimation
NCT000054086	NCT00005408_6_T1	PHENOTYPE	11	11	resistant
NCT000054086	NCT00005408_6_T2	GENE	18	18	trimmed
NCT000054093	NCT00005409_3_T0	PHENOTYPE	15	16	cardiovascular disease
NCT000054093	NCT00005409_3_T1	PHENOTYPE	6	8	low blood pressures
NCT000054094	NCT00005409_4_T0	PHENOTYPE	22	22	Hypertension
NCT000054095	NCT00005409_5_T0	PHENOTYPE	20	20	reflected
NCT000054095	NCT00005409_5_T1	PHENOTYPE	7	8	cardiovascular disease
NCT000054095	NCT00005409_5_T2	PHENOTYPE	31	33	high blood pressure
NCT000054095	NCT00005409_5_T3	PHENOTYPE	11	13	lower blood pressure
NCT000054098	NCT00005409_8_T0	PHENOTYPE	19	19	reflected
NCT000054098	NCT00005409_8_T1	PHENOTYPE	6	8	lower blood pressure
NCT000054098	NCT00005409_8_T2	PHENOTYPE	30	32	low blood pressure
NCT000054099	NCT00005409_9_T0	PHENOTYPE	26	26	hypertension
NCT0000540910	NCT00005409_10_T0	GENE	3	3	had
NCT000054102	NCT00005410_2_T0	GENE	5	5	CHD
NCT000054104	NCT00005410_4_T0	PHENOTYPE	13	13	infarctions
NCT000054104	NCT00005410_4_T1	PHENOTYPE	8	9	myocardial infarction
NCT000054106	NCT00005410_6_T0	GENE	12	12	CHD
NCT000054107	NCT00005410_7_T0	PHENOTYPE	16	16	Enlargement
NCT000054107	NCT00005410_7_T1	PHENOTYPE	19	20	Myocardial Infarction
NCT000054118	NCT00005411_8_T0	PHENOTYPE	15	16	effects increased
NCT0000541111	NCT00005411_11_T0	PHENOTYPE	3	3	CVD
NCT0000541113	NCT00005411_13_T0	PHENOTYPE	0	0	Perceptions
NCT0000541113	NCT00005411_13_T1	PHENOTYPE	3	4	Life Stress
NCT0000541113	NCT00005411_13_T2	PHENOTYPE	8	10	Type A Behavior
NCT0000541115	NCT00005411_15_T0	GENE	10	10	apo
NCT0000541115	NCT00005411_15_T1	GENE	8	8	HDL
NCT000054124	NCT00005412_4_T0	PHENOTYPE	13	13	atherosclerosis
NCT000054126	NCT00005412_6_T0	PHENOTYPE	34	34	atherosclerosis
NCT000054126	NCT00005412_6_T1	COMPOUND	23	24	vitamin E
NCT000054128	NCT00005412_8_T0	PHENOTYPE	7	7	atherosclerosis
NCT000054128	NCT00005412_8_T1	ORGAN	5	6	carotid artery
NCT000054129	NCT00005412_9_T0	PHENOTYPE	8	8	atherosclerosis
NCT000054129	NCT00005412_9_T1	ORGAN	6	7	carotid artery
NCT0000541210	NCT00005412_10_T0	PHENOTYPE	0	0	Secondary
NCT000054134	NCT00005413_4_T0	ORGAN	12	12	heart
NCT000054134	NCT00005413_4_T1	GENE	13	13	has
NCT000054134	NCT00005413_4_T2	PHENOTYPE	8	9	vascular disease
NCT000054134	NCT00005413_4_T3	PHENOTYPE	27	28	vascular disease
NCT000054134	NCT00005413_4_T4	PHENOTYPE	42	44	coronary artery disease
NCT000054138	NCT00005413_8_T0	GENE	38	38	has
NCT000054138	NCT00005413_8_T1	PHENOTYPE	40	41	cardiovascular disease
NCT000054139	NCT00005413_9_T0	GENE	3	3	twins
NCT0000541310	NCT00005413_10_T0	PHENOTYPE	8	9	myocardial disease
NCT0000541311	NCT00005413_11_T0	PHENOTYPE	6	6	estimation
NCT0000541312	NCT00005413_12_T0	GENE	10	10	twins
NCT000054142	NCT00005414_2_T0	GENE	23	23	probable
NCT000054142	NCT00005414_2_T1	PHENOTYPE	27	27	progression
NCT000054145	NCT00005414_5_T0	PHENOTYPE	14	15	cardiovascular disease
NCT000054146	NCT00005414_6_T0	GENE	12	12	had
NCT000054155	NCT00005415_5_T0	PHENOTYPE	4	4	regression
NCT000054156	NCT00005415_6_T0	PHENOTYPE	19	19	enabling
NCT000054162	NCT00005416_2_T0	PHENOTYPE	7	7	reflected
NCT0000541611	NCT00005416_11_T0	PHENOTYPE	26	26	CVD
NCT000054173	NCT00005417_3_T0	GENE	14	14	had
NCT000054173	NCT00005417_3_T1	ORGAN	28	28	Transplant
NCT000054174	NCT00005417_4_T0	PHENOTYPE	9	9	Hypertension
NCT000054174	NCT00005417_4_T1	GENE	14	14	HSTP
NCT000054176	NCT00005417_6_T0	GENE	7	7	HSTP
NCT000054177	NCT00005417_7_T0	ORGAN	29	29	Transplant
NCT000054177	NCT00005417_7_T1	PHENOTYPE	21	22	renal disease
NCT000054180	NCT00005418_0_T0	PHENOTYPE	2	2	Cardiotoxicity
NCT000054180	NCT00005418_0_T1	PHENOTYPE	6	6	Cancer
NCT000054184	NCT00005418_4_T0	PHENOTYPE	24	24	cardiotoxicity
NCT000054185	NCT00005418_5_T0	PHENOTYPE	4	4	cardiotoxicity
NCT000054186	NCT00005418_6_T0	COMPOUND	7	7	cyclophosphamide
NCT000054188	NCT00005418_8_T0	PHENOTYPE	15	15	cardiotoxicity
NCT000054189	NCT00005418_9_T0	GENE	8	8	SAS
NCT000054189	NCT00005418_9_T1	GENE	22	22	POG
NCT000054189	NCT00005418_9_T2	PHENOTYPE	20	20	Oncology
NCT000054192	NCT00005419_2_T0	PHENOTYPE	6	7	chronic diseases
NCT000054195	NCT00005419_5_T0	PHENOTYPE	16	17	chronic diseases
NCT000054196	NCT00005419_6_T0	PHENOTYPE	7	7	diseases
NCT000054196	NCT00005419_6_T1	PHENOTYPE	21	21	intensities
NCT000054196	NCT00005419_6_T2	PHENOTYPE	34	34	hypertension
NCT000054196	NCT00005419_6_T3	GENE	37	37	CHD
NCT000054196	NCT00005419_6_T4	PHENOTYPE	35	35	NIDDM
NCT000054197	NCT00005419_7_T0	PHENOTYPE	8	9	chronic diseases
NCT000054198	NCT00005419_8_T0	GENE	2	2	has
NCT000054198	NCT00005419_8_T1	GENE	8	8	span
NCT000054199	NCT00005419_9_T0	PHENOTYPE	8	8	attributable
NCT000054199	NCT00005419_9_T1	PHENOTYPE	12	12	hypertension
NCT000054199	NCT00005419_9_T2	GENE	15	15	CHD
NCT000054199	NCT00005419_9_T3	PHENOTYPE	13	13	NIDDM
NCT0000541910	NCT00005419_10_T0	PHENOTYPE	24	24	diseases
NCT000054203	NCT00005420_3_T0	PHENOTYPE	7	7	strategies
NCT000054203	NCT00005420_3_T1	PHENOTYPE	11	13	quality of life
NCT000054204	NCT00005420_4_T0	PHENOTYPE	19	21	quality of life
NCT000054205	NCT00005420_5_T0	PHENOTYPE	20	20	strategies
NCT000054205	NCT00005420_5_T1	GENE	10	10	structural
NCT000054205	NCT00005420_5_T2	PHENOTYPE	29	30	cardiovascular disease
NCT000054205	NCT00005420_5_T3	PHENOTYPE	25	27	quality of life
NCT000054206	NCT00005420_6_T0	PHENOTYPE	30	30	arthritis
NCT000054206	NCT00005420_6_T1	GENE	2	2	contrasted
NCT000054206	NCT00005420_6_T2	PHENOTYPE	11	11	hypertension
NCT000054207	NCT00005420_7_T0	PHENOTYPE	3	3	secondary
NCT000054208	NCT00005420_8_T0	PHENOTYPE	20	20	centers
NCT000054208	NCT00005420_8_T1	GENE	12	12	had
NCT0000542012	NCT00005420_12_T0	PHENOTYPE	22	22	strokes
NCT0000542012	NCT00005420_12_T1	PHENOTYPE	15	15	hypertension
NCT0000542012	NCT00005420_12_T2	PHENOTYPE	30	30	hypertension
NCT0000542013	NCT00005420_13_T0	PHENOTYPE	25	25	strategies
NCT0000542013	NCT00005420_13_T1	PHENOTYPE	13	15	quality of life
NCT0000542016	NCT00005420_16_T0	PHENOTYPE	13	15	quality of life
NCT000054211	NCT00005421_1_T0	GENE	11	11	had
NCT000054215	NCT00005421_5_T0	GENE	12	12	reduced
NCT0000542114	NCT00005421_14_T0	PHENOTYPE	20	20	hypertension
NCT000054224	NCT00005422_4_T0	GENE	3	3	had
NCT000054226	NCT00005422_6_T0	PHENOTYPE	13	13	allergies
NCT000054228	NCT00005422_8_T0	PHENOTYPE	19	20	lung function
NCT0000542210	NCT00005422_10_T0	GENE	8	8	unbalanced
NCT0000542210	NCT00005422_10_T1	PHENOTYPE	27	28	lung function
NCT000054232	NCT00005423_2_T0	PHENOTYPE	18	18	CVD
NCT000054232	NCT00005423_2_T1	COMPOUND	12	12	sodium
NCT000054234	NCT00005423_4_T0	PHENOTYPE	22	22	CVD
NCT000054235	NCT00005423_5_T0	PHENOTYPE	40	40	CVD
NCT000054235	NCT00005423_5_T1	PHENOTYPE	70	70	CVD
NCT000054235	NCT00005423_5_T2	PHENOTYPE	24	24	associations
NCT000054235	NCT00005423_5_T3	PHENOTYPE	65	65	associations
NCT000054237	NCT00005423_7_T0	ORGAN	11	11	serum
NCT000054237	NCT00005423_7_T1	PHENOTYPE	29	29	chronic
NCT000054238	NCT00005423_8_T0	PHENOTYPE	0	0	CVD
NCT000054239	NCT00005423_9_T0	PHENOTYPE	26	26	CVD
NCT000054242	NCT00005424_2_T0	GENE	7	7	has
NCT000054242	NCT00005424_2_T1	PHENOTYPE	13	14	cardiovascular disease
NCT000054243	NCT00005424_3_T0	GENE	13	13	has
NCT000054245	NCT00005424_5_T0	PHENOTYPE	23	24	cardiovascular disease
NCT000054246	NCT00005424_6_T0	GENE	3	3	has
NCT000054246	NCT00005424_6_T1	PHENOTYPE	9	10	cardiovascular disease
NCT0000542415	NCT00005424_15_T0	PHENOTYPE	11	12	cardiovascular disease
NCT000054252	NCT00005425_2_T0	PHENOTYPE	11	11	regression
NCT000054253	NCT00005425_3_T0	PHENOTYPE	11	11	symptoms
NCT000054253	NCT00005425_3_T1	PHENOTYPE	41	41	regression
NCT000054253	NCT00005425_3_T2	PHENOTYPE	19	19	allergy
NCT000054253	NCT00005425_3_T3	PHENOTYPE	13	13	asthma
NCT000054262	NCT00005426_2_T0	GENE	11	11	HDL
NCT000054262	NCT00005426_2_T1	GENE	10	10	lipoprotein
NCT000054262	NCT00005426_2_T2	GENE	5	5	Dr
NCT000054262	NCT00005426_2_T3	GENE	15	15	gel
NCT000054265	NCT00005426_5_T0	GENE	16	16	reduced
NCT000054265	NCT00005426_5_T1	PHENOTYPE	7	9	coronary heart disease
NCT0000542612	NCT00005426_12_T0	GENE	7	7	reduced
NCT0000542612	NCT00005426_12_T1	GENE	10	10	reduced
NCT0000542612	NCT00005426_12_T2	COMPOUND	28	28	gemfibrozil
NCT0000542612	NCT00005426_12_T3	COMPOUND	27	27	probucol
NCT0000542612	NCT00005426_12_T4	COMPOUND	23	23	colestipol
NCT0000542612	NCT00005426_12_T5	COMPOUND	26	26	clofibrate
NCT0000542612	NCT00005426_12_T6	COMPOUND	29	29	fenofibrate
NCT0000542612	NCT00005426_12_T7	COMPOUND	30	30	lovastatin
NCT0000542612	NCT00005426_12_T8	ORGAN	32	32	gum
NCT0000542612	NCT00005426_12_T9	COMPOUND	24	25	nicotinic acid
NCT0000542614	NCT00005426_14_T0	PHENOTYPE	4	4	associations
NCT0000542614	NCT00005426_14_T1	PHENOTYPE	8	8	adiposity
NCT0000542614	NCT00005426_14_T2	COMPOUND	14	14	glucose
NCT0000542614	NCT00005426_14_T3	GENE	12	12	insulin
NCT000054273	NCT00005427_3_T0	PHENOTYPE	17	17	illnesses
NCT000054273	NCT00005427_3_T1	COMPOUND	9	10	nitrogen dioxide
NCT000054273	NCT00005427_3_T2	PHENOTYPE	14	15	respiratory symptoms
NCT000054274	NCT00005427_4_T0	PHENOTYPE	25	25	concentrations
NCT000054274	NCT00005427_4_T1	PHENOTYPE	17	18	respiratory symptom
NCT000054277	NCT00005427_7_T0	PHENOTYPE	18	18	severity
NCT000054277	NCT00005427_7_T1	PHENOTYPE	28	28	severity
NCT000054277	NCT00005427_7_T2	PHENOTYPE	60	60	severity
NCT000054277	NCT00005427_7_T3	PHENOTYPE	72	72	severity
NCT000054277	NCT00005427_7_T4	PHENOTYPE	21	21	illnesses
NCT000054277	NCT00005427_7_T5	PHENOTYPE	31	31	illnesses
NCT000054277	NCT00005427_7_T6	PHENOTYPE	45	45	illnesses
NCT000054277	NCT00005427_7_T7	PHENOTYPE	63	63	illnesses
NCT000054277	NCT00005427_7_T8	PHENOTYPE	75	75	illnesses
NCT000054277	NCT00005427_7_T9	PHENOTYPE	83	83	illnesses
NCT000054277	NCT00005427_7_T10	PHENOTYPE	52	52	asthma
NCT000054277	NCT00005427_7_T11	PHENOTYPE	42	42	wheezing
NCT000054277	NCT00005427_7_T12	PHENOTYPE	44	44	wheezing
NCT000054277	NCT00005427_7_T13	PHENOTYPE	96	96	perceptions
NCT000054277	NCT00005427_7_T14	PHENOTYPE	107	108	Clinical findings
NCT000054282	NCT00005428_2_T0	PHENOTYPE	2	2	Secondary
NCT000054282	NCT00005428_2_T1	PHENOTYPE	14	15	hypertension genetic
NCT000054285	NCT00005428_5_T0	GENE	10	10	extended
NCT000054286	NCT00005428_6_T0	PHENOTYPE	9	9	hypertension
NCT000054288	NCT00005428_8_T0	PHENOTYPE	55	55	obesity
NCT000054293	NCT00005429_3_T0	GENE	2	2	has
NCT000054293	NCT00005429_3_T1	PHENOTYPE	10	10	chronic
NCT000054293	NCT00005429_3_T2	PHENOTYPE	11	12	cardiovascular diseases
NCT000054294	NCT00005429_4_T0	PHENOTYPE	18	20	coronary artery disease
NCT000054307	NCT00005430_7_T0	PHENOTYPE	3	3	regression
NCT000054307	NCT00005430_7_T1	PHENOTYPE	21	22	cardiovascular disease
NCT000054307	NCT00005430_7_T2	PHENOTYPE	23	25	coronary heart disease
NCT000054308	NCT00005430_8_T0	PHENOTYPE	28	28	regression
NCT000054309	NCT00005430_9_T0	PHENOTYPE	16	16	regression
NCT000054309	NCT00005430_9_T1	PHENOTYPE	24	24	regression
NCT0000543010	NCT00005430_10_T0	PHENOTYPE	16	16	regression
NCT000054321	NCT00005432_1_T0	GENE	19	19	IND
NCT000054324	NCT00005432_4_T0	GENE	4	4	had
NCT000054324	NCT00005432_4_T1	PHENOTYPE	28	31	very low birth weight
NCT000054325	NCT00005432_5_T0	GENE	2	2	broadened
NCT000054326	NCT00005432_6_T0	PHENOTYPE	5	5	centered
NCT000054326	NCT00005432_6_T1	GENE	24	24	reduced
NCT000054326	NCT00005432_6_T2	PHENOTYPE	39	40	respiratory disease
NCT0000543212	NCT00005432_12_T0	PHENOTYPE	9	9	centers
NCT0000543214	NCT00005432_14_T0	PHENOTYPE	0	0	Regression
NCT000054331	NCT00005433_1_T0	PHENOTYPE	7	7	Atherosclerosis
NCT000054333	NCT00005433_3_T0	GENE	14	14	reduced
NCT000054334	NCT00005433_4_T0	GENE	18	18	has
NCT000054335	NCT00005433_5_T0	GENE	13	13	has
NCT000054336	NCT00005433_6_T0	PHENOTYPE	10	10	progression
NCT0000543311	NCT00005433_11_T0	PHENOTYPE	0	2	Coronary artery atherosclerosis
NCT0000543317	NCT00005433_17_T0	PHENOTYPE	16	16	associations
NCT0000543317	NCT00005433_17_T1	PHENOTYPE	24	24	progression
NCT0000543317	NCT00005433_17_T2	PHENOTYPE	27	29	coronary heart disease
NCT000054342	NCT00005434_2_T0	PHENOTYPE	4	4	inhibition
NCT000054342	NCT00005434_2_T1	PHENOTYPE	12	12	hypertension
NCT000054344	NCT00005434_4_T0	PHENOTYPE	4	4	hypertension
NCT000054346	NCT00005434_6_T0	COMPOUND	15	15	hydrochloride
NCT000054346	NCT00005434_6_T1	COMPOUND	14	14	naltrexone
NCT000054346	NCT00005434_6_T2	PHENOTYPE	38	38	hypertension
NCT000054347	NCT00005434_7_T0	COMPOUND	16	16	naltrexone
NCT000054348	NCT00005434_8_T0	PHENOTYPE	15	15	hypertension
NCT000054348	NCT00005434_8_T1	PHENOTYPE	39	39	hypertension
NCT000054355	NCT00005435_5_T0	PHENOTYPE	0	0	Hostility
NCT000054355	NCT00005435_5_T1	PHENOTYPE	8	8	Hostility
NCT000054356	NCT00005435_6_T0	PHENOTYPE	8	8	hostility
NCT000054356	NCT00005435_6_T1	PHENOTYPE	21	21	hostility
NCT000054356	NCT00005435_6_T2	PHENOTYPE	12	12	harassment
NCT000054357	NCT00005435_7_T0	PHENOTYPE	16	16	hostility
NCT000054358	NCT00005435_8_T0	PHENOTYPE	6	6	harassment
NCT000054359	NCT00005435_9_T0	PHENOTYPE	3	3	harassment
NCT0000543510	NCT00005435_10_T0	PHENOTYPE	26	26	associations
NCT0000543510	NCT00005435_10_T1	PHENOTYPE	25	25	hostility
NCT0000543510	NCT00005435_10_T2	PHENOTYPE	14	14	harassment
NCT000054363	NCT00005436_3_T0	PHENOTYPE	46	46	hyperlipidemia
NCT000054363	NCT00005436_3_T1	PHENOTYPE	18	18	lupus
NCT000054363	NCT00005436_3_T2	PHENOTYPE	36	36	lupus
NCT000054363	NCT00005436_3_T3	PHENOTYPE	44	44	obesity
NCT000054363	NCT00005436_3_T4	PHENOTYPE	39	39	vasculitis
NCT000054363	NCT00005436_3_T5	PHENOTYPE	13	13	secondary
NCT000054363	NCT00005436_3_T6	COMPOUND	28	28	prednisone
NCT000054363	NCT00005436_3_T7	PHENOTYPE	30	30	hypertension
NCT000054363	NCT00005436_3_T8	PHENOTYPE	47	47	hypertension
NCT000054363	NCT00005436_3_T9	PHENOTYPE	24	25	premature atherosclerosis
NCT000054363	NCT00005436_3_T10	PHENOTYPE	15	16	antiphospholipid antibodies
NCT000054363	NCT00005436_3_T11	PHENOTYPE	11	12	hypercoagulable state
NCT000054363	NCT00005436_3_T12	PHENOTYPE	55	57	coronary artery disease
NCT000054364	NCT00005436_4_T0	PHENOTYPE	18	18	reflected
NCT000054373	NCT00005437_3_T0	PHENOTYPE	10	10	hypertension
NCT000054373	NCT00005437_3_T1	PHENOTYPE	12	12	obesity
NCT000054375	NCT00005437_5_T0	GENE	26	26	had
NCT0000543710	NCT00005437_10_T0	PHENOTYPE	2	2	maturation
NCT0000543711	NCT00005437_11_T0	BIOLOGICAL_PROCESS	5	5	drinking
NCT0000543713	NCT00005437_13_T0	PHENOTYPE	1	1	maturation
NCT0000543713	NCT00005437_13_T1	BIOLOGICAL_PROCESS	5	5	menarche
NCT0000543714	NCT00005437_14_T0	TISSUE	8	9	body fat
NCT000054380	NCT00005438_0_T0	CELL	6	6	Cell
NCT000054392	NCT00005439_2_T0	PHENOTYPE	10	10	hypertension
NCT000054392	NCT00005439_2_T1	PHENOTYPE	12	12	hypercholesterolemia
NCT000054394	NCT00005439_4_T0	GENE	3	3	sparse
NCT000054395	NCT00005439_5_T0	GENE	11	11	had
NCT000054396	NCT00005439_6_T0	PHENOTYPE	17	17	labeling
NCT000054397	NCT00005439_7_T0	PHENOTYPE	20	21	cardiovascular disease
NCT000054398	NCT00005439_8_T0	PHENOTYPE	104	104	hyperlipidemia
NCT000054398	NCT00005439_8_T1	COMPOUND	84	84	calcium
NCT000054398	NCT00005439_8_T2	GENE	21	21	BP
NCT000054398	NCT00005439_8_T3	GENE	37	37	BP
NCT000054398	NCT00005439_8_T4	GENE	54	54	BP
NCT000054398	NCT00005439_8_T5	GENE	78	78	BP
NCT000054398	NCT00005439_8_T6	PHENOTYPE	102	102	hypertension
NCT000054400	NCT00005440_0_T0	PHENOTYPE	4	4	Asthma
NCT000054403	NCT00005440_3_T0	PHENOTYPE	18	18	severity
NCT000054403	NCT00005440_3_T1	PHENOTYPE	9	9	asthma
NCT000054403	NCT00005440_3_T2	PHENOTYPE	13	14	chronic diseases
NCT000054404	NCT00005440_4_T0	PHENOTYPE	21	21	self-efficacy
NCT000054404	NCT00005440_4_T1	PHENOTYPE	20	20	asthma
NCT000054404	NCT00005440_4_T2	PHENOTYPE	33	33	asthma
NCT000054405	NCT00005440_5_T0	PHENOTYPE	9	9	severity
NCT000054405	NCT00005440_5_T1	PHENOTYPE	15	15	asthma
NCT000054407	NCT00005440_7_T0	PHENOTYPE	16	16	asthma
NCT000054408	NCT00005440_8_T0	GENE	3	3	log
NCT000054408	NCT00005440_8_T1	PHENOTYPE	12	12	asthma
NCT000054409	NCT00005440_9_T0	PHENOTYPE	31	31	symptoms
NCT000054409	NCT00005440_9_T1	PHENOTYPE	22	22	severity
NCT000054409	NCT00005440_9_T2	PHENOTYPE	27	27	severity
NCT000054410	NCT00005441_0_T0	GENE	5	5	CHD
NCT000054410	NCT00005441_0_T1	PHENOTYPE	7	7	NIDDM
NCT000054413	NCT00005441_3_T0	PHENOTYPE	12	14	coronary heart diseases
NCT000054414	NCT00005441_4_T0	PHENOTYPE	18	20	coronary heart disease
NCT000054418	NCT00005441_8_T0	ORGAN	9	9	serum
NCT000054419	NCT00005441_9_T0	PHENOTYPE	7	7	perceived
NCT000054419	NCT00005441_9_T1	PHENOTYPE	3	3	self-efficacy
NCT0000544112	NCT00005441_12_T0	PHENOTYPE	44	46	coronary heart disease
NCT000054423	NCT00005442_3_T0	PHENOTYPE	71	71	practices
NCT000054423	NCT00005442_3_T1	PHENOTYPE	24	26	coronary heart disease
NCT000054423	NCT00005442_3_T2	PHENOTYPE	54	56	coronary heart disease
NCT000054423	NCT00005442_3_T3	PHENOTYPE	87	89	coronary heart disease
NCT000054426	NCT00005442_6_T0	PHENOTYPE	25	27	coronary heart disease
NCT000054428	NCT00005442_8_T0	PHENOTYPE	36	37	heart disease
NCT000054428	NCT00005442_8_T1	PHENOTYPE	14	16	coronary heart disease
NCT000054435	NCT00005443_5_T0	COMPOUND	25	25	glucose
NCT000054435	NCT00005443_5_T1	PHENOTYPE	37	37	self-image
NCT000054435	NCT00005443_5_T2	PHENOTYPE	18	18	hostility
NCT000054435	NCT00005443_5_T3	PHENOTYPE	28	29	substance use
NCT000054435	NCT00005443_5_T4	TISSUE	19	20	body fat
NCT000054437	NCT00005443_7_T0	GENE	10	10	II
NCT000054439	NCT00005443_9_T0	COMPOUND	19	19	glucose
NCT000054439	NCT00005443_9_T1	PHENOTYPE	21	21	concentrations
NCT000054439	NCT00005443_9_T2	GENE	17	17	insulin
NCT000054439	NCT00005443_9_T3	GENE	12	12	lipoprotein
NCT000054439	NCT00005443_9_T4	ORGAN	20	20	serum
NCT0000544311	NCT00005443_11_T0	PHENOTYPE	25	25	hypertension
NCT000054442	NCT00005444_2_T0	PHENOTYPE	12	12	understood
NCT000054443	NCT00005444_3_T0	PHENOTYPE	12	12	hypertension
NCT000054443	NCT00005444_3_T1	PHENOTYPE	10	10	susceptible
NCT000054444	NCT00005444_4_T0	PHENOTYPE	2	2	hypertension
NCT000054446	NCT00005444_6_T0	COMPOUND	23	23	sodium
NCT000054446	NCT00005444_6_T1	COMPOUND	25	25	potassium
NCT000054446	NCT00005444_6_T2	GENE	20	20	BP
NCT000054446	NCT00005444_6_T3	PHENOTYPE	21	21	obesity
NCT000054447	NCT00005444_7_T0	ORGAN	2	2	plasma
NCT000054447	NCT00005444_7_T1	PHENOTYPE	21	21	hypertension
NCT000054449	NCT00005444_9_T0	PHENOTYPE	46	46	hypertension
NCT0000544410	NCT00005444_10_T0	ORGAN	0	0	Plasma
NCT000054454	NCT00005445_4_T0	PHENOTYPE	17	17	asthma
NCT000054464	NCT00005446_4_T0	PHENOTYPE	10	12	coronary heart disease
NCT000054465	NCT00005446_5_T0	PHENOTYPE	11	12	myocardial infarction
NCT000054465	NCT00005446_5_T1	PHENOTYPE	5	7	coronary heart disease
NCT000054465	NCT00005446_5_T2	PHENOTYPE	16	18	coronary heart disease
NCT000054466	NCT00005446_6_T0	GENE	1	1	nested
NCT000054466	NCT00005446_6_T1	PHENOTYPE	38	39	heart disease
NCT000054468	NCT00005446_8_T0	COMPOUND	11	11	estrogen
NCT000054468	NCT00005446_8_T1	PHENOTYPE	2	2	regression
NCT000054469	NCT00005446_9_T0	COMPOUND	3	3	estrogen
NCT000054473	NCT00005447_3_T0	PHENOTYPE	2	2	focused
NCT000054473	NCT00005447_3_T1	GENE	5	5	30
NCT000054476	NCT00005447_6_T0	GENE	12	12	CHD
NCT000054478	NCT00005447_8_T0	GENE	3	3	extended
NCT000054478	NCT00005447_8_T1	PHENOTYPE	49	50	myocardial infarction
NCT000054478	NCT00005447_8_T2	PHENOTYPE	14	15	Heart Disease
NCT000054479	NCT00005447_9_T0	PHENOTYPE	19	19	recurrent
NCT0000544710	NCT00005447_10_T0	TISSUE	19	20	body fat
NCT000054483	NCT00005448_3_T0	COMPOUND	5	5	MgSO4
NCT000054485	NCT00005448_5_T0	PHENOTYPE	7	7	complication
NCT000054486	NCT00005448_6_T0	PHENOTYPE	5	6	pulmonary toxicity
NCT000054488	NCT00005448_8_T0	COMPOUND	14	14	MgSO4
NCT000054488	NCT00005448_8_T1	PHENOTYPE	11	12	pulmonary edema
NCT000054489	NCT00005448_9_T0	COMPOUND	29	29	MgSO4
NCT000054489	NCT00005448_9_T1	GENE	5	5	nested
NCT000054489	NCT00005448_9_T2	PHENOTYPE	23	24	pulmonary edema
NCT0000544810	NCT00005448_10_T0	COMPOUND	32	32	MgSO4
NCT0000544810	NCT00005448_10_T1	PHENOTYPE	28	29	pulmonary edema
NCT0000544811	NCT00005448_11_T0	PHENOTYPE	7	8	preterm labor
NCT0000544812	NCT00005448_12_T0	COMPOUND	9	9	MgSO4
NCT0000544812	NCT00005448_12_T1	COMPOUND	18	18	MgSO4
NCT0000544813	NCT00005448_13_T0	GENE	4	4	probable
NCT0000544813	NCT00005448_13_T1	GENE	7	7	met
NCT0000544813	NCT00005448_13_T2	PHENOTYPE	12	13	pulmonary edema
NCT0000544815	NCT00005448_15_T0	COMPOUND	26	26	MgSO4
NCT0000544815	NCT00005448_15_T1	PHENOTYPE	22	23	pulmonary edema
NCT000054492	NCT00005449_2_T0	PHENOTYPE	25	26	cardiovascular disease
NCT000054492	NCT00005449_2_T1	PHENOTYPE	16	17	psychological stress
NCT000054493	NCT00005449_3_T0	PHENOTYPE	26	26	ischemia
NCT000054493	NCT00005449_3_T1	PHENOTYPE	14	15	psychological stress
NCT000054493	NCT00005449_3_T2	PHENOTYPE	1	2	myocardial ischemia
NCT000054493	NCT00005449_3_T3	PHENOTYPE	18	19	mental stress
NCT000054494	NCT00005449_4_T0	PHENOTYPE	3	3	severity
NCT000054494	NCT00005449_4_T1	PHENOTYPE	7	8	myocardial ischemia
NCT000054496	NCT00005449_6_T0	PHENOTYPE	21	22	psychological stress
NCT000054498	NCT00005449_8_T0	COMPOUND	4	4	catecholamine
NCT000054499	NCT00005449_9_T0	GENE	12	12	reduced
NCT000054499	NCT00005449_9_T1	PHENOTYPE	15	15	ischemia
NCT0000544910	NCT00005449_10_T0	PHENOTYPE	27	27	ischemia
NCT0000544913	NCT00005449_13_T0	ORGAN	21	21	heart
NCT0000544913	NCT00005449_13_T1	PHENOTYPE	29	29	ischemia
NCT000054502	NCT00005450_2_T0	PHENOTYPE	11	12	cerebrovascular disease
NCT000054503	NCT00005450_3_T0	PHENOTYPE	16	16	strategies
NCT000054503	NCT00005450_3_T1	PHENOTYPE	12	13	cardiovascular disease
NCT000054513	NCT00005451_3_T0	GENE	2	2	had
NCT000054513	NCT00005451_3_T1	GENE	10	10	had
NCT000054514	NCT00005451_4_T0	GENE	15	15	had
NCT000054515	NCT00005451_5_T0	GENE	3	3	had
NCT000054516	NCT00005451_6_T0	GENE	2	2	had
NCT000054524	NCT00005452_4_T0	GENE	1	1	ran
NCT000054533	NCT00005453_3_T0	GENE	1	1	has
NCT000054535	NCT00005453_5_T0	GENE	4	4	had
NCT0000545311	NCT00005453_11_T0	COMPOUND	11	11	lovastatin
NCT0000545312	NCT00005453_12_T0	GENE	13	13	MEMS
NCT0000545315	NCT00005453_15_T0	COMPOUND	24	25	cholesterol lowering
NCT0000545316	NCT00005453_16_T0	PHENOTYPE	31	31	generalized
NCT0000545316	NCT00005453_16_T1	PHENOTYPE	27	28	problem solving
NCT000054553	NCT00005455_3_T0	PHENOTYPE	41	41	cardiomyopathy
NCT000054553	NCT00005455_3_T1	PHENOTYPE	37	37	chronic
NCT000054553	NCT00005455_3_T2	PHENOTYPE	16	17	Chagas cardiomyopathy
NCT000054554	NCT00005455_4_T0	PHENOTYPE	17	19	coronary artery disease
NCT000054554	NCT00005455_4_T1	PHENOTYPE	13	15	idiopathic dilated cardiomyopathy
NCT000054560	NCT00005456_0_T0	PHENOTYPE	10	10	Hypertension
NCT000054560	NCT00005456_0_T1	BIOLOGICAL_PROCESS	4	4	Metabolism
NCT000054563	NCT00005456_3_T0	PHENOTYPE	9	9	hypertension
NCT000054564	NCT00005456_4_T0	COMPOUND	3	3	calcium
NCT000054564	NCT00005456_4_T1	BIOLOGICAL_PROCESS	4	4	metabolism
NCT000054565	NCT00005456_5_T0	GENE	17	17	had
NCT000054565	NCT00005456_5_T1	PHENOTYPE	23	23	preeclampsia
NCT000054565	NCT00005456_5_T2	PHENOTYPE	14	14	chronic
NCT000054565	NCT00005456_5_T3	PHENOTYPE	15	15	hypertension
NCT000054569	NCT00005456_9_T0	COMPOUND	27	27	calcium
NCT000054569	NCT00005456_9_T1	PHENOTYPE	33	33	hypocalciuria
NCT000054569	NCT00005456_9_T2	PHENOTYPE	35	35	preeclampsia
NCT000054569	NCT00005456_9_T3	GENE	19	20	parathyroid hormone
NCT000054569	NCT00005456_9_T4	PHENOTYPE	16	17	serum calcium
NCT0000545610	NCT00005456_10_T0	BIOLOGICAL_PROCESS	20	20	natriuresis
NCT0000545610	NCT00005456_10_T1	BIOLOGICAL_PROCESS	15	15	vasoconstriction
NCT0000545610	NCT00005456_10_T2	PHENOTYPE	8	8	preeclampsia
NCT0000545610	NCT00005456_10_T3	PHENOTYPE	17	17	hypertension
NCT0000545610	NCT00005456_10_T4	GENE	6	6	PRA
NCT0000545611	NCT00005456_11_T0	COMPOUND	9	9	calcium
NCT0000545611	NCT00005456_11_T1	COMPOUND	16	16	calcium
NCT0000545611	NCT00005456_11_T2	COMPOUND	13	13	progesterone
NCT0000545611	NCT00005456_11_T3	PHENOTYPE	26	26	preeclampsia
NCT0000545611	NCT00005456_11_T4	ORGAN	7	7	serum
NCT0000545611	NCT00005456_11_T5	GENE	10	10	PRA
NCT0000545611	NCT00005456_11_T6	COMPOUND	11	11	estradiol
NCT0000545611	NCT00005456_11_T7	GENE	5	6	parathyroid hormone
NCT0000545612	NCT00005456_12_T0	PHENOTYPE	0	0	Acute
NCT0000545612	NCT00005456_12_T1	PHENOTYPE	10	10	preeclampsia
NCT0000545614	NCT00005456_14_T0	PHENOTYPE	15	15	acute
NCT0000545614	NCT00005456_14_T1	CELL	7	7	lymphocytes
NCT0000545614	NCT00005456_14_T2	COMPOUND	2	2	calcium
NCT0000545614	NCT00005456_14_T3	CELL	5	5	platelets
NCT000054572	NCT00005457_2_T0	GENE	14	14	log
NCT0000545710	NCT00005457_10_T0	PHENOTYPE	14	15	rare disease
NCT000054585	NCT00005458_5_T0	GENE	15	15	CHD
NCT000054586	NCT00005458_6_T0	PHENOTYPE	43	43	strategies
NCT000054586	NCT00005458_6_T1	PHENOTYPE	9	11	coronary heart disease
NCT0000545811	NCT00005458_11_T0	PHENOTYPE	1	1	regression
NCT0000545811	NCT00005458_11_T1	PHENOTYPE	32	32	bronchitis
NCT0000545811	NCT00005458_11_T2	GENE	30	30	CHD
NCT0000545812	NCT00005458_12_T0	PHENOTYPE	1	1	regression
NCT0000545813	NCT00005458_13_T0	GENE	7	7	had
NCT000054592	NCT00005459_2_T0	GENE	1	1	has
NCT000054592	NCT00005459_2_T1	PHENOTYPE	9	10	insulin sensitivity
NCT000054594	NCT00005459_4_T0	PHENOTYPE	8	8	PCOS
NCT000054594	NCT00005459_4_T1	PHENOTYPE	18	18	PCOS
NCT000054594	NCT00005459_4_T2	PHENOTYPE	14	16	coronary heart disease
NCT000054595	NCT00005459_5_T0	PHENOTYPE	18	18	PCOS
NCT000054596	NCT00005459_6_T0	PHENOTYPE	13	13	PCOS
NCT000054596	NCT00005459_6_T1	PHENOTYPE	31	31	PCOS
NCT000054596	NCT00005459_6_T2	PHENOTYPE	27	29	coronary heart disease
NCT000054597	NCT00005459_7_T0	PHENOTYPE	10	10	PCOS
NCT000054598	NCT00005459_8_T0	PHENOTYPE	21	21	PCOS
NCT000054598	NCT00005459_8_T1	PHENOTYPE	12	14	coronary heart disease
NCT000054599	NCT00005459_9_T0	COMPOUND	17	17	glucose
NCT000054599	NCT00005459_9_T1	PHENOTYPE	39	39	concentrations
NCT000054599	NCT00005459_9_T2	GENE	19	19	insulin
NCT000054599	NCT00005459_9_T3	GENE	38	38	hormone
NCT000054599	NCT00005459_9_T4	GENE	11	11	HDL
NCT000054599	NCT00005459_9_T5	PHENOTYPE	35	35	PCOS
NCT000054599	NCT00005459_9_T6	ORGAN	37	37	serum
NCT0000545910	NCT00005459_10_T0	PHENOTYPE	7	7	PCOS
NCT0000545910	NCT00005459_10_T1	GENE	13	13	hormone
NCT0000545912	NCT00005459_12_T0	ORGAN	4	4	thyroid
NCT0000545912	NCT00005459_12_T1	PHENOTYPE	7	8	pituitary disease
NCT0000545913	NCT00005459_13_T0	PHENOTYPE	21	21	atherosclerosis
NCT0000545913	NCT00005459_13_T1	PHENOTYPE	11	11	PCOS
NCT0000545914	NCT00005459_14_T0	PHENOTYPE	16	16	atherosclerosis
NCT0000545914	NCT00005459_14_T1	PHENOTYPE	2	2	PCOS
NCT0000545915	NCT00005459_15_T0	PHENOTYPE	9	9	atherosclerosis
NCT0000545915	NCT00005459_15_T1	PHENOTYPE	6	6	PCOS
NCT0000545916	NCT00005459_16_T0	PHENOTYPE	21	21	atherosclerosis
NCT0000545916	NCT00005459_16_T1	PHENOTYPE	14	14	PCOS
NCT0000545916	NCT00005459_16_T2	GENE	15	15	had
NCT0000545919	NCT00005459_19_T0	PHENOTYPE	5	5	atherosclerosis
NCT0000545919	NCT00005459_19_T1	GENE	27	27	insulin
NCT0000545919	NCT00005459_19_T2	COMPOUND	34	34	testosterone
NCT0000545919	NCT00005459_19_T3	GENE	22	22	HDL
NCT0000545919	NCT00005459_19_T4	PHENOTYPE	18	18	PCOS
NCT0000545919	NCT00005459_19_T5	GENE	24	24	LDL
NCT0000545919	NCT00005459_19_T6	COMPOUND	41	41	BMI
NCT0000545919	NCT00005459_19_T7	PHENOTYPE	7	8	vascular disease
NCT0000545920	NCT00005459_20_T0	PHENOTYPE	8	8	PCOS
NCT0000545920	NCT00005459_20_T1	ORGAN	24	24	abdomen
NCT0000545920	NCT00005459_20_T2	TISSUE	14	15	intra-abdominal fat
NCT0000545920	NCT00005459_20_T3	TISSUE	30	31	body fat
NCT0000545921	NCT00005459_21_T0	PHENOTYPE	6	6	atherosclerosis
NCT0000545923	NCT00005459_23_T0	GENE	1	1	insulin
NCT0000545923	NCT00005459_23_T1	COMPOUND	2	2	testosterone
NCT0000545923	NCT00005459_23_T2	GENE	16	16	paired
NCT0000545923	NCT00005459_23_T3	PHENOTYPE	4	6	coronary heart disease
NCT0000545924	NCT00005459_24_T0	PHENOTYPE	7	7	PCOS
NCT0000545924	NCT00005459_24_T1	PHENOTYPE	1	1	regression
NCT0000545924	NCT00005459_24_T2	GENE	12	12	had
NCT0000545924	NCT00005459_24_T3	TISSUE	16	17	intra-abdominal fat
NCT000054602	NCT00005460_2_T0	GENE	7	7	had
NCT000054603	NCT00005460_3_T0	GENE	26	26	bypass
NCT000054603	NCT00005460_3_T1	PHENOTYPE	23	24	myocardial infarction
NCT000054614	NCT00005461_4_T0	PHENOTYPE	25	25	asthma
NCT000054614	NCT00005461_4_T1	PHENOTYPE	30	30	asthma
NCT000054614	NCT00005461_4_T2	PHENOTYPE	43	43	asthma
NCT000054614	NCT00005461_4_T3	PHENOTYPE	17	17	symptoms
NCT000054614	NCT00005461_4_T4	PHENOTYPE	47	48	respiratory symptoms
NCT000054614	NCT00005461_4_T5	PHENOTYPE	39	41	perception in children
NCT000054615	NCT00005461_5_T0	PHENOTYPE	12	12	symptoms
NCT000054615	NCT00005461_5_T1	PHENOTYPE	10	10	self-perception
NCT000054616	NCT00005461_6_T0	PHENOTYPE	9	9	severity
NCT000054616	NCT00005461_6_T1	PHENOTYPE	8	8	asthma
NCT000054616	NCT00005461_6_T2	PHENOTYPE	30	30	asthma
NCT000054616	NCT00005461_6_T3	PHENOTYPE	34	34	asthma
NCT000054619	NCT00005461_9_T0	PHENOTYPE	26	26	self-perception
NCT000054619	NCT00005461_9_T1	PHENOTYPE	6	6	repression
NCT0000546110	NCT00005461_10_T0	PHENOTYPE	6	6	self-perception
NCT0000546114	NCT00005461_14_T0	PHENOTYPE	14	14	asthma
NCT0000546115	NCT00005461_15_T0	PHENOTYPE	33	33	hypoxia
NCT0000546115	NCT00005461_15_T1	PHENOTYPE	45	45	hypercapnia
NCT0000546115	NCT00005461_15_T2	GENE	12	12	had
NCT0000546115	NCT00005461_15_T3	GENE	18	18	had
NCT0000546115	NCT00005461_15_T4	GENE	26	26	had
NCT0000546115	NCT00005461_15_T5	GENE	36	36	had
NCT0000546115	NCT00005461_15_T6	PHENOTYPE	7	7	asthmatics
NCT0000546115	NCT00005461_15_T7	PHENOTYPE	31	31	progressive
NCT0000546115	NCT00005461_15_T8	PHENOTYPE	44	44	progressive
NCT0000546115	NCT00005461_15_T9	PHENOTYPE	15	16	asthma attacks
NCT0000546117	NCT00005461_17_T0	PHENOTYPE	10	10	asthma
NCT0000546117	NCT00005461_17_T1	PHENOTYPE	15	15	asthma
NCT0000546118	NCT00005461_18_T0	PHENOTYPE	37	37	asthma
NCT000054621	NCT00005462_1_T0	ORGAN	9	9	Heart
NCT000054621	NCT00005462_1_T1	PHENOTYPE	18	18	atherosclerosis
NCT000054621	NCT00005462_1_T2	GENE	6	6	San
NCT000054624	NCT00005462_4_T0	GENE	3	3	lipoprotein
NCT000054625	NCT00005462_5_T0	PHENOTYPE	10	10	concentrations
NCT000054625	NCT00005462_5_T1	GENE	4	4	lipoprotein
NCT000054625	NCT00005462_5_T2	ORGAN	9	9	plasma
NCT000054626	NCT00005462_6_T0	GENE	2	2	lipoprotein
NCT000054626	NCT00005462_6_T1	GENE	19	19	lipoprotein
NCT000054627	NCT00005462_7_T0	PHENOTYPE	10	10	localize
NCT000054627	NCT00005462_7_T1	PHENOTYPE	23	23	obesity
NCT000054627	NCT00005462_7_T2	PHENOTYPE	21	21	NIDDM
NCT0000546212	NCT00005462_12_T0	GENE	8	8	lipoprotein
NCT0000546215	NCT00005462_15_T0	PHENOTYPE	13	14	false positives
NCT0000546216	NCT00005462_16_T0	PHENOTYPE	21	21	atherosclerosis
NCT0000546216	NCT00005462_16_T1	PHENOTYPE	10	10	localize
NCT0000546216	NCT00005462_16_T2	PHENOTYPE	24	24	obesity
NCT0000546216	NCT00005462_16_T3	PHENOTYPE	22	22	NIDDM
NCT0000546217	NCT00005462_17_T0	GENE	17	17	STR
NCT0000546218	NCT00005462_18_T0	PHENOTYPE	25	25	localize
NCT0000546218	NCT00005462_18_T1	GENE	5	5	has
NCT0000546220	NCT00005462_20_T0	PHENOTYPE	12	12	localize
NCT0000546222	NCT00005462_22_T0	PHENOTYPE	8	8	obesity
NCT0000546222	NCT00005462_22_T1	PHENOTYPE	6	6	NIDDM
NCT0000546223	NCT00005462_23_T0	GENE	6	6	has
NCT0000546226	NCT00005462_26_T0	GENE	12	12	insulin
NCT0000546226	NCT00005462_26_T1	PHENOTYPE	8	9	glucose tolerance
NCT0000546227	NCT00005462_27_T0	ORGAN	10	12	internal carotid artery
NCT0000546230	NCT00005462_30_T0	GENE	37	37	HDL
NCT0000546230	NCT00005462_30_T1	PHENOTYPE	24	24	concentrations
NCT0000546230	NCT00005462_30_T2	GENE	10	10	LDL
NCT0000546230	NCT00005462_30_T3	ORGAN	34	34	plasma
NCT000054631	NCT00005463_1_T0	GENE	7	7	CHD
NCT000054631	NCT00005463_1_T1	GENE	28	28	CHD
NCT000054631	NCT00005463_1_T2	PHENOTYPE	4	6	Coronary Heart Disease
NCT000054635	NCT00005463_5_T0	GENE	19	19	LDL
NCT000054635	NCT00005463_5_T1	GENE	7	7	CHD
NCT000054636	NCT00005463_6_T0	PHENOTYPE	62	62	strategies
NCT000054636	NCT00005463_6_T1	GENE	1	1	CHD
NCT000054636	NCT00005463_6_T2	GENE	30	30	CHD
NCT000054636	NCT00005463_6_T3	GENE	45	45	CHD
NCT000054636	NCT00005463_6_T4	GENE	86	86	CHD
NCT000054636	NCT00005463_6_T5	PHENOTYPE	27	28	cholesterol levels
NCT000054636	NCT00005463_6_T6	PHENOTYPE	115	116	cholesterol levels
NCT000054636	NCT00005463_6_T7	PHENOTYPE	78	79	adverse effects
NCT000054636	NCT00005463_6_T8	PHENOTYPE	73	75	quality of life
NCT000054642	NCT00005464_2_T0	COMPOUND	22	22	sodium
NCT000054642	NCT00005464_2_T1	PHENOTYPE	12	12	withdrawn
NCT000054642	NCT00005464_2_T2	PHENOTYPE	1	1	DISH
NCT000054642	NCT00005464_2_T3	PHENOTYPE	19	20	weight reduction
NCT000054643	NCT00005464_3_T0	PHENOTYPE	22	22	DISH
NCT000054645	NCT00005464_5_T0	PHENOTYPE	15	15	relapse
NCT000054646	NCT00005464_6_T0	PHENOTYPE	12	12	DISH
NCT000054646	NCT00005464_6_T1	PHENOTYPE	17	17	DISH
NCT000054646	NCT00005464_6_T2	PHENOTYPE	30	30	DISH
NCT000054647	NCT00005464_7_T0	PHENOTYPE	14	14	DISH
NCT000054647	NCT00005464_7_T1	PHENOTYPE	21	21	DISH
NCT000054652	NCT00005465_2_T0	PHENOTYPE	19	21	mode of inheritance
NCT000054653	NCT00005465_3_T0	PHENOTYPE	13	15	coronary heart disease
NCT000054655	NCT00005465_5_T0	GENE	10	10	ALP
NCT000054655	NCT00005465_5_T1	GENE	26	26	ALP
NCT000054655	NCT00005465_5_T2	BIOLOGICAL_PROCESS	5	6	lipoprotein metabolism
NCT000054656	NCT00005465_6_T0	GENE	9	9	ALP
NCT000054659	NCT00005465_9_T0	GENE	25	25	apo
NCT000054659	NCT00005465_9_T1	GENE	15	15	ALP
NCT0000546510	NCT00005465_10_T0	GENE	33	33	ALP
NCT0000546510	NCT00005465_10_T1	PHENOTYPE	24	24	RFLPs
NCT0000546510	NCT00005465_10_T2	PHENOTYPE	20	23	restriction fragment length polymorphisms
NCT0000546511	NCT00005465_11_T0	GENE	29	29	apo
NCT0000546511	NCT00005465_11_T1	GENE	5	5	ALP
NCT0000546511	NCT00005465_11_T2	GENE	19	19	ALP
NCT000054663	NCT00005466_3_T0	COMPOUND	2	2	estrogen
NCT000054663	NCT00005466_3_T1	COMPOUND	11	11	estrogen
NCT000054663	NCT00005466_3_T2	COMPOUND	41	41	estrogen
NCT000054663	NCT00005466_3_T3	PHENOTYPE	9	10	endometrial cancer
NCT000054663	NCT00005466_3_T4	PHENOTYPE	34	35	endometrial cancer
NCT000054664	NCT00005466_4_T0	PHENOTYPE	14	14	menopausal
NCT000054664	NCT00005466_4_T1	PHENOTYPE	11	12	cardiovascular disease
NCT000054665	NCT00005466_5_T0	GENE	4	4	had
NCT000054668	NCT00005466_8_T0	COMPOUND	6	6	estrogen
NCT000054669	NCT00005466_9_T0	PHENOTYPE	5	5	regression
NCT0000546610	NCT00005466_10_T0	PHENOTYPE	6	6	acute
NCT0000546610	NCT00005466_10_T1	COMPOUND	14	14	estrogen
NCT000054670	NCT00005467_0_T0	PHENOTYPE	2	2	Severity
NCT000054670	NCT00005467_0_T1	PHENOTYPE	6	8	Sickle Cell Disease
NCT000054673	NCT00005467_3_T0	GENE	2	2	hematocrit
NCT000054685	NCT00005468_5_T0	PHENOTYPE	19	19	associations
NCT000054688	NCT00005468_8_T0	COMPOUND	23	23	caffeine
NCT000054695	NCT00005469_5_T0	GENE	2	2	had
NCT000054695	NCT00005469_5_T1	PHENOTYPE	18	19	hypertensive disease
NCT000054696	NCT00005469_6_T0	PHENOTYPE	13	13	Hypertension
NCT000054699	NCT00005469_9_T0	PHENOTYPE	7	7	maturation
NCT0000546911	NCT00005469_11_T0	GENE	4	4	had
NCT0000546911	NCT00005469_11_T1	GENE	8	8	hormone
NCT0000546911	NCT00005469_11_T2	PHENOTYPE	12	13	blood viscosity
NCT0000546914	NCT00005469_14_T0	PHENOTYPE	9	9	Hypertension
NCT000054702	NCT00005470_2_T0	PHENOTYPE	12	12	obesity
NCT000054703	NCT00005470_3_T0	PHENOTYPE	11	11	obesity
NCT000054704	NCT00005470_4_T0	PHENOTYPE	7	7	obesity
NCT000054705	NCT00005470_5_T0	PHENOTYPE	15	17	total peripheral resistance
NCT000054706	NCT00005470_6_T0	PHENOTYPE	6	6	obesity
NCT000054707	NCT00005470_7_T0	PHENOTYPE	47	47	severity
NCT000054707	NCT00005470_7_T1	PHENOTYPE	3	3	obesity
NCT000054707	NCT00005470_7_T2	PHENOTYPE	49	49	obesity
NCT000054707	NCT00005470_7_T3	PHENOTYPE	15	17	total peripheral resistance
NCT000054708	NCT00005470_8_T0	PHENOTYPE	24	24	obesity
NCT000054708	NCT00005470_8_T1	PHENOTYPE	26	28	blood pressure elevation
NCT000054709	NCT00005470_9_T0	PHENOTYPE	5	5	obesity
NCT000054709	NCT00005470_9_T1	PHENOTYPE	22	22	obesity
NCT000054709	NCT00005470_9_T2	PHENOTYPE	25	27	elevated blood pressure
NCT0000547010	NCT00005470_10_T0	PHENOTYPE	15	15	strategies
NCT0000547010	NCT00005470_10_T1	PHENOTYPE	26	26	hypertension
NCT0000547010	NCT00005470_10_T2	PHENOTYPE	23	23	obesity
NCT0000547010	NCT00005470_10_T3	PHENOTYPE	36	37	cardiovascular disease
NCT0000547013	NCT00005470_13_T0	GENE	2	2	has
NCT0000547016	NCT00005470_16_T0	PHENOTYPE	16	18	total peripheral resistance
NCT0000547017	NCT00005470_17_T0	GENE	21	21	ventricular
NCT0000547017	NCT00005470_17_T1	GENE	27	27	ventricular
NCT0000547017	NCT00005470_17_T2	GENE	34	34	ventricular
NCT0000547017	NCT00005470_17_T3	ORGAN	24	24	heart
NCT0000547017	NCT00005470_17_T4	PHENOTYPE	30	31	blood viscosity
NCT0000547017	NCT00005470_17_T5	PHENOTYPE	12	14	total peripheral resistance
NCT000054712	NCT00005471_2_T0	PHENOTYPE	12	12	anxious
NCT000054712	NCT00005471_2_T1	GENE	18	18	reduced
NCT000054714	NCT00005471_4_T0	PHENOTYPE	11	11	physiology
NCT000054714	NCT00005471_4_T1	PHENOTYPE	26	28	sudden cardiac death
NCT000054715	NCT00005471_5_T0	PHENOTYPE	15	16	sudden death
NCT000054717	NCT00005471_7_T0	PHENOTYPE	35	35	symptoms
NCT000054717	NCT00005471_7_T1	PHENOTYPE	41	42	anxiety disorders
NCT000054718	NCT00005471_8_T0	PHENOTYPE	7	7	anxious
NCT000054718	NCT00005471_8_T1	PHENOTYPE	9	9	anxious
NCT000054718	NCT00005471_8_T2	ORGAN	18	18	heart
NCT000054719	NCT00005471_9_T0	PHENOTYPE	2	4	total peripheral resistance
NCT000054720	NCT00005472_0_T0	PHENOTYPE	6	6	Hypertension
NCT000054720	NCT00005472_0_T1	PHENOTYPE	0	1	Job Strain
NCT000054723	NCT00005472_3_T0	PHENOTYPE	0	0	Hypertension
NCT000054723	NCT00005472_3_T1	PHENOTYPE	1	1	affects
NCT000054723	NCT00005472_3_T2	PHENOTYPE	12	13	essential hypertension
NCT000054724	NCT00005472_4_T0	PHENOTYPE	2	2	CVD
NCT000054724	NCT00005472_4_T1	GENE	7	7	has
NCT000054724	NCT00005472_4_T2	PHENOTYPE	15	16	essential hypertension
NCT000054724	NCT00005472_4_T3	PHENOTYPE	5	6	job strain
NCT000054725	NCT00005472_5_T0	PHENOTYPE	14	14	CVD
NCT000054725	NCT00005472_5_T1	GENE	5	5	had
NCT000054725	NCT00005472_5_T2	PHENOTYPE	21	21	hypertension
NCT000054725	NCT00005472_5_T3	PHENOTYPE	11	12	job strain
NCT000054725	NCT00005472_5_T4	PHENOTYPE	15	17	coronary heart disease
NCT000054726	NCT00005472_6_T0	PHENOTYPE	0	1	Job strain
NCT000054727	NCT00005472_7_T0	PHENOTYPE	4	5	job strain
NCT000054728	NCT00005472_8_T0	PHENOTYPE	9	9	CVD
NCT000054728	NCT00005472_8_T1	PHENOTYPE	11	11	hypertension
NCT000054728	NCT00005472_8_T2	PHENOTYPE	7	8	job strain
NCT000054729	NCT00005472_9_T0	PHENOTYPE	3	4	job strain
NCT000054729	NCT00005472_9_T1	PHENOTYPE	19	20	job strain
NCT0000547210	NCT00005472_10_T0	PHENOTYPE	9	10	job strain
NCT0000547211	NCT00005472_11_T0	PHENOTYPE	9	10	job strain
NCT0000547212	NCT00005472_12_T0	PHENOTYPE	13	14	Cardiovascular Disease
NCT0000547213	NCT00005472_13_T0	GENE	2	2	had
NCT0000547213	NCT00005472_13_T1	PHENOTYPE	61	61	CVD
NCT0000547213	NCT00005472_13_T2	PHENOTYPE	66	66	hypertension
NCT0000547213	NCT00005472_13_T3	PHENOTYPE	19	20	job strain
NCT0000547213	NCT00005472_13_T4	PHENOTYPE	33	34	job strain
NCT0000547213	NCT00005472_13_T5	PHENOTYPE	46	47	job strain
NCT0000547214	NCT00005472_14_T0	GENE	0	0	Paul
NCT0000547214	NCT00005472_14_T1	PHENOTYPE	33	33	CVD
NCT0000547214	NCT00005472_14_T2	PHENOTYPE	31	32	cardiovascular disease
NCT0000547214	NCT00005472_14_T3	PHENOTYPE	9	10	job strain
NCT000054730	NCT00005473_0_T0	PHENOTYPE	0	1	Cardiovascular Disease
NCT000054735	NCT00005473_5_T0	GENE	36	36	CHD
NCT000054735	NCT00005473_5_T1	GENE	67	67	CHD
NCT000054735	NCT00005473_5_T2	PHENOTYPE	33	35	coronary heart disease
NCT000054736	NCT00005473_6_T0	ORGAN	13	13	Heart
NCT000054738	NCT00005473_8_T0	PHENOTYPE	3	5	coronary heart disease
NCT0000547311	NCT00005473_11_T0	GENE	16	16	contrasted
NCT0000547313	NCT00005473_13_T0	PHENOTYPE	17	17	regression
NCT0000547313	NCT00005473_13_T1	PHENOTYPE	18	18	regression
NCT0000547314	NCT00005473_14_T0	PHENOTYPE	5	5	regression
NCT000054743	NCT00005474_3_T0	PHENOTYPE	22	22	atherogenesis
NCT000054743	NCT00005474_3_T1	PHENOTYPE	8	8	hyperglycemia
NCT000054744	NCT00005474_4_T0	COMPOUND	23	23	glucose
NCT000054744	NCT00005474_4_T1	PHENOTYPE	20	20	complications
NCT000054746	NCT00005474_6_T0	PHENOTYPE	11	12	Cardiovascular Disease
NCT000054746	NCT00005474_6_T1	PHENOTYPE	14	15	Diabetes Mellitus
NCT0000547410	NCT00005474_10_T0	PHENOTYPE	9	9	Diabetes
NCT0000547412	NCT00005474_12_T0	PHENOTYPE	19	19	Complications
NCT0000547412	NCT00005474_12_T1	PHENOTYPE	33	33	Complications
NCT0000547412	NCT00005474_12_T2	PHENOTYPE	16	16	Diabetes
NCT0000547412	NCT00005474_12_T3	PHENOTYPE	30	30	Diabetes
NCT0000547412	NCT00005474_12_T4	PHENOTYPE	46	46	Diabetes
NCT0000547412	NCT00005474_12_T5	PHENOTYPE	50	51	Kidney Diseases
NCT0000547413	NCT00005474_13_T0	PHENOTYPE	22	22	microalbuminuria
NCT0000547414	NCT00005474_14_T0	GENE	27	27	collagen
NCT0000547414	NCT00005474_14_T1	PHENOTYPE	12	12	resistant
NCT0000547416	NCT00005474_16_T0	PHENOTYPE	21	22	disease progression
NCT0000547420	NCT00005474_20_T0	GENE	18	18	fibrinogen
NCT0000547420	NCT00005474_20_T1	BIOLOGICAL_PROCESS	0	0	Hemostasis
NCT0000547420	NCT00005474_20_T2	GENE	16	16	PAI-1
NCT0000547423	NCT00005474_23_T0	TISSUE	42	42	membranes
NCT0000547423	NCT00005474_23_T1	GENE	48	48	structural
NCT0000547423	NCT00005474_23_T2	PHENOTYPE	56	57	vascular disease
NCT0000547423	NCT00005474_23_T3	TISSUE	40	41	skeletal muscle
NCT0000547423	NCT00005474_23_T4	PHENOTYPE	31	32	insulin resistance
NCT0000547423	NCT00005474_23_T5	TISSUE	15	16	body fat
NCT0000547423	NCT00005474_23_T6	BIOLOGICAL_PROCESS	25	27	fatty acid metabolism
NCT0000547424	NCT00005474_24_T0	TISSUE	26	26	membranes
NCT0000547424	NCT00005474_24_T1	PHENOTYPE	10	10	complications
NCT0000547424	NCT00005474_24_T2	PHENOTYPE	33	34	insulin resistance
NCT0000547427	NCT00005474_27_T0	PHENOTYPE	26	26	encoded
NCT0000547428	NCT00005474_28_T0	GENE	5	5	FY
NCT000054753	NCT00005475_3_T0	PHENOTYPE	15	15	allergy
NCT000054756	NCT00005475_6_T0	PHENOTYPE	20	20	symptoms
NCT000054756	NCT00005475_6_T1	PHENOTYPE	34	34	symptoms
NCT000054756	NCT00005475_6_T2	PHENOTYPE	52	52	symptoms
NCT000054756	NCT00005475_6_T3	PHENOTYPE	28	28	asthma
NCT000054756	NCT00005475_6_T4	PHENOTYPE	49	49	asthma
NCT000054756	NCT00005475_6_T5	PHENOTYPE	51	51	asthma
NCT000054756	NCT00005475_6_T6	BIOLOGICAL_PROCESS	23	23	sensitization
NCT000054756	NCT00005475_6_T7	BIOLOGICAL_PROCESS	44	44	sensitization
NCT000054756	NCT00005475_6_T8	PHENOTYPE	59	60	lung function
NCT000054758	NCT00005475_8_T0	PHENOTYPE	10	10	atopy
NCT000054758	NCT00005475_8_T1	PHENOTYPE	17	18	lung function
NCT000054759	NCT00005475_9_T0	COMPOUND	12	12	methacholine
NCT000054759	NCT00005475_9_T1	PHENOTYPE	1	2	lung function
NCT0000547510	NCT00005475_10_T0	PHENOTYPE	7	7	symptoms
NCT0000547510	NCT00005475_10_T1	PHENOTYPE	14	14	atopy
NCT0000547510	NCT00005475_10_T2	COMPOUND	11	11	methacholine
NCT0000547510	NCT00005475_10_T3	CELL	16	16	lymphocyte
NCT0000547510	NCT00005475_10_T4	PHENOTYPE	8	9	lung function
NCT0000547512	NCT00005475_12_T0	PHENOTYPE	27	27	asthma
NCT0000547513	NCT00005475_13_T0	PHENOTYPE	102	102	illnesses
NCT0000547513	NCT00005475_13_T1	PHENOTYPE	37	37	progression
NCT0000547513	NCT00005475_13_T2	COMPOUND	52	52	BHR
NCT0000547513	NCT00005475_13_T3	COMPOUND	77	77	BHR
NCT0000547513	NCT00005475_13_T4	PHENOTYPE	107	107	initiation
NCT0000547513	NCT00005475_13_T5	PHENOTYPE	59	59	inflammation
NCT0000547513	NCT00005475_13_T6	PHENOTYPE	29	29	eosinophilia
NCT0000547513	NCT00005475_13_T7	PHENOTYPE	83	83	allergy
NCT0000547513	NCT00005475_13_T8	PHENOTYPE	13	13	asthma
NCT0000547513	NCT00005475_13_T9	PHENOTYPE	20	20	asthma
NCT0000547513	NCT00005475_13_T10	PHENOTYPE	41	41	asthma
NCT0000547513	NCT00005475_13_T11	PHENOTYPE	75	75	asthma
NCT0000547513	NCT00005475_13_T12	PHENOTYPE	103	103	asthma
NCT0000547513	NCT00005475_13_T13	PHENOTYPE	124	124	asthma
NCT0000547513	NCT00005475_13_T14	PHENOTYPE	14	14	symptoms
NCT0000547513	NCT00005475_13_T15	PHENOTYPE	76	76	symptoms
NCT0000547513	NCT00005475_13_T16	PHENOTYPE	104	104	symptoms
NCT0000547513	NCT00005475_13_T17	PHENOTYPE	11	11	remission
NCT0000547513	NCT00005475_13_T18	PHENOTYPE	9	9	persistence
NCT0000547513	NCT00005475_13_T19	PHENOTYPE	93	94	lung function
NCT0000547513	NCT00005475_13_T20	ORGAN	79	80	immune system
NCT0000547513	NCT00005475_13_T21	PHENOTYPE	50	51	bronchial hyperresponsiveness
NCT0000547513	NCT00005475_13_T22	ORGAN	100	101	respiratory tract
NCT000054762	NCT00005476_2_T0	PHENOTYPE	16	16	CVD
NCT000054762	NCT00005476_2_T1	PHENOTYPE	14	15	cardiovascular disease
NCT000054763	NCT00005476_3_T0	PHENOTYPE	33	33	CVD
NCT000054763	NCT00005476_3_T1	PHENOTYPE	31	31	pathophysiology
NCT000054764	NCT00005476_4_T0	GENE	3	3	has
NCT000054765	NCT00005476_5_T0	GENE	7	7	twins
NCT000054768	NCT00005476_8_T0	PHENOTYPE	13	13	SVR
NCT000054768	NCT00005476_8_T1	PHENOTYPE	10	12	systemic vascular resistance
NCT0000547610	NCT00005476_10_T0	GENE	18	18	ventricular
NCT0000547610	NCT00005476_10_T1	PHENOTYPE	12	14	systemic vascular resistance
NCT0000547611	NCT00005476_11_T0	GENE	22	22	ventricular
NCT0000547611	NCT00005476_11_T1	PHENOTYPE	16	18	systemic vascular resistance
NCT0000547612	NCT00005476_12_T0	GENE	18	18	ventricular
NCT0000547612	NCT00005476_12_T1	PHENOTYPE	3	5	systemic vascular resistance
NCT0000547613	NCT00005476_13_T0	GENE	21	21	twins
NCT0000547613	NCT00005476_13_T1	GENE	2	2	has
NCT0000547613	NCT00005476_13_T2	GENE	4	4	extended
NCT000054782	NCT00005478_2_T0	GENE	29	29	20.1
NCT000054782	NCT00005478_2_T1	GENE	24	24	49.1
NCT000054788	NCT00005478_8_T0	GENE	19	19	DHEAS
NCT000054788	NCT00005478_8_T1	COMPOUND	16	16	testosterone
NCT000054788	NCT00005478_8_T2	COMPOUND	17	17	estradiol
NCT000054792	NCT00005479_2_T0	PHENOTYPE	4	6	coronary artery disease
NCT000054792	NCT00005479_2_T1	PHENOTYPE	0	2	Atherosclerotic cardiovascular disease
NCT000054794	NCT00005479_4_T0	PHENOTYPE	14	15	Cardiovascular Disease
NCT000054794	NCT00005479_4_T1	PHENOTYPE	17	18	Diabetes Mellitus
NCT000054795	NCT00005479_5_T0	PHENOTYPE	9	10	Juvenile Diabetes
NCT000054797	NCT00005479_7_T0	PHENOTYPE	18	18	Diabetes
NCT000054799	NCT00005479_9_T0	PHENOTYPE	22	22	ASCVD
NCT000054799	NCT00005479_9_T1	PHENOTYPE	19	21	atherosclerotic cardiovascular disease
NCT0000547910	NCT00005479_10_T0	PHENOTYPE	8	10	coronary artery disease
NCT0000547912	NCT00005479_12_T0	PHENOTYPE	13	15	coronary artery disease
NCT0000547913	NCT00005479_13_T0	COMPOUND	25	25	palmitate
NCT0000547913	NCT00005479_13_T1	GENE	21	21	apoE
NCT0000547913	NCT00005479_13_T2	COMPOUND	24	24	retinyl
NCT0000547914	NCT00005479_14_T0	GENE	8	8	apoCIII
NCT0000547914	NCT00005479_14_T1	GENE	5	5	apoE
NCT0000547914	NCT00005479_14_T2	GENE	6	6	LPL
NCT0000547917	NCT00005479_17_T0	GENE	13	13	insulin
NCT0000547917	NCT00005479_17_T1	GENE	3	3	IRAS
NCT0000547917	NCT00005479_17_T2	PHENOTYPE	10	11	insulin resistance
NCT0000547918	NCT00005479_18_T0	CELL	4	5	endothelial cells
NCT0000547918	NCT00005479_18_T1	PHENOTYPE	15	16	endothelial dysfunction
NCT0000547919	NCT00005479_19_T0	GENE	2	2	VCAM-1
NCT0000547920	NCT00005479_20_T0	GENE	7	7	VCAM-1
NCT0000547920	NCT00005479_20_T1	ORGAN	4	4	plasma
NCT0000547920	NCT00005479_20_T2	GENE	5	5	PMI
NCT0000547920	NCT00005479_20_T3	PHENOTYPE	15	17	coronary artery disease
NCT0000547921	NCT00005479_21_T0	GENE	13	13	FY
NCT000054801	NCT00005480_1_T0	PHENOTYPE	14	15	cardiovascular disease
NCT000054801	NCT00005480_1_T1	PHENOTYPE	31	32	cardiovascular disease
NCT000054803	NCT00005480_3_T0	PHENOTYPE	9	9	strategies
NCT000054804	NCT00005480_4_T0	GENE	16	16	had
NCT000054804	NCT00005480_4_T1	PHENOTYPE	8	9	cardiovascular disease
NCT000054807	NCT00005480_7_T0	PHENOTYPE	12	12	secondary
NCT0000548010	NCT00005480_10_T0	COMPOUND	18	18	1
NCT0000548010	NCT00005480_10_T1	GENE	8	8	had
NCT0000548010	NCT00005480_10_T2	PHENOTYPE	11	12	cardiovascular disease
NCT0000548011	NCT00005480_11_T0	COMPOUND	1	1	2
NCT0000548011	NCT00005480_11_T1	PHENOTYPE	21	22	cardiovascular disease
NCT0000548012	NCT00005480_12_T0	COMPOUND	1	1	3
NCT0000548013	NCT00005480_13_T0	PHENOTYPE	15	15	regression
NCT000054813	NCT00005481_3_T0	BIOLOGICAL_PROCESS	15	16	platelet activation
NCT000054823	NCT00005482_3_T0	COMPOUND	22	22	homocyst_e_ine
NCT000054825	NCT00005482_5_T0	PHENOTYPE	22	22	CVD
NCT000054825	NCT00005482_5_T1	COMPOUND	8	8	homocysteine
NCT000054825	NCT00005482_5_T2	COMPOUND	9	9	folate
NCT000054825	NCT00005482_5_T3	PHENOTYPE	15	16	cardiovascular disease
NCT000054827	NCT00005482_7_T0	COMPOUND	10	10	homocysteine
NCT000054827	NCT00005482_7_T1	ORGAN	7	7	plasma
NCT000054827	NCT00005482_7_T2	PHENOTYPE	20	21	myocardial infarction
NCT000054828	NCT00005482_8_T0	PHENOTYPE	17	17	atherosclerosis
NCT000054828	NCT00005482_8_T1	PHENOTYPE	14	14	progression
NCT000054832	NCT00005483_2_T0	PHENOTYPE	8	8	hyperhomocysteinemia
NCT000054832	NCT00005483_2_T1	PHENOTYPE	12	13	cardiovascular disease
NCT000054832	NCT00005483_2_T2	PHENOTYPE	26	27	vascular disease
NCT000054833	NCT00005483_3_T0	COMPOUND	10	10	homocysteine
NCT000054833	NCT00005483_3_T1	COMPOUND	23	23	homocysteine
NCT000054833	NCT00005483_3_T2	PHENOTYPE	11	11	concentrations
NCT000054833	NCT00005483_3_T3	PHENOTYPE	24	24	concentrations
NCT000054835	NCT00005483_5_T0	PHENOTYPE	8	8	hyperhomocysteinemia
NCT000054837	NCT00005483_7_T0	COMPOUND	3	3	homocysteine
NCT000054837	NCT00005483_7_T1	PHENOTYPE	9	10	vascular disease
NCT000054838	NCT00005483_8_T0	COMPOUND	14	14	homocysteine
NCT000054838	NCT00005483_8_T1	PHENOTYPE	18	18	hyperhomocysteinemia
NCT000054838	NCT00005483_8_T2	ORGAN	5	5	plasma
NCT0000548310	NCT00005483_10_T0	PHENOTYPE	8	8	hyperhomocysteinemia
NCT0000548310	NCT00005483_10_T1	PHENOTYPE	12	13	cardiovascular disease
NCT0000548310	NCT00005483_10_T2	PHENOTYPE	25	26	vascular disease
NCT000054842	NCT00005484_2_T0	PHENOTYPE	4	4	focused
NCT000054842	NCT00005484_2_T1	PHENOTYPE	12	12	asthma
NCT000054843	NCT00005484_3_T0	PHENOTYPE	18	18	asthma
NCT000054844	NCT00005484_4_T0	PHENOTYPE	21	21	asthma
NCT000054846	NCT00005484_6_T0	PHENOTYPE	17	17	asthma
NCT000054846	NCT00005484_6_T1	PHENOTYPE	30	30	asthma
NCT000054847	NCT00005484_7_T0	PHENOTYPE	11	11	asthma
NCT000054849	NCT00005484_9_T0	PHENOTYPE	44	44	symptoms
NCT000054849	NCT00005484_9_T1	PHENOTYPE	21	21	attitudes
NCT000054849	NCT00005484_9_T2	PHENOTYPE	13	13	atopy
NCT000054849	NCT00005484_9_T3	PHENOTYPE	23	23	asthma
NCT000054849	NCT00005484_9_T4	PHENOTYPE	32	32	asthma
NCT000054849	NCT00005484_9_T5	PHENOTYPE	37	37	asthma
NCT000054849	NCT00005484_9_T6	PHENOTYPE	43	43	asthma
NCT000054849	NCT00005484_9_T7	PHENOTYPE	38	39	lung function
NCT000054853	NCT00005485_3_T0	PHENOTYPE	3	3	JHS
NCT000054854	NCT00005485_4_T0	PHENOTYPE	1	1	JHS
NCT000054854	NCT00005485_4_T1	PHENOTYPE	12	12	Atherosclerosis
NCT000054855	NCT00005485_5_T0	GENE	10	10	MS
NCT000054855	NCT00005485_5_T1	GENE	14	14	MSA
NCT000054856	NCT00005485_6_T0	PHENOTYPE	28	28	secondary
NCT000054856	NCT00005485_6_T1	PHENOTYPE	7	7	recruitment
NCT000054856	NCT00005485_6_T2	PHENOTYPE	17	17	Atherosclerosis
NCT000054857	NCT00005485_7_T0	GENE	14	14	nested
NCT000054857	NCT00005485_7_T1	PHENOTYPE	0	0	Recruitment
NCT000054858	NCT00005485_8_T0	GENE	12	12	MSA
NCT0000548510	NCT00005485_10_T0	PHENOTYPE	28	28	CVD
NCT0000548510	NCT00005485_10_T1	PHENOTYPE	1	1	JHS
NCT0000548510	NCT00005485_10_T2	GENE	49	49	MRI
NCT0000548510	NCT00005485_10_T3	ORGAN	60	60	abdomen
NCT0000548510	NCT00005485_10_T4	ORGAN	58	58	aorta
NCT0000548510	NCT00005485_10_T5	GENE	27	27	putative
NCT0000548510	NCT00005485_10_T6	ORGAN	57	57	heart
NCT0000548511	NCT00005485_11_T0	GENE	7	7	putative
NCT0000548512	NCT00005485_12_T0	CELL	5	5	lymphocytes
NCT0000548512	NCT00005485_12_T1	GENE	1	1	has
NCT0000548515	NCT00005485_15_T0	PHENOTYPE	1	1	JHS
NCT000054867	NCT00005486_7_T0	PHENOTYPE	15	15	Centers
NCT000054869	NCT00005486_9_T0	GENE	7	7	eg
NCT000054869	NCT00005486_9_T1	COMPOUND	25	25	oxygen
NCT0000548610	NCT00005486_10_T0	GENE	10	10	FY
NCT000054871	NCT00005487_1_T0	GENE	12	12	NC
NCT000054871	NCT00005487_1_T1	GENE	24	24	MD
NCT000054871	NCT00005487_1_T2	PHENOTYPE	9	9	centers
NCT000054871	NCT00005487_1_T3	GENE	26	26	Paul
NCT000054871	NCT00005487_1_T4	GENE	34	34	CA
NCT000054873	NCT00005487_3_T0	PHENOTYPE	7	7	CVD
NCT000054873	NCT00005487_3_T1	PHENOTYPE	4	4	focused
NCT000054877	NCT00005487_7_T0	PHENOTYPE	10	10	Centers
NCT000054877	NCT00005487_7_T1	PHENOTYPE	7	7	Center
NCT0000548710	NCT00005487_10_T0	GENE	11	11	MRI
NCT0000548710	NCT00005487_10_T1	GENE	26	26	MRI
NCT0000548710	NCT00005487_10_T2	PHENOTYPE	32	32	progression
NCT0000548710	NCT00005487_10_T3	PHENOTYPE	16	17	Cardiovascular Disease
NCT0000548712	NCT00005487_12_T0	PHENOTYPE	11	11	CVD
NCT0000548712	NCT00005487_12_T1	PHENOTYPE	24	24	dilation
NCT0000548712	NCT00005487_12_T2	GENE	18	18	MRI
NCT0000548712	NCT00005487_12_T3	GENE	33	33	putative
NCT0000548712	NCT00005487_12_T4	ORGAN	22	23	brachial artery
NCT0000548712	NCT00005487_12_T5	ORGAN	25	26	radial artery
NCT0000548713	NCT00005487_13_T0	GENE	24	24	MRI
NCT0000548713	NCT00005487_13_T1	GENE	26	26	MRI
NCT0000548713	NCT00005487_13_T2	GENE	20	20	abdominal
NCT0000548713	NCT00005487_13_T3	PHENOTYPE	14	15	cognitive function
NCT0000548714	NCT00005487_14_T0	GENE	7	7	putative
NCT0000548715	NCT00005487_15_T0	CELL	17	17	lymphocytes
NCT0000548715	NCT00005487_15_T1	GENE	1	1	has
NCT0000548717	NCT00005487_17_T0	GENE	9	9	MESA
NCT0000548717	NCT00005487_17_T1	PHENOTYPE	19	21	chronic lung disease
NCT0000548718	NCT00005487_18_T0	GENE	13	13	MESA
NCT0000548719	NCT00005487_19_T0	GENE	1	1	MESA
NCT0000548720	NCT00005487_20_T0	ORGAN	13	13	serum
NCT0000548720	NCT00005487_20_T1	ORGAN	14	14	plasma
NCT000054882	NCT00005488_2_T0	GENE	4	4	had
NCT000054887	NCT00005488_7_T0	ORGAN	17	17	plasma
NCT0000548810	NCT00005488_10_T0	CELL	15	15	cells
NCT0000548810	NCT00005488_10_T1	ORGAN	12	12	plasma
NCT0000548811	NCT00005488_11_T0	GENE	11	11	polymerase
NCT0000548811	NCT00005488_11_T1	COMPOUND	21	21	oligonucleotide
NCT0000548811	NCT00005488_11_T2	GENE	16	16	fragment
NCT0000548811	NCT00005488_11_T3	CELL	5	5	cells
NCT0000548811	NCT00005488_11_T4	PHENOTYPE	19	19	RFLP
NCT0000548811	NCT00005488_11_T5	GENE	14	14	PCR
NCT0000548812	NCT00005488_12_T0	COMPOUND	8	8	homocysteine
NCT0000548812	NCT00005488_12_T1	ORGAN	0	0	Plasma
NCT0000548812	NCT00005488_12_T2	PHENOTYPE	9	9	concentrations
NCT0000548812	NCT00005488_12_T3	GENE	6	6	lipoprotein
NCT000054904	NCT00005490_4_T0	GENE	9	9	Dr
NCT000054904	NCT00005490_4_T1	GENE	17	17	Dr
NCT000054904	NCT00005490_4_T2	GENE	25	25	Dr
NCT000054906	NCT00005490_6_T0	PHENOTYPE	34	34	CVD
NCT000054906	NCT00005490_6_T1	PHENOTYPE	43	43	CVD
NCT000054906	NCT00005490_6_T2	GENE	32	32	MS
NCT000054907	NCT00005490_7_T0	PHENOTYPE	32	32	CVD
NCT000054907	NCT00005490_7_T1	GENE	0	0	Dr
NCT000054908	NCT00005490_8_T0	PHENOTYPE	43	43	CVD
NCT0000549010	NCT00005490_10_T0	GENE	0	0	Dr
NCT0000549010	NCT00005490_10_T1	GENE	16	16	Dr
NCT0000549010	NCT00005490_10_T2	GENE	29	29	Dr
NCT0000549011	NCT00005490_11_T0	PHENOTYPE	16	16	CVD
NCT0000549011	NCT00005490_11_T1	PHENOTYPE	38	38	CVD
NCT0000549011	NCT00005490_11_T2	GENE	43	43	HDL
NCT0000549011	NCT00005490_11_T3	ORGAN	41	41	plasma
NCT0000549011	NCT00005490_11_T4	GENE	0	0	Dr
NCT0000549011	NCT00005490_11_T5	GENE	24	24	Dr
NCT0000549011	NCT00005490_11_T6	GENE	27	27	Dr
NCT0000549012	NCT00005490_12_T0	PHENOTYPE	18	18	CVD
NCT0000549013	NCT00005490_13_T0	PHENOTYPE	26	26	CVD
NCT000054923	NCT00005492_3_T0	PHENOTYPE	3	3	focused
NCT000054924	NCT00005492_4_T0	PHENOTYPE	38	38	foundering
NCT000054924	NCT00005492_4_T1	GENE	3	3	CHD
NCT000054925	NCT00005492_5_T0	GENE	22	22	II
NCT000054927	NCT00005492_7_T0	GENE	14	14	II
NCT000054928	NCT00005492_8_T0	PHENOTYPE	21	21	fitted
NCT000054929	NCT00005492_9_T0	PHENOTYPE	14	14	attributable
NCT000054930	NCT00005493_0_T0	PHENOTYPE	4	4	CVD
NCT000054933	NCT00005493_3_T0	PHENOTYPE	7	7	strokes
NCT000054934	NCT00005493_4_T0	COMPOUND	2	2	carotene
NCT000054934	NCT00005493_4_T1	GENE	1	1	beta
NCT000054935	NCT00005493_5_T0	COMPOUND	11	11	aspirin
NCT000054936	NCT00005493_6_T0	PHENOTYPE	24	24	strokes
NCT000054936	NCT00005493_6_T1	GENE	27	27	3.5
NCT000054936	NCT00005493_6_T2	GENE	11	11	had
NCT000054936	NCT00005493_6_T3	GENE	25	25	had
NCT000054937	NCT00005493_7_T0	COMPOUND	8	8	aspirin
NCT000054937	NCT00005493_7_T1	COMPOUND	22	22	aspirin
NCT000054937	NCT00005493_7_T2	COMPOUND	34	34	aspirin
NCT000054938	NCT00005493_8_T0	COMPOUND	7	7	aspirin
NCT000054938	NCT00005493_8_T1	COMPOUND	12	12	aspirin
NCT000054939	NCT00005493_9_T0	COMPOUND	9	9	aspirin
NCT0000549310	NCT00005493_10_T0	COMPOUND	13	13	aspirin
NCT000054942	NCT00005494_2_T0	GENE	12	12	had
NCT000054945	NCT00005494_5_T0	PHENOTYPE	39	39	injuries
NCT000054945	NCT00005494_5_T1	PHENOTYPE	15	15	cancers
NCT000054945	NCT00005494_5_T2	PHENOTYPE	35	37	coronary heart disease
NCT000054947	NCT00005494_7_T0	PHENOTYPE	1	1	injuries
NCT000054948	NCT00005494_8_T0	PHENOTYPE	24	24	cancers
NCT000054948	NCT00005494_8_T1	GENE	20	20	CHD
NCT000054948	NCT00005494_8_T2	PHENOTYPE	28	29	breast cancer
NCT0000549411	NCT00005494_11_T0	PHENOTYPE	33	33	adiposity
NCT0000549411	NCT00005494_11_T1	GENE	15	15	CHD
NCT0000549411	NCT00005494_11_T2	PHENOTYPE	9	10	dose-response relationship
NCT000054952	NCT00005495_2_T0	PHENOTYPE	21	21	secondary
NCT000054953	NCT00005495_3_T0	PHENOTYPE	1	1	secondary
NCT000054953	NCT00005495_3_T1	PHENOTYPE	11	12	cholesterol levels
NCT000054953	NCT00005495_3_T2	PHENOTYPE	7	9	high blood pressure
NCT000054956	NCT00005495_6_T0	PHENOTYPE	32	33	cholesterol levels
NCT000054956	NCT00005495_6_T1	PHENOTYPE	28	30	lower blood pressure
NCT000054957	NCT00005495_7_T0	PHENOTYPE	18	18	strategies
NCT000054963	NCT00005496_3_T0	GENE	18	18	TNF-alpha
NCT000054963	NCT00005496_3_T1	GENE	20	20	ICAM
NCT000054963	NCT00005496_3_T2	PHENOTYPE	34	34	pneumoniae
NCT000054963	NCT00005496_3_T3	GENE	4	4	nested
NCT000054963	NCT00005496_3_T4	GENE	17	17	interleukin-6
NCT000054963	NCT00005496_3_T5	GENE	22	22	VCAM
NCT000054963	NCT00005496_3_T6	PHENOTYPE	16	16	inflammation
NCT000054963	NCT00005496_3_T7	ORGAN	8	8	plasma
NCT000054963	NCT00005496_3_T8	PHENOTYPE	37	38	Herpes simplex
NCT000054963	NCT00005496_3_T9	PHENOTYPE	29	30	antibody titers
NCT000054963	NCT00005496_3_T10	PHENOTYPE	35	36	Helicobacter pylori
NCT000054963	NCT00005496_3_T11	PHENOTYPE	27	28	chronic infection
NCT000054964	NCT00005496_4_T0	PHENOTYPE	12	12	CVA
NCT000054968	NCT00005496_8_T0	PHENOTYPE	14	14	inflammation
NCT000054968	NCT00005496_8_T1	GENE	4	4	has
NCT000054968	NCT00005496_8_T2	PHENOTYPE	21	22	myocardial infarction
NCT000054968	NCT00005496_8_T3	GENE	15	16	C-reactive protein
NCT000054973	NCT00005497_3_T0	COMPOUND	30	30	ibuprofen
NCT000054973	NCT00005497_3_T1	COMPOUND	28	28	aspirin
NCT000054974	NCT00005497_4_T0	PHENOTYPE	2	2	exposures
NCT000054974	NCT00005497_4_T1	GENE	23	23	3-2
NCT000054974	NCT00005497_4_T2	COMPOUND	7	7	ibuprofen
NCT000054975	NCT00005497_5_T0	GENE	5	5	had
NCT000054977	NCT00005497_7_T0	PHENOTYPE	14	14	malformations
NCT000054977	NCT00005497_7_T1	PHENOTYPE	17	17	PPHN
NCT000054977	NCT00005497_7_T2	GENE	13	13	had
NCT000054977	NCT00005497_7_T3	GENE	20	20	had
NCT0000549710	NCT00005497_10_T0	PHENOTYPE	18	18	PPHN
NCT000054980	NCT00005498_0_T0	GENE	9	9	ty
NCT000054980	NCT00005498_0_T1	PHENOTYPE	1	1	Hostility
NCT000054985	NCT00005498_5_T0	PHENOTYPE	19	19	hostility
NCT000054985	NCT00005498_5_T1	PHENOTYPE	15	15	feelings
NCT000054988	NCT00005498_8_T0	PHENOTYPE	24	24	Intensity
NCT000054988	NCT00005498_8_T1	PHENOTYPE	25	25	Content
NCT000054988	NCT00005498_8_T2	PHENOTYPE	18	18	Hostility
NCT000054988	NCT00005498_8_T3	PHENOTYPE	22	22	hostility
NCT000054988	NCT00005498_8_T4	PHENOTYPE	34	34	hostility
NCT000054989	NCT00005498_9_T0	PHENOTYPE	22	22	CVD
NCT000054989	NCT00005498_9_T1	PHENOTYPE	3	3	regression
NCT000054989	NCT00005498_9_T2	PHENOTYPE	12	12	hostility
NCT000054992	NCT00005499_2_T0	PHENOTYPE	32	32	CHF
NCT000054992	NCT00005499_2_T1	PHENOTYPE	29	31	congestive heart failure
NCT000054994	NCT00005499_4_T0	PHENOTYPE	9	9	CHF
NCT000054994	NCT00005499_4_T1	PHENOTYPE	23	23	CHF
NCT000054994	NCT00005499_4_T2	PHENOTYPE	46	46	CHF
NCT000054994	NCT00005499_4_T3	PHENOTYPE	71	71	CHF
NCT000054994	NCT00005499_4_T4	GENE	10	10	had
NCT000054994	NCT00005499_4_T5	GENE	24	24	had
NCT000054994	NCT00005499_4_T6	GENE	40	40	had
NCT000054994	NCT00005499_4_T7	GENE	52	52	had
NCT000054994	NCT00005499_4_T8	PHENOTYPE	51	51	hypertension
NCT000054994	NCT00005499_4_T9	PHENOTYPE	57	58	myocardial infarction
NCT000054994	NCT00005499_4_T10	PHENOTYPE	63	65	coronary artery disease
NCT000055002	NCT00005500_2_T0	PHENOTYPE	5	5	asthma
NCT000055003	NCT00005500_3_T0	PHENOTYPE	12	12	asthma
NCT000055006	NCT00005500_6_T0	GENE	3	3	CSGA
NCT000055006	NCT00005500_6_T1	PHENOTYPE	8	8	centers
NCT000055007	NCT00005500_7_T0	PHENOTYPE	10	10	asthma
NCT000055008	NCT00005500_8_T0	COMPOUND	10	10	methacholine
NCT000055009	NCT00005500_9_T0	GENE	10	10	sib
NCT000055013	NCT00005501_3_T0	GENE	9	9	has
NCT000055016	NCT00005501_6_T0	GENE	13	13	has
NCT000055018	NCT00005501_8_T0	ORGAN	33	33	Heart
NCT000055018	NCT00005501_8_T1	PHENOTYPE	48	48	Hypertension
NCT000055018	NCT00005501_8_T2	GENE	38	38	II
NCT000055018	NCT00005501_8_T3	GENE	40	40	III
NCT000055019	NCT00005501_9_T0	PHENOTYPE	37	39	coronary heart disease
NCT000055021	NCT00005502_1_T0	GENE	10	10	CHD
NCT000055023	NCT00005502_3_T0	GENE	9	9	CHD
NCT000055023	NCT00005502_3_T1	GENE	12	12	CHD
NCT000055023	NCT00005502_3_T2	PHENOTYPE	6	8	coronary heart disease
NCT000055025	NCT00005502_5_T0	PHENOTYPE	16	17	coronary disease
NCT000055027	NCT00005502_7_T0	PHENOTYPE	11	11	reperfusion
NCT000055027	NCT00005502_7_T1	PHENOTYPE	27	28	heart failure
NCT000055027	NCT00005502_7_T2	PHENOTYPE	6	7	myocardial infarction
NCT000055029	NCT00005502_9_T0	GENE	26	26	has
NCT000055029	NCT00005502_9_T1	GENE	9	9	CHD
NCT000055029	NCT00005502_9_T2	PHENOTYPE	22	23	coronary disease
NCT0000550210	NCT00005502_10_T0	PHENOTYPE	17	17	acute
NCT0000550210	NCT00005502_10_T1	PHENOTYPE	36	36	acute
NCT0000550210	NCT00005502_10_T2	GENE	12	12	CHD
NCT0000550210	NCT00005502_10_T3	GENE	37	37	CHD
NCT0000550211	NCT00005502_11_T0	PHENOTYPE	44	44	severity
NCT0000550211	NCT00005502_11_T1	GENE	37	37	CRP
NCT0000550211	NCT00005502_11_T2	PHENOTYPE	11	11	acute
NCT0000550211	NCT00005502_11_T3	GENE	30	30	troponin
NCT0000550211	NCT00005502_11_T4	PHENOTYPE	12	14	coronary heart disease
NCT0000550212	NCT00005502_12_T0	GENE	27	27	troponin
NCT0000550212	NCT00005502_12_T1	PHENOTYPE	21	22	myocardial infarction
NCT0000550213	NCT00005502_13_T0	GENE	12	12	troponin
NCT0000550213	NCT00005502_13_T1	PHENOTYPE	32	33	myocardial infarction
NCT000055032	NCT00005503_2_T0	PHENOTYPE	13	13	pulse
NCT000055033	NCT00005503_3_T0	PHENOTYPE	21	21	maturation
NCT000055033	NCT00005503_3_T1	PHENOTYPE	3	4	clinical findings
NCT000055045	NCT00005504_5_T0	PHENOTYPE	18	18	associations
NCT000055045	NCT00005504_5_T1	COMPOUND	63	63	homocysteine
NCT000055045	NCT00005504_5_T2	GENE	51	51	thrombin
NCT000055045	NCT00005504_5_T3	GENE	1	1	nested
NCT000055045	NCT00005504_5_T4	PHENOTYPE	20	21	venous thromboembolism
NCT000055045	NCT00005504_5_T5	GENE	42	44	plasminogen activator inhibitor-1
NCT000055045	NCT00005504_5_T6	GENE	36	38	factor V Leiden
NCT000055046	NCT00005504_6_T0	PHENOTYPE	36	36	obesity
NCT000055046	NCT00005504_6_T1	GENE	32	32	hormone
NCT000055052	NCT00005505_2_T0	PHENOTYPE	6	6	CVD
NCT000055056	NCT00005505_6_T0	PHENOTYPE	6	6	CVD
NCT000055056	NCT00005505_6_T1	PHENOTYPE	0	0	Associations
NCT000055057	NCT00005505_7_T0	PHENOTYPE	18	18	CVD
NCT0000550512	NCT00005505_12_T0	PHENOTYPE	11	11	associations
NCT0000550512	NCT00005505_12_T1	PHENOTYPE	5	5	regression
NCT0000550513	NCT00005505_13_T0	GENE	18	18	nested
NCT0000550513	NCT00005505_13_T1	GENE	24	24	nested
NCT000055067	NCT00005506_7_T0	GENE	2	2	had
NCT000055068	NCT00005506_8_T0	GENE	2	2	had
NCT000055068	NCT00005506_8_T1	ORGAN	3	4	brachial artery
NCT0000550611	NCT00005506_11_T0	PHENOTYPE	7	7	dilation
NCT000055072	NCT00005507_2_T0	GENE	10	10	had
NCT000055072	NCT00005507_2_T1	PHENOTYPE	15	16	cardiovascular disease
NCT000055073	NCT00005507_3_T0	GENE	30	30	bypass
NCT000055073	NCT00005507_3_T1	GENE	28	28	CA
NCT000055073	NCT00005507_3_T2	PHENOTYPE	7	8	cardiovascular disease
NCT000055076	NCT00005507_6_T0	GENE	2	2	had
NCT000055078	NCT00005507_8_T0	ORGAN	20	20	Heart
NCT000055078	NCT00005507_8_T1	PHENOTYPE	21	21	Association
NCT000055082	NCT00005508_2_T0	GENE	14	14	CHD
NCT000055082	NCT00005508_2_T1	COMPOUND	9	9	thallium
NCT000055087	NCT00005508_7_T0	PHENOTYPE	14	14	acute
NCT000055087	NCT00005508_7_T1	PHENOTYPE	35	35	progression
NCT000055087	NCT00005508_7_T2	GENE	15	15	CHD
NCT000055087	NCT00005508_7_T3	GENE	38	38	CHD
NCT000055087	NCT00005508_7_T4	GENE	46	46	CHD
NCT000055087	NCT00005508_7_T5	GENE	52	52	CHD
NCT000055093	NCT00005509_3_T0	PHENOTYPE	6	6	CVD
NCT000055094	NCT00005509_4_T0	PHENOTYPE	25	25	CVD
NCT000055094	NCT00005509_4_T1	PHENOTYPE	27	27	practices
NCT000055094	NCT00005509_4_T2	PHENOTYPE	32	32	practices
NCT000055095	NCT00005509_5_T0	PHENOTYPE	18	18	CVD
NCT000055095	NCT00005509_5_T1	PHENOTYPE	24	24	practices
NCT000055096	NCT00005509_6_T0	PHENOTYPE	21	21	CVD
NCT000055096	NCT00005509_6_T1	PHENOTYPE	30	30	CVD
NCT000055096	NCT00005509_6_T2	PHENOTYPE	61	61	CVD
NCT000055096	NCT00005509_6_T3	GENE	14	14	had
NCT000055096	NCT00005509_6_T4	GENE	54	54	had
NCT000055096	NCT00005509_6_T5	PHENOTYPE	34	34	practices
NCT000055097	NCT00005509_7_T0	PHENOTYPE	14	14	CVD
NCT000055097	NCT00005509_7_T1	PHENOTYPE	16	16	practices
NCT000055099	NCT00005509_9_T0	PHENOTYPE	33	33	CVD
NCT000055099	NCT00005509_9_T1	ORGAN	29	29	heart
NCT000055100	NCT00005510_0_T0	ORGAN	1	1	Heart
NCT000055100	NCT00005510_0_T1	PHENOTYPE	4	4	Obesity
NCT000055104	NCT00005510_4_T0	ORGAN	13	13	Heart
NCT000055104	NCT00005510_4_T1	TISSUE	20	21	body fat
NCT000055105	NCT00005510_5_T0	COMPOUND	7	7	BMI
NCT000055110	NCT00005511_0_T0	GENE	5	5	Traits
NCT000055110	NCT00005511_0_T1	PHENOTYPE	7	8	Sleep Apnea
NCT000055113	NCT00005511_3_T0	PHENOTYPE	25	27	obstructive sleep apnea
NCT000055115	NCT00005511_5_T0	GENE	13	13	reduced
NCT000055115	NCT00005511_5_T1	PHENOTYPE	22	23	sleep apnea
NCT000055116	NCT00005511_6_T0	TISSUE	21	21	tissues
NCT000055116	NCT00005511_6_T1	ORGAN	25	26	soft palate
NCT000055117	NCT00005511_7_T0	GENE	21	21	had
NCT000055118	NCT00005511_8_T0	PHENOTYPE	16	17	Sleep Apnea
NCT000055119	NCT00005511_9_T0	GENE	7	7	structural
NCT000055119	NCT00005511_9_T1	PHENOTYPE	11	12	sleep apnea
NCT0000551111	NCT00005511_11_T0	GENE	5	5	structural
NCT0000551111	NCT00005511_11_T1	PHENOTYPE	15	16	sleep apnea
NCT0000551112	NCT00005511_12_T0	GENE	5	5	structural
NCT0000551112	NCT00005511_12_T1	PHENOTYPE	22	23	sleep apnea
NCT0000551113	NCT00005511_13_T0	TISSUE	12	12	tissues
NCT0000551113	NCT00005511_13_T1	GENE	51	51	structural
NCT0000551113	NCT00005511_13_T2	PHENOTYPE	55	56	sleep apnea
NCT0000551113	NCT00005511_13_T3	PHENOTYPE	32	34	obstructive sleep apnea
NCT0000551114	NCT00005511_14_T0	PHENOTYPE	29	29	obesity
NCT0000551114	NCT00005511_14_T1	GENE	9	9	NM
NCT000055122	NCT00005512_2_T0	PHENOTYPE	10	12	elevated blood pressure
NCT000055123	NCT00005512_3_T0	PHENOTYPE	12	12	hypertension
NCT000055123	NCT00005512_3_T1	PHENOTYPE	10	10	obesity
NCT000055124	NCT00005512_4_T0	PHENOTYPE	27	27	CVD
NCT000055124	NCT00005512_4_T1	PHENOTYPE	32	32	hypertension
NCT000055124	NCT00005512_4_T2	PHENOTYPE	31	31	obesity
NCT000055126	NCT00005512_6_T0	PHENOTYPE	14	14	hypertension
NCT000055126	NCT00005512_6_T1	PHENOTYPE	12	12	obesity
NCT000055127	NCT00005512_7_T0	PHENOTYPE	8	9	individual differences
NCT000055136	NCT00005513_6_T0	GENE	32	32	apoE
NCT000055136	NCT00005513_6_T1	PHENOTYPE	27	28	cardiovascular disease
NCT000055137	NCT00005513_7_T0	PHENOTYPE	14	15	cardiovascular disease
NCT000055146	NCT00005514_6_T0	PHENOTYPE	24	24	Hypertension
NCT000055148	NCT00005514_8_T0	PHENOTYPE	15	15	inflammation
NCT000055148	NCT00005514_8_T1	ORGAN	12	12	plasma
NCT000055148	NCT00005514_8_T2	PHENOTYPE	26	26	obesity
NCT000055149	NCT00005514_9_T0	GENE	47	47	ACE
NCT000055149	NCT00005514_9_T1	GENE	44	44	VCAM-1
NCT000055149	NCT00005514_9_T2	GENE	46	46	NOS3
NCT000055149	NCT00005514_9_T3	GENE	40	40	PON1
NCT000055149	NCT00005514_9_T4	GENE	42	42	TNF-a
NCT000055149	NCT00005514_9_T5	GENE	50	50	angiotensinogen
NCT000055149	NCT00005514_9_T6	PHENOTYPE	24	24	inflammation
NCT000055149	NCT00005514_9_T7	GENE	41	41	IL-6
NCT000055149	NCT00005514_9_T8	GENE	43	43	ICAM-1
NCT000055149	NCT00005514_9_T9	GENE	51	51	ANG
NCT000055149	NCT00005514_9_T10	GENE	36	36	PPARa
NCT000055149	NCT00005514_9_T11	PHENOTYPE	26	27	endothelial dysfunction
NCT000055149	NCT00005514_9_T12	PHENOTYPE	32	34	coronary heart disease
NCT000055152	NCT00005515_2_T0	PHENOTYPE	1	1	menopausal
NCT000055152	NCT00005515_2_T1	PHENOTYPE	26	28	Factor V Leiden
NCT000055153	NCT00005515_3_T0	PHENOTYPE	14	14	menopausal
NCT000055153	NCT00005515_3_T1	GENE	19	19	hormone
NCT000055154	NCT00005515_4_T0	PHENOTYPE	1	1	menopausal
NCT000055154	NCT00005515_4_T1	PHENOTYPE	16	16	menopausal
NCT000055155	NCT00005515_5_T0	PHENOTYPE	6	6	menopausal
NCT000055155	NCT00005515_5_T1	PHENOTYPE	15	16	venous thromboembolism
NCT000055158	NCT00005515_8_T0	GENE	11	11	hormone
NCT000055159	NCT00005515_9_T0	CELL	14	14	cells
NCT000055159	NCT00005515_9_T1	CELL	18	18	cells
NCT000055159	NCT00005515_9_T2	ORGAN	15	15	plasma
NCT0000551510	NCT00005515_10_T0	CELL	5	5	cells
NCT000055162	NCT00005516_2_T0	PHENOTYPE	21	21	susceptible
NCT000055165	NCT00005516_5_T0	PHENOTYPE	22	22	exposures
NCT000055166	NCT00005516_6_T0	BIOLOGICAL_PROCESS	0	0	Behavior
NCT000055166	NCT00005516_6_T1	PHENOTYPE	6	8	quality of life
NCT000055172	NCT00005517_2_T0	PHENOTYPE	6	6	CHF
NCT000055172	NCT00005517_2_T1	PHENOTYPE	12	12	acute
NCT000055174	NCT00005517_4_T0	PHENOTYPE	2	2	CHF
NCT000055174	NCT00005517_4_T1	PHENOTYPE	10	10	CHF
NCT000055174	NCT00005517_4_T2	PHENOTYPE	6	6	recurrent
NCT000055175	NCT00005517_5_T0	PHENOTYPE	4	4	CHF
NCT000055175	NCT00005517_5_T1	GENE	26	26	Paul
NCT000055176	NCT00005517_6_T0	PHENOTYPE	7	7	CHF
NCT000055177	NCT00005517_7_T0	PHENOTYPE	7	7	CHF
NCT000055177	NCT00005517_7_T1	GENE	17	17	600
NCT000055180	NCT00005518_0_T0	PHENOTYPE	4	5	Hemophilia A
NCT000055192	NCT00005519_2_T0	GENE	16	16	has
NCT000055192	NCT00005519_2_T1	GENE	13	13	CHD
NCT000055192	NCT00005519_2_T2	PHENOTYPE	10	12	coronary heart disease
NCT000055194	NCT00005519_4_T0	GENE	16	16	has
NCT000055194	NCT00005519_4_T1	GENE	13	13	CHD
NCT000055195	NCT00005519_5_T0	COMPOUND	70	70	potassium
NCT000055195	NCT00005519_5_T1	COMPOUND	68	68	sodium
NCT000055195	NCT00005519_5_T2	COMPOUND	86	87	vitamin E
NCT000055195	NCT00005519_5_T3	COMPOUND	89	90	folic acid
NCT000055195	NCT00005519_5_T4	PHENOTYPE	19	21	coronary heart disease
NCT000055195	NCT00005519_5_T5	PHENOTYPE	59	61	coronary heart disease
NCT000055195	NCT00005519_5_T6	PHENOTYPE	74	76	coronary heart disease
NCT000055195	NCT00005519_5_T7	PHENOTYPE	95	97	coronary heart disease
NCT000055195	NCT00005519_5_T8	PHENOTYPE	115	117	coronary heart disease
NCT000055196	NCT00005519_6_T0	COMPOUND	12	12	folate
NCT000055196	NCT00005519_6_T1	ORGAN	6	6	serum
NCT000055196	NCT00005519_6_T2	COMPOUND	7	8	vitamin A
NCT000055196	NCT00005519_6_T3	PHENOTYPE	17	19	coronary heart disease
NCT0000551913	NCT00005519_13_T0	GENE	15	15	CHD
NCT000055203	NCT00005520_3_T0	GENE	2	2	has
NCT000055203	NCT00005520_3_T1	BIOLOGICAL_PROCESS	18	20	response to diuretic
NCT000055205	NCT00005520_5_T0	BIOLOGICAL_PROCESS	16	16	vasoconstriction
NCT000055213	NCT00005521_3_T0	GENE	3	3	has
NCT000055214	NCT00005521_4_T0	GENE	4	4	has
NCT000055214	NCT00005521_4_T1	PHENOTYPE	18	18	hypertension
NCT0000552111	NCT00005521_11_T0	GENE	5	5	FY
NCT0000552111	NCT00005521_11_T1	GENE	27	27	BP
NCT000055222	NCT00005522_2_T0	GENE	6	6	has
NCT000055222	NCT00005522_2_T1	GENE	11	11	CHD
NCT000055223	NCT00005522_3_T0	PHENOTYPE	23	23	CVD
NCT000055223	NCT00005522_3_T1	PHENOTYPE	21	22	cardiovascular disease
NCT0000552210	NCT00005522_10_T0	PHENOTYPE	3	3	secondary
NCT0000552210	NCT00005522_10_T1	PHENOTYPE	12	12	associations
NCT0000552211	NCT00005522_11_T0	PHENOTYPE	23	23	associations
NCT000055232	NCT00005523_2_T0	PHENOTYPE	23	23	asthma
NCT000055233	NCT00005523_3_T0	GENE	20	20	reduced
NCT000055233	NCT00005523_3_T1	PHENOTYPE	11	11	aids
NCT000055235	NCT00005523_5_T0	GENE	8	8	allergen
NCT000055236	NCT00005523_6_T0	GENE	13	13	allergen
NCT000055236	NCT00005523_6_T1	PHENOTYPE	5	5	asthma
NCT000055236	NCT00005523_6_T2	PHENOTYPE	6	8	quality of life
NCT000055237	NCT00005523_7_T0	PHENOTYPE	0	0	Secondary
NCT000055237	NCT00005523_7_T1	PHENOTYPE	4	4	self-efficacy
NCT000055237	NCT00005523_7_T2	PHENOTYPE	6	7	environmental allergy
NCT000055244	NCT00005524_4_T0	GENE	4	4	has
NCT000055248	NCT00005524_8_T0	PHENOTYPE	22	23	arterial stiffness
NCT000055252	NCT00005525_2_T0	PHENOTYPE	11	11	obesity
NCT000055252	NCT00005525_2_T1	PHENOTYPE	7	8	sleep apnea
NCT000055254	NCT00005525_4_T0	GENE	14	14	II
NCT000055254	NCT00005525_4_T1	PHENOTYPE	29	29	symptoms
NCT000055254	NCT00005525_4_T2	PHENOTYPE	42	42	symptoms
NCT000055254	NCT00005525_4_T3	GENE	39	39	twins
NCT000055254	NCT00005525_4_T4	PHENOTYPE	27	28	sleep apnea
NCT000055258	NCT00005525_8_T0	GENE	21	21	had
NCT000055282	NCT00005528_2_T0	GENE	13	13	HDL
NCT000055282	NCT00005528_2_T1	GENE	12	12	lipoprotein
NCT000055282	NCT00005528_2_T2	PHENOTYPE	20	20	obesity
NCT000055283	NCT00005528_3_T0	GENE	9	9	lipoprotein
NCT000055283	NCT00005528_3_T1	ORGAN	6	6	serum
NCT000055286	NCT00005528_6_T0	GENE	10	10	lipoprotein
NCT000055289	NCT00005528_9_T0	PHENOTYPE	1	1	adiposity
NCT000055289	NCT00005528_9_T1	GENE	6	6	insulin
NCT000055292	NCT00005529_2_T0	PHENOTYPE	15	17	coronary heart disease
NCT000055293	NCT00005529_3_T0	GENE	10	10	CHD
NCT000055296	NCT00005529_6_T0	ORGAN	26	26	Heart
NCT000055296	NCT00005529_6_T1	PHENOTYPE	8	8	CVD
NCT000055296	NCT00005529_6_T2	PHENOTYPE	6	7	cardiovascular disease
NCT000055297	NCT00005529_7_T0	GENE	4	4	II
NCT000055298	NCT00005529_8_T0	GENE	2	2	II
NCT000055298	NCT00005529_8_T1	PHENOTYPE	31	31	CVD
NCT000055298	NCT00005529_8_T2	PHENOTYPE	28	28	perceptions
NCT0000552910	NCT00005529_10_T0	PHENOTYPE	21	22	cardiovascular disease
NCT0000552912	NCT00005529_12_T0	PHENOTYPE	10	10	centers
NCT000055302	NCT00005530_2_T0	PHENOTYPE	14	14	NIDDM
NCT000055305	NCT00005530_5_T0	PHENOTYPE	6	6	hyperinsulinemia
NCT000055305	NCT00005530_5_T1	PHENOTYPE	9	10	insulin resistance
NCT0000553010	NCT00005530_10_T0	PHENOTYPE	28	28	CVD
NCT0000553011	NCT00005530_11_T0	GENE	27	27	IRAS
NCT000055310	NCT00005531_0_T0	PHENOTYPE	3	3	Sarcoidosis
NCT000055313	NCT00005531_3_T0	PHENOTYPE	3	3	sarcoidosis
NCT000055314	NCT00005531_4_T0	PHENOTYPE	30	30	sarcoidosis
NCT000055315	NCT00005531_5_T0	PHENOTYPE	3	3	sarcoidosis
NCT000055316	NCT00005531_6_T0	PHENOTYPE	16	16	sarcoidosis
NCT000055317	NCT00005531_7_T0	PHENOTYPE	6	6	sarcoidosis
NCT000055317	NCT00005531_7_T1	PHENOTYPE	28	30	of disease transmission
NCT000055318	NCT00005531_8_T0	PHENOTYPE	12	12	sarcoidosis
NCT000055319	NCT00005531_9_T0	PHENOTYPE	16	16	severity
NCT000055319	NCT00005531_9_T1	PHENOTYPE	5	5	sarcoidosis
NCT0000553110	NCT00005531_10_T0	PHENOTYPE	7	7	sarcoidosis
NCT0000553110	NCT00005531_10_T1	PHENOTYPE	18	18	understood
NCT000055320	NCT00005532_0_T0	ORGAN	2	2	Plasma
NCT000055320	NCT00005532_0_T1	GENE	1	1	Fat
NCT000055320	NCT00005532_0_T2	GENE	6	6	CHD
NCT000055323	NCT00005532_3_T0	GENE	26	26	lipoprotein
NCT000055323	NCT00005532_3_T1	GENE	15	15	LDL
NCT000055323	NCT00005532_3_T2	PHENOTYPE	16	17	cholesterol levels
NCT000055325	NCT00005532_5_T0	ORGAN	15	15	plasma
NCT000055327	NCT00005532_7_T0	PHENOTYPE	15	15	concentrations
NCT000055327	NCT00005532_7_T1	PHENOTYPE	21	21	fed
NCT000055327	NCT00005532_7_T2	GENE	13	13	LDL
NCT0000553210	NCT00005532_10_T0	GENE	12	12	reduced
NCT0000553212	NCT00005532_12_T0	GENE	5	5	FY
NCT0000553212	NCT00005532_12_T1	PHENOTYPE	20	20	intent
NCT0000553212	NCT00005532_12_T2	PHENOTYPE	27	28	cardiovascular disease
NCT0000553214	NCT00005532_14_T0	GENE	11	11	LDL
NCT0000553219	NCT00005532_19_T0	COMPOUND	12	12	sterol
NCT0000553219	NCT00005532_19_T1	GENE	43	43	PUFA
NCT0000553219	NCT00005532_19_T2	GENE	40	40	MUFA
NCT0000553219	NCT00005532_19_T3	GENE	37	37	SFA
NCT0000553220	NCT00005532_20_T0	COMPOUND	18	18	sterol
NCT000055333	NCT00005533_3_T0	PHENOTYPE	12	12	hostility
NCT000055334	NCT00005533_4_T0	GENE	17	17	had
NCT000055334	NCT00005533_4_T1	PHENOTYPE	12	14	coronary artery disease
NCT000055335	NCT00005533_5_T0	PHENOTYPE	23	23	severity
NCT000055335	NCT00005533_5_T1	PHENOTYPE	6	6	hostility
NCT000055338	NCT00005533_8_T0	GENE	29	29	had
NCT000055338	NCT00005533_8_T1	PHENOTYPE	8	8	hostility
NCT000055338	NCT00005533_8_T2	PHENOTYPE	17	17	AMI
NCT000055338	NCT00005533_8_T3	PHENOTYPE	6	7	depressive personality
NCT000055338	NCT00005533_8_T4	PHENOTYPE	14	16	acute myocardial infarction
NCT000055339	NCT00005533_9_T0	PHENOTYPE	4	4	associations
NCT0000553310	NCT00005533_10_T0	PHENOTYPE	18	18	hostility
NCT0000553310	NCT00005533_10_T1	PHENOTYPE	19	20	depressive personality
NCT0000553312	NCT00005533_12_T0	GENE	5	5	FY
NCT0000553313	NCT00005533_13_T0	GENE	2	2	has
NCT0000553313	NCT00005533_13_T1	GENE	4	4	extended
NCT0000553319	NCT00005533_19_T0	PHENOTYPE	24	25	job strain
NCT0000553320	NCT00005533_20_T0	PHENOTYPE	4	5	depressive symptoms
NCT0000553321	NCT00005533_21_T0	PHENOTYPE	5	5	strategies
NCT0000553322	NCT00005533_22_T0	PHENOTYPE	24	25	job strain
NCT0000553324	NCT00005533_24_T0	BIOLOGICAL_PROCESS	17	17	drinking
NCT0000553324	NCT00005533_24_T1	PHENOTYPE	16	16	binge
NCT0000553324	NCT00005533_24_T2	PHENOTYPE	8	8	hostility
NCT0000553324	NCT00005533_24_T3	PHENOTYPE	20	21	behavior problems
NCT0000553325	NCT00005533_25_T0	PHENOTYPE	7	7	associations
NCT0000553325	NCT00005533_25_T1	PHENOTYPE	9	9	hostility
NCT0000553327	NCT00005533_27_T0	PHENOTYPE	21	22	cardiac events
NCT0000553327	NCT00005533_27_T1	PHENOTYPE	12	13	depressive symptom
NCT0000553329	NCT00005533_29_T0	PHENOTYPE	7	8	cardiac events
NCT000055340	NCT00005534_0_T0	PHENOTYPE	3	4	Ventricular Dysfunction
NCT000055343	NCT00005534_3_T0	PHENOTYPE	0	0	CHF
NCT000055343	NCT00005534_3_T1	PHENOTYPE	6	7	cardiovascular disease
NCT000055345	NCT00005534_5_T0	GENE	15	15	ventricular
NCT000055346	NCT00005534_6_T0	GENE	3	3	ventricular
NCT000055349	NCT00005534_9_T0	ORGAN	1	1	plasma
NCT0000553410	NCT00005534_10_T0	ORGAN	28	28	Heart
NCT0000553410	NCT00005534_10_T1	GENE	11	11	ventricular
NCT0000553411	NCT00005534_11_T0	PHENOTYPE	17	18	cardiovascular disease
NCT0000553412	NCT00005534_12_T0	PHENOTYPE	15	15	symptoms
NCT0000553412	NCT00005534_12_T1	GENE	5	5	ventricular
NCT0000553413	NCT00005534_13_T0	ORGAN	0	0	Plasma
NCT0000553415	NCT00005534_15_T0	ORGAN	6	6	plasma
NCT0000553417	NCT00005534_17_T0	PHENOTYPE	29	29	progressive
NCT0000553417	NCT00005534_17_T1	ORGAN	22	22	plasma
NCT0000553417	NCT00005534_17_T2	GENE	10	10	ventricular
NCT0000553417	NCT00005534_17_T3	GENE	15	15	ventricular
NCT0000553417	NCT00005534_17_T4	GENE	33	33	ventricular
NCT0000553417	NCT00005534_17_T5	GENE	41	41	ventricular
NCT0000553417	NCT00005534_17_T6	GENE	23	25	brain natriuretic peptide
NCT0000553417	NCT00005534_17_T7	GENE	44	46	brain natriuretic peptide
NCT000055352	NCT00005535_2_T0	GENE	34	34	twins
NCT000055352	NCT00005535_2_T1	PHENOTYPE	10	10	localize
NCT000055352	NCT00005535_2_T2	PHENOTYPE	37	38	phenotypic variability
NCT000055354	NCT00005535_4_T0	GENE	7	7	twins
NCT000055354	NCT00005535_4_T1	GENE	8	8	had
NCT000055354	NCT00005535_4_T2	GENE	25	25	had
NCT000055354	NCT00005535_4_T3	GENE	30	30	had
NCT000055362	NCT00005536_2_T0	PHENOTYPE	19	21	end-stage renal disease
NCT000055363	NCT00005536_3_T0	GENE	16	16	had
NCT000055363	NCT00005536_3_T1	GENE	11	11	Dr
NCT000055363	NCT00005536_3_T2	PHENOTYPE	24	26	end-stage renal disease
NCT000055363	NCT00005536_3_T3	PHENOTYPE	32	34	End-Stage Renal Disease
NCT000055364	NCT00005536_4_T0	PHENOTYPE	12	14	end-stage renal disease
NCT000055366	NCT00005536_6_T0	GENE	31	31	SSLP
NCT000055366	NCT00005536_6_T1	PHENOTYPE	14	16	end-stage renal disease
NCT000055373	NCT00005537_3_T0	PHENOTYPE	25	25	asthma
NCT000055373	NCT00005537_3_T1	GENE	36	36	sib
NCT000055378	NCT00005537_8_T0	GENE	18	18	sib
NCT000055379	NCT00005537_9_T0	GENE	14	14	sib
NCT0000553710	NCT00005537_10_T0	PHENOTYPE	6	6	Asthma
NCT0000553712	NCT00005537_12_T0	GENE	19	19	IgE
NCT0000553712	NCT00005537_12_T1	GENE	9	9	reduced
NCT0000553712	NCT00005537_12_T2	ORGAN	18	18	serum
NCT0000553712	NCT00005537_12_T3	PHENOTYPE	27	28	respiratory symptoms
NCT0000553712	NCT00005537_12_T4	PHENOTYPE	24	26	peripheral blood eosinophilia
NCT000055386	NCT00005538_6_T0	COMPOUND	11	11	estrogen
NCT000055387	NCT00005538_7_T0	COMPOUND	10	10	estrogen
NCT0000553810	NCT00005538_10_T0	GENE	18	18	CHD
NCT0000553810	NCT00005538_10_T1	PHENOTYPE	14	15	psychological stress
NCT000055396	NCT00005539_6_T0	GENE	12	12	10
NCT000055398	NCT00005539_8_T0	PHENOTYPE	12	12	generalized
NCT000055398	NCT00005539_8_T1	PHENOTYPE	10	10	focal
NCT000055398	NCT00005539_8_T2	PHENOTYPE	13	15	retinal arteriolar narrowing
NCT0000553910	NCT00005539_10_T0	GENE	14	14	fibrinogen
NCT0000553910	NCT00005539_10_T1	ORGAN	20	21	lower extremity
NCT0000553912	NCT00005539_12_T0	GENE	7	7	van
NCT0000553914	NCT00005539_14_T0	COMPOUND	22	22	creatinine
NCT0000553914	NCT00005539_14_T1	GENE	24	24	fibrinogen
NCT0000553914	NCT00005539_14_T2	ORGAN	12	12	serum
NCT0000553914	NCT00005539_14_T3	ORGAN	21	21	serum
NCT0000553914	NCT00005539_14_T4	GENE	8	8	hemoglobin
NCT0000553918	NCT00005539_18_T0	PHENOTYPE	18	19	cardiovascular disease
NCT000055406	NCT00005540_6_T0	GENE	49	49	CHD
NCT000055406	NCT00005540_6_T1	GENE	63	63	CHD
NCT000055406	NCT00005540_6_T2	GENE	84	84	CHD
NCT000055406	NCT00005540_6_T3	GENE	97	97	CHD
NCT000055406	NCT00005540_6_T4	PHENOTYPE	115	115	obesity
NCT000055406	NCT00005540_6_T5	PHENOTYPE	109	110	cholesterol levels
NCT000055411	NCT00005541_1_T0	PHENOTYPE	18	19	Blood Diseases
NCT000055416	NCT00005541_6_T0	PHENOTYPE	4	4	learned
NCT0000554122	NCT00005541_22_T0	PHENOTYPE	7	8	iron overload
NCT0000554124	NCT00005541_24_T0	PHENOTYPE	0	0	Hemochromatosis
NCT0000554124	NCT00005541_24_T1	PHENOTYPE	14	14	strategies
NCT0000554131	NCT00005541_31_T0	GENE	9	9	transferrin
NCT0000554131	NCT00005541_31_T1	PHENOTYPE	14	14	resolved
NCT0000554133	NCT00005541_33_T0	PHENOTYPE	17	17	Centers
NCT0000554133	NCT00005541_33_T1	GENE	21	21	transferrin
NCT0000554134	NCT00005541_34_T0	PHENOTYPE	4	4	recruitment
NCT0000554134	NCT00005541_34_T1	PHENOTYPE	2	2	strategies
NCT0000554135	NCT00005541_35_T0	GENE	11	11	ferritin
NCT0000554135	NCT00005541_35_T1	GENE	3	3	transferrin
NCT0000554135	NCT00005541_35_T2	ORGAN	10	10	serum
NCT0000554135	NCT00005541_35_T3	PHENOTYPE	22	24	elevated transferrin saturation
NCT0000554135	NCT00005541_35_T4	PHENOTYPE	33	35	elevated transferrin saturation
NCT0000554139	NCT00005541_39_T0	GENE	26	26	ferritin
NCT0000554139	NCT00005541_39_T1	GENE	24	24	transferrin
NCT0000554141	NCT00005541_41_T0	PHENOTYPE	4	6	elevated transferrin saturation
NCT0000554142	NCT00005541_42_T0	PHENOTYPE	22	22	attitudes
NCT0000554150	NCT00005541_50_T0	GENE	6	6	extended
NCT0000554153	NCT00005541_53_T0	PHENOTYPE	20	20	experiences
NCT0000554157	NCT00005541_57_T0	PHENOTYPE	9	9	experiences
NCT0000554157	NCT00005541_57_T1	PHENOTYPE	26	26	experiences
NCT0000554158	NCT00005541_58_T0	PHENOTYPE	19	20	iron overload
NCT0000554161	NCT00005541_61_T0	PHENOTYPE	5	5	Centers
NCT0000554161	NCT00005541_61_T1	PHENOTYPE	16	16	Centers
NCT0000554161	NCT00005541_61_T2	PHENOTYPE	22	22	Center
NCT0000554161	NCT00005541_61_T3	GENE	2	2	has
NCT000055422	NCT00005542_2_T0	PHENOTYPE	3	3	sarcoidosis
NCT000055423	NCT00005542_3_T0	PHENOTYPE	0	0	Sarcoidosis
NCT000055424	NCT00005542_4_T0	PHENOTYPE	19	19	sarcoidosis
NCT000055426	NCT00005542_6_T0	PHENOTYPE	18	18	sarcoidosis
NCT000055429	NCT00005542_9_T0	PHENOTYPE	23	23	Center
NCT000055434	NCT00005543_4_T0	PHENOTYPE	18	18	impairment
NCT000055437	NCT00005543_7_T0	GENE	4	4	had
NCT000055440	NCT00005544_0_T0	PHENOTYPE	4	6	Adult Onset Asthma
NCT000055443	NCT00005544_3_T0	PHENOTYPE	7	7	adult-onset
NCT000055443	NCT00005544_3_T1	PHENOTYPE	8	8	asthma
NCT000055443	NCT00005544_3_T2	PHENOTYPE	4	5	occupational exposures
NCT000055444	NCT00005544_4_T0	PHENOTYPE	17	17	adult-onset
NCT000055444	NCT00005544_4_T1	PHENOTYPE	18	18	asthma
NCT000055445	NCT00005544_5_T0	PHENOTYPE	22	22	exposures
NCT000055445	NCT00005544_5_T1	PHENOTYPE	16	16	adult-onset
NCT000055445	NCT00005544_5_T2	PHENOTYPE	5	5	asthma
NCT000055445	NCT00005544_5_T3	PHENOTYPE	17	17	asthma
NCT000055446	NCT00005544_6_T0	PHENOTYPE	18	18	exposures
NCT000055446	NCT00005544_6_T1	PHENOTYPE	26	26	asthma
NCT000055447	NCT00005544_7_T0	PHENOTYPE	11	11	asthma
NCT000055448	NCT00005544_8_T0	PHENOTYPE	17	17	adult-onset
NCT000055448	NCT00005544_8_T1	PHENOTYPE	18	18	asthma
NCT000055448	NCT00005544_8_T2	PHENOTYPE	25	25	asthma
NCT0000554410	NCT00005544_10_T0	PHENOTYPE	21	21	asthma
NCT0000554411	NCT00005544_11_T0	PHENOTYPE	59	59	adult-onset
NCT0000554411	NCT00005544_11_T1	PHENOTYPE	83	83	adult-onset
NCT0000554411	NCT00005544_11_T2	PHENOTYPE	42	42	asthma
NCT0000554411	NCT00005544_11_T3	PHENOTYPE	60	60	asthma
NCT0000554411	NCT00005544_11_T4	PHENOTYPE	84	84	asthma
NCT0000554411	NCT00005544_11_T5	PHENOTYPE	105	105	asthma
NCT0000554411	NCT00005544_11_T6	GENE	33	33	nested
NCT0000554411	NCT00005544_11_T7	PHENOTYPE	123	123	secondary
NCT0000554411	NCT00005544_11_T8	PHENOTYPE	72	72	asthmatics
NCT0000554411	NCT00005544_11_T9	GENE	22	22	met
NCT0000554411	NCT00005544_11_T10	PHENOTYPE	27	28	occupational asthma
NCT0000554411	NCT00005544_11_T11	PHENOTYPE	86	87	lung function
NCT0000554411	NCT00005544_11_T12	PHENOTYPE	91	93	quality of life
NCT000055464	NCT00005546_4_T0	PHENOTYPE	21	21	recurrence
NCT000055464	NCT00005546_4_T1	PHENOTYPE	23	24	heart disease
NCT000055469	NCT00005546_9_T0	GENE	20	20	CHD
NCT000055471	NCT00005547_1_T0	PHENOTYPE	16	16	secondary
NCT000055471	NCT00005547_1_T1	PHENOTYPE	11	11	pneumoniae
NCT000055471	NCT00005547_1_T2	PHENOTYPE	19	20	Helicobacter pylori
NCT000055473	NCT00005547_3_T0	PHENOTYPE	10	10	atherosclerosis
NCT000055474	NCT00005547_4_T0	PHENOTYPE	3	3	inflammation
NCT000055474	NCT00005547_4_T1	BIOLOGICAL_PROCESS	5	5	hemostasis
NCT000055474	NCT00005547_4_T2	PHENOTYPE	13	14	myocardial infarction
NCT000055479	NCT00005547_9_T0	GENE	20	20	CRP
NCT000055479	NCT00005547_9_T1	PHENOTYPE	8	8	pneumoniae
NCT000055479	NCT00005547_9_T2	GENE	9	9	IgG
NCT000055479	NCT00005547_9_T3	GENE	14	14	IgG
NCT000055479	NCT00005547_9_T4	ORGAN	2	2	serum
NCT000055479	NCT00005547_9_T5	GENE	10	10	IgM
NCT000055479	NCT00005547_9_T6	GENE	18	19	C-reactive protein
NCT0000554710	NCT00005547_10_T0	PHENOTYPE	18	18	HSV
NCT0000554710	NCT00005547_10_T1	PHENOTYPE	13	13	HAV
NCT0000554710	NCT00005547_10_T2	PHENOTYPE	10	11	hepatitis A
NCT0000554710	NCT00005547_10_T3	PHENOTYPE	8	9	Helicobacter pylori
NCT0000554710	NCT00005547_10_T4	PHENOTYPE	15	16	herpes simplex
NCT0000554713	NCT00005547_13_T0	GENE	14	14	CRP
NCT0000554713	NCT00005547_13_T1	GENE	15	15	fibrinogen
NCT0000554713	NCT00005547_13_T2	PHENOTYPE	12	12	inflammation
NCT0000554713	NCT00005547_13_T3	GENE	19	19	inhibitor-1
NCT0000554713	NCT00005547_13_T4	BIOLOGICAL_PROCESS	10	10	hemostasis
NCT000055482	NCT00005548_2_T0	PHENOTYPE	15	15	interests
NCT000055482	NCT00005548_2_T1	GENE	9	9	CHD
NCT000055483	NCT00005548_3_T0	GENE	17	17	CHD
NCT0000554810	NCT00005548_10_T0	GENE	29	29	CHD
NCT0000554811	NCT00005548_11_T0	ORGAN	7	7	Heart
NCT0000554811	NCT00005548_11_T1	COMPOUND	39	39	glucose
NCT0000554811	NCT00005548_11_T2	GENE	25	25	CHD
NCT000055490	NCT00005549_0_T0	COMPOUND	0	0	Isocyanate
NCT000055490	NCT00005549_0_T1	PHENOTYPE	7	7	Asthma
NCT000055490	NCT00005549_0_T2	CELL	3	4	T Cells
NCT000055493	NCT00005549_3_T0	PHENOTYPE	7	7	asthma
NCT000055494	NCT00005549_4_T0	COMPOUND	5	5	isocyanate
NCT000055494	NCT00005549_4_T1	CELL	7	7	T-cell
NCT000055495	NCT00005549_5_T0	COMPOUND	3	3	isocyanate
NCT000055495	NCT00005549_5_T1	COMPOUND	26	26	isocyanate
NCT000055495	NCT00005549_5_T2	BIOLOGICAL_PROCESS	20	20	sensitization
NCT000055495	NCT00005549_5_T3	CELL	5	5	T-cells
NCT000055497	NCT00005549_7_T0	GENE	5	5	FY
NCT000055501	NCT00005550_1_T0	GENE	5	5	allergen
NCT000055503	NCT00005550_3_T0	PHENOTYPE	0	0	Asthma
NCT000055504	NCT00005550_4_T0	PHENOTYPE	5	5	inflammation
NCT000055504	NCT00005550_4_T1	PHENOTYPE	0	0	Asthma
NCT000055506	NCT00005550_6_T0	PHENOTYPE	8	8	asthmatics
NCT000055506	NCT00005550_6_T1	CELL	6	6	cells
NCT000055506	NCT00005550_6_T2	GENE	18	18	IL-1
NCT000055506	NCT00005550_6_T3	GENE	25	25	GM-CSF
NCT000055506	NCT00005550_6_T4	GENE	19	19	IL-8
NCT000055506	NCT00005550_6_T5	CELL	2	3	alveolar macrophages
NCT000055506	NCT00005550_6_T6	GENE	21	24	granulocyte macrophage-colony stimulating factor
NCT0000555010	NCT00005550_10_T0	GENE	10	10	ECP
NCT0000555010	NCT00005550_10_T1	PHENOTYPE	16	16	inflammation
NCT0000555010	NCT00005550_10_T2	GENE	8	8	IL-8
NCT000055513	NCT00005551_3_T0	PHENOTYPE	11	11	hypopneas
NCT000055513	NCT00005551_3_T1	PHENOTYPE	9	9	apneas
NCT000055515	NCT00005551_5_T0	PHENOTYPE	12	12	insights
NCT000055515	NCT00005551_5_T1	PHENOTYPE	19	20	cardiovascular morbidity
NCT000055519	NCT00005551_9_T0	PHENOTYPE	15	15	severity
NCT000055519	NCT00005551_9_T1	PHENOTYPE	28	28	arousal
NCT0000555115	NCT00005551_15_T0	PHENOTYPE	10	10	sequelae
NCT0000555115	NCT00005551_15_T1	BIOLOGICAL_PROCESS	5	5	aging
NCT000055522	NCT00005552_2_T0	COMPOUND	8	8	isocyanate
NCT000055522	NCT00005552_2_T1	BIOLOGICAL_PROCESS	16	16	sensitization
NCT000055525	NCT00005552_5_T0	PHENOTYPE	25	25	asthma
NCT000055525	NCT00005552_5_T1	BIOLOGICAL_PROCESS	22	22	sensitization
NCT000055529	NCT00005552_9_T0	PHENOTYPE	30	30	exposures
NCT000055529	NCT00005552_9_T1	COMPOUND	28	28	isocyanate
NCT000055529	NCT00005552_9_T2	PHENOTYPE	11	11	asthma
NCT0000555210	NCT00005552_10_T0	COMPOUND	37	37	isocyanate
NCT0000555210	NCT00005552_10_T1	BIOLOGICAL_PROCESS	55	55	sensitization
NCT000055533	NCT00005553_3_T0	PHENOTYPE	13	13	complication
NCT000055535	NCT00005553_5_T0	PHENOTYPE	0	0	Recurrences
NCT000055536	NCT00005553_6_T0	TISSUE	9	9	myocardium
NCT0000555310	NCT00005553_10_T0	PHENOTYPE	31	31	recurrence
NCT0000555311	NCT00005553_11_T0	PHENOTYPE	15	16	supraventricular tachycardia
NCT0000555312	NCT00005553_12_T0	PHENOTYPE	31	31	complication
NCT0000555312	NCT00005553_12_T1	PHENOTYPE	13	13	centers
NCT000055542	NCT00005554_2_T0	PHENOTYPE	25	26	cardiac events
NCT000055542	NCT00005554_2_T1	PHENOTYPE	21	22	coronary restenosis
NCT000055543	NCT00005554_3_T0	PHENOTYPE	22	24	quality of life
NCT000055545	NCT00005554_5_T0	PHENOTYPE	17	17	progression
NCT000055545	NCT00005554_5_T1	PHENOTYPE	12	12	hostility
NCT000055545	NCT00005554_5_T2	PHENOTYPE	19	20	coronary disease
NCT000055548	NCT00005554_8_T0	PHENOTYPE	28	28	progression
NCT000055548	NCT00005554_8_T1	GENE	13	13	has
NCT000055548	NCT00005554_8_T2	PHENOTYPE	30	32	coronary artery disease
NCT0000555410	NCT00005554_10_T0	PHENOTYPE	25	25	progression
NCT0000555410	NCT00005554_10_T1	PHENOTYPE	11	11	recurrent
NCT0000555410	NCT00005554_10_T2	PHENOTYPE	12	13	cardiac events
NCT0000555410	NCT00005554_10_T3	PHENOTYPE	27	29	coronary artery disease
NCT0000555412	NCT00005554_12_T0	PHENOTYPE	26	26	progression
NCT0000555412	NCT00005554_12_T1	PHENOTYPE	12	12	recurrent
NCT0000555412	NCT00005554_12_T2	PHENOTYPE	13	14	cardiac events
NCT0000555412	NCT00005554_12_T3	PHENOTYPE	28	30	coronary artery disease
NCT000055554	NCT00005555_4_T0	GENE	22	22	3.4
NCT000055554	NCT00005555_4_T1	GENE	39	39	3.4
NCT000055554	NCT00005555_4_T2	GENE	53	53	3.4
NCT000055554	NCT00005555_4_T3	GENE	24	24	5.7
NCT000055554	NCT00005555_4_T4	GENE	32	32	5.7
NCT000055554	NCT00005555_4_T5	GENE	46	46	5.7
NCT000055554	NCT00005555_4_T6	ORGAN	13	13	heart
NCT000055554	NCT00005555_4_T7	GENE	27	28	Group 1
NCT000055556	NCT00005555_6_T0	GENE	4	4	1.4
NCT000055559	NCT00005555_9_T0	GENE	5	5	1.4
NCT0000555511	NCT00005555_11_T0	BIOLOGICAL_PROCESS	9	11	response to exercise
NCT0000555513	NCT00005555_13_T0	PHENOTYPE	51	51	secondary
NCT0000555513	NCT00005555_13_T1	GENE	40	40	max
NCT0000555514	NCT00005555_14_T0	PHENOTYPE	6	6	perceived
NCT0000555514	NCT00005555_14_T1	PHENOTYPE	10	12	quality of life
NCT000055562	NCT00005556_2_T0	ORGAN	8	8	marrow
NCT000055562	NCT00005556_2_T1	ORGAN	26	26	marrow
NCT000055563	NCT00005556_3_T0	ORGAN	25	25	marrow
NCT000055566	NCT00005556_6_T0	ORGAN	14	14	marrow
NCT000055566	NCT00005556_6_T1	PHENOTYPE	41	41	centers
NCT000055572	NCT00005557_2_T0	PHENOTYPE	12	12	hypertension
NCT000055572	NCT00005557_2_T1	PHENOTYPE	13	14	cardiovascular disease
NCT000055573	NCT00005557_3_T0	PHENOTYPE	15	16	sleep disorders
NCT000055594	NCT00005559_4_T0	GENE	0	0	Transferrin
NCT000055597	NCT00005559_7_T0	GENE	21	21	III
NCT000055598	NCT00005559_8_T0	GENE	8	8	transferrin
NCT000055600	NCT00005560_0_T0	PHENOTYPE	5	6	Sleep Apnea
NCT000055603	NCT00005560_3_T0	PHENOTYPE	16	18	obstructive sleep apnea
NCT000055605	NCT00005560_5_T0	PHENOTYPE	10	10	snoring
NCT000055608	NCT00005560_8_T0	PHENOTYPE	47	47	ventilation
NCT000055620	NCT00005562_0_T0	GENE	6	6	CHD
NCT000055620	NCT00005562_0_T1	ORGAN	0	1	Coronary Artery
NCT000055624	NCT00005562_4_T0	GENE	14	14	has
NCT000055624	NCT00005562_4_T1	GENE	30	30	has
NCT000055624	NCT00005562_4_T2	GENE	20	20	CHD
NCT000055627	NCT00005562_7_T0	GENE	9	9	HDL
NCT000055627	NCT00005562_7_T1	PHENOTYPE	12	13	plasma glucose
NCT000055628	NCT00005562_8_T0	GENE	0	0	CAC
NCT000055628	NCT00005562_8_T1	GENE	3	3	has
NCT000055628	NCT00005562_8_T2	GENE	8	8	CHD
NCT000055628	NCT00005562_8_T3	GENE	12	12	CHD
NCT000055629	NCT00005562_9_T0	PHENOTYPE	24	24	CVD
NCT000055629	NCT00005562_9_T1	GENE	5	5	CAC
NCT000055629	NCT00005562_9_T2	GENE	17	17	had
NCT000055629	NCT00005562_9_T3	GENE	11	11	CHD
NCT0000556210	NCT00005562_10_T0	GENE	4	4	CAC
NCT0000556210	NCT00005562_10_T1	GENE	14	14	CAC
NCT0000556210	NCT00005562_10_T2	GENE	16	16	CHD
NCT0000556211	NCT00005562_11_T0	GENE	7	7	CHD
NCT0000556212	NCT00005562_12_T0	PHENOTYPE	23	23	exposures
NCT0000556212	NCT00005562_12_T1	GENE	12	12	CAC
NCT0000556213	NCT00005562_13_T0	GENE	1	1	CAC
NCT0000556213	NCT00005562_13_T1	GENE	26	26	CHD
NCT000055632	NCT00005563_2_T0	GENE	4	4	MARC
NCT000055632	NCT00005563_2_T1	GENE	10	10	MARC
NCT000055632	NCT00005563_2_T2	GENE	5	5	Dr
NCT000055633	NCT00005563_3_T0	GENE	1	1	MARC
NCT000055634	NCT00005563_4_T0	GENE	3	3	MARC
NCT000055634	NCT00005563_4_T1	GENE	4	4	has
NCT000055635	NCT00005563_5_T0	GENE	4	4	MARC
NCT000055636	NCT00005563_6_T0	PHENOTYPE	85	85	relapse
NCT000055636	NCT00005563_6_T1	PHENOTYPE	44	44	asthma
NCT000055636	NCT00005563_6_T2	PHENOTYPE	54	54	asthma
NCT000055636	NCT00005563_6_T3	PHENOTYPE	81	81	asthma
NCT000055636	NCT00005563_6_T4	PHENOTYPE	9	10	acute asthma
NCT000055636	NCT00005563_6_T5	PHENOTYPE	35	36	acute asthma
NCT000055636	NCT00005563_6_T6	PHENOTYPE	63	64	acute asthma
NCT000055636	NCT00005563_6_T7	PHENOTYPE	72	74	severe acute asthma
NCT000055640	NCT00005564_0_T0	PHENOTYPE	3	3	Asthma
NCT000055643	NCT00005564_3_T0	PHENOTYPE	15	15	understood
NCT000055645	NCT00005564_5_T0	PHENOTYPE	29	29	secondary
NCT000055645	NCT00005564_5_T1	PHENOTYPE	4	4	asthma
NCT000055645	NCT00005564_5_T2	PHENOTYPE	20	20	asthma
NCT000055645	NCT00005564_5_T3	PHENOTYPE	5	7	quality of life
NCT000055646	NCT00005564_6_T0	PHENOTYPE	8	8	allergy
NCT000055646	NCT00005564_6_T1	PHENOTYPE	15	15	asthma
NCT000055649	NCT00005564_9_T0	PHENOTYPE	3	3	severity
NCT0000556410	NCT00005564_10_T0	PHENOTYPE	9	9	severity
NCT0000556411	NCT00005564_11_T0	GENE	2	2	extended
NCT0000556412	NCT00005564_12_T0	PHENOTYPE	7	7	asthma
NCT000055652	NCT00005565_2_T0	PHENOTYPE	0	0	Hypobetalipoproteinemia
NCT000055653	NCT00005565_3_T0	ORGAN	24	24	Heart
NCT000055653	NCT00005565_3_T1	PHENOTYPE	34	34	mutation
NCT000055653	NCT00005565_3_T2	GENE	39	39	lipoprotein
NCT000055653	NCT00005565_3_T3	GENE	8	8	truncated
NCT000055653	NCT00005565_3_T4	GENE	0	0	Dr
NCT000055654	NCT00005565_4_T0	GENE	8	8	apoB-100
NCT000055656	NCT00005565_6_T0	PHENOTYPE	11	11	mutation
NCT000055657	NCT00005565_7_T0	BIOLOGICAL_PROCESS	19	19	metabolism
NCT000055659	NCT00005565_9_T0	GENE	15	15	apoB-100
NCT000055659	NCT00005565_9_T1	CELL	21	21	hepatocytes
NCT0000556511	NCT00005565_11_T0	GENE	2	2	has
NCT0000556511	NCT00005565_11_T1	GENE	4	4	extended
NCT000055665	NCT00005566_5_T0	PHENOTYPE	5	5	conceptualization
NCT000055667	NCT00005566_7_T0	PHENOTYPE	13	13	feelings
NCT0000556611	NCT00005566_11_T0	PHENOTYPE	18	18	feelings
NCT000055674	NCT00005567_4_T0	GENE	2	2	has
NCT000055677	NCT00005567_7_T0	GENE	3	3	has
NCT000055679	NCT00005567_9_T0	PHENOTYPE	9	9	practices
NCT000055692	NCT00005569_2_T0	GENE	9	9	elastase
NCT000055692	NCT00005569_2_T1	GENE	5	5	SLPI
NCT000055693	NCT00005569_3_T0	PHENOTYPE	15	15	inflammation
NCT000055693	NCT00005569_3_T1	MOLECULAR_FUNCTION	12	13	elastase activity
NCT000055693	NCT00005569_3_T2	PHENOTYPE	7	9	impaired wound healing
NCT000055697	NCT00005569_7_T0	GENE	12	12	SLPI
NCT000055697	NCT00005569_7_T1	GENE	9	9	gel
NCT000055697	NCT00005569_7_T2	GENE	28	28	gel
NCT000055697	NCT00005569_7_T3	PHENOTYPE	21	22	skin wound
NCT0000556910	NCT00005569_10_T0	GENE	19	19	SLPI
NCT0000556910	NCT00005569_10_T1	GENE	4	4	ml
NCT0000556910	NCT00005569_10_T2	GENE	7	7	ml
NCT0000556912	NCT00005569_12_T0	GENE	4	4	ml
NCT0000556915	NCT00005569_15_T0	PHENOTYPE	14	14	wounds
NCT0000556915	NCT00005569_15_T1	GENE	21	21	has
NCT0000556915	NCT00005569_15_T2	PHENOTYPE	4	5	tingling sensation
NCT0000556918	NCT00005569_18_T0	PHENOTYPE	12	12	inflammation
NCT0000556918	NCT00005569_18_T1	GENE	8	8	reduced
NCT0000556918	NCT00005569_18_T2	BIOLOGICAL_PROCESS	19	20	wound healing
NCT0000556918	NCT00005569_18_T3	MOLECULAR_FUNCTION	9	10	elastase activity
NCT0000556919	NCT00005569_19_T0	PHENOTYPE	17	17	wounds
NCT0000556919	NCT00005569_19_T1	PHENOTYPE	30	30	wounds
NCT0000556919	NCT00005569_19_T2	GENE	14	14	SLPI
NCT0000556919	NCT00005569_19_T3	GENE	27	27	SLPI
NCT0000556920	NCT00005569_20_T0	GENE	3	3	SLPI
NCT0000556922	NCT00005569_22_T0	PHENOTYPE	1	1	wounds
NCT0000556922	NCT00005569_22_T1	PHENOTYPE	10	10	wounds
NCT0000556929	NCT00005569_29_T0	PHENOTYPE	3	3	menopausal
NCT0000556929	NCT00005569_29_T1	GENE	15	15	hormone
NCT0000556929	NCT00005569_29_T2	BIOLOGICAL_PROCESS	6	6	menarche
NCT0000556930	NCT00005569_30_T0	PHENOTYPE	11	11	HIV
NCT0000556930	NCT00005569_30_T1	PHENOTYPE	4	5	Hepatitis B
NCT0000556934	NCT00005569_34_T0	COMPOUND	21	21	azathioprine
NCT0000556935	NCT00005569_35_T0	GENE	8	8	HRT
NCT0000556936	NCT00005569_36_T0	PHENOTYPE	9	9	malignancy
NCT0000556936	NCT00005569_36_T1	PHENOTYPE	7	8	cardiovascular disease
NCT0000556936	NCT00005569_36_T2	PHENOTYPE	14	15	Alzheimer's disease
NCT0000556936	NCT00005569_36_T3	PHENOTYPE	11	13	inflammatory bowel disease
NCT0000556937	NCT00005569_37_T0	PHENOTYPE	6	6	anemia
NCT0000556937	NCT00005569_37_T1	PHENOTYPE	7	7	leukocytosis
NCT0000556937	NCT00005569_37_T2	PHENOTYPE	8	9	bleeding disorder
NCT000055701	NCT00005570_1_T0	CELL	20	20	platelet
NCT000055705	NCT00005570_5_T0	CELL	20	20	platelet
NCT0000557012	NCT00005570_12_T0	PHENOTYPE	11	11	Hepatitis
NCT0000557012	NCT00005570_12_T1	PHENOTYPE	9	9	HIV
NCT0000557012	NCT00005570_12_T2	PHENOTYPE	7	7	Immunodeficiency
NCT0000557013	NCT00005570_13_T0	PHENOTYPE	12	12	autoimmune
NCT0000557013	NCT00005570_13_T1	PHENOTYPE	7	7	thrombocytopenia
NCT0000557013	NCT00005570_13_T2	PHENOTYPE	16	16	thrombocytopenia
NCT0000557013	NCT00005570_13_T3	PHENOTYPE	19	19	disorders
NCT0000557013	NCT00005570_13_T4	PHENOTYPE	21	22	liver disease
NCT0000557013	NCT00005570_13_T5	PHENOTYPE	10	11	lupus erythematosus
NCT0000557013	NCT00005570_13_T6	ORGAN	17	18	bone marrow
NCT0000557013	NCT00005570_13_T7	PHENOTYPE	13	14	thyroid disorders
NCT0000557014	NCT00005570_14_T0	PHENOTYPE	4	4	disorders
NCT000055712	NCT00005571_2_T0	PHENOTYPE	5	5	dermatomyositis
NCT000055712	NCT00005571_2_T1	COMPOUND	8	8	prednisone
NCT000055713	NCT00005571_3_T0	PHENOTYPE	20	20	inflammation
NCT000055713	NCT00005571_3_T1	PHENOTYPE	7	7	blocks
NCT000055714	NCT00005571_4_T0	GENE	8	8	had
NCT000055714	NCT00005571_4_T1	PHENOTYPE	9	9	dermatomyositis
NCT000055714	NCT00005571_4_T2	COMPOUND	21	21	prednisone
NCT000055714	NCT00005571_4_T3	COMPOUND	29	29	prednisone
NCT0000557117	NCT00005571_17_T0	TISSUE	6	6	muscles
NCT0000557117	NCT00005571_17_T1	GENE	3	3	MRI
NCT0000557120	NCT00005571_20_T0	ORGAN	28	28	microvasculature
NCT0000557123	NCT00005571_23_T0	GENE	16	16	C5
NCT0000557123	NCT00005571_23_T1	GENE	18	18	C5a
NCT0000557125	NCT00005571_25_T0	GENE	0	0	C5
NCT0000557125	NCT00005571_25_T1	PHENOTYPE	1	1	inhibition
NCT0000557125	NCT00005571_25_T2	PHENOTYPE	10	10	dermatomyositis
NCT0000557126	NCT00005571_26_T0	GENE	10	10	C5
NCT0000557127	NCT00005571_27_T0	GENE	16	16	CDR
NCT0000557127	NCT00005571_27_T1	GENE	6	6	C5
NCT0000557128	NCT00005571_28_T0	GENE	15	15	IND
NCT0000557134	NCT00005571_34_T0	PHENOTYPE	17	17	pharmacodynamics
NCT0000557134	NCT00005571_34_T1	PHENOTYPE	15	15	pharmacokinetics
NCT0000557135	NCT00005571_35_T0	PHENOTYPE	8	9	adverse events
NCT0000557136	NCT00005571_36_T0	GENE	40	40	MRI
NCT0000557136	NCT00005571_36_T1	PHENOTYPE	49	49	secondary
NCT0000557136	NCT00005571_36_T2	PHENOTYPE	38	39	enzyme level
NCT0000557142	NCT00005571_42_T0	GENE	14	14	MTX
NCT0000557145	NCT00005571_45_T0	GENE	15	15	WBC
NCT0000557145	NCT00005571_45_T1	CELL	23	23	neutrophils
NCT0000557145	NCT00005571_45_T2	CELL	31	31	platelets
NCT0000557145	NCT00005571_45_T3	GENE	7	7	hemoglobin
NCT0000557145	NCT00005571_45_T4	GENE	13	13	8.5
NCT0000557147	NCT00005571_47_T0	PHENOTYPE	3	3	menopausal
NCT0000557147	NCT00005571_47_T1	PHENOTYPE	5	5	sterile
NCT0000557148	NCT00005571_48_T0	PHENOTYPE	2	3	liver disease
NCT0000557149	NCT00005571_49_T0	PHENOTYPE	21	22	Hepatitis C
NCT0000557149	NCT00005571_49_T1	PHENOTYPE	18	19	Hepatitis B
NCT0000557149	NCT00005571_49_T2	PHENOTYPE	4	7	alcohol or drug abuse
NCT0000557150	NCT00005571_50_T0	COMPOUND	6	6	creatinine
NCT0000557150	NCT00005571_50_T1	GENE	12	12	2.0
NCT0000557150	NCT00005571_50_T2	PHENOTYPE	2	3	renal insufficiency
NCT0000557153	NCT00005571_53_T0	PHENOTYPE	4	4	suspicion
NCT0000557153	NCT00005571_53_T1	PHENOTYPE	15	16	bacterial infection
NCT0000557156	NCT00005571_56_T0	PHENOTYPE	2	3	joint disease
NCT0000557158	NCT00005571_58_T0	PHENOTYPE	7	8	complement deficiency
NCT0000557159	NCT00005571_59_T0	PHENOTYPE	4	5	allergic reaction
NCT0000557163	NCT00005571_63_T0	PHENOTYPE	4	4	HIV
NCT0000557163	NCT00005571_63_T1	PHENOTYPE	11	11	myositis
NCT0000557163	NCT00005571_63_T2	PHENOTYPE	5	6	Lyme disease
NCT000055721	NCT00005572_1_T0	PHENOTYPE	7	7	HIV
NCT000055721	NCT00005572_1_T1	ORGAN	12	13	immune system
NCT000055728	NCT00005572_8_T0	GENE	34	34	3b
NCT000055728	NCT00005572_8_T1	GENE	25	26	Group 1
NCT000055741	NCT00005574_1_T0	COMPOUND	10	10	gentamicin
NCT000055741	NCT00005574_1_T1	PHENOTYPE	8	9	muscular dystrophy
NCT000055741	NCT00005574_1_T2	TISSUE	16	17	muscle tissue
NCT000055742	NCT00005574_2_T0	PHENOTYPE	9	10	nonsense mutations
NCT000055742	NCT00005574_2_T1	PHENOTYPE	4	6	Becker muscular dystrophy
NCT000055744	NCT00005574_4_T0	TISSUE	1	2	muscle tissue
NCT000055748	NCT00005574_8_T0	PHENOTYPE	8	9	drug levels
NCT000055749	NCT00005574_9_T0	ORGAN	7	7	kidney
NCT0000557415	NCT00005574_15_T0	GENE	10	10	dystrophin
NCT0000557416	NCT00005574_16_T0	PHENOTYPE	6	7	nonsense mutations
NCT0000557417	NCT00005574_17_T0	BIOLOGICAL_PROCESS	10	10	translation
NCT0000557420	NCT00005574_20_T0	COMPOUND	12	12	gentamicin
NCT0000557421	NCT00005574_21_T0	GENE	13	13	dystrophin
NCT0000557422	NCT00005574_22_T0	GENE	1	1	dystrophin
NCT0000557428	NCT00005574_28_T0	ORGAN	1	1	limb
NCT0000557428	NCT00005574_28_T1	PHENOTYPE	4	4	weakness
NCT0000557432	NCT00005574_32_T0	ORGAN	5	5	kidney
NCT0000557432	NCT00005574_32_T1	COMPOUND	9	9	creatinine
NCT0000557432	NCT00005574_32_T2	ORGAN	8	8	serum
NCT0000557434	NCT00005574_34_T0	COMPOUND	12	12	creatinine
NCT0000557434	NCT00005574_34_T1	PHENOTYPE	8	8	initiation
NCT0000557434	NCT00005574_34_T2	COMPOUND	10	10	prednisone
NCT000055751	NCT00005575_1_T0	PHENOTYPE	9	9	suffering
NCT000055761	NCT00005576_1_T0	PHENOTYPE	17	17	peripheral
NCT000055761	NCT00005576_1_T1	CELL	11	11	cells
NCT000055761	NCT00005576_1_T2	GENE	4	4	sargramostim
NCT000055761	NCT00005576_1_T3	ORGAN	14	15	bone marrow
NCT000055762	NCT00005576_2_T0	CELL	11	11	cells
NCT000055762	NCT00005576_2_T1	GENE	0	0	Interleukin-2
NCT000055762	NCT00005576_2_T2	CELL	5	7	white blood cells
NCT000055763	NCT00005576_3_T0	CELL	12	12	cells
NCT000055763	NCT00005576_3_T1	GENE	7	7	interleukin-2
NCT000055763	NCT00005576_3_T2	PHENOTYPE	11	11	tumor
NCT000055763	NCT00005576_3_T3	GENE	5	5	sargramostim
NCT000055767	NCT00005576_7_T0	PHENOTYPE	2	2	toxic
NCT000055769	NCT00005576_9_T0	PHENOTYPE	2	2	pharmacokinetics
NCT0000557611	NCT00005576_11_T0	CELL	10	10	cells
NCT0000557611	NCT00005576_11_T1	GENE	4	4	IL-2
NCT0000557611	NCT00005576_11_T2	PHENOTYPE	9	9	tumor
NCT0000557611	NCT00005576_11_T3	ORGAN	21	22	bone marrow
NCT0000557613	NCT00005576_13_T0	PHENOTYPE	10	10	metastases
NCT0000557613	NCT00005576_13_T1	CELL	7	7	cells
NCT0000557613	NCT00005576_13_T2	PHENOTYPE	6	6	tumor
NCT0000557613	NCT00005576_13_T3	ORGAN	8	9	bone marrow
NCT0000557615	NCT00005576_15_T0	COMPOUND	4	4	isotretinoin
NCT0000557617	NCT00005576_17_T0	COMPOUND	58	58	isotretinoin
NCT0000557617	NCT00005576_17_T1	GENE	43	43	interleukin-2
NCT0000557617	NCT00005576_17_T2	GENE	48	48	0.3
NCT0000557617	NCT00005576_17_T3	GENE	26	26	GM-CSF
NCT0000557617	NCT00005576_17_T4	GENE	3	3	IV
NCT0000557617	NCT00005576_17_T5	GENE	27	27	IV
NCT0000557617	NCT00005576_17_T6	GENE	44	44	IV
NCT0000557617	NCT00005576_17_T7	GENE	9	9	7-10
NCT0000557617	NCT00005576_17_T8	GENE	50	50	7-10
NCT0000557617	NCT00005576_17_T9	GENE	25	25	sargramostim
NCT0000557618	NCT00005576_18_T0	PHENOTYPE	13	13	toxicity
NCT0000557619	NCT00005576_19_T0	GENE	14	14	MTD
NCT0000557620	NCT00005576_20_T0	PHENOTYPE	21	21	toxicity
NCT0000557620	NCT00005576_20_T1	GENE	1	1	MTD
NCT0000557621	NCT00005576_21_T0	GENE	10	10	MTD
NCT0000557623	NCT00005576_23_T0	GENE	3	3	6-16
NCT000055770	NCT00005577_0_T0	PHENOTYPE	6	7	Solid Tumors
NCT000055772	NCT00005577_2_T0	CELL	10	10	cells
NCT000055772	NCT00005577_2_T1	PHENOTYPE	9	9	tumor
NCT000055774	NCT00005577_4_T0	COMPOUND	6	6	gemcitabine
NCT000055774	NCT00005577_4_T1	PHENOTYPE	13	14	solid tumors
NCT000055776	NCT00005577_6_T0	PHENOTYPE	2	2	toxicity
NCT000055776	NCT00005577_6_T1	COMPOUND	4	4	gemcitabine
NCT000055778	NCT00005577_8_T0	COMPOUND	5	5	gemcitabine
NCT0000557710	NCT00005577_10_T0	COMPOUND	5	5	gemcitabine
NCT0000557712	NCT00005577_12_T0	COMPOUND	2	2	gemcitabine
NCT0000557712	NCT00005577_12_T1	GENE	3	3	IV
NCT0000557713	NCT00005577_13_T0	PHENOTYPE	27	27	toxicity
NCT0000557713	NCT00005577_13_T1	PHENOTYPE	23	24	disease progression
NCT0000557714	NCT00005577_14_T0	COMPOUND	8	8	gemcitabine
NCT0000557714	NCT00005577_14_T1	GENE	14	14	MTD
NCT0000557715	NCT00005577_15_T0	PHENOTYPE	22	22	toxicity
NCT0000557715	NCT00005577_15_T1	GENE	1	1	MTD
NCT000055781	NCT00005578_1_T0	COMPOUND	4	4	dexrazoxane
NCT000055781	NCT00005578_1_T1	CELL	8	8	cells
NCT000055781	NCT00005578_1_T2	PHENOTYPE	12	14	effects of chemotherapy
NCT000055782	NCT00005578_2_T0	COMPOUND	15	15	dexrazoxane
NCT000055782	NCT00005578_2_T1	GENE	3	3	III
NCT000055782	NCT00005578_2_T2	PHENOTYPE	21	22	Hodgkin's disease
NCT000055784	NCT00005578_4_T0	COMPOUND	5	5	bleomycin
NCT000055784	NCT00005578_4_T1	COMPOUND	6	6	vincristine
NCT000055784	NCT00005578_4_T2	GENE	14	14	G-CSF
NCT000055784	NCT00005578_4_T3	GENE	13	13	filgrastim
NCT000055784	NCT00005578_4_T4	COMPOUND	10	10	cyclophosphamide
NCT000055784	NCT00005578_4_T5	COMPOUND	7	7	etoposide
NCT000055784	NCT00005578_4_T6	COMPOUND	4	4	doxorubicin
NCT000055784	NCT00005578_4_T7	COMPOUND	8	8	prednisone
NCT000055784	NCT00005578_4_T8	PHENOTYPE	24	25	Hodgkin's disease
NCT000055786	NCT00005578_6_T0	GENE	0	0	Tailor
NCT000055788	NCT00005578_8_T0	COMPOUND	4	4	dexrazoxane
NCT000055788	NCT00005578_8_T1	PHENOTYPE	9	10	cardiac toxicity
NCT0000557811	NCT00005578_11_T0	COMPOUND	17	17	bleomycin
NCT0000557811	NCT00005578_11_T1	COMPOUND	19	19	vincristine
NCT0000557811	NCT00005578_11_T2	GENE	33	33	0.6
NCT0000557811	NCT00005578_11_T3	COMPOUND	25	25	cyclophosphamide
NCT0000557811	NCT00005578_11_T4	COMPOUND	11	11	etoposide
NCT0000557811	NCT00005578_11_T5	COMPOUND	9	9	doxorubicin
NCT0000557811	NCT00005578_11_T6	COMPOUND	30	30	prednisone
NCT0000557812	NCT00005578_12_T0	GENE	1	1	G-CSF
NCT0000557816	NCT00005578_16_T0	PHENOTYPE	5	5	remission
NCT0000557816	NCT00005578_16_T1	GENE	22	22	2.8
NCT0000557816	NCT00005578_16_T2	GENE	6	6	CR
NCT0000557816	NCT00005578_16_T3	GENE	9	9	CR
NCT000055791	NCT00005579_1_T0	GENE	2	2	II
NCT000055791	NCT00005579_1_T1	PHENOTYPE	15	16	indolent lymphoma
NCT000055791	NCT00005579_1_T2	PHENOTYPE	17	18	Waldenstrom's macroglobulinemia
NCT000055791	NCT00005579_1_T3	COMPOUND	9	10	dolastatin 10
NCT000055791	NCT00005579_1_T4	PHENOTYPE	20	22	chronic lymphocytic leukemia
NCT000055794	NCT00005579_4_T0	PHENOTYPE	9	10	indolent lymphoma
NCT000055794	NCT00005579_4_T1	PHENOTYPE	12	13	Waldenstrom's macroglobulinemia
NCT000055794	NCT00005579_4_T2	PHENOTYPE	5	7	chronic lymphocytic leukemia
NCT000055795	NCT00005579_5_T0	GENE	5	5	IV
NCT000055795	NCT00005579_5_T1	COMPOUND	3	4	dolastatin 10
NCT000055796	NCT00005579_6_T0	PHENOTYPE	7	7	toxicity
NCT000055796	NCT00005579_6_T1	PHENOTYPE	4	5	disease progression
NCT000055801	NCT00005580_1_T0	CELL	9	9	cells
NCT000055802	NCT00005580_2_T0	COMPOUND	12	12	fludarabine
NCT000055802	NCT00005580_2_T1	PHENOTYPE	24	25	Hodgkin's lymphoma
NCT000055802	NCT00005580_2_T2	COMPOUND	9	10	bryostatin 1
NCT000055802	NCT00005580_2_T3	PHENOTYPE	18	20	chronic lymphocytic leukemia
NCT000055807	NCT00005580_7_T0	COMPOUND	8	8	fludarabine
NCT000055807	NCT00005580_7_T1	GENE	17	17	MTD
NCT000055807	NCT00005580_7_T2	COMPOUND	10	11	bryostatin 1
NCT000055808	NCT00005580_8_T0	PHENOTYPE	17	17	toxicity
NCT000055808	NCT00005580_8_T1	GENE	1	1	MTD
NCT000055809	NCT00005580_9_T0	COMPOUND	4	4	fludarabine
NCT000055809	NCT00005580_9_T1	GENE	2	2	MTD
NCT000055809	NCT00005580_9_T2	COMPOUND	10	11	bryostatin 1
NCT000055811	NCT00005581_1_T0	CELL	9	9	cells
NCT000055811	NCT00005581_1_T1	PHENOTYPE	8	8	tumor
NCT000055812	NCT00005581_2_T0	PHENOTYPE	13	14	breast cancer
NCT000055813	NCT00005581_3_T0	GENE	21	21	II
NCT000055813	NCT00005581_3_T1	GENE	3	3	III
NCT000055813	NCT00005581_3_T2	PHENOTYPE	23	26	stage III breast cancer
NCT000055815	NCT00005581_5_T0	COMPOUND	13	13	paclitaxel
NCT000055815	NCT00005581_5_T1	GENE	26	26	III
NCT000055815	NCT00005581_5_T2	COMPOUND	15	15	cyclophosphamide
NCT000055815	NCT00005581_5_T3	COMPOUND	11	11	epirubicin
NCT000055815	NCT00005581_5_T4	COMPOUND	16	16	epirubicin
NCT000055815	NCT00005581_5_T5	PHENOTYPE	27	28	breast cancer
NCT000055817	NCT00005581_7_T0	PHENOTYPE	1	3	quality of life
NCT0000558114	NCT00005581_14_T0	PHENOTYPE	10	10	toxicity
NCT0000558114	NCT00005581_14_T1	PHENOTYPE	6	7	disease progression
NCT0000558115	NCT00005581_15_T0	COMPOUND	11	11	tamoxifen
NCT0000558115	NCT00005581_15_T1	GENE	7	8	hormone receptor
NCT0000558117	NCT00005581_17_T0	PHENOTYPE	0	2	Quality of life
NCT000055831	NCT00005583_1_T0	CELL	10	10	cells
NCT000055831	NCT00005583_1_T1	PHENOTYPE	9	9	tumor
NCT000055832	NCT00005583_2_T0	PHENOTYPE	20	21	endometrial cancer
NCT000055833	NCT00005583_3_T0	GENE	4	4	III
NCT000055833	NCT00005583_3_T1	PHENOTYPE	28	29	endometrial cancer
NCT000055839	NCT00005583_9_T0	COMPOUND	10	10	epirubicin
NCT000055839	NCT00005583_9_T1	COMPOUND	8	8	doxorubicin
NCT000055839	NCT00005583_9_T2	COMPOUND	2	2	cisplatin
NCT000055839	NCT00005583_9_T3	GENE	3	3	IV
NCT000055839	NCT00005583_9_T4	GENE	11	11	IV
NCT000055841	NCT00005584_1_T0	CELL	8	8	cells
NCT000055842	NCT00005584_2_T0	CELL	9	9	cells
NCT000055843	NCT00005584_3_T0	PHENOTYPE	14	15	Hodgkin's lymphoma
NCT000055844	NCT00005584_4_T0	GENE	3	3	III
NCT000055844	NCT00005584_4_T1	PHENOTYPE	25	26	Hodgkin's lymphoma
NCT000055849	NCT00005584_9_T0	PHENOTYPE	3	4	Hodgkin's lymphoma
NCT0000558410	NCT00005584_10_T0	PHENOTYPE	4	4	closed
NCT0000558410	NCT00005584_10_T1	PHENOTYPE	14	14	closed
NCT0000558410	NCT00005584_10_T2	GENE	10	11	Group 1
NCT0000558410	NCT00005584_10_T3	PHENOTYPE	23	24	Hodgkin's lymphoma
NCT0000558423	NCT00005584_23_T0	GENE	3	3	II
NCT0000558424	NCT00005584_24_T0	PHENOTYPE	0	2	Quality of life
NCT0000558426	NCT00005584_26_T0	GENE	16	16	7.7
NCT0000558427	NCT00005584_27_T0	GENE	14	14	3.8
NCT0000558427	NCT00005584_27_T1	GENE	5	6	group 2
NCT000055851	NCT00005585_1_T0	CELL	9	9	cells
NCT000055852	NCT00005585_2_T0	PHENOTYPE	14	17	childhood acute lymphoblastic leukemia
NCT000055853	NCT00005585_3_T0	GENE	4	4	III
NCT000055853	NCT00005585_3_T1	PHENOTYPE	23	25	acute lymphoblastic leukemia
NCT000055857	NCT00005585_7_T0	GENE	6	6	1.4
NCT000055861	NCT00005586_1_T0	CELL	9	9	cells
NCT000055861	NCT00005586_1_T1	PHENOTYPE	8	8	tumor
NCT000055862	NCT00005586_2_T0	GENE	16	16	had
NCT000055862	NCT00005586_2_T1	PHENOTYPE	20	21	colorectal cancer
NCT000055863	NCT00005586_3_T0	GENE	4	4	III
NCT000055863	NCT00005586_3_T1	GENE	27	27	has
NCT000055863	NCT00005586_3_T2	COMPOUND	8	8	leucovorin
NCT000055863	NCT00005586_3_T3	PHENOTYPE	24	25	colorectal cancer
NCT000055871	NCT00005587_1_T0	PHENOTYPE	16	17	breast cancer
NCT000055872	NCT00005587_2_T0	GENE	3	3	III
NCT000055872	NCT00005587_2_T1	PHENOTYPE	23	25	stage breast cancer
NCT000055878	NCT00005587_8_T0	GENE	17	17	Gy
NCT000055879	NCT00005587_9_T0	PHENOTYPE	0	2	Quality of life
NCT000055881	NCT00005588_1_T0	PHENOTYPE	16	17	breast cancer
NCT000055882	NCT00005588_2_T0	GENE	3	3	III
NCT000055882	NCT00005588_2_T1	PHENOTYPE	24	26	stage breast cancer
NCT000055888	NCT00005588_8_T0	GENE	17	17	Gy
NCT000055889	NCT00005588_9_T0	PHENOTYPE	0	2	Quality of life
NCT000055897	NCT00005589_7_T0	PHENOTYPE	7	7	remission
NCT000055897	NCT00005589_7_T1	PHENOTYPE	14	14	remission
NCT000055899	NCT00005589_9_T0	GENE	9	9	3.4
NCT000055899	NCT00005589_9_T1	COMPOUND	6	6	cyclophosphamide
NCT000055899	NCT00005589_9_T2	GENE	7	7	IV
NCT0000558910	NCT00005589_10_T0	GENE	1	1	G-CSF
NCT0000558911	NCT00005589_11_T0	PHENOTYPE	10	10	purging
NCT0000558911	NCT00005589_11_T1	PHENOTYPE	13	13	purging
NCT0000558913	NCT00005589_13_T0	CELL	0	3	Peripheral blood stem cells
NCT0000558914	NCT00005589_14_T0	COMPOUND	26	26	cytarabine
NCT0000558914	NCT00005589_14_T1	COMPOUND	46	46	1
NCT0000558914	NCT00005589_14_T2	COMPOUND	11	11	2
NCT0000558914	NCT00005589_14_T3	COMPOUND	19	19	2
NCT0000558914	NCT00005589_14_T4	COMPOUND	25	25	2
NCT0000558914	NCT00005589_14_T5	COMPOUND	37	37	2
NCT0000558914	NCT00005589_14_T6	COMPOUND	39	39	melphalan
NCT0000558914	NCT00005589_14_T7	COMPOUND	16	16	etoposide
NCT0000558914	NCT00005589_14_T8	GENE	9	9	IV
NCT0000558914	NCT00005589_14_T9	GENE	17	17	IV
NCT0000558914	NCT00005589_14_T10	GENE	27	27	IV
NCT0000558914	NCT00005589_14_T11	GENE	40	40	IV
NCT0000558915	NCT00005589_15_T0	GENE	9	9	2.4
NCT0000558915	NCT00005589_15_T1	COMPOUND	3	3	cyclophosphamide
NCT0000558915	NCT00005589_15_T2	COMPOUND	12	12	cyclophosphamide
NCT0000558918	NCT00005589_18_T0	ORGAN	14	14	transplant
NCT000055901	NCT00005590_1_T0	COMPOUND	6	6	levofloxacin
NCT000055902	NCT00005590_2_T0	COMPOUND	10	10	levofloxacin
NCT000055902	NCT00005590_2_T1	PHENOTYPE	22	22	lymphoma
NCT000055902	NCT00005590_2_T2	GENE	3	3	III
NCT000055902	NCT00005590_2_T3	PHENOTYPE	19	20	solid tumors
NCT000055912	NCT00005591_2_T0	CELL	10	10	cells
NCT000055912	NCT00005591_2_T1	PHENOTYPE	9	9	tumor
NCT000055913	NCT00005591_3_T0	GENE	2	2	II
NCT000055913	NCT00005591_3_T1	COMPOUND	11	11	gemcitabine
NCT000055913	NCT00005591_3_T2	PHENOTYPE	21	25	recurrent cancer of the pancreas
NCT000055915	NCT00005591_5_T0	PHENOTYPE	5	5	progression
NCT000055915	NCT00005591_5_T1	COMPOUND	31	31	gemcitabine
NCT000055915	NCT00005591_5_T2	PHENOTYPE	21	21	recurrent
NCT000055915	NCT00005591_5_T3	PHENOTYPE	11	13	quality of life
NCT000055915	NCT00005591_5_T4	PHENOTYPE	22	25	adenocarcinoma of the pancreas
NCT000055917	NCT00005591_7_T0	PHENOTYPE	4	4	toxicity
NCT000055919	NCT00005591_9_T0	GENE	7	7	IV
NCT0000559110	NCT00005591_10_T0	GENE	11	11	1.2
NCT0000559110	NCT00005591_10_T1	COMPOUND	18	18	gemcitabine
NCT0000559110	NCT00005591_10_T2	GENE	9	9	IV
NCT0000559110	NCT00005591_10_T3	GENE	19	19	IV
NCT0000559112	NCT00005591_12_T0	GENE	9	9	IV
NCT0000559113	NCT00005591_13_T0	GENE	1	1	IV
NCT0000559114	NCT00005591_14_T0	PHENOTYPE	7	7	toxicity
NCT0000559114	NCT00005591_14_T1	PHENOTYPE	9	10	disease progression
NCT0000559115	NCT00005591_15_T0	PHENOTYPE	0	2	Quality of life
NCT0000559116	NCT00005591_16_T0	PHENOTYPE	9	10	disease progression
NCT000055921	NCT00005592_1_T0	GENE	2	2	II
NCT000055921	NCT00005592_1_T1	COMPOUND	11	12	ibritumomab tiuxetan
NCT000055921	NCT00005592_1_T2	PHENOTYPE	21	22	Hodgkin's lymphoma
NCT000055923	NCT00005592_3_T0	CELL	10	10	cells
NCT000055923	NCT00005592_3_T1	PHENOTYPE	9	9	lymphoma
NCT000055926	NCT00005592_6_T0	CELL	21	21	B-cell
NCT000055926	NCT00005592_6_T1	PHENOTYPE	20	20	transformed
NCT000055926	NCT00005592_6_T2	COMPOUND	8	9	ibritumomab tiuxetan
NCT000055926	NCT00005592_6_T3	PHENOTYPE	22	23	Hodgkin's lymphoma
NCT000055928	NCT00005592_8_T0	GENE	3	3	IV
NCT000055928	NCT00005592_8_T1	GENE	13	13	IV
NCT000055929	NCT00005592_9_T0	GENE	5	5	IV
NCT000055929	NCT00005592_9_T1	COMPOUND	3	4	ibritumomab tiuxetan
NCT0000559213	NCT00005592_13_T0	PHENOTYPE	18	18	lymphoma
NCT0000559213	NCT00005592_13_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000559213	NCT00005592_13_T2	PHENOTYPE	16	17	high grade
NCT000055931	NCT00005593_1_T0	CELL	9	9	cells
NCT000055934	NCT00005593_4_T0	PHENOTYPE	3	3	leukemia
NCT000055934	NCT00005593_4_T1	ORGAN	6	7	bone marrow
NCT000055938	NCT00005593_8_T0	PHENOTYPE	6	6	toxicities
NCT0000559312	NCT00005593_12_T0	PHENOTYPE	3	3	toxicities
NCT0000559312	NCT00005593_12_T1	COMPOUND	9	9	topotecan
NCT0000559313	NCT00005593_13_T0	COMPOUND	8	8	topotecan
NCT0000559314	NCT00005593_14_T0	GENE	13	13	1.5
NCT0000559314	NCT00005593_14_T1	COMPOUND	6	6	fludarabine
NCT0000559314	NCT00005593_14_T2	GENE	3	3	IV
NCT0000559314	NCT00005593_14_T3	GENE	7	7	IV
NCT0000559314	NCT00005593_14_T4	GENE	16	16	IV
NCT0000559314	NCT00005593_14_T5	COMPOUND	15	15	topotecan
NCT0000559315	NCT00005593_15_T0	PHENOTYPE	3	3	leukemia
NCT0000559315	NCT00005593_15_T1	ORGAN	6	7	bone marrow
NCT0000559316	NCT00005593_16_T0	GENE	8	8	1.2
NCT0000559316	NCT00005593_16_T1	PHENOTYPE	6	6	remission
NCT0000559316	NCT00005593_16_T2	COMPOUND	16	16	fludarabine
NCT0000559316	NCT00005593_16_T3	GENE	21	21	4-8
NCT0000559316	NCT00005593_16_T4	COMPOUND	19	19	topotecan
NCT0000559317	NCT00005593_17_T0	GENE	14	14	MTD
NCT0000559317	NCT00005593_17_T1	COMPOUND	8	8	topotecan
NCT0000559318	NCT00005593_18_T0	COMPOUND	8	8	topotecan
NCT0000559319	NCT00005593_19_T0	PHENOTYPE	19	19	toxicity
NCT0000559319	NCT00005593_19_T1	GENE	1	1	MTD
NCT000055941	NCT00005594_1_T0	GENE	2	2	II
NCT000055941	NCT00005594_1_T1	PHENOTYPE	16	17	advanced cancer
NCT000055941	NCT00005594_1_T2	PHENOTYPE	17	20	cancer of the pancreas
NCT000055945	NCT00005594_5_T0	PHENOTYPE	7	7	progression
NCT000055945	NCT00005594_5_T1	PHENOTYPE	12	15	adenocarcinoma of the pancreas
NCT000055949	NCT00005594_9_T0	GENE	11	11	II
NCT0000559410	NCT00005594_10_T0	GENE	5	5	IV
NCT0000559411	NCT00005594_11_T0	PHENOTYPE	16	16	toxicity
NCT0000559411	NCT00005594_11_T1	PHENOTYPE	18	19	disease progression
NCT000055951	NCT00005595_1_T0	GENE	2	2	II
NCT000055951	NCT00005595_1_T1	COMPOUND	9	10	arsenic trioxide
NCT000055951	NCT00005595_1_T2	PHENOTYPE	19	20	Hodgkin's disease
NCT000055953	NCT00005595_3_T0	PHENOTYPE	19	19	relapse
NCT000055953	NCT00005595_3_T1	PHENOTYPE	15	15	remission
NCT000055953	NCT00005595_3_T2	COMPOUND	4	5	arsenic trioxide
NCT000055953	NCT00005595_3_T3	PHENOTYPE	31	32	Hodgkin's disease
NCT000055955	NCT00005595_5_T0	PHENOTYPE	2	2	toxicities
NCT000055959	NCT00005595_9_T0	GENE	6	6	1.2
NCT000055959	NCT00005595_9_T1	GENE	4	4	IV
NCT000055959	NCT00005595_9_T2	COMPOUND	2	3	arsenic trioxide
NCT0000559511	NCT00005595_11_T0	GENE	5	5	CR
NCT0000559511	NCT00005595_11_T1	GENE	15	15	CR
NCT0000559512	NCT00005595_12_T0	PHENOTYPE	7	7	toxicity
NCT0000559512	NCT00005595_12_T1	PHENOTYPE	9	10	disease progression
NCT000055961	NCT00005596_1_T0	CELL	9	9	cells
NCT000055962	NCT00005596_2_T0	PHENOTYPE	13	15	acute lymphoblastic leukemia
NCT000055963	NCT00005596_3_T0	GENE	4	4	III
NCT000055963	NCT00005596_3_T1	PHENOTYPE	25	27	acute lymphoblastic leukemia
NCT000055967	NCT00005596_7_T0	GENE	8	8	MTX
NCT000055967	NCT00005596_7_T1	COMPOUND	14	14	calcium
NCT000055967	NCT00005596_7_T2	COMPOUND	13	13	leucovorin
NCT000055971	NCT00005597_1_T0	COMPOUND	9	9	temozolomide
NCT000055971	NCT00005597_1_T1	GENE	2	2	II
NCT000055971	NCT00005597_1_T2	PHENOTYPE	18	20	gastrointestinal stromal tumors
NCT000055975	NCT00005597_5_T0	COMPOUND	3	3	temozolomide
NCT000055975	NCT00005597_5_T1	GENE	8	8	1.5
NCT000055976	NCT00005597_6_T0	PHENOTYPE	13	13	toxicity
NCT000055976	NCT00005597_6_T1	PHENOTYPE	9	10	disease progression
NCT000055977	NCT00005597_7_T0	GENE	6	6	CR
NCT000055977	NCT00005597_7_T1	GENE	14	14	CR
NCT000055982	NCT00005598_2_T0	CELL	8	8	cells
NCT000055982	NCT00005598_2_T1	COMPOUND	3	3	amifostine
NCT000055985	NCT00005598_5_T0	COMPOUND	7	7	amifostine
NCT000055985	NCT00005598_5_T1	PHENOTYPE	11	12	myelodysplastic syndromes
NCT000055987	NCT00005598_7_T0	PHENOTYPE	2	2	toxicity
NCT0000559811	NCT00005598_11_T0	BIOLOGICAL_PROCESS	17	17	hematopoiesis
NCT0000559811	NCT00005598_11_T1	GENE	10	10	ras
NCT0000559811	NCT00005598_11_T2	GENE	8	8	FAB
NCT0000559813	NCT00005598_13_T0	ORGAN	11	12	bone marrow
NCT0000559813	NCT00005598_13_T1	CELL	13	15	hematopoietic progenitor cells
NCT0000559815	NCT00005598_15_T0	PHENOTYPE	2	2	adhesion
NCT0000559815	NCT00005598_15_T1	CELL	1	1	neutrophil
NCT0000559815	NCT00005598_15_T2	BIOLOGICAL_PROCESS	4	4	chemotaxis
NCT0000559816	NCT00005598_16_T0	GENE	6	6	1.3
NCT0000559816	NCT00005598_16_T1	GENE	25	25	1.7
NCT0000559816	NCT00005598_16_T2	COMPOUND	3	3	amifostine
NCT0000559816	NCT00005598_16_T3	GENE	4	4	IV
NCT0000559818	NCT00005598_18_T0	PHENOTYPE	26	26	toxicity
NCT0000559818	NCT00005598_18_T1	PHENOTYPE	4	4	remission
NCT0000559818	NCT00005598_18_T2	PHENOTYPE	18	18	remission
NCT0000559818	NCT00005598_18_T3	PHENOTYPE	22	23	disease progression
NCT000055991	NCT00005599_1_T0	CELL	9	9	cells
NCT000055991	NCT00005599_1_T1	PHENOTYPE	8	8	tumor
NCT000055992	NCT00005599_2_T0	GENE	2	2	II
NCT000055992	NCT00005599_2_T1	COMPOUND	12	12	paclitaxel
NCT000055992	NCT00005599_2_T2	PHENOTYPE	25	26	stomach cancer
NCT000055992	NCT00005599_2_T3	COMPOUND	9	10	bryostatin 1
NCT000055992	NCT00005599_2_T4	PHENOTYPE	21	23	metastatic esophageal cancer
NCT000055995	NCT00005599_5_T0	COMPOUND	2	2	paclitaxel
NCT000055995	NCT00005599_5_T1	GENE	3	3	IV
NCT000055995	NCT00005599_5_T2	GENE	13	13	IV
NCT000055995	NCT00005599_5_T3	COMPOUND	11	12	bryostatin 1
NCT000055996	NCT00005599_6_T0	PHENOTYPE	10	10	toxicity
NCT000055996	NCT00005599_6_T1	PHENOTYPE	12	13	disease progression
NCT000055997	NCT00005599_7_T0	PHENOTYPE	0	2	Quality of life
NCT000055998	NCT00005599_8_T0	GENE	14	14	1.2
NCT000056001	NCT00005600_1_T0	TISSUE	19	20	lymph node
NCT000056001	NCT00005600_1_T1	PHENOTYPE	28	31	stage II breast cancer
NCT000056012	NCT00005601_2_T0	CELL	11	11	cells
NCT000056013	NCT00005601_3_T0	GENE	2	2	II
NCT000056013	NCT00005601_3_T1	PHENOTYPE	19	20	Hodgkin's lymphoma
NCT000056015	NCT00005601_5_T0	GENE	4	4	IV
NCT000056016	NCT00005601_6_T0	COMPOUND	2	2	dexamethasone
NCT000056016	NCT00005601_6_T1	COMPOUND	18	18	cytarabine
NCT000056016	NCT00005601_6_T2	GENE	38	38	3/12
NCT000056016	NCT00005601_6_T3	GENE	8	8	1.4
NCT000056016	NCT00005601_6_T4	GENE	34	34	GM-CSF
NCT000056016	NCT00005601_6_T5	COMPOUND	9	9	cisplatin
NCT000056016	NCT00005601_6_T6	GENE	5	5	IV
NCT000056016	NCT00005601_6_T7	GENE	10	10	IV
NCT000056016	NCT00005601_6_T8	GENE	19	19	IV
NCT000056016	NCT00005601_6_T9	GENE	33	33	sargramostim
NCT000056017	NCT00005601_7_T0	PHENOTYPE	16	16	toxicity
NCT000056017	NCT00005601_7_T1	PHENOTYPE	12	13	disease progression
NCT000056022	NCT00005602_2_T0	CELL	10	10	cells
NCT000056022	NCT00005602_2_T1	PHENOTYPE	9	9	tumor
NCT000056023	NCT00005602_3_T0	PHENOTYPE	25	25	gliomas
NCT000056023	NCT00005602_3_T1	ORGAN	23	24	brain stem
NCT000056025	NCT00005602_5_T0	GENE	11	11	6.5
NCT000056026	NCT00005602_6_T0	GENE	3	3	IV
NCT000056026	NCT00005602_6_T1	GENE	10	10	IV
NCT000056027	NCT00005602_7_T0	PHENOTYPE	44	44	toxicity
NCT000056027	NCT00005602_7_T1	GENE	37	37	6.5
NCT000056031	NCT00005603_1_T0	CELL	10	10	cells
NCT000056032	NCT00005603_2_T0	PHENOTYPE	13	15	acute lymphoblastic leukemia
NCT000056033	NCT00005603_3_T0	GENE	2	2	III
NCT000056033	NCT00005603_3_T1	PHENOTYPE	18	20	acute lymphoblastic leukemia
NCT000056036	NCT00005603_6_T0	COMPOUND	3	3	methotrexate
NCT000056036	NCT00005603_6_T1	GENE	5	5	IT
NCT000056037	NCT00005603_7_T0	COMPOUND	9	9	methotrexate
NCT000056037	NCT00005603_7_T1	GENE	10	10	IT
NCT000056038	NCT00005603_8_T0	GENE	2	2	M1
NCT000056038	NCT00005603_8_T1	ORGAN	3	4	bone marrow
NCT000056039	NCT00005603_9_T0	COMPOUND	17	17	vincristine
NCT000056039	NCT00005603_9_T1	GENE	29	29	36
NCT000056039	NCT00005603_9_T2	GENE	37	37	36
NCT000056039	NCT00005603_9_T3	GENE	32	32	IM
NCT000056039	NCT00005603_9_T4	GENE	2	2	M2
NCT000056039	NCT00005603_9_T5	GENE	31	31	asparaginase
NCT000056039	NCT00005603_9_T6	COMPOUND	10	10	prednisone
NCT000056039	NCT00005603_9_T7	GENE	18	18	IV
NCT000056039	NCT00005603_9_T8	GENE	21	21	IV
NCT000056039	NCT00005603_9_T9	COMPOUND	20	20	daunorubicin
NCT000056039	NCT00005603_9_T10	ORGAN	3	4	bone marrow
NCT0000560313	NCT00005603_13_T0	COMPOUND	29	29	methotrexate
NCT0000560313	NCT00005603_13_T1	GENE	16	16	WBC
NCT0000560313	NCT00005603_13_T2	GENE	28	28	IT
NCT0000560315	NCT00005603_15_T0	COMPOUND	4	4	methotrexate
NCT0000560315	NCT00005603_15_T1	COMPOUND	13	13	methotrexate
NCT0000560315	NCT00005603_15_T2	GENE	12	12	IT
NCT0000560317	NCT00005603_17_T0	GENE	14	14	3-1
NCT000056040	NCT00005604_0_T0	GENE	2	2	Interleukin-2
NCT000056040	NCT00005604_0_T1	PHENOTYPE	8	9	Solid Tumors
NCT000056042	NCT00005604_2_T0	CELL	4	4	cells
NCT000056042	NCT00005604_2_T1	CELL	23	23	cells
NCT000056042	NCT00005604_2_T2	PHENOTYPE	3	3	tumor
NCT000056042	NCT00005604_2_T3	PHENOTYPE	11	11	tumor
NCT000056042	NCT00005604_2_T4	CELL	17	19	white blood cells
NCT000056043	NCT00005604_3_T0	CELL	11	11	cells
NCT000056043	NCT00005604_3_T1	GENE	0	0	Interleukin-2
NCT000056043	NCT00005604_3_T2	CELL	5	7	white blood cells
NCT000056045	NCT00005604_5_T0	PHENOTYPE	3	3	toxicity
NCT000056045	NCT00005604_5_T1	GENE	9	9	SC
NCT000056045	NCT00005604_5_T2	GENE	10	10	IL-2
NCT000056045	NCT00005604_5_T3	GENE	6	6	MTD
NCT000056045	NCT00005604_5_T4	GENE	18	18	IV
NCT000056047	NCT00005604_7_T0	GENE	12	12	SC
NCT000056047	NCT00005604_7_T1	GENE	13	13	IL-2
NCT000056047	NCT00005604_7_T2	GENE	9	9	IV
NCT000056049	NCT00005604_9_T0	GENE	5	5	SC
NCT000056049	NCT00005604_9_T1	GENE	6	6	IL-2
NCT000056049	NCT00005604_9_T2	GENE	7	7	has
NCT000056049	NCT00005604_9_T3	GENE	24	24	IV
NCT0000560411	NCT00005604_11_T0	GENE	2	2	interleukin-12
NCT0000560411	NCT00005604_11_T1	GENE	3	3	IL-12
NCT0000560411	NCT00005604_11_T2	GENE	4	4	IV
NCT0000560412	NCT00005604_12_T0	GENE	10	10	interleukin-2
NCT0000560412	NCT00005604_12_T1	GENE	11	11	IL-2
NCT0000560412	NCT00005604_12_T2	GENE	23	23	IL-12
NCT0000560413	NCT00005604_13_T0	GENE	3	3	IL-2
NCT0000560413	NCT00005604_13_T1	GENE	5	5	IL-12
NCT0000560414	NCT00005604_14_T0	PHENOTYPE	13	13	toxicity
NCT0000560414	NCT00005604_14_T1	PHENOTYPE	9	10	disease progression
NCT0000560415	NCT00005604_15_T0	PHENOTYPE	11	12	disease progression
NCT0000560416	NCT00005604_16_T0	GENE	10	10	IL-2
NCT0000560416	NCT00005604_16_T1	GENE	8	8	IL-12
NCT0000560416	NCT00005604_16_T2	GENE	16	16	MTD
NCT0000560417	NCT00005604_17_T0	PHENOTYPE	17	17	toxicity
NCT0000560417	NCT00005604_17_T1	GENE	1	1	MTD
NCT000056051	NCT00005605_1_T0	COMPOUND	8	8	tamoxifen
NCT000056051	NCT00005605_1_T1	PHENOTYPE	11	12	bone loss
NCT000056051	NCT00005605_1_T2	PHENOTYPE	14	15	heart disease
NCT000056051	NCT00005605_1_T3	PHENOTYPE	28	31	stage II breast cancer
NCT000056053	NCT00005605_3_T0	COMPOUND	12	12	tamoxifen
NCT000056054	NCT00005605_4_T0	COMPOUND	8	8	tamoxifen
NCT000056055	NCT00005605_5_T0	COMPOUND	15	15	estradiol
NCT000056055	NCT00005605_5_T1	GENE	14	14	hormone
NCT000056056	NCT00005605_6_T0	ORGAN	11	11	spine
NCT000056056	NCT00005605_6_T1	ORGAN	7	8	femoral neck
NCT000056061	NCT00005606_1_T0	GENE	2	2	II
NCT000056061	NCT00005606_1_T1	PHENOTYPE	9	9	peripheral
NCT000056061	NCT00005606_1_T2	CELL	11	11	lymphocyte
NCT000056061	NCT00005606_1_T3	PHENOTYPE	17	18	lymphoproliferative disorders
NCT000056061	NCT00005606_1_T4	PHENOTYPE	24	25	virus infection
NCT000056063	NCT00005606_3_T0	GENE	5	5	Barr
NCT000056063	NCT00005606_3_T1	CELL	9	9	lymphocytes
NCT000056063	NCT00005606_3_T2	PHENOTYPE	4	4	Epstein
NCT000056064	NCT00005606_4_T0	GENE	15	15	Barr
NCT000056064	NCT00005606_4_T1	CELL	19	19	lymphocytes
NCT000056064	NCT00005606_4_T2	ORGAN	11	11	transplant
NCT000056064	NCT00005606_4_T3	PHENOTYPE	14	14	Epstein
NCT000056064	NCT00005606_4_T4	GENE	20	20	IV
NCT000056064	NCT00005606_4_T5	PHENOTYPE	3	4	EBV viremia
NCT000056064	NCT00005606_4_T6	PHENOTYPE	8	9	lymphoproliferative disease
NCT000056065	NCT00005606_5_T0	CELL	5	5	lymphocytes
NCT000056065	NCT00005606_5_T1	CELL	8	8	lymphocytes
NCT000056065	NCT00005606_5_T2	CELL	19	19	lymphocytes
NCT000056065	NCT00005606_5_T3	PHENOTYPE	13	13	proliferation
NCT000056066	NCT00005606_6_T0	PHENOTYPE	9	10	EBV viremia
NCT000056066	NCT00005606_6_T1	PHENOTYPE	12	13	lymphoproliferative disease
NCT000056067	NCT00005606_7_T0	PHENOTYPE	8	8	toxicity
NCT000056067	NCT00005606_7_T1	CELL	12	12	lymphocytes
NCT000056071	NCT00005607_1_T0	CELL	9	9	cells
NCT000056071	NCT00005607_1_T1	PHENOTYPE	8	8	tumor
NCT000056072	NCT00005607_2_T0	GENE	2	2	II
NCT000056072	NCT00005607_2_T1	ORGAN	24	24	esophagus
NCT000056072	NCT00005607_2_T2	PHENOTYPE	18	22	recurrent cancer of the stomach
NCT000056074	NCT00005607_4_T0	COMPOUND	20	20	irinotecan
NCT000056074	NCT00005607_4_T1	COMPOUND	24	24	calcium
NCT000056074	NCT00005607_4_T2	COMPOUND	23	23	leucovorin
NCT000056074	NCT00005607_4_T3	PHENOTYPE	9	9	recurrent
NCT000056074	NCT00005607_4_T4	ORGAN	15	16	gastroesophageal junction
NCT000056074	NCT00005607_4_T5	PHENOTYPE	10	13	adenocarcinoma of the stomach
NCT000056076	NCT00005607_6_T0	PHENOTYPE	5	5	toxicity
NCT000056076	NCT00005607_6_T1	PHENOTYPE	9	9	toxicity
NCT000056077	NCT00005607_7_T0	COMPOUND	3	3	irinotecan
NCT000056077	NCT00005607_7_T1	COMPOUND	9	9	calcium
NCT000056077	NCT00005607_7_T2	COMPOUND	8	8	leucovorin
NCT000056077	NCT00005607_7_T3	GENE	4	4	IV
NCT000056077	NCT00005607_7_T4	GENE	10	10	IV
NCT000056077	NCT00005607_7_T5	GENE	16	16	IV
NCT000056078	NCT00005607_8_T0	PHENOTYPE	10	10	toxicity
NCT000056078	NCT00005607_8_T1	PHENOTYPE	12	13	disease progression
NCT000056081	NCT00005608_1_T0	CELL	9	9	cells
NCT000056081	NCT00005608_1_T1	PHENOTYPE	8	8	tumor
NCT000056082	NCT00005608_2_T0	GENE	2	2	II
NCT000056082	NCT00005608_2_T1	COMPOUND	11	11	leucovorin
NCT000056082	NCT00005608_2_T2	PHENOTYPE	17	19	metastatic breast cancer
NCT000056084	NCT00005608_4_T0	COMPOUND	16	16	calcium
NCT000056084	NCT00005608_4_T1	COMPOUND	15	15	leucovorin
NCT000056084	NCT00005608_4_T2	PHENOTYPE	8	10	metastatic breast cancer
NCT000056086	NCT00005608_6_T0	PHENOTYPE	3	4	disease progression
NCT000056088	NCT00005608_8_T0	PHENOTYPE	2	2	toxicity
NCT000056089	NCT00005608_9_T0	COMPOUND	8	8	calcium
NCT000056089	NCT00005608_9_T1	COMPOUND	7	7	leucovorin
NCT0000560810	NCT00005608_10_T0	PHENOTYPE	13	13	toxicity
NCT0000560810	NCT00005608_10_T1	PHENOTYPE	15	16	disease progression
NCT000056091	NCT00005609_1_T0	GENE	2	2	II
NCT000056091	NCT00005609_1_T1	PHENOTYPE	15	16	Waldenstrom's macroglobulinemia
NCT000056093	NCT00005609_3_T0	PHENOTYPE	12	13	Waldenstrom's macroglobulinemia
NCT000056095	NCT00005609_5_T0	PHENOTYPE	13	13	hypotensive
NCT000056095	NCT00005609_5_T1	PHENOTYPE	3	3	toxicities
NCT000056095	NCT00005609_5_T2	PHENOTYPE	11	11	febrile
NCT000056097	NCT00005609_7_T0	COMPOUND	15	16	purine nucleoside
NCT000056098	NCT00005609_8_T0	GENE	3	3	IV
NCT000056101	NCT00005610_1_T0	CELL	9	9	cells
NCT000056101	NCT00005610_1_T1	GENE	1	1	sargramostim
NCT000056104	NCT00005610_4_T0	PHENOTYPE	11	11	progression
NCT000056104	NCT00005610_4_T1	GENE	7	7	GM-CSF
NCT000056104	NCT00005610_4_T2	GENE	6	6	sargramostim
NCT000056104	NCT00005610_4_T3	PHENOTYPE	24	25	metastatic melanoma
NCT000056108	NCT00005610_8_T0	PHENOTYPE	2	4	quality of life
NCT000056109	NCT00005610_9_T0	GENE	5	5	GM-CSF
NCT000056109	NCT00005610_9_T1	GENE	4	4	sargramostim
NCT0000561010	NCT00005610_10_T0	PHENOTYPE	16	16	toxicity
NCT0000561010	NCT00005610_10_T1	PHENOTYPE	12	13	disease progression
NCT0000561011	NCT00005610_11_T0	PHENOTYPE	0	2	Quality of life
NCT0000561012	NCT00005610_12_T0	GENE	9	9	1.5
NCT000056111	NCT00005611_1_T0	PHENOTYPE	16	17	solid tumors
NCT000056113	NCT00005611_3_T0	GENE	8	8	II
NCT000056113	NCT00005611_3_T1	PHENOTYPE	21	21	malignancies
NCT000056113	NCT00005611_3_T2	PHENOTYPE	12	12	toxicities
NCT000056115	NCT00005611_5_T0	PHENOTYPE	3	3	pharmacokinetics
NCT000056115	NCT00005611_5_T1	ORGAN	2	2	plasma
NCT000056119	NCT00005611_9_T0	GENE	3	3	IV
NCT0000561110	NCT00005611_10_T0	PHENOTYPE	13	13	toxicity
NCT0000561110	NCT00005611_10_T1	PHENOTYPE	9	10	disease progression
NCT0000561111	NCT00005611_11_T0	GENE	14	14	MTD
NCT0000561112	NCT00005611_12_T0	PHENOTYPE	18	18	toxicities
NCT0000561112	NCT00005611_12_T1	GENE	1	1	MTD
NCT0000561113	NCT00005611_13_T0	PHENOTYPE	7	7	toxicities
NCT000056126	NCT00005612_6_T0	COMPOUND	10	10	etoposide
NCT000056126	NCT00005612_6_T1	COMPOUND	6	6	topotecan
NCT0000561212	NCT00005612_12_T0	PHENOTYPE	18	18	concentrations
NCT0000561212	NCT00005612_12_T1	GENE	9	9	HDC
NCT0000561212	NCT00005612_12_T2	ORGAN	17	17	plasma
NCT0000561212	NCT00005612_12_T3	COMPOUND	20	20	topotecan
NCT0000561214	NCT00005612_14_T0	GENE	10	10	STAT
NCT0000561214	NCT00005612_14_T1	BIOLOGICAL_PROCESS	9	9	transcription
NCT0000561214	NCT00005612_14_T2	GENE	14	14	bcl-2
NCT0000561214	NCT00005612_14_T3	MOLECULAR_FUNCTION	4	8	signal transducers and activators of
NCT0000561216	NCT00005612_16_T0	GENE	4	4	STAT
NCT0000561216	NCT00005612_16_T1	PHENOTYPE	20	20	relapse
NCT0000561216	NCT00005612_16_T2	PHENOTYPE	14	14	tumor
NCT0000561216	NCT00005612_16_T3	GENE	17	17	HDC
NCT0000561216	NCT00005612_16_T4	GENE	10	10	bcl-2
NCT0000561218	NCT00005612_18_T0	PHENOTYPE	4	4	pharmacodynamic
NCT0000561218	NCT00005612_18_T1	COMPOUND	9	9	topotecan
NCT0000561219	NCT00005612_19_T0	COMPOUND	8	8	topotecan
NCT0000561220	NCT00005612_20_T0	COMPOUND	22	22	paclitaxel
NCT0000561220	NCT00005612_20_T1	COMPOUND	16	16	cyclophosphamide
NCT0000561220	NCT00005612_20_T2	GENE	17	17	IV
NCT0000561220	NCT00005612_20_T3	GENE	23	23	IV
NCT0000561221	NCT00005612_21_T0	CELL	29	29	cells
NCT0000561221	NCT00005612_21_T1	GENE	3	3	filgrastim
NCT0000561221	NCT00005612_21_T2	GENE	4	4	G-CSF
NCT0000561221	NCT00005612_21_T3	GENE	28	28	CD34
NCT0000561221	NCT00005612_21_T4	CELL	18	21	peripheral blood stem cells
NCT0000561222	NCT00005612_22_T0	COMPOUND	54	54	3
NCT0000561222	NCT00005612_22_T1	COMPOUND	45	45	etoposide
NCT0000561222	NCT00005612_22_T2	GENE	17	17	IV
NCT0000561222	NCT00005612_22_T3	GENE	27	27	IV
NCT0000561222	NCT00005612_22_T4	GENE	46	46	IV
NCT0000561222	NCT00005612_22_T5	COMPOUND	26	26	topotecan
NCT0000561222	NCT00005612_22_T6	COMPOUND	63	63	topotecan
NCT0000561223	NCT00005612_23_T0	GENE	14	14	MTD
NCT0000561223	NCT00005612_23_T1	COMPOUND	8	8	topotecan
NCT0000561224	NCT00005612_24_T0	PHENOTYPE	20	20	toxicity
NCT0000561224	NCT00005612_24_T1	GENE	1	1	MTD
NCT0000561227	NCT00005612_27_T0	GENE	12	12	3.4
NCT000056137	NCT00005613_7_T0	PHENOTYPE	2	2	toxicities
NCT0000561311	NCT00005613_11_T0	GENE	1	1	OR
NCT0000561312	NCT00005613_12_T0	COMPOUND	18	18	3
NCT0000561312	NCT00005613_12_T1	COMPOUND	23	23	3
NCT0000561312	NCT00005613_12_T2	COMPOUND	29	29	3
NCT0000561312	NCT00005613_12_T3	COMPOUND	9	9	cyclophosphamide
NCT0000561312	NCT00005613_12_T4	COMPOUND	26	26	etoposide
NCT0000561312	NCT00005613_12_T5	PHENOTYPE	0	0	Conditioning
NCT0000561312	NCT00005613_12_T6	GENE	10	10	IV
NCT0000561312	NCT00005613_12_T7	GENE	21	21	IV
NCT0000561312	NCT00005613_12_T8	GENE	27	27	IV
NCT0000561317	NCT00005613_17_T0	PHENOTYPE	18	18	lymphoma
NCT0000561317	NCT00005613_17_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000561317	NCT00005613_17_T2	PHENOTYPE	16	17	high grade
NCT000056141	NCT00005614_1_T0	GENE	2	2	II
NCT000056141	NCT00005614_1_T1	COMPOUND	9	9	gemcitabine
NCT000056141	NCT00005614_1_T2	PHENOTYPE	16	18	metastatic breast cancer
NCT000056143	NCT00005614_3_T0	COMPOUND	6	6	gemcitabine
NCT000056143	NCT00005614_3_T1	PHENOTYPE	14	16	metastatic breast cancer
NCT000056145	NCT00005614_5_T0	PHENOTYPE	2	4	quality of life
NCT000056146	NCT00005614_6_T0	COMPOUND	3	3	gemcitabine
NCT000056146	NCT00005614_6_T1	GENE	4	4	IV
NCT000056147	NCT00005614_7_T0	PHENOTYPE	20	20	toxicity
NCT000056147	NCT00005614_7_T1	PHENOTYPE	16	17	disease progression
NCT000056148	NCT00005614_8_T0	PHENOTYPE	0	2	Quality of life
NCT000056152	NCT00005615_2_T0	CELL	8	8	cells
NCT000056152	NCT00005615_2_T1	PHENOTYPE	7	7	tumor
NCT000056153	NCT00005615_3_T0	CELL	10	10	cells
NCT000056153	NCT00005615_3_T1	PHENOTYPE	9	9	tumor
NCT000056153	NCT00005615_3_T2	GENE	1	1	interferon
NCT000056154	NCT00005615_4_T0	GENE	25	25	has
NCT000056154	NCT00005615_4_T1	GENE	9	9	interferon
NCT000056154	NCT00005615_4_T2	PHENOTYPE	19	20	stage III
NCT000056154	NCT00005615_4_T3	PHENOTYPE	22	23	recurrent melanoma
NCT000056157	NCT00005615_7_T0	PHENOTYPE	4	4	toxicity
NCT000056157	NCT00005615_7_T1	GENE	11	11	interferon
NCT000056157	NCT00005615_7_T2	PHENOTYPE	16	17	stage III
NCT000056157	NCT00005615_7_T3	PHENOTYPE	19	20	recurrent melanoma
NCT000056159	NCT00005615_9_T0	GENE	2	2	interferon
NCT000056159	NCT00005615_9_T1	GENE	4	4	IV
NCT0000561511	NCT00005615_11_T0	PHENOTYPE	19	19	toxicity
NCT0000561511	NCT00005615_11_T1	GENE	0	0	Interferon
NCT0000561511	NCT00005615_11_T2	PHENOTYPE	15	16	disease progression
NCT000056161	NCT00005616_1_T0	PHENOTYPE	17	18	colorectal cancer
NCT000056163	NCT00005616_3_T0	PHENOTYPE	2	2	toxicity
NCT000056163	NCT00005616_3_T1	PHENOTYPE	20	21	colorectal cancer
NCT000056165	NCT00005616_5_T0	PHENOTYPE	2	2	pharmacokinetics
NCT000056165	NCT00005616_5_T1	COMPOUND	12	12	iodine
NCT000056167	NCT00005616_7_T0	ORGAN	8	8	serum
NCT0000561611	NCT00005616_11_T0	COMPOUND	8	8	iodine
NCT0000561611	NCT00005616_11_T1	GENE	11	11	IV
NCT0000561613	NCT00005616_13_T0	GENE	14	14	MTD
NCT0000561614	NCT00005616_14_T0	PHENOTYPE	18	18	toxicities
NCT0000561614	NCT00005616_14_T1	GENE	1	1	MTD
NCT000056171	NCT00005617_1_T0	GENE	17	17	IV
NCT000056171	NCT00005617_1_T1	PHENOTYPE	20	21	malignant melanoma
NCT000056173	NCT00005617_3_T0	PHENOTYPE	5	5	toxicity
NCT000056173	NCT00005617_3_T1	GENE	7	7	1.3
NCT000056176	NCT00005617_6_T0	GENE	5	5	14
NCT000056177	NCT00005617_7_T0	CELL	1	1	cells
NCT000056177	NCT00005617_7_T1	GENE	14	14	MART-1
NCT000056177	NCT00005617_7_T2	CELL	7	8	dendritic cells
NCT000056178	NCT00005617_8_T0	GENE	4	4	MART-1
NCT000056178	NCT00005617_8_T1	GENE	8	8	IV
NCT000056179	NCT00005617_9_T0	GENE	8	8	MART-1
NCT000056179	NCT00005617_9_T1	GENE	16	16	MTD
NCT0000561710	NCT00005617_10_T0	PHENOTYPE	17	17	toxicity
NCT0000561710	NCT00005617_10_T1	GENE	1	1	MTD
NCT0000561714	NCT00005617_14_T0	GENE	3	3	1.5
NCT0000561714	NCT00005617_14_T1	GENE	1	1	75
NCT0000561715	NCT00005617_15_T0	GENE	0	0	II
NCT0000561715	NCT00005617_15_T1	GENE	1	1	1.5
NCT0000561716	NCT00005617_16_T0	PHENOTYPE	3	3	metastasis
NCT0000561716	NCT00005617_16_T1	GENE	0	0	III
NCT0000561716	NCT00005617_16_T2	GENE	2	2	nodal
NCT0000561716	NCT00005617_16_T3	PHENOTYPE	14	15	in-transit metastasis
NCT0000561716	NCT00005617_16_T4	TISSUE	7	8	lymph node
NCT0000561717	NCT00005617_17_T0	PHENOTYPE	3	3	metastasis
NCT0000561717	NCT00005617_17_T1	PHENOTYPE	8	8	metastasis
NCT0000561717	NCT00005617_17_T2	GENE	0	0	IV
NCT0000561720	NCT00005617_20_T0	GENE	1	1	9.0
NCT000056181	NCT00005618_1_T0	GENE	2	2	II
NCT000056181	NCT00005618_1_T1	COMPOUND	9	10	arsenic trioxide
NCT000056181	NCT00005618_1_T2	PHENOTYPE	18	21	refractory chronic myelogenous leukemia
NCT000056183	NCT00005618_3_T0	PHENOTYPE	13	13	chronic
NCT000056183	NCT00005618_3_T1	COMPOUND	5	6	arsenic trioxide
NCT000056183	NCT00005618_3_T2	PHENOTYPE	16	20	blastic phase chronic myelogenous leukemia
NCT000056185	NCT00005618_5_T0	PHENOTYPE	5	6	adverse experience
NCT000056186	NCT00005618_6_T0	PHENOTYPE	8	8	chronic
NCT000056186	NCT00005618_6_T1	PHENOTYPE	14	15	blastic phase
NCT000056187	NCT00005618_7_T0	GENE	22	22	3.5
NCT000056187	NCT00005618_7_T1	GENE	4	4	IV
NCT000056187	NCT00005618_7_T2	COMPOUND	2	3	arsenic trioxide
NCT000056188	NCT00005618_8_T0	PHENOTYPE	13	13	toxicity
NCT000056188	NCT00005618_8_T1	PHENOTYPE	15	16	disease progression
NCT0000561810	NCT00005618_10_T0	PHENOTYPE	12	12	chronic
NCT000056194	NCT00005619_4_T0	GENE	26	26	polymerase
NCT000056194	NCT00005619_4_T1	ORGAN	3	4	bone marrow
NCT000056194	NCT00005619_4_T2	ORGAN	13	14	bone marrow
NCT000056194	NCT00005619_4_T3	PHENOTYPE	18	20	minimal residual disease
NCT000056195	NCT00005619_5_T0	PHENOTYPE	8	9	disease relapse
NCT000056221	NCT00005622_1_T0	CELL	12	13	stem cells
NCT000056221	NCT00005622_1_T1	ORGAN	6	7	immune system
NCT000056222	NCT00005622_2_T0	CELL	39	39	platelets
NCT000056222	NCT00005622_2_T1	CELL	2	3	stem cells
NCT000056222	NCT00005622_2_T2	CELL	30	31	stem cells
NCT000056222	NCT00005622_2_T3	ORGAN	26	27	bone marrow
NCT000056222	NCT00005622_2_T4	CELL	32	34	red blood cells
NCT000056222	NCT00005622_2_T5	CELL	35	37	white blood cells
NCT000056223	NCT00005622_3_T0	GENE	3	3	II
NCT000056223	NCT00005622_3_T1	PHENOTYPE	18	18	leukemia
NCT000056223	NCT00005622_3_T2	PHENOTYPE	19	19	lymphoma
NCT000056223	NCT00005622_3_T3	ORGAN	12	12	transplant
NCT000056223	NCT00005622_3_T4	ORGAN	10	11	bone marrow
NCT000056223	NCT00005622_3_T5	PHENOTYPE	22	23	hematologic disorders
NCT000056225	NCT00005622_5_T0	COMPOUND	18	18	3
NCT000056225	NCT00005622_5_T1	COMPOUND	3	3	cyclophosphamide
NCT000056225	NCT00005622_5_T2	GENE	4	4	IV
NCT000056225	NCT00005622_5_T3	ORGAN	23	24	bone marrow
NCT000056227	NCT00005622_7_T0	COMPOUND	19	19	calcium
NCT000056227	NCT00005622_7_T1	COMPOUND	11	11	methotrexate
NCT000056227	NCT00005622_7_T2	COMPOUND	18	18	leucovorin
NCT000056231	NCT00005623_1_T0	COMPOUND	8	9	cyproterone acetate
NCT000056231	NCT00005623_1_T1	PHENOTYPE	14	15	hot flashes
NCT000056235	NCT00005623_5_T0	COMPOUND	8	9	cyproterone acetate
NCT000056235	NCT00005623_5_T1	COMPOUND	28	29	cyproterone acetate
NCT000056236	NCT00005623_6_T0	PHENOTYPE	0	2	Quality of life
NCT000056241	NCT00005624_1_T0	GENE	2	2	II
NCT000056241	NCT00005624_1_T1	PHENOTYPE	16	16	myeloma
NCT000056244	NCT00005624_4_T0	PHENOTYPE	10	10	myeloma
NCT0000562411	NCT00005624_11_T0	PHENOTYPE	10	10	toxicity
NCT0000562411	NCT00005624_11_T1	PHENOTYPE	6	7	disease progression
NCT000056250	NCT00005625_0_T0	PHENOTYPE	8	9	Metastatic Osteosarcoma
NCT000056252	NCT00005625_2_T0	GENE	2	2	II
NCT000056252	NCT00005625_2_T1	PHENOTYPE	18	19	metastatic osteosarcoma
NCT000056254	NCT00005625_4_T0	PHENOTYPE	12	13	metastatic osteosarcoma
NCT000056256	NCT00005625_6_T0	PHENOTYPE	3	3	toxicity
NCT000056258	NCT00005625_8_T0	GENE	4	4	IV
NCT000056259	NCT00005625_9_T0	PHENOTYPE	10	10	toxicity
NCT000056259	NCT00005625_9_T1	PHENOTYPE	12	13	disease progression
NCT0000562510	NCT00005625_10_T0	GENE	5	5	CR
NCT0000562510	NCT00005625_10_T1	GENE	14	14	CR
NCT0000562511	NCT00005625_11_T0	PHENOTYPE	7	8	disease progression
NCT0000562512	NCT00005625_12_T0	PHENOTYPE	7	8	disease progression
NCT000056261	NCT00005626_1_T0	GENE	2	2	II
NCT000056261	NCT00005626_1_T1	PHENOTYPE	22	22	leukemia
NCT000056261	NCT00005626_1_T2	COMPOUND	9	9	irinotecan
NCT000056261	NCT00005626_1_T3	PHENOTYPE	19	20	Hodgkin's lymphoma
NCT000056263	NCT00005626_3_T0	COMPOUND	27	27	irinotecan
NCT000056263	NCT00005626_3_T1	PHENOTYPE	23	24	prolymphocytic leukemia
NCT000056263	NCT00005626_3_T2	PHENOTYPE	15	16	Hodgkin's lymphoma
NCT000056263	NCT00005626_3_T3	PHENOTYPE	19	21	chronic lymphocytic leukemia
NCT000056265	NCT00005626_5_T0	PHENOTYPE	2	2	toxicity
NCT0000562610	NCT00005626_10_T0	COMPOUND	3	3	irinotecan
NCT0000562610	NCT00005626_10_T1	GENE	4	4	IV
NCT0000562611	NCT00005626_11_T0	PHENOTYPE	16	16	toxicity
NCT0000562611	NCT00005626_11_T1	PHENOTYPE	12	13	disease progression
NCT0000562615	NCT00005626_15_T0	PHENOTYPE	18	18	lymphoma
NCT0000562615	NCT00005626_15_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000562615	NCT00005626_15_T2	PHENOTYPE	16	17	high grade
NCT000056271	NCT00005627_1_T0	CELL	9	9	cells
NCT000056271	NCT00005627_1_T1	PHENOTYPE	8	8	tumor
NCT000056274	NCT00005627_4_T0	COMPOUND	8	8	docetaxel
NCT000056275	NCT00005627_5_T0	GENE	21	21	1.3
NCT000056275	NCT00005627_5_T1	COMPOUND	11	11	docetaxel
NCT000056275	NCT00005627_5_T2	GENE	9	9	1.5
NCT000056275	NCT00005627_5_T3	COMPOUND	3	3	estramustine
NCT000056275	NCT00005627_5_T4	GENE	12	12	IV
NCT000056276	NCT00005627_6_T0	GENE	4	4	IV
NCT000056277	NCT00005627_7_T0	PHENOTYPE	15	15	toxicity
NCT000056277	NCT00005627_7_T1	PHENOTYPE	17	18	disease progression
NCT000056278	NCT00005627_8_T0	COMPOUND	8	8	docetaxel
NCT000056278	NCT00005627_8_T1	GENE	2	2	3.5
NCT000056278	NCT00005627_8_T2	GENE	14	14	MTD
NCT000056279	NCT00005627_9_T0	PHENOTYPE	21	21	toxicity
NCT000056279	NCT00005627_9_T1	GENE	1	1	MTD
NCT000056281	NCT00005628_1_T0	GENE	2	2	II
NCT000056281	NCT00005628_1_T1	PHENOTYPE	16	16	recurrent
NCT000056281	NCT00005628_1_T2	PHENOTYPE	17	19	soft tissue sarcoma
NCT000056287	NCT00005628_7_T0	PHENOTYPE	2	2	tumor
NCT000056289	NCT00005628_9_T0	PHENOTYPE	21	21	toxicity
NCT000056289	NCT00005628_9_T1	PHENOTYPE	17	18	disease progression
NCT0000562810	NCT00005628_10_T0	PHENOTYPE	8	8	recurrence
NCT000056292	NCT00005629_2_T0	PHENOTYPE	16	17	liver cancer
NCT000056302	NCT00005630_2_T0	PHENOTYPE	17	17	peripheral
NCT000056302	NCT00005630_2_T1	CELL	11	11	cells
NCT000056302	NCT00005630_2_T2	GENE	4	4	sargramostim
NCT000056302	NCT00005630_2_T3	ORGAN	14	15	bone marrow
NCT000056305	NCT00005630_5_T0	COMPOUND	9	9	1_10
NCT000056305	NCT00005630_5_T1	GENE	4	4	GM-CSF
NCT000056305	NCT00005630_5_T2	GENE	3	3	sargramostim
NCT000056307	NCT00005630_7_T0	PHENOTYPE	16	16	toxicity
NCT000056307	NCT00005630_7_T1	PHENOTYPE	12	13	disease progression
NCT000056311	NCT00005631_1_T0	CELL	10	10	cells
NCT000056312	NCT00005631_2_T0	CELL	11	11	cells
NCT000056319	NCT00005631_9_T0	PHENOTYPE	8	8	peripheral
NCT000056319	NCT00005631_9_T1	CELL	10	11	progenitor cells
NCT0000563111	NCT00005631_11_T0	PHENOTYPE	4	4	toxicity
NCT0000563112	NCT00005631_12_T0	COMPOUND	6	6	ifosfamide
NCT0000563112	NCT00005631_12_T1	GENE	25	25	3.5
NCT0000563112	NCT00005631_12_T2	COMPOUND	18	18	etoposide
NCT0000563112	NCT00005631_12_T3	GENE	7	7	IV
NCT0000563112	NCT00005631_12_T4	GENE	13	13	IV
NCT0000563112	NCT00005631_12_T5	GENE	19	19	IV
NCT0000563114	NCT00005631_14_T0	COMPOUND	6	6	2
NCT0000563114	NCT00005631_14_T1	PHENOTYPE	8	8	initiation
NCT0000563114	NCT00005631_14_T2	GENE	3	3	IV
NCT0000563115	NCT00005631_15_T0	GENE	5	5	SC
NCT0000563115	NCT00005631_15_T1	GENE	2	2	filgrastim
NCT0000563115	NCT00005631_15_T2	GENE	3	3	G-CSF
NCT0000563116	NCT00005631_16_T0	GENE	15	15	SC
NCT0000563116	NCT00005631_16_T1	GENE	14	14	G-CSF
NCT0000563116	NCT00005631_16_T2	CELL	18	21	peripheral blood stem cells
NCT0000563117	NCT00005631_17_T0	CELL	11	11	cells
NCT0000563117	NCT00005631_17_T1	GENE	10	10	CD34
NCT0000563118	NCT00005631_18_T0	CELL	5	5	cells
NCT0000563118	NCT00005631_18_T1	GENE	4	4	CD34
NCT0000563118	NCT00005631_18_T2	ORGAN	11	12	bone marrow
NCT000056321	NCT00005632_1_T0	CELL	9	9	cells
NCT000056321	NCT00005632_1_T1	PHENOTYPE	8	8	tumor
NCT000056327	NCT00005632_7_T0	GENE	23	23	1.3
NCT000056327	NCT00005632_7_T1	GENE	4	4	MUC-1
NCT000056327	NCT00005632_7_T2	GENE	7	7	MUC-1
NCT000056327	NCT00005632_7_T3	GENE	11	11	limpet
NCT000056328	NCT00005632_8_T0	PHENOTYPE	12	13	disease progression
NCT000056330	NCT00005633_0_T0	PHENOTYPE	11	11	Melanoma
NCT000056330	NCT00005633_0_T1	GENE	7	7	III
NCT000056330	NCT00005633_0_T2	GENE	10	10	IV
NCT000056332	NCT00005633_2_T0	PHENOTYPE	20	21	stage III
NCT000056332	NCT00005633_2_T1	PHENOTYPE	23	25	stage IV melanoma
NCT000056334	NCT00005633_4_T0	GENE	21	21	HSP70
NCT000056334	NCT00005633_4_T1	GENE	14	14	BiP
NCT000056334	NCT00005633_4_T2	PHENOTYPE	37	37	melanoma
NCT000056334	NCT00005633_4_T3	PHENOTYPE	23	23	immunity
NCT000056334	NCT00005633_4_T4	GENE	6	6	tyrosinase
NCT000056334	NCT00005633_4_T5	GENE	25	25	tyrosinase
NCT000056334	NCT00005633_4_T6	GENE	36	36	IV
NCT000056334	NCT00005633_4_T7	GENE	9	9	gp100
NCT000056334	NCT00005633_4_T8	GENE	27	27	gp100
NCT000056334	NCT00005633_4_T9	GENE	11	11	fused
NCT000056334	NCT00005633_4_T10	GENE	13	13	OVA
NCT000056334	NCT00005633_4_T11	PHENOTYPE	33	34	stage III
NCT000056334	NCT00005633_4_T12	GENE	17	20	heat shock protein 70
NCT000056336	NCT00005633_6_T0	GENE	9	9	gp100
NCT000056336	NCT00005633_6_T1	GENE	7	7	tyrosinase
NCT000056339	NCT00005633_9_T0	GENE	12	12	gp100
NCT000056339	NCT00005633_9_T1	GENE	8	8	tyrosinase
NCT0000563310	NCT00005633_10_T0	PHENOTYPE	41	41	toxicity
NCT0000563310	NCT00005633_10_T1	GENE	17	17	HSP70
NCT0000563310	NCT00005633_10_T2	GENE	10	10	BiP
NCT0000563310	NCT00005633_10_T3	GENE	4	4	tyrosinase
NCT0000563310	NCT00005633_10_T4	GENE	7	7	fused
NCT0000563310	NCT00005633_10_T5	GENE	6	6	gp100
NCT0000563310	NCT00005633_10_T6	GENE	9	9	OVA
NCT0000563310	NCT00005633_10_T7	PHENOTYPE	37	38	disease progression
NCT0000563310	NCT00005633_10_T8	GENE	13	16	heat shock protein 70
NCT0000563311	NCT00005633_11_T0	GENE	10	10	gp100
NCT0000563311	NCT00005633_11_T1	GENE	8	8	tyrosinase
NCT0000563312	NCT00005633_12_T0	CELL	19	19	T-cell
NCT000056341	NCT00005634_1_T0	COMPOUND	9	9	suberoylanilide
NCT000056341	NCT00005634_1_T1	PHENOTYPE	21	22	solid tumors
NCT000056343	NCT00005634_3_T0	PHENOTYPE	14	14	malignancies
NCT000056343	NCT00005634_3_T1	COMPOUND	6	6	suberoylanilide
NCT000056347	NCT00005634_7_T0	CELL	12	12	cells
NCT000056347	NCT00005634_7_T1	TISSUE	8	8	tissues
NCT000056347	NCT00005634_7_T2	PHENOTYPE	11	11	tumor
NCT000056349	NCT00005634_9_T0	GENE	12	12	1.3
NCT000056349	NCT00005634_9_T1	COMPOUND	2	2	suberoylanilide
NCT000056349	NCT00005634_9_T2	GENE	6	6	IV
NCT0000563410	NCT00005634_10_T0	PHENOTYPE	16	16	toxicity
NCT0000563410	NCT00005634_10_T1	PHENOTYPE	12	13	disease progression
NCT0000563412	NCT00005634_12_T0	PHENOTYPE	18	18	toxicity
NCT0000563412	NCT00005634_12_T1	PHENOTYPE	36	36	toxicity
NCT0000563412	NCT00005634_12_T2	PHENOTYPE	13	13	experiences
NCT0000563412	NCT00005634_12_T3	GENE	1	1	MTD
NCT0000563412	NCT00005634_12_T4	PHENOTYPE	21	22	hemoglobin anemia
NCT0000563412	NCT00005634_12_T5	PHENOTYPE	39	40	hemoglobin anemia
NCT0000563413	NCT00005634_13_T0	GENE	13	13	MTD
NCT0000563414	NCT00005634_14_T0	PHENOTYPE	17	17	toxicity
NCT0000563414	NCT00005634_14_T1	GENE	1	1	MTD
NCT000056351	NCT00005635_1_T0	CELL	10	10	cells
NCT000056351	NCT00005635_1_T1	PHENOTYPE	9	9	tumor
NCT000056352	NCT00005635_2_T0	CELL	10	10	cells
NCT000056352	NCT00005635_2_T1	PHENOTYPE	9	9	tumor
NCT000056353	NCT00005635_3_T0	GENE	3	3	II
NCT000056353	NCT00005635_3_T1	COMPOUND	16	16	paclitaxel
NCT000056353	NCT00005635_3_T2	GENE	27	27	HER2
NCT000056353	NCT00005635_3_T3	PHENOTYPE	22	24	metastatic breast cancer
NCT000056355	NCT00005635_5_T0	COMPOUND	10	10	paclitaxel
NCT000056355	NCT00005635_5_T1	GENE	14	14	HER2
NCT000056355	NCT00005635_5_T2	PHENOTYPE	16	18	metastatic breast cancer
NCT000056359	NCT00005635_9_T0	COMPOUND	6	6	paclitaxel
NCT000056359	NCT00005635_9_T1	PHENOTYPE	2	2	pharmacokinetics
NCT0000563512	NCT00005635_12_T0	COMPOUND	14	14	paclitaxel
NCT0000563512	NCT00005635_12_T1	GENE	8	8	IV
NCT0000563512	NCT00005635_12_T2	GENE	15	15	IV
NCT0000563513	NCT00005635_13_T0	PHENOTYPE	17	17	toxicity
NCT0000563513	NCT00005635_13_T1	PHENOTYPE	13	14	disease progression
NCT0000563516	NCT00005635_16_T0	PHENOTYPE	16	16	toxicity
NCT0000563516	NCT00005635_16_T1	GENE	3	3	SC
NCT0000563516	NCT00005635_16_T2	PHENOTYPE	12	13	disease progression
NCT000056361	NCT00005636_1_T0	COMPOUND	13	13	pemetrexed
NCT000056361	NCT00005636_1_T1	COMPOUND	14	14	disodium
NCT000056361	NCT00005636_1_T2	COMPOUND	6	6	cisplatin
NCT000056361	NCT00005636_1_T3	PHENOTYPE	16	20	malignant mesothelioma of the pleura
NCT000056362	NCT00005636_2_T0	COMPOUND	14	14	pemetrexed
NCT000056362	NCT00005636_2_T1	GENE	3	3	III
NCT000056362	NCT00005636_2_T2	COMPOUND	15	15	disodium
NCT000056362	NCT00005636_2_T3	COMPOUND	10	10	cisplatin
NCT000056362	NCT00005636_2_T4	PHENOTYPE	21	25	malignant mesothelioma of the pleura
NCT000056364	NCT00005636_4_T0	COMPOUND	11	11	cisplatin
NCT000056364	NCT00005636_4_T1	PHENOTYPE	5	7	malignant pleural mesothelioma
NCT000056366	NCT00005636_6_T0	PHENOTYPE	6	6	progression
NCT000056368	NCT00005636_8_T0	PHENOTYPE	1	1	tumor
NCT0000563612	NCT00005636_12_T0	PHENOTYPE	1	1	toxicity
NCT0000563614	NCT00005636_14_T0	PHENOTYPE	1	1	pharmacokinetics
NCT0000563620	NCT00005636_20_T0	PHENOTYPE	18	18	toxicity
NCT0000563620	NCT00005636_20_T1	PHENOTYPE	14	15	disease progression
NCT000056371	NCT00005637_1_T0	CELL	10	10	cells
NCT000056371	NCT00005637_1_T1	PHENOTYPE	9	9	tumor
NCT000056372	NCT00005637_2_T0	PHENOTYPE	19	20	malignant glioma
NCT000056374	NCT00005637_4_T0	COMPOUND	7	7	temozolomide
NCT000056375	NCT00005637_5_T0	COMPOUND	3	3	temozolomide
NCT000056375	NCT00005637_5_T1	COMPOUND	21	21	temozolomide
NCT000056375	NCT00005637_5_T2	GENE	8	8	1.28
NCT000056375	NCT00005637_5_T3	GENE	13	13	1.3
NCT000056375	NCT00005637_5_T4	GENE	11	11	IV
NCT000056376	NCT00005637_6_T0	PHENOTYPE	15	15	toxicity
NCT000056376	NCT00005637_6_T1	PHENOTYPE	17	18	disease progression
NCT000056377	NCT00005637_7_T0	COMPOUND	8	8	temozolomide
NCT000056377	NCT00005637_7_T1	GENE	14	14	MTD
NCT000056378	NCT00005637_8_T0	PHENOTYPE	17	17	toxicity
NCT000056378	NCT00005637_8_T1	GENE	1	1	MTD
NCT0000563710	NCT00005637_10_T0	GENE	14	14	1.2
NCT000056381	NCT00005638_1_T0	CELL	8	8	cells
NCT000056381	NCT00005638_1_T1	PHENOTYPE	7	7	tumor
NCT000056382	NCT00005638_2_T0	CELL	9	9	cells
NCT000056382	NCT00005638_2_T1	PHENOTYPE	8	8	tumor
NCT000056383	NCT00005638_3_T0	PHENOTYPE	18	19	advanced cancer
NCT000056383	NCT00005638_3_T1	PHENOTYPE	19	22	cancer of the esophagus
NCT000056385	NCT00005638_5_T0	COMPOUND	8	8	irinotecan
NCT000056386	NCT00005638_6_T0	COMPOUND	12	12	irinotecan
NCT000056386	NCT00005638_6_T1	COMPOUND	5	5	cisplatin
NCT000056386	NCT00005638_6_T2	GENE	6	6	IV
NCT000056386	NCT00005638_6_T3	GENE	13	13	IV
NCT000056388	NCT00005638_8_T0	COMPOUND	4	4	irinotecan
NCT000056388	NCT00005638_8_T1	COMPOUND	2	2	cisplatin
NCT000056389	NCT00005638_9_T0	COMPOUND	8	8	irinotecan
NCT000056389	NCT00005638_9_T1	GENE	14	14	MTD
NCT0000563810	NCT00005638_10_T0	PHENOTYPE	18	18	toxicities
NCT0000563810	NCT00005638_10_T1	GENE	1	1	MTD
NCT000056391	NCT00005639_1_T0	CELL	9	9	cells
NCT000056391	NCT00005639_1_T1	PHENOTYPE	8	8	tumor
NCT000056392	NCT00005639_2_T0	PHENOTYPE	24	25	solid tumors
NCT000056395	NCT00005639_5_T0	COMPOUND	8	8	sodium
NCT000056395	NCT00005639_5_T1	GENE	13	13	1.7
NCT000056395	NCT00005639_5_T2	GENE	10	10	IV
NCT000056396	NCT00005639_6_T0	PHENOTYPE	13	13	toxicity
NCT000056396	NCT00005639_6_T1	PHENOTYPE	9	10	disease progression
NCT000056397	NCT00005639_7_T0	GENE	20	20	MTD
NCT000056398	NCT00005639_8_T0	PHENOTYPE	18	18	toxicities
NCT000056398	NCT00005639_8_T1	GENE	1	1	MTD
NCT000056409	NCT00005640_9_T0	GENE	17	17	sentinel
NCT000056409	NCT00005640_9_T1	ORGAN	18	18	lymph
NCT000056409	NCT00005640_9_T2	GENE	11	11	gamma
NCT0000564010	NCT00005640_10_T0	PHENOTYPE	8	9	primary tumor
NCT000056412	NCT00005641_2_T0	CELL	7	7	cells
NCT000056412	NCT00005641_2_T1	CELL	2	3	T cells
NCT000056417	NCT00005641_7_T0	PHENOTYPE	4	5	graft failure
NCT000056419	NCT00005641_9_T0	PHENOTYPE	2	2	relapse
NCT0000564111	NCT00005641_11_T0	PHENOTYPE	6	6	GVHD
NCT0000564111	NCT00005641_11_T1	GENE	10	10	globulin
NCT0000564111	NCT00005641_11_T2	GENE	12	12	IV
NCT0000564111	NCT00005641_11_T3	COMPOUND	20	20	1
NCT0000564111	NCT00005641_11_T4	COMPOUND	18	18	2
NCT0000564111	NCT00005641_11_T5	CELL	9	9	thymocyte
NCT0000564111	NCT00005641_11_T6	PHENOTYPE	2	5	graft vs host disease
NCT0000564115	NCT00005641_15_T0	GENE	10	10	MTX
NCT0000564115	NCT00005641_15_T1	COMPOUND	9	9	methotrexate
NCT0000564115	NCT00005641_15_T2	GENE	8	8	IT
NCT0000564115	NCT00005641_15_T3	PHENOTYPE	4	5	acute leukemia
NCT0000564116	NCT00005641_16_T0	GENE	5	5	MTX
NCT0000564116	NCT00005641_16_T1	GENE	16	16	MTX
NCT0000564116	NCT00005641_16_T2	COMPOUND	21	21	calcium
NCT0000564116	NCT00005641_16_T3	GENE	4	4	IT
NCT0000564116	NCT00005641_16_T4	GENE	15	15	IT
NCT0000564116	NCT00005641_16_T5	COMPOUND	20	20	leucovorin
NCT0000564118	NCT00005641_18_T0	COMPOUND	24	24	cyclosporine
NCT0000564118	NCT00005641_18_T1	COMPOUND	33	33	1
NCT0000564118	NCT00005641_18_T2	COMPOUND	8	8	methylprednisolone
NCT0000564118	NCT00005641_18_T3	PHENOTYPE	4	4	GVHD
NCT0000564118	NCT00005641_18_T4	GENE	9	9	IV
NCT0000564118	NCT00005641_18_T5	GENE	25	25	IV
NCT000056420	NCT00005642_0_T0	PHENOTYPE	6	7	Solid Tumors
NCT000056422	NCT00005642_2_T0	PHENOTYPE	16	17	solid tumors
NCT000056424	NCT00005642_4_T0	GENE	3	3	IV
NCT000056425	NCT00005642_5_T0	PHENOTYPE	10	10	toxicity
NCT000056425	NCT00005642_5_T1	PHENOTYPE	6	7	disease progression
NCT000056427	NCT00005642_7_T0	PHENOTYPE	11	12	solid tumors
NCT000056429	NCT00005642_9_T0	ORGAN	6	6	plasma
NCT0000564219	NCT00005642_19_T0	GENE	3	3	IV
NCT0000564220	NCT00005642_20_T0	PHENOTYPE	10	10	toxicity
NCT0000564220	NCT00005642_20_T1	PHENOTYPE	6	7	disease progression
NCT0000564222	NCT00005642_22_T0	PHENOTYPE	16	16	toxicity
NCT0000564222	NCT00005642_22_T1	PHENOTYPE	14	15	grade 1
NCT000056433	NCT00005643_3_T0	COMPOUND	6	6	HCl
NCT000056433	NCT00005643_3_T1	COMPOUND	5	5	doxorubicin
NCT000056433	NCT00005643_3_T2	PHENOTYPE	11	11	recurrent
NCT000056433	NCT00005643_3_T3	PHENOTYPE	14	15	uterine sarcoma
NCT000056435	NCT00005643_5_T0	PHENOTYPE	6	6	toxicity
NCT000056436	NCT00005643_6_T0	COMPOUND	4	4	HCl
NCT000056436	NCT00005643_6_T1	COMPOUND	3	3	doxorubicin
NCT000056436	NCT00005643_6_T2	GENE	6	6	IV
NCT000056437	NCT00005643_7_T0	PHENOTYPE	10	10	toxicity
NCT000056437	NCT00005643_7_T1	PHENOTYPE	12	13	disease progression
NCT000056441	NCT00005644_1_T0	CELL	9	9	cells
NCT000056442	NCT00005644_2_T0	GENE	2	2	II
NCT000056442	NCT00005644_2_T1	ORGAN	23	23	kidney
NCT000056442	NCT00005644_2_T2	TISSUE	20	20	urothelium
NCT000056442	NCT00005644_2_T3	PHENOTYPE	16	17	advanced cancer
NCT000056444	NCT00005644_4_T0	COMPOUND	3	3	paclitaxel
NCT000056444	NCT00005644_4_T1	COMPOUND	11	11	gemcitabine
NCT000056444	NCT00005644_4_T2	GENE	4	4	IV
NCT000056444	NCT00005644_4_T3	GENE	12	12	IV
NCT000056445	NCT00005644_5_T0	PHENOTYPE	16	16	toxicity
NCT000056445	NCT00005644_5_T1	PHENOTYPE	18	19	disease progression
NCT000056451	NCT00005645_1_T0	GENE	2	2	II
NCT000056451	NCT00005645_1_T1	GENE	23	23	has
NCT000056451	NCT00005645_1_T2	PHENOTYPE	15	16	stage III
NCT000056451	NCT00005645_1_T3	PHENOTYPE	18	21	stage IV ovarian cancer
NCT000056453	NCT00005645_3_T0	GENE	11	11	IV
NCT000056453	NCT00005645_3_T1	PHENOTYPE	8	9	stage III
NCT000056453	NCT00005645_3_T2	PHENOTYPE	12	14	ovarian epithelial cancer
NCT000056455	NCT00005645_5_T0	GENE	11	11	CA125
NCT000056457	NCT00005645_7_T0	PHENOTYPE	9	9	toxicity
NCT000056457	NCT00005645_7_T1	PHENOTYPE	4	5	tumor progression
NCT0000564510	NCT00005645_10_T0	PHENOTYPE	19	19	toxicity
NCT0000564510	NCT00005645_10_T1	PHENOTYPE	15	16	disease progression
NCT000056466	NCT00005646_6_T0	PHENOTYPE	4	4	progression
NCT000056468	NCT00005646_8_T0	PHENOTYPE	2	2	toxicity
NCT0000564610	NCT00005646_10_T0	COMPOUND	2	2	paclitaxel
NCT0000564610	NCT00005646_10_T1	GENE	3	3	IV
NCT0000564611	NCT00005646_11_T0	PHENOTYPE	16	16	toxicity
NCT0000564611	NCT00005646_11_T1	PHENOTYPE	12	13	disease progression
NCT000056471	NCT00005647_1_T0	CELL	10	10	cells
NCT000056471	NCT00005647_1_T1	PHENOTYPE	9	9	tumor
NCT000056472	NCT00005647_2_T0	CELL	8	8	cells
NCT000056473	NCT00005647_3_T0	COMPOUND	11	11	paclitaxel
NCT000056473	NCT00005647_3_T1	PHENOTYPE	17	17	recurrent
NCT000056473	NCT00005647_3_T2	PHENOTYPE	21	22	metastatic cancer
NCT000056473	NCT00005647_3_T3	PHENOTYPE	22	26	cancer of the head and
NCT000056477	NCT00005647_7_T0	COMPOUND	2	2	paclitaxel
NCT000056477	NCT00005647_7_T1	GENE	3	3	IV
NCT000056477	NCT00005647_7_T2	GENE	12	12	IV
NCT000056478	NCT00005647_8_T0	PHENOTYPE	11	11	toxicity
NCT000056478	NCT00005647_8_T1	PHENOTYPE	7	8	disease progression
NCT000056479	NCT00005647_9_T0	COMPOUND	8	8	paclitaxel
NCT000056479	NCT00005647_9_T1	GENE	16	16	MTD
NCT0000564710	NCT00005647_10_T0	PHENOTYPE	20	20	toxicities
NCT0000564710	NCT00005647_10_T1	GENE	1	1	MTD
NCT000056483	NCT00005648_3_T0	COMPOUND	16	16	gemcitabine
NCT000056483	NCT00005648_3_T1	PHENOTYPE	24	25	pancreatic cancer
NCT000056484	NCT00005648_4_T0	PHENOTYPE	17	17	toxicity
NCT000056484	NCT00005648_4_T1	COMPOUND	7	7	gemcitabine
NCT000056484	NCT00005648_4_T2	PHENOTYPE	13	14	disease progression
NCT000056488	NCT00005648_8_T0	PHENOTYPE	29	29	toxicity
NCT000056488	NCT00005648_8_T1	COMPOUND	2	2	gemcitabine
NCT000056488	NCT00005648_8_T2	COMPOUND	4	4	tipifarnib
NCT000056488	NCT00005648_8_T3	PHENOTYPE	25	26	disease progression
NCT000056491	NCT00005649_1_T0	CELL	9	9	cells
NCT000056491	NCT00005649_1_T1	PHENOTYPE	8	8	tumor
NCT000056492	NCT00005649_2_T0	GENE	2	2	II
NCT000056492	NCT00005649_2_T1	COMPOUND	11	11	capecitabine
NCT000056492	NCT00005649_2_T2	COMPOUND	9	9	paclitaxel
NCT000056492	NCT00005649_2_T3	PHENOTYPE	17	19	metastatic breast cancer
NCT000056494	NCT00005649_4_T0	COMPOUND	11	11	paclitaxel
NCT000056494	NCT00005649_4_T1	COMPOUND	13	13	capecitabine
NCT000056494	NCT00005649_4_T2	PHENOTYPE	23	25	metastatic breast cancer
NCT000056496	NCT00005649_6_T0	COMPOUND	11	11	capecitabine
NCT000056496	NCT00005649_6_T1	COMPOUND	2	2	paclitaxel
NCT000056496	NCT00005649_6_T2	GENE	3	3	IV
NCT000056497	NCT00005649_7_T0	PHENOTYPE	13	13	toxicity
NCT000056497	NCT00005649_7_T1	PHENOTYPE	9	10	disease progression
NCT000056501	NCT00005650_1_T0	PHENOTYPE	7	9	primary ciliary dyskinesia
NCT000056506	NCT00005650_6_T0	PHENOTYPE	10	10	mutation
NCT000056521	NCT00005652_1_T0	PHENOTYPE	12	14	immune thrombocytopenic purpura
NCT000056523	NCT00005652_3_T0	PHENOTYPE	2	2	toxicity
NCT000056545	NCT00005654_5_T0	COMPOUND	11	12	clomiphene citrate
NCT000056552	NCT00005655_2_T0	GENE	0	0	IL-2
NCT000056552	NCT00005655_2_T1	PHENOTYPE	7	7	melanoma
NCT000056552	NCT00005655_2_T2	PHENOTYPE	9	10	kidney cancer
NCT000056555	NCT00005655_5_T0	ORGAN	11	11	kidney
NCT000056555	NCT00005655_5_T1	PHENOTYPE	10	10	cancers
NCT000056555	NCT00005655_5_T2	PHENOTYPE	14	14	sarcomas
NCT000056557	NCT00005655_7_T0	GENE	10	10	MRI
NCT000056557	NCT00005655_7_T1	ORGAN	0	1	Bone marrow
NCT000056559	NCT00005655_9_T0	GENE	7	7	IL-2
NCT000056559	NCT00005655_9_T1	GENE	9	9	IL-12
NCT0000565511	NCT00005655_11_T0	GENE	12	12	IL-12
NCT0000565516	NCT00005655_16_T0	PHENOTYPE	8	8	tumor
NCT0000565516	NCT00005655_16_T1	GENE	32	32	stops
NCT0000565517	NCT00005655_17_T0	PHENOTYPE	1	1	tumor
NCT0000565518	NCT00005655_18_T0	ORGAN	14	15	immune system
NCT0000565521	NCT00005655_21_T0	PHENOTYPE	1	1	tumor
NCT0000565521	NCT00005655_21_T1	PHENOTYPE	2	2	regression
NCT0000565522	NCT00005655_22_T0	GENE	23	23	IL-2
NCT0000565522	NCT00005655_22_T1	GENE	13	13	IL-12
NCT0000565522	NCT00005655_22_T2	PHENOTYPE	20	20	pulse
NCT0000565522	NCT00005655_22_T3	PHENOTYPE	9	9	toxicities
NCT0000565522	NCT00005655_22_T4	PHENOTYPE	31	32	solid tumors
NCT0000565523	NCT00005655_23_T0	PHENOTYPE	3	3	pharmacokinetics
NCT0000565523	NCT00005655_23_T1	PHENOTYPE	16	17	solid tumors
NCT0000565524	NCT00005655_24_T0	PHENOTYPE	20	20	tumor
NCT0000565524	NCT00005655_24_T1	PHENOTYPE	13	13	neovascularization
NCT0000565524	NCT00005655_24_T2	PHENOTYPE	36	37	solid tumors
NCT0000565524	NCT00005655_24_T3	BIOLOGICAL_PROCESS	15	16	gene expression
NCT0000565526	NCT00005655_26_T0	PHENOTYPE	4	5	solid tumors
NCT0000565529	NCT00005655_29_T0	COMPOUND	17	17	thallium
NCT0000565530	NCT00005655_30_T0	GENE	4	4	IL-12
NCT0000565531	NCT00005655_31_T0	COMPOUND	2	3	I dose
NCT0000565533	NCT00005655_33_T0	GENE	0	0	IL-2
NCT0000565533	NCT00005655_33_T1	GENE	20	20	IL-12
NCT0000565536	NCT00005655_36_T0	PHENOTYPE	0	0	Tumor
NCT0000565539	NCT00005655_39_T0	PHENOTYPE	14	15	evaluable disease
NCT0000565539	NCT00005655_39_T1	PHENOTYPE	5	6	hematologic malignancy
NCT0000565540	NCT00005655_40_T0	PHENOTYPE	8	8	carcinomas
NCT0000565540	NCT00005655_40_T1	PHENOTYPE	12	12	sarcomas
NCT0000565540	NCT00005655_40_T2	PHENOTYPE	2	3	solid tumors
NCT0000565545	NCT00005655_45_T0	PHENOTYPE	10	11	systemic illness
NCT0000565545	NCT00005655_45_T1	PHENOTYPE	5	6	acute infection
NCT0000565546	NCT00005655_46_T0	PHENOTYPE	20	20	toxicity
NCT0000565546	NCT00005655_46_T1	PHENOTYPE	4	5	hepatitis B
NCT0000565550	NCT00005655_50_T0	PHENOTYPE	15	15	initiation
NCT0000565552	NCT00005655_52_T0	COMPOUND	17	17	thallium
NCT0000565555	NCT00005655_55_T0	PHENOTYPE	5	6	brain metastases
NCT0000565557	NCT00005655_57_T0	PHENOTYPE	4	5	pleural effusion
NCT0000565558	NCT00005655_58_T0	PHENOTYPE	2	3	malignant hyperthermia
NCT0000565559	NCT00005655_59_T0	PHENOTYPE	4	5	autoimmune disease
NCT0000565561	NCT00005655_61_T0	PHENOTYPE	8	9	bowel obstruction
NCT0000565568	NCT00005655_68_T0	PHENOTYPE	5	5	leukemia
NCT0000565568	NCT00005655_68_T1	PHENOTYPE	7	7	lymphoma
NCT0000565568	NCT00005655_68_T2	PHENOTYPE	2	3	hematologic malignancies
NCT0000565569	NCT00005655_69_T0	ORGAN	2	3	bone marrow
NCT0000565570	NCT00005655_70_T0	PHENOTYPE	23	24	disease progression
NCT000056571	NCT00005657_1_T0	PHENOTYPE	15	15	progression
NCT000056572	NCT00005657_2_T0	COMPOUND	8	8	HCV
NCT000056573	NCT00005657_3_T0	PHENOTYPE	30	30	leprosy
NCT000056573	NCT00005657_3_T1	PHENOTYPE	29	29	tuberculosis
NCT000056573	NCT00005657_3_T2	PHENOTYPE	28	28	malaria
NCT000056573	NCT00005657_3_T3	PHENOTYPE	26	26	infections
NCT000056573	NCT00005657_3_T4	PHENOTYPE	33	34	hepatitis B
NCT000056573	NCT00005657_3_T5	BIOLOGICAL_PROCESS	9	10	immune response
NCT000056574	NCT00005657_4_T0	PHENOTYPE	7	7	peripheral
NCT000056574	NCT00005657_4_T1	PHENOTYPE	53	53	sequelae
NCT000056574	NCT00005657_4_T2	CELL	10	10	cells
NCT000056574	NCT00005657_4_T3	COMPOUND	21	21	HCV
NCT000056574	NCT00005657_4_T4	COMPOUND	55	55	HCV
NCT000056574	NCT00005657_4_T5	PHENOTYPE	35	36	disease progression
NCT000056575	NCT00005657_5_T0	PHENOTYPE	11	12	liver diseases
NCT000056578	NCT00005657_8_T0	PHENOTYPE	15	15	progression
NCT000056579	NCT00005657_9_T0	COMPOUND	8	8	HCV
NCT0000565710	NCT00005657_10_T0	PHENOTYPE	30	30	leprosy
NCT0000565710	NCT00005657_10_T1	PHENOTYPE	29	29	tuberculosis
NCT0000565710	NCT00005657_10_T2	PHENOTYPE	28	28	malaria
NCT0000565710	NCT00005657_10_T3	PHENOTYPE	26	26	infections
NCT0000565710	NCT00005657_10_T4	PHENOTYPE	33	34	hepatitis B
NCT0000565710	NCT00005657_10_T5	BIOLOGICAL_PROCESS	9	10	immune response
NCT0000565711	NCT00005657_11_T0	PHENOTYPE	7	7	peripheral
NCT0000565711	NCT00005657_11_T1	PHENOTYPE	53	53	sequelae
NCT0000565711	NCT00005657_11_T2	CELL	10	10	cells
NCT0000565711	NCT00005657_11_T3	COMPOUND	21	21	HCV
NCT0000565711	NCT00005657_11_T4	COMPOUND	55	55	HCV
NCT0000565711	NCT00005657_11_T5	PHENOTYPE	35	36	disease progression
NCT0000565712	NCT00005657_12_T0	PHENOTYPE	11	12	liver diseases
NCT0000565717	NCT00005657_17_T0	PHENOTYPE	10	10	vasculitis
NCT0000565717	NCT00005657_17_T1	COMPOUND	6	6	HCV
NCT0000565717	NCT00005657_17_T2	PHENOTYPE	9	9	glomerulonephritis
NCT0000565717	NCT00005657_17_T3	PHENOTYPE	8	8	cryoglobulinemia
NCT0000565718	NCT00005657_18_T0	PHENOTYPE	2	3	rapidly progressive
NCT0000565718	NCT00005657_18_T1	PHENOTYPE	5	6	liver disease
NCT0000565718	NCT00005657_18_T2	PHENOTYPE	8	9	hepatocellular carcinoma
NCT0000565720	NCT00005657_20_T0	PHENOTYPE	7	7	infections
NCT0000565720	NCT00005657_20_T1	COMPOUND	6	6	HCV
NCT0000565721	NCT00005657_21_T0	GENE	5	5	twins
NCT0000565721	NCT00005657_21_T1	COMPOUND	0	0	HCV
NCT0000565723	NCT00005657_23_T0	GENE	6	6	Hct
NCT0000565724	NCT00005657_24_T0	COMPOUND	2	2	HCV
NCT000056582	NCT00005658_2_T0	PHENOTYPE	11	11	symptoms
NCT000056582	NCT00005658_2_T1	PHENOTYPE	6	6	schizophrenia
NCT000056582	NCT00005658_2_T2	PHENOTYPE	8	9	schizoaffective disorder
NCT000056585	NCT00005658_5_T0	GENE	27	27	MRI
NCT000056586	NCT00005658_6_T0	GENE	2	2	MRI
NCT000056587	NCT00005658_7_T0	PHENOTYPE	14	14	schizophrenia
NCT000056588	NCT00005658_8_T0	COMPOUND	8	8	glycine
NCT0000565811	NCT00005658_11_T0	PHENOTYPE	3	3	pulse
NCT0000565816	NCT00005658_16_T0	COMPOUND	8	8	glycine
NCT0000565820	NCT00005658_20_T0	PHENOTYPE	12	12	symptoms
NCT0000565820	NCT00005658_20_T1	COMPOUND	7	7	glycine
NCT0000565820	NCT00005658_20_T2	PHENOTYPE	14	14	schizophrenia
NCT0000565821	NCT00005658_21_T0	COMPOUND	14	14	glycine
NCT0000565821	NCT00005658_21_T1	PHENOTYPE	23	24	psychotic disorders
NCT0000565822	NCT00005658_22_T0	PHENOTYPE	10	10	recruitment
NCT0000565822	NCT00005658_22_T1	PHENOTYPE	24	26	early onset schizophrenia
NCT0000565825	NCT00005658_25_T0	PHENOTYPE	4	4	symptoms
NCT0000565825	NCT00005658_25_T1	COMPOUND	16	16	lithium
NCT0000565829	NCT00005658_29_T0	PHENOTYPE	9	9	schizophrenia
NCT0000565829	NCT00005658_29_T1	PHENOTYPE	21	21	psychosis
NCT0000565829	NCT00005658_29_T2	PHENOTYPE	13	14	psychotic disorder
NCT0000565830	NCT00005658_30_T0	GENE	3	3	had
NCT0000565831	NCT00005658_31_T0	COMPOUND	14	14	olanzapine
NCT0000565831	NCT00005658_31_T1	COMPOUND	12	12	clozapine
NCT0000565833	NCT00005658_33_T0	PHENOTYPE	11	12	drug abuse
NCT000056606	NCT00005660_6_T0	PHENOTYPE	8	9	xeroderma pigmentosum
NCT000056606	NCT00005660_6_T1	PHENOTYPE	4	5	skin cancers
NCT000056607	NCT00005660_7_T0	ORGAN	17	17	liver
NCT000056608	NCT00005660_8_T0	PHENOTYPE	5	5	hypertriglyceridemia
NCT000056609	NCT00005660_9_T0	COMPOUND	5	5	creatinine
NCT0000566012	NCT00005660_12_T0	COMPOUND	6	6	etretinate
NCT0000566012	NCT00005660_12_T1	PHENOTYPE	21	22	skin disease
NCT000056632	NCT00005663_2_T0	PHENOTYPE	27	27	symptoms
NCT000056632	NCT00005663_2_T1	PHENOTYPE	32	32	recurrence
NCT000056632	NCT00005663_2_T2	PHENOTYPE	31	31	HSV
NCT000056634	NCT00005663_4_T0	PHENOTYPE	3	3	recurrence
NCT000056634	NCT00005663_4_T1	PHENOTYPE	21	21	recurrence
NCT000056638	NCT00005663_8_T0	PHENOTYPE	7	7	recurrence
NCT000056638	NCT00005663_8_T1	PHENOTYPE	6	6	HSV
NCT000056642	NCT00005664_2_T0	GENE	8	8	saliva
NCT000056642	NCT00005664_2_T1	ORGAN	22	22	ovaries
NCT000056642	NCT00005664_2_T2	ORGAN	24	24	testes
NCT000056642	NCT00005664_2_T3	ORGAN	20	21	thyroid gland
NCT000056642	NCT00005664_2_T4	ORGAN	25	26	adrenal glands
NCT000056645	NCT00005664_5_T0	PHENOTYPE	8	9	hereditary disorder
NCT000056647	NCT00005664_7_T0	GENE	6	6	saliva
NCT000056648	NCT00005664_8_T0	PHENOTYPE	4	5	endocrine disorders
NCT000056654	NCT00005665_4_T0	GENE	12	12	insulin
NCT000056657	NCT00005665_7_T0	GENE	3	3	II
NCT000056657	NCT00005665_7_T1	PHENOTYPE	13	13	ingested
NCT000056657	NCT00005665_7_T2	GENE	17	17	IFN-a
NCT000056659	NCT00005665_9_T0	GENE	9	9	C-peptide
NCT000056662	NCT00005666_2_T0	CELL	28	28	cells
NCT000056662	NCT00005666_2_T1	PHENOTYPE	27	27	tumor
NCT000056662	NCT00005666_2_T2	ORGAN	36	36	lungs
NCT000056663	NCT00005666_3_T0	PHENOTYPE	32	33	lung cancer
NCT000056664	NCT00005666_4_T0	COMPOUND	22	22	glucose
NCT000056664	NCT00005666_4_T1	TISSUE	11	11	tissues
NCT000056664	NCT00005666_4_T2	TISSUE	16	16	tissues
NCT000056667	NCT00005666_7_T0	PHENOTYPE	20	21	lung cancer
NCT000056668	NCT00005666_8_T0	TISSUE	11	11	tissues
NCT000056672	NCT00005667_2_T0	ORGAN	2	2	liver
NCT000056673	NCT00005667_3_T0	ORGAN	11	11	liver
NCT000056674	NCT00005667_4_T0	ORGAN	17	17	liver
NCT000056674	NCT00005667_4_T1	COMPOUND	11	11	vancomycin
NCT000056674	NCT00005667_4_T2	PHENOTYPE	12	12	resistant
NCT000056676	NCT00005667_6_T0	ORGAN	10	10	liver
NCT000056678	NCT00005667_8_T0	ORGAN	29	29	Transplant
NCT0000566712	NCT00005667_12_T0	ORGAN	23	23	liver
NCT0000566713	NCT00005667_13_T0	ORGAN	4	4	liver
NCT0000566714	NCT00005667_14_T0	PHENOTYPE	19	19	complications
NCT0000566716	NCT00005667_16_T0	ORGAN	9	9	transplant
NCT000056680	NCT00005668_0_T0	PHENOTYPE	19	19	Aspergilloma
NCT000056682	NCT00005668_2_T0	PHENOTYPE	0	0	Aspergilloma
NCT000056682	NCT00005668_2_T1	ORGAN	7	7	lungs
NCT000056693	NCT00005669_3_T0	PHENOTYPE	0	0	Overweight
NCT000056696	NCT00005669_6_T0	COMPOUND	9	9	metformin
NCT000056697	NCT00005669_7_T0	COMPOUND	15	15	metformin
NCT000056698	NCT00005669_8_T0	GENE	37	37	MRI
NCT000056698	NCT00005669_8_T1	GENE	5	5	2.3
NCT000056698	NCT00005669_8_T2	PHENOTYPE	56	57	metabolic rate
NCT000056698	NCT00005669_8_T3	PHENOTYPE	48	49	insulin resistance
NCT000056698	NCT00005669_8_T4	TISSUE	30	31	body fat
NCT000056698	NCT00005669_8_T5	TISSUE	41	42	body fat
NCT0000566910	NCT00005669_10_T0	GENE	21	21	insulin
NCT0000566911	NCT00005669_11_T0	BIOLOGICAL_PROCESS	37	37	eating
NCT0000566911	NCT00005669_11_T1	PHENOTYPE	13	13	hunger
NCT0000566911	NCT00005669_11_T2	PHENOTYPE	42	42	hunger
NCT0000566912	NCT00005669_12_T0	COMPOUND	18	18	hydrogen
NCT0000566912	NCT00005669_12_T1	COMPOUND	20	20	oxygen
NCT0000566912	NCT00005669_12_T2	PHENOTYPE	6	7	drinking heavy
NCT0000566913	NCT00005669_13_T0	BIOLOGICAL_PROCESS	10	10	drinking
NCT0000566914	NCT00005669_14_T0	PHENOTYPE	17	17	hunger
NCT0000566916	NCT00005669_16_T0	COMPOUND	10	10	metformin
NCT0000566919	NCT00005669_19_T0	COMPOUND	12	12	metformin
NCT0000566919	NCT00005669_19_T1	COMPOUND	20	20	metformin
NCT0000566920	NCT00005669_20_T0	COMPOUND	8	8	metformin
NCT0000566924	NCT00005669_24_T0	PHENOTYPE	1	1	obesity
NCT0000566927	NCT00005669_27_T0	PHENOTYPE	10	10	obesity
NCT0000566927	NCT00005669_27_T1	PHENOTYPE	12	13	insulin resistance
NCT0000566930	NCT00005669_30_T0	COMPOUND	4	4	metformin
NCT0000566930	NCT00005669_30_T1	GENE	7	7	has
NCT0000566930	NCT00005669_30_T2	PHENOTYPE	5	6	weight loss
NCT0000566934	NCT00005669_34_T0	COMPOUND	6	6	metformin
NCT0000566934	NCT00005669_34_T1	PHENOTYPE	13	14	insulin sensitivity
NCT0000566934	NCT00005669_34_T2	PHENOTYPE	11	12	energy expenditure
NCT0000566935	NCT00005669_35_T0	COMPOUND	13	13	metformin
NCT0000566939	NCT00005669_39_T0	PHENOTYPE	0	0	Hyperinsulinemia
NCT0000566939	NCT00005669_39_T1	GENE	4	4	insulin
NCT0000566941	NCT00005669_41_T0	PHENOTYPE	0	0	Obesity
NCT0000566942	NCT00005669_42_T0	GENE	14	14	hemoglobin
NCT0000566942	NCT00005669_42_T1	PHENOTYPE	4	5	plasma glucose
NCT0000566943	NCT00005669_43_T0	PHENOTYPE	17	19	negative pregnancy test
NCT0000566944	NCT00005669_44_T0	COMPOUND	3	3	creatinine
NCT0000566944	NCT00005669_44_T1	GENE	8	8	1.0
NCT0000566945	NCT00005669_45_T0	PHENOTYPE	10	10	hypoxia
NCT0000566945	NCT00005669_45_T1	PHENOTYPE	3	4	pulmonary disease
NCT0000566950	NCT00005669_50_T0	PHENOTYPE	0	1	Weight loss
NCT0000566951	NCT00005669_51_T0	PHENOTYPE	4	4	disorders
NCT0000566951	NCT00005669_51_T1	PHENOTYPE	7	7	obesity
NCT0000566951	NCT00005669_51_T2	PHENOTYPE	9	10	Cushing's Syndrome
NCT0000566952	NCT00005669_52_T0	PHENOTYPE	14	15	psychiatric disorder
NCT0000566952	NCT00005669_52_T1	PHENOTYPE	10	11	substance abuse
NCT0000566954	NCT00005669_54_T0	PHENOTYPE	10	10	dyslipidemia
NCT0000566954	NCT00005669_54_T1	PHENOTYPE	8	8	hypertension
NCT000056715	NCT00005671_5_T0	PHENOTYPE	3	3	General
NCT000056717	NCT00005671_7_T0	PHENOTYPE	4	4	self-assessment
NCT0000567110	NCT00005671_10_T0	PHENOTYPE	2	2	fatigue
NCT0000567110	NCT00005671_10_T1	PHENOTYPE	5	5	outlook
NCT0000567117	NCT00005671_17_T0	PHENOTYPE	7	7	perceptions
NCT0000567117	NCT00005671_17_T1	PHENOTYPE	4	4	focused
NCT0000567117	NCT00005671_17_T2	GENE	3	3	has
NCT0000567117	NCT00005671_17_T3	PHENOTYPE	12	12	chronic
NCT0000567118	NCT00005671_18_T0	PHENOTYPE	18	18	symptoms
NCT0000567118	NCT00005671_18_T1	PHENOTYPE	31	33	left ventricular dysfunction
NCT0000567118	NCT00005671_18_T2	PHENOTYPE	13	15	Quality of Life
NCT0000567118	NCT00005671_18_T3	PHENOTYPE	26	29	chronic ischemic heart disease
NCT0000567119	NCT00005671_19_T0	PHENOTYPE	7	7	symptoms
NCT0000567123	NCT00005671_23_T0	ORGAN	33	33	Heart
NCT0000567123	NCT00005671_23_T1	PHENOTYPE	27	27	Angina
NCT0000567123	NCT00005671_23_T2	ORGAN	34	34	Transplant
NCT0000567123	NCT00005671_23_T3	PHENOTYPE	15	16	Heart Failure
NCT0000567124	NCT00005671_24_T0	GENE	11	11	METS
NCT0000567124	NCT00005671_24_T1	GENE	22	22	viability
NCT0000567124	NCT00005671_24_T2	COMPOUND	8	8	thallium
NCT0000567127	NCT00005671_27_T0	PHENOTYPE	29	29	affects
NCT0000567127	NCT00005671_27_T1	GENE	19	19	ventricular
NCT0000567127	NCT00005671_27_T2	PHENOTYPE	23	24	chronic illness
NCT0000567127	NCT00005671_27_T3	PHENOTYPE	14	16	ischemic heart disease
NCT0000567129	NCT00005671_29_T0	PHENOTYPE	1	3	ventricular ejection fraction
NCT000056732	NCT00005673_2_T0	GENE	29	29	protease
NCT000056732	NCT00005673_2_T1	GENE	9	10	reverse transcriptase
NCT000056732	NCT00005673_2_T2	GENE	24	25	reverse transcriptase
NCT000056734	NCT00005673_4_T0	COMPOUND	18	18	nevirapine
NCT000056734	NCT00005673_4_T1	COMPOUND	20	20	delavirdine
NCT000056734	NCT00005673_4_T2	PHENOTYPE	0	0	HIV
NCT000056734	NCT00005673_4_T3	COMPOUND	17	17	efavirenz
NCT000056738	NCT00005673_8_T0	COMPOUND	11	11	capravirine
NCT000056738	NCT00005673_8_T1	GENE	17	17	0.5
NCT0000567312	NCT00005673_12_T0	COMPOUND	6	6	efavirenz
NCT0000567315	NCT00005673_15_T0	COMPOUND	4	4	capravirine
NCT0000567315	NCT00005673_15_T1	COMPOUND	10	10	capravirine
NCT0000567315	NCT00005673_15_T2	COMPOUND	12	12	ritonavir
NCT0000567315	NCT00005673_15_T3	GENE	14	15	protease inhibitor
NCT0000567319	NCT00005673_19_T0	COMPOUND	11	11	capravirine
NCT0000567319	NCT00005673_19_T1	GENE	17	17	0.5
NCT0000567324	NCT00005673_24_T0	COMPOUND	38	38	capravirine
NCT0000567324	NCT00005673_24_T1	ORGAN	42	44	central nervous system
NCT0000567329	NCT00005673_29_T0	COMPOUND	15	15	capravirine
NCT0000567329	NCT00005673_29_T1	COMPOUND	36	36	capravirine
NCT0000567329	NCT00005673_29_T2	COMPOUND	63	63	capravirine
NCT0000567329	NCT00005673_29_T3	PHENOTYPE	24	24	HIV
NCT0000567329	NCT00005673_29_T4	PHENOTYPE	46	46	HIV
NCT0000567329	NCT00005673_29_T5	PHENOTYPE	70	70	HIV
NCT0000567329	NCT00005673_29_T6	COMPOUND	22	22	ritonavir
NCT0000567329	NCT00005673_29_T7	COMPOUND	42	42	ritonavir
NCT0000567329	NCT00005673_29_T8	COMPOUND	66	66	ritonavir
NCT0000567329	NCT00005673_29_T9	PHENOTYPE	13	13	pharmacokinetics
NCT0000567329	NCT00005673_29_T10	PHENOTYPE	34	34	pharmacokinetics
NCT0000567329	NCT00005673_29_T11	PHENOTYPE	57	57	pharmacokinetics
NCT0000567329	NCT00005673_29_T12	COMPOUND	44	44	abacavir
NCT0000567329	NCT00005673_29_T13	COMPOUND	68	68	abacavir
NCT0000567329	NCT00005673_29_T14	COMPOUND	19	19	efavirenz
NCT0000567329	NCT00005673_29_T15	COMPOUND	40	40	efavirenz
NCT0000567329	NCT00005673_29_T16	COMPOUND	64	64	efavirenz
NCT0000567331	NCT00005673_31_T0	COMPOUND	12	12	capravirine
NCT0000567331	NCT00005673_31_T1	PHENOTYPE	18	18	HIV
NCT0000567331	NCT00005673_31_T2	PHENOTYPE	6	6	pharmacokinetics
NCT0000567333	NCT00005673_33_T0	GENE	1	1	II
NCT0000567333	NCT00005673_33_T1	COMPOUND	14	14	capravirine
NCT0000567333	NCT00005673_33_T2	PHENOTYPE	16	16	HIV
NCT0000567333	NCT00005673_33_T3	PHENOTYPE	8	8	pharmacokinetics
NCT0000567335	NCT00005673_35_T0	COMPOUND	2	2	capravirine
NCT0000567338	NCT00005673_38_T0	PHENOTYPE	7	7	Allergy
NCT0000567338	NCT00005673_38_T1	PHENOTYPE	9	10	Infectious Diseases
NCT0000567344	NCT00005673_44_T0	PHENOTYPE	6	6	chronic
NCT0000567344	NCT00005673_44_T1	COMPOUND	11	11	lamivudine
NCT0000567344	NCT00005673_44_T2	PHENOTYPE	7	8	Hepatitis B
NCT0000567351	NCT00005673_51_T0	GENE	9	9	blot
NCT0000567354	NCT00005673_54_T0	CELL	3	3	neutrophil
NCT0000567354	NCT00005673_54_T1	CELL	11	11	platelets
NCT0000567354	NCT00005673_54_T2	GENE	18	18	hemoglobin
NCT0000567355	NCT00005673_55_T0	COMPOUND	4	4	creatinine
NCT0000567355	NCT00005673_55_T1	GENE	10	10	1.5
NCT0000567355	NCT00005673_55_T2	ORGAN	3	3	serum
NCT0000567356	NCT00005673_56_T0	ORGAN	1	1	liver
NCT0000567356	NCT00005673_56_T1	GENE	17	17	1.5
NCT0000567356	NCT00005673_56_T2	PHENOTYPE	10	11	total bilirubin
NCT0000567356	NCT00005673_56_T3	GENE	6	7	alanine aminotransferase
NCT0000567356	NCT00005673_56_T4	GENE	3	4	aspartate aminotransferase
NCT0000567358	NCT00005673_58_T0	GENE	3	3	had
NCT0000567358	NCT00005673_58_T1	GENE	10	11	reverse transcriptase
NCT0000567360	NCT00005673_60_T0	COMPOUND	10	10	abacavir
NCT0000567364	NCT00005673_64_T0	PHENOTYPE	6	6	chronic
NCT0000567364	NCT00005673_64_T1	COMPOUND	10	10	lamivudine
NCT0000567364	NCT00005673_64_T2	PHENOTYPE	7	8	Hepatitis B
NCT0000567370	NCT00005673_70_T0	GENE	5	5	interferon
NCT000056743	NCT00005674_3_T0	GENE	1	1	has
NCT000056743	NCT00005674_3_T1	BIOLOGICAL_PROCESS	24	25	cellular metabolism
NCT000056745	NCT00005674_5_T0	CELL	11	11	cells
NCT000056745	NCT00005674_5_T1	PHENOTYPE	8	9	energy metabolism
NCT000056746	NCT00005674_6_T0	TISSUE	12	12	muscles
NCT000056746	NCT00005674_6_T1	GENE	1	1	has
NCT000056746	NCT00005674_6_T2	PHENOTYPE	7	8	energy metabolism
NCT000056749	NCT00005674_9_T0	COMPOUND	1	1	creatine
NCT000056749	NCT00005674_9_T1	GENE	2	2	has
NCT0000567412	NCT00005674_12_T0	COMPOUND	12	12	creatine
NCT0000567413	NCT00005674_13_T0	PHENOTYPE	9	9	centers
NCT000056750	NCT00005675_0_T0	PHENOTYPE	6	6	Scleroderma
NCT000056752	NCT00005675_2_T0	GENE	15	15	CI
NCT000056752	NCT00005675_2_T1	GENE	14	14	collagen
NCT000056754	NCT00005675_4_T0	GENE	11	11	CI
NCT000056756	NCT00005675_6_T0	GENE	8	8	CI
NCT000056762	NCT00005676_2_T0	GENE	25	25	LPL
NCT000056762	NCT00005676_2_T1	GENE	16	16	CHD
NCT000056762	NCT00005676_2_T2	GENE	45	45	CHD
NCT000056762	NCT00005676_2_T3	GENE	23	24	lipoprotein lipase
NCT000056777	NCT00005677_7_T0	PHENOTYPE	6	6	enthusiastic
NCT0000567711	NCT00005677_11_T0	PHENOTYPE	5	5	centers
NCT0000567711	NCT00005677_11_T1	GENE	15	15	had
NCT0000567712	NCT00005677_12_T0	GENE	22	22	shifted
NCT0000567713	NCT00005677_13_T0	PHENOTYPE	4	4	centers
NCT0000567718	NCT00005677_18_T0	GENE	2	2	III
NCT0000567721	NCT00005677_21_T0	PHENOTYPE	28	28	restenosis
NCT0000567721	NCT00005677_21_T1	PHENOTYPE	8	8	occlusions
NCT0000567721	NCT00005677_21_T2	PHENOTYPE	6	6	chronic
NCT0000567723	NCT00005677_23_T0	GENE	22	22	balloon
NCT0000567723	NCT00005677_23_T1	PHENOTYPE	23	23	dilation
NCT0000567723	NCT00005677_23_T2	PHENOTYPE	8	8	occlusions
NCT0000567726	NCT00005677_26_T0	PHENOTYPE	15	15	complication
NCT0000567730	NCT00005677_30_T0	GENE	21	21	PCI
NCT0000567730	NCT00005677_30_T1	GENE	7	7	has
NCT0000567730	NCT00005677_30_T2	GENE	23	23	extended
NCT0000567731	NCT00005677_31_T0	GENE	11	11	balloon
NCT0000567731	NCT00005677_31_T1	PHENOTYPE	30	30	distal
NCT0000567731	NCT00005677_31_T2	GENE	7	7	PCI
NCT0000567731	NCT00005677_31_T3	GENE	8	8	has
NCT0000567732	NCT00005677_32_T0	GENE	11	11	PCI
NCT0000567732	NCT00005677_32_T1	PHENOTYPE	28	28	practices
NCT0000567735	NCT00005677_35_T0	PHENOTYPE	19	19	symptoms
NCT0000567735	NCT00005677_35_T1	PHENOTYPE	17	17	recurrence
NCT0000567735	NCT00005677_35_T2	PHENOTYPE	8	8	restenosis
NCT0000567735	NCT00005677_35_T3	PHENOTYPE	0	0	Secondary
NCT0000567743	NCT00005677_43_T0	PHENOTYPE	1	1	centers
NCT0000567744	NCT00005677_44_T0	PHENOTYPE	13	13	centers
NCT0000567748	NCT00005677_48_T0	PHENOTYPE	0	0	Secondary
NCT0000567749	NCT00005677_49_T0	PHENOTYPE	4	4	secondary
NCT0000567756	NCT00005677_56_T0	GENE	13	13	balloon
NCT0000567757	NCT00005677_57_T0	PHENOTYPE	4	4	complications
NCT0000567759	NCT00005677_59_T0	PHENOTYPE	8	8	strategies
NCT0000567762	NCT00005677_62_T0	GENE	4	4	extended
NCT0000567762	NCT00005677_62_T1	GENE	28	28	PCI
NCT0000567762	NCT00005677_62_T2	GENE	65	65	PCI
NCT0000567762	NCT00005677_62_T3	GENE	94	94	PCI
NCT0000567762	NCT00005677_62_T4	GENE	126	126	PCI
NCT0000567764	NCT00005677_64_T0	PHENOTYPE	41	43	peripheral arterial disease
NCT0000567766	NCT00005677_66_T0	GENE	11	11	Wave
NCT0000567766	NCT00005677_66_T1	GENE	15	15	Wave
NCT0000567766	NCT00005677_66_T2	PHENOTYPE	20	20	centers
NCT0000567769	NCT00005677_69_T0	PHENOTYPE	26	27	myocardial infarction
NCT0000567769	NCT00005677_69_T1	PHENOTYPE	31	32	stent thrombosis
NCT0000567769	NCT00005677_69_T2	PHENOTYPE	4	5	myocardial infarctions
NCT000056785	NCT00005678_5_T0	PHENOTYPE	1	1	centers
NCT000056785	NCT00005678_5_T1	PHENOTYPE	8	10	coronary heart disease
NCT0000567810	NCT00005678_10_T0	PHENOTYPE	19	19	circulation
NCT000056790	NCT00005679_0_T0	PHENOTYPE	3	3	Atherosclerosis
NCT000056793	NCT00005679_3_T0	PHENOTYPE	8	8	atherosclerosis
NCT000056793	NCT00005679_3_T1	PHENOTYPE	6	6	severity
NCT000056793	NCT00005679_3_T2	GENE	1	1	IAP
NCT000056793	NCT00005679_3_T3	PHENOTYPE	25	27	ischemic heart disease
NCT000056794	NCT00005679_4_T0	PHENOTYPE	5	6	fatty streaks
NCT000056795	NCT00005679_5_T0	PHENOTYPE	0	1	Fibrous plaques
NCT000056796	NCT00005679_6_T0	PHENOTYPE	13	13	atherosclerosis
NCT000056796	NCT00005679_6_T1	CELL	34	34	cells
NCT000056796	NCT00005679_6_T2	TISSUE	46	46	tissues
NCT000056796	NCT00005679_6_T3	GENE	5	5	IAP
NCT000056796	NCT00005679_6_T4	GENE	14	14	has
NCT000056797	NCT00005679_7_T0	PHENOTYPE	33	34	fibrous plaque
NCT000056797	NCT00005679_7_T1	PHENOTYPE	20	21	fatty streak
NCT000056797	NCT00005679_7_T2	PHENOTYPE	51	52	fibrous plaques
NCT000056797	NCT00005679_7_T3	PHENOTYPE	44	45	fatty streaks
NCT000056798	NCT00005679_8_T0	PHENOTYPE	11	11	atherosclerosis
NCT000056798	NCT00005679_8_T1	PHENOTYPE	4	4	associations
NCT000056798	NCT00005679_8_T2	PHENOTYPE	17	17	progression
NCT000056799	NCT00005679_9_T0	PHENOTYPE	24	24	Atherosclerosis
NCT0000567910	NCT00005679_10_T0	PHENOTYPE	28	28	atherosclerosis
NCT0000567913	NCT00005679_13_T0	GENE	13	13	San
NCT0000567914	NCT00005679_14_T0	PHENOTYPE	17	19	coronary heart disease
NCT0000567917	NCT00005679_17_T0	PHENOTYPE	6	6	centers
NCT0000567917	NCT00005679_17_T1	PHENOTYPE	10	10	centers
NCT0000567919	NCT00005679_19_T0	GENE	6	6	Dr
NCT0000567921	NCT00005679_21_T0	CELL	8	8	macrophages
NCT0000567921	NCT00005679_21_T1	ORGAN	14	15	coronary arteries
NCT0000567921	NCT00005679_21_T2	CELL	10	12	smooth muscle cells
NCT0000567923	NCT00005679_23_T0	COMPOUND	19	19	calcium
NCT0000567924	NCT00005679_24_T0	PHENOTYPE	17	17	atherosclerosis
NCT0000567924	NCT00005679_24_T1	COMPOUND	12	12	histamine
NCT0000567924	NCT00005679_24_T2	TISSUE	32	32	adventitia
NCT0000567924	NCT00005679_24_T3	GENE	0	0	Dr
NCT0000567924	NCT00005679_24_T4	CELL	28	29	mast cells
NCT0000567927	NCT00005679_27_T0	GENE	6	6	apo
NCT0000567927	NCT00005679_27_T1	COMPOUND	11	11	oligonucleotide
NCT0000567928	NCT00005679_28_T0	PHENOTYPE	12	12	pathology
NCT0000567929	NCT00005679_29_T0	PHENOTYPE	32	32	progression
NCT0000567929	NCT00005679_29_T1	PHENOTYPE	40	40	proliferative
NCT0000567929	NCT00005679_29_T2	PHENOTYPE	45	46	progressive disease
NCT0000567929	NCT00005679_29_T3	PHENOTYPE	18	19	fibrous plaques
NCT0000567929	NCT00005679_29_T4	PHENOTYPE	14	15	fatty streaks
NCT0000567929	NCT00005679_29_T5	PHENOTYPE	55	56	viral infections
NCT0000567930	NCT00005679_30_T0	PHENOTYPE	15	15	Atherogenesis
NCT0000567930	NCT00005679_30_T1	GENE	1	1	FY
NCT0000567933	NCT00005679_33_T0	PHENOTYPE	21	22	fibrous plaques
NCT0000567933	NCT00005679_33_T1	PHENOTYPE	18	19	fatty streaks
NCT000056804	NCT00005680_4_T0	PHENOTYPE	19	19	understood
NCT000056808	NCT00005680_8_T0	PHENOTYPE	18	18	obesity
NCT0000568013	NCT00005680_13_T0	PHENOTYPE	13	14	cardiovascular disease
NCT0000568013	NCT00005680_13_T1	PHENOTYPE	46	47	mental illness
NCT0000568013	NCT00005680_13_T2	PHENOTYPE	26	27	respiratory problems
NCT0000568014	NCT00005680_14_T0	PHENOTYPE	0	2	Type A behavior
NCT0000568016	NCT00005680_16_T0	PHENOTYPE	8	10	ischemic heart disease
NCT0000568020	NCT00005680_20_T0	PHENOTYPE	8	8	sickness
NCT0000568020	NCT00005680_20_T1	PHENOTYPE	18	18	spells
NCT0000568022	NCT00005680_22_T0	PHENOTYPE	27	28	individual differences
NCT0000568023	NCT00005680_23_T0	PHENOTYPE	4	5	individual differences
NCT0000568024	NCT00005680_24_T0	COMPOUND	7	7	1
NCT0000568024	NCT00005680_24_T1	BIOLOGICAL_PROCESS	53	53	aging
NCT0000568024	NCT00005680_24_T2	PHENOTYPE	60	61	coronary disease
NCT0000568024	NCT00005680_24_T3	PHENOTYPE	23	24	vascular disease
NCT000056812	NCT00005681_2_T0	PHENOTYPE	9	10	coronary atherosclerosis
NCT000056812	NCT00005681_2_T1	PHENOTYPE	1	2	myocardial ischemia
NCT000056815	NCT00005681_5_T0	GENE	3	3	has
NCT000056815	NCT00005681_5_T1	PHENOTYPE	7	7	ischemia
NCT000056815	NCT00005681_5_T2	PHENOTYPE	20	21	coronary disease
NCT000056816	NCT00005681_6_T0	PHENOTYPE	14	14	symptoms
NCT000056816	NCT00005681_6_T1	PHENOTYPE	5	5	affects
NCT000056816	NCT00005681_6_T2	PHENOTYPE	4	4	ischemia
NCT000056816	NCT00005681_6_T3	PHENOTYPE	28	28	ischemia
NCT000056817	NCT00005681_7_T0	PHENOTYPE	33	33	ischemia
NCT000056817	NCT00005681_7_T1	PHENOTYPE	49	49	ischemia
NCT000056817	NCT00005681_7_T2	PHENOTYPE	57	57	ischemia
NCT000056817	NCT00005681_7_T3	PHENOTYPE	78	78	symptoms
NCT000056817	NCT00005681_7_T4	PHENOTYPE	13	14	myocardial ischemia
NCT000056817	NCT00005681_7_T5	PHENOTYPE	84	85	myocardial ischemia
NCT000056817	NCT00005681_7_T6	PHENOTYPE	21	23	coronary artery disease
NCT0000568111	NCT00005681_11_T0	ORGAN	44	44	arteries
NCT0000568111	NCT00005681_11_T1	PHENOTYPE	28	28	ischemia
NCT0000568111	NCT00005681_11_T2	GENE	16	16	LDL
NCT0000568111	NCT00005681_11_T3	GENE	19	19	LDL
NCT0000568111	NCT00005681_11_T4	ORGAN	15	15	plasma
NCT0000568111	NCT00005681_11_T5	PHENOTYPE	32	34	coronary artery disease
NCT0000568113	NCT00005681_13_T0	TISSUE	7	7	endothelium
NCT0000568113	NCT00005681_13_T1	BIOLOGICAL_PROCESS	8	8	vasomotion
NCT0000568113	NCT00005681_13_T2	PHENOTYPE	21	21	ischemia
NCT0000568113	NCT00005681_13_T3	PHENOTYPE	24	24	dysfunction
NCT0000568113	NCT00005681_13_T4	COMPOUND	50	50	probucol
NCT0000568113	NCT00005681_13_T5	GENE	42	42	LDL
NCT0000568113	NCT00005681_13_T6	GENE	51	51	LDL
NCT0000568113	NCT00005681_13_T7	GENE	54	54	LDL
NCT0000568113	NCT00005681_13_T8	COMPOUND	41	41	lovastatin
NCT0000568113	NCT00005681_13_T9	COMPOUND	48	48	lovastatin
NCT0000568113	NCT00005681_13_T10	ORGAN	11	12	brachial artery
NCT0000568114	NCT00005681_14_T0	GENE	10	10	III
NCT000056820	NCT00005682_0_T0	PHENOTYPE	0	1	Aplastic Anemia
NCT000056823	NCT00005682_3_T0	COMPOUND	3	3	phenylbutazone
NCT000056823	NCT00005682_3_T1	COMPOUND	2	2	chloramphenicol
NCT000056824	NCT00005682_4_T0	GENE	15	16	too few
NCT000056825	NCT00005682_5_T0	PHENOTYPE	5	6	aplastic anemia
NCT000056827	NCT00005682_7_T0	PHENOTYPE	3	4	aplastic anemia
NCT000056829	NCT00005682_9_T0	PHENOTYPE	20	20	exposures
NCT000056829	NCT00005682_9_T1	PHENOTYPE	16	17	viral infections
NCT000056829	NCT00005682_9_T2	PHENOTYPE	49	50	aplastic anemia
NCT0000568210	NCT00005682_10_T0	PHENOTYPE	5	6	aplastic anemia
NCT000056835	NCT00005683_5_T0	PHENOTYPE	11	11	pathology
NCT000056835	NCT00005683_5_T1	PHENOTYPE	38	39	lung injury
NCT000056839	NCT00005683_9_T0	GENE	9	9	SOD
NCT0000568310	NCT00005683_10_T0	PHENOTYPE	16	16	sequelae
NCT000056842	NCT00005684_2_T0	PHENOTYPE	11	11	Diseases
NCT000056843	NCT00005684_3_T0	COMPOUND	18	18	warfarin
NCT000056843	NCT00005684_3_T1	COMPOUND	24	24	warfarin
NCT000056845	NCT00005684_5_T0	COMPOUND	9	9	warfarin
NCT000056845	NCT00005684_5_T1	COMPOUND	15	15	warfarin
NCT000056847	NCT00005684_7_T0	PHENOTYPE	0	0	Secondary
NCT000056847	NCT00005684_7_T1	PHENOTYPE	12	12	bleeding
NCT000056847	NCT00005684_7_T2	PHENOTYPE	13	13	complications
NCT000056847	NCT00005684_7_T3	PHENOTYPE	8	8	recurrent
NCT000056847	NCT00005684_7_T4	PHENOTYPE	9	10	venous thromboembolism
NCT000056848	NCT00005684_8_T0	GENE	52	52	reduced
NCT000056848	NCT00005684_8_T1	COMPOUND	57	57	warfarin
NCT000056848	NCT00005684_8_T2	PHENOTYPE	22	22	thrombosis
NCT000056848	NCT00005684_8_T3	GENE	33	33	VII
NCT000056848	NCT00005684_8_T4	PHENOTYPE	41	41	recurrent
NCT000056848	NCT00005684_8_T5	PHENOTYPE	8	9	antiphospholipid antibodies
NCT000056848	NCT00005684_8_T6	PHENOTYPE	43	44	thromboembolic events
NCT000056848	NCT00005684_8_T7	MOLECULAR_FUNCTION	13	15	activated protein C
NCT000056854	NCT00005685_4_T0	GENE	2	2	has
NCT000056855	NCT00005685_5_T0	GENE	3	3	had
NCT000056855	NCT00005685_5_T1	PHENOTYPE	16	16	hypertension
NCT000056855	NCT00005685_5_T2	PHENOTYPE	33	33	hypertension
NCT000056858	NCT00005685_8_T0	PHENOTYPE	19	19	hostility
NCT000056858	NCT00005685_8_T1	PHENOTYPE	7	7	hypertension
NCT000056858	NCT00005685_8_T2	PHENOTYPE	12	14	Type A behavior
NCT000056859	NCT00005685_9_T0	ORGAN	4	6	sympathetic nervous system
NCT0000568513	NCT00005685_13_T0	COMPOUND	14	14	norepinephrine
NCT0000568513	NCT00005685_13_T1	GENE	28	28	structural
NCT0000568513	NCT00005685_13_T2	COMPOUND	12	12	epinephrine
NCT0000568515	NCT00005685_15_T0	PHENOTYPE	8	8	hostility
NCT0000568517	NCT00005685_17_T0	COMPOUND	8	8	estrogen
NCT0000568517	NCT00005685_17_T1	PHENOTYPE	11	13	total peripheral resistance
NCT000056862	NCT00005686_2_T0	PHENOTYPE	1	2	weight losses
NCT000056864	NCT00005686_4_T0	PHENOTYPE	0	0	Obese
NCT000056866	NCT00005686_6_T0	COMPOUND	23	23	glucose
NCT000056866	NCT00005686_6_T1	GENE	21	21	insulin
NCT000056866	NCT00005686_6_T2	BIOLOGICAL_PROCESS	27	27	eating
NCT000056866	NCT00005686_6_T3	PHENOTYPE	13	15	coronary heart disease
NCT0000568610	NCT00005686_10_T0	PHENOTYPE	13	14	decision making
NCT0000568612	NCT00005686_12_T0	PHENOTYPE	0	0	Overweight
NCT0000568616	NCT00005686_16_T0	GENE	5	5	FY
NCT0000568616	NCT00005686_16_T1	PHENOTYPE	14	15	weight losses
NCT0000568619	NCT00005686_19_T0	PHENOTYPE	14	15	weight losses
NCT0000568620	NCT00005686_20_T0	PHENOTYPE	28	29	weight loss
NCT0000568620	NCT00005686_20_T1	PHENOTYPE	34	36	quality of life
NCT0000568621	NCT00005686_21_T0	PHENOTYPE	9	10	weight loss
NCT0000568621	NCT00005686_21_T1	PHENOTYPE	25	26	weight loss
NCT000056873	NCT00005687_3_T0	PHENOTYPE	4	4	focused
NCT000056874	NCT00005687_4_T0	PHENOTYPE	53	53	relapse
NCT000056874	NCT00005687_4_T1	PHENOTYPE	68	68	relapse
NCT000056874	NCT00005687_4_T2	PHENOTYPE	30	30	strategies
NCT000056874	NCT00005687_4_T3	GENE	24	24	extended
NCT000056876	NCT00005687_6_T0	PHENOTYPE	0	0	Secondary
NCT000056876	NCT00005687_6_T1	PHENOTYPE	14	14	relapse
NCT000056877	NCT00005687_7_T0	GENE	13	13	452
NCT000056877	NCT00005687_7_T1	GENE	21	21	452
NCT000056877	NCT00005687_7_T2	PHENOTYPE	33	33	relapse
NCT000056877	NCT00005687_7_T3	GENE	26	26	had
NCT000056877	NCT00005687_7_T4	COMPOUND	11	11	N
NCT000056877	NCT00005687_7_T5	COMPOUND	19	19	N
NCT0000568714	NCT00005687_14_T0	CELL	14	14	cells
NCT0000568717	NCT00005687_17_T0	PHENOTYPE	22	22	relapse
NCT0000568717	NCT00005687_17_T1	PHENOTYPE	30	30	relapse
NCT000056881	NCT00005688_1_T0	PHENOTYPE	20	21	cardiac arrhythmias
NCT000056881	NCT00005688_1_T1	PHENOTYPE	10	11	psychological factors
NCT000056883	NCT00005688_3_T0	PHENOTYPE	13	13	somatization
NCT000056883	NCT00005688_3_T1	PHENOTYPE	11	12	heart disease
NCT000056883	NCT00005688_3_T2	PHENOTYPE	7	8	life stress
NCT000056883	NCT00005688_3_T3	PHENOTYPE	5	6	psychiatric diagnosis
NCT000056883	NCT00005688_3_T4	PHENOTYPE	3	4	cardiac symptoms
NCT000056887	NCT00005688_7_T0	PHENOTYPE	9	9	palpitation
NCT000056887	NCT00005688_7_T1	PHENOTYPE	45	45	palpitation
NCT000056887	NCT00005688_7_T2	GENE	39	39	had
NCT000056887	NCT00005688_7_T3	PHENOTYPE	62	62	symptoms
NCT000056887	NCT00005688_7_T4	PHENOTYPE	60	60	arrhythmias
NCT000056887	NCT00005688_7_T5	PHENOTYPE	24	24	arousal
NCT000056887	NCT00005688_7_T6	PHENOTYPE	40	41	heart disease
NCT000056887	NCT00005688_7_T7	PHENOTYPE	13	14	panic disorder
NCT000056887	NCT00005688_7_T8	ORGAN	21	23	sympathetic nervous system
NCT000056888	NCT00005688_8_T0	PHENOTYPE	16	16	palpitations
NCT000056889	NCT00005688_9_T0	PHENOTYPE	12	12	somatization
NCT0000568811	NCT00005688_11_T0	PHENOTYPE	26	26	somatization
NCT0000568811	NCT00005688_11_T1	PHENOTYPE	14	15	psychological factors
NCT0000568812	NCT00005688_12_T0	PHENOTYPE	19	19	palpitation
NCT000056893	NCT00005689_3_T0	PHENOTYPE	10	10	attitudes
NCT000056894	NCT00005689_4_T0	PHENOTYPE	7	8	cholesterol levels
NCT0000568913	NCT00005689_13_T0	GENE	18	18	had
NCT0000568913	NCT00005689_13_T1	GENE	3	3	extended
NCT0000568914	NCT00005689_14_T0	PHENOTYPE	2	2	associations
NCT0000569011	NCT00005690_11_T0	GENE	9	9	bypass
NCT0000569011	NCT00005690_11_T1	GENE	28	28	bypass
NCT0000569012	NCT00005690_12_T0	PHENOTYPE	7	7	strategies
NCT0000569012	NCT00005690_12_T1	PHENOTYPE	19	20	cognitive deterioration
NCT0000569012	NCT00005690_12_T2	PHENOTYPE	24	26	quality of life
NCT0000569016	NCT00005690_16_T0	GENE	11	11	bypass
NCT0000569020	NCT00005690_20_T0	PHENOTYPE	11	13	quality of life
NCT0000569021	NCT00005690_21_T0	GENE	23	23	III
NCT000056915	NCT00005691_5_T0	PHENOTYPE	12	12	strains
NCT000056918	NCT00005691_8_T0	PHENOTYPE	21	23	coronary heart disease
NCT000056919	NCT00005691_9_T0	PHENOTYPE	6	6	strain
NCT000056919	NCT00005691_9_T1	PHENOTYPE	26	26	strain
NCT000056919	NCT00005691_9_T2	PHENOTYPE	24	24	chronic
NCT0000569110	NCT00005691_10_T0	ORGAN	15	15	heart
NCT0000569110	NCT00005691_10_T1	PHENOTYPE	32	32	ischemia
NCT0000569110	NCT00005691_10_T2	PHENOTYPE	26	27	cardiac dysrhythmia
NCT0000569112	NCT00005691_12_T0	COMPOUND	3	3	cortisol
NCT0000569112	NCT00005691_12_T1	COMPOUND	5	5	estrogen
NCT0000569112	NCT00005691_12_T2	GENE	4	4	prolactin
NCT0000569112	NCT00005691_12_T3	COMPOUND	6	6	testosterone
NCT0000569112	NCT00005691_12_T4	GENE	8	8	somatostatin
NCT0000569112	NCT00005691_12_T5	GENE	7	7	gastrin
NCT0000569114	NCT00005691_14_T0	PHENOTYPE	19	19	symptoms
NCT0000569114	NCT00005691_14_T1	PHENOTYPE	21	23	coronary heart disease
NCT000056922	NCT00005692_2_T0	PHENOTYPE	18	18	associations
NCT000056922	NCT00005692_2_T1	GENE	5	5	had
NCT000056922	NCT00005692_2_T2	GENE	10	10	CHD
NCT000056924	NCT00005692_4_T0	PHENOTYPE	6	6	diseases
NCT000056924	NCT00005692_4_T1	GENE	15	15	CHD
NCT000056925	NCT00005692_5_T0	GENE	1	1	fibrinogen
NCT000056925	NCT00005692_5_T1	GENE	4	4	VII
NCT000056925	NCT00005692_5_T2	GENE	10	10	CHD
NCT000056926	NCT00005692_6_T0	PHENOTYPE	8	8	thrombosis
NCT000056928	NCT00005692_8_T0	PHENOTYPE	18	18	associations
NCT000056928	NCT00005692_8_T1	GENE	5	5	had
NCT000056928	NCT00005692_8_T2	GENE	10	10	CHD
NCT0000569210	NCT00005692_10_T0	PHENOTYPE	22	22	disorders
NCT0000569210	NCT00005692_10_T1	PHENOTYPE	20	20	thrombosis
NCT0000569210	NCT00005692_10_T2	GENE	17	17	CHD
NCT0000569213	NCT00005692_13_T0	PHENOTYPE	8	8	inflammation
NCT0000569213	NCT00005692_13_T1	PHENOTYPE	13	14	cardiovascular disease
NCT000056938	NCT00005693_8_T0	GENE	4	4	had
NCT0000569311	NCT00005693_11_T0	GENE	0	0	Stars
NCT0000569315	NCT00005693_15_T0	PHENOTYPE	5	6	weight loss
NCT000056944	NCT00005694_4_T0	PHENOTYPE	25	25	Condition
NCT000056945	NCT00005694_5_T0	PHENOTYPE	3	3	Condition
NCT000056946	NCT00005694_6_T0	PHENOTYPE	3	3	Condition
NCT000056949	NCT00005694_9_T0	GENE	14	14	kit
NCT0000569411	NCT00005694_11_T0	PHENOTYPE	17	17	Condition
NCT0000569412	NCT00005694_12_T0	PHENOTYPE	35	35	Condition
NCT0000569413	NCT00005694_13_T0	BIOLOGICAL_PROCESS	15	15	eating
NCT0000569413	NCT00005694_13_T1	GENE	10	10	CHD
NCT000056956	NCT00005695_6_T0	GENE	10	10	ventricular
NCT000056956	NCT00005695_6_T1	PHENOTYPE	17	18	essential hypertension
NCT000056957	NCT00005695_7_T0	PHENOTYPE	17	17	impedance
NCT000056957	NCT00005695_7_T1	GENE	26	26	had
NCT000056957	NCT00005695_7_T2	GENE	35	35	ventricular
NCT000056957	NCT00005695_7_T3	PHENOTYPE	11	13	total peripheral resistance
NCT000056958	NCT00005695_8_T0	GENE	9	9	reduced
NCT000056958	NCT00005695_8_T1	TISSUE	11	12	body fat
NCT0000569514	NCT00005695_14_T0	ORGAN	8	8	heart
NCT0000569517	NCT00005695_17_T0	COMPOUND	9	9	oxygen
NCT000056961	NCT00005696_1_T0	PHENOTYPE	14	14	atherosclerosis
NCT000056961	NCT00005696_1_T1	GENE	32	32	bypass
NCT000056961	NCT00005696_1_T2	GENE	1	1	MARS
NCT000056961	NCT00005696_1_T3	ORGAN	33	33	grafts
NCT000056961	NCT00005696_1_T4	ORGAN	30	31	coronary artery
NCT000056963	NCT00005696_3_T0	ORGAN	30	31	coronary artery
NCT000056963	NCT00005696_3_T1	PHENOTYPE	15	16	cholesterol levels
NCT000056963	NCT00005696_3_T2	PHENOTYPE	23	25	coronary artery disease
NCT000056964	NCT00005696_4_T0	PHENOTYPE	19	19	atherosclerosis
NCT000056964	NCT00005696_4_T1	ORGAN	22	23	coronary artery
NCT000056965	NCT00005696_5_T0	PHENOTYPE	22	22	atherosclerosis
NCT000056965	NCT00005696_5_T1	ORGAN	32	33	coronary artery
NCT000056966	NCT00005696_6_T0	GENE	35	35	lipoprotein
NCT000056966	NCT00005696_6_T1	GENE	3	3	MARS
NCT000056967	NCT00005696_7_T0	PHENOTYPE	34	34	atherosclerosis
NCT000056967	NCT00005696_7_T1	GENE	15	15	lipoprotein
NCT000056967	NCT00005696_7_T2	GENE	20	20	AI
NCT000056967	NCT00005696_7_T3	GENE	7	7	HDL
NCT000056967	NCT00005696_7_T4	GENE	4	4	LDL
NCT000056967	NCT00005696_7_T5	GENE	12	12	LDL
NCT000056967	NCT00005696_7_T6	GENE	3	3	VLDL
NCT000056967	NCT00005696_7_T7	GENE	22	22	CIII
NCT000056968	NCT00005696_8_T0	PHENOTYPE	3	3	Atherosclerosis
NCT0000569610	NCT00005696_10_T0	PHENOTYPE	40	41	coronary atherosclerosis
NCT0000569611	NCT00005696_11_T0	ORGAN	19	20	coronary artery
NCT0000569613	NCT00005696_13_T0	ORGAN	9	10	coronary artery
NCT0000569613	NCT00005696_13_T1	ORGAN	21	22	coronary artery
NCT0000569613	NCT00005696_13_T2	ORGAN	15	16	carotid artery
NCT0000569614	NCT00005696_14_T0	GENE	14	14	lipoprotein
NCT0000569614	NCT00005696_14_T1	ORGAN	9	9	arteries
NCT0000569614	NCT00005696_14_T2	PHENOTYPE	19	20	vascular lesions
NCT0000569615	NCT00005696_15_T0	PHENOTYPE	1	1	associations
NCT0000569615	NCT00005696_15_T1	PHENOTYPE	24	25	drug effect
NCT000056973	NCT00005697_3_T0	GENE	0	0	PANDA
NCT000056977	NCT00005697_7_T0	COMPOUND	7	7	cotinine
NCT000056979	NCT00005697_9_T0	GENE	1	1	PANDA
NCT0000569710	NCT00005697_10_T0	GENE	7	7	separated
NCT0000569710	NCT00005697_10_T1	GENE	3	3	PANDA
NCT0000569710	NCT00005697_10_T2	PHENOTYPE	22	22	practices
NCT000056983	NCT00005698_3_T0	PHENOTYPE	0	0	Hypertension
NCT000056987	NCT00005698_7_T0	PHENOTYPE	21	21	hypertension
NCT000056988	NCT00005698_8_T0	PHENOTYPE	45	47	elevated blood pressure
NCT000056989	NCT00005698_9_T0	PHENOTYPE	74	74	strategies
NCT000056989	NCT00005698_9_T1	PHENOTYPE	9	9	hypertension
NCT000056989	NCT00005698_9_T2	PHENOTYPE	49	49	hypertension
NCT000056993	NCT00005699_3_T0	PHENOTYPE	18	18	hypertension
NCT000056995	NCT00005699_5_T0	PHENOTYPE	16	16	hypertension
NCT000056996	NCT00005699_6_T0	PHENOTYPE	8	8	strategies
NCT0000569910	NCT00005699_10_T0	PHENOTYPE	11	11	hypertension
NCT0000569910	NCT00005699_10_T1	PHENOTYPE	16	18	high blood pressure
NCT0000569912	NCT00005699_12_T0	PHENOTYPE	3	3	hypertension
NCT0000569914	NCT00005699_14_T0	PHENOTYPE	28	28	strategies
NCT0000569914	NCT00005699_14_T1	PHENOTYPE	21	21	hypertension
NCT0000569914	NCT00005699_14_T2	PHENOTYPE	26	26	hypertension
NCT0000569915	NCT00005699_15_T0	PHENOTYPE	14	14	strategies
NCT0000569917	NCT00005699_17_T0	GENE	24	24	had
NCT0000569918	NCT00005699_18_T0	PHENOTYPE	13	13	strategies
NCT000057003	NCT00005700_3_T0	PHENOTYPE	2	2	syndromes
NCT000057003	NCT00005700_3_T1	PHENOTYPE	13	13	hypertension
NCT000057003	NCT00005700_3_T2	PHENOTYPE	9	9	hypercholesterolemia
NCT000057003	NCT00005700_3_T3	PHENOTYPE	8	8	obesity
NCT000057003	NCT00005700_3_T4	PHENOTYPE	10	11	glucose intolerance
NCT000057007	NCT00005700_7_T0	BIOLOGICAL_PROCESS	22	22	eating
NCT000057009	NCT00005700_9_T0	GENE	25	25	SFA
NCT0000570013	NCT00005700_13_T0	ORGAN	5	5	serum
NCT0000570014	NCT00005700_14_T0	PHENOTYPE	12	12	secondary
NCT0000570014	NCT00005700_14_T1	BIOLOGICAL_PROCESS	20	20	eating
NCT0000570016	NCT00005700_16_T0	GENE	0	0	Dr
NCT0000570016	NCT00005700_16_T1	GENE	4	4	Dr
NCT000057010	NCT00005701_0_T0	PHENOTYPE	0	0	Acute
NCT000057010	NCT00005701_0_T1	PHENOTYPE	1	2	Cardiac Ischemia
NCT000057013	NCT00005701_3_T0	GENE	22	22	ACI
NCT000057013	NCT00005701_3_T1	PHENOTYPE	13	13	focused
NCT000057013	NCT00005701_3_T2	GENE	12	12	has
NCT000057013	NCT00005701_3_T3	PHENOTYPE	6	7	cardiac disease
NCT000057014	NCT00005701_4_T0	GENE	7	7	ACI
NCT000057014	NCT00005701_4_T1	GENE	82	82	ACI
NCT000057016	NCT00005701_6_T0	GENE	9	9	ACI
NCT0000570111	NCT00005701_11_T0	PHENOTYPE	52	52	acute
NCT0000570111	NCT00005701_11_T1	GENE	45	45	ACI
NCT000057022	NCT00005702_2_T0	PHENOTYPE	6	7	cardiovascular disease
NCT000057022	NCT00005702_2_T1	PHENOTYPE	17	18	respiratory disease
NCT000057027	NCT00005702_7_T0	PHENOTYPE	20	20	symptoms
NCT000057027	NCT00005702_7_T1	PHENOTYPE	22	23	physical addiction
NCT0000570211	NCT00005702_11_T0	GENE	36	36	PA
NCT0000570211	NCT00005702_11_T1	GENE	40	40	PA
NCT0000570211	NCT00005702_11_T2	GENE	2	2	met
NCT0000570212	NCT00005702_12_T0	GENE	44	44	PA
NCT0000570212	NCT00005702_12_T1	GENE	16	16	structural
NCT000057033	NCT00005703_3_T0	BIOLOGICAL_PROCESS	0	1	Platelet activation
NCT000057035	NCT00005703_5_T0	GENE	1	1	had
NCT000057039	NCT00005703_9_T0	GENE	42	42	tPA
NCT000057039	NCT00005703_9_T1	GENE	4	4	kininogen
NCT000057039	NCT00005703_9_T2	GENE	41	41	TAT
NCT000057039	NCT00005703_9_T3	GENE	38	38	prothrombin
NCT000057039	NCT00005703_9_T4	GENE	29	29	TF
NCT000057039	NCT00005703_9_T5	GENE	40	40	FPA
NCT000057039	NCT00005703_9_T6	GENE	47	47	alpha2
NCT000057039	NCT00005703_9_T7	CELL	49	49	platelet
NCT000057039	NCT00005703_9_T8	ORGAN	46	46	plasma
NCT000057039	NCT00005703_9_T9	GENE	12	15	low molecular weight kininogen
NCT000057039	NCT00005703_9_T10	GENE	6	9	high molecular weight kininogen
NCT000057040	NCT00005704_0_T0	PHENOTYPE	4	5	Weight Gain
NCT000057053	NCT00005705_3_T0	GENE	1	1	has
NCT000057075	NCT00005707_5_T0	PHENOTYPE	28	28	hypertension
NCT000057076	NCT00005707_6_T0	PHENOTYPE	3	3	focused
NCT000057077	NCT00005707_7_T0	PHENOTYPE	6	6	strategies
NCT000057077	NCT00005707_7_T1	PHENOTYPE	4	4	focused
NCT000057078	NCT00005707_8_T0	PHENOTYPE	52	52	hypertension
NCT000057078	NCT00005707_8_T1	PHENOTYPE	54	54	hypertension
NCT0000570710	NCT00005707_10_T0	GENE	12	12	TSU
NCT0000570711	NCT00005707_11_T0	GENE	1	1	had
NCT0000570712	NCT00005707_12_T0	GENE	15	15	had
NCT0000570713	NCT00005707_13_T0	GENE	5	5	had
NCT0000570714	NCT00005707_14_T0	GENE	9	9	had
NCT000057080	NCT00005708_0_T0	PHENOTYPE	5	5	Hypertension
NCT000057084	NCT00005708_4_T0	PHENOTYPE	4	4	Hypertension
NCT000057084	NCT00005708_4_T1	PHENOTYPE	12	12	Hypertension
NCT000057084	NCT00005708_4_T2	GENE	7	7	HIP
NCT000057086	NCT00005708_6_T0	PHENOTYPE	14	14	initiation
NCT000057086	NCT00005708_6_T1	GENE	17	17	HIP
NCT000057089	NCT00005708_9_T0	GENE	3	3	pre
NCT0000570810	NCT00005708_10_T0	PHENOTYPE	10	10	insights
NCT0000570810	NCT00005708_10_T1	PHENOTYPE	17	17	attitudes
NCT0000570810	NCT00005708_10_T2	PHENOTYPE	0	0	Quality-of-life
NCT0000570810	NCT00005708_10_T3	PHENOTYPE	16	16	hypertension
NCT0000570811	NCT00005708_11_T0	PHENOTYPE	20	20	secondary
NCT0000570811	NCT00005708_11_T1	PHENOTYPE	9	9	obesity
NCT0000570812	NCT00005708_12_T0	PHENOTYPE	14	14	strategies
NCT0000570812	NCT00005708_12_T1	PHENOTYPE	9	9	adaptation
NCT0000570812	NCT00005708_12_T2	GENE	1	1	HIP
NCT000057090	NCT00005709_0_T0	BIOLOGICAL_PROCESS	0	1	Lipoprotein Metabolism
NCT000057092	NCT00005709_2_T0	GENE	17	17	insulin
NCT000057092	NCT00005709_2_T1	PHENOTYPE	20	21	cardiovascular disease
NCT000057094	NCT00005709_4_T0	PHENOTYPE	29	29	centers
NCT000057094	NCT00005709_4_T1	PHENOTYPE	37	38	cardiovascular diseases
NCT000057099	NCT00005709_9_T0	GENE	23	23	LDL
NCT000057099	NCT00005709_9_T1	PHENOTYPE	8	8	hyperinsulinemia
NCT000057099	NCT00005709_9_T2	GENE	16	16	VLDL
NCT000057099	NCT00005709_9_T3	GENE	19	19	secreted
NCT000057104	NCT00005710_4_T0	PHENOTYPE	8	8	relapse
NCT000057108	NCT00005710_8_T0	PHENOTYPE	25	26	cardiovascular disease
NCT000057110	NCT00005711_0_T0	PHENOTYPE	5	5	Asthma
NCT000057113	NCT00005711_3_T0	PHENOTYPE	3	3	symptoms
NCT000057113	NCT00005711_3_T1	PHENOTYPE	5	5	asthma
NCT000057113	NCT00005711_3_T2	PHENOTYPE	8	8	asthma
NCT000057117	NCT00005711_7_T0	PHENOTYPE	14	14	asthma
NCT0000571110	NCT00005711_10_T0	PHENOTYPE	23	23	asthma
NCT0000571111	NCT00005711_11_T0	PHENOTYPE	3	3	focused
NCT0000571111	NCT00005711_11_T1	PHENOTYPE	10	10	asthma
NCT0000571111	NCT00005711_11_T2	PHENOTYPE	20	22	quality of life
NCT0000571112	NCT00005711_12_T0	PHENOTYPE	28	28	asthma
NCT0000571113	NCT00005711_13_T0	PHENOTYPE	14	14	Asthma
NCT0000571114	NCT00005711_14_T0	PHENOTYPE	27	27	asthma
NCT0000571114	NCT00005711_14_T1	PHENOTYPE	46	46	asthma
NCT0000571116	NCT00005711_16_T0	PHENOTYPE	7	7	asthma
NCT0000571117	NCT00005711_17_T0	PHENOTYPE	25	25	attitudes
NCT0000571117	NCT00005711_17_T1	PHENOTYPE	27	27	asthma
NCT0000571122	NCT00005711_22_T0	PHENOTYPE	13	13	focused
NCT0000571122	NCT00005711_22_T1	PHENOTYPE	22	22	asthma
NCT0000571126	NCT00005711_26_T0	PHENOTYPE	20	22	quality of life
NCT0000571127	NCT00005711_27_T0	PHENOTYPE	0	0	Secondary
NCT000057123	NCT00005712_3_T0	PHENOTYPE	14	14	Asthma
NCT000057124	NCT00005712_4_T0	COMPOUND	19	19	1
NCT000057129	NCT00005712_9_T0	PHENOTYPE	6	6	adaptation
NCT000057129	NCT00005712_9_T1	PHENOTYPE	0	0	Asthma
NCT000057131	NCT00005713_1_T0	PHENOTYPE	11	11	asthma
NCT000057132	NCT00005713_2_T0	PHENOTYPE	15	15	asthma
NCT000057133	NCT00005713_3_T0	PHENOTYPE	40	40	asthma
NCT000057136	NCT00005713_6_T0	PHENOTYPE	23	23	asthma
NCT000057138	NCT00005713_8_T0	PHENOTYPE	8	8	asthma
NCT0000571310	NCT00005713_10_T0	PHENOTYPE	17	17	reinforcement
NCT0000571311	NCT00005713_11_T0	PHENOTYPE	9	9	Asthma
NCT0000571311	NCT00005713_11_T1	PHENOTYPE	19	19	Asthma
NCT0000571313	NCT00005713_13_T0	PHENOTYPE	42	42	asthma
NCT0000571313	NCT00005713_13_T1	GENE	39	39	had
NCT0000571313	NCT00005713_13_T2	PHENOTYPE	31	32	childhood asthma
NCT0000571313	NCT00005713_13_T3	PHENOTYPE	62	64	quality of life
NCT0000571315	NCT00005713_15_T0	GENE	2	2	had
NCT0000571315	NCT00005713_15_T1	PHENOTYPE	13	13	asthma
NCT0000571316	NCT00005713_16_T0	PHENOTYPE	5	5	generalized
NCT0000571318	NCT00005713_18_T0	PHENOTYPE	2	2	asthma
NCT000057142	NCT00005714_2_T0	PHENOTYPE	5	5	symptoms
NCT000057142	NCT00005714_2_T1	GENE	4	4	reduced
NCT000057142	NCT00005714_2_T2	PHENOTYPE	0	0	Asthma
NCT000057143	NCT00005714_3_T0	GENE	31	31	reduced
NCT000057143	NCT00005714_3_T1	PHENOTYPE	17	17	asthma
NCT000057144	NCT00005714_4_T0	PHENOTYPE	16	16	asthma
NCT000057145	NCT00005714_5_T0	PHENOTYPE	14	14	Asthma
NCT000057148	NCT00005714_8_T0	GENE	4	4	NAC
NCT000057148	NCT00005714_8_T1	GENE	38	38	NAC
NCT000057148	NCT00005714_8_T2	PHENOTYPE	14	14	asthma
NCT000057148	NCT00005714_8_T3	PHENOTYPE	23	23	asthma
NCT000057149	NCT00005714_9_T0	PHENOTYPE	10	10	attitudes
NCT000057149	NCT00005714_9_T1	PHENOTYPE	12	12	asthma
NCT000057149	NCT00005714_9_T2	GENE	24	24	ER
NCT000057149	NCT00005714_9_T3	PHENOTYPE	22	22	symptoms
NCT000057149	NCT00005714_9_T4	GENE	34	34	NAC
NCT0000571410	NCT00005714_10_T0	PHENOTYPE	58	58	Centers
NCT0000571410	NCT00005714_10_T1	COMPOUND	9	9	theophylline
NCT0000571410	NCT00005714_10_T2	GENE	26	26	NAC
NCT0000571410	NCT00005714_10_T3	ORGAN	8	8	serum
NCT000057150	NCT00005715_0_T0	PHENOTYPE	6	6	Asthma
NCT000057154	NCT00005715_4_T0	PHENOTYPE	12	12	asthma
NCT000057154	NCT00005715_4_T1	PHENOTYPE	15	15	understood
NCT000057156	NCT00005715_6_T0	PHENOTYPE	14	14	asthma
NCT000057157	NCT00005715_7_T0	PHENOTYPE	14	14	Asthma
NCT000057158	NCT00005715_8_T0	PHENOTYPE	4	4	asthma
NCT000057159	NCT00005715_9_T0	PHENOTYPE	2	2	asthma
NCT000057159	NCT00005715_9_T1	PHENOTYPE	16	16	asthma
NCT0000571510	NCT00005715_10_T0	PHENOTYPE	9	9	asthma
NCT0000571512	NCT00005715_12_T0	GENE	3	3	1.5
NCT0000571513	NCT00005715_13_T0	PHENOTYPE	20	20	asthma
NCT0000571513	NCT00005715_13_T1	PHENOTYPE	26	26	asthma
NCT0000571517	NCT00005715_17_T0	PHENOTYPE	9	9	acute
NCT0000571517	NCT00005715_17_T1	PHENOTYPE	23	23	asthma
NCT0000571517	NCT00005715_17_T2	PHENOTYPE	19	19	self-esteem
NCT000057162	NCT00005716_2_T0	PHENOTYPE	6	6	Asthma
NCT000057163	NCT00005716_3_T0	PHENOTYPE	17	17	asthma
NCT000057166	NCT00005716_6_T0	PHENOTYPE	0	0	Secondary
NCT000057166	NCT00005716_6_T1	PHENOTYPE	4	4	practices
NCT000057175	NCT00005717_5_T0	PHENOTYPE	8	8	emphysema
NCT000057175	NCT00005717_5_T1	PHENOTYPE	10	11	chronic bronchitis
NCT000057176	NCT00005717_6_T0	GENE	12	12	had
NCT000057182	NCT00005718_2_T0	ORGAN	14	14	capillary
NCT000057182	NCT00005718_2_T1	PHENOTYPE	5	5	practices
NCT000057183	NCT00005718_3_T0	GENE	6	6	176
NCT000057184	NCT00005718_4_T0	GENE	3	3	LDL
NCT000057184	NCT00005718_4_T1	GENE	25	25	met
NCT000057184	NCT00005718_4_T2	PHENOTYPE	4	5	cholesterol levels
NCT000057187	NCT00005718_7_T0	ORGAN	10	10	plasma
NCT000057187	NCT00005718_7_T1	PHENOTYPE	11	12	cholesterol levels
NCT000057189	NCT00005718_9_T0	GENE	3	3	LDL
NCT000057189	NCT00005718_9_T1	ORGAN	2	2	plasma
NCT000057189	NCT00005718_9_T2	PHENOTYPE	4	5	cholesterol levels
NCT000057192	NCT00005719_2_T0	GENE	3	3	TLC
NCT000057193	NCT00005719_3_T0	PHENOTYPE	29	29	focused
NCT000057195	NCT00005719_5_T0	GENE	13	13	had
NCT000057198	NCT00005719_8_T0	PHENOTYPE	0	0	Secondary
NCT0000571910	NCT00005719_10_T0	GENE	3	3	separated
NCT000057204	NCT00005720_4_T0	PHENOTYPE	11	11	generalization
NCT000057205	NCT00005720_5_T0	PHENOTYPE	24	24	strategies
NCT000057205	NCT00005720_5_T1	PHENOTYPE	44	44	strategies
NCT000057206	NCT00005720_6_T0	GENE	11	11	E1
NCT000057207	NCT00005720_7_T0	GENE	4	4	E1
NCT000057207	NCT00005720_7_T1	GENE	12	12	C1
NCT000057209	NCT00005720_9_T0	COMPOUND	10	10	cotinine
NCT000057216	NCT00005721_6_T0	PHENOTYPE	21	21	strategies
NCT000057217	NCT00005721_7_T0	PHENOTYPE	18	18	strategies
NCT000057222	NCT00005722_2_T0	PHENOTYPE	3	3	obesity
NCT000057222	NCT00005722_2_T1	PHENOTYPE	17	18	heart disease
NCT000057229	NCT00005722_9_T0	GENE	7	7	had
NCT0000572210	NCT00005722_10_T0	PHENOTYPE	19	19	Initiative
NCT0000572210	NCT00005722_10_T1	PHENOTYPE	4	6	High Blood Pressure
NCT0000572211	NCT00005722_11_T0	GENE	11	12	in excess
NCT0000572214	NCT00005722_14_T0	GENE	6	6	had
NCT000057230	NCT00005723_0_T0	ORGAN	7	7	Heart
NCT000057233	NCT00005723_3_T0	PHENOTYPE	21	21	practices
NCT000057233	NCT00005723_3_T1	PHENOTYPE	40	41	cholesterol levels
NCT000057238	NCT00005723_8_T0	GENE	5	5	3.4
NCT000057238	NCT00005723_8_T1	PHENOTYPE	14	14	practices
NCT000057238	NCT00005723_8_T2	PHENOTYPE	21	22	cholesterol levels
NCT000057244	NCT00005724_4_T0	GENE	4	4	had
NCT000057245	NCT00005724_5_T0	GENE	22	22	tailor
NCT000057249	NCT00005724_9_T0	PHENOTYPE	7	7	comprehension
NCT0000572410	NCT00005724_10_T0	GENE	2	2	II
NCT0000572411	NCT00005724_11_T0	PHENOTYPE	13	13	centers
NCT0000572411	NCT00005724_11_T1	PHENOTYPE	40	40	hypertension
NCT0000572411	NCT00005724_11_T2	PHENOTYPE	38	38	obesity
NCT000057258	NCT00005725_8_T0	ORGAN	11	11	serum
NCT0000572510	NCT00005725_10_T0	PHENOTYPE	4	4	CVD
NCT0000572510	NCT00005725_10_T1	PHENOTYPE	0	0	Secondary
NCT000057263	NCT00005726_3_T0	PHENOTYPE	20	21	chronic disease
NCT000057264	NCT00005726_4_T0	GENE	15	15	30.9
NCT000057264	NCT00005726_4_T1	GENE	7	7	had
NCT000057265	NCT00005726_5_T0	GENE	11	11	had
NCT000057265	NCT00005726_5_T1	GENE	13	13	had
NCT000057265	NCT00005726_5_T2	PHENOTYPE	16	17	cholesterol level
NCT000057266	NCT00005726_6_T0	PHENOTYPE	9	9	CVD
NCT000057268	NCT00005726_8_T0	PHENOTYPE	6	6	strategies
NCT000057268	NCT00005726_8_T1	GENE	16	16	Expanded
NCT000057269	NCT00005726_9_T0	PHENOTYPE	13	13	perceived
NCT000057269	NCT00005726_9_T1	PHENOTYPE	10	10	interests
NCT000057269	NCT00005726_9_T2	PHENOTYPE	1	1	intent
NCT000057269	NCT00005726_9_T3	PHENOTYPE	19	20	cardiovascular disease
NCT0000572610	NCT00005726_10_T0	PHENOTYPE	8	8	strategies
NCT0000572610	NCT00005726_10_T1	PHENOTYPE	35	36	cardiovascular disease
NCT0000572611	NCT00005726_11_T0	GENE	25	25	HDL
NCT0000572611	NCT00005726_11_T1	ORGAN	22	22	plasma
NCT0000572612	NCT00005726_12_T0	GENE	11	11	had
NCT0000572616	NCT00005726_16_T0	ORGAN	7	7	plasma
NCT0000572616	NCT00005726_16_T1	PHENOTYPE	8	9	cholesterol level
NCT000057274	NCT00005727_4_T0	PHENOTYPE	6	6	associations
NCT000057274	NCT00005727_4_T1	GENE	3	3	had
NCT000057274	NCT00005727_4_T2	PHENOTYPE	9	9	practices
NCT000057274	NCT00005727_4_T3	PHENOTYPE	28	28	practices
NCT000057274	NCT00005727_4_T4	PHENOTYPE	17	17	hypercholesterolemia
NCT000057274	NCT00005727_4_T5	PHENOTYPE	44	44	CVD
NCT000057274	NCT00005727_4_T6	PHENOTYPE	18	18	obesity
NCT000057275	NCT00005727_5_T0	PHENOTYPE	9	9	CVD
NCT000057277	NCT00005727_7_T0	GENE	19	19	20.35
NCT000057278	NCT00005727_8_T0	GENE	7	7	Expanded
NCT000057279	NCT00005727_9_T0	PHENOTYPE	3	3	CVD
NCT0000572710	NCT00005727_10_T0	GENE	26	26	SI
NCT0000572710	NCT00005727_10_T1	GENE	24	24	UC
NCT0000572711	NCT00005727_11_T0	GENE	1	1	UC
NCT0000572712	NCT00005727_12_T0	PHENOTYPE	6	6	CVD
NCT0000572713	NCT00005727_13_T0	PHENOTYPE	1	1	learned
NCT0000572714	NCT00005727_14_T0	GENE	8	8	had
NCT0000572714	NCT00005727_14_T1	PHENOTYPE	13	13	CVD
NCT0000572714	NCT00005727_14_T2	GENE	6	6	SI
NCT0000572714	NCT00005727_14_T3	ORGAN	27	27	serum
NCT0000572715	NCT00005727_15_T0	PHENOTYPE	34	34	practices
NCT0000572715	NCT00005727_15_T1	PHENOTYPE	1	1	generalization
NCT000057285	NCT00005728_5_T0	BIOLOGICAL_PROCESS	8	8	eating
NCT000057285	NCT00005728_5_T1	PHENOTYPE	87	87	generalization
NCT000057286	NCT00005728_6_T0	GENE	2	2	had
NCT000057287	NCT00005728_7_T0	BIOLOGICAL_PROCESS	26	26	eating
NCT000057289	NCT00005728_9_T0	PHENOTYPE	6	6	adaptation
NCT000057289	NCT00005728_9_T1	PHENOTYPE	15	15	comprehension
NCT0000572810	NCT00005728_10_T0	GENE	1	1	II
NCT0000572811	NCT00005728_11_T0	PHENOTYPE	19	20	cholesterol levels
NCT0000572812	NCT00005728_12_T0	GENE	1	1	III
NCT0000572814	NCT00005728_14_T0	GENE	4	4	II
NCT0000572814	NCT00005728_14_T1	GENE	6	6	III
NCT000057290	NCT00005729_0_T0	PHENOTYPE	0	0	CVD
NCT000057295	NCT00005729_5_T0	GENE	29	29	CPR
NCT000057298	NCT00005729_8_T0	PHENOTYPE	9	9	reinforcement
NCT000057298	NCT00005729_8_T1	GENE	1	1	booster
NCT000057298	NCT00005729_8_T2	PHENOTYPE	14	15	problem solving
NCT0000572911	NCT00005729_11_T0	PHENOTYPE	8	8	adaptations
NCT0000572915	NCT00005729_15_T0	GENE	0	0	SLT
NCT000057302	NCT00005730_2_T0	ORGAN	6	7	Bone Marrow
NCT000057303	NCT00005730_3_T0	PHENOTYPE	17	17	diseases
NCT000057303	NCT00005730_3_T1	GENE	5	5	had
NCT000057303	NCT00005730_3_T2	ORGAN	24	25	immune system
NCT000057303	NCT00005730_3_T3	ORGAN	2	3	bone marrow
NCT000057303	NCT00005730_3_T4	ORGAN	20	21	bone marrow
NCT000057304	NCT00005730_4_T0	ORGAN	9	9	marrow
NCT000057305	NCT00005730_5_T0	ORGAN	11	11	transplant
NCT000057305	NCT00005730_5_T1	ORGAN	9	10	bone marrow
NCT000057307	NCT00005730_7_T0	ORGAN	21	21	marrow
NCT000057307	NCT00005730_7_T1	PHENOTYPE	18	18	diseases
NCT000057307	NCT00005730_7_T2	ORGAN	22	22	transplant
NCT000057307	NCT00005730_7_T3	GENE	24	24	had
NCT000057307	NCT00005730_7_T4	ORGAN	6	7	bone marrow
NCT000057308	NCT00005730_8_T0	ORGAN	27	28	bone marrow
NCT000057309	NCT00005730_9_T0	GENE	3	3	had
NCT000057309	NCT00005730_9_T1	ORGAN	9	9	transplants
NCT0000573010	NCT00005730_10_T0	ORGAN	18	18	transplant
NCT0000573013	NCT00005730_13_T0	ORGAN	24	24	marrow
NCT0000573013	NCT00005730_13_T1	ORGAN	59	59	marrow
NCT0000573013	NCT00005730_13_T2	PHENOTYPE	42	42	centers
NCT0000573013	NCT00005730_13_T3	ORGAN	41	41	transplant
NCT0000573013	NCT00005730_13_T4	ORGAN	21	21	transplants
NCT0000573013	NCT00005730_13_T5	ORGAN	25	25	transplants
NCT0000573013	NCT00005730_13_T6	ORGAN	60	60	transplants
NCT0000573013	NCT00005730_13_T7	ORGAN	14	15	bone marrow
NCT0000573014	NCT00005730_14_T0	ORGAN	23	23	marrow
NCT0000573014	NCT00005730_14_T1	PHENOTYPE	25	25	recruitment
NCT000057312	NCT00005731_2_T0	PHENOTYPE	17	17	Strategies
NCT000057312	NCT00005731_2_T1	PHENOTYPE	22	22	Asthma
NCT000057312	NCT00005731_2_T2	PHENOTYPE	37	37	Asthma
NCT000057313	NCT00005731_3_T0	PHENOTYPE	9	9	Asthma
NCT000057313	NCT00005731_3_T1	PHENOTYPE	39	39	Asthma
NCT000057313	NCT00005731_3_T2	PHENOTYPE	51	51	Asthma
NCT000057322	NCT00005732_2_T0	PHENOTYPE	17	17	Strategies
NCT000057322	NCT00005732_2_T1	PHENOTYPE	22	22	Asthma
NCT000057322	NCT00005732_2_T2	PHENOTYPE	37	37	Asthma
NCT000057332	NCT00005733_2_T0	PHENOTYPE	17	17	Strategies
NCT000057332	NCT00005733_2_T1	PHENOTYPE	22	22	Asthma
NCT000057332	NCT00005733_2_T2	PHENOTYPE	37	37	Asthma
NCT000057340	NCT00005734_0_T0	PHENOTYPE	3	3	Asthma
NCT000057344	NCT00005734_4_T0	GENE	4	4	had
NCT000057345	NCT00005734_5_T0	PHENOTYPE	9	9	asthma
NCT000057346	NCT00005734_6_T0	PHENOTYPE	9	9	asthma
NCT000057346	NCT00005734_6_T1	PHENOTYPE	31	31	asthma
NCT000057346	NCT00005734_6_T2	PHENOTYPE	22	24	fear and anxiety
NCT000057347	NCT00005734_7_T0	PHENOTYPE	8	8	asthma
NCT000057348	NCT00005734_8_T0	PHENOTYPE	18	18	asthma
NCT0000573410	NCT00005734_10_T0	PHENOTYPE	7	7	asthma
NCT0000573410	NCT00005734_10_T1	PHENOTYPE	13	13	asthma
NCT0000573410	NCT00005734_10_T2	PHENOTYPE	27	27	asthma
NCT0000573415	NCT00005734_15_T0	PHENOTYPE	2	2	asthma
NCT0000573416	NCT00005734_16_T0	PHENOTYPE	17	17	asthma
NCT0000573416	NCT00005734_16_T1	PHENOTYPE	13	15	quality of life
NCT000057353	NCT00005735_3_T0	PHENOTYPE	13	13	asthma
NCT000057353	NCT00005735_3_T1	PHENOTYPE	35	35	asthma
NCT000057355	NCT00005735_5_T0	PHENOTYPE	11	11	asthma
NCT000057355	NCT00005735_5_T1	PHENOTYPE	24	24	asthma
NCT000057355	NCT00005735_5_T2	PHENOTYPE	36	36	asthma
NCT000057357	NCT00005735_7_T0	PHENOTYPE	7	7	asthma
NCT000057357	NCT00005735_7_T1	PHENOTYPE	14	14	asthma
NCT000057358	NCT00005735_8_T0	PHENOTYPE	17	17	asthma
NCT000057358	NCT00005735_8_T1	PHENOTYPE	30	30	asthma
NCT000057358	NCT00005735_8_T2	GENE	13	13	had
NCT000057363	NCT00005736_3_T0	PHENOTYPE	17	17	asthma
NCT000057363	NCT00005736_3_T1	PHENOTYPE	36	36	asthma
NCT000057364	NCT00005736_4_T0	GENE	4	4	nested
NCT000057365	NCT00005736_5_T0	PHENOTYPE	15	15	asthma
NCT000057367	NCT00005736_7_T0	PHENOTYPE	4	4	asthma
NCT000057375	NCT00005737_5_T0	PHENOTYPE	23	23	tuberculosis
NCT000057375	NCT00005737_5_T1	GENE	25	25	stops
NCT000057375	NCT00005737_5_T2	PHENOTYPE	10	11	active tuberculosis
NCT000057376	NCT00005737_6_T0	PHENOTYPE	2	3	active tuberculosis
NCT000057379	NCT00005737_9_T0	PHENOTYPE	1	1	resistant
NCT0000573711	NCT00005737_11_T0	PHENOTYPE	9	10	active tuberculosis
NCT0000573713	NCT00005737_13_T0	PHENOTYPE	15	15	tuberculosis
NCT0000573714	NCT00005737_14_T0	PHENOTYPE	13	13	Tuberculosis
NCT0000573715	NCT00005737_15_T0	BIOLOGICAL_PROCESS	17	17	Behavior
NCT000057387	NCT00005738_7_T0	PHENOTYPE	23	23	tuberculosis
NCT000057387	NCT00005738_7_T1	GENE	25	25	stops
NCT000057387	NCT00005738_7_T2	PHENOTYPE	10	11	active tuberculosis
NCT000057388	NCT00005738_8_T0	PHENOTYPE	2	3	active tuberculosis
NCT0000573811	NCT00005738_11_T0	PHENOTYPE	1	1	resistant
NCT0000573813	NCT00005738_13_T0	PHENOTYPE	9	10	active tuberculosis
NCT0000573815	NCT00005738_15_T0	PHENOTYPE	15	15	tuberculosis
NCT0000573816	NCT00005738_16_T0	PHENOTYPE	13	13	Tuberculosis
NCT0000573817	NCT00005738_17_T0	BIOLOGICAL_PROCESS	17	17	Behavior
NCT0000573822	NCT00005738_22_T0	COMPOUND	17	17	isoniazid
NCT000057393	NCT00005739_3_T0	GENE	18	18	DOT
NCT000057394	NCT00005739_4_T0	GENE	16	16	DOT
NCT000057399	NCT00005739_9_T0	PHENOTYPE	23	23	tuberculosis
NCT000057399	NCT00005739_9_T1	GENE	25	25	stops
NCT000057399	NCT00005739_9_T2	PHENOTYPE	10	11	active tuberculosis
NCT0000573910	NCT00005739_10_T0	PHENOTYPE	2	3	active tuberculosis
NCT0000573913	NCT00005739_13_T0	PHENOTYPE	1	1	resistant
NCT0000573915	NCT00005739_15_T0	PHENOTYPE	9	10	active tuberculosis
NCT0000573917	NCT00005739_17_T0	PHENOTYPE	15	15	tuberculosis
NCT0000573918	NCT00005739_18_T0	PHENOTYPE	13	13	Tuberculosis
NCT0000573919	NCT00005739_19_T0	BIOLOGICAL_PROCESS	17	17	Behavior
NCT000057406	NCT00005740_6_T0	PHENOTYPE	23	23	tuberculosis
NCT000057406	NCT00005740_6_T1	GENE	25	25	stops
NCT000057406	NCT00005740_6_T2	PHENOTYPE	10	11	active tuberculosis
NCT000057407	NCT00005740_7_T0	PHENOTYPE	2	3	active tuberculosis
NCT0000574010	NCT00005740_10_T0	PHENOTYPE	1	1	resistant
NCT0000574012	NCT00005740_12_T0	PHENOTYPE	9	10	active tuberculosis
NCT0000574014	NCT00005740_14_T0	PHENOTYPE	15	15	tuberculosis
NCT0000574015	NCT00005740_15_T0	PHENOTYPE	13	13	Tuberculosis
NCT0000574016	NCT00005740_16_T0	BIOLOGICAL_PROCESS	17	17	Behavior
NCT000057415	NCT00005741_5_T0	PHENOTYPE	23	23	tuberculosis
NCT000057415	NCT00005741_5_T1	GENE	25	25	stops
NCT000057415	NCT00005741_5_T2	PHENOTYPE	10	11	active tuberculosis
NCT000057416	NCT00005741_6_T0	PHENOTYPE	2	3	active tuberculosis
NCT000057419	NCT00005741_9_T0	PHENOTYPE	1	1	resistant
NCT0000574111	NCT00005741_11_T0	PHENOTYPE	9	10	active tuberculosis
NCT0000574113	NCT00005741_13_T0	PHENOTYPE	15	15	tuberculosis
NCT0000574114	NCT00005741_14_T0	PHENOTYPE	13	13	Tuberculosis
NCT0000574115	NCT00005741_15_T0	BIOLOGICAL_PROCESS	17	17	Behavior
NCT0000574119	NCT00005741_19_T0	PHENOTYPE	24	24	practices
NCT0000574121	NCT00005741_21_T0	GENE	8	8	II
NCT000057420	NCT00005742_0_T0	PHENOTYPE	5	5	Tuberculosis
NCT000057426	NCT00005742_6_T0	PHENOTYPE	23	23	tuberculosis
NCT000057426	NCT00005742_6_T1	GENE	25	25	stops
NCT000057426	NCT00005742_6_T2	PHENOTYPE	10	11	active tuberculosis
NCT000057427	NCT00005742_7_T0	PHENOTYPE	2	3	active tuberculosis
NCT0000574210	NCT00005742_10_T0	PHENOTYPE	1	1	resistant
NCT0000574212	NCT00005742_12_T0	PHENOTYPE	9	10	active tuberculosis
NCT0000574214	NCT00005742_14_T0	PHENOTYPE	15	15	tuberculosis
NCT0000574215	NCT00005742_15_T0	PHENOTYPE	13	13	Tuberculosis
NCT0000574216	NCT00005742_16_T0	BIOLOGICAL_PROCESS	17	17	Behavior
NCT0000574223	NCT00005742_23_T0	PHENOTYPE	21	21	strategies
NCT000057430	NCT00005743_0_T0	PHENOTYPE	5	6	Weight Loss
NCT000057434	NCT00005743_4_T0	PHENOTYPE	6	7	weight loss
NCT000057436	NCT00005743_6_T0	PHENOTYPE	18	19	weight loss
NCT000057437	NCT00005743_7_T0	PHENOTYPE	21	22	weight loss
NCT000057439	NCT00005743_9_T0	PHENOTYPE	7	8	weight loss
NCT0000574310	NCT00005743_10_T0	PHENOTYPE	3	4	cardiovascular disease
NCT000057442	NCT00005744_2_T0	PHENOTYPE	20	21	energy expenditure
NCT000057450	NCT00005745_0_T0	PHENOTYPE	5	5	Fluctuations
NCT000057452	NCT00005745_2_T0	PHENOTYPE	8	8	fluctuations
NCT000057454	NCT00005745_4_T0	PHENOTYPE	1	2	weight losses
NCT000057455	NCT00005745_5_T0	PHENOTYPE	12	13	weight losses
NCT000057458	NCT00005745_8_T0	PHENOTYPE	8	8	fluctuation
NCT000057458	NCT00005745_8_T1	GENE	10	10	20
NCT0000574514	NCT00005745_14_T0	PHENOTYPE	0	0	Hypertension
NCT000057462	NCT00005746_2_T0	PHENOTYPE	20	20	atherosclerosis
NCT000057462	NCT00005746_2_T1	PHENOTYPE	6	8	coronary heart disease
NCT000057463	NCT00005746_3_T0	PHENOTYPE	11	12	coronary disease
NCT000057468	NCT00005746_8_T0	GENE	22	22	LDL
NCT000057468	NCT00005746_8_T1	GENE	13	13	CHD
NCT000057468	NCT00005746_8_T2	PHENOTYPE	10	12	coronary heart disease
NCT0000574610	NCT00005746_10_T0	PHENOTYPE	21	21	anxious
NCT0000574611	NCT00005746_11_T0	PHENOTYPE	7	7	focused
NCT0000574614	NCT00005746_14_T0	GENE	9	9	CO
NCT0000574614	NCT00005746_14_T1	COMPOUND	7	8	carbon monoxide
NCT0000574616	NCT00005746_16_T0	PHENOTYPE	0	0	Diabetes
NCT0000574618	NCT00005746_18_T0	BIOLOGICAL_PROCESS	12	12	phlebotomy
NCT0000574618	NCT00005746_18_T1	GENE	26	26	had
NCT0000574618	NCT00005746_18_T2	GENE	14	14	CO
NCT0000574618	NCT00005746_18_T3	GENE	11	11	BP
NCT0000574619	NCT00005746_19_T0	PHENOTYPE	11	11	concentrations
NCT0000574619	NCT00005746_19_T1	ORGAN	10	10	plasma
NCT000057482	NCT00005748_2_T0	GENE	20	20	had
NCT000057482	NCT00005748_2_T1	PHENOTYPE	35	35	hypertension
NCT000057482	NCT00005748_2_T2	GENE	15	15	BP
NCT000057484	NCT00005748_4_T0	GENE	14	14	reduced
NCT000057484	NCT00005748_4_T1	GENE	28	28	TM
NCT000057484	NCT00005748_4_T2	PHENOTYPE	8	8	hypertension
NCT000057485	NCT00005748_5_T0	PHENOTYPE	26	26	hypertension
NCT000057485	NCT00005748_5_T1	GENE	12	12	BP
NCT000057485	NCT00005748_5_T2	GENE	39	39	CHD
NCT000057485	NCT00005748_5_T3	PHENOTYPE	9	10	borderline hypertension
NCT000057486	NCT00005748_6_T0	COMPOUND	9	9	sodium
NCT000057486	NCT00005748_6_T1	GENE	1	1	BP
NCT000057486	NCT00005748_6_T2	PHENOTYPE	12	13	weight loss
NCT000057487	NCT00005748_7_T0	GENE	9	9	TM
NCT000057487	NCT00005748_7_T1	GENE	27	27	BP
NCT000057487	NCT00005748_7_T2	PHENOTYPE	15	16	cardiovascular morbidity
NCT000057488	NCT00005748_8_T0	PHENOTYPE	14	14	hypertension
NCT000057488	NCT00005748_8_T1	GENE	23	23	BP
NCT000057489	NCT00005748_9_T0	ORGAN	27	27	Heart
NCT000057489	NCT00005748_9_T1	PHENOTYPE	48	48	CVD
NCT000057489	NCT00005748_9_T2	GENE	13	13	SBP
NCT000057489	NCT00005748_9_T3	GENE	16	16	DBP
NCT000057489	NCT00005748_9_T4	GENE	12	12	BP
NCT000057489	NCT00005748_9_T5	GENE	19	19	Hg
NCT0000574810	NCT00005748_10_T0	GENE	9	9	TM
NCT0000574811	NCT00005748_11_T0	GENE	7	7	BP
NCT0000574812	NCT00005748_12_T0	PHENOTYPE	0	0	Secondary
NCT0000574812	NCT00005748_12_T1	GENE	6	6	BP
NCT0000574813	NCT00005748_13_T0	GENE	14	14	BP
NCT000057493	NCT00005749_3_T0	GENE	3	3	has
NCT000057493	NCT00005749_3_T1	GENE	10	10	has
NCT000057494	NCT00005749_4_T0	PHENOTYPE	5	5	relapse
NCT000057494	NCT00005749_4_T1	GENE	17	17	had
NCT000057494	NCT00005749_4_T2	PHENOTYPE	9	9	reinforcement
NCT0000574911	NCT00005749_11_T0	GENE	15	15	PAR
NCT0000574911	NCT00005749_11_T1	PHENOTYPE	17	17	CVD
NCT0000574912	NCT00005749_12_T0	PHENOTYPE	6	6	self-efficacy
NCT0000574915	NCT00005749_15_T0	PHENOTYPE	20	20	diseases
NCT000057503	NCT00005750_3_T0	PHENOTYPE	2	2	obesity
NCT000057503	NCT00005750_3_T1	PHENOTYPE	17	17	obesity
NCT000057503	NCT00005750_3_T2	PHENOTYPE	21	21	obesity
NCT000057503	NCT00005750_3_T3	PHENOTYPE	26	26	obesity
NCT000057503	NCT00005750_3_T4	PHENOTYPE	0	0	Onset
NCT0000575012	NCT00005750_12_T0	PHENOTYPE	12	12	attitudes
NCT0000575014	NCT00005750_14_T0	PHENOTYPE	26	26	adiposity
NCT0000575014	NCT00005750_14_T1	GENE	21	21	had
NCT0000575015	NCT00005750_15_T0	PHENOTYPE	10	10	obesity
NCT0000575016	NCT00005750_16_T0	PHENOTYPE	0	0	Secondary
NCT0000575016	NCT00005750_16_T1	PHENOTYPE	36	36	perceived
NCT0000575016	NCT00005750_16_T2	PHENOTYPE	34	34	attitudes
NCT0000575016	NCT00005750_16_T3	PHENOTYPE	37	37	self-efficacy
NCT0000575016	NCT00005750_16_T4	PHENOTYPE	10	10	obesity
NCT000057514	NCT00005751_4_T0	PHENOTYPE	7	7	resolved
NCT000057514	NCT00005751_4_T1	PHENOTYPE	15	16	endothelial dysfunction
NCT000057515	NCT00005751_5_T0	PHENOTYPE	7	7	hypertension
NCT000057515	NCT00005751_5_T1	PHENOTYPE	6	6	hypercholesterolemia
NCT000057515	NCT00005751_5_T2	PHENOTYPE	10	11	glucose levels
NCT000057515	NCT00005751_5_T3	PHENOTYPE	16	17	endothelial dysfunction
NCT000057516	NCT00005751_6_T0	GENE	4	4	has
NCT000057516	NCT00005751_6_T1	PHENOTYPE	9	10	endothelial dysfunction
NCT000057519	NCT00005751_9_T0	PHENOTYPE	26	27	cardiovascular disease
NCT0000575110	NCT00005751_10_T0	PHENOTYPE	13	13	recurrent
NCT0000575111	NCT00005751_11_T0	PHENOTYPE	16	17	cardiovascular disease
NCT0000575111	NCT00005751_11_T1	PHENOTYPE	8	9	endothelial dysfunction
NCT000057522	NCT00005752_2_T0	PHENOTYPE	7	7	CVD
NCT000057522	NCT00005752_2_T1	PHENOTYPE	1	1	overweight
NCT000057522	NCT00005752_2_T2	PHENOTYPE	15	15	overweight
NCT000057522	NCT00005752_2_T3	PHENOTYPE	5	6	cardiovascular disease
NCT000057525	NCT00005752_5_T0	PHENOTYPE	13	13	suffered
NCT000057525	NCT00005752_5_T1	PHENOTYPE	10	10	overweight
NCT000057527	NCT00005752_7_T0	PHENOTYPE	6	6	perceptions
NCT000057527	NCT00005752_7_T1	PHENOTYPE	11	11	perceptions
NCT000057527	NCT00005752_7_T2	PHENOTYPE	13	13	overweight
NCT000057527	NCT00005752_7_T3	PHENOTYPE	0	1	Weight loss
NCT000057528	NCT00005752_8_T0	GENE	4	4	has
NCT000057528	NCT00005752_8_T1	GENE	17	17	has
NCT000057528	NCT00005752_8_T2	PHENOTYPE	30	30	overweight
NCT000057528	NCT00005752_8_T3	PHENOTYPE	24	25	weight perceptions
NCT000057529	NCT00005752_9_T0	PHENOTYPE	30	31	weight loss
NCT0000575210	NCT00005752_10_T0	GENE	4	4	had
NCT0000575210	NCT00005752_10_T1	GENE	25	25	2a
NCT0000575210	NCT00005752_10_T2	GENE	41	41	2b
NCT0000575210	NCT00005752_10_T3	PHENOTYPE	16	16	overweight
NCT0000575210	NCT00005752_10_T4	PHENOTYPE	38	38	overweight
NCT0000575210	NCT00005752_10_T5	PHENOTYPE	58	58	overweight
NCT0000575210	NCT00005752_10_T6	PHENOTYPE	32	33	weight perceptions
NCT000057534	NCT00005753_4_T0	PHENOTYPE	12	12	secondary
NCT000057546	NCT00005754_6_T0	PHENOTYPE	21	21	atherosclerosis
NCT000057546	NCT00005754_6_T1	COMPOUND	16	16	calcium
NCT000057546	NCT00005754_6_T2	GENE	17	17	CAC
NCT000057546	NCT00005754_6_T3	PHENOTYPE	32	32	hypertrophy
NCT000057546	NCT00005754_6_T4	GENE	25	25	ventricular
NCT000057546	NCT00005754_6_T5	ORGAN	14	15	coronary artery
NCT000057546	NCT00005754_6_T6	PHENOTYPE	34	35	diabetic cardiomyopathy
NCT0000575410	NCT00005754_10_T0	GENE	28	28	CAC
NCT0000575413	NCT00005754_13_T0	PHENOTYPE	9	10	cardiac events
NCT0000575415	NCT00005754_15_T0	GENE	3	3	extended
NCT000057552	NCT00005755_2_T0	PHENOTYPE	11	11	exposures
NCT000057552	NCT00005755_2_T1	PHENOTYPE	4	6	adult onset asthma
NCT000057553	NCT00005755_3_T0	PHENOTYPE	7	7	asthma
NCT000057553	NCT00005755_3_T1	GENE	8	8	has
NCT000057554	NCT00005755_4_T0	PHENOTYPE	1	2	occupational asthma
NCT000057555	NCT00005755_5_T0	PHENOTYPE	17	17	atopy
NCT000057555	NCT00005755_5_T1	PHENOTYPE	15	15	asthma
NCT000057557	NCT00005755_7_T0	PHENOTYPE	30	30	diseases
NCT000057557	NCT00005755_7_T1	PHENOTYPE	19	19	asthma
NCT000057557	NCT00005755_7_T2	PHENOTYPE	15	15	exposures
NCT000057557	NCT00005755_7_T3	PHENOTYPE	27	28	respiratory symptoms
NCT000057559	NCT00005755_9_T0	PHENOTYPE	29	29	atopy
NCT000057559	NCT00005755_9_T1	PHENOTYPE	25	25	asthma
NCT000057559	NCT00005755_9_T2	PHENOTYPE	23	23	remission
NCT000057559	NCT00005755_9_T3	PHENOTYPE	8	9	occupational asthma
NCT000057559	NCT00005755_9_T4	PHENOTYPE	27	28	respiratory symptoms
NCT000057559	NCT00005755_9_T5	PHENOTYPE	35	36	lung function
NCT0000575510	NCT00005755_10_T0	GENE	16	16	IgE
NCT0000575510	NCT00005755_10_T1	COMPOUND	8	8	methacholine
NCT0000575511	NCT00005755_11_T0	PHENOTYPE	14	14	diseases
NCT0000575511	NCT00005755_11_T1	PHENOTYPE	11	12	respiratory symptoms
NCT0000575511	NCT00005755_11_T2	PHENOTYPE	26	27	environmental exposures
NCT000057562	NCT00005756_2_T0	PHENOTYPE	18	18	pulse
NCT000057562	NCT00005756_2_T1	PHENOTYPE	28	29	cognitive function
NCT000057562	NCT00005756_2_T2	PHENOTYPE	10	11	aortic calcification
NCT000057563	NCT00005756_3_T0	GENE	3	3	SHEP
NCT000057563	NCT00005756_3_T1	GENE	28	28	SHEP
NCT000057563	NCT00005756_3_T2	GENE	9	9	has
NCT000057564	NCT00005756_4_T0	COMPOUND	8	8	calcium
NCT000057564	NCT00005756_4_T1	ORGAN	23	24	coronary arteries
NCT000057565	NCT00005756_5_T0	PHENOTYPE	4	4	calcification
NCT000057566	NCT00005756_6_T0	PHENOTYPE	13	13	atherosclerosis
NCT000057566	NCT00005756_6_T1	PHENOTYPE	4	5	vascular stiffness
NCT000057568	NCT00005756_8_T0	GENE	2	2	has
NCT000057569	NCT00005756_9_T0	GENE	12	12	SHEP
NCT000057569	NCT00005756_9_T1	BIOLOGICAL_PROCESS	3	3	aging
NCT000057569	NCT00005756_9_T2	PHENOTYPE	1	1	hypertension
NCT000057569	NCT00005756_9_T3	PHENOTYPE	24	25	cognitive function
NCT000057569	NCT00005756_9_T4	PHENOTYPE	10	11	vascular dementia
NCT000057569	NCT00005756_9_T5	PHENOTYPE	7	8	cognitive impairment
NCT0000575610	NCT00005756_10_T0	PHENOTYPE	15	15	atherosclerosis
NCT0000575610	NCT00005756_10_T1	PHENOTYPE	7	8	cognitive function
NCT0000575611	NCT00005756_11_T0	PHENOTYPE	15	16	systolic hypertension
NCT0000575612	NCT00005756_12_T0	PHENOTYPE	11	12	systolic hypertension
NCT0000575613	NCT00005756_13_T0	PHENOTYPE	36	36	atherosclerosis
NCT0000575613	NCT00005756_13_T1	PHENOTYPE	18	19	systolic hypertension
NCT000057573	NCT00005757_3_T0	PHENOTYPE	6	6	nephropathy
NCT000057575	NCT00005757_5_T0	PHENOTYPE	3	3	resistant
NCT000057575	NCT00005757_5_T1	PHENOTYPE	14	14	resistant
NCT000057577	NCT00005757_7_T0	GENE	13	13	bradykinin
NCT000057577	NCT00005757_7_T1	GENE	7	7	Ang
NCT000057577	NCT00005757_7_T2	PHENOTYPE	4	5	decreased sensitivity
NCT000057578	NCT00005757_8_T0	GENE	28	28	II
NCT000057578	NCT00005757_8_T1	GENE	22	22	receptor
NCT000057578	NCT00005757_8_T2	GENE	30	30	receptor
NCT000057578	NCT00005757_8_T3	GENE	18	18	bradykinin
NCT000057578	NCT00005757_8_T4	BIOLOGICAL_PROCESS	23	23	sensitization
NCT000057578	NCT00005757_8_T5	GENE	27	27	Ang
NCT000057578	NCT00005757_8_T6	MOLECULAR_FUNCTION	8	9	ACE activity
NCT000057579	NCT00005757_9_T0	GENE	27	27	II
NCT000057579	NCT00005757_9_T1	GENE	21	21	receptor
NCT000057579	NCT00005757_9_T2	GENE	29	29	receptor
NCT000057579	NCT00005757_9_T3	GENE	18	18	bradykinin
NCT000057579	NCT00005757_9_T4	BIOLOGICAL_PROCESS	22	22	sensitization
NCT000057579	NCT00005757_9_T5	GENE	26	26	Ang
NCT000057579	NCT00005757_9_T6	MOLECULAR_FUNCTION	8	9	ACE activity
NCT0000575710	NCT00005757_10_T0	GENE	29	29	II
NCT0000575710	NCT00005757_10_T1	GENE	6	6	ACE
NCT0000575710	NCT00005757_10_T2	GENE	35	35	bradykinin
NCT0000575710	NCT00005757_10_T3	GENE	25	25	Ang
NCT0000575710	NCT00005757_10_T4	GENE	28	28	Ang
NCT0000575710	NCT00005757_10_T5	PHENOTYPE	4	4	hypertension
NCT0000575710	NCT00005757_10_T6	MOLECULAR_FUNCTION	10	11	ACE activity
NCT000057580	NCT00005758_0_T0	PHENOTYPE	4	4	HIV
NCT000057583	NCT00005758_3_T0	PHENOTYPE	14	14	HIV
NCT000057583	NCT00005758_3_T1	PHENOTYPE	20	20	HIV
NCT000057584	NCT00005758_4_T0	PHENOTYPE	5	5	HIV
NCT000057587	NCT00005758_7_T0	GENE	2	2	has
NCT000057588	NCT00005758_8_T0	PHENOTYPE	9	9	HIV
NCT000057588	NCT00005758_8_T1	BIOLOGICAL_PROCESS	14	15	immune response
NCT0000575811	NCT00005758_11_T0	GENE	7	7	p24
NCT0000575811	NCT00005758_11_T1	PHENOTYPE	3	3	proliferative
NCT0000575811	NCT00005758_11_T2	PHENOTYPE	20	20	progression
NCT0000575811	NCT00005758_11_T3	GENE	5	5	LPR
NCT0000575811	NCT00005758_11_T4	CELL	2	2	lymphocyte
NCT0000575823	NCT00005758_23_T0	GENE	5	5	IFA
NCT0000575825	NCT00005758_25_T0	PHENOTYPE	3	3	HIV
NCT0000575827	NCT00005758_27_T0	PHENOTYPE	33	33	HIV
NCT0000575828	NCT00005758_28_T0	PHENOTYPE	21	21	peripheral
NCT0000575828	NCT00005758_28_T1	CELL	24	24	cells
NCT000057603	NCT00005760_3_T0	ORGAN	21	21	hips
NCT000057603	NCT00005760_3_T1	ORGAN	20	20	abdomen
NCT000057603	NCT00005760_3_T2	GENE	12	12	4.5
NCT000057603	NCT00005760_3_T3	TISSUE	15	16	body fat
NCT000057604	NCT00005760_4_T0	COMPOUND	19	19	glucose
NCT000057604	NCT00005760_4_T1	GENE	23	23	insulin
NCT000057604	NCT00005760_4_T2	PHENOTYPE	3	4	heart disease
NCT000057604	NCT00005760_4_T3	PHENOTYPE	6	8	high blood pressure
NCT000057607	NCT00005760_7_T0	PHENOTYPE	21	21	Center
NCT0000576011	NCT00005760_11_T0	GENE	17	17	insulin
NCT0000576022	NCT00005760_22_T0	PHENOTYPE	7	7	complications
NCT0000576022	NCT00005760_22_T1	PHENOTYPE	9	9	obesity
NCT0000576022	NCT00005760_22_T2	TISSUE	15	17	abdominal adipose tissue
NCT0000576023	NCT00005760_23_T0	PHENOTYPE	27	27	obesity
NCT0000576023	NCT00005760_23_T1	TISSUE	8	10	subcutaneous adipose tissue
NCT0000576024	NCT00005760_24_T0	GENE	18	18	has
NCT0000576024	NCT00005760_24_T1	TISSUE	15	17	subcutaneous adipose tissue
NCT0000576029	NCT00005760_29_T0	PHENOTYPE	14	15	insulin insensitivity
NCT0000576032	NCT00005760_32_T0	PHENOTYPE	0	0	Obesity
NCT0000576033	NCT00005760_33_T0	COMPOUND	15	15	DXA
NCT0000576034	NCT00005760_34_T0	PHENOTYPE	9	9	hyperinsulinemia
NCT0000576034	NCT00005760_34_T1	PHENOTYPE	2	4	Type 2 Diabetes
NCT0000576034	NCT00005760_34_T2	PHENOTYPE	5	7	impaired glucose tolerance
NCT0000576037	NCT00005760_37_T0	PHENOTYPE	9	11	negative pregnancy test
NCT0000576039	NCT00005760_39_T0	PHENOTYPE	9	10	renal disease
NCT0000576040	NCT00005760_40_T0	COMPOUND	9	9	creatinine
NCT0000576040	NCT00005760_40_T1	COMPOUND	19	19	creatinine
NCT0000576040	NCT00005760_40_T2	ORGAN	18	18	serum
NCT0000576042	NCT00005760_42_T0	PHENOTYPE	9	10	cardiac disease
NCT0000576043	NCT00005760_43_T0	PHENOTYPE	3	4	stage 3
NCT0000576044	NCT00005760_44_T0	PHENOTYPE	9	10	pulmonary disease
NCT0000576044	NCT00005760_44_T1	PHENOTYPE	13	14	bronchial asthma
NCT0000576044	NCT00005760_44_T2	PHENOTYPE	16	17	chronic bronchitis
NCT0000576048	NCT00005760_48_T0	PHENOTYPE	7	7	syndromes
NCT0000576049	NCT00005760_49_T0	GENE	16	16	CAGE
NCT0000576049	NCT00005760_49_T1	PHENOTYPE	9	9	alcoholism
NCT0000576049	NCT00005760_49_T2	PHENOTYPE	6	7	substance abuse
NCT0000576050	NCT00005760_50_T0	COMPOUND	24	24	orlistat
NCT0000576050	NCT00005760_50_T1	COMPOUND	26	26	acarbose
NCT0000576050	NCT00005760_50_T2	PHENOTYPE	20	21	nutrient absorption
NCT0000576051	NCT00005760_51_T0	COMPOUND	12	12	metformin
NCT0000576052	NCT00005760_52_T0	GENE	2	2	insulin
NCT000057610	NCT00005761_0_T0	PHENOTYPE	3	4	Diabetic Retinopathy
NCT000057613	NCT00005761_3_T0	PHENOTYPE	7	8	diabetic retinopathy
NCT000057618	NCT00005761_8_T0	ORGAN	8	8	serum
NCT0000576111	NCT00005761_11_T0	PHENOTYPE	3	4	plasma glucose
NCT0000576115	NCT00005761_15_T0	PHENOTYPE	3	3	ketoacidosis
NCT0000576119	NCT00005761_19_T0	PHENOTYPE	3	6	abnormal glucose tolerance test
NCT0000576121	NCT00005761_21_T0	PHENOTYPE	0	0	Opacities
NCT0000576121	NCT00005761_21_T1	PHENOTYPE	7	8	pupillary dilation
NCT000057621	NCT00005762_1_T0	PHENOTYPE	14	15	HIV infections
NCT000057623	NCT00005762_3_T0	GENE	19	19	PI
NCT000057624	NCT00005762_4_T0	PHENOTYPE	6	6	tolerance
NCT000057627	NCT00005762_7_T0	GENE	1	1	ACTG
NCT000057627	NCT00005762_7_T1	PHENOTYPE	8	9	virologic failure
NCT000057628	NCT00005762_8_T0	GENE	9	9	PK
NCT000057632	NCT00005763_2_T0	GENE	2	2	has
NCT000057632	NCT00005763_2_T1	PHENOTYPE	21	21	hypertension
NCT000057633	NCT00005763_3_T0	GENE	3	3	has
NCT000057635	NCT00005763_5_T0	COMPOUND	14	14	sodium
NCT000057635	NCT00005763_5_T1	GENE	24	24	has
NCT000057637	NCT00005763_7_T0	COMPOUND	23	23	sodium
NCT000057638	NCT00005763_8_T0	COMPOUND	11	11	sodium
NCT000057639	NCT00005763_9_T0	PHENOTYPE	13	13	associations
NCT0000576310	NCT00005763_10_T0	COMPOUND	22	22	sodium
NCT0000576310	NCT00005763_10_T1	GENE	25	25	had
NCT0000576312	NCT00005763_12_T0	COMPOUND	12	12	sodium
NCT0000576313	NCT00005763_13_T0	PHENOTYPE	20	20	estimation
NCT0000576313	NCT00005763_13_T1	PHENOTYPE	31	31	centers
NCT0000576313	NCT00005763_13_T2	GENE	8	8	had
NCT0000576314	NCT00005763_14_T0	GENE	21	21	has
NCT0000576316	NCT00005763_16_T0	PHENOTYPE	9	9	Center
NCT0000576316	NCT00005763_16_T1	PHENOTYPE	19	19	centers
NCT0000576316	NCT00005763_16_T2	GENE	20	20	had
NCT0000576317	NCT00005763_17_T0	ORGAN	33	33	Heart
NCT0000576317	NCT00005763_17_T1	ORGAN	37	37	Heart
NCT0000576317	NCT00005763_17_T2	ORGAN	41	41	Heart
NCT0000576317	NCT00005763_17_T3	ORGAN	45	45	Heart
NCT0000576317	NCT00005763_17_T4	PHENOTYPE	16	16	Hypertension
NCT0000576322	NCT00005763_22_T0	PHENOTYPE	15	15	hypertension
NCT0000576322	NCT00005763_22_T1	PHENOTYPE	19	20	cardiovascular disease
NCT0000576323	NCT00005763_23_T0	COMPOUND	5	5	sodium
NCT0000576323	NCT00005763_23_T1	COMPOUND	11	11	creatinine
NCT0000576323	NCT00005763_23_T2	COMPOUND	6	6	potassium
NCT0000576323	NCT00005763_23_T3	COMPOUND	8	8	calcium
NCT0000576323	NCT00005763_23_T4	COMPOUND	9	9	magnesium
NCT0000576323	NCT00005763_23_T5	COMPOUND	7	7	chloride
NCT0000576325	NCT00005763_25_T0	COMPOUND	11	12	uric acid
NCT0000576327	NCT00005763_27_T0	GENE	66	66	BP
NCT0000576327	NCT00005763_27_T1	PHENOTYPE	27	27	centers
NCT0000576327	NCT00005763_27_T2	PHENOTYPE	46	46	centers
NCT0000576328	NCT00005763_28_T0	COMPOUND	14	14	N
NCT0000576329	NCT00005763_29_T0	GENE	15	15	had
NCT000057642	NCT00005764_2_T0	GENE	17	17	2.2
NCT000057642	NCT00005764_2_T1	COMPOUND	6	6	abacavir
NCT000057642	NCT00005764_2_T2	PHENOTYPE	14	15	lactate levels
NCT000057646	NCT00005764_6_T0	PHENOTYPE	15	16	lactate levels
NCT000057646	NCT00005764_6_T1	TISSUE	9	10	body fat
NCT000057647	NCT00005764_7_T0	BIOLOGICAL_PROCESS	30	30	metabolism
NCT000057647	NCT00005764_7_T1	PHENOTYPE	15	15	quality-of-life
NCT000057647	NCT00005764_7_T2	PHENOTYPE	9	9	lipodystrophy
NCT000057647	NCT00005764_7_T3	PHENOTYPE	19	20	Body Image
NCT000057651	NCT00005765_1_T0	COMPOUND	21	21	nicotine
NCT000057651	NCT00005765_1_T1	ORGAN	22	22	gum
NCT000057652	NCT00005765_2_T0	PHENOTYPE	14	14	addiction
NCT000057668	NCT00005766_8_T0	COMPOUND	15	15	creatine
NCT0000576610	NCT00005766_10_T0	PHENOTYPE	13	14	motor function
NCT0000576610	NCT00005766_10_T1	ORGAN	11	12	upper extremity
NCT000057671	NCT00005767_1_T0	ORGAN	11	11	intestine
NCT000057671	NCT00005767_1_T1	ORGAN	13	13	liver
NCT000057672	NCT00005767_2_T0	COMPOUND	21	21	methionine
NCT000057672	NCT00005767_2_T1	COMPOUND	20	20	alanine
NCT000057673	NCT00005767_3_T0	COMPOUND	15	15	leucine
NCT000057673	NCT00005767_3_T1	PHENOTYPE	32	33	renal disease
NCT000057681	NCT00005768_1_T0	COMPOUND	20	20	estrogen
NCT000057681	NCT00005768_1_T1	PHENOTYPE	4	4	menopausal
NCT000057681	NCT00005768_1_T2	GENE	14	14	70
NCT000057681	NCT00005768_1_T3	GENE	6	6	yrs
NCT000057681	NCT00005768_1_T4	GENE	15	15	yrs
NCT000057684	NCT00005768_4_T0	COMPOUND	4	4	estrogen
NCT000057685	NCT00005768_5_T0	COMPOUND	14	14	estrogen
NCT000057686	NCT00005768_6_T0	COMPOUND	11	11	estrogen
NCT000057686	NCT00005768_6_T1	COMPOUND	22	22	estrogen
NCT000057691	NCT00005769_1_T0	COMPOUND	9	9	estradiol
NCT000057691	NCT00005769_1_T1	PHENOTYPE	15	16	insulin sensitivity
NCT000057691	NCT00005769_1_T2	BIOLOGICAL_PROCESS	21	22	glucose metabolism
NCT000057692	NCT00005769_2_T0	GENE	11	11	CEE
NCT000057692	NCT00005769_2_T1	COMPOUND	10	10	estrogen
NCT000057692	NCT00005769_2_T2	COMPOUND	14	14	estrogen
NCT000057692	NCT00005769_2_T3	PHENOTYPE	24	24	menopausal
NCT000057692	NCT00005769_2_T4	PHENOTYPE	33	35	cessation of menses
NCT000057700	NCT00005770_0_T0	TISSUE	8	9	Connective Tissue
NCT000057705	NCT00005770_5_T0	PHENOTYPE	8	8	winding
NCT000057705	NCT00005770_5_T1	GENE	10	10	collagen
NCT000057705	NCT00005770_5_T2	TISSUE	12	13	elastic fibers
NCT000057706	NCT00005770_6_T0	CELL	23	23	cells
NCT000057706	NCT00005770_6_T1	GENE	6	6	collagen
NCT000057707	NCT00005770_7_T0	TISSUE	29	30	subcutaneous tissue
NCT000057712	NCT00005771_2_T0	GENE	12	12	abdominal
NCT000057712	NCT00005771_2_T1	GENE	19	19	abdominal
NCT000057713	NCT00005771_3_T0	TISSUE	19	19	muscles
NCT000057716	NCT00005771_6_T0	GENE	0	1	Group 1
NCT000057720	NCT00005772_0_T0	PHENOTYPE	3	4	Birth Asphyxia
NCT000057723	NCT00005772_3_T0	PHENOTYPE	9	9	encephalopathy
NCT000057724	NCT00005772_4_T0	GENE	24	24	II
NCT000057724	NCT00005772_4_T1	GENE	21	21	34.35
NCT000057725	NCT00005772_5_T0	GENE	11	11	abdominal
NCT000057725	NCT00005772_5_T1	PHENOTYPE	1	1	electroencephalograms
NCT000057726	NCT00005772_6_T0	GENE	16	16	6/7
NCT000057729	NCT00005772_9_T0	PHENOTYPE	8	9	near drownings
NCT0000577212	NCT00005772_12_T0	PHENOTYPE	9	9	encephalopathy
NCT0000577213	NCT00005772_13_T0	GENE	24	24	II
NCT0000577213	NCT00005772_13_T1	GENE	21	21	34.35
NCT0000577214	NCT00005772_14_T0	GENE	11	11	abdominal
NCT0000577214	NCT00005772_14_T1	PHENOTYPE	1	1	electroencephalograms
NCT0000577216	NCT00005772_16_T0	PHENOTYPE	22	24	hypoxic ischemic encephalopathy
NCT0000577217	NCT00005772_17_T0	GENE	5	5	6/7
NCT000057732	NCT00005773_2_T0	PHENOTYPE	11	11	initiation
NCT000057733	NCT00005773_3_T0	GENE	2	2	had
NCT000057738	NCT00005773_8_T0	PHENOTYPE	5	5	initiation
NCT000057739	NCT00005773_9_T0	COMPOUND	12	13	nitric oxide
NCT000057739	NCT00005773_9_T1	PHENOTYPE	19	20	respiratory failure
NCT000057739	NCT00005773_9_T2	PHENOTYPE	27	28	respiratory failure
NCT0000577312	NCT00005773_12_T0	PHENOTYPE	11	11	initiation
NCT0000577313	NCT00005773_13_T0	GENE	2	2	had
NCT0000577317	NCT00005773_17_T0	GENE	10	10	25
NCT0000577317	NCT00005773_17_T1	GENE	26	26	30
NCT0000577319	NCT00005773_19_T0	PHENOTYPE	1	1	recruitment
NCT000057741	NCT00005774_1_T0	PHENOTYPE	1	2	premature infants
NCT000057741	NCT00005774_1_T1	PHENOTYPE	5	6	respiratory distress
NCT000057745	NCT00005774_5_T0	PHENOTYPE	1	2	premature infants
NCT000057745	NCT00005774_5_T1	PHENOTYPE	5	6	respiratory distress
NCT000057747	NCT00005774_7_T0	GENE	16	16	CPAP
NCT000057749	NCT00005774_9_T0	PHENOTYPE	9	9	ventilation
NCT0000577410	NCT00005774_10_T0	PHENOTYPE	38	38	initiation
NCT0000577410	NCT00005774_10_T1	GENE	26	26	CPAP
NCT0000577410	NCT00005774_10_T2	PHENOTYPE	41	41	ventilation
NCT0000577411	NCT00005774_11_T0	PHENOTYPE	10	10	recruitment
NCT000057761	NCT00005776_1_T0	GENE	46	46	bypass
NCT000057761	NCT00005776_1_T1	GENE	8	8	had
NCT000057761	NCT00005776_1_T2	COMPOUND	31	31	oxygen
NCT000057761	NCT00005776_1_T3	COMPOUND	25	26	nitric oxide
NCT000057764	NCT00005776_4_T0	PHENOTYPE	2	3	pulmonary hypertension
NCT000057767	NCT00005776_7_T0	PHENOTYPE	8	8	bleeding
NCT000057768	NCT00005776_8_T0	PHENOTYPE	17	17	ventilation
NCT000057768	NCT00005776_8_T1	BIOLOGICAL_PROCESS	7	7	gestation
NCT000057769	NCT00005776_9_T0	COMPOUND	13	13	oxygen
NCT000057771	NCT00005777_1_T0	COMPOUND	40	40	dexamethasone
NCT000057771	NCT00005777_1_T1	GENE	34	34	48
NCT000057771	NCT00005777_1_T2	PHENOTYPE	18	18	ventilation
NCT000057771	NCT00005777_1_T3	PHENOTYPE	31	31	ventilation
NCT000057771	NCT00005777_1_T4	GENE	39	39	tapered
NCT000057771	NCT00005777_1_T5	GENE	26	26	52
NCT000057771	NCT00005777_1_T6	GENE	28	28	Hg
NCT000057771	NCT00005777_1_T7	GENE	36	36	Hg
NCT000057771	NCT00005777_1_T8	PHENOTYPE	19	23	partial pressure of carbon dioxide
NCT000057772	NCT00005777_2_T0	PHENOTYPE	6	6	BPD
NCT000057773	NCT00005777_3_T0	PHENOTYPE	11	11	complications
NCT000057776	NCT00005777_6_T0	PHENOTYPE	11	11	BPD
NCT000057776	NCT00005777_6_T1	PHENOTYPE	7	7	ventilation
NCT000057777	NCT00005777_7_T0	COMPOUND	40	40	dexamethasone
NCT000057777	NCT00005777_7_T1	GENE	34	34	48
NCT000057777	NCT00005777_7_T2	PHENOTYPE	18	18	ventilation
NCT000057777	NCT00005777_7_T3	PHENOTYPE	31	31	ventilation
NCT000057777	NCT00005777_7_T4	GENE	39	39	tapered
NCT000057777	NCT00005777_7_T5	GENE	26	26	52
NCT000057777	NCT00005777_7_T6	GENE	28	28	Hg
NCT000057777	NCT00005777_7_T7	GENE	36	36	Hg
NCT000057777	NCT00005777_7_T8	PHENOTYPE	19	23	partial pressure of carbon dioxide
NCT000057778	NCT00005777_8_T0	PHENOTYPE	6	6	BPD
NCT000057779	NCT00005777_9_T0	PHENOTYPE	11	11	complications
NCT000057785	NCT00005778_5_T0	GENE	6	6	has
NCT000057786	NCT00005778_6_T0	BIOLOGICAL_PROCESS	28	28	quiescence
NCT000057786	NCT00005778_6_T1	PHENOTYPE	16	16	chronic
NCT000057786	NCT00005778_6_T2	PHENOTYPE	4	4	lupus
NCT000057787	NCT00005778_7_T0	ORGAN	16	16	kidney
NCT000057788	NCT00005778_8_T0	PHENOTYPE	17	18	renal failure
NCT0000577811	NCT00005778_11_T0	PHENOTYPE	16	16	toxicity
NCT0000577811	NCT00005778_11_T1	COMPOUND	4	4	cyclophosphamide
NCT0000577811	NCT00005778_11_T2	GENE	14	14	has
NCT0000577811	NCT00005778_11_T3	GENE	3	3	IV
NCT0000577811	NCT00005778_11_T4	PHENOTYPE	18	20	premature ovarian failure
NCT0000577812	NCT00005778_12_T0	COMPOUND	11	11	cyclophosphamide
NCT0000577812	NCT00005778_12_T1	PHENOTYPE	19	19	lupus
NCT0000577813	NCT00005778_13_T0	COMPOUND	28	28	cyclophosphamide
NCT0000577813	NCT00005778_13_T1	COMPOUND	35	35	cyclophosphamide
NCT0000577813	NCT00005778_13_T2	PHENOTYPE	18	18	lupus
NCT0000577813	NCT00005778_13_T3	PHENOTYPE	42	42	lupus
NCT0000577813	NCT00005778_13_T4	GENE	34	34	IV
NCT0000577814	NCT00005778_14_T0	PHENOTYPE	32	32	complications
NCT0000577814	NCT00005778_14_T1	GENE	40	40	1.4
NCT0000577814	NCT00005778_14_T2	PHENOTYPE	29	29	infections
NCT0000577814	NCT00005778_14_T3	COMPOUND	12	12	cyclophosphamide
NCT0000577814	NCT00005778_14_T4	COMPOUND	34	34	cyclophosphamide
NCT0000577814	NCT00005778_14_T5	GENE	11	11	IV
NCT0000577815	NCT00005778_15_T0	COMPOUND	6	6	cyclophosphamide
NCT0000577821	NCT00005778_21_T0	COMPOUND	1	1	cyclophosphamide
NCT0000577821	NCT00005778_21_T1	COMPOUND	16	16	prednisone
NCT000057790	NCT00005779_0_T0	GENE	10	10	IL-12
NCT000057792	NCT00005779_2_T0	CELL	19	19	cells
NCT000057792	NCT00005779_2_T1	CELL	29	29	cells
NCT000057792	NCT00005779_2_T2	PHENOTYPE	28	28	HIV
NCT000057792	NCT00005779_2_T3	GENE	17	17	IL-12
NCT000057792	NCT00005779_2_T4	GENE	2	2	has
NCT000057792	NCT00005779_2_T5	CELL	23	24	T lymphocytes
NCT000057794	NCT00005779_4_T0	PHENOTYPE	8	8	symptoms
NCT000057794	NCT00005779_4_T1	PHENOTYPE	2	2	HIV
NCT000057796	NCT00005779_6_T0	GENE	1	1	IL-12
NCT000057796	NCT00005779_6_T1	ORGAN	7	8	immune system
NCT000057798	NCT00005779_8_T0	GENE	2	2	CTL
NCT000057798	NCT00005779_8_T1	PHENOTYPE	6	7	disease progression
NCT000057799	NCT00005779_9_T0	GENE	8	8	CTL
NCT0000577910	NCT00005779_10_T0	PHENOTYPE	17	17	HIV
NCT0000577910	NCT00005779_10_T1	GENE	18	18	gp120
NCT0000577910	NCT00005779_10_T2	GENE	23	23	CTL
NCT0000577911	NCT00005779_11_T0	GENE	1	1	IL-12
NCT0000577914	NCT00005779_14_T0	PHENOTYPE	19	19	toxicity
NCT0000577915	NCT00005779_15_T0	GENE	19	19	IL-12
NCT0000577915	NCT00005779_15_T1	PHENOTYPE	2	3	adverse events
NCT0000577916	NCT00005779_16_T0	PHENOTYPE	16	16	toxicity
NCT0000577917	NCT00005779_17_T0	GENE	19	19	IL-12
NCT0000577917	NCT00005779_17_T1	PHENOTYPE	2	3	adverse events
NCT0000577919	NCT00005779_19_T0	PHENOTYPE	1	1	toxicity
NCT0000577919	NCT00005779_19_T1	PHENOTYPE	20	20	toxicity
NCT0000577919	NCT00005779_19_T2	GENE	6	6	IL-12
NCT000057801	NCT00005780_1_T0	PHENOTYPE	4	4	lymphoma
NCT000057801	NCT00005780_1_T1	PHENOTYPE	8	8	remission
NCT000057804	NCT00005780_4_T0	PHENOTYPE	35	35	tumor
NCT000057804	NCT00005780_4_T1	ORGAN	36	37	bone marrow
NCT000057804	NCT00005780_4_T2	PHENOTYPE	11	12	lung function
NCT000057805	NCT00005780_5_T0	PHENOTYPE	25	25	tumor
NCT000057805	NCT00005780_5_T1	PHENOTYPE	21	21	remission
NCT000057808	NCT00005780_8_T0	CELL	10	10	cells
NCT000057808	NCT00005780_8_T1	PHENOTYPE	9	9	lymphoma
NCT0000578010	NCT00005780_10_T0	GENE	0	0	G-CSF
NCT0000578010	NCT00005780_10_T1	ORGAN	11	12	immune system
NCT0000578010	NCT00005780_10_T2	ORGAN	5	6	bone marrow
NCT0000578012	NCT00005780_12_T0	GENE	16	16	insulin
NCT0000578012	NCT00005780_12_T1	GENE	9	9	G-CSF
NCT0000578018	NCT00005780_18_T0	PHENOTYPE	13	13	recurrence
NCT0000578018	NCT00005780_18_T1	PHENOTYPE	4	4	lymphoma
NCT0000578030	NCT00005780_30_T0	PHENOTYPE	15	15	symptoms
NCT0000578032	NCT00005780_32_T0	GENE	9	9	cm
NCT0000578032	NCT00005780_32_T1	TISSUE	0	1	Lymph node
NCT0000578032	NCT00005780_32_T2	CELL	18	20	circulating tumor cells
NCT0000578035	NCT00005780_35_T0	ORGAN	10	10	heart
NCT0000578035	NCT00005780_35_T1	PHENOTYPE	6	7	myocardial infarction
NCT0000578035	NCT00005780_35_T2	PHENOTYPE	3	5	ischemic heart disease
NCT0000578036	NCT00005780_36_T0	COMPOUND	1	1	MUGA
NCT0000578038	NCT00005780_38_T0	PHENOTYPE	4	4	HIV
NCT0000578038	NCT00005780_38_T1	PHENOTYPE	8	9	hepatitis B
NCT0000578041	NCT00005780_41_T0	PHENOTYPE	6	6	lymphoma
NCT0000578041	NCT00005780_41_T1	ORGAN	2	4	central nervous system
NCT000057815	NCT00005781_5_T0	PHENOTYPE	5	6	skin cancer
NCT000057819	NCT00005781_9_T0	PHENOTYPE	15	16	skin disorders
NCT0000578112	NCT00005781_12_T0	GENE	26	26	SP
NCT0000578112	NCT00005781_12_T1	PHENOTYPE	1	2	skin disease
NCT0000578113	NCT00005781_13_T0	PHENOTYPE	27	28	clinical findings
NCT0000578114	NCT00005781_14_T0	COMPOUND	13	13	NCI
NCT0000578118	NCT00005781_18_T0	ORGAN	16	16	extremities
NCT000057821	NCT00005782_1_T0	CELL	0	1	Stem cells
NCT000057821	NCT00005782_1_T1	CELL	16	17	blood cells
NCT000057821	NCT00005782_1_T2	ORGAN	4	5	bone marrow
NCT000057823	NCT00005782_3_T0	GENE	2	2	G-CSF
NCT000057823	NCT00005782_3_T1	GENE	8	8	hormone
NCT000057823	NCT00005782_3_T2	CELL	10	11	stem cells
NCT000057823	NCT00005782_3_T3	ORGAN	20	21	bone marrow
NCT000057827	NCT00005782_7_T0	CELL	6	7	stem cells
NCT0000578210	NCT00005782_10_T0	GENE	5	5	G-CSF
NCT0000578211	NCT00005782_11_T0	CELL	4	5	stem cells
NCT0000578225	NCT00005782_25_T0	PHENOTYPE	7	8	recurrent infections
NCT0000578225	NCT00005782_25_T1	PHENOTYPE	2	3	systemic infection
NCT0000578226	NCT00005782_26_T0	COMPOUND	12	12	1
NCT0000578226	NCT00005782_26_T1	COMPOUND	3	3	creatinine
NCT0000578226	NCT00005782_26_T2	PHENOTYPE	9	9	proteinuria
NCT0000578227	NCT00005782_27_T0	ORGAN	1	1	liver
NCT0000578227	NCT00005782_27_T1	COMPOUND	3	3	bilirubin
NCT0000578228	NCT00005782_28_T0	CELL	5	5	granulocytes
NCT0000578228	NCT00005782_28_T1	GENE	17	17	MCV
NCT0000578228	NCT00005782_28_T2	GENE	19	19	MCHC
NCT0000578228	NCT00005782_28_T3	GENE	3	3	WBC
NCT0000578228	NCT00005782_28_T4	CELL	9	9	platelets
NCT0000578228	NCT00005782_28_T5	GENE	13	13	hemoglobin
NCT0000578229	NCT00005782_29_T0	GENE	17	17	G-CSF
NCT0000578229	NCT00005782_29_T1	ORGAN	9	9	serum
NCT0000578230	NCT00005782_30_T0	PHENOTYPE	18	18	HIV
NCT0000578230	NCT00005782_30_T1	GENE	10	10	RPR
NCT0000578230	NCT00005782_30_T2	PHENOTYPE	9	9	syphilis
NCT0000578230	NCT00005782_30_T3	PHENOTYPE	11	12	hepatitis B
NCT0000578234	NCT00005782_34_T0	PHENOTYPE	7	8	parasitic infection
NCT0000578235	NCT00005782_35_T0	PHENOTYPE	4	6	positive pregnancy test
NCT0000578236	NCT00005782_36_T0	PHENOTYPE	11	11	lupus
NCT0000578236	NCT00005782_36_T1	PHENOTYPE	3	4	autoimmune disease
NCT0000578236	NCT00005782_36_T2	PHENOTYPE	7	8	rheumatoid arthritis
NCT0000578238	NCT00005782_38_T0	PHENOTYPE	5	6	hematologic disorders
NCT0000578240	NCT00005782_40_T0	PHENOTYPE	1	1	allergy
NCT0000578240	NCT00005782_40_T1	GENE	3	3	G-CSF
NCT000057831	NCT00005783_1_T0	GENE	2	2	hemoglobin
NCT000057831	NCT00005783_1_T1	CELL	10	12	red blood cells
NCT000057833	NCT00005783_3_T0	PHENOTYPE	6	6	severity
NCT000057833	NCT00005783_3_T1	GENE	11	11	has
NCT000057837	NCT00005783_7_T0	COMPOUND	21	21	hydroxyurea
NCT000057837	NCT00005783_7_T1	GENE	0	0	SCF
NCT000057838	NCT00005783_8_T0	PHENOTYPE	18	18	disorders
NCT000057838	NCT00005783_8_T1	GENE	8	8	SCF
NCT0000578311	NCT00005783_11_T0	GENE	2	2	hemoglobin
NCT0000578311	NCT00005783_11_T1	CELL	10	12	red blood cells
NCT0000578313	NCT00005783_13_T0	PHENOTYPE	6	6	severity
NCT0000578313	NCT00005783_13_T1	GENE	11	11	has
NCT0000578317	NCT00005783_17_T0	COMPOUND	21	21	hydroxyurea
NCT0000578317	NCT00005783_17_T1	GENE	0	0	SCF
NCT0000578318	NCT00005783_18_T0	PHENOTYPE	18	18	disorders
NCT0000578318	NCT00005783_18_T1	GENE	8	8	SCF
NCT0000578321	NCT00005783_21_T0	GENE	3	3	had
NCT0000578326	NCT00005783_26_T0	PHENOTYPE	1	1	retinopathy
NCT0000578326	NCT00005783_26_T1	PHENOTYPE	0	0	Bilateral
NCT0000578327	NCT00005783_27_T0	TISSUE	3	3	bones
NCT0000578327	NCT00005783_27_T1	PHENOTYPE	0	0	Osteonecrosis
NCT0000578329	NCT00005783_29_T0	COMPOUND	7	7	hydroxyurea
NCT0000578329	NCT00005783_29_T1	COMPOUND	14	14	hydroxyurea
NCT0000578333	NCT00005783_33_T0	COMPOUND	4	4	arginine
NCT0000578333	NCT00005783_33_T1	COMPOUND	1	1	hydroxyurea
NCT0000578333	NCT00005783_33_T2	COMPOUND	5	5	butyrate
NCT0000578333	NCT00005783_33_T3	GENE	2	2	erythropoietin
NCT0000578336	NCT00005783_36_T0	PHENOTYPE	1	1	allergy
NCT0000578337	NCT00005783_37_T0	PHENOTYPE	6	6	asthma
NCT0000578337	NCT00005783_37_T1	PHENOTYPE	5	5	recurrent
NCT0000578340	NCT00005783_40_T0	PHENOTYPE	4	4	urticaria
NCT0000578343	NCT00005783_43_T0	GENE	4	5	monoamine oxidase
NCT000057843	NCT00005784_3_T0	PHENOTYPE	33	34	retinal disease
NCT000057843	NCT00005784_3_T1	PHENOTYPE	20	21	diabetic retinopathy
NCT000057843	NCT00005784_3_T2	PHENOTYPE	23	24	macular degeneration
NCT000057843	NCT00005784_3_T3	PHENOTYPE	28	30	central serous retinopathy
NCT000057843	NCT00005784_3_T4	PHENOTYPE	25	27	vascular occlusive disease
NCT0000578417	NCT00005784_17_T0	PHENOTYPE	14	15	retinal diseases
NCT0000578418	NCT00005784_18_T0	PHENOTYPE	28	28	diseases
NCT0000578418	NCT00005784_18_T1	PHENOTYPE	11	12	retinal diseases
NCT0000578419	NCT00005784_19_T0	PHENOTYPE	10	11	retinal diseases
NCT0000578424	NCT00005784_24_T0	PHENOTYPE	18	19	retinal disease
NCT0000578430	NCT00005784_30_T0	PHENOTYPE	2	3	diabetic retinopathy
NCT0000578430	NCT00005784_30_T1	PHENOTYPE	6	7	macular degeneration
NCT0000578431	NCT00005784_31_T0	PHENOTYPE	10	11	retinal disease
NCT0000578431	NCT00005784_31_T1	PHENOTYPE	5	7	central serous retinopathy
NCT0000578431	NCT00005784_31_T2	PHENOTYPE	2	4	vascular occlusive disease
NCT000057850	NCT00005785_0_T0	CELL	0	1	Stem Cell
NCT000057850	NCT00005785_0_T1	ORGAN	3	4	Bone Marrow
NCT000057850	NCT00005785_0_T2	PHENOTYPE	10	11	Blood Cancer
NCT000057852	NCT00005785_2_T0	PHENOTYPE	0	0	HIV
NCT000057852	NCT00005785_2_T1	ORGAN	8	8	transplant
NCT000057852	NCT00005785_2_T2	ORGAN	6	7	bone marrow
NCT000057853	NCT00005785_3_T0	CELL	7	8	stem cells
NCT000057853	NCT00005785_3_T1	ORGAN	11	12	bone marrow
NCT000057854	NCT00005785_4_T0	PHENOTYPE	13	13	progression
NCT000057854	NCT00005785_4_T1	PHENOTYPE	16	17	HIV infection
NCT000057855	NCT00005785_5_T0	CELL	14	15	Stem cells
NCT000057855	NCT00005785_5_T1	ORGAN	8	9	bone marrow
NCT000057855	NCT00005785_5_T2	ORGAN	21	22	bone marrow
NCT000057857	NCT00005785_7_T0	GENE	22	22	separated
NCT000057857	NCT00005785_7_T1	CELL	1	1	cells
NCT000057857	NCT00005785_7_T2	CELL	71	71	cells
NCT000057857	NCT00005785_7_T3	PHENOTYPE	60	60	HIV
NCT000057857	NCT00005785_7_T4	BIOLOGICAL_PROCESS	61	61	reproduction
NCT000057857	NCT00005785_7_T5	CELL	20	21	stem cells
NCT000057857	NCT00005785_7_T6	CELL	67	68	stem cells
NCT000057859	NCT00005785_9_T0	CELL	12	12	lymphocytes
NCT000057859	NCT00005785_9_T1	CELL	8	10	white blood cells
NCT0000578510	NCT00005785_10_T0	CELL	0	1	Stem cells
NCT0000578511	NCT00005785_11_T0	CELL	3	3	cells
NCT0000578512	NCT00005785_12_T0	CELL	1	2	stem cells
NCT0000578513	NCT00005785_13_T0	CELL	3	3	cells
NCT0000578514	NCT00005785_14_T0	CELL	13	13	cells
NCT0000578514	NCT00005785_14_T1	COMPOUND	6	6	fludarabine
NCT0000578514	NCT00005785_14_T2	COMPOUND	5	5	cyclophosphamide
NCT0000578514	NCT00005785_14_T3	COMPOUND	8	8	cyclosporin
NCT0000578517	NCT00005785_17_T0	CELL	10	10	lymphocytes
NCT0000578520	NCT00005785_20_T0	GENE	3	3	has
NCT0000578521	NCT00005785_21_T0	PHENOTYPE	42	42	conditioning
NCT0000578521	NCT00005785_21_T1	GENE	20	20	has
NCT0000578522	NCT00005785_22_T0	PHENOTYPE	3	3	HIV
NCT0000578522	NCT00005785_22_T1	GENE	5	5	has
NCT0000578522	NCT00005785_22_T2	PHENOTYPE	16	17	hematologic malignancies
NCT0000578523	NCT00005785_23_T0	PHENOTYPE	7	7	HIV
NCT0000578523	NCT00005785_23_T1	PHENOTYPE	15	15	progression
NCT0000578528	NCT00005785_28_T0	PHENOTYPE	24	24	toxicity
NCT0000578528	NCT00005785_28_T1	PHENOTYPE	22	22	engraftment
NCT0000578529	NCT00005785_29_T0	PHENOTYPE	19	19	complications
NCT0000578529	NCT00005785_29_T1	ORGAN	17	17	transplant
NCT0000578530	NCT00005785_30_T0	PHENOTYPE	6	6	complications
NCT0000578530	NCT00005785_30_T1	PHENOTYPE	26	26	HIV
NCT0000578530	NCT00005785_30_T2	ORGAN	4	4	transplant
NCT0000578530	NCT00005785_30_T3	ORGAN	15	15	transplant
NCT0000578530	NCT00005785_30_T4	ORGAN	10	10	transplants
NCT0000578531	NCT00005785_31_T0	PHENOTYPE	16	17	HIV infection
NCT0000578533	NCT00005785_33_T0	PHENOTYPE	7	7	engraftment
NCT0000578533	NCT00005785_33_T1	PHENOTYPE	14	14	acute
NCT0000578533	NCT00005785_33_T2	CELL	41	41	cells
NCT0000578533	NCT00005785_33_T3	ORGAN	18	18	transplant
NCT0000578533	NCT00005785_33_T4	PHENOTYPE	35	35	persistence
NCT0000578533	NCT00005785_33_T5	PHENOTYPE	17	17	GVHD
NCT0000578533	NCT00005785_33_T6	PHENOTYPE	16	16	chronic
NCT0000578537	NCT00005785_37_T0	PHENOTYPE	3	3	AML
NCT0000578537	NCT00005785_37_T1	PHENOTYPE	4	4	AML
NCT0000578537	NCT00005785_37_T2	PHENOTYPE	10	10	remission
NCT0000578537	NCT00005785_37_T3	PHENOTYPE	0	2	Acute myelogenous leukemia
NCT0000578539	NCT00005785_39_T0	PHENOTYPE	0	2	Chronic myelomonocytic leukemia
NCT0000578541	NCT00005785_41_T0	PHENOTYPE	2	3	in remission
NCT0000578541	NCT00005785_41_T1	PHENOTYPE	0	1	Multiple myeloma
NCT0000578542	NCT00005785_42_T0	PHENOTYPE	3	3	dysfunction
NCT0000578544	NCT00005785_44_T0	PHENOTYPE	1	3	ventricular ejection fraction
NCT0000578547	NCT00005785_47_T0	GENE	3	3	G-CSF
NCT0000578547	NCT00005785_47_T1	PHENOTYPE	22	23	heart disease
NCT0000578547	NCT00005785_47_T2	CELL	6	9	peripheral blood stem cells
NCT0000578552	NCT00005785_52_T0	PHENOTYPE	3	4	psychiatric disorder
NCT0000578552	NCT00005785_52_T1	PHENOTYPE	6	7	mental deficiency
NCT0000578554	NCT00005785_54_T0	BIOLOGICAL_PROCESS	3	4	glomerular filtration
NCT0000578555	NCT00005785_55_T0	COMPOUND	4	4	bilirubin
NCT0000578555	NCT00005785_55_T1	ORGAN	3	3	serum
NCT0000578556	NCT00005785_56_T0	PHENOTYPE	3	3	HIV
NCT0000578557	NCT00005785_57_T0	COMPOUND	6	6	HCV
NCT0000578557	NCT00005785_57_T1	PHENOTYPE	5	5	HBV
NCT0000578558	NCT00005785_58_T0	PHENOTYPE	8	8	relapse
NCT0000578558	NCT00005785_58_T1	PHENOTYPE	5	5	diseases
NCT000057862	NCT00005786_2_T0	PHENOTYPE	5	5	toxicity
NCT000057862	NCT00005786_2_T1	COMPOUND	8	9	arsenic trioxide
NCT000057862	NCT00005786_2_T2	PHENOTYPE	16	17	low-grade lymphomas
NCT000057864	NCT00005786_4_T0	COMPOUND	10	11	arsenic trioxide
NCT000057864	NCT00005786_4_T1	PHENOTYPE	17	18	low-grade lymphomas
NCT000057866	NCT00005786_6_T0	COMPOUND	6	7	arsenic trioxide
NCT000057866	NCT00005786_6_T1	COMPOUND	21	22	arsenic trioxide
NCT000057866	NCT00005786_6_T2	PHENOTYPE	26	27	low-grade lymphomas
NCT000057866	NCT00005786_6_T3	PHENOTYPE	17	19	mechanism of action
NCT000057868	NCT00005786_8_T0	GENE	6	6	1.4
NCT000057868	NCT00005786_8_T1	GENE	10	10	1.5
NCT000057868	NCT00005786_8_T2	GENE	4	4	IV
NCT000057868	NCT00005786_8_T3	COMPOUND	2	3	arsenic trioxide
NCT000057869	NCT00005786_9_T0	PHENOTYPE	16	16	toxicity
NCT000057869	NCT00005786_9_T1	PHENOTYPE	18	19	disease progression
NCT000057871	NCT00005787_1_T0	ORGAN	14	14	transplant
NCT000057871	NCT00005787_1_T1	CELL	2	4	peripheral stem cells
NCT000057874	NCT00005787_4_T0	PHENOTYPE	2	2	peripheral
NCT000057874	NCT00005787_4_T1	CELL	5	5	cells
NCT000057875	NCT00005787_5_T0	GENE	11	11	interleukin-3
NCT000057875	NCT00005787_5_T1	GENE	17	17	epoetin
NCT000057875	NCT00005787_5_T2	GENE	12	12	filgrastim
NCT000057875	NCT00005787_5_T3	GENE	13	13	G-CSF
NCT000057875	NCT00005787_5_T4	GENE	15	15	GM-CSF
NCT000057875	NCT00005787_5_T5	GENE	14	14	sargramostim
NCT000057875	NCT00005787_5_T6	GENE	9	10	flt3 ligand
NCT000057876	NCT00005787_6_T0	GENE	0	0	Expanded
NCT000057884	NCT00005788_4_T0	GENE	2	2	interleukin-2
NCT000057885	NCT00005788_5_T0	PHENOTYPE	13	13	toxicity
NCT000057885	NCT00005788_5_T1	PHENOTYPE	9	10	disease progression
NCT000057887	NCT00005788_7_T0	PHENOTYPE	17	17	toxicity
NCT000057887	NCT00005788_7_T1	PHENOTYPE	13	14	disease progression
NCT000057902	NCT00005790_2_T0	PHENOTYPE	9	10	brain tumors
NCT000057906	NCT00005790_6_T0	GENE	7	7	MRI
NCT000057906	NCT00005790_6_T1	GENE	16	16	MRI
NCT000057907	NCT00005790_7_T0	COMPOUND	2	2	gadopentetate
NCT000057907	NCT00005790_7_T1	GENE	11	11	MRI
NCT000057907	NCT00005790_7_T2	GENE	4	4	IV
NCT000057908	NCT00005790_8_T0	GENE	11	11	MRI
NCT000057909	NCT00005790_9_T0	GENE	6	9	urokinase type plasminogen activator
NCT000057910	NCT00005791_0_T0	PHENOTYPE	10	11	Solid Tumors
NCT000057912	NCT00005791_2_T0	CELL	9	9	cells
NCT000057912	NCT00005791_2_T1	PHENOTYPE	8	8	tumor
NCT000057913	NCT00005791_3_T0	PHENOTYPE	20	21	solid tumors
NCT000057915	NCT00005791_5_T0	COMPOUND	7	7	irinotecan
NCT000057915	NCT00005791_5_T1	COMPOUND	14	14	cisplatin
NCT000057915	NCT00005791_5_T2	PHENOTYPE	22	23	solid tumors
NCT000057917	NCT00005791_7_T0	PHENOTYPE	4	4	toxicity
NCT000057919	NCT00005791_9_T0	GENE	4	4	II
NCT0000579115	NCT00005791_15_T0	GENE	17	17	dehydrogenase
NCT0000579115	NCT00005791_15_T1	GENE	8	9	thymidylate synthase
NCT0000579115	NCT00005791_15_T2	GENE	13	14	thymidine phosphorylase
NCT0000579115	NCT00005791_15_T3	GENE	10	11	topoisomerase I
NCT0000579116	NCT00005791_16_T0	COMPOUND	8	8	irinotecan
NCT0000579117	NCT00005791_17_T0	COMPOUND	16	16	irinotecan
NCT0000579117	NCT00005791_17_T1	COMPOUND	2	2	cisplatin
NCT0000579117	NCT00005791_17_T2	GENE	3	3	IV
NCT0000579117	NCT00005791_17_T3	GENE	10	10	IV
NCT0000579117	NCT00005791_17_T4	GENE	17	17	IV
NCT0000579118	NCT00005791_18_T0	PHENOTYPE	10	10	toxicity
NCT0000579118	NCT00005791_18_T1	PHENOTYPE	12	13	disease progression
NCT0000579119	NCT00005791_19_T0	COMPOUND	8	8	irinotecan
NCT0000579119	NCT00005791_19_T1	GENE	16	16	MTD
NCT0000579120	NCT00005791_20_T0	PHENOTYPE	22	22	toxicities
NCT0000579120	NCT00005791_20_T1	GENE	1	1	MTD
NCT0000579122	NCT00005791_22_T0	GENE	14	14	1.2
NCT000057926	NCT00005792_6_T0	COMPOUND	10	10	melphalan
NCT000057926	NCT00005792_6_T1	COMPOUND	6	6	topotecan
NCT000057926	NCT00005792_6_T2	COMPOUND	12	13	etoposide phosphate
NCT0000579210	NCT00005792_10_T0	PHENOTYPE	18	18	toxicity
NCT0000579210	NCT00005792_10_T1	PHENOTYPE	10	10	pharmacodynamic
NCT0000579213	NCT00005792_13_T0	COMPOUND	8	8	topotecan
NCT0000579214	NCT00005792_14_T0	COMPOUND	4	4	cyclophosphamide
NCT0000579214	NCT00005792_14_T1	GENE	5	5	IV
NCT0000579215	NCT00005792_15_T0	CELL	0	3	Peripheral blood stem cells
NCT0000579216	NCT00005792_16_T0	COMPOUND	8	8	melphalan
NCT0000579216	NCT00005792_16_T1	GENE	9	9	IV
NCT0000579216	NCT00005792_16_T2	GENE	15	15	IV
NCT0000579216	NCT00005792_16_T3	COMPOUND	14	14	topotecan
NCT0000579217	NCT00005792_17_T0	COMPOUND	12	12	3
NCT0000579217	NCT00005792_17_T1	COMPOUND	1	1	phosphate
NCT0000579217	NCT00005792_17_T2	GENE	2	2	IV
NCT0000579219	NCT00005792_19_T0	GENE	14	14	MTD
NCT0000579219	NCT00005792_19_T1	COMPOUND	8	8	topotecan
NCT0000579220	NCT00005792_20_T0	PHENOTYPE	18	18	toxicities
NCT0000579220	NCT00005792_20_T1	GENE	1	1	MTD
NCT0000579221	NCT00005792_21_T0	GENE	3	3	2.3
NCT000057931	NCT00005793_1_T0	CELL	9	9	cells
NCT000057934	NCT00005793_4_T0	GENE	16	16	II
NCT000057934	NCT00005793_4_T1	COMPOUND	7	7	topotecan
NCT000057935	NCT00005793_5_T0	COMPOUND	13	13	cytarabine
NCT000057935	NCT00005793_5_T1	GENE	12	12	1.3
NCT000057935	NCT00005793_5_T2	GENE	18	18	1.5
NCT000057935	NCT00005793_5_T3	COMPOUND	26	26	etoposide
NCT000057935	NCT00005793_5_T4	GENE	6	6	IV
NCT000057935	NCT00005793_5_T5	GENE	14	14	IV
NCT000057935	NCT00005793_5_T6	GENE	20	20	IV
NCT000057935	NCT00005793_5_T7	GENE	27	27	IV
NCT000057935	NCT00005793_5_T8	COMPOUND	19	19	topotecan
NCT000057935	NCT00005793_5_T9	COMPOUND	5	5	daunorubicin
NCT000057936	NCT00005793_6_T0	COMPOUND	15	15	cytarabine
NCT000057936	NCT00005793_6_T1	PHENOTYPE	8	8	remission
NCT000057936	NCT00005793_6_T2	GENE	16	16	IV
NCT000057938	NCT00005793_8_T0	PHENOTYPE	11	11	toxicity
NCT000057938	NCT00005793_8_T1	PHENOTYPE	0	0	Consolidation
NCT000057938	NCT00005793_8_T2	PHENOTYPE	13	14	disease progression
NCT000057939	NCT00005793_9_T0	GENE	14	14	MTD
NCT000057939	NCT00005793_9_T1	COMPOUND	8	8	topotecan
NCT0000579310	NCT00005793_10_T0	PHENOTYPE	21	21	toxicity
NCT0000579310	NCT00005793_10_T1	GENE	1	1	MTD
NCT0000579311	NCT00005793_11_T0	GENE	17	17	II
NCT0000579311	NCT00005793_11_T1	GENE	2	2	MTD
NCT0000579313	NCT00005793_13_T0	GENE	16	16	II
NCT000057940	NCT00005794_0_T0	PHENOTYPE	6	7	Solid Tumors
NCT000057942	NCT00005794_2_T0	COMPOUND	9	9	perifosine
NCT000057942	NCT00005794_2_T1	PHENOTYPE	16	17	solid tumors
NCT000057945	NCT00005794_5_T0	COMPOUND	7	7	perifosine
NCT000057945	NCT00005794_5_T1	GENE	13	13	4-8
NCT000057946	NCT00005794_6_T0	PHENOTYPE	10	10	toxicity
NCT000057946	NCT00005794_6_T1	PHENOTYPE	12	13	disease progression
NCT000057947	NCT00005794_7_T0	COMPOUND	12	12	perifosine
NCT000057947	NCT00005794_7_T1	GENE	18	18	MTD
NCT000057948	NCT00005794_8_T0	PHENOTYPE	17	17	toxic
NCT000057948	NCT00005794_8_T1	GENE	1	1	MTD
NCT000057955	NCT00005795_5_T0	PHENOTYPE	2	2	toxicities
NCT000057958	NCT00005795_8_T0	GENE	7	7	1.4
NCT000057958	NCT00005795_8_T1	GENE	5	5	IV
NCT000057958	NCT00005795_8_T2	COMPOUND	3	4	arsenic trioxide
NCT000057958	NCT00005795_8_T3	ORGAN	17	18	bone marrow
NCT000057959	NCT00005795_9_T0	COMPOUND	7	8	arsenic trioxide
NCT0000579510	NCT00005795_10_T0	PHENOTYPE	13	13	toxicity
NCT0000579510	NCT00005795_10_T1	PHENOTYPE	15	16	disease progression
NCT0000579511	NCT00005795_11_T0	GENE	5	5	CR
NCT0000579511	NCT00005795_11_T1	GENE	14	14	CR
NCT000057961	NCT00005796_1_T0	CELL	9	9	cells
NCT000057961	NCT00005796_1_T1	PHENOTYPE	8	8	tumor
NCT000057962	NCT00005796_2_T0	CELL	7	9	peripheral stem cells
NCT000057963	NCT00005796_3_T0	PHENOTYPE	20	20	tumors
NCT000057965	NCT00005796_5_T0	PHENOTYPE	2	2	toxicity
NCT000057965	NCT00005796_5_T1	PHENOTYPE	31	31	tumors
NCT000057965	NCT00005796_5_T2	CELL	11	11	cells
NCT000057965	NCT00005796_5_T3	COMPOUND	19	19	O6-methylguanine
NCT000057965	NCT00005796_5_T4	GENE	10	10	CD34
NCT000057965	NCT00005796_5_T5	GENE	20	21	DNA methyltransferase
NCT000057967	NCT00005796_7_T0	GENE	19	19	fragment
NCT000057967	NCT00005796_7_T1	GENE	13	13	ex
NCT000057967	NCT00005796_7_T2	CELL	7	7	cells
NCT000057967	NCT00005796_7_T3	CELL	28	28	cells
NCT000057967	NCT00005796_7_T4	GENE	17	17	fibronectin
NCT000057969	NCT00005796_9_T0	PHENOTYPE	4	4	engraftment
NCT000057969	NCT00005796_9_T1	CELL	6	6	cells
NCT000057969	NCT00005796_9_T2	BIOLOGICAL_PROCESS	12	12	transduction
NCT0000579611	NCT00005796_11_T0	GENE	15	15	ex
NCT0000579611	NCT00005796_11_T1	CELL	10	10	cells
NCT0000579611	NCT00005796_11_T2	BIOLOGICAL_PROCESS	18	18	transduction
NCT0000579613	NCT00005796_13_T0	PHENOTYPE	13	13	initiation
NCT0000579613	NCT00005796_13_T1	GENE	3	3	filgrastim
NCT0000579613	NCT00005796_13_T2	GENE	4	4	G-CSF
NCT0000579613	NCT00005796_13_T3	GENE	7	7	IV
NCT0000579614	NCT00005796_14_T0	CELL	10	10	cells
NCT0000579614	NCT00005796_14_T1	GENE	16	16	fibronectin
NCT0000579614	NCT00005796_14_T2	COMPOUND	22	22	O6-methylguanine
NCT0000579614	NCT00005796_14_T3	GENE	9	9	CD34
NCT0000579614	NCT00005796_14_T4	GENE	23	24	DNA methyltransferase
NCT0000579614	NCT00005796_14_T5	CELL	0	3	Peripheral blood stem cells
NCT0000579615	NCT00005796_15_T0	COMPOUND	6	6	vincristine
NCT0000579615	NCT00005796_15_T1	GENE	16	16	1.7
NCT0000579615	NCT00005796_15_T2	GENE	7	7	IV
NCT0000579615	NCT00005796_15_T3	COMPOUND	13	13	procarbazine
NCT0000579615	NCT00005796_15_T4	COMPOUND	4	4	lomustine
NCT0000579616	NCT00005796_16_T0	PHENOTYPE	16	16	toxicity
NCT0000579616	NCT00005796_16_T1	PHENOTYPE	12	13	disease progression
NCT0000579617	NCT00005796_17_T0	PHENOTYPE	4	4	tumors
NCT0000579618	NCT00005796_18_T0	CELL	6	6	cells
NCT0000579618	NCT00005796_18_T1	GENE	5	5	CD34
NCT0000579619	NCT00005796_19_T0	CELL	8	8	cells
NCT0000579619	NCT00005796_19_T1	GENE	7	7	CD34
NCT0000579620	NCT00005796_20_T0	CELL	2	2	cells
NCT0000579620	NCT00005796_20_T1	GENE	1	1	CD34
NCT000057971	NCT00005797_1_T0	CELL	12	13	stem cells
NCT000057971	NCT00005797_1_T1	ORGAN	6	7	immune system
NCT000057972	NCT00005797_2_T0	CELL	30	30	platelets
NCT000057972	NCT00005797_2_T1	CELL	3	4	stem cells
NCT000057972	NCT00005797_2_T2	CELL	21	22	stem cells
NCT000057972	NCT00005797_2_T3	ORGAN	18	19	bone marrow
NCT000057972	NCT00005797_2_T4	CELL	23	25	red blood cells
NCT000057972	NCT00005797_2_T5	CELL	26	28	white blood cells
NCT000057973	NCT00005797_3_T0	GENE	3	3	II
NCT000057973	NCT00005797_3_T1	PHENOTYPE	19	19	cancers
NCT000057973	NCT00005797_3_T2	ORGAN	12	12	transplant
NCT000057973	NCT00005797_3_T3	ORGAN	10	11	bone marrow
NCT000057977	NCT00005797_7_T0	COMPOUND	3	3	busulfan
NCT000057977	NCT00005797_7_T1	COMPOUND	22	22	2
NCT000057977	NCT00005797_7_T2	COMPOUND	20	20	3
NCT000057977	NCT00005797_7_T3	COMPOUND	13	13	cyclophosphamide
NCT000057977	NCT00005797_7_T4	GENE	14	14	IV
NCT0000579711	NCT00005797_11_T0	ORGAN	1	2	bone marrow
NCT0000579712	NCT00005797_12_T0	COMPOUND	5	5	cyclosporine
NCT0000579712	NCT00005797_12_T1	COMPOUND	7	7	methotrexate
NCT0000579712	NCT00005797_12_T2	PHENOTYPE	9	12	graft versus host disease
NCT0000579714	NCT00005797_14_T0	PHENOTYPE	15	15	malignancies
NCT000057988	NCT00005798_8_T0	CELL	1	4	Peripheral blood stem cells
NCT000057989	NCT00005798_9_T0	COMPOUND	8	8	thiotepa
NCT000057989	NCT00005798_9_T1	COMPOUND	3	3	cyclophosphamide
NCT000057989	NCT00005798_9_T2	GENE	4	4	IV
NCT000057989	NCT00005798_9_T3	GENE	9	9	IV
NCT000057989	NCT00005798_9_T4	GENE	15	15	IV
NCT0000579812	NCT00005798_12_T0	TISSUE	9	10	lymph nodes
NCT0000579812	NCT00005798_12_T1	TISSUE	19	20	lymph nodes
NCT000057992	NCT00005799_2_T0	CELL	12	13	stem cells
NCT000057992	NCT00005799_2_T1	ORGAN	6	7	immune system
NCT000057993	NCT00005799_3_T0	CELL	9	9	cells
NCT000057993	NCT00005799_3_T1	CELL	16	16	cells
NCT000057993	NCT00005799_3_T2	CELL	2	3	stem cells
NCT000057994	NCT00005799_4_T0	ORGAN	13	13	transplant
NCT000057994	NCT00005799_4_T1	CELL	9	9	lymphocyte
NCT000057994	NCT00005799_4_T2	CELL	6	7	T cells
NCT000057996	NCT00005799_6_T0	COMPOUND	1	1	cyclosporine
NCT000057996	NCT00005799_6_T1	COMPOUND	6	6	cyclosporine
NCT000057996	NCT00005799_6_T2	ORGAN	4	4	transplant
NCT000057996	NCT00005799_6_T3	ORGAN	12	12	transplant
NCT000057996	NCT00005799_6_T4	COMPOUND	8	9	mycophenolate mofetil
NCT0000579911	NCT00005799_11_T0	COMPOUND	13	13	2
NCT0000579911	NCT00005799_11_T1	PHENOTYPE	1	1	CONDITIONING
NCT0000579911	NCT00005799_11_T2	COMPOUND	5	5	fludarabine
NCT0000579911	NCT00005799_11_T3	COMPOUND	6	6	phosphate
NCT0000579911	NCT00005799_11_T4	GENE	8	8	IV
NCT0000579914	NCT00005799_14_T0	COMPOUND	3	3	cyclosporine
NCT0000579914	NCT00005799_14_T1	COMPOUND	11	11	3
NCT0000579914	NCT00005799_14_T2	GENE	8	8	BID
NCT0000579914	NCT00005799_14_T3	GENE	23	23	BID
NCT0000579914	NCT00005799_14_T4	COMPOUND	20	21	mycophenolate mofetil
NCT0000579915	NCT00005799_15_T0	PHENOTYPE	19	19	immunosuppression
NCT0000579915	NCT00005799_15_T1	PHENOTYPE	6	7	progressive disease
NCT0000579915	NCT00005799_15_T2	PHENOTYPE	12	13	graft-versus-host disease
NCT000058001	NCT00005800_1_T0	CELL	9	9	cells
NCT000058001	NCT00005800_1_T1	PHENOTYPE	8	8	tumor
NCT000058002	NCT00005800_2_T0	GENE	2	2	II
NCT000058002	NCT00005800_2_T1	COMPOUND	11	11	docetaxel
NCT000058002	NCT00005800_2_T2	COMPOUND	9	9	doxorubicin
NCT000058002	NCT00005800_2_T3	PHENOTYPE	17	20	stage III breast cancer
NCT000058004	NCT00005800_4_T0	COMPOUND	3	3	doxorubicin
NCT000058004	NCT00005800_4_T1	GENE	4	4	IV
NCT000058005	NCT00005800_5_T0	COMPOUND	7	7	docetaxel
NCT000058005	NCT00005800_5_T1	GENE	8	8	IV
NCT000058006	NCT00005800_6_T0	GENE	7	7	3-10
NCT000058006	NCT00005800_6_T1	COMPOUND	12	12	docetaxel
NCT000058006	NCT00005800_6_T2	GENE	1	1	G-CSF
NCT000058006	NCT00005800_6_T3	COMPOUND	10	10	doxorubicin
NCT000058007	NCT00005800_7_T0	TISSUE	17	18	lymph node
NCT000058012	NCT00005801_2_T0	CELL	3	5	white blood cells
NCT000058012	NCT00005801_2_T1	CELL	14	16	peripheral stem cells
NCT000058019	NCT00005801_9_T0	PHENOTYPE	8	8	AML
NCT000058019	NCT00005801_9_T1	PHENOTYPE	14	14	remission
NCT0000580110	NCT00005801_10_T0	PHENOTYPE	1	1	Conditioning
NCT0000580110	NCT00005801_10_T1	CELL	14	17	peripheral blood stem cells
NCT0000580111	NCT00005801_11_T0	CELL	5	5	lymphocytes
NCT0000580111	NCT00005801_11_T1	CELL	1	1	lymphocyte
NCT0000580112	NCT00005801_12_T0	CELL	25	25	lymphocytes
NCT0000580112	NCT00005801_12_T1	PHENOTYPE	11	11	GVHD
NCT0000580112	NCT00005801_12_T2	CELL	16	16	lymphocyte
NCT0000580112	NCT00005801_12_T3	PHENOTYPE	7	10	graft versus host disease
NCT0000580113	NCT00005801_13_T0	PHENOTYPE	9	9	GVHD
NCT000058021	NCT00005802_1_T0	PHENOTYPE	10	10	leukemia
NCT000058021	NCT00005802_1_T1	CELL	11	11	cells
NCT000058021	NCT00005802_1_T2	GENE	0	0	Interleukin-2
NCT000058021	NCT00005802_1_T3	CELL	5	7	white blood cells
NCT000058022	NCT00005802_2_T0	CELL	16	16	cells
NCT000058022	NCT00005802_2_T1	GENE	6	6	interleukin-2
NCT000058022	NCT00005802_2_T2	CELL	2	4	white blood cells
NCT000058025	NCT00005802_5_T0	GENE	8	8	interleukin-2
NCT000058025	NCT00005802_5_T1	GENE	9	9	IL-2
NCT000058028	NCT00005802_8_T0	PHENOTYPE	3	3	relapse
NCT0000580210	NCT00005802_10_T0	GENE	6	6	IV
NCT0000580210	NCT00005802_10_T1	CELL	4	4	lymphocyte
NCT0000580211	NCT00005802_11_T0	GENE	4	4	IL-2
NCT0000580211	NCT00005802_11_T1	GENE	5	5	IV
NCT0000580212	NCT00005802_12_T0	GENE	4	4	IL-2
NCT0000580213	NCT00005802_13_T0	GENE	8	8	IL-2
NCT0000580213	NCT00005802_13_T1	GENE	14	14	MTD
NCT0000580214	NCT00005802_14_T0	PHENOTYPE	19	19	toxicities
NCT0000580214	NCT00005802_14_T1	GENE	1	1	MTD
NCT0000580215	NCT00005802_15_T0	GENE	8	8	MTD
NCT000058032	NCT00005803_2_T0	CELL	11	11	cells
NCT000058032	NCT00005803_2_T1	CELL	2	3	stem cells
NCT000058036	NCT00005803_6_T0	PHENOTYPE	3	3	relapse
NCT0000580315	NCT00005803_15_T0	COMPOUND	3	3	cyclosporine
NCT0000580315	NCT00005803_15_T1	COMPOUND	9	9	3
NCT0000580315	NCT00005803_15_T2	GENE	6	6	BID
NCT0000580316	NCT00005803_16_T0	GENE	6	6	BID
NCT0000580316	NCT00005803_16_T1	GENE	22	22	BID
NCT0000580316	NCT00005803_16_T2	GENE	17	17	TID
NCT0000580316	NCT00005803_16_T3	COMPOUND	3	4	mycophenolate mofetil
NCT0000580317	NCT00005803_17_T0	PHENOTYPE	20	20	GVHD
NCT0000580317	NCT00005803_17_T1	CELL	5	5	lymphocyte
NCT0000580317	NCT00005803_17_T2	PHENOTYPE	18	19	graft-vs-host disease
NCT0000580317	NCT00005803_17_T3	PHENOTYPE	12	13	disease progression
NCT0000580318	NCT00005803_18_T0	GENE	14	14	1.5
NCT000058041	NCT00005804_1_T0	CELL	10	10	cells
NCT000058042	NCT00005804_2_T0	CELL	21	21	cells
NCT000058042	NCT00005804_2_T1	PHENOTYPE	20	20	tumor
NCT000058042	NCT00005804_2_T2	ORGAN	3	4	bone marrow
NCT000058043	NCT00005804_3_T0	GENE	2	2	II
NCT000058043	NCT00005804_3_T1	PHENOTYPE	17	18	hematologic cancer
NCT000058043	NCT00005804_3_T2	ORGAN	9	10	bone marrow
NCT000058047	NCT00005804_7_T0	COMPOUND	11	11	2
NCT000058047	NCT00005804_7_T1	COMPOUND	9	9	3
NCT000058047	NCT00005804_7_T2	COMPOUND	4	4	cyclophosphamide
NCT000058047	NCT00005804_7_T3	GENE	5	5	IV
NCT000058048	NCT00005804_8_T0	ORGAN	10	10	marrow
NCT000058048	NCT00005804_8_T1	ORGAN	19	19	testes
NCT000058048	NCT00005804_8_T2	PHENOTYPE	5	6	high-grade lymphoma
NCT000058048	NCT00005804_8_T3	PHENOTYPE	7	8	intermediate-grade lymphoma
NCT000058048	NCT00005804_8_T4	PHENOTYPE	2	4	acute lymphocytic leukemia
NCT000058049	NCT00005804_9_T0	GENE	18	18	HLA-A
NCT000058049	NCT00005804_9_T1	GENE	25	25	HLA-A
NCT000058049	NCT00005804_9_T2	GENE	33	33	HLA-A
NCT000058049	NCT00005804_9_T3	GENE	40	40	HLA-DRB1
NCT000058049	NCT00005804_9_T4	GENE	42	42	DQB1
NCT000058049	NCT00005804_9_T5	ORGAN	7	8	bone marrow
NCT000058051	NCT00005805_1_T0	PHENOTYPE	15	15	fatigue
NCT000058051	NCT00005805_1_T1	GENE	3	3	III
NCT000058051	NCT00005805_1_T2	GENE	23	23	hormone
NCT000058053	NCT00005805_3_T0	PHENOTYPE	11	11	fatigue
NCT000058053	NCT00005805_3_T1	PHENOTYPE	20	21	malignant disease
NCT000058055	NCT00005805_5_T0	PHENOTYPE	4	4	fatigue
NCT000058057	NCT00005805_7_T0	PHENOTYPE	10	10	fatigue
NCT0000580512	NCT00005805_12_T0	PHENOTYPE	13	13	toxicity
NCT0000580512	NCT00005805_12_T1	PHENOTYPE	10	10	symptoms
NCT0000580513	NCT00005805_13_T0	PHENOTYPE	11	11	Fatigue
NCT000058062	NCT00005806_2_T0	CELL	9	9	cells
NCT000058062	NCT00005806_2_T1	PHENOTYPE	8	8	tumor
NCT000058069	NCT00005806_9_T0	COMPOUND	9	9	paclitaxel
NCT0000580611	NCT00005806_11_T0	COMPOUND	14	14	paclitaxel
NCT0000580618	NCT00005806_18_T0	COMPOUND	2	2	paclitaxel
NCT0000580618	NCT00005806_18_T1	GENE	3	3	IV
NCT0000580618	NCT00005806_18_T2	GENE	10	10	IV
NCT0000580619	NCT00005806_19_T0	COMPOUND	10	10	paclitaxel
NCT0000580624	NCT00005806_24_T0	COMPOUND	1	1	2
NCT0000580626	NCT00005806_26_T0	COMPOUND	2	2	paclitaxel
NCT0000580627	NCT00005806_27_T0	COMPOUND	8	8	paclitaxel
NCT0000580628	NCT00005806_28_T0	PHENOTYPE	16	16	toxicity
NCT0000580628	NCT00005806_28_T1	PHENOTYPE	18	19	disease progression
NCT0000580629	NCT00005806_29_T0	GENE	21	21	MTD
NCT0000580630	NCT00005806_30_T0	PHENOTYPE	22	22	toxicities
NCT0000580630	NCT00005806_30_T1	GENE	1	1	MTD
NCT000058071	NCT00005807_1_T0	PHENOTYPE	16	16	recurrent
NCT000058071	NCT00005807_1_T1	PHENOTYPE	20	21	ovarian cancer
NCT000058071	NCT00005807_1_T2	PHENOTYPE	22	23	breast cancer
NCT000058071	NCT00005807_1_T3	PHENOTYPE	28	29	solid tumors
NCT000058075	NCT00005807_5_T0	PHENOTYPE	10	10	toxicity
NCT000058075	NCT00005807_5_T1	PHENOTYPE	6	7	disease progression
NCT000058076	NCT00005807_6_T0	GENE	14	14	MTD
NCT000058078	NCT00005807_8_T0	PHENOTYPE	10	10	toxicity
NCT000058078	NCT00005807_8_T1	PHENOTYPE	7	7	progression
NCT000058085	NCT00005808_5_T0	COMPOUND	7	7	lutetium
NCT000058086	NCT00005808_6_T0	COMPOUND	1	1	1
NCT000058086	NCT00005808_6_T1	COMPOUND	4	4	lutetium
NCT000058086	NCT00005808_6_T2	GENE	6	6	IV
NCT000058087	NCT00005808_7_T0	COMPOUND	27	27	lutetium
NCT000058088	NCT00005808_8_T0	COMPOUND	1	1	2
NCT000058088	NCT00005808_8_T1	COMPOUND	4	4	lutetium
NCT000058088	NCT00005808_8_T2	GENE	6	6	IV
NCT000058089	NCT00005808_9_T0	ORGAN	9	9	cervix
NCT0000580810	NCT00005808_10_T0	ORGAN	13	13	cervix
NCT0000580811	NCT00005808_11_T0	COMPOUND	8	8	lutetium
NCT0000580811	NCT00005808_11_T1	GENE	23	23	MTD
NCT0000580812	NCT00005808_12_T0	PHENOTYPE	17	17	toxicity
NCT0000580812	NCT00005808_12_T1	GENE	1	1	MTD
NCT000058091	NCT00005809_1_T0	PHENOTYPE	20	20	neoplasia
NCT000058093	NCT00005809_3_T0	PHENOTYPE	10	10	pathology
NCT000058093	NCT00005809_3_T1	GENE	35	35	cm
NCT000058093	NCT00005809_3_T2	PHENOTYPE	20	20	neoplasia
NCT000058101	NCT00005810_1_T0	PHENOTYPE	17	17	peripheral
NCT000058101	NCT00005810_1_T1	CELL	11	11	cells
NCT000058101	NCT00005810_1_T2	GENE	4	4	filgrastim
NCT000058101	NCT00005810_1_T3	ORGAN	14	15	bone marrow
NCT000058101	NCT00005810_1_T4	ORGAN	24	25	immune system
NCT000058101	NCT00005810_1_T5	PHENOTYPE	30	32	effects of chemotherapy
NCT000058106	NCT00005810_6_T0	PHENOTYPE	2	2	toxicity
NCT000058112	NCT00005811_2_T0	PHENOTYPE	19	19	progression
NCT000058112	NCT00005811_2_T1	PHENOTYPE	24	24	recurrent
NCT000058112	NCT00005811_2_T2	COMPOUND	6	6	topotecan
NCT000058112	NCT00005811_2_T3	PHENOTYPE	27	28	neoplastic meningitis
NCT000058112	NCT00005811_2_T4	ORGAN	15	17	central nervous system
NCT000058114	NCT00005811_4_T0	PHENOTYPE	4	4	toxicity
NCT000058116	NCT00005811_6_T0	GENE	11	11	CSF
NCT000058117	NCT00005811_7_T0	PHENOTYPE	15	15	medulloblastoma
NCT000058117	NCT00005811_7_T1	PHENOTYPE	18	19	solid tumors
NCT000058117	NCT00005811_7_T2	PHENOTYPE	8	10	acute lymphoblastic leukemia
NCT000058118	NCT00005811_8_T0	COMPOUND	17	17	hydrochloride
NCT000058118	NCT00005811_8_T1	PHENOTYPE	0	0	Recurrent
NCT000058118	NCT00005811_8_T2	GENE	19	19	IT
NCT000058118	NCT00005811_8_T3	COMPOUND	16	16	topotecan
NCT000058118	NCT00005811_8_T4	PHENOTYPE	2	4	acute lymphoblastic leukemia
NCT000058119	NCT00005811_9_T0	PHENOTYPE	28	28	toxicity
NCT000058119	NCT00005811_9_T1	COMPOUND	11	11	hydrochloride
NCT000058119	NCT00005811_9_T2	GENE	12	12	IT
NCT000058119	NCT00005811_9_T3	COMPOUND	10	10	topotecan
NCT000058119	NCT00005811_9_T4	PHENOTYPE	24	25	disease progression
NCT0000581110	NCT00005811_10_T0	COMPOUND	11	11	hydrochloride
NCT0000581110	NCT00005811_10_T1	GENE	12	12	IT
NCT0000581110	NCT00005811_10_T2	COMPOUND	10	10	topotecan
NCT000058121	NCT00005812_1_T0	COMPOUND	9	9	temozolomide
NCT000058121	NCT00005812_1_T1	GENE	2	2	II
NCT000058121	NCT00005812_1_T2	PHENOTYPE	22	22	lymphoma
NCT000058121	NCT00005812_1_T3	PHENOTYPE	15	16	leptomeningeal metastases
NCT000058121	NCT00005812_1_T4	PHENOTYPE	19	20	solid tumor
NCT000058123	NCT00005812_3_T0	COMPOUND	4	4	temozolomide
NCT000058124	NCT00005812_4_T0	PHENOTYPE	10	10	toxicity
NCT000058124	NCT00005812_4_T1	PHENOTYPE	12	13	disease progression
NCT000058125	NCT00005812_5_T0	GENE	5	5	CR
NCT000058125	NCT00005812_5_T1	GENE	12	12	CR
NCT000058126	NCT00005812_6_T0	GENE	3	3	CR
NCT000058127	NCT00005812_7_T0	PHENOTYPE	0	2	Quality of life
NCT000058131	NCT00005813_1_T0	PHENOTYPE	21	21	recurrent
NCT000058131	NCT00005813_1_T1	PHENOTYPE	24	25	glioblastoma multiforme
NCT000058131	NCT00005813_1_T2	CELL	13	15	white blood cells
NCT000058134	NCT00005813_4_T0	PHENOTYPE	7	7	tumor
NCT000058135	NCT00005813_5_T0	CELL	16	16	monocytes
NCT000058135	NCT00005813_5_T1	GENE	1	1	2.4
NCT000058137	NCT00005813_7_T0	CELL	15	15	monocytes
NCT000058137	NCT00005813_7_T1	GENE	21	21	MTD
NCT000058138	NCT00005813_8_T0	PHENOTYPE	18	18	toxicities
NCT000058138	NCT00005813_8_T1	GENE	1	1	MTD
NCT000058140	NCT00005814_0_T0	GENE	11	11	III
NCT000058140	NCT00005814_0_T1	GENE	14	14	IV
NCT000058140	NCT00005814_0_T2	PHENOTYPE	15	18	Head and Neck Cancer
NCT000058142	NCT00005814_2_T0	CELL	10	10	cells
NCT000058142	NCT00005814_2_T1	PHENOTYPE	9	9	tumor
NCT000058143	NCT00005814_3_T0	CELL	8	8	cells
NCT000058143	NCT00005814_3_T1	PHENOTYPE	7	7	tumor
NCT000058144	NCT00005814_4_T0	CELL	13	13	cells
NCT000058144	NCT00005814_4_T1	PHENOTYPE	12	12	tumor
NCT000058145	NCT00005814_5_T0	GENE	2	2	II
NCT000058145	NCT00005814_5_T1	GENE	25	25	IV
NCT000058145	NCT00005814_5_T2	COMPOUND	11	11	cisplatin
NCT000058145	NCT00005814_5_T3	PHENOTYPE	21	22	stage III
NCT000058145	NCT00005814_5_T4	PHENOTYPE	26	29	head and neck cancer
NCT0000581411	NCT00005814_11_T0	PHENOTYPE	3	4	disease progression
NCT0000581413	NCT00005814_13_T0	PHENOTYPE	9	11	quality of life
NCT0000581414	NCT00005814_14_T0	GENE	8	8	IV
NCT0000581415	NCT00005814_15_T0	COMPOUND	2	2	cisplatin
NCT0000581415	NCT00005814_15_T1	GENE	3	3	IV
NCT0000581416	NCT00005814_16_T0	GENE	7	7	1.4
NCT0000581417	NCT00005814_17_T0	GENE	11	11	IV
NCT0000581417	NCT00005814_17_T1	GENE	18	18	7-10
NCT0000581418	NCT00005814_18_T0	GENE	17	17	3.4
NCT0000581418	NCT00005814_18_T1	PHENOTYPE	0	2	Quality of life
NCT000058150	NCT00005815_0_T0	PHENOTYPE	12	12	Melanoma
NCT000058150	NCT00005815_0_T1	GENE	8	8	III
NCT000058150	NCT00005815_0_T2	GENE	11	11	IV
NCT000058153	NCT00005815_3_T0	CELL	8	8	cells
NCT000058153	NCT00005815_3_T1	COMPOUND	3	3	thalidomide
NCT000058153	NCT00005815_3_T2	PHENOTYPE	7	7	tumor
NCT000058154	NCT00005815_4_T0	COMPOUND	8	8	temozolomide
NCT000058154	NCT00005815_4_T1	COMPOUND	10	10	thalidomide
NCT000058154	NCT00005815_4_T2	PHENOTYPE	16	17	stage III
NCT000058154	NCT00005815_4_T3	PHENOTYPE	19	21	stage IV melanoma
NCT000058156	NCT00005815_6_T0	COMPOUND	8	8	temozolomide
NCT000058156	NCT00005815_6_T1	GENE	19	19	II
NCT000058157	NCT00005815_7_T0	COMPOUND	3	3	temozolomide
NCT000058157	NCT00005815_7_T1	GENE	10	10	2.4
NCT000058158	NCT00005815_8_T0	COMPOUND	3	3	thalidomide
NCT000058159	NCT00005815_9_T0	PHENOTYPE	7	7	toxicity
NCT000058159	NCT00005815_9_T1	PHENOTYPE	9	10	disease progression
NCT0000581510	NCT00005815_10_T0	COMPOUND	8	8	temozolomide
NCT0000581510	NCT00005815_10_T1	GENE	14	14	MTD
NCT0000581511	NCT00005815_11_T0	PHENOTYPE	18	18	toxicities
NCT0000581511	NCT00005815_11_T1	GENE	1	1	MTD
NCT0000581512	NCT00005815_12_T0	COMPOUND	13	13	temozolomide
NCT0000581512	NCT00005815_12_T1	GENE	20	20	II
NCT0000581512	NCT00005815_12_T2	COMPOUND	15	15	thalidomide
NCT0000581512	NCT00005815_12_T3	GENE	2	2	MTD
NCT0000581513	NCT00005815_13_T0	GENE	32	32	II
NCT000058161	NCT00005816_1_T0	PHENOTYPE	16	17	stage III
NCT000058161	NCT00005816_1_T1	PHENOTYPE	19	22	stage IV kidney cancer
NCT000058165	NCT00005816_5_T0	PHENOTYPE	2	2	toxicity
NCT000058167	NCT00005816_7_T0	BIOLOGICAL_PROCESS	6	8	cellular immune response
NCT0000581611	NCT00005816_11_T0	GENE	15	15	MTD
NCT0000581611	NCT00005816_11_T1	GENE	9	9	IV
NCT0000581612	NCT00005816_12_T0	PHENOTYPE	17	17	toxicity
NCT0000581612	NCT00005816_12_T1	GENE	1	1	MTD
NCT000058171	NCT00005817_1_T0	CELL	10	10	cells
NCT000058171	NCT00005817_1_T1	PHENOTYPE	9	9	tumor
NCT000058173	NCT00005817_3_T0	PHENOTYPE	11	12	breast cancer
NCT000058173	NCT00005817_3_T1	COMPOUND	5	6	rebeccamycin analog
NCT000058175	NCT00005817_5_T0	PHENOTYPE	3	3	toxicity
NCT000058175	NCT00005817_5_T1	PHENOTYPE	15	16	breast cancer
NCT000058175	NCT00005817_5_T2	COMPOUND	8	9	rebeccamycin analog
NCT000058177	NCT00005817_7_T0	GENE	5	5	II
NCT000058177	NCT00005817_7_T1	CELL	9	9	lymphocytes
NCT000058177	NCT00005817_7_T2	COMPOUND	13	14	rebeccamycin analog
NCT000058177	NCT00005817_7_T3	GENE	2	3	topoisomerase I
NCT000058183	NCT00005818_3_T0	PHENOTYPE	8	8	toxicity
NCT000058183	NCT00005818_3_T1	COMPOUND	14	14	irinotecan
NCT000058183	NCT00005818_3_T2	GENE	5	5	MTD
NCT000058183	NCT00005818_3_T3	PHENOTYPE	19	20	colorectal cancer
NCT000058185	NCT00005818_5_T0	GENE	19	19	MTD
NCT000058185	NCT00005818_5_T1	PHENOTYPE	3	4	disease progression
NCT000058187	NCT00005818_7_T0	PHENOTYPE	4	4	tolerance
NCT000058189	NCT00005818_9_T0	COMPOUND	2	2	irinotecan
NCT000058189	NCT00005818_9_T1	GENE	12	12	1.4
NCT000058189	NCT00005818_9_T2	GENE	26	26	1/6
NCT000058189	NCT00005818_9_T3	GENE	3	3	IV
NCT000058189	NCT00005818_9_T4	GENE	15	15	IV
NCT0000581810	NCT00005818_10_T0	PHENOTYPE	10	10	toxicity
NCT0000581810	NCT00005818_10_T1	PHENOTYPE	12	13	disease progression
NCT0000581811	NCT00005818_11_T0	GENE	14	14	MTD
NCT0000581812	NCT00005818_12_T0	PHENOTYPE	21	21	toxicity
NCT0000581812	NCT00005818_12_T1	GENE	1	1	MTD
NCT0000581813	NCT00005818_13_T0	GENE	20	20	II
NCT0000581813	NCT00005818_13_T1	COMPOUND	15	15	irinotecan
NCT0000581813	NCT00005818_13_T2	GENE	2	2	MTD
NCT000058190	NCT00005819_0_T0	PHENOTYPE	7	8	Solid Tumors
NCT000058192	NCT00005819_2_T0	CELL	9	9	cells
NCT000058192	NCT00005819_2_T1	PHENOTYPE	8	8	tumor
NCT000058193	NCT00005819_3_T0	PHENOTYPE	21	22	solid tumors
NCT000058196	NCT00005819_6_T0	COMPOUND	7	7	paclitaxel
NCT000058196	NCT00005819_6_T1	COMPOUND	9	9	cisplatin
NCT000058197	NCT00005819_7_T0	COMPOUND	3	3	fenretinide
NCT000058198	NCT00005819_8_T0	COMPOUND	2	2	paclitaxel
NCT000058198	NCT00005819_8_T1	COMPOUND	8	8	cisplatin
NCT000058198	NCT00005819_8_T2	GENE	3	3	IV
NCT000058198	NCT00005819_8_T3	GENE	9	9	IV
NCT000058199	NCT00005819_9_T0	PHENOTYPE	13	13	toxicity
NCT000058199	NCT00005819_9_T1	PHENOTYPE	9	10	disease progression
NCT0000581910	NCT00005819_10_T0	COMPOUND	8	8	paclitaxel
NCT0000581910	NCT00005819_10_T1	COMPOUND	10	10	cisplatin
NCT0000581910	NCT00005819_10_T2	GENE	16	16	MTD
NCT0000581911	NCT00005819_11_T0	PHENOTYPE	21	21	toxicity
NCT0000581911	NCT00005819_11_T1	GENE	1	1	MTD
NCT0000581912	NCT00005819_12_T0	GENE	18	18	II
NCT0000581912	NCT00005819_12_T1	COMPOUND	11	11	paclitaxel
NCT0000581912	NCT00005819_12_T2	COMPOUND	13	13	cisplatin
NCT0000581912	NCT00005819_12_T3	GENE	2	2	MTD
NCT000058204	NCT00005820_4_T0	PHENOTYPE	13	13	toxicity
NCT000058204	NCT00005820_4_T1	PHENOTYPE	9	10	disease progression
NCT000058205	NCT00005820_5_T0	PHENOTYPE	11	11	relapse
NCT000058205	NCT00005820_5_T1	PHENOTYPE	9	9	progression
NCT000058215	NCT00005821_5_T0	GENE	4	4	gamma
NCT000058217	NCT00005821_7_T0	GENE	7	7	dye
NCT000058217	NCT00005821_7_T1	PHENOTYPE	10	10	tumor
NCT000058217	NCT00005821_7_T2	GENE	13	13	gamma
NCT000058217	NCT00005821_7_T3	PHENOTYPE	24	25	sentinel node
NCT000058217	NCT00005821_7_T4	COMPOUND	4	5	patent blue
NCT000058218	NCT00005821_8_T0	GENE	10	10	dye
NCT000058218	NCT00005821_8_T1	COMPOUND	7	8	patent blue
NCT000058219	NCT00005821_9_T0	TISSUE	1	2	lymph nodes
NCT0000582110	NCT00005821_10_T0	ORGAN	15	15	axilla
NCT0000582110	NCT00005821_10_T1	GENE	3	3	lump
NCT0000582111	NCT00005821_11_T0	GENE	8	8	dye
NCT0000582111	NCT00005821_11_T1	COMPOUND	5	6	patent blue
NCT000058221	NCT00005822_1_T0	CELL	10	10	cells
NCT000058221	NCT00005822_1_T1	PHENOTYPE	9	9	tumor
NCT000058222	NCT00005822_2_T0	CELL	8	8	cells
NCT000058223	NCT00005822_3_T0	COMPOUND	12	12	doxorubicin
NCT000058223	NCT00005822_3_T1	GENE	22	22	IV
NCT000058223	NCT00005822_3_T2	PHENOTYPE	23	25	inflammatory breast cancer
NCT000058225	NCT00005822_5_T0	COMPOUND	6	6	doxorubicin
NCT000058228	NCT00005822_8_T0	GENE	10	10	1.3
NCT000058228	NCT00005822_8_T1	COMPOUND	2	2	doxorubicin
NCT000058228	NCT00005822_8_T2	GENE	3	3	IV
NCT000058229	NCT00005822_9_T0	COMPOUND	6	6	doxorubicin
NCT000058229	NCT00005822_9_T1	GENE	13	13	IV
NCT0000582210	NCT00005822_10_T0	PHENOTYPE	16	16	toxicity
NCT0000582210	NCT00005822_10_T1	PHENOTYPE	12	13	disease progression
NCT0000582211	NCT00005822_11_T0	TISSUE	17	18	lymph nodes
NCT0000582211	NCT00005822_11_T1	ORGAN	13	14	chest wall
NCT0000582212	NCT00005822_12_T0	COMPOUND	2	2	estrogen
NCT0000582212	NCT00005822_12_T1	COMPOUND	10	10	tamoxifen
NCT0000582212	NCT00005822_12_T2	PHENOTYPE	4	6	progesterone receptor positive
NCT0000582213	NCT00005822_13_T0	COMPOUND	10	10	doxorubicin
NCT0000582213	NCT00005822_13_T1	GENE	16	16	MTD
NCT0000582214	NCT00005822_14_T0	PHENOTYPE	21	21	toxicity
NCT0000582214	NCT00005822_14_T1	GENE	1	1	MTD
NCT0000582215	NCT00005822_15_T0	GENE	2	2	MTD
NCT0000582216	NCT00005822_16_T0	PHENOTYPE	7	8	disease progression
NCT000058238	NCT00005823_8_T0	COMPOUND	10	10	cytarabine
NCT000058238	NCT00005823_8_T1	GENE	8	8	1.3
NCT000058238	NCT00005823_8_T2	COMPOUND	21	21	1_10
NCT000058238	NCT00005823_8_T3	GENE	3	3	IV
NCT000058238	NCT00005823_8_T4	GENE	11	11	IV
NCT000058238	NCT00005823_8_T5	COMPOUND	2	2	daunorubicin
NCT0000582311	NCT00005823_11_T0	PHENOTYPE	6	6	remission
NCT000058244	NCT00005824_4_T0	GENE	21	21	SC
NCT000058244	NCT00005824_4_T1	GENE	18	18	filgrastim
NCT000058244	NCT00005824_4_T2	COMPOUND	7	7	cyclophosphamide
NCT000058244	NCT00005824_4_T3	GENE	19	19	G-CSF
NCT000058244	NCT00005824_4_T4	GENE	8	8	IV
NCT000058245	NCT00005824_5_T0	CELL	7	7	cells
NCT000058245	NCT00005824_5_T1	GENE	6	6	CD34
NCT000058246	NCT00005824_6_T0	GENE	26	26	IV
NCT000058246	NCT00005824_6_T1	COMPOUND	7	7	busulfan
NCT000058246	NCT00005824_6_T2	COMPOUND	34	34	2
NCT000058246	NCT00005824_6_T3	COMPOUND	32	32	3
NCT000058246	NCT00005824_6_T4	PHENOTYPE	2	2	conditioning
NCT000058246	NCT00005824_6_T5	COMPOUND	25	25	cyclophosphamide
NCT000058248	NCT00005824_8_T0	GENE	5	5	SC
NCT000058248	NCT00005824_8_T1	GENE	0	0	G-CSF
NCT000058248	NCT00005824_8_T2	GENE	3	3	IV
NCT0000582412	NCT00005824_12_T0	PHENOTYPE	18	18	lymphoma
NCT0000582412	NCT00005824_12_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0000582412	NCT00005824_12_T2	PHENOTYPE	16	17	high grade
NCT000058252	NCT00005825_2_T0	CELL	9	9	cells
NCT000058252	NCT00005825_2_T1	PHENOTYPE	8	8	tumor
NCT000058255	NCT00005825_5_T0	COMPOUND	21	21	vinorelbine
NCT000058255	NCT00005825_5_T1	COMPOUND	15	15	cisplatin
NCT000058255	NCT00005825_5_T2	GENE	16	16	IV
NCT000058255	NCT00005825_5_T3	GENE	22	22	IV
NCT000058255	NCT00005825_5_T4	GENE	30	30	IV
NCT000058256	NCT00005825_6_T0	PHENOTYPE	13	13	toxicity
NCT000058256	NCT00005825_6_T1	PHENOTYPE	9	10	disease progression
NCT000058261	NCT00005826_1_T0	GENE	2	2	II
NCT000058261	NCT00005826_1_T1	PHENOTYPE	15	16	glioblastoma multiforme
NCT000058263	NCT00005826_3_T0	PHENOTYPE	5	5	toxicities
NCT000058263	NCT00005826_3_T1	PHENOTYPE	11	12	glioblastoma multiforme
NCT000058265	NCT00005826_5_T0	PHENOTYPE	8	8	progression
NCT000058267	NCT00005826_7_T0	GENE	7	7	1.5
NCT000058268	NCT00005826_8_T0	PHENOTYPE	13	13	toxicity
NCT000058268	NCT00005826_8_T1	PHENOTYPE	9	10	disease progression
NCT000058269	NCT00005826_9_T0	PHENOTYPE	7	8	disease progression
NCT000058278	NCT00005827_8_T0	PHENOTYPE	13	13	toxicity
NCT000058278	NCT00005827_8_T1	PHENOTYPE	9	10	disease progression
NCT000058288	NCT00005828_8_T0	COMPOUND	5	6	tea extract
NCT0000582810	NCT00005828_10_T0	PHENOTYPE	2	3	disease progression
NCT0000582811	NCT00005828_11_T0	PHENOTYPE	11	12	disease progression
NCT0000582812	NCT00005828_12_T0	PHENOTYPE	1	2	disease progression
NCT000058291	NCT00005829_1_T0	GENE	2	2	II
NCT000058291	NCT00005829_1_T1	COMPOUND	9	9	gemcitabine
NCT000058291	NCT00005829_1_T2	PHENOTYPE	15	18	recurrent chronic lymphocytic leukemia
NCT000058293	NCT00005829_3_T0	PHENOTYPE	9	9	remission
NCT000058293	NCT00005829_3_T1	COMPOUND	20	20	gemcitabine
NCT000058293	NCT00005829_3_T2	PHENOTYPE	13	13	recurrent
NCT000058293	NCT00005829_3_T3	PHENOTYPE	14	17	B-cell chronic lymphocytic leukemia
NCT000058295	NCT00005829_5_T0	PHENOTYPE	2	2	toxicities
NCT000058296	NCT00005829_6_T0	COMPOUND	3	3	gemcitabine
NCT000058296	NCT00005829_6_T1	GENE	4	4	IV
NCT000058298	NCT00005829_8_T0	PHENOTYPE	4	4	remission
NCT000058298	NCT00005829_8_T1	PHENOTYPE	6	6	remission
NCT000058298	NCT00005829_8_T2	PHENOTYPE	9	9	remission
NCT000058298	NCT00005829_8_T3	PHENOTYPE	12	12	remission
NCT000058299	NCT00005829_9_T0	PHENOTYPE	3	3	remission
NCT0000582910	NCT00005829_10_T0	PHENOTYPE	10	10	relapse
NCT0000582910	NCT00005829_10_T1	PHENOTYPE	7	8	disease progression
NCT0000582911	NCT00005829_11_T0	PHENOTYPE	3	3	remission
NCT000058301	NCT00005830_1_T0	CELL	10	10	cells
NCT000058301	NCT00005830_1_T1	PHENOTYPE	9	9	tumor
NCT000058302	NCT00005830_2_T0	CELL	8	8	cells
NCT000058302	NCT00005830_2_T1	PHENOTYPE	7	7	tumor
NCT000058303	NCT00005830_3_T0	CELL	9	9	cells
NCT000058303	NCT00005830_3_T1	PHENOTYPE	8	8	tumor
NCT000058305	NCT00005830_5_T0	GENE	18	18	IV
NCT000058305	NCT00005830_5_T1	GENE	10	10	abdominal
NCT000058305	NCT00005830_5_T2	COMPOUND	4	4	doxorubicin
NCT000058305	NCT00005830_5_T3	COMPOUND	6	6	cisplatin
NCT000058305	NCT00005830_5_T4	PHENOTYPE	15	16	stage III
NCT000058305	NCT00005830_5_T5	PHENOTYPE	19	20	endometrial cancer
NCT000058307	NCT00005830_7_T0	PHENOTYPE	5	5	toxic
NCT000058307	NCT00005830_7_T1	PHENOTYPE	16	16	toxic
NCT000058307	NCT00005830_7_T2	PHENOTYPE	2	2	acute
NCT000058307	NCT00005830_7_T3	PHENOTYPE	4	4	chronic
NCT000058309	NCT00005830_9_T0	COMPOUND	2	2	doxorubicin
NCT000058309	NCT00005830_9_T1	COMPOUND	5	5	cisplatin
NCT000058309	NCT00005830_9_T2	GENE	3	3	IV
NCT000058309	NCT00005830_9_T3	GENE	6	6	IV
NCT0000583011	NCT00005830_11_T0	GENE	4	4	abdominal
NCT0000583013	NCT00005830_13_T0	GENE	14	14	3.5
NCT000058310	NCT00005831_0_T0	PHENOTYPE	9	9	Recurrent
NCT000058310	NCT00005831_0_T1	PHENOTYPE	12	14	Urinary Tract Cancer
NCT000058313	NCT00005831_3_T0	CELL	10	10	cells
NCT000058313	NCT00005831_3_T1	PHENOTYPE	9	9	tumor
NCT000058315	NCT00005831_5_T0	PHENOTYPE	3	3	toxicity
NCT000058315	NCT00005831_5_T1	COMPOUND	9	9	paclitaxel
NCT000058315	NCT00005831_5_T2	PHENOTYPE	21	21	cancers
NCT000058315	NCT00005831_5_T3	COMPOUND	12	12	gemcitabine
NCT000058315	NCT00005831_5_T4	GENE	24	24	HER2
NCT000058315	NCT00005831_5_T5	PHENOTYPE	19	19	recurrent
NCT0000583111	NCT00005831_11_T0	GENE	18	18	FISH
NCT0000583111	NCT00005831_11_T1	GENE	13	13	HER2
NCT0000583111	NCT00005831_11_T2	PHENOTYPE	9	10	bladder cancer
NCT0000583116	NCT00005831_16_T0	GENE	5	5	CR
NCT0000583116	NCT00005831_16_T1	GENE	10	10	CR
NCT0000583117	NCT00005831_17_T0	PHENOTYPE	18	18	toxicity
NCT0000583117	NCT00005831_17_T1	GENE	12	12	CR
NCT0000583117	NCT00005831_17_T2	PHENOTYPE	14	15	disease progression
NCT0000583118	NCT00005831_18_T0	PHENOTYPE	4	5	disease progression
NCT000058321	NCT00005832_1_T0	GENE	2	2	II
NCT000058321	NCT00005832_1_T1	PHENOTYPE	18	20	metastatic pancreatic cancer
NCT000058323	NCT00005832_3_T0	PHENOTYPE	10	13	adenocarcinoma of the pancreas
NCT000058327	NCT00005832_7_T0	PHENOTYPE	4	4	severity
NCT000058327	NCT00005832_7_T1	PHENOTYPE	6	6	toxicities
NCT000058329	NCT00005832_9_T0	PHENOTYPE	13	13	toxicity
NCT000058329	NCT00005832_9_T1	PHENOTYPE	9	10	disease progression
NCT000058331	NCT00005833_1_T0	GENE	2	2	II
NCT000058331	NCT00005833_1_T1	PHENOTYPE	15	15	recurrent
NCT000058331	NCT00005833_1_T2	PHENOTYPE	18	19	colorectal cancer
NCT000058335	NCT00005833_5_T0	PHENOTYPE	10	11	colorectal cancer
NCT000058339	NCT00005833_9_T0	PHENOTYPE	4	4	severity
NCT000058339	NCT00005833_9_T1	PHENOTYPE	6	6	toxicities
NCT0000583312	NCT00005833_12_T0	PHENOTYPE	13	13	toxicity
NCT0000583312	NCT00005833_12_T1	PHENOTYPE	9	10	disease progression
NCT0000583314	NCT00005833_14_T0	GENE	14	14	5.7
NCT000058342	NCT00005834_2_T0	COMPOUND	14	14	thalidomide
NCT000058342	NCT00005834_2_T1	PHENOTYPE	16	17	multiple myeloma
NCT000058343	NCT00005834_3_T0	COMPOUND	15	15	thalidomide
NCT000058343	NCT00005834_3_T1	GENE	3	3	III
NCT000058343	NCT00005834_3_T2	PHENOTYPE	21	23	refractory multiple myeloma
NCT000058345	NCT00005834_5_T0	COMPOUND	17	17	dexamethasone
NCT000058345	NCT00005834_5_T1	GENE	23	23	G-CSF
NCT000058345	NCT00005834_5_T2	COMPOUND	27	27	thalidomide
NCT000058345	NCT00005834_5_T3	PHENOTYPE	7	7	remission
NCT000058345	NCT00005834_5_T4	GENE	22	22	filgrastim
NCT000058345	NCT00005834_5_T5	COMPOUND	18	18	cyclophosphamide
NCT000058345	NCT00005834_5_T6	COMPOUND	19	19	etoposide
NCT000058345	NCT00005834_5_T7	COMPOUND	20	20	cisplatin
NCT000058345	NCT00005834_5_T8	PHENOTYPE	12	14	refractory multiple myeloma
NCT000058347	NCT00005834_7_T0	PHENOTYPE	5	5	toxic
NCT000058349	NCT00005834_9_T0	COMPOUND	24	24	thalidomide
NCT000058349	NCT00005834_9_T1	GENE	19	19	1.2
NCT000058349	NCT00005834_9_T2	GENE	21	21	3.4
NCT000058349	NCT00005834_9_T3	PHENOTYPE	13	13	resistant
NCT0000583412	NCT00005834_12_T0	GENE	3	3	filgrastim
NCT0000583412	NCT00005834_12_T1	GENE	4	4	G-CSF
NCT0000583413	NCT00005834_13_T0	GENE	3	3	3.4
NCT0000583416	NCT00005834_16_T0	PHENOTYPE	13	14	disease progression
NCT000058356	NCT00005835_6_T0	COMPOUND	8	8	melphalan
NCT000058357	NCT00005835_7_T0	COMPOUND	21	21	melphalan
NCT000058357	NCT00005835_7_T1	GENE	48	48	G-CSF
NCT000058357	NCT00005835_7_T2	GENE	4	4	IV
NCT000058357	NCT00005835_7_T3	GENE	22	22	IV
NCT000058357	NCT00005835_7_T4	GENE	39	39	IV
NCT000058357	NCT00005835_7_T5	GENE	51	51	IV
NCT000058357	NCT00005835_7_T6	COMPOUND	30	30	2
NCT000058357	NCT00005835_7_T7	COMPOUND	28	28	3
NCT000058357	NCT00005835_7_T8	GENE	47	47	filgrastim
NCT000058357	NCT00005835_7_T9	COMPOUND	2	3	buthionine sulfoximine
NCT000058357	NCT00005835_7_T10	ORGAN	37	38	bone marrow
NCT000058357	NCT00005835_7_T11	CELL	32	35	peripheral blood stem cells
NCT000058358	NCT00005835_8_T0	COMPOUND	8	8	melphalan
NCT000058358	NCT00005835_8_T1	GENE	14	14	MTD
NCT000058359	NCT00005835_9_T0	PHENOTYPE	21	21	toxicity
NCT000058359	NCT00005835_9_T1	GENE	1	1	MTD
NCT0000583512	NCT00005835_12_T0	PHENOTYPE	9	9	toxic
NCT0000583512	NCT00005835_12_T1	PHENOTYPE	15	16	secondary malignancies
NCT0000583513	NCT00005835_13_T0	GENE	14	14	2.3
NCT000058360	NCT00005836_0_T0	COMPOUND	20	20	Platinum
NCT000058360	NCT00005836_0_T1	PHENOTYPE	5	5	Recurrent
NCT000058360	NCT00005836_0_T2	PHENOTYPE	13	14	Peritoneal Cancer
NCT000058360	NCT00005836_0_T3	PHENOTYPE	8	10	Ovarian Epithelial Cancer
NCT000058362	NCT00005836_2_T0	GENE	2	2	II
NCT000058362	NCT00005836_2_T1	COMPOUND	9	9	oxaliplatin
NCT000058362	NCT00005836_2_T2	GENE	26	26	has
NCT000058362	NCT00005836_2_T3	PHENOTYPE	15	15	recurrent
NCT000058362	NCT00005836_2_T4	PHENOTYPE	23	24	peritoneal cancer
NCT000058362	NCT00005836_2_T5	PHENOTYPE	18	20	ovarian epithelial cancer
NCT000058364	NCT00005836_4_T0	PHENOTYPE	17	17	resistant
NCT000058364	NCT00005836_4_T1	COMPOUND	16	16	platinum
NCT000058364	NCT00005836_4_T2	COMPOUND	5	5	oxaliplatin
NCT000058364	NCT00005836_4_T3	PHENOTYPE	13	13	recurrent
NCT000058364	NCT00005836_4_T4	PHENOTYPE	21	23	primary peritoneal carcinoma
NCT000058366	NCT00005836_6_T0	PHENOTYPE	6	6	toxicity
NCT000058367	NCT00005836_7_T0	COMPOUND	3	3	oxaliplatin
NCT000058367	NCT00005836_7_T1	GENE	4	4	IV
NCT000058368	NCT00005836_8_T0	PHENOTYPE	16	16	toxicity
NCT000058368	NCT00005836_8_T1	PHENOTYPE	18	19	disease progression
NCT000058371	NCT00005837_1_T0	GENE	2	2	II
NCT000058371	NCT00005837_1_T1	COMPOUND	9	9	oxaliplatin
NCT000058371	NCT00005837_1_T2	PHENOTYPE	15	15	recurrent
NCT000058371	NCT00005837_1_T3	PHENOTYPE	18	19	cervical cancer
NCT000058375	NCT00005837_5_T0	PHENOTYPE	6	6	toxicity
NCT000058376	NCT00005837_6_T0	COMPOUND	3	3	oxaliplatin
NCT000058376	NCT00005837_6_T1	GENE	4	4	IV
NCT000058377	NCT00005837_7_T0	PHENOTYPE	16	16	toxicity
NCT000058377	NCT00005837_7_T1	PHENOTYPE	18	19	disease progression
NCT000058381	NCT00005838_1_T0	CELL	9	9	cells
NCT000058381	NCT00005838_1_T1	PHENOTYPE	8	8	tumor
NCT000058382	NCT00005838_2_T0	CELL	8	8	cells
NCT000058382	NCT00005838_2_T1	PHENOTYPE	7	7	tumor
NCT000058388	NCT00005838_8_T0	PHENOTYPE	4	4	tumor
NCT000058388	NCT00005838_8_T1	PHENOTYPE	6	6	tumor
NCT0000583812	NCT00005838_12_T0	COMPOUND	19	19	vinorelbine
NCT0000583812	NCT00005838_12_T1	COMPOUND	23	23	paclitaxel
NCT0000583812	NCT00005838_12_T2	COMPOUND	17	17	cisplatin
NCT0000583816	NCT00005838_16_T0	COMPOUND	22	22	vinorelbine
NCT0000583816	NCT00005838_16_T1	COMPOUND	41	41	paclitaxel
NCT0000583816	NCT00005838_16_T2	COMPOUND	12	12	cisplatin
NCT0000583816	NCT00005838_16_T3	GENE	13	13	IV
NCT0000583816	NCT00005838_16_T4	GENE	23	23	IV
NCT0000583816	NCT00005838_16_T5	GENE	36	36	IV
NCT0000583816	NCT00005838_16_T6	GENE	42	42	IV
NCT000058390	NCT00005839_0_T0	PHENOTYPE	9	9	Recurrent
NCT000058390	NCT00005839_0_T1	PHENOTYPE	10	11	Solid Tumor
NCT000058392	NCT00005839_2_T0	CELL	9	9	cells
NCT000058392	NCT00005839_2_T1	PHENOTYPE	8	8	tumor
NCT000058393	NCT00005839_3_T0	COMPOUND	12	12	capecitabine
NCT000058393	NCT00005839_3_T1	COMPOUND	9	9	oxaliplatin
NCT000058393	NCT00005839_3_T2	PHENOTYPE	20	20	recurrent
NCT000058393	NCT00005839_3_T3	PHENOTYPE	21	22	solid tumors
NCT000058395	NCT00005839_5_T0	COMPOUND	6	6	capecitabine
NCT000058395	NCT00005839_5_T1	COMPOUND	12	12	oxaliplatin
NCT000058395	NCT00005839_5_T2	PHENOTYPE	18	18	recurrent
NCT000058395	NCT00005839_5_T3	PHENOTYPE	19	20	solid tumors
NCT000058397	NCT00005839_7_T0	PHENOTYPE	2	2	toxicities
NCT000058398	NCT00005839_8_T0	COMPOUND	8	8	capecitabine
NCT000058399	NCT00005839_9_T0	COMPOUND	12	12	capecitabine
NCT000058399	NCT00005839_9_T1	COMPOUND	2	2	oxaliplatin
NCT000058399	NCT00005839_9_T2	GENE	3	3	IV
NCT0000583910	NCT00005839_10_T0	PHENOTYPE	13	13	toxicity
NCT0000583910	NCT00005839_10_T1	PHENOTYPE	9	10	disease progression
NCT0000583911	NCT00005839_11_T0	COMPOUND	8	8	capecitabine
NCT0000583911	NCT00005839_11_T1	GENE	14	14	MTD
NCT0000583912	NCT00005839_12_T0	PHENOTYPE	18	18	toxicity
NCT0000583912	NCT00005839_12_T1	GENE	1	1	MTD
NCT0000583913	NCT00005839_13_T0	PHENOTYPE	4	5	disease progression
NCT000058401	NCT00005840_1_T0	CELL	10	10	cells
NCT000058401	NCT00005840_1_T1	PHENOTYPE	9	9	tumor
NCT000058402	NCT00005840_2_T0	CELL	8	8	cells
NCT000058402	NCT00005840_2_T1	PHENOTYPE	7	7	tumor
NCT000058404	NCT00005840_4_T0	COMPOUND	8	8	paclitaxel
NCT000058404	NCT00005840_4_T1	COMPOUND	10	10	cisplatin
NCT000058404	NCT00005840_4_T2	GENE	21	21	IV
NCT000058404	NCT00005840_4_T3	PHENOTYPE	18	19	stage III
NCT000058404	NCT00005840_4_T4	PHENOTYPE	22	23	endometrial cancer
NCT000058406	NCT00005840_6_T0	PHENOTYPE	4	5	disease progression
NCT000058407	NCT00005840_7_T0	COMPOUND	7	7	paclitaxel
NCT000058407	NCT00005840_7_T1	COMPOUND	9	9	cisplatin
NCT000058408	NCT00005840_8_T0	COMPOUND	2	2	paclitaxel
NCT000058408	NCT00005840_8_T1	COMPOUND	8	8	cisplatin
NCT000058408	NCT00005840_8_T2	GENE	3	3	IV
NCT000058408	NCT00005840_8_T3	GENE	9	9	IV
NCT000058409	NCT00005840_9_T0	GENE	4	4	abdominal
NCT0000584010	NCT00005840_10_T0	COMPOUND	8	8	paclitaxel
NCT0000584010	NCT00005840_10_T1	COMPOUND	10	10	cisplatin
NCT0000584010	NCT00005840_10_T2	GENE	16	16	MTD
NCT0000584011	NCT00005840_11_T0	PHENOTYPE	21	21	toxicity
NCT0000584011	NCT00005840_11_T1	GENE	1	1	MTD
NCT0000584012	NCT00005840_12_T0	GENE	2	2	MTD
NCT0000584014	NCT00005840_14_T0	GENE	21	21	II
NCT000058410	NCT00005841_0_T0	PHENOTYPE	11	11	Melanoma
NCT000058410	NCT00005841_0_T1	GENE	7	7	III
NCT000058410	NCT00005841_0_T2	GENE	10	10	IV
NCT000058412	NCT00005841_2_T0	GENE	3	3	filgrastim
NCT000058412	NCT00005841_2_T1	PHENOTYPE	16	16	melanoma
NCT000058413	NCT00005841_3_T0	GENE	27	27	has
NCT000058413	NCT00005841_3_T1	PHENOTYPE	20	21	stage III
NCT000058413	NCT00005841_3_T2	PHENOTYPE	23	25	stage IV melanoma
NCT000058415	NCT00005841_5_T0	ORGAN	8	8	liver
NCT000058415	NCT00005841_5_T1	PHENOTYPE	17	17	melanoma
NCT000058415	NCT00005841_5_T2	PHENOTYPE	41	41	melanoma
NCT000058415	NCT00005841_5_T3	GENE	40	40	IV
NCT000058415	NCT00005841_5_T4	GENE	6	6	filgrastim
NCT000058415	NCT00005841_5_T5	COMPOUND	9	9	tyrosine
NCT000058415	NCT00005841_5_T6	PHENOTYPE	37	38	stage III
NCT000058415	NCT00005841_5_T7	GENE	12	13	fusion protein
NCT000058417	NCT00005841_7_T0	PHENOTYPE	2	2	toxicity
NCT000058419	NCT00005841_9_T0	GENE	8	8	gp100
NCT000058419	NCT00005841_9_T1	GENE	6	6	MART-1
NCT000058419	NCT00005841_9_T2	GENE	5	5	tyrosinase
NCT0000584110	NCT00005841_10_T0	ORGAN	11	11	liver
NCT0000584110	NCT00005841_10_T1	GENE	9	9	filgrastim
NCT0000584110	NCT00005841_10_T2	COMPOUND	12	12	tyrosine
NCT0000584110	NCT00005841_10_T3	GENE	16	17	fusion protein
NCT0000584111	NCT00005841_11_T0	PHENOTYPE	2	2	melanoma
NCT0000584112	NCT00005841_12_T0	GENE	3	4	fusion protein
NCT0000584113	NCT00005841_13_T0	GENE	16	16	MTD
NCT0000584113	NCT00005841_13_T1	GENE	9	10	fusion protein
NCT0000584114	NCT00005841_14_T0	PHENOTYPE	18	18	toxicity
NCT0000584114	NCT00005841_14_T1	GENE	1	1	MTD
NCT0000584115	NCT00005841_15_T0	PHENOTYPE	22	23	disease progression
NCT000058422	NCT00005842_2_T0	CELL	10	10	cells
NCT000058422	NCT00005842_2_T1	PHENOTYPE	9	9	tumor
NCT000058423	NCT00005842_3_T0	CELL	8	8	cells
NCT000058423	NCT00005842_3_T1	PHENOTYPE	7	7	tumor
NCT000058425	NCT00005842_5_T0	PHENOTYPE	17	18	metastatic adenocarcinoma
NCT000058427	NCT00005842_7_T0	PHENOTYPE	4	4	pharmacokinetics
NCT000058427	NCT00005842_7_T1	PHENOTYPE	2	2	toxicities
NCT0000584211	NCT00005842_11_T0	PHENOTYPE	12	12	toxicity
NCT0000584213	NCT00005842_13_T0	GENE	4	4	IV
NCT0000584214	NCT00005842_14_T0	PHENOTYPE	13	13	toxicity
NCT0000584214	NCT00005842_14_T1	PHENOTYPE	9	10	disease progression
NCT0000584215	NCT00005842_15_T0	GENE	14	14	MTD
NCT0000584216	NCT00005842_16_T0	PHENOTYPE	19	19	toxicities
NCT0000584216	NCT00005842_16_T1	GENE	1	1	MTD
NCT0000584216	NCT00005842_16_T2	PHENOTYPE	16	16	experiences
NCT0000584217	NCT00005842_17_T0	PHENOTYPE	7	7	toxicity
NCT000058431	NCT00005843_1_T0	CELL	10	10	cells
NCT000058431	NCT00005843_1_T1	PHENOTYPE	9	9	tumor
NCT000058433	NCT00005843_3_T0	PHENOTYPE	10	12	metastatic pancreatic cancer
NCT000058435	NCT00005843_5_T0	PHENOTYPE	6	6	progression
NCT000058437	NCT00005843_7_T0	PHENOTYPE	2	2	pharmacokinetics
NCT0000584310	NCT00005843_10_T0	PHENOTYPE	13	13	toxicity
NCT0000584310	NCT00005843_10_T1	PHENOTYPE	9	10	disease progression
NCT000058440	NCT00005844_0_T0	PHENOTYPE	6	7	Solid Tumors
NCT000058442	NCT00005844_2_T0	COMPOUND	9	9	oxaliplatin
NCT000058442	NCT00005844_2_T1	PHENOTYPE	16	17	solid tumors
NCT000058445	NCT00005844_5_T0	GENE	18	18	OR
NCT000058445	NCT00005844_5_T1	COMPOUND	2	2	oxaliplatin
NCT000058445	NCT00005844_5_T2	GENE	3	3	IV
NCT000058446	NCT00005844_6_T0	PHENOTYPE	10	10	toxicity
NCT000058446	NCT00005844_6_T1	PHENOTYPE	6	7	disease progression
NCT000058447	NCT00005844_7_T0	COMPOUND	8	8	oxaliplatin
NCT000058447	NCT00005844_7_T1	GENE	14	14	MTD
NCT000058448	NCT00005844_8_T0	PHENOTYPE	23	23	toxicity
NCT000058448	NCT00005844_8_T1	GENE	1	1	MTD
NCT000058449	NCT00005844_9_T0	GENE	6	6	1.4
NCT000058449	NCT00005844_9_T1	COMPOUND	20	20	oxaliplatin
NCT000058449	NCT00005844_9_T2	GENE	2	2	MTD
NCT000058455	NCT00005845_5_T0	GENE	19	19	RAS
NCT000058455	NCT00005845_5_T1	BIOLOGICAL_PROCESS	17	17	prenylation
NCT000058455	NCT00005845_5_T2	MOLECULAR_FUNCTION	15	16	FTase activity
NCT000058457	NCT00005845_7_T0	COMPOUND	2	2	tipifarnib
NCT000058457	NCT00005845_7_T1	GENE	7	7	BID
NCT000058458	NCT00005845_8_T0	PHENOTYPE	18	18	toxicity
NCT000058458	NCT00005845_8_T1	PHENOTYPE	14	15	disease progression
NCT000058471	NCT00005847_1_T0	CELL	9	9	cells
NCT000058471	NCT00005847_1_T1	PHENOTYPE	8	8	tumor
NCT000058472	NCT00005847_2_T0	CELL	13	13	cells
NCT000058472	NCT00005847_2_T1	ORGAN	8	9	immune system
NCT000058479	NCT00005847_9_T0	GENE	9	9	1.5
NCT000058479	NCT00005847_9_T1	COMPOUND	1	1	estramustine
NCT0000584711	NCT00005847_11_T0	PHENOTYPE	10	10	toxicity
NCT0000584711	NCT00005847_11_T1	PHENOTYPE	12	13	disease progression
NCT000058485	NCT00005848_5_T0	PHENOTYPE	4	4	pharmacokinetics
NCT000058487	NCT00005848_7_T0	PHENOTYPE	13	13	toxicity
NCT000058487	NCT00005848_7_T1	PHENOTYPE	9	10	disease progression
NCT000058492	NCT00005849_2_T0	CELL	9	9	cells
NCT000058492	NCT00005849_2_T1	PHENOTYPE	8	8	tumor
NCT000058497	NCT00005849_7_T0	PHENOTYPE	7	8	tumor progression
NCT0000584911	NCT00005849_11_T0	COMPOUND	2	2	paclitaxel
NCT0000584911	NCT00005849_11_T1	GENE	3	3	IV
NCT0000584911	NCT00005849_11_T2	GENE	16	16	IV
NCT0000584911	NCT00005849_11_T3	COMPOUND	14	15	bryostatin 1
NCT0000584912	NCT00005849_12_T0	PHENOTYPE	19	19	toxicity
NCT0000584912	NCT00005849_12_T1	PHENOTYPE	15	16	disease progression
NCT000058502	NCT00005850_2_T0	PHENOTYPE	14	14	fatigue
NCT000058502	NCT00005850_2_T1	PHENOTYPE	20	22	quality of life
NCT000058508	NCT00005850_8_T0	PHENOTYPE	0	0	Secondary
NCT0000585013	NCT00005850_13_T0	PHENOTYPE	3	3	toxicity
NCT000058511	NCT00005851_1_T0	ORGAN	3	3	transplant
NCT000058511	NCT00005851_1_T1	ORGAN	14	14	transplants
NCT000058511	NCT00005851_1_T2	ORGAN	12	13	bone marrow
NCT000058512	NCT00005851_2_T0	ORGAN	16	16	marrow
NCT000058512	NCT00005851_2_T1	CELL	17	17	cells
NCT000058512	NCT00005851_2_T2	ORGAN	8	9	immune system
NCT000058513	NCT00005851_3_T0	CELL	5	5	cells
NCT000058513	NCT00005851_3_T1	PHENOTYPE	12	12	tumor
NCT000058514	NCT00005851_4_T0	ORGAN	4	4	graft
NCT000058514	NCT00005851_4_T1	PHENOTYPE	6	6	tumor
NCT000058514	NCT00005851_4_T2	GENE	9	9	has
NCT000058515	NCT00005851_5_T0	CELL	22	22	cells
NCT000058515	NCT00005851_5_T1	ORGAN	8	8	transplant
NCT000058515	NCT00005851_5_T2	CELL	32	33	stem cells
NCT0000585111	NCT00005851_11_T0	PHENOTYPE	11	13	metastatic renal cancer
NCT0000585114	NCT00005851_14_T0	COMPOUND	3	3	cyclosporine
NCT0000585114	NCT00005851_14_T1	COMPOUND	18	18	3
NCT0000585114	NCT00005851_14_T2	GENE	8	8	BID
NCT0000585114	NCT00005851_14_T3	GENE	15	15	BID
NCT0000585114	NCT00005851_14_T4	GENE	10	10	IV
NCT0000585114	NCT00005851_14_T5	GENE	31	31	IV
NCT0000585114	NCT00005851_14_T6	GENE	37	37	TID
NCT0000585114	NCT00005851_14_T7	COMPOUND	27	28	mycophenolate mofetil
NCT0000585115	NCT00005851_15_T0	PHENOTYPE	15	15	GVHD
NCT0000585115	NCT00005851_15_T1	PHENOTYPE	13	14	graft-vs-host disease
NCT0000585116	NCT00005851_16_T0	PHENOTYPE	19	19	GVHD
NCT0000585116	NCT00005851_16_T1	PHENOTYPE	13	14	disease progression
NCT000058521	NCT00005852_1_T0	GENE	2	2	II
NCT000058521	NCT00005852_1_T1	ORGAN	28	28	transplant
NCT000058521	NCT00005852_1_T2	ORGAN	9	10	bone marrow
NCT000058521	NCT00005852_1_T3	ORGAN	26	27	bone marrow
NCT000058521	NCT00005852_1_T4	PHENOTYPE	17	19	severe aplastic anemia
NCT000058523	NCT00005852_3_T0	ORGAN	20	20	transplant
NCT000058523	NCT00005852_3_T1	PHENOTYPE	2	3	graft failure
NCT000058523	NCT00005852_3_T2	ORGAN	18	19	bone marrow
NCT000058523	NCT00005852_3_T3	PHENOTYPE	11	13	severe aplastic anemia
NCT000058525	NCT00005852_5_T0	ORGAN	25	25	graft
NCT000058525	NCT00005852_5_T1	GENE	9	9	globulin
NCT000058525	NCT00005852_5_T2	PHENOTYPE	11	11	conditioning
NCT000058525	NCT00005852_5_T3	COMPOUND	6	6	cyclophosphamide
NCT000058525	NCT00005852_5_T4	ORGAN	18	18	transplant
NCT000058525	NCT00005852_5_T5	ORGAN	16	17	bone marrow
NCT000058527	NCT00005852_7_T0	ORGAN	25	25	graft
NCT000058527	NCT00005852_7_T1	COMPOUND	4	4	methylprednisolone
NCT000058527	NCT00005852_7_T2	GENE	34	34	globulin
NCT000058527	NCT00005852_7_T3	GENE	6	6	CD3
NCT000058527	NCT00005852_7_T4	PHENOTYPE	11	11	conditioning
NCT000058527	NCT00005852_7_T5	COMPOUND	31	31	cyclophosphamide
NCT000058527	NCT00005852_7_T6	ORGAN	18	18	transplant
NCT000058527	NCT00005852_7_T7	ORGAN	16	17	bone marrow
NCT0000585212	NCT00005852_12_T0	PHENOTYPE	9	10	aplastic anemia
NCT0000585212	NCT00005852_12_T1	PHENOTYPE	14	15	graft failure
NCT000058531	NCT00005853_1_T0	CELL	10	10	cells
NCT000058541	NCT00005854_1_T0	GENE	2	2	II
NCT000058541	NCT00005854_1_T1	PHENOTYPE	17	18	hematologic cancer
NCT000058541	NCT00005854_1_T2	ORGAN	9	10	bone marrow
NCT000058543	NCT00005854_3_T0	PHENOTYPE	4	4	severity
NCT000058543	NCT00005854_3_T1	GENE	23	23	ex
NCT000058543	NCT00005854_3_T2	ORGAN	16	17	bone marrow
NCT000058543	NCT00005854_3_T3	PHENOTYPE	28	29	hematologic malignancies
NCT000058543	NCT00005854_3_T4	PHENOTYPE	6	10	acute graft versus host disease
NCT000058545	NCT00005854_5_T0	PHENOTYPE	2	2	engraftment
NCT000058549	NCT00005854_9_T0	PHENOTYPE	6	6	relapse
NCT0000585411	NCT00005854_11_T0	PHENOTYPE	4	4	tolerance
NCT0000585413	NCT00005854_13_T0	CELL	13	15	bone marrow cells
NCT0000585413	NCT00005854_13_T1	CELL	5	7	white blood cells
NCT0000585414	NCT00005854_14_T0	COMPOUND	20	20	2
NCT0000585414	NCT00005854_14_T1	COMPOUND	18	18	3
NCT0000585414	NCT00005854_14_T2	COMPOUND	14	14	cyclophosphamide
NCT0000585414	NCT00005854_14_T3	GENE	15	15	IV
NCT0000585416	NCT00005854_16_T0	GENE	16	16	11
NCT0000585416	NCT00005854_16_T1	COMPOUND	18	18	cyclosporine
NCT0000585416	NCT00005854_16_T2	COMPOUND	12	12	1
NCT0000585416	NCT00005854_16_T3	COMPOUND	22	22	1
NCT0000585416	NCT00005854_16_T4	COMPOUND	8	8	methotrexate
NCT0000585416	NCT00005854_16_T5	GENE	9	9	IV
NCT0000585416	NCT00005854_16_T6	GENE	19	19	IV
NCT0000585416	NCT00005854_16_T7	ORGAN	2	3	bone marrow
NCT0000585418	NCT00005854_18_T0	GENE	14	14	1.2
NCT000058551	NCT00005855_1_T0	CELL	9	9	cells
NCT000058551	NCT00005855_1_T1	PHENOTYPE	8	8	tumor
NCT000058552	NCT00005855_2_T0	COMPOUND	14	14	efaproxiral
NCT000058552	NCT00005855_2_T1	PHENOTYPE	30	30	progressive
NCT000058552	NCT00005855_2_T2	PHENOTYPE	32	32	recurrent
NCT000058552	NCT00005855_2_T3	PHENOTYPE	33	34	malignant glioma
NCT000058554	NCT00005855_4_T0	COMPOUND	10	10	efaproxiral
NCT000058555	NCT00005855_5_T0	GENE	15	15	1.2
NCT000058555	NCT00005855_5_T1	GENE	3	3	IV
NCT000058555	NCT00005855_5_T2	GENE	13	13	IV
NCT000058556	NCT00005855_6_T0	PHENOTYPE	16	16	toxicity
NCT000058556	NCT00005855_6_T1	PHENOTYPE	18	19	disease progression
NCT000058557	NCT00005855_7_T0	GENE	14	14	MTD
NCT000058558	NCT00005855_8_T0	PHENOTYPE	21	21	toxicity
NCT000058558	NCT00005855_8_T1	GENE	1	1	MTD
NCT000058559	NCT00005855_9_T0	GENE	20	20	II
NCT000058559	NCT00005855_9_T1	GENE	2	2	MTD
NCT0000585512	NCT00005855_12_T0	GENE	11	11	II
NCT000058562	NCT00005856_2_T0	COMPOUND	6	6	oxaliplatin
NCT000058562	NCT00005856_2_T1	GENE	26	26	P450
NCT000058562	NCT00005856_2_T2	PHENOTYPE	12	13	glioblastoma multiforme
NCT000058564	NCT00005856_4_T0	PHENOTYPE	3	3	toxicity
NCT000058566	NCT00005856_6_T0	PHENOTYPE	2	2	pharmacokinetics
NCT000058566	NCT00005856_6_T1	PHENOTYPE	18	18	pharmacokinetics
NCT000058566	NCT00005856_6_T2	GENE	14	14	P450
NCT0000585610	NCT00005856_10_T0	PHENOTYPE	3	4	drug toxicity
NCT0000585611	NCT00005856_11_T0	GENE	14	14	II
NCT0000585611	NCT00005856_11_T1	COMPOUND	9	9	oxaliplatin
NCT0000585612	NCT00005856_12_T0	GENE	10	10	P450
NCT0000585613	NCT00005856_13_T0	COMPOUND	4	4	oxaliplatin
NCT0000585613	NCT00005856_13_T1	GENE	5	5	IV
NCT0000585614	NCT00005856_14_T0	PHENOTYPE	16	16	toxicity
NCT0000585614	NCT00005856_14_T1	PHENOTYPE	18	19	disease progression
NCT0000585616	NCT00005856_16_T0	PHENOTYPE	17	17	toxicity
NCT0000585616	NCT00005856_16_T1	GENE	1	1	MTD
NCT0000585617	NCT00005856_17_T0	GENE	1	1	II
NCT0000585617	NCT00005856_17_T1	COMPOUND	4	4	oxaliplatin
NCT0000585617	NCT00005856_17_T2	GENE	11	11	MTD
NCT0000585618	NCT00005856_18_T0	PHENOTYPE	10	11	disease progression
NCT0000585620	NCT00005856_20_T0	GENE	11	11	II
NCT000058571	NCT00005857_1_T0	CELL	10	10	cells
NCT000058571	NCT00005857_1_T1	PHENOTYPE	9	9	tumor
NCT000058572	NCT00005857_2_T0	CELL	10	10	cells
NCT000058572	NCT00005857_2_T1	PHENOTYPE	9	9	tumor
NCT000058576	NCT00005857_6_T0	PHENOTYPE	15	15	toxicity
NCT000058578	NCT00005857_8_T0	PHENOTYPE	15	15	toxicity
NCT000058579	NCT00005857_9_T0	COMPOUND	13	13	docetaxel
NCT000058579	NCT00005857_9_T1	PHENOTYPE	2	2	progressive
NCT000058579	NCT00005857_9_T2	GENE	14	14	IV
NCT000058579	NCT00005857_9_T3	GENE	30	30	IV
NCT0000585710	NCT00005857_10_T0	PHENOTYPE	18	18	toxicity
NCT0000585710	NCT00005857_10_T1	PHENOTYPE	14	15	disease progression
NCT0000585711	NCT00005857_11_T0	PHENOTYPE	15	15	progressive
NCT000058585	NCT00005858_5_T0	PHENOTYPE	2	2	toxicity
NCT000058585	NCT00005858_5_T1	PHENOTYPE	4	4	pharmacokinetics
NCT000058589	NCT00005858_9_T0	GENE	4	4	IV
NCT0000585810	NCT00005858_10_T0	PHENOTYPE	13	13	toxicity
NCT0000585810	NCT00005858_10_T1	PHENOTYPE	9	10	disease progression
NCT0000585811	NCT00005858_11_T0	GENE	15	15	MTD
NCT0000585812	NCT00005858_12_T0	PHENOTYPE	21	21	toxicity
NCT0000585812	NCT00005858_12_T1	GENE	1	1	MTD
NCT000058591	NCT00005859_1_T0	GENE	2	2	II
NCT000058591	NCT00005859_1_T1	PHENOTYPE	17	17	progressive
NCT000058591	NCT00005859_1_T2	COMPOUND	9	9	tipifarnib
NCT000058591	NCT00005859_1_T3	PHENOTYPE	15	15	recurrent
NCT000058591	NCT00005859_1_T4	PHENOTYPE	18	19	malignant glioma
NCT000058596	NCT00005859_6_T0	COMPOUND	3	3	tipifarnib
NCT000058598	NCT00005859_8_T0	PHENOTYPE	21	21	toxicity
NCT000058598	NCT00005859_8_T1	GENE	1	1	MTD
NCT0000585910	NCT00005859_10_T0	PHENOTYPE	27	27	progression
NCT0000585913	NCT00005859_13_T0	GENE	1	1	II
NCT0000585913	NCT00005859_13_T1	GENE	30	30	II
NCT0000585913	NCT00005859_13_T2	GENE	37	37	II
NCT0000585913	NCT00005859_13_T3	PHENOTYPE	10	10	closed
NCT0000585913	NCT00005859_13_T4	PHENOTYPE	26	27	glioblastoma multiforme
NCT000058601	NCT00005860_1_T0	CELL	9	9	cells
NCT000058601	NCT00005860_1_T1	PHENOTYPE	8	8	tumor
NCT000058602	NCT00005860_2_T0	COMPOUND	9	9	oxaliplatin
NCT000058602	NCT00005860_2_T1	COMPOUND	15	15	leucovorin
NCT000058602	NCT00005860_2_T2	PHENOTYPE	21	22	metastatic cancer
NCT000058602	NCT00005860_2_T3	PHENOTYPE	22	25	cancer of the peritoneum
NCT000058604	NCT00005860_4_T0	COMPOUND	8	8	oxaliplatin
NCT000058605	NCT00005860_5_T0	COMPOUND	4	4	oxaliplatin
NCT000058606	NCT00005860_6_T0	COMPOUND	11	11	calcium
NCT000058606	NCT00005860_6_T1	COMPOUND	20	20	calcium
NCT000058606	NCT00005860_6_T2	COMPOUND	6	6	oxaliplatin
NCT000058606	NCT00005860_6_T3	COMPOUND	10	10	leucovorin
NCT000058606	NCT00005860_6_T4	COMPOUND	19	19	leucovorin
NCT000058607	NCT00005860_7_T0	PHENOTYPE	13	13	toxicity
NCT000058607	NCT00005860_7_T1	PHENOTYPE	9	10	disease progression
NCT000058609	NCT00005860_9_T0	COMPOUND	8	8	oxaliplatin
NCT000058609	NCT00005860_9_T1	GENE	14	14	MTD
NCT0000586010	NCT00005860_10_T0	PHENOTYPE	22	22	toxicity
NCT0000586010	NCT00005860_10_T1	GENE	1	1	MTD
NCT000058611	NCT00005861_1_T0	GENE	2	2	II
NCT000058611	NCT00005861_1_T1	COMPOUND	10	10	doxorubicin
NCT000058611	NCT00005861_1_T2	PHENOTYPE	16	16	recurrent
NCT000058611	NCT00005861_1_T3	PHENOTYPE	17	18	stage III
NCT000058611	NCT00005861_1_T4	PHENOTYPE	20	23	stage IV endometrial cancer
NCT000058613	NCT00005861_3_T0	COMPOUND	4	4	HCl
NCT000058613	NCT00005861_3_T1	COMPOUND	3	3	doxorubicin
NCT000058613	NCT00005861_3_T2	GENE	6	6	IV
NCT000058614	NCT00005861_4_T0	PHENOTYPE	13	13	toxicity
NCT000058614	NCT00005861_4_T1	PHENOTYPE	9	10	disease progression
NCT000058623	NCT00005862_3_T0	PHENOTYPE	15	15	recurrent
NCT000058623	NCT00005862_3_T1	PHENOTYPE	20	22	gastrointestinal stromal tumor
NCT000058623	NCT00005862_3_T2	PHENOTYPE	16	18	soft tissue sarcoma
NCT000058627	NCT00005862_7_T0	GENE	3	3	IV
NCT000058628	NCT00005862_8_T0	PHENOTYPE	13	13	toxicity
NCT000058628	NCT00005862_8_T1	PHENOTYPE	9	10	disease progression
NCT000058631	NCT00005863_1_T0	PHENOTYPE	17	17	peripheral
NCT000058631	NCT00005863_1_T1	CELL	11	11	cells
NCT000058631	NCT00005863_1_T2	GENE	4	4	filgrastim
NCT000058631	NCT00005863_1_T3	ORGAN	14	15	bone marrow
NCT000058631	NCT00005863_1_T4	ORGAN	24	25	immune system
NCT000058631	NCT00005863_1_T5	PHENOTYPE	30	32	effects of chemotherapy
NCT000058636	NCT00005863_6_T0	GENE	38	38	de
NCT000058636	NCT00005863_6_T1	PHENOTYPE	8	8	resistant
NCT000058636	NCT00005863_6_T2	PHENOTYPE	41	42	secondary leukemia
NCT000058637	NCT00005863_7_T0	PHENOTYPE	12	12	remission
NCT000058637	NCT00005863_7_T1	PHENOTYPE	2	3	relapsed disease
NCT0000586312	NCT00005863_12_T0	PHENOTYPE	8	8	remission
NCT0000586313	NCT00005863_13_T0	PHENOTYPE	0	2	Quality of life
NCT0000586314	NCT00005863_14_T0	GENE	12	12	4.5
NCT000058641	NCT00005864_1_T0	GENE	2	2	II
NCT000058641	NCT00005864_1_T1	COMPOUND	9	10	chloroquinoxaline sulfonamide
NCT000058641	NCT00005864_1_T2	PHENOTYPE	16	19	stage IV colorectal cancer
NCT000058643	NCT00005864_3_T0	PHENOTYPE	5	5	toxicities
NCT000058643	NCT00005864_3_T1	COMPOUND	7	8	chloroquinoxaline sulfonamide
NCT000058643	NCT00005864_3_T2	PHENOTYPE	12	15	stage IV colorectal cancer
NCT000058645	NCT00005864_5_T0	GENE	4	4	IV
NCT000058645	NCT00005864_5_T1	COMPOUND	2	3	chloroquinoxaline sulfonamide
NCT000058646	NCT00005864_6_T0	PHENOTYPE	13	13	toxicity
NCT000058646	NCT00005864_6_T1	PHENOTYPE	9	10	disease progression
NCT000058652	NCT00005865_2_T0	CELL	9	9	cells
NCT000058652	NCT00005865_2_T1	PHENOTYPE	8	8	tumor
NCT000058658	NCT00005865_8_T0	PHENOTYPE	2	4	quality of life
NCT0000586510	NCT00005865_10_T0	PHENOTYPE	2	2	pharmacokinetics
NCT0000586515	NCT00005865_15_T0	PHENOTYPE	10	10	toxicity
NCT0000586515	NCT00005865_15_T1	PHENOTYPE	6	7	disease progression
NCT0000586516	NCT00005865_16_T0	PHENOTYPE	0	2	Quality of life
NCT0000586610	NCT00005866_10_T0	PHENOTYPE	9	10	disease progression
NCT000058671	NCT00005867_1_T0	PHENOTYPE	14	15	Hodgkin's lymphoma
NCT000058672	NCT00005867_2_T0	GENE	4	4	III
NCT000058672	NCT00005867_2_T1	PHENOTYPE	24	25	Hodgkin's lymphoma
NCT000058676	NCT00005867_6_T0	PHENOTYPE	19	19	toxicity
NCT000058676	NCT00005867_6_T1	PHENOTYPE	15	16	disease progression
NCT000058678	NCT00005867_8_T0	PHENOTYPE	19	19	toxicity
NCT000058678	NCT00005867_8_T1	PHENOTYPE	15	16	disease progression
NCT000058682	NCT00005868_2_T0	CELL	9	9	cells
NCT000058682	NCT00005868_2_T1	PHENOTYPE	8	8	tumor
NCT000058686	NCT00005868_6_T0	COMPOUND	2	2	docetaxel
NCT000058686	NCT00005868_6_T1	COMPOUND	11	11	cisplatin
NCT000058686	NCT00005868_6_T2	GENE	3	3	IV
NCT000058686	NCT00005868_6_T3	GENE	12	12	IV
NCT000058687	NCT00005868_7_T0	PHENOTYPE	16	16	toxicity
NCT000058687	NCT00005868_7_T1	PHENOTYPE	12	13	disease progression
NCT000058691	NCT00005869_1_T0	COMPOUND	11	11	gemcitabine
NCT000058691	NCT00005869_1_T1	PHENOTYPE	13	14	pancreatic cancer
NCT000058692	NCT00005869_2_T0	GENE	3	3	III
NCT000058692	NCT00005869_2_T1	COMPOUND	12	12	gemcitabine
NCT000058692	NCT00005869_2_T2	PHENOTYPE	22	24	metastatic pancreatic cancer
NCT000058696	NCT00005869_6_T0	PHENOTYPE	2	2	toxicity
NCT000058698	NCT00005869_8_T0	PHENOTYPE	5	6	measurable disease
NCT0000586911	NCT00005869_11_T0	PHENOTYPE	15	15	toxicity
NCT0000586911	NCT00005869_11_T1	PHENOTYPE	11	12	disease progression
NCT0000586914	NCT00005869_14_T0	PHENOTYPE	15	15	toxicity
NCT0000586914	NCT00005869_14_T1	PHENOTYPE	11	12	disease progression
NCT0000586916	NCT00005869_16_T0	COMPOUND	11	11	gemcitabine
NCT0000586916	NCT00005869_16_T1	GENE	12	12	IV
NCT000058701	NCT00005870_1_T0	PHENOTYPE	14	17	cancer of the pancreas
NCT000058702	NCT00005870_2_T0	GENE	3	3	III
NCT000058702	NCT00005870_2_T1	PHENOTYPE	21	21	recurrent
NCT000058702	NCT00005870_2_T2	PHENOTYPE	23	24	refractory cancer
NCT000058702	NCT00005870_2_T3	PHENOTYPE	24	27	cancer of the pancreas
NCT000058704	NCT00005870_4_T0	PHENOTYPE	14	14	progression
NCT000058704	NCT00005870_4_T1	PHENOTYPE	18	18	recurrent
NCT000058704	NCT00005870_4_T2	PHENOTYPE	21	24	adenocarcinoma of the pancreas
NCT000058706	NCT00005870_6_T0	PHENOTYPE	2	2	toxicity
NCT0000587010	NCT00005870_10_T0	PHENOTYPE	15	15	toxicity
NCT0000587010	NCT00005870_10_T1	PHENOTYPE	11	12	disease progression
NCT0000587013	NCT00005870_13_T0	COMPOUND	6	6	gemcitabine
NCT0000587014	NCT00005870_14_T0	COMPOUND	21	21	gemcitabine
NCT0000587015	NCT00005870_15_T0	COMPOUND	4	4	gemcitabine
NCT0000587018	NCT00005870_18_T0	PHENOTYPE	4	5	disease progression
NCT000058711	NCT00005871_1_T0	PHENOTYPE	13	14	pancreatic cancer
NCT000058712	NCT00005871_2_T0	GENE	3	3	III
NCT000058712	NCT00005871_2_T1	COMPOUND	32	32	gemcitabine
NCT000058712	NCT00005871_2_T2	PHENOTYPE	20	20	recurrent
NCT000058712	NCT00005871_2_T3	PHENOTYPE	23	24	pancreatic cancer
NCT000058714	NCT00005871_4_T0	PHENOTYPE	5	5	recurrent
NCT000058714	NCT00005871_4_T1	PHENOTYPE	8	9	pancreatic cancer
NCT0000587110	NCT00005871_10_T0	PHENOTYPE	2	2	toxicities
NCT0000587115	NCT00005871_15_T0	PHENOTYPE	14	14	toxicity
NCT0000587115	NCT00005871_15_T1	PHENOTYPE	10	11	disease progression
NCT0000587116	NCT00005871_16_T0	PHENOTYPE	2	2	tumor
NCT0000587116	NCT00005871_16_T1	PHENOTYPE	3	3	regression
NCT000058726	NCT00005872_6_T0	PHENOTYPE	4	4	pharmacokinetics
NCT000058726	NCT00005872_6_T1	PHENOTYPE	2	2	toxicities
NCT000058727	NCT00005872_7_T0	GENE	8	8	1.5
NCT000058728	NCT00005872_8_T0	PHENOTYPE	11	11	toxicity
NCT000058728	NCT00005872_8_T1	PHENOTYPE	7	8	disease progression
NCT000058731	NCT00005873_1_T0	GENE	2	2	II
NCT000058731	NCT00005873_1_T1	PHENOTYPE	16	16	recurrent
NCT000058731	NCT00005873_1_T2	PHENOTYPE	18	20	metastatic breast cancer
NCT000058733	NCT00005873_3_T0	PHENOTYPE	2	2	toxicity
NCT000058733	NCT00005873_3_T1	PHENOTYPE	11	11	recurrent
NCT000058733	NCT00005873_3_T2	PHENOTYPE	13	15	metastatic breast cancer
NCT000058737	NCT00005873_7_T0	PHENOTYPE	12	12	toxicity
NCT000058737	NCT00005873_7_T1	ORGAN	1	1	serum
NCT000058739	NCT00005873_9_T0	PHENOTYPE	7	7	toxicity
NCT000058739	NCT00005873_9_T1	GENE	4	4	II
NCT000058739	NCT00005873_9_T2	GENE	1	2	topoisomerase I
NCT0000587310	NCT00005873_10_T0	GENE	8	8	1.5
NCT0000587312	NCT00005873_12_T0	PHENOTYPE	19	19	toxicity
NCT0000587312	NCT00005873_12_T1	PHENOTYPE	15	16	disease progression
NCT000058741	NCT00005874_1_T0	GENE	2	2	II
NCT000058741	NCT00005874_1_T1	PHENOTYPE	19	21	soft tissue sarcomas
NCT000058743	NCT00005874_3_T0	PHENOTYPE	4	4	toxicity
NCT000058743	NCT00005874_3_T1	PHENOTYPE	15	15	leiomyosarcomas
NCT000058743	NCT00005874_3_T2	PHENOTYPE	18	20	soft tissue sarcomas
NCT000058744	NCT00005874_4_T0	PHENOTYPE	7	7	leiomyosarcomas
NCT000058744	NCT00005874_4_T1	PHENOTYPE	10	12	soft tissue sarcomas
NCT000058745	NCT00005874_5_T0	GENE	7	7	1.5
NCT000058746	NCT00005874_6_T0	PHENOTYPE	11	11	toxicity
NCT000058746	NCT00005874_6_T1	PHENOTYPE	7	8	disease progression
NCT000058751	NCT00005875_1_T0	GENE	2	2	II
NCT000058751	NCT00005875_1_T1	PHENOTYPE	15	16	metastatic melanoma
NCT000058753	NCT00005875_3_T0	PHENOTYPE	4	4	toxicity
NCT000058753	NCT00005875_3_T1	PHENOTYPE	10	11	metastatic melanoma
NCT000058755	NCT00005875_5_T0	GENE	7	7	1.5
NCT000058756	NCT00005875_6_T0	PHENOTYPE	18	18	toxicity
NCT000058756	NCT00005875_6_T1	PHENOTYPE	14	15	disease progression
NCT000058761	NCT00005876_1_T0	GENE	2	2	II
NCT000058761	NCT00005876_1_T1	PHENOTYPE	18	20	metastatic stomach cancer
NCT000058763	NCT00005876_3_T0	ORGAN	27	28	gastroesophageal junction
NCT000058763	NCT00005876_3_T1	PHENOTYPE	21	22	metastatic adenocarcinoma
NCT000058763	NCT00005876_3_T2	PHENOTYPE	22	25	adenocarcinoma of the stomach
NCT000058765	NCT00005876_5_T0	PHENOTYPE	2	2	toxicity
NCT000058767	NCT00005876_7_T0	GENE	6	6	1.5
NCT000058768	NCT00005876_8_T0	PHENOTYPE	15	15	toxicity
NCT000058768	NCT00005876_8_T1	PHENOTYPE	11	12	disease progression
NCT000058771	NCT00005877_1_T0	GENE	2	2	II
NCT000058771	NCT00005877_1_T1	PHENOTYPE	17	19	recurrent colorectal cancer
NCT000058773	NCT00005877_3_T0	PHENOTYPE	10	11	disease progression
NCT000058773	NCT00005877_3_T1	PHENOTYPE	20	22	metastatic colorectal cancer
NCT000058775	NCT00005877_5_T0	PHENOTYPE	3	3	toxicity
NCT000058775	NCT00005877_5_T1	PHENOTYPE	5	5	pharmacokinetics
NCT000058777	NCT00005877_7_T0	GENE	6	6	1.5
NCT000058778	NCT00005877_8_T0	PHENOTYPE	15	15	toxicity
NCT000058778	NCT00005877_8_T1	PHENOTYPE	11	12	disease progression
NCT000058781	NCT00005878_1_T0	PHENOTYPE	10	11	Barrett's esophagus
NCT000058782	NCT00005878_2_T0	GENE	3	3	II
NCT000058782	NCT00005878_2_T1	COMPOUND	10	10	celecoxib
NCT000058782	NCT00005878_2_T2	PHENOTYPE	18	19	Barrett's esophagus
NCT000058785	NCT00005878_5_T0	PHENOTYPE	9	9	dysplasia
NCT000058790	NCT00005879_0_T0	PHENOTYPE	8	8	Hyperplasia
NCT000058790	NCT00005879_0_T1	PHENOTYPE	3	4	Breast Cancer
NCT000058793	NCT00005879_3_T0	GENE	3	3	II
NCT000058793	NCT00005879_3_T1	PHENOTYPE	19	19	hyperplasia
NCT000058793	NCT00005879_3_T2	PHENOTYPE	13	14	breast cancer
NCT000058799	NCT00005879_9_T0	PHENOTYPE	0	2	Quality of life
NCT000058801	NCT00005880_1_T0	COMPOUND	3	3	budesonide
NCT000058801	NCT00005880_1_T1	PHENOTYPE	11	12	bronchial dysplasia
NCT000058802	NCT00005880_2_T0	GENE	4	4	II
NCT000058802	NCT00005880_2_T1	COMPOUND	11	11	budesonide
NCT000058802	NCT00005880_2_T2	PHENOTYPE	20	21	bronchial dysplasia
NCT000058804	NCT00005880_4_T0	PHENOTYPE	14	14	dysplastic
NCT000058804	NCT00005880_4_T1	COMPOUND	5	5	budesonide
NCT000058808	NCT00005880_8_T0	PHENOTYPE	2	2	regression
NCT000058808	NCT00005880_8_T1	PHENOTYPE	4	5	bronchial dysplasia
NCT000058808	NCT00005880_8_T2	PHENOTYPE	17	18	atypical cells
NCT0000588014	NCT00005880_14_T0	GENE	17	17	3.4
NCT0000588014	NCT00005880_14_T1	GENE	21	21	3.4
NCT0000588018	NCT00005880_18_T0	PHENOTYPE	13	13	toxicity
NCT0000588018	NCT00005880_18_T1	PHENOTYPE	9	10	disease progression
NCT000058811	NCT00005881_1_T0	PHENOTYPE	8	10	quality of life
NCT000058814	NCT00005881_4_T0	PHENOTYPE	24	24	cancers
NCT000058814	NCT00005881_4_T1	PHENOTYPE	7	9	quality of life
NCT000058831	NCT00005883_1_T0	COMPOUND	1	1	isothiocyanate
NCT000058831	NCT00005883_1_T1	PHENOTYPE	7	8	lung cancer
NCT000058832	NCT00005883_2_T0	COMPOUND	5	5	phenethyl
NCT000058832	NCT00005883_2_T1	COMPOUND	6	6	isothiocyanate
NCT000058832	NCT00005883_2_T2	PHENOTYPE	9	10	lung cancer
NCT000058834	NCT00005883_4_T0	COMPOUND	7	7	phenethyl
NCT000058834	NCT00005883_4_T1	COMPOUND	8	8	isothiocyanate
NCT000058836	NCT00005883_6_T0	COMPOUND	6	6	phenethyl
NCT000058836	NCT00005883_6_T1	COMPOUND	7	7	isothiocyanate
NCT000058836	NCT00005883_6_T2	PHENOTYPE	4	4	pharmacokinetics
NCT000058836	NCT00005883_6_T3	COMPOUND	21	21	4__methylnitrosamino__1__3_pyridyl__1_butanone
NCT000058838	NCT00005883_8_T0	COMPOUND	10	10	phenethyl
NCT000058838	NCT00005883_8_T1	COMPOUND	11	11	isothiocyanate
NCT000058838	NCT00005883_8_T2	BIOLOGICAL_PROCESS	8	8	metabolism
NCT000058839	NCT00005883_9_T0	GENE	10	10	log
NCT0000588310	NCT00005883_10_T0	COMPOUND	2	2	phenethyl
NCT0000588310	NCT00005883_10_T1	COMPOUND	3	3	isothiocyanate
NCT0000588311	NCT00005883_11_T0	COMPOUND	8	8	phenethyl
NCT0000588311	NCT00005883_11_T1	COMPOUND	9	9	isothiocyanate
NCT0000588311	NCT00005883_11_T2	GENE	15	15	MTD
NCT0000588312	NCT00005883_12_T0	PHENOTYPE	18	18	toxicities
NCT0000588312	NCT00005883_12_T1	GENE	1	1	MTD
NCT000058843	NCT00005884_3_T0	GENE	3	3	III
NCT000058843	NCT00005884_3_T1	PHENOTYPE	13	14	skin cancer
NCT000058843	NCT00005884_3_T2	PHENOTYPE	25	26	skin cancer
NCT000058847	NCT00005884_7_T0	GENE	4	4	TPA
NCT000058847	NCT00005884_7_T1	PHENOTYPE	2	2	inhibition
NCT000058847	NCT00005884_7_T2	COMPOUND	16	16	DFMO
NCT000058847	NCT00005884_7_T3	MOLECULAR_FUNCTION	5	7	ornithine decarboxylase activity
NCT000058849	NCT00005884_9_T0	PHENOTYPE	2	2	inhibition
NCT000058849	NCT00005884_9_T1	COMPOUND	15	15	DFMO
NCT0000588411	NCT00005884_11_T0	PHENOTYPE	4	4	toxic
NCT0000588417	NCT00005884_17_T0	PHENOTYPE	10	10	toxicity
NCT0000588417	NCT00005884_17_T1	GENE	3	3	3.5
NCT000058861	NCT00005886_1_T0	COMPOUND	15	15	estrogen
NCT000058861	NCT00005886_1_T1	COMPOUND	3	3	tamoxifen
NCT000058861	NCT00005886_1_T2	PHENOTYPE	8	9	breast cancer
NCT000058862	NCT00005886_2_T0	PHENOTYPE	17	17	tumor
NCT000058862	NCT00005886_2_T1	COMPOUND	10	10	tamoxifen
NCT000058862	NCT00005886_2_T2	PHENOTYPE	28	29	breast cancer
NCT000058866	NCT00005886_6_T0	PHENOTYPE	21	21	toxicity
NCT000058866	NCT00005886_6_T1	PHENOTYPE	17	18	disease progression
NCT000058871	NCT00005887_1_T0	CELL	7	7	cells
NCT000058871	NCT00005887_1_T1	PHENOTYPE	6	6	tumor
NCT000058872	NCT00005887_2_T0	GENE	3	3	III
NCT000058872	NCT00005887_2_T1	PHENOTYPE	24	25	brain metastases
NCT000058875	NCT00005887_5_T0	GENE	14	14	II
NCT000058875	NCT00005887_5_T1	GENE	10	10	RPA
NCT000058875	NCT00005887_5_T2	PHENOTYPE	8	8	Oncology
NCT000058878	NCT00005887_8_T0	PHENOTYPE	24	25	disease progression
NCT000058878	NCT00005887_8_T1	PHENOTYPE	0	2	Quality of life
NCT000058879	NCT00005887_9_T0	PHENOTYPE	12	13	disease progression
NCT000058881	NCT00005888_1_T0	PHENOTYPE	19	19	fed
NCT000058881	NCT00005888_1_T1	PHENOTYPE	6	6	sepsis
NCT000058881	NCT00005888_1_T2	PHENOTYPE	8	9	necrotizing enterocolitis
NCT000058881	NCT00005888_1_T3	PHENOTYPE	4	5	late onset
NCT000058881	NCT00005888_1_T4	PHENOTYPE	15	17	low birth weight
NCT000058883	NCT00005888_3_T0	PHENOTYPE	19	19	sepsis
NCT000058883	NCT00005888_3_T1	PHENOTYPE	5	6	antibody titers
NCT000058883	NCT00005888_3_T2	PHENOTYPE	17	18	late onset
NCT0000588814	NCT00005888_14_T0	ORGAN	0	1	Cord blood
NCT0000588818	NCT00005888_18_T0	PHENOTYPE	11	12	Infant Development
NCT000058891	NCT00005889_1_T0	BIOLOGICAL_PROCESS	0	0	Gluconeogenesis
NCT000058892	NCT00005889_2_T0	PHENOTYPE	18	20	blood sugar levels
NCT000058893	NCT00005889_3_T0	PHENOTYPE	37	39	blood sugar levels
NCT000058893	NCT00005889_3_T1	PHENOTYPE	6	9	very low birth weight
NCT000058895	NCT00005889_5_T0	GENE	11	11	12
NCT000058895	NCT00005889_5_T1	COMPOUND	35	35	glucose
NCT000058895	NCT00005889_5_T2	BIOLOGICAL_PROCESS	47	47	lipolysis
NCT000058895	NCT00005889_5_T3	BIOLOGICAL_PROCESS	39	39	gluconeogenesis
NCT000058895	NCT00005889_5_T4	GENE	8	8	IV
NCT000058895	NCT00005889_5_T5	GENE	23	23	IV
NCT000058895	NCT00005889_5_T6	GENE	41	41	IV
NCT000058895	NCT00005889_5_T7	GENE	50	50	IV
NCT000058895	NCT00005889_5_T8	BIOLOGICAL_PROCESS	56	56	proteolysis
NCT000058895	NCT00005889_5_T9	BIOLOGICAL_PROCESS	20	21	protein oxidation
NCT000058896	NCT00005889_6_T0	COMPOUND	20	20	leucine
NCT000058896	NCT00005889_6_T1	COMPOUND	17	17	glucose
NCT000058896	NCT00005889_6_T2	GENE	28	28	4.5
NCT000058896	NCT00005889_6_T3	COMPOUND	18	18	glycerol
NCT000058896	NCT00005889_6_T4	GENE	31	31	9.5
NCT000058896	NCT00005889_6_T5	COMPOUND	9	9	urea
NCT000058897	NCT00005889_7_T0	COMPOUND	1	1	glucose
NCT000058897	NCT00005889_7_T1	COMPOUND	8	8	glucose
NCT000058897	NCT00005889_7_T2	COMPOUND	12	12	glucose
NCT000058897	NCT00005889_7_T3	PHENOTYPE	13	13	falls
NCT000058897	NCT00005889_7_T4	GENE	9	9	IV
NCT0000588911	NCT00005889_11_T0	COMPOUND	5	5	glucose
NCT0000588911	NCT00005889_11_T1	GENE	8	8	reduced
NCT0000588912	NCT00005889_12_T0	GENE	1	1	II
NCT0000588912	NCT00005889_12_T1	GENE	11	11	IV
NCT0000588913	NCT00005889_13_T0	GENE	1	1	III
NCT0000588913	NCT00005889_13_T1	GENE	14	14	IV
NCT0000588913	NCT00005889_13_T2	COMPOUND	13	13	glycerol
NCT0000588915	NCT00005889_15_T0	GENE	4	4	glucagon
NCT0000588915	NCT00005889_15_T1	GENE	5	5	IV
NCT0000588916	NCT00005889_16_T0	COMPOUND	11	11	glucose
NCT0000588916	NCT00005889_16_T1	GENE	6	6	glucagon
NCT0000588916	NCT00005889_16_T2	GENE	7	7	IV
NCT0000588916	NCT00005889_16_T3	GENE	10	10	IV
NCT0000588916	NCT00005889_16_T4	GENE	18	18	IV
NCT000058900	NCT00005890_0_T0	PHENOTYPE	9	10	Septic Shock
NCT000058902	NCT00005890_2_T0	PHENOTYPE	13	14	septic shock
NCT000058902	NCT00005890_2_T1	PHENOTYPE	8	9	adrenal dysfunction
NCT000058904	NCT00005890_4_T0	PHENOTYPE	20	21	septic shock
NCT000058904	NCT00005890_4_T1	PHENOTYPE	12	13	multiorgan failure
NCT000058904	NCT00005890_4_T2	PHENOTYPE	17	18	adrenal dysfunction
NCT000058906	NCT00005890_6_T0	COMPOUND	4	4	cortisol
NCT000058906	NCT00005890_6_T1	GENE	6	6	corticotropin
NCT000058906	NCT00005890_6_T2	GENE	15	15	corticotropin
NCT000058906	NCT00005890_6_T3	ORGAN	3	3	plasma
NCT000058906	NCT00005890_6_T4	GENE	17	17	IV
NCT000058907	NCT00005890_7_T0	PHENOTYPE	1	2	cortisol levels
NCT000058908	NCT00005890_8_T0	COMPOUND	7	7	cortisol
NCT000058908	NCT00005890_8_T1	COMPOUND	0	0	Corticotropin
NCT000058909	NCT00005890_9_T0	ORGAN	4	4	heart
NCT0000589010	NCT00005890_10_T0	PHENOTYPE	5	6	septic shock
NCT0000589010	NCT00005890_10_T1	PHENOTYPE	8	11	multiple organ system failure
NCT000058911	NCT00005891_1_T0	COMPOUND	6	6	cyclophosphamide
NCT000058911	NCT00005891_1_T1	PHENOTYPE	30	31	aplastic anemia
NCT000058911	NCT00005891_1_T2	ORGAN	23	24	bone marrow
NCT000058913	NCT00005891_3_T0	ORGAN	3	4	bone marrow
NCT000058923	NCT00005892_3_T0	ORGAN	3	4	bone marrow
NCT000058931	NCT00005893_1_T0	PHENOTYPE	15	16	hematologic disorders
NCT000058931	NCT00005893_1_T1	ORGAN	4	5	bone marrow
NCT000058935	NCT00005893_5_T0	GENE	41	41	globulin
NCT000058935	NCT00005893_5_T1	COMPOUND	31	31	busulfan
NCT000058935	NCT00005893_5_T2	CELL	40	40	thymocyte
NCT000058935	NCT00005893_5_T3	COMPOUND	51	51	cyclophosphamide
NCT000058935	NCT00005893_5_T4	PHENOTYPE	4	4	thalassemia
NCT000058935	NCT00005893_5_T5	ORGAN	5	5	liver
NCT000058935	NCT00005893_5_T6	GENE	50	50	1.5
NCT000058935	NCT00005893_5_T7	GENE	10	10	cm
NCT000058935	NCT00005893_5_T8	GENE	42	42	IV
NCT000058935	NCT00005893_5_T9	GENE	52	52	IV
NCT000058935	NCT00005893_5_T10	COMPOUND	47	47	1
NCT000058935	NCT00005893_5_T11	COMPOUND	9	9	2
NCT000058935	NCT00005893_5_T12	COMPOUND	57	57	2
NCT000058935	NCT00005893_5_T13	COMPOUND	3	3	3
NCT000058935	NCT00005893_5_T14	COMPOUND	55	55	3
NCT000058935	NCT00005893_5_T15	PHENOTYPE	26	26	conditioning
NCT000058935	NCT00005893_5_T16	PHENOTYPE	20	21	portal fibrosis
NCT000058935	NCT00005893_5_T17	ORGAN	12	13	costal margin
NCT000058963	NCT00005896_3_T0	ORGAN	14	14	marrow
NCT000058963	NCT00005896_3_T1	PHENOTYPE	4	4	engraftment
NCT000058968	NCT00005896_8_T0	GENE	4	4	IV
NCT000058983	NCT00005898_3_T0	PHENOTYPE	4	4	acute
NCT000058983	NCT00005898_3_T1	PHENOTYPE	6	8	chronic graft-versus-host disease
NCT000058987	NCT00005898_7_T0	PHENOTYPE	2	2	toxicity
NCT000059005	NCT00005900_5_T0	GENE	26	26	has
NCT000059005	NCT00005900_5_T1	ORGAN	5	5	serum
NCT000059005	NCT00005900_5_T2	PHENOTYPE	29	30	pulmonary complications
NCT000059005	NCT00005900_5_T3	PHENOTYPE	15	16	pulmonary complication
NCT000059011	NCT00005901_1_T0	GENE	6	6	collagen
NCT000059011	NCT00005901_1_T1	PHENOTYPE	3	4	genetic disorder
NCT000059012	NCT00005901_2_T0	TISSUE	5	5	bones
NCT000059012	NCT00005901_2_T1	GENE	2	2	collagen
NCT000059012	NCT00005901_2_T2	PHENOTYPE	14	14	fractures
NCT000059012	NCT00005901_2_T3	PHENOTYPE	10	11	osteogenesis imperfecta
NCT000059015	NCT00005901_5_T0	GENE	12	12	III
NCT000059015	NCT00005901_5_T1	GENE	14	14	IV
NCT000059015	NCT00005901_5_T2	PHENOTYPE	9	10	osteogenesis imperfecta
NCT000059016	NCT00005901_6_T0	COMPOUND	24	24	pamidronate
NCT0000590116	NCT00005901_16_T0	TISSUE	26	26	bones
NCT0000590116	NCT00005901_16_T1	PHENOTYPE	32	32	fracture
NCT0000590117	NCT00005901_17_T0	COMPOUND	11	11	hydroxyapatite
NCT0000590117	NCT00005901_17_T1	COMPOUND	5	5	pyrophosphate
NCT0000590119	NCT00005901_19_T0	COMPOUND	3	3	bisphosphonates
NCT0000590119	NCT00005901_19_T1	TISSUE	21	22	bone matrix
NCT0000590119	NCT00005901_19_T2	PHENOTYPE	29	30	systemic disease
NCT0000590119	NCT00005901_19_T3	PHENOTYPE	37	38	systemic disease
NCT0000590119	NCT00005901_19_T4	BIOLOGICAL_PROCESS	18	19	bone mineralization
NCT0000590119	NCT00005901_19_T5	PHENOTYPE	43	44	tissue calcification
NCT0000590120	NCT00005901_20_T0	BIOLOGICAL_PROCESS	8	9	bone resorption
NCT0000590121	NCT00005901_21_T0	COMPOUND	11	11	pamidronate
NCT0000590121	NCT00005901_21_T1	GENE	16	16	III
NCT0000590121	NCT00005901_21_T2	GENE	18	18	IV
NCT0000590121	NCT00005901_21_T3	PHENOTYPE	19	20	osteogenesis imperfecta
NCT0000590125	NCT00005901_25_T0	BIOLOGICAL_PROCESS	22	22	Growth
NCT0000590125	NCT00005901_25_T1	MOLECULAR_FUNCTION	31	32	Growth Hormone
NCT0000590125	NCT00005901_25_T2	PHENOTYPE	24	25	Basilar Invagination
NCT0000590125	NCT00005901_25_T3	PHENOTYPE	27	28	Osteogenesis Imperfecta
NCT0000590125	NCT00005901_25_T4	PHENOTYPE	35	36	Osteogenesis Imperfecta
NCT0000590126	NCT00005901_26_T0	ORGAN	26	26	spine
NCT0000590126	NCT00005901_26_T1	PHENOTYPE	30	30	fracture
NCT0000590126	NCT00005901_26_T2	ORGAN	23	24	lower extremities
NCT0000590129	NCT00005901_29_T0	GENE	19	19	III
NCT0000590129	NCT00005901_29_T1	GENE	21	21	IV
NCT0000590129	NCT00005901_29_T2	GENE	39	39	fused
NCT0000590129	NCT00005901_29_T3	ORGAN	35	35	epiphyses
NCT0000590129	NCT00005901_29_T4	PHENOTYPE	16	17	osteogenesis imperfecta
NCT0000590130	NCT00005901_30_T0	PHENOTYPE	9	9	scoliosis
NCT0000590130	NCT00005901_30_T1	PHENOTYPE	16	16	scoliosis
NCT0000590130	NCT00005901_30_T2	GENE	17	17	has
NCT0000590130	NCT00005901_30_T3	PHENOTYPE	29	30	basilar invagination
NCT0000590131	NCT00005901_31_T0	COMPOUND	5	5	bisphosphonates
NCT0000590132	NCT00005901_32_T0	GENE	22	22	GH
NCT000059023	NCT00005902_3_T0	GENE	6	6	MRI
NCT000059023	NCT00005902_3_T1	ORGAN	11	12	spinal cord
NCT000059025	NCT00005902_5_T0	GENE	16	16	MRI
NCT000059025	NCT00005902_5_T1	ORGAN	22	22	spine
NCT000059027	NCT00005902_7_T0	PHENOTYPE	5	7	spinal cord tumors
NCT000059028	NCT00005902_8_T0	PHENOTYPE	5	5	tumors
NCT000059028	NCT00005902_8_T1	PHENOTYPE	21	21	decisions
NCT0000590210	NCT00005902_10_T0	ORGAN	6	6	cerebrum
NCT0000590211	NCT00005902_11_T0	PHENOTYPE	11	11	cysts
NCT0000590211	NCT00005902_11_T1	PHENOTYPE	13	13	syrinx
NCT0000590213	NCT00005902_13_T0	PHENOTYPE	14	14	tumor
NCT0000590213	NCT00005902_13_T1	PHENOTYPE	0	0	Focused
NCT0000590228	NCT00005902_28_T0	GENE	13	13	MRI
NCT0000590228	NCT00005902_28_T1	PHENOTYPE	10	10	hemangioblastomas
NCT0000590228	NCT00005902_28_T2	ORGAN	8	9	spinal cord
NCT0000590234	NCT00005902_34_T0	GENE	6	6	MRI
NCT0000590234	NCT00005902_34_T1	GENE	12	12	IV
NCT0000590240	NCT00005902_40_T0	PHENOTYPE	0	0	Allergy
NCT0000590240	NCT00005902_40_T1	GENE	4	4	MRI
NCT000059031	NCT00005903_1_T0	ORGAN	19	19	abdomen
NCT000059036	NCT00005903_6_T0	ORGAN	25	25	abdomen
NCT000059038	NCT00005903_8_T0	PHENOTYPE	6	6	anesthesia
NCT0000590314	NCT00005903_14_T0	GENE	4	4	GDNF
NCT0000590315	NCT00005903_15_T0	CELL	14	14	cells
NCT0000590315	NCT00005903_15_T1	COMPOUND	19	19	dopamine
NCT0000590315	NCT00005903_15_T2	PHENOTYPE	24	25	balance problems
NCT0000590316	NCT00005903_16_T0	GENE	3	3	GDNF
NCT0000590316	NCT00005903_16_T1	PHENOTYPE	11	12	Parkinson's disease
NCT0000590318	NCT00005903_18_T0	PHENOTYPE	10	11	adverse events
NCT0000590319	NCT00005903_19_T0	GENE	20	20	putative
NCT0000590319	NCT00005903_19_T1	PHENOTYPE	8	9	right sided
NCT0000590322	NCT00005903_22_T0	ORGAN	3	3	limb
NCT0000590322	NCT00005903_22_T1	COMPOUND	12	12	levodopa
NCT0000590322	NCT00005903_22_T2	PHENOTYPE	4	4	dysfunction
NCT0000590330	NCT00005903_30_T0	GENE	9	9	DPA
NCT0000590333	NCT00005903_33_T0	PHENOTYPE	13	13	bilateral
NCT0000590335	NCT00005903_35_T0	COMPOUND	2	2	levodopa
NCT0000590335	NCT00005903_35_T1	COMPOUND	3	3	dopamine
NCT0000590337	NCT00005903_37_T0	PHENOTYPE	6	6	hallucinations
NCT0000590337	NCT00005903_37_T1	PHENOTYPE	4	4	psychosis
NCT0000590339	NCT00005903_39_T0	PHENOTYPE	22	22	bilateral
NCT0000590339	NCT00005903_39_T1	PHENOTYPE	12	12	sepsis
NCT0000590339	NCT00005903_39_T2	BIOLOGICAL_PROCESS	18	19	wound healing
NCT0000590339	NCT00005903_39_T3	PHENOTYPE	8	9	bleeding diathesis
NCT0000590341	NCT00005903_41_T0	PHENOTYPE	8	9	cerebrovascular disease
NCT0000590341	NCT00005903_41_T1	PHENOTYPE	20	21	alcohol abuse
NCT0000590341	NCT00005903_41_T2	PHENOTYPE	5	6	head trauma
NCT0000590343	NCT00005903_43_T0	GENE	9	9	MRI
NCT0000590343	NCT00005903_43_T1	PHENOTYPE	27	29	nervous system abnormality
NCT0000590343	NCT00005903_43_T2	ORGAN	26	28	central nervous system
NCT0000590347	NCT00005903_47_T0	PHENOTYPE	58	58	chronic
NCT0000590347	NCT00005903_47_T1	PHENOTYPE	29	30	cardiovascular disease
NCT0000590347	NCT00005903_47_T2	PHENOTYPE	5	6	laboratory abnormality
NCT0000590347	NCT00005903_47_T3	PHENOTYPE	9	10	degenerative arthritis
NCT000059051	NCT00005905_1_T0	GENE	5	5	leptin
NCT000059051	NCT00005905_1_T1	PHENOTYPE	2	2	lipodystrophy
NCT000059051	NCT00005905_1_T2	GENE	8	8	hormone
NCT000059051	NCT00005905_1_T3	CELL	12	13	fat cells
NCT000059053	NCT00005905_3_T0	GENE	3	3	hormone
NCT000059053	NCT00005905_3_T1	PHENOTYPE	10	11	liver disease
NCT000059054	NCT00005905_4_T0	PHENOTYPE	6	6	lipodystrophy
NCT0000590510	NCT00005905_10_T0	PHENOTYPE	5	5	hunger
NCT0000590510	NCT00005905_10_T1	PHENOTYPE	24	24	hunger
NCT0000590513	NCT00005905_13_T0	GENE	6	6	leptin
NCT0000590515	NCT00005905_15_T0	PHENOTYPE	13	15	drug side effects
NCT0000590519	NCT00005905_19_T0	PHENOTYPE	16	16	symptoms
NCT0000590523	NCT00005905_23_T0	TISSUE	15	16	adipose tissue
NCT0000590523	NCT00005905_23_T1	PHENOTYPE	7	8	insulin resistance
NCT0000590524	NCT00005905_24_T0	GENE	9	9	insulin
NCT0000590524	NCT00005905_24_T1	GENE	4	4	leptin
NCT0000590524	NCT00005905_24_T2	GENE	6	6	hormone
NCT0000590524	NCT00005905_24_T3	TISSUE	0	1	Adipose tissue
NCT0000590531	NCT00005905_31_T0	COMPOUND	10	10	glucose
NCT0000590531	NCT00005905_31_T1	GENE	11	11	insulin
NCT0000590532	NCT00005905_32_T0	PHENOTYPE	15	15	pathology
NCT0000590532	NCT00005905_32_T1	ORGAN	14	14	liver
NCT0000590532	NCT00005905_32_T2	GENE	11	11	axis
NCT0000590534	NCT00005905_34_T0	GENE	1	1	leptin
NCT0000590535	NCT00005905_35_T0	ORGAN	16	16	liver
NCT0000590535	NCT00005905_35_T1	TISSUE	9	10	body fat
NCT0000590537	NCT00005905_37_T0	GENE	12	12	3.0
NCT0000590537	NCT00005905_37_T1	GENE	5	5	4.0
NCT0000590537	NCT00005905_37_T2	GENE	1	1	leptin
NCT0000590539	NCT00005905_39_T0	GENE	1	1	insulin
NCT0000590539	NCT00005905_39_T1	PHENOTYPE	7	7	hypertriglyceridemia
NCT0000590540	NCT00005905_40_T0	PHENOTYPE	1	1	General
NCT000059062	NCT00005906_2_T0	PHENOTYPE	5	5	symptoms
NCT000059062	NCT00005906_2_T1	GENE	6	6	has
NCT000059063	NCT00005906_3_T0	GENE	3	3	somatostatin
NCT000059063	NCT00005906_3_T1	COMPOUND	5	5	octreotide
NCT000059063	NCT00005906_3_T2	PHENOTYPE	14	15	chylous effusions
NCT000059069	NCT00005906_9_T0	PHENOTYPE	7	7	proliferation
NCT000059069	NCT00005906_9_T1	PHENOTYPE	0	0	Lymphangioleiomyomas
NCT000059069	NCT00005906_9_T2	ORGAN	15	16	lymphatic system
NCT000059069	NCT00005906_9_T3	CELL	10	12	smooth muscle cells
NCT0000590610	NCT00005906_10_T0	PHENOTYPE	1	1	lymphangioleiomyomas
NCT0000590612	NCT00005906_12_T0	PHENOTYPE	8	8	symptoms
NCT0000590612	NCT00005906_12_T1	GENE	19	19	has
NCT0000590612	NCT00005906_12_T2	ORGAN	12	13	lower extremities
NCT0000590613	NCT00005906_13_T0	PHENOTYPE	27	27	peripheral
NCT0000590613	NCT00005906_13_T1	PHENOTYPE	28	28	lymphedema
NCT0000590613	NCT00005906_13_T2	PHENOTYPE	24	24	chyluria
NCT0000590613	NCT00005906_13_T3	PHENOTYPE	25	25	ascites
NCT0000590613	NCT00005906_13_T4	GENE	3	3	somatostatin
NCT0000590613	NCT00005906_13_T5	COMPOUND	5	5	octreotide
NCT0000590613	NCT00005906_13_T6	PHENOTYPE	22	23	chylous effusions
NCT0000590615	NCT00005906_15_T0	COMPOUND	3	3	octreotide
NCT0000590622	NCT00005906_22_T0	PHENOTYPE	2	3	hepatitis B
NCT0000590622	NCT00005906_22_T1	PHENOTYPE	4	5	hepatitis C
NCT0000590622	NCT00005906_22_T2	PHENOTYPE	10	11	liver diseases
NCT0000590623	NCT00005906_23_T0	ORGAN	0	0	Transplant
NCT0000590627	NCT00005906_27_T0	COMPOUND	5	5	creatinine
NCT0000590627	NCT00005906_27_T1	GENE	8	8	1.5
NCT0000590628	NCT00005906_28_T0	PHENOTYPE	2	3	HIV infection
NCT000059071	NCT00005907_1_T0	CELL	21	21	platelets
NCT000059071	NCT00005907_1_T1	CELL	10	10	cells
NCT000059071	NCT00005907_1_T2	ORGAN	2	2	transplant
NCT000059071	NCT00005907_1_T3	CELL	17	19	red blood cells
NCT000059071	NCT00005907_1_T4	CELL	14	16	white blood cells
NCT000059073	NCT00005907_3_T0	ORGAN	12	12	transplant
NCT000059073	NCT00005907_3_T1	GENE	9	9	had
NCT000059074	NCT00005907_4_T0	GENE	24	24	had
NCT000059074	NCT00005907_4_T1	PHENOTYPE	16	17	hepatitis B
NCT000059074	NCT00005907_4_T2	PHENOTYPE	25	26	hepatitis B
NCT000059077	NCT00005907_7_T0	GENE	19	19	booster
NCT000059078	NCT00005907_8_T0	ORGAN	14	14	transplant
NCT000059078	NCT00005907_8_T1	PHENOTYPE	19	20	a hepatitis
NCT000059078	NCT00005907_8_T2	PHENOTYPE	8	9	hepatitis B
NCT000059078	NCT00005907_8_T3	PHENOTYPE	20	21	hepatitis B
NCT000059079	NCT00005907_9_T0	BIOLOGICAL_PROCESS	26	27	immune response
NCT0000590712	NCT00005907_12_T0	CELL	11	11	lymphocytes
NCT0000590712	NCT00005907_12_T1	ORGAN	0	0	Serum
NCT0000590712	NCT00005907_12_T2	PHENOTYPE	1	2	antibody titers
NCT0000590715	NCT00005907_15_T0	PHENOTYPE	2	3	hepatitis B
NCT0000590716	NCT00005907_16_T0	ORGAN	7	7	serum
NCT0000590718	NCT00005907_18_T0	PHENOTYPE	5	6	adverse event
NCT0000590720	NCT00005907_20_T0	ORGAN	0	0	Serum
NCT0000590720	NCT00005907_20_T1	GENE	1	1	hemoglobin
NCT0000590721	NCT00005907_21_T0	PHENOTYPE	3	4	hepatitis B
NCT0000590722	NCT00005907_22_T0	GENE	9	9	booster
NCT0000590722	NCT00005907_22_T1	PHENOTYPE	7	8	hepatitis B
NCT0000590727	NCT00005907_27_T0	ORGAN	7	7	serum
NCT0000590728	NCT00005907_28_T0	PHENOTYPE	5	6	adverse event
NCT0000590730	NCT00005907_30_T0	ORGAN	0	0	Serum
NCT0000590730	NCT00005907_30_T1	GENE	1	1	hemoglobin
NCT0000590731	NCT00005907_31_T0	PHENOTYPE	3	4	hepatitis B
NCT0000590733	NCT00005907_33_T0	COMPOUND	5	5	cyclosporine
NCT0000590734	NCT00005907_34_T0	GENE	5	5	II
NCT0000590734	NCT00005907_34_T1	PHENOTYPE	1	3	acute graft-versus-host disease
NCT0000590735	NCT00005907_35_T0	ORGAN	11	11	liver
NCT0000590735	NCT00005907_35_T1	PHENOTYPE	7	7	localized
NCT0000590735	NCT00005907_35_T2	PHENOTYPE	12	12	dysfunction
NCT0000590735	NCT00005907_35_T3	PHENOTYPE	1	3	chronic graft-versus-host disease
NCT000059082	NCT00005908_2_T0	COMPOUND	14	14	capecitabine
NCT000059082	NCT00005908_2_T1	COMPOUND	16	16	docetaxel
NCT000059083	NCT00005908_3_T0	GENE	8	8	II
NCT000059083	NCT00005908_3_T1	PHENOTYPE	14	14	tumor
NCT000059083	NCT00005908_3_T2	GENE	10	10	III
NCT000059083	NCT00005908_3_T3	PHENOTYPE	11	12	breast cancer
NCT000059084	NCT00005908_4_T0	COMPOUND	17	17	capecitabine
NCT000059084	NCT00005908_4_T1	COMPOUND	19	19	docetaxel
NCT000059084	NCT00005908_4_T2	COMPOUND	13	13	cyclophosphamide
NCT000059084	NCT00005908_4_T3	COMPOUND	10	10	doxorubicin
NCT000059085	NCT00005908_5_T0	PHENOTYPE	14	14	tumor
NCT000059088	NCT00005908_8_T0	PHENOTYPE	10	10	tumor
NCT000059089	NCT00005908_9_T0	ORGAN	14	14	underarm
NCT000059089	NCT00005908_9_T1	ORGAN	22	22	underarm
NCT000059089	NCT00005908_9_T2	TISSUE	15	16	lymph nodes
NCT000059089	NCT00005908_9_T3	TISSUE	23	24	lymph nodes
NCT0000590810	NCT00005908_10_T0	COMPOUND	16	16	cyclophosphamide
NCT0000590810	NCT00005908_10_T1	COMPOUND	14	14	doxorubicin
NCT0000590812	NCT00005908_12_T0	CELL	14	14	cells
NCT0000590812	NCT00005908_12_T1	PHENOTYPE	9	9	tumor
NCT0000590812	NCT00005908_12_T2	PHENOTYPE	13	13	tumor
NCT0000590812	NCT00005908_12_T3	GENE	3	3	had
NCT0000590812	NCT00005908_12_T4	GENE	25	25	had
NCT0000590812	NCT00005908_12_T5	TISSUE	19	20	lymph nodes
NCT0000590813	NCT00005908_13_T0	PHENOTYPE	4	4	tumors
NCT0000590813	NCT00005908_13_T1	COMPOUND	8	8	tamoxifen
NCT0000590813	NCT00005908_13_T2	GENE	2	2	hormone
NCT0000590814	NCT00005908_14_T0	ORGAN	62	62	heart
NCT0000590814	NCT00005908_14_T1	PHENOTYPE	10	10	tumor
NCT0000590814	NCT00005908_14_T2	PHENOTYPE	18	18	tumor
NCT0000590816	NCT00005908_16_T0	PHENOTYPE	24	24	recurrence
NCT0000590816	NCT00005908_16_T1	PHENOTYPE	17	17	tumor
NCT0000590817	NCT00005908_17_T0	PHENOTYPE	24	24	tumor
NCT0000590817	NCT00005908_17_T1	GENE	20	20	cDNA
NCT0000590820	NCT00005908_20_T0	PHENOTYPE	12	12	toxicities
NCT0000590821	NCT00005908_21_T0	PHENOTYPE	4	4	tumor
NCT0000590823	NCT00005908_23_T0	PHENOTYPE	9	9	tumor
NCT0000590825	NCT00005908_25_T0	CELL	7	7	neutrophil
NCT0000590825	NCT00005908_25_T1	PHENOTYPE	13	14	platelet count
NCT0000590826	NCT00005908_26_T0	COMPOUND	6	6	creatinine
NCT0000590826	NCT00005908_26_T1	GENE	9	9	1/6
NCT0000590831	NCT00005908_31_T0	PHENOTYPE	6	7	breast cancer
NCT0000590832	NCT00005908_32_T0	COMPOUND	7	7	raloxifene
NCT0000590832	NCT00005908_32_T1	COMPOUND	5	5	tamoxifen
NCT0000590833	NCT00005908_33_T0	PHENOTYPE	1	1	malignancy
NCT000059090	NCT00005909_0_T0	PHENOTYPE	2	2	Alkaptonuria
NCT000059093	NCT00005909_3_T0	ORGAN	7	8	heart valve
NCT000059093	NCT00005909_3_T1	PHENOTYPE	4	5	kidney stones
NCT000059094	NCT00005909_4_T0	PHENOTYPE	0	0	Alkaptonuria
NCT000059094	NCT00005909_4_T1	GENE	1	1	has
NCT0000590910	NCT00005909_10_T0	GENE	4	4	ml
NCT0000590910	NCT00005909_10_T1	GENE	20	20	ml
NCT0000590913	NCT00005909_13_T0	PHENOTYPE	16	16	arthritis
NCT0000590913	NCT00005909_13_T1	ORGAN	22	23	heart valve
NCT0000590916	NCT00005909_16_T0	PHENOTYPE	14	14	blocks
NCT0000590916	NCT00005909_16_T1	COMPOUND	17	18	homogentisic acid
NCT0000590918	NCT00005909_18_T0	PHENOTYPE	13	13	spondylosis
NCT0000590918	NCT00005909_18_T1	PHENOTYPE	14	14	arthropathy
NCT0000590918	NCT00005909_18_T2	PHENOTYPE	16	16	fractures
NCT0000590918	NCT00005909_18_T3	PHENOTYPE	0	0	Symptoms
NCT0000590919	NCT00005909_19_T0	ORGAN	0	1	Cardiac valve
NCT0000590920	NCT00005909_20_T0	COMPOUND	21	21	oxygen
NCT0000590920	NCT00005909_20_T1	COMPOUND	10	11	homogentisic acid
NCT0000590922	NCT00005909_22_T0	GENE	3	5	homogentisic acid oxidase
NCT0000590926	NCT00005909_26_T0	PHENOTYPE	13	13	secondary
NCT0000590926	NCT00005909_26_T1	PHENOTYPE	0	0	Mutation
NCT0000590928	NCT00005909_28_T0	PHENOTYPE	6	6	Alkaptonuria
NCT000059100	NCT00005910_0_T0	PHENOTYPE	5	5	Insulinomas
NCT000059100	NCT00005910_0_T1	PHENOTYPE	3	4	Pancreatic Tumors
NCT000059102	NCT00005910_2_T0	PHENOTYPE	1	1	tumors
NCT000059102	NCT00005910_2_T1	GENE	14	14	MRI
NCT000059105	NCT00005910_5_T0	PHENOTYPE	16	16	insulinoma
NCT000059105	NCT00005910_5_T1	PHENOTYPE	11	11	hypoglycemia
NCT000059107	NCT00005910_7_T0	PHENOTYPE	2	2	tumors
NCT000059107	NCT00005910_7_T1	ORGAN	17	17	liver
NCT000059107	NCT00005910_7_T2	ORGAN	14	14	pancreas
NCT0000591010	NCT00005910_10_T0	ORGAN	7	7	gallbladder
NCT0000591010	NCT00005910_10_T1	ORGAN	17	17	pancreas
NCT0000591012	NCT00005910_12_T0	PHENOTYPE	7	7	tumor
NCT0000591013	NCT00005910_13_T0	PHENOTYPE	2	2	tumor
NCT0000591015	NCT00005910_15_T0	PHENOTYPE	2	2	tumor
NCT0000591016	NCT00005910_16_T0	ORGAN	23	23	pancreas
NCT0000591016	NCT00005910_16_T1	PHENOTYPE	2	2	tumor
NCT0000591019	NCT00005910_19_T0	PHENOTYPE	14	14	localize
NCT0000591019	NCT00005910_19_T1	GENE	7	7	MRI
NCT0000591021	NCT00005910_21_T0	PHENOTYPE	13	13	localize
NCT0000591021	NCT00005910_21_T1	PHENOTYPE	15	15	insulinoma
NCT0000591027	NCT00005910_27_T0	ORGAN	6	6	serum
NCT0000591027	NCT00005910_27_T1	PHENOTYPE	1	3	negative pregnancy test
NCT0000591029	NCT00005910_29_T0	GENE	6	6	MRI
NCT0000591029	NCT00005910_29_T1	PHENOTYPE	2	3	metastatic disease
NCT0000591030	NCT00005910_30_T0	PHENOTYPE	0	1	Platelet count
NCT000059114	NCT00005911_4_T0	GENE	0	0	MRI
NCT000059115	NCT00005911_5_T0	ORGAN	5	5	pupils
NCT000059119	NCT00005911_9_T0	ORGAN	13	13	eyes
NCT0000591117	NCT00005911_17_T0	PHENOTYPE	14	14	dilation
NCT0000591117	NCT00005911_17_T1	PHENOTYPE	4	4	glaucoma
NCT0000591117	NCT00005911_17_T2	PHENOTYPE	3	3	uveitis
NCT0000591117	NCT00005911_17_T3	PHENOTYPE	20	21	allergic reaction
NCT0000591117	NCT00005911_17_T4	PHENOTYPE	11	12	adverse reaction
NCT000059122	NCT00005912_2_T0	GENE	2	2	reduced
NCT000059122	NCT00005912_2_T1	PHENOTYPE	17	18	fungal infections
NCT000059123	NCT00005912_3_T0	PHENOTYPE	12	13	fungal infections
NCT0000591210	NCT00005912_10_T0	COMPOUND	5	5	voriconazole
NCT0000591213	NCT00005912_13_T0	ORGAN	31	31	liver
NCT0000591213	NCT00005912_13_T1	BIOLOGICAL_PROCESS	17	17	metabolism
NCT0000591214	NCT00005912_14_T0	PHENOTYPE	6	6	fungi
NCT0000591215	NCT00005912_15_T0	PHENOTYPE	6	7	fungal infections
NCT0000591217	NCT00005912_17_T0	COMPOUND	8	8	voriconazole
NCT0000591218	NCT00005912_18_T0	PHENOTYPE	3	3	concentrations
NCT0000591218	NCT00005912_18_T1	COMPOUND	9	9	voriconazole
NCT0000591218	NCT00005912_18_T2	ORGAN	2	2	plasma
NCT0000591219	NCT00005912_19_T0	COMPOUND	13	13	voriconazole
NCT0000591220	NCT00005912_20_T0	COMPOUND	1	1	voriconazole
NCT0000591220	NCT00005912_20_T1	PHENOTYPE	15	16	invasive mycoses
NCT0000591225	NCT00005912_25_T0	COMPOUND	10	10	voriconazole
NCT0000591225	NCT00005912_25_T1	PHENOTYPE	6	7	invasive mycoses
NCT0000591227	NCT00005912_27_T0	PHENOTYPE	7	7	neutropenia
NCT0000591228	NCT00005912_28_T0	GENE	18	18	BID
NCT0000591229	NCT00005912_29_T0	PHENOTYPE	2	2	pharmacokinetics
NCT0000591230	NCT00005912_30_T0	PHENOTYPE	23	23	neutropenia
NCT0000591232	NCT00005912_32_T0	COMPOUND	7	7	voriconazole
NCT0000591232	NCT00005912_32_T1	COMPOUND	27	27	voriconazole
NCT0000591232	NCT00005912_32_T2	ORGAN	4	4	plasma
NCT0000591234	NCT00005912_34_T0	PHENOTYPE	21	21	leukemia
NCT0000591234	NCT00005912_34_T1	PHENOTYPE	22	22	lymphoma
NCT0000591234	NCT00005912_34_T2	PHENOTYPE	6	6	neutropenia
NCT0000591234	NCT00005912_34_T3	ORGAN	31	32	bone marrow
NCT0000591234	NCT00005912_34_T4	PHENOTYPE	23	24	aplastic anemia
NCT0000591236	NCT00005912_36_T0	PHENOTYPE	8	10	negative pregnancy test
NCT0000591239	NCT00005912_39_T0	COMPOUND	21	21	cisapride
NCT0000591239	NCT00005912_39_T1	COMPOUND	19	19	terfenadine
NCT0000591240	NCT00005912_40_T0	COMPOUND	11	11	voriconazole
NCT0000591240	NCT00005912_40_T1	GENE	4	4	CYP2C19
NCT0000591240	NCT00005912_40_T2	ORGAN	10	10	plasma
NCT0000591241	NCT00005912_41_T0	COMPOUND	15	15	rifampicin
NCT0000591241	NCT00005912_41_T1	COMPOUND	19	19	nevirapine
NCT0000591241	NCT00005912_41_T2	COMPOUND	37	37	voriconazole
NCT0000591241	NCT00005912_41_T3	COMPOUND	16	16	rifabutin
NCT0000591241	NCT00005912_41_T4	COMPOUND	18	18	phenytoin
NCT0000591241	NCT00005912_41_T5	COMPOUND	17	17	carbamazepine
NCT0000591242	NCT00005912_42_T0	COMPOUND	5	5	astemizole
NCT0000591243	NCT00005912_43_T0	PHENOTYPE	29	30	opportunistic infections
NCT0000591246	NCT00005912_46_T0	PHENOTYPE	8	9	cardiac arrhythmia
NCT0000591248	NCT00005912_48_T0	COMPOUND	10	10	creatine
NCT0000591248	NCT00005912_48_T1	PHENOTYPE	6	7	renal impairment
NCT0000591249	NCT00005912_49_T0	COMPOUND	1	1	creatinine
NCT0000591249	NCT00005912_49_T1	GENE	4	4	reduced
NCT0000591250	NCT00005912_50_T0	COMPOUND	13	13	creatinine
NCT000059141	NCT00005914_1_T0	PHENOTYPE	12	13	major depression
NCT000059148	NCT00005914_8_T0	PHENOTYPE	2	3	recurrent depression
NCT000059149	NCT00005914_9_T0	PHENOTYPE	16	16	disorders
NCT0000591410	NCT00005914_10_T0	PHENOTYPE	18	19	severe depression
NCT0000591413	NCT00005914_13_T0	PHENOTYPE	12	13	major depression
NCT000059154	NCT00005915_4_T0	PHENOTYPE	5	5	HIV
NCT000059154	NCT00005915_4_T1	GENE	17	17	MDR
NCT000059155	NCT00005915_5_T0	PHENOTYPE	14	14	HIV
NCT000059155	NCT00005915_5_T1	GENE	19	19	MDR
NCT0000591511	NCT00005915_11_T0	GENE	25	25	GART
NCT0000591513	NCT00005915_13_T0	GENE	12	12	GART
NCT0000591515	NCT00005915_15_T0	PHENOTYPE	8	8	progression
NCT0000591515	NCT00005915_15_T1	PHENOTYPE	7	7	experiences
NCT000059164	NCT00005916_4_T0	PHENOTYPE	20	20	allergies
NCT000059164	NCT00005916_4_T1	PHENOTYPE	22	22	tuberculosis
NCT000059167	NCT00005916_7_T0	GENE	7	7	hormone
NCT0000591613	NCT00005916_13_T0	CELL	8	10	white blood cells
NCT0000591621	NCT00005916_21_T0	GENE	13	13	IL-2
NCT0000591624	NCT00005916_24_T0	PHENOTYPE	17	17	peripheral
NCT0000591624	NCT00005916_24_T1	CELL	18	19	blood cells
NCT0000591634	NCT00005916_34_T0	PHENOTYPE	5	5	vaccinia
NCT0000591634	NCT00005916_34_T1	PHENOTYPE	7	7	smallpox
NCT0000591635	NCT00005916_35_T0	PHENOTYPE	12	12	smallpox
NCT0000591637	NCT00005916_37_T0	PHENOTYPE	14	14	vaccinia
NCT0000591637	NCT00005916_37_T1	PHENOTYPE	6	6	allergy
NCT0000591638	NCT00005916_38_T0	GENE	22	22	8.0
NCT0000591638	NCT00005916_38_T1	CELL	9	9	platelets
NCT0000591638	NCT00005916_38_T2	GENE	16	16	hemoglobin
NCT0000591638	NCT00005916_38_T3	CELL	1	1	lymphocyte
NCT0000591639	NCT00005916_39_T0	PHENOTYPE	18	18	hematuria
NCT0000591639	NCT00005916_39_T1	PHENOTYPE	15	15	proteinuria
NCT0000591639	NCT00005916_39_T2	PHENOTYPE	13	14	grade 1
NCT0000591641	NCT00005916_41_T0	PHENOTYPE	10	10	hematuria
NCT0000591641	NCT00005916_41_T1	PHENOTYPE	22	22	pathology
NCT0000591644	NCT00005916_44_T0	PHENOTYPE	31	31	toxicities
NCT0000591646	NCT00005916_46_T0	GENE	17	17	had
NCT0000591646	NCT00005916_46_T1	GENE	11	11	nodal
NCT0000591647	NCT00005916_47_T0	PHENOTYPE	43	43	acute
NCT0000591647	NCT00005916_47_T1	PHENOTYPE	2	2	vaccinia
NCT0000591647	NCT00005916_47_T2	PHENOTYPE	34	34	eczema
NCT0000591647	NCT00005916_47_T3	PHENOTYPE	44	44	chronic
NCT0000591647	NCT00005916_47_T4	PHENOTYPE	52	52	burns
NCT0000591647	NCT00005916_47_T5	PHENOTYPE	61	61	rashes
NCT0000591647	NCT00005916_47_T6	PHENOTYPE	53	53	impetigo
NCT0000591647	NCT00005916_47_T7	PHENOTYPE	57	57	acne
NCT0000591647	NCT00005916_47_T8	PHENOTYPE	88	88	HIV
NCT0000591647	NCT00005916_47_T9	PHENOTYPE	78	78	immunodeficient
NCT0000591647	NCT00005916_47_T10	PHENOTYPE	38	39	skin disorders
NCT0000591647	NCT00005916_47_T11	PHENOTYPE	50	51	atopic dermatitis
NCT0000591647	NCT00005916_47_T12	PHENOTYPE	47	48	skin conditions
NCT0000591647	NCT00005916_47_T13	PHENOTYPE	54	55	varicella zoster
NCT0000591650	NCT00005916_50_T0	PHENOTYPE	3	3	infections
NCT0000591650	NCT00005916_50_T1	GENE	17	17	has
NCT0000591650	NCT00005916_50_T2	PHENOTYPE	8	8	chronic
NCT0000591652	NCT00005916_52_T0	PHENOTYPE	6	6	encephalitis
NCT0000591652	NCT00005916_52_T1	PHENOTYPE	5	5	seizures
NCT0000591652	NCT00005916_52_T2	PHENOTYPE	8	9	multiple sclerosis
NCT0000591653	NCT00005916_53_T0	PHENOTYPE	3	5	allergy to eggs
NCT0000591654	NCT00005916_54_T0	GENE	21	21	IL-2
NCT0000591654	NCT00005916_54_T1	PHENOTYPE	7	8	pulmonary disease
NCT0000591654	NCT00005916_54_T2	PHENOTYPE	5	6	cardiac disease
NCT0000591654	NCT00005916_54_T3	PHENOTYPE	9	10	autoimmune disease
NCT0000591654	NCT00005916_54_T4	PHENOTYPE	14	15	hepatic dysfunction
NCT000059172	NCT00005917_2_T0	GENE	10	10	fusion
NCT000059172	NCT00005917_2_T1	PHENOTYPE	15	15	vesicles
NCT000059179	NCT00005917_9_T0	GENE	3	3	has
NCT000059179	NCT00005917_9_T1	ORGAN	19	21	peripheral nervous system
NCT0000591710	NCT00005917_10_T0	PHENOTYPE	24	24	pathophysiology
NCT0000591710	NCT00005917_10_T1	ORGAN	8	8	transplant
NCT0000591710	NCT00005917_10_T2	ORGAN	33	34	immune systems
NCT0000591710	NCT00005917_10_T3	PHENOTYPE	16	17	neurological symptoms
NCT0000591710	NCT00005917_10_T4	ORGAN	6	7	bone marrow
NCT0000591713	NCT00005917_13_T0	GENE	10	10	fusion
NCT0000591713	NCT00005917_13_T1	PHENOTYPE	15	15	vesicles
NCT0000591714	NCT00005917_14_T0	GENE	5	5	LYST
NCT0000591714	NCT00005917_14_T1	BIOLOGICAL_PROCESS	13	14	axonal transport
NCT0000591716	NCT00005917_16_T0	GENE	4	4	4.5
NCT000059181	NCT00005918_1_T0	GENE	7	7	extended
NCT000059183	NCT00005918_3_T0	PHENOTYPE	5	5	HIV
NCT000059184	NCT00005918_4_T0	COMPOUND	4	4	efavirenz
NCT000059184	NCT00005918_4_T1	COMPOUND	7	7	lamivudine
NCT0000591913	NCT00005919_13_T0	ORGAN	3	4	trabecular meshwork
NCT0000591918	NCT00005919_18_T0	ORGAN	3	3	pupils
NCT000059200	NCT00005920_0_T0	PHENOTYPE	9	9	Thrush
NCT000059203	NCT00005920_3_T0	PHENOTYPE	9	9	symptoms
NCT000059214	NCT00005921_4_T0	PHENOTYPE	0	0	Pharmacokinetics
NCT000059228	NCT00005922_8_T0	GENE	14	14	reduced
NCT000059228	NCT00005922_8_T1	PHENOTYPE	26	26	reinforcement
NCT000059229	NCT00005922_9_T0	PHENOTYPE	11	11	reinforcement
NCT0000592210	NCT00005922_10_T0	PHENOTYPE	7	7	conditioning
NCT0000592210	NCT00005922_10_T1	PHENOTYPE	13	13	reinforcement
NCT0000592211	NCT00005922_11_T0	PHENOTYPE	27	28	autoimmune disorders
NCT0000592211	NCT00005922_11_T1	PHENOTYPE	34	35	chronic diseases
NCT000059230	NCT00005923_0_T0	ORGAN	10	11	Ankle Joint
NCT000059230	NCT00005923_0_T1	PHENOTYPE	5	6	Progesterone Levels
NCT000059230	NCT00005923_0_T2	PHENOTYPE	11	12	Joint Laxity
NCT000059232	NCT00005923_2_T0	GENE	36	36	neuromuscular
NCT000059232	NCT00005923_2_T1	COMPOUND	7	7	estrogen
NCT000059232	NCT00005923_2_T2	COMPOUND	17	17	estrogen
NCT000059232	NCT00005923_2_T3	COMPOUND	9	9	progesterone
NCT000059232	NCT00005923_2_T4	PHENOTYPE	33	34	joint laxity
NCT000059233	NCT00005923_3_T0	COMPOUND	3	3	estrogen
NCT000059233	NCT00005923_3_T1	COMPOUND	5	5	progesterone
NCT000059233	NCT00005923_3_T2	BIOLOGICAL_PROCESS	15	16	menstrual cycle
NCT000059234	NCT00005923_4_T0	PHENOTYPE	0	1	Joint laxity
NCT000059235	NCT00005923_5_T0	COMPOUND	18	18	estrogen
NCT000059235	NCT00005923_5_T1	PHENOTYPE	20	21	progesterone levels
NCT000059235	NCT00005923_5_T2	ORGAN	6	7	ankle joint
NCT000059235	NCT00005923_5_T3	PHENOTYPE	7	8	joint laxity
NCT000059243	NCT00005924_3_T0	PHENOTYPE	7	7	symptoms
NCT000059244	NCT00005924_4_T0	PHENOTYPE	8	9	infectious mononucleosis
NCT000059245	NCT00005924_5_T0	CELL	18	20	white blood cells
NCT000059247	NCT00005924_7_T0	PHENOTYPE	26	26	Transmission
NCT000059247	NCT00005924_7_T1	PHENOTYPE	34	34	centers
NCT000059247	NCT00005924_7_T2	PHENOTYPE	23	24	Herpes Simplex
NCT0000592411	NCT00005924_11_T0	PHENOTYPE	19	19	spit
NCT0000592413	NCT00005924_13_T0	ORGAN	0	0	Blood
NCT0000592413	NCT00005924_13_T1	ORGAN	24	25	immune system
NCT0000592414	NCT00005924_14_T0	GENE	6	6	has
NCT0000592415	NCT00005924_15_T0	PHENOTYPE	12	12	fever
NCT0000592415	NCT00005924_15_T1	PHENOTYPE	4	4	symptoms
NCT0000592415	NCT00005924_15_T2	PHENOTYPE	6	6	mononucleosis
NCT0000592415	NCT00005924_15_T3	PHENOTYPE	14	15	sore throat
NCT0000592415	NCT00005924_15_T4	PHENOTYPE	8	10	enlarged lymph nodes
NCT0000592419	NCT00005924_19_T0	COMPOUND	31	31	acyclovir
NCT0000592419	NCT00005924_19_T1	CELL	15	16	B cells
NCT0000592420	NCT00005924_20_T0	PHENOTYPE	20	22	genital herpes simplex
NCT0000592420	NCT00005924_20_T1	PHENOTYPE	21	24	herpes simplex virus infection
NCT0000592423	NCT00005924_23_T0	PHENOTYPE	8	8	insights
NCT0000592423	NCT00005924_23_T1	PHENOTYPE	13	13	persistence
NCT0000592429	NCT00005924_29_T0	PHENOTYPE	2	4	recurrent genital herpes
NCT0000592431	NCT00005924_31_T0	PHENOTYPE	19	19	HSV
NCT0000592431	NCT00005924_31_T1	ORGAN	22	22	genital
NCT0000592431	NCT00005924_31_T2	PHENOTYPE	26	27	positive serology
NCT0000592431	NCT00005924_31_T3	PHENOTYPE	6	7	genital herpes
NCT0000592431	NCT00005924_31_T4	PHENOTYPE	11	12	genital herpes
NCT0000592432	NCT00005924_32_T0	GENE	23	23	Blot
NCT0000592432	NCT00005924_32_T1	PHENOTYPE	8	8	HSV
NCT0000592432	NCT00005924_32_T2	ORGAN	9	9	genital
NCT0000592434	NCT00005924_34_T0	PHENOTYPE	6	6	recurrences
NCT0000592434	NCT00005924_34_T1	PHENOTYPE	0	0	Recurrence
NCT0000592436	NCT00005924_36_T0	PHENOTYPE	7	7	HSV
NCT0000592441	NCT00005924_41_T0	PHENOTYPE	8	8	malignancy
NCT0000592441	NCT00005924_41_T1	PHENOTYPE	16	16	HIV
NCT0000592445	NCT00005924_45_T0	COMPOUND	7	7	creatine
NCT0000592445	NCT00005924_45_T1	GENE	10	10	1.5
NCT0000592445	NCT00005924_45_T2	ORGAN	6	6	serum
NCT0000592458	NCT00005924_58_T0	PHENOTYPE	0	2	Positive pregnancy test
NCT0000592459	NCT00005924_59_T0	PHENOTYPE	0	1	Swallowing disorders
NCT000059251	NCT00005925_1_T0	GENE	11	11	GABA
NCT000059251	NCT00005925_1_T1	PHENOTYPE	17	17	seizures
NCT000059251	NCT00005925_1_T2	GENE	12	12	has
NCT000059252	NCT00005925_2_T0	PHENOTYPE	13	13	seizures
NCT000059253	NCT00005925_3_T0	PHENOTYPE	8	9	intractable epilepsy
NCT000059254	NCT00005925_4_T0	GENE	40	40	MRI
NCT000059254	NCT00005925_4_T1	PHENOTYPE	17	17	Epilepsy
NCT000059256	NCT00005925_6_T0	GENE	7	7	MRI
NCT000059259	NCT00005925_9_T0	PHENOTYPE	23	24	intractable epilepsy
NCT0000592510	NCT00005925_10_T0	GENE	0	0	MRI
NCT0000592513	NCT00005925_13_T0	PHENOTYPE	7	7	numbness
NCT0000592513	NCT00005925_13_T1	PHENOTYPE	6	6	weakness
NCT0000592513	NCT00005925_13_T2	PHENOTYPE	9	9	sleepiness
NCT0000592513	NCT00005925_13_T3	PHENOTYPE	5	5	headache
NCT0000592514	NCT00005925_14_T0	COMPOUND	8	8	muscimol
NCT0000592523	NCT00005925_23_T0	PHENOTYPE	3	3	seizures
NCT0000592524	NCT00005925_24_T0	PHENOTYPE	9	9	seizure
NCT0000592524	NCT00005925_24_T1	PHENOTYPE	26	26	seizure
NCT0000592524	NCT00005925_24_T2	CELL	13	13	neurons
NCT0000592524	NCT00005925_24_T3	PHENOTYPE	4	4	cuts
NCT0000592524	NCT00005925_24_T4	CELL	14	15	nerve cells
NCT0000592530	NCT00005925_30_T0	PHENOTYPE	16	16	seizure
NCT0000592530	NCT00005925_30_T1	PHENOTYPE	9	9	suppression
NCT0000592530	NCT00005925_30_T2	PHENOTYPE	14	14	elimination
NCT0000592531	NCT00005925_31_T0	PHENOTYPE	21	21	epileptic
NCT0000592531	NCT00005925_31_T1	PHENOTYPE	12	13	intractable epilepsy
NCT0000592532	NCT00005925_32_T0	PHENOTYPE	21	21	epileptic
NCT0000592532	NCT00005925_32_T1	PHENOTYPE	11	12	intractable epilepsy
NCT0000592533	NCT00005925_33_T0	PHENOTYPE	25	25	seizure
NCT0000592533	NCT00005925_33_T1	PHENOTYPE	12	13	intractable epilepsy
NCT0000592534	NCT00005925_34_T0	PHENOTYPE	11	11	seizure
NCT0000592534	NCT00005925_34_T1	PHENOTYPE	25	25	seizure
NCT0000592535	NCT00005925_35_T0	COMPOUND	16	16	muscimol
NCT0000592535	NCT00005925_35_T1	GENE	22	22	receptor
NCT0000592535	NCT00005925_35_T2	GENE	21	21	GABA
NCT0000592537	NCT00005925_37_T0	PHENOTYPE	4	4	epileptic
NCT0000592537	NCT00005925_37_T1	PHENOTYPE	15	16	intractable epilepsy
NCT0000592538	NCT00005925_38_T0	PHENOTYPE	19	19	seizure
NCT0000592538	NCT00005925_38_T1	PHENOTYPE	6	6	epileptic
NCT0000592538	NCT00005925_38_T2	PHENOTYPE	32	32	naming
NCT0000592538	NCT00005925_38_T3	PHENOTYPE	3	3	pathophysiology
NCT0000592538	NCT00005925_38_T4	PHENOTYPE	27	28	motor function
NCT0000592543	NCT00005925_43_T0	PHENOTYPE	3	5	complex partial seizures
NCT0000592551	NCT00005925_51_T0	PHENOTYPE	2	2	seizure
NCT0000592551	NCT00005925_51_T1	ORGAN	10	11	cerebral hemisphere
NCT0000592555	NCT00005925_55_T0	GENE	4	4	MRI
NCT0000592557	NCT00005925_57_T0	PHENOTYPE	2	3	bleeding disorder
NCT0000592561	NCT00005925_61_T0	PHENOTYPE	1	1	seizure
NCT0000592561	NCT00005925_61_T1	PHENOTYPE	2	2	foci
NCT0000592561	NCT00005925_61_T2	ORGAN	14	15	cerebral hemispheres
NCT000059261	NCT00005926_1_T0	PHENOTYPE	6	7	pancreatic cancer
NCT000059262	NCT00005926_2_T0	CELL	3	3	cells
NCT000059262	NCT00005926_2_T1	PHENOTYPE	1	1	damages
NCT000059262	NCT00005926_2_T2	PHENOTYPE	2	2	tumor
NCT000059262	NCT00005926_2_T3	PHENOTYPE	8	11	effects of radiation therapy
NCT000059263	NCT00005926_3_T0	PHENOTYPE	10	10	tumors
NCT000059263	NCT00005926_3_T1	GENE	7	7	has
NCT000059263	NCT00005926_3_T2	PHENOTYPE	16	17	breast cancer
NCT000059265	NCT00005926_5_T0	PHENOTYPE	2	3	pancreatic cancer
NCT000059266	NCT00005926_6_T0	ORGAN	21	21	abdomen
NCT000059266	NCT00005926_6_T1	ORGAN	23	23	pelvis
NCT000059268	NCT00005926_8_T0	PHENOTYPE	5	5	anesthesia
NCT000059269	NCT00005926_9_T0	ORGAN	10	10	abdomen
NCT0000592610	NCT00005926_10_T0	PHENOTYPE	17	17	tumor
NCT0000592610	NCT00005926_10_T1	PHENOTYPE	26	26	tumor
NCT0000592610	NCT00005926_10_T2	ORGAN	12	13	abdominal cavity
NCT0000592612	NCT00005926_12_T0	PHENOTYPE	7	9	Quality of Life
NCT0000592613	NCT00005926_13_T0	PHENOTYPE	5	5	feelings
NCT0000592616	NCT00005926_16_T0	GENE	12	12	IV
NCT0000592617	NCT00005926_17_T0	ORGAN	4	4	abdomen
NCT0000592620	NCT00005926_20_T0	PHENOTYPE	9	9	anesthesia
NCT0000592621	NCT00005926_21_T0	PHENOTYPE	2	2	tumor
NCT0000592622	NCT00005926_22_T0	PHENOTYPE	14	14	tumors
NCT0000592622	NCT00005926_22_T1	PHENOTYPE	26	26	tumors
NCT0000592623	NCT00005926_23_T0	GENE	6	6	IV
NCT0000592630	NCT00005926_30_T0	COMPOUND	8	8	gemcitabine
NCT0000592631	NCT00005926_31_T0	PHENOTYPE	6	6	toxicity
NCT0000592631	NCT00005926_31_T1	PHENOTYPE	7	7	tumor
NCT0000592633	NCT00005926_33_T0	COMPOUND	12	12	2
NCT0000592633	NCT00005926_33_T1	GENE	3	3	HER2
NCT0000592633	NCT00005926_33_T2	PHENOTYPE	0	0	Tumors
NCT0000592636	NCT00005926_36_T0	COMPOUND	5	5	creatinine
NCT0000592636	NCT00005926_36_T1	COMPOUND	11	11	creatinine
NCT0000592636	NCT00005926_36_T2	GENE	8	8	1.5
NCT0000592636	NCT00005926_36_T3	ORGAN	4	4	serum
NCT0000592637	NCT00005926_37_T0	GENE	4	4	ANC
NCT0000592637	NCT00005926_37_T1	CELL	9	9	platelets
NCT0000592640	NCT00005926_40_T0	COMPOUND	7	7	gemcitabine
NCT0000592640	NCT00005926_40_T1	PHENOTYPE	13	14	pancreatic cancer
NCT0000592642	NCT00005926_42_T0	PHENOTYPE	21	21	toxicity
NCT0000592642	NCT00005926_42_T1	PHENOTYPE	4	4	tumor
NCT0000592643	NCT00005926_43_T0	PHENOTYPE	7	7	metastases
NCT0000592643	NCT00005926_43_T1	PHENOTYPE	10	10	carcinomatosis
NCT0000592643	NCT00005926_43_T2	PHENOTYPE	11	12	liver metastases
NCT0000592644	NCT00005926_44_T0	PHENOTYPE	2	3	second malignancy
NCT0000592644	NCT00005926_44_T1	PHENOTYPE	10	11	cervical carcinoma
NCT0000592644	NCT00005926_44_T2	PHENOTYPE	6	8	melanoma skin cancer
NCT0000592645	NCT00005926_45_T0	PHENOTYPE	17	18	psychiatric disease
NCT0000592648	NCT00005926_48_T0	GENE	5	5	abdominal
NCT000059270	NCT00005927_0_T0	PHENOTYPE	2	4	Adrenal Gland Tumors
NCT000059272	NCT00005927_2_T0	PHENOTYPE	0	0	Tumors
NCT000059273	NCT00005927_3_T0	PHENOTYPE	7	7	tumors
NCT000059275	NCT00005927_5_T0	PHENOTYPE	5	7	adrenal gland tumors
NCT000059276	NCT00005927_6_T0	PHENOTYPE	12	14	adrenal gland tumor
NCT000059279	NCT00005927_9_T0	ORGAN	11	11	genitals
NCT0000592713	NCT00005927_13_T0	GENE	6	6	MRI
NCT0000592715	NCT00005927_15_T0	PHENOTYPE	6	6	tumor
NCT0000592717	NCT00005927_17_T0	GENE	9	9	IV
NCT0000592717	NCT00005927_17_T1	PHENOTYPE	20	21	hormone levels
NCT0000592718	NCT00005927_18_T0	GENE	22	22	IV
NCT0000592718	NCT00005927_18_T1	GENE	32	32	IV
NCT0000592718	NCT00005927_18_T2	GENE	16	16	hormone
NCT0000592722	NCT00005927_22_T0	PHENOTYPE	5	5	tumor
NCT0000592725	NCT00005927_25_T0	PHENOTYPE	2	3	malignant tumor
NCT0000592735	NCT00005927_35_T0	COMPOUND	21	21	DHEA
NCT0000592735	NCT00005927_35_T1	COMPOUND	30	30	estrogen
NCT0000592735	NCT00005927_35_T2	COMPOUND	29	29	testosterone
NCT0000592735	NCT00005927_35_T3	BIOLOGICAL_PROCESS	28	28	androstenedione
NCT0000592735	NCT00005927_35_T4	COMPOUND	20	20	dehydroepiandrosterone
NCT0000592735	NCT00005927_35_T5	COMPOUND	32	32	estrone
NCT0000592735	NCT00005927_35_T6	GENE	26	26	DHEAS
NCT0000592735	NCT00005927_35_T7	GENE	24	24	sulfated
NCT0000592735	NCT00005927_35_T8	ORGAN	9	10	adrenal gland
NCT0000592739	NCT00005927_39_T0	COMPOUND	21	21	cortisol
NCT0000592739	NCT00005927_39_T1	PHENOTYPE	27	27	tumors
NCT0000592739	NCT00005927_39_T2	GENE	18	18	receptor
NCT0000592739	NCT00005927_39_T3	COMPOUND	23	23	aldosterone
NCT0000592739	NCT00005927_39_T4	GENE	24	24	hormone
NCT0000592742	NCT00005927_42_T0	PHENOTYPE	15	15	tumors
NCT0000592742	NCT00005927_42_T1	ORGAN	18	19	adrenal gland
NCT0000592744	NCT00005927_44_T0	PHENOTYPE	14	14	strategies
NCT0000592744	NCT00005927_44_T1	PHENOTYPE	19	20	malignant tumors
NCT0000592746	NCT00005927_46_T0	PHENOTYPE	37	37	tumors
NCT0000592746	NCT00005927_46_T1	COMPOUND	17	17	aldosterone
NCT0000592746	NCT00005927_46_T2	PHENOTYPE	28	29	primary hyperaldosteronism
NCT0000592747	NCT00005927_47_T0	PHENOTYPE	14	14	hypercortisolism
NCT0000592747	NCT00005927_47_T1	PHENOTYPE	10	10	rigor
NCT0000592747	NCT00005927_47_T2	PHENOTYPE	27	27	hyperaldosteronism
NCT0000592747	NCT00005927_47_T3	PHENOTYPE	43	43	hypertension
NCT0000592762	NCT00005927_62_T0	COMPOUND	5	5	cortisol
NCT0000592762	NCT00005927_62_T1	PHENOTYPE	19	19	tumor
NCT0000592762	NCT00005927_62_T2	PHENOTYPE	2	3	adrenal tumors
NCT000059283	NCT00005928_3_T0	PHENOTYPE	19	20	heart failure
NCT000059283	NCT00005928_3_T1	PHENOTYPE	16	17	heart attack
NCT000059283	NCT00005928_3_T2	MOLECULAR_FUNCTION	9	10	ACE inhibitor
NCT000059283	NCT00005928_3_T3	PHENOTYPE	4	6	coronary artery disease
NCT000059284	NCT00005928_4_T0	PHENOTYPE	25	25	inflammation
NCT000059284	NCT00005928_4_T1	ORGAN	11	11	artery
NCT000059284	NCT00005928_4_T2	ORGAN	23	24	blood vessel
NCT000059285	NCT00005928_5_T0	PHENOTYPE	13	13	atherosclerosis
NCT000059285	NCT00005928_5_T1	PHENOTYPE	8	10	coronary artery disease
NCT000059286	NCT00005928_6_T0	ORGAN	9	9	heart
NCT000059286	NCT00005928_6_T1	ORGAN	11	12	blood vessel
NCT000059287	NCT00005928_7_T0	MOLECULAR_FUNCTION	10	11	ACE inhibitor
NCT000059289	NCT00005928_9_T0	MOLECULAR_FUNCTION	5	6	ACE inhibitor
NCT0000592811	NCT00005928_11_T0	GENE	19	19	cc
NCT0000592811	NCT00005928_11_T1	ORGAN	24	24	kidney
NCT0000592811	NCT00005928_11_T2	GENE	20	20	1.2
NCT0000592812	NCT00005928_12_T0	PHENOTYPE	19	19	Center
NCT0000592813	NCT00005928_13_T0	GENE	5	5	cc
NCT0000592813	NCT00005928_13_T1	COMPOUND	12	12	sodium
NCT0000592813	NCT00005928_13_T2	COMPOUND	14	14	potassium
NCT0000592813	NCT00005928_13_T3	PHENOTYPE	19	19	inflammation
NCT0000592814	NCT00005928_14_T0	ORGAN	13	13	arteries
NCT0000592814	NCT00005928_14_T1	ORGAN	11	12	carotid arteries
NCT0000592814	NCT00005928_14_T2	ORGAN	37	38	carotid arteries
NCT0000592814	NCT00005928_14_T3	PHENOTYPE	34	36	right and left
NCT0000592815	NCT00005928_15_T0	ORGAN	0	0	Heart
NCT0000592815	NCT00005928_15_T1	GENE	16	16	cuff
NCT0000592817	NCT00005928_17_T0	GENE	3	3	MRI
NCT0000592817	NCT00005928_17_T1	GENE	18	18	MRI
NCT0000592818	NCT00005928_18_T0	GENE	7	7	coil
NCT0000592818	NCT00005928_18_T1	GENE	6	6	MRI
NCT0000592821	NCT00005928_21_T0	ORGAN	1	1	heart
NCT0000592823	NCT00005928_23_T0	PHENOTYPE	3	4	vascular inflammation
NCT0000592826	NCT00005928_26_T0	GENE	27	27	MRI
NCT0000592826	NCT00005928_26_T1	GENE	41	41	reduced
NCT0000592826	NCT00005928_26_T2	PHENOTYPE	38	38	inflammation
NCT0000592826	NCT00005928_26_T3	ORGAN	35	35	serum
NCT0000592826	NCT00005928_26_T4	ORGAN	30	31	carotid arteries
NCT0000592826	NCT00005928_26_T5	PHENOTYPE	16	17	vascular inflammation
NCT0000592826	NCT00005928_26_T6	PHENOTYPE	42	43	vascular inflammation
NCT0000592826	NCT00005928_26_T7	MOLECULAR_FUNCTION	12	13	ACE inhibitor
NCT0000592826	NCT00005928_26_T8	MOLECULAR_FUNCTION	54	55	ACE inhibitor
NCT0000592826	NCT00005928_26_T9	PHENOTYPE	21	23	coronary artery disease
NCT0000592830	NCT00005928_30_T0	MOLECULAR_FUNCTION	1	2	ACE inhibitor
NCT0000592831	NCT00005928_31_T0	COMPOUND	3	3	creatinine
NCT0000592831	NCT00005928_31_T1	GENE	6	6	2.0
NCT0000592831	NCT00005928_31_T2	PHENOTYPE	1	2	renal insufficiency
NCT0000592833	NCT00005928_33_T0	PHENOTYPE	1	1	claustrophobia
NCT0000592835	NCT00005928_35_T0	GENE	1	1	MRI
NCT0000592835	NCT00005928_35_T1	BIOLOGICAL_PROCESS	8	8	AICD
NCT0000592836	NCT00005928_36_T0	PHENOTYPE	10	10	lupus
NCT0000592836	NCT00005928_36_T1	PHENOTYPE	2	3	inflammatory disorder
NCT0000592836	NCT00005928_36_T2	PHENOTYPE	7	8	periarteritis nodosa
NCT0000592836	NCT00005928_36_T3	PHENOTYPE	12	13	temporal arteritis
NCT0000592836	NCT00005928_36_T4	PHENOTYPE	5	6	rheumatoid arthritis
NCT000059312	NCT00005931_2_T0	PHENOTYPE	7	7	toxicity
NCT000059312	NCT00005931_2_T1	PHENOTYPE	49	49	toxicity
NCT000059312	NCT00005931_2_T2	PHENOTYPE	46	46	experiences
NCT000059312	NCT00005931_2_T3	GENE	3	3	has
NCT000059312	NCT00005931_2_T4	PHENOTYPE	22	23	disease progression
NCT000059312	NCT00005931_2_T5	PHENOTYPE	51	52	tumor progression
NCT000059334	NCT00005933_4_T0	GENE	13	13	cystic
NCT000059334	NCT00005933_4_T1	PHENOTYPE	18	19	frequent infections
NCT000059335	NCT00005933_5_T0	PHENOTYPE	10	10	disorders
NCT000059335	NCT00005933_5_T1	GENE	6	6	GCD
NCT000059335	NCT00005933_5_T2	PHENOTYPE	12	13	cystic fibrosis
NCT0000593312	NCT00005933_12_T0	PHENOTYPE	3	3	disorders
NCT0000593312	NCT00005933_12_T1	PHENOTYPE	11	11	infections
NCT0000593312	NCT00005933_12_T2	PHENOTYPE	7	7	recurrent
NCT0000593318	NCT00005933_18_T0	CELL	6	6	leukocyte
NCT0000593318	NCT00005933_18_T1	PHENOTYPE	17	18	cognitive functioning
NCT0000593319	NCT00005933_19_T0	PHENOTYPE	24	24	severity
NCT0000593319	NCT00005933_19_T1	PHENOTYPE	7	8	cognitive functioning
NCT000059340	NCT00005934_0_T0	PHENOTYPE	6	6	Thalassemia
NCT000059345	NCT00005934_5_T0	CELL	23	23	cells
NCT000059345	NCT00005934_5_T1	GENE	4	4	hemoglobin
NCT000059345	NCT00005934_5_T2	GENE	16	16	hemoglobin
NCT000059346	NCT00005934_6_T0	GENE	6	6	hemoglobin
NCT000059348	NCT00005934_8_T0	GENE	5	5	lessen
NCT000059348	NCT00005934_8_T1	COMPOUND	10	10	5_azacytidine
NCT000059348	NCT00005934_8_T2	COMPOUND	34	34	5_azacytidine
NCT000059349	NCT00005934_9_T0	PHENOTYPE	9	10	thalassemia major
NCT0000593412	NCT00005934_12_T0	GENE	2	2	MRI
NCT0000593412	NCT00005934_12_T1	CELL	22	24	red blood cells
NCT0000593414	NCT00005934_14_T0	ORGAN	5	5	ears
NCT0000593416	NCT00005934_16_T0	COMPOUND	10	10	5_azacytidine
NCT0000593418	NCT00005934_18_T0	COMPOUND	4	4	5_azacytidine
NCT0000593418	NCT00005934_18_T1	COMPOUND	14	14	5_azacytidine
NCT0000593420	NCT00005934_20_T0	COMPOUND	15	15	5_azacytidine
NCT0000593423	NCT00005934_23_T0	ORGAN	0	1	Bone marrow
NCT0000593424	NCT00005934_24_T0	GENE	0	0	MRI
NCT0000593426	NCT00005934_26_T0	ORGAN	0	1	Bone marrow
NCT0000593434	NCT00005934_34_T0	PHENOTYPE	18	18	complications
NCT0000593434	NCT00005934_34_T1	PHENOTYPE	0	0	Complications
NCT0000593434	NCT00005934_34_T2	PHENOTYPE	2	3	iron overload
NCT0000593434	NCT00005934_34_T3	PHENOTYPE	20	21	iron overload
NCT0000593435	NCT00005934_35_T0	PHENOTYPE	0	0	Complications
NCT0000593435	NCT00005934_35_T1	PHENOTYPE	16	16	progressive
NCT0000593435	NCT00005934_35_T2	PHENOTYPE	12	12	endocrinopathy
NCT0000593435	NCT00005934_35_T3	PHENOTYPE	2	3	iron overload
NCT0000593435	NCT00005934_35_T4	PHENOTYPE	5	6	heart failure
NCT0000593435	NCT00005934_35_T5	PHENOTYPE	17	18	liver dysfunction
NCT000059351	NCT00005935_1_T0	PHENOTYPE	14	14	bleeding
NCT000059351	NCT00005935_1_T1	PHENOTYPE	10	10	fatigue
NCT000059351	NCT00005935_1_T2	PHENOTYPE	18	18	infections
NCT000059351	NCT00005935_1_T3	GENE	5	6	too few
NCT000059351	NCT00005935_1_T4	CELL	7	8	blood cells
NCT000059351	NCT00005935_1_T5	PHENOTYPE	11	12	easy bruising
NCT000059351	NCT00005935_1_T6	PHENOTYPE	2	3	aplastic anemia
NCT000059352	NCT00005935_2_T0	PHENOTYPE	11	11	autoimmune
NCT000059352	NCT00005935_2_T1	ORGAN	17	18	immune system
NCT000059352	NCT00005935_2_T2	CELL	22	23	blood cells
NCT000059352	NCT00005935_2_T3	ORGAN	26	27	bone marrow
NCT000059356	NCT00005935_6_T0	PHENOTYPE	8	10	severe aplastic anemia
NCT000059357	NCT00005935_7_T0	COMPOUND	9	9	cyclosporine
NCT000059357	NCT00005935_7_T1	COMPOUND	15	15	cyclosporine
NCT000059358	NCT00005935_8_T0	COMPOUND	3	3	cyclosporine
NCT000059359	NCT00005935_9_T0	COMPOUND	3	3	cyclosporine
NCT000059359	NCT00005935_9_T1	COMPOUND	11	11	cyclosporine
NCT0000593511	NCT00005935_11_T0	ORGAN	20	21	immune system
NCT0000593511	NCT00005935_11_T1	ORGAN	24	25	bone marrow
NCT0000593512	NCT00005935_12_T0	PHENOTYPE	2	2	aspirations
NCT0000593512	NCT00005935_12_T1	ORGAN	0	1	Bone marrow
NCT0000593514	NCT00005935_14_T0	COMPOUND	16	16	cyclosporine
NCT0000593514	NCT00005935_14_T1	ORGAN	13	13	liver
NCT0000593516	NCT00005935_16_T0	GENE	2	2	ml
NCT0000593518	NCT00005935_18_T0	PHENOTYPE	17	17	pathophysiology
NCT0000593518	NCT00005935_18_T1	GENE	6	6	has
NCT0000593520	NCT00005935_20_T0	PHENOTYPE	11	12	aplastic anemia
NCT0000593521	NCT00005935_21_T0	PHENOTYPE	22	22	relapse
NCT0000593521	NCT00005935_21_T1	PHENOTYPE	24	24	pancytopenia
NCT0000593527	NCT00005935_27_T0	ORGAN	15	15	graft
NCT0000593528	NCT00005935_28_T0	PHENOTYPE	4	4	toxicity
NCT0000593528	NCT00005935_28_T1	COMPOUND	7	7	cyclosporine
NCT0000593528	NCT00005935_28_T2	GENE	1	1	has
NCT0000593528	NCT00005935_28_T3	ORGAN	14	14	kidneys
NCT0000593529	NCT00005935_29_T0	COMPOUND	21	21	cyclosporine
NCT0000593529	NCT00005935_29_T1	COMPOUND	25	25	cyclosporine
NCT0000593530	NCT00005935_30_T0	COMPOUND	6	6	cyclosporine
NCT0000593530	NCT00005935_30_T1	COMPOUND	17	17	cyclosporine
NCT0000593530	NCT00005935_30_T2	PHENOTYPE	32	32	toxic
NCT0000593530	NCT00005935_30_T3	PHENOTYPE	23	23	relapse
NCT0000593530	NCT00005935_30_T4	PHENOTYPE	25	26	aplastic anemia
NCT0000593532	NCT00005935_32_T0	PHENOTYPE	16	16	severity
NCT0000593532	NCT00005935_32_T1	PHENOTYPE	2	2	relapse
NCT000059361	NCT00005936_1_T0	ORGAN	5	5	liver
NCT000059361	NCT00005936_1_T1	ORGAN	8	8	liver
NCT000059362	NCT00005936_2_T0	ORGAN	3	3	liver
NCT000059362	NCT00005936_2_T1	ORGAN	9	9	liver
NCT000059363	NCT00005936_3_T0	ORGAN	3	3	liver
NCT000059363	NCT00005936_3_T1	ORGAN	16	16	liver
NCT000059365	NCT00005936_5_T0	PHENOTYPE	6	6	hepatitis
NCT000059367	NCT00005936_7_T0	ORGAN	14	14	liver
NCT000059367	NCT00005936_7_T1	PHENOTYPE	8	8	diseases
NCT000059368	NCT00005936_8_T0	ORGAN	10	10	liver
NCT000059368	NCT00005936_8_T1	ORGAN	14	14	liver
NCT000059369	NCT00005936_9_T0	ORGAN	1	1	liver
NCT000059369	NCT00005936_9_T1	ORGAN	25	25	liver
NCT000059369	NCT00005936_9_T2	ORGAN	2	2	transplant
